Cancer_type	QTL_type	tag_SNP	LD	SNP	SNP_position	Alleles	Methylation_probe	Methylation_position	Probe_related_gene	Beta	t-stat	Correlation_coefficient (r)	p-value	Traits
LGG	cis	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.2	-0.36	2.35e-15	Mood instability;
LGG	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.23	-0.32	1.97e-12	Colorectal cancer;
LGG	cis	rs4716602	0.596	rs12386682	chr7:156158265	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.5	-0.4	1.14e-19	Anti-saccade response;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg22398616	chr13:53314203	LECT1	-0.48	-9.87	-0.42	5.65e-21	Lewy body disease;
LGG	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg26384229	chr12:38710491	ALG10B	0.64	12.28	0.5	3.31e-30	Morning vs. evening chronotype;
LGG	trans	rs9409565	0.787	rs11789704	chr9:97233408	C/T	cg05679027	chr9:99775184	HIATL2	-0.47	-7.79	-0.34	4.4e-14	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg13385794	chr1:248469461	NA	0.49	8.35	0.36	8.06e-16	Common traits (Other);
LGG	cis	rs3820068	0.580	rs12747696	chr1:16002978	A/G	cg05660106	chr1:15850417	CASP9	0.74	13.26	0.52	2.92e-34	Systolic blood pressure;
LGG	cis	rs907683	0.559	rs4674394	chr2:220289870	C/T	cg15015639	chr2:220282977	DES	-0.35	-10.11	-0.43	7.83e-22	Resting heart rate;
LGG	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg08499158	chr17:42289980	UBTF	0.4	7.28	0.32	1.41e-12	Red cell distribution width;Reticulocyte count;
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg27219399	chr15:67835830	MAP2K5	0.32	6.98	0.31	1.01e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.4	-0.47	1.01e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-14.07	-0.55	1.13e-37	Bipolar disorder;
LGG	cis	rs11250464	0.517	rs2892335	chr10:1432136	T/G	cg08668359	chr10:1443807	ADARB2	0.49	9.1	0.39	2.64e-18	Radiation response;
LGG	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg08847533	chr14:75593920	NEK9	0.63	12.06	0.49	2.7e-29	Height;
LGG	cis	rs9902453	0.845	rs10853135	chr17:28188675	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.83	0.54	1.13e-36	Coffee consumption (cups per day);
LGG	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg04607235	chr12:12878440	APOLD1	-0.62	-8.79	-0.38	2.92e-17	Systemic lupus erythematosus;
LGG	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.32	0.58	3.64e-43	Platelet count;
LGG	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.5	0.58	5.94e-44	Mean platelet volume;
LGG	cis	rs6963495	0.745	rs73192153	chr7:105212418	A/T	cg19920283	chr7:105172520	RINT1	0.64	8.24	0.36	1.78e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg27542038	chr10:14027202	FRMD4A	-0.78	-15.55	-0.59	3.6e-44	Adiponectin levels;
LGG	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs9815354	0.638	rs76276404	chr3:41931770	A/G	cg03022575	chr3:42003672	ULK4	0.82	9.5	0.4	1.11e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg27189623	chr16:705930	WDR90	0.4	7.75	0.34	5.72e-14	Height;
LGG	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg00777063	chr17:45855553	NA	-0.32	-6.78	-0.3	3.76e-11	IgG glycosylation;
LGG	cis	rs6430585	0.528	rs3099429	chr2:136655582	T/A	cg07169764	chr2:136633963	MCM6	1.19	21.59	0.71	5.07e-72	Corneal structure;
LGG	cis	rs9354308	0.781	rs9363455	chr6:66547322	T/G	cg07460842	chr6:66804631	NA	-0.46	-7.85	-0.34	2.86e-14	Metabolite levels;
LGG	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg07930552	chr6:133119739	C6orf192	1.09	9.5	0.4	1.13e-19	Type 2 diabetes nephropathy;
LGG	trans	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg02002194	chr4:3960332	NA	-0.45	-7.99	-0.35	1.07e-14	Red cell distribution width;
LGG	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.42	-0.44	5.34e-23	Response to antipsychotic treatment;
LGG	cis	rs472402	0.580	rs4702373	chr5:6633222	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-6.92	-0.31	1.51e-11	Response to amphetamines;
LGG	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg24829409	chr8:58192753	C8orf71	-0.49	-7.47	-0.33	4.06e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg08125733	chr17:73851984	WBP2	0.73	11.46	0.47	6.11e-27	Psoriasis;
LGG	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.62	11.94	0.49	7.87e-29	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.51	0.37	2.48e-16	Schizophrenia;
LGG	cis	rs11644362	0.966	rs1433746	chr16:12992204	T/C	cg08528231	chr16:12997261	SHISA9	-0.36	-7.13	-0.31	3.78e-12	Positive affect;Subjective well-being;
LGG	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg03762349	chr15:79060523	ADAMTS7	0.37	7.95	0.35	1.4e-14	Sudden cardiac arrest;
LGG	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg01420254	chr6:26195488	NA	-0.84	-10.92	-0.45	7.47e-25	Gout;Renal underexcretion gout;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.13	-0.31	3.79e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg06212747	chr3:49208901	KLHDC8B	0.67	11.42	0.47	8.48e-27	Parkinson's disease;
LGG	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg09361094	chr10:834503	NA	0.29	7.79	0.34	4.5e-14	Survival in rectal cancer;
LGG	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg23324259	chr8:82754387	SNX16	-0.46	-7.42	-0.33	5.66e-13	Diastolic blood pressure;
LGG	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg08400814	chr5:56204995	C5orf35	-0.47	-7.62	-0.33	1.46e-13	Initial pursuit acceleration;
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.5	8.95	0.38	8.76e-18	Glycated hemoglobin levels;
LGG	cis	rs1927702	0.706	rs7031840	chr9:16011920	C/T	cg14451791	chr9:16040625	NA	0.28	6.87	0.3	2.14e-11	Body mass index;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13465890	chr3:170372073	NA	0.4	7.46	0.33	4.2e-13	Electrocardiographic conduction measures;
LGG	cis	rs2455799	0.613	rs4685269	chr3:15942354	A/G	cg16303742	chr3:15540471	COLQ	-0.37	-7.25	-0.32	1.71e-12	Mean platelet volume;
LGG	cis	rs7666738	0.544	rs35160902	chr4:98974690	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg07538946	chr5:131705188	SLC22A5	0.64	7.56	0.33	2.21e-13	Rheumatoid arthritis;
LGG	cis	rs9815354	0.812	rs766286	chr3:41838329	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg00080972	chr5:178986291	RUFY1	0.52	8.94	0.38	9.32e-18	Lung cancer;
LGG	cis	rs9815354	0.953	rs1716641	chr3:41921681	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.22	-0.36	2.02e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs72634501	0.568	rs590214	chr1:39612493	A/G	cg18385671	chr1:39797026	MACF1	0.47	10.01	0.42	1.76e-21	HDL cholesterol;
LGG	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.19	-0.36	2.54e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg16662043	chr16:48846231	NA	-0.35	-6.75	-0.3	4.38e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs910187	0.641	rs3818010	chr20:45816562	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.05	-0.39	4.09e-18	Migraine;
LGG	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg10523679	chr1:76189770	ACADM	0.81	13.95	0.54	3.69e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01516580	chr16:19179433	SYT17	0.47	7.1	0.31	4.88e-12	Gut microbiome composition (summer);
LGG	cis	rs6894268	0.762	rs4701139	chr5:179033094	G/A	cg22014891	chr5:179071901	C5orf60	-0.37	-7.36	-0.32	8.29e-13	Eating disorders;
LGG	cis	rs7937612	1.000	rs7117321	chr11:120239051	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.33e-32	Intraocular pressure;
LGG	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.01	-0.35	9.69e-15	HDL cholesterol;
LGG	cis	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg06521331	chr12:34319734	NA	0.41	6.93	0.31	1.46e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg05234568	chr11:5960015	NA	-0.66	-10.56	-0.44	1.63e-23	DNA methylation (variation);
LGG	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07080220	chr10:102295463	HIF1AN	0.67	11.49	0.47	4.64e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.45	-0.33	4.59e-13	Menopause (age at onset);
LGG	cis	rs988958	0.833	rs2424	chr2:42285575	T/A	cg19376973	chr2:42229025	NA	0.51	7.24	0.32	1.87e-12	Hypospadias;
LGG	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg27490568	chr2:178487706	NA	0.81	14.31	0.55	1.02e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg11161011	chr14:65562177	MAX	-0.66	-12.24	-0.49	4.91e-30	Obesity-related traits;
LGG	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-20.68	-0.69	9.28e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.9	0.34	2.03e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg00908189	chr16:619842	PIGQ	0.85	15.64	0.59	1.38e-44	Height;
LGG	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.25	-0.32	1.8e-12	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg02187348	chr16:89574699	SPG7	0.58	9.56	0.41	7.16e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg15145296	chr3:125709740	NA	-0.6	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02475777	chr4:1388615	CRIPAK	0.58	10.54	0.44	2.03e-23	Longevity;
LGG	cis	rs1816752	0.901	rs28600047	chr13:25041108	T/C	cg22771759	chr13:24902376	NA	0.42	7.15	0.32	3.3e-12	Obesity-related traits;
LGG	cis	rs57502260	0.749	rs67446678	chr11:68227466	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-7.47	-0.33	4.05e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs35740288	0.822	rs10520599	chr15:86223097	C/T	cg04173714	chr15:86211321	AKAP13	0.45	7.8	0.34	4.26e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg06623630	chr22:50017776	C22orf34	-0.37	-7.87	-0.34	2.55e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.76	-0.3	4.23e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg13482628	chr17:19912719	NA	0.63	12.45	0.5	6.59e-31	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg21139845	chr12:7053993	C12orf57	-0.44	-6.86	-0.3	2.26e-11	Coronary artery disease;
LGG	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg25174290	chr11:3078921	CARS	0.75	16.09	0.6	1.39e-46	Longevity;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg19500098	chr13:21900506	NA	0.42	8.45	0.37	3.83e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.65	8.67	0.37	7.61e-17	Diabetic retinopathy;
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26617929	chr16:1858877	NA	-0.62	-8.56	-0.37	1.7e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.22e-18	Alzheimer's disease;
LGG	cis	rs12347191	0.500	rs1912998	chr9:100621386	T/C	cg13688889	chr9:100608707	NA	-0.82	-16.07	-0.6	1.65e-46	Orofacial clefts;
LGG	cis	rs926392	0.666	rs35166252	chr20:37695601	C/T	cg16355469	chr20:37678765	NA	0.55	8.69	0.37	6.21e-17	Dialysis-related mortality;
LGG	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	8.61	0.37	1.15e-16	Cognitive test performance;
LGG	cis	rs3820068	0.532	rs74057713	chr1:15944620	G/C	cg05660106	chr1:15850417	CASP9	0.86	17.76	0.64	3.28e-54	Systolic blood pressure;
LGG	cis	rs564799	0.966	rs6441290	chr3:159732892	T/C	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	9.91	0.42	4.16e-21	Longevity;
LGG	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg12011299	chr4:100065546	ADH4	0.41	8.02	0.35	8.94e-15	Smoking initiation;
LGG	cis	rs7172689	0.529	rs17875494	chr15:81587527	C/A	cg11808699	chr15:81528661	IL16	-0.49	-7.13	-0.31	3.91e-12	Inattentive symptoms;
LGG	cis	rs73086581	1.000	rs73086535	chr20:3944150	T/C	cg02187196	chr20:3869020	PANK2	0.84	11.71	0.48	6.16e-28	Response to antidepressants in depression;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21144673	chr22:42017783	PPPDE2;XRCC6	0.43	7.26	0.32	1.7e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg04851639	chr8:1020857	NA	-0.43	-9.01	-0.39	5.63e-18	Schizophrenia;
LGG	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.33	-0.36	9.3e-16	Neuroticism;
LGG	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg25811766	chr13:21894605	NA	-0.59	-7.74	-0.34	6.1e-14	White matter hyperintensity burden;
LGG	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.55	-0.44	1.79e-23	Height;
LGG	cis	rs870825	0.616	rs35818632	chr4:185649661	G/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.12	0.72	1.58e-74	Blood protein levels;
LGG	cis	rs11931598	0.783	rs870660	chr4:7052182	T/C	cg02503808	chr4:7069936	GRPEL1	0.42	6.93	0.31	1.42e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.81	-0.45	1.93e-24	Resting heart rate;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg15242686	chr22:24348715	GSTTP1	0.37	6.83	0.3	2.6e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.05	0.35	7.08e-15	Schizophrenia;
LGG	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg02461776	chr11:598696	PHRF1	0.42	6.87	0.3	2.02e-11	Systemic lupus erythematosus;
LGG	cis	rs910873	0.505	rs6087607	chr20:33197489	A/G	cg12302830	chr20:33297742	TP53INP2	-0.45	-7.1	-0.31	4.81e-12	Melanoma;
LGG	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.62	-0.37	1.07e-16	Platelet distribution width;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	10.44	0.44	4.88e-23	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg05313129	chr8:58192883	C8orf71	-0.81	-12.29	-0.5	3.16e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.92	-0.31	1.54e-11	Neuroticism;
LGG	trans	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.74	-0.34	6.33e-14	Resting heart rate;
LGG	cis	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.16	-0.32	3.17e-12	Small cell lung carcinoma;
LGG	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg06766960	chr11:133703094	NA	-0.51	-10.08	-0.42	9.82e-22	Childhood ear infection;
LGG	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.21	-0.46	5.86e-26	IgG glycosylation;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg03188948	chr7:1209495	NA	0.62	8.23	0.36	1.92e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg15704280	chr7:45808275	SEPT13	0.92	16.49	0.61	2.08e-48	Height;
LGG	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg25237894	chr2:233734115	C2orf82	-0.73	-15.53	-0.59	4.54e-44	Coronary artery disease;
LGG	cis	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs9640161	0.663	rs1916932	chr7:150021644	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.83	-0.59	2.04e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9810089	0.843	rs681783	chr3:136035303	C/T	cg12473912	chr3:136751656	NA	0.41	6.96	0.31	1.19e-11	Gestational age at birth (child effect);
LGG	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.54	-0.56	1.03e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs4671458	0.948	rs72815379	chr2:63600430	C/T	cg17519650	chr2:63277830	OTX1	-0.61	-7.77	-0.34	5.06e-14	Subjective well-being;
LGG	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg02753203	chr1:228287806	NA	-0.63	-11.73	-0.48	5.49e-28	Diastolic blood pressure;
LGG	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.04	0.35	7.69e-15	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg10056627	chr6:42928773	GNMT	-0.26	-7.03	-0.31	7.25e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.73	-0.41	1.74e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs244293	0.700	rs12939352	chr17:53007655	T/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.4	-6.72	-0.3	5.37e-11	Menarche (age at onset);
LGG	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg21775007	chr8:11205619	TDH	0.43	6.89	0.31	1.8e-11	Myopia (pathological);
LGG	cis	rs9358372	0.929	rs9348445	chr6:20810047	T/C	cg13405222	chr6:20811065	CDKAL1	-0.71	-15.71	-0.59	7.03e-45	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg02972257	chr16:68554789	NA	-0.56	-8.48	-0.37	2.97e-16	Ulcerative colitis;
LGG	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.17	-0.32	3e-12	Arsenic metabolism;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00689492	chr4:1303491	MAEA	-0.45	-7.63	-0.33	1.39e-13	Obesity-related traits;
LGG	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-10.55	-0.44	1.82e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2599510	0.811	rs1153121	chr2:32524912	G/A	cg02381751	chr2:32503542	YIPF4	0.5	8.13	0.35	4.05e-15	Interleukin-18 levels;
LGG	cis	rs10267417	0.603	rs13228500	chr7:19939331	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	6.86	0.3	2.19e-11	Night sleep phenotypes;
LGG	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg15596359	chr8:11213517	TDH	0.39	7.96	0.35	1.36e-14	Retinal vascular caliber;
LGG	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.36e-13	HDL cholesterol;
LGG	cis	rs887829	0.570	rs6753569	chr2:234595817	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.19	0.68	1.74e-65	Calcium levels;
LGG	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.06	-0.31	6e-12	Triglycerides;
LGG	cis	rs55871839	0.536	rs10091451	chr8:59814953	A/T	cg07426533	chr8:59803705	TOX	-0.57	-12.56	-0.5	2.47e-31	Pneumonia;
LGG	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg24232236	chr22:38142998	TRIOBP	0.37	7.23	0.32	1.98e-12	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11890956	chr21:40555474	PSMG1	-0.96	-19.49	-0.67	3.07e-62	Cognitive function;
LGG	cis	rs7294478	0.586	rs6487290	chr12:7256077	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.28	-6.94	-0.31	1.36e-11	Neuritic plaque;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg11062466	chr8:58055876	NA	0.62	9.84	0.42	7.26e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3126085	0.877	rs4456098	chr1:152176034	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.83	0.38	2.23e-17	Atopic dermatitis;
LGG	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg24642439	chr20:33292090	TP53INP2	0.82	14.87	0.57	3.61e-41	Coronary artery disease;
LGG	cis	rs112591243	0.685	rs78443123	chr21:47953331	G/T	cg10657630	chr21:48055338	PRMT2	0.87	7.66	0.34	1.11e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs8064024	0.599	rs3185547	chr16:4931100	A/C	cg04440724	chr16:4920505	UBN1	-0.5	-9.94	-0.42	3.17e-21	Cancer;
LGG	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-7.5	-0.33	3.28e-13	Height;
LGG	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg02153584	chr22:29168773	CCDC117	0.58	8.1	0.35	4.91e-15	Lymphocyte counts;
LGG	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg27661571	chr11:113659931	NA	-0.69	-7.59	-0.33	1.82e-13	Height;
LGG	cis	rs701145	0.585	rs357482	chr3:153889855	A/G	cg12800244	chr3:153838788	SGEF	0.8	8.48	0.37	3.07e-16	Coronary artery disease;
LGG	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg19997662	chr15:101784653	CHSY1	0.85	18.22	0.65	2.51e-56	Corneal structure;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg01657329	chr11:68192670	LRP5	-0.57	-10.84	-0.45	1.52e-24	Total body bone mineral density;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg05863683	chr7:1912471	MAD1L1	0.39	7.54	0.33	2.51e-13	Schizophrenia;
LGG	cis	rs2708240	0.905	rs2710108	chr7:147574174	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs745821	0.879	rs17742138	chr18:48144571	C/G	cg18923635	chr18:48083994	NA	-0.41	-7.09	-0.31	5.01e-12	Diastolic blood pressure;
LGG	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.41e-12	Schizophrenia;
LGG	cis	rs10173297	0.686	rs1965733	chr2:3709129	T/C	cg14882966	chr2:3699353	NA	0.58	7.39	0.32	7.07e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1065852	0.526	rs739296	chr22:42389948	A/G	cg15128208	chr22:42549153	NA	-0.43	-7.49	-0.33	3.43e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.45	-0.37	3.85e-16	Neuroticism;
LGG	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.76	0.57	1.06e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg04986931	chr22:39850128	NA	0.41	8.81	0.38	2.55e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	12.83	0.51	1.85e-32	Response to antipsychotic treatment;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Electroencephalogram traits;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.62	-0.33	1.49e-13	Lung cancer;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.91e-17	Lung cancer;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-7.21	-0.32	2.26e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.21	-0.32	2.25e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.36	-0.53	1.2e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg23173402	chr1:227635558	NA	0.57	8.98	0.39	7.02e-18	Major depressive disorder;
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs8078723	1.000	rs8070454	chr17:38160754	C/T	cg17467752	chr17:38218738	THRA	0.74	13.9	0.54	6.07e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg25986240	chr4:9926439	SLC2A9	0.49	10.68	0.44	5.74e-24	Bone mineral density;
LGG	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg09222892	chr1:25734099	RHCE	0.45	9.43	0.4	1.99e-19	Erythrocyte sedimentation rate;
LGG	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-10.2	-0.43	3.54e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg09307838	chr4:120376055	NA	-0.82	-13.78	-0.54	1.89e-36	Corneal astigmatism;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg00405596	chr8:11794950	NA	-0.41	-6.72	-0.3	5.44e-11	Neuroticism;
LGG	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.43	-0.33	5.23e-13	Testicular germ cell tumor;
LGG	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.75	0.41	1.49e-20	Ovarian reserve;
LGG	trans	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg17712092	chr4:129076599	LARP1B	-0.73	-14.04	-0.55	1.44e-37	Eosinophil percentage of white cells;
LGG	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.86	0.34	2.72e-14	Mood instability;
LGG	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg13073564	chr4:8508604	NA	0.59	11.72	0.48	6e-28	Response to antineoplastic agents;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27108047	chr17:73257286	GGA3;MRPS7	-0.47	-7.99	-0.35	1.12e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.01	-0.31	8.71e-12	Joint mobility (Beighton score);
LGG	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg00198680	chr16:28758506	NA	0.28	6.96	0.31	1.21e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg03605463	chr16:89740564	NA	0.42	7.01	0.31	8.65e-12	Vitiligo;
LGG	trans	rs9354308	0.764	rs9342516	chr6:66602580	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg02227867	chr8:22457446	C8orf58	-0.43	-8.11	-0.35	4.59e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2033908	0.620	rs1992334	chr11:12851645	C/T	cg25843174	chr11:12811716	TEAD1	-0.34	-7.2	-0.32	2.44e-12	Sitting height ratio;
LGG	cis	rs910187	0.624	rs6066219	chr20:45793967	A/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.66	-0.34	1.07e-13	Migraine;
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.3	5.18e-11	Aortic root size;
LGG	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg15269541	chr15:43626905	ADAL	-0.45	-6.78	-0.3	3.61e-11	Lung cancer in ever smokers;
LGG	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	12.28	0.5	3.5e-30	Neutrophil percentage of white cells;
LGG	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.36	-0.72	1.17e-75	Primary sclerosing cholangitis;
LGG	cis	rs12210905	1.000	rs12192049	chr6:27056739	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	trans	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg10756647	chr7:56101905	PSPH	0.74	8.62	0.37	1.05e-16	Diabetic kidney disease;
LGG	cis	rs11064837	0.523	rs11064873	chr12:120104992	A/G	cg25937854	chr12:120150414	CIT	-0.69	-11.45	-0.47	6.98e-27	Schizophrenia;
LGG	cis	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.59	-0.41	5.56e-20	Morning vs. evening chronotype;
LGG	cis	rs9318086	0.712	rs9510916	chr13:24442789	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.52	0.4	9.64e-20	Myopia (pathological);
LGG	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg21972741	chr5:435613	AHRR	0.46	7.88	0.34	2.41e-14	Cystic fibrosis severity;
LGG	cis	rs2688608	0.698	rs2227578	chr10:75678715	C/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.21	-0.32	2.32e-12	Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.51	0.37	2.4e-16	Prudent dietary pattern;
LGG	cis	rs6772849	0.896	rs4857859	chr3:128348014	G/T	cg08795948	chr3:128337044	NA	0.66	11.27	0.46	3.36e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs7017914	0.967	rs17688313	chr8:71683864	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	0.38	6.84	0.3	2.5e-11	Bone mineral density;
LGG	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg08645402	chr16:4508243	NA	0.44	7.19	0.32	2.57e-12	Schizophrenia;
LGG	cis	rs4819852	0.662	rs2073748	chr22:19968971	G/A	cg07821417	chr22:19972146	ARVCF	0.5	10.79	0.45	2.27e-24	Pulse pressure;
LGG	cis	rs2798269	1.000	rs2761911	chr13:22131801	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg13256891	chr4:100009986	ADH5	0.38	6.71	0.3	5.73e-11	Alcohol dependence;
LGG	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg07148914	chr20:33460835	GGT7	-0.47	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs902774	0.691	rs66534130	chr12:53330595	A/G	cg05393297	chr12:53359155	NA	-0.38	-7.67	-0.34	1.06e-13	Prostate cancer;
LGG	cis	rs7928758	1.000	rs7928758	chr11:134265967	T/G	cg15243474	chr11:134282918	B3GAT1	1.09	14.59	0.56	6.39e-40	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg19223190	chr17:80058835	NA	0.44	8.56	0.37	1.66e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18876405	chr7:65276391	NA	-0.59	-10.7	-0.45	4.94e-24	Aortic root size;
LGG	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8064024	0.590	rs7186142	chr16:4900987	A/G	cg04440724	chr16:4920505	UBN1	-0.56	-12.22	-0.49	6.07e-30	Cancer;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg27597069	chr6:37321822	RNF8	-0.4	-6.93	-0.31	1.4e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	trans	rs9944715	1.000	rs9951624	chr18:43840829	A/G	cg01718231	chr17:29326311	RNF135	-0.42	-6.7	-0.3	6.04e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg11441379	chr12:63026424	NA	0.68	9.52	0.4	9.65e-20	IgG glycosylation;
LGG	cis	rs12618769	0.571	rs72821939	chr2:99138872	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg13902645	chr11:5959945	NA	-0.66	-10.84	-0.45	1.44e-24	DNA methylation (variation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05267963	chr11:63952891	STIP1	0.51	7.51	0.33	3.09e-13	Gut microbiome composition (summer);
LGG	cis	rs926392	0.932	rs6513589	chr20:37686585	A/G	cg16355469	chr20:37678765	NA	0.45	7.37	0.32	7.75e-13	Dialysis-related mortality;
LGG	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg12310025	chr6:25882481	NA	-0.43	-6.87	-0.3	2.07e-11	Iron status biomarkers;
LGG	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg10818794	chr15:86012489	AKAP13	-0.37	-7.97	-0.35	1.29e-14	Interstitial lung disease;
LGG	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	7.83	0.34	3.36e-14	IgG glycosylation;
LGG	cis	rs4732038	1.000	rs3792574	chr7:134254029	C/T	cg06906464	chr7:134288099	NA	-0.5	-12.56	-0.5	2.47e-31	Longevity;
LGG	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-8.85	-0.38	1.87e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11644478	chr21:40555479	PSMG1	0.76	13.79	0.54	1.77e-36	Cognitive function;
LGG	cis	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg21775007	chr8:11205619	TDH	-0.52	-8.58	-0.37	1.45e-16	Triglycerides;
LGG	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.1	-0.35	4.76e-15	Monocyte count;
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg19077165	chr18:44547161	KATNAL2	0.59	11.0	0.46	3.83e-25	Personality dimensions;
LGG	cis	rs62120679	0.552	rs4807227	chr19:2318180	C/T	cg07474816	chr19:2321113	NA	0.44	7.32	0.32	1.07e-12	Parkinson's disease;
LGG	cis	rs4538187	0.671	rs56904032	chr2:64236488	C/T	cg02541582	chr2:64069798	UGP2	-0.61	-12.85	-0.51	1.61e-32	Systolic blood pressure;
LGG	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs941873	0.900	rs4979861	chr10:81131595	A/G	cg09469691	chr10:81107165	PPIF	0.62	10.79	0.45	2.4e-24	Height;
LGG	cis	rs1127311	0.875	rs9427102	chr1:154586957	A/G	cg11650704	chr1:154556575	ADAR	-0.5	-9.82	-0.42	8.45e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg08499158	chr17:42289980	UBTF	-0.55	-9.37	-0.4	3.22e-19	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs7412746	0.658	rs11589458	chr1:150792616	A/G	cg15448220	chr1:150897856	SETDB1	0.38	7.13	0.31	3.94e-12	Melanoma;
LGG	cis	rs8179	0.645	rs10953072	chr7:92256339	A/C	cg15732164	chr7:92237376	CDK6	-0.49	-9.23	-0.39	9.49e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg05294307	chr14:35346193	BAZ1A	0.54	7.58	0.33	1.96e-13	Psoriasis;
LGG	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg02187348	chr16:89574699	SPG7	0.43	7.04	0.31	7.2e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14159672	chr1:205819179	PM20D1	0.66	13.71	0.54	3.71e-36	Menarche (age at onset);
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg14789911	chr21:47582049	C21orf56	-0.51	-9.1	-0.39	2.6e-18	Testicular germ cell tumor;
LGG	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg06916706	chr16:4465613	CORO7	-0.98	-16.91	-0.62	2.72e-50	Schizophrenia;
LGG	cis	rs679087	1.000	rs302317	chr12:29921443	G/A	cg14258853	chr12:29935411	TMTC1	-0.43	-8.56	-0.37	1.62e-16	Schizophrenia;
LGG	cis	rs7523273	0.565	rs1998539	chr1:207886596	G/A	cg22525895	chr1:207977042	MIR29B2	0.46	8.67	0.37	7.36e-17	Schizophrenia;
LGG	cis	rs2173063	1.000	rs74029114	chr15:93128194	G/T	cg07052004	chr15:93132129	NA	0.66	7.39	0.32	6.87e-13	Subcutaneous adipose tissue;
LGG	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	10.23	0.43	2.89e-22	Breast cancer;
LGG	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21659725	chr3:3221576	CRBN	0.66	12.3	0.5	2.8e-30	Intelligence (multi-trait analysis);
LGG	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	cg15522984	chr1:182991683	LAMC1	0.45	9.04	0.39	4.34e-18	Colorectal cancer;
LGG	cis	rs28830936	1.000	rs28444909	chr15:41953105	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.18	-0.49	8.84e-30	Diastolic blood pressure;
LGG	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.89	-0.38	1.41e-17	Response to antipsychotic treatment;
LGG	cis	rs4690686	0.500	rs17062797	chr4:177262063	G/A	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	13.29	0.53	2.36e-34	Total body bone mineral density;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.87e-14	Life satisfaction;
LGG	cis	rs524281	0.692	rs10791845	chr11:65834340	C/G	cg16950941	chr11:66035639	RAB1B	0.5	8.2	0.36	2.45e-15	Electroencephalogram traits;
LGG	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg06611532	chr13:114900021	NA	0.28	7.03	0.31	7.27e-12	Schizophrenia;
LGG	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg25358565	chr5:93447407	FAM172A	1.29	16.09	0.6	1.34e-46	Diabetic retinopathy;
LGG	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg21055462	chr7:100276975	NA	0.36	7.35	0.32	9.15e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17209837	1.000	rs4148807	chr7:87105812	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-12.06	-0.49	2.69e-29	Gallbladder cancer;
LGG	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg09818912	chr17:20140352	CYTSB	-0.34	-7.95	-0.35	1.42e-14	Schizophrenia;
LGG	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.31	-0.36	1.11e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg11814155	chr7:99998594	ZCWPW1	0.64	9.81	0.41	9.01e-21	Platelet count;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.19	-0.46	6.78e-26	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19034708	chr8:17780168	PCM1	0.46	7.36	0.32	8.22e-13	Cognitive performance;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs4006360	0.535	rs2173202	chr17:39235235	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.52	11.31	0.47	2.42e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs858239	0.541	rs4624924	chr7:23168843	A/C	cg23682824	chr7:23144976	KLHL7	0.42	6.99	0.31	9.56e-12	Cerebrospinal fluid biomarker levels;
LGG	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08862035	chr2:2617432	NA	0.41	6.66	0.3	7.7e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4988958	0.527	rs3771155	chr2:103037826	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg20608306	chr11:116969690	SIK3	0.33	8.81	0.38	2.6e-17	Blood protein levels;
LGG	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18252515	chr7:66147081	NA	-0.41	-6.9	-0.31	1.76e-11	Aortic root size;
LGG	cis	rs55871839	0.708	rs4738730	chr8:59808935	A/T	cg07426533	chr8:59803705	TOX	-0.56	-12.61	-0.51	1.48e-31	Pneumonia;
LGG	cis	rs6586163	0.843	rs7069061	chr10:90754909	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.9	-0.31	1.72e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03264133	chr6:25882463	NA	0.52	9.43	0.4	1.92e-19	Intelligence (multi-trait analysis);
LGG	cis	rs782590	0.837	rs809732	chr2:55914621	T/C	cg18811423	chr2:55921094	PNPT1	0.94	22.87	0.73	4.85e-78	Metabolic syndrome;
LGG	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.72	0.51	5.32e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs55665837	0.583	rs78843135	chr11:14411254	T/G	cg19336497	chr11:14380999	RRAS2	-0.51	-9.97	-0.42	2.41e-21	Vitamin D levels;
LGG	cis	rs77633900	0.772	rs77582696	chr15:76669153	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.39	-0.36	5.81e-16	Non-glioblastoma glioma;Glioma;
LGG	trans	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.51	0.47	4.01e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg14210321	chr2:106509881	NCK2	0.51	8.79	0.38	2.91e-17	Addiction;
LGG	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg05234568	chr11:5960015	NA	-0.76	-12.77	-0.51	3.27e-32	DNA methylation (variation);
LGG	trans	rs7944735	0.508	rs4147730	chr11:47605427	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.77	0.3	4e-11	Intraocular pressure;
LGG	trans	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg06521331	chr12:34319734	NA	-0.53	-9.16	-0.39	1.64e-18	Morning vs. evening chronotype;
LGG	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg08916839	chr5:415575	AHRR	0.99	14.14	0.55	5.35e-38	Fat distribution (HIV);
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs7666738	0.830	rs9995370	chr4:98732145	T/G	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs34734847	1.000	rs56273049	chr12:121156041	A/T	cg21892295	chr12:121157589	UNC119B	-0.47	-8.83	-0.38	2.18e-17	Mean corpuscular volume;
LGG	cis	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg24623649	chr8:11872141	NA	0.33	7.74	0.34	6.17e-14	Monocyte count;
LGG	cis	rs12410462	0.551	rs753541	chr1:227866483	A/G	cg23173402	chr1:227635558	NA	0.35	6.65	0.3	8.38e-11	Major depressive disorder;
LGG	cis	rs7216064	0.906	rs7223643	chr17:65830282	A/G	cg12091567	chr17:66097778	LOC651250	-0.61	-8.83	-0.38	2.19e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6840360	1.000	rs7663045	chr4:152676350	T/C	cg22705602	chr4:152727874	NA	-0.27	-6.78	-0.3	3.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1975974	0.511	rs56047890	chr17:21733405	G/A	cg18423549	chr17:21743878	NA	-0.52	-7.97	-0.35	1.24e-14	Psoriasis;
LGG	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15369054	chr17:80825471	TBCD	0.59	10.93	0.45	6.71e-25	Breast cancer;
LGG	cis	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.19e-26	Morning vs. evening chronotype;
LGG	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-9.43	-0.4	1.92e-19	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23355997	chr17:7154831	DULLARD;C17orf81	0.43	7.03	0.31	7.23e-12	Gut microbiome composition (summer);
LGG	trans	rs6787172	0.702	rs1730042	chr3:157991826	G/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs981844	0.740	rs1020702	chr4:154685712	A/C	cg14289246	chr4:154710475	SFRP2	-0.6	-10.8	-0.45	2.16e-24	Response to statins (LDL cholesterol change);
LGG	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs11945232	1.000	rs4314250	chr4:88340969	A/G	cg23841344	chr4:88312519	HSD17B11	0.51	9.13	0.39	2.19e-18	Intelligence (multi-trait analysis);
LGG	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg04662567	chr6:169592167	NA	-0.89	-12.41	-0.5	1.02e-30	Pulse pressure;
LGG	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.45	-0.37	3.8e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg12708336	chr17:41446283	NA	-0.34	-8.22	-0.36	2.13e-15	Menopause (age at onset);
LGG	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg08344181	chr3:125677491	NA	-0.87	-8.58	-0.37	1.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6594713	0.921	rs35886114	chr5:112724197	C/T	cg12552261	chr5:112820674	MCC	0.51	7.26	0.32	1.63e-12	Brain cytoarchitecture;
LGG	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.76	0.45	3.05e-24	Mean platelet volume;
LGG	cis	rs11676348	0.935	rs4674250	chr2:218977531	G/A	cg00012203	chr2:219082015	ARPC2	-0.49	-8.75	-0.38	3.95e-17	Ulcerative colitis;
LGG	cis	rs11758351	0.500	rs74660303	chr6:26183710	C/T	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.82e-12	Gout;Renal underexcretion gout;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg21545522	chr1:205238299	TMCC2	-0.49	-8.84	-0.38	2.01e-17	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs4727027	0.933	rs2158633	chr7:148832652	C/T	cg23583168	chr7:148888333	NA	-0.89	-17.1	-0.62	3.5e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg08621203	chr6:150244597	RAET1G	-0.48	-7.12	-0.31	4.1e-12	Lung cancer;
LGG	cis	rs7923837	0.650	rs10882098	chr10:94444793	C/T	cg25093409	chr10:94429542	NA	0.52	10.22	0.43	3.05e-22	Body mass index;Multiple sclerosis;
LGG	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg13736514	chr6:26305472	NA	-0.42	-8.46	-0.37	3.61e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.2e-11	Depression;
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	7.5	0.33	3.23e-13	Bipolar disorder;
LGG	cis	rs7143963	0.943	rs11160699	chr14:103252270	G/A	cg23020514	chr14:103360112	TRAF3	0.52	9.5	0.4	1.12e-19	Body mass index;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg23129478	chr18:44337922	ST8SIA5	0.37	7.02	0.31	8.19e-12	Personality dimensions;
LGG	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.24	0.36	1.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11645453	chr3:52864694	ITIH4	0.42	6.96	0.31	1.14e-11	Bipolar disorder;
LGG	cis	rs17092148	1.000	rs6060043	chr20:33364584	C/T	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs9902453	0.765	rs2628167	chr17:28064498	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.24	-0.55	2.1e-38	Coffee consumption (cups per day);
LGG	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.53	0.53	2.14e-35	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-10.84	-0.45	1.43e-24	Reticulocyte count;
LGG	cis	rs9309473	1.000	rs11689392	chr2:73622026	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.6	-0.33	1.71e-13	Metabolite levels;
LGG	cis	rs1018836	0.923	rs12680211	chr8:91633434	C/T	cg16814680	chr8:91681699	NA	-0.81	-14.97	-0.57	1.38e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg02725872	chr8:58115012	NA	-0.88	-11.94	-0.49	7.93e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.76e-44	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11723795	chr14:91975931	SMEK1	-0.38	-7.05	-0.31	6.41e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10743315	0.557	rs17270134	chr12:19367047	G/A	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	9.1	0.39	2.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg13789015	chr9:136890014	NCRNA00094	0.56	10.53	0.44	2.14e-23	Platelet distribution width;
LGG	cis	rs12410462	0.591	rs2644161	chr1:227706319	A/G	cg04117972	chr1:227635322	NA	-0.47	-8.54	-0.37	1.98e-16	Major depressive disorder;
LGG	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	8.98	0.39	6.9e-18	Eosinophil percentage of white cells;
LGG	cis	rs5758659	0.716	rs86669	chr22:42680800	C/T	cg15128208	chr22:42549153	NA	-0.47	-9.47	-0.4	1.46e-19	Cognitive function;
LGG	trans	rs12517041	1.000	rs1428622	chr5:23286204	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.9	-0.45	8.86e-25	Calcium levels;
LGG	cis	rs4950928	0.823	rs946262	chr1:203158229	C/T	cg17014757	chr1:203156097	CHI3L1	0.35	7.18	0.32	2.83e-12	YKL-40 levels;
LGG	cis	rs3780378	1.000	rs10815158	chr9:5112844	G/A	cg02405213	chr9:5042618	JAK2	-0.51	-8.95	-0.38	8.77e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9815354	0.812	rs12186050	chr3:41836879	G/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.43	7.03	0.31	7.44e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19171272	chr22:38449367	NA	-0.55	-10.4	-0.44	6.47e-23	Glioblastoma;Glioma;
LGG	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg06766960	chr11:133703094	NA	0.46	9.23	0.39	9.69e-19	Childhood ear infection;
LGG	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs4006360	0.546	rs6416912	chr17:39253337	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.27	-0.46	3.3e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg12292205	chr6:26970375	C6orf41	-0.75	-14.99	-0.57	1.1e-41	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg03929089	chr4:120376271	NA	-0.93	-19.06	-0.66	3.28e-60	Height;
LGG	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg08807101	chr21:30365312	RNF160	0.91	19.23	0.67	5.3e-61	Dental caries;
LGG	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.29	-0.32	1.34e-12	Uric acid levels;
LGG	cis	rs7077256	0.564	rs2393971	chr10:65173373	G/A	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg24450063	chr1:156163899	SLC25A44	1.02	17.39	0.63	1.75e-52	Testicular germ cell tumor;
LGG	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg16339924	chr4:17578868	LAP3	-0.59	-10.28	-0.43	1.88e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3540	0.960	rs12440447	chr15:91022694	C/G	cg22089800	chr15:90895588	ZNF774	0.51	8.05	0.35	6.93e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs6787172	0.593	rs73170315	chr3:158057601	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.29	-0.32	1.33e-12	Subjective well-being;
LGG	trans	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg11812906	chr14:75593930	NEK9	0.54	10.04	0.42	1.33e-21	Height;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg14926445	chr8:58193284	C8orf71	-0.82	-10.61	-0.44	1.09e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg21724239	chr8:58056113	NA	0.64	9.66	0.41	3.13e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.44e-12	Bipolar disorder;
LGG	cis	rs4664308	0.935	rs6744567	chr2:160933781	C/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-17.95	-0.64	4.34e-55	Idiopathic membranous nephropathy;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03452623	chr4:187889614	NA	-1.04	-29.39	-0.81	6.88e-108	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01104198	chr2:203735673	ICA1L	0.41	7.12	0.31	4.16e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg27488648	chr11:118477034	PHLDB1	0.3	7.24	0.32	1.88e-12	Systemic lupus erythematosus;
LGG	cis	rs9443189	0.570	rs567903	chr6:76327851	C/T	cg01950844	chr6:76311363	SENP6	0.77	10.19	0.43	3.76e-22	Prostate cancer;
LGG	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg00938859	chr5:1591904	SDHAP3	0.9	13.02	0.52	3.2e-33	Breast cancer;
LGG	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg24812749	chr6:127587940	RNF146	0.95	15.51	0.58	5.64e-44	Breast cancer;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	cis	rs1978968	0.640	rs2083882	chr22:18395241	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.42	8.0	0.35	9.93e-15	Presence of antiphospholipid antibodies;
LGG	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.67	-0.44	6.37e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg25664220	chr3:72788482	NA	-0.32	-8.8	-0.38	2.73e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg18681998	chr4:17616180	MED28	0.8	17.52	0.63	4.3e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg26655873	chr3:72818019	SHQ1	-0.37	-7.62	-0.33	1.43e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06850241	chr22:41845214	NA	-0.42	-6.77	-0.3	3.97e-11	Vitiligo;
LGG	cis	rs4924935	0.581	rs8070669	chr17:18774708	A/T	cg26378065	chr17:18585709	ZNF286B	0.53	7.2	0.32	2.47e-12	Pancreatic cancer;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg26174226	chr8:58114915	NA	-0.54	-8.0	-0.35	1.01e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.569	rs1986124	chr7:124641717	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.26	0.32	1.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.75	-0.3	4.48e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4561483	0.582	rs3850997	chr16:12043512	G/T	cg08843971	chr16:11963173	GSPT1	-0.58	-12.63	-0.51	1.27e-31	Testicular germ cell tumor;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26897989	chr16:1907736	C16orf73	-0.83	-13.91	-0.54	5.55e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-12.14	-0.49	1.22e-29	Vitiligo;
LGG	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg00579200	chr11:133705235	NA	-0.55	-10.37	-0.43	8.68e-23	Childhood ear infection;
LGG	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg26150922	chr2:100937072	LONRF2	-0.56	-9.76	-0.41	1.42e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12476592	0.571	rs1031221	chr2:63742810	C/T	cg17519650	chr2:63277830	OTX1	0.45	6.91	0.31	1.64e-11	Childhood ear infection;
LGG	cis	rs8028182	0.636	rs7184046	chr15:75866150	G/C	cg20655648	chr15:75932815	IMP3	0.44	7.26	0.32	1.62e-12	Sudden cardiac arrest;
LGG	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.88	-0.3	1.98e-11	Neuroticism;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08677398	chr8:58056175	NA	0.52	7.9	0.34	2.04e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg21545522	chr1:205238299	TMCC2	0.48	8.51	0.37	2.4e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg06558623	chr16:89946397	TCF25	1.2	13.28	0.53	2.42e-34	Skin colour saturation;
LGG	cis	rs6429082	0.715	rs2131924	chr1:235580928	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.55	-8.98	-0.38	7.07e-18	Adiposity;
LGG	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg06606381	chr12:133084897	FBRSL1	-0.88	-9.31	-0.4	5.28e-19	Depression;
LGG	cis	rs892961	1.000	rs11077907	chr17:75400706	G/A	cg05865280	chr17:75406074	SEPT9	0.42	9.7	0.41	2.18e-20	Airflow obstruction;
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.89	-0.34	2.28e-14	Life satisfaction;
LGG	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.58	0.41	5.83e-20	Height;
LGG	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg06885757	chr1:42089581	HIVEP3	0.56	12.81	0.51	2.21e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg14228332	chr4:119757509	SEC24D	0.98	10.1	0.43	8.01e-22	Cannabis dependence symptom count;
LGG	cis	rs2644899	0.750	rs2604869	chr19:41283693	G/A	cg24958765	chr19:41283667	RAB4B	0.49	7.15	0.32	3.36e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9487094	0.922	rs59056467	chr6:109767931	C/T	cg01125227	chr6:109776195	MICAL1	0.56	9.58	0.41	5.94e-20	Height;
LGG	cis	rs11874712	1.000	rs9961065	chr18:43653327	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.91	-0.45	7.82e-25	Migraine - clinic-based;
LGG	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22496380	chr5:211416	CCDC127	-1.25	-17.76	-0.64	3.25e-54	Breast cancer;
LGG	cis	rs9815354	0.723	rs77572508	chr3:41938044	C/A	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs74781061	0.860	rs2289187	chr15:74744399	C/T	cg02384859	chr15:74862662	ARID3B	-0.35	-7.29	-0.32	1.32e-12	Endometriosis;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg06197492	chr11:2016605	H19	0.5	10.52	0.44	2.36e-23	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4356932	0.967	rs9999755	chr4:76961802	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs6735179	0.641	rs10164792	chr2:1753375	G/A	cg10160682	chr2:1713001	PXDN	-0.52	-8.94	-0.38	9.13e-18	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg21724239	chr8:58056113	NA	0.53	7.62	0.33	1.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.38e-16	Aortic root size;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg10852096	chr15:79043040	NA	-0.26	-7.25	-0.32	1.7e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.16	-0.32	3.17e-12	Small cell lung carcinoma;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.25	0.36	1.64e-15	Obesity-related traits;
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg19635926	chr16:89946313	TCF25	0.77	7.8	0.34	4.07e-14	Skin colour saturation;
LGG	cis	rs36051895	0.594	rs7029244	chr9:5180961	A/C	cg02405213	chr9:5042618	JAK2	-0.76	-14.69	-0.56	2.18e-40	Pediatric autoimmune diseases;
LGG	cis	rs11645898	0.513	rs55741258	chr16:72112480	C/T	cg14768367	chr16:72042858	DHODH	-0.53	-7.74	-0.34	6.46e-14	Blood protein levels;
LGG	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	10.02	0.42	1.55e-21	Response to antipsychotic treatment;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05025164	chr4:1340916	KIAA1530	0.87	17.24	0.63	8.19e-52	Longevity;
LGG	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.0	0.39	6.08e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg07414643	chr4:187882934	NA	-0.53	-10.87	-0.45	1.13e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs76070545	0.551	rs10104521	chr8:104228671	T/C	cg03923813	chr8:104230441	BAALC	-1.2	-13.64	-0.54	7.45e-36	Alzheimer disease and age of onset;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.05	-0.31	6.61e-12	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11162385	chr20:25604740	NANP	0.44	7.33	0.32	1.06e-12	Cognitive performance;
LGG	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-11.12	-0.46	1.23e-25	Coronary artery disease;
LGG	trans	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg05926928	chr17:57297772	GDPD1	-0.55	-9.07	-0.39	3.45e-18	Schizophrenia;
LGG	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg03970086	chr16:88974840	CBFA2T3	0.44	8.88	0.38	1.45e-17	Social autistic-like traits;
LGG	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11644478	chr21:40555479	PSMG1	0.74	12.56	0.5	2.52e-31	Cognitive function;
LGG	trans	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg10756647	chr7:56101905	PSPH	0.82	9.9	0.42	4.37e-21	Diabetic kidney disease;
LGG	cis	rs1595825	0.891	rs1030796	chr2:198674673	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.65	-0.3	8.53e-11	Ulcerative colitis;
LGG	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg06565975	chr8:143823917	SLURP1	-0.54	-13.27	-0.52	2.7e-34	Urinary tract infection frequency;
LGG	cis	rs1021993	0.597	rs4844807	chr1:209511114	T/A	cg24446417	chr1:209558027	NA	-0.69	-10.09	-0.42	8.85e-22	Gut microbiome composition (winter);
LGG	cis	rs6704644	0.651	rs7587876	chr2:234316032	A/G	cg27060346	chr2:234359958	DGKD	-0.62	-7.64	-0.33	1.27e-13	Bilirubin levels;
LGG	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-10.4	-0.44	6.64e-23	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.616	rs7654208	chr4:185648877	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs3820068	0.581	rs3940061	chr1:15941276	C/T	cg05660106	chr1:15850417	CASP9	0.86	17.39	0.63	1.68e-52	Systolic blood pressure;
LGG	cis	rs4788570	0.615	rs6499526	chr16:71648299	C/T	cg06353428	chr16:71660113	MARVELD3	1.26	20.51	0.69	5.45e-67	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.658	rs6925823	chr6:101179273	C/A	cg09795085	chr6:101329169	ASCC3	-0.49	-8.33	-0.36	9.33e-16	Neuroticism;
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.9	-0.31	1.75e-11	Bipolar disorder;
LGG	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg14983838	chr19:29218262	NA	0.72	11.42	0.47	8.83e-27	Methadone dose in opioid dependence;
LGG	cis	rs7267979	1.000	rs4815407	chr20:25341478	G/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.76e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg23625390	chr15:77176239	SCAPER	-0.69	-13.57	-0.53	1.45e-35	Blood metabolite levels;
LGG	cis	rs6546550	0.901	rs6729760	chr2:70161032	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.09	-0.35	5.24e-15	Prevalent atrial fibrillation;
LGG	cis	rs6424115	0.708	rs12748109	chr1:24181177	C/T	cg15997130	chr1:24165203	NA	-0.43	-10.44	-0.44	4.7e-23	Immature fraction of reticulocytes;
LGG	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg16387850	chr1:46982889	NA	-0.31	-7.58	-0.33	1.91e-13	Monobrow;
LGG	cis	rs6964587	0.869	rs7810391	chr7:91520227	G/A	cg17063962	chr7:91808500	NA	-0.41	-7.17	-0.32	3e-12	Breast cancer;
LGG	cis	rs774359	0.871	rs3849941	chr9:27538948	A/G	cg21249376	chr9:27528432	MOBKL2B	-0.39	-7.4	-0.33	6.33e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06634786	chr22:41940651	POLR3H	-0.69	-11.43	-0.47	8.11e-27	Vitiligo;
LGG	cis	rs1983170	0.736	rs11164909	chr1:92002506	T/C	cg25838465	chr1:92012736	NA	0.5	6.75	0.3	4.35e-11	Eosinophil percentage of white cells;
LGG	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.37e-11	Blood metabolite levels;
LGG	cis	rs6984449	0.516	rs4921645	chr8:19303736	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-10.11	-0.43	7.85e-22	Educational attainment;
LGG	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	13.69	0.54	4.83e-36	Hip circumference adjusted for BMI;
LGG	cis	rs2033732	0.706	rs966286	chr8:85068865	C/T	cg05716166	chr8:85095498	RALYL	-0.43	-6.95	-0.31	1.27e-11	Body mass index;
LGG	cis	rs701145	0.585	rs1713810	chr3:153876826	C/T	cg12800244	chr3:153838788	SGEF	-0.67	-7.54	-0.33	2.49e-13	Coronary artery disease;
LGG	cis	rs476633	0.595	rs11857726	chr15:41530359	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.71	-12.56	-0.5	2.33e-31	Glomerular filtration rate (creatinine);
LGG	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg14541582	chr5:601475	NA	-0.69	-10.81	-0.45	1.99e-24	Obesity-related traits;
LGG	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.83	0.3	2.6e-11	Sjögren's syndrome;
LGG	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg14631276	chr8:145163102	KIAA1875	-1.15	-12.49	-0.5	4.7e-31	Blood metabolite levels;
LGG	trans	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-11.55	-0.47	2.71e-27	Brugada syndrome;
LGG	cis	rs3820068	0.705	rs4645992	chr1:15849742	G/T	cg05660106	chr1:15850417	CASP9	1.12	25.6	0.77	1.04e-90	Systolic blood pressure;
LGG	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.73	-0.3	4.9e-11	Retinal vascular caliber;
LGG	cis	rs244731	0.959	rs4976677	chr5:176629546	G/A	cg17509989	chr5:176798049	RGS14	-0.58	-8.26	-0.36	1.49e-15	Urate levels in lean individuals;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg22398616	chr13:53314203	LECT1	-0.44	-7.97	-0.35	1.27e-14	Lewy body disease;
LGG	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.99	0.39	6.14e-18	Motion sickness;
LGG	trans	rs637571	0.726	rs689274	chr11:65665988	A/G	cg17712092	chr4:129076599	LARP1B	-0.86	-18.25	-0.65	1.77e-56	Eosinophil percentage of white cells;
LGG	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.31	0.65	9.53e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.01	0.39	5.22e-18	Motion sickness;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg25338242	chr13:114786047	RASA3	0.4	7.36	0.32	8.45e-13	Schizophrenia;
LGG	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.18	-0.43	4.35e-22	Total body bone mineral density;
LGG	cis	rs1318772	0.932	rs35077609	chr5:112922316	G/C	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.69e-13	F-cell distribution;
LGG	cis	rs6988985	0.678	rs1799998	chr8:143999600	A/G	cg10324643	chr8:143916377	GML	0.45	9.35	0.4	3.87e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.2	0.43	3.67e-22	Iron status biomarkers;
LGG	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.43	7.76	0.34	5.37e-14	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg03570417	chr12:132312461	MMP17	0.41	7.81	0.34	3.92e-14	Migraine;
LGG	cis	rs2692947	0.727	rs749457	chr2:96795944	A/G	cg22654517	chr2:96458247	NA	0.38	8.23	0.36	1.91e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg20821713	chr7:1055600	C7orf50	0.51	8.18	0.36	2.81e-15	Bronchopulmonary dysplasia;
LGG	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.55	0.56	9.04e-40	Colorectal cancer;
LGG	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.79e-14	Iron status biomarkers;
LGG	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.12	-0.31	4.03e-12	Refractive error;
LGG	cis	rs11112613	0.762	rs66754070	chr12:105949779	G/A	cg03607813	chr12:105948248	NA	0.63	11.19	0.46	7.13e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg22907277	chr7:1156413	C7orf50	0.69	8.71	0.38	5.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.11	-0.31	4.47e-12	HDL cholesterol;
LGG	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23598886	chr18:12777645	NA	0.75	10.48	0.44	3.41e-23	Inflammatory skin disease;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg19143629	chr17:61920732	SMARCD2	0.4	6.87	0.3	2.02e-11	Prudent dietary pattern;
LGG	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg03114573	chr12:45410052	DBX2	-0.52	-8.84	-0.38	1.95e-17	Gut microbiome composition (summer);
LGG	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg04490037	chr7:50633773	DDC	0.33	7.34	0.32	9.61e-13	Systemic sclerosis;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21963583	chr11:68658836	MRPL21	0.58	10.01	0.42	1.82e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg14993813	chr1:46806288	NSUN4	-0.54	-8.5	-0.37	2.59e-16	Menopause (age at onset);
LGG	cis	rs11587400	0.656	rs12738051	chr1:115096964	A/G	cg12756093	chr1:115239321	AMPD1	0.38	6.83	0.3	2.65e-11	Autism;
LGG	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.42	-0.36	4.93e-16	Type 2 diabetes;
LGG	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg25019033	chr10:957182	NA	-0.58	-10.89	-0.45	9.43e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.82	0.57	5.81e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg13232821	chr7:50628718	DDC	0.37	7.55	0.33	2.38e-13	Malaria;
LGG	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg24112000	chr20:60950667	NA	-0.36	-7.86	-0.34	2.64e-14	Colorectal cancer;
LGG	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg27129171	chr3:47204927	SETD2	0.78	15.03	0.57	6.87e-42	Colorectal cancer;
LGG	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg08085267	chr17:45401833	C17orf57	0.59	11.75	0.48	4.53e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg00339695	chr16:24857497	SLC5A11	0.41	7.01	0.31	8.66e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg23306229	chr2:178417860	TTC30B	0.73	8.62	0.37	1.03e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs41271951	0.512	rs114222784	chr1:151084781	C/T	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg15501526	chr10:2543763	NA	-0.69	-14.54	-0.56	9.85e-40	Age-related hearing impairment;
LGG	trans	rs7939886	0.920	rs60446066	chr11:56102442	A/G	cg15704280	chr7:45808275	SEPT13	0.8	7.23	0.32	1.97e-12	Myopia (pathological);
LGG	cis	rs10089	1.000	rs59484271	chr5:127503781	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.71	10.72	0.45	4.24e-24	Ileal carcinoids;
LGG	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg24692254	chr21:30365293	RNF160	-0.67	-12.32	-0.5	2.41e-30	Pancreatic cancer;
LGG	cis	rs67366981	0.720	rs4447349	chr14:77685381	G/A	cg22824376	chr14:77648248	TMEM63C	0.89	11.57	0.47	2.21e-27	Obsessive-compulsive symptoms;
LGG	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg02297831	chr4:17616191	MED28	0.5	9.46	0.4	1.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01516881	chr6:292596	DUSP22	-0.7	-11.84	-0.48	1.93e-28	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.23	0.49	5.17e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.9	0.31	1.69e-11	Lung cancer;
LGG	cis	rs4700695	0.719	rs27586	chr5:65445873	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.76	-0.51	3.52e-32	Diastolic blood pressure;
LGG	cis	rs67133203	0.607	rs706801	chr12:51366092	A/G	cg14688905	chr12:51403056	SLC11A2	0.59	10.28	0.43	1.9e-22	Urinary tract infection frequency;
LGG	cis	rs2652834	0.808	rs11071723	chr15:63355275	A/T	cg05507819	chr15:63340323	TPM1	0.6	8.08	0.35	5.72e-15	HDL cholesterol;
LGG	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg19183879	chr15:85880815	NA	-0.64	-13.04	-0.52	2.57e-33	Central corneal thickness;Corneal structure;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.38	-0.36	6.19e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg02466173	chr16:30829666	NA	0.6	11.8	0.48	2.91e-28	Dementia with Lewy bodies;
LGG	cis	rs5771225	0.563	rs1129880	chr22:50694297	A/G	cg08875078	chr22:50639485	SELO	0.47	6.86	0.3	2.21e-11	Late-onset Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg07538946	chr5:131705188	SLC22A5	0.65	7.7	0.34	8.11e-14	Rheumatoid arthritis;
LGG	cis	rs36051895	0.632	rs62541944	chr9:5159318	G/T	cg02405213	chr9:5042618	JAK2	-0.75	-13.72	-0.54	3.41e-36	Pediatric autoimmune diseases;
LGG	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg00198680	chr16:28758506	NA	0.29	7.13	0.31	3.89e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs1059312	0.545	rs7312683	chr12:129280105	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.6	-11.33	-0.47	1.97e-26	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	8.87	0.38	1.56e-17	Obesity-related traits;
LGG	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg11764359	chr7:65958608	NA	0.63	9.77	0.41	1.25e-20	Aortic root size;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	7.02	0.31	7.78e-12	Schizophrenia;
LGG	cis	rs1003719	0.680	rs2187577	chr21:38533341	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.3	-0.58	4.41e-43	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10869376	chr13:41345315	MRPS31	0.56	8.9	0.38	1.23e-17	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.39	0.4	2.71e-19	Life satisfaction;
LGG	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-7.3	-0.32	1.26e-12	Inflammatory bowel disease;
LGG	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17376030	chr22:41985996	PMM1	-0.49	-7.96	-0.35	1.38e-14	Vitiligo;
LGG	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.95e-24	Morning vs. evening chronotype;
LGG	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	10.23	0.43	2.72e-22	Aortic root size;
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg10189774	chr4:17578691	LAP3	0.41	7.45	0.33	4.76e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg02187348	chr16:89574699	SPG7	-0.51	-7.75	-0.34	6.02e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs2040771	0.804	rs7286849	chr22:19223579	C/A	cg02655711	chr22:19163373	SLC25A1	0.47	8.49	0.37	2.91e-16	Metabolite levels (small molecules and protein measures);
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg16586182	chr3:47516702	SCAP	0.57	9.72	0.41	1.88e-20	Birth weight;
LGG	cis	rs9788721	0.836	rs7181486	chr15:78741618	C/T	cg18825076	chr15:78729989	IREB2	0.57	9.46	0.4	1.61e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2290159	0.800	rs9809947	chr3:12655944	T/C	cg23032965	chr3:12705835	RAF1	0.67	9.79	0.41	1.05e-20	Cholesterol, total;
LGG	cis	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg05299278	chr17:33885742	SLFN14	0.43	8.29	0.36	1.26e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg02227867	chr8:22457446	C8orf58	0.4	7.41	0.33	5.95e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg18357526	chr6:26021779	HIST1H4A	0.83	14.86	0.57	3.98e-41	Intelligence (multi-trait analysis);
LGG	cis	rs7726414	1.000	rs115808154	chr5:133464275	A/G	cg13371777	chr5:133582659	NA	-0.67	-7.19	-0.32	2.67e-12	Systemic lupus erythematosus;
LGG	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg12751644	chr20:60527061	NA	-0.3	-7.05	-0.31	6.51e-12	Body mass index;
LGG	cis	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.56	-0.37	1.71e-16	Hip circumference adjusted for BMI;
LGG	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg09640425	chr7:158790006	NA	-0.36	-6.82	-0.3	2.8e-11	Facial morphology (factor 20);
LGG	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg26354017	chr1:205819088	PM20D1	0.45	7.44	0.33	5.08e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg11728900	chr10:13203459	MCM10	0.41	6.72	0.3	5.39e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs75920871	0.623	rs7932655	chr11:116962563	T/A	cg20608306	chr11:116969690	SIK3	-0.34	-8.04	-0.35	7.35e-15	Subjective well-being;
LGG	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg09818912	chr17:20140352	CYTSB	-0.3	-6.93	-0.31	1.43e-11	Schizophrenia;
LGG	cis	rs1018836	0.892	rs11776824	chr8:91553256	T/C	cg16814680	chr8:91681699	NA	-0.72	-12.94	-0.52	6.84e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1124376	1.000	rs73038113	chr3:20139025	T/A	cg05072819	chr3:20081367	KAT2B	0.64	8.53	0.37	2.15e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7523273	0.586	rs2761425	chr1:207894033	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.57	-0.37	1.58e-16	Schizophrenia;
LGG	cis	rs2816316	1.000	rs2984920	chr1:192544795	A/G	cg02586212	chr1:192544902	RGS1	0.45	8.73	0.38	4.48e-17	Celiac disease;
LGG	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg01620082	chr3:125678407	NA	-0.69	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg15028436	chr7:37888078	TXNDC3	0.56	8.72	0.38	5.09e-17	Alzheimer's disease (late onset);
LGG	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg25174290	chr11:3078921	CARS	-0.52	-9.55	-0.41	7.84e-20	Calcium levels;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg06374794	chr16:88002281	BANP	0.45	8.5	0.37	2.6e-16	Menopause (age at onset);
LGG	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg26031613	chr14:104095156	KLC1	-0.61	-9.72	-0.41	1.85e-20	Reticulocyte count;
LGG	cis	rs1570884	0.503	rs7982555	chr13:50111510	G/A	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.71	-0.3	5.65e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.79e-31	Lymphocyte counts;
LGG	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg21605333	chr4:119757512	SEC24D	1.48	15.11	0.57	3.24e-42	Cannabis dependence symptom count;
LGG	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.62	-9.96	-0.42	2.59e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg12011299	chr4:100065546	ADH4	0.41	8.02	0.35	8.94e-15	Smoking initiation;
LGG	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg10224037	chr5:178157518	ZNF354A	0.77	12.63	0.51	1.22e-31	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15861578	chr12:56511939	ZC3H10	0.55	8.68	0.37	6.95e-17	Gut microbiome composition (summer);
LGG	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11764359	chr7:65958608	NA	-0.56	-9.39	-0.4	2.73e-19	Calcium levels;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.31	1.77e-11	Obesity-related traits;
LGG	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg00579200	chr11:133705235	NA	-0.57	-11.06	-0.46	2.25e-25	Childhood ear infection;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg16885296	chr6:26284938	NA	0.38	8.17	0.35	2.99e-15	Educational attainment;
LGG	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs35740288	0.929	rs3858927	chr15:86301616	C/G	cg04173714	chr15:86211321	AKAP13	0.41	7.13	0.31	4e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9902453	0.904	rs7213076	chr17:28419428	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.18	-0.52	6.75e-34	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10721359	chr6:26538456	HMGN4	0.45	6.67	0.3	7.21e-11	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.72e-18	Aortic root size;
LGG	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg17971929	chr21:40555470	PSMG1	-0.69	-12.69	-0.51	7.37e-32	Cognitive function;
LGG	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg10523679	chr1:76189770	ACADM	0.71	10.7	0.45	4.94e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4538187	1.000	rs35002211	chr2:64152855	A/G	cg02541582	chr2:64069798	UGP2	-0.62	-14.25	-0.55	1.85e-38	Systolic blood pressure;
LGG	cis	rs4917300	0.571	rs2029620	chr8:143111294	T/C	cg06573787	chr8:143070187	NA	0.6	10.06	0.42	1.2e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs912057	0.585	rs1745341	chr6:6744990	T/C	cg06612196	chr6:6737390	NA	0.5	10.76	0.45	3.03e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.01	-0.35	9.54e-15	Triglycerides;
LGG	cis	rs4430311	0.723	rs3856231	chr1:243768906	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.5	-0.58	6.18e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10991814	0.920	rs75779763	chr9:94060031	G/A	cg14446406	chr9:93919335	NA	-0.68	-7.89	-0.34	2.22e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01733783	chr9:128003852	HSPA5	0.44	7.74	0.34	6.09e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.47	-0.33	4.16e-13	Systemic lupus erythematosus;
LGG	cis	rs679087	1.000	rs302321	chr12:29928388	A/C	cg14258853	chr12:29935411	TMTC1	0.44	8.86	0.38	1.74e-17	Schizophrenia;
LGG	cis	rs6942756	0.806	rs2718115	chr7:128871532	A/G	cg02491457	chr7:128862824	NA	0.66	12.54	0.5	3.04e-31	White matter hyperintensity burden;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17842157	chr17:42200988	HDAC5	-0.36	-6.7	-0.3	6.04e-11	Brain structure;
LGG	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03713592	chr11:72463424	ARAP1	0.39	7.57	0.33	2.09e-13	Type 2 diabetes;
LGG	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg08400814	chr5:56204995	C5orf35	0.5	7.59	0.33	1.81e-13	Initial pursuit acceleration;
LGG	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	cg15522984	chr1:182991683	LAMC1	-0.43	-8.57	-0.37	1.53e-16	Colorectal cancer;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.57	0.33	2.02e-13	Schizophrenia;
LGG	cis	rs7944584	0.610	rs2596407	chr11:47361838	A/G	cg20307385	chr11:47447363	PSMC3	-0.65	-12.83	-0.51	1.83e-32	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg05552183	chr6:42928497	GNMT	0.44	13.13	0.52	1.11e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7202877	0.706	rs4888393	chr16:75413673	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.2	0.32	2.5e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg16434002	chr17:42200994	HDAC5	-0.54	-10.03	-0.42	1.44e-21	Total body bone mineral density;
LGG	cis	rs7191700	0.509	rs416603	chr16:11364079	A/T	cg00044050	chr16:11439710	C16orf75	-0.52	-8.85	-0.38	1.9e-17	Multiple sclerosis;
LGG	cis	rs3816183	0.597	rs7589931	chr2:42834310	G/A	cg14631114	chr2:43023945	NA	0.34	6.67	0.3	7.51e-11	Hypospadias;
LGG	cis	rs41271473	0.800	rs12133951	chr1:228791179	A/C	cg10167378	chr1:228756711	NA	0.63	8.2	0.36	2.3e-15	Chronic lymphocytic leukemia;
LGG	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg14784868	chr12:69753453	YEATS4	0.7	11.05	0.46	2.42e-25	Response to diuretic therapy;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg18402987	chr7:1209562	NA	0.74	10.89	0.45	9.37e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.13	-0.43	6.67e-22	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-6.99	-0.31	9.65e-12	Schizophrenia;
LGG	cis	rs7582720	1.000	rs6722332	chr2:203745327	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6772849	0.930	rs7639400	chr3:128323356	T/C	cg08795948	chr3:128337044	NA	0.66	10.96	0.45	5.23e-25	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg02951883	chr7:2050386	MAD1L1	0.66	12.24	0.49	4.93e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg01181863	chr3:195395398	SDHAP2	0.59	8.63	0.37	9.65e-17	Red cell distribution width;
LGG	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs55788414	0.932	rs12716908	chr16:81186245	T/C	cg06400318	chr16:81190750	PKD1L2	-0.98	-11.23	-0.46	4.98e-26	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2562456	0.833	rs62110428	chr19:21613656	C/T	cg00806126	chr19:22604979	ZNF98	-0.56	-7.48	-0.33	3.69e-13	Pain;
LGG	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs7077256	0.564	rs12783001	chr10:65091110	A/G	cg02276361	chr10:65351566	REEP3	-0.33	-6.81	-0.3	3.12e-11	Intelligence (multi-trait analysis);
LGG	cis	rs975722	0.543	rs78753764	chr7:117073191	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	8.46	0.37	3.52e-16	Coronary artery disease;
LGG	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg16583315	chr14:65563665	MAX	-0.35	-6.8	-0.3	3.26e-11	Obesity-related traits;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg20309703	chr11:118481025	PHLDB1	-0.55	-10.09	-0.42	9.22e-22	Cholesterol, total;
LGG	cis	rs72827839	0.696	rs77244957	chr17:46325577	T/C	cg02219949	chr17:45927392	SP6	0.52	6.75	0.3	4.31e-11	Ease of getting up in the morning;
LGG	cis	rs6594499	0.872	rs6859041	chr5:110435231	G/A	cg04022379	chr5:110408740	TSLP	0.42	7.7	0.34	8.05e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4731207	0.596	rs7787605	chr7:124659982	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.99	-0.31	9.8e-12	Cutaneous malignant melanoma;
LGG	cis	rs5756391	0.546	rs4820262	chr22:37317109	T/C	cg21209356	chr22:37319042	CSF2RB	0.42	9.53	0.4	8.85e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg00850481	chr1:228891306	NA	-0.51	-8.74	-0.38	4.18e-17	Chronic lymphocytic leukemia;
LGG	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg20026190	chr17:76395443	PGS1	0.57	10.1	0.42	8.26e-22	HDL cholesterol levels;
LGG	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg19131313	chr8:1704013	NA	-0.3	-6.69	-0.3	6.49e-11	Systolic blood pressure;
LGG	cis	rs61931739	0.613	rs4931773	chr12:33749131	G/A	cg06521331	chr12:34319734	NA	-0.38	-6.7	-0.3	6.14e-11	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	0.44	7.5	0.33	3.31e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs867371	0.502	rs7176926	chr15:82538094	A/G	cg00614314	chr15:82944287	LOC80154	0.47	7.9	0.34	2.06e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg19507638	chr5:93509721	C5orf36	-0.41	-6.78	-0.3	3.71e-11	Diabetic retinopathy;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg13047869	chr3:10149882	C3orf24	0.54	9.2	0.39	1.24e-18	Alzheimer's disease;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg24607181	chr17:41446203	NA	-0.29	-6.65	-0.3	8.03e-11	Menopause (age at onset);
LGG	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg15212455	chr7:39170539	POU6F2	0.47	10.76	0.45	3e-24	IgG glycosylation;
LGG	cis	rs12711979	0.509	rs13005405	chr2:3826324	C/T	cg17052675	chr2:3827356	NA	-0.49	-9.64	-0.41	3.79e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs28655083	0.529	rs285023	chr16:77099783	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.93	0.31	1.39e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6764363	0.527	rs13062390	chr3:280054	C/T	cg02057681	chr3:285234	CHL1	-0.43	-7.65	-0.33	1.21e-13	Sudden cardiac arrest;
LGG	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.76	0.41	1.4e-20	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23784313	chr12:15942613	EPS8	0.5	7.58	0.33	1.89e-13	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.740	rs11250077	chr8:10656437	T/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.32	-0.32	1.14e-12	Neuroticism;
LGG	cis	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg13789015	chr9:136890014	NCRNA00094	0.56	10.53	0.44	2.11e-23	Platelet distribution width;
LGG	cis	rs73198271	0.740	rs10105920	chr8:8648737	A/G	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.73	-0.3	5.05e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.36	-0.4	3.49e-19	Mood instability;
LGG	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.96	-0.38	7.72e-18	Response to antipsychotic treatment;
LGG	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	12.72	0.51	5.34e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg14088196	chr11:70211408	PPFIA1	0.95	13.37	0.53	1.01e-34	Coronary artery disease;
LGG	cis	rs4561483	0.549	rs33659	chr16:11963361	A/G	cg08843971	chr16:11963173	GSPT1	-0.59	-14.99	-0.57	1.09e-41	Testicular germ cell tumor;
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg16359550	chr11:109292809	C11orf87	0.67	14.0	0.55	2.3e-37	Schizophrenia;
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg02503808	chr4:7069936	GRPEL1	-0.87	-13.6	-0.53	1.16e-35	Monocyte percentage of white cells;
LGG	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg20302533	chr7:39170763	POU6F2	0.54	13.22	0.52	4.66e-34	IgG glycosylation;
LGG	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg11166453	chr1:247681781	NA	0.66	10.64	0.44	8.62e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9942416	0.660	rs1817869	chr5:74989037	T/C	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg03733263	chr8:22462867	KIAA1967	1.08	26.29	0.77	6.86e-94	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg25214090	chr10:38739885	LOC399744	0.63	11.1	0.46	1.46e-25	Corneal astigmatism;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg03929089	chr4:120376271	NA	-0.56	-9.97	-0.42	2.53e-21	Coronary artery disease;
LGG	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.81	-0.38	2.5e-17	Initial pursuit acceleration;
LGG	cis	rs9354308	0.714	rs1846566	chr6:66615707	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.81	-0.3	3.03e-11	Metabolite levels;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.34	0.58	3.23e-43	Lung cancer;
LGG	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg08198773	chr8:1697536	NA	0.42	7.45	0.33	4.58e-13	Systolic blood pressure;
LGG	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg08847533	chr14:75593920	NEK9	-0.59	-11.17	-0.46	8.35e-26	Height;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg07712598	chr2:242165230	NA	0.41	7.68	0.34	9.6e-14	Body fat percentage;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-8.97	-0.38	7.2e-18	Urate levels;
LGG	cis	rs17301259	0.548	rs2718405	chr7:88402192	C/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.05	-0.31	6.5e-12	Heschl's gyrus morphology;
LGG	cis	rs9460578	0.566	rs9465913	chr6:20830953	A/G	cg13405222	chr6:20811065	CDKAL1	0.76	17.14	0.62	2.47e-51	Breast cancer;
LGG	cis	rs1882538	0.569	rs11562037	chr7:133076885	A/G	cg10665199	chr7:133106180	EXOC4	0.55	9.38	0.4	2.98e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9443189	0.763	rs2748952	chr6:76444360	G/A	cg01950844	chr6:76311363	SENP6	-0.53	-7.03	-0.31	7.45e-12	Prostate cancer;
LGG	cis	rs35160687	0.829	rs13017143	chr2:86466549	C/T	cg10973622	chr2:86423274	IMMT	-0.45	-7.69	-0.34	9.18e-14	Night sleep phenotypes;
LGG	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg03433033	chr1:76189801	ACADM	0.76	13.98	0.54	2.7e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg12708336	chr17:41446283	NA	-0.32	-7.73	-0.34	6.62e-14	Menopause (age at onset);
LGG	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	8.14	0.35	3.65e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg01081584	chr15:40268610	EIF2AK4	-0.93	-9.87	-0.42	5.7e-21	Response to haloperidol in psychosis;
LGG	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	8.54	0.37	1.94e-16	Thyroid stimulating hormone;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07677032	chr17:61819896	STRADA	0.68	12.62	0.51	1.37e-31	Prudent dietary pattern;
LGG	cis	rs368123	1.000	rs393271	chr6:160742239	A/G	cg07349212	chr6:160770346	SLC22A3	-0.33	-6.8	-0.3	3.19e-11	Waist circumference;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	trans	rs9914544	0.505	rs59633160	chr17:18761396	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.58	-0.33	1.88e-13	Educational attainment (years of education);
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.92	-0.42	3.79e-21	Lung cancer;
LGG	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24229701	chr12:130821962	PIWIL1	0.43	7.54	0.33	2.57e-13	Menopause (age at onset);
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg07511668	chr11:68622177	NA	0.5	9.14	0.39	1.92e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg00990874	chr7:1149470	C7orf50	-0.69	-11.27	-0.46	3.25e-26	Bronchopulmonary dysplasia;
LGG	cis	rs10949834	0.504	rs12539781	chr7:73568425	C/T	cg07137043	chr7:73588983	EIF4H	-0.59	-9.23	-0.39	9.84e-19	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg12395012	chr8:11607386	GATA4	0.39	6.8	0.3	3.16e-11	Retinal vascular caliber;
LGG	cis	rs6594713	0.837	rs13181732	chr5:112724778	C/T	cg12552261	chr5:112820674	MCC	-0.51	-6.65	-0.3	8.42e-11	Brain cytoarchitecture;
LGG	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22857025	chr5:266934	NA	-0.99	-9.51	-0.4	1.07e-19	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22037798	chr1:231473786	C1orf124;EXOC8	0.47	7.89	0.34	2.28e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg24812749	chr6:127587940	RNF146	0.74	12.2	0.49	6.73e-30	Breast cancer;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.33	0.43	1.18e-22	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg05335186	chr13:53173507	NA	0.53	11.08	0.46	1.84e-25	Lewy body disease;
LGG	cis	rs7572644	0.639	rs3792253	chr2:28002002	T/C	cg27432699	chr2:27873401	GPN1	0.49	7.51	0.33	2.97e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg17376030	chr22:41985996	PMM1	0.51	8.31	0.36	1.03e-15	Vitiligo;
LGG	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.5	-7.82	-0.34	3.6e-14	Menarche (age at onset);
LGG	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg00376283	chr12:123451042	ABCB9	0.62	11.47	0.47	5.84e-27	Platelet count;
LGG	cis	rs701145	0.585	rs357487	chr3:153885199	G/C	cg12800244	chr3:153838788	SGEF	0.8	8.43	0.36	4.57e-16	Coronary artery disease;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg19006130	chr11:118478252	PHLDB1	-0.4	-6.78	-0.3	3.64e-11	Cholesterol, total;
LGG	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg10523679	chr1:76189770	ACADM	0.82	15.43	0.58	1.25e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2798269	0.933	rs2476639	chr13:22137266	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	2.01e-11	PR segment;
LGG	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg22072935	chr14:105399595	NA	0.52	9.66	0.41	3.07e-20	Rheumatoid arthritis;
LGG	cis	rs8054556	0.539	rs12596543	chr16:30029135	A/G	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	2.98e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg02297831	chr4:17616191	MED28	0.48	8.85	0.38	1.94e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611519	0.580	rs7286603	chr22:41440061	T/C	cg03806693	chr22:41940476	POLR3H	-0.49	-8.11	-0.35	4.5e-15	Neuroticism;
LGG	cis	rs7124681	0.546	rs7941399	chr11:47890421	A/T	cg20307385	chr11:47447363	PSMC3	0.57	11.14	0.46	1.05e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs17776563	0.887	rs11631086	chr15:89137185	G/A	cg05013243	chr15:89149849	MIR1179	-0.5	-10.28	-0.43	1.88e-22	Thyroid hormone levels;
LGG	cis	rs4919044	0.599	rs17378057	chr10:94703333	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.26	-0.32	1.65e-12	Coronary artery disease;
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg16434002	chr17:42200994	HDAC5	-0.56	-10.31	-0.43	1.46e-22	Total body bone mineral density;
LGG	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg24848339	chr3:12840334	CAND2	0.44	10.67	0.44	6.48e-24	QRS complex (12-leadsum);
LGG	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24110177	chr3:50126178	RBM5	-0.56	-10.21	-0.43	3.35e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	0.626	rs68009402	chr7:91516226	G/A	cg17063962	chr7:91808500	NA	-0.44	-7.98	-0.35	1.14e-14	Breast cancer;
LGG	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs12220238	0.915	rs11000948	chr10:76031721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.67	-8.62	-0.37	1.11e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1707322	0.662	rs11211160	chr1:46146229	T/A	cg03146154	chr1:46216737	IPP	0.55	10.49	0.44	3.19e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs708547	0.647	rs6843644	chr4:57891239	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	8.6	0.37	1.2e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg18446336	chr7:2847575	GNA12	-0.28	-6.7	-0.3	6.1e-11	Height;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.18	0.32	2.81e-12	Life satisfaction;
LGG	trans	rs56804039	1.000	rs34154295	chr8:8383477	C/T	cg02002194	chr4:3960332	NA	0.44	6.99	0.31	9.54e-12	Cervical cancer;
LGG	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.38	-0.43	7.79e-23	Subjective well-being;
LGG	cis	rs2073300	0.609	rs79250740	chr20:23417165	G/A	cg12062639	chr20:23401060	NAPB	0.92	8.71	0.38	5.57e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg20848291	chr7:100343083	ZAN	-0.6	-9.78	-0.41	1.13e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.43	-0.4	1.96e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg09044154	chr16:88155775	NA	-0.5	-7.54	-0.33	2.55e-13	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05977900	chr3:182512126	ATP11B	0.47	7.3	0.32	1.23e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg26513180	chr16:89883248	FANCA	0.67	7.41	0.33	5.87e-13	Skin colour saturation;
LGG	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.39	0.53	8.87e-35	Bladder cancer;
LGG	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-11.26	-0.46	3.75e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg20026190	chr17:76395443	PGS1	0.44	7.63	0.33	1.38e-13	HDL cholesterol levels;
LGG	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg15485101	chr11:133734466	NA	0.62	10.8	0.45	2.12e-24	Childhood ear infection;
LGG	cis	rs7216064	1.000	rs62084249	chr17:65874998	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs7017914	0.934	rs10504479	chr8:71577515	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg27121462	chr16:89883253	FANCA	0.62	11.57	0.47	2.22e-27	Vitiligo;
LGG	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg07636037	chr3:49044803	WDR6	0.9	16.29	0.6	1.68e-47	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6028335	0.610	rs16987687	chr20:37566737	T/C	cg16355469	chr20:37678765	NA	0.54	7.23	0.32	2.07e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs537930	0.734	rs39599	chr5:134364102	C/T	cg24576358	chr5:134350122	NA	0.36	6.84	0.3	2.49e-11	Height;
LGG	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.23	-0.36	1.86e-15	Monocyte count;
LGG	cis	rs3790455	0.610	rs1185700	chr1:156450719	G/A	cg14087168	chr1:156450669	MEF2D	-0.66	-10.03	-0.42	1.46e-21	Migraine;
LGG	cis	rs9457247	0.967	rs2757054	chr6:167380501	A/G	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs3741151	0.773	rs73546720	chr11:73252409	C/T	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	12.98	0.52	4.5e-33	Lung cancer in ever smokers;
LGG	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.85	-0.71	2.96e-73	Height;
LGG	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg09307838	chr4:120376055	NA	-0.87	-14.46	-0.56	2.19e-39	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs972578	0.967	rs2038059	chr22:43334398	T/G	cg01576275	chr22:43409880	NA	-0.23	-6.69	-0.3	6.48e-11	Mean platelet volume;
LGG	cis	rs920590	0.796	rs10888170	chr8:19635328	C/T	cg03894339	chr8:19674705	INTS10	0.52	8.29	0.36	1.23e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	9.09	0.39	2.95e-18	Personality dimensions;
LGG	cis	rs2131877	0.956	rs2279634	chr3:194868944	G/T	cg07250128	chr3:194833983	C3orf21	0.41	7.59	0.33	1.83e-13	Non-small cell lung cancer;
LGG	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.17	0.35	2.97e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg01280390	chr8:19363452	CSGALNACT1	0.6	16.66	0.61	3.65e-49	Oropharynx cancer;
LGG	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.86	0.38	1.71e-17	Neuroticism;
LGG	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.17	-0.32	3.02e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs806321	0.534	rs1269274	chr13:50895638	A/T	cg10393508	chr13:50950265	NA	-0.33	-8.5	-0.37	2.72e-16	Multiple sclerosis;
LGG	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg19847130	chr8:10466454	RP1L1	0.32	6.75	0.3	4.55e-11	Neuroticism;
LGG	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg17376030	chr22:41985996	PMM1	0.41	6.7	0.3	6.21e-11	Vitiligo;
LGG	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg18357526	chr6:26021779	HIST1H4A	0.79	15.05	0.57	5.8e-42	Intelligence (multi-trait analysis);
LGG	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg26446133	chr18:72167187	CNDP2	-0.45	-6.94	-0.31	1.34e-11	Refractive error;
LGG	cis	rs7191439	0.589	rs12709104	chr16:88757940	G/A	cg02389323	chr16:88786976	FAM38A	0.73	8.0	0.35	1.03e-14	Plateletcrit;
LGG	cis	rs6754311	0.773	rs632632	chr2:136638216	A/G	cg07169764	chr2:136633963	MCM6	0.74	12.51	0.5	3.76e-31	Mosquito bite size;
LGG	cis	rs2066819	1.000	rs77131854	chr12:56664231	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-15.26	-0.58	7.29e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	13.93	0.54	4.46e-37	Hip circumference adjusted for BMI;
LGG	cis	rs2117029	1.000	rs2117029	chr12:49408440	A/T	cg24176009	chr12:49580217	TUBA1A	0.42	7.63	0.33	1.31e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg07959490	chr17:80112427	CCDC57	0.47	9.32	0.4	4.66e-19	Life satisfaction;
LGG	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg23649088	chr2:200775458	C2orf69	0.4	7.0	0.31	8.76e-12	QT interval;
LGG	cis	rs10462794	1.000	rs7728048	chr5:4487664	T/C	cg18482690	chr5:4511582	NA	-0.4	-6.77	-0.3	3.97e-11	DNA methylation (variation);
LGG	cis	rs11170468	0.697	rs7972883	chr12:39433334	G/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.84	-0.3	2.44e-11	Body mass index;
LGG	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.97	0.49	5.85e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg15627072	chr1:2432621	PLCH2	0.39	9.54	0.41	8.33e-20	Ulcerative colitis;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg15704280	chr7:45808275	SEPT13	0.49	7.91	0.35	1.9e-14	HDL cholesterol;
LGG	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg01017244	chr2:74357527	NA	0.45	8.45	0.37	3.69e-16	Gestational age at birth (maternal effect);
LGG	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg20703242	chr1:230279135	GALNT2	0.36	7.48	0.33	3.7e-13	Coronary artery disease;
LGG	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	12.74	0.51	4.45e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.43	-0.33	5.45e-13	Hepatitis;
LGG	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.28	-0.36	1.31e-15	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11249189	chr17:42148592	G6PC3	0.43	7.08	0.31	5.28e-12	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	7.77	0.34	5.15e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs988958	0.527	rs1440098	chr2:42291028	A/G	cg27428208	chr2:42229179	NA	0.37	7.8	0.34	4.19e-14	Hypospadias;
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg12751644	chr20:60527061	NA	-0.44	-9.46	-0.4	1.51e-19	Obesity-related traits;
LGG	cis	rs4538187	0.906	rs6546035	chr2:64092331	C/T	cg19915305	chr2:64069682	UGP2	0.65	14.96	0.57	1.42e-41	Systolic blood pressure;
LGG	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.86	-0.34	2.63e-14	Diabetic retinopathy;
LGG	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg13482628	chr17:19912719	NA	0.53	9.99	0.42	2.09e-21	Schizophrenia;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.8	0.34	4.1e-14	Longevity;
LGG	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.02	0.49	3.74e-29	Prudent dietary pattern;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.77e-14	Personality dimensions;
LGG	cis	rs11209002	0.956	rs2013772	chr1:67581445	A/T	cg02640540	chr1:67518911	SLC35D1	0.46	6.89	0.3	1.86e-11	Crohn's disease;
LGG	cis	rs4727027	0.704	rs12537763	chr7:148903984	G/A	cg23583168	chr7:148888333	NA	-0.94	-19.18	-0.67	8.64e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7909791	0.632	rs3752949	chr10:105670503	A/G	cg11005552	chr10:105648138	OBFC1	0.65	9.56	0.41	6.86e-20	White matter hyperintensity burden;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg05793240	chr7:2802953	GNA12	0.36	8.01	0.35	9.38e-15	Height;
LGG	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg03161606	chr19:29218774	NA	0.53	7.41	0.33	6.25e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02567788	chr10:71992279	PPA1	0.48	7.46	0.33	4.4e-13	Gut microbiome composition (summer);
LGG	cis	rs2288073	0.801	rs2384008	chr2:24373150	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-8.6	-0.37	1.27e-16	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13129662	chr17:48227708	PPP1R9B	0.4	6.75	0.3	4.53e-11	Bipolar disorder;
LGG	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg00647317	chr7:50633725	DDC	0.35	8.51	0.37	2.4e-16	Systemic sclerosis;
LGG	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg21211680	chr2:198530	NA	-1.15	-19.4	-0.67	8.19e-62	Blood protein levels;
LGG	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg18137308	chr11:63775436	MACROD1	0.29	6.89	0.3	1.86e-11	Pulse pressure;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.39	0.58	1.76e-43	Lung cancer;
LGG	cis	rs8179	1.000	rs42031	chr7:92237396	A/T	cg15732164	chr7:92237376	CDK6	-0.7	-12.53	-0.5	3.12e-31	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.28	-0.32	1.44e-12	Mood instability;
LGG	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.22	-0.39	1.04e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9815354	0.812	rs17218441	chr3:41987044	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4679121	0.554	rs16837488	chr3:126166762	T/C	cg05485589	chr3:126194908	ZXDC	-0.92	-6.65	-0.3	8.03e-11	Pursuit maintenance gain;
LGG	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg06421707	chr20:25228305	PYGB	0.5	10.8	0.45	2.15e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10492096	0.947	rs10849482	chr12:6635274	G/A	cg13857086	chr12:6580257	VAMP1	0.51	7.27	0.32	1.5e-12	Hip geometry;
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06850241	chr22:41845214	NA	-0.46	-7.0	-0.31	9.04e-12	Vitiligo;
LGG	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.94	0.38	9.01e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs41271473	0.948	rs72750016	chr1:228816786	G/C	cg00850481	chr1:228891306	NA	-0.48	-7.87	-0.34	2.55e-14	Chronic lymphocytic leukemia;
LGG	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg09137382	chr11:130731461	NA	0.36	6.92	0.31	1.54e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02678909	chr10:111767639	ADD3	-0.41	-7.13	-0.31	3.88e-12	Brain structure;
LGG	cis	rs990171	0.913	rs6543132	chr2:103029410	A/G	cg05295703	chr2:102895712	NA	-0.56	-9.71	-0.41	2.04e-20	Lymphocyte counts;
LGG	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-10.0	-0.42	1.97e-21	Vitiligo;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg06916706	chr16:4465613	CORO7	-0.87	-15.17	-0.58	1.71e-42	Schizophrenia;
LGG	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	Neuroticism;
LGG	cis	rs10463554	0.824	rs60588319	chr5:102324360	G/A	cg23492399	chr5:102201601	PAM	-0.6	-9.16	-0.39	1.73e-18	Parkinson's disease;
LGG	cis	rs755249	0.567	rs66727439	chr1:39711930	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.2	0.32	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.23	-0.36	1.91e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14442939	chr10:27389572	ANKRD26	0.81	13.48	0.53	3.53e-35	Breast cancer;
LGG	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg20476274	chr7:133979776	SLC35B4	-0.73	-14.04	-0.55	1.45e-37	Mean platelet volume;
LGG	cis	rs9354308	0.764	rs9453471	chr6:66598984	A/C	cg07460842	chr6:66804631	NA	0.41	6.95	0.31	1.28e-11	Metabolite levels;
LGG	cis	rs2213920	0.619	rs7857548	chr9:118199365	C/T	cg13918206	chr9:118159781	DEC1	0.63	8.93	0.38	1.01e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg05169160	chr2:178484487	TTC30A	0.35	6.9	0.31	1.69e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg20607798	chr8:58055168	NA	0.67	7.68	0.34	9.84e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	cis	rs17253792	0.822	rs10137340	chr14:56050989	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.54	-0.5	2.89e-31	Putamen volume;
LGG	cis	rs12580194	0.593	rs60220253	chr12:55717410	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.42	-0.4	2.15e-19	Cancer;
LGG	cis	rs6754311	0.513	rs1438304	chr2:136503157	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-13.65	-0.54	6.64e-36	Mosquito bite size;
LGG	cis	rs7215564	0.908	rs4889884	chr17:78664465	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg05791153	chr7:19748676	TWISTNB	0.76	10.1	0.43	7.94e-22	Thyroid stimulating hormone;
LGG	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg15208524	chr1:10270712	KIF1B	0.47	8.09	0.35	5.26e-15	Hepatocellular carcinoma;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg22907277	chr7:1156413	C7orf50	0.85	15.18	0.58	1.6e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1550582	0.547	rs6991998	chr8:135580221	C/A	cg17885191	chr8:135476712	NA	0.59	8.79	0.38	3.05e-17	Educational attainment;
LGG	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg21427119	chr20:30132790	HM13	-0.58	-8.97	-0.38	7.37e-18	Mean corpuscular hemoglobin;
LGG	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg13679303	chr9:96623674	NA	-0.39	-6.99	-0.31	9.38e-12	DNA methylation (variation);
LGG	cis	rs9557207	1.000	rs9805153	chr13:99988631	T/C	cg24509225	chr13:100037070	UBAC2	0.71	12.71	0.51	6.12e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs3126085	0.935	rs3126072	chr1:152279729	C/T	cg26876637	chr1:152193138	HRNR	-0.54	-8.74	-0.38	4.24e-17	Atopic dermatitis;
LGG	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg20608306	chr11:116969690	SIK3	0.41	10.95	0.45	5.8e-25	Subjective well-being;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.65	-0.37	8.59e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg06115741	chr20:33292138	TP53INP2	0.57	8.99	0.39	6.25e-18	Coronary artery disease;
LGG	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.97	-0.52	4.98e-33	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08185661	chr11:7273498	SYT9	0.45	7.43	0.33	5.41e-13	Gut microbiome composition (summer);
LGG	trans	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19847514	chr15:74286884	PML	-0.42	-7.06	-0.31	6.12e-12	Pancreatic cancer;
LGG	cis	rs12724450	0.793	rs11809332	chr1:150317818	A/T	cg03818307	chr1:150480534	ECM1	0.51	7.12	0.31	4.16e-12	Blood protein levels;
LGG	cis	rs9831754	0.756	rs12714468	chr3:78445878	A/T	cg06138941	chr3:78371609	NA	-0.81	-15.64	-0.59	1.45e-44	Calcium levels;
LGG	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg26150922	chr2:100937072	LONRF2	-0.47	-8.54	-0.37	1.98e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.99	-16.64	-0.61	4.68e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.43	-0.4	1.95e-19	Educational attainment;
LGG	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg12924262	chr12:102091054	CHPT1	0.64	12.67	0.51	8.27e-32	Blood protein levels;
LGG	trans	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg02175503	chr12:58329896	NA	0.56	9.51	0.4	1.06e-19	Intelligence (multi-trait analysis);
LGG	cis	rs876084	0.510	rs10096137	chr8:121101910	A/G	cg06265175	chr8:121136014	COL14A1	0.45	9.0	0.39	5.9e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06634786	chr22:41940651	POLR3H	-0.74	-12.38	-0.5	1.38e-30	Vitiligo;
LGG	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.62	-0.33	1.43e-13	Lung cancer in ever smokers;
LGG	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.83	0.38	2.25e-17	Vitiligo;
LGG	cis	rs13102973	0.931	rs13134190	chr4:135854932	T/C	cg14419869	chr4:135874104	NA	0.57	10.87	0.45	1.11e-24	Subjective well-being;
LGG	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg24253500	chr15:84953950	NA	-0.61	-11.31	-0.47	2.33e-26	Schizophrenia;
LGG	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.42	0.44	5.63e-23	Diabetic retinopathy;
LGG	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg18196295	chr10:418757	DIP2C	0.6	11.92	0.48	9.22e-29	Psychosis in Alzheimer's disease;
LGG	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg02151108	chr14:50098012	C14orf104	-0.42	-8.99	-0.39	6.32e-18	Carotid intima media thickness;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg03528353	chr17:61819722	STRADA	0.44	7.38	0.32	7.58e-13	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.28	0.32	1.44e-12	Menopause (age at onset);
LGG	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg03733263	chr8:22462867	KIAA1967	1.13	31.03	0.82	3.64e-115	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg23029597	chr12:123009494	RSRC2	-0.94	-17.17	-0.62	1.76e-51	Body mass index;
LGG	cis	rs12210905	0.841	rs116485609	chr6:26864205	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-7.36	-0.32	8.72e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2070997	0.756	rs3808820	chr9:133726956	A/T	cg13397898	chr9:133768931	QRFP	0.38	7.85	0.34	2.85e-14	Response to amphetamines;
LGG	cis	rs6456156	1.000	rs7761159	chr6:167519907	T/A	cg07741184	chr6:167504864	NA	0.34	7.79	0.34	4.4e-14	Primary biliary cholangitis;
LGG	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg22875332	chr1:76189707	ACADM	0.6	9.65	0.41	3.38e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg03795903	chr2:30669940	LCLAT1	1.01	10.31	0.43	1.45e-22	Midgestational circulating levels of PBDEs (fetal genetic effect);
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	9.49	0.4	1.27e-19	Renal function-related traits (BUN);
LGG	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg08975724	chr8:8085496	FLJ10661	0.46	8.97	0.38	7.2e-18	Mood instability;
LGG	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.87	0.38	1.58e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	12.87	0.51	1.3e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11245990	chr11:68621969	NA	0.45	9.27	0.4	7.01e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg03701759	chr13:99174930	STK24	-0.37	-7.28	-0.32	1.43e-12	Longevity;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg02462569	chr6:150064036	NUP43	0.4	8.69	0.37	6.38e-17	Lung cancer;
LGG	cis	rs7654585	0.782	rs2309288	chr4:25947097	C/A	cg10409131	chr4:25915609	C4orf52	0.5	8.34	0.36	8.62e-16	Obesity-related traits;
LGG	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	cis	rs9487051	1.000	rs1546723	chr6:109625879	G/A	cg21918786	chr6:109611834	NA	-0.39	-7.3	-0.32	1.22e-12	Reticulocyte fraction of red cells;
LGG	cis	rs963731	0.649	rs1454227	chr2:39249328	T/C	cg04010122	chr2:39346883	SOS1	-0.78	-7.41	-0.33	6.03e-13	Corticobasal degeneration;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.4	-0.36	5.53e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg25319279	chr11:5960081	NA	-0.55	-8.55	-0.37	1.79e-16	DNA methylation (variation);
LGG	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.65	-0.3	8.5e-11	Parkinson's disease;
LGG	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-9.32	-0.4	4.81e-19	Menarche (age at onset);
LGG	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg15145296	chr3:125709740	NA	-0.6	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg08392591	chr16:89556376	ANKRD11	0.64	10.29	0.43	1.74e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg03517284	chr6:25882590	NA	-0.41	-7.28	-0.32	1.48e-12	Height;
LGG	trans	rs800082	0.867	rs2717393	chr3:144280290	T/C	cg24215973	chr2:240111563	HDAC4	0.48	8.35	0.36	7.91e-16	Smoking behavior;
LGG	cis	rs4417704	0.551	rs12620108	chr2:241874076	G/A	cg05025159	chr2:241905733	NA	-0.49	-10.03	-0.42	1.44e-21	Joint mobility (Beighton score);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg19656070	chr17:3571978	TMEM93;TAX1BP3	0.42	7.26	0.32	1.63e-12	Body mass index;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	8.8	0.38	2.73e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01823544	chr7:119912693	KCND2	0.41	6.66	0.3	7.69e-11	Schizophrenia;
LGG	cis	rs9358372	1.000	rs9358372	chr6:20812588	C/T	cg13405222	chr6:20811065	CDKAL1	-0.68	-14.97	-0.57	1.31e-41	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg04226714	chr8:49833948	SNAI2	-0.46	-8.09	-0.35	5.42e-15	Life satisfaction;
LGG	cis	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg08112188	chr17:47440006	ZNF652	-0.45	-7.4	-0.33	6.3e-13	Cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15365949	chr3:15141111	ZFYVE20	0.43	6.97	0.31	1.11e-11	Gut microbiome composition (summer);
LGG	cis	rs427394	0.664	rs274697	chr5:6731477	A/C	cg15145174	chr5:6755386	POLS	-0.38	-7.21	-0.32	2.37e-12	Menopause (age at onset);
LGG	cis	rs9487094	0.670	rs11153183	chr6:109817276	T/G	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	6.9e-15	Height;
LGG	cis	rs986417	1.000	rs10142455	chr14:60980963	G/A	cg27398547	chr14:60952738	C14orf39	0.73	7.13	0.31	3.81e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	cis	rs7291412	0.929	rs7289457	chr22:46456603	C/T	cg23564243	chr22:46441127	LOC100271722	-0.4	-6.82	-0.3	2.82e-11	Dupuytren's disease;Subjective well-being;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20593599	chr17:20756118	NA	0.36	6.85	0.3	2.34e-11	Electrocardiographic conduction measures;
LGG	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.93	-14.25	-0.55	1.75e-38	HIV-1 control;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs9463078	0.764	rs10948190	chr6:44942300	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.55	-0.37	1.86e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.73	-0.34	6.56e-14	Testicular germ cell tumor;
LGG	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg26811252	chr16:29126840	RRN3P2	0.77	12.18	0.49	8.3e-30	Menopause (age at onset);
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.44	0.33	4.98e-13	Schizophrenia;
LGG	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg09624528	chr10:1369823	ADARB2	0.68	13.1	0.52	1.36e-33	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9814567	1.000	rs9856693	chr3:134306913	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg03511173	chr18:77590860	NA	0.67	8.46	0.37	3.6e-16	Opioid sensitivity;
LGG	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg27478167	chr7:817139	HEATR2	-0.44	-6.99	-0.31	9.55e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.67	-13.73	-0.54	3.16e-36	IgG glycosylation;
LGG	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.8	0.45	2.1e-24	Body mass index;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs10214930	0.697	rs1554641	chr7:27594687	A/G	cg22168087	chr7:27702803	HIBADH	0.45	6.66	0.3	7.6e-11	Hypospadias;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg06654118	chr4:1303317	MAEA	-0.44	-7.46	-0.33	4.45e-13	Obesity-related traits;
LGG	cis	rs2070488	0.965	rs2300668	chr3:38540541	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.82	-17.47	-0.63	7.44e-53	Electrocardiographic conduction measures;
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg13047869	chr3:10149882	C3orf24	0.56	9.43	0.4	1.99e-19	Alzheimer's disease;
LGG	cis	rs10936602	0.527	rs9882101	chr3:169548655	G/A	cg08193579	chr3:169529701	LRRC34	0.36	7.17	0.32	2.91e-12	Renal cell carcinoma;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg01988459	chr11:68622903	NA	-0.62	-12.43	-0.5	8.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.56	-0.53	1.67e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg13013644	chr5:502571	SLC9A3	-0.36	-7.4	-0.33	6.47e-13	Cystic fibrosis severity;
LGG	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg15627072	chr1:2432621	PLCH2	-0.39	-8.53	-0.37	2.15e-16	Ulcerative colitis;
LGG	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.91	-0.38	1.14e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg09307838	chr4:120376055	NA	0.74	12.4	0.5	1.09e-30	Corneal astigmatism;
LGG	cis	rs7523050	0.643	rs7522324	chr1:109399644	T/C	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg11861562	chr11:117069780	TAGLN	0.26	7.08	0.31	5.34e-12	Blood protein levels;
LGG	cis	rs1519814	0.696	rs7821842	chr8:121033982	C/T	cg22335954	chr8:121166405	COL14A1	-0.48	-8.77	-0.38	3.52e-17	Breast cancer;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg01673284	chr16:4527211	HMOX2	-0.37	-7.34	-0.32	9.73e-13	Schizophrenia;
LGG	trans	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg06521331	chr12:34319734	NA	0.46	8.05	0.35	6.82e-15	Bladder cancer;
LGG	cis	rs2290405	0.532	rs11248050	chr4:854409	T/C	cg24922022	chr4:827675	NA	0.36	7.59	0.33	1.72e-13	Systemic sclerosis;
LGG	cis	rs28374715	0.662	rs28827035	chr15:41492290	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.01	-17.84	-0.64	1.43e-54	Ulcerative colitis;
LGG	cis	rs2302729	0.578	rs10848682	chr12:2771756	C/G	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.58	-0.5	2.08e-31	Sleep quality;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg26338869	chr17:61819248	STRADA	-0.59	-9.78	-0.41	1.17e-20	Prudent dietary pattern;
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg00405596	chr8:11794950	NA	-0.48	-8.12	-0.35	4.24e-15	Retinal vascular caliber;
LGG	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.42	-0.36	4.7e-16	Response to antipsychotic treatment;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02286335	chr10:58121068	ZWINT	0.41	6.91	0.31	1.65e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg13206674	chr6:150067644	NUP43	0.41	8.62	0.37	1.05e-16	Testicular germ cell tumor;
LGG	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	trans	rs1547374	0.694	rs225349	chr21:43776890	C/T	cg09521743	chr10:75415752	SYNPO2L	0.33	7.27	0.32	1.54e-12	Pancreatic cancer;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg15242686	chr22:24348715	GSTTP1	0.56	10.64	0.44	8.77e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3540	0.513	rs2589957	chr15:90903311	A/G	cg22089800	chr15:90895588	ZNF774	0.75	14.01	0.55	1.91e-37	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg00647317	chr7:50633725	DDC	0.36	8.61	0.37	1.15e-16	Body mass index;
LGG	cis	rs981844	0.712	rs4696507	chr4:154753702	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs17221829	0.965	rs72952901	chr11:89457303	A/G	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.58	-0.33	1.93e-13	Anxiety in major depressive disorder;
LGG	cis	rs9715521	0.935	rs34361458	chr4:59838192	C/A	cg11281224	chr4:60001000	NA	-0.43	-7.18	-0.32	2.83e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07974063	chr11:59383409	OSBP	0.48	7.12	0.31	4.1e-12	Gut microbiome composition (summer);
LGG	cis	rs4974559	0.790	rs6850727	chr4:1323273	G/C	cg02980000	chr4:1222292	CTBP1	0.75	10.8	0.45	2.08e-24	Systolic blood pressure;
LGG	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg14703610	chr5:56206110	C5orf35	0.46	8.05	0.35	7e-15	Coronary artery disease;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg23758822	chr17:41437982	NA	0.88	13.18	0.52	6.76e-34	Menopause (age at onset);
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg13282195	chr8:144660772	NAPRT1	0.94	7.34	0.32	9.73e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs72700829	0.593	rs77209899	chr1:150992019	G/A	cg11822372	chr1:151115635	SEMA6C	-0.68	-7.21	-0.32	2.32e-12	Schizophrenia;
LGG	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	5.91e-19	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.69	0.3	6.37e-11	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs55692411	0.517	rs62262106	chr3:49991427	A/G	cg24110177	chr3:50126178	RBM5	-0.51	-7.86	-0.34	2.78e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02759005	chr3:53925912	SELK	0.4	6.66	0.3	7.79e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11245990	chr11:68621969	NA	0.41	8.72	0.38	5.09e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg09021430	chr5:549028	NA	-0.69	-9.65	-0.41	3.44e-20	Obesity-related traits;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs56146971	0.703	rs79190905	chr14:91848149	C/T	cg14409461	chr14:91925021	SMEK1	-0.43	-7.0	-0.31	8.75e-12	Alzheimer disease and age of onset;
LGG	cis	rs478607	0.831	rs61884374	chr11:64388929	A/G	cg19395706	chr11:64412079	NRXN2	0.43	7.15	0.32	3.48e-12	Urate levels;
LGG	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg02227867	chr8:22457446	C8orf58	-0.45	-8.58	-0.37	1.49e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16152813	chr16:30042407	FAM57B	0.58	9.56	0.41	6.88e-20	Gut microbiome composition (summer);
LGG	cis	rs1568889	1.000	rs12808162	chr11:28067027	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.14	0.58	2.33e-42	Bipolar disorder;
LGG	cis	rs7582720	1.000	rs72936348	chr2:204064839	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.42	0.4	2.21e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg18761221	chr20:60518478	NA	-0.41	-6.73	-0.3	4.98e-11	Body mass index;
LGG	cis	rs4006360	0.610	rs4986661	chr17:39250448	C/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.37	-0.36	6.89e-16	Mean corpuscular volume;
LGG	trans	rs6787172	0.728	rs827134	chr3:158069197	C/G	cg23275840	chr4:47708675	CORIN	0.4	8.47	0.37	3.35e-16	Subjective well-being;
LGG	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	9.02	0.39	4.84e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg25919922	chr13:100150906	NA	-0.71	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg11584989	chr19:19387371	SF4	0.75	12.48	0.5	4.98e-31	Bipolar disorder;
LGG	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.33	0.36	8.92e-16	Monocyte count;
LGG	cis	rs10267417	0.603	rs10277701	chr7:19886762	G/C	cg05791153	chr7:19748676	TWISTNB	0.64	8.28	0.36	1.35e-15	Night sleep phenotypes;
LGG	trans	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-7.01	-0.31	8.26e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg04132472	chr17:19861366	AKAP10	0.26	7.27	0.32	1.5e-12	Schizophrenia;
LGG	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg00405596	chr8:11794950	NA	-0.42	-7.22	-0.32	2.15e-12	Neuroticism;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.21e-13	Personality dimensions;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs9815354	0.680	rs73073262	chr3:42018443	G/T	cg03022575	chr3:42003672	ULK4	0.75	8.18	0.36	2.8e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs763121	0.853	rs2072798	chr22:39148483	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	17.04	0.62	6.93e-51	Menopause (age at onset);
LGG	cis	rs2235573	0.836	rs132928	chr22:38486738	T/C	cg19171272	chr22:38449367	NA	0.45	8.61	0.37	1.18e-16	Glioblastoma;Glioma;
LGG	cis	rs2976388	0.669	rs1836633	chr8:143774592	G/A	cg06565975	chr8:143823917	SLURP1	0.36	8.97	0.38	7.53e-18	Urinary tract infection frequency;
LGG	cis	rs10465746	0.780	rs11163862	chr1:84355418	A/T	cg10977910	chr1:84465055	TTLL7	-0.59	-11.28	-0.46	2.96e-26	Obesity-related traits;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.17e-14	Lung cancer;
LGG	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.77	0.51	3.18e-32	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00023288	chr2:44223284	LRPPRC	0.44	7.04	0.31	7.13e-12	Cognitive performance;
LGG	cis	rs11112613	0.713	rs11112588	chr12:105943801	A/C	cg03607813	chr12:105948248	NA	0.62	10.66	0.44	7.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg08125733	chr17:73851984	WBP2	0.87	9.6	0.41	5.12e-20	Psoriasis;
LGG	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.09	0.35	5.39e-15	Iron status biomarkers;
LGG	cis	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.21	-0.46	5.84e-26	Morning vs. evening chronotype;
LGG	cis	rs2540226	0.539	rs6707177	chr2:39918915	A/G	cg02886589	chr2:39892450	TMEM178	0.3	8.26	0.36	1.51e-15	Personality dimensions;
LGG	cis	rs7666738	0.791	rs11735105	chr4:98937357	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs67311347	0.544	rs2278929	chr3:40351008	C/G	cg13683864	chr3:40499215	RPL14	0.83	16.88	0.62	3.67e-50	Renal cell carcinoma;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-10.67	-0.44	6.39e-24	Prostate cancer;
LGG	cis	rs754423	0.515	rs12433236	chr14:52544615	G/A	cg12071775	chr14:52591786	NA	-0.43	-7.11	-0.31	4.55e-12	Craniofacial microsomia;
LGG	cis	rs45544231	0.569	rs11642645	chr16:52558907	C/A	cg09051775	chr16:52580266	TOX3	-0.41	-6.89	-0.3	1.86e-11	Restless legs syndrome;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg11878867	chr6:150167359	LRP11	-0.37	-7.8	-0.34	4.04e-14	Lung cancer;
LGG	cis	rs9308731	0.787	rs13388990	chr2:111862303	T/C	cg19992207	chr2:111874495	ACOXL	-0.38	-6.75	-0.3	4.37e-11	Chronic lymphocytic leukemia;
LGG	cis	rs35740288	0.787	rs35250181	chr15:86242662	T/G	cg07943548	chr15:86304357	KLHL25	-0.36	-6.99	-0.31	9.69e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg13482628	chr17:19912719	NA	0.52	9.56	0.41	7.14e-20	Schizophrenia;
LGG	cis	rs7666738	0.830	rs13136930	chr4:98937933	A/T	cg05340658	chr4:99064831	C4orf37	0.51	8.52	0.37	2.33e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72781680	0.752	rs72796116	chr2:23913769	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	8.95	0.38	8.84e-18	Lymphocyte counts;
LGG	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg00409905	chr10:38381863	ZNF37A	0.5	7.41	0.33	6.21e-13	Obesity (extreme);
LGG	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg20244327	chr10:3283946	NA	-0.32	-8.53	-0.37	2.17e-16	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs73198271	0.562	rs3827810	chr8:8659040	T/G	cg01851573	chr8:8652454	MFHAS1	0.53	8.47	0.37	3.17e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs968451	0.762	rs5757618	chr22:39724551	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	12.22	0.49	5.77e-30	Primary biliary cholangitis;
LGG	cis	rs10189230	0.868	rs1367242	chr2:222353441	A/G	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.85e-32	Urate levels in lean individuals;
LGG	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg05555928	chr11:63887634	MACROD1	0.43	7.88	0.34	2.32e-14	Platelet count;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs1696756	0.638	rs1290396	chr17:77830767	C/T	cg07923794	chr17:77834237	NA	-0.82	-12.52	-0.5	3.54e-31	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	0.45	7.69	0.34	8.67e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Vitiligo;
LGG	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg04851639	chr8:1020857	NA	-0.43	-9.35	-0.4	3.77e-19	Schizophrenia;
LGG	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.66	-13.87	-0.54	7.9e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.34e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.95	0.38	8.96e-18	Lung cancer;
LGG	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	cis	rs9534288	0.763	rs9534273	chr13:46566988	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.22	-0.52	4.31e-34	Blood protein levels;
LGG	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg05890377	chr2:74357713	NA	0.48	9.69	0.41	2.48e-20	Gestational age at birth (maternal effect);
LGG	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.39	-0.4	2.63e-19	Schizophrenia;
LGG	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.54	-0.37	1.88e-16	Retinal vascular caliber;
LGG	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg15823100	chr22:32027580	PISD	-0.81	-8.97	-0.38	7.63e-18	Age-related hearing impairment;
LGG	trans	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg02002194	chr4:3960332	NA	-0.47	-8.73	-0.38	4.76e-17	Joint mobility (Beighton score);
LGG	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Vitiligo;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg00830817	chr11:109293614	C11orf87	0.41	7.0	0.31	9.08e-12	Schizophrenia;
LGG	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg00319359	chr11:70116639	PPFIA1	0.61	6.84	0.3	2.47e-11	Coronary artery disease;
LGG	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg10840412	chr1:235813424	GNG4	0.51	6.95	0.31	1.22e-11	Bipolar disorder;
LGG	trans	rs11875185	0.510	rs75616291	chr18:55646483	G/A	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg17376030	chr22:41985996	PMM1	-0.49	-8.07	-0.35	6.03e-15	Vitiligo;
LGG	cis	rs4432842	0.802	rs10461439	chr5:57167172	A/C	cg08523694	chr5:57076192	NA	0.5	8.26	0.36	1.52e-15	Birth weight;
LGG	cis	rs9309473	0.583	rs11126397	chr2:73588733	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-8.81	-0.38	2.51e-17	Metabolite levels;
LGG	cis	rs7168592	1.000	rs36082322	chr15:101749641	T/C	cg24254196	chr15:101719523	CHSY1	-0.62	-6.76	-0.3	4.2e-11	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22857025	chr5:266934	NA	-1.5	-24.24	-0.75	2.06e-84	Breast cancer;
LGG	cis	rs2640806	0.505	rs6999279	chr8:97361753	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.17	0.32	2.95e-12	Obesity-related traits;
LGG	cis	rs7582720	0.667	rs114863726	chr2:204158375	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.27	0.4	6.87e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs887829	0.570	rs6736743	chr2:234595950	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.8	-0.3	3.21e-11	Bipolar disorder;
LGG	trans	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.51	10.26	0.43	2.16e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-13.49	-0.53	3.13e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.16	0.32	3.2e-12	Lung cancer;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg16482183	chr6:26056742	HIST1H1C	0.46	7.57	0.33	2.02e-13	Iron status biomarkers;
LGG	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg25237894	chr2:233734115	C2orf82	0.65	12.26	0.5	3.89e-30	Coronary artery disease;
LGG	cis	rs6964587	0.967	rs12531966	chr7:91765840	A/G	cg17063962	chr7:91808500	NA	0.54	9.75	0.41	1.44e-20	Breast cancer;
LGG	cis	rs4356203	0.905	rs536628	chr11:17208092	A/G	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.21	-0.32	2.25e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17140673	chr4:111117400	ELOVL6	0.47	7.34	0.32	9.53e-13	Gut microbiome composition (summer);
LGG	cis	rs1670533	1.000	rs651017	chr4:1091062	A/G	cg27284194	chr4:1044797	NA	0.54	9.79	0.41	1.04e-20	Recombination rate (females);
LGG	cis	rs7072216	0.763	rs45523432	chr10:100167436	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01672886	chr3:133525182	SRPRB	0.37	6.72	0.3	5.24e-11	Obesity-related traits;
LGG	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg05973401	chr12:123451056	ABCB9	0.49	7.53	0.33	2.67e-13	Neutrophil percentage of white cells;
LGG	cis	rs11168618	0.846	rs11168580	chr12:48850424	G/T	cg24011408	chr12:48396354	COL2A1	0.5	8.15	0.35	3.45e-15	Adiponectin levels;
LGG	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.4	-6.65	-0.3	8.08e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg23788917	chr6:8435910	SLC35B3	-0.52	-8.81	-0.38	2.44e-17	Motion sickness;
LGG	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	12.5	0.5	4.16e-31	Lung cancer in ever smokers;
LGG	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg13010199	chr12:38710504	ALG10B	0.46	8.85	0.38	1.89e-17	Morning vs. evening chronotype;
LGG	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg25173405	chr17:45401733	C17orf57	-0.75	-13.39	-0.53	8.72e-35	Glaucoma (primary open-angle);
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	8.71	0.38	5.53e-17	Obesity-related traits;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg05313129	chr8:58192883	C8orf71	-0.65	-9.31	-0.4	5.36e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs139371	0.713	rs139313	chr22:39499575	G/T	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.7	-0.3	6.06e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg17201900	chr20:34330562	RBM39	0.5	6.78	0.3	3.67e-11	Total cholesterol levels;
LGG	trans	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.75	-0.48	4.63e-28	Mean corpuscular volume;
LGG	cis	rs4474465	0.688	rs4944210	chr11:78282878	C/T	cg27205649	chr11:78285834	NARS2	0.6	11.14	0.46	1.04e-25	Alzheimer's disease (survival time);
LGG	cis	rs6121246	0.559	rs6060944	chr20:30372114	G/A	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg27087555	chr16:88793112	FAM38A	-1.44	-18.72	-0.66	1.19e-58	Plateletcrit;
LGG	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg02153584	chr22:29168773	CCDC117	0.6	9.8	0.41	9.73e-21	Lymphocyte counts;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04772025	chr11:68637568	NA	-0.68	-11.89	-0.48	1.18e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17767392	0.670	rs61989245	chr14:71719976	A/G	cg02058870	chr14:72053146	SIPA1L1	0.35	7.37	0.32	7.95e-13	Mitral valve prolapse;
LGG	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	7.91	0.34	1.93e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7727544	0.625	rs4705916	chr5:131407493	C/A	cg07395648	chr5:131743802	NA	-0.39	-8.41	-0.36	4.94e-16	Blood metabolite levels;
LGG	cis	rs763121	0.962	rs138703	chr22:39132748	C/T	cg06022373	chr22:39101656	GTPBP1	0.82	16.27	0.6	2.08e-47	Menopause (age at onset);
LGG	cis	rs4262150	0.672	rs72806795	chr5:152356256	C/A	cg12297329	chr5:152029980	NA	-0.56	-8.76	-0.38	3.66e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15596359	chr8:11213517	TDH	0.42	8.68	0.37	6.71e-17	Retinal vascular caliber;
LGG	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.1	0.31	4.62e-12	Tonsillectomy;
LGG	cis	rs17221829	0.555	rs72969140	chr11:89328303	G/A	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.19	-0.36	2.51e-15	Anxiety in major depressive disorder;
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.52	-8.01	-0.35	9.14e-15	Ankle injury;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.07e-12	Bipolar disorder;
LGG	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg08999081	chr20:33150536	PIGU	0.39	9.72	0.41	1.91e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07067521	chr19:41196729	NUMBL	0.47	7.65	0.33	1.2e-13	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg21775007	chr8:11205619	TDH	0.46	7.7	0.34	8.1e-14	Mood instability;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg04234412	chr22:24373322	LOC391322	-0.71	-14.56	-0.56	8.01e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12379764	chr21:47803548	PCNT	-0.46	-7.93	-0.35	1.69e-14	Testicular germ cell tumor;
LGG	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs75920871	0.623	rs17120244	chr11:116919511	C/T	cg20608306	chr11:116969690	SIK3	-0.3	-6.86	-0.3	2.27e-11	Subjective well-being;
LGG	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg02461776	chr11:598696	PHRF1	0.54	8.61	0.37	1.17e-16	Systemic lupus erythematosus;
LGG	cis	rs9583531	0.891	rs3742182	chr13:111375132	C/T	cg24331049	chr13:111365604	ING1	0.85	11.86	0.48	1.55e-28	Coronary artery disease;
LGG	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg00530320	chr1:46809349	NSUN4	0.45	8.29	0.36	1.27e-15	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.8	-0.3	3.16e-11	Aortic root size;
LGG	cis	rs13064447	0.789	rs55976129	chr3:12762067	T/C	cg23032965	chr3:12705835	RAF1	-0.5	-7.53	-0.33	2.62e-13	Major depression and alcohol dependence;
LGG	cis	rs7945718	0.621	rs4606460	chr11:12687781	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg00543991	chr22:32367038	NA	0.78	8.64	0.37	9.45e-17	Childhood ear infection;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg20308403	chr7:2120281	MAD1L1	0.33	6.96	0.31	1.2e-11	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs2117029	0.523	rs12227296	chr12:49530495	T/A	cg24176009	chr12:49580217	TUBA1A	0.63	12.29	0.5	3.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg26116260	chr4:7069785	GRPEL1	-1.09	-18.28	-0.65	1.41e-56	Monocyte percentage of white cells;
LGG	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg04553112	chr3:125709451	NA	-0.53	-6.67	-0.3	7.49e-11	Blood pressure (smoking interaction);
LGG	cis	rs2991971	0.934	rs11580609	chr1:45975856	C/G	cg24296786	chr1:45957014	TESK2	0.41	7.46	0.33	4.41e-13	High light scatter reticulocyte count;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07677032	chr17:61819896	STRADA	0.68	12.53	0.5	3.08e-31	Prudent dietary pattern;
LGG	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg25173405	chr17:45401733	C17orf57	0.52	8.8	0.38	2.8e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4841097	0.876	rs11774267	chr8:8947722	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.57	-0.37	1.54e-16	Platelet distribution width;
LGG	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg11901034	chr3:128598214	ACAD9	-0.46	-6.95	-0.31	1.25e-11	IgG glycosylation;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.28	-0.43	1.84e-22	Lung cancer;
LGG	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06634786	chr22:41940651	POLR3H	0.76	12.2	0.49	6.91e-30	Vitiligo;
LGG	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg25358565	chr5:93447407	FAM172A	1.39	17.14	0.62	2.41e-51	Diabetic retinopathy;
LGG	cis	rs16976116	0.901	rs62020097	chr15:55491007	A/T	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3767633	0.925	rs4233380	chr1:161892483	A/C	cg09175582	chr1:161736000	ATF6	0.73	8.93	0.38	9.83e-18	IgG glycosylation;
LGG	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg24558204	chr6:135376177	HBS1L	-0.56	-9.49	-0.4	1.2e-19	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg07303275	chr16:75499416	TMEM170A	-0.43	-7.63	-0.33	1.39e-13	Dupuytren's disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07001481	chr17:5389669	DERL2;MIS12	0.4	6.73	0.3	5.02e-11	Bipolar disorder;
LGG	cis	rs73787773	0.644	rs73227498	chr5:111485904	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.63	-7.93	-0.35	1.62e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08645402	chr16:4508243	NA	0.49	8.68	0.37	6.76e-17	Schizophrenia;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.4e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg00631329	chr6:26305371	NA	-0.44	-7.43	-0.33	5.14e-13	Educational attainment;
LGG	cis	rs703842	1.000	rs10877012	chr12:58162085	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	8.03	0.35	8.13e-15	Multiple sclerosis;
LGG	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg15327641	chr2:3715039	ALLC	-0.37	-8.3	-0.36	1.14e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4671458	0.626	rs72821628	chr2:63695036	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-6.97	-0.31	1.07e-11	Subjective well-being;
LGG	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg26655873	chr3:72818019	SHQ1	-0.37	-7.52	-0.33	2.85e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6594713	0.921	rs7725712	chr5:112744642	T/C	cg12552261	chr5:112820674	MCC	0.5	7.18	0.32	2.8e-12	Brain cytoarchitecture;
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg18446336	chr7:2847575	GNA12	-0.28	-7.23	-0.32	1.98e-12	Height;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg00490583	chr16:1843685	IGFALS	-0.42	-7.23	-0.32	2.01e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6976053	0.935	rs7803865	chr7:100505792	C/T	cg03098644	chr7:100410630	EPHB4	0.39	7.09	0.31	5.19e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg21911579	chr5:131705225	SLC22A5	0.7	7.74	0.34	6.13e-14	Rheumatoid arthritis;
LGG	cis	rs79839061	0.656	rs3775126	chr4:886345	C/T	cg07828340	chr4:882639	GAK	0.94	9.98	0.42	2.19e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6430585	0.583	rs79633114	chr2:136586825	C/T	cg07169764	chr2:136633963	MCM6	1.31	26.34	0.77	4.09e-94	Corneal structure;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	9.87	0.42	5.46e-21	Obesity-related traits;
LGG	cis	rs36051895	0.632	rs7047795	chr9:5181467	C/T	cg02405213	chr9:5042618	JAK2	-0.79	-15.48	-0.58	7.7e-44	Pediatric autoimmune diseases;
LGG	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg24848339	chr3:12840334	CAND2	0.38	8.61	0.37	1.18e-16	QRS complex (12-leadsum);
LGG	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.74e-14	Neuroticism;
LGG	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg24397884	chr7:158709396	WDR60	1.11	16.98	0.62	1.21e-50	Height;
LGG	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.61	0.33	1.52e-13	Educational attainment;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg07511668	chr11:68622177	NA	0.5	9.69	0.41	2.45e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.69	0.51	6.91e-32	Obesity-related traits;
LGG	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg09085632	chr11:111637200	PPP2R1B	1.02	20.04	0.68	9.2e-65	Primary sclerosing cholangitis;
LGG	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg02023728	chr11:77925099	USP35	-0.38	-6.78	-0.3	3.67e-11	Alzheimer's disease (survival time);
LGG	cis	rs2074193	0.627	rs61927860	chr12:47770057	A/G	cg02516419	chr12:47771422	NA	0.72	10.64	0.44	8.64e-24	Migraine with aura;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.21e-23	Renal function-related traits (BUN);
LGG	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg03606772	chr1:152487856	CRCT1	0.29	6.83	0.3	2.76e-11	Hair morphology;
LGG	cis	rs9308731	1.000	rs6542334	chr2:111907214	G/A	cg19992207	chr2:111874495	ACOXL	-0.39	-7.24	-0.32	1.83e-12	Chronic lymphocytic leukemia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06008158	chr8:17781352	PCM1	-0.54	-7.98	-0.35	1.15e-14	Systemic lupus erythematosus;
LGG	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg25809561	chr17:30822961	MYO1D	0.4	9.88	0.42	5.29e-21	Schizophrenia;
LGG	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg08999081	chr20:33150536	PIGU	0.31	6.96	0.31	1.17e-11	Coronary artery disease;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg05512869	chr6:112525703	LAMA4	0.33	7.01	0.31	8.6e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.22	-0.36	2.11e-15	Neuroticism;
LGG	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.45	-7.85	-0.34	2.84e-14	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6704644	0.651	rs7597465	chr2:234328182	G/C	cg27060346	chr2:234359958	DGKD	-0.61	-7.52	-0.33	2.97e-13	Bilirubin levels;
LGG	cis	rs11700980	0.636	rs118001912	chr21:30210959	C/A	cg24692254	chr21:30365293	RNF160	-0.61	-7.08	-0.31	5.29e-12	QRS complex (12-leadsum);
LGG	cis	rs5758659	0.633	rs762995	chr22:42672124	A/G	cg15128208	chr22:42549153	NA	-0.48	-9.63	-0.41	3.91e-20	Cognitive function;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg19635926	chr16:89946313	TCF25	0.74	8.16	0.35	3.1e-15	Skin colour saturation;
LGG	cis	rs10262624	1.000	rs2023786	chr7:23915153	G/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs11971779	0.590	rs4732374	chr7:139091453	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs858239	0.601	rs929508	chr7:23166709	C/A	cg23682824	chr7:23144976	KLHL7	0.42	7.04	0.31	6.95e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg10661904	chr17:79619235	PDE6G	-0.51	-10.53	-0.44	2.22e-23	Eye color traits;
LGG	cis	rs2270450	0.650	rs9381475	chr6:46699292	C/T	cg10156739	chr6:46714674	LOC100287718	-0.45	-9.66	-0.41	3.12e-20	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs2562152	0.515	rs2562176	chr16:146487	G/C	cg02949481	chr16:131562	MPG	0.96	11.97	0.49	5.75e-29	Glioblastoma;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14893161	chr1:205819251	PM20D1	0.97	24.56	0.75	7.1e-86	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02664216	chr12:19592651	AEBP2	0.51	8.02	0.35	8.93e-15	Gut microbiome composition (summer);
LGG	cis	rs7412746	0.658	rs4970987	chr1:150949682	T/C	cg15448220	chr1:150897856	SETDB1	0.39	7.08	0.31	5.53e-12	Melanoma;
LGG	cis	rs77303550	1.000	rs217181	chr16:72114002	A/G	cg01557791	chr16:72042693	DHODH	-0.58	-8.76	-0.38	3.58e-17	Metabolite levels (small molecules and protein measures);
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7614311	0.636	rs73117066	chr3:63926236	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-8.07	-0.35	6.32e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	trans	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg08344181	chr3:125677491	NA	-0.53	-6.96	-0.31	1.14e-11	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg26783146	chr16:4423632	VASN;CORO7	-0.34	-6.83	-0.3	2.75e-11	Schizophrenia;
LGG	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg21699342	chr2:239360505	ASB1	0.4	7.75	0.34	5.73e-14	Multiple system atrophy;
LGG	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.93	0.52	7.17e-33	Intelligence (multi-trait analysis);
LGG	cis	rs12505749	0.542	rs12508008	chr4:57353767	G/A	cg07846311	chr4:57371927	ARL9	-0.32	-7.94	-0.35	1.52e-14	Airflow obstruction;
LGG	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	7.95	0.35	1.43e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	12.86	0.51	1.47e-32	Response to antipsychotic treatment;
LGG	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.02	0.39	5.19e-18	Neuroticism;
LGG	cis	rs77972916	0.505	rs6727824	chr2:43528377	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.28	-0.43	1.76e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg04672837	chr16:48644449	N4BP1	-0.55	-9.04	-0.39	4.45e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs12517041	1.000	rs10068478	chr5:23297003	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg15971980	chr6:150254442	NA	-0.44	-8.31	-0.36	1.05e-15	Lung cancer;
LGG	cis	rs3762637	0.943	rs9822345	chr3:122245598	A/G	cg24169773	chr3:122142474	KPNA1	-0.6	-10.17	-0.43	4.44e-22	LDL cholesterol levels;
LGG	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg12310025	chr6:25882481	NA	-0.44	-7.06	-0.31	6.22e-12	Iron status biomarkers;
LGG	cis	rs745821	0.701	rs56367672	chr18:48090299	C/G	cg18923635	chr18:48083994	NA	0.43	7.71	0.34	7.82e-14	Diastolic blood pressure;
LGG	cis	rs4851266	1.000	rs999052	chr2:100836106	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs2236918	0.932	rs2488471	chr1:242019831	T/C	cg17736920	chr1:242011382	EXO1	0.5	8.95	0.38	8.5e-18	Menopause (age at onset);
LGG	cis	rs17039065	0.920	rs72891077	chr4:109470816	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.24e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg10792982	chr14:105748885	BRF1	0.66	13.26	0.52	3.09e-34	Mean platelet volume;Platelet distribution width;
LGG	trans	rs5756813	1.000	rs1074407	chr22:38156183	T/A	cg19894588	chr14:64061835	NA	0.69	12.13	0.49	1.4e-29	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07280387	chr12:120763487	PLA2G1B	-0.46	-6.75	-0.3	4.46e-11	Systemic lupus erythematosus;
LGG	cis	rs6586163	0.934	rs7897395	chr10:90754607	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.9	-0.31	1.72e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg04553112	chr3:125709451	NA	0.53	6.71	0.3	5.81e-11	Blood pressure (smoking interaction);
LGG	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	10.37	0.43	8.15e-23	Mean platelet volume;
LGG	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.63	-0.44	9.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.3	-0.4	5.63e-19	Mood instability;
LGG	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg24825693	chr3:157122686	VEPH1	-0.35	-7.34	-0.32	9.91e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg27129171	chr3:47204927	SETD2	0.83	15.96	0.6	5.28e-46	Colorectal cancer;
LGG	cis	rs67133203	0.808	rs12810700	chr12:51511264	T/C	cg14688905	chr12:51403056	SLC11A2	0.7	10.2	0.43	3.55e-22	Urinary tract infection frequency;
LGG	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-6.66	-0.3	7.69e-11	Huntington's disease progression;
LGG	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg14784868	chr12:69753453	YEATS4	0.76	15.11	0.57	3.12e-42	Blood protein levels;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg14926445	chr8:58193284	C8orf71	-0.72	-8.51	-0.37	2.41e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.54	-6.94	-0.31	1.3e-11	Smoking behavior;
LGG	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg13907859	chr11:120009124	TRIM29	-0.45	-7.94	-0.35	1.57e-14	Stroke (pediatric);
LGG	cis	rs7928758	0.887	rs74622686	chr11:134264227	A/G	cg15243474	chr11:134282918	B3GAT1	1.22	15.98	0.6	4.38e-46	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs36051895	0.664	rs3780372	chr9:5097544	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-15.78	-0.59	3.54e-45	Pediatric autoimmune diseases;
LGG	cis	rs4517514	0.509	rs12276499	chr11:89855565	C/G	cg14505434	chr11:89522851	NA	0.66	8.32	0.36	1.01e-15	Trans fatty acid levels;
LGG	cis	rs6764363	0.609	rs162737	chr3:295097	A/G	cg02057681	chr3:285234	CHL1	0.41	7.79	0.34	4.52e-14	Sudden cardiac arrest;
LGG	cis	rs9297145	0.565	rs6952161	chr7:98733337	A/G	cg05967295	chr7:98741636	SMURF1	0.65	11.82	0.48	2.35e-28	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7188861	0.681	rs8050084	chr16:11407280	G/A	cg01510278	chr16:11456238	NA	-0.28	-6.65	-0.3	8.07e-11	HDL cholesterol;
LGG	cis	rs7617773	0.780	rs34589064	chr3:48339549	G/A	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.79	0.38	2.88e-17	Thyroid stimulating hormone;
LGG	cis	rs9463078	0.547	rs4711798	chr6:44750777	A/G	cg25276700	chr6:44698697	NA	-0.39	-7.87	-0.34	2.55e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg11764359	chr7:65958608	NA	-0.71	-12.52	-0.5	3.41e-31	Aortic root size;
LGG	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg23815491	chr16:72088622	HP	0.5	11.26	0.46	3.58e-26	Fibrinogen levels;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg21724239	chr8:58056113	NA	-0.59	-9.14	-0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg06074448	chr4:187884817	NA	-0.6	-13.75	-0.54	2.52e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6866614	0.608	rs17132288	chr5:131336105	C/T	cg07395648	chr5:131743802	NA	-0.39	-8.47	-0.37	3.22e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg07541023	chr7:19748670	TWISTNB	0.47	7.4	0.33	6.47e-13	Thyroid stimulating hormone;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06651054	chr15:83680015	C15orf40	0.52	7.9	0.34	2e-14	Gut microbiome composition (summer);
LGG	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.78e-101	Cognitive ability;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02228635	chr1:93298093	RPL5	0.48	8.07	0.35	6.12e-15	Cognitive performance;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22433210	chr17:43662623	NA	0.91	14.98	0.57	1.14e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-12.27	-0.5	3.79e-30	Migraine;Coronary artery disease;
LGG	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg07148914	chr20:33460835	GGT7	0.55	9.08	0.39	3.15e-18	Height;
LGG	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg27144592	chr16:783916	NARFL	0.8	14.1	0.55	8.33e-38	Height;
LGG	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg00919237	chr7:87102261	ABCB4	-0.79	-15.91	-0.59	8.87e-46	Gallbladder cancer;
LGG	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg07915516	chr16:377344	AXIN1	-0.28	-6.96	-0.31	1.19e-11	Body mass index;
LGG	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg18473234	chr19:5097819	KDM4B	-0.41	-7.22	-0.32	2.19e-12	Monocyte percentage of white cells;
LGG	cis	rs2075466	0.514	rs77491748	chr16:4889369	C/T	cg04440724	chr16:4920505	UBN1	-0.62	-9.0	-0.39	5.66e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.47	-0.61	2.51e-48	Skin colour saturation;
LGG	cis	rs1562975	0.609	rs62316329	chr4:109419399	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	8.32	0.36	9.69e-16	Height;
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.83	-0.42	7.88e-21	Neuroticism;
LGG	cis	rs35771425	0.564	rs35995968	chr1:211410223	G/A	cg10512769	chr1:211675356	NA	-0.65	-8.2	-0.36	2.39e-15	Educational attainment (years of education);
LGG	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg16662043	chr16:48846231	NA	0.37	7.24	0.32	1.89e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg24110177	chr3:50126178	RBM5	0.4	6.82	0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg06848047	chr4:90757629	SNCA	0.4	7.45	0.33	4.53e-13	Dementia with Lewy bodies;
LGG	cis	rs11877825	0.826	rs9946239	chr18:10567346	A/G	cg07277756	chr18:10589357	NA	-0.55	-10.17	-0.43	4.74e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg26354017	chr1:205819088	PM20D1	0.59	11.49	0.47	4.72e-27	Menarche (age at onset);
LGG	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.63e-34	Corneal astigmatism;
LGG	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg17330251	chr7:94953956	PON1	-0.43	-8.3	-0.36	1.18e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg14416269	chr4:6271139	WFS1	-0.51	-9.24	-0.39	8.7e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17253792	0.822	rs79291233	chr14:56065302	G/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.44e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg15704280	chr7:45808275	SEPT13	0.48	7.97	0.35	1.25e-14	HDL cholesterol;
LGG	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.66	-0.37	8.19e-17	Triglycerides;
LGG	cis	rs1670533	1.000	rs6839931	chr4:1053172	A/G	cg27284194	chr4:1044797	NA	0.54	9.85	0.42	6.81e-21	Recombination rate (females);
LGG	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg22681709	chr2:178499509	PDE11A	-0.45	-6.95	-0.31	1.26e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg06640241	chr16:89574553	SPG7	-0.69	-10.82	-0.45	1.79e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg11366901	chr6:160182831	ACAT2	0.93	14.05	0.55	1.3e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6743226	0.603	rs62186406	chr2:242233456	A/G	cg10021735	chr2:242295487	FARP2	0.4	6.92	0.31	1.48e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs2481665	0.772	rs12730782	chr1:62537265	A/G	cg18591186	chr1:62594603	INADL	-0.52	-10.35	-0.43	1.03e-22	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.98	0.6	4.25e-46	HDL cholesterol levels;
LGG	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg06191203	chr2:152266755	RIF1	-0.43	-7.57	-0.33	2.03e-13	Lung cancer;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg24623649	chr8:11872141	NA	-0.3	-6.9	-0.31	1.76e-11	Neuroticism;
LGG	cis	rs7166081	1.000	rs4352000	chr15:67643705	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.85	-0.3	2.39e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.23	-0.36	1.96e-15	Aortic root size;
LGG	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.48	0.33	3.72e-13	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04553410	chr7:150864885	GBX1	0.44	7.72	0.34	7.31e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.556	rs11774220	chr8:10070148	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.27	0.36	1.48e-15	Neuroticism;
LGG	cis	rs5769707	0.839	rs73176988	chr22:49989649	G/T	cg20744362	chr22:50050164	C22orf34	0.37	7.17	0.32	2.92e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg23782820	chr8:58130467	NA	0.5	6.93	0.31	1.38e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10744422	1.000	rs7972447	chr12:123354545	C/G	cg25930673	chr12:123319894	HIP1R	-0.69	-9.05	-0.39	4e-18	Schizophrenia;
LGG	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg00198680	chr16:28758506	NA	0.28	6.96	0.31	1.21e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1018697	1.000	rs2150928	chr10:104550985	G/A	cg04362960	chr10:104952993	NT5C2	0.49	9.02	0.39	5.16e-18	Colorectal adenoma (advanced);
LGG	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.2	-0.39	1.27e-18	Neuroticism;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.65	11.61	0.47	1.53e-27	Obesity-related traits;
LGG	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.03	-0.55	1.56e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg05692746	chr2:100937584	LONRF2	-0.62	-11.24	-0.46	4.28e-26	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.09e-15	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.72e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg24596788	chr1:163392923	NA	-0.68	-12.79	-0.51	2.63e-32	Motion sickness;
LGG	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg13114125	chr14:105738426	BRF1	-0.85	-16.2	-0.6	4.24e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1878931	0.582	rs9921152	chr16:3421199	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	11.51	0.47	3.86e-27	Body mass index (adult);
LGG	cis	rs9815354	1.000	rs6768563	chr3:41865541	G/A	cg03022575	chr3:42003672	ULK4	0.69	8.77	0.38	3.32e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6450176	0.625	rs16881958	chr5:53288201	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-13.59	-0.53	1.26e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01614864	chr2:61765423	XPO1	0.46	6.95	0.31	1.25e-11	Gut microbiome composition (summer);
LGG	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.12	0.57	2.86e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.0	-0.31	8.93e-12	Schizophrenia;
LGG	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.31e-13	HDL cholesterol;
LGG	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg06611532	chr13:114900021	NA	0.29	7.27	0.32	1.58e-12	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16362983	chr14:50335243	NA	0.44	7.29	0.32	1.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.65	0.34	1.16e-13	Neutrophil percentage of white cells;
LGG	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.31	20.94	0.7	5.47e-69	Hemostatic factors and hematological phenotypes;
LGG	cis	rs11971779	0.648	rs59791374	chr7:139116962	C/T	cg07862535	chr7:139043722	LUC7L2	0.46	7.64	0.33	1.24e-13	Diisocyanate-induced asthma;
LGG	cis	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg06609049	chr19:2785107	THOP1	0.65	10.01	0.42	1.8e-21	Total cholesterol levels;
LGG	cis	rs7909791	0.632	rs11191853	chr10:105657363	C/G	cg11005552	chr10:105648138	OBFC1	0.66	9.45	0.4	1.62e-19	White matter hyperintensity burden;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.88	0.57	3.42e-41	Platelet count;
LGG	cis	rs4380275	0.782	rs11127506	chr2:751300	A/G	cg14072418	chr2:740025	NA	0.36	6.99	0.31	9.77e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00292662	chr22:38071168	LGALS1	0.65	14.78	0.57	9.43e-41	Fat distribution (HIV);
LGG	trans	rs57046232	0.552	rs6054147	chr20:6336002	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.41	-6.82	-0.3	2.78e-11	Colorectal cancer;
LGG	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg15269541	chr15:43626905	ADAL	-0.44	-8.0	-0.35	1.01e-14	Lung cancer in ever smokers;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11220663	chr2:70994863	ADD2	0.4	6.78	0.3	3.63e-11	Bipolar disorder;
LGG	cis	rs7512552	0.839	rs3896342	chr1:150411312	T/C	cg15654264	chr1:150340011	RPRD2	0.46	9.43	0.4	1.92e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg12081754	chr8:22256438	SLC39A14	0.72	13.62	0.53	9.57e-36	Verbal declarative memory;
LGG	cis	rs1420338	0.933	rs6462533	chr7:34168028	G/A	cg01275685	chr7:34179230	BMPER	-0.53	-9.77	-0.41	1.31e-20	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.08	0.31	5.4e-12	Height;
LGG	cis	rs7843479	0.965	rs13278159	chr8:21799737	C/A	cg17168535	chr8:21777572	XPO7	0.61	10.01	0.42	1.75e-21	Mean corpuscular volume;
LGG	cis	rs10760279	0.584	rs10760280	chr9:126112812	A/G	cg14503395	chr9:126128745	CRB2	0.39	6.79	0.3	3.55e-11	Body mass index;
LGG	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg16070123	chr10:51489643	NA	0.4	7.06	0.31	5.99e-12	Prostate-specific antigen levels;
LGG	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.24	0.32	1.92e-12	Morning vs. evening chronotype;
LGG	cis	rs7202877	0.656	rs247427	chr16:75439132	T/C	cg03315344	chr16:75512273	CHST6	-0.52	-6.99	-0.31	9.49e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs10991814	0.925	rs10991809	chr9:93946555	G/A	cg14446406	chr9:93919335	NA	-0.64	-7.73	-0.34	6.65e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg15312298	chr8:127570908	FAM84B	0.43	6.82	0.3	2.81e-11	Mitral valve prolapse;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01956158	chr8:132916947	EFR3A	0.48	7.87	0.34	2.52e-14	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.55	-0.37	1.74e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg12654349	chr5:56205094	C5orf35	0.58	9.92	0.42	3.8e-21	Initial pursuit acceleration;
LGG	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.82	13.44	0.53	5.25e-35	Cognitive test performance;
LGG	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg07777115	chr5:623756	CEP72	-0.56	-7.17	-0.32	2.89e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg22920501	chr2:26401640	FAM59B	-0.39	-7.66	-0.34	1.06e-13	Gut microbiome composition (summer);
LGG	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg17646820	chr3:66848679	NA	0.52	7.9	0.34	2.05e-14	Type 2 diabetes;
LGG	cis	rs7072216	0.763	rs9787550	chr10:100169051	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.7e-12	Metabolite levels;
LGG	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg00631329	chr6:26305371	NA	-0.46	-7.6	-0.33	1.69e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs1864585	0.520	rs73208769	chr8:10665984	A/T	cg26278703	chr11:58910052	FAM111A	0.52	6.81	0.3	3.11e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.7	-0.45	4.96e-24	Vitiligo;
LGG	cis	rs17767392	1.000	rs17767392	chr14:71764777	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg02725872	chr8:58115012	NA	-0.84	-11.77	-0.48	3.75e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs8032158	0.702	rs11632977	chr15:56131609	T/C	cg02198044	chr15:56286336	NEDD4	-0.52	-8.78	-0.38	3.2e-17	Keloid;
LGG	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.7	0.45	4.9299999999999996e-24	Lung cancer in ever smokers;
LGG	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.54	0.41	8.52e-20	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.39	0.32	6.94e-13	Prudent dietary pattern;
LGG	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg09307838	chr4:120376055	NA	0.67	11.56	0.47	2.39e-27	Corneal astigmatism;
LGG	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.09	-0.31	5.16e-12	Restless legs syndrome;
LGG	cis	rs9771228	0.585	rs10269368	chr7:32271514	A/G	cg27532318	chr7:32358331	NA	0.52	7.51	0.33	3.08e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg12923728	chr3:195709715	SDHAP1	0.56	9.55	0.41	7.72e-20	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13369206	chr2:3606108	RNASEH1	0.48	7.34	0.32	9.75e-13	Gut microbiome composition (summer);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16706631	chr6:26204823	HIST1H4E	-0.49	-7.17	-0.32	3.01e-12	Systemic lupus erythematosus;
LGG	cis	rs7444	0.941	rs5754295	chr22:21951740	C/A	cg05046821	chr22:21984468	YDJC	-0.38	-6.9	-0.31	1.77e-11	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.17	-0.32	2.9e-12	Bipolar disorder;
LGG	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	8.35	0.36	8.03e-16	Obesity-related traits;
LGG	trans	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg18335740	chr13:41363409	SLC25A15	-0.59	-11.32	-0.47	2.22e-26	Lewy body disease;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.58	-11.63	-0.48	1.34e-27	IgG glycosylation;
LGG	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg00383909	chr3:49044727	WDR6	0.57	8.07	0.35	6.09e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.75	0.51	3.88e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.79	-0.3	3.45e-11	Total body bone mineral density;
LGG	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.14	0.31	3.52e-12	Retinal vascular caliber;
LGG	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.93	-0.35	1.65e-14	Diabetic retinopathy;
LGG	cis	rs60180747	1.000	rs80326387	chr15:66705043	G/A	cg07575407	chr15:66541975	MEGF11	0.34	6.86	0.3	2.19e-11	Testicular germ cell tumor;
LGG	cis	rs6840360	0.573	rs7692939	chr4:152258455	C/T	cg25486957	chr4:152246857	NA	-0.41	-7.26	-0.32	1.65e-12	Intelligence (multi-trait analysis);
LGG	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg22916017	chr11:64110731	CCDC88B	-0.51	-10.51	-0.44	2.56e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.26	-0.32	1.63e-12	Neuroticism;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.39	0.32	6.77e-13	Menopause (age at onset);
LGG	cis	rs11203032	0.831	rs11203028	chr10:90956550	C/T	cg16672925	chr10:90967113	CH25H	0.8	11.38	0.47	1.23e-26	Heart failure;
LGG	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg06360820	chr2:242988706	NA	-0.9	-11.56	-0.47	2.45e-27	Obesity-related traits;
LGG	cis	rs3126085	0.935	rs10888473	chr1:152220235	G/A	cg26876637	chr1:152193138	HRNR	0.55	8.98	0.39	6.74e-18	Atopic dermatitis;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg05793240	chr7:2802953	GNA12	-0.34	-7.72	-0.34	7.2e-14	Height;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg15695648	chr17:53828850	PCTP	0.39	6.68	0.3	6.9e-11	Body mass index;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.44	0.56	2.81e-39	Lung cancer;
LGG	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg01221209	chr5:554886	NA	-0.49	-7.16	-0.32	3.23e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg02002194	chr4:3960332	NA	0.38	6.88	0.3	1.92e-11	Joint mobility (Beighton score);
LGG	cis	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg00806126	chr19:22604979	ZNF98	0.64	9.56	0.41	7.05e-20	Pain;
LGG	cis	rs4704187	0.617	rs7356697	chr5:74354542	A/G	cg03227963	chr5:74354835	NA	0.34	7.53	0.33	2.62e-13	Response to amphetamines;
LGG	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.38	-0.32	7.39e-13	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.18	-0.39	1.45e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg24607181	chr17:41446203	NA	-0.3	-6.9	-0.31	1.7e-11	Menopause (age at onset);
LGG	cis	rs4689642	0.507	rs11728437	chr4:7223543	C/T	cg21353189	chr4:7228343	SORCS2	-0.33	-7.14	-0.31	3.74e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg00277334	chr10:82204260	NA	-0.53	-12.8	-0.51	2.51e-32	Post bronchodilator FEV1;
LGG	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg03929089	chr4:120376271	NA	-0.98	-21.52	-0.71	1.06e-71	Coronary artery disease;
LGG	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	4.01e-13	Schizophrenia;
LGG	cis	rs1256061	0.654	rs1256031	chr14:64746179	C/T	cg23250157	chr14:64679961	SYNE2	0.38	7.09	0.31	5.02e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4936894	0.519	rs3905280	chr11:124149820	A/C	cg27160556	chr11:124181099	OR8D1	-0.44	-10.25	-0.43	2.28e-22	Aging (time to death);
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.19	-0.32	2.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs35176054	0.643	rs112169230	chr10:105501779	C/T	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.97	-0.31	1.09e-11	Atrial fibrillation;
LGG	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg05925327	chr15:68127851	NA	0.37	8.59	0.37	1.3e-16	Restless legs syndrome;
LGG	cis	rs4950322	0.542	rs3766519	chr1:146686372	C/T	cg22381352	chr1:146742008	CHD1L	-0.49	-8.06	-0.35	6.68e-15	Protein quantitative trait loci;
LGG	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg15627072	chr1:2432621	PLCH2	0.38	8.29	0.36	1.25e-15	Ulcerative colitis;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs10979	0.964	rs9496682	chr6:143898805	A/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.19	-0.49	7.52e-30	Hypospadias;
LGG	cis	rs6141769	0.542	rs6058840	chr20:31319116	A/T	cg13636640	chr20:31349939	DNMT3B	0.45	6.67	0.3	7.32e-11	Subjective well-being;
LGG	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg09238746	chr17:78121135	EIF4A3	-0.9	-15.57	-0.59	2.85e-44	Yeast infection;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-10.71	-0.45	4.57e-24	Prostate cancer;
LGG	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg07679836	chr6:33548423	BAK1	0.62	10.04	0.42	1.38e-21	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LGG	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Body mass index;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg13395646	chr4:1353034	KIAA1530	-0.47	-8.22	-0.36	2.06e-15	Longevity;
LGG	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg11247378	chr22:39784982	NA	-0.31	-8.49	-0.37	2.78e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01423820	chr14:77228690	VASH1	0.41	7.02	0.31	7.95e-12	Bipolar disorder;
LGG	cis	rs7648466	0.592	rs2087726	chr3:46208310	G/A	cg13144783	chr3:46249795	CCR1	-0.62	-13.53	-0.53	2.29e-35	Eotaxin levels;
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22433210	chr17:43662623	NA	0.79	13.33	0.53	1.56e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg06521331	chr12:34319734	NA	-0.6	-11.19	-0.46	6.75e-26	Morning vs. evening chronotype;
LGG	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg21427119	chr20:30132790	HM13	-0.45	-7.52	-0.33	2.87e-13	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs11074306	0.561	rs8029641	chr15:28077003	C/A	cg26402630	chr15:28053930	OCA2	0.34	6.8	0.3	3.33e-11	Uveal melanoma;
LGG	trans	rs7210837	0.656	rs10852836	chr17:16783575	G/C	cg11294312	chr17:28900046	NA	-0.73	-9.33	-0.4	4.45e-19	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg08198773	chr8:1697536	NA	0.36	6.94	0.31	1.37e-11	Systolic blood pressure;
LGG	cis	rs7149337	0.805	rs4350491	chr14:51675798	A/G	cg23942311	chr14:51606299	NA	0.33	7.15	0.32	3.33e-12	Cancer;
LGG	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06028808	chr11:68637592	NA	-0.69	-12.03	-0.49	3.38e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg19773385	chr1:10388646	KIF1B	-0.47	-10.33	-0.43	1.16e-22	Hepatocellular carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20087221	chr10:98135160	TLL2	0.46	6.92	0.31	1.54e-11	Gut microbiome composition (summer);
LGG	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg27572855	chr1:25598939	RHD	-0.49	-11.04	-0.46	2.5e-25	Erythrocyte sedimentation rate;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.72	-0.3	5.22e-11	Intelligence (multi-trait analysis);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg02985366	chr16:32360428	NA	-0.45	-7.0	-0.31	9.23e-12	Menopause (age at onset);
LGG	cis	rs283228	0.605	rs495408	chr6:101722656	A/T	cg27451362	chr6:101846650	GRIK2	0.73	10.85	0.45	1.38e-24	Coenzyme Q10 levels;
LGG	cis	rs6908034	0.660	rs6918235	chr6:19788427	A/T	cg02682789	chr6:19804855	NA	0.89	7.95	0.35	1.48e-14	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs4740619	0.933	rs1396707	chr9:15705395	G/T	cg14451791	chr9:16040625	NA	-0.38	-9.68	-0.41	2.74e-20	Body mass index;
LGG	trans	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg18335740	chr13:41363409	SLC25A15	0.64	13.02	0.52	3.16e-33	Lewy body disease;
LGG	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-14.07	-0.55	1.06e-37	Schizophrenia;
LGG	cis	rs11734570	0.581	rs73811715	chr4:38590569	A/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.24	0.36	1.72e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs861020	1.000	rs12134698	chr1:209987801	C/A	cg05527609	chr1:210001259	C1orf107	-0.73	-10.13	-0.43	6.29e-22	Orofacial clefts;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.95	-0.31	1.24e-11	Longevity;Endometriosis;
LGG	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg09307838	chr4:120376055	NA	0.72	12.42	0.5	9.37e-31	Corneal astigmatism;
LGG	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg20703242	chr1:230279135	GALNT2	0.41	7.23	0.32	2.06e-12	Coronary artery disease;
LGG	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg06808227	chr14:105710500	BRF1	-0.65	-11.28	-0.46	3.15e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs55788414	0.505	rs7190543	chr16:81189320	T/C	cg06400318	chr16:81190750	PKD1L2	-0.76	-11.01	-0.46	3.45e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22464182	chr2:148602625	ACVR2A	-0.47	-6.9	-0.31	1.7e-11	Systemic lupus erythematosus;
LGG	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg22601191	chr20:60968625	CABLES2	0.51	7.39	0.32	6.89e-13	Colorectal cancer;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg25358565	chr5:93447407	FAM172A	1.26	15.55	0.59	3.66e-44	Diabetic retinopathy;
LGG	cis	rs11628318	0.515	rs11627756	chr14:103096606	C/T	cg12046867	chr14:103022105	NA	-0.4	-7.59	-0.33	1.81e-13	Platelet count;
LGG	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg13699009	chr12:122356056	WDR66	0.45	11.59	0.47	1.92e-27	Mean corpuscular volume;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.96	0.6	5.53e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.98	-0.39	7.02e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg02640540	chr1:67518911	SLC35D1	0.35	6.72	0.3	5.33e-11	Lymphocyte percentage of white cells;
LGG	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg21095983	chr6:86352623	SYNCRIP	0.61	11.39	0.47	1.12e-26	Smooth-surface caries;
LGG	cis	rs11971779	0.680	rs6954531	chr7:139054706	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.97	0.31	1.08e-11	Diisocyanate-induced asthma;
LGG	cis	rs240764	0.614	rs12210312	chr6:101170849	A/G	cg09795085	chr6:101329169	ASCC3	-0.4	-6.68	-0.3	6.75e-11	Neuroticism;
LGG	cis	rs7737355	0.947	rs3776027	chr5:130802970	T/C	cg06307176	chr5:131281290	NA	-0.53	-9.01	-0.39	5.31e-18	Life satisfaction;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg13047869	chr3:10149882	C3orf24	0.46	7.61	0.33	1.58e-13	Alzheimer's disease;
LGG	cis	rs9715521	0.677	rs11944208	chr4:59860652	G/A	cg11281224	chr4:60001000	NA	-0.56	-9.97	-0.42	2.38e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg02002194	chr4:3960332	NA	0.5	9.28	0.4	6.3e-19	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20366603	chr17:7218821	GPS2	0.49	7.23	0.32	1.98e-12	Gut microbiome composition (summer);
LGG	cis	rs877426	0.681	rs56352545	chr13:114839620	A/G	cg00571178	chr13:114841904	RASA3	-0.54	-9.41	-0.4	2.33e-19	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg24006582	chr15:45444508	DUOX1	-0.66	-12.48	-0.5	5.26e-31	Uric acid levels;
LGG	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg11584989	chr19:19387371	SF4	0.74	12.12	0.49	1.54e-29	Bipolar disorder;
LGG	trans	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg21659725	chr3:3221576	CRBN	0.56	7.19	0.32	2.67e-12	Menarche (age at onset);
LGG	cis	rs8064024	0.501	rs28375268	chr16:4949528	G/T	cg04440724	chr16:4920505	UBN1	0.47	9.17	0.39	1.53e-18	Cancer;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	12.07	0.49	2.33e-29	Obesity-related traits;
LGG	cis	rs17208368	0.574	rs72802767	chr16:55093956	T/A	cg11181171	chr16:55090946	NA	0.46	7.61	0.33	1.6e-13	Hypospadias;
LGG	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg15038512	chr6:170123185	PHF10	0.56	6.95	0.31	1.24e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg02297831	chr4:17616191	MED28	-0.48	-9.15	-0.39	1.86e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1707322	0.928	rs6681068	chr1:46398382	G/A	cg03146154	chr1:46216737	IPP	0.53	10.03	0.42	1.49e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs877282	0.898	rs11253348	chr10:765852	C/T	cg22713356	chr15:30763199	NA	0.51	7.51	0.33	3.17e-13	Uric acid levels;
LGG	cis	rs62380364	0.774	rs7730255	chr5:88158146	G/C	cg22951263	chr5:87985283	NA	-0.38	-6.65	-0.3	8.21e-11	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22825116	chr2:88991018	RPIA	0.43	7.19	0.32	2.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg23306229	chr2:178417860	TTC30B	0.55	7.07	0.31	5.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs593982	0.920	rs487264	chr11:65481465	A/C	cg08755490	chr11:65554678	OVOL1	0.73	8.81	0.38	2.45e-17	Atopic dermatitis;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.94	-0.57	1.72e-41	Platelet count;
LGG	cis	rs9807841	0.858	rs34626880	chr19:10840428	T/C	cg17710535	chr19:10819994	QTRT1	0.49	7.78	0.34	4.68e-14	Inflammatory skin disease;
LGG	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.77	-0.3	3.93e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg06374794	chr16:88002281	BANP	0.44	8.32	0.36	9.79e-16	Menopause (age at onset);
LGG	cis	rs3219090	0.962	rs1805414	chr1:226573364	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.13	0.49	1.38e-29	Melanoma;
LGG	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg17376030	chr22:41985996	PMM1	0.56	9.51	0.4	1.08e-19	Vitiligo;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18030105	chr11:3396237	ZNF195	-0.57	-6.75	-0.3	4.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg06215416	chr1:2383473	NA	-0.39	-10.49	-0.44	2.94e-23	Schizophrenia;
LGG	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.59	-0.33	1.76e-13	Mean corpuscular hemoglobin;
LGG	cis	rs61931739	0.649	rs708139	chr12:33733265	C/A	cg06521331	chr12:34319734	NA	-0.4	-7.02	-0.31	7.97e-12	Morning vs. evening chronotype;
LGG	trans	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.09	-0.31	5.05e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09656405	chr15:69745057	RPLP1	0.56	9.07	0.39	3.28e-18	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09688588	chr3:191047460	CCDC50;UTS2D	0.51	8.01	0.35	9.15e-15	Gut microbiome composition (summer);
LGG	cis	rs2224391	0.628	rs2753238	chr6:5252795	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.4	-0.33	6.33e-13	Height;
LGG	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg06026331	chr20:60912101	LAMA5	0.6	10.12	0.43	7.06e-22	Colorectal cancer;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg16141378	chr3:129829833	LOC729375	-0.5	-12.21	-0.49	6.21e-30	Mood instability;
LGG	trans	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.94	-0.31	1.37e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04205664	chr7:139209511	CLEC2L	0.3	6.74	0.3	4.61e-11	Menarche (age at onset);
LGG	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg02640540	chr1:67518911	SLC35D1	0.38	7.36	0.32	8.52e-13	Lymphocyte percentage of white cells;
LGG	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg21665744	chr7:39171113	POU6F2	0.38	7.34	0.32	9.38e-13	IgG glycosylation;
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg21775007	chr8:11205619	TDH	0.44	7.4	0.33	6.63e-13	Neuroticism;
LGG	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.94e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4740619	0.766	rs7034781	chr9:15753528	C/T	cg14451791	chr9:16040625	NA	-0.29	-7.38	-0.32	7.38e-13	Body mass index;
LGG	cis	rs6445975	0.572	rs7642018	chr3:58353263	T/C	cg24175188	chr3:58374923	PXK	-0.55	-8.84	-0.38	2.01e-17	Systemic lupus erythematosus;
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg26578617	chr4:90757533	SNCA	-0.44	-8.8	-0.38	2.72e-17	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.61	0.37	1.14e-16	Lung cancer;
LGG	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg23057051	chr16:89984268	MC1R	0.38	7.18	0.32	2.76e-12	Vitiligo;
LGG	cis	rs17683430	0.614	rs2006233	chr22:32530848	A/G	cg02631450	chr22:32366979	NA	0.64	7.45	0.33	4.61e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4566357	1.000	rs6436649	chr2:227923952	A/G	cg11843606	chr2:227700838	RHBDD1	-0.41	-7.19	-0.32	2.69e-12	Coronary artery disease;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg06873352	chr17:61820015	STRADA	-0.69	-12.53	-0.5	3.13e-31	Prudent dietary pattern;
LGG	cis	rs4363385	0.791	rs11205177	chr1:153002502	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	trans	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.28	0.43	1.83e-22	Mean corpuscular volume;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.96	-0.38	7.9e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7027203	0.964	rs6479512	chr9:96556985	G/A	cg14598338	chr9:96623480	NA	0.5	8.59	0.37	1.32e-16	DNA methylation (variation);
LGG	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg08461772	chr7:95026248	PON3	0.38	8.35	0.36	7.98e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs262150	0.566	rs262159	chr7:158772172	C/T	cg13444538	chr7:158905317	VIPR2	-0.45	-8.13	-0.35	3.91e-15	Facial morphology (factor 20);
LGG	cis	rs7582720	1.000	rs76298043	chr2:203814694	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg27523141	chr10:43048294	ZNF37B	-0.36	-7.38	-0.32	7.57e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7301826	0.651	rs1554807	chr12:131280417	C/T	cg11011512	chr12:131303247	STX2	-0.41	-8.74	-0.38	4.42e-17	Plasma plasminogen activator levels;
LGG	trans	rs2736345	0.788	rs998683	chr8:11353000	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-6.93	-0.31	1.44e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg00170343	chr3:11313890	ATG7	0.53	6.77	0.3	3.89e-11	Circulating chemerin levels;
LGG	cis	rs1322639	0.614	rs9364361	chr6:169580499	C/T	cg03254818	chr6:169586852	NA	0.61	9.04	0.39	4.36e-18	Pulse pressure;
LGG	cis	rs12410462	0.551	rs2819502	chr1:227712652	T/C	cg23173402	chr1:227635558	NA	0.38	7.15	0.32	3.46e-12	Major depressive disorder;
LGG	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21659725	chr3:3221576	CRBN	0.84	16.66	0.61	3.71e-49	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs17655565	0.636	rs17119838	chr12:52716596	C/T	cg08257133	chr12:52711352	KRT83	0.56	8.42	0.36	4.88e-16	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs5769707	0.605	rs6009791	chr22:50025265	T/C	cg06623630	chr22:50017776	C22orf34	-0.5	-10.23	-0.43	2.71e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg22437258	chr11:111473054	SIK2	0.55	9.68	0.41	2.66e-20	Primary sclerosing cholangitis;
LGG	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg26031613	chr14:104095156	KLC1	-0.6	-9.34	-0.4	4.01e-19	Reticulocyte count;
LGG	cis	rs2205829	0.563	rs4413607	chr6:27475120	A/C	cg18711553	chr6:27366782	ZNF391	-0.47	-8.95	-0.38	8.51e-18	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs61990749	0.597	rs9323650	chr14:78150336	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.53	6.65	0.3	8.23e-11	Fibroblast growth factor basic levels;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.49	-0.44	3.13e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg01028140	chr2:1542097	TPO	-0.54	-9.81	-0.41	8.8e-21	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.33e-11	Lung cancer;
LGG	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg07943548	chr15:86304357	KLHL25	-0.35	-7.03	-0.31	7.48e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9914988	0.778	rs35398767	chr17:27122960	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.08	0.49	2.05e-29	Prudent dietary pattern;
LGG	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.94	0.31	1.32e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs17767392	0.834	rs55863348	chr14:71724293	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.68	-0.37	6.64e-17	Mitral valve prolapse;
LGG	cis	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-11.15	-0.46	9.36e-26	Blood pressure (smoking interaction);
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.52	-8.83	-0.38	2.23e-17	Longevity;Endometriosis;
LGG	cis	rs4731207	0.724	rs4146110	chr7:124561208	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.77e-14	Cutaneous malignant melanoma;
LGG	cis	rs10940138	0.830	rs16897180	chr5:67220196	A/C	ch.5.1281357F	chr5:67228439	NA	-0.77	-13.41	-0.53	6.87e-35	Menarche (age at onset);
LGG	cis	rs3740909	1.000	rs79206156	chr11:125897289	A/G	cg24940576	chr11:125904314	CDON	-0.5	-6.98	-0.31	1.04e-11	Blood protein levels;
LGG	cis	rs4356203	0.905	rs214906	chr11:17181340	C/T	cg15432903	chr11:17409602	KCNJ11	0.39	7.34	0.32	9.86e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2016266	0.787	rs56358776	chr12:53682457	G/A	cg04065151	chr12:53682969	ESPL1	0.59	9.93	0.42	3.3e-21	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	-0.44	-7.28	-0.32	1.41e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs9929218	0.954	rs4420522	chr16:68822971	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-11.83	-0.48	2.13e-28	Colorectal cancer;
LGG	cis	rs1371614	0.589	rs935018	chr2:27106625	A/T	cg12045002	chr2:27069975	DPYSL5	-0.32	-7.04	-0.31	6.86e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg19442545	chr10:75533431	FUT11	-0.46	-7.48	-0.33	3.76e-13	Inflammatory bowel disease;
LGG	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg22852734	chr6:133119734	C6orf192	1.31	10.21	0.43	3.38e-22	Type 2 diabetes nephropathy;
LGG	trans	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.86	0.64	1.22e-54	Exhaled nitric oxide output;
LGG	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg08250081	chr4:10125330	NA	0.62	11.5	0.47	4.47e-27	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.13	-0.31	3.97e-12	Neuroticism;
LGG	cis	rs9300255	0.516	rs6488868	chr12:123799974	A/G	cg00376283	chr12:123451042	ABCB9	0.54	9.05	0.39	3.88e-18	Neutrophil percentage of white cells;
LGG	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15128208	chr22:42549153	NA	0.48	9.75	0.41	1.46e-20	Cognitive function;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-7.66	-0.34	1.09e-13	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.01e-12	Lung cancer;
LGG	cis	rs6964587	1.000	rs2299238	chr7:91654517	G/A	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs921968	0.509	rs72963905	chr2:219547027	T/G	cg01130898	chr2:219473002	PLCD4	0.49	8.42	0.36	4.8e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.7	-0.34	8.46e-14	Joint mobility (Beighton score);
LGG	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg19455335	chr8:22457658	C8orf58	-0.44	-8.95	-0.38	8.78e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.09	0.31	5.04e-12	Retinal vascular caliber;
LGG	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs6942756	0.747	rs691124	chr7:129098439	A/G	cg02491457	chr7:128862824	NA	-0.67	-11.68	-0.48	8.16e-28	White matter hyperintensity burden;
LGG	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg24565620	chr2:194026	NA	-0.7	-10.7	-0.45	4.91e-24	Blood protein levels;
LGG	cis	rs11700980	0.551	rs56852856	chr21:30114177	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	10.63	0.44	9.25e-24	Chronic sinus infection;
LGG	trans	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg25214090	chr10:38739885	LOC399744	0.68	12.22	0.49	5.6e-30	Corneal astigmatism;
LGG	cis	rs3805663	0.932	rs31209	chr5:134360431	A/T	cg24576358	chr5:134350122	NA	0.35	7.44	0.33	4.98e-13	Testicular germ cell tumor;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg08040740	chr19:11925285	ZNF440	-0.38	-6.71	-0.3	5.57e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.82	0.3	2.93e-11	Carotid intima media thickness;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.66	-0.59	1.14e-44	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.47	-0.33	4.01e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg08461772	chr7:95026248	PON3	0.37	8.08	0.35	5.87e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg04733989	chr22:42467013	NAGA	-0.38	-6.82	-0.3	2.83e-11	Cognitive function;
LGG	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.13	0.49	1.29e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03264133	chr6:25882463	NA	-0.63	-11.42	-0.47	8.52e-27	Intelligence (multi-trait analysis);
LGG	cis	rs17030434	0.822	rs28367474	chr4:154718642	A/G	cg14289246	chr4:154710475	SFRP2	-0.6	-9.92	-0.42	3.63e-21	Electrocardiographic conduction measures;
LGG	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg19875535	chr5:140030758	IK	0.55	11.4	0.47	1.01e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7666738	0.791	rs4440223	chr4:99044796	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6032067	0.639	rs62205502	chr20:43864197	G/C	cg10761708	chr20:43804764	PI3	0.57	8.76	0.38	3.76e-17	Blood protein levels;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-11.27	-0.46	3.45e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.49	-0.4	1.19e-19	Body mass index;
LGG	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.44	0.4	1.89e-19	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg04132472	chr17:19861366	AKAP10	-0.26	-7.11	-0.31	4.53e-12	Schizophrenia;
LGG	cis	rs7582720	0.778	rs6719001	chr2:203777903	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15557168	chr22:42548783	NA	-0.32	-6.92	-0.31	1.49e-11	Cognitive function;
LGG	cis	rs7267979	0.586	rs11087505	chr20:25196520	T/A	cg06421707	chr20:25228305	PYGB	0.4	8.0	0.35	9.83e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04530015	chr2:215796436	ABCA12	0.46	8.48	0.37	3.14e-16	Neuroblastoma;
LGG	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.4e-12	Schizophrenia;
LGG	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg13009111	chr11:71350975	NA	-0.35	-7.85	-0.34	2.93e-14	Myopia (pathological);
LGG	cis	rs1620921	0.563	rs2465849	chr6:161280167	C/T	cg01280913	chr6:161186852	NA	-0.37	-7.43	-0.33	5.15e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg17691542	chr6:26056736	HIST1H1C	0.68	11.25	0.46	3.85e-26	Iron status biomarkers;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	23.73	0.74	5.13e-82	Chronic sinus infection;
LGG	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg03929089	chr4:120376271	NA	-0.65	-7.83	-0.34	3.43e-14	D-dimer levels;
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.97e-41	Skin colour saturation;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg27347728	chr4:17578864	LAP3	-0.38	-6.71	-0.3	5.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.55	0.37	1.82e-16	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09075925	chr2:71504843	NA	0.48	7.33	0.32	1.04e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.27	-0.32	1.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	0.735	rs1341272	chr6:109507533	C/T	cg21918786	chr6:109611834	NA	0.41	7.68	0.34	9.62e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7917772	0.582	rs10786682	chr10:104318322	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.72	-0.48	5.87e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2011503	0.509	rs73006705	chr19:19781917	A/G	cg11584989	chr19:19387371	SF4	0.56	8.13	0.35	3.92e-15	Bipolar disorder;
LGG	cis	rs9397585	0.599	rs685826	chr6:153411255	C/T	cg17707550	chr6:153380415	RGS17	-0.4	-7.09	-0.31	5.03e-12	Body mass index;
LGG	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.57	-0.37	1.52e-16	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.52	-0.37	2.27e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg04025307	chr7:1156635	C7orf50	0.77	11.21	0.46	5.88e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg15268244	chr15:77196840	NA	-0.35	-7.65	-0.33	1.2e-13	Blood metabolite levels;
LGG	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg02487422	chr3:49467188	NICN1	0.41	6.95	0.31	1.28e-11	Parkinson's disease;
LGG	cis	rs244731	0.959	rs3105419	chr5:176551396	G/C	cg17509989	chr5:176798049	RGS14	0.56	7.64	0.33	1.22e-13	Urate levels in lean individuals;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04041942	chr8:28747613	INTS9;HMBOX1	0.44	7.13	0.31	3.9e-12	Cognitive performance;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.17	0.39	1.51e-18	Bipolar disorder;
LGG	cis	rs2241941	0.840	rs11600101	chr11:20628072	T/G	cg09136245	chr11:20631761	SLC6A5	-0.45	-8.05	-0.35	7.2e-15	Obesity-related traits;
LGG	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.7	0.34	8.24e-14	Hip circumference adjusted for BMI;
LGG	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.21	-0.43	3.4e-22	Total cholesterol levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg21893314	chr15:40453133	BUB1B	0.44	7.3	0.32	1.29e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	trans	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.35	-0.32	8.86e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.35	0.32	9.34e-13	Lung cancer;
LGG	trans	rs253959	0.545	rs10072417	chr5:115433603	G/C	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.75	0.3	4.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17209837	1.000	rs7802783	chr7:87130397	A/G	cg00919237	chr7:87102261	ABCB4	0.66	10.41	0.44	5.81e-23	Gallbladder cancer;
LGG	cis	rs9733	0.650	rs11204668	chr1:150543686	G/A	cg13175981	chr1:150552382	MCL1	0.58	9.92	0.42	3.84e-21	Tonsillectomy;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg23758822	chr17:41437982	NA	0.88	13.08	0.52	1.67e-33	Menopause (age at onset);
LGG	cis	rs2729354	0.768	rs2848640	chr11:57262680	A/G	cg24343310	chr11:57249947	NA	0.42	8.17	0.35	2.98e-15	Blood protein levels;
LGG	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.97	-0.35	1.24e-14	Monocyte count;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-10.43	-0.44	5.27e-23	Longevity;Endometriosis;
LGG	cis	rs17776563	0.614	rs6496500	chr15:89126190	T/G	cg05013243	chr15:89149849	MIR1179	-0.36	-7.34	-0.32	9.66e-13	Thyroid hormone levels;
LGG	cis	rs11190604	0.945	rs2495735	chr10:102338609	G/A	cg07570687	chr10:102243282	WNT8B	0.39	6.7	0.3	6.17e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.22	0.32	2.1e-12	Neuroticism;
LGG	cis	rs10751667	0.580	rs11246363	chr11:971667	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg25986240	chr4:9926439	SLC2A9	0.52	11.36	0.47	1.48e-26	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg16590910	chr6:42928470	GNMT	0.41	11.5	0.47	4.39e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg07150166	chr2:30669952	LCLAT1	0.68	8.91	0.38	1.16e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs11225247	0.655	rs112276332	chr11:102226953	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.53	0.33	2.69e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg01631408	chr1:248437212	OR2T33	-0.37	-6.89	-0.31	1.79e-11	Common traits (Other);
LGG	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg21775007	chr8:11205619	TDH	-0.51	-8.49	-0.37	2.83e-16	Triglycerides;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg13453750	chr1:205783389	SLC41A1	-0.4	-7.7	-0.34	8.06e-14	Menarche (age at onset);
LGG	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.72	0.51	5.26e-32	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12591302	chr10:99258515	UBTD1;MMS19	0.45	6.93	0.31	1.43e-11	Gut microbiome composition (summer);
LGG	cis	rs308971	0.563	rs454615	chr3:12077010	A/G	cg15873301	chr3:12045459	SYN2	0.56	7.25	0.32	1.74e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg27490568	chr2:178487706	NA	-0.52	-10.13	-0.43	6.69e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg13147721	chr7:65941812	NA	0.84	10.19	0.43	4.03e-22	Diabetic kidney disease;
LGG	cis	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg06521331	chr12:34319734	NA	-0.55	-9.38	-0.4	2.95e-19	Morning vs. evening chronotype;
LGG	cis	rs477692	0.673	rs579325	chr10:131363688	C/T	cg05714579	chr10:131428358	MGMT	0.48	9.21	0.39	1.11e-18	Response to temozolomide;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-16.76	-0.61	1.33e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg10596483	chr8:143751796	JRK	0.58	9.5	0.4	1.17e-19	Schizophrenia;
LGG	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.03	-0.35	8.39e-15	Mean corpuscular volume;
LGG	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.9	-0.34	2.09e-14	Monocyte count;
LGG	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg17971929	chr21:40555470	PSMG1	0.71	13.41	0.53	6.99e-35	Cognitive function;
LGG	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg22875332	chr1:76189707	ACADM	-0.54	-8.09	-0.35	5.12e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg20608306	chr11:116969690	SIK3	0.42	13.32	0.53	1.71e-34	Blood protein levels;
LGG	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg21724239	chr8:58056113	NA	0.61	9.33	0.4	4.41e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.51	-0.33	3.13e-13	Testicular germ cell tumor;
LGG	cis	rs4702718	0.632	rs1866386	chr5:10682728	G/A	cg18867653	chr5:10760375	DAP	0.3	7.36	0.32	8.47e-13	Obesity-related traits;
LGG	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs1375194	0.606	rs13393407	chr2:33818198	C/T	cg04131969	chr2:33951647	MYADML	-0.56	-9.84	-0.42	6.88e-21	Response to antidepressants in depression;
LGG	cis	rs36051895	0.625	rs12340333	chr9:5176215	C/G	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs3796352	0.527	rs11715498	chr3:52943551	G/C	cg04865290	chr3:52927548	TMEM110	-0.46	-7.45	-0.33	4.61e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9443189	0.570	rs72884926	chr6:76266208	T/C	cg01950844	chr6:76311363	SENP6	0.76	9.98	0.42	2.22e-21	Prostate cancer;
LGG	cis	rs9796	0.866	rs66818965	chr15:41402279	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.92	-0.38	1.06e-17	Menopause (age at onset);
LGG	cis	rs9487094	0.813	rs6920962	chr6:109724490	A/T	cg01125227	chr6:109776195	MICAL1	0.44	7.55	0.33	2.37e-13	Height;
LGG	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg13402656	chr8:1511478	DLGAP2	-0.79	-15.03	-0.57	7.12e-42	Lung cancer;
LGG	cis	rs2797160	1.000	rs1777195	chr6:126006861	A/C	cg05901451	chr6:126070800	HEY2	0.44	7.47	0.33	4.15e-13	Endometrial cancer;
LGG	cis	rs7020830	0.858	rs67036212	chr9:37133538	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	34.41	0.85	1.18e-129	Schizophrenia;
LGG	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg05163923	chr11:71159392	DHCR7	0.72	14.24	0.55	1.97e-38	Vitamin D levels;
LGG	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg12292205	chr6:26970375	C6orf41	-0.41	-6.79	-0.3	3.51e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg08888203	chr3:10149979	C3orf24	0.5	8.23	0.36	1.89e-15	Alzheimer's disease;
LGG	cis	rs7017914	0.967	rs13254908	chr8:71626098	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg09021430	chr5:549028	NA	-0.68	-9.5	-0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg07930552	chr6:133119739	C6orf192	0.85	11.84	0.48	1.98e-28	Type 2 diabetes nephropathy;
LGG	cis	rs894344	0.812	rs894358	chr8:135600716	C/G	cg17885191	chr8:135476712	NA	0.39	6.66	0.3	7.56e-11	Systolic blood pressure;
LGG	cis	rs9834373	0.853	rs13322529	chr3:78495795	A/G	cg06138941	chr3:78371609	NA	-0.51	-9.18	-0.39	1.47e-18	Protein quantitative trait loci;
LGG	trans	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-7.19	-0.32	2.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	1.000	rs17327139	chr5:112710785	A/G	cg12552261	chr5:112820674	MCC	0.7	8.04	0.35	7.45e-15	F-cell distribution;
LGG	cis	rs10489202	0.634	rs11582396	chr1:168077636	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-9.99	-0.42	2.03e-21	Schizophrenia;
LGG	cis	rs6834538	0.577	rs10034556	chr4:113449650	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.49	8.38	0.36	6.26e-16	Free thyroxine concentration;
LGG	cis	rs11874712	1.000	rs9945751	chr18:43673265	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs4731207	0.698	rs7796015	chr7:124521146	C/T	cg05630886	chr7:124431682	NA	-0.34	-7.93	-0.35	1.68e-14	Cutaneous malignant melanoma;
LGG	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs12893597	0.715	rs74639969	chr14:76832150	A/G	cg20290672	chr14:76816747	NA	-0.5	-7.61	-0.33	1.56e-13	Maximal oxygen uptake response;
LGG	cis	rs12318506	0.826	rs11180453	chr12:75694006	T/C	cg04728562	chr12:75699417	CAPS2	-1.25	-10.23	-0.43	2.67e-22	Coronary artery calcification;
LGG	trans	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-11.55	-0.47	2.71e-27	Brugada syndrome;
LGG	trans	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg06529181	chr19:52193933	NA	0.53	7.91	0.35	1.93e-14	IgG glycosylation;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg01988459	chr11:68622903	NA	-0.62	-12.61	-0.51	1.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.24	-0.36	1.82e-15	Alzheimer's disease (survival time);
LGG	cis	rs10851478	0.500	rs10519225	chr15:49720778	G/A	cg08060515	chr15:49448048	GALK2;COPS2	0.42	7.47	0.33	3.93e-13	Oral cavity cancer;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11245990	chr11:68621969	NA	-0.41	-8.65	-0.37	8.49e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.830	rs11727612	chr4:99001662	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.21	-0.46	5.84e-26	Personality dimensions;
LGG	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.58	0.47	2.02e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	10.11	0.43	7.72e-22	Obesity-related traits;
LGG	trans	rs800082	0.698	rs800077	chr3:144349940	A/G	cg24215973	chr2:240111563	HDAC4	-0.74	-13.47	-0.53	3.97e-35	Smoking behavior;
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg21798802	chr22:38057573	PDXP	0.61	14.05	0.55	1.38e-37	Fat distribution (HIV);
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg26384229	chr12:38710491	ALG10B	0.63	12.22	0.49	6.04e-30	Morning vs. evening chronotype;
LGG	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.9	0.34	2.1e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7412746	0.621	rs7518156	chr1:150945794	A/C	cg15448220	chr1:150897856	SETDB1	0.38	7.0	0.31	9.15e-12	Melanoma;
LGG	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.85	-0.45	1.39e-24	Bipolar disorder;
LGG	cis	rs911263	0.603	rs10483807	chr14:68808824	A/G	cg18825221	chr14:68749962	RAD51L1	0.37	8.16	0.35	3.2e-15	Primary biliary cholangitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25533547	chr2:73053217	EXOC6B	0.43	6.84	0.3	2.45e-11	Cognitive performance;
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.5	-0.33	3.19e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.551	rs2814084	chr1:227714296	C/A	cg04117972	chr1:227635322	NA	0.46	8.4	0.36	5.52e-16	Major depressive disorder;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10189230	0.674	rs2710511	chr2:222384480	A/C	cg14652038	chr2:222343519	EPHA4	-0.41	-7.96	-0.35	1.31e-14	Urate levels in lean individuals;
LGG	cis	rs6840360	0.567	rs6844259	chr4:152291184	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	6.9	0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs365132	1.000	rs601923	chr5:176417386	C/G	cg16309518	chr5:176445507	NA	-0.55	-12.21	-0.49	6.56e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.37	0.36	6.7e-16	Parkinson's disease;
LGG	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg10253484	chr15:75165896	SCAMP2	-0.42	-7.14	-0.31	3.72e-12	Breast cancer;
LGG	cis	rs2273669	0.667	rs7765732	chr6:109347057	A/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs55633855	0.516	rs11603556	chr11:88147078	A/G	cg08522340	chr11:88068493	CTSC	-0.4	-6.89	-0.3	1.82e-11	Body mass index;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	9.56	0.41	7.13e-20	Menarche (age at onset);
LGG	cis	rs6714710	0.603	rs10432626	chr2:98561153	C/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.48	0.4	1.31e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs12615966	0.651	rs72830472	chr2:105407426	C/T	cg16465502	chr2:105461796	NA	0.99	11.27	0.46	3.25e-26	Pancreatic cancer;
LGG	cis	rs7717393	0.786	rs10042069	chr5:155764895	C/A	cg04435420	chr5:155754009	SGCD	0.77	9.66	0.41	3.21e-20	Egg allergy;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.92	-0.38	1.13e-17	Menopause (age at onset);
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.31	0.32	1.19e-12	Lung cancer;
LGG	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.1	0.57	3.42e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg27124370	chr19:33622961	WDR88	0.51	9.49	0.4	1.26e-19	Colorectal cancer;
LGG	cis	rs4919044	0.545	rs9420603	chr10:94777490	T/C	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.07	-0.31	5.73e-12	Coronary artery disease;
LGG	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.09	-0.31	5e-12	Triglycerides;
LGG	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg14952266	chr13:112191215	NA	0.54	11.34	0.47	1.73e-26	Hepatitis;
LGG	cis	rs9487051	1.000	rs9386796	chr6:109618704	C/T	cg21918786	chr6:109611834	NA	-0.44	-8.19	-0.36	2.48e-15	Reticulocyte fraction of red cells;
LGG	cis	rs8179	1.000	rs42033	chr7:92237533	A/T	cg15732164	chr7:92237376	CDK6	-0.69	-12.39	-0.5	1.25e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg02002194	chr4:3960332	NA	-0.51	-9.67	-0.41	2.8e-20	Retinal vascular caliber;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00166722	chr3:10149974	C3orf24	0.54	9.12	0.39	2.24e-18	Alzheimer's disease;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00864171	chr11:67383662	NA	0.54	9.51	0.4	1.01e-19	Mean corpuscular volume;
LGG	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg09307838	chr4:120376055	NA	0.71	11.79	0.48	3.01e-28	Corneal astigmatism;
LGG	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg14019146	chr3:50243930	SLC38A3	0.4	8.63	0.37	9.62e-17	Menarche (age at onset);
LGG	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg25706552	chr1:244017396	NA	0.51	8.45	0.37	3.82e-16	RR interval (heart rate);
LGG	cis	rs7937612	1.000	rs1892894	chr11:120254684	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.25	-0.52	3.23e-34	Intraocular pressure;
LGG	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg20336341	chr7:50628841	DDC	0.51	9.51	0.4	1e-19	Malaria;
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	15.15	0.58	2.21e-42	Platelet count;
LGG	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs11792861	0.816	rs113624314	chr9:111689953	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.34	0.43	1.12e-22	Menarche (age at onset);
LGG	cis	rs1318772	0.577	rs57625584	chr5:112973379	T/A	cg12552261	chr5:112820674	MCC	0.58	6.92	0.31	1.47e-11	F-cell distribution;
LGG	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg25173405	chr17:45401733	C17orf57	-0.71	-12.0	-0.49	4.41e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg22907277	chr7:1156413	C7orf50	0.67	6.69	0.3	6.35e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1003719	0.715	rs2051398	chr21:38550258	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.78	15.08	0.57	4.23e-42	Eye color traits;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg16359550	chr11:109292809	C11orf87	-0.7	-14.7	-0.56	2.05e-40	Schizophrenia;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	15.63	0.59	1.61e-44	Platelet count;
LGG	cis	rs611744	0.967	rs596245	chr8:109240822	G/A	cg21045802	chr8:109455806	TTC35	0.38	6.79	0.3	3.38e-11	Dupuytren's disease;
LGG	cis	rs7129220	0.588	rs7105321	chr11:10111339	T/C	cg01453529	chr11:10209919	SBF2	-0.43	-7.09	-0.31	5.03e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg19784903	chr17:45786737	TBKBP1	0.36	7.87	0.34	2.53e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10463554	0.927	rs56361326	chr5:102389888	T/C	cg23492399	chr5:102201601	PAM	-0.49	-7.4	-0.33	6.47e-13	Parkinson's disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25846022	chr1:78444909	FUBP1	0.39	6.7	0.3	6.14e-11	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs7980799	0.935	rs1905408	chr12:33516963	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-8.57	-0.37	1.59e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1209950	1.000	rs1209950	chr21:40173528	A/G	cg01359822	chr21:40176597	ETS2	-0.33	-7.53	-0.33	2.59e-13	Non-small cell lung cancer (survival);
LGG	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.55	0.41	7.72e-20	Mean corpuscular volume;
LGG	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg19784903	chr17:45786737	TBKBP1	0.31	6.66	0.3	7.93e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg00188032	chr5:96141721	ERAP1	0.53	6.97	0.31	1.13e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg07274523	chr3:49395745	GPX1	0.57	9.46	0.4	1.56e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.36	-6.99	-0.31	9.58e-12	Longevity;Endometriosis;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.44	-0.33	5.1e-13	Menopause (age at onset);
LGG	cis	rs7727544	0.582	rs10052046	chr5:131544466	G/T	cg07395648	chr5:131743802	NA	-0.39	-8.47	-0.37	3.19e-16	Blood metabolite levels;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13732083	chr21:47605072	C21orf56	0.46	7.63	0.33	1.32e-13	Testicular germ cell tumor;
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg13047869	chr3:10149882	C3orf24	0.46	7.76	0.34	5.5e-14	Alzheimer's disease;
LGG	cis	rs7582720	0.945	rs114604411	chr2:203811912	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg26043149	chr18:55253948	FECH	0.42	6.89	0.3	1.8e-11	Bone mineral density;
LGG	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.3	-0.32	1.26e-12	Hemoglobin concentration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13390975	chr5:34915890	BRIX1;RAD1	0.4	6.65	0.3	8.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6496667	0.532	rs2601207	chr15:90963542	C/G	cg22089800	chr15:90895588	ZNF774	-0.49	-7.92	-0.35	1.76e-14	Rheumatoid arthritis;
LGG	cis	rs7226408	0.857	rs72885273	chr18:34438538	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.99	-0.74	2.92e-83	Primary sclerosing cholangitis;
LGG	cis	rs77972916	0.505	rs3851318	chr2:43532808	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.38	-0.4	3.06e-19	Granulocyte percentage of myeloid white cells;
LGG	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	12.37	0.5	1.4e-30	Parkinson's disease;
LGG	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06873352	chr17:61820015	STRADA	0.75	14.07	0.55	1.05e-37	Prudent dietary pattern;
LGG	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg15704280	chr7:45808275	SEPT13	0.89	18.24	0.65	2.01e-56	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.36	-0.32	8.21e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs61989804	0.826	rs61987803	chr14:65718067	G/A	cg15999311	chr14:65749247	NA	0.65	7.08	0.31	5.47e-12	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.67	-0.41	2.92e-20	Neuroticism;
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg14346243	chr4:90757452	SNCA	0.4	7.84	0.34	3.21e-14	Dementia with Lewy bodies;
LGG	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.5	-0.33	3.3e-13	Colorectal cancer;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.18	-0.39	1.42e-18	Obesity-related traits;
LGG	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.12	-0.49	1.53e-29	Height;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg08999081	chr20:33150536	PIGU	-0.4	-10.04	-0.42	1.41e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs1847505	0.609	rs7993826	chr13:61505940	A/G	cg25164009	chr13:61490935	NA	0.62	9.46	0.4	1.58e-19	Polychlorinated biphenyl levels;
LGG	cis	rs1788820	0.957	rs891389	chr18:21087531	C/T	cg14672496	chr18:21087552	C18orf8	-0.39	-7.25	-0.32	1.77e-12	Body mass index;
LGG	cis	rs10895140	0.665	rs4531429	chr11:101515904	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg17706124	chr4:3521738	LRPAP1	0.37	6.91	0.31	1.61e-11	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs11018904	0.906	rs7925507	chr11:89940146	T/C	cg27158573	chr11:89632121	NA	-0.42	-7.56	-0.33	2.19e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.5	6.99	0.31	9.57e-12	Birth weight;
LGG	cis	rs2658782	1.000	rs2658778	chr11:93148948	C/G	cg15737290	chr11:93063684	CCDC67	0.58	8.51	0.37	2.44e-16	Pulmonary function decline;
LGG	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.89	0.54	6.41e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21659725	chr3:3221576	CRBN	-0.58	-9.9	-0.42	4.19e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7408868	0.908	rs10418660	chr19:15278635	A/G	cg14696996	chr19:15285081	NOTCH3	1.1	13.17	0.52	7.11e-34	Pulse pressure;
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18404041	chr3:52824283	ITIH1	-0.48	-9.2	-0.39	1.27e-18	Electroencephalogram traits;
LGG	cis	rs9362426	0.608	rs56329400	chr6:88158712	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.47	-8.71	-0.38	5.57e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.61	-0.37	1.15e-16	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg02002194	chr4:3960332	NA	0.41	7.56	0.33	2.22e-13	Neuroticism;
LGG	cis	rs10193935	0.901	rs13429697	chr2:42529818	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.42	-0.4	2.23e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12360000	0.931	rs10903571	chr10:1898257	G/A	cg26364871	chr10:1889757	NA	-0.77	-15.21	-0.58	1.11e-42	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-10.84	-0.45	1.46e-24	Parkinson's disease;
LGG	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	6.78	0.3	3.65e-11	Menopause (age at onset);
LGG	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-8.81	-0.38	2.53e-17	Menarche (age at onset);
LGG	cis	rs4262150	0.689	rs11167584	chr5:152004727	A/C	cg12297329	chr5:152029980	NA	-0.83	-17.09	-0.62	3.92e-51	Bipolar disorder and schizophrenia;
LGG	cis	rs10189230	1.000	rs10189230	chr2:222357961	T/A	cg14652038	chr2:222343519	EPHA4	0.6	12.55	0.5	2.79e-31	Urate levels in lean individuals;
LGG	cis	rs7084783	0.519	rs10879	chr10:105354556	A/G	cg00126946	chr10:105363258	SH3PXD2A	-0.48	-8.42	-0.36	4.75e-16	Fear of pain;
LGG	cis	rs4919087	0.926	rs2861875	chr10:98990139	C/G	cg25902810	chr10:99078978	FRAT1	-0.52	-9.78	-0.41	1.17e-20	Monocyte count;
LGG	cis	rs6964587	0.626	rs7785941	chr7:91531024	T/C	cg17063962	chr7:91808500	NA	-0.44	-8.02	-0.35	8.8e-15	Breast cancer;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22433210	chr17:43662623	NA	0.92	15.26	0.58	6.93e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs9287719	0.967	rs10929686	chr2:10743705	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	trans	rs7474896	0.616	rs2474561	chr10:38373544	C/T	cg17830980	chr10:43048298	ZNF37B	-0.49	-7.81	-0.34	3.8e-14	Obesity (extreme);
LGG	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	trans	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.16	-0.43	4.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00490583	chr16:1843685	IGFALS	-0.47	-8.12	-0.35	4.37e-15	Ankle injury;
LGG	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg02023728	chr11:77925099	USP35	0.39	7.04	0.31	6.81e-12	Alzheimer's disease (survival time);
LGG	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg20744362	chr22:50050164	C22orf34	0.42	7.21	0.32	2.23e-12	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs17685	0.672	rs56343450	chr7:75796235	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg06951627	chr6:26196580	NA	0.53	7.74	0.34	6.29e-14	Gout;Renal underexcretion gout;
LGG	cis	rs9788721	0.806	rs4887056	chr15:78734585	A/G	cg18825076	chr15:78729989	IREB2	-0.57	-9.43	-0.4	1.99e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9381107	0.932	rs9369200	chr6:9453471	C/T	cg14735645	chr6:9486422	NA	-0.43	-7.29	-0.32	1.35e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg22044901	chr15:68126292	NA	-0.42	-7.31	-0.32	1.18e-12	Obesity;
LGG	cis	rs9796	0.689	rs692195	chr15:41444894	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.58	-0.41	5.71e-20	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.31	0.4	5.27e-19	Lung cancer;
LGG	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg01620082	chr3:125678407	NA	-0.83	-9.32	-0.4	4.63e-19	Depression;
LGG	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.78	-0.3	3.67e-11	Neuroticism;
LGG	trans	rs970548	0.738	rs1051713	chr10:45938746	C/T	cg20477318	chr10:51623047	TIMM23	0.63	7.56	0.33	2.16e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.63	0.48	1.27e-27	Mean corpuscular volume;
LGG	cis	rs17445240	0.901	rs6754703	chr2:3707646	C/A	cg16123090	chr2:3699210	NA	0.75	8.48	0.37	3.1e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.19	-0.36	2.5e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3816183	0.626	rs6724638	chr2:42895487	C/T	cg14631114	chr2:43023945	NA	0.35	6.94	0.31	1.33e-11	Hypospadias;
LGG	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg16141378	chr3:129829833	LOC729375	-0.45	-11.14	-0.46	1.03e-25	Mood instability;
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg16141378	chr3:129829833	LOC729375	0.41	9.44	0.4	1.78e-19	Triglycerides;
LGG	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg27129171	chr3:47204927	SETD2	0.72	12.6	0.51	1.73e-31	Birth weight;
LGG	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	8.26	0.36	1.54e-15	Menarche (age at onset);
LGG	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg00409905	chr10:38381863	ZNF37A	0.53	10.55	0.44	1.9e-23	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	trans	rs877282	1.000	rs12779159	chr10:772143	T/C	cg22713356	chr15:30763199	NA	0.56	8.39	0.36	5.84e-16	Uric acid levels;
LGG	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg05973401	chr12:123451056	ABCB9	0.5	7.69	0.34	8.94e-14	Neutrophil percentage of white cells;
LGG	cis	rs7444	0.941	rs4821116	chr22:21973319	A/G	cg22858872	chr22:21984481	YDJC	0.37	6.86	0.3	2.28e-11	Systemic lupus erythematosus;
LGG	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	trans	rs1478898	0.569	rs2264306	chr8:11388449	G/A	cg02002194	chr4:3960332	NA	0.45	7.4	0.33	6.56e-13	Morning vs. evening chronotype;
LGG	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg02023728	chr11:77925099	USP35	0.45	7.74	0.34	6.5e-14	Testicular germ cell tumor;
LGG	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg25039879	chr17:56429692	SUPT4H1	0.61	8.55	0.37	1.81e-16	Cognitive test performance;
LGG	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg10840412	chr1:235813424	GNG4	0.52	7.06	0.31	6.2e-12	Bipolar disorder;
LGG	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg25457927	chr22:38595422	NA	-0.5	-13.48	-0.53	3.76e-35	Cutaneous nevi;
LGG	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg15268244	chr15:77196840	NA	0.43	9.36	0.4	3.41e-19	Blood metabolite levels;
LGG	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg03078520	chr22:18463400	MICAL3	-0.5	-9.75	-0.41	1.46e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg10167378	chr1:228756711	NA	0.57	8.1	0.35	5.08e-15	Chronic lymphocytic leukemia;
LGG	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg11693508	chr17:37793320	STARD3	0.62	9.36	0.4	3.5e-19	Bipolar disorder;
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.02	-0.31	7.78e-12	Bipolar disorder;
LGG	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.37	-0.32	7.85e-13	Total body bone mineral density;
LGG	trans	rs1422110	0.647	rs10063838	chr5:85530546	T/C	cg01787110	chr1:109008453	NBPF6	-0.86	-14.74	-0.57	1.36e-40	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.27	-0.36	1.44e-15	Depression;
LGG	cis	rs9811920	0.809	rs4928153	chr3:99808445	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.63	-0.37	9.86e-17	Axial length;
LGG	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg12310025	chr6:25882481	NA	0.75	14.79	0.57	8.2e-41	Blood metabolite levels;
LGG	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg19773385	chr1:10388646	KIF1B	-0.46	-9.94	-0.42	3.11e-21	Hepatocellular carcinoma;
LGG	cis	rs7512552	0.803	rs11205385	chr1:150476516	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.25	0.39	8.34e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18688522	chr17:2498022	PAFAH1B1	0.53	7.92	0.35	1.79e-14	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16970804	chr5:43042108	LOC153684	0.53	8.53	0.37	2.15e-16	Cognitive performance;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	0.43	7.06	0.31	6.04e-12	Cognitive performance;
LGG	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg22974920	chr21:40686053	BRWD1	-0.42	-6.65	-0.3	8.44e-11	Cognitive function;
LGG	cis	rs2273669	0.915	rs10872028	chr6:109313728	A/G	cg05315195	chr6:109294784	ARMC2	0.52	7.5	0.33	3.25e-13	Prostate cancer;
LGG	trans	rs7181230	0.885	rs8026641	chr15:40338861	C/T	cg22705835	chr10:65332833	REEP3	0.55	9.16	0.39	1.64e-18	Dehydroepiandrosterone sulphate levels;
LGG	trans	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg06027949	chr8:82754900	SNX16	0.54	8.34	0.36	8.36e-16	Diastolic blood pressure;
LGG	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.07	-0.31	5.85e-12	Educational attainment;
LGG	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.26	0.36	1.54e-15	Initial pursuit acceleration;
LGG	trans	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg18187862	chr3:45730750	SACM1L	0.54	8.89	0.38	1.37e-17	Primary sclerosing cholangitis;
LGG	cis	rs2455826	0.500	rs2455852	chr3:15688688	C/T	cg16303742	chr3:15540471	COLQ	-0.5	-10.11	-0.43	7.51e-22	Inflammatory skin disease;
LGG	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg04568710	chr12:38710424	ALG10B	0.38	8.23	0.36	1.88e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12016809	chr21:47604291	C21orf56	0.49	8.38	0.36	6.25e-16	Testicular germ cell tumor;
LGG	trans	rs12517041	1.000	rs4374724	chr5:23309672	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	cis	rs9359856	0.623	rs1179903	chr6:90321736	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.71	-10.19	-0.43	3.96e-22	Bipolar disorder;
LGG	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg13075951	chr6:39282393	KCNK17	0.26	6.8	0.3	3.14e-11	Type 2 diabetes;
LGG	cis	rs1003719	0.788	rs2251161	chr21:38467857	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.62e-53	Eye color traits;
LGG	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.56e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg23845249	chr11:68861649	NA	0.44	7.81	0.34	3.77e-14	Blond vs. brown hair color;
LGG	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.87	-0.45	1.14e-24	Aortic root size;
LGG	cis	rs757278	0.608	rs11767185	chr7:117345652	G/A	cg10524701	chr7:117356490	CTTNBP2	0.47	8.48	0.37	3.1e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs8114671	0.647	rs6060268	chr20:33734293	T/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.7	0.37	5.8e-17	Height;
LGG	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg14101638	chr12:121416612	HNF1A	0.35	7.46	0.33	4.27e-13	N-glycan levels;
LGG	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg26818010	chr10:134567672	INPP5A	-0.57	-9.29	-0.4	5.98e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.51	-0.37	2.41e-16	Personality dimensions;
LGG	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg10189774	chr4:17578691	LAP3	0.43	7.47	0.33	4.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9362395	1	rs9362395	chr6:87854341	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.84	-10.18	-0.43	4.4e-22	Schizophrenia;
LGG	trans	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg06521331	chr12:34319734	NA	0.47	8.26	0.36	1.51e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00149659	chr3:10157352	C3orf10	-0.83	-10.71	-0.45	4.81e-24	Alzheimer's disease;
LGG	cis	rs68170813	0.559	rs2894459	chr7:106960166	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.58	-0.44	1.41e-23	Coronary artery disease;
LGG	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg16586182	chr3:47516702	SCAP	-0.78	-15.62	-0.59	1.77e-44	Colorectal cancer;
LGG	cis	rs67366981	1.000	rs17105547	chr14:77698358	G/A	cg22824376	chr14:77648248	TMEM63C	0.72	7.53	0.33	2.73e-13	Obsessive-compulsive symptoms;
LGG	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg01528321	chr10:82214614	TSPAN14	0.67	11.99	0.49	4.89e-29	Post bronchodilator FEV1;
LGG	cis	rs477692	0.967	rs519690	chr10:131424033	G/A	cg05714579	chr10:131428358	MGMT	0.56	11.5	0.47	4.42e-27	Response to temozolomide;
LGG	cis	rs7715811	1.000	rs6554812	chr5:13762972	T/C	cg07548982	chr5:13769939	DNAH5	-0.47	-9.87	-0.42	5.48e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs2933343	1.000	rs1683811	chr3:128612113	A/C	cg25356066	chr3:128598488	ACAD9	0.46	6.83	0.3	2.63e-11	IgG glycosylation;
LGG	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.29	-0.55	1.23e-38	Heart rate;
LGG	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg01864069	chr14:103024347	NA	0.47	8.36	0.36	7.2e-16	Platelet count;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg13113052	chr18:51796328	POLI	0.41	6.74	0.3	4.79e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25072359	chr17:41440525	NA	0.53	10.09	0.42	8.73e-22	Menopause (age at onset);
LGG	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg12011299	chr4:100065546	ADH4	0.39	7.97	0.35	1.28e-14	Alcohol dependence;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-7.16	-0.32	3.28e-12	Obesity-related traits;
LGG	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg14593290	chr7:50529359	DDC	0.62	11.24	0.46	4.55e-26	Malaria;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-16.19	-0.6	4.91e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2247341	0.894	rs2592831	chr4:1711404	T/C	cg08446824	chr4:1720184	TMEM129	-0.66	-12.39	-0.5	1.25e-30	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg00666640	chr1:248458726	OR2T12	0.56	7.77	0.34	5.27e-14	Common traits (Other);
LGG	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg26384229	chr12:38710491	ALG10B	-0.73	-13.86	-0.54	8.38e-37	Morning vs. evening chronotype;
LGG	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.54	0.33	2.42e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg27129171	chr3:47204927	SETD2	0.79	15.35	0.58	2.88e-43	Colorectal cancer;
LGG	trans	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg25214090	chr10:38739885	LOC399744	0.44	7.61	0.33	1.54e-13	Corneal astigmatism;
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.62	-0.37	1.05e-16	Aortic root size;
LGG	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs12908161	0.959	rs34342559	chr15:85331271	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.81e-12	Schizophrenia;
LGG	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18876405	chr7:65276391	NA	0.6	11.0	0.46	3.64e-25	Aortic root size;
LGG	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.69	-0.3	6.56e-11	Iron status biomarkers;
LGG	cis	rs6754311	0.593	rs313523	chr2:136432103	G/A	cg07169764	chr2:136633963	MCM6	0.75	13.11	0.52	1.33e-33	Mosquito bite size;
LGG	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.4	-0.33	6.58e-13	Triglycerides;
LGG	cis	rs2486288	0.539	rs2433601	chr15:45716425	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	11.84	0.48	2e-28	Glomerular filtration rate;
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.25	0.46	3.97e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs73086581	1.000	rs17215054	chr20:3944779	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg11494091	chr17:61959527	GH2	0.56	9.18	0.39	1.49e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.81	-0.3	3.08e-11	Bone mineral density;
LGG	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg24011408	chr12:48396354	COL2A1	0.52	8.14	0.35	3.56e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg03762820	chr2:43823654	THADA	-0.37	-6.72	-0.3	5.39e-11	Iris color (L* coordinate);
LGG	cis	rs7529073	0.545	rs1431985	chr1:214148246	C/T	cg05052969	chr1:214156842	NA	0.53	10.55	0.44	1.85e-23	Schizophrenia;
LGG	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg01620082	chr3:125678407	NA	-0.64	-7.17	-0.32	2.97e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11081185	chr11:208423	RIC8A;BET1L	-0.51	-7.42	-0.33	5.84e-13	Systemic lupus erythematosus;
LGG	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg06606381	chr12:133084897	FBRSL1	-0.8	-8.06	-0.35	6.53e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg21775007	chr8:11205619	TDH	0.44	6.9	0.31	1.75e-11	Neuroticism;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg22072935	chr14:105399595	NA	0.49	9.25	0.4	8.02e-19	Rheumatoid arthritis;
LGG	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg08773314	chr2:239334832	ASB1	-0.43	-8.26	-0.36	1.59e-15	Multiple system atrophy;
LGG	cis	rs4851266	0.966	rs1465800	chr2:100834777	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	trans	rs7980799	0.935	rs10772076	chr12:33553574	A/C	cg13010199	chr12:38710504	ALG10B	-0.38	-6.79	-0.3	3.49e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs1032833	0.732	rs17454108	chr2:179987043	T/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg02073558	chr3:44770973	ZNF501	-0.68	-12.53	-0.5	3.1e-31	Depressive symptoms;
LGG	cis	rs910187	0.596	rs12329631	chr20:45794427	C/T	cg27589058	chr20:45804311	EYA2	-0.32	-7.85	-0.34	2.9e-14	Migraine;
LGG	cis	rs11644362	0.966	rs1433746	chr16:12992204	T/C	cg06890432	chr16:12997467	SHISA9	-0.32	-6.87	-0.3	2.14e-11	Positive affect;Subjective well-being;
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs10267417	0.603	rs10252481	chr7:19915690	C/G	cg05791153	chr7:19748676	TWISTNB	0.53	6.81	0.3	2.95e-11	Night sleep phenotypes;
LGG	cis	rs7166081	0.951	rs67872952	chr15:67561598	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.98	-0.31	1.01e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4356203	0.870	rs7342262	chr11:17285807	A/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.58	-0.33	1.89e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7917772	0.545	rs10786681	chr10:104317357	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.8	0.48	2.75e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.79e-17	Lung cancer;
LGG	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg20913747	chr6:44695427	NA	-0.66	-11.25	-0.46	4.09e-26	Total body bone mineral density;
LGG	cis	rs2273669	0.588	rs12201102	chr6:109317388	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg22907277	chr7:1156413	C7orf50	0.67	8.5	0.37	2.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4950322	0.857	rs7522219	chr1:146838619	T/C	cg22381352	chr1:146742008	CHD1L	-0.47	-7.82	-0.34	3.57e-14	Protein quantitative trait loci;
LGG	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	11.76	0.48	3.95e-28	Colorectal cancer;
LGG	cis	rs1465370	0.711	rs2302823	chr7:130008159	A/G	cg04743876	chr7:130013617	NA	0.33	7.24	0.32	1.84e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg11965913	chr1:205819406	PM20D1	0.92	21.38	0.7	4.48e-71	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs2729354	0.693	rs2584862	chr11:57241956	T/A	cg24343310	chr11:57249947	NA	0.42	8.01	0.35	9.68e-15	Blood protein levels;
LGG	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg07636037	chr3:49044803	WDR6	0.78	13.99	0.54	2.54e-37	Menarche (age at onset);
LGG	cis	rs988958	1.000	rs988959	chr2:42287389	C/T	cg19376973	chr2:42229025	NA	0.42	6.85	0.3	2.33e-11	Hypospadias;
LGG	cis	rs12220238	1.000	rs12252705	chr10:75984863	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.82	0.48	2.37e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs283228	0.617	rs1948050	chr6:101803594	G/A	cg27451362	chr6:101846650	GRIK2	0.86	13.56	0.53	1.59e-35	Coenzyme Q10 levels;
LGG	cis	rs4148087	1.000	rs4148100	chr21:43640169	T/C	cg10192877	chr21:43641690	ABCG1	-0.41	-7.09	-0.31	5.09e-12	Eating disorder in bipolar disorder;
LGG	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg14829360	chr17:73884958	NA	-0.8	-14.47	-0.56	2.02e-39	Psoriasis;
LGG	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg19913688	chr11:428466	ANO9	-0.67	-8.64	-0.37	9.1e-17	Body mass index;
LGG	cis	rs10865541	0.869	rs13020433	chr2:3417577	G/A	cg11642891	chr2:3452563	TTC15	-0.42	-8.12	-0.35	4.11e-15	Obesity-related traits;
LGG	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg23601095	chr6:26197514	HIST1H3D	0.51	7.22	0.32	2.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg06221963	chr1:154839813	KCNN3	-0.52	-10.72	-0.45	4.17e-24	Prostate cancer;
LGG	cis	rs17767392	0.881	rs67489015	chr14:71964521	G/A	cg02058870	chr14:72053146	SIPA1L1	0.44	8.72	0.38	5.19e-17	Mitral valve prolapse;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.32	-0.32	1.13e-12	Life satisfaction;
LGG	trans	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg07817883	chr1:32538562	TMEM39B	1.13	10.6	0.44	1.2e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg18129748	chr3:49941408	MST1R	-0.22	-6.86	-0.3	2.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1461503	0.834	rs6589961	chr11:122820281	C/T	cg27398637	chr11:122830231	C11orf63	-0.71	-14.19	-0.55	3.25e-38	Menarche (age at onset);
LGG	cis	rs3750965	0.919	rs12280942	chr11:68859683	A/G	cg11927738	chr11:68850580	TPCN2	-0.39	-6.98	-0.31	9.99e-12	Hair color;
LGG	cis	rs7789940	0.951	rs7779014	chr7:75975586	C/T	cg10167463	chr7:75959203	YWHAG	-0.46	-7.83	-0.34	3.29e-14	Multiple sclerosis;
LGG	trans	rs3960554	0.808	rs111764601	chr7:75706141	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.27	0.5	3.76e-30	Eotaxin levels;
LGG	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.96	0.31	1.15e-11	Educational attainment;
LGG	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26617929	chr16:1858877	NA	-0.62	-8.69	-0.37	6.34e-17	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7944735	0.508	rs74335517	chr11:47479168	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.75	0.3	4.51e-11	Intraocular pressure;
LGG	cis	rs6540556	0.723	rs6679099	chr1:209895852	T/G	cg23920097	chr1:209922102	NA	-0.43	-7.23	-0.32	2.06e-12	Red blood cell count;
LGG	cis	rs12039371	0.866	rs12136316	chr1:183986964	A/T	cg01436608	chr1:184005534	GLT25D2	0.53	6.96	0.31	1.18e-11	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg18477163	chr1:228402036	OBSCN	-0.27	-7.29	-0.32	1.35e-12	Diastolic blood pressure;
LGG	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-13.99	-0.55	2.47e-37	Response to antipsychotic treatment;
LGG	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg22875332	chr1:76189707	ACADM	0.61	10.89	0.45	9.33e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3735485	0.738	rs62458155	chr7:45118198	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.54	-0.41	7.97e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg25554036	chr4:6271136	WFS1	-0.62	-11.08	-0.46	1.82e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg16141378	chr3:129829833	LOC729375	-0.34	-6.86	-0.3	2.22e-11	Neuroticism;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg16301924	chr13:53314226	LECT1	-0.44	-9.01	-0.39	5.46e-18	Lewy body disease;
LGG	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg08807101	chr21:30365312	RNF160	0.76	13.86	0.54	8.31e-37	Selective IgA deficiency;
LGG	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg02503808	chr4:7069936	GRPEL1	-1.0	-8.81	-0.38	2.6e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg08085267	chr17:45401833	C17orf57	-0.5	-9.24	-0.39	9.12e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2285947	0.935	rs10258022	chr7:21583667	A/G	cg03697024	chr7:21583438	DNAH11	0.35	8.82	0.38	2.34e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.67	0.44	6.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16534505	chr17:4890669	CAMTA2	-0.39	-6.8	-0.3	3.25e-11	Brain structure;
LGG	cis	rs4380275	0.931	rs4538239	chr2:774238	C/T	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg07395648	chr5:131743802	NA	-0.55	-12.84	-0.51	1.75e-32	Blood metabolite levels;
LGG	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.4	-0.36	5.6e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08704250	chr15:31115839	NA	-0.41	-7.17	-0.32	2.93e-12	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04175879	chr20:46130755	NCOA3	0.49	7.62	0.33	1.42e-13	Gut microbiome composition (summer);
LGG	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg09165964	chr15:75287851	SCAMP5	0.54	10.04	0.42	1.34e-21	Breast cancer;
LGG	cis	rs9649465	1.000	rs3807634	chr7:123382290	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.93	-0.38	1.04e-17	Migraine;
LGG	cis	rs4731207	0.564	rs13234634	chr7:124676033	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.13	-0.31	3.91e-12	Cutaneous malignant melanoma;
LGG	cis	rs2229238	0.868	rs12408461	chr1:154512710	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.97	0.31	1.12e-11	Coronary heart disease;
LGG	cis	rs42648	0.869	rs1015404	chr7:89913946	G/C	cg25739043	chr7:89950458	NA	-0.43	-9.19	-0.39	1.32e-18	Homocysteine levels;
LGG	cis	rs4740619	0.905	rs7873776	chr9:15791681	G/A	cg14451791	chr9:16040625	NA	-0.36	-9.45	-0.4	1.74e-19	Body mass index;
LGG	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg00339695	chr16:24857497	SLC5A11	0.4	6.95	0.31	1.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs911263	0.603	rs1956529	chr14:68788924	A/G	cg18825221	chr14:68749962	RAD51L1	-0.35	-7.55	-0.33	2.3e-13	Primary biliary cholangitis;
LGG	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg25237894	chr2:233734115	C2orf82	-0.65	-12.39	-0.5	1.17e-30	Coronary artery disease;
LGG	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg18165381	chr3:44552316	NA	-0.42	-6.96	-0.31	1.2e-11	Depressive symptoms;
LGG	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg19812747	chr11:111475976	SIK2	0.47	9.33	0.4	4.27e-19	Primary sclerosing cholangitis;
LGG	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.0	-0.46	3.52e-25	Migraine;Coronary artery disease;
LGG	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg11161011	chr14:65562177	MAX	-0.65	-12.5	-0.5	4.4e-31	Obesity-related traits;
LGG	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-13.68	-0.54	5.28e-36	Heart rate;
LGG	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-8.97	-0.38	7.59e-18	Morning vs. evening chronotype;
LGG	cis	rs4950322	1.000	rs4448568	chr1:146849017	A/T	cg22381352	chr1:146742008	CHD1L	-0.44	-6.98	-0.31	1.04e-11	Protein quantitative trait loci;
LGG	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.57e-16	Vitiligo;
LGG	cis	rs9457247	0.967	rs1794696	chr6:167396174	T/C	cg07741184	chr6:167504864	NA	0.33	7.19	0.32	2.69e-12	Crohn's disease;
LGG	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.72	-0.64	5.42e-54	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04518972	chr3:23245400	UBE2E2	0.47	7.07	0.31	5.66e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15906409	chr17:17685582	RAI1	0.49	7.21	0.32	2.29e-12	Gut microbiome composition (summer);
LGG	cis	rs7129556	0.815	rs11607715	chr11:77238859	T/C	cg12586386	chr11:77299805	AQP11	0.5	7.93	0.35	1.65e-14	Weight loss (gastric bypass surgery);
LGG	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.48	0.4	1.38e-19	Gout;Renal underexcretion gout;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03647317	chr4:187891568	NA	-0.41	-8.83	-0.38	2.2e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.4	0.4	2.48e-19	Diabetic retinopathy;
LGG	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.07	-0.78	1.93e-97	Schizophrenia;
LGG	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg25019033	chr10:957182	NA	-0.56	-10.24	-0.43	2.66e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg24060327	chr5:131705240	SLC22A5	0.49	8.51	0.37	2.46e-16	Blood metabolite levels;
LGG	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.9	0.31	1.77e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs5771225	0.563	rs6010220	chr22:50693554	A/G	cg08875078	chr22:50639485	SELO	0.47	6.95	0.31	1.22e-11	Late-onset Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg13147721	chr7:65941812	NA	-0.79	-9.48	-0.4	1.32e-19	Diabetic kidney disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13284864	chr3:142895279	NA	-0.38	-6.68	-0.3	6.76e-11	Intelligence (multi-trait analysis);
LGG	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg12856521	chr11:46389249	DGKZ	0.43	7.52	0.33	2.94e-13	Leprosy;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	1.96e-12	Bipolar disorder;
LGG	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg12560992	chr17:57184187	TRIM37	-0.87	-15.29	-0.58	5.17e-43	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.632	rs13438452	chr7:23174182	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.21	0.32	2.31e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4950322	0.570	rs72691102	chr1:146772888	A/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg04117972	chr1:227635322	NA	0.72	11.2	0.46	6.29e-26	Major depressive disorder;
LGG	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg27129171	chr3:47204927	SETD2	0.82	15.73	0.59	5.73e-45	Colorectal cancer;
LGG	cis	rs6598955	0.543	rs3795689	chr1:26560366	C/G	cg04990556	chr1:26633338	UBXN11	0.72	10.72	0.45	4.17e-24	Obesity-related traits;
LGG	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg13683864	chr3:40499215	RPL14	-1.15	-28.0	-0.79	1.18e-101	Renal cell carcinoma;
LGG	cis	rs727505	1.000	rs56313563	chr7:124507003	G/A	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg24803719	chr17:45855879	NA	-0.23	-7.02	-0.31	7.83e-12	IgG glycosylation;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	7.51	0.33	3.11e-13	Obesity-related traits;
LGG	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08045932	chr20:61659980	NA	-0.58	-12.72	-0.51	5.12e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7126328	1	rs7126328	chr11:120244577	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.89	-0.51	1.06e-32	Intraocular pressure;
LGG	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.67	-0.41	2.79e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2274273	0.837	rs10141483	chr14:55786871	T/C	cg04306507	chr14:55594613	LGALS3	0.64	18.05	0.64	1.53e-55	Protein biomarker;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	5.88e-17	IgG glycosylation;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.83	-0.42	7.91e-21	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11987759	chr7:65425863	GUSB	0.38	7.36	0.32	8.47e-13	Aortic root size;
LGG	cis	rs9863	0.828	rs952632	chr12:124469738	A/G	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.99e-12	White blood cell count;
LGG	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs9462027	0.595	rs74912731	chr6:34767268	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.41	-6.96	-0.31	1.18e-11	Systemic lupus erythematosus;
LGG	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4148660	0.719	rs10841914	chr12:22094801	A/G	cg14669847	chr12:22099120	NA	0.4	7.21	0.32	2.36e-12	Gout;
LGG	cis	rs8017423	0.967	rs2277516	chr14:90722824	G/C	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg23752985	chr2:85803571	VAMP8	0.39	7.65	0.33	1.2e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg00543991	chr22:32367038	NA	0.78	8.58	0.37	1.46e-16	Childhood ear infection;
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.34	-0.47	1.73e-26	Intelligence (multi-trait analysis);
LGG	cis	rs12681366	0.571	rs2919654	chr8:95476273	T/A	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg22444338	chr7:1054449	C7orf50	0.43	9.29	0.4	6.07e-19	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg26174226	chr8:58114915	NA	-0.5	-7.27	-0.32	1.51e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1594829	0.553	rs2046224	chr8:26151604	G/T	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-7.37	-0.32	7.77e-13	Ovarian reserve;
LGG	cis	rs11877825	0.568	rs1442689	chr18:10566345	T/C	cg25239095	chr18:10589360	NA	0.41	7.73	0.34	6.92e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg07636037	chr3:49044803	WDR6	0.74	12.97	0.52	4.77e-33	Menarche (age at onset);
LGG	cis	rs738321	0.658	rs5756916	chr22:38507047	G/A	cg03162506	chr22:38580953	NA	0.37	8.64	0.37	9.09e-17	Breast cancer;
LGG	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg16586182	chr3:47516702	SCAP	0.74	13.46	0.53	4.28e-35	Colorectal cancer;
LGG	cis	rs6554196	0.508	rs6554199	chr4:55522488	G/T	cg18836493	chr4:55524333	KIT	-0.42	-7.81	-0.34	3.92e-14	Monocyte count;
LGG	cis	rs11785693	0.862	rs62489554	chr8:4960685	T/C	cg26367366	chr8:4980734	NA	0.94	13.91	0.54	5.33e-37	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.4	-0.36	5.6e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg06885757	chr1:42089581	HIVEP3	-0.65	-14.71	-0.56	1.75e-40	Airway imaging phenotypes;
LGG	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg27532318	chr7:32358331	NA	0.81	8.42	0.36	4.81e-16	Body mass index;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	11.6	0.47	1.77e-27	Personality dimensions;
LGG	cis	rs7572733	0.534	rs1607374	chr2:198800440	A/G	cg00792783	chr2:198669748	PLCL1	0.7	11.07	0.46	1.95e-25	Dermatomyositis;
LGG	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-6.99	-0.31	9.41e-12	Diastolic blood pressure;
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17554472	chr22:41940697	POLR3H	-0.5	-7.11	-0.31	4.43e-12	Vitiligo;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg19261559	chr20:49575107	MOCS3;DPM1	-0.45	-7.65	-0.33	1.15e-13	Educational attainment (years of education);
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg20453264	chr5:131705742	SLC22A5	-0.61	-7.78	-0.34	4.69e-14	Rheumatoid arthritis;
LGG	cis	rs17767392	1.000	rs61991248	chr14:71860529	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.67e-18	Mitral valve prolapse;
LGG	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-14.27	-0.55	1.44e-38	Colorectal cancer;
LGG	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg16486109	chr11:613632	IRF7	0.39	6.9	0.31	1.69e-11	Systemic lupus erythematosus;
LGG	cis	rs17027750	0.532	rs1672767	chr3:3198513	A/G	cg16797762	chr3:3221439	CRBN	-0.48	-7.41	-0.33	6.13e-13	Basophil percentage of granulocytes;Basophil percentage of white cells;
LGG	cis	rs9403521	1.000	rs6901659	chr6:143985106	T/C	cg18240653	chr6:144019428	PHACTR2	-0.65	-9.77	-0.41	1.25e-20	Obesity-related traits;
LGG	cis	rs8005677	0.828	rs712486	chr14:23425041	A/G	cg25600027	chr14:23388339	RBM23	-0.41	-6.88	-0.3	1.99e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.4	-8.14	-0.35	3.65e-15	Personality dimensions;
LGG	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.64e-21	Diabetic retinopathy;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg00689492	chr4:1303491	MAEA	0.46	7.85	0.34	3.02e-14	Obesity-related traits;
LGG	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.54	0.33	2.42e-13	Neuroticism;
LGG	cis	rs1620921	0.655	rs59754710	chr6:161187850	C/A	cg01280913	chr6:161186852	NA	-0.33	-6.87	-0.3	2.13e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2692947	0.644	rs2969491	chr2:96794982	C/T	cg22654517	chr2:96458247	NA	0.36	7.38	0.32	7.57e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.54	-11.58	-0.47	2.08e-27	Multiple sclerosis;
LGG	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg26384229	chr12:38710491	ALG10B	0.8	16.05	0.6	1.99e-46	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg07701084	chr6:150067640	NUP43	0.67	12.57	0.5	2.2e-31	Lung cancer;
LGG	cis	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.06	-0.46	2.15e-25	Morning vs. evening chronotype;
LGG	cis	rs921968	0.608	rs11678428	chr2:219352598	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.83	-0.3	2.68e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4472734	0.813	rs6698007	chr1:214624286	A/C	cg00063699	chr1:214624242	PTPN14	-0.41	-8.91	-0.38	1.14e-17	Height;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg05335186	chr13:53173507	NA	0.36	6.86	0.3	2.17e-11	Lewy body disease;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.76	-0.34	5.6e-14	Skin colour saturation;
LGG	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.08	-0.31	5.21e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.2e-31	Prostate cancer;
LGG	cis	rs2011503	1.000	rs8111093	chr19:19505548	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.65	0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-9.18	-0.39	1.45e-18	Diabetic retinopathy;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg05335186	chr13:53173507	NA	0.44	8.62	0.37	1.05e-16	Lewy body disease;
LGG	cis	rs12681366	0.614	rs2921385	chr8:95459348	C/T	cg13257157	chr8:95487014	RAD54B	-0.38	-7.02	-0.31	8.02e-12	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24098762	chr5:137667672	CDC25C	0.55	8.24	0.36	1.82e-15	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.85	-0.38	1.81e-17	Response to antipsychotic treatment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24631913	chr5:87971905	LOC645323	0.42	6.85	0.3	2.36e-11	Cognitive performance;
LGG	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg21058520	chr6:100914733	NA	0.39	6.73	0.3	5.02e-11	Neuroticism;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg12728061	chr1:2383438	NA	-0.46	-11.05	-0.46	2.29e-25	Non-obstructive azoospermia;
LGG	trans	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-11.23	-0.46	4.63e-26	Mean corpuscular volume;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17192681	chr2:10953115	PDIA6	-0.44	-7.34	-0.32	9.66e-13	Brain structure;
LGG	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.36	-0.47	1.55e-26	Schizophrenia;
LGG	trans	rs55821297	0.612	rs2017368	chr4:111364167	T/C	cg10580549	chr19:53101634	ZNF137	0.55	6.97	0.31	1.1e-11	Iris color (a* coordinate);
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg26578617	chr4:90757533	SNCA	-0.44	-8.77	-0.38	3.56e-17	Dementia with Lewy bodies;
LGG	cis	rs787274	1.000	rs787271	chr9:115549463	C/T	cg13803584	chr9:115635662	SNX30	-0.55	-7.85	-0.34	3.01e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2777491	0.874	rs13379756	chr15:41663896	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.02	-0.64	2.18e-55	Ulcerative colitis;
LGG	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.75	-0.34	5.89e-14	Cognitive test performance;
LGG	cis	rs975739	0.872	rs1766354	chr13:78373024	C/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.61e-11	Hair color;
LGG	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg15268244	chr15:77196840	NA	0.48	10.27	0.43	2.06e-22	Blood metabolite levels;
LGG	cis	rs7267979	1.000	rs2424700	chr20:25266513	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.28	0.43	1.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs668210	0.793	rs1192184	chr11:65773382	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.74	-9.73	-0.41	1.75e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg07157834	chr1:205819609	PM20D1	-0.38	-7.77	-0.34	5.17e-14	Prostate-specific antigen levels;
LGG	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg16301924	chr13:53314226	LECT1	0.4	7.62	0.33	1.45e-13	Lewy body disease;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.72	-0.34	7.35e-14	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg06558623	chr16:89946397	TCF25	1.15	12.61	0.51	1.44e-31	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14217534	chr12:49525474	TUBA1B	0.47	6.74	0.3	4.86e-11	Gut microbiome composition (summer);
LGG	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg19468946	chr17:37922297	IKZF3	-0.43	-7.73	-0.34	6.88e-14	Self-reported allergy;
LGG	cis	rs7326068	0.610	rs2762999	chr13:21445243	G/A	cg04906043	chr13:21280425	IL17D	-0.49	-7.71	-0.34	7.95e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs9915657	0.870	rs35271702	chr17:70140516	G/A	cg09344028	chr17:70110421	NA	0.46	10.14	0.43	5.7e-22	Thyroid hormone levels;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg06719900	chr11:109292894	C11orf87	0.44	8.12	0.35	4.14e-15	Schizophrenia;
LGG	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.16	0.55	4.6e-38	Bladder cancer;
LGG	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs12479064	0.666	rs11887935	chr2:100127570	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.21	-0.43	3.27e-22	Chronic sinus infection;
LGG	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26850624	chr5:429559	AHRR	0.3	6.98	0.31	1.04e-11	Cystic fibrosis severity;
LGG	cis	rs2708240	0.666	rs2710104	chr7:147592649	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-8.33	-0.36	9.22e-16	QT interval (drug interaction);
LGG	cis	rs2742417	0.603	rs2742372	chr3:45783472	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg16583315	chr14:65563665	MAX	-0.42	-8.46	-0.37	3.51e-16	Obesity-related traits;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00689492	chr4:1303491	MAEA	0.48	8.25	0.36	1.63e-15	Obesity-related traits;
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg15921436	chr17:44337874	NA	-0.5	-10.6	-0.44	1.17e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7666738	0.830	rs1025204	chr4:99023441	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.25e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7572733	0.515	rs13408411	chr2:198825462	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs6761276	0.635	rs4849150	chr2:113830582	A/C	cg05949173	chr2:113825882	IL1F10	0.41	7.38	0.32	7.27e-13	Protein quantitative trait loci;
LGG	cis	rs832540	0.656	rs2408597	chr5:56098632	G/A	cg12654349	chr5:56205094	C5orf35	-0.39	-6.86	-0.3	2.19e-11	Coronary artery disease;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg06558623	chr16:89946397	TCF25	0.99	12.93	0.52	6.98e-33	Skin colour saturation;
LGG	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs9462027	0.597	rs6940215	chr6:34706358	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.42	-7.78	-0.34	4.72e-14	Systemic lupus erythematosus;
LGG	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg07636037	chr3:49044803	WDR6	1.09	27.05	0.78	2.24e-97	Parkinson's disease;
LGG	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.46e-12	Total cholesterol levels;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.62e-13	Prudent dietary pattern;
LGG	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg09904177	chr6:26538194	HMGN4	0.78	18.1	0.64	9.33e-56	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.68	-0.41	2.57e-20	Colorectal cancer;
LGG	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg11584989	chr19:19387371	SF4	-0.75	-12.46	-0.5	5.96e-31	Bipolar disorder;
LGG	cis	rs919433	0.889	rs10931782	chr2:198211579	G/A	cg00792783	chr2:198669748	PLCL1	-0.45	-7.07	-0.31	5.73e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4629180	0.562	rs10198901	chr2:102127937	G/A	cg16435561	chr2:102091048	RFX8	0.47	8.81	0.38	2.47e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs240764	0.621	rs10457844	chr6:101196532	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-7.93	-0.35	1.62e-14	Neuroticism;
LGG	cis	rs10267417	0.657	rs7800274	chr7:19871184	G/T	cg05791153	chr7:19748676	TWISTNB	0.63	8.1	0.35	4.84e-15	Night sleep phenotypes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20905746	chr15:79165638	MORF4L1	0.4	6.72	0.3	5.33e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14169450	chr9:139327907	INPP5E	-0.4	-7.41	-0.33	6.23e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg10847948	chr11:71163743	NADSYN1	0.58	8.79	0.38	3.04e-17	Vitamin D levels;
LGG	cis	rs6500602	0.685	rs62037617	chr16:4435163	G/C	cg19168338	chr16:4465731	CORO7	-0.69	-11.68	-0.48	8.29e-28	Schizophrenia;
LGG	cis	rs17023223	0.537	rs2765530	chr1:119584396	G/A	cg05756136	chr1:119680316	WARS2	-0.41	-8.61	-0.37	1.13e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg18335740	chr13:41363409	SLC25A15	0.55	10.3	0.43	1.59e-22	Lewy body disease;
LGG	cis	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg05084668	chr3:125655381	ALG1L	-1.07	-12.48	-0.5	5.03e-31	Blood pressure (smoking interaction);
LGG	cis	rs2640806	0.505	rs11997560	chr8:97366006	A/G	cg22138393	chr8:97340270	PTDSS1	-0.29	-7.69	-0.34	9.14e-14	Obesity-related traits;
LGG	cis	rs9308731	0.966	rs1877331	chr2:111906510	G/A	cg26001287	chr2:111877753	BCL2L11	-0.39	-7.82	-0.34	3.48e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg10057126	chr4:77819792	ANKRD56	0.35	6.83	0.3	2.62e-11	Emphysema distribution in smoking;
LGG	cis	rs4268898	0.965	rs13033241	chr2:24476118	G/C	cg06627628	chr2:24431161	ITSN2	0.51	8.71	0.38	5.36e-17	Asthma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14022721	chr22:25507536	KIAA1671	0.47	7.69	0.34	8.68e-14	Gut microbiome composition (summer);
LGG	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg20336341	chr7:50628841	DDC	-0.42	-7.25	-0.32	1.76e-12	Malaria;
LGG	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg18876405	chr7:65276391	NA	-0.63	-11.82	-0.48	2.39e-28	Aortic root size;
LGG	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.49	0.4	1.2e-19	Blood metabolite levels;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg09699651	chr6:150184138	LRP11	0.52	9.33	0.4	4.52e-19	Lung cancer;
LGG	cis	rs9311474	0.935	rs7622851	chr3:52333671	C/G	cg14092988	chr3:52407081	DNAH1	0.28	7.35	0.32	9.17e-13	Electroencephalogram traits;
LGG	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg06885757	chr1:42089581	HIVEP3	0.63	15.36	0.58	2.5e-43	Airway imaging phenotypes;
LGG	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg26441486	chr22:50317300	CRELD2	-0.4	-7.4	-0.33	6.48e-13	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.62	-0.33	1.42e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs136211	0.577	rs9610498	chr22:36777739	C/T	cg21778268	chr22:36877729	TXN2	-0.39	-6.77	-0.3	3.85e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	-0.43	-7.01	-0.31	8.69e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27492418	chr7:38948804	VPS41	0.42	6.99	0.31	9.55e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg15103426	chr22:29168792	CCDC117	0.7	11.24	0.46	4.33e-26	Lymphocyte counts;
LGG	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg12395012	chr8:11607386	GATA4	0.41	7.34	0.32	9.36e-13	Monocyte count;
LGG	cis	rs9815354	1.000	rs76471037	chr3:41799414	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.52	0.33	2.8e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4901847	1.000	rs12884702	chr14:58555329	A/T	cg15908186	chr14:58618357	C14orf37	0.52	9.29	0.4	6.21e-19	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg01673284	chr16:4527211	HMOX2	0.32	6.74	0.3	4.59e-11	Schizophrenia;
LGG	trans	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.36	-0.4	3.44e-19	Bladder cancer;
LGG	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.82	-0.3	2.9e-11	Mood instability;
LGG	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	21.44	0.71	2.58e-71	Homoarginine levels;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.11	-0.31	4.31e-12	Obesity-related traits;
LGG	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg14191688	chr11:70257035	CTTN	0.6	8.52	0.37	2.23e-16	Coronary artery disease;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.89e-18	Menopause (age at onset);
LGG	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.34e-12	Retinal vascular caliber;
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.78	-0.3	3.72e-11	Total body bone mineral density;
LGG	cis	rs74781061	0.929	rs8043032	chr15:74836316	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg09117114	chr16:67998030	SLC12A4	0.38	6.69	0.3	6.43e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs77741769	0.529	rs2047568	chr12:121243790	A/G	cg02419362	chr12:121203948	SPPL3	-0.52	-8.98	-0.39	6.94e-18	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.46e-13	Menopause (age at onset);
LGG	cis	rs10819861	0.620	rs10989244	chr9:98856772	C/G	cg14508093	chr9:98862825	NA	0.3	7.13	0.31	3.88e-12	Electrocardiographic traits;
LGG	trans	rs1459104	1.000	rs7925158	chr11:55158563	A/G	cg15704280	chr7:45808275	SEPT13	0.66	6.66	0.3	7.62e-11	Body mass index;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	trans	rs2562456	0.833	rs4321312	chr19:21519416	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.41	-0.33	6.21e-13	Pain;
LGG	cis	rs7178909	0.800	rs3825866	chr15:90437638	A/T	cg19708238	chr15:90437601	AP3S2	0.41	6.82	0.3	2.92e-11	Common traits (Other);
LGG	cis	rs4006360	0.646	rs8080164	chr17:39292845	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-10.06	-0.42	1.13e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg21827317	chr3:136751795	NA	0.52	9.61	0.41	4.5e-20	Neuroticism;
LGG	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg18240062	chr17:79603768	NPLOC4	-0.61	-10.18	-0.43	4.16e-22	Eye color traits;
LGG	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg16329650	chr2:213403929	ERBB4	0.48	7.93	0.35	1.68e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs55882075	0.765	rs34329357	chr5:179130408	G/C	cg14593053	chr5:179126677	CANX	0.4	6.79	0.3	3.5e-11	Monocyte percentage of white cells;
LGG	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg24011408	chr12:48396354	COL2A1	-0.5	-7.84	-0.34	3.13e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9309473	0.898	rs11126404	chr2:73796924	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.73	-0.34	6.71e-14	Metabolite levels;
LGG	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-19.14	-0.66	1.44e-60	Cognitive function;
LGG	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg06718696	chr17:78121285	EIF4A3	0.43	7.16	0.32	3.09e-12	Yeast infection;
LGG	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs950169	0.922	rs11635505	chr15:85097034	A/C	cg03959625	chr15:84868606	LOC388152	-0.58	-9.24	-0.39	9.07e-19	Schizophrenia;
LGG	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg18876405	chr7:65276391	NA	-0.55	-9.88	-0.42	5.26e-21	Aortic root size;
LGG	cis	rs2274273	0.870	rs7160523	chr14:55594560	G/T	cg04306507	chr14:55594613	LGALS3	0.65	18.42	0.65	2.94e-57	Protein biomarker;
LGG	cis	rs377457	1.000	rs377457	chr16:85735652	A/G	cg08768472	chr16:85689701	KIAA0182	-0.44	-8.17	-0.35	3e-15	Type 2 diabetes;
LGG	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03576123	chr11:487126	PTDSS2	-1.31	-17.33	-0.63	3.17e-52	Body mass index;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg19143629	chr17:61920732	SMARCD2	0.4	6.86	0.3	2.28e-11	Prudent dietary pattern;
LGG	cis	rs1953600	0.870	rs2573353	chr10:81940917	A/C	cg04850286	chr10:81895943	PLAC9	-0.44	-9.92	-0.42	3.69e-21	Sarcoidosis;
LGG	cis	rs17321999	0.909	rs9967884	chr2:30488183	A/G	cg05247661	chr2:30472410	LBH	0.48	7.85	0.34	2.94e-14	Systemic lupus erythematosus;
LGG	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg14598338	chr9:96623480	NA	-0.53	-9.63	-0.41	3.95e-20	DNA methylation (variation);
LGG	cis	rs6504108	0.522	rs2924257	chr17:46317555	C/G	cg02219949	chr17:45927392	SP6	0.38	7.04	0.31	7.2e-12	Body mass index;
LGG	cis	rs10791097	0.720	rs6590517	chr11:130733505	C/T	cg12179176	chr11:130786555	SNX19	0.8	16.09	0.6	1.44e-46	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg06238570	chr21:40685208	BRWD1	0.53	8.68	0.37	6.65e-17	Cognitive function;
LGG	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg09307838	chr4:120376055	NA	0.67	10.64	0.44	8.3e-24	Educational attainment;
LGG	cis	rs6594713	0.921	rs6870401	chr5:112738364	C/G	cg12552261	chr5:112820674	MCC	0.5	7.23	0.32	2.06e-12	Brain cytoarchitecture;
LGG	trans	rs9650657	0.738	rs11250078	chr8:10666581	G/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.1	-0.31	4.82e-12	Neuroticism;
LGG	cis	rs947211	0.800	rs1341249	chr1:205759876	T/C	cg24503407	chr1:205819492	PM20D1	0.47	7.05	0.31	6.72e-12	Parkinson's disease;
LGG	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg03474202	chr17:45855739	NA	-0.27	-8.0	-0.35	1.02e-14	IgG glycosylation;
LGG	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg01028140	chr2:1542097	TPO	-0.58	-10.11	-0.43	7.42e-22	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs67478160	0.643	rs1535098	chr14:104216513	T/A	cg26031613	chr14:104095156	KLC1	-0.44	-7.27	-0.32	1.55e-12	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17295589	chr17:62019144	SCN4A	0.39	6.68	0.3	6.93e-11	Pancreatic cancer;
LGG	cis	rs13394619	0.775	rs10200851	chr2:11722082	C/T	cg07314298	chr2:11723111	GREB1	-0.49	-10.29	-0.43	1.62e-22	Endometriosis;
LGG	cis	rs4824093	0.610	rs77128035	chr22:50241024	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-6.99	-0.31	9.88e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3743102	0.591	rs8040152	chr15:83356728	C/T	cg00614314	chr15:82944287	LOC80154	-0.71	-7.5	-0.33	3.32e-13	Colorectal adenoma (advanced);
LGG	cis	rs12496230	0.909	rs13075691	chr3:66857626	T/A	cg04995300	chr3:66848608	NA	0.43	6.95	0.31	1.24e-11	Type 2 diabetes;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18402987	chr7:1209562	NA	0.45	8.66	0.37	7.72e-17	Longevity;Endometriosis;
LGG	trans	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg10756647	chr7:56101905	PSPH	0.76	8.72	0.38	5.04e-17	Diabetic kidney disease;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07659893	chr17:61819838	STRADA	-0.48	-7.86	-0.34	2.63e-14	Prudent dietary pattern;
LGG	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg23933602	chr10:16859644	RSU1	0.66	9.76	0.41	1.33e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg20608306	chr11:116969690	SIK3	0.42	13.29	0.53	2.2e-34	Blood protein levels;
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg11062466	chr8:58055876	NA	0.5	8.44	0.37	3.97e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg25208724	chr1:156163844	SLC25A44	1.15	20.51	0.69	5.8e-67	Testicular germ cell tumor;
LGG	trans	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-11.43	-0.47	8.22e-27	Mean corpuscular volume;
LGG	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg02549819	chr16:58548995	SETD6	1.43	13.68	0.54	5.3e-36	Schizophrenia;
LGG	cis	rs3206736	0.732	rs329557	chr7:35103469	A/G	cg13400248	chr7:35225412	NA	0.39	7.16	0.32	3.19e-12	Diastolic blood pressure;
LGG	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg26384229	chr12:38710491	ALG10B	0.6	11.18	0.46	7.48e-26	Morning vs. evening chronotype;
LGG	cis	rs6445975	0.667	rs6445963	chr3:58234479	G/A	cg24175188	chr3:58374923	PXK	0.39	7.32	0.32	1.13e-12	Systemic lupus erythematosus;
LGG	cis	rs9457247	0.765	rs12212247	chr6:167413539	T/C	cg07741184	chr6:167504864	NA	0.42	9.37	0.4	3.29e-19	Crohn's disease;
LGG	cis	rs7255045	0.752	rs10404876	chr19:12987605	T/C	cg07955356	chr19:12992479	DNASE2	0.41	6.91	0.31	1.61e-11	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg26174226	chr8:58114915	NA	-0.6	-8.19	-0.36	2.56e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.4	-8.65	-0.37	8.73e-17	Personality dimensions;
LGG	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.41	-7.56	-0.33	2.16e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-9.15	-0.39	1.87e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4262150	0.672	rs72806711	chr5:152340090	A/T	cg12297329	chr5:152029980	NA	-0.58	-9.33	-0.4	4.56e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9341835	0.618	rs1779747	chr6:64141100	C/T	cg00787780	chr6:64151745	NA	-0.45	-8.24	-0.36	1.73e-15	Schizophrenia;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg18446336	chr7:2847575	GNA12	0.3	7.99	0.35	1.06e-14	Height;
LGG	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg27129171	chr3:47204927	SETD2	0.72	12.34	0.5	1.92e-30	Birth weight;
LGG	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12618769	0.652	rs3754878	chr2:99179384	G/A	cg18455616	chr2:99124870	INPP4A	0.27	7.6	0.33	1.67e-13	Bipolar disorder;
LGG	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.9	0.31	1.77e-11	Hemoglobin concentration;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg15537850	chr8:144661051	NAPRT1	0.99	7.53	0.33	2.71e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs12912251	1.000	rs12901215	chr15:38992893	G/A	cg01338139	chr15:38987640	C15orf53	-0.55	-8.56	-0.37	1.67e-16	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.04	-0.31	6.78e-12	Pancreatic cancer;
LGG	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.28e-14	Dementia with Lewy bodies;
LGG	cis	rs10463554	0.727	rs34768	chr5:102491502	A/G	cg23492399	chr5:102201601	PAM	-0.58	-8.57	-0.37	1.57e-16	Parkinson's disease;
LGG	cis	rs2070488	0.965	rs9877282	chr3:38541452	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-18.2	-0.65	3.18e-56	Electrocardiographic conduction measures;
LGG	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg02023728	chr11:77925099	USP35	0.44	7.63	0.33	1.32e-13	Testicular germ cell tumor;
LGG	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg16230307	chr14:35515116	FAM177A1	0.89	13.2	0.52	5.43e-34	Psoriasis;
LGG	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg17971929	chr21:40555470	PSMG1	-0.67	-12.32	-0.5	2.3e-30	Cognitive function;
LGG	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg02228329	chr11:64053129	BAD;GPR137	-0.52	-6.94	-0.31	1.36e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7666738	0.830	rs7682991	chr4:98982595	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	cis	rs6918586	0.616	rs1056314	chr6:26114653	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	9.68	0.41	2.75e-20	Schizophrenia;
LGG	cis	rs11792861	0.926	rs72607163	chr9:111803128	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.54e-19	Menarche (age at onset);
LGG	cis	rs4363385	0.574	rs6671520	chr1:152944156	C/T	cg13444842	chr1:152974279	SPRR3	-0.51	-10.37	-0.43	8.86e-23	Inflammatory skin disease;
LGG	cis	rs72781680	0.848	rs6748727	chr2:24041058	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.21e-18	Lymphocyte counts;
LGG	cis	rs1838472	0.607	rs1997422	chr3:123980608	A/G	cg05766129	chr3:123988013	KALRN	0.4	7.29	0.32	1.33e-12	Schizophrenia;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10388316	chr1:1710208	NADK	0.47	7.01	0.31	8.54e-12	Lung cancer in ever smokers;
LGG	cis	rs10227331	0.692	rs34036749	chr7:157298870	T/C	cg04156418	chr7:157293606	NA	0.55	11.88	0.48	1.3e-28	Inattentive symptoms;
LGG	cis	rs73193808	0.614	rs9976839	chr21:30562710	G/A	cg03476357	chr21:30257390	N6AMT1	0.41	6.95	0.31	1.22e-11	Coronary artery disease;
LGG	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg27147174	chr7:100797783	AP1S1	-0.7	-13.44	-0.53	5.42e-35	Life satisfaction;
LGG	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs514024	0.668	rs1573178	chr9:130372487	A/G	cg13643465	chr9:130375613	STXBP1	0.55	10.26	0.43	2.17e-22	Eating disorders (purging via substances);
LGG	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg26513180	chr16:89883248	FANCA	0.98	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.29e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg05967123	chr1:156737250	PRCC	0.38	6.68	0.3	7.03e-11	Body mass index;
LGG	cis	rs6577655	0.517	rs62525562	chr8:135587076	C/T	cg17885191	chr8:135476712	NA	0.59	8.77	0.38	3.38e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.02	0.62	7.97e-51	Tonsillectomy;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg01238044	chr22:24384105	GSTT1	0.46	7.69	0.34	9.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.97	-17.93	-0.64	5.57e-55	Homoarginine levels;
LGG	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.87	-0.3	2.13e-11	Height;
LGG	cis	rs7100689	0.753	rs1572816	chr10:82137600	A/G	cg01528321	chr10:82214614	TSPAN14	0.96	17.06	0.62	5.2e-51	Post bronchodilator FEV1;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00761968	chr13:53314142	LECT1	0.42	8.51	0.37	2.47e-16	Lewy body disease;
LGG	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.05	-0.31	6.45e-12	Testicular germ cell tumor;
LGG	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg02254774	chr11:50257496	LOC441601	0.57	6.72	0.3	5.3e-11	Myopia (pathological);
LGG	cis	rs9397585	0.857	rs28495170	chr6:153373975	C/G	cg17707550	chr6:153380415	RGS17	0.62	14.47	0.56	2.05e-39	Body mass index;
LGG	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg06885757	chr1:42089581	HIVEP3	0.57	13.02	0.52	3.21e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00656411	chr7:140773422	NA	0.43	6.73	0.3	5.07e-11	Cognitive performance;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18451256	chr2:128284158	IWS1	0.38	6.76	0.3	4.26e-11	Obesity-related traits;
LGG	cis	rs2905347	0.529	rs2961292	chr7:22683137	C/T	cg23521230	chr7:22704884	NA	0.4	7.23	0.32	2.06e-12	Major depression and alcohol dependence;
LGG	trans	rs8073060	0.614	rs225275	chr17:33972567	G/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.0	-0.64	2.54e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs929596	0.785	rs34352510	chr2:234650562	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-14.01	-0.55	1.98e-37	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg19635926	chr16:89946313	TCF25	-0.73	-7.37	-0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg04065206	chr12:109973212	UBE3B	-0.46	-6.77	-0.3	3.82e-11	Neuroticism;
LGG	cis	rs972578	0.765	rs4822213	chr22:43270819	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.93	-0.31	1.45e-11	Mean platelet volume;
LGG	cis	rs6840360	0.642	rs7666571	chr4:152443273	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.88e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01140101	chr1:202113040	ARL8A	0.46	7.37	0.32	7.97e-13	Gut microbiome composition (summer);
LGG	cis	rs3099143	0.901	rs28551558	chr15:77234637	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-9.2	-0.39	1.22e-18	Recalcitrant atopic dermatitis;
LGG	cis	rs7216064	1.000	rs55939964	chr17:65869297	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg02002194	chr4:3960332	NA	-0.44	-8.47	-0.37	3.21e-16	Monocyte count;
LGG	trans	rs9944715	1.000	rs718514	chr18:43856354	A/C	cg01718231	chr17:29326311	RNF135	-0.42	-6.65	-0.3	8.52e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs17221829	0.931	rs35892874	chr11:89452677	C/T	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.42	-0.33	5.5e-13	Anxiety in major depressive disorder;
LGG	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.43	0.5	8.59e-31	Hip circumference adjusted for BMI;
LGG	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.42e-11	Obesity-related traits;
LGG	cis	rs9296092	0.538	rs78061112	chr6:33526587	T/G	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-10.63	-0.44	9.49e-24	Platelet count;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-17.12	-0.62	2.88e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6032067	0.777	rs56191952	chr20:43802487	A/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs972578	0.702	rs2092212	chr22:43318948	G/C	cg01576275	chr22:43409880	NA	-0.22	-6.7	-0.3	6.03e-11	Mean platelet volume;
LGG	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs9534288	0.830	rs2296641	chr13:46632226	A/C	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00149659	chr3:10157352	C3orf10	0.81	8.85	0.38	1.92e-17	Alzheimer's disease;
LGG	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.26	0.4	7.41e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3806933	0.522	rs13179305	chr5:110444474	G/A	cg04022379	chr5:110408740	TSLP	0.48	8.02	0.35	8.99e-15	Eosinophilic esophagitis;
LGG	cis	rs2692947	0.832	rs4907212	chr2:96410048	T/A	cg22654517	chr2:96458247	NA	0.37	7.87	0.34	2.49e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10532262	chr3:172428426	NCEH1	0.43	7.49	0.33	3.6e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg04986931	chr22:39850128	NA	0.34	7.66	0.34	1.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2562456	0.833	rs2650776	chr19:21613397	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.65	-0.33	1.2e-13	Pain;
LGG	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg23845249	chr11:68861649	NA	0.45	8.06	0.35	6.79e-15	Blond vs. brown hair color;
LGG	cis	rs9814567	0.752	rs4955542	chr3:134328740	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.71	-0.45	4.66e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9972944	0.729	rs1421033	chr17:63766714	A/C	cg07283582	chr17:63770753	CCDC46	-0.42	-8.27	-0.36	1.42e-15	Total body bone mineral density;
LGG	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg20991723	chr1:152506922	NA	-0.73	-15.0	-0.57	9.89e-42	Hair morphology;
LGG	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.48	-0.44	3.2e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6121246	0.609	rs1009453	chr20:30404840	C/G	cg13852791	chr20:30311386	BCL2L1	0.94	18.18	0.65	3.75e-56	Mean corpuscular hemoglobin;
LGG	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.7	14.4	0.56	4.24e-39	Chronic sinus infection;
LGG	cis	rs4704846	0.821	rs6861017	chr5:156540396	A/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.77	0.38	3.44e-17	Aortic root size;
LGG	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg27411982	chr8:10470053	RP1L1	0.46	8.03	0.35	8.04e-15	Mean corpuscular hemoglobin;
LGG	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg16586182	chr3:47516702	SCAP	0.74	13.2	0.52	5.25e-34	Colorectal cancer;
LGG	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.17	0.32	3.03e-12	Systemic lupus erythematosus;
LGG	cis	rs9783347	1.000	rs10741742	chr11:18342160	G/T	cg03595886	chr11:18357587	GTF2H1	-0.38	-7.78	-0.34	4.63e-14	Pancreatic cancer;
LGG	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg23978390	chr7:1156363	C7orf50	0.45	7.48	0.33	3.64e-13	Longevity;Endometriosis;
LGG	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.36	-6.72	-0.3	5.5e-11	Total cholesterol levels;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.36	0.58	2.38e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.87	-0.34	2.54e-14	Body mass index;
LGG	trans	rs6825911	0.638	rs1320281	chr4:111371195	C/T	cg10580549	chr19:53101634	ZNF137	0.55	6.99	0.31	9.67e-12	Blood pressure;
LGG	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg05036130	chr6:150231994	NA	0.33	6.66	0.3	7.93e-11	Testicular germ cell tumor;
LGG	cis	rs56399783	0.614	rs73047355	chr7:2758145	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.04	0.31	6.77e-12	Childhood ear infection;
LGG	cis	rs17453880	0.963	rs6872161	chr5:151947543	T/A	cg12297329	chr5:152029980	NA	-0.83	-19.39	-0.67	9.44e-62	Subjective well-being;
LGG	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg17294928	chr15:75287854	SCAMP5	-0.56	-10.38	-0.43	7.55e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs6489882	0.867	rs4988618	chr12:113363178	G/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.18e-13	Chronic lymphocytic leukemia;
LGG	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.68	-14.67	-0.56	2.7e-40	Multiple sclerosis;
LGG	cis	rs7945718	0.621	rs10765984	chr11:12672669	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.18	0.32	2.86e-12	Educational attainment (years of education);
LGG	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg26818010	chr10:134567672	INPP5A	-0.68	-10.28	-0.43	1.79e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2236293	0.757	rs10758328	chr9:35856434	C/T	cg12876594	chr9:35791798	NPR2	0.36	6.99	0.31	9.67e-12	Blood protein levels;
LGG	cis	rs13102973	0.965	rs55967588	chr4:135860189	G/A	cg14419869	chr4:135874104	NA	0.57	10.93	0.45	6.97e-25	Subjective well-being;
LGG	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg04287289	chr16:89883240	FANCA	-0.45	-7.85	-0.34	2.83e-14	Vitiligo;
LGG	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.71	-0.34	8.01e-14	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.51e-24	Diabetic retinopathy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05447186	chr20:3869454	PANK2	-0.4	-6.69	-0.3	6.43e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6087990	0.769	rs17123658	chr20:31390840	C/A	cg13636640	chr20:31349939	DNMT3B	0.92	19.59	0.67	1.12e-62	Ulcerative colitis;
LGG	cis	rs228437	1.000	rs985121	chr6:134930893	C/T	cg24504307	chr6:134963096	NA	0.41	7.6	0.33	1.62e-13	Melanoma;
LGG	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.15	0.43	5.41e-22	Aortic root size;
LGG	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	10.5	0.44	2.79e-23	Mean platelet volume;
LGG	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg24692254	chr21:30365293	RNF160	-0.58	-8.44	-0.37	4.1e-16	Cognitive test performance;
LGG	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg03929089	chr4:120376271	NA	0.71	9.81	0.41	8.94e-21	Axial length;
LGG	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.41	-0.33	5.91e-13	IgG glycosylation;
LGG	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg23649088	chr2:200775458	C2orf69	0.43	7.49	0.33	3.52e-13	Asthma (bronchodilator response);
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.85	-0.38	1.81e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg00129232	chr17:37814104	STARD3	0.57	8.44	0.37	4.11e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.28	-0.58	5.43e-43	Chronic sinus infection;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg15242686	chr22:24348715	GSTTP1	0.4	7.56	0.33	2.14e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4740619	0.544	rs9407647	chr9:15824569	A/G	cg14451791	chr9:16040625	NA	0.32	7.86	0.34	2.81e-14	Body mass index;
LGG	cis	rs4950322	0.580	rs17355474	chr1:146592123	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-7.42	-0.33	5.84e-13	Protein quantitative trait loci;
LGG	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg00531865	chr16:30841666	NA	-0.55	-10.4	-0.44	6.55e-23	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.18	-0.39	1.44e-18	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg08677398	chr8:58056175	NA	0.45	7.15	0.32	3.33e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg20503657	chr10:835505	NA	0.96	12.82	0.51	2.07e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg10587741	chr22:38071170	LGALS1	-0.33	-6.74	-0.3	4.72e-11	Glioblastoma;Glioma;
LGG	cis	rs7635838	0.684	rs384989	chr3:11320120	C/T	cg00170343	chr3:11313890	ATG7	0.48	8.32	0.36	1.02e-15	HDL cholesterol;
LGG	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.06	-0.46	2.26e-25	Coronary artery disease;
LGG	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.94	-0.38	9e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19462847	chr11:6633911	TAF10	0.46	6.69	0.3	6.65e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs2190422	0.862	rs6465919	chr7:103069035	C/G	cg18108683	chr7:102477205	FBXL13	-0.39	-6.92	-0.31	1.48e-11	Morning vs. evening chronotype;
LGG	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg11845111	chr2:191398756	TMEM194B	0.36	7.96	0.35	1.38e-14	Pulse pressure;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	9.91	0.42	3.94e-21	Obesity-related traits;
LGG	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.68	-0.37	6.86e-17	Mean corpuscular volume;
LGG	cis	rs9393777	0.623	rs16891717	chr6:26477143	T/A	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4774899	0.934	rs4774250	chr15:57487863	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.29	-0.32	1.35e-12	Urinary tract infection frequency;
LGG	cis	rs77372450	0.636	rs6889203	chr5:156993871	G/C	cg25387487	chr5:157003181	ADAM19	-0.57	-7.05	-0.31	6.52e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs9296092	0.538	rs9469486	chr6:33516849	G/A	cg13560919	chr6:33536144	NA	-1.05	-21.66	-0.71	2.2e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7789940	0.810	rs12533978	chr7:75943352	T/C	cg10167463	chr7:75959203	YWHAG	-0.46	-7.4	-0.33	6.51e-13	Multiple sclerosis;
LGG	cis	rs2084898	0.882	rs7114201	chr11:120050113	T/A	cg07435449	chr11:120005650	TRIM29	-0.67	-7.91	-0.35	1.87e-14	Stroke (pediatric);
LGG	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg23231163	chr10:75533350	FUT11	0.41	7.05	0.31	6.38e-12	Inflammatory bowel disease;
LGG	cis	rs9810089	0.843	rs838202	chr3:136035217	G/A	cg21827317	chr3:136751795	NA	0.47	8.3	0.36	1.14e-15	Gestational age at birth (child effect);
LGG	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02509985	chr11:9483081	ZNF143	0.5	7.37	0.32	7.65e-13	Gut microbiome composition (summer);
LGG	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg02002194	chr4:3960332	NA	0.5	9.36	0.4	3.47e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg18551225	chr6:44695536	NA	-0.63	-10.22	-0.43	2.97e-22	Total body bone mineral density;
LGG	cis	rs7091068	0.754	rs6583903	chr10:95422174	T/C	cg20715218	chr10:95462985	C10orf4	0.66	10.49	0.44	2.98e-23	Urinary tract infection frequency;
LGG	cis	rs7572644	0.699	rs898032	chr2:28202936	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.66	-0.3	7.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs240764	0.658	rs12194255	chr6:101168439	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-8.06	-0.35	6.51e-15	Neuroticism;
LGG	trans	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.31	-0.36	1.08e-15	Joint mobility (Beighton score);
LGG	cis	rs9506514	0.509	rs9509294	chr13:21174645	T/A	cg27499820	chr13:21296301	IL17D	0.23	6.82	0.3	2.94e-11	Coronary artery calcification;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg11878867	chr6:150167359	LRP11	0.53	10.88	0.45	1.03e-24	Lung cancer;
LGG	cis	rs8056893	0.807	rs7194378	chr16:68359734	G/A	cg07273125	chr16:68295692	NA	0.36	6.88	0.3	1.95e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.34	-0.43	1.09e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg17376030	chr22:41985996	PMM1	-0.42	-6.91	-0.31	1.56e-11	Vitiligo;
LGG	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg13907859	chr11:120009124	TRIM29	-0.47	-8.89	-0.38	1.33e-17	Stroke (pediatric);
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg14689365	chr7:158441557	NCAPG2	0.58	9.53	0.4	9.06e-20	Height;
LGG	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg13010199	chr12:38710504	ALG10B	-0.46	-8.17	-0.35	2.92e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-10.87	-0.45	1.18e-24	Chronic sinus infection;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14275457	chr9:132934675	FREQ	0.45	6.73	0.3	5.11e-11	Hip circumference;
LGG	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg14092988	chr3:52407081	DNAH1	0.29	7.59	0.33	1.8e-13	Bipolar disorder;
LGG	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.06	0.78	2.19e-97	Height;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.59	-9.96	-0.42	2.67e-21	Obesity-related traits;
LGG	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-9.78	-0.41	1.19e-20	Tonsillectomy;
LGG	cis	rs7737355	0.853	rs245799	chr5:130672748	C/A	cg06307176	chr5:131281290	NA	-0.48	-7.97	-0.35	1.21e-14	Life satisfaction;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-7.7	-0.34	8.22e-14	Longevity;Endometriosis;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg19635926	chr16:89946313	TCF25	0.76	7.28	0.32	1.41e-12	Skin colour saturation;
LGG	cis	rs7666738	0.830	rs60391193	chr4:98933912	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.2	0.32	2.44e-12	Tonsillectomy;
LGG	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-8.71	-0.38	5.41e-17	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04127825	chr1:167503222	NA	0.52	8.22	0.36	2.09e-15	Gut microbiome composition (summer);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15586420	chr15:90294517	MESP1	0.39	6.98	0.31	1.03e-11	Bipolar disorder;
LGG	cis	rs4262150	0.726	rs10515675	chr5:152013789	G/C	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	trans	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.67	-0.34	1.03e-13	Heart rate;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.61	-0.37	1.15e-16	Longevity;Endometriosis;
LGG	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg23649088	chr2:200775458	C2orf69	-0.46	-8.17	-0.35	2.96e-15	QT interval;
LGG	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.86	-0.3	2.28e-11	Neuroticism;
LGG	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-10.1	-0.43	7.96e-22	Morning vs. evening chronotype;
LGG	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.59e-25	Aortic root size;
LGG	cis	rs7191439	0.790	rs2306046	chr16:88781419	A/G	cg02389323	chr16:88786976	FAM38A	1.08	13.21	0.52	5.15e-34	Plateletcrit;
LGG	trans	rs9929218	0.551	rs3785133	chr16:68728611	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	25.55	0.76	1.79e-90	Colorectal cancer;
LGG	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg00129232	chr17:37814104	STARD3	0.61	11.43	0.47	7.83e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-7.4	-0.33	6.39e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs1904096	0.506	rs4558832	chr4:95148042	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.01	-0.46	3.26e-25	Type 2 diabetes;
LGG	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.44	-0.63	1.05e-52	Chronic sinus infection;
LGG	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg20891283	chr12:69753455	YEATS4	0.96	22.88	0.73	4.47e-78	Blood protein levels;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg14926445	chr8:58193284	C8orf71	-0.65	-8.1	-0.35	4.82e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	7.59	0.33	1.72e-13	Educational attainment;
LGG	trans	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg11441553	chr12:57614120	NXPH4	-0.61	-7.58	-0.33	1.94e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg14593290	chr7:50529359	DDC	-0.67	-12.05	-0.49	2.71e-29	Malaria;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg14159672	chr1:205819179	PM20D1	0.87	19.97	0.68	1.95e-64	Menarche (age at onset);
LGG	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.93	15.25	0.58	7.89e-43	Cognitive test performance;
LGG	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	trans	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg20325293	chr4:54244256	FIP1L1	-0.79	-7.65	-0.33	1.15e-13	IgG glycosylation;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.71	0.51	5.87e-32	IgG glycosylation;
LGG	cis	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg16876255	chr19:9731953	ZNF561	0.73	6.91	0.31	1.57e-11	Pursuit maintenance gain;
LGG	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-10.89	-0.45	9.36e-25	Chronic sinus infection;
LGG	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg22676075	chr6:135203613	NA	0.46	8.09	0.35	5.16e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6719977	0.569	rs6756140	chr2:42968936	C/T	cg14631114	chr2:43023945	NA	0.45	9.5	0.4	1.09e-19	Hyperactive-impulsive symptoms;
LGG	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	10.86	0.45	1.21e-24	Lung cancer in ever smokers;
LGG	cis	rs727505	1.000	rs56356267	chr7:124557549	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.56	-0.53	1.69e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4713118	0.621	rs10484403	chr6:28033523	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.93	-0.31	1.43e-11	Parkinson's disease;
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg02002194	chr4:3960332	NA	0.51	9.73	0.41	1.78e-20	Neuroticism;
LGG	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg22044901	chr15:68126292	NA	-0.38	-6.78	-0.3	3.61e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs2076222	1.000	rs2076349	chr1:209800230	C/T	cg00257659	chr1:209800214	LAMB3	-1.16	-11.4	-0.47	1.03e-26	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
LGG	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.13	-0.39	2.2e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.49	-0.33	3.49e-13	Lung cancer;
LGG	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.78	0.3	3.65e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2108225	0.872	rs7792139	chr7:107445433	G/A	cg18560240	chr7:107437656	SLC26A3	-0.57	-10.06	-0.42	1.18e-21	Ulcerative colitis;
LGG	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22496380	chr5:211416	CCDC127	-1.22	-17.5	-0.63	5.08e-53	Breast cancer;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs7512552	0.839	rs2794684	chr1:150320571	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg21385522	chr1:16154831	NA	-0.67	-11.37	-0.47	1.41e-26	Dilated cardiomyopathy;
LGG	cis	rs7512552	0.839	rs834236	chr1:150362968	C/T	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.55	9.91	0.42	4.11e-21	Longevity;
LGG	cis	rs4700695	0.841	rs784276	chr5:65317332	A/T	cg21114390	chr5:65439923	SFRS12	0.58	7.38	0.32	7.63e-13	Facial morphology (factor 19);
LGG	cis	rs1697139	0.583	rs11739603	chr5:66540687	C/T	cg11553311	chr5:66541588	NA	0.45	10.06	0.42	1.15e-21	Breast cancer;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.37	0.36	6.87e-16	Type 2 diabetes;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04008888	chr11:68622739	NA	-0.57	-11.89	-0.48	1.22e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	7.93e-13	Platelet count;
LGG	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg18876405	chr7:65276391	NA	-0.67	-12.61	-0.51	1.51e-31	Aortic root size;
LGG	cis	rs262150	0.714	rs2657397	chr7:158785095	C/T	cg19418458	chr7:158789849	NA	-0.46	-9.41	-0.4	2.35e-19	Facial morphology (factor 20);
LGG	trans	rs6787172	0.702	rs1724654	chr3:157973793	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg20637307	chr2:213403960	ERBB4	-0.45	-8.73	-0.38	4.67e-17	QT interval (ambient particulate matter interaction);
LGG	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg27205649	chr11:78285834	NARS2	0.5	8.53	0.37	2.04e-16	Alzheimer's disease (survival time);
LGG	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.12	0.39	2.25e-18	Common traits (Other);
LGG	trans	rs2018683	0.677	rs12531456	chr7:28970611	A/C	cg19402173	chr7:128379420	CALU	-0.53	-9.27	-0.4	7.34e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs7143963	0.666	rs2403102	chr14:103306215	C/T	cg23020514	chr14:103360112	TRAF3	0.42	8.69	0.37	6.33e-17	Body mass index;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.16	-0.35	3.13e-15	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg11764359	chr7:65958608	NA	0.64	9.89	0.42	4.69e-21	Aortic root size;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18765753	chr7:1198926	ZFAND2A	-0.51	-9.03	-0.39	4.77e-18	Longevity;Endometriosis;
LGG	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg27661571	chr11:113659931	NA	-0.59	-8.38	-0.36	6.23e-16	Hip circumference adjusted for BMI;
LGG	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg24623649	chr8:11872141	NA	0.31	7.16	0.32	3.1e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4566357	0.695	rs11892058	chr2:227951063	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.39	-0.32	6.97e-13	Coronary artery disease;
LGG	cis	rs72781680	1.000	rs56104215	chr2:24133590	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg00599393	chr8:22457479	C8orf58	-0.46	-8.31	-0.36	1.08e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg14541582	chr5:601475	NA	-0.56	-9.01	-0.39	5.62e-18	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg03060546	chr3:49711283	APEH	-0.65	-10.71	-0.45	4.64e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs73416724	1.000	rs79329802	chr6:43387332	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.43	0.36	4.34e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7712401	0.580	rs42536	chr5:122276423	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg01657329	chr11:68192670	LRP5	0.62	10.26	0.43	2.12e-22	Bone mineral density (spine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06787431	chr3:185827293	ETV5	0.43	6.94	0.31	1.29e-11	Cognitive performance;
LGG	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-9.56	-0.41	7.12e-20	Erythrocyte sedimentation rate;
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg25072359	chr17:41440525	NA	0.42	7.84	0.34	3.05e-14	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg15596359	chr8:11213517	TDH	-0.33	-6.65	-0.3	8.08e-11	Retinal vascular caliber;
LGG	cis	rs963731	0.649	rs297153	chr2:39326835	C/G	cg04010122	chr2:39346883	SOS1	-0.93	-8.24	-0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs6430585	0.527	rs2289959	chr2:136423904	C/T	cg07169764	chr2:136633963	MCM6	0.97	16.25	0.6	2.68e-47	Corneal structure;
LGG	cis	rs11264213	0.901	rs72661636	chr1:36426483	T/C	cg27506609	chr1:36549197	TEKT2	0.83	8.36	0.36	7.54e-16	Schizophrenia;
LGG	cis	rs240764	0.604	rs9322173	chr6:101203889	G/A	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.85e-15	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09226173	chr5:122111107	SNX2	0.52	8.16	0.35	3.18e-15	Gut microbiome composition (summer);
LGG	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-11.61	-0.47	1.6e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06850241	chr22:41845214	NA	-0.43	-6.73	-0.3	4.99e-11	Vitiligo;
LGG	cis	rs793571	0.502	rs411007	chr15:59078502	G/C	cg05156742	chr15:59063176	FAM63B	0.65	12.04	0.49	3.13e-29	Schizophrenia;
LGG	cis	rs919433	0.589	rs7601800	chr2:198395099	T/C	cg00792783	chr2:198669748	PLCL1	0.49	7.79	0.34	4.48e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.64	-0.33	1.27e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg08677398	chr8:58056175	NA	0.44	7.55	0.33	2.38e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.85	0.57	4.57e-41	Heart rate;
LGG	cis	rs4727027	0.899	rs11768971	chr7:148825826	C/G	cg23583168	chr7:148888333	NA	-0.88	-17.14	-0.62	2.44e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg14403583	chr14:105418241	AHNAK2	-0.78	-15.69	-0.59	8.11e-45	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.86	-0.3	2.18e-11	Lung cancer;
LGG	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg26384229	chr12:38710491	ALG10B	-0.72	-13.64	-0.54	7.71e-36	Morning vs. evening chronotype;
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg04166393	chr7:2884313	GNA12	0.47	9.37	0.4	3.17e-19	Height;
LGG	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg08461772	chr7:95026248	PON3	0.38	8.21	0.36	2.2e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg23782820	chr8:58130467	NA	0.57	8.37	0.36	6.67e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06028808	chr11:68637592	NA	0.73	12.18	0.49	8.32e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg00225070	chr15:80189496	MTHFS	0.38	6.98	0.31	1.01e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs12618769	0.597	rs4851138	chr2:99065464	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs858239	0.539	rs6976957	chr7:23187333	T/A	cg23682824	chr7:23144976	KLHL7	0.41	6.71	0.3	5.65e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg25319279	chr11:5960081	NA	0.51	7.99	0.35	1.09e-14	DNA methylation (variation);
LGG	cis	rs1062746	0.694	rs62053080	chr16:87378214	T/G	cg02258303	chr16:87377426	FBXO31	-0.53	-9.74	-0.41	1.59e-20	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg08847533	chr14:75593920	NEK9	-0.54	-9.99	-0.42	2.15e-21	Height;
LGG	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg02002194	chr4:3960332	NA	0.44	8.02	0.35	8.7e-15	Neuroticism;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.54	-9.12	-0.39	2.39e-18	Obesity-related traits;
LGG	cis	rs7553864	0.667	rs10873820	chr1:87605973	C/G	cg17420885	chr1:87600446	LOC339524	0.37	6.79	0.3	3.36e-11	Smoking behavior;
LGG	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg04691961	chr3:161091175	C3orf57	0.49	10.8	0.45	2.08e-24	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.12	-0.39	2.26e-18	Vitiligo;
LGG	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.66	-8.23	-0.36	1.92e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7712401	0.601	rs246265	chr5:122254950	C/T	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	7.8	0.34	4.17e-14	Menarche (age at onset);
LGG	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg00908189	chr16:619842	PIGQ	0.53	7.77	0.34	5.13e-14	Height;
LGG	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.85e-33	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.649	rs815044	chr12:33722209	A/G	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	11.3	0.46	2.61e-26	Response to antipsychotic treatment;
LGG	cis	rs28655083	0.956	rs1485792	chr16:77100439	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-7.85	-0.34	2.92e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6032067	0.538	rs17422688	chr20:43739119	G/A	cg10761708	chr20:43804764	PI3	0.68	10.08	0.42	1.01e-21	Blood protein levels;
LGG	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg02221750	chr19:17393354	ANKLE1	0.62	9.25	0.39	8.45e-19	Systemic lupus erythematosus;
LGG	cis	rs1371614	0.550	rs2384508	chr2:27143056	T/A	cg12045002	chr2:27069975	DPYSL5	0.32	6.67	0.3	7.31e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs9914544	0.545	rs2892016	chr17:18786776	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-8.11	-0.35	4.56e-15	Educational attainment (years of education);
LGG	cis	rs881375	0.501	rs10739591	chr9:123885728	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.63	0.37	9.8e-17	Rheumatoid arthritis;
LGG	cis	rs16957091	0.862	rs7169009	chr15:43030861	C/T	cg07484255	chr15:43025164	CDAN1	-0.48	-6.87	-0.3	2.12e-11	MGMT methylation in smokers;
LGG	cis	rs12282928	1.000	rs11039675	chr11:48336301	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs8056893	0.550	rs10852440	chr16:68317061	T/C	cg07273125	chr16:68295692	NA	0.49	11.06	0.46	2.13e-25	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4604732	0.631	rs34330532	chr1:247626844	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.44	-0.33	4.96e-13	Iron status biomarkers;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.81	-0.38	2.55e-17	Lung cancer;
LGG	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.6	-0.37	1.24e-16	Headache;
LGG	cis	rs9399135	0.869	rs9402675	chr6:135325794	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg20503657	chr10:835505	NA	0.53	6.83	0.3	2.74e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs7166081	1.000	rs4238407	chr15:67633784	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9869826	0.892	rs685887	chr3:50677055	C/A	cg00383909	chr3:49044727	WDR6	0.75	6.65	0.3	8.03e-11	Blood protein levels;Bacteremia;
LGG	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Vitiligo;
LGG	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg16414030	chr3:133502952	NA	-0.48	-7.92	-0.35	1.77e-14	Iron status biomarkers;
LGG	cis	rs2562456	0.917	rs9304987	chr19:21682274	A/T	cg00806126	chr19:22604979	ZNF98	0.62	9.35	0.4	3.83e-19	Pain;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.88	0.57	3.42e-41	Platelet count;
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg26513180	chr16:89883248	FANCA	0.94	21.76	0.71	8.08e-73	Vitiligo;
LGG	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg18129748	chr3:49941408	MST1R	0.22	6.91	0.31	1.62e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg08930214	chr7:62859557	LOC100287834	0.45	7.62	0.33	1.4e-13	Obesity-related traits;
LGG	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg21138405	chr5:131827807	IRF1	0.29	6.9	0.31	1.72e-11	Breast cancer;Mosquito bite size;
LGG	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg02002194	chr4:3960332	NA	-0.48	-9.22	-0.39	1.06e-18	Neuroticism;
LGG	cis	rs8056064	0.739	rs1350891	chr16:82806302	C/G	cg08271366	chr16:82816457	CDH13	-0.43	-7.46	-0.33	4.18e-13	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs9814567	1.000	rs13087875	chr3:134261123	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4363385	0.693	rs418550	chr1:153048045	A/T	cg13444842	chr1:152974279	SPRR3	-0.4	-8.05	-0.35	7.03e-15	Inflammatory skin disease;
LGG	cis	rs975722	0.540	rs39324	chr7:116969876	A/G	cg10524701	chr7:117356490	CTTNBP2	0.37	7.79	0.34	4.45e-14	Coronary artery disease;
LGG	cis	rs4356932	1.000	rs3921	chr4:76942943	C/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.35	-0.4	3.86e-19	Aortic root size;
LGG	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg27490568	chr2:178487706	NA	0.48	9.45	0.4	1.72e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg23335576	chr14:104009727	NA	0.49	8.57	0.37	1.52e-16	Reticulocyte count;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.0	-17.0	-0.62	1.03e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9318086	0.648	rs9510927	chr13:24467641	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	9.51	0.4	1.06e-19	Myopia (pathological);
LGG	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg23029597	chr12:123009494	RSRC2	-0.89	-16.48	-0.61	2.28e-48	Body mass index;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02071572	chr4:1403502	NA	0.38	6.99	0.31	9.8e-12	Longevity;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	cis	rs12447804	0.863	rs12929002	chr16:58085882	A/G	cg03859792	chr16:58121049	NA	-0.47	-7.15	-0.32	3.42e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg13560919	chr6:33536144	NA	-0.39	-7.01	-0.31	8.42e-12	Crohn's disease;
LGG	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-10.79	-0.45	2.31e-24	Chronic sinus infection;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.28	-0.53	2.47e-34	Aortic root size;
LGG	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.94	-0.35	1.58e-14	Initial pursuit acceleration;
LGG	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.74	14.4	0.56	4.11e-39	Total body bone mineral density;
LGG	cis	rs13102973	0.899	rs7442212	chr4:135899800	A/G	cg14419869	chr4:135874104	NA	-0.46	-8.25	-0.36	1.63e-15	Subjective well-being;
LGG	trans	rs877282	1.000	rs12219807	chr10:772870	A/C	cg22713356	chr15:30763199	NA	0.56	8.63	0.37	1.02e-16	Uric acid levels;
LGG	cis	rs11023332	1.000	rs11023332	chr11:14784110	G/C	cg19336497	chr11:14380999	RRAS2	-0.37	-7.0	-0.31	9.14e-12	Adiponectin levels;Vitamin D levels;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg02733842	chr7:1102375	C7orf50	0.43	7.52	0.33	2.94e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg24634471	chr8:143751801	JRK	0.52	8.35	0.36	8.21e-16	Schizophrenia;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07362569	chr17:61921086	SMARCD2	0.48	9.29	0.4	6.17e-19	Prudent dietary pattern;
LGG	cis	rs12210905	1.000	rs3531	chr6:27095313	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg11166453	chr1:247681781	NA	0.64	9.7	0.41	2.29e-20	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg15327641	chr2:3715039	ALLC	0.32	6.82	0.3	2.92e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7091068	0.671	rs1096025	chr10:95404701	T/C	cg20715218	chr10:95462985	C10orf4	-0.59	-9.35	-0.4	3.64e-19	Urinary tract infection frequency;
LGG	cis	rs1079204	1.000	rs10178462	chr2:219083353	G/T	cg05728596	chr2:219128475	GPBAR1	1.09	10.21	0.43	3.17e-22	Smooth-surface caries;
LGG	trans	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.45	7.76	0.34	5.3e-14	Endometrial cancer;
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg14346243	chr4:90757452	SNCA	-0.41	-8.33	-0.36	8.96e-16	Dementia with Lewy bodies;
LGG	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg15979348	chr13:112237479	NA	0.42	7.14	0.31	3.68e-12	Menarche (age at onset);
LGG	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.41	0.33	6.21e-13	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg00409905	chr10:38381863	ZNF37A	0.52	10.39	0.43	7.38e-23	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs208520	0.690	rs207740	chr6:66764132	T/G	cg07460842	chr6:66804631	NA	0.96	18.04	0.64	1.81e-55	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg20587970	chr11:113659929	NA	-1.28	-23.47	-0.74	7.76e-81	Hip circumference adjusted for BMI;
LGG	cis	rs6547631	0.844	rs13012309	chr2:85907924	G/A	cg24620635	chr2:85921963	GNLY	0.38	7.23	0.32	1.99e-12	Blood protein levels;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.76	0.3	4.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6960043	0.905	rs7786873	chr7:15060410	A/G	cg19272540	chr7:15055459	NA	-0.39	-8.63	-0.37	9.75e-17	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26742440	chr11:73472391	RAB6A	0.47	7.59	0.33	1.76e-13	Gut microbiome composition (summer);
LGG	trans	rs800082	1.000	rs4681363	chr3:144287355	A/G	cg24215973	chr2:240111563	HDAC4	-0.49	-8.52	-0.37	2.22e-16	Smoking behavior;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg09448879	chr15:79043637	NA	-0.55	-14.39	-0.56	4.68e-39	Coronary artery disease or large artery stroke;
LGG	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.26	0.32	1.66e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.34e-23	Bipolar disorder;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05913233	chr17:7518500	FXR2;SHBG	-0.41	-6.69	-0.3	6.28e-11	Pancreatic cancer;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14932684	chr12:42632001	YAF2	0.43	6.87	0.3	2.06e-11	Cognitive performance;
LGG	cis	rs2302729	0.578	rs2302728	chr12:2774668	A/C	cg19945202	chr12:2788847	CACNA1C	0.75	13.65	0.54	6.87e-36	Sleep quality;
LGG	cis	rs1497828	0.956	rs2646799	chr1:217522196	T/C	cg04411442	chr1:217543379	NA	-0.48	-8.11	-0.35	4.59e-15	Dialysis-related mortality;
LGG	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg13679303	chr9:96623674	NA	-0.38	-7.13	-0.31	3.94e-12	DNA methylation (variation);
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg23601416	chr22:19950040	COMT	-0.34	-8.76	-0.38	3.68e-17	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.25e-11	Menopause (age at onset);
LGG	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.98	-0.35	1.14e-14	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572644	0.640	rs11127125	chr2:28023120	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.79	0.3	3.52e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs13102973	0.720	rs13137300	chr4:135889460	G/A	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs6716455	0.852	rs6738373	chr2:151023850	C/A	cg24691911	chr2:150991316	NA	0.42	6.95	0.31	1.23e-11	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score);
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg05313129	chr8:58192883	C8orf71	-0.68	-8.74	-0.38	4.32e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.67	0.37	7.6e-17	Longevity;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg02127607	chr17:61920694	SMARCD2	-0.45	-8.0	-0.35	9.86e-15	Prudent dietary pattern;
LGG	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg15704280	chr7:45808275	SEPT13	0.89	18.24	0.65	2.01e-56	Height;
LGG	trans	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg23762105	chr12:34175262	ALG10	0.34	6.68	0.3	6.78e-11	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg21475434	chr5:93447410	FAM172A	0.65	6.67	0.3	7.2e-11	Diabetic retinopathy;
LGG	cis	rs6430585	0.528	rs6711493	chr2:136692553	A/G	cg07169764	chr2:136633963	MCM6	1.16	22.12	0.72	1.67e-74	Corneal structure;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg14646974	chr10:38645378	HSD17B7P2	0.41	6.97	0.31	1.09e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg18937875	chr11:14930189	NA	-0.46	-7.49	-0.33	3.5e-13	Vitamin D levels;
LGG	cis	rs1957429	0.808	rs1467573	chr14:65347583	T/C	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23927769	chr6:41755626	TOMM6	0.4	7.12	0.31	4.19e-12	Obesity-related traits;
LGG	cis	rs11644362	0.966	rs36056252	chr16:12994672	T/G	cg06890432	chr16:12997467	SHISA9	-0.32	-6.93	-0.31	1.38e-11	Positive affect;Subjective well-being;
LGG	cis	rs4740619	0.587	rs1328273	chr9:16023469	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.72	-0.45	4.34e-24	Body mass index;
LGG	cis	rs7020830	0.867	rs1472169	chr9:37209396	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	32.1	0.83	8.35e-120	Schizophrenia;
LGG	cis	rs4936894	0.500	rs4354702	chr11:124156637	T/G	cg27160556	chr11:124181099	OR8D1	-0.45	-10.38	-0.43	7.58e-23	Aging (time to death);
LGG	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-13.95	-0.54	3.53e-37	Platelet distribution width;
LGG	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.6e-20	Diabetic retinopathy;
LGG	cis	rs737008	0.922	rs376374	chr16:11370616	G/A	cg00044050	chr16:11439710	C16orf75	-0.45	-6.75	-0.3	4.37e-11	Obesity-related traits;
LGG	cis	rs3857067	0.934	rs899132	chr4:95040022	A/C	cg11021082	chr4:95130006	SMARCAD1	0.43	8.06	0.35	6.73e-15	QT interval;
LGG	cis	rs3735485	0.800	rs1859486	chr7:45064690	T/A	cg03440944	chr7:45023329	C7orf40	0.55	9.4	0.4	2.62e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg24692254	chr21:30365293	RNF160	0.64	11.69	0.48	7.94e-28	Pancreatic cancer;
LGG	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9929218	0.731	rs72785179	chr16:68767912	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.44	-0.56	2.77e-39	Colorectal cancer;
LGG	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg02002194	chr4:3960332	NA	-0.48	-8.94	-0.38	9.67e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs981844	0.583	rs62323859	chr4:154629690	G/A	cg14289246	chr4:154710475	SFRP2	0.62	8.96	0.38	7.96e-18	Response to statins (LDL cholesterol change);
LGG	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.9	-0.42	4.23e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg11062466	chr8:58055876	NA	0.48	8.38	0.36	6.42e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg04990556	chr1:26633338	UBXN11	0.61	8.19	0.36	2.51e-15	Obesity-related traits;
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg16141378	chr3:129829833	LOC729375	0.38	8.88	0.38	1.52e-17	Morning vs. evening chronotype;
LGG	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg16141378	chr3:129829833	LOC729375	-0.32	-7.12	-0.31	4.14e-12	Myopia (pathological);
LGG	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg16339924	chr4:17578868	LAP3	0.58	9.53	0.4	9.16e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6163	0.540	rs11191385	chr10:104513049	G/T	cg25143771	chr10:104629124	AS3MT	0.39	6.7	0.3	6.06e-11	Waist circumference;Hip circumference;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.02	-0.31	7.88e-12	Menopause (age at onset);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25305259	chr10:51911889	NA	0.37	7.3	0.32	1.25e-12	Electrocardiographic conduction measures;
LGG	cis	rs4262150	0.810	rs72797243	chr5:151999906	G/A	cg12297329	chr5:152029980	NA	-0.81	-15.95	-0.6	5.57e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs9581857	0.685	rs9319368	chr13:28042275	T/G	cg01674679	chr13:27998804	GTF3A	-0.68	-7.94	-0.35	1.51e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.39	-0.36	5.82e-16	Inflammatory skin disease;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg08344181	chr3:125677491	NA	-0.73	-8.39	-0.36	5.94e-16	Squamous cell lung carcinoma;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.28	0.32	1.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg08999081	chr20:33150536	PIGU	-0.38	-9.66	-0.41	3.01e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg13206674	chr6:150067644	NUP43	0.68	16.1	0.6	1.19e-46	Lung cancer;
LGG	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2735413	0.563	rs2072663	chr16:78064733	C/A	cg04733911	chr16:78082701	NA	0.57	7.76	0.34	5.35e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.38	-0.58	1.96e-43	Prudent dietary pattern;
LGG	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6456156	0.774	rs6916486	chr6:167530735	T/C	cg07741184	chr6:167504864	NA	-0.3	-6.69	-0.3	6.65e-11	Primary biliary cholangitis;
LGG	cis	rs13314892	0.764	rs59846970	chr3:69861053	C/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs9942416	0.660	rs166183	chr5:74977845	T/C	cg19683494	chr5:74908142	NA	-0.44	-6.84	-0.3	2.47e-11	Age-related disease endophenotypes;
LGG	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg20026190	chr17:76395443	PGS1	0.58	10.13	0.43	6.36e-22	HDL cholesterol levels;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.71	0.3	5.58e-11	Longevity;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg08847533	chr14:75593920	NEK9	-0.6	-11.29	-0.46	2.79e-26	Height;
LGG	cis	rs888194	0.738	rs2241212	chr12:109939641	T/A	cg19025524	chr12:109796872	NA	-0.39	-7.66	-0.34	1.1e-13	Neuroticism;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.02e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs8073060	0.586	rs9303690	chr17:34005513	C/T	cg19694781	chr19:47549865	TMEM160	-1.17	-18.48	-0.65	1.56e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg24558204	chr6:135376177	HBS1L	-0.57	-9.66	-0.41	3.18e-20	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg01181863	chr3:195395398	SDHAP2	0.48	7.27	0.32	1.54e-12	Mean corpuscular volume;
LGG	cis	rs4917300	0.606	rs6583569	chr8:143115609	G/A	cg26003909	chr8:143102224	NA	-0.35	-6.81	-0.3	3.01e-11	Amyotrophic lateral sclerosis;
LGG	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg03929089	chr4:120376271	NA	0.67	6.89	0.3	1.81e-11	Intraocular pressure;
LGG	cis	rs12190007	0.508	rs9406321	chr6:169726841	A/T	cg16388071	chr6:169726476	NA	0.58	11.29	0.46	2.93e-26	Obesity-related traits;
LGG	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg14983838	chr19:29218262	NA	0.75	10.26	0.43	2.17e-22	Methadone dose in opioid dependence;
LGG	cis	rs2742417	1.000	rs1969624	chr3:45734818	C/T	cg04837898	chr3:45731254	SACM1L	0.38	7.57	0.33	2.05e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs10484885	0.591	rs72912551	chr6:90178347	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.64	-7.42	-0.33	5.58e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg03188948	chr7:1209495	NA	0.42	7.55	0.33	2.3e-13	Longevity;Endometriosis;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg16301924	chr13:53314226	LECT1	0.43	8.8	0.38	2.79e-17	Lewy body disease;
LGG	cis	rs12912251	0.947	rs7177621	chr15:38999394	C/G	cg01338139	chr15:38987640	C15orf53	-0.58	-8.87	-0.38	1.57e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.07	-0.31	5.83e-12	Iron status biomarkers;
LGG	cis	rs7512552	0.803	rs7513205	chr1:150472781	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.3	0.4	5.79e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs655601	0.643	rs112702671	chr5:180220930	C/T	cg13724780	chr5:180237085	MGAT1	1.02	9.07	0.39	3.32e-18	Quantitative traits;
LGG	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.87	0.34	2.5e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs6840360	0.548	rs4254751	chr4:152322571	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.35	0.32	9.15e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.15	0.35	3.42e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6860806	0.531	rs272888	chr5:131665423	T/C	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Breast cancer;
LGG	cis	rs2916247	1.000	rs1443559	chr8:92997242	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.65	-0.37	8.85e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3815700	1.000	rs7248273	chr19:33096816	C/T	cg02997394	chr19:33096574	ANKRD27	0.87	12.86	0.51	1.45e-32	Eosinophilic esophagitis;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24451858	chr11:75379620	MAP6	0.5	8.09	0.35	5.17e-15	Cognitive performance;
LGG	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.01	-0.39	5.46e-18	Response to antipsychotic treatment;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg01879757	chr17:41196368	BRCA1	-0.41	-7.26	-0.32	1.62e-12	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs9309473	1.000	rs6705489	chr2:73648811	G/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.95	-0.35	1.48e-14	Metabolite levels;
LGG	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg20673091	chr1:2541236	MMEL1	0.59	13.26	0.52	2.95e-34	Ulcerative colitis;
LGG	cis	rs2033908	0.558	rs6486064	chr11:12869509	T/C	cg25843174	chr11:12811716	TEAD1	-0.33	-6.86	-0.3	2.22e-11	Sitting height ratio;
LGG	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	trans	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.76	0.34	5.31e-14	Obesity-related traits;
LGG	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg15704280	chr7:45808275	SEPT13	0.73	8.63	0.37	1.01e-16	Intraocular pressure;
LGG	cis	rs1847202	0.859	rs11923247	chr3:72923306	A/G	cg25664220	chr3:72788482	NA	-0.27	-7.67	-0.34	1e-13	Motion sickness;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1971762	0.527	rs7952858	chr12:54039692	C/G	cg06632207	chr12:54070931	ATP5G2	0.24	7.3	0.32	1.27e-12	Height;
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.24	-0.43	2.57e-22	Bipolar disorder;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13537196	chr9:15553060	C9orf93	0.39	6.89	0.3	1.82e-11	Bilirubin levels;
LGG	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06873352	chr17:61820015	STRADA	0.47	7.29	0.32	1.35e-12	Height;
LGG	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-10.67	-0.44	6.57e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.71	-0.34	7.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17253792	0.822	rs75560658	chr14:56079896	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg21545522	chr1:205238299	TMCC2	0.38	7.22	0.32	2.22e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6138458	0.962	rs6036976	chr20:24901567	T/G	cg26195577	chr20:24973756	C20orf3	-1.22	-25.7	-0.77	3.48e-91	Blood protein levels;
LGG	cis	rs11069349	0.608	rs9585056	chr13:100081766	A/G	cg25919922	chr13:100150906	NA	-0.57	-8.67	-0.37	7.5e-17	Self-reported allergy;
LGG	cis	rs34172651	0.537	rs8049014	chr16:24698903	A/G	cg02428538	chr16:24856791	SLC5A11	-0.58	-9.35	-0.4	3.66e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg04287289	chr16:89883240	FANCA	0.81	16.64	0.61	4.34e-49	Vitiligo;
LGG	cis	rs7267979	1.000	rs2297496	chr20:25295787	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs870825	0.587	rs6826883	chr4:185616167	A/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.71	0.73	2.9e-77	Blood protein levels;
LGG	trans	rs3960554	0.529	rs7800970	chr7:75880198	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.59	-9.36	-0.4	3.54e-19	Eotaxin levels;
LGG	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	9.2e-12	Schizophrenia;
LGG	cis	rs7584330	0.744	rs58223447	chr2:238378644	G/C	cg16989719	chr2:238392110	NA	-0.37	-7.39	-0.32	6.78e-13	Prostate cancer;
LGG	trans	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg06875740	chr19:51307921	C19orf48	-0.69	-8.58	-0.37	1.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21659725	chr3:3221576	CRBN	-0.61	-9.7	-0.41	2.3e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.2	-0.32	2.44e-12	Coronary artery disease;
LGG	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg26116260	chr4:7069785	GRPEL1	0.49	8.56	0.37	1.73e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg13334819	chr7:99746414	C7orf59	0.5	7.18	0.32	2.84e-12	Coronary artery disease;
LGG	cis	rs490234	0.841	rs536861	chr9:128313444	A/C	cg14078157	chr9:128172775	NA	0.44	8.25	0.36	1.69e-15	Mean arterial pressure;
LGG	cis	rs34599045	0.522	rs34417380	chr1:153025499	A/G	cg07796016	chr1:152779584	LCE1C	-0.9	-8.04	-0.35	7.63e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7177699	0.557	rs7165902	chr15:79115872	T/G	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	10.95	0.45	5.49e-25	Personality dimensions;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13012494	chr21:47604986	C21orf56	0.64	10.67	0.44	6.34e-24	Testicular germ cell tumor;
LGG	trans	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg18187862	chr3:45730750	SACM1L	0.54	8.97	0.38	7.67e-18	Primary sclerosing cholangitis;
LGG	cis	rs7584262	0.737	rs58360854	chr2:42243076	A/G	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Bone mineral density;
LGG	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	trans	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg02002194	chr4:3960332	NA	-0.47	-8.77	-0.38	3.52e-17	Joint mobility (Beighton score);
LGG	cis	rs78579285	0.622	rs4782322	chr16:88797669	T/G	cg06225923	chr16:88797506	FAM38A	-0.49	-6.65	-0.3	8.41e-11	Joint mobility (Beighton score);
LGG	cis	rs1062177	0.756	rs2915826	chr5:151119963	G/A	cg00977110	chr5:151150581	G3BP1	-0.48	-7.58	-0.33	1.91e-13	Preschool internalizing problems;
LGG	cis	rs17039065	0.920	rs7674961	chr4:109440528	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.71	0.34	7.57e-14	Gut microbiome composition (summer);
LGG	cis	rs4742903	1.000	rs1026181	chr9:106893334	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.17	0.36	2.91e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9443645	0.527	rs9350792	chr6:79587173	A/G	cg18132916	chr6:79620363	NA	-0.27	-7.08	-0.31	5.37e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg04851639	chr8:1020857	NA	-0.42	-8.57	-0.37	1.52e-16	Schizophrenia;
LGG	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.88	-0.38	1.51e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23434654	chr5:121648409	SNCAIP	0.46	7.49	0.33	3.56e-13	Cognitive performance;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04008888	chr11:68622739	NA	0.56	11.87	0.48	1.43e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01334186	chr1:151372572	PSMB4	0.51	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg05775895	chr3:12838266	CAND2	-0.61	-10.68	-0.44	6.19e-24	QRS complex (12-leadsum);
LGG	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg12654349	chr5:56205094	C5orf35	-0.41	-7.29	-0.32	1.34e-12	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg01879757	chr17:41196368	BRCA1	-0.37	-7.35	-0.32	9.2e-13	Menopause (age at onset);
LGG	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg16586182	chr3:47516702	SCAP	-0.56	-9.51	-0.4	1.06e-19	Birth weight;
LGG	cis	rs209489	1.000	rs209505	chr6:53192022	C/T	cg15607103	chr6:53167650	ELOVL5	0.54	7.63	0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg03689076	chr20:33865952	NA	0.65	8.38	0.36	6.53e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs8114671	0.967	rs2069945	chr20:33761837	C/G	cg24642439	chr20:33292090	TP53INP2	0.52	8.33	0.36	8.99e-16	Height;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.65	-0.34	1.14e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg06766960	chr11:133703094	NA	-0.5	-9.98	-0.42	2.3e-21	Childhood ear infection;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.55	-9.81	-0.41	9.38e-21	Longevity;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.1	-0.46	1.47e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs17001868	0.892	rs12483888	chr22:40801312	A/G	cg07138101	chr22:40742427	ADSL	0.65	7.15	0.32	3.36e-12	Mammographic density (dense area);
LGG	cis	rs113084984	0.718	rs12620490	chr2:11682796	A/T	cg07314298	chr2:11723111	GREB1	0.36	6.73	0.3	5.06e-11	Breast cancer;
LGG	cis	rs5015933	0.966	rs7870475	chr9:128134034	T/C	cg14078157	chr9:128172775	NA	-0.38	-7.33	-0.32	1.05e-12	Body mass index;
LGG	cis	rs1018836	0.859	rs10808614	chr8:91569677	C/G	cg16814680	chr8:91681699	NA	-0.73	-13.22	-0.52	4.52e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg09845145	chr15:78292470	TBC1D2B	-0.67	-13.24	-0.52	3.73e-34	Coronary artery disease or large artery stroke;
LGG	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.36	-0.32	8.2e-13	Neuroticism;
LGG	cis	rs7715806	0.500	rs17649350	chr5:75006156	C/T	cg19683494	chr5:74908142	NA	-0.52	-6.87	-0.3	2.09e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg12046867	chr14:103022105	NA	-0.44	-8.84	-0.38	2.06e-17	Platelet count;
LGG	cis	rs12282928	1.000	rs7130032	chr11:48326963	C/A	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs6759839	0.761	rs6753768	chr2:16620437	G/T	cg09580478	chr2:16689509	NA	0.47	7.31	0.32	1.15e-12	Mean platelet volume;
LGG	cis	rs7927771	0.929	rs66749409	chr11:47568074	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.73	-0.38	4.72e-17	Subjective well-being;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.51	0.69	5.31e-67	Alzheimer's disease;
LGG	cis	rs77372450	0.636	rs6556090	chr5:157001183	A/C	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.12	-0.31	4.22e-12	Menopause (age at onset);
LGG	cis	rs907683	0.570	rs3755056	chr2:220281016	T/A	cg15015639	chr2:220282977	DES	0.35	9.85	0.42	6.66e-21	Resting heart rate;
LGG	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg23625390	chr15:77176239	SCAPER	-0.65	-12.88	-0.51	1.15e-32	Blood metabolite levels;
LGG	trans	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg16011800	chr17:1958478	HIC1	0.63	9.44	0.4	1.8e-19	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs698833	0.780	rs9309115	chr2:44510146	A/T	cg00619915	chr2:44497795	NA	-0.48	-6.99	-0.31	9.93e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs17767392	1.000	rs35854505	chr14:71841477	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.0	0.39	6e-18	Mitral valve prolapse;
LGG	cis	rs10791097	0.547	rs3829271	chr11:130753912	T/A	cg12179176	chr11:130786555	SNX19	0.84	17.42	0.63	1.21e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg15105969	chr2:36825350	FEZ2	0.46	6.66	0.3	7.65e-11	Height;
LGG	cis	rs11157436	0.602	rs11157438	chr14:22637043	C/T	cg00994629	chr14:22694547	NA	0.34	7.18	0.32	2.88e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg19508488	chr2:152266495	RIF1	0.48	8.54	0.37	1.93e-16	Lung cancer;
LGG	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg03929089	chr4:120376271	NA	0.68	7.47	0.33	3.93e-13	Axial length;
LGG	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg23231163	chr10:75533350	FUT11	-0.41	-7.06	-0.31	6.2e-12	Inflammatory bowel disease;
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg25072359	chr17:41440525	NA	0.52	9.97	0.42	2.42e-21	Menopause (age at onset);
LGG	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs6763768	0.606	rs6798771	chr3:53312915	C/T	cg16894138	chr3:53270350	TKT	0.43	8.18	0.36	2.73e-15	Bacterial meningitis;
LGG	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg02297831	chr4:17616191	MED28	0.5	9.58	0.41	6.14e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00495681	chr13:53174319	NA	0.68	13.47	0.53	3.85e-35	Lewy body disease;
LGG	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg16400903	chr5:693638	TPPP	0.45	6.82	0.3	2.9100000000000002e-11	Obesity-related traits;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg05863683	chr7:1912471	MAD1L1	0.5	9.93	0.42	3.34e-21	Testicular germ cell tumor;
LGG	cis	rs77741769	0.571	rs34009825	chr12:121326183	A/G	cg02419362	chr12:121203948	SPPL3	0.54	9.33	0.4	4.32e-19	Mean corpuscular volume;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg09303159	chr6:26284866	NA	0.36	8.18	0.36	2.83e-15	Educational attainment;
LGG	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg27205649	chr11:78285834	NARS2	0.51	8.69	0.37	6.37e-17	Alzheimer's disease (survival time);
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg12708336	chr17:41446283	NA	-0.31	-7.37	-0.32	7.92e-13	Menopause (age at onset);
LGG	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg08048268	chr3:133502702	NA	-0.6	-11.15	-0.46	9.7e-26	Iron status biomarkers;
LGG	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg19847130	chr8:10466454	RP1L1	0.32	6.97	0.31	1.08e-11	Neuroticism;
LGG	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg06889755	chr6:150326021	RAET1K	-0.34	-7.15	-0.32	3.31e-12	Alopecia areata;
LGG	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg00409905	chr10:38381863	ZNF37A	0.47	7.02	0.31	7.88e-12	Obesity (extreme);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.95	0.35	1.42e-14	Prudent dietary pattern;
LGG	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg09904177	chr6:26538194	HMGN4	0.72	15.7	0.59	8.01e-45	Intelligence (multi-trait analysis);
LGG	cis	rs151234	0.741	rs11644791	chr16:28601186	G/C	cg01378222	chr16:28622494	SULT1A1	-0.73	-10.01	-0.42	1.8e-21	Platelet distribution width;
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.7	0.34	8.27e-14	Glycated hemoglobin levels;
LGG	cis	rs6450176	1.000	rs60652351	chr5:53306140	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.25	0.36	1.64e-15	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg24607181	chr17:41446203	NA	0.3	7.0	0.31	9.26e-12	Menopause (age at onset);
LGG	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg03606772	chr1:152487856	CRCT1	0.31	7.29	0.32	1.34e-12	Hair morphology;
LGG	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.55	0.37	1.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03576123	chr11:487126	PTDSS2	-1.3	-17.29	-0.63	5.13e-52	Body mass index;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13012494	chr21:47604986	C21orf56	0.55	9.64	0.41	3.55e-20	Testicular germ cell tumor;
LGG	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.08	-0.31	5.41e-12	Neuroticism;
LGG	cis	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.54	-0.47	3e-27	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg24375607	chr4:120327624	NA	0.66	10.7	0.45	5e-24	Corneal astigmatism;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-16.49	-0.61	2.1e-48	Personality dimensions;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg20308403	chr7:2120281	MAD1L1	-0.34	-7.2	-0.32	2.47e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7072216	0.763	rs7914401	chr10:100163928	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.2	-0.32	2.47e-12	Metabolite levels;
LGG	cis	rs6963495	0.818	rs116457537	chr7:105152072	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs514024	0.801	rs2988580	chr9:130482966	C/G	cg13643465	chr9:130375613	STXBP1	0.6	11.13	0.46	1.2e-25	Eating disorders (purging via substances);
LGG	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.46	-0.4	1.56e-19	Breast cancer;
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.73	0.41	1.69e-20	Bipolar disorder;
LGG	cis	rs3791556	0.853	rs12623679	chr2:240126789	G/A	cg21996813	chr2:240149575	HDAC4	-0.59	-7.22	-0.32	2.2e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg21100191	chr22:23484243	RTDR1	1.0	23.82	0.74	1.77e-82	Bone mineral density;
LGG	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.1	-0.49	1.78e-29	Total body bone mineral density;
LGG	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg13385794	chr1:248469461	NA	0.47	7.82	0.34	3.5e-14	Common traits (Other);
LGG	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.77	14.33	0.55	7.91e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg03806693	chr22:41940476	POLR3H	1.09	19.86	0.68	5.84e-64	Vitiligo;
LGG	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg02023728	chr11:77925099	USP35	0.39	6.79	0.3	3.51e-11	Alzheimer's disease (survival time);
LGG	cis	rs17253792	0.822	rs12100949	chr14:56040787	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-11.23	-0.46	4.6e-26	Putamen volume;
LGG	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg10587741	chr22:38071170	LGALS1	0.65	12.63	0.51	1.23e-31	Fat distribution (HIV);
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.83	0.3	2.6e-11	Schizophrenia;
LGG	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.57e-21	Corneal astigmatism;
LGG	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27297192	chr10:134578999	INPP5A	0.33	7.14	0.31	3.63e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg05082376	chr22:42548792	NA	0.39	8.06	0.35	6.65e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11168187	0.891	rs726588	chr12:48124151	A/C	cg12761788	chr12:48120090	P11	0.45	7.46	0.33	4.31e-13	Vertical cup-disc ratio;
LGG	cis	rs9557207	1.000	rs9300539	chr13:100005169	A/C	cg24509225	chr13:100037070	UBAC2	-0.66	-11.24	-0.46	4.33e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs4740619	0.682	rs10738422	chr9:15998987	C/G	cg14451791	chr9:16040625	NA	-0.4	-10.45	-0.44	4.46e-23	Body mass index;
LGG	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.91	-0.38	1.22e-17	Aortic root size;
LGG	cis	rs3736594	0.649	rs867282	chr2:27951658	A/G	cg27432699	chr2:27873401	GPN1	-0.6	-9.36	-0.4	3.42e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.87	-0.51	1.28e-32	Chronic sinus infection;
LGG	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg11871910	chr12:69753446	YEATS4	0.92	22.08	0.72	2.4e-74	Blood protein levels;
LGG	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg11812906	chr14:75593930	NEK9	0.5	9.55	0.41	7.75e-20	Height;
LGG	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg11161011	chr14:65562177	MAX	-0.65	-12.49	-0.5	4.56e-31	Obesity-related traits;
LGG	cis	rs67133203	0.756	rs11831946	chr12:51446936	A/C	cg14688905	chr12:51403056	SLC11A2	0.72	10.97	0.45	4.97e-25	Urinary tract infection frequency;
LGG	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg25664220	chr3:72788482	NA	-0.32	-8.79	-0.38	3.03e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg05091796	chr16:4465799	CORO7	-0.79	-13.02	-0.52	3.11e-33	Schizophrenia;
LGG	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs2153535	1.000	rs11243251	chr6:8368207	G/A	cg07606381	chr6:8435919	SLC35B3	-0.4	-6.86	-0.3	2.26e-11	Motion sickness;
LGG	cis	rs2932538	0.961	rs4240534	chr1:113175429	T/A	cg22162597	chr1:113214053	CAPZA1	-0.63	-11.75	-0.48	4.31e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	7.89	0.34	2.21e-14	Tonsillectomy;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06564818	chr18:33162094	NA	0.41	6.82	0.3	2.9100000000000002e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg00129232	chr17:37814104	STARD3	-0.62	-11.49	-0.47	4.65e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs11677416	1.000	rs3783555	chr2:113531093	T/C	cg27083787	chr2:113543245	IL1A	0.52	8.73	0.38	4.55e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg08807101	chr21:30365312	RNF160	-0.81	-14.67	-0.56	2.76e-40	Selective IgA deficiency;
LGG	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.44e-42	Heart rate;
LGG	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg16070123	chr10:51489643	NA	-0.39	-7.17	-0.32	3.03e-12	Prostate-specific antigen levels;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg25703541	chr22:24373054	LOC391322	0.97	19.78	0.68	1.47e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg06529181	chr19:52193933	NA	0.52	7.88	0.34	2.36e-14	IgG glycosylation;
LGG	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.33	-0.32	1.01e-12	Initial pursuit acceleration;
LGG	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg24110177	chr3:50126178	RBM5	-0.57	-8.92	-0.38	1.1e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg26150922	chr2:100937072	LONRF2	-0.59	-11.27	-0.46	3.48e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg11062466	chr8:58055876	NA	0.52	7.95	0.35	1.44e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07923666	chr12:49932857	KCNH3	-0.51	-7.57	-0.33	2.06e-13	Resting heart rate;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07791516	chr6:150247246	NA	0.33	6.94	0.31	1.35e-11	Lung cancer;
LGG	cis	rs888194	0.738	rs4766611	chr12:109987838	A/G	cg19025524	chr12:109796872	NA	-0.35	-7.06	-0.31	5.99e-12	Neuroticism;
LGG	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.34	-0.36	8.3e-16	Breast cancer;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07308232	chr7:1071921	C7orf50	-0.55	-10.1	-0.42	8.57e-22	Longevity;Endometriosis;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs11874712	0.545	rs12963615	chr18:43641707	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.66	-15.93	-0.59	7.42e-46	Migraine - clinic-based;
LGG	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.15	-0.49	1.07e-29	Platelet distribution width;
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00864171	chr11:67383662	NA	-0.52	-7.87	-0.34	2.53e-14	Mean corpuscular volume;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05856399	chr6:109804852	ZBTB24	0.47	6.98	0.31	1.03e-11	Hepatitis;
LGG	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg20673091	chr1:2541236	MMEL1	-0.77	-18.11	-0.64	8.17e-56	Ulcerative colitis;
LGG	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg18335740	chr13:41363409	SLC25A15	-0.61	-12.09	-0.49	1.91e-29	Lewy body disease;
LGG	cis	rs6977955	1.000	rs11495981	chr7:28177301	A/G	cg23620719	chr7:28220237	JAZF1	-0.43	-6.75	-0.3	4.48e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10924309	0.737	rs3766648	chr1:245852388	C/T	cg00036263	chr1:245852353	KIF26B	-0.46	-7.24	-0.32	1.88e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg25664220	chr3:72788482	NA	-0.27	-7.83	-0.34	3.37e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg04362960	chr10:104952993	NT5C2	0.57	10.78	0.45	2.49e-24	Arsenic metabolism;
LGG	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.19	-0.7	3.57e-70	Leprosy;
LGG	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg05925327	chr15:68127851	NA	-0.38	-7.82	-0.34	3.48e-14	Restless legs syndrome;
LGG	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg13009111	chr11:71350975	NA	-0.33	-7.24	-0.32	1.89e-12	Monocyte count;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.74	0.3	4.71e-11	Schizophrenia;
LGG	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg24450063	chr1:156163899	SLC25A44	1.08	22.56	0.72	1.43e-76	Testicular germ cell tumor;
LGG	cis	rs7124681	0.584	rs7950674	chr11:47871017	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.04	0.46	2.57e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs57590327	0.555	rs7634258	chr3:81799100	T/C	cg07356753	chr3:81810745	GBE1	-0.51	-8.2	-0.36	2.37e-15	Extraversion;
LGG	trans	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg06636001	chr8:8085503	FLJ10661	0.38	7.06	0.31	6.19e-12	Neuroticism;
LGG	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.32	-0.32	1.08e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.03	0.52	2.71e-33	Colorectal cancer;
LGG	cis	rs16866061	1.000	rs72974222	chr2:225424143	C/T	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs834603	0.575	rs1799376	chr7:47479583	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.88	0.34	2.36e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	7.74	0.34	6.41e-14	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10176457	chr19:797221	PTBP1	0.48	7.4	0.33	6.36e-13	Gut microbiome composition (summer);
LGG	trans	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg22358067	chr17:16797159	NA	0.52	7.35	0.32	8.9e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg00531865	chr16:30841666	NA	-0.49	-10.09	-0.42	8.83e-22	Dementia with Lewy bodies;
LGG	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg21230503	chr5:139085173	NA	-0.33	-7.99	-0.35	1.1e-14	Schizophrenia;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg25004347	chr4:1352787	KIAA1530	-0.38	-6.72	-0.3	5.39e-11	Obesity-related traits;
LGG	trans	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.16e-27	Corneal astigmatism;
LGG	cis	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg04672837	chr16:48644449	N4BP1	0.56	9.32	0.4	4.8e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg01657329	chr11:68192670	LRP5	-0.6	-10.77	-0.45	2.83e-24	Bone mineral density;
LGG	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg24690094	chr11:67383802	NA	-0.4	-6.94	-0.31	1.32e-11	Mean corpuscular volume;
LGG	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg27129171	chr3:47204927	SETD2	-0.8	-14.53	-0.56	1.14e-39	Colorectal cancer;
LGG	cis	rs4363385	0.647	rs56158137	chr1:152994380	A/T	cg13444842	chr1:152974279	SPRR3	-0.49	-9.95	-0.42	2.85e-21	Inflammatory skin disease;
LGG	cis	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.73	-0.34	6.99e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg02002194	chr4:3960332	NA	0.47	9.09	0.39	2.96e-18	Neuroticism;
LGG	cis	rs1707322	0.752	rs4607935	chr1:46117161	C/T	cg03146154	chr1:46216737	IPP	0.55	10.71	0.45	4.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26160543	chr1:27019643	NA	0.41	6.75	0.3	4.56e-11	Cognitive performance;
LGG	cis	rs12282928	0.918	rs6485815	chr11:48243186	A/C	cg26585981	chr11:48327164	OR4S1	-0.43	-6.88	-0.3	1.96e-11	Migraine - clinic-based;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg06916706	chr16:4465613	CORO7	-0.86	-15.83	-0.59	2.03e-45	Schizophrenia;
LGG	cis	rs12618769	0.597	rs2278212	chr2:99136266	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.88	0.38	1.48e-17	Alzheimer's disease;
LGG	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	trans	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg26043149	chr18:55253948	FECH	-0.46	-7.55	-0.33	2.34e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs240110	0.588	rs9390675	chr6:101204973	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.03	0.31	7.33e-12	Neuroticism;
LGG	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg02002194	chr4:3960332	NA	-0.38	-6.76	-0.3	4.25e-11	Retinal vascular caliber;
LGG	cis	rs2455799	0.613	rs2166759	chr3:15856285	A/G	cg16303742	chr3:15540471	COLQ	0.4	7.84	0.34	3.16e-14	Mean platelet volume;
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.85	-0.45	1.32e-24	Triglycerides;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-9.49	-0.4	1.24e-19	Menopause (age at onset);
LGG	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.64	-0.37	9.34e-17	Alzheimer's disease (survival time);
LGG	cis	rs12999616	0.602	rs17489259	chr2:98392302	G/A	cg26665480	chr2:98280029	ACTR1B	0.55	7.64	0.33	1.27e-13	Colorectal cancer;
LGG	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg17376030	chr22:41985996	PMM1	0.45	7.23	0.32	1.97e-12	Vitiligo;
LGG	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg14416269	chr4:6271139	WFS1	0.48	8.92	0.38	1.06e-17	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg21775007	chr8:11205619	TDH	-0.55	-8.9	-0.38	1.22e-17	Neuroticism;
LGG	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.11	-0.39	2.51e-18	Prostate cancer;
LGG	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg00092383	chr7:157075207	NA	0.67	9.5	0.4	1.16e-19	Type 2 diabetes;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg04166393	chr7:2884313	GNA12	0.46	8.53	0.37	2.16e-16	Height;
LGG	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.42	-0.4	2.08e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08677398	chr8:58056175	NA	0.47	7.28	0.32	1.44e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7226408	0.857	rs61044601	chr18:34440179	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-9.64	-0.41	3.54e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00761968	chr13:53314142	LECT1	-0.38	-7.96	-0.35	1.32e-14	Lewy body disease;
LGG	cis	rs9427116	0.502	rs9426827	chr1:154589965	T/C	cg11650704	chr1:154556575	ADAR	-0.49	-9.61	-0.41	4.8e-20	Blood protein levels;
LGG	cis	rs6763768	0.752	rs3774417	chr3:53538107	A/T	cg16894138	chr3:53270350	TKT	0.41	7.25	0.32	1.73e-12	Bacterial meningitis;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg09873164	chr1:152488093	CRCT1	0.56	11.59	0.47	1.98e-27	Hair morphology;
LGG	cis	rs9859260	0.961	rs11185506	chr3:195797576	G/C	cg12923728	chr3:195709715	SDHAP1	-0.39	-6.92	-0.31	1.53e-11	Mean corpuscular volume;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.63	11.38	0.47	1.31e-26	Obesity-related traits;
LGG	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg22676075	chr6:135203613	NA	-0.48	-8.42	-0.36	4.77e-16	Red blood cell count;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg05868516	chr6:26286170	HIST1H4H	0.47	8.25	0.36	1.68e-15	Educational attainment;
LGG	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg04398451	chr17:18023971	MYO15A	-0.84	-18.97	-0.66	8.94e-60	Total body bone mineral density;
LGG	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg05623727	chr3:50126028	RBM5	-0.39	-8.32	-0.36	1e-15	Menarche (age at onset);
LGG	cis	rs6918586	0.658	rs13161	chr6:26114702	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.68	-0.41	2.75e-20	Schizophrenia;
LGG	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg00701064	chr4:6280414	WFS1	0.62	12.36	0.5	1.59e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg14191688	chr11:70257035	CTTN	0.55	8.07	0.35	6.19e-15	Coronary artery disease;
LGG	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg24812749	chr6:127587940	RNF146	0.96	15.73	0.59	5.72e-45	Breast cancer;
LGG	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg02931644	chr1:25747376	RHCE	0.44	9.65	0.41	3.28e-20	Plateletcrit;Mean corpuscular volume;
LGG	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.22	0.32	2.17e-12	Neuroticism;
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg13699009	chr12:122356056	WDR66	0.57	15.03	0.57	6.92e-42	Mean corpuscular volume;
LGG	cis	rs11229555	0.609	rs12575080	chr11:58224917	A/G	cg15696309	chr11:58395628	NA	-0.96	-15.5	-0.58	5.72e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg24623649	chr8:11872141	NA	0.29	6.9	0.31	1.74e-11	Myopia (pathological);
LGG	cis	rs926938	0.563	rs360630	chr1:115415132	C/T	cg12756093	chr1:115239321	AMPD1	0.44	8.28	0.36	1.35e-15	Autism;
LGG	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg03254818	chr6:169586852	NA	0.63	9.14	0.39	2e-18	Pulse pressure;
LGG	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.06	0.42	1.13e-21	Motion sickness;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg08621203	chr6:150244597	RAET1G	0.42	7.12	0.31	4.06e-12	Lung cancer;
LGG	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15664640	chr17:80829946	TBCD	0.48	9.47	0.4	1.44e-19	Breast cancer;
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg20607798	chr8:58055168	NA	0.58	6.7	0.3	6.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2247341	0.577	rs2236995	chr4:1704542	T/G	cg08629884	chr4:1719983	TMEM129	-0.39	-7.22	-0.32	2.11e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs1372520	0.577	rs748849	chr4:90734961	G/A	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.87e-15	Neuroticism;
LGG	cis	rs7843479	0.965	rs878872	chr8:21834567	A/G	cg17168535	chr8:21777572	XPO7	0.62	10.11	0.43	7.61e-22	Mean corpuscular volume;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg13453750	chr1:205783389	SLC41A1	-0.42	-7.96	-0.35	1.36e-14	Menarche (age at onset);
LGG	cis	rs526231	0.543	rs246905	chr5:102590943	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.66	-0.34	1.11e-13	Primary biliary cholangitis;
LGG	cis	rs1018836	0.923	rs1858674	chr8:91580665	G/T	cg16814680	chr8:91681699	NA	-0.8	-14.63	-0.56	3.91e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.73	0.3	5.07e-11	Glycated hemoglobin levels;
LGG	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg23625390	chr15:77176239	SCAPER	-0.67	-12.15	-0.49	1.16e-29	Blood metabolite levels;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-12.09	-0.49	2.04e-29	Vitiligo;
LGG	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.58	-0.44	1.38e-23	Chronic sinus infection;
LGG	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.92	0.57	2.31e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	cg15522984	chr1:182991683	LAMC1	0.43	8.7	0.37	5.78e-17	Colorectal cancer;
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg02297831	chr4:17616191	MED28	0.52	9.51	0.4	1.08e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06850241	chr22:41845214	NA	0.43	6.87	0.3	2.06e-11	Vitiligo;
LGG	cis	rs4727027	0.899	rs7791496	chr7:148863674	C/G	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.99	0.52	3.89e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.52	-0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg02772935	chr3:125709198	NA	-0.55	-7.0	-0.31	8.77e-12	Blood pressure (smoking interaction);
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg08835221	chr22:38071607	LGALS1	0.27	7.55	0.33	2.4e-13	Fat distribution (HIV);
LGG	cis	rs7572733	0.773	rs16866970	chr2:198511086	G/A	cg00792783	chr2:198669748	PLCL1	0.41	6.73	0.3	4.95e-11	Dermatomyositis;
LGG	cis	rs6138458	1.000	rs6138458	chr20:24973769	C/T	cg26195577	chr20:24973756	C20orf3	1.25	26.44	0.78	1.45e-94	Blood protein levels;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs903263	0.601	rs12404263	chr1:84551736	G/A	cg10977910	chr1:84465055	TTLL7	0.44	7.73	0.34	6.72e-14	Breast cancer (male);
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg06138931	chr13:21896616	NA	0.37	7.4	0.33	6.51e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.26	-0.46	3.78e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg12633918	chr20:23549525	CST9L	-0.33	-6.78	-0.3	3.68e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.71	0.3	5.52e-11	Bladder cancer;
LGG	cis	rs6735179	1.000	rs1124200	chr2:1778558	A/G	cg10160682	chr2:1713001	PXDN	-0.43	-7.29	-0.32	1.36e-12	Response to antipsychotic treatment;
LGG	cis	rs12949688	1.000	rs7212186	chr17:55818454	C/A	cg12229367	chr17:55822335	NA	0.43	8.09	0.35	5.35e-15	Schizophrenia;
LGG	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg01191920	chr7:158217561	PTPRN2	-0.8	-18.46	-0.65	1.95e-57	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs3087591	1.000	rs3087591	chr17:29630970	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-13.72	-0.54	3.57e-36	Hip circumference;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4684776	1.000	rs2442782	chr3:11483793	C/T	cg24705426	chr3:11550659	ATG7	-0.45	-8.12	-0.35	4.37e-15	Small vessel stroke;
LGG	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26076054	chr5:421317	AHRR	-0.54	-8.95	-0.38	8.96e-18	Cystic fibrosis severity;
LGG	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-12.38	-0.5	1.31e-30	Vitiligo;
LGG	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7623687	0.786	rs73082337	chr3:49009570	C/G	cg19401529	chr3:49056140	DALRD3	0.68	7.88	0.34	2.41e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs972578	0.765	rs5759081	chr22:43396445	A/G	cg01576275	chr22:43409880	NA	-0.23	-7.12	-0.31	4.1e-12	Mean platelet volume;
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg16606324	chr3:10149918	C3orf24	0.53	6.87	0.3	2.04e-11	Alzheimer's disease;
LGG	cis	rs35771425	1.000	rs34221813	chr1:211595896	C/T	cg10512769	chr1:211675356	NA	-0.74	-11.97	-0.49	5.93e-29	Educational attainment (years of education);
LGG	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.44	0.44	4.64e-23	Neuroticism;
LGG	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.41e-11	Blood metabolite levels;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.45	-0.47	6.57e-27	Intelligence (multi-trait analysis);
LGG	trans	rs208520	0.661	rs207090	chr6:66783963	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.38	-0.65	4.6e-57	Exhaled nitric oxide output;
LGG	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.04	-0.39	4.26e-18	Post bronchodilator FEV1;
LGG	trans	rs225245	0.765	rs226428	chr17:34049950	C/T	cg19694781	chr19:47549865	TMEM160	0.42	7.11	0.31	4.48e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2249694	0.960	rs4351776	chr10:135415572	G/T	cg20169779	chr10:135381914	SYCE1	-0.5	-7.81	-0.34	3.88e-14	Obesity-related traits;
LGG	cis	rs7765175	1.000	rs56412849	chr6:113671153	A/G	cg26552650	chr6:113682475	NA	-0.33	-7.16	-0.32	3.23e-12	Coronary artery calcification;
LGG	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.31	-0.32	1.16e-12	Neuroticism;
LGG	cis	rs4919087	0.715	rs13439	chr10:99006083	C/T	cg25902810	chr10:99078978	FRAT1	-0.42	-7.15	-0.32	3.5e-12	Monocyte count;
LGG	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.15	-0.35	3.31e-15	Small cell lung carcinoma;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg05692746	chr2:100937584	LONRF2	-0.67	-12.49	-0.5	4.52e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs727505	1.000	rs55964341	chr7:124517280	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg27129171	chr3:47204927	SETD2	-0.78	-14.83	-0.57	5.69e-41	Colorectal cancer;
LGG	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg14593290	chr7:50529359	DDC	-0.5	-8.7	-0.37	5.79e-17	Malaria;
LGG	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg03264133	chr6:25882463	NA	-0.45	-7.05	-0.31	6.68e-12	Iron status biomarkers;
LGG	cis	rs12431410	0.584	rs7146207	chr14:60237862	C/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.43	-0.33	5.28e-13	Schizophrenia;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg07677032	chr17:61819896	STRADA	0.43	6.67	0.3	7.48e-11	Height;
LGG	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg01324343	chr3:183735012	ABCC5	0.84	17.46	0.63	8.34e-53	Anterior chamber depth;
LGG	cis	rs27524	0.734	rs27037	chr5:96094694	T/G	cg17330273	chr5:96107758	CAST;ERAP1	0.32	6.68	0.3	6.73e-11	Psoriasis;Hodgkin's lymphoma;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg10295955	chr4:187884368	NA	-1.16	-31.61	-0.83	1.07e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.6	0.37	1.25e-16	Aortic root size;
LGG	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg15596359	chr8:11213517	TDH	-0.41	-8.63	-0.37	1.01e-16	Retinal vascular caliber;
LGG	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg11812906	chr14:75593930	NEK9	-0.52	-8.96	-0.38	8.24e-18	Height;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg11062466	chr8:58055876	NA	0.61	9.74	0.41	1.62e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.19e-26	Morning vs. evening chronotype;
LGG	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg26396452	chr14:65542826	MAX	0.49	10.3	0.43	1.54e-22	Obesity-related traits;
LGG	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg26816564	chr1:7831052	VAMP3	-0.74	-11.4	-0.47	1.1e-26	Inflammatory bowel disease;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11245990	chr11:68621969	NA	0.41	8.66	0.37	7.66e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1371867	0.846	rs1788203	chr8:101303721	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg09596252	chr17:78655493	RPTOR	-0.42	-7.5	-0.33	3.18e-13	Obesity;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg09426994	chr11:118478258	PHLDB1	0.43	7.83	0.34	3.29e-14	Cholesterol, total;
LGG	cis	rs10173297	0.686	rs62108696	chr2:3707852	T/C	cg20720597	chr2:3699334	NA	0.55	6.97	0.31	1.13e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs524281	0.954	rs549187	chr11:65898631	C/T	cg16950941	chr11:66035639	RAB1B	-0.48	-7.36	-0.32	8.43e-13	Electroencephalogram traits;
LGG	cis	rs1062746	0.771	rs12928484	chr16:87377837	G/A	cg02258303	chr16:87377426	FBXO31	-0.59	-11.33	-0.47	1.98e-26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.35	8.75	0.38	4.06e-17	Systemic lupus erythematosus;
LGG	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg23933602	chr10:16859644	RSU1	0.63	9.18	0.39	1.46e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1707322	0.721	rs28442079	chr1:46172001	A/G	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg11040518	chr10:102331378	NA	-0.39	-7.26	-0.32	1.63e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg03528353	chr17:61819722	STRADA	-0.44	-7.48	-0.33	3.76e-13	Prudent dietary pattern;
LGG	cis	rs700651	0.675	rs1371665	chr2:198942568	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.48	0.33	3.81e-13	Intracranial aneurysm;
LGG	cis	rs12618769	0.597	rs10514774	chr2:99028695	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	7.63e-17	Bipolar disorder;
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs6977955	1.000	rs917117	chr7:28176305	G/A	cg23620719	chr7:28220237	JAZF1	0.44	6.9	0.31	1.66e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.06	0.31	6.3e-12	Educational attainment;
LGG	cis	rs6066825	0.644	rs6090894	chr20:47334688	G/T	cg18078177	chr20:47281410	PREX1	0.46	7.7	0.34	8.1e-14	Colorectal cancer;
LGG	cis	rs16957091	0.954	rs8026233	chr15:43024999	G/C	cg07484255	chr15:43025164	CDAN1	-0.49	-7.03	-0.31	7.33e-12	MGMT methylation in smokers;
LGG	cis	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-9.08	-0.39	3.21e-18	Kawasaki disease;
LGG	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.67	-0.51	8.82e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs975722	0.638	rs6466618	chr7:117324019	G/A	cg10524701	chr7:117356490	CTTNBP2	0.47	9.66	0.41	3.11e-20	Coronary artery disease;
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.78	-0.3	3.65e-11	Bipolar disorder;
LGG	cis	rs6988985	0.647	rs28459852	chr8:143986436	T/A	cg10324643	chr8:143916377	GML	0.45	9.32	0.4	4.87e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs6066825	0.590	rs6063307	chr20:47304045	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.04	0.35	7.81e-15	Colorectal cancer;
LGG	cis	rs7737355	0.812	rs11746227	chr5:130961236	C/T	cg06307176	chr5:131281290	NA	0.53	8.72	0.38	4.88e-17	Life satisfaction;
LGG	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg05890377	chr2:74357713	NA	0.5	10.1	0.42	8.53e-22	Gestational age at birth (maternal effect);
LGG	cis	rs11169552	0.510	rs11169515	chr12:51053515	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.84	-0.34	3.14e-14	Colorectal cancer;
LGG	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.92	-0.31	1.47e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg18187862	chr3:45730750	SACM1L	0.54	8.65	0.37	8.73e-17	Primary sclerosing cholangitis;
LGG	cis	rs4950322	0.580	rs7515160	chr1:146592296	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-7.65	-0.33	1.2e-13	Protein quantitative trait loci;
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg11211951	chr8:145729740	GPT	-0.52	-12.15	-0.49	1.17e-29	Age at first birth;
LGG	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg02002194	chr4:3960332	NA	-0.52	-9.79	-0.41	1.09e-20	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26661543	chr18:2570950	NDC80;METTL4	0.44	6.9	0.31	1.76e-11	Gut microbiome composition (summer);
LGG	cis	rs722599	0.961	rs2359239	chr14:75326771	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.67	-12.41	-0.5	9.6e-31	IgG glycosylation;
LGG	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs7226408	0.600	rs323324	chr18:34720887	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.11	-0.39	2.48e-18	Obesity-related traits;
LGG	cis	rs6547631	0.622	rs10187164	chr2:85928209	G/C	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs9326248	0.689	rs236916	chr11:117089628	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.6	-6.75	-0.3	4.45e-11	Blood protein levels;
LGG	cis	rs6540556	0.723	rs12059226	chr1:209906675	A/G	cg23920097	chr1:209922102	NA	-0.41	-7.03	-0.31	7.47e-12	Red blood cell count;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg08621203	chr6:150244597	RAET1G	0.42	7.01	0.31	8.25e-12	Lung cancer;
LGG	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.41	0.44	6.18e-23	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg06654118	chr4:1303317	MAEA	0.46	7.96	0.35	1.31e-14	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.2	-0.39	1.23e-18	Lung cancer;
LGG	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03352830	chr11:487213	PTDSS2	0.9	10.98	0.45	4.52e-25	Body mass index;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs17453880	0.929	rs10041396	chr5:152041300	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.59	-0.74	2.26e-81	Subjective well-being;
LGG	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg03929089	chr4:120376271	NA	-0.69	-10.81	-0.45	1.93e-24	Height;
LGG	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg13683864	chr3:40499215	RPL14	1.15	28.26	0.8	7.65e-103	Renal cell carcinoma;
LGG	cis	rs9790314	0.723	rs12631850	chr3:160883062	C/T	cg03342759	chr3:160939853	NMD3	0.61	10.86	0.45	1.21e-24	Morning vs. evening chronotype;
LGG	cis	rs6909430	0.731	rs9490788	chr6:98622703	C/T	cg12860156	chr6:98744658	NA	-0.38	-6.78	-0.3	3.59e-11	Quantitative traits;
LGG	cis	rs2735413	0.914	rs2707604	chr16:78054853	A/G	cg04733911	chr16:78082701	NA	-0.71	-15.61	-0.59	2.02e-44	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg17127132	chr2:85788382	GGCX	0.47	8.15	0.35	3.42e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg19500275	chr17:80737654	TBCD	0.52	6.82	0.3	2.86e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7119	0.745	rs11632602	chr15:77809764	C/G	cg10437265	chr15:77819839	NA	0.25	7.08	0.31	5.23e-12	Type 2 diabetes;
LGG	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.77	-0.78	4.45e-96	Schizophrenia;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg23302884	chr18:44338147	ST8SIA5	0.35	6.84	0.3	2.58e-11	Personality dimensions;
LGG	cis	rs4731207	0.596	rs10226659	chr7:124609868	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.83	-0.3	2.67e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6964587	1.000	rs11981461	chr7:91692662	A/G	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	cis	rs1387259	0.839	rs7487682	chr12:48579665	A/C	cg24011408	chr12:48396354	COL2A1	-0.55	-9.16	-0.39	1.68e-18	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs9815354	1.000	rs73081353	chr3:41906448	T/A	cg03022575	chr3:42003672	ULK4	0.74	9.27	0.4	6.95e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4696584	0.877	rs1490677	chr4:155380037	C/A	cg04517429	chr4:155413618	DCHS2	-0.34	-7.3	-0.32	1.25e-12	Folding of antihelix;
LGG	cis	rs11608355	0.508	rs11066394	chr12:109799212	C/A	cg19025524	chr12:109796872	NA	-0.47	-8.63	-0.37	9.93e-17	Neuroticism;
LGG	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg01017244	chr2:74357527	NA	0.46	8.58	0.37	1.4e-16	Gestational age at birth (maternal effect);
LGG	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg12439423	chr8:41522721	ANK1	0.47	8.71	0.38	5.26e-17	Type 2 diabetes;
LGG	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg01448562	chr3:133502909	NA	-0.52	-8.67	-0.37	7.1e-17	Iron status biomarkers;
LGG	cis	rs3087591	0.762	rs7502029	chr17:29590791	T/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.28	0.55	1.33e-38	Hip circumference;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.93	0.38	1.04e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02792140	chr19:3505953	FZR1	0.48	7.13	0.31	3.81e-12	Gut microbiome composition (summer);
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18000306	chr6:288505	NA	0.61	10.84	0.45	1.43e-24	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16232504	chr1:99127707	SNX7	0.4	7.08	0.31	5.21e-12	Obesity-related traits;
LGG	cis	rs6868223	0.964	rs3935844	chr5:33639682	C/T	cg10594543	chr5:33649717	ADAMTS12	0.58	13.27	0.52	2.88e-34	Mortality in heart failure;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.75	0.38	4.08e-17	Lung cancer;
LGG	cis	rs12200560	0.524	rs1413525	chr6:97073096	C/T	cg06623918	chr6:96969491	KIAA0776	0.43	7.2	0.32	2.42e-12	Coronary heart disease;
LGG	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg16586182	chr3:47516702	SCAP	0.77	15.4	0.58	1.62e-43	Colorectal cancer;
LGG	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.47	-0.75	1.7e-85	Height;
LGG	cis	rs2470578	0.792	rs2733516	chr3:17252724	T/G	cg20981856	chr3:17787350	NA	0.35	6.64	0.3	8.55e-11	Schizophrenia;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.05	-0.35	7.24e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.51	0.33	3.1e-13	Joint mobility (Beighton score);
LGG	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15506890	chr2:3487001	NA	-0.6	-11.53	-0.47	3.27e-27	Neurofibrillary tangles;
LGG	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg21435375	chr2:172878103	MAP1D	0.3	6.77	0.3	3.91e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg20607798	chr8:58055168	NA	-0.57	-6.66	-0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg03709012	chr19:19516395	GATAD2A	-0.84	-17.06	-0.62	5.5e-51	Tonsillectomy;
LGG	cis	rs61935443	0.778	rs78522691	chr12:95267340	G/T	cg21533806	chr12:95267307	NA	0.51	7.07	0.31	5.67e-12	Schizophrenia;
LGG	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg00277334	chr10:82204260	NA	-0.37	-8.11	-0.35	4.46e-15	Post bronchodilator FEV1;
LGG	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg17859187	chr1:168147929	TIPRL	0.46	6.65	0.3	8.33e-11	Schizophrenia;
LGG	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg13010199	chr12:38710504	ALG10B	0.66	13.25	0.52	3.48e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs9902453	0.934	rs12453172	chr17:28441590	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.18	0.52	6.65e-34	Coffee consumption (cups per day);
LGG	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.44e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs889398	0.738	rs7196842	chr16:69923333	T/C	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.68	-0.3	6.94e-11	Body mass index;
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.22	-0.43	3.13e-22	Bipolar disorder;
LGG	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg06197492	chr11:2016605	H19	0.45	8.83	0.38	2.13e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.03e-37	Bladder cancer;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg26384229	chr12:38710491	ALG10B	0.62	11.99	0.49	5.05e-29	Morning vs. evening chronotype;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg01238044	chr22:24384105	GSTT1	-0.46	-7.8	-0.34	4.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg06115741	chr20:33292138	TP53INP2	0.49	8.17	0.36	2.87e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4731207	0.596	rs6954614	chr7:124629794	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs526231	0.543	rs246906	chr5:102566471	A/G	cg23492399	chr5:102201601	PAM	-0.58	-8.34	-0.36	8.5e-16	Primary biliary cholangitis;
LGG	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-10.61	-0.44	1.13e-23	Caffeine consumption;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg19147804	chr7:1989927	MAD1L1	-0.52	-10.24	-0.43	2.47e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg00914033	chr10:81664698	NA	-0.42	-6.71	-0.3	5.87e-11	Sitting height ratio;
LGG	cis	rs2298450	0.550	rs36037816	chr21:37656115	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.88	-0.38	1.43e-17	Schizophrenia;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-9.91	-0.42	3.92e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg15440763	chr7:158190612	PTPRN2	0.46	9.77	0.41	1.22e-20	Obesity-related traits;
LGG	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg08847533	chr14:75593920	NEK9	0.54	9.7	0.41	2.19e-20	Height;
LGG	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg21475434	chr5:93447410	FAM172A	0.73	7.32	0.32	1.09e-12	Diabetic retinopathy;
LGG	cis	rs80282103	0.618	rs76068439	chr10:1121018	T/A	cg08668510	chr10:1095578	IDI1	0.87	7.71	0.34	7.67e-14	Glomerular filtration rate (creatinine);
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.7	-0.41	2.19e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg09165964	chr15:75287851	SCAMP5	-0.56	-10.59	-0.44	1.26e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs3857747	0.759	rs4640968	chr7:40450451	G/A	cg00420559	chr7:40367873	C7orf10	-0.39	-7.92	-0.35	1.76e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg26384229	chr12:38710491	ALG10B	-0.74	-14.19	-0.55	3.18e-38	Morning vs. evening chronotype;
LGG	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg10792982	chr14:105748885	BRF1	0.67	13.54	0.53	2.05e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9811920	0.638	rs793474	chr3:99544380	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.12	0.39	2.26e-18	Axial length;
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg22907277	chr7:1156413	C7orf50	0.45	7.52	0.33	2.78e-13	Longevity;Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26633120	chr2:105654408	MRPS9	-0.47	-6.82	-0.3	2.79e-11	Systemic lupus erythematosus;
LGG	cis	rs7737355	0.947	rs9327620	chr5:130996451	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	2.92e-19	Life satisfaction;
LGG	trans	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg07211511	chr3:129823064	LOC729375	-1.04	-14.96	-0.57	1.46e-41	Blood pressure (smoking interaction);
LGG	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.18	0.32	2.85e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg04568710	chr12:38710424	ALG10B	0.41	8.74	0.38	4.29e-17	Morning vs. evening chronotype;
LGG	cis	rs36051895	0.593	rs12340379	chr9:5176352	C/T	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26306683	chr17:18585705	ZNF286B	0.48	9.21	0.39	1.1e-18	Educational attainment (years of education);
LGG	cis	rs6912958	0.712	rs4498321	chr6:88339251	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.73	-0.38	4.67e-17	Monocyte percentage of white cells;
LGG	trans	rs6787172	0.652	rs827109	chr3:157980974	G/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs701145	0.585	rs1713853	chr3:153795595	A/G	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.47	0.53	4.04e-35	Bladder cancer;
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg25866889	chr13:114914595	NA	-0.35	-7.17	-0.32	2.97e-12	Schizophrenia;
LGG	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg13647721	chr17:30228624	UTP6	0.8	12.67	0.51	8.63e-32	Hip circumference adjusted for BMI;
LGG	cis	rs4262150	0.667	rs4145743	chr5:152275279	G/T	cg12297329	chr5:152029980	NA	0.6	11.9	0.48	1.09e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7020830	0.898	rs12554874	chr9:37073902	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	31.32	0.82	1.95e-116	Schizophrenia;
LGG	cis	rs2067615	0.524	rs754184	chr12:107117521	A/G	cg15890332	chr12:107067104	RFX4	0.44	12.98	0.52	4.44e-33	Heart rate;
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.18e-15	Bipolar disorder;
LGG	cis	rs4075765	0.881	rs72889643	chr11:26236292	G/T	cg19182008	chr11:26298241	NA	0.85	8.13	0.35	3.87e-15	Cannabis dependence symptom count;
LGG	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg10523679	chr1:76189770	ACADM	-0.73	-11.25	-0.46	3.92e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2011503	0.882	rs2060276	chr19:19522491	T/G	cg11584989	chr19:19387371	SF4	0.75	11.66	0.48	1.04e-27	Bipolar disorder;
LGG	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg05985134	chr18:33552581	C18orf21	0.65	10.24	0.43	2.6e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs981844	0.712	rs878911	chr4:154755615	A/G	cg14289246	chr4:154710475	SFRP2	-0.56	-9.63	-0.41	4.07e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs7301016	0.846	rs7296573	chr12:63033041	A/C	cg01804193	chr12:63026212	NA	0.55	7.13	0.31	3.82e-12	IgG glycosylation;
LGG	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs9657904	1.000	rs9826886	chr3:105551692	G/A	cg14088669	chr1:158435396	OR10K1	-0.4	-6.76	-0.3	4.22e-11	Multiple sclerosis;
LGG	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg05791153	chr7:19748676	TWISTNB	0.68	9.91	0.42	4.02e-21	Thyroid stimulating hormone;
LGG	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg04731861	chr2:219085781	ARPC2	-0.49	-12.74	-0.51	4.36e-32	Colorectal cancer;
LGG	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-13.31	-0.53	1.93e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg05091796	chr16:4465799	CORO7	-0.84	-13.08	-0.52	1.67e-33	Schizophrenia;
LGG	cis	rs701145	0.585	rs1713813	chr3:153873643	T/G	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg08621203	chr6:150244597	RAET1G	0.46	8.14	0.35	3.71e-15	Lung cancer;
LGG	cis	rs7301016	1.000	rs11174494	chr12:62864877	A/T	cg11441379	chr12:63026424	NA	0.66	8.78	0.38	3.16e-17	IgG glycosylation;
LGG	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.0	-0.35	1.04e-14	Retinal vascular caliber;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg13129662	chr17:48227708	PPP1R9B	-0.43	-6.66	-0.3	7.91e-11	Coronary artery disease;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06028808	chr11:68637592	NA	0.75	13.16	0.52	7.71e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg20368463	chr18:77673604	PQLC1	0.58	7.52	0.33	2.81e-13	Opioid sensitivity;
LGG	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg10560079	chr2:191398806	TMEM194B	0.36	8.07	0.35	6.11e-15	Pulse pressure;
LGG	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2073300	1.000	rs74273799	chr20:23444492	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11644478	chr21:40555479	PSMG1	-0.71	-12.61	-0.51	1.51e-31	Cognitive function;
LGG	cis	rs35740288	0.688	rs12904047	chr15:86212866	A/G	cg04173714	chr15:86211321	AKAP13	0.49	8.85	0.38	1.8e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg02931644	chr1:25747376	RHCE	0.42	9.04	0.39	4.46e-18	Erythrocyte sedimentation rate;
LGG	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg08344181	chr3:125677491	NA	-0.65	-7.23	-0.32	1.95e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg09845145	chr15:78292470	TBC1D2B	-0.6	-10.89	-0.45	9.74e-25	Coronary artery disease or large artery stroke;
LGG	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.13e-26	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg06212747	chr3:49208901	KLHDC8B	0.67	11.49	0.47	4.64e-27	Parkinson's disease;
LGG	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg15704280	chr7:45808275	SEPT13	0.78	9.04	0.39	4.17e-18	Axial length;
LGG	trans	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg15556689	chr8:8085844	FLJ10661	0.4	6.93	0.31	1.38e-11	Retinal vascular caliber;
LGG	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg02002194	chr4:3960332	NA	0.42	7.69	0.34	8.73e-14	Triglycerides;
LGG	trans	rs75804782	0.521	rs72994973	chr2:239428315	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.68	0.37	7.02e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs4478037	0.822	rs9826234	chr3:33123832	A/C	cg19404215	chr3:33155277	CRTAP	0.74	9.24	0.39	9.27e-19	Major depressive disorder;
LGG	cis	rs4704187	0.687	rs1477934	chr5:74423243	A/T	cg03227963	chr5:74354835	NA	0.31	6.65	0.3	8.04e-11	Response to amphetamines;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs2236918	0.687	rs2797601	chr1:242029249	C/G	cg17736920	chr1:242011382	EXO1	0.39	7.0	0.31	9.23e-12	Menopause (age at onset);
LGG	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.77	0.54	2.18e-36	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05491587	chr18:77659695	KCNG2	-0.53	-7.06	-0.31	6.06e-12	Opioid sensitivity;
LGG	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.09	-0.42	8.7e-22	Sudden cardiac arrest;
LGG	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.63	-0.37	9.9900000000000006e-17	Neuroticism;
LGG	cis	rs3806843	0.520	rs246051	chr5:140326464	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg07936489	chr17:37558343	FBXL20	-0.96	-15.05	-0.57	5.63e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg09998033	chr7:158218633	PTPRN2	-0.55	-10.34	-0.43	1.05e-22	Obesity-related traits;
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.21	-0.43	3.31e-22	Neuroticism;
LGG	cis	rs1555322	0.530	rs6058224	chr20:33881774	C/T	cg17927777	chr20:33865990	NA	0.63	9.3	0.4	5.37e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg20790798	chr5:1857306	NA	-0.43	-7.17	-0.32	2.93e-12	Cardiovascular disease risk factors;
LGG	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg09696939	chr10:60272079	BICC1	-0.39	-7.61	-0.33	1.51e-13	Refractive error;
LGG	cis	rs11229555	0.645	rs7116007	chr11:58218701	C/T	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2046867	0.661	rs6790583	chr3:72901701	G/T	cg25664220	chr3:72788482	NA	-0.28	-7.95	-0.35	1.46e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9457247	0.510	rs6456151	chr6:167471851	A/C	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Crohn's disease;
LGG	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.61	-0.44	1.08e-23	Total body bone mineral density;
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg18357526	chr6:26021779	HIST1H4A	0.59	10.17	0.43	4.56e-22	Height;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs6735179	0.603	rs10164788	chr2:1753379	G/A	cg20570797	chr2:1712800	PXDN	-0.47	-8.13	-0.35	4.09e-15	Response to antipsychotic treatment;
LGG	cis	rs2455799	0.634	rs62243671	chr3:15921098	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.09e-14	Mean platelet volume;
LGG	cis	rs7760949	0.925	rs9464420	chr6:13925892	C/T	cg27413430	chr6:13925136	RNF182	0.52	7.68	0.34	9.74e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg20578329	chr17:80767326	TBCD	-0.81	-12.65	-0.51	1.01e-31	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs6466055	0.777	rs3779210	chr7:104828098	C/T	cg04380332	chr7:105027541	SRPK2	-0.37	-6.97	-0.31	1.07e-11	Schizophrenia;
LGG	cis	rs4919694	0.611	rs7091462	chr10:104948615	C/T	cg04362960	chr10:104952993	NT5C2	0.89	13.71	0.54	3.65e-36	Arsenic metabolism;
LGG	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06562184	chr8:19319451	CSGALNACT1	0.37	7.5	0.33	3.39e-13	Oropharynx cancer;
LGG	cis	rs883115	0.810	rs10916653	chr1:224785503	G/A	cg01808320	chr1:224927238	CNIH3	-0.41	-7.59	-0.33	1.8e-13	Cancer;
LGG	cis	rs7000551	0.725	rs2469757	chr8:22360938	C/T	cg12081754	chr8:22256438	SLC39A14	0.62	11.58	0.47	2.01e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs16937	0.662	rs10900468	chr1:205163057	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.58e-13	Schizophrenia;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18402987	chr7:1209562	NA	0.39	7.05	0.31	6.48e-12	Longevity;Endometriosis;
LGG	trans	rs62458065	0.640	rs4141788	chr7:32519264	T/C	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.45	-0.33	4.72e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.09e-25	Corneal astigmatism;
LGG	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg17467752	chr17:38218738	THRA	-0.44	-7.08	-0.31	5.51e-12	Lymphocyte counts;
LGG	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg03929089	chr4:120376271	NA	0.74	8.57	0.37	1.57e-16	Axial length;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg21130718	chr4:1044621	NA	0.46	9.32	0.4	4.71e-19	Recombination rate (males);
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07677032	chr17:61819896	STRADA	-0.56	-9.84	-0.42	7.03e-21	Prudent dietary pattern;
LGG	cis	rs7617773	1.000	rs6442108	chr3:48192959	G/C	cg11946769	chr3:48343235	NME6	-0.54	-8.58	-0.37	1.47e-16	Coronary artery disease;
LGG	trans	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg17763188	chr8:6692148	XKR5	0.41	7.0	0.31	9.12e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg23306229	chr2:178417860	TTC30B	0.66	8.6	0.37	1.27e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg24375607	chr4:120327624	NA	0.6	10.21	0.43	3.26e-22	Corneal astigmatism;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.56	9.56	0.41	7.05e-20	Obesity-related traits;
LGG	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03517284	chr6:25882590	NA	-0.55	-10.56	-0.44	1.69e-23	Blood metabolite levels;
LGG	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.98	0.7	3.6e-69	Gut microbiome composition (summer);
LGG	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg25811766	chr13:21894605	NA	-0.59	-7.74	-0.34	6.1e-14	White matter hyperintensity burden;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00860640	chr1:145516730	PEX11B;GNRHR2	0.43	6.94	0.31	1.33e-11	Cognitive performance;
LGG	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg02002194	chr4:3960332	NA	0.43	7.66	0.34	1.1e-13	Retinal vascular caliber;
LGG	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.16	0.43	5.07e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg11062466	chr8:58055876	NA	0.44	6.86	0.3	2.27e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg27446573	chr6:127587934	RNF146	1.14	22.6	0.72	9.29e-77	Breast cancer;
LGG	cis	rs1355223	0.902	rs1539250	chr11:34742775	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.34	-0.36	8.64e-16	Schizophrenia;
LGG	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg18942110	chr15:91072797	CRTC3	-0.29	-6.65	-0.3	8.17e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4561483	0.831	rs8052900	chr16:11940390	T/C	cg08843971	chr16:11963173	GSPT1	0.6	13.96	0.54	3.23e-37	Testicular germ cell tumor;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10927271	chr22:46610313	PPARA	-0.4	-7.5	-0.33	3.24e-13	Bipolar disorder;
LGG	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.5	-8.86	-0.38	1.78e-17	Response to antipsychotic treatment;
LGG	cis	rs4006360	0.554	rs1848810	chr17:39236025	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.56	-0.47	2.49e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg02158880	chr13:53174818	NA	0.47	9.58	0.41	5.88e-20	Lewy body disease;
LGG	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg13607699	chr17:42295918	UBTF	-0.43	-6.87	-0.3	2.02e-11	Total body bone mineral density;
LGG	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.55	0.47	2.85e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21862992	chr11:68658383	NA	0.44	7.41	0.33	6.23e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4262150	0.764	rs12188564	chr5:151936546	G/A	cg12297329	chr5:152029980	NA	-0.71	-13.47	-0.53	4.16e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2798269	1.000	rs2761916	chr13:22148286	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.88	-0.3	1.94e-11	PR segment;
LGG	cis	rs9309473	1.000	rs11903916	chr2:73815328	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.33	-0.32	1.01e-12	Metabolite levels;
LGG	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg07061783	chr6:25882402	NA	-0.43	-7.45	-0.33	4.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.03e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3764563	0.935	rs4807958	chr19:15718042	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.9	-0.34	2.12e-14	Inflammatory biomarkers;
LGG	cis	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg19847130	chr8:10466454	RP1L1	-0.37	-7.83	-0.34	3.37e-14	Neuroticism;
LGG	cis	rs758324	0.773	rs2404777	chr5:131172803	C/A	cg06307176	chr5:131281290	NA	0.53	8.87	0.38	1.58e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs8064024	0.650	rs3813749	chr16:4919127	T/C	cg08329684	chr16:4932620	PPL	0.54	12.19	0.49	7.63e-30	Cancer;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.34	-0.36	8.35e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg06875740	chr19:51307921	C19orf48	-0.75	-6.95	-0.31	1.27e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	13.87	0.54	7.53e-37	Cognitive test performance;
LGG	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-7.52	-0.33	2.93e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	8.05	0.35	6.93e-15	Menarche (age at onset);
LGG	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3816183	1.000	rs893731	chr2:43015432	T/C	cg14631114	chr2:43023945	NA	0.51	9.65	0.41	3.34e-20	Hypospadias;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg24846343	chr22:24311635	DDTL	0.6	11.81	0.48	2.45e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.87	-0.38	1.59e-17	Neuroticism;
LGG	cis	rs3784262	0.669	rs4646580	chr15:58329211	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.98	-0.31	1.01e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9309473	0.500	rs11688718	chr2:73760939	C/T	cg20560298	chr2:73613845	ALMS1	-0.36	-6.69	-0.3	6.51e-11	Metabolite levels;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.92e-43	Prudent dietary pattern;
LGG	trans	rs3764147	0.509	rs9595019	chr13:44380677	G/A	cg12856521	chr11:46389249	DGKZ	0.55	7.59	0.33	1.83e-13	Inflammatory bowel disease;Crohn's disease;Leprosy;
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg05335186	chr13:53173507	NA	0.48	9.98	0.42	2.24e-21	Lewy body disease;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00761968	chr13:53314142	LECT1	0.34	7.1	0.31	4.81e-12	Lewy body disease;
LGG	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg03342759	chr3:160939853	NMD3	-0.61	-11.2	-0.46	6.21e-26	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg03806693	chr22:41940476	POLR3H	-0.82	-14.45	-0.56	2.58e-39	Vitiligo;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.05	0.39	4e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.41	-0.36	5.28e-16	IgG glycosylation;
LGG	cis	rs13064447	0.753	rs9868500	chr3:12747690	A/G	cg23032965	chr3:12705835	RAF1	0.49	7.66	0.34	1.12e-13	Major depression and alcohol dependence;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.22e-18	Alzheimer's disease;
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.1	-0.46	1.55e-25	IgG glycosylation;
LGG	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg17376030	chr22:41985996	PMM1	-0.65	-10.49	-0.44	3.09e-23	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1707322	0.691	rs12031182	chr1:46220999	C/T	cg03146154	chr1:46216737	IPP	0.57	11.07	0.46	2.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg24692254	chr21:30365293	RNF160	-0.95	-24.11	-0.75	8.15e-84	Dental caries;
LGG	cis	rs7267979	1.000	rs6037121	chr20:25428311	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-9.12	-0.39	2.28e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4774899	0.752	rs2951906	chr15:57337969	G/C	cg08128148	chr15:57256372	TCF12	-0.28	-6.84	-0.3	2.58e-11	Urinary tract infection frequency;
LGG	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.16	-0.32	3.09e-12	Bipolar disorder;
LGG	cis	rs870825	0.929	rs72689272	chr4:185592515	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	19.01	0.66	5.58e-60	Blood protein levels;
LGG	trans	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg11441553	chr12:57614120	NXPH4	-0.61	-7.61	-0.33	1.58e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs1707322	0.686	rs3014251	chr1:46077428	G/C	cg03146154	chr1:46216737	IPP	-0.58	-10.82	-0.45	1.84e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3849570	0.961	rs3821548	chr3:81758728	C/G	cg07356753	chr3:81810745	GBE1	-0.49	-8.02	-0.35	8.43e-15	Waist circumference;Body mass index;
LGG	cis	rs2597513	1.000	rs2597513	chr3:13555836	C/T	cg24006715	chr3:13568212	NA	0.61	10.29	0.43	1.72e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs12967678	1	rs12967678	chr18:12805388	G/A	cg23544223	chr18:12777786	NA	-0.52	-6.81	-0.3	3.05e-11	Selective IgA deficiency;
LGG	cis	rs74781061	0.932	rs11854461	chr15:74739741	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.09	-0.31	5e-12	Endometriosis;
LGG	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg09754948	chr16:28834200	ATXN2L	0.49	7.71	0.34	7.95e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg12463550	chr7:65579703	CRCP	0.49	8.21	0.36	2.22e-15	Aortic root size;
LGG	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg00757033	chr12:89920650	WDR51B	0.62	9.0	0.39	5.99e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2041895	0.509	rs7976343	chr12:107296028	T/C	cg13944111	chr12:107296891	NA	0.26	6.91	0.31	1.57e-11	Glaucoma (low intraocular pressure);
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.22e-13	Personality dimensions;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.08	0.35	5.85e-15	Longevity;
LGG	cis	rs9287719	0.934	rs6721510	chr2:10751046	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.22	0.39	1.04e-18	Cannabis dependence symptom count;
LGG	cis	rs3845702	0.736	rs115569960	chr2:180848214	C/T	cg01881094	chr2:180872142	CWC22	1.29	16.8	0.62	8.69e-50	Schizophrenia;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06112835	chr11:68658793	MRPL21	0.62	10.39	0.43	6.91e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg11494091	chr17:61959527	GH2	-0.71	-12.84	-0.51	1.75e-32	Height;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg02002194	chr4:3960332	NA	-0.38	-6.75	-0.3	4.31e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7095944	0.644	rs4962694	chr10:126436717	G/T	cg08799069	chr10:126477246	METTL10	-0.48	-10.79	-0.45	2.25e-24	Asthma;
LGG	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg11502198	chr6:26597334	ABT1	-0.92	-7.86	-0.34	2.77e-14	Small cell lung carcinoma;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.57	0.53	1.45e-35	Obesity-related traits;
LGG	cis	rs11112613	0.713	rs871220	chr12:105938558	G/A	cg03607813	chr12:105948248	NA	0.62	10.6	0.44	1.17e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg16586182	chr3:47516702	SCAP	-0.55	-9.46	-0.4	1.52e-19	Birth weight;
LGG	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.05	-0.35	7.28e-15	Parkinson's disease;
LGG	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg26656751	chr17:43910226	CRHR1	0.37	6.81	0.3	3.02e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10816533	1.000	rs4344199	chr9:99549449	A/G	cg13983307	chr9:99539795	ZNF510	0.71	6.9	0.31	1.76e-11	Height;
LGG	cis	rs1371867	0.875	rs1788187	chr8:101336099	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs7097610	1	rs7097610	chr10:82304162	C/T	cg01528321	chr10:82214614	TSPAN14	-0.85	-10.46	-0.44	4.03e-23	Post bronchodilator FEV1;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg01988459	chr11:68622903	NA	-0.62	-12.43	-0.5	8.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.31	-0.32	1.22e-12	Bipolar disorder;
LGG	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.95	-0.38	8.54e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9326248	0.861	rs1871757	chr11:117030581	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.59	7.76	0.34	5.31e-14	Blood protein levels;
LGG	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg17749961	chr2:30669863	LCLAT1	0.67	9.33	0.4	4.43e-19	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg18187862	chr3:45730750	SACM1L	0.42	6.95	0.31	1.22e-11	Primary sclerosing cholangitis;
LGG	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg16662043	chr16:48846231	NA	0.38	7.37	0.32	8.07e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6429422	0.725	rs2787232	chr1:243306475	G/C	cg02356786	chr1:243265016	LOC731275	0.38	6.96	0.31	1.15e-11	Cognitive ability (multi-trait analysis);
LGG	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.33	0.4	4.39e-19	Retinal vascular caliber;
LGG	trans	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg26043149	chr18:55253948	FECH	0.94	16.37	0.61	7.69e-48	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.01e-21	Lung cancer;
LGG	cis	rs4819388	0.650	rs8127114	chr21:45644504	T/C	cg01992765	chr21:45622493	NA	-0.45	-8.71	-0.38	5.47e-17	Celiac disease;
LGG	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.89	0.57	3.1e-41	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00791468	chr1:111148984	KCNA2	0.42	6.81	0.3	2.97e-11	Cognitive performance;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.45e-21	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg11494091	chr17:61959527	GH2	0.51	7.8	0.34	4.18e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.7	0.41	2.19e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2718058	0.692	rs2709117	chr7:37787807	A/G	cg24998770	chr7:37888106	TXNDC3	0.54	8.92	0.38	1.05e-17	Alzheimer's disease (late onset);
LGG	cis	rs3771570	1.000	rs4346380	chr2:242263223	G/A	cg21155796	chr2:242212141	HDLBP	0.73	8.95	0.38	8.43e-18	Prostate cancer;
LGG	cis	rs11588062	0.628	rs3737744	chr1:46810530	C/T	cg08947153	chr1:46664340	POMGNT1	-0.41	-7.32	-0.32	1.11e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs526231	0.575	rs26822	chr5:102518795	A/G	cg23492399	chr5:102201601	PAM	-0.58	-8.62	-0.37	1.05e-16	Primary biliary cholangitis;
LGG	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg13271783	chr10:134563150	INPP5A	-0.57	-8.45	-0.37	3.74e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10214930	0.560	rs42088	chr7:27701861	C/T	cg22168087	chr7:27702803	HIBADH	-0.53	-8.65	-0.37	8.27e-17	Hypospadias;
LGG	cis	rs1719271	0.908	rs4776639	chr15:65165459	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.67	-0.3	7.35e-11	Platelet count;
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg07389463	chr12:132296394	NA	0.44	9.47	0.4	1.4e-19	Migraine;
LGG	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg27124370	chr19:33622961	WDR88	0.5	9.12	0.39	2.24e-18	Colorectal cancer;
LGG	trans	rs9354308	0.764	rs9345702	chr6:66578835	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.09	-0.31	5.16e-12	Metabolite levels;
LGG	cis	rs6500395	0.532	rs4421983	chr16:48723648	G/T	cg04672837	chr16:48644449	N4BP1	-0.49	-8.36	-0.36	7.53e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.57	-9.92	-0.42	3.83e-21	Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.17	-0.32	2.99e-12	Lung cancer;
LGG	trans	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg25214090	chr10:38739885	LOC399744	0.57	10.3	0.43	1.5e-22	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.56	0.37	1.64e-16	Lung cancer;
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.34	0.53	1.35e-34	Tonsillectomy;
LGG	trans	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-31.88	-0.83	7.02e-119	Exhaled nitric oxide output;
LGG	cis	rs2066819	1.000	rs11171803	chr12:56718422	T/C	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09217309	chr6:150244204	RAET1G	0.41	7.47	0.33	4.09e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg23782820	chr8:58130467	NA	-0.55	-8.05	-0.35	6.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg13010199	chr12:38710504	ALG10B	0.76	16.24	0.6	2.86e-47	Heart rate;
LGG	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.35	-0.32	9.11e-13	Total body bone mineral density;
LGG	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg00129232	chr17:37814104	STARD3	-0.71	-14.3	-0.55	1.17e-38	Glomerular filtration rate (creatinine);
LGG	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg03806693	chr22:41940476	POLR3H	-0.98	-17.5	-0.63	5.33e-53	Vitiligo;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg23758822	chr17:41437982	NA	0.85	14.52	0.56	1.18e-39	Menopause (age at onset);
LGG	cis	rs11874712	1.000	rs56181324	chr18:43678024	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.69	-0.48	7.49e-28	Migraine - clinic-based;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.24e-18	Lung cancer;
LGG	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg18850127	chr7:39170497	POU6F2	0.55	12.37	0.5	1.5e-30	IgG glycosylation;
LGG	cis	rs703842	1.000	rs8181644	chr12:58173466	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	7.58	0.33	1.85e-13	Multiple sclerosis;
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.57e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg04181038	chr4:183730758	NA	0.56	7.68	0.34	9.51e-14	Pediatric autoimmune diseases;
LGG	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs994014	0.612	rs7680637	chr4:82239054	C/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.27	-0.32	1.5e-12	Height;
LGG	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg16885296	chr6:26284938	NA	0.35	7.21	0.32	2.24e-12	Educational attainment;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12016809	chr21:47604291	C21orf56	-0.59	-9.91	-0.42	3.93e-21	Testicular germ cell tumor;
LGG	cis	rs903263	0.512	rs1325602	chr1:84505777	C/T	cg10977910	chr1:84465055	TTLL7	0.47	8.19	0.36	2.47e-15	Breast cancer (male);
LGG	cis	rs9992101	0.564	rs12506745	chr4:77220837	A/C	cg17010112	chr4:77227123	STBD1	-0.46	-9.55	-0.41	7.7e-20	Creatinine levels;
LGG	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg23752985	chr2:85803571	VAMP8	0.44	8.77	0.38	3.5e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7072216	0.763	rs733346	chr10:100164325	A/C	cg26618903	chr10:100175079	PYROXD2	-0.28	-7.09	-0.31	5.11e-12	Metabolite levels;
LGG	cis	rs17767392	1.000	rs7156460	chr14:71855334	A/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.07	0.39	3.33e-18	Mitral valve prolapse;
LGG	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg26384229	chr12:38710491	ALG10B	0.89	20.09	0.68	5.23e-65	Morning vs. evening chronotype;
LGG	cis	rs7177699	0.581	rs7165081	chr15:79123396	C/G	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg07936489	chr17:37558343	FBXL20	0.84	15.6	0.59	2.08e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg04632378	chr13:21900426	NA	0.42	9.28	0.4	6.75e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg02153584	chr22:29168773	CCDC117	0.64	9.96	0.42	2.57e-21	Lymphocyte counts;
LGG	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg25883020	chr8:41504993	NKX6-3	0.33	7.21	0.32	2.24e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg23533926	chr12:111358616	MYL2	-0.44	-7.19	-0.32	2.55e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9937943	0.667	rs11862508	chr16:74598688	T/C	cg01733217	chr16:74700730	RFWD3	0.67	9.25	0.39	8.61e-19	Neutrophil percentage of white cells;
LGG	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg24375607	chr4:120327624	NA	0.65	10.73	0.45	4e-24	Corneal astigmatism;
LGG	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.54e-17	Aortic root size;
LGG	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-12.59	-0.51	1.79e-31	HDL cholesterol;
LGG	trans	rs7937682	0.564	rs7115263	chr11:111379054	C/A	cg18187862	chr3:45730750	SACM1L	-0.43	-6.95	-0.31	1.23e-11	Primary sclerosing cholangitis;
LGG	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg04455712	chr21:45112962	RRP1B	-0.54	-9.86	-0.42	6.04e-21	Mean corpuscular volume;
LGG	cis	rs77633900	0.772	rs166933	chr15:76736265	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-8.35	-0.36	8.12e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg18188782	chr20:61659543	NA	0.4	6.76	0.3	4.15e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg24634471	chr8:143751801	JRK	0.51	7.77	0.34	4.94e-14	Schizophrenia;
LGG	cis	rs11225247	1.000	rs12269847	chr11:102269743	G/C	cg06323957	chr11:102217781	BIRC2	0.8	7.03	0.31	7.51e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9357271	1.000	rs4711544	chr6:38352283	C/A	cg07362130	chr6:38359646	BTBD9	-0.47	-10.85	-0.45	1.36e-24	Restless legs syndrome;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.46	0.4	1.56e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg14926445	chr8:58193284	C8orf71	-0.53	-7.47	-0.33	4.01e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs877282	0.853	rs7079450	chr10:755932	T/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs8014204	0.762	rs973879	chr14:75297727	T/C	cg06637938	chr14:75390232	RPS6KL1	0.65	11.9	0.48	1.15e-28	Caffeine consumption;
LGG	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	24.95	0.76	1.02e-87	IgG glycosylation;
LGG	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg00102166	chr1:43425337	SLC2A1	-0.38	-7.39	-0.32	6.72e-13	Red cell distribution width;
LGG	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg00405596	chr8:11794950	NA	0.44	7.53	0.33	2.74e-13	Mood instability;
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg25174290	chr11:3078921	CARS	-0.51	-9.37	-0.4	3.32e-19	Calcium levels;
LGG	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg27446573	chr6:127587934	RNF146	1.13	22.38	0.72	1.01e-75	Breast cancer;
LGG	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	14.19	0.55	3.38e-38	Cognitive test performance;
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg11764359	chr7:65958608	NA	-0.73	-12.79	-0.51	2.64e-32	Aortic root size;
LGG	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.19	0.36	2.48e-15	Birth weight;
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18252515	chr7:66147081	NA	0.44	7.33	0.32	1.04e-12	Aortic root size;
LGG	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg16230307	chr14:35515116	FAM177A1	0.41	7.34	0.32	9.97e-13	Psoriasis;
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.19	-0.39	1.38e-18	Neuroticism;
LGG	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	7.42	0.33	5.73e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.59	0.51	1.76e-31	Prudent dietary pattern;
LGG	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	11.95	0.49	6.86e-29	Colorectal cancer;
LGG	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg13207630	chr7:32358064	NA	0.66	7.17	0.32	3.06e-12	Body mass index;
LGG	cis	rs17767392	0.918	rs2108707	chr14:71791170	G/C	cg02058870	chr14:72053146	SIPA1L1	0.47	9.38	0.4	2.99e-19	Mitral valve prolapse;
LGG	cis	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg19847130	chr8:10466454	RP1L1	0.35	7.25	0.32	1.77e-12	Neuroticism;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg21782813	chr7:2030301	MAD1L1	0.38	8.36	0.36	7.39e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg21659725	chr3:3221576	CRBN	-0.64	-6.82	-0.3	2.79e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.12e-12	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.97	0.38	7.19e-18	Rheumatoid arthritis;
LGG	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.65	0.41	3.44e-20	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.4	0.36	5.51e-16	Bipolar disorder;
LGG	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg10847948	chr11:71163743	NADSYN1	0.58	8.74	0.38	4.28e-17	Vitamin D levels;
LGG	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg05775895	chr3:12838266	CAND2	0.8	15.45	0.58	9.5e-44	QRS complex (12-leadsum);
LGG	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg01181863	chr3:195395398	SDHAP2	-0.7	-12.45	-0.5	6.61e-31	Bronchopulmonary dysplasia;
LGG	cis	rs9649213	0.586	rs11768599	chr7:97974555	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.47	-0.37	3.17e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7916697	0.947	rs1900004	chr10:70000881	C/T	cg18338521	chr10:69995036	NA	-0.33	-7.42	-0.33	5.82e-13	Optic disc area;
LGG	trans	rs12339094	0.932	rs7022568	chr9:90405244	C/T	cg24436365	chr6:63940138	NA	0.44	6.95	0.31	1.22e-11	Smoking quantity;
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg06074448	chr4:187884817	NA	-0.58	-12.76	-0.51	3.64e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.33	0.32	1.06e-12	Hip circumference adjusted for BMI;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg13268919	chr11:842945	TSPAN4;POLR2L	-0.36	-6.74	-0.3	4.85e-11	Iris color (L* coordinate);
LGG	cis	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-11.75	-0.48	4.4e-28	Resting heart rate;
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.55	0.37	1.77e-16	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.64	-0.37	8.91e-17	Menopause (age at onset);
LGG	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.33	0.32	1.07e-12	Mood instability;
LGG	trans	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.91	-0.48	1.03e-28	Platelet distribution width;
LGG	cis	rs2120243	0.533	rs1500921	chr3:157055427	C/T	cg24825693	chr3:157122686	VEPH1	-0.37	-8.07	-0.35	6.03e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg20587970	chr11:113659929	NA	-1.09	-14.66	-0.56	3.06e-40	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.32	3.6e-12	Lung cancer;
LGG	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg15208524	chr1:10270712	KIF1B	0.44	7.92	0.35	1.77e-14	Hepatocellular carcinoma;
LGG	cis	rs1355223	0.902	rs286862	chr11:34718779	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.86	0.3	2.18e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1707322	1.000	rs12060274	chr1:46291062	G/T	cg03146154	chr1:46216737	IPP	0.55	10.54	0.44	1.94e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25172604	chr17:41446521	NA	-0.29	-6.68	-0.3	6.78e-11	Menopause (age at onset);
LGG	cis	rs3857067	1.000	rs1588385	chr4:95017161	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs7000551	0.642	rs2449328	chr8:22375043	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	12.02	0.49	3.63e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg14074117	chr16:1909714	C16orf73	-0.5	-7.5	-0.33	3.21e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-9.7	-0.41	2.18e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs365132	1.000	rs353490	chr5:176433063	C/T	cg16309518	chr5:176445507	NA	-0.55	-12.26	-0.5	3.98e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4774899	0.966	rs12914481	chr15:57484613	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.28	-0.32	1.4e-12	Urinary tract infection frequency;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg21911579	chr5:131705225	SLC22A5	0.69	7.69	0.34	8.98e-14	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.42	0.33	5.7e-13	Lung cancer;
LGG	cis	rs17445240	0.901	rs6754703	chr2:3707646	C/A	cg13452994	chr2:3699195	NA	0.59	6.71	0.3	5.55e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.45	-0.4	1.7e-19	Morning vs. evening chronotype;
LGG	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg10792982	chr14:105748885	BRF1	0.66	13.51	0.53	2.67e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg12560992	chr17:57184187	TRIM37	-0.8	-13.52	-0.53	2.47e-35	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg02002194	chr4:3960332	NA	0.54	10.47	0.44	3.77e-23	Retinal vascular caliber;
LGG	cis	rs4363385	0.574	rs4845503	chr1:152959939	A/G	cg13444842	chr1:152974279	SPRR3	-0.49	-9.92	-0.42	3.56e-21	Inflammatory skin disease;
LGG	cis	rs4006360	0.629	rs7214220	chr17:39236627	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.2	-0.46	6.07e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.93	-0.38	1.05e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2274273	0.624	rs3783651	chr14:55850973	G/C	cg04306507	chr14:55594613	LGALS3	0.52	12.26	0.5	4.06e-30	Protein biomarker;
LGG	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg01262667	chr19:19385393	TM6SF2	0.36	7.26	0.32	1.6e-12	Bipolar disorder;
LGG	trans	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.19	0.46	6.66e-26	Mean corpuscular volume;
LGG	cis	rs2865126	0.644	rs8098584	chr18:10736934	G/A	cg21165219	chr18:10698044	FAM38B	-0.52	-8.52	-0.37	2.29e-16	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg10360139	chr7:1886902	MAD1L1	0.45	8.04	0.35	7.42e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg12924262	chr12:102091054	CHPT1	0.65	13.0	0.52	3.62e-33	Blood protein levels;
LGG	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg10326726	chr10:51549505	MSMB	0.62	12.55	0.5	2.72e-31	Prostate-specific antigen levels;
LGG	cis	rs643506	0.874	rs631318	chr11:111677695	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.41	-6.74	-0.3	4.69e-11	Breast cancer;
LGG	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Bone mineral density;
LGG	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg18252515	chr7:66147081	NA	-1.37	-14.52	-0.56	1.24e-39	Diabetic kidney disease;
LGG	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg03060546	chr3:49711283	APEH	-0.53	-7.11	-0.31	4.31e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg14664628	chr15:75095509	CSK	-0.56	-10.53	-0.44	2.22e-23	Breast cancer;
LGG	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg20493526	chr2:3714936	ALLC	0.46	9.98	0.42	2.21e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg07211511	chr3:129823064	LOC729375	-0.83	-11.5	-0.47	4.15e-27	Blood pressure (smoking interaction);
LGG	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg11062466	chr8:58055876	NA	0.44	7.3	0.32	1.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg24232236	chr22:38142998	TRIOBP	0.35	6.66	0.3	7.84e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.86	-0.38	1.76e-17	Lung cancer;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.76	0.54	2.29e-36	Obesity-related traits;
LGG	cis	rs72634258	0.945	rs6577459	chr1:8100173	G/T	cg00042356	chr1:8021962	PARK7	0.84	10.95	0.45	5.76e-25	Inflammatory bowel disease;
LGG	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg14227996	chr4:17616232	MED28	0.56	7.77	0.34	5.04e-14	Opioid sensitivity;
LGG	cis	rs17445240	0.515	rs9308790	chr2:3705712	C/T	cg17046650	chr2:3699563	NA	0.67	10.15	0.43	5.57e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.53	-0.44	2.16e-23	Lymphocyte counts;
LGG	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg23231163	chr10:75533350	FUT11	-0.41	-6.8	-0.3	3.33e-11	Inflammatory bowel disease;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg02462569	chr6:150064036	NUP43	-0.43	-9.0	-0.39	6.05e-18	Lung cancer;
LGG	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg21435375	chr2:172878103	MAP1D	-0.32	-7.27	-0.32	1.52e-12	Schizophrenia;
LGG	cis	rs2073300	1.000	rs6137971	chr20:23456429	G/T	cg12062639	chr20:23401060	NAPB	0.84	6.8	0.3	3.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.88	-0.42	5.19e-21	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs274567	0.501	rs274571	chr5:131712125	A/G	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Blood metabolite levels;
LGG	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	16.66	0.61	3.67e-49	Response to antipsychotic treatment;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg05868516	chr6:26286170	HIST1H4H	0.45	7.68	0.34	9.88e-14	Educational attainment;
LGG	cis	rs4731207	0.662	rs6973134	chr7:124515373	G/A	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs1465370	0.692	rs2402996	chr7:130017003	C/T	cg04743876	chr7:130013617	NA	0.37	8.64	0.37	9.05e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg03929089	chr4:120376271	NA	0.67	9.24	0.39	9.16e-19	Intraocular pressure;
LGG	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.44	-0.5	7.71e-31	Depression;
LGG	cis	rs6546537	0.955	rs35947226	chr2:69845829	C/G	cg10773587	chr2:69614142	GFPT1	-0.49	-8.18	-0.36	2.68e-15	Serum thyroid-stimulating hormone levels;
LGG	cis	rs17092148	1.000	rs2378260	chr20:33374897	G/A	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.72	-0.34	7.14e-14	Neuroticism;
LGG	cis	rs9513627	1.000	rs6491512	chr13:100199741	C/T	cg25919922	chr13:100150906	NA	0.72	7.64	0.33	1.26e-13	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.34	0.53	1.42e-34	Lung cancer;
LGG	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.63	-0.37	9.79e-17	IgG glycosylation;
LGG	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg12011299	chr4:100065546	ADH4	0.4	7.88	0.34	2.37e-14	Smoking initiation;
LGG	cis	rs41271473	0.687	rs35832347	chr1:228883738	G/C	cg00850481	chr1:228891306	NA	-0.56	-11.13	-0.46	1.18e-25	Chronic lymphocytic leukemia;
LGG	cis	rs12534701	1.000	rs13232266	chr7:154681363	A/T	cg24255201	chr7:154684926	DPP6	0.56	10.48	0.44	3.48e-23	Colorectal cancer (diet interaction);
LGG	cis	rs1707322	0.896	rs785512	chr1:46534543	A/G	cg03146154	chr1:46216737	IPP	-0.54	-9.74	-0.41	1.62e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg21775007	chr8:11205619	TDH	0.5	8.18	0.36	2.77e-15	Retinal vascular caliber;
LGG	cis	rs10937275	0.623	rs34421968	chr3:186645080	T/C	cg26193484	chr3:186648175	ST6GAL1	0.88	9.18	0.39	1.47e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6141769	0.542	rs6057625	chr20:31304994	G/A	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.72	-0.3	5.48e-11	Subjective well-being;
LGG	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg00857998	chr1:205179979	DSTYK	0.47	6.88	0.3	2e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7523273	0.606	rs2796283	chr1:207978732	C/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-12.23	-0.49	5.36e-30	Schizophrenia;
LGG	trans	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg17763188	chr8:6692148	XKR5	0.42	6.96	0.31	1.16e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg18898632	chr2:242989856	NA	-0.91	-9.92	-0.42	3.64e-21	Obesity-related traits;
LGG	cis	rs11123406	0.723	rs60665449	chr2:111959687	G/A	cg26001287	chr2:111877753	BCL2L11	0.35	6.68	0.3	7.07e-11	Type 2 diabetes;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.16	0.32	3.14e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg02900749	chr2:68251473	NA	-0.97	-10.52	-0.44	2.34e-23	Pursuit maintenance gain;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.08	-0.57	4.37e-42	Platelet count;
LGG	cis	rs6871536	1.000	rs2522394	chr5:131944129	G/A	cg04303330	chr5:131992430	IL13	0.28	6.85	0.3	2.41e-11	Asthma (childhood onset);
LGG	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg05775895	chr3:12838266	CAND2	0.79	15.92	0.59	7.96e-46	QRS complex (12-leadsum);
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg26513180	chr16:89883248	FANCA	1.0	9.57	0.41	6.29e-20	Skin colour saturation;
LGG	cis	rs10504073	0.584	rs11786103	chr8:49904077	A/G	cg00325661	chr8:49890786	NA	0.8	16.16	0.6	6.69e-47	Blood metabolite ratios;
LGG	cis	rs55788414	0.932	rs12102691	chr16:81181460	G/T	cg06400318	chr16:81190750	PKD1L2	-0.79	-9.77	-0.41	1.32e-20	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg23750338	chr8:142222470	SLC45A4	0.59	12.3	0.5	2.81e-30	Immature fraction of reticulocytes;
LGG	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg27446573	chr6:127587934	RNF146	1.12	21.84	0.71	3.16e-73	Breast cancer;
LGG	cis	rs58616815	0.857	rs1341826	chr10:92160932	C/A	cg17905462	chr10:92153495	NA	-0.25	-6.68	-0.3	6.92e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01769037	chr6:15246613	JARID2	-0.46	-7.78	-0.34	4.77e-14	Body fat percentage;
LGG	cis	rs17221829	0.537	rs7933470	chr11:89376963	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg04851639	chr8:1020857	NA	-0.34	-7.01	-0.31	8.4e-12	Schizophrenia;
LGG	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7617773	0.817	rs9847953	chr3:48282695	A/G	cg11946769	chr3:48343235	NME6	0.62	10.26	0.43	2.24e-22	Coronary artery disease;
LGG	cis	rs758324	0.812	rs11954609	chr5:131165738	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.57	-0.37	1.61e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg17809284	chr5:56205270	C5orf35	-0.57	-10.61	-0.44	1.08e-23	Initial pursuit acceleration;
LGG	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg26116260	chr4:7069785	GRPEL1	-1.04	-15.54	-0.59	3.98e-44	Monocyte percentage of white cells;
LGG	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg23205692	chr1:25664452	TMEM50A	0.45	9.45	0.4	1.75e-19	Erythrocyte sedimentation rate;
LGG	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg09048205	chr5:1608656	LOC728613	-0.46	-7.35	-0.32	8.82e-13	Breast cancer;
LGG	cis	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg06521331	chr12:34319734	NA	0.41	6.84	0.3	2.57e-11	Morning vs. evening chronotype;
LGG	cis	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg06360820	chr2:242988706	NA	-0.55	-7.58	-0.33	1.9e-13	Obesity-related traits;
LGG	cis	rs6728642	0.572	rs60621865	chr2:97598001	T/C	cg26665480	chr2:98280029	ACTR1B	-0.84	-11.07	-0.46	1.99e-25	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	trans	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.33	0.55	8.14e-39	Exhaled nitric oxide output;
LGG	cis	rs77633900	0.772	rs284884	chr15:76828289	A/G	cg21673338	chr15:77095150	SCAPER	-0.63	-8.18	-0.36	2.69e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7551222	0.752	rs4951075	chr1:204464446	C/A	cg20240347	chr1:204465584	NA	-0.56	-11.27	-0.46	3.3e-26	Schizophrenia;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.54	-0.37	1.97e-16	Personality dimensions;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.51	-9.59	-0.41	5.62e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg23750338	chr8:142222470	SLC45A4	-0.57	-11.57	-0.47	2.27e-27	Immature fraction of reticulocytes;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02640306	chr2:191745287	GLS	0.4	6.85	0.3	2.33e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs11875185	0.510	rs4084179	chr18:55608000	A/T	cg15513957	chr14:69354734	ACTN1	0.92	9.01	0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs503425	0.818	rs2508922	chr11:118681088	G/A	cg19182353	chr11:118479428	PHLDB1	-0.49	-7.02	-0.31	7.93e-12	Systemic lupus erythematosus;
LGG	cis	rs883565	0.569	rs1274969	chr3:39169712	T/C	cg01426195	chr3:39028469	NA	0.64	13.63	0.54	8.08e-36	Handedness;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	9.37	0.4	3.1e-19	Height;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs7727544	0.582	rs4361509	chr5:131536753	A/G	cg07395648	chr5:131743802	NA	0.39	8.59	0.37	1.39e-16	Blood metabolite levels;
LGG	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg20821713	chr7:1055600	C7orf50	0.52	8.5	0.37	2.59e-16	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.82	0.51	2.04e-32	Obesity-related traits;
LGG	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.12e-12	Height;
LGG	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg21545522	chr1:205238299	TMCC2	0.48	8.56	0.37	1.64e-16	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg10122932	chr7:99698990	MCM7;AP4M1	0.4	6.79	0.3	3.51e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9814567	1.000	rs11928499	chr3:134232350	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.1	0.52	1.46e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg13147721	chr7:65941812	NA	-0.83	-10.22	-0.43	3.1e-22	Diabetic kidney disease;
LGG	cis	rs4243971	0.516	rs1412997	chr20:30942598	A/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.65	0.3	8.04e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.8	-0.34	4.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.05e-54	Refractive error;
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-9.25	-0.39	8.4e-19	Vitiligo;
LGG	cis	rs28489187	0.683	rs1554597	chr1:85877098	C/T	cg02862864	chr1:85742044	BCL10	0.37	6.72	0.3	5.25e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg05973401	chr12:123451056	ABCB9	0.51	8.22	0.36	2.13e-15	Neutrophil percentage of white cells;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.8e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg21798802	chr22:38057573	PDXP	0.46	8.59	0.37	1.37e-16	Fat distribution (HIV);
LGG	cis	rs721399	0.539	rs10088333	chr8:18267878	G/A	cg18736775	chr8:18248649	NAT2	-0.76	-11.45	-0.47	6.71e-27	Blood metabolite levels;
LGG	cis	rs7712401	0.562	rs62377399	chr5:122324679	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs12410462	0.591	rs2814061	chr1:227735114	C/T	cg21459583	chr1:227974177	NA	0.36	6.77	0.3	3.91e-11	Major depressive disorder;
LGG	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-21.5	-0.71	1.33e-71	Coronary artery disease;
LGG	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg09904177	chr6:26538194	HMGN4	0.78	18.22	0.65	2.65e-56	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.25	0.36	1.62e-15	Neuroticism;
LGG	cis	rs6940638	0.688	rs1028308	chr6:27129757	G/A	cg12826209	chr6:26865740	GUSBL1	0.47	7.73	0.34	6.82e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg12310025	chr6:25882481	NA	-0.44	-7.46	-0.33	4.2e-13	Iron status biomarkers;
LGG	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg13010199	chr12:38710504	ALG10B	0.36	6.79	0.3	3.35e-11	Morning vs. evening chronotype;
LGG	cis	rs13065560	0.533	rs4580488	chr3:38882438	G/T	cg01426195	chr3:39028469	NA	-0.39	-7.95	-0.35	1.46e-14	Interleukin-18 levels;
LGG	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg02002194	chr4:3960332	NA	0.42	7.61	0.33	1.51e-13	Morning vs. evening chronotype;
LGG	trans	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg19894588	chr14:64061835	NA	0.43	6.87	0.3	2.12e-11	Glioblastoma;Glioma;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.48	0.37	3.07e-16	Triglycerides;
LGG	cis	rs72781680	0.716	rs72788284	chr2:24097539	A/G	cg08917208	chr2:24149416	ATAD2B	0.63	8.26	0.36	1.56e-15	Lymphocyte counts;
LGG	cis	rs4851254	0.618	rs35730185	chr2:100648085	G/A	cg17356467	chr2:100759845	AFF3	0.47	7.62	0.33	1.44e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2066819	1.000	rs41392645	chr12:56696742	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg01043669	chr3:72786069	NA	0.43	6.85	0.3	2.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg14784868	chr12:69753453	YEATS4	0.71	13.22	0.52	4.63e-34	Blood protein levels;
LGG	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.05	-0.42	1.22e-21	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs240764	0.817	rs2036052	chr6:101154909	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.62	-0.33	1.41e-13	Neuroticism;
LGG	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg04691961	chr3:161091175	C3orf57	0.43	9.02	0.39	5.22e-18	Morning vs. evening chronotype;
LGG	cis	rs2731664	0.740	rs2731670	chr5:176848019	G/T	cg23176889	chr5:176863531	GRK6	0.61	11.85	0.48	1.79e-28	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21767703	chr1:236444768	ERO1LB	0.47	7.8	0.34	4.06e-14	Cognitive performance;
LGG	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg13073564	chr4:8508604	NA	-0.52	-10.61	-0.44	1.07e-23	Response to antineoplastic agents;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10201608	chr2:85788586	GGCX	0.46	6.99	0.31	9.52e-12	Gut microbiome composition (summer);
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07132326	chr6:150258058	NA	0.37	8.09	0.35	5.36e-15	Testicular germ cell tumor;
LGG	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.44	0.33	5.05e-13	Total cholesterol levels;
LGG	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg08250081	chr4:10125330	NA	0.44	8.63	0.37	1.02e-16	Bone mineral density;
LGG	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.28	0.36	1.36e-15	Diabetic kidney disease;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg06951627	chr6:26196580	NA	0.48	7.11	0.31	4.51e-12	Gout;Renal underexcretion gout;
LGG	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg23899408	chr19:12877188	HOOK2	0.49	7.97	0.35	1.22e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg10253484	chr15:75165896	SCAMP2	0.44	7.07	0.31	5.93e-12	Systemic lupus erythematosus;
LGG	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06470251	chr20:60548479	NA	0.54	9.25	0.4	8.06e-19	Body mass index;
LGG	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg21211680	chr2:198530	NA	-1.27	-22.36	-0.72	1.27e-75	Blood protein levels;
LGG	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.15	-0.35	3.45e-15	Educational attainment;
LGG	cis	rs1982963	1.000	rs3818187	chr14:52509788	A/G	cg05884192	chr14:52515736	NID2	0.34	7.36	0.32	8.33e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg19554555	chr3:13937349	NA	-0.54	-9.8	-0.41	9.73e-21	Ovarian reserve;
LGG	cis	rs7267979	0.966	rs2482918	chr20:25412135	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.07	-0.42	1.02e-21	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11088226	0.581	rs2016103	chr21:33878030	G/A	cg09050820	chr6:167586206	TCP10L2	0.47	7.74	0.34	6.21e-14	Gastritis;
LGG	cis	rs2013441	0.866	rs2526492	chr17:20095615	C/A	cg13482628	chr17:19912719	NA	-0.41	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	cis	rs9462027	0.651	rs6940395	chr6:34736553	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.06	-0.46	2.14e-25	Systemic lupus erythematosus;
LGG	cis	rs701145	0.585	rs62276841	chr3:153783645	C/T	cg17054900	chr3:154042577	DHX36	-0.77	-9.27	-0.4	7.13e-19	Coronary artery disease;
LGG	cis	rs9487094	1.000	rs12197114	chr6:109735498	T/C	cg16315928	chr6:109776240	MICAL1	0.55	9.36	0.4	3.45e-19	Height;
LGG	trans	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg16141378	chr3:129829833	LOC729375	0.44	10.37	0.43	8.82e-23	Mood instability;
LGG	cis	rs11239187	0.566	rs1383375	chr10:45101255	A/T	cg03916630	chr10:45065415	NA	0.35	8.47	0.37	3.39e-16	Body mass index;
LGG	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg05585630	chr7:157510462	PTPRN2	-0.48	-8.68	-0.37	6.7e-17	Intelligence (multi-trait analysis);
LGG	cis	rs137603	1.000	rs137604	chr22:39694594	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.44	-7.49	-0.33	3.51e-13	Primary biliary cholangitis;
LGG	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg04842962	chr6:43655489	MRPS18A	-0.76	-13.91	-0.54	5.38e-37	IgG glycosylation;
LGG	cis	rs3820068	0.506	rs17448966	chr1:15990983	T/G	cg05660106	chr1:15850417	CASP9	0.83	16.55	0.61	1.18e-48	Systolic blood pressure;
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg08835221	chr22:38071607	LGALS1	0.28	7.7	0.34	8.18e-14	Fat distribution (HIV);
LGG	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg12560992	chr17:57184187	TRIM37	-0.72	-12.41	-0.5	9.62e-31	Primary tooth development (time to first tooth eruption);
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.1	-0.31	4.84e-12	Menopause (age at onset);
LGG	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg02640540	chr1:67518911	SLC35D1	0.38	7.07	0.31	5.77e-12	Lymphocyte percentage of white cells;
LGG	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.58	-0.44	1.42e-23	Chronic sinus infection;
LGG	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg16400903	chr5:693638	TPPP	0.45	6.8	0.3	3.23e-11	Obesity-related traits;
LGG	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg03342759	chr3:160939853	NMD3	0.63	11.02	0.46	3.04e-25	Morning vs. evening chronotype;
LGG	cis	rs240764	0.578	rs1414734	chr6:101201823	T/C	cg09795085	chr6:101329169	ASCC3	0.48	8.29	0.36	1.21e-15	Neuroticism;
LGG	cis	rs607541	1.000	rs2083729	chr15:45935159	C/T	cg26924012	chr15:45694286	SPATA5L1	0.53	7.4	0.33	6.58e-13	Obesity-related traits;
LGG	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg22771759	chr13:24902376	NA	0.43	7.33	0.32	1.05e-12	Obesity-related traits;
LGG	cis	rs8077889	1.000	rs2066725	chr17:41891473	A/G	cg26893861	chr17:41843967	DUSP3	0.9	15.75	0.59	4.37e-45	Triglycerides;
LGG	cis	rs735539	0.645	rs9552252	chr13:21192905	C/T	cg04906043	chr13:21280425	IL17D	-0.55	-8.86	-0.38	1.7e-17	Dental caries;
LGG	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs7166081	1.000	rs4238407	chr15:67633784	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.87	-0.3	2.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-29.54	-0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg22875332	chr1:76189707	ACADM	0.56	8.81	0.38	2.48e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg13010199	chr12:38710504	ALG10B	0.58	11.12	0.46	1.27e-25	Morning vs. evening chronotype;
LGG	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg18851795	chr1:204543875	NA	-0.35	-6.72	-0.3	5.28e-11	Schizophrenia;
LGG	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg14092988	chr3:52407081	DNAH1	0.32	8.42	0.36	4.85e-16	Bipolar disorder;
LGG	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.51	-0.33	2.98e-13	Testicular germ cell tumor;
LGG	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg05696931	chr1:227175867	NA	-0.39	-7.66	-0.34	1.1e-13	Myeloid white cell count;
LGG	trans	rs11250097	0.543	rs68164957	chr8:10799489	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.84	-0.34	3.08e-14	Neuroticism;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg21775007	chr8:11205619	TDH	0.8	14.23	0.55	2.15e-38	Retinal vascular caliber;
LGG	cis	rs6694672	1.000	rs6428385	chr1:197048391	C/T	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.49	-0.33	3.57e-13	Depression;
LGG	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21841704	chr3:138327835	FAIM	0.51	7.56	0.33	2.15e-13	Hip circumference;
LGG	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg08885076	chr2:99613938	TSGA10	-0.53	-11.12	-0.46	1.25e-25	Chronic sinus infection;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg21827317	chr3:136751795	NA	0.52	9.65	0.41	3.38e-20	Gestational age at birth (child effect);
LGG	cis	rs368123	0.924	rs393324	chr6:160707650	T/C	cg07349212	chr6:160770346	SLC22A3	-0.33	-7.09	-0.31	5.14e-12	Waist circumference;
LGG	trans	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.46	-0.33	4.18e-13	Intelligence (multi-trait analysis);
LGG	trans	rs12517041	1.000	rs4547895	chr5:23323269	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.77	-0.48	3.61e-28	Calcium levels;
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.59	-0.41	5.31e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	0.692	rs4729018	chr7:91644613	C/T	cg17063962	chr7:91808500	NA	0.49	9.21	0.39	1.18e-18	Breast cancer;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg26174226	chr8:58114915	NA	-0.53	-7.46	-0.33	4.33e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg03929089	chr4:120376271	NA	-0.56	-9.79	-0.41	1.07e-20	HDL cholesterol;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg27357151	chr19:41304979	EGLN2	0.41	7.11	0.31	4.52e-12	Bilirubin levels;
LGG	cis	rs11585357	0.501	rs17458091	chr1:17595925	A/G	cg08277548	chr1:17600880	PADI3	-0.65	-6.75	-0.3	4.41e-11	Hair shape;
LGG	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg05973401	chr12:123451056	ABCB9	0.47	7.87	0.34	2.57e-14	Platelet count;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs7927771	0.524	rs10838771	chr11:47831332	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-10.84	-0.45	1.55e-24	Subjective well-being;
LGG	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg05096777	chr10:104283225	SUFU	0.32	6.88	0.3	1.95e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg09307838	chr4:120376055	NA	0.5	8.23	0.36	1.89e-15	Diastolic blood pressure;
LGG	cis	rs9902453	0.817	rs9909128	chr17:28161482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.97	0.54	3.01e-37	Coffee consumption (cups per day);
LGG	cis	rs11514810	1.000	rs4076699	chr7:1435521	C/T	cg01003211	chr7:1472830	NA	-0.55	-7.45	-0.33	4.59e-13	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg14088196	chr11:70211408	PPFIA1	0.67	8.82	0.38	2.39e-17	Coronary artery disease;
LGG	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05210886	chr1:245133216	EFCAB2	0.51	9.01	0.39	5.61e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg15971980	chr6:150254442	NA	0.43	8.02	0.35	8.85e-15	Lung cancer;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg03575189	chr17:44344142	NA	0.46	6.76	0.3	4.22e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.02	-0.31	7.78e-12	Migraine;Coronary artery disease;
LGG	cis	rs1451375	0.698	rs68143668	chr7:50638110	C/T	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.12e-13	Malaria;
LGG	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg17788362	chr6:86352627	SYNCRIP	0.54	9.21	0.39	1.17e-18	Smooth-surface caries;
LGG	cis	rs368123	1.000	rs437539	chr6:160725560	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.78e-12	Waist circumference;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20288129	chr3:122745632	SEMA5B	-0.47	-6.79	-0.3	3.55e-11	Systemic lupus erythematosus;
LGG	cis	rs600231	0.690	rs1152619	chr11:65255589	C/A	cg17120908	chr11:65337727	SSSCA1	-0.66	-11.37	-0.47	1.35e-26	Bone mineral density;
LGG	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg20573242	chr4:122745356	CCNA2	-0.46	-7.95	-0.35	1.47e-14	Type 2 diabetes;
LGG	trans	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05926928	chr17:57297772	GDPD1	0.55	9.14	0.39	1.95e-18	Schizophrenia;
LGG	cis	rs2173063	1.000	rs77960949	chr15:93149198	T/C	cg07052004	chr15:93132129	NA	0.73	7.44	0.33	5.06e-13	Subcutaneous adipose tissue;
LGG	cis	rs4262150	0.960	rs4310018	chr5:152286204	C/T	cg12297329	chr5:152029980	NA	0.59	11.36	0.47	1.47e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg16141378	chr3:129829833	LOC729375	0.35	7.88	0.34	2.38e-14	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg02725872	chr8:58115012	NA	-0.97	-12.73	-0.51	4.69e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	8.97	0.38	7.54e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg19847130	chr8:10466454	RP1L1	0.34	7.16	0.32	3.27e-12	Neuroticism;
LGG	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.58	-0.37	1.49e-16	Mood instability;
LGG	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	8.37	0.36	6.73e-16	Colorectal cancer;
LGG	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15369054	chr17:80825471	TBCD	-0.58	-10.36	-0.43	9.16e-23	Breast cancer;
LGG	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-15.94	-0.6	6.47e-46	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg11062466	chr8:58055876	NA	0.64	10.16	0.43	4.9e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.66	-0.34	1.13e-13	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg18850127	chr7:39170497	POU6F2	0.55	12.34	0.5	1.93e-30	IgG glycosylation;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15891747	chr1:202896310	KLHL12	0.47	6.89	0.3	1.81e-11	Hip circumference;
LGG	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.08	0.39	3.24e-18	Aortic root size;
LGG	cis	rs7149337	0.805	rs2999361	chr14:51605358	G/A	cg23942311	chr14:51606299	NA	0.32	7.09	0.31	5.09e-12	Cancer;
LGG	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.33e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs755249	0.567	rs16826009	chr1:39716902	A/G	cg18385671	chr1:39797026	MACF1	0.44	7.44	0.33	4.96e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9929218	1.000	rs13334471	chr16:68800452	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.81	-0.51	2.22e-32	Colorectal cancer;
LGG	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.08	-0.35	5.58e-15	Coronary artery disease;
LGG	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg17211192	chr8:82754475	SNX16	-0.8	-12.59	-0.51	1.76e-31	Diastolic blood pressure;
LGG	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg03060546	chr3:49711283	APEH	0.64	8.51	0.37	2.47e-16	Menarche (age at onset);
LGG	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg06713675	chr4:122721982	EXOSC9	-0.52	-8.49	-0.37	2.91e-16	Type 2 diabetes;
LGG	trans	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg07211511	chr3:129823064	LOC729375	-1.06	-15.19	-0.58	1.39e-42	Blood pressure (smoking interaction);
LGG	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg17050807	chr22:42548356	NA	-0.38	-7.3	-0.32	1.29e-12	Schizophrenia;
LGG	cis	rs4804815	0.780	rs4804231	chr19:7839803	C/A	cg09310891	chr19:7854403	CLEC4GP1	0.53	8.23	0.36	1.92e-15	Neutrophil count;
LGG	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.31	-0.36	1.06e-15	Depression;
LGG	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg08885076	chr2:99613938	TSGA10	-0.49	-10.01	-0.42	1.7e-21	Chronic sinus infection;
LGG	cis	rs40363	0.645	rs4786421	chr16:3522303	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.45	7.05	0.31	6.54e-12	Tuberculosis;
LGG	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg22732515	chr19:44031385	ETHE1	0.54	9.4	0.4	2.51e-19	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg17145862	chr1:211918768	LPGAT1	0.98	26.2	0.77	1.85e-93	Leprosy;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.39	0.36	6.13e-16	Tonsillectomy;
LGG	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg15736062	chr7:158136485	PTPRN2	0.37	7.38	0.32	7.2e-13	Calcium levels;
LGG	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-7.42	-0.33	5.76e-13	Alzheimer's disease (late onset);
LGG	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07080220	chr10:102295463	HIF1AN	0.69	11.62	0.48	1.48e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg16920238	chr17:80076378	CCDC57	0.35	8.12	0.35	4.11e-15	Life satisfaction;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	trans	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.57	-8.61	-0.37	1.12e-16	Body mass index;
LGG	trans	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs6537837	1.000	rs7371	chr1:110135308	G/A	cg05049280	chr1:110155535	GNAT2	0.33	6.71	0.3	5.65e-11	Major depressive disorder;
LGG	cis	rs12780845	0.540	rs10904884	chr10:17180100	A/G	cg01003015	chr10:17271136	VIM	-0.43	-7.18	-0.32	2.75e-12	Homocysteine levels;
LGG	cis	rs3784262	0.669	rs7178598	chr15:58309016	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.02	-0.31	7.73e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07167872	chr1:205819463	PM20D1	0.57	11.5	0.47	4.31e-27	Menarche (age at onset);
LGG	cis	rs9309473	0.528	rs2091022	chr2:73564570	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.36	-0.36	7.61e-16	Metabolite levels;
LGG	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg19507638	chr5:93509721	C5orf36	-0.73	-9.98	-0.42	2.28e-21	Diabetic retinopathy;
LGG	cis	rs7100689	0.646	rs1934694	chr10:82125325	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	trans	rs629535	0.665	rs2433331	chr8:70041943	T/C	cg21567404	chr3:27674614	NA	0.4	6.72	0.3	5.35e-11	Dupuytren's disease;
LGG	cis	rs4150161	0.591	rs3785036	chr16:84219810	T/G	cg10106505	chr16:84220380	TAF1C	-0.83	-7.05	-0.31	6.53e-12	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.67	-0.3	7.43e-11	Lung cancer;
LGG	cis	rs7301826	0.651	rs12228959	chr12:131296068	T/G	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	trans	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.45	-0.33	4.69e-13	Menarche (age at onset);
LGG	trans	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.29e-18	Bladder cancer;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg00405596	chr8:11794950	NA	-0.42	-6.77	-0.3	3.89e-11	Neuroticism;
LGG	cis	rs6032067	0.850	rs34274189	chr20:43864298	G/T	cg10761708	chr20:43804764	PI3	0.76	11.37	0.47	1.35e-26	Blood protein levels;
LGG	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg04842962	chr6:43655489	MRPS18A	0.98	15.66	0.59	1.14e-44	IgG glycosylation;
LGG	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.33	4.17e-13	Height;
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg05941027	chr17:61774174	LIMD2	0.34	8.34	0.36	8.58e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.65	0.33	1.2e-13	Neutrophil percentage of white cells;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03452623	chr4:187889614	NA	1.05	28.86	0.8	1.57e-105	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.7	-12.51	-0.5	3.88e-31	Chronic sinus infection;
LGG	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.41	-6.86	-0.3	2.19e-11	Carotid intima media thickness;
LGG	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg15268244	chr15:77196840	NA	0.48	10.26	0.43	2.14e-22	Blood metabolite levels;
LGG	cis	rs2191566	0.664	rs7254261	chr19:44565427	A/G	cg20607764	chr19:44506953	ZNF230	-0.38	-6.94	-0.31	1.36e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	17.62	0.63	1.44e-53	Smoking behavior;
LGG	cis	rs593531	0.571	rs10793081	chr11:74092403	T/C	cg18195628	chr11:73498948	MRPL48	-0.41	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg23173402	chr1:227635558	NA	-0.53	-9.31	-0.4	5.02e-19	Major depressive disorder;
LGG	cis	rs7192750	0.586	rs11648353	chr16:71986764	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.29e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg04546413	chr19:29218101	NA	0.76	12.68	0.51	7.99e-32	Methadone dose in opioid dependence;
LGG	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg20503657	chr10:835505	NA	0.95	12.81	0.51	2.3e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs10197940	0.578	rs2444264	chr2:152310928	G/T	cg19508488	chr2:152266495	RIF1	-0.47	-8.62	-0.37	1.07e-16	Lung cancer;
LGG	cis	rs9397585	0.636	rs10872697	chr6:153401046	T/G	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs9581857	0.615	rs9581849	chr13:28005782	G/T	cg01674679	chr13:27998804	GTF3A	-0.67	-7.59	-0.33	1.84e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs3762318	0.806	rs4655689	chr1:67659421	A/G	cg17031739	chr1:67600172	NA	-0.47	-6.65	-0.3	8.21e-11	Leprosy;
LGG	cis	rs11166927	0.524	rs7814631	chr8:140811743	T/C	cg16909799	chr8:140841666	TRAPPC9	0.4	7.48	0.33	3.81e-13	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg09307838	chr4:120376055	NA	-0.8	-13.09	-0.52	1.5e-33	Corneal astigmatism;
LGG	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg15269541	chr15:43626905	ADAL	-0.45	-7.76	-0.34	5.65e-14	Lung cancer in ever smokers;
LGG	trans	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.84	15.95	0.6	5.8e-46	Lymphocyte counts;
LGG	cis	rs4268898	0.662	rs9917315	chr2:24431501	C/A	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg10523679	chr1:76189770	ACADM	-0.79	-16.35	-0.6	9.69e-48	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg12463550	chr7:65579703	CRCP	0.47	7.73	0.34	6.59e-14	Aortic root size;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25072359	chr17:41440525	NA	0.52	10.07	0.42	1.02e-21	Menopause (age at onset);
LGG	cis	rs600231	0.542	rs11227196	chr11:65234922	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.61	-0.37	1.13e-16	Bone mineral density;
LGG	cis	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.91	-0.31	1.63e-11	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25722142	chr6:139695762	CITED2	0.47	7.53	0.33	2.66e-13	Gut microbiome composition (summer);
LGG	cis	rs17672112	0.681	rs614094	chr6:101344679	T/C	cg27451362	chr6:101846650	GRIK2	0.74	9.71	0.41	2.13e-20	Putamen volume;
LGG	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg11764359	chr7:65958608	NA	-0.8	-14.86	-0.57	3.89e-41	Aortic root size;
LGG	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg06636001	chr8:8085503	FLJ10661	0.48	8.66	0.37	7.73e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg08280861	chr8:58055591	NA	0.58	9.99	0.42	2.03e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs1456305	0.514	rs4571699	chr8:128099269	A/G	cg22517681	chr1:24995876	SRRM1	0.53	8.51	0.37	2.41e-16	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12393716	chr11:62495049	TTC9C;HNRNPUL2	0.5	7.77	0.34	5e-14	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg04503457	chr17:41445688	NA	-0.4	-9.56	-0.41	6.92e-20	Menopause (age at onset);
LGG	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg23625390	chr15:77176239	SCAPER	0.5	10.05	0.42	1.3e-21	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11239187	0.586	rs11239158	chr10:45078332	G/A	cg03916630	chr10:45065415	NA	0.35	8.43	0.36	4.51e-16	Body mass index;
LGG	cis	rs834603	0.541	rs1704965	chr7:47470215	C/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg08125733	chr17:73851984	WBP2	0.87	13.34	0.53	1.44e-34	Psoriasis;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.87	-0.3	2.11e-11	Menopause (age at onset);
LGG	cis	rs774359	0.797	rs1319236	chr9:27507209	G/A	cg21249376	chr9:27528432	MOBKL2B	-0.42	-8.46	-0.37	3.41e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.92	-0.35	1.78e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9811920	0.609	rs4928232	chr3:99694217	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.88	-0.38	1.52e-17	Axial length;
LGG	cis	rs2421770	0.532	rs7105829	chr11:35345626	C/T	cg10331829	chr11:35343789	SLC1A2	0.34	7.48	0.33	3.73e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg14912033	chr15:79043428	NA	-0.33	-6.74	-0.3	4.83e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg18898632	chr2:242989856	NA	-0.91	-9.94	-0.42	3.05e-21	Obesity-related traits;
LGG	cis	rs11064837	0.504	rs7972445	chr12:120055409	T/C	cg25937854	chr12:120150414	CIT	-0.58	-10.11	-0.43	7.78e-22	Schizophrenia;
LGG	cis	rs9534288	0.699	rs2146885	chr13:46659853	A/G	cg15192986	chr13:46630673	CPB2	-0.7	-14.39	-0.56	4.61e-39	Blood protein levels;
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg10505658	chr17:80084571	CCDC57	0.34	6.76	0.3	4.13e-11	Life satisfaction;
LGG	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg11752832	chr7:134001865	SLC35B4	0.63	11.57	0.47	2.36e-27	Mean platelet volume;
LGG	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg21211680	chr2:198530	NA	1.29	21.83	0.71	3.65e-73	Blood protein levels;
LGG	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg20673091	chr1:2541236	MMEL1	-0.75	-17.93	-0.64	5.34e-55	Ulcerative colitis;
LGG	cis	rs4356203	0.905	rs656623	chr11:17219179	C/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.23	-0.32	2.02e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs77633900	0.772	rs283802	chr15:76791270	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-8.46	-0.37	3.61e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9463078	0.585	rs1521355	chr6:44932755	T/C	cg25276700	chr6:44698697	NA	-0.33	-6.92	-0.31	1.53e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.72	-0.38	5.2e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.05e-17	Menopause (age at onset);
LGG	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg17330251	chr7:94953956	PON1	-0.42	-8.35	-0.36	8.26e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs17767392	0.670	rs61991192	chr14:71742923	A/G	cg02058870	chr14:72053146	SIPA1L1	0.36	7.63	0.33	1.33e-13	Mitral valve prolapse;
LGG	cis	rs2273669	0.667	rs6916819	chr6:109371129	A/G	cg05315195	chr6:109294784	ARMC2	-0.6	-8.4	-0.36	5.37e-16	Prostate cancer;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.68	0.37	7.01e-17	Obesity-related traits;
LGG	trans	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg26384229	chr12:38710491	ALG10B	-0.61	-11.04	-0.46	2.59e-25	Morning vs. evening chronotype;
LGG	cis	rs701145	0.938	rs165275	chr3:153991875	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	trans	rs7777677	0.925	rs6956756	chr7:142369666	A/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs7586879	0.681	rs28836469	chr2:25117215	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.86	0.51	1.4e-32	Body mass index;
LGG	cis	rs4845570	0.764	rs12122917	chr1:151716712	C/A	cg07092448	chr1:151763213	TDRKH	-1.07	-15.39	-0.58	1.93e-43	Coronary artery disease;
LGG	cis	rs36051895	0.632	rs12337904	chr9:5144606	C/G	cg02405213	chr9:5042618	JAK2	-0.79	-15.42	-0.58	1.34e-43	Pediatric autoimmune diseases;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg05025164	chr4:1340916	KIAA1530	0.59	10.97	0.45	4.68e-25	Longevity;
LGG	cis	rs6032067	0.852	rs6032064	chr20:43854827	A/G	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg11812906	chr14:75593930	NEK9	-0.45	-8.4	-0.36	5.48e-16	Height;
LGG	trans	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg06521331	chr12:34319734	NA	0.45	8.46	0.37	3.66e-16	Morning vs. evening chronotype;
LGG	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02825527	chr7:2087843	MAD1L1	-0.54	-9.12	-0.39	2.33e-18	Neuroticism;
LGG	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg14346243	chr4:90757452	SNCA	0.33	6.68	0.3	6.91e-11	Dementia with Lewy bodies;
LGG	cis	rs2124969	0.549	rs56296079	chr2:160941461	C/T	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.52	-0.4	9.92e-20	Waist circumference adjusted for body mass index;
LGG	cis	rs1003719	0.715	rs1981432	chr21:38541356	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-14.59	-0.56	6.4e-40	Eye color traits;
LGG	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg05182265	chr7:156933206	UBE3C	-0.37	-7.48	-0.33	3.74e-13	Body mass index;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg19143629	chr17:61920732	SMARCD2	-0.45	-7.56	-0.33	2.14e-13	Prudent dietary pattern;
LGG	cis	rs368123	0.961	rs415148	chr6:160736679	C/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.27	-0.32	1.5e-12	Waist circumference;
LGG	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.82	0.45	1.82e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg26655873	chr3:72818019	SHQ1	0.36	7.38	0.32	7.45e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.55	0.41	7.4e-20	Diabetic kidney disease;
LGG	cis	rs9914988	0.778	rs9907185	chr17:27122414	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs4780401	0.609	rs8063099	chr16:11806714	T/G	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.91	-0.51	8.9e-33	Rheumatoid arthritis;
LGG	cis	rs4731207	0.596	rs10954051	chr7:124579236	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg27572855	chr1:25598939	RHD	0.49	11.17	0.46	7.97e-26	Erythrocyte sedimentation rate;
LGG	cis	rs17331151	0.573	rs11626	chr3:52873984	C/T	cg04865290	chr3:52927548	TMEM110	-0.43	-7.5	-0.33	3.39e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs55665837	1.000	rs10832268	chr11:14465068	C/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.74	-0.38	4.34e-17	Vitamin D levels;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg25174290	chr11:3078921	CARS	-0.68	-13.65	-0.54	7.05e-36	Longevity;
LGG	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.3	-0.53	2.1e-34	Retinal vascular caliber;
LGG	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg13010199	chr12:38710504	ALG10B	0.63	12.63	0.51	1.28e-31	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg11878867	chr6:150167359	LRP11	-0.36	-7.4	-0.33	6.29e-13	Testicular germ cell tumor;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.01	-0.42	1.79e-21	Longevity;Endometriosis;
LGG	cis	rs2013441	1.000	rs17759923	chr17:20022035	G/A	cg09818912	chr17:20140352	CYTSB	-0.31	-7.11	-0.31	4.32e-12	Obesity-related traits;
LGG	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg20302533	chr7:39170763	POU6F2	0.5	11.54	0.47	2.97e-27	IgG glycosylation;
LGG	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg02753203	chr1:228287806	NA	-0.66	-12.45	-0.5	6.96e-31	Diastolic blood pressure;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg11707556	chr5:10655725	ANKRD33B	0.66	11.28	0.46	2.97e-26	Coronary artery disease;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.55	0.37	1.82e-16	Prudent dietary pattern;
LGG	trans	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.09	0.42	9.24e-22	Mean corpuscular volume;
LGG	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg12560992	chr17:57184187	TRIM37	0.82	14.36	0.56	6.19e-39	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg07382826	chr16:28625726	SULT1A1	0.38	7.77	0.34	5.2e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	15.57	0.59	2.99e-44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7617773	0.851	rs7647817	chr3:48236507	G/A	cg11946769	chr3:48343235	NME6	0.68	11.19	0.46	6.83e-26	Coronary artery disease;
LGG	cis	rs7614311	0.689	rs73122704	chr3:63841228	C/T	cg22134162	chr3:63841271	THOC7	-0.46	-8.1	-0.35	5.03e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs1867631	0.585	rs11208940	chr1:67127242	A/G	cg13052034	chr1:66999238	SGIP1	-0.34	-6.82	-0.3	2.93e-11	Menopause (age at onset);
LGG	cis	rs7772486	0.875	rs7767660	chr6:146436550	T/C	cg23711669	chr6:146136114	FBXO30	0.38	6.78	0.3	3.64e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.82	-0.3	2.86e-11	Bipolar disorder;
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19717773	chr7:2847554	GNA12	-0.37	-8.69	-0.37	6.31e-17	Height;
LGG	cis	rs4731207	0.698	rs6966415	chr7:124531469	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs4330281	0.715	rs4908940	chr3:17797271	A/C	cg20981856	chr3:17787350	NA	-0.4	-7.23	-0.32	1.94e-12	Schizophrenia;
LGG	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg27490568	chr2:178487706	NA	0.52	10.05	0.42	1.31e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg00012203	chr2:219082015	ARPC2	0.85	17.12	0.62	2.79e-51	Colorectal cancer;
LGG	cis	rs10267417	0.603	rs13307910	chr7:19858392	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	7.5	0.33	3.38e-13	Night sleep phenotypes;
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	7.82	0.34	3.57e-14	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs4774899	1.000	rs12901780	chr15:57258531	T/A	cg08128148	chr15:57256372	TCF12	-0.34	-8.16	-0.35	3.14e-15	Urinary tract infection frequency;
LGG	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.28	-0.36	1.3e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.78e-16	Aortic root size;
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.22	0.32	2.1e-12	Height;
LGG	trans	rs9354308	0.667	rs9294660	chr6:66585334	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg08621203	chr6:150244597	RAET1G	0.44	6.65	0.3	8.24e-11	Lung cancer;
LGG	cis	rs1568889	0.838	rs11030229	chr11:28173634	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.22	0.67	5.77e-61	Bipolar disorder;
LGG	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.68	0.41	2.72e-20	Ovarian reserve;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg21226059	chr5:178986404	RUFY1	-0.49	-8.7	-0.37	5.74e-17	Lung cancer;
LGG	cis	rs7660883	0.897	rs2125787	chr4:87996623	A/G	cg21988461	chr4:88008667	AFF1	-0.35	-10.15	-0.43	5.62e-22	HDL cholesterol levels;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18619541	chr12:123459241	OGFOD2;ABCB9	0.39	6.85	0.3	2.34e-11	Obesity-related traits;
LGG	cis	rs9341808	0.727	rs9352809	chr6:80999316	C/T	cg08355045	chr6:80787529	NA	0.38	7.37	0.32	8.04e-13	Sitting height ratio;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg03665457	chr10:38645376	HSD17B7P2	0.43	7.22	0.32	2.21e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs834603	0.546	rs1534138	chr7:47482750	T/C	cg23694490	chr7:47445681	TNS3	-0.41	-11.89	-0.48	1.24e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26452244	chr6:10695099	C6orf52;PAK1IP1	0.48	8.12	0.35	4.32e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg24881330	chr22:46731750	TRMU	0.73	7.4	0.33	6.27e-13	LDL cholesterol;Cholesterol, total;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20791839	chr3:53926047	SELK	0.43	7.29	0.32	1.37e-12	Parental extreme longevity (95 years and older);
LGG	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-7.88	-0.34	2.41e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15124968	chr5:140855469	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGC3;PCDHGB6;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.45	7.29	0.32	1.34e-12	Gut microbiome composition (summer);
LGG	cis	rs208520	0.837	rs208489	chr6:66927584	G/A	cg07460842	chr6:66804631	NA	-0.93	-16.02	-0.6	2.96e-46	Exhaled nitric oxide output;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg06719900	chr11:109292894	C11orf87	0.44	8.44	0.37	4.06e-16	Schizophrenia;
LGG	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg10911889	chr6:126070802	HEY2	0.46	8.04	0.35	7.56e-15	Brugada syndrome;
LGG	cis	rs6997458	0.742	rs11985029	chr8:86347116	C/T	cg02393479	chr8:86352350	CA3	-0.31	-6.78	-0.3	3.6e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.0	-0.31	9.04e-12	Systemic lupus erythematosus;
LGG	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.92	-0.38	1.09e-17	Morning vs. evening chronotype;
LGG	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg04455712	chr21:45112962	RRP1B	0.57	10.09	0.42	8.63e-22	Mean corpuscular volume;
LGG	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	cis	rs6960043	0.818	rs10264063	chr7:15053193	G/C	cg19272540	chr7:15055459	NA	0.36	8.1	0.35	4.81e-15	Type 2 diabetes;
LGG	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	trans	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg05059571	chr16:84539110	KIAA1609	-0.45	-8.32	-0.36	9.82e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4812048	0.793	rs62205397	chr20:57597011	C/T	cg23907860	chr20:57583709	CTSZ	0.48	6.81	0.3	3.09e-11	Mean platelet volume;
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs60180747	0.909	rs78135660	chr15:66769029	G/A	cg07575407	chr15:66541975	MEGF11	0.38	7.15	0.32	3.4e-12	Testicular germ cell tumor;
LGG	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg15038512	chr6:170123185	PHF10	0.52	6.73	0.3	5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.07e-18	Bipolar disorder;
LGG	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg18446336	chr7:2847575	GNA12	-0.29	-7.07	-0.31	5.9e-12	Height;
LGG	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg00990874	chr7:1149470	C7orf50	-0.64	-9.22	-0.39	1.08e-18	Bronchopulmonary dysplasia;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.78	0.3	3.68e-11	Vitiligo;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.13	-0.31	4e-12	Monocyte percentage of white cells;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg23758822	chr17:41437982	NA	0.87	15.26	0.58	6.8e-43	Menopause (age at onset);
LGG	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.96	0.38	8.14e-18	Colorectal cancer;
LGG	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg18351406	chr4:77819688	ANKRD56	0.45	7.77	0.34	5.23e-14	Emphysema distribution in smoking;
LGG	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.9	18.43	0.65	2.65e-57	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4356975	0.563	rs6600893	chr4:69978901	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.7	0.3	6.06e-11	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg22535103	chr8:58192502	C8orf71	-0.72	-9.45	-0.4	1.68e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	27.18	0.78	5.88e-98	Height;
LGG	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	13.27	0.52	2.86e-34	Type 2 diabetes;
LGG	trans	rs7980799	0.717	rs1905412	chr12:33496183	C/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.66	-0.3	7.68e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9443189	0.526	rs10943255	chr6:76225928	T/A	cg01950844	chr6:76311363	SENP6	0.75	9.7	0.41	2.32e-20	Prostate cancer;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg21605333	chr4:119757512	SEC24D	0.72	7.74	0.34	6.41e-14	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.47	-0.37	3.31e-16	Life satisfaction;
LGG	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg07382826	chr16:28625726	SULT1A1	0.38	7.81	0.34	3.96e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.56e-19	Diabetic retinopathy;
LGG	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg21366198	chr4:185655624	MLF1IP	-0.46	-8.04	-0.35	7.8e-15	Kawasaki disease;
LGG	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg13147721	chr7:65941812	NA	-0.83	-10.28	-0.43	1.76e-22	Diabetic kidney disease;
LGG	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg16141378	chr3:129829833	LOC729375	-0.34	-7.25	-0.32	1.73e-12	Schizophrenia;
LGG	cis	rs3540	0.533	rs1869179	chr15:90895564	A/C	cg22089800	chr15:90895588	ZNF774	0.75	14.2	0.55	3.02e-38	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.91	0.31	1.57e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00424166	chr6:150045504	NUP43	-0.33	-6.89	-0.3	1.88e-11	Lung cancer;
LGG	cis	rs6032067	0.527	rs6104011	chr20:43733503	G/A	cg10761708	chr20:43804764	PI3	0.55	8.5	0.37	2.59e-16	Blood protein levels;
LGG	cis	rs9462027	0.561	rs2262245	chr6:34567694	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.33	-0.43	1.18e-22	Systemic lupus erythematosus;
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg12395012	chr8:11607386	GATA4	-0.4	-7.38	-0.32	7.25e-13	Mood instability;
LGG	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg00934597	chr7:893267	UNC84A	-0.53	-8.71	-0.38	5.53e-17	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.55	-0.41	7.77e-20	Lung cancer;
LGG	cis	rs1707322	1.000	rs7519181	chr1:46387829	G/C	cg03146154	chr1:46216737	IPP	0.54	10.21	0.43	3.34e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2201728	0.702	rs17583844	chr4:100186223	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.25	-0.32	1.82e-12	Bipolar disorder;
LGG	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg25664220	chr3:72788482	NA	-0.32	-8.81	-0.38	2.49e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg09307838	chr4:120376055	NA	0.72	12.13	0.49	1.36e-29	Corneal astigmatism;
LGG	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.65	-0.41	3.45e-20	Retinal vascular caliber;
LGG	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg21427119	chr20:30132790	HM13	-0.57	-8.9	-0.38	1.28e-17	Mean corpuscular hemoglobin;
LGG	trans	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.29	-0.32	1.39e-12	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15062310	chr7:100450120	SLC12A9	0.45	7.51	0.33	3.12e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs231513	0.911	rs231521	chr17:41955158	A/G	cg26893861	chr17:41843967	DUSP3	-0.58	-6.81	-0.3	2.99e-11	Cognitive function;
LGG	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg25039879	chr17:56429692	SUPT4H1	0.63	8.84	0.38	2.09e-17	Cognitive test performance;
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg14689365	chr7:158441557	NCAPG2	0.61	10.31	0.43	1.45e-22	Height;
LGG	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg00129232	chr17:37814104	STARD3	-0.48	-8.94	-0.38	9.12e-18	Self-reported allergy;
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg24250549	chr1:154909240	PMVK	0.73	14.48	0.56	1.87e-39	Prostate cancer;
LGG	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg07636037	chr3:49044803	WDR6	0.76	13.66	0.54	6.06e-36	Menarche (age at onset);
LGG	cis	rs4700695	0.925	rs6449799	chr5:65394476	A/G	cg21114390	chr5:65439923	SFRS12	-0.53	-6.77	-0.3	3.93e-11	Facial morphology (factor 19);
LGG	cis	rs8060686	0.641	rs12600199	chr16:68069742	C/T	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.44	-0.33	4.87e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9581857	0.685	rs12584061	chr13:28024544	C/T	cg01674679	chr13:27998804	GTF3A	-0.62	-7.45	-0.33	4.58e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs4690686	0.538	rs4690428	chr4:177263665	C/T	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg21775007	chr8:11205619	TDH	0.8	14.17	0.55	4.03e-38	Retinal vascular caliber;
LGG	cis	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg06521331	chr12:34319734	NA	0.64	11.7	0.48	7.28e-28	Morning vs. evening chronotype;
LGG	cis	rs162227	1	rs162227	chr5:60260543	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.57	-0.33	2.07e-13	Parkinson's disease;
LGG	cis	rs977987	0.864	rs37594	chr16:75496943	T/C	cg03315344	chr16:75512273	CHST6	-0.57	-11.16	-0.46	8.79e-26	Dupuytren's disease;
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.4	1.49e-19	Bipolar disorder;
LGG	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg00666640	chr1:248458726	OR2T12	0.6	9.53	0.4	9.2e-20	Common traits (Other);
LGG	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg19554555	chr3:13937349	NA	-0.55	-9.92	-0.42	3.63e-21	Ovarian reserve;
LGG	cis	rs17227506	0.693	rs4531057	chr8:13457799	C/T	cg03566418	chr8:13424080	C8orf48	-0.59	-9.65	-0.41	3.4e-20	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg04691961	chr3:161091175	C3orf57	-0.5	-10.88	-0.45	1.05e-24	Morning vs. evening chronotype;
LGG	trans	rs17685	0.725	rs7795291	chr7:75725206	C/A	cg19862616	chr7:65841803	NCRNA00174	1.08	26.02	0.77	1.22e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.51	1.76e-31	Motion sickness;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg01114163	chr5:1856713	NA	-0.41	-7.12	-0.31	4.24e-12	Cardiovascular disease risk factors;
LGG	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg25986240	chr4:9926439	SLC2A9	-0.51	-9.35	-0.4	3.88e-19	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg27661571	chr11:113659931	NA	-0.59	-8.38	-0.36	6.23e-16	Hip circumference adjusted for BMI;
LGG	trans	rs877282	1.000	rs11253366	chr10:773386	C/T	cg22713356	chr15:30763199	NA	0.57	8.78	0.38	3.21e-17	Uric acid levels;
LGG	cis	rs4417704	0.551	rs4675789	chr2:241875481	A/G	cg14055004	chr2:241860995	NA	-0.28	-7.4	-0.33	6.56e-13	Joint mobility (Beighton score);
LGG	cis	rs754466	1.000	rs56256440	chr10:79698207	A/G	cg17075019	chr10:79541650	NA	-0.82	-13.89	-0.54	6.37e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.22	0.36	2.01e-15	Schizophrenia;
LGG	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.85	-9.04	-0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs6714710	0.603	rs13034929	chr2:98402772	G/C	cg26665480	chr2:98280029	ACTR1B	0.64	10.43	0.44	5.15e-23	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg05091796	chr16:4465799	CORO7	0.56	8.99	0.39	6.44e-18	Schizophrenia;
LGG	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12402800	chr5:56204917	C5orf35	0.45	6.72	0.3	5.35e-11	Initial pursuit acceleration;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1018836	0.923	rs13262354	chr8:91635731	G/A	cg16814680	chr8:91681699	NA	-0.83	-15.39	-0.58	1.77e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2479724	0.901	rs33954419	chr6:41786136	A/G	cg17623882	chr6:41773611	USP49	-0.52	-9.2	-0.39	1.21e-18	Menarche (age at onset);
LGG	cis	rs68170813	0.652	rs6976759	chr7:107158506	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-8.63	-0.37	9.68e-17	Coronary artery disease;
LGG	cis	rs2074585	0.647	rs2601188	chr15:90929563	A/G	cg22089800	chr15:90895588	ZNF774	-0.71	-13.11	-0.52	1.33e-33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg19077165	chr18:44547161	KATNAL2	-0.62	-11.53	-0.47	3.13e-27	Personality dimensions;
LGG	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.53	-0.37	2.03e-16	Triglycerides;
LGG	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg23939001	chr4:940644	TMEM175	0.51	9.76	0.41	1.43e-20	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg04989706	chr14:50066350	PPIL5	-0.53	-8.39	-0.36	5.96e-16	Carotid intima media thickness;
LGG	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg08999081	chr20:33150536	PIGU	0.3	6.92	0.31	1.54e-11	Coronary artery disease;
LGG	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg16576597	chr16:28551801	NUPR1	0.31	7.01	0.31	8.73e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs883565	0.502	rs4374473	chr3:38942618	C/T	cg01426195	chr3:39028469	NA	0.59	12.53	0.5	3.18e-31	Handedness;
LGG	cis	rs7267979	1.000	rs2424716	chr20:25423538	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.14	0.43	6.11e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg05313129	chr8:58192883	C8orf71	-0.81	-11.87	-0.48	1.5e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs12681366	0.614	rs3099401	chr8:95485531	T/C	cg13257157	chr8:95487014	RAD54B	0.37	6.74	0.3	4.74e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg17951613	chr5:131705445	SLC22A5	0.63	7.14	0.31	3.68e-12	Rheumatoid arthritis;
LGG	cis	rs4604732	0.642	rs4400652	chr1:247636479	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.51	0.37	2.36e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9357271	0.955	rs4714158	chr6:38375334	A/G	cg07362130	chr6:38359646	BTBD9	-0.47	-10.8	-0.45	2.02e-24	Restless legs syndrome;
LGG	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg07936489	chr17:37558343	FBXL20	-1.02	-14.56	-0.56	8.12e-40	Glomerular filtration rate (creatinine);
LGG	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg20578329	chr17:80767326	TBCD	-0.43	-7.78	-0.34	4.79e-14	Breast cancer;
LGG	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg08999081	chr20:33150536	PIGU	0.31	6.93	0.31	1.43e-11	Coronary artery disease;
LGG	cis	rs7831492	0.564	rs60792897	chr8:41609623	C/T	cg17182837	chr8:41585554	ANK1	-0.58	-10.32	-0.43	1.28e-22	Colorectal cancer;
LGG	cis	rs2154319	0.887	rs6696524	chr1:41539494	A/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.92	-0.38	1.12e-17	Height;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-6.95	-0.31	1.25e-11	Lung cancer;
LGG	cis	rs7582720	1.000	rs74675536	chr2:203673073	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.63	0.41	3.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg16507663	chr6:150244633	RAET1G	0.44	8.32	0.36	1.03e-15	Lung cancer;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.26	-0.46	3.55e-26	Tonsillectomy;
LGG	cis	rs1045902	0.583	rs2303904	chr2:73447775	C/T	cg01422370	chr2:73384389	NA	-0.44	-7.85	-0.34	2.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6764363	0.527	rs7640724	chr3:283039	G/A	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.69e-13	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.54e-12	Lung cancer;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg19901468	chr14:105411992	AHNAK2	-0.91	-19.2	-0.67	7.3e-61	Rheumatoid arthritis;
LGG	trans	rs7939886	0.920	rs10431119	chr11:55977069	C/T	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	trans	rs970548	0.685	rs1487562	chr10:45928822	C/T	cg20477318	chr10:51623047	TIMM23	0.61	7.5	0.33	3.23e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs9557207	0.538	rs7317996	chr13:99805319	C/T	cg24509225	chr13:100037070	UBAC2	0.37	7.41	0.33	5.9e-13	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.52	0.33	2.86e-13	Menarche (age at onset);
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.76	10.26	0.43	2.08e-22	Lung function (FEV1/FVC);
LGG	cis	rs9863	0.828	rs1187415	chr12:124491529	C/G	cg13487667	chr12:124434373	CCDC92	0.34	6.97	0.31	1.13e-11	White blood cell count;
LGG	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg17971929	chr21:40555470	PSMG1	-0.56	-9.72	-0.41	1.92e-20	Menarche (age at onset);
LGG	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-8.36	-0.36	7.59e-16	Height;
LGG	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg11764359	chr7:65958608	NA	-0.62	-10.75	-0.45	3.36e-24	Aortic root size;
LGG	cis	rs28374715	0.562	rs8036686	chr15:41550333	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.84	-14.64	-0.56	3.66e-40	Ulcerative colitis;
LGG	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.28	-0.32	1.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg15268244	chr15:77196840	NA	-0.31	-6.91	-0.31	1.62e-11	Blood metabolite levels;
LGG	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg25664220	chr3:72788482	NA	-0.27	-8.08	-0.35	5.78e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08645402	chr16:4508243	NA	0.47	8.64	0.37	9.46e-17	Schizophrenia;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg16395133	chr6:150326394	RAET1K	0.27	6.76	0.3	4.05e-11	Alopecia areata;
LGG	cis	rs806215	1.000	rs712698	chr7:127249098	C/T	cg25922125	chr7:127225783	GCC1	0.75	10.3	0.43	1.48e-22	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.39	-0.36	5.98e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg21385522	chr1:16154831	NA	0.66	10.87	0.45	1.12e-24	Dilated cardiomyopathy;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.1	-0.31	4.85e-12	Longevity;Endometriosis;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg12458913	chr13:53173898	NA	0.93	23.05	0.73	7.59e-79	Lewy body disease;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs6732160	0.932	rs768851	chr2:73378241	G/A	cg01422370	chr2:73384389	NA	0.53	10.16	0.43	5.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs504918	0.588	rs11712619	chr3:124019802	C/T	cg05766129	chr3:123988013	KALRN	-0.57	-10.24	-0.43	2.45e-22	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg18926786	chr6:150244388	RAET1G	0.31	6.68	0.3	6.73e-11	Testicular germ cell tumor;
LGG	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg13147721	chr7:65941812	NA	-0.83	-10.09	-0.42	8.77e-22	Diabetic kidney disease;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg24829409	chr8:58192753	C8orf71	-0.72	-9.55	-0.41	7.27e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg02002194	chr4:3960332	NA	-0.46	-8.86	-0.38	1.68e-17	Monocyte count;
LGG	cis	rs4684776	1.000	rs4684068	chr3:11437513	A/G	cg24705426	chr3:11550659	ATG7	-0.41	-7.59	-0.33	1.79e-13	Small vessel stroke;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg20295408	chr7:1910781	MAD1L1	-0.4	-6.75	-0.3	4.35e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9814567	1.000	rs2370642	chr3:134222136	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.91	-0.51	8.87e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs754423	0.585	rs7157151	chr14:52571583	C/T	cg12071775	chr14:52591786	NA	-0.43	-7.11	-0.31	4.4e-12	Craniofacial microsomia;
LGG	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg25823085	chr7:87105416	ABCB4	-0.28	-6.91	-0.31	1.58e-11	Gallbladder cancer;
LGG	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg15704280	chr7:45808275	SEPT13	-0.57	-9.57	-0.41	6.7e-20	HDL cholesterol;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.38e-11	Menopause (age at onset);
LGG	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg05621596	chr22:47072043	GRAMD4	0.33	6.68	0.3	6.87e-11	Urate levels in obese individuals;
LGG	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg24083324	chr1:214162604	PROX1	-0.49	-8.96	-0.38	8.1e-18	Schizophrenia;
LGG	cis	rs13102973	0.965	rs28826933	chr4:135876644	T/A	cg14419869	chr4:135874104	NA	-0.57	-10.9	-0.45	8.6e-25	Subjective well-being;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg11859384	chr17:80120422	CCDC57	-0.46	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs4330281	0.647	rs56059241	chr3:17732173	C/A	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs758324	0.783	rs2074808	chr5:131329591	A/G	cg06307176	chr5:131281290	NA	-0.53	-6.83	-0.3	2.6e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg04362960	chr10:104952993	NT5C2	0.48	8.09	0.35	5.38e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	8.68	0.37	6.84e-17	Breast cancer;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.07e-12	Bipolar disorder;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.66	-0.3	7.91e-11	Obesity-related traits;
LGG	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.87e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2377058	0.924	rs76762453	chr16:89723602	G/A	cg16725984	chr16:89735184	C16orf55	-0.4	-6.76	-0.3	4.25e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7091068	0.507	rs913046	chr10:95408484	A/C	cg20715218	chr10:95462985	C10orf4	0.56	9.51	0.4	1.02e-19	Urinary tract infection frequency;
LGG	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg07648498	chr16:89883185	FANCA	0.41	7.05	0.31	6.69e-12	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11807492	chr7:99870057	GATS	0.46	6.83	0.3	2.63e-11	Gut microbiome composition (summer);
LGG	cis	rs6764363	0.506	rs4684336	chr3:283808	T/C	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.72e-13	Sudden cardiac arrest;
LGG	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg10587741	chr22:38071170	LGALS1	0.59	13.97	0.54	2.99e-37	Fat distribution (HIV);
LGG	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg22875332	chr1:76189707	ACADM	-0.59	-9.02	-0.39	5.14e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg00343986	chr7:65444356	GUSB	0.42	7.19	0.32	2.68e-12	Aortic root size;
LGG	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	8.65	0.37	8.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9457247	0.967	rs388406	chr6:167409562	A/G	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	trans	rs8073060	0.586	rs35542792	chr17:33903886	A/G	cg19694781	chr19:47549865	TMEM160	1.12	16.98	0.62	1.25e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-11.04	-0.46	2.64e-25	Chronic sinus infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09771049	chr17:66031798	KPNA2	0.5	8.48	0.37	2.98e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.0	-0.39	5.68e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7646881	0.812	rs61696028	chr3:158455703	A/C	cg19483011	chr3:158453295	NA	-0.6	-7.97	-0.35	1.27e-14	Tetralogy of Fallot;
LGG	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg11845111	chr2:191398756	TMEM194B	0.36	8.07	0.35	5.97e-15	Pulse pressure;
LGG	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg19676328	chr12:49525230	TUBA1B	-0.58	-8.69	-0.37	6.53e-17	Total cholesterol levels;
LGG	cis	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.14	-0.35	3.62e-15	Small cell lung carcinoma;
LGG	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg13013644	chr5:502571	SLC9A3	0.33	7.3	0.32	1.27e-12	Cystic fibrosis severity;
LGG	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08045932	chr20:61659980	NA	0.6	13.16	0.52	8.02e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg13880726	chr7:1868755	MAD1L1	0.38	6.67	0.3	7.28e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg16301924	chr13:53314226	LECT1	-0.42	-8.35	-0.36	7.73e-16	Lewy body disease;
LGG	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06634786	chr22:41940651	POLR3H	0.66	11.2	0.46	6.54e-26	Vitiligo;
LGG	cis	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg06521331	chr12:34319734	NA	-0.59	-10.35	-0.43	9.91e-23	Morning vs. evening chronotype;
LGG	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	12.63	0.51	1.27e-31	Total body bone mineral density;
LGG	cis	rs7572733	0.840	rs700648	chr2:198622636	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs912057	0.841	rs1294423	chr6:6743795	C/T	cg06612196	chr6:6737390	NA	0.46	9.39	0.4	2.8e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg02187348	chr16:89574699	SPG7	0.66	11.2	0.46	6.2e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs9948	0.786	rs62156226	chr2:97417108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	5.09e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-9.92	-0.42	3.59e-21	Longevity;Endometriosis;
LGG	cis	rs963731	0.649	rs74258982	chr2:39344474	T/C	cg04010122	chr2:39346883	SOS1	0.93	8.09	0.35	5.25e-15	Corticobasal degeneration;
LGG	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg20608306	chr11:116969690	SIK3	-0.37	-9.88	-0.42	4.96e-21	Subjective well-being;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-11.25	-0.46	3.91e-26	Prudent dietary pattern;
LGG	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.25	-0.32	1.77e-12	Morning vs. evening chronotype;
LGG	trans	rs208520	1.000	rs208523	chr6:66954195	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg06636001	chr8:8085503	FLJ10661	0.7	14.5	0.56	1.46e-39	Neuroticism;
LGG	cis	rs858239	0.571	rs6953020	chr7:23172132	T/C	cg23682824	chr7:23144976	KLHL7	0.41	6.8	0.3	3.24e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12250496	chr4:62066787	NA	0.43	6.83	0.3	2.71e-11	Cognitive performance;
LGG	cis	rs975739	0.657	rs9544676	chr13:78597386	T/C	cg07847733	chr13:78271382	SLAIN1	0.45	7.72	0.34	7.35e-14	Hair color;
LGG	trans	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg25214090	chr10:38739885	LOC399744	-0.51	-9.36	-0.4	3.53e-19	Corneal astigmatism;
LGG	trans	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.15	-0.32	3.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg06640241	chr16:89574553	SPG7	0.71	12.41	0.5	1.02e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg07117364	chr1:16154769	NA	-0.48	-8.97	-0.38	7.54e-18	Dilated cardiomyopathy;
LGG	cis	rs13421350	1.000	rs13387602	chr2:173315717	A/G	cg15021238	chr2:173305865	ITGA6	-0.43	-6.94	-0.31	1.32e-11	Diabetic kidney disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg05012946	chr17:35305634	AATF	0.4	6.78	0.3	3.64e-11	Menarche (age at onset);
LGG	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg00431813	chr7:1051703	C7orf50	-0.38	-8.19	-0.36	2.52e-15	Longevity;Endometriosis;
LGG	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.12	-0.31	4.04e-12	Refractive error;
LGG	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg01631408	chr1:248437212	OR2T33	0.53	9.62	0.41	4.28e-20	Common traits (Other);
LGG	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg00543991	chr22:32367038	NA	0.76	8.36	0.36	7.18e-16	Childhood ear infection;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-7.83	-0.34	3.32e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26306683	chr17:18585705	ZNF286B	-0.41	-6.99	-0.31	9.87e-12	Pancreatic cancer;
LGG	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.74	0.51	4.46e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg10847948	chr11:71163743	NADSYN1	-0.52	-9.77	-0.41	1.28e-20	Vitamin D levels;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg01145232	chr6:150245071	RAET1G	0.48	8.7	0.37	5.69e-17	Lung cancer;
LGG	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg22771759	chr13:24902376	NA	0.42	7.24	0.32	1.88e-12	Obesity-related traits;
LGG	cis	rs2075466	0.514	rs12444795	chr16:4890066	C/T	cg04440724	chr16:4920505	UBN1	-0.62	-9.0	-0.39	5.66e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.18	-0.36	2.68e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.13	0.55	6.2e-38	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.2	-28.89	-0.8	1.18e-105	Primary sclerosing cholangitis;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg13384949	chr1:2383501	NA	-0.6	-13.45	-0.53	4.71e-35	Non-obstructive azoospermia;
LGG	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.4	-0.33	6.38e-13	Initial pursuit acceleration;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.81	-0.38	2.49e-17	Lung cancer;
LGG	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs600231	0.613	rs3825071	chr11:65212122	C/T	cg17120908	chr11:65337727	SSSCA1	-0.58	-8.43	-0.36	4.48e-16	Bone mineral density;
LGG	cis	rs751728	1.000	rs751728	chr6:33764033	C/T	cg25922239	chr6:33757077	LEMD2	0.69	12.41	0.5	9.5e-31	Crohn's disease;
LGG	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg13147721	chr7:65941812	NA	-0.79	-9.52	-0.4	9.54e-20	Diabetic kidney disease;
LGG	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.69	-0.37	6.31e-17	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4604732	0.642	rs10925048	chr1:247640736	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.69	0.37	6.18e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg02023728	chr11:77925099	USP35	0.45	7.88	0.34	2.34e-14	Testicular germ cell tumor;
LGG	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4731207	0.596	rs7779594	chr7:124636995	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg19717773	chr7:2847554	GNA12	-0.44	-10.3	-0.43	1.5e-22	Plateletcrit;
LGG	cis	rs12681287	0.640	rs13256765	chr8:87457833	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs1883415	0.534	rs2760149	chr6:24477848	C/T	cg20631270	chr6:24437470	GPLD1	0.49	8.53	0.37	2.15e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.86	0.34	2.69e-14	Coronary artery disease;
LGG	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11890956	chr21:40555474	PSMG1	1.14	26.36	0.77	3.2e-94	Cognitive function;
LGG	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg16230307	chr14:35515116	FAM177A1	0.41	7.36	0.32	8.63e-13	Psoriasis;
LGG	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg15664640	chr17:80829946	TBCD	-0.66	-9.66	-0.41	3.21e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs12464559	0.649	rs12693116	chr2:152623917	A/G	cg01189475	chr2:152685088	ARL5A	0.75	6.77	0.3	3.93e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15128208	chr22:42549153	NA	-0.37	-7.31	-0.32	1.16e-12	Cognitive function;
LGG	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg07936489	chr17:37558343	FBXL20	0.83	15.37	0.58	2.22e-43	Glomerular filtration rate (creatinine);
LGG	trans	rs9354308	0.764	rs1938100	chr6:66599919	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.0	-0.52	3.76e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.614	rs216477	chr17:28866744	A/C	cg01831904	chr17:28903510	LRRC37B2	0.68	8.53	0.37	2.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg05639522	chr1:247681581	NA	0.62	10.36	0.43	9.31e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06873352	chr17:61820015	STRADA	0.73	13.35	0.53	1.28e-34	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25450986	chr17:38574356	TOP2A	0.46	7.4	0.33	6.32e-13	Cognitive performance;
LGG	cis	rs965513	0.932	rs10818050	chr9:100538923	A/G	cg13688889	chr9:100608707	NA	-0.52	-9.35	-0.4	3.8e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg26155939	chr18:44337853	ST8SIA5	0.36	6.66	0.3	7.78e-11	Personality dimensions;
LGG	cis	rs2371030	0.965	rs4672590	chr2:211575322	G/C	cg18417063	chr2:211583084	NA	-0.64	-12.53	-0.5	3.18e-31	Non-small cell lung cancer;
LGG	cis	rs2797369	0.656	rs2749134	chr6:101491049	T/A	cg27451362	chr6:101846650	GRIK2	0.85	11.33	0.47	2.03e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg25427524	chr10:38739819	LOC399744	-0.37	-6.69	-0.3	6.57e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.56	9.66	0.41	3.1e-20	Birth weight;
LGG	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.92	0.42	3.7e-21	Colorectal cancer;
LGG	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg18551225	chr6:44695536	NA	-0.67	-10.86	-0.45	1.27e-24	Total body bone mineral density;
LGG	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.13	-0.49	1.38e-29	Morning vs. evening chronotype;
LGG	cis	rs11877825	0.826	rs8098954	chr18:10578697	A/G	cg07277756	chr18:10589357	NA	0.58	10.3	0.43	1.56e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg27205649	chr11:78285834	NARS2	0.51	8.8	0.38	2.72e-17	Alzheimer's disease (survival time);
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.55	8.29	0.36	1.28e-15	Platelet count;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg15948088	chr11:109293068	C11orf87	-0.5	-8.82	-0.38	2.4e-17	Schizophrenia;
LGG	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06634786	chr22:41940651	POLR3H	0.78	12.8	0.51	2.52e-32	Vitiligo;
LGG	cis	rs10504130	0.569	rs4534123	chr8:52677857	G/T	cg24946253	chr8:52722146	PXDNL	0.45	6.65	0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs59197085	0.636	rs754920	chr7:128468412	A/G	cg00734629	chr7:128471146	FLNC	-0.33	-6.73	-0.3	4.89e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-8.79	-0.38	3.03e-17	Educational attainment (years of education);
LGG	cis	rs1185460	0.967	rs1786685	chr11:118938957	G/A	cg23280166	chr11:118938394	VPS11	0.6	11.24	0.46	4.21e-26	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.967	rs1906450	chr17:28515744	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	13.1	0.52	1.47e-33	Coffee consumption (cups per day);
LGG	cis	rs1256531	0.661	rs28666667	chr14:66226100	C/T	cg15999311	chr14:65749247	NA	0.83	7.0	0.31	9.31e-12	Conduct disorder (symptom count);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05603938	chr12:6960421	USP5;CDCA3	0.42	6.9	0.31	1.67e-11	Cognitive performance;
LGG	cis	rs490234	0.615	rs2819625	chr9:128156648	A/G	cg14078157	chr9:128172775	NA	-0.45	-8.58	-0.37	1.49e-16	Mean arterial pressure;
LGG	cis	rs17152411	0.652	rs4246208	chr10:126654898	C/T	cg06432487	chr10:126623651	NA	0.39	6.73	0.3	5.08e-11	Height;
LGG	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs11229555	0.598	rs11229426	chr11:58180063	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2729354	0.903	rs2729371	chr11:57321322	A/G	cg24343310	chr11:57249947	NA	0.38	7.01	0.31	8.45e-12	Blood protein levels;
LGG	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg25457927	chr22:38595422	NA	-0.43	-10.09	-0.42	8.89e-22	Breast cancer;
LGG	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.34	-0.32	9.8e-13	Joint mobility (Beighton score);
LGG	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.45	0.37	3.78e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg20813462	chr7:2646259	IQCE	0.55	7.11	0.31	4.55e-12	Urate levels in lean individuals;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg21575558	chr1:222763513	TAF1A	0.4	6.97	0.31	1.11e-11	Bipolar disorder;
LGG	cis	rs7646881	1.000	rs73015649	chr3:158450298	C/G	cg19483011	chr3:158453295	NA	-0.66	-9.73	-0.41	1.77e-20	Tetralogy of Fallot;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.05	0.39	3.89e-18	Obesity-related traits;
LGG	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg18131467	chr2:239335373	ASB1	1.03	23.64	0.74	1.26e-81	Multiple system atrophy;
LGG	cis	rs870825	0.616	rs10428373	chr4:185639002	A/T	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs6942756	0.806	rs2718096	chr7:128951000	A/G	cg02491457	chr7:128862824	NA	0.63	11.65	0.48	1.09e-27	White matter hyperintensity burden;
LGG	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.94	0.52	6.52e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	7.55	0.33	2.32e-13	Height;
LGG	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.72	-0.48	5.88e-28	Life satisfaction;
LGG	cis	rs61931739	0.592	rs708140	chr12:33719563	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg06092702	chr1:163392909	NA	0.47	8.33	0.36	9.02e-16	Motion sickness;
LGG	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg00898013	chr13:113819073	PROZ	0.47	8.36	0.36	7.61e-16	Platelet distribution width;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08677398	chr8:58056175	NA	0.67	8.84	0.38	2.03e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-9.62	-0.41	4.26e-20	Colorectal cancer;
LGG	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg21452805	chr1:244014465	NA	0.62	7.41	0.33	6.14e-13	RR interval (heart rate);
LGG	trans	rs3960554	0.610	rs11971800	chr7:75731608	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.8	0.51	2.48e-32	Eotaxin levels;
LGG	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.28e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7818345	0.512	rs4922029	chr8:19304533	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.41	-9.01	-0.39	5.37e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.32	0.58	3.69e-43	Nonalcoholic fatty liver disease;
LGG	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg27279351	chr12:120934652	DYNLL1	0.81	13.09	0.52	1.62e-33	High light scatter reticulocyte count;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2073300	1.000	rs6137977	chr20:23464191	G/T	cg12062639	chr20:23401060	NAPB	0.84	6.81	0.3	3.12e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2307022	0.671	rs8052988	chr16:68375606	C/T	cg07273125	chr16:68295692	NA	0.39	8.5	0.37	2.72e-16	Body mass index;
LGG	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-6.85	-0.3	2.35e-11	Large artery stroke;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.65	-0.37	8.73e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.49	-9.3	-0.4	5.73e-19	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg13263323	chr15:86062960	AKAP13	-0.39	-8.42	-0.36	4.89e-16	Interstitial lung disease;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg14668821	chr17:77704760	ENPP7	-0.42	-8.39	-0.36	6.15e-16	Menopause (age at onset);
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00864171	chr11:67383662	NA	0.55	9.55	0.41	7.75e-20	Mean corpuscular volume;
LGG	cis	rs9403521	1.000	rs6915784	chr6:143984268	A/C	cg18240653	chr6:144019428	PHACTR2	-0.64	-9.74	-0.41	1.63e-20	Obesity-related traits;
LGG	cis	rs10089	0.552	rs58595196	chr5:127558338	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	7.7	0.34	8.26e-14	Ileal carcinoids;
LGG	cis	rs4959677	0.868	rs1010762	chr6:2476867	C/T	cg23817096	chr6:1620687	NA	-0.31	-7.31	-0.32	1.21e-12	Orthostatic hypotension;
LGG	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg13798912	chr7:905769	UNC84A	-0.57	-7.06	-0.31	6.28e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg24253500	chr15:84953950	NA	0.42	6.92	0.31	1.5e-11	Schizophrenia;
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs11885103	0.754	rs11127478	chr2:592455	T/C	cg21195176	chr2:593345	NA	0.4	7.69	0.34	8.87e-14	Heschl's gyrus morphology;
LGG	cis	rs7432375	0.966	rs6808312	chr3:136371504	C/T	cg12473912	chr3:136751656	NA	-0.4	-6.85	-0.3	2.36e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg05368731	chr17:41323189	NBR1	0.87	16.81	0.62	7.6e-50	Menopause (age at onset);
LGG	cis	rs6429082	0.749	rs3819974	chr1:235601958	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.6	-10.0	-0.42	1.88e-21	Adiposity;
LGG	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.1	0.35	5.04e-15	Retinal vascular caliber;
LGG	cis	rs17253792	0.822	rs75509578	chr14:56133493	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.78e-31	Putamen volume;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg22875332	chr1:76189707	ACADM	0.61	10.31	0.43	1.37e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.77e-20	Hypertriglyceridemia;
LGG	cis	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg14593290	chr7:50529359	DDC	-0.43	-8.16	-0.35	3.25e-15	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	18.28	0.65	1.33e-56	Obesity-related traits;
LGG	cis	rs12476592	0.571	rs166384	chr2:63863630	G/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.87	-0.3	2.1e-11	Childhood ear infection;
LGG	cis	rs4716602	0.794	rs10242287	chr7:156162410	C/T	cg16983916	chr7:156159713	NA	-0.4	-7.42	-0.33	5.55e-13	Anti-saccade response;
LGG	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg08344181	chr3:125677491	NA	-0.9	-9.06	-0.39	3.73e-18	Depression;
LGG	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg09060608	chr5:178986726	RUFY1	0.43	6.66	0.3	7.66e-11	Lung cancer;
LGG	cis	rs12282928	1.000	rs10769344	chr11:48333823	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.12	-0.43	7.22e-22	Schizophrenia;
LGG	cis	rs3767633	0.925	rs10753666	chr1:161861147	C/G	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.08e-14	Height;
LGG	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg14593290	chr7:50529359	DDC	-0.67	-11.95	-0.49	6.91e-29	Malaria;
LGG	cis	rs7106204	0.534	rs78539127	chr11:24256698	T/A	ch.11.24196551F	chr11:24239977	NA	0.83	9.32	0.4	4.68e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg26913058	chr16:419975	MRPL28	-0.48	-7.62	-0.33	1.47e-13	Body mass index;
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.65	0.33	1.19e-13	Bipolar disorder;
LGG	cis	rs864537	0.618	rs2995089	chr1:167431193	G/A	cg09179987	chr1:167433047	CD247	0.44	10.02	0.42	1.59e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.01	-0.46	3.33e-25	Urinary metabolites;
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg09264619	chr17:80180166	NA	0.35	7.02	0.31	8.05e-12	Life satisfaction;
LGG	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg02002194	chr4:3960332	NA	0.52	10.49	0.44	3.08e-23	Neuroticism;
LGG	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.56	0.37	1.63e-16	Aortic root size;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg24575275	chr7:1094737	C7orf50	-0.39	-7.68	-0.34	9.61e-14	Longevity;Endometriosis;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg01673284	chr16:4527211	HMOX2	0.35	7.02	0.31	8.04e-12	Schizophrenia;
LGG	cis	rs62025270	0.510	rs76204898	chr15:86294126	G/A	cg25843651	chr15:86329602	KLHL25	0.63	7.68	0.34	9.78e-14	Idiopathic pulmonary fibrosis;
LGG	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg12386194	chr3:101231763	SENP7	0.74	13.09	0.52	1.62e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg11644478	chr21:40555479	PSMG1	0.88	16.42	0.61	4.64e-48	Cognitive function;
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg05868516	chr6:26286170	HIST1H4H	0.45	7.67	0.34	9.93e-14	Educational attainment;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.57	0.47	2.21e-27	Obesity-related traits;
LGG	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg03929089	chr4:120376271	NA	-0.5	-8.35	-0.36	8e-16	Height;
LGG	trans	rs2562456	0.833	rs62107541	chr19:21518535	T/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs4466137	1.000	rs1154888	chr5:82977410	C/A	cg16102102	chr5:83017553	HAPLN1	-0.62	-11.35	-0.47	1.58e-26	Prostate cancer;
LGG	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg02753203	chr1:228287806	NA	-0.87	-16.48	-0.61	2.28e-48	Diastolic blood pressure;
LGG	cis	rs9487094	0.961	rs1040284	chr6:109673933	T/C	cg01125227	chr6:109776195	MICAL1	0.52	8.97	0.38	7.38e-18	Height;
LGG	cis	rs9470366	0.535	rs762624	chr6:36645588	A/C	cg08179530	chr6:36648295	CDKN1A	0.66	10.68	0.44	5.81e-24	QRS duration;
LGG	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg26818010	chr10:134567672	INPP5A	-0.68	-10.28	-0.43	1.82e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg08885076	chr2:99613938	TSGA10	0.42	8.97	0.38	7.64e-18	Chronic sinus infection;
LGG	cis	rs7538876	1.000	rs942457	chr1:17739586	G/A	cg10329579	chr1:17754830	RCC2	-0.49	-9.32	-0.4	4.7e-19	Basal cell carcinoma;
LGG	cis	rs8030485	1.000	rs12593555	chr15:79411268	G/T	cg17916960	chr15:79447300	NA	0.4	6.76	0.3	4.17e-11	Left ventricle wall thickness;
LGG	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.63	-12.51	-0.5	3.86e-31	IgG glycosylation;
LGG	cis	rs740474	0.831	rs2302103	chr5:140955777	C/T	cg00076195	chr5:140892677	NA	0.49	8.94	0.38	9.62e-18	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg24692254	chr21:30365293	RNF160	1.03	27.55	0.79	1.26e-99	Dental caries;
LGG	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.14	0.35	3.62e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6993813	0.967	rs6469805	chr8:120048149	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.29	7.48	0.33	3.87e-13	Bone mineral density (hip);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05665937	chr4:1216051	CTBP1	0.54	9.89	0.42	4.67e-21	Obesity-related traits;
LGG	cis	rs6500395	0.928	rs4785532	chr16:48695500	G/A	cg16662043	chr16:48846231	NA	-0.36	-7.14	-0.32	3.56e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg11764359	chr7:65958608	NA	0.63	10.41	0.44	5.88e-23	Aortic root size;
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg26513180	chr16:89883248	FANCA	0.84	8.86	0.38	1.68e-17	Skin colour saturation;
LGG	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg14210321	chr2:106509881	NCK2	-0.56	-9.86	-0.42	6.31e-21	Addiction;
LGG	cis	rs4950322	0.570	rs4950403	chr1:146791441	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs921968	0.643	rs471846	chr2:219432237	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.82	-0.3	2.86e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg18187862	chr3:45730750	SACM1L	-0.68	-11.01	-0.46	3.4e-25	Primary sclerosing cholangitis;
LGG	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg05555928	chr11:63887634	MACROD1	0.6	8.86	0.38	1.73e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.89	-10.93	-0.45	6.79e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg08344181	chr3:125677491	NA	-0.82	-7.78	-0.34	4.85e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4799461	0.802	rs1557339	chr18:35129076	C/A	cg27332583	chr18:35150602	NA	-0.55	-11.08	-0.46	1.88e-25	Neuroticism;
LGG	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg08847533	chr14:75593920	NEK9	0.62	12.22	0.49	5.66e-30	Height;
LGG	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.5	-0.37	2.72e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.36	-0.4	3.41e-19	Headache;
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00290607	chr11:67383545	NA	0.62	11.83	0.48	2.07e-28	Mean corpuscular volume;
LGG	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg24450063	chr1:156163899	SLC25A44	0.92	8.6	0.37	1.23e-16	Paclitaxel disposition in epithelial ovarian cancer;
LGG	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.3	-0.4	5.58e-19	Height;
LGG	cis	rs537930	0.560	rs28264	chr5:134352570	A/G	cg24576358	chr5:134350122	NA	0.42	9.29	0.4	6.23e-19	Height;
LGG	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-6.87	-0.3	2.07e-11	Cognitive function;
LGG	cis	rs9487094	0.670	rs13220915	chr6:109824826	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.76	0.34	5.31e-14	Height;
LGG	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.76	-0.78	4.73e-96	Primary sclerosing cholangitis;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg07959490	chr17:80112427	CCDC57	0.47	9.51	0.4	1.03e-19	Life satisfaction;
LGG	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.49e-19	Fuchs's corneal dystrophy;
LGG	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg21395723	chr22:39101663	GTPBP1	0.38	6.73	0.3	5.17e-11	Menopause (age at onset);
LGG	cis	rs8067545	0.935	rs7209734	chr17:19988543	C/A	cg13482628	chr17:19912719	NA	0.64	12.9	0.51	9.87e-33	Schizophrenia;
LGG	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.75	0.45	3.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg26384229	chr12:38710491	ALG10B	-0.71	-13.45	-0.53	5.02e-35	Morning vs. evening chronotype;
LGG	trans	rs61332075	0.518	rs56171132	chr2:239378856	C/T	cg01134436	chr17:81009848	B3GNTL1	0.82	8.84	0.38	1.94e-17	Lung function (FEV1/FVC);
LGG	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs228437	0.802	rs228449	chr6:134903629	A/G	cg24504307	chr6:134963096	NA	0.35	6.77	0.3	4.02e-11	Melanoma;
LGG	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg00717180	chr2:96193071	NA	-0.42	-7.49	-0.33	3.61e-13	Height;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg14227996	chr4:17616232	MED28	0.69	8.35	0.36	8.04e-16	Opioid sensitivity;
LGG	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	14.55	0.56	9.61e-40	Total body bone mineral density;
LGG	cis	rs708547	0.792	rs7667084	chr4:57727435	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.51	-7.93	-0.35	1.69e-14	Response to bleomycin (chromatid breaks);
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.75	-0.48	4.59e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.42e-50	Skin colour saturation;
LGG	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg07148914	chr20:33460835	GGT7	0.58	9.56	0.41	7e-20	Height;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.74	10.39	0.43	6.88e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3219090	0.962	rs2027439	chr1:226575749	T/C	cg17127702	chr1:226594323	PARP1	0.38	12.13	0.49	1.38e-29	Melanoma;
LGG	cis	rs16866061	0.888	rs6748341	chr2:225377574	C/G	cg12698349	chr2:225449008	CUL3	0.92	18.95	0.66	1.09e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9682041	0.597	rs13076319	chr3:170104630	T/G	cg11886554	chr3:170076028	SKIL	0.57	7.45	0.33	4.58e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg08807101	chr21:30365312	RNF160	0.62	10.88	0.45	1.02e-24	Dental caries;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg01145232	chr6:150245071	RAET1G	0.34	6.71	0.3	5.54e-11	Lung cancer;
LGG	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-23.64	-0.74	1.25e-81	Lymphocyte percentage of white cells;
LGG	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg13263323	chr15:86062960	AKAP13	-0.34	-6.91	-0.31	1.64e-11	Coronary artery disease;
LGG	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg00898013	chr13:113819073	PROZ	-0.48	-9.62	-0.41	4.43e-20	Platelet distribution width;
LGG	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03888520	chr22:42978243	RRP7B	0.39	6.97	0.31	1.09e-11	Obesity-related traits;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg06719900	chr11:109292894	C11orf87	0.43	7.81	0.34	3.83e-14	Schizophrenia;
LGG	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg16576597	chr16:28551801	NUPR1	0.44	10.28	0.43	1.9e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg13944838	chr5:179740914	GFPT2	-0.68	-12.5	-0.5	4.45e-31	Height;
LGG	cis	rs4417704	0.551	rs7585067	chr2:241893465	T/C	cg14055004	chr2:241860995	NA	0.28	7.36	0.32	8.39e-13	Joint mobility (Beighton score);
LGG	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg08645402	chr16:4508243	NA	0.44	7.52	0.33	2.9e-13	Schizophrenia;
LGG	cis	rs17253792	0.908	rs74354306	chr14:56065778	T/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.7	-0.51	6.5e-32	Putamen volume;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg11360546	chr7:1094263	C7orf50	-0.42	-7.84	-0.34	3.09e-14	Longevity;Endometriosis;
LGG	cis	rs11157436	0.602	rs17255447	chr14:22635355	A/G	cg00994629	chr14:22694547	NA	-0.32	-7.01	-0.31	8.34e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.76	0.45	2.86e-24	Personality dimensions;
LGG	cis	rs4262150	0.810	rs35124713	chr5:151951108	G/A	cg12297329	chr5:152029980	NA	-0.79	-15.39	-0.58	1.88e-43	Bipolar disorder and schizophrenia;
LGG	trans	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg22232500	chr2:134024266	NCKAP5	0.61	8.3	0.36	1.13e-15	Bipolar disorder;
LGG	cis	rs4950322	0.515	rs17160050	chr1:146727213	T/C	cg22381352	chr1:146742008	CHD1L	-0.47	-7.86	-0.34	2.72e-14	Protein quantitative trait loci;
LGG	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg15017067	chr4:17643749	FAM184B	0.32	7.45	0.33	4.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs190945449	1	rs190945449	chr6:26828359	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	7.26	0.32	1.61e-12	Urinary tract infection frequency;
LGG	cis	rs9487094	0.885	rs1358997	chr6:109701660	G/C	cg16315928	chr6:109776240	MICAL1	0.53	9.19	0.39	1.36e-18	Height;
LGG	cis	rs7100689	0.784	rs4258322	chr10:82184770	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	21.21	0.7	2.8e-70	Post bronchodilator FEV1;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13012494	chr21:47604986	C21orf56	0.58	10.19	0.43	4.02e-22	Testicular germ cell tumor;
LGG	trans	rs28595532	0.557	rs7696047	chr4:119303024	G/A	cg26518628	chr1:97050305	NA	-0.93	-12.31	-0.5	2.46e-30	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg06916706	chr16:4465613	CORO7	-0.71	-12.37	-0.5	1.48e-30	Schizophrenia;
LGG	trans	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg25214090	chr10:38739885	LOC399744	0.68	12.18	0.49	8.23e-30	Corneal astigmatism;
LGG	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg06618935	chr21:46677482	NA	-0.46	-8.98	-0.39	6.75e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9287719	0.967	rs12467642	chr2:10761484	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.45	-0.33	4.67e-13	Prostate cancer;
LGG	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg02023728	chr11:77925099	USP35	0.43	7.65	0.33	1.19e-13	Testicular germ cell tumor;
LGG	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.5	-0.37	2.72e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15557168	chr22:42548783	NA	0.35	7.59	0.33	1.75e-13	Cognitive function;
LGG	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.06	-0.31	6e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs483180	0.532	rs561931	chr1:120254506	A/G	cg19096424	chr1:120255104	PHGDH	0.7	12.4	0.5	1.09e-30	Macular telangiectasia type 2;
LGG	cis	rs368123	1.000	rs394463	chr6:160732925	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.48	-0.33	3.87e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.96	-0.42	2.68e-21	Body mass index;
LGG	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg14664628	chr15:75095509	CSK	-0.89	-18.12	-0.64	7.2e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.53	10.14	0.43	5.99e-22	Longevity;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg11301795	chr4:187892539	NA	-0.91	-22.38	-0.72	9.99e-76	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	7.02	0.31	8.04e-12	Height;
LGG	trans	rs1941687	0.673	rs4427879	chr18:31404751	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.93	-0.38	9.76e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs926938	0.521	rs360649	chr1:115439668	G/C	cg12756093	chr1:115239321	AMPD1	0.46	8.48	0.37	2.97e-16	Autism;
LGG	cis	rs12431410	0.550	rs11623385	chr14:60226298	C/T	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06470251	chr20:60548479	NA	0.47	8.32	0.36	1.03e-15	Body mass index;
LGG	cis	rs1847505	0.562	rs75643704	chr13:61431974	G/T	cg25164009	chr13:61490935	NA	0.57	9.67	0.41	2.82e-20	Polychlorinated biphenyl levels;
LGG	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	13.23	0.52	4.09e-34	IgG glycosylation;
LGG	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg00531865	chr16:30841666	NA	-0.55	-10.94	-0.45	6.13e-25	Multiple myeloma;
LGG	trans	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg00938859	chr5:1591904	SDHAP3	0.9	12.33	0.5	2.01e-30	Breast cancer;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg16060761	chr17:80687452	NA	-0.41	-6.7	-0.3	6.06e-11	Glycated hemoglobin levels;
LGG	cis	rs910187	0.678	rs1046661	chr20:45817149	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-9.21	-0.39	1.11e-18	Migraine;
LGG	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-6.99	-0.31	9.39e-12	IgG glycosylation;
LGG	cis	rs9815354	1.000	rs9855965	chr3:41860508	C/T	cg03022575	chr3:42003672	ULK4	0.66	8.49	0.37	2.93e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs36071027	0.577	rs11740411	chr5:158396215	C/T	cg18496440	chr5:158532302	NA	0.41	6.85	0.3	2.36e-11	Carotid intima media thickness;
LGG	cis	rs11096990	0.892	rs11930865	chr4:39220331	T/C	cg24403649	chr4:39172243	NA	-0.45	-7.41	-0.33	5.88e-13	Cognitive function;
LGG	trans	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6732160	0.691	rs13402225	chr2:73416906	T/G	cg01422370	chr2:73384389	NA	0.47	9.12	0.39	2.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.84	0.3	2.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.79	-0.45	2.35e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.54	0.41	8.13e-20	Red cell distribution width;
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.27	0.46	3.32e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.94e-13	Menopause (age at onset);
LGG	trans	rs826838	1.000	rs826851	chr12:39112639	A/G	cg06521331	chr12:34319734	NA	0.41	7.35	0.32	8.82e-13	Heart rate;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-11.77	-0.48	3.58e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg24829409	chr8:58192753	C8orf71	-0.72	-9.6	-0.41	4.89e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg16724585	chr3:197361211	NA	-0.46	-8.12	-0.35	4.11e-15	Pancreatic cancer;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg17951613	chr5:131705445	SLC22A5	0.67	7.58	0.33	1.92e-13	Rheumatoid arthritis;
LGG	cis	rs9880211	0.948	rs34135127	chr3:136226498	T/C	cg21827317	chr3:136751795	NA	-0.5	-7.34	-0.32	9.5e-13	Body mass index;Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07001481	chr17:5389669	DERL2;MIS12	0.48	7.97	0.35	1.2e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs12942207	1	rs12942207	chr17:45968294	C/T	cg02219949	chr17:45927392	SP6	0.5	8.86	0.38	1.73e-17	Birth weight;
LGG	cis	rs72792276	1.000	rs17164395	chr5:127395526	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.65	6.68	0.3	7.08e-11	Red cell distribution width;
LGG	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.48	-0.4	1.34e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg22875332	chr1:76189707	ACADM	0.6	8.93	0.38	1e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.24	0.39	9.18e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12291225	0.679	rs1043237	chr11:14289053	A/T	cg19336497	chr11:14380999	RRAS2	-0.52	-10.62	-0.44	1.02e-23	Sense of smell;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.47	0.56	2.11e-39	Lung cancer;
LGG	cis	rs2250417	0.935	rs10891343	chr11:112080384	T/C	cg04929355	chr11:112034997	IL18	-0.33	-6.98	-0.31	1.04e-11	Inflammatory biomarkers;Protein quantitative trait loci;
LGG	trans	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg19894588	chr14:64061835	NA	-0.64	-10.21	-0.43	3.18e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg05863683	chr7:1912471	MAD1L1	0.46	8.95	0.38	8.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg26655873	chr3:72818019	SHQ1	0.35	7.03	0.31	7.69e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2290402	0.536	rs2335172	chr4:855282	G/A	cg09237302	chr4:906077	GAK	-0.43	-7.34	-0.32	9.89e-13	Type 2 diabetes;
LGG	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg24450063	chr1:156163899	SLC25A44	1.01	20.78	0.69	3.1e-68	Testicular germ cell tumor;
LGG	cis	rs2133450	0.967	rs17697014	chr3:7342273	T/G	cg19930620	chr3:7340148	GRM7	-0.39	-8.59	-0.37	1.3e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00684032	chr4:1343700	KIAA1530	0.67	13.79	0.54	1.74e-36	Obesity-related traits;
LGG	cis	rs4764487	0.685	rs740839	chr12:6338637	C/T	cg08284733	chr12:6341482	CD9	0.36	9.64	0.41	3.69e-20	Mean platelet volume;
LGG	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg27523141	chr10:43048294	ZNF37B	0.43	8.53	0.37	2.13e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1385374	0.858	rs11059933	chr12:129303593	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	6.8	0.3	3.26e-11	Systemic lupus erythematosus;
LGG	trans	rs12517041	1.000	rs58571178	chr5:23294196	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs9534288	0.830	rs1126364	chr13:46633394	C/G	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg24375607	chr4:120327624	NA	0.52	8.23	0.36	1.89e-15	Educational attainment;
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg11502198	chr6:26597334	ABT1	-0.62	-10.78	-0.45	2.47e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg14598338	chr9:96623480	NA	-0.54	-9.72	-0.41	1.85e-20	DNA methylation (variation);
LGG	trans	rs7939886	0.920	rs11227729	chr11:56039901	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.7	0.34	8.47e-14	Myopia (pathological);
LGG	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg00666640	chr1:248458726	OR2T12	0.55	8.66	0.37	7.85e-17	Common traits (Other);
LGG	cis	rs17331151	0.505	rs79993196	chr3:52697566	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.52	6.8	0.3	3.31e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs1713854	chr3:153848030	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg08188268	chr10:116634841	FAM160B1	0.32	6.96	0.31	1.19e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg18245976	chr7:158708271	WDR60	-0.56	-7.58	-0.33	1.91e-13	Height;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs6580649	0.941	rs11612970	chr12:48451009	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg03959625	chr15:84868606	LOC388152	0.57	9.27	0.4	7.34e-19	Schizophrenia;
LGG	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.73	-12.93	-0.52	7.18e-33	Body mass index;
LGG	cis	rs4268898	0.931	rs34504814	chr2:24503766	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-8.9	-0.38	1.27e-17	Asthma;
LGG	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg04568710	chr12:38710424	ALG10B	0.35	6.94	0.31	1.35e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs79387448	0.701	rs11465584	chr2:102982629	G/A	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.86	-0.3	2.26e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg27476859	chr7:2772710	GNA12	0.4	6.78	0.3	3.77e-11	Height;
LGG	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg18245976	chr7:158708271	WDR60	0.43	7.18	0.32	2.75e-12	Height;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14085606	chr9:130454671	STXBP1	0.37	6.76	0.3	4.27e-11	Electrocardiographic conduction measures;
LGG	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	9.62	0.41	4.35e-20	Height;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.75	0.38	3.86e-17	Lung cancer;
LGG	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs131777	0.545	rs131759	chr22:51015481	G/A	cg05418105	chr22:50981406	NA	-0.37	-6.67	-0.3	7.5e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs79839061	0.610	rs1564282	chr4:852313	C/T	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.69	0.41	2.47e-20	Schizophrenia;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg11764359	chr7:65958608	NA	0.73	13.2	0.52	5.46e-34	Aortic root size;
LGG	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg08975724	chr8:8085496	FLJ10661	0.37	6.87	0.3	2.12e-11	Retinal vascular caliber;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.12	-0.43	6.93e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9682041	0.877	rs10804841	chr3:170072031	T/A	cg11886554	chr3:170076028	SKIL	0.67	8.88	0.38	1.45e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg18135555	chr8:22132992	PIWIL2	0.39	10.0	0.42	1.87e-21	Hypertriglyceridemia;
LGG	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg05535760	chr7:792225	HEATR2	0.98	14.67	0.56	2.86e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs3845702	0.736	rs3843323	chr2:180856459	T/C	cg01881094	chr2:180872142	CWC22	-1.27	-16.94	-0.62	1.84e-50	Schizophrenia;
LGG	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg14228332	chr4:119757509	SEC24D	0.99	10.05	0.42	1.29e-21	Cannabis dependence symptom count;
LGG	cis	rs922107	0.967	rs6699344	chr1:90023768	G/A	cg01128109	chr1:89989507	LRRC8B	-0.32	-7.37	-0.32	7.84e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg19673125	chr6:150240577	RAET1G	0.35	8.52	0.37	2.28e-16	Testicular germ cell tumor;
LGG	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg02836325	chr17:76403955	PGS1	-0.8	-17.61	-0.63	1.66e-53	HDL cholesterol levels;
LGG	cis	rs7726354	0.793	rs112476198	chr5:56020572	T/C	cg27303933	chr5:56029418	NA	0.53	7.55	0.33	2.33e-13	Breast cancer (early onset);
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg05335186	chr13:53173507	NA	0.48	10.18	0.43	4.27e-22	Lewy body disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01423820	chr14:77228690	VASH1	-0.48	-6.99	-0.31	9.55e-12	Systemic lupus erythematosus;
LGG	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg13385794	chr1:248469461	NA	0.43	7.69	0.34	8.74e-14	Common traits (Other);
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg08621203	chr6:150244597	RAET1G	0.44	7.62	0.33	1.41e-13	Lung cancer;
LGG	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.1	-0.43	8.04e-22	Morning vs. evening chronotype;
LGG	cis	rs12476592	0.543	rs1446569	chr2:63818314	C/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.54	-0.33	2.56e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.13e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04729371	chr11:111637213	PPP2R1B	0.43	7.09	0.31	5.07e-12	Cognitive performance;
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg03351412	chr1:154909251	PMVK	0.66	12.3	0.5	2.83e-30	Prostate cancer;
LGG	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg21459583	chr1:227974177	NA	0.72	10.22	0.43	3.14e-22	Major depressive disorder;
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10802521	chr3:52805072	NEK4	-0.39	-7.07	-0.31	5.68e-12	Bipolar disorder;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.68e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	0.688	rs12212348	chr6:27361242	T/C	cg15325629	chr6:28072465	NA	0.91	6.78	0.3	3.76e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4732038	0.691	rs10239772	chr7:134246261	T/C	cg06906464	chr7:134288099	NA	-0.48	-11.42	-0.47	9.08e-27	Longevity;
LGG	cis	rs2282802	0.677	rs9686454	chr5:139627813	T/C	cg26211634	chr5:139558579	C5orf32	0.34	7.44	0.33	4.87e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.24	0.32	1.88e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-10.36	-0.43	9.42e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.24	-0.36	1.75e-15	Bipolar disorder;
LGG	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-17.38	-0.63	1.79e-52	Skin colour saturation;
LGG	trans	rs17685	0.625	rs1639630	chr7:75730499	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.97	0.77	2.03e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg08925882	chr11:67350491	GSTP1	-0.35	-6.85	-0.3	2.34e-11	Mean corpuscular volume;
LGG	cis	rs1707322	0.752	rs28438704	chr1:46170544	G/A	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg11878867	chr6:150167359	LRP11	-0.49	-10.06	-0.42	1.15e-21	Lung cancer;
LGG	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg07061783	chr6:25882402	NA	-0.42	-7.05	-0.31	6.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1878931	0.615	rs6501171	chr16:3402610	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	19.24	0.67	4.92e-61	Body mass index (adult);
LGG	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.48	-0.44	3.29e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.593	rs1944118	chr11:111352032	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.6	-10.29	-0.43	1.68e-22	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05665937	chr4:1216051	CTBP1	0.5	9.29	0.4	5.97e-19	Obesity-related traits;
LGG	cis	rs6558174	0.930	rs1038311	chr8:22489247	T/C	cg03733263	chr8:22462867	KIAA1967	0.65	10.97	0.45	4.71e-25	Breast cancer;
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg10505658	chr17:80084571	CCDC57	0.34	6.85	0.3	2.43e-11	Life satisfaction;
LGG	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	13.66	0.54	6.05e-36	Type 2 diabetes;
LGG	cis	rs9462027	0.628	rs3734264	chr6:34831866	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.29	-0.46	2.9e-26	Systemic lupus erythematosus;
LGG	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg12292205	chr6:26970375	C6orf41	0.68	12.87	0.51	1.25e-32	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04887335	chr3:196044632	TCTEX1D2	-0.45	-7.58	-0.33	1.95e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg19784903	chr17:45786737	TBKBP1	0.36	7.93	0.35	1.62e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg08807101	chr21:30365312	RNF160	0.53	8.34	0.36	8.72e-16	Selective IgA deficiency;
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg04503457	chr17:41445688	NA	-0.41	-9.67	-0.41	2.93e-20	Menopause (age at onset);
LGG	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	13.11	0.52	1.33e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17767392	0.846	rs61991246	chr14:71859858	G/A	cg02058870	chr14:72053146	SIPA1L1	0.38	8.02	0.35	8.5e-15	Mitral valve prolapse;
LGG	cis	rs11229555	1.000	rs2275993	chr11:58379987	A/G	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.33	0.55	8.16e-39	Exhaled nitric oxide output;
LGG	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg19338460	chr6:170058176	WDR27	-0.51	-7.76	-0.34	5.35e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg19862616	chr7:65841803	NCRNA00174	0.74	7.68	0.34	9.68e-14	Mononucleosis;
LGG	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs4262150	0.774	rs4958326	chr5:152053477	A/T	cg12297329	chr5:152029980	NA	-0.82	-15.53	-0.59	4.26e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.64	0.41	3.61e-20	Coronary artery disease;
LGG	cis	rs77633900	0.772	rs2957611	chr15:76704878	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-8.32	-0.36	9.76e-16	Non-glioblastoma glioma;Glioma;
LGG	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg02002194	chr4:3960332	NA	0.49	9.19	0.39	1.36e-18	Neuroticism;
LGG	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg15485101	chr11:133734466	NA	-0.6	-10.61	-0.44	1.07e-23	Childhood ear infection;
LGG	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg17691542	chr6:26056736	HIST1H1C	0.67	11.11	0.46	1.33e-25	Iron status biomarkers;
LGG	cis	rs9863	0.896	rs76283024	chr12:124466779	G/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.19	-0.32	2.61e-12	White blood cell count;
LGG	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	9.6	0.41	5.16e-20	Response to antipsychotic treatment;
LGG	cis	rs1620921	0.565	rs67368974	chr6:161264124	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.41	-0.33	5.88e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg08847533	chr14:75593920	NEK9	-0.59	-10.41	-0.44	5.99e-23	Height;
LGG	cis	rs7737355	0.738	rs3776001	chr5:130957992	T/A	cg06307176	chr5:131281290	NA	0.54	8.97	0.38	7.5e-18	Life satisfaction;
LGG	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19671926	chr4:122722719	EXOSC9	0.52	8.12	0.35	4.41e-15	Type 2 diabetes;
LGG	cis	rs79349575	0.783	rs12601955	chr17:47034420	C/T	cg16584676	chr17:46985605	UBE2Z	0.5	8.46	0.37	3.52e-16	Type 2 diabetes;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg13628971	chr7:2884303	GNA12	0.51	10.28	0.43	1.81e-22	Height;
LGG	cis	rs2279817	0.735	rs11580813	chr1:17981913	C/T	cg21791023	chr1:18019539	ARHGEF10L	0.57	7.55	0.33	2.27e-13	Neuroticism;
LGG	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg07382826	chr16:28625726	SULT1A1	0.42	8.77	0.38	3.34e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg11266682	chr4:10021025	SLC2A9	0.48	9.31	0.4	5.34e-19	Bone mineral density;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.31	0.32	1.21e-12	Homoarginine levels;
LGG	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg19774624	chr17:42201019	HDAC5	0.7	13.82	0.54	1.3e-36	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg25718383	chr7:130020096	CPA1	-0.31	-8.15	-0.35	3.31e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2916247	1.000	rs2920463	chr8:93008292	A/G	cg10183463	chr8:93005414	RUNX1T1	0.41	8.57	0.37	1.54e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg05868516	chr6:26286170	HIST1H4H	0.45	7.67	0.34	9.93e-14	Educational attainment;
LGG	trans	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.76	-0.51	3.65e-32	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08645402	chr16:4508243	NA	-0.49	-9.29	-0.4	6.09e-19	Schizophrenia;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg11360546	chr7:1094263	C7orf50	-0.39	-6.91	-0.31	1.61e-11	Longevity;Endometriosis;
LGG	cis	rs3099143	0.901	rs1611866	chr15:77236291	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-9.34	-0.4	4.15e-19	Recalcitrant atopic dermatitis;
LGG	cis	rs9810089	0.749	rs664088	chr3:136036986	T/C	cg21827317	chr3:136751795	NA	0.46	8.2	0.36	2.37e-15	Gestational age at birth (child effect);
LGG	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-12.72	-0.51	5.56e-32	Bipolar disorder;
LGG	cis	rs7712401	0.580	rs185008	chr5:122274734	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg02733842	chr7:1102375	C7orf50	0.64	10.51	0.44	2.53e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1371867	0.846	rs1660327	chr8:101292206	A/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	6.7e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs12439619	0.508	rs8023960	chr15:82499045	C/T	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-8.03	-0.35	7.85e-15	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.91	0.57	2.51e-41	Cannabis dependence symptom count;
LGG	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg08305652	chr11:111469057	NA	-0.45	-8.92	-0.38	1.07e-17	Primary sclerosing cholangitis;
LGG	cis	rs858239	0.600	rs7790157	chr7:23126998	G/A	cg23682824	chr7:23144976	KLHL7	0.45	7.81	0.34	3.96e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2235642	0.787	rs2235646	chr16:1601287	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.52	0.4	9.48e-20	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25172604	chr17:41446521	NA	-0.3	-7.04	-0.31	7.03e-12	Menopause (age at onset);
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg01081584	chr15:40268610	EIF2AK4	-0.87	-11.16	-0.46	9.01e-26	Response to haloperidol in psychosis;
LGG	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.38	0.4	2.86e-19	Blood metabolite levels;
LGG	cis	rs701145	0.585	rs1713852	chr3:153795487	C/G	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18252515	chr7:66147081	NA	-0.4	-6.89	-0.31	1.8e-11	Aortic root size;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg02018176	chr4:1364513	KIAA1530	0.38	8.67	0.37	7.1e-17	Obesity-related traits;
LGG	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg06885757	chr1:42089581	HIVEP3	0.57	12.92	0.51	7.97e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.44	-0.37	4.08e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg07005078	chr4:17578674	LAP3	0.36	6.8	0.3	3.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg00579200	chr11:133705235	NA	-0.54	-10.55	-0.44	1.76e-23	Childhood ear infection;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	30.37	0.82	2.98e-112	Prudent dietary pattern;
LGG	cis	rs7301016	0.707	rs11174588	chr12:63052601	G/T	cg11441379	chr12:63026424	NA	0.58	8.12	0.35	4.22e-15	IgG glycosylation;
LGG	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.85	0.38	1.8e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg02836325	chr17:76403955	PGS1	-0.71	-14.47	-0.56	1.98e-39	HDL cholesterol levels;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg13047869	chr3:10149882	C3orf24	0.61	8.6	0.37	1.23e-16	Alzheimer's disease;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.08	-0.39	3.23e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7267979	0.966	rs6050611	chr20:25414419	A/G	cg06421707	chr20:25228305	PYGB	0.46	9.86	0.42	6e-21	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.37	0.4	3.21e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.26	-0.43	2.22e-22	Morning vs. evening chronotype;
LGG	cis	rs1003719	0.680	rs3737540	chr21:38523266	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.47	-0.58	8.06e-44	Eye color traits;
LGG	cis	rs4356975	0.527	rs12643840	chr4:69947963	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.65	0.3	8.48e-11	Obesity-related traits;
LGG	trans	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg23484912	chr5:273055	PDCD6	-0.4	-7.83	-0.34	3.41e-14	Mean corpuscular volume;
LGG	cis	rs3820928	0.874	rs12467261	chr2:227888838	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.64	-0.33	1.3e-13	Pulmonary function;
LGG	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg21775007	chr8:11205619	TDH	-0.45	-7.3	-0.32	1.24e-12	Mood instability;
LGG	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs300774	0.925	rs447775	chr2:106413	T/A	cg04617936	chr2:214353	NA	-0.5	-7.47	-0.33	4.06e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg27661571	chr11:113659931	NA	-0.67	-9.58	-0.41	5.98e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	19.11	0.66	1.99e-60	Alzheimer's disease;
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg16339924	chr4:17578868	LAP3	0.63	11.01	0.46	3.33e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg19635926	chr16:89946313	TCF25	0.66	7.85	0.34	2.82e-14	Skin colour saturation;
LGG	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg11621586	chr10:70884670	VPS26A	1.14	21.73	0.71	1.07e-72	Left atrial antero-posterior diameter;
LGG	cis	rs35160687	0.644	rs2113615	chr2:86517602	G/A	cg10973622	chr2:86423274	IMMT	-0.4	-7.01	-0.31	8.52e-12	Night sleep phenotypes;
LGG	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg02002194	chr4:3960332	NA	-0.54	-10.68	-0.44	6.09e-24	Neuroticism;
LGG	cis	rs3206736	0.548	rs329235	chr7:35056166	C/T	cg13400248	chr7:35225412	NA	-0.54	-9.59	-0.41	5.53e-20	Diastolic blood pressure;
LGG	cis	rs3820928	1.000	rs7592387	chr2:227777095	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.26	-0.32	1.64e-12	Pulmonary function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11050527	chr8:54755511	ATP6V1H	0.5	8.16	0.35	3.16e-15	Gut microbiome composition (summer);
LGG	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg16576597	chr16:28551801	NUPR1	0.44	10.07	0.42	1.08e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg21605333	chr4:119757512	SEC24D	1.41	13.12	0.52	1.21e-33	Cannabis dependence symptom count;
LGG	cis	rs13382862	0.823	rs12710743	chr2:20880714	T/C	cg27141850	chr2:20869434	GDF7	-0.23	-6.84	-0.3	2.58e-11	Abdominal aortic aneurysm;
LGG	cis	rs2070997	0.618	rs3780282	chr9:133743654	G/A	cg03924115	chr9:133768966	QRFP	0.41	7.21	0.32	2.34e-12	Response to amphetamines;
LGG	cis	rs4689642	0.507	rs4689086	chr4:7222064	G/A	cg21353189	chr4:7228343	SORCS2	0.32	6.72	0.3	5.31e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg04362095	chr11:63592001	C11orf84	-0.57	-11.14	-0.46	1.06e-25	Pulse pressure;
LGG	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg13798912	chr7:905769	UNC84A	0.56	6.92	0.31	1.56e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1475911	1.000	rs17114359	chr21:43510437	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-8.22	-0.36	2.07e-15	IgG glycosylation;
LGG	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg22676075	chr6:135203613	NA	0.45	7.64	0.33	1.27e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs7939886	0.920	rs1481926	chr11:55973281	C/T	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg24687543	chr11:63912206	MACROD1	0.6	8.39	0.36	5.92e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg00225070	chr15:80189496	MTHFS	0.4	7.67	0.34	1.01e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11920090	0.858	rs66683764	chr3:170720960	A/G	cg09710316	chr3:170744871	SLC2A2	0.68	8.91	0.38	1.22e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs35740288	0.822	rs2241268	chr15:86278309	G/A	cg04173714	chr15:86211321	AKAP13	0.42	7.15	0.32	3.48e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8014204	0.533	rs12889955	chr14:75172999	G/A	cg06637938	chr14:75390232	RPS6KL1	0.64	11.97	0.49	6.14e-29	Caffeine consumption;
LGG	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	7.09	0.31	4.99e-12	Resting heart rate;
LGG	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg13010199	chr12:38710504	ALG10B	0.45	7.91	0.35	1.85e-14	Morning vs. evening chronotype;
LGG	cis	rs7590720	0.959	rs2372684	chr2:216884764	C/A	cg12620499	chr2:216877984	MREG	0.77	14.39	0.56	4.61e-39	Alcohol dependence;
LGG	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg09137382	chr11:130731461	NA	0.35	6.71	0.3	5.57e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg01028140	chr2:1542097	TPO	-0.43	-8.13	-0.35	3.91e-15	IgG glycosylation;
LGG	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg08079166	chr15:68083412	MAP2K5	-0.36	-7.94	-0.35	1.52e-14	Restless legs syndrome;
LGG	cis	rs4144027	0.967	rs10133399	chr14:104361843	A/T	cg26031613	chr14:104095156	KLC1	-0.42	-7.11	-0.31	4.32e-12	Blood metabolite levels;
LGG	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg10596483	chr8:143751796	JRK	0.58	9.39	0.4	2.77e-19	Schizophrenia;
LGG	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg06026331	chr20:60912101	LAMA5	0.71	12.87	0.51	1.25e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg06766960	chr11:133703094	NA	-0.58	-11.39	-0.47	1.16e-26	Childhood ear infection;
LGG	trans	rs6787172	0.677	rs1193506	chr3:157993471	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg01200585	chr1:228362443	C1orf69	0.48	8.06	0.35	6.76e-15	Diastolic blood pressure;
LGG	cis	rs3931	0.607	rs11676084	chr2:169703974	C/T	cg22278106	chr2:169746720	SPC25	0.54	7.73	0.34	6.84e-14	Monocyte count;
LGG	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.94e-11	Aortic root size;
LGG	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.57	-11.37	-0.47	1.34e-26	IgG glycosylation;
LGG	cis	rs2267708	0.504	rs3903523	chr7:124668032	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.09	-0.31	5.01e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	cis	rs889398	0.617	rs6499265	chr16:69897998	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.66	-0.34	1.13e-13	Body mass index;
LGG	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7633787	0.570	rs1905812	chr3:23124742	C/G	cg00327796	chr3:23032191	NA	-0.38	-6.96	-0.31	1.2e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.23e-21	Aortic root size;
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.21	0.36	2.22e-15	Alzheimer's disease;
LGG	cis	rs34845616	0.551	rs12576074	chr11:133686324	A/G	cg06067394	chr11:133789110	IGSF9B	-0.41	-7.11	-0.31	4.38e-12	Hand grip strength;
LGG	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.11	-0.43	7.87e-22	Total body bone mineral density;
LGG	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg04989706	chr14:50066350	PPIL5	-0.6	-9.82	-0.42	8.1899999999999992e-21	Carotid intima media thickness;
LGG	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg10523679	chr1:76189770	ACADM	0.81	14.71	0.56	1.88e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9309473	1.000	rs7580825	chr2:73635148	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.93	-0.35	1.67e-14	Metabolite levels;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.72	-0.38	4.91e-17	Life satisfaction;
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg13047869	chr3:10149882	C3orf24	0.48	7.83	0.34	3.28e-14	Alzheimer's disease;
LGG	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs4262150	0.810	rs55648940	chr5:151951656	C/T	cg12297329	chr5:152029980	NA	-0.81	-15.62	-0.59	1.76e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg24607181	chr17:41446203	NA	-0.3	-6.83	-0.3	2.71e-11	Menopause (age at onset);
LGG	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.85	-0.66	3.05e-59	Monocyte count;
LGG	cis	rs4742903	0.967	rs6479215	chr9:106885243	A/G	cg14250997	chr9:106856677	SMC2	-0.39	-8.31	-0.36	1.09e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg24189917	chr7:1970923	MAD1L1	-0.54	-7.93	-0.35	1.67e-14	Bipolar disorder;
LGG	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg27411982	chr8:10470053	RP1L1	0.44	7.28	0.32	1.49e-12	Neuroticism;
LGG	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-8.89	-0.38	1.33e-17	Height;
LGG	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg24699146	chr1:24152579	HMGCL	-0.27	-7.99	-0.35	1.11e-14	Immature fraction of reticulocytes;
LGG	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg26384229	chr12:38710491	ALG10B	0.98	22.08	0.72	2.42e-74	Bladder cancer;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs963731	0.579	rs1470914	chr2:39245756	T/G	cg04010122	chr2:39346883	SOS1	-0.75	-7.77	-0.34	5.05e-14	Corticobasal degeneration;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg14092988	chr3:52407081	DNAH1	0.29	7.89	0.34	2.22e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg03929089	chr4:120376271	NA	0.82	8.62	0.37	1.05e-16	Myopia (pathological);
LGG	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg04733989	chr22:42467013	NAGA	0.57	10.33	0.43	1.23e-22	Schizophrenia;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.07	-0.35	6.1e-15	IgG glycosylation;
LGG	cis	rs2562456	0.917	rs2681392	chr19:21695987	T/G	cg00806126	chr19:22604979	ZNF98	0.63	9.22	0.39	1.05e-18	Pain;
LGG	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg19980929	chr12:42632907	YAF2	-0.38	-8.52	-0.37	2.27e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs16866061	1.000	rs72972378	chr2:225372562	A/G	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	1.01e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.16	-0.32	3.29e-12	Total cholesterol levels;
LGG	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg00504896	chr12:9437009	LOC642846	-0.59	-12.49	-0.5	4.89e-31	Breast size;
LGG	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg05623727	chr3:50126028	RBM5	-0.4	-8.8	-0.38	2.68e-17	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg12458913	chr13:53173898	NA	0.55	9.97	0.42	2.37e-21	Lewy body disease;
LGG	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.79	-16.14	-0.6	8.24e-47	Caffeine consumption;
LGG	cis	rs9443645	0.527	rs1413968	chr6:79791042	A/G	cg18132916	chr6:79620363	NA	-0.26	-6.72	-0.3	5.2e-11	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg20587970	chr11:113659929	NA	-1.34	-24.01	-0.74	2.48e-83	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18876405	chr7:65276391	NA	-0.53	-9.34	-0.4	4.17e-19	Aortic root size;
LGG	cis	rs1018836	0.665	rs7000724	chr8:91516335	A/T	cg16814680	chr8:91681699	NA	-0.7	-11.94	-0.49	8.03e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg08305652	chr11:111469057	NA	-0.46	-9.31	-0.4	5e-19	Primary sclerosing cholangitis;
LGG	cis	rs1953600	0.837	rs3098105	chr10:81953266	C/T	cg04850286	chr10:81895943	PLAC9	0.44	9.79	0.41	1.09e-20	Sarcoidosis;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.82	0.42	8.54e-21	Schizophrenia;
LGG	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg23625390	chr15:77176239	SCAPER	0.46	8.87	0.38	1.57e-17	Blood metabolite levels;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.32	6.72	0.3	5.4e-11	Schizophrenia;
LGG	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg06606381	chr12:133084897	FBRSL1	-0.93	-9.57	-0.41	6.54e-20	Depression;
LGG	cis	rs6496044	0.568	rs11855789	chr15:86066403	G/A	cg13263323	chr15:86062960	AKAP13	-0.37	-8.2	-0.36	2.32e-15	Interstitial lung disease;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.8	-0.34	4.01e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg06916706	chr16:4465613	CORO7	0.71	12.25	0.49	4.43e-30	Schizophrenia;
LGG	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg02187348	chr16:89574699	SPG7	0.62	10.27	0.43	1.97e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg15268244	chr15:77196840	NA	-0.32	-7.2	-0.32	2.49e-12	Blood metabolite levels;
LGG	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg08125733	chr17:73851984	WBP2	0.71	10.82	0.45	1.71e-24	Psoriasis;
LGG	cis	rs25645	0.744	rs66826786	chr17:38206092	T/C	cg17467752	chr17:38218738	THRA	-0.7	-12.35	-0.5	1.76e-30	Myeloid white cell count;
LGG	cis	rs4740619	0.588	rs1328278	chr9:16030535	G/A	cg14451791	chr9:16040625	NA	-0.42	-11.23	-0.46	4.82e-26	Body mass index;
LGG	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs1355223	0.902	rs12800220	chr11:34701617	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.05	-0.31	6.62e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg17330251	chr7:94953956	PON1	-0.43	-8.38	-0.36	6.2e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.99e-12	Calcium levels;
LGG	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg15596359	chr8:11213517	TDH	0.43	8.81	0.38	2.62e-17	Retinal vascular caliber;
LGG	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg07395648	chr5:131743802	NA	-0.43	-9.14	-0.39	1.93e-18	Blood metabolite levels;
LGG	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg24011408	chr12:48396354	COL2A1	0.48	7.42	0.33	5.82e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg20744362	chr22:50050164	C22orf34	0.36	7.06	0.31	6.16e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg21775007	chr8:11205619	TDH	-0.76	-13.14	-0.52	9.51e-34	Retinal vascular caliber;
LGG	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg12573674	chr2:1569213	NA	-0.65	-10.37	-0.43	8.53e-23	IgG glycosylation;
LGG	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg13385794	chr1:248469461	NA	0.44	7.27	0.32	1.5e-12	Common traits (Other);
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.39	0.36	5.94e-16	Bipolar disorder;
LGG	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg07243736	chr16:783730	NARFL	0.6	10.09	0.42	9.12e-22	Height;
LGG	cis	rs9534288	0.783	rs1126366	chr13:46633148	C/G	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-10.51	-0.44	2.56e-23	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.33	-0.32	1.02e-12	Life satisfaction;
LGG	cis	rs12249377	0.519	rs12259401	chr10:92594121	T/G	cg14313238	chr10:92632228	RPP30	0.39	7.0	0.31	8.95e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs3087591	1.000	rs2051506	chr17:29699860	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.64	-0.56	3.74e-40	Hip circumference;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.93	-0.57	1.96e-41	Platelet count;
LGG	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg02073558	chr3:44770973	ZNF501	-0.67	-12.53	-0.5	3.1e-31	Depressive symptoms;
LGG	cis	rs440932	0.747	rs330946	chr8:9022177	A/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.76	0.3	4.19e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs67311347	1.000	rs9822644	chr3:40426609	G/A	cg13683864	chr3:40499215	RPL14	-1.15	-25.98	-0.77	1.83e-92	Renal cell carcinoma;
LGG	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.63	-12.18	-0.49	8.63e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11971779	0.680	rs4732369	chr7:139069173	C/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.0	0.31	8.94e-12	Diisocyanate-induced asthma;
LGG	trans	rs7944735	0.817	rs7924699	chr11:47893120	A/T	cg15704280	chr7:45808275	SEPT13	0.6	7.61	0.33	1.56e-13	Intraocular pressure;
LGG	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg27478167	chr7:817139	HEATR2	-0.48	-6.84	-0.3	2.53e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg21395723	chr22:39101663	GTPBP1	0.38	6.66	0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.69	-11.64	-0.48	1.19e-27	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg20607798	chr8:58055168	NA	0.72	8.12	0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9596837	0.514	rs2785815	chr13:54274882	A/G	ch.13.53330881F	chr13:54432880	NA	-0.41	-6.65	-0.3	8.2e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.56	-0.37	1.71e-16	Alzheimer's disease (survival time);
LGG	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg21918786	chr6:109611834	NA	-0.48	-8.87	-0.38	1.56e-17	Reticulocyte fraction of red cells;
LGG	cis	rs763121	0.853	rs9610993	chr22:39042818	C/A	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.12	17.1	0.62	3.5e-51	Platelet count;
LGG	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg08200770	chr17:80723486	TBCD	-0.47	-8.37	-0.36	6.66e-16	Glycated hemoglobin levels;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg05793240	chr7:2802953	GNA12	0.35	8.06	0.35	6.51e-15	Height;
LGG	cis	rs8077059	1.000	rs4793565	chr17:55809518	C/G	cg12582317	chr17:55822272	NA	0.39	7.12	0.31	4.25e-12	Sex hormone-binding globulin levels;
LGG	cis	rs7483296	0.705	rs898614	chr11:115408679	C/T	cg02820646	chr11:115398838	NA	0.43	7.54	0.33	2.56e-13	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.76	-0.51	3.63e-32	Obesity-related traits;
LGG	cis	rs7923609	0.967	rs10761762	chr10:65184717	T/C	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg04691961	chr3:161091175	C3orf57	-0.66	-15.99	-0.6	3.94e-46	Morning vs. evening chronotype;
LGG	cis	rs6500637	0.591	rs2075466	chr16:4872970	G/C	cg08329684	chr16:4932620	PPL	0.46	8.69	0.37	6.16e-17	Cancer;
LGG	cis	rs6489882	0.836	rs10774676	chr12:113362407	C/T	cg25319449	chr12:113376135	OAS3	0.41	7.44	0.33	4.86e-13	Chronic lymphocytic leukemia;
LGG	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg02002194	chr4:3960332	NA	0.42	7.72	0.34	7.13e-14	Retinal vascular caliber;
LGG	cis	rs2346177	0.576	rs1530621	chr2:46688688	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	8.9	0.38	1.23e-17	HDL cholesterol;
LGG	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	7.81	0.34	3.93e-14	Menarche (age at onset);
LGG	cis	rs365132	0.875	rs2962844	chr5:176333748	G/T	cg16309518	chr5:176445507	NA	-0.51	-11.14	-0.46	1.1e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06481639	chr22:41940642	POLR3H	0.56	7.95	0.35	1.44e-14	Cannabis dependence symptom count;
LGG	cis	rs4006360	0.629	rs2132842	chr17:39234214	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.19	-0.46	6.96e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg05294307	chr14:35346193	BAZ1A	-0.49	-7.0	-0.31	8.98e-12	Psoriasis;
LGG	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg23649088	chr2:200775458	C2orf69	0.56	8.89	0.38	1.35e-17	Schizophrenia;
LGG	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg04691961	chr3:161091175	C3orf57	-0.44	-9.01	-0.39	5.39e-18	Morning vs. evening chronotype;
LGG	cis	rs526231	0.543	rs152137	chr5:102560063	C/T	cg23492399	chr5:102201601	PAM	-0.6	-8.62	-0.37	1.03e-16	Primary biliary cholangitis;
LGG	cis	rs15676	0.947	rs2805103	chr9:131598897	T/A	cg04621255	chr9:131581398	ENDOG	-0.42	-7.36	-0.32	8.6e-13	Blood metabolite levels;
LGG	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg06623918	chr6:96969491	KIAA0776	-0.78	-15.31	-0.58	4.17e-43	Headache;
LGG	cis	rs34172651	0.917	rs11074654	chr16:24813743	A/G	cg02428538	chr16:24856791	SLC5A11	-0.45	-7.78	-0.34	4.61e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg12486710	chr1:178512616	C1orf220	0.42	8.39	0.36	5.89e-16	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs877282	0.853	rs7079299	chr10:756455	A/G	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	cg07928641	chr1:182991847	LAMC1	0.45	9.04	0.39	4.44e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4006360	0.685	rs2320221	chr17:39251266	A/C	cg16985667	chr17:39306289	KRTAP4-5	0.45	9.66	0.41	3.07e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs6429082	0.818	rs291391	chr1:235649955	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.15	0.43	5.23e-22	Adiposity;
LGG	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg17971929	chr21:40555470	PSMG1	-0.48	-8.0	-0.35	1.04e-14	Menarche (age at onset);
LGG	cis	rs360798	0.532	rs12994674	chr2:62996645	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.9	-0.31	1.72e-11	Coronary artery disease;
LGG	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg24692254	chr21:30365293	RNF160	-0.77	-16.07	-0.6	1.63e-46	Dental caries;
LGG	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11764359	chr7:65958608	NA	0.57	9.57	0.41	6.57e-20	Calcium levels;
LGG	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg13647721	chr17:30228624	UTP6	0.65	8.73	0.38	4.78e-17	Hip circumference adjusted for BMI;
LGG	cis	rs6547631	0.622	rs12845	chr2:85925848	C/G	cg24620635	chr2:85921963	GNLY	0.5	10.02	0.42	1.66e-21	Blood protein levels;
LGG	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08704250	chr15:31115839	NA	-0.46	-8.47	-0.37	3.3e-16	Huntington's disease progression;
LGG	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.45	-0.4	1.72e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs12545109	0.800	rs1440746	chr8:57415912	G/A	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	10.38	0.43	8.04e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3870371	1.000	rs7816221	chr8:122696143	A/G	cg15679747	chr8:122755315	NA	0.34	6.68	0.3	6.84e-11	Periodontal disease-related phenotypes;
LGG	cis	rs4704187	0.687	rs4345300	chr5:74376571	C/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	cis	rs7849585	0.830	rs7861829	chr9:139120043	C/G	cg14094347	chr9:139131620	QSOX2	0.49	9.4	0.4	2.47e-19	Height;
LGG	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg00405596	chr8:11794950	NA	0.43	7.39	0.32	6.95e-13	Mood instability;
LGG	trans	rs17685	0.725	rs4476928	chr7:75642107	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.05	-25.1	-0.76	2.04e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10751667	0.600	rs10751665	chr11:941300	G/A	cg22143635	chr11:980567	AP2A2	0.42	7.74	0.34	6.41e-14	Alzheimer's disease (late onset);
LGG	cis	rs4356975	0.563	rs6600896	chr4:69986718	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.82	0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg24642844	chr7:1081250	C7orf50	-0.6	-7.87	-0.34	2.54e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg00080972	chr5:178986291	RUFY1	-0.5	-8.61	-0.37	1.2e-16	Lung cancer;
LGG	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg19700328	chr14:106028568	NA	-0.6	-10.1	-0.42	8.12e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2742417	0.967	rs2742462	chr3:45774696	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.39	-0.32	6.94e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4148087	1.000	rs4148101	chr21:43640183	G/A	cg10192877	chr21:43641690	ABCG1	-0.41	-7.09	-0.31	5.09e-12	Eating disorder in bipolar disorder;
LGG	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg21130718	chr4:1044621	NA	0.39	7.7	0.34	8.27e-14	Recombination rate (males);
LGG	cis	rs7173389	1.000	rs7172808	chr15:73663632	A/G	cg01796676	chr15:73680284	NA	0.48	8.33	0.36	9.54e-16	Resting heart rate;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.12e-25	Corneal astigmatism;
LGG	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.52	0.4	9.37e-20	Diabetic retinopathy;
LGG	cis	rs2287838	0.716	rs7256625	chr19:10007171	C/G	cg00846166	chr19:10022875	OLFM2	0.33	7.44	0.33	5.09e-13	Sleep duration;
LGG	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg00701064	chr4:6280414	WFS1	0.7	15.15	0.58	2.09e-42	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	6.99	0.31	9.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9463078	0.691	rs12194311	chr6:45329048	C/A	cg25276700	chr6:44698697	NA	0.32	6.73	0.3	5.12e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11644478	chr21:40555479	PSMG1	0.96	18.04	0.64	1.81e-55	Cognitive function;
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.96	-0.31	1.17e-11	Bipolar disorder;
LGG	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg06951627	chr6:26196580	NA	0.51	7.4	0.33	6.39e-13	Gout;Renal underexcretion gout;
LGG	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg24642439	chr20:33292090	TP53INP2	0.55	9.22	0.39	1.02e-18	Glomerular filtration rate (creatinine);
LGG	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg08344181	chr3:125677491	NA	-0.67	-7.56	-0.33	2.13e-13	Depression;
LGG	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23248424	chr5:179741104	GFPT2	-0.57	-9.61	-0.41	4.65e-20	Height;
LGG	cis	rs6663390	0.831	rs2267894	chr1:208085735	G/A	cg03990033	chr1:208084030	CD34	0.55	7.73	0.34	6.67e-14	Facial morphology (factor 18);
LGG	trans	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.66	-11.34	-0.47	1.85e-26	Platelet distribution width;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg25632114	chr8:95732714	DPY19L4	0.4	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-12.69	-0.51	6.83e-32	Chronic sinus infection;
LGG	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.2e-45	Glomerular filtration rate (creatinine);
LGG	trans	rs78049276	0.736	rs6842241	chr4:148400819	C/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-8.11	-0.35	4.54e-15	Pulse pressure;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.51	9.72	0.41	1.98e-20	Obesity-related traits;
LGG	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs7584262	1.000	rs7584262	chr2:42250549	C/T	cg19376973	chr2:42229025	NA	0.65	10.71	0.45	4.72e-24	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00367659	chr17:33288544	CCT6B;ZNF830	0.47	7.7	0.34	8.12e-14	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11530914	chr16:67281528	FHOD1;SLC9A5	0.4	6.85	0.3	2.29e-11	Gut microbiome composition (summer);
LGG	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs8050755	0.764	rs2516734	chr16:2105335	C/G	cg04515572	chr16:2107413	TSC2	-0.64	-8.95	-0.38	8.41e-18	Major depressive disorder;
LGG	cis	rs2797369	0.713	rs1928068	chr6:101589545	G/A	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.43	0.36	4.48e-16	Platelet count;
LGG	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.09	0.31	5.09e-12	Bladder cancer;
LGG	trans	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg06521331	chr12:34319734	NA	0.44	7.45	0.33	4.58e-13	Morning vs. evening chronotype;
LGG	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg02891314	chr5:179741120	GFPT2	0.62	11.65	0.48	1.11e-27	Height;
LGG	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.04	-0.31	6.99e-12	Type 2 diabetes;
LGG	cis	rs950027	0.620	rs1153857	chr15:45659095	G/T	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.42	0.36	4.74e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs7326068	0.610	rs7990231	chr13:21337838	C/T	cg04906043	chr13:21280425	IL17D	-0.44	-7.14	-0.31	3.72e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs2066819	1.000	rs117779516	chr12:56750872	G/C	cg26714650	chr12:56694279	CS	-1.57	-14.39	-0.56	4.76e-39	Psoriasis vulgaris;
LGG	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg02855558	chr7:158107723	PTPRN2	-0.41	-7.39	-0.32	6.85e-13	Calcium levels;
LGG	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.37e-50	Platelet distribution width;
LGG	cis	rs3820928	0.967	rs16822905	chr2:227770727	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.81e-12	Pulmonary function;
LGG	cis	rs17208368	0.628	rs4784470	chr16:55092840	T/C	cg11181171	chr16:55090946	NA	0.46	7.67	0.34	9.97e-14	Hypospadias;
LGG	cis	rs7071206	0.740	rs2048781	chr10:79422975	T/C	cg07817648	chr10:79422355	NA	-0.71	-13.7	-0.54	4.31e-36	Bone mineral density;
LGG	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs9443189	0.570	rs6931578	chr6:76272310	C/T	cg01950844	chr6:76311363	SENP6	0.76	9.96	0.42	2.55e-21	Prostate cancer;
LGG	cis	rs2371030	0.833	rs1024898	chr2:211593520	A/G	cg18417063	chr2:211583084	NA	-0.57	-10.49	-0.44	2.95e-23	Non-small cell lung cancer;
LGG	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.45	0.33	4.56e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11792861	0.926	rs11787878	chr9:111866749	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg10167378	chr1:228756711	NA	0.71	9.48	0.4	1.3e-19	Chronic lymphocytic leukemia;
LGG	cis	rs3733418	0.860	rs2056252	chr4:165947490	A/G	cg10852876	chr4:165953100	TRIM60	0.52	7.19	0.32	2.68e-12	Obesity-related traits;
LGG	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.29	-0.36	1.2e-15	Depression;
LGG	cis	rs17381785	0.545	rs1494947	chr4:14969983	T/G	cg12377275	chr4:15005593	CPEB2	0.74	14.84	0.57	5.12e-41	Urate levels in overweight individuals;
LGG	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg21385522	chr1:16154831	NA	-0.97	-15.15	-0.58	2.04e-42	Dilated cardiomyopathy;
LGG	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg18129748	chr3:49941408	MST1R	0.21	6.79	0.3	3.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg10505658	chr17:80084571	CCDC57	0.42	8.6	0.37	1.27e-16	Life satisfaction;
LGG	cis	rs7975161	0.786	rs10861181	chr12:104651110	T/C	cg25273343	chr12:104657179	TXNRD1	-0.74	-10.55	-0.44	1.79e-23	Toenail selenium levels;
LGG	cis	rs4764487	0.760	rs2268009	chr12:6340388	A/G	cg08284733	chr12:6341482	CD9	0.36	9.76	0.41	1.36e-20	Mean platelet volume;
LGG	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg09461388	chr22:46763229	CELSR1	-0.71	-6.96	-0.31	1.14e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.52	0.83	1.28e-121	Prudent dietary pattern;
LGG	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg10523679	chr1:76189770	ACADM	0.82	15.69	0.59	8.13e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg04317338	chr11:64019027	PLCB3	0.66	7.88	0.34	2.35e-14	Mean platelet volume;
LGG	cis	rs2247341	0.965	rs13138643	chr4:1740675	G/A	cg08629884	chr4:1719983	TMEM129	-0.56	-10.67	-0.44	6.57e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8067545	0.750	rs62067555	chr17:20001502	T/C	cg13482628	chr17:19912719	NA	0.63	12.4	0.5	1.13e-30	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs2976388	1.000	rs1045605	chr8:143764101	C/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.31	-0.43	1.41e-22	Urinary tract infection frequency;
LGG	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg02002194	chr4:3960332	NA	0.4	7.18	0.32	2.75e-12	Morning vs. evening chronotype;
LGG	cis	rs7512552	0.966	rs10788873	chr1:150250534	T/A	cg15654264	chr1:150340011	RPRD2	-0.39	-7.92	-0.35	1.75e-14	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg02023728	chr11:77925099	USP35	0.44	7.59	0.33	1.74e-13	Testicular germ cell tumor;
LGG	trans	rs3857536	0.730	rs7766281	chr6:66988573	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.0	-0.31	8.93e-12	Blood trace element (Cu levels);
LGG	cis	rs4262150	0.883	rs72799188	chr5:152186304	A/T	cg12297329	chr5:152029980	NA	-0.7	-13.15	-0.52	8.67e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs7523273	0.586	rs7518047	chr1:207899332	T/C	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.75	-0.38	4.07e-17	Schizophrenia;
LGG	cis	rs737693	0.915	rs28381684	chr11:102737192	A/T	cg19620758	chr11:102826565	MMP13	0.53	6.67	0.3	7.4e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.56	-0.37	1.63e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg01028140	chr2:1542097	TPO	-0.49	-9.05	-0.39	3.97e-18	IgG glycosylation;
LGG	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.85	0.51	1.62e-32	Hip circumference adjusted for BMI;
LGG	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg02631450	chr22:32366979	NA	0.92	9.33	0.4	4.4e-19	Childhood ear infection;
LGG	trans	rs7819412	0.558	rs11777486	chr8:10908287	C/A	cg15556689	chr8:8085844	FLJ10661	0.43	7.06	0.31	6.32e-12	Triglycerides;
LGG	cis	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg21775007	chr8:11205619	TDH	0.57	9.47	0.4	1.39e-19	Triglycerides;
LGG	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.65	0.3	8.05e-11	Vitiligo;
LGG	cis	rs7508	0.640	rs6988638	chr8:17911732	C/G	cg18067069	chr8:17937731	ASAH1	-0.33	-7.48	-0.33	3.81e-13	Atrial fibrillation;
LGG	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs3219090	0.962	rs1865220	chr1:226602286	C/T	cg17127702	chr1:226594323	PARP1	-0.39	-12.35	-0.5	1.69e-30	Melanoma;
LGG	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg05444541	chr17:17804740	TOM1L2	0.7	16.55	0.61	1.11e-48	Total body bone mineral density;
LGG	trans	rs3206736	0.548	rs2526545	chr7:35020183	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.21	0.32	2.27e-12	Diastolic blood pressure;
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.41	-0.33	6.11e-13	Neuroticism;
LGG	cis	rs9513627	1.000	rs3928271	chr13:100186958	G/A	cg25919922	chr13:100150906	NA	0.73	7.69	0.34	9e-14	Obesity-related traits;
LGG	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg14673194	chr17:80132900	CCDC57	0.41	7.2	0.32	2.42e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg07538946	chr5:131705188	SLC22A5	-0.64	-7.62	-0.33	1.46e-13	Rheumatoid arthritis;
LGG	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg00495681	chr13:53174319	NA	0.8	17.23	0.63	9.06e-52	Lewy body disease;
LGG	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg16339924	chr4:17578868	LAP3	-0.64	-10.75	-0.45	3.3e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg19508488	chr2:152266495	RIF1	0.59	10.44	0.44	4.86e-23	Lung cancer;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.63	-0.51	1.27e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg01966878	chr4:90757139	SNCA	-0.34	-7.07	-0.31	5.85e-12	Dementia with Lewy bodies;
LGG	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.75	-0.34	5.75e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9354308	0.764	rs2351724	chr6:66602952	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.57	-0.33	2.01e-13	Initial pursuit acceleration;
LGG	cis	rs2285947	0.967	rs2285944	chr7:21582964	A/T	cg04471919	chr7:21584483	DNAH11	0.5	13.72	0.54	3.55e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg11859384	chr17:80120422	CCDC57	-0.46	-7.97	-0.35	1.25e-14	Life satisfaction;
LGG	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	10.98	0.45	4.5e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg26031613	chr14:104095156	KLC1	1.14	27.5	0.79	2.2e-99	Body mass index;
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.01	-0.55	2e-37	Alzheimer's disease;
LGG	cis	rs9487094	1.000	rs35056702	chr6:109736326	C/T	cg16315928	chr6:109776240	MICAL1	0.47	7.97	0.35	1.26e-14	Height;
LGG	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg24397884	chr7:158709396	WDR60	-1.04	-24.48	-0.75	1.65e-85	Height;
LGG	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg00012203	chr2:219082015	ARPC2	-0.84	-17.1	-0.62	3.58e-51	Colorectal cancer;
LGG	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg03433033	chr1:76189801	ACADM	0.68	10.12	0.43	7.09e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg11859384	chr17:80120422	CCDC57	0.4	6.97	0.31	1.09e-11	Life satisfaction;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg15971980	chr6:150254442	NA	0.46	8.58	0.37	1.5e-16	Lung cancer;
LGG	cis	rs3820068	0.603	rs6429769	chr1:15968610	C/G	cg05660106	chr1:15850417	CASP9	0.85	17.7	0.64	6.6e-54	Systolic blood pressure;
LGG	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg07636037	chr3:49044803	WDR6	0.91	16.76	0.61	1.27e-49	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg26655873	chr3:72818019	SHQ1	0.34	6.9	0.31	1.76e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4639966	0.684	rs487177	chr11:118657297	C/G	cg20110707	chr11:118481992	PHLDB1	-0.42	-6.75	-0.3	4.35e-11	Systemic lupus erythematosus;
LGG	cis	rs36051895	0.589	rs1322222	chr9:5190444	A/G	cg02405213	chr9:5042618	JAK2	-0.78	-14.68	-0.56	2.4e-40	Pediatric autoimmune diseases;
LGG	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg10483660	chr13:112241077	NA	0.35	7.73	0.34	6.82e-14	Hepatitis;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.52	0.83	1.28e-121	Prudent dietary pattern;
LGG	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg15704280	chr7:45808275	SEPT13	0.69	9.49	0.4	1.22e-19	Intraocular pressure;
LGG	cis	rs4262150	0.739	rs72795394	chr5:151948590	G/T	cg12297329	chr5:152029980	NA	-0.79	-15.37	-0.58	2.36e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26306683	chr17:18585705	ZNF286B	0.48	9.03	0.39	4.62e-18	Educational attainment (years of education);
LGG	cis	rs2011503	0.509	rs11668721	chr19:19760916	G/A	cg11584989	chr19:19387371	SF4	0.59	8.41	0.36	4.96e-16	Bipolar disorder;
LGG	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08491964	chr18:53255771	TCF4	0.46	7.2	0.32	2.46e-12	Gut microbiome composition (summer);
LGG	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.55e-12	Hemoglobin concentration;
LGG	cis	rs763121	0.853	rs138716	chr22:39146527	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	16.51	0.61	1.74e-48	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11835582	chr4:175205044	FBXO8;KIAA1712	0.42	6.71	0.3	5.87e-11	Cognitive performance;
LGG	cis	rs911555	0.755	rs34411783	chr14:103900639	G/A	cg24130564	chr14:104152367	KLC1	0.38	7.08	0.31	5.41e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg08048268	chr3:133502702	NA	0.42	7.68	0.34	9.56e-14	Iron status biomarkers;
LGG	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg17202724	chr17:61916730	SMARCD2	-0.39	-7.43	-0.33	5.27e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.5	-0.44	2.87e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04798930	chr2:37193060	STRN	0.41	6.98	0.31	1.05e-11	Body mass index;
LGG	cis	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.95	-0.35	1.41e-14	Resting heart rate;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg15971980	chr6:150254442	NA	0.45	8.45	0.37	3.68e-16	Lung cancer;
LGG	cis	rs80282103	0.618	rs11250264	chr10:1151723	A/C	cg08668510	chr10:1095578	IDI1	0.77	7.63	0.33	1.32e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs2712184	0.967	rs11892032	chr2:217668981	G/A	cg05032264	chr2:217675019	NA	-0.54	-12.56	-0.5	2.35e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs4774899	1.000	rs12916478	chr15:57502856	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.87	-0.3	2.09e-11	Urinary tract infection frequency;
LGG	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg25457927	chr22:38595422	NA	-0.41	-10.15	-0.43	5.67e-22	Cutaneous nevi;
LGG	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg00290607	chr11:67383545	NA	-0.49	-8.67	-0.37	7.43e-17	Mean corpuscular volume;
LGG	trans	rs9929218	0.906	rs4783571	chr16:68806778	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.82	-0.51	2e-32	Colorectal cancer;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.44	-8.77	-0.38	3.48e-17	Schizophrenia;
LGG	cis	rs4918072	0.637	rs61861137	chr10:105613383	A/G	cg11005552	chr10:105648138	OBFC1	0.68	10.26	0.43	2.19e-22	Coronary artery disease;
LGG	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	9.43	0.4	2.05e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	10.3	0.43	1.51e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9462027	1.000	rs9296133	chr6:34777533	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-8.38	-0.36	6.22e-16	Systemic lupus erythematosus;
LGG	cis	rs16854884	0.657	rs6769910	chr3:143737830	C/G	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.82	0.48	2.28e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg05182265	chr7:156933206	UBE3C	-0.35	-7.18	-0.32	2.78e-12	Body mass index;
LGG	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	10.83	0.45	1.61e-24	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg07930552	chr6:133119739	C6orf192	0.84	10.77	0.45	2.77e-24	Type 2 diabetes nephropathy;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg04098458	chr2:149402448	EPC2	-0.41	-6.87	-0.3	2.09e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs2290159	0.800	rs5746193	chr3:12658601	C/T	cg23032965	chr3:12705835	RAF1	0.67	9.79	0.41	1.05e-20	Cholesterol, total;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.59e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.34	-7.88	-0.34	2.28e-14	Schizophrenia;
LGG	cis	rs7635838	0.751	rs9811658	chr3:11395833	A/G	cg00170343	chr3:11313890	ATG7	0.49	8.2	0.36	2.38e-15	HDL cholesterol;
LGG	trans	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg02002194	chr4:3960332	NA	0.5	8.89	0.38	1.4e-17	Neuroticism;
LGG	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg02269571	chr22:50332266	NA	0.66	8.76	0.38	3.6e-17	Schizophrenia;
LGG	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-14.04	-0.55	1.44e-37	Morning vs. evening chronotype;
LGG	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20916646	chr4:852691	GAK	0.74	11.5	0.47	4.41e-27	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.38	0.36	6.31e-16	Tonsillectomy;
LGG	cis	rs9362426	0.524	rs76730959	chr6:88138102	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.97	-14.7	-0.56	2.03e-40	Depressive episodes in bipolar disorder;
LGG	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	9.79	0.41	1.06e-20	Aortic root size;
LGG	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg27087555	chr16:88793112	FAM38A	-1.37	-19.93	-0.68	2.93e-64	Plateletcrit;
LGG	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-12.49	-0.5	4.85e-31	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.52	0.56	1.3e-39	Obesity-related traits;
LGG	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg21238619	chr17:78079768	GAA	-0.33	-7.13	-0.31	3.83e-12	Yeast infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04371633	chr14:65381025	CHURC1	0.45	7.42	0.33	5.52e-13	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg21132104	chr15:45694354	SPATA5L1	-0.73	-10.98	-0.45	4.44e-25	Homoarginine levels;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.82	0.38	2.4e-17	Platelet count;
LGG	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg02931644	chr1:25747376	RHCE	-0.41	-9.06	-0.39	3.74e-18	Erythrocyte sedimentation rate;
LGG	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg00012203	chr2:219082015	ARPC2	-0.68	-12.35	-0.5	1.73e-30	Colorectal cancer;
LGG	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg26248373	chr2:1572462	NA	-0.72	-8.46	-0.37	3.52e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg05091796	chr16:4465799	CORO7	-0.61	-9.54	-0.41	8.02e-20	Schizophrenia;
LGG	cis	rs12200782	0.872	rs10484440	chr6:26453742	C/T	cg11502198	chr6:26597334	ABT1	0.77	7.83	0.34	3.31e-14	Small cell lung carcinoma;
LGG	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg12419862	chr22:24373484	LOC391322	0.83	12.83	0.51	1.9e-32	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg24375607	chr4:120327624	NA	0.67	10.86	0.45	1.3e-24	Corneal astigmatism;
LGG	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg25039879	chr17:56429692	SUPT4H1	0.56	8.04	0.35	7.82e-15	Cognitive test performance;
LGG	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg02297831	chr4:17616191	MED28	0.5	9.46	0.4	1.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg26384229	chr12:38710491	ALG10B	0.61	11.87	0.48	1.52e-28	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg22907277	chr7:1156413	C7orf50	0.75	9.84	0.42	7.15e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg26384229	chr12:38710491	ALG10B	0.82	16.44	0.61	3.76e-48	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg12708336	chr17:41446283	NA	-0.31	-7.13	-0.31	3.81e-12	Menopause (age at onset);
LGG	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs2274273	0.624	rs1972221	chr14:55785381	C/A	cg04306507	chr14:55594613	LGALS3	0.54	12.51	0.5	3.98e-31	Protein biomarker;
LGG	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03352830	chr11:487213	PTDSS2	0.87	11.33	0.47	1.93e-26	Body mass index;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg15454534	chr1:248569605	OR2T1	0.38	6.86	0.3	2.2e-11	Common traits (Other);
LGG	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg11584989	chr19:19387371	SF4	0.66	10.91	0.45	8.1e-25	Bipolar disorder;
LGG	cis	rs35079168	0.735	rs1887309	chr9:137308242	A/G	cg00753924	chr9:137298813	RXRA	0.43	7.93	0.35	1.61e-14	Intelligence;
LGG	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg11502198	chr6:26597334	ABT1	0.54	9.09	0.39	2.81e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg17127132	chr2:85788382	GGCX	-0.45	-7.9	-0.34	2.01e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4664304	0.658	rs2667012	chr2:160867553	G/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.91	-0.34	1.92e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6063312	1.000	rs6063312	chr20:47343059	G/T	cg18078177	chr20:47281410	PREX1	0.73	8.78	0.38	3.29e-17	Tonometry;
LGG	cis	rs7766436	1.000	rs7766436	chr6:22598259	C/T	cg13666174	chr6:22585274	NA	-0.44	-10.3	-0.43	1.5e-22	Coronary artery disease;
LGG	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	17.16	0.62	1.9e-51	Response to antipsychotic treatment;
LGG	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-9.98	-0.42	2.27e-21	Morning vs. evening chronotype;
LGG	cis	rs745570	1.000	rs745570	chr17:77781725	A/G	cg25456068	chr17:77800718	NA	-0.54	-11.82	-0.48	2.4e-28	Breast cancer;
LGG	cis	rs72925845	0.577	rs691346	chr17:76429137	G/T	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs7572733	0.773	rs11690491	chr2:198514924	C/T	cg00792783	chr2:198669748	PLCL1	0.41	6.73	0.3	4.95e-11	Dermatomyositis;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.13	-0.31	3.82e-12	Personality dimensions;
LGG	cis	rs1620921	0.565	rs28448569	chr6:161271706	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg08999081	chr20:33150536	PIGU	-0.31	-7.18	-0.32	2.71e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7113850	0.541	rs7948382	chr11:24246608	T/C	ch.11.24196551F	chr11:24239977	NA	0.92	10.55	0.44	1.79e-23	Bone fracture in osteoporosis;
LGG	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg01411142	chr8:19674711	INTS10	0.48	7.37	0.32	7.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	trans	rs7939886	0.920	rs74962317	chr11:56036589	C/T	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2816316	1.000	rs2816316	chr1:192536813	C/A	cg02586212	chr1:192544902	RGS1	0.45	9.22	0.39	1.09e-18	Celiac disease;
LGG	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg21775007	chr8:11205619	TDH	-0.57	-9.41	-0.4	2.34e-19	Neuroticism;
LGG	cis	rs2067615	0.524	rs7309351	chr12:107077432	C/T	cg15890332	chr12:107067104	RFX4	-0.44	-12.99	-0.52	3.98e-33	Heart rate;
LGG	cis	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg19171272	chr22:38449367	NA	-0.62	-12.24	-0.49	4.75e-30	Glioblastoma;Glioma;
LGG	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg10483660	chr13:112241077	NA	-0.37	-7.92	-0.35	1.72e-14	Hepatitis;
LGG	cis	rs1847505	0.609	rs7327556	chr13:61487578	C/A	cg25164009	chr13:61490935	NA	0.58	9.03	0.39	4.69e-18	Polychlorinated biphenyl levels;
LGG	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg25919922	chr13:100150906	NA	-0.73	-7.54	-0.33	2.46e-13	Obesity-related traits;
LGG	cis	rs11650494	0.710	rs16948078	chr17:47474800	C/T	cg08112188	chr17:47440006	ZNF652	-1.08	-11.86	-0.48	1.57e-28	Prostate cancer;
LGG	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg13010199	chr12:38710504	ALG10B	0.45	8.0	0.35	9.88e-15	Morning vs. evening chronotype;
LGG	cis	rs7928758	0.887	rs117735303	chr11:134271893	C/T	cg15243474	chr11:134282918	B3GAT1	1.24	16.66	0.61	3.55e-49	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg21775007	chr8:11205619	TDH	0.84	15.73	0.59	5.41e-45	Retinal vascular caliber;
LGG	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg04455712	chr21:45112962	RRP1B	0.52	9.61	0.41	4.78e-20	Mean corpuscular volume;
LGG	cis	rs10463554	0.963	rs11242485	chr5:102382034	G/A	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs10884984	0.802	rs17127463	chr10:112263999	A/G	cg18756771	chr10:112261994	DUSP5	0.66	12.25	0.49	4.57e-30	Facial morphology (factor 22);
LGG	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.69	-0.3	6.49e-11	Pediatric bone mineral density (spine);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09986774	chr16:69166346	CHTF8;CIRH1A	0.6	7.1	0.31	4.76e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg12458913	chr13:53173898	NA	0.81	18.07	0.64	1.23e-55	Lewy body disease;
LGG	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg23933602	chr10:16859644	RSU1	0.67	9.8	0.41	9.85e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.09	-0.39	2.92e-18	Prostate cancer;
LGG	trans	rs1459104	0.704	rs12806568	chr11:54892378	G/A	cg03929089	chr4:120376271	NA	0.72	6.97	0.31	1.08e-11	Body mass index;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.36	0.32	8.2e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.63	-0.37	9.91e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs5762813	0.614	rs59203761	chr22:29293369	C/T	cg15103426	chr22:29168792	CCDC117	0.64	6.7	0.3	6.21e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg16511985	chr3:153974050	SGEF	0.49	8.19	0.36	2.61e-15	Coronary artery disease;
LGG	cis	rs7712401	0.580	rs35902490	chr5:122323398	G/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs17453880	0.929	rs7725525	chr5:152041960	C/G	cg10931792	chr5:152022470	NA	-0.39	-8.43	-0.36	4.46e-16	Subjective well-being;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg23758822	chr17:41437982	NA	0.87	15.48	0.58	7.51e-44	Menopause (age at onset);
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg13282195	chr8:144660772	NAPRT1	0.94	7.34	0.32	9.73e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	9.49	0.4	1.23e-19	Blood metabolite levels;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.18	-0.32	2.79e-12	Longevity;Endometriosis;
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7760949	0.889	rs9475787	chr6:13926102	G/C	cg27413430	chr6:13925136	RNF182	0.49	7.42	0.33	5.53e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg00405596	chr8:11794950	NA	0.65	11.5	0.47	4.36e-27	Myopia (pathological);
LGG	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.29	-0.36	1.27e-15	Retinal vascular caliber;
LGG	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg07636037	chr3:49044803	WDR6	0.54	7.22	0.32	2.09e-12	Menarche (age at onset);
LGG	cis	rs3820928	0.845	rs1917126	chr2:227840923	G/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.14e-14	Pulmonary function;
LGG	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs4538187	0.855	rs11125981	chr2:63911761	G/A	cg02541582	chr2:64069798	UGP2	-0.53	-10.95	-0.45	5.65e-25	Systolic blood pressure;
LGG	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-11.83	-0.48	2.2e-28	Pancreatic cancer;
LGG	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24429831	chr19:36120171	RBM42	0.46	7.39	0.32	6.83e-13	Cognitive performance;
LGG	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.73	12.77	0.51	3.36e-32	Response to antipsychotic treatment;
LGG	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg04374321	chr14:90722782	PSMC1	-0.51	-8.63	-0.37	1.02e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs834811	0.829	rs10252049	chr7:135903178	G/A	cg01726295	chr7:135938950	NA	-0.35	-6.92	-0.31	1.53e-11	Post-traumatic stress disorder;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg23978390	chr7:1156363	C7orf50	0.44	6.69	0.3	6.58e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs867371	0.929	rs1501371	chr15:82460440	A/C	cg00614314	chr15:82944287	LOC80154	0.59	9.79	0.41	1.07e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs3857067	0.806	rs6825522	chr4:95108140	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.35	1.87e-14	QT interval;
LGG	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg08392591	chr16:89556376	ANKRD11	0.61	9.68	0.41	2.75e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg19635926	chr16:89946313	TCF25	0.69	6.76	0.3	4.25e-11	Skin colour saturation;
LGG	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg27432699	chr2:27873401	GPN1	0.68	14.05	0.55	1.28e-37	Oral cavity cancer;
LGG	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.54	-0.33	2.55e-13	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg26656751	chr17:43910226	CRHR1	0.49	8.95	0.38	8.61e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9880211	1.000	rs12695645	chr3:135990881	A/T	cg21827317	chr3:136751795	NA	-0.47	-6.81	-0.3	3.09e-11	Body mass index;Height;
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-11.65	-0.48	1.06e-27	Bipolar disorder;
LGG	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg16586182	chr3:47516702	SCAP	-0.43	-7.07	-0.31	5.84e-12	Birth weight;
LGG	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg25811766	chr13:21894605	NA	0.6	8.24	0.36	1.83e-15	White matter hyperintensity burden;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs7503807	0.515	rs12453034	chr17:78682756	G/A	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs2729354	0.768	rs2581922	chr11:57265400	C/T	cg24343310	chr11:57249947	NA	0.41	8.16	0.35	3.13e-15	Blood protein levels;
LGG	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.45	-0.71	2.26e-71	Monocyte count;
LGG	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg25382214	chr1:3105252	PRDM16	-0.41	-7.84	-0.34	3.05e-14	Migraine;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg27471124	chr11:109292789	C11orf87	0.49	9.32	0.4	4.91e-19	Schizophrenia;
LGG	cis	rs7192380	0.965	rs7205551	chr16:69605968	G/A	cg00738113	chr16:70207722	CLEC18C	-0.28	-7.92	-0.35	1.79e-14	Sjögren's syndrome;
LGG	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg05425664	chr17:57184151	TRIM37	0.66	9.91	0.42	4.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.15	0.32	3.4e-12	Lung cancer;
LGG	cis	rs13102973	0.899	rs4643872	chr4:135901432	A/G	cg14419869	chr4:135874104	NA	0.47	8.56	0.37	1.68e-16	Subjective well-being;
LGG	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.17	-0.39	1.51e-18	Lung cancer;
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg22044901	chr15:68126292	NA	-0.42	-7.47	-0.33	3.95e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg00383909	chr3:49044727	WDR6	0.56	8.04	0.35	7.83e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg05887092	chr17:76393375	PGS1	0.72	15.71	0.59	6.71e-45	HDL cholesterol levels;
LGG	cis	rs6546324	0.625	rs2902008	chr2:67802950	T/C	cg18237512	chr2:67827392	NA	-0.38	-6.75	-0.3	4.47e-11	Endometriosis;
LGG	cis	rs698813	0.572	rs4953076	chr2:44480950	G/C	cg00619915	chr2:44497795	NA	-0.6	-8.75	-0.38	4.14e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.73	-0.64	4.64e-54	Exhaled nitric oxide output;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.91	0.31	1.66e-11	Longevity;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg24575275	chr7:1094737	C7orf50	-0.42	-8.24	-0.36	1.75e-15	Longevity;Endometriosis;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg16606324	chr3:10149918	C3orf24	0.51	6.75	0.3	4.41e-11	Alzheimer's disease;
LGG	cis	rs7000551	0.675	rs2443503	chr8:22381850	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	12.28	0.5	3.22e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg16885296	chr6:26284938	NA	0.39	8.63	0.37	9.86e-17	Educational attainment;
LGG	trans	rs2562456	0.641	rs62107468	chr19:21489979	A/C	cg00806126	chr19:22604979	ZNF98	-0.56	-7.48	-0.33	3.76e-13	Pain;
LGG	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg27490568	chr2:178487706	NA	-0.86	-14.53	-0.56	1.07e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04008888	chr11:68622739	NA	-0.58	-12.08	-0.49	2.14e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg10189774	chr4:17578691	LAP3	0.4	7.01	0.31	8.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg20476274	chr7:133979776	SLC35B4	0.76	14.94	0.57	1.78e-41	Mean platelet volume;
LGG	cis	rs2274273	0.588	rs7154831	chr14:55823965	A/C	cg04306507	chr14:55594613	LGALS3	0.52	12.28	0.5	3.23e-30	Protein biomarker;
LGG	cis	rs17221829	0.644	rs7943100	chr11:89382037	C/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.08	-0.39	3.16e-18	Anxiety in major depressive disorder;
LGG	cis	rs6500637	0.631	rs12921187	chr16:4943019	T/G	cg04440724	chr16:4920505	UBN1	0.56	12.05	0.49	2.75e-29	Cancer;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg18240062	chr17:79603768	NPLOC4	-0.61	-10.23	-0.43	2.79e-22	Eye color traits;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.42	0.33	5.67e-13	Prudent dietary pattern;
LGG	cis	rs4865875	1.000	rs12514244	chr5:54120184	G/A	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg21775007	chr8:11205619	TDH	-0.53	-8.9	-0.38	1.26e-17	Neuroticism;
LGG	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg26528311	chr1:38462546	FHL3	0.33	8.99	0.39	6.35e-18	Coronary artery disease;
LGG	trans	rs826838	1.000	rs826886	chr12:39095797	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.65	-0.33	1.14e-13	Heart rate;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03647317	chr4:187891568	NA	-0.41	-8.73	-0.38	4.58e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg15162869	chr22:32027605	PISD	-0.7	-7.37	-0.32	7.92e-13	Age-related hearing impairment;
LGG	cis	rs17092148	0.790	rs6087602	chr20:33170689	G/A	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.97	-0.31	1.07e-11	Neuroticism;
LGG	cis	rs3096299	0.838	rs3102384	chr16:89411661	T/G	cg06640241	chr16:89574553	SPG7	0.59	9.67	0.41	2.82e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg24812749	chr6:127587940	RNF146	0.7	11.18	0.46	7.77e-26	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12560154	chr19:11925149	ZNF440	0.4	7.01	0.31	8.3e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3087591	0.960	rs2952991	chr17:29526742	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.5	0.56	1.49e-39	Hip circumference;
LGG	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg16586182	chr3:47516702	SCAP	-0.8	-15.38	-0.58	2.12e-43	Colorectal cancer;
LGG	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	2.06e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.25	-0.32	1.75e-12	Blood metabolite levels;
LGG	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg17644776	chr2:200775616	C2orf69	0.48	8.14	0.35	3.7e-15	Systolic blood pressure;
LGG	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	9.91	0.42	3.98e-21	Aortic root size;
LGG	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23221052	chr5:179740743	GFPT2	-0.62	-11.34	-0.47	1.79e-26	Height;
LGG	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg05973401	chr12:123451056	ABCB9	0.48	8.0	0.35	1.04e-14	Platelet count;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.38	-0.36	6.19e-16	Skin colour saturation;
LGG	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.45	-0.33	4.61e-13	Psoriasis;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg15991262	chr7:23720454	C7orf46	0.42	9.73	0.41	1.81e-20	Schizophrenia;
LGG	cis	rs17001868	0.892	rs73167023	chr22:40799954	T/C	cg07138101	chr22:40742427	ADSL	0.62	6.82	0.3	2.9100000000000002e-11	Mammographic density (dense area);
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg07061783	chr6:25882402	NA	0.38	6.75	0.3	4.43e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.97	-0.52	4.72e-33	Intelligence (multi-trait analysis);
LGG	cis	rs1408799	0.654	rs7025842	chr9:12760647	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	4.99e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs7572733	0.935	rs700679	chr2:198706916	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.6e-16	Dermatomyositis;
LGG	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg19901956	chr11:77921274	USP35	-0.41	-6.76	-0.3	4.09e-11	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg00666640	chr1:248458726	OR2T12	0.58	9.39	0.4	2.76e-19	Common traits (Other);
LGG	trans	rs2018683	0.933	rs12536127	chr7:28985967	T/C	cg19402173	chr7:128379420	CALU	-0.67	-11.95	-0.49	7.3e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs17685	0.753	rs1859791	chr7:75786043	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.7	0.77	3.67e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.48e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13102973	0.646	rs4428339	chr4:135886187	C/T	cg14419869	chr4:135874104	NA	0.46	7.9	0.34	2.06e-14	Subjective well-being;
LGG	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-11.9	-0.48	1.08e-28	Migraine;Coronary artery disease;
LGG	cis	rs2249625	0.504	rs2496508	chr6:72891398	A/G	cg27608224	chr6:72922399	RIMS1	0.32	7.29	0.32	1.35e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.52	-0.33	2.78e-13	Neuroticism;
LGG	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-14.59	-0.56	6.27e-40	Schizophrenia;
LGG	cis	rs9398803	1.000	rs9398803	chr6:126683594	A/G	cg19875578	chr6:126661172	C6orf173	0.56	10.14	0.43	5.73e-22	Male-pattern baldness;
LGG	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21659725	chr3:3221576	CRBN	-0.61	-9.53	-0.4	8.61e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg11050988	chr7:1952600	MAD1L1	-0.41	-10.11	-0.43	7.57e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9640161	0.750	rs11538922	chr7:150035183	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.79	-16.18	-0.6	5.31e-47	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7666738	0.830	rs13133355	chr4:98919415	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.81	0.34	3.76e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	6.68	0.3	6.78e-11	Menopause (age at onset);
LGG	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg01864069	chr14:103024347	NA	-0.66	-9.38	-0.4	2.98e-19	Platelet count;
LGG	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00863353	chr20:9049694	NA	0.42	6.66	0.3	7.59e-11	Gut microbiome composition (summer);
LGG	cis	rs7945705	0.846	rs4929912	chr11:8816695	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.44	-8.85	-0.38	1.91e-17	Hemoglobin concentration;
LGG	cis	rs1018697	0.518	rs2482506	chr10:104563743	C/G	cg04362960	chr10:104952993	NT5C2	-0.63	-9.9	-0.42	4.53e-21	Colorectal adenoma (advanced);
LGG	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg09237302	chr4:906077	GAK	-0.46	-7.73	-0.34	6.77e-14	Type 2 diabetes;
LGG	cis	rs17039065	1.000	rs56717804	chr4:109394241	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs1957429	0.808	rs11158564	chr14:65335082	G/A	cg23373153	chr14:65346875	NA	1.05	13.12	0.52	1.16e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.04	-0.31	7.09e-12	Renal cell carcinoma;
LGG	cis	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.88	-0.48	1.3e-28	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.39e-13	Prudent dietary pattern;
LGG	cis	rs6728642	0.908	rs6731522	chr2:97647997	A/G	cg26665480	chr2:98280029	ACTR1B	-0.74	-8.8	-0.38	2.8e-17	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs4538187	0.627	rs11694253	chr2:63948135	T/G	cg19915305	chr2:64069682	UGP2	-0.64	-11.58	-0.47	2.03e-27	Systolic blood pressure;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.44	8.68	0.37	6.62e-17	Schizophrenia;
LGG	trans	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg06875740	chr19:51307921	C19orf48	-0.66	-6.83	-0.3	2.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11096990	0.892	rs11937540	chr4:39181517	A/G	cg24403649	chr4:39172243	NA	-0.45	-7.47	-0.33	4.12e-13	Cognitive function;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	1e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg25767906	chr1:53392781	SCP2	0.42	8.17	0.35	3.05e-15	Monocyte count;
LGG	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4731207	0.596	rs10247349	chr7:124607495	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	cis	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.21	-0.46	5.85e-26	Morning vs. evening chronotype;
LGG	cis	rs4356932	1.000	rs4859598	chr4:76959828	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg00367659	chr17:33288544	CCT6B;ZNF830	0.4	6.92	0.31	1.49e-11	Body mass index;
LGG	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg20302533	chr7:39170763	POU6F2	0.49	11.94	0.49	7.89e-29	IgG glycosylation;
LGG	cis	rs78545713	0.536	rs78759249	chr6:26208956	G/A	cg01420254	chr6:26195488	NA	0.8	7.59	0.33	1.77e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg08888203	chr3:10149979	C3orf24	-0.55	-9.34	-0.4	4.22e-19	Alzheimer's disease;
LGG	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg09085632	chr11:111637200	PPP2R1B	1.14	25.68	0.77	4.51e-91	Primary sclerosing cholangitis;
LGG	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg11166453	chr1:247681781	NA	0.63	9.92	0.42	3.79e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9810089	0.843	rs556788	chr3:136027549	A/G	cg21827317	chr3:136751795	NA	0.45	7.82	0.34	3.51e-14	Gestational age at birth (child effect);
LGG	cis	rs74781061	0.929	rs4886599	chr15:74776783	T/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg09165964	chr15:75287851	SCAMP5	0.65	12.26	0.49	4.23e-30	Breast cancer;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.86	-0.54	8.81e-37	Alzheimer's disease;
LGG	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.81	-0.38	2.6e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9912468	0.754	rs4791069	chr17:64316508	A/T	cg19474267	chr17:64306194	PRKCA	0.94	25.15	0.76	1.26e-88	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1021993	0.597	rs17014320	chr1:209512173	T/C	cg24446417	chr1:209558027	NA	-0.69	-10.09	-0.42	8.85e-22	Gut microbiome composition (winter);
LGG	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.44	-0.37	4.2e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.55e-14	Gut microbiome composition (summer);
LGG	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02788857	chr8:22132959	PIWIL2	0.5	11.86	0.48	1.69e-28	Hypertriglyceridemia;
LGG	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	18.57	0.65	5.9e-58	Smoking behavior;
LGG	cis	rs3087591	0.683	rs2525564	chr17:29652531	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	12.34	0.5	1.99e-30	Hip circumference;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.25	0.43	2.29e-22	Obesity-related traits;
LGG	cis	rs3806843	0.576	rs246059	chr5:140325010	G/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7246865	0.859	rs1379281	chr19:17189786	A/G	cg19418318	chr19:17219073	MYO9B	-0.32	-8.39	-0.36	5.72e-16	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.71e-16	Life satisfaction;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg08621203	chr6:150244597	RAET1G	0.46	8.03	0.35	8.4e-15	Lung cancer;
LGG	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.11	-0.43	7.68e-22	Morning vs. evening chronotype;
LGG	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Body mass index;
LGG	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg02002194	chr4:3960332	NA	-0.51	-9.96	-0.42	2.75e-21	Mood instability;
LGG	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg05044414	chr3:183734942	ABCC5	0.78	17.09	0.62	4.17e-51	Anterior chamber depth;
LGG	cis	rs3087591	0.708	rs964288	chr17:29679246	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.55	0.5	2.6e-31	Hip circumference;
LGG	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs836589	0.506	rs13385676	chr2:173576301	A/T	cg06468108	chr2:173539091	NA	-0.5	-7.3	-0.32	1.24e-12	Erectile dysfunction in type 1 diabetes;
LGG	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.04	-0.31	7.04e-12	HDL cholesterol;
LGG	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.77	0.3	3.91e-11	Cognitive ability;
LGG	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg26655873	chr3:72818019	SHQ1	0.34	7.24	0.32	1.83e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.95	0.35	1.41e-14	Obesity-related traits;
LGG	cis	rs8170	0.603	rs4808621	chr19:17414267	C/T	cg04749549	chr19:17459798	NA	-0.39	-7.08	-0.31	5.47e-12	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg18357526	chr6:26021779	HIST1H4A	0.81	14.2	0.55	3.16e-38	Intelligence (multi-trait analysis);
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg00607725	chr16:70380558	DDX19A	-0.42	-6.66	-0.3	7.83e-11	Height;
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg19774624	chr17:42201019	HDAC5	-0.97	-20.5	-0.69	6.45e-67	Total body bone mineral density;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg10818794	chr15:86012489	AKAP13	0.56	12.72	0.51	5.44e-32	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg06221963	chr1:154839813	KCNN3	-0.5	-10.0	-0.42	1.89e-21	Prostate cancer;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs988958	0.526	rs10166598	chr2:42242872	A/G	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Hypospadias;
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg04450456	chr4:17643702	FAM184B	0.32	6.9	0.31	1.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg18357526	chr6:26021779	HIST1H4A	0.43	7.0	0.31	9.1e-12	Height;
LGG	cis	rs1707322	1.000	rs11211223	chr1:46380605	C/T	cg03146154	chr1:46216737	IPP	0.55	10.18	0.43	4.06e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg25427524	chr10:38739819	LOC399744	0.47	8.97	0.38	7.2e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs78487399	0.808	rs6544664	chr2:43729108	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg14036092	chr11:66035641	RAB1B	0.46	8.03	0.35	7.86e-15	Gout;
LGG	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg00383909	chr3:49044727	WDR6	0.57	8.07	0.35	6.08e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg24189917	chr7:1970923	MAD1L1	-0.47	-6.97	-0.31	1.11e-11	Bipolar disorder;
LGG	cis	rs68170813	0.559	rs113211438	chr7:106969198	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.4	-0.44	6.48e-23	Coronary artery disease;
LGG	cis	rs10876993	0.890	rs7963927	chr12:58046272	T/G	cg18357645	chr12:58087776	OS9	0.66	12.07	0.49	2.4e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg25566285	chr7:158114605	PTPRN2	-0.99	-26.64	-0.78	1.75e-95	Calcium levels;
LGG	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.08	-0.46	1.86e-25	Lung cancer;
LGG	cis	rs9611519	0.964	rs20551	chr22:41548008	A/G	cg03806693	chr22:41940476	POLR3H	-0.55	-8.46	-0.37	3.54e-16	Neuroticism;
LGG	cis	rs10193935	0.786	rs10178087	chr2:42409631	C/A	cg27598129	chr2:42591480	NA	-0.62	-9.18	-0.39	1.43e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg25174290	chr11:3078921	CARS	-0.52	-9.49	-0.4	1.21e-19	Calcium levels;
LGG	cis	rs11608355	0.515	rs7311488	chr12:109930905	C/G	cg05360138	chr12:110035743	NA	-0.86	-12.3	-0.5	2.84e-30	Neuroticism;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16680214	chr1:154839983	KCNN3	-0.47	-9.42	-0.4	2.17e-19	Prostate cancer;
LGG	cis	rs3816183	0.959	rs893733	chr2:43016838	C/T	cg14631114	chr2:43023945	NA	0.51	9.5	0.4	1.14e-19	Hypospadias;
LGG	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg16576597	chr16:28551801	NUPR1	0.37	8.67	0.37	7.34e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg20120463	chr17:44301886	NA	-0.48	-7.32	-0.32	1.11e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-15.02	-0.57	8.25e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg05527609	chr1:210001259	C1orf107	-0.49	-6.86	-0.3	2.25e-11	Red blood cell count;
LGG	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.02	-0.42	1.57e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.98	-0.39	6.62e-18	Longevity;
LGG	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-11.46	-0.47	6.08e-27	Migraine;Coronary artery disease;
LGG	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg23000734	chr10:126850823	CTBP2	-0.31	-9.41	-0.4	2.38e-19	Menarche (age at onset);
LGG	cis	rs6694672	1.000	rs1627765	chr1:197033043	C/T	cg13682187	chr1:196946512	CFHR5	0.49	6.87	0.3	2.07e-11	Asthma;
LGG	cis	rs10197940	0.967	rs4664423	chr2:152266311	T/C	cg19508488	chr2:152266495	RIF1	0.7	13.56	0.53	1.59e-35	Lung cancer;
LGG	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.59	-0.33	1.83e-13	Schizophrenia;
LGG	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg16395133	chr6:150326394	RAET1K	0.28	7.01	0.31	8.51e-12	Alopecia areata;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.48e-86	Prudent dietary pattern;
LGG	cis	rs12230513	0.732	rs7966770	chr12:55844717	T/C	cg19537932	chr12:55886519	OR6C68	-0.61	-10.97	-0.45	4.7e-25	Contrast sensitivity;
LGG	cis	rs9715521	0.835	rs9714848	chr4:59824650	C/T	cg11281224	chr4:60001000	NA	-0.44	-7.35	-0.32	8.84e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs975739	0.872	rs1766332	chr13:78370956	T/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.7e-11	Hair color;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.67	9.32	0.4	4.58e-19	Lung function (FEV1/FVC);
LGG	trans	rs11134654	1.000	rs1422160	chr5:170243433	A/G	cg20034712	chr19:52675470	ZNF836	-0.46	-7.52	-0.33	2.89e-13	Smooth-surface caries;
LGG	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.6	0.51	1.61e-31	Coronary artery disease;
LGG	trans	rs2270927	0.510	rs2358712	chr5:75580687	A/G	cg13563193	chr19:33072644	PDCD5	0.85	10.16	0.43	4.88e-22	Mean corpuscular volume;
LGG	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg15627072	chr1:2432621	PLCH2	-0.36	-8.18	-0.36	2.72e-15	Ulcerative colitis;
LGG	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg14191688	chr11:70257035	CTTN	0.6	8.6	0.37	1.2e-16	Coronary artery disease;
LGG	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08564027	chr20:61660810	NA	1.02	25.49	0.76	3.34e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg02972257	chr16:68554789	NA	-0.57	-8.41	-0.36	5.1e-16	Ulcerative colitis;
LGG	cis	rs2070488	0.775	rs7649984	chr3:38570221	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.35	-0.55	6.69e-39	Electrocardiographic conduction measures;
LGG	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.06	0.49	2.67e-29	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	9.05	0.39	4.05e-18	Obesity-related traits;
LGG	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Lung cancer;
LGG	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs367943	0.665	rs2115210	chr5:112966125	T/C	cg12552261	chr5:112820674	MCC	0.52	8.97	0.38	7.3e-18	Type 2 diabetes;
LGG	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg18252515	chr7:66147081	NA	-1.35	-14.72	-0.56	1.68e-40	Diabetic kidney disease;
LGG	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24229701	chr12:130821962	PIWIL1	-0.43	-7.56	-0.33	2.15e-13	Menopause (age at onset);
LGG	trans	rs73198271	0.603	rs777705	chr8:8586868	C/T	cg16141378	chr3:129829833	LOC729375	0.35	6.9	0.31	1.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.17	-0.32	2.95e-12	Coronary artery disease;
LGG	cis	rs2282802	0.685	rs67813630	chr5:139623592	C/A	cg26211634	chr5:139558579	C5orf32	0.33	7.32	0.32	1.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg01864069	chr14:103024347	NA	-0.68	-9.54	-0.41	7.95e-20	Platelet count;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs12479064	0.507	rs6720885	chr2:99971289	A/G	cg23527387	chr2:100056660	REV1	0.44	9.81	0.41	9.41e-21	Chronic sinus infection;
LGG	cis	rs6942756	0.774	rs2402944	chr7:128951402	G/T	cg02491457	chr7:128862824	NA	-0.62	-11.78	-0.48	3.33e-28	White matter hyperintensity burden;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.45	-0.61	3.24e-48	Skin colour saturation;
LGG	cis	rs503734	0.666	rs2682390	chr3:101096532	C/T	cg27318481	chr3:100970896	IMPG2	-0.36	-7.22	-0.32	2.11e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.48	0.44	3.35e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.36	-0.4	3.55e-19	Life satisfaction;
LGG	cis	rs2710642	0.927	rs6705798	chr2:63259881	C/T	cg17519650	chr2:63277830	OTX1	0.48	7.78	0.34	4.7e-14	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg14101638	chr12:121416612	HNF1A	-0.44	-9.56	-0.41	6.8e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	10.5	0.44	2.75e-23	Total body bone mineral density;
LGG	cis	rs9583531	0.660	rs80030913	chr13:111336866	G/C	cg24331049	chr13:111365604	ING1	-0.72	-7.39	-0.32	7.11e-13	Coronary artery disease;
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.35	-8.28	-0.36	1.37e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs151997	0.962	rs152687	chr5:50208563	A/G	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs11877825	0.826	rs6505573	chr18:10579542	G/A	cg07277756	chr18:10589357	NA	0.56	9.89	0.42	4.55e-21	Gut microbiota (bacterial taxa);
LGG	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg19700328	chr14:106028568	NA	-0.59	-9.87	-0.42	5.61e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2377585	0.524	rs11612882	chr12:8843133	A/G	cg03761649	chr12:8850719	RIMKLB	-0.46	-7.94	-0.35	1.5e-14	Reticulocyte fraction of red cells;
LGG	trans	rs877282	0.853	rs7092652	chr10:756109	G/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	trans	rs931812	1.000	rs931812	chr8:101919321	A/G	cg20993868	chr7:22813445	NA	-0.64	-12.29	-0.5	3.16e-30	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs902774	0.585	rs7399070	chr12:53355678	G/T	cg05393297	chr12:53359155	NA	-0.56	-6.98	-0.31	1.06e-11	Prostate cancer;
LGG	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.66	0.34	1.12e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9462027	0.628	rs9462010	chr6:34716605	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg13736514	chr6:26305472	NA	-0.49	-10.08	-0.42	9.89e-22	Educational attainment;
LGG	cis	rs12200782	0.649	rs7757048	chr6:26390039	C/A	cg27193005	chr6:26382695	BTN2A2	-0.51	-7.27	-0.32	1.59e-12	Small cell lung carcinoma;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg14926445	chr8:58193284	C8orf71	-0.87	-13.12	-0.52	1.19e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg14983838	chr19:29218262	NA	0.7	11.37	0.47	1.35e-26	Methadone dose in opioid dependence;
LGG	cis	rs225245	0.782	rs321601	chr17:33892087	A/C	cg05299278	chr17:33885742	SLFN14	-0.41	-7.93	-0.35	1.69e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7582720	0.943	rs72932556	chr2:203845996	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.67	-0.37	7.11e-17	Triglycerides;
LGG	cis	rs17102884	0.506	rs4899541	chr14:75403437	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.63	-11.44	-0.47	7.12e-27	Neuroticism;
LGG	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg16482183	chr6:26056742	HIST1H1C	0.61	9.81	0.42	8.77e-21	Iron status biomarkers;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg04287289	chr16:89883240	FANCA	0.68	7.11	0.31	4.36e-12	Skin colour saturation;
LGG	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg22875332	chr1:76189707	ACADM	-0.58	-8.86	-0.38	1.75e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.1e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg06640241	chr16:89574553	SPG7	-0.69	-12.1	-0.49	1.77e-29	Multiple myeloma (IgH translocation);
LGG	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.08	-0.35	5.75e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22175811	chr17:7590052	TP53;WRAP53	0.39	7.03	0.31	7.47e-12	Obesity-related traits;
LGG	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg04842962	chr6:43655489	MRPS18A	1.12	24.45	0.75	2.26e-85	IgG glycosylation;
LGG	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg02002194	chr4:3960332	NA	-0.47	-8.68	-0.37	6.84e-17	Retinal vascular caliber;
LGG	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg27129171	chr3:47204927	SETD2	0.72	11.24	0.46	4.42e-26	Birth weight;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg22535103	chr8:58192502	C8orf71	-0.87	-11.15	-0.46	9.71e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.22	-0.32	2.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg00857998	chr1:205179979	DSTYK	0.47	6.74	0.3	4.58e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6733011	0.508	rs13004700	chr2:99527568	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.02	-0.31	7.76e-12	Bipolar disorder;
LGG	cis	rs9557207	0.851	rs12864373	chr13:99889098	T/A	cg24509225	chr13:100037070	UBAC2	0.7	12.59	0.51	1.81e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg26752003	chr8:145688521	CYHR1	-0.52	-11.18	-0.46	7.25e-26	Age at first birth;
LGG	cis	rs57504626	1	rs57504626	chr19:19720399	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.01	0.31	8.33e-12	Total cholesterol change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.77	-11.66	-0.48	9.96e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.32	-0.32	1.14e-12	Joint mobility (Beighton score);
LGG	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.43	-0.4	1.95e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs889398	0.802	rs8051168	chr16:69887274	T/A	cg00738113	chr16:70207722	CLEC18C	-0.25	-6.92	-0.31	1.49e-11	Body mass index;
LGG	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg00666640	chr1:248458726	OR2T12	0.63	10.23	0.43	2.87e-22	Common traits (Other);
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg17376030	chr22:41985996	PMM1	-0.64	-9.31	-0.4	5.36e-19	Vitiligo;
LGG	cis	rs6032067	0.759	rs6032043	chr20:43817897	A/C	cg10761708	chr20:43804764	PI3	0.61	9.31	0.4	5.1e-19	Blood protein levels;
LGG	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg10847948	chr11:71163743	NADSYN1	-0.66	-13.14	-0.52	9.21e-34	Vitamin D levels;
LGG	cis	rs9815354	1.000	rs6796210	chr3:41851718	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg09408571	chr1:101003634	GPR88	-0.33	-8.43	-0.36	4.51e-16	Breast cancer;
LGG	cis	rs477692	0.549	rs7079744	chr10:131454790	G/A	cg05714579	chr10:131428358	MGMT	-0.47	-8.63	-0.37	9.91e-17	Response to temozolomide;
LGG	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-11.58	-0.47	2.11e-27	Response to antipsychotic treatment;
LGG	cis	rs9487094	0.710	rs10499052	chr6:109885475	G/A	cg01125227	chr6:109776195	MICAL1	0.48	7.66	0.34	1.11e-13	Height;
LGG	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg00757033	chr12:89920650	WDR51B	-0.59	-8.77	-0.38	3.32e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1568889	0.838	rs10835304	chr11:28296529	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.1	0.66	2.14e-60	Bipolar disorder;
LGG	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6694672	1.000	rs2336597	chr1:196993339	C/T	cg13682187	chr1:196946512	CFHR5	-0.5	-6.85	-0.3	2.41e-11	Asthma;
LGG	cis	rs3008870	0.959	rs2815359	chr1:67494374	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	22.78	0.73	1.38e-77	Lymphocyte percentage of white cells;
LGG	cis	rs1878931	0.580	rs3848355	chr16:3407489	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.96	20.6	0.69	2.08e-67	Body mass index (adult);
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.07e-20	Lung cancer;
LGG	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.98	-0.49	5.35e-29	Parkinson's disease;
LGG	cis	rs919433	0.617	rs10931791	chr2:198573612	A/C	cg00792783	chr2:198669748	PLCL1	-0.55	-8.6	-0.37	1.28e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg02269571	chr22:50332266	NA	-0.54	-8.5	-0.37	2.68e-16	Schizophrenia;
LGG	cis	rs972578	0.765	rs5751391	chr22:43261499	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.95	-0.31	1.28e-11	Mean platelet volume;
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg23594656	chr7:65796392	TPST1	0.42	9.25	0.4	8.16e-19	Aortic root size;
LGG	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.75	0.41	1.45e-20	Blood metabolite levels;
LGG	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.29e-18	Rheumatoid arthritis;
LGG	cis	rs2742417	0.603	rs2673055	chr3:45772772	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.38	-0.4	3.04e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.09	-0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.48	0.69	7.42e-67	Platelet count;
LGG	trans	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.86e-14	Resting heart rate;
LGG	cis	rs12677663	1.000	rs12677663	chr8:74007347	G/T	cg19518093	chr8:74006994	C8orf84	-0.5	-9.9	-0.42	4.28e-21	Crohn's disease;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.98	-0.42	2.25e-21	Platelet count;
LGG	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.48e-12	Iron status biomarkers;
LGG	cis	rs4356932	1.000	rs7655350	chr4:76977073	A/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	6.68e-11	Blood protein levels;
LGG	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04530015	chr2:215796436	ABCA12	-0.45	-7.72	-0.34	7.2e-14	Neuroblastoma;
LGG	cis	rs12137294	0.829	rs1172154	chr1:205220639	T/G	cg00889227	chr1:205173544	DSTYK	-0.27	-6.75	-0.3	4.49e-11	Red cell distribution width;
LGG	cis	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg21696256	chr3:125484277	NA	-0.45	-7.54	-0.33	2.44e-13	Blood pressure (smoking interaction);
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00689492	chr4:1303491	MAEA	0.43	7.46	0.33	4.33e-13	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.51	-0.4	1.01e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25072359	chr17:41440525	NA	0.52	10.12	0.43	6.72e-22	Menopause (age at onset);
LGG	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg15627072	chr1:2432621	PLCH2	0.43	10.63	0.44	8.82e-24	Ulcerative colitis;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg02951883	chr7:2050386	MAD1L1	-0.77	-16.17	-0.6	6.12e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs1620921	0.537	rs28655734	chr6:161271783	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1372520	0.564	rs356186	chr4:90705364	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-7.32	-0.32	1.09e-12	Neuroticism;
LGG	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg15556689	chr8:8085844	FLJ10661	0.46	7.67	0.34	1.01e-13	Neuroticism;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg11764359	chr7:65958608	NA	0.74	13.28	0.53	2.58e-34	Aortic root size;
LGG	trans	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	trans	rs208520	0.690	rs851467	chr6:66802721	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs7216064	1.000	rs3206817	chr17:65892834	A/G	cg12091567	chr17:66097778	LOC651250	-0.58	-8.35	-0.36	7.91e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2860975	1.000	rs7920659	chr10:96767924	T/C	cg09036531	chr10:96991505	NA	-0.48	-8.89	-0.38	1.4e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.35	-0.43	9.69e-23	Morning vs. evening chronotype;
LGG	cis	rs774359	0.789	rs2440620	chr9:27497621	T/C	cg22262168	chr9:27528999	MOBKL2B	0.44	6.77	0.3	3.81e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs1062177	1.000	rs2964584	chr5:151142878	T/C	cg00977110	chr5:151150581	G3BP1	0.49	7.85	0.34	2.9e-14	Preschool internalizing problems;
LGG	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs708547	0.871	rs2687238	chr4:57880474	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs6963495	0.818	rs6944787	chr7:105147309	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.9	0.34	2e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs617791	0.508	rs747526	chr11:65776071	C/A	cg17712092	chr4:129076599	LARP1B	-0.57	-9.57	-0.41	6.45e-20	Breast cancer;
LGG	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.98	-0.31	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.32	-0.4	4.81e-19	Menarche (age at onset);
LGG	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg23730037	chr7:158596552	ESYT2	-0.41	-6.93	-0.31	1.38e-11	Height;
LGG	cis	rs8009147	1	rs8009147	chr14:104264662	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg27396498	chr16:55794478	CES4	0.45	9.06	0.39	3.7e-18	Response to dabigatran etexilate treatment;
LGG	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-11.45	-0.47	6.7e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2652834	1.000	rs2729785	chr15:63402574	G/A	cg05507819	chr15:63340323	TPM1	0.61	8.32	0.36	1.03e-15	HDL cholesterol;
LGG	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg25358565	chr5:93447407	FAM172A	-0.82	-11.35	-0.47	1.58e-26	Diabetic retinopathy;
LGG	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.15	-0.35	3.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.56e-25	Corneal astigmatism;
LGG	trans	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg07393940	chr7:158741817	NA	-0.6	-10.73	-0.45	3.91e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7666738	0.716	rs28792413	chr4:99083707	G/A	cg05340658	chr4:99064831	C4orf37	0.44	7.12	0.31	4.03e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7737355	0.947	rs32113	chr5:131049585	G/T	cg06307176	chr5:131281290	NA	-0.57	-9.55	-0.41	7.66e-20	Life satisfaction;
LGG	cis	rs2377058	0.961	rs16965913	chr16:89734788	C/T	cg07835443	chr16:89734986	C16orf55	-0.47	-7.94	-0.35	1.53e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg07615347	chr10:60278583	BICC1	0.63	18.18	0.65	3.87e-56	Refractive error;
LGG	cis	rs6430585	0.640	rs6716070	chr2:136544651	G/T	cg07169764	chr2:136633963	MCM6	-1.26	-23.76	-0.74	3.48e-82	Corneal structure;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	12.15	0.49	1.07e-29	Lymphocyte counts;
LGG	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg06697600	chr4:7070879	GRPEL1	0.52	8.01	0.35	9.32e-15	Monocyte percentage of white cells;
LGG	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg01528321	chr10:82214614	TSPAN14	0.69	12.55	0.5	2.58e-31	Post bronchodilator FEV1;
LGG	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg15733309	chr7:157513707	PTPRN2	0.78	18.23	0.65	2.35e-56	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.37	0.4	3.11e-19	Lung cancer;
LGG	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg08344181	chr3:125677491	NA	-0.56	-7.28	-0.32	1.45e-12	Depression;
LGG	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg15145296	chr3:125709740	NA	-0.6	-7.7	-0.34	8.29e-14	Blood pressure (smoking interaction);
LGG	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg00701064	chr4:6280414	WFS1	0.67	13.22	0.52	4.41e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg09307838	chr4:120376055	NA	0.72	12.11	0.49	1.59e-29	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.48e-13	Lung cancer;
LGG	cis	rs11971779	0.553	rs7799742	chr7:139051878	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08832723	chr5:6756238	POLS	-0.39	-7.66	-0.34	1.11e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs67133203	0.851	rs7959075	chr12:51361171	C/A	cg14688905	chr12:51403056	SLC11A2	0.78	11.86	0.48	1.62e-28	Urinary tract infection frequency;
LGG	cis	rs806215	0.526	rs10954164	chr7:127533877	T/C	cg25922125	chr7:127225783	GCC1	-0.47	-6.88	-0.3	1.97e-11	Type 2 diabetes;
LGG	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg14092571	chr14:90743983	NA	-0.42	-7.55	-0.33	2.35e-13	Longevity;
LGG	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	9.83	0.42	7.82e-21	Schizophrenia;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.31	0.5	2.63e-30	Prudent dietary pattern;
LGG	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg06623630	chr22:50017776	C22orf34	-0.45	-8.91	-0.38	1.21e-17	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6539288	0.630	rs10778520	chr12:107364873	A/G	cg15890332	chr12:107067104	RFX4	-0.3	-8.16	-0.35	3.19e-15	Total body bone mineral density;
LGG	cis	rs1707322	1.000	rs785486	chr1:46575148	G/C	cg03146154	chr1:46216737	IPP	-0.54	-9.45	-0.4	1.66e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg09307838	chr4:120376055	NA	0.72	12.09	0.49	2e-29	Corneal astigmatism;
LGG	cis	rs701145	0.938	rs701144	chr3:154059576	C/T	cg17054900	chr3:154042577	DHX36	1.0	12.28	0.5	3.29e-30	Coronary artery disease;
LGG	cis	rs981844	0.712	rs6535956	chr4:154746001	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.82e-21	Response to statins (LDL cholesterol change);
LGG	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg08344181	chr3:125677491	NA	-0.66	-7.79	-0.34	4.59e-14	Depression;
LGG	cis	rs3617	0.652	rs60332615	chr3:52867595	C/A	cg11645453	chr3:52864694	ITIH4	-0.43	-7.28	-0.32	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs912057	1.000	rs912057	chr6:6736931	C/T	cg06612196	chr6:6737390	NA	-0.43	-8.82	-0.38	2.39e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7572733	0.875	rs771018	chr2:198650259	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.99	0.35	1.07e-14	Dermatomyositis;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg27286069	chr11:118481882	PHLDB1	0.53	10.17	0.43	4.6e-22	Cholesterol, total;
LGG	trans	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.69	-0.34	8.99e-14	Mood instability;
LGG	cis	rs7851660	0.839	rs10113884	chr9:100624622	C/T	cg13688889	chr9:100608707	NA	-0.63	-12.56	-0.5	2.39e-31	Strep throat;
LGG	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg05791153	chr7:19748676	TWISTNB	0.76	9.49	0.4	1.18e-19	Thyroid stimulating hormone;
LGG	cis	rs240764	0.578	rs62422070	chr6:101260827	T/G	cg09795085	chr6:101329169	ASCC3	0.45	7.72	0.34	6.99e-14	Neuroticism;
LGG	cis	rs2820315	0.867	rs2820319	chr1:201878650	G/A	cg10061532	chr1:201886748	LMOD1	0.33	7.05	0.31	6.45e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	cis	rs4538187	0.826	rs1440002	chr2:64147834	G/A	cg19915305	chr2:64069682	UGP2	-0.57	-13.01	-0.52	3.49e-33	Systolic blood pressure;
LGG	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.89	-0.3	1.87e-11	Mood instability;
LGG	cis	rs10929925	0.966	rs12104847	chr2:6157860	T/C	cg00493617	chr2:6141445	NA	0.32	7.15	0.32	3.38e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs7172689	1.000	rs66535467	chr15:81542872	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg13010199	chr12:38710504	ALG10B	0.6	10.91	0.45	7.81e-25	Heart rate;
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg06074448	chr4:187884817	NA	-0.58	-12.85	-0.51	1.58e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.62e-12	IgG glycosylation;
LGG	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.57	-0.33	2.01e-13	Initial pursuit acceleration;
LGG	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.19e-13	White matter hyperintensity burden;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg26043149	chr18:55253948	FECH	-0.47	-7.66	-0.34	1.08e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00346009	chr12:118541298	VSIG10	0.38	6.78	0.3	3.74e-11	Obesity-related traits;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.77	0.34	4.99e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7923837	1.000	rs7087591	chr10:94473629	G/A	cg25093409	chr10:94429542	NA	0.4	7.27	0.32	1.52e-12	Body mass index;Multiple sclerosis;
LGG	trans	rs800082	1.000	rs9817588	chr3:144288302	A/T	cg24215973	chr2:240111563	HDAC4	-0.49	-8.52	-0.37	2.22e-16	Smoking behavior;
LGG	cis	rs2415984	0.579	rs61993338	chr14:46969142	T/C	cg14871534	chr14:47121158	RPL10L	-0.59	-10.29	-0.43	1.63e-22	Number of children ever born;
LGG	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg10845886	chr2:3471009	TTC15	-0.48	-9.76	-0.41	1.39e-20	Neurofibrillary tangles;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg10756647	chr7:56101905	PSPH	0.7	7.13	0.31	3.81e-12	Diabetic kidney disease;
LGG	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg04166393	chr7:2884313	GNA12	0.45	8.61	0.37	1.14e-16	Height;
LGG	trans	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg24247370	chr13:99142703	STK24	-0.37	-6.7	-0.3	5.89e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs73787773	0.629	rs27982	chr5:111463837	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	0.52	6.68	0.3	6.92e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11225247	0.764	rs11225237	chr11:102250527	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs11158198	0.738	rs10134110	chr14:58573183	C/G	cg15908186	chr14:58618357	C14orf37	0.52	9.07	0.39	3.49e-18	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg26695010	chr11:65641043	EFEMP2	-0.6	-10.66	-0.44	7.4e-24	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.94	-0.42	3.03e-21	Response to antipsychotic treatment;
LGG	cis	rs1620921	0.598	rs12176297	chr6:161266417	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.01e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1816854	0.938	rs7966902	chr12:44200485	A/C	cg20956634	chr12:44200518	TWF1	0.53	7.71	0.34	7.92e-14	Inflammatory bowel disease;
LGG	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg03795903	chr2:30669940	LCLAT1	-0.53	-7.33	-0.32	1e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.73	-15.13	-0.58	2.5e-42	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg13206674	chr6:150067644	NUP43	0.63	14.19	0.55	3.41e-38	Lung cancer;
LGG	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06915872	chr16:87998081	BANP	0.46	6.87	0.3	2.14e-11	Menopause (age at onset);
LGG	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.87	0.34	2.61e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	cis	rs72781680	1.000	rs72788286	chr2:24098321	A/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.59	0.41	5.63e-20	Lymphocyte counts;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21963583	chr11:68658836	MRPL21	0.58	10.16	0.43	5.07e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs986417	0.748	rs1956552	chr14:60942685	A/G	cg27398547	chr14:60952738	C14orf39	0.7	6.83	0.3	2.76e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4478137	0.824	rs4691905	chr4:164221437	T/C	cg06758707	chr4:164254230	NPY1R	0.73	13.34	0.53	1.43e-34	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg04025307	chr7:1156635	C7orf50	0.84	17.81	0.64	1.98e-54	Longevity;Endometriosis;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04064611	chr7:72298987	SBDSP;TYW1B	0.39	6.7	0.3	5.91e-11	Body mass index;
LGG	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	8.0	0.35	1.04e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs16854884	0.710	rs1530479	chr3:143819653	C/T	cg06585982	chr3:143692056	C3orf58	0.49	8.03	0.35	8.41e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs847577	0.674	rs7790479	chr7:97713101	C/G	cg13397024	chr7:97797637	LMTK2	-0.35	-6.65	-0.3	8.25e-11	Breast cancer;
LGG	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04530015	chr2:215796436	ABCA12	0.46	8.48	0.37	3.14e-16	Neuroblastoma;
LGG	cis	rs9398803	0.723	rs853973	chr6:127068347	A/G	cg19875578	chr6:126661172	C6orf173	-0.49	-9.02	-0.39	5.1e-18	Male-pattern baldness;
LGG	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg14689365	chr7:158441557	NCAPG2	0.58	7.01	0.31	8.26e-12	Height;
LGG	cis	rs7172689	0.866	rs68081678	chr15:81576030	A/G	cg11808699	chr15:81528661	IL16	-0.48	-9.67	-0.41	2.9e-20	Inattentive symptoms;
LGG	cis	rs1577917	0.740	rs7752502	chr6:86410651	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.41	0.36	5.17e-16	Response to antipsychotic treatment;
LGG	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.78	0.3	3.78e-11	Carotid intima media thickness;
LGG	cis	rs12410462	0.591	rs2644146	chr1:227733917	C/G	cg04117972	chr1:227635322	NA	0.46	8.37	0.36	6.87e-16	Major depressive disorder;
LGG	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg11502198	chr6:26597334	ABT1	0.69	12.48	0.5	5.04e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg15596359	chr8:11213517	TDH	-0.39	-8.03	-0.35	8.14e-15	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05665937	chr4:1216051	CTBP1	0.46	8.3	0.36	1.14e-15	Obesity-related traits;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg01966878	chr4:90757139	SNCA	-0.38	-7.79	-0.34	4.5e-14	Dementia with Lewy bodies;
LGG	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11792861	0.962	rs3829084	chr9:111801724	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.59	-9.57	-0.41	6.5e-20	Menarche (age at onset);
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.13	0.6	8.94e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg07157834	chr1:205819609	PM20D1	-0.39	-6.67	-0.3	7.31e-11	Parkinson's disease;
LGG	cis	rs737693	1.000	rs72981698	chr11:102726540	C/T	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.79	-0.45	2.26e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.83	0.38	2.13e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg10402321	chr1:26617780	UBXN11	-0.36	-6.96	-0.31	1.14e-11	Obesity-related traits;
LGG	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg15704280	chr7:45808275	SEPT13	-0.66	-12.11	-0.49	1.59e-29	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.05	0.46	2.28e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs782590	0.522	rs12329050	chr2:55894428	G/A	cg18811423	chr2:55921094	PNPT1	-0.75	-14.17	-0.55	4.18e-38	Metabolic syndrome;
LGG	cis	rs4321325	0.668	rs56346774	chr2:127932551	G/A	cg11380483	chr2:127933992	NA	0.69	8.84	0.38	2.08e-17	Protein C levels;
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.66	-11.07	-0.46	1.95e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs250677	0.687	rs171636	chr5:148434545	G/A	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.81	-0.3	3.02e-11	Breast cancer;
LGG	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg12463550	chr7:65579703	CRCP	0.63	7.48	0.33	3.67e-13	Diabetic kidney disease;
LGG	cis	rs36715	1.000	rs36693	chr5:127548700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.55	0.33	2.27e-13	Breast cancer;
LGG	cis	rs6429082	0.764	rs291369	chr1:235691913	T/C	cg26050004	chr1:235667680	B3GALNT2	0.63	10.3	0.43	1.51e-22	Adiposity;
LGG	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg08250081	chr4:10125330	NA	0.35	6.74	0.3	4.71e-11	Bone mineral density;
LGG	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg27398817	chr8:82754497	SNX16	-0.8	-11.54	-0.47	3.04e-27	Diastolic blood pressure;
LGG	cis	rs10463554	0.927	rs464702	chr5:102406884	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.58	-0.33	1.92e-13	Parkinson's disease;
LGG	trans	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.41e-17	Bladder cancer;
LGG	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg26384229	chr12:38710491	ALG10B	-0.88	-20.72	-0.69	5.81e-68	Heart rate;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs1444936	chr15:67635549	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.87	-0.3	2.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg18252515	chr7:66147081	NA	-1.34	-19.13	-0.66	1.46e-60	Diabetic kidney disease;
LGG	cis	rs3093024	0.595	rs4412174	chr6:167476066	A/G	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Rheumatoid arthritis;
LGG	cis	rs8068544	0.748	rs75881902	chr17:40156612	C/A	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.45	-0.56	2.5e-39	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg07636037	chr3:49044803	WDR6	0.79	14.14	0.55	5.32e-38	Menarche (age at onset);
LGG	cis	rs6735179	0.550	rs2382559	chr2:1757522	T/C	cg10160682	chr2:1713001	PXDN	-0.54	-9.59	-0.41	5.55e-20	Response to antipsychotic treatment;
LGG	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg07636037	chr3:49044803	WDR6	0.99	21.94	0.71	1.11e-73	Menarche (age at onset);
LGG	cis	rs2070488	0.662	rs6599203	chr3:38487802	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	12.21	0.49	6.4e-30	Electrocardiographic conduction measures;
LGG	cis	rs7503807	0.515	rs12453880	chr17:78637655	A/G	cg08454507	chr17:78755406	RPTOR	-0.48	-9.29	-0.4	6.13e-19	Obesity;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.25	-0.32	1.8e-12	Life satisfaction;
LGG	cis	rs75920871	0.588	rs688456	chr11:116722551	G/T	cg20608306	chr11:116969690	SIK3	-0.3	-7.46	-0.33	4.25e-13	Subjective well-being;
LGG	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg24848339	chr3:12840334	CAND2	0.46	11.05	0.46	2.43e-25	QRS complex (12-leadsum);
LGG	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.22	-0.43	3.11e-22	Total body bone mineral density;
LGG	cis	rs17092148	1.000	rs6088603	chr20:33370945	A/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs1461503	0.932	rs10790542	chr11:122838243	C/T	cg27398637	chr11:122830231	C11orf63	-0.72	-14.33	-0.55	7.93e-39	Menarche (age at onset);
LGG	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	7.28	0.32	1.49e-12	Response to antipsychotic treatment;
LGG	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg07382826	chr16:28625726	SULT1A1	0.43	9.2	0.39	1.18e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00097539	chr10:101946149	ERLIN1	0.48	7.44	0.33	5.02e-13	Gut microbiome composition (summer);
LGG	cis	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.75	-0.57	1.27e-40	IgG glycosylation;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs76419734	0.510	rs2544402	chr4:106687733	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.66	-0.34	1.13e-13	Post bronchodilator FEV1;
LGG	cis	rs3818285	0.655	rs588160	chr10:111641538	C/T	cg00817464	chr10:111662876	XPNPEP1	0.49	10.03	0.42	1.46e-21	Superior crus of antihelix expression;
LGG	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.45	-0.33	4.73e-13	Restless legs syndrome;
LGG	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	-0.81	-13.51	-0.53	2.59e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg27446573	chr6:127587934	RNF146	1.13	22.0	0.71	6.18e-74	Breast cancer;
LGG	trans	rs3808502	0.534	rs1529858	chr8:11145662	G/T	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.12e-11	Neuroticism;
LGG	cis	rs611744	0.816	rs626211	chr8:109189448	A/C	cg21045802	chr8:109455806	TTC35	0.4	7.15	0.32	3.5e-12	Dupuytren's disease;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg02158880	chr13:53174818	NA	0.48	9.83	0.42	7.66e-21	Lewy body disease;
LGG	cis	rs11779988	0.598	rs7844114	chr8:17909492	C/T	cg18067069	chr8:17937731	ASAH1	-0.32	-7.61	-0.33	1.52e-13	Breast cancer;
LGG	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03576123	chr11:487126	PTDSS2	0.94	13.8	0.54	1.58e-36	Body mass index;
LGG	cis	rs4321325	0.546	rs11886766	chr2:127948621	G/A	cg11380483	chr2:127933992	NA	0.63	8.78	0.38	3.24e-17	Protein C levels;
LGG	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg12091567	chr17:66097778	LOC651250	0.78	12.93	0.52	6.95e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11971779	0.680	rs17691238	chr7:139052284	A/G	cg07862535	chr7:139043722	LUC7L2	-0.41	-6.93	-0.31	1.41e-11	Diisocyanate-induced asthma;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.6	-10.15	-0.43	5.51e-22	Longevity;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs883565	0.771	rs1053516	chr3:39137883	G/A	cg01426195	chr3:39028469	NA	-0.66	-13.49	-0.53	3.12e-35	Handedness;
LGG	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg03162506	chr22:38580953	NA	0.38	9.61	0.41	4.83e-20	Cutaneous nevi;
LGG	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg19338460	chr6:170058176	WDR27	-0.6	-8.23	-0.36	1.98e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.69	-0.54	4.72e-36	Personality dimensions;
LGG	cis	rs11203032	0.831	rs9651424	chr10:90932935	A/G	cg16672925	chr10:90967113	CH25H	0.76	10.95	0.45	5.8e-25	Heart failure;
LGG	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg05163923	chr11:71159392	DHCR7	0.72	14.08	0.55	1.03e-37	Vitamin D levels;
LGG	cis	rs6430585	0.528	rs115469964	chr2:136696608	A/C	cg07169764	chr2:136633963	MCM6	1.27	25.45	0.76	5.25e-90	Corneal structure;
LGG	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg00825309	chr19:58991885	ZNF446	-0.48	-9.67	-0.41	2.85e-20	Uric acid clearance;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.58	-0.44	1.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	7.01	0.31	8.22e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg25880573	chr1:24073129	TCEB3	-0.31	-6.86	-0.3	2.25e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs11605924	0.819	rs12805422	chr11:45839889	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.5	-8.6	-0.37	1.25e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg25986240	chr4:9926439	SLC2A9	-0.34	-6.98	-0.31	1.02e-11	Bone mineral density;
LGG	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg04149295	chr10:70884716	VPS26A	0.48	7.19	0.32	2.55e-12	Left atrial antero-posterior diameter;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg20887711	chr4:1340912	KIAA1530	0.39	6.72	0.3	5.28e-11	Obesity-related traits;
LGG	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg08773314	chr2:239334832	ASB1	0.43	8.25	0.36	1.7e-15	Multiple system atrophy;
LGG	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs722599	0.748	rs59112602	chr14:75358817	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.19	-0.43	3.78e-22	IgG glycosylation;
LGG	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.86e-13	Life satisfaction;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.53e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-7.33	-0.32	1e-12	Systemic lupus erythematosus;
LGG	cis	rs2976388	0.566	rs6998746	chr8:143802456	A/C	cg06565975	chr8:143823917	SLURP1	0.5	12.24	0.49	4.87e-30	Urinary tract infection frequency;
LGG	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg22906224	chr7:99728672	NA	0.55	8.94	0.38	9.65e-18	Coronary artery disease;
LGG	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg04935436	chr20:30431758	NA	0.41	7.21	0.32	2.24e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2559856	0.967	rs7970837	chr12:102081576	A/G	cg15068132	chr12:102092402	CHPT1	-0.37	-6.73	-0.3	5.08e-11	Blood protein levels;
LGG	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg06532163	chr17:45867833	NA	0.54	9.15	0.39	1.78e-18	IgG glycosylation;
LGG	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.26	-0.32	1.7e-12	Schizophrenia;
LGG	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.62e-22	Diabetic kidney disease;
LGG	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg09201001	chr11:18656081	SPTY2D1	0.98	21.16	0.7	5.2e-70	Breast cancer;
LGG	cis	rs362272	0.524	rs10937924	chr4:3374898	T/C	cg06533319	chr4:3265114	C4orf44	-0.35	-6.94	-0.31	1.32e-11	Serum sulfate level;
LGG	cis	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	8.25	0.36	1.69e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg12927641	chr6:109611667	NA	-0.37	-7.08	-0.31	5.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	trans	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17712092	chr4:129076599	LARP1B	0.73	14.02	0.55	1.76e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	11.71	0.48	6.2e-28	Post bronchodilator FEV1;
LGG	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs17453880	0.929	rs4958570	chr5:152022254	C/G	cg12297329	chr5:152029980	NA	-0.9	-23.95	-0.74	4.87e-83	Subjective well-being;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg05941027	chr17:61774174	LIMD2	0.35	8.92	0.38	1.12e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.34	-0.32	9.45e-13	Refractive error;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg11062466	chr8:58055876	NA	0.49	8.09	0.35	5.38e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg24558204	chr6:135376177	HBS1L	0.63	10.99	0.45	4.06e-25	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg14227996	chr4:17616232	MED28	0.73	9.02	0.39	4.99e-18	Opioid sensitivity;
LGG	trans	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.71	-0.64	5.47e-54	Exhaled nitric oxide output;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg06634786	chr22:41940651	POLR3H	-0.44	-6.88	-0.3	1.99e-11	Neuroticism;
LGG	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg12496657	chr2:105488809	NA	0.39	6.8	0.3	3.23e-11	Body mass index;
LGG	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg03929089	chr4:120376271	NA	0.69	9.5	0.4	1.1e-19	Axial length;
LGG	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg20628663	chr10:43360327	NA	0.42	8.64	0.37	9.37e-17	Blood protein levels;
LGG	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09833538	chr9:123605306	PSMD5;LOC253039	0.45	7.14	0.31	3.7e-12	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02047359	chr10:75174015	ANXA7	0.49	7.88	0.34	2.36e-14	Gut microbiome composition (summer);
LGG	trans	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.09	0.42	9e-22	Metabolite levels;
LGG	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg16301924	chr13:53314226	LECT1	-0.34	-6.83	-0.3	2.7e-11	Lewy body disease;
LGG	cis	rs4268898	0.662	rs59996104	chr2:24404064	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-12.47	-0.5	5.89e-31	Asthma;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg18105134	chr13:113819100	PROZ	0.72	15.46	0.58	8.78e-44	Platelet distribution width;
LGG	cis	rs262150	0.788	rs2657389	chr7:158763795	G/A	cg19418458	chr7:158789849	NA	-0.46	-9.45	-0.4	1.73e-19	Facial morphology (factor 20);
LGG	cis	rs6942756	0.713	rs691158	chr7:129129982	G/T	cg02491457	chr7:128862824	NA	-0.66	-11.54	-0.47	3.09e-27	White matter hyperintensity burden;
LGG	cis	rs4262150	0.667	rs13188558	chr5:152274276	G/A	cg12297329	chr5:152029980	NA	0.61	11.99	0.49	4.74e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg19468946	chr17:37922297	IKZF3	-0.43	-7.76	-0.34	5.38e-14	Self-reported allergy;
LGG	cis	rs2463822	1.000	rs2513744	chr11:62077785	C/A	cg06239285	chr11:62104954	ASRGL1	1.14	15.49	0.58	6.58e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg27490568	chr2:178487706	NA	0.51	10.22	0.43	3.13e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs9443189	0.762	rs2748943	chr6:76435543	C/T	cg01950844	chr6:76311363	SENP6	-0.53	-7.07	-0.31	5.85e-12	Prostate cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09823679	chr13:53425813	NA	-0.43	-7.2	-0.32	2.46e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	11.15	0.46	9.65e-26	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.22	-0.46	5.34e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.88	0.45	1.03e-24	Aortic root size;
LGG	cis	rs13421350	0.579	rs28485589	chr2:173303031	A/G	cg15021238	chr2:173305865	ITGA6	-0.8	-9.2	-0.39	1.2e-18	Diabetic kidney disease;
LGG	cis	rs4789294	1.000	rs4789294	chr17:74419177	A/G	cg27112972	chr17:74378252	NA	-0.29	-7.14	-0.31	3.74e-12	Lymphocyte percentage of white cells;
LGG	cis	rs870825	0.655	rs12502771	chr4:185635834	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.42e-48	Morning vs. evening chronotype;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.2	-0.32	2.47e-12	Schizophrenia;
LGG	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg21045802	chr8:109455806	TTC35	0.53	9.71	0.41	1.99e-20	Dupuytren's disease;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg05793240	chr7:2802953	GNA12	0.36	8.39	0.36	5.84e-16	Height;
LGG	cis	rs4711350	0.723	rs549652	chr6:33686103	G/A	cg06471254	chr6:33690276	IP6K3	0.53	7.51	0.33	3.17e-13	Schizophrenia;
LGG	cis	rs9381040	0.610	rs4140580	chr6:41041742	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.68	-0.3	6.83e-11	Alzheimer's disease (late onset);
LGG	cis	rs4538187	1.000	rs34122334	chr2:64169309	A/G	cg14150252	chr2:64069583	UGP2	-0.49	-9.73	-0.41	1.69e-20	Systolic blood pressure;
LGG	cis	rs787274	0.543	rs1041086	chr9:115627744	C/G	cg13803584	chr9:115635662	SNX30	-0.65	-9.38	-0.4	2.92e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs921968	0.643	rs586374	chr2:219383003	A/C	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.82	16.1	0.6	1.26e-46	Hip circumference adjusted for BMI;
LGG	cis	rs953387	0.866	rs10193587	chr2:136925439	A/G	cg07169764	chr2:136633963	MCM6	0.48	7.45	0.33	4.71e-13	Arthritis (juvenile idiopathic);
LGG	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06634786	chr22:41940651	POLR3H	0.74	12.31	0.5	2.54e-30	Vitiligo;
LGG	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg15047889	chr8:124780837	FAM91A1	-0.48	-6.92	-0.31	1.49e-11	Pancreatic cancer;
LGG	cis	rs741702	0.928	rs2965214	chr19:13029188	G/A	cg04657146	chr19:12876947	HOOK2	0.43	7.06	0.31	6.08e-12	Red blood cell traits;
LGG	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.69	-0.37	6.44e-17	Hemoglobin concentration;
LGG	cis	rs11627756	0.957	rs4906236	chr14:103077242	G/A	cg12046867	chr14:103022105	NA	-0.44	-8.12	-0.35	4.15e-15	Mean platelet volume;
LGG	cis	rs67311347	1.000	rs9854493	chr3:40423622	T/C	cg13683864	chr3:40499215	RPL14	-1.15	-25.95	-0.77	2.47e-92	Renal cell carcinoma;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19717773	chr7:2847554	GNA12	-0.34	-7.05	-0.31	6.38e-12	Height;
LGG	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg23057051	chr16:89984268	MC1R	-0.36	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs7572644	0.679	rs4447576	chr2:28076248	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15369054	chr17:80825471	TBCD	0.49	7.14	0.32	3.52e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs977987	0.843	rs28558946	chr16:75489322	G/T	cg03315344	chr16:75512273	CHST6	0.55	10.9	0.45	8.92e-25	Dupuytren's disease;
LGG	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg00376283	chr12:123451042	ABCB9	0.67	11.6	0.47	1.77e-27	Neutrophil percentage of white cells;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.62	-0.33	1.43e-13	Rheumatoid arthritis;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg11062466	chr8:58055876	NA	0.44	7.75	0.34	6.01e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg03511173	chr18:77590860	NA	0.62	7.77	0.34	5.16e-14	Opioid sensitivity;
LGG	cis	rs854037	0.752	rs10940579	chr5:57130818	T/C	cg08523694	chr5:57076192	NA	0.52	8.36	0.36	7.46e-16	Birth weight;
LGG	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg16077055	chr2:106428750	NCK2	0.31	8.22	0.36	2.08e-15	Addiction;
LGG	cis	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg04990556	chr1:26633338	UBXN11	0.58	8.31	0.36	1.08e-15	Obesity-related traits;
LGG	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg01169559	chr10:831247	NA	0.53	9.31	0.4	5.34e-19	Uric acid levels;
LGG	cis	rs1451375	0.617	rs745043	chr7:50543955	T/G	cg20336341	chr7:50628841	DDC	-0.41	-7.1	-0.31	4.78e-12	Malaria;
LGG	cis	rs17433780	0.860	rs10922545	chr1:89492201	C/T	cg09516651	chr1:89888402	LOC400759	0.76	17.4	0.63	1.52e-52	Carotid intima media thickness;
LGG	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.3e-14	Calcium levels;
LGG	cis	rs7215564	0.908	rs115148337	chr17:78688545	G/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.08	-0.35	5.84e-15	Myopia (pathological);
LGG	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg06640241	chr16:89574553	SPG7	0.53	8.91	0.38	1.21e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs6964587	1.000	rs2299240	chr7:91654618	A/G	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs17152411	0.652	rs4962412	chr10:126654643	C/G	cg06432487	chr10:126623651	NA	0.39	6.75	0.3	4.5e-11	Height;
LGG	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.82	-15.26	-0.58	6.87e-43	Height;
LGG	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg20302533	chr7:39170763	POU6F2	0.5	11.52	0.47	3.69e-27	IgG glycosylation;
LGG	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg08344181	chr3:125677491	NA	-0.56	-7.32	-0.32	1.11e-12	Depression;
LGG	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.61	10.3	0.43	1.54e-22	Response to antipsychotic treatment;
LGG	cis	rs9462027	0.628	rs9689820	chr6:34752963	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg00717180	chr2:96193071	NA	-0.44	-8.0	-0.35	9.86e-15	Height;
LGG	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26306683	chr17:18585705	ZNF286B	0.42	7.27	0.32	1.57e-12	Pancreatic cancer;
LGG	cis	rs4330281	0.608	rs17043494	chr3:17402806	T/C	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.71e-11	Schizophrenia;
LGG	cis	rs4478137	0.501	rs6828399	chr4:164228471	T/C	cg06758707	chr4:164254230	NPY1R	-0.54	-7.99	-0.35	1.1e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6546550	0.901	rs3732266	chr2:70057448	T/G	cg02498382	chr2:70120550	SNRNP27	-0.41	-7.63	-0.33	1.37e-13	Prevalent atrial fibrillation;
LGG	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg04691961	chr3:161091175	C3orf57	0.45	9.27	0.4	7.16e-19	Morning vs. evening chronotype;
LGG	cis	rs34929064	1.000	rs35610974	chr7:22723960	G/A	cg18045685	chr7:22629474	NA	0.57	9.06	0.39	3.64e-18	Major depression and alcohol dependence;
LGG	cis	rs2303319	1.000	rs62188121	chr2:162232085	T/C	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg26441486	chr22:50317300	CRELD2	0.4	7.19	0.32	2.58e-12	Schizophrenia;
LGG	cis	rs4740619	0.684	rs1887669	chr9:16035428	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.97	-0.45	4.58e-25	Body mass index;
LGG	cis	rs10932679	0.532	rs2024488	chr2:217662968	G/A	cg05032264	chr2:217675019	NA	-0.43	-8.62	-0.37	1.05e-16	Pulse pressure;
LGG	cis	rs4356932	1.000	rs4484324	chr4:76984713	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs6732160	0.574	rs7557055	chr2:73472670	G/A	cg01422370	chr2:73384389	NA	0.47	9.0	0.39	5.8e-18	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg24209194	chr3:40518798	ZNF619	-0.42	-6.8	-0.3	3.24e-11	Renal cell carcinoma;
LGG	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg25174290	chr11:3078921	CARS	-0.47	-8.37	-0.36	6.74e-16	Calcium levels;
LGG	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg25986240	chr4:9926439	SLC2A9	-0.46	-9.83	-0.42	8.07e-21	Bone mineral density;
LGG	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.56e-12	Refractive error;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg20891283	chr12:69753455	YEATS4	0.78	12.55	0.5	2.57e-31	Response to diuretic therapy;
LGG	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.91e-22	Height;
LGG	cis	rs457717	0.798	rs6881371	chr5:75922669	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.4	-7.62	-0.33	1.45e-13	Hearing impairment;
LGG	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.16	0.43	5.15e-22	Iron status biomarkers;
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg27476859	chr7:2772710	GNA12	0.43	7.38	0.32	7.33e-13	Height;
LGG	cis	rs12643440	0.538	rs62296684	chr4:17137455	A/T	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs4731207	0.698	rs10260710	chr7:124455986	C/A	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg15948088	chr11:109293068	C11orf87	0.57	9.59	0.41	5.56e-20	Schizophrenia;
LGG	cis	rs262150	1.000	rs262149	chr7:158778256	A/G	cg19418458	chr7:158789849	NA	0.49	9.58	0.41	5.98e-20	Facial morphology (factor 20);
LGG	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg03114573	chr12:45410052	DBX2	-0.51	-8.8	-0.38	2.77e-17	Gut microbiome composition (summer);
LGG	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.69	0.51	7.06e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs3206736	0.548	rs10254796	chr7:35070935	A/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.22	0.32	2.15e-12	Diastolic blood pressure;
LGG	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg03030879	chr14:75389066	RPS6KL1	0.38	6.98	0.31	1.03e-11	Caffeine consumption;
LGG	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg16325326	chr1:53192061	ZYG11B	-0.76	-18.38	-0.65	4.49e-57	Monocyte count;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.44	-0.37	4.02e-16	Obesity-related traits;
LGG	cis	rs2742417	1.000	rs2673039	chr3:45748435	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.82	-0.45	1.81e-24	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-8.82	-0.38	2.26e-17	Parkinson's disease;
LGG	cis	rs7077256	0.542	rs12761965	chr10:65213644	G/A	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.97	0.35	1.27e-14	Personality dimensions;
LGG	cis	rs919433	0.963	rs4850787	chr2:198181750	G/A	cg00792783	chr2:198669748	PLCL1	-0.43	-6.74	-0.3	4.85e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-9.22	-0.39	1.02e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9487094	0.778	rs11757877	chr6:109681882	T/C	cg16315928	chr6:109776240	MICAL1	0.51	8.44	0.37	4.02e-16	Height;
LGG	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg04362960	chr10:104952993	NT5C2	0.47	8.05	0.35	6.84e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6835098	0.520	rs2127896	chr4:174211285	G/A	cg08422745	chr4:174089978	GALNT7	-0.47	-7.52	-0.33	2.91e-13	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg07636037	chr3:49044803	WDR6	-0.87	-14.38	-0.56	5.03e-39	Menarche (age at onset);
LGG	cis	rs13088318	0.504	rs535173	chr3:101055424	T/C	cg11279151	chr3:101281821	RG9MTD1	0.39	7.48	0.33	3.89e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.98	-0.39	6.61e-18	Response to antipsychotic treatment;
LGG	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg02753203	chr1:228287806	NA	0.9	18.84	0.66	3.43e-59	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg05941027	chr17:61774174	LIMD2	0.36	9.06	0.39	3.63e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7166081	1.000	rs16950776	chr15:67510604	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.86	-0.3	2.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg10621924	chr7:39171070	POU6F2	0.33	6.89	0.31	1.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1670533	1.000	rs13134921	chr4:1054177	A/G	cg27284194	chr4:1044797	NA	0.55	9.83	0.42	7.7e-21	Recombination rate (females);
LGG	trans	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19894588	chr14:64061835	NA	0.63	10.69	0.44	5.64e-24	Glioblastoma;Glioma;
LGG	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.76	-0.3	4.15e-11	Chronic lymphocytic leukemia;
LGG	cis	rs888194	0.690	rs11067231	chr12:109993603	C/A	cg19025524	chr12:109796872	NA	-0.34	-6.89	-0.31	1.8e-11	Neuroticism;
LGG	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.78	-8.69	-0.37	6.26e-17	Response to haloperidol in psychosis;
LGG	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs7683537	0.887	rs7678412	chr4:185648611	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Systemic lupus erythematosus;
LGG	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.84	-0.3	2.55e-11	Inflammatory bowel disease;
LGG	cis	rs208520	0.874	rs208512	chr6:66943869	C/G	cg07460842	chr6:66804631	NA	-0.89	-15.4	-0.58	1.6e-43	Exhaled nitric oxide output;
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg07157834	chr1:205819609	PM20D1	0.42	7.07	0.31	5.76e-12	Parkinson's disease;
LGG	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg02772935	chr3:125709198	NA	-0.52	-6.65	-0.3	8.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.52	0.37	2.3e-16	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg26597838	chr10:835615	NA	0.75	10.33	0.43	1.24e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9443645	0.901	rs2174739	chr6:79659170	C/T	cg18132916	chr6:79620363	NA	0.31	8.51	0.37	2.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3845702	0.736	rs6727890	chr2:180832675	T/C	cg01881094	chr2:180872142	CWC22	-1.25	-16.87	-0.62	3.8300000000000002e-50	Schizophrenia;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-8.06	-0.35	6.68e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2201728	0.702	rs66673210	chr4:100192413	C/T	cg07219303	chr4:100140905	ADH6	-0.37	-6.95	-0.31	1.27e-11	Cardiac Troponin-T levels;
LGG	cis	rs4450131	1.000	rs4450131	chr10:126383363	C/T	cg08799069	chr10:126477246	METTL10	-0.31	-6.74	-0.3	4.78e-11	White blood cell count (basophil);
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg09699651	chr6:150184138	LRP11	0.57	9.56	0.41	6.83e-20	Lung cancer;
LGG	cis	rs9948	0.786	rs62156225	chr2:97414118	T/C	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	5.09e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2235649	0.833	rs9925460	chr16:1849943	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.65	-0.3	8.34e-11	Blood metabolite levels;
LGG	cis	rs4889855	0.578	rs7216808	chr17:78484187	A/G	cg16591659	chr17:78472290	NA	-0.42	-9.38	-0.4	2.9e-19	Fractional excretion of uric acid;
LGG	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-10.88	-0.45	1.05e-24	Bipolar disorder;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.63	0.44	8.86e-24	Personality dimensions;
LGG	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.71	-0.41	2.01e-20	Diabetic retinopathy;
LGG	cis	rs4650994	0.623	rs7534394	chr1:178622760	G/A	cg12486710	chr1:178512616	C1orf220	-0.39	-7.73	-0.34	6.61e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.48	-0.47	5.31e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	11.29	0.46	2.82e-26	HIV-1 control;
LGG	cis	rs1784581	0.802	rs6455787	chr6:162411378	G/A	cg17173639	chr6:162384350	PARK2	0.76	17.85	0.64	1.35e-54	Itch intensity from mosquito bite;
LGG	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg09361094	chr10:834503	NA	-0.3	-7.95	-0.35	1.49e-14	Survival in rectal cancer;
LGG	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-10.85	-0.45	1.37e-24	Reticulocyte count;
LGG	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.77	-0.54	2.06e-36	Alzheimer's disease;
LGG	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.73	-0.34	6.61e-14	Joint mobility (Beighton score);
LGG	cis	rs4788570	0.566	rs2052873	chr16:71505303	C/T	cg06353428	chr16:71660113	MARVELD3	-0.86	-11.55	-0.47	2.69e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22433210	chr17:43662623	NA	0.63	10.85	0.45	1.33e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.5	0.33	3.35e-13	Eosinophil percentage of white cells;
LGG	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg10840412	chr1:235813424	GNG4	0.5	6.83	0.3	2.73e-11	Bipolar disorder;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.54	0.33	2.45e-13	Schizophrenia;
LGG	cis	rs2066819	0.786	rs111580405	chr12:56739557	A/G	cg26714650	chr12:56694279	CS	-1.59	-16.49	-0.61	2.05e-48	Psoriasis vulgaris;
LGG	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg00012203	chr2:219082015	ARPC2	0.78	14.73	0.56	1.49e-40	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LGG	cis	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg07460842	chr6:66804631	NA	-0.75	-14.08	-0.55	9.61e-38	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs12249377	0.519	rs7087400	chr10:92587180	A/G	cg14313238	chr10:92632228	RPP30	0.4	7.16	0.32	3.22e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs12681366	0.734	rs716770	chr8:95390921	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.77	0.3	3.82e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1707322	0.721	rs10890346	chr1:46223892	C/T	cg03146154	chr1:46216737	IPP	-0.58	-11.39	-0.47	1.17e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6976053	0.935	rs3847063	chr7:100498475	C/T	cg03098644	chr7:100410630	EPHB4	0.39	6.9	0.31	1.68e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.19	0.36	2.6e-15	Iron status biomarkers;
LGG	cis	rs9460578	0.561	rs4612156	chr6:20882841	C/G	cg13405222	chr6:20811065	CDKAL1	-0.53	-9.61	-0.41	4.58e-20	Breast cancer;
LGG	cis	rs1125355	0.690	rs62183660	chr2:159639316	A/G	cg02251393	chr2:159651559	DAPL1	0.43	8.89	0.38	1.41e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12618769	0.597	rs55934321	chr2:99099417	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.53	0.37	2.15e-16	Bipolar disorder;
LGG	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg22906224	chr7:99728672	NA	0.56	8.87	0.38	1.55e-17	Coronary artery disease;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg07308232	chr7:1071921	C7orf50	-0.43	-6.95	-0.31	1.25e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11662586	0.573	rs7238269	chr18:77706294	A/G	cg20368463	chr18:77673604	PQLC1	0.66	13.08	0.52	1.8e-33	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg25008857	chr14:105974488	NA	0.55	9.41	0.4	2.28e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22146484	chr8:57123862	CHCHD7;PLAG1	0.45	7.32	0.32	1.09e-12	Gut microbiome composition (summer);
LGG	cis	rs7737355	0.947	rs31258	chr5:130824536	G/A	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	7.04e-18	Life satisfaction;
LGG	cis	rs4262150	0.883	rs72802853	chr5:152218058	C/T	cg12297329	chr5:152029980	NA	-0.67	-12.46	-0.5	6.02e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg15627072	chr1:2432621	PLCH2	0.37	8.22	0.36	2.02e-15	Ulcerative colitis;
LGG	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.89	0.45	9.85e-25	Mean platelet volume;
LGG	cis	rs62025270	0.688	rs62022941	chr15:86256055	G/A	cg25843651	chr15:86329602	KLHL25	0.56	8.64	0.37	8.94e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg21100191	chr22:23484243	RTDR1	0.99	22.76	0.73	1.62e-77	Bone mineral density;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.15	-0.52	8.87e-34	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.97	-0.31	1.1e-11	Neuroticism;
LGG	trans	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg25214090	chr10:38739885	LOC399744	0.7	12.54	0.5	3.07e-31	Corneal astigmatism;
LGG	cis	rs56399783	0.901	rs11764225	chr7:2775607	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.3	0.32	1.24e-12	Childhood ear infection;
LGG	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg25319279	chr11:5960081	NA	-0.47	-7.74	-0.34	6.09e-14	DNA methylation (variation);
LGG	cis	rs9902453	0.967	rs12150261	chr17:28320473	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.06	-0.52	2.03e-33	Coffee consumption (cups per day);
LGG	cis	rs7241530	0.536	rs34361461	chr18:75890482	A/G	cg14642773	chr18:75888474	NA	0.46	8.98	0.39	7.05e-18	Educational attainment (years of education);
LGG	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg18681998	chr4:17616180	MED28	0.83	18.26	0.65	1.74e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01235203	chr3:187461998	BCL6	0.46	7.47	0.33	3.91e-13	Cognitive performance;
LGG	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07570687	chr10:102243282	WNT8B	0.43	7.22	0.32	2.09e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.64e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.21	-0.36	2.26e-15	Glycated hemoglobin levels;
LGG	cis	rs727505	1.000	rs6943653	chr7:124512249	G/A	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08856697	chr17:61627902	DCAF7	-0.48	-7.06	-0.31	6.07e-12	Gut microbiome composition (summer);
LGG	cis	rs12780845	0.558	rs7090965	chr10:17216803	A/G	cg01003015	chr10:17271136	VIM	0.43	7.28	0.32	1.48e-12	Homocysteine levels;
LGG	cis	rs745080	0.519	rs2884225	chr14:52941274	G/A	cg23333723	chr14:53022898	GPR137C	-0.41	-8.37	-0.36	6.82e-16	Orofacial clefts;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg08888203	chr3:10149979	C3orf24	0.57	9.76	0.41	1.33e-20	Alzheimer's disease;
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24783322	chr8:49834643	SNAI2	0.46	7.08	0.31	5.33e-12	Gut microbiome composition (summer);
LGG	cis	rs3087591	0.708	rs2525574	chr17:29705947	T/C	cg24425628	chr17:29625626	OMG;NF1	0.6	12.63	0.51	1.26e-31	Hip circumference;
LGG	trans	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.85	16.45	0.61	3.24e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.03	0.46	2.88e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.88	0.3	1.91e-11	Aortic root size;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.67	-12.11	-0.49	1.6e-29	Obesity-related traits;
LGG	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11890956	chr21:40555474	PSMG1	-1.0	-21.47	-0.71	1.74e-71	Cognitive function;
LGG	cis	rs55788414	0.789	rs4630561	chr16:81183108	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.94e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs4819852	1.000	rs1034565	chr22:19984211	A/G	cg07821417	chr22:19972146	ARVCF	-0.63	-13.71	-0.54	3.8e-36	Pulse pressure;
LGG	cis	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.06	0.35	6.36e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1152591	0.543	rs1152594	chr14:64675044	C/T	cg21174375	chr14:64681225	SYNE2	-0.43	-8.05	-0.35	6.83e-15	Atrial fibrillation;
LGG	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.31	0.32	1.15e-12	Refractive error;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17300391	chr3:116164035	LSAMP	0.39	6.83	0.3	2.71e-11	Bipolar disorder;
LGG	trans	rs9354308	0.738	rs2211637	chr6:66596941	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.68	-0.3	6.84e-11	Metabolite levels;
LGG	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg05555928	chr11:63887634	MACROD1	0.62	9.03	0.39	4.58e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2354432	0.607	rs1530336	chr1:146685121	G/A	cg25205988	chr1:146714368	CHD1L	1.09	9.39	0.4	2.82e-19	Mitochondrial DNA levels;
LGG	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.33	-0.32	1.03e-12	Retinal vascular caliber;
LGG	cis	rs9462027	0.628	rs10947532	chr6:34780315	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	cis	rs6815814	0.699	rs11730390	chr4:38881414	T/C	cg06935464	chr4:38784597	TLR10	0.56	7.79	0.34	4.37e-14	Breast cancer;
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.97	-0.45	4.84e-25	Neuroticism;
LGG	cis	rs11157436	0.602	rs11157435	chr14:22636784	A/C	cg00994629	chr14:22694547	NA	0.33	7.12	0.31	4.23e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	trans	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg25214090	chr10:38739885	LOC399744	0.56	10.25	0.43	2.27e-22	Corneal astigmatism;
LGG	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.59	-0.37	1.31e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.35	0.5	1.77e-30	Lymphocyte counts;
LGG	cis	rs17321999	1.000	rs72787722	chr2:30489941	T/C	cg05247661	chr2:30472410	LBH	0.54	8.51	0.37	2.48e-16	Systemic lupus erythematosus;
LGG	cis	rs9287719	0.967	rs6712304	chr2:10754375	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.44e-13	Prostate cancer;
LGG	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg13944111	chr12:107296891	NA	0.28	7.51	0.33	3.16e-13	Triglyceride levels;
LGG	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg26913058	chr16:419975	MRPL28	-0.51	-8.1	-0.35	5e-15	Body mass index;
LGG	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07234876	chr8:600039	NA	0.97	10.23	0.43	2.71e-22	IgG glycosylation;
LGG	trans	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07923666	chr12:49932857	KCNH3	-0.53	-7.92	-0.35	1.73e-14	Resting heart rate;
LGG	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg02487422	chr3:49467188	NICN1	0.57	10.48	0.44	3.33e-23	Resting heart rate;
LGG	cis	rs735539	0.636	rs9579928	chr13:21274807	C/G	cg04906043	chr13:21280425	IL17D	0.52	8.54	0.37	1.94e-16	Dental caries;
LGG	cis	rs11605275	1.000	rs11605275	chr11:20031865	C/T	cg14835545	chr11:20032148	NAV2	-0.95	-11.1	-0.46	1.48e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.21	0.39	1.16e-18	Fuchs's corneal dystrophy;
LGG	cis	rs12931792	0.782	rs6565176	chr16:30174926	T/C	cg17640201	chr16:30407289	ZNF48	0.52	8.78	0.38	3.23e-17	Tonsillectomy;
LGG	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg17085576	chr10:5658249	NA	-0.42	-7.76	-0.34	5.34e-14	Breast cancer;
LGG	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg10523679	chr1:76189770	ACADM	0.83	14.28	0.55	1.31e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg00071950	chr4:10020882	SLC2A9	0.43	8.84	0.38	2.05e-17	Bone mineral density;
LGG	cis	rs3803915	1.000	rs3803915	chr19:2160529	C/A	cg27073066	chr19:2169160	DOT1L	1.03	12.77	0.51	3.48e-32	Body mass index;Myocardial infarction;
LGG	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg09448879	chr15:79043637	NA	-0.43	-8.46	-0.37	3.57e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg25019033	chr10:957182	NA	-0.58	-11.83	-0.48	2.2e-28	Eosinophil percentage of granulocytes;
LGG	cis	rs7312774	0.618	rs57361179	chr12:107337483	T/C	cg16260113	chr12:107380972	MTERFD3	0.93	8.66	0.37	7.83e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg19748678	chr4:122722346	EXOSC9	0.49	9.3	0.4	5.71e-19	Type 2 diabetes;
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03264133	chr6:25882463	NA	-0.92	-17.43	-0.63	1.12e-52	Intelligence (multi-trait analysis);
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.6	8.84	0.38	1.96e-17	Renal function-related traits (BUN);
LGG	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg20887711	chr4:1340912	KIAA1530	0.61	12.12	0.49	1.49e-29	Longevity;
LGG	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg16850897	chr7:100343110	ZAN	-0.55	-7.51	-0.33	3.09e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg14789911	chr21:47582049	C21orf56	-0.53	-9.38	-0.4	2.88e-19	Testicular germ cell tumor;
LGG	cis	rs7717393	0.786	rs9313900	chr5:155800253	C/T	cg12904904	chr5:155754151	SGCD	-0.69	-7.63	-0.33	1.39e-13	Egg allergy;
LGG	cis	rs9303280	0.901	rs1008723	chr17:38066267	G/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.83	-0.38	2.21e-17	Self-reported allergy;
LGG	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.1	0.52	1.35e-33	Lung cancer in ever smokers;
LGG	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg08807101	chr21:30365312	RNF160	0.77	14.08	0.55	9.7e-38	Selective IgA deficiency;
LGG	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.17	-0.58	1.76e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs12493885	0.729	rs10513452	chr3:153640429	A/C	cg12800244	chr3:153838788	SGEF	-0.65	-7.32	-0.32	1.08e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs67311347	1.000	rs9882171	chr3:40518821	G/A	cg24209194	chr3:40518798	ZNF619	0.45	7.1	0.31	4.67e-12	Renal cell carcinoma;
LGG	cis	rs11225247	1.000	rs75217705	chr11:102294079	C/T	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg18681998	chr4:17616180	MED28	0.86	19.57	0.67	1.42e-62	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs834603	0.575	rs1799376	chr7:47479583	C/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.91	-0.48	1e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs36051895	0.632	rs1328919	chr9:5166548	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.11	-0.57	3.19e-42	Pediatric autoimmune diseases;
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.808	rs12452288	chr17:28235220	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.64	0.54	7.54e-36	Coffee consumption (cups per day);
LGG	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.91	0.31	1.61e-11	Aortic root size;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00166722	chr3:10149974	C3orf24	0.52	8.92	0.38	1.13e-17	Alzheimer's disease;
LGG	cis	rs6762644	0.507	rs9311400	chr3:4764171	A/G	cg11584376	chr3:4789075	ITPR1	-0.39	-8.44	-0.37	4.22e-16	Breast cancer;
LGG	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg17145862	chr1:211918768	LPGAT1	-0.87	-19.96	-0.68	2.03e-64	Leprosy;
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.82	0.3	2.78e-11	Vitiligo;
LGG	cis	rs9393777	0.623	rs3757150	chr6:26476782	T/A	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10426930	0.752	rs56249413	chr19:5036730	G/A	cg15621731	chr19:5074616	KDM4B	-0.33	-8.07	-0.35	6.29e-15	Monocyte percentage of white cells;
LGG	trans	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg06521331	chr12:34319734	NA	0.45	8.07	0.35	5.89e-15	Bladder cancer;
LGG	cis	rs9815354	1.000	rs9854833	chr3:41775577	C/T	cg03022575	chr3:42003672	ULK4	0.66	8.28	0.36	1.3e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.33	-0.43	1.23e-22	Aortic root size;
LGG	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg06917634	chr15:78832804	PSMA4	0.69	13.59	0.53	1.22e-35	Sudden cardiac arrest;
LGG	cis	rs2235649	0.625	rs56206107	chr16:1947425	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.43	-6.83	-0.3	2.6e-11	Blood metabolite levels;
LGG	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg16070123	chr10:51489643	NA	-0.4	-7.34	-0.32	9.57e-13	Prostate-specific antigen levels;
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.08e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg24764310	chr7:157512201	PTPRN2	-0.36	-7.15	-0.32	3.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg14926445	chr8:58193284	C8orf71	-0.8	-10.32	-0.43	1.27e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs67133203	0.808	rs12819517	chr12:51517710	C/T	cg14688905	chr12:51403056	SLC11A2	0.71	10.36	0.43	9.59e-23	Urinary tract infection frequency;
LGG	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.91	0.42	3.93e-21	Morning vs. evening chronotype;
LGG	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.54	-0.41	8.07e-20	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.41	6.92	0.31	1.51e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2408955	0.522	rs6580650	chr12:48418556	G/T	cg24011408	chr12:48396354	COL2A1	-0.6	-9.9	-0.42	4.54e-21	Glycated hemoglobin levels;
LGG	cis	rs7241530	0.662	rs6506756	chr18:75905196	C/G	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.55e-19	Educational attainment (years of education);
LGG	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	cg15522984	chr1:182991683	LAMC1	0.44	8.78	0.38	3.29e-17	Fuchs's corneal dystrophy;
LGG	cis	rs524281	0.861	rs11227415	chr11:65885459	C/T	cg16950941	chr11:66035639	RAB1B	0.46	6.69	0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg23758822	chr17:41437982	NA	0.88	13.09	0.52	1.5e-33	Menopause (age at onset);
LGG	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg24692254	chr21:30365293	RNF160	-0.66	-12.15	-0.49	1.13e-29	Pancreatic cancer;
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg05941027	chr17:61774174	LIMD2	0.36	8.71	0.38	5.27e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg04287289	chr16:89883240	FANCA	0.6	6.85	0.3	2.32e-11	Interleukin-17 levels;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg21366198	chr4:185655624	MLF1IP	0.44	7.68	0.34	9.3e-14	Kawasaki disease;
LGG	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg05925327	chr15:68127851	NA	-0.39	-8.11	-0.35	4.62e-15	Restless legs syndrome;
LGG	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg04469686	chr1:162760199	HSD17B7	0.47	7.17	0.32	2.93e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg01324343	chr3:183735012	ABCC5	-0.79	-14.29	-0.55	1.29e-38	Anterior chamber depth;
LGG	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	8.74	0.38	4.28e-17	Coronary artery disease;
LGG	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg14664628	chr15:75095509	CSK	-0.56	-10.48	-0.44	3.4e-23	Breast cancer;
LGG	cis	rs6784615	0.590	rs7620015	chr3:52510697	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	-0.62	-7.24	-0.32	1.9e-12	Waist-hip ratio;
LGG	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-9.34	-0.4	4.13e-19	Coronary artery disease;
LGG	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.75	0.3	4.53e-11	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4936894	0.500	rs7107539	chr11:124180282	G/T	cg27160556	chr11:124181099	OR8D1	0.46	10.77	0.45	2.68e-24	Aging (time to death);
LGG	cis	rs9457247	0.967	rs376097	chr6:167410878	A/G	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.71	-0.45	4.72e-24	Lung cancer;
LGG	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23598886	chr18:12777645	NA	0.74	10.36	0.43	9.15e-23	Inflammatory skin disease;
LGG	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg17757837	chr7:157058334	UBE3C	-0.78	-15.99	-0.6	3.83e-46	Body mass index;
LGG	cis	rs1015291	0.708	rs10770561	chr12:19999041	C/T	cg25401612	chr12:20009446	NA	0.36	7.71	0.34	7.92e-14	Diastolic blood pressure;
LGG	cis	rs10791097	0.506	rs10750446	chr11:130706918	T/C	cg12179176	chr11:130786555	SNX19	-0.54	-9.14	-0.39	1.98e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs897984	0.542	rs4468641	chr16:31096876	A/C	cg02466173	chr16:30829666	NA	-0.41	-7.5	-0.33	3.22e-13	Dementia with Lewy bodies;
LGG	cis	rs6761276	0.505	rs13019891	chr2:113829869	G/T	cg05949173	chr2:113825882	IL1F10	0.52	10.43	0.44	5.22e-23	Protein quantitative trait loci;
LGG	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg12463550	chr7:65579703	CRCP	0.81	8.69	0.37	6.2e-17	Diabetic kidney disease;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg26513180	chr16:89883248	FANCA	0.83	8.72	0.38	5.12e-17	Skin colour saturation;
LGG	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg22437258	chr11:111473054	SIK2	-0.53	-8.72	-0.38	5.06e-17	Primary sclerosing cholangitis;
LGG	cis	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg13443165	chr9:33130375	B4GALT1	0.73	13.89	0.54	6.5e-37	IgG glycosylation;
LGG	cis	rs3087591	0.683	rs4368212	chr17:29639263	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	12.32	0.5	2.32e-30	Hip circumference;
LGG	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg17050807	chr22:42548356	NA	-0.39	-7.54	-0.33	2.44e-13	Schizophrenia;
LGG	cis	rs7267979	0.718	rs2983489	chr20:25244120	C/A	cg06421707	chr20:25228305	PYGB	0.44	9.23	0.39	9.38e-19	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6840360	0.533	rs1397683	chr4:152715916	T/C	cg22705602	chr4:152727874	NA	0.37	9.38	0.4	2.89e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05165339	chr4:1420672	NA	0.31	8.27	0.36	1.39e-15	Obesity-related traits;
LGG	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19524238	chr7:2802976	GNA12	0.32	7.78	0.34	4.82e-14	Height;
LGG	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg06618935	chr21:46677482	NA	0.5	9.8	0.41	9.87e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28647808	0.881	rs28602295	chr9:136267471	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs17253792	0.822	rs80085988	chr14:56096173	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg25173405	chr17:45401733	C17orf57	0.49	8.52	0.37	2.34e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg01221209	chr5:554886	NA	-0.47	-9.54	-0.41	8.22e-20	Ulcerative colitis;
LGG	cis	rs6784615	0.744	rs123603	chr3:52432033	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.89	0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs9513627	0.915	rs73556179	chr13:100122009	G/A	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs4262150	0.883	rs72799200	chr5:152191955	A/T	cg12297329	chr5:152029980	NA	-0.68	-12.82	-0.51	2.03e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg23894439	chr1:183413866	NA	-0.47	-8.8	-0.38	2.67e-17	Systemic lupus erythematosus;
LGG	cis	rs4722585	0.533	rs12334205	chr7:26202490	G/A	cg07876897	chr7:26191696	NFE2L3	0.37	7.37	0.32	7.92e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg19539972	chr4:7069911	GRPEL1	0.79	10.67	0.44	6.3e-24	Monocyte percentage of white cells;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17983571	chr10:65186953	JMJD1C	-0.58	-6.74	-0.3	4.64e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17539620	0.624	rs871068	chr6:154837514	C/A	cg17771515	chr6:154831774	CNKSR3	0.62	7.63	0.33	1.4e-13	Lipoprotein (a) levels;
LGG	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12765878	0.603	rs1570221	chr10:105656874	G/A	cg11005552	chr10:105648138	OBFC1	-0.73	-12.81	-0.51	2.23e-32	Coronary artery disease;
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.45	0.47	6.73e-27	Bipolar disorder;
LGG	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg01324343	chr3:183735012	ABCC5	0.86	18.39	0.65	4.4e-57	Anterior chamber depth;
LGG	cis	rs36093844	0.800	rs1445504	chr11:85584879	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7113850	0.541	rs76166238	chr11:24235418	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.47	0.44	3.72e-23	Bone fracture in osteoporosis;
LGG	cis	rs13424612	0.965	rs2289407	chr2:240954110	A/G	cg01812947	chr2:240904978	NDUFA10	0.41	6.87	0.3	2.09e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs6032067	0.929	rs2664581	chr20:43804522	A/C	cg10761708	chr20:43804764	PI3	0.74	11.75	0.48	4.38e-28	Blood protein levels;
LGG	trans	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg10840412	chr1:235813424	GNG4	0.56	7.35	0.32	8.88e-13	Bipolar disorder;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-15.11	-0.57	3.1e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs753778	0.559	rs2288997	chr8:142200731	A/G	cg18755752	chr8:142205143	DENND3	0.43	7.27	0.32	1.51e-12	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg24812749	chr6:127587940	RNF146	0.7	11.51	0.47	3.87e-27	Breast cancer;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs17672112	0.512	rs67917362	chr6:101370358	A/G	cg27451362	chr6:101846650	GRIK2	0.54	7.9	0.34	2.06e-14	Putamen volume;
LGG	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-8.17	-0.35	3.04e-15	Height;
LGG	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs2274273	1.000	rs67805055	chr14:55587552	C/T	cg04306507	chr14:55594613	LGALS3	0.62	17.11	0.62	3.24e-51	Protein biomarker;
LGG	cis	rs12049351	0.665	rs6665874	chr1:229589011	A/T	cg13547644	chr1:229569608	ACTA1	0.32	7.16	0.32	3.16e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg06221963	chr1:154839813	KCNN3	-0.5	-10.0	-0.42	1.89e-21	Prostate cancer;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.38e-50	Skin colour saturation;
LGG	cis	rs2688608	0.672	rs2227576	chr10:75678276	T/G	cg10168709	chr10:75599394	CAMK2G	-0.35	-7.01	-0.31	8.31e-12	Inflammatory bowel disease;
LGG	cis	rs9811920	0.809	rs6802817	chr3:99779264	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.5	-0.37	2.55e-16	Axial length;
LGG	cis	rs7582720	1.000	rs72926772	chr2:203804289	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4262150	0.960	rs7702551	chr5:152280130	A/C	cg12297329	chr5:152029980	NA	0.6	11.44	0.47	7.5e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs8064029	1.000	rs8064029	chr16:4913369	C/T	cg04440724	chr16:4920505	UBN1	-0.65	-7.85	-0.34	2.84e-14	Cancer;
LGG	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.07	0.31	5.76e-12	Bladder cancer;
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07157506	chr18:12883603	PTPN2	0.53	8.33	0.36	9.1e-16	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.87	0.42	5.71e-21	Prudent dietary pattern;
LGG	cis	rs9640161	0.789	rs2159234	chr7:150020422	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.59	-0.59	2.37e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg26174226	chr8:58114915	NA	-0.57	-7.77	-0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg03315344	chr16:75512273	CHST6	-0.5	-10.12	-0.43	7.26e-22	Dupuytren's disease;
LGG	cis	rs9815354	1.000	rs1716984	chr3:41965532	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.03e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.82	-0.34	3.56e-14	Personality dimensions;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg13880726	chr7:1868755	MAD1L1	0.45	7.81	0.34	3.9e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1007190	0.881	rs12941574	chr17:43030679	C/T	cg15406952	chr17:42872593	NA	-1.02	-10.85	-0.45	1.32e-24	DNA methylation (variation);
LGG	cis	rs240764	0.612	rs7773661	chr6:100919209	A/G	cg21058520	chr6:100914733	NA	0.47	8.13	0.35	4.04e-15	Neuroticism;
LGG	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg26384229	chr12:38710491	ALG10B	0.93	20.4	0.69	1.82e-66	Bladder cancer;
LGG	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg09238746	chr17:78121135	EIF4A3	-0.9	-15.48	-0.58	7.68e-44	Yeast infection;
LGG	cis	rs903263	0.901	rs3768258	chr1:84670457	A/G	cg10977910	chr1:84465055	TTLL7	0.4	6.69	0.3	6.3e-11	Breast cancer (male);
LGG	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg02574844	chr11:5959923	NA	-0.55	-8.58	-0.37	1.44e-16	DNA methylation (variation);
LGG	cis	rs2236918	0.643	rs1776139	chr1:242027363	T/G	cg17736920	chr1:242011382	EXO1	0.38	6.96	0.31	1.16e-11	Menopause (age at onset);
LGG	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg26150922	chr2:100937072	LONRF2	-0.55	-9.66	-0.41	3.01e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17453880	0.929	rs4958322	chr5:152020639	A/G	cg10931792	chr5:152022470	NA	0.4	8.7	0.37	5.85e-17	Subjective well-being;
LGG	cis	rs17208368	0.628	rs58863998	chr16:55100720	G/A	cg09947736	chr16:55091198	NA	0.67	12.52	0.5	3.54e-31	Hypospadias;
LGG	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.34	-0.5	1.88e-30	Response to antipsychotic treatment;
LGG	cis	rs9915657	0.773	rs9896360	chr17:70099469	C/G	cg09344028	chr17:70110421	NA	0.59	14.16	0.55	4.33e-38	Thyroid hormone levels;
LGG	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg00717180	chr2:96193071	NA	-0.49	-9.32	-0.4	4.75e-19	HDL cholesterol;
LGG	cis	rs67311347	0.544	rs9814779	chr3:40340431	T/C	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.9e-45	Renal cell carcinoma;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg24829409	chr8:58192753	C8orf71	-0.72	-9.6	-0.41	4.89e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.09	0.39	2.98e-18	Coronary artery disease;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2797369	0.665	rs817227	chr6:101464086	A/G	cg27451362	chr6:101846650	GRIK2	0.78	10.31	0.43	1.43e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs6988985	0.818	rs7463212	chr8:143991858	A/T	cg10324643	chr8:143916377	GML	-0.42	-8.73	-0.38	4.48e-17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg00383909	chr3:49044727	WDR6	0.43	7.12	0.31	4.21e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2729354	0.817	rs2467327	chr11:57279228	A/G	cg24343310	chr11:57249947	NA	0.45	8.52	0.37	2.32e-16	Blood protein levels;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg05025164	chr4:1340916	KIAA1530	-0.57	-9.97	-0.42	2.49e-21	Obesity-related traits;
LGG	cis	rs6489785	0.775	rs1168945	chr12:121327716	A/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.79	-0.3	3.55e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg01145232	chr6:150245071	RAET1G	0.33	7.07	0.31	5.82e-12	Testicular germ cell tumor;
LGG	cis	rs12949688	0.601	rs11079325	chr17:55834785	A/C	cg12582317	chr17:55822272	NA	0.48	10.97	0.45	4.97e-25	Schizophrenia;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.2	0.36	2.45e-15	Schizophrenia;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg05793240	chr7:2802953	GNA12	0.34	8.43	0.36	4.55e-16	Height;
LGG	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.3	-0.55	1.15e-38	Type 2 diabetes;
LGG	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.31	0.36	1.07e-15	Coronary artery disease;
LGG	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14952266	chr13:112191215	NA	-0.43	-7.74	-0.34	6.36e-14	Menarche (age at onset);
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg04503457	chr17:41445688	NA	-0.4	-9.95	-0.42	2.8e-21	Menopause (age at onset);
LGG	cis	rs7301826	1.000	rs1609985	chr12:131320170	A/G	cg11011512	chr12:131303247	STX2	0.34	7.44	0.33	5.05e-13	Plasma plasminogen activator levels;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.39	6.81	0.3	3.06e-11	Height;
LGG	cis	rs73086581	1.000	rs73086581	chr20:3977325	T/C	cg02187196	chr20:3869020	PANK2	0.8	11.22	0.46	5.33e-26	Response to antidepressants in depression;
LGG	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.03	-0.31	7.39e-12	Neuroticism;
LGG	cis	rs2455799	0.593	rs13078487	chr3:15929590	G/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.38	-0.32	7.55e-13	Mean platelet volume;
LGG	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg26039829	chr8:22132926	PIWIL2	0.53	12.34	0.5	1.93e-30	Hypertriglyceridemia;
LGG	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg16141378	chr3:129829833	LOC729375	0.46	10.57	0.44	1.56e-23	Retinal vascular caliber;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16327326	chr16:1662895	IFT140	0.44	7.32	0.32	1.09e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.12	0.68	3.87e-65	Smoking behavior;
LGG	cis	rs6032067	0.929	rs6017513	chr20:43835232	A/C	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.71	0.3	5.61e-11	Alzheimer's disease;
LGG	cis	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg07460842	chr6:66804631	NA	-0.95	-17.33	-0.63	3.31e-52	Exhaled nitric oxide output;
LGG	cis	rs9354308	0.764	rs9345708	chr6:66587096	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs36051895	0.695	rs11794778	chr9:5023794	G/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.03	-0.57	7.4e-42	Pediatric autoimmune diseases;
LGG	cis	rs6894268	0.762	rs6892309	chr5:179031198	T/A	cg22014891	chr5:179071901	C5orf60	-0.37	-7.37	-0.32	7.69e-13	Eating disorders;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-12.7	-0.51	6.77e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg13482628	chr17:19912719	NA	0.54	10.05	0.42	1.27e-21	Schizophrenia;
LGG	cis	rs10267417	0.557	rs10249101	chr7:19895397	T/G	cg05791153	chr7:19748676	TWISTNB	0.57	7.6	0.33	1.65e-13	Night sleep phenotypes;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.19	0.43	3.78e-22	Prudent dietary pattern;
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg06848047	chr4:90757629	SNCA	-0.39	-7.24	-0.32	1.94e-12	Dementia with Lewy bodies;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10284592	chr11:57434942	ZDHHC5	-0.49	-7.14	-0.31	3.62e-12	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg06636001	chr8:8085503	FLJ10661	0.57	10.89	0.45	9.31e-25	Retinal vascular caliber;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15344914	chr12:54567476	NA	-0.43	-6.88	-0.3	1.94e-11	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg08888203	chr3:10149979	C3orf24	0.57	9.54	0.41	8.44e-20	Alzheimer's disease;
LGG	cis	rs6787391	0.933	rs9841951	chr3:4742896	A/G	cg11584376	chr3:4789075	ITPR1	-0.34	-7.08	-0.31	5.22e-12	Breast cancer;
LGG	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-7.96	-0.35	1.31e-14	Longevity;Endometriosis;
LGG	trans	rs2840044	1.000	rs10068	chr17:33901965	C/G	cg19694781	chr19:47549865	TMEM160	0.54	8.94	0.38	9.07e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg16950941	chr11:66035639	RAB1B	0.56	10.44	0.44	4.68e-23	Gout;
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18252515	chr7:66147081	NA	0.42	7.1	0.31	4.59e-12	Aortic root size;
LGG	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.0	0.42	1.83e-21	Diabetic retinopathy;
LGG	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg05535760	chr7:792225	HEATR2	0.97	14.59	0.56	6.26e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-8.7	-0.37	5.68e-17	Kawasaki disease;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg16141378	chr3:129829833	LOC729375	0.38	9.05	0.39	4.01e-18	Joint mobility (Beighton score);
LGG	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg21918786	chr6:109611834	NA	-0.48	-8.89	-0.38	1.32e-17	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-6.79	-0.3	3.37e-11	Height;
LGG	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22496380	chr5:211416	CCDC127	-1.14	-9.68	-0.41	2.54e-20	Breast cancer;
LGG	cis	rs12915845	0.545	rs12907930	chr15:89083314	A/G	cg05013243	chr15:89149849	MIR1179	-0.35	-7.2	-0.32	2.43e-12	Menarche (age at onset);
LGG	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg01493522	chr13:37497338	NA	-0.51	-8.59	-0.37	1.34e-16	Coronary artery disease;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg14338887	chr6:42928500	GNMT	0.28	9.23	0.39	1e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg10965432	chr16:53537025	AKTIP	0.44	6.76	0.3	4.17e-11	Emphysema imaging phenotypes;
LGG	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.42	0.53	6.5e-35	Colorectal cancer;
LGG	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.42	6.66	0.3	7.92e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg04317338	chr11:64019027	PLCB3	0.66	8.25	0.36	1.64e-15	Mean platelet volume;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.96	0.38	7.89e-18	Obesity-related traits;
LGG	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg02891314	chr5:179741120	GFPT2	-0.61	-11.48	-0.47	5.17e-27	Height;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11890956	chr21:40555474	PSMG1	-0.75	-12.91	-0.51	8.95e-33	Menarche (age at onset);
LGG	cis	rs3857067	0.806	rs7676797	chr4:95099194	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.92	-0.35	1.74e-14	QT interval;
LGG	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs4417704	0.525	rs7585348	chr2:241893716	T/C	cg26818257	chr2:241905806	NA	0.5	10.98	0.45	4.52e-25	Joint mobility (Beighton score);
LGG	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs4662945	0.603	rs10168574	chr2:130267823	C/T	cg05962382	chr2:130345044	NA	-0.48	-8.23	-0.36	1.91e-15	Response to cytidine analogues (gemcitabine);
LGG	cis	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg26695010	chr11:65641043	EFEMP2	0.5	8.13	0.35	4.01e-15	DNA methylation (variation);
LGG	cis	rs926938	0.563	rs360652	chr1:115445478	C/T	cg12756093	chr1:115239321	AMPD1	0.46	8.61	0.37	1.12e-16	Autism;
LGG	cis	rs2540226	0.539	rs2716682	chr2:39909067	A/T	cg02886589	chr2:39892450	TMEM178	0.31	8.68	0.37	6.59e-17	Personality dimensions;
LGG	cis	rs2289328	1.000	rs11634187	chr15:40722781	T/G	cg13931752	chr15:40660718	DISP2	0.39	7.67	0.34	1.04e-13	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.28	-0.36	1.37e-15	Menarche (age at onset);
LGG	trans	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.77	-0.41	1.23e-20	Mean corpuscular volume;
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.29	0.4	6.22e-19	Monocyte count;
LGG	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg14541582	chr5:601475	NA	-0.57	-9.16	-0.39	1.71e-18	Ulcerative colitis;
LGG	cis	rs10876993	0.928	rs1689595	chr12:58056763	C/T	cg18357645	chr12:58087776	OS9	0.7	13.0	0.52	3.67e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs12200782	0.649	rs3757142	chr6:26380545	A/G	cg27193005	chr6:26382695	BTN2A2	-0.54	-7.65	-0.33	1.2e-13	Small cell lung carcinoma;
LGG	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.72	-0.38	5.2e-17	Bladder cancer;
LGG	cis	rs7717393	1.000	rs10079754	chr5:155747951	G/C	cg19569526	chr5:155754265	SGCD	0.79	7.32	0.32	1.08e-12	Egg allergy;
LGG	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg07936489	chr17:37558343	FBXL20	1.02	15.34	0.58	3.11e-43	Glomerular filtration rate (creatinine);
LGG	trans	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg07211511	chr3:129823064	LOC729375	-0.69	-9.74	-0.41	1.57e-20	Blood pressure (smoking interaction);
LGG	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs6554196	0.580	rs2159935	chr4:55521017	G/A	cg18836493	chr4:55524333	KIT	-0.39	-7.11	-0.31	4.56e-12	Monocyte count;
LGG	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12432903	chr7:1882776	MAD1L1	0.54	8.76	0.38	3.82e-17	Bipolar disorder;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg13206674	chr6:150067644	NUP43	0.6	13.32	0.53	1.77e-34	Lung cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23068057	chr6:136611228	BCLAF1	0.42	6.8	0.3	3.15e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9658691	0.607	rs12411483	chr10:90780910	G/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.74	-9.22	-0.39	1.05e-18	Mosquito bite size;
LGG	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg12310025	chr6:25882481	NA	-0.43	-6.97	-0.31	1.09e-11	Iron status biomarkers;
LGG	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg08807101	chr21:30365312	RNF160	-0.8	-15.74	-0.59	5.17e-45	Dental caries;
LGG	cis	rs3741151	1.000	rs76570090	chr11:73066321	A/T	cg17517138	chr11:73019481	ARHGEF17	1.03	10.37	0.43	8.61e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg09307838	chr4:120376055	NA	0.8	13.14	0.52	9.94e-34	Corneal astigmatism;
LGG	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.24	0.55	2.05e-38	Obesity-related traits;
LGG	cis	rs16854884	1.000	rs35887108	chr3:143780632	C/T	cg06585982	chr3:143692056	C3orf58	0.54	8.22	0.36	2.12e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs10875746	0.768	rs12305182	chr12:48421407	G/T	cg24011408	chr12:48396354	COL2A1	-0.53	-7.36	-0.32	8.25e-13	Longevity (90 years and older);
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg14338887	chr6:42928500	GNMT	0.23	7.15	0.32	3.38e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.53	8.56	0.37	1.67e-16	Vitiligo;
LGG	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11574514	1.000	rs8061384	chr16:67911874	T/G	cg09738193	chr16:67926317	PSKH1	-0.73	-6.79	-0.3	3.42e-11	Crohn's disease;
LGG	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11764359	chr7:65958608	NA	-0.59	-10.03	-0.42	1.53e-21	Aortic root size;
LGG	cis	rs2952156	1.000	rs2952156	chr17:37876835	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-13.46	-0.53	4.35e-35	Asthma;
LGG	cis	rs4788570	0.667	rs8053186	chr16:71790166	G/A	cg06353428	chr16:71660113	MARVELD3	1.25	19.52	0.67	2.26e-62	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.853	rs1013338	chr22:38974154	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.14	0.64	5.73e-56	Menopause (age at onset);
LGG	cis	rs921968	0.540	rs646295	chr2:219408558	A/C	cg02985541	chr2:219472218	PLCD4	0.28	6.69	0.3	6.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs854037	0.698	rs13190636	chr5:57069293	T/C	cg08523694	chr5:57076192	NA	0.5	7.09	0.31	4.95e-12	Birth weight;
LGG	trans	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg10756647	chr7:56101905	PSPH	0.84	9.93	0.42	3.53e-21	Diabetic kidney disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03272292	chr12:48577362	C12orf68	0.4	6.69	0.3	6.41e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9890032	0.532	rs1808257	chr17:29039966	A/G	cg13385521	chr17:29058706	SUZ12P	0.44	6.71	0.3	5.54e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.78	-0.3	3.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg02951883	chr7:2050386	MAD1L1	-0.76	-15.57	-0.59	2.98e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs4664308	0.967	rs17241973	chr2:160918601	A/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.19	-0.65	3.49e-56	Idiopathic membranous nephropathy;
LGG	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg09307838	chr4:120376055	NA	0.79	12.86	0.51	1.39e-32	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.5	-0.33	3.19e-13	Life satisfaction;
LGG	trans	rs804280	0.662	rs810738	chr8:11611206	A/G	cg02002194	chr4:3960332	NA	-0.49	-7.75	-0.34	5.99e-14	Myopia (pathological);
LGG	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs2249625	0.545	rs2463743	chr6:72874741	C/T	cg27608224	chr6:72922399	RIMS1	0.32	7.27	0.32	1.58e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-9.32	-0.4	4.81e-19	Menarche (age at onset);
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg24690094	chr11:67383802	NA	0.47	8.38	0.36	6.52e-16	Mean corpuscular volume;
LGG	cis	rs4148660	0.719	rs35497512	chr12:22098810	G/A	cg14669847	chr12:22099120	NA	-0.41	-7.33	-0.32	1.04e-12	Gout;
LGG	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.42	-0.33	5.8e-13	Testicular germ cell tumor;
LGG	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.83e-13	Refractive error;
LGG	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg10224037	chr5:178157518	ZNF354A	0.74	11.77	0.48	3.61e-28	Neutrophil percentage of white cells;
LGG	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-6.91	-0.31	1.63e-11	Asthma (childhood onset);
LGG	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.15e-11	Renal cell carcinoma;
LGG	cis	rs4731207	0.698	rs4731222	chr7:124481635	G/A	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	7.0	0.31	9.24e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11644478	chr21:40555479	PSMG1	0.93	17.42	0.63	1.29e-52	Cognitive function;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22168489	chr12:122356033	WDR66	0.45	11.11	0.46	1.41e-25	Mean corpuscular volume;
LGG	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	cis	rs9914988	0.943	rs4313850	chr17:27080768	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.25	-0.32	1.75e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.72e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.61	-0.37	1.19e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12765878	0.812	rs7076119	chr10:105667110	T/C	cg11005552	chr10:105648138	OBFC1	-0.81	-16.18	-0.6	5.12e-47	Coronary artery disease;
LGG	cis	rs9503598	0.636	rs7775474	chr6:3468224	T/C	cg00476032	chr6:3446245	SLC22A23	0.54	10.98	0.45	4.19e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17554472	chr22:41940697	POLR3H	-0.46	-6.89	-0.31	1.82e-11	Vitiligo;
LGG	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.87	0.38	1.61e-17	Neuroticism;
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg13939156	chr17:80058883	NA	0.53	10.91	0.45	8.11e-25	Life satisfaction;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg12705353	chr12:122356852	WDR66	0.24	6.83	0.3	2.67e-11	Mean corpuscular volume;
LGG	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg16980736	chr17:78789706	RPTOR	0.59	7.86	0.34	2.81e-14	Myopia (pathological);
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg04503457	chr17:41445688	NA	-0.39	-9.23	-0.39	9.61e-19	Menopause (age at onset);
LGG	cis	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-7.68	-0.34	9.28e-14	Endometrial cancer;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-7.76	-0.34	5.49e-14	Longevity;Endometriosis;
LGG	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg04521981	chr16:55850985	CES1	-0.43	-7.18	-0.32	2.82e-12	Response to dabigatran etexilate treatment;
LGG	cis	rs2671245	0.933	rs1165486	chr1:56186258	C/T	cg11523071	chr1:56160889	NA	-0.3	-6.72	-0.3	5.2e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg11360546	chr7:1094263	C7orf50	-0.41	-7.39	-0.32	6.98e-13	Longevity;Endometriosis;
LGG	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg25338242	chr13:114786047	RASA3	0.4	7.36	0.32	8.21e-13	Schizophrenia;
LGG	cis	rs75059851	1.000	rs73036063	chr11:133828758	G/A	cg20042908	chr11:133852938	NA	-0.69	-12.23	-0.49	5.44e-30	Schizophrenia;
LGG	cis	rs10089	1.000	rs1962291	chr5:127445373	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-11.98	-0.49	5.29e-29	Ileal carcinoids;
LGG	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg04691961	chr3:161091175	C3orf57	0.43	9.05	0.39	4.06e-18	Morning vs. evening chronotype;
LGG	cis	rs679087	0.612	rs7970465	chr12:29905251	C/T	cg14258853	chr12:29935411	TMTC1	-0.38	-7.07	-0.31	5.8e-12	Schizophrenia;
LGG	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.66	-13.5	-0.53	3.09e-35	IgG glycosylation;
LGG	cis	rs1345301	0.587	rs12464251	chr2:102867208	C/G	cg05295703	chr2:102895712	NA	0.49	9.88	0.42	5.02e-21	Waist circumference;
LGG	cis	rs526231	0.543	rs34791	chr5:102462104	C/A	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg19554555	chr3:13937349	NA	-0.54	-9.85	-0.42	6.82e-21	Ovarian reserve;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg01765077	chr12:122356316	WDR66	-0.28	-7.86	-0.34	2.78e-14	Mean corpuscular volume;
LGG	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.03	-0.31	7.38e-12	Caffeine consumption;
LGG	cis	rs774359	0.797	rs774351	chr9:27516640	A/C	cg21249376	chr9:27528432	MOBKL2B	0.43	8.87	0.38	1.57e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg27478167	chr7:817139	HEATR2	-0.42	-6.8	-0.3	3.16e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24308560	chr3:49941425	MST1R	0.23	7.07	0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.821	rs12949024	chr17:29445086	A/T	cg24425628	chr17:29625626	OMG;NF1	0.71	13.72	0.54	3.56e-36	Hip circumference;
LGG	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.64	15.87	0.59	1.31e-45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg15627072	chr1:2432621	PLCH2	-0.36	-8.15	-0.35	3.37e-15	Ulcerative colitis;
LGG	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg08344181	chr3:125677491	NA	-0.76	-8.18	-0.36	2.75e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9923856	0.614	rs62026377	chr16:11229128	G/T	cg16765268	chr16:11229200	CLEC16A	0.37	6.91	0.31	1.62e-11	Atopic dermatitis;Adult asthma;
LGG	cis	rs4843185	0.769	rs709805	chr16:85706564	A/G	cg08861369	chr16:85671714	KIAA0182	-0.46	-7.03	-0.31	7.24e-12	Platelet distribution width;
LGG	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.42	0.33	5.83e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.597	rs17031146	chr2:99036683	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.36	0.36	7.4e-16	Bipolar disorder;
LGG	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg00531865	chr16:30841666	NA	-0.5	-9.93	-0.42	3.35e-21	Dementia with Lewy bodies;
LGG	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg07615347	chr10:60278583	BICC1	0.63	17.98	0.64	3.2e-55	Refractive error;
LGG	cis	rs6942756	0.955	rs9641849	chr7:128899238	C/T	cg02491457	chr7:128862824	NA	-0.77	-14.15	-0.55	4.98e-38	White matter hyperintensity burden;
LGG	cis	rs10193935	0.901	rs10179237	chr2:42515501	C/T	cg27598129	chr2:42591480	NA	-0.56	-8.42	-0.36	4.59e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.02	0.39	5.03e-18	Resting heart rate;
LGG	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg07615347	chr10:60278583	BICC1	-0.61	-16.98	-0.62	1.32e-50	Refractive error;
LGG	cis	rs10463554	0.927	rs257315	chr5:102421429	C/A	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.58e-13	Parkinson's disease;
LGG	cis	rs9487094	0.689	rs9487103	chr6:109751495	A/C	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.18e-11	Height;
LGG	cis	rs7586879	0.593	rs10200566	chr2:25130462	G/T	cg04586622	chr2:25135609	ADCY3	-0.44	-11.65	-0.48	1.12e-27	Body mass index;
LGG	cis	rs4953318	1.000	rs4953318	chr2:46355051	A/C	cg12428440	chr2:46370979	PRKCE	0.38	7.26	0.32	1.61e-12	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg11520003	chr13:113540631	ATP11A	-0.36	-7.46	-0.33	4.37e-13	Interstitial lung disease;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg04025307	chr7:1156635	C7orf50	0.58	8.06	0.35	6.69e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.6	0.41	4.87e-20	Height;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.61	-10.42	-0.44	5.6e-23	Obesity-related traits;
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg00713939	chr8:144660590	NAPRT1	0.89	7.25	0.32	1.81e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs584438	0.873	rs584828	chr17:38599230	C/T	cg09358481	chr17:38600305	IGFBP4	-0.46	-8.98	-0.39	6.92e-18	Height;
LGG	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	cis	rs10089	1.000	rs6595800	chr5:127411647	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.07	0.46	2.02e-25	Ileal carcinoids;
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.48	0.37	3.03e-16	Aortic root size;
LGG	cis	rs4474465	1.000	rs966456	chr11:78168603	T/A	cg02023728	chr11:77925099	USP35	0.4	6.9	0.31	1.75e-11	Alzheimer's disease (survival time);
LGG	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	7.97	0.35	1.26e-14	Bipolar disorder;
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg06719900	chr11:109292894	C11orf87	0.45	8.32	0.36	1.01e-15	Schizophrenia;
LGG	cis	rs9443645	0.869	rs9448591	chr6:79606490	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3824867	0.920	rs7101772	chr11:47449378	A/G	cg20307385	chr11:47447363	PSMC3	-0.46	-7.31	-0.32	1.18e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2692947	0.550	rs4613327	chr2:96583823	G/A	cg22654517	chr2:96458247	NA	0.38	7.53	0.33	2.7e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.97	-0.31	1.11e-11	Uric acid levels;
LGG	cis	rs6547631	0.622	rs2366807	chr2:85926598	G/A	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.82e-11	Blood protein levels;
LGG	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg00666640	chr1:248458726	OR2T12	0.62	10.03	0.42	1.5e-21	Common traits (Other);
LGG	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg26354017	chr1:205819088	PM20D1	0.42	7.36	0.32	8.67e-13	Menarche (age at onset);
LGG	cis	rs11920090	0.932	rs55980684	chr3:170701427	A/G	cg09710316	chr3:170744871	SLC2A2	0.59	8.4	0.36	5.64e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg05082376	chr22:42548792	NA	-0.39	-8.21	-0.36	2.16e-15	Schizophrenia;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03647317	chr4:187891568	NA	-0.42	-8.97	-0.38	7.53e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6547631	0.622	rs1837115	chr2:85928411	C/A	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.59e-22	Blood protein levels;
LGG	cis	rs1417569	0.546	rs2934649	chr10:31226419	G/T	cg00428179	chr10:31322131	ZNF438	0.36	8.33	0.36	8.99e-16	Tuberculosis;
LGG	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.53	-0.56	1.12e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504130	0.542	rs1589079	chr8:52836299	T/C	cg13492337	chr8:52722140	PXDNL	-0.51	-7.92	-0.35	1.77e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg20637307	chr2:213403960	ERBB4	0.47	8.65	0.37	8.46e-17	Symmetrical dimethylarginine levels;
LGG	cis	rs9894429	0.646	rs7406828	chr17:79619226	A/G	cg10661904	chr17:79619235	PDE6G	0.52	10.58	0.44	1.41e-23	Eye color traits;
LGG	cis	rs2274273	0.638	rs11622636	chr14:55647840	C/T	cg04306507	chr14:55594613	LGALS3	0.52	11.83	0.48	2.19e-28	Protein biomarker;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18766912	chr15:25683909	UBE3A	0.46	7.29	0.32	1.32e-12	Cognitive performance;
LGG	cis	rs6964587	1.000	rs7806157	chr7:91601930	A/G	cg17063962	chr7:91808500	NA	0.49	8.59	0.37	1.34e-16	Breast cancer;
LGG	trans	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg18335740	chr13:41363409	SLC25A15	0.62	12.33	0.5	2.15e-30	Lewy body disease;
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07648498	chr16:89883185	FANCA	0.4	6.85	0.3	2.39e-11	Vitiligo;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08677398	chr8:58056175	NA	0.47	7.81	0.34	3.88e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg08048268	chr3:133502702	NA	-0.6	-11.33	-0.47	2.01e-26	Iron status biomarkers;
LGG	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs2213920	0.679	rs9409160	chr9:118227046	G/A	cg13918206	chr9:118159781	DEC1	0.54	7.32	0.32	1.09e-12	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs9547692	0.878	rs9547688	chr13:37449413	G/A	cg02985381	chr13:37494744	SMAD9	0.7	12.05	0.49	2.79e-29	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00149659	chr3:10157352	C3orf10	0.77	9.64	0.41	3.72e-20	Alzheimer's disease;
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg02002194	chr4:3960332	NA	-0.5	-9.87	-0.42	5.71e-21	Mood instability;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21862992	chr11:68658383	NA	0.51	8.61	0.37	1.12e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg24110177	chr3:50126178	RBM5	-0.62	-11.32	-0.47	2.17e-26	Body mass index;
LGG	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-12.74	-0.51	4.56e-32	Chronic sinus infection;
LGG	trans	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs1595825	0.891	rs16825917	chr2:198805185	C/T	cg00982548	chr2:198649783	BOLL	-0.53	-7.01	-0.31	8.75e-12	Ulcerative colitis;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	Neuroticism;
LGG	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.13	0.39	2.11e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9486719	0.749	rs1009596	chr6:96843688	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg17644776	chr2:200775616	C2orf69	0.59	8.31	0.36	1.03e-15	Schizophrenia;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.63	0.44	9.13e-24	Personality dimensions;
LGG	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-11.12	-0.46	1.3e-25	Hemoglobin concentration;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg19168338	chr16:4465731	CORO7	-0.73	-13.49	-0.53	3.41e-35	Schizophrenia;
LGG	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg15268244	chr15:77196840	NA	-0.32	-7.12	-0.31	4.17e-12	Blood metabolite levels;
LGG	cis	rs600231	0.577	rs12269965	chr11:65232087	C/T	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.61	-0.37	1.13e-16	Bone mineral density;
LGG	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg24253500	chr15:84953950	NA	0.42	7.1	0.31	4.88e-12	Schizophrenia;
LGG	cis	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	10.27	0.43	1.96e-22	Mean corpuscular hemoglobin;
LGG	cis	rs2594989	0.943	rs346068	chr3:11302933	A/G	cg01796438	chr3:11312864	ATG7	-0.59	-7.99	-0.35	1.1e-14	Circulating chemerin levels;
LGG	cis	rs1595825	0.838	rs16826872	chr2:198898055	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.9	-0.31	1.72e-11	Ulcerative colitis;
LGG	cis	rs10883723	0.668	rs12414407	chr10:104387019	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.72	-13.95	-0.54	3.51e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.19	-0.78	5.4e-98	Schizophrenia;
LGG	cis	rs7301826	0.610	rs36051740	chr12:131292722	G/A	cg11011512	chr12:131303247	STX2	-0.39	-8.47	-0.37	3.22e-16	Plasma plasminogen activator levels;
LGG	trans	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-27.75	-0.79	1.62e-100	Exhaled nitric oxide output;
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg26138144	chr22:38071188	LGALS1	0.91	24.34	0.75	7.06e-85	Fat distribution (HIV);
LGG	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg26666090	chr16:58549219	SETD6	1.17	10.31	0.43	1.42e-22	Schizophrenia;
LGG	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.21	0.36	2.18e-15	Coronary artery disease;
LGG	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg16070123	chr10:51489643	NA	0.41	7.52	0.33	2.78e-13	Prostate-specific antigen levels;
LGG	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg02733842	chr7:1102375	C7orf50	-0.44	-7.35	-0.32	9.28e-13	Bronchopulmonary dysplasia;
LGG	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg25019033	chr10:957182	NA	-0.55	-10.02	-0.42	1.61e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.43e-20	Heart rate;
LGG	cis	rs9814567	1.000	rs9851441	chr3:134315091	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.88	-0.51	1.15e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.0	0.64	2.58e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg08499158	chr17:42289980	UBTF	0.55	10.41	0.44	6.27e-23	Total body bone mineral density;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01753731	chr4:903032	GAK	0.38	7.18	0.32	2.74e-12	Electrocardiographic conduction measures;
LGG	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg02487422	chr3:49467188	NICN1	0.43	6.99	0.31	9.47e-12	Resting heart rate;
LGG	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg13902645	chr11:5959945	NA	-0.67	-10.88	-0.45	1.05e-24	DNA methylation (variation);
LGG	trans	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.45	0.47	6.7e-27	Corneal astigmatism;
LGG	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14019695	chr9:139328340	INPP5E	-0.37	-6.75	-0.3	4.37e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7301826	1.000	rs4759787	chr12:131290180	A/C	cg11011512	chr12:131303247	STX2	0.35	7.55	0.33	2.34e-13	Plasma plasminogen activator levels;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg10950524	chr7:2139216	MAD1L1	0.31	6.9	0.31	1.7e-11	Schizophrenia;
LGG	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs12928939	0.517	rs17358402	chr16:71967927	C/T	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.42	-0.53	6.19e-35	Post bronchodilator FEV1;
LGG	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.62	-0.37	1.04e-16	Lung cancer;
LGG	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg19748678	chr4:122722346	EXOSC9	0.51	9.69	0.41	2.42e-20	Type 2 diabetes;
LGG	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.78e-12	Blood metabolite levels;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg14668821	chr17:77704760	ENPP7	0.43	8.48	0.37	3.07e-16	Menopause (age at onset);
LGG	trans	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.97	0.45	4.86e-25	Parkinson's disease;
LGG	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-16.89	-0.62	3.15e-50	Body mass index;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg05313129	chr8:58192883	C8orf71	-0.67	-8.68	-0.37	6.57e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01778450	chr5:92920498	NR2F1	0.6	6.75	0.3	4.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg02466173	chr16:30829666	NA	-0.55	-9.91	-0.42	3.96e-21	Multiple myeloma;
LGG	cis	rs6489882	0.867	rs6489875	chr12:113368030	G/A	cg25319449	chr12:113376135	OAS3	-0.41	-7.63	-0.33	1.33e-13	Chronic lymphocytic leukemia;
LGG	cis	rs1847505	0.609	rs9538998	chr13:61571160	A/G	cg25164009	chr13:61490935	NA	-0.61	-11.77	-0.48	3.83e-28	Polychlorinated biphenyl levels;
LGG	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.57	0.33	2.01e-13	Total cholesterol levels;
LGG	cis	rs9462027	0.628	rs11757370	chr6:34760736	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12016809	chr21:47604291	C21orf56	0.58	10.52	0.44	2.43e-23	Testicular germ cell tumor;
LGG	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg04568710	chr12:38710424	ALG10B	0.4	8.53	0.37	2.17e-16	Morning vs. evening chronotype;
LGG	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.72	0.3	5.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.47	-7.2	-0.32	2.41e-12	Parkinson's disease;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07532744	chr12:62860172	MON2	-0.42	-7.28	-0.32	1.47e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.68	-11.77	-0.48	3.78e-28	Longevity;Endometriosis;
LGG	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg17230874	chr3:125932073	NA	0.73	15.66	0.59	1.2e-44	Metabolite levels;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.4e-16	Obesity-related traits;
LGG	cis	rs4794202	0.534	rs9897598	chr17:45923496	G/A	cg02219949	chr17:45927392	SP6	0.55	7.16	0.32	3.11e-12	Alzheimer's disease (cognitive decline);
LGG	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg24375607	chr4:120327624	NA	0.66	11.04	0.46	2.64e-25	Corneal astigmatism;
LGG	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg03213289	chr20:61660250	NA	0.66	14.39	0.56	4.34e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.74	-0.3	4.74e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	17.55	0.63	3.13e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs10851411	0.542	rs10454692	chr15:42857055	T/C	cg21293051	chr15:42870591	STARD9	0.5	7.13	0.31	3.99e-12	Glucose homeostasis traits;
LGG	cis	rs2302729	0.545	rs10161181	chr12:2770730	A/C	cg19945202	chr12:2788847	CACNA1C	-0.72	-12.27	-0.5	3.75e-30	Sleep quality;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg24829409	chr8:58192753	C8orf71	-0.87	-13.72	-0.54	3.36e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.01e-44	Body mass index;
LGG	cis	rs975739	1.000	rs1668621	chr13:78384443	T/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.59e-11	Hair color;
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs2652822	0.710	rs55862039	chr15:63451563	C/T	cg02713581	chr15:63449717	RPS27L	0.48	8.2	0.36	2.42e-15	Metabolic traits;
LGG	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg17545662	chr6:170176663	C6orf70	0.73	6.95	0.31	1.29e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17428076	0.830	rs6704590	chr2:172878554	C/G	cg21435375	chr2:172878103	MAP1D	0.46	9.88	0.42	4.96e-21	Myopia;
LGG	cis	rs9354308	0.764	rs9345719	chr6:66609462	A/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.6e-11	Metabolite levels;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.31	-0.36	1.07e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs4714291	0.792	rs9471241	chr6:40080211	C/T	cg02267698	chr19:7991119	CTXN1	-0.62	-9.96	-0.42	2.58e-21	Strep throat;
LGG	cis	rs774359	0.789	rs2246591	chr9:27507804	A/G	cg21249376	chr9:27528432	MOBKL2B	0.45	8.7	0.38	5.64e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg24397884	chr7:158709396	WDR60	1.0	14.85	0.57	4.68e-41	Height;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.08	0.35	5.5e-15	Bipolar disorder;
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg13206674	chr6:150067644	NUP43	-0.4	-6.81	-0.3	2.98e-11	Lung cancer;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg23782820	chr8:58130467	NA	0.54	7.56	0.33	2.26e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.12	-0.46	1.23e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.61	0.33	1.54e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs735539	0.645	rs9552248	chr13:21159200	G/A	cg04906043	chr13:21280425	IL17D	-0.51	-8.29	-0.36	1.19e-15	Dental caries;
LGG	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.43	-0.36	4.33e-16	Diabetic kidney disease;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg05279229	chr7:1896384	MAD1L1	0.4	7.1	0.31	4.71e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs988958	0.567	rs6718777	chr2:42246498	G/A	cg27428208	chr2:42229179	NA	0.52	9.13	0.39	2.05e-18	Hypospadias;
LGG	cis	rs4906332	1.000	rs3783398	chr14:103949378	C/T	cg26031613	chr14:104095156	KLC1	0.5	7.51	0.33	2.97e-13	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg00339695	chr16:24857497	SLC5A11	0.4	6.94	0.31	1.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs17221829	0.764	rs7931085	chr11:89386197	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs11239187	0.586	rs10900075	chr10:45073383	C/T	cg03916630	chr10:45065415	NA	-0.36	-8.72	-0.38	5.2e-17	Body mass index;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg11584989	chr19:19387371	SF4	0.43	7.81	0.34	3.87e-14	Tonsillectomy;
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg11764359	chr7:65958608	NA	-0.74	-13.08	-0.52	1.68e-33	Aortic root size;
LGG	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg00012203	chr2:219082015	ARPC2	-0.67	-12.04	-0.49	3.01e-29	Colorectal cancer;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.0	0.49	4.46e-29	Prudent dietary pattern;
LGG	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.67e-15	Coronary artery disease;
LGG	cis	rs7666738	0.791	rs7660866	chr4:98961335	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17253792	0.822	rs10083493	chr14:56045411	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-12.27	-0.5	3.59e-30	Putamen volume;
LGG	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.68	-13.24	-0.52	3.85e-34	Lymphocyte percentage of white cells;
LGG	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg25919922	chr13:100150906	NA	-0.73	-7.54	-0.33	2.46e-13	Obesity-related traits;
LGG	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg01181863	chr3:195395398	SDHAP2	-0.72	-12.11	-0.49	1.65e-29	Pancreatic cancer;
LGG	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg08250081	chr4:10125330	NA	0.39	7.55	0.33	2.26e-13	Bone mineral density;
LGG	cis	rs926392	0.965	rs6028258	chr20:37692844	T/A	cg16355469	chr20:37678765	NA	0.44	7.12	0.31	4.18e-12	Dialysis-related mortality;
LGG	cis	rs4538187	0.951	rs13018690	chr2:64151381	A/C	cg02541582	chr2:64069798	UGP2	-0.61	-13.98	-0.54	2.56e-37	Systolic blood pressure;
LGG	trans	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg00953403	chr17:74099816	EXOC7	0.43	7.21	0.32	2.25e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs67133203	0.904	rs35999440	chr12:51335145	G/A	cg14688905	chr12:51403056	SLC11A2	0.69	10.32	0.43	1.31e-22	Urinary tract infection frequency;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg11878867	chr6:150167359	LRP11	0.49	10.09	0.42	9.22e-22	Lung cancer;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg05368731	chr17:41323189	NBR1	0.97	19.11	0.66	1.91e-60	Menopause (age at onset);
LGG	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg15268244	chr15:77196840	NA	-0.46	-9.73	-0.41	1.76e-20	Blood metabolite levels;
LGG	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.63	-0.33	1.35e-13	Calcium levels;
LGG	trans	rs6787172	0.728	rs1526190	chr3:158090172	T/C	cg23275840	chr4:47708675	CORIN	-0.4	-8.51	-0.37	2.41e-16	Subjective well-being;
LGG	cis	rs34172651	0.874	rs200534	chr16:24752641	G/A	cg02428538	chr16:24856791	SLC5A11	0.48	8.13	0.35	3.82e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11225247	0.685	rs12273698	chr11:102234776	A/G	cg06323957	chr11:102217781	BIRC2	0.79	7.52	0.33	2.94e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.94	-0.52	6.44e-33	Alzheimer's disease;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.41	-0.33	5.88e-13	Electroencephalogram traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00603498	chr17:5322775	RPAIN;NUP88	-0.49	-7.15	-0.32	3.37e-12	Systemic lupus erythematosus;
LGG	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.22	-0.52	4.3e-34	Gut microbiome composition (summer);
LGG	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg21890820	chr11:65308645	LTBP3	0.7	7.44	0.33	4.8e-13	Height;
LGG	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.49	-0.4	1.25e-19	Parkinson's disease;
LGG	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg08344181	chr3:125677491	NA	0.64	7.43	0.33	5.32e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	1.000	rs6670821	chr1:11308762	T/C	cg08854313	chr1:11322531	MTOR	0.75	16.6	0.61	6.45e-49	Body mass index;
LGG	cis	rs10937275	1.000	rs10937275	chr3:186650790	A/G	cg26193484	chr3:186648175	ST6GAL1	-0.86	-8.96	-0.38	8.18e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg24623649	chr8:11872141	NA	-0.3	-7.23	-0.32	1.95e-12	Systolic blood pressure;
LGG	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.48	0.5	5e-31	Coronary artery disease;
LGG	cis	rs9815354	0.597	rs73073281	chr3:42026366	C/T	cg03022575	chr3:42003672	ULK4	0.75	8.17	0.35	2.97e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg13902645	chr11:5959945	NA	-0.73	-11.35	-0.47	1.61e-26	DNA methylation (variation);
LGG	cis	rs2455826	0.958	rs2455820	chr3:15653613	T/C	cg16303742	chr3:15540471	COLQ	0.41	7.06	0.31	5.93e-12	Inflammatory skin disease;
LGG	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.06	0.39	3.67e-18	Neuroticism;
LGG	cis	rs12580194	0.593	rs55659159	chr12:55747754	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-9.31	-0.4	4.99e-19	Cancer;
LGG	cis	rs2270450	0.704	rs6901132	chr6:46631801	A/G	cg10156739	chr6:46714674	LOC100287718	-0.34	-7.99	-0.35	1.05e-14	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.83e-16	Bone mineral density;
LGG	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg19748678	chr4:122722346	EXOSC9	0.51	9.66	0.41	3.01e-20	Type 2 diabetes;
LGG	cis	rs4330281	0.647	rs11927654	chr3:17723430	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.17	-0.32	3.07e-12	Schizophrenia;
LGG	cis	rs7017914	0.967	rs7814648	chr8:71603984	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.98e-25	Hepatitis;
LGG	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg00666640	chr1:248458726	OR2T12	0.48	7.31	0.32	1.18e-12	Common traits (Other);
LGG	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg01028140	chr2:1542097	TPO	-0.48	-8.84	-0.38	2.08e-17	IgG glycosylation;
LGG	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.32	-0.32	1.12e-12	Testicular germ cell tumor;
LGG	cis	rs11792861	0.890	rs3087979	chr9:111781779	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.47	0.4	1.45e-19	Menarche (age at onset);
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.86	-0.38	1.73e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg02297831	chr4:17616191	MED28	-0.5	-9.11	-0.39	2.42e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg07636037	chr3:49044803	WDR6	0.76	13.12	0.52	1.17e-33	Menarche (age at onset);
LGG	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg04317338	chr11:64019027	PLCB3	-0.63	-7.74	-0.34	6.5e-14	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11151929	chr3:120068323	LRRC58	0.46	6.66	0.3	7.79e-11	Gut microbiome composition (summer);
LGG	trans	rs11760633	0.615	rs62435650	chr7:1823265	A/G	cg22232500	chr2:134024266	NCKAP5	0.48	6.83	0.3	2.6e-11	Coronary artery disease;
LGG	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg01200585	chr1:228362443	C1orf69	0.46	8.07	0.35	6.16e-15	Diastolic blood pressure;
LGG	cis	rs6424115	0.708	rs11803575	chr1:24182348	A/T	cg15997130	chr1:24165203	NA	-0.42	-10.21	-0.43	3.32e-22	Immature fraction of reticulocytes;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg02592271	chr2:27665507	KRTCAP3	0.32	8.36	0.36	7.29e-16	Total body bone mineral density;
LGG	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg08297393	chr2:100937505	LONRF2	0.47	8.3	0.36	1.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4919694	0.611	rs2271750	chr10:105174869	A/G	cg04362960	chr10:104952993	NT5C2	-0.81	-11.09	-0.46	1.71e-25	Arsenic metabolism;
LGG	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg27087555	chr16:88793112	FAM38A	-1.23	-11.63	-0.48	1.26e-27	Plateletcrit;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.32	0.47	2.07e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg04731861	chr2:219085781	ARPC2	0.52	13.59	0.53	1.19e-35	Colorectal cancer;
LGG	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-9.06	-0.39	3.62e-18	Blood protein levels;
LGG	cis	rs4731207	0.596	rs1031956	chr7:124627183	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3087591	0.960	rs2952984	chr17:29469614	T/C	cg24425628	chr17:29625626	OMG;NF1	0.69	14.34	0.55	7.39e-39	Hip circumference;
LGG	cis	rs7215564	0.908	rs74002838	chr17:78682157	C/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg02886208	chr11:14281011	SPON1	-0.36	-6.9	-0.31	1.69e-11	Sense of smell;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08219700	chr8:58056026	NA	0.44	6.82	0.3	2.8e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg11764359	chr7:65958608	NA	0.73	13.16	0.52	7.64e-34	Aortic root size;
LGG	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	cg07245641	chr1:182991651	LAMC1	0.41	9.33	0.4	4.27e-19	Colorectal cancer;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03517284	chr6:25882590	NA	-0.52	-9.78	-0.41	1.2e-20	Height;
LGG	cis	rs6546537	0.869	rs35024605	chr2:69820332	A/G	cg10773587	chr2:69614142	GFPT1	-0.45	-7.61	-0.33	1.6e-13	Serum thyroid-stimulating hormone levels;
LGG	trans	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg03929089	chr4:120376271	NA	-0.47	-7.7	-0.34	8.12e-14	HDL cholesterol;
LGG	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.83	0.34	3.46e-14	Eosinophil percentage of white cells;
LGG	cis	rs7503807	0.515	rs12944407	chr17:78691979	C/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs35425515	0.571	rs71486110	chr10:98888767	C/T	cg09122387	chr10:98855762	SLIT1	0.61	6.68	0.3	6.72e-11	Bipolar disorder;
LGG	cis	rs6694672	0.867	rs1764629	chr1:197216632	A/G	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs8133932	0.701	rs7279887	chr21:47301148	T/C	cg13695288	chr21:47294981	PCBP3	-0.37	-7.39	-0.32	6.76e-13	Schizophrenia;
LGG	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg17809284	chr5:56205270	C5orf35	-0.5	-8.15	-0.35	3.5e-15	Initial pursuit acceleration;
LGG	cis	rs732765	0.734	rs17183139	chr14:75153950	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.83	-0.3	2.6e-11	Non-small cell lung cancer;
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg09033563	chr22:24373618	LOC391322	0.46	6.67	0.3	7.25e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs10905065	0.829	rs2246399	chr10:5799286	T/A	cg11519256	chr10:5708881	ASB13	-0.4	-6.71	-0.3	5.57e-11	Menopause (age at onset);
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00761968	chr13:53314142	LECT1	-0.36	-7.88	-0.34	2.35e-14	Lewy body disease;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.46	-8.28	-0.36	1.31e-15	Obesity-related traits;
LGG	cis	rs7173743	0.756	rs4539564	chr15:79128499	G/A	cg00540400	chr15:79124168	NA	0.42	8.62	0.37	1.03e-16	Coronary artery disease;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16405210	chr4:1374714	KIAA1530	-0.55	-9.85	-0.42	6.8e-21	Longevity;
LGG	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg04995300	chr3:66848608	NA	0.53	7.95	0.35	1.49e-14	Type 2 diabetes;
LGG	cis	rs9297145	0.585	rs62473049	chr7:98777685	T/C	cg05967295	chr7:98741636	SMURF1	-0.65	-11.67	-0.48	9.16e-28	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs139371	0.516	rs139287	chr22:39495870	C/A	cg17972162	chr22:39496387	APOBEC3H	-0.28	-7.09	-0.31	5.03e-12	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs4727027	0.933	rs12667123	chr7:148850621	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.1	-0.62	3.63e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03506944	chr4:154074021	TRIM2	0.45	7.33	0.32	1.05e-12	Cognitive performance;
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg00800038	chr16:89945340	TCF25	-0.71	-8.48	-0.37	3.09e-16	Skin colour saturation;
LGG	cis	rs9457247	1.000	rs405553	chr6:167395058	A/G	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg16339924	chr4:17578868	LAP3	-0.65	-11.1	-0.46	1.51e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs56399783	0.901	rs7803944	chr7:2809087	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.4	0.33	6.32e-13	Childhood ear infection;
LGG	cis	rs7726354	0.793	rs111944656	chr5:56008230	G/T	cg27303933	chr5:56029418	NA	0.49	6.79	0.3	3.36e-11	Breast cancer (early onset);
LGG	cis	rs9815354	0.951	rs9817510	chr3:41813108	C/T	cg03022575	chr3:42003672	ULK4	0.61	7.8	0.34	4.27e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2016266	0.929	rs1318648	chr12:53670545	C/A	cg04065151	chr12:53682969	ESPL1	-0.59	-10.13	-0.43	6.5600000000000005e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg23625390	chr15:77176239	SCAPER	0.52	10.45	0.44	4.34e-23	Blood metabolite levels;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg07142201	chr11:109293216	C11orf87	-0.85	-16.61	-0.61	6.44e-49	Schizophrenia;
LGG	trans	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg07962051	chr8:9412923	TNKS	-0.41	-7.66	-0.34	1.12e-13	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
LGG	cis	rs977987	0.806	rs11642572	chr16:75452782	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs735539	0.645	rs3825444	chr13:21173926	A/G	cg04906043	chr13:21280425	IL17D	-0.51	-8.29	-0.36	1.24e-15	Dental caries;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18500714	chr14:100706288	YY1	0.41	6.9	0.31	1.73e-11	Bipolar disorder;
LGG	cis	rs9863	0.931	rs35825716	chr12:124427524	G/C	cg13487667	chr12:124434373	CCDC92	-0.37	-7.28	-0.32	1.46e-12	White blood cell count;
LGG	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg10818794	chr15:86012489	AKAP13	0.36	7.38	0.32	7.47e-13	Bulimia nervosa;
LGG	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg19539972	chr4:7069911	GRPEL1	-0.77	-10.11	-0.43	7.88e-22	Monocyte percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26597500	chr13:73356092	PIBF1;DIS3	0.47	7.61	0.33	1.55e-13	Cognitive performance;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg07701084	chr6:150067640	NUP43	0.6	11.09	0.46	1.7e-25	Lung cancer;
LGG	cis	rs6763768	0.606	rs13082092	chr3:53373204	T/G	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs4713118	0.621	rs4713132	chr6:28034035	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.7	-0.3	6.1e-11	Parkinson's disease;
LGG	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-9.06	-0.39	3.59e-18	Height;
LGG	cis	rs11650494	0.710	rs2165701	chr17:47475822	A/G	cg08112188	chr17:47440006	ZNF652	1.16	12.4	0.5	1.12e-30	Prostate cancer;
LGG	cis	rs12618769	0.625	rs4850877	chr2:99112154	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg26668828	chr6:292823	DUSP22	-0.52	-9.17	-0.39	1.53e-18	Menopause (age at onset);
LGG	cis	rs9992101	0.578	rs4859663	chr4:77235756	C/A	cg17010112	chr4:77227123	STBD1	-0.48	-9.91	-0.42	4.1e-21	Creatinine levels;
LGG	cis	rs5769707	0.749	rs3884944	chr22:50062996	T/C	cg20744362	chr22:50050164	C22orf34	0.37	7.12	0.31	4.22e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	19.89	0.68	4.6e-64	Alzheimer's disease;
LGG	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.76	-0.51	3.82e-32	Diastolic blood pressure;
LGG	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg22643751	chr7:855365	UNC84A	0.35	6.67	0.3	7.4e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.25	-0.39	8.54e-19	Longevity;Endometriosis;
LGG	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg21452805	chr1:244014465	NA	0.65	7.86	0.34	2.71e-14	RR interval (heart rate);
LGG	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg19183879	chr15:85880815	NA	0.42	7.56	0.33	2.18e-13	Bulimia nervosa;
LGG	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg20913747	chr6:44695427	NA	-0.63	-10.26	-0.43	2.11e-22	Total body bone mineral density;
LGG	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.79	0.41	1.04e-20	Bipolar disorder;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07701084	chr6:150067640	NUP43	0.43	8.0	0.35	1.01e-14	Testicular germ cell tumor;
LGG	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	8.17	0.36	2.88e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1451375	0.794	rs11238134	chr7:50542927	A/C	cg14593290	chr7:50529359	DDC	-0.4	-7.37	-0.32	7.75e-13	Malaria;
LGG	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.52	-9.6	-0.41	4.93e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4702718	0.549	rs267982	chr5:10715677	C/T	cg14521931	chr5:10832172	NA	-0.46	-8.93	-0.38	9.83e-18	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11980791	chr9:131084797	COQ4;TRUB2	0.44	7.29	0.32	1.31e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9849248	0.627	rs9284814	chr3:88273071	G/A	cg14530983	chr3:88190749	ZNF654	-0.5	-7.13	-0.31	3.97e-12	Menarche (age at onset);
LGG	cis	rs504918	0.556	rs11706831	chr3:124021252	C/T	cg05766129	chr3:123988013	KALRN	0.58	10.29	0.43	1.66e-22	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03253314	chr19:17445711	ANO8	0.58	6.8	0.3	3.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg10847948	chr11:71163743	NADSYN1	0.65	11.59	0.47	1.98e-27	Vitamin D levels;
LGG	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.75	-0.69	4.13e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9837602	0.507	rs793453	chr3:99529095	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.31	-0.36	1.03e-15	Breast cancer;
LGG	cis	rs9463078	0.838	rs9381359	chr6:44990625	A/G	cg25276700	chr6:44698697	NA	-0.35	-7.2	-0.32	2.43e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.27	0.52	2.77e-34	Lung cancer in ever smokers;
LGG	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg26384229	chr12:38710491	ALG10B	0.75	14.88	0.57	3.34e-41	Morning vs. evening chronotype;
LGG	trans	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.96	0.35	1.32e-14	Neuroticism;
LGG	cis	rs72781680	0.716	rs2551334	chr2:24000396	G/A	cg08917208	chr2:24149416	ATAD2B	0.64	8.3	0.36	1.12e-15	Lymphocyte counts;
LGG	cis	rs11748327	0.959	rs12653958	chr5:4032849	A/G	cg01025095	chr5:4101132	NA	-0.56	-9.0	-0.39	5.87e-18	Myocardial infarction;
LGG	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-11.11	-0.46	1.36e-25	Platelet distribution width;
LGG	cis	rs4356203	0.875	rs680205	chr11:17207757	C/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.25	-0.32	1.82e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6963495	0.769	rs73192134	chr7:105189338	T/C	cg19920283	chr7:105172520	RINT1	0.64	8.39	0.36	6e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs7667	0.881	rs12033437	chr1:19749894	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.4	-7.09	-0.31	5.08e-12	Crohn's disease and psoriasis;
LGG	cis	rs6735179	0.532	rs6756670	chr2:1761496	A/G	cg20570797	chr2:1712800	PXDN	-0.47	-8.52	-0.37	2.22e-16	Response to antipsychotic treatment;
LGG	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg27523141	chr10:43048294	ZNF37B	0.36	7.55	0.33	2.32e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg11846333	chr4:119757529	SEC24D	0.84	7.8	0.34	4.07e-14	Cannabis dependence symptom count;
LGG	trans	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg16141378	chr3:129829833	LOC729375	0.31	6.86	0.3	2.25e-11	Monocyte count;
LGG	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.97	0.31	1.08e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.82	0.54	1.34e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg15997130	chr1:24165203	NA	0.49	13.47	0.53	3.91e-35	Immature fraction of reticulocytes;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.74	-0.34	6.15e-14	Skin colour saturation;
LGG	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg12560992	chr17:57184187	TRIM37	-0.88	-15.88	-0.59	1.16e-45	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.920	rs7113835	chr11:55947007	C/T	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg18654377	chr3:49208889	KLHDC8B	-0.45	-7.0	-0.31	9.31e-12	Parkinson's disease;
LGG	cis	rs763121	0.889	rs4820335	chr22:38935927	C/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-15.13	-0.58	2.74e-42	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04074766	chr7:100861094	ZNHIT1;PLOD3	0.45	7.49	0.33	3.56e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1506636	1.000	rs600774	chr7:123397831	C/T	cg03229431	chr7:123269106	ASB15	0.73	17.77	0.64	2.97e-54	Plateletcrit;Platelet count;
LGG	trans	rs11875185	0.915	rs17064171	chr18:55638112	T/C	cg15513957	chr14:69354734	ACTN1	-0.76	-8.14	-0.35	3.62e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs988958	0.565	rs4952399	chr2:42289107	A/G	cg19376973	chr2:42229025	NA	-0.39	-7.07	-0.31	5.62e-12	Hypospadias;
LGG	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-9.6	-0.41	4.96e-20	Morning vs. evening chronotype;
LGG	cis	rs2282300	0.739	rs16920406	chr11:30216158	A/C	cg25418670	chr11:30344373	C11orf46	-0.56	-7.89	-0.34	2.13e-14	Morning vs. evening chronotype;
LGG	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg00383909	chr3:49044727	WDR6	1.03	12.41	0.5	1.01e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7951870	0.617	rs12361673	chr11:46723937	G/A	cg03339077	chr11:47165057	C11orf49	-0.41	-7.11	-0.31	4.5e-12	Schizophrenia;
LGG	cis	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg12486710	chr1:178512616	C1orf220	0.51	10.48	0.44	3.44e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4075765	1.000	rs4075765	chr11:26209271	G/T	cg19182008	chr11:26298241	NA	0.77	7.41	0.33	5.89e-13	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08280861	chr8:58055591	NA	0.59	7.33	0.32	1.02e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1408799	0.732	rs2093830	chr9:12756889	G/A	cg05274944	chr9:12693694	TYRP1	0.34	8.2	0.36	2.36e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.71	-0.51	6.08e-32	Alzheimer's disease;
LGG	cis	rs988958	0.675	rs7583681	chr2:42225701	G/A	cg19376973	chr2:42229025	NA	0.62	9.73	0.41	1.83e-20	Hypospadias;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.95	17.65	0.63	1.07e-53	Cognitive ability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21512275	chr2:157198069	NA	0.45	6.85	0.3	2.32e-11	Gut microbiome composition (summer);
LGG	cis	rs977987	0.868	rs10871313	chr16:75507094	C/T	cg07303275	chr16:75499416	TMEM170A	0.46	8.19	0.36	2.63e-15	Dupuytren's disease;
LGG	trans	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs3747547	0.818	rs6476665	chr9:37948238	A/C	cg13774184	chr9:37916125	SHB	-0.76	-8.74	-0.38	4.36e-17	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs554111	1.000	rs554111	chr1:21042300	C/G	cg15613048	chr1:21044031	KIF17	-0.35	-7.08	-0.31	5.36e-12	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs2273669	0.667	rs117941557	chr6:109298135	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.33	-0.36	9.39e-16	Prostate cancer;
LGG	cis	rs1707322	1.000	rs10890378	chr1:46410657	A/G	cg03146154	chr1:46216737	IPP	-0.54	-10.39	-0.43	7.29e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12714538	chr1:151372147	PSMB4	-0.44	-7.02	-0.31	7.98e-12	Pancreatic cancer;
LGG	cis	rs2188561	0.697	rs34986332	chr7:107379455	G/C	cg16793755	chr7:107334138	SLC26A4	0.41	7.32	0.32	1.07e-12	Alcohol consumption;
LGG	cis	rs11657217	1.000	rs8081537	chr17:77708264	A/G	cg06901238	chr17:77706717	ENPP7	0.45	8.97	0.38	7.18e-18	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.4	-0.36	5.51e-16	Neuroticism;
LGG	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg07142201	chr11:109293216	C11orf87	0.67	11.78	0.48	3.48e-28	Schizophrenia;
LGG	cis	rs75059851	1.000	rs73036064	chr11:133829442	G/A	cg17703048	chr11:133852993	NA	-0.79	-13.84	-0.54	1.02e-36	Schizophrenia;
LGG	cis	rs7085104	0.513	rs619824	chr10:104581288	G/T	cg04362960	chr10:104952993	NT5C2	0.46	8.47	0.37	3.17e-16	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg22482690	chr17:47019901	SNF8	0.34	6.68	0.3	6.67e-11	Type 2 diabetes;
LGG	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg05308233	chr10:104796373	CNNM2	0.31	7.04	0.31	7.03e-12	Arsenic metabolism;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	trans	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg25214090	chr10:38739885	LOC399744	-0.65	-11.66	-0.48	1.03e-27	Corneal astigmatism;
LGG	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg18478394	chr8:109455254	TTC35	0.4	8.07	0.35	6.3e-15	Dupuytren's disease;
LGG	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg14088196	chr11:70211408	PPFIA1	0.94	13.24	0.52	3.72e-34	Coronary artery disease;
LGG	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg00631329	chr6:26305371	NA	-0.48	-7.97	-0.35	1.26e-14	Educational attainment;
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg16141378	chr3:129829833	LOC729375	-0.44	-10.54	-0.44	2.04e-23	Mood instability;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg21775007	chr8:11205619	TDH	-0.47	-7.77	-0.34	5.19e-14	Neuroticism;
LGG	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg11473876	chr11:109292803	C11orf87	0.79	17.3	0.63	4.2e-52	Schizophrenia;
LGG	cis	rs7444	0.825	rs2298428	chr22:21982892	C/T	cg05046821	chr22:21984468	YDJC	-0.4	-6.94	-0.31	1.36e-11	Systemic lupus erythematosus;
LGG	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg02153584	chr22:29168773	CCDC117	-0.6	-9.78	-0.41	1.21e-20	Lymphocyte counts;
LGG	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg08508325	chr11:3079039	CARS	0.39	7.21	0.32	2.24e-12	Calcium levels;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	10.05	0.42	1.25e-21	Schizophrenia;
LGG	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg14835575	chr10:16859367	RSU1	0.56	11.32	0.47	2.09e-26	Platelet distribution width;
LGG	cis	rs6546537	0.915	rs4852866	chr2:69829916	T/C	cg10773587	chr2:69614142	GFPT1	-0.42	-7.06	-0.31	5.99e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs11645898	0.872	rs72787093	chr16:72190766	C/T	cg14768367	chr16:72042858	DHODH	-0.8	-10.94	-0.45	6.38e-25	Blood protein levels;
LGG	cis	rs7178909	0.902	rs8034116	chr15:90441568	A/G	cg19708238	chr15:90437601	AP3S2	0.4	6.69	0.3	6.32e-11	Common traits (Other);
LGG	cis	rs1355223	0.533	rs1597960	chr11:34726969	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.16	-0.32	3.15e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.74	0.3	4.81e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg05447186	chr20:3869454	PANK2	0.51	7.26	0.32	1.6e-12	Breast cancer;
LGG	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg19913688	chr11:428466	ANO9	-0.67	-8.54	-0.37	1.9e-16	Body mass index;
LGG	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.23	0.32	1.99e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg06102954	chr21:42741788	MX2	0.4	7.57	0.33	2.06e-13	Melanoma;
LGG	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6547631	0.622	rs12845	chr2:85925848	C/G	cg19805943	chr2:85933069	NA	0.32	6.78	0.3	3.65e-11	Blood protein levels;
LGG	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg04455712	chr21:45112962	RRP1B	0.49	9.28	0.4	6.79e-19	Mean corpuscular volume;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.08	-0.46	1.85e-25	Personality dimensions;
LGG	cis	rs3740909	1.000	rs75029148	chr11:125889464	A/G	cg24940576	chr11:125904314	CDON	-0.48	-7.22	-0.32	2.11e-12	Blood protein levels;
LGG	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg01528321	chr10:82214614	TSPAN14	0.76	13.99	0.55	2.35e-37	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.8	0.48	2.8e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04080417	chr5:1859792	NA	-0.53	-8.78	-0.38	3.3e-17	Cardiovascular disease risk factors;
LGG	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg26248373	chr2:1572462	NA	-0.69	-8.96	-0.38	8.26e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg26354017	chr1:205819088	PM20D1	0.56	9.3	0.4	5.42e-19	Parkinson's disease;
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.33e-23	Bipolar disorder;
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg26750617	chr12:132293702	NA	-0.35	-7.24	-0.32	1.86e-12	Migraine;
LGG	trans	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg00938859	chr5:1591904	SDHAP3	-0.71	-7.73	-0.34	6.95e-14	Breast cancer;
LGG	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg17809284	chr5:56205270	C5orf35	-0.36	-6.94	-0.31	1.35e-11	Coronary artery disease;
LGG	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg26924012	chr15:45694286	SPATA5L1	1.04	22.27	0.72	3.33e-75	Homoarginine levels;
LGG	trans	rs13128441	0.593	rs13114652	chr4:5147606	C/T	cg26099876	chr8:141644609	EIF2C2	-0.55	-7.93	-0.35	1.64e-14	Celiac disease;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.57e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg18898632	chr2:242989856	NA	-0.77	-9.09	-0.39	2.96e-18	Obesity-related traits;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg26516362	chr5:178986906	RUFY1	-0.41	-7.5	-0.33	3.22e-13	Lung cancer;
LGG	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg15704280	chr7:45808275	SEPT13	0.54	8.63	0.37	1.01e-16	HDL cholesterol;
LGG	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.08	-0.31	5.26e-12	Neuroticism;
LGG	cis	rs4774899	0.932	rs12902170	chr15:57522836	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.17e-12	Urinary tract infection frequency;
LGG	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg05729581	chr11:3078854	CARS	-0.55	-9.7	-0.41	2.29e-20	Longevity;
LGG	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg16586182	chr3:47516702	SCAP	-0.75	-13.75	-0.54	2.49e-36	Colorectal cancer;
LGG	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg00012203	chr2:219082015	ARPC2	0.85	17.1	0.62	3.64e-51	Colorectal cancer;
LGG	cis	rs4730779	0.534	rs39321	chr7:116968909	C/G	cg10524701	chr7:117356490	CTTNBP2	0.37	7.33	0.32	1.03e-12	Waist circumference;
LGG	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg09441152	chr18:77712293	PQLC1	0.4	6.84	0.3	2.53e-11	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.18	-0.32	2.8e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7512552	0.803	rs9436127	chr1:150490565	G/A	cg15654264	chr1:150340011	RPRD2	0.44	9.07	0.39	3.49e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7551222	0.681	rs2045623	chr1:204497413	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.34	-0.47	1.86e-26	Schizophrenia;
LGG	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.13	-0.35	3.97e-15	IgG glycosylation;
LGG	cis	rs2380220	0.510	rs9387562	chr6:96057006	G/T	cg04719120	chr6:96025338	MANEA	0.56	7.9	0.34	2e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs3816788	0.792	rs729180	chr8:21817245	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.22	0.6	3.45e-47	Lung cancer in ever smokers;
LGG	cis	rs490234	1.000	rs490234	chr9:128303734	T/C	cg14078157	chr9:128172775	NA	0.38	7.23	0.32	2.05e-12	Mean arterial pressure;
LGG	cis	rs308971	0.563	rs2600271	chr3:12036176	A/G	cg15873301	chr3:12045459	SYN2	0.51	6.67	0.3	7.37e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs1670533	1.000	rs11735663	chr4:1051845	C/T	cg27284194	chr4:1044797	NA	0.54	9.61	0.41	4.65e-20	Recombination rate (females);
LGG	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.46	0.56	2.15e-39	Tonsillectomy;
LGG	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Calcium levels;
LGG	cis	rs10155981	0.510	rs41398948	chr7:22591226	A/T	cg05062323	chr7:22590069	NA	0.86	10.33	0.43	1.2e-22	Bilirubin levels;
LGG	cis	rs17655565	1.000	rs17126640	chr12:52704991	C/T	cg02645295	chr12:52705424	NA	-0.66	-9.17	-0.39	1.54e-18	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg26695010	chr11:65641043	EFEMP2	0.47	7.41	0.33	6.19e-13	Breast cancer;
LGG	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.12	-0.39	2.34e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs9929218	0.529	rs17715450	chr16:68729785	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	21.05	0.7	1.74e-69	Colorectal cancer;
LGG	cis	rs1620921	0.595	rs68142848	chr6:161273257	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs60180747	0.909	rs17200912	chr15:66730307	C/T	cg07575407	chr15:66541975	MEGF11	0.37	7.18	0.32	2.78e-12	Testicular germ cell tumor;
LGG	cis	rs7294478	0.586	rs744141	chr12:7255170	C/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.28	-7.18	-0.32	2.71e-12	Neuritic plaque;
LGG	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.85	-0.34	2.99e-14	Neuroticism;
LGG	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg09818912	chr17:20140352	CYTSB	-0.3	-6.93	-0.31	1.43e-11	Schizophrenia;
LGG	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.79	-0.51	2.73e-32	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.02	-0.39	5.01e-18	Prostate cancer;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg27205649	chr11:78285834	NARS2	0.45	7.33	0.32	1.05e-12	Testicular germ cell tumor;
LGG	cis	rs11158198	0.559	rs12881190	chr14:58607284	A/C	cg15908186	chr14:58618357	C14orf37	0.58	10.1	0.42	8.51e-22	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg18850127	chr7:39170497	POU6F2	0.64	16.35	0.6	9.69e-48	IgG glycosylation;
LGG	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg16512390	chr1:228756714	NA	0.47	8.06	0.35	6.39e-15	Chronic lymphocytic leukemia;
LGG	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg13010199	chr12:38710504	ALG10B	0.55	9.75	0.41	1.51e-20	Resting heart rate;
LGG	trans	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg06521331	chr12:34319734	NA	-0.51	-8.91	-0.38	1.14e-17	Bladder cancer;
LGG	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.37	0.32	8.16e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12458462	0.892	rs12456692	chr18:77482189	C/T	cg11879182	chr18:77439856	CTDP1	0.79	14.55	0.56	9.54e-40	Monocyte count;
LGG	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15664640	chr17:80829946	TBCD	0.78	14.85	0.57	4.31e-41	Breast cancer;
LGG	cis	rs6732160	0.564	rs2043096	chr2:73375723	T/C	cg01422370	chr2:73384389	NA	0.57	9.76	0.41	1.32e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3816788	0.792	rs7013323	chr8:21869024	C/G	cg17168535	chr8:21777572	XPO7	0.77	14.84	0.57	4.94e-41	Lung cancer in ever smokers;
LGG	cis	rs713587	0.719	rs58048722	chr2:25187825	C/T	cg04586622	chr2:25135609	ADCY3	-0.38	-9.85	-0.42	6.33e-21	Body mass index in non-asthmatics;
LGG	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg07936489	chr17:37558343	FBXL20	0.79	11.75	0.48	4.43e-28	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07006042	chr3:141595655	ATP1B3	0.42	6.94	0.31	1.32e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs11191205	0.686	rs10786640	chr10:103392633	A/T	cg15320455	chr10:103880129	LDB1	0.5	7.07	0.31	5.73e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs7572733	0.935	rs10198606	chr2:198769739	C/G	cg00792783	chr2:198669748	PLCL1	-0.48	-8.12	-0.35	4.36e-15	Dermatomyositis;
LGG	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg25986240	chr4:9926439	SLC2A9	-0.5	-9.43	-0.4	1.95e-19	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2290159	0.800	rs6766666	chr3:12690855	A/C	cg23032965	chr3:12705835	RAF1	-0.69	-10.1	-0.43	7.96e-22	Cholesterol, total;
LGG	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.76	-0.38	3.69e-17	Myopia (pathological);
LGG	cis	rs4731207	0.596	rs1525612	chr7:124684047	G/C	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg04662567	chr6:169592167	NA	-0.85	-11.78	-0.48	3.23e-28	Pulse pressure;
LGG	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg08085267	chr17:45401833	C17orf57	0.55	10.02	0.42	1.64e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs16912285	0.688	rs35683920	chr11:24358521	A/G	ch.11.24196551F	chr11:24239977	NA	0.94	12.8	0.51	2.53e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.4	-0.36	5.57e-16	Diabetic retinopathy;
LGG	cis	rs12956009	0.518	rs1434518	chr18:44833498	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.19	0.32	2.6e-12	Educational attainment (years of education);
LGG	cis	rs2071403	0.966	rs13400534	chr2:1411883	A/G	cg06500727	chr2:1417164	TPO	0.51	9.67	0.41	2.84e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg11494091	chr17:61959527	GH2	0.63	10.47	0.44	3.64e-23	Height;
LGG	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	10.7	0.45	5.1900000000000004e-24	Blood metabolite levels;
LGG	cis	rs6429082	0.967	rs704710	chr1:235621026	A/G	cg26050004	chr1:235667680	B3GALNT2	0.51	8.5	0.37	2.55e-16	Adiposity;
LGG	cis	rs9399135	0.967	rs6923827	chr6:135335382	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.06e-19	Red blood cell count;
LGG	cis	rs3813359	0.546	rs62431208	chr6:130556214	T/C	cg23281432	chr6:130554730	NA	0.5	6.72	0.3	5.34e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-10.97	-0.45	4.88e-25	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.32	-7.1	-0.31	4.75e-12	Personality dimensions;
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.04	0.39	4.14e-18	Total body bone mineral density;
LGG	cis	rs2916247	0.954	rs991872	chr8:93164442	G/A	cg10183463	chr8:93005414	RUNX1T1	0.35	7.1	0.31	4.59e-12	Intelligence (multi-trait analysis);
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg18322023	chr17:7141420	PHF23	0.38	6.77	0.3	3.98e-11	Coronary artery disease;
LGG	cis	rs35740288	0.822	rs1961601	chr15:86229606	T/C	cg04173714	chr15:86211321	AKAP13	0.47	8.14	0.35	3.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.19	-0.36	2.59e-15	Neuroticism;
LGG	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg27129171	chr3:47204927	SETD2	0.83	15.94	0.6	6.24e-46	Colorectal cancer;
LGG	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg05729581	chr11:3078854	CARS	0.54	9.7	0.41	2.23e-20	Longevity;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.71	-12.93	-0.52	7.04e-33	Longevity;Endometriosis;
LGG	cis	rs10267417	0.603	rs4275127	chr7:19911062	A/G	cg05791153	chr7:19748676	TWISTNB	0.58	7.64	0.33	1.23e-13	Night sleep phenotypes;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.43	0.65	2.86e-57	Menopause (age at onset);
LGG	cis	rs9513627	1.000	rs4294655	chr13:100216696	A/G	cg15490075	chr13:100150979	NA	0.63	6.66	0.3	7.99e-11	Obesity-related traits;
LGG	cis	rs4356932	1.000	rs10017657	chr4:76985178	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.57	-10.16	-0.43	4.83e-22	Height;
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg18898632	chr2:242989856	NA	-0.86	-9.74	-0.41	1.63e-20	Obesity-related traits;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05025164	chr4:1340916	KIAA1530	0.81	15.56	0.59	3.36e-44	Longevity;
LGG	cis	rs870825	0.860	rs34985821	chr4:185599489	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	20.17	0.68	2.08e-65	Blood protein levels;
LGG	cis	rs607541	0.850	rs74009656	chr15:45935007	C/T	cg26924012	chr15:45694286	SPATA5L1	0.53	7.4	0.33	6.58e-13	Obesity-related traits;
LGG	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg02227867	chr8:22457446	C8orf58	-0.45	-8.53	-0.37	2.04e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg06827562	chr3:125932279	NA	0.58	13.52	0.53	2.5e-35	Metabolite levels;
LGG	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	6.66	0.3	7.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs525304	0.903	rs471931	chr11:70509777	C/T	cg07091154	chr11:70562728	SHANK2	0.36	6.8	0.3	3.17e-11	Response to fenofibrate (adiponectin levels);
LGG	cis	rs3762637	1.000	rs76599189	chr3:122124076	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-9.44	-0.4	1.85e-19	LDL cholesterol levels;
LGG	cis	rs11792861	0.781	rs11793272	chr9:111762102	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.08	0.42	9.87e-22	Menarche (age at onset);
LGG	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg06046430	chr4:77819534	ANKRD56	0.56	11.36	0.47	1.49e-26	Emphysema distribution in smoking;
LGG	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-7.24	-0.32	1.86e-12	Aortic root size;
LGG	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg00339695	chr16:24857497	SLC5A11	0.39	6.75	0.3	4.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504130	0.569	rs11784869	chr8:52819511	C/A	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs72781680	1.000	rs72781663	chr2:24221694	C/G	cg08917208	chr2:24149416	ATAD2B	0.78	8.77	0.38	3.55e-17	Lymphocyte counts;
LGG	cis	rs9314323	0.524	rs7816609	chr8:26202482	A/C	cg11498726	chr8:26250323	BNIP3L	-0.37	-7.82	-0.34	3.64e-14	Red cell distribution width;
LGG	cis	rs9527	0.615	rs11191401	chr10:104573403	A/G	cg04362960	chr10:104952993	NT5C2	0.51	8.9	0.38	1.24e-17	Arsenic metabolism;
LGG	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg14227996	chr4:17616232	MED28	-0.56	-6.69	-0.3	6.58e-11	Opioid sensitivity;
LGG	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26398791	chr1:38455867	SF3A3	0.37	6.71	0.3	5.59e-11	Bilirubin levels;
LGG	cis	rs7843479	1.000	rs727694	chr8:21849962	T/C	cg17168535	chr8:21777572	XPO7	0.58	9.45	0.4	1.69e-19	Mean corpuscular volume;
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg08508337	chr8:144660607	NAPRT1	0.87	6.86	0.3	2.26e-11	Attention deficit hyperactivity disorder;
LGG	trans	rs2840044	1.000	rs2840044	chr17:33892068	A/G	cg19694781	chr19:47549865	TMEM160	0.55	9.05	0.39	3.84e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs11096990	0.551	rs11724855	chr4:39164999	G/A	cg24403649	chr4:39172243	NA	0.39	6.94	0.31	1.36e-11	Cognitive function;
LGG	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg05775895	chr3:12838266	CAND2	0.64	11.06	0.46	2.18e-25	QRS complex (12-leadsum);
LGG	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.73	16.96	0.62	1.59e-50	Multiple sclerosis;
LGG	cis	rs6504950	0.566	rs7226272	chr17:53046447	G/A	cg19360675	chr17:53046073	COX11;STXBP4	0.4	6.8	0.3	3.19e-11	Breast cancer;
LGG	cis	rs2011503	0.941	rs113145184	chr19:19419984	T/C	cg11584989	chr19:19387371	SF4	0.79	13.22	0.52	4.42e-34	Bipolar disorder;
LGG	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.19e-35	Anterior chamber depth;
LGG	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg23601095	chr6:26197514	HIST1H3D	0.71	9.0	0.39	6.01e-18	Gout;Renal underexcretion gout;
LGG	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg18135555	chr8:22132992	PIWIL2	0.38	10.04	0.42	1.32e-21	Hypertriglyceridemia;
LGG	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg05925327	chr15:68127851	NA	-0.37	-7.64	-0.33	1.27e-13	Restless legs syndrome;
LGG	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg10253484	chr15:75165896	SCAMP2	0.46	7.23	0.32	2.05e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7444	0.941	rs140499	chr22:21927231	C/T	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.55e-14	Systemic lupus erythematosus;
LGG	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.42e-11	Obesity-related traits;
LGG	cis	rs8112449	0.894	rs12982179	chr19:10512400	G/A	cg21868191	chr19:10515988	NA	-0.48	-8.22	-0.36	2.07e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.69	-0.44	5.58e-24	Height;
LGG	cis	rs9875589	0.509	rs6775534	chr3:14051001	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	9.37	0.4	3.16e-19	Ovarian reserve;
LGG	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.31e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7927771	0.832	rs7105851	chr11:47383275	T/C	cg20307385	chr11:47447363	PSMC3	0.56	10.26	0.43	2.12e-22	Subjective well-being;
LGG	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg15621731	chr19:5074616	KDM4B	0.31	7.71	0.34	7.61e-14	Monocyte percentage of white cells;
LGG	cis	rs9595066	0.667	rs3809350	chr13:44736179	T/C	cg04068111	chr13:44716778	NA	-0.52	-7.65	-0.34	1.16e-13	Schizophrenia;
LGG	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27110132	chr16:3661765	BTBD12	0.4	6.69	0.3	6.48e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs270601	0.633	rs733300	chr5:131572243	A/G	cg07395648	chr5:131743802	NA	-0.35	-6.74	-0.3	4.67e-11	Acylcarnitine levels;
LGG	cis	rs9463078	0.702	rs929614	chr6:44771934	C/A	cg25276700	chr6:44698697	NA	-0.43	-9.31	-0.4	5.18e-19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg16454426	chr8:49984564	C8orf22	-0.33	-6.76	-0.3	4.25e-11	Blood metabolite levels;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.92	-0.48	9.03e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg08400814	chr5:56204995	C5orf35	0.4	7.09	0.31	5.13e-12	Initial pursuit acceleration;
LGG	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg17294928	chr15:75287854	SCAMP5	0.65	12.26	0.5	4.03e-30	Breast cancer;
LGG	cis	rs4148087	1.000	rs4148100	chr21:43640169	T/C	cg08841829	chr21:43638893	ABCG1	-0.67	-9.64	-0.41	3.53e-20	Eating disorder in bipolar disorder;
LGG	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-19.58	-0.67	1.25e-62	Vitiligo;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.07	-0.31	5.68e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs919433	0.680	rs788022	chr2:198280586	T/C	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1505368	0.817	rs1283310	chr2:213273891	A/G	cg16329650	chr2:213403929	ERBB4	0.46	7.98	0.35	1.16e-14	Symmetrical dimethylarginine levels;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.46	0.37	3.45e-16	Personality dimensions;
LGG	cis	rs2084898	1.000	rs73004764	chr11:120055326	C/G	cg07435449	chr11:120005650	TRIM29	-0.65	-7.31	-0.32	1.18e-12	Stroke (pediatric);
LGG	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg15268244	chr15:77196840	NA	-0.36	-8.18	-0.36	2.7e-15	Blood metabolite levels;
LGG	cis	rs9487094	0.670	rs11755641	chr6:109907936	A/T	cg01125227	chr6:109776195	MICAL1	0.44	7.61	0.33	1.56e-13	Height;
LGG	cis	rs9858542	0.537	rs9863142	chr3:49366741	C/G	cg00383909	chr3:49044727	WDR6	0.55	7.98	0.35	1.19e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg18854424	chr1:2615690	NA	-0.35	-7.12	-0.31	4.09e-12	Ulcerative colitis;
LGG	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg26913058	chr16:419975	MRPL28	0.47	7.47	0.33	3.98e-13	Morning vs. evening chronotype;
LGG	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.89	-0.42	4.89e-21	Pancreatic cancer;
LGG	trans	rs61931739	0.555	rs1482982	chr12:33691601	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.68	-0.37	6.55e-17	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg16586182	chr3:47516702	SCAP	0.77	15.49	0.58	6.71e-44	Colorectal cancer;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.63	10.86	0.45	1.24e-24	Obesity-related traits;
LGG	cis	rs17014483	0.749	rs3017905	chr4:89632132	C/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.8	0.3	3.31e-11	Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.38	-0.32	7.46e-13	HDL cholesterol;
LGG	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.38	0.47	1.29e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg00225070	chr15:80189496	MTHFS	0.37	6.75	0.3	4.34e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg05468064	chr22:46423449	NA	0.4	7.76	0.34	5.59e-14	Dupuytren's disease;
LGG	trans	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.85	-0.34	2.83e-14	Resting heart rate;
LGG	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg11764359	chr7:65958608	NA	-0.8	-14.94	-0.57	1.73e-41	Aortic root size;
LGG	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.16	0.32	3.17e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.64	11.29	0.46	2.89e-26	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.83	0.34	3.41e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.84e-46	Morning vs. evening chronotype;
LGG	cis	rs9357271	0.736	rs4714162	chr6:38418303	A/C	cg07362130	chr6:38359646	BTBD9	-0.4	-8.4	-0.36	5.67e-16	Restless legs syndrome;
LGG	cis	rs611744	0.810	rs672161	chr8:109164182	G/A	cg21045802	chr8:109455806	TTC35	0.39	6.96	0.31	1.15e-11	Dupuytren's disease;
LGG	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	cis	rs4731207	0.596	rs1481332	chr7:124577262	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26807731	chr16:46655402	SHCBP1	0.5	7.47	0.33	4.13e-13	Gut microbiome composition (summer);
LGG	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg11266682	chr4:10021025	SLC2A9	0.47	9.31	0.4	5.04e-19	Bone mineral density;
LGG	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg06360820	chr2:242988706	NA	-0.96	-11.88	-0.48	1.3e-28	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg08999081	chr20:33150536	PIGU	0.34	8.57	0.37	1.57e-16	Coronary artery disease;
LGG	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.13	-0.31	3.84e-12	Life satisfaction;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.65	0.3	8.28e-11	Schizophrenia;
LGG	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg21775007	chr8:11205619	TDH	-0.79	-13.86	-0.54	8.56e-37	Retinal vascular caliber;
LGG	cis	rs73110464	0.505	rs2638503	chr12:53307369	C/G	cg05393297	chr12:53359155	NA	-0.29	-6.97	-0.31	1.09e-11	Cancer (pleiotropy);
LGG	trans	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg16339924	chr4:17578868	LAP3	0.5	8.34	0.36	8.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs7712401	0.601	rs30049	chr5:122306097	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs10463554	0.926	rs3776858	chr5:102357494	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.55	-0.33	2.4e-13	Parkinson's disease;
LGG	cis	rs9487094	0.744	rs13204787	chr6:109939486	A/G	cg01125227	chr6:109776195	MICAL1	0.48	7.58	0.33	1.89e-13	Height;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.09	0.31	5.19e-12	Longevity;
LGG	cis	rs8017423	0.935	rs7144335	chr14:90732280	A/G	cg04374321	chr14:90722782	PSMC1	-0.88	-18.22	-0.65	2.6e-56	Mortality in heart failure;
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17554472	chr22:41940697	POLR3H	-0.5	-7.07	-0.31	5.6e-12	Vitiligo;
LGG	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06634786	chr22:41940651	POLR3H	-0.71	-11.84	-0.48	1.88e-28	Vitiligo;
LGG	trans	rs7939886	0.920	rs17150048	chr11:56063711	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27189623	chr16:705930	WDR90	0.4	7.6	0.33	1.62e-13	Height;
LGG	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.65	-7.91	-0.34	1.93e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04396242	chr4:130014437	SCLT1;C4orf33	0.46	7.0	0.31	9.27e-12	Gut microbiome composition (summer);
LGG	cis	rs72781680	0.898	rs12623316	chr2:24087857	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.09	0.39	2.8e-18	Lymphocyte counts;
LGG	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg22643751	chr7:855365	UNC84A	-0.4	-6.88	-0.3	1.98e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs11096990	0.892	rs1473364	chr4:39212879	A/G	cg24403649	chr4:39172243	NA	0.48	7.91	0.34	1.95e-14	Cognitive function;
LGG	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg21970626	chr13:21893289	NA	-0.4	-9.05	-0.39	4.11e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg27511599	chr7:32358540	NA	0.56	6.72	0.3	5.27e-11	Body mass index;
LGG	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.82	-0.34	3.72e-14	Neuroticism;
LGG	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.27	0.36	1.43e-15	Type 2 diabetes;
LGG	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.66	0.37	8.08e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg23188684	chr11:67383651	NA	0.53	9.02	0.39	5.11e-18	Mean corpuscular volume;
LGG	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-9.72	-0.41	1.97e-20	Height;
LGG	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.85	0.38	1.84e-17	Axial length;
LGG	cis	rs4356203	0.905	rs598946	chr11:17209087	C/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.93	-0.38	1.05e-17	Mean corpuscular volume;
LGG	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.08e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs503734	0.666	rs2553427	chr3:101106527	C/T	cg27318481	chr3:100970896	IMPG2	0.36	7.29	0.32	1.39e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9902453	0.765	rs2729436	chr17:28120670	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg19774624	chr17:42201019	HDAC5	-0.95	-20.9	-0.7	8.67e-69	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	1.000	rs17762102	chr2:24085606	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.55e-20	Lymphocyte counts;
LGG	cis	rs68170813	0.599	rs12532849	chr7:106959226	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.76	-0.45	3.1e-24	Coronary artery disease;
LGG	cis	rs6714710	0.603	rs12988571	chr2:98405695	C/T	cg26665480	chr2:98280029	ACTR1B	0.6	9.75	0.41	1.44e-20	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs758324	0.947	rs11242098	chr5:131206837	T/G	cg06307176	chr5:131281290	NA	0.53	8.78	0.38	3.16e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs703842	1.000	rs11172333	chr12:58170335	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	8.12	0.35	4.13e-15	Multiple sclerosis;
LGG	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.6	-0.44	1.2e-23	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg12708336	chr17:41446283	NA	-0.3	-6.95	-0.31	1.25e-11	Menopause (age at onset);
LGG	cis	rs16837677	1.000	rs75548851	chr1:156764177	G/A	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg03653399	chr8:142233436	SLC45A4	0.39	7.46	0.33	4.25e-13	Immature fraction of reticulocytes;
LGG	cis	rs17504614	0.634	rs17041068	chr2:51069115	A/G	cg23851515	chr2:51057218	NRXN1	0.45	7.43	0.33	5.31e-13	Educational attainment (years of education);
LGG	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg18898632	chr2:242989856	NA	-0.88	-10.54	-0.44	1.92e-23	Obesity-related traits;
LGG	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg21045802	chr8:109455806	TTC35	0.53	9.93	0.42	3.28e-21	Dupuytren's disease;
LGG	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg12463550	chr7:65579703	CRCP	-0.75	-8.34	-0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg13334819	chr7:99746414	C7orf59	0.48	7.52	0.33	2.88e-13	Coronary artery disease;
LGG	cis	rs1707322	0.752	rs28568986	chr1:46207743	C/T	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23556447	chr6:90529595	MDN1	0.51	8.85	0.38	1.8e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg08470875	chr2:26401718	FAM59B	0.43	8.24	0.36	1.73e-15	Gut microbiome composition (summer);
LGG	trans	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs4748857	0.947	rs12413144	chr10:23575249	G/C	cg18853376	chr10:23633759	C10orf67	0.36	6.8	0.3	3.3e-11	Systemic lupus erythematosus;
LGG	cis	rs4742903	0.875	rs4543600	chr9:106939884	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg07882059	chr11:68924751	NA	0.41	7.33	0.32	1.02e-12	Blond vs. brown hair color;
LGG	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg10326726	chr10:51549505	MSMB	0.64	12.8	0.51	2.4e-32	Prostate-specific antigen levels;
LGG	cis	rs7928758	0.887	rs74622686	chr11:134264227	A/G	cg25213107	chr11:134282864	B3GAT1	1.19	14.32	0.55	9.56e-39	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg14829360	chr17:73884958	NA	-0.66	-7.97	-0.35	1.21e-14	Psoriasis;
LGG	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9952991	0.566	rs7234029	chr18:12877060	C/T	cg23598886	chr18:12777645	NA	0.53	7.73	0.34	6.71e-14	Inflammatory skin disease;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg11878867	chr6:150167359	LRP11	-0.39	-8.15	-0.35	3.55e-15	Testicular germ cell tumor;
LGG	cis	rs10465746	0.967	rs12118434	chr1:84328629	C/T	cg10977910	chr1:84465055	TTLL7	0.53	9.44	0.4	1.81e-19	Obesity-related traits;
LGG	cis	rs9296092	0.517	rs7775914	chr6:33518110	T/C	cg13560919	chr6:33536144	NA	-1.05	-21.81	-0.71	4.6e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.16	-0.43	5.16e-22	Total body bone mineral density;
LGG	cis	rs77633900	0.772	rs2078437	chr15:76669580	A/G	cg21673338	chr15:77095150	SCAPER	0.63	8.57	0.37	1.55e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs72930659	0.515	rs12419854	chr11:68886460	A/T	cg07882059	chr11:68924751	NA	0.43	6.94	0.31	1.32e-11	Blond vs non-blond hair color;Brown vs. non-brown hair color;Light vs. dark hair color;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg24846343	chr22:24311635	DDTL	0.51	9.71	0.41	2.11e-20	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02788857	chr8:22132959	PIWIL2	0.5	11.67	0.48	9.09e-28	Hypertriglyceridemia;
LGG	cis	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg07460842	chr6:66804631	NA	0.57	9.55	0.41	7.54e-20	Metabolite levels;
LGG	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.59	-0.53	1.24e-35	Alzheimer's disease;
LGG	cis	rs6977955	1.000	rs10951192	chr7:28161033	C/G	cg23620719	chr7:28220237	JAZF1	-0.41	-6.66	-0.3	7.9e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-8.34	-0.36	8.59e-16	Ovarian reserve;
LGG	cis	rs7444	0.941	rs140489	chr22:21921294	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-8.05	-0.35	6.98e-15	Systemic lupus erythematosus;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg25161386	chr17:27621177	NUFIP2	0.45	6.87	0.3	2.06e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg09631472	chr10:76586650	MYST4	0.46	7.35	0.32	9.3e-13	Emphysema imaging phenotypes;
LGG	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs1595825	0.891	rs2164070	chr2:198881730	G/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.9	-0.31	1.69e-11	Ulcerative colitis;
LGG	cis	rs787274	1.000	rs1891403	chr9:115527183	C/T	cg13803584	chr9:115635662	SNX30	-0.52	-7.31	-0.32	1.21e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg00898013	chr13:113819073	PROZ	-0.45	-8.79	-0.38	3.05e-17	Platelet distribution width;
LGG	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg03929089	chr4:120376271	NA	0.71	7.02	0.31	7.98e-12	Body mass index;
LGG	cis	rs7020830	0.931	rs13293916	chr9:37136359	C/G	cg14294708	chr9:37120828	ZCCHC7	1.17	33.1	0.84	4.16e-124	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12427896	chr2:111880694	BCL2L11	0.43	7.13	0.31	3.99e-12	Gut microbiome composition (summer);
LGG	cis	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg20368463	chr18:77673604	PQLC1	-0.5	-8.98	-0.39	6.7e-18	Schizophrenia;
LGG	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg25173405	chr17:45401733	C17orf57	-0.55	-9.12	-0.39	2.34e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05025164	chr4:1340916	KIAA1530	-0.89	-17.74	-0.64	4.15e-54	Longevity;
LGG	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.22	0.7	2.68e-70	Morning vs. evening chronotype;
LGG	cis	rs9323205	0.577	rs9672038	chr14:51724856	A/G	cg23942311	chr14:51606299	NA	-0.35	-7.08	-0.31	5.51e-12	Cancer;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.46	-0.5	5.98e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs9863	0.828	rs7975482	chr12:124481690	A/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.34	-0.32	9.44e-13	White blood cell count;
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg24690094	chr11:67383802	NA	0.41	7.2	0.32	2.43e-12	Mean corpuscular volume;
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.29	0.36	1.21e-15	Alzheimer's disease;
LGG	cis	rs7646881	1.000	rs7646881	chr3:158453279	C/A	cg19483011	chr3:158453295	NA	-0.65	-9.78	-0.41	1.21e-20	Tetralogy of Fallot;
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.24e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	7.06	0.31	6.17e-12	Renal function-related traits (BUN);
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.01	0.39	5.31e-18	Alzheimer's disease;
LGG	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.02	-0.35	8.64e-15	HDL cholesterol;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.2	0.32	2.49e-12	Schizophrenia;
LGG	cis	rs8017423	1.000	rs2184281	chr14:90685923	A/G	cg04374321	chr14:90722782	PSMC1	-0.9	-18.56	-0.65	7e-58	Mortality in heart failure;
LGG	trans	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.84	-0.3	2.47e-11	Retinal vascular caliber;
LGG	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg20578329	chr17:80767326	TBCD	-0.48	-8.33	-0.36	8.95e-16	Breast cancer;
LGG	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Vitiligo;
LGG	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg20302533	chr7:39170763	POU6F2	0.58	15.01	0.57	8.91e-42	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09280429	chr2:239111682	ILKAP	0.51	7.69	0.34	9.1e-14	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.85e-37	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.24	-0.36	1.75e-15	Bipolar disorder;
LGG	cis	rs8064029	1.000	rs72633272	chr16:4903536	C/G	cg04440724	chr16:4920505	UBN1	-0.62	-7.55	-0.33	2.26e-13	Cancer;
LGG	cis	rs6708331	0.938	rs36025045	chr2:70348961	C/A	cg01613454	chr2:70366299	NA	0.54	9.43	0.4	1.96e-19	Obesity-related traits;
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.43	-0.44	5.3e-23	Bipolar disorder;
LGG	cis	rs782590	0.967	rs1975487	chr2:55809054	A/G	cg18811423	chr2:55921094	PNPT1	0.87	19.57	0.67	1.42e-62	Metabolic syndrome;
LGG	trans	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.82e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06112835	chr11:68658793	MRPL21	0.6	9.94	0.42	3.03e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg16482183	chr6:26056742	HIST1H1C	0.52	9.32	0.4	4.91e-19	Height;
LGG	cis	rs11018904	0.906	rs36177012	chr11:89933319	T/C	cg27158573	chr11:89632121	NA	-0.42	-7.56	-0.33	2.19e-13	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg06521331	chr12:34319734	NA	-0.5	-9.31	-0.4	5.07e-19	Bladder cancer;
LGG	cis	rs7017914	0.967	rs35960437	chr8:71661960	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.51e-11	Bone mineral density;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg14004847	chr7:1930337	MAD1L1	0.41	7.31	0.32	1.18e-12	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg04672837	chr16:48644449	N4BP1	0.57	9.33	0.4	4.53e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg24247370	chr13:99142703	STK24	-0.4	-7.15	-0.32	3.41e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	9.29e-26	Colorectal cancer;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06850241	chr22:41845214	NA	-0.45	-6.96	-0.31	1.2e-11	Vitiligo;
LGG	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11644478	chr21:40555479	PSMG1	-0.58	-9.59	-0.41	5.6e-20	Menarche (age at onset);
LGG	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg00491522	chr10:135256596	NA	0.51	8.13	0.35	4.02e-15	Systemic lupus erythematosus;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20471045	chr19:49568214	NTF4	-0.37	-6.78	-0.3	3.78e-11	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19894588	chr14:64061835	NA	0.63	10.48	0.44	3.26e-23	Glioblastoma;Glioma;
LGG	cis	rs4936894	0.500	rs10893206	chr11:124174874	A/G	cg27160556	chr11:124181099	OR8D1	0.46	10.52	0.44	2.39e-23	Aging (time to death);
LGG	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg18876405	chr7:65276391	NA	-0.62	-11.62	-0.48	1.48e-27	Aortic root size;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg18681998	chr4:17616180	MED28	0.79	16.47	0.61	2.59e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.06	0.62	5.68e-51	Alzheimer's disease;
LGG	cis	rs6807915	0.624	rs7610451	chr3:12293739	G/A	cg22839075	chr3:12045461	SYN2	0.4	6.85	0.3	2.32e-11	Leprosy;
LGG	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg03474202	chr17:45855739	NA	-0.25	-7.0	-0.31	9e-12	IgG glycosylation;
LGG	cis	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg07460842	chr6:66804631	NA	-0.8	-12.95	-0.52	6.23e-33	Exhaled nitric oxide output;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg07538946	chr5:131705188	SLC22A5	0.64	7.53	0.33	2.68e-13	Rheumatoid arthritis;
LGG	cis	rs10266483	0.774	rs642909	chr7:63770321	T/C	cg24201672	chr7:64023550	ZNF680	-0.45	-6.78	-0.3	3.75e-11	Response to statin therapy;
LGG	cis	rs250677	0.652	rs250680	chr5:148436024	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.22	-0.32	2.1e-12	Breast cancer;
LGG	cis	rs4924590	0.531	rs12913835	chr15:42227869	C/T	cg20935245	chr15:42234343	EHD4	0.42	8.35	0.36	8.1e-16	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LGG	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-13.6	-0.53	1.11e-35	Bladder cancer;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs11875185	0.510	rs73451172	chr18:55618172	A/G	cg15513957	chr14:69354734	ACTN1	-0.93	-9.19	-0.39	1.38e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4237845	0.761	rs11172378	chr12:58298161	C/T	cg02175503	chr12:58329896	NA	0.63	11.32	0.47	2.19e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7011049	0.778	rs7823580	chr8:53870595	C/G	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs7737355	0.947	rs2215190	chr5:130921666	C/T	cg06307176	chr5:131281290	NA	0.54	8.98	0.39	6.82e-18	Life satisfaction;
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26897989	chr16:1907736	C16orf73	-0.85	-14.04	-0.55	1.54e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg01028140	chr2:1542097	TPO	-0.55	-8.46	-0.37	3.54e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg05163923	chr11:71159392	DHCR7	0.73	14.42	0.56	3.53e-39	Vitamin D levels;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg04450456	chr4:17643702	FAM184B	0.32	6.77	0.3	3.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg25986240	chr4:9926439	SLC2A9	0.44	9.46	0.4	1.56e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	trans	rs7777677	1.000	rs7777677	chr7:142371448	C/T	cg18540325	chr9:33795118	PRSS3	-0.42	-7.17	-0.32	3.02e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	11.75	0.48	4.45e-28	Personality dimensions;
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	9.91	0.42	4.06e-21	Total body bone mineral density;
LGG	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.32	-0.36	9.6e-16	Monocyte count;
LGG	cis	rs73001065	0.636	rs8182472	chr19:19539891	A/G	cg03709012	chr19:19516395	GATAD2A	0.94	10.6	0.44	1.15e-23	LDL cholesterol;
LGG	cis	rs7818345	0.569	rs4631483	chr8:19357923	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.45	10.88	0.45	1.02e-24	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Colorectal cancer;
LGG	cis	rs1784581	0.802	rs9365359	chr6:162423945	C/A	cg17173639	chr6:162384350	PARK2	0.76	17.91	0.64	7.1e-55	Itch intensity from mosquito bite;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg15017067	chr4:17643749	FAM184B	-0.3	-7.01	-0.31	8.49e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs36051895	0.632	rs7871515	chr9:5175288	A/G	cg02405213	chr9:5042618	JAK2	0.75	14.84	0.57	4.83e-41	Pediatric autoimmune diseases;
LGG	cis	rs3767633	0.528	rs4417044	chr1:161888955	T/C	cg03391019	chr1:161927947	ATF6	0.63	12.77	0.51	3.43e-32	IgG glycosylation;
LGG	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.1e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg09307838	chr4:120376055	NA	0.81	13.59	0.53	1.26e-35	Corneal astigmatism;
LGG	cis	rs10489202	0.583	rs201539	chr1:167995407	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-10.57	-0.44	1.52e-23	Schizophrenia;
LGG	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg08528231	chr16:12997261	SHISA9	-0.34	-6.94	-0.31	1.3e-11	Positive affect;Subjective well-being;
LGG	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.3	-0.4	5.65e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.54	-0.44	1.94e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.21e-35	Obesity-related traits;
LGG	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-8.48	-0.37	3.05e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18876405	chr7:65276391	NA	0.55	9.88	0.42	5.09e-21	Aortic root size;
LGG	cis	rs16854884	1.000	rs62269906	chr3:143808812	A/G	cg06585982	chr3:143692056	C3orf58	0.54	8.16	0.35	3.1e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08219700	chr8:58056026	NA	0.46	7.0	0.31	8.79e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.59	8.83	0.38	2.11e-17	Blood protein levels;
LGG	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	7.55	0.33	2.33e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg07393940	chr7:158741817	NA	-0.61	-11.1	-0.46	1.49e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.21	-0.36	2.24e-15	Mood instability;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg18379455	chr17:41446167	NA	-0.33	-6.71	-0.3	5.71e-11	Menopause (age at onset);
LGG	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg22771759	chr13:24902376	NA	0.41	7.04	0.31	6.92e-12	Obesity-related traits;
LGG	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	trans	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.87	-0.38	1.54e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.21	-0.49	6.49e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.35	0.36	8.12e-16	Aortic root size;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg16270222	chr17:41446396	NA	-0.31	-7.3	-0.32	1.26e-12	Menopause (age at onset);
LGG	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.97	0.64	3.71e-55	Nonalcoholic fatty liver disease;
LGG	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg04731861	chr2:219085781	ARPC2	0.46	11.2	0.46	6.17e-26	Colorectal cancer;
LGG	cis	rs4302748	0.862	rs57854543	chr7:36184158	C/G	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.01	-0.31	8.67e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg22467129	chr15:76604101	ETFA	-0.47	-7.93	-0.35	1.69e-14	Blood metabolite levels;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.34	0.36	8.52e-16	Schizophrenia;
LGG	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7666738	0.830	rs62318906	chr4:99037110	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg20608306	chr11:116969690	SIK3	-0.39	-10.42	-0.44	5.52e-23	Subjective well-being;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg12395012	chr8:11607386	GATA4	0.4	6.94	0.31	1.35e-11	Neuroticism;
LGG	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11718235	chr19:56915184	ZNF583	0.47	8.08	0.35	5.54e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg24623649	chr8:11872141	NA	0.29	6.85	0.3	2.41e-11	Systolic blood pressure;
LGG	cis	rs6882046	0.513	rs447801	chr5:88002653	T/C	cg22951263	chr5:87985283	NA	-0.55	-10.29	-0.43	1.61e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.32	-7.11	-0.31	4.29e-12	Personality dimensions;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg08344181	chr3:125677491	NA	-0.65	-7.55	-0.33	2.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg12473912	chr3:136751656	NA	0.44	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg01448562	chr3:133502909	NA	-0.74	-13.73	-0.54	3e-36	Iron status biomarkers;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg05692746	chr2:100937584	LONRF2	-0.62	-11.34	-0.47	1.72e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	12.98	0.52	4.39e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg03795903	chr2:30669940	LCLAT1	0.54	7.56	0.33	2.24e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-11.31	-0.47	2.3e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2077654	0.822	rs4148634	chr11:17429872	G/A	cg25308976	chr11:17434268	ABCC8	0.87	10.11	0.43	7.75e-22	Gout;
LGG	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg22875332	chr1:76189707	ACADM	0.54	7.35	0.32	9.13e-13	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.51	-0.4	1.01e-19	Height;
LGG	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg07541023	chr7:19748670	TWISTNB	0.48	7.67	0.34	1.01e-13	Thyroid stimulating hormone;
LGG	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg18876405	chr7:65276391	NA	0.45	7.84	0.34	3.11e-14	Calcium levels;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg27400746	chr16:89904261	SPIRE2	-0.88	-15.08	-0.57	4.33e-42	Skin colour saturation;
LGG	cis	rs8077889	1.000	rs113919636	chr17:41877740	A/C	cg26893861	chr17:41843967	DUSP3	0.91	15.71	0.59	7.17e-45	Triglycerides;
LGG	cis	rs10743315	0.732	rs76467196	chr12:19441277	A/G	cg02471346	chr12:19282374	PLEKHA5	0.6	6.87	0.3	2.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg15971980	chr6:150254442	NA	0.44	8.32	0.36	1.02e-15	Lung cancer;
LGG	cis	rs6840360	0.642	rs1470280	chr4:152431770	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.38	0.32	7.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12195424	0.558	rs75574110	chr6:56299478	A/T	cg07152817	chr6:56299822	NA	-0.98	-10.57	-0.44	1.54e-23	Cerebrospinal fluid clusterin levels;
LGG	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg06885757	chr1:42089581	HIVEP3	-0.63	-13.91	-0.54	5.56e-37	Airway imaging phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24153548	chr3:100119764	LNP1;TOMM70A	0.48	7.2	0.32	2.48e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.85	-0.51	1.58e-32	Alzheimer's disease;
LGG	trans	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.51	-0.4	1.08e-19	Brugada syndrome;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg03575189	chr17:44344142	NA	0.48	7.11	0.31	4.31e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.72	0.34	7.09e-14	Longevity;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg21782813	chr7:2030301	MAD1L1	0.56	14.47	0.56	1.96e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs6032067	0.929	rs2143944	chr20:43819370	G/A	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg23173402	chr1:227635558	NA	0.72	11.16	0.46	9.14e-26	Major depressive disorder;
LGG	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12826209	chr6:26865740	GUSBL1	0.56	6.74	0.3	4.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg04117972	chr1:227635322	NA	0.57	9.4	0.4	2.62e-19	Major depressive disorder;
LGG	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg12373951	chr3:133503437	NA	-0.39	-6.85	-0.3	2.39e-11	Iron status biomarkers;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00689492	chr4:1303491	MAEA	0.47	8.02	0.35	8.95e-15	Obesity-related traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23087992	chr3:181430208	SOX2OT;SOX2	0.6	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg04287289	chr16:89883240	FANCA	-0.82	-8.7	-0.38	5.64e-17	Caffeine consumption;
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.13	0.43	6.39e-22	Height;
LGG	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg12751644	chr20:60527061	NA	-0.31	-7.17	-0.32	2.93e-12	Body mass index;
LGG	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	10.91	0.45	8.18e-25	Neuroticism;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg00495681	chr13:53174319	NA	0.66	12.54	0.5	2.85e-31	Lewy body disease;
LGG	cis	rs787274	0.718	rs4979171	chr9:115627262	T/C	cg13803584	chr9:115635662	SNX30	-0.68	-7.75	-0.34	5.85e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17039065	1.000	rs16996970	chr4:109384458	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.1	0.31	4.8e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg08621203	chr6:150244597	RAET1G	0.42	7.09	0.31	4.99e-12	Lung cancer;
LGG	cis	rs3820928	0.874	rs1320407	chr2:227867385	G/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.46	-0.33	4.37e-13	Pulmonary function;
LGG	cis	rs11239187	0.888	rs2170228	chr10:45106025	A/G	cg03916630	chr10:45065415	NA	0.35	7.59	0.33	1.78e-13	Body mass index;
LGG	cis	rs78487399	0.808	rs10180005	chr2:43737465	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.75	-0.38	4.1e-17	Monocyte count;
LGG	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.68e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg20587970	chr11:113659929	NA	-1.16	-19.76	-0.68	1.69e-63	Hip circumference adjusted for BMI;
LGG	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg04842962	chr6:43655489	MRPS18A	1.12	24.5	0.75	1.3e-85	IgG glycosylation;
LGG	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.25	-0.49	4.24e-30	Colorectal cancer;
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg04166393	chr7:2884313	GNA12	0.44	8.37	0.36	6.91e-16	Height;
LGG	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.06	-0.39	3.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6138458	0.847	rs56312312	chr20:24959386	C/A	cg26195577	chr20:24973756	C20orf3	1.26	23.08	0.73	5.11e-79	Blood protein levels;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg11905131	chr22:24372483	LOC391322	-0.41	-7.05	-0.31	6.46e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs112591243	0.685	rs80124066	chr21:47912913	A/G	cg10657630	chr21:48055338	PRMT2	0.87	7.67	0.34	1.01e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs7129556	0.911	rs11237244	chr11:77335336	A/G	cg12586386	chr11:77299805	AQP11	0.51	8.4	0.36	5.6e-16	Weight loss (gastric bypass surgery);
LGG	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg20587970	chr11:113659929	NA	-1.08	-16.33	-0.6	1.19e-47	Hip circumference adjusted for BMI;
LGG	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.9	0.42	4.28e-21	Ovarian reserve;
LGG	cis	rs13314892	0.802	rs62250980	chr3:69844608	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.72e-14	QRS complex (12-leadsum);
LGG	cis	rs28830936	1.000	rs17678767	chr15:42096422	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.11	-0.52	1.24e-33	Diastolic blood pressure;
LGG	cis	rs9425766	0.640	rs2281486	chr1:173822221	A/G	cg06124660	chr1:173389066	NA	-0.44	-7.81	-0.34	3.77e-14	Life satisfaction;
LGG	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg04521981	chr16:55850985	CES1	0.43	6.94	0.31	1.37e-11	Response to dabigatran etexilate treatment;
LGG	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg18898632	chr2:242989856	NA	-0.8	-9.91	-0.42	4.01e-21	Obesity-related traits;
LGG	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.44	-0.37	3.99e-16	Schizophrenia;
LGG	cis	rs7843479	1.000	rs67385415	chr8:21853733	T/C	cg17168535	chr8:21777572	XPO7	0.59	9.64	0.41	3.65e-20	Mean corpuscular volume;
LGG	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7572644	0.608	rs75429814	chr2:27961614	T/C	cg27432699	chr2:27873401	GPN1	0.53	6.99	0.31	9.63e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg12395012	chr8:11607386	GATA4	0.41	7.29	0.32	1.39e-12	Monocyte count;
LGG	cis	rs73787773	0.669	rs73227487	chr5:111462440	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.18	-0.36	2.84e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22857025	chr5:266934	NA	-1.55	-25.44	-0.76	5.97e-90	Breast cancer;
LGG	cis	rs9397585	0.963	rs9371670	chr6:153395594	C/G	cg17707550	chr6:153380415	RGS17	0.5	10.86	0.45	1.31e-24	Body mass index;
LGG	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg17145862	chr1:211918768	LPGAT1	0.79	17.25	0.63	7.79e-52	Leprosy;
LGG	cis	rs4731207	0.536	rs1904971	chr7:124669695	T/C	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.81e-12	Cutaneous malignant melanoma;
LGG	cis	rs13082711	0.911	rs6775176	chr3:27432475	G/A	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3087591	0.879	rs12103564	chr17:29607243	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.02	-0.55	1.82e-37	Hip circumference;
LGG	cis	rs57502260	0.704	rs923346	chr11:68182375	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-8.3	-0.36	1.19e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg15105011	chr4:940614	TMEM175	0.4	7.67	0.34	1e-13	Sjögren's syndrome;
LGG	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg16400903	chr5:693638	TPPP	0.45	6.92	0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg22961513	chr11:14280813	SPON1	0.3	6.89	0.3	1.84e-11	Sense of smell;
LGG	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg16141378	chr3:129829833	LOC729375	-0.39	-8.63	-0.37	1.01e-16	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.66	-0.44	6.98e-24	Lung cancer;
LGG	cis	rs67478160	0.595	rs2295146	chr14:104199356	C/T	cg26031613	chr14:104095156	KLC1	-0.53	-8.6	-0.37	1.2e-16	Schizophrenia;
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg27121462	chr16:89883253	FANCA	-0.63	-11.92	-0.48	9.29e-29	Vitiligo;
LGG	cis	rs17092148	1.000	rs11699062	chr20:33400379	A/T	cg12302830	chr20:33297742	TP53INP2	0.47	7.82	0.34	3.56e-14	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11019462	chr21:43299789	PRDM15	0.4	6.68	0.3	6.96e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg18187862	chr3:45730750	SACM1L	0.66	11.0	0.46	3.68e-25	Primary sclerosing cholangitis;
LGG	cis	rs10927875	0.965	rs3961710	chr1:16313172	C/T	cg21385522	chr1:16154831	NA	-0.79	-14.19	-0.55	3.21e-38	Dilated cardiomyopathy;
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg19812747	chr11:111475976	SIK2	0.49	10.24	0.43	2.64e-22	Primary sclerosing cholangitis;
LGG	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.15	-0.55	5.16e-38	Platelet distribution width;
LGG	trans	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg14416269	chr4:6271139	WFS1	0.43	6.98	0.31	1.03e-11	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs490234	0.812	rs17259739	chr9:128456639	C/T	cg14078157	chr9:128172775	NA	0.5	8.51	0.37	2.48e-16	Mean arterial pressure;
LGG	trans	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.53e-30	Corneal astigmatism;
LGG	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.67	-0.41	2.82e-20	Alcohol dependence;
LGG	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.59	8.03	0.35	8.3e-15	Schizophrenia;
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg07701084	chr6:150067640	NUP43	0.47	7.4	0.33	6.2800000000000005e-13	Lung cancer;
LGG	cis	rs11319879	1	rs11319879	chr10:94453475	TA/T	cg25093409	chr10:94429542	NA	0.59	12.21	0.49	6.44e-30	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;
LGG	cis	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.66e-22	Motion sickness;
LGG	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg20608306	chr11:116969690	SIK3	-0.41	-10.4	-0.44	6.79e-23	Subjective well-being;
LGG	trans	rs459571	0.959	rs456205	chr9:136911146	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.82	-0.48	2.4e-28	Platelet distribution width;
LGG	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg09264619	chr17:80180166	NA	0.5	9.63	0.41	3.88e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg11211951	chr8:145729740	GPT	-0.56	-13.38	-0.53	9.81e-35	Age at first birth;
LGG	cis	rs12505749	0.542	rs6824893	chr4:57372243	A/G	cg07846311	chr4:57371927	ARL9	-0.33	-8.07	-0.35	6.2e-15	Airflow obstruction;
LGG	cis	rs782590	0.935	rs6739513	chr2:55749902	G/A	cg18811423	chr2:55921094	PNPT1	0.87	20.02	0.68	1.05e-64	Metabolic syndrome;
LGG	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg13482628	chr17:19912719	NA	-0.5	-9.1	-0.39	2.79e-18	Obesity-related traits;
LGG	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg21466736	chr12:48725269	NA	-0.36	-7.29	-0.32	1.4e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26734620	chr12:56694298	CS	-0.79	-7.37	-0.32	7.94e-13	Psoriasis vulgaris;
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.11e-13	Tonsillectomy;
LGG	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg22771759	chr13:24902376	NA	0.41	7.04	0.31	6.92e-12	Obesity-related traits;
LGG	cis	rs12143943	0.835	rs12402641	chr1:204452779	G/A	cg20240347	chr1:204465584	NA	-0.34	-7.22	-0.32	2.09e-12	Cognitive performance;
LGG	cis	rs7071206	0.704	rs11002234	chr10:79434458	A/G	cg07817648	chr10:79422355	NA	-0.57	-10.83	-0.45	1.57e-24	Bone mineral density;
LGG	cis	rs1190596	0.830	rs61992489	chr14:102553167	T/G	cg23904247	chr14:102554826	HSP90AA1	-0.26	-6.93	-0.31	1.43e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg27489772	chr12:121021490	NA	-0.58	-7.51	-0.33	3.13e-13	Type 1 diabetes nephropathy;
LGG	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.61e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-8.08	-0.35	5.64e-15	Breast cancer;
LGG	cis	rs3784262	0.669	rs4646642	chr15:58246916	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.89	-0.31	1.81e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg16486109	chr11:613632	IRF7	0.41	6.81	0.3	3e-11	Systemic lupus erythematosus;
LGG	cis	rs2073300	1.000	rs6132626	chr20:23444672	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg05025164	chr4:1340916	KIAA1530	0.44	7.12	0.31	4.05e-12	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg04226714	chr8:49833948	SNAI2	-0.49	-8.91	-0.38	1.22e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.99	-0.35	1.11e-14	Initial pursuit acceleration;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.42	-0.4	2.11e-19	Menopause (age at onset);
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg02524346	chr8:600233	NA	-1.16	-11.64	-0.48	1.2100000000000001e-27	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg12708336	chr17:41446283	NA	-0.3	-6.97	-0.31	1.09e-11	Menopause (age at onset);
LGG	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg03929089	chr4:120376271	NA	0.68	8.08	0.35	5.64e-15	Intraocular pressure;
LGG	cis	rs3806843	0.518	rs2569188	chr5:140008419	G/A	cg19875535	chr5:140030758	IK	-0.43	-8.28	-0.36	1.32e-15	Depressive symptoms (multi-trait analysis);
LGG	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg06623630	chr22:50017776	C22orf34	-0.46	-9.05	-0.39	4.03e-18	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4731207	0.671	rs5022495	chr7:124444024	A/T	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg22535103	chr8:58192502	C8orf71	-0.8	-10.65	-0.44	7.49e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7572733	0.515	rs893808	chr2:198860837	C/G	cg00792783	chr2:198669748	PLCL1	0.68	11.09	0.46	1.69e-25	Dermatomyositis;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09699651	chr6:150184138	LRP11	0.58	11.21	0.46	5.69e-26	Testicular germ cell tumor;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.55e-15	Bipolar disorder;
LGG	cis	rs12410462	0.591	rs2819496	chr1:227733902	G/A	cg23173402	chr1:227635558	NA	0.36	6.89	0.3	1.86e-11	Major depressive disorder;
LGG	cis	rs7666738	0.830	rs7673880	chr4:99057262	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.75e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9596863	0.851	rs9568913	chr13:54340500	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.18	0.32	2.84e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg21724239	chr8:58056113	NA	0.49	7.43	0.33	5.36e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.44e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12493885	0.725	rs11717851	chr3:153741735	G/A	cg12800244	chr3:153838788	SGEF	-0.77	-9.28	-0.4	6.6e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg21724239	chr8:58056113	NA	0.49	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.73	-13.42	-0.53	6.65e-35	Obesity-related traits;
LGG	cis	rs3806843	0.576	rs246063	chr5:140324492	T/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7765175	0.698	rs6905600	chr6:113668457	G/T	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.41e-13	Coronary artery calcification;
LGG	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.59	16.95	0.62	1.65e-50	Oropharynx cancer;
LGG	cis	rs9640161	0.659	rs17837498	chr7:150009679	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.71	-14.74	-0.57	1.31e-40	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9547996	0.842	rs56361602	chr13:38214916	T/C	cg17979426	chr13:38220150	TRPC4	-0.4	-7.64	-0.33	1.27e-13	Diastolic blood pressure;
LGG	cis	rs10267417	0.603	rs10264784	chr7:19909530	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	7.49	0.33	3.55e-13	Night sleep phenotypes;
LGG	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.18	0.43	4.4e-22	Motion sickness;
LGG	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg26384229	chr12:38710491	ALG10B	0.72	14.67	0.56	2.8e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg00631329	chr6:26305371	NA	-0.39	-6.84	-0.3	2.54e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6429082	0.597	rs6683978	chr1:235541425	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.9	-0.38	1.29e-17	Adiposity;
LGG	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg24687543	chr11:63912206	MACROD1	0.61	8.47	0.37	3.17e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	12.19	0.49	7.99e-30	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21659725	chr3:3221576	CRBN	-0.68	-12.81	-0.51	2.25e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.953	rs4615050	chr3:41942498	T/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs151997	0.962	rs27844	chr5:50190680	T/G	cg06027927	chr5:50259733	NA	0.68	10.98	0.45	4.49e-25	Callous-unemotional behaviour;
LGG	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.02	-13.89	-0.54	6.17e-37	Lung cancer in ever smokers;
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg26513180	chr16:89883248	FANCA	0.95	21.96	0.71	8.62e-74	Vitiligo;
LGG	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg06636001	chr8:8085503	FLJ10661	0.59	11.68	0.48	8.16e-28	Mood instability;
LGG	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg05692746	chr2:100937584	LONRF2	-0.6	-9.88	-0.42	5.2e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg24450063	chr1:156163899	SLC25A44	0.92	8.63	0.37	9.81e-17	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs2016266	0.502	rs7954558	chr12:53638137	G/A	cg04065151	chr12:53682969	ESPL1	-0.83	-16.58	-0.61	7.97e-49	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg02428538	chr16:24856791	SLC5A11	0.71	11.06	0.46	2.2e-25	Intelligence (multi-trait analysis);
LGG	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg27279351	chr12:120934652	DYNLL1	0.81	12.97	0.52	4.74e-33	High light scatter reticulocyte count;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	19.86	0.68	5.97e-64	Alzheimer's disease;
LGG	cis	rs7077256	0.564	rs34037284	chr10:65211850	T/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.93	-0.31	1.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05901451	chr6:126070800	HEY2	-0.79	-16.64	-0.61	4.4e-49	Brugada syndrome;
LGG	cis	rs7000551	0.751	rs2449329	chr8:22374794	G/T	cg12081754	chr8:22256438	SLC39A14	0.64	12.0	0.49	4.32e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03517284	chr6:25882590	NA	-0.68	-13.0	-0.52	3.53e-33	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg02023728	chr11:77925099	USP35	0.4	7.13	0.31	3.82e-12	Alzheimer's disease (survival time);
LGG	cis	rs9354308	0.764	rs4710545	chr6:66584855	T/G	cg07460842	chr6:66804631	NA	-0.41	-7.02	-0.31	8.11e-12	Metabolite levels;
LGG	cis	rs7149337	0.805	rs2999357	chr14:51606001	C/G	cg23942311	chr14:51606299	NA	0.32	7.09	0.31	5.09e-12	Cancer;
LGG	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg23029597	chr12:123009494	RSRC2	-0.81	-14.72	-0.56	1.71e-40	Body mass index;
LGG	cis	rs36093844	0.651	rs55978615	chr11:85546391	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2224391	0.628	rs2773307	chr6:5244290	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-7.6	-0.33	1.61e-13	Height;
LGG	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.53	-10.01	-0.42	1.81e-21	Rheumatoid arthritis;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg04025307	chr7:1156635	C7orf50	0.89	19.46	0.67	4.31e-62	Longevity;Endometriosis;
LGG	cis	rs12410462	0.591	rs2453682	chr1:227710381	T/C	cg23173402	chr1:227635558	NA	0.38	7.15	0.32	3.46e-12	Major depressive disorder;
LGG	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg01420254	chr6:26195488	NA	0.92	12.41	0.5	1.03e-30	Gout;Renal underexcretion gout;
LGG	cis	rs4780401	0.728	rs6498239	chr16:11780774	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-6.98	-0.31	9.96e-12	Rheumatoid arthritis;
LGG	cis	rs9311474	1.000	rs7614727	chr3:52295895	C/T	cg14092988	chr3:52407081	DNAH1	0.27	7.37	0.32	8.11e-13	Electroencephalogram traits;
LGG	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.29e-11	Obesity-related traits;
LGG	cis	rs6867032	0.527	rs4371796	chr5:1977785	C/T	cg26168224	chr5:2018326	NA	-0.96	-13.93	-0.54	4.43e-37	Gut microbiome composition (winter);
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.73	-0.59	5.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg01262667	chr19:19385393	TM6SF2	0.34	6.91	0.31	1.59e-11	Bipolar disorder;
LGG	cis	rs1957429	0.731	rs1951495	chr14:65336690	T/C	cg23373153	chr14:65346875	NA	1.02	11.89	0.48	1.26e-28	Pediatric areal bone mineral density (radius);
LGG	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg27446573	chr6:127587934	RNF146	0.93	17.35	0.63	2.51e-52	Breast cancer;
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg23594656	chr7:65796392	TPST1	0.42	8.91	0.38	1.2e-17	Aortic root size;
LGG	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg24101359	chr6:42928495	GNMT	0.39	8.6	0.37	1.25e-16	Blood protein levels;
LGG	cis	rs2735413	0.564	rs74715500	chr16:78095412	A/C	cg04733911	chr16:78082701	NA	0.63	8.96	0.38	7.77e-18	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs67311347	0.544	rs6769627	chr3:40327845	G/A	cg13683864	chr3:40499215	RPL14	-0.82	-16.21	-0.6	4.09e-47	Renal cell carcinoma;
LGG	cis	rs919433	0.783	rs787979	chr2:198242868	A/T	cg00792783	chr2:198669748	PLCL1	0.47	7.44	0.33	4.78e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs72772090	0.539	rs72773986	chr5:96159717	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.21	-0.36	2.23e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4730250	0.707	rs257385	chr7:106807448	T/C	cg02696742	chr7:106810147	HBP1	-0.83	-11.6	-0.47	1.78e-27	Osteoarthritis;
LGG	cis	rs4917300	0.606	rs10875481	chr8:143100478	G/A	cg06573787	chr8:143070187	NA	-0.6	-10.11	-0.43	7.7e-22	Amyotrophic lateral sclerosis;
LGG	cis	rs7143963	0.636	rs11160706	chr14:103361736	A/G	cg23020514	chr14:103360112	TRAF3	-0.39	-8.21	-0.36	2.28e-15	Body mass index;
LGG	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.81	0.38	2.46e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.9	0.64	7.77e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.38	0.32	7.61e-13	Retinal vascular caliber;
LGG	cis	rs240764	0.697	rs12189562	chr6:101168679	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-6.79	-0.3	3.54e-11	Neuroticism;
LGG	cis	rs16976116	0.855	rs11856010	chr15:55495008	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs68170813	0.559	rs17427123	chr7:106823661	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-11.12	-0.46	1.31e-25	Coronary artery disease;
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.65	-0.34	1.14e-13	Rheumatoid arthritis;
LGG	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.58	-0.44	1.44e-23	Heart rate;
LGG	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02251663	chr11:14281053	SPON1	-0.31	-7.47	-0.33	4.05e-13	Mitochondrial DNA levels;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs4148087	0.932	rs2839477	chr21:43611735	C/T	cg08841829	chr21:43638893	ABCG1	-0.51	-6.9	-0.31	1.67e-11	Eating disorder in bipolar disorder;
LGG	cis	rs2587949	0.615	rs1829725	chr3:4212908	C/G	cg16519197	chr3:4211558	NA	-0.33	-6.68	-0.3	6.84e-11	Periodontitis (DPAL);
LGG	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.98	0.42	2.16e-21	Motion sickness;
LGG	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.75	15.6	0.59	2.2e-44	Chronic sinus infection;
LGG	cis	rs11874712	0.545	rs9955008	chr18:43658888	A/G	cg26436583	chr18:43649176	PSTPIP2	0.46	9.51	0.4	1.01e-19	Migraine - clinic-based;
LGG	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.33	-0.36	9.1e-16	Triglycerides;
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg05692746	chr2:100937584	LONRF2	-0.67	-12.55	-0.5	2.71e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg16662043	chr16:48846231	NA	0.37	7.19	0.32	2.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.91	0.31	1.63e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4919044	0.808	rs12416051	chr10:94788835	C/T	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs968451	0.865	rs12627761	chr22:39724137	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.81	-11.98	-0.49	5.36e-29	Primary biliary cholangitis;
LGG	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs4906332	1.000	rs2065015	chr14:103904061	G/T	cg26031613	chr14:104095156	KLC1	0.51	7.81	0.34	3.97e-14	Coronary artery disease;
LGG	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg26441486	chr22:50317300	CRELD2	0.4	6.96	0.31	1.18e-11	Schizophrenia;
LGG	cis	rs4474465	1.000	rs11602360	chr11:78179336	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.44	0.36	4.24e-16	Alzheimer's disease (survival time);
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.3	0.58	4.79e-43	Lung cancer;
LGG	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	9.56	0.41	7.19e-20	Schizophrenia;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs9354308	0.764	rs4543355	chr6:66606120	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs9880211	0.699	rs13433688	chr3:136409171	C/T	cg21827317	chr3:136751795	NA	-0.47	-6.88	-0.3	1.96e-11	Body mass index;Height;
LGG	cis	rs2479724	0.755	rs4318867	chr6:41753670	G/T	cg17623882	chr6:41773611	USP49	0.49	8.56	0.37	1.63e-16	Menarche (age at onset);
LGG	trans	rs12517041	1.000	rs2356713	chr5:23284777	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.9	-0.45	8.86e-25	Calcium levels;
LGG	cis	rs11690935	0.632	rs6723259	chr2:172622527	A/C	cg13550731	chr2:172543902	DYNC1I2	0.71	14.44	0.56	2.75e-39	Schizophrenia;
LGG	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00424166	chr6:150045504	NUP43	0.36	7.46	0.33	4.34e-13	Lung cancer;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.33	0.55	7.9e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	10.99	0.45	4.17e-25	Bone mineral density;
LGG	cis	rs3824867	0.920	rs9734013	chr11:47451517	G/T	cg20307385	chr11:47447363	PSMC3	-0.46	-7.3	-0.32	1.22e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4566357	0.615	rs4675139	chr2:227908527	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.12	-0.39	2.22e-18	Coronary artery disease;
LGG	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.0	-0.35	1.04e-14	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-7.43	-0.33	5.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17067123	0.539	rs75564322	chr4:180066838	A/G	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg05535760	chr7:792225	HEATR2	-0.62	-9.31	-0.4	5.15e-19	Cerebrospinal P-tau181p levels;
LGG	cis	rs13314892	0.764	rs58711181	chr3:69880552	C/T	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.44e-14	QRS complex (12-leadsum);
LGG	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg08999081	chr20:33150536	PIGU	0.39	9.73	0.41	1.76e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7914558	1.000	rs3740387	chr10:104849468	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.76	0.45	2.99e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.72	0.38	5.02e-17	Height;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.74	-14.4	-0.56	4.14e-39	Longevity;Endometriosis;
LGG	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.92	0.42	3.58e-21	Lung cancer in ever smokers;
LGG	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.09	-0.31	5.16e-12	Restless legs syndrome;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08645402	chr16:4508243	NA	0.49	8.88	0.38	1.48e-17	Schizophrenia;
LGG	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg22232500	chr2:134024266	NCKAP5	0.7	9.44	0.4	1.85e-19	Bipolar disorder;
LGG	cis	rs11229555	0.609	rs11229451	chr11:58201687	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.5	0.4	1.09e-19	Neuroticism;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07677032	chr17:61819896	STRADA	0.68	12.62	0.51	1.37e-31	Prudent dietary pattern;
LGG	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg07606381	chr6:8435919	SLC35B3	-0.68	-12.5	-0.5	4.3e-31	Motion sickness;
LGG	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg26827852	chr1:89887630	LOC400759	0.3	6.68	0.3	6.91e-11	Carotid intima media thickness;
LGG	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg14541582	chr5:601475	NA	-0.68	-10.65	-0.44	7.51e-24	Obesity-related traits;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.34	0.36	8.56e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg05380793	chr13:73301995	C13orf37;C13orf34	0.42	6.88	0.3	1.95e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg09307838	chr4:120376055	NA	0.74	12.65	0.51	1.01e-31	Corneal astigmatism;
LGG	cis	rs74417235	0.684	rs13185173	chr5:154055081	A/G	cg08754654	chr5:154026448	NA	0.53	10.86	0.45	1.22e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	trans	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.66	-0.3	7.65e-11	Neuroticism;
LGG	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.35	6.76	0.3	4.05e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7975161	0.579	rs7962423	chr12:104710910	G/A	cg25273343	chr12:104657179	TXNRD1	-0.77	-7.39	-0.32	6.88e-13	Toenail selenium levels;
LGG	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg07120314	chr15:79043507	NA	0.59	9.22	0.39	1.09e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg15068132	chr12:102092402	CHPT1	-0.36	-6.7	-0.3	6.21e-11	Blood protein levels;
LGG	cis	rs1568889	1.000	rs61889026	chr11:28274803	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	13.6	0.53	1.15e-35	Bipolar disorder;
LGG	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs2282978	0.557	rs3731343	chr7:92273536	G/T	cg15732164	chr7:92237376	CDK6	0.32	6.92	0.31	1.48e-11	Height;
LGG	cis	rs72781680	0.528	rs56258075	chr2:24104256	C/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.06	0.39	3.8e-18	Lymphocyte counts;
LGG	cis	rs8064024	0.582	rs2660241	chr16:4940023	T/C	cg08329684	chr16:4932620	PPL	0.5	10.17	0.43	4.57e-22	Cancer;
LGG	trans	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg21659725	chr3:3221576	CRBN	0.56	7.64	0.33	1.27e-13	Menarche (age at onset);
LGG	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg11738485	chr19:12877000	HOOK2	0.44	7.05	0.31	6.52e-12	Red blood cell traits;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	12.13	0.49	1.35e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.83	-0.34	3.45e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-7.69	-0.34	8.94e-14	Response to antipsychotic treatment;
LGG	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg14210321	chr2:106509881	NCK2	-0.49	-8.4	-0.36	5.38e-16	Addiction;
LGG	cis	rs963731	0.649	rs3765058	chr2:39189636	A/G	cg04010122	chr2:39346883	SOS1	0.8	7.02	0.31	7.86e-12	Corticobasal degeneration;
LGG	cis	rs72781680	1.000	rs7594510	chr2:24173377	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg15921436	chr17:44337874	NA	0.45	10.4	0.44	6.35e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs564799	0.966	rs2366644	chr3:159736572	T/G	cg04855961	chr3:159719849	NA	-0.27	-7.43	-0.33	5.23e-13	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9810089	0.967	rs10935177	chr3:135851077	G/T	cg21827317	chr3:136751795	NA	-0.39	-6.8	-0.3	3.31e-11	Gestational age at birth (child effect);
LGG	cis	rs7241530	0.662	rs12966267	chr18:75900507	T/C	cg14642773	chr18:75888474	NA	0.46	9.15	0.39	1.79e-18	Educational attainment (years of education);
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg10950524	chr7:2139216	MAD1L1	0.33	7.19	0.32	2.62e-12	Schizophrenia;
LGG	cis	rs9398803	0.678	rs4895811	chr6:126899853	T/A	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.96e-19	Male-pattern baldness;
LGG	cis	rs4746818	1.000	rs9299502	chr10:70876934	C/T	cg04149295	chr10:70884716	VPS26A	0.46	7.03	0.31	7.33e-12	Left atrial antero-posterior diameter;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05665937	chr4:1216051	CTBP1	-0.41	-7.26	-0.32	1.62e-12	Obesity-related traits;
LGG	cis	rs713587	0.525	rs11687089	chr2:25082926	T/C	cg04586622	chr2:25135609	ADCY3	0.41	11.0	0.46	3.66e-25	Body mass index in non-asthmatics;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08052428	chr9:135996421	RALGDS	0.5	8.12	0.35	4.27e-15	Gut microbiome composition (summer);
LGG	trans	rs2548003	1.000	rs2548007	chr5:28735278	T/A	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.76e-11	Hip geometry;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg03264133	chr6:25882463	NA	-0.38	-6.69	-0.3	6.57e-11	Blood metabolite levels;
LGG	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg19442545	chr10:75533431	FUT11	-0.41	-6.75	-0.3	4.38e-11	Inflammatory bowel disease;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.58	0.33	1.88e-13	Prudent dietary pattern;
LGG	cis	rs17221829	0.733	rs11018699	chr11:89379962	A/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.19	-0.39	1.31e-18	Anxiety in major depressive disorder;
LGG	cis	rs4780401	0.587	rs9931332	chr16:11807517	G/C	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.88	-0.51	1.21e-32	Rheumatoid arthritis;
LGG	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg03605463	chr16:89740564	NA	0.61	10.85	0.45	1.33e-24	Vitiligo;
LGG	cis	rs115344852	0.575	rs1015811	chr6:28448086	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.48	-6.9	-0.31	1.73e-11	Epithelial ovarian cancer;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.79	0.48	2.99e-28	Obesity-related traits;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg21396487	chr1:173793343	CENPL;DARS2	-0.46	-7.43	-0.33	5.22e-13	Alzheimer's disease (survival time);
LGG	trans	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg18187862	chr3:45730750	SACM1L	-0.54	-8.77	-0.38	3.35e-17	Primary sclerosing cholangitis;
LGG	cis	rs972578	0.560	rs8136052	chr22:43323582	G/T	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.47e-11	Mean platelet volume;
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.19e-20	Tonsillectomy;
LGG	cis	rs4595586	0.967	rs1400280	chr12:39241240	A/G	cg26384229	chr12:38710491	ALG10B	-0.44	-7.79	-0.34	4.36e-14	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26567249	chr8:97247842	UQCRB	-0.58	-8.68	-0.37	6.91e-17	Systemic lupus erythematosus;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg13699009	chr12:122356056	WDR66	-0.51	-13.72	-0.54	3.54e-36	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.2	-0.32	2.45e-12	Lung cancer;
LGG	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg02023728	chr11:77925099	USP35	0.4	7.09	0.31	5.15e-12	Alzheimer's disease (survival time);
LGG	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg00717180	chr2:96193071	NA	-0.41	-7.28	-0.32	1.49e-12	HDL cholesterol;
LGG	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg04455712	chr21:45112962	RRP1B	0.48	8.87	0.38	1.6e-17	Mean corpuscular volume;
LGG	cis	rs9534288	0.843	rs2094245	chr13:46602207	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.01	-0.52	3.44e-33	Blood protein levels;
LGG	cis	rs4262150	0.846	rs72802861	chr5:152230416	C/T	cg12297329	chr5:152029980	NA	-0.66	-12.38	-0.5	1.27e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg10407489	chr4:1043616	NA	-0.32	-7.38	-0.32	7.32e-13	Recombination rate (males);
LGG	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.27e-18	Blood metabolite levels;
LGG	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg19913688	chr11:428466	ANO9	-0.71	-8.98	-0.39	6.68e-18	Body mass index;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg15268244	chr15:77196840	NA	-0.32	-6.89	-0.31	1.79e-11	Blood metabolite levels;
LGG	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg15268244	chr15:77196840	NA	0.44	9.49	0.4	1.26e-19	Blood metabolite levels;
LGG	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.84	0.34	3.17e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs12600053	0.658	rs4783076	chr16:84848220	T/C	cg09249803	chr16:84846936	NA	0.37	8.06	0.35	6.74e-15	Asthma (childhood onset);
LGG	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.64e-12	Mean corpuscular hemoglobin;
LGG	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg16096631	chr1:42092165	HIVEP3	0.71	18.6	0.65	4.41e-58	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs36051895	0.658	rs10815145	chr9:5013309	G/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.68	-0.59	9.48e-45	Pediatric autoimmune diseases;
LGG	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg14979609	chr8:8086686	FLJ10661	-0.34	-8.75	-0.38	4.08e-17	Mood instability;
LGG	cis	rs17818399	0.735	rs11894342	chr2:46836439	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-8.39	-0.36	5.87e-16	Height;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs6964587	1.000	rs6952671	chr7:91597934	C/A	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27261837	chr1:146714163	CHD1L	0.41	6.87	0.3	2.05e-11	Gut microbiome composition (summer);
LGG	cis	rs975722	0.638	rs10226907	chr7:117328370	C/T	cg10524701	chr7:117356490	CTTNBP2	0.49	10.06	0.42	1.12e-21	Coronary artery disease;
LGG	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg17703048	chr11:133852993	NA	-0.46	-8.73	-0.38	4.83e-17	Hand grip strength;
LGG	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.05	0.66	3.71e-60	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04011206	chr18:74204120	NA	0.4	6.72	0.3	5.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.05	-0.46	2.31e-25	Prostate cancer;
LGG	trans	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17712092	chr4:129076599	LARP1B	0.73	14.02	0.55	1.76e-37	Eosinophil percentage of white cells;
LGG	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.53	-6.7	-0.3	6.05e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4891159	0.724	rs690639	chr18:74108957	C/T	cg24786174	chr18:74118243	ZNF516	0.57	13.04	0.52	2.54e-33	Longevity;
LGG	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.07	0.75	1.28e-83	Chronic sinus infection;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.28	-0.32	1.43e-12	Bipolar disorder;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg18279126	chr7:2041391	MAD1L1	0.32	6.67	0.3	7.18e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs60180747	1.000	rs79809053	chr15:66753168	G/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.6	10.71	0.45	4.61e-24	Testicular germ cell tumor;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.24	0.6	3.04e-47	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-9.16	-0.39	1.65e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg18240062	chr17:79603768	NPLOC4	0.67	11.33	0.47	2.01e-26	Eye color traits;
LGG	trans	rs6076960	0.684	rs6054041	chr20:6247288	C/T	cg21095983	chr6:86352623	SYNCRIP	0.58	10.54	0.44	2.01e-23	Smooth-surface caries;
LGG	cis	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg06521331	chr12:34319734	NA	0.41	7.12	0.31	4.19e-12	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg20713898	chr8:124780851	FAM91A1	-0.47	-7.14	-0.31	3.74e-12	Pancreatic cancer;
LGG	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg16797656	chr11:68205561	LRP5	0.39	6.87	0.3	2.14e-11	Total body bone mineral density;
LGG	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg08470875	chr2:26401718	FAM59B	-0.36	-6.76	-0.3	4.04e-11	Gut microbiome composition (summer);
LGG	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.16e-12	Arsenic metabolism;
LGG	cis	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs12928939	0.517	rs12934512	chr16:71965230	C/G	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.42	-0.53	6.19e-35	Post bronchodilator FEV1;
LGG	cis	rs4356975	0.563	rs4521414	chr4:69973525	C/A	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg02002194	chr4:3960332	NA	-0.51	-10.25	-0.43	2.35e-22	Mood instability;
LGG	cis	rs6840360	0.571	rs718800	chr4:152549307	A/T	cg25486957	chr4:152246857	NA	0.48	7.82	0.34	3.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.864	rs3781626	chr11:47442893	A/T	cg20307385	chr11:47447363	PSMC3	-0.59	-10.82	-0.45	1.76e-24	Subjective well-being;
LGG	cis	rs1719271	0.831	rs1684040	chr15:65176584	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.25	-0.32	1.78e-12	Platelet count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22827060	chr13:30424359	UBL3	0.58	6.68	0.3	6.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.41	-8.1	-0.35	4.77e-15	Schizophrenia;
LGG	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg26384229	chr12:38710491	ALG10B	0.67	12.11	0.49	1.57e-29	Resting heart rate;
LGG	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.64e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.25	0.32	1.72e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.52	-0.37	2.3e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	10.45	0.44	4.31e-23	Exhaled nitric oxide output;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg07308232	chr7:1071921	C7orf50	-0.72	-14.57	-0.56	7.6e-40	Longevity;Endometriosis;
LGG	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg21053147	chr12:120880522	NA	-0.53	-7.83	-0.34	3.45e-14	Type 1 diabetes nephropathy;
LGG	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg12179176	chr11:130786555	SNX19	0.84	17.53	0.63	3.88e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg13010199	chr12:38710504	ALG10B	-0.53	-10.45	-0.44	4.25e-23	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs79839061	0.610	rs11733713	chr4:869169	A/G	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg01448562	chr3:133502909	NA	-0.73	-13.6	-0.53	1.16e-35	Iron status biomarkers;
LGG	cis	rs9486719	0.947	rs12210834	chr6:96890407	A/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs72781680	1.000	rs72781634	chr2:24199102	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg24112000	chr20:60950667	NA	0.36	8.44	0.37	4.16e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2012796	0.957	rs7151434	chr14:81819468	A/G	cg02996355	chr14:81879375	NA	0.44	7.11	0.31	4.41e-12	Night sleep phenotypes;
LGG	trans	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg02030672	chr11:45687055	CHST1	0.49	8.9	0.38	1.29e-17	Obesity-related traits;
LGG	trans	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg26174226	chr8:58114915	NA	-0.52	-7.16	-0.32	3.11e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg27205649	chr11:78285834	NARS2	-0.49	-8.37	-0.36	6.65e-16	Alzheimer's disease (survival time);
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg23034840	chr1:205782522	SLC41A1	0.77	12.05	0.49	2.83e-29	Prostate-specific antigen levels;
LGG	cis	rs3762637	1.000	rs11932	chr3:122141135	A/G	cg24169773	chr3:122142474	KPNA1	0.6	10.77	0.45	2.71e-24	LDL cholesterol levels;
LGG	cis	rs12956009	0.583	rs12327454	chr18:44863964	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.67e-12	Educational attainment (years of education);
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.29	0.4	6.06e-19	Lung cancer;
LGG	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg11871910	chr12:69753446	YEATS4	0.73	14.57	0.56	7.19e-40	Blood protein levels;
LGG	trans	rs526821	0.595	rs629948	chr11:55356448	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.26	-0.36	1.57e-15	Breast cancer;
LGG	cis	rs7011049	1.000	rs72643590	chr8:53849595	A/G	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.69	-0.3	6.44e-11	Triglycerides;
LGG	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05901451	chr6:126070800	HEY2	-0.83	-17.77	-0.64	2.93e-54	Brugada syndrome;
LGG	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg20735989	chr4:730612	PCGF3	-0.6	-10.43	-0.44	5.22e-23	White blood cell count;
LGG	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.3	-0.43	1.49e-22	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg26150922	chr2:100937072	LONRF2	-0.49	-8.78	-0.38	3.06e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6138458	1.000	rs227658	chr20:24932028	A/G	cg26195577	chr20:24973756	C20orf3	1.24	25.95	0.77	2.62e-92	Blood protein levels;
LGG	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg20307385	chr11:47447363	PSMC3	-0.42	-6.97	-0.31	1.1e-11	Migraine - clinic-based;
LGG	cis	rs2544527	0.819	rs2693019	chr2:15922288	T/C	cg26669897	chr2:15909070	NA	0.32	7.6	0.33	1.61e-13	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.47e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg16524936	chr4:1340807	KIAA1530	-0.47	-7.39	-0.32	6.93e-13	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg22517653	chr1:2918612	NA	-0.48	-7.34	-0.32	9.38e-13	Plateletcrit;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg22907277	chr7:1156413	C7orf50	0.68	12.38	0.5	1.35e-30	Longevity;Endometriosis;
LGG	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.24e-14	HDL cholesterol;
LGG	cis	rs963731	0.649	rs77498284	chr2:39349726	C/A	cg04010122	chr2:39346883	SOS1	0.93	8.24	0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs506338	0.517	rs17146216	chr11:64451281	C/G	cg19395706	chr11:64412079	NRXN2	0.39	7.48	0.33	3.88e-13	Body mass index;Urate levels;
LGG	cis	rs3806843	1.000	rs11167609	chr5:140200426	T/G	cg19875535	chr5:140030758	IK	0.5	10.32	0.43	1.27e-22	Depressive symptoms (multi-trait analysis);
LGG	trans	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg25214090	chr10:38739885	LOC399744	-0.66	-11.36	-0.47	1.55e-26	Corneal astigmatism;
LGG	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-12.4	-0.5	1.12e-30	Schizophrenia;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg24607181	chr17:41446203	NA	-0.31	-7.22	-0.32	2.15e-12	Menopause (age at onset);
LGG	trans	rs11976180	1.000	rs2951308	chr7:143767149	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	0.37	6.76	0.3	4.23e-11	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06024111	chr6:43597558	MAD2L1BP;GTPBP2	0.41	6.77	0.3	4.03e-11	Cognitive performance;
LGG	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.77	0.51	3.18e-32	Motion sickness;
LGG	cis	rs4006360	0.531	rs4544293	chr17:39241359	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg03653399	chr8:142233436	SLC45A4	0.42	8.21	0.36	2.2e-15	Immature fraction of reticulocytes;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg12708336	chr17:41446283	NA	-0.33	-7.89	-0.34	2.22e-14	Menopause (age at onset);
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-11.7	-0.48	7.3e-28	Prudent dietary pattern;
LGG	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-12.49	-0.5	4.82e-31	Bladder cancer;
LGG	cis	rs1408799	0.579	rs970946	chr9:12738690	A/C	cg05274944	chr9:12693694	TYRP1	0.32	7.01	0.31	8.41e-12	Eye color;Blue vs. green eyes;
LGG	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-6.84	-0.3	2.53e-11	Obesity (extreme);
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-13.72	-0.54	3.37e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs9914544	0.564	rs11868520	chr17:18770367	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.16e-13	Educational attainment (years of education);
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs4919087	0.748	rs701817	chr10:98977329	G/C	cg25902810	chr10:99078978	FRAT1	-0.44	-7.64	-0.33	1.3e-13	Monocyte count;
LGG	cis	rs708547	0.647	rs1626594	chr4:57878254	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.12e-12	Morning vs. evening chronotype;
LGG	cis	rs9287719	0.967	rs7587231	chr2:10740093	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs58785573	0.504	rs9522	chr4:38666972	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.5	8.66	0.37	8.12e-17	Lymphocyte percentage of white cells;
LGG	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg11764359	chr7:65958608	NA	0.63	10.89	0.45	9.58e-25	Aortic root size;
LGG	cis	rs4846580	0.613	rs6682254	chr1:219912567	T/C	cg08034750	chr1:219919793	NA	0.41	7.19	0.32	2.55e-12	Total body bone mineral density;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05165339	chr4:1420672	NA	-0.27	-7.09	-0.31	4.94e-12	Longevity;
LGG	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg10483660	chr13:112241077	NA	0.35	6.95	0.31	1.24e-11	Menarche (age at onset);
LGG	cis	rs13314892	0.689	rs57829272	chr3:69863286	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs4740619	0.502	rs9298739	chr9:15833655	T/C	cg14451791	chr9:16040625	NA	0.31	7.48	0.33	3.8e-13	Body mass index;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.09e-42	Colorectal cancer;
LGG	cis	rs11645898	0.872	rs55955726	chr16:72213691	G/C	cg14768367	chr16:72042858	DHODH	-0.76	-10.3	-0.43	1.59e-22	Blood protein levels;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.13	-0.31	3.82e-12	Schizophrenia;
LGG	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.55	0.33	2.33e-13	Educational attainment;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9341808	0.754	rs978814	chr6:80959912	G/T	cg08355045	chr6:80787529	NA	0.41	7.89	0.34	2.27e-14	Sitting height ratio;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs308971	0.656	rs2648347	chr3:12057200	T/G	cg22839075	chr3:12045461	SYN2	0.46	6.66	0.3	7.71e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.25	-0.52	3.24e-34	Personality dimensions;
LGG	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg13010199	chr12:38710504	ALG10B	0.52	10.11	0.43	7.91e-22	Morning vs. evening chronotype;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.36	-0.5	1.59e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg24575275	chr7:1094737	C7orf50	-0.35	-6.75	-0.3	4.57e-11	Longevity;Endometriosis;
LGG	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg23583168	chr7:148888333	NA	-0.86	-16.43	-0.61	4.01e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg26811252	chr16:29126840	RRN3P2	0.76	11.97	0.49	6.19e-29	Menopause (age at onset);
LGG	cis	rs9486719	1.000	rs1303852	chr6:96864523	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs6076065	0.963	rs6048777	chr20:23373302	C/T	cg11657817	chr20:23433608	CST11	0.34	6.88	0.3	1.96e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs77741769	0.571	rs61946382	chr12:121344574	A/T	cg02419362	chr12:121203948	SPPL3	0.54	9.39	0.4	2.71e-19	Mean corpuscular volume;
LGG	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg15268244	chr15:77196840	NA	0.48	10.3	0.43	1.53e-22	Blood metabolite levels;
LGG	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs745080	0.519	rs11851679	chr14:52983362	G/T	cg23333723	chr14:53022898	GPR137C	-0.4	-8.02	-0.35	8.82e-15	Orofacial clefts;
LGG	trans	rs75804782	0.572	rs56400267	chr2:239247213	G/A	cg01134436	chr17:81009848	B3GNTL1	0.81	7.11	0.31	4.48e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2916247	1.000	rs7827887	chr8:93026374	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.61	-0.37	1.16e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg25566285	chr7:158114605	PTPRN2	-0.95	-23.65	-0.74	1.1e-81	Calcium levels;
LGG	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02251663	chr11:14281053	SPON1	-0.3	-7.08	-0.31	5.37e-12	Mitochondrial DNA levels;
LGG	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg04132472	chr17:19861366	AKAP10	0.26	7.09	0.31	5.08e-12	Schizophrenia;
LGG	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg02002194	chr4:3960332	NA	-0.39	-7.0	-0.31	8.83e-12	Retinal vascular caliber;
LGG	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15369054	chr17:80825471	TBCD	-0.4	-7.77	-0.34	5.01e-14	Breast cancer;
LGG	cis	rs12153243	0.565	rs72804712	chr5:142881622	A/G	cg13907255	chr5:142895549	NA	-0.49	-8.11	-0.35	4.56e-15	Migraine;
LGG	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg15268244	chr15:77196840	NA	0.48	10.18	0.43	4.36e-22	Blood metabolite levels;
LGG	cis	rs9815354	0.812	rs967619	chr3:41876710	C/G	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12431410	0.550	rs1957997	chr14:60224547	T/G	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	cis	rs4948275	0.773	rs2606081	chr10:63292251	C/T	cg03237606	chr10:63212265	TMEM26	-0.39	-7.0	-0.31	8.92e-12	Night sleep phenotypes;
LGG	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg11693508	chr17:37793320	STARD3	-0.64	-9.39	-0.4	2.68e-19	Bipolar disorder;
LGG	cis	rs10929925	1.000	rs10929925	chr2:6155557	C/A	cg00493617	chr2:6141445	NA	0.3	6.87	0.3	2.11e-11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg22244940	chr12:132335942	MMP17	0.49	8.76	0.38	3.73e-17	Migraine;
LGG	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg12525768	chr7:29689996	LOC646762	0.55	7.84	0.34	3.07e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg22771759	chr13:24902376	NA	0.41	7.01	0.31	8.54e-12	Obesity-related traits;
LGG	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg00647317	chr7:50633725	DDC	-0.32	-7.37	-0.32	7.82e-13	Malaria;
LGG	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.43	7.17	0.32	3.07e-12	Multiple sclerosis;
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.82	0.3	2.85e-11	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs4789693	0.938	rs8078595	chr17:80426988	G/T	cg04308225	chr17:80449738	NA	0.63	9.31	0.4	5e-19	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	cg07245641	chr1:182991651	LAMC1	0.4	9.07	0.39	3.51e-18	Colorectal cancer;
LGG	cis	rs9341808	0.530	rs3805877	chr6:81031529	T/A	cg08355045	chr6:80787529	NA	0.36	7.04	0.31	6.99e-12	Sitting height ratio;
LGG	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg21926883	chr2:100939477	LONRF2	0.65	15.11	0.57	3.15e-42	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg11050988	chr7:1952600	MAD1L1	0.29	7.05	0.31	6.34e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7923837	0.893	rs10882104	chr10:94470515	T/C	cg25093409	chr10:94429542	NA	0.39	6.99	0.31	9.79e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg24623649	chr8:11872141	NA	-0.31	-7.32	-0.32	1.11e-12	Neuroticism;
LGG	cis	rs3816183	0.585	rs10208367	chr2:42881492	T/C	cg14631114	chr2:43023945	NA	0.36	6.85	0.3	2.31e-11	Hypospadias;
LGG	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg04455712	chr21:45112962	RRP1B	0.51	9.7	0.41	2.31e-20	Mean corpuscular volume;
LGG	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15557168	chr22:42548783	NA	-0.4	-8.98	-0.39	6.9e-18	Cognitive function;
LGG	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg06623918	chr6:96969491	KIAA0776	0.76	14.84	0.57	4.99e-41	Headache;
LGG	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg06766960	chr11:133703094	NA	-0.56	-11.09	-0.46	1.66e-25	Childhood ear infection;
LGG	trans	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg06521331	chr12:34319734	NA	0.44	8.02	0.35	8.9e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.4	-8.11	-0.35	4.74e-15	Schizophrenia;
LGG	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg05985134	chr18:33552581	C18orf21	0.63	9.88	0.42	5.09e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs350251	0.899	rs350275	chr16:12233099	G/C	cg02910054	chr16:12241554	SNX29	0.48	8.96	0.38	7.73e-18	Intelligence (multi-trait analysis);
LGG	cis	rs754423	0.515	rs1956291	chr14:52555673	C/T	cg12071775	chr14:52591786	NA	-0.41	-6.71	-0.3	5.53e-11	Craniofacial microsomia;
LGG	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.71	15.08	0.57	4.48e-42	Lymphocyte percentage of white cells;
LGG	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg23173402	chr1:227635558	NA	0.71	11.64	0.48	1.18e-27	Major depressive disorder;
LGG	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg08250081	chr4:10125330	NA	-0.39	-7.69	-0.34	9.08e-14	Bone mineral density;
LGG	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg07915516	chr16:377344	AXIN1	0.28	6.99	0.31	9.92e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs7402982	0.647	rs4966007	chr15:99200056	G/A	cg03437748	chr15:99193247	IGF1R	0.79	13.48	0.53	3.59e-35	Birth weight;
LGG	cis	rs12580194	1.000	rs12579915	chr12:55696789	C/T	cg19537932	chr12:55886519	OR6C68	0.37	6.72	0.3	5.37e-11	Cancer;
LGG	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg03162506	chr22:38580953	NA	0.4	9.78	0.41	1.14e-20	Breast cancer;
LGG	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg10847948	chr11:71163743	NADSYN1	-0.56	-9.64	-0.41	3.7799999999999997e-20	Vitamin D levels;
LGG	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg18681998	chr4:17616180	MED28	0.87	20.01	0.68	1.15e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9596863	0.898	rs9568902	chr13:54324954	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	7.3	0.32	1.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.2	0.32	2.49e-12	Refractive error;
LGG	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg14598338	chr9:96623480	NA	-0.54	-9.74	-0.41	1.56e-20	DNA methylation (variation);
LGG	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22496380	chr5:211416	CCDC127	-1.07	-10.26	-0.43	2.11e-22	Breast cancer;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg07701084	chr6:150067640	NUP43	0.65	12.17	0.49	9.17e-30	Lung cancer;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	20.33	0.69	4.07e-66	Platelet count;
LGG	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg13902645	chr11:5959945	NA	-0.67	-10.85	-0.45	1.42e-24	DNA methylation (variation);
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25172604	chr17:41446521	NA	-0.3	-6.98	-0.31	1.06e-11	Menopause (age at onset);
LGG	cis	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg16608652	chr1:193155390	B3GALT2;CDC73	-0.28	-7.27	-0.32	1.5e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs526231	0.578	rs42860	chr5:102428118	G/T	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.58e-13	Primary biliary cholangitis;
LGG	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-12.47	-0.5	5.52e-31	Morning vs. evening chronotype;
LGG	trans	rs4714291	0.963	rs1721411	chr6:40102390	T/G	cg02267698	chr19:7991119	CTXN1	0.59	9.36	0.4	3.35e-19	Strep throat;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg16606324	chr3:10149918	C3orf24	0.58	7.7	0.34	8.38e-14	Alzheimer's disease;
LGG	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg09085632	chr11:111637200	PPP2R1B	1.18	25.8	0.77	1.29e-91	Primary sclerosing cholangitis;
LGG	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg25885449	chr18:77638415	KCNG2	0.35	6.89	0.31	1.8e-11	Schizophrenia;
LGG	cis	rs6032067	0.714	rs6032057	chr20:43839761	A/G	cg10761708	chr20:43804764	PI3	0.58	8.93	0.38	9.74e-18	Blood protein levels;
LGG	cis	rs12049351	0.613	rs10916483	chr1:229601014	C/A	cg13547644	chr1:229569608	ACTA1	0.33	7.27	0.32	1.53e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg03970086	chr16:88974840	CBFA2T3	0.44	8.57	0.37	1.59e-16	Social autistic-like traits;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25072359	chr17:41440525	NA	0.51	10.07	0.42	1.02e-21	Menopause (age at onset);
LGG	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg08297393	chr2:100937505	LONRF2	-0.47	-8.47	-0.37	3.29e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.85	-13.22	-0.52	4.27e-34	Body mass index;
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22968622	chr17:43663579	NA	1.09	21.59	0.71	4.76e-72	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.51	-9.03	-0.39	4.77e-18	Longevity;Endometriosis;
LGG	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg13647721	chr17:30228624	UTP6	0.65	8.36	0.36	7.41e-16	Hip circumference adjusted for BMI;
LGG	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	13.32	0.53	1.78e-34	Monocyte count;
LGG	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg07395648	chr5:131743802	NA	-0.51	-11.81	-0.48	2.48e-28	Blood metabolite levels;
LGG	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg16262614	chr3:133464971	TF	0.48	8.89	0.38	1.37e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs7301826	0.651	rs10744484	chr12:131298506	T/G	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs67133203	0.659	rs4471501	chr12:51425352	T/C	cg14688905	chr12:51403056	SLC11A2	-0.6	-10.18	-0.43	4.2e-22	Urinary tract infection frequency;
LGG	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg05090351	chr10:126851162	NA	0.33	8.31	0.36	1.04e-15	Menarche (age at onset);
LGG	cis	rs3087591	0.708	rs17885030	chr17:29655218	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	12.2	0.49	7.27e-30	Hip circumference;
LGG	cis	rs2274273	0.624	rs67412516	chr14:55853237	A/T	cg04306507	chr14:55594613	LGALS3	0.52	12.19	0.49	7.98e-30	Protein biomarker;
LGG	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	16.59	0.61	7.65e-49	Smoking behavior;
LGG	cis	rs6964587	0.773	rs62467797	chr7:91889722	G/A	cg17063962	chr7:91808500	NA	0.48	8.21	0.36	2.24e-15	Breast cancer;
LGG	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	9.3	0.4	5.46e-19	Homoarginine levels;
LGG	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg25358565	chr5:93447407	FAM172A	-1.28	-15.86	-0.59	1.47e-45	Diabetic retinopathy;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.26	-0.4	7.64e-19	Aortic root size;
LGG	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg11887960	chr12:57824829	NA	0.55	6.74	0.3	4.76e-11	Obesity-related traits;
LGG	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg00666640	chr1:248458726	OR2T12	0.6	9.68	0.41	2.72e-20	Common traits (Other);
LGG	cis	rs12210905	0.925	rs7753284	chr6:26991615	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg06713675	chr4:122721982	EXOSC9	0.44	7.0	0.31	8.82e-12	Type 2 diabetes;
LGG	cis	rs2133450	0.526	rs12495356	chr3:7348994	T/C	cg19930620	chr3:7340148	GRM7	-0.42	-9.42	-0.4	2.22e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.41e-23	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg09795085	chr6:101329169	ASCC3	-0.41	-6.73	-0.3	4.9e-11	Neuroticism;
LGG	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg05294307	chr14:35346193	BAZ1A	-0.37	-7.11	-0.31	4.51e-12	Psoriasis;
LGG	cis	rs12956009	0.583	rs16952069	chr18:44904220	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.25	0.32	1.81e-12	Educational attainment (years of education);
LGG	cis	rs6882716	1.000	rs6882716	chr5:10797886	G/A	cg14521931	chr5:10832172	NA	-0.97	-15.11	-0.57	3.27e-42	Alcohol consumption (maxi-drinks);
LGG	cis	rs7107174	1.000	rs11237438	chr11:77998488	T/C	cg02023728	chr11:77925099	USP35	0.44	7.63	0.33	1.32e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.54	0.33	2.44e-13	Lung cancer;
LGG	cis	rs919433	0.680	rs8539	chr2:198362018	A/G	cg00792783	chr2:198669748	PLCL1	0.48	7.17	0.32	3.03e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg03806693	chr22:41940476	POLR3H	-0.96	-16.46	-0.61	2.94e-48	Vitiligo;
LGG	cis	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg11502198	chr6:26597334	ABT1	-0.83	-6.86	-0.3	2.2e-11	Small cell lung carcinoma;
LGG	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs611744	0.870	rs633794	chr8:109174702	A/G	cg21045802	chr8:109455806	TTC35	0.39	6.9	0.31	1.7e-11	Dupuytren's disease;
LGG	cis	rs67478160	0.634	rs2024669	chr14:104275602	G/C	cg26031613	chr14:104095156	KLC1	-0.46	-7.43	-0.33	5.33e-13	Schizophrenia;
LGG	trans	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg10756647	chr7:56101905	PSPH	-0.82	-9.55	-0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg00531865	chr16:30841666	NA	0.55	11.68	0.48	8.37e-28	Dementia with Lewy bodies;
LGG	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.51	-0.53	2.65e-35	Bladder cancer;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14893161	chr1:205819251	PM20D1	0.87	20.38	0.69	2.33e-66	Menarche (age at onset);
LGG	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.01	-0.39	5.35e-18	Mean corpuscular volume;
LGG	cis	rs2251666	0.539	rs17703146	chr16:4860105	T/C	cg04440724	chr16:4920505	UBN1	-0.6	-9.01	-0.39	5.52e-18	Cancer;
LGG	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg12458913	chr13:53173898	NA	0.88	20.49	0.69	6.84e-67	Lewy body disease;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg11494091	chr17:61959527	GH2	0.99	23.98	0.74	3.43e-83	Prudent dietary pattern;
LGG	cis	rs4919694	0.611	rs76695159	chr10:105070837	C/T	cg04362960	chr10:104952993	NT5C2	0.92	11.87	0.48	1.51e-28	Arsenic metabolism;
LGG	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg03342759	chr3:160939853	NMD3	0.44	7.4	0.33	6.58e-13	Morning vs. evening chronotype;
LGG	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08109568	chr15:31115862	NA	0.58	9.73	0.41	1.79e-20	Huntington's disease progression;
LGG	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-13.64	-0.54	7.44e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2540226	0.530	rs2716687	chr2:39903463	C/T	cg02886589	chr2:39892450	TMEM178	-0.31	-8.72	-0.38	5.11e-17	Personality dimensions;
LGG	cis	rs1881509	0.702	rs1554856	chr11:1433896	G/T	cg07067744	chr11:1421172	BRSK2	0.34	6.83	0.3	2.66e-11	Heroin dependence;
LGG	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg23306229	chr2:178417860	TTC30B	0.75	9.75	0.41	1.52e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs938554	0.513	rs1014290	chr4:10001861	G/A	cg25986240	chr4:9926439	SLC2A9	-0.38	-6.91	-0.31	1.62e-11	Blood metabolite levels;
LGG	cis	rs4700695	0.925	rs12653007	chr5:65396965	G/A	cg21114390	chr5:65439923	SFRS12	-0.53	-6.83	-0.3	2.64e-11	Facial morphology (factor 19);
LGG	cis	rs1920116	0.778	rs13074500	chr3:169565571	C/T	cg08193579	chr3:169529701	LRRC34	-0.41	-7.04	-0.31	6.86e-12	Glioma (high-grade);
LGG	cis	rs1707322	1.000	rs785469	chr1:46521091	C/T	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	9.3e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg16512390	chr1:228756714	NA	0.48	6.9	0.31	1.68e-11	Chronic lymphocytic leukemia;
LGG	trans	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg21775007	chr8:11205619	TDH	0.42	6.87	0.3	2.09e-11	Mood instability;
LGG	cis	rs16854884	1.000	rs16854884	chr3:143778708	A/C	cg06585982	chr3:143692056	C3orf58	0.55	8.66	0.37	7.88e-17	Economic and political preferences (feminism/equality);
LGG	cis	rs7928758	0.887	rs111711955	chr11:134264529	A/G	cg22777979	chr11:134283252	B3GAT1	1.03	12.87	0.51	1.32e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4660214	0.614	rs6688708	chr1:39758993	C/G	cg18385671	chr1:39797026	MACF1	-0.47	-9.69	-0.41	2.39e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2224391	0.704	rs9504371	chr6:5261608	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.11	-0.35	4.58e-15	Height;
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.59	0.63	2.06e-53	Alzheimer's disease;
LGG	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg02153584	chr22:29168773	CCDC117	0.68	11.44	0.47	7.57e-27	Lymphocyte counts;
LGG	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	cis	rs11264213	0.892	rs12034163	chr1:36191030	C/G	cg27506609	chr1:36549197	TEKT2	0.7	7.88	0.34	2.3e-14	Schizophrenia;
LGG	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.5	0.37	2.57e-16	Dupuytren's disease;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg18350739	chr11:68623251	NA	-0.88	-22.28	-0.72	2.86e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs422249	0.512	rs174576	chr11:61603510	C/A	cg19610905	chr11:61596333	FADS2	-0.77	-14.24	-0.55	2.08e-38	Trans fatty acid levels;
LGG	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg06916706	chr16:4465613	CORO7	-0.98	-16.74	-0.61	1.55e-49	Schizophrenia;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg27476859	chr7:2772710	GNA12	0.43	7.26	0.32	1.61e-12	Height;
LGG	cis	rs1461503	0.932	rs56778812	chr11:122840491	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.73	0.41	1.75e-20	Height;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06850241	chr22:41845214	NA	0.46	7.2	0.32	2.37e-12	Vitiligo;
LGG	cis	rs4742903	0.935	rs4743694	chr9:106933163	C/G	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg25809561	chr17:30822961	MYO1D	0.41	10.08	0.42	1e-21	Schizophrenia;
LGG	cis	rs1497828	0.956	rs1566178	chr1:217526431	G/A	cg04411442	chr1:217543379	NA	-0.48	-8.22	-0.36	2.02e-15	Dialysis-related mortality;
LGG	cis	rs9419702	0.614	rs4373847	chr10:133532408	C/T	cg04492858	chr10:133558786	NA	0.43	8.63	0.37	1.02e-16	Survival in rectal cancer;
LGG	cis	rs8062405	0.540	rs193628	chr16:28582142	G/T	cg00198680	chr16:28758506	NA	-0.29	-7.37	-0.32	7.99e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19524238	chr7:2802976	GNA12	0.41	9.16	0.39	1.64e-18	Height;
LGG	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg05535760	chr7:792225	HEATR2	0.8	12.97	0.52	5.03e-33	Cerebrospinal P-tau181p levels;
LGG	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg22980697	chr10:16874865	CUBN	0.57	9.07	0.39	3.28e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs17023223	0.537	rs61319010	chr1:119743011	T/A	cg05756136	chr1:119680316	WARS2	-0.43	-8.5	-0.37	2.55e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg19773385	chr1:10388646	KIF1B	-0.47	-9.21	-0.39	1.1e-18	Hepatocellular carcinoma;
LGG	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg08847335	chr10:891726	LARP4B	-0.49	-8.92	-0.38	1.13e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg08344181	chr3:125677491	NA	-0.86	-8.39	-0.36	5.97e-16	Depression;
LGG	trans	rs11250097	0.501	rs2409665	chr8:10736233	G/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.05	-0.31	6.74e-12	Neuroticism;
LGG	cis	rs13314892	0.728	rs62252232	chr3:69889257	A/T	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs4740619	0.766	rs1341735	chr9:15799423	T/C	cg14451791	chr9:16040625	NA	0.32	8.27	0.36	1.42e-15	Body mass index;
LGG	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg13385794	chr1:248469461	NA	0.49	8.24	0.36	1.78e-15	Common traits (Other);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06037631	chr2:74942369	NA	-0.47	-6.83	-0.3	2.71e-11	Systemic lupus erythematosus;
LGG	cis	rs10751667	0.643	rs10902245	chr11:953014	C/T	cg22143635	chr11:980567	AP2A2	-0.43	-8.04	-0.35	7.3e-15	Alzheimer's disease (late onset);
LGG	cis	rs8017423	0.967	rs7151776	chr14:90724803	A/G	cg04374321	chr14:90722782	PSMC1	0.88	19.15	0.66	1.27e-60	Mortality in heart failure;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.99	14.9	0.57	2.73e-41	Platelet count;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.1	-0.42	8.49e-22	Platelet count;
LGG	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg16586182	chr3:47516702	SCAP	-0.56	-9.37	-0.4	3.15e-19	Birth weight;
LGG	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg03315344	chr16:75512273	CHST6	0.59	11.8	0.48	2.72e-28	Dupuytren's disease;
LGG	cis	rs7737355	1.000	rs798412	chr5:130698474	C/A	cg06307176	chr5:131281290	NA	-0.51	-8.55	-0.37	1.8e-16	Life satisfaction;
LGG	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg19717773	chr7:2847554	GNA12	-0.42	-9.73	-0.41	1.74e-20	Height;
LGG	trans	rs75804782	0.630	rs57033609	chr2:239228512	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	7.22	0.32	2.09e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2408955	0.521	rs11168437	chr12:48566156	C/T	cg24011408	chr12:48396354	COL2A1	0.58	9.57	0.41	6.46e-20	Glycated hemoglobin levels;
LGG	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg24253500	chr15:84953950	NA	0.42	7.02	0.31	7.99e-12	Schizophrenia;
LGG	cis	rs6901004	0.803	rs9320360	chr6:111462272	G/T	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.67	-0.34	1.01e-13	Blood metabolite levels;
LGG	cis	rs7598759	0.548	rs6750795	chr2:232378231	T/C	cg19187155	chr2:232395269	NMUR1	0.56	10.34	0.43	1.1e-22	Noise-induced hearing loss;
LGG	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.54	-0.41	8.18e-20	Mean corpuscular volume;
LGG	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.32	0.43	1.36e-22	Tonsillectomy;
LGG	cis	rs13102973	0.965	rs6838419	chr4:135875682	T/C	cg14419869	chr4:135874104	NA	-0.57	-10.9	-0.45	8.6e-25	Subjective well-being;
LGG	cis	rs6901004	0.803	rs4947107	chr6:111442505	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-7.89	-0.34	2.23e-14	Blood metabolite levels;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg07414643	chr4:187882934	NA	0.56	11.8	0.48	2.86e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2712184	0.846	rs7598172	chr2:217677999	G/T	cg05032264	chr2:217675019	NA	-0.44	-9.61	-0.41	4.71e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs937213	0.573	rs12592831	chr15:40302441	G/A	cg22705835	chr10:65332833	REEP3	0.41	7.29	0.32	1.36e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg01966878	chr4:90757139	SNCA	-0.33	-6.75	-0.3	4.39e-11	Dementia with Lewy bodies;
LGG	cis	rs1904096	0.506	rs8336	chr4:95211610	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-11.04	-0.46	2.53e-25	Type 2 diabetes;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg16301924	chr13:53314226	LECT1	0.42	8.4	0.36	5.38e-16	Lewy body disease;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.2e-31	Prostate cancer;
LGG	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg26513180	chr16:89883248	FANCA	0.65	12.05	0.49	2.8e-29	Vitiligo;
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs5758511	0.773	rs1894714	chr22:42349134	T/G	cg15128208	chr22:42549153	NA	-0.57	-8.92	-0.38	1.07e-17	Birth weight;
LGG	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.24e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6750795	0.569	rs1667308	chr2:232406344	T/C	cg19187155	chr2:232395269	NMUR1	0.51	9.67	0.41	2.88e-20	Height;
LGG	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.63	0.41	4.11e-20	Lung cancer in ever smokers;
LGG	cis	rs7911264	0.739	rs10736069	chr10:94395393	T/C	cg25093409	chr10:94429542	NA	0.49	9.51	0.4	1.06e-19	Inflammatory bowel disease;
LGG	cis	rs10463554	0.963	rs26524	chr5:102456304	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.59	-0.33	1.81e-13	Parkinson's disease;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.84	-0.34	3.19e-14	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg05444541	chr17:17804740	TOM1L2	-0.59	-13.05	-0.52	2.19e-33	Total body bone mineral density;
LGG	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08508325	chr11:3079039	CARS	0.4	7.87	0.34	2.51e-14	Calcium levels;
LGG	cis	rs7717393	1.000	rs13358340	chr5:155757872	C/T	cg19569526	chr5:155754265	SGCD	0.83	7.96	0.35	1.38e-14	Egg allergy;
LGG	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.23	-0.43	2.85e-22	Chronic sinus infection;
LGG	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.8e-22	Neutrophil percentage of white cells;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.96e-21	Tonsillectomy;
LGG	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg15704280	chr7:45808275	SEPT13	-0.46	-7.46	-0.33	4.29e-13	HDL cholesterol;
LGG	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg09873164	chr1:152488093	CRCT1	0.62	15.32	0.58	3.96e-43	Hair morphology;
LGG	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg19729930	chr2:74357872	NA	0.41	8.35	0.36	8.03e-16	Gestational age at birth (maternal effect);
LGG	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	9.61	0.41	4.81e-20	Coronary artery disease;
LGG	trans	rs1864585	0.520	rs73208766	chr8:10664537	C/T	cg26278703	chr11:58910052	FAM111A	0.52	6.81	0.3	3.11e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00116463	chr17:19266443	B9D1	-0.48	-7.9	-0.34	2.11e-14	Pancreatic cancer;
LGG	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg21545522	chr1:205238299	TMCC2	0.48	8.5	0.37	2.64e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.55	-0.53	1.85e-35	Personality dimensions;
LGG	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg27476859	chr7:2772710	GNA12	0.52	10.19	0.43	3.88e-22	Height;
LGG	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg26384229	chr12:38710491	ALG10B	0.89	19.91	0.68	3.49e-64	Bladder cancer;
LGG	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.14	12.44	0.5	7.53e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg03528353	chr17:61819722	STRADA	0.44	7.57	0.33	2.05e-13	Prudent dietary pattern;
LGG	cis	rs11874712	1.000	rs11082510	chr18:43656620	T/A	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.75	-0.45	3.34e-24	Migraine - clinic-based;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg14346243	chr4:90757452	SNCA	-0.37	-7.63	-0.33	1.31e-13	Dementia with Lewy bodies;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09238957	chr16:46723420	ORC6L;VPS35	0.41	6.9	0.31	1.75e-11	Bipolar disorder;
LGG	cis	rs283228	0.917	rs2579930	chr6:101829131	G/A	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs8180040	0.966	rs9683177	chr3:47490493	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-15.4	-0.58	1.64e-43	Colorectal cancer;
LGG	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-17.6	-0.63	1.87e-53	Vitiligo;
LGG	cis	rs1639906	0.528	rs1626670	chr7:2268970	A/G	cg08027265	chr7:2291960	NA	-0.55	-11.06	-0.46	2.17e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg05887092	chr17:76393375	PGS1	-0.69	-14.88	-0.57	3.23e-41	HDL cholesterol levels;
LGG	cis	rs2108225	0.714	rs929393	chr7:107437048	C/T	cg18560240	chr7:107437656	SLC26A3	-0.62	-11.06	-0.46	2.09e-25	Ulcerative colitis;
LGG	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.26	0.36	1.57e-15	Aortic root size;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg04287289	chr16:89883240	FANCA	0.74	7.9	0.34	2.07e-14	Skin colour saturation;
LGG	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg21775007	chr8:11205619	TDH	-0.58	-9.58	-0.41	5.95e-20	Retinal vascular caliber;
LGG	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.06	-0.31	6.13e-12	Total cholesterol levels;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07132326	chr6:150258058	NA	0.38	8.08	0.35	5.55e-15	Testicular germ cell tumor;
LGG	trans	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg26043149	chr18:55253948	FECH	0.41	6.88	0.3	1.93e-11	Bone mineral density;
LGG	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.89	0.57	2.87e-41	Cannabis dependence symptom count;
LGG	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.62e-14	Testicular germ cell tumor;
LGG	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	4.97e-87	Height;
LGG	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg27490568	chr2:178487706	NA	-0.37	-7.62	-0.33	1.49e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.76	-0.45	3.1e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg23958373	chr8:599963	NA	1.12	11.08	0.46	1.86e-25	IgG glycosylation;
LGG	trans	rs7181230	0.885	rs749748	chr15:40349909	C/G	cg22705835	chr10:65332833	REEP3	-0.62	-10.29	-0.43	1.61e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs708547	0.541	rs6554392	chr4:57739948	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.43	-6.93	-0.31	1.42e-11	Response to bleomycin (chromatid breaks);
LGG	cis	rs40363	0.645	rs250633	chr16:3523002	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-7.06	-0.31	6.12e-12	Tuberculosis;
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18252515	chr7:66147081	NA	0.45	7.48	0.33	3.79e-13	Aortic root size;
LGG	trans	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.71e-27	Corneal astigmatism;
LGG	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg04691961	chr3:161091175	C3orf57	-0.55	-12.7	-0.51	6.34e-32	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.81	-0.34	3.94e-14	Myopia (pathological);
LGG	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg10818794	chr15:86012489	AKAP13	0.38	8.18	0.36	2.81e-15	Coronary artery disease;
LGG	cis	rs939658	1.000	rs12439908	chr15:79456381	T/C	cg17916960	chr15:79447300	NA	0.63	12.32	0.5	2.24e-30	Refractive error;
LGG	cis	rs877282	1.000	rs877282	chr10:771532	G/A	cg17470449	chr10:769945	NA	0.64	8.06	0.35	6.5e-15	Uric acid levels;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.28	0.32	1.47e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg19223190	chr17:80058835	NA	-0.45	-8.73	-0.38	4.54e-17	Life satisfaction;
LGG	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs910187	0.605	rs2281367	chr20:45808960	T/C	cg27589058	chr20:45804311	EYA2	-0.36	-9.43	-0.4	1.93e-19	Migraine;
LGG	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg23750338	chr8:142222470	SLC45A4	-0.57	-11.88	-0.48	1.34e-28	Immature fraction of reticulocytes;
LGG	cis	rs1941023	0.503	rs12798266	chr11:60118851	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-8.29	-0.36	1.28e-15	Congenital heart disease (maternal effect);
LGG	cis	rs2242663	0.798	rs1791679	chr11:66337874	C/A	cg01599099	chr11:66649832	PC	0.41	8.21	0.36	2.25e-15	Bipolar disorder;
LGG	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg17644776	chr2:200775616	C2orf69	0.53	8.43	0.36	4.57e-16	Osteoporosis;
LGG	cis	rs6546550	0.901	rs6750488	chr2:70146125	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.99	-0.35	1.08e-14	Prevalent atrial fibrillation;
LGG	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15541040	chr2:3486749	NA	-0.47	-8.53	-0.37	2.08e-16	Neurofibrillary tangles;
LGG	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.28	0.32	1.41e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9326248	0.574	rs1263173	chr11:116681008	C/T	cg20608306	chr11:116969690	SIK3	0.3	8.06	0.35	6.74e-15	Blood protein levels;
LGG	cis	rs6772849	1.000	rs9836257	chr3:128303483	C/T	cg08795948	chr3:128337044	NA	0.53	8.71	0.38	5.27e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg26076054	chr5:421317	AHRR	0.42	7.83	0.34	3.43e-14	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14184786	chr14:94547643	IFI27L1;DDX24	0.46	7.03	0.31	7.35e-12	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	13.42	0.53	6.17e-35	Total body bone mineral density;
LGG	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg15309053	chr8:964076	NA	0.37	7.37	0.32	7.91e-13	Schizophrenia;
LGG	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.33	0.7	8.12e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9463078	0.803	rs2396380	chr6:45043557	T/A	cg25276700	chr6:44698697	NA	-0.37	-7.7	-0.34	8.15e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	cis	rs6460942	0.841	rs17443848	chr7:12443688	A/G	cg06484146	chr7:12443880	VWDE	-0.39	-7.29	-0.32	1.34e-12	Coronary artery disease;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs4936894	0.500	rs11602170	chr11:124167103	C/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.68	-0.44	5.91e-24	Aging (time to death);
LGG	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.45	-0.61	3.39e-48	Height;
LGG	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg06618935	chr21:46677482	NA	-0.48	-8.51	-0.37	2.41e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Gut microbiome composition (summer);
LGG	cis	rs1927790	0.727	rs9556554	chr13:96960146	C/T	cg02571835	chr13:96230311	CLDN10	-0.35	-7.02	-0.31	7.84e-12	Body mass index;
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs7937612	1.000	rs4938804	chr11:120273865	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.03	-0.52	2.66e-33	Intraocular pressure;
LGG	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg23625390	chr15:77176239	SCAPER	-0.72	-14.43	-0.56	3.19e-39	Blood metabolite levels;
LGG	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg06453172	chr10:134556979	INPP5A	-0.58	-8.63	-0.37	9.79e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.94	-0.38	9.56e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.87	-0.3	2.04e-11	Lung cancer;
LGG	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg07005078	chr4:17578674	LAP3	0.38	6.8	0.3	3.21e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2018683	0.870	rs13232487	chr7:28985119	C/A	cg19402173	chr7:128379420	CALU	-0.67	-12.18	-0.49	8.53e-30	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23213170	chr9:108320507	FKTN	0.48	7.13	0.31	3.8e-12	Gut microbiome composition (summer);
LGG	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.6	-9.18	-0.39	1.45e-18	Blood protein levels;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.84e-12	Lung cancer;
LGG	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg07395648	chr5:131743802	NA	-0.52	-11.9	-0.48	1.08e-28	Blood metabolite levels;
LGG	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg15704280	chr7:45808275	SEPT13	0.85	8.83	0.38	2.16e-17	Myopia (pathological);
LGG	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg24253500	chr15:84953950	NA	0.42	6.9	0.31	1.73e-11	Schizophrenia;
LGG	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg08807101	chr21:30365312	RNF160	-0.56	-9.58	-0.41	5.89e-20	Pancreatic cancer;
LGG	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg22916017	chr11:64110731	CCDC88B	-0.49	-6.68	-0.3	7.05e-11	Mean platelet volume;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.98	-0.6	4.15e-46	Platelet count;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.02e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.624	rs8005450	chr14:55799165	A/T	cg04306507	chr14:55594613	LGALS3	0.53	12.56	0.5	2.43e-31	Protein biomarker;
LGG	cis	rs6942756	0.680	rs691555	chr7:129135770	C/T	cg02491457	chr7:128862824	NA	-0.59	-10.14	-0.43	5.86e-22	White matter hyperintensity burden;
LGG	cis	rs7949566	0.833	rs1007690	chr11:126274003	C/T	cg05055844	chr11:126275997	ST3GAL4	-0.42	-9.34	-0.4	4.17e-19	Platelet distribution width;Mean platelet volume;
LGG	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03517284	chr6:25882590	NA	-0.51	-9.41	-0.4	2.36e-19	Height;
LGG	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg25173405	chr17:45401733	C17orf57	0.47	8.08	0.35	5.62e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.1	-0.31	4.59e-12	Retinal vascular caliber;
LGG	cis	rs17001868	0.568	rs10854729	chr22:40750612	T/C	cg07138101	chr22:40742427	ADSL	0.62	8.05	0.35	6.8e-15	Mammographic density (dense area);
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.11	-0.46	1.44e-25	Hemoglobin concentration;
LGG	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg03929089	chr4:120376271	NA	-0.98	-21.12	-0.7	7.97e-70	Coronary artery disease;
LGG	cis	rs73071352	0.577	rs73075228	chr3:42049629	T/G	cg03022575	chr3:42003672	ULK4	0.76	8.44	0.37	4.05e-16	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
LGG	trans	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg02030672	chr11:45687055	CHST1	-0.5	-9.05	-0.39	3.9e-18	Obesity-related traits;
LGG	cis	rs6714710	0.535	rs13033383	chr2:98339513	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	9.19	0.39	1.38e-18	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg05444541	chr17:17804740	TOM1L2	0.69	16.55	0.61	1.17e-48	Total body bone mineral density;
LGG	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg02023728	chr11:77925099	USP35	0.4	7.05	0.31	6.54e-12	Alzheimer's disease (survival time);
LGG	cis	rs990171	0.913	rs6718157	chr2:103079814	A/T	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg27532318	chr7:32358331	NA	0.71	7.25	0.32	1.78e-12	Body mass index;
LGG	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs7267979	1.000	rs2856	chr20:25433536	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.47	0.44	3.64e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.82	-0.48	2.29e-28	Tonsillectomy;
LGG	cis	rs9354308	0.714	rs9294667	chr6:66598740	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs17776563	0.639	rs11073791	chr15:89114799	T/C	cg05013243	chr15:89149849	MIR1179	-0.33	-6.75	-0.3	4.45e-11	Thyroid hormone levels;
LGG	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.07	0.39	3.51e-18	Diabetic retinopathy;
LGG	cis	rs4006360	0.506	rs8080177	chr17:39301645	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.58	-12.69	-0.51	7.18e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.59	-0.67	1.16e-62	Blood trace element (Zn levels);
LGG	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.93	-0.48	8.54e-29	Depressive symptoms (multi-trait analysis);
LGG	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg09448879	chr15:79043637	NA	0.43	8.61	0.37	1.19e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs9815354	0.812	rs57209010	chr3:41854743	A/T	cg03022575	chr3:42003672	ULK4	0.79	9.21	0.39	1.18e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.1	0.42	8.3e-22	Obesity-related traits;
LGG	cis	rs13382275	0.544	rs10188791	chr2:952234	T/C	cg10902693	chr2:875509	NA	0.44	7.81	0.34	3.9e-14	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02018176	chr4:1364513	KIAA1530	-0.58	-13.73	-0.54	3.1e-36	Longevity;
LGG	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg23231163	chr10:75533350	FUT11	0.42	7.25	0.32	1.72e-12	Inflammatory bowel disease;
LGG	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.96	0.45	5.09e-25	Lung cancer in ever smokers;
LGG	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.73e-27	Schizophrenia;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.19	-0.46	6.65e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19717773	chr7:2847554	GNA12	-0.37	-8.59	-0.37	1.34e-16	Height;
LGG	cis	rs11168187	0.843	rs6580635	chr12:48116573	G/A	cg12761788	chr12:48120090	P11	0.5	8.72	0.38	4.91e-17	Vertical cup-disc ratio;
LGG	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.26e-17	Height;
LGG	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg02574844	chr11:5959923	NA	-0.55	-8.7	-0.37	5.95e-17	DNA methylation (variation);
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg00405596	chr8:11794950	NA	-0.44	-7.39	-0.32	6.77e-13	Triglycerides;
LGG	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-13.32	-0.53	1.68e-34	Bladder cancer;
LGG	trans	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg18187862	chr3:45730750	SACM1L	0.58	9.49	0.4	1.27e-19	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7582720	1.000	rs3845800	chr2:203734365	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.77	-9.65	-0.41	3.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg00549575	chr11:8008752	EIF3F	0.43	6.7	0.3	6.04e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	9.75	0.41	1.47e-20	Neuroticism;
LGG	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg03476357	chr21:30257390	N6AMT1	0.46	7.9	0.34	2.02e-14	Cognitive test performance;
LGG	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.25e-11	Electroencephalogram traits;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13309018	chr9:130965761	CIZ1;DNM1	0.45	6.86	0.3	2.15e-11	Gut microbiome composition (summer);
LGG	cis	rs7267979	0.966	rs2387885	chr20:25415224	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.28	-0.43	1.77e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs73198271	0.603	rs557892	chr8:8596048	A/C	cg16141378	chr3:129829833	LOC729375	0.35	6.93	0.31	1.39e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.77	-0.54	2.14e-36	Tonsillectomy;
LGG	cis	rs4788570	0.615	rs7188675	chr16:71680002	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	21.36	0.7	5.64e-71	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21963583	chr11:68658836	MRPL21	0.6	10.06	0.42	1.15e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9487094	0.744	rs11964533	chr6:110059000	G/A	cg16315928	chr6:109776240	MICAL1	0.49	7.92	0.35	1.83e-14	Height;
LGG	trans	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg11430096	chr6:110968061	CDK19	0.68	7.1	0.31	4.76e-12	Prostate cancer;
LGG	cis	rs892085	0.681	rs873016	chr19:10894728	G/A	cg17710535	chr19:10819994	QTRT1	0.5	8.86	0.38	1.72e-17	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg21972741	chr5:435613	AHRR	0.5	8.95	0.38	8.72e-18	Cystic fibrosis severity;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22409420	chr18:53255401	TCF4	-0.36	-6.81	-0.3	3.05e-11	Brain structure;
LGG	cis	rs1568889	1.000	rs61889054	chr11:28333000	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.74	12.87	0.51	1.27e-32	Bipolar disorder;
LGG	cis	rs185694	0.947	rs169331	chr13:30878695	G/T	cg07600127	chr13:30881527	KATNAL1	-0.54	-6.92	-0.31	1.55e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg14926445	chr8:58193284	C8orf71	-0.86	-12.12	-0.49	1.53e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	0.821	rs111571980	chr2:24201695	C/G	cg08917208	chr2:24149416	ATAD2B	0.65	8.67	0.37	7.44e-17	Lymphocyte counts;
LGG	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg17145862	chr1:211918768	LPGAT1	0.71	10.73	0.45	3.86e-24	Crohn's disease;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg02153584	chr22:29168773	CCDC117	0.63	9.71	0.41	2.06e-20	Lymphocyte counts;
LGG	cis	rs1408799	0.682	rs1325117	chr9:12613472	G/A	cg05274944	chr9:12693694	TYRP1	0.32	7.46	0.33	4.17e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs7412746	0.646	rs1972060	chr1:150937594	T/C	cg15448220	chr1:150897856	SETDB1	0.36	6.68	0.3	7.05e-11	Melanoma;
LGG	cis	rs7444	0.941	rs2283789	chr22:21944478	T/G	cg05046821	chr22:21984468	YDJC	-0.38	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.2	0.46	6.22e-26	Morning vs. evening chronotype;
LGG	cis	rs9487094	0.670	rs729888	chr6:109957323	A/G	cg16315928	chr6:109776240	MICAL1	-0.49	-8.37	-0.36	6.87e-16	Height;
LGG	cis	rs2594989	1.000	rs2606761	chr3:11344427	G/A	cg01796438	chr3:11312864	ATG7	-0.6	-8.34	-0.36	8.62e-16	Circulating chemerin levels;
LGG	cis	rs9467160	0.871	rs7762593	chr6:24449417	G/A	cg20631270	chr6:24437470	GPLD1	0.52	7.74	0.34	6.51e-14	Liver enzyme levels;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg13264159	chr8:625131	ERICH1	-1.03	-11.92	-0.48	9.55e-29	IgG glycosylation;
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.16	-0.43	5.16e-22	Total body bone mineral density;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg03188948	chr7:1209495	NA	0.45	8.09	0.35	5.32e-15	Longevity;Endometriosis;
LGG	cis	rs1832871	0.711	rs9459954	chr6:158709345	G/T	cg07215822	chr6:158701037	NA	-0.41	-6.75	-0.3	4.38e-11	Height;
LGG	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg09624528	chr10:1369823	ADARB2	-0.41	-7.31	-0.32	1.22e-12	Radiation response;
LGG	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg08807101	chr21:30365312	RNF160	0.92	19.42	0.67	6.8e-62	Dental caries;
LGG	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.23	-0.32	2.04e-12	Hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.99	0.35	1.06e-14	Lung cancer;
LGG	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg23009067	chr7:2775923	GNA12	0.25	7.03	0.31	7.28e-12	Height;
LGG	cis	rs9311474	0.967	rs11717383	chr3:52287468	G/T	cg14092988	chr3:52407081	DNAH1	0.28	7.45	0.33	4.54e-13	Electroencephalogram traits;
LGG	cis	rs2797369	0.713	rs2813638	chr6:101571556	A/G	cg27451362	chr6:101846650	GRIK2	0.83	10.79	0.45	2.21e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18252515	chr7:66147081	NA	-0.43	-7.31	-0.32	1.15e-12	Aortic root size;
LGG	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.4	9.54e-20	Schizophrenia;
LGG	cis	rs740474	0.569	rs9324851	chr5:140884527	A/G	cg00076195	chr5:140892677	NA	0.38	6.94	0.31	1.36e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17433780	0.897	rs12120863	chr1:89501522	T/C	cg09516651	chr1:89888402	LOC400759	0.77	17.45	0.63	8.98e-53	Carotid intima media thickness;
LGG	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg24253500	chr15:84953950	NA	0.41	6.83	0.3	2.74e-11	Schizophrenia;
LGG	cis	rs1497828	0.956	rs5002693	chr1:217530191	T/A	cg04411442	chr1:217543379	NA	-0.47	-8.02	-0.35	8.51e-15	Dialysis-related mortality;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02594498	chr15:22893147	CYFIP1	0.42	6.73	0.3	5.03e-11	Cognitive performance;
LGG	cis	rs7666738	0.830	rs17027102	chr4:98919221	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-8.36	-0.36	7.35e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.16	-0.49	1.06e-29	Response to antipsychotic treatment;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.7	-0.34	8.05e-14	Testicular germ cell tumor;
LGG	cis	rs3742264	0.656	rs9534281	chr13:46586976	G/A	cg15192986	chr13:46630673	CPB2	-0.36	-6.97	-0.31	1.07e-11	Blood protein levels;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg15971980	chr6:150254442	NA	0.46	8.7	0.37	6.05e-17	Lung cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg12517452	chr5:52084045	ITGA1;PELO	-0.39	-6.77	-0.3	3.81e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs701145	0.585	rs1727944	chr3:153826603	A/C	cg12800244	chr3:153838788	SGEF	-0.78	-8.6	-0.37	1.26e-16	Coronary artery disease;
LGG	cis	rs2494938	0.819	rs10947898	chr6:40532893	C/G	cg14084896	chr6:40530702	LRFN2	0.31	6.89	0.3	1.82e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.75e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9807989	0.524	rs6543126	chr2:103027104	G/A	cg03938978	chr2:103052716	IL18RAP	0.4	9.36	0.4	3.5e-19	Asthma;
LGG	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg26384229	chr12:38710491	ALG10B	0.73	14.72	0.56	1.58e-40	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.82	-0.48	2.33e-28	Morning vs. evening chronotype;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.21	-0.43	3.37e-22	Tonsillectomy;
LGG	cis	rs11971779	1.000	rs11971779	chr7:139040258	A/G	cg07862535	chr7:139043722	LUC7L2	-0.68	-10.05	-0.42	1.26e-21	Diisocyanate-induced asthma;
LGG	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg02297831	chr4:17616191	MED28	0.43	8.01	0.35	9.7e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg01631408	chr1:248437212	OR2T33	-0.38	-7.1	-0.31	4.75e-12	Common traits (Other);
LGG	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.16	-0.35	3.25e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.34	-0.36	8.71e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.64	-0.51	1.1e-31	Uric acid levels;
LGG	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg11366901	chr6:160182831	ACAT2	1.05	16.13	0.6	9.49e-47	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	9.0	0.39	5.71e-18	Neuroticism;
LGG	cis	rs4731207	0.697	rs4360235	chr7:124526542	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs3799379	0.550	rs77631260	chr6:26379440	A/T	cg12826209	chr6:26865740	GUSBL1	0.46	7.02	0.31	7.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg09307838	chr4:120376055	NA	0.67	10.12	0.43	7.15e-22	Corneal astigmatism;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg12016809	chr21:47604291	C21orf56	0.5	8.61	0.37	1.16e-16	Testicular germ cell tumor;
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg07870213	chr5:140052090	DND1	-0.86	-15.61	-0.59	1.95e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11625487	0.645	rs8006951	chr14:77965304	G/A	cg20045696	chr14:77926864	AHSA1	0.58	7.53	0.33	2.73e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg27471124	chr11:109292789	C11orf87	0.64	12.36	0.5	1.57e-30	Schizophrenia;
LGG	cis	rs780094	0.500	rs7570476	chr2:27784658	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	4.88e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg01081584	chr15:40268610	EIF2AK4	0.64	9.21	0.39	1.17e-18	Response to haloperidol in psychosis;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.31	0.32	1.15e-12	Prudent dietary pattern;
LGG	cis	rs988958	0.526	rs12712827	chr2:42244794	T/G	cg19376973	chr2:42229025	NA	0.64	9.52	0.4	9.47e-20	Hypospadias;
LGG	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.19	0.36	2.51e-15	Rheumatoid arthritis;
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg05169099	chr5:481640	SLC9A3	0.46	6.82	0.3	2.86e-11	Fat distribution (HIV);
LGG	cis	rs4704846	0.757	rs7725390	chr5:156503785	A/G	cg12943317	chr5:156479607	HAVCR1	0.55	7.79	0.34	4.45e-14	Blood protein levels;
LGG	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22496380	chr5:211416	CCDC127	-1.16	-11.3	-0.46	2.62e-26	Breast cancer;
LGG	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg25986240	chr4:9926439	SLC2A9	-0.35	-7.25	-0.32	1.73e-12	Bone mineral density;
LGG	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-7.44	-0.33	4.92e-13	Facial emotion recognition (sad faces);
LGG	cis	rs7119	0.717	rs62009070	chr15:77817884	G/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg26811252	chr16:29126840	RRN3P2	0.69	10.84	0.45	1.55e-24	Menopause (age at onset);
LGG	cis	rs7945718	0.935	rs11022501	chr11:12809314	T/C	cg25843174	chr11:12811716	TEAD1	0.4	8.28	0.36	1.32e-15	Educational attainment (years of education);
LGG	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg05707623	chr12:122985044	ZCCHC8	0.67	9.49	0.4	1.22e-19	Body mass index;
LGG	cis	rs6087771	0.781	rs6089067	chr20:30358894	G/C	cg13852791	chr20:30311386	BCL2L1	0.92	17.79	0.64	2.44e-54	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg23129478	chr18:44337922	ST8SIA5	-0.38	-7.32	-0.32	1.1e-12	Personality dimensions;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.24	-0.32	1.86e-12	Menopause (age at onset);
LGG	cis	rs1408224	0.608	rs9534447	chr13:47212722	G/C	cg24453118	chr13:47229927	LRCH1	-0.3	-6.92	-0.31	1.5e-11	QRS complex (12-leadsum);
LGG	cis	rs11239187	0.523	rs1962990	chr10:45074504	C/T	cg03916630	chr10:45065415	NA	0.41	7.38	0.32	7.44e-13	Body mass index;
LGG	cis	rs72781680	0.716	rs2712079	chr2:24082061	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	8.25	0.36	1.69e-15	Lymphocyte counts;
LGG	cis	rs2086824	0.702	rs3114891	chr16:89399455	A/G	cg06640241	chr16:89574553	SPG7	0.56	9.38	0.4	3.03e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.93	-0.38	1.01e-17	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.18e-31	Prudent dietary pattern;
LGG	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg13679303	chr9:96623674	NA	-0.38	-6.84	-0.3	2.46e-11	DNA methylation (variation);
LGG	cis	rs4356203	0.905	rs11024148	chr11:17096059	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.39	-0.32	7.14e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14230542	chr1:110577941	FAM40A	0.41	6.66	0.3	7.73e-11	Cognitive performance;
LGG	cis	rs61931739	0.649	rs815047	chr12:33726459	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	trans	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg16583315	chr14:65563665	MAX	-0.37	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs490234	0.719	rs13287525	chr9:128219180	T/C	cg14078157	chr9:128172775	NA	-0.47	-8.71	-0.38	5.6e-17	Mean arterial pressure;
LGG	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg26384229	chr12:38710491	ALG10B	1.06	26.15	0.77	3.03e-93	Heart rate;
LGG	cis	rs8010715	0.848	rs927494	chr14:24600390	A/T	cg06429887	chr14:24600500	FITM1	0.38	7.71	0.34	7.99e-14	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.28	-0.4	6.77e-19	Menopause (age at onset);
LGG	cis	rs7666738	0.606	rs4637413	chr4:99088151	A/G	cg05340658	chr4:99064831	C4orf37	0.43	6.95	0.31	1.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg25457927	chr22:38595422	NA	-0.42	-10.38	-0.43	8.13e-23	Breast cancer;
LGG	cis	rs7586879	0.929	rs6545808	chr2:25124388	C/A	cg04586622	chr2:25135609	ADCY3	0.39	9.92	0.42	3.81e-21	Body mass index;
LGG	cis	rs763121	0.853	rs5750659	chr22:39068789	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs40363	0.645	rs1690450	chr16:3521051	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-7.06	-0.31	6.32e-12	Tuberculosis;
LGG	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg11764359	chr7:65958608	NA	0.6	10.38	0.43	7.55e-23	Aortic root size;
LGG	cis	rs4363385	0.572	rs12041126	chr1:152938045	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-8.77	-0.38	3.52e-17	Inflammatory skin disease;
LGG	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02711726	chr17:80685570	FN3KRP	-0.55	-9.6	-0.41	5.04e-20	Glycated hemoglobin levels;
LGG	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg05625103	chr10:2543513	NA	0.42	8.1	0.35	5e-15	Age-related hearing impairment;
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.29	0.32	1.32e-12	Renal function-related traits (BUN);
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg04287289	chr16:89883240	FANCA	0.81	16.88	0.62	3.76e-50	Vitiligo;
LGG	cis	rs9649465	1.000	rs2299982	chr7:123356511	A/C	cg03229431	chr7:123269106	ASB15	-0.41	-9.04	-0.39	4.45e-18	Migraine;
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg18681998	chr4:17616180	MED28	0.84	18.67	0.66	2.16e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.91	-0.42	3.93e-21	Pancreatic cancer;
LGG	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.14e-12	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12016039	chr2:54013874	LOC100302652;ASB3;ERLEC1	0.47	7.57	0.33	2.11e-13	Cognitive performance;
LGG	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg25039879	chr17:56429692	SUPT4H1	0.63	8.77	0.38	3.48e-17	Cognitive test performance;
LGG	cis	rs4262150	0.764	rs2964230	chr5:151932606	A/T	cg12297329	chr5:152029980	NA	-0.71	-13.53	-0.53	2.23e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg02753203	chr1:228287806	NA	0.76	14.61	0.56	4.78e-40	Diastolic blood pressure;
LGG	cis	rs11683229	0.925	rs13028634	chr2:63480964	G/A	cg19915305	chr2:64069682	UGP2	-0.47	-7.12	-0.31	4.07e-12	Protein quantitative trait loci;
LGG	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg20387954	chr3:183756860	HTR3D	0.42	7.92	0.35	1.8e-14	Anterior chamber depth;
LGG	trans	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.25	0.49	4.32e-30	Corneal astigmatism;
LGG	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg19507638	chr5:93509721	C5orf36	0.42	6.9	0.31	1.68e-11	Diabetic retinopathy;
LGG	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg25319279	chr11:5960081	NA	-0.55	-8.62	-0.37	1.1e-16	DNA methylation (variation);
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14400631	chr11:14666512	PDE3B;PSMA1	0.43	6.94	0.31	1.33e-11	Cognitive performance;
LGG	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.58e-12	Iron status biomarkers;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.95	0.31	1.21e-11	Lung cancer;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.12	-0.46	1.23e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03006225	chr1:16010482	PLEKHM2	0.37	7.09	0.31	5.07e-12	Gut microbiome composition (summer);
LGG	cis	rs4804815	0.780	rs75533704	chr19:7840557	G/T	cg09310891	chr19:7854403	CLEC4GP1	0.54	8.36	0.36	7.51e-16	Neutrophil count;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg13628971	chr7:2884303	GNA12	0.5	9.84	0.42	7.23e-21	Height;
LGG	cis	rs757278	0.551	rs1468262	chr7:117372203	G/A	cg10524701	chr7:117356490	CTTNBP2	0.41	7.06	0.31	6.16e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs6032067	0.929	rs56131549	chr20:43842014	A/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	trans	rs6787172	0.622	rs2362970	chr3:158130643	G/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.44	-0.33	4.91e-13	Subjective well-being;
LGG	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.41	-0.47	9.81e-27	Oropharynx cancer;
LGG	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.09	0.42	9.1e-22	Retinal vascular caliber;
LGG	cis	rs4950322	0.570	rs1999820	chr1:146741989	C/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	trans	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg19676328	chr12:49525230	TUBA1B	-0.61	-9.9	-0.42	4.31e-21	Total cholesterol levels;
LGG	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg01528321	chr10:82214614	TSPAN14	0.76	13.88	0.54	7.44e-37	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg23815491	chr16:72088622	HP	0.51	11.6	0.47	1.7e-27	Fibrinogen levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07608032	chr19:21579862	ZNF493	0.48	7.86	0.34	2.78e-14	Cognitive performance;
LGG	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	11.94	0.49	7.62e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-8.2	-0.36	2.34e-15	Personality dimensions;
LGG	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg22875332	chr1:76189707	ACADM	0.58	10.29	0.43	1.65e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs77633900	0.772	rs157788	chr15:76806011	T/C	cg21673338	chr15:77095150	SCAPER	-0.63	-8.11	-0.35	4.62e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg22920501	chr2:26401640	FAM59B	0.38	7.69	0.34	9.14e-14	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg00405596	chr8:11794950	NA	-0.42	-6.82	-0.3	2.93e-11	Neuroticism;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14928532	chr9:133454630	LOC100272217;FUBP3	-0.47	-7.93	-0.35	1.64e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg07117364	chr1:16154769	NA	-0.48	-7.29	-0.32	1.36e-12	Dilated cardiomyopathy;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg06640241	chr16:89574553	SPG7	0.71	12.29	0.5	3.01e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg24530489	chr15:56299380	NA	-0.84	-7.8	-0.34	4.11e-14	Delta-5 desaturase activity;
LGG	cis	rs8135665	0.600	rs3026682	chr22:38452482	G/A	cg19171272	chr22:38449367	NA	-0.45	-7.87	-0.34	2.62e-14	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	trans	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg25214090	chr10:38739885	LOC399744	-0.51	-9.4	-0.4	2.58e-19	Corneal astigmatism;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.17	-0.36	2.94e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1538970	0.961	rs7543428	chr1:45839643	A/G	cg05343316	chr1:45956843	TESK2	0.69	11.73	0.48	5.26e-28	Platelet count;
LGG	trans	rs10242455	0.702	rs7794068	chr7:99146873	A/T	cg09045935	chr12:6379348	NA	0.89	7.88	0.34	2.3e-14	Blood metabolite levels;
LGG	cis	rs10231759	0.617	rs4463336	chr7:150513582	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.43	0.36	4.39e-16	Height;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26714650	chr12:56694279	CS	-1.5	-17.98	-0.64	3.33e-55	Psoriasis vulgaris;
LGG	trans	rs1032833	0.732	rs11892241	chr2:180016581	C/T	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs4666002	0.750	rs13021208	chr2:27901728	C/T	cg27432699	chr2:27873401	GPN1	0.55	7.7	0.34	8.59e-14	Phospholipid levels (plasma);
LGG	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg08999081	chr20:33150536	PIGU	-0.35	-8.94	-0.38	9.16e-18	Coronary artery disease;
LGG	cis	rs2050392	1.000	rs2183176	chr10:30698544	C/T	cg25182066	chr10:30743637	MAP3K8	0.51	10.63	0.44	8.84e-24	Inflammatory bowel disease;
LGG	cis	rs476633	0.708	rs11857484	chr15:41441734	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-11.7	-0.48	7.15e-28	Glomerular filtration rate (creatinine);
LGG	cis	rs7219021	0.705	rs999475	chr17:46988044	C/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.78	-0.3	3.69e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg05887092	chr17:76393375	PGS1	0.72	15.84	0.59	1.89e-45	HDL cholesterol levels;
LGG	cis	rs6489785	0.521	rs668622	chr12:121198299	G/A	cg02419362	chr12:121203948	SPPL3	0.5	8.53	0.37	2.06e-16	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	1.05e-35	Corneal astigmatism;
LGG	cis	rs9354308	0.809	rs9345693	chr6:66550984	T/C	cg07460842	chr6:66804631	NA	-0.45	-7.69	-0.34	8.61e-14	Metabolite levels;
LGG	cis	rs7584330	0.737	rs1497129	chr2:238369184	C/T	cg16989719	chr2:238392110	NA	-0.32	-6.85	-0.3	2.37e-11	Prostate cancer;
LGG	cis	rs2268241	0.938	rs2268242	chr21:34781104	C/T	cg14850771	chr21:34775459	IFNGR2	0.77	9.25	0.39	8.61e-19	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg11878867	chr6:150167359	LRP11	-0.38	-7.95	-0.35	1.46e-14	Testicular germ cell tumor;
LGG	cis	rs6977660	0.941	rs10273208	chr7:19816371	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.79	0.38	2.88e-17	Thyroid stimulating hormone;
LGG	cis	rs7172689	0.565	rs4344696	chr15:81543495	G/T	cg11808699	chr15:81528661	IL16	-0.32	-7.34	-0.32	9.61e-13	Inattentive symptoms;
LGG	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.85	-0.38	1.89e-17	Bipolar disorder;
LGG	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg01403660	chr11:68851641	TPCN2	0.51	7.19	0.32	2.58e-12	Blond vs. brown hair color;
LGG	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg12591125	chr7:1885375	MAD1L1	0.43	7.21	0.32	2.36e-12	Bipolar disorder;
LGG	cis	rs9644630	0.745	rs7816777	chr8:19371767	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.55	14.31	0.55	1.02e-38	Oropharynx cancer;
LGG	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.88	-0.34	2.39e-14	Mean platelet volume;
LGG	cis	rs9309473	0.607	rs7586361	chr2:73601606	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-8.66	-0.37	8.18e-17	Metabolite levels;
LGG	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10101463	chr1:202780506	NA	-0.48	-6.98	-0.31	1.01e-11	Systemic lupus erythematosus;
LGG	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	trans	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg25214090	chr10:38739885	LOC399744	0.59	10.2	0.43	3.59e-22	Corneal astigmatism;
LGG	cis	rs2486288	0.656	rs11854325	chr15:45548959	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.89	-0.42	4.69e-21	Glomerular filtration rate;
LGG	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg22120825	chr2:201024476	NA	0.51	6.76	0.3	4.17e-11	Schizophrenia;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.1	0.31	4.79e-12	Longevity;
LGG	cis	rs3820928	0.874	rs10933163	chr2:227815286	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs4148883	0.504	rs28720150	chr4:100132790	T/G	cg12011299	chr4:100065546	ADH4	-0.33	-7.01	-0.31	8.21e-12	Alcohol dependence;
LGG	cis	rs9815354	0.767	rs111708447	chr3:41809583	G/A	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03183872	chr20:3140552	FASTKD5;UBOX5	0.45	7.58	0.33	1.91e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs13031619	0.517	rs10864995	chr2:3683557	C/T	cg01268866	chr2:3683757	COLEC11	0.55	9.7	0.41	2.32e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7215564	0.730	rs4889877	chr17:78662459	A/C	cg16980736	chr17:78789706	RPTOR	-0.61	-8.04	-0.35	7.33e-15	Myopia (pathological);
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg10852096	chr15:79043040	NA	-0.29	-8.41	-0.36	5.02e-16	Coronary artery disease or large artery stroke;
LGG	trans	rs9354308	0.738	rs1938116	chr6:66593478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.84	-0.3	2.54e-11	Metabolite levels;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.75	0.34	5.81e-14	Lung cancer;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.13	0.39	2.06e-18	Lung cancer;
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.76	-0.3	4.29e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	12.07	0.49	2.32e-29	Longevity;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg05335186	chr13:53173507	NA	0.74	18.8	0.66	5.01e-59	Lewy body disease;
LGG	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg26597838	chr10:835615	NA	0.56	7.22	0.32	2.13e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs4629710	0.592	rs1885641	chr6:131553986	A/G	cg12606694	chr6:131520996	AKAP7	0.51	8.27	0.36	1.4e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg07148914	chr20:33460835	GGT7	0.57	9.44	0.4	1.87e-19	Height;
LGG	cis	rs4919694	1.000	rs12241091	chr10:104808997	G/A	cg04362960	chr10:104952993	NT5C2	1.07	15.29	0.58	5.26e-43	Arsenic metabolism;
LGG	cis	rs4700695	0.841	rs152996	chr5:65256506	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs9912468	0.676	rs10048158	chr17:64236318	T/C	cg19474267	chr17:64306194	PRKCA	-0.78	-16.87	-0.62	4.18e-50	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs6445975	0.666	rs2070662	chr3:58415590	C/A	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs10484885	0.648	rs2777848	chr6:90535993	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.92	-16.62	-0.61	5.45e-49	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.11	-0.46	1.39e-25	Resting heart rate;
LGG	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.47	-0.33	4.05e-13	Joint mobility (Beighton score);
LGG	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg24692254	chr21:30365293	RNF160	1.04	29.25	0.81	2.64e-107	Dental caries;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12977696	chr17:1303516	YWHAE	0.45	6.65	0.3	8.24e-11	Gut microbiome composition (summer);
LGG	cis	rs11874712	0.899	rs56075249	chr18:43670863	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.69	-0.48	7.49e-28	Migraine - clinic-based;
LGG	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg21545522	chr1:205238299	TMCC2	0.39	7.29	0.32	1.32e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs11758351	0.500	rs74660303	chr6:26183710	C/T	cg23601095	chr6:26197514	HIST1H3D	0.89	6.75	0.3	4.55e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2797369	0.574	rs1935822	chr6:101671472	C/T	cg27451362	chr6:101846650	GRIK2	-0.51	-7.85	-0.34	2.94e-14	Renal function-related traits (eGRFcrea);
LGG	cis	rs36051895	0.623	rs10975023	chr9:5239549	A/G	cg02405213	chr9:5042618	JAK2	0.76	13.61	0.53	1e-35	Pediatric autoimmune diseases;
LGG	cis	rs950027	0.620	rs1145076	chr15:45684508	G/T	cg26924012	chr15:45694286	SPATA5L1	0.68	12.24	0.49	5.06e-30	Response to fenofibrate (adiponectin levels);
LGG	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	trans	rs9900280	1.000	rs8081267	chr17:27763910	G/T	cg19781109	chr15:93443708	CHD2	-0.4	-6.71	-0.3	5.66e-11	Mean platelet volume;
LGG	cis	rs34467563	0.872	rs6993594	chr8:97353450	A/G	cg22138393	chr8:97340270	PTDSS1	0.3	6.67	0.3	7.54e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9397585	0.614	rs10457884	chr6:153403820	T/C	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs7267979	0.932	rs367666	chr20:25449818	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.21	0.43	3.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17830980	chr10:43048298	ZNF37B	-0.58	-13.0	-0.52	3.81e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg19168338	chr16:4465731	CORO7	-0.9	-17.04	-0.62	6.98e-51	Schizophrenia;
LGG	cis	rs9393777	0.623	rs56296968	chr6:26474571	C/T	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.689	rs1476387	chr6:109764535	G/T	cg01125227	chr6:109776195	MICAL1	0.4	6.97	0.31	1.09e-11	Height;
LGG	cis	rs3820928	0.874	rs2276593	chr2:227898434	A/G	cg11843606	chr2:227700838	RHBDD1	0.42	7.21	0.32	2.29e-12	Pulmonary function;
LGG	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg09307838	chr4:120376055	NA	0.71	11.78	0.48	3.39e-28	Corneal astigmatism;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg05091796	chr16:4465799	CORO7	0.59	9.14	0.39	1.91e-18	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26257210	chr1:6305348	HES3	0.56	7.0	0.31	9.32e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg11878867	chr6:150167359	LRP11	0.59	12.68	0.51	8.02e-32	Lung cancer;
LGG	cis	rs2708240	1.000	rs2247143	chr7:147581107	C/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.84	-0.3	2.48e-11	QT interval (drug interaction);
LGG	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.85	-0.38	1.9e-17	Bone mineral density;
LGG	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	7.05	0.31	6.49e-12	Resting heart rate;
LGG	cis	rs921968	0.643	rs1344645	chr2:219538019	A/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.32	-0.32	1.14e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs17039065	0.920	rs17039101	chr4:109434632	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.62	0.33	1.48e-13	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg19223190	chr17:80058835	NA	0.46	8.43	0.36	4.34e-16	Life satisfaction;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25072359	chr17:41440525	NA	-0.51	-10.04	-0.42	1.39e-21	Menopause (age at onset);
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg05368731	chr17:41323189	NBR1	0.9	17.85	0.64	1.28e-54	Menopause (age at onset);
LGG	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	7.66	0.34	1.1e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3008870	1.000	rs3008888	chr1:67368965	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.46	0.72	4.04e-76	Lymphocyte percentage of white cells;
LGG	cis	rs4319547	0.956	rs7397990	chr12:123119472	T/C	cg23029597	chr12:123009494	RSRC2	-0.91	-17.81	-0.64	2.07e-54	Body mass index;
LGG	trans	rs2574985	0.739	rs3011801	chr10:52324262	G/A	cg18558237	chr10:81444220	LOC650623	0.45	6.83	0.3	2.72e-11	Subjective well-being;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg05863683	chr7:1912471	MAD1L1	0.46	9.05	0.39	3.85e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.56	-0.33	2.13e-13	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	6.99e-21	Common traits (Other);
LGG	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg04490037	chr7:50633773	DDC	0.32	7.18	0.32	2.76e-12	Systemic sclerosis;
LGG	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.24	0.43	2.55e-22	Mean corpuscular hemoglobin;
LGG	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg13482628	chr17:19912719	NA	0.61	12.18	0.49	8.76e-30	Schizophrenia;
LGG	cis	rs4731207	0.596	rs10231818	chr7:124574184	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.4	0.36	5.64e-16	Tonsillectomy;
LGG	cis	rs6429082	0.871	rs9662392	chr1:235576949	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.45	-7.39	-0.32	7.11e-13	Adiposity;
LGG	trans	rs673253	0.686	rs2819333	chr1:44014573	A/T	cg03888578	chr1:93646377	CCDC18;TMED5	0.45	6.9	0.31	1.67e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28374715	0.532	rs1899	chr15:41689232	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.35	-33.7	-0.84	1.13e-126	Ulcerative colitis;
LGG	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.18	0.39	1.38e-18	Diabetic retinopathy;
LGG	cis	rs9596863	1.000	rs9316669	chr13:54401836	C/G	ch.13.53330881F	chr13:54432880	NA	0.51	6.95	0.31	1.27e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs911263	0.603	rs2145422	chr14:68797169	G/C	cg18825221	chr14:68749962	RAD51L1	0.37	8.03	0.35	8.08e-15	Primary biliary cholangitis;
LGG	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg08603382	chr10:743973	NA	0.45	8.18	0.36	2.75e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg25237894	chr2:233734115	C2orf82	-0.66	-12.43	-0.5	8.5e-31	Coronary artery disease;
LGG	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg10523679	chr1:76189770	ACADM	0.73	11.87	0.48	1.45e-28	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26110653	chr13:38924412	UFM1	0.44	7.38	0.32	7.53e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10193935	0.605	rs10169492	chr2:42401961	G/T	cg27598129	chr2:42591480	NA	-0.64	-9.4	-0.4	2.52e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62025270	0.688	rs62025272	chr15:86313622	G/A	cg25843651	chr15:86329602	KLHL25	0.64	10.68	0.44	6.18e-24	Idiopathic pulmonary fibrosis;
LGG	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg00080972	chr5:178986291	RUFY1	-0.48	-7.73	-0.34	6.93e-14	Lung cancer;
LGG	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg25817165	chr18:72167213	CNDP2	-0.66	-13.33	-0.53	1.51e-34	Refractive error;
LGG	cis	rs1109114	0.844	rs7717353	chr5:148633424	G/A	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.34	-0.47	1.82e-26	Body mass index;
LGG	cis	rs13394619	0.775	rs10165819	chr2:11722102	A/T	cg07314298	chr2:11723111	GREB1	-0.5	-10.38	-0.43	7.77e-23	Endometriosis;
LGG	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27297192	chr10:134578999	INPP5A	0.32	7.34	0.32	9.87e-13	Migraine;
LGG	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg08344181	chr3:125677491	NA	-0.9	-9.06	-0.39	3.73e-18	Depression;
LGG	trans	rs877282	1.000	rs11253361	chr10:770387	T/C	cg22713356	chr15:30763199	NA	0.55	8.26	0.36	1.57e-15	Uric acid levels;
LGG	cis	rs283228	0.583	rs546327	chr6:101744207	A/G	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg04546413	chr19:29218101	NA	-0.7	-9.94	-0.42	3.26e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg00031303	chr3:195681400	NA	-0.45	-6.99	-0.31	9.89e-12	Mean corpuscular volume;
LGG	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.46	0.63	8.12e-53	Cognitive function;
LGG	trans	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.81	-0.41	9.12e-21	Bladder cancer;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg11062466	chr8:58055876	NA	0.52	8.97	0.38	7.17e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs34978289	1	rs34978289	chr6:2504622	C/CT	cg23817096	chr6:1620687	NA	-0.34	-8.21	-0.36	2.19e-15	Immature fraction of reticulocytes;
LGG	cis	rs921968	0.678	rs500422	chr2:219432995	C/A	cg01130898	chr2:219473002	PLCD4	-0.4	-6.87	-0.3	2.11e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs112591243	0.685	rs2839323	chr21:47978421	G/A	cg10657630	chr21:48055338	PRMT2	0.87	7.5	0.33	3.23e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs11169552	0.510	rs4768907	chr12:51119307	A/G	cg12884762	chr12:50931848	DIP2B	-0.4	-7.65	-0.34	1.17e-13	Colorectal cancer;
LGG	cis	rs4684776	0.867	rs13058769	chr3:11342305	A/G	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.59	-0.33	1.73e-13	Calcium levels;
LGG	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg02002194	chr4:3960332	NA	-0.52	-9.59	-0.41	5.53e-20	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg15971980	chr6:150254442	NA	0.45	8.57	0.37	1.6e-16	Lung cancer;
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06634786	chr22:41940651	POLR3H	0.78	12.78	0.51	2.99e-32	Vitiligo;
LGG	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg17691542	chr6:26056736	HIST1H1C	0.87	13.88	0.54	7.43e-37	Iron status biomarkers;
LGG	cis	rs4664304	0.966	rs925411	chr2:160745785	G/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.4	-0.33	6.58e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-13.6	-0.53	1.11e-35	Bladder cancer;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg11878867	chr6:150167359	LRP11	-0.6	-12.8	-0.51	2.45e-32	Lung cancer;
LGG	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg27411982	chr8:10470053	RP1L1	0.48	8.18	0.36	2.77e-15	Neuroticism;
LGG	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg02002194	chr4:3960332	NA	-0.44	-8.4	-0.36	5.34e-16	Mood instability;
LGG	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	10.99	0.45	4.02e-25	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg06808227	chr14:105710500	BRF1	-0.62	-10.88	-0.45	1.02e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7949566	0.841	rs10790802	chr11:126277812	C/T	cg05055844	chr11:126275997	ST3GAL4	0.43	9.2	0.39	1.25e-18	Platelet distribution width;Mean platelet volume;
LGG	cis	rs9487094	0.922	rs10499053	chr6:109940498	A/G	cg16315928	chr6:109776240	MICAL1	0.54	9.08	0.39	3.21e-18	Height;
LGG	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg26384229	chr12:38710491	ALG10B	0.87	18.95	0.66	1.04e-59	Morning vs. evening chronotype;
LGG	cis	rs10936602	0.520	rs3732451	chr3:169558025	C/T	cg08193579	chr3:169529701	LRRC34	0.39	7.82	0.34	3.6e-14	Renal cell carcinoma;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.08	-0.31	5.4e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg13770153	chr20:60521292	NA	-0.43	-7.09	-0.31	5.04e-12	Body mass index;
LGG	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg07120314	chr15:79043507	NA	-0.37	-7.21	-0.32	2.25e-12	Sudden cardiac arrest;
LGG	trans	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.62	0.37	1.05e-16	Diabetic kidney disease;
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg15133208	chr4:90757351	SNCA	-0.34	-7.67	-0.34	1.04e-13	Dementia with Lewy bodies;
LGG	cis	rs12579753	0.667	rs10862391	chr12:82307080	A/G	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.32	-0.32	1.11e-12	Resting heart rate;
LGG	cis	rs9463078	0.683	rs227850	chr6:44699068	C/T	cg25276700	chr6:44698697	NA	0.43	8.75	0.38	4.05e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1015291	0.708	rs2638435	chr12:19999520	C/T	cg25401612	chr12:20009446	NA	-0.35	-7.36	-0.32	8.62e-13	Diastolic blood pressure;
LGG	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.91	-0.31	1.57e-11	Common traits (Other);
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.51e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-10.43	-0.44	4.9e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.72	-0.38	5e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4363385	0.571	rs387930	chr1:153050058	A/G	cg13444842	chr1:152974279	SPRR3	-0.39	-7.77	-0.34	5.03e-14	Inflammatory skin disease;
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19717773	chr7:2847554	GNA12	-0.33	-6.95	-0.31	1.24e-11	Height;
LGG	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.88	0.38	1.51e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12915845	0.603	rs11073783	chr15:89043761	C/T	cg05013243	chr15:89149849	MIR1179	0.36	7.4	0.33	6.52e-13	Menarche (age at onset);
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.19	-0.39	1.33e-18	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.11	11.91	0.48	1.01e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16000406	chr19:5866712	FUT5	0.3	6.97	0.31	1.11e-11	Menarche (age at onset);
LGG	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.46	0.63	8.05e-53	Sudden cardiac arrest;
LGG	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.87	-0.3	2.08e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00149659	chr3:10157352	C3orf10	0.83	10.84	0.45	1.54e-24	Alzheimer's disease;
LGG	cis	rs7538876	0.935	rs4920607	chr1:17760098	A/G	cg10329579	chr1:17754830	RCC2	-0.54	-10.38	-0.43	7.62e-23	Basal cell carcinoma;
LGG	cis	rs10463554	0.526	rs114525197	chr5:102443045	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.38	-0.36	6.2e-16	Parkinson's disease;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11605275	1.000	rs78249104	chr11:20027680	G/T	cg14835545	chr11:20032148	NAV2	-0.86	-8.94	-0.38	9.49e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.5	-0.33	3.21e-13	Schizophrenia;
LGG	cis	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg06521331	chr12:34319734	NA	-0.64	-12.57	-0.5	2.3e-31	Morning vs. evening chronotype;
LGG	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.88	-0.34	2.31e-14	Life satisfaction;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg13009111	chr11:71350975	NA	0.38	8.77	0.38	3.33e-17	Neuroticism;
LGG	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	7.38	0.32	7.19e-13	Total cholesterol levels;
LGG	cis	rs3806843	0.966	rs4141841	chr5:140203432	C/T	cg19875535	chr5:140030758	IK	0.49	9.98	0.42	2.33e-21	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg03806693	chr22:41940476	POLR3H	1.03	17.47	0.63	7.16e-53	Vitiligo;
LGG	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg22920501	chr2:26401640	FAM59B	0.46	9.51	0.4	1.07e-19	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg02461956	chr11:134093940	NCAPD3;VPS26B	-0.42	-6.92	-0.31	1.5e-11	Leprosy;
LGG	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	9.29	0.4	5.84e-19	Joint mobility (Beighton score);
LGG	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg15979348	chr13:112237479	NA	0.46	7.85	0.34	2.83e-14	Menarche (age at onset);
LGG	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.52e-12	Schizophrenia;
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.68e-18	Alzheimer's disease;
LGG	cis	rs963731	0.579	rs6739807	chr2:39287668	G/A	cg04010122	chr2:39346883	SOS1	-0.72	-7.83	-0.34	3.4e-14	Corticobasal degeneration;
LGG	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg20387954	chr3:183756860	HTR3D	0.42	7.98	0.35	1.18e-14	Anterior chamber depth;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04025590	chr1:26560450	CCDC21	0.41	6.66	0.3	7.74e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.83e-31	Corneal astigmatism;
LGG	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2074193	0.627	rs215366	chr12:47741051	T/C	cg02516419	chr12:47771422	NA	-0.65	-9.26	-0.4	7.93e-19	Migraine with aura;
LGG	cis	rs9733	0.744	rs12126004	chr1:150889877	T/C	cg13175981	chr1:150552382	MCL1	0.55	8.86	0.38	1.7e-17	Tonsillectomy;
LGG	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg18551225	chr6:44695536	NA	-0.71	-12.43	-0.5	7.99e-31	Total body bone mineral density;
LGG	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg08085267	chr17:45401833	C17orf57	0.59	11.69	0.48	7.82e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg02733842	chr7:1102375	C7orf50	0.42	7.4	0.33	6.56e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1318772	0.800	rs34158516	chr5:112919000	G/A	cg12552261	chr5:112820674	MCC	0.68	7.73	0.34	6.7e-14	F-cell distribution;
LGG	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.17	-0.35	2.95e-15	Mean corpuscular volume;
LGG	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Vitiligo;
LGG	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg07964753	chr8:142112622	NA	-0.5	-7.42	-0.33	5.48e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20887711	chr4:1340912	KIAA1530	0.58	11.19	0.46	7.09e-26	Obesity-related traits;
LGG	trans	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.22	-0.32	2.1e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11645453	chr3:52864694	ITIH4	0.44	7.39	0.32	6.76e-13	Bipolar disorder;
LGG	cis	rs7267979	1.000	rs2259956	chr20:25282433	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.76	-0.38	3.62e-17	Obesity-related traits;
LGG	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg26769984	chr7:1090371	C7orf50	0.42	7.51	0.33	2.98e-13	Bronchopulmonary dysplasia;
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg26138144	chr22:38071188	LGALS1	0.91	24.49	0.75	1.35e-85	Fat distribution (HIV);
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.6	-10.45	-0.44	4.37e-23	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.84	0.42	7.28e-21	Bipolar disorder;
LGG	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg01620082	chr3:125678407	NA	-0.97	-9.36	-0.4	3.6e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg20821713	chr7:1055600	C7orf50	-0.51	-7.68	-0.34	9.44e-14	Bronchopulmonary dysplasia;
LGG	cis	rs4731207	0.536	rs2127967	chr7:124605672	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs13082711	0.522	rs578501	chr3:27344963	A/G	cg02860705	chr3:27208620	NA	0.59	11.1	0.46	1.52e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.64	0.54	7.83e-36	Lung cancer;
LGG	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg22875332	chr1:76189707	ACADM	-0.6	-8.95	-0.38	8.31e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9487051	0.768	rs351752	chr6:109536034	C/A	cg21918786	chr6:109611834	NA	-0.37	-6.75	-0.3	4.33e-11	Reticulocyte fraction of red cells;
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	24.98	0.76	7.4e-88	Height;
LGG	cis	rs2073300	1.000	rs6132625	chr20:23444671	C/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.18	0.65	3.87e-56	Refractive error;
LGG	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg07549998	chr6:150325970	RAET1K	-0.38	-7.28	-0.32	1.44e-12	Alopecia areata;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13338022	chr15:43029438	CDAN1	0.5	7.76	0.34	5.67e-14	Gut microbiome composition (summer);
LGG	cis	rs17767392	0.681	rs61989208	chr14:71691037	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.97	-0.31	1.07e-11	Mitral valve prolapse;
LGG	cis	rs7586879	0.639	rs3903070	chr2:25123463	C/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	trans	rs2270927	0.790	rs6874435	chr5:75574855	A/G	cg13563193	chr19:33072644	PDCD5	0.66	9.6	0.41	5.09e-20	Mean corpuscular volume;
LGG	cis	rs17683430	0.681	rs12159823	chr22:32563229	A/G	cg02631450	chr22:32366979	NA	0.64	7.33	0.32	1.01e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg25010415	chr3:25329845	NA	-0.41	-6.75	-0.3	4.4e-11	Apolipoprotein A-IV levels;
LGG	cis	rs13108043	0.605	rs35182728	chr4:87963321	A/G	cg11209507	chr4:87813803	C4orf36	0.55	7.19	0.32	2.62e-12	Red blood cell count;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00689492	chr4:1303491	MAEA	0.47	7.99	0.35	1.06e-14	Obesity-related traits;
LGG	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg20476274	chr7:133979776	SLC35B4	0.54	9.55	0.41	7.31e-20	Mean platelet volume;
LGG	cis	rs9487094	0.614	rs11968978	chr6:110096896	A/G	cg01125227	chr6:109776195	MICAL1	0.51	8.34	0.36	8.59e-16	Height;
LGG	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg23933602	chr10:16859644	RSU1	1.01	25.19	0.76	8e-89	Platelet distribution width;
LGG	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg15268244	chr15:77196840	NA	0.47	10.12	0.43	7.15e-22	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20141549	chr3:51534298	VPRBP	0.49	7.89	0.34	2.25e-14	Cognitive performance;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs537930	0.925	rs299372	chr5:134340030	A/G	cg24576358	chr5:134350122	NA	-0.45	-9.15	-0.39	1.83e-18	Height;
LGG	trans	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.48	-0.33	3.79e-13	Testicular germ cell tumor;
LGG	cis	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.75e-15	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.47e-27	Personality dimensions;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg11235426	chr6:292522	DUSP22	-0.59	-9.84	-0.42	7.06e-21	Menopause (age at onset);
LGG	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg14835575	chr10:16859367	RSU1	0.79	14.39	0.56	4.76e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.78e-12	Aortic root size;
LGG	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg15841412	chr13:111365552	ING1	-0.45	-6.76	-0.3	4.05e-11	Coronary artery disease;
LGG	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg17127132	chr2:85788382	GGCX	0.47	8.14	0.35	3.61e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.42	-0.33	5.77e-13	Lung cancer in ever smokers;
LGG	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg18795169	chr1:18902165	NA	-1.06	-34.25	-0.85	5.38e-129	Urate levels in lean individuals;
LGG	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.73	-0.34	6.67e-14	HDL cholesterol;
LGG	trans	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg06875740	chr19:51307921	C19orf48	-0.58	-9.35	-0.4	3.76e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23633679	chr1:173793655	CENPL;DARS2	-0.4	-6.8	-0.3	3.25e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg19774624	chr17:42201019	HDAC5	0.67	11.87	0.48	1.55e-28	Total body bone mineral density;
LGG	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	13.52	0.53	2.5e-35	Menarche (age at onset);
LGG	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.68	-0.37	6.9e-17	Cognitive function;
LGG	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg07148914	chr20:33460835	GGT7	0.56	9.3	0.4	5.43e-19	Height;
LGG	cis	rs13102973	0.965	rs13142779	chr4:135872841	G/T	cg14419869	chr4:135874104	NA	0.58	11.08	0.46	1.8e-25	Subjective well-being;
LGG	cis	rs12681288	0.748	rs2701935	chr8:1028618	T/A	cg04851639	chr8:1020857	NA	-0.41	-8.03	-0.35	7.92e-15	Schizophrenia;
LGG	cis	rs3816183	0.756	rs4953667	chr2:43055805	A/G	cg14631114	chr2:43023945	NA	0.45	8.21	0.36	2.19e-15	Hypospadias;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01592526	chr17:73663357	RECQL5;SAP30BP	0.45	6.73	0.3	5.09e-11	Gut microbiome composition (summer);
LGG	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg10574377	chr1:18908098	NA	0.34	6.66	0.3	7.61e-11	Urate levels in lean individuals;
LGG	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg24232236	chr22:38142998	TRIOBP	0.37	7.25	0.32	1.72e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12956009	0.518	rs10164267	chr18:44820032	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-6.75	-0.3	4.5e-11	Educational attainment (years of education);
LGG	cis	rs72781680	0.716	rs2712068	chr2:23984000	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	8.57	0.37	1.59e-16	Lymphocyte counts;
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg02524346	chr8:600233	NA	1.14	11.39	0.47	1.12e-26	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs6860806	0.507	rs270601	chr5:131656997	T/C	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Breast cancer;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg13699009	chr12:122356056	WDR66	0.58	15.73	0.59	5.88e-45	Mean corpuscular volume;
LGG	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.36	-0.36	7.45e-16	Myopia (pathological);
LGG	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg21435375	chr2:172878103	MAP1D	-0.32	-7.26	-0.32	1.7e-12	Schizophrenia;
LGG	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg21775007	chr8:11205619	TDH	0.8	14.08	0.55	1.02e-37	Retinal vascular caliber;
LGG	cis	rs7647973	0.961	rs4955430	chr3:49378088	G/A	cg07636037	chr3:49044803	WDR6	0.77	13.53	0.53	2.27e-35	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg11952622	chr19:58962976	ZNF324B	-0.45	-6.66	-0.3	7.97e-11	Mean platelet volume;
LGG	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg00149659	chr3:10157352	C3orf10	0.55	8.12	0.35	4.29e-15	Alzheimer's disease;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.52	-8.19	-0.36	2.48e-15	Longevity;
LGG	cis	rs11901793	0.505	rs11688053	chr2:237494289	A/T	cg25295825	chr2:237489920	CXCR7	0.85	10.54	0.44	1.98e-23	Total mean fractional anisotropy measurement in first episode schizophrenia;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg13047869	chr3:10149882	C3orf24	-0.54	-9.15	-0.39	1.77e-18	Alzheimer's disease;
LGG	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.7	-0.45	5.01e-24	Vitiligo;
LGG	cis	rs2033732	0.706	rs9298418	chr8:85066831	T/C	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg17376030	chr22:41985996	PMM1	-0.43	-6.96	-0.31	1.2e-11	Vitiligo;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.68	-0.48	8.72e-28	Tonsillectomy;
LGG	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.02	-0.31	7.79e-12	HDL cholesterol;
LGG	cis	rs7226408	0.857	rs17652513	chr18:34483319	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.42	-6.9	-0.31	1.7e-11	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg07701084	chr6:150067640	NUP43	0.67	12.8	0.51	2.43e-32	Lung cancer;
LGG	trans	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg00938859	chr5:1591904	SDHAP3	0.9	11.92	0.48	8.96e-29	Breast cancer;
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg26656751	chr17:43910226	CRHR1	0.45	8.18	0.36	2.84e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.08	0.46	1.8e-25	Personality dimensions;
LGG	cis	rs2644899	0.750	rs2607424	chr19:41275147	C/T	cg24958765	chr19:41283667	RAB4B	-0.48	-7.31	-0.32	1.17e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg04492858	chr10:133558786	NA	0.43	8.92	0.38	1.07e-17	Survival in rectal cancer;
LGG	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	2.93e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9354308	0.764	rs9363472	chr6:66584142	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.770	rs2275527	chr1:11190646	A/G	cg08854313	chr1:11322531	MTOR	0.7	14.08	0.55	9.94e-38	Body mass index;
LGG	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg26818257	chr2:241905806	NA	0.51	11.56	0.47	2.58e-27	Joint mobility (Beighton score);
LGG	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg25019033	chr10:957182	NA	-0.58	-12.3	-0.5	2.67e-30	Eosinophil percentage of granulocytes;
LGG	cis	rs1372520	0.873	rs2736989	chr4:90776257	T/C	cg15133208	chr4:90757351	SNCA	-0.4	-8.16	-0.35	3.21e-15	Neuroticism;
LGG	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg20503657	chr10:835505	NA	0.95	13.01	0.52	3.47e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg18350739	chr11:68623251	NA	-0.84	-21.6	-0.71	4.23e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs870825	0.581	rs7675106	chr4:185652388	C/G	cg04058563	chr4:185651563	MLF1IP	-1.0	-22.1	-0.72	2.05e-74	Blood protein levels;
LGG	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg13010199	chr12:38710504	ALG10B	0.75	16.01	0.6	3.22e-46	Heart rate;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg18350739	chr11:68623251	NA	-0.86	-21.88	-0.71	2.07e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg25706552	chr1:244017396	NA	0.51	8.5	0.37	2.7e-16	RR interval (heart rate);
LGG	cis	rs67133203	0.904	rs12821444	chr12:51361498	A/G	cg14688905	chr12:51403056	SLC11A2	0.77	11.76	0.48	3.88e-28	Urinary tract infection frequency;
LGG	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg11584989	chr19:19387371	SF4	0.74	12.11	0.49	1.59e-29	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26756684	chr17:79213028	C17orf89;C17orf56	0.48	7.03	0.31	7.31e-12	Gut microbiome composition (summer);
LGG	cis	rs988958	0.565	rs34629045	chr2:42237224	A/G	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.35	-0.32	9.12e-13	HDL cholesterol;
LGG	cis	rs4363385	0.693	rs76987906	chr1:152964530	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.88	-0.38	1.53e-17	Inflammatory skin disease;
LGG	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.88	0.38	1.53e-17	Colorectal cancer;
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.52	-0.4	9.83e-20	Triglycerides;
LGG	cis	rs12410462	0.591	rs903695	chr1:227733069	A/G	cg04117972	chr1:227635322	NA	0.44	8.32	0.36	9.68e-16	Major depressive disorder;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13732083	chr21:47605072	C21orf56	-0.48	-8.1	-0.35	4.8e-15	Testicular germ cell tumor;
LGG	cis	rs2247341	0.893	rs743569	chr4:1719620	T/G	cg08446824	chr4:1720184	TMEM129	-0.68	-12.91	-0.51	8.69e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs11718455	0.960	rs13083325	chr3:44005333	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.63e-11	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.67	-0.63	8.63e-54	Breast cancer;
LGG	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs12711979	0.509	rs10181286	chr2:3824567	G/A	cg17052675	chr2:3827356	NA	-0.49	-9.69	-0.41	2.47e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11695601	chr2:175870435	CHN1	0.57	8.95	0.38	8.62e-18	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg10818794	chr15:86012489	AKAP13	-0.39	-8.28	-0.36	1.3e-15	Coronary artery disease;
LGG	cis	rs735539	0.521	rs2762996	chr13:21373908	A/C	cg04906043	chr13:21280425	IL17D	-0.45	-7.17	-0.32	2.97e-12	Dental caries;
LGG	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg12698349	chr2:225449008	CUL3	-0.7	-11.88	-0.48	1.38e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs17270561	0.775	rs12191655	chr6:25803095	G/T	cg16482183	chr6:26056742	HIST1H1C	0.8	10.17	0.43	4.5e-22	Iron status biomarkers;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg05313129	chr8:58192883	C8orf71	-0.47	-8.12	-0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.26e-15	Bipolar disorder;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.85	-0.34	2.99e-14	Schizophrenia;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg05941027	chr17:61774174	LIMD2	0.36	8.83	0.38	2.2e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06476805	chr3:123304425	PTPLB	0.39	6.76	0.3	4.2e-11	Bilirubin levels;
LGG	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs36051895	0.559	rs10815172	chr9:5212254	T/A	cg02405213	chr9:5042618	JAK2	-0.64	-11.55	-0.47	2.63e-27	Pediatric autoimmune diseases;
LGG	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg19338460	chr6:170058176	WDR27	-0.58	-8.08	-0.35	5.77e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.09	0.39	2.85e-18	Obesity-related traits;
LGG	cis	rs870825	0.616	rs7678949	chr4:185635018	G/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.74	0.73	2.07e-77	Blood protein levels;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg11062466	chr8:58055876	NA	0.59	9.28	0.4	6.33e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02071572	chr4:1403502	NA	0.38	7.03	0.31	7.68e-12	Longevity;
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg27587195	chr5:112824172	MCC	0.45	7.34	0.32	9.49e-13	Type 2 diabetes;
LGG	cis	rs10463316	0.855	rs13359064	chr5:150765575	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.2	-0.43	3.51e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6430585	0.591	rs12475553	chr2:136483355	G/T	cg07169764	chr2:136633963	MCM6	1.13	18.72	0.66	1.18e-58	Corneal structure;
LGG	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg24642439	chr20:33292090	TP53INP2	0.62	10.7	0.45	5.1900000000000004e-24	Coronary artery disease;
LGG	cis	rs3820068	0.705	rs4646091	chr1:15822043	T/C	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.08	0.49	2.09e-29	Hip circumference adjusted for BMI;
LGG	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11644478	chr21:40555479	PSMG1	0.93	17.68	0.63	7.8e-54	Cognitive function;
LGG	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27286337	chr10:134555280	INPP5A	-0.86	-13.32	-0.53	1.68e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17767392	0.958	rs34469007	chr14:71916923	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	3e-18	Mitral valve prolapse;
LGG	cis	rs8032158	0.855	rs9920184	chr15:56228989	T/G	cg02198044	chr15:56286336	NEDD4	-0.74	-12.82	-0.51	1.98e-32	Keloid;
LGG	cis	rs4330281	0.647	rs6772394	chr3:17488124	C/T	cg20981856	chr3:17787350	NA	0.35	6.72	0.3	5.22e-11	Schizophrenia;
LGG	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.69	-0.41	2.48e-20	Retinal vascular caliber;
LGG	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg08250081	chr4:10125330	NA	-0.44	-8.61	-0.37	1.14e-16	Bone mineral density;
LGG	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg23306229	chr2:178417860	TTC30B	0.73	8.62	0.37	1.03e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.92	0.48	9.56e-29	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-11.05	-0.46	2.35e-25	Longevity;
LGG	cis	rs2742417	1.000	rs1877933	chr3:45753487	C/T	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	11.27	0.46	3.34e-26	Bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21483475	chr3:154042025	DHX36	-0.48	-6.94	-0.31	1.31e-11	Systemic lupus erythematosus;
LGG	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg22437258	chr11:111473054	SIK2	0.55	9.53	0.4	9.06e-20	Primary sclerosing cholangitis;
LGG	trans	rs17685	0.884	rs8565	chr7:75630274	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.95	-19.84	-0.68	7.39e-64	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.7	-0.34	8.55e-14	Heart rate;
LGG	cis	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg21775007	chr8:11205619	TDH	0.82	14.6	0.56	5.49e-40	Retinal vascular caliber;
LGG	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg17215666	chr7:56131930	SUMF2	0.45	7.47	0.33	4.06e-13	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs3126085	0.935	rs11204943	chr1:152203906	A/C	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-6.73	-0.3	5.04e-11	Height;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.4	0.58	1.65e-43	Lung cancer;
LGG	trans	rs9354308	0.738	rs1499704	chr6:66593133	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	7.38	0.32	7.28e-13	Systemic lupus erythematosus;
LGG	cis	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg04990556	chr1:26633338	UBXN11	0.62	8.37	0.36	6.9e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7737355	1.000	rs6596010	chr5:130625411	G/A	cg06307176	chr5:131281290	NA	0.51	8.54	0.37	1.89e-16	Life satisfaction;
LGG	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.88	0.42	4.97e-21	Cannabis dependence symptom count;
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.99	-12.95	-0.52	6e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-14.93	-0.57	1.96e-41	Headache;
LGG	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg12046867	chr14:103022105	NA	-0.74	-12.34	-0.5	1.92e-30	Platelet count;
LGG	cis	rs8016982	0.963	rs7149672	chr14:81657336	A/G	cg01989461	chr14:81687754	GTF2A1	0.64	12.64	0.51	1.12e-31	Schizophrenia;
LGG	cis	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg24110177	chr3:50126178	RBM5	0.41	7.0	0.31	9.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7928758	0.887	rs11825120	chr11:134271805	A/G	cg15243474	chr11:134282918	B3GAT1	1.16	15.72	0.59	5.95e-45	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg02269571	chr22:50332266	NA	-0.67	-9.93	-0.42	3.38e-21	Schizophrenia;
LGG	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg13009111	chr11:71350975	NA	-0.33	-7.13	-0.31	3.95e-12	Monocyte count;
LGG	cis	rs2718058	0.517	rs11972986	chr7:37799809	A/G	cg24998770	chr7:37888106	TXNDC3	-0.42	-6.91	-0.31	1.6e-11	Alzheimer's disease (late onset);
LGG	cis	rs9811920	0.660	rs11719468	chr3:99671848	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-7.51	-0.33	3.03e-13	Axial length;
LGG	cis	rs12545109	0.800	rs1467124	chr8:57418862	T/G	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs889122	0.513	rs10403584	chr19:10013440	G/A	cg00846166	chr19:10022875	OLFM2	0.33	7.27	0.32	1.53e-12	Menarche (age at onset);
LGG	cis	rs10463316	0.894	rs7729216	chr5:150762277	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.73	-0.41	1.71e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10743315	0.643	rs75189071	chr12:19329505	C/T	cg02471346	chr12:19282374	PLEKHA5	0.85	7.86	0.34	2.69e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6450176	1.000	rs7735253	chr5:53297611	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.56	-0.47	2.56e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs67133203	0.659	rs7488909	chr12:51425837	G/A	cg14688905	chr12:51403056	SLC11A2	-0.6	-10.24	-0.43	2.55e-22	Urinary tract infection frequency;
LGG	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	trans	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg13565492	chr6:43139072	SRF	-0.75	-9.12	-0.39	2.37e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.43	0.56	2.94e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg15268244	chr15:77196840	NA	0.49	10.46	0.44	3.94e-23	Blood metabolite levels;
LGG	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg06951627	chr6:26196580	NA	0.45	6.75	0.3	4.51e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9381107	0.932	rs116221613	chr6:9445051	G/A	cg14735645	chr6:9486422	NA	-0.42	-7.22	-0.32	2.2e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.63	-15.66	-0.59	1.17e-44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg07661805	chr8:143867942	LY6D	-0.3	-8.16	-0.35	3.22e-15	Urinary tract infection frequency;
LGG	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	cg15522984	chr1:182991683	LAMC1	0.43	8.3	0.36	1.12e-15	Fuchs's corneal dystrophy;
LGG	cis	rs1670533	1.000	rs11731320	chr4:1057916	T/A	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs13191362	0.507	rs2846566	chr6:163059714	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.58	-8.01	-0.35	9.6e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4789693	0.873	rs8069111	chr17:80395457	G/A	cg04308225	chr17:80449738	NA	0.57	8.21	0.36	2.23e-15	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg03806693	chr22:41940476	POLR3H	0.97	15.85	0.59	1.64e-45	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.15e-12	HDL cholesterol;
LGG	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg02466173	chr16:30829666	NA	-0.55	-9.91	-0.42	3.91e-21	Multiple myeloma;
LGG	cis	rs1899546	0.624	rs12363019	chr11:24374545	T/A	ch.11.24196551F	chr11:24239977	NA	-0.42	-7.12	-0.31	4.23e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6546537	0.550	rs4241252	chr2:69777065	C/A	cg10773587	chr2:69614142	GFPT1	-0.45	-7.85	-0.34	2.88e-14	Serum thyroid-stimulating hormone levels;
LGG	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg23625390	chr15:77176239	SCAPER	-0.69	-12.33	-0.5	2.02e-30	Blood metabolite levels;
LGG	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.58	-0.33	1.85e-13	Schizophrenia;
LGG	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04139300	chr20:40247070	CHD6	0.4	7.04	0.31	7.02e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9815354	0.767	rs75651509	chr3:41953564	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.9	0.48	1.17e-28	Hip circumference adjusted for BMI;
LGG	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg02574844	chr11:5959923	NA	-0.62	-9.62	-0.41	4.15e-20	DNA methylation (variation);
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg17202724	chr17:61916730	SMARCD2	-0.61	-15.0	-0.57	9.64e-42	Prudent dietary pattern;
LGG	cis	rs367615	0.918	rs4576198	chr5:108867350	T/G	cg17395555	chr5:108820864	NA	0.66	9.28	0.4	6.71e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-10.58	-0.44	1.37e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg25358565	chr5:93447407	FAM172A	1.32	16.4	0.61	5.75e-48	Diabetic retinopathy;
LGG	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg16850897	chr7:100343110	ZAN	-0.64	-9.4	-0.4	2.59e-19	Other erythrocyte phenotypes;
LGG	trans	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg05059571	chr16:84539110	KIAA1609	0.58	11.03	0.46	2.83e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg02187348	chr16:89574699	SPG7	0.46	7.41	0.33	5.85e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21584983	chr19:11640070	ECSIT	0.51	8.02	0.35	8.75e-15	Gut microbiome composition (summer);
LGG	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.57	-8.59	-0.37	1.3e-16	Yeast infection;
LGG	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg22044901	chr15:68126292	NA	-0.4	-6.78	-0.3	3.71e-11	Restless legs syndrome;
LGG	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg08997352	chr12:9597637	DDX12	-0.77	-15.07	-0.57	5.05e-42	Breast size;
LGG	cis	rs12738007	0.840	rs2819602	chr1:29573723	C/T	cg11747820	chr1:29584023	PTPRU	-0.3	-6.8	-0.3	3.27e-11	Schizophrenia;
LGG	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.19	-0.36	2.59e-15	Morning vs. evening chronotype;
LGG	cis	rs4330281	0.626	rs9861749	chr3:17409919	G/A	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	7.02e-11	Schizophrenia;
LGG	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg16434002	chr17:42200994	HDAC5	0.44	7.86	0.34	2.72e-14	Total body bone mineral density;
LGG	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs2227564	0.700	rs12413039	chr10:75524759	C/G	cg00564723	chr10:75632066	CAMK2G	0.42	8.46	0.37	3.66e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11748327	0.580	rs11738089	chr5:4020601	G/A	cg01025095	chr5:4101132	NA	-0.44	-7.18	-0.32	2.81e-12	Myocardial infarction;
LGG	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg25208724	chr1:156163844	SLC25A44	1.12	25.35	0.76	1.42e-89	Testicular germ cell tumor;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg08035479	chr8:58172643	NA	-0.53	-8.11	-0.35	4.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg02503808	chr4:7069936	GRPEL1	1.03	15.75	0.59	4.54e-45	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.66	0.37	7.8e-17	Bipolar disorder;
LGG	cis	rs887829	0.570	rs6753320	chr2:234595615	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.51	8.51	0.37	2.49e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg27535305	chr1:53392650	SCP2	0.35	7.84	0.34	3.1e-14	Monocyte count;
LGG	cis	rs9783347	0.714	rs4150606	chr11:18363569	C/A	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.25	-0.49	4.26e-30	Pancreatic cancer;
LGG	cis	rs2640806	0.525	rs11777772	chr8:97341406	G/A	cg22138393	chr8:97340270	PTDSS1	-0.26	-6.77	-0.3	3.98e-11	Obesity-related traits;
LGG	trans	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs55871839	0.533	rs7813733	chr8:59852429	C/T	cg07426533	chr8:59803705	TOX	0.62	13.09	0.52	1.57e-33	Pneumonia;
LGG	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg15212455	chr7:39170539	POU6F2	0.47	10.89	0.45	9.91e-25	IgG glycosylation;
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg21775007	chr8:11205619	TDH	0.51	7.8	0.34	4.11e-14	Neuroticism;
LGG	cis	rs10267417	0.603	rs6948539	chr7:19879812	C/T	cg05791153	chr7:19748676	TWISTNB	0.66	8.4	0.36	5.44e-16	Night sleep phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09370442	chr15:41523368	CHP;EXD1	0.46	7.0	0.31	9.08e-12	Gut microbiome composition (summer);
LGG	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.07	-0.49	2.45e-29	Corneal structure;
LGG	cis	rs7010267	0.773	rs72680380	chr8:119932741	T/A	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.82	-0.42	8.27e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg04287289	chr16:89883240	FANCA	0.43	7.55	0.33	2.38e-13	Vitiligo;
LGG	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg12165864	chr7:66369176	NA	-0.55	-8.67	-0.37	7.33e-17	Corneal structure;
LGG	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg19507638	chr5:93509721	C5orf36	0.37	6.66	0.3	7.69e-11	Diabetic retinopathy;
LGG	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.6	0.37	1.29e-16	Aortic root size;
LGG	cis	rs17286411	0.777	rs4788569	chr16:71914785	A/G	cg03805757	chr16:71968109	PKD1L3	0.34	7.08	0.31	5.46e-12	Blood protein levels;
LGG	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	8.59	0.37	1.29e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.43e-15	Bipolar disorder;
LGG	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg25008857	chr14:105974488	NA	0.57	10.2	0.43	3.67e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs12210905	1.000	rs12189835	chr6:27198271	T/C	cg15325629	chr6:28072465	NA	0.77	6.67	0.3	7.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg08250081	chr4:10125330	NA	0.36	6.82	0.3	2.77e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6138458	1.000	rs4273288	chr20:24900873	G/A	cg26195577	chr20:24973756	C20orf3	-1.22	-25.7	-0.77	3.48e-91	Blood protein levels;
LGG	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg18446336	chr7:2847575	GNA12	-0.32	-8.31	-0.36	1.04e-15	Height;
LGG	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg15997130	chr1:24165203	NA	-0.47	-12.84	-0.51	1.77e-32	Immature fraction of reticulocytes;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.38e-45	Morning vs. evening chronotype;
LGG	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.61	-0.37	1.12e-16	Platelet distribution width;
LGG	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg13736514	chr6:26305472	NA	-0.48	-8.87	-0.38	1.65e-17	Educational attainment;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg04490037	chr7:50633773	DDC	0.34	7.27	0.32	1.59e-12	Systemic sclerosis;
LGG	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.31	-0.53	1.95e-34	Personality dimensions;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg19635926	chr16:89946313	TCF25	0.69	7.85	0.34	2.9e-14	Skin colour saturation;
LGG	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.34e-31	Motion sickness;
LGG	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.16	0.43	4.89e-22	Parkinson's disease;
LGG	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg21479132	chr6:26055353	NA	0.82	7.98	0.35	1.17e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9296092	0.538	rs62407564	chr6:33534010	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.43	-0.71	2.78e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg10587741	chr22:38071170	LGALS1	0.83	22.14	0.72	1.32e-74	Fat distribution (HIV);
LGG	trans	rs6787172	0.629	rs1526194	chr3:158017859	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg23978390	chr7:1156363	C7orf50	0.42	6.95	0.31	1.25e-11	Longevity;Endometriosis;
LGG	cis	rs10504130	0.569	rs13275967	chr8:52673876	C/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.76	-0.3	4.23e-11	Migraine;Coronary artery disease;
LGG	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03576123	chr11:487126	PTDSS2	-1.21	-15.45	-0.58	1e-43	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06364629	chr2:27592939	EIF2B4;SNX17	-0.46	-6.66	-0.3	7.66e-11	Systemic lupus erythematosus;
LGG	cis	rs727505	0.954	rs59670428	chr7:124520966	C/A	cg23710748	chr7:124431027	NA	-0.47	-8.94	-0.38	9.36e-18	Lewy body disease;
LGG	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	7.66	0.34	1.1e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06850241	chr22:41845214	NA	0.4	6.65	0.3	8.26e-11	Vitiligo;
LGG	cis	rs67460515	0.506	rs935497	chr3:160600563	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-10.88	-0.45	1.04e-24	Parkinson's disease;
LGG	cis	rs9815354	0.597	rs73075211	chr3:42033424	G/T	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.43e-20	Heart rate;
LGG	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs638893	0.636	rs61901411	chr11:118665324	C/T	cg13782932	chr11:118662891	DDX6	-0.4	-7.03	-0.31	7.56e-12	Vitiligo;
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg11584989	chr19:19387371	SF4	0.44	7.94	0.35	1.51e-14	Tonsillectomy;
LGG	cis	rs472402	0.580	rs10076470	chr5:6632875	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.06	-0.31	6.21e-12	Response to amphetamines;
LGG	cis	rs1568889	0.774	rs11030235	chr11:28212375	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.41e-61	Bipolar disorder;
LGG	cis	rs439731	0.518	rs2260241	chr16:1075147	G/A	cg15246706	chr16:1060558	NA	-0.54	-6.83	-0.3	2.71e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.85	-0.66	3.05e-59	Monocyte count;
LGG	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg01831904	chr17:28903510	LRRC37B2	0.91	11.16	0.46	8.64e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg17201900	chr20:34330562	RBM39	0.51	6.9	0.31	1.7e-11	Total cholesterol levels;
LGG	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg09873164	chr1:152488093	CRCT1	0.63	15.68	0.59	9.85e-45	Hair morphology;
LGG	cis	rs7928758	0.767	rs1866768	chr11:134274710	A/G	cg15243474	chr11:134282918	B3GAT1	0.78	12.2	0.49	7.29e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12042938	0.935	rs1094653	chr1:231794794	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	10.19	0.43	3.89e-22	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg08085267	chr17:45401833	C17orf57	0.68	13.04	0.52	2.55e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.82	0.42	8.5e-21	Hypertriglyceridemia;
LGG	cis	rs9467160	0.581	rs2817246	chr6:24472336	C/T	cg20631270	chr6:24437470	GPLD1	0.44	6.95	0.31	1.28e-11	Liver enzyme levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09883264	chr5:141489170	NDFIP1	0.4	7.12	0.31	4.15e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg08621203	chr6:150244597	RAET1G	-0.47	-8.0	-0.35	9.76e-15	Lung cancer;
LGG	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-13.74	-0.54	2.74e-36	Body mass index;
LGG	cis	rs11096990	0.892	rs11730558	chr4:39229771	A/G	cg24403649	chr4:39172243	NA	0.48	7.79	0.34	4.39e-14	Cognitive function;
LGG	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12893428	chr3:195717962	SDHAP1	0.51	10.64	0.44	8.64e-24	Pancreatic cancer;
LGG	cis	rs2274273	0.661	rs8019978	chr14:55557284	A/G	cg04306507	chr14:55594613	LGALS3	-0.5	-12.63	-0.51	1.29e-31	Protein biomarker;
LGG	cis	rs6141769	0.518	rs28510728	chr20:31287891	G/A	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.81	-0.3	3.12e-11	Subjective well-being;
LGG	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg22044901	chr15:68126292	NA	-0.4	-6.76	-0.3	4.12e-11	Restless legs syndrome;
LGG	cis	rs11064837	0.523	rs7979627	chr12:120100204	A/G	cg25937854	chr12:120150414	CIT	-0.68	-11.45	-0.47	6.56e-27	Schizophrenia;
LGG	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.81e-52	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg11952622	chr19:58962976	ZNF324B	-0.37	-7.09	-0.31	4.93e-12	Uric acid clearance;
LGG	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Vitiligo;
LGG	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg16473166	chr22:50639996	SELO	-0.59	-9.98	-0.42	2.27e-21	Obesity-related traits;
LGG	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg15309053	chr8:964076	NA	0.38	7.53	0.33	2.62e-13	Schizophrenia;
LGG	cis	rs7765175	0.698	rs6904981	chr6:113668106	G/A	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.41e-13	Coronary artery calcification;
LGG	cis	rs7166081	1.000	rs2289789	chr15:67532383	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.98	-0.31	1.04e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg11518657	chr1:67396239	MIER1	-0.49	-7.42	-0.33	5.51e-13	Lymphocyte percentage of white cells;
LGG	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04004882	chr2:215674386	BARD1	-0.55	-8.63	-0.37	9.66e-17	Neuroblastoma;
LGG	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg09324608	chr17:30823087	MYO1D	0.31	7.52	0.33	2.79e-13	Schizophrenia;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg13736514	chr6:26305472	NA	-0.46	-9.87	-0.42	5.67e-21	Educational attainment;
LGG	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg11161011	chr14:65562177	MAX	-0.76	-14.48	-0.56	1.83e-39	Obesity-related traits;
LGG	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg14993813	chr1:46806288	NSUN4	-0.55	-9.05	-0.39	4.02e-18	Menopause (age at onset);
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.75	0.34	6.02e-14	Neuroticism;
LGG	cis	rs2470578	0.792	rs1375818	chr3:17270900	T/C	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.75e-11	Schizophrenia;
LGG	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-18.21	-0.65	2.83e-56	Brugada syndrome;
LGG	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg00666640	chr1:248458726	OR2T12	0.59	9.4	0.4	2.59e-19	Common traits (Other);
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs11203032	0.831	rs10887920	chr10:90924415	C/T	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.32	0.6	1.32e-47	Obesity-related traits;
LGG	trans	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.71	-0.64	5.47e-54	Exhaled nitric oxide output;
LGG	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6430585	0.528	rs78274583	chr2:136734569	C/T	cg07169764	chr2:136633963	MCM6	1.23	22.6	0.72	9.25e-77	Corneal structure;
LGG	cis	rs7660883	1.000	rs3736669	chr4:87992753	G/A	cg21988461	chr4:88008667	AFF1	-0.32	-8.68	-0.37	6.54e-17	HDL cholesterol levels;
LGG	cis	rs7071206	0.947	rs1877998	chr10:79411740	C/T	cg07817648	chr10:79422355	NA	-0.73	-13.44	-0.53	5.15e-35	Bone mineral density;
LGG	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg27121462	chr16:89883253	FANCA	0.62	11.48	0.47	5.01e-27	Vitiligo;
LGG	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.79	-0.45	2.24e-24	Migraine;Coronary artery disease;
LGG	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg25566285	chr7:158114605	PTPRN2	0.7	11.69	0.48	7.9e-28	Response to amphetamines;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg11062466	chr8:58055876	NA	0.61	9.73	0.41	1.72e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg09873164	chr1:152488093	CRCT1	-0.61	-14.96	-0.57	1.48e-41	Hair morphology;
LGG	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg11871910	chr12:69753446	YEATS4	0.92	21.33	0.7	7.91e-71	Blood protein levels;
LGG	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.4	0.36	5.43e-16	Educational attainment;
LGG	cis	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg09307838	chr4:120376055	NA	0.5	8.2	0.36	2.37e-15	Diastolic blood pressure;
LGG	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg17201900	chr20:34330562	RBM39	0.52	7.07	0.31	5.59e-12	Total cholesterol levels;
LGG	cis	rs7928758	0.887	rs78642342	chr11:134269120	G/A	cg22777979	chr11:134283252	B3GAT1	1.02	12.88	0.51	1.21e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg15704280	chr7:45808275	SEPT13	0.89	18.34	0.65	6.83e-57	Coronary artery disease;
LGG	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg12800244	chr3:153838788	SGEF	-0.78	-8.19	-0.36	2.49e-15	Coronary artery disease;
LGG	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.24	-0.6	2.99e-47	Headache;
LGG	cis	rs9457247	0.967	rs433191	chr6:167409662	T/A	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.0	-0.35	9.84e-15	HDL cholesterol;
LGG	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.23	-0.43	2.75e-22	Neuroticism;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg14926445	chr8:58193284	C8orf71	-0.79	-9.65	-0.41	3.4e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1784581	0.588	rs6455789	chr6:162417948	C/T	cg17173639	chr6:162384350	PARK2	0.64	13.4	0.53	8.06e-35	Itch intensity from mosquito bite;
LGG	cis	rs4604732	0.678	rs74154674	chr1:247625685	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg03433033	chr1:76189801	ACADM	0.8	16.35	0.61	8.99e-48	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs7937612	1.000	rs7101415	chr11:120239088	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.3	-0.5	2.67e-30	Intraocular pressure;
LGG	cis	rs11209002	0.614	rs4655673	chr1:67555018	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	7.42	0.33	5.54e-13	Crohn's disease;
LGG	cis	rs4631830	0.683	rs10763193	chr10:51504938	G/A	cg16070123	chr10:51489643	NA	0.41	7.53	0.33	2.63e-13	Prostate-specific antigen levels;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg05793240	chr7:2802953	GNA12	0.33	8.01	0.35	9.55e-15	Height;
LGG	cis	rs10463316	0.817	rs7701271	chr5:150776708	A/G	cg03212797	chr5:150827313	SLC36A1	0.56	9.6	0.41	4.97e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg24130564	chr14:104152367	KLC1	-0.43	-8.18	-0.36	2.79e-15	Body mass index;
LGG	cis	rs7582720	1.000	rs72934765	chr2:203758551	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.72	0.41	1.83e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg13736514	chr6:26305472	NA	-0.48	-9.13	-0.39	2.17e-18	Educational attainment;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg12708336	chr17:41446283	NA	-0.33	-7.79	-0.34	4.4e-14	Menopause (age at onset);
LGG	cis	rs9513627	0.915	rs4324006	chr13:100122545	A/G	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg00376283	chr12:123451042	ABCB9	0.61	9.29	0.4	6.01e-19	Neutrophil percentage of white cells;
LGG	cis	rs72960926	1.000	rs2171709	chr6:75100810	A/T	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs2479724	0.846	rs2254474	chr6:41843044	T/G	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	cis	rs10779751	0.887	rs6686835	chr1:11305316	G/A	cg08854313	chr1:11322531	MTOR	0.74	16.64	0.61	4.65e-49	Body mass index;
LGG	trans	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg16141378	chr3:129829833	LOC729375	0.43	10.03	0.42	1.5e-21	Mood instability;
LGG	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	trans	rs2562456	0.876	rs4638726	chr19:21592512	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.36	-0.32	8.33e-13	Pain;
LGG	trans	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-10.54	-0.44	1.92e-23	Ulcerative colitis;
LGG	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg25427524	chr10:38739819	LOC399744	-0.58	-11.23	-0.46	4.8e-26	Extrinsic epigenetic age acceleration;
LGG	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg26039829	chr8:22132926	PIWIL2	0.53	12.33	0.5	2.01e-30	Hypertriglyceridemia;
LGG	cis	rs4478037	0.822	rs3924696	chr3:33122013	T/C	cg19404215	chr3:33155277	CRTAP	0.72	9.06	0.39	3.54e-18	Major depressive disorder;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18180673	chr5:137827632	NA	0.44	7.23	0.32	2.07e-12	Cognitive performance;
LGG	cis	rs9393777	0.588	rs6456728	chr6:26477779	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	12.1	0.49	1.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2668423	0.922	rs2668417	chr19:1365827	C/G	cg02639931	chr19:1387894	NDUFS7	-0.83	-14.04	-0.55	1.49e-37	Nonalcoholic fatty liver disease;
LGG	cis	rs6723226	0.766	rs398290	chr2:32503526	T/C	cg02381751	chr2:32503542	YIPF4	0.77	13.06	0.52	2.18e-33	Intelligence (multi-trait analysis);
LGG	cis	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg00262122	chr8:11665843	FDFT1	0.46	7.56	0.33	2.26e-13	Myopia (pathological);
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.59e-18	Life satisfaction;
LGG	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.03	-0.52	2.71e-33	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.68	0.34	9.63e-14	Lung cancer;
LGG	cis	rs1577917	0.545	rs9450325	chr6:86475814	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	8.17	0.36	2.9e-15	Response to antipsychotic treatment;
LGG	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg24375607	chr4:120327624	NA	0.66	10.66	0.44	7.37e-24	Corneal astigmatism;
LGG	cis	rs4760636	0.512	rs11168177	chr12:48014529	T/C	cg12761788	chr12:48120090	P11	0.48	7.69	0.34	9.2e-14	Urate levels;
LGG	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18876405	chr7:65276391	NA	0.48	8.67	0.37	7.35e-17	Aortic root size;
LGG	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg26384229	chr12:38710491	ALG10B	0.76	15.58	0.59	2.69e-44	Morning vs. evening chronotype;
LGG	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg09855544	chr8:135498122	ZFAT	0.46	7.85	0.34	3.01e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05165339	chr4:1420672	NA	-0.35	-8.71	-0.38	5.44e-17	Longevity;
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.75	0.34	6e-14	Neuroticism;
LGG	cis	rs2013441	1.000	rs34089239	chr17:20057959	G/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.92	-0.31	1.55e-11	Lung cancer;
LGG	cis	rs9733	0.536	rs10888385	chr1:150574302	T/C	cg13175981	chr1:150552382	MCL1	0.58	9.97	0.42	2.47e-21	Tonsillectomy;
LGG	cis	rs4704187	0.640	rs1600075	chr5:74418304	G/A	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs763121	0.925	rs4821815	chr22:39105707	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	18.07	0.64	1.23e-55	Menopause (age at onset);
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.89	0.34	2.22e-14	Bipolar disorder;
LGG	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.44	-0.37	4.22e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04575467	chr8:41997444	NA	0.37	6.78	0.3	3.75e-11	Bilirubin levels;
LGG	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg20848291	chr7:100343083	ZAN	-0.67	-9.92	-0.42	3.64e-21	Other erythrocyte phenotypes;
LGG	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg26655873	chr3:72818019	SHQ1	0.36	7.03	0.31	7.5e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg23484912	chr5:273055	PDCD6	0.43	8.78	0.38	3.18e-17	Pancreatic cancer;
LGG	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg25922239	chr6:33757077	LEMD2	0.42	7.26	0.32	1.61e-12	Crohn's disease;
LGG	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg05527609	chr1:210001259	C1orf107	-0.56	-6.93	-0.31	1.42e-11	Red blood cell count;
LGG	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.68	-8.57	-0.37	1.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1555322	1.000	rs2425034	chr20:33855814	G/C	cg17927777	chr20:33865990	NA	0.68	7.65	0.33	1.21e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.3	-0.32	1.28e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.49e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9287719	0.967	rs10167129	chr2:10758575	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg04111992	chr7:158790115	NA	-0.36	-7.39	-0.32	6.93e-13	Facial morphology (factor 20);
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs921968	0.678	rs689116	chr2:219433888	C/A	cg01130898	chr2:219473002	PLCD4	-0.4	-6.93	-0.31	1.44e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg14092988	chr3:52407081	DNAH1	-0.35	-9.24	-0.39	8.98e-19	Bipolar disorder;
LGG	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-6.92	-0.31	1.52e-11	Migraine - clinic-based;
LGG	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg02073558	chr3:44770973	ZNF501	0.7	13.43	0.53	5.7e-35	Depressive symptoms;
LGG	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06481639	chr22:41940642	POLR3H	0.52	7.77	0.34	5.05e-14	Vitiligo;
LGG	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg02002194	chr4:3960332	NA	-0.43	-8.13	-0.35	4.07e-15	Mood instability;
LGG	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg03517284	chr6:25882590	NA	-0.43	-6.88	-0.3	1.97e-11	Iron status biomarkers;
LGG	trans	rs9929218	0.953	rs16260	chr16:68771034	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.77	-0.57	1.04e-40	Colorectal cancer;
LGG	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg06640241	chr16:89574553	SPG7	0.93	17.9	0.64	7.96e-55	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.29	-0.32	1.36e-12	Lung cancer;
LGG	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg13385521	chr17:29058706	SUZ12P	-0.91	-10.82	-0.45	1.75e-24	Body mass index;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg16141378	chr3:129829833	LOC729375	0.36	8.2	0.36	2.42e-15	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.44	-0.33	4.83e-13	Triglycerides;
LGG	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-7.0	-0.31	8.75e-12	Blood metabolite levels;
LGG	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg16950941	chr11:66035639	RAB1B	0.54	9.87	0.42	5.42e-21	Gout;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs2708977	0.637	rs675239	chr2:97076556	A/G	cg01950434	chr2:97203154	ARID5A	-0.47	-7.26	-0.32	1.64e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg04398451	chr17:18023971	MYO15A	-0.86	-19.68	-0.67	4.11e-63	Total body bone mineral density;
LGG	cis	rs267939	0.501	rs267958	chr5:10737997	A/G	cg14521931	chr5:10832172	NA	-0.38	-6.88	-0.3	1.98e-11	Gut microbiota (functional units);Ulcerative colitis;
LGG	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg14675211	chr2:100938903	LONRF2	0.68	12.31	0.5	2.61e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.95	0.54	3.75e-37	Lung cancer in ever smokers;
LGG	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.97	-0.42	2.36e-21	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.18	-0.43	4.14e-22	Height;
LGG	cis	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12765878	1.000	rs11191848	chr10:105650837	T/C	cg11005552	chr10:105648138	OBFC1	1.03	27.18	0.78	5.76e-98	Coronary artery disease;
LGG	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	10.17	0.43	4.45e-22	Eye color traits;
LGG	cis	rs6840360	0.593	rs1429558	chr4:152685406	A/T	cg22705602	chr4:152727874	NA	-0.4	-10.26	-0.43	2.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2404618	0.624	rs4338133	chr8:1477507	T/C	cg13402656	chr8:1511478	DLGAP2	-0.74	-13.72	-0.54	3.29e-36	Lung cancer;
LGG	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg11279151	chr3:101281821	RG9MTD1	0.44	7.87	0.34	2.58e-14	Colorectal cancer;
LGG	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg00579200	chr11:133705235	NA	-0.58	-11.08	-0.46	1.83e-25	Childhood ear infection;
LGG	cis	rs7553864	0.667	rs1886633	chr1:87610356	G/A	cg17420885	chr1:87600446	LOC339524	-0.36	-6.96	-0.31	1.17e-11	Smoking behavior;
LGG	cis	rs76935404	0.811	rs12151139	chr19:41433543	A/G	cg04176888	chr19:41596066	CYP2A13	-0.4	-6.79	-0.3	3.39e-11	nicotine metabolite ratio in current smokers;
LGG	cis	rs74781061	0.929	rs8037436	chr15:74798508	T/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.15	-0.32	3.31e-12	Endometriosis;
LGG	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	13.56	0.53	1.59e-35	Calcium levels;
LGG	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg08847533	chr14:75593920	NEK9	-0.53	-10.08	-0.42	9.87e-22	Height;
LGG	trans	rs6787172	0.702	rs9857883	chr3:157887272	A/C	cg23275840	chr4:47708675	CORIN	0.41	8.8	0.38	2.81e-17	Subjective well-being;
LGG	cis	rs7226408	0.857	rs11081989	chr18:34713367	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs77741769	0.534	rs58918988	chr12:121332953	G/A	cg02419362	chr12:121203948	SPPL3	0.54	9.41	0.4	2.34e-19	Mean corpuscular volume;
LGG	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.77	-0.68	1.57e-63	Blood trace element (Zn levels);
LGG	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg05753993	chr18:77199432	NFATC1	0.36	6.65	0.3	8.33e-11	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg02002194	chr4:3960332	NA	-0.42	-7.6	-0.33	1.64e-13	Retinal vascular caliber;
LGG	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg01244601	chr4:120671846	NA	-0.38	-7.26	-0.32	1.69e-12	Corneal astigmatism;
LGG	cis	rs2117029	0.553	rs2162644	chr12:49548190	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.86	0.51	1.37e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.51	0.56	1.42e-39	Cognitive test performance;
LGG	cis	rs1408799	0.598	rs13283345	chr9:12650198	A/C	cg05274944	chr9:12693694	TYRP1	-0.34	-7.56	-0.33	2.15e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs6708331	0.540	rs11890701	chr2:70360457	T/A	cg01613454	chr2:70366299	NA	0.56	11.31	0.47	2.27e-26	Obesity-related traits;
LGG	cis	rs4671458	0.625	rs4671522	chr2:63844917	G/T	cg17519650	chr2:63277830	OTX1	0.52	7.18	0.32	2.72e-12	Subjective well-being;
LGG	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg17971929	chr21:40555470	PSMG1	-0.48	-7.96	-0.35	1.35e-14	Menarche (age at onset);
LGG	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.97e-13	Refractive error;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12016809	chr21:47604291	C21orf56	0.6	9.68	0.41	2.67e-20	Testicular germ cell tumor;
LGG	cis	rs9814567	0.752	rs9836401	chr3:134336897	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.98	-0.45	4.27e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1873147	0.569	rs8034365	chr15:63309203	C/T	cg12160578	chr15:63334699	TPM1	0.57	7.9	0.34	1.99e-14	Orofacial clefts;
LGG	cis	rs8078723	1.000	rs1042658	chr17:38173902	C/T	cg17467752	chr17:38218738	THRA	0.74	13.85	0.54	9.36e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg13482628	chr17:19912719	NA	0.53	10.1	0.42	8.58e-22	Schizophrenia;
LGG	cis	rs4417704	0.551	rs6735127	chr2:241885932	G/T	cg26818257	chr2:241905806	NA	0.48	10.83	0.45	1.63e-24	Joint mobility (Beighton score);
LGG	trans	rs72991	0.561	rs75755602	chr11:121231729	T/C	cg27192990	chr6:129479024	LAMA2	-0.6	-9.54	-0.41	8.26e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg04503457	chr17:41445688	NA	-0.39	-8.99	-0.39	6.46e-18	Menopause (age at onset);
LGG	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg07936489	chr17:37558343	FBXL20	-0.57	-9.7	-0.41	2.16e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg20368463	chr18:77673604	PQLC1	-0.56	-7.28	-0.32	1.47e-12	Opioid sensitivity;
LGG	cis	rs9783347	0.961	rs4150616	chr11:18365114	A/T	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.49	-0.33	3.42e-13	Pancreatic cancer;
LGG	cis	rs2075466	0.508	rs75637175	chr16:4948388	T/C	cg04440724	chr16:4920505	UBN1	-0.56	-7.94	-0.35	1.56e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17253792	0.822	rs112418863	chr14:56114079	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.44	-0.58	1.07e-43	Chronic sinus infection;
LGG	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg18252515	chr7:66147081	NA	-1.37	-14.83	-0.57	5.4e-41	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25789201	chr7:72395803	POM121	0.56	8.89	0.38	1.39e-17	Gut microbiome composition (summer);
LGG	cis	rs977987	0.843	rs11644741	chr16:75466433	C/A	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03768106	chr11:111957237	TIMM8B;SDHD	0.48	7.83	0.34	3.47e-14	Cognitive performance;
LGG	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.64	-0.63	1.22e-53	Breast cancer;
LGG	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs17453880	0.929	rs7707955	chr5:152042028	G/T	cg10931792	chr5:152022470	NA	-0.4	-8.76	-0.38	3.75e-17	Subjective well-being;
LGG	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13097342	chr7:38217509	STARD3NL	0.41	6.75	0.3	4.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs7523273	0.606	rs2724388	chr1:207933577	T/G	cg22525895	chr1:207977042	MIR29B2	0.61	11.88	0.48	1.33e-28	Schizophrenia;
LGG	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.08	0.7	1.2e-69	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17816390	chr8:37553296	ZNF703	-0.41	-6.81	-0.3	3.01e-11	Brain structure;
LGG	cis	rs977987	0.843	rs12149063	chr16:75451758	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg25427524	chr10:38739819	LOC399744	-0.48	-7.35	-0.32	9e-13	Obesity (extreme);
LGG	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	7.72	0.34	7.19e-14	Total cholesterol levels;
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.35	0.32	8.91e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs9354308	0.764	rs9294671	chr6:66604731	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.3e-17	Schizophrenia;
LGG	cis	rs8062405	0.558	rs151228	chr16:28563026	A/G	cg00198680	chr16:28758506	NA	0.28	7.19	0.32	2.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1003719	0.553	rs1063948	chr21:38574674	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.87	-0.57	3.77e-41	Eye color traits;
LGG	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg27446573	chr6:127587934	RNF146	-1.08	-19.75	-0.68	1.97e-63	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05672380	chr19:36505394	ALKBH6	0.5	7.47	0.33	3.99e-13	Gut microbiome composition (summer);
LGG	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12379764	chr21:47803548	PCNT	-0.44	-7.23	-0.32	2.01e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg03528353	chr17:61819722	STRADA	0.43	7.16	0.32	3.2e-12	Prudent dietary pattern;
LGG	cis	rs35160687	0.623	rs718292	chr2:86473740	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.38	-7.04	-0.31	7.2e-12	Night sleep phenotypes;
LGG	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg25730555	chr22:47059586	GRAMD4	0.4	6.8	0.3	3.19e-11	Urate levels in obese individuals;
LGG	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg24375607	chr4:120327624	NA	-0.53	-8.47	-0.37	3.33e-16	Corneal astigmatism;
LGG	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12615966	1.000	rs9941641	chr2:105384179	A/G	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	cis	rs709400	0.628	rs2273699	chr14:103923475	A/G	cg26031613	chr14:104095156	KLC1	0.79	14.15	0.55	4.87e-38	Body mass index;
LGG	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.56	-0.37	1.69e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7017914	0.935	rs6981435	chr8:71637148	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg12654349	chr5:56205094	C5orf35	-0.53	-8.83	-0.38	2.22e-17	Coronary artery disease;
LGG	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.42	-6.65	-0.3	8.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg02753203	chr1:228287806	NA	-0.64	-11.94	-0.49	7.54e-29	Diastolic blood pressure;
LGG	cis	rs7166081	1.000	rs16953610	chr15:67501592	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7940866	0.804	rs3910267	chr11:130810282	C/T	cg12179176	chr11:130786555	SNX19	0.77	14.89	0.57	2.86e-41	Schizophrenia;
LGG	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs9972944	0.756	rs8072765	chr17:63763508	T/C	cg07283582	chr17:63770753	CCDC46	-0.42	-8.28	-0.36	1.35e-15	Total body bone mineral density;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg06925179	chr17:43578568	NA	0.43	10.15	0.43	5.66e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7666738	0.830	rs28769113	chr4:98950371	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg18252515	chr7:66147081	NA	-0.76	-12.11	-0.49	1.63e-29	Corneal structure;
LGG	cis	rs9549328	0.879	rs12428058	chr13:113636504	G/A	cg08528486	chr13:113648767	MCF2L	-0.33	-6.77	-0.3	3.92e-11	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18350792	chr12:112563442	TRAFD1	0.49	7.83	0.34	3.29e-14	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04273556	chr9:35096672	PIGO	0.47	7.82	0.34	3.54e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.1	0.57	3.48e-42	Cannabis dependence symptom count;
LGG	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg21775007	chr8:11205619	TDH	-0.55	-8.96	-0.38	8.01e-18	Retinal vascular caliber;
LGG	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Vitiligo;
LGG	cis	rs9486719	1.000	rs2179126	chr6:96871350	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.47	-0.74	8.28e-81	Primary sclerosing cholangitis;
LGG	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg02574844	chr11:5959923	NA	-0.55	-8.66	-0.37	8.01e-17	DNA methylation (variation);
LGG	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg26384229	chr12:38710491	ALG10B	0.96	20.85	0.7	1.49e-68	Morning vs. evening chronotype;
LGG	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg12193833	chr17:30244370	NA	-0.29	-7.11	-0.31	4.41e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs6964587	1.000	rs756647	chr7:91586389	A/G	cg17063962	chr7:91808500	NA	0.48	8.54	0.37	1.93e-16	Breast cancer;
LGG	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg08807101	chr21:30365312	RNF160	-0.61	-10.45	-0.44	4.32e-23	Dental caries;
LGG	cis	rs7100689	0.577	rs756208	chr10:82041751	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	14.14	0.55	5.25e-38	Post bronchodilator FEV1;
LGG	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg11812906	chr14:75593930	NEK9	0.55	10.24	0.43	2.47e-22	Height;
LGG	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.76	0.38	3.69e-17	Systolic blood pressure;
LGG	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg10596483	chr8:143751796	JRK	0.51	7.94	0.35	1.55e-14	Schizophrenia;
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.6	7.05	0.31	6.61e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7582720	1.000	rs72928608	chr2:203836507	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg26384229	chr12:38710491	ALG10B	0.88	19.85	0.68	6.43e-64	Morning vs. evening chronotype;
LGG	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg23740940	chr11:68924746	NA	0.43	6.95	0.31	1.29e-11	Blond vs. brown hair color;
LGG	cis	rs3806843	0.900	rs2563279	chr5:140131535	G/A	cg19875535	chr5:140030758	IK	-0.52	-10.58	-0.44	1.4e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg10621924	chr7:39171070	POU6F2	0.44	8.55	0.37	1.77e-16	IgG glycosylation;
LGG	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	10.29	0.43	1.66e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7582720	1.000	rs72934535	chr2:203968973	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.58	0.37	1.47e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs806215	0.951	rs327510	chr7:127257894	G/A	cg25922125	chr7:127225783	GCC1	0.67	9.79	0.41	1.12e-20	Type 2 diabetes;
LGG	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg08297393	chr2:100937505	LONRF2	-0.45	-7.82	-0.34	3.59e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg14004847	chr7:1930337	MAD1L1	0.54	9.2	0.39	1.2e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg11764359	chr7:65958608	NA	0.7	11.72	0.48	5.75e-28	Aortic root size;
LGG	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.72	-0.3	5.39e-11	Alzheimer's disease (survival time);
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg26513180	chr16:89883248	FANCA	0.98	9.26	0.4	7.7e-19	Skin colour saturation;
LGG	cis	rs9378357	0.850	rs9392474	chr6:3293731	G/A	cg08754725	chr6:3293098	SLC22A23	-0.8	-7.93	-0.35	1.71e-14	Obesity-related traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13803262	chr18:54305799	TXNL1	0.61	6.84	0.3	2.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08677398	chr8:58056175	NA	-0.56	-8.83	-0.38	2.19e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs897080	0.515	rs1085444	chr2:44624155	A/G	cg00619915	chr2:44497795	NA	-0.48	-6.75	-0.3	4.57e-11	Height;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg00636124	chr16:27215281	JMJD5	0.41	6.85	0.3	2.4e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7000551	0.505	rs13258195	chr8:22227271	A/G	cg12081754	chr8:22256438	SLC39A14	-1.17	-24.11	-0.75	8.11e-84	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg17376030	chr22:41985996	PMM1	0.43	7.02	0.31	7.95e-12	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01582056	chr18:33161179	NA	0.44	6.76	0.3	4.06e-11	Gut microbiome composition (summer);
LGG	trans	rs12517041	0.935	rs2099089	chr5:23287372	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.03	-0.46	2.94e-25	Calcium levels;
LGG	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-8.06	-0.35	6.65e-15	Educational attainment;
LGG	cis	rs9581857	0.685	rs9579084	chr13:28028201	A/G	cg01674679	chr13:27998804	GTF3A	0.65	7.73	0.34	6.89e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg19812747	chr11:111475976	SIK2	-0.41	-8.67	-0.37	7.18e-17	Primary sclerosing cholangitis;
LGG	cis	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg24375607	chr4:120327624	NA	0.6	10.09	0.42	8.88e-22	Corneal astigmatism;
LGG	trans	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg21053147	chr12:120880522	NA	0.52	7.87	0.34	2.56e-14	Type 1 diabetes nephropathy;
LGG	cis	rs10089	0.951	rs56066100	chr5:127460571	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08741578	chr4:4250464	TMEM128	0.44	6.98	0.31	1e-11	Cognitive performance;
LGG	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg01864069	chr14:103024347	NA	-0.46	-8.14	-0.35	3.72e-15	Platelet count;
LGG	trans	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg25214090	chr10:38739885	LOC399744	-0.67	-11.69	-0.48	7.8e-28	Corneal astigmatism;
LGG	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.76	0.3	4.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10089	0.953	rs6879970	chr5:127387178	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	11.31	0.47	2.39e-26	Ileal carcinoids;
LGG	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg12395012	chr8:11607386	GATA4	0.39	7.06	0.31	6.12e-12	Neuroticism;
LGG	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg19812747	chr11:111475976	SIK2	0.35	6.95	0.31	1.23e-11	Primary sclerosing cholangitis;
LGG	cis	rs2273669	0.915	rs4992384	chr6:109292806	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-7.29	-0.32	1.35e-12	Prostate cancer;
LGG	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06470251	chr20:60548479	NA	0.42	7.26	0.32	1.62e-12	Body mass index;
LGG	cis	rs6815814	0.904	rs7664239	chr4:38786304	T/C	cg06935464	chr4:38784597	TLR10	0.54	8.9	0.38	1.28e-17	Breast cancer;
LGG	cis	rs113084984	0.642	rs35417544	chr2:11680403	C/T	cg07314298	chr2:11723111	GREB1	0.36	6.81	0.3	2.97e-11	Breast cancer;
LGG	cis	rs7949566	0.557	rs2230278	chr11:126277216	C/T	cg05055844	chr11:126275997	ST3GAL4	0.38	7.57	0.33	1.99e-13	Platelet distribution width;Mean platelet volume;
LGG	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs727505	1.000	rs56387611	chr7:124479180	G/A	cg23710748	chr7:124431027	NA	-0.53	-10.05	-0.42	1.24e-21	Lewy body disease;
LGG	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.96	0.49	6.25e-29	Rheumatoid arthritis;
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg08297393	chr2:100937505	LONRF2	-0.57	-9.7	-0.41	2.31e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	1.000	rs336570	chr3:161072054	A/G	cg04691961	chr3:161091175	C3orf57	0.64	15.13	0.58	2.74e-42	Morning vs. evening chronotype;
LGG	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	7.24	0.32	1.88e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8017423	0.904	rs2149647	chr14:90769539	C/T	cg04374321	chr14:90722782	PSMC1	-0.83	-16.66	-0.61	3.55e-49	Mortality in heart failure;
LGG	cis	rs72781680	1.000	rs963725	chr2:24148231	T/C	cg08917208	chr2:24149416	ATAD2B	0.94	10.2	0.43	3.71e-22	Lymphocyte counts;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.55	9.98	0.42	2.24e-21	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23747904	chr2:120301847	PCDP1	0.44	7.7	0.34	8.28e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.87	-0.34	2.56e-14	Resting heart rate;
LGG	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs9914988	0.943	rs7224870	chr17:27102620	A/G	cg20469991	chr17:27169893	C17orf63	-0.53	-6.72	-0.3	5.37e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg08885076	chr2:99613938	TSGA10	-0.31	-6.68	-0.3	7.07e-11	Fear of minor pain;
LGG	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg20302533	chr7:39170763	POU6F2	0.32	7.67	0.34	1.03e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg08297393	chr2:100937505	LONRF2	0.54	10.21	0.43	3.16e-22	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26446827	chr20:18268978	ZNF133	0.51	8.36	0.36	7.56e-16	Cognitive performance;
LGG	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg11812906	chr14:75593930	NEK9	0.54	10.0	0.42	1.84e-21	Height;
LGG	cis	rs12765878	0.812	rs2984132	chr10:105657892	T/C	cg11005552	chr10:105648138	OBFC1	-0.82	-16.42	-0.61	4.56e-48	Coronary artery disease;
LGG	cis	rs818427	0.896	rs351770	chr5:112199199	C/A	cg07820702	chr5:112228657	REEP5	0.35	6.66	0.3	7.74e-11	Total body bone mineral density;
LGG	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg17885191	chr8:135476712	NA	0.44	6.99	0.31	9.83e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg06074448	chr4:187884817	NA	-0.58	-12.75	-0.51	4.11e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.06	0.42	1.12e-21	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01171597	chr15:73075587	ADPGK	0.47	6.93	0.31	1.38e-11	Gut microbiome composition (summer);
LGG	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.26	0.36	1.52e-15	Alcohol dependence;
LGG	cis	rs6735179	0.729	rs2382560	chr2:1762828	A/G	cg10160682	chr2:1713001	PXDN	-0.53	-9.57	-0.41	6.29e-20	Response to antipsychotic treatment;
LGG	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05901451	chr6:126070800	HEY2	-0.81	-17.07	-0.62	4.81e-51	Brugada syndrome;
LGG	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg17691542	chr6:26056736	HIST1H1C	0.72	12.45	0.5	7.04e-31	Height;
LGG	cis	rs7512552	0.839	rs1260405	chr1:150304781	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.32	0.4	4.66e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg04455712	chr21:45112962	RRP1B	0.53	9.74	0.41	1.56e-20	Mean corpuscular volume;
LGG	cis	rs7463659	0.935	rs7844624	chr8:135433894	T/C	cg09855544	chr8:135498122	ZFAT	-0.43	-8.03	-0.35	8.38e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg19847130	chr8:10466454	RP1L1	-0.33	-7.2	-0.32	2.39e-12	Mood instability;
LGG	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg26655873	chr3:72818019	SHQ1	0.34	6.97	0.31	1.12e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.81e-33	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.73	0.56	1.56e-40	Platelet count;
LGG	cis	rs6028335	0.825	rs17764246	chr20:37724966	C/A	cg16355469	chr20:37678765	NA	0.52	6.84	0.3	2.5e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg20891283	chr12:69753455	YEATS4	0.95	21.64	0.71	2.81e-72	Blood protein levels;
LGG	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg07382826	chr16:28625726	SULT1A1	-0.35	-6.83	-0.3	2.69e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9359856	0.636	rs3748085	chr6:90315789	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.55	-7.28	-0.32	1.48e-12	Bipolar disorder;
LGG	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg13010199	chr12:38710504	ALG10B	0.71	14.25	0.55	1.8e-38	Bladder cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23587005	chr12:9600941	DDX12	0.51	8.64	0.37	9.45e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs7572644	0.640	rs9678430	chr2:28057129	G/C	cg27432699	chr2:27873401	GPN1	0.44	6.66	0.3	7.64e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs368123	0.960	rs678145	chr6:160720627	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs1693575	0.624	rs1693568	chr8:101677693	G/A	cg06874326	chr8:101662790	SNX31	-0.36	-7.24	-0.32	1.85e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg26116260	chr4:7069785	GRPEL1	-0.92	-8.04	-0.35	7.34e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg04025307	chr7:1156635	C7orf50	0.66	8.5	0.37	2.58e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.74	0.38	4.37e-17	Lung cancer;
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.7	-0.34	8.12e-14	Systolic blood pressure;
LGG	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg03453431	chr7:157225567	NA	-0.54	-9.62	-0.41	4.3e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	13.45	0.53	4.89e-35	HIV-1 control;
LGG	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs807669	0.900	rs712964	chr22:19156117	T/C	cg02655711	chr22:19163373	SLC25A1	0.69	13.6	0.53	1.07e-35	Metabolite levels;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs7408868	0.563	rs11085949	chr19:15296917	G/T	cg14696996	chr19:15285081	NOTCH3	0.89	11.64	0.48	1.17e-27	Pulse pressure;
LGG	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg11764359	chr7:65958608	NA	-0.78	-14.43	-0.56	3.07e-39	Aortic root size;
LGG	cis	rs1784581	1.000	rs1784582	chr6:162400712	A/G	cg17173639	chr6:162384350	PARK2	-0.84	-21.09	-0.7	1.06e-69	Itch intensity from mosquito bite;
LGG	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.26	-0.32	1.66e-12	Psoriasis;
LGG	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg23306229	chr2:178417860	TTC30B	0.68	8.0	0.35	1.03e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs941408	1.000	rs941408	chr19:2814181	C/T	cg22153745	chr1:153894579	GATAD2B	-0.66	-10.54	-0.44	2.07e-23	Total cholesterol levels;
LGG	cis	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg07460842	chr6:66804631	NA	0.96	17.85	0.64	1.32e-54	Exhaled nitric oxide output;
LGG	cis	rs68170813	0.559	rs76859341	chr7:107070146	C/G	cg02696742	chr7:106810147	HBP1	-0.7	-9.94	-0.42	3.1e-21	Coronary artery disease;
LGG	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg10518543	chr12:38710700	ALG10B	0.41	6.69	0.3	6.41e-11	Morning vs. evening chronotype;
LGG	cis	rs7113850	0.541	rs77868378	chr11:24233684	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.43	0.44	5.12e-23	Bone fracture in osteoporosis;
LGG	cis	rs36051895	0.502	rs12347799	chr9:5215954	G/A	cg02405213	chr9:5042618	JAK2	-0.62	-11.49	-0.47	4.59e-27	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg13206674	chr6:150067644	NUP43	0.62	13.94	0.54	3.84e-37	Lung cancer;
LGG	cis	rs926938	0.520	rs6660624	chr1:115272163	G/A	cg12756093	chr1:115239321	AMPD1	-0.53	-8.96	-0.38	7.72e-18	Autism;
LGG	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7607369	0.782	rs639913	chr2:219365971	A/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.44	-0.37	4.22e-16	Resting heart rate;
LGG	cis	rs2115630	0.936	rs6496318	chr15:85215229	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-7.32	-0.32	1.13e-12	P wave terminal force;
LGG	cis	rs17253792	0.732	rs10146604	chr14:56045770	C/G	cg01858014	chr14:56050164	KTN1	-0.89	-12.27	-0.5	3.59e-30	Putamen volume;
LGG	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg12310025	chr6:25882481	NA	-0.68	-13.2	-0.52	5.51e-34	Intelligence (multi-trait analysis);
LGG	cis	rs1185460	0.565	rs1043314	chr11:118915944	A/G	cg12636538	chr11:118901039	SLC37A4	-0.64	-13.35	-0.53	1.31e-34	Coronary artery disease;
LGG	cis	rs9443645	0.901	rs9352675	chr6:79612800	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs75059851	0.756	rs2000853	chr11:133838417	A/G	cg20042908	chr11:133852938	NA	-0.77	-14.28	-0.55	1.33e-38	Schizophrenia;
LGG	cis	rs526231	0.543	rs171558	chr5:102577894	G/C	cg23492399	chr5:102201601	PAM	-0.59	-8.51	-0.37	2.35e-16	Primary biliary cholangitis;
LGG	cis	rs3206736	0.548	rs1637676	chr7:35000559	A/G	cg13400248	chr7:35225412	NA	0.53	9.42	0.4	2.2e-19	Diastolic blood pressure;
LGG	cis	rs9581857	0.685	rs10467687	chr13:28036516	G/A	cg01674679	chr13:27998804	GTF3A	-0.64	-7.5	-0.33	3.23e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg26384229	chr12:38710491	ALG10B	1.08	29.58	0.81	9.59e-109	Heart rate;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26759552	chr7:139877471	LOC100134229;JHDM1D	0.47	7.54	0.33	2.57e-13	Cognitive performance;
LGG	cis	rs17453880	0.889	rs6871986	chr5:151947459	T/C	cg10931792	chr5:152022470	NA	0.38	8.02	0.35	8.75e-15	Subjective well-being;
LGG	trans	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg18335740	chr13:41363409	SLC25A15	0.91	21.8	0.71	5.1e-73	Lewy body disease;
LGG	cis	rs6546550	0.935	rs60207187	chr2:70093910	G/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.97	-0.35	1.28e-14	Prevalent atrial fibrillation;
LGG	cis	rs735860	0.674	rs209485	chr6:53174448	C/T	cg10236188	chr6:53219634	NA	-0.36	-6.92	-0.31	1.49e-11	Glaucoma;
LGG	cis	rs867371	0.502	rs1846908	chr15:82522526	T/C	cg00614314	chr15:82944287	LOC80154	0.47	7.82	0.34	3.67e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8064024	0.681	rs9925944	chr16:4885229	G/A	cg08329684	chr16:4932620	PPL	0.51	11.42	0.47	8.75e-27	Cancer;
LGG	cis	rs2377585	0.524	rs11616092	chr12:8845493	A/G	cg03761649	chr12:8850719	RIMKLB	0.48	8.06	0.35	6.78e-15	Reticulocyte fraction of red cells;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02977157	chr20:13765764	C20orf7;ESF1	0.39	6.8	0.3	3.17e-11	Bilirubin levels;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg05368731	chr17:41323189	NBR1	0.97	19.13	0.66	1.62e-60	Menopause (age at onset);
LGG	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22618164	chr12:122356400	WDR66	-0.31	-8.5	-0.37	2.63e-16	Mean corpuscular volume;
LGG	cis	rs13266463	0.858	rs13255588	chr8:143384727	C/G	cg16886403	chr8:143471632	TSNARE1	0.44	7.02	0.31	7.99e-12	Schizophrenia;
LGG	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11971779	0.616	rs10278377	chr7:139103071	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	cis	rs9467773	0.587	rs9467722	chr6:26352566	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-8.22	-0.36	2.1e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg17691542	chr6:26056736	HIST1H1C	0.48	8.4	0.36	5.35e-16	Height;
LGG	cis	rs870825	0.616	rs28459754	chr4:185636280	C/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg00686598	chr14:53173677	PSMC6	1.34	14.88	0.57	3.38e-41	Alzheimer's disease (late onset);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg03162506	chr22:38580953	NA	0.4	9.76	0.41	1.38e-20	Breast cancer;
LGG	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg02811702	chr13:24901961	NA	0.39	7.34	0.32	9.48e-13	Obesity-related traits;
LGG	cis	rs9914988	0.943	rs9890155	chr17:27125467	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15532942	chr18:77220712	NFATC1	0.51	7.37	0.32	7.67e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs5742933	0.857	rs7571089	chr2:190561793	G/A	cg04003228	chr2:190539410	ANKAR	-0.5	-7.39	-0.32	6.73e-13	Ferritin levels;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg19673125	chr6:150240577	RAET1G	0.34	8.35	0.36	8.09e-16	Testicular germ cell tumor;
LGG	cis	rs972578	0.702	rs2413723	chr22:43200220	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.8	-0.3	3.24e-11	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg24642439	chr20:33292090	TP53INP2	0.82	14.81	0.57	6.69e-41	Coronary artery disease;
LGG	cis	rs4474465	0.850	rs10751294	chr11:78253303	T/A	cg02023728	chr11:77925099	USP35	-0.39	-6.85	-0.3	2.41e-11	Alzheimer's disease (survival time);
LGG	cis	rs2629540	0.847	rs10901811	chr10:126417914	G/A	cg08799069	chr10:126477246	METTL10	0.66	13.52	0.53	2.43e-35	Cocaine dependence;
LGG	cis	rs56161922	0.749	rs3738469	chr1:207818422	G/A	cg09557387	chr1:207818395	CR1L	0.98	9.6	0.41	4.92e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg05665937	chr4:1216051	CTBP1	0.42	7.65	0.34	1.14e-13	Obesity-related traits;
LGG	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.4	8.11	0.35	4.43e-15	Educational attainment;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.22	0.32	2.15e-12	Prudent dietary pattern;
LGG	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-10.65	-0.44	7.41e-24	Morning vs. evening chronotype;
LGG	cis	rs80282103	0.867	rs3793781	chr10:1081293	G/T	cg08668510	chr10:1095578	IDI1	0.8	8.16	0.35	3.12e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg05096777	chr10:104283225	SUFU	0.31	6.71	0.3	5.58e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12464559	0.522	rs13016166	chr2:152624144	G/A	cg01189475	chr2:152685088	ARL5A	0.67	7.1	0.31	4.73e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg08999081	chr20:33150536	PIGU	0.38	9.64	0.41	3.76e-20	Coronary artery disease;
LGG	cis	rs8077889	0.917	rs60335331	chr17:41907509	A/G	cg26893861	chr17:41843967	DUSP3	0.9	15.65	0.59	1.3e-44	Triglycerides;
LGG	cis	rs2114646	0.652	rs59465792	chr2:170635501	G/T	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25682936	chr1:38455768	SF3A3	0.47	7.52	0.33	2.82e-13	Gut microbiome composition (summer);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg17437930	chr7:24619232	MPP6	-0.4	-6.8	-0.3	3.17e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg19980929	chr12:42632907	YAF2	0.39	8.96	0.38	7.79e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-11.45	-0.47	6.76e-27	Height;
LGG	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg03805757	chr16:71968109	PKD1L3	0.46	8.64	0.37	9.47e-17	Post bronchodilator FEV1;
LGG	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.85	0.51	1.48e-32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg11812906	chr14:75593930	NEK9	0.54	10.1	0.42	8.45e-22	Height;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg27661571	chr11:113659931	NA	-0.65	-9.31	-0.4	5.27e-19	Hip circumference adjusted for BMI;
LGG	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg16386425	chr10:429943	DIP2C	0.49	9.89	0.42	4.78e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs9649465	1.000	rs7776792	chr7:123335350	C/T	cg03229431	chr7:123269106	ASB15	0.4	8.92	0.38	1.08e-17	Migraine;
LGG	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg02153584	chr22:29168773	CCDC117	-0.59	-9.64	-0.41	3.57e-20	Lymphocyte counts;
LGG	cis	rs4363385	0.719	rs2066005	chr1:152923113	G/C	cg07796016	chr1:152779584	LCE1C	-0.45	-7.07	-0.31	5.9e-12	Inflammatory skin disease;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.69	0.34	8.81e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs556990	0.574	rs473598	chr13:113801189	C/T	cg18105134	chr13:113819100	PROZ	-0.57	-9.23	-0.39	9.87e-19	Blood protein levels;
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-7.11	-0.31	4.44e-12	Life satisfaction;
LGG	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.93	0.35	1.64e-14	Birth weight;
LGG	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.6	0.72	9.29e-77	Breast cancer;
LGG	cis	rs13082711	0.871	rs35701251	chr3:27529753	T/A	cg02860705	chr3:27208620	NA	0.72	12.71	0.51	5.96e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg04267008	chr7:1944627	MAD1L1	-0.5	-8.22	-0.36	2.1e-15	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.52	-0.4	9.38e-20	Lung cancer;
LGG	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.68e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg21452805	chr1:244014465	NA	0.6	7.04	0.31	7.02e-12	RR interval (heart rate);
LGG	cis	rs907683	0.584	rs12920	chr2:220285666	C/G	cg15015639	chr2:220282977	DES	0.35	10.2	0.43	3.67e-22	Resting heart rate;
LGG	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.72	-0.34	7.25e-14	Calcium levels;
LGG	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-13.82	-0.54	1.32e-36	Parkinson's disease;
LGG	cis	rs919433	0.617	rs4850807	chr2:198575975	G/A	cg00792783	chr2:198669748	PLCL1	-0.61	-9.89	-0.42	4.82e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.5	-0.4	1.1e-19	Diabetic retinopathy;
LGG	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg13607699	chr17:42295918	UBTF	-0.42	-6.68	-0.3	7.04e-11	Total body bone mineral density;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg15971980	chr6:150254442	NA	0.45	8.41	0.36	4.98e-16	Lung cancer;
LGG	cis	rs3768617	0.868	rs2296299	chr1:183104013	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.9	0.31	1.71e-11	Fuchs's corneal dystrophy;
LGG	trans	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-7.07	-0.31	5.88e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9783347	0.961	rs12293544	chr11:18348581	T/C	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs7777754	0.734	rs4947709	chr7:50672907	A/G	cg00647317	chr7:50633725	DDC	0.31	7.41	0.33	5.85e-13	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg05165339	chr4:1420672	NA	-0.26	-6.83	-0.3	2.64e-11	Longevity;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg11494091	chr17:61959527	GH2	0.99	24.36	0.75	5.56e-85	Prudent dietary pattern;
LGG	cis	rs9810089	0.708	rs711977	chr3:136227387	G/A	cg21827317	chr3:136751795	NA	0.45	8.02	0.35	8.66e-15	Gestational age at birth (child effect);
LGG	cis	rs6489882	0.867	rs1859336	chr12:113367309	A/G	cg25319449	chr12:113376135	OAS3	0.44	7.47	0.33	4.13e-13	Chronic lymphocytic leukemia;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg11301795	chr4:187892539	NA	-0.94	-25.33	-0.76	1.79e-89	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.12	0.31	4.08e-12	Renal function-related traits (BUN);
LGG	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg24692254	chr21:30365293	RNF160	0.82	16.86	0.62	4.71e-50	Selective IgA deficiency;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.88	-0.34	2.4e-14	Mood instability;
LGG	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12756686	chr19:29218302	NA	0.71	11.56	0.47	2.4200000000000002e-27	Methadone dose in opioid dependence;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg18479299	chr3:125709523	NA	-0.57	-7.15	-0.32	3.48e-12	Blood pressure (smoking interaction);
LGG	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg16662043	chr16:48846231	NA	-0.38	-7.22	-0.32	2.13e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08273501	chr6:170599869	DLL1	0.43	6.71	0.3	5.8e-11	Gut microbiome composition (summer);
LGG	cis	rs308971	0.656	rs307563	chr3:12055011	G/T	cg02700894	chr3:12045449	SYN2	0.49	6.98	0.31	1.03e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs7474896	0.609	rs1830612	chr10:37999883	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-7.78	-0.34	4.63e-14	Obesity (extreme);
LGG	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.03	0.35	8.13e-15	Neuroticism;
LGG	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.21	0.36	2.14e-15	Retinal vascular caliber;
LGG	cis	rs4731207	0.596	rs12113770	chr7:124589740	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.32	-0.32	1.08e-12	Hepatitis;
LGG	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg20040747	chr15:74715105	SEMA7A	0.4	8.65	0.37	8.33e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg15309053	chr8:964076	NA	0.39	8.28	0.36	1.37e-15	Schizophrenia;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg26656751	chr17:43910226	CRHR1	0.48	8.95	0.38	8.59e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.92	0.42	3.58e-21	Lymphocyte counts;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg00364696	chr7:1142433	C7orf50	-0.39	-7.65	-0.34	1.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.43	0.65	2.76e-57	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.41	-0.36	5.07e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	trans	rs4714291	0.963	rs9369159	chr6:39998853	T/C	cg02267698	chr19:7991119	CTXN1	0.59	9.1	0.39	2.75e-18	Strep throat;
LGG	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg02002194	chr4:3960332	NA	0.38	6.88	0.3	1.99e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.61	-0.56	5.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg16339924	chr4:17578868	LAP3	0.62	10.16	0.43	4.81e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06156847	chr2:113672199	IL1F7	0.38	7.52	0.33	2.82e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg06916706	chr16:4465613	CORO7	-0.74	-13.01	-0.52	3.23e-33	Schizophrenia;
LGG	cis	rs8170	0.603	rs3745187	chr19:17414126	C/T	cg04749549	chr19:17459798	NA	-0.39	-7.18	-0.32	2.81e-12	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.526	rs12712830	chr2:42252955	T/G	cg19376973	chr2:42229025	NA	0.63	9.48	0.4	1.28e-19	Hypospadias;
LGG	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.72	-0.3	5.19e-11	Parkinson's disease;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.6	0.47	1.68e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg08975724	chr8:8085496	FLJ10661	0.58	11.84	0.48	1.89e-28	Neuroticism;
LGG	cis	rs8064024	0.538	rs12446456	chr16:4922201	C/T	cg04440724	chr16:4920505	UBN1	-0.6	-13.45	-0.53	4.69e-35	Cancer;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.98	-0.42	2.21e-21	Educational attainment;
LGG	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg18322822	chr5:1119648	NA	0.43	7.77	0.34	5.26e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9487051	0.834	rs6919423	chr6:109558471	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.88	-0.3	1.89e-11	Reticulocyte fraction of red cells;
LGG	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg17971929	chr21:40555470	PSMG1	-0.67	-12.1	-0.49	1.84e-29	Cognitive function;
LGG	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.39	-6.72	-0.3	5.52e-11	Primary biliary cholangitis;
LGG	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.09	-0.31	5.14e-12	Iron status biomarkers;
LGG	cis	rs36715	0.953	rs2617613	chr5:127552589	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.45	7.17	0.32	2.9e-12	Breast cancer;
LGG	cis	rs9972944	0.589	rs11870559	chr17:63772633	G/A	cg07283582	chr17:63770753	CCDC46	0.39	7.26	0.32	1.62e-12	Total body bone mineral density;
LGG	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg10661904	chr17:79619235	PDE6G	-0.5	-10.27	-0.43	1.93e-22	Eye color traits;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.67	0.67	4.55e-63	Platelet count;
LGG	cis	rs9611519	1.000	rs5758268	chr22:41622419	A/T	cg03806693	chr22:41940476	POLR3H	-0.49	-7.65	-0.33	1.19e-13	Neuroticism;
LGG	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	5.9e-49	Hip circumference adjusted for BMI;
LGG	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg12623918	chr2:306882	NA	0.53	9.8	0.41	1.03e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg13114125	chr14:105738426	BRF1	-0.84	-15.99	-0.6	3.87e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7681423	0.951	rs13109457	chr4:155514879	G/A	cg20735720	chr4:155535218	FGG	-0.55	-9.58	-0.41	5.75e-20	Fibrinogen;
LGG	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15128208	chr22:42549153	NA	-0.49	-9.56	-0.41	6.89e-20	Cognitive function;
LGG	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs9354308	0.727	rs9363480	chr6:66601316	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	cis	rs17539620	0.624	rs62432739	chr6:154835926	A/G	cg17771515	chr6:154831774	CNKSR3	0.61	7.54	0.33	2.44e-13	Lipoprotein (a) levels;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg05313129	chr8:58192883	C8orf71	-0.58	-7.71	-0.34	7.75e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17169635	0.879	rs7801596	chr7:134544054	T/A	cg02516134	chr7:134575187	CALD1	-0.39	-8.48	-0.37	3.16e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg15268244	chr15:77196840	NA	0.48	10.19	0.43	3.77e-22	Blood metabolite levels;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.23	-0.36	1.94e-15	Longevity;Endometriosis;
LGG	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg09998033	chr7:158218633	PTPRN2	0.48	8.95	0.38	8.61e-18	Obesity-related traits;
LGG	cis	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg19399532	chr1:178512495	C1orf220	0.54	10.89	0.45	9.86e-25	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg20271681	chr21:44299600	WDR4	-0.37	-6.98	-0.31	1.04e-11	Iris color (L* coordinate);
LGG	trans	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.94	-0.45	6.31e-25	Neuroticism;
LGG	cis	rs7106204	0.748	rs7101572	chr11:24213982	A/G	ch.11.24196551F	chr11:24239977	NA	1.05	16.54	0.61	1.24e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.79	-0.41	1.06e-20	Height;
LGG	cis	rs7523273	0.606	rs2281289	chr1:207978916	C/T	cg22525895	chr1:207977042	MIR29B2	-0.63	-12.44	-0.5	7.55e-31	Schizophrenia;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg17202724	chr17:61916730	SMARCD2	0.54	12.37	0.5	1.38e-30	Prudent dietary pattern;
LGG	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg24692254	chr21:30365293	RNF160	1.04	29.87	0.81	4.89e-110	Dental caries;
LGG	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg19784903	chr17:45786737	TBKBP1	0.36	7.93	0.35	1.62e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3857067	0.806	rs2171379	chr4:95100243	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.34	1.95e-14	QT interval;
LGG	cis	rs7666738	0.830	rs13137808	chr4:99047095	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4252707	1	rs4252707	chr1:204508147	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.42	-8.12	-0.35	4.37e-15	Glioma;Non-glioblastoma glioma;
LGG	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	10.89	0.45	9.85e-25	Mean platelet volume;
LGG	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg12379764	chr21:47803548	PCNT	0.7	12.15	0.49	1.1e-29	Lymphocyte counts;
LGG	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg00717180	chr2:96193071	NA	-0.51	-9.56	-0.41	6.84e-20	Coronary artery disease;
LGG	cis	rs7113874	0.524	rs10769922	chr11:8621752	G/A	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.69e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7241530	0.662	rs6506752	chr18:75904844	C/A	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	trans	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg07817883	chr1:32538562	TMEM39B	1.15	12.07	0.49	2.45e-29	Granulocyte percentage of myeloid white cells;
LGG	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21659725	chr3:3221576	CRBN	0.92	20.52	0.69	4.79e-67	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.91	0.38	1.13e-17	Aortic root size;
LGG	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg08997352	chr12:9597637	DDX12	-0.75	-14.1	-0.55	7.82e-38	Breast size;
LGG	cis	rs11677416	1.000	rs3783520	chr2:113544339	C/T	cg27083787	chr2:113543245	IL1A	0.54	8.83	0.38	2.13e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13442822	chr19:45583103	GEMIN7	0.41	6.82	0.3	2.85e-11	Gut microbiome composition (summer);
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.86	0.38	1.73e-17	Platelet count;
LGG	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7010267	0.596	rs67819415	chr8:120016916	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.54	0.37	1.94e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.89	0.34	2.22e-14	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg13939156	chr17:80058883	NA	-0.47	-9.01	-0.39	5.56e-18	Life satisfaction;
LGG	cis	rs6546550	0.901	rs6739780	chr2:70138111	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.97	-0.31	1.07e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2173063	1.000	rs74029111	chr15:93127039	G/A	cg07052004	chr15:93132129	NA	0.62	7.06	0.31	6.02e-12	Subcutaneous adipose tissue;
LGG	cis	rs698813	0.604	rs58667148	chr2:44481443	G/A	cg00619915	chr2:44497795	NA	-0.6	-8.77	-0.38	3.44e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg06917634	chr15:78832804	PSMA4	-0.68	-13.47	-0.53	3.79e-35	Sudden cardiac arrest;
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg06074448	chr4:187884817	NA	0.58	12.71	0.51	5.66e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg08470875	chr2:26401718	FAM59B	-0.4	-7.68	-0.34	9.42e-14	Gut microbiome composition (summer);
LGG	cis	rs16854884	0.683	rs6766544	chr3:143736659	G/T	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg20913747	chr6:44695427	NA	-0.5	-8.98	-0.39	6.95e-18	Total body bone mineral density;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs3820928	0.874	rs10166736	chr2:227900419	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.34	-0.32	9.41e-13	Pulmonary function;
LGG	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-8.27	-0.36	1.45e-15	Ovarian reserve;
LGG	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg12219531	chr12:120966889	COQ5	0.66	10.77	0.45	2.68e-24	High light scatter reticulocyte count;
LGG	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15506890	chr2:3487001	NA	-0.55	-10.12	-0.43	6.95e-22	Neurofibrillary tangles;
LGG	cis	rs9796	0.621	rs2578655	chr15:41462809	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.84	-0.42	7.43e-21	Menopause (age at onset);
LGG	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg08807101	chr21:30365312	RNF160	-0.8	-15.72	-0.59	6.07e-45	Dental caries;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-8.54	-0.37	2.02e-16	Menopause (age at onset);
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg11473876	chr11:109292803	C11orf87	0.77	17.05	0.62	6.08e-51	Schizophrenia;
LGG	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg10253484	chr15:75165896	SCAMP2	0.51	7.51	0.33	3.1e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg11502198	chr6:26597334	ABT1	0.71	12.97	0.52	4.71e-33	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs7241530	0.636	rs4799010	chr18:75910590	T/A	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	7.97e-17	Educational attainment (years of education);
LGG	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.95	16.93	0.62	2.07e-50	Lymphocyte percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06752163	chr3:170588210	RPL22L1	0.45	7.45	0.33	4.53e-13	Cognitive performance;
LGG	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.87e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6121246	0.559	rs6119728	chr20:30413121	G/A	cg13852791	chr20:30311386	BCL2L1	0.94	18.21	0.65	2.71e-56	Mean corpuscular hemoglobin;
LGG	cis	rs12220238	1.000	rs7083534	chr10:75955672	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4363385	0.818	rs12085426	chr1:153003074	C/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.97	-0.38	7.38e-18	Inflammatory skin disease;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.42	-0.33	5.75e-13	Life satisfaction;
LGG	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg03929089	chr4:120376271	NA	0.66	6.77	0.3	3.9e-11	Intraocular pressure;
LGG	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg02002194	chr4:3960332	NA	-0.38	-6.79	-0.3	3.51e-11	Retinal vascular caliber;
LGG	trans	rs1962073	0.528	rs12544112	chr8:10318815	C/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.07	0.35	6.08e-15	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg25208724	chr1:156163844	SLC25A44	1.15	20.54	0.69	3.99e-67	Testicular germ cell tumor;
LGG	cis	rs2976388	0.934	rs2920279	chr8:143762135	A/C	cg06565975	chr8:143823917	SLURP1	-0.41	-10.41	-0.44	6.28e-23	Urinary tract infection frequency;
LGG	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg25706281	chr1:46860511	FAAH	-0.3	-7.34	-0.32	9.89e-13	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs6539288	0.674	rs4964494	chr12:107284460	A/G	cg15890332	chr12:107067104	RFX4	0.37	10.43	0.44	5.08e-23	Total body bone mineral density;
LGG	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	6.95	0.31	1.28e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6426558	0.537	rs2813969	chr1:227404082	T/C	cg10327440	chr1:227177885	CDC42BPA	0.6	9.95	0.42	2.87e-21	Neutrophil percentage of white cells;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00142150	chr22:38071001	LGALS1	0.92	19.75	0.68	1.93e-63	Fat distribution (HIV);
LGG	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg11166453	chr1:247681781	NA	0.64	10.04	0.42	1.34e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.7	-11.45	-0.47	6.54e-27	Height;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.68	-0.37	6.9e-17	Kawasaki disease;
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.66	0.34	1.1e-13	Prostate cancer;
LGG	cis	rs651907	0.588	rs1707613	chr3:101637189	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.88	0.34	2.43e-14	Colorectal cancer;
LGG	trans	rs853679	0.607	rs34691223	chr6:28258208	C/A	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg07538946	chr5:131705188	SLC22A5	0.67	7.8	0.34	4.22e-14	Rheumatoid arthritis;
LGG	cis	rs7944584	0.879	rs11039182	chr11:47346723	T/C	cg20307385	chr11:47447363	PSMC3	0.67	12.57	0.5	2.22e-31	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01112527	chr2:1479810	TPO	-0.36	-6.71	-0.3	5.61e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg27119904	chr13:114814333	RASA3	0.36	7.59	0.33	1.75e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs3762637	0.941	rs112768052	chr3:122169384	G/A	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg05896524	chr21:47604654	C21orf56	0.59	10.54	0.44	1.92e-23	Testicular germ cell tumor;
LGG	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg26818010	chr10:134567672	INPP5A	-0.51	-8.55	-0.37	1.85e-16	Migraine;
LGG	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg12310025	chr6:25882481	NA	-0.53	-10.15	-0.43	5.56e-22	Blood metabolite levels;
LGG	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.76	-0.51	3.8e-32	Uric acid levels;
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg05768032	chr16:30646687	NA	0.4	6.69	0.3	6.28e-11	Multiple myeloma;
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.22	0.39	1.04e-18	Triglycerides;
LGG	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27297192	chr10:134578999	INPP5A	0.32	7.5	0.33	3.23e-13	Migraine;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg04503457	chr17:41445688	NA	-0.38	-9.36	-0.4	3.53e-19	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.49	-0.37	2.85e-16	Personality dimensions;
LGG	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.62	-10.49	-0.44	3e-23	Cognitive test performance;
LGG	cis	rs713587	0.571	rs2917916	chr2:25316336	A/C	cg04586622	chr2:25135609	ADCY3	-0.27	-6.87	-0.3	2.14e-11	Body mass index in non-asthmatics;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg23758822	chr17:41437982	NA	0.86	14.74	0.57	1.37e-40	Menopause (age at onset);
LGG	cis	rs686320	0.667	rs666834	chr11:65183815	A/G	cg17392047	chr11:65247138	NA	-0.53	-6.67	-0.3	7.52e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1691799	0.867	rs1168356	chr12:66750469	A/G	cg16791601	chr12:66731901	HELB	-0.64	-14.86	-0.57	4.23e-41	White blood cell count (basophil);
LGG	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2708240	0.967	rs1922892	chr7:147576411	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg06636001	chr8:8085503	FLJ10661	0.49	9.45	0.4	1.74e-19	Neuroticism;
LGG	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg03342759	chr3:160939853	NMD3	0.44	7.31	0.32	1.16e-12	Morning vs. evening chronotype;
LGG	cis	rs7712401	0.601	rs2910140	chr5:122264395	T/A	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs9787249	0.957	rs1046988	chr1:40219065	A/G	cg02773041	chr1:40204384	PPIE	-0.53	-9.61	-0.41	4.75e-20	Blood protein levels;
LGG	cis	rs6430585	0.528	rs16832205	chr2:136684632	G/A	cg07169764	chr2:136633963	MCM6	1.22	22.34	0.72	1.46e-75	Corneal structure;
LGG	cis	rs2070997	0.527	rs3847192	chr9:133724916	T/G	cg13397898	chr9:133768931	QRFP	0.38	7.57	0.33	2.06e-13	Response to amphetamines;
LGG	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg20673091	chr1:2541236	MMEL1	-0.77	-16.36	-0.61	8.23e-48	Ulcerative colitis;
LGG	trans	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg24247370	chr13:99142703	STK24	0.36	6.86	0.3	2.23e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-20.98	-0.7	3.38e-69	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11890956	chr21:40555474	PSMG1	-0.7	-11.82	-0.48	2.27e-28	Menarche (age at onset);
LGG	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg00857998	chr1:205179979	DSTYK	0.47	6.86	0.3	2.2e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.26	-0.52	3.14e-34	Alzheimer's disease;
LGG	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.84	0.62	5.42e-50	Smoking behavior;
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.17	0.35	3e-15	Mood instability;
LGG	cis	rs8078723	1.000	rs4794823	chr17:38166265	A/T	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg09165964	chr15:75287851	SCAMP5	-1.08	-22.62	-0.72	7.18e-77	Blood trace element (Zn levels);
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.79	0.3	3.39e-11	Renal cell carcinoma;
LGG	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg24375607	chr4:120327624	NA	0.67	10.96	0.45	5.18e-25	Corneal astigmatism;
LGG	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg27102117	chr16:15229624	NA	-0.49	-9.63	-0.41	3.81e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.23	0.32	2.06e-12	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg20302533	chr7:39170763	POU6F2	0.48	12.1	0.49	1.85e-29	IgG glycosylation;
LGG	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg16751781	chr15:78858589	CHRNA5	-0.45	-8.88	-0.38	1.44e-17	Sudden cardiac arrest;
LGG	cis	rs6558530	0.625	rs7459507	chr8:1698192	A/G	cg25947184	chr8:1697459	NA	0.47	8.17	0.35	2.98e-15	Systolic blood pressure;
LGG	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg20290983	chr6:43655470	MRPS18A	0.96	16.02	0.6	2.78e-46	IgG glycosylation;
LGG	trans	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg10756647	chr7:56101905	PSPH	0.79	9.49	0.4	1.26e-19	Gout;
LGG	cis	rs1318772	1.000	rs11241202	chr5:112692298	G/A	cg12552261	chr5:112820674	MCC	0.69	8.51	0.37	2.41e-16	F-cell distribution;
LGG	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg17644776	chr2:200775616	C2orf69	0.57	7.09	0.31	5.13e-12	Schizophrenia;
LGG	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7444	0.941	rs131665	chr22:21920903	A/G	cg22858872	chr22:21984481	YDJC	-0.36	-6.72	-0.3	5.51e-11	Systemic lupus erythematosus;
LGG	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	10.25	0.43	2.4e-22	Red cell distribution width;
LGG	cis	rs12450688	1	rs12450688	chr17:38144229	G/A	cg17467752	chr17:38218738	THRA	-0.61	-11.18	-0.46	7.48e-26	Sum eosinophil basophil counts;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg27432699	chr2:27873401	GPN1	0.52	8.99	0.39	6.45e-18	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	8.05e-21	Skin colour saturation;
LGG	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg04691961	chr3:161091175	C3orf57	0.44	9.38	0.4	2.93e-19	Morning vs. evening chronotype;
LGG	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg16576597	chr16:28551801	NUPR1	0.35	8.02	0.35	8.49e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-8.68	-0.37	6.73e-17	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.77	-0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs1777194	chr6:126004883	G/A	cg05901451	chr6:126070800	HEY2	-0.45	-7.46	-0.33	4.37e-13	Endometrial cancer;
LGG	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg11752832	chr7:134001865	SLC35B4	0.63	11.47	0.47	5.59e-27	Mean platelet volume;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg18245976	chr7:158708271	WDR60	-0.57	-10.38	-0.43	7.99e-23	Height;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg13877915	chr19:58951672	ZNF132	-1.02	-26.35	-0.77	3.55e-94	Uric acid clearance;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg07142201	chr11:109293216	C11orf87	0.54	9.69	0.41	2.42e-20	Schizophrenia;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg12310025	chr6:25882481	NA	-0.52	-10.05	-0.42	1.24e-21	Height;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg15971980	chr6:150254442	NA	0.46	8.68	0.37	7.04e-17	Lung cancer;
LGG	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg07701084	chr6:150067640	NUP43	0.69	13.23	0.52	3.88e-34	Lung cancer;
LGG	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg13385794	chr1:248469461	NA	0.48	8.24	0.36	1.76e-15	Common traits (Other);
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06028808	chr11:68637592	NA	0.71	12.37	0.5	1.4e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg26384229	chr12:38710491	ALG10B	0.85	16.62	0.61	5.77e-49	Morning vs. evening chronotype;
LGG	cis	rs7267979	1.000	rs6083825	chr20:25366424	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-14.34	-0.55	7.57e-39	Response to antipsychotic treatment;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05165339	chr4:1420672	NA	-0.36	-9.11	-0.39	2.51e-18	Longevity;
LGG	cis	rs17162190	0.698	rs4970466	chr1:26849312	G/A	cg23229016	chr1:26872525	RPS6KA1	0.26	7.1	0.31	4.78e-12	Mean corpuscular volume;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg19803976	chr18:11850907	CHMP1B;GNAL	-0.38	-6.77	-0.3	4e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg20573242	chr4:122745356	CCNA2	0.59	11.37	0.47	1.39e-26	Type 2 diabetes;
LGG	trans	rs75804782	0.641	rs72985387	chr2:239336589	G/A	cg01134436	chr17:81009848	B3GNTL1	0.85	8.92	0.38	1.12e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3087591	0.960	rs2905878	chr17:29511199	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs1030877	0.515	rs1866038	chr2:105878522	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.67	10.51	0.44	2.57e-23	Obesity-related traits;
LGG	cis	rs68170813	0.652	rs56949084	chr7:107157387	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-8.63	-0.37	9.68e-17	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.3e-19	Lung cancer;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg18350739	chr11:68623251	NA	-0.88	-21.33	-0.7	8.3e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.17	-0.49	9.6e-30	Cognitive function;
LGG	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg27523141	chr10:43048294	ZNF37B	0.32	6.7	0.3	6.15e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7937612	1.000	rs7948928	chr11:120273224	C/G	cg24566217	chr11:120254723	ARHGEF12	0.53	12.8	0.51	2.39e-32	Intraocular pressure;
LGG	trans	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.78	14.65	0.56	3.45e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg22852734	chr6:133119734	C6orf192	-1.08	-15.24	-0.58	8.29e-43	Type 2 diabetes nephropathy;
LGG	cis	rs7666738	0.830	rs7664340	chr4:99037820	C/T	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.57e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg11473876	chr11:109292803	C11orf87	0.48	9.48	0.4	1.34e-19	Schizophrenia;
LGG	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.46	-0.33	4.18e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8133932	0.654	rs7410101	chr21:47328383	G/A	cg11214348	chr21:47283868	PCBP3	0.45	7.96	0.35	1.35e-14	Schizophrenia;
LGG	cis	rs2764208	0.576	rs2815003	chr6:34635809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-7.72	-0.34	7.19e-14	Systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg12654349	chr5:56205094	C5orf35	-0.6	-10.26	-0.43	2.14e-22	Initial pursuit acceleration;
LGG	cis	rs4740619	0.587	rs2382551	chr9:16033443	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.38	-0.47	1.22e-26	Body mass index;
LGG	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg00543991	chr22:32367038	NA	-0.72	-8.79	-0.38	2.89e-17	Childhood ear infection;
LGG	cis	rs7572644	0.699	rs13411592	chr2:28098724	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-6.94	-0.31	1.33e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.99e-13	Refractive error;
LGG	cis	rs17221829	0.965	rs3871189	chr11:89451250	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.67	-0.34	1.05e-13	Anxiety in major depressive disorder;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11644478	chr21:40555479	PSMG1	0.85	14.89	0.57	3.05e-41	Cognitive function;
LGG	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg16507663	chr6:150244633	RAET1G	0.51	10.41	0.44	6.19e-23	Testicular germ cell tumor;
LGG	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg01403660	chr11:68851641	TPCN2	0.51	7.13	0.31	3.84e-12	Blond vs. brown hair color;
LGG	cis	rs9487094	0.922	rs11153181	chr6:109750027	A/T	cg01125227	chr6:109776195	MICAL1	0.53	8.99	0.39	6.47e-18	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23239637	chr2:1507832	TPO	0.32	6.74	0.3	4.75e-11	Pancreatic cancer;
LGG	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.59	-0.69	2.35e-67	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22159483	chr17:1588198	PRPF8	0.5	8.1	0.35	5.08e-15	Gut microbiome composition (summer);
LGG	cis	rs12210905	0.565	rs9689239	chr6:26881879	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-7.36	-0.32	8.72e-13	Hip circumference adjusted for BMI;
LGG	trans	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg20477318	chr10:51623047	TIMM23	0.63	7.64	0.33	1.24e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg22916017	chr11:64110731	CCDC88B	-0.46	-6.74	-0.3	4.66e-11	Mean platelet volume;
LGG	cis	rs258892	0.895	rs13158966	chr5:72059510	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg01864069	chr14:103024347	NA	-0.7	-10.94	-0.45	6.41e-25	Platelet count;
LGG	trans	rs73191547	0.782	rs59255182	chr8:10040205	T/C	cg06636001	chr8:8085503	FLJ10661	0.43	7.74	0.34	6.2e-14	Schizophrenia;
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-12.83	-0.51	1.91e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.5	-0.61	2.03e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg04025307	chr7:1156635	C7orf50	0.82	14.75	0.57	1.26e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg24247370	chr13:99142703	STK24	-0.4	-7.15	-0.32	3.48e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-20.86	-0.7	1.26e-68	Vitiligo;
LGG	trans	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13082711	0.595	rs34453788	chr3:27330153	T/C	cg02860705	chr3:27208620	NA	0.92	17.16	0.62	1.96e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.96	0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.02	-0.39	4.87e-18	Menopause (age at onset);
LGG	trans	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-10.83	-0.45	1.65e-24	Blood trace element (Cu levels);
LGG	cis	rs938554	0.513	rs3775947	chr4:9995240	C/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-7.08	-0.31	5.27e-12	Blood metabolite levels;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg18032289	chr17:61959525	GH2	-0.42	-6.97	-0.31	1.08e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg03806693	chr22:41940476	POLR3H	-0.66	-11.0	-0.46	3.76e-25	Neuroticism;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.66	0.48	1.05e-27	Electroencephalogram traits;
LGG	cis	rs6466055	0.720	rs1204077	chr7:104984019	T/C	cg04380332	chr7:105027541	SRPK2	0.39	7.27	0.32	1.57e-12	Schizophrenia;
LGG	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	trans	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg11430096	chr6:110968061	CDK19	0.5	8.52	0.37	2.24e-16	Cancer;
LGG	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg17971929	chr21:40555470	PSMG1	0.83	15.95	0.6	6.11e-46	Cognitive function;
LGG	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	19.1	0.66	2.18e-60	Menopause (age at onset);
LGG	cis	rs72700829	0.593	rs80350997	chr1:150992010	G/A	cg11822372	chr1:151115635	SEMA6C	-0.68	-7.21	-0.32	2.32e-12	Schizophrenia;
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs4727027	0.933	rs9718383	chr7:148857624	A/T	cg23583168	chr7:148888333	NA	0.84	16.56	0.61	1e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08677398	chr8:58056175	NA	0.58	8.86	0.38	1.68e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg06521331	chr12:34319734	NA	-0.48	-8.46	-0.37	3.51e-16	Bladder cancer;
LGG	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg26513180	chr16:89883248	FANCA	0.65	12.13	0.49	1.39e-29	Vitiligo;
LGG	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-10.99	-0.45	3.96e-25	Urinary metabolites;
LGG	trans	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg02900749	chr2:68251473	NA	-1.07	-11.53	-0.47	3.22e-27	Pursuit maintenance gain;
LGG	cis	rs2933343	0.903	rs2638846	chr3:128587163	A/T	cg25356066	chr3:128598488	ACAD9	0.46	6.69	0.3	6.53e-11	IgG glycosylation;
LGG	cis	rs7336332	0.598	rs1885989	chr13:28010117	G/A	cg01674679	chr13:27998804	GTF3A	-0.65	-8.29	-0.36	1.21e-15	Weight;
LGG	trans	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.41	-0.33	6e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg08400814	chr5:56204995	C5orf35	0.41	7.27	0.32	1.51e-12	Initial pursuit acceleration;
LGG	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg24058013	chr18:77568902	NA	-0.45	-7.39	-0.32	7.04e-13	Schizophrenia;
LGG	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.09	0.31	4.92e-12	Schizophrenia;
LGG	cis	rs2718058	0.565	rs2598078	chr7:37864078	G/C	cg24998770	chr7:37888106	TXNDC3	0.45	7.25	0.32	1.72e-12	Alzheimer's disease (late onset);
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg18538332	chr22:24372958	LOC391322	0.44	7.12	0.31	4.16e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1015291	0.635	rs2694979	chr12:20010276	A/G	cg25401612	chr12:20009446	NA	-0.35	-7.31	-0.32	1.22e-12	Diastolic blood pressure;
LGG	cis	rs1010254	0.510	rs56245652	chr5:151762153	A/G	cg12297329	chr5:152029980	NA	-0.5	-7.17	-0.32	3.01e-12	Optic nerve measurement (cup area);
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	9.37	0.4	3.13e-19	Retinal vascular caliber;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.95	-0.38	8.44e-18	Personality dimensions;
LGG	cis	rs6963495	0.818	rs73192149	chr7:105210910	A/G	cg19920283	chr7:105172520	RINT1	0.64	8.37	0.36	6.92e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs7937612	1.000	rs7131597	chr11:120303939	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.81	-0.51	2.21e-32	Intraocular pressure;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18765753	chr7:1198926	ZFAND2A	-0.53	-9.84	-0.42	7.28e-21	Longevity;Endometriosis;
LGG	cis	rs12476592	0.602	rs262478	chr2:63872386	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.94	-0.31	1.37e-11	Childhood ear infection;
LGG	cis	rs295140	1.000	rs12614621	chr2:201171207	G/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.71	-0.75	1.43e-86	Height;
LGG	cis	rs9815354	0.951	rs1619558	chr3:41914213	C/G	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17021463	0.679	rs11097427	chr4:95333201	A/G	cg11021082	chr4:95130006	SMARCAD1	0.5	7.57	0.33	2.02e-13	Testicular germ cell tumor;
LGG	cis	rs13418717	0.793	rs58039373	chr2:127667254	C/T	cg25501666	chr2:127640322	NA	1.06	8.0	0.35	1.02e-14	Heart failure;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg16507663	chr6:150244633	RAET1G	0.49	10.15	0.43	5.22e-22	Testicular germ cell tumor;
LGG	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg08648136	chr8:956695	NA	0.36	7.57	0.33	2.04e-13	Schizophrenia;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19971804	chr2:39102883	MORN2;DHX57	0.39	6.86	0.3	2.25e-11	Obesity-related traits;
LGG	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.1	-0.35	4.95e-15	Myopia (pathological);
LGG	cis	rs9796	0.870	rs11854472	chr15:41357687	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.69	-0.37	6.44e-17	Menopause (age at onset);
LGG	cis	rs3825932	0.736	rs1036939	chr15:79237324	C/A	cg25744700	chr15:79237217	CTSH	0.35	6.81	0.3	3.06e-11	Type 1 diabetes;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.92	-0.31	1.53e-11	Personality dimensions;
LGG	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.49	0.33	3.53e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	11.12	0.46	1.33e-25	Personality dimensions;
LGG	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg06640241	chr16:89574553	SPG7	0.71	12.22	0.49	6.05e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs2742417	0.967	rs1609553	chr3:45735142	T/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24110177	chr3:50126178	RBM5	0.56	10.22	0.43	2.96e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg21466736	chr12:48725269	NA	-0.37	-7.45	-0.33	4.54e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg16662043	chr16:48846231	NA	0.37	7.2	0.32	2.53e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7267979	0.966	rs6037103	chr20:25369095	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg11878867	chr6:150167359	LRP11	-0.4	-8.36	-0.36	7.45e-16	Testicular germ cell tumor;
LGG	cis	rs2916247	0.954	rs7004515	chr8:93119689	G/A	cg10183463	chr8:93005414	RUNX1T1	0.37	7.66	0.34	1.08e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg23815491	chr16:72088622	HP	-0.36	-7.45	-0.33	4.72e-13	Fibrinogen levels;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg05377417	chr17:59940892	BRIP1	-0.43	-7.3	-0.32	1.25e-12	Alzheimer's disease (survival time);
LGG	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg21665744	chr7:39171113	POU6F2	0.38	7.32	0.32	1.1e-12	IgG glycosylation;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg07636037	chr3:49044803	WDR6	0.87	17.05	0.62	5.79e-51	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.49	0.44	3.17e-23	Testicular germ cell tumor;
LGG	trans	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.51	10.19	0.43	3.8e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.62	-0.53	9.33e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg12179176	chr11:130786555	SNX19	0.77	14.9	0.57	2.67e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg14784868	chr12:69753453	YEATS4	0.7	13.13	0.52	1.09e-33	Blood protein levels;
LGG	cis	rs10089	0.953	rs4835940	chr5:127406596	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.4	0.47	1.04e-26	Ileal carcinoids;
LGG	cis	rs2806561	0.695	rs66592286	chr1:23333649	G/C	cg19743168	chr1:23544995	NA	0.36	7.23	0.32	1.95e-12	Height;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	7.77	0.34	5.15e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10048158	0.510	rs3785617	chr17:64219015	T/C	cg19474267	chr17:64306194	PRKCA	-0.58	-10.62	-0.44	9.63e-24	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg02574844	chr11:5959923	NA	-0.54	-8.56	-0.37	1.74e-16	DNA methylation (variation);
LGG	cis	rs4891159	0.757	rs11665518	chr18:74147054	C/T	cg24786174	chr18:74118243	ZNF516	-0.58	-13.58	-0.53	1.4e-35	Longevity;
LGG	cis	rs17030434	0.953	rs10014299	chr4:154700858	A/G	cg14289246	chr4:154710475	SFRP2	-0.76	-11.66	-0.48	9.66e-28	Electrocardiographic conduction measures;
LGG	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg00188032	chr5:96141721	ERAP1	0.53	7.25	0.32	1.81e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02446871	chr1:29241833	EPB41	0.44	7.33	0.32	1.01e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg02959939	chr21:47813025	PCNT	-0.38	-6.96	-0.31	1.16e-11	Lymphocyte counts;
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg10505658	chr17:80084571	CCDC57	0.34	6.77	0.3	3.99e-11	Life satisfaction;
LGG	cis	rs12210905	0.925	rs12193820	chr6:27113811	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.67	-8.14	-0.35	3.57e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7834745	0.501	rs12679857	chr8:119977337	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.3	6.76	0.3	4.11e-11	Eosinophil counts;Sum eosinophil basophil counts;
LGG	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg02151108	chr14:50098012	C14orf104	-0.48	-10.33	-0.43	1.17e-22	Carotid intima media thickness;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg08707078	chr7:23720292	C7orf46	0.39	8.78	0.38	3.08e-17	Schizophrenia;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11245990	chr11:68621969	NA	0.41	8.76	0.38	3.77e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg10253484	chr15:75165896	SCAMP2	-0.5	-8.02	-0.35	8.68e-15	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg01028140	chr2:1542097	TPO	-0.46	-8.52	-0.37	2.34e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.82	-0.34	3.55e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg18446336	chr7:2847575	GNA12	-0.29	-7.31	-0.32	1.22e-12	Height;
LGG	cis	rs7424096	0.555	rs75219072	chr2:37225706	C/T	cg14987922	chr2:37194071	STRN	0.47	6.92	0.31	1.55e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-10.66	-0.44	7.27e-24	Bladder cancer;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.81	-0.45	1.86e-24	Lung cancer;
LGG	trans	rs9354308	0.868	rs9363456	chr6:66548343	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	trans	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg10756647	chr7:56101905	PSPH	0.47	7.01	0.31	8.24e-12	Corneal structure;
LGG	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	trans	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.75	-0.41	1.52e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04008888	chr11:68622739	NA	-0.55	-11.72	-0.48	5.78e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07701084	chr6:150067640	NUP43	0.64	12.11	0.49	1.69e-29	Lung cancer;
LGG	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg16141378	chr3:129829833	LOC729375	0.32	7.28	0.32	1.43e-12	Schizophrenia;
LGG	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg04733989	chr22:42467013	NAGA	0.57	10.18	0.43	4.26e-22	Schizophrenia;
LGG	cis	rs12545109	0.917	rs1370304	chr8:57322822	G/C	cg19413350	chr8:57351067	NA	-0.41	-6.69	-0.3	6.5e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.14	-0.52	9.51e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.11	-0.35	4.72e-15	IgG glycosylation;
LGG	cis	rs509477	0.887	rs595309	chr18:32562402	A/G	cg23791764	chr18:32556832	MAPRE2	0.51	8.21	0.36	2.24e-15	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg12463550	chr7:65579703	CRCP	-0.67	-7.94	-0.35	1.5e-14	Diabetic kidney disease;
LGG	cis	rs55883249	1.000	rs62119422	chr2:9726599	A/G	cg23886495	chr2:9695866	ADAM17	0.65	9.37	0.4	3.28e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg02753203	chr1:228287806	NA	-0.65	-11.95	-0.49	7.16e-29	Diastolic blood pressure;
LGG	trans	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26093954	chr3:50375239	RASSF1	0.5	6.91	0.31	1.65e-11	IgG glycosylation;
LGG	cis	rs11157436	0.602	rs2331594	chr14:22639768	A/G	cg00994629	chr14:22694547	NA	0.33	7.16	0.32	3.25e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09223439	chr15:65282374	SPG21	0.37	6.66	0.3	7.64e-11	Obesity-related traits;
LGG	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.89e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1659258	0.568	rs1258438	chr2:88605767	C/T	cg00685853	chr2:88648947	NA	-0.45	-6.7	-0.3	6.2e-11	Visceral fat;
LGG	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.35e-14	Bone mineral density;
LGG	cis	rs4740619	0.689	rs12379234	chr9:15932372	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.17	-0.43	4.47e-22	Body mass index;
LGG	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.05	-0.46	2.34e-25	Coronary artery disease;
LGG	cis	rs7928758	0.887	rs11822913	chr11:134271645	T/A	cg22777979	chr11:134283252	B3GAT1	0.97	13.06	0.52	2.03e-33	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-9.82	-0.42	8.54e-21	Colorectal cancer;
LGG	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg02389323	chr16:88786976	FAM38A	0.93	12.04	0.49	3.13e-29	Plateletcrit;
LGG	cis	rs6547631	0.594	rs12620113	chr2:85936833	G/T	cg24620635	chr2:85921963	GNLY	0.49	9.79	0.41	1.1e-20	Blood protein levels;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.84e-14	Height;
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg02158880	chr13:53174818	NA	0.43	8.56	0.37	1.7e-16	Lewy body disease;
LGG	cis	rs7255436	0.965	rs7351098	chr19:8451671	G/C	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.74	-0.3	4.67e-11	HDL cholesterol;
LGG	cis	rs6537837	1.000	rs7355157	chr1:110129835	T/C	cg05049280	chr1:110155535	GNAT2	0.35	7.2	0.32	2.47e-12	Major depressive disorder;
LGG	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg12395012	chr8:11607386	GATA4	0.38	7.11	0.31	4.37e-12	Monocyte count;
LGG	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg13482628	chr17:19912719	NA	-0.54	-10.11	-0.43	7.34e-22	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10185519	chr16:30621987	ZNF689	-0.4	-6.65	-0.3	8.06e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7551222	0.752	rs11240755	chr1:204478649	C/T	cg20240347	chr1:204465584	NA	-0.56	-11.14	-0.46	1.07e-25	Schizophrenia;
LGG	cis	rs13033859	0.526	rs6548221	chr2:295255	C/T	cg04617936	chr2:214353	NA	0.44	7.18	0.32	2.74e-12	Mitochondrial DNA levels;
LGG	cis	rs864537	0.646	rs1723018	chr1:167433420	A/G	cg09179987	chr1:167433047	CD247	0.45	10.42	0.44	5.68e-23	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.02	0.42	1.55e-21	Neutrophil percentage of white cells;
LGG	trans	rs12339094	0.872	rs7022221	chr9:90405089	C/T	cg24436365	chr6:63940138	NA	0.41	6.84	0.3	2.49e-11	Smoking quantity;
LGG	trans	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.65	-0.33	1.19e-13	Heart rate;
LGG	cis	rs11971779	0.680	rs2355785	chr7:139070983	C/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.72	0.51	5.44e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.65	-0.3	8.07e-11	Resting heart rate;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.55	0.5	2.59e-31	Total body bone mineral density;
LGG	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg23740940	chr11:68924746	NA	0.43	6.93	0.31	1.44e-11	Blond vs. brown hair color;
LGG	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	6.84e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	9.06	0.39	3.7e-18	Thyroid stimulating hormone;
LGG	trans	rs9409565	0.717	rs61470662	chr9:97189472	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-8.13	-0.35	3.98e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs1620921	0.901	rs783182	chr6:161168548	G/A	cg01280913	chr6:161186852	NA	-0.35	-7.33	-0.32	1.06e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1497828	0.956	rs2646824	chr1:217537766	C/G	cg04411442	chr1:217543379	NA	-0.47	-8.07	-0.35	6.1e-15	Dialysis-related mortality;
LGG	cis	rs7503807	0.515	rs12946217	chr17:78686566	C/A	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs1018836	0.608	rs10094978	chr8:91509054	C/T	cg16814680	chr8:91681699	NA	-0.6	-9.97	-0.42	2.36e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs17001868	0.568	rs760700	chr22:40800071	C/T	cg07138101	chr22:40742427	ADSL	-0.64	-8.49	-0.37	2.77e-16	Mammographic density (dense area);
LGG	cis	rs4819388	0.668	rs7276227	chr21:45641702	C/T	cg01992765	chr21:45622493	NA	0.46	8.86	0.38	1.77e-17	Celiac disease;
LGG	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	trans	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg02002194	chr4:3960332	NA	0.38	6.97	0.31	1.08e-11	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27338695	chr8:41435702	AGPAT6	0.47	6.94	0.31	1.34e-11	Hip circumference;
LGG	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-12.35	-0.5	1.71e-30	Monocyte percentage of white cells;
LGG	cis	rs7508	0.694	rs2410446	chr8:17923142	G/A	cg18067069	chr8:17937731	ASAH1	-0.38	-8.8	-0.38	2.78e-17	Atrial fibrillation;
LGG	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg25019033	chr10:957182	NA	-0.55	-10.17	-0.43	4.47e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg03762349	chr15:79060523	ADAMTS7	0.32	7.05	0.31	6.71e-12	Sudden cardiac arrest;
LGG	cis	rs72772090	0.710	rs11750399	chr5:96077940	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-8.16	-0.35	3.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg27205649	chr11:78285834	NARS2	0.43	7.1	0.31	4.78e-12	Testicular germ cell tumor;
LGG	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg20628663	chr10:43360327	NA	0.38	7.54	0.33	2.52e-13	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10835914	chr14:73493957	ZFYVE1	0.46	6.7	0.3	6.19e-11	Gut microbiome composition (summer);
LGG	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg03254818	chr6:169586852	NA	0.63	9.24	0.39	8.66e-19	Pulse pressure;
LGG	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg19628046	chr18:33552617	C18orf21	0.51	7.06	0.31	6.12e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs3824344	0.545	rs6476606	chr9:37005561	A/G	cg14294708	chr9:37120828	ZCCHC7	0.41	6.66	0.3	7.73e-11	Intelligence;
LGG	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg09754948	chr16:28834200	ATXN2L	0.47	7.35	0.32	9.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9354308	0.764	rs1938112	chr6:66567508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.45e-21	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.69	-0.37	6.25e-17	Menopause (age at onset);
LGG	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg06718696	chr17:78121285	EIF4A3	-0.44	-7.45	-0.33	4.71e-13	Yeast infection;
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs1927790	0.727	rs7996549	chr13:96975175	T/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.98	-0.31	1.05e-11	Body mass index;
LGG	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg21452805	chr1:244014465	NA	-0.69	-8.44	-0.37	3.95e-16	RR interval (heart rate);
LGG	cis	rs28374715	0.662	rs72737793	chr15:41516823	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-17.9	-0.64	7.55e-55	Ulcerative colitis;
LGG	trans	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg07211511	chr3:129823064	LOC729375	-1.36	-20.68	-0.69	9.28e-68	Blood pressure (smoking interaction);
LGG	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg24623649	chr8:11872141	NA	0.32	7.48	0.33	3.88e-13	Monocyte count;
LGG	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg13907859	chr11:120009124	TRIM29	-0.51	-9.31	-0.4	4.96e-19	Stroke (pediatric);
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg03806693	chr22:41940476	POLR3H	1.04	17.73	0.64	4.63e-54	Vitiligo;
LGG	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg02711726	chr17:80685570	FN3KRP	0.66	13.53	0.53	2.14e-35	Glycated hemoglobin levels;
LGG	trans	rs1032833	0.732	rs4499457	chr2:180003076	T/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg27446573	chr6:127587934	RNF146	0.93	17.54	0.63	3.54e-53	Breast cancer;
LGG	cis	rs9398803	0.698	rs1262550	chr6:127078110	A/C	cg19875578	chr6:126661172	C6orf173	-0.49	-9.03	-0.39	4.58e-18	Male-pattern baldness;
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-0.67	-9.21	-0.39	1.12e-18	Lung function (FEV1/FVC);
LGG	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.96	-0.42	2.58e-21	Lung cancer;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.28	0.43	1.83e-22	Retinal vascular caliber;
LGG	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.85	-12.61	-0.51	1.53e-31	Iron status biomarkers;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg16797656	chr11:68205561	LRP5	0.38	6.8	0.3	3.3e-11	Total body bone mineral density;
LGG	cis	rs11785693	0.862	rs11786186	chr8:4999059	G/C	cg26367366	chr8:4980734	NA	1.0	15.18	0.58	1.58e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.64	0.69	1.4e-67	Alzheimer's disease;
LGG	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.46e-18	Corneal astigmatism;
LGG	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg24450063	chr1:156163899	SLC25A44	1.09	19.02	0.66	4.95e-60	Testicular germ cell tumor;
LGG	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18876405	chr7:65276391	NA	0.49	8.82	0.38	2.41e-17	Aortic root size;
LGG	cis	rs6800768	0.663	rs59911620	chr3:24092004	G/C	cg10674438	chr3:24145617	LOC152024	-0.48	-8.71	-0.38	5.36e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg13565492	chr6:43139072	SRF	-0.6	-7.73	-0.34	6.61e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg05985134	chr18:33552581	C18orf21	0.65	10.17	0.43	4.42e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06873352	chr17:61820015	STRADA	-0.68	-12.46	-0.5	6.44e-31	Prudent dietary pattern;
LGG	cis	rs2798269	0.902	rs718426	chr13:22085659	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.85	-0.3	2.43e-11	PR segment;
LGG	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.69	-0.59	8.61e-45	Gallbladder cancer;
LGG	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg11757124	chr7:157526947	PTPRN2	-0.51	-9.34	-0.4	4.12e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg02048412	chr16:4421654	VASN;CORO7	0.28	6.84	0.3	2.46e-11	Schizophrenia;
LGG	cis	rs9549260	0.755	rs7328677	chr13:41229905	A/G	cg21288729	chr13:41239152	FOXO1	0.33	6.68	0.3	6.7e-11	Red blood cell count;
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg03806693	chr22:41940476	POLR3H	-1.13	-20.22	-0.68	1.27e-65	Vitiligo;
LGG	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg16230307	chr14:35515116	FAM177A1	0.4	7.18	0.32	2.84e-12	Psoriasis;
LGG	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg09696939	chr10:60272079	BICC1	0.37	7.27	0.32	1.56e-12	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03079549	chr15:45879223	PLDN	0.47	6.97	0.31	1.12e-11	Gut microbiome composition (summer);
LGG	cis	rs7917772	0.582	rs10786696	chr10:104378134	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.63	0.48	1.37e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7241530	0.610	rs61530283	chr18:75891789	A/G	cg14642773	chr18:75888474	NA	0.47	9.04	0.39	4.43e-18	Educational attainment (years of education);
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-10.34	-0.43	1.12e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.89	-0.31	1.8e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg23758822	chr17:41437982	NA	0.9	15.9	0.59	1e-45	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg26513180	chr16:89883248	FANCA	1.0	9.64	0.41	3.56e-20	Skin colour saturation;
LGG	cis	rs7737355	0.812	rs10040442	chr5:130753077	C/G	cg06307176	chr5:131281290	NA	-0.52	-8.88	-0.38	1.48e-17	Life satisfaction;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg03188948	chr7:1209495	NA	0.41	7.13	0.31	3.8e-12	Longevity;Endometriosis;
LGG	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg06026331	chr20:60912101	LAMA5	0.77	13.85	0.54	9.78e-37	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg23939001	chr4:940644	TMEM175	0.68	16.41	0.61	5e-48	Sjögren's syndrome;
LGG	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg09165964	chr15:75287851	SCAMP5	0.56	10.61	0.44	1.13e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg10760299	chr15:45669010	GATM	0.41	8.05	0.35	7.26e-15	Homoarginine levels;
LGG	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs10463554	0.926	rs26429	chr5:102366053	C/T	cg23492399	chr5:102201601	PAM	0.46	6.91	0.31	1.6e-11	Parkinson's disease;
LGG	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg21435375	chr2:172878103	MAP1D	-0.31	-6.9	-0.31	1.7e-11	Schizophrenia;
LGG	cis	rs11229555	0.609	rs7927730	chr11:58187906	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.45	-0.58	9.75e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.32	0.32	1.07e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	10.11	0.43	7.81e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg17133734	chr15:86042851	AKAP13	-0.28	-6.79	-0.3	3.39e-11	Coronary artery disease;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.21	-0.32	2.28e-12	Bipolar disorder;
LGG	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.22e-13	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04884122	chr14:23504085	PSMB5	0.53	7.85	0.34	2.95e-14	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.8	-16.31	-0.6	1.39e-47	Personality dimensions;
LGG	cis	rs921968	0.643	rs3932856	chr2:219320207	C/A	cg02985541	chr2:219472218	PLCD4	0.29	6.9	0.31	1.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7226408	0.857	rs3747896	chr18:34647323	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.14	-0.31	3.71e-12	Obesity-related traits;
LGG	cis	rs4851266	0.898	rs13026143	chr2:100865406	A/G	cg21926883	chr2:100939477	LONRF2	0.46	8.37	0.36	7.13e-16	Educational attainment;
LGG	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg07148914	chr20:33460835	GGT7	0.45	7.13	0.31	3.9e-12	Height;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-18.78	-0.66	6.71e-59	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg11890956	chr21:40555474	PSMG1	-0.71	-12.07	-0.49	2.31e-29	Menarche (age at onset);
LGG	cis	rs2742540	0.505	rs2742493	chr11:8967592	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.53	11.29	0.46	2.75e-26	Hematocrit;
LGG	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg08717414	chr16:71523259	ZNF19	-0.53	-8.38	-0.36	6.2e-16	Blood protein levels;
LGG	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	18.41	0.65	3.26e-57	Smoking behavior;
LGG	cis	rs8064024	0.599	rs3185547	chr16:4931100	A/C	cg08329684	chr16:4932620	PPL	0.49	10.07	0.42	1.08e-21	Cancer;
LGG	cis	rs17604090	1.000	rs28591682	chr7:29690811	T/C	cg19413766	chr7:29689036	LOC646762	-0.58	-7.13	-0.31	3.92e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg25706552	chr1:244017396	NA	0.53	8.61	0.37	1.18e-16	RR interval (heart rate);
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.7	-12.54	-0.5	2.87e-31	Obesity-related traits;
LGG	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg27490568	chr2:178487706	NA	0.5	9.99	0.42	2e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	9.22	0.39	1.09e-18	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04887335	chr3:196044632	TCTEX1D2	0.44	7.25	0.32	1.78e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-9.9	-0.42	4.24e-21	Platelet distribution width;
LGG	cis	rs2976388	1.000	rs2920295	chr8:143764937	A/G	cg06565975	chr8:143823917	SLURP1	-0.41	-10.36	-0.43	9.07e-23	Urinary tract infection frequency;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.3e-17	Schizophrenia;
LGG	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	11.33	0.47	2e-26	Lung cancer in ever smokers;
LGG	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg18032289	chr17:61959525	GH2	-0.4	-6.97	-0.31	1.1e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs834603	0.575	rs2462638	chr7:47471286	A/G	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.87e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs911555	0.723	rs6575991	chr14:103908433	C/T	cg24130564	chr14:104152367	KLC1	0.37	7.04	0.31	7.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10262624	1.000	rs10950975	chr7:23917480	G/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg12458913	chr13:53173898	NA	0.63	12.28	0.5	3.4e-30	Lewy body disease;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg02127607	chr17:61920694	SMARCD2	0.46	8.32	0.36	1.02e-15	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	6.13e-37	Prudent dietary pattern;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07876051	chr10:3159145	PFKP	0.34	7.37	0.32	8.11e-13	Electrocardiographic conduction measures;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03264133	chr6:25882463	NA	-0.4	-6.93	-0.31	1.45e-11	Height;
LGG	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg02524346	chr8:600233	NA	1.35	12.69	0.51	7.01e-32	IgG glycosylation;
LGG	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.32	-0.32	1.08e-12	Fear of minor pain;
LGG	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg15596359	chr8:11213517	TDH	-0.35	-7.35	-0.32	8.87e-13	Retinal vascular caliber;
LGG	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.23e-20	Diabetic retinopathy;
LGG	cis	rs887829	0.570	rs13015720	chr2:234600999	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.94	-0.35	1.51e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.83	-0.3	2.69e-11	Aortic root size;
LGG	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.37	0.32	7.93e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs528418	0.540	rs6908878	chr6:145704346	A/G	cg03642472	chr6:145670687	NA	0.57	7.63	0.33	1.32e-13	Methadone dose in opioid dependence;
LGG	cis	rs2463822	1.000	rs2513071	chr11:62098387	A/C	cg06239285	chr11:62104954	ASRGL1	1.16	16.25	0.6	2.59e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs4771450	0.925	rs4587822	chr13:103970458	C/A	cg02987523	chr13:103978230	NA	-0.32	-6.84	-0.3	2.54e-11	Uric acid levels;
LGG	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.59	-0.33	1.72e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs1555322	1.000	rs2425032	chr20:33855454	T/C	cg17927777	chr20:33865990	NA	0.68	7.65	0.33	1.21e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs4148883	0.689	rs2602861	chr4:100030896	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.66	0.37	8.19e-17	Alcohol dependence;
LGG	cis	rs2880765	0.525	rs2062234	chr15:86054490	A/G	cg10818794	chr15:86012489	AKAP13	-0.45	-9.4	-0.4	2.57e-19	Coronary artery disease;
LGG	cis	rs11864453	0.682	rs10852509	chr16:72026010	G/A	cg01557791	chr16:72042693	DHODH	-0.4	-6.82	-0.3	2.87e-11	Fibrinogen levels;
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.91e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	cg15522984	chr1:182991683	LAMC1	0.46	8.94	0.38	9.13e-18	Colorectal cancer;
LGG	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00761968	chr13:53314142	LECT1	0.44	9.69	0.41	2.41e-20	Lewy body disease;
LGG	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg09165964	chr15:75287851	SCAMP5	-0.54	-10.04	-0.42	1.38e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7666738	0.791	rs6851549	chr4:99029827	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs12431410	0.892	rs1952035	chr14:60164101	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.12	0.31	4.06e-12	Schizophrenia;
LGG	cis	rs4891159	0.790	rs8085133	chr18:74144083	A/C	cg24786174	chr18:74118243	ZNF516	-0.63	-15.24	-0.58	8.81e-43	Longevity;
LGG	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-27.12	-0.78	1.12e-97	Height;
LGG	cis	rs17102423	0.661	rs11627540	chr14:65614892	C/T	cg11161011	chr14:65562177	MAX	-0.74	-13.02	-0.52	3.12e-33	Obesity-related traits;
LGG	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg03078520	chr22:18463400	MICAL3	-0.63	-12.26	-0.49	4.2000000000000004e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs4731207	0.591	rs1481336	chr7:124696739	G/C	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.75	-0.3	4.47e-11	Neuroticism;
LGG	cis	rs2797160	1.000	rs6904992	chr6:126016003	G/A	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs11800820	0.557	rs55881259	chr1:246665951	C/T	cg16700716	chr1:246684329	NA	0.43	7.71	0.34	7.8500000000000006e-14	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg18926786	chr6:150244388	RAET1G	0.32	6.82	0.3	2.9e-11	Testicular germ cell tumor;
LGG	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-10.01	-0.42	1.71e-21	Hip circumference adjusted for BMI;
LGG	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.9	0.45	8.59e-25	Aortic root size;
LGG	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg17202724	chr17:61916730	SMARCD2	0.43	8.51	0.37	2.44e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg21699342	chr2:239360505	ASB1	0.39	7.53	0.33	2.65e-13	Multiple system atrophy;
LGG	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.25	0.43	2.38e-22	Diabetic retinopathy;
LGG	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg08999081	chr20:33150536	PIGU	-0.4	-10.04	-0.42	1.38e-21	Glomerular filtration rate (creatinine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01301138	chr16:82660630	CDH13	0.41	6.68	0.3	6.87e-11	Cognitive performance;
LGG	cis	rs7937612	1.000	rs10790382	chr11:120288372	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.02	-0.52	3.06e-33	Intraocular pressure;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg18538332	chr22:24372958	LOC391322	-0.43	-7.06	-0.31	6.26e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg16141378	chr3:129829833	LOC729375	-0.52	-13.13	-0.52	1.05e-33	Mood instability;
LGG	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-15.58	-0.59	2.65e-44	Intelligence (multi-trait analysis);
LGG	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg12395012	chr8:11607386	GATA4	0.41	7.31	0.32	1.2e-12	Monocyte count;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6466055	0.777	rs2240463	chr7:104844328	C/T	cg04380332	chr7:105027541	SRPK2	-0.37	-6.94	-0.31	1.3e-11	Schizophrenia;
LGG	trans	rs2270927	0.510	rs35984318	chr5:75573566	T/G	cg13563193	chr19:33072644	PDCD5	0.82	9.92	0.42	3.56e-21	Mean corpuscular volume;
LGG	cis	rs3735485	0.800	rs1315920	chr7:45080933	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.38	0.4	3.03e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9902453	0.933	rs7216487	chr17:28502642	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.72	0.51	5.16e-32	Coffee consumption (cups per day);
LGG	cis	rs6942756	0.774	rs2694574	chr7:128908963	A/G	cg02491457	chr7:128862824	NA	0.65	12.16	0.49	1.01e-29	White matter hyperintensity burden;
LGG	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg13770153	chr20:60521292	NA	-0.54	-8.49	-0.37	2.89e-16	Body mass index;
LGG	cis	rs209489	1.000	rs209521	chr6:53210355	A/G	cg15607103	chr6:53167650	ELOVL5	-0.52	-7.44	-0.33	5.08e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.37	0.4	3.12e-19	Alzheimer's disease;
LGG	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg02073558	chr3:44770973	ZNF501	0.86	19.14	0.66	1.43e-60	Depressive symptoms;
LGG	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.35	0.63	2.56e-52	Refractive error;
LGG	cis	rs975722	0.967	rs1208524	chr7:117334852	C/T	cg10524701	chr7:117356490	CTTNBP2	0.51	11.59	0.47	1.97e-27	Coronary artery disease;
LGG	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg27398817	chr8:82754497	SNX16	-0.71	-10.94	-0.45	6.39e-25	Diastolic blood pressure;
LGG	cis	rs4740619	0.870	rs11562188	chr9:15857072	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.1	-0.43	7.99e-22	Body mass index;
LGG	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg19507638	chr5:93509721	C5orf36	-0.72	-10.01	-0.42	1.71e-21	Diabetic retinopathy;
LGG	cis	rs7945718	0.591	rs4489724	chr11:12684166	G/T	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs7193541	0.640	rs4072222	chr16:74706736	A/C	cg01733217	chr16:74700730	RFWD3	1.08	32.26	0.83	1.72e-120	Multiple myeloma;
LGG	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.84e-40	Cognitive test performance;
LGG	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.79e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10335543	chr14:102829157	TECPR2;CINP	-0.45	-6.9	-0.31	1.66e-11	Pancreatic cancer;
LGG	cis	rs4006360	0.628	rs6416911	chr17:39253311	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-10.96	-0.45	5.27e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2916247	0.908	rs2339457	chr8:93103628	A/G	cg10183463	chr8:93005414	RUNX1T1	0.39	7.85	0.34	2.98e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7402982	0.934	rs6598539	chr15:99204483	T/C	cg03437748	chr15:99193247	IGF1R	0.92	19.62	0.67	7.83e-63	Birth weight;
LGG	cis	rs7567389	0.502	rs2069919	chr2:128179553	G/A	cg10021288	chr2:128175891	PROC	0.39	6.94	0.31	1.3e-11	Self-rated health;
LGG	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg24675658	chr1:53192096	ZYG11B	0.5	10.26	0.43	2.18e-22	Monocyte count;
LGG	cis	rs7766436	0.848	rs16901663	chr6:22598054	T/C	cg13666174	chr6:22585274	NA	-0.51	-11.61	-0.47	1.52e-27	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg05941027	chr17:61774174	LIMD2	0.34	8.53	0.37	2.05e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06634786	chr22:41940651	POLR3H	0.68	10.97	0.45	4.81e-25	Vitiligo;
LGG	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg27422857	chr2:105853526	NA	-0.38	-6.98	-0.31	1.03e-11	Type 2 diabetes;
LGG	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.34	0.32	9.84e-13	Retinal vascular caliber;
LGG	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.95e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg02811702	chr13:24901961	NA	0.39	7.35	0.32	9.22e-13	Obesity-related traits;
LGG	cis	rs3820068	0.608	rs12091326	chr1:16048005	A/G	cg05660106	chr1:15850417	CASP9	0.75	13.81	0.54	1.36e-36	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06045225	chr5:65892993	MAST4	0.42	7.11	0.31	4.36e-12	Cognitive performance;
LGG	cis	rs9902453	0.836	rs62070337	chr17:28466257	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.59	0.53	1.2e-35	Coffee consumption (cups per day);
LGG	cis	rs28588043	0.877	rs72710573	chr1:170987674	A/G	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg21366198	chr4:185655624	MLF1IP	-0.43	-7.6	-0.33	1.65e-13	Kawasaki disease;
LGG	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	7.7	0.34	8.4e-14	Schizophrenia;
LGG	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.13	0.39	2.07e-18	Resting heart rate;
LGG	cis	rs9393777	0.513	rs9295702	chr6:26634040	T/C	cg12826209	chr6:26865740	GUSBL1	0.82	12.12	0.49	1.53e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg04369109	chr6:150039330	LATS1	-0.4	-6.72	-0.3	5.24e-11	Lung cancer;
LGG	cis	rs7558370	0.737	rs112914737	chr2:3713431	G/A	cg16123090	chr2:3699210	NA	0.81	7.61	0.33	1.54e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4731207	0.564	rs10270051	chr7:124649393	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-7.34	-0.32	1e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg10204951	chr7:910479	UNC84A	0.49	6.64	0.3	8.59e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg26384229	chr12:38710491	ALG10B	0.78	16.04	0.6	2.38e-46	Heart rate;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.53	0.37	2.14e-16	Lung cancer;
LGG	cis	rs6062302	0.534	rs1556456	chr20:62216289	T/C	cg16989086	chr20:62203971	PRIC285	0.48	6.99	0.31	9.53e-12	Glioblastoma;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg06916706	chr16:4465613	CORO7	-0.84	-15.42	-0.58	1.3e-43	Schizophrenia;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27144592	chr16:783916	NARFL	0.4	6.7	0.3	6.16e-11	Height;
LGG	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg04287289	chr16:89883240	FANCA	0.54	9.84	0.42	7.13e-21	Vitiligo;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.65	0.34	1.16e-13	Lung cancer;
LGG	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.54e-68	Diabetic kidney disease;
LGG	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg07936489	chr17:37558343	FBXL20	-0.98	-15.17	-0.58	1.66e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg05623727	chr3:50126028	RBM5	0.36	7.67	0.34	1e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs2282970	chr7:91584281	A/G	cg17063962	chr7:91808500	NA	0.49	8.75	0.38	4.09e-17	Breast cancer;
LGG	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg15212455	chr7:39170539	POU6F2	0.41	9.34	0.4	3.97e-19	IgG glycosylation;
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs67385638	0.962	rs2071348	chr11:5264146	T/G	cg12559170	chr11:5275217	HBG2	0.57	12.74	0.51	4.32e-32	Hemoglobin levels;
LGG	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.51	0.44	2.52e-23	Iron status biomarkers;
LGG	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg08250081	chr4:10125330	NA	-0.36	-6.93	-0.31	1.38e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1506636	1.000	rs656425	chr7:123424525	A/C	cg03229431	chr7:123269106	ASB15	0.73	17.88	0.64	9.97e-55	Plateletcrit;Platelet count;
LGG	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg24611264	chr11:120008944	TRIM29	-0.37	-9.4	-0.4	2.56e-19	Stroke (pediatric);
LGG	cis	rs13314892	0.692	rs62252239	chr3:69893971	G/T	cg17445875	chr3:69859618	MITF	-0.41	-7.9	-0.34	2.07e-14	QRS complex (12-leadsum);
LGG	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Myopia (pathological);
LGG	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg22044901	chr15:68126292	NA	-0.41	-6.84	-0.3	2.58e-11	Restless legs syndrome;
LGG	cis	rs6860806	0.507	rs582490	chr5:131710095	G/A	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Breast cancer;
LGG	cis	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	7.53	0.33	2.76e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.55	0.37	1.74e-16	Lung cancer;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.14e-36	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03180980	chr15:83240633	CPEB1	0.47	7.54	0.33	2.51e-13	Gut microbiome composition (summer);
LGG	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg11247378	chr22:39784982	NA	-0.31	-8.64	-0.37	8.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.09	-0.39	2.92e-18	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18342900	chr16:46865048	C16orf87	0.45	6.98	0.31	1.02e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08094291	chr1:44883137	RNF220	0.41	6.74	0.3	4.74e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25072359	chr17:41440525	NA	0.5	9.91	0.42	4.17e-21	Menopause (age at onset);
LGG	cis	rs11920090	0.800	rs6800180	chr3:170747810	A/G	cg09710316	chr3:170744871	SLC2A2	0.64	8.37	0.36	7e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg18350739	chr11:68623251	NA	-0.87	-22.82	-0.73	8.7e-78	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09650667	chr3:139108740	COPB2	0.41	7.11	0.31	4.34e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg02023728	chr11:77925099	USP35	0.46	7.84	0.34	3.11e-14	Testicular germ cell tumor;
LGG	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg08727972	chr1:148025634	NBPF14	-0.38	-7.04	-0.31	6.85e-12	Hip geometry;
LGG	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-7.96	-0.35	1.38e-14	Self-reported allergy;
LGG	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg10122326	chr6:28072925	NA	0.95	7.19	0.32	2.58e-12	Hip circumference adjusted for BMI;
LGG	trans	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg07211511	chr3:129823064	LOC729375	-1.3	-16.0	-0.6	3.37e-46	Blood pressure (smoking interaction);
LGG	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg15704280	chr7:45808275	SEPT13	0.87	9.09	0.39	2.83e-18	Myopia (pathological);
LGG	cis	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg24375607	chr4:120327624	NA	0.68	11.22	0.46	5.27e-26	Corneal astigmatism;
LGG	cis	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg25986240	chr4:9926439	SLC2A9	-0.52	-9.95	-0.42	2.81e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs11025559	0.812	rs10833336	chr11:20514288	C/G	cg19653624	chr11:20408972	PRMT3	-0.5	-8.44	-0.37	3.96e-16	Pursuit maintenance gain;
LGG	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11890956	chr21:40555474	PSMG1	-0.99	-21.57	-0.71	6.28e-72	Cognitive function;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.67	13.3	0.53	2.16e-34	Obesity-related traits;
LGG	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs10489202	1.000	rs66950781	chr1:168018779	C/A	cg24449463	chr1:168025552	DCAF6	-0.62	-10.17	-0.43	4.45e-22	Schizophrenia;
LGG	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.03	-21.86	-0.71	2.62e-73	Homoarginine levels;
LGG	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg21605333	chr4:119757512	SEC24D	1.44	14.86	0.57	4.02e-41	Cannabis dependence symptom count;
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	10.92	0.45	7.53e-25	Bipolar disorder;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-10.01	-0.42	1.78e-21	Platelet count;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg08888203	chr3:10149979	C3orf24	0.58	9.63	0.41	4.03e-20	Alzheimer's disease;
LGG	trans	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.56	-0.41	7.1e-20	Bladder cancer;
LGG	cis	rs2133450	0.780	rs13082785	chr3:7358711	G/A	cg19930620	chr3:7340148	GRM7	-0.37	-7.9	-0.34	2.06e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.81	0.3	3.05e-11	Longevity;
LGG	cis	rs8048589	0.603	rs2457193	chr16:12178797	C/T	cg02910054	chr16:12241554	SNX29	0.42	7.2	0.32	2.42e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs11874712	1.000	rs28504655	chr18:43665348	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	trans	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.74e-12	Morning vs. evening chronotype;
LGG	cis	rs754466	0.874	rs55910200	chr10:79665173	T/C	cg17075019	chr10:79541650	NA	-0.81	-13.69	-0.54	4.82e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6815814	0.950	rs5743557	chr4:38806827	G/A	cg06935464	chr4:38784597	TLR10	0.61	8.29	0.36	1.22e-15	Breast cancer;
LGG	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg26441486	chr22:50317300	CRELD2	0.42	7.5	0.33	3.29e-13	Schizophrenia;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg23102388	chr7:1867652	MAD1L1	-0.36	-6.89	-0.3	1.82e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg23815491	chr16:72088622	HP	0.51	9.46	0.4	1.54e-19	Blood protein levels;
LGG	cis	rs9487051	0.768	rs427960	chr6:109524939	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.18	-0.32	2.77e-12	Reticulocyte fraction of red cells;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05025164	chr4:1340916	KIAA1530	0.65	12.17	0.49	9.31e-30	Longevity;
LGG	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26687661	chr11:121526609	NA	0.54	8.15	0.35	3.33e-15	Gut microbiome composition (summer);
LGG	cis	rs2236293	0.755	rs10758324	chr9:35799078	C/G	cg12876594	chr9:35791798	NPR2	0.43	8.24	0.36	1.8e-15	Blood protein levels;
LGG	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg02153584	chr22:29168773	CCDC117	0.6	9.52	0.4	9.55e-20	Lymphocyte counts;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.3	0.36	1.13e-15	Platelet count;
LGG	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg13010199	chr12:38710504	ALG10B	0.77	15.63	0.59	1.52e-44	Heart rate;
LGG	cis	rs10050311	0.698	rs10516778	chr4:87636051	G/A	cg11209507	chr4:87813803	C4orf36	0.51	6.72	0.3	5.41e-11	Insulin-related traits;
LGG	cis	rs9815354	0.680	rs75308766	chr3:42031894	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg00204512	chr16:28754710	NA	0.26	7.19	0.32	2.7e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11712217	chr17:80455631	NA	0.47	7.52	0.33	2.82e-13	Cognitive performance;
LGG	cis	rs60180747	1.000	rs59718328	chr15:66662620	A/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.54	9.68	0.41	2.75e-20	Testicular germ cell tumor;
LGG	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg11812906	chr14:75593930	NEK9	0.52	9.76	0.41	1.4e-20	Height;
LGG	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.47	-0.37	3.21e-16	Blood metabolite levels;
LGG	cis	rs17253792	0.915	rs75296402	chr14:56182491	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-9.98	-0.42	2.16e-21	Putamen volume;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.24	0.36	1.79e-15	Lung cancer;
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg22903471	chr2:27725779	GCKR	-0.54	-12.57	-0.5	2.12e-31	Total body bone mineral density;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12887734	0.524	rs4900599	chr14:104283444	G/T	cg26031613	chr14:104095156	KLC1	-0.56	-8.84	-0.38	2.01e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg02002194	chr4:3960332	NA	0.43	7.56	0.33	2.21e-13	Neuroticism;
LGG	cis	rs883565	0.740	rs11708354	chr3:39115626	A/T	cg01426195	chr3:39028469	NA	-0.7	-15.93	-0.6	6.94e-46	Handedness;
LGG	cis	rs6908034	0.769	rs6916589	chr6:19761363	T/G	cg02682789	chr6:19804855	NA	0.83	8.97	0.38	7.31e-18	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6963495	0.818	rs55922564	chr7:105155890	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.04	-0.46	2.62e-25	Neuroticism;
LGG	cis	rs7226408	0.817	rs55766643	chr18:34448069	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.16e-44	Lung cancer;
LGG	cis	rs8062405	0.755	rs62034350	chr16:28562256	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.83	0.38	2.25e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	trans	rs931812	0.895	rs4734013	chr8:101908687	A/C	cg20993868	chr7:22813445	NA	0.71	13.55	0.53	1.75e-35	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2643217	0.953	rs2643214	chr15:39004866	A/C	cg10631289	chr15:39006617	NA	-0.43	-7.41	-0.33	5.94e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	14.19	0.55	3.21e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.85	-0.3	2.36e-11	Iron status biomarkers;
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg13628971	chr7:2884303	GNA12	0.55	11.43	0.47	7.96e-27	Height;
LGG	cis	rs79839061	0.610	rs62297087	chr4:913289	T/A	cg07828340	chr4:882639	GAK	0.92	9.69	0.41	2.45e-20	Intelligence (multi-trait analysis);
LGG	cis	rs34734847	1.000	rs10431385	chr12:121128882	T/C	cg21892295	chr12:121157589	UNC119B	-0.45	-8.56	-0.37	1.72e-16	Mean corpuscular volume;
LGG	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.64	-0.41	3.55e-20	Blood protein levels;
LGG	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg08807101	chr21:30365312	RNF160	0.57	9.12	0.39	2.39e-18	Pancreatic cancer;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg01238044	chr22:24384105	GSTT1	0.41	6.93	0.31	1.46e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9341808	0.718	rs2874829	chr6:80856097	A/G	cg08355045	chr6:80787529	NA	0.41	7.97	0.35	1.26e-14	Sitting height ratio;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.21	0.32	2.27e-12	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg04503457	chr17:41445688	NA	-0.37	-8.59	-0.37	1.29e-16	Menopause (age at onset);
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22168489	chr12:122356033	WDR66	-0.41	-9.72	-0.41	1.84e-20	Mean corpuscular volume;
LGG	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg22432760	chr17:80829718	TBCD	0.41	7.03	0.31	7.28e-12	Breast cancer;
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg05941027	chr17:61774174	LIMD2	0.35	8.8	0.38	2.74e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs504918	0.588	rs1444761	chr3:123974876	G/A	cg05766129	chr3:123988013	KALRN	-0.59	-10.46	-0.44	4.12e-23	Schizophrenia;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg07869994	chr3:174095190	NA	0.42	7.64	0.33	1.3e-13	Parkinson's disease (motor and cognition);
LGG	cis	rs7412746	0.611	rs72704679	chr1:150897477	C/T	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Melanoma;
LGG	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg02820901	chr13:113351484	ATP11A	0.54	6.69	0.3	6.5e-11	Glycated hemoglobin levels;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg10505658	chr17:80084571	CCDC57	0.41	8.44	0.36	4.24e-16	Life satisfaction;
LGG	trans	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05025164	chr4:1340916	KIAA1530	-0.49	-8.34	-0.36	8.6e-16	Obesity-related traits;
LGG	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg27398817	chr8:82754497	SNX16	-0.73	-10.72	-0.45	4.19e-24	Diastolic blood pressure;
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08704250	chr15:31115839	NA	0.49	8.83	0.38	2.11e-17	Huntington's disease progression;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.08	0.66	2.51e-60	Platelet count;
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.14	-0.31	3.64e-12	Life satisfaction;
LGG	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg03929089	chr4:120376271	NA	0.86	17.37	0.63	2.07e-52	Coronary artery disease;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-14.06	-0.55	1.19e-37	Platelet count;
LGG	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg17644776	chr2:200775616	C2orf69	0.72	13.04	0.52	2.5e-33	Osteoporosis;
LGG	cis	rs4356932	1.000	rs6532158	chr4:76977964	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.67	-0.3	7.16e-11	Blood protein levels;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.47	0.37	3.19e-16	Schizophrenia;
LGG	cis	rs7123876	0.830	rs59311588	chr11:72435996	A/G	cg04827223	chr11:72435913	ARAP1	-0.48	-8.36	-0.36	7.56e-16	Body mass index;
LGG	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.43	-0.33	5.31e-13	Body mass index;
LGG	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	6.91e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.9	-0.34	2.09e-14	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg19635926	chr16:89946313	TCF25	0.69	7.85	0.34	2.9e-14	Skin colour saturation;
LGG	cis	rs3857536	0.740	rs7773577	chr6:66892124	G/A	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg23009067	chr7:2775923	GNA12	0.25	7.05	0.31	6.37e-12	Height;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg23985595	chr17:80112537	CCDC57	0.46	9.19	0.39	1.33e-18	Life satisfaction;
LGG	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg12654349	chr5:56205094	C5orf35	0.81	11.52	0.47	3.45e-27	Initial pursuit acceleration;
LGG	cis	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg07460842	chr6:66804631	NA	0.47	8.18	0.36	2.86e-15	Blood trace element (Cu levels);
LGG	cis	rs1595825	0.891	rs16824264	chr2:198675917	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg07936489	chr17:37558343	FBXL20	-0.49	-7.97	-0.35	1.29e-14	Asthma;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.42	-0.4	2.12e-19	Triglycerides;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	3.99e-17	Lung cancer;
LGG	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg05973401	chr12:123451056	ABCB9	0.47	7.89	0.34	2.27e-14	Platelet count;
LGG	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.46	0.44	3.81e-23	Resting heart rate;
LGG	cis	rs9462027	0.606	rs7768759	chr6:34795685	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.39	-0.47	1.16e-26	Systemic lupus erythematosus;
LGG	cis	rs9400467	0.537	rs354533	chr6:111487104	T/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.7	0.3	6.15e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.27	-0.4	7.19e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	trans	rs826838	1.000	rs826892	chr12:39100790	T/C	cg06521331	chr12:34319734	NA	0.45	8.29	0.36	1.21e-15	Heart rate;
LGG	cis	rs11971779	0.680	rs4732373	chr7:139086535	T/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg25174290	chr11:3078921	CARS	-0.46	-8.12	-0.35	4.38e-15	Calcium levels;
LGG	cis	rs17331151	0.573	rs13080929	chr3:52885112	A/C	cg04865290	chr3:52927548	TMEM110	-0.44	-7.49	-0.33	3.54e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg17971929	chr21:40555470	PSMG1	-0.51	-8.56	-0.37	1.65e-16	Menarche (age at onset);
LGG	cis	rs7666738	0.830	rs4699331	chr4:99059816	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.66	-0.37	7.78e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs2797369	0.570	rs2770337	chr6:101577043	C/T	cg27451362	chr6:101846650	GRIK2	0.56	8.28	0.36	1.32e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs870825	0.616	rs28500698	chr4:185627746	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.63	-10.63	-0.44	9.32e-24	Longevity;Endometriosis;
LGG	cis	rs9397585	0.791	rs7755574	chr6:153364643	G/T	cg17707550	chr6:153380415	RGS17	0.62	14.38	0.56	4.86e-39	Body mass index;
LGG	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg23533926	chr12:111358616	MYL2	-0.44	-7.27	-0.32	1.56e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg04317338	chr11:64019027	PLCB3	0.65	8.22	0.36	2.04e-15	Mean platelet volume;
LGG	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg04455712	chr21:45112962	RRP1B	-0.5	-9.55	-0.41	7.74e-20	Mean corpuscular volume;
LGG	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg13010199	chr12:38710504	ALG10B	0.46	8.92	0.38	1.09e-17	Morning vs. evening chronotype;
LGG	cis	rs1015291	0.680	rs1586837	chr12:19998282	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.3	-0.32	1.24e-12	Diastolic blood pressure;
LGG	cis	rs7202877	0.656	rs9923834	chr16:75507253	T/A	cg03315344	chr16:75512273	CHST6	0.5	6.72	0.3	5.41e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21302120	chr4:24585281	DHX15	-0.55	-8.15	-0.35	3.41e-15	Systemic lupus erythematosus;
LGG	cis	rs4144743	1.000	rs7223003	chr17:45324293	G/A	cg18085866	chr17:45331354	ITGB3	-0.77	-9.64	-0.41	3.54e-20	Body mass index;
LGG	cis	rs7216064	1.000	rs6504548	chr17:65886048	T/C	cg12091567	chr17:66097778	LOC651250	-0.65	-9.59	-0.41	5.65e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg10483660	chr13:112241077	NA	0.36	7.09	0.31	4.96e-12	Menarche (age at onset);
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-10.75	-0.45	3.15e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.29	-0.36	1.2e-15	Tonsillectomy;
LGG	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg09307838	chr4:120376055	NA	-0.72	-12.41	-0.5	9.93e-31	Corneal astigmatism;
LGG	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg13880726	chr7:1868755	MAD1L1	-0.38	-6.74	-0.3	4.8e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.02	0.49	3.83e-29	Hip circumference adjusted for BMI;
LGG	cis	rs259282	0.605	rs28615461	chr19:33110149	T/C	cg02997394	chr19:33096574	ANKRD27	-0.35	-6.65	-0.3	8.35e-11	Schizophrenia;
LGG	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg27205649	chr11:78285834	NARS2	-0.43	-7.11	-0.31	4.29e-12	Testicular germ cell tumor;
LGG	cis	rs4363385	0.510	rs17627288	chr1:152923848	C/T	cg13444842	chr1:152974279	SPRR3	-0.48	-9.55	-0.41	7.64e-20	Inflammatory skin disease;
LGG	cis	rs701145	0.585	rs1727948	chr3:153876929	G/T	cg12800244	chr3:153838788	SGEF	0.78	8.47	0.37	3.4e-16	Coronary artery disease;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg00800038	chr16:89945340	TCF25	-0.6	-8.48	-0.37	3.06e-16	Skin colour saturation;
LGG	cis	rs4474465	0.920	rs10128743	chr11:78214673	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.58	-0.33	1.96e-13	Alzheimer's disease (survival time);
LGG	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg22535103	chr8:58192502	C8orf71	-0.97	-15.29	-0.58	5.31e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg23625390	chr15:77176239	SCAPER	0.41	7.95	0.35	1.39e-14	Blood metabolite levels;
LGG	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.45	-0.44	4.39e-23	Mood instability;
LGG	trans	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg06521331	chr12:34319734	NA	0.42	7.62	0.33	1.41e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6540556	0.682	rs11119332	chr1:209892960	C/T	cg23920097	chr1:209922102	NA	-0.42	-7.01	-0.31	8.51e-12	Red blood cell count;
LGG	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg00745463	chr17:30367425	LRRC37B	0.61	7.56	0.33	2.12e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs1707322	1.000	rs1768817	chr1:46514534	C/G	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	8.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3806843	1.000	rs10066278	chr5:140156318	A/C	cg19875535	chr5:140030758	IK	0.51	10.62	0.44	1.02e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg16141378	chr3:129829833	LOC729375	0.35	7.95	0.35	1.4e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs67311347	0.544	rs67533651	chr3:40338367	T/A	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.84e-45	Renal cell carcinoma;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg27432699	chr2:27873401	GPN1	-0.53	-9.07	-0.39	3.46e-18	Total body bone mineral density;
LGG	cis	rs11971779	0.680	rs7804388	chr7:139086413	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg21775007	chr8:11205619	TDH	-0.5	-8.18	-0.36	2.84e-15	Neuroticism;
LGG	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg22601191	chr20:60968625	CABLES2	0.5	9.28	0.4	6.49e-19	Colorectal cancer;
LGG	cis	rs13177180	0.642	rs6894123	chr5:114865876	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.28	-0.32	1.46e-12	Conotruncal heart defects (inherited effects);
LGG	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg22875332	chr1:76189707	ACADM	0.62	10.41	0.44	6.27e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg03563238	chr19:33554763	RHPN2	0.42	10.06	0.42	1.15e-21	Bone properties (heel);
LGG	cis	rs2976388	0.556	rs4736323	chr8:143830359	C/T	cg10596483	chr8:143751796	JRK	-0.46	-6.76	-0.3	4.23e-11	Urinary tract infection frequency;
LGG	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	13.49	0.53	3.14e-35	HIV-1 control;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg13647721	chr17:30228624	UTP6	0.61	7.91	0.35	1.85e-14	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	16.83	0.62	6.17e-50	Tonsillectomy;
LGG	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg27523141	chr10:43048294	ZNF37B	0.39	7.72	0.34	7.48e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg06494592	chr3:125709126	NA	-0.54	-6.86	-0.3	2.16e-11	Blood pressure (smoking interaction);
LGG	cis	rs9357271	1.000	rs9394493	chr6:38350804	C/T	cg07362130	chr6:38359646	BTBD9	-0.47	-10.74	-0.45	3.59e-24	Restless legs syndrome;
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	10.49	0.44	3.04e-23	Total body bone mineral density;
LGG	trans	rs7961581	0.748	rs1798078	chr12:71595123	A/T	cg05003554	chr5:24488076	CDH10	-0.41	-6.82	-0.3	2.85e-11	Type 2 diabetes;
LGG	cis	rs4604732	0.631	rs12038793	chr1:247624262	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.6	-9.25	-0.4	8.14e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg11441553	chr12:57614120	NXPH4	-0.61	-7.55	-0.33	2.38e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17767392	0.874	rs34649709	chr14:71762296	G/T	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg19761014	chr17:28927070	LRRC37B2	0.72	9.11	0.39	2.5e-18	Body mass index;
LGG	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11203032	1.000	rs61853072	chr10:90961500	A/T	cg16672925	chr10:90967113	CH25H	0.84	11.62	0.48	1.42e-27	Heart failure;
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.17	0.52	7.05e-34	Lung cancer in ever smokers;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.08	-0.57	4.37e-42	Platelet count;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.51	0.4	1.04e-19	Lung cancer;
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.45e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs4293296	0.525	rs17726476	chr14:54813815	A/C	cg11186706	chr14:54815745	NA	0.59	7.99	0.35	1.09e-14	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.28	0.36	1.37e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.08	0.42	9.49e-22	Mean corpuscular volume;
LGG	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg26655873	chr3:72818019	SHQ1	0.34	6.81	0.3	3.1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3735485	0.800	rs6463260	chr7:45050890	A/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20644453	chr21:33985338	C21orf59	0.58	8.98	0.39	6.61e-18	Gut microbiome composition (summer);
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg13264159	chr8:625131	ERICH1	-0.86	-9.57	-0.41	6.66e-20	IgG glycosylation;
LGG	cis	rs9611519	0.542	rs8139770	chr22:41416181	C/T	cg03806693	chr22:41940476	POLR3H	-0.46	-7.66	-0.34	1.13e-13	Neuroticism;
LGG	cis	rs3925075	0.966	rs7195915	chr16:31344455	A/G	cg02846316	chr16:31340340	ITGAM	0.4	7.94	0.35	1.5e-14	IgA nephropathy;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg21637282	chr17:45000248	GOSR2	0.39	7.1	0.31	4.76e-12	Body mass index;
LGG	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg20387954	chr3:183756860	HTR3D	0.53	10.19	0.43	3.9e-22	Anterior chamber depth;
LGG	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg22906224	chr7:99728672	NA	-0.58	-9.32	-0.4	4.87e-19	Coronary artery disease;
LGG	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.06	0.39	3.57e-18	Resting heart rate;
LGG	cis	rs4700695	0.719	rs27080	chr5:65442271	A/G	cg21114390	chr5:65439923	SFRS12	-0.72	-10.54	-0.44	2.04e-23	Facial morphology (factor 19);
LGG	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg21427119	chr20:30132790	HM13	-0.4	-6.92	-0.31	1.49e-11	Mean corpuscular hemoglobin;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-9.38	-0.4	3e-19	Personality dimensions;
LGG	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	10.91	0.45	8.17e-25	Mean platelet volume;
LGG	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02711726	chr17:80685570	FN3KRP	-0.56	-9.84	-0.42	7.02e-21	Glycated hemoglobin levels;
LGG	cis	rs28655083	0.828	rs11640648	chr16:77122494	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.56	9.1	0.39	2.68e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg13770153	chr20:60521292	NA	-0.42	-6.87	-0.3	2.12e-11	Body mass index;
LGG	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg25486957	chr4:152246857	NA	-0.38	-6.67	-0.3	7.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg19717773	chr7:2847554	GNA12	-0.35	-7.64	-0.33	1.24e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08862035	chr2:2617432	NA	0.42	6.68	0.3	6.8e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10233018	0.639	rs6943120	chr7:117591388	C/G	cg21880328	chr7:117514017	CTTNBP2	-0.32	-6.71	-0.3	5.72e-11	Depressive symptoms;Depression;
LGG	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg16586182	chr3:47516702	SCAP	-0.76	-13.99	-0.55	2.34e-37	Colorectal cancer;
LGG	trans	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg23205692	chr1:25664452	TMEM50A	0.47	9.94	0.42	3.19e-21	Erythrocyte sedimentation rate;
LGG	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.95	-0.31	1.24e-11	Total body bone mineral density;
LGG	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.72	-13.77	-0.54	2.02e-36	Menarche (age at onset);
LGG	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg04287289	chr16:89883240	FANCA	-0.45	-7.99	-0.35	1.08e-14	Vitiligo;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.54e-11	Aortic root size;
LGG	cis	rs72781680	0.898	rs12614616	chr2:23996501	T/G	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs13401104	0.716	rs6741020	chr2:237125567	T/C	cg15742758	chr2:237126235	ASB18	0.45	7.58	0.33	1.95e-13	Educational attainment;
LGG	cis	rs2594989	1.000	rs2606740	chr3:11392441	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-7.28	-0.32	1.44e-12	Circulating chemerin levels;
LGG	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg01448562	chr3:133502909	NA	-0.64	-10.56	-0.44	1.64e-23	Iron status biomarkers;
LGG	cis	rs4917300	0.632	rs7813106	chr8:143107922	A/T	cg06573787	chr8:143070187	NA	0.58	9.66	0.41	3.12e-20	Amyotrophic lateral sclerosis;
LGG	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg12386194	chr3:101231763	SENP7	0.45	8.04	0.35	7.72e-15	Colorectal cancer;
LGG	cis	rs17021463	0.673	rs17377118	chr4:95285622	G/A	cg11021082	chr4:95130006	SMARCAD1	0.39	6.74	0.3	4.83e-11	Testicular germ cell tumor;
LGG	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg12386194	chr3:101231763	SENP7	0.41	7.54	0.33	2.46e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg10160682	chr2:1713001	PXDN	-0.54	-9.72	-0.41	1.96e-20	Response to antipsychotic treatment;
LGG	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.7	0.54	4.12e-36	IgG glycosylation;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.59	0.51	1.76e-31	Prudent dietary pattern;
LGG	cis	rs9309473	0.950	rs13427832	chr2:73844818	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.61	-0.33	1.5e-13	Metabolite levels;
LGG	cis	rs42648	0.623	rs194505	chr7:89841307	G/A	cg25739043	chr7:89950458	NA	-0.34	-7.02	-0.31	8.15e-12	Homocysteine levels;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg11494091	chr17:61959527	GH2	-1.04	-26.51	-0.78	7.24e-95	Prudent dietary pattern;
LGG	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg09044154	chr16:88155775	NA	-0.48	-7.23	-0.32	2.05e-12	Menopause (age at onset);
LGG	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	trans	rs7980799	0.816	rs4587807	chr12:33510115	C/T	cg13010199	chr12:38710504	ALG10B	-0.37	-6.93	-0.31	1.39e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.49	0.33	3.52e-13	Rheumatoid arthritis;
LGG	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg24690094	chr11:67383802	NA	-0.4	-7.02	-0.31	7.78e-12	Mean corpuscular volume;
LGG	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg16584290	chr5:462447	EXOC3	0.46	9.45	0.4	1.67e-19	Cystic fibrosis severity;
LGG	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg03805757	chr16:71968109	PKD1L3	-0.48	-8.86	-0.38	1.78e-17	Post bronchodilator FEV1;
LGG	cis	rs4742903	0.846	rs4743699	chr9:107002261	T/A	cg14250997	chr9:106856677	SMC2	0.37	7.6	0.33	1.61e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	18.59	0.65	4.79e-58	Gut microbiome composition (summer);
LGG	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg20608306	chr11:116969690	SIK3	-0.42	-11.18	-0.46	7.23e-26	Subjective well-being;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.47	-0.37	3.22e-16	Obesity-related traits;
LGG	cis	rs4253772	0.591	rs6008365	chr22:46652929	G/A	cg24881330	chr22:46731750	TRMU	0.7	8.75	0.38	4.01e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7394190	0.748	rs16930909	chr10:75561582	T/C	cg07699608	chr10:75541558	CHCHD1	0.55	7.46	0.33	4.37e-13	Incident atrial fibrillation;
LGG	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg00198680	chr16:28758506	NA	-0.29	-6.76	-0.3	4.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11112613	0.713	rs17037317	chr12:105952058	T/C	cg03607813	chr12:105948248	NA	0.59	10.85	0.45	1.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg14926445	chr8:58193284	C8orf71	-0.78	-9.65	-0.41	3.41e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs6834538	1.000	rs6816676	chr4:113483843	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.55	8.89	0.38	1.42e-17	Free thyroxine concentration;
LGG	cis	rs13314892	0.692	rs2014255	chr3:69895022	G/A	cg17445875	chr3:69859618	MITF	-0.41	-7.94	-0.35	1.54e-14	QRS complex (12-leadsum);
LGG	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.72	0.45	4.24e-24	Morning vs. evening chronotype;
LGG	trans	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.11e-13	Cognitive test performance;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg15971980	chr6:150254442	NA	0.45	8.63	0.37	9.97e-17	Lung cancer;
LGG	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg27446573	chr6:127587934	RNF146	0.9	16.69	0.61	2.55e-49	Breast cancer;
LGG	cis	rs755249	0.510	rs1184716	chr1:39846489	C/T	cg18385671	chr1:39797026	MACF1	0.47	9.83	0.42	8.03e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg27661571	chr11:113659931	NA	-0.69	-9.42	-0.4	2.18e-19	Hip circumference adjusted for BMI;
LGG	cis	rs2976388	1.000	rs1045574	chr8:143763958	C/T	cg06565975	chr8:143823917	SLURP1	-0.4	-10.17	-0.43	4.71e-22	Urinary tract infection frequency;
LGG	cis	rs1018836	0.544	rs2339154	chr8:91459316	T/C	cg16814680	chr8:91681699	NA	-0.47	-7.75	-0.34	5.89e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.830	rs35531558	chr4:98938217	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.91e-21	Tonsillectomy;
LGG	cis	rs7017914	0.934	rs7009297	chr8:71672366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25172604	chr17:41446521	NA	-0.29	-6.85	-0.3	2.41e-11	Menopause (age at onset);
LGG	cis	rs7814319	0.966	rs2319603	chr8:97270991	G/A	cg20787634	chr8:97240163	UQCRB	-0.78	-18.56	-0.65	7.09e-58	Lung function (FVC);
LGG	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg16482183	chr6:26056742	HIST1H1C	0.82	11.47	0.47	5.59e-27	Iron status biomarkers;
LGG	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg02466173	chr16:30829666	NA	-0.39	-6.9	-0.31	1.67e-11	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg10295955	chr4:187884368	NA	-1.15	-30.47	-0.82	1.08e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs903263	1.000	rs2134647	chr1:84678418	C/T	cg10977910	chr1:84465055	TTLL7	0.41	6.91	0.31	1.6e-11	Breast cancer (male);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs1371867	0.846	rs2439460	chr8:101312665	C/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.59	-0.37	1.36e-16	Atrioventricular conduction;
LGG	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg04117972	chr1:227635322	NA	0.74	12.02	0.49	3.74e-29	Major depressive disorder;
LGG	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.28	-0.36	1.35e-15	Joint mobility (Beighton score);
LGG	trans	rs629535	0.862	rs2178955	chr8:70045303	C/T	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs17767392	0.881	rs1029570	chr14:72043200	A/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.28	0.36	1.34e-15	Mitral valve prolapse;
LGG	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg07777115	chr5:623756	CEP72	-0.62	-7.92	-0.35	1.79e-14	Obesity-related traits;
LGG	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg17911788	chr17:44343683	NA	-0.47	-7.91	-0.34	1.93e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg27490568	chr2:178487706	NA	0.52	10.05	0.42	1.31e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs912057	0.695	rs1294419	chr6:6742549	C/G	cg06612196	chr6:6737390	NA	0.46	9.38	0.4	3.05e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22968622	chr17:43663579	NA	-0.79	-15.5	-0.58	5.88e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg05896524	chr21:47604654	C21orf56	0.55	9.34	0.4	4.08e-19	Testicular germ cell tumor;
LGG	cis	rs9814567	0.964	rs9841180	chr3:134191880	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-11.98	-0.49	5.23e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9487094	0.670	rs12212476	chr6:109822605	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.65	0.33	1.19e-13	Height;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7742824	0.917	rs10085205	chr6:44084883	A/G	cg04074908	chr6:44101190	TMEM63B	-0.63	-13.11	-0.52	1.3e-33	Major depressive disorder;
LGG	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.79	-0.34	4.49e-14	Type 2 diabetes;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24899068	chr19:49999470	RPS11	0.41	6.74	0.3	4.65e-11	Cognitive performance;
LGG	cis	rs9309473	0.848	rs17009159	chr2:73797762	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg13206674	chr6:150067644	NUP43	0.66	15.4	0.58	1.63e-43	Lung cancer;
LGG	cis	rs72781680	1.000	rs55773155	chr2:24255081	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	9.72	0.41	1.93e-20	Lymphocyte counts;
LGG	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.87	-0.3	2.13e-11	Total cholesterol levels;
LGG	cis	rs6918586	0.557	rs198827	chr6:26121002	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.61	-0.41	4.8e-20	Schizophrenia;
LGG	cis	rs12476592	0.602	rs7563623	chr2:63720210	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	cis	rs2933343	0.729	rs1680794	chr3:128620390	A/G	cg11901034	chr3:128598214	ACAD9	-0.44	-6.67	-0.3	7.13e-11	IgG glycosylation;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg26174226	chr8:58114915	NA	0.5	7.05	0.31	6.61e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.43	-0.44	5.04e-23	Bipolar disorder;
LGG	cis	rs2067615	0.524	rs4246257	chr12:107062329	C/T	cg15890332	chr12:107067104	RFX4	0.41	12.01	0.49	4.24e-29	Heart rate;
LGG	trans	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg06606381	chr12:133084897	FBRSL1	-0.63	-8.12	-0.35	4.22e-15	Depression;
LGG	trans	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.96	-0.31	1.14e-11	Neuroticism;
LGG	cis	rs17253792	0.822	rs78143160	chr14:56150097	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg26396452	chr14:65542826	MAX	0.48	10.19	0.43	3.84e-22	Obesity-related traits;
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg24575275	chr7:1094737	C7orf50	0.36	6.91	0.31	1.61e-11	Longevity;Endometriosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12460105	chr5:68665773	RAD17;TAF9	0.42	7.31	0.32	1.19e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg23029597	chr12:123009494	RSRC2	-0.87	-16.71	-0.61	2.12e-49	Body mass index;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.7	-0.48	7.02e-28	Neuroticism;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg21724239	chr8:58056113	NA	0.51	7.72	0.34	7.13e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4330281	0.647	rs13083917	chr3:17713516	T/A	cg20981856	chr3:17787350	NA	-0.4	-7.53	-0.33	2.7e-13	Schizophrenia;
LGG	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg15704280	chr7:45808275	SEPT13	0.87	13.68	0.54	5.13e-36	Height;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6424115	0.729	rs586173	chr1:24055718	A/G	cg15997130	chr1:24165203	NA	-0.37	-9.68	-0.41	2.73e-20	Immature fraction of reticulocytes;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg13880726	chr7:1868755	MAD1L1	0.44	7.51	0.33	3.12e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.77	0.3	3.88e-11	Carotid intima media thickness;
LGG	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21862992	chr11:68658383	NA	0.51	8.6	0.37	1.21e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13102973	0.611	rs4298187	chr4:135886186	G/A	cg14419869	chr4:135874104	NA	0.46	7.9	0.34	2.06e-14	Subjective well-being;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.2	0.39	1.28e-18	Lung cancer;
LGG	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	trans	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg25214090	chr10:38739885	LOC399744	0.64	11.57	0.47	2.26e-27	Corneal astigmatism;
LGG	cis	rs7122937	0.677	rs11022922	chr11:2479195	C/T	cg27115973	chr11:2481206	KCNQ1	0.38	6.88	0.3	1.9e-11	QT interval;
LGG	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.16	0.6	6.61e-47	Anterior chamber depth;
LGG	cis	rs7394190	0.748	rs4746147	chr10:75527708	A/G	cg07699608	chr10:75541558	CHCHD1	0.55	7.39	0.32	6.71e-13	Incident atrial fibrillation;
LGG	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg03433033	chr1:76189801	ACADM	0.77	13.2	0.52	5.42e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg27119904	chr13:114814333	RASA3	0.38	8.18	0.36	2.69e-15	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.98	-0.42	2.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg18258770	chr4:90757814	SNCA	-0.42	-7.73	-0.34	6.59e-14	Dementia with Lewy bodies;
LGG	cis	rs7799006	0.929	rs35629140	chr7:2257171	G/C	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.63	-0.33	1.39e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg15103426	chr22:29168792	CCDC117	-0.61	-9.18	-0.39	1.39e-18	Lymphocyte counts;
LGG	cis	rs733592	0.929	rs4760678	chr12:48461581	T/C	cg24011408	chr12:48396354	COL2A1	-0.65	-10.95	-0.45	5.82e-25	Plateletcrit;
LGG	cis	rs2455799	0.634	rs62243670	chr3:15918990	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.73	-0.34	6.63e-14	Mean platelet volume;
LGG	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg27572855	chr1:25598939	RHD	0.52	11.73	0.48	5.4e-28	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs2294693	1.000	rs2294693	chr6:41005502	T/C	cg14769373	chr6:40998127	UNC5CL	-0.41	-6.9	-0.31	1.75e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	trans	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs758324	0.947	rs173812	chr5:131319460	A/G	cg06307176	chr5:131281290	NA	-0.57	-9.28	-0.4	6.67e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs877282	0.755	rs2486578	chr10:785227	C/T	cg22713356	chr15:30763199	NA	-0.48	-7.88	-0.34	2.29e-14	Uric acid levels;
LGG	cis	rs755249	0.756	rs72637908	chr1:40023047	T/A	cg18385671	chr1:39797026	MACF1	0.35	6.75	0.3	4.49e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs763121	0.853	rs5750664	chr22:39072769	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs2734839	0.964	rs12364051	chr11:113305314	A/G	cg14159747	chr11:113255604	NA	0.27	7.21	0.32	2.31e-12	Information processing speed;
LGG	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg20503657	chr10:835505	NA	0.96	12.91	0.51	8.6e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.39e-20	Morning vs. evening chronotype;
LGG	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-8.09	-0.35	5.2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7017914	0.783	rs13252584	chr8:71689031	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	trans	rs61931739	0.649	rs815044	chr12:33722209	A/G	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg21963583	chr11:68658836	MRPL21	0.6	10.37	0.43	8.34e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9308433	0.529	rs10465696	chr1:214499883	G/A	cg06198575	chr1:214491504	SMYD2	0.51	7.79	0.34	4.59e-14	IgG glycosylation;
LGG	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg03929089	chr4:120376271	NA	-0.81	-15.66	-0.59	1.19e-44	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23712970	chr14:23540735	ACIN1	0.44	6.93	0.31	1.38e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05980081	chr15:64385876	FAM96A	0.49	7.15	0.32	3.43e-12	Gut microbiome composition (summer);
LGG	cis	rs4566357	1.000	rs7577005	chr2:227921573	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs2273669	0.667	rs112319185	chr6:109305318	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.96	-0.45	5.2e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1497828	0.912	rs2646827	chr1:217540571	G/A	cg04411442	chr1:217543379	NA	-0.48	-8.24	-0.36	1.85e-15	Dialysis-related mortality;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22336633	chr11:17099688	RPS13	0.5	7.75	0.34	5.87e-14	Gut microbiome composition (summer);
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg13903179	chr13:21900392	NA	0.41	7.23	0.32	2.05e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs975722	0.632	rs6972168	chr7:117084585	T/G	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.2	-0.39	1.28e-18	Coronary artery disease;
LGG	cis	rs34599045	0.522	rs79934428	chr1:152917491	G/T	cg07796016	chr1:152779584	LCE1C	-0.87	-8.05	-0.35	6.84e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg20608306	chr11:116969690	SIK3	0.42	13.32	0.53	1.77e-34	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00664135	chr6:135819137	C6orf217;AHI1	0.41	6.81	0.3	2.98e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg10253484	chr15:75165896	SCAMP2	0.44	7.04	0.31	6.84e-12	Systemic lupus erythematosus;
LGG	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.82	-0.48	2.26e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7923609	0.967	rs7912893	chr10:65162000	T/A	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.67	-0.41	2.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs138904061	1	rs138904061	chr3:105174202	T/C	cg11620689	chr3:105244696	ALCAM	-0.48	-7.81	-0.34	3.96e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4478858	0.684	rs10798839	chr1:31731758	C/G	cg19084893	chr1:31688959	NA	0.31	6.65	0.3	8.4e-11	Alcohol dependence;
LGG	trans	rs2562456	0.833	rs55961038	chr19:21558007	T/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.75	-0.34	5.85e-14	Pain;
LGG	cis	rs6732160	0.834	rs57456443	chr2:73366441	C/A	cg01422370	chr2:73384389	NA	0.53	9.94	0.42	3.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs800082	1.000	rs6440259	chr3:144286614	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.53	0.37	2.12e-16	Smoking behavior;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg09264619	chr17:80180166	NA	0.37	7.36	0.32	8.42e-13	Life satisfaction;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.42e-16	Life satisfaction;
LGG	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg26384229	chr12:38710491	ALG10B	0.97	22.13	0.72	1.45e-74	Bladder cancer;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg27532560	chr4:187881888	NA	-0.59	-12.79	-0.51	2.85e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.51	0.5	3.95e-31	Motion sickness;
LGG	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg10661904	chr17:79619235	PDE6G	0.53	10.88	0.45	1.09e-24	Eye color traits;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg22072935	chr14:105399595	NA	-0.54	-10.83	-0.45	1.63e-24	Rheumatoid arthritis;
LGG	trans	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs6723226	0.721	rs3769600	chr2:32616879	G/A	cg02381751	chr2:32503542	YIPF4	-0.64	-11.03	-0.46	2.72e-25	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25172604	chr17:41446521	NA	0.31	7.41	0.33	6.19e-13	Menopause (age at onset);
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs919433	0.783	rs2565155	chr2:198236425	A/G	cg00792783	chr2:198669748	PLCL1	0.46	7.34	0.32	9.4e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs11088226	0.681	rs2833902	chr21:33940458	A/G	cg09050820	chr6:167586206	TCP10L2	0.9	12.64	0.51	1.16e-31	Gastritis;
LGG	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg19507638	chr5:93509721	C5orf36	-0.64	-9.21	-0.39	1.1e-18	Diabetic retinopathy;
LGG	cis	rs240764	0.619	rs11756783	chr6:101118109	A/T	cg09795085	chr6:101329169	ASCC3	0.41	6.89	0.3	1.83e-11	Neuroticism;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg24829409	chr8:58192753	C8orf71	-0.83	-12.83	-0.51	1.9e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.8	-0.38	2.67e-17	Personality dimensions;
LGG	cis	rs1878931	0.543	rs17612463	chr16:3420479	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	11.51	0.47	3.86e-27	Body mass index (adult);
LGG	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.87	0.3	2.14e-11	Bipolar disorder;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg24341944	chr3:157827791	RSRC1	-0.44	-6.86	-0.3	2.28e-11	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	8.83	0.38	2.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg02158880	chr13:53174818	NA	-0.4	-7.82	-0.34	3.51e-14	Lewy body disease;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.37	6.79	0.3	3.53e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg12070911	chr6:150209640	RAET1E	0.31	7.59	0.33	1.72e-13	Lung cancer;
LGG	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	14.15	0.55	5.13e-38	Cognitive test performance;
LGG	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg07027305	chr7:2059796	MAD1L1	0.3	6.68	0.3	6.91e-11	Bipolar disorder;
LGG	cis	rs7674212	0.570	rs2069274	chr4:104020781	C/G	cg16532752	chr4:104119610	CENPE	-0.41	-7.28	-0.32	1.48e-12	Type 2 diabetes;
LGG	cis	rs1682825	0.790	rs73812277	chr3:10751837	C/A	cg23512531	chr3:10780469	NA	0.61	7.48	0.33	3.82e-13	Economic and political preferences (feminism/equality);
LGG	cis	rs17039065	1.000	rs72889383	chr4:109391962	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg04450456	chr4:17643702	FAM184B	0.34	7.59	0.33	1.8e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07243736	chr16:783730	NARFL	0.42	7.18	0.32	2.74e-12	Height;
LGG	cis	rs1555133	0.694	rs2295764	chr20:31025163	A/G	cg00028034	chr20:30779307	TSPYL3	0.33	6.75	0.3	4.52e-11	Monocyte count;
LGG	cis	rs17776563	0.548	rs17776648	chr15:89145377	G/A	cg05013243	chr15:89149849	MIR1179	-0.33	-6.84	-0.3	2.49e-11	Thyroid hormone levels;
LGG	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.35	-0.32	9.04e-13	Refractive error;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23604584	chr13:50367114	KPNA3	0.46	7.72	0.34	7.31e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.57	-0.47	2.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg01043669	chr3:72786069	NA	0.42	7.15	0.32	3.32e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg18357526	chr6:26021779	HIST1H4A	0.83	16.02	0.6	2.78e-46	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.846	rs34911660	chr14:71752344	C/T	cg02058870	chr14:72053146	SIPA1L1	0.4	8.52	0.37	2.28e-16	Mitral valve prolapse;
LGG	cis	rs12155623	0.668	rs6472114	chr8:49789561	T/C	cg22283653	chr8:49824208	NA	-0.68	-13.68	-0.54	5.16e-36	Sudden cardiac arrest;
LGG	cis	rs8016982	0.674	rs8004096	chr14:81701082	T/G	cg01989461	chr14:81687754	GTF2A1	0.77	17.86	0.64	1.14e-54	Schizophrenia;
LGG	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.1	0.35	5.01e-15	Iron status biomarkers;
LGG	cis	rs12360000	1.000	rs12360000	chr10:1897978	G/A	cg26364871	chr10:1889757	NA	-0.76	-14.57	-0.56	7.22e-40	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg27129171	chr3:47204927	SETD2	0.72	12.48	0.5	5.11e-31	Birth weight;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22968622	chr17:43663579	NA	1.07	20.05	0.68	7.69e-65	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg27366882	chr3:133540807	NA	-0.47	-9.59	-0.41	5.54e-20	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs7666738	0.570	rs11097612	chr4:99079772	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.9	0.31	1.68e-11	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg06875740	chr19:51307921	C19orf48	-0.65	-6.78	-0.3	3.72e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg16325326	chr1:53192061	ZYG11B	0.62	13.32	0.53	1.74e-34	Monocyte count;
LGG	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg24375607	chr4:120327624	NA	0.69	11.26	0.46	3.84e-26	Corneal astigmatism;
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs4356203	0.875	rs7125607	chr11:17096150	T/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.39	-0.32	7.15e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.8	-0.3	3.2e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1348850	0.519	rs1527406	chr2:178525655	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-8.11	-0.35	4.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg07052231	chr12:7363540	PEX5	0.39	7.0	0.31	9.28e-12	IgG glycosylation;
LGG	cis	rs7572733	0.534	rs11890137	chr2:198816662	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs314370	0.570	rs314314	chr7:100423841	C/T	cg03098644	chr7:100410630	EPHB4	-0.41	-6.74	-0.3	4.84e-11	Resting heart rate;
LGG	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg21453758	chr17:80185943	SLC16A3	-0.33	-6.9	-0.31	1.74e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg00531865	chr16:30841666	NA	0.54	10.35	0.43	1.01e-22	Dementia with Lewy bodies;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg26318627	chr11:63887540	MACROD1	-0.45	-7.07	-0.31	5.83e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs727505	0.583	rs17147421	chr7:124383948	C/T	cg23710748	chr7:124431027	NA	-0.43	-8.42	-0.36	4.73e-16	Lewy body disease;
LGG	cis	rs72792276	1.000	rs10519971	chr5:127379216	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.65	-6.71	-0.3	5.65e-11	Red cell distribution width;
LGG	cis	rs7586879	1.000	rs10207698	chr2:25117672	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs7582720	0.945	rs72932709	chr2:203639501	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	9.05	0.39	3.87e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg02733842	chr7:1102375	C7orf50	0.67	10.07	0.42	1.1e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7727544	0.582	rs10478998	chr5:131516531	G/A	cg07395648	chr5:131743802	NA	-0.4	-8.66	-0.37	7.71e-17	Blood metabolite levels;
LGG	cis	rs77741769	0.571	rs12831094	chr12:121292704	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.13	0.39	2.1e-18	Mean corpuscular volume;
LGG	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg13550731	chr2:172543902	DYNC1I2	1.05	26.51	0.78	6.99e-95	Schizophrenia;
LGG	cis	rs7717393	1.000	rs11950100	chr5:155755768	G/A	cg12904904	chr5:155754151	SGCD	0.88	8.54	0.37	2e-16	Egg allergy;
LGG	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg06360820	chr2:242988706	NA	-0.88	-11.57	-0.47	2.32e-27	Obesity-related traits;
LGG	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg00898013	chr13:113819073	PROZ	0.43	8.75	0.38	4.07e-17	Platelet distribution width;
LGG	cis	rs12049351	0.665	rs10799532	chr1:229584620	T/G	cg13547644	chr1:229569608	ACTA1	0.32	7.13	0.31	3.83e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs500492	0.508	rs2573149	chr16:1073149	G/A	cg08273874	chr16:1060765	NA	-0.49	-7.19	-0.32	2.64e-12	Polycystic ovary syndrome;
LGG	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.42	-0.4	2.16e-19	Height;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.5	-0.33	3.19e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs7112925	0.738	rs11227673	chr11:66832528	C/T	cg24851651	chr11:66362959	CCS	-0.33	-6.82	-0.3	2.89e-11	Height;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13732083	chr21:47605072	C21orf56	0.48	8.28	0.36	1.34e-15	Testicular germ cell tumor;
LGG	cis	rs2173063	1.000	rs16947102	chr15:93147260	G/A	cg07052004	chr15:93132129	NA	0.71	7.3	0.32	1.22e-12	Subcutaneous adipose tissue;
LGG	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22857025	chr5:266934	NA	1.01	14.21	0.55	2.78e-38	Breast cancer;
LGG	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg13798912	chr7:905769	UNC84A	0.54	6.91	0.31	1.64e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs13102973	0.932	rs11099305	chr4:135895569	C/G	cg14419869	chr4:135874104	NA	0.56	10.67	0.44	6.66e-24	Subjective well-being;
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-6.72	-0.3	5.45e-11	Vitiligo;
LGG	cis	rs12724450	0.793	rs12735903	chr1:150359085	G/A	cg03818307	chr1:150480534	ECM1	0.51	7.13	0.31	3.96e-12	Blood protein levels;
LGG	cis	rs75059851	0.756	rs11223655	chr11:133842707	G/A	cg17703048	chr11:133852993	NA	-0.87	-15.95	-0.6	6.02e-46	Schizophrenia;
LGG	cis	rs11203032	1.000	rs11203032	chr10:90964614	T/G	cg16672925	chr10:90967113	CH25H	0.85	11.88	0.48	1.36e-28	Heart failure;
LGG	cis	rs6840360	0.593	rs4696103	chr4:152564611	A/G	cg25486957	chr4:152246857	NA	-0.48	-7.87	-0.34	2.61e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2084898	1.000	rs2084897	chr11:120026600	C/T	cg07435449	chr11:120005650	TRIM29	-0.63	-7.62	-0.33	1.47e-13	Stroke (pediatric);
LGG	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg22509179	chr1:25234806	RUNX3	0.65	13.66	0.54	6.47e-36	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg14593290	chr7:50529359	DDC	0.68	11.97	0.49	6.04e-29	Malaria;
LGG	cis	rs2235649	0.746	rs35104579	chr16:1848657	A/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs4731207	0.596	rs723443	chr7:124659301	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.44	7.07	0.31	5.82e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg04287289	chr16:89883240	FANCA	0.73	8.07	0.35	5.93e-15	Skin colour saturation;
LGG	trans	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.5	-0.4	1.15e-19	Gout;
LGG	cis	rs7648466	1.000	rs7648466	chr3:46187522	C/T	cg13144783	chr3:46249795	CCR1	0.65	12.31	0.5	2.54e-30	Eotaxin levels;
LGG	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg08470875	chr2:26401718	FAM59B	-0.41	-8.12	-0.35	4.29e-15	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.61	-0.37	1.12e-16	Neuroticism;
LGG	cis	rs6500395	0.962	rs11648101	chr16:48714178	C/T	cg04672837	chr16:48644449	N4BP1	0.51	8.39	0.36	6.08e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs6963495	0.818	rs6956249	chr7:105149743	A/T	cg19920283	chr7:105172520	RINT1	0.6	7.86	0.34	2.8e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7818345	1.000	rs4409408	chr8:19311538	T/G	cg01280390	chr8:19363452	CSGALNACT1	0.3	6.88	0.3	1.94e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05409276	chr17:73400549	GRB2	-0.53	-7.83	-0.34	3.29e-14	Systemic lupus erythematosus;
LGG	trans	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.66	-0.37	8.2e-17	Blood pressure (smoking interaction);
LGG	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg02002194	chr4:3960332	NA	-0.5	-9.41	-0.4	2.32e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7944735	0.564	rs60929305	chr11:47523589	C/T	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.49e-11	Intraocular pressure;
LGG	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg26441486	chr22:50317300	CRELD2	0.42	7.07	0.31	5.59e-12	Schizophrenia;
LGG	cis	rs9902453	0.868	rs8066602	chr17:28523085	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	12.69	0.51	6.92e-32	Coffee consumption (cups per day);
LGG	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.64	-0.54	7.22e-36	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg08188268	chr10:116634841	FAM160B1	0.31	7.01	0.31	8.65e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs2273669	0.667	rs6918331	chr6:109317394	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg05163923	chr11:71159392	DHCR7	-0.57	-8.25	-0.36	1.63e-15	Vitamin D levels;
LGG	cis	rs9814567	1.000	rs1874883	chr3:134205071	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.07	-0.52	1.89e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7927771	0.800	rs55876153	chr11:47416636	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.51	-0.44	2.53e-23	Subjective well-being;
LGG	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg17971929	chr21:40555470	PSMG1	0.87	17.32	0.63	3.49e-52	Cognitive function;
LGG	trans	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg21775007	chr8:11205619	TDH	0.45	7.05	0.31	6.51e-12	Systolic blood pressure;
LGG	cis	rs6568686	0.577	rs174398	chr6:111919462	C/T	cg21044968	chr6:111895086	TRAF3IP2	0.38	6.73	0.3	4.9e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg11789530	chr4:8429930	ACOX3	-0.68	-10.98	-0.45	4.24e-25	Response to antineoplastic agents;
LGG	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-11.46	-0.47	6.08e-27	Migraine;Coronary artery disease;
LGG	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.14	-0.35	3.69e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7939886	0.844	rs12421584	chr11:55937410	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs17767392	0.881	rs1859643	chr14:72055468	G/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.25	0.39	8.28e-19	Mitral valve prolapse;
LGG	cis	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs258892	0.895	rs155432	chr5:72138608	G/T	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs55871839	0.708	rs2326213	chr8:59812459	A/G	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	18.26	0.65	1.66e-56	Alzheimer's disease;
LGG	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.62	11.9	0.48	1.11e-28	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.531	rs6544611	chr2:43122486	T/C	cg14631114	chr2:43023945	NA	0.42	7.31	0.32	1.19e-12	Hypospadias;
LGG	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg22044901	chr15:68126292	NA	-0.43	-7.35	-0.32	9.2e-13	Obesity;
LGG	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3e-13	Schizophrenia;
LGG	cis	rs7027203	0.797	rs57882762	chr9:96580825	T/G	cg14598338	chr9:96623480	NA	-0.53	-9.56	-0.41	7.12e-20	DNA methylation (variation);
LGG	cis	rs12618769	0.572	rs4851141	chr2:99112966	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.08	-0.35	5.84e-15	Neuroticism;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00933542	chr6:150070202	PCMT1	0.39	7.24	0.32	1.88e-12	Lung cancer;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.8e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17445240	0.901	rs13418767	chr2:3704830	G/T	cg16123090	chr2:3699210	NA	0.67	7.57	0.33	2.02e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3747547	0.892	rs11792678	chr9:38020036	A/G	cg13774184	chr9:37916125	SHB	-0.71	-7.24	-0.32	1.87e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	10.33	0.43	1.2e-22	Educational attainment;
LGG	cis	rs6840360	1.000	rs6535819	chr4:152651503	A/G	cg22705602	chr4:152727874	NA	-0.27	-6.82	-0.3	2.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg24006582	chr15:45444508	DUOX1	-0.71	-13.64	-0.54	7.67e-36	Uric acid levels;
LGG	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.62	-0.37	1.08e-16	Educational attainment (years of education);
LGG	cis	rs17767392	0.958	rs34957192	chr14:71752336	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.12	-0.39	2.25e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08280861	chr8:58055591	NA	0.63	7.75	0.34	5.73e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs1357245	0.692	rs34978733	chr3:27204567	T/C	cg02860705	chr3:27208620	NA	-0.38	-6.91	-0.31	1.59e-11	Breast cancer;
LGG	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.43	-0.4	1.95e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.59	0.41	5.68e-20	Longevity;
LGG	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-15.11	-0.57	3.33e-42	Morning vs. evening chronotype;
LGG	cis	rs9863	0.828	rs11057408	chr12:124464836	G/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.13	-0.31	3.79e-12	White blood cell count;
LGG	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.37	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg23231163	chr10:75533350	FUT11	-0.4	-6.72	-0.3	5.36e-11	Inflammatory bowel disease;
LGG	cis	rs60180747	0.909	rs74956204	chr15:66794352	G/A	cg07575407	chr15:66541975	MEGF11	0.39	7.29	0.32	1.33e-12	Testicular germ cell tumor;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg05091796	chr16:4465799	CORO7	-0.76	-12.41	-0.5	9.58e-31	Schizophrenia;
LGG	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg25866889	chr13:114914595	NA	-0.35	-7.11	-0.31	4.28e-12	Schizophrenia;
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg22753661	chr15:79092743	ADAMTS7	0.41	7.01	0.31	8.59e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg23845249	chr11:68861649	NA	0.44	7.84	0.34	3.19e-14	Blond vs. brown hair color;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.5	-0.44	2.77e-23	Bipolar disorder;
LGG	cis	rs4330281	0.647	rs6788763	chr3:17519053	T/C	cg20981856	chr3:17787350	NA	0.36	6.82	0.3	2.79e-11	Schizophrenia;
LGG	cis	rs9547996	0.879	rs61957472	chr13:38139860	C/A	cg17979426	chr13:38220150	TRPC4	-0.35	-6.73	-0.3	4.95e-11	Diastolic blood pressure;
LGG	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg10845886	chr2:3471009	TTC15	-0.43	-8.08	-0.35	5.82e-15	Neurofibrillary tangles;
LGG	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg02002194	chr4:3960332	NA	0.43	7.8	0.34	4e-14	Retinal vascular caliber;
LGG	cis	rs9341808	0.754	rs3805925	chr6:80883833	T/C	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.74e-14	Sitting height ratio;
LGG	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.09	-0.52	1.6e-33	Vitamin D levels;
LGG	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21963583	chr11:68658836	MRPL21	0.58	10.27	0.43	1.96e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9596863	0.898	rs7328420	chr13:54320465	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	7.3	0.32	1.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2282802	0.685	rs2337138	chr5:139691664	A/C	cg26211634	chr5:139558579	C5orf32	0.35	7.77	0.34	4.94e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6835098	0.961	rs2078475	chr4:174098226	A/C	cg08422745	chr4:174089978	GALNT7	0.84	14.59	0.56	5.91e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22023784	chr20:54933826	C20orf108	0.45	6.65	0.3	8.11e-11	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.15e-84	Height;
LGG	trans	rs9354308	0.764	rs9283824	chr6:66597980	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs9863	0.896	rs34854841	chr12:124451504	A/G	cg13487667	chr12:124434373	CCDC92	-0.38	-7.31	-0.32	1.2e-12	White blood cell count;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg11494091	chr17:61959527	GH2	1.03	26.34	0.77	4.11e-94	Prudent dietary pattern;
LGG	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg04362960	chr10:104952993	NT5C2	0.56	10.45	0.44	4.28e-23	Arsenic metabolism;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg17951613	chr5:131705445	SLC22A5	-0.59	-6.8	-0.3	3.27e-11	Rheumatoid arthritis;
LGG	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg06238570	chr21:40685208	BRWD1	-0.53	-8.71	-0.38	5.62e-17	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09000178	chr16:67063319	CBFB	0.42	6.93	0.31	1.4e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg01657329	chr11:68192670	LRP5	0.62	10.28	0.43	1.9e-22	Bone mineral density (spine);
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg02158880	chr13:53174818	NA	0.42	8.32	0.36	9.78e-16	Lewy body disease;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.69	0.34	8.73e-14	Longevity;
LGG	cis	rs12135191	0.900	rs12138809	chr1:236485187	C/T	cg21399712	chr1:236511386	NA	-0.4	-7.82	-0.34	3.57e-14	Urate levels (BMI interaction);
LGG	cis	rs9457247	0.967	rs424185	chr6:167410907	C/T	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg12560992	chr17:57184187	TRIM37	0.54	8.6	0.37	1.21e-16	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg09699651	chr6:150184138	LRP11	0.48	8.39	0.36	6.03e-16	Lung cancer;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.06	0.68	7.06e-65	Alzheimer's disease;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7226408	0.857	rs72892518	chr18:34665420	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.12	-0.31	4.11e-12	Obesity-related traits;
LGG	cis	rs3087591	0.922	rs12939969	chr17:29463577	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.67	0.56	2.72e-40	Hip circumference;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg02951883	chr7:2050386	MAD1L1	0.73	15.19	0.58	1.38e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg02640540	chr1:67518911	SLC35D1	0.37	7.17	0.32	2.9e-12	Lymphocyte percentage of white cells;
LGG	cis	rs9649465	1.000	rs13230294	chr7:123380821	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	trans	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg06521331	chr12:34319734	NA	0.44	7.83	0.34	3.25e-14	Bladder cancer;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7267979	0.932	rs1541061	chr20:25521057	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.93	0.42	3.45e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	8.11	0.35	4.59e-15	Prudent dietary pattern;
LGG	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg01528321	chr10:82214614	TSPAN14	0.67	12.0	0.49	4.3e-29	Post bronchodilator FEV1;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19853927	chr3:153839743	SGEF	0.42	7.15	0.32	3.35e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs503734	0.502	rs1994201	chr3:100970062	C/T	cg27318481	chr3:100970896	IMPG2	0.58	13.21	0.52	4.7e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.64	-0.33	1.23e-13	Colorectal cancer;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.87	-0.3	2.03e-11	Personality dimensions;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25072359	chr17:41440525	NA	0.53	10.18	0.43	4.36e-22	Menopause (age at onset);
LGG	cis	rs4363385	0.791	rs4041401	chr1:152985629	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.52e-17	Inflammatory skin disease;
LGG	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	6.21e-34	Resting heart rate;
LGG	cis	rs6860806	0.507	rs183898	chr5:131716902	C/G	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.01e-21	Breast cancer;
LGG	cis	rs7617773	0.780	rs11718350	chr3:48360992	T/G	cg11946769	chr3:48343235	NME6	0.71	11.94	0.49	7.5e-29	Coronary artery disease;
LGG	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg20587970	chr11:113659929	NA	-1.36	-24.15	-0.75	5.62e-84	Hip circumference adjusted for BMI;
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs3106136	0.546	rs2664881	chr4:95143484	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.94	-0.45	6.4e-25	Capecitabine sensitivity;
LGG	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.71	7.84	0.34	3.15e-14	Smoking behavior;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg04863758	chr4:1303710	MAEA	0.42	7.3	0.32	1.3e-12	Obesity-related traits;
LGG	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.13	-0.35	3.93e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg08847533	chr14:75593920	NEK9	-0.59	-10.68	-0.44	6.21e-24	Height;
LGG	cis	rs870825	0.616	rs6552804	chr4:185637699	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs1707322	0.686	rs2991979	chr1:46055858	A/G	cg03146154	chr1:46216737	IPP	-0.55	-10.1	-0.42	8.44e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6546537	0.911	rs13027712	chr2:69891367	C/T	cg10773587	chr2:69614142	GFPT1	-0.45	-7.34	-0.32	9.65e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs7166081	1.000	rs12901312	chr15:67591972	C/A	cg05925327	chr15:68127851	NA	-0.33	-6.94	-0.31	1.31e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.74	-0.59	4.86e-45	Skin colour saturation;
LGG	cis	rs4740619	0.792	rs13295778	chr9:15798634	C/T	cg14451791	chr9:16040625	NA	0.33	8.34	0.36	8.4e-16	Body mass index;
LGG	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg14926445	chr8:58193284	C8orf71	-0.86	-12.12	-0.49	1.53e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg23461800	chr14:103021989	NA	-0.52	-8.39	-0.36	5.9e-16	Platelet count;
LGG	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg21775007	chr8:11205619	TDH	-0.61	-9.69	-0.41	2.43e-20	Systolic blood pressure;
LGG	cis	rs7580658	0.711	rs12469035	chr2:127984917	A/G	cg10021288	chr2:128175891	PROC	-0.59	-12.0	-0.49	4.53e-29	Protein C levels;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg17951613	chr5:131705445	SLC22A5	0.61	6.92	0.31	1.52e-11	Rheumatoid arthritis;
LGG	cis	rs721917	0.586	rs2758550	chr10:81692362	C/T	cg25562619	chr10:81652821	NA	-0.34	-7.63	-0.33	1.34e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	6.67	0.3	7.43e-11	Monocyte count;
LGG	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.64	9.22	0.39	1.05e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg10230308	chr17:61678218	TACO1	-0.4	-6.87	-0.3	2.06e-11	Select biomarker traits;
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg11965913	chr1:205819406	PM20D1	-0.52	-9.52	-0.4	9.91e-20	Menarche (age at onset);
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg24503407	chr1:205819492	PM20D1	-0.52	-8.6	-0.37	1.2e-16	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.99e-48	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs620875	0.920	rs585079	chr11:126846430	T/C	cg06504925	chr11:126872760	NA	-0.53	-7.1	-0.31	4.65e-12	Response to antipsychotic treatment;
LGG	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-14.82	-0.57	5.94e-41	Colorectal cancer;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.33	0.32	1e-12	Schizophrenia;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs56146971	0.763	rs55950330	chr14:91872978	C/T	cg14409461	chr14:91925021	SMEK1	-0.42	-6.78	-0.3	3.76e-11	Alzheimer disease and age of onset;
LGG	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.2	-0.43	3.52e-22	Glycated hemoglobin levels;
LGG	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.38	-0.53	9.46e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg04287289	chr16:89883240	FANCA	0.79	16.5	0.61	1.92e-48	Vitiligo;
LGG	cis	rs12134040	0.557	rs61835534	chr1:236521578	A/G	cg21399712	chr1:236511386	NA	-0.36	-6.95	-0.31	1.22e-11	Urate levels (BMI interaction);
LGG	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg08048268	chr3:133502702	NA	-0.6	-11.17	-0.46	8.5e-26	Iron status biomarkers;
LGG	cis	rs11169552	0.510	rs4768853	chr12:50981785	A/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.47	-0.33	4.09e-13	Colorectal cancer;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.52	-0.67	2.31e-62	Rheumatoid arthritis;
LGG	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.13e-42	Aortic root size;
LGG	cis	rs1030877	0.960	rs3792049	chr2:105901908	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.72	-13.64	-0.54	7.21e-36	Obesity-related traits;
LGG	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg25930673	chr12:123319894	HIP1R	-0.77	-9.86	-0.42	5.83e-21	Schizophrenia;
LGG	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg20283391	chr11:68216788	NA	-0.5	-8.21	-0.36	2.17e-15	Total body bone mineral density;
LGG	cis	rs1891275	0.515	rs1361552	chr10:93534624	T/C	cg07889827	chr10:93443413	NA	-0.25	-6.67	-0.3	7.45e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.41	-8.41	-0.36	5.28e-16	Schizophrenia;
LGG	cis	rs5756391	0.782	rs735563	chr22:37296931	G/A	cg21209356	chr22:37319042	CSF2RB	0.34	7.46	0.33	4.33e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs365132	0.517	rs6881002	chr5:176336755	T/C	cg16309518	chr5:176445507	NA	0.5	10.0	0.42	1.83e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.97	0.64	3.57e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg13147721	chr7:65941812	NA	-0.8	-9.69	-0.41	2.46e-20	Diabetic kidney disease;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg02297831	chr4:17616191	MED28	0.51	9.5	0.4	1.1e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	4.14e-17	Lung cancer;
LGG	cis	rs17221829	0.627	rs7130892	chr11:89386606	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-6.99	-0.31	9.67e-12	Vitiligo;
LGG	cis	rs11700980	0.551	rs60360679	chr21:30118752	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.69	-0.3	6.66e-11	QRS complex (12-leadsum);
LGG	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-11.39	-0.47	1.19e-26	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg00677455	chr12:58241039	CTDSP2	0.43	7.7	0.34	8.56e-14	Multiple sclerosis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17996757	chr7:131013207	MKLN1	0.4	7.12	0.31	4.08e-12	Bipolar disorder;
LGG	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs4900538	0.821	rs12586673	chr14:102827643	C/T	cg18135206	chr14:102964638	TECPR2	-0.69	-12.04	-0.49	3.05e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg16482183	chr6:26056742	HIST1H1C	0.4	6.83	0.3	2.63e-11	Height;
LGG	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg15454534	chr1:248569605	OR2T1	0.38	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg26354017	chr1:205819088	PM20D1	0.54	8.72	0.38	5.01e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs9815354	1.000	rs939558	chr3:41976040	C/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.31	0.32	1.17e-12	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs56161922	0.818	rs111340461	chr1:207870682	A/C	cg09557387	chr1:207818395	CR1L	0.93	8.93	0.38	9.79e-18	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23857200	chr19:39882127	MED29;PAF1	0.44	6.67	0.3	7.19e-11	Gut microbiome composition (summer);
LGG	cis	rs7567389	0.583	rs11683427	chr2:127956543	A/G	cg11380483	chr2:127933992	NA	0.55	10.19	0.43	3.75e-22	Self-rated health;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00684032	chr4:1343700	KIAA1530	0.64	12.92	0.51	8.3e-33	Obesity-related traits;
LGG	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.29	0.58	5.11e-43	Platelet count;
LGG	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg22771759	chr13:24902376	NA	0.42	7.06	0.31	6.05e-12	Obesity-related traits;
LGG	cis	rs6834538	0.894	rs34712587	chr4:113485894	A/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.57	9.03	0.39	4.6e-18	Free thyroxine concentration;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.09	0.35	5.2e-15	Prostate cancer;
LGG	cis	rs7011049	0.749	rs112133624	chr8:53866605	T/C	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	5.74e-16	Systolic blood pressure;
LGG	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg08923054	chr8:41654455	ANK1	0.84	14.42	0.56	3.24e-39	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9948	0.881	rs7580942	chr2:97468276	C/G	cg01990225	chr2:97406019	LMAN2L	-0.61	-6.88	-0.3	1.89e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg12623918	chr2:306882	NA	0.53	9.86	0.42	6.01e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4262150	0.767	rs55786399	chr5:151945469	A/T	cg12297329	chr5:152029980	NA	-0.79	-15.1	-0.57	3.43e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg10760299	chr15:45669010	GATM	-0.4	-7.92	-0.35	1.76e-14	Homoarginine levels;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg11494091	chr17:61959527	GH2	1.0	24.55	0.75	7.72e-86	Prudent dietary pattern;
LGG	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.28	-0.36	1.37e-15	Triglycerides;
LGG	trans	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg06521331	chr12:34319734	NA	0.39	6.66	0.3	7.55e-11	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11084020	chr7:27779567	TAX1BP1	-0.54	-8.04	-0.35	7.46e-15	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.77	0.34	5.24e-14	Vitiligo;
LGG	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg05526886	chr2:227700861	RHBDD1	-0.49	-7.87	-0.34	2.45e-14	Coronary artery disease;
LGG	cis	rs7129220	0.512	rs1867138	chr11:10228728	A/G	cg01453529	chr11:10209919	SBF2	-0.47	-7.33	-0.32	1.06e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2273669	0.915	rs4470881	chr6:109309287	A/G	cg05315195	chr6:109294784	ARMC2	-0.5	-7.16	-0.32	3.27e-12	Prostate cancer;
LGG	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg21609526	chr1:3105151	PRDM16	0.64	10.86	0.45	1.25e-24	Migraine;
LGG	cis	rs2334880	0.678	rs16973190	chr16:71508501	T/C	cg06353428	chr16:71660113	MARVELD3	-1.01	-13.74	-0.54	2.93e-36	Malaria;
LGG	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23221052	chr5:179740743	GFPT2	-0.62	-11.22	-0.46	5.31e-26	Height;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg16507663	chr6:150244633	RAET1G	-0.44	-7.15	-0.32	3.42e-12	Lung cancer;
LGG	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	trans	rs853679	0.760	rs967005	chr6:28210688	C/T	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.39e-11	Depression;
LGG	cis	rs367615	0.959	rs2201016	chr5:108947287	T/C	cg17395555	chr5:108820864	NA	0.63	8.89	0.38	1.41e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg10382835	chr6:42185730	MRPS10	0.65	7.15	0.32	3.3e-12	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	cis	rs2797160	1.000	rs984040	chr6:126021277	A/G	cg05901451	chr6:126070800	HEY2	0.43	7.34	0.32	9.8e-13	Endometrial cancer;
LGG	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg21385522	chr1:16154831	NA	0.63	10.44	0.44	4.79e-23	Dilated cardiomyopathy;
LGG	cis	rs4702718	0.603	rs2930049	chr5:10699490	A/G	cg18867653	chr5:10760375	DAP	0.29	7.21	0.32	2.34e-12	Obesity-related traits;
LGG	trans	rs800082	0.966	rs2575192	chr3:144281170	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.31	0.36	1.11e-15	Smoking behavior;
LGG	trans	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg10756647	chr7:56101905	PSPH	-0.64	-7.27	-0.32	1.57e-12	Diabetic kidney disease;
LGG	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg23461800	chr14:103021989	NA	-0.5	-9.2	-0.39	1.24e-18	Platelet count;
LGG	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.89	-0.34	2.18e-14	Blood metabolite levels;
LGG	cis	rs42648	0.935	rs42659	chr7:89981958	A/G	cg25739043	chr7:89950458	NA	-0.38	-8.0	-0.35	9.98e-15	Homocysteine levels;
LGG	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.74	0.34	6.52e-14	Cannabis dependence symptom count;
LGG	cis	rs12286929	0.687	rs6589487	chr11:115089927	T/C	cg04055981	chr11:115044050	NA	-0.39	-7.33	-0.32	1.02e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.88	-0.38	1.48e-17	Myopia (pathological);
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg24623649	chr8:11872141	NA	-0.34	-8.18	-0.36	2.67e-15	Triglycerides;
LGG	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg03060546	chr3:49711283	APEH	-0.69	-11.66	-0.48	1.02e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs651907	0.967	rs694936	chr3:101587793	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.42	7.41	0.33	5.94e-13	Colorectal cancer;
LGG	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.36	0.36	7.14e-16	Educational attainment;
LGG	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.67	-0.3	7.41e-11	Renal cell carcinoma;
LGG	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs4319547	0.626	rs10744210	chr12:122931793	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.23	-0.43	2.85e-22	Body mass index;
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.69	-0.3	6.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3847687	0.869	rs11061300	chr12:131523261	G/A	cg06093039	chr12:131527216	GPR133	0.32	7.89	0.34	2.18e-14	Longevity;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.5	9.67	0.41	2.81e-20	Glycated hemoglobin levels;
LGG	cis	rs877282	0.853	rs12779017	chr10:763619	T/C	cg17470449	chr10:769945	NA	0.56	6.79	0.3	3.51e-11	Uric acid levels;
LGG	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.39	-8.67	-0.37	7.21e-17	Bacteremia;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg02725872	chr8:58115012	NA	-0.84	-12.01	-0.49	3.91e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg17545662	chr6:170176663	C6orf70	0.66	7.82	0.34	3.53e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2239547	0.563	rs4687699	chr3:53101224	C/T	cg11645453	chr3:52864694	ITIH4	0.67	10.6	0.44	1.23e-23	Schizophrenia;
LGG	cis	rs36051895	0.587	rs7871070	chr9:5040786	T/A	cg02405213	chr9:5042618	JAK2	-0.84	-16.26	-0.6	2.38e-47	Pediatric autoimmune diseases;
LGG	cis	rs12195424	1.000	rs12195424	chr6:56298722	G/A	cg07152817	chr6:56299822	NA	-0.54	-7.09	-0.31	4.96e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs7113850	0.512	rs11027747	chr11:24197995	A/G	ch.11.24196551F	chr11:24239977	NA	-0.68	-8.7	-0.37	5.84e-17	Bone fracture in osteoporosis;
LGG	trans	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg20587970	chr11:113659929	NA	-0.7	-11.52	-0.47	3.66e-27	Hip circumference adjusted for BMI;
LGG	cis	rs919433	0.783	rs788007	chr2:198233676	T/G	cg00792783	chr2:198669748	PLCL1	0.46	7.31	0.32	1.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7923609	0.934	rs10761771	chr10:65230164	T/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.7	-0.3	6.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.12e-25	Corneal astigmatism;
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.78	-0.3	3.71e-11	Bipolar disorder;
LGG	cis	rs96067	0.711	rs795047	chr1:36637708	C/T	cg24686825	chr1:36642396	MAP7D1	0.45	9.37	0.4	3.16e-19	Corneal structure;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg05941027	chr17:61774174	LIMD2	0.37	9.64	0.41	3.75e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7216064	0.953	rs58141639	chr17:65864902	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.07e-17	Lung cancer;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.75	0.45	3.31e-24	Personality dimensions;
LGG	cis	rs2841233	0.692	rs2028416	chr14:105348552	C/T	cg16576083	chr14:105354267	KIAA0284	0.35	7.15	0.32	3.45e-12	IgG glycosylation;
LGG	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg14675211	chr2:100938903	LONRF2	0.46	7.21	0.32	2.26e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.61	-0.33	1.5700000000000001e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg21775007	chr8:11205619	TDH	0.46	6.94	0.31	1.31e-11	Neuroticism;
LGG	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg26384229	chr12:38710491	ALG10B	1.06	28.12	0.79	3.3e-102	Heart rate;
LGG	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg23461800	chr14:103021989	NA	-0.59	-10.86	-0.45	1.28e-24	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04529602	chr19:14228303	PRKACA	0.48	6.98	0.31	1.04e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.46	-7.85	-0.34	2.84e-14	Height;
LGG	cis	rs7010267	0.596	rs12682278	chr8:120032328	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.32	-8.17	-0.35	2.98e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs6540556	0.723	rs6672256	chr1:209894043	A/T	cg23920097	chr1:209922102	NA	0.41	6.75	0.3	4.31e-11	Red blood cell count;
LGG	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.99	0.55	2.34e-37	Lung cancer in ever smokers;
LGG	cis	rs2075371	0.501	rs1643043	chr7:134013902	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	8.86	0.38	1.68e-17	Mean platelet volume;
LGG	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg06521331	chr12:34319734	NA	0.43	7.64	0.33	1.23e-13	Heart rate;
LGG	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg23682824	chr7:23144976	KLHL7	0.39	6.84	0.3	2.49e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg06241208	chr11:30344200	C11orf46	0.51	6.75	0.3	4.52e-11	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs11971779	0.680	rs4398844	chr7:139043139	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.98e-12	Diisocyanate-induced asthma;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.77	-15.34	-0.58	3.17e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6704644	0.932	rs3796092	chr2:234390469	A/C	cg27060346	chr2:234359958	DGKD	0.57	6.76	0.3	4.23e-11	Bilirubin levels;
LGG	cis	rs6743226	0.603	rs3771343	chr2:242204286	A/G	cg10021735	chr2:242295487	FARP2	0.41	7.3	0.32	1.23e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs2282032	1.000	rs114316342	chr14:90736477	C/T	cg04374321	chr14:90722782	PSMC1	0.49	6.71	0.3	5.69e-11	Longevity;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.19	-0.36	2.54e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.6	-0.47	1.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-8.45	-0.37	3.7e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg05926928	chr17:57297772	GDPD1	-1.06	-14.03	-0.55	1.67e-37	Opioid sensitivity;
LGG	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs11630290	0.592	rs12324668	chr15:64161786	A/T	cg12036633	chr15:63758958	NA	0.49	6.92	0.31	1.51e-11	Iris characteristics;
LGG	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.58	0.53	1.38e-35	Cognitive test performance;
LGG	trans	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg10756647	chr7:56101905	PSPH	0.8	9.38	0.4	2.9e-19	Diabetic kidney disease;
LGG	cis	rs972578	1.000	rs738381	chr22:43404107	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.75	-0.3	4.53e-11	Mean platelet volume;
LGG	cis	rs11971779	0.680	rs10265718	chr7:139100068	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-6.9	-0.31	1.76e-11	Ankle injury;
LGG	cis	rs4538187	0.529	rs13013890	chr2:63654109	G/A	cg02541582	chr2:64069798	UGP2	-0.5	-7.61	-0.33	1.51e-13	Systolic blood pressure;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11316940	chr10:69524027	NA	0.4	7.01	0.31	8.3e-12	Obesity-related traits;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg06916706	chr16:4465613	CORO7	-0.87	-15.97	-0.6	4.64e-46	Schizophrenia;
LGG	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg04731861	chr2:219085781	ARPC2	-0.44	-10.83	-0.45	1.66e-24	Colorectal cancer;
LGG	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.07	-0.55	1.08e-37	Platelet distribution width;
LGG	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	9.99	0.42	2e-21	Iron status biomarkers;
LGG	cis	rs698813	0.674	rs6544752	chr2:44499049	G/A	cg00619915	chr2:44497795	NA	-0.6	-8.68	-0.37	6.81e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg05696931	chr1:227175867	NA	-0.39	-7.66	-0.34	1.09e-13	Myeloid white cell count;
LGG	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.5	0.33	3.29e-13	Schizophrenia;
LGG	trans	rs9650657	0.740	rs2277130	chr8:10677601	G/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.22	-0.32	2.11e-12	Neuroticism;
LGG	cis	rs818427	0.927	rs153546	chr5:112238039	A/C	cg07820702	chr5:112228657	REEP5	-0.36	-6.74	-0.3	4.77e-11	Total body bone mineral density;
LGG	cis	rs17253792	0.822	rs10137364	chr14:56059987	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.13	-0.31	3.83e-12	Life satisfaction;
LGG	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.81	0.54	1.46e-36	Eye color traits;
LGG	cis	rs12711979	0.509	rs10195596	chr2:3824222	T/G	cg17052675	chr2:3827356	NA	-0.49	-9.7	-0.41	2.29e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.09	0.39	2.94e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg22901337	chr14:23790498	PABPN1	-0.38	-6.97	-0.31	1.12e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2018683	0.707	rs917216	chr7:28971472	A/G	cg19402173	chr7:128379420	CALU	-0.54	-9.32	-0.4	4.75e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.6	-0.33	1.71e-13	Pancreatic cancer;
LGG	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.56	0.44	1.65e-23	Diabetic retinopathy;
LGG	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg00198680	chr16:28758506	NA	0.29	6.96	0.31	1.14e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.32	0.36	1.02e-15	Tonsillectomy;
LGG	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg00531865	chr16:30841666	NA	-0.71	-17.52	-0.63	4.43e-53	Dementia with Lewy bodies;
LGG	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg25019033	chr10:957182	NA	-0.54	-9.96	-0.42	2.63e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.2	-0.32	2.43e-12	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.01	0.39	5.61e-18	Motion sickness;
LGG	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.63e-18	Motion sickness;
LGG	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.47	0.33	4.07e-13	Total cholesterol levels;
LGG	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg12573674	chr2:1569213	NA	-0.61	-9.83	-0.42	7.55e-21	IgG glycosylation;
LGG	cis	rs1707322	0.890	rs2297883	chr1:46511487	G/C	cg03146154	chr1:46216737	IPP	-0.53	-10.07	-0.42	1.08e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg24699146	chr1:24152579	HMGCL	0.26	7.84	0.34	3.03e-14	Immature fraction of reticulocytes;
LGG	cis	rs514024	0.700	rs10118731	chr9:130418652	G/A	cg13643465	chr9:130375613	STXBP1	0.62	11.73	0.48	5.13e-28	Eating disorders (purging via substances);
LGG	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg22348356	chr13:114891224	RASA3	0.4	7.83	0.34	3.25e-14	Schizophrenia;
LGG	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg00647317	chr7:50633725	DDC	-0.32	-7.17	-0.32	2.99e-12	Malaria;
LGG	cis	rs2694528	0.844	rs6894261	chr5:60057873	T/C	cg11474532	chr5:59995715	DEPDC1B	0.73	7.81	0.34	3.74e-14	Parkinson's disease;
LGG	cis	rs526231	0.543	rs34785	chr5:102458103	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg05896524	chr21:47604654	C21orf56	-0.59	-10.67	-0.44	6.78e-24	Testicular germ cell tumor;
LGG	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg24130564	chr14:104152367	KLC1	-0.76	-16.8	-0.62	8.75e-50	Intelligence (multi-trait analysis);
LGG	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg02002194	chr4:3960332	NA	-0.38	-7.0	-0.31	9.1e-12	Neuroticism;
LGG	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.3e-14	Aortic root size;
LGG	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg12310025	chr6:25882481	NA	0.52	9.53	0.41	8.63e-20	Blood metabolite levels;
LGG	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.92e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07080220	chr10:102295463	HIF1AN	0.64	11.11	0.46	1.45e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7681440	0.626	rs2289515	chr4:90816790	T/A	cg26578617	chr4:90757533	SNCA	-0.36	-6.93	-0.31	1.42e-11	Dementia with Lewy bodies;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	cis	rs2718058	0.515	rs1584611	chr7:37874039	T/C	cg24998770	chr7:37888106	TXNDC3	0.54	9.5	0.4	1.14e-19	Alzheimer's disease (late onset);
LGG	cis	rs68170813	0.652	rs7784906	chr7:107148386	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-8.63	-0.37	9.68e-17	Coronary artery disease;
LGG	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.35	-0.47	1.63e-26	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg16507663	chr6:150244633	RAET1G	0.44	8.34	0.36	8.38e-16	Lung cancer;
LGG	cis	rs9354308	0.764	rs4327677	chr6:66594700	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg05368731	chr17:41323189	NBR1	0.89	17.65	0.63	1.07e-53	Menopause (age at onset);
LGG	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.5	0.37	2.63e-16	Prudent dietary pattern;
LGG	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.7	-0.34	8.06e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg16885296	chr6:26284938	NA	0.35	7.1	0.31	4.6e-12	Educational attainment;
LGG	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg03162506	chr22:38580953	NA	0.36	8.52	0.37	2.27e-16	Breast cancer;
LGG	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg24998770	chr7:37888106	TXNDC3	0.58	9.92	0.42	3.64e-21	Alzheimer's disease (late onset);
LGG	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.23	-0.32	2.04e-12	Common traits (Other);
LGG	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg11757124	chr7:157526947	PTPRN2	-0.79	-14.28	-0.55	1.32e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	8.03	0.35	7.89e-15	Educational attainment;
LGG	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg08344181	chr3:125677491	NA	-0.65	-7.71	-0.34	7.73e-14	Depression;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25072359	chr17:41440525	NA	0.52	9.9	0.42	4.45e-21	Menopause (age at onset);
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.81	0.3	3.03e-11	Prudent dietary pattern;
LGG	trans	rs12339094	0.932	rs7025854	chr9:90405614	A/T	cg24436365	chr6:63940138	NA	0.42	6.73	0.3	4.92e-11	Smoking quantity;
LGG	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-6.71	-0.3	5.6e-11	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg06521331	chr12:34319734	NA	0.44	7.77	0.34	5e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg01206211	chr2:36825736	FEZ2	0.42	7.84	0.34	3.14e-14	Height;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.75	-0.38	4.05e-17	IgG glycosylation;
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg16434002	chr17:42200994	HDAC5	-0.54	-10.01	-0.42	1.78e-21	Total body bone mineral density;
LGG	cis	rs12493885	0.654	rs61793488	chr3:153730551	T/C	cg17054900	chr3:154042577	DHX36	-0.72	-8.75	-0.38	3.92e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4330281	0.647	rs12493567	chr3:17426616	A/G	cg20981856	chr3:17787350	NA	0.35	6.66	0.3	7.82e-11	Schizophrenia;
LGG	cis	rs9640161	0.789	rs34311995	chr7:150059255	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-10.68	-0.44	6e-24	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7100689	0.646	rs10887808	chr10:82137367	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	15.38	0.58	2.04e-43	Post bronchodilator FEV1;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.5	-0.4	1.14e-19	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4936894	0.500	rs10893201	chr11:124165209	A/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.87	-0.45	1.2e-24	Aging (time to death);
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg11473876	chr11:109292803	C11orf87	0.46	9.31	0.4	5.01e-19	Schizophrenia;
LGG	cis	rs12580194	0.593	rs11171432	chr12:55757696	G/C	cg19537932	chr12:55886519	OR6C68	-0.55	-10.12	-0.43	7e-22	Cancer;
LGG	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg13877915	chr19:58951672	ZNF132	0.59	8.52	0.37	2.26e-16	Mean platelet volume;
LGG	cis	rs988913	1.000	rs1393776	chr6:54763018	A/C	cg03513858	chr6:54763001	FAM83B	0.3	6.66	0.3	7.82e-11	Menarche (age at onset);
LGG	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.89e-22	Cannabis dependence symptom count;
LGG	trans	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg09048205	chr5:1608656	LOC728613	-0.5	-8.42	-0.36	4.84e-16	Breast cancer;
LGG	cis	rs607541	0.764	rs629466	chr15:45934745	A/T	cg26924012	chr15:45694286	SPATA5L1	0.54	7.59	0.33	1.8e-13	Obesity-related traits;
LGG	trans	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.93	0.42	3.43e-21	Mean corpuscular volume;
LGG	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg19773385	chr1:10388646	KIF1B	-0.47	-9.21	-0.39	1.1e-18	Hepatocellular carcinoma;
LGG	cis	rs151997	0.671	rs27845	chr5:50197420	A/C	cg06027927	chr5:50259733	NA	0.62	10.38	0.43	7.77e-23	Callous-unemotional behaviour;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg07157834	chr1:205819609	PM20D1	-0.39	-7.16	-0.32	3.17e-12	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	4.85e-22	Menopause (age at onset);
LGG	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg07541023	chr7:19748670	TWISTNB	0.46	7.19	0.32	2.59e-12	Thyroid stimulating hormone;
LGG	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg07423050	chr13:99094983	FARP1	-0.56	-10.84	-0.45	1.53e-24	Longevity;
LGG	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg05484508	chr16:89589025	SPG7	0.44	7.13	0.31	3.82e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs3093024	0.839	rs968334	chr6:167526096	T/C	cg07741184	chr6:167504864	NA	-0.37	-8.08	-0.35	5.66e-15	Rheumatoid arthritis;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	1.88e-24	Alzheimer's disease;
LGG	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg13010199	chr12:38710504	ALG10B	0.47	8.47	0.37	3.38e-16	Morning vs. evening chronotype;
LGG	cis	rs4132509	1.000	rs9287269	chr1:243954551	G/A	cg21452805	chr1:244014465	NA	0.66	7.94	0.35	1.52e-14	RR interval (heart rate);
LGG	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg17294928	chr15:75287854	SCAMP5	-0.8	-8.72	-0.38	5.1e-17	Lung cancer;
LGG	cis	rs56145559	1	rs56145559	chr2:73623439	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.84	-0.34	3.22e-14	Schizophrenia;
LGG	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.71	0.3	5.85e-11	Bone mineral density;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs68170813	0.559	rs79564258	chr7:107059803	C/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.15	-0.43	5.48e-22	Coronary artery disease;
LGG	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg02574844	chr11:5959923	NA	-0.57	-8.86	-0.38	1.74e-17	DNA methylation (variation);
LGG	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.63	0.63	1.41e-53	Cognitive function;
LGG	cis	rs12493885	0.585	rs787811	chr3:153622907	G/T	cg17054900	chr3:154042577	DHX36	-0.57	-7.15	-0.32	3.51e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg24011408	chr12:48396354	COL2A1	0.52	8.14	0.35	3.56e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25452632	chr12:56754141	STAT2	0.41	7.17	0.32	3.01e-12	Bilirubin levels;
LGG	cis	rs2354432	0.607	rs7553584	chr1:146693429	A/G	cg25205988	chr1:146714368	CHD1L	-1.09	-9.39	-0.4	2.82e-19	Mitochondrial DNA levels;
LGG	cis	rs2562456	0.516	rs56072098	chr19:21651960	G/T	cg00806126	chr19:22604979	ZNF98	0.63	9.28	0.4	6.55e-19	Pain;
LGG	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs7216064	0.953	rs62086044	chr17:65970837	G/T	cg12091567	chr17:66097778	LOC651250	-0.62	-9.25	-0.39	8.43e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs17767392	0.881	rs12880188	chr14:72009745	C/G	cg02058870	chr14:72053146	SIPA1L1	0.43	9.13	0.39	2.18e-18	Mitral valve prolapse;
LGG	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg15440763	chr7:158190612	PTPRN2	-0.45	-9.75	-0.41	1.55e-20	Obesity-related traits;
LGG	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg07395648	chr5:131743802	NA	-0.56	-13.28	-0.53	2.43e-34	Blood metabolite levels;
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg00800038	chr16:89945340	TCF25	-0.73	-8.33	-0.36	9.06e-16	Skin colour saturation;
LGG	cis	rs7660883	0.897	rs236987	chr4:88009779	C/T	cg21988461	chr4:88008667	AFF1	-0.35	-9.77	-0.41	1.3e-20	HDL cholesterol levels;
LGG	cis	rs4965869	0.866	rs11856843	chr15:101976244	T/C	cg12371147	chr15:101978424	PCSK6	-0.42	-7.65	-0.33	1.17e-13	Platelet-derived growth factor BB levels;
LGG	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg03162506	chr22:38580953	NA	0.41	9.76	0.41	1.35e-20	Breast cancer;
LGG	cis	rs7766436	0.767	rs6456497	chr6:22603559	G/A	cg13666174	chr6:22585274	NA	-0.35	-8.53	-0.37	2.11e-16	Coronary artery disease;
LGG	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg10760299	chr15:45669010	GATM	0.37	7.08	0.31	5.47e-12	Homoarginine levels;
LGG	cis	rs12580194	0.593	rs7959837	chr12:55734511	G/A	cg19537932	chr12:55886519	OR6C68	-0.53	-9.65	-0.41	3.49e-20	Cancer;
LGG	cis	rs10924309	0.737	rs6701023	chr1:245854503	C/G	cg00036263	chr1:245852353	KIF26B	0.44	7.02	0.31	8.05e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg15242686	chr22:24348715	GSTTP1	0.37	6.96	0.31	1.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg12432903	chr7:1882776	MAD1L1	0.49	7.22	0.32	2.16e-12	Bipolar disorder;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg25703541	chr22:24373054	LOC391322	-0.99	-20.84	-0.7	1.59e-68	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.7	-0.79	2.69e-100	Schizophrenia;
LGG	cis	rs7917772	0.536	rs11191361	chr10:104411958	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.8	0.48	2.78e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6942756	0.713	rs692597	chr7:129132554	T/G	cg02491457	chr7:128862824	NA	-0.63	-10.99	-0.45	3.91e-25	White matter hyperintensity burden;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg13903179	chr13:21900392	NA	0.47	8.71	0.38	5.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg15268244	chr15:77196840	NA	0.47	9.96	0.42	2.71e-21	Blood metabolite levels;
LGG	cis	rs12049351	0.665	rs12140368	chr1:229571570	C/T	cg13547644	chr1:229569608	ACTA1	0.32	6.99	0.31	9.81e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs9916302	0.904	rs11654018	chr17:37703740	C/T	cg07936489	chr17:37558343	FBXL20	0.84	15.62	0.59	1.69e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-16.51	-0.61	1.72e-48	Total body bone mineral density;
LGG	cis	rs10864907	0.614	rs12468164	chr2:113712783	C/T	cg06156847	chr2:113672199	IL1F7	0.37	7.41	0.33	5.89e-13	Pulmonary function;
LGG	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.77	0.34	5.28e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs28374715	0.662	rs8038983	chr15:41473316	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-18.2	-0.65	3.03e-56	Ulcerative colitis;
LGG	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg23029597	chr12:123009494	RSRC2	-0.91	-16.78	-0.61	1.05e-49	Body mass index;
LGG	trans	rs61931739	0.620	rs7138912	chr12:33701863	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.58	-0.37	1.4e-16	Morning vs. evening chronotype;
LGG	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg09173681	chr1:183549694	NCF2	-0.37	-8.31	-0.36	1.07e-15	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg14664628	chr15:75095509	CSK	0.57	9.77	0.41	1.27e-20	Systemic lupus erythematosus;
LGG	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg21775007	chr8:11205619	TDH	-0.47	-7.66	-0.34	1.07e-13	Triglycerides;
LGG	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg02002194	chr4:3960332	NA	0.53	9.71	0.41	1.99e-20	Retinal vascular caliber;
LGG	cis	rs7301016	0.707	rs7302602	chr12:63052199	C/T	cg11441379	chr12:63026424	NA	-0.55	-7.81	-0.34	3.94e-14	IgG glycosylation;
LGG	cis	rs6688613	0.685	rs10918599	chr1:166918786	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.45	6.71	0.3	5.84e-11	Refractive astigmatism;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.04	-0.46	2.68e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg21775007	chr8:11205619	TDH	-0.43	-6.94	-0.31	1.33e-11	Triglycerides;
LGG	cis	rs921968	0.643	rs545460	chr2:219392159	A/G	cg01130898	chr2:219473002	PLCD4	-0.39	-6.68	-0.3	6.98e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08280861	chr8:58055591	NA	0.64	7.98	0.35	1.18e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.55	0.41	7.39e-20	Renal function-related traits (BUN);
LGG	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg20913747	chr6:44695427	NA	-0.51	-7.46	-0.33	4.31e-13	Total body bone mineral density;
LGG	cis	rs17221829	0.733	rs10830333	chr11:89399224	T/C	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.7	-0.37	5.68e-17	Anxiety in major depressive disorder;
LGG	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg16329650	chr2:213403929	ERBB4	0.5	8.09	0.35	5.1e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs735539	0.555	rs2762990	chr13:21371427	T/C	cg04906043	chr13:21280425	IL17D	-0.45	-7.16	-0.32	3.18e-12	Dental caries;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	10.35	0.43	1.04e-22	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.7	-0.59	8e-45	Skin colour saturation;
LGG	cis	rs11792861	0.816	rs11791845	chr9:111683898	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.22	0.43	3e-22	Menarche (age at onset);
LGG	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.06	0.39	3.61e-18	Resting heart rate;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.85	0.3	2.4e-11	Schizophrenia;
LGG	cis	rs4148883	0.645	rs2851287	chr4:100014548	G/A	cg12011299	chr4:100065546	ADH4	0.4	8.46	0.37	3.57e-16	Alcohol dependence;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg22907277	chr7:1156413	C7orf50	0.68	8.51	0.37	2.35e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13102973	0.640	rs10434069	chr4:135840778	G/A	cg14419869	chr4:135874104	NA	0.51	9.51	0.4	1.01e-19	Subjective well-being;
LGG	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05926928	chr17:57297772	GDPD1	1.38	21.4	0.71	3.86e-71	Opioid sensitivity;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.25	0.49	4.53e-30	Prudent dietary pattern;
LGG	cis	rs6909430	0.808	rs2505060	chr6:98583468	G/A	cg12860156	chr6:98744658	NA	-0.42	-7.29	-0.32	1.39e-12	Quantitative traits;
LGG	cis	rs13177180	0.705	rs256965	chr5:114937967	G/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.42	-9.32	-0.4	4.78e-19	Conotruncal heart defects (inherited effects);
LGG	cis	rs7928758	1.000	rs58475265	chr11:134264142	T/C	cg25213107	chr11:134282864	B3GAT1	0.95	12.38	0.5	1.26e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.55	0.33	2.32e-13	Educational attainment;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg19223190	chr17:80058835	NA	-0.45	-8.9	-0.38	1.23e-17	Life satisfaction;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.94	-0.38	9.34e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg20309703	chr11:118481025	PHLDB1	0.57	11.13	0.46	1.19e-25	Cholesterol, total;
LGG	cis	rs4776059	1.000	rs3751614	chr15:52901638	T/C	cg22715398	chr15:52968154	KIAA1370	-0.51	-8.56	-0.37	1.73e-16	Schizophrenia;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.68	0.61	3.07e-49	Personality dimensions;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.3	0.32	1.23e-12	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg02631450	chr22:32366979	NA	0.99	9.32	0.4	4.83e-19	Childhood ear infection;
LGG	cis	rs1784581	1.000	rs1618170	chr6:162400337	C/T	cg17173639	chr6:162384350	PARK2	-0.84	-21.09	-0.7	1.06e-69	Itch intensity from mosquito bite;
LGG	cis	rs2227564	0.620	rs3812637	chr10:75568846	C/T	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.84	-0.42	7.33e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.83	-0.38	2.16e-17	Colorectal cancer;
LGG	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg14191688	chr11:70257035	CTTN	0.55	8.32	0.36	1.01e-15	Coronary artery disease;
LGG	cis	rs9938149	0.736	rs7501402	chr16:88320911	A/T	cg05435882	chr16:88311214	NA	-0.38	-6.69	-0.3	6.42e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs7727544	0.904	rs6897575	chr5:131604535	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.91	-0.31	1.61e-11	Blood metabolite levels;
LGG	cis	rs3617	0.625	rs2535633	chr3:52859630	C/G	cg11645453	chr3:52864694	ITIH4	-0.45	-7.62	-0.33	1.41e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.93	-0.31	1.43e-11	Response to amphetamines;
LGG	trans	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg25214090	chr10:38739885	LOC399744	0.65	11.51	0.47	3.89e-27	Corneal astigmatism;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg00080972	chr5:178986291	RUFY1	0.53	8.76	0.38	3.83e-17	Lung cancer;
LGG	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.33	-0.36	9.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg08847533	chr14:75593920	NEK9	0.55	10.35	0.43	9.91e-23	Height;
LGG	cis	rs8017423	0.967	rs17188605	chr14:90722579	C/T	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg18681998	chr4:17616180	MED28	0.87	19.94	0.68	2.59e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4262150	0.810	rs72797215	chr5:151960560	C/G	cg12297329	chr5:152029980	NA	-0.81	-15.87	-0.59	1.37e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg08621203	chr6:150244597	RAET1G	0.41	6.94	0.31	1.32e-11	Lung cancer;
LGG	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.38	-0.4	3.01e-19	Bone mineral density;
LGG	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg01631408	chr1:248437212	OR2T33	0.52	9.51	0.4	1.03e-19	Common traits (Other);
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.67	0.34	9.99e-14	Schizophrenia;
LGG	cis	rs7949566	0.639	rs752806	chr11:126293239	A/T	cg05055844	chr11:126275997	ST3GAL4	-0.33	-6.79	-0.3	3.39e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs7586879	0.616	rs6545814	chr2:25131316	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.94	0.52	6.77e-33	Body mass index;
LGG	cis	rs6942756	1.000	rs13235749	chr7:128879678	C/G	cg02491457	chr7:128862824	NA	-0.78	-14.38	-0.56	5.03e-39	White matter hyperintensity burden;
LGG	cis	rs509477	0.718	rs273356	chr18:32597462	A/T	cg23791764	chr18:32556832	MAPRE2	0.44	7.44	0.33	4.98e-13	Cerebrospinal fluid AB1-42 levels;
LGG	trans	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs9875589	0.509	rs7614591	chr3:14061118	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs3092073	0.624	rs11696196	chr20:44574533	C/T	cg27529037	chr20:44575021	PCIF1	0.39	7.35	0.32	8.77e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg06529181	chr19:52193933	NA	0.54	8.09	0.35	5.45e-15	IgG glycosylation;
LGG	cis	rs7000551	0.689	rs6997299	chr8:22324268	T/C	cg12081754	chr8:22256438	SLC39A14	0.68	13.07	0.52	1.83e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg24623649	chr8:11872141	NA	-0.29	-6.79	-0.3	3.52e-11	Triglycerides;
LGG	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.86	-0.45	1.24e-24	Morning vs. evening chronotype;
LGG	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg13144783	chr3:46249795	CCR1	0.62	13.42	0.53	6.24e-35	Eotaxin levels;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13012494	chr21:47604986	C21orf56	-0.58	-10.15	-0.43	5.63e-22	Testicular germ cell tumor;
LGG	cis	rs4771450	0.962	rs7336353	chr13:103974900	G/A	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs757081	0.667	rs17641418	chr11:17161341	T/C	cg15432903	chr11:17409602	KCNJ11	-0.56	-9.29	-0.4	6.01e-19	Systolic blood pressure;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06032540	chr15:43941563	CATSPER2	0.38	6.93	0.31	1.38e-11	Menarche (age at onset);
LGG	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg17764715	chr19:33622953	WDR88	0.6	10.93	0.45	7e-25	Bone properties (heel);
LGG	cis	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg00383909	chr3:49044727	WDR6	1.12	12.32	0.5	2.4e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.85e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg23782820	chr8:58130467	NA	0.54	7.46	0.33	4.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg02733842	chr7:1102375	C7orf50	0.74	10.88	0.45	1.03e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs701145	0.585	rs1527799	chr3:153811226	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.86	0.38	1.79e-17	Coronary artery disease;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4730250	0.707	rs257382	chr7:106804249	A/G	cg02696742	chr7:106810147	HBP1	-0.8	-11.41	-0.47	9.86e-27	Osteoarthritis;
LGG	trans	rs9354308	0.868	rs2882754	chr6:66537341	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.51	8.71	0.38	5.57e-17	Metabolite levels;
LGG	trans	rs783540	1.000	rs698500	chr15:83237769	T/C	cg16105309	chr15:79090380	ADAMTS7	0.42	7.31	0.32	1.15e-12	Schizophrenia;
LGG	cis	rs10991814	0.920	rs78978656	chr9:94090130	G/A	cg14446406	chr9:93919335	NA	-0.68	-7.67	-0.34	9.91e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07440826	chr16:89882328	FANCA	-0.27	-6.87	-0.3	2.03e-11	Schizophrenia;
LGG	cis	rs61931739	0.547	rs7966400	chr12:33703107	C/T	cg06521331	chr12:34319734	NA	0.4	6.86	0.3	2.26e-11	Morning vs. evening chronotype;
LGG	cis	rs524281	0.861	rs11227409	chr11:65870938	A/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg24922022	chr4:827675	NA	0.41	8.34	0.36	8.42e-16	Systemic sclerosis;
LGG	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.01	-0.64	2.4e-55	Blood trace element (Zn levels);
LGG	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg15704280	chr7:45808275	SEPT13	0.78	8.01	0.35	9.3e-15	Axial length;
LGG	trans	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg17830980	chr10:43048298	ZNF37B	0.4	8.87	0.38	1.57e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg15704280	chr7:45808275	SEPT13	0.73	9.88	0.42	5.14e-21	Axial length;
LGG	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	cg07245641	chr1:182991651	LAMC1	0.4	8.87	0.38	1.59e-17	Colorectal cancer;
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.38	-0.32	7.58e-13	Prostate cancer;
LGG	cis	rs1707322	0.752	rs61784793	chr1:46149285	G/A	cg03146154	chr1:46216737	IPP	0.55	10.28	0.43	1.79e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg03078520	chr22:18463400	MICAL3	-0.69	-14.91	-0.57	2.38e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Calcium levels;
LGG	cis	rs2408955	0.500	rs12816820	chr12:48558325	A/G	cg24011408	chr12:48396354	COL2A1	0.57	9.44	0.4	1.88e-19	Glycated hemoglobin levels;
LGG	cis	rs912057	0.833	rs1294421	chr6:6743149	A/C	cg06612196	chr6:6737390	NA	0.46	9.39	0.4	2.66e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.41	10.52	0.44	2.29e-23	IgG glycosylation;
LGG	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg05775895	chr3:12838266	CAND2	0.69	12.77	0.51	3.3e-32	QRS complex (12-leadsum);
LGG	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06634786	chr22:41940651	POLR3H	-0.64	-10.89	-0.45	9.9e-25	Vitiligo;
LGG	cis	rs9297145	0.565	rs7794690	chr7:98764768	G/A	cg05967295	chr7:98741636	SMURF1	-0.68	-12.39	-0.5	1.15e-30	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7766436	0.621	rs9460765	chr6:22601221	G/A	cg13666174	chr6:22585274	NA	-0.33	-7.88	-0.34	2.3e-14	Coronary artery disease;
LGG	cis	rs4481887	0.504	rs6587434	chr1:248355563	G/A	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Common traits (Other);
LGG	cis	rs7555523	0.887	rs7518099	chr1:165736880	C/T	cg24409356	chr1:165738333	TMCO1	0.76	9.18	0.39	1.44e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs963731	0.571	rs4670270	chr2:39230351	G/A	cg04010122	chr2:39346883	SOS1	-0.79	-6.8	-0.3	3.33e-11	Corticobasal degeneration;
LGG	cis	rs8049040	1.000	rs7197127	chr16:71473836	G/A	cg08717414	chr16:71523259	ZNF19	-0.41	-6.75	-0.3	4.49e-11	Blood protein levels;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg05368731	chr17:41323189	NBR1	0.95	18.84	0.66	3.49e-59	Menopause (age at onset);
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg21548813	chr6:291882	DUSP22	-0.49	-8.71	-0.38	5.49e-17	Menopause (age at onset);
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.27	-0.32	1.52e-12	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.24e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs6076960	0.744	rs6053961	chr20:6176793	A/G	cg17788362	chr6:86352627	SYNCRIP	0.44	7.53	0.33	2.61e-13	Smooth-surface caries;
LGG	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06530960	chr19:49140787	SEC1;DBP	-0.53	-9.35	-0.4	3.75e-19	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg07117364	chr1:16154769	NA	-0.47	-7.1	-0.31	4.81e-12	Dilated cardiomyopathy;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg03511735	chr8:142405227	NA	-0.36	-7.1	-0.31	4.81e-12	Corneal astigmatism;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg12070911	chr6:150209640	RAET1E	0.33	8.13	0.35	3.98e-15	Lung cancer;
LGG	cis	rs3806843	1.000	rs10073974	chr5:140165231	T/C	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg13010199	chr12:38710504	ALG10B	0.59	11.56	0.47	2.48e-27	Morning vs. evening chronotype;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg20419181	chr4:38063874	TBC1D1	-0.41	-7.13	-0.31	3.89e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	trans	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg26384229	chr12:38710491	ALG10B	0.82	16.66	0.61	3.53e-49	Morning vs. evening chronotype;
LGG	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.55e-19	Colorectal cancer;
LGG	cis	rs6754311	0.731	rs7579771	chr2:136580260	T/A	cg07169764	chr2:136633963	MCM6	0.75	12.75	0.51	3.85e-32	Mosquito bite size;
LGG	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.63	0.33	1.39e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9470366	0.883	rs9462207	chr6:36627599	T/C	cg08179530	chr6:36648295	CDKN1A	0.64	9.19	0.39	1.32e-18	QRS duration;
LGG	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg15704280	chr7:45808275	SEPT13	0.72	9.93	0.42	3.43e-21	Axial length;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.44	0.37	4.03e-16	Prostate cancer;
LGG	trans	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg07211511	chr3:129823064	LOC729375	-0.5	-7.45	-0.33	4.74e-13	Blood pressure (smoking interaction);
LGG	cis	rs653465	0.678	rs11129261	chr3:27141808	T/A	cg02860705	chr3:27208620	NA	-0.4	-7.69	-0.34	8.82e-14	Breast cancer (early onset);
LGG	trans	rs11088226	0.681	rs16989507	chr21:33939509	T/G	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg12639453	chr1:2035780	PRKCZ	-0.66	-15.62	-0.59	1.67e-44	Height;
LGG	cis	rs35123781	1.000	rs9687282	chr5:139065988	T/G	cg21230503	chr5:139085173	NA	0.33	7.72	0.34	7.34e-14	Schizophrenia;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg07870213	chr5:140052090	DND1	0.93	17.17	0.62	1.81e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2721811	0.535	rs2721805	chr7:24780316	C/T	cg06301139	chr7:24798175	DFNA5	-0.46	-8.73	-0.38	4.63e-17	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg03293884	chr10:82215075	TSPAN14	-0.45	-8.91	-0.38	1.18e-17	Post bronchodilator FEV1;
LGG	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg02002194	chr4:3960332	NA	-0.44	-7.68	-0.34	9.55e-14	Neuroticism;
LGG	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg02297831	chr4:17616191	MED28	-0.48	-8.66	-0.37	7.72e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg06221963	chr1:154839813	KCNN3	-0.53	-11.18	-0.46	7.78e-26	Prostate cancer;
LGG	cis	rs4731207	0.596	rs7802210	chr7:124632460	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg18187862	chr3:45730750	SACM1L	0.43	7.01	0.31	8.58e-12	Primary sclerosing cholangitis;
LGG	trans	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19894588	chr14:64061835	NA	-0.57	-8.97	-0.38	7.21e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg26174226	chr8:58114915	NA	-0.52	-7.7	-0.34	8.2e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg06521331	chr12:34319734	NA	-0.63	-11.42	-0.47	8.76e-27	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg19507638	chr5:93509721	C5orf36	-0.7	-9.77	-0.41	1.23e-20	Diabetic retinopathy;
LGG	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg01028140	chr2:1542097	TPO	-0.58	-10.05	-0.42	1.29e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	-0.55	-9.66	-0.41	3.15e-20	Birth weight;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg14668632	chr7:2872130	GNA12	0.38	7.99	0.35	1.11e-14	Height;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.54	0.44	1.97e-23	Lung cancer in ever smokers;
LGG	cis	rs9796	0.621	rs557864	chr15:41471358	T/C	cg18705301	chr15:41695430	NDUFAF1	0.58	9.96	0.42	2.7e-21	Menopause (age at onset);
LGG	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.27	-0.6	2.18e-47	Headache;
LGG	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs240764	0.658	rs7451736	chr6:101189901	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg04743876	chr7:130013617	NA	0.37	8.36	0.36	7.3e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg26874164	chr19:58962979	ZNF324B	0.36	7.05	0.31	6.47e-12	Uric acid clearance;
LGG	cis	rs9467711	0.651	rs13191776	chr6:25955741	C/T	cg21479132	chr6:26055353	NA	0.82	7.23	0.32	2.08e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg11752832	chr7:134001865	SLC35B4	0.56	9.94	0.42	3.04e-21	Mean platelet volume;
LGG	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg00666640	chr1:248458726	OR2T12	0.58	9.36	0.4	3.6e-19	Common traits (Other);
LGG	trans	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg10756647	chr7:56101905	PSPH	0.46	6.98	0.31	1.04e-11	Corneal structure;
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.29	-0.32	1.39e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17253792	0.822	rs75936910	chr14:56149351	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg01059449	chr18:44338099	ST8SIA5	0.32	6.76	0.3	4.1e-11	Personality dimensions;
LGG	cis	rs11644362	0.966	rs4781348	chr16:12986742	A/C	cg06890432	chr16:12997467	SHISA9	-0.33	-7.19	-0.32	2.57e-12	Positive affect;Subjective well-being;
LGG	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.4	-6.92	-0.31	1.48e-11	Total body bone mineral density;
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg00149659	chr3:10157352	C3orf10	0.8	9.66	0.41	3.17e-20	Alzheimer's disease;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05025164	chr4:1340916	KIAA1530	0.65	12.24	0.49	5.02e-30	Longevity;
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.73	0.38	4.49e-17	Height;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00166722	chr3:10149974	C3orf24	0.51	8.62	0.37	1.1e-16	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.01	0.39	5.31e-18	Alzheimer's disease;
LGG	cis	rs4474465	0.850	rs4441045	chr11:78220436	G/T	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg14829155	chr15:31115871	NA	-0.55	-8.91	-0.38	1.16e-17	Huntington's disease progression;
LGG	cis	rs3204270	0.639	rs62080213	chr17:79642531	C/T	cg18367735	chr17:79674897	NA	0.57	7.34	0.32	9.82e-13	Dental caries;
LGG	cis	rs459571	1.000	rs467387	chr9:136907005	G/A	cg13789015	chr9:136890014	NCRNA00094	0.57	10.69	0.44	5.48e-24	Platelet distribution width;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05496738	chr2:26101556	ASXL2	-0.42	-6.65	-0.3	8.18e-11	Pancreatic cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19727439	chr1:37500508	GRIK3	0.61	6.96	0.31	1.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg24375607	chr4:120327624	NA	0.66	10.71	0.45	4.62e-24	Corneal astigmatism;
LGG	cis	rs10991814	0.920	rs79043982	chr9:94012532	G/A	cg14446406	chr9:93919335	NA	-0.75	-8.49	-0.37	2.89e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07701084	chr6:150067640	NUP43	0.42	7.68	0.34	9.88e-14	Testicular germ cell tumor;
LGG	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg26384229	chr12:38710491	ALG10B	-0.6	-10.85	-0.45	1.37e-24	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.05	0.39	4.13e-18	Blood metabolite levels;
LGG	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	17.61	0.63	1.63e-53	Smoking behavior;
LGG	cis	rs7166081	1.000	rs12911370	chr15:67546321	C/T	cg05925327	chr15:68127851	NA	-0.34	-7.18	-0.32	2.85e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03576123	chr11:487126	PTDSS2	-1.34	-17.31	-0.63	3.77e-52	Body mass index;
LGG	cis	rs3781663	0.553	rs875108	chr11:70004695	G/A	cg06393558	chr11:69982916	ANO1	-0.41	-7.81	-0.34	3.91e-14	Survival in rectal cancer;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19524238	chr7:2802976	GNA12	0.38	8.74	0.38	4.2e-17	Height;
LGG	trans	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg02002194	chr4:3960332	NA	0.42	7.36	0.32	8.54e-13	Mood instability;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg13206674	chr6:150067644	NUP43	0.67	14.98	0.57	1.24e-41	Lung cancer;
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg21775007	chr8:11205619	TDH	-0.41	-6.69	-0.3	6.33e-11	Neuroticism;
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.56	0.37	1.7e-16	Prostate cancer;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.09	0.35	5.25e-15	Schizophrenia;
LGG	cis	rs66561647	0.929	rs67423398	chr8:128972220	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.47	8.18	0.36	2.68e-15	Hemoglobin concentration;
LGG	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-17.3	-0.63	4.26e-52	Vitiligo;
LGG	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg03929089	chr4:120376271	NA	-0.44	-7.03	-0.31	7.34e-12	HDL cholesterol;
LGG	cis	rs10929925	0.931	rs4670030	chr2:6158152	A/G	cg00493617	chr2:6141445	NA	0.31	7.07	0.31	5.71e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg14917874	chr2:235941519	SH3BP4	0.47	8.35	0.36	7.77e-16	Dialysis-related mortality;
LGG	cis	rs7216064	1.000	rs8081517	chr17:65845697	A/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg09165964	chr15:75287851	SCAMP5	-0.85	-12.53	-0.5	3.35e-31	Blood trace element (Zn levels);
LGG	cis	rs2905347	0.656	rs2051723	chr7:22665843	C/G	cg18045685	chr7:22629474	NA	-0.73	-15.24	-0.58	8.94e-43	Major depression and alcohol dependence;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02399449	chr7:90032850	CLDN12	0.46	6.76	0.3	4.21e-11	Gut microbiome composition (summer);
LGG	cis	rs1707322	0.716	rs6694889	chr1:46101806	A/C	cg03146154	chr1:46216737	IPP	0.57	10.89	0.45	9.75e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg03605463	chr16:89740564	NA	0.49	8.47	0.37	3.17e-16	Hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.13	0.31	3.87e-12	Lung cancer;
LGG	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg03563238	chr19:33554763	RHPN2	-0.39	-8.89	-0.38	1.42e-17	Colorectal cancer;
LGG	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.62	0.33	1.47e-13	Height;
LGG	cis	rs1062177	0.756	rs2964587	chr5:151119972	C/T	cg00977110	chr5:151150581	G3BP1	-0.48	-7.58	-0.33	1.91e-13	Preschool internalizing problems;
LGG	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg05973401	chr12:123451056	ABCB9	0.45	7.55	0.33	2.35e-13	Platelet count;
LGG	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.03	0.62	7.3e-51	Alzheimer's disease;
LGG	cis	rs7119	0.745	rs12911649	chr15:77807127	C/T	cg10437265	chr15:77819839	NA	0.25	6.87	0.3	2.03e-11	Type 2 diabetes;
LGG	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg08999081	chr20:33150536	PIGU	0.32	7.62	0.33	1.4e-13	Coronary artery disease;
LGG	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg18551225	chr6:44695536	NA	-0.61	-9.78	-0.41	1.15e-20	Total body bone mineral density;
LGG	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.92	-0.38	1.11e-17	Morning vs. evening chronotype;
LGG	cis	rs9810089	0.835	rs654237	chr3:136068699	T/C	cg21827317	chr3:136751795	NA	0.43	7.47	0.33	4.12e-13	Gestational age at birth (child effect);
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg05791153	chr7:19748676	TWISTNB	0.95	12.43	0.5	8.34e-31	Thyroid stimulating hormone;
LGG	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg04733989	chr22:42467013	NAGA	0.54	9.4	0.4	2.5e-19	Schizophrenia;
LGG	cis	rs4917300	0.572	rs7814797	chr8:143114963	C/T	cg06573787	chr8:143070187	NA	0.6	9.94	0.42	3.06e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs9636252	0.605	rs6431979	chr2:9279886	G/A	cg20341998	chr2:9276514	NA	0.38	7.38	0.32	7.4e-13	IgG glycosylation;
LGG	cis	rs10193935	0.892	rs12622152	chr2:42482929	C/A	cg27598129	chr2:42591480	NA	-0.64	-9.68	-0.41	2.66e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.77	-0.3	3.8e-11	Testicular germ cell tumor;
LGG	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg16141378	chr3:129829833	LOC729375	0.36	8.12	0.35	4.4e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg22980697	chr10:16874865	CUBN	0.59	9.45	0.4	1.66e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg08250081	chr4:10125330	NA	-0.36	-7.01	-0.31	8.44e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	trans	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.69	-0.41	2.53e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg09699651	chr6:150184138	LRP11	0.55	9.6	0.41	4.96e-20	Lung cancer;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg10295955	chr4:187884368	NA	-1.13	-31.71	-0.83	4.08e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs911263	0.603	rs11158730	chr14:68812756	A/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.42	0.36	4.68e-16	Primary biliary cholangitis;
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg12705353	chr12:122356852	WDR66	0.23	6.72	0.3	5.5e-11	Mean corpuscular volume;
LGG	cis	rs7010267	0.642	rs11992136	chr8:120003727	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.39	10.12	0.43	7.2e-22	Total body bone mineral density (age 45-60);
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg08621203	chr6:150244597	RAET1G	0.47	8.22	0.36	2.12e-15	Lung cancer;
LGG	cis	rs17504614	0.591	rs10460542	chr2:51074740	G/A	cg23851515	chr2:51057218	NRXN1	0.46	7.43	0.33	5.28e-13	Educational attainment (years of education);
LGG	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg13444538	chr7:158905317	VIPR2	-0.41	-6.7	-0.3	6.03e-11	Facial morphology (factor 20);
LGG	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg21226059	chr5:178986404	RUFY1	0.43	7.04	0.31	7.08e-12	Lung cancer;
LGG	cis	rs3816183	0.568	rs4280501	chr2:43127045	A/G	cg14631114	chr2:43023945	NA	0.43	7.3	0.32	1.27e-12	Hypospadias;
LGG	cis	rs11693319	0.720	rs17453452	chr2:179816165	G/C	cg17765952	chr2:179737173	CCDC141	0.51	7.36	0.32	8.67e-13	Blood pressure measurement (cold pressor test);
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg11494091	chr17:61959527	GH2	0.56	9.15	0.39	1.85e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.89e-22	Arsenic metabolism;
LGG	cis	rs17321999	0.516	rs72787741	chr2:30503987	C/G	cg05247661	chr2:30472410	LBH	0.66	7.99	0.35	1.07e-14	Systemic lupus erythematosus;
LGG	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg08648136	chr8:956695	NA	0.43	9.3	0.4	5.66e-19	Schizophrenia;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg17961943	chr2:28857916	PLB1	0.34	7.12	0.31	4.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07570687	chr10:102243282	WNT8B	0.41	6.92	0.31	1.5e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg25986240	chr4:9926439	SLC2A9	0.44	9.17	0.39	1.59e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.72	0.3	5.33e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs55788414	0.860	rs1806875	chr16:81184069	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg12573674	chr2:1569213	NA	-0.61	-9.33	-0.4	4.5e-19	IgG glycosylation;
LGG	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg26384229	chr12:38710491	ALG10B	0.65	12.49	0.5	4.66e-31	Morning vs. evening chronotype;
LGG	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg16662043	chr16:48846231	NA	0.37	7.25	0.32	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2227564	0.597	rs2633305	chr10:75652123	A/G	cg00564723	chr10:75632066	CAMK2G	-0.44	-8.95	-0.38	8.76e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	7.3	0.32	1.23e-12	Schizophrenia;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.52	-0.53	2.48e-35	Alzheimer's disease;
LGG	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.84	-0.34	3.1e-14	IgG glycosylation;
LGG	cis	rs73416724	1.000	rs77538445	chr6:43285773	A/C	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.74e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17209837	1.000	rs2302386	chr7:87091944	A/G	cg00919237	chr7:87102261	ABCB4	-0.69	-11.18	-0.46	7.65e-26	Gallbladder cancer;
LGG	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg22517653	chr1:2918612	NA	-0.51	-7.08	-0.31	5.44e-12	Plateletcrit;
LGG	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg09307838	chr4:120376055	NA	0.81	13.49	0.53	3.28e-35	Corneal astigmatism;
LGG	cis	rs17154702	0.506	rs28583936	chr8:8647160	C/T	cg01851573	chr8:8652454	MFHAS1	0.5	6.71	0.3	5.65e-11	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs6748734	0.581	rs4675847	chr2:241865156	A/G	cg26818257	chr2:241905806	NA	0.51	10.83	0.45	1.57e-24	Urinary metabolites;
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07243736	chr16:783730	NARFL	0.41	7.11	0.31	4.3e-12	Height;
LGG	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs9436747	0.585	rs6662904	chr1:65997740	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	0.44	8.31	0.36	1.1e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs9534288	0.699	rs2146884	chr13:46660392	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.36	-0.56	6.12e-39	Blood protein levels;
LGG	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg19455335	chr8:22457658	C8orf58	0.37	7.5	0.33	3.3e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs9859260	0.961	rs2300780	chr3:195790291	T/C	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.84	-0.3	2.59e-11	Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2455799	0.613	rs1969095	chr3:15733552	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.88	-0.34	2.34e-14	Mean platelet volume;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25545336	chr2:223520958	FARSB	-0.41	-7.08	-0.31	5.22e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08219700	chr8:58056026	NA	0.44	7.01	0.31	8.28e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.76	0.3	4.23e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs12517041	1.000	rs10520890	chr5:23290143	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.75	10.77	0.45	2.67e-24	Calcium levels;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg23978390	chr7:1156363	C7orf50	0.46	7.68	0.34	9.83e-14	Longevity;Endometriosis;
LGG	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	-0.45	-7.31	-0.32	1.22e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9914988	0.943	rs4795457	chr17:27087929	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.35	-0.32	9.04e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.02	-20.47	-0.69	8.66e-67	Primary sclerosing cholangitis;
LGG	cis	rs9942416	0.660	rs111937612	chr5:74979631	C/T	cg19683494	chr5:74908142	NA	0.44	6.88	0.3	2.01e-11	Age-related disease endophenotypes;
LGG	cis	rs2073499	1.000	rs12629572	chr3:50324672	T/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.62	7.06	0.31	6.21e-12	Schizophrenia;
LGG	cis	rs3764563	1.000	rs602300	chr19:15693041	G/A	cg20725493	chr19:15740067	CYP4F8	0.57	6.79	0.3	3.52e-11	Inflammatory biomarkers;
LGG	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg02403541	chr12:121454288	C12orf43	0.74	12.83	0.51	1.84e-32	N-glycan levels;
LGG	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs12911832	0.958	rs12912003	chr15:58986001	A/T	cg05156742	chr15:59063176	FAM63B	0.57	9.05	0.39	3.95e-18	Schizophrenia;
LGG	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.41	0.33	6.08e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4262150	0.883	rs72802887	chr5:152249082	A/G	cg12297329	chr5:152029980	NA	-0.65	-12.09	-0.49	1.96e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg08400814	chr5:56204995	C5orf35	-0.45	-7.24	-0.32	1.87e-12	Initial pursuit acceleration;
LGG	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg22875332	chr1:76189707	ACADM	-0.53	-8.2	-0.36	2.38e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.64	-0.37	9.21e-17	Calcium levels;
LGG	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg12658982	chr7:29603541	PRR15	-0.4	-8.38	-0.36	6.58e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	9.99	0.42	2e-21	Motion sickness;
LGG	cis	rs9512730	0.553	rs1007701	chr13:28049143	C/G	cg04070771	chr13:27998621	GTF3A	-0.51	-7.7	-0.34	8.34e-14	Schizophrenia;
LGG	cis	rs11877825	0.826	rs8088116	chr18:10579879	T/A	cg25239095	chr18:10589360	NA	0.48	8.78	0.38	3.15e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs62209	1.000	rs1295901	chr10:11009675	A/G	cg26901096	chr10:10994189	LOC254312	0.51	8.4	0.36	5.56e-16	Alzheimer's disease (late onset);
LGG	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.26	0.43	2.12e-22	Morning vs. evening chronotype;
LGG	cis	rs7924176	0.601	rs10824072	chr10:75873892	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.9	-0.31	1.7e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs4774899	0.932	rs12912353	chr15:57516037	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.1	-0.31	4.71e-12	Urinary tract infection frequency;
LGG	cis	rs3126085	0.935	rs1466757	chr1:152212469	G/A	cg26876637	chr1:152193138	HRNR	0.56	9.19	0.39	1.3e-18	Atopic dermatitis;
LGG	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.05	-0.35	7.01e-15	HDL cholesterol;
LGG	cis	rs78487399	0.731	rs72790940	chr2:43768545	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-6.87	-0.3	2.03e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs12220238	0.818	rs10824082	chr10:75904080	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.73	0.48	5.19e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4819052	0.540	rs7282639	chr21:46491155	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.45	-6.88	-0.3	1.99e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4774899	0.752	rs2920269	chr15:57363922	G/C	cg08128148	chr15:57256372	TCF12	-0.29	-6.92	-0.31	1.49e-11	Urinary tract infection frequency;
LGG	cis	rs11096990	0.594	rs2381373	chr4:39282303	A/C	cg24403649	chr4:39172243	NA	-0.4	-7.17	-0.32	3.03e-12	Cognitive function;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.56	-0.33	2.16e-13	Menopause (age at onset);
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16346588	chr10:242978	ZMYND11	0.4	6.92	0.31	1.5e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs1044826	0.518	rs295488	chr3:139239323	C/T	cg15131784	chr3:139108705	COPB2	0.4	6.8	0.3	3.34e-11	Obesity-related traits;
LGG	cis	rs357618	1.000	rs357625	chr5:150848874	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.72	-0.3	5.19e-11	Basophil percentage of white cells;
LGG	cis	rs12615966	0.651	rs72830470	chr2:105406694	C/T	cg16465502	chr2:105461796	NA	0.99	11.3	0.46	2.59e-26	Pancreatic cancer;
LGG	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.31	0.32	1.2e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg03213289	chr20:61660250	NA	0.65	14.36	0.56	5.95e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13191362	1.000	rs67094146	chr6:163145412	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.68	0.48	8.64e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg26150922	chr2:100937072	LONRF2	-0.58	-10.93	-0.45	6.84e-25	Intelligence (multi-trait analysis);
LGG	cis	rs72949976	0.734	rs62189579	chr2:214016984	T/A	cg08319019	chr2:214017104	IKZF2	-0.65	-11.05	-0.46	2.33e-25	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs655029	0.837	rs632964	chr2:31463866	G/C	cg14018959	chr2:31480232	EHD3	-0.35	-6.85	-0.3	2.38e-11	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
LGG	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg04662567	chr6:169592167	NA	0.84	14.3	0.55	1.16e-38	Pulse pressure;
LGG	cis	rs2131877	0.956	rs60143196	chr3:194871710	A/G	cg07250128	chr3:194833983	C3orf21	0.41	7.6	0.33	1.67e-13	Non-small cell lung cancer;
LGG	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg01191920	chr7:158217561	PTPRN2	-0.79	-17.89	-0.64	8.2e-55	Obesity-related traits;
LGG	trans	rs8073060	0.559	rs10438814	chr17:34007065	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.98	-0.64	3.38e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg15596359	chr8:11213517	TDH	-0.42	-8.98	-0.39	6.97e-18	Retinal vascular caliber;
LGG	cis	rs9543976	0.623	rs3783028	chr13:76165282	T/C	cg12827798	chr13:76122768	UCHL3	-0.44	-6.76	-0.3	4.2e-11	Diabetic retinopathy;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.61	-0.44	1.12e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg00376283	chr12:123451042	ABCB9	0.62	9.98	0.42	2.31e-21	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs6787391	0.933	rs12330193	chr3:4748862	C/T	cg11584376	chr3:4789075	ITPR1	-0.34	-7.15	-0.32	3.38e-12	Breast cancer;
LGG	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.27	-42.89	-0.89	2.16e-163	Myeloid white cell count;
LGG	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg03806693	chr22:41940476	POLR3H	-0.82	-14.41	-0.56	3.77e-39	Vitiligo;
LGG	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg09818912	chr17:20140352	CYTSB	0.31	7.27	0.32	1.57e-12	Schizophrenia;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	7.93	0.35	1.66e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg12923728	chr3:195709715	SDHAP1	0.57	9.59	0.41	5.67e-20	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11653500	chr13:80915061	SPRY2	0.47	7.54	0.33	2.44e-13	Cognitive performance;
LGG	cis	rs9902453	0.933	rs2054846	chr17:28507693	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.31	-0.53	1.85e-34	Coffee consumption (cups per day);
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg14829155	chr15:31115871	NA	-0.55	-9.43	-0.4	1.94e-19	Huntington's disease progression;
LGG	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg03806693	chr22:41940476	POLR3H	1.02	16.74	0.61	1.59e-49	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg03606772	chr1:152487856	CRCT1	0.29	6.8	0.3	3.24e-11	Hair morphology;
LGG	cis	rs12711979	0.509	rs1031478	chr2:3827425	G/A	cg17052675	chr2:3827356	NA	-0.51	-9.93	-0.42	3.36e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg11642891	chr2:3452563	TTC15	-0.47	-9.48	-0.4	1.37e-19	Obesity-related traits;
LGG	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06481639	chr22:41940642	POLR3H	0.48	6.95	0.31	1.23e-11	Vitiligo;
LGG	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03112782	chr1:37979729	MEAF6	0.46	7.59	0.33	1.77e-13	Gut microbiome composition (summer);
LGG	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg01448562	chr3:133502909	NA	-0.52	-8.7	-0.37	5.9e-17	Iron status biomarkers;
LGG	cis	rs7091068	0.707	rs829107	chr10:95418102	C/T	cg20715218	chr10:95462985	C10orf4	-0.58	-8.02	-0.35	8.86e-15	Urinary tract infection frequency;
LGG	cis	rs2797160	0.967	rs1343120	chr6:125992810	A/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.95	-0.31	1.24e-11	Endometrial cancer;
LGG	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.04	0.31	7.06e-12	Retinal vascular caliber;
LGG	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg17691542	chr6:26056736	HIST1H1C	0.8	11.22	0.46	5.4e-26	Iron status biomarkers;
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.01	0.57	8.41e-42	Alzheimer's disease;
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg15665833	chr6:26285013	NA	0.39	7.64	0.33	1.22e-13	Educational attainment;
LGG	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.46	-0.37	3.67e-16	Monocyte count;
LGG	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg26513180	chr16:89883248	FANCA	-0.63	-11.46	-0.47	6.14e-27	Vitiligo;
LGG	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg27205649	chr11:78285834	NARS2	-0.48	-7.75	-0.34	5.68e-14	Testicular germ cell tumor;
LGG	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00292662	chr22:38071168	LGALS1	0.7	13.3	0.53	2.13e-34	Fat distribution (HIV);
LGG	cis	rs9944715	0.954	rs6507680	chr18:43766986	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.37	-6.86	-0.3	2.15e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2267681	0.508	rs4726815	chr7:139514460	C/G	cg14116596	chr7:139528673	TBXAS1	0.32	7.05	0.31	6.46e-12	Cervical cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13560408	chr14:77843201	C14orf174;TMED8	0.6	6.78	0.3	3.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8060686	0.641	rs7188085	chr16:68113873	A/G	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.91e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg02151108	chr14:50098012	C14orf104	-0.46	-9.9	-0.42	4.23e-21	Carotid intima media thickness;
LGG	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg25718383	chr7:130020096	CPA1	-0.33	-8.59	-0.37	1.35e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg10840412	chr1:235813424	GNG4	0.53	7.41	0.33	6.02e-13	Bipolar disorder;
LGG	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.87	-0.34	2.45e-14	Retinal vascular caliber;
LGG	cis	rs12765878	0.513	rs10883922	chr10:105595430	C/G	cg11005552	chr10:105648138	OBFC1	-0.7	-11.95	-0.49	7.23e-29	Coronary artery disease;
LGG	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg04568710	chr12:38710424	ALG10B	0.34	6.97	0.31	1.08e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500395	0.584	rs9922553	chr16:48739059	A/G	cg16662043	chr16:48846231	NA	0.44	7.9	0.34	2.02e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18252515	chr7:66147081	NA	0.41	6.92	0.31	1.48e-11	Aortic root size;
LGG	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg04568710	chr12:38710424	ALG10B	0.36	7.72	0.34	7.29e-14	Bladder cancer;
LGG	cis	rs9443645	0.901	rs9343860	chr6:79739010	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.46	-0.37	3.47e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12893428	chr3:195717962	SDHAP1	0.51	10.77	0.45	2.83e-24	Pancreatic cancer;
LGG	cis	rs17209837	0.646	rs55747905	chr7:87127099	T/C	cg00919237	chr7:87102261	ABCB4	-0.8	-15.38	-0.58	2.02e-43	Gallbladder cancer;
LGG	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg15394860	chr11:2017084	H19	-0.43	-8.78	-0.38	3.08e-17	DNA methylation (variation);
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg15242686	chr22:24348715	GSTTP1	0.39	7.07	0.31	5.61e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7582720	1.000	rs72932725	chr2:203649341	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.51	0.4	1.07e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.83	-17.38	-0.63	1.97e-52	Chronic sinus infection;
LGG	cis	rs9810089	0.934	rs1279949	chr3:135996870	T/A	cg21827317	chr3:136751795	NA	0.45	7.86	0.34	2.73e-14	Gestational age at birth (child effect);
LGG	cis	rs2050392	0.767	rs1536833	chr10:30699265	C/T	cg25182066	chr10:30743637	MAP3K8	0.6	12.3	0.5	2.9e-30	Inflammatory bowel disease;
LGG	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	trans	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg26043149	chr18:55253948	FECH	0.4	6.67	0.3	7.1e-11	Bone mineral density;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg04709771	chr16:646395	RAB40C	0.37	6.7	0.3	5.89e-11	Height;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.17	0.32	3e-12	Lung cancer;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.37	7.39	0.32	6.8e-13	Schizophrenia;
LGG	cis	rs7503807	0.515	rs12450876	chr17:78682630	A/G	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.77	-0.48	3.79e-28	Tonsillectomy;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18162120	chr1:224621880	WDR26	0.61	6.98	0.31	1e-11	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08447479	chr16:75589467	TMEM231	-0.49	-6.97	-0.31	1.09e-11	Systemic lupus erythematosus;
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg05555928	chr11:63887634	MACROD1	-0.79	-10.59	-0.44	1.26e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg27400746	chr16:89904261	SPIRE2	-0.92	-14.6	-0.56	5.27e-40	Skin colour saturation;
LGG	trans	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg18187862	chr3:45730750	SACM1L	-0.6	-9.67	-0.41	2.92e-20	Primary sclerosing cholangitis;
LGG	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg09044154	chr16:88155775	NA	-0.51	-7.68	-0.34	9.28e-14	Menopause (age at onset);
LGG	cis	rs3008870	0.755	rs2065002	chr1:67487119	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.7	-14.48	-0.56	1.93e-39	Lymphocyte percentage of white cells;
LGG	cis	rs787274	0.681	rs787284	chr9:115538040	A/G	cg13803584	chr9:115635662	SNX30	-0.55	-7.73	-0.34	6.75e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.3e-31	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11646757	chr7:128095699	C7orf68	0.44	6.66	0.3	7.7e-11	Gut microbiome composition (summer);
LGG	trans	rs12517041	1.000	rs34069672	chr5:23281789	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.17e-25	Calcium levels;
LGG	cis	rs55883249	0.957	rs62119431	chr2:9750461	G/A	cg23886495	chr2:9695866	ADAM17	0.65	9.47	0.4	1.49e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs13082711	0.595	rs13075389	chr3:27339586	C/T	cg02860705	chr3:27208620	NA	0.94	17.58	0.63	2.23e-53	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.37	0.67	1.12e-61	Platelet count;
LGG	cis	rs1461503	0.934	rs7107560	chr11:122845380	T/C	cg27398637	chr11:122830231	C11orf63	-0.69	-13.43	-0.53	5.59e-35	Menarche (age at onset);
LGG	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg18225595	chr11:63971243	STIP1	0.63	11.77	0.48	3.66e-28	Platelet count;
LGG	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg11941060	chr3:133502564	NA	-0.48	-8.12	-0.35	4.26e-15	Iron status biomarkers;
LGG	cis	rs7444	0.941	rs2266964	chr22:21958304	A/G	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04772025	chr11:68637568	NA	0.72	12.55	0.5	2.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17453880	0.929	rs4487479	chr5:152008600	C/G	cg10931792	chr5:152022470	NA	0.37	8.09	0.35	5.35e-15	Subjective well-being;
LGG	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg02820901	chr13:113351484	ATP11A	0.62	7.38	0.32	7.53e-13	Glycated hemoglobin levels;
LGG	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.76	-8.58	-0.37	1.42e-16	Diabetic retinopathy;
LGG	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg07936489	chr17:37558343	FBXL20	-0.48	-7.98	-0.35	1.14e-14	Asthma;
LGG	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.49	-0.33	3.42e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-11.33	-0.47	1.96e-26	Brugada syndrome;
LGG	trans	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg05059571	chr16:84539110	KIAA1609	-0.57	-11.12	-0.46	1.31e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7072216	0.763	rs2147901	chr10:100165496	A/C	cg26618903	chr10:100175079	PYROXD2	0.28	7.11	0.31	4.31e-12	Metabolite levels;
LGG	cis	rs9443645	0.527	rs2105143	chr6:79742947	G/A	cg18132916	chr6:79620363	NA	-0.27	-7.07	-0.31	5.69e-12	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs357476	chr3:153892844	A/G	cg17054900	chr3:154042577	DHX36	-0.85	-9.87	-0.42	5.7e-21	Coronary artery disease;
LGG	cis	rs751728	0.717	rs2281816	chr6:33772335	A/G	cg25922239	chr6:33757077	LEMD2	0.65	10.17	0.43	4.8e-22	Crohn's disease;
LGG	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.2	0.39	1.24e-18	Sudden cardiac arrest;
LGG	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg04568710	chr12:38710424	ALG10B	0.35	7.35	0.32	9.22e-13	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21788624	chr2:20251350	LAPTM4A	-0.37	-6.99	-0.31	9.63e-12	Brain structure;
LGG	trans	rs800082	0.507	rs2575183	chr3:144260523	C/T	cg24215973	chr2:240111563	HDAC4	0.37	6.77	0.3	3.92e-11	Smoking behavior;
LGG	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg03433033	chr1:76189801	ACADM	-0.65	-9.32	-0.4	4.88e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9309711	0.772	rs9309715	chr2:3492318	C/G	cg10845886	chr2:3471009	TTC15	0.68	13.12	0.52	1.14e-33	Neurofibrillary tangles;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg26116260	chr4:7069785	GRPEL1	1.15	22.56	0.72	1.35e-76	Monocyte percentage of white cells;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.67e-16	Rheumatoid arthritis;
LGG	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22168489	chr12:122356033	WDR66	-0.33	-7.64	-0.33	1.27e-13	Mean corpuscular volume;
LGG	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg01557791	chr16:72042693	DHODH	-0.56	-10.07	-0.42	1.09e-21	Fibrinogen levels;
LGG	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg21055462	chr7:100276975	NA	0.36	7.39	0.32	7.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg10596483	chr8:143751796	JRK	0.59	9.69	0.41	2.51e-20	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00232805	chr2:97779565	ANKRD36	0.48	7.42	0.33	5.59e-13	Gut microbiome composition (summer);
LGG	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08564027	chr20:61660810	NA	0.98	22.98	0.73	1.58e-78	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12282928	1.000	rs2128677	chr11:48319974	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg13683864	chr3:40499215	RPL14	1.02	22.84	0.73	6.95e-78	Renal cell carcinoma;
LGG	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.5	0.37	2.61e-16	Schizophrenia;
LGG	cis	rs7226408	0.600	rs1147761	chr18:34401160	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.1	-0.35	4.75e-15	Obesity-related traits;
LGG	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg15557168	chr22:42548783	NA	-0.45	-9.85	-0.42	6.46e-21	Schizophrenia;
LGG	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg03254818	chr6:169586852	NA	0.58	8.51	0.37	2.41e-16	Pulse pressure;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-7.5	-0.33	3.39e-13	Lung cancer;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg13385794	chr1:248469461	NA	0.5	8.34	0.36	8.77e-16	Common traits (Other);
LGG	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.64e-21	Diabetic retinopathy;
LGG	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.06	-0.42	1.17e-21	Lung cancer;
LGG	cis	rs55871839	0.708	rs4738733	chr8:59813760	T/C	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.03	-0.31	7.34e-12	HDL cholesterol;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.47	0.37	3.33e-16	Obesity-related traits;
LGG	cis	rs6065	0.529	rs1056626	chr17:4931553	G/T	cg16045459	chr17:4872488	CAMTA2;SPAG7	-0.45	-6.91	-0.31	1.57e-11	Platelet count;
LGG	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.9	0.34	2.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg25664220	chr3:72788482	NA	0.32	9.02	0.39	4.99e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg26384229	chr12:38710491	ALG10B	0.97	21.32	0.7	9.26e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg23815491	chr16:72088622	HP	0.55	11.66	0.48	1.03e-27	Fibrinogen levels;
LGG	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg17145862	chr1:211918768	LPGAT1	0.99	26.21	0.77	1.66e-93	Leprosy;
LGG	cis	rs9682041	0.627	rs34392658	chr3:170091584	C/T	cg11886554	chr3:170076028	SKIL	0.56	7.46	0.33	4.44e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2070677	0.708	rs12762259	chr10:135350365	C/T	cg20169779	chr10:135381914	SYCE1	0.95	12.51	0.5	4.04e-31	Gout;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.7	0.84	2.04e-122	Prudent dietary pattern;
LGG	cis	rs12135191	0.771	rs12724867	chr1:236497614	G/A	cg21399712	chr1:236511386	NA	-0.41	-7.75	-0.34	5.77e-14	Urate levels (BMI interaction);
LGG	cis	rs6489882	1.000	rs7977345	chr12:113380708	A/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.34	-0.32	9.99e-13	Chronic lymphocytic leukemia;
LGG	cis	rs2133450	1.000	rs2133450	chr3:7336452	A/C	cg19930620	chr3:7340148	GRM7	-0.37	-8.02	-0.35	8.96e-15	Early response to risperidone in schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11028747	chr7:102104916	LRWD1;ALKBH4	-0.43	-7.21	-0.32	2.29e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11074306	0.561	rs28473720	chr15:28067697	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11414415	chr11:57069640	TNKS1BP1	0.39	6.91	0.31	1.58e-11	Electrocardiographic conduction measures;
LGG	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg13010199	chr12:38710504	ALG10B	0.4	7.65	0.33	1.21e-13	Morning vs. evening chronotype;
LGG	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg07061783	chr6:25882402	NA	-0.43	-7.28	-0.32	1.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6764363	0.565	rs625589	chr3:288775	A/T	cg02057681	chr3:285234	CHL1	0.41	7.59	0.33	1.83e-13	Sudden cardiac arrest;
LGG	cis	rs9583531	0.527	rs6492302	chr13:111352354	C/T	cg24331049	chr13:111365604	ING1	-0.85	-15.6	-0.59	2.06e-44	Coronary artery disease;
LGG	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg24189917	chr7:1970923	MAD1L1	-0.51	-7.86	-0.34	2.67e-14	Bipolar disorder;
LGG	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg22044901	chr15:68126292	NA	-0.42	-7.01	-0.31	8.63e-12	Restless legs syndrome;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.51	-0.37	2.35e-16	Life satisfaction;
LGG	cis	rs7091068	0.615	rs11187609	chr10:95467031	A/C	cg20715218	chr10:95462985	C10orf4	0.67	10.94	0.45	6.1e-25	Urinary tract infection frequency;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg12419862	chr22:24373484	LOC391322	-0.89	-18.38	-0.65	4.88e-57	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs266717	0.816	rs266754	chr3:186508966	C/T	cg00373256	chr3:186519153	RFC4	-0.43	-8.64	-0.37	9.5e-17	Adiponectin levels;
LGG	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.26	-0.32	1.66e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.15	-0.35	3.55e-15	Response to antipsychotic treatment;
LGG	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg10518543	chr12:38710700	ALG10B	0.41	6.65	0.3	8.2e-11	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg25214090	chr10:38739885	LOC399744	0.56	10.38	0.43	7.62e-23	Corneal astigmatism;
LGG	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg19507638	chr5:93509721	C5orf36	0.41	6.93	0.31	1.42e-11	Diabetic retinopathy;
LGG	cis	rs690037	0.528	rs568833	chr3:16367836	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.51	-8.83	-0.38	2.21e-17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg24623649	chr8:11872141	NA	-0.29	-7.05	-0.31	6.52e-12	Neuroticism;
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg16301924	chr13:53314226	LECT1	-0.46	-9.19	-0.39	1.34e-18	Lewy body disease;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg24846343	chr22:24311635	DDTL	0.61	11.79	0.48	3.12e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs529866	0.500	rs918739	chr16:11439733	G/T	cg00044050	chr16:11439710	C16orf75	-0.51	-8.11	-0.35	4.65e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.69	-0.44	5.45e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg13010199	chr12:38710504	ALG10B	0.71	14.15	0.55	4.8e-38	Morning vs. evening chronotype;
LGG	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg05044414	chr3:183734942	ABCC5	0.57	11.37	0.47	1.34e-26	Anterior chamber depth;
LGG	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg06353428	chr16:71660113	MARVELD3	-0.57	-9.01	-0.39	5.51e-18	Blood protein levels;
LGG	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.43	-0.4	1.94e-19	Schizophrenia;
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.74	0.3	4.85e-11	Aortic root size;
LGG	cis	rs12291225	0.585	rs10832246	chr11:14380828	G/A	cg19336497	chr11:14380999	RRAS2	-0.63	-13.39	-0.53	8.83e-35	Sense of smell;
LGG	cis	rs7020830	0.825	rs66684257	chr9:37199087	G/T	cg14294708	chr9:37120828	ZCCHC7	1.14	30.99	0.82	5.32e-115	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17539315	chr12:50794919	LARP4	0.5	7.84	0.34	3.13e-14	Gut microbiome composition (summer);
LGG	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg13770691	chr19:1021866	C19orf6	0.39	7.86	0.34	2.72e-14	Eosinophil percentage of granulocytes;
LGG	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.16	0.52	7.63e-34	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg08822215	chr16:89438651	ANKRD11	0.35	7.0	0.31	9.16e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg13385794	chr1:248469461	NA	0.49	8.45	0.37	3.81e-16	Common traits (Other);
LGG	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg12310025	chr6:25882481	NA	0.48	8.89	0.38	1.33e-17	Blood metabolite levels;
LGG	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.88	-0.3	1.97e-11	Blood metabolite levels;
LGG	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25172604	chr17:41446521	NA	-0.3	-6.92	-0.31	1.54e-11	Menopause (age at onset);
LGG	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs60180747	0.544	rs11630157	chr15:66553425	C/T	cg07575407	chr15:66541975	MEGF11	0.64	13.72	0.54	3.37e-36	Testicular germ cell tumor;
LGG	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.6	-0.33	1.66e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg09307838	chr4:120376055	NA	0.7	11.5	0.47	4.13e-27	Corneal astigmatism;
LGG	cis	rs714515	0.900	rs6697844	chr1:172308238	C/T	cg01573306	chr1:172330400	DNM3	-0.34	-7.47	-0.33	4.08e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg26031613	chr14:104095156	KLC1	1.15	27.82	0.79	7.71e-101	Body mass index;
LGG	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.9	-0.34	2.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs4845333	chr1:152982877	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.5	-9.1	-0.39	2.73e-18	Rheumatoid arthritis;
LGG	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg17644776	chr2:200775616	C2orf69	0.61	8.49	0.37	2.86e-16	Schizophrenia;
LGG	cis	rs2133450	0.751	rs55888066	chr3:7367119	T/C	cg19930620	chr3:7340148	GRM7	-0.35	-7.57	-0.33	2.08e-13	Early response to risperidone in schizophrenia;
LGG	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg16141378	chr3:129829833	LOC729375	-0.42	-9.91	-0.42	3.94e-21	Mood instability;
LGG	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg19077165	chr18:44547161	KATNAL2	0.52	9.26	0.4	7.47e-19	Educational attainment;
LGG	cis	rs36051895	0.664	rs28378223	chr9:5113087	C/G	cg02405213	chr9:5042618	JAK2	-0.8	-15.25	-0.58	7.54e-43	Pediatric autoimmune diseases;
LGG	cis	rs3806843	0.735	rs2563314	chr5:140047289	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.75	-0.3	4.55e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.58	0.41	5.88e-20	Fuchs's corneal dystrophy;
LGG	cis	rs885389	1.000	rs885389	chr12:131621762	C/T	cg07124762	chr12:131619285	GPR133	0.44	8.32	0.36	9.96e-16	RR interval (heart rate);
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg11494091	chr17:61959527	GH2	0.62	10.43	0.44	5.2e-23	Height;
LGG	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg26384229	chr12:38710491	ALG10B	0.82	18.28	0.65	1.41e-56	Bladder cancer;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg08885076	chr2:99613938	TSGA10	0.41	8.34	0.36	8.85e-16	Chronic sinus infection;
LGG	cis	rs42648	0.837	rs42615	chr7:89950501	G/T	cg25739043	chr7:89950458	NA	-0.44	-9.35	-0.4	3.73e-19	Homocysteine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00613399	chr15:89010912	MRPL46;MRPS11	0.48	7.55	0.33	2.38e-13	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg05692746	chr2:100937584	LONRF2	-0.67	-12.43	-0.5	8.41e-31	Intelligence (multi-trait analysis);
LGG	cis	rs2188554	0.785	rs11772396	chr7:117132919	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.38	-6.73	-0.3	4.88e-11	Esophageal adenocarcinoma;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs1843834	0.858	rs6731785	chr2:225491143	A/G	cg22455342	chr2:225449267	CUL3	0.64	11.03	0.46	2.8e-25	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1465370	0.720	rs2402995	chr7:130016595	C/T	cg25718383	chr7:130020096	CPA1	0.32	8.33	0.36	9.14e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-12.79	-0.51	2.77e-32	Coronary artery disease;
LGG	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg20219074	chr11:18656078	SPTY2D1	0.83	15.22	0.58	1.1e-42	Breast cancer;
LGG	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.61	-0.53	1.06e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs3820928	1.000	rs4675119	chr2:227774635	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.18	-0.32	2.77e-12	Pulmonary function;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12220238	0.659	rs10824208	chr10:76357634	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.76	9.01	0.39	5.31e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10751667	0.666	rs10794347	chr11:939863	G/A	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs13108043	0.639	rs34745873	chr4:87882815	A/C	cg11209507	chr4:87813803	C4orf36	0.61	7.78	0.34	4.79e-14	Red blood cell count;
LGG	cis	rs11877825	0.826	rs3911954	chr18:10569112	C/T	cg07277756	chr18:10589357	NA	0.59	10.8	0.45	2.2e-24	Gut microbiota (bacterial taxa);
LGG	cis	rs60180747	0.909	rs76095247	chr15:66593468	A/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.54	8.99	0.39	6.34e-18	Testicular germ cell tumor;
LGG	cis	rs6604026	1.000	rs6604026	chr1:93303603	A/G	cg22128645	chr1:93425802	FAM69A	-0.36	-6.74	-0.3	4.59e-11	Multiple sclerosis;
LGG	cis	rs12474201	0.572	rs7596521	chr2:46918665	A/G	cg06386533	chr2:46925753	SOCS5	0.48	7.52	0.33	2.85e-13	Height;
LGG	cis	rs7192380	0.651	rs34769743	chr16:69580490	C/T	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.46	-0.37	3.59e-16	Sjögren's syndrome;
LGG	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg18681998	chr4:17616180	MED28	0.73	15.01	0.57	8.48e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	cis	rs1670533	0.932	rs4690347	chr4:1057328	A/G	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg19143629	chr17:61920732	SMARCD2	0.4	6.75	0.3	4.5e-11	Prudent dietary pattern;
LGG	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.76	-8.56	-0.37	1.66e-16	Response to haloperidol in psychosis;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.44e-15	Alzheimer's disease;
LGG	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg03929089	chr4:120376271	NA	-1.02	-22.5	-0.72	2.6e-76	Height;
LGG	cis	rs9487094	0.626	rs2025148	chr6:110027943	G/T	cg01125227	chr6:109776195	MICAL1	0.43	7.54	0.33	2.46e-13	Height;
LGG	cis	rs17767392	0.846	rs61991246	chr14:71859858	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.54	-0.37	1.99e-16	Mitral valve prolapse;
LGG	cis	rs9400467	0.500	rs1361425	chr6:111472243	A/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-7.89	-0.34	2.26e-14	Blood metabolite levels;Amino acid levels;
LGG	cis	rs881375	0.715	rs10985073	chr9:123643855	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	12.67	0.51	8.52e-32	Rheumatoid arthritis;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg08925882	chr11:67350491	GSTP1	-0.35	-6.9	-0.31	1.74e-11	Mean corpuscular volume;
LGG	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15369054	chr17:80825471	TBCD	-0.52	-9.68	-0.41	2.58e-20	Breast cancer;
LGG	cis	rs11608355	0.846	rs4766471	chr12:109853462	G/A	cg19025524	chr12:109796872	NA	-0.4	-6.84	-0.3	2.5e-11	Neuroticism;
LGG	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-8.08	-0.35	5.83e-15	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.963	rs10890373	chr1:46393755	A/C	cg03146154	chr1:46216737	IPP	0.54	9.86	0.42	5.97e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4363385	0.818	rs57311099	chr1:153005597	A/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13082711	0.911	rs6777272	chr3:27488310	T/G	cg02860705	chr3:27208620	NA	0.73	13.17	0.52	7.03e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs8002861	0.935	rs9567299	chr13:44456969	G/A	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5e-12	Leprosy;
LGG	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg26248373	chr2:1572462	NA	-0.72	-9.0	-0.39	5.94e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg24623649	chr8:11872141	NA	-0.31	-7.22	-0.32	2.2e-12	Neuroticism;
LGG	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs4356975	0.563	rs35402056	chr4:69974267	A/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.68	0.3	6.67e-11	Obesity-related traits;
LGG	cis	rs1707322	1.000	rs785478	chr1:46491635	C/T	cg03146154	chr1:46216737	IPP	-0.53	-9.99	-0.42	2.04e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg05368731	chr17:41323189	NBR1	0.86	16.5	0.61	1.96e-48	Menopause (age at onset);
LGG	trans	rs12310956	0.510	rs4931759	chr12:33871969	T/C	cg26384229	chr12:38710491	ALG10B	0.63	12.24	0.49	5.03e-30	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.74	-0.41	1.61e-20	Aortic root size;
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg17951613	chr5:131705445	SLC22A5	0.67	7.5	0.33	3.23e-13	Rheumatoid arthritis;
LGG	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg07943548	chr15:86304357	KLHL25	-0.35	-6.82	-0.3	2.84e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2712184	0.875	rs1015784	chr2:217681833	G/C	cg05032264	chr2:217675019	NA	-0.45	-9.82	-0.42	8.26e-21	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	17.14	0.62	2.45e-51	Smoking behavior;
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg06848047	chr4:90757629	SNCA	-0.4	-7.52	-0.33	2.85e-13	Dementia with Lewy bodies;
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg13009111	chr11:71350975	NA	-0.3	-6.68	-0.3	6.85e-11	Neuroticism;
LGG	cis	rs4474465	0.607	rs4945303	chr11:78283803	A/G	cg27205649	chr11:78285834	NARS2	0.61	11.49	0.47	4.59e-27	Alzheimer's disease (survival time);
LGG	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs6988985	0.678	rs9643358	chr8:144003138	G/C	cg10324643	chr8:143916377	GML	0.45	9.38	0.4	3.07e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg06875740	chr19:51307921	C19orf48	-0.69	-8.58	-0.37	1.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg06618935	chr21:46677482	NA	-0.5	-9.72	-0.41	1.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs12295403	0.691	rs9705036	chr11:18686916	A/G	cg09201001	chr11:18656081	SPTY2D1	-0.41	-7.06	-0.31	6.15e-12	Ovarian reserve;
LGG	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg27426351	chr10:43362370	NA	0.53	7.64	0.33	1.22e-13	Blood protein levels;
LGG	trans	rs75804782	0.521	rs56176151	chr2:239440220	T/C	cg01134436	chr17:81009848	B3GNTL1	0.76	8.34	0.36	8.81e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9880211	1.000	rs28634226	chr3:136129882	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.96	-0.31	1.17e-11	Body mass index;Height;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg08355456	chr11:67383691	NA	0.49	8.25	0.36	1.68e-15	Mean corpuscular volume;
LGG	cis	rs6663390	0.510	rs1932818	chr1:208078257	C/T	cg03990033	chr1:208084030	CD34	0.57	7.57	0.33	2.08e-13	Facial morphology (factor 18);
LGG	cis	rs7572733	0.555	rs7420608	chr2:198915930	A/T	cg00792783	chr2:198669748	PLCL1	0.57	8.89	0.38	1.33e-17	Dermatomyositis;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg00080972	chr5:178986291	RUFY1	-0.47	-8.06	-0.35	6.42e-15	Lung cancer;
LGG	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg24130564	chr14:104152367	KLC1	0.72	16.72	0.61	2e-49	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.37	0.32	7.99e-13	Coronary artery disease;
LGG	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.98e-25	Hepatitis;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.61	-0.41	4.76e-20	Schizophrenia;
LGG	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg15704280	chr7:45808275	SEPT13	-0.64	-8.21	-0.36	2.28e-15	Axial length;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg05052969	chr1:214156842	NA	-0.44	-8.59	-0.37	1.34e-16	Schizophrenia;
LGG	cis	rs8017423	0.967	rs61592400	chr14:90703252	T/C	cg04374321	chr14:90722782	PSMC1	0.89	18.93	0.66	1.26e-59	Mortality in heart failure;
LGG	cis	rs2274273	0.624	rs8003279	chr14:55864130	A/G	cg04306507	chr14:55594613	LGALS3	0.5	11.13	0.46	1.17e-25	Protein biomarker;
LGG	cis	rs17221829	0.555	rs11605844	chr11:89348975	T/C	cg02982614	chr11:89391479	FOLH1B	-0.37	-8.28	-0.36	1.31e-15	Anxiety in major depressive disorder;
LGG	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg09085632	chr11:111637200	PPP2R1B	1.2	28.77	0.8	3.89e-105	Primary sclerosing cholangitis;
LGG	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg08048268	chr3:133502702	NA	-0.61	-11.47	-0.47	5.38e-27	Iron status biomarkers;
LGG	cis	rs10929925	0.966	rs2693838	chr2:6148783	C/A	cg00493617	chr2:6141445	NA	0.32	7.24	0.32	1.85e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.6	0.59	2.17e-44	Headache;
LGG	trans	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06108461	chr20:60628389	TAF4	-0.69	-12.24	-0.49	4.79e-30	Body mass index;
LGG	cis	rs3789045	0.779	rs12043569	chr1:204560004	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.9	-0.38	1.31e-17	Educational attainment (college completion);
LGG	cis	rs6580649	0.941	rs17122612	chr12:48459488	C/G	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.34e-22	Total body bone mineral density;
LGG	cis	rs4851266	1.000	rs11687241	chr2:100824595	A/G	cg21926883	chr2:100939477	LONRF2	-0.44	-7.95	-0.35	1.43e-14	Educational attainment;
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.57	-0.41	6.31e-20	Triglycerides;
LGG	trans	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.71	-13.07	-0.52	1.81e-33	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.07	0.55	1.07e-37	Obesity-related traits;
LGG	trans	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg18335740	chr13:41363409	SLC25A15	0.66	13.65	0.54	6.58e-36	Lewy body disease;
LGG	cis	rs1881509	0.702	rs6578333	chr11:1436714	G/C	cg07067744	chr11:1421172	BRSK2	0.34	6.82	0.3	2.93e-11	Heroin dependence;
LGG	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-7.41	-0.33	6.09e-13	HDL cholesterol;
LGG	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg22681709	chr2:178499509	PDE11A	-0.49	-6.87	-0.3	2.09e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7010267	0.596	rs1485285	chr8:120036138	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.78	0.38	3.3e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs2290402	0.536	rs58429160	chr4:875266	G/A	cg09237302	chr4:906077	GAK	-0.43	-7.42	-0.33	5.81e-13	Type 2 diabetes;
LGG	trans	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.55	-0.33	2.32e-13	Educational attainment (years of education);
LGG	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.14	0.35	3.67e-15	Diabetic kidney disease;
LGG	trans	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg10756647	chr7:56101905	PSPH	0.83	9.55	0.41	7.4e-20	Diabetic kidney disease;
LGG	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg03929089	chr4:120376271	NA	-0.43	-6.88	-0.3	1.93e-11	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.39e-20	Prudent dietary pattern;
LGG	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.33	-0.47	1.93e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg24558204	chr6:135376177	HBS1L	0.59	10.12	0.43	7e-22	Red blood cell count;
LGG	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg18538332	chr22:24372958	LOC391322	-0.47	-7.69	-0.34	9.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg18379455	chr17:41446167	NA	-0.32	-7.55	-0.33	2.32e-13	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.75	0.54	2.5e-36	Obesity-related traits;
LGG	cis	rs2694528	0.844	rs1870682	chr5:60081296	T/C	cg11474532	chr5:59995715	DEPDC1B	0.73	7.75	0.34	5.96e-14	Parkinson's disease;
LGG	cis	rs3733585	0.664	rs17185870	chr4:9958214	C/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.69	0.34	8.89e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	4.96e-19	Coronary artery disease;
LGG	cis	rs8133932	0.701	rs6518258	chr21:47281829	C/T	cg13695288	chr21:47294981	PCBP3	-0.36	-7.27	-0.32	1.54e-12	Schizophrenia;
LGG	cis	rs9513627	1.000	rs73556178	chr13:100121947	T/C	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg19980929	chr12:42632907	YAF2	0.4	9.08	0.39	3.06e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4730250	0.640	rs7783562	chr7:106917438	G/T	cg02696742	chr7:106810147	HBP1	-0.6	-7.42	-0.33	5.77e-13	Osteoarthritis;
LGG	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.74	0.3	4.6e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg12395012	chr8:11607386	GATA4	0.37	6.73	0.3	5.1e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg12292205	chr6:26970375	C6orf41	-0.76	-15.06	-0.57	5.38e-42	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.32	0.4	4.74e-19	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25643088	chr3:52874325	TMEM110	0.46	7.81	0.34	3.82e-14	Gut microbiome composition (summer);
LGG	cis	rs9341835	0.740	rs4710255	chr6:64156268	A/C	cg00787780	chr6:64151745	NA	0.41	7.56	0.33	2.22e-13	Schizophrenia;
LGG	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-20.68	-0.69	9.3e-68	Gut microbiome composition (summer);
LGG	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.54	0.5	2.93e-31	Lung cancer in ever smokers;
LGG	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg14088196	chr11:70211408	PPFIA1	0.94	13.16	0.52	7.85e-34	Coronary artery disease;
LGG	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg04731861	chr2:219085781	ARPC2	-0.43	-10.56	-0.44	1.72e-23	Colorectal cancer;
LGG	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg06640241	chr16:89574553	SPG7	0.72	12.59	0.5	1.91e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	3.04e-11	Corneal structure;
LGG	cis	rs914187	0.548	rs2837992	chr21:42620520	A/G	cg21268422	chr21:42620091	BACE2	0.51	9.57	0.41	6.65e-20	Body mass index;
LGG	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07080220	chr10:102295463	HIF1AN	0.69	11.63	0.48	1.28e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg05768032	chr16:30646687	NA	0.42	7.14	0.32	3.54e-12	Multiple myeloma;
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.08	-0.31	5.44e-12	Bipolar disorder;
LGG	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.9	0.31	1.68e-11	Systemic lupus erythematosus;
LGG	cis	rs912057	0.632	rs1294429	chr6:6744652	G/A	cg06612196	chr6:6737390	NA	0.5	10.77	0.45	2.8e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs73227498	0.590	rs7700705	chr5:111491629	G/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.48	-6.74	-0.3	4.84e-11	Thyroid cancer;
LGG	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg01221209	chr5:554886	NA	-0.47	-10.06	-0.42	1.17e-21	Obesity-related traits;
LGG	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg25817165	chr18:72167213	CNDP2	-0.64	-12.92	-0.51	8.19e-33	Refractive error;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.25	-0.32	1.8e-12	Inflammatory bowel disease;
LGG	cis	rs1062177	1.000	rs2016409	chr5:151126324	G/T	cg00977110	chr5:151150581	G3BP1	-0.49	-7.85	-0.34	2.97e-14	Preschool internalizing problems;
LGG	trans	rs783540	0.934	rs4779050	chr15:83368738	T/G	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.29	-0.32	1.31e-12	Schizophrenia;
LGG	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs17221829	0.965	rs10830362	chr11:89457908	T/C	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.54	-0.33	2.47e-13	Anxiety in major depressive disorder;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.5	-0.44	2.92e-23	Prostate cancer;
LGG	trans	rs6787172	0.535	rs2176893	chr3:158062027	G/A	cg23275840	chr4:47708675	CORIN	-0.36	-7.41	-0.33	6.08e-13	Subjective well-being;
LGG	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.74	0.34	6.12e-14	HDL cholesterol;
LGG	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-9.94	-0.42	3.1e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4700695	0.841	rs428880	chr5:65245133	C/A	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg09163369	chr1:210001066	C1orf107	0.36	6.68	0.3	6.97e-11	Orofacial clefts;
LGG	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg14500267	chr11:67383377	NA	-0.4	-7.27	-0.32	1.54e-12	Mean corpuscular volume;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs425535	0.757	rs352026	chr4:74796030	A/G	cg01447579	chr4:74847100	PF4	0.54	6.68	0.3	6.69e-11	Blood protein levels;
LGG	trans	rs643955	0.611	rs35044612	chr8:9864980	T/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.86	-0.3	2.27e-11	Systemic lupus erythematosus;
LGG	cis	rs7188861	0.861	rs2032931	chr16:11444469	C/T	cg01510278	chr16:11456238	NA	-0.32	-7.65	-0.33	1.18e-13	HDL cholesterol;
LGG	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg08999081	chr20:33150536	PIGU	-0.31	-7.35	-0.32	9.28e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs921968	0.541	rs12619347	chr2:219419935	T/C	cg01130898	chr2:219473002	PLCD4	0.45	7.76	0.34	5.31e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4430311	0.723	rs55778834	chr1:243753910	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.67	-0.59	1.05e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg09307838	chr4:120376055	NA	0.78	12.08	0.49	2.2e-29	Corneal astigmatism;
LGG	cis	rs1707322	0.721	rs4660883	chr1:46236098	C/T	cg03146154	chr1:46216737	IPP	0.52	9.48	0.4	1.3e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11748327	0.580	rs11739657	chr5:4024922	T/A	cg01025095	chr5:4101132	NA	-0.45	-7.35	-0.32	9.06e-13	Myocardial infarction;
LGG	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg13010199	chr12:38710504	ALG10B	0.77	16.59	0.61	7.31e-49	Heart rate;
LGG	trans	rs7777677	0.925	rs4726546	chr7:142368318	T/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.85e-12	Refractive error;
LGG	cis	rs4725982	0.506	rs6464118	chr7:150573270	C/T	cg08530064	chr7:150598393	NA	0.29	6.86	0.3	2.18e-11	Electrocardiographic traits;QT interval;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.18	0.36	2.78e-15	Longevity;
LGG	cis	rs6500395	1.000	rs1558815	chr16:48704869	C/A	cg16662043	chr16:48846231	NA	-0.37	-7.33	-0.32	1.02e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs12310956	0.510	rs4931758	chr12:33871870	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.64	0.37	9.12e-17	Morning vs. evening chronotype;
LGG	cis	rs2033732	0.706	rs6473526	chr8:85070305	T/C	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg18681998	chr4:17616180	MED28	0.85	18.88	0.66	2.31e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	8.58	0.37	1.46e-16	Hip circumference adjusted for BMI;
LGG	cis	rs10463554	0.963	rs3776857	chr5:102358160	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.54	-0.33	2.54e-13	Parkinson's disease;
LGG	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs782590	0.934	rs17369191	chr2:55757885	T/C	cg18811423	chr2:55921094	PNPT1	0.88	20.25	0.69	9.27e-66	Metabolic syndrome;
LGG	cis	rs12195424	0.730	rs1323319	chr6:56305612	G/A	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs6694672	1.000	rs1576878	chr1:196991325	A/C	cg13682187	chr1:196946512	CFHR5	0.51	6.95	0.31	1.22e-11	Asthma;
LGG	cis	rs722599	0.639	rs2193596	chr14:75234101	A/C	cg06637938	chr14:75390232	RPS6KL1	0.57	8.68	0.37	6.83e-17	IgG glycosylation;
LGG	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.7	0.64	6.64e-54	Vitiligo;
LGG	cis	rs67478160	0.655	rs4900598	chr14:104281541	T/C	cg26031613	chr14:104095156	KLC1	-0.46	-7.63	-0.33	1.32e-13	Schizophrenia;
LGG	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6542826	0.546	rs7605405	chr2:110042960	C/A	cg20706049	chr2:110026630	SH3RF3	0.34	7.97	0.35	1.25e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11628318	0.515	rs1951630	chr14:103076807	A/T	cg12046867	chr14:103022105	NA	-0.4	-7.52	-0.33	2.93e-13	Platelet count;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.22	0.43	3.11e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.83	-0.34	3.29e-14	Diabetic retinopathy;
LGG	cis	rs2354432	0.882	rs11576360	chr1:146740576	G/A	cg25205988	chr1:146714368	CHD1L	1.36	19.2	0.67	7.15e-61	Mitochondrial DNA levels;
LGG	cis	rs3087591	0.708	rs7503922	chr17:29641935	C/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.42	0.5	9.12e-31	Hip circumference;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17994840	chr10:134572417	INPP5A	0.36	6.65	0.3	8.37e-11	Body fat percentage;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15884411	chr2:96932403	CIAO1;TMEM127	0.53	8.31	0.36	1.11e-15	Gut microbiome composition (summer);
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg15383120	chr6:291909	DUSP22	-0.53	-8.73	-0.38	4.83e-17	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.72e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg03929089	chr4:120376271	NA	0.72	8.15	0.35	3.39e-15	Axial length;
LGG	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.62	0.33	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3219090	1.000	rs2793382	chr1:226583417	C/T	cg17127702	chr1:226594323	PARP1	0.38	12.22	0.49	5.75e-30	Melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13789548	chr4:122872838	TRPC3	0.46	6.8	0.3	3.3e-11	Gut microbiome composition (summer);
LGG	cis	rs10463554	0.892	rs158246	chr5:102408849	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg26031613	chr14:104095156	KLC1	1.15	26.24	0.77	1.2e-93	Body mass index;
LGG	cis	rs2708377	0.656	rs116607079	chr12:11262044	C/T	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.79	-0.3	3.42e-11	Bitter taste perception;
LGG	cis	rs1372356	0.816	rs8014682	chr14:88535240	T/C	cg18078958	chr14:88630771	NA	0.32	7.64	0.33	1.27e-13	Food antigen IgG levels;
LGG	cis	rs1003719	0.667	rs6517404	chr21:38494918	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.76	14.77	0.57	1.03e-40	Eye color traits;
LGG	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg07615347	chr10:60278583	BICC1	0.63	17.85	0.64	1.3e-54	Refractive error;
LGG	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg24692254	chr21:30365293	RNF160	0.65	11.31	0.47	2.39e-26	Cognitive test performance;
LGG	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg02640540	chr1:67518911	SLC35D1	0.37	7.36	0.32	8.28e-13	Lymphocyte percentage of white cells;
LGG	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg19812747	chr11:111475976	SIK2	0.43	8.68	0.37	7.01e-17	Primary sclerosing cholangitis;
LGG	cis	rs2802728	0.881	rs13374280	chr1:243570531	T/C	cg05593162	chr1:243577377	SDCCAG8	0.5	7.09	0.31	4.95e-12	Toenail selenium levels;
LGG	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.11	-0.35	4.62e-15	Neuroticism;
LGG	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03264133	chr6:25882463	NA	0.66	12.19	0.49	8.02e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2562456	0.874	rs2562417	chr19:21711202	T/C	cg00806126	chr19:22604979	ZNF98	0.65	9.41	0.4	2.35e-19	Pain;
LGG	cis	rs7500448	0.523	rs72792120	chr16:83021333	G/C	cg03011928	chr16:83023240	CDH13	-0.32	-6.73	-0.3	4.95e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Pulse pressure;Coronary artery disease;
LGG	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.94	0.57	1.87e-41	Colorectal cancer;
LGG	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.5	-9.62	-0.41	4.21e-20	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.8	0.48	2.92e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.71	-0.34	7.73e-14	Sudden cardiac arrest;
LGG	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg16339924	chr4:17578868	LAP3	-0.6	-9.69	-0.41	2.48e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg07615347	chr10:60278583	BICC1	0.62	17.35	0.63	2.56e-52	Refractive error;
LGG	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.06	0.39	3.67e-18	Cognitive test performance;
LGG	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg17145862	chr1:211918768	LPGAT1	0.71	12.72	0.51	5.3e-32	Crohn's disease;
LGG	cis	rs2236918	0.643	rs3121389	chr1:242020264	C/T	cg17736920	chr1:242011382	EXO1	0.39	7.02	0.31	7.75e-12	Menopause (age at onset);
LGG	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.53	0.33	2.61e-13	Glycated hemoglobin levels;
LGG	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg09048205	chr5:1608656	LOC728613	-0.5	-8.52	-0.37	2.26e-16	Breast cancer;
LGG	cis	rs3796352	1.000	rs3796352	chr3:52913279	C/T	cg12962167	chr3:53033115	SFMBT1	0.79	8.05	0.35	6.9e-15	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs9657904	0.950	rs11921710	chr3:105565615	G/A	cg14088669	chr1:158435396	OR10K1	-0.41	-6.95	-0.31	1.28e-11	Multiple sclerosis;
LGG	cis	rs9583531	0.891	rs9521906	chr13:111358000	T/G	cg24331049	chr13:111365604	ING1	-0.86	-11.9	-0.48	1.09e-28	Coronary artery disease;
LGG	cis	rs4604732	0.631	rs1106721	chr1:247624676	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg26384229	chr12:38710491	ALG10B	1.06	28.19	0.79	1.66e-102	Heart rate;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Bipolar disorder;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.74	0.41	1.59e-20	Longevity;
LGG	cis	rs4132509	0.744	rs320305	chr1:243859909	G/T	cg21452805	chr1:244014465	NA	0.9	9.96	0.42	2.64e-21	RR interval (heart rate);
LGG	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg10935138	chr17:73851978	WBP2	0.55	8.11	0.35	4.61e-15	Psoriasis;
LGG	cis	rs72781680	0.898	rs17762651	chr2:24115922	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.06	0.39	3.8e-18	Lymphocyte counts;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg05091796	chr16:4465799	CORO7	-0.74	-11.99	-0.49	5.01e-29	Schizophrenia;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.71	-0.41	2.04e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7011049	0.778	rs73601293	chr8:53870103	G/T	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.02	-0.39	5.16e-18	Myopia (pathological);
LGG	cis	rs6840360	0.615	rs72728179	chr4:152477877	A/G	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7551222	0.752	rs12032733	chr1:204481209	G/A	cg20240347	chr1:204465584	NA	-0.56	-11.28	-0.46	3.14e-26	Schizophrenia;
LGG	cis	rs2415984	0.622	rs1761027	chr14:46929611	G/A	cg14871534	chr14:47121158	RPL10L	0.57	10.04	0.42	1.42e-21	Number of children ever born;
LGG	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg02023728	chr11:77925099	USP35	0.44	7.63	0.33	1.32e-13	Testicular germ cell tumor;
LGG	cis	rs7226408	0.600	rs6507184	chr18:34509273	A/G	cg15022739	chr18:34823045	BRUNOL4	0.42	8.92	0.38	1.07e-17	Obesity-related traits;
LGG	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg26396452	chr14:65542826	MAX	-0.5	-10.31	-0.43	1.36e-22	Obesity-related traits;
LGG	cis	rs847649	0.961	rs10250490	chr7:102537277	A/G	cg18108683	chr7:102477205	FBXL13	-0.63	-13.54	-0.53	1.96e-35	Morning vs. evening chronotype;
LGG	cis	rs1506636	1.000	rs2215553	chr7:123318478	G/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.75	-0.3	4.56e-11	Mean platelet volume;
LGG	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs79839061	0.518	rs3755960	chr4:895060	G/T	cg07828340	chr4:882639	GAK	0.93	9.83	0.42	7.45e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs28622458	chr4:98916651	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9849248	0.627	rs2735559	chr3:88106618	G/A	cg14530983	chr3:88190749	ZNF654	0.54	7.73	0.34	6.77e-14	Menarche (age at onset);
LGG	cis	rs13394619	0.875	rs7576826	chr2:11723021	C/T	cg07314298	chr2:11723111	GREB1	-0.47	-9.64	-0.41	3.8e-20	Endometriosis;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg23782820	chr8:58130467	NA	0.5	7.67	0.34	1.05e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-10.5	-0.44	2.78e-23	Parkinson's disease;
LGG	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg11764359	chr7:65958608	NA	0.61	10.63	0.44	9.18e-24	Aortic root size;
LGG	cis	rs4595586	0.545	rs12827823	chr12:39392144	G/T	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg02219949	chr17:45927392	SP6	0.42	7.24	0.32	1.94e-12	Ease of getting up in the morning;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03306564	chr11:64902099	SYVN1	0.52	7.93	0.35	1.71e-14	Gut microbiome composition (summer);
LGG	trans	rs9657904	0.687	rs1992522	chr3:105544863	C/T	cg14088669	chr1:158435396	OR10K1	0.42	7.81	0.34	3.89e-14	Multiple sclerosis;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg13880726	chr7:1868755	MAD1L1	0.45	7.87	0.34	2.62e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg18252515	chr7:66147081	NA	-1.31	-19.1	-0.66	2.09e-60	Diabetic kidney disease;
LGG	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-8.04	-0.35	7.72e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs300703	0.719	rs385909	chr2:199678	A/G	cg21211680	chr2:198530	NA	1.3	22.08	0.72	2.4e-74	Blood protein levels;
LGG	cis	rs11249608	0.548	rs10516150	chr5:178459169	G/C	cg21905437	chr5:178450457	ZNF879	0.46	6.65	0.3	8.26e-11	Pubertal anthropometrics;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg14668821	chr17:77704760	ENPP7	0.42	8.32	0.36	9.86e-16	Menopause (age at onset);
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03713592	chr11:72463424	ARAP1	0.38	7.31	0.32	1.21e-12	Type 2 diabetes;
LGG	cis	rs4474465	0.850	rs4579956	chr11:78232445	G/C	cg27205649	chr11:78285834	NARS2	0.5	8.39	0.36	5.91e-16	Alzheimer's disease (survival time);
LGG	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg00666640	chr1:248458726	OR2T12	0.55	8.79	0.38	3.06e-17	Common traits (Other);
LGG	cis	rs9815354	1.000	rs6803652	chr3:41824556	A/G	cg03022575	chr3:42003672	ULK4	0.61	7.89	0.34	2.2e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11074306	0.561	rs7162123	chr15:28063263	T/C	cg26402630	chr15:28053930	OCA2	0.36	7.21	0.32	2.3e-12	Uveal melanoma;
LGG	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg00376283	chr12:123451042	ABCB9	0.6	9.2	0.39	1.18e-18	Neutrophil percentage of white cells;
LGG	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.36e-18	Motion sickness;
LGG	trans	rs11088226	0.581	rs2833860	chr21:33882309	G/A	cg09050820	chr6:167586206	TCP10L2	0.49	7.97	0.35	1.22e-14	Gastritis;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg02063458	chr16:48190773	NA	0.54	6.94	0.31	1.3e-11	Colorectal cancer;
LGG	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg21427119	chr20:30132790	HM13	-0.43	-7.42	-0.33	5.65e-13	Mean corpuscular hemoglobin;
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00166722	chr3:10149974	C3orf24	0.53	8.92	0.38	1.13e-17	Alzheimer's disease;
LGG	cis	rs16976116	0.901	rs28591259	chr15:55498940	T/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.48	-0.44	3.43e-23	Total cholesterol levels;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.32	3.05e-12	Lung cancer;
LGG	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.11	0.31	4.4e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs877282	0.755	rs11253399	chr10:790030	T/A	cg22713356	chr15:30763199	NA	0.49	7.81	0.34	3.75e-14	Uric acid levels;
LGG	cis	rs4356203	0.905	rs214940	chr11:17186855	A/G	cg15432903	chr11:17409602	KCNJ11	-0.37	-6.8	-0.3	3.27e-11	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10929925	0.931	rs2609183	chr2:6161040	G/A	cg00493617	chr2:6141445	NA	0.33	7.45	0.33	4.49e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.29	0.32	1.39e-12	Menopause (age at onset);
LGG	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs17221829	0.836	rs3931233	chr11:89451588	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.76	-0.34	5.44e-14	Anxiety in major depressive disorder;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg06112835	chr11:68658793	MRPL21	0.64	10.4	0.44	6.59e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2077654	0.556	rs2299638	chr11:17443587	A/G	cg25308976	chr11:17434268	ABCC8	-0.56	-7.37	-0.32	7.97e-13	Gout;
LGG	cis	rs4731207	0.596	rs2170351	chr7:124642197	A/G	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10548355	chr11:70129868	PPFIA1;MIR548K	0.37	6.77	0.3	3.85e-11	Gut microbiome composition (summer);
LGG	cis	rs6684428	0.518	rs7553701	chr1:56367159	G/T	cg11651538	chr1:56320950	NA	-0.47	-8.31	-0.36	1.07e-15	Airflow obstruction;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.48	-0.33	3.67e-13	Personality dimensions;
LGG	cis	rs721048	1.000	rs17432497	chr2:63027337	T/G	cg17519650	chr2:63277830	OTX1	0.55	6.97	0.31	1.12e-11	Prostate cancer;
LGG	cis	rs3816183	0.958	rs7582883	chr2:43023004	C/T	cg14631114	chr2:43023945	NA	0.48	9.04	0.39	4.44e-18	Hypospadias;
LGG	cis	rs151997	1.000	rs151997	chr5:50233199	A/G	cg06027927	chr5:50259733	NA	-0.62	-10.42	-0.44	5.43e-23	Callous-unemotional behaviour;
LGG	cis	rs782590	0.967	rs4672054	chr2:55773093	C/A	cg18811423	chr2:55921094	PNPT1	0.88	20.47	0.69	8.34e-67	Metabolic syndrome;
LGG	cis	rs10875746	0.669	rs61941006	chr12:48631133	G/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.42	-0.33	5.51e-13	Longevity (90 years and older);
LGG	cis	rs7172677	1.000	rs2029519	chr15:75415962	A/G	cg14664628	chr15:75095509	CSK	-0.45	-6.96	-0.31	1.17e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12410462	0.551	rs67216605	chr1:227901637	A/G	cg21459583	chr1:227974177	NA	0.36	6.67	0.3	7.44e-11	Major depressive disorder;
LGG	cis	rs9487051	0.652	rs9372210	chr6:109601703	G/C	cg21918786	chr6:109611834	NA	-0.42	-7.88	-0.34	2.37e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg11814155	chr7:99998594	ZCWPW1	0.61	9.39	0.4	2.67e-19	Platelet count;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs892961	0.932	rs67415822	chr17:75412678	A/G	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg07061783	chr6:25882402	NA	-0.49	-8.48	-0.37	3.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg09537434	chr19:41945824	ATP5SL	0.87	23.24	0.73	9.58e-80	Height;
LGG	cis	rs7216064	1.000	rs4790908	chr17:65852907	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs881375	0.933	rs7021206	chr9:123684157	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-11.98	-0.49	5.35e-29	Rheumatoid arthritis;
LGG	trans	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg06521331	chr12:34319734	NA	0.5	9.35	0.4	3.71e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	7.67	0.34	1.01e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.24	-0.43	2.48e-22	Chronic sinus infection;
LGG	cis	rs9596863	1.000	rs9596862	chr13:54432908	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.2	0.32	2.45e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs10791097	0.694	rs11222369	chr11:130744670	A/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg01028140	chr2:1542097	TPO	-0.46	-8.57	-0.37	1.53e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01341218	chr17:43662625	NA	0.95	16.81	0.62	7.42e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg03959625	chr15:84868606	LOC388152	0.48	7.12	0.31	4.25e-12	Schizophrenia;
LGG	cis	rs17052344	0.582	rs111876736	chr17:21747067	A/G	cg18423549	chr17:21743878	NA	-0.53	-8.09	-0.35	5.35e-15	Cutaneous psoriasis;
LGG	cis	rs9470366	0.545	rs2395655	chr6:36645696	C/T	cg08179530	chr6:36648295	CDKN1A	-0.82	-16.36	-0.61	8.13e-48	QRS duration;
LGG	cis	rs2235642	1.000	rs2076438	chr16:1584618	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.36	8.8	0.38	2.65e-17	Coronary artery disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg11817910	chr12:31944836	H3F3C	0.43	7.94	0.35	1.53e-14	Menarche (age at onset);
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.87	0.34	2.6e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.11	-0.46	1.44e-25	Breast cancer;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.32	-0.47	2.21e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.27	0.36	1.44e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2652822	0.933	rs7170846	chr15:63449543	A/C	cg02713581	chr15:63449717	RPS27L	0.5	8.55	0.37	1.8e-16	Metabolic traits;
LGG	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg05535760	chr7:792225	HEATR2	0.78	12.48	0.5	4.97e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs7614311	0.555	rs58676857	chr3:63903883	G/A	cg22134162	chr3:63841271	THOC7	-0.43	-8.14	-0.35	3.77e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.7	0.56	1.99e-40	Cognitive test performance;
LGG	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7909791	0.606	rs3814219	chr10:105647095	A/G	cg11005552	chr10:105648138	OBFC1	-0.61	-9.38	-0.4	3.06e-19	White matter hyperintensity burden;
LGG	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10794720	0.867	rs78029387	chr10:1138589	C/T	cg08668510	chr10:1095578	IDI1	0.87	7.63	0.33	1.34e-13	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08280861	chr8:58055591	NA	0.5	6.7	0.3	5.95e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg27471124	chr11:109292789	C11orf87	0.45	8.46	0.37	3.64e-16	Schizophrenia;
LGG	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg24642439	chr20:33292090	TP53INP2	-0.58	-9.83	-0.42	7.45e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs3741151	0.892	rs60078907	chr11:73085834	T/C	cg17517138	chr11:73019481	ARHGEF17	0.86	8.97	0.38	7.48e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	cis	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg08930214	chr7:62859557	LOC100287834	0.45	7.32	0.32	1.13e-12	Obesity-related traits;
LGG	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.11	0.62	3.29e-51	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs3820068	0.705	rs4646109	chr1:15817319	T/C	cg05660106	chr1:15850417	CASP9	1.05	23.34	0.74	3.22e-80	Systolic blood pressure;
LGG	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	6.06e-14	Testicular germ cell tumor;
LGG	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.53	0.37	2.09e-16	Retinal vascular caliber;
LGG	cis	rs7216064	1.000	rs7212293	chr17:65847325	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.11	-0.39	2.43e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs735860	0.726	rs209518	chr6:53208016	C/A	cg10236188	chr6:53219634	NA	0.35	6.78	0.3	3.72e-11	Glaucoma;
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.93	-0.38	1.03e-17	Prostate cancer;
LGG	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg02002194	chr4:3960332	NA	0.44	8.05	0.35	6.82e-15	Retinal vascular caliber;
LGG	cis	rs28453840	1	rs28453840	chr2:136522941	G/A	cg07169764	chr2:136633963	MCM6	-0.78	-13.63	-0.54	8.62e-36	Cholesterol, total;
LGG	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08045932	chr20:61659980	NA	0.6	13.02	0.52	3.16e-33	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs9409565	0.513	rs16912862	chr9:97050005	A/G	cg05679027	chr9:99775184	HIATL2	-0.58	-10.09	-0.42	8.96e-22	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs7512552	0.839	rs12045304	chr1:150399818	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.32	0.4	4.66e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03232484	chr7:93633800	BET1	0.38	7.03	0.31	7.55e-12	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg12708336	chr17:41446283	NA	-0.29	-6.72	-0.3	5.26e-11	Menopause (age at onset);
LGG	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg14210321	chr2:106509881	NCK2	-0.53	-9.1	-0.39	2.61e-18	Addiction;
LGG	cis	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg18131467	chr2:239335373	ASB1	-0.66	-6.64	-0.3	8.62e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg11878867	chr6:150167359	LRP11	0.38	7.91	0.35	1.87e-14	Testicular germ cell tumor;
LGG	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg06606381	chr12:133084897	FBRSL1	-0.93	-9.92	-0.42	3.74e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	trans	rs6601327	0.665	rs10113186	chr8:9655426	T/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.95	-0.31	1.22e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg15704280	chr7:45808275	SEPT13	0.89	18.24	0.65	2.01e-56	Coronary artery disease;
LGG	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.91	0.31	1.65e-11	Birth weight;
LGG	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.77	16.64	0.61	4.54e-49	Chronic sinus infection;
LGG	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg25486957	chr4:152246857	NA	-0.52	-8.57	-0.37	1.61e-16	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg02269571	chr22:50332266	NA	-0.72	-10.94	-0.45	6.37e-25	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25072359	chr17:41440525	NA	0.53	10.22	0.43	3.1e-22	Menopause (age at onset);
LGG	cis	rs55871839	0.684	rs7829715	chr8:59803836	C/T	cg07426533	chr8:59803705	TOX	0.57	12.86	0.51	1.44e-32	Pneumonia;
LGG	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.62	-0.37	1.07e-16	Menopause (age at onset);
LGG	cis	rs500492	0.618	rs2473158	chr16:1075241	G/A	cg08273874	chr16:1060765	NA	-0.55	-8.0	-0.35	1.01e-14	Polycystic ovary syndrome;
LGG	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg15621731	chr19:5074616	KDM4B	0.29	7.28	0.32	1.47e-12	Monocyte percentage of white cells;
LGG	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg17885191	chr8:135476712	NA	0.44	6.99	0.31	9.83e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg00864171	chr11:67383662	NA	-0.43	-7.17	-0.32	2.9e-12	Mean corpuscular volume;
LGG	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	12.77	0.51	3.48e-32	Total body bone mineral density;
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg00405596	chr8:11794950	NA	-0.41	-6.74	-0.3	4.74e-11	Neuroticism;
LGG	cis	rs8064024	0.681	rs7194890	chr16:4883781	T/A	cg04440724	chr16:4920505	UBN1	-0.54	-11.95	-0.49	7.06e-29	Cancer;
LGG	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg14500267	chr11:67383377	NA	-0.41	-7.48	-0.33	3.82e-13	Mean corpuscular volume;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg18681998	chr4:17616180	MED28	0.89	20.47	0.69	9.02e-67	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg18350739	chr11:68623251	NA	-0.81	-20.3	-0.69	5.53e-66	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4561483	0.624	rs2215928	chr16:11927918	A/T	cg08843971	chr16:11963173	GSPT1	-0.53	-12.46	-0.5	6.07e-31	Testicular germ cell tumor;
LGG	cis	rs17641971	0.862	rs341817	chr8:50023600	A/C	cg00325661	chr8:49890786	NA	-0.47	-7.98	-0.35	1.2e-14	Blood metabolite levels;
LGG	cis	rs7590368	0.926	rs12623588	chr2:10957612	C/G	cg15705551	chr2:10952987	PDIA6	-0.66	-10.08	-0.42	9.72e-22	Educational attainment (years of education);
LGG	cis	rs2380220	1.000	rs9400318	chr6:95972381	T/A	cg04719120	chr6:96025338	MANEA	0.52	6.78	0.3	3.71e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg13206674	chr6:150067644	NUP43	0.63	14.29	0.55	1.27e-38	Lung cancer;
LGG	cis	rs7566780	0.575	rs4560110	chr2:16702136	A/G	cg09580478	chr2:16689509	NA	0.46	7.28	0.32	1.47e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.67	12.12	0.49	1.55e-29	Colorectal cancer;
LGG	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg02187348	chr16:89574699	SPG7	0.58	9.45	0.4	1.71e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs1790761	0.967	rs869736	chr11:67205462	C/A	cg14500267	chr11:67383377	NA	-0.38	-6.96	-0.31	1.14e-11	Mean corpuscular volume;
LGG	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.16	-0.43	5.21e-22	Sudden cardiac arrest;
LGG	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg12463550	chr7:65579703	CRCP	-0.74	-8.04	-0.35	7.73e-15	Diabetic kidney disease;
LGG	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.38	7.7	0.34	8.3e-14	Oropharynx cancer;
LGG	trans	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-7.67	-0.34	1.03e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg12751644	chr20:60527061	NA	-0.3	-6.73	-0.3	5.08e-11	Body mass index;
LGG	cis	rs994014	0.629	rs7685645	chr4:82239938	G/A	cg07938847	chr4:82126349	PRKG2	-0.29	-7.11	-0.31	4.44e-12	Height;
LGG	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.41	0.44	6.18e-23	Diabetic retinopathy;
LGG	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg13010199	chr12:38710504	ALG10B	0.47	8.85	0.38	1.8e-17	Morning vs. evening chronotype;
LGG	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg09596252	chr17:78655493	RPTOR	0.48	8.49	0.37	2.83e-16	Obesity;
LGG	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.1	-0.31	4.84e-12	Menopause (age at onset);
LGG	cis	rs2221894	0.506	rs1512851	chr8:28770472	G/T	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.77	-0.34	5.16e-14	Obesity-related traits;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.67	9.36	0.4	3.47e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg26043149	chr18:55253948	FECH	-0.41	-6.79	-0.3	3.38e-11	Bone mineral density;
LGG	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg02886208	chr11:14281011	SPON1	-0.35	-6.75	-0.3	4.37e-11	Sense of smell;
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14159672	chr1:205819179	PM20D1	0.44	6.93	0.31	1.41e-11	Parkinson's disease;
LGG	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11644478	chr21:40555479	PSMG1	-0.59	-9.87	-0.42	5.78e-21	Menarche (age at onset);
LGG	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.36	-0.4	3.45e-19	Response to antipsychotic treatment;
LGG	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg26031613	chr14:104095156	KLC1	-0.61	-9.57	-0.41	6.37e-20	Reticulocyte count;
LGG	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.71	0.34	7.52e-14	Schizophrenia;
LGG	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg02002194	chr4:3960332	NA	0.49	9.38	0.4	3.02e-19	Mood instability;
LGG	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg12373951	chr3:133503437	NA	0.39	6.8	0.3	3.21e-11	Iron status biomarkers;
LGG	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-10.59	-0.44	1.29e-23	Height;
LGG	trans	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.36	-0.36	7.41e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs11971779	0.941	rs6954453	chr7:139031794	C/T	cg07862535	chr7:139043722	LUC7L2	0.67	10.13	0.43	6.34e-22	Diisocyanate-induced asthma;
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg07308232	chr7:1071921	C7orf50	0.72	14.61	0.56	5.07e-40	Longevity;Endometriosis;
LGG	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg03477792	chr4:77819574	ANKRD56	0.52	9.36	0.4	3.39e-19	Emphysema distribution in smoking;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg13453750	chr1:205783389	SLC41A1	-0.49	-9.6	-0.41	5.25e-20	Menarche (age at onset);
LGG	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg26528311	chr1:38462546	FHL3	-0.36	-9.97	-0.42	2.37e-21	Coronary artery disease;
LGG	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg04691961	chr3:161091175	C3orf57	-0.45	-8.79	-0.38	2.87e-17	Parkinson's disease;
LGG	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg02855558	chr7:158107723	PTPRN2	-0.39	-7.14	-0.32	3.58e-12	Calcium levels;
LGG	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs231513	0.911	rs124721	chr17:41959808	T/C	cg26893861	chr17:41843967	DUSP3	-0.58	-6.79	-0.3	3.54e-11	Cognitive function;
LGG	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg03342759	chr3:160939853	NMD3	-0.75	-13.34	-0.53	1.42e-34	Parkinson's disease;
LGG	cis	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg21775007	chr8:11205619	TDH	-0.57	-9.15	-0.39	1.85e-18	Retinal vascular caliber;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-12.67	-0.51	8.69e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.77	0.41	1.3e-20	Prudent dietary pattern;
LGG	cis	rs2108225	0.837	rs6958729	chr7:107451211	A/G	cg18560240	chr7:107437656	SLC26A3	0.61	10.76	0.45	3.01e-24	Ulcerative colitis;
LGG	cis	rs7805747	0.961	rs55779150	chr7:151406449	A/T	cg17611936	chr7:151411526	PRKAG2	0.53	8.0	0.35	1.02e-14	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.21e-20	Life satisfaction;
LGG	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg24058013	chr18:77568902	NA	-0.45	-7.49	-0.33	3.4e-13	Schizophrenia;
LGG	cis	rs6445975	0.666	rs4681680	chr3:58332217	A/G	cg24175188	chr3:58374923	PXK	0.55	8.97	0.38	7.12e-18	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12016809	chr21:47604291	C21orf56	0.42	6.91	0.31	1.59e-11	Testicular germ cell tumor;
LGG	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg22753661	chr15:79092743	ADAMTS7	0.4	6.91	0.31	1.56e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg12419862	chr22:24373484	LOC391322	-1.12	-28.0	-0.79	1.2e-101	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg27400746	chr16:89904261	SPIRE2	-0.92	-14.18	-0.55	3.61e-38	Skin colour saturation;
LGG	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg21387009	chr3:10280255	IRAK2	-0.37	-6.86	-0.3	2.22e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs12210905	0.925	rs11966939	chr6:27003749	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg25174290	chr11:3078921	CARS	0.74	15.01	0.57	9.13e-42	Longevity;
LGG	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg10596483	chr8:143751796	JRK	0.53	8.31	0.36	1.09e-15	Schizophrenia;
LGG	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Myopia (pathological);
LGG	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg17971929	chr21:40555470	PSMG1	-0.53	-9.02	-0.39	5.09e-18	Menarche (age at onset);
LGG	cis	rs55871839	0.684	rs9298002	chr8:59815118	T/C	cg07426533	chr8:59803705	TOX	-0.59	-13.49	-0.53	3.32e-35	Pneumonia;
LGG	cis	rs7715811	1.000	rs6860236	chr5:13762013	C/T	cg07548982	chr5:13769939	DNAH5	-0.47	-9.89	-0.42	4.92e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs6748734	0.581	rs4234092	chr2:241866389	T/C	cg05025159	chr2:241905733	NA	0.53	10.18	0.43	4.34e-22	Urinary metabolites;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg13628971	chr7:2884303	GNA12	0.53	10.34	0.43	1.14e-22	Height;
LGG	cis	rs9682041	0.688	rs7621787	chr3:170146862	T/A	cg11886554	chr3:170076028	SKIL	0.99	10.72	0.45	4.4e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg12982090	chr3:42733453	KBTBD5	-0.92	-14.33	-0.55	8.37e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg17830980	chr10:43048298	ZNF37B	0.51	10.08	0.42	9.48e-22	Extrinsic epigenetic age acceleration;
LGG	trans	rs61931739	0.578	rs1482992	chr12:33599387	G/A	cg26384229	chr12:38710491	ALG10B	-0.46	-7.93	-0.35	1.64e-14	Morning vs. evening chronotype;
LGG	trans	rs6787172	0.592	rs6767008	chr3:158101060	C/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.35	-0.32	9.18e-13	Subjective well-being;
LGG	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg06637938	chr14:75390232	RPS6KL1	0.83	17.56	0.63	2.84e-53	Caffeine consumption;
LGG	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg09517075	chr8:22133004	PIWIL2	0.44	9.7	0.41	2.16e-20	Hypertriglyceridemia;
LGG	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.09	0.35	5.2e-15	Retinal vascular caliber;
LGG	cis	rs6604026	0.922	rs71652510	chr1:93366357	T/C	cg22128645	chr1:93425802	FAM69A	-0.4	-7.18	-0.32	2.87e-12	Multiple sclerosis;
LGG	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.04	-0.42	1.34e-21	Aortic root size;
LGG	cis	rs834603	0.575	rs1612394	chr7:47467609	G/A	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1355223	0.506	rs6484738	chr11:34860858	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.47	-8.03	-0.35	7.89e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg09426994	chr11:118478258	PHLDB1	0.43	7.84	0.34	3.19e-14	Cholesterol, total;
LGG	cis	rs7444	0.825	rs5994638	chr22:21953276	A/G	cg05046821	chr22:21984468	YDJC	-0.37	-7.03	-0.31	7.31e-12	Systemic lupus erythematosus;
LGG	trans	rs9929218	0.954	rs12924033	chr16:68822599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-11.82	-0.48	2.44e-28	Colorectal cancer;
LGG	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg07303275	chr16:75499416	TMEM170A	0.42	7.53	0.33	2.64e-13	Dupuytren's disease;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs2077654	0.822	rs12293228	chr11:17436951	C/T	cg25308976	chr11:17434268	ABCC8	0.8	9.73	0.41	1.82e-20	Gout;
LGG	cis	rs4460629	0.804	rs56112907	chr1:155070862	C/A	cg13808842	chr1:155066096	NA	-0.29	-6.9	-0.31	1.68e-11	Serum magnesium levels;
LGG	cis	rs7666738	0.830	rs11947027	chr4:99005941	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.49	0.37	2.76e-16	Lung cancer;
LGG	cis	rs4148087	1.000	rs2168344	chr21:43621496	C/G	cg08841829	chr21:43638893	ABCG1	-0.59	-7.96	-0.35	1.33e-14	Eating disorder in bipolar disorder;
LGG	cis	rs4664308	0.967	rs56293836	chr2:160910958	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs9604529	0.759	rs79192570	chr13:114625570	G/A	cg03343631	chr13:114764489	RASA3	-0.54	-7.02	-0.31	7.85e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6840360	0.541	rs4696251	chr4:152266326	T/C	cg25486957	chr4:152246857	NA	-0.41	-7.22	-0.32	2.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6430585	0.527	rs1900306	chr2:136416533	G/A	cg07169764	chr2:136633963	MCM6	1.09	18.37	0.65	4.92e-57	Corneal structure;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg06074448	chr4:187884817	NA	-0.6	-13.38	-0.53	9.5e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg04691961	chr3:161091175	C3orf57	-0.45	-8.74	-0.38	4.15e-17	Parkinson's disease;
LGG	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.86	-16.76	-0.61	1.27e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11890956	chr21:40555474	PSMG1	-0.74	-12.88	-0.51	1.19e-32	Menarche (age at onset);
LGG	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg08949735	chr16:89699720	DPEP1	-0.48	-9.89	-0.42	4.73e-21	Vitiligo;
LGG	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg01620082	chr3:125678407	NA	-1.07	-10.26	-0.43	2.1e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.93	0.35	1.62e-14	Personality dimensions;
LGG	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg08847533	chr14:75593920	NEK9	-0.57	-10.59	-0.44	1.27e-23	Height;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4622507	0.688	rs4784464	chr16:55073590	T/C	cg09947736	chr16:55091198	NA	0.65	10.42	0.44	5.64e-23	Social communication problems;
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg25072359	chr17:41440525	NA	0.52	9.77	0.41	1.23e-20	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs3126085	0.935	rs1496049	chr1:152161949	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-7.92	-0.35	1.75e-14	Atopic dermatitis;
LGG	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg20302533	chr7:39170763	POU6F2	0.32	7.72	0.34	7.34e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4865875	1.000	rs4865874	chr5:54100296	C/A	cg22421804	chr5:54100067	NA	0.51	7.65	0.33	1.21e-13	Sense of smell;
LGG	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg20637307	chr2:213403960	ERBB4	-0.45	-8.79	-0.38	3.03e-17	QT interval (ambient particulate matter interaction);
LGG	cis	rs4664304	1.000	rs4664304	chr2:160794008	A/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.76	-0.34	5.53e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg00149659	chr3:10157352	C3orf10	0.86	11.06	0.46	2.16e-25	Alzheimer's disease;
LGG	cis	rs4740619	0.870	rs10756671	chr9:15548007	A/T	cg14451791	chr9:16040625	NA	-0.39	-9.8	-0.41	1e-20	Body mass index;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00864171	chr11:67383662	NA	0.55	9.58	0.41	6e-20	Mean corpuscular volume;
LGG	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.51	9.24	0.39	9.16e-19	HDL cholesterol;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17428076	0.872	rs17428174	chr2:172886148	A/G	cg21435375	chr2:172878103	MAP1D	0.44	9.5	0.4	1.17e-19	Myopia;
LGG	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg01000188	chr9:133769184	QRFP	0.29	7.4	0.33	6.49e-13	Response to amphetamines;
LGG	cis	rs9972944	1.000	rs9972944	chr17:63771079	A/G	cg07283582	chr17:63770753	CCDC46	0.44	8.75	0.38	4.04e-17	Total body bone mineral density;
LGG	trans	rs877282	0.898	rs71489279	chr10:760510	T/C	cg22713356	chr15:30763199	NA	0.49	7.55	0.33	2.39e-13	Uric acid levels;
LGG	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg11764359	chr7:65958608	NA	-0.61	-8.92	-0.38	1.12e-17	Aortic root size;
LGG	cis	rs6547631	0.622	rs6740635	chr2:85933527	C/G	cg19805943	chr2:85933069	NA	0.32	6.78	0.3	3.6e-11	Blood protein levels;
LGG	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.2	-0.52	5.5e-34	Gut microbiome composition (summer);
LGG	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-10.43	-0.44	4.9e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg15971980	chr6:150254442	NA	0.43	8.11	0.35	4.63e-15	Lung cancer;
LGG	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-9.2	-0.39	1.2e-18	Neuroticism;
LGG	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg15596359	chr8:11213517	TDH	0.4	8.11	0.35	4.5e-15	Retinal vascular caliber;
LGG	cis	rs2688608	0.592	rs7923045	chr10:75487498	A/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-6.94	-0.31	1.33e-11	Inflammatory bowel disease;
LGG	cis	rs3806843	0.868	rs2262574	chr5:140123635	G/T	cg19875535	chr5:140030758	IK	-0.55	-11.32	-0.47	2.18e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg00898013	chr13:113819073	PROZ	-0.51	-10.02	-0.42	1.55e-21	Platelet distribution width;
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17219203	chr10:38645113	HSD17B7P2	0.46	7.22	0.32	2.14e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg02711726	chr17:80685570	FN3KRP	-0.64	-12.22	-0.49	5.61e-30	Glycated hemoglobin levels;
LGG	cis	rs8133932	0.654	rs10854474	chr21:47332700	A/G	cg11214348	chr21:47283868	PCBP3	0.45	7.98	0.35	1.17e-14	Schizophrenia;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-17.2	-0.62	1.31e-51	Personality dimensions;
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg02002194	chr4:3960332	NA	0.45	8.69	0.37	6.16e-17	Systolic blood pressure;
LGG	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.94	0.52	6.37e-33	Cognitive test performance;
LGG	cis	rs9814567	1.000	rs35718987	chr3:134272783	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg16141378	chr3:129829833	LOC729375	0.39	8.92	0.38	1.11e-17	Neuroticism;
LGG	cis	rs4917300	0.566	rs1388799	chr8:143100593	A/G	cg06573787	chr8:143070187	NA	0.6	10.05	0.42	1.26e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs12618769	0.570	rs17444095	chr2:99075817	C/G	cg18455616	chr2:99124870	INPP4A	0.28	8.31	0.36	1.09e-15	Bipolar disorder;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.97	0.31	1.09e-11	Obesity-related traits;
LGG	cis	rs3857747	0.827	rs10263744	chr7:40436624	A/G	cg00420559	chr7:40367873	C7orf10	-0.39	-7.97	-0.35	1.2e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	10.2	0.43	3.51e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs9487094	1.000	rs9480955	chr6:109744533	T/A	cg16315928	chr6:109776240	MICAL1	0.47	7.9	0.34	1.99e-14	Height;
LGG	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg22916017	chr11:64110731	CCDC88B	-0.53	-7.12	-0.31	4.2e-12	Mean platelet volume;
LGG	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg26384229	chr12:38710491	ALG10B	0.93	21.35	0.7	6.68e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.24	-32.28	-0.83	1.41e-120	Chronic sinus infection;
LGG	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14829155	chr15:31115871	NA	-0.67	-11.29	-0.46	2.74e-26	Huntington's disease progression;
LGG	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg20302533	chr7:39170763	POU6F2	0.32	7.65	0.33	1.22e-13	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12501923	chr17:73937416	FBF1	0.43	6.88	0.3	1.94e-11	Cognitive performance;
LGG	cis	rs55665837	1.000	rs12283797	chr11:14442262	C/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.86e-17	Vitamin D levels;
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg05556477	chr5:131705319	SLC22A5	0.81	9.8	0.41	9.82e-21	Rheumatoid arthritis;
LGG	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs4363385	0.719	rs12748969	chr1:152932654	T/C	cg07796016	chr1:152779584	LCE1C	-0.48	-7.66	-0.34	1.13e-13	Inflammatory skin disease;
LGG	cis	rs151997	1.000	rs152690	chr5:50213584	A/T	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg23311950	chr12:74931760	LOC552889	0.39	8.11	0.35	4.64e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2227564	0.620	rs11000785	chr10:75575963	T/C	cg00564723	chr10:75632066	CAMK2G	-0.48	-10.28	-0.43	1.76e-22	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1079204	1.000	rs7600989	chr2:219119134	G/T	cg05728596	chr2:219128475	GPBAR1	1.08	10.03	0.42	1.45e-21	Smooth-surface caries;
LGG	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg03162506	chr22:38580953	NA	0.28	6.86	0.3	2.16e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs4888262	0.508	rs4887779	chr16:74647795	A/G	cg01733217	chr16:74700730	RFWD3	-0.9	-18.35	-0.65	6.42e-57	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.4	-0.5	1.14e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.1	28.16	0.79	2.17e-102	Exhaled nitric oxide output;
LGG	cis	rs4740619	0.933	rs10810433	chr9:15707406	A/T	cg14451791	chr9:16040625	NA	-0.36	-9.07	-0.39	3.36e-18	Body mass index;
LGG	cis	rs9354308	0.764	rs1938108	chr6:66570993	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg04226714	chr8:49833948	SNAI2	-0.5	-9.09	-0.39	2.85e-18	Life satisfaction;
LGG	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg23625390	chr15:77176239	SCAPER	-0.67	-13.67	-0.54	5.48e-36	Blood metabolite levels;
LGG	cis	rs2455601	0.638	rs2248245	chr11:8988350	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-10.97	-0.45	4.75e-25	Schizophrenia;
LGG	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21582582	chr3:182698605	DCUN1D1	0.38	6.7	0.3	6.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg12437481	chr16:420112	MRPL28	-0.47	-8.22	-0.36	2.03e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.41	-0.4	2.31e-19	Response to antipsychotic treatment;
LGG	cis	rs3126085	0.735	rs4845752	chr1:152226576	C/A	cg26876637	chr1:152193138	HRNR	0.55	8.97	0.38	7.58e-18	Atopic dermatitis;
LGG	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11644478	chr21:40555479	PSMG1	0.88	16.42	0.61	4.64e-48	Cognitive function;
LGG	cis	rs77372450	0.636	rs11749144	chr5:157026996	A/G	cg25387487	chr5:157003181	ADAM19	-0.56	-7.09	-0.31	4.95e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs2290402	0.536	rs4690340	chr4:848280	G/T	cg09237302	chr4:906077	GAK	-0.43	-7.41	-0.33	6e-13	Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg15038512	chr6:170123185	PHF10	0.53	6.67	0.3	7.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11657217	0.677	rs8067469	chr17:77698322	G/A	cg06901238	chr17:77706717	ENPP7	0.48	10.08	0.42	1.02e-21	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs2033732	0.789	rs7821259	chr8:85081619	T/G	cg05716166	chr8:85095498	RALYL	0.54	8.94	0.38	9.65e-18	Body mass index;
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg00713939	chr8:144660590	NAPRT1	0.89	7.27	0.32	1.56e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs45544231	0.523	rs8044585	chr16:52579906	C/A	cg09051775	chr16:52580266	TOX3	-0.46	-7.81	-0.34	3.98e-14	Restless legs syndrome;
LGG	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.53	-0.37	2.17e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-11.67	-0.48	9.6e-28	Vitiligo;
LGG	cis	rs2120243	0.539	rs4680358	chr3:157069275	A/G	cg24825693	chr3:157122686	VEPH1	-0.52	-11.39	-0.47	1.17e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg08508337	chr8:144660607	NAPRT1	0.86	6.71	0.3	5.83e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	10.97	0.45	4.8e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.18e-13	Heart rate;
LGG	cis	rs7666738	0.830	rs35938349	chr4:98974998	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.73	-14.4	-0.56	4.13e-39	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg24503407	chr1:205819492	PM20D1	-0.49	-8.57	-0.37	1.56e-16	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08280861	chr8:58055591	NA	0.61	7.73	0.34	6.53e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04008888	chr11:68622739	NA	-0.54	-11.55	-0.47	2.73e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	11.65	0.48	1.08e-27	Hemoglobin concentration;
LGG	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	11.0	0.46	3.67e-25	Mean platelet volume;
LGG	cis	rs9914988	1.000	rs9895443	chr17:27182944	A/G	cg20469991	chr17:27169893	C17orf63	-0.53	-6.68	-0.3	6.8e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg11494091	chr17:61959527	GH2	1.01	25.08	0.76	2.74e-88	Prudent dietary pattern;
LGG	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.6	-0.33	1.66e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12039371	1.000	rs12039371	chr1:183985803	A/C	cg01436608	chr1:184005534	GLT25D2	0.51	6.68	0.3	6.82e-11	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.46	-0.63	8.1e-53	Chronic sinus infection;
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.18e-17	Aortic root size;
LGG	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs73036520	0.560	rs346750	chr19:45737218	G/T	cg01416317	chr19:45737208	EXOC3L2	-0.51	-12.88	-0.51	1.15e-32	Monocyte percentage of white cells;
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg26874164	chr19:58962979	ZNF324B	-0.46	-9.05	-0.39	3.92e-18	Uric acid clearance;
LGG	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg25703541	chr22:24373054	LOC391322	0.91	13.79	0.54	1.74e-36	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.77	0.3	3.82e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg16141378	chr3:129829833	LOC729375	0.36	8.12	0.35	4.4e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2114646	0.731	rs56665752	chr2:170635443	G/C	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.93	-0.35	1.69e-14	HDL cholesterol;
LGG	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06481639	chr22:41940642	POLR3H	0.46	6.65	0.3	8.46e-11	Vitiligo;
LGG	cis	rs9443645	0.901	rs9443638	chr6:79720867	T/A	cg18132916	chr6:79620363	NA	-0.3	-8.37	-0.36	7.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.95	-0.38	8.89e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07308232	chr7:1071921	C7orf50	-0.49	-8.97	-0.38	7.39e-18	Longevity;Endometriosis;
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.67	-0.34	1.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg11502198	chr6:26597334	ABT1	0.7	12.68	0.51	7.88e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg12708336	chr17:41446283	NA	-0.3	-6.74	-0.3	4.67e-11	Menopause (age at onset);
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00290607	chr11:67383545	NA	0.62	11.86	0.48	1.56e-28	Mean corpuscular volume;
LGG	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg20336341	chr7:50628841	DDC	0.36	7.04	0.31	6.92e-12	Malaria;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg10377629	chr17:1388950	MYO1C	-0.4	-6.78	-0.3	3.63e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.47	10.88	0.45	1.1e-24	Oropharynx cancer;
LGG	trans	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg22153745	chr1:153894579	GATAD2B	-0.63	-10.29	-0.43	1.62e-22	Total cholesterol levels;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.5	-0.33	3.29e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17526506	chr2:120124281	DBI;C2orf76	-0.4	-6.74	-0.3	4.66e-11	Brain structure;
LGG	cis	rs7633770	0.841	rs6442010	chr3:46669500	A/T	cg11219411	chr3:46661640	NA	0.59	14.32	0.55	8.72e-39	Coronary artery disease;
LGG	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg07636037	chr3:49044803	WDR6	0.6	10.48	0.44	3.28e-23	Resting heart rate;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22822383	chr19:58987261	ZNF446	0.47	7.55	0.33	2.26e-13	Cognitive performance;
LGG	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs796364	0.525	rs10931895	chr2:201143242	C/T	cg23649088	chr2:200775458	C2orf69	0.47	6.79	0.3	3.46e-11	Schizophrenia;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.99	-0.39	6.58e-18	Neuroticism;
LGG	cis	rs4417704	0.525	rs7585348	chr2:241893716	T/C	cg05025159	chr2:241905733	NA	0.52	10.58	0.44	1.38e-23	Joint mobility (Beighton score);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08731084	chr12:44229880	TMEM117	-0.4	-6.75	-0.3	4.58e-11	Brain structure;
LGG	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg00376283	chr12:123451042	ABCB9	0.66	11.41	0.47	9.78e-27	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1538970	0.962	rs2185549	chr1:45814103	C/T	cg05343316	chr1:45956843	TESK2	-0.72	-12.11	-0.49	1.58e-29	Platelet count;
LGG	cis	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9796	0.558	rs8043253	chr15:41503730	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.97	-0.42	2.46e-21	Menopause (age at onset);
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.78	-0.51	3.13e-32	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01458961	chr4:102269425	PPP3CA	0.46	7.39	0.32	6.81e-13	Cognitive performance;
LGG	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg15704280	chr7:45808275	SEPT13	0.51	8.77	0.38	3.46e-17	HDL cholesterol;
LGG	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.69	-0.34	9.01e-14	Cognitive test performance;
LGG	cis	rs6754311	0.731	rs309168	chr2:136670298	C/T	cg07169764	chr2:136633963	MCM6	0.77	12.79	0.51	2.71e-32	Mosquito bite size;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00684032	chr4:1343700	KIAA1530	0.48	9.38	0.4	2.9e-19	Obesity-related traits;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.42	0.36	4.88e-16	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.44	0.4	1.77e-19	Diabetic retinopathy;
LGG	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.95	0.57	1.56e-41	Cognitive test performance;
LGG	cis	rs3816183	0.586	rs6752377	chr2:42779382	A/C	cg14631114	chr2:43023945	NA	0.34	6.67	0.3	7.16e-11	Hypospadias;
LGG	cis	rs2033732	0.706	rs10103882	chr8:85073033	C/T	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg26441486	chr22:50317300	CRELD2	0.36	6.69	0.3	6.63e-11	Schizophrenia;
LGG	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg02023728	chr11:77925099	USP35	0.38	6.78	0.3	3.74e-11	Alzheimer's disease (survival time);
LGG	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs2594989	0.837	rs7642031	chr3:11453754	G/A	cg01796438	chr3:11312864	ATG7	-0.53	-7.01	-0.31	8.32e-12	Circulating chemerin levels;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg19635926	chr16:89946313	TCF25	0.81	9.09	0.39	3.03e-18	Skin colour saturation;
LGG	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg02836325	chr17:76403955	PGS1	-0.8	-17.57	-0.63	2.64e-53	HDL cholesterol levels;
LGG	cis	rs11150038	0.702	rs9927969	chr16:78097665	T/C	cg04733911	chr16:78082701	NA	0.63	8.76	0.38	3.78e-17	Colorectal or endometrial cancer;
LGG	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs17767392	0.881	rs17767680	chr14:71997594	G/A	cg02058870	chr14:72053146	SIPA1L1	0.44	8.96	0.38	8.13e-18	Mitral valve prolapse;
LGG	cis	rs4742903	0.967	rs10512325	chr9:106861191	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.5e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7100689	0.646	rs10736345	chr10:82134140	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg02127607	chr17:61920694	SMARCD2	0.46	8.27	0.36	1.39e-15	Prudent dietary pattern;
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07608032	chr19:21579862	ZNF493	0.5	8.52	0.37	2.21e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs2073499	0.810	rs78501918	chr3:50369914	A/G	cg03645007	chr3:50255295	SLC38A3	0.6	6.65	0.3	8.49e-11	Schizophrenia;
LGG	cis	rs620875	1.000	rs480493	chr11:126849576	A/T	cg06504925	chr11:126872760	NA	-0.55	-7.73	-0.34	6.61e-14	Response to antipsychotic treatment;
LGG	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg15704280	chr7:45808275	SEPT13	0.73	10.18	0.43	4.28e-22	Axial length;
LGG	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg05082376	chr22:42548792	NA	-0.35	-7.07	-0.31	5.64e-12	Schizophrenia;
LGG	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg26384229	chr12:38710491	ALG10B	0.89	19.77	0.68	1.69e-63	Bladder cancer;
LGG	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg26769984	chr7:1090371	C7orf50	0.57	10.2	0.43	3.6e-22	Bronchopulmonary dysplasia;
LGG	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg00976097	chr5:421733	AHRR	-0.43	-7.17	-0.32	3.01e-12	Cystic fibrosis severity;
LGG	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg06028605	chr16:24865363	SLC5A11	0.49	8.06	0.35	6.41e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg15017067	chr4:17643749	FAM184B	0.3	6.95	0.31	1.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9487094	0.670	rs2024850	chr6:109818456	C/T	cg16315928	chr6:109776240	MICAL1	-0.48	-8.19	-0.36	2.55e-15	Height;
LGG	cis	rs2798269	1.000	rs11148159	chr13:22141526	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.67	-0.3	7.14e-11	PR segment;
LGG	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg18681998	chr4:17616180	MED28	0.87	20.11	0.68	3.95e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.36	-0.36	7.45e-16	Myopia (pathological);
LGG	cis	rs8044868	0.586	rs7190994	chr16:72099241	T/A	cg23815491	chr16:72088622	HP	0.39	8.29	0.36	1.26e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg10402321	chr1:26617780	UBXN11	-0.35	-6.74	-0.3	4.82e-11	Obesity-related traits;
LGG	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9815354	0.857	rs13087502	chr3:42015110	A/G	cg03022575	chr3:42003672	ULK4	0.6	7.49	0.33	3.61e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg20587970	chr11:113659929	NA	-1.28	-23.45	-0.74	9.81e-81	Hip circumference adjusted for BMI;
LGG	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs867371	0.820	rs12443224	chr15:82495610	C/T	cg00614314	chr15:82944287	LOC80154	0.46	7.45	0.33	4.71e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9467773	0.526	rs9688946	chr6:26367445	C/A	cg09904177	chr6:26538194	HMGN4	-0.42	-7.41	-0.33	6.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.698	rs6956638	chr7:124530115	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-7.05	-0.31	6.64e-12	Renal cell carcinoma;
LGG	cis	rs806215	0.723	rs1090682	chr7:127245159	T/C	cg25922125	chr7:127225783	GCC1	0.75	10.3	0.43	1.53e-22	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.83	-0.3	2.64e-11	Lung cancer;
LGG	cis	rs250677	0.687	rs384979	chr5:148459267	C/T	cg18129178	chr5:148520854	ABLIM3	0.43	7.11	0.31	4.47e-12	Breast cancer;
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg13047869	chr3:10149882	C3orf24	0.61	8.7	0.37	5.91e-17	Alzheimer's disease;
LGG	cis	rs9515201	0.818	rs9521733	chr13:111034542	C/T	cg06243866	chr13:111019493	COL4A2	0.62	12.0	0.49	4.46e-29	White matter hyperintensity burden;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.21e-16	Lung cancer;
LGG	cis	rs2282802	0.685	rs7715538	chr5:139665181	T/C	cg26211634	chr5:139558579	C5orf32	0.35	7.59	0.33	1.72e-13	Intelligence (multi-trait analysis);
LGG	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg22455342	chr2:225449267	CUL3	0.45	7.52	0.33	2.9e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg25237894	chr2:233734115	C2orf82	0.65	12.5	0.5	4.28e-31	Coronary artery disease;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg02725872	chr8:58115012	NA	-0.93	-13.0	-0.52	3.82e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.27	0.32	1.54e-12	Total cholesterol levels;
LGG	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg03709012	chr19:19516395	GATAD2A	0.97	14.47	0.56	1.97e-39	Nonalcoholic fatty liver disease;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg03351412	chr1:154909251	PMVK	0.67	13.01	0.52	3.47e-33	Prostate cancer;
LGG	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15506890	chr2:3487001	NA	-0.53	-10.14	-0.43	6.15e-22	Neurofibrillary tangles;
LGG	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	trans	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg10756647	chr7:56101905	PSPH	0.78	9.1	0.39	2.6e-18	Diabetic kidney disease;
LGG	cis	rs7717393	1.000	rs1857770	chr5:155769455	T/G	cg19569526	chr5:155754265	SGCD	0.85	7.97	0.35	1.24e-14	Egg allergy;
LGG	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg25486957	chr4:152246857	NA	-0.39	-6.86	-0.3	2.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2777491	0.957	rs8027626	chr15:41711514	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.06	-0.68	7e-65	Ulcerative colitis;
LGG	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg26384229	chr12:38710491	ALG10B	-0.84	-19.05	-0.66	3.5e-60	Bladder cancer;
LGG	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg26656751	chr17:43910226	CRHR1	0.48	8.65	0.37	8.68e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.43	0.58	1.24e-43	Lung cancer;
LGG	cis	rs714515	0.835	rs2001127	chr1:172361516	C/T	cg01573306	chr1:172330400	DNM3	0.34	7.34	0.32	9.5e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs3762637	0.941	rs9810996	chr3:122074387	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-8.84	-0.38	1.97e-17	LDL cholesterol levels;
LGG	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg19992207	chr2:111874495	ACOXL	-0.38	-7.02	-0.31	7.97e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg13752114	chr3:195489708	MUC4	-0.66	-8.97	-0.38	7.42e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.76	0.34	5.43e-14	Height;
LGG	trans	rs2161208	1.000	rs72772170	chr5:85391141	A/G	cg01787110	chr1:109008453	NBPF6	-0.55	-7.89	-0.34	2.23e-14	Daytime sleep phenotypes;
LGG	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.26	-0.43	2.24e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.1	-0.31	4.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.91	0.57	2.51e-41	Cannabis dependence symptom count;
LGG	cis	rs7166081	1.000	rs2278670	chr15:67484297	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.3	-6.72	-0.3	5.26e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6693567	0.545	rs4970922	chr1:150458094	C/A	cg15654264	chr1:150340011	RPRD2	0.33	6.75	0.3	4.46e-11	Migraine;
LGG	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18876405	chr7:65276391	NA	-0.59	-11.13	-0.46	1.17e-25	Aortic root size;
LGG	cis	rs12618769	0.597	rs3769712	chr2:99153443	A/T	cg18455616	chr2:99124870	INPP4A	0.27	7.71	0.34	7.61e-14	Bipolar disorder;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.6	-0.37	1.23e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07988820	chr12:82153109	PPFIA2	0.77	11.07	0.46	1.94e-25	Resting heart rate;
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.57	0.37	1.51e-16	Aortic root size;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07685180	chr8:600429	NA	1.04	10.56	0.44	1.67e-23	IgG glycosylation;
LGG	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	12.13	0.49	1.33e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg10253484	chr15:75165896	SCAMP2	-0.67	-10.26	-0.43	2.1e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.58	-0.72	1.14e-76	Height;
LGG	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-10.49	-0.44	3.18e-23	Hepatocellular carcinoma;
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.7	0.34	8.11e-14	Rheumatoid arthritis;
LGG	cis	rs3824867	0.920	rs7130693	chr11:47452321	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2066819	1.000	rs75754909	chr12:56726349	A/G	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg05147244	chr20:61493195	TCFL5	0.73	7.31	0.32	1.16e-12	Obesity-related traits;
LGG	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.67	-0.37	7.32e-17	Retinal vascular caliber;
LGG	cis	rs7923837	0.616	rs12219514	chr10:94466439	A/G	cg25093409	chr10:94429542	NA	0.51	10.19	0.43	3.91e-22	Body mass index;Multiple sclerosis;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.32	-0.32	1.11e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg22358067	chr17:16797159	NA	-0.51	-7.19	-0.32	2.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg18402987	chr7:1209562	NA	0.37	6.75	0.3	4.41e-11	Longevity;Endometriosis;
LGG	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22857025	chr5:266934	NA	-1.16	-10.51	-0.44	2.68e-23	Breast cancer;
LGG	cis	rs7927771	0.524	rs7124396	chr11:47787434	T/G	cg20307385	chr11:47447363	PSMC3	-0.56	-10.93	-0.45	6.72e-25	Subjective well-being;
LGG	cis	rs4889911	0.544	rs2587498	chr17:77830737	G/A	cg07923794	chr17:77834237	NA	-0.82	-12.52	-0.5	3.54e-31	Electroencephalogram traits;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.93	-0.31	1.44e-11	Menopause (age at onset);
LGG	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.57	-8.95	-0.38	8.76e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg27490568	chr2:178487706	NA	-0.45	-8.71	-0.38	5.44e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs950169	0.579	rs11633088	chr15:84672181	A/T	cg24253500	chr15:84953950	NA	-0.45	-7.27	-0.32	1.54e-12	Schizophrenia;
LGG	trans	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.29	0.5	3.13e-30	Type 2 diabetes;
LGG	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg03929089	chr4:120376271	NA	-1.03	-23.58	-0.74	2.44e-81	Height;
LGG	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg19729930	chr2:74357872	NA	0.53	11.31	0.47	2.35e-26	Gestational age at birth (maternal effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10134882	chr12:65563916	LEMD3	0.53	8.38	0.36	6.63e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg21724239	chr8:58056113	NA	0.45	6.93	0.31	1.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.655	rs7808203	chr7:124502136	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs7584262	0.740	rs13414536	chr2:42245179	T/C	cg27252766	chr2:42229092	NA	0.48	6.73	0.3	4.89e-11	Bone mineral density;
LGG	cis	rs4959677	0.729	rs12203777	chr6:2471498	G/A	cg20147862	chr6:2634573	C6orf195	-0.35	-7.21	-0.32	2.34e-12	Orthostatic hypotension;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.56	-9.26	-0.4	7.83e-19	Longevity;Endometriosis;
LGG	cis	rs10186029	0.582	rs2371795	chr2:213994789	C/G	cg08319019	chr2:214017104	IKZF2	0.4	7.12	0.31	4.05e-12	Systemic sclerosis;
LGG	cis	rs9815354	0.812	rs10510731	chr3:41853310	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs28830936	0.966	rs4924576	chr15:42119593	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.56	-12.66	-0.51	9.33e-32	Diastolic blood pressure;
LGG	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg01262667	chr19:19385393	TM6SF2	0.43	10.79	0.45	2.4e-24	Tonsillectomy;
LGG	trans	rs7939886	0.920	rs2054610	chr11:56087942	T/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.87	-0.51	1.24e-32	Alzheimer's disease;
LGG	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11748327	0.580	rs10064077	chr5:4012213	T/C	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.27e-12	Myocardial infarction;
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.28	-0.43	1.87e-22	Platelet count;
LGG	cis	rs17366136	0.895	rs1122913	chr7:22602932	A/G	cg23261107	chr7:22602895	NA	-0.41	-8.26	-0.36	1.52e-15	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
LGG	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg16691251	chr5:66510806	NA	-0.33	-6.77	-0.3	3.87e-11	Breast cancer;
LGG	cis	rs2862064	0.613	rs2862060	chr5:156443895	A/C	cg12943317	chr5:156479607	HAVCR1	-0.82	-10.69	-0.44	5.64e-24	Platelet count;
LGG	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg13010199	chr12:38710504	ALG10B	-0.56	-10.65	-0.44	7.99e-24	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg23625390	chr15:77176239	SCAPER	-0.45	-8.87	-0.38	1.66e-17	Blood metabolite levels;
LGG	cis	rs988958	0.567	rs10193034	chr2:42249064	G/A	cg19376973	chr2:42229025	NA	0.65	9.84	0.42	7.01e-21	Hypospadias;
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg08344181	chr3:125677491	NA	-0.89	-8.58	-0.37	1.42e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.99	0.42	2.04e-21	Height;
LGG	cis	rs929596	0.564	rs2602373	chr2:234561953	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.13	-0.39	2.18e-18	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.44	-6.74	-0.3	4.81e-11	Tonsillectomy;
LGG	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.78e-48	Intelligence (multi-trait analysis);
LGG	cis	rs9912468	0.802	rs11079650	chr17:64322017	A/C	cg19474267	chr17:64306194	PRKCA	-0.97	-28.4	-0.8	1.77e-103	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg05064044	chr6:292385	DUSP22	-0.44	-7.66	-0.34	1.12e-13	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02470625	chr7:39453784	POU6F2	0.43	7.07	0.31	5.69e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg26384229	chr12:38710491	ALG10B	-0.77	-15.4	-0.58	1.68e-43	Morning vs. evening chronotype;
LGG	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.82	0.34	3.52e-14	Red cell distribution width;
LGG	cis	rs9912468	0.535	rs2013785	chr17:64236477	A/G	cg19474267	chr17:64306194	PRKCA	-0.68	-13.83	-0.54	1.12e-36	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg02002194	chr4:3960332	NA	0.5	9.42	0.4	2.12e-19	Neuroticism;
LGG	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg15644404	chr18:77186268	NFATC1	-0.81	-9.97	-0.42	2.42e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg03342759	chr3:160939853	NMD3	-0.74	-13.23	-0.52	4.18e-34	Parkinson's disease;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.69	-12.71	-0.51	6.07e-32	Longevity;Endometriosis;
LGG	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg04833646	chr19:10679720	CDKN2D	1.03	16.28	0.6	1.92e-47	Red cell distribution width;
LGG	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg12661370	chr5:149340060	SLC26A2	0.5	8.45	0.37	3.69e-16	HIV-1 control;
LGG	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg08733933	chr1:2954429	NA	-0.4	-8.67	-0.37	7.54e-17	Plateletcrit;
LGG	cis	rs6138458	0.743	rs3746330	chr20:24999795	A/G	cg26195577	chr20:24973756	C20orf3	0.93	17.69	0.64	7.02e-54	Blood protein levels;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.81e-20	Lung cancer;
LGG	cis	rs7010267	0.596	rs6984572	chr8:120054168	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.8	0.38	2.7e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.82	-0.38	2.4e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7927771	0.524	rs10838758	chr11:47771476	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg18551225	chr6:44695536	NA	-0.62	-9.97	-0.42	2.37e-21	Total body bone mineral density;
LGG	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg11766577	chr21:47581405	C21orf56	-0.42	-7.0	-0.31	8.82e-12	Testicular germ cell tumor;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg03351412	chr1:154909251	PMVK	0.64	11.94	0.49	7.95e-29	Prostate cancer;
LGG	trans	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.43	0.33	5.22e-13	Retinal vascular caliber;
LGG	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.3	0.32	1.25e-12	Refractive error;
LGG	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.6e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs2455601	1.000	rs11042114	chr11:8919889	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.57	-0.47	2.18e-27	Schizophrenia;
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg02023728	chr11:77925099	USP35	-0.38	-6.67	-0.3	7.16e-11	Alzheimer's disease (survival time);
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.99	0.45	3.89e-25	Personality dimensions;
LGG	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg11189052	chr15:85197271	WDR73	-0.51	-8.26	-0.36	1.55e-15	P wave terminal force;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.38	-0.58	1.96e-43	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15012161	chr6:113955683	NA	0.36	7.83	0.34	3.33e-14	Gut microbiome composition (summer);
LGG	cis	rs240764	0.594	rs9403997	chr6:101163433	A/C	cg09795085	chr6:101329169	ASCC3	0.43	7.22	0.32	2.12e-12	Neuroticism;
LGG	cis	rs708547	0.874	rs7674167	chr4:57721477	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.46	-0.33	4.42e-13	Response to bleomycin (chromatid breaks);
LGG	cis	rs34734847	0.842	rs556001	chr12:121152967	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-7.24	-0.32	1.89e-12	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg16434002	chr17:42200994	HDAC5	-0.5	-9.19	-0.39	1.33e-18	Total body bone mineral density;
LGG	cis	rs1881509	0.702	rs4963078	chr11:1435329	G/A	cg07067744	chr11:1421172	BRSK2	0.34	6.75	0.3	4.39e-11	Heroin dependence;
LGG	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg21095983	chr6:86352623	SYNCRIP	0.58	10.54	0.44	1.94e-23	Smooth-surface caries;
LGG	cis	rs9487094	0.961	rs11153180	chr6:109744441	C/T	cg16315928	chr6:109776240	MICAL1	0.55	9.19	0.39	1.36e-18	Height;
LGG	cis	rs4077515	0.934	rs78428995	chr9:139281847	T/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.2	0.32	2.47e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg26396452	chr14:65542826	MAX	0.49	10.39	0.43	7.37e-23	Obesity-related traits;
LGG	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.69	-0.3	6.31e-11	Neuroticism;
LGG	cis	rs11588062	0.687	rs3991796	chr1:46802608	C/T	cg08947153	chr1:46664340	POMGNT1	0.41	7.19	0.32	2.58e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9486719	0.790	rs2499790	chr6:96845078	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg02640540	chr1:67518911	SLC35D1	0.36	7.13	0.31	3.79e-12	Lymphocyte percentage of white cells;
LGG	cis	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg06609049	chr19:2785107	THOP1	0.92	14.97	0.57	1.35e-41	Total cholesterol levels;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg16507663	chr6:150244633	RAET1G	0.41	7.78	0.34	4.69e-14	Lung cancer;
LGG	cis	rs6429082	0.521	rs704711	chr1:235629802	G/A	cg26050004	chr1:235667680	B3GALNT2	0.85	17.11	0.62	3.38e-51	Adiposity;
LGG	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.47e-20	Educational attainment;
LGG	cis	rs1878931	0.624	rs27235	chr16:3439138	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-11.7	-0.48	7.27e-28	Body mass index (adult);
LGG	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg00976097	chr5:421733	AHRR	-0.42	-6.96	-0.31	1.15e-11	Cystic fibrosis severity;
LGG	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg19507638	chr5:93509721	C5orf36	0.43	7.04	0.31	7.16e-12	Diabetic retinopathy;
LGG	cis	rs8077889	0.750	rs80053172	chr17:41936843	C/T	cg26893861	chr17:41843967	DUSP3	0.91	12.28	0.5	3.46e-30	Triglycerides;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.49	-0.4	1.23e-19	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06951450	chr11:126138433	FOXRED1;SRPR	0.42	6.93	0.31	1.43e-11	Gut microbiome composition (summer);
LGG	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs1957429	0.808	rs1570296	chr14:65332294	T/A	cg23373153	chr14:65346875	NA	1.06	13.48	0.53	3.6e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg12386194	chr3:101231763	SENP7	0.47	8.33	0.36	9.55e-16	Colorectal cancer;
LGG	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg15325629	chr6:28072465	NA	0.79	7.61	0.33	1.58e-13	Parkinson's disease;
LGG	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg17182837	chr8:41585554	ANK1	-0.54	-7.81	-0.34	3.73e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg23752985	chr2:85803571	VAMP8	-0.43	-8.17	-0.35	2.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.62	-8.58	-0.37	1.45e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg25214090	chr10:38739885	LOC399744	0.59	10.2	0.43	3.55e-22	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg15242686	chr22:24348715	GSTTP1	0.45	8.32	0.36	9.89e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6909430	1.000	rs9401724	chr6:98687596	C/T	cg12860156	chr6:98744658	NA	-0.44	-7.56	-0.33	2.24e-13	Quantitative traits;
LGG	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg13385794	chr1:248469461	NA	-0.49	-8.39	-0.36	6.03e-16	Common traits (Other);
LGG	cis	rs877426	0.681	rs61973920	chr13:114836067	C/A	cg00571178	chr13:114841904	RASA3	-0.54	-9.48	-0.4	1.38e-19	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs7914558	1.000	rs7899084	chr10:104872547	A/T	cg04362960	chr10:104952993	NT5C2	0.54	10.37	0.43	8.7e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg19628046	chr18:33552617	C18orf21	0.51	7.54	0.33	2.49e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg07120314	chr15:79043507	NA	-0.35	-6.95	-0.31	1.23e-11	Sudden cardiac arrest;
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg02524346	chr8:600233	NA	1.15	11.31	0.47	2.25e-26	IgG glycosylation;
LGG	cis	rs2071403	0.901	rs9711204	chr2:1406012	C/T	cg06500727	chr2:1417164	TPO	-0.55	-10.63	-0.44	9.49e-24	Thyroid peroxidase antibody positivity;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs7786808	0.760	rs10259321	chr7:158221038	G/A	cg12438819	chr7:158236134	PTPRN2	-0.31	-8.23	-0.36	1.89e-15	Obesity-related traits;
LGG	trans	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg06521331	chr12:34319734	NA	-0.43	-7.61	-0.33	1.52e-13	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1493916	0.748	rs7230463	chr18:31309133	G/C	cg27147174	chr7:100797783	AP1S1	-0.64	-11.65	-0.48	1.07e-27	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18106800	chr5:94890715	ARSK;TTC37	0.5	8.5	0.37	2.68e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.27	0.4	6.94e-19	Schizophrenia;
LGG	cis	rs8017423	0.933	rs7150378	chr14:90724566	G/A	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.74e-60	Mortality in heart failure;
LGG	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19748678	chr4:122722346	EXOSC9	-0.43	-7.61	-0.33	1.55e-13	Type 2 diabetes;
LGG	cis	rs9362426	0.887	rs1209113	chr6:88079456	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	9.98	0.42	2.21e-21	Depressive episodes in bipolar disorder;
LGG	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs2742417	1.000	rs2673035	chr3:45753665	C/G	cg04837898	chr3:45731254	SACM1L	-0.39	-7.85	-0.34	3.01e-14	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2735413	0.918	rs36068555	chr16:78077082	G/A	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg06238570	chr21:40685208	BRWD1	0.43	6.73	0.3	5.15e-11	Cognitive function;
LGG	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg01028140	chr2:1542097	TPO	-0.5	-9.3	-0.4	5.75e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg17971929	chr21:40555470	PSMG1	0.89	17.61	0.63	1.75e-53	Cognitive function;
LGG	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg03929089	chr4:120376271	NA	0.76	7.93	0.35	1.66e-14	Axial length;
LGG	cis	rs2797369	0.570	rs2770334	chr6:101575412	C/T	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.86e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg02151108	chr14:50098012	C14orf104	-0.43	-9.34	-0.4	4.2e-19	Carotid intima media thickness;
LGG	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg02903104	chr8:1507517	DLGAP2	0.34	7.07	0.31	5.9e-12	Lung cancer;
LGG	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs55665837	1.000	rs10047429	chr11:14439032	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.96e-17	Vitamin D levels;
LGG	cis	rs137887	1.000	rs137886	chr22:50464397	A/G	cg17558497	chr22:50464837	TTLL8	0.44	8.43	0.36	4.35e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.36	0.43	9.08e-23	Diabetic retinopathy;
LGG	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg01631408	chr1:248437212	OR2T33	-0.56	-10.1	-0.42	8.27e-22	Common traits (Other);
LGG	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg24642439	chr20:33292090	TP53INP2	-0.48	-7.64	-0.33	1.28e-13	Height;
LGG	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg10483660	chr13:112241077	NA	0.42	8.51	0.37	2.45e-16	Menarche (age at onset);
LGG	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg07636037	chr3:49044803	WDR6	-0.79	-13.78	-0.54	1.86e-36	Menarche (age at onset);
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg15242686	chr22:24348715	GSTTP1	0.37	6.66	0.3	7.86e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08280861	chr8:58055591	NA	0.54	6.93	0.31	1.39e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.32	-0.32	1.12e-12	Triglycerides;
LGG	cis	rs11700980	0.636	rs35497275	chr21:30275022	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-7.56	-0.33	2.21e-13	QRS complex (12-leadsum);
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.45	-0.33	4.73e-13	Menopause (age at onset);
LGG	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9649213	0.614	rs10953254	chr7:97914305	A/G	cg09267113	chr7:98030324	BAIAP2L1	-0.44	-7.42	-0.33	5.59e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.27	-0.43	1.97e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs2371030	1.000	rs4517917	chr2:211568913	C/T	cg18417063	chr2:211583084	NA	-0.63	-12.17	-0.49	9.57e-30	Non-small cell lung cancer;
LGG	cis	rs7113850	0.541	rs77227176	chr11:24208375	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	9.96	0.42	2.71e-21	Bone fracture in osteoporosis;
LGG	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg14829155	chr15:31115871	NA	-0.58	-10.01	-0.42	1.79e-21	Huntington's disease progression;
LGG	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.69	-0.51	7.39e-32	Uric acid levels;
LGG	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg12395012	chr8:11607386	GATA4	0.41	7.25	0.32	1.71e-12	Myopia (pathological);
LGG	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.87	18.46	0.65	1.9e-57	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.04	-0.39	4.32e-18	Retinal vascular caliber;
LGG	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg08048268	chr3:133502702	NA	-0.6	-11.28	-0.46	3.16e-26	Iron status biomarkers;
LGG	trans	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.58	-0.33	1.93e-13	Resting heart rate;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.32	-0.32	1.11e-12	Menopause (age at onset);
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg04824913	chr4:887549	GAK	0.43	7.41	0.33	5.88e-13	Sjögren's syndrome;
LGG	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg06421707	chr20:25228305	PYGB	0.53	12.04	0.49	2.98e-29	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7017914	0.934	rs6998024	chr8:71660840	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.44e-11	Bone mineral density;
LGG	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.41	6.66	0.3	7.96e-11	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg26597838	chr10:835615	NA	0.55	7.17	0.32	2.93e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-9.24	-0.39	9.18e-19	Vitiligo;
LGG	trans	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	8.87	0.38	1.56e-17	Lewy body disease;
LGG	cis	rs4356932	1.000	rs10017431	chr4:76955406	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.05	0.35	6.86e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2652834	0.851	rs1126310	chr15:63428765	G/A	cg05507819	chr15:63340323	TPM1	0.5	7.05	0.31	6.5e-12	HDL cholesterol;
LGG	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.86	-0.34	2.65e-14	Initial pursuit acceleration;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	9.97	0.42	2.35e-21	Longevity;
LGG	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.72	-0.45	4.26e-24	Height;
LGG	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg24130564	chr14:104152367	KLC1	-0.39	-7.18	-0.32	2.81e-12	Reticulocyte count;
LGG	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg16576597	chr16:28551801	NUPR1	-0.35	-7.53	-0.33	2.76e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.92e-14	Bipolar disorder;
LGG	cis	rs2415984	0.715	rs2600812	chr14:46951737	G/T	cg14871534	chr14:47121158	RPL10L	0.38	6.7	0.3	5.91e-11	Number of children ever born;
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg04287289	chr16:89883240	FANCA	-0.88	-8.75	-0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg05692746	chr2:100937584	LONRF2	-0.65	-11.94	-0.49	7.88e-29	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg08875078	chr22:50639485	SELO	0.54	9.01	0.39	5.63e-18	Obesity-related traits;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg19003389	chr17:17876154	LRRC48;TOM1L2	-0.36	-6.81	-0.3	3.11e-11	Brain structure;
LGG	trans	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg10756647	chr7:56101905	PSPH	0.79	9.23	0.39	9.61e-19	Diabetic kidney disease;
LGG	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg09307838	chr4:120376055	NA	0.7	11.28	0.46	2.99e-26	Corneal astigmatism;
LGG	cis	rs7589342	0.745	rs933793	chr2:106511846	C/T	cg14210321	chr2:106509881	NCK2	0.51	9.03	0.39	4.49e-18	Addiction;
LGG	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg26695010	chr11:65641043	EFEMP2	0.46	7.29	0.32	1.31e-12	Breast cancer;
LGG	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6834538	0.597	rs7676819	chr4:113552891	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.37	0.36	6.73e-16	Free thyroxine concentration;
LGG	cis	rs77372450	0.636	rs55699399	chr5:157028363	C/A	cg25387487	chr5:157003181	ADAM19	-0.56	-7.13	-0.31	4e-12	Bipolar disorder (body mass index interaction);
LGG	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10281996	chr11:69290977	NA	0.36	6.65	0.3	8.26e-11	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-7.88	-0.34	2.36e-14	Lung cancer;
LGG	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.67	-0.34	1.03e-13	Testicular germ cell tumor;
LGG	trans	rs6787172	0.651	rs9870802	chr3:158148169	C/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.24	-0.32	1.83e-12	Subjective well-being;
LGG	cis	rs6120849	0.754	rs6120797	chr20:33606002	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg26384229	chr12:38710491	ALG10B	1.06	28.86	0.8	1.48e-105	Heart rate;
LGG	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.59	-0.33	1.76e-13	Colorectal cancer;
LGG	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs8017423	0.935	rs3737035	chr14:90745422	T/C	cg04374321	chr14:90722782	PSMC1	-0.86	-17.48	-0.63	6.73e-53	Mortality in heart failure;
LGG	cis	rs6558530	0.965	rs730379	chr8:1708093	A/C	cg08198773	chr8:1697536	NA	0.36	6.95	0.31	1.21e-11	Systolic blood pressure;
LGG	cis	rs12200782	0.577	rs3757144	chr6:26380922	G/C	cg27193005	chr6:26382695	BTN2A2	-0.51	-7.45	-0.33	4.72e-13	Small cell lung carcinoma;
LGG	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg09033563	chr22:24373618	LOC391322	-0.5	-8.36	-0.36	7.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6964587	0.626	rs10243083	chr7:91552530	G/A	cg17063962	chr7:91808500	NA	-0.47	-8.76	-0.38	3.66e-17	Breast cancer;
LGG	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg01631408	chr1:248437212	OR2T33	0.5	9.0	0.39	5.73e-18	Common traits (Other);
LGG	cis	rs722599	0.748	rs1059326	chr14:75369385	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.6	-10.03	-0.42	1.52e-21	IgG glycosylation;
LGG	trans	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17763188	chr8:6692148	XKR5	0.42	7.03	0.31	7.28e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7998202	0.667	rs282579	chr13:113358436	G/C	cg17218041	chr13:113365319	ATP11A	-0.42	-7.09	-0.31	5.14e-12	Glycated hemoglobin levels;
LGG	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24308560	chr3:49941425	MST1R	0.22	6.87	0.3	2.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg16070123	chr10:51489643	NA	0.39	7.4	0.33	6.61e-13	Prostate-specific antigen levels;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.23	0.49	5.13e-30	Prudent dietary pattern;
LGG	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg08222618	chr4:941054	TMEM175	0.65	11.38	0.47	1.27e-26	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.13	0.31	3.88e-12	Height;
LGG	cis	rs7226408	0.802	rs72885298	chr18:34452064	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02002494	chr3:119013045	CDGAP	0.5	7.87	0.34	2.6e-14	Gut microbiome composition (summer);
LGG	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs3741151	0.892	rs7930454	chr11:73085034	T/C	cg17517138	chr11:73019481	ARHGEF17	0.86	8.97	0.38	7.48e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs853679	0.517	rs9368557	chr6:28131537	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-7.04	-0.31	6.91e-12	Obesity (extreme);
LGG	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg27053975	chr1:166958233	MAEL	-0.47	-6.66	-0.3	7.62e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs7143963	0.609	rs4906270	chr14:103364737	G/T	cg23020514	chr14:103360112	TRAF3	0.37	7.25	0.32	1.73e-12	Body mass index;
LGG	cis	rs758324	0.947	rs2088719	chr5:131184439	C/T	cg06307176	chr5:131281290	NA	0.57	9.43	0.4	1.95e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg11062466	chr8:58055876	NA	0.43	7.21	0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg12395012	chr8:11607386	GATA4	0.44	8.08	0.35	5.52e-15	Morning vs. evening chronotype;
LGG	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg24558204	chr6:135376177	HBS1L	0.61	10.63	0.44	9.29e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24308560	chr3:49941425	MST1R	0.23	7.16	0.32	3.21e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg06521331	chr12:34319734	NA	0.42	7.37	0.32	7.7e-13	Morning vs. evening chronotype;
LGG	cis	rs1127311	1.000	rs1127311	chr1:154556663	G/A	cg11650704	chr1:154556575	ADAR	-0.49	-9.76	-0.41	1.38e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9309473	0.948	rs10170849	chr2:73747932	G/A	cg20560298	chr2:73613845	ALMS1	-0.47	-7.9	-0.34	2.03e-14	Metabolite levels;
LGG	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg04743876	chr7:130013617	NA	0.36	8.29	0.36	1.26e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg02002194	chr4:3960332	NA	-0.43	-7.52	-0.33	2.89e-13	Systemic lupus erythematosus;
LGG	cis	rs748404	0.578	rs2278856	chr15:43631356	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	7.07	0.31	5.65e-12	Lung cancer;
LGG	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg02023728	chr11:77925099	USP35	0.4	7.1	0.31	4.85e-12	Alzheimer's disease (survival time);
LGG	cis	rs2764208	0.535	rs2744970	chr6:34581937	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.36	-0.32	8.65e-13	Systemic lupus erythematosus;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.8	-0.3	3.26e-11	Longevity;Endometriosis;
LGG	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg12708336	chr17:41446283	NA	-0.3	-6.94	-0.31	1.33e-11	Menopause (age at onset);
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.4	0.58	1.69e-43	Coronary artery disease;
LGG	trans	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg10756647	chr7:56101905	PSPH	0.83	9.85	0.42	6.73e-21	Diabetic kidney disease;
LGG	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg26116260	chr4:7069785	GRPEL1	-0.85	-8.69	-0.37	6.41e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9948	0.541	rs62152907	chr2:97572772	G/A	cg26665480	chr2:98280029	ACTR1B	-0.68	-8.12	-0.35	4.32e-15	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4740619	0.901	rs10810431	chr9:15706641	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.26	-0.43	2.16e-22	Body mass index;
LGG	cis	rs10876993	0.928	rs2640637	chr12:58077586	G/A	cg18357645	chr12:58087776	OS9	0.71	13.07	0.52	1.9e-33	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs7656342	0.808	rs10003216	chr4:9766749	A/G	cg00513012	chr19:6746184	TRIP10	-0.34	-6.73	-0.3	4.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11608355	0.508	rs1469944	chr12:109847587	A/T	cg19025524	chr12:109796872	NA	-0.47	-8.24	-0.36	1.75e-15	Neuroticism;
LGG	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg24558204	chr6:135376177	HBS1L	0.56	9.61	0.41	4.49e-20	Red blood cell count;
LGG	cis	rs16976116	0.901	rs28526269	chr15:55499190	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.48	-12.0	-0.49	4.5e-29	Tonsillectomy;
LGG	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg00717180	chr2:96193071	NA	-0.46	-8.41	-0.36	5.04e-16	HDL cholesterol;
LGG	cis	rs6723226	0.503	rs4952262	chr2:32597234	G/A	cg02381751	chr2:32503542	YIPF4	-0.54	-8.74	-0.38	4.2e-17	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06634786	chr22:41940651	POLR3H	0.77	12.25	0.49	4.37e-30	Vitiligo;
LGG	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs2735413	0.560	rs73562716	chr16:78126415	A/G	cg04733911	chr16:78082701	NA	0.65	10.5	0.44	2.77e-23	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.21	-0.36	2.18e-15	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg26597838	chr10:835615	NA	0.64	9.4	0.4	2.44e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs3857536	0.730	rs6455092	chr6:66961914	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-7.3	-0.32	1.25e-12	Blood trace element (Cu levels);
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07308232	chr7:1071921	C7orf50	-0.59	-11.33	-0.47	1.96e-26	Longevity;Endometriosis;
LGG	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg25039879	chr17:56429692	SUPT4H1	0.56	8.04	0.35	7.82e-15	Cognitive test performance;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg02018176	chr4:1364513	KIAA1530	0.47	11.01	0.46	3.5e-25	Obesity-related traits;
LGG	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15664640	chr17:80829946	TBCD	-0.81	-15.93	-0.6	6.8e-46	Breast cancer;
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.38	-0.72	9.78e-76	Coronary artery disease;
LGG	cis	rs12615966	0.872	rs72830464	chr2:105395283	G/A	cg16465502	chr2:105461796	NA	0.88	10.61	0.44	1.11e-23	Pancreatic cancer;
LGG	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs7215564	0.818	rs34756632	chr17:78618859	C/T	cg16980736	chr17:78789706	RPTOR	-0.68	-8.71	-0.38	5.48e-17	Myopia (pathological);
LGG	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg11764359	chr7:65958608	NA	0.63	10.9	0.45	8.94e-25	Aortic root size;
LGG	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg02614661	chr16:87878292	SLC7A5	0.41	7.33	0.32	1.05e-12	Blood metabolite levels;
LGG	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg26384229	chr12:38710491	ALG10B	-0.85	-19.93	-0.68	2.8e-64	Heart rate;
LGG	cis	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg15596359	chr8:11213517	TDH	-0.4	-8.23	-0.36	1.97e-15	Retinal vascular caliber;
LGG	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg07052231	chr12:7363540	PEX5	-0.4	-7.13	-0.31	3.88e-12	IgG glycosylation;
LGG	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg26597838	chr10:835615	NA	0.95	13.07	0.52	1.94e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs7666738	0.830	rs11097600	chr4:98959564	T/G	cg05340658	chr4:99064831	C4orf37	0.48	7.85	0.34	2.88e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6142618	0.562	rs2235898	chr20:30719062	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs4728302	0.703	rs3823572	chr7:133680601	G/A	cg10665199	chr7:133106180	EXOC4	0.41	6.9	0.31	1.69e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg21961890	chr7:12510665	NA	0.36	7.09	0.31	5.2e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-13.26	-0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg09904177	chr6:26538194	HMGN4	0.59	8.53	0.37	2.1e-16	Small cell lung carcinoma;
LGG	cis	rs1003719	0.715	rs2156077	chr21:38539357	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.31	-0.58	4.04e-43	Eye color traits;
LGG	trans	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07923666	chr12:49932857	KCNH3	-0.53	-7.92	-0.35	1.78e-14	Resting heart rate;
LGG	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.02e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	trans	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg13565492	chr6:43139072	SRF	-0.88	-14.93	-0.57	2.08e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.13	0.35	3.83e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-8.33	-0.36	9.5e-16	Aortic root size;
LGG	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11628318	0.563	rs4906234	chr14:103076928	G/C	cg12046867	chr14:103022105	NA	-0.43	-8.04	-0.35	7.31e-15	Platelet count;
LGG	trans	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs9914988	0.943	rs9907178	chr17:27124307	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs4974559	0.501	rs730830	chr4:1240091	T/C	cg02980000	chr4:1222292	CTBP1	-0.97	-11.8	-0.48	2.88e-28	Systolic blood pressure;
LGG	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg18551225	chr6:44695536	NA	-0.7	-11.49	-0.47	4.71e-27	Total body bone mineral density;
LGG	cis	rs209489	0.892	rs74500636	chr6:53166993	G/C	cg15607103	chr6:53167650	ELOVL5	0.72	8.15	0.35	3.37e-15	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs701145	0.640	rs184825	chr3:153931342	C/G	cg12800244	chr3:153838788	SGEF	-0.81	-8.22	-0.36	2.01e-15	Coronary artery disease;
LGG	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg24189917	chr7:1970923	MAD1L1	-0.51	-7.85	-0.34	2.88e-14	Bipolar disorder;
LGG	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.79	-0.54	1.74e-36	Response to antipsychotic treatment;
LGG	cis	rs4865875	1.000	rs4451013	chr5:54118593	C/G	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.55	-9.49	-0.4	1.24e-19	Renal function-related traits (BUN);
LGG	cis	rs240764	0.658	rs13196803	chr6:101188052	A/T	cg09795085	chr6:101329169	ASCC3	-0.47	-7.95	-0.35	1.44e-14	Neuroticism;
LGG	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg00409905	chr10:38381863	ZNF37A	0.51	7.58	0.33	1.92e-13	Obesity (extreme);
LGG	cis	rs7932354	0.528	rs10466478	chr11:47162604	A/C	cg03339077	chr11:47165057	C11orf49	-0.56	-10.42	-0.44	5.44e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg17545662	chr6:170176663	C6orf70	0.68	8.69	0.37	6.49e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.27	-0.79	2.28e-98	Height;
LGG	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg14228332	chr4:119757509	SEC24D	0.97	9.22	0.39	1.04e-18	Cannabis dependence symptom count;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.37	-0.36	6.91e-16	Aortic root size;
LGG	cis	rs6750047	1.000	rs6750047	chr2:38276549	A/G	cg07380506	chr2:38303506	CYP1B1	0.44	7.55	0.33	2.39e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-10.06	-0.42	1.17e-21	Morning vs. evening chronotype;
LGG	cis	rs1345301	0.587	rs10186746	chr2:102866377	G/A	cg05295703	chr2:102895712	NA	0.5	10.06	0.42	1.11e-21	Waist circumference;
LGG	cis	rs12731740	0.908	rs11118555	chr1:207940853	T/A	cg22525895	chr1:207977042	MIR29B2	-0.63	-7.31	-0.32	1.17e-12	Biomedical quantitative traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02202141	chr3:35681158	NA	0.4	6.73	0.3	5.15e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg26116260	chr4:7069785	GRPEL1	1.14	21.7	0.71	1.5e-72	Monocyte percentage of white cells;
LGG	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.13	-0.52	1.02e-33	Gut microbiome composition (summer);
LGG	cis	rs3762637	1.000	rs9843165	chr3:122131111	G/C	cg24169773	chr3:122142474	KPNA1	-0.61	-10.44	-0.44	4.86e-23	LDL cholesterol levels;
LGG	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.99	-0.49	4.85e-29	Height;
LGG	cis	rs12579753	0.667	rs11495227	chr12:82302032	C/T	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.3	-0.32	1.29e-12	Resting heart rate;
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg09060608	chr5:178986726	RUFY1	-0.49	-8.71	-0.38	5.56e-17	Lung cancer;
LGG	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.52	-0.33	2.96e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg07382826	chr16:28625726	SULT1A1	0.36	7.49	0.33	3.51e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg13010199	chr12:38710504	ALG10B	0.68	14.0	0.55	2.24e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg15133208	chr4:90757351	SNCA	-0.34	-7.72	-0.34	7.31e-14	Dementia with Lewy bodies;
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg02297831	chr4:17616191	MED28	0.49	8.89	0.38	1.36e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7172689	0.908	rs67106133	chr15:81564437	G/A	cg11808699	chr15:81528661	IL16	-0.48	-9.63	-0.41	3.95e-20	Inattentive symptoms;
LGG	cis	rs2798269	0.544	rs1200030	chr13:22160604	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.39	-0.32	7.13e-13	PR segment;
LGG	trans	rs17685	0.712	rs6464994	chr7:75784668	C/T	cg19862616	chr7:65841803	NCRNA00174	1.06	24.81	0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10698964	chr15:50647173	FLJ10038;GABPB1;LOC100129387	0.42	7.01	0.31	8.37e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs7166081	1.000	rs12910062	chr15:67537210	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.1	-0.31	4.6e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2084898	1.000	rs73004754	chr11:120053576	G/A	cg13907859	chr11:120009124	TRIM29	0.88	11.43	0.47	8.25e-27	Stroke (pediatric);
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	trans	rs61931739	0.649	rs861526	chr12:33726434	A/G	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg10636054	chr15:40330586	SRP14	0.59	7.03	0.31	7.4e-12	Response to haloperidol in psychosis;
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.28	-0.4	6.31e-19	Monocyte count;
LGG	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg08250081	chr4:10125330	NA	0.36	6.92	0.31	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.02	17.48	0.63	6.23e-53	Chronic sinus infection;
LGG	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg06431347	chr2:235935754	SH3BP4	0.42	9.49	0.4	1.24e-19	Dialysis-related mortality;
LGG	cis	rs7567389	0.576	rs2069902	chr2:128174863	C/G	cg10021288	chr2:128175891	PROC	0.39	6.91	0.31	1.61e-11	Self-rated health;
LGG	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg00405596	chr8:11794950	NA	0.46	7.78	0.34	4.89e-14	Mood instability;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg16885296	chr6:26284938	NA	0.41	8.79	0.38	3.01e-17	Educational attainment;
LGG	cis	rs4948102	0.686	rs7801467	chr7:56160977	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.06	0.31	6.31e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs10895140	0.626	rs1938847	chr11:101522031	A/T	cg23650423	chr11:101454676	TRPC6	-0.4	-6.79	-0.3	3.53e-11	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs77972916	0.609	rs13414381	chr2:43567218	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-7.03	-0.31	7.67e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg02151108	chr14:50098012	C14orf104	-0.48	-10.28	-0.43	1.81e-22	Carotid intima media thickness;
LGG	cis	rs74781061	0.932	rs11629946	chr15:74871891	A/G	cg02384859	chr15:74862662	ARID3B	0.34	7.4	0.33	6.55e-13	Endometriosis;
LGG	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg11693508	chr17:37793320	STARD3	0.67	9.64	0.41	3.7e-20	Bipolar disorder;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg26656751	chr17:43910226	CRHR1	0.43	8.15	0.35	3.45e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg10636054	chr15:40330586	SRP14	1.19	13.91	0.54	5.45e-37	Corneal curvature;
LGG	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06481639	chr22:41940642	POLR3H	-0.53	-7.92	-0.35	1.74e-14	Vitiligo;
LGG	cis	rs1059312	0.500	rs10734964	chr12:129286486	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.59	-10.77	-0.45	2.82e-24	Systemic lupus erythematosus;
LGG	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.76	-0.38	3.76e-17	Depression;
LGG	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.1	0.57	3.66e-42	Cognitive test performance;
LGG	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg22705602	chr4:152727874	NA	-0.33	-7.69	-0.34	8.72e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg26116260	chr4:7069785	GRPEL1	0.98	14.82	0.57	6.29e-41	Monocyte percentage of white cells;
LGG	cis	rs6772849	1.000	rs66910450	chr3:128303893	C/T	cg08795948	chr3:128337044	NA	0.53	8.71	0.38	5.27e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs17453880	0.929	rs12517092	chr5:152054744	A/C	cg10931792	chr5:152022470	NA	0.39	8.52	0.37	2.19e-16	Subjective well-being;
LGG	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.21	-0.32	2.26e-12	Coronary artery disease;
LGG	cis	rs10262624	1.000	rs10950973	chr7:23917277	G/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.78e-11	Schizophrenia;
LGG	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg00784671	chr22:46762841	CELSR1	-0.65	-7.07	-0.31	5.81e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2013441	0.508	rs1468953	chr17:19970321	G/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg11764359	chr7:65958608	NA	0.61	9.8	0.41	9.58e-21	Aortic root size;
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.35	-0.36	7.75e-16	Tonsillectomy;
LGG	cis	rs981844	0.666	rs7691303	chr4:154684198	T/C	cg14289246	chr4:154710475	SFRP2	-0.6	-10.74	-0.45	3.42e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg05163923	chr11:71159392	DHCR7	0.72	14.24	0.55	1.97e-38	Vitamin D levels;
LGG	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg03517284	chr6:25882590	NA	0.41	6.75	0.3	4.34e-11	Iron status biomarkers;
LGG	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.75	-0.3	4.4e-11	Neuroticism;
LGG	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.56e-18	Common traits (Other);
LGG	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.87	-0.45	1.17e-24	Hemoglobin concentration;
LGG	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg06532163	chr17:45867833	NA	0.55	9.33	0.4	4.58e-19	IgG glycosylation;
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.35	-0.36	7.72e-16	Aortic root size;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.3	-0.55	1.1e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.71	16.27	0.6	2.1e-47	Schizophrenia;
LGG	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg17757837	chr7:157058334	UBE3C	-0.91	-20.83	-0.7	1.71e-68	Body mass index;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12016809	chr21:47604291	C21orf56	0.49	8.66	0.37	7.79e-17	Testicular germ cell tumor;
LGG	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg14416269	chr4:6271139	WFS1	0.52	9.61	0.41	4.56e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg05096777	chr10:104283225	SUFU	0.32	7.12	0.31	4.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9596863	0.898	rs9568898	chr13:54317030	G/T	ch.13.53330881F	chr13:54432880	NA	0.5	6.88	0.3	1.91e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07570687	chr10:102243282	WNT8B	0.41	7.17	0.32	2.95e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg05925327	chr15:68127851	NA	-0.38	-7.71	-0.34	7.66e-14	Restless legs syndrome;
LGG	trans	rs11976180	1.000	rs1919949	chr7:143767723	G/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.39	-7.06	-0.31	6.26e-12	Obesity-related traits;
LGG	cis	rs1040	1.000	rs10945405	chr6:169621136	C/T	cg04662567	chr6:169592167	NA	0.41	7.53	0.33	2.62e-13	Joint mobility (Beighton score);
LGG	cis	rs870825	0.929	rs72689263	chr4:185590961	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.65	-0.71	2.46e-72	Height;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg03727229	chr11:118479170	PHLDB1	-0.44	-8.08	-0.35	5.75e-15	Glioma;
LGG	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07570687	chr10:102243282	WNT8B	0.44	7.34	0.32	9.85e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9902453	1.000	rs4795525	chr17:28388487	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs10463316	0.817	rs10476770	chr5:150777720	G/C	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.64	-0.41	3.57e-20	Metabolite levels (Pyroglutamine);
LGG	trans	rs3960554	0.529	rs1859795	chr7:75877354	A/G	cg19862616	chr7:65841803	NCRNA00174	0.62	9.84	0.42	7.26e-21	Eotaxin levels;
LGG	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.65	0.3	8.38e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg03929089	chr4:120376271	NA	0.69	10.83	0.45	1.69e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3735485	0.800	rs4724351	chr7:45059545	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.52	0.4	9.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs847649	1.000	rs847649	chr7:102556011	C/T	cg18108683	chr7:102477205	FBXL13	-0.63	-13.71	-0.54	3.84e-36	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7098414	0.531	rs4120852	chr10:82018594	G/T	cg01528321	chr10:82214614	TSPAN14	0.64	11.06	0.46	2.2e-25	Post bronchodilator FEV1;
LGG	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg13939156	chr17:80058883	NA	0.46	7.77	0.34	5.04e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.42	0.44	5.67e-23	Resting heart rate;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.24	0.32	1.89e-12	Life satisfaction;
LGG	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg27121462	chr16:89883253	FANCA	0.62	11.0	0.46	3.57e-25	Schizophrenia;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg17644776	chr2:200775616	C2orf69	-0.47	-7.95	-0.35	1.42e-14	QT interval;
LGG	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg04287289	chr16:89883240	FANCA	0.8	16.57	0.61	9.4e-49	Vitiligo;
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg03036210	chr16:89904091	SPIRE2	-0.58	-7.53	-0.33	2.69e-13	Skin colour saturation;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg16141378	chr3:129829833	LOC729375	0.39	9.35	0.4	3.74e-19	Joint mobility (Beighton score);
LGG	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.93e-13	Neuroticism;
LGG	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2455799	0.613	rs7642876	chr3:15883094	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.84	-0.34	3.12e-14	Mean platelet volume;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs1775715	0.644	rs2799022	chr10:32137198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.34	6.72	0.3	5.41e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs8114671	0.967	rs6142322	chr20:33788538	C/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.48	-0.33	3.87e-13	Height;
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg18963800	chr10:38644991	HSD17B7P2	0.46	7.38	0.32	7.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6764363	0.504	rs4003415	chr3:281306	T/C	cg02057681	chr3:285234	CHL1	-0.41	-7.34	-0.32	9.38e-13	Sudden cardiac arrest;
LGG	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.98	-0.52	4.38e-33	Gut microbiome composition (summer);
LGG	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.67	-0.44	6.54e-24	Breast cancer;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg08677398	chr8:58056175	NA	0.44	7.35	0.32	9.16e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14159747	chr11:113255604	NA	0.31	8.54	0.37	1.93e-16	Neuroticism;
LGG	cis	rs1784581	0.894	rs1790000	chr6:162388707	A/G	cg17173639	chr6:162384350	PARK2	0.89	23.36	0.74	2.68e-80	Itch intensity from mosquito bite;
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg07615347	chr10:60278583	BICC1	0.62	17.78	0.64	2.64e-54	Refractive error;
LGG	cis	rs2455799	0.613	rs2246960	chr3:15717693	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.9	-0.34	1.98e-14	Mean platelet volume;
LGG	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.59	0.56	6.18e-40	Colorectal cancer;
LGG	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.1	-0.31	4.79e-12	Caffeine consumption;
LGG	cis	rs3736594	0.802	rs9678824	chr2:27964328	G/C	cg27432699	chr2:27873401	GPN1	0.57	9.34	0.4	4.17e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg06532163	chr17:45867833	NA	0.55	9.33	0.4	4.58e-19	IgG glycosylation;
LGG	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.69e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg17691542	chr6:26056736	HIST1H1C	0.47	8.32	0.36	9.75e-16	Height;
LGG	cis	rs4240897	0.835	rs4845891	chr1:12042506	T/C	cg07603449	chr1:11986842	KIAA2013	-0.26	-7.08	-0.31	5.4e-12	Tuberculosis;
LGG	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg08999081	chr20:33150536	PIGU	0.4	10.13	0.43	6.34e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7226408	0.857	rs55804703	chr18:34452703	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.79	-0.3	3.51e-11	Retinal vascular caliber;
LGG	cis	rs2274273	0.529	rs10131562	chr14:55847015	G/A	cg04306507	chr14:55594613	LGALS3	0.52	12.54	0.5	2.87e-31	Protein biomarker;
LGG	cis	rs2410601	0.520	rs1426916	chr8:18882501	C/G	cg03215416	chr8:18823341	PSD3	-0.41	-7.45	-0.33	4.73e-13	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg15921436	chr17:44337874	NA	-0.53	-11.33	-0.47	2.04e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7084402	0.935	rs1658456	chr10:60304326	C/T	cg07615347	chr10:60278583	BICC1	0.65	18.85	0.66	3e-59	Refractive error;
LGG	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg05793240	chr7:2802953	GNA12	0.37	8.32	0.36	1.01e-15	Height;
LGG	cis	rs8028182	0.636	rs8023815	chr15:75814704	G/A	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs2303319	1.000	rs16845747	chr2:162133525	C/T	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7586879	0.828	rs9631062	chr2:25110084	C/T	cg04586622	chr2:25135609	ADCY3	0.36	8.71	0.38	5.51e-17	Body mass index;
LGG	cis	rs2236293	0.754	rs10814287	chr9:35860483	C/T	cg12876594	chr9:35791798	NPR2	-0.41	-7.69	-0.34	8.68e-14	Blood protein levels;
LGG	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-16.84	-0.62	5.45e-50	Coronary artery disease;
LGG	cis	rs1639906	0.965	rs1639909	chr7:2233045	A/C	cg20308403	chr7:2120281	MAD1L1	0.35	7.8	0.34	4.08e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.33	-0.32	1.05e-12	Total body bone mineral density;
LGG	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg14541582	chr5:601475	NA	-0.62	-10.05	-0.42	1.27e-21	Obesity-related traits;
LGG	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg26597838	chr10:835615	NA	0.74	10.05	0.42	1.21e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05665937	chr4:1216051	CTBP1	-0.5	-8.92	-0.38	1.13e-17	Obesity-related traits;
LGG	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.71	0.41	2.1e-20	Hypertriglyceridemia;
LGG	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.24	-0.32	1.89e-12	Breast cancer;
LGG	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.45	-0.58	9.56e-44	Body mass index;
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg04450456	chr4:17643702	FAM184B	0.34	7.38	0.32	7.32e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.51e-22	Motion sickness;
LGG	cis	rs11264213	0.892	rs7530222	chr1:36200778	T/C	cg27506609	chr1:36549197	TEKT2	0.69	7.88	0.34	2.39e-14	Schizophrenia;
LGG	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg18245976	chr7:158708271	WDR60	-0.56	-7.16	-0.32	3.11e-12	Height;
LGG	cis	rs13082711	0.911	rs11708710	chr3:27457348	A/C	cg02860705	chr3:27208620	NA	0.73	12.95	0.52	5.95e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7084783	0.566	rs7475602	chr10:105404862	A/C	cg00126946	chr10:105363258	SH3PXD2A	0.41	7.73	0.34	6.6e-14	Fear of pain;
LGG	cis	rs11096990	0.819	rs1367297	chr4:39161234	A/C	cg24403649	chr4:39172243	NA	-0.49	-7.88	-0.34	2.38e-14	Cognitive function;
LGG	cis	rs7808935	0.628	rs72598551	chr7:27939885	C/T	cg22168087	chr7:27702803	HIBADH	0.71	9.96	0.42	2.59e-21	Prostate cancer;
LGG	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg08344181	chr3:125677491	NA	-0.77	-7.4	-0.33	6.54e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs68170813	0.559	rs2395880	chr7:107074264	A/G	cg02696742	chr7:106810147	HBP1	-0.72	-9.92	-0.42	3.77e-21	Coronary artery disease;
LGG	trans	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	trans	rs783540	0.967	rs7494860	chr15:83334419	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.41	-7.24	-0.32	1.89e-12	Schizophrenia;
LGG	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs7614311	0.731	rs3774721	chr3:63954649	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.93	-0.35	1.61e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs2455799	0.613	rs62241264	chr3:15943471	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-7.29	-0.32	1.38e-12	Mean platelet volume;
LGG	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg03342759	chr3:160939853	NMD3	0.44	7.47	0.33	4e-13	Morning vs. evening chronotype;
LGG	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg21827317	chr3:136751795	NA	0.51	9.22	0.39	1.02e-18	Neuroticism;Schizophrenia;
LGG	cis	rs66887589	0.967	rs13104219	chr4:120438174	G/T	cg09307838	chr4:120376055	NA	0.46	7.89	0.34	2.13e-14	Diastolic blood pressure;
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.26e-15	Life satisfaction;
LGG	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg26384229	chr12:38710491	ALG10B	0.79	15.53	0.59	4.22e-44	Morning vs. evening chronotype;
LGG	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg21772509	chr8:41503840	NKX6-3	0.87	19.59	0.67	1.06e-62	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	trans	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-8.04	-0.35	7.68e-15	Lung cancer;
LGG	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs34929064	0.718	rs62447650	chr7:22729751	T/C	cg18045685	chr7:22629474	NA	0.6	8.62	0.37	1.1e-16	Major depression and alcohol dependence;
LGG	cis	rs17767392	0.881	rs8017775	chr14:72029436	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.46	-9.71	-0.41	2.07e-20	Mitral valve prolapse;
LGG	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs12431410	0.550	rs34338270	chr14:60215298	G/A	cg07950296	chr14:60194823	RTN1	-0.36	-7.03	-0.31	7.43e-12	Schizophrenia;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18252515	chr7:66147081	NA	0.46	7.37	0.32	7.66e-13	Aortic root size;
LGG	cis	rs2865126	0.818	rs7241380	chr18:10762962	A/G	cg21165219	chr18:10698044	FAM38B	0.44	7.21	0.32	2.29e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg22105103	chr4:187893119	NA	0.56	10.68	0.44	6.13e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-9.02	-0.39	5.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-7.22	-0.32	2.12e-12	Subjective well-being;
LGG	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg05090351	chr10:126851162	NA	-0.33	-8.43	-0.36	4.46e-16	Menarche (age at onset);
LGG	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg00666640	chr1:248458726	OR2T12	0.56	8.88	0.38	1.45e-17	Common traits (Other);
LGG	trans	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg21659725	chr3:3221576	CRBN	-0.66	-7.01	-0.31	8.26e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21659725	chr3:3221576	CRBN	-0.66	-12.25	-0.49	4.38e-30	Intelligence (multi-trait analysis);
LGG	cis	rs367943	0.666	rs10051834	chr5:112693803	C/T	cg12552261	chr5:112820674	MCC	0.57	10.12	0.43	7.28e-22	Type 2 diabetes;
LGG	trans	rs7178375	1.000	rs28881289	chr15:31223955	A/G	cg04373760	chr16:53404718	NA	0.55	8.4	0.36	5.41e-16	Hypertriglyceridemia;
LGG	cis	rs4950322	0.518	rs72692968	chr1:146804615	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs7818345	0.935	rs4333618	chr8:19283442	G/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.75	0.3	4.36e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg13514129	chr1:39547527	MACF1	0.68	12.6	0.51	1.69e-31	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.98	0.31	9.97e-12	Educational attainment;
LGG	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg06453172	chr10:134556979	INPP5A	-0.49	-7.52	-0.33	2.88e-13	Migraine;
LGG	cis	rs351855	0.642	rs2546095	chr5:176509584	G/T	cg19956155	chr5:176511416	NA	0.35	8.74	0.38	4.34e-17	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg00599393	chr8:22457479	C8orf58	-0.48	-8.81	-0.38	2.6e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg14228332	chr4:119757509	SEC24D	0.98	9.49	0.4	1.23e-19	Cannabis dependence symptom count;
LGG	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg13114125	chr14:105738426	BRF1	-0.85	-16.13	-0.6	9.46e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9815354	0.812	rs58442057	chr3:41827209	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg05082376	chr22:42548792	NA	-0.37	-7.73	-0.34	6.9e-14	Schizophrenia;
LGG	cis	rs12410462	0.591	rs1495851	chr1:227711073	C/A	cg23173402	chr1:227635558	NA	0.38	7.15	0.32	3.46e-12	Major depressive disorder;
LGG	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14154082	chr13:112174009	NA	0.42	9.23	0.39	9.85e-19	Menarche (age at onset);
LGG	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg07936489	chr17:37558343	FBXL20	-0.49	-8.28	-0.36	1.34e-15	Asthma;
LGG	cis	rs6834538	1.000	rs2351761	chr4:113447911	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.59	0.37	1.34e-16	Free thyroxine concentration;
LGG	trans	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg13565492	chr6:43139072	SRF	-0.59	-8.57	-0.37	1.57e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg01557791	chr16:72042693	DHODH	-0.51	-9.36	-0.4	3.54e-19	Fibrinogen levels;
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg11494091	chr17:61959527	GH2	0.51	8.34	0.36	8.73e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg14664628	chr15:75095509	CSK	0.54	10.56	0.44	1.62e-23	Breast cancer;
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg26513180	chr16:89883248	FANCA	0.67	7.46	0.33	4.4e-13	Skin colour saturation;
LGG	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.79	-0.51	2.64e-32	Response to antipsychotic treatment;
LGG	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.11	-0.43	7.89e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.85	0.54	9.65e-37	Lung cancer;
LGG	cis	rs4363385	0.747	rs4845334	chr1:152982998	T/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg01673284	chr16:4527211	HMOX2	0.38	7.64	0.33	1.29e-13	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07235253	chr7:99156031	ZNF655	0.41	6.98	0.31	1.03e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6032067	0.641	rs6032006	chr20:43755053	G/A	cg10761708	chr20:43804764	PI3	0.68	10.11	0.43	7.86e-22	Blood protein levels;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg12419862	chr22:24373484	LOC391322	-1.05	-23.42	-0.74	1.33e-80	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.62	0.33	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.73	0.69	5.08e-68	Alzheimer's disease;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg04863758	chr4:1303710	MAEA	0.41	7.22	0.32	2.11e-12	Obesity-related traits;
LGG	cis	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg21775007	chr8:11205619	TDH	-0.59	-9.63	-0.41	3.9e-20	Retinal vascular caliber;
LGG	cis	rs1190596	0.581	rs1190571	chr14:102634901	C/A	cg23904247	chr14:102554826	HSP90AA1	-0.24	-6.69	-0.3	6.46e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs9790314	0.663	rs17826438	chr3:160640295	C/T	cg04691961	chr3:161091175	C3orf57	0.44	9.33	0.4	4.37e-19	Morning vs. evening chronotype;
LGG	cis	rs11877825	0.826	rs3911954	chr18:10569112	C/T	cg25239095	chr18:10589360	NA	0.49	9.2	0.39	1.28e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs10791097	0.694	rs7106684	chr11:130758153	A/T	cg12179176	chr11:130786555	SNX19	0.84	17.15	0.62	2.19e-51	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs17685	0.784	rs1637043	chr7:75699099	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.91	0.77	3.84e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg13736514	chr6:26305472	NA	0.35	6.92	0.31	1.56e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg13770153	chr20:60521292	NA	-0.49	-8.11	-0.35	4.47e-15	Body mass index;
LGG	cis	rs4727027	0.933	rs13225884	chr7:148857795	A/G	cg23583168	chr7:148888333	NA	-0.85	-16.38	-0.61	6.92e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs12493885	0.769	rs61791508	chr3:153750816	A/G	cg17054900	chr3:154042577	DHX36	-0.66	-8.52	-0.37	2.26e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg08222618	chr4:941054	TMEM175	-0.48	-9.0	-0.39	5.65e-18	Parkinson's disease;
LGG	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg06421707	chr20:25228305	PYGB	0.5	10.9	0.45	8.97e-25	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-9.5	-0.4	1.11e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg16482183	chr6:26056742	HIST1H1C	1.0	15.28	0.58	5.95e-43	Iron status biomarkers;
LGG	cis	rs7633770	0.786	rs6808214	chr3:46682746	T/C	cg11219411	chr3:46661640	NA	0.59	14.09	0.55	9.38e-38	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg09048205	chr5:1608656	LOC728613	-0.51	-8.29	-0.36	1.22e-15	Breast cancer;
LGG	cis	rs4478037	0.822	rs9875140	chr3:33117068	T/A	cg19404215	chr3:33155277	CRTAP	0.82	9.69	0.41	2.45e-20	Major depressive disorder;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.09e-14	Life satisfaction;
LGG	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg05234568	chr11:5960015	NA	-0.77	-12.56	-0.5	2.39e-31	DNA methylation (variation);
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg00761968	chr13:53314142	LECT1	-0.36	-7.61	-0.33	1.54e-13	Lewy body disease;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.03	-0.31	7.3e-12	Bipolar disorder;
LGG	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg08999081	chr20:33150536	PIGU	0.3	6.68	0.3	7.08e-11	Coronary artery disease;
LGG	cis	rs12042938	0.600	rs1094656	chr1:231773675	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	10.37	0.43	8.45e-23	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4740619	0.740	rs7019323	chr9:15769256	A/G	cg14451791	chr9:16040625	NA	0.33	8.54	0.37	1.97e-16	Body mass index;
LGG	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.61	-0.33	1.55e-13	Type 2 diabetes;
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg07005078	chr4:17578674	LAP3	0.38	7.01	0.31	8.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.73	0.38	4.72e-17	Schizophrenia;
LGG	cis	rs1957429	0.520	rs66511472	chr14:65330330	C/A	cg23373153	chr14:65346875	NA	-1.02	-11.16	-0.46	9.12e-26	Pediatric areal bone mineral density (radius);
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.45	-0.44	4.33e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg12070911	chr6:150209640	RAET1E	0.32	7.74	0.34	6.29e-14	Lung cancer;
LGG	cis	rs1883415	0.534	rs760905	chr6:24479782	T/C	cg20631270	chr6:24437470	GPLD1	0.49	8.52	0.37	2.19e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg09085632	chr11:111637200	PPP2R1B	0.99	19.1	0.66	2.17e-60	Primary sclerosing cholangitis;
LGG	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.02	-0.31	7.78e-12	Schizophrenia;
LGG	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg15596359	chr8:11213517	TDH	-0.34	-6.77	-0.3	3.83e-11	Retinal vascular caliber;
LGG	cis	rs3820928	0.874	rs6706802	chr2:227850776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.87	-0.34	2.58e-14	Pulmonary function;
LGG	trans	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg07211511	chr3:129823064	LOC729375	-1.33	-21.03	-0.7	1.99e-69	Blood pressure (smoking interaction);
LGG	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg17294928	chr15:75287854	SCAMP5	-0.55	-10.24	-0.43	2.46e-22	Caffeine consumption;
LGG	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg20026190	chr17:76395443	PGS1	0.44	7.63	0.33	1.32e-13	HDL cholesterol levels;
LGG	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg03929089	chr4:120376271	NA	0.69	10.9	0.45	9.14e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg19168338	chr16:4465731	CORO7	-1.12	-23.2	-0.73	1.51e-79	Schizophrenia;
LGG	cis	rs2294693	0.947	rs736795	chr6:40998141	G/A	cg14769373	chr6:40998127	UNC5CL	-0.44	-7.78	-0.34	4.68e-14	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg04166393	chr7:2884313	GNA12	0.44	8.14	0.35	3.74e-15	Height;
LGG	cis	rs709400	0.628	rs11622320	chr14:103912194	A/T	cg26031613	chr14:104095156	KLC1	0.79	13.67	0.54	5.37e-36	Body mass index;
LGG	trans	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg11441553	chr12:57614120	NXPH4	-0.61	-7.62	-0.33	1.47e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs774359	0.744	rs895021	chr9:27484911	G/A	cg21249376	chr9:27528432	MOBKL2B	0.46	8.27	0.36	1.46e-15	Amyotrophic lateral sclerosis;
LGG	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.61	-12.54	-0.5	2.89e-31	Height;
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08677398	chr8:58056175	NA	0.46	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.76	0.38	3.78e-17	Platelet count;
LGG	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.24e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg09307838	chr4:120376055	NA	-0.67	-11.67	-0.48	9.38e-28	Corneal astigmatism;
LGG	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg03929089	chr4:120376271	NA	-0.62	-7.82	-0.34	3.59e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9863	0.861	rs12809125	chr12:124407991	A/G	cg13487667	chr12:124434373	CCDC92	-0.35	-7.03	-0.31	7.39e-12	White blood cell count;
LGG	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-7.32	-0.32	1.08e-12	Initial pursuit acceleration;
LGG	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg19761014	chr17:28927070	LRRC37B2	0.7	8.91	0.38	1.2e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg12395012	chr8:11607386	GATA4	0.41	7.39	0.32	6.93e-13	Monocyte count;
LGG	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	13.5	0.53	2.85e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg21420622	chr7:105162941	PUS7	-0.45	-6.7	-0.3	5.91e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.84	-17.76	-0.64	3.24e-54	Schizophrenia;
LGG	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg20503657	chr10:835505	NA	0.75	10.23	0.43	2.85e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11245990	chr11:68621969	NA	-0.4	-8.72	-0.38	5.16e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16447950	chr5:562315	NA	-0.54	-6.7	-0.3	5.96e-11	Obesity-related traits;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.57	-0.53	1.47e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg03060546	chr3:49711283	APEH	-0.62	-10.27	-0.43	2.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11239187	0.530	rs10047393	chr10:45061109	C/T	cg03916630	chr10:45065415	NA	0.37	8.96	0.38	8.26e-18	Body mass index;
LGG	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg23939001	chr4:940644	TMEM175	-0.43	-8.44	-0.37	4.04e-16	Parkinson's disease;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	7.11	0.31	4.41e-12	Longevity;
LGG	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg20336341	chr7:50628841	DDC	0.35	6.85	0.3	2.31e-11	Malaria;
LGG	cis	rs3816183	0.558	rs10211285	chr2:42861167	G/T	cg14631114	chr2:43023945	NA	0.35	7.0	0.31	8.78e-12	Hypospadias;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10802521	chr3:52805072	NEK4	-0.44	-7.48	-0.33	3.72e-13	Bipolar disorder;
LGG	cis	rs6694672	1.000	rs7411719	chr1:197085676	T/A	cg13682187	chr1:196946512	CFHR5	0.51	7.21	0.32	2.3e-12	Asthma;
LGG	cis	rs2235573	0.836	rs132932	chr22:38488616	A/T	cg19171272	chr22:38449367	NA	0.45	8.52	0.37	2.28e-16	Glioblastoma;Glioma;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg08677398	chr8:58056175	NA	0.44	6.96	0.31	1.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg13010199	chr12:38710504	ALG10B	0.57	11.14	0.46	1.03e-25	Morning vs. evening chronotype;
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg24101359	chr6:42928495	GNMT	0.57	16.92	0.62	2.51e-50	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg04861929	chr11:109293070	C11orf87	0.57	9.81	0.41	8.98e-21	Schizophrenia;
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs193541	0.501	rs3943379	chr5:122056137	A/G	cg19412675	chr5:122181750	SNX24	0.5	7.75	0.34	5.79e-14	Glucose homeostasis traits;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.48	-7.58	-0.33	1.95e-13	Coronary artery disease;
LGG	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.22	0.32	2.09e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs975722	0.639	rs43025	chr7:117104507	C/T	cg10524701	chr7:117356490	CTTNBP2	0.43	9.58	0.41	5.77e-20	Coronary artery disease;
LGG	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg09307838	chr4:120376055	NA	0.82	13.74	0.54	2.87e-36	Corneal astigmatism;
LGG	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg26528311	chr1:38462546	FHL3	-0.33	-8.07	-0.35	6.19e-15	Coronary artery disease;
LGG	cis	rs7635838	0.654	rs346083	chr3:11280017	T/C	cg00170343	chr3:11313890	ATG7	0.57	9.26	0.4	7.48e-19	HDL cholesterol;
LGG	cis	rs1018697	1.000	rs7092051	chr10:104559477	C/T	cg04362960	chr10:104952993	NT5C2	0.49	9.09	0.39	2.88e-18	Colorectal adenoma (advanced);
LGG	cis	rs4356203	0.846	rs1685932	chr11:17223903	G/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.23	-0.32	2.02e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg13010199	chr12:38710504	ALG10B	0.49	9.23	0.39	9.87e-19	Morning vs. evening chronotype;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.8	0.48	2.8e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs75920871	0.925	rs11823918	chr11:116960497	G/C	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs6450176	1.000	rs3776715	chr5:53299095	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg18064842	chr5:14874549	NA	0.47	10.72	0.45	4.13e-24	Blood metabolite levels;
LGG	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-9.03	-0.39	4.48e-18	Kawasaki disease;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02018176	chr4:1364513	KIAA1530	0.65	16.07	0.6	1.65e-46	Longevity;
LGG	cis	rs2421770	0.560	rs7114936	chr11:35374075	A/G	cg10331829	chr11:35343789	SLC1A2	-0.33	-7.36	-0.32	8.71e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs3736485	0.609	rs744039	chr15:51973373	T/C	cg13474965	chr15:52030001	LYSMD2	0.4	6.69	0.3	6.48e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6087990	0.568	rs853854	chr20:31420757	T/A	cg13636640	chr20:31349939	DNMT3B	0.73	14.16	0.55	4.62e-38	Ulcerative colitis;
LGG	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg09307838	chr4:120376055	NA	0.72	12.16	0.49	1.06e-29	Corneal astigmatism;
LGG	trans	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg26043149	chr18:55253948	FECH	0.49	8.54	0.37	2.02e-16	Bone mineral density;
LGG	cis	rs10940138	0.501	rs6877885	chr5:67249661	G/C	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.04	-0.35	7.46e-15	Menarche (age at onset);
LGG	cis	rs1927702	0.706	rs17352900	chr9:16012195	C/T	cg14451791	chr9:16040625	NA	0.28	6.73	0.3	4.95e-11	Body mass index;
LGG	cis	rs34467563	0.669	rs17709616	chr8:97391030	A/T	cg22138393	chr8:97340270	PTDSS1	0.28	6.93	0.31	1.42e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-12.82	-0.51	2.11e-32	Response to antipsychotic treatment;
LGG	cis	rs9682041	0.696	rs11709437	chr3:170085568	T/G	cg11886554	chr3:170076028	SKIL	0.67	8.65	0.37	8.42e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7202877	0.561	rs9933956	chr16:75362813	T/C	cg03315344	chr16:75512273	CHST6	0.52	6.99	0.31	9.4e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg08847533	chr14:75593920	NEK9	-0.54	-10.01	-0.42	1.7e-21	Height;
LGG	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg26384229	chr12:38710491	ALG10B	0.64	12.25	0.49	4.45e-30	Morning vs. evening chronotype;
LGG	cis	rs9733	0.744	rs4970976	chr1:150779524	T/A	cg13175981	chr1:150552382	MCL1	0.55	8.83	0.38	2.24e-17	Tonsillectomy;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.42	-0.44	5.8e-23	Bipolar disorder;
LGG	cis	rs4474465	0.850	rs7938816	chr11:78266227	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.51	0.37	2.5e-16	Alzheimer's disease (survival time);
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg19673125	chr6:150240577	RAET1G	0.37	9.07	0.39	3.42e-18	Testicular germ cell tumor;
LGG	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg20368463	chr18:77673604	PQLC1	0.57	7.48	0.33	3.79e-13	Opioid sensitivity;
LGG	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.91	0.42	4.02e-21	Height;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.87	-0.48	1.46e-28	Personality dimensions;
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06634786	chr22:41940651	POLR3H	-0.81	-13.13	-0.52	1.11e-33	Vitiligo;
LGG	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg12573674	chr2:1569213	NA	-0.62	-9.88	-0.42	5.1e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.85e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7089973	0.872	rs34064819	chr10:116621154	C/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.41	0.33	6.03e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11018904	0.906	rs36177012	chr11:89933319	T/C	cg16176437	chr11:89678848	NA	0.39	6.67	0.3	7.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg24375607	chr4:120327624	NA	0.66	10.66	0.44	7.37e-24	Corneal astigmatism;
LGG	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg15208524	chr1:10270712	KIF1B	0.42	7.22	0.32	2.12e-12	Hepatocellular carcinoma;
LGG	cis	rs3806843	0.518	rs2563310	chr5:140015741	A/G	cg19875535	chr5:140030758	IK	-0.43	-8.36	-0.36	7.33e-16	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg26116260	chr4:7069785	GRPEL1	1.15	22.53	0.72	2.05e-76	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg03665457	chr10:38645376	HSD17B7P2	0.47	7.46	0.33	4.42e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00684032	chr4:1343700	KIAA1530	0.47	9.04	0.39	4.35e-18	Obesity-related traits;
LGG	cis	rs4460629	0.521	rs12039316	chr1:155073221	C/T	cg13808842	chr1:155066096	NA	-0.33	-8.09	-0.35	5.48e-15	Serum magnesium levels;
LGG	cis	rs17767392	0.794	rs61989255	chr14:71729657	G/A	cg02058870	chr14:72053146	SIPA1L1	0.41	8.08	0.35	5.6e-15	Mitral valve prolapse;
LGG	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg01028140	chr2:1542097	TPO	-0.42	-8.11	-0.35	4.55e-15	IgG glycosylation;
LGG	cis	rs9831754	1.000	rs9822043	chr3:78352113	T/C	cg06138941	chr3:78371609	NA	-0.97	-20.57	-0.69	3.07e-67	Calcium levels;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4936891	1.000	rs10790625	chr11:123917393	G/A	cg22125253	chr11:123886957	OR10G4	-0.55	-10.45	-0.44	4.46e-23	Male fertility;
LGG	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg24209194	chr3:40518798	ZNF619	-0.45	-7.1	-0.31	4.67e-12	Renal cell carcinoma;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.44	0.56	2.68e-39	Platelet count;
LGG	cis	rs2463822	1.000	rs2463820	chr11:62112290	A/T	cg06239285	chr11:62104954	ASRGL1	1.14	15.49	0.58	6.43e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg04727924	chr7:799746	HEATR2	-0.47	-7.52	-0.33	2.83e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg14191688	chr11:70257035	CTTN	0.54	8.0	0.35	1.04e-14	Coronary artery disease;
LGG	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg12855166	chr17:30846586	MYO1D	0.38	6.73	0.3	5.05e-11	Schizophrenia;
LGG	cis	rs9443645	0.901	rs6940637	chr6:79705845	C/T	cg18132916	chr6:79620363	NA	-0.3	-8.28	-0.36	1.37e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504073	0.647	rs4873314	chr8:50011656	A/C	cg00325661	chr8:49890786	NA	0.75	14.53	0.56	1.07e-39	Blood metabolite ratios;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs2710642	0.815	rs6545971	chr2:63074986	A/T	cg17519650	chr2:63277830	OTX1	0.5	8.3	0.36	1.15e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg12623918	chr2:306882	NA	0.53	9.86	0.42	5.85e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg22232500	chr2:134024266	NCKAP5	0.56	7.93	0.35	1.68e-14	Neuroticism;
LGG	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg08875078	chr22:50639485	SELO	0.55	8.16	0.35	3.17e-15	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.56	-0.41	6.98e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs7267979	0.934	rs2261115	chr20:25259807	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.09	0.42	8.99e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.68	-0.3	7.03e-11	Longevity;Endometriosis;
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	4.94e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs1555322	0.530	rs2425053	chr20:33881820	A/G	cg17927777	chr20:33865990	NA	0.65	9.27	0.4	6.81e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg20283391	chr11:68216788	NA	-0.51	-8.12	-0.35	4.32e-15	Total body bone mineral density;
LGG	cis	rs3857747	0.861	rs9648486	chr7:40420032	A/G	cg00420559	chr7:40367873	C7orf10	0.36	7.31	0.32	1.19e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs9828933	0.678	rs704366	chr3:63871648	A/G	cg17941049	chr3:63904683	ATXN7	-0.7	-7.92	-0.35	1.8e-14	Type 2 diabetes;
LGG	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.77	0.34	5.03e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2117029	0.555	rs7958241	chr12:49509262	C/T	cg24176009	chr12:49580217	TUBA1A	-0.6	-11.72	-0.48	5.73e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.18	-0.32	2.78e-12	Neuroticism;
LGG	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.06	-0.46	2.25e-25	Mean platelet volume;
LGG	cis	rs9287719	0.837	rs4233882	chr2:10755564	A/G	cg02196655	chr2:10830764	NOL10	-0.41	-6.92	-0.31	1.55e-11	Prostate cancer;
LGG	cis	rs10463554	0.963	rs34774	chr5:102450820	G/T	cg23492399	chr5:102201601	PAM	-0.5	-7.54	-0.33	2.48e-13	Parkinson's disease;
LGG	cis	rs3806843	0.569	rs753279	chr5:140023818	A/G	cg19875535	chr5:140030758	IK	-0.43	-8.44	-0.37	4.04e-16	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg13939156	chr17:80058883	NA	-0.48	-8.99	-0.39	6.14e-18	Life satisfaction;
LGG	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg02951883	chr7:2050386	MAD1L1	-0.56	-10.83	-0.45	1.57e-24	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs988958	0.565	rs10166263	chr2:42235265	C/T	cg27252766	chr2:42229092	NA	0.52	7.34	0.32	9.46e-13	Hypospadias;
LGG	cis	rs56404409	0.826	rs77277044	chr11:123325012	A/C	cg04681489	chr11:123325084	NA	-0.44	-7.78	-0.34	4.83e-14	Ulcerative colitis;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Electroencephalogram traits;
LGG	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg19980929	chr12:42632907	YAF2	0.34	7.69	0.34	8.81e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.49	0.5	4.87e-31	Colorectal cancer;
LGG	cis	rs6763768	0.606	rs3732834	chr3:53324915	A/G	cg16894138	chr3:53270350	TKT	-0.44	-8.46	-0.37	3.45e-16	Bacterial meningitis;
LGG	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg02023728	chr11:77925099	USP35	0.39	6.86	0.3	2.22e-11	Alzheimer's disease (survival time);
LGG	cis	rs9394152	0.845	rs9296092	chr6:33478496	C/T	cg13560919	chr6:33536144	NA	-0.67	-12.37	-0.5	1.4e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs3087591	0.639	rs757379	chr17:29724557	G/A	cg24425628	chr17:29625626	OMG;NF1	0.58	11.91	0.48	1.05e-28	Hip circumference;
LGG	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg22535103	chr8:58192502	C8orf71	-0.99	-15.11	-0.57	3.1e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs6456042	0.893	rs3127424	chr6:166539090	A/G	cg11088901	chr6:166572345	T	-0.36	-7.54	-0.33	2.56e-13	Asthma;
LGG	cis	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg04990556	chr1:26633338	UBXN11	0.59	7.77	0.34	5.03e-14	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09652807	chr17:2652918	MIR1253	0.49	7.15	0.32	3.48e-12	Hip circumference;
LGG	cis	rs3106136	0.872	rs10030713	chr4:95238536	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.96	-0.31	1.15e-11	Capecitabine sensitivity;
LGG	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-7.43	-0.33	5.22e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg09904177	chr6:26538194	HMGN4	0.67	14.0	0.55	2.12e-37	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg20608306	chr11:116969690	SIK3	0.33	8.81	0.38	2.6e-17	Blood protein levels;
LGG	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg08344181	chr3:125677491	NA	-0.64	-7.23	-0.32	2.05e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.87	-0.42	5.48e-21	Carotid intima media thickness;
LGG	cis	rs12367572	0.501	rs8181757	chr12:45486220	G/A	cg03114573	chr12:45410052	DBX2	-0.49	-8.09	-0.35	5.44e-15	Gut microbiome composition (summer);
LGG	cis	rs1018697	1.000	rs10786710	chr10:104548739	C/T	cg04362960	chr10:104952993	NT5C2	0.49	9.03	0.39	4.76e-18	Colorectal adenoma (advanced);
LGG	cis	rs986417	0.748	rs10145546	chr14:61100892	A/G	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2354432	0.607	rs4314933	chr1:146821386	T/C	cg25205988	chr1:146714368	CHD1L	1.22	12.37	0.5	1.49e-30	Mitochondrial DNA levels;
LGG	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg10621924	chr7:39171070	POU6F2	0.39	8.18	0.36	2.67e-15	IgG glycosylation;
LGG	cis	rs4262150	0.726	rs11956651	chr5:152011814	C/T	cg12297329	chr5:152029980	NA	-0.83	-17.13	-0.62	2.76e-51	Bipolar disorder and schizophrenia;
LGG	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg14664628	chr15:75095509	CSK	-0.56	-10.59	-0.44	1.35e-23	Breast cancer;
LGG	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg08112188	chr17:47440006	ZNF652	1.3	15.43	0.58	1.2e-43	Prostate cancer;
LGG	cis	rs4919087	0.748	rs1147600	chr10:98981643	T/C	cg25902810	chr10:99078978	FRAT1	-0.43	-7.31	-0.32	1.15e-12	Monocyte count;
LGG	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.56	-13.14	-0.52	9.59e-34	Diastolic blood pressure;
LGG	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg00666640	chr1:248458726	OR2T12	0.59	9.67	0.41	2.88e-20	Common traits (Other);
LGG	cis	rs3762637	0.943	rs10222564	chr3:122266336	T/C	cg24169773	chr3:122142474	KPNA1	-0.59	-10.14	-0.43	6.16e-22	LDL cholesterol levels;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.39	-0.32	6.76e-13	Tonsillectomy;
LGG	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs10089	0.953	rs10223203	chr5:127527646	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.74	-11.7	-0.48	7.14e-28	Ileal carcinoids;
LGG	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	7.49	0.33	3.49e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs11225247	0.881	rs11604189	chr11:102219863	T/G	cg06323957	chr11:102217781	BIRC2	0.83	7.02	0.31	7.79e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12591125	chr7:1885375	MAD1L1	0.47	7.32	0.32	1.1e-12	Bipolar disorder;
LGG	cis	rs7975161	0.630	rs6539131	chr12:104644697	A/G	cg25273343	chr12:104657179	TXNRD1	-0.81	-7.44	-0.33	4.79e-13	Toenail selenium levels;
LGG	cis	rs7255045	0.752	rs2242514	chr19:12982798	C/T	cg07955356	chr19:12992479	DNASE2	-0.41	-6.88	-0.3	1.89e-11	Mean corpuscular volume;
LGG	cis	rs2694528	0.686	rs6864253	chr5:59862743	A/G	cg11474532	chr5:59995715	DEPDC1B	0.81	8.08	0.35	5.83e-15	Parkinson's disease;
LGG	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.51	0.63	4.81e-53	Cognitive function;
LGG	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg06886374	chr16:1844152	IGFALS	-0.44	-8.01	-0.35	9.55e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2816316	1.000	rs2760527	chr1:192536758	G/A	cg10861751	chr1:192544716	RGS1	0.34	6.85	0.3	2.41e-11	Celiac disease;
LGG	cis	rs6578185	0.810	rs3935445	chr8:142452618	C/A	cg07762003	chr8:142452454	FLJ43860	-0.63	-12.95	-0.52	5.71e-33	Endometriosis;
LGG	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.63	8.99	0.39	6.19e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2693698	0.502	rs807733	chr14:99688409	G/A	cg07440398	chr14:99712966	BCL11B	0.48	9.88	0.42	5.32e-21	Schizophrenia;
LGG	trans	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.67	-0.37	7.58e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs763121	0.853	rs5757232	chr22:39071677	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs7089973	0.872	rs35628210	chr10:116630031	G/A	cg08188268	chr10:116634841	FAM160B1	0.33	7.17	0.32	2.96e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.31	0.4	5.24e-19	Lung cancer in ever smokers;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.1	0.84	4.05e-124	Prudent dietary pattern;
LGG	cis	rs9462027	0.606	rs2814987	chr6:34605145	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.67	-0.44	6.39e-24	Systemic lupus erythematosus;
LGG	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg11789530	chr4:8429930	ACOX3	-0.64	-10.48	-0.44	3.21e-23	Response to antineoplastic agents;
LGG	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.87e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	10.06	0.42	1.17e-21	Bipolar disorder;
LGG	cis	rs611744	0.870	rs613261	chr8:109165949	A/G	cg21045802	chr8:109455806	TTC35	0.39	6.96	0.31	1.15e-11	Dupuytren's disease;
LGG	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg19336497	chr11:14380999	RRAS2	-0.58	-11.8	-0.48	2.84e-28	Sense of smell;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	13.84	0.54	1.1e-36	Alzheimer's disease;
LGG	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs7568458	0.660	rs55692129	chr2:85792404	A/T	cg17127132	chr2:85788382	GGCX	0.52	8.17	0.35	2.97e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg09818912	chr17:20140352	CYTSB	0.3	7.13	0.31	3.83e-12	Schizophrenia;
LGG	cis	rs12915845	0.545	rs7402591	chr15:89078434	T/C	cg05013243	chr15:89149849	MIR1179	0.35	7.06	0.31	6.24e-12	Menarche (age at onset);
LGG	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg20673091	chr1:2541236	MMEL1	0.77	18.04	0.64	1.73e-55	Ulcerative colitis;
LGG	cis	rs67311347	1.000	rs2168111	chr3:40395325	T/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.15	-0.68	2.83e-65	Renal cell carcinoma;
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19524238	chr7:2802976	GNA12	0.32	7.55	0.33	2.35e-13	Height;
LGG	trans	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg15534507	chr18:15165202	NA	-0.34	-7.26	-0.32	1.64e-12	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
LGG	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg25338242	chr13:114786047	RASA3	0.41	7.33	0.32	1e-12	Schizophrenia;
LGG	cis	rs7927771	0.524	rs10769299	chr11:47865160	G/T	cg20307385	chr11:47447363	PSMC3	0.57	11.08	0.46	1.88e-25	Subjective well-being;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13472734	chr3:196359441	NA	0.42	7.13	0.31	4.01e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.64e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg26924012	chr15:45694286	SPATA5L1	1.04	21.36	0.7	5.81e-71	Homoarginine levels;
LGG	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.44	-9.62	-0.41	4.29e-20	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs877282	1.000	rs112522746	chr10:772288	T/C	cg17470449	chr10:769945	NA	0.65	8.32	0.36	1e-15	Uric acid levels;
LGG	cis	rs709400	0.663	rs17679475	chr14:103916958	A/G	cg26031613	chr14:104095156	KLC1	0.77	13.63	0.54	7.96e-36	Body mass index;
LGG	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.35	-0.43	1e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11096990	0.593	rs7685619	chr4:39213399	T/G	cg24403649	chr4:39172243	NA	0.42	7.53	0.33	2.71e-13	Cognitive function;
LGG	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg14055004	chr2:241860995	NA	0.28	7.39	0.32	6.76e-13	Joint mobility (Beighton score);
LGG	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.51	0.44	2.56e-23	Morning vs. evening chronotype;
LGG	cis	rs1420338	0.967	rs10807873	chr7:34171276	C/T	cg01275685	chr7:34179230	BMPER	-0.51	-9.1	-0.39	2.79e-18	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	trans	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg25482853	chr8:67687455	SGK3	0.48	7.43	0.33	5.28e-13	Ulcerative colitis;
LGG	cis	rs476633	0.708	rs8030657	chr15:41444979	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-11.62	-0.48	1.44e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7267979	1.000	rs6050544	chr20:25320228	T/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.86e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg13683864	chr3:40499215	RPL14	1.16	29.59	0.81	8.26e-109	Renal cell carcinoma;
LGG	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg18876405	chr7:65276391	NA	-0.62	-11.62	-0.48	1.48e-27	Aortic root size;
LGG	cis	rs28374715	0.662	rs28554139	chr15:41531084	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.03	-18.27	-0.65	1.45e-56	Ulcerative colitis;
LGG	cis	rs17604090	0.816	rs10248839	chr7:29697253	T/C	cg19413766	chr7:29689036	LOC646762	-0.58	-7.13	-0.31	3.91e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs754423	0.547	rs6572814	chr14:52543421	C/T	cg12071775	chr14:52591786	NA	0.42	6.8	0.3	3.26e-11	Craniofacial microsomia;
LGG	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	11.71	0.48	6.63e-28	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.56	-0.37	1.68e-16	Retinal vascular caliber;
LGG	cis	rs17039065	0.920	rs73838440	chr4:109457882	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	7.72	0.34	7.12e-14	Gut microbiome composition (summer);
LGG	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg27398817	chr8:82754497	SNX16	-0.71	-11.04	-0.46	2.57e-25	Diastolic blood pressure;
LGG	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg10596483	chr8:143751796	JRK	0.53	8.27	0.36	1.43e-15	Schizophrenia;
LGG	cis	rs7011049	0.778	rs111990543	chr8:53867626	T/G	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg14784868	chr12:69753453	YEATS4	0.43	6.77	0.3	4.01e-11	Response to diuretic therapy;
LGG	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg10857441	chr5:6722123	POLS	-0.27	-6.68	-0.3	6.71e-11	Menopause (age at onset);
LGG	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.82	0.34	3.61e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.18	-0.49	8.24e-30	Response to antipsychotic treatment;
LGG	cis	rs9487094	0.696	rs1853330	chr6:109696751	G/T	cg01125227	chr6:109776195	MICAL1	0.38	6.74	0.3	4.8e-11	Height;
LGG	cis	rs2976388	0.647	rs13272904	chr8:143782614	T/C	cg06565975	chr8:143823917	SLURP1	0.38	9.6	0.41	4.87e-20	Urinary tract infection frequency;
LGG	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg02886208	chr11:14281011	SPON1	-0.36	-7.03	-0.31	7.54e-12	Sense of smell;
LGG	trans	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	6.83	0.3	2.74e-11	Neuroticism;
LGG	cis	rs137603	0.602	rs137654	chr22:39732413	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.7	-13.77	-0.54	2.12e-36	Primary biliary cholangitis;
LGG	cis	rs2230307	0.536	rs534252	chr1:100472604	A/G	cg24955406	chr1:100503596	HIAT1	0.56	8.05	0.35	6.88e-15	Carotid intima media thickness;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24110177	chr3:50126178	RBM5	0.59	10.86	0.45	1.22e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg24209194	chr3:40518798	ZNF619	0.44	6.76	0.3	4.19e-11	Renal cell carcinoma;
LGG	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	trans	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-12.01	-0.49	4.23e-29	Vitiligo;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.51	0.65	1.14e-57	Menopause (age at onset);
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.69	0.3	6.34e-11	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3219090	0.962	rs2793378	chr1:226597341	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	cis	rs12410462	0.636	rs2819511	chr1:227698474	A/G	cg04117972	chr1:227635322	NA	0.47	8.6	0.37	1.26e-16	Major depressive disorder;
LGG	cis	rs4865169	0.560	rs1277312	chr4:57902945	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.46	7.93	0.35	1.67e-14	Breast cancer;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg06654118	chr4:1303317	MAEA	0.47	8.14	0.35	3.69e-15	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16338035	chr3:143691269	C3orf58	0.52	7.78	0.34	4.63e-14	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.11	-0.49	1.69e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg16096631	chr1:42092165	HIVEP3	0.63	13.51	0.53	2.71e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-13.05	-0.52	2.2e-33	Menarche (age at onset);
LGG	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg20735989	chr4:730612	PCGF3	-0.61	-10.71	-0.45	4.46e-24	White blood cell count;
LGG	cis	rs6708331	0.816	rs10196979	chr2:70367397	A/T	cg01613454	chr2:70366299	NA	0.52	9.2	0.39	1.21e-18	Obesity-related traits;
LGG	cis	rs7010267	0.740	rs1905786	chr8:119951692	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	7.97	0.35	1.23e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg21100191	chr22:23484243	RTDR1	0.88	17.41	0.63	1.33e-52	Bone mineral density;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08677398	chr8:58056175	NA	0.6	13.41	0.53	6.93e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.670	rs749517	chr6:109852916	A/G	cg16315928	chr6:109776240	MICAL1	-0.46	-8.0	-0.35	9.86e-15	Height;
LGG	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg00701064	chr4:6280414	WFS1	-0.73	-16.74	-0.61	1.57e-49	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2916247	0.954	rs10110490	chr8:93147036	G/T	cg10183463	chr8:93005414	RUNX1T1	0.37	7.86	0.34	2.7e-14	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.99	-0.39	6.41e-18	Mean corpuscular volume;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg22963979	chr7:1858916	MAD1L1	0.38	7.77	0.34	4.98e-14	Schizophrenia;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.39	-0.43	7.21e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.24	-0.36	1.8e-15	Obesity-related traits;
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg19077165	chr18:44547161	KATNAL2	0.53	9.58	0.41	5.98e-20	Personality dimensions;
LGG	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg03806693	chr22:41940476	POLR3H	-0.93	-16.08	-0.6	1.52e-46	Vitiligo;
LGG	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs3126085	0.935	rs2184951	chr1:152273168	T/G	cg26876637	chr1:152193138	HRNR	-0.51	-7.92	-0.35	1.82e-14	Atopic dermatitis;
LGG	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg03030879	chr14:75389066	RPS6KL1	0.46	8.08	0.35	5.83e-15	Caffeine consumption;
LGG	cis	rs12431410	0.550	rs11844387	chr14:60224724	C/T	cg07950296	chr14:60194823	RTN1	-0.37	-7.11	-0.31	4.3e-12	Schizophrenia;
LGG	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	25.27	0.76	3.54e-89	Height;
LGG	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.36	7.91	0.35	1.89e-14	Schizophrenia;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	8.68	0.37	6.57e-17	Platelet count;
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg24596788	chr1:163392923	NA	0.68	13.06	0.52	2.17e-33	Motion sickness;
LGG	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg22643751	chr7:855365	UNC84A	0.37	7.0	0.31	8.8e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg22907277	chr7:1156413	C7orf50	0.67	6.68	0.3	7.05e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs36051895	0.695	rs10974922	chr9:5028813	C/T	cg02405213	chr9:5042618	JAK2	-0.84	-16.29	-0.6	1.79e-47	Pediatric autoimmune diseases;
LGG	cis	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg12486710	chr1:178512616	C1orf220	0.51	10.29	0.43	1.67e-22	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg06875740	chr19:51307921	C19orf48	-0.72	-6.78	-0.3	3.62e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.44	8.2e-24	Neuroticism;
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.89	-0.51	1.03e-32	Alzheimer's disease;
LGG	cis	rs6807915	0.603	rs7611617	chr3:12289142	C/T	cg15873301	chr3:12045459	SYN2	-0.42	-7.13	-0.31	3.8e-12	Leprosy;
LGG	cis	rs2562456	0.876	rs2681370	chr19:21736838	T/C	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01570182	chr17:44337453	NA	-0.5	-9.08	-0.39	3.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-6.95	-0.31	1.27e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4662945	0.603	rs1453147	chr2:130271510	A/C	cg05962382	chr2:130345044	NA	-0.46	-7.91	-0.35	1.86e-14	Response to cytidine analogues (gemcitabine);
LGG	trans	rs4942242	1.000	rs9533566	chr13:44224691	T/C	cg19169023	chr15:41853346	TYRO3	-0.32	-6.81	-0.3	3.01e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23116984	chr15:34517290	TMEM85	0.51	7.78	0.34	4.81e-14	Gut microbiome composition (summer);
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg13647721	chr17:30228624	UTP6	0.64	7.98	0.35	1.16e-14	Hip circumference adjusted for BMI;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg13111374	chr4:17812581	NCAPG;DCAF16	0.71	6.71	0.3	5.62e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg01028140	chr2:1542097	TPO	-0.45	-8.4	-0.36	5.66e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1816854	0.938	rs7966902	chr12:44200485	A/C	cg00106942	chr12:44200524	TWF1	0.46	7.11	0.31	4.36e-12	Inflammatory bowel disease;
LGG	cis	rs9486719	0.857	rs13208321	chr6:96860354	C/T	cg06623918	chr6:96969491	KIAA0776	-0.67	-10.32	-0.43	1.32e-22	Migraine;Coronary artery disease;
LGG	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg25885449	chr18:77638415	KCNG2	0.35	6.89	0.31	1.8e-11	Schizophrenia;
LGG	cis	rs2013441	0.866	rs2703797	chr17:20080301	T/C	cg13482628	chr17:19912719	NA	-0.4	-6.92	-0.31	1.53e-11	Obesity-related traits;
LGG	cis	rs4731207	0.596	rs6466973	chr7:124605426	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg07541023	chr7:19748670	TWISTNB	-0.61	-8.59	-0.37	1.33e-16	Thyroid stimulating hormone;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.1	0.31	4.8e-12	Schizophrenia;
LGG	cis	rs7143963	1.000	rs4553557	chr14:103309743	C/T	cg23020514	chr14:103360112	TRAF3	0.52	10.1	0.42	8.46e-22	Body mass index;
LGG	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg06494592	chr3:125709126	NA	-0.52	-6.7	-0.3	5.91e-11	Blood pressure (smoking interaction);
LGG	cis	rs9467160	0.581	rs2244216	chr6:24466721	C/T	cg20631270	chr6:24437470	GPLD1	0.44	6.99	0.31	9.49e-12	Liver enzyme levels;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.76	0.84	6.51e-127	Prudent dietary pattern;
LGG	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.28	0.32	1.42e-12	Morning vs. evening chronotype;
LGG	trans	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg00711542	chr16:29343894	RUNDC2C	0.4	6.87	0.3	2.14e-11	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4849975	0.510	rs13432750	chr2:3708503	G/A	cg14882966	chr2:3699353	NA	0.6	7.62	0.33	1.48e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10089	1.000	rs4835944	chr5:127490870	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-11.06	-0.46	2.14e-25	Ileal carcinoids;
LGG	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg04362960	chr10:104952993	NT5C2	0.48	7.99	0.35	1.05e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg02487422	chr3:49467188	NICN1	0.39	6.74	0.3	4.64e-11	Parkinson's disease;
LGG	cis	rs9811920	0.638	rs793440	chr3:99643176	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	9.03	0.39	4.64e-18	Axial length;
LGG	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg15873301	chr3:12045459	SYN2	0.44	7.78	0.34	4.73e-14	Leprosy;
LGG	cis	rs10979	0.679	rs9321918	chr6:143883460	T/C	cg25407410	chr6:143891975	LOC285740	-0.61	-9.78	-0.41	1.16e-20	Hypospadias;
LGG	trans	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg25042112	chr7:64838748	ZNF92	-0.47	-6.86	-0.3	2.16e-11	Pain;
LGG	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.27	0.5	3.61e-30	Height;
LGG	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9815354	0.556	rs73073276	chr3:42025354	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7666738	0.830	rs1124253	chr4:98949682	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9987353	0.519	rs11779181	chr8:9063027	A/G	cg16141378	chr3:129829833	LOC729375	-0.3	-6.74	-0.3	4.83e-11	Recombination measurement;
LGG	cis	rs2978263	0.628	rs13273840	chr8:30315040	C/T	cg05780722	chr8:30327988	RBPMS	-0.32	-6.67	-0.3	7.21e-11	Cognitive performance;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg16099169	chr2:106886729	NA	-0.32	-8.11	-0.35	4.73e-15	Facial morphology (factor 23);
LGG	cis	rs7923609	0.905	rs7092784	chr10:65214749	C/T	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.67	-0.3	7.21e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.54	2.54e-37	Bladder cancer;
LGG	cis	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg25986240	chr4:9926439	SLC2A9	-0.5	-9.38	-0.4	2.85e-19	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.64	-0.37	9.02e-17	Platelet distribution width;
LGG	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg06917763	chr7:130033247	NA	0.36	7.77	0.34	5.27e-14	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs17453880	0.929	rs55869831	chr5:151957634	A/C	cg10931792	chr5:152022470	NA	0.38	8.27	0.36	1.45e-15	Subjective well-being;
LGG	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg18252515	chr7:66147081	NA	-1.18	-18.15	-0.64	5.24e-56	Diabetic kidney disease;
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg16606324	chr3:10149918	C3orf24	-0.59	-6.72	-0.3	5.48e-11	Alzheimer's disease;
LGG	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-7.6	-0.33	1.65e-13	Height;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg03806693	chr22:41940476	POLR3H	1.03	17.07	0.62	5.16e-51	Cannabis dependence symptom count;
LGG	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg03060546	chr3:49711283	APEH	0.46	7.8	0.34	4.11e-14	Menarche (age at onset);
LGG	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.63	-0.72	6.81e-77	Primary sclerosing cholangitis;
LGG	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg15557168	chr22:42548783	NA	-0.41	-8.23	-0.36	1.97e-15	Schizophrenia;
LGG	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.3	-0.4	5.65e-19	Glomerular filtration rate (creatinine);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg25880573	chr1:24073129	TCEB3	0.33	7.25	0.32	1.75e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12951224	chr8:38126910	PPAPDC1B	0.49	7.36	0.32	8.27e-13	Gut microbiome composition (summer);
LGG	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.04	-0.31	6.77e-12	Systolic blood pressure;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg04267008	chr7:1944627	MAD1L1	-0.65	-11.39	-0.47	1.19e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.98	-0.31	1.04e-11	Type 2 diabetes;
LGG	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg16141378	chr3:129829833	LOC729375	0.36	8.61	0.37	1.11e-16	Neuroticism;
LGG	cis	rs11696739	0.513	rs34600126	chr20:1597433	G/T	cg27365103	chr20:1578550	SIRPB1	-0.39	-6.81	-0.3	2.96e-11	Mean platelet volume;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg04450456	chr4:17643702	FAM184B	0.31	6.71	0.3	5.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7267979	0.966	rs6037083	chr20:25290543	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.24	-0.43	2.5e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2033732	0.706	rs7826406	chr8:85061639	G/A	cg05716166	chr8:85095498	RALYL	0.44	6.95	0.31	1.22e-11	Body mass index;
LGG	cis	rs7582720	1.000	rs72936882	chr2:203794439	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2249694	0.959	rs2987799	chr10:135380499	T/G	cg20169779	chr10:135381914	SYCE1	0.49	7.34	0.32	9.77e-13	Obesity-related traits;
LGG	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg15268244	chr15:77196840	NA	0.43	9.4	0.4	2.45e-19	Blood metabolite levels;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg02811702	chr13:24901961	NA	0.39	7.21	0.32	2.24e-12	Obesity-related traits;
LGG	cis	rs7091068	0.721	rs618951	chr10:95404967	A/G	cg20715218	chr10:95462985	C10orf4	-0.59	-9.41	-0.4	2.33e-19	Urinary tract infection frequency;
LGG	cis	rs7428	0.527	rs6547612	chr2:85551184	C/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-14.06	-0.55	1.26e-37	Ear protrusion;
LGG	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.48	-0.33	3.76e-13	Neuroticism;
LGG	trans	rs58106596	0.800	rs11686900	chr2:232568692	A/G	cg01370599	chr3:116745421	NA	0.7	10.62	0.44	9.93e-24	White blood cell count;Lymphocyte counts;
LGG	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.83	-17.42	-0.63	1.2e-52	Caffeine consumption;
LGG	cis	rs7077256	0.564	rs34730656	chr10:65156965	G/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs7521181	chr1:152955223	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.14	-0.39	1.97e-18	Inflammatory skin disease;
LGG	cis	rs4665809	1.000	rs11678157	chr2:26321526	T/C	cg22920501	chr2:26401640	FAM59B	-0.37	-7.57	-0.33	1.97e-13	Gut microbiome composition (summer);
LGG	cis	rs9849248	0.627	rs10858	chr3:88107989	G/C	cg14530983	chr3:88190749	ZNF654	0.56	7.81	0.34	3.74e-14	Menarche (age at onset);
LGG	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.72	-0.38	4.95e-17	Cognitive function;
LGG	cis	rs11096990	0.613	rs35391082	chr4:39192653	C/T	cg24403649	chr4:39172243	NA	0.42	7.51	0.33	3.03e-13	Cognitive function;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08219700	chr8:58056026	NA	0.43	6.85	0.3	2.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs4038782	0.503	rs7201526	chr16:4907082	C/A	cg04440724	chr16:4920505	UBN1	-0.65	-10.06	-0.42	1.19e-21	Cancer;
LGG	cis	rs4732038	0.739	rs17775910	chr7:134252639	C/T	cg06906464	chr7:134288099	NA	-0.48	-11.37	-0.47	1.36e-26	Longevity;
LGG	cis	rs61931739	0.620	rs61927756	chr12:33709931	A/G	cg06521331	chr12:34319734	NA	0.39	6.68	0.3	6.75e-11	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg15971980	chr6:150254442	NA	0.46	8.74	0.38	4.34e-17	Lung cancer;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg13880726	chr7:1868755	MAD1L1	0.41	7.27	0.32	1.5e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7851660	0.901	rs7873389	chr9:100609230	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.69	-0.56	2.31e-40	Strep throat;
LGG	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg26384229	chr12:38710491	ALG10B	0.71	13.03	0.52	2.71e-33	Resting heart rate;
LGG	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15532942	chr18:77220712	NFATC1	0.47	7.42	0.33	5.65e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2046867	0.818	rs9814945	chr3:72803590	C/T	cg25664220	chr3:72788482	NA	-0.32	-8.93	-0.38	9.85e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7226408	0.553	rs4799891	chr18:34491524	T/C	cg15022739	chr18:34823045	BRUNOL4	0.41	8.84	0.38	2.06e-17	Obesity-related traits;
LGG	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06481639	chr22:41940642	POLR3H	-0.48	-7.33	-0.32	1.04e-12	Vitiligo;
LGG	cis	rs11671005	0.779	rs3794971	chr19:58985866	T/C	cg13877915	chr19:58951672	ZNF132	0.62	7.98	0.35	1.17e-14	Mean platelet volume;
LGG	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg02297831	chr4:17616191	MED28	-0.46	-8.52	-0.37	2.22e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg14664628	chr15:75095509	CSK	-0.65	-12.91	-0.51	8.53e-33	Breast cancer;
LGG	cis	rs6450176	1.000	rs60492935	chr5:53306240	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2227564	0.620	rs11000787	chr10:75584383	T/C	cg00564723	chr10:75632066	CAMK2G	-0.5	-10.56	-0.44	1.72e-23	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1595825	0.891	rs41468149	chr2:198910107	C/G	cg00982548	chr2:198649783	BOLL	0.52	6.98	0.31	1.05e-11	Ulcerative colitis;
LGG	cis	rs727505	0.909	rs1031957	chr7:124627301	T/C	cg23710748	chr7:124431027	NA	-0.52	-9.5	-0.4	1.12e-19	Lewy body disease;
LGG	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg00129232	chr17:37814104	STARD3	0.61	11.48	0.47	5.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.6	-0.33	1.69e-13	Mean corpuscular hemoglobin;
LGG	cis	rs62025270	0.688	rs7179917	chr15:86265644	G/A	cg25843651	chr15:86329602	KLHL25	0.59	9.05	0.39	3.94e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg05696931	chr1:227175867	NA	0.39	7.56	0.33	2.17e-13	Myeloid white cell count;
LGG	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg18200150	chr17:30822561	MYO1D	-0.49	-9.46	-0.4	1.6e-19	Schizophrenia;
LGG	cis	rs9788721	0.836	rs17483929	chr15:78742376	C/T	cg18825076	chr15:78729989	IREB2	-0.58	-9.5	-0.4	1.1e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9547996	0.879	rs61957472	chr13:38139860	C/A	cg13634560	chr13:38173852	POSTN	-0.36	-7.2	-0.32	2.4e-12	Diastolic blood pressure;
LGG	cis	rs1345301	1.000	rs1345302	chr2:102873369	A/G	cg05295703	chr2:102895712	NA	0.38	7.6	0.33	1.67e-13	Waist circumference;
LGG	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg26818257	chr2:241905806	NA	0.38	7.19	0.32	2.59e-12	Urinary metabolites;
LGG	cis	rs988958	0.567	rs2165239	chr2:42254356	C/T	cg19376973	chr2:42229025	NA	0.63	10.17	0.43	4.53e-22	Hypospadias;
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg18446336	chr7:2847575	GNA12	-0.26	-6.89	-0.3	1.83e-11	Height;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg26513180	chr16:89883248	FANCA	0.88	8.54	0.37	1.95e-16	Skin colour saturation;
LGG	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs7944735	0.508	rs59652089	chr11:47907350	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.66	0.3	7.56e-11	Intraocular pressure;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg08677398	chr8:58056175	NA	0.47	6.98	0.31	1.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg15103426	chr22:29168792	CCDC117	-0.62	-9.34	-0.4	3.97e-19	Lymphocyte counts;
LGG	cis	rs10155981	0.510	rs4719706	chr7:22592796	G/A	cg06110297	chr7:22589830	NA	-0.72	-6.98	-0.31	1.04e-11	Bilirubin levels;
LGG	cis	rs3206736	0.520	rs328934	chr7:35043726	C/A	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg20308403	chr7:2120281	MAD1L1	0.31	6.73	0.3	5e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg17182837	chr8:41585554	ANK1	-0.54	-7.87	-0.34	2.49e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.9	0.64	7.77e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2074193	0.525	rs215371	chr12:47742529	T/C	cg02516419	chr12:47771422	NA	-0.54	-7.89	-0.34	2.19e-14	Migraine with aura;
LGG	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	8.46	0.37	3.63e-16	Menarche (age at onset);
LGG	cis	rs887829	0.641	rs7586110	chr2:234590527	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.4	-0.36	5.53e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2173063	1.000	rs74029110	chr15:93126790	G/A	cg07052004	chr15:93132129	NA	0.62	7.06	0.31	6.02e-12	Subcutaneous adipose tissue;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	17.09	0.62	4.21e-51	Tonsillectomy;
LGG	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-12.09	-0.49	1.98e-29	Morning vs. evening chronotype;
LGG	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg12379764	chr21:47803548	PCNT	0.69	12.1	0.49	1.76e-29	Lymphocyte counts;
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-8.62	-0.37	1.04e-16	Total body bone mineral density;
LGG	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg05793240	chr7:2802953	GNA12	0.32	7.96	0.35	1.38e-14	Height;
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-12.86	-0.51	1.4e-32	Menopause (age at onset);
LGG	cis	rs7917772	0.503	rs7902306	chr10:104290462	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.07	0.49	2.35e-29	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg10167378	chr1:228756711	NA	0.5	7.94	0.35	1.54e-14	Chronic lymphocytic leukemia;
LGG	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg20587970	chr11:113659929	NA	-1.07	-16.16	-0.6	6.93e-47	Hip circumference adjusted for BMI;
LGG	cis	rs789852	1.000	rs711980	chr3:194324558	G/C	cg18000598	chr3:194342907	TMEM44	-0.86	-8.09	-0.35	5.22e-15	QT interval;
LGG	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg08085267	chr17:45401833	C17orf57	-0.63	-13.05	-0.52	2.23e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15369054	chr17:80825471	TBCD	0.36	6.98	0.31	1.04e-11	Breast cancer;
LGG	cis	rs9462027	0.606	rs205258	chr6:34564243	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.55	-0.44	1.84e-23	Systemic lupus erythematosus;
LGG	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg27661571	chr11:113659931	NA	-0.68	-9.26	-0.4	7.53e-19	Hip circumference adjusted for BMI;
LGG	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg00599393	chr8:22457479	C8orf58	-0.47	-8.61	-0.37	1.17e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2303319	1.000	rs1559629	chr2:162270728	C/T	cg13806767	chr2:162164127	PSMD14	-0.68	-7.82	-0.34	3.48e-14	Cognitive function;
LGG	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12195424	0.730	rs77253530	chr6:56303095	G/T	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs13040088	1.000	rs2295000	chr20:61536938	A/G	cg23096297	chr20:61557774	DIDO1	-0.89	-12.56	-0.5	2.41e-31	Menopause (age at onset);
LGG	cis	rs7928758	1.000	rs58475265	chr11:134264142	T/C	cg15243474	chr11:134282918	B3GAT1	0.99	14.02	0.55	1.88e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.74	-0.38	4.18e-17	HDL cholesterol;
LGG	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03401266	chr3:192445594	FGF12	0.41	6.9	0.31	1.71e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg11161011	chr14:65562177	MAX	0.62	11.66	0.48	1.04e-27	Obesity-related traits;
LGG	cis	rs6800768	0.658	rs10865795	chr3:24101342	T/C	cg10674438	chr3:24145617	LOC152024	-0.32	-6.72	-0.3	5.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2239547	0.618	rs4687658	chr3:52860366	C/G	cg11645453	chr3:52864694	ITIH4	0.72	11.24	0.46	4.56e-26	Schizophrenia;
LGG	trans	rs7181230	0.885	rs2412478	chr15:40361172	C/T	cg22705835	chr10:65332833	REEP3	-0.61	-10.12	-0.43	7.2e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs698813	0.604	rs11676798	chr2:44479982	G/C	cg00619915	chr2:44497795	NA	-0.6	-8.92	-0.38	1.12e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14240646	chr10:27532245	ACBD5	-0.73	-10.36	-0.43	9.22e-23	Breast cancer;
LGG	cis	rs593982	0.925	rs603509	chr11:65507605	C/T	cg08755490	chr11:65554678	OVOL1	-0.71	-11.52	-0.47	3.5e-27	Atopic dermatitis;
LGG	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.66	0.44	7.09e-24	Diabetic retinopathy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24647403	chr3:97483221	ARL6	0.38	6.72	0.3	5.22e-11	Obesity-related traits;
LGG	trans	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	8.29	0.36	1.23e-15	Mean corpuscular volume;
LGG	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.74	14.67	0.56	2.82e-40	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7508	0.653	rs6586683	chr8:17920623	C/T	cg18067069	chr8:17937731	ASAH1	0.37	8.46	0.37	3.59e-16	Atrial fibrillation;
LGG	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.7	0.3	6.11e-11	Bronchopulmonary dysplasia;
LGG	cis	rs9362426	0.524	rs16879281	chr6:88126423	G/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.96	-14.65	-0.56	3.48e-40	Depressive episodes in bipolar disorder;
LGG	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg26384229	chr12:38710491	ALG10B	0.93	20.98	0.7	3.43e-69	Bladder cancer;
LGG	trans	rs10853191	0.558	rs12455435	chr18:10848797	A/G	cg11727592	chr13:46916922	C13orf18	0.3	6.67	0.3	7.15e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs6456156	0.586	rs6456150	chr6:167468922	A/G	cg07741184	chr6:167504864	NA	0.4	9.23	0.39	9.38e-19	Primary biliary cholangitis;
LGG	cis	rs2290402	1.000	rs2290402	chr4:941518	C/T	cg09237302	chr4:906077	GAK	-0.44	-7.16	-0.32	3.11e-12	Type 2 diabetes;
LGG	trans	rs7404843	1.000	rs7404843	chr16:15530708	T/G	cg02716450	chr16:28638775	NA	-0.68	-7.06	-0.31	5.95e-12	Testicular germ cell tumor;
LGG	cis	rs1699337	0.538	rs66615477	chr3:12298314	G/T	cg22839075	chr3:12045461	SYN2	-0.39	-6.65	-0.3	8.08e-11	Cholesterol, total;
LGG	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.16e-21	Prudent dietary pattern;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg24846343	chr22:24311635	DDTL	0.57	10.86	0.45	1.21e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg02004499	chr7:4244250	SDK1	0.64	11.99	0.49	4.89e-29	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LGG	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.25	-0.32	1.78e-12	Alzheimer's disease (late onset);
LGG	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.05	0.52	2.31e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg11494091	chr17:61959527	GH2	1.04	26.57	0.78	3.78e-95	Prudent dietary pattern;
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.51	-8.61	-0.37	1.15e-16	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg11871910	chr12:69753446	YEATS4	0.69	8.23	0.36	1.98e-15	Response to diuretic therapy;
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.26	-0.32	1.63e-12	Neuroticism;
LGG	cis	rs6763768	0.600	rs11705809	chr3:53363940	T/C	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-9.89	-0.42	4.85e-21	Vitiligo;
LGG	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg27129171	chr3:47204927	SETD2	0.78	14.8	0.57	7.26e-41	Colorectal cancer;
LGG	cis	rs427394	0.632	rs169285	chr5:6736587	G/C	cg15145174	chr5:6755386	POLS	-0.44	-8.06	-0.35	6.51e-15	Menopause (age at onset);
LGG	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22605943	chr3:107243790	BBX	0.56	8.73	0.38	4.62e-17	Gut microbiome composition (summer);
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-14.55	-0.56	9.25e-40	Platelet count;
LGG	cis	rs10895140	0.756	rs2186577	chr11:101508379	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs6725041	0.547	rs1394784	chr2:213209325	G/A	cg20637307	chr2:213403960	ERBB4	-0.45	-8.65	-0.37	8.7e-17	QT interval (ambient particulate matter interaction);
LGG	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.18	-0.36	2.8e-15	HDL cholesterol;
LGG	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-7.5	-0.33	3.29e-13	Alzheimer's disease (late onset);
LGG	cis	rs12586317	0.557	rs4488360	chr14:35656211	G/C	cg05294307	chr14:35346193	BAZ1A	-0.37	-6.95	-0.31	1.21e-11	Psoriasis;
LGG	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg17294928	chr15:75287854	SCAMP5	-0.83	-11.12	-0.46	1.26e-25	Blood trace element (Zn levels);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15163974	chr1:165797511	UCK2	0.49	7.27	0.32	1.51e-12	Gut microbiome composition (summer);
LGG	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg21055462	chr7:100276975	NA	0.35	6.72	0.3	5.25e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8077889	0.871	rs8065043	chr17:41900984	G/A	cg26893861	chr17:41843967	DUSP3	0.9	15.65	0.59	1.3e-44	Triglycerides;
LGG	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03576123	chr11:487126	PTDSS2	-1.19	-15.15	-0.58	2.15e-42	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13808561	chr11:43333782	API5	0.5	7.27	0.32	1.52e-12	Gut microbiome composition (summer);
LGG	cis	rs2587949	0.571	rs2629250	chr3:4239394	A/G	cg16519197	chr3:4211558	NA	-0.35	-7.07	-0.31	5.88e-12	Periodontitis (DPAL);
LGG	cis	rs9815354	1.000	rs79548696	chr3:41803385	C/T	cg03022575	chr3:42003672	ULK4	0.59	7.64	0.33	1.28e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg07615347	chr10:60278583	BICC1	0.61	17.3	0.63	4.51e-52	Refractive error;
LGG	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg03213289	chr20:61660250	NA	0.63	12.8	0.51	2.58e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6754459	0.666	rs11674266	chr2:3705291	A/G	cg20493526	chr2:3714936	ALLC	0.33	6.85	0.3	2.32e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs8048589	0.515	rs4780412	chr16:12232409	A/G	cg02910054	chr16:12241554	SNX29	0.68	10.99	0.45	4.02e-25	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg22601191	chr20:60968625	CABLES2	0.45	8.63	0.37	1e-16	Colorectal cancer;
LGG	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg24558204	chr6:135376177	HBS1L	0.6	10.35	0.43	9.82e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg05444541	chr17:17804740	TOM1L2	-0.6	-13.28	-0.53	2.52e-34	Total body bone mineral density;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg07414643	chr4:187882934	NA	-0.56	-11.45	-0.47	6.56e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg24642844	chr7:1081250	C7orf50	-0.74	-12.37	-0.5	1.39e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7647973	1.000	rs3866330	chr3:49582994	T/C	cg07636037	chr3:49044803	WDR6	0.79	14.14	0.55	5.32e-38	Menarche (age at onset);
LGG	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg02836325	chr17:76403955	PGS1	0.7	13.7	0.54	4.19e-36	HDL cholesterol levels;
LGG	cis	rs36051895	0.664	rs3780371	chr9:5095191	T/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.02	-0.57	7.74e-42	Pediatric autoimmune diseases;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg19077165	chr18:44547161	KATNAL2	-0.59	-10.93	-0.45	6.58e-25	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12045676	chr19:18794818	CRTC1	0.5	7.47	0.33	4.02e-13	Gut microbiome composition (summer);
LGG	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg03476357	chr21:30257390	N6AMT1	-0.55	-8.42	-0.36	4.61e-16	Cognitive test performance;
LGG	cis	rs6976053	0.846	rs3931823	chr7:100500781	A/G	cg03098644	chr7:100410630	EPHB4	-0.41	-7.43	-0.33	5.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg01620082	chr3:125678407	NA	0.61	7.51	0.33	2.98e-13	Depression;
LGG	cis	rs10979	0.965	rs9403508	chr6:143887857	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.07e-31	Hypospadias;
LGG	cis	rs4689642	0.709	rs4689090	chr4:7226751	G/T	cg21353189	chr4:7228343	SORCS2	0.38	8.98	0.39	6.98e-18	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg05793240	chr7:2802953	GNA12	-0.35	-7.94	-0.35	1.59e-14	Height;
LGG	cis	rs701145	0.585	rs1727953	chr3:153871392	G/T	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg05692746	chr2:100937584	LONRF2	-0.61	-11.0	-0.46	3.61e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.36	0.81	9.16e-108	Chronic sinus infection;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21894883	chr8:126010778	SQLE	0.46	6.72	0.3	5.46e-11	Hip circumference;
LGG	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.72	0.34	7.11e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.26	-0.32	1.64e-12	Joint mobility (Beighton score);
LGG	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg24623649	chr8:11872141	NA	-0.3	-7.1	-0.31	4.6e-12	Systolic blood pressure;
LGG	cis	rs9596863	0.898	rs13378524	chr13:54372390	G/A	ch.13.53330881F	chr13:54432880	NA	0.52	7.09	0.31	5.18e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27297192	chr10:134578999	INPP5A	0.29	6.93	0.31	1.39e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg02811702	chr13:24901961	NA	0.4	7.48	0.33	3.76e-13	Obesity-related traits;
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.26	-0.46	3.64e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs457717	0.730	rs462587	chr5:75944276	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.3	-6.72	-0.3	5.45e-11	Hearing impairment;
LGG	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg01620082	chr3:125678407	NA	-0.89	-7.86	-0.34	2.63e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1538970	1.000	rs9326141	chr1:45828943	A/G	cg05343316	chr1:45956843	TESK2	-0.65	-10.96	-0.45	5.42e-25	Platelet count;
LGG	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.91	0.38	1.2e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs36051895	0.623	rs10975024	chr9:5246403	A/T	cg02405213	chr9:5042618	JAK2	-0.7	-12.68	-0.51	7.88e-32	Pediatric autoimmune diseases;
LGG	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg13147721	chr7:65941812	NA	-0.79	-9.58	-0.41	5.9e-20	Diabetic kidney disease;
LGG	cis	rs10773046	0.740	rs9669530	chr12:124369811	C/A	cg18594669	chr12:124364423	DNAH10	0.34	6.87	0.3	2.07e-11	Osteoarthritis (hip);
LGG	cis	rs2239547	0.522	rs2710345	chr3:52976075	T/C	cg11645453	chr3:52864694	ITIH4	-0.67	-10.33	-0.43	1.17e-22	Schizophrenia;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg27532560	chr4:187881888	NA	-0.59	-12.78	-0.51	3e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4950322	0.563	rs11809328	chr1:146578263	A/G	cg22381352	chr1:146742008	CHD1L	-0.42	-7.24	-0.32	1.82e-12	Protein quantitative trait loci;
LGG	cis	rs9487051	0.676	rs6910119	chr6:109599263	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.31e-14	Reticulocyte fraction of red cells;
LGG	cis	rs8141529	0.509	rs5762853	chr22:29245231	T/G	cg15103426	chr22:29168792	CCDC117	0.66	9.74	0.41	1.67e-20	Lymphocyte counts;
LGG	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg18854424	chr1:2615690	NA	0.34	7.5	0.33	3.32e-13	Ulcerative colitis;
LGG	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06873352	chr17:61820015	STRADA	0.46	7.33	0.32	1.06e-12	Height;
LGG	cis	rs1707322	1.000	rs6687301	chr1:46382852	T/C	cg03146154	chr1:46216737	IPP	0.54	10.11	0.43	7.71e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12249377	0.519	rs35987367	chr10:92591992	C/T	cg14313238	chr10:92632228	RPP30	0.4	7.05	0.31	6.64e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs1719271	0.831	rs1719270	chr15:65183184	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.24	-0.32	1.93e-12	Platelet count;
LGG	cis	rs72949976	0.646	rs11681232	chr2:214033002	G/A	cg08319019	chr2:214017104	IKZF2	0.65	12.21	0.49	6.65e-30	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs9660992	0.736	rs1668868	chr1:205240141	G/T	cg21545522	chr1:205238299	TMCC2	0.44	8.29	0.36	1.24e-15	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg08885076	chr2:99613938	TSGA10	0.35	7.35	0.32	8.97e-13	Chronic sinus infection;
LGG	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg00334542	chr7:100209784	MOSPD3	-0.52	-7.32	-0.32	1.11e-12	Other erythrocyte phenotypes;
LGG	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg13010199	chr12:38710504	ALG10B	0.62	13.05	0.52	2.29e-33	Bladder cancer;
LGG	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.94	-0.78	7.39e-97	Height;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06028808	chr11:68637592	NA	0.68	11.97	0.49	6.01e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.41	-0.44	6.29e-23	Hemoglobin concentration;
LGG	cis	rs4911253	0.527	rs853859	chr20:31402269	A/G	cg13636640	chr20:31349939	DNMT3B	0.62	11.6	0.47	1.68e-27	Lymphocyte counts;
LGG	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg02002194	chr4:3960332	NA	-0.37	-6.86	-0.3	2.16e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg13010199	chr12:38710504	ALG10B	0.52	10.15	0.43	5.35e-22	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.03	-0.31	7.57e-12	Bipolar disorder;
LGG	cis	rs4073221	0.520	rs66659472	chr3:18196527	G/A	cg07694806	chr3:18168406	NA	-0.61	-7.66	-0.34	1.09e-13	Parkinson's disease;
LGG	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.38	-0.32	7.32e-13	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg16301924	chr13:53314226	LECT1	-0.47	-9.15	-0.39	1.82e-18	Lewy body disease;
LGG	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg20308403	chr7:2120281	MAD1L1	0.36	7.66	0.34	1.06e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2668423	0.501	rs502121	chr19:1387299	T/C	cg02639931	chr19:1387894	NDUFS7	-0.99	-22.9	-0.73	3.59e-78	Nonalcoholic fatty liver disease;
LGG	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.47	0.44	3.5e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4973397	0.643	rs2034413	chr2:232288149	C/T	cg13347044	chr2:232276743	NA	0.34	6.84	0.3	2.57e-11	Anti-saccade response;
LGG	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg25801113	chr15:45476975	SHF	-0.88	-18.85	-0.66	3e-59	Uric acid levels;
LGG	trans	rs9409565	0.821	rs9299419	chr9:97066584	C/T	cg05679027	chr9:99775184	HIATL2	0.51	8.48	0.37	2.97e-16	Colorectal cancer (alcohol consumption interaction);
LGG	trans	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	cis	rs9581857	0.685	rs9319370	chr13:28042493	G/T	cg01674679	chr13:27998804	GTF3A	-0.68	-7.92	-0.35	1.73e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg07460842	chr6:66804631	NA	-0.57	-9.7	-0.41	2.25e-20	Metabolite levels;
LGG	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg01206211	chr2:36825736	FEZ2	0.4	7.71	0.34	8.01e-14	Height;
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg22044901	chr15:68126292	NA	-0.43	-7.3	-0.32	1.25e-12	Obesity;
LGG	cis	rs929596	0.755	rs4148325	chr2:234673309	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-13.5	-0.53	3.02e-35	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06470251	chr20:60548479	NA	0.47	7.8	0.34	4.18e-14	Body mass index;
LGG	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	8.1	0.35	4.79e-15	Menarche (age at onset);
LGG	cis	rs3818285	0.655	rs623980	chr10:111646147	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.49	-10.1	-0.42	8.27e-22	Superior crus of antihelix expression;
LGG	cis	rs6686643	0.868	rs9333471	chr1:165619712	A/G	cg19407955	chr1:165599744	MGST3	-0.53	-7.95	-0.35	1.41e-14	Total ventricular volume;
LGG	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg04455712	chr21:45112962	RRP1B	0.52	10.04	0.42	1.32e-21	Mean corpuscular volume;
LGG	cis	rs6540556	0.859	rs12079960	chr1:209937168	A/C	cg23920097	chr1:209922102	NA	-0.42	-7.59	-0.33	1.76e-13	Red blood cell count;
LGG	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.7	-0.37	6.03e-17	Neuroticism;
LGG	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg13009111	chr11:71350975	NA	0.35	7.7	0.34	8.43e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.2	-0.32	2.38e-12	Coronary artery disease;
LGG	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg13902645	chr11:5959945	NA	-0.73	-11.31	-0.47	2.39e-26	DNA methylation (variation);
LGG	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg05623727	chr3:50126028	RBM5	-0.4	-8.72	-0.38	4.88e-17	Body mass index;
LGG	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg07002422	chr16:996172	LMF1	-0.5	-9.66	-0.41	3.15e-20	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg20503657	chr10:835505	NA	0.75	10.52	0.44	2.43e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs6764363	0.654	rs408741	chr3:297900	A/C	cg02057681	chr3:285234	CHL1	0.38	6.9	0.31	1.74e-11	Sudden cardiac arrest;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.28	-0.32	1.43e-12	Menopause (age at onset);
LGG	cis	rs804280	0.565	rs2645453	chr8:11622001	G/A	cg12395012	chr8:11607386	GATA4	-0.59	-11.21	-0.46	5.75e-26	Myopia (pathological);
LGG	cis	rs10850519	0.751	rs34228916	chr12:115942842	C/G	cg18639984	chr12:115943877	NA	-0.42	-9.02	-0.39	4.98e-18	Diastolic blood pressure;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg06221963	chr1:154839813	KCNN3	-0.5	-10.0	-0.42	1.89e-21	Prostate cancer;
LGG	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg17294928	chr15:75287854	SCAMP5	0.57	10.3	0.43	1.59e-22	Breast cancer;
LGG	cis	rs7894051	0.717	rs4838741	chr10:135206873	C/T	cg05676341	chr10:135206831	MTG1	0.74	8.6	0.37	1.23e-16	Lifespan;
LGG	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.26	-0.32	1.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg06221963	chr1:154839813	KCNN3	-0.4	-7.75	-0.34	5.93e-14	Prostate cancer;
LGG	cis	rs1878931	0.520	rs12447807	chr16:3413896	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	22.24	0.72	4.34e-75	Body mass index (adult);
LGG	cis	rs2230307	0.536	rs684519	chr1:100604715	T/G	cg24955406	chr1:100503596	HIAT1	-0.58	-7.97	-0.35	1.22e-14	Carotid intima media thickness;
LGG	cis	rs11630290	0.649	rs1036910	chr15:64157015	T/C	cg12036633	chr15:63758958	NA	0.49	6.94	0.31	1.36e-11	Iris characteristics;
LGG	cis	rs4742903	0.935	rs1507509	chr9:106984902	A/T	cg14250997	chr9:106856677	SMC2	0.4	8.31	0.36	1.05e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg05096777	chr10:104283225	SUFU	0.32	6.86	0.3	2.27e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg07460842	chr6:66804631	NA	0.49	8.5	0.37	2.58e-16	Blood trace element (Cu levels);
LGG	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.79	-0.45	2.24e-24	Migraine;Coronary artery disease;
LGG	cis	rs283228	0.798	rs2152991	chr6:101776490	T/G	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-9.54	-0.41	8.01e-20	Prostate cancer;
LGG	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.94	-0.35	1.58e-14	Hemoglobin concentration;
LGG	trans	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.48e-28	Corneal astigmatism;
LGG	cis	rs883565	0.528	rs35946914	chr3:38992107	A/G	cg01426195	chr3:39028469	NA	-0.56	-11.79	-0.48	2.97e-28	Handedness;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.64	0.63	1.18e-53	Platelet count;
LGG	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg08498830	chr11:832797	CD151	-0.44	-7.15	-0.32	3.43e-12	Mean platelet volume;
LGG	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg02023728	chr11:77925099	USP35	0.45	7.85	0.34	3.01e-14	Testicular germ cell tumor;
LGG	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.23	0.46	4.82e-26	Hemoglobin concentration;
LGG	cis	rs7781557	0.640	rs6964296	chr7:102572942	C/T	cg18108683	chr7:102477205	FBXL13	-0.5	-7.66	-0.34	1.12e-13	Colorectal adenoma (advanced);
LGG	cis	rs4262150	0.726	rs6895969	chr5:152015208	G/A	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs1256061	0.624	rs1152578	chr14:64697037	T/C	cg23250157	chr14:64679961	SYNE2	0.39	7.01	0.31	8.36e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs7124681	0.565	rs2203712	chr11:47534964	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.24	0.46	4.2e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.6e-35	Resting heart rate;
LGG	cis	rs4731207	0.570	rs7784614	chr7:124677191	C/G	cg05630886	chr7:124431682	NA	-0.31	-7.11	-0.31	4.45e-12	Cutaneous malignant melanoma;
LGG	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg21775007	chr8:11205619	TDH	-0.5	-7.66	-0.34	1.12e-13	Neuroticism;
LGG	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.62	-0.63	1.48e-53	Refractive error;
LGG	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg25237894	chr2:233734115	C2orf82	-0.6	-11.36	-0.47	1.53e-26	Coronary artery disease;
LGG	cis	rs16944613	0.588	rs8024734	chr15:91107067	T/C	cg22089800	chr15:90895588	ZNF774	-0.59	-7.33	-0.32	1e-12	Colorectal cancer;
LGG	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg21053147	chr12:120880522	NA	-0.53	-8.12	-0.35	4.14e-15	Type 1 diabetes nephropathy;
LGG	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg06102954	chr21:42741788	MX2	0.4	7.51	0.33	3e-13	Melanoma;
LGG	cis	rs7914558	0.966	rs10883817	chr10:104755431	C/T	cg04362960	chr10:104952993	NT5C2	0.52	9.84	0.42	6.99e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.14	-0.35	3.78e-15	Restless legs syndrome;
LGG	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17221829	0.764	rs12146462	chr11:89385374	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	8.37	0.36	6.86e-16	Lung cancer in ever smokers;
LGG	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg02487422	chr3:49467188	NICN1	0.45	7.27	0.32	1.55e-12	Resting heart rate;
LGG	cis	rs9309473	0.528	rs11126396	chr2:73565143	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-7.7	-0.34	8.28e-14	Metabolite levels;
LGG	trans	rs11875185	0.510	rs77783725	chr18:55635436	A/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11225247	1.000	rs115349957	chr11:102271809	C/G	cg06323957	chr11:102217781	BIRC2	0.79	6.81	0.3	3.09e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2413583	0.591	rs114556035	chr22:39734647	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.63	0.33	1.36e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-23.48	-0.74	7.17e-81	Blood trace element (Zn levels);
LGG	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg10057126	chr4:77819792	ANKRD56	0.36	6.95	0.31	1.26e-11	Emphysema distribution in smoking;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs9287719	0.935	rs6751075	chr2:10723546	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg14664628	chr15:75095509	CSK	0.61	10.12	0.43	7.09e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs55871839	0.684	rs6988143	chr8:59810572	C/T	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg02073558	chr3:44770973	ZNF501	0.85	18.96	0.66	9.6e-60	Depressive symptoms;
LGG	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.27e-12	Diabetic retinopathy;
LGG	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.52	-0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg17644776	chr2:200775616	C2orf69	-0.44	-7.29	-0.32	1.35e-12	QT interval;
LGG	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg18089426	chr14:101175970	NA	0.68	11.33	0.47	1.9e-26	Plateletcrit;
LGG	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg07701084	chr6:150067640	NUP43	0.62	11.64	0.48	1.17e-27	Lung cancer;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07659893	chr17:61819838	STRADA	0.48	8.12	0.35	4.19e-15	Prudent dietary pattern;
LGG	cis	rs13108043	0.605	rs62305658	chr4:87876408	T/C	cg11209507	chr4:87813803	C4orf36	0.61	8.07	0.35	5.99e-15	Red blood cell count;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg19507638	chr5:93509721	C5orf36	-0.7	-9.56	-0.41	6.84e-20	Diabetic retinopathy;
LGG	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg04691961	chr3:161091175	C3orf57	-0.49	-9.93	-0.42	3.39e-21	Parkinson's disease;
LGG	cis	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg21775007	chr8:11205619	TDH	-0.48	-7.33	-0.32	1.04e-12	Neuroticism;
LGG	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg00188032	chr5:96141721	ERAP1	0.54	7.12	0.31	4.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs35176054	0.730	rs7906955	chr10:105518544	G/A	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.79	-0.3	3.43e-11	Atrial fibrillation;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg16141378	chr3:129829833	LOC729375	0.45	10.57	0.44	1.53e-23	Triglycerides;
LGG	cis	rs1707322	0.717	rs1547925	chr1:46085356	C/T	cg03146154	chr1:46216737	IPP	-0.57	-11.01	-0.46	3.3e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg17885191	chr8:135476712	NA	0.43	6.88	0.3	1.96e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.21	0.49	6.14e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.5e-11	Myopia (pathological);
LGG	cis	rs11971779	0.680	rs6962637	chr7:139051350	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	trans	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.7	-0.3	6.11e-11	Mood instability;
LGG	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg10057126	chr4:77819792	ANKRD56	0.36	6.95	0.31	1.26e-11	Emphysema distribution in smoking;
LGG	cis	rs8014204	0.762	rs12891131	chr14:75240090	A/G	cg06637938	chr14:75390232	RPS6KL1	0.64	11.59	0.47	1.86e-27	Caffeine consumption;
LGG	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg15128208	chr22:42549153	NA	0.79	12.59	0.51	1.77e-31	Birth weight;
LGG	cis	rs2463822	1.000	rs2513052	chr11:62108248	C/G	cg06239285	chr11:62104954	ASRGL1	1.13	15.8	0.59	2.76e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs11023332	0.706	rs10766197	chr11:14921880	G/A	cg18937875	chr11:14930189	NA	-0.56	-9.54	-0.41	8.43e-20	Adiponectin levels;Vitamin D levels;
LGG	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg03162506	chr22:38580953	NA	0.39	9.37	0.4	3.24e-19	Breast cancer;
LGG	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-10.96	-0.45	5.02e-25	Mean platelet volume;
LGG	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg27129171	chr3:47204927	SETD2	0.48	7.71	0.34	7.98e-14	Birth weight;
LGG	cis	rs757081	0.636	rs214934	chr11:17193475	T/A	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.68	-0.37	6.91e-17	Systolic blood pressure;
LGG	cis	rs4330281	0.935	rs6577593	chr3:17829430	G/A	cg20981856	chr3:17787350	NA	-0.36	-6.65	-0.3	8.29e-11	Schizophrenia;
LGG	cis	rs1506636	0.646	rs805789	chr7:123221920	G/T	cg03229431	chr7:123269106	ASB15	-0.55	-12.19	-0.49	7.73e-30	Plateletcrit;Platelet count;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05165339	chr4:1420672	NA	-0.36	-9.12	-0.39	2.27e-18	Longevity;
LGG	cis	rs7215564	0.730	rs76008137	chr17:78586213	G/C	cg16980736	chr17:78789706	RPTOR	-0.64	-8.35	-0.36	8.17e-16	Myopia (pathological);
LGG	cis	rs972578	0.791	rs2092210	chr22:43318700	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.72	-0.3	5.38e-11	Mean platelet volume;
LGG	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg02269571	chr22:50332266	NA	-0.65	-9.73	-0.41	1.76e-20	Schizophrenia;
LGG	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg09873164	chr1:152488093	CRCT1	0.63	15.41	0.58	1.48e-43	Hair morphology;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg13206674	chr6:150067644	NUP43	0.66	14.78	0.57	9.31e-41	Lung cancer;
LGG	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.54	0.44	1.97e-23	Ulcerative colitis;
LGG	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.6	-7.28	-0.32	1.46e-12	Body mass index;
LGG	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg00990874	chr7:1149470	C7orf50	-0.82	-14.53	-0.56	1.07e-39	Bronchopulmonary dysplasia;
LGG	cis	rs7590368	0.961	rs13432104	chr2:10960661	T/C	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg04234412	chr22:24373322	LOC391322	-0.77	-16.49	-0.61	2.16e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg25801113	chr15:45476975	SHF	-0.87	-18.73	-0.66	1.07e-58	Uric acid levels;
LGG	cis	rs2236918	1.000	rs1635509	chr1:242028027	C/T	cg17736920	chr1:242011382	EXO1	0.51	9.27	0.4	7e-19	Menopause (age at onset);
LGG	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-15.71	-0.59	6.62e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.13	-0.31	3.97e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg01191920	chr7:158217561	PTPRN2	-0.77	-17.05	-0.62	6.02e-51	Obesity-related traits;
LGG	cis	rs4959677	0.698	rs9501849	chr6:2479770	A/G	cg23817096	chr6:1620687	NA	-0.34	-8.21	-0.36	2.24e-15	Orthostatic hypotension;
LGG	cis	rs7949566	0.665	rs4937124	chr11:126278563	A/G	cg05055844	chr11:126275997	ST3GAL4	0.4	8.41	0.36	5.19e-16	Platelet distribution width;Mean platelet volume;
LGG	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg17788362	chr6:86352627	SYNCRIP	0.55	9.74	0.41	1.65e-20	Smooth-surface caries;
LGG	cis	rs2798269	0.902	rs10492455	chr13:22102976	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.01	-0.31	8.52e-12	PR segment;
LGG	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.22	0.52	4.57e-34	Psoriasis;
LGG	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04743933	chr7:129844923	TMEM209	0.47	8.01	0.35	9.67e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2120243	0.539	rs1840668	chr3:157098721	T/C	cg24825693	chr3:157122686	VEPH1	-0.57	-13.24	-0.52	3.68e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs35740288	0.731	rs11638407	chr15:86094655	A/C	cg04173714	chr15:86211321	AKAP13	0.47	8.41	0.36	5.01e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7168592	1.000	rs35050682	chr15:101737021	G/C	cg24254196	chr15:101719523	CHSY1	-0.64	-7.04	-0.31	6.9e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg07460842	chr6:66804631	NA	0.94	17.08	0.62	4.24e-51	Exhaled nitric oxide levels;
LGG	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.46	0.53	4.28e-35	Colorectal cancer;
LGG	cis	rs858239	0.670	rs3807452	chr7:23162081	C/T	cg23682824	chr7:23144976	KLHL7	-0.41	-7.01	-0.31	8.5e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg13699009	chr12:122356056	WDR66	0.55	14.76	0.57	1.1e-40	Mean corpuscular volume;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.39	0.32	7.07e-13	Tonsillectomy;
LGG	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg18357645	chr12:58087776	OS9	0.4	6.91	0.31	1.56e-11	Multiple sclerosis;
LGG	cis	rs9834373	0.811	rs9837213	chr3:78481884	A/G	cg06138941	chr3:78371609	NA	-0.52	-9.24	-0.39	9.07e-19	Protein quantitative trait loci;
LGG	cis	rs34599045	0.522	rs35036485	chr1:152983644	A/G	cg07796016	chr1:152779584	LCE1C	-0.88	-7.47	-0.33	4.1e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1420338	0.867	rs7795950	chr7:34161715	A/G	cg01275685	chr7:34179230	BMPER	-0.49	-8.84	-0.38	2.08e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	trans	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg00938859	chr5:1591904	SDHAP3	0.9	12.33	0.5	2.01e-30	Breast cancer;
LGG	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg24692254	chr21:30365293	RNF160	-0.88	-20.2	-0.68	1.63e-65	Dental caries;
LGG	cis	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg07460842	chr6:66804631	NA	-1.14	-31.77	-0.83	2.22e-118	Exhaled nitric oxide output;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg07414643	chr4:187882934	NA	0.57	11.78	0.48	3.35e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17641971	0.899	rs341804	chr8:49991553	G/C	cg16454426	chr8:49984564	C8orf22	-0.33	-6.65	-0.3	8.04e-11	Blood metabolite levels;
LGG	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.11	-0.43	7.3e-22	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.67	-0.56	2.72e-40	Blood metabolite levels;
LGG	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg20336341	chr7:50628841	DDC	0.39	7.53	0.33	2.67e-13	Malaria;
LGG	cis	rs953387	0.910	rs16833335	chr2:136949744	C/T	cg07169764	chr2:136633963	MCM6	0.53	8.71	0.38	5.3e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg26516362	chr5:178986906	RUFY1	0.39	6.65	0.3	8.36e-11	Lung cancer;
LGG	cis	rs9287719	0.901	rs10210859	chr2:10733929	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs2916247	1.000	rs2920470	chr8:92977484	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.25	-0.36	1.72e-15	Intelligence (multi-trait analysis);
LGG	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.92	-0.31	1.52e-11	Myopia (pathological);
LGG	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.66	-0.34	1.11e-13	Height;
LGG	cis	rs77633900	0.614	rs2468116	chr15:76870998	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-10.41	-0.44	6.28e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg07701084	chr6:150067640	NUP43	0.48	7.39	0.32	7.07e-13	Lung cancer;
LGG	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs4716602	0.548	rs34245976	chr7:156160897	T/G	cg16983916	chr7:156159713	NA	-0.49	-9.51	-0.4	1e-19	Anti-saccade response;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg04503457	chr17:41445688	NA	-0.38	-9.29	-0.4	5.82e-19	Menopause (age at onset);
LGG	cis	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg12486710	chr1:178512616	C1orf220	0.42	8.39	0.36	5.9e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg06521331	chr12:34319734	NA	-0.41	-7.4	-0.33	6.63e-13	Morning vs. evening chronotype;
LGG	trans	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg26043149	chr18:55253948	FECH	-0.41	-6.75	-0.3	4.31e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7173743	0.730	rs6495340	chr15:79128396	A/G	cg00540400	chr15:79124168	NA	0.42	8.62	0.37	1.03e-16	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07600871	chr18:35146474	BRUNOL4	0.48	7.34	0.32	9.91e-13	Gut microbiome composition (summer);
LGG	cis	rs854037	0.759	rs56029970	chr5:57093259	T/C	cg08523694	chr5:57076192	NA	0.57	7.12	0.31	4.02e-12	Birth weight;
LGG	trans	rs17685	0.712	rs10952842	chr7:75780413	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	24.81	0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6120849	0.663	rs6119548	chr20:33552612	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.87	0.3	2.02e-11	Protein C levels;
LGG	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.51	-0.33	3.01e-13	IgG glycosylation;
LGG	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg27490568	chr2:178487706	NA	0.52	10.19	0.43	3.75e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21862992	chr11:68658383	NA	0.5	8.13	0.35	3.96e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg09307838	chr4:120376055	NA	0.79	12.84	0.51	1.77e-32	Corneal astigmatism;
LGG	cis	rs703842	1.000	rs3782130	chr12:58161898	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	8.1	0.35	4.84e-15	Multiple sclerosis;
LGG	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg08250081	chr4:10125330	NA	0.37	7.03	0.31	7.67e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6840360	0.642	rs2709817	chr4:152382050	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.6	-0.37	1.21e-16	Aortic root size;
LGG	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg09137382	chr11:130731461	NA	0.35	6.77	0.3	3.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg22916017	chr11:64110731	CCDC88B	0.54	11.48	0.47	4.98e-27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs3106136	0.900	rs13142645	chr4:95208714	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.34	-0.36	8.61e-16	Capecitabine sensitivity;
LGG	cis	rs926938	0.527	rs7526844	chr1:115543759	T/C	cg12756093	chr1:115239321	AMPD1	0.41	7.86	0.34	2.81e-14	Autism;
LGG	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg22980697	chr10:16874865	CUBN	0.58	9.29	0.4	5.99e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6445975	0.667	rs4681672	chr3:58230436	C/T	cg24175188	chr3:58374923	PXK	0.39	7.29	0.32	1.33e-12	Systemic lupus erythematosus;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg25270632	chr7:43751042	C7orf44	-0.58	-6.83	-0.3	2.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-11.29	-0.46	2.85e-26	Bronchopulmonary dysplasia;
LGG	cis	rs9660992	0.762	rs1172129	chr1:205244972	T/A	cg21545522	chr1:205238299	TMCC2	0.43	7.89	0.34	2.27e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9807989	0.507	rs4851004	chr2:103009537	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.54	-0.41	8.04e-20	Asthma;
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg17202724	chr17:61916730	SMARCD2	0.45	8.88	0.38	1.47e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg26513180	chr16:89883248	FANCA	-0.7	-8.04	-0.35	7.81e-15	Skin colour saturation;
LGG	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.75	-10.34	-0.43	1.08e-22	Blood trace element (Cu levels);
LGG	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg08847533	chr14:75593920	NEK9	0.62	11.94	0.49	7.47e-29	Height;
LGG	cis	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg07460842	chr6:66804631	NA	-0.5	-8.44	-0.37	3.99e-16	Metabolite levels;
LGG	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg25019033	chr10:957182	NA	-0.61	-11.03	-0.46	2.74e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	14.04	0.55	1.54e-37	Total body bone mineral density;
LGG	cis	rs4919044	0.866	rs1475366	chr10:94781857	T/C	cg05127821	chr10:94822908	CYP26C1	-0.46	-7.2	-0.32	2.4e-12	Coronary artery disease;
LGG	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs7567389	0.626	rs11683344	chr2:127956252	A/C	cg11380483	chr2:127933992	NA	0.56	10.17	0.43	4.69e-22	Self-rated health;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.26	-7.75	-0.34	5.86e-14	IgG glycosylation;
LGG	cis	rs6504108	0.602	rs11872095	chr17:46271172	T/G	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.45e-15	Body mass index;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-8.22	-0.36	2.03e-15	Body mass index;
LGG	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.86	-0.38	1.74e-17	Self-reported allergy;
LGG	cis	rs8064024	0.501	rs28375268	chr16:4949528	G/T	cg08329684	chr16:4932620	PPL	-0.48	-9.86	-0.42	5.87e-21	Cancer;
LGG	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-12.97	-0.52	5.04e-33	Body mass index;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg05368731	chr17:41323189	NBR1	0.86	16.5	0.61	1.85e-48	Menopause (age at onset);
LGG	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg13647721	chr17:30228624	UTP6	0.68	7.18	0.32	2.75e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4919044	0.674	rs11187260	chr10:94809187	A/G	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12531328	chr13:31192104	USPL1	0.41	7.39	0.32	6.95e-13	Obesity-related traits;
LGG	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-6.88	-0.3	1.94e-11	Daytime sleep phenotypes;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg02158880	chr13:53174818	NA	0.47	9.74	0.41	1.67e-20	Lewy body disease;
LGG	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg21053147	chr12:120880522	NA	-0.56	-8.75	-0.38	4.07e-17	Type 1 diabetes nephropathy;
LGG	cis	rs2658782	0.789	rs2605574	chr11:93136444	T/G	cg15737290	chr11:93063684	CCDC67	0.49	7.56	0.33	2.19e-13	Pulmonary function decline;
LGG	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg15103426	chr22:29168792	CCDC117	0.62	9.5	0.4	1.09e-19	Lymphocyte counts;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02475777	chr4:1388615	CRIPAK	0.43	7.96	0.35	1.31e-14	Longevity;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.56	11.12	0.46	1.25e-25	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.67	0.44	6.76e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.71	12.92	0.51	8.3e-33	Obesity-related traits;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.84	-0.38	2.06e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06481639	chr22:41940642	POLR3H	-0.61	-8.78	-0.38	3.29e-17	Vitiligo;
LGG	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.18	0.49	8.23e-30	Hip circumference adjusted for BMI;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg22903471	chr2:27725779	GCKR	-0.57	-12.93	-0.51	7.57e-33	Total body bone mineral density;
LGG	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg05444541	chr17:17804740	TOM1L2	0.61	14.52	0.56	1.2e-39	Total body bone mineral density;
LGG	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6692729	0.527	rs2073489	chr1:227063671	T/C	cg08708961	chr1:227070630	PSEN2	-0.29	-7.02	-0.31	8.1e-12	Electrodermal activity;
LGG	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26076054	chr5:421317	AHRR	-0.46	-7.66	-0.34	1.12e-13	Cystic fibrosis severity;
LGG	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg05793240	chr7:2802953	GNA12	0.3	7.4	0.33	6.51e-13	Height;
LGG	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg25319279	chr11:5960081	NA	-0.48	-8.14	-0.35	3.82e-15	DNA methylation (variation);
LGG	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.95	-0.31	1.28e-11	Schizophrenia;
LGG	cis	rs10464366	0.843	rs13242209	chr7:39110241	C/T	cg18850127	chr7:39170497	POU6F2	0.51	11.36	0.47	1.55e-26	IgG glycosylation;
LGG	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.89e-22	Arsenic metabolism;
LGG	cis	rs1408799	0.630	rs7030485	chr9:12761819	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.53	0.37	2.09e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs12775980	0.737	rs74129721	chr10:29847287	A/C	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg08250081	chr4:10125330	NA	0.69	12.43	0.5	8.1e-31	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs8113308	0.810	rs8105110	chr19:52452116	C/T	cg24732339	chr19:52471368	ZNF350	-0.44	-6.78	-0.3	3.57e-11	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LGG	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7568458	0.516	rs62166769	chr2:85812784	T/A	cg23752985	chr2:85803571	VAMP8	0.41	7.49	0.33	3.46e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12545109	0.765	rs2055985	chr8:57410821	T/A	cg19413350	chr8:57351067	NA	-0.43	-6.92	-0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs12615966	1.000	rs17030292	chr2:105383596	C/G	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.15	-0.39	1.84e-18	Bone mineral density;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg01458961	chr4:102269425	PPP3CA	-0.4	-6.9	-0.31	1.66e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg24829409	chr8:58192753	C8orf71	-0.88	-13.53	-0.53	2.31e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.647	rs7548977	chr1:152987365	T/G	cg13444842	chr1:152974279	SPRR3	-0.5	-10.03	-0.42	1.47e-21	Inflammatory skin disease;
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg16606324	chr3:10149918	C3orf24	0.53	6.97	0.31	1.13e-11	Alzheimer's disease;
LGG	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg19507638	chr5:93509721	C5orf36	0.42	6.92	0.31	1.53e-11	Diabetic retinopathy;
LGG	cis	rs72781680	0.898	rs6545127	chr2:24060670	C/T	cg08917208	chr2:24149416	ATAD2B	0.8	9.18	0.39	1.4e-18	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg19143629	chr17:61920732	SMARCD2	0.41	7.14	0.31	3.65e-12	Prudent dietary pattern;
LGG	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg22546130	chr22:19950026	COMT	-0.44	-10.14	-0.43	5.85e-22	Blood metabolite levels;
LGG	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg02297831	chr4:17616191	MED28	0.5	9.48	0.4	1.3e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2735413	0.918	rs1922621	chr16:78075015	A/G	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12667521	chr19:29218732	NA	0.61	9.34	0.4	4.07e-19	Methadone dose in opioid dependence;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg26150922	chr2:100937072	LONRF2	-0.51	-8.13	-0.35	4.09e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.35	-0.32	8.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3735485	0.689	rs10235778	chr7:45050206	A/T	cg03440944	chr7:45023329	C7orf40	0.55	9.52	0.4	9.44e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg25358565	chr5:93447407	FAM172A	1.39	17.14	0.62	2.41e-51	Diabetic retinopathy;
LGG	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg02002194	chr4:3960332	NA	0.38	6.92	0.31	1.5e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7666738	0.830	rs13124127	chr4:98990729	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.88	0.34	2.37e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20859525	chr6:80714300	TTK	0.37	6.68	0.3	6.71e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg12813108	chr7:99719912	CNPY4	-0.63	-10.02	-0.42	1.57e-21	Lung function (FEV1/FVC);
LGG	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.62	-0.33	1.47e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	13.39	0.53	8.74e-35	Total body bone mineral density;
LGG	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg02187348	chr16:89574699	SPG7	0.5	7.54	0.33	2.5e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg05091796	chr16:4465799	CORO7	-0.73	-11.59	-0.47	1.86e-27	Schizophrenia;
LGG	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg03806693	chr22:41940476	POLR3H	1.05	17.73	0.64	4.76e-54	Vitiligo;
LGG	cis	rs16957091	1.000	rs12917018	chr15:43024063	C/T	cg07484255	chr15:43025164	CDAN1	-0.49	-7.03	-0.31	7.33e-12	MGMT methylation in smokers;
LGG	cis	rs3806843	0.838	rs2262567	chr5:140132134	T/A	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	trans	rs2018683	0.600	rs6948880	chr7:29003478	C/T	cg19402173	chr7:128379420	CALU	-0.73	-13.23	-0.52	4.05e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg15269541	chr15:43626905	ADAL	-0.44	-7.5	-0.33	3.2e-13	Lung cancer in ever smokers;
LGG	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg06421707	chr20:25228305	PYGB	0.51	11.0	0.46	3.6e-25	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.34	-0.6	9.86e-48	Height;
LGG	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg02023728	chr11:77925099	USP35	0.47	8.31	0.36	1.03e-15	Testicular germ cell tumor;
LGG	cis	rs9596863	0.851	rs4632022	chr13:54379457	C/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.99	-0.39	6.54e-18	Body mass index;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	16.96	0.62	1.56e-50	Platelet count;
LGG	cis	rs8014204	0.762	rs7144654	chr14:75298637	A/G	cg06637938	chr14:75390232	RPS6KL1	0.65	11.9	0.48	1.15e-28	Caffeine consumption;
LGG	cis	rs2013441	0.866	rs12949485	chr17:20021661	A/G	cg09818912	chr17:20140352	CYTSB	-0.32	-6.99	-0.31	9.34e-12	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg21475434	chr5:93447410	FAM172A	0.67	6.95	0.31	1.29e-11	Diabetic retinopathy;
LGG	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg20493526	chr2:3714936	ALLC	0.47	10.29	0.43	1.69e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.99	-0.49	4.85e-29	Height;
LGG	cis	rs36093844	0.948	rs7128854	chr11:85552167	C/T	cg16165120	chr11:85566439	CCDC83	-0.38	-6.94	-0.31	1.32e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.99	0.71	6.89e-74	Bladder cancer;
LGG	cis	rs2067615	0.579	rs1811458	chr12:107203683	G/A	cg15890332	chr12:107067104	RFX4	0.4	11.69	0.48	7.89e-28	Heart rate;
LGG	cis	rs7216064	0.953	rs8073510	chr17:65839210	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.47	-0.33	3.93e-13	Testicular germ cell tumor;
LGG	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg07395648	chr5:131743802	NA	0.51	10.68	0.44	6.22e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg13482628	chr17:19912719	NA	-0.54	-10.13	-0.43	6.32e-22	Schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25846022	chr1:78444909	FUBP1	0.38	6.69	0.3	6.65e-11	Bilirubin levels;
LGG	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg12219531	chr12:120966889	COQ5	0.63	10.36	0.43	9.27e-23	High light scatter reticulocyte count;
LGG	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg10503236	chr1:231470652	EXOC8	-0.38	-7.33	-0.32	1e-12	Hemoglobin concentration;
LGG	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg24692254	chr21:30365293	RNF160	-0.86	-19.49	-0.67	3.36e-62	Dental caries;
LGG	cis	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.97	-0.49	6.09e-29	Morning vs. evening chronotype;
LGG	cis	rs3857067	1.000	rs3857067	chr4:95026434	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.55	-0.33	2.27e-13	QT interval;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg19223190	chr17:80058835	NA	0.44	8.55	0.37	1.81e-16	Life satisfaction;
LGG	cis	rs1475911	1.000	rs12482477	chr21:43517233	T/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.5	-8.8	-0.38	2.76e-17	IgG glycosylation;
LGG	trans	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.74	-0.41	1.63e-20	Bladder cancer;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg05091796	chr16:4465799	CORO7	-0.98	-16.65	-0.61	3.95e-49	Schizophrenia;
LGG	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg05194412	chr2:137003533	NA	-0.31	-6.67	-0.3	7.26e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs2916247	1.000	rs11990286	chr8:93061406	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7020830	0.861	rs13289001	chr9:37311592	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	35.1	0.85	1.54e-132	Schizophrenia;
LGG	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.82	-0.3	2.94e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7301016	0.947	rs10877862	chr12:62888647	T/C	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs832540	0.556	rs4146565	chr5:56093825	T/C	cg12654349	chr5:56205094	C5orf35	-0.42	-7.28	-0.32	1.45e-12	Coronary artery disease;
LGG	cis	rs8133932	0.654	rs382303	chr21:47349284	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.97	-0.35	1.26e-14	Schizophrenia;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.13	-0.35	3.9e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2717559	0.622	rs13255523	chr8:143887054	A/G	cg06565975	chr8:143823917	SLURP1	-0.34	-8.6	-0.37	1.21e-16	Urinary tract infection frequency;
LGG	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg19507638	chr5:93509721	C5orf36	-0.65	-9.09	-0.39	2.88e-18	Diabetic retinopathy;
LGG	cis	rs1867631	1.000	rs10789213	chr1:67128201	T/C	cg13052034	chr1:66999238	SGIP1	0.45	8.66	0.37	7.92e-17	Menopause (age at onset);
LGG	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg12560992	chr17:57184187	TRIM37	-0.53	-8.59	-0.37	1.33e-16	Testicular germ cell tumor;
LGG	cis	rs9309473	0.583	rs6709853	chr2:73576065	T/A	cg20560298	chr2:73613845	ALMS1	-0.46	-8.27	-0.36	1.44e-15	Metabolite levels;
LGG	cis	rs17641971	0.899	rs341828	chr8:50001946	A/G	cg00325661	chr8:49890786	NA	-0.46	-7.68	-0.34	9.31e-14	Blood metabolite levels;
LGG	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg25664220	chr3:72788482	NA	-0.33	-9.34	-0.4	3.93e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg13647721	chr17:30228624	UTP6	-0.71	-7.97	-0.35	1.25e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg06360820	chr2:242988706	NA	-0.89	-11.48	-0.47	5.3e-27	Obesity-related traits;
LGG	cis	rs6912958	0.781	rs9444519	chr6:88290398	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg19635926	chr16:89946313	TCF25	0.75	7.32	0.32	1.08e-12	Skin colour saturation;
LGG	cis	rs7000551	0.751	rs2469755	chr8:22360212	G/A	cg12081754	chr8:22256438	SLC39A14	0.64	12.11	0.49	1.56e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6825911	0.767	rs6848906	chr4:111386198	T/C	cg10580549	chr19:53101634	ZNF137	0.44	6.66	0.3	7.69e-11	Blood pressure;
LGG	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.2	-0.46	6.5e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg02153584	chr22:29168773	CCDC117	0.59	7.13	0.31	3.86e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg21918786	chr6:109611834	NA	-0.48	-8.89	-0.38	1.34e-17	Reticulocyte fraction of red cells;
LGG	cis	rs4732038	0.715	rs1966139	chr7:134258275	A/T	cg06906464	chr7:134288099	NA	-0.49	-11.65	-0.48	1.1e-27	Longevity;
LGG	cis	rs6142618	0.562	rs6142613	chr20:30712006	A/G	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg04703951	chr17:43578652	NA	-0.29	-6.67	-0.3	7.24e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7766436	0.648	rs2876643	chr6:22591525	C/A	cg13666174	chr6:22585274	NA	-0.4	-9.85	-0.42	6.52e-21	Coronary artery disease;
LGG	cis	rs6032067	1.000	rs34685021	chr20:43888042	A/G	cg10761708	chr20:43804764	PI3	0.72	10.07	0.42	1.07e-21	Blood protein levels;
LGG	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9443189	0.763	rs2647411	chr6:76433692	C/T	cg01950844	chr6:76311363	SENP6	-0.52	-6.79	-0.3	3.48e-11	Prostate cancer;
LGG	cis	rs6735179	0.565	rs736870	chr2:1748702	T/C	cg20570797	chr2:1712800	PXDN	-0.46	-8.01	-0.35	9.39e-15	Response to antipsychotic treatment;
LGG	cis	rs11877825	0.826	rs4643401	chr18:10579303	G/C	cg25239095	chr18:10589360	NA	0.48	8.65	0.37	8.67e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs12431410	0.550	rs6573283	chr14:60228848	A/G	cg07950296	chr14:60194823	RTN1	-0.35	-6.83	-0.3	2.75e-11	Schizophrenia;
LGG	cis	rs1566085	0.704	rs903961	chr8:142652560	A/T	cg26331504	chr8:142652174	NA	-0.29	-6.89	-0.3	1.88e-11	Intelligence (multi-trait analysis);
LGG	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg12856521	chr11:46389249	DGKZ	0.52	9.26	0.4	7.46e-19	Leprosy;
LGG	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg13010199	chr12:38710504	ALG10B	0.73	14.18	0.55	3.8e-38	Bladder cancer;
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.86	-0.38	1.68e-17	Height;
LGG	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg08470875	chr2:26401718	FAM59B	0.38	7.06	0.31	5.97e-12	Gut microbiome composition (summer);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg11305259	chr19:6199442	NA	-0.34	-6.98	-0.31	1.06e-11	Iris color (L* coordinate);
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.25	0.36	1.7e-15	Obesity-related traits;
LGG	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-9.9	-0.42	4.37e-21	Morning vs. evening chronotype;
LGG	cis	rs4774830	0.744	rs62046394	chr15:56316356	C/A	cg05129572	chr15:56138634	NEDD4	0.74	7.11	0.31	4.4e-12	Delta-5 desaturase activity;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg06112835	chr11:68658793	MRPL21	0.62	10.5	0.44	2.84e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-9.51	-0.4	1.01e-19	Total body bone mineral density;
LGG	cis	rs41271473	0.898	rs72750015	chr1:228811318	A/G	cg16512390	chr1:228756714	NA	0.49	6.78	0.3	3.66e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4727027	0.704	rs12704073	chr7:148905067	G/A	cg23583168	chr7:148888333	NA	-0.94	-19.2	-0.67	6.9600000000000007e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg00711542	chr16:29343894	RUNDC2C	0.42	7.07	0.31	5.79e-12	Menopause (age at onset);
LGG	cis	rs7727544	0.645	rs272857	chr5:131685297	G/A	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.76	-0.38	3.74e-17	Blood metabolite levels;
LGG	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg27279351	chr12:120934652	DYNLL1	0.81	13.07	0.52	1.93e-33	High light scatter reticulocyte count;
LGG	cis	rs6834538	0.539	rs10434013	chr4:113401356	T/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	7.46	0.33	4.24e-13	Free thyroxine concentration;
LGG	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.52	7.19	0.32	2.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.36	-0.36	7.45e-16	Myopia (pathological);
LGG	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-9.18	-0.39	1.48e-18	Vitiligo;
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-16.37	-0.61	7.62e-48	Total body bone mineral density;
LGG	cis	rs72799341	1.000	rs72799341	chr16:30936743	G/A	cg00531865	chr16:30841666	NA	-0.51	-9.04	-0.39	4.28e-18	Diastolic blood pressure;
LGG	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg24642439	chr20:33292090	TP53INP2	0.56	9.4	0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs228437	1.000	rs6928242	chr6:134936389	T/G	cg24504307	chr6:134963096	NA	0.41	7.63	0.33	1.32e-13	Melanoma;
LGG	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-12.98	-0.52	4.35e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs9354308	0.764	rs1938111	chr6:66567345	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	trans	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.32	0.36	9.58e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4073582	1.000	rs524859	chr11:66041079	G/A	cg16950941	chr11:66035639	RAB1B	0.41	6.94	0.31	1.29e-11	Gout;
LGG	cis	rs3820928	0.839	rs35068645	chr2:227844265	T/C	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.14e-14	Pulmonary function;
LGG	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.89	-0.38	1.38e-17	Self-reported allergy;
LGG	cis	rs503734	0.875	rs13089552	chr3:101011010	T/C	cg27318481	chr3:100970896	IMPG2	-0.36	-7.28	-0.32	1.42e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06037631	chr2:74942369	NA	0.46	7.51	0.33	3.17e-13	Cognitive performance;
LGG	cis	rs9902453	0.935	rs7220151	chr17:28334710	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg16141378	chr3:129829833	LOC729375	0.42	9.5	0.4	1.17e-19	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.68	12.68	0.51	7.66e-32	Obesity-related traits;
LGG	cis	rs911555	0.755	rs2273702	chr14:103918182	C/G	cg24130564	chr14:104152367	KLC1	0.37	7.02	0.31	8.03e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.67	-0.44	6.63e-24	Triglycerides;
LGG	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg27446573	chr6:127587934	RNF146	0.82	14.39	0.56	4.51e-39	Breast cancer;
LGG	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.17	0.46	7.85e-26	Bone mineral density;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg26656751	chr17:43910226	CRHR1	0.47	8.72	0.38	5.03e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg00198680	chr16:28758506	NA	0.28	6.92	0.31	1.47e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg02297831	chr4:17616191	MED28	0.51	9.31	0.4	5.08e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs981844	0.683	rs4696191	chr4:154740668	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs4363385	0.740	rs1697428	chr1:153015761	C/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.18e-16	Inflammatory skin disease;
LGG	cis	rs4075765	0.881	rs117810194	chr11:26232762	G/A	cg19182008	chr11:26298241	NA	0.85	8.13	0.35	3.87e-15	Cannabis dependence symptom count;
LGG	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3768617	0.677	rs12739316	chr1:183052080	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.36	7.06	0.31	6.21e-12	Fuchs's corneal dystrophy;
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.04e-12	Bipolar disorder;
LGG	cis	rs7523273	0.526	rs558248	chr1:208047435	A/G	cg22525895	chr1:207977042	MIR29B2	-0.47	-8.46	-0.37	3.51e-16	Schizophrenia;
LGG	cis	rs9878978	0.691	rs13064000	chr3:2440071	G/A	cg21928760	chr3:2462534	CNTN4	0.46	8.86	0.38	1.77e-17	Blood pressure (smoking interaction);
LGG	cis	rs4919694	1.000	rs11191439	chr10:104638723	C/T	cg04362960	chr10:104952993	NT5C2	-1.1	-15.42	-0.58	1.3e-43	Arsenic metabolism;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.94	0.38	9.58e-18	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.26e-16	Response to antipsychotic treatment;
LGG	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-14.22	-0.55	2.47e-38	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs17092148	1.000	rs910872	chr20:33334540	T/C	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04008888	chr11:68622739	NA	-0.55	-11.7	-0.48	6.94e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-9.68	-0.41	2.67e-20	Kawasaki disease;
LGG	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg03342759	chr3:160939853	NMD3	-0.45	-7.72	-0.34	7.09e-14	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg26174226	chr8:58114915	NA	-0.6	-8.24	-0.36	1.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.85	-0.42	6.41e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs56283067	0.847	rs12215181	chr6:44736076	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.7	-0.48	6.89e-28	Total body bone mineral density;
LGG	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg13114125	chr14:105738426	BRF1	-0.88	-17.44	-0.63	1.04e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs35740288	0.929	rs11636821	chr15:86306005	T/G	cg04173714	chr15:86211321	AKAP13	0.41	7.11	0.31	4.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs72634258	0.945	rs12753070	chr1:8114319	C/G	cg00042356	chr1:8021962	PARK7	0.83	10.81	0.45	1.91e-24	Inflammatory bowel disease;
LGG	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg08999081	chr20:33150536	PIGU	0.44	11.32	0.47	2.16e-26	Coronary artery disease;
LGG	trans	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg25482853	chr8:67687455	SGK3	0.67	9.62	0.41	4.3e-20	Obesity-related traits;
LGG	cis	rs4746818	1.000	rs7476357	chr10:70935660	G/A	cg11621586	chr10:70884670	VPS26A	1.12	20.33	0.69	3.75e-66	Left atrial antero-posterior diameter;
LGG	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg18451016	chr1:38461880	NA	0.53	10.89	0.45	9.37e-25	Coronary artery disease;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.7	-0.48	6.74e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06567423	chr11:125462867	STT3A	0.51	7.7	0.34	8.52e-14	Gut microbiome composition (summer);
LGG	cis	rs537930	0.560	rs1635405	chr5:134349667	C/T	cg24576358	chr5:134350122	NA	0.45	9.96	0.42	2.71e-21	Height;
LGG	cis	rs4891159	0.756	rs8084155	chr18:74134952	A/G	cg24786174	chr18:74118243	ZNF516	-0.65	-16.08	-0.6	1.45e-46	Longevity;
LGG	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.41	6.68	0.3	6.9e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg23202291	chr11:1979235	NA	0.55	11.91	0.48	9.92e-29	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs8044868	0.530	rs9924964	chr16:72085561	T/A	cg23815491	chr16:72088622	HP	0.36	7.6	0.33	1.67e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg03293884	chr10:82215075	TSPAN14	-0.45	-9.04	-0.39	4.22e-18	Post bronchodilator FEV1;
LGG	cis	rs539514	0.563	rs7983875	chr13:76329245	T/C	cg04757411	chr13:76259545	LMO7	-0.28	-7.14	-0.32	3.52e-12	Type 1 diabetes;
LGG	cis	rs774359	0.789	rs2764331	chr9:27492934	C/T	cg14173147	chr9:27528300	MOBKL2B	0.46	8.81	0.38	2.44e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs708547	0.874	rs1630798	chr4:57883558	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg15596359	chr8:11213517	TDH	-0.41	-8.3	-0.36	1.11e-15	Retinal vascular caliber;
LGG	cis	rs2282802	0.685	rs6867870	chr5:139641896	C/A	cg26211634	chr5:139558579	C5orf32	0.34	7.58	0.33	1.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg13770153	chr20:60521292	NA	-0.5	-8.07	-0.35	6.29e-15	Body mass index;
LGG	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.85	0.45	1.37e-24	Morning vs. evening chronotype;
LGG	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg12179176	chr11:130786555	SNX19	0.77	14.74	0.57	1.36e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs11229555	0.645	rs11229460	chr11:58208343	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg08297393	chr2:100937505	LONRF2	-0.52	-9.8	-0.41	9.65e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg23422044	chr7:1970798	MAD1L1	-0.68	-11.9	-0.48	1.08e-28	Bipolar disorder;
LGG	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-13.84	-0.54	1.04e-36	Parkinson's disease;
LGG	cis	rs7267979	1.000	rs6132835	chr20:25434667	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.8	-15.76	-0.59	4.04e-45	Obesity-related traits;
LGG	cis	rs7011049	1.000	rs11985185	chr8:53834494	T/C	cg26025543	chr8:53854495	NA	0.73	9.7	0.41	2.25e-20	Systolic blood pressure;
LGG	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg01631408	chr1:248437212	OR2T33	-0.44	-7.4	-0.33	6.34e-13	Common traits (Other);
LGG	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg15269541	chr15:43626905	ADAL	-0.44	-7.42	-0.33	5.77e-13	Lung cancer in ever smokers;
LGG	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg13256891	chr4:100009986	ADH5	0.55	9.49	0.4	1.23e-19	Smoking initiation;
LGG	cis	rs13102973	0.640	rs6833827	chr4:135839731	T/C	cg14419869	chr4:135874104	NA	0.5	9.37	0.4	3.24e-19	Subjective well-being;
LGG	trans	rs78049276	0.736	rs17612742	chr4:148414651	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	0.56	7.45	0.33	4.48e-13	Pulse pressure;
LGG	cis	rs9393777	0.588	rs6941920	chr6:26492149	C/T	cg12826209	chr6:26865740	GUSBL1	0.84	12.67	0.51	8.93e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.582	rs12784963	chr10:104336986	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.42	-0.47	8.87e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3784262	1.000	rs4646619	chr15:58258342	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.39	-0.36	6.08e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.72	0.3	5.36e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg09021430	chr5:549028	NA	-0.69	-8.7	-0.37	6.02e-17	Lung disease severity in cystic fibrosis;
LGG	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.86	-9.94	-0.42	3.14e-21	Diabetic retinopathy;
LGG	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg07636037	chr3:49044803	WDR6	0.91	16.71	0.61	2.09e-49	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.18e-58	Menopause (age at onset);
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg16301924	chr13:53314226	LECT1	0.55	12.02	0.49	3.67e-29	Lewy body disease;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08677398	chr8:58056175	NA	0.51	8.0	0.35	1e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.922	rs1048203	chr6:109762236	G/A	cg01125227	chr6:109776195	MICAL1	0.56	9.46	0.4	1.6e-19	Height;
LGG	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02251663	chr11:14281053	SPON1	-0.34	-8.34	-0.36	8.52e-16	Mitochondrial DNA levels;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00294572	chr6:26285232	NA	0.42	7.68	0.34	9.84e-14	Educational attainment;
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg05692746	chr2:100937584	LONRF2	-0.6	-10.75	-0.45	3.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs858239	0.669	rs1006709	chr7:23140099	C/T	cg23682824	chr7:23144976	KLHL7	0.45	7.83	0.34	3.37e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg23845249	chr11:68861649	NA	0.45	8.02	0.35	8.65e-15	Blond vs. brown hair color;
LGG	trans	rs1997103	0.911	rs9642575	chr7:55399090	C/T	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.48	-0.47	5.14e-27	Urinary metabolites;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2377585	0.653	rs10770955	chr12:8842752	C/T	cg03761649	chr12:8850719	RIMKLB	0.48	8.07	0.35	6.27e-15	Reticulocyte fraction of red cells;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06028808	chr11:68637592	NA	-0.66	-11.39	-0.47	1.19e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.24	-0.36	1.8e-15	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19613828	chr19:9420501	NA	0.46	7.19	0.32	2.7e-12	Gut microbiome composition (summer);
LGG	cis	rs7923609	0.967	rs10740126	chr10:65210935	A/G	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg25885449	chr18:77638415	KCNG2	0.34	6.75	0.3	4.33e-11	Schizophrenia;
LGG	cis	rs9362426	0.524	rs6454606	chr6:88100806	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	-0.93	-14.42	-0.56	3.44e-39	Depressive episodes in bipolar disorder;
LGG	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs2455799	0.613	rs6772879	chr3:15741793	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.74	-0.34	6.3e-14	Mean platelet volume;
LGG	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-7.07	-0.31	5.58e-12	Educational attainment;
LGG	cis	rs7077256	0.521	rs71508969	chr10:65254510	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-12.09	-0.49	2.04e-29	Systolic blood pressure;
LGG	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg26384229	chr12:38710491	ALG10B	0.72	14.49	0.56	1.59e-39	Morning vs. evening chronotype;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	9.54	0.41	8.01e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.13	0.35	4.01e-15	Rheumatoid arthritis;
LGG	cis	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg03342759	chr3:160939853	NMD3	0.45	7.41	0.33	6.05e-13	Morning vs. evening chronotype;
LGG	cis	rs8017423	0.967	rs7154683	chr14:90700692	A/G	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.81e-57	Mortality in heart failure;
LGG	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg12165864	chr7:66369176	NA	-0.58	-9.37	-0.4	3.26e-19	Corneal structure;
LGG	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg07519485	chr6:33762594	MLN	-0.32	-7.01	-0.31	8.48e-12	Crohn's disease;
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg13939156	chr17:80058883	NA	-0.47	-9.14	-0.39	1.98e-18	Life satisfaction;
LGG	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg23750338	chr8:142222470	SLC45A4	-0.58	-12.06	-0.49	2.53e-29	Immature fraction of reticulocytes;
LGG	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg13147721	chr7:65941812	NA	0.8	9.91	0.42	4.15e-21	Diabetic kidney disease;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg07636037	chr3:49044803	WDR6	-0.78	-13.6	-0.53	1.08e-35	Menarche (age at onset);
LGG	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg15162869	chr22:32027605	PISD	-0.76	-7.83	-0.34	3.42e-14	Age-related hearing impairment;
LGG	trans	rs73198271	0.960	rs11778970	chr8:8609334	G/C	cg16141378	chr3:129829833	LOC729375	0.37	6.96	0.31	1.19e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg03301075	chr11:3254240	MRGPRE	0.38	6.98	0.31	1.03e-11	Monocyte count;
LGG	cis	rs1555322	1.000	rs2425041	chr20:33859013	C/A	cg17927777	chr20:33865990	NA	0.76	8.0	0.35	1.02e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs9462027	0.606	rs7759227	chr6:34728230	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs9814567	1.000	rs4955485	chr3:134295843	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.4	-0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg04065151	chr12:53682969	ESPL1	-0.55	-9.08	-0.39	3.24e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs679087	0.932	rs10843506	chr12:29930883	G/A	cg14258853	chr12:29935411	TMTC1	0.41	8.48	0.37	2.97e-16	Schizophrenia;
LGG	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg11941060	chr3:133502564	NA	-0.53	-9.19	-0.39	1.29e-18	Iron status biomarkers;
LGG	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	22.29	0.72	2.71e-75	Homoarginine levels;
LGG	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg11764359	chr7:65958608	NA	0.55	9.41	0.4	2.32e-19	Aortic root size;
LGG	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	13.05	0.52	2.38e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10847980	0.590	rs12299742	chr12:123323357	T/G	cg25930673	chr12:123319894	HIP1R	1.17	9.76	0.41	1.41e-20	Adiponectin levels;
LGG	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg21972741	chr5:435613	AHRR	0.5	8.93	0.38	1.01e-17	Cystic fibrosis severity;
LGG	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.86	0.34	2.77e-14	Retinal vascular caliber;
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.88e-11	Aortic root size;
LGG	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.6	-0.56	5.8e-40	Schizophrenia;
LGG	cis	rs2195525	0.572	rs7927959	chr11:119218616	A/T	cg01451205	chr11:119252210	USP2	-0.4	-6.7	-0.3	6.02e-11	Urate levels;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg08888203	chr3:10149979	C3orf24	0.56	9.37	0.4	3.12e-19	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12495954	chr16:53738234	FTO;RPGRIP1L	0.46	7.43	0.33	5.3e-13	Cognitive performance;
LGG	cis	rs3857747	0.861	rs4723961	chr7:40451459	G/A	cg00420559	chr7:40367873	C7orf10	-0.37	-7.59	-0.33	1.78e-13	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs4466137	0.953	rs1585153	chr5:83000385	A/T	cg16102102	chr5:83017553	HAPLN1	-0.61	-11.17	-0.46	8.3e-26	Prostate cancer;
LGG	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg00149659	chr3:10157352	C3orf10	0.56	7.91	0.34	1.97e-14	Alzheimer's disease;
LGG	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg24253500	chr15:84953950	NA	-0.41	-7.65	-0.33	1.19e-13	P wave terminal force;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg02297831	chr4:17616191	MED28	0.51	9.56	0.41	7.02e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7712401	0.623	rs426877	chr5:122314635	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs17253792	0.822	rs74968702	chr14:56076818	A/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.12	0.39	2.31e-18	Triglycerides;
LGG	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	6.97	0.31	1.13e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.13	-0.31	3.77e-12	Lung cancer;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05025164	chr4:1340916	KIAA1530	0.87	17.03	0.62	7.27e-51	Longevity;
LGG	cis	rs13102973	0.965	rs28874134	chr4:135867088	C/A	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08952343	chr8:19615134	NA	0.39	7.09	0.31	4.93e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.11e-31	Motion sickness;
LGG	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg18129748	chr3:49941408	MST1R	0.22	6.93	0.31	1.4e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7851660	0.527	rs7870795	chr9:100574120	A/G	cg13688889	chr9:100608707	NA	-0.86	-18.6	-0.65	4.62e-58	Strep throat;
LGG	trans	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs283228	0.617	rs499209	chr6:101762322	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18876405	chr7:65276391	NA	-0.59	-10.75	-0.45	3.25e-24	Aortic root size;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg19980929	chr12:42632907	YAF2	0.35	7.95	0.35	1.46e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs16976116	0.901	rs1061870	chr15:55496769	G/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28655083	1.000	rs28655083	chr16:77061214	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.48	-7.6	-0.33	1.69e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4538187	0.661	rs17562423	chr2:64200119	T/C	cg14150252	chr2:64069583	UGP2	-0.49	-7.99	-0.35	1.06e-14	Systolic blood pressure;
LGG	cis	rs4764487	0.760	rs4764486	chr12:6327989	A/G	cg08284733	chr12:6341482	CD9	0.33	8.55	0.37	1.81e-16	Mean platelet volume;
LGG	cis	rs4742903	0.870	rs1354894	chr9:106975237	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.26	0.36	1.57e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	1.94e-11	HDL cholesterol;
LGG	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.0	-0.31	8.95e-12	Schizophrenia;
LGG	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.63	0.37	1.01e-16	Colorectal cancer;
LGG	cis	rs17331151	0.505	rs13086936	chr3:52659079	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.5	6.66	0.3	7.6e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs2294693	0.891	rs4714420	chr6:40992799	T/C	cg14769373	chr6:40998127	UNC5CL	-0.42	-7.08	-0.31	5.49e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs11920090	0.932	rs61791106	chr3:170729414	G/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.55	0.37	1.74e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4926298	1.000	rs11085829	chr19:13174312	G/A	cg04657146	chr19:12876947	HOOK2	-0.42	-6.96	-0.31	1.2e-11	Bipolar disorder;
LGG	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-11.98	-0.49	5.35e-29	Parkinson's disease;
LGG	cis	rs7591446	0.517	rs13427985	chr2:45838840	C/A	cg15146906	chr2:45838581	SRBD1	0.53	6.98	0.31	1.03e-11	Squamous cell lung carcinoma;
LGG	cis	rs7937612	1.000	rs7924963	chr11:120233536	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.76	-0.51	3.8e-32	Intraocular pressure;
LGG	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg09361094	chr10:834503	NA	-0.28	-7.28	-0.32	1.42e-12	Survival in rectal cancer;
LGG	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg04657146	chr19:12876947	HOOK2	0.45	7.32	0.32	1.13e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs350251	0.934	rs1704112	chr16:12211425	C/G	cg02910054	chr16:12241554	SNX29	0.44	8.12	0.35	4.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg07959490	chr17:80112427	CCDC57	0.37	7.25	0.32	1.78e-12	Life satisfaction;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.32	0.4	4.93e-19	Bipolar disorder;
LGG	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15596359	chr8:11213517	TDH	0.43	8.87	0.38	1.6e-17	Retinal vascular caliber;
LGG	cis	rs11169552	0.510	rs12231317	chr12:51041005	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.48	-0.33	3.73e-13	Colorectal cancer;
LGG	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.41	-7.24	-0.32	1.93e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.52	-0.37	2.2e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.47	-8.18	-0.36	2.83e-15	Total body bone mineral density;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg06968155	chr5:131705112	SLC22A5	0.77	8.61	0.37	1.16e-16	Rheumatoid arthritis;
LGG	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.69	0.37	6.09e-17	Joint mobility (Beighton score);
LGG	cis	rs1909881	0.504	rs56314554	chr8:96499795	T/C	cg04203453	chr8:96504381	NA	-0.76	-11.79	-0.48	3.05e-28	Obesity-related traits;
LGG	cis	rs2016266	0.859	rs11170506	chr12:53730759	G/T	cg04065151	chr12:53682969	ESPL1	0.57	8.84	0.38	2.01e-17	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.15	-0.35	3.31e-15	Small cell lung carcinoma;
LGG	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg25019033	chr10:957182	NA	-0.53	-8.98	-0.39	7.03e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg05793240	chr7:2802953	GNA12	0.36	8.03	0.35	7.85e-15	Height;
LGG	cis	rs1018697	1.000	rs1018697	chr10:104549224	C/A	cg04362960	chr10:104952993	NT5C2	0.49	9.02	0.39	5.16e-18	Colorectal adenoma (advanced);
LGG	cis	rs17767392	0.813	rs34991781	chr14:71921576	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.84	-0.38	1.95e-17	Mitral valve prolapse;
LGG	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg09307838	chr4:120376055	NA	0.73	12.58	0.5	1.99e-31	Corneal astigmatism;
LGG	cis	rs2274273	0.837	rs8011329	chr14:55677255	G/A	cg04306507	chr14:55594613	LGALS3	0.6	16.48	0.61	2.26e-48	Protein biomarker;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-12.35	-0.5	1.81e-30	Personality dimensions;
LGG	cis	rs9473924	0.542	rs2857482	chr6:50790642	C/T	cg14470998	chr6:50812995	TFAP2B	0.69	8.11	0.35	4.45e-15	Body mass index;
LGG	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.04e-21	Aortic root size;
LGG	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-19.22	-0.67	5.7e-61	Bladder cancer;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.13	0.52	1.09e-33	Prudent dietary pattern;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg08677398	chr8:58056175	NA	0.44	7.4	0.33	6.46e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg05484376	chr2:27715224	FNDC4	0.44	9.5	0.4	1.11e-19	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg09264619	chr17:80180166	NA	-0.38	-7.61	-0.33	1.55e-13	Life satisfaction;
LGG	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg05044414	chr3:183734942	ABCC5	0.57	11.34	0.47	1.82e-26	Anterior chamber depth;
LGG	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg08847533	chr14:75593920	NEK9	-0.59	-11.11	-0.46	1.37e-25	Height;
LGG	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg22348356	chr13:114891224	RASA3	0.4	7.69	0.34	8.73e-14	Schizophrenia;
LGG	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg18551225	chr6:44695536	NA	-0.68	-11.32	-0.47	2.09e-26	Total body bone mineral density;
LGG	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg04398451	chr17:18023971	MYO15A	-0.86	-19.87	-0.68	5.39e-64	Total body bone mineral density;
LGG	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.35	0.43	1.03e-22	Aortic root size;
LGG	cis	rs3106136	0.609	rs11097406	chr4:95146042	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.76	-0.3	4.16e-11	Capecitabine sensitivity;
LGG	cis	rs7027203	0.790	rs10123836	chr9:96584109	G/T	cg14598338	chr9:96623480	NA	-0.54	-9.72	-0.41	1.94e-20	DNA methylation (variation);
LGG	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.05	-0.39	3.85e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6787172	0.667	rs1212739	chr3:158028041	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.89	0.38	1.33e-17	Subjective well-being;
LGG	cis	rs36051895	0.632	rs1581927	chr9:5177462	C/T	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs9557207	0.950	rs8181880	chr13:100027957	C/T	cg24509225	chr13:100037070	UBAC2	-0.72	-13.15	-0.52	8.82e-34	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2371030	0.965	rs12998879	chr2:211583332	G/A	cg18417063	chr2:211583084	NA	-0.63	-12.25	-0.49	4.43e-30	Non-small cell lung cancer;
LGG	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg13907859	chr11:120009124	TRIM29	-0.46	-8.46	-0.37	3.48e-16	Stroke (pediatric);
LGG	trans	rs11989744	1.000	rs17089546	chr8:23571807	G/A	cg03492747	chr16:86543808	FOXF1	0.52	7.84	0.34	3.1e-14	Waist-hip ratio;
LGG	cis	rs9942416	0.660	rs34905687	chr5:74997736	A/G	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs7572733	0.534	rs734037	chr2:198749269	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03576123	chr11:487126	PTDSS2	-1.31	-17.4	-0.63	1.57e-52	Body mass index;
LGG	cis	rs10046574	0.656	rs17403326	chr7:135194440	T/G	cg27474649	chr7:135195673	CNOT4	0.71	8.25	0.36	1.63e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg26384229	chr12:38710491	ALG10B	0.85	19.14	0.66	1.39e-60	Bladder cancer;
LGG	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs17767392	0.958	rs61989367	chr14:71907295	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.74e-18	Mitral valve prolapse;
LGG	cis	rs1843834	0.929	rs4674934	chr2:225516468	A/T	cg22455342	chr2:225449267	CUL3	-0.56	-9.78	-0.41	1.14e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs504918	0.525	rs920894	chr3:123987216	G/A	cg05766129	chr3:123988013	KALRN	0.61	11.56	0.47	2.51e-27	Schizophrenia;
LGG	cis	rs7927771	1.000	rs10838738	chr11:47663049	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-8.61	-0.37	1.15e-16	Subjective well-being;
LGG	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.39	-0.36	5.73e-16	Neuroticism;
LGG	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	13.87	0.54	8.13e-37	Mean platelet volume;
LGG	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg12081754	chr8:22256438	SLC39A14	1.19	30.96	0.82	7.47e-115	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg11766577	chr21:47581405	C21orf56	-0.59	-10.84	-0.45	1.46e-24	Testicular germ cell tumor;
LGG	cis	rs11605924	1.000	rs12794698	chr11:45871861	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-7.78	-0.34	4.7e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.7	-0.37	5.67e-17	Menopause (age at onset);
LGG	cis	rs9462027	0.585	rs2814974	chr6:34572028	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.35	-0.43	1.03e-22	Systemic lupus erythematosus;
LGG	cis	rs2108225	0.934	rs4730269	chr7:107455719	T/G	cg18560240	chr7:107437656	SLC26A3	-0.55	-9.79	-0.41	1.1e-20	Ulcerative colitis;
LGG	cis	rs67478160	0.654	rs1535097	chr14:104216649	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-7.14	-0.32	3.52e-12	Schizophrenia;
LGG	trans	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg20587970	chr11:113659929	NA	-0.75	-11.95	-0.49	7.28e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg12560992	chr17:57184187	TRIM37	-0.81	-13.75	-0.54	2.51e-36	Intelligence (multi-trait analysis);
LGG	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg12011299	chr4:100065546	ADH4	-0.34	-7.46	-0.33	4.2e-13	Alcohol dependence;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02343318	chr19:37329498	ZNF790	0.46	7.42	0.33	5.47e-13	Cognitive performance;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.22	-0.58	1.08e-42	Prudent dietary pattern;
LGG	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19717773	chr7:2847554	GNA12	-0.37	-8.66	-0.37	8.1e-17	Height;
LGG	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs9457247	0.765	rs9459836	chr6:167419105	G/A	cg07741184	chr6:167504864	NA	0.42	9.37	0.4	3.23e-19	Crohn's disease;
LGG	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg08125733	chr17:73851984	WBP2	0.84	9.15	0.39	1.79e-18	Psoriasis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	0.51	8.26	0.36	1.49e-15	Cognitive performance;
LGG	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg03959625	chr15:84868606	LOC388152	0.55	8.69	0.37	6.42e-17	Schizophrenia;
LGG	cis	rs477692	1.000	rs580745	chr10:131414401	G/A	cg05714579	chr10:131428358	MGMT	0.58	12.18	0.49	8.61e-30	Response to temozolomide;
LGG	cis	rs17767392	0.958	rs34480562	chr14:71979724	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.15	-0.39	1.76e-18	Mitral valve prolapse;
LGG	cis	rs7940866	0.874	rs7111478	chr11:130819628	A/G	cg12179176	chr11:130786555	SNX19	0.75	14.11	0.55	7.15e-38	Schizophrenia;
LGG	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg23594656	chr7:65796392	TPST1	-0.37	-8.12	-0.35	4.33e-15	Aortic root size;
LGG	trans	rs2562456	0.793	rs627522	chr19:21495804	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-8.03	-0.35	7.97e-15	Pain;
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.43	-0.4	1.93e-19	Platelet count;
LGG	cis	rs6504108	0.624	rs2021752	chr17:46240263	A/G	cg02219949	chr17:45927392	SP6	-0.43	-8.17	-0.35	3.07e-15	Body mass index;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.27	0.55	1.47e-38	Platelet count;
LGG	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg14456004	chr13:21872349	NA	1.38	25.87	0.77	5.81e-92	White matter hyperintensity burden;
LGG	cis	rs3087591	0.887	rs2905796	chr17:29537586	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.18	0.55	3.66e-38	Hip circumference;
LGG	cis	rs67311347	0.955	rs73078170	chr3:40483947	C/T	cg13683864	chr3:40499215	RPL14	-1.17	-26.22	-0.77	1.48e-93	Renal cell carcinoma;
LGG	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg12463550	chr7:65579703	CRCP	0.75	7.98	0.35	1.18e-14	Gout;
LGG	cis	rs9811920	0.638	rs10936008	chr3:99686665	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	8.89	0.38	1.38e-17	Axial length;
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.3	-0.36	1.19e-15	Bipolar disorder;
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.43e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg12310025	chr6:25882481	NA	0.43	7.13	0.31	4.01e-12	Iron status biomarkers;
LGG	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	7.91	0.35	1.9e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg18404041	chr3:52824283	ITIH1	-0.56	-10.85	-0.45	1.34e-24	Bipolar disorder;
LGG	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg27476859	chr7:2772710	GNA12	0.65	13.34	0.53	1.35e-34	Height;
LGG	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg14673194	chr17:80132900	CCDC57	-0.45	-8.27	-0.36	1.48e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9880211	0.800	rs9845862	chr3:136472573	T/C	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs988958	1.000	rs988958	chr2:42287306	A/G	cg19376973	chr2:42229025	NA	-0.42	-6.76	-0.3	4.08e-11	Hypospadias;
LGG	trans	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.94	0.45	5.99e-25	Corneal astigmatism;
LGG	cis	rs71403859	0.730	rs12923781	chr16:71653464	G/A	cg08717414	chr16:71523259	ZNF19	-1.13	-14.53	-0.56	1.06e-39	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	cis	rs62025270	0.632	rs13379832	chr15:86115900	A/T	cg25843651	chr15:86329602	KLHL25	0.53	7.91	0.35	1.86e-14	Idiopathic pulmonary fibrosis;
LGG	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg12310025	chr6:25882481	NA	-0.56	-10.51	-0.44	2.66e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg05863683	chr7:1912471	MAD1L1	0.43	8.24	0.36	1.73e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg15921436	chr17:44337874	NA	0.6	13.0	0.52	3.59e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10463554	0.927	rs34813	chr5:102433409	G/A	cg23492399	chr5:102201601	PAM	-0.52	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27286337	chr10:134555280	INPP5A	0.82	11.99	0.49	5.13e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.61e-17	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg11890956	chr21:40555474	PSMG1	1.21	29.71	0.81	2.54e-109	Cognitive function;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04129946	chr2:201753996	PPIL3;NIF3L1	0.44	7.24	0.32	1.87e-12	Cognitive performance;
LGG	cis	rs9472414	0.510	rs227839	chr6:44685610	A/G	cg20913747	chr6:44695427	NA	0.5	8.3	0.36	1.17e-15	Height;
LGG	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg16724585	chr3:197361211	NA	-0.47	-8.17	-0.35	2.98e-15	Pancreatic cancer;
LGG	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg13512537	chr8:22265999	SLC39A14	-0.47	-8.35	-0.36	7.88e-16	Verbal declarative memory;
LGG	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg16301924	chr13:53314226	LECT1	-0.35	-7.0	-0.31	8.83e-12	Lewy body disease;
LGG	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg13445358	chr12:53661749	ESPL1	-0.41	-7.56	-0.33	2.22e-13	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg16141378	chr3:129829833	LOC729375	0.39	9.23	0.39	9.38e-19	Joint mobility (Beighton score);
LGG	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	14.03	0.55	1.55e-37	IgG glycosylation;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg00106254	chr7:1943704	MAD1L1	0.44	7.68	0.34	9.58e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs350251	0.934	rs350255	chr16:12205542	A/G	cg02910054	chr16:12241554	SNX29	0.45	8.2	0.36	2.44e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg08916839	chr5:415575	AHRR	0.96	14.14	0.55	5.65e-38	Fat distribution (HIV);
LGG	cis	rs12724450	0.793	rs11799813	chr1:150335740	A/G	cg03818307	chr1:150480534	ECM1	0.49	6.8	0.3	3.23e-11	Blood protein levels;
LGG	cis	rs1878931	0.559	rs1968055	chr16:3392053	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.76	13.95	0.54	3.63e-37	Body mass index (adult);
LGG	cis	rs7103648	0.897	rs11606287	chr11:47407439	C/A	cg20307385	chr11:47447363	PSMC3	0.93	20.78	0.69	2.9e-68	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.26	0.32	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg25718383	chr7:130020096	CPA1	0.32	8.39	0.36	6.07e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.28	0.32	1.4e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.43	0.58	1.24e-43	Lung cancer;
LGG	cis	rs9902453	1.000	rs28664971	chr17:28437410	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.34	0.53	1.34e-34	Coffee consumption (cups per day);
LGG	cis	rs7712401	0.601	rs246306	chr5:122279218	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs9581857	0.685	rs9581856	chr13:28025615	G/C	cg01674679	chr13:27998804	GTF3A	-0.66	-7.77	-0.34	5.27e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg02820901	chr13:113351484	ATP11A	0.58	6.95	0.31	1.26e-11	Glycated hemoglobin levels;
LGG	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.08	0.31	5.25e-12	Educational attainment;
LGG	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg06634786	chr22:41940651	POLR3H	0.79	11.46	0.47	5.89e-27	Vitiligo;
LGG	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	14.94	0.57	1.83e-41	Caffeine consumption;
LGG	cis	rs9503598	0.644	rs7774747	chr6:3430996	A/G	cg00476032	chr6:3446245	SLC22A23	-0.43	-8.36	-0.36	7.39e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06634786	chr22:41940651	POLR3H	0.71	11.41	0.47	9.33e-27	Vitiligo;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg00453349	chr2:110371869	SEPT10;ANKRD57	0.39	6.78	0.3	3.78e-11	Coronary artery disease;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00149659	chr3:10157352	C3orf10	0.9	11.43	0.47	7.92e-27	Alzheimer's disease;
LGG	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg06374794	chr16:88002281	BANP	0.45	8.47	0.37	3.27e-16	Menopause (age at onset);
LGG	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.6	7.8	0.34	4.04e-14	HIV-1 control;
LGG	cis	rs2236267	0.726	rs1940551	chr14:88603859	T/C	cg18078958	chr14:88630771	NA	-0.32	-7.4	-0.33	6.53e-13	Food antigen IgG levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02265379	chr5:87898506	LOC645323	0.38	6.87	0.3	2.07e-11	Menarche (age at onset);
LGG	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg21775007	chr8:11205619	TDH	0.78	14.31	0.55	9.86e-39	Retinal vascular caliber;
LGG	cis	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg24623649	chr8:11872141	NA	-0.29	-6.79	-0.3	3.35e-11	Triglycerides;
LGG	cis	rs4950928	0.823	rs7541061	chr1:203163367	G/T	cg17014757	chr1:203156097	CHI3L1	0.38	7.8	0.34	4.22e-14	YKL-40 levels;
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.75	0.38	4.14e-17	Lung cancer in ever smokers;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg12458913	chr13:53173898	NA	0.57	10.64	0.44	8.7e-24	Lewy body disease;
LGG	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg23231163	chr10:75533350	FUT11	-0.41	-6.84	-0.3	2.55e-11	Inflammatory bowel disease;
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg10207240	chr12:122356781	WDR66	0.28	8.34	0.36	8.48e-16	Mean corpuscular volume;
LGG	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg17788362	chr6:86352627	SYNCRIP	0.5	8.81	0.38	2.57e-17	Smooth-surface caries;
LGG	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	23.98	0.74	3.32e-83	Chronic sinus infection;
LGG	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.89	0.3	1.83e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6537837	0.838	rs6663547	chr1:110114229	A/C	cg05049280	chr1:110155535	GNAT2	0.32	6.79	0.3	3.45e-11	Major depressive disorder;
LGG	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.84	0.34	3.04e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08645402	chr16:4508243	NA	0.44	8.11	0.35	4.7e-15	Schizophrenia;
LGG	cis	rs12220238	0.841	rs11000993	chr10:76084111	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.94	0.38	9.5e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg21782813	chr7:2030301	MAD1L1	0.47	10.99	0.46	3.84e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg04362960	chr10:104952993	NT5C2	0.57	10.75	0.45	3.23e-24	Arsenic metabolism;
LGG	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg09461388	chr22:46763229	CELSR1	-0.7	-7.16	-0.32	3.09e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs208520	0.955	rs208532	chr6:66961280	T/A	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs4917300	0.606	rs4917286	chr8:143113916	A/G	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.32e-11	Amyotrophic lateral sclerosis;
LGG	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs34172651	0.571	rs9922156	chr16:24704329	C/A	cg02428538	chr16:24856791	SLC5A11	0.57	9.18	0.39	1.44e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10895140	0.794	rs10750609	chr11:101500781	C/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.85	-0.3	2.37e-11	Menarche (age at onset);
LGG	cis	rs11971779	0.648	rs66463279	chr7:139118661	A/G	cg07862535	chr7:139043722	LUC7L2	0.46	7.46	0.33	4.23e-13	Diisocyanate-induced asthma;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg00666640	chr1:248458726	OR2T12	0.62	10.01	0.42	1.69e-21	Common traits (Other);
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg02725872	chr8:58115012	NA	-0.86	-11.91	-0.48	1.04e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg19628046	chr18:33552617	C18orf21	0.53	7.73	0.34	6.92e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg05026014	chr4:1749153	NA	-0.29	-7.91	-0.34	1.94e-14	Hip circumference adjusted for BMI;Height;
LGG	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-7.03	-0.31	7.24e-12	Response to amphetamines;
LGG	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg05044414	chr3:183734942	ABCC5	0.73	16.05	0.6	2.04e-46	Anterior chamber depth;
LGG	cis	rs9443189	0.570	rs529383	chr6:76297847	T/G	cg01950844	chr6:76311363	SENP6	0.75	9.5	0.4	1.14e-19	Prostate cancer;
LGG	cis	rs4660214	0.666	rs11205828	chr1:39719346	C/T	cg18385671	chr1:39797026	MACF1	-0.46	-9.56	-0.41	7.07e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg20991723	chr1:152506922	NA	-0.72	-14.9	-0.57	2.65e-41	Hair morphology;
LGG	cis	rs7572733	0.555	rs1837495	chr2:198921201	A/G	cg00792783	chr2:198669748	PLCL1	-0.55	-8.7	-0.37	5.81e-17	Dermatomyositis;
LGG	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.04	-0.31	7.14e-12	Systemic lupus erythematosus;
LGG	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17655565	0.636	rs74607560	chr12:52718196	A/G	cg08257133	chr12:52711352	KRT83	0.53	7.63	0.33	1.35e-13	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-13.08	-0.52	1.73e-33	Extrinsic epigenetic age acceleration;
LGG	trans	rs9657904	0.738	rs13060223	chr3:105495841	A/C	cg14088669	chr1:158435396	OR10K1	0.4	7.46	0.33	4.35e-13	Multiple sclerosis;
LGG	cis	rs4731207	0.698	rs7794631	chr7:124551925	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	trans	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg06521331	chr12:34319734	NA	-0.48	-8.58	-0.37	1.43e-16	Bladder cancer;
LGG	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg07169764	chr2:136633963	MCM6	-0.46	-7.34	-0.32	9.96e-13	Colorectal cancer;
LGG	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-12.86	-0.51	1.35e-32	HDL cholesterol;
LGG	cis	rs2640806	0.505	rs7012725	chr8:97361834	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.17	0.32	2.95e-12	Obesity-related traits;
LGG	cis	rs7188861	0.724	rs34437200	chr16:11391710	G/A	cg01510278	chr16:11456238	NA	0.31	7.39	0.32	6.72e-13	HDL cholesterol;
LGG	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.82	13.09	0.52	1.55e-33	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.93	0.38	1e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.5	-0.4	1.15e-19	Personality dimensions;
LGG	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg08048268	chr3:133502702	NA	-0.6	-11.22	-0.46	5.2e-26	Iron status biomarkers;
LGG	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04845077	chr9:34126958	DCAF12	0.43	7.23	0.32	1.96e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7939886	0.920	rs59895837	chr11:56096099	T/A	cg15704280	chr7:45808275	SEPT13	0.8	7.23	0.32	1.97e-12	Myopia (pathological);
LGG	cis	rs12681366	0.734	rs2515153	chr8:95423924	G/A	cg13257157	chr8:95487014	RAD54B	-0.36	-6.68	-0.3	7.09e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg12623918	chr2:306882	NA	0.53	9.93	0.42	3.38e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4356932	1.000	rs7684889	chr4:76963264	T/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	5.07e-11	Blood protein levels;
LGG	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg21435375	chr2:172878103	MAP1D	-0.31	-7.0	-0.31	9.13e-12	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg24112000	chr20:60950667	NA	-0.37	-8.59	-0.37	1.38e-16	Colorectal cancer;
LGG	cis	rs7712401	0.601	rs30069	chr5:122293026	A/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs751728	1.000	rs755496	chr6:33734376	C/G	cg25922239	chr6:33757077	LEMD2	0.68	11.56	0.47	2.39e-27	Crohn's disease;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13469180	chr3:47324151	KIF9;KLHL18	0.46	7.16	0.32	3.09e-12	Gut microbiome composition (summer);
LGG	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg18876405	chr7:65276391	NA	-0.63	-11.74	-0.48	4.9e-28	Aortic root size;
LGG	cis	rs7166081	1.000	rs1444936	chr15:67635549	G/A	cg05925327	chr15:68127851	NA	-0.33	-6.97	-0.31	1.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9287719	0.967	rs6432120	chr2:10753771	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg05775895	chr3:12838266	CAND2	0.77	14.48	0.56	1.92e-39	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg16507663	chr6:150244633	RAET1G	0.45	8.46	0.37	3.62e-16	Lung cancer;
LGG	cis	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg07460842	chr6:66804631	NA	0.96	17.79	0.64	2.44e-54	Exhaled nitric oxide output;
LGG	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg09060608	chr5:178986726	RUFY1	0.45	7.99	0.35	1.09e-14	Lung cancer;
LGG	cis	rs17767392	0.834	rs72728406	chr14:71734992	G/A	cg02058870	chr14:72053146	SIPA1L1	0.44	8.54	0.37	2e-16	Mitral valve prolapse;
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	11.94	0.49	7.5e-29	Total body bone mineral density;
LGG	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg21775979	chr11:780331	NA	0.43	8.62	0.37	1.1e-16	Breast cancer;
LGG	cis	rs9443645	0.901	rs10943612	chr6:79698380	C/T	cg18132916	chr6:79620363	NA	-0.3	-8.37	-0.36	7.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11064837	0.523	rs10774511	chr12:120095932	C/A	cg25937854	chr12:120150414	CIT	-0.67	-10.84	-0.45	1.47e-24	Schizophrenia;
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg16920238	chr17:80076378	CCDC57	0.35	8.07	0.35	6.25e-15	Life satisfaction;
LGG	cis	rs2320614	0.679	rs72631678	chr4:164102715	G/A	cg15586945	chr4:164088095	NAF1	-0.5	-8.83	-0.38	2.11e-17	Lung adenocarcinoma;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg26513180	chr16:89883248	FANCA	0.84	8.05	0.35	6.98e-15	Skin colour saturation;
LGG	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg24375607	chr4:120327624	NA	0.67	10.97	0.45	4.7e-25	Corneal astigmatism;
LGG	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	8.01e-13	Platelet count;
LGG	cis	rs6573604	1.000	rs8017974	chr14:65775187	T/C	cg15999311	chr14:65749247	NA	0.46	6.7	0.3	6.1e-11	N-glycan levels;
LGG	cis	rs6764363	0.504	rs4684334	chr3:278697	A/C	cg02057681	chr3:285234	CHL1	-0.42	-7.62	-0.33	1.48e-13	Sudden cardiac arrest;
LGG	cis	rs476633	0.708	rs28656781	chr15:41447440	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.71	-11.62	-0.48	1.44e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs17604090	0.793	rs66956566	chr7:29688702	A/G	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01635816	chr20:2082448	STK35	0.49	7.7	0.34	8.13e-14	Gut microbiome composition (summer);
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg03804240	chr11:118481350	PHLDB1	-0.4	-7.84	-0.34	3.17e-14	Cholesterol, total;
LGG	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg13444538	chr7:158905317	VIPR2	0.35	6.91	0.31	1.65e-11	Facial morphology (factor 20);
LGG	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg26597838	chr10:835615	NA	0.64	9.65	0.41	3.5e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.02e-12	HDL cholesterol;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16207974	chr18:12431241	SLMO1	0.4	6.72	0.3	5.21e-11	Pancreatic cancer;
LGG	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg02996355	chr14:81879375	NA	-0.77	-13.09	-0.52	1.58e-33	Prudent dietary pattern;
LGG	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg08807101	chr21:30365312	RNF160	-0.82	-16.79	-0.62	9.28e-50	Dental caries;
LGG	cis	rs2602381	0.599	rs2602377	chr2:234582212	G/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.65e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.21	0.43	3.33e-22	Mean corpuscular volume;
LGG	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg27129171	chr3:47204927	SETD2	-0.79	-13.85	-0.54	9.72e-37	Colorectal cancer;
LGG	cis	rs4731207	0.535	rs7806126	chr7:124601875	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg07936489	chr17:37558343	FBXL20	-0.43	-6.96	-0.31	1.18e-11	Asthma;
LGG	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.13	0.31	3.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg07747251	chr5:1868357	NA	0.47	9.47	0.4	1.46e-19	Cardiovascular disease risk factors;
LGG	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.8	0.45	2.2e-24	Rheumatoid arthritis;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-9.91	-0.42	4.08e-21	IgG glycosylation;
LGG	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg20913747	chr6:44695427	NA	-0.54	-8.03	-0.35	7.97e-15	Total body bone mineral density;
LGG	cis	rs9487051	0.676	rs4383852	chr6:109594475	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7215564	0.908	rs35844609	chr17:78664850	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs9796	0.621	rs28737302	chr15:41469943	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.95	-0.42	2.79e-21	Menopause (age at onset);
LGG	cis	rs7659604	0.540	rs13113421	chr4:122670064	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.16	0.32	3.2e-12	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.75e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs36093844	0.752	rs17744699	chr11:85597163	C/T	cg16165120	chr11:85566439	CCDC83	-0.43	-6.73	-0.3	4.96e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs17122278	0.929	rs11216917	chr11:118462160	T/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.29	-0.63	5.07e-52	Skin colour saturation;
LGG	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg18681998	chr4:17616180	MED28	0.83	18.51	0.65	1.21e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2658782	0.654	rs2605622	chr11:93248242	A/G	cg15737290	chr11:93063684	CCDC67	0.45	6.74	0.3	4.83e-11	Pulmonary function decline;
LGG	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.39	-7.56	-0.33	2.16e-13	Obesity;
LGG	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg12046867	chr14:103022105	NA	-0.8	-15.9	-0.59	1.01e-45	Platelet count;
LGG	cis	rs1003719	0.715	rs2156078	chr21:38546473	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.31	-0.58	4.35e-43	Eye color traits;
LGG	cis	rs1639906	1.000	rs1637759	chr7:2220053	C/T	cg20308403	chr7:2120281	MAD1L1	0.34	7.49	0.33	3.6e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.89	0.59	1.07e-45	Lymphocyte percentage of white cells;
LGG	trans	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.94	0.45	6.29e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12362504	0.532	rs4910076	chr11:9925352	G/A	cg07197493	chr11:9884649	SBF2	-0.34	-6.68	-0.3	7.02e-11	Survival in pancreatic cancer;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11905131	chr22:24372483	LOC391322	-0.48	-8.49	-0.37	2.84e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg18357526	chr6:26021779	HIST1H4A	0.64	10.56	0.44	1.73e-23	Uric acid levels;
LGG	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.49	-0.63	5.75e-53	Refractive error;
LGG	cis	rs73086581	0.891	rs73084555	chr20:3893800	A/T	cg02187196	chr20:3869020	PANK2	0.86	9.92	0.42	3.57e-21	Response to antidepressants in depression;
LGG	cis	rs9486719	1.000	rs2142653	chr6:96871520	C/A	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs13418717	1.000	rs7572403	chr2:127662420	G/A	cg25501666	chr2:127640322	NA	1.05	8.06	0.35	6.74e-15	Heart failure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18909530	chr10:14216100	FRMD4A	0.51	8.22	0.36	2.1e-15	Gut microbiome composition (summer);
LGG	trans	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg05623727	chr3:50126028	RBM5	-0.35	-7.16	-0.32	3.19e-12	Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14062745	chr2:65357211	RAB1A	-0.45	-7.08	-0.31	5.5e-12	Pancreatic cancer;
LGG	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg20891283	chr12:69753455	YEATS4	0.97	22.86	0.73	5.46e-78	Blood protein levels;
LGG	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg00531865	chr16:30841666	NA	0.44	9.39	0.4	2.72e-19	Triglycerides;
LGG	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg23933602	chr10:16859644	RSU1	0.63	9.24	0.39	8.79e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs701145	0.585	rs1727940	chr3:153827257	C/G	cg17054900	chr3:154042577	DHX36	0.74	8.85	0.38	1.82e-17	Coronary artery disease;
LGG	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-8.81	-0.38	2.53e-17	Schizophrenia;
LGG	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.3	0.43	1.59e-22	Lung cancer in ever smokers;
LGG	cis	rs4731207	0.698	rs6466954	chr7:124515346	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	3.93e-21	Colorectal cancer;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg21058520	chr6:100914733	NA	0.39	6.84	0.3	2.57e-11	Neuroticism;
LGG	trans	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg05926928	chr17:57297772	GDPD1	-0.57	-9.03	-0.39	4.5e-18	Schizophrenia;
LGG	cis	rs7134594	0.677	rs2075440	chr12:109859100	C/T	cg19025524	chr12:109796872	NA	0.47	9.65	0.41	3.24e-20	HDL cholesterol;
LGG	cis	rs6087990	0.748	rs4911255	chr20:31357580	A/T	cg13636640	chr20:31349939	DNMT3B	0.97	21.24	0.7	2.19e-70	Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg21535247	chr6:8435926	SLC35B3	0.56	9.62	0.41	4.43e-20	Motion sickness;
LGG	cis	rs6694672	1.000	rs1412640	chr1:197070815	T/C	cg13682187	chr1:196946512	CFHR5	0.51	7.11	0.31	4.36e-12	Asthma;
LGG	cis	rs17504614	0.597	rs17569963	chr2:51077569	A/G	cg23851515	chr2:51057218	NRXN1	-0.73	-10.91	-0.45	7.99e-25	Educational attainment (years of education);
LGG	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg21545522	chr1:205238299	TMCC2	0.47	8.44	0.37	4.2e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg01673284	chr16:4527211	HMOX2	0.36	7.19	0.32	2.55e-12	Schizophrenia;
LGG	cis	rs4731207	0.596	rs12537473	chr7:124586711	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6450176	0.909	rs10940353	chr5:53299959	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.26	-0.46	3.66e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg03264133	chr6:25882463	NA	-0.5	-9.0	-0.39	5.77e-18	Height;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.32	0.36	9.99e-16	Platelet count;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg14926445	chr8:58193284	C8orf71	-0.72	-8.52	-0.37	2.24e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4720575	0.519	rs2881493	chr7:47078434	C/G	cg00036614	chr7:47093842	NA	-0.39	-6.79	-0.3	3.48e-11	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs4713118	0.513	rs202908	chr6:28011551	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.48	-7.01	-0.31	8.58e-12	Parkinson's disease;
LGG	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22795590	chr2:213401801	ERBB4	0.43	6.69	0.3	6.52e-11	Gut microbiome composition (summer);
LGG	trans	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-11.98	-0.49	5.35e-29	Obesity-related traits;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg07964539	chr6:41890080	BYSL;MED20	-0.38	-6.65	-0.3	8.4e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg09307838	chr4:120376055	NA	-0.8	-13.41	-0.53	7e-35	Corneal astigmatism;
LGG	cis	rs2629540	0.793	rs10794180	chr10:126449306	T/A	cg08799069	chr10:126477246	METTL10	-0.68	-14.5	-0.56	1.53e-39	Cocaine dependence;
LGG	trans	rs2840044	1.000	rs225251	chr17:33951228	A/C	cg19694781	chr19:47549865	TMEM160	-0.55	-9.06	-0.39	3.73e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.68	0.41	2.68e-20	Schizophrenia;
LGG	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg17691542	chr6:26056736	HIST1H1C	0.91	13.38	0.53	9.25e-35	Iron status biomarkers;
LGG	cis	rs9815354	1.000	rs1717021	chr3:41983860	A/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg08250081	chr4:10125330	NA	0.67	12.26	0.5	3.97e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg13628971	chr7:2884303	GNA12	0.55	11.92	0.48	9.07e-29	Height;
LGG	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg12654349	chr5:56205094	C5orf35	-0.42	-7.45	-0.33	4.5e-13	Coronary artery disease;
LGG	cis	rs947474	0.887	rs10796035	chr10:6396623	G/A	cg19837174	chr10:6389707	NA	0.64	9.42	0.4	2.08e-19	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg07777115	chr5:623756	CEP72	-0.57	-7.19	-0.32	2.54e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.38e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10463554	0.927	rs34769	chr5:102447227	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg11502198	chr6:26597334	ABT1	-0.57	-9.68	-0.41	2.59e-20	Intelligence (multi-trait analysis);
LGG	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg05491587	chr18:77659695	KCNG2	0.37	6.72	0.3	5.46e-11	Schizophrenia;
LGG	cis	rs911119	1.000	rs3827142	chr20:23617007	G/A	cg16589663	chr20:23618590	CST3	0.48	6.77	0.3	4.03e-11	Chronic kidney disease;
LGG	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.84	-0.3	2.58e-11	Alzheimer's disease (survival time);
LGG	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg23625390	chr15:77176239	SCAPER	-0.73	-14.62	-0.56	4.43e-40	Blood metabolite levels;
LGG	trans	rs800082	1.000	rs800082	chr3:144340205	A/G	cg24215973	chr2:240111563	HDAC4	0.46	8.09	0.35	5.17e-15	Smoking behavior;
LGG	cis	rs11191205	0.686	rs11191067	chr10:103379882	G/T	cg15320455	chr10:103880129	LDB1	0.48	7.02	0.31	7.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12369635	1.000	rs12372807	chr12:129561332	C/T	cg01909103	chr12:129572610	TMEM132D	-0.66	-6.65	-0.3	8.35e-11	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg26441486	chr22:50317300	CRELD2	0.41	7.33	0.32	1.05e-12	Schizophrenia;
LGG	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg08250081	chr4:10125330	NA	0.67	12.31	0.5	2.48e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03576123	chr11:487126	PTDSS2	-1.23	-16.54	-0.61	1.32e-48	Body mass index;
LGG	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg10253484	chr15:75165896	SCAMP2	0.68	10.98	0.45	4.33e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg00898013	chr13:113819073	PROZ	0.42	8.63	0.37	9.56e-17	Platelet distribution width;
LGG	cis	rs3820068	0.544	rs7551750	chr1:16035008	T/C	cg05660106	chr1:15850417	CASP9	0.76	14.24	0.55	1.98e-38	Systolic blood pressure;
LGG	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg24503407	chr1:205819492	PM20D1	-0.4	-7.18	-0.32	2.75e-12	Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg27539214	chr16:67997921	SLC12A4	-0.47	-7.38	-0.32	7.6e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-6.75	-0.3	4.33e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg02002194	chr4:3960332	NA	0.48	9.14	0.39	2e-18	Mood instability;
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg02093833	chr17:16287835	NA	0.36	6.83	0.3	2.74e-11	Monocyte count;
LGG	trans	rs75804782	0.641	rs112066551	chr2:239362486	G/A	cg01134436	chr17:81009848	B3GNTL1	0.85	8.92	0.38	1.06e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.42	7.5	0.33	3.18e-13	IgG glycosylation;
LGG	cis	rs75804782	0.557	rs10178728	chr2:239360121	T/A	cg18131467	chr2:239335373	ASB1	-0.63	-8.2	-0.36	2.31e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.78	-0.3	3.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg12310025	chr6:25882481	NA	-0.44	-7.98	-0.35	1.2e-14	Height;
LGG	trans	rs8105895	0.877	rs62112919	chr19:22227145	T/C	cg19945060	chr8:41508779	NA	0.45	6.69	0.3	6.5e-11	Body mass index (change over time);
LGG	trans	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.45	-8.9	-0.38	1.28e-17	Obesity-related traits;
LGG	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg05692746	chr2:100937584	LONRF2	-0.5	-8.44	-0.36	4.23e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg04568710	chr12:38710424	ALG10B	0.36	7.41	0.33	6.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg13010199	chr12:38710504	ALG10B	0.45	8.0	0.35	9.88e-15	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20295408	chr7:1910781	MAD1L1	-0.4	-6.86	-0.3	2.18e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs3806843	0.576	rs246021	chr5:140334504	C/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3761847	0.508	rs4837813	chr9:123934463	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.56	10.17	0.43	4.67e-22	Rheumatoid arthritis;
LGG	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg13802316	chr11:70253460	CTTN	0.59	7.73	0.34	6.84e-14	Coronary artery disease;
LGG	cis	rs67133203	0.716	rs67293043	chr12:51532069	C/T	cg14688905	chr12:51403056	SLC11A2	0.72	10.85	0.45	1.38e-24	Urinary tract infection frequency;
LGG	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg25174290	chr11:3078921	CARS	0.73	15.27	0.58	6.1e-43	Longevity;
LGG	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.71	-0.3	5.8200000000000003e-11	Iron status biomarkers;
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs4948275	0.773	rs2787694	chr10:63289836	A/C	cg03237606	chr10:63212265	TMEM26	-0.39	-7.04	-0.31	6.83e-12	Night sleep phenotypes;
LGG	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs7412746	0.634	rs12096831	chr1:150864113	T/G	cg15448220	chr1:150897856	SETDB1	0.4	7.39	0.32	6.79e-13	Melanoma;
LGG	cis	rs11159840	0.609	rs8010926	chr14:88617243	T/C	cg18078958	chr14:88630771	NA	-0.3	-7.13	-0.31	3.99e-12	Left ventricular obstructive tract defect (inherited effect);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01423820	chr14:77228690	VASH1	0.41	7.19	0.32	2.62e-12	Bilirubin levels;
LGG	trans	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg01238044	chr22:24384105	GSTT1	-0.58	-9.96	-0.42	2.56e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs35486314	1	rs35486314	chr1:150901861	A/AT	cg13175981	chr1:150552382	MCL1	0.55	8.7	0.37	5.87e-17	Monocyte chemoattractant protein-1 levels;
LGG	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg25457927	chr22:38595422	NA	-0.4	-10.32	-0.43	1.36e-22	Cutaneous nevi;
LGG	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04935121	chr11:63775413	MACROD1	0.29	7.01	0.31	8.66e-12	Pulse pressure;
LGG	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg05169099	chr5:481640	SLC9A3	0.46	6.84	0.3	2.59e-11	Fat distribution (HIV);
LGG	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs911555	0.723	rs12436956	chr14:103852607	G/T	cg24130564	chr14:104152367	KLC1	0.36	6.73	0.3	5.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.63e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7647973	1.000	rs9860055	chr3:49506900	C/T	cg07636037	chr3:49044803	WDR6	-0.78	-13.85	-0.54	1e-36	Menarche (age at onset);
LGG	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.47	-0.33	4.04e-13	Morning vs. evening chronotype;
LGG	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.99	0.45	4.1e-25	Parkinson's disease;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg13880726	chr7:1868755	MAD1L1	-0.43	-7.45	-0.33	4.54e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg08975724	chr8:8085496	FLJ10661	0.38	7.05	0.31	6.57e-12	Retinal vascular caliber;
LGG	cis	rs12519773	0.597	rs10514370	chr5:92435481	G/T	cg18783429	chr5:92414398	NA	0.31	7.26	0.32	1.66e-12	Migraine;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02475777	chr4:1388615	CRIPAK	0.6	10.74	0.45	3.55e-24	Longevity;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.01	0.31	8.46e-12	Lung cancer;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg00405596	chr8:11794950	NA	-0.62	-10.99	-0.45	4.1e-25	Monocyte count;
LGG	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05165339	chr4:1420672	NA	-0.35	-9.04	-0.39	4.23e-18	Longevity;
LGG	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg19700328	chr14:106028568	NA	-0.62	-10.15	-0.43	5.45e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	2.89e-12	Menopause (age at onset);
LGG	cis	rs3847687	0.901	rs12370258	chr12:131527301	G/T	cg06093039	chr12:131527216	GPR133	0.33	8.19	0.36	2.62e-15	Longevity;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg05313129	chr8:58192883	C8orf71	-0.63	-8.47	-0.37	3.37e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	1.000	rs4740619	chr9:15634326	T/C	cg14451791	chr9:16040625	NA	-0.37	-9.38	-0.4	2.97e-19	Body mass index;
LGG	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	11.11	0.46	1.45e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7666738	0.830	rs11725652	chr4:98878362	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.8	0.34	4.2e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04978709	chr7:75101039	POM121C	0.42	8.57	0.37	1.52e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11203032	0.831	rs11203019	chr10:90952774	A/T	cg16672925	chr10:90967113	CH25H	0.79	11.31	0.47	2.33e-26	Heart failure;
LGG	cis	rs883565	0.569	rs1274972	chr3:39161456	G/A	cg01426195	chr3:39028469	NA	-0.65	-14.08	-0.55	1.02e-37	Handedness;
LGG	cis	rs620875	1.000	rs645298	chr11:126851646	C/T	cg06504925	chr11:126872760	NA	-0.54	-7.58	-0.33	1.86e-13	Response to antipsychotic treatment;
LGG	cis	rs440932	1.000	rs365309	chr8:9026940	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.21	-0.32	2.23e-12	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.31	-0.79	1.61e-98	Primary sclerosing cholangitis;
LGG	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg06353428	chr16:71660113	MARVELD3	0.42	7.16	0.32	3.17e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg05707623	chr12:122985044	ZCCHC8	0.67	9.82	0.42	8.08e-21	Body mass index;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg22907277	chr7:1156413	C7orf50	0.79	10.63	0.44	9.24e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	9.97	0.42	2.38e-21	Renal function-related traits (BUN);
LGG	cis	rs4730250	0.707	rs10953537	chr7:107027905	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.38	-0.43	7.56e-23	Osteoarthritis;
LGG	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg13010199	chr12:38710504	ALG10B	0.69	14.52	0.56	1.27e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.12e-19	Obesity-related traits;
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06850241	chr22:41845214	NA	0.44	7.14	0.32	3.54e-12	Vitiligo;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.2	-0.32	2.47e-12	Neuroticism;
LGG	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg16141378	chr3:129829833	LOC729375	0.33	7.43	0.33	5.25e-13	Monocyte count;
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg16590910	chr6:42928470	GNMT	0.36	9.71	0.41	2.04e-20	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2279817	1.000	rs1339801	chr1:18020298	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.7	13.02	0.52	2.98e-33	Neuroticism;
LGG	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg22875332	chr1:76189707	ACADM	-0.57	-8.44	-0.37	4.05e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs988958	0.526	rs7604533	chr2:42243861	A/T	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Hypospadias;
LGG	cis	rs4700695	0.614	rs152998	chr5:65213066	A/G	cg21114390	chr5:65439923	SFRS12	-0.61	-7.22	-0.32	2.18e-12	Facial morphology (factor 19);
LGG	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg27523141	chr10:43048294	ZNF37B	0.39	7.57	0.33	2.04e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25756869	chr18:51884989	C18orf54	-0.41	-7.12	-0.31	4.2e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06634786	chr22:41940651	POLR3H	0.75	12.34	0.5	1.84e-30	Vitiligo;
LGG	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg27661571	chr11:113659931	NA	-0.48	-6.87	-0.3	2.15e-11	Hip circumference adjusted for BMI;
LGG	cis	rs428668	0.523	rs10060607	chr5:150679304	A/C	cg11125805	chr5:150678162	SLC36A3	0.32	6.64	0.3	8.57e-11	Skin aging (microtopography measurement);
LGG	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg02640540	chr1:67518911	SLC35D1	0.36	7.15	0.32	3.51e-12	Lymphocyte percentage of white cells;
LGG	cis	rs8005677	1.000	rs7155857	chr14:23400059	C/A	cg25600027	chr14:23388339	RBM23	-0.44	-7.22	-0.32	2.08e-12	Cognitive ability (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12709244	chr17:7123282	DLG4;ACADVL	-0.41	-6.68	-0.3	6.69e-11	Pancreatic cancer;
LGG	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg13802316	chr11:70253460	CTTN	-0.65	-8.83	-0.38	2.18e-17	Coronary artery disease;
LGG	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.65	0.34	1.15e-13	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg15704280	chr7:45808275	SEPT13	0.49	8.0	0.35	1.04e-14	HDL cholesterol;
LGG	cis	rs7408868	0.908	rs62113793	chr19:15277336	G/A	cg14696996	chr19:15285081	NOTCH3	1.07	12.9	0.51	9.39e-33	Pulse pressure;
LGG	cis	rs9534288	0.956	rs2094244	chr13:46605803	T/C	cg15192986	chr13:46630673	CPB2	-0.71	-15.77	-0.59	3.64e-45	Blood protein levels;
LGG	cis	rs7546668	0.947	rs4645989	chr1:15850343	A/G	cg21858823	chr1:15850916	CASP9	0.38	7.0	0.31	8.83e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6807915	0.603	rs9823123	chr3:12288569	A/C	cg22839075	chr3:12045461	SYN2	-0.4	-6.83	-0.3	2.69e-11	Leprosy;
LGG	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-7.67	-0.34	1.06e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9457247	1.000	rs429083	chr6:167383972	T/C	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg12070911	chr6:150209640	RAET1E	-0.29	-7.0	-0.31	9.19e-12	Lung cancer;
LGG	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg02297831	chr4:17616191	MED28	0.5	9.25	0.4	8.17e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7551222	0.691	rs4951077	chr1:204482262	G/A	cg20240347	chr1:204465584	NA	-0.56	-11.16	-0.46	9.27e-26	Schizophrenia;
LGG	cis	rs427394	0.659	rs187295	chr5:6734326	C/T	cg15145174	chr5:6755386	POLS	-0.44	-8.0	-0.35	1e-14	Menopause (age at onset);
LGG	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06634786	chr22:41940651	POLR3H	0.78	12.38	0.5	1.35e-30	Vitiligo;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06558623	chr16:89946397	TCF25	1.16	14.89	0.57	2.95e-41	Skin colour saturation;
LGG	cis	rs58235267	0.553	rs11890276	chr2:63366191	C/T	cg17519650	chr2:63277830	OTX1	0.57	10.74	0.45	3.43e-24	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	trans	rs11088226	1.000	rs78679088	chr21:33910827	G/A	cg09050820	chr6:167586206	TCP10L2	0.69	9.87	0.42	5.53e-21	Gastritis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04949346	chr2:169746998	SPC25	0.48	7.78	0.34	4.61e-14	Cognitive performance;
LGG	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg21775007	chr8:11205619	TDH	0.62	10.19	0.43	3.83e-22	Retinal vascular caliber;
LGG	cis	rs4732038	0.565	rs6954495	chr7:134279190	C/T	cg06906464	chr7:134288099	NA	-0.72	-20.7	-0.69	6.88e-68	Longevity;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg15763984	chr4:1342303	KIAA1530	0.38	6.75	0.3	4.33e-11	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14298792	chr15:30685198	CHRFAM7A	0.55	8.18	0.36	2.85e-15	Huntington's disease progression;
LGG	cis	rs17039065	0.834	rs6810454	chr4:109466993	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.11	0.31	4.5e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.68	-0.34	9.63e-14	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01634758	chr19:2136136	AP3D1	-0.38	-6.7	-0.3	6.24e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg24110177	chr3:50126178	RBM5	0.61	11.14	0.46	1.11e-25	Body mass index;
LGG	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg07615347	chr10:60278583	BICC1	0.62	17.71	0.64	5.51e-54	Refractive error;
LGG	cis	rs1707322	0.963	rs10789478	chr1:46350506	C/T	cg03146154	chr1:46216737	IPP	0.55	10.33	0.43	1.17e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.37	-0.36	6.88e-16	Inflammatory skin disease;
LGG	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-10.84	-0.45	1.52e-24	Morning vs. evening chronotype;
LGG	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg23649088	chr2:200775458	C2orf69	-0.47	-8.16	-0.35	3.25e-15	QT interval;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs13115356	chr4:98933171	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.61	0.33	1.55e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3816183	0.530	rs2374437	chr2:42864970	G/A	cg14631114	chr2:43023945	NA	0.34	6.81	0.3	3.04e-11	Hypospadias;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg02725872	chr8:58115012	NA	-0.91	-11.94	-0.49	7.79e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs3815700	1.000	rs2287670	chr19:33095057	G/A	cg02997394	chr19:33096574	ANKRD27	0.87	12.87	0.51	1.29e-32	Eosinophilic esophagitis;
LGG	cis	rs6489785	0.775	rs2650006	chr12:121352206	G/A	cg02419362	chr12:121203948	SPPL3	0.46	7.14	0.31	3.73e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.69	0.41	2.53e-20	Height;
LGG	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg13010199	chr12:38710504	ALG10B	-0.51	-9.96	-0.42	2.59e-21	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg27129171	chr3:47204927	SETD2	0.77	14.93	0.57	1.91e-41	Colorectal cancer;
LGG	cis	rs6815814	0.861	rs1135430	chr4:38789361	T/C	cg06935464	chr4:38784597	TLR10	0.54	8.64	0.37	9.25e-17	Breast cancer;
LGG	cis	rs2172802	0.638	rs1587294	chr4:62503816	T/C	cg04118610	chr4:62707027	LPHN3	0.4	6.66	0.3	7.71e-11	Partial epilepsies;
LGG	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg07936489	chr17:37558343	FBXL20	-0.86	-16.11	-0.6	1.16e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg05623727	chr3:50126028	RBM5	-0.4	-8.43	-0.36	4.33e-16	Menarche (age at onset);
LGG	cis	rs3790455	1.000	rs1925950	chr1:156450740	G/A	cg14087168	chr1:156450669	MEF2D	0.48	7.9	0.34	2.07e-14	Migraine;
LGG	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg02389323	chr16:88786976	FAM38A	1.08	13.09	0.52	1.62e-33	Plateletcrit;
LGG	cis	rs17604090	0.938	rs115369413	chr7:29685040	T/G	cg19413766	chr7:29689036	LOC646762	-0.61	-7.79	-0.34	4.47e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg04315214	chr1:2043799	PRKCZ	0.33	8.08	0.35	5.61e-15	Height;
LGG	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs68170813	0.641	rs12538848	chr7:106984569	G/T	cg02696742	chr7:106810147	HBP1	-0.69	-9.76	-0.41	1.39e-20	Coronary artery disease;
LGG	cis	rs73081554	0.611	rs4681852	chr3:58409173	A/T	cg24175188	chr3:58374923	PXK	0.56	7.64	0.33	1.22e-13	Rheumatoid arthritis;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.26	-0.46	3.63e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.34	0.47	1.81e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg00376283	chr12:123451042	ABCB9	0.56	8.74	0.38	4.42e-17	Neutrophil percentage of white cells;
LGG	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.58	-0.33	1.88e-13	Lung cancer;
LGG	cis	rs1040	0.727	rs9294977	chr6:169624172	A/G	cg04662567	chr6:169592167	NA	0.47	8.16	0.35	3.16e-15	Joint mobility (Beighton score);
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg19223190	chr17:80058835	NA	-0.46	-9.05	-0.39	3.96e-18	Life satisfaction;
LGG	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10895140	0.756	rs2226558	chr11:101509560	C/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14932684	chr12:42632001	YAF2	0.42	7.15	0.32	3.42e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.65	-8.89	-0.38	1.37e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12195424	0.730	rs76211102	chr6:56305340	G/A	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg24623649	chr8:11872141	NA	0.31	7.09	0.31	4.94e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs981844	0.712	rs4469056	chr4:154745796	A/T	cg14289246	chr4:154710475	SFRP2	0.57	9.74	0.41	1.56e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	9.49	0.4	1.26e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12367572	0.620	rs2544102	chr12:45420127	A/G	cg03114573	chr12:45410052	DBX2	-0.7	-12.62	-0.51	1.42e-31	Gut microbiome composition (summer);
LGG	cis	rs1003719	0.788	rs9974286	chr21:38456832	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-17.2	-0.62	1.3e-51	Eye color traits;
LGG	cis	rs8064024	0.649	rs11076849	chr16:4888304	G/T	cg08329684	chr16:4932620	PPL	0.5	11.36	0.47	1.5e-26	Cancer;
LGG	cis	rs2274273	1.000	rs1047556	chr14:55600282	A/T	cg04306507	chr14:55594613	LGALS3	0.61	17.16	0.62	2.01e-51	Protein biomarker;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg05941027	chr17:61774174	LIMD2	0.36	9.1	0.39	2.78e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7215564	0.908	rs35434628	chr17:78714760	C/T	cg16980736	chr17:78789706	RPTOR	-0.58	-7.8	-0.34	4.04e-14	Myopia (pathological);
LGG	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg06241208	chr11:30344200	C11orf46	-0.51	-6.71	-0.3	5.65e-11	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg25214090	chr10:38739885	LOC399744	0.56	10.36	0.43	9.53e-23	Corneal astigmatism;
LGG	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.82	0.45	1.8e-24	Diabetic retinopathy;
LGG	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.81	-0.34	3.89e-14	Mood instability;
LGG	cis	rs3767633	0.502	rs2499845	chr1:161933066	G/C	cg03391019	chr1:161927947	ATF6	0.58	11.32	0.47	2.23e-26	IgG glycosylation;
LGG	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2.06e-21	Height;
LGG	cis	rs367943	0.712	rs13157609	chr5:112683583	G/A	cg12552261	chr5:112820674	MCC	0.54	9.78	0.41	1.17e-20	Type 2 diabetes;
LGG	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	9.25	0.39	8.49e-19	Height;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.32	-0.53	1.73e-34	Alzheimer's disease;
LGG	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs2735413	0.958	rs11150034	chr16:78066369	G/A	cg04733911	chr16:78082701	NA	-0.76	-17.4	-0.63	1.58e-52	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.93	0.54	4.36e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.93	0.38	1.01e-17	Motion sickness;
LGG	cis	rs4330281	0.647	rs35234876	chr3:17432517	G/C	cg20981856	chr3:17787350	NA	0.36	6.78	0.3	3.75e-11	Schizophrenia;
LGG	cis	rs2737618	0.674	rs2249150	chr1:200083654	G/A	cg21825944	chr1:200113062	NR5A2	-0.59	-11.67	-0.48	9.44e-28	Uric acid levels;
LGG	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.01	-24.8	-0.76	5.3e-87	Chronic sinus infection;
LGG	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg06453172	chr10:134556979	INPP5A	-0.51	-8.22	-0.36	2.04e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4356932	0.875	rs10034055	chr4:76970539	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.05e-11	Blood protein levels;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	8.93	0.38	1.03e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4919044	0.808	rs11187252	chr10:94796166	A/T	cg05127821	chr10:94822908	CYP26C1	-0.48	-8.05	-0.35	7e-15	Coronary artery disease;
LGG	cis	rs10463316	0.817	rs6895187	chr5:150775909	G/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.2	-0.43	3.69e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6732160	0.588	rs11126392	chr2:73374454	A/G	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg19761014	chr17:28927070	LRRC37B2	0.6	7.59	0.33	1.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg10840412	chr1:235813424	GNG4	0.59	8.16	0.35	3.19e-15	Bipolar disorder;
LGG	cis	rs921968	0.643	rs2243911	chr2:219529348	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.2	0.32	2.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg14004847	chr7:1930337	MAD1L1	-0.41	-6.77	-0.3	3.99e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.94	-0.31	1.34e-11	Migraine;Coronary artery disease;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg06654118	chr4:1303317	MAEA	0.46	7.9	0.34	2.06e-14	Obesity-related traits;
LGG	cis	rs10262624	0.967	rs13244145	chr7:23917742	C/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg14210321	chr2:106509881	NCK2	-0.49	-8.42	-0.36	4.69e-16	Addiction;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.51e-20	Prudent dietary pattern;
LGG	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg10523679	chr1:76189770	ACADM	0.7	12.18	0.49	8.66e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg27661571	chr11:113659931	NA	-0.69	-9.57	-0.41	6.32e-20	Hip circumference adjusted for BMI;
LGG	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Mean corpuscular hemoglobin;
LGG	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.67	-13.29	-0.53	2.29e-34	Total body bone mineral density;
LGG	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.52	0.44	2.35e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4363385	0.818	rs557553	chr1:153010370	T/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.5	-0.37	2.63e-16	Inflammatory skin disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14212634	chr20:3189677	ITPA	0.4	6.79	0.3	3.5e-11	Bipolar disorder;
LGG	cis	rs11718455	0.960	rs34073911	chr3:44054348	T/C	cg21419209	chr3:44054225	NA	-0.45	-7.1	-0.31	4.85e-12	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs10462794	1.000	rs6882500	chr5:4485755	C/T	cg18482690	chr5:4511582	NA	0.38	6.7	0.3	6.22e-11	DNA methylation (variation);
LGG	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg15890332	chr12:107067104	RFX4	0.31	8.45	0.37	3.73e-16	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.43	-7.06	-0.31	6.2e-12	Prudent dietary pattern;
LGG	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.46	-0.44	3.96e-23	Neuroticism;
LGG	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg03701759	chr13:99174930	STK24	-0.36	-6.97	-0.31	1.06e-11	Neuroticism;
LGG	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg01200585	chr1:228362443	C1orf69	0.47	8.23	0.36	1.85e-15	Diastolic blood pressure;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19524238	chr7:2802976	GNA12	0.38	8.6	0.37	1.23e-16	Height;
LGG	cis	rs7129220	0.588	rs7938534	chr11:10105925	G/T	cg01453529	chr11:10209919	SBF2	-0.42	-6.9	-0.31	1.69e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2652834	0.851	rs11071721	chr15:63350218	T/C	cg05507819	chr15:63340323	TPM1	0.6	8.1	0.35	4.85e-15	HDL cholesterol;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00376625	chr10:65388821	NA	-0.47	-6.81	-0.3	2.97e-11	Systemic lupus erythematosus;
LGG	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.41	-0.33	6.03e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.76	-0.38	3.7e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg03036210	chr16:89904091	SPIRE2	-0.5	-7.17	-0.32	3.02e-12	Skin colour saturation;
LGG	cis	rs4742903	1.000	rs3818625	chr9:106856452	G/A	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg13770153	chr20:60521292	NA	-0.46	-7.71	-0.34	7.87e-14	Body mass index;
LGG	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.1	-0.35	5.06e-15	Calcium levels;
LGG	cis	rs4474465	0.562	rs10793318	chr11:78215898	A/C	cg27205649	chr11:78285834	NARS2	0.48	8.18	0.36	2.7e-15	Alzheimer's disease (survival time);
LGG	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.74	13.59	0.53	1.27e-35	Blood protein levels;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.51e-24	Diabetic retinopathy;
LGG	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7617773	0.744	rs2125482	chr3:48323133	T/G	cg11946769	chr3:48343235	NME6	0.63	10.56	0.44	1.65e-23	Coronary artery disease;
LGG	cis	rs3956705	0.762	rs13437980	chr7:32997749	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.53	8.55	0.37	1.82e-16	Red cell distribution width;
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.05	0.52	2.22e-33	Tonsillectomy;
LGG	cis	rs593982	0.858	rs480989	chr11:65493992	A/G	cg08755490	chr11:65554678	OVOL1	0.72	10.18	0.43	4.12e-22	Atopic dermatitis;
LGG	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg04234412	chr22:24373322	LOC391322	-0.66	-12.0	-0.49	4.6e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06873352	chr17:61820015	STRADA	0.46	7.23	0.32	1.96e-12	Height;
LGG	cis	rs11105298	0.891	rs4842664	chr12:89938030	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.15	-0.39	1.89e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02625641	chr15:59041175	ADAM10	0.42	6.98	0.31	1.04e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7444	0.941	rs5749502	chr22:21945096	T/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.53e-14	Systemic lupus erythematosus;
LGG	trans	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.73	0.48	5.2e-28	Corneal astigmatism;
LGG	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08862035	chr2:2617432	NA	0.42	6.71	0.3	5.74e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs782590	0.935	rs2627779	chr2:55892356	A/G	cg18811423	chr2:55921094	PNPT1	0.91	20.93	0.7	6.05e-69	Metabolic syndrome;
LGG	cis	rs6840360	0.642	rs2724568	chr4:152352223	C/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	4.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9460578	0.508	rs6923264	chr6:20823756	T/C	cg13405222	chr6:20811065	CDKAL1	0.76	17.31	0.63	3.92e-52	Breast cancer;
LGG	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg02002194	chr4:3960332	NA	0.39	7.11	0.31	4.51e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg23649088	chr2:200775458	C2orf69	0.63	11.21	0.46	5.8e-26	Osteoporosis;
LGG	cis	rs7853377	0.723	rs2780103	chr9:86574568	C/T	cg12437157	chr9:86433764	GKAP1	0.4	6.96	0.31	1.14e-11	Height;
LGG	cis	rs13082711	0.595	rs4973761	chr3:27358620	T/C	cg02860705	chr3:27208620	NA	0.93	16.94	0.62	2.02e-50	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg23649088	chr2:200775458	C2orf69	0.79	15.82	0.59	2.34e-45	Osteoporosis;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.16	-0.32	3.1e-12	Height;
LGG	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.89	0.42	4.7e-21	Lung cancer in ever smokers;
LGG	cis	rs2832270	0.562	rs2832188	chr21:30487263	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-6.78	-0.3	3.57e-11	Response to mTOR inhibitor (everolimus);
LGG	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg21435375	chr2:172878103	MAP1D	-0.31	-6.91	-0.31	1.58e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg09699651	chr6:150184138	LRP11	0.53	9.4	0.4	2.58e-19	Lung cancer;
LGG	cis	rs4727027	0.800	rs12530946	chr7:148887942	A/G	cg23583168	chr7:148888333	NA	-0.88	-18.51	-0.65	1.11e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs457717	0.706	rs466393	chr5:75949876	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.32	6.88	0.3	1.96e-11	Hearing impairment;
LGG	cis	rs2916247	1.000	rs2916247	chr8:93013666	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg02023728	chr11:77925099	USP35	0.45	7.91	0.34	1.96e-14	Testicular germ cell tumor;
LGG	cis	rs9649465	1.000	rs6466881	chr7:123337734	G/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.21e-25	Homoarginine levels;
LGG	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg24623649	chr8:11872141	NA	-0.31	-7.43	-0.33	5.28e-13	Neuroticism;
LGG	cis	rs6496667	0.683	rs2589973	chr15:90892293	C/T	cg22089800	chr15:90895588	ZNF774	0.57	9.69	0.41	2.45e-20	Rheumatoid arthritis;
LGG	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg26248373	chr2:1572462	NA	-0.73	-9.42	-0.4	2.14e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg27411982	chr8:10470053	RP1L1	0.39	6.69	0.3	6.31e-11	Mood instability;
LGG	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.25	0.32	1.78e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7945718	0.591	rs4515952	chr11:12690200	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs6988985	0.791	rs13276226	chr8:143998662	G/A	cg10324643	chr8:143916377	GML	-0.38	-7.56	-0.33	2.22e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21659725	chr3:3221576	CRBN	0.74	11.84	0.48	1.9e-28	Resting heart rate;
LGG	trans	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg01620082	chr3:125678407	NA	-0.69	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg18351406	chr4:77819688	ANKRD56	0.47	8.04	0.35	7.31e-15	Emphysema distribution in smoking;
LGG	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.35	-0.32	9.32e-13	Intelligence (multi-trait analysis);
LGG	cis	rs35740288	0.770	rs11636185	chr15:86183118	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.04e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg02254774	chr11:50257496	LOC441601	0.58	6.78	0.3	3.68e-11	Myopia (pathological);
LGG	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-9.42	-0.4	2.16e-19	Aortic root size;
LGG	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg04672837	chr16:48644449	N4BP1	0.56	9.32	0.4	4.95e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg27476859	chr7:2772710	GNA12	0.53	10.34	0.43	1.1e-22	Height;
LGG	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg01130898	chr2:219473002	PLCD4	-0.39	-6.69	-0.3	6.41e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs774359	0.789	rs2440619	chr9:27514323	G/A	cg14173147	chr9:27528300	MOBKL2B	0.45	8.79	0.38	2.85e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg23933602	chr10:16859644	RSU1	0.63	9.24	0.39	9.14e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs11885103	0.791	rs28698506	chr2:584970	T/C	cg21195176	chr2:593345	NA	0.39	7.41	0.33	6e-13	Heschl's gyrus morphology;
LGG	cis	rs13108043	0.605	rs62306511	chr4:87962705	G/A	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.36	-0.32	8.72e-13	Total body bone mineral density;
LGG	cis	rs714515	0.502	rs4916254	chr1:172364012	G/A	cg01573306	chr1:172330400	DNM3	0.42	9.37	0.4	3.19e-19	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.41	-0.53	6.89e-35	Response to antipsychotic treatment;
LGG	trans	rs7830939	0.586	rs28734832	chr8:9321947	C/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.76	0.3	4.25e-11	Neuroticism;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg15971980	chr6:150254442	NA	0.44	8.67	0.37	7.6e-17	Testicular germ cell tumor;
LGG	cis	rs1018836	0.700	rs7824376	chr8:91521498	T/C	cg16814680	chr8:91681699	NA	-0.74	-12.66	-0.51	9.42e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg24110177	chr3:50126178	RBM5	-0.6	-10.88	-0.45	1.04e-24	Intelligence (multi-trait analysis);
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.07	0.42	1.03e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	cis	rs10197940	0.753	rs2290368	chr2:152266473	T/C	cg06191203	chr2:152266755	RIF1	-0.55	-10.11	-0.43	7.5e-22	Lung cancer;
LGG	cis	rs7551222	0.681	rs4245739	chr1:204518842	G/T	cg20240347	chr1:204465584	NA	-0.45	-8.0	-0.35	9.92e-15	Schizophrenia;
LGG	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg08330972	chr4:2403930	ZFYVE28	-0.5	-8.69	-0.37	6.54e-17	Cognitive function;
LGG	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg09754948	chr16:28834200	ATXN2L	0.42	6.81	0.3	3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg26617929	chr16:1858877	NA	0.52	7.05	0.31	6.72e-12	Insulin-like growth factors;
LGG	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg27129171	chr3:47204927	SETD2	-0.78	-14.53	-0.56	1.16e-39	Colorectal cancer;
LGG	cis	rs883565	0.606	rs6763607	chr3:39091596	C/G	cg01426195	chr3:39028469	NA	-0.67	-15.25	-0.58	7.95e-43	Handedness;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.47	0.4	1.43e-19	Life satisfaction;
LGG	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4538187	0.855	rs11125981	chr2:63911761	G/A	cg19915305	chr2:64069682	UGP2	-0.6	-11.63	-0.48	1.29e-27	Systolic blood pressure;
LGG	cis	rs6815814	0.950	rs73236615	chr4:38786869	G/T	cg06935464	chr4:38784597	TLR10	0.6	8.41	0.36	5.07e-16	Breast cancer;
LGG	cis	rs1018836	0.632	rs7017630	chr8:91482604	A/G	cg16814680	chr8:91681699	NA	-0.66	-11.29	-0.46	2.74e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg16584290	chr5:462447	EXOC3	0.45	9.41	0.4	2.33e-19	Cystic fibrosis severity;
LGG	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg25801113	chr15:45476975	SHF	-0.88	-19.15	-0.66	1.2e-60	Uric acid levels;
LGG	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9948	0.529	rs2139406	chr2:97366779	A/G	cg01990225	chr2:97406019	LMAN2L	-0.73	-7.72	-0.34	7.42e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg04000281	chr11:63949212	NA	-0.46	-8.57	-0.37	1.52e-16	Platelet count;
LGG	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.5	-0.53	2.93e-35	Longevity;
LGG	cis	rs8064024	0.676	rs56919624	chr16:4877593	C/A	cg08329684	chr16:4932620	PPL	0.4	8.47	0.37	3.33e-16	Cancer;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg01262667	chr19:19385393	TM6SF2	0.45	11.41	0.47	9.92e-27	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs17685	0.775	rs11761172	chr7:75761547	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg13660082	chr14:53194042	PSMC6	-0.54	-7.5	-0.33	3.18e-13	Alzheimer's disease (late onset);
LGG	trans	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg01314568	chr7:57830625	NA	-0.48	-7.79	-0.34	4.52e-14	Obesity-related traits;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg21139845	chr12:7053993	C12orf57	0.4	6.79	0.3	3.5e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg24607181	chr17:41446203	NA	-0.3	-7.03	-0.31	7.45e-12	Menopause (age at onset);
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.11	-0.55	7.17e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2470578	0.792	rs2733527	chr3:17237409	A/T	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.22e-11	Schizophrenia;
LGG	trans	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg02002194	chr4:3960332	NA	0.43	8.32	0.36	9.71e-16	Systolic blood pressure;
LGG	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg03060546	chr3:49711283	APEH	0.69	11.51	0.47	3.87e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.62	-0.37	1.04e-16	Lung cancer;
LGG	cis	rs9318086	0.648	rs7330140	chr13:24473074	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.26	0.4	7.82e-19	Myopia (pathological);
LGG	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.35	0.36	8.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg22563815	chr15:78856949	CHRNA5	0.27	6.82	0.3	2.9100000000000002e-11	Sudden cardiac arrest;
LGG	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg15352829	chr14:105391018	PLD4	-0.47	-11.1	-0.46	1.49e-25	Systemic lupus erythematosus;
LGG	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg06917634	chr15:78832804	PSMA4	-0.83	-17.59	-0.63	2.03e-53	Sudden cardiac arrest;
LGG	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg07636037	chr3:49044803	WDR6	1.09	27.79	0.79	1.04e-100	Parkinson's disease;
LGG	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	-0.39	-6.69	-0.3	6.63e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg22771759	chr13:24902376	NA	0.42	7.06	0.31	6.05e-12	Obesity-related traits;
LGG	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.21	0.32	2.37e-12	Facial emotion recognition (sad faces);
LGG	cis	rs1978968	0.717	rs34263881	chr22:18401597	G/C	cg03078520	chr22:18463400	MICAL3	-0.51	-9.77	-0.41	1.31e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg00530320	chr1:46809349	NSUN4	0.46	8.48	0.37	3.01e-16	Menopause (age at onset);
LGG	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg11247378	chr22:39784982	NA	-0.31	-8.7	-0.37	5.7e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2115630	0.805	rs8042926	chr15:85205454	T/A	cg12501888	chr15:85177176	SCAND2	-0.43	-7.12	-0.31	4.13e-12	P wave terminal force;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg20887711	chr4:1340912	KIAA1530	0.64	12.89	0.51	1.08e-32	Longevity;
LGG	cis	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg06521331	chr12:34319734	NA	-0.51	-8.69	-0.37	6.46e-17	Resting heart rate;
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs911263	0.603	rs12880109	chr14:68813032	C/T	cg18825221	chr14:68749962	RAD51L1	0.37	8.16	0.35	3.26e-15	Primary biliary cholangitis;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.04	-0.31	6.77e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23990641	chr6:118823964	C6orf204;BRD7P3	0.35	7.17	0.32	3.02e-12	Electrocardiographic conduction measures;
LGG	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15506890	chr2:3487001	NA	-0.55	-10.64	-0.44	8.51e-24	Neurofibrillary tangles;
LGG	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg24565620	chr2:194026	NA	0.71	8.95	0.38	8.35e-18	Blood protein levels;
LGG	cis	rs9513627	1.000	rs4285989	chr13:100132342	A/G	cg15490075	chr13:100150979	NA	0.67	7.07	0.31	5.61e-12	Obesity-related traits;
LGG	cis	rs1670533	1.000	rs6852558	chr4:1059944	C/T	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.53e-21	Recombination rate (females);
LGG	cis	rs1519814	1.000	rs7000103	chr8:121166200	A/C	cg22335954	chr8:121166405	COL14A1	-0.56	-11.25	-0.46	4.05e-26	Breast cancer;
LGG	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Myopia (pathological);
LGG	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.16	0.39	1.7e-18	Motion sickness;
LGG	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-7.85	-0.34	2.93e-14	Schizophrenia;
LGG	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg07395648	chr5:131743802	NA	-0.44	-9.59	-0.41	5.4e-20	Blood metabolite levels;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg07608032	chr19:21579862	ZNF493	-0.39	-6.89	-0.3	1.77e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs8017423	0.630	rs12589687	chr14:90819570	C/G	cg04374321	chr14:90722782	PSMC1	-0.65	-12.78	-0.51	2.9e-32	Mortality in heart failure;
LGG	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg00717180	chr2:96193071	NA	-0.39	-6.9	-0.31	1.69e-11	Coronary artery disease;
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.35e-11	Aortic root size;
LGG	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg11502198	chr6:26597334	ABT1	0.59	10.11	0.43	7.78e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg22875332	chr1:76189707	ACADM	-0.59	-11.28	-0.46	3.12e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs735539	0.593	rs35584557	chr13:21366557	T/C	cg04906043	chr13:21280425	IL17D	-0.45	-7.16	-0.32	3.18e-12	Dental caries;
LGG	cis	rs11971779	0.616	rs1862878	chr7:139019914	C/G	cg07862535	chr7:139043722	LUC7L2	0.41	6.8	0.3	3.21e-11	Diisocyanate-induced asthma;
LGG	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg23625390	chr15:77176239	SCAPER	-0.68	-12.09	-0.49	1.98e-29	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg13147721	chr7:65941812	NA	-0.77	-9.49	-0.4	1.23e-19	Diabetic kidney disease;
LGG	cis	rs7106204	0.686	rs16912345	chr11:24283119	A/G	ch.11.24196551F	chr11:24239977	NA	0.88	9.73	0.41	1.8e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7412746	0.634	rs2124952	chr1:150923774	T/A	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.68	-0.3	6.8e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9457247	1.000	rs415890	chr6:167406633	C/G	cg07741184	chr6:167504864	NA	-0.32	-7.05	-0.31	6.53e-12	Crohn's disease;
LGG	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg16850897	chr7:100343110	ZAN	-0.65	-9.7	-0.41	2.25e-20	Other erythrocyte phenotypes;
LGG	cis	rs362296	0.698	rs3095073	chr4:3263138	C/T	cg06533319	chr4:3265114	C4orf44	0.52	10.87	0.45	1.18e-24	Parental longevity (mother's age at death);
LGG	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg27523141	chr10:43048294	ZNF37B	-0.36	-7.47	-0.33	4.14e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg08824895	chr13:115047677	UPF3A	0.41	7.02	0.31	8.09e-12	Schizophrenia;
LGG	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg18252515	chr7:66147081	NA	-1.35	-19.0	-0.66	6.12e-60	Diabetic kidney disease;
LGG	cis	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg07460842	chr6:66804631	NA	-0.95	-17.42	-0.63	1.25e-52	Exhaled nitric oxide output;
LGG	cis	rs9815354	0.953	rs11717170	chr3:42002811	G/C	cg03022575	chr3:42003672	ULK4	-0.65	-8.37	-0.36	7.04e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11739541	chr12:49582842	TUBA1A	0.44	7.14	0.31	3.65e-12	Cognitive performance;
LGG	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg16230307	chr14:35515116	FAM177A1	0.88	13.03	0.52	2.75e-33	Psoriasis;
LGG	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg19524238	chr7:2802976	GNA12	0.38	8.63	0.37	1.01e-16	Height;
LGG	cis	rs9354308	0.764	rs9342516	chr6:66602580	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	trans	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg02158880	chr13:53174818	NA	0.36	6.67	0.3	7.13e-11	Lewy body disease;
LGG	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.67	0.44	6.8e-24	Blood protein levels;
LGG	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.83	0.3	2.63e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4262150	0.810	rs4958320	chr5:151964215	G/A	cg12297329	chr5:152029980	NA	-0.79	-15.56	-0.59	3.24e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs2916247	0.954	rs12056584	chr8:93141987	T/C	cg10183463	chr8:93005414	RUNX1T1	0.37	7.62	0.33	1.45e-13	Intelligence (multi-trait analysis);
LGG	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.08e-14	Type 2 diabetes;
LGG	cis	rs11677416	0.813	rs4848299	chr2:113523454	C/A	cg27083787	chr2:113543245	IL1A	0.53	8.8	0.38	2.69e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg15440763	chr7:158190612	PTPRN2	0.46	9.4	0.4	2.55e-19	Obesity-related traits;
LGG	cis	rs13202913	0.709	rs11965449	chr6:151830598	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.52	-7.11	-0.31	4.31e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7666738	0.606	rs28481322	chr4:99086638	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.95	0.31	1.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs977987	0.806	rs2161684	chr16:75479153	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.29	0.43	1.6400000000000001e-22	Dupuytren's disease;
LGG	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg04617936	chr2:214353	NA	0.51	7.71	0.34	7.72e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg07661805	chr8:143867942	LY6D	0.27	7.38	0.32	7.29e-13	Urinary tract infection frequency;
LGG	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.4	-7.55	-0.33	2.3e-13	Coronary artery disease;
LGG	cis	rs28374715	0.662	rs28382348	chr15:41487934	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.01	-17.98	-0.64	3.25e-55	Ulcerative colitis;
LGG	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg03342759	chr3:160939853	NMD3	-0.44	-7.46	-0.33	4.41e-13	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg04691961	chr3:161091175	C3orf57	-0.44	-9.38	-0.4	2.93e-19	Morning vs. evening chronotype;
LGG	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg02002194	chr4:3960332	NA	0.47	9.14	0.39	1.97e-18	Joint mobility (Beighton score);
LGG	trans	rs6787172	0.837	rs1656373	chr3:158273521	C/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.23	-0.32	2.06e-12	Subjective well-being;
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00761968	chr13:53314142	LECT1	-0.43	-9.54	-0.41	8.18e-20	Lewy body disease;
LGG	cis	rs730566	1.000	rs4858819	chr3:48478088	C/T	cg07636037	chr3:49044803	WDR6	-0.56	-9.11	-0.39	2.56e-18	Prion diseases;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.55	0.41	7.39e-20	Renal function-related traits (BUN);
LGG	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg27624424	chr6:160112604	SOD2	0.69	10.03	0.42	1.49e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.3	-0.4	5.79e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg11887960	chr12:57824829	NA	0.59	7.24	0.32	1.88e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9788682	0.747	rs2568499	chr15:78722359	T/C	cg06917634	chr15:78832804	PSMA4	0.53	7.95	0.35	1.46e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9467773	0.572	rs3846846	chr6:26445039	A/G	cg09904177	chr6:26538194	HMGN4	-0.44	-7.81	-0.34	3.88e-14	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg06521331	chr12:34319734	NA	-0.4	-7.24	-0.32	1.91e-12	Morning vs. evening chronotype;
LGG	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg08344181	chr3:125677491	NA	-0.7	-7.93	-0.35	1.67e-14	Depression;
LGG	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg13482628	chr17:19912719	NA	0.62	12.14	0.49	1.23e-29	Schizophrenia;
LGG	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg13647721	chr17:30228624	UTP6	0.66	8.94	0.38	9.47e-18	Hip circumference adjusted for BMI;
LGG	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.81	-0.34	3.8e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	7.02	0.31	7.75e-12	Birth weight;
LGG	cis	rs1881509	0.660	rs4963080	chr11:1435853	A/G	cg07067744	chr11:1421172	BRSK2	0.35	6.9	0.31	1.69e-11	Heroin dependence;
LGG	cis	rs12618769	0.597	rs72819965	chr2:99023719	G/C	cg18455616	chr2:99124870	INPP4A	0.28	8.23	0.36	1.86e-15	Bipolar disorder;
LGG	cis	rs2692947	0.832	rs2438972	chr2:96690873	T/C	cg22654517	chr2:96458247	NA	0.37	8.04	0.35	7.81e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg13259177	chr13:114761607	RASA3	-0.78	-11.01	-0.46	3.39e-25	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg21644426	chr2:191273491	MFSD6	0.59	10.18	0.43	4.36e-22	Pulse pressure;
LGG	cis	rs722599	0.748	rs7145173	chr14:75351647	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.23	-0.43	2.81e-22	IgG glycosylation;
LGG	cis	rs7072216	0.727	rs7915108	chr10:100164441	T/C	cg26618903	chr10:100175079	PYROXD2	-0.28	-6.8	-0.3	3.28e-11	Metabolite levels;
LGG	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg10847948	chr11:71163743	NADSYN1	0.63	11.42	0.47	8.6e-27	Vitamin D levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18854735	chr1:1822972	GNB1	0.44	7.06	0.31	6.28e-12	Cognitive performance;
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg03036210	chr16:89904091	SPIRE2	-0.48	-6.85	-0.3	2.29e-11	Skin colour saturation;
LGG	cis	rs4974559	0.947	rs28418481	chr4:1330975	C/G	cg02980000	chr4:1222292	CTBP1	0.67	9.92	0.42	3.8e-21	Systolic blood pressure;
LGG	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg09441152	chr18:77712293	PQLC1	0.49	8.87	0.38	1.64e-17	Schizophrenia;
LGG	cis	rs8067287	0.688	rs8081126	chr17:16845362	T/C	cg26910001	chr17:16838321	NA	-0.4	-7.92	-0.35	1.75e-14	Diabetic kidney disease;
LGG	cis	rs4959677	0.935	rs4959187	chr6:2494871	A/G	cg20147862	chr6:2634573	C6orf195	-0.4	-8.68	-0.37	6.82e-17	Orthostatic hypotension;
LGG	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.48	-0.37	3.06e-16	Calcium levels;
LGG	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.77	0.3	3.89e-11	Type 2 diabetes;
LGG	cis	rs6546550	0.935	rs13392884	chr2:70036711	A/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-7.14	-0.32	3.59e-12	Prevalent atrial fibrillation;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.67	0.34	1e-13	Longevity;
LGG	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg00490583	chr16:1843685	IGFALS	-0.44	-9.69	-0.41	2.43e-20	Insulin-like growth factors;
LGG	cis	rs4742903	0.935	rs10120101	chr9:107000909	C/T	cg14250997	chr9:106856677	SMC2	0.36	7.4	0.33	6.3e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg22643751	chr7:855365	UNC84A	0.36	6.85	0.3	2.39e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs3540	0.960	rs2238325	chr15:91011262	C/T	cg22089800	chr15:90895588	ZNF774	-0.51	-8.02	-0.35	8.86e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs35146811	0.586	rs12705067	chr7:99594726	T/C	cg22906224	chr7:99728672	NA	0.52	8.46	0.37	3.66e-16	Coronary artery disease;
LGG	cis	rs9814567	1.000	rs28409322	chr3:134252385	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs13132184	0.507	rs67733859	chr4:38042347	G/A	cg24826020	chr4:38070998	TBC1D1	0.5	8.5	0.37	2.54e-16	Verbal declarative memory;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg12395012	chr8:11607386	GATA4	0.4	7.39	0.32	6.98e-13	Neuroticism;
LGG	cis	rs17208368	0.723	rs1386266	chr16:55088588	C/A	cg11181171	chr16:55090946	NA	0.44	6.64	0.3	8.55e-11	Hypospadias;
LGG	cis	rs3087591	1.000	rs12600974	chr17:29589360	A/G	cg24425628	chr17:29625626	OMG;NF1	0.71	14.79	0.57	7.86e-41	Hip circumference;
LGG	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.51	8.34	0.36	8.51e-16	Hip circumference adjusted for BMI;
LGG	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg01620082	chr3:125678407	NA	-0.88	-7.46	-0.33	4.3e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9462027	0.628	rs3734268	chr6:34716028	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg18404041	chr3:52824283	ITIH1	-0.59	-11.44	-0.47	7.13e-27	Bipolar disorder;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.95	-0.45	5.6e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs12887734	0.569	rs66953418	chr14:104271470	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-8.68	-0.37	6.59e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg01200585	chr1:228362443	C1orf69	0.46	8.07	0.35	5.89e-15	Diastolic blood pressure;
LGG	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2120019	1.000	rs12903201	chr15:75370776	A/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.59	-0.61	7.35e-49	Blood trace element (Zn levels);
LGG	cis	rs283228	0.798	rs2518342	chr6:101772222	G/T	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06634786	chr22:41940651	POLR3H	0.76	12.14	0.49	1.25e-29	Vitiligo;
LGG	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.79	0.3	3.37e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7529073	0.683	rs340882	chr1:214145731	C/G	cg05052969	chr1:214156842	NA	-0.51	-9.99	-0.42	2.11e-21	Schizophrenia;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg21827317	chr3:136751795	NA	0.53	10.01	0.42	1.72e-21	Neuroticism;
LGG	cis	rs72781680	0.898	rs72782138	chr2:24048162	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.71e-18	Lymphocyte counts;
LGG	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg14835575	chr10:16859367	RSU1	0.8	14.87	0.57	3.6700000000000003e-41	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs9815354	0.812	rs77732985	chr3:41945872	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9357271	0.956	rs4711543	chr6:38342215	A/G	cg07362130	chr6:38359646	BTBD9	-0.47	-10.76	-0.45	2.98e-24	Restless legs syndrome;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17696166	chr17:36981606	CCDC49	0.44	7.25	0.32	1.75e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12079745	0.590	rs7544446	chr1:169256524	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.99	-7.24	-0.32	1.85e-12	QT interval;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.32	-0.43	1.34e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg13072238	chr3:49761600	GMPPB	0.54	7.07	0.31	5.73e-12	Menarche (age at onset);
LGG	trans	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg06521331	chr12:34319734	NA	-0.52	-9.57	-0.41	6.37e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg17376030	chr22:41985996	PMM1	-0.51	-8.25	-0.36	1.67e-15	Vitiligo;
LGG	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs59104589	0.521	rs2240482	chr2:242405021	C/T	cg13788902	chr2:242434635	STK25	0.4	6.92	0.31	1.47e-11	Fibrinogen levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26260386	chr4:140477698	SETD7	0.42	7.01	0.31	8.65e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7072216	0.763	rs942804	chr10:100168499	C/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.14	-0.32	3.52e-12	Metabolite levels;
LGG	cis	rs10193935	1.000	rs13411405	chr2:42413811	C/A	cg27598129	chr2:42591480	NA	-0.64	-9.41	-0.4	2.35e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6450176	1.000	rs6450175	chr5:53297824	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.56	-0.47	2.56e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg21605333	chr4:119757512	SEC24D	0.79	8.63	0.37	1.01e-16	Cannabis dependence symptom count;
LGG	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg09818912	chr17:20140352	CYTSB	0.3	6.86	0.3	2.19e-11	Obesity-related traits;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.66	0.59	1.1e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9547996	0.879	rs1006416	chr13:38164445	G/A	cg17979426	chr13:38220150	TRPC4	0.36	6.82	0.3	2.87e-11	Diastolic blood pressure;
LGG	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg11584989	chr19:19387371	SF4	0.8	12.66	0.51	9.72e-32	Bipolar disorder;
LGG	trans	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg12288994	chr5:1860383	NA	0.78	15.74	0.59	5.27e-45	Cardiovascular disease risk factors;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.1	0.43	8.03e-22	Schizophrenia;
LGG	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	14.53	0.56	1.17e-39	Caffeine consumption;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04772025	chr11:68637568	NA	0.71	12.53	0.5	3.19e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.29	0.32	1.39e-12	Menopause (age at onset);
LGG	cis	rs8179	0.645	rs7804293	chr7:92287849	T/G	cg15732164	chr7:92237376	CDK6	-0.53	-9.96	-0.42	2.73e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg21972741	chr5:435613	AHRR	0.49	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs975739	0.966	rs1823554	chr13:78382705	A/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.72	0.3	5.34e-11	Hair color;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.62	0.44	9.61e-24	Lung cancer in ever smokers;
LGG	cis	rs2797369	0.713	rs4537154	chr6:101569879	A/C	cg27451362	chr6:101846650	GRIK2	-0.84	-11.2	-0.46	6.29e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg11584989	chr19:19387371	SF4	0.4	7.22	0.32	2.09e-12	Tonsillectomy;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg01516881	chr6:292596	DUSP22	-0.47	-8.05	-0.35	7.3e-15	Menopause (age at onset);
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg21605986	chr5:175788725	KIAA1191	0.4	6.67	0.3	7.51e-11	Prudent dietary pattern;
LGG	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.57	-0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06481639	chr22:41940642	POLR3H	-0.64	-9.2	-0.39	1.23e-18	Vitiligo;
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.7e-12	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg14926445	chr8:58193284	C8orf71	-0.84	-10.55	-0.44	1.76e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg04568710	chr12:38710424	ALG10B	0.35	7.16	0.32	3.23e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg02269571	chr22:50332266	NA	0.63	10.09	0.42	8.75e-22	Schizophrenia;
LGG	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.47	-0.33	4.11e-13	Total body bone mineral density;
LGG	cis	rs4936894	0.500	rs10790650	chr11:124080388	A/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.96	-0.45	5.06e-25	Aging (time to death);
LGG	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	cis	rs7566780	0.661	rs4393752	chr2:16652659	T/C	cg09580478	chr2:16689509	NA	0.47	6.77	0.3	3.85e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.47	0.33	4.1e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.34	-0.36	8.38e-16	Aortic root size;
LGG	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg19183879	chr15:85880815	NA	-0.5	-9.42	-0.4	2.09e-19	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	trans	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg08344181	chr3:125677491	NA	-0.48	-6.86	-0.3	2.24e-11	Depression;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10827094	chr12:117468061	FBXW8	0.36	6.98	0.31	1.02e-11	Electrocardiographic conduction measures;
LGG	cis	rs4845570	0.920	rs6694952	chr1:151760131	T/C	cg07092448	chr1:151763213	TDRKH	1.11	17.56	0.63	2.72e-53	Coronary artery disease;
LGG	cis	rs1371867	0.846	rs1692007	chr8:101268343	T/C	cg06636551	chr8:101224915	SPAG1	0.47	8.71	0.38	5.52e-17	Atrioventricular conduction;
LGG	cis	rs4730779	0.543	rs1042077	chr7:117235055	T/G	cg10524701	chr7:117356490	CTTNBP2	0.4	7.77	0.34	5.27e-14	Waist circumference;
LGG	cis	rs9815354	1.000	rs9830064	chr3:41881801	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13040021	chr20:5093911	C20orf30	0.5	7.58	0.33	1.84e-13	Gut microbiome composition (summer);
LGG	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg03161606	chr19:29218774	NA	0.68	10.54	0.44	2.04e-23	Methadone dose in opioid dependence;
LGG	cis	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg00405596	chr8:11794950	NA	-0.41	-6.73	-0.3	4.9e-11	Retinal vascular caliber;
LGG	cis	rs950027	0.620	rs1346267	chr15:45690989	A/G	cg26924012	chr15:45694286	SPATA5L1	0.67	11.94	0.49	8.12e-29	Response to fenofibrate (adiponectin levels);
LGG	trans	rs12517041	1.000	rs2217309	chr5:23313736	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs9925964	0.591	rs11649653	chr16:30918487	C/G	cg00531865	chr16:30841666	NA	0.37	7.78	0.34	4.61e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs972578	0.765	rs5759006	chr22:43273740	C/G	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.95e-11	Mean platelet volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11877270	chr2:65658583	SPRED2	0.5	8.19	0.36	2.5e-15	Cognitive performance;
LGG	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg04455712	chr21:45112962	RRP1B	-0.51	-9.85	-0.42	6.44e-21	Mean corpuscular volume;
LGG	cis	rs774359	0.789	rs17769038	chr9:27489693	G/A	cg21249376	chr9:27528432	MOBKL2B	0.47	8.29	0.36	1.26e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg10253484	chr15:75165896	SCAMP2	0.56	7.3	0.32	1.28e-12	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LGG	cis	rs4417704	0.551	rs4077132	chr2:241889937	A/G	cg05025159	chr2:241905733	NA	0.49	10.02	0.42	1.55e-21	Joint mobility (Beighton score);
LGG	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.29	0.4	5.9e-19	Mean corpuscular volume;
LGG	cis	rs4750440	0.523	rs4565800	chr10:14032326	G/C	cg27542038	chr10:14027202	FRMD4A	-0.74	-14.4	-0.56	4.08e-39	Adiponectin levels;
LGG	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg11040518	chr10:102331378	NA	0.38	7.12	0.31	4.13e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg24898562	chr19:15543952	WIZ	0.42	7.09	0.31	4.91e-12	Hepatitis;
LGG	trans	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-11.3	-0.46	2.58e-26	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17384381	0.953	rs11161599	chr1:85795965	A/G	cg16011679	chr1:85725395	C1orf52	-0.69	-10.67	-0.44	6.68e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12190007	0.508	rs6605538	chr6:169731432	G/A	cg16388071	chr6:169726476	NA	0.56	11.69	0.48	7.55e-28	Obesity-related traits;
LGG	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.65	0.44	7.42e-24	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg21926883	chr2:100939477	LONRF2	-0.44	-7.98	-0.35	1.17e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.77	-0.38	3.54e-17	Dementia with Lewy bodies;
LGG	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.47	0.53	4.15e-35	IgG glycosylation;
LGG	cis	rs73001065	0.591	rs56273306	chr19:19621004	T/C	cg03709012	chr19:19516395	GATAD2A	0.98	10.82	0.45	1.84e-24	LDL cholesterol;
LGG	trans	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.38	-0.4	3.04e-19	Bladder cancer;
LGG	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg02403541	chr12:121454288	C12orf43	0.53	8.48	0.37	3.02e-16	N-glycan levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14966562	chr5:32444709	ZFR	0.45	6.69	0.3	6.32e-11	Gut microbiome composition (summer);
LGG	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1881396	0.531	rs72613829	chr2:27902987	C/T	cg27432699	chr2:27873401	GPN1	0.58	7.5	0.33	3.28e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg00405596	chr8:11794950	NA	-0.43	-6.72	-0.3	5.24e-11	Retinal vascular caliber;
LGG	cis	rs17125944	0.615	rs2357945	chr14:53318434	A/G	cg00686598	chr14:53173677	PSMC6	-0.7	-7.28	-0.32	1.42e-12	Alzheimer's disease (late onset);
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14893161	chr1:205819251	PM20D1	-0.55	-10.36	-0.43	8.96e-23	Menarche (age at onset);
LGG	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.03e-21	Common traits (Other);
LGG	cis	rs12220238	1.000	rs10824084	chr10:75911415	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.75	0.48	4.56e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg23978390	chr7:1156363	C7orf50	0.55	9.45	0.4	1.72e-19	Longevity;Endometriosis;
LGG	cis	rs988958	0.567	rs6718777	chr2:42246498	G/A	cg19376973	chr2:42229025	NA	0.63	10.25	0.43	2.38e-22	Hypospadias;
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.77	-14.34	-0.55	7.5e-39	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg03733263	chr8:22462867	KIAA1967	1.09	28.56	0.8	3.31e-104	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.45e-22	Menopause (age at onset);
LGG	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg00784671	chr22:46762841	CELSR1	-0.63	-7.41	-0.33	5.93e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2479106	0.892	rs2458490	chr9:126598435	T/C	cg16191174	chr9:126692580	DENND1A	0.45	6.7	0.3	6.03e-11	Polycystic ovary syndrome;
LGG	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg15997130	chr1:24165203	NA	-0.49	-13.23	-0.52	3.88e-34	Immature fraction of reticulocytes;
LGG	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.58	-0.61	8.36e-49	Height;
LGG	cis	rs8077889	0.917	rs72836547	chr17:41902799	G/T	cg26893861	chr17:41843967	DUSP3	0.94	15.79	0.59	3.06e-45	Triglycerides;
LGG	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg21692620	chr17:40835849	CNTNAP1	-0.33	-7.42	-0.33	5.68e-13	Colorectal or endometrial cancer;
LGG	cis	rs362272	0.525	rs1313768	chr4:3054017	T/C	cg02566259	chr4:3043199	NA	0.34	8.6	0.37	1.25e-16	Serum sulfate level;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg00830817	chr11:109293614	C11orf87	0.42	6.88	0.3	1.94e-11	Schizophrenia;
LGG	cis	rs12580194	0.593	rs7971053	chr12:55729947	A/C	cg19537932	chr12:55886519	OR6C68	-0.53	-9.45	-0.4	1.64e-19	Cancer;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg17734273	chr15:78292508	TBC1D2B	0.31	7.0	0.31	8.82e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs9902453	0.612	rs2617868	chr17:28073247	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.36	-0.56	5.86e-39	Coffee consumption (cups per day);
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.62	-10.71	-0.45	4.45e-24	Obesity-related traits;
LGG	cis	rs11676348	0.818	rs7423433	chr2:218985084	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-9.87	-0.42	5.57e-21	Ulcerative colitis;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs1034435	0.692	rs6008739	chr22:48892542	T/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.9	-0.62	2.89e-50	Late-onset Alzheimer's disease;
LGG	cis	rs1018836	0.923	rs4735256	chr8:91612145	C/G	cg16814680	chr8:91681699	NA	-0.86	-16.18	-0.6	5.21e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12681287	0.640	rs13264364	chr8:87466385	G/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.67	13.61	0.53	1.05e-35	Menarche (age at onset);
LGG	cis	rs7432375	0.641	rs835649	chr3:136671890	G/A	cg21827317	chr3:136751795	NA	0.44	7.81	0.34	3.96e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg13939156	chr17:80058883	NA	0.49	9.89	0.42	4.72e-21	Life satisfaction;
LGG	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg16797656	chr11:68205561	LRP5	0.51	9.92	0.42	3.73e-21	Total body bone mineral density;
LGG	cis	rs6868223	0.836	rs12186661	chr5:33644382	G/A	cg10594543	chr5:33649717	ADAMTS12	0.64	14.86	0.57	4.04e-41	Mortality in heart failure;
LGG	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg27411982	chr8:10470053	RP1L1	0.46	8.01	0.35	9.71e-15	Joint mobility (Beighton score);
LGG	cis	rs754466	0.606	rs11002306	chr10:79591519	A/T	cg17075019	chr10:79541650	NA	-0.96	-21.52	-0.71	1.06e-71	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg14835575	chr10:16859367	RSU1	0.75	13.92	0.54	5.02e-37	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.9	10.22	0.43	3.15e-22	Diabetic retinopathy;
LGG	cis	rs8077889	0.871	rs8081101	chr17:41904332	C/T	cg26893861	chr17:41843967	DUSP3	0.9	15.49	0.58	6.74e-44	Triglycerides;
LGG	cis	rs45544231	0.593	rs3095601	chr16:52580285	G/T	cg09051775	chr16:52580266	TOX3	-0.45	-7.51	-0.33	3.05e-13	Restless legs syndrome;
LGG	cis	rs9863	0.861	rs7973683	chr12:124449223	C/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.04	-0.31	6.79e-12	White blood cell count;
LGG	cis	rs737693	0.564	rs72983568	chr11:102773998	T/G	cg14995062	chr11:102826570	MMP13	0.51	7.36	0.32	8.24e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg06611532	chr13:114900021	NA	0.28	6.86	0.3	2.27e-11	Schizophrenia;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-9.12	-0.39	2.29e-18	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21948169	chr10:70320051	TET1	0.4	6.72	0.3	5.48e-11	Gut microbiome composition (summer);
LGG	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg07061783	chr6:25882402	NA	-0.44	-7.52	-0.33	2.96e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg11861562	chr11:117069780	TAGLN	0.27	7.16	0.32	3.1e-12	Blood protein levels;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs737008	0.960	rs11640295	chr16:11390728	C/G	cg00044050	chr16:11439710	C16orf75	0.54	7.91	0.35	1.87e-14	Obesity-related traits;
LGG	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg18200150	chr17:30822561	MYO1D	0.8	19.11	0.66	1.87e-60	Schizophrenia;
LGG	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.43	-0.36	4.27e-16	Schizophrenia;
LGG	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg17145862	chr1:211918768	LPGAT1	0.79	17.19	0.62	1.35e-51	Leprosy;
LGG	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg24375607	chr4:120327624	NA	0.6	10.03	0.42	1.47e-21	Corneal astigmatism;
LGG	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg12856521	chr11:46389249	DGKZ	-0.74	-13.22	-0.52	4.29e-34	Crohn's disease;
LGG	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	10.55	0.44	1.89e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Vitiligo;
LGG	cis	rs1957429	0.731	rs28370916	chr14:65346094	A/G	cg23373153	chr14:65346875	NA	1.15	15.16	0.58	1.94e-42	Pediatric areal bone mineral density (radius);
LGG	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg03929089	chr4:120376271	NA	-0.98	-21.19	-0.7	3.82e-70	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16318349	chr1:154917307	PBXIP1	0.27	7.38	0.32	7.58e-13	Prostate cancer;
LGG	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.36	6.65	0.3	8.34e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.4	-0.4	2.48e-19	Depression;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg04455712	chr21:45112962	RRP1B	0.51	9.66	0.41	3.11e-20	Mean corpuscular volume;
LGG	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg08648136	chr8:956695	NA	0.42	9.09	0.39	2.96e-18	Schizophrenia;
LGG	cis	rs1003719	0.788	rs1543749	chr21:38446621	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs9472414	0.510	rs7746032	chr6:44708613	A/T	cg20913747	chr6:44695427	NA	0.46	7.61	0.33	1.59e-13	Height;
LGG	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs9815354	1.000	rs6805880	chr3:41865397	A/G	cg03022575	chr3:42003672	ULK4	0.68	8.7	0.37	5.97e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2737618	0.722	rs2816978	chr1:200078773	A/G	cg21825944	chr1:200113062	NR5A2	-0.6	-11.42	-0.47	8.72e-27	Uric acid levels;
LGG	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg02002194	chr4:3960332	NA	-0.51	-9.56	-0.41	7e-20	Retinal vascular caliber;
LGG	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs999943	0.846	rs2274200	chr6:33625696	T/C	cg14003231	chr6:33640908	ITPR3	0.63	14.42	0.56	3.3e-39	Obesity (extreme);
LGG	cis	rs7666738	0.830	rs62318504	chr4:98935558	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.17	-0.49	9.33e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg03433033	chr1:76189801	ACADM	0.78	14.33	0.55	8.55e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.6	0.33	1.62e-13	Obesity-related traits;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00028636	chr12:6876321	PTMS	-0.41	-6.79	-0.3	3.54e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7226408	0.857	rs55731927	chr18:34731431	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs77633900	0.614	rs2439984	chr15:76923917	T/C	cg21673338	chr15:77095150	SCAPER	-0.65	-10.1	-0.43	7.96e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.81e-22	Motion sickness;
LGG	cis	rs9398803	0.651	rs9388509	chr6:126989977	G/A	cg19875578	chr6:126661172	C6orf173	0.52	9.53	0.41	8.63e-20	Male-pattern baldness;
LGG	trans	rs6076960	0.684	rs6054041	chr20:6247288	C/T	cg17788362	chr6:86352627	SYNCRIP	0.53	9.05	0.39	3.92e-18	Smooth-surface caries;
LGG	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg17788362	chr6:86352627	SYNCRIP	0.54	9.13	0.39	2.08e-18	Smooth-surface caries;
LGG	cis	rs701145	0.585	rs242577	chr3:153941208	G/A	cg12800244	chr3:153838788	SGEF	0.84	8.33	0.36	9.55e-16	Coronary artery disease;
LGG	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.31	0.36	1.09e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs9308731	0.863	rs616582	chr2:111941995	T/C	cg19992207	chr2:111874495	ACOXL	-0.39	-6.93	-0.31	1.44e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.21	-0.36	2.27e-15	Coronary artery disease;
LGG	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg02549819	chr16:58548995	SETD6	1.45	13.97	0.54	2.81e-37	Schizophrenia;
LGG	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.54	-7.73	-0.34	6.67e-14	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.64e-12	Lung cancer;
LGG	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.54	-0.41	7.96e-20	Aortic root size;
LGG	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.32	0.32	1.1e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs5015933	0.966	rs10986724	chr9:128131519	A/G	cg14078157	chr9:128172775	NA	0.35	6.81	0.3	3.13e-11	Body mass index;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg17074213	chr1:92351695	TGFBR3	-0.39	-6.84	-0.3	2.56e-11	Sitting height ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24261270	chr8:22462105	KIAA1967	0.51	7.91	0.35	1.92e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.77	0.3	3.93e-11	Lung cancer;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg08742575	chr21:47604166	C21orf56	-0.53	-8.94	-0.38	9.62e-18	Testicular germ cell tumor;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.58	0.33	1.85e-13	Longevity;
LGG	trans	rs225245	0.541	rs321613	chr17:33881718	G/A	cg19694781	chr19:47549865	TMEM160	-0.53	-9.45	-0.4	1.69e-19	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs12949688	0.575	rs10083864	chr17:55837910	C/T	cg12582317	chr17:55822272	NA	-0.44	-10.03	-0.42	1.45e-21	Schizophrenia;
LGG	cis	rs1010254	0.510	rs55689355	chr5:151756636	C/G	cg12297329	chr5:152029980	NA	-0.5	-7.21	-0.32	2.22e-12	Optic nerve measurement (cup area);
LGG	cis	rs4888378	0.576	rs8050367	chr16:75313258	A/G	cg07303275	chr16:75499416	TMEM170A	-0.45	-7.23	-0.32	1.99e-12	Coronary artery disease;
LGG	cis	rs2985684	0.846	rs10150624	chr14:50051565	A/G	cg02151108	chr14:50098012	C14orf104	-0.42	-8.99	-0.39	6.32e-18	Carotid intima media thickness;
LGG	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.66	0.34	1.11e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.79	0.66	5.99e-59	Personality dimensions;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg08302650	chr8:145750040	LRRC24;LRRC14	-0.37	-8.16	-0.35	3.24e-15	Age at first birth;
LGG	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14442939	chr10:27389572	ANKRD26	0.73	11.21	0.46	5.75e-26	Breast cancer;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg17202724	chr17:61916730	SMARCD2	0.56	12.98	0.52	4.43e-33	Prudent dietary pattern;
LGG	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg03162506	chr22:38580953	NA	0.28	6.84	0.3	2.45e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs11585357	0.947	rs6684387	chr1:17611519	T/C	cg08277548	chr1:17600880	PADI3	0.7	8.37	0.36	6.82e-16	Hair shape;
LGG	cis	rs4363385	0.776	rs3170863	chr1:152944594	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-8.47	-0.37	3.2e-16	Inflammatory skin disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13841901	chr1:45805975	MUTYH;TOE1	0.41	6.92	0.31	1.52e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs36071027	0.615	rs34569927	chr5:158421240	A/C	cg23468002	chr5:158532401	NA	0.43	7.19	0.32	2.6e-12	Carotid intima media thickness;
LGG	cis	rs1111571	0.576	rs1465469	chr16:68397916	T/G	cg07273125	chr16:68295692	NA	0.38	8.2	0.36	2.31e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg01943577	chr7:158741284	NA	-0.45	-8.07	-0.35	6.1e-15	Height;
LGG	cis	rs3008870	0.755	rs1121824	chr1:67475616	C/A	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.89	0.59	1.07e-45	Lymphocyte percentage of white cells;
LGG	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-8.02	-0.35	8.85e-15	Vitiligo;
LGG	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg08700190	chr5:6636046	SRD5A1	-0.33	-6.99	-0.31	9.74e-12	Response to amphetamines;
LGG	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg26031613	chr14:104095156	KLC1	-0.68	-10.92	-0.45	7.68e-25	Reticulocyte count;
LGG	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.07e-11	Blood metabolite levels;
LGG	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	trans	rs56804039	1.000	rs59620654	chr8:8382632	A/G	cg02002194	chr4:3960332	NA	0.44	7.02	0.31	7.83e-12	Cervical cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02213678	chr16:85112535	KIAA0513	0.41	8.21	0.36	2.3e-15	Menarche (age at onset);
LGG	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-17.28	-0.63	5.35e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.72	0.3	5.34e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6964587	1.000	rs2188154	chr7:91595138	T/A	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	cis	rs9543976	1.000	rs7989568	chr13:76155564	T/C	cg01531495	chr13:76123901	UCHL3	0.62	7.52	0.33	2.8e-13	Diabetic retinopathy;
LGG	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.58	-0.41	6.1e-20	Height;
LGG	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.01	-0.31	8.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-8.67	-0.37	7.27e-17	Height;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.58e-16	Obesity-related traits;
LGG	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7241530	0.662	rs55745067	chr18:75902055	A/G	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs12791968	1.000	rs12791968	chr11:45001490	C/T	cg11846598	chr11:44996168	LOC221122	0.68	12.96	0.52	5.27e-33	Inhibitory control;
LGG	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg04568710	chr12:38710424	ALG10B	-0.41	-8.67	-0.37	7.12e-17	Morning vs. evening chronotype;
LGG	cis	rs2282802	0.685	rs13170475	chr5:139671062	C/T	cg26211634	chr5:139558579	C5orf32	0.34	7.53	0.33	2.74e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.09	0.31	4.96e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs975722	0.540	rs10953845	chr7:117065996	C/T	cg10524701	chr7:117356490	CTTNBP2	0.39	8.24	0.36	1.79e-15	Coronary artery disease;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18657643	chr3:195545456	NA	0.48	7.07	0.31	5.74e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2117029	0.521	rs12227610	chr12:49539936	G/A	cg24176009	chr12:49580217	TUBA1A	0.63	12.16	0.49	1.04e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg04673462	chr1:38461896	NA	0.49	9.31	0.4	5.1e-19	Coronary artery disease;
LGG	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-8.99	-0.39	6.37e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs62209	0.800	rs17149174	chr10:11002510	A/G	cg26901096	chr10:10994189	LOC254312	0.57	8.64	0.37	9.4e-17	Alzheimer's disease (late onset);
LGG	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	trans	rs75804782	0.641	rs56134361	chr2:239318905	A/G	cg01134436	chr17:81009848	B3GNTL1	0.85	8.97	0.38	7.27e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg05234568	chr11:5960015	NA	-0.71	-11.72	-0.48	6.02e-28	DNA methylation (variation);
LGG	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg06046430	chr4:77819534	ANKRD56	0.55	11.07	0.46	2.03e-25	Emphysema distribution in smoking;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg00405596	chr8:11794950	NA	-0.45	-7.19	-0.32	2.55e-12	Neuroticism;
LGG	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.37	-0.4	3.17e-19	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg00689492	chr4:1303491	MAEA	-0.44	-7.41	-0.33	6.09e-13	Obesity-related traits;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-9.81	-0.41	8.83e-21	Lung function (FEV1/FVC);
LGG	cis	rs7077256	0.564	rs35468796	chr10:65163006	T/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4727027	0.625	rs75129390	chr7:148846775	T/A	cg23583168	chr7:148888333	NA	-0.85	-16.19	-0.6	5.06e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg24829409	chr8:58192753	C8orf71	0.82	11.54	0.47	3.02e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg24253500	chr15:84953950	NA	0.42	6.92	0.31	1.53e-11	Schizophrenia;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.01	-0.46	3.25e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.37	6.71	0.3	5.72e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-16.26	-0.6	2.45e-47	Menarche (age at onset);
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.12	-0.31	4.19e-12	Personality dimensions;
LGG	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.56	-0.47	2.52e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs4684776	0.676	rs2067471	chr3:11299602	A/G	cg24705426	chr3:11550659	ATG7	-0.4	-7.22	-0.32	2.09e-12	Small vessel stroke;
LGG	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.65	-0.56	3.49e-40	Aortic root size;
LGG	cis	rs12681287	0.547	rs71502658	chr8:87478785	T/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg08994789	chr17:28903642	LRRC37B2	0.69	8.38	0.36	6.42e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1375194	0.582	rs4670735	chr2:33801456	C/T	cg04131969	chr2:33951647	MYADML	-0.59	-10.28	-0.43	1.81e-22	Response to antidepressants in depression;
LGG	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg13207630	chr7:32358064	NA	0.66	7.14	0.31	3.64e-12	Body mass index;
LGG	cis	rs4919087	0.590	rs2861877	chr10:99053316	C/A	cg25902810	chr10:99078978	FRAT1	-0.42	-6.87	-0.3	2.02e-11	Monocyte count;
LGG	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.5	0.4	1.12e-19	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.66	-0.34	1.11e-13	Longevity;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs9557704	0.551	rs9557677	chr13:102146585	C/T	cg13538571	chr13:102108074	ITGBL1	-0.41	-6.87	-0.3	2.11e-11	Waist-to-hip circumference ratio (dietary energy interaction);
LGG	cis	rs4919087	0.892	rs10882881	chr10:99010067	T/A	cg25902810	chr10:99078978	FRAT1	0.48	8.98	0.39	6.92e-18	Monocyte count;
LGG	cis	rs798766	0.904	rs13142863	chr4:1755549	T/G	cg00006948	chr4:1768889	NA	-0.49	-6.66	-0.3	7.88e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg09307838	chr4:120376055	NA	0.79	13.01	0.52	3.43e-33	Corneal astigmatism;
LGG	cis	rs6840360	0.642	rs28666858	chr4:152416382	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.33	0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-13.38	-0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg04025307	chr7:1156635	C7orf50	0.78	10.92	0.45	7.12e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2274273	1.000	rs74617736	chr14:55620919	C/T	cg04306507	chr14:55594613	LGALS3	0.58	15.49	0.58	6.92e-44	Protein biomarker;
LGG	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg08807101	chr21:30365312	RNF160	-0.83	-16.9	-0.62	2.98e-50	Dental caries;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg02725872	chr8:58115012	NA	-0.84	-11.77	-0.48	3.75e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.93	-0.59	7.23e-46	Longevity;
LGG	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg27432699	chr2:27873401	GPN1	0.68	14.05	0.55	1.28e-37	Oral cavity cancer;
LGG	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg07117364	chr1:16154769	NA	-0.48	-8.99	-0.39	6.3e-18	Dilated cardiomyopathy;
LGG	cis	rs12738007	0.967	rs12032476	chr1:29529943	C/T	cg11747820	chr1:29584023	PTPRU	-0.32	-7.3	-0.32	1.26e-12	Schizophrenia;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg11584989	chr19:19387371	SF4	0.4	7.2	0.32	2.4e-12	Tonsillectomy;
LGG	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg00857998	chr1:205179979	DSTYK	0.56	9.08	0.39	3.09e-18	Red blood cell count;
LGG	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.76	0.41	1.34e-20	Schizophrenia;
LGG	cis	rs8141529	0.551	rs16986864	chr22:29350911	G/T	cg15103426	chr22:29168792	CCDC117	0.6	7.02	0.31	7.7e-12	Lymphocyte counts;
LGG	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg00012203	chr2:219082015	ARPC2	-0.53	-8.72	-0.38	4.96e-17	Colorectal cancer;
LGG	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg26384229	chr12:38710491	ALG10B	0.72	14.75	0.57	1.2e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.99	0.35	1.07e-14	Educational attainment;
LGG	cis	rs8133932	0.906	rs71324444	chr21:47198301	G/A	cg11214348	chr21:47283868	PCBP3	-0.42	-7.05	-0.31	6.49e-12	Schizophrenia;
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg04553112	chr3:125709451	NA	-0.55	-7.0	-0.31	8.92e-12	Blood pressure (smoking interaction);
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs4417704	0.551	rs10169544	chr2:241899356	A/C	cg14055004	chr2:241860995	NA	0.28	7.26	0.32	1.64e-12	Joint mobility (Beighton score);
LGG	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg15704280	chr7:45808275	SEPT13	0.85	8.87	0.38	1.62e-17	Myopia (pathological);
LGG	cis	rs4936894	0.500	rs10893191	chr11:124121469	C/A	cg27160556	chr11:124181099	OR8D1	-0.47	-10.89	-0.45	9.42e-25	Aging (time to death);
LGG	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg16339924	chr4:17578868	LAP3	-0.52	-8.7	-0.37	5.68e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg19147804	chr7:1989927	MAD1L1	-0.5	-9.84	-0.42	7.27e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7577696	0.597	rs7556942	chr2:32295694	G/A	cg02381751	chr2:32503542	YIPF4	-0.46	-6.75	-0.3	4.5e-11	Inflammatory biomarkers;
LGG	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg11062466	chr8:58055876	NA	0.44	7.35	0.32	9.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg23594656	chr7:65796392	TPST1	-0.4	-8.89	-0.38	1.34e-17	Aortic root size;
LGG	cis	rs35740288	0.545	rs11637283	chr15:86316103	C/T	cg04173714	chr15:86211321	AKAP13	0.44	7.16	0.32	3.14e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg17951613	chr5:131705445	SLC22A5	0.68	7.69	0.34	9.06e-14	Rheumatoid arthritis;
LGG	trans	rs17685	0.712	rs7778735	chr7:75770237	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14262570	chr15:65133625	PLEKHO2	0.45	6.7	0.3	6.01e-11	Gut microbiome composition (summer);
LGG	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.26	0.32	1.64e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs440932	1.000	rs365309	chr8:9026940	C/T	cg16141378	chr3:129829833	LOC729375	0.33	6.82	0.3	2.89e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs36051895	0.589	rs16922786	chr9:5200714	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-13.6	-0.53	1.14e-35	Pediatric autoimmune diseases;
LGG	cis	rs9487051	0.807	rs1915835	chr6:109597483	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.81	-0.34	3.91e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg23758822	chr17:41437982	NA	0.84	14.62	0.56	4.33e-40	Menopause (age at onset);
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg12728061	chr1:2383438	NA	-0.39	-11.16	-0.46	8.78e-26	Schizophrenia;
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03517284	chr6:25882590	NA	0.52	9.6	0.41	5e-20	Blood metabolite levels;
LGG	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg00631329	chr6:26305371	NA	-0.47	-8.5	-0.37	2.62e-16	Educational attainment;
LGG	cis	rs2070677	0.935	rs12255182	chr10:135404096	G/A	cg20169779	chr10:135381914	SYCE1	-0.97	-12.76	-0.51	3.65e-32	Gout;
LGG	cis	rs6964587	0.967	rs12671991	chr7:91559481	T/C	cg17063962	chr7:91808500	NA	-0.49	-8.68	-0.37	6.57e-17	Breast cancer;
LGG	cis	rs7666738	0.830	rs7691433	chr4:98968118	A/T	cg05340658	chr4:99064831	C4orf37	0.48	7.96	0.35	1.3e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-11.04	-0.46	2.67e-25	Total body bone mineral density;
LGG	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg04990556	chr1:26633338	UBXN11	-0.49	-7.62	-0.33	1.46e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg21926883	chr2:100939477	LONRF2	-0.43	-6.89	-0.31	1.8e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg22903471	chr2:27725779	GCKR	0.38	8.48	0.37	2.97e-16	Oral cavity cancer;
LGG	cis	rs9354308	0.764	rs4710546	chr6:66605677	A/G	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg20913747	chr6:44695427	NA	-0.64	-11.07	-0.46	1.95e-25	Total body bone mineral density;
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg14789911	chr21:47582049	C21orf56	-0.4	-6.7	-0.3	6.06e-11	Testicular germ cell tumor;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg27151812	chr13:88323452	SLITRK5	0.46	8.41	0.36	5.13e-16	Menarche (age at onset);
LGG	cis	rs6752107	0.503	rs12997325	chr2:234237387	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	8.44	0.37	4.14e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3764400	0.506	rs2036521	chr17:46328976	T/G	cg10706073	chr17:46328419	SKAP1	-0.44	-6.72	-0.3	5.21e-11	Body mass index;
LGG	cis	rs10849893	0.538	rs4980986	chr12:121914808	A/T	cg01154721	chr12:121881891	KDM2B	-0.42	-7.25	-0.32	1.71e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs11168618	0.846	rs7958521	chr12:48877400	G/A	cg24011408	chr12:48396354	COL2A1	0.49	7.99	0.35	1.1e-14	Adiponectin levels;
LGG	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.6	-11.18	-0.46	7.23e-26	Height;
LGG	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	8.74	0.38	4.24e-17	Mood instability;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.28	-0.32	1.45e-12	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg05793240	chr7:2802953	GNA12	0.34	8.05	0.35	7.26e-15	Height;
LGG	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-9.0	-0.39	5.73e-18	Morning vs. evening chronotype;
LGG	cis	rs2777491	0.915	rs28526381	chr15:41621842	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.72	-0.48	5.83e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg06766960	chr11:133703094	NA	-0.54	-10.97	-0.45	4.64e-25	Childhood ear infection;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.72	-0.54	3.34e-36	Personality dimensions;
LGG	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs11574514	1.000	rs7195415	chr16:67689057	G/A	cg09738193	chr16:67926317	PSKH1	-0.71	-6.98	-0.31	1e-11	Crohn's disease;
LGG	cis	rs2729354	1.000	rs2848630	chr11:57356907	T/C	cg24343310	chr11:57249947	NA	0.36	6.7	0.3	5.94e-11	Blood protein levels;
LGG	cis	rs9814567	0.806	rs7626557	chr3:134318213	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12135191	0.933	rs10495376	chr1:236461110	C/T	cg21399712	chr1:236511386	NA	-0.39	-7.51	-0.33	3e-13	Urate levels (BMI interaction);
LGG	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg12552261	chr5:112820674	MCC	-0.75	-14.03	-0.55	1.62e-37	Type 2 diabetes;
LGG	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg04673462	chr1:38461896	NA	-0.38	-6.79	-0.3	3.54e-11	Hypothyroidism;
LGG	cis	rs227833	0.826	rs4714813	chr6:44709890	C/A	cg20913747	chr6:44695427	NA	0.4	6.86	0.3	2.15e-11	Monobrow;
LGG	cis	rs2862064	0.818	rs4704839	chr5:156484626	A/T	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.69	-0.45	5.3e-24	Platelet count;
LGG	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.48	-0.33	3.81e-13	Morning vs. evening chronotype;
LGG	cis	rs3857067	0.806	rs12505596	chr4:95109600	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.55	-0.33	2.38e-13	QT interval;
LGG	cis	rs8133932	0.861	rs71324439	chr21:47085925	A/C	cg11214348	chr21:47283868	PCBP3	-0.43	-7.1	-0.31	4.77e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg07382826	chr16:28625726	SULT1A1	0.42	8.89	0.38	1.33e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.96	-0.35	1.37e-14	Heart rate;
LGG	cis	rs9394159	0.583	rs6457738	chr6:33617464	C/T	cg14003231	chr6:33640908	ITPR3	-0.4	-9.65	-0.41	3.38e-20	Graves' disease;
LGG	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg23166289	chr1:210001082	C1orf107	0.37	7.3	0.32	1.28e-12	Orofacial clefts;
LGG	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.33	0.63	3.17e-52	Response to antipsychotic treatment;
LGG	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg09873164	chr1:152488093	CRCT1	0.64	15.62	0.59	1.68e-44	Hair morphology;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg02002194	chr4:3960332	NA	-0.38	-6.75	-0.3	4.5e-11	Mood instability;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06867829	chr12:24715508	SOX5	0.41	6.81	0.3	3.06e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg16724585	chr3:197361211	NA	-0.49	-8.53	-0.37	2.05e-16	Pancreatic cancer;
LGG	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12756686	chr19:29218302	NA	0.7	11.72	0.48	5.61e-28	Methadone dose in opioid dependence;
LGG	cis	rs2820315	0.867	rs2644135	chr1:201856256	C/G	cg10061532	chr1:201886748	LMOD1	-0.33	-6.89	-0.3	1.85e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.16	-0.78	7.4e-98	Height;
LGG	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg17885191	chr8:135476712	NA	-0.51	-8.45	-0.37	3.68e-16	Hypertension (SNP x SNP interaction);
LGG	cis	rs42648	0.935	rs2188233	chr7:89958315	G/A	cg25739043	chr7:89950458	NA	-0.42	-8.91	-0.38	1.22e-17	Homocysteine levels;
LGG	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg04568710	chr12:38710424	ALG10B	0.39	8.45	0.37	3.92e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8028182	0.636	rs7166737	chr15:75682513	A/G	cg20655648	chr15:75932815	IMP3	0.45	7.55	0.33	2.29e-13	Sudden cardiac arrest;
LGG	cis	rs73086581	0.741	rs17212649	chr20:3853093	A/G	cg02187196	chr20:3869020	PANK2	0.91	12.52	0.5	3.67e-31	Response to antidepressants in depression;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.86	-11.58	-0.47	2.11e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs209489	0.892	rs112499221	chr6:53113320	G/A	cg15607103	chr6:53167650	ELOVL5	0.64	7.69	0.34	8.87e-14	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs7177699	0.534	rs4387568	chr15:79109514	C/G	cg00540400	chr15:79124168	NA	-0.54	-11.48	-0.47	5.26e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1018697	0.897	rs2150929	chr10:104550937	T/A	cg04362960	chr10:104952993	NT5C2	0.49	9.02	0.39	5.16e-18	Colorectal adenoma (advanced);
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg06848047	chr4:90757629	SNCA	-0.4	-7.52	-0.33	2.85e-13	Dementia with Lewy bodies;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg16421803	chr2:25194856	DNAJC27	-0.42	-7.14	-0.31	3.63e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg15971980	chr6:150254442	NA	0.45	8.46	0.37	3.51e-16	Lung cancer;
LGG	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg08344181	chr3:125677491	NA	-0.79	-8.29	-0.36	1.26e-15	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg26554054	chr8:600488	NA	-0.84	-8.98	-0.39	6.94e-18	IgG glycosylation;
LGG	cis	rs2373794	1.000	rs417614	chr2:40377084	A/G	cg17740179	chr2:40377776	SLC8A1	0.96	20.83	0.7	1.78e-68	Asthma;
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-6.93	-0.31	1.45e-11	Tonsillectomy;
LGG	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg21545522	chr1:205238299	TMCC2	0.37	7.06	0.31	6.09e-12	Red blood cell count;
LGG	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg11812906	chr14:75593930	NEK9	0.53	9.71	0.41	2.01e-20	Height;
LGG	cis	rs4740619	0.544	rs7857126	chr9:15829949	C/T	cg14451791	chr9:16040625	NA	0.33	8.25	0.36	1.71e-15	Body mass index;
LGG	cis	rs4432842	1.000	rs4432842	chr5:57172078	A/G	cg08523694	chr5:57076192	NA	0.49	9.38	0.4	3.06e-19	Birth weight;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.24	0.84	1.06e-124	Prudent dietary pattern;
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg04824913	chr4:887549	GAK	0.43	7.37	0.32	8.13e-13	Sjögren's syndrome;
LGG	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.97	0.31	1.11e-11	Cognitive ability;
LGG	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg12463550	chr7:65579703	CRCP	0.74	7.94	0.35	1.56e-14	Diabetic kidney disease;
LGG	trans	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg06521331	chr12:34319734	NA	0.53	9.61	0.41	4.72e-20	Bladder cancer;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg07747251	chr5:1868357	NA	0.47	9.61	0.41	4.83e-20	Cardiovascular disease risk factors;
LGG	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	8.76	0.38	3.6e-17	Bipolar disorder;
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg14092988	chr3:52407081	DNAH1	0.3	8.07	0.35	5.99e-15	Bipolar disorder;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg03351412	chr1:154909251	PMVK	0.67	12.89	0.51	1.05e-32	Prostate cancer;
LGG	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg00376283	chr12:123451042	ABCB9	-0.56	-8.59	-0.37	1.35e-16	Neutrophil percentage of white cells;
LGG	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg20387954	chr3:183756860	HTR3D	0.45	8.64	0.37	8.93e-17	Anterior chamber depth;
LGG	cis	rs4732038	0.669	rs6955887	chr7:134263676	A/G	cg06906464	chr7:134288099	NA	-0.63	-17.45	-0.63	9.2e-53	Longevity;
LGG	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.37	0.32	7.79e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs7830939	1.000	rs7830939	chr8:9380132	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.86	-0.3	2.28e-11	Neuroticism;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs503734	0.666	rs6773536	chr3:101119305	G/C	cg27318481	chr3:100970896	IMPG2	0.36	7.24	0.32	1.84e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4262150	0.526	rs4309960	chr5:151971852	A/G	cg12297329	chr5:152029980	NA	-0.87	-21.93	-0.71	1.23e-73	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18099408	chr3:52552593	STAB1	-0.37	-7.23	-0.32	2e-12	Bipolar disorder;
LGG	cis	rs7226408	0.802	rs72894332	chr18:34717721	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs12949688	0.967	rs2332966	chr17:55819335	T/C	cg12582317	chr17:55822272	NA	0.69	19.92	0.68	3.06e-64	Schizophrenia;
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg19223190	chr17:80058835	NA	-0.49	-9.77	-0.41	1.23e-20	Life satisfaction;
LGG	trans	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.53	0.37	2.17e-16	Triglycerides;
LGG	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs7133214	0.824	rs12581729	chr12:27938571	G/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.89	-0.3	1.83e-11	Gut microbiota (functional units);
LGG	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg07915516	chr16:377344	AXIN1	0.28	7.18	0.32	2.88e-12	Morning vs. evening chronotype;
LGG	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg24848339	chr3:12840334	CAND2	0.4	8.9	0.38	1.23e-17	QRS complex (12-leadsum);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg11023815	chr6:34725573	SNRPC	-0.35	-7.12	-0.31	4.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg12011299	chr4:100065546	ADH4	0.4	7.88	0.34	2.36e-14	Smoking initiation;
LGG	cis	rs4148087	1.000	rs9981390	chr21:43634081	G/A	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg18379455	chr17:41446167	NA	-0.31	-7.27	-0.32	1.54e-12	Menopause (age at onset);
LGG	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs9849248	0.627	rs7430022	chr3:88226532	C/A	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.63	12.6	0.51	1.6e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg19731401	chr7:2775893	GNA12	0.36	7.47	0.33	4.12e-13	Childhood ear infection;
LGG	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg04455712	chr21:45112962	RRP1B	0.51	9.7	0.41	2.24e-20	Mean corpuscular volume;
LGG	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.6	-0.47	1.73e-27	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21702128	chr5:142784721	NR3C1	0.5	7.78	0.34	4.81e-14	Gut microbiome composition (summer);
LGG	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg07541023	chr7:19748670	TWISTNB	0.54	7.76	0.34	5.56e-14	Thyroid stimulating hormone;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.34	-0.32	9.79e-13	Lung cancer;
LGG	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.96	-17.84	-0.64	1.4e-54	Homoarginine levels;
LGG	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02886208	chr11:14281011	SPON1	0.52	11.47	0.47	5.46e-27	Mitochondrial DNA levels;
LGG	cis	rs1904096	0.506	rs4693381	chr4:95206855	A/T	cg11021082	chr4:95130006	SMARCAD1	0.59	11.26	0.46	3.71e-26	Type 2 diabetes;
LGG	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg00409905	chr10:38381863	ZNF37A	0.67	13.57	0.53	1.52e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.93	-0.35	1.66e-14	IgG glycosylation;
LGG	cis	rs763121	0.853	rs2294296	chr22:39053049	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-16.04	-0.6	2.37e-46	Mean platelet volume;Platelet distribution width;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01301138	chr16:82660630	CDH13	0.37	6.7	0.3	6.07e-11	Obesity-related traits;
LGG	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg20283391	chr11:68216788	NA	-0.51	-8.08	-0.35	5.61e-15	Total body bone mineral density;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.27	7.38	0.32	7.43e-13	IgG glycosylation;
LGG	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.23e-33	Breast cancer;
LGG	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg11161011	chr14:65562177	MAX	-0.63	-12.18	-0.49	8.23e-30	Obesity-related traits;
LGG	cis	rs668210	0.739	rs1151511	chr11:65756283	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	9.68	0.41	2.59e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.59	-0.33	1.79e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18621852	chr3:10150065	C3orf24	0.41	6.76	0.3	4.14e-11	Alzheimer's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14189758	chr20:36156486	BLCAP	0.43	7.85	0.34	2.91e-14	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.81	0.57	6.63e-41	Cognitive test performance;
LGG	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg11494091	chr17:61959527	GH2	0.59	9.59	0.41	5.61e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1793639	0.606	rs10894490	chr11:131929618	C/T	cg13908476	chr11:131942942	NTM	0.65	12.69	0.51	6.91e-32	Myopia;
LGG	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg06634786	chr22:41940651	POLR3H	-0.56	-9.27	-0.4	7.32e-19	Neuroticism;
LGG	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-9.87	-0.42	5.48e-21	Aortic root size;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg26516362	chr5:178986906	RUFY1	-0.41	-7.59	-0.33	1.73e-13	Lung cancer;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-10.11	-0.43	7.52e-22	Chronic sinus infection;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.16	-0.46	9.04e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg14092571	chr14:90743983	NA	0.42	7.5	0.33	3.21e-13	Longevity;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.63	11.34	0.47	1.84e-26	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg15971980	chr6:150254442	NA	0.45	8.32	0.36	1.02e-15	Lung cancer;
LGG	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs11608355	0.515	rs7976796	chr12:109928013	C/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs9487094	0.710	rs71558370	chr6:109776903	G/T	cg01125227	chr6:109776195	MICAL1	0.51	7.85	0.34	2.99e-14	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg22037798	chr1:231473786	C1orf124;EXOC8	-0.43	-7.14	-0.31	3.55e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6430585	0.527	rs2278731	chr2:136396300	T/C	cg07169764	chr2:136633963	MCM6	1.0	16.6	0.61	6.57e-49	Corneal structure;
LGG	cis	rs12049351	0.613	rs7514990	chr1:229581166	T/C	cg13547644	chr1:229569608	ACTA1	0.32	7.07	0.31	5.6e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg00701064	chr4:6280414	WFS1	0.73	16.07	0.6	1.68e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg03806693	chr22:41940476	POLR3H	0.89	14.85	0.57	4.38e-41	Vitiligo;
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg16606324	chr3:10149918	C3orf24	0.64	7.17	0.32	2.94e-12	Alzheimer's disease;
LGG	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg06634786	chr22:41940651	POLR3H	-0.63	-9.96	-0.42	2.65e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg00149659	chr3:10157352	C3orf10	0.55	8.17	0.35	2.97e-15	Alzheimer's disease;
LGG	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.53	0.33	2.69e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15506890	chr2:3487001	NA	-0.52	-10.09	-0.42	8.66e-22	Neurofibrillary tangles;
LGG	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.82	-0.34	3.65e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg16301924	chr13:53314226	LECT1	0.4	7.66	0.34	1.1e-13	Lewy body disease;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg01673284	chr16:4527211	HMOX2	0.33	6.67	0.3	7.35e-11	Schizophrenia;
LGG	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg20637307	chr2:213403960	ERBB4	-0.49	-9.13	-0.39	2.14e-18	Symmetrical dimethylarginine levels;
LGG	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg26924012	chr15:45694286	SPATA5L1	1.04	22.53	0.72	2.04e-76	Homoarginine levels;
LGG	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg06970220	chr1:156163860	SLC25A44	0.46	6.66	0.3	7.55e-11	Testicular germ cell tumor;
LGG	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg00677455	chr12:58241039	CTDSP2	0.44	8.07	0.35	6.12e-15	Multiple sclerosis;
LGG	cis	rs9427116	0.502	rs6699825	chr1:154582970	A/G	cg11650704	chr1:154556575	ADAR	-0.49	-9.53	-0.41	8.8e-20	Blood protein levels;
LGG	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg20720597	chr2:3699334	NA	0.89	9.34	0.4	4.05e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	6.95	0.31	1.28e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg02297831	chr4:17616191	MED28	0.51	9.62	0.41	4.25e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.4	0.33	6.3e-13	Prudent dietary pattern;
LGG	cis	rs9398803	0.965	rs4895807	chr6:126686513	C/G	cg19875578	chr6:126661172	C6orf173	0.57	10.38	0.43	7.96e-23	Male-pattern baldness;
LGG	cis	rs4936894	0.500	rs11604309	chr11:124167162	A/C	cg27160556	chr11:124181099	OR8D1	-0.48	-11.28	-0.46	3.07e-26	Aging (time to death);
LGG	cis	rs7226408	0.857	rs72885275	chr18:34439624	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6964587	1.000	rs6956431	chr7:91750016	T/C	cg17063962	chr7:91808500	NA	0.5	9.12	0.39	2.39e-18	Breast cancer;
LGG	cis	rs17286411	0.750	rs4788568	chr16:71913025	C/T	cg06353428	chr16:71660113	MARVELD3	0.41	7.35	0.32	9.18e-13	Blood protein levels;
LGG	cis	rs4690686	0.538	rs7436387	chr4:177257723	T/G	cg17059388	chr4:177262070	NA	0.96	21.26	0.7	1.69e-70	Essential tremor;
LGG	cis	rs3087591	0.708	rs12940802	chr17:29643564	C/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.41	0.5	9.73e-31	Hip circumference;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.41	0.33	6e-13	Lung cancer;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.06	0.55	1.18e-37	Prudent dietary pattern;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg06766960	chr11:133703094	NA	0.49	9.91	0.42	3.94e-21	Childhood ear infection;
LGG	cis	rs1003719	0.715	rs4261789	chr21:38503762	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-14.37	-0.56	5.32e-39	Eye color traits;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.77	0.34	5.01e-14	Lung cancer;
LGG	cis	rs7937890	0.559	rs6486197	chr11:14529874	C/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07988820	chr12:82153109	PPFIA2	0.58	8.55	0.37	1.83e-16	Resting heart rate;
LGG	cis	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg02972257	chr16:68554789	NA	0.43	6.65	0.3	8.43e-11	Colorectal cancer;
LGG	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.65	-0.56	3.26e-40	Response to antipsychotic treatment;
LGG	cis	rs9287719	0.753	rs2018512	chr2:10759279	T/G	cg02196655	chr2:10830764	NOL10	-0.47	-8.16	-0.35	3.12e-15	Prostate cancer;
LGG	cis	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg06521331	chr12:34319734	NA	-0.42	-7.5	-0.33	3.3e-13	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg10756647	chr7:56101905	PSPH	0.78	9.37	0.4	3.3e-19	Diabetic kidney disease;
LGG	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg26138144	chr22:38071188	LGALS1	0.68	15.8	0.59	2.8e-45	Fat distribution (HIV);
LGG	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.49	0.4	1.18e-19	Red cell distribution width;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.57	7.65	0.34	1.17e-13	Lung function (FEV1/FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03276167	chr6:86388360	SNHG5;SNORD50B;SNORD50A	0.49	7.69	0.34	8.95e-14	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg02631450	chr22:32366979	NA	1.01	9.66	0.41	3.22e-20	Childhood ear infection;
LGG	cis	rs17767392	0.781	rs14030	chr14:71956141	A/C	cg02058870	chr14:72053146	SIPA1L1	0.39	8.14	0.35	3.67e-15	Mitral valve prolapse;
LGG	cis	rs6807915	0.504	rs167467	chr3:12281183	A/G	cg15873301	chr3:12045459	SYN2	0.41	7.25	0.32	1.82e-12	Leprosy;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg10756647	chr7:56101905	PSPH	0.85	9.98	0.42	2.27e-21	Diabetic kidney disease;
LGG	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	trans	rs2840044	1.000	rs1671656	chr17:33939661	C/T	cg19694781	chr19:47549865	TMEM160	-0.56	-9.32	-0.4	4.67e-19	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11764359	chr7:65958608	NA	-0.57	-9.64	-0.41	3.8e-20	Aortic root size;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.61	-0.41	4.85e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg11878867	chr6:150167359	LRP11	0.4	6.91	0.31	1.62e-11	Lung cancer;
LGG	cis	rs4671458	0.762	rs12464471	chr2:63686428	A/G	cg17519650	chr2:63277830	OTX1	-0.53	-6.89	-0.3	1.87e-11	Subjective well-being;
LGG	cis	rs4713118	0.513	rs149955	chr6:28036225	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.94	-0.31	1.29e-11	Parkinson's disease;
LGG	cis	rs17002988	0.605	rs4443313	chr4:79040704	A/G	cg07442568	chr4:78980533	FRAS1	0.4	6.77	0.3	3.97e-11	Uric acid levels;
LGG	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg19554555	chr3:13937349	NA	0.7	13.4	0.53	7.93e-35	Ovarian reserve;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.58	10.04	0.42	1.39e-21	Obesity-related traits;
LGG	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.15	0.35	3.31e-15	Colorectal cancer;
LGG	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg02153584	chr22:29168773	CCDC117	0.69	11.67	0.48	9.1e-28	Lymphocyte counts;
LGG	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg03433033	chr1:76189801	ACADM	0.78	13.64	0.54	7.49e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2290159	0.898	rs2290160	chr3:12633083	A/G	cg23032965	chr3:12705835	RAF1	0.56	8.44	0.37	4.1e-16	Cholesterol, total;
LGG	cis	rs6835098	0.924	rs2332669	chr4:174163398	G/A	cg08422745	chr4:174089978	GALNT7	-0.79	-13.92	-0.54	4.88e-37	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs2046867	0.908	rs62251650	chr3:72809823	T/C	cg25664220	chr3:72788482	NA	-0.31	-8.81	-0.38	2.58e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.15e-23	Lymphocyte counts;
LGG	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.23	0.43	2.82e-22	Motion sickness;
LGG	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg08999081	chr20:33150536	PIGU	-0.3	-7.06	-0.31	6.11e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs11792861	0.591	rs4978763	chr9:111728067	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	11.5	0.47	4.44e-27	Menarche (age at onset);
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg25173464	chr15:68126554	NA	-0.33	-6.98	-0.31	1.05e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs9657904	0.813	rs28533328	chr3:105559353	T/C	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.4e-14	Multiple sclerosis;
LGG	trans	rs13128441	0.593	rs7672067	chr4:5154673	G/A	cg26099876	chr8:141644609	EIF2C2	-0.51	-7.54	-0.33	2.59e-13	Celiac disease;
LGG	cis	rs11690935	0.527	rs7586556	chr2:172901887	G/C	cg13550731	chr2:172543902	DYNC1I2	0.7	13.89	0.54	6.24e-37	Schizophrenia;
LGG	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg25554036	chr4:6271136	WFS1	0.62	11.58	0.47	2.02e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22769031	chr20:35580195	SAMHD1	0.38	6.79	0.3	3.37e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16402894	chr11:11864017	USP47	0.43	7.18	0.32	2.87e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg18876405	chr7:65276391	NA	0.45	7.93	0.35	1.62e-14	Calcium levels;
LGG	trans	rs1941687	0.831	rs12965856	chr18:31344080	A/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.74	-0.38	4.25e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-8.7	-0.37	5.94e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8016982	0.617	rs2241621	chr14:81737076	G/T	cg01989461	chr14:81687754	GTF2A1	-0.67	-13.94	-0.54	3.93e-37	Schizophrenia;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.3e-14	Tonsillectomy;
LGG	cis	rs185694	0.948	rs200512	chr13:30906446	C/T	cg07600127	chr13:30881527	KATNAL1	-0.51	-6.74	-0.3	4.85e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs67311347	0.544	rs1902073	chr3:40333497	C/T	cg13683864	chr3:40499215	RPL14	-0.82	-16.52	-0.61	1.57e-48	Renal cell carcinoma;
LGG	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03517284	chr6:25882590	NA	-0.54	-10.28	-0.43	1.84e-22	Blood metabolite levels;
LGG	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg06951627	chr6:26196580	NA	0.48	7.21	0.32	2.22e-12	Gout;Renal underexcretion gout;
LGG	cis	rs9398803	0.865	rs2184967	chr6:126773487	C/T	cg19875578	chr6:126661172	C6orf173	0.57	10.41	0.44	5.91e-23	Male-pattern baldness;
LGG	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg13114125	chr14:105738426	BRF1	-0.88	-17.44	-0.63	1.04e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6450176	1.000	rs67430852	chr5:53290586	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-10.81	-0.45	1.92e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg20503657	chr10:835505	NA	0.63	9.43	0.4	2.06e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7119038	0.509	rs10892258	chr11:118579865	A/G	cg20309703	chr11:118481025	PHLDB1	-0.4	-6.89	-0.3	1.87e-11	Sjögren's syndrome;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg22771759	chr13:24902376	NA	0.47	7.89	0.34	2.14e-14	Obesity-related traits;
LGG	cis	rs6942756	0.955	rs2056694	chr7:128923817	C/T	cg02491457	chr7:128862824	NA	-0.76	-13.64	-0.54	7.5e-36	White matter hyperintensity burden;
LGG	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.5	-0.33	3.23e-13	Iron status biomarkers;
LGG	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg04990556	chr1:26633338	UBXN11	-0.71	-14.06	-0.55	1.2e-37	Obesity-related traits;
LGG	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg16387850	chr1:46982889	NA	0.33	7.69	0.34	9.08e-14	Monobrow;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs137603	0.623	rs137657	chr22:39733242	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.7	-13.54	-0.53	1.97e-35	Primary biliary cholangitis;
LGG	cis	rs9359856	0.623	rs1179906	chr6:90323624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.69	-10.18	-0.43	4.34e-22	Bipolar disorder;
LGG	cis	rs7843479	0.828	rs4357289	chr8:21777476	G/A	cg17168535	chr8:21777572	XPO7	0.59	9.5	0.4	1.15e-19	Mean corpuscular volume;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.52	-0.5	3.56e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	0.812	rs57162396	chr3:41896031	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg26174226	chr8:58114915	NA	-0.61	-8.45	-0.37	3.67e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.42e-12	Blood metabolite levels;
LGG	cis	rs13095912	0.752	rs13092283	chr3:185338005	T/C	cg11274856	chr3:185301563	NA	0.49	7.9	0.34	2.03e-14	Systolic blood pressure;
LGG	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	8.99	0.39	6.3e-18	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9487094	0.670	rs11754340	chr6:109905992	A/C	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.31e-15	Height;
LGG	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.08	0.42	1e-21	Joint mobility (Beighton score);
LGG	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg17294928	chr15:75287854	SCAMP5	-0.85	-15.28	-0.58	5.65e-43	Blood trace element (Zn levels);
LGG	cis	rs6964587	0.621	rs38798	chr7:92044539	C/A	cg17063962	chr7:91808500	NA	-0.44	-7.79	-0.34	4.58e-14	Breast cancer;
LGG	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.15	-0.52	8.45e-34	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs7166081	1.000	rs8025621	chr15:67556726	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.69	-0.3	6.44e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04008888	chr11:68622739	NA	-0.55	-11.57	-0.47	2.21e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg16584676	chr17:46985605	UBE2Z	-0.52	-9.19	-0.39	1.35e-18	Type 2 diabetes;
LGG	cis	rs3791406	0.929	rs3828202	chr2:240030122	A/G	cg14550559	chr2:240039617	HDAC4	-0.45	-8.06	-0.35	6.73e-15	Skin aging (microtopography measurement);
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.86	-0.34	2.81e-14	Neuroticism;
LGG	cis	rs1620921	0.563	rs9456598	chr6:161272283	A/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg07930552	chr6:133119739	C6orf192	0.86	11.45	0.47	6.9e-27	Type 2 diabetes nephropathy;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04008888	chr11:68622739	NA	-0.54	-11.65	-0.48	1.05e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg04025307	chr7:1156635	C7orf50	0.68	8.61	0.37	1.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17428076	0.836	rs12622895	chr2:172686304	G/T	cg21435375	chr2:172878103	MAP1D	-0.39	-8.55	-0.37	1.77e-16	Myopia;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.64	-0.44	8.14e-24	Longevity;Endometriosis;
LGG	cis	rs3617	0.599	rs12487379	chr3:52895785	G/A	cg11645453	chr3:52864694	ITIH4	0.43	7.36	0.32	8.52e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7523050	0.643	rs35860016	chr1:109404639	C/T	cg08274380	chr1:109419600	GPSM2	0.99	12.11	0.49	1.58e-29	Fat distribution (HIV);
LGG	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg02175503	chr12:58329896	NA	0.54	8.89	0.38	1.32e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg00405596	chr8:11794950	NA	0.64	11.3	0.46	2.58e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs701145	0.585	rs1470662	chr3:153870997	T/G	cg17054900	chr3:154042577	DHX36	0.78	9.3	0.4	5.7e-19	Coronary artery disease;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09376537	chr17:48638103	CACNA1G	-0.41	-6.73	-0.3	5.16e-11	Body fat percentage;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg13206674	chr6:150067644	NUP43	0.66	14.86	0.57	4.07e-41	Lung cancer;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg04861929	chr11:109293070	C11orf87	0.56	10.17	0.43	4.57e-22	Schizophrenia;
LGG	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg08344181	chr3:125677491	NA	-0.58	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg15704280	chr7:45808275	SEPT13	0.84	8.83	0.38	2.18e-17	Myopia (pathological);
LGG	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg18876405	chr7:65276391	NA	0.64	11.88	0.48	1.34e-28	Aortic root size;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg14004847	chr7:1930337	MAD1L1	0.47	8.5	0.37	2.6e-16	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06939115	chr16:47007824	DNAJA2	0.42	6.86	0.3	2.19e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1843834	0.755	rs10192196	chr2:225577135	C/T	cg22455342	chr2:225449267	CUL3	0.47	8.1	0.35	5.06e-15	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08758916	chr22:40440666	TNRC6B	0.43	6.94	0.31	1.36e-11	Gut microbiome composition (summer);
LGG	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg08048268	chr3:133502702	NA	-0.46	-8.01	-0.35	9.21e-15	Iron status biomarkers;
LGG	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg16506815	chr2:162101123	NA	0.27	6.89	0.3	1.89e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.16	0.32	3.23e-12	Height;
LGG	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg24812749	chr6:127587940	RNF146	0.7	11.16	0.46	8.6e-26	Breast cancer;
LGG	cis	rs12477438	0.520	rs2290255	chr2:99999097	G/T	cg23527387	chr2:100056660	REV1	0.44	9.64	0.41	3.74e-20	Chronic sinus infection;
LGG	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-7.54	-0.33	2.51e-13	Mean corpuscular volume;
LGG	cis	rs698813	0.604	rs12712917	chr2:44482190	A/G	cg00619915	chr2:44497795	NA	-0.59	-8.67	-0.37	7.58e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs4740619	0.967	rs4741529	chr9:15656259	G/C	cg14451791	chr9:16040625	NA	-0.4	-10.33	-0.43	1.22e-22	Body mass index;
LGG	cis	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg21775007	chr8:11205619	TDH	-0.55	-8.36	-0.36	7.41e-16	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23012527	chr1:201508712	NA	0.46	7.22	0.32	2.08e-12	Cognitive performance;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg02158880	chr13:53174818	NA	0.47	8.96	0.38	8.26e-18	Lewy body disease;
LGG	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs12617721	0.718	rs72819964	chr2:99019138	T/C	cg18455616	chr2:99124870	INPP4A	0.31	8.03	0.35	8.22e-15	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07222113	chr8:104427719	DCAF13;SLC25A32	0.41	6.98	0.31	1.02e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3784262	0.715	rs1994927	chr15:58347949	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.96	-0.31	1.14e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.73	-0.41	1.76e-20	Schizophrenia;
LGG	cis	rs283228	0.550	rs668048	chr6:101827363	G/A	cg27451362	chr6:101846650	GRIK2	1.02	15.11	0.57	3.07e-42	Coenzyme Q10 levels;
LGG	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg05044414	chr3:183734942	ABCC5	0.56	11.37	0.47	1.4e-26	Anterior chamber depth;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.51	8.05	0.35	7.13e-15	Longevity;
LGG	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs10237118	1.000	rs10280493	chr7:140230269	A/G	cg09787580	chr7:140227335	DENND2A	-0.69	-8.21	-0.36	2.26e-15	Optic nerve measurement (cup area);
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.01	0.35	9.58e-15	Prudent dietary pattern;
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg20119798	chr7:94954144	PON1	-0.37	-7.79	-0.34	4.59e-14	Paraoxonase activity;
LGG	cis	rs3617	0.598	rs56214994	chr3:52878600	G/C	cg11645453	chr3:52864694	ITIH4	-0.44	-7.38	-0.32	7.33e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg21724239	chr8:58056113	NA	0.53	7.58	0.33	1.92e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs16944613	0.588	rs8030799	chr15:91109374	G/C	cg22089800	chr15:90895588	ZNF774	-0.54	-6.68	-0.3	6.94e-11	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17541922	chr11:86511813	PRSS23	-0.41	-7.05	-0.31	6.68e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.9	0.42	4.24e-21	Height;
LGG	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg02158880	chr13:53174818	NA	0.66	15.34	0.58	3.13e-43	Lewy body disease;
LGG	cis	rs11718455	0.960	rs17076255	chr3:44002093	C/T	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.56e-11	Coronary artery disease;
LGG	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs1061377	0.501	rs62308278	chr4:39162658	G/T	cg24403649	chr4:39172243	NA	0.41	7.26	0.32	1.64e-12	Uric acid levels;
LGG	trans	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg19694781	chr19:47549865	TMEM160	-0.55	-8.99	-0.39	6.25e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs963731	0.649	rs297125	chr2:39314969	G/A	cg04010122	chr2:39346883	SOS1	-0.91	-7.99	-0.35	1.11e-14	Corticobasal degeneration;
LGG	cis	rs12618769	0.597	rs4850875	chr2:99069815	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.55	-0.61	1.11e-48	Intelligence (multi-trait analysis);
LGG	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg19920283	chr7:105172520	RINT1	0.61	8.42	0.36	4.59e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg02187348	chr16:89574699	SPG7	0.58	9.76	0.41	1.36e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs17092148	1.000	rs7265992	chr20:33525407	G/A	cg12302830	chr20:33297742	TP53INP2	0.45	7.5	0.33	3.2e-13	Neuroticism;
LGG	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg05890377	chr2:74357713	NA	0.48	9.81	0.41	8.91e-21	Gestational age at birth (maternal effect);
LGG	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg27427491	chr17:78079615	GAA	0.29	7.71	0.34	7.73e-14	Yeast infection;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg13047869	chr3:10149882	C3orf24	0.56	9.34	0.4	4.14e-19	Alzheimer's disease;
LGG	cis	rs35740288	0.731	rs11634651	chr15:86093926	A/C	cg04173714	chr15:86211321	AKAP13	0.48	8.79	0.38	2.9e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10892173	0.765	rs1892903	chr11:117669619	A/G	cg21640587	chr11:117668038	DSCAML1	0.48	7.93	0.35	1.68e-14	Myopia;
LGG	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.7	-9.28	-0.4	6.55e-19	Diabetic retinopathy;
LGG	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.88	-0.34	2.32e-14	IgG glycosylation;
LGG	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-9.12	-0.39	2.34e-18	Asthma;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25450986	chr17:38574356	TOP2A	0.4	6.91	0.31	1.62e-11	Bilirubin levels;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg12708336	chr17:41446283	NA	-0.31	-7.34	-0.32	9.73e-13	Menopause (age at onset);
LGG	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.5	-9.24	-0.39	9.25e-19	Height;
LGG	cis	rs6840360	0.593	rs6855883	chr4:152688997	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs6466966	chr7:124580327	A/G	cg05630886	chr7:124431682	NA	0.31	7.16	0.32	3.22e-12	Cutaneous malignant melanoma;
LGG	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg02466173	chr16:30829666	NA	-0.55	-9.89	-0.42	4.56e-21	Multiple myeloma;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg19168338	chr16:4465731	CORO7	-0.72	-13.29	-0.53	2.27e-34	Schizophrenia;
LGG	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	8.52e-63	Diabetic kidney disease;
LGG	cis	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg21775007	chr8:11205619	TDH	-0.8	-13.79	-0.54	1.81e-36	Retinal vascular caliber;
LGG	cis	rs12580194	0.593	rs61957885	chr12:55720876	C/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.44	-0.4	1.76e-19	Cancer;
LGG	cis	rs2084898	1.000	rs73004786	chr11:120058833	G/A	cg07435449	chr11:120005650	TRIM29	-0.65	-7.36	-0.32	8.67e-13	Stroke (pediatric);
LGG	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg04568710	chr12:38710424	ALG10B	0.37	7.99	0.35	1.05e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6120849	0.586	rs2025096	chr20:33540000	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.88	0.3	1.95e-11	Protein C levels;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.44	-0.33	4.92e-13	Neuroticism;
LGG	trans	rs6787172	0.622	rs6798940	chr3:158093021	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs1788820	0.917	rs1788819	chr18:21100504	G/A	cg14672496	chr18:21087552	C18orf8	0.39	7.35	0.32	9.14e-13	Body mass index;
LGG	cis	rs6142618	0.562	rs4911550	chr20:30739442	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs5756391	0.782	rs735561	chr22:37296999	G/A	cg21209356	chr22:37319042	CSF2RB	0.35	7.96	0.35	1.37e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg06623630	chr22:50017776	C22orf34	-0.35	-7.31	-0.32	1.22e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg14019146	chr3:50243930	SLC38A3	0.54	11.7	0.48	6.85e-28	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19524238	chr7:2802976	GNA12	0.37	8.33	0.36	9.5e-16	Height;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg02951883	chr7:2050386	MAD1L1	-0.8	-18.15	-0.64	5.62e-56	Bipolar disorder and schizophrenia;
LGG	cis	rs28530618	0.603	rs4594522	chr20:31254984	T/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.85	-0.3	2.4e-11	Birth weight;
LGG	cis	rs7192380	0.893	rs12921782	chr16:69780022	C/T	cg00738113	chr16:70207722	CLEC18C	0.31	8.9	0.38	1.3e-17	Sjögren's syndrome;
LGG	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06156847	chr2:113672199	IL1F7	0.38	7.45	0.33	4.59e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1707322	0.717	rs3014237	chr1:46090252	A/G	cg03146154	chr1:46216737	IPP	-0.54	-10.11	-0.43	7.58e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6694672	0.867	rs510135	chr1:197187779	C/T	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs2389217	0.509	rs2389219	chr12:33722185	T/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs477692	0.967	rs488143	chr10:131407369	A/C	cg05714579	chr10:131428358	MGMT	0.65	13.86	0.54	8.29e-37	Response to temozolomide;
LGG	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg15704280	chr7:45808275	SEPT13	0.74	8.98	0.39	6.81e-18	Intraocular pressure;
LGG	cis	rs6541297	0.715	rs4846840	chr1:230302521	A/C	cg05784532	chr1:230284198	GALNT2	0.37	6.77	0.3	3.9e-11	Coronary artery disease;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg09448879	chr15:79043637	NA	-0.54	-13.74	-0.54	2.75e-36	Coronary artery disease or large artery stroke;
LGG	cis	rs953387	0.956	rs4954572	chr2:136926719	G/T	cg07169764	chr2:136633963	MCM6	0.54	8.9	0.38	1.23e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg21053147	chr12:120880522	NA	-0.54	-8.04	-0.35	7.36e-15	Type 1 diabetes nephropathy;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs17253792	0.822	rs8013831	chr14:56172898	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.81	-0.51	2.18e-32	Putamen volume;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.24	-0.36	1.74e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg06529181	chr19:52193933	NA	0.54	8.14	0.35	3.77e-15	IgG glycosylation;
LGG	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.79	-0.34	4.5e-14	IgG glycosylation;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.61e-14	Lung cancer;
LGG	cis	rs2013441	0.866	rs2526470	chr17:20160270	C/T	cg13482628	chr17:19912719	NA	-0.41	-6.98	-0.31	1.04e-11	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25172604	chr17:41446521	NA	0.29	6.79	0.3	3.43e-11	Menopause (age at onset);
LGG	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg16583315	chr14:65563665	MAX	-0.42	-8.53	-0.37	2.03e-16	Obesity-related traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06789412	chr3:101405552	RPL24	-0.5	-7.32	-0.32	1.12e-12	Systemic lupus erythematosus;
LGG	trans	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	27.64	0.79	4.77e-100	Exhaled nitric oxide output;
LGG	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg13010199	chr12:38710504	ALG10B	0.45	8.14	0.35	3.71e-15	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.73	0.41	1.71e-20	Skin colour saturation;
LGG	cis	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg00405596	chr8:11794950	NA	0.65	11.26	0.46	3.83e-26	Myopia (pathological);
LGG	cis	rs1555133	0.518	rs6141714	chr20:31002352	T/A	cg00028034	chr20:30779307	TSPYL3	0.32	6.69	0.3	6.5e-11	Monocyte count;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg21724239	chr8:58056113	NA	0.52	7.77	0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.42	0.36	4.91e-16	Aortic root size;
LGG	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.02	-0.35	8.99e-15	Obesity;
LGG	trans	rs9354308	0.764	rs9345715	chr6:66603371	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs472402	0.580	rs4702373	chr5:6633222	C/T	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.2	-0.32	2.43e-12	Response to amphetamines;
LGG	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.32	-0.32	1.13e-12	Body mass index;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg25172604	chr17:41446521	NA	-0.3	-7.08	-0.31	5.22e-12	Menopause (age at onset);
LGG	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg19680485	chr15:31195859	MTMR15	-0.46	-7.0	-0.31	9.07e-12	Huntington's disease progression;
LGG	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg24812749	chr6:127587940	RNF146	0.95	16.01	0.6	3.29e-46	Breast cancer;
LGG	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-12.7	-0.51	6.76e-32	Bladder cancer;
LGG	cis	rs16976116	0.803	rs28590021	chr15:55490993	C/T	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg03517284	chr6:25882590	NA	-0.43	-6.76	-0.3	4.12e-11	Height;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.81	-0.59	2.41e-45	Height;
LGG	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-12.88	-0.51	1.15e-32	Response to antipsychotic treatment;
LGG	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.58	-0.33	1.88e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg02153584	chr22:29168773	CCDC117	-0.59	-8.7	-0.37	6.01e-17	Lymphocyte counts;
LGG	cis	rs9796	0.870	rs3214068	chr15:41313064	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.43	-0.36	4.45e-16	Menopause (age at onset);
LGG	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs6489785	0.522	rs1718188	chr12:121343893	T/A	cg02419362	chr12:121203948	SPPL3	-0.5	-8.72	-0.38	5.03e-17	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.39	0.32	7e-13	Neuroticism;
LGG	trans	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg08344181	chr3:125677491	NA	-0.48	-6.82	-0.3	2.77e-11	Depression;
LGG	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.66	-0.34	1.13e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.49	0.53	3.37e-35	Lung cancer;
LGG	cis	rs6500602	0.685	rs62037617	chr16:4435163	G/C	cg08645402	chr16:4508243	NA	0.44	7.66	0.34	1.08e-13	Schizophrenia;
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg03517284	chr6:25882590	NA	-0.41	-7.34	-0.32	9.36e-13	Height;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	8.28	0.36	1.35e-15	Longevity;
LGG	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.22	0.58	1.08e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	3.94e-11	Parkinson's disease;
LGG	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg05729581	chr11:3078854	CARS	-0.53	-9.04	-0.39	4.25e-18	Longevity;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.84	-0.42	7.33e-21	Lung cancer;
LGG	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.73e-27	Schizophrenia;
LGG	cis	rs8049040	0.547	rs12934168	chr16:71436778	C/T	cg08717414	chr16:71523259	ZNF19	-0.46	-6.98	-0.31	9.99e-12	Blood protein levels;
LGG	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg10847948	chr11:71163743	NADSYN1	0.61	8.82	0.38	2.34e-17	Vitamin D levels;
LGG	trans	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg07817883	chr1:32538562	TMEM39B	0.64	8.04	0.35	7.66e-15	Monocyte percentage of white cells;
LGG	trans	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.82	0.42	8.26e-21	Diabetic kidney disease;
LGG	cis	rs367615	0.537	rs17161729	chr5:108660528	C/G	cg17395555	chr5:108820864	NA	-0.74	-12.16	-0.49	9.81e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg21862992	chr11:68658383	NA	0.49	8.35	0.36	7.83e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs1465370	0.682	rs62471720	chr7:130016359	C/G	cg06917763	chr7:130033247	NA	0.33	7.24	0.32	1.89e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs4427176	0.507	rs7015963	chr8:9580854	G/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs4774899	1.000	rs34262415	chr15:57253829	C/T	cg08128148	chr15:57256372	TCF12	0.32	7.58	0.33	1.93e-13	Urinary tract infection frequency;
LGG	cis	rs72781680	0.948	rs113530757	chr2:24142500	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs9534288	0.833	rs56813530	chr13:46622039	A/C	cg15192986	chr13:46630673	CPB2	-0.73	-16.04	-0.6	2.23e-46	Blood protein levels;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg11657817	chr20:23433608	CST11	0.41	8.34	0.36	8.46e-16	Facial morphology (factor 15, philtrum width);
LGG	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg10840412	chr1:235813424	GNG4	-0.54	-7.49	-0.33	3.6e-13	Bipolar disorder;
LGG	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.6	11.75	0.48	4.47e-28	Colorectal cancer;
LGG	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg10253484	chr15:75165896	SCAMP2	0.51	7.66	0.34	1.08e-13	Systemic lupus erythematosus;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.03	0.42	1.46e-21	Tonsillectomy;
LGG	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg07465881	chr4:1713556	SLBP	0.46	7.23	0.32	1.98e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg22643751	chr7:855365	UNC84A	0.43	7.69	0.34	8.66e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs73001065	0.591	rs2285626	chr19:19467545	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	11.09	0.46	1.63e-25	LDL cholesterol;
LGG	cis	rs75920871	0.563	rs112895963	chr11:116937159	A/T	cg20608306	chr11:116969690	SIK3	-0.33	-6.76	-0.3	4.16e-11	Subjective well-being;
LGG	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg23894439	chr1:183413866	NA	-0.49	-9.2	-0.39	1.27e-18	Systemic lupus erythematosus;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg11220663	chr2:70994863	ADD2	0.44	7.19	0.32	2.56e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg17595323	chr11:93583763	C11orf90	-0.44	-7.94	-0.35	1.5e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg19847130	chr8:10466454	RP1L1	0.31	6.74	0.3	4.64e-11	Neuroticism;
LGG	cis	rs7193541	0.965	rs4402594	chr16:74701360	C/T	cg01733217	chr16:74700730	RFWD3	0.89	20.26	0.69	8.05e-66	Multiple myeloma;
LGG	cis	rs240764	0.736	rs9968897	chr6:100945858	G/A	cg21058520	chr6:100914733	NA	0.5	8.68	0.37	6.86e-17	Neuroticism;
LGG	cis	rs6546550	0.901	rs34586537	chr2:70163316	G/T	cg02498382	chr2:70120550	SNRNP27	0.41	7.77	0.34	5.09e-14	Prevalent atrial fibrillation;
LGG	cis	rs8180040	0.800	rs56250009	chr3:47279497	G/C	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6e-39	Colorectal cancer;
LGG	cis	rs3762637	0.941	rs60222267	chr3:122179632	G/T	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs4700695	0.545	rs253275	chr5:65509809	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-8.35	-0.36	8.2e-16	Facial morphology (factor 19);
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.42	0.36	4.79e-16	Platelet count;
LGG	cis	rs6743226	0.776	rs2166191	chr2:242152886	T/A	cg10021735	chr2:242295487	FARP2	0.41	7.49	0.33	3.53e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg24060327	chr5:131705240	SLC22A5	-0.45	-7.52	-0.33	2.91e-13	Blood metabolite levels;
LGG	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg16584676	chr17:46985605	UBE2Z	0.52	9.25	0.39	8.6e-19	Type 2 diabetes;
LGG	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg04607235	chr12:12878440	APOLD1	-0.54	-7.87	-0.34	2.53e-14	Systemic lupus erythematosus;
LGG	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.32	0.47	2.1e-26	Hemoglobin concentration;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg07414643	chr4:187882934	NA	0.55	11.32	0.47	2.16e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg06885757	chr1:42089581	HIVEP3	0.57	13.17	0.52	7.06e-34	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg21948465	chr5:131705150	SLC22A5	0.68	7.47	0.33	4.13e-13	Rheumatoid arthritis;
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg09754948	chr16:28834200	ATXN2L	-0.5	-8.04	-0.35	7.33e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs61332075	0.518	rs72994950	chr2:239422993	T/C	cg01134436	chr17:81009848	B3GNTL1	0.79	8.68	0.37	6.71e-17	Lung function (FEV1/FVC);
LGG	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg10057126	chr4:77819792	ANKRD56	0.36	6.83	0.3	2.72e-11	Emphysema distribution in smoking;
LGG	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg18154014	chr19:37997991	ZNF793	-0.45	-7.85	-0.34	2.87e-14	Coronary artery calcification;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.29	-0.32	1.33e-12	Lung cancer;
LGG	cis	rs3099143	1.000	rs7178759	chr15:77143513	A/G	cg21673338	chr15:77095150	SCAPER	0.62	10.41	0.44	6.11e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg23422044	chr7:1970798	MAD1L1	-0.51	-9.51	-0.4	1.06e-19	Neuroticism;
LGG	cis	rs9868809	0.772	rs34096717	chr3:48719453	A/C	cg00383909	chr3:49044727	WDR6	0.84	10.12	0.43	7.18e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06558623	chr16:89946397	TCF25	1.2	14.08	0.55	1e-37	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.32	-0.5	2.24e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.09	0.35	5.29e-15	Diabetic kidney disease;
LGG	cis	rs2117029	0.556	rs1057725	chr12:49522578	T/C	cg24176009	chr12:49580217	TUBA1A	0.65	12.66	0.51	9.35e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	0.717	rs34263881	chr22:18401597	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.48	-0.4	1.34e-19	Presence of antiphospholipid antibodies;
LGG	trans	rs9354308	0.764	rs4710542	chr6:66584434	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs61931739	0.649	rs708136	chr12:33737411	A/G	cg26384229	chr12:38710491	ALG10B	0.47	8.46	0.37	3.47e-16	Morning vs. evening chronotype;
LGG	cis	rs11123610	0.520	rs66646194	chr2:3720420	G/A	cg26344334	chr2:3718215	ALLC	-0.49	-8.34	-0.36	8.34e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.84	0.45	1.51e-24	Obesity-related traits;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg01966878	chr4:90757139	SNCA	-0.37	-7.68	-0.34	9.78e-14	Dementia with Lewy bodies;
LGG	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.42	0.5	8.89e-31	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg23649088	chr2:200775458	C2orf69	0.8	16.14	0.6	8.14e-47	Osteoporosis;
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.24	0.49	4.93e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.576	rs246006	chr5:140339228	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg16141378	chr3:129829833	LOC729375	0.32	6.66	0.3	7.87e-11	Neuroticism;
LGG	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11890956	chr21:40555474	PSMG1	-0.97	-20.17	-0.68	2.17e-65	Cognitive function;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07362569	chr17:61921086	SMARCD2	0.49	9.46	0.4	1.58e-19	Prudent dietary pattern;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.57	-0.33	2.07e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg21211680	chr2:198530	NA	-1.17	-14.75	-0.57	1.26e-40	Blood protein levels;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.53	0.37	2.14e-16	Schizophrenia;
LGG	trans	rs7944735	0.817	rs2305983	chr11:47858755	C/T	cg03929089	chr4:120376271	NA	0.56	6.9	0.31	1.68e-11	Intraocular pressure;
LGG	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg00021532	chr16:4324280	TFAP4	0.49	12.95	0.52	6.03e-33	Prostate-specific antigen levels;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	10.92	0.45	7.5e-25	Personality dimensions;
LGG	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg21395723	chr22:39101663	GTPBP1	0.37	6.65	0.3	8.46e-11	Menopause (age at onset);
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.11	0.57	3.15e-42	Prostate cancer;
LGG	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg13802316	chr11:70253460	CTTN	-0.73	-10.19	-0.43	4e-22	Coronary artery disease;
LGG	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg13256891	chr4:100009986	ADH5	0.55	9.73	0.41	1.7e-20	Alcohol dependence;
LGG	trans	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg16141378	chr3:129829833	LOC729375	0.39	7.15	0.32	3.42e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg06092702	chr1:163392909	NA	-0.47	-8.31	-0.36	1.09e-15	Motion sickness;
LGG	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg08344181	chr3:125677491	NA	-0.65	-7.54	-0.33	2.42e-13	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.93	-0.78	8.57e-97	Height;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04772025	chr11:68637568	NA	0.77	13.8	0.54	1.59e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg01411142	chr8:19674711	INTS10	-0.44	-7.02	-0.31	7.96e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1691799	0.867	rs1027401	chr12:66760892	C/G	cg16791601	chr12:66731901	HELB	-0.64	-15.07	-0.57	5.01e-42	White blood cell count (basophil);
LGG	cis	rs6568686	0.627	rs17539951	chr6:111664969	G/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg00531865	chr16:30841666	NA	-0.54	-10.87	-0.45	1.11e-24	Multiple myeloma;
LGG	cis	rs9944715	0.911	rs8085138	chr18:43768751	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.36	-6.68	-0.3	6.84e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.3	-0.32	1.25e-12	Refractive error;
LGG	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg15736062	chr7:158136485	PTPRN2	0.52	9.41	0.4	2.33e-19	Response to amphetamines;
LGG	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.99	-0.52	4.18e-33	Schizophrenia;
LGG	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg13683864	chr3:40499215	RPL14	-1.13	-26.58	-0.78	3.22e-95	Renal cell carcinoma;
LGG	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.28	-0.43	1.89e-22	Subjective well-being;
LGG	cis	rs2370759	1.000	rs11599044	chr10:32615445	A/G	cg01819863	chr10:32635814	EPC1	1.09	15.7	0.59	7.73e-45	Sexual dysfunction (female);
LGG	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.41	-0.44	5.8e-23	Total body bone mineral density;
LGG	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg18937875	chr11:14930189	NA	-0.47	-7.6	-0.33	1.71e-13	Vitamin D levels;
LGG	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.41	7.07	0.31	5.65e-12	Depressive symptoms;
LGG	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg24631222	chr15:78858424	CHRNA5	-0.42	-6.68	-0.3	6.99e-11	Post bronchodilator FEV1;
LGG	cis	rs7635838	0.619	rs347614	chr3:11276399	T/C	cg00170343	chr3:11313890	ATG7	0.56	9.26	0.4	7.95e-19	HDL cholesterol;
LGG	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg01579765	chr21:45077557	HSF2BP	0.38	8.88	0.38	1.47e-17	Mean corpuscular volume;
LGG	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg16070123	chr10:51489643	NA	0.41	7.53	0.33	2.63e-13	Prostate-specific antigen levels;
LGG	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg13482628	chr17:19912719	NA	0.54	10.28	0.43	1.84e-22	Schizophrenia;
LGG	trans	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg02297831	chr4:17616191	MED28	0.5	9.41	0.4	2.42e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03264133	chr6:25882463	NA	-0.58	-11.02	-0.46	3.15e-25	Blood metabolite levels;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.43	0.33	5.32e-13	Rheumatoid arthritis;
LGG	cis	rs4731207	0.698	rs4422720	chr7:124499402	C/G	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	13.49	0.53	3.12e-35	Cognitive test performance;
LGG	cis	rs7572733	0.935	rs1518366	chr2:198809196	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.2	0.36	2.44e-15	Dermatomyositis;
LGG	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg02959939	chr21:47813025	PCNT	-0.36	-6.75	-0.3	4.56e-11	Lymphocyte counts;
LGG	cis	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg02972257	chr16:68554789	NA	0.56	8.24	0.36	1.82e-15	Ulcerative colitis;
LGG	cis	rs8016982	0.593	rs7160569	chr14:81713686	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	18.83	0.66	3.63e-59	Schizophrenia;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	11.08	0.46	1.79e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.21	-0.32	2.36e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-11.93	-0.49	8.22e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7945705	0.818	rs2742537	chr11:8908389	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.51	-11.23	-0.46	4.72e-26	Hemoglobin concentration;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.36	-0.36	7.47e-16	Height;
LGG	cis	rs2274273	0.837	rs7146748	chr14:55747086	G/A	cg04306507	chr14:55594613	LGALS3	0.63	17.74	0.64	4.26e-54	Protein biomarker;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg12070911	chr6:150209640	RAET1E	0.3	7.09	0.31	4.99e-12	Lung cancer;
LGG	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg15162869	chr22:32027605	PISD	-0.67	-7.14	-0.32	3.58e-12	Age-related hearing impairment;
LGG	cis	rs977987	0.864	rs40446	chr16:75496658	T/C	cg07303275	chr16:75499416	TMEM170A	-0.43	-7.63	-0.33	1.39e-13	Dupuytren's disease;
LGG	cis	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.7	-0.56	2.03e-40	IgG glycosylation;
LGG	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg03606772	chr1:152487856	CRCT1	0.32	7.59	0.33	1.82e-13	Hair morphology;
LGG	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg14541582	chr5:601475	NA	-0.69	-10.64	-0.44	8.45e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs7582720	1.000	rs78907692	chr2:203932176	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.34	0.4	3.94e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.32e-28	Gout;Renal underexcretion gout;
LGG	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.62	-0.33	1.42e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg08999081	chr20:33150536	PIGU	-0.4	-10.11	-0.43	7.51e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg11584989	chr19:19387371	SF4	0.4	7.25	0.32	1.8e-12	Tonsillectomy;
LGG	cis	rs4851266	0.933	rs6709656	chr2:100806719	A/G	cg21926883	chr2:100939477	LONRF2	-0.42	-7.5	-0.33	3.21e-13	Educational attainment;
LGG	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg03433033	chr1:76189801	ACADM	0.64	10.9	0.45	8.64e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23435730	chr3:127770634	SEC61A1	0.48	7.41	0.33	6.16e-13	Gut microbiome composition (summer);
LGG	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg04287289	chr16:89883240	FANCA	0.8	16.03	0.6	2.46e-46	Schizophrenia;
LGG	cis	rs6743226	0.934	rs4303713	chr2:242257859	G/A	cg10021735	chr2:242295487	FARP2	0.54	9.88	0.42	5.26e-21	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg20913747	chr6:44695427	NA	-0.67	-11.98	-0.49	5.56e-29	Total body bone mineral density;
LGG	cis	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg07460842	chr6:66804631	NA	0.96	17.9	0.64	7.68e-55	Exhaled nitric oxide output;
LGG	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg14952266	chr13:112191215	NA	0.52	11.02	0.46	2.96e-25	Hepatitis;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.26	-0.43	2.08e-22	Bipolar disorder;
LGG	cis	rs240764	0.578	rs6927598	chr6:101232729	T/C	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs12476592	0.602	rs10865338	chr2:63732509	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	11.56	0.47	2.55e-27	Parkinson's disease;
LGG	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.92e-26	Corneal astigmatism;
LGG	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg20302533	chr7:39170763	POU6F2	0.47	11.05	0.46	2.29e-25	IgG glycosylation;
LGG	cis	rs1867631	0.585	rs12062570	chr1:67086285	T/C	cg13052034	chr1:66999238	SGIP1	0.33	6.77	0.3	3.8e-11	Menopause (age at onset);
LGG	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg11161011	chr14:65562177	MAX	-0.77	-14.96	-0.57	1.53e-41	Obesity-related traits;
LGG	cis	rs478222	1.000	rs478222	chr2:25301755	A/T	cg04586622	chr2:25135609	ADCY3	-0.31	-7.86	-0.34	2.68e-14	Type 1 diabetes;
LGG	cis	rs9807841	0.727	rs7247567	chr19:10856418	C/T	cg17710535	chr19:10819994	QTRT1	0.49	8.49	0.37	2.92e-16	Inflammatory skin disease;
LGG	cis	rs13088645	0.532	rs7623580	chr3:134164345	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.47	7.92	0.35	1.74e-14	Coronary artery disease;
LGG	trans	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg26518628	chr1:97050305	NA	-0.86	-7.89	-0.34	2.21e-14	Cannabis dependence symptom count;
LGG	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg08733933	chr1:2954429	NA	-0.39	-8.67	-0.37	7.5e-17	Plateletcrit;
LGG	trans	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.74	0.3	4.87e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04156016	chr5:1868137	NA	0.33	7.28	0.32	1.47e-12	Cardiovascular disease risk factors;
LGG	cis	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	6.64	0.3	8.63e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11608355	0.521	rs6606704	chr12:109814036	T/C	cg19025524	chr12:109796872	NA	-0.56	-12.45	-0.5	7.12e-31	Neuroticism;
LGG	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg05425664	chr17:57184151	TRIM37	-0.44	-6.93	-0.31	1.45e-11	Testicular germ cell tumor;
LGG	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg18850127	chr7:39170497	POU6F2	0.37	8.42	0.36	4.9e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg01765077	chr12:122356316	WDR66	0.29	8.1	0.35	4.9e-15	Mean corpuscular volume;
LGG	cis	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs806215	1.000	rs712700	chr7:127250907	T/C	cg25922125	chr7:127225783	GCC1	0.75	10.33	0.43	1.16e-22	Type 2 diabetes;
LGG	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.04	-0.35	7.49e-15	Menarche (age at onset);
LGG	cis	rs4302748	0.862	rs12533280	chr7:36171953	C/T	cg24442661	chr7:36192818	EEPD1	0.55	7.18	0.32	2.73e-12	Platelet count;
LGG	cis	rs9359856	0.913	rs9362665	chr6:90309844	C/T	cg13799429	chr6:90582589	CASP8AP2	0.45	6.86	0.3	2.25e-11	Bipolar disorder;
LGG	cis	rs9879311	0.966	rs28113	chr3:10400643	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.37	7.25	0.32	1.8e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7927771	0.725	rs11039265	chr11:47523214	C/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.76	-0.38	3.83e-17	Subjective well-being;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg16301924	chr13:53314226	LECT1	-0.48	-9.35	-0.4	3.67e-19	Lewy body disease;
LGG	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg23505145	chr19:12996616	KLF1	0.41	7.22	0.32	2.11e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg12654349	chr5:56205094	C5orf35	0.4	7.13	0.31	3.99e-12	Coronary artery disease;
LGG	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg25173405	chr17:45401733	C17orf57	0.49	8.55	0.37	1.86e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs72925845	0.519	rs587370	chr17:76427286	C/T	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg13736514	chr6:26305472	NA	0.45	8.95	0.38	8.7e-18	Mosquito bite size;
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg08621203	chr6:150244597	RAET1G	0.45	6.72	0.3	5.34e-11	Lung cancer;
LGG	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg25482853	chr8:67687455	SGK3	-1.04	-13.42	-0.53	6.24e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs12765878	0.580	rs10786772	chr10:105610326	A/G	cg11005552	chr10:105648138	OBFC1	0.7	11.91	0.48	9.98e-29	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16836995	chr17:43662488	NA	0.46	7.04	0.31	7.12e-12	Gut microbiome composition (summer);
LGG	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg10664184	chr19:17420304	DDA1	0.55	8.51	0.37	2.5e-16	Systemic lupus erythematosus;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02775028	chr4:184580387	C4orf41;RWDD4A	-0.43	-7.18	-0.32	2.72e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.81	0.54	1.37e-36	Bladder cancer;
LGG	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg12552261	chr5:112820674	MCC	0.75	14.29	0.55	1.21e-38	Type 2 diabetes;
LGG	cis	rs67311347	0.544	rs6787516	chr3:40355616	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-15.74	-0.59	4.83e-45	Renal cell carcinoma;
LGG	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg18252515	chr7:66147081	NA	-1.37	-19.1	-0.66	2.22e-60	Diabetic kidney disease;
LGG	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg13647721	chr17:30228624	UTP6	-0.76	-9.87	-0.42	5.36e-21	Hip circumference adjusted for BMI;
LGG	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg24634471	chr8:143751801	JRK	0.53	8.46	0.37	3.59e-16	Schizophrenia;
LGG	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.26	0.32	1.66e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.57	-0.41	6.62e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-13.13	-0.52	1.11e-33	Morning vs. evening chronotype;
LGG	cis	rs477692	0.563	rs7079165	chr10:131430240	G/A	cg05714579	chr10:131428358	MGMT	-0.81	-19.36	-0.67	1.25e-61	Response to temozolomide;
LGG	cis	rs4926611	0.762	rs7551844	chr1:54061333	A/G	cg23596471	chr1:54105337	GLIS1	0.39	8.05	0.35	6.81e-15	Hand grip strength;
LGG	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg00864171	chr11:67383662	NA	-0.42	-6.74	-0.3	4.6e-11	Mean corpuscular volume;
LGG	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg25801113	chr15:45476975	SHF	0.85	18.87	0.66	2.36e-59	Uric acid levels;
LGG	cis	rs7119	0.643	rs12904384	chr15:77410878	T/G	cg17802220	chr15:77601643	NA	-0.46	-10.13	-0.43	6.53e-22	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.25	0.52	3.19e-34	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs629535	0.767	rs72654070	chr8:70079369	G/A	cg21567404	chr3:27674614	NA	-0.4	-6.7	-0.3	6.22e-11	Dupuytren's disease;
LGG	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg16586182	chr3:47516702	SCAP	-0.76	-15.06	-0.57	5.06e-42	Colorectal cancer;
LGG	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-22.46	-0.72	4.08e-76	Monocyte count;
LGG	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg19507638	chr5:93509721	C5orf36	-0.73	-10.08	-0.42	9.4e-22	Diabetic retinopathy;
LGG	cis	rs9815354	0.812	rs73071341	chr3:41826211	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.36	0.4	3.41e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02018176	chr4:1364513	KIAA1530	0.52	12.68	0.51	8.03e-32	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16649755	chr6:88412160	NCRNA00120;AKIRIN2	0.48	8.06	0.35	6.56e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg00864171	chr11:67383662	NA	-0.47	-8.16	-0.35	3.18e-15	Mean corpuscular volume;
LGG	cis	rs4936894	0.500	rs12363393	chr11:124117562	A/T	cg27160556	chr11:124181099	OR8D1	-0.46	-10.65	-0.44	7.54e-24	Aging (time to death);
LGG	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg12560992	chr17:57184187	TRIM37	0.87	15.5	0.58	5.91e-44	Intelligence (multi-trait analysis);
LGG	cis	rs17092148	1.000	rs1884431	chr20:33338585	G/A	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.87	-0.34	2.56e-14	Neuroticism;
LGG	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.65	-0.37	8.67e-17	Lung cancer;
LGG	cis	rs250677	0.687	rs2963484	chr5:148451127	A/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.14	-0.31	3.63e-12	Breast cancer;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.81	0.34	3.79e-14	Lung cancer;
LGG	cis	rs1003719	0.742	rs8129231	chr21:38501034	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.06	-0.57	5.36e-42	Eye color traits;
LGG	cis	rs10274279	0.660	rs9638055	chr7:157379914	A/G	cg09270525	chr7:157391030	PTPRN2	0.82	13.63	0.54	8.44e-36	Myopia (pathological);
LGG	cis	rs10193935	0.748	rs12467253	chr2:42697588	A/C	cg27598129	chr2:42591480	NA	0.67	9.79	0.41	1.12e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg23302884	chr18:44338147	ST8SIA5	0.38	7.7	0.34	8.46e-14	Personality dimensions;
LGG	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg00701064	chr4:6280414	WFS1	0.73	16.43	0.61	4.2e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs16854884	0.657	rs35309714	chr3:143735011	T/A	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs12450239	0.700	rs35693727	chr17:77438248	A/G	cg07832143	chr17:77435199	HRNBP3	0.47	9.03	0.39	4.81e-18	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12413365	chr12:12510412	LOH12CR1;LOH12CR2	0.45	6.87	0.3	2.13e-11	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-10.61	-0.44	1.13e-23	Body mass index;
LGG	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg13013644	chr5:502571	SLC9A3	0.32	7.18	0.32	2.8e-12	Cystic fibrosis severity;
LGG	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-14.02	-0.55	1.81e-37	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg16586182	chr3:47516702	SCAP	0.67	12.42	0.5	8.82e-31	Colorectal cancer;
LGG	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg01493522	chr13:37497338	NA	-0.5	-8.57	-0.37	1.51e-16	Coronary artery disease;
LGG	cis	rs6815814	0.950	rs45588337	chr4:38807328	A/G	cg06935464	chr4:38784597	TLR10	0.6	8.31	0.36	1.08e-15	Breast cancer;
LGG	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs6456042	1.000	rs3099299	chr6:166526587	C/T	cg11088901	chr6:166572345	T	-0.35	-7.14	-0.32	3.56e-12	Asthma;
LGG	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg25801113	chr15:45476975	SHF	-0.87	-19.0	-0.66	6.33e-60	Uric acid levels;
LGG	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	8.36	0.36	7.66e-16	Coronary artery disease;
LGG	cis	rs72781680	0.716	rs2712071	chr2:23990419	A/G	cg08917208	chr2:24149416	ATAD2B	0.65	8.44	0.37	4.03e-16	Lymphocyte counts;
LGG	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-7.73	-0.34	6.71e-14	Mood instability;
LGG	cis	rs1018836	0.923	rs7826178	chr8:91649592	C/A	cg16814680	chr8:91681699	NA	-0.85	-16.35	-0.6	9.26e-48	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2224391	0.628	rs2773311	chr6:5250866	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-7.63	-0.33	1.35e-13	Height;
LGG	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs1003719	0.788	rs2040341	chr21:38489753	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.33	0.63	3.07e-52	Eye color traits;
LGG	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg25801113	chr15:45476975	SHF	-0.88	-19.24	-0.67	4.94e-61	Uric acid levels;
LGG	cis	rs17776563	0.887	rs7164137	chr15:89136177	C/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.28	-0.43	1.88e-22	Thyroid hormone levels;
LGG	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06634786	chr22:41940651	POLR3H	-0.69	-11.36	-0.47	1.5e-26	Vitiligo;
LGG	cis	rs35740288	0.580	rs34635893	chr15:86340248	C/T	cg04173714	chr15:86211321	AKAP13	0.41	6.85	0.3	2.37e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.69	-0.34	8.87e-14	Height;
LGG	cis	rs3750082	0.582	rs6462436	chr7:32970900	T/C	cg08946731	chr7:32981826	RP9P	0.55	8.58	0.37	1.43e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg13385794	chr1:248469461	NA	0.45	7.72	0.34	7.12e-14	Common traits (Other);
LGG	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg26384229	chr12:38710491	ALG10B	0.72	14.25	0.55	1.88e-38	Bladder cancer;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg13397359	chr6:42928475	GNMT	0.62	18.46	0.65	1.91e-57	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9354308	0.764	rs1938083	chr6:66611568	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg21972741	chr5:435613	AHRR	0.46	8.23	0.36	1.89e-15	Cystic fibrosis severity;
LGG	cis	rs16854884	0.586	rs7650172	chr3:143729408	G/C	cg06585982	chr3:143692056	C3orf58	0.68	12.29	0.5	2.97e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.95	0.54	3.75e-37	Lung cancer in ever smokers;
LGG	cis	rs4478858	0.735	rs10914361	chr1:31817542	T/G	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.75e-31	Motion sickness;
LGG	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg07636037	chr3:49044803	WDR6	0.78	14.0	0.55	2.16e-37	Menarche (age at onset);
LGG	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg06640241	chr16:89574553	SPG7	0.71	11.94	0.49	7.71e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg18681998	chr4:17616180	MED28	0.87	20.33	0.69	3.74e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg04911050	chr16:677664	RAB40C	0.35	6.96	0.31	1.17e-11	Height;
LGG	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.27	-0.36	1.46e-15	Neuroticism;
LGG	trans	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg21659725	chr3:3221576	CRBN	-0.45	-7.37	-0.32	8.15e-13	Menarche (age at onset);
LGG	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg09137382	chr11:130731461	NA	0.36	6.88	0.3	2e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs12230513	0.732	rs7310335	chr12:55884439	C/T	cg19537932	chr12:55886519	OR6C68	-0.61	-11.06	-0.46	2.23e-25	Contrast sensitivity;
LGG	cis	rs2346160	0.899	rs206980	chr6:167691798	A/G	cg20683250	chr6:167653907	NA	0.42	6.93	0.31	1.43e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg12193833	chr17:30244370	NA	-0.28	-7.04	-0.31	7.15e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg03342759	chr3:160939853	NMD3	0.45	7.55	0.33	2.35e-13	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.03	0.52	2.86e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg11812906	chr14:75593930	NEK9	-0.5	-9.44	-0.4	1.9e-19	Height;
LGG	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg07541023	chr7:19748670	TWISTNB	0.56	7.81	0.34	3.91e-14	Thyroid stimulating hormone;
LGG	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.53	-0.44	2.13e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.25e-22	Cognitive ability;
LGG	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg06115741	chr20:33292138	TP53INP2	-0.52	-8.58	-0.37	1.49e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.78	-0.34	4.73e-14	Neuroticism;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.21	0.36	2.3e-15	Obesity-related traits;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08677398	chr8:58056175	NA	0.47	7.76	0.34	5.6e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg23815491	chr16:72088622	HP	0.51	9.55	0.41	7.79e-20	Blood protein levels;
LGG	cis	rs9309473	1.000	rs56672945	chr2:73622663	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-8.04	-0.35	7.36e-15	Metabolite levels;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg19077165	chr18:44547161	KATNAL2	-0.58	-10.8	-0.45	2.06e-24	Personality dimensions;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg19635926	chr16:89946313	TCF25	0.71	7.98	0.35	1.13e-14	Skin colour saturation;
LGG	cis	rs9783347	0.961	rs12293544	chr11:18348581	T/C	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg05234568	chr11:5960015	NA	-0.66	-10.57	-0.44	1.59e-23	DNA methylation (variation);
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.25	-0.32	1.77e-12	Dementia with Lewy bodies;
LGG	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-9.76	-0.41	1.39e-20	Menarche (age at onset);
LGG	cis	rs2729354	0.768	rs2584856	chr11:57267312	C/A	cg24343310	chr11:57249947	NA	0.42	8.31	0.36	1.08e-15	Blood protein levels;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.75e-26	Bipolar disorder;
LGG	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.91	0.45	7.98e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.32e-12	Hair morphology;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	7.32	0.32	1.13e-12	Schizophrenia;
LGG	cis	rs4732038	0.834	rs782538	chr7:134254427	G/A	cg06906464	chr7:134288099	NA	-0.44	-9.95	-0.42	2.84e-21	Longevity;
LGG	cis	rs12476592	0.516	rs6734648	chr2:63801525	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs7100689	0.646	rs4265545	chr10:82119271	G/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6993813	0.837	rs4495461	chr8:120019317	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.87	0.3	2.13e-11	Bone mineral density (hip);
LGG	cis	rs4716602	0.898	rs1534001	chr7:156163283	A/G	cg16983916	chr7:156159713	NA	-0.38	-6.72	-0.3	5.34e-11	Anti-saccade response;
LGG	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.51	-0.44	2.63e-23	Vitiligo;
LGG	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg05973401	chr12:123451056	ABCB9	0.43	7.3	0.32	1.25e-12	Platelet count;
LGG	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	cis	rs806215	0.547	rs806172	chr7:127297002	G/A	cg25922125	chr7:127225783	GCC1	0.52	7.61	0.33	1.56e-13	Type 2 diabetes;
LGG	cis	rs11920090	0.656	rs55692140	chr3:170631635	A/G	cg09710316	chr3:170744871	SLC2A2	0.67	7.83	0.34	3.47e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2282802	0.651	rs6863474	chr5:139630862	C/T	cg26211634	chr5:139558579	C5orf32	0.34	7.58	0.33	1.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1719271	0.710	rs3183338	chr15:65159797	T/G	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.66	-0.3	7.6e-11	Platelet count;
LGG	cis	rs1355223	0.525	rs7129517	chr11:34872236	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.23	-0.36	1.95e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4767841	0.935	rs3213625	chr12:120158529	G/T	cg25937854	chr12:120150414	CIT	0.39	6.68	0.3	6.8e-11	Urgency urinary incontinence;
LGG	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg23461800	chr14:103021989	NA	-0.59	-10.79	-0.45	2.23e-24	Platelet count;
LGG	cis	rs877282	0.838	rs11253408	chr10:796374	T/C	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.86	-0.34	2.69e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-8.18	-0.36	2.7e-15	Cognitive test performance;
LGG	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.83	0.51	1.96e-32	Alzheimer's disease;
LGG	cis	rs7851660	0.844	rs993501	chr9:100623377	A/G	cg13688889	chr9:100608707	NA	0.63	12.72	0.51	5.35e-32	Strep throat;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg13939156	chr17:80058883	NA	0.49	9.76	0.41	1.38e-20	Life satisfaction;
LGG	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg13798912	chr7:905769	UNC84A	-0.57	-7.18	-0.32	2.83e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs700651	0.821	rs700690	chr2:198727626	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.53e-25	Intracranial aneurysm;
LGG	cis	rs4950322	1.000	rs1806618	chr1:146848796	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-6.98	-0.31	1.04e-11	Protein quantitative trait loci;
LGG	cis	rs17039065	0.920	rs73838438	chr4:109451248	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.47	-0.33	4.02e-13	HDL cholesterol;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06916706	chr16:4465613	CORO7	-0.84	-14.34	-0.55	7.32e-39	Schizophrenia;
LGG	cis	rs7226408	0.857	rs72885294	chr18:34450941	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.9	-0.34	1.99e-14	Restless legs syndrome;
LGG	cis	rs10267417	0.603	rs10242559	chr7:19898042	C/T	cg05791153	chr7:19748676	TWISTNB	0.55	7.28	0.32	1.49e-12	Night sleep phenotypes;
LGG	cis	rs8077889	0.703	rs231531	chr17:41946180	A/C	cg26893861	chr17:41843967	DUSP3	0.69	10.01	0.42	1.8e-21	Triglycerides;
LGG	cis	rs5756391	0.568	rs5756407	chr22:37316259	A/G	cg21209356	chr22:37319042	CSF2RB	0.39	9.09	0.39	2.88e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00425885	chr1:7792442	CAMTA1	0.48	6.66	0.3	7.98e-11	Inflammatory bowel disease;
LGG	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.05	0.31	6.37e-12	Neuroticism;
LGG	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg03264133	chr6:25882463	NA	-0.49	-7.9	-0.34	2.05e-14	Iron status biomarkers;
LGG	trans	rs11088226	0.758	rs2833864	chr21:33888393	A/C	cg09050820	chr6:167586206	TCP10L2	0.62	9.09	0.39	2.9e-18	Gastritis;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg03351412	chr1:154909251	PMVK	-0.66	-12.51	-0.5	3.71e-31	Prostate cancer;
LGG	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg27087555	chr16:88793112	FAM38A	0.63	9.66	0.41	3.12e-20	Autism spectrum disorder-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04575467	chr8:41997444	NA	0.43	7.35	0.32	9.32e-13	Cognitive performance;
LGG	trans	rs11976180	1.000	rs2961118	chr7:143755443	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.37	-6.8	-0.3	3.3e-11	Obesity-related traits;
LGG	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg02002194	chr4:3960332	NA	0.43	7.56	0.33	2.16e-13	Retinal vascular caliber;
LGG	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg11878867	chr6:150167359	LRP11	-0.5	-10.28	-0.43	1.87e-22	Lung cancer;
LGG	cis	rs9814567	1.000	rs11927068	chr3:134266321	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7917772	0.582	rs10883744	chr10:104347247	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.59e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg27411982	chr8:10470053	RP1L1	0.47	7.95	0.35	1.41e-14	Retinal vascular caliber;
LGG	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.27	-0.43	2.04e-22	Total body bone mineral density;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.06	0.52	2.01e-33	Tonsillectomy;
LGG	cis	rs5769707	0.967	rs9616327	chr22:50010891	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.54	0.33	2.59e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2033732	0.706	rs7821182	chr8:85060586	C/T	cg05716166	chr8:85095498	RALYL	0.43	6.95	0.31	1.24e-11	Body mass index;
LGG	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.2	0.49	7.1e-30	Prudent dietary pattern;
LGG	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	8.41	0.36	4.94e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17376030	chr22:41985996	PMM1	0.58	9.16	0.39	1.69e-18	Vitiligo;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21963583	chr11:68658836	MRPL21	0.58	9.97	0.42	2.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1459104	1.000	rs59570125	chr11:55180057	G/A	cg15704280	chr7:45808275	SEPT13	0.69	6.89	0.3	1.89e-11	Body mass index;
LGG	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.42	-0.36	4.7e-16	Myopia (pathological);
LGG	trans	rs9657904	0.805	rs971110	chr3:105547464	T/C	cg14088669	chr1:158435396	OR10K1	0.43	8.11	0.35	4.58e-15	Multiple sclerosis;
LGG	cis	rs10392	0.850	rs74272986	chr20:37558270	A/G	cg16355469	chr20:37678765	NA	0.53	6.99	0.31	9.66e-12	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg15242686	chr22:24348715	GSTTP1	0.37	6.8	0.3	3.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6759839	0.844	rs16982394	chr2:16624749	A/C	cg09580478	chr2:16689509	NA	0.47	7.38	0.32	7.42e-13	Mean platelet volume;
LGG	cis	rs3784262	0.740	rs4646596	chr15:58300895	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.21	-0.32	2.35e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg04824913	chr4:887549	GAK	-0.82	-18.15	-0.64	5.5e-56	Systemic sclerosis;
LGG	cis	rs876084	0.505	rs7834024	chr8:121103053	T/C	cg06265175	chr8:121136014	COL14A1	0.47	9.43	0.4	1.97e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg15979348	chr13:112237479	NA	0.47	7.95	0.35	1.47e-14	Menarche (age at onset);
LGG	cis	rs1021993	0.545	rs76234951	chr1:209551226	A/T	cg24446417	chr1:209558027	NA	-0.76	-11.36	-0.47	1.51e-26	Gut microbiome composition (winter);
LGG	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-11.01	-0.46	3.45e-25	Body mass index;
LGG	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg03929089	chr4:120376271	NA	0.68	8.07	0.35	6.23e-15	Intraocular pressure;
LGG	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.71	0.3	5.67e-11	Bladder cancer;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.65	-10.9	-0.45	8.99e-25	Renal function-related traits (BUN);
LGG	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg22467129	chr15:76604101	ETFA	-0.43	-7.15	-0.32	3.44e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06003169	chr4:103422460	NFKB1	0.45	6.67	0.3	7.51e-11	Gut microbiome composition (summer);
LGG	cis	rs988958	0.675	rs35531047	chr2:42220435	T/A	cg27252766	chr2:42229092	NA	0.52	8.26	0.36	1.58e-15	Hypospadias;
LGG	cis	rs883565	0.655	rs7649923	chr3:39102137	G/A	cg01426195	chr3:39028469	NA	-0.73	-16.96	-0.62	1.62e-50	Handedness;
LGG	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg14664628	chr15:75095509	CSK	-1.14	-25.49	-0.76	3.37e-90	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4689642	0.507	rs7699290	chr4:7218746	G/A	cg21353189	chr4:7228343	SORCS2	0.31	6.79	0.3	3.53e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs17102423	0.533	rs3783715	chr14:65490018	C/G	cg11161011	chr14:65562177	MAX	-0.76	-12.23	-0.49	5.24e-30	Obesity-related traits;
LGG	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.86	-0.3	2.23e-11	Mood instability;
LGG	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-9.17	-0.39	1.52e-18	Blood metabolite levels;
LGG	cis	rs11168187	0.891	rs2283345	chr12:48109024	A/G	cg12761788	chr12:48120090	P11	0.51	8.47	0.37	3.18e-16	Vertical cup-disc ratio;
LGG	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.25	-0.36	1.68e-15	Neuroticism;
LGG	cis	rs9487094	0.961	rs9480957	chr6:109751601	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.65	0.37	8.52e-17	Height;
LGG	cis	rs10189230	0.967	rs12479119	chr2:222354213	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.66	0.51	9.13e-32	Urate levels in lean individuals;
LGG	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg13514129	chr1:39547527	MACF1	0.7	12.64	0.51	1.18e-31	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1707322	0.963	rs9787412	chr1:46371596	C/T	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3736485	0.609	rs11638154	chr15:51969416	C/T	cg13474965	chr15:52030001	LYSMD2	0.4	6.65	0.3	8.08e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs5769707	0.609	rs2071890	chr22:50001291	G/A	cg06623630	chr22:50017776	C22orf34	-0.47	-9.7	-0.41	2.19e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs3768617	0.811	rs10911233	chr1:183052585	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.82	0.3	2.83e-11	Fuchs's corneal dystrophy;
LGG	cis	rs11203032	1.000	rs11203031	chr10:90964395	G/T	cg16672925	chr10:90967113	CH25H	0.8	11.59	0.47	1.84e-27	Heart failure;
LGG	cis	rs7927771	0.832	rs4752993	chr11:47410951	T/C	cg20307385	chr11:47447363	PSMC3	0.57	10.36	0.43	9.33e-23	Subjective well-being;
LGG	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.1	0.7	9.74e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg21211680	chr2:198530	NA	1.17	19.44	0.67	5.69e-62	Blood protein levels;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.2	-0.39	1.26e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11971779	0.941	rs74299967	chr7:139043769	G/T	cg07862535	chr7:139043722	LUC7L2	0.68	10.29	0.43	1.7e-22	Diisocyanate-induced asthma;
LGG	trans	rs9650657	0.740	rs12676417	chr8:10668634	C/T	cg06636001	chr8:8085503	FLJ10661	0.39	7.05	0.31	6.62e-12	Neuroticism;
LGG	trans	rs826838	0.868	rs864324	chr12:39122853	A/G	cg06521331	chr12:34319734	NA	-0.44	-7.93	-0.35	1.67e-14	Heart rate;
LGG	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.75	0.3	4.36e-11	Glycated hemoglobin levels;
LGG	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.73	-0.38	4.57e-17	Mood instability;
LGG	cis	rs570399	0.816	rs507288	chr1:37203702	A/G	cg24672014	chr1:37203461	NA	0.38	8.72	0.38	5.04e-17	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg27326856	chr19:37663410	ZNF585A	0.39	6.99	0.31	9.6e-12	Obesity-related traits;
LGG	cis	rs11239187	0.586	rs1904836	chr10:45117122	A/C	cg03916630	chr10:45065415	NA	0.3	6.8	0.3	3.23e-11	Body mass index;
LGG	cis	rs599083	0.530	rs686921	chr11:68170833	G/T	cg16797656	chr11:68205561	LRP5	-0.45	-7.38	-0.32	7.15e-13	Bone mineral density (spine);
LGG	cis	rs78456975	1.000	rs6708604	chr2:1556887	C/T	cg26248373	chr2:1572462	NA	-0.72	-9.01	-0.39	5.33e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.98e-21	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07494646	chr22:37415349	MPST;TST	-0.36	-6.68	-0.3	6.98e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-9.0	-0.39	5.66e-18	Longevity;
LGG	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.68	0.34	9.29e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs870825	0.616	rs7683537	chr4:185631998	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs4731207	0.596	rs7788066	chr7:124630145	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.81	-0.3	3.02e-11	Cutaneous malignant melanoma;
LGG	cis	rs75920871	0.925	rs7950381	chr11:116963897	C/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs6961069	0.806	rs10499859	chr7:80258810	A/G	cg04458919	chr7:80252533	CD36	0.29	7.05	0.31	6.71e-12	Platelet count;
LGG	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg18357526	chr6:26021779	HIST1H4A	0.84	15.4	0.58	1.59e-43	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.02	-17.3	-0.63	4.37e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.13	0.31	3.87e-12	Lung cancer;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-15.9	-0.59	9.32e-46	Tonsillectomy;
LGG	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg09021430	chr5:549028	NA	-0.53	-10.23	-0.43	2.86e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08645402	chr16:4508243	NA	0.5	9.46	0.4	1.52e-19	Schizophrenia;
LGG	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-7.66	-0.34	1.12e-13	Obesity (extreme);
LGG	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg19761014	chr17:28927070	LRRC37B2	0.68	8.48	0.37	2.97e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg24575275	chr7:1094737	C7orf50	-0.37	-7.39	-0.32	7.14e-13	Longevity;Endometriosis;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg19635926	chr16:89946313	TCF25	0.74	8.17	0.36	2.87e-15	Interleukin-17 levels;
LGG	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	27.21	0.78	4.38e-98	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1933488	0.521	rs1281962	chr6:153431376	G/C	cg17707550	chr6:153380415	RGS17	0.35	7.39	0.32	7.03e-13	Prostate cancer;
LGG	cis	rs9783347	0.714	rs11024614	chr11:18326758	C/T	cg03595886	chr11:18357587	GTF2H1	-0.47	-11.24	-0.46	4.4e-26	Pancreatic cancer;
LGG	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-10.45	-0.44	4.37e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg15704280	chr7:45808275	SEPT13	-0.59	-10.1	-0.42	8.14e-22	HDL cholesterol;
LGG	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg08847533	chr14:75593920	NEK9	-0.53	-9.8	-0.41	9.76e-21	Height;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.26	-0.32	1.63e-12	Obesity-related traits;
LGG	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.92	0.35	1.81e-14	Retinal vascular caliber;
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.28	0.32	1.45e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.57	-0.33	2e-13	Neuroticism;
LGG	cis	rs7020830	0.861	rs13295981	chr9:37330067	C/T	cg14294708	chr9:37120828	ZCCHC7	1.2	35.49	0.86	3.43e-134	Schizophrenia;
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg17911788	chr17:44343683	NA	0.63	9.39	0.4	2.77e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg19336497	chr11:14380999	RRAS2	-0.35	-6.82	-0.3	2.87e-11	Mitochondrial DNA levels;
LGG	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg27523141	chr10:43048294	ZNF37B	0.38	7.49	0.33	3.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg18825076	chr15:78729989	IREB2	-0.47	-7.58	-0.33	1.9e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11644478	chr21:40555479	PSMG1	0.92	18.08	0.64	1.08e-55	Cognitive function;
LGG	cis	rs17767392	0.836	rs35415083	chr14:72009196	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.41	0.4	2.35e-19	Mitral valve prolapse;
LGG	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg12438819	chr7:158236134	PTPRN2	0.35	9.11	0.39	2.55e-18	Obesity-related traits;
LGG	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27532318	chr7:32358331	NA	0.88	8.29	0.36	1.2e-15	Body mass index;
LGG	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg19183879	chr15:85880815	NA	0.41	7.42	0.33	5.71e-13	Bulimia nervosa;
LGG	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.82	0.3	2.81e-11	Bone mineral density;
LGG	cis	rs35740288	0.694	rs17618909	chr15:86095462	A/C	cg04173714	chr15:86211321	AKAP13	0.46	8.3	0.36	1.12e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg24631222	chr15:78858424	CHRNA5	0.43	6.84	0.3	2.46e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4919087	0.715	rs2484881	chr10:98998266	C/T	cg25902810	chr10:99078978	FRAT1	-0.44	-7.45	-0.33	4.62e-13	Monocyte count;
LGG	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg08717414	chr16:71523259	ZNF19	-0.47	-7.13	-0.31	3.93e-12	Post bronchodilator FEV1;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg17545662	chr6:170176663	C6orf70	0.69	8.78	0.38	3.14e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7177699	0.557	rs8026598	chr15:79112938	A/G	cg00540400	chr15:79124168	NA	0.54	11.36	0.47	1.49e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9596863	1.000	rs7993989	chr13:54464591	C/T	ch.13.53330881F	chr13:54432880	NA	-0.55	-7.55	-0.33	2.35e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.22	0.32	2.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg18335740	chr13:41363409	SLC25A15	0.97	23.44	0.74	1.07e-80	Lewy body disease;
LGG	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg11752832	chr7:134001865	SLC35B4	0.62	11.26	0.46	3.72e-26	Mean platelet volume;
LGG	cis	rs12210905	0.565	rs2393805	chr6:26828664	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-7.36	-0.32	8.72e-13	Hip circumference adjusted for BMI;
LGG	trans	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg07211511	chr3:129823064	LOC729375	-0.65	-8.9	-0.38	1.3e-17	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg19223190	chr17:80058835	NA	-0.45	-8.76	-0.38	3.78e-17	Life satisfaction;
LGG	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg15665833	chr6:26285013	NA	0.37	6.95	0.31	1.27e-11	Educational attainment;
LGG	cis	rs785830	0.749	rs663309	chr9:266795	G/A	cg14500300	chr9:211689	NA	0.29	7.2	0.32	2.49e-12	Platelet distribution width;
LGG	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg01579765	chr21:45077557	HSF2BP	-0.35	-7.27	-0.32	1.59e-12	Mean corpuscular volume;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg05091796	chr16:4465799	CORO7	-0.81	-13.53	-0.53	2.29e-35	Schizophrenia;
LGG	trans	rs9657904	0.865	rs4447799	chr3:105584684	A/G	cg14088669	chr1:158435396	OR10K1	0.42	8.0	0.35	1.03e-14	Multiple sclerosis;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg13010199	chr12:38710504	ALG10B	0.55	9.75	0.41	1.51e-20	Resting heart rate;
LGG	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	15.23	0.58	9.21e-43	Total body bone mineral density;
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.53e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs6694672	1.000	rs1794003	chr1:197024643	G/A	cg13682187	chr1:196946512	CFHR5	0.52	7.3	0.32	1.25e-12	Asthma;
LGG	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.08e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg18654377	chr3:49208889	KLHDC8B	-0.53	-8.45	-0.37	3.77e-16	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-8.54	-0.37	1.92e-16	Lung cancer;
LGG	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg15997130	chr1:24165203	NA	-0.47	-12.84	-0.51	1.77e-32	Immature fraction of reticulocytes;
LGG	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg26769984	chr7:1090371	C7orf50	0.45	7.57	0.33	2.03e-13	Bronchopulmonary dysplasia;
LGG	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.22	-0.32	2.15e-12	Neuroticism;
LGG	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg27476859	chr7:2772710	GNA12	0.54	10.53	0.44	2.14e-23	Height;
LGG	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.69	-11.86	-0.48	1.67e-28	Height;
LGG	cis	rs9814567	1.000	rs9884031	chr3:134256500	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg02574844	chr11:5959923	NA	0.62	11.43	0.47	7.68e-27	DNA methylation (variation);
LGG	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg00898013	chr13:113819073	PROZ	-0.48	-9.87	-0.42	5.42e-21	Platelet distribution width;
LGG	cis	rs7215564	0.818	rs34760119	chr17:78604583	G/T	cg16980736	chr17:78789706	RPTOR	-0.65	-8.49	-0.37	2.76e-16	Myopia (pathological);
LGG	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11890956	chr21:40555474	PSMG1	1.19	30.91	0.82	1.24e-114	Cognitive function;
LGG	cis	rs4409675	0.576	rs6564	chr1:28212975	A/G	cg23691781	chr1:28212827	C1orf38	-0.4	-10.95	-0.45	5.65e-25	Corneal astigmatism;
LGG	cis	rs9462027	0.583	rs9462022	chr6:34761684	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs3820068	0.705	rs11583306	chr1:15860803	A/G	cg05660106	chr1:15850417	CASP9	-1.12	-27.18	-0.78	6.26e-98	Systolic blood pressure;
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17376030	chr22:41985996	PMM1	0.62	9.73	0.41	1.75e-20	Vitiligo;
LGG	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg07395648	chr5:131743802	NA	-0.5	-11.76	-0.48	3.9e-28	Blood metabolite levels;
LGG	cis	rs4363385	0.668	rs6587717	chr1:152984443	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.99e-18	Inflammatory skin disease;
LGG	cis	rs1971762	0.509	rs1247955	chr12:53964133	G/T	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.86	-0.3	2.2e-11	Height;
LGG	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg02002194	chr4:3960332	NA	0.47	8.34	0.36	8.5e-16	Systolic blood pressure;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13732083	chr21:47605072	C21orf56	0.57	8.8	0.38	2.67e-17	Testicular germ cell tumor;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg02733842	chr7:1102375	C7orf50	0.47	7.72	0.34	7.17e-14	Bronchopulmonary dysplasia;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg13009111	chr11:71350975	NA	0.3	6.85	0.3	2.43e-11	Systolic blood pressure;
LGG	cis	rs2859741	0.528	rs6686296	chr1:37489380	G/T	cg09363841	chr1:37513479	NA	0.56	11.82	0.48	2.29e-28	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00166722	chr3:10149974	C3orf24	0.54	8.94	0.38	9.13e-18	Alzheimer's disease;
LGG	cis	rs7747724	0.715	rs2745933	chr6:20750714	T/C	cg13405222	chr6:20811065	CDKAL1	0.47	9.29	0.4	6.05e-19	Bladder cancer;
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg05313129	chr8:58192883	C8orf71	-0.6	-8.46	-0.37	3.58e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg12310025	chr6:25882481	NA	0.59	11.45	0.47	6.72e-27	Blood metabolite levels;
LGG	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg06153925	chr17:78755379	RPTOR	0.41	6.76	0.3	4.19e-11	Myopia (pathological);
LGG	trans	rs1994135	0.565	rs1905240	chr12:33645009	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-8.65	-0.37	8.58e-17	Resting heart rate;
LGG	cis	rs35771425	0.600	rs67772854	chr1:211533990	A/G	cg10512769	chr1:211675356	NA	-0.62	-8.24	-0.36	1.8e-15	Educational attainment (years of education);
LGG	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg00531865	chr16:30841666	NA	-0.55	-11.25	-0.46	4.14e-26	Multiple myeloma;
LGG	cis	rs526231	0.543	rs152123	chr5:102531919	A/G	cg23492399	chr5:102201601	PAM	0.52	7.42	0.33	5.67e-13	Primary biliary cholangitis;
LGG	trans	rs12517041	1.000	rs6880744	chr5:23299825	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.15e-25	Calcium levels;
LGG	cis	rs17604090	0.818	rs73090342	chr7:29687540	T/C	cg19413766	chr7:29689036	LOC646762	-0.58	-7.2	-0.32	2.49e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.93	-0.57	2.07e-41	Aortic root size;
LGG	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.55	-0.33	2.4e-13	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg04568710	chr12:38710424	ALG10B	0.34	6.89	0.3	1.83e-11	Bladder cancer;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg06916706	chr16:4465613	CORO7	-0.86	-14.73	-0.56	1.53e-40	Schizophrenia;
LGG	cis	rs9487094	0.626	rs2025148	chr6:110027943	G/T	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.14e-15	Height;
LGG	cis	rs887829	0.694	rs7583278	chr2:234617407	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.54	-0.37	1.88e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2018055	0.644	rs13202267	chr6:117798377	A/G	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs7945718	0.875	rs6486057	chr11:12810338	T/A	cg25843174	chr11:12811716	TEAD1	0.41	8.56	0.37	1.7e-16	Educational attainment (years of education);
LGG	cis	rs77861329	1.000	rs9816434	chr3:52197513	C/T	cg08692210	chr3:52188851	WDR51A	0.73	6.77	0.3	3.9e-11	Macrophage inflammatory protein 1b levels;
LGG	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.91	0.42	4.17e-21	Height;
LGG	cis	rs4363385	0.818	rs11205175	chr1:153001296	A/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.76	-0.38	3.77e-17	Inflammatory skin disease;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs2201728	0.967	rs13104485	chr4:100140823	T/A	cg07219303	chr4:100140905	ADH6	-0.42	-8.24	-0.36	1.82e-15	Cardiac Troponin-T levels;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00149659	chr3:10157352	C3orf10	-0.85	-10.89	-0.45	9.51e-25	Alzheimer's disease;
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs975722	0.934	rs3735645	chr7:117354866	A/G	cg10524701	chr7:117356490	CTTNBP2	0.51	11.71	0.48	6.29e-28	Coronary artery disease;
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg03808351	chr9:123631620	PHF19	0.28	7.04	0.31	7.2e-12	Birth weight;
LGG	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.31	-0.32	1.16e-12	Hepatitis;
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.39	-0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-27.12	-0.78	1.12e-97	Height;
LGG	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg15268244	chr15:77196840	NA	0.47	10.02	0.42	1.67e-21	Blood metabolite levels;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.42	-0.53	6.52e-35	Alzheimer's disease;
LGG	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg25866889	chr13:114914595	NA	-0.36	-7.03	-0.31	7.62e-12	Schizophrenia;
LGG	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg12223502	chr10:5658492	NA	-0.35	-6.76	-0.3	4.27e-11	Breast cancer;
LGG	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg07549590	chr16:15018862	NA	-0.43	-7.74	-0.34	6.42e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.14e-41	Aortic root size;
LGG	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg10167378	chr1:228756711	NA	0.57	8.01	0.35	9.33e-15	Chronic lymphocytic leukemia;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg18681998	chr4:17616180	MED28	0.85	18.31	0.65	9.33e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12545912	0.770	rs12114182	chr8:9537635	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.08	0.31	5.37e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26076054	chr5:421317	AHRR	-0.46	-7.73	-0.34	6.72e-14	Cystic fibrosis severity;
LGG	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg20302533	chr7:39170763	POU6F2	0.32	7.74	0.34	6.48e-14	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs1056053	0.514	rs1056051	chr6:166571579	T/G	cg11088901	chr6:166572345	T	-0.52	-9.92	-0.42	3.71e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg24250549	chr1:154909240	PMVK	-0.4	-6.75	-0.3	4.46e-11	Schizophrenia;
LGG	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg20608306	chr11:116969690	SIK3	0.35	10.52	0.44	2.36e-23	Blood protein levels;
LGG	cis	rs4629180	0.544	rs7595274	chr2:102140086	T/C	cg16435561	chr2:102091048	RFX8	0.49	9.1	0.39	2.75e-18	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.32	-0.32	1.11e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.29	0.36	1.23e-15	Schizophrenia;
LGG	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg00898013	chr13:113819073	PROZ	0.41	8.01	0.35	9.25e-15	Platelet distribution width;
LGG	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg03929089	chr4:120376271	NA	0.74	8.48	0.37	2.99e-16	Axial length;
LGG	cis	rs4639966	0.836	rs4499035	chr11:118610463	C/T	cg20309703	chr11:118481025	PHLDB1	-0.46	-6.8	-0.3	3.19e-11	Systemic lupus erythematosus;
LGG	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.65	0.79	4.42e-100	Parkinson's disease;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-10.77	-0.45	2.73e-24	Prostate cancer;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-9.07	-0.39	3.38e-18	Vitiligo;
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg13628971	chr7:2884303	GNA12	0.55	11.52	0.47	3.44e-27	Height;
LGG	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.55	0.44	1.91e-23	Arsenic metabolism;
LGG	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg15627072	chr1:2432621	PLCH2	0.36	7.95	0.35	1.4e-14	Ulcerative colitis;
LGG	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12229367	chr17:55822335	NA	0.46	8.84	0.38	2.01e-17	Schizophrenia;
LGG	trans	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.3	-0.36	1.14e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg07615347	chr10:60278583	BICC1	0.63	17.36	0.63	2.22e-52	Refractive error;
LGG	cis	rs7666738	0.830	rs10021044	chr4:99002488	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg00012203	chr2:219082015	ARPC2	-0.67	-12.46	-0.5	5.96e-31	Colorectal cancer;
LGG	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg01620082	chr3:125678407	NA	-0.66	-7.34	-0.32	9.78e-13	Depression;
LGG	cis	rs3771570	0.901	rs4675944	chr2:242430170	C/T	cg21155796	chr2:242212141	HDLBP	0.61	8.29	0.36	1.25e-15	Prostate cancer;
LGG	cis	rs13108043	0.605	rs35886751	chr4:87935533	T/G	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.18	-0.62	1.54e-51	Breast cancer;
LGG	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg12924262	chr12:102091054	CHPT1	0.64	12.67	0.51	8.27e-32	Blood protein levels;
LGG	cis	rs9649465	1.000	rs4588795	chr7:123349924	A/G	cg03229431	chr7:123269106	ASB15	0.4	8.94	0.38	9.21e-18	Migraine;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg21911579	chr5:131705225	SLC22A5	0.63	6.99	0.31	9.72e-12	Rheumatoid arthritis;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg18032289	chr17:61959525	GH2	-0.38	-6.69	-0.3	6.54e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Bladder cancer;
LGG	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg23625390	chr15:77176239	SCAPER	0.49	9.68	0.41	2.6e-20	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.33	-0.36	9.18e-16	Life satisfaction;
LGG	cis	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg16576597	chr16:28551801	NUPR1	0.36	8.4	0.36	5.65e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9296092	0.517	rs113111213	chr6:33520790	A/G	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16937126	chr8:38088972	DDHD2	0.46	6.73	0.3	5.12e-11	Gut microbiome composition (summer);
LGG	trans	rs877282	0.891	rs12357999	chr10:796468	A/C	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs2952156	1.000	rs2934967	chr17:37870378	G/A	cg00129232	chr17:37814104	STARD3	-0.68	-13.47	-0.53	3.9e-35	Asthma;
LGG	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.22	-0.32	2.16e-12	Bone mineral density;
LGG	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06133097	chr7:32552212	AVL9	-0.4	-7.61	-0.33	1.59e-13	Cognitive ability;
LGG	cis	rs4918072	0.753	rs1114994	chr10:105709550	C/T	cg11005552	chr10:105648138	OBFC1	0.44	7.39	0.32	6.77e-13	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg02002194	chr4:3960332	NA	0.4	7.1	0.31	4.84e-12	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs854037	0.759	rs10940577	chr5:57091121	A/T	cg08523694	chr5:57076192	NA	0.57	7.12	0.31	4.25e-12	Birth weight;
LGG	cis	rs2235573	0.527	rs139885	chr22:38371039	C/T	cg19171272	chr22:38449367	NA	-0.48	-8.72	-0.38	5.04e-17	Glioblastoma;Glioma;
LGG	cis	rs7666738	0.830	rs7696568	chr4:99005333	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10214930	0.697	rs6963421	chr7:27692428	T/G	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg27398817	chr8:82754497	SNX16	-0.76	-11.2	-0.46	6.49e-26	Diastolic blood pressure;
LGG	cis	rs2050392	0.792	rs303434	chr10:30714440	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.86	-0.45	1.27e-24	Inflammatory bowel disease;
LGG	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.44	-0.37	4.03e-16	Morning vs. evening chronotype;
LGG	trans	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.42	-0.36	4.82e-16	Lung cancer in ever smokers;
LGG	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg02390115	chr1:21767211	NBPF3	0.58	11.18	0.46	7.23e-26	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg02023728	chr11:77925099	USP35	0.4	7.06	0.31	6.17e-12	Alzheimer's disease (survival time);
LGG	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.43	-0.33	5.29e-13	Electroencephalogram traits;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4764487	1.000	rs4764487	chr12:6332838	A/G	cg08284733	chr12:6341482	CD9	0.35	8.56	0.37	1.65e-16	Mean platelet volume;
LGG	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg25173405	chr17:45401733	C17orf57	0.45	7.58	0.33	1.84e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	11.14	0.46	1.05e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg18188782	chr20:61659543	NA	0.4	6.73	0.3	5.03e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs6163	0.727	rs284854	chr10:104574562	T/G	cg04362960	chr10:104952993	NT5C2	-0.44	-7.87	-0.34	2.47e-14	Waist circumference;Hip circumference;
LGG	cis	rs10979	0.669	rs9484764	chr6:143867336	G/T	cg25407410	chr6:143891975	LOC285740	-0.48	-7.79	-0.34	4.29e-14	Hypospadias;
LGG	cis	rs9470366	0.545	rs6930083	chr6:36634156	A/G	cg08179530	chr6:36648295	CDKN1A	-0.64	-11.01	-0.46	3.49e-25	QRS duration;
LGG	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.58	-0.33	1.86e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7666738	0.800	rs2839836	chr4:98970512	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6964587	1.000	rs7789492	chr7:91668854	C/T	cg17063962	chr7:91808500	NA	0.49	8.68	0.37	6.66e-17	Breast cancer;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21963583	chr11:68658836	MRPL21	0.61	10.57	0.44	1.55e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1978968	0.763	rs9605480	chr22:18465105	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.7	-0.54	3.99e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.27	-0.32	1.51e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs13382862	0.862	rs340595	chr2:20889714	A/G	cg27141850	chr2:20869434	GDF7	-0.23	-6.74	-0.3	4.74e-11	Abdominal aortic aneurysm;
LGG	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.17	0.46	8.27e-26	Bone mineral density;
LGG	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg17757837	chr7:157058334	UBE3C	0.76	15.41	0.58	1.56e-43	Body mass index;
LGG	cis	rs4664304	0.900	rs62176692	chr2:160743463	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.31	-0.32	1.2e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-15.77	-0.59	3.64e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.2	-0.58	1.3e-42	Chronic sinus infection;
LGG	cis	rs7666738	0.712	rs34043080	chr4:99008748	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.89	0.34	2.16e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	13.04	0.52	2.5e-33	Alzheimer's disease;
LGG	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg16400903	chr5:693638	TPPP	0.49	7.03	0.31	7.44e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg03342759	chr3:160939853	NMD3	-0.62	-10.98	-0.45	4.56e-25	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.37	-8.08	-0.35	5.73e-15	Personality dimensions;
LGG	cis	rs6426558	0.537	rs12039370	chr1:227326472	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.63	-10.47	-0.44	3.71e-23	Neutrophil percentage of white cells;
LGG	cis	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg03060546	chr3:49711283	APEH	0.55	8.57	0.37	1.6e-16	Resting heart rate;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2797369	0.656	rs640315	chr6:101352773	G/T	cg27451362	chr6:101846650	GRIK2	0.77	10.74	0.45	3.68e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs6504950	0.566	rs7208403	chr17:53046667	C/A	cg19360675	chr17:53046073	COX11;STXBP4	0.4	6.91	0.31	1.63e-11	Breast cancer;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00631329	chr6:26305371	NA	-0.52	-9.4	-0.4	2.62e-19	Educational attainment;
LGG	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg03762349	chr15:79060523	ADAMTS7	0.37	7.92	0.35	1.78e-14	Sudden cardiac arrest;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg19774624	chr17:42201019	HDAC5	0.84	16.39	0.61	6.38e-48	Total body bone mineral density;
LGG	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.15	-0.32	3.49e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.55	-0.5	2.63e-31	Depression;
LGG	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg03929089	chr4:120376271	NA	-0.7	-8.28	-0.36	1.29e-15	Axial length;
LGG	cis	rs2404602	0.692	rs35557205	chr15:77130711	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.04	0.39	4.3e-18	Blood metabolite levels;
LGG	trans	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.34	-0.65	7.39e-57	Exhaled nitric oxide output;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg10587741	chr22:38071170	LGALS1	0.82	21.87	0.71	2.34e-73	Fat distribution (HIV);
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg11062466	chr8:58055876	NA	0.58	13.2	0.52	5.38e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.723	rs3766619	chr1:209895298	C/G	cg23920097	chr1:209922102	NA	-0.43	-7.23	-0.32	2.06e-12	Red blood cell count;
LGG	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg24331049	chr13:111365604	ING1	0.87	16.36	0.61	8.4e-48	Coronary artery disease;
LGG	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg26384229	chr12:38710491	ALG10B	0.91	20.33	0.69	3.8e-66	Bladder cancer;
LGG	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13012494	chr21:47604986	C21orf56	0.55	9.6	0.41	5e-20	Testicular germ cell tumor;
LGG	cis	rs2470578	0.766	rs2733528	chr3:17236255	A/G	cg20981856	chr3:17787350	NA	0.35	6.74	0.3	4.68e-11	Schizophrenia;
LGG	cis	rs3733585	0.673	rs4455410	chr4:9953297	C/T	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.7	-0.34	8.49e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01585723	chr16:33734837	NA	0.47	8.14	0.35	3.69e-15	Menopause (age at onset);
LGG	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg09307838	chr4:120376055	NA	0.72	12.28	0.5	3.47e-30	Corneal astigmatism;
LGG	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg18105134	chr13:113819100	PROZ	-0.7	-14.03	-0.55	1.71e-37	Platelet distribution width;
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.34	-0.32	9.99e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg20219074	chr11:18656078	SPTY2D1	0.83	15.13	0.58	2.61e-42	Breast cancer;
LGG	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs4690686	0.538	rs13120287	chr4:177260184	T/C	cg17059388	chr4:177262070	NA	0.97	21.21	0.7	2.88e-70	Essential tremor;
LGG	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg14664628	chr15:75095509	CSK	-0.78	-15.98	-0.6	4.13e-46	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg22072935	chr14:105399595	NA	0.52	10.11	0.43	7.66e-22	Rheumatoid arthritis;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg19223190	chr17:80058835	NA	0.44	8.57	0.37	1.51e-16	Life satisfaction;
LGG	cis	rs7666738	0.830	rs17027198	chr4:98991085	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.38e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.22	0.32	2.17e-12	Neuroticism;
LGG	cis	rs4774899	1.000	rs12050758	chr15:57495303	A/G	cg08128148	chr15:57256372	TCF12	-0.3	-7.03	-0.31	7.58e-12	Urinary tract infection frequency;
LGG	cis	rs3206736	0.548	rs328937	chr7:35049131	T/C	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.63e-19	Diastolic blood pressure;
LGG	cis	rs11105298	0.891	rs10858890	chr12:89907166	A/G	cg00757033	chr12:89920650	WDR51B	0.66	9.68	0.41	2.66e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7408868	0.831	rs7245850	chr19:15274585	A/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.03	0.52	2.75e-33	Pulse pressure;
LGG	cis	rs929596	0.785	rs6747843	chr2:234664354	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-13.52	-0.53	2.35e-35	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.49	0.37	2.9e-16	Height;
LGG	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs72925845	0.577	rs691328	chr17:76429313	G/A	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.14	0.39	2.01e-18	Obesity-related traits;
LGG	cis	rs11229555	1.000	rs11603890	chr11:58402251	T/C	cg15696309	chr11:58395628	NA	-0.98	-17.52	-0.63	4.36e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6764363	0.527	rs3872654	chr3:282657	G/C	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.69e-13	Sudden cardiac arrest;
LGG	cis	rs2133450	0.712	rs62237081	chr3:7366057	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.21	-0.36	2.29e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.71	0.45	4.52e-24	Systolic blood pressure;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg27326856	chr19:37663410	ZNF585A	-0.42	-6.72	-0.3	5.33e-11	Height;
LGG	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.65	-0.33	1.21e-13	Total cholesterol levels;
LGG	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg22491629	chr6:157744540	C6orf35	-0.92	-13.13	-0.52	1.06e-33	Hemostatic factors and hematological phenotypes;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg20607798	chr8:58055168	NA	0.57	6.86	0.3	2.26e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.740	rs6474962	chr9:15747795	A/G	cg14451791	chr9:16040625	NA	0.34	8.64	0.37	9.44e-17	Body mass index;
LGG	cis	rs9650657	0.737	rs2116095	chr8:10635297	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.66	-0.3	7.75e-11	Neuroticism;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg02725872	chr8:58115012	NA	-1.05	-15.05	-0.57	6.18e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2013441	1.000	rs2703806	chr17:20108239	A/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs7824557	0.806	rs11777002	chr8:11096153	G/C	cg21775007	chr8:11205619	TDH	-0.51	-7.99	-0.35	1.05e-14	Retinal vascular caliber;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.25	-0.43	2.36e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs425535	0.757	rs164615	chr4:74801525	A/G	cg01447579	chr4:74847100	PF4	0.54	6.64	0.3	8.6e-11	Blood protein levels;
LGG	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs7119	0.679	rs12909808	chr15:77816944	A/G	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21640587	chr11:117668038	DSCAML1	0.93	15.53	0.59	4.56e-44	Myopia;
LGG	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs477692	0.905	rs7905466	chr10:131438937	A/T	cg05714579	chr10:131428358	MGMT	-0.61	-12.54	-0.5	2.86e-31	Response to temozolomide;
LGG	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg25319279	chr11:5960081	NA	-0.43	-6.88	-0.3	1.93e-11	DNA methylation (variation);
LGG	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg15268244	chr15:77196840	NA	-0.32	-7.06	-0.31	6.15e-12	Blood metabolite levels;
LGG	cis	rs4722166	0.630	rs10950916	chr7:22799667	C/T	cg05265849	chr7:22767390	IL6	0.42	7.87	0.34	2.53e-14	Lung cancer;
LGG	cis	rs3859192	0.599	rs2270401	chr17:38176256	A/T	cg17467752	chr17:38218738	THRA	-0.58	-9.73	-0.41	1.69e-20	White blood cell count;
LGG	cis	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg04990556	chr1:26633338	UBXN11	-0.69	-13.78	-0.54	1.9e-36	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09364122	chr1:942198	NA	0.37	6.96	0.31	1.16e-11	Pancreatic cancer;
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19717773	chr7:2847554	GNA12	-0.37	-8.66	-0.37	7.74e-17	Height;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-8.09	-0.35	5.38e-15	Bladder cancer;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg16301924	chr13:53314226	LECT1	0.54	11.8	0.48	2.71e-28	Lewy body disease;
LGG	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.27	-0.46	3.36e-26	Type 2 diabetes;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg09033563	chr22:24373618	LOC391322	-0.52	-8.42	-0.36	4.78e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.73e-36	Breast cancer;
LGG	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg24848339	chr3:12840334	CAND2	0.44	10.73	0.45	3.89e-24	QRS complex (12-leadsum);
LGG	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg10596483	chr8:143751796	JRK	-0.54	-8.84	-0.38	2.05e-17	Schizophrenia;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg07636037	chr3:49044803	WDR6	0.71	11.42	0.47	8.41e-27	Menarche (age at onset);
LGG	cis	rs9640161	0.673	rs11773351	chr7:150030963	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.78	-15.74	-0.59	4.86e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg08461457	chr11:2027003	NA	0.36	6.77	0.3	3.81e-11	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg25703541	chr22:24373054	LOC391322	-0.89	-18.46	-0.65	1.89e-57	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11168187	0.891	rs7133585	chr12:48128410	G/A	cg12761788	chr12:48120090	P11	0.47	7.73	0.34	6.56e-14	Vertical cup-disc ratio;
LGG	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg24692254	chr21:30365293	RNF160	-0.56	-9.48	-0.4	1.28e-19	Cognitive test performance;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.01	0.42	1.68e-21	Longevity;
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg06197492	chr11:2016605	H19	0.5	10.24	0.43	2.5e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs10267417	0.603	rs10227497	chr7:19917006	A/G	cg05791153	chr7:19748676	TWISTNB	0.53	6.73	0.3	5.11e-11	Night sleep phenotypes;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg08888203	chr3:10149979	C3orf24	-0.57	-9.49	-0.4	1.19e-19	Alzheimer's disease;
LGG	cis	rs7586879	0.639	rs2033653	chr2:25103446	C/T	cg04586622	chr2:25135609	ADCY3	-0.44	-11.92	-0.48	9.74e-29	Body mass index;
LGG	cis	rs1775715	0.677	rs2799034	chr10:32175896	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.75	0.3	4.35e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg13482628	chr17:19912719	NA	-0.5	-9.25	-0.39	8.61e-19	Obesity-related traits;
LGG	cis	rs7107174	0.892	rs11601866	chr11:78011153	G/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.35	0.36	8.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17286411	0.814	rs12708919	chr16:71986995	A/G	cg03805757	chr16:71968109	PKD1L3	-0.35	-7.25	-0.32	1.71e-12	Blood protein levels;
LGG	cis	rs240764	0.782	rs369125	chr6:101118400	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	5.01e-14	Neuroticism;
LGG	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg11161011	chr14:65562177	MAX	-0.68	-13.04	-0.52	2.64e-33	Obesity-related traits;
LGG	cis	rs368123	1.000	rs380143	chr6:160731356	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.95e-12	Waist circumference;
LGG	trans	rs4841097	0.876	rs11774267	chr8:8947722	T/A	cg02002194	chr4:3960332	NA	0.37	6.68	0.3	7.01e-11	Platelet distribution width;
LGG	cis	rs1659258	0.568	rs1258408	chr2:88619494	C/T	cg00685853	chr2:88648947	NA	0.44	6.77	0.3	3.81e-11	Visceral fat;
LGG	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg15704280	chr7:45808275	SEPT13	-0.59	-9.97	-0.42	2.47e-21	HDL cholesterol;
LGG	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg01631408	chr1:248437212	OR2T33	0.5	9.03	0.39	4.77e-18	Common traits (Other);
LGG	cis	rs2916247	1.000	rs6986808	chr8:93024393	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.58	-0.37	1.44e-16	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.932	rs28594349	chr4:185574415	G/A	cg04058563	chr4:185651563	MLF1IP	1.0	18.02	0.64	2.06e-55	Blood protein levels;
LGG	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.05	0.31	6.7e-12	Aortic root size;
LGG	cis	rs112591243	0.685	rs2839341	chr21:47990008	A/G	cg10657630	chr21:48055338	PRMT2	-0.86	-7.4	-0.33	6.62e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg04703951	chr17:43578652	NA	0.39	7.95	0.35	1.45e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg06074448	chr4:187884817	NA	-0.59	-13.21	-0.52	4.99e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.32	0.4	4.71e-19	Lung cancer;
LGG	cis	rs6430585	0.591	rs4585083	chr2:136486342	C/T	cg07169764	chr2:136633963	MCM6	1.11	18.4	0.65	3.94e-57	Corneal structure;
LGG	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06470251	chr20:60548479	NA	0.43	7.55	0.33	2.41e-13	Body mass index;
LGG	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs7666738	0.927	rs4699328	chr4:99055890	C/T	cg05340658	chr4:99064831	C4orf37	0.49	7.92	0.35	1.75e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9512730	0.553	rs9512702	chr13:28033485	A/G	cg04070771	chr13:27998621	GTF3A	0.5	7.51	0.33	3.03e-13	Schizophrenia;
LGG	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.95	0.35	1.42e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg26318627	chr11:63887540	MACROD1	-0.47	-6.72	-0.3	5.45e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg08847533	chr14:75593920	NEK9	-0.6	-11.6	-0.47	1.79e-27	Height;
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg24690094	chr11:67383802	NA	0.47	8.42	0.36	4.87e-16	Mean corpuscular volume;
LGG	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg07120314	chr15:79043507	NA	-0.35	-6.96	-0.31	1.16e-11	Sudden cardiac arrest;
LGG	cis	rs17209837	0.920	rs4148817	chr7:87087397	C/G	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00149659	chr3:10157352	C3orf10	0.89	11.46	0.47	6.12e-27	Alzheimer's disease;
LGG	cis	rs4919694	1.000	rs4917382	chr10:104838510	G/A	cg04362960	chr10:104952993	NT5C2	1.06	15.51	0.58	5.26e-44	Arsenic metabolism;
LGG	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg11189052	chr15:85197271	WDR73	-0.46	-7.33	-0.32	1.06e-12	P wave terminal force;
LGG	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	24.6	0.75	4.31e-86	IgG glycosylation;
LGG	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.34	-0.32	9.77e-13	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg12070911	chr6:150209640	RAET1E	0.32	7.64	0.33	1.25e-13	Lung cancer;
LGG	cis	rs8064024	0.557	rs7193783	chr16:4949608	A/C	cg08329684	chr16:4932620	PPL	-0.47	-9.53	-0.4	9e-20	Cancer;
LGG	cis	rs10908907	0.955	rs4877118	chr9:92258048	A/T	cg01515543	chr9:92254510	LOC100129066	0.44	7.96	0.35	1.3e-14	Alcoholism (heaviness of drinking);
LGG	cis	rs6121246	0.609	rs2377317	chr20:30402502	A/G	cg13852791	chr20:30311386	BCL2L1	-0.93	-18.1	-0.64	8.83e-56	Mean corpuscular hemoglobin;
LGG	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.47	-0.4	1.42e-19	Intelligence (multi-trait analysis);
LGG	trans	rs11782517	0.883	rs13274653	chr8:10106801	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-6.9	-0.31	1.74e-11	Nose size;
LGG	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	6.74	0.3	4.63e-11	Height;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg01238044	chr22:24384105	GSTT1	-0.58	-10.02	-0.42	1.64e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs459571	0.834	rs379417	chr9:136890704	G/A	cg13789015	chr9:136890014	NCRNA00094	0.59	11.1	0.46	1.49e-25	Platelet distribution width;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.65	-0.33	1.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.72	0.34	7.11e-14	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg04503457	chr17:41445688	NA	-0.38	-8.89	-0.38	1.39e-17	Menopause (age at onset);
LGG	cis	rs909685	0.590	rs3747177	chr22:39746168	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	10.0	0.42	1.93e-21	Rheumatoid arthritis;
LGG	cis	rs9783347	0.621	rs10832923	chr11:18391237	G/C	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.17	-0.49	9.4e-30	Pancreatic cancer;
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.3	0.46	2.54e-26	Tonsillectomy;
LGG	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.57	-0.33	2.04e-13	Mood instability;
LGG	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.55	-0.71	7.5e-72	Coronary artery disease;
LGG	cis	rs9534288	0.957	rs2404731	chr13:46618384	T/C	cg15192986	chr13:46630673	CPB2	-0.72	-15.74	-0.59	5.06e-45	Blood protein levels;
LGG	cis	rs7216064	1.000	rs12452511	chr17:65832576	A/G	cg12091567	chr17:66097778	LOC651250	-0.59	-8.69	-0.37	6.49e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2531992	0.620	rs2041248	chr16:4032489	T/G	cg05927578	chr16:4029543	ADCY9	0.74	10.51	0.44	2.58e-23	Waist circumference;
LGG	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg03060546	chr3:49711283	APEH	-0.66	-10.9	-0.45	8.65e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs526231	0.543	rs34807	chr5:102428522	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-10.02	-0.42	1.57e-21	Bipolar disorder;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.6	-0.41	5.12e-20	Life satisfaction;
LGG	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg16230307	chr14:35515116	FAM177A1	0.57	8.92	0.38	1.13e-17	Psoriasis;
LGG	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg17294928	chr15:75287854	SCAMP5	-0.95	-16.93	-0.62	2.08e-50	Blood trace element (Zn levels);
LGG	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg21775007	chr8:11205619	TDH	0.5	7.97	0.35	1.28e-14	Neuroticism;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg02975922	chr3:195473998	MUC4	-0.54	-8.92	-0.38	1.12e-17	Pancreatic cancer;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg11235426	chr6:292522	DUSP22	-0.6	-10.05	-0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg25427524	chr10:38739819	LOC399744	0.5	7.35	0.32	9.05e-13	Obesity (extreme);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	11.64	0.48	1.2100000000000001e-27	Lymphocyte counts;
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	trans	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg16141378	chr3:129829833	LOC729375	0.36	7.88	0.34	2.37e-14	Joint mobility (Beighton score);
LGG	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg01028140	chr2:1542097	TPO	-0.51	-8.04	-0.35	7.36e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs28735056	0.904	rs9967107	chr18:77633343	C/T	cg20368463	chr18:77673604	PQLC1	0.4	6.87	0.3	2.09e-11	Schizophrenia;
LGG	cis	rs12681287	0.640	rs7007855	chr8:87429491	T/G	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs11608355	0.521	rs7967632	chr12:109848000	C/G	cg19025524	chr12:109796872	NA	-0.59	-12.65	-0.51	1.07e-31	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12562500	chr19:6361639	CLPP	0.46	6.86	0.3	2.16e-11	Gut microbiome composition (summer);
LGG	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg09222892	chr1:25734099	RHCE	0.48	10.5	0.44	2.92e-23	Plateletcrit;Mean corpuscular volume;
LGG	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg16141378	chr3:129829833	LOC729375	-0.39	-9.0	-0.39	5.78e-18	Neuroticism;
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg25767906	chr1:53392781	SCP2	-0.33	-6.72	-0.3	5.39e-11	Monocyte count;
LGG	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.11	-24.91	-0.76	1.6e-87	Height;
LGG	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg16576597	chr16:28551801	NUPR1	0.3	6.73	0.3	4.97e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg05313129	chr8:58192883	C8orf71	-0.59	-7.44	-0.33	4.88e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs58649573	0.509	rs917783	chr9:126790607	A/C	cg14112217	chr9:126806003	NA	0.39	7.55	0.33	2.37e-13	Post-traumatic stress disorder;
LGG	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg03806693	chr22:41940476	POLR3H	-1.04	-17.65	-0.63	1.06e-53	Vitiligo;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.53	8.7	0.37	5.98e-17	Lymphocyte counts;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.78	-14.71	-0.56	1.77e-40	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs4774899	0.934	rs4774913	chr15:57487770	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.29	-0.32	1.34e-12	Urinary tract infection frequency;
LGG	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg04234412	chr22:24373322	LOC391322	0.8	16.39	0.61	6.21e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.41e-11	Aortic root size;
LGG	cis	rs10819861	0.655	rs55821317	chr9:98868372	G/A	cg14508093	chr9:98862825	NA	0.29	6.78	0.3	3.79e-11	Electrocardiographic traits;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs3859192	0.561	rs12453343	chr17:38181176	C/A	cg17467752	chr17:38218738	THRA	-0.57	-9.69	-0.41	2.47e-20	White blood cell count;
LGG	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg09307838	chr4:120376055	NA	-0.78	-12.8	-0.51	2.5e-32	Corneal astigmatism;
LGG	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.42	-0.33	5.6e-13	Retinal vascular caliber;
LGG	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg03929089	chr4:120376271	NA	0.74	8.43	0.36	4.43e-16	Axial length;
LGG	cis	rs722599	0.683	rs10144860	chr14:75286426	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	8.91	0.38	1.14e-17	IgG glycosylation;
LGG	cis	rs2133450	0.935	rs7609608	chr3:7330179	G/A	cg19930620	chr3:7340148	GRM7	-0.39	-8.69	-0.37	6.49e-17	Early response to risperidone in schizophrenia;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.28	0.32	1.48e-12	Obesity-related traits;
LGG	trans	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-10.97	-0.45	4.97e-25	Red cell distribution width;
LGG	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg14664628	chr15:75095509	CSK	-0.57	-10.77	-0.45	2.83e-24	Breast cancer;
LGG	cis	rs2421770	0.532	rs10836374	chr11:35345764	A/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.4	-0.33	6.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs3784262	0.669	rs34226780	chr15:58280168	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.9	-0.31	1.7e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg03877680	chr5:178157825	ZNF354A	0.6	8.85	0.38	1.88e-17	Neutrophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.3	0.58	4.79e-43	Lung cancer;
LGG	cis	rs3816183	1.000	rs1821981	chr2:43018916	A/G	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.13e-19	Hypospadias;
LGG	cis	rs12618769	0.656	rs3820943	chr2:99123177	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03576123	chr11:487126	PTDSS2	-0.56	-7.32	-0.32	1.14e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9915657	0.743	rs9894720	chr17:70097607	C/T	cg09344028	chr17:70110421	NA	0.57	12.68	0.51	7.96e-32	Thyroid hormone levels;
LGG	cis	rs4926611	0.736	rs1474462	chr1:54120058	G/A	cg23596471	chr1:54105337	GLIS1	0.33	7.0	0.31	8.89e-12	Hand grip strength;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg06636001	chr8:8085503	FLJ10661	0.62	12.09	0.49	1.93e-29	Neuroticism;
LGG	cis	rs10824796	1.000	rs7096206	chr10:54531685	C/G	cg27418851	chr10:54531653	MBL2	0.44	8.56	0.37	1.72e-16	Blood protein levels;
LGG	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12049351	0.665	rs35085232	chr1:229602080	A/C	cg13547644	chr1:229569608	ACTA1	0.32	7.1	0.31	4.85e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.11	-0.31	4.53e-12	Total body bone mineral density;
LGG	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg08885076	chr2:99613938	TSGA10	0.39	8.37	0.36	6.9e-16	Chronic sinus infection;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg21724239	chr8:58056113	NA	0.49	7.33	0.32	1.01e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg05793240	chr7:2802953	GNA12	0.32	7.88	0.34	2.38e-14	Height;
LGG	cis	rs2282802	0.685	rs11745502	chr5:139558808	G/A	cg26211634	chr5:139558579	C5orf32	-0.35	-7.63	-0.33	1.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs751728	1.000	rs1359781	chr6:33762104	T/C	cg25922239	chr6:33757077	LEMD2	0.7	12.52	0.5	3.58e-31	Crohn's disease;
LGG	cis	rs888468	1.000	rs7295812	chr12:4536096	T/G	cg25948690	chr12:4554596	FGF6	0.4	6.86	0.3	2.25e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	17.84	0.64	1.45e-54	Chronic sinus infection;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.2	-0.49	7.27e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15320075	chr8:145703422	NA	-0.55	-10.07	-0.42	1.06e-21	Age at first birth;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs2408955	0.561	rs9971924	chr12:48479832	C/G	cg24011408	chr12:48396354	COL2A1	-0.58	-9.67	-0.41	2.88e-20	Glycated hemoglobin levels;
LGG	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.38	0.5	1.35e-30	Vitiligo;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg22875332	chr1:76189707	ACADM	-0.62	-8.3	-0.36	1.12e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	8.29	0.36	1.21e-15	Iron status biomarkers;
LGG	cis	rs757278	0.591	rs6980032	chr7:117303145	G/T	cg10524701	chr7:117356490	CTTNBP2	0.45	7.97	0.35	1.29e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs12618769	0.625	rs72821955	chr2:99159792	G/A	cg18455616	chr2:99124870	INPP4A	0.27	7.75	0.34	6.04e-14	Bipolar disorder;
LGG	cis	rs7106204	0.514	rs7123539	chr11:24272000	G/A	ch.11.24196551F	chr11:24239977	NA	-0.91	-12.32	-0.5	2.28e-30	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs931812	0.535	rs3100053	chr8:101944559	T/A	cg20993868	chr7:22813445	NA	0.39	7.36	0.32	8.68e-13	Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg21893314	chr15:40453133	BUB1B	0.4	6.85	0.3	2.32e-11	Body mass index;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.39	-0.47	1.14e-26	Neuroticism;
LGG	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg27411982	chr8:10470053	RP1L1	0.45	7.58	0.33	1.85e-13	Neuroticism;
LGG	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg27624424	chr6:160112604	SOD2	0.66	9.54	0.41	8.1e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17767392	0.958	rs35760654	chr14:71983757	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.13	0.39	2.12e-18	Mitral valve prolapse;
LGG	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-12.05	-0.49	2.72e-29	Mean platelet volume;
LGG	trans	rs7181230	0.813	rs4924417	chr15:40366939	G/C	cg22705835	chr10:65332833	REEP3	-0.61	-9.94	-0.42	3.12e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs9486719	1.000	rs34209750	chr6:96882215	G/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs2802728	0.881	rs57809797	chr1:243537914	A/G	cg05593162	chr1:243577377	SDCCAG8	0.55	7.54	0.33	2.51e-13	Toenail selenium levels;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.06	-0.46	2.17e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs881375	0.678	rs4836834	chr9:123665901	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.04	0.52	2.56e-33	Rheumatoid arthritis;
LGG	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs12519773	0.501	rs4321736	chr5:92533363	C/T	cg18783429	chr5:92414398	NA	0.31	7.66	0.34	1.06e-13	Migraine;
LGG	cis	rs11169552	0.510	rs4768903	chr12:51045449	A/G	cg12884762	chr12:50931848	DIP2B	-0.39	-7.21	-0.32	2.35e-12	Colorectal cancer;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.2e-48	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg00666640	chr1:248458726	OR2T12	0.61	9.93	0.42	3.52e-21	Common traits (Other);
LGG	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	6.2800000000000005e-19	Coronary artery disease;
LGG	cis	rs11229555	0.645	rs7947248	chr11:58197750	C/T	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12249377	0.519	rs7906960	chr10:92586205	A/G	cg14313238	chr10:92632228	RPP30	0.4	7.16	0.32	3.22e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs4330281	0.692	rs4908971	chr3:17789074	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.17	-0.32	3.01e-12	Schizophrenia;
LGG	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.37	-0.36	6.71e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg15665833	chr6:26285013	NA	0.39	7.69	0.34	8.63e-14	Educational attainment;
LGG	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.53	-0.4	9.22e-20	Retinal vascular caliber;
LGG	trans	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.69	10.78	0.45	2.54e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.1	0.31	4.81e-12	Heart rate;
LGG	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg18187862	chr3:45730750	SACM1L	0.64	10.5	0.44	2.74e-23	Primary sclerosing cholangitis;
LGG	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05901451	chr6:126070800	HEY2	-0.65	-12.25	-0.49	4.23e-30	Brugada syndrome;
LGG	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.78e-31	Motion sickness;
LGG	cis	rs2735413	1.000	rs2735413	chr16:78053643	A/T	cg04733911	chr16:78082701	NA	-0.71	-15.79	-0.59	3.05e-45	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs653465	0.739	rs7618042	chr3:27207700	C/T	cg02860705	chr3:27208620	NA	0.41	7.9	0.34	2.1e-14	Breast cancer (early onset);
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg01069141	chr11:67398826	TBX10;NUDT8	-0.4	-6.93	-0.31	1.38e-11	Mean corpuscular volume;
LGG	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg18245976	chr7:158708271	WDR60	-0.58	-7.6	-0.33	1.69e-13	Height;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.37e-11	Lung cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26450586	chr10:72972207	UNC5B	0.6	6.81	0.3	3.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19942237	chr7:29603211	PRR15	-0.28	-6.74	-0.3	4.74e-11	Facial emotion recognition (angry faces);
LGG	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.21e-38	Tonsillectomy;
LGG	trans	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg18335740	chr13:41363409	SLC25A15	0.59	11.71	0.48	6.37e-28	Lewy body disease;
LGG	cis	rs42648	0.564	rs39283	chr7:89788806	C/A	cg04070188	chr7:89809444	NA	-0.28	-6.79	-0.3	3.37e-11	Homocysteine levels;
LGG	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg08400814	chr5:56204995	C5orf35	0.4	7.22	0.32	2.2e-12	Initial pursuit acceleration;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg19168338	chr16:4465731	CORO7	-1.12	-24.51	-0.75	1.17e-85	Schizophrenia;
LGG	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.02	-0.42	1.63e-21	Morning vs. evening chronotype;
LGG	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.64	8.98	0.39	6.99e-18	Blood protein levels;
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.4	-0.4	2.58e-19	Aortic root size;
LGG	cis	rs9810089	0.934	rs684195	chr3:135993599	A/C	cg21827317	chr3:136751795	NA	0.45	7.82	0.34	3.51e-14	Gestational age at birth (child effect);
LGG	cis	rs3816183	0.626	rs6544569	chr2:42816929	C/T	cg14631114	chr2:43023945	NA	0.33	6.66	0.3	7.69e-11	Hypospadias;
LGG	cis	rs2282300	0.739	rs34044331	chr11:30264486	T/C	cg25418670	chr11:30344373	C11orf46	-0.56	-7.82	-0.34	3.51e-14	Morning vs. evening chronotype;
LGG	cis	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg07460842	chr6:66804631	NA	-0.48	-8.41	-0.36	5.29e-16	Blood trace element (Cu levels);
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg01673284	chr16:4527211	HMOX2	0.36	7.32	0.32	1.12e-12	Schizophrenia;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.85	0.45	1.34e-24	Personality dimensions;
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00864171	chr11:67383662	NA	0.53	9.19	0.39	1.31e-18	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.99	-0.31	9.52e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs329674	0.597	rs329665	chr11:133757175	C/T	cg06766960	chr11:133703094	NA	-0.62	-6.9	-0.31	1.73e-11	Bipolar disorder;
LGG	cis	rs10170846	0.861	rs4674677	chr2:223529658	G/A	cg25565276	chr2:223520875	FARSB	0.63	11.12	0.46	1.23e-25	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs7712401	0.540	rs27617	chr5:122236534	T/A	cg19412675	chr5:122181750	SNX24	0.44	7.11	0.31	4.29e-12	Mean platelet volume;
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.34	-0.47	1.72e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg08975724	chr8:8085496	FLJ10661	0.44	8.19	0.36	2.55e-15	Mood instability;
LGG	cis	rs10739695	0.572	rs1318074	chr9:130380101	A/G	cg13643465	chr9:130375613	STXBP1	0.51	8.79	0.38	2.94e-17	Monocyte percentage of white cells;
LGG	trans	rs1478897	0.575	rs12679960	chr8:11430990	C/T	cg02002194	chr4:3960332	NA	-0.44	-7.36	-0.32	8.5e-13	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg19635926	chr16:89946313	TCF25	0.8	8.95	0.38	8.39e-18	Skin colour saturation;
LGG	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.6	-0.44	1.19e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg06521331	chr12:34319734	NA	-0.53	-8.78	-0.38	3.13e-17	Resting heart rate;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg15383120	chr6:291909	DUSP22	0.54	8.88	0.38	1.45e-17	Menopause (age at onset);
LGG	cis	rs9916302	0.904	rs2338798	chr17:37547269	T/C	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.2e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2451279	0.565	rs2451257	chr6:159507026	C/T	cg01046905	chr6:159515345	NA	0.33	6.93	0.31	1.46e-11	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg02297831	chr4:17616191	MED28	0.47	8.79	0.38	2.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.28	0.32	1.48e-12	Neuroticism;
LGG	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	8.01e-13	Platelet count;
LGG	cis	rs10463554	0.667	rs57714862	chr5:102382729	G/C	cg23492399	chr5:102201601	PAM	-0.5	-7.39	-0.32	7.05e-13	Parkinson's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06476228	chr15:49447928	GALK2;COPS2	0.57	8.53	0.37	2.08e-16	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.38	-0.32	7.59e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg07936489	chr17:37558343	FBXL20	0.84	15.6	0.59	2.08e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15557168	chr22:42548783	NA	-0.34	-7.75	-0.34	5.76e-14	Cognitive function;
LGG	cis	rs12477438	0.520	rs11884686	chr2:99997493	T/C	cg23527387	chr2:100056660	REV1	0.44	9.77	0.41	1.32e-20	Chronic sinus infection;
LGG	trans	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.08	0.42	9.77e-22	Mean corpuscular volume;
LGG	cis	rs7929679	0.571	rs10768099	chr11:34797334	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.89	0.3	1.84e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-9.83	-0.42	8.02e-21	Menarche (age at onset);
LGG	trans	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.39	-0.43	7.22e-23	Total cholesterol levels;
LGG	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.52	0.4	9.82e-20	Bone mineral density;
LGG	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03517284	chr6:25882590	NA	0.49	9.03	0.39	4.5e-18	Blood metabolite levels;
LGG	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg08344181	chr3:125677491	NA	-0.67	-7.97	-0.35	1.21e-14	Depression;
LGG	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08109568	chr15:31115862	NA	0.6	10.2	0.43	3.62e-22	Huntington's disease progression;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18713687	chr3:195489789	MUC4	-0.63	-8.62	-0.37	1.1e-16	Lung disease severity in cystic fibrosis;
LGG	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.65	-0.41	3.3e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.96	-0.52	5.58e-33	Intelligence (multi-trait analysis);
LGG	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg24503407	chr1:205819492	PM20D1	0.48	8.11	0.35	4.72e-15	Parkinson's disease;
LGG	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02825527	chr7:2087843	MAD1L1	-0.37	-7.29	-0.32	1.32e-12	Neuroticism;
LGG	cis	rs1707322	0.686	rs2050376	chr1:46078630	C/T	cg03146154	chr1:46216737	IPP	0.61	10.62	0.44	9.76e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13968953	chr3:97483466	ARL6	0.4	6.84	0.3	2.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs597583	0.806	rs10892135	chr11:117392826	G/A	cg27161313	chr11:117392002	DSCAML1	-0.52	-8.45	-0.37	3.75e-16	Putamen volume;
LGG	cis	rs9810089	0.967	rs7372313	chr3:135872958	G/C	cg21827317	chr3:136751795	NA	0.4	6.9	0.31	1.75e-11	Gestational age at birth (child effect);
LGG	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg27205649	chr11:78285834	NARS2	-0.48	-8.31	-0.36	1.11e-15	Alzheimer's disease (survival time);
LGG	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg11161011	chr14:65562177	MAX	-0.77	-15.16	-0.58	1.92e-42	Obesity-related traits;
LGG	cis	rs9916302	0.706	rs801418	chr17:37457982	G/C	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs4740619	0.782	rs11793900	chr9:15705718	A/T	cg14451791	chr9:16040625	NA	0.32	8.2	0.36	2.39e-15	Body mass index;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg20308403	chr7:2120281	MAD1L1	0.32	6.89	0.3	1.83e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7929679	0.602	rs10836311	chr11:34809166	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.39	6.66	0.3	7.94e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23091741	chr1:226111643	PYCR2	0.45	7.14	0.31	3.57e-12	Cognitive performance;
LGG	cis	rs4750440	0.736	rs4748070	chr10:14031388	G/A	cg27542038	chr10:14027202	FRMD4A	-0.7	-13.6	-0.53	1.14e-35	Adiponectin levels;
LGG	cis	rs11645898	0.935	rs3812985	chr16:72187957	A/T	cg14768367	chr16:72042858	DHODH	-0.69	-9.65	-0.41	3.35e-20	Blood protein levels;
LGG	cis	rs151997	0.538	rs1345777	chr5:50263788	A/G	cg06027927	chr5:50259733	NA	-0.62	-10.15	-0.43	5.61e-22	Callous-unemotional behaviour;
LGG	cis	rs2865126	0.644	rs5024299	chr18:10741011	C/T	cg21165219	chr18:10698044	FAM38B	-0.48	-7.91	-0.34	1.95e-14	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs1018836	0.886	rs12545351	chr8:91636668	C/T	cg16814680	chr8:91681699	NA	-0.84	-16.1	-0.6	1.19e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.31	-0.55	1.01e-38	HDL cholesterol levels;
LGG	cis	rs7742824	1.000	rs7742030	chr6:44065062	C/T	cg04074908	chr6:44101190	TMEM63B	0.68	13.15	0.52	8.43e-34	Major depressive disorder;
LGG	cis	rs9811920	0.609	rs2452320	chr3:99645216	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg03433033	chr1:76189801	ACADM	-0.78	-13.04	-0.52	2.42e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27286337	chr10:134555280	INPP5A	0.85	12.34	0.5	1.94e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2224391	1.000	rs2753249	chr6:5263475	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.05	-0.35	7.03e-15	Height;
LGG	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg03060546	chr3:49711283	APEH	-0.7	-11.87	-0.48	1.51e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.77	-0.61	1.2e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg04287289	chr16:89883240	FANCA	0.8	7.92	0.35	1.8e-14	Skin colour saturation;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs77669868	0.929	rs3782004	chr11:114070250	T/C	cg01914181	chr11:114070210	ZBTB16	0.7	9.21	0.39	1.09e-18	Monocyte percentage of white cells;
LGG	cis	rs36051895	0.695	rs10974921	chr9:5024427	T/A	cg02405213	chr9:5042618	JAK2	-0.83	-14.63	-0.56	3.98e-40	Pediatric autoimmune diseases;
LGG	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg21211680	chr2:198530	NA	1.28	15.95	0.6	5.64e-46	Blood protein levels;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg21911579	chr5:131705225	SLC22A5	-0.64	-7.28	-0.32	1.49e-12	Rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.06	0.42	1.12e-21	Motion sickness;
LGG	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg13010199	chr12:38710504	ALG10B	0.67	13.54	0.53	2.06e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9814567	1.000	rs9871305	chr3:134213538	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	4.18e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11677416	1.000	rs2071375	chr2:113535438	C/T	cg27083787	chr2:113543245	IL1A	0.53	9.01	0.39	5.42e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs698833	0.926	rs1065786	chr2:44660616	G/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.45	-6.91	-0.31	1.57e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7799006	0.929	rs71525363	chr7:2268792	G/A	cg02951883	chr7:2050386	MAD1L1	-0.43	-7.34	-0.32	9.53e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2963155	0.518	rs55817235	chr5:142765733	C/T	cg17617527	chr5:142782415	NR3C1	1.0	12.72	0.51	5.37e-32	Breast cancer;
LGG	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.19	-0.36	2.54e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.89	-0.34	2.27e-14	Neuroticism;
LGG	cis	rs6083	0.536	rs4528512	chr15:58852226	A/T	cg05156742	chr15:59063176	FAM63B	0.43	7.81	0.34	3.9e-14	Schizophrenia;
LGG	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg26384229	chr12:38710491	ALG10B	0.64	12.44	0.5	7.61e-31	Morning vs. evening chronotype;
LGG	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.4	6.76	0.3	4.19e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg20607798	chr8:58055168	NA	0.67	10.44	0.44	4.74e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg08822215	chr16:89438651	ANKRD11	-0.4	-7.54	-0.33	2.57e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01449415	chr16:3184811	ZNF213	0.46	7.34	0.32	9.81e-13	Cognitive performance;
LGG	cis	rs2033732	0.706	rs1370420	chr8:85068234	G/T	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00495681	chr13:53174319	NA	0.59	11.15	0.46	1.01e-25	Lewy body disease;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16405210	chr4:1374714	KIAA1530	-0.83	-15.85	-0.59	1.57e-45	Longevity;
LGG	cis	rs2274273	0.805	rs28612464	chr14:55816411	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	4.92e-51	Protein biomarker;
LGG	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.65	-0.3	8.51e-11	Iron status biomarkers;
LGG	cis	rs79387448	0.701	rs10515921	chr2:102981018	T/G	cg20060108	chr2:102954350	IL1RL1	-0.43	-6.72	-0.3	5.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg00647317	chr7:50633725	DDC	0.46	11.09	0.46	1.63e-25	Systemic sclerosis;
LGG	cis	rs6540556	0.834	rs11119337	chr1:209934133	A/G	cg23920097	chr1:209922102	NA	-0.41	-7.65	-0.33	1.19e-13	Red blood cell count;
LGG	cis	rs73086581	0.891	rs55871214	chr20:3965706	A/C	cg02187196	chr20:3869020	PANK2	0.84	11.71	0.48	6.16e-28	Response to antidepressants in depression;
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.74	-0.41	1.62e-20	Neuroticism;
LGG	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs2562456	0.754	rs62107469	chr19:21495501	T/C	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7267979	1.000	rs1888999	chr20:25291848	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.33	0.43	1.24e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.78	-0.3	3.76e-11	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04891921	chr3:134514173	EPHB1	0.44	7.1	0.31	4.8e-12	Cognitive performance;
LGG	cis	rs11690935	0.632	rs11690807	chr2:172628120	G/A	cg13550731	chr2:172543902	DYNC1I2	0.7	14.27	0.55	1.53e-38	Schizophrenia;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.42	-0.36	4.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg11789530	chr4:8429930	ACOX3	-0.81	-15.55	-0.59	3.47e-44	Response to antineoplastic agents;
LGG	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg05887092	chr17:76393375	PGS1	0.72	16.04	0.6	2.22e-46	HDL cholesterol levels;
LGG	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg20891558	chr2:74357851	NA	0.49	9.53	0.41	8.75e-20	Gestational age at birth (maternal effect);
LGG	cis	rs6450176	0.638	rs1542167	chr5:53305742	T/G	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-16.5	-0.61	1.96e-48	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs972578	0.715	rs4822211	chr22:43267831	G/T	cg01576275	chr22:43409880	NA	-0.23	-6.86	-0.3	2.16e-11	Mean platelet volume;
LGG	cis	rs75059851	0.756	rs11223654	chr11:133841579	C/T	cg17703048	chr11:133852993	NA	-0.87	-15.95	-0.6	6.02e-46	Schizophrenia;
LGG	cis	rs11874712	1.000	rs9783884	chr18:43651133	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.92	-0.45	7.41e-25	Migraine - clinic-based;
LGG	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg13072238	chr3:49761600	GMPPB	0.55	7.64	0.33	1.29e-13	Menarche (age at onset);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26446827	chr20:18268978	ZNF133	0.41	6.96	0.31	1.2e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs10779751	0.690	rs910661	chr1:11130116	C/A	cg08854313	chr1:11322531	MTOR	0.75	16.61	0.61	6.26e-49	Body mass index;
LGG	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg14132834	chr19:41945861	ATP5SL	-0.5	-9.81	-0.41	9.18e-21	Height;
LGG	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg24881330	chr22:46731750	TRMU	0.69	6.98	0.31	9.97e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs526231	0.547	rs34780	chr5:102453557	G/A	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg15704280	chr7:45808275	SEPT13	-0.95	-19.75	-0.68	1.92e-63	Coronary artery disease;
LGG	cis	rs17756712	0.666	rs1099773	chr6:646076	G/C	cg14374089	chr6:596013	EXOC2	0.46	7.27	0.32	1.54e-12	Vertical cup-disc ratio;
LGG	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.95	-0.38	8.8e-18	Response to antipsychotic treatment;
LGG	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-10.81	-0.45	1.97e-24	Vitiligo;
LGG	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg26578617	chr4:90757533	SNCA	-0.4	-8.08	-0.35	5.66e-15	Dementia with Lewy bodies;
LGG	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg12395012	chr8:11607386	GATA4	0.36	6.65	0.3	8.41e-11	Morning vs. evening chronotype;
LGG	trans	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg18187862	chr3:45730750	SACM1L	-0.68	-11.02	-0.46	3.09e-25	Primary sclerosing cholangitis;
LGG	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.58	-0.33	1.88e-13	Neuroticism;
LGG	cis	rs4731207	0.596	rs10252798	chr7:124637211	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.93	-0.31	1.41e-11	Cutaneous malignant melanoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05447186	chr20:3869454	PANK2	0.53	8.71	0.38	5.37e-17	Cognitive performance;
LGG	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.73	-0.3	5.14e-11	Mean platelet volume;
LGG	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg06637938	chr14:75390232	RPS6KL1	0.56	10.31	0.43	1.39e-22	Height;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	trans	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg15921436	chr17:44337874	NA	0.53	11.43	0.47	7.78e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs171408	0.895	rs1667464	chr3:8613279	C/G	cg03557445	chr3:8615444	LOH3CR2A	-0.48	-8.61	-0.37	1.11e-16	Mitral valve prolapse;
LGG	cis	rs571497	0.583	rs62128261	chr19:7837989	G/C	cg00371453	chr19:7854482	CLEC4GP1	0.81	9.04	0.39	4.37e-18	Monocyte count;
LGG	cis	rs236907	0.859	rs1801898	chr1:171765964	A/G	cg14032218	chr1:171755066	METTL13	-0.43	-7.11	-0.31	4.35e-12	Mean platelet volume;
LGG	cis	rs988958	0.565	rs6752691	chr2:42235581	C/T	cg27428208	chr2:42229179	NA	0.48	7.58	0.33	1.85e-13	Hypospadias;
LGG	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg09307838	chr4:120376055	NA	0.72	12.07	0.49	2.35e-29	Corneal astigmatism;
LGG	cis	rs7226408	0.600	rs11665174	chr18:34515400	A/G	cg15022739	chr18:34823045	BRUNOL4	0.41	8.83	0.38	2.2e-17	Obesity-related traits;
LGG	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg14581129	chr12:53358946	NA	-0.29	-7.15	-0.32	3.38e-12	Prostate cancer;
LGG	trans	rs970548	0.779	rs56145077	chr10:45939991	C/T	cg14222797	chr10:16859974	RSU1	-0.65	-7.64	-0.33	1.25e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg07005078	chr4:17578674	LAP3	-0.37	-6.76	-0.3	4.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.67	-0.37	7.13e-17	Chronic sinus infection;
LGG	trans	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg06521331	chr12:34319734	NA	-0.54	-9.4	-0.4	2.47e-19	Bladder cancer;
LGG	cis	rs2239547	0.657	rs12496077	chr3:52886241	G/A	cg11645453	chr3:52864694	ITIH4	0.73	11.28	0.46	3.1e-26	Schizophrenia;
LGG	cis	rs35740288	0.770	rs11631018	chr15:86140534	G/A	cg04173714	chr15:86211321	AKAP13	0.46	8.19	0.36	2.52e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-14.8	-0.57	7.75e-41	Glomerular filtration rate (creatinine);
LGG	cis	rs55665837	1.000	rs10832276	chr11:14483274	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.52	-0.37	2.32e-16	Vitamin D levels;
LGG	cis	rs713587	0.520	rs519111	chr2:25333735	T/C	cg04586622	chr2:25135609	ADCY3	-0.32	-7.83	-0.34	3.36e-14	Body mass index in non-asthmatics;
LGG	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg06271696	chr7:157225062	NA	-0.62	-13.84	-0.54	1.01e-36	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg11366901	chr6:160182831	ACAT2	1.05	15.97	0.6	4.76e-46	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.01	-0.39	5.26e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg23958373	chr8:599963	NA	-1.28	-10.72	-0.45	4.22e-24	IgG glycosylation;
LGG	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.6e-17	Schizophrenia;
LGG	cis	rs6704644	0.932	rs72982316	chr2:234416719	C/T	cg27060346	chr2:234359958	DGKD	-0.58	-7.09	-0.31	4.99e-12	Bilirubin levels;
LGG	trans	rs9657904	0.951	rs6437626	chr3:105599207	T/C	cg14088669	chr1:158435396	OR10K1	0.39	6.66	0.3	7.75e-11	Multiple sclerosis;
LGG	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	9.48	0.4	1.37e-19	Lung cancer in ever smokers;
LGG	cis	rs55788414	0.932	rs2317119	chr16:81182854	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	6.07e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7267979	1.000	rs1888997	chr20:25298988	G/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.87e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7914558	1.000	rs11191541	chr10:104824199	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.69	0.44	5.43e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07981822	chr2:26568781	SELI;GPR113	0.49	7.22	0.32	2.1e-12	Gut microbiome composition (summer);
LGG	cis	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs7927771	0.524	rs12226431	chr11:47805856	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.14	0.46	1.04e-25	Subjective well-being;
LGG	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-14.92	-0.57	2.25e-41	Response to antipsychotic treatment;
LGG	cis	rs4330281	0.608	rs13322641	chr3:17378509	G/A	cg20981856	chr3:17787350	NA	0.36	6.81	0.3	3.03e-11	Schizophrenia;
LGG	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.79	12.75	0.51	4.19e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4595586	0.505	rs12826314	chr12:39379435	A/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.63	0.61	4.9e-49	Platelet count;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg22535103	chr8:58192502	C8orf71	-0.98	-14.95	-0.57	1.63e-41	Developmental language disorder (linguistic errors);
LGG	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs80058639	1	rs80058639	chr8:1164069	GC/G	cg00178551	chr8:1164044	NA	0.65	6.66	0.3	7.85e-11	Response to paliperidone in schizophrenia (Multivariate);
LGG	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.6	0.33	1.7e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7828089	0.744	rs10108011	chr8:22320806	C/T	cg12081754	chr8:22256438	SLC39A14	0.58	10.61	0.44	1.07e-23	Verbal declarative memory;
LGG	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-11.1	-0.46	1.55e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15664640	chr17:80829946	TBCD	-0.8	-15.73	-0.59	5.42e-45	Breast cancer;
LGG	cis	rs427394	0.659	rs175594	chr5:6729885	T/G	cg15145174	chr5:6755386	POLS	-0.44	-8.07	-0.35	6.01e-15	Menopause (age at onset);
LGG	cis	rs7336332	0.511	rs7998978	chr13:27999457	T/C	cg01674679	chr13:27998804	GTF3A	-0.7	-9.03	-0.39	4.65e-18	Weight;
LGG	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg07274523	chr3:49395745	GPX1	0.56	9.35	0.4	3.89e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3126085	1.000	rs11590365	chr1:152165489	C/A	cg26876637	chr1:152193138	HRNR	-0.5	-7.12	-0.31	4.05e-12	Atopic dermatitis;
LGG	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg15145296	chr3:125709740	NA	-0.59	-7.71	-0.34	7.57e-14	Blood pressure (smoking interaction);
LGG	cis	rs75059851	1.000	rs73036062	chr11:133828187	G/A	cg20042908	chr11:133852938	NA	-0.69	-12.13	-0.49	1.38e-29	Schizophrenia;
LGG	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg12623918	chr2:306882	NA	0.51	9.33	0.4	4.31e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7503807	0.515	rs12945216	chr17:78670642	C/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.3	-0.4	5.68e-19	Obesity;
LGG	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.41	0.44	6.16e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.26	-0.32	1.69e-12	Life satisfaction;
LGG	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg05425664	chr17:57184151	TRIM37	0.7	11.41	0.47	9.94e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.515	rs12943155	chr17:78667125	A/G	cg22878693	chr17:78755604	RPTOR	-0.56	-9.27	-0.4	7.02e-19	Obesity;
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.55	-0.33	2.35e-13	Dementia with Lewy bodies;
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.36e-18	Height;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg23958373	chr8:599963	NA	1.25	12.22	0.49	5.78e-30	IgG glycosylation;
LGG	trans	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.46	-0.65	2.06e-57	Exhaled nitric oxide output;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg12708336	chr17:41446283	NA	-0.33	-7.99	-0.35	1.11e-14	Menopause (age at onset);
LGG	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg02574844	chr11:5959923	NA	-0.59	-9.03	-0.39	4.48e-18	DNA methylation (variation);
LGG	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	9.61	0.41	4.8e-20	Educational attainment (years of education);
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg15971980	chr6:150254442	NA	0.45	8.32	0.36	1.02e-15	Lung cancer;
LGG	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg21226059	chr5:178986404	RUFY1	-0.43	-7.06	-0.31	6.25e-12	Lung cancer;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11644478	chr21:40555479	PSMG1	0.89	15.59	0.59	2.39e-44	Cognitive function;
LGG	cis	rs2285947	0.933	rs10275354	chr7:21580599	G/A	cg04471919	chr7:21584483	DNAH11	0.47	12.4	0.5	1.1e-30	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11229555	0.645	rs10466659	chr11:58190112	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.73	-0.3	5.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8028182	0.636	rs7171507	chr15:75737287	T/C	cg20655648	chr15:75932815	IMP3	0.46	7.79	0.34	4.29e-14	Sudden cardiac arrest;
LGG	cis	rs11785693	0.909	rs62489558	chr8:4968620	G/A	cg26367366	chr8:4980734	NA	1.0	15.06	0.57	5.34e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17427856	chr6:90539462	CASP8AP2	-0.48	-7.07	-0.31	5.76e-12	Systemic lupus erythematosus;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.94	0.35	1.55e-14	Longevity;
LGG	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg09173681	chr1:183549694	NCF2	0.37	8.52	0.37	2.3e-16	Systemic lupus erythematosus;
LGG	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.19e-22	Neutrophil percentage of white cells;
LGG	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	11.25	0.46	3.88e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1691799	0.899	rs1168320	chr12:66744849	C/T	cg16791601	chr12:66731901	HELB	-0.66	-15.52	-0.58	4.9e-44	White blood cell count (basophil);
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg08677398	chr8:58056175	NA	0.46	7.18	0.32	2.76e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.958	rs4902938	chr14:72014778	T/C	cg02058870	chr14:72053146	SIPA1L1	-0.46	-9.41	-0.4	2.35e-19	Mitral valve prolapse;
LGG	trans	rs7939886	0.920	rs1031978	chr11:55965641	G/T	cg15704280	chr7:45808275	SEPT13	0.83	7.78	0.34	4.68e-14	Myopia (pathological);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17146150	chr15:56657437	TEX9	0.55	8.28	0.36	1.3e-15	Gut microbiome composition (summer);
LGG	cis	rs59918340	0.728	rs35257077	chr8:142235049	C/T	cg03653399	chr8:142233436	SLC45A4	-0.42	-8.12	-0.35	4.11e-15	Immature fraction of reticulocytes;
LGG	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1018697	0.966	rs10748832	chr10:104568480	G/A	cg04362960	chr10:104952993	NT5C2	0.52	9.3	0.4	5.4e-19	Colorectal adenoma (advanced);
LGG	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg18165381	chr3:44552316	NA	-0.42	-7.11	-0.31	4.55e-12	Depressive symptoms;
LGG	cis	rs74781061	0.929	rs7171838	chr15:74864119	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.53e-12	Endometriosis;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg05941027	chr17:61774174	LIMD2	0.37	9.49	0.4	1.22e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg02269571	chr22:50332266	NA	-0.63	-10.12	-0.43	7.22e-22	Schizophrenia;
LGG	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg07936489	chr17:37558343	FBXL20	1.0	15.63	0.59	1.55e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg06353428	chr16:71660113	MARVELD3	0.41	6.75	0.3	4.45e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs12765878	1.000	rs2273698	chr10:105649158	G/A	cg11005552	chr10:105648138	OBFC1	1.04	27.19	0.78	5.22e-98	Coronary artery disease;
LGG	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg17691542	chr6:26056736	HIST1H1C	-0.43	-7.35	-0.32	8.98e-13	Blood metabolite levels;
LGG	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-25.88	-0.77	5.15e-92	Height;
LGG	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg03476357	chr21:30257390	N6AMT1	-0.54	-8.04	-0.35	7.72e-15	Cognitive test performance;
LGG	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.89e-22	Cannabis dependence symptom count;
LGG	cis	rs10895140	0.756	rs2000517	chr11:101503495	A/G	cg23650423	chr11:101454676	TRPC6	0.43	7.04	0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs8073060	0.586	rs72829923	chr17:34045089	T/A	cg19694781	chr19:47549865	TMEM160	1.16	17.64	0.63	1.17e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs807669	0.548	rs885979	chr22:19198375	T/C	cg02655711	chr22:19163373	SLC25A1	0.64	12.34	0.5	1.97e-30	Metabolite levels;
LGG	cis	rs12731740	0.831	rs35029161	chr1:207927153	T/C	cg22525895	chr1:207977042	MIR29B2	-0.62	-7.18	-0.32	2.85e-12	Biomedical quantitative traits;
LGG	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg00334542	chr7:100209784	MOSPD3	-0.56	-7.76	-0.34	5.46e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg10840412	chr1:235813424	GNG4	0.67	9.13	0.39	2.06e-18	Bipolar disorder;
LGG	cis	rs7572733	0.534	rs700673	chr2:198692929	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg22771759	chr13:24902376	NA	0.44	7.28	0.32	1.4e-12	Obesity-related traits;
LGG	cis	rs9398803	0.650	rs9401874	chr6:126625617	A/C	cg19875578	chr6:126661172	C6orf173	-0.41	-7.09	-0.31	5.01e-12	Male-pattern baldness;
LGG	cis	rs10463554	0.892	rs257305	chr5:102417237	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg12463550	chr7:65579703	CRCP	0.79	8.53	0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg12310025	chr6:25882481	NA	-0.53	-10.15	-0.43	5.56e-22	Blood metabolite levels;
LGG	cis	rs9878978	0.754	rs6787085	chr3:2436234	A/T	cg21928760	chr3:2462534	CNTN4	-0.39	-7.85	-0.34	2.86e-14	Blood pressure (smoking interaction);
LGG	cis	rs11748327	0.843	rs6895675	chr5:4074287	G/C	cg01025095	chr5:4101132	NA	-0.6	-9.71	-0.41	2.1e-20	Myocardial infarction;
LGG	cis	rs9463078	0.966	rs9357471	chr6:45090977	C/T	cg25276700	chr6:44698697	NA	-0.37	-7.69	-0.34	8.65e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4919044	1.000	rs17108050	chr10:94772223	A/G	cg05127821	chr10:94822908	CYP26C1	-0.49	-7.54	-0.33	2.48e-13	Coronary artery disease;
LGG	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg03733263	chr8:22462867	KIAA1967	0.97	23.29	0.73	5.59e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9557207	0.950	rs35715041	chr13:99942021	T/C	cg24509225	chr13:100037070	UBAC2	0.68	12.22	0.49	5.78e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs61990749	0.597	rs1978416	chr14:78227901	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg00666640	chr1:248458726	OR2T12	0.62	10.0	0.42	1.85e-21	Common traits (Other);
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.85	0.48	1.79e-28	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg12708336	chr17:41446283	NA	-0.3	-6.91	-0.31	1.6e-11	Menopause (age at onset);
LGG	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.33	-6.98	-0.31	1.03e-11	Hemoglobin concentration;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg21775007	chr8:11205619	TDH	-0.47	-7.11	-0.31	4.39e-12	Myopia (pathological);
LGG	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg26513180	chr16:89883248	FANCA	-0.41	-7.23	-0.32	2.03e-12	Vitiligo;
LGG	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg13010199	chr12:38710504	ALG10B	0.7	13.95	0.54	3.72e-37	Bladder cancer;
LGG	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	3.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs858239	0.600	rs61292332	chr7:23131862	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.23	0.32	1.98e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-10.35	-0.43	1e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6426558	0.559	rs485234	chr1:227317747	A/G	cg10327440	chr1:227177885	CDC42BPA	0.63	10.47	0.44	3.71e-23	Neutrophil percentage of white cells;
LGG	cis	rs2735413	0.958	rs2735401	chr16:78057103	A/C	cg04733911	chr16:78082701	NA	0.73	16.34	0.6	1.07e-47	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg01988459	chr11:68622903	NA	-0.62	-12.47	-0.5	5.68e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10155981	0.510	rs4722159	chr7:22584279	C/G	cg06110297	chr7:22589830	NA	-0.65	-7.24	-0.32	1.87e-12	Bilirubin levels;
LGG	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg21211680	chr2:198530	NA	-1.24	-18.9	-0.66	1.74e-59	Blood protein levels;
LGG	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-11.15	-0.46	9.75e-26	Morning vs. evening chronotype;
LGG	trans	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg08344181	chr3:125677491	NA	-0.47	-6.82	-0.3	2.9e-11	Depression;
LGG	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg20848291	chr7:100343083	ZAN	-0.46	-6.66	-0.3	7.56e-11	Mean corpuscular hemoglobin;
LGG	cis	rs10267417	0.603	rs73267155	chr7:19939513	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	6.86	0.3	2.19e-11	Night sleep phenotypes;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-9.78	-0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg18357526	chr6:26021779	HIST1H4A	0.45	7.2	0.32	2.51e-12	Height;
LGG	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.51	7.77	0.34	5.12e-14	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05165339	chr4:1420672	NA	-0.31	-8.26	-0.36	1.5e-15	Longevity;
LGG	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg15704280	chr7:45808275	SEPT13	0.5	8.17	0.35	2.88e-15	HDL cholesterol;
LGG	cis	rs28374715	0.662	rs1554445	chr15:41503198	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.02	-17.84	-0.64	1.45e-54	Ulcerative colitis;
LGG	cis	rs11627756	0.957	rs12434778	chr14:103142135	G/T	cg01864069	chr14:103024347	NA	0.42	6.82	0.3	2.78e-11	Mean platelet volume;
LGG	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg11871910	chr12:69753446	YEATS4	1.04	28.61	0.8	2.12e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.34	0.53	1.38e-34	IgG glycosylation;
LGG	cis	rs9400467	0.537	rs73528979	chr6:111430404	G/A	cg15721981	chr6:111408429	SLC16A10	0.58	7.08	0.31	5.55e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg13010199	chr12:38710504	ALG10B	0.76	16.37	0.61	7.25e-48	Heart rate;
LGG	cis	rs2230307	0.656	rs1395332	chr1:100503993	A/C	cg24955406	chr1:100503596	HIAT1	0.58	8.33	0.36	9.11e-16	Carotid intima media thickness;
LGG	cis	rs7539409	0.915	rs1977119	chr1:84275509	A/G	cg10977910	chr1:84465055	TTLL7	0.65	7.55	0.33	2.32e-13	Alzheimer's disease;
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs988958	0.567	rs34117938	chr2:42258394	A/C	cg27428208	chr2:42229179	NA	0.55	9.32	0.4	4.74e-19	Hypospadias;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25172604	chr17:41446521	NA	-0.31	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	cis	rs9811920	0.609	rs4244713	chr3:99679584	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.06	-0.39	3.62e-18	Axial length;
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg16301924	chr13:53314226	LECT1	-0.54	-11.68	-0.48	8.61e-28	Lewy body disease;
LGG	cis	rs42648	0.935	rs42627	chr7:89961876	C/T	cg25739043	chr7:89950458	NA	-0.41	-8.68	-0.37	6.79e-17	Homocysteine levels;
LGG	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.4	-0.4	2.44e-19	Mean corpuscular volume;
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26617929	chr16:1858877	NA	-0.59	-8.46	-0.37	3.54e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9487094	0.666	rs4946967	chr6:109678572	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.85	0.34	2.94e-14	Height;
LGG	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg18351406	chr4:77819688	ANKRD56	0.46	8.0	0.35	9.8e-15	Emphysema distribution in smoking;
LGG	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.33	-0.36	9.48e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2050392	0.590	rs303433	chr10:30714963	A/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.31	-0.5	2.42e-30	Inflammatory bowel disease;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg03528353	chr17:61819722	STRADA	-0.4	-6.75	-0.3	4.36e-11	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21735344	chr14:102553260	HSP90AA1	0.57	8.91	0.38	1.19e-17	Gut microbiome composition (summer);
LGG	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg22432760	chr17:80829718	TBCD	0.4	6.98	0.31	1.05e-11	Breast cancer;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-9.43	-0.4	1.92e-19	Longevity;Endometriosis;
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.82	-0.3	2.77e-11	Total body bone mineral density;
LGG	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg24692254	chr21:30365293	RNF160	0.69	12.68	0.51	7.87e-32	Cognitive test performance;
LGG	cis	rs1707322	1.000	rs2458400	chr1:46530798	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.87	-0.42	5.57e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg27239842	chr4:2403781	ZFYVE28	-0.46	-7.83	-0.34	3.31e-14	Cognitive function;
LGG	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.36	-0.32	8.7e-13	Retinal vascular caliber;
LGG	cis	rs11239187	0.523	rs12774273	chr10:45100642	A/G	cg03916630	chr10:45065415	NA	0.42	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs17021463	0.902	rs62320439	chr4:95248721	G/C	cg11021082	chr4:95130006	SMARCAD1	0.52	9.72	0.41	1.95e-20	Testicular germ cell tumor;
LGG	cis	rs72781680	0.898	rs72782117	chr2:24026921	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.54	0.41	7.94e-20	Lymphocyte counts;
LGG	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.67	-0.34	1.06e-13	HDL cholesterol;
LGG	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg00599393	chr8:22457479	C8orf58	-0.46	-8.19	-0.36	2.54e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg17691542	chr6:26056736	HIST1H1C	0.53	9.72	0.41	1.84e-20	Height;
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.03	-0.35	8.13e-15	Skin colour saturation;
LGG	cis	rs10979	1.000	rs9496671	chr6:143884742	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.28	-0.5	3.38e-30	Hypospadias;
LGG	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg00543991	chr22:32367038	NA	0.78	8.57	0.37	1.56e-16	Childhood ear infection;
LGG	cis	rs1045714	0.895	rs73043180	chr7:2645972	C/T	cg14042143	chr7:2646782	IQCE	0.81	12.44	0.5	7.82e-31	Urate levels in lean individuals;
LGG	cis	rs7929679	0.521	rs10836304	chr11:34794024	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.43	-7.27	-0.32	1.54e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.41	-0.36	5.1e-16	Tonsillectomy;
LGG	cis	rs870825	0.587	rs58332461	chr4:185639742	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs7567389	0.504	rs2069895	chr2:128174068	A/G	cg10021288	chr2:128175891	PROC	0.38	6.71	0.3	5.86e-11	Self-rated health;
LGG	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.2e-32	Morning vs. evening chronotype;
LGG	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.97	0.35	1.21e-14	Monocyte count;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg19077165	chr18:44547161	KATNAL2	0.68	13.12	0.52	1.18e-33	Personality dimensions;
LGG	cis	rs9859260	0.925	rs3761717	chr3:195797947	G/C	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.95	-0.31	1.22e-11	Mean corpuscular volume;
LGG	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg10326726	chr10:51549505	MSMB	0.69	14.05	0.55	1.29e-37	Prostate-specific antigen levels;
LGG	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.54	-0.33	2.49e-13	Blood protein levels;
LGG	cis	rs4268898	0.735	rs34125395	chr2:24558242	C/T	cg06627628	chr2:24431161	ITSN2	0.42	6.93	0.31	1.38e-11	Asthma;
LGG	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg02389323	chr16:88786976	FAM38A	1.07	12.8	0.51	2.62e-32	Plateletcrit;
LGG	cis	rs4845570	0.764	rs12141652	chr1:151716711	A/T	cg07092448	chr1:151763213	TDRKH	-1.07	-15.39	-0.58	1.93e-43	Coronary artery disease;
LGG	trans	rs1997103	0.911	rs6945663	chr7:55407011	C/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4987668	0.708	rs11977017	chr7:142636704	T/C	cg19410471	chr7:142636507	C7orf34	0.51	8.15	0.35	3.43e-15	Cancer;
LGG	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg09307838	chr4:120376055	NA	0.67	11.67	0.48	9.3e-28	Corneal astigmatism;
LGG	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg13647721	chr17:30228624	UTP6	0.6	7.73	0.34	6.6e-14	Hip circumference adjusted for BMI;
LGG	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg23594656	chr7:65796392	TPST1	0.39	8.49	0.37	2.91e-16	Aortic root size;
LGG	trans	rs12517041	1.000	rs7722738	chr5:23288074	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs1506636	1.000	rs2215554	chr7:123347063	A/C	cg03229431	chr7:123269106	ASB15	-0.71	-17.33	-0.63	3.05e-52	Plateletcrit;Platelet count;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.03	-0.52	2.7e-33	Alzheimer's disease;
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.32	-0.36	9.83e-16	Neuroticism;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg13047869	chr3:10149882	C3orf24	0.55	9.4	0.4	2.58e-19	Alzheimer's disease;
LGG	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg13207630	chr7:32358064	NA	0.63	6.9	0.31	1.72e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23715700	chr19:16188274	TPM4	0.53	8.34	0.36	8.83e-16	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.767	rs79323474	chr3:42000973	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2084898	1.000	rs73004754	chr11:120053576	G/A	cg07435449	chr11:120005650	TRIM29	-0.67	-7.57	-0.33	2.03e-13	Stroke (pediatric);
LGG	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg00647317	chr7:50633725	DDC	0.37	9.18	0.39	1.42e-18	Systemic sclerosis;
LGG	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg26384229	chr12:38710491	ALG10B	0.97	20.69	0.69	7.71e-68	Bladder cancer;
LGG	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg20573242	chr4:122745356	CCNA2	-0.45	-7.88	-0.34	2.44e-14	Type 2 diabetes;
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg17178900	chr1:205818956	PM20D1	-0.36	-7.43	-0.33	5.24e-13	Menarche (age at onset);
LGG	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.47	0.53	4.02e-35	IgG glycosylation;
LGG	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.86	0.34	2.69e-14	Schizophrenia;
LGG	cis	rs6430585	0.528	rs3098102	chr2:136654833	C/T	cg07169764	chr2:136633963	MCM6	1.13	20.14	0.68	2.88e-65	Corneal structure;
LGG	cis	rs9942416	0.660	rs17563863	chr5:74998334	G/A	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.72	-0.38	5.11e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg12165864	chr7:66369176	NA	-0.58	-9.37	-0.4	3.33e-19	Corneal structure;
LGG	cis	rs11920090	0.860	rs11720145	chr3:170739663	G/A	cg09710316	chr3:170744871	SLC2A2	0.63	8.49	0.37	2.81e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg16141378	chr3:129829833	LOC729375	-0.45	-10.97	-0.45	4.97e-25	Mood instability;
LGG	cis	rs12464559	0.522	rs12472627	chr2:152633114	C/T	cg01189475	chr2:152685088	ARL5A	0.69	7.05	0.31	6.6e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg05863683	chr7:1912471	MAD1L1	0.42	7.87	0.34	2.48e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25373794	chr1:162760220	HSD17B7	-0.41	-6.67	-0.3	7.13e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2227564	0.649	rs2243610	chr10:75601653	A/T	cg00564723	chr10:75632066	CAMK2G	-0.5	-11.05	-0.46	2.33e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27532318	chr7:32358331	NA	-0.7	-7.24	-0.32	1.88e-12	Body mass index;
LGG	cis	rs1943345	1.000	rs1943345	chr11:82876270	G/T	cg07047830	chr11:82868014	PCF11	-0.46	-7.53	-0.33	2.7e-13	Obesity-related traits;
LGG	cis	rs7572644	0.640	rs11891769	chr2:28025580	G/C	cg27432699	chr2:27873401	GPN1	0.48	6.96	0.31	1.14e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg11441553	chr12:57614120	NXPH4	-0.56	-6.79	-0.3	3.38e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg09648091	chr16:2264881	PGP	0.42	6.97	0.31	1.07e-11	Response to antipsychotic treatment;
LGG	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg24006582	chr15:45444508	DUOX1	0.67	12.25	0.49	4.47e-30	Uric acid levels;
LGG	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.13	0.52	1.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg08297393	chr2:100937505	LONRF2	-0.57	-10.68	-0.44	5.92e-24	Intelligence (multi-trait analysis);
LGG	cis	rs988958	0.675	rs35657711	chr2:42216386	T/C	cg27428208	chr2:42229179	NA	0.55	9.22	0.39	1.07e-18	Hypospadias;
LGG	cis	rs17767392	0.958	rs61989374	chr14:71940581	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg19168338	chr16:4465731	CORO7	-0.93	-18.79	-0.66	5.75e-59	Schizophrenia;
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg02725872	chr8:58115012	NA	-0.89	-17.43	-0.63	1.1e-52	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg13206674	chr6:150067644	NUP43	0.65	14.96	0.57	1.54e-41	Lung cancer;
LGG	cis	rs7255436	0.965	rs4044435	chr19:8448177	T/C	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.75	-0.3	4.39e-11	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.52e-14	Lung cancer;
LGG	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg17971929	chr21:40555470	PSMG1	-0.7	-13.23	-0.52	4.23e-34	Cognitive function;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00689492	chr4:1303491	MAEA	0.47	8.24	0.36	1.74e-15	Obesity-related traits;
LGG	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.44	-0.53	5.12e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg18681998	chr4:17616180	MED28	0.88	20.4	0.69	1.78e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1009647	0.645	rs73271727	chr14:55600430	G/T	cg04306507	chr14:55594613	LGALS3	0.46	7.61	0.33	1.53e-13	Testicular germ cell tumor;
LGG	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.16	0.35	3.15e-15	Mean platelet volume;
LGG	cis	rs12971120	0.588	rs12606654	chr18:72126710	C/T	cg25817165	chr18:72167213	CNDP2	-0.46	-7.28	-0.32	1.48e-12	Refractive error;
LGG	cis	rs3008870	1.000	rs3008894	chr1:67377739	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.04	22.42	0.72	6.18e-76	Lymphocyte percentage of white cells;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22433210	chr17:43662623	NA	0.83	13.81	0.54	1.38e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.52	0.56	1.19e-39	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg19784903	chr17:45786737	TBKBP1	0.37	8.15	0.35	3.42e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs35740288	0.721	rs11636347	chr15:86241233	A/G	cg07943548	chr15:86304357	KLHL25	-0.36	-6.88	-0.3	1.96e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg24375607	chr4:120327624	NA	0.6	10.0	0.42	1.92e-21	Corneal astigmatism;
LGG	cis	rs10499694	0.967	rs7786398	chr7:50612906	G/A	cg00647317	chr7:50633725	DDC	0.37	8.99	0.39	6.33e-18	Body mass index;
LGG	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg19508488	chr2:152266495	RIF1	0.52	9.15	0.39	1.78e-18	Squamous cell lung carcinoma;
LGG	cis	rs11920090	0.932	rs12496506	chr3:170693011	C/T	cg09710316	chr3:170744871	SLC2A2	0.61	8.62	0.37	1.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.52	-0.33	2.93e-13	Depression;
LGG	cis	rs1010254	0.510	rs957211	chr5:151757858	T/A	cg08593883	chr5:151785301	NMUR2	-0.45	-6.91	-0.31	1.58e-11	Optic nerve measurement (cup area);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23825981	chr20:60982038	CABLES2	0.46	6.95	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	cis	rs2051773	0.567	rs12794156	chr11:17063005	G/C	cg15432903	chr11:17409602	KCNJ11	-0.5	-7.45	-0.33	4.66e-13	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg04989706	chr14:50066350	PPIL5	-0.58	-9.22	-0.39	1.04e-18	Carotid intima media thickness;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg16270222	chr17:41446396	NA	-0.31	-7.41	-0.33	5.91e-13	Menopause (age at onset);
LGG	cis	rs7584262	0.740	rs13401256	chr2:42245188	G/A	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	3.03e-11	Bone mineral density;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg00106254	chr7:1943704	MAD1L1	0.44	7.58	0.33	1.89e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg06521331	chr12:34319734	NA	-0.45	-7.71	-0.34	7.97e-14	Heart rate;
LGG	cis	rs6594499	0.872	rs1379298	chr5:110435726	T/C	cg04022379	chr5:110408740	TSLP	0.42	7.7	0.34	8.23e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	trans	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.75	0.64	3.64e-54	Exhaled nitric oxide output;
LGG	cis	rs7760949	0.889	rs9475806	chr6:13934527	A/G	cg27413430	chr6:13925136	RNF182	0.49	7.32	0.32	1.07e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg11366901	chr6:160182831	ACAT2	1.06	16.49	0.61	2.24e-48	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17166499	0.634	rs73064133	chr7:12846220	A/C	cg12945054	chr7:12841881	NA	-0.68	-7.49	-0.33	3.58e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.59	-0.37	1.36e-16	Cognitive function;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.06	-0.49	2.67e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg17330251	chr7:94953956	PON1	-0.44	-8.55	-0.37	1.78e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.52	-0.5	3.58e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg01673284	chr16:4527211	HMOX2	-0.36	-7.06	-0.31	6.09e-12	Schizophrenia;
LGG	cis	rs1538970	0.781	rs12049503	chr1:46021556	G/T	cg05343316	chr1:45956843	TESK2	0.8	13.51	0.53	2.57e-35	Platelet count;
LGG	cis	rs25645	0.760	rs11870683	chr17:38129841	T/A	cg17467752	chr17:38218738	THRA	-0.57	-9.34	-0.4	4.22e-19	Myeloid white cell count;
LGG	cis	rs2862064	0.872	rs2902132	chr5:156445525	C/T	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.79	-0.45	2.21e-24	Platelet count;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs6076339	chr20:25348712	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.37	-0.43	8.77e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg23029597	chr12:123009494	RSRC2	-0.95	-18.14	-0.64	6.16e-56	Body mass index;
LGG	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.58e-45	Morning vs. evening chronotype;
LGG	cis	rs68170813	0.559	rs75672288	chr7:107031549	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.46	-0.44	4.04e-23	Coronary artery disease;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	7.34	0.32	9.43e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg12011299	chr4:100065546	ADH4	0.39	7.57	0.33	1.97e-13	Alcohol dependence;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg16507663	chr6:150244633	RAET1G	0.42	7.66	0.34	1.1e-13	Lung cancer;
LGG	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg08603382	chr10:743973	NA	-0.4	-7.16	-0.32	3.16e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11866815	0.649	rs12921862	chr16:381927	C/A	cg07915516	chr16:377344	AXIN1	-0.48	-11.06	-0.46	2.24e-25	Body mass index;
LGG	cis	rs17253792	0.822	rs10083431	chr14:56068348	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs1878931	0.582	rs27231	chr16:3434966	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	11.38	0.47	1.27e-26	Body mass index (adult);
LGG	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.86	-9.97	-0.42	2.53e-21	Diabetic retinopathy;
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg07978099	chr16:83986941	OSGIN1	0.7	13.93	0.54	4.35e-37	Pursuit maintenance gain;
LGG	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	10.69	0.44	5.47e-24	Pancreatic cancer;
LGG	cis	rs537930	0.925	rs538853	chr5:134348825	G/A	cg24576358	chr5:134350122	NA	0.46	9.32	0.4	4.76e-19	Height;
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1983891	1.000	rs9381080	chr6:41527698	G/C	cg20194872	chr6:41519635	FOXP4	0.58	9.86	0.42	6.09e-21	Prostate cancer;
LGG	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.47e-11	Type 2 diabetes;
LGG	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03576123	chr11:487126	PTDSS2	1.25	16.84	0.62	5.75e-50	Body mass index;
LGG	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15596359	chr8:11213517	TDH	0.41	8.4	0.36	5.4e-16	Retinal vascular caliber;
LGG	cis	rs6456156	0.819	rs4709148	chr6:167521676	T/C	cg07741184	chr6:167504864	NA	0.32	7.02	0.31	7.77e-12	Primary biliary cholangitis;
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.59e-11	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19717773	chr7:2847554	GNA12	-0.36	-8.31	-0.36	1.1e-15	Height;
LGG	cis	rs17767392	0.881	rs35054229	chr14:71785202	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.08	-0.39	3.23e-18	Mitral valve prolapse;
LGG	cis	rs193541	0.593	rs246309	chr5:122269719	A/C	cg19412675	chr5:122181750	SNX24	0.55	8.97	0.38	7.19e-18	Glucose homeostasis traits;
LGG	cis	rs365132	0.875	rs2962842	chr5:176338955	A/G	cg16309518	chr5:176445507	NA	-0.51	-11.17	-0.46	8.44e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4824093	0.610	rs73441745	chr22:50237606	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.76	-0.3	4.09e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17257554	chr2:242004824	SNED1	0.46	8.39	0.36	6.09e-16	Electrocardiographic conduction measures;
LGG	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05665937	chr4:1216051	CTBP1	0.54	9.92	0.42	3.61e-21	Obesity-related traits;
LGG	trans	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg18187862	chr3:45730750	SACM1L	0.65	10.78	0.45	2.61e-24	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.2	0.39	1.25e-18	Diabetic retinopathy;
LGG	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs3820068	0.581	rs56128111	chr1:15928948	T/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	trans	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17712092	chr4:129076599	LARP1B	0.75	14.51	0.56	1.32e-39	Eosinophil percentage of white cells;
LGG	cis	rs8008758	0.517	rs1772024	chr14:101695220	A/C	cg26224664	chr14:101693935	NA	0.85	20.16	0.68	2.29e-65	Body mass index (alcohol intake interaction);
LGG	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg18856731	chr12:58011764	NA	-0.33	-6.7	-0.3	6.23e-11	Multiple sclerosis;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.58e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18531175	chr5:43483681	C5orf28	-0.48	-8.46	-0.37	3.49e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	21.13	0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg02753203	chr1:228287806	NA	-0.64	-11.58	-0.47	2.03e-27	Diastolic blood pressure;
LGG	trans	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg19894588	chr14:64061835	NA	-0.61	-9.26	-0.4	7.42e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3761218	1.000	rs3761218	chr20:3776175	A/G	cg25011176	chr20:3776985	CDC25B	0.47	7.42	0.33	5.68e-13	Bipolar disorder;
LGG	cis	rs367943	0.698	rs13167361	chr5:112961789	C/G	cg12552261	chr5:112820674	MCC	0.53	9.6	0.41	5.04e-20	Type 2 diabetes;
LGG	cis	rs977987	0.806	rs72787160	chr16:75445162	G/C	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg22920501	chr2:26401640	FAM59B	-0.39	-7.76	-0.34	5.59e-14	Gut microbiome composition (summer);
LGG	cis	rs3762637	0.943	rs10439995	chr3:122189160	C/A	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg09873164	chr1:152488093	CRCT1	0.63	15.67	0.59	1e-44	Hair morphology;
LGG	cis	rs11064837	0.523	rs7967558	chr12:120097006	T/G	cg25937854	chr12:120150414	CIT	-0.68	-11.27	-0.46	3.5e-26	Schizophrenia;
LGG	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg05973401	chr12:123451056	ABCB9	-0.45	-6.66	-0.3	8.02e-11	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs3126085	0.935	rs6675889	chr1:152213066	G/A	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs490234	0.702	rs4838274	chr9:128345994	C/A	cg14078157	chr9:128172775	NA	-0.55	-10.25	-0.43	2.42e-22	Mean arterial pressure;
LGG	cis	rs9944715	1.000	rs9963843	chr18:43842618	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.73	-0.3	4.98e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg15596359	chr8:11213517	TDH	-0.41	-8.37	-0.36	7.11e-16	Retinal vascular caliber;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg04287289	chr16:89883240	FANCA	0.91	8.63	0.37	1e-16	Skin colour saturation;
LGG	trans	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.68	0.63	7.72e-54	Exhaled nitric oxide output;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09238957	chr16:46723420	ORC6L;VPS35	0.4	7.09	0.31	4.92e-12	Obesity-related traits;
LGG	cis	rs9321453	1.000	rs9321453	chr6:134773554	T/C	cg08754004	chr6:134775465	NA	-0.46	-6.72	-0.3	5.47e-11	Urate levels;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg14416269	chr4:6271139	WFS1	-0.52	-9.51	-0.4	1.06e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg01864069	chr14:103024347	NA	0.67	9.48	0.4	1.37e-19	Platelet count;
LGG	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs10493773	0.775	rs2069208	chr1:86117583	T/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-11.81	-0.48	2.55e-28	Urate levels in overweight individuals;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg16507663	chr6:150244633	RAET1G	0.43	8.09	0.35	5.25e-15	Lung cancer;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.68	-12.65	-0.51	9.91e-32	Lymphocyte counts;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03452623	chr4:187889614	NA	-1.04	-30.18	-0.81	1.97e-111	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs787274	0.850	rs1324931	chr9:115634282	A/G	cg13803584	chr9:115635662	SNX30	0.52	7.01	0.31	8.66e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg23649088	chr2:200775458	C2orf69	0.58	6.94	0.31	1.35e-11	Schizophrenia;
LGG	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg11887960	chr12:57824829	NA	0.54	6.65	0.3	8.49e-11	Obesity-related traits;
LGG	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.03	0.31	7.34e-12	Neuroticism;
LGG	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.15	-0.35	3.39e-15	Coronary artery disease;
LGG	cis	rs9807989	0.507	rs4479442	chr2:103054074	A/T	cg03938978	chr2:103052716	IL18RAP	0.42	9.72	0.41	1.88e-20	Asthma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00431236	chr2:264988	ACP1;SH3YL1	-0.41	-7.0	-0.31	9.07e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.83	0.34	3.46e-14	Lung cancer;
LGG	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg09048205	chr5:1608656	LOC728613	-0.53	-8.54	-0.37	1.88e-16	Breast cancer;
LGG	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.07	0.42	1.04e-21	Motion sickness;
LGG	trans	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.67	0.41	2.96e-20	Mean corpuscular volume;
LGG	trans	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.25	-0.36	1.63e-15	Blood trace element (Cu levels);
LGG	cis	rs9443645	0.869	rs6926537	chr6:79554193	T/A	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6580649	0.771	rs1034762	chr12:48389643	G/T	cg24011408	chr12:48396354	COL2A1	-0.6	-7.27	-0.32	1.5e-12	Lung cancer;
LGG	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg14703610	chr5:56206110	C5orf35	0.45	7.86	0.34	2.63e-14	Coronary artery disease;
LGG	trans	rs8129326	0.685	rs9980888	chr21:35792223	A/G	cg07474852	chr4:123073612	NA	0.48	8.63	0.37	9.9900000000000006e-17	Cancer;
LGG	cis	rs2282802	0.685	rs7730245	chr5:139628163	C/A	cg26211634	chr5:139558579	C5orf32	0.34	7.35	0.32	8.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12912251	1.000	rs12912251	chr15:38986368	G/T	cg01338139	chr15:38987640	C15orf53	-0.56	-9.08	-0.39	3.21e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg14829155	chr15:31115871	NA	-0.56	-8.47	-0.37	3.22e-16	Huntington's disease progression;
LGG	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg14346243	chr4:90757452	SNCA	0.33	6.67	0.3	7.16e-11	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.34	-0.32	9.48e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs793571	0.590	rs17190727	chr15:59073790	C/A	cg05156742	chr15:59063176	FAM63B	0.6	10.24	0.43	2.51e-22	Schizophrenia;
LGG	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17712092	chr4:129076599	LARP1B	0.75	14.21	0.55	2.87e-38	Eosinophil percentage of white cells;
LGG	cis	rs919433	0.679	rs7600862	chr2:198534514	C/T	cg00792783	chr2:198669748	PLCL1	0.55	9.06	0.39	3.71e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1620921	1.000	rs1621801	chr6:161196966	A/C	cg01280913	chr6:161186852	NA	-0.32	-6.68	-0.3	6.88e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg14675211	chr2:100938903	LONRF2	0.49	8.02	0.35	8.88e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2346177	0.875	rs2166745	chr2:46646879	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.29	-0.43	1.68e-22	HDL cholesterol;
LGG	cis	rs1124376	0.748	rs6771367	chr3:20160266	A/T	cg05072819	chr3:20081367	KAT2B	0.6	8.02	0.35	8.59e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs66716358	0.676	rs1869481	chr11:44319905	T/C	cg16977035	chr11:44330474	ALX4	-0.37	-9.42	-0.4	2.22e-19	Monobrow;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg20308403	chr7:2120281	MAD1L1	0.34	7.38	0.32	7.59e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.21	0.75	2.93e-84	Chronic sinus infection;
LGG	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.3	-0.32	1.29e-12	Initial pursuit acceleration;
LGG	cis	rs6723226	0.699	rs805830	chr2:32501475	T/C	cg02381751	chr2:32503542	YIPF4	0.68	11.2	0.46	6.03e-26	Intelligence (multi-trait analysis);
LGG	trans	rs17685	0.633	rs3801471	chr7:75696188	T/G	cg19862616	chr7:65841803	NCRNA00174	1.06	25.46	0.76	4.66e-90	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg12560992	chr17:57184187	TRIM37	0.89	15.78	0.59	3.41e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2953145	0.545	rs2975755	chr2:241524919	G/A	cg07929629	chr2:241523174	NA	0.63	11.04	0.46	2.6e-25	Bipolar disorder;
LGG	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.6	-0.56	5.8e-40	Schizophrenia;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg12070911	chr6:150209640	RAET1E	0.28	6.79	0.3	3.52e-11	Lung cancer;
LGG	cis	rs7250872	0.568	rs12462721	chr19:1842884	G/A	cg18850929	chr19:1828978	REXO1	0.49	7.87	0.34	2.51e-14	Bipolar disorder;
LGG	cis	rs12220238	0.841	rs10824161	chr10:76133762	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.7	-8.86	-0.38	1.69e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg20607798	chr8:58055168	NA	0.69	8.05	0.35	6.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10895140	0.756	rs2226559	chr11:101518016	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.78	-0.3	3.62e-11	Menarche (age at onset);
LGG	cis	rs9527	0.830	rs10883790	chr10:104640955	A/C	cg04362960	chr10:104952993	NT5C2	0.58	10.16	0.43	4.97e-22	Arsenic metabolism;
LGG	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg04287289	chr16:89883240	FANCA	0.55	10.14	0.43	5.95e-22	Vitiligo;
LGG	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg02975922	chr3:195473998	MUC4	-0.53	-8.73	-0.38	4.64e-17	Pancreatic cancer;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg18350739	chr11:68623251	NA	-0.86	-22.25	-0.72	3.92e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg07061783	chr6:25882402	NA	0.45	7.86	0.34	2.71e-14	Blood metabolite levels;
LGG	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.83	-0.48	2.16e-28	Mean platelet volume;
LGG	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg07943548	chr15:86304357	KLHL25	0.32	6.64	0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2455799	0.613	rs4684259	chr3:15791279	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg05729581	chr11:3078854	CARS	-0.55	-9.67	-0.41	2.79e-20	Longevity;
LGG	cis	rs10193935	0.901	rs3088290	chr2:42578143	A/G	cg27598129	chr2:42591480	NA	-0.66	-9.76	-0.41	1.4e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg20120463	chr17:44301886	NA	-0.42	-6.66	-0.3	7.83e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.38	0.53	9.69e-35	Colorectal cancer;
LGG	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg25173405	chr17:45401733	C17orf57	0.48	8.47	0.37	3.38e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs72781680	0.752	rs55801864	chr2:23922325	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.21	0.39	1.11e-18	Lymphocyte counts;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg05335186	chr13:53173507	NA	0.52	11.24	0.46	4.23e-26	Lewy body disease;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg05335186	chr13:53173507	NA	0.4	7.57	0.33	2e-13	Lewy body disease;
LGG	cis	rs2905347	0.520	rs2905309	chr7:22648542	C/T	cg23521230	chr7:22704884	NA	0.54	10.07	0.42	1.04e-21	Major depression and alcohol dependence;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	8.17	0.36	2.88e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs244899	0.935	rs2432643	chr5:167925030	G/T	cg06604206	chr5:167912465	RARS	-0.53	-11.76	-0.48	4.16e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6740322	0.895	rs6544643	chr2:43560072	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-10.03	-0.42	1.45e-21	Coronary artery disease;
LGG	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26897989	chr16:1907736	C16orf73	0.81	13.41	0.53	7.12e-35	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg06623630	chr22:50017776	C22orf34	-0.45	-8.91	-0.38	1.21e-17	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg00149659	chr3:10157352	C3orf10	0.59	8.45	0.37	3.81e-16	Alzheimer's disease;
LGG	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg02002194	chr4:3960332	NA	-0.38	-6.83	-0.3	2.7e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7020830	0.931	rs13297576	chr9:37142189	A/C	cg14294708	chr9:37120828	ZCCHC7	1.2	36.32	0.86	1.28e-137	Schizophrenia;
LGG	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg05333889	chr7:157238977	NA	-0.58	-11.62	-0.48	1.5e-27	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg06808227	chr14:105710500	BRF1	0.6	11.21	0.46	5.95e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg03036210	chr16:89904091	SPIRE2	-0.55	-7.34	-0.32	9.75e-13	Skin colour saturation;
LGG	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg27490568	chr2:178487706	NA	0.51	10.09	0.42	9.12e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg06885757	chr1:42089581	HIVEP3	-0.67	-15.52	-0.59	4.64e-44	Airway imaging phenotypes;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs11122272	0.735	rs973252	chr1:231520802	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.06	0.42	1.15e-21	Cognitive ability;
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.57e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4742903	0.935	rs726203	chr9:106906437	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.42	0.36	4.86e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.62	-0.48	1.48e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.21	0.32	2.35e-12	Prudent dietary pattern;
LGG	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.78	-0.3	3.58e-11	Neuroticism;
LGG	cis	rs11700980	0.551	rs73898412	chr21:30118790	T/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.69	-0.3	6.66e-11	QRS complex (12-leadsum);
LGG	cis	rs3924048	0.574	rs11121928	chr1:12615888	C/G	cg00291366	chr1:12616550	NA	0.37	8.9	0.38	1.26e-17	Optic cup area;
LGG	trans	rs800082	0.690	rs2118001	chr3:144336609	T/C	cg24215973	chr2:240111563	HDAC4	-0.63	-12.06	-0.49	2.49e-29	Smoking behavior;
LGG	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.58e-15	Retinal vascular caliber;
LGG	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.61	-7.9	-0.34	2.06e-14	Smoking behavior;
LGG	cis	rs2470578	0.792	rs2596645	chr3:17296356	T/C	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.4e-11	Schizophrenia;
LGG	cis	rs897984	0.513	rs17839568	chr16:31099783	T/C	cg00531865	chr16:30841666	NA	-0.48	-10.14	-0.43	5.93e-22	Dementia with Lewy bodies;
LGG	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg11984989	chr7:158649758	WDR60	1.0	13.79	0.54	1.81e-36	Height;
LGG	cis	rs9467160	0.834	rs9467172	chr6:24455175	A/G	cg20631270	chr6:24437470	GPLD1	0.54	8.1	0.35	4.98e-15	Liver enzyme levels;
LGG	cis	rs10991814	1.000	rs77983835	chr9:93956086	C/T	cg14446406	chr9:93919335	NA	-0.77	-8.43	-0.36	4.33e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg20573242	chr4:122745356	CCNA2	0.54	10.14	0.43	5.99e-22	Type 2 diabetes;
LGG	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg18854424	chr1:2615690	NA	-0.35	-7.17	-0.32	2.97e-12	Ulcerative colitis;
LGG	cis	rs2235649	0.828	rs9938694	chr16:1849872	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.16e-11	Blood metabolite levels;
LGG	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg20302533	chr7:39170763	POU6F2	0.48	11.45	0.47	6.7399999999999993e-27	IgG glycosylation;
LGG	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg01448562	chr3:133502909	NA	-0.52	-8.7	-0.37	5.9e-17	Iron status biomarkers;
LGG	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg09696939	chr10:60272079	BICC1	0.36	6.96	0.31	1.17e-11	Refractive error;
LGG	cis	rs12493885	0.697	rs55681402	chr3:153659873	G/A	cg17054900	chr3:154042577	DHX36	-0.8	-9.31	-0.4	5.02e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.28	0.63	5.61e-52	Chronic sinus infection;
LGG	cis	rs36071027	0.554	rs34366240	chr5:158425013	C/A	cg07810726	chr5:158524649	EBF1	0.38	6.78	0.3	3.67e-11	Carotid intima media thickness;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2862064	1.000	rs2055429	chr5:156455113	C/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-9.37	-0.4	3.22e-19	Platelet count;
LGG	cis	rs981844	0.712	rs10009854	chr4:154741785	C/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23544223	chr18:12777786	NA	-0.54	-7.93	-0.35	1.64e-14	Inflammatory skin disease;
LGG	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg05784532	chr1:230284198	GALNT2	0.51	9.05	0.39	3.84e-18	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs62238980	0.614	rs77696994	chr22:32390280	C/T	cg02631450	chr22:32366979	NA	0.97	8.48	0.37	3e-16	Childhood ear infection;
LGG	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg17294928	chr15:75287854	SCAMP5	0.6	11.19	0.46	6.56e-26	Breast cancer;
LGG	cis	rs12956009	0.583	rs9653018	chr18:44895853	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.45	0.33	4.72e-13	Educational attainment (years of education);
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg03188948	chr7:1209495	NA	0.49	7.84	0.34	3.11e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17067123	0.614	rs6813463	chr4:180068739	A/T	cg26610307	chr4:180072759	NA	-0.48	-6.79	-0.3	3.47e-11	Response to hepatitis C treatment;
LGG	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg23625390	chr15:77176239	SCAPER	0.48	9.27	0.4	7.23e-19	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg08621203	chr6:150244597	RAET1G	0.45	7.66	0.34	1.09e-13	Lung cancer;
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21014159	chr11:117668035	DSCAML1	0.48	7.33	0.32	1.07e-12	Myopia;
LGG	cis	rs12643440	0.538	rs2314601	chr4:17139932	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.81	-0.45	1.97e-24	Hemoglobin concentration;
LGG	trans	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.39e-11	Depression;
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.9	0.7	8.53e-69	Platelet count;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.72	-13.12	-0.52	1.22e-33	Lymphocyte counts;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01570182	chr17:44337453	NA	0.71	11.89	0.48	1.27e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.18e-14	Restless legs syndrome;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04022019	chr8:104427717	DCAF13;SLC25A32	0.38	6.89	0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.6	-7.16	-0.32	3.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15355387	chr3:85007817	CADM2	0.44	7.46	0.33	4.27e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.91	-0.31	1.66e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs910187	0.596	rs6066222	chr20:45801917	G/A	cg27589058	chr20:45804311	EYA2	-0.38	-10.15	-0.43	5.53e-22	Migraine;
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg11584989	chr19:19387371	SF4	-0.42	-7.51	-0.33	3.1e-13	Tonsillectomy;
LGG	cis	rs2201728	1.000	rs6818892	chr4:100158920	G/C	cg07219303	chr4:100140905	ADH6	-0.42	-8.35	-0.36	8.24e-16	Cardiac Troponin-T levels;
LGG	trans	rs6825911	0.638	rs2348214	chr4:111369566	T/G	cg10580549	chr19:53101634	ZNF137	0.55	6.97	0.31	1.13e-11	Blood pressure;
LGG	cis	rs12908161	0.959	rs62019472	chr15:85331493	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.22	0.32	2.22e-12	Schizophrenia;
LGG	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg25986240	chr4:9926439	SLC2A9	0.39	7.72	0.34	7.28e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7814319	0.674	rs2643339	chr8:97246978	C/A	cg20787634	chr8:97240163	UQCRB	-0.68	-14.01	-0.55	1.9e-37	Lung function (FVC);
LGG	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.61	-15.81	-0.59	2.44e-45	Multiple sclerosis;
LGG	cis	rs11920090	0.789	rs73169738	chr3:170747095	A/G	cg09710316	chr3:170744871	SLC2A2	0.7	8.5	0.37	2.54e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg12486710	chr1:178512616	C1orf220	0.49	10.19	0.43	3.99e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg11062466	chr8:58055876	NA	0.51	8.24	0.36	1.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs7937890	0.559	rs2575838	chr11:14498221	C/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs9487094	0.961	rs11153171	chr6:109653825	C/T	cg16315928	chr6:109776240	MICAL1	0.43	7.23	0.32	2e-12	Height;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04696559	chr5:36152378	SKP2;LMBRD2	0.39	7.0	0.31	9.31e-12	Obesity-related traits;
LGG	trans	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.46	0.33	4.35e-13	Mood instability;
LGG	cis	rs11225247	1.000	rs116917439	chr11:102314742	A/G	cg06323957	chr11:102217781	BIRC2	0.77	6.72	0.3	5.38e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.98	0.42	2.17e-21	Height;
LGG	cis	rs4330281	0.608	rs4484221	chr3:17702593	C/G	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg24675658	chr1:53192096	ZYG11B	0.62	13.32	0.53	1.64e-34	Monocyte count;
LGG	cis	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg10587741	chr22:38071170	LGALS1	-0.33	-6.71	-0.3	5.6e-11	Glioblastoma;Glioma;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg19554555	chr3:13937349	NA	-0.57	-10.2	-0.43	3.5e-22	Ovarian reserve;
LGG	cis	rs9357271	0.696	rs62397050	chr6:38405652	T/C	cg07362130	chr6:38359646	BTBD9	-0.41	-8.3	-0.36	1.18e-15	Restless legs syndrome;
LGG	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.38	8.02	0.35	8.72e-15	Obesity-related traits;
LGG	cis	rs4948102	0.642	rs4948104	chr7:56142519	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.4	7.04	0.31	7.11e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs981844	0.848	rs17279789	chr4:154643245	T/C	cg14289246	chr4:154710475	SFRP2	0.67	10.71	0.45	4.71e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs8017423	0.647	rs11623736	chr14:90746471	G/T	cg04374321	chr14:90722782	PSMC1	-0.86	-17.48	-0.63	6.73e-53	Mortality in heart failure;
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg08677398	chr8:58056175	NA	0.45	7.45	0.33	4.76e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg08302650	chr8:145750040	LRRC24;LRRC14	-0.37	-8.37	-0.36	6.75e-16	Age at first birth;
LGG	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08109568	chr15:31115862	NA	0.62	10.47	0.44	3.73e-23	Huntington's disease progression;
LGG	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg20290983	chr6:43655470	MRPS18A	1.08	23.54	0.74	3.62e-81	IgG glycosylation;
LGG	cis	rs3849046	0.781	rs10070909	chr5:137916793	G/T	cg10920316	chr5:137946599	NA	0.43	6.86	0.3	2.2e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg06606381	chr12:133084897	FBRSL1	-1.29	-11.24	-0.46	4.47e-26	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.73	0.41	1.81e-20	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg08999081	chr20:33150536	PIGU	0.3	6.92	0.31	1.54e-11	Coronary artery disease;
LGG	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg00383909	chr3:49044727	WDR6	0.44	7.1	0.31	4.59e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.26	-0.63	6.46e-52	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18206459	chr2:208030726	KLF7	0.53	8.1	0.35	4.96e-15	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.27	-0.32	1.59e-12	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19370980	chr7:94537747	PPP1R9A	0.42	6.65	0.3	8.12e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-11.29	-0.46	2.77e-26	Morning vs. evening chronotype;
LGG	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs67478160	0.654	rs11628240	chr14:104218135	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.8e-13	Schizophrenia;
LGG	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg04743876	chr7:130013617	NA	0.37	8.56	0.37	1.66e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	32.95	0.84	1.74e-123	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19793034	chr4:1284190	MAEA	0.51	7.86	0.34	2.78e-14	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27597069	chr6:37321822	RNF8	0.48	8.05	0.35	7.29e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs72634258	0.796	rs6703955	chr1:8165975	C/G	cg00042356	chr1:8021962	PARK7	-0.5	-7.06	-0.31	5.98e-12	Inflammatory bowel disease;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.93	-0.42	3.34e-21	Bipolar disorder;
LGG	cis	rs74417235	0.684	rs71590150	chr5:154060512	A/T	cg08754654	chr5:154026448	NA	0.47	9.26	0.4	7.53e-19	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6694672	1.000	rs7541429	chr1:197099485	A/G	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.74e-12	Asthma;
LGG	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.1	-0.35	4.86e-15	Joint mobility (Beighton score);
LGG	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg14703610	chr5:56206110	C5orf35	0.42	7.25	0.32	1.79e-12	Breast cancer;Breast cancer (early onset);
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg14926445	chr8:58193284	C8orf71	-0.71	-9.28	-0.4	6.75e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2131877	0.913	rs950256	chr3:194847752	C/T	cg07250128	chr3:194833983	C3orf21	0.4	7.44	0.33	5e-13	Non-small cell lung cancer;
LGG	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg23625390	chr15:77176239	SCAPER	-0.72	-14.29	-0.55	1.18e-38	Blood metabolite levels;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.19	0.32	2.62e-12	Height;
LGG	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg22920501	chr2:26401640	FAM59B	-0.41	-7.99	-0.35	1.11e-14	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg13047869	chr3:10149882	C3orf24	0.47	7.66	0.34	1.06e-13	Alzheimer's disease;
LGG	cis	rs758324	0.947	rs4705835	chr5:131116899	T/C	cg06307176	chr5:131281290	NA	0.57	9.47	0.4	1.47e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.68	0.34	9.29e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs926392	0.896	rs742276	chr20:37679849	C/T	cg16355469	chr20:37678765	NA	0.47	7.84	0.34	3.12e-14	Dialysis-related mortality;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00689492	chr4:1303491	MAEA	-0.44	-7.42	-0.33	5.58e-13	Obesity-related traits;
LGG	trans	rs11782517	0.920	rs4258008	chr8:10115960	T/C	cg02002194	chr4:3960332	NA	-0.45	-6.79	-0.3	3.55e-11	Nose size;
LGG	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.69	0.34	8.62e-14	Nonalcoholic fatty liver disease;
LGG	trans	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg03929089	chr4:120376271	NA	-0.63	-7.42	-0.33	5.7e-13	Intraocular pressure;
LGG	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	8.85	0.38	1.86e-17	Bipolar disorder;
LGG	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6693567	0.545	rs7411534	chr1:150447269	C/T	cg15654264	chr1:150340011	RPRD2	0.32	6.67	0.3	7.15e-11	Migraine;
LGG	cis	rs3742264	0.656	rs9534263	chr13:46541450	C/T	cg15192986	chr13:46630673	CPB2	-0.36	-6.88	-0.3	1.98e-11	Blood protein levels;
LGG	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg15208524	chr1:10270712	KIF1B	0.46	7.89	0.34	2.22e-14	Hepatocellular carcinoma;
LGG	trans	rs2574985	0.813	rs1203403	chr10:52199188	A/T	cg18558237	chr10:81444220	LOC650623	0.44	6.71	0.3	5.59e-11	Subjective well-being;
LGG	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg09048205	chr5:1608656	LOC728613	0.42	7.17	0.32	2.92e-12	Breast cancer;
LGG	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg05425664	chr17:57184151	TRIM37	-0.45	-7.17	-0.32	2.98e-12	Testicular germ cell tumor;
LGG	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg14829360	chr17:73884958	NA	-0.52	-9.99	-0.42	2.02e-21	White matter hyperintensity burden;
LGG	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg24006582	chr15:45444508	DUOX1	-0.7	-13.56	-0.53	1.59e-35	Uric acid levels;
LGG	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg25801113	chr15:45476975	SHF	0.87	19.83	0.68	8.4e-64	Uric acid levels;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	9.09e-16	Personality dimensions;
LGG	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.16e-13	Dupuytren's disease;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18766912	chr15:25683909	UBE3A	0.48	8.08	0.35	5.58e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00142150	chr22:38071001	LGALS1	0.92	19.75	0.68	1.93e-63	Fat distribution (HIV);
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg08621203	chr6:150244597	RAET1G	-0.41	-6.9	-0.31	1.7e-11	Lung cancer;
LGG	cis	rs7940866	0.838	rs1991898	chr11:130801786	C/G	cg12179176	chr11:130786555	SNX19	-0.77	-15.01	-0.57	8.4e-42	Schizophrenia;
LGG	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg12046867	chr14:103022105	NA	0.74	12.2	0.49	7.05e-30	Platelet count;
LGG	cis	rs7565124	0.818	rs13415152	chr2:20233345	G/A	cg24657347	chr2:20261756	NA	-0.62	-9.97	-0.42	2.51e-21	Major depressive disorder;
LGG	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg24585782	chr17:78113791	EIF4A3	0.35	6.88	0.3	1.93e-11	Yeast infection;
LGG	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg25237894	chr2:233734115	C2orf82	-0.71	-15.14	-0.58	2.31e-42	Coronary artery disease;
LGG	trans	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg20587970	chr11:113659929	NA	-0.7	-11.15	-0.46	1e-25	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4356932	1.000	rs10017484	chr4:76984936	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.32	-0.5	2.26e-30	Alzheimer's disease;
LGG	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg02187348	chr16:89574699	SPG7	0.47	7.8	0.34	4.04e-14	Multiple myeloma (IgH translocation);
LGG	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.94	0.35	1.59e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.8e-22	Neutrophil percentage of white cells;
LGG	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg07636037	chr3:49044803	WDR6	-0.89	-14.59	-0.56	5.87e-40	Menarche (age at onset);
LGG	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	24.79	0.76	5.98e-87	IgG glycosylation;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12016809	chr21:47604291	C21orf56	0.49	8.21	0.36	2.16e-15	Testicular germ cell tumor;
LGG	trans	rs1032833	0.732	rs17363246	chr2:179983495	A/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs10513788	0.540	rs1542694	chr3:181982899	C/T	cg01449425	chr3:181957089	NA	0.41	7.67	0.34	1.01e-13	Cognitive function;
LGG	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg00426182	chr6:28072559	NA	0.98	7.27	0.32	1.5e-12	Hip circumference adjusted for BMI;
LGG	cis	rs36071027	0.593	rs11745589	chr5:158428274	A/T	cg23468002	chr5:158532401	NA	0.42	7.04	0.31	7.08e-12	Carotid intima media thickness;
LGG	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.9e-41	Vitiligo;
LGG	cis	rs975739	0.553	rs1970038	chr13:78580944	T/G	cg07847733	chr13:78271382	SLAIN1	0.44	7.62	0.33	1.43e-13	Hair color;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg13206674	chr6:150067644	NUP43	0.68	16.0	0.6	3.52e-46	Lung cancer;
LGG	cis	rs9863	0.828	rs12809473	chr12:124476599	T/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.99e-12	White blood cell count;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg15327641	chr2:3715039	ALLC	-0.32	-6.88	-0.3	1.97e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.901	rs11760293	chr7:148811725	A/G	cg23583168	chr7:148888333	NA	-0.87	-16.79	-0.62	9.3e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11635401	chr19:17322527	MYO9B	0.41	7.2	0.32	2.51e-12	Electrocardiographic conduction measures;
LGG	cis	rs5742933	0.857	rs10931430	chr2:190542186	T/C	cg04003228	chr2:190539410	ANKAR	-0.51	-7.52	-0.33	2.91e-13	Ferritin levels;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg19006130	chr11:118478252	PHLDB1	0.4	6.98	0.31	1.01e-11	Cholesterol, total;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05754148	chr16:3507555	NAT15	0.48	7.89	0.34	2.27e-14	Cognitive performance;
LGG	cis	rs977987	0.836	rs8055974	chr16:75470986	C/G	cg03315344	chr16:75512273	CHST6	0.5	10.01	0.42	1.8e-21	Dupuytren's disease;
LGG	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.45	-0.37	3.9e-16	Systolic blood pressure;
LGG	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	cg07245641	chr1:182991651	LAMC1	0.42	9.39	0.4	2.68e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.32	0.32	1.07e-12	Neuroticism;
LGG	cis	rs9944715	0.859	rs7236687	chr18:43736484	C/G	cg26436583	chr18:43649176	PSTPIP2	0.42	8.01	0.35	9.16e-15	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs4664308	0.840	rs1870102	chr2:161070582	A/G	cg03641300	chr2:160917029	PLA2R1	-0.75	-15.04	-0.57	6.8e-42	Idiopathic membranous nephropathy;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.81	-0.48	2.59e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs17767392	0.871	rs2108706	chr14:71799175	T/G	cg02058870	chr14:72053146	SIPA1L1	0.38	7.91	0.34	1.97e-14	Mitral valve prolapse;
LGG	cis	rs6952809	0.532	rs6952152	chr7:2440912	G/A	cg23289794	chr7:2394357	EIF3B	-0.8	-10.1	-0.42	8.62e-22	Multiple sclerosis;
LGG	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg11871910	chr12:69753446	YEATS4	0.76	15.93	0.59	7.52e-46	Blood protein levels;
LGG	cis	rs12360000	0.863	rs12360520	chr10:1912835	A/T	cg26364871	chr10:1889757	NA	-0.71	-13.43	-0.53	6.11e-35	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs11239187	0.586	rs2061970	chr10:45089486	G/A	cg03916630	chr10:45065415	NA	0.35	8.2	0.36	2.46e-15	Body mass index;
LGG	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg12463550	chr7:65579703	CRCP	-0.76	-8.39	-0.36	5.82e-16	Gout;
LGG	trans	rs34421088	0.506	rs2572426	chr8:11147123	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.84	-0.3	2.59e-11	Neuroticism;
LGG	cis	rs4917300	0.606	rs902822	chr8:143105435	T/C	cg06573787	chr8:143070187	NA	0.59	9.95	0.42	2.8e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg06886374	chr16:1844152	IGFALS	-0.46	-8.11	-0.35	4.63e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg24955955	chr5:415729	AHRR	0.81	10.9	0.45	8.86e-25	Fat distribution (HIV);
LGG	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4987668	0.708	rs10259499	chr7:142635850	G/A	cg19410471	chr7:142636507	C7orf34	0.5	8.02	0.35	8.88e-15	Cancer;
LGG	cis	rs4363385	0.693	rs821755	chr1:153036245	G/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg09904177	chr6:26538194	HMGN4	-0.67	-13.66	-0.54	6.14e-36	Intelligence (multi-trait analysis);
LGG	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs755249	0.567	rs3118014	chr1:39914090	G/A	cg18385671	chr1:39797026	MACF1	0.45	7.64	0.33	1.24e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg11764359	chr7:65958608	NA	-0.55	-9.44	-0.4	1.78e-19	Aortic root size;
LGG	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-7.59	-0.33	1.8e-13	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg01494348	chr8:144660395	NAPRT1	0.93	7.21	0.32	2.32e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg12379940	chr13:44947923	SERP2	0.46	6.75	0.3	4.5e-11	Hip circumference;
LGG	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-9.58	-0.41	5.94e-20	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg07701084	chr6:150067640	NUP43	0.69	12.04	0.49	3.06e-29	Lung cancer;
LGG	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg14088196	chr11:70211408	PPFIA1	0.82	11.22	0.46	5.36e-26	Coronary artery disease;
LGG	cis	rs1707322	0.716	rs28375469	chr1:46195375	T/C	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg26897989	chr16:1907736	C16orf73	-0.86	-13.96	-0.54	3.14e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg11766577	chr21:47581405	C21orf56	-0.49	-8.56	-0.37	1.74e-16	Testicular germ cell tumor;
LGG	cis	rs17767392	0.958	rs17767446	chr14:71820963	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.2	-0.39	1.24e-18	Mitral valve prolapse;
LGG	cis	rs7106204	0.609	rs11827033	chr11:24305935	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	10.01	0.42	1.74e-21	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.51	-0.37	2.43e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg03929089	chr4:120376271	NA	0.73	8.44	0.37	4.1e-16	Axial length;
LGG	cis	rs11630290	0.592	rs11071767	chr15:64154635	A/G	cg12036633	chr15:63758958	NA	-0.5	-7.21	-0.32	2.27e-12	Iris characteristics;
LGG	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.77	0.54	2.18e-36	Type 2 diabetes;
LGG	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	-0.47	-6.97	-0.31	1.07e-11	Cystic fibrosis severity;
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.48	-0.44	3.36e-23	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs1983891	0.908	rs2148342	chr6:41519522	G/A	cg20194872	chr6:41519635	FOXP4	0.61	10.53	0.44	2.24e-23	Prostate cancer;
LGG	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg22920501	chr2:26401640	FAM59B	-0.41	-8.05	-0.35	6.94e-15	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg22535103	chr8:58192502	C8orf71	-0.58	-9.68	-0.41	2.61e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4356932	1.000	rs4583787	chr4:76955069	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs74781061	1.000	rs74781061	chr15:74888196	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.37	-0.32	8.12e-13	Endometriosis;
LGG	cis	rs4417704	0.551	rs6753109	chr2:241877597	C/T	cg14055004	chr2:241860995	NA	-0.29	-7.56	-0.33	2.18e-13	Joint mobility (Beighton score);
LGG	cis	rs11023332	0.706	rs11023379	chr11:14929960	C/T	cg18937875	chr11:14930189	NA	-0.54	-9.18	-0.39	1.47e-18	Adiponectin levels;Vitamin D levels;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg21724239	chr8:58056113	NA	0.49	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.28	-0.36	1.29e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	cis	rs12431410	0.550	rs11848764	chr14:60224802	T/G	cg07950296	chr14:60194823	RTN1	-0.38	-7.29	-0.32	1.38e-12	Schizophrenia;
LGG	cis	rs12765878	0.967	rs7920217	chr10:105668172	C/T	cg11005552	chr10:105648138	OBFC1	1.04	27.3	0.79	1.66e-98	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.7	0.34	8.05e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg25042112	chr7:64838748	ZNF92	-0.47	-6.67	-0.3	7.33e-11	Pain;
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs1966248	0.543	rs4895991	chr6:134116003	C/T	cg25632230	chr6:134101081	NA	-0.35	-7.65	-0.33	1.19e-13	Coronary artery disease;
LGG	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.49	0.65	1.4e-57	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.09	-0.31	5.07e-12	Blood metabolite levels;
LGG	cis	rs4561483	0.771	rs7202234	chr16:11942322	A/G	cg08843971	chr16:11963173	GSPT1	0.6	14.94	0.57	1.71e-41	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04421424	chr19:57791681	ZNF460	0.42	6.8	0.3	3.22e-11	Gut microbiome composition (summer);
LGG	cis	rs10937275	1.000	rs35461422	chr3:186649678	A/G	cg13419791	chr3:186648285	ST6GAL1	0.79	8.09	0.35	5.42e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg15269541	chr15:43626905	ADAL	-0.4	-6.75	-0.3	4.37e-11	Lung cancer in ever smokers;
LGG	cis	rs6754311	0.517	rs1469996	chr2:136542560	A/G	cg07169764	chr2:136633963	MCM6	0.98	17.84	0.64	1.47e-54	Mosquito bite size;
LGG	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg13010199	chr12:38710504	ALG10B	0.57	10.72	0.45	4.24e-24	Morning vs. evening chronotype;
LGG	cis	rs981844	0.813	rs72731678	chr4:154671476	T/C	cg14289246	chr4:154710475	SFRP2	0.7	11.71	0.48	6.31e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs6460942	0.841	rs17444203	chr7:12461864	C/G	cg06484146	chr7:12443880	VWDE	0.36	7.04	0.31	7.04e-12	Coronary artery disease;
LGG	cis	rs4430311	0.688	rs4658590	chr1:243908796	A/T	cg25706552	chr1:244017396	NA	-0.65	-15.97	-0.6	4.55e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg00129232	chr17:37814104	STARD3	-0.59	-10.94	-0.45	6.08e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg11161011	chr14:65562177	MAX	-0.61	-11.63	-0.48	1.34e-27	Obesity-related traits;
LGG	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg10857441	chr5:6722123	POLS	-0.28	-6.89	-0.3	1.84e-11	Menopause (age at onset);
LGG	cis	rs240110	0.515	rs12530388	chr6:101329173	A/C	cg09795085	chr6:101329169	ASCC3	0.48	7.95	0.35	1.48e-14	Neuroticism;
LGG	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg01631408	chr1:248437212	OR2T33	-0.55	-10.0	-0.42	1.9e-21	Common traits (Other);
LGG	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14373873	chr11:113211441	TTC12	0.56	12.37	0.5	1.51e-30	Neuroticism;
LGG	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.69	-0.3	6.42e-11	Sudden cardiac arrest;
LGG	trans	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg25214090	chr10:38739885	LOC399744	0.56	10.23	0.43	2.76e-22	Corneal astigmatism;
LGG	cis	rs926938	0.563	rs360661	chr1:115455280	G/A	cg12756093	chr1:115239321	AMPD1	0.46	8.61	0.37	1.12e-16	Autism;
LGG	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg26031613	chr14:104095156	KLC1	-0.8	-14.36	-0.55	6.39e-39	Body mass index;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.62	-0.33	1.44e-13	Life satisfaction;
LGG	cis	rs701145	0.938	rs355780	chr3:153978289	C/T	cg17054900	chr3:154042577	DHX36	0.99	12.39	0.5	1.24e-30	Coronary artery disease;
LGG	trans	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.89	-0.38	1.4e-17	Bladder cancer;
LGG	trans	rs17807624	0.702	rs7815172	chr8:11453671	T/C	cg02002194	chr4:3960332	NA	-0.42	-7.43	-0.33	5.14e-13	Systemic lupus erythematosus;
LGG	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg22705602	chr4:152727874	NA	-0.32	-7.46	-0.33	4.39e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg05335186	chr13:53173507	NA	0.48	9.96	0.42	2.72e-21	Lewy body disease;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg00933542	chr6:150070202	PCMT1	0.37	6.87	0.3	2.07e-11	Lung cancer;
LGG	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	13.81	0.54	1.42e-36	Mean platelet volume;
LGG	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg05308233	chr10:104796373	CNNM2	0.3	6.81	0.3	3.04e-11	Arsenic metabolism;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg02951883	chr7:2050386	MAD1L1	-0.72	-13.92	-0.54	4.63e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg21479132	chr6:26055353	NA	0.74	7.29	0.32	1.34e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2282300	0.739	rs10742237	chr11:30310659	C/T	cg25418670	chr11:30344373	C11orf46	0.56	7.9	0.34	2e-14	Morning vs. evening chronotype;
LGG	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.97	-0.31	1.09e-11	Lung cancer;
LGG	cis	rs4846580	0.660	rs4846577	chr1:219897707	T/A	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	cis	rs9443645	0.808	rs9361484	chr6:79758218	C/A	cg18132916	chr6:79620363	NA	-0.31	-8.33	-0.36	9.01e-16	Intelligence (multi-trait analysis);
LGG	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg13010199	chr12:38710504	ALG10B	0.44	8.55	0.37	1.81e-16	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.71	-0.41	2.05e-20	Retinal vascular caliber;
LGG	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg22732515	chr19:44031385	ETHE1	0.54	9.42	0.4	2.2e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg19168338	chr16:4465731	CORO7	-1.13	-25.25	-0.76	4.36e-89	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.63	-0.41	3.82e-20	Life satisfaction;
LGG	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs9733	0.744	rs12758227	chr1:150844583	C/A	cg13175981	chr1:150552382	MCL1	0.53	8.58	0.37	1.43e-16	Tonsillectomy;
LGG	cis	rs9783347	1.000	rs4150622	chr11:18365710	A/G	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.17	-0.32	3.01e-12	Pancreatic cancer;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg01988459	chr11:68622903	NA	0.63	12.78	0.51	3.03e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9815354	0.812	rs73077359	chr3:41850016	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	5.92e-13	HDL cholesterol;
LGG	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg08807101	chr21:30365312	RNF160	-0.58	-7.97	-0.35	1.27e-14	Cognitive test performance;
LGG	cis	rs10504130	0.569	rs12681734	chr8:52806195	T/A	cg22653915	chr8:52722023	PXDNL	-0.43	-6.89	-0.3	1.83e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9814567	0.555	rs1498726	chr3:134167300	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.55	9.78	0.41	1.15e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	11.95	0.49	7.28e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7011049	1.000	rs79169015	chr8:53843908	C/T	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg12011299	chr4:100065546	ADH4	0.4	7.86	0.34	2.79e-14	Smoking initiation;
LGG	cis	rs4268898	0.662	rs9784114	chr2:24437517	C/T	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	8.66	0.37	8.02e-17	Bipolar disorder;
LGG	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.81	0.3	3.1e-11	Carotid intima media thickness;
LGG	cis	rs911263	0.603	rs12881502	chr14:68783791	A/C	cg18825221	chr14:68749962	RAD51L1	0.38	8.38	0.36	6.5e-16	Primary biliary cholangitis;
LGG	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.22e-12	Neuroticism;
LGG	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.56	-0.44	1.68e-23	Bladder cancer;
LGG	cis	rs7267979	1.000	rs2259873	chr20:25280781	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3815700	1.000	rs8100168	chr19:33093084	G/A	cg02997394	chr19:33096574	ANKRD27	0.87	12.01	0.49	4.01e-29	Eosinophilic esophagitis;
LGG	cis	rs4764487	0.760	rs740840	chr12:6337254	G/T	cg08284733	chr12:6341482	CD9	0.38	10.32	0.43	1.35e-22	Mean platelet volume;
LGG	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg18198730	chr1:247681584	NA	-0.74	-12.65	-0.51	1.05e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg19774624	chr17:42201019	HDAC5	-0.95	-20.61	-0.69	1.9e-67	Total body bone mineral density;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg02353165	chr6:42928485	GNMT	0.48	14.23	0.55	2.15e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	trans	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg24247370	chr13:99142703	STK24	-0.38	-6.91	-0.31	1.56e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-7.12	-0.31	4.06e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg03929089	chr4:120376271	NA	0.69	9.5	0.4	1.1e-19	Axial length;
LGG	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg27490568	chr2:178487706	NA	0.49	9.62	0.41	4.15e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504073	0.669	rs818560	chr8:50035417	C/T	cg00325661	chr8:49890786	NA	0.69	13.53	0.53	2.31e-35	Blood metabolite ratios;
LGG	cis	rs1975974	1.000	rs1985718	chr17:21731656	C/T	cg18423549	chr17:21743878	NA	-0.47	-6.76	-0.3	4.09e-11	Psoriasis;
LGG	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg00717180	chr2:96193071	NA	0.4	7.13	0.31	3.83e-12	Height;
LGG	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.56	-7.94	-0.35	1.58e-14	Diabetic retinopathy;
LGG	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg22484793	chr3:52261325	TLR9	0.31	7.32	0.32	1.08e-12	Bipolar disorder;
LGG	trans	rs1728785	0.901	rs1170438	chr16:68608256	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.49	0.44	3.12e-23	Ulcerative colitis;
LGG	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg22153745	chr1:153894579	GATAD2B	-0.58	-8.65	-0.37	8.29e-17	Total cholesterol levels;
LGG	cis	rs2456568	0.741	rs2102332	chr11:93635281	G/T	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg03188948	chr7:1209495	NA	0.53	7.38	0.32	7.29e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg18379455	chr17:41446167	NA	-0.32	-7.2	-0.32	2.44e-12	Menopause (age at onset);
LGG	cis	rs3796352	1.000	rs11713290	chr3:52971579	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7107174	0.892	rs12284390	chr11:78103902	C/A	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.56	-0.67	1.56e-62	Height;
LGG	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.78e-31	Motion sickness;
LGG	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.65	-0.33	1.21e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg15556689	chr8:8085844	FLJ10661	0.5	9.15	0.39	1.76e-18	Retinal vascular caliber;
LGG	cis	rs79146658	0.688	rs7570928	chr2:179712600	C/T	cg17765952	chr2:179737173	CCDC141	-0.59	-8.49	-0.37	2.83e-16	Diastolic blood pressure;
LGG	cis	rs1957429	0.901	rs1467569	chr14:65347986	T/C	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.41	0.33	5.98e-13	Intraocular pressure;
LGG	cis	rs6840360	0.617	rs2724563	chr4:152349959	G/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	7.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg01864069	chr14:103024347	NA	-0.7	-10.73	-0.45	3.83e-24	Platelet count;
LGG	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.35	-0.4	3.78e-19	Neuroticism;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.84	0.3	2.53e-11	Lung cancer;
LGG	cis	rs368123	1.000	rs376440	chr6:160727941	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg05368731	chr17:41323189	NBR1	-0.79	-14.93	-0.57	1.91e-41	Menopause (age at onset);
LGG	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg11764359	chr7:65958608	NA	-0.55	-9.39	-0.4	2.65e-19	Aortic root size;
LGG	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.12	-0.49	1.5e-29	Height;
LGG	cis	rs7586879	0.789	rs11688754	chr2:25133885	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.39	0.4	2.7e-19	Body mass index;
LGG	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16346588	chr10:242978	ZMYND11	0.4	6.74	0.3	4.75e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs3849570	0.925	rs13091492	chr3:81891476	A/G	cg07356753	chr3:81810745	GBE1	-0.42	-6.83	-0.3	2.61e-11	Waist circumference;Body mass index;
LGG	cis	rs12042938	0.507	rs1765776	chr1:231731607	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.78	-15.24	-0.58	8.85e-43	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg02297831	chr4:17616191	MED28	0.51	9.43	0.4	1.98e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs963731	0.579	rs7582918	chr2:39185813	G/C	cg04010122	chr2:39346883	SOS1	-0.72	-7.44	-0.33	4.96e-13	Corticobasal degeneration;
LGG	cis	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg06609049	chr19:2785107	THOP1	0.64	9.87	0.42	5.57e-21	Total cholesterol levels;
LGG	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.24	-0.32	1.93e-12	Bipolar disorder;
LGG	cis	rs80282103	0.618	rs11818314	chr10:1148157	G/C	cg08668510	chr10:1095578	IDI1	0.77	7.63	0.33	1.32e-13	Glomerular filtration rate (creatinine);
LGG	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.66	-0.63	9.99e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs11696845	0.965	rs34485448	chr20:43370519	T/G	cg25301532	chr20:43378953	KCNK15	0.37	8.1	0.35	4.85e-15	Obesity-related traits;
LGG	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.9	0.48	1.15e-28	Hip circumference adjusted for BMI;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg24250549	chr1:154909240	PMVK	0.74	15.16	0.58	1.98e-42	Prostate cancer;
LGG	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs752010	1.000	rs2077172	chr1:42093340	A/G	cg16096631	chr1:42092165	HIVEP3	0.7	18.48	0.65	1.56e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9460578	0.595	rs4546483	chr6:20884080	G/A	cg13405222	chr6:20811065	CDKAL1	-0.53	-9.55	-0.41	7.31e-20	Breast cancer;
LGG	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg06623918	chr6:96969491	KIAA0776	0.79	16.12	0.6	9.56e-47	Headache;
LGG	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg15704280	chr7:45808275	SEPT13	0.76	8.94	0.38	9.52e-18	Intraocular pressure;
LGG	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg23461800	chr14:103021989	NA	-0.52	-8.39	-0.36	5.9e-16	Platelet count;
LGG	cis	rs2377585	0.563	rs10842109	chr12:8841077	G/A	cg03761649	chr12:8850719	RIMKLB	0.48	7.92	0.35	1.82e-14	Reticulocyte fraction of red cells;
LGG	trans	rs7560272	0.723	rs6743576	chr2:73814333	G/A	cg23020402	chr6:24666573	ACOT13;TTRAP	0.43	6.76	0.3	4.12e-11	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.43	-0.33	5.37e-13	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.75	-0.3	4.48e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg16339924	chr4:17578868	LAP3	0.64	11.11	0.46	1.41e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2692947	0.673	rs2229169	chr2:96780716	T/G	cg22654517	chr2:96458247	NA	-0.37	-7.53	-0.33	2.76e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.6e-32	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.84	0.48	1.96e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs7172689	0.954	rs7179134	chr15:81533378	G/A	cg11808699	chr15:81528661	IL16	-0.49	-10.06	-0.42	1.19e-21	Inattentive symptoms;
LGG	cis	rs4788570	0.625	rs4788813	chr16:71625572	T/C	cg06353428	chr16:71660113	MARVELD3	1.26	18.49	0.65	1.39e-57	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg18681998	chr4:17616180	MED28	0.85	18.91	0.66	1.63e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg22782929	chr10:21784432	C10orf114	0.75	7.12	0.31	4.01e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs988958	0.600	rs10205005	chr2:42248713	A/G	cg19376973	chr2:42229025	NA	0.65	9.81	0.41	8.93e-21	Hypospadias;
LGG	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg08188268	chr10:116634841	FAM160B1	0.35	7.36	0.32	8.18e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14159747	chr11:113255604	NA	0.32	8.59	0.37	1.35e-16	Neuroticism;
LGG	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg04831495	chr15:85060580	GOLGA6L5	0.34	6.83	0.3	2.61e-11	Bulimia nervosa;
LGG	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-9.25	-0.4	8.14e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.53	-0.5	3.31e-31	Obesity-related traits;
LGG	trans	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.26	-0.4	7.96e-19	Bladder cancer;
LGG	cis	rs9964724	0.865	rs12967855	chr18:35138245	A/G	cg27332583	chr18:35150602	NA	-0.41	-8.46	-0.37	3.63e-16	Educational attainment (years of education);
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.43	0.58	1.23e-43	Lung cancer;
LGG	cis	rs2797160	1.000	rs1739348	chr6:126014573	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg21724239	chr8:58056113	NA	0.46	7.15	0.32	3.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg22907277	chr7:1156413	C7orf50	0.43	7.66	0.34	1.07e-13	Longevity;Endometriosis;
LGG	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg23205692	chr1:25664452	TMEM50A	0.47	10.15	0.43	5.41e-22	Erythrocyte sedimentation rate;
LGG	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.26	-0.46	3.53e-26	Body mass index;
LGG	cis	rs9462027	0.628	rs6919654	chr6:34810739	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.32	-0.47	2.13e-26	Systemic lupus erythematosus;
LGG	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg00990874	chr7:1149470	C7orf50	-0.68	-10.25	-0.43	2.35e-22	Bronchopulmonary dysplasia;
LGG	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg07636037	chr3:49044803	WDR6	-0.76	-13.57	-0.53	1.48e-35	Menarche (age at onset);
LGG	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18876405	chr7:65276391	NA	0.49	8.8	0.38	2.83e-17	Aortic root size;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg22907277	chr7:1156413	C7orf50	0.7	8.76	0.38	3.72e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg18876405	chr7:65276391	NA	-0.45	-7.9	-0.34	2.09e-14	Calcium levels;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.27	0.36	1.41e-15	Bipolar disorder;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg14017655	chr6:133562193	EYA4	0.41	7.28	0.32	1.42e-12	Total body bone mineral density;
LGG	cis	rs9361491	0.587	rs9352694	chr6:79800818	A/G	cg18132916	chr6:79620363	NA	-0.26	-6.67	-0.3	7.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7100689	0.622	rs1417221	chr10:82100428	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.74	0.57	1.42e-40	Post bronchodilator FEV1;
LGG	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg16797656	chr11:68205561	LRP5	0.58	11.15	0.46	9.35e-26	Total body bone mineral density;
LGG	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg09137382	chr11:130731461	NA	0.35	6.69	0.3	6.51e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2073499	0.873	rs6446202	chr3:50219991	C/G	cg03645007	chr3:50255295	SLC38A3	0.57	6.68	0.3	6.78e-11	Schizophrenia;
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.79e-21	Aortic root size;
LGG	cis	rs2415984	0.622	rs28487986	chr14:46924435	T/G	cg14871534	chr14:47121158	RPL10L	-0.6	-10.4	-0.44	6.56e-23	Number of children ever born;
LGG	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg16540259	chr10:75572220	NDST2	-0.39	-7.14	-0.32	3.52e-12	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00292435	chr9:91925643	CKS2	0.46	6.91	0.31	1.62e-11	Gut microbiome composition (summer);
LGG	trans	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg25214090	chr10:38739885	LOC399744	0.56	10.37	0.43	8.42e-23	Educational attainment;
LGG	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg10792982	chr14:105748885	BRF1	0.53	10.8	0.45	2.1e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg06532163	chr17:45867833	NA	0.54	9.13	0.39	2.13e-18	IgG glycosylation;
LGG	cis	rs2066819	1.000	rs2371494	chr12:56728000	G/A	cg26734620	chr12:56694298	CS	0.75	6.77	0.3	3.9e-11	Psoriasis vulgaris;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg00180470	chr16:11343465	NA	0.48	7.55	0.33	2.33e-13	Beard thickness;
LGG	trans	rs1997103	1.000	rs6977292	chr7:55396335	T/C	cg20935933	chr6:143382018	AIG1	0.58	9.08	0.39	3.17e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.13e-42	Aortic root size;
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.71	-0.38	5.62e-17	Menopause (age at onset);
LGG	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.31e-17	Retinal vascular caliber;
LGG	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg04662567	chr6:169592167	NA	-0.64	-12.8	-0.51	2.51e-32	Pulse pressure;
LGG	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg23594656	chr7:65796392	TPST1	-0.36	-7.82	-0.34	3.53e-14	Aortic root size;
LGG	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg06618935	chr21:46677482	NA	0.44	8.59	0.37	1.37e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.34	-0.36	8.88e-16	Personality dimensions;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.51	-0.33	3.17e-13	Lung cancer;
LGG	cis	rs3816183	0.598	rs2374438	chr2:42909010	A/G	cg14631114	chr2:43023945	NA	0.36	7.11	0.31	4.5e-12	Hypospadias;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.08	-0.31	5.44e-12	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22496380	chr5:211416	CCDC127	-1.09	-9.85	-0.42	6.73e-21	Breast cancer;
LGG	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19997236	chr12:121790271	ANAPC5	0.46	6.9	0.31	1.67e-11	Gut microbiome composition (summer);
LGG	cis	rs1126510	0.897	rs12459883	chr19:47126614	C/G	cg07844738	chr19:47129343	PTGIR	0.29	6.75	0.3	4.5e-11	Ulcerative colitis;
LGG	cis	rs11239187	0.566	rs28525234	chr10:45098405	T/C	cg03916630	chr10:45065415	NA	0.35	8.47	0.37	3.23e-16	Body mass index;
LGG	cis	rs11920090	0.932	rs1905504	chr3:170695532	T/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg05896524	chr21:47604654	C21orf56	0.63	11.39	0.47	1.18e-26	Testicular germ cell tumor;
LGG	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg07636037	chr3:49044803	WDR6	-0.9	-18.6	-0.65	4.66e-58	Menarche (age at onset);
LGG	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.45	-0.37	3.85e-16	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs12233741	chr4:98950296	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2282802	0.711	rs3777095	chr5:139660916	G/A	cg26211634	chr5:139558579	C5orf32	0.35	7.65	0.34	1.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9543976	0.623	rs9544004	chr13:76191884	G/A	cg01531495	chr13:76123901	UCHL3	0.51	6.65	0.3	8.13e-11	Diabetic retinopathy;
LGG	cis	rs7765175	0.698	rs9400613	chr6:113675822	C/T	cg26552650	chr6:113682475	NA	0.34	7.51	0.33	3e-13	Coronary artery calcification;
LGG	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.93	-0.38	1.05e-17	Mean corpuscular volume;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11877270	chr2:65658583	SPRED2	0.41	7.0	0.31	9.02e-12	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg08847335	chr10:891726	LARP4B	-0.55	-9.06	-0.39	3.57e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9341835	0.511	rs1744146	chr6:64221869	A/C	cg00787780	chr6:64151745	NA	-0.39	-6.97	-0.31	1.11e-11	Schizophrenia;
LGG	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.25	0.43	2.33e-22	Colorectal cancer;
LGG	cis	rs2067615	0.507	rs11113083	chr12:107073316	C/A	cg15890332	chr12:107067104	RFX4	0.44	12.87	0.51	1.24e-32	Heart rate;
LGG	cis	rs4950322	0.542	rs4950382	chr1:146648224	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-7.65	-0.34	1.14e-13	Protein quantitative trait loci;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg04863758	chr4:1303710	MAEA	0.46	7.7	0.34	8.51e-14	Obesity-related traits;
LGG	cis	rs36051895	0.623	rs6476956	chr9:5261238	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-13.41	-0.53	6.93e-35	Pediatric autoimmune diseases;
LGG	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg10596483	chr8:143751796	JRK	0.59	9.69	0.41	2.51e-20	Schizophrenia;
LGG	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg02836325	chr17:76403955	PGS1	-0.7	-14.27	-0.55	1.47e-38	HDL cholesterol levels;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg20607798	chr8:58055168	NA	0.58	8.93	0.38	9.77e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.3	-0.43	1.6e-22	Alzheimer's disease;
LGG	cis	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg00614314	chr15:82944287	LOC80154	-0.46	-7.83	-0.34	3.4e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.7	0.64	6.58e-54	Alzheimer's disease;
LGG	cis	rs926938	0.563	rs360635	chr1:115420518	A/C	cg12756093	chr1:115239321	AMPD1	0.44	8.19	0.36	2.5e-15	Autism;
LGG	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg20573242	chr4:122745356	CCNA2	-0.45	-7.86	-0.34	2.8e-14	Type 2 diabetes;
LGG	cis	rs79146658	0.850	rs73973186	chr2:179780448	A/G	cg17765952	chr2:179737173	CCDC141	0.6	8.43	0.36	4.47e-16	Diastolic blood pressure;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.66	-0.56	3.04e-40	Platelet count;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.37	-0.74	2.24e-80	Primary sclerosing cholangitis;
LGG	cis	rs7193541	0.662	rs8052367	chr16:74658867	G/A	cg01733217	chr16:74700730	RFWD3	1.1	34.57	0.85	2.35e-130	Multiple myeloma;
LGG	cis	rs10876993	0.890	rs1092472	chr12:58036688	G/T	cg18357645	chr12:58087776	OS9	0.67	12.18	0.49	8.48e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg07701084	chr6:150067640	NUP43	0.67	12.57	0.5	2.2e-31	Lung cancer;
LGG	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg06238570	chr21:40685208	BRWD1	-0.51	-8.61	-0.37	1.19e-16	Cognitive function;
LGG	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.77	-0.38	3.32e-17	Mean corpuscular volume;
LGG	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	7.86	0.34	2.63e-14	Menarche (age at onset);
LGG	cis	rs2247341	0.577	rs2236995	chr4:1704542	T/G	cg08446824	chr4:1720184	TMEM129	-0.52	-9.41	-0.4	2.31e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs981844	0.712	rs10014763	chr4:154739140	C/T	cg14289246	chr4:154710475	SFRP2	0.55	9.47	0.4	1.47e-19	Response to statins (LDL cholesterol change);
LGG	cis	rs2658782	0.756	rs3019222	chr11:93079718	C/T	cg15737290	chr11:93063684	CCDC67	0.56	8.24	0.36	1.81e-15	Pulmonary function decline;
LGG	cis	rs10791097	0.694	rs4264159	chr11:130755784	G/T	cg09137382	chr11:130731461	NA	0.35	6.77	0.3	3.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg16141378	chr3:129829833	LOC729375	0.44	10.28	0.43	1.8e-22	Retinal vascular caliber;
LGG	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg14088196	chr11:70211408	PPFIA1	0.92	13.14	0.52	9.66e-34	Coronary artery disease;
LGG	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg27053975	chr1:166958233	MAEL	-0.49	-6.78	-0.3	3.75e-11	Obesity-related traits;
LGG	cis	rs28655083	0.828	rs7404322	chr16:77130003	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.56	9.38	0.4	2.86e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.37e-31	Motion sickness;
LGG	cis	rs4734806	1.000	rs35931188	chr8:105702502	A/G	cg01675814	chr8:105601641	LRP12	0.57	7.59	0.33	1.78e-13	Periodontitis (DPAL);
LGG	cis	rs357618	1.000	rs357620	chr5:150847121	A/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.8	-0.3	3.2e-11	Basophil percentage of white cells;
LGG	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg16325326	chr1:53192061	ZYG11B	-0.73	-17.37	-0.63	2.14e-52	Monocyte count;
LGG	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.62	0.59	1.74e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6743226	0.811	rs10933537	chr2:242154930	C/G	cg10021735	chr2:242295487	FARP2	-0.41	-7.4	-0.33	6.32e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg26441486	chr22:50317300	CRELD2	0.4	6.79	0.3	3.41e-11	Schizophrenia;
LGG	trans	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs7617773	0.780	rs6793239	chr3:48351618	G/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	trans	rs7246760	1.000	rs59867671	chr19:9933558	G/C	cg02900749	chr2:68251473	NA	-1.08	-11.55	-0.47	2.69e-27	Pursuit maintenance gain;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs367943	0.871	rs348938	chr5:112825032	C/A	cg12552261	chr5:112820674	MCC	-0.65	-11.97	-0.49	6.17e-29	Type 2 diabetes;
LGG	cis	rs10231759	0.617	rs2080054	chr7:150515674	T/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.39	8.89	0.38	1.39e-17	Height;
LGG	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg26396452	chr14:65542826	MAX	0.45	8.8	0.38	2.75e-17	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03356760	chr6:37665051	MDGA1	0.47	7.1	0.31	4.74e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs45544231	0.544	rs9926163	chr16:52565641	G/T	cg09051775	chr16:52580266	TOX3	-0.42	-7.24	-0.32	1.85e-12	Restless legs syndrome;
LGG	cis	rs2346177	0.844	rs4953371	chr2:46651143	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-9.26	-0.4	7.91e-19	HDL cholesterol;
LGG	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg06212747	chr3:49208901	KLHDC8B	0.42	6.76	0.3	4.13e-11	Resting heart rate;
LGG	cis	rs7584330	0.657	rs7599658	chr2:238352898	A/C	cg16989719	chr2:238392110	NA	0.35	7.15	0.32	3.33e-12	Prostate cancer;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.56	-0.33	2.19e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-9.9	-0.42	4.23e-21	Body mass index;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18404041	chr3:52824283	ITIH1	-0.37	-7.24	-0.32	1.83e-12	Bipolar disorder;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.42	-0.33	5.6e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7546	0.504	rs2015319	chr16:4936280	C/G	cg04440724	chr16:4920505	UBN1	0.54	11.44	0.47	7.38e-27	Cancer;
LGG	cis	rs4722166	0.695	rs35779989	chr7:22800314	A/C	cg05265849	chr7:22767390	IL6	0.37	7.09	0.31	5.14e-12	Lung cancer;
LGG	cis	rs1044573	0.526	rs6050422	chr20:25177920	A/G	cg06421707	chr20:25228305	PYGB	0.39	8.19	0.36	2.5e-15	Allergic rhinitis;
LGG	cis	rs11969893	0.850	rs9390713	chr6:101424262	G/A	cg12253828	chr6:101329408	ASCC3	1.16	8.25	0.36	1.65e-15	Economic and political preferences (immigration/crime);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13519464	chr19:9938554	UBL5	0.46	7.39	0.32	6.99e-13	Cognitive performance;
LGG	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.85	0.42	6.35e-21	Coronary artery disease;
LGG	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	16.37	0.61	7.37e-48	Smoking behavior;
LGG	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-8.11	-0.35	4.42e-15	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-9.11	-0.39	2.58e-18	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg12070911	chr6:150209640	RAET1E	0.28	7.17	0.32	2.93e-12	Testicular germ cell tumor;
LGG	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg03806693	chr22:41940476	POLR3H	0.9	14.88	0.57	3.2e-41	Vitiligo;
LGG	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg08344181	chr3:125677491	NA	-0.61	-7.11	-0.31	4.54e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7503807	0.688	rs11150745	chr17:78757626	A/G	cg06799305	chr17:78551370	RPTOR	0.33	6.65	0.3	8.26e-11	Obesity;
LGG	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg01988459	chr11:68622903	NA	-0.6	-12.32	-0.5	2.4e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6141769	0.518	rs28378056	chr20:31298317	G/C	cg13636640	chr20:31349939	DNMT3B	-0.47	-6.97	-0.31	1.06e-11	Subjective well-being;
LGG	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg09904177	chr6:26538194	HMGN4	0.67	13.69	0.54	4.71e-36	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg25237894	chr2:233734115	C2orf82	-0.56	-10.65	-0.44	7.53e-24	Coronary artery disease;
LGG	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs13082711	0.522	rs674303	chr3:27332177	T/C	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11123610	0.520	rs13409381	chr2:3722579	A/G	cg26344334	chr2:3718215	ALLC	-0.45	-7.46	-0.33	4.19e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg09048205	chr5:1608656	LOC728613	-0.51	-8.28	-0.36	1.37e-15	Breast cancer;
LGG	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg02002194	chr4:3960332	NA	0.41	7.5	0.33	3.29e-13	Morning vs. evening chronotype;
LGG	cis	rs72781680	0.848	rs55725028	chr2:23966447	A/G	cg08917208	chr2:24149416	ATAD2B	0.88	9.28	0.4	6.38e-19	Lymphocyte counts;
LGG	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg13010199	chr12:38710504	ALG10B	0.45	8.28	0.36	1.37e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs3740909	1.000	rs79068099	chr11:125897208	A/T	cg24940576	chr11:125904314	CDON	-0.49	-6.95	-0.31	1.28e-11	Blood protein levels;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.73	-0.34	6.73e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	9.83	0.42	7.9e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg12386194	chr3:101231763	SENP7	0.75	13.05	0.52	2.33e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.39	8.5e-19	Diabetic retinopathy;
LGG	cis	rs741702	0.892	rs1799918	chr19:13002400	G/C	cg23899408	chr19:12877188	HOOK2	-0.49	-7.88	-0.34	2.35e-14	Red blood cell traits;
LGG	cis	rs17739167	0.550	rs6493014	chr15:42225008	A/G	cg20935245	chr15:42234343	EHD4	-0.46	-8.96	-0.38	7.75e-18	Monocyte count;
LGG	cis	rs57502260	0.834	rs3736228	chr11:68201295	A/G	cg01657329	chr11:68192670	LRP5	0.59	7.56	0.33	2.16e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg20916646	chr4:852691	GAK	0.62	10.41	0.44	6.09e-23	Sjögren's syndrome;
LGG	cis	rs12049351	0.507	rs11803533	chr1:229568632	A/G	cg13547644	chr1:229569608	ACTA1	0.32	6.84	0.3	2.45e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg12458913	chr13:53173898	NA	-0.57	-10.67	-0.44	6.74e-24	Lewy body disease;
LGG	cis	rs17534004	1.000	rs17534004	chr13:31469665	C/T	cg00367615	chr13:31480979	C13orf33	0.32	6.86	0.3	2.21e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg13010199	chr12:38710504	ALG10B	0.69	13.88	0.54	7.34e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg02187348	chr16:89574699	SPG7	0.62	10.46	0.44	4.12e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs4356932	1.000	rs13130018	chr4:76955519	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg00209037	chr22:46443395	NA	0.24	6.78	0.3	3.6e-11	Dupuytren's disease;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.48	-0.4	1.3e-19	Obesity-related traits;
LGG	cis	rs2710642	0.962	rs4671051	chr2:63032696	A/T	cg17519650	chr2:63277830	OTX1	-0.47	-7.86	-0.34	2.8e-14	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs300774	0.925	rs300721	chr2:134436	A/T	cg04617936	chr2:214353	NA	-0.5	-7.67	-0.34	1.01e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg00129232	chr17:37814104	STARD3	0.76	16.49	0.61	2.19e-48	Asthma;
LGG	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg09264619	chr17:80180166	NA	0.52	10.21	0.43	3.25e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.47	4.6e-27	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.516	rs115135603	chr3:42031622	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17445240	0.515	rs9308790	chr2:3705712	C/T	cg20720597	chr2:3699334	NA	0.55	7.65	0.34	1.16e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs10743315	0.557	rs16915104	chr12:19287838	A/C	cg02471346	chr12:19282374	PLEKHA5	-0.85	-7.91	-0.35	1.9e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18150362	chr5:102456168	GIN1	0.42	6.76	0.3	4.15e-11	Cognitive performance;
LGG	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.04	0.55	1.47e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.02	-0.39	5.03e-18	Headache;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.02	0.31	7.72e-12	Prudent dietary pattern;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16355531	chr10:126370306	FAM53B	0.36	6.8	0.3	3.26e-11	Electrocardiographic conduction measures;
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg16590910	chr6:42928470	GNMT	0.46	13.43	0.53	6.04e-35	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10937275	0.826	rs62294592	chr3:186635584	C/T	cg16751732	chr3:186648392	ST6GAL1	0.69	6.88	0.3	2.01e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7843479	0.582	rs11779655	chr8:21794041	A/G	cg17168535	chr8:21777572	XPO7	-0.83	-16.57	-0.61	8.84e-49	Mean corpuscular volume;
LGG	cis	rs57244997	1.000	rs57244997	chr6:162397506	G/A	cg17173639	chr6:162384350	PARK2	-0.67	-8.24	-0.36	1.84e-15	Mosquito bite size;
LGG	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.39	-0.43	6.91e-23	Depression;
LGG	cis	rs988958	0.565	rs35033846	chr2:42237228	G/A	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7312774	0.618	rs7953093	chr12:107334540	G/A	cg16260113	chr12:107380972	MTERFD3	0.92	8.42	0.36	4.76e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg03342759	chr3:160939853	NMD3	-0.51	-8.58	-0.37	1.4e-16	Kawasaki disease;
LGG	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.46	-0.33	4.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg04362960	chr10:104952993	NT5C2	0.53	9.68	0.41	2.58e-20	Arsenic metabolism;
LGG	cis	rs1506636	1.000	rs644958	chr7:123400873	C/T	cg03229431	chr7:123269106	ASB15	0.73	18.22	0.65	2.5e-56	Plateletcrit;Platelet count;
LGG	cis	rs924607	0.898	rs1697990	chr5:626278	A/G	cg09021430	chr5:549028	NA	0.51	10.01	0.42	1.69e-21	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg23505145	chr19:12996616	KLF1	0.39	7.08	0.31	5.36e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2066819	0.786	rs116934693	chr12:56696545	T/G	cg26714650	chr12:56694279	CS	-1.57	-16.14	-0.6	8.42e-47	Psoriasis vulgaris;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-7.12	-0.31	4.1e-12	Neuroticism;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg23978390	chr7:1156363	C7orf50	0.49	7.62	0.33	1.48e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08645402	chr16:4508243	NA	0.54	9.78	0.41	1.19e-20	Schizophrenia;
LGG	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg25174290	chr11:3078921	CARS	-0.51	-9.24	-0.39	8.83e-19	Calcium levels;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg10792982	chr14:105748885	BRF1	0.67	13.92	0.54	4.79e-37	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.61	10.55	0.44	1.76e-23	Obesity-related traits;
LGG	cis	rs9393813	0.626	rs7772739	chr6:27318848	G/A	cg18711553	chr6:27366782	ZNF391	0.5	9.71	0.41	2.14e-20	Bipolar disorder;
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16318349	chr1:154917307	PBXIP1	-0.29	-7.49	-0.33	3.43e-13	Prostate cancer;
LGG	cis	rs3925075	0.966	rs7195945	chr16:31344309	T/C	cg02846316	chr16:31340340	ITGAM	0.4	7.94	0.35	1.5e-14	IgA nephropathy;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg21724239	chr8:58056113	NA	0.59	9.07	0.39	3.47e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg14088196	chr11:70211408	PPFIA1	0.99	13.03	0.52	2.9e-33	Coronary artery disease;
LGG	trans	rs7824557	0.806	rs11777002	chr8:11096153	G/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.67	-0.34	1.01e-13	Retinal vascular caliber;
LGG	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01261044	chr14:35451962	SRP54	0.5	7.91	0.35	1.86e-14	Gut microbiome composition (summer);
LGG	cis	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg08930214	chr7:62859557	LOC100287834	0.43	7.03	0.31	7.64e-12	Obesity-related traits;
LGG	cis	rs4731207	0.591	rs11772336	chr7:124589796	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg18240062	chr17:79603768	NPLOC4	-0.75	-13.86	-0.54	8.31e-37	Eye color traits;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg11062466	chr8:58055876	NA	0.61	10.17	0.43	4.77e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6920364	1	rs6920364	chr6:167376466	G/C	cg07741184	chr6:167504864	NA	-0.32	-7.08	-0.31	5.45e-12	Lung cancer;
LGG	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg12193833	chr17:30244370	NA	-0.27	-6.66	-0.3	7.82e-11	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	trans	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg21659725	chr3:3221576	CRBN	0.55	7.15	0.32	3.42e-12	Menarche (age at onset);
LGG	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.48	-0.37	2.96e-16	Retinal vascular caliber;
LGG	cis	rs41271951	0.512	rs11204765	chr1:151016757	G/A	cg11822372	chr1:151115635	SEMA6C	-0.67	-6.99	-0.31	9.81e-12	Blood protein levels;
LGG	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07611812	chr8:53627203	RB1CC1	0.5	7.42	0.33	5.75e-13	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-12.47	-0.5	5.4e-31	Morning vs. evening chronotype;
LGG	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg10326726	chr10:51549505	MSMB	-0.69	-14.37	-0.56	5.66e-39	Prostate-specific antigen levels;
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg20308403	chr7:2120281	MAD1L1	0.33	7.14	0.31	3.67e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26617929	chr16:1858877	NA	-0.61	-8.77	-0.38	3.4e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.76	-0.41	1.42e-20	Life satisfaction;
LGG	cis	rs56161922	1.000	rs11118363	chr1:207859251	G/A	cg09557387	chr1:207818395	CR1L	-0.94	-9.47	-0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg21053147	chr12:120880522	NA	-0.54	-7.96	-0.35	1.38e-14	Type 1 diabetes nephropathy;
LGG	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg19508488	chr2:152266495	RIF1	0.62	10.97	0.45	4.74e-25	Lung cancer;
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg24250549	chr1:154909240	PMVK	0.75	15.22	0.58	1.02e-42	Prostate cancer;
LGG	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.63	-0.33	1.34e-13	Neuroticism;
LGG	cis	rs171408	0.843	rs355139	chr3:8621431	G/A	cg03557445	chr3:8615444	LOH3CR2A	-0.47	-8.45	-0.37	3.94e-16	Mitral valve prolapse;
LGG	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.59	7.96	0.35	1.33e-14	HIV-1 control;
LGG	trans	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg18187862	chr3:45730750	SACM1L	-0.69	-11.6	-0.47	1.69e-27	Primary sclerosing cholangitis;
LGG	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.11	0.35	4.45e-15	HIV-1 control;
LGG	cis	rs4262150	0.803	rs72799144	chr5:152102662	T/C	cg12297329	chr5:152029980	NA	-0.75	-13.57	-0.53	1.55e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs17253792	0.822	rs10136155	chr14:56049129	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.38	-0.5	1.3e-30	Putamen volume;
LGG	cis	rs17776563	0.922	rs12148331	chr15:89110081	C/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.12	-0.43	6.86e-22	Thyroid hormone levels;
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg15664640	chr17:80829946	TBCD	0.49	9.53	0.41	8.54e-20	Breast cancer;
LGG	cis	rs7619833	0.728	rs1352944	chr3:27374101	C/A	cg02860705	chr3:27208620	NA	-0.39	-7.37	-0.32	8.05e-13	Breast cancer;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.08	-0.35	5.57e-15	Schizophrenia;
LGG	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.87	-14.32	-0.55	9.41e-39	Cognitive test performance;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.31	0.36	1.04e-15	Prudent dietary pattern;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs41271951	0.512	rs11204774	chr1:151062957	C/T	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.95	-0.31	1.21e-11	Blood protein levels;
LGG	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg25554036	chr4:6271136	WFS1	0.61	11.48	0.47	5.28e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg16339924	chr4:17578868	LAP3	-0.65	-11.14	-0.46	1.04e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7647973	1.000	rs6805609	chr3:49471522	C/G	cg07636037	chr3:49044803	WDR6	-0.74	-13.1	-0.52	1.37e-33	Menarche (age at onset);
LGG	cis	rs1519814	0.696	rs7821583	chr8:121033862	A/G	cg22335954	chr8:121166405	COL14A1	-0.5	-8.95	-0.38	8.91e-18	Breast cancer;
LGG	cis	rs11203032	0.901	rs4073283	chr10:90958000	G/C	cg16672925	chr10:90967113	CH25H	0.79	11.46	0.47	6.14e-27	Heart failure;
LGG	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg23845249	chr11:68861649	NA	0.45	8.09	0.35	5.36e-15	Blond vs. brown hair color;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21788624	chr2:20251350	LAPTM4A	0.41	7.03	0.31	7.33e-12	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06470251	chr20:60548479	NA	0.47	8.29	0.36	1.22e-15	Body mass index;
LGG	cis	rs2013441	1.000	rs1373147	chr17:20206645	T/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.93	-16.09	-0.6	1.35e-46	Chronic sinus infection;
LGG	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-10.65	-0.44	7.82e-24	Chronic sinus infection;
LGG	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.51	0.56	1.31e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg23173402	chr1:227635558	NA	0.45	7.64	0.33	1.28e-13	Major depressive disorder;
LGG	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg04568710	chr12:38710424	ALG10B	0.33	6.78	0.3	3.68e-11	Bladder cancer;
LGG	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs910316	0.789	rs175457	chr14:75584507	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.73	-0.41	1.8e-20	Height;
LGG	cis	rs4731207	1.000	rs4731207	chr7:124396645	G/A	cg05630886	chr7:124431682	NA	0.31	7.32	0.32	1.09e-12	Cutaneous malignant melanoma;
LGG	cis	rs1348850	0.914	rs3902850	chr2:178315899	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.4	-0.36	5.52e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.25	-0.43	2.42e-22	Lymphocyte counts;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02769172	chr11:67981027	SUV420H1	0.62	7.02	0.31	8.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.3	-0.32	1.27e-12	Lung cancer;
LGG	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.51	-0.67	2.65e-62	Coronary artery disease;
LGG	cis	rs7020830	0.898	rs308495	chr9:37277603	G/T	cg14294708	chr9:37120828	ZCCHC7	1.15	30.94	0.82	9.2e-115	Schizophrenia;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg15664640	chr17:80829946	TBCD	-0.46	-8.35	-0.36	8.04e-16	Glycated hemoglobin levels;
LGG	cis	rs858239	0.601	rs6969733	chr7:23168377	T/C	cg23682824	chr7:23144976	KLHL7	0.4	6.68	0.3	6.83e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3762637	0.943	rs3817040	chr3:122254769	G/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.54	-0.44	2.08e-23	LDL cholesterol levels;
LGG	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.09e-11	Blood metabolite levels;
LGG	cis	rs28655083	0.636	rs1485793	chr16:77101836	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-6.95	-0.31	1.25e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3736594	0.513	rs3811644	chr2:27802805	A/G	cg27432699	chr2:27873401	GPN1	0.57	8.48	0.37	3.02e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg02273617	chr15:68117586	LBXCOR1	0.32	7.1	0.31	4.77e-12	Restless legs syndrome;
LGG	cis	rs981844	1.000	rs55722886	chr4:154668335	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.51	0.47	4.02e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs4740619	0.507	rs10962252	chr9:16012562	C/T	cg14451791	chr9:16040625	NA	0.28	6.8	0.3	3.15e-11	Body mass index;
LGG	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg00339695	chr16:24857497	SLC5A11	0.41	7.04	0.31	6.89e-12	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs12618769	0.652	rs11537554	chr2:99216531	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.79	0.34	4.51e-14	Bipolar disorder;
LGG	cis	rs2777491	1.000	rs316613	chr15:41747598	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-19.57	-0.67	1.39e-62	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9309473	0.687	rs6706235	chr2:73613558	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-9.29	-0.4	6.2800000000000005e-19	Metabolite levels;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg14926445	chr8:58193284	C8orf71	-0.84	-12.07	-0.49	2.31e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.81	0.41	9.2e-21	Colorectal cancer;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg13206674	chr6:150067644	NUP43	0.43	7.48	0.33	3.88e-13	Lung cancer;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.37	-0.53	1.01e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg26513180	chr16:89883248	FANCA	0.7	7.8	0.34	4.09e-14	Skin colour saturation;
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-12.59	-0.5	1.88e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-12.69	-0.51	7.36e-32	Response to antipsychotic treatment;
LGG	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15664640	chr17:80829946	TBCD	-0.8	-15.7	-0.59	7.47e-45	Breast cancer;
LGG	cis	rs7119038	0.509	rs11216956	chr11:118575326	G/A	cg20309703	chr11:118481025	PHLDB1	0.41	6.92	0.31	1.47e-11	Sjögren's syndrome;
LGG	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg03477792	chr4:77819574	ANKRD56	0.51	8.95	0.38	8.44e-18	Emphysema distribution in smoking;
LGG	cis	rs963731	0.649	rs10153761	chr2:39262068	C/T	cg04010122	chr2:39346883	SOS1	-0.86	-7.51	-0.33	3.12e-13	Corticobasal degeneration;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21698802	chr8:91013697	DECR1	0.43	7.16	0.32	3.09e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3845702	0.668	rs6759271	chr2:180844303	T/C	cg01881094	chr2:180872142	CWC22	-1.25	-16.87	-0.62	3.8300000000000002e-50	Schizophrenia;
LGG	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg00850481	chr1:228891306	NA	-0.48	-8.27	-0.36	1.45e-15	Chronic lymphocytic leukemia;
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.38	-0.32	7.6e-13	Neuroticism;
LGG	cis	rs58235267	0.591	rs4671457	chr2:63346356	C/T	cg17519650	chr2:63277830	OTX1	0.53	9.61	0.41	4.77e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-13.13	-0.52	1.02e-33	Schizophrenia;
LGG	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.14	0.31	3.65e-12	Height;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg13453750	chr1:205783389	SLC41A1	-0.48	-9.45	-0.4	1.75e-19	Menarche (age at onset);
LGG	cis	rs4774899	0.932	rs12911297	chr15:57581311	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg07460842	chr6:66804631	NA	-0.5	-8.4	-0.36	5.51e-16	Metabolite levels;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00149659	chr3:10157352	C3orf10	0.75	9.46	0.4	1.56e-19	Alzheimer's disease;
LGG	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	8.25	0.36	1.7e-15	Thyroid stimulating hormone;
LGG	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.75	-0.3	4.32e-11	Blood metabolite levels;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg11062466	chr8:58055876	NA	0.52	7.92	0.35	1.75e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg12070911	chr6:150209640	RAET1E	0.29	7.13	0.31	3.93e-12	Lung cancer;
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg05868516	chr6:26286170	HIST1H4H	0.45	7.55	0.33	2.32e-13	Educational attainment;
LGG	cis	rs4731207	0.662	rs35630355	chr7:124549333	T/A	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.49	0.37	2.86e-16	Schizophrenia;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg01494348	chr8:144660395	NAPRT1	0.91	7.31	0.32	1.17e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-13.57	-0.53	1.46e-35	Coronary artery disease;
LGG	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.9	0.51	9.48e-33	Intelligence (multi-trait analysis);
LGG	cis	rs6580649	0.941	rs72644844	chr12:48465425	A/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs73198271	0.740	rs10110711	chr8:8650456	C/T	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2797369	0.574	rs6570987	chr6:101598264	T/C	cg27451362	chr6:101846650	GRIK2	0.45	7.0	0.31	9.16e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-7.9	-0.34	1.98e-14	Neuroticism;
LGG	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06470251	chr20:60548479	NA	0.4	6.91	0.31	1.6e-11	Body mass index;
LGG	cis	rs10464366	0.597	rs10951590	chr7:39091043	C/T	cg18850127	chr7:39170497	POU6F2	0.34	7.63	0.33	1.37e-13	IgG glycosylation;
LGG	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.54	-0.72	1.78e-76	Schizophrenia;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.98	-0.31	1.01e-11	Prostate cancer;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg23758822	chr17:41437982	NA	0.9	15.87	0.59	1.28e-45	Menopause (age at onset);
LGG	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg26513180	chr16:89883248	FANCA	0.65	12.23	0.49	5.52e-30	Vitiligo;
LGG	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg11366901	chr6:160182831	ACAT2	1.05	15.97	0.6	4.76e-46	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2708977	1.000	rs1011040	chr2:97212755	A/G	cg01950434	chr2:97203154	ARID5A	-0.53	-8.27	-0.36	1.4e-15	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg27523141	chr10:43048294	ZNF37B	-0.33	-6.77	-0.3	3.79e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg26384229	chr12:38710491	ALG10B	-0.72	-13.67	-0.54	5.55e-36	Morning vs. evening chronotype;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27189623	chr16:705930	WDR90	0.42	8.09	0.35	5.37e-15	Height;
LGG	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs12928939	0.954	rs8057568	chr16:71811995	G/A	cg03805757	chr16:71968109	PKD1L3	-0.55	-10.46	-0.44	3.91e-23	Post bronchodilator FEV1;
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.93	-0.38	1.01e-17	Lymphocyte counts;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg12070911	chr6:150209640	RAET1E	0.33	8.23	0.36	1.9e-15	Lung cancer;
LGG	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg11247378	chr22:39784982	NA	-0.31	-8.48	-0.37	3.04e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg21171335	chr12:122356390	WDR66	-0.28	-7.97	-0.35	1.23e-14	Mean corpuscular volume;
LGG	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg02985381	chr13:37494744	SMAD9	0.7	12.33	0.5	2.03e-30	Coronary artery disease;
LGG	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.79	0.3	3.55e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg02820901	chr13:113351484	ATP11A	-0.6	-7.0	-0.31	8.81e-12	Glycated hemoglobin levels;
LGG	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12124516	chr2:136634144	MCM6	0.45	7.57	0.33	2.06e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg02030672	chr11:45687055	CHST1	0.47	8.41	0.36	5.18e-16	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02470124	chr7:25165302	CYCS	0.46	6.93	0.31	1.39e-11	Gut microbiome composition (summer);
LGG	cis	rs1570884	0.767	rs7996207	chr13:50122681	G/A	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.88	-0.3	1.97e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs668210	0.793	rs619701	chr11:65772080	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.74	-9.73	-0.41	1.75e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17030434	0.784	rs6835640	chr4:154650494	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-9.74	-0.41	1.58e-20	Electrocardiographic conduction measures;
LGG	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg02297831	chr4:17616191	MED28	0.45	8.33	0.36	9.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg11317459	chr13:21872234	NA	-1.18	-19.36	-0.67	1.31e-61	White matter hyperintensity burden;
LGG	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-7.8	-0.34	4.2e-14	Schizophrenia;
LGG	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg05887092	chr17:76393375	PGS1	0.71	15.73	0.59	5.75e-45	HDL cholesterol levels;
LGG	cis	rs60180747	0.909	rs11638268	chr15:66770164	G/A	cg07575407	chr15:66541975	MEGF11	0.38	7.15	0.32	3.4e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07677032	chr17:61819896	STRADA	0.68	12.57	0.5	2.15e-31	Prudent dietary pattern;
LGG	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.44	0.44	4.66e-23	Height;
LGG	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg01169559	chr10:831247	NA	0.52	9.15	0.39	1.79e-18	Uric acid levels;
LGG	cis	rs365132	0.875	rs547798	chr5:176326721	C/A	cg16309518	chr5:176445507	NA	-0.51	-11.19	-0.46	7.01e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg02023728	chr11:77925099	USP35	0.47	7.94	0.35	1.58e-14	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16511870	chr7:6145057	USP42	0.49	7.56	0.33	2.2e-13	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06438815	chr21:46292710	PTTG1IP	0.45	7.24	0.32	1.94e-12	Gut microbiome composition (summer);
LGG	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg14784868	chr12:69753453	YEATS4	0.9	20.16	0.68	2.39e-65	Blood protein levels;
LGG	cis	rs4262150	0.960	rs4285285	chr5:152289810	C/T	cg12297329	chr5:152029980	NA	0.6	11.31	0.47	2.38e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-13.8	-0.54	1.56e-36	Chronic sinus infection;
LGG	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.53	-0.37	2.04e-16	Mood instability;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg07614371	chr15:38746870	FAM98B	-0.4	-6.79	-0.3	3.36e-11	Leprosy;
LGG	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs9636202	1.000	rs12459965	chr19:18452195	C/T	cg02383626	chr19:18455508	PGPEP1	0.91	18.38	0.65	4.73e-57	Life satisfaction;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.67	-0.3	7.25e-11	Total body bone mineral density;
LGG	cis	rs1558375	0.679	rs31670	chr7:87059164	C/T	cg00919237	chr7:87102261	ABCB4	0.54	9.68	0.41	2.66e-20	Gallbladder cancer;
LGG	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg21775007	chr8:11205619	TDH	0.81	14.31	0.55	9.68e-39	Retinal vascular caliber;
LGG	cis	rs4478858	0.647	rs7524117	chr1:31738416	A/G	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.15e-11	Alcohol dependence;
LGG	cis	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.31	-0.32	1.18e-12	Neuroticism;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.36	0.32	8.18e-13	Lung cancer;
LGG	cis	rs4474465	0.573	rs7101478	chr11:78272517	C/A	cg27205649	chr11:78285834	NARS2	0.54	9.59	0.41	5.63e-20	Alzheimer's disease (survival time);
LGG	cis	rs2797160	1.000	rs1777225	chr6:126018270	T/C	cg05901451	chr6:126070800	HEY2	0.45	7.6	0.33	1.64e-13	Endometrial cancer;
LGG	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg14416269	chr4:6271139	WFS1	0.51	9.22	0.39	1.02e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs10979	0.651	rs9321921	chr6:143895053	C/T	cg25407410	chr6:143891975	LOC285740	-0.63	-10.1	-0.43	7.98e-22	Hypospadias;
LGG	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.92	-0.31	1.53e-11	Blood metabolite levels;
LGG	cis	rs3747547	0.818	rs7027014	chr9:37943571	T/C	cg13774184	chr9:37916125	SHB	-0.73	-8.23	-0.36	1.85e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg07600871	chr18:35146474	BRUNOL4	-0.4	-6.84	-0.3	2.52e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs722599	0.683	rs7160852	chr14:75239424	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	8.87	0.38	1.55e-17	IgG glycosylation;
LGG	cis	rs1670533	1.000	rs629260	chr4:1086764	A/G	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs990171	1.000	rs10469840	chr2:103093243	T/C	cg05295703	chr2:102895712	NA	-0.52	-8.93	-0.38	1.02e-17	Lymphocyte counts;
LGG	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg06637938	chr14:75390232	RPS6KL1	0.52	9.16	0.39	1.66e-18	Height;
LGG	cis	rs733592	0.507	rs7138917	chr12:48455255	G/A	cg24011408	chr12:48396354	COL2A1	-0.66	-11.52	-0.47	3.42e-27	Plateletcrit;
LGG	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.2	-0.32	2.38e-12	Systolic blood pressure;
LGG	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.48	-0.44	3.36e-23	Hemoglobin concentration;
LGG	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg21995147	chr19:1064017	ABCA7	-0.47	-7.39	-0.32	6.97e-13	Alzheimer's disease (late onset);
LGG	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-6.76	-0.3	4.17e-11	Lung cancer;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.74	-0.45	3.46e-24	Lung cancer;
LGG	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg21724239	chr8:58056113	NA	0.53	7.53	0.33	2.67e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	1.000	rs13112665	chr4:135898581	C/A	cg14419869	chr4:135874104	NA	0.57	10.6	0.44	1.2e-23	Subjective well-being;
LGG	trans	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.27e-14	Heart rate;
LGG	cis	rs7998202	0.667	rs914018	chr13:113354819	A/G	cg17218041	chr13:113365319	ATP11A	-0.47	-7.73	-0.34	6.84e-14	Glycated hemoglobin levels;
LGG	cis	rs7166081	1.000	rs2289262	chr15:67501033	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.73	-0.3	5.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3796352	1.000	rs13069006	chr3:52973305	G/C	cg12962167	chr3:53033115	SFMBT1	0.77	8.07	0.35	6.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	7.58	0.33	1.84e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4538187	1.000	rs10183479	chr2:64085114	G/A	cg19915305	chr2:64069682	UGP2	0.68	15.66	0.59	1.18e-44	Systolic blood pressure;
LGG	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08564027	chr20:61660810	NA	1.02	25.08	0.76	2.73e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg07414643	chr4:187882934	NA	0.58	12.13	0.49	1.39e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.63	-0.56	4.11e-40	IgG glycosylation;
LGG	cis	rs1957429	0.520	rs72625643	chr14:65340964	C/G	cg23373153	chr14:65346875	NA	-0.96	-9.42	-0.4	2.18e-19	Pediatric areal bone mineral density (radius);
LGG	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg21427119	chr20:30132790	HM13	-0.58	-8.97	-0.38	7.37e-18	Mean corpuscular hemoglobin;
LGG	cis	rs4330281	0.608	rs17043492	chr3:17402565	T/C	cg20981856	chr3:17787350	NA	0.35	6.81	0.3	2.95e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.63	-0.41	3.81e-20	Lung cancer;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg05313129	chr8:58192883	C8orf71	0.73	10.13	0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs9314614	0.899	rs2977802	chr8:6694845	C/G	cg11829072	chr8:125463024	TRMT12	0.4	6.66	0.3	7.55e-11	IgA nephropathy;White blood cell count (basophil);
LGG	cis	rs870825	0.616	rs55674580	chr4:185626605	C/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg22906224	chr7:99728672	NA	-0.57	-9.34	-0.4	4.06e-19	Coronary artery disease;
LGG	cis	rs3806843	0.868	rs2531352	chr5:140119534	A/G	cg19875535	chr5:140030758	IK	-0.54	-11.24	-0.46	4.43e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs2339490	chr1:152984612	A/G	cg13444842	chr1:152974279	SPRR3	0.45	9.38	0.4	2.89e-19	Inflammatory skin disease;
LGG	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.91	-0.31	1.61e-11	Myopia (pathological);
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	15.0	0.57	9.67e-42	Obesity-related traits;
LGG	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.15	-0.35	3.47e-15	Total body bone mineral density;
LGG	cis	rs2224391	0.590	rs2773298	chr6:5242067	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.9	-0.31	1.76e-11	Height;
LGG	cis	rs7077256	0.564	rs34028683	chr10:65165762	T/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.56	-0.37	1.64e-16	Platelet distribution width;
LGG	cis	rs11190604	1.000	rs76683169	chr10:102358397	A/T	cg07080220	chr10:102295463	HIF1AN	0.6	8.89	0.38	1.37e-17	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2334880	0.680	rs1364210	chr16:71603487	G/A	cg06353428	chr16:71660113	MARVELD3	-1.25	-18.63	-0.65	3.29e-58	Malaria;
LGG	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.0	-0.35	1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1997103	1.000	rs1997102	chr7:55399322	A/C	cg20935933	chr6:143382018	AIG1	-0.47	-7.43	-0.33	5.12e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3741151	0.686	rs12290701	chr11:73271988	T/C	cg17517138	chr11:73019481	ARHGEF17	0.67	7.01	0.31	8.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg16141378	chr3:129829833	LOC729375	-0.39	-8.47	-0.37	3.32e-16	Triglycerides;
LGG	trans	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg06521331	chr12:34319734	NA	-0.5	-8.6	-0.37	1.23e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg20913747	chr6:44695427	NA	-0.66	-11.36	-0.47	1.53e-26	Total body bone mineral density;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25104868	chr10:69634168	NA	0.41	6.91	0.31	1.66e-11	Electrocardiographic conduction measures;
LGG	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.58	-7.72	-0.34	7.26e-14	Smoking behavior;
LGG	cis	rs4740619	0.682	rs10810514	chr9:16011896	C/G	cg14451791	chr9:16040625	NA	-0.4	-10.2	-0.43	3.54e-22	Body mass index;
LGG	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg02269571	chr22:50332266	NA	-0.55	-8.51	-0.37	2.49e-16	Schizophrenia;
LGG	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg11752832	chr7:134001865	SLC35B4	0.62	11.15	0.46	9.93e-26	Mean platelet volume;
LGG	cis	rs9581857	0.579	rs3759434	chr13:27997700	A/C	cg01674679	chr13:27998804	GTF3A	-0.68	-8.62	-0.37	1.08e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.76	-0.34	5.64e-14	Psoriasis;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.68	0.34	9.23e-14	Menopause (age at onset);
LGG	cis	rs933688	0.532	rs28637141	chr5:90538743	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.54	-6.94	-0.31	1.3e-11	Smoking behavior;
LGG	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.94	-0.35	1.52e-14	HDL cholesterol;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.45	-0.56	2.58e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs17655565	1.000	rs17126647	chr12:52706194	C/T	cg08257133	chr12:52711352	KRT83	0.57	8.02	0.35	8.99e-15	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs35740288	0.929	rs11630585	chr15:86306004	C/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.27	-0.32	1.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg19507638	chr5:93509721	C5orf36	-0.65	-9.4	-0.4	2.48e-19	Diabetic retinopathy;
LGG	cis	rs727505	1.000	rs34986416	chr7:124441017	A/G	cg23710748	chr7:124431027	NA	-0.55	-10.31	-0.43	1.39e-22	Lewy body disease;
LGG	cis	rs12912251	0.894	rs7183893	chr15:38996981	A/C	cg01338139	chr15:38987640	C15orf53	-0.56	-8.85	-0.38	1.81e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs721917	0.545	rs2758542	chr10:81657702	T/C	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs6988636	1.000	rs11988157	chr8:124194740	A/G	cg23067535	chr8:124195133	FAM83A	0.59	7.09	0.31	5.06e-12	Urinary uromodulin levels;
LGG	trans	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg02002194	chr4:3960332	NA	0.42	7.54	0.33	2.51e-13	Mood instability;
LGG	cis	rs4950322	1.000	rs4950322	chr1:146854836	A/G	cg22381352	chr1:146742008	CHD1L	0.44	6.9	0.31	1.74e-11	Protein quantitative trait loci;
LGG	cis	rs2963155	0.518	rs33389	chr5:142700499	C/T	cg17617527	chr5:142782415	NR3C1	1.01	13.35	0.53	1.26e-34	Breast cancer;
LGG	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg01625945	chr7:157512322	PTPRN2	-0.33	-6.89	-0.31	1.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg12929805	chr1:2399054	NA	-0.52	-10.54	-0.44	1.99e-23	Non-obstructive azoospermia;
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.28e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg03188948	chr7:1209495	NA	0.65	8.47	0.37	3.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs877282	0.945	rs71491311	chr10:791747	G/A	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs12360000	0.541	rs10903583	chr10:1913891	A/G	cg26364871	chr10:1889757	NA	-0.52	-9.89	-0.42	4.89e-21	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg07936489	chr17:37558343	FBXL20	0.85	15.86	0.59	1.47e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs11971779	0.584	rs10236055	chr7:139069991	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs67133203	0.756	rs12814498	chr12:51517358	G/T	cg14688905	chr12:51403056	SLC11A2	0.69	10.2	0.43	3.6e-22	Urinary tract infection frequency;
LGG	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22618164	chr12:122356400	WDR66	0.33	9.82	0.42	8.29e-21	Mean corpuscular volume;
LGG	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.91	0.57	2.38e-41	Platelet count;
LGG	cis	rs4740619	0.689	rs10810503	chr9:15953051	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.92	-0.42	3.73e-21	Body mass index;
LGG	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg04065151	chr12:53682969	ESPL1	-0.56	-9.28	-0.4	6.46e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs283228	1.000	rs517552	chr6:101792329	G/T	cg27451362	chr6:101846650	GRIK2	0.54	8.98	0.39	6.62e-18	Coenzyme Q10 levels;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs2033908	0.502	rs12361858	chr11:12857064	C/T	cg25843174	chr11:12811716	TEAD1	-0.34	-7.11	-0.31	4.57e-12	Sitting height ratio;
LGG	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-6.87	-0.3	2.06e-11	Huntington's disease progression;
LGG	cis	rs12477438	0.501	rs3792137	chr2:100061748	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.96	-0.31	1.19e-11	Chronic sinus infection;
LGG	cis	rs2905347	0.726	rs2905320	chr7:22704243	C/A	cg18045685	chr7:22629474	NA	-0.66	-13.78	-0.54	1.83e-36	Major depression and alcohol dependence;
LGG	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg13385794	chr1:248469461	NA	0.5	8.34	0.36	8.8e-16	Common traits (Other);
LGG	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg07777115	chr5:623756	CEP72	-0.63	-8.16	-0.35	3.15e-15	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03324837	chr17:61044407	NA	0.5	8.28	0.36	1.33e-15	Cognitive performance;
LGG	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg12927641	chr6:109611667	NA	-0.38	-7.36	-0.32	8.22e-13	Reticulocyte fraction of red cells;
LGG	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.12	0.35	4.33e-15	Alzheimer's disease;
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.71	-0.61	2.08e-49	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.642	rs7658169	chr4:152353414	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.01	0.31	8.3e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	cis	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg12486710	chr1:178512616	C1orf220	-0.41	-8.31	-0.36	1.1e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs6787172	0.592	rs7648196	chr3:158104706	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.7	0.45	4.87e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg13397359	chr6:42928475	GNMT	0.57	16.04	0.6	2.21e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg07460842	chr6:66804631	NA	0.57	9.52	0.4	1e-19	Metabolite levels;
LGG	cis	rs503734	0.666	rs2141180	chr3:101179057	C/T	cg27318481	chr3:100970896	IMPG2	-0.35	-7.25	-0.32	1.73e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.75	-0.45	3.26e-24	Lung cancer;
LGG	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17219203	chr10:38645113	HSD17B7P2	0.42	6.97	0.31	1.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg05784532	chr1:230284198	GALNT2	0.52	9.19	0.39	1.3e-18	Coronary artery disease;
LGG	cis	rs2562456	0.876	rs11085467	chr19:21751843	A/G	cg00806126	chr19:22604979	ZNF98	-0.64	-9.71	-0.41	2.13e-20	Pain;
LGG	cis	rs2470578	0.792	rs283915	chr3:17329768	T/C	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.58e-11	Schizophrenia;
LGG	cis	rs9557207	0.901	rs3742130	chr13:99907341	G/A	cg24509225	chr13:100037070	UBAC2	0.69	12.04	0.49	3.01e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.73	-0.3	5.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg09303159	chr6:26284866	NA	0.31	6.97	0.31	1.11e-11	Educational attainment;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02071572	chr4:1403502	NA	0.41	7.01	0.31	8.37e-12	Longevity;
LGG	cis	rs6142618	0.523	rs6141636	chr20:30798668	A/G	cg00028034	chr20:30779307	TSPYL3	0.35	7.71	0.34	7.78e-14	Inflammatory bowel disease;
LGG	cis	rs711245	0.899	rs848603	chr2:36773868	C/T	cg09467607	chr2:36825704	FEZ2	0.46	9.01	0.39	5.62e-18	Height;
LGG	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs735539	0.521	rs2585897	chr13:21398979	A/G	cg04906043	chr13:21280425	IL17D	0.52	8.22	0.36	2.08e-15	Dental caries;
LGG	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.6e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg23594656	chr7:65796392	TPST1	-0.32	-6.84	-0.3	2.49e-11	Aortic root size;
LGG	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.3	-0.36	1.14e-15	Breast cancer;
LGG	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg05973401	chr12:123451056	ABCB9	0.48	7.17	0.32	3.08e-12	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg23758822	chr17:41437982	NA	0.88	15.64	0.59	1.46e-44	Menopause (age at onset);
LGG	cis	rs6964587	0.967	rs6465353	chr7:91779971	G/T	cg17063962	chr7:91808500	NA	-0.52	-9.59	-0.41	5.3e-20	Breast cancer;
LGG	cis	rs9815354	0.830	rs1716698	chr3:41957466	T/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.26	-0.36	1.58e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1670533	1.000	rs7660779	chr4:1075940	A/G	cg27284194	chr4:1044797	NA	0.55	9.88	0.42	5.14e-21	Recombination rate (females);
LGG	trans	rs6787172	0.623	rs4680434	chr3:158153016	T/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	8.91e-13	Subjective well-being;
LGG	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12923728	chr3:195709715	SDHAP1	-0.73	-12.43	-0.5	8.46e-31	Pancreatic cancer;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.54	-0.37	1.89e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1982963	0.950	rs1566132	chr14:52511836	C/T	cg05884192	chr14:52515736	NID2	-0.33	-7.38	-0.32	7.6e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg03060546	chr3:49711283	APEH	-0.7	-11.7	-0.48	7.19e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg17788362	chr6:86352627	SYNCRIP	0.53	9.42	0.4	2.17e-19	Smooth-surface caries;
LGG	cis	rs6988985	0.678	rs28659182	chr8:143999919	T/A	cg10324643	chr8:143916377	GML	0.45	9.35	0.4	3.87e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.98	0.57	1.16e-41	Cognitive test performance;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg01147727	chr14:105363015	KIAA0284	-0.45	-7.0	-0.31	8.93e-12	IgG glycosylation;
LGG	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg25706552	chr1:244017396	NA	-0.52	-6.84	-0.3	2.53e-11	RR interval (heart rate);
LGG	cis	rs4006360	0.588	rs2001523	chr17:39262814	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.47	-9.58	-0.41	6.09e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg12800244	chr3:153838788	SGEF	0.58	8.24	0.36	1.82e-15	Coronary artery disease;
LGG	cis	rs7129556	0.737	rs10899404	chr11:77462792	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.48	0.33	3.84e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	13.61	0.53	1.01e-35	Total body bone mineral density;
LGG	cis	rs12681287	0.640	rs4961193	chr8:87486168	C/T	cg27223183	chr8:87520930	FAM82B	0.5	7.71	0.34	7.92e-14	Caudate activity during reward;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg17202724	chr17:61916730	SMARCD2	0.59	13.73	0.54	3.06e-36	Prudent dietary pattern;
LGG	cis	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs12431410	0.550	rs55787031	chr14:60211706	T/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.35	-0.32	8.77e-13	Schizophrenia;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7923609	1.000	rs10822149	chr10:64987412	G/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.81	-0.3	3.11e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg16359550	chr11:109292809	C11orf87	0.4	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg11062466	chr8:58055876	NA	0.45	7.69	0.34	8.82e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs9354308	0.764	rs4334963	chr6:66606476	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg15704280	chr7:45808275	SEPT13	0.49	8.11	0.35	4.6e-15	HDL cholesterol;
LGG	cis	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg15596359	chr8:11213517	TDH	-0.37	-7.84	-0.34	3.1e-14	Retinal vascular caliber;
LGG	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.64	0.33	1.25e-13	Monocyte count;
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17554472	chr22:41940697	POLR3H	-0.48	-6.7	-0.3	5.92e-11	Vitiligo;
LGG	cis	rs2273669	0.667	rs76249006	chr6:109366740	G/A	cg05315195	chr6:109294784	ARMC2	-0.62	-8.37	-0.36	6.92e-16	Prostate cancer;
LGG	cis	rs4481887	0.861	rs6676064	chr1:248443890	G/C	cg13385794	chr1:248469461	NA	0.47	7.75	0.34	5.72e-14	Common traits (Other);
LGG	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg15557168	chr22:42548783	NA	-0.34	-7.6	-0.33	1.67e-13	Cognitive function;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05863683	chr7:1912471	MAD1L1	0.42	8.03	0.35	8.1e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9547996	0.842	rs9547965	chr13:38153888	G/A	cg17979426	chr13:38220150	TRPC4	-0.35	-6.66	-0.3	7.73e-11	Diastolic blood pressure;
LGG	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg03605463	chr16:89740564	NA	0.42	7.06	0.31	5.93e-12	Vitiligo;
LGG	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg24011408	chr12:48396354	COL2A1	0.5	7.87	0.34	2.48e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.71	-0.38	5.48e-17	Blood metabolite levels;
LGG	cis	rs3780378	0.682	rs7861763	chr9:5273194	C/T	cg02405213	chr9:5042618	JAK2	-0.4	-6.98	-0.31	1.03e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg04672837	chr16:48644449	N4BP1	0.5	8.39	0.36	5.89e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3767633	0.858	rs7532448	chr1:161862745	C/T	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg14541582	chr5:601475	NA	-0.68	-10.59	-0.44	1.29e-23	Obesity-related traits;
LGG	cis	rs7582720	1.000	rs7605484	chr2:203724495	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.62	0.41	4.31e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.08	0.35	5.73e-15	Longevity;
LGG	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg04731861	chr2:219085781	ARPC2	0.46	11.15	0.46	9.46e-26	Colorectal cancer;
LGG	cis	rs139371	0.713	rs139315	chr22:39499653	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.93	-0.31	1.43e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg03735888	chr19:58951602	ZNF132	0.44	8.8	0.38	2.7e-17	Uric acid clearance;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06745507	chr15:44085196	SERF2	0.48	7.77	0.34	4.98e-14	Cognitive performance;
LGG	cis	rs7843479	0.511	rs4379446	chr8:21777595	C/G	cg17168535	chr8:21777572	XPO7	0.82	15.95	0.6	5.55e-46	Mean corpuscular volume;
LGG	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg08733933	chr1:2954429	NA	-0.42	-8.22	-0.36	2.01e-15	Plateletcrit;
LGG	cis	rs8067545	0.640	rs17759083	chr17:19963605	T/A	cg13482628	chr17:19912719	NA	0.57	10.76	0.45	2.94e-24	Schizophrenia;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg22535103	chr8:58192502	C8orf71	-0.83	-10.59	-0.44	1.32e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28655083	0.529	rs4544253	chr16:77104774	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.51	0.33	3.12e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.0	-0.31	8.96e-12	Aortic root size;
LGG	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg08807101	chr21:30365312	RNF160	0.77	14.86	0.57	3.96e-41	Dental caries;
LGG	cis	rs1355223	0.902	rs2185700	chr11:34724204	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.7	-0.3	6.1e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6489882	0.867	rs4766676	chr12:113365581	A/G	cg25319449	chr12:113376135	OAS3	0.4	7.27	0.32	1.59e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7215564	0.908	rs2315923	chr17:78693678	A/G	cg06153925	chr17:78755379	RPTOR	0.39	6.7	0.3	6.25e-11	Myopia (pathological);
LGG	cis	rs883565	0.655	rs1608728	chr3:39089560	C/T	cg01426195	chr3:39028469	NA	-0.73	-17.11	-0.62	3.4e-51	Handedness;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1408799	0.671	rs2890965	chr9:12744670	T/G	cg05274944	chr9:12693694	TYRP1	0.33	7.81	0.34	3.76e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg17971929	chr21:40555470	PSMG1	0.88	17.68	0.63	7.51e-54	Cognitive function;
LGG	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.08e-23	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04498032	chr1:155242826	CLK2	0.47	7.04	0.31	7.13e-12	Gut microbiome composition (summer);
LGG	cis	rs1670533	1.000	rs10084849	chr4:1053586	T/C	cg27284194	chr4:1044797	NA	0.54	9.72	0.41	1.84e-20	Recombination rate (females);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg06654118	chr4:1303317	MAEA	-0.42	-7.04	-0.31	7.2e-12	Obesity-related traits;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg05313129	chr8:58192883	C8orf71	0.77	10.77	0.45	2.84e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.0	0.31	9.26e-12	Lung cancer;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.46	0.37	3.66e-16	Schizophrenia;
LGG	cis	rs4639966	0.797	rs11217021	chr11:118640828	T/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	cis	rs2797369	0.713	rs1163806	chr6:101490087	C/T	cg27451362	chr6:101846650	GRIK2	0.85	11.39	0.47	1.19e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs4356932	0.935	rs4129781	chr4:76959388	C/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03452623	chr4:187889614	NA	1.03	29.05	0.8	2.27e-106	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg20845748	chr21:45719832	PFKL	0.6	6.71	0.3	5.56e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg22437258	chr11:111473054	SIK2	0.57	10.07	0.42	1.07e-21	Primary sclerosing cholangitis;
LGG	cis	rs10463554	0.963	rs34829	chr5:102443964	A/T	cg23492399	chr5:102201601	PAM	-0.49	-7.38	-0.32	7.24e-13	Parkinson's disease;
LGG	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.89	-0.45	9.48e-25	Vitiligo;
LGG	cis	rs113835537	0.529	rs7950790	chr11:66258053	G/A	cg24851651	chr11:66362959	CCS	0.45	8.03	0.35	7.94e-15	Airway imaging phenotypes;
LGG	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18876405	chr7:65276391	NA	-0.6	-11.0	-0.46	3.64e-25	Aortic root size;
LGG	cis	rs10089	0.953	rs3805615	chr5:127519049	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.63	0.48	1.33e-27	Ileal carcinoids;
LGG	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.41	0.44	5.94e-23	Calcium levels;
LGG	cis	rs12519773	0.526	rs4469186	chr5:92520266	T/C	cg18783429	chr5:92414398	NA	0.32	7.76	0.34	5.62e-14	Migraine;
LGG	cis	rs6964587	0.869	rs6975243	chr7:91514672	G/A	cg17063962	chr7:91808500	NA	-0.4	-6.97	-0.31	1.13e-11	Breast cancer;
LGG	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs780094	0.500	rs74175068	chr2:27833502	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.3	5.3e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg25208724	chr1:156163844	SLC25A44	1.27	32.35	0.83	6.52e-121	Testicular germ cell tumor;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg01673284	chr16:4527211	HMOX2	0.32	6.74	0.3	4.77e-11	Schizophrenia;
LGG	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	9.78	0.41	1.18e-20	Rheumatoid arthritis;
LGG	cis	rs6565180	0.963	rs4787642	chr16:30359408	T/C	cg17640201	chr16:30407289	ZNF48	-0.83	-15.81	-0.59	2.47e-45	Tonsillectomy;
LGG	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg06532163	chr17:45867833	NA	0.55	9.33	0.4	4.58e-19	IgG glycosylation;
LGG	cis	rs1018697	1.000	rs7088711	chr10:104559266	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-9.11	-0.39	2.44e-18	Colorectal adenoma (advanced);
LGG	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.08e-14	Type 2 diabetes;
LGG	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg13256891	chr4:100009986	ADH5	0.57	9.72	0.41	1.87e-20	Alcohol dependence;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.78	-0.41	1.21e-20	Lung cancer;
LGG	trans	rs6787172	0.667	rs1618381	chr3:158028070	C/T	cg23275840	chr4:47708675	CORIN	0.4	8.72	0.38	4.83e-17	Subjective well-being;
LGG	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-14.21	-0.55	2.77e-38	Dental caries;
LGG	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.13	0.39	2.09e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg26384229	chr12:38710491	ALG10B	0.57	10.28	0.43	1.75e-22	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg20302533	chr7:39170763	POU6F2	0.53	13.06	0.52	2.01e-33	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.68	0.37	7.05e-17	Platelet count;
LGG	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.59	-0.53	1.19e-35	Response to antipsychotic treatment;
LGG	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg18351406	chr4:77819688	ANKRD56	0.47	8.1	0.35	4.81e-15	Emphysema distribution in smoking;
LGG	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs17030434	0.749	rs1125228	chr4:154769052	C/T	cg14289246	chr4:154710475	SFRP2	-0.47	-7.58	-0.33	1.87e-13	Electrocardiographic conduction measures;
LGG	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg10840412	chr1:235813424	GNG4	0.67	9.05	0.39	4.1e-18	Bipolar disorder;
LGG	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg26384229	chr12:38710491	ALG10B	1.02	26.13	0.77	3.81e-93	Heart rate;
LGG	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.93	0.42	3.46e-21	Rheumatoid arthritis;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.46	8.14	0.35	3.65e-15	Obesity-related traits;
LGG	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg15704280	chr7:45808275	SEPT13	0.74	8.09	0.35	5.24e-15	Intraocular pressure;
LGG	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.59	-0.33	1.81e-13	Morning vs. evening chronotype;
LGG	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg13660082	chr14:53194042	PSMC6	0.57	8.66	0.37	7.75e-17	Alzheimer's disease (late onset);
LGG	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg18131467	chr2:239335373	ASB1	1.01	22.89	0.73	4.1e-78	Multiple system atrophy;
LGG	cis	rs17023223	0.537	rs12092807	chr1:119750644	A/G	cg05756136	chr1:119680316	WARS2	0.47	8.31	0.36	1.06e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg24998770	chr7:37888106	TXNDC3	0.66	11.22	0.46	5.23e-26	Alzheimer's disease (late onset);
LGG	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.76	0.41	1.34e-20	Mean corpuscular volume;
LGG	cis	rs8095374	0.869	rs9955853	chr18:43829655	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.38	-8.23	-0.36	1.96e-15	Clinical laboratory measurements;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.23	-0.43	2.74e-22	Lymphocyte counts;
LGG	cis	rs67478160	0.595	rs12889993	chr14:104274294	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.47	-0.33	4.12e-13	Schizophrenia;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.52	-0.61	1.5e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23544223	chr18:12777786	NA	-0.54	-7.96	-0.35	1.35e-14	Inflammatory skin disease;
LGG	trans	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.73e-12	Morning vs. evening chronotype;
LGG	cis	rs35740288	0.770	rs12906580	chr15:86155287	C/T	cg04173714	chr15:86211321	AKAP13	-0.46	-8.52	-0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.33	-0.32	1e-12	Hemoglobin concentration;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg11473876	chr11:109292803	C11orf87	-0.79	-17.57	-0.63	2.52e-53	Schizophrenia;
LGG	cis	rs273218	1.000	rs168861	chr5:53377310	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.65	9.13	0.39	2.12e-18	Migraine;
LGG	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg15595755	chr5:1867978	NA	0.43	7.14	0.31	3.68e-12	Cardiovascular disease risk factors;
LGG	cis	rs9581857	0.547	rs17753121	chr13:28052613	T/C	cg01674679	chr13:27998804	GTF3A	-0.63	-7.31	-0.32	1.16e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2640806	0.525	rs2271775	chr8:97343176	G/T	cg22138393	chr8:97340270	PTDSS1	-0.27	-7.06	-0.31	6.25e-12	Obesity-related traits;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg17876456	chr1:182638158	RGS8	-0.41	-6.73	-0.3	4.93e-11	Apolipoprotein A-IV levels;
LGG	cis	rs42648	1.000	rs42648	chr7:89977760	A/G	cg25739043	chr7:89950458	NA	-0.38	-7.88	-0.34	2.41e-14	Homocysteine levels;
LGG	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.42	-0.44	5.51e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg14092988	chr3:52407081	DNAH1	0.32	8.24	0.36	1.82e-15	Bipolar disorder;
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg03609493	chr4:11370314	MIR572	0.41	6.93	0.31	1.41e-11	Monocyte count;
LGG	cis	rs12367572	0.620	rs2731053	chr12:45410728	G/A	cg03114573	chr12:45410052	DBX2	-0.69	-12.77	-0.51	3.2e-32	Gut microbiome composition (summer);
LGG	trans	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg05059571	chr16:84539110	KIAA1609	-0.56	-11.0	-0.46	3.83e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg12454169	chr2:30669597	LCLAT1	0.54	7.75	0.34	5.79e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.17	-0.36	2.88e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7666738	0.830	rs115279324	chr4:99042114	T/C	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11971779	0.680	rs7783619	chr7:139061437	G/A	cg07862535	chr7:139043722	LUC7L2	0.41	6.78	0.3	3.61e-11	Diisocyanate-induced asthma;
LGG	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg17595323	chr11:93583763	C11orf90	0.46	7.86	0.34	2.68e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18252515	chr7:66147081	NA	-0.41	-6.92	-0.31	1.47e-11	Aortic root size;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg12940439	chr1:67600707	NA	0.46	9.19	0.39	1.36e-18	Psoriasis;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.42	-0.53	6.52e-35	Alzheimer's disease;
LGG	cis	rs4330281	0.647	rs6809062	chr3:17711772	G/A	cg20981856	chr3:17787350	NA	-0.4	-7.53	-0.33	2.77e-13	Schizophrenia;
LGG	cis	rs894344	0.650	rs56411737	chr8:135582243	C/T	cg09855544	chr8:135498122	ZFAT	0.42	7.58	0.33	1.92e-13	Systolic blood pressure;
LGG	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg21453758	chr17:80185943	SLC16A3	0.34	7.48	0.33	3.73e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg13770153	chr20:60521292	NA	-0.5	-8.11	-0.35	4.55e-15	Body mass index;
LGG	cis	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.78	-0.45	2.46e-24	Resting heart rate;
LGG	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg09845145	chr15:78292470	TBC1D2B	-0.45	-7.97	-0.35	1.29e-14	Diastolic blood pressure;
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg06074448	chr4:187884817	NA	-0.6	-13.75	-0.54	2.52e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs977987	0.864	rs37592	chr16:75496791	G/C	cg03315344	chr16:75512273	CHST6	-0.57	-11.16	-0.46	8.79e-26	Dupuytren's disease;
LGG	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.15e-11	Iron status biomarkers;
LGG	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.56	-0.37	1.62e-16	Eye color traits;
LGG	cis	rs490234	0.932	rs474489	chr9:128317881	C/G	cg14078157	chr9:128172775	NA	0.41	7.57	0.33	2.1e-13	Mean arterial pressure;
LGG	cis	rs1007190	1.000	rs1007190	chr17:43038209	C/T	cg15406952	chr17:42872593	NA	0.65	7.76	0.34	5.37e-14	DNA methylation (variation);
LGG	cis	rs889398	0.835	rs62050037	chr16:69784670	T/C	cg00738113	chr16:70207722	CLEC18C	0.24	6.65	0.3	8.26e-11	Body mass index;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07243736	chr16:783730	NARFL	0.41	7.15	0.32	3.35e-12	Height;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07308232	chr7:1071921	C7orf50	-0.7	-14.01	-0.55	1.96e-37	Longevity;Endometriosis;
LGG	cis	rs4330281	0.669	rs9875973	chr3:17584573	T/C	cg20981856	chr3:17787350	NA	0.39	7.21	0.32	2.34e-12	Schizophrenia;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg11984989	chr7:158649758	WDR60	1.04	22.61	0.72	8.65e-77	Height;
LGG	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg20387954	chr3:183756860	HTR3D	0.65	13.1	0.52	1.44e-33	Anterior chamber depth;
LGG	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg00149659	chr3:10157352	C3orf10	0.58	8.27	0.36	1.42e-15	Alzheimer's disease;
LGG	cis	rs3204270	0.639	rs11867543	chr17:79655046	C/T	cg18367735	chr17:79674897	NA	0.6	7.85	0.34	2.88e-14	Dental caries;
LGG	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg05335186	chr13:53173507	NA	0.74	18.7	0.66	1.61e-58	Lewy body disease;
LGG	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.73	-0.45	3.95e-24	Vitiligo;
LGG	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.09e-22	Height;
LGG	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.55	-0.74	3.41e-81	Primary sclerosing cholangitis;
LGG	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg15921436	chr17:44337874	NA	-0.44	-10.39	-0.43	7.2e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13082711	0.911	rs73046191	chr3:27454398	T/A	cg02860705	chr3:27208620	NA	0.68	12.24	0.49	5.01e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-7.97	-0.35	1.24e-14	Personality dimensions;
LGG	cis	rs9400467	0.537	rs1891387	chr6:111462290	A/G	cg15721981	chr6:111408429	SLC16A10	0.56	6.84	0.3	2.48e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs751728	0.638	rs4607416	chr6:33784998	G/C	cg25922239	chr6:33757077	LEMD2	0.55	8.29	0.36	1.26e-15	Crohn's disease;
LGG	cis	rs4363385	0.782	rs310126	chr1:153019416	A/C	cg13444842	chr1:152974279	SPRR3	-0.38	-7.93	-0.35	1.67e-14	Inflammatory skin disease;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.2	-0.6	4.3e-47	Longevity;
LGG	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg25174290	chr11:3078921	CARS	-0.53	-9.79	-0.41	1.08e-20	Calcium levels;
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg02158880	chr13:53174818	NA	0.4	7.8	0.34	4.02e-14	Lewy body disease;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg04861929	chr11:109293070	C11orf87	0.52	9.62	0.41	4.34e-20	Schizophrenia;
LGG	cis	rs1256531	0.661	rs55648350	chr14:66054778	T/C	cg15999311	chr14:65749247	NA	0.79	6.7	0.3	5.96e-11	Conduct disorder (symptom count);
LGG	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg08250081	chr4:10125330	NA	0.68	12.32	0.5	2.38e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg00857998	chr1:205179979	DSTYK	0.57	9.23	0.39	9.36e-19	Red blood cell count;
LGG	cis	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg23625390	chr15:77176239	SCAPER	-0.74	-14.78	-0.57	8.82e-41	Blood metabolite levels;
LGG	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.99	-0.45	4.13e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4077515	0.870	rs10781510	chr9:139279173	G/A	cg21253087	chr9:139290292	SNAPC4	0.35	7.1	0.31	4.74e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg04986931	chr22:39850128	NA	0.34	7.69	0.34	8.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.05	-0.31	6.67e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs943466	0.614	rs4711345	chr6:33730954	G/A	cg25922239	chr6:33757077	LEMD2	-0.43	-7.29	-0.32	1.32e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7336332	0.598	rs76790205	chr13:28002885	C/T	cg01674679	chr13:27998804	GTF3A	-0.67	-8.57	-0.37	1.56e-16	Weight;
LGG	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg24331049	chr13:111365604	ING1	0.89	16.58	0.61	8.53e-49	Coronary artery disease;
LGG	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg08344181	chr3:125677491	NA	-0.88	-8.68	-0.37	6.63e-17	Depression;
LGG	cis	rs35740288	0.770	rs11630286	chr15:86202529	T/C	cg04173714	chr15:86211321	AKAP13	0.49	8.85	0.38	1.93e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg06637938	chr14:75390232	RPS6KL1	0.75	14.66	0.56	2.91e-40	Caffeine consumption;
LGG	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.61	-17.46	-0.63	7.8e-53	Oropharynx cancer;
LGG	trans	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-16.98	-0.62	1.31e-50	Exhaled nitric oxide output;
LGG	cis	rs11239187	0.548	rs10047389	chr10:45060956	G/A	cg03916630	chr10:45065415	NA	0.37	9.05	0.39	4.08e-18	Body mass index;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg06916706	chr16:4465613	CORO7	-1.07	-20.61	-0.69	1.95e-67	Schizophrenia;
LGG	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.23e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg22072935	chr14:105399595	NA	0.53	10.08	0.42	9.6e-22	Rheumatoid arthritis;
LGG	cis	rs62209	0.530	rs17444979	chr10:10994159	C/T	cg26901096	chr10:10994189	LOC254312	0.65	10.73	0.45	3.87e-24	Alzheimer's disease (late onset);
LGG	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-17.5	-0.63	5.38e-53	Vitiligo;
LGG	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg06191203	chr2:152266755	RIF1	-0.42	-6.8	-0.3	3.24e-11	Squamous cell lung carcinoma;
LGG	cis	rs4689388	0.824	rs4580722	chr4:6306144	C/A	cg14416269	chr4:6271139	WFS1	0.49	8.84	0.38	2.05e-17	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg27490568	chr2:178487706	NA	0.69	12.22	0.49	5.67e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2797369	0.656	rs2756040	chr6:101366027	G/A	cg27451362	chr6:101846650	GRIK2	0.77	10.66	0.44	6.96e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg12615879	chr12:58013172	SLC26A10	0.33	7.37	0.32	7.98e-13	Multiple sclerosis;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.54	-0.33	2.45e-13	Skin colour saturation;
LGG	cis	rs7580658	0.637	rs1566822	chr2:127987391	A/G	cg10021288	chr2:128175891	PROC	-0.62	-12.47	-0.5	5.78e-31	Protein C levels;
LGG	cis	rs2016266	0.684	rs4759021	chr12:53714868	G/A	cg04065151	chr12:53682969	ESPL1	0.63	10.09	0.42	9e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg12800244	chr3:153838788	SGEF	0.57	8.18	0.36	2.78e-15	Coronary artery disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04562562	chr17:61044133	NA	0.6	6.69	0.3	6.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg24375607	chr4:120327624	NA	0.69	11.16	0.46	9.17e-26	Corneal astigmatism;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13552710	chr2:30144547	ALK	-0.37	-6.67	-0.3	7.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00149659	chr3:10157352	C3orf10	0.9	11.5	0.47	4.3e-27	Alzheimer's disease;
LGG	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg25174290	chr11:3078921	CARS	-0.52	-9.45	-0.4	1.67e-19	Calcium levels;
LGG	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.81	-0.38	2.61e-17	Myopia (pathological);
LGG	cis	rs9290877	0.667	rs9290878	chr3:188450118	C/T	cg17392043	chr3:188495102	LPP	-0.4	-6.79	-0.3	3.56e-11	IgE levels;
LGG	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg10596483	chr8:143751796	JRK	0.53	8.27	0.36	1.43e-15	Schizophrenia;
LGG	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg12654349	chr5:56205094	C5orf35	-0.41	-7.42	-0.33	5.68e-13	Coronary artery disease;
LGG	cis	rs854037	0.512	rs10461438	chr5:57123592	T/C	cg08523694	chr5:57076192	NA	0.53	7.0	0.31	8.75e-12	Birth weight;
LGG	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg12386194	chr3:101231763	SENP7	0.44	7.67	0.34	1.06e-13	Colorectal cancer;
LGG	cis	rs6912958	0.500	rs2025486	chr6:87796886	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-10.04	-0.42	1.34e-21	Monocyte percentage of white cells;
LGG	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.38	0.32	7.45e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.71	-7.49	-0.33	3.45e-13	Facial emotion recognition (sad faces);
LGG	cis	rs4566357	0.615	rs10177528	chr2:227913706	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.07	-0.39	3.34e-18	Coronary artery disease;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07308232	chr7:1071921	C7orf50	-0.5	-9.19	-0.39	1.32e-18	Longevity;Endometriosis;
LGG	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.16	-0.39	1.66e-18	Type 2 diabetes;
LGG	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	9.29	0.4	5.97e-19	Mood instability;
LGG	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg01411142	chr8:19674711	INTS10	0.8	10.25	0.43	2.26e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.47	0.5	5.54e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09947615	chr4:42659549	ATP8A1	0.41	7.03	0.31	7.22e-12	Bilirubin levels;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.18e-12	Menopause (age at onset);
LGG	cis	rs6708331	0.517	rs6546572	chr2:70373642	C/T	cg01613454	chr2:70366299	NA	0.54	11.2	0.46	6.19e-26	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.85	-0.51	1.5e-32	Alzheimer's disease;
LGG	cis	rs9487094	0.645	rs34533653	chr6:109800691	T/A	cg01125227	chr6:109776195	MICAL1	0.48	7.37	0.32	7.91e-13	Height;
LGG	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg03078520	chr22:18463400	MICAL3	-0.69	-14.46	-0.56	2.19e-39	Presence of antiphospholipid antibodies;
LGG	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg15208524	chr1:10270712	KIF1B	0.45	7.85	0.34	2.87e-14	Hepatocellular carcinoma;
LGG	trans	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs7851660	0.844	rs10123699	chr9:100637859	A/G	cg13688889	chr9:100608707	NA	-0.59	-11.69	-0.48	7.95e-28	Strep throat;
LGG	cis	rs1385374	0.858	rs10847692	chr12:129289679	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	trans	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg24247370	chr13:99142703	STK24	0.36	6.69	0.3	6.46e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1125355	0.690	rs72939209	chr2:159642803	A/G	cg02251393	chr2:159651559	DAPL1	0.42	8.76	0.38	3.81e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.08e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs11877825	0.826	rs8088116	chr18:10579879	T/A	cg07277756	chr18:10589357	NA	0.58	10.38	0.43	7.9e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs2802728	0.881	rs12239149	chr1:243548722	C/A	cg05593162	chr1:243577377	SDCCAG8	0.51	7.29	0.32	1.39e-12	Toenail selenium levels;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg19635926	chr16:89946313	TCF25	0.79	8.01	0.35	9.17e-15	Skin colour saturation;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.55	-9.72	-0.41	1.92e-20	Longevity;Endometriosis;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg00933542	chr6:150070202	PCMT1	0.37	6.65	0.3	8.45e-11	Lung cancer;
LGG	cis	rs1127311	1.000	rs10908419	chr1:154567699	G/A	cg11650704	chr1:154556575	ADAR	-0.5	-9.89	-0.42	4.58e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1983891	0.955	rs9381076	chr6:41517564	G/A	cg20194872	chr6:41519635	FOXP4	0.6	10.43	0.44	4.92e-23	Prostate cancer;
LGG	cis	rs17373728	0.710	rs2221810	chr8:76221468	C/G	cg07016329	chr8:76221503	NA	-0.62	-11.54	-0.47	2.85e-27	Diabetic kidney disease;
LGG	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	Neuroticism;
LGG	cis	rs977987	0.872	rs1542864	chr16:75471378	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.09	0.42	9.23e-22	Dupuytren's disease;
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.13	-0.49	1.36e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg01620082	chr3:125678407	NA	-0.73	-7.71	-0.34	7.7e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12286929	0.583	rs10458966	chr11:115102758	T/C	cg04055981	chr11:115044050	NA	0.36	6.78	0.3	3.57e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21190381	chr2:53994763	LOC100302652;ASB3;CHAC2	0.43	6.88	0.3	1.91e-11	Gut microbiome composition (summer);
LGG	cis	rs1983891	0.706	rs3800285	chr6:41558443	C/T	cg20194872	chr6:41519635	FOXP4	-0.51	-8.87	-0.38	1.65e-17	Prostate cancer;
LGG	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.6	-0.56	5.39e-40	Headache;
LGG	cis	rs832540	0.656	rs6893754	chr5:56100006	G/A	cg12654349	chr5:56205094	C5orf35	-0.38	-6.85	-0.3	2.4e-11	Coronary artery disease;
LGG	cis	rs9487094	0.670	rs12201356	chr6:110015875	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.66	0.34	1.07e-13	Height;
LGG	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00292662	chr22:38071168	LGALS1	0.65	14.88	0.57	3.15e-41	Fat distribution (HIV);
LGG	cis	rs11608355	0.597	rs9943699	chr12:109840876	G/C	cg19025524	chr12:109796872	NA	-0.57	-12.3	-0.5	2.68e-30	Neuroticism;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg17178900	chr1:205818956	PM20D1	0.58	12.79	0.51	2.71e-32	Menarche (age at onset);
LGG	cis	rs4595586	0.632	rs1356266	chr12:39403581	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-8.55	-0.37	1.86e-16	Morning vs. evening chronotype;
LGG	cis	rs283228	0.793	rs2797365	chr6:101718055	G/A	cg27451362	chr6:101846650	GRIK2	0.56	8.66	0.37	7.99e-17	Coenzyme Q10 levels;
LGG	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs12731740	1.000	rs12565089	chr1:208017129	A/C	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.43	-0.33	5.28e-13	Biomedical quantitative traits;
LGG	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.65	0.63	1.1e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8077889	0.703	rs231532	chr17:41945769	C/T	cg26893861	chr17:41843967	DUSP3	-0.71	-10.3	-0.43	1.51e-22	Triglycerides;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.43	-0.44	5.14e-23	Bladder cancer;
LGG	cis	rs6693567	0.545	rs35705743	chr1:150451832	G/A	cg15654264	chr1:150340011	RPRD2	0.32	6.69	0.3	6.63e-11	Migraine;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg04080417	chr5:1859792	NA	-0.53	-8.7	-0.37	5.98e-17	Cardiovascular disease risk factors;
LGG	cis	rs4742903	0.935	rs17236663	chr9:106928402	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.2	0.36	2.37e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3008870	1.000	rs3008848	chr1:67379284	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	22.83	0.73	7.75e-78	Lymphocyte percentage of white cells;
LGG	trans	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg16141378	chr3:129829833	LOC729375	0.42	9.82	0.42	8.68e-21	Mood instability;
LGG	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg06970220	chr1:156163860	SLC25A44	0.45	6.68	0.3	6.71e-11	Testicular germ cell tumor;
LGG	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg21130718	chr4:1044621	NA	-0.39	-7.69	-0.34	8.96e-14	Recombination rate (males);
LGG	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg14784868	chr12:69753453	YEATS4	0.73	13.96	0.54	3.26e-37	Blood protein levels;
LGG	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg02187348	chr16:89574699	SPG7	0.58	9.58	0.41	6.17e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.24e-25	Corneal astigmatism;
LGG	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs11605275	1.000	rs76399107	chr11:20029148	C/T	cg14835545	chr11:20032148	NAV2	-0.83	-8.67	-0.37	7.59e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4262150	0.920	rs13187261	chr5:152286739	G/A	cg12297329	chr5:152029980	NA	0.6	11.38	0.47	1.27e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg05368731	chr17:41323189	NBR1	0.96	18.93	0.66	1.25e-59	Menopause (age at onset);
LGG	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	10.12	0.43	6.73e-22	Neuroticism;
LGG	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg22348356	chr13:114891224	RASA3	0.39	7.5	0.33	3.23e-13	Schizophrenia;
LGG	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg13334819	chr7:99746414	C7orf59	0.5	7.83	0.34	3.44e-14	Coronary artery disease;
LGG	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg15268244	chr15:77196840	NA	0.43	8.28	0.36	1.36e-15	Blood metabolite levels;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.35	-7.46	-0.33	4.31e-13	Schizophrenia;
LGG	trans	rs6601327	0.600	rs7828039	chr8:9654757	G/C	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.56e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg05025164	chr4:1340916	KIAA1530	0.47	7.75	0.34	6.02e-14	Obesity-related traits;
LGG	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg17971929	chr21:40555470	PSMG1	0.79	14.2	0.55	3.06e-38	Cognitive function;
LGG	trans	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.78e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16632994	chr5:158690246	UBLCP1	0.45	7.4	0.33	6.37e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.72	0.45	4.37e-24	Obesity-related traits;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02542118	chr2:61245510	PEX13;PUS10	0.38	6.76	0.3	4.19e-11	Obesity-related traits;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg25703541	chr22:24373054	LOC391322	-0.85	-16.2	-0.6	4.16e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg02733842	chr7:1102375	C7orf50	0.68	7.98	0.35	1.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-7.84	-0.34	3.15e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs3806843	0.576	rs246034	chr5:140332064	A/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg15704280	chr7:45808275	SEPT13	-0.84	-16.23	-0.6	3.21e-47	Height;
LGG	trans	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.66	0.48	1.05e-27	Corneal astigmatism;
LGG	cis	rs9815354	0.812	rs7639859	chr3:42001987	C/T	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs638893	0.636	rs7119702	chr11:118607694	G/A	cg13782932	chr11:118662891	DDX6	0.37	6.79	0.3	3.38e-11	Vitiligo;
LGG	cis	rs7166081	1.000	rs4776348	chr15:67533304	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.02	-0.31	8.19e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs941764	0.965	rs747159	chr14:91841030	A/C	cg10511902	chr14:91842949	CCDC88C	-0.68	-15.51	-0.58	5.52e-44	Breast cancer;
LGG	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs273218	1.000	rs156437	chr5:53376454	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.62	8.83	0.38	2.22e-17	Migraine;
LGG	cis	rs9457247	0.602	rs9457262	chr6:167473685	A/G	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Crohn's disease;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.63	-12.45	-0.5	7.1e-31	Obesity-related traits;
LGG	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg17108064	chr15:78857060	CHRNA5	0.45	9.24	0.39	9e-19	Sudden cardiac arrest;
LGG	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg01324343	chr3:183735012	ABCC5	0.87	18.6	0.65	4.45e-58	Anterior chamber depth;
LGG	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg24112000	chr20:60950667	NA	0.36	8.14	0.35	3.68e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-6.74	-0.3	4.87e-11	Ulcerative colitis;
LGG	cis	rs721917	0.506	rs2819113	chr10:81650743	C/T	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg00933542	chr6:150070202	PCMT1	0.39	6.9	0.31	1.68e-11	Lung cancer;
LGG	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg06121193	chr1:90282411	NA	-0.38	-7.28	-0.32	1.4e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg07211511	chr3:129823064	LOC729375	-0.5	-7.49	-0.33	3.56e-13	Blood pressure (smoking interaction);
LGG	cis	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.25	0.32	1.77e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs7799771	chr7:124649937	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.12	0.35	4.22e-15	Longevity;
LGG	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.41e-20	Heart rate;
LGG	cis	rs2249625	0.508	rs60020363	chr6:72844706	C/T	cg27608224	chr6:72922399	RIMS1	-0.33	-7.27	-0.32	1.57e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-10.63	-0.44	9.14e-24	Total body bone mineral density;
LGG	cis	rs2380220	1.000	rs2380222	chr6:95975395	C/T	cg04719120	chr6:96025338	MANEA	0.52	6.78	0.3	3.71e-11	Behavioural disinhibition (generation interaction);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14715482	chr5:10377171	MARCH6	0.39	6.79	0.3	3.45e-11	Menarche (age at onset);
LGG	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg20578329	chr17:80767326	TBCD	0.44	7.66	0.34	1.1e-13	Breast cancer;
LGG	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg11502198	chr6:26597334	ABT1	0.71	12.59	0.5	1.9e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg24247370	chr13:99142703	STK24	-0.42	-7.38	-0.32	7.35e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg02466173	chr16:30829666	NA	-0.42	-8.06	-0.35	6.37e-15	Triglycerides;
LGG	cis	rs2334880	0.678	rs7186112	chr16:71840073	A/T	cg06353428	chr16:71660113	MARVELD3	1.26	19.74	0.68	2.13e-63	Malaria;
LGG	cis	rs73787773	0.668	rs56010932	chr5:111481403	A/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.58	-7.6	-0.33	1.63e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg09426994	chr11:118478258	PHLDB1	0.39	6.69	0.3	6.59e-11	Cholesterol, total;
LGG	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21582582	chr3:182698605	DCUN1D1	0.51	9.35	0.4	3.64e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1595825	0.891	rs996427	chr2:198685609	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-7.02	-0.31	7.89e-12	Ulcerative colitis;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25072359	chr17:41440525	NA	0.51	9.95	0.42	2.95e-21	Menopause (age at onset);
LGG	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg00531865	chr16:30841666	NA	-0.38	-7.96	-0.35	1.3e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2279817	0.691	rs7543007	chr1:17990475	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.58	-9.0	-0.39	6.07e-18	Neuroticism;
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg14137381	chr5:502291	SLC9A3	-0.33	-6.9	-0.31	1.74e-11	Cystic fibrosis severity;
LGG	cis	rs11696845	0.666	rs13042905	chr20:43379454	T/C	cg25301532	chr20:43378953	KCNK15	0.48	11.86	0.48	1.61e-28	Obesity-related traits;
LGG	cis	rs2594989	1.000	rs2606747	chr3:11374955	T/C	cg01796438	chr3:11312864	ATG7	-0.57	-7.88	-0.34	2.4e-14	Circulating chemerin levels;
LGG	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg15268244	chr15:77196840	NA	0.48	10.31	0.43	1.41e-22	Blood metabolite levels;
LGG	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg27490568	chr2:178487706	NA	0.53	10.41	0.44	5.94e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10947003	chr16:67218230	KIAA0895L	0.45	6.7	0.3	6.05e-11	Gut microbiome composition (summer);
LGG	cis	rs1044826	0.647	rs4683463	chr3:139196946	T/G	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg13256891	chr4:100009986	ADH5	0.56	9.35	0.4	3.61e-19	Alcohol dependence;
LGG	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.71	-0.3	5.79e-11	Neuroticism;
LGG	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg04733989	chr22:42467013	NAGA	-0.57	-10.23	-0.43	2.69e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.37e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.48	-9.14	-0.39	2e-18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs36051895	0.623	rs1575283	chr9:5238588	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-14.24	-0.55	2.07e-38	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.67	-0.3	7.1e-11	Lung cancer;
LGG	cis	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.62	-0.41	4.27e-20	Morning vs. evening chronotype;
LGG	cis	rs6993813	0.505	rs35533151	chr8:120023725	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.44	0.37	4.2e-16	Bone mineral density (hip);
LGG	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.87	-14.99	-0.57	1.1e-41	Chronic sinus infection;
LGG	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg02002194	chr4:3960332	NA	0.48	9.27	0.4	7.07e-19	Mood instability;
LGG	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg04842962	chr6:43655489	MRPS18A	1.11	24.49	0.75	1.42e-85	IgG glycosylation;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg02275930	chr1:2372054	NA	-0.83	-17.34	-0.63	3e-52	Non-obstructive azoospermia;
LGG	cis	rs12153243	0.714	rs66524576	chr5:142895661	G/A	cg13907255	chr5:142895549	NA	-0.49	-8.75	-0.38	4.07e-17	Migraine;
LGG	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.37	-0.36	6.65e-16	Alzheimer's disease (survival time);
LGG	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg08603382	chr10:743973	NA	0.39	7.11	0.31	4.46e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs9912468	0.933	rs17633437	chr17:64301842	A/G	cg19474267	chr17:64306194	PRKCA	0.94	24.85	0.76	2.98e-87	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs7572733	0.555	rs6729473	chr2:198763928	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.19	0.46	7.05e-26	Dermatomyositis;
LGG	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.88	-0.38	1.43e-17	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01538984	chr7:140396422	LOC100134713;NDUFB2	0.53	8.59	0.37	1.39e-16	Gut microbiome composition (summer);
LGG	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.69	7.58	0.33	1.95e-13	Initial pursuit acceleration;
LGG	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg15841412	chr13:111365552	ING1	0.44	6.93	0.31	1.4e-11	Coronary artery disease;
LGG	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg26384229	chr12:38710491	ALG10B	-0.75	-14.59	-0.56	5.93e-40	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg06623918	chr6:96969491	KIAA0776	0.76	10.55	0.44	1.9e-23	Migraine;Coronary artery disease;
LGG	cis	rs7851660	0.874	rs1955145	chr9:100634751	A/C	cg13688889	chr9:100608707	NA	0.58	11.83	0.48	2.17e-28	Strep throat;
LGG	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.19	0.36	2.49e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7666738	0.830	rs7662199	chr4:99019766	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.93	0.35	1.71e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg06360820	chr2:242988706	NA	-0.55	-7.54	-0.33	2.44e-13	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg04267008	chr7:1944627	MAD1L1	0.46	7.84	0.34	3.14e-14	Schizophrenia;
LGG	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg13010199	chr12:38710504	ALG10B	0.46	8.68	0.37	6.91e-17	Morning vs. evening chronotype;
LGG	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.71	-0.3	5.79e-11	Neuroticism;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg07142201	chr11:109293216	C11orf87	0.51	9.41	0.4	2.25e-19	Schizophrenia;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg01988459	chr11:68622903	NA	-0.64	-12.76	-0.51	3.59e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01341218	chr17:43662625	NA	0.66	11.93	0.48	8.67e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11644478	chr21:40555479	PSMG1	0.91	17.22	0.62	1.06e-51	Cognitive function;
LGG	cis	rs1003719	0.715	rs13046581	chr21:38551985	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.08	-0.57	4.13e-42	Eye color traits;
LGG	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg06654118	chr4:1303317	MAEA	0.48	8.07	0.35	6.16e-15	Obesity-related traits;
LGG	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19717773	chr7:2847554	GNA12	-0.38	-8.58	-0.37	1.45e-16	Height;
LGG	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.39	0.61	5.8e-48	Hip circumference adjusted for BMI;
LGG	cis	rs10979	1.000	rs13211390	chr6:143888010	A/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.47	-0.5	5.64e-31	Hypospadias;
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.33	-0.43	1.22e-22	Intelligence (multi-trait analysis);
LGG	cis	rs11239187	0.530	rs10160128	chr10:45059857	G/C	cg03916630	chr10:45065415	NA	0.36	8.63	0.37	9.63e-17	Body mass index;
LGG	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.3	-0.4	5.47e-19	Ovarian reserve;
LGG	cis	rs17641971	0.899	rs341804	chr8:49991553	G/C	cg00325661	chr8:49890786	NA	-0.5	-8.52	-0.37	2.19e-16	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16370446	chr4:15683284	LOC285550	0.44	7.52	0.33	2.79e-13	Bipolar disorder;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg24690094	chr11:67383802	NA	-0.54	-8.54	-0.37	1.88e-16	Mean corpuscular volume;
LGG	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.56	9.82	0.42	8.11e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg26031613	chr14:104095156	KLC1	0.78	14.02	0.55	1.88e-37	Body mass index;
LGG	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg17644776	chr2:200775616	C2orf69	-0.67	-8.48	-0.37	3.05e-16	Schizophrenia;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg18402987	chr7:1209562	NA	0.49	8.29	0.36	1.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.46	-0.33	4.41e-13	Lung cancer;
LGG	cis	rs2180341	0.814	rs6905553	chr6:127727407	A/G	cg27446573	chr6:127587934	RNF146	0.93	17.35	0.63	2.51e-52	Breast cancer;
LGG	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg25457927	chr22:38595422	NA	-0.43	-11.1	-0.46	1.5e-25	Cutaneous nevi;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7444	0.941	rs11089629	chr22:21958872	T/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg03929089	chr4:120376271	NA	0.44	7.09	0.31	5.2e-12	HDL cholesterol;
LGG	cis	rs68170813	0.559	rs12536574	chr7:106810997	A/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.93	-0.45	7e-25	Coronary artery disease;
LGG	cis	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-11.0	-0.46	3.59e-25	Resting heart rate;
LGG	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg08125733	chr17:73851984	WBP2	0.71	10.81	0.45	1.95e-24	Psoriasis;
LGG	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.03	-0.31	7.48e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9379945	1	rs9379945	chr6:26907831	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.56	-0.33	2.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg02158880	chr13:53174818	NA	0.67	15.33	0.58	3.5e-43	Lewy body disease;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg04287289	chr16:89883240	FANCA	0.84	7.87	0.34	2.57e-14	Skin colour saturation;
LGG	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.93	-0.38	1.02e-17	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10974632	chr14:51562381	TRIM9	0.42	6.98	0.31	1.03e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9929218	0.551	rs1886697	chr16:68716179	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.12	31.55	0.83	1.94e-117	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg00092383	chr7:157075207	NA	-0.38	-6.69	-0.3	6.27e-11	Body mass index;
LGG	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.08	-0.31	5.47e-12	Total cholesterol levels;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg20042908	chr11:133852938	NA	-0.35	-6.71	-0.3	5.76e-11	Hand grip strength;
LGG	cis	rs832540	0.656	rs832567	chr5:56152416	C/A	cg12654349	chr5:56205094	C5orf35	-0.42	-7.36	-0.32	8.39e-13	Coronary artery disease;
LGG	cis	rs11920090	0.858	rs55692900	chr3:170701587	T/G	cg09710316	chr3:170744871	SLC2A2	0.65	8.4	0.36	5.47e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg21055462	chr7:100276975	NA	0.45	9.58	0.41	5.95e-20	Other erythrocyte phenotypes;
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg05313129	chr8:58192883	C8orf71	-0.6	-8.45	-0.37	3.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg16606324	chr3:10149918	C3orf24	0.61	6.97	0.31	1.11e-11	Alzheimer's disease;
LGG	cis	rs422249	0.512	rs174562	chr11:61585144	A/G	cg19610905	chr11:61596333	FADS2	-0.8	-14.28	-0.55	1.3e-38	Trans fatty acid levels;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg18350739	chr11:68623251	NA	-0.87	-22.45	-0.72	4.75e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.86	-0.3	2.17e-11	Triglycerides;
LGG	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.16	-0.49	1.01e-29	HDL cholesterol;
LGG	cis	rs113835537	0.529	rs17147644	chr11:66256660	C/T	cg24851651	chr11:66362959	CCS	0.43	7.58	0.33	1.84e-13	Airway imaging phenotypes;
LGG	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg02002194	chr4:3960332	NA	0.47	8.62	0.37	1.1e-16	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg21948465	chr5:131705150	SLC22A5	-0.65	-7.5	-0.33	3.22e-13	Rheumatoid arthritis;
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg27476859	chr7:2772710	GNA12	0.48	9.03	0.39	4.67e-18	Height;
LGG	cis	rs78366141	0.649	rs10428273	chr4:89672738	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.83	7.9	0.34	2.02e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg26769984	chr7:1090371	C7orf50	0.43	7.69	0.34	8.88e-14	Bronchopulmonary dysplasia;
LGG	cis	rs9378357	0.572	rs4435990	chr6:3280644	C/T	cg08754725	chr6:3293098	SLC22A23	0.56	6.78	0.3	3.66e-11	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg00495681	chr13:53174319	NA	0.44	7.24	0.32	1.91e-12	Lewy body disease;
LGG	cis	rs9486719	0.843	rs2499787	chr6:96841762	G/C	cg06623918	chr6:96969491	KIAA0776	0.74	9.7	0.41	2.17e-20	Migraine;Coronary artery disease;
LGG	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.48	-0.4	1.31e-19	Common traits (Other);
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.5	-0.47	4.22e-27	Personality dimensions;
LGG	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg00129232	chr17:37814104	STARD3	-0.62	-11.58	-0.47	2.04e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg20573242	chr4:122745356	CCNA2	0.55	10.26	0.43	2.18e-22	Type 2 diabetes;
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.85	-0.34	2.9e-14	Total body bone mineral density;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg06916706	chr16:4465613	CORO7	-1.13	-22.62	-0.72	7.36e-77	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.23	0.32	1.96e-12	Menopause (age at onset);
LGG	cis	rs686320	0.748	rs673753	chr11:65206017	A/G	cg17392047	chr11:65247138	NA	-0.5	-6.65	-0.3	8.16e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg18402987	chr7:1209562	NA	0.67	9.13	0.39	2.15e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18876405	chr7:65276391	NA	0.51	9.02	0.39	5.03e-18	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16533672	chr13:50160050	RCBTB1	0.46	6.79	0.3	3.56e-11	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02501334	chr17:66508232	PRKAR1A	0.45	7.53	0.33	2.74e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4704187	0.712	rs7701262	chr5:74365986	C/T	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg02975922	chr3:195473998	MUC4	0.45	7.15	0.32	3.36e-12	Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg14191688	chr11:70257035	CTTN	0.6	8.51	0.37	2.45e-16	Coronary artery disease;
LGG	cis	rs7789940	0.904	rs73140040	chr7:75936240	C/T	cg10167463	chr7:75959203	YWHAG	-0.44	-7.24	-0.32	1.94e-12	Multiple sclerosis;
LGG	cis	rs10214930	0.697	rs6462024	chr7:27562340	A/G	cg22168087	chr7:27702803	HIBADH	0.45	6.7	0.3	6.14e-11	Hypospadias;
LGG	cis	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg26384229	chr12:38710491	ALG10B	0.99	23.79	0.74	2.47e-82	Heart rate;
LGG	cis	rs3816183	1.000	rs3816179	chr2:43015401	T/C	cg27299406	chr2:43020013	HAAO	-0.28	-6.83	-0.3	2.69e-11	Hypospadias;
LGG	cis	rs6835098	0.961	rs28709762	chr4:174099149	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-14.8	-0.57	7.38e-41	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs3803915	0.866	rs7251881	chr19:2169067	G/A	cg27073066	chr19:2169160	DOT1L	1.03	12.97	0.52	4.9e-33	Body mass index;Myocardial infarction;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.69	0.34	9.05e-14	Longevity;
LGG	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.49e-24	Aortic root size;
LGG	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg04662567	chr6:169592167	NA	0.75	9.78	0.41	1.21e-20	Pulse pressure;
LGG	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg02614661	chr16:87878292	SLC7A5	-0.36	-7.25	-0.32	1.81e-12	Blood metabolite levels;
LGG	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	8.2	0.36	2.43e-15	Iron status biomarkers;
LGG	cis	rs10504073	0.669	rs4493917	chr8:50015846	C/T	cg00325661	chr8:49890786	NA	0.74	14.19	0.55	3.39e-38	Blood metabolite ratios;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.17	-0.39	1.61e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.67	-0.34	9.97e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.99	0.88	2.39e-148	Chronic sinus infection;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg11494091	chr17:61959527	GH2	0.97	22.35	0.72	1.41e-75	Prudent dietary pattern;
LGG	cis	rs10861661	0.963	rs10861669	chr12:107200068	C/A	cg15890332	chr12:107067104	RFX4	0.3	6.7	0.3	6.25e-11	Triglyceride levels;
LGG	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg11247378	chr22:39784982	NA	-0.32	-8.93	-0.38	9.8e-18	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08677398	chr8:58056175	NA	0.57	9.17	0.39	1.53e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.97	-10.2	-0.43	3.54e-22	Diabetic retinopathy;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11298680	chr1:28559461	DNAJC8	0.43	7.51	0.33	3.05e-13	Bilirubin levels;
LGG	cis	rs2221894	0.506	rs17526904	chr8:28947843	C/T	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.78	-0.34	4.8e-14	Obesity-related traits;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg02127607	chr17:61920694	SMARCD2	0.45	8.13	0.35	3.93e-15	Prudent dietary pattern;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg12692727	chr7:1102344	C7orf50	0.49	6.87	0.3	2.12e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4363385	0.510	rs10888528	chr1:153050516	A/G	cg13444842	chr1:152974279	SPRR3	0.48	9.55	0.41	7.82e-20	Inflammatory skin disease;
LGG	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14019695	chr9:139328340	INPP5E	0.42	7.51	0.33	3.06e-13	Monocyte percentage of white cells;
LGG	cis	rs55788414	0.932	rs12103358	chr16:81185844	C/G	cg06400318	chr16:81190750	PKD1L2	-0.79	-10.23	-0.43	2.7e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05052898	chr14:88789655	KCNK10	0.6	6.86	0.3	2.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-7.44	-0.33	4.81e-13	Inflammatory bowel disease;
LGG	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg00339695	chr16:24857497	SLC5A11	0.35	6.97	0.31	1.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg14416269	chr4:6271139	WFS1	0.54	9.75	0.41	1.46e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg05084668	chr3:125655381	ALG1L	-0.85	-10.62	-0.44	1.03e-23	Blood pressure (smoking interaction);
LGG	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs6752107	0.500	rs11893210	chr2:234204672	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	8.41	0.36	5.3e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4650994	0.816	rs1074896	chr1:178591190	A/G	cg12486710	chr1:178512616	C1orf220	-0.4	-7.98	-0.35	1.13e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg11764359	chr7:65958608	NA	0.77	13.98	0.54	2.71e-37	Aortic root size;
LGG	cis	rs7216064	0.765	rs6504550	chr17:65894542	A/G	cg12091567	chr17:66097778	LOC651250	-0.58	-8.99	-0.39	6.42e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg00339695	chr16:24857497	SLC5A11	0.33	6.65	0.3	8.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10895140	0.718	rs10736620	chr11:101519731	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.87	-0.3	2.13e-11	Menarche (age at onset);
LGG	cis	rs7315438	0.556	rs10850519	chr12:115928440	C/G	cg18639984	chr12:115943877	NA	-0.36	-7.5	-0.33	3.35e-13	Colorectal cancer;
LGG	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg08508325	chr11:3079039	CARS	0.6	12.75	0.51	4.09e-32	Longevity;
LGG	trans	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg02002194	chr4:3960332	NA	0.4	6.89	0.3	1.78e-11	Mood instability;
LGG	cis	rs3768617	0.811	rs61808068	chr1:182979377	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.06e-11	Fuchs's corneal dystrophy;
LGG	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg09264619	chr17:80180166	NA	0.51	10.08	0.42	9.65e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Bladder cancer;
LGG	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg11317459	chr13:21872234	NA	-1.18	-19.46	-0.67	4.49e-62	White matter hyperintensity burden;
LGG	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.83	0.34	3.41e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-6.67	-0.3	7.38e-11	Vitiligo;
LGG	cis	rs7590368	0.926	rs12621237	chr2:10957538	T/C	cg15705551	chr2:10952987	PDIA6	0.66	10.08	0.42	9.72e-22	Educational attainment (years of education);
LGG	cis	rs10937275	0.793	rs35376159	chr3:186648929	T/A	cg26193484	chr3:186648175	ST6GAL1	0.89	9.23	0.39	9.58e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07659893	chr17:61819838	STRADA	-0.41	-6.66	-0.3	8.02e-11	Prudent dietary pattern;
LGG	cis	rs4330281	0.647	rs5014632	chr3:17695082	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.51	-0.33	3.12e-13	Schizophrenia;
LGG	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg21862992	chr11:68658383	NA	0.52	8.44	0.37	4.03e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs42648	1.000	rs42656	chr7:89981636	A/G	cg25739043	chr7:89950458	NA	-0.36	-7.57	-0.33	1.99e-13	Homocysteine levels;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.37	0.43	8.54e-23	Prudent dietary pattern;
LGG	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-8.48	-0.37	2.96e-16	Ulcerative colitis;
LGG	cis	rs7929679	0.551	rs10466455	chr11:34780936	C/T	cg06937548	chr11:34938143	PDHX;APIP	-0.41	-7.0	-0.31	8.8e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.55e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg12386194	chr3:101231763	SENP7	-0.68	-11.34	-0.47	1.78e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.74e-21	Diabetic retinopathy;
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg09303159	chr6:26284866	NA	-0.31	-6.94	-0.31	1.35e-11	Educational attainment;
LGG	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.59	-7.02	-0.31	7.84e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11971779	0.793	rs11764426	chr7:139024050	C/G	cg07862535	chr7:139043722	LUC7L2	0.5	8.06	0.35	6.76e-15	Diisocyanate-induced asthma;
LGG	cis	rs3845702	0.736	rs72960701	chr2:180851202	A/T	cg01881094	chr2:180872142	CWC22	1.28	16.67	0.61	3.15e-49	Schizophrenia;
LGG	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg27489772	chr12:121021490	NA	-0.56	-7.5	-0.33	3.39e-13	Type 1 diabetes nephropathy;
LGG	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.02	-0.46	2.99e-25	Hemoglobin concentration;
LGG	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs3747547	1.000	rs11788065	chr9:37925826	G/C	cg13774184	chr9:37916125	SHB	-0.67	-6.65	-0.3	8.07e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs4380275	0.782	rs4854276	chr2:764357	C/T	cg02758766	chr2:740531	NA	-0.38	-6.77	-0.3	4.02e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-14.39	-0.56	4.47e-39	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.16	-0.32	3.11e-12	IgG glycosylation;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.68	0.34	9.41e-14	Schizophrenia;
LGG	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.09	0.52	1.6e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17286411	0.750	rs35619990	chr16:71949266	C/T	cg03805757	chr16:71968109	PKD1L3	0.34	7.07	0.31	5.84e-12	Blood protein levels;
LGG	cis	rs892961	0.720	rs103458	chr17:75416031	A/G	cg05865280	chr17:75406074	SEPT9	0.41	9.41	0.4	2.31e-19	Airflow obstruction;
LGG	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg03701759	chr13:99174930	STK24	-0.37	-7.14	-0.31	3.64e-12	Longevity;
LGG	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg11247378	chr22:39784982	NA	-0.32	-9.59	-0.41	5.61e-20	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10861342	0.786	rs11112393	chr12:105548053	C/T	cg23923672	chr12:105501055	KIAA1033	0.79	7.49	0.33	3.58e-13	IgG glycosylation;
LGG	cis	rs4959677	0.698	rs1891199	chr6:2481290	A/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.38	-0.36	6.59e-16	Orthostatic hypotension;
LGG	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg15704280	chr7:45808275	SEPT13	0.87	13.67	0.54	5.55e-36	Coronary artery disease;
LGG	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.73	0.3	4.88e-11	Depression;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg07636037	chr3:49044803	WDR6	0.77	13.68	0.54	4.95e-36	Menarche (age at onset);
LGG	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.71	-0.38	5.48e-17	Life satisfaction;
LGG	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.51	0.33	3.02e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs754423	0.515	rs1956283	chr14:52550736	T/C	cg12071775	chr14:52591786	NA	-0.43	-7.05	-0.31	6.65e-12	Craniofacial microsomia;
LGG	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.37	-0.32	8.08e-13	Total cholesterol levels;
LGG	cis	rs6800768	0.658	rs4241523	chr3:24102422	T/C	cg10674438	chr3:24145617	LOC152024	-0.32	-6.68	-0.3	6.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9771228	0.965	rs215622	chr7:32357659	C/T	cg27532318	chr7:32358331	NA	-0.43	-6.79	-0.3	3.45e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.46	0.33	4.35e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.37	-0.36	6.79e-16	Ulcerative colitis;
LGG	cis	rs7215564	0.908	rs59252837	chr17:78717155	A/G	cg16980736	chr17:78789706	RPTOR	-0.59	-7.74	-0.34	6.45e-14	Myopia (pathological);
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.16	0.66	1.13e-60	Personality dimensions;
LGG	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg24623649	chr8:11872141	NA	0.3	6.99	0.31	9.56e-12	Neuroticism;
LGG	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg05425664	chr17:57184151	TRIM37	0.58	9.3	0.4	5.73e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg05863683	chr7:1912471	MAD1L1	0.43	8.39	0.36	6.04e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs17208368	0.628	rs2397356	chr16:55098986	C/G	cg11181171	chr16:55090946	NA	0.46	7.75	0.34	5.97e-14	Hypospadias;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	trans	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.84	0.59	1.87e-45	Morning vs. evening chronotype;
LGG	cis	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.87	-0.3	2.13e-11	Neuroticism;
LGG	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11608355	0.515	rs12831026	chr12:109903651	C/T	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.34e-29	Neuroticism;
LGG	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.73	-0.34	6.59e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg04731861	chr2:219085781	ARPC2	0.42	10.41	0.44	5.87e-23	Colorectal cancer;
LGG	cis	rs4380275	1.000	rs4854376	chr2:763683	A/T	cg14072418	chr2:740025	NA	-0.39	-7.24	-0.32	1.9e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	cis	rs870825	0.929	rs870822	chr4:185588200	C/T	cg04058563	chr4:185651563	MLF1IP	0.99	16.89	0.62	3.13e-50	Blood protein levels;
LGG	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg20476274	chr7:133979776	SLC35B4	0.79	15.87	0.59	1.33e-45	Mean platelet volume;
LGG	cis	rs6714710	0.603	rs11680321	chr2:98379267	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	9.39	0.4	2.63e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7224668	0.647	rs9898133	chr17:79249997	C/T	cg03823431	chr17:79229385	SLC38A10	0.35	7.54	0.33	2.58e-13	IgG glycosylation;
LGG	cis	rs9880211	1.000	rs34757183	chr3:136143668	G/T	cg21827317	chr3:136751795	NA	-0.48	-7.09	-0.31	4.9e-12	Body mass index;Height;
LGG	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08109568	chr15:31115862	NA	-0.54	-9.53	-0.41	8.56e-20	Huntington's disease progression;
LGG	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg11789530	chr4:8429930	ACOX3	-0.88	-17.48	-0.63	6.44e-53	Response to antineoplastic agents;
LGG	cis	rs4713675	0.546	rs10947430	chr6:33658534	G/A	cg14003231	chr6:33640908	ITPR3	0.29	6.7	0.3	6.2e-11	Plateletcrit;
LGG	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg00717180	chr2:96193071	NA	0.41	7.29	0.32	1.38e-12	HDL cholesterol;
LGG	cis	rs4315565	0.764	rs4467309	chr2:69286921	C/T	cg13358873	chr2:69271042	ANTXR1	0.51	8.35	0.36	8.2e-16	Height;
LGG	trans	rs9914544	0.545	rs4393623	chr17:18775900	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.75	-0.34	5.82e-14	Educational attainment (years of education);
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg23758822	chr17:41437982	NA	0.86	15.24	0.58	8.63e-43	Menopause (age at onset);
LGG	cis	rs6909430	0.901	rs1032210	chr6:98596683	G/T	cg12860156	chr6:98744658	NA	-0.45	-7.54	-0.33	2.47e-13	Quantitative traits;
LGG	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg07936489	chr17:37558343	FBXL20	0.84	15.57	0.59	2.96e-44	Glomerular filtration rate (creatinine);
LGG	trans	rs7939886	0.920	rs11227638	chr11:56019585	A/T	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	cis	rs9354308	0.764	rs3939863	chr6:66601673	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg08344181	chr3:125677491	NA	-0.63	-7.1	-0.31	4.63e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg18477163	chr1:228402036	OBSCN	0.27	7.28	0.32	1.47e-12	Diastolic blood pressure;
LGG	cis	rs4774899	0.966	rs2585082	chr15:57257958	A/C	cg08128148	chr15:57256372	TCF12	-0.33	-7.9	-0.34	1.98e-14	Urinary tract infection frequency;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04798930	chr2:37193060	STRN	0.38	6.9	0.31	1.71e-11	Obesity-related traits;
LGG	cis	rs240764	0.853	rs12374612	chr6:100955752	C/T	cg21058520	chr6:100914733	NA	0.44	7.53	0.33	2.6e-13	Neuroticism;
LGG	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg27205649	chr11:78285834	NARS2	0.51	8.79	0.38	2.91e-17	Alzheimer's disease (survival time);
LGG	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg00784671	chr22:46762841	CELSR1	-0.57	-7.26	-0.32	1.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1971762	0.545	rs10783585	chr12:53977317	T/G	cg06632207	chr12:54070931	ATP5G2	0.22	6.95	0.31	1.25e-11	Height;
LGG	cis	rs858239	0.699	rs1881201	chr7:23194013	C/T	cg23682824	chr7:23144976	KLHL7	-0.41	-7.09	-0.31	5.08e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg14689365	chr7:158441557	NCAPG2	0.62	10.21	0.43	3.42e-22	Height;
LGG	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg16662043	chr16:48846231	NA	0.37	7.26	0.32	1.64e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.19	0.68	1.68e-65	Alzheimer's disease;
LGG	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg00700412	chr12:58011837	NA	0.34	6.67	0.3	7.45e-11	Multiple sclerosis;
LGG	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg13147721	chr7:65941812	NA	-0.79	-9.72	-0.41	1.92e-20	Diabetic kidney disease;
LGG	cis	rs6496044	0.548	rs7163032	chr15:86072419	T/A	cg13263323	chr15:86062960	AKAP13	-0.38	-8.33	-0.36	9.12e-16	Interstitial lung disease;
LGG	cis	rs6594713	0.819	rs13180522	chr5:112726022	A/G	cg12552261	chr5:112820674	MCC	0.54	8.15	0.35	3.51e-15	Brain cytoarchitecture;
LGG	cis	rs7917772	0.503	rs7093285	chr10:104374815	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.17	0.55	4.02e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg25019033	chr10:957182	NA	-0.6	-12.68	-0.51	7.51e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs12618769	0.625	rs3769733	chr2:99100716	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.39	0.36	5.97e-16	Bipolar disorder;
LGG	cis	rs10893109	0.517	rs1563126	chr11:123773612	T/C	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.6e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs751728	0.965	rs9394168	chr6:33759701	T/A	cg25922239	chr6:33757077	LEMD2	0.7	12.27	0.5	3.81e-30	Crohn's disease;
LGG	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg26811252	chr16:29126840	RRN3P2	0.68	10.53	0.44	2.11e-23	Menopause (age at onset);
LGG	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg03264133	chr6:25882463	NA	-0.58	-11.08	-0.46	1.77e-25	Blood metabolite levels;
LGG	cis	rs13424612	1.000	rs1465880	chr2:240932326	G/A	cg01812947	chr2:240904978	NDUFA10	0.42	7.06	0.31	6.13e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs774359	0.789	rs2764332	chr9:27492522	T/A	cg21249376	chr9:27528432	MOBKL2B	0.46	8.64	0.37	9.27e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs16944613	0.588	rs8030799	chr15:91109374	G/C	cg26821196	chr15:91095069	CRTC3	0.55	8.5	0.37	2.58e-16	Colorectal cancer;
LGG	cis	rs4843185	0.669	rs4843506	chr16:85715440	T/A	cg26571870	chr16:85723150	GINS2	-0.42	-7.74	-0.34	6.38e-14	Platelet distribution width;
LGG	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18252515	chr7:66147081	NA	0.41	7.07	0.31	5.71e-12	Aortic root size;
LGG	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.59	0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.46	-0.5	5.98e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.716	rs11097615	chr4:99092773	T/C	cg05340658	chr4:99064831	C4orf37	0.43	7.1	0.31	4.78e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.54	-10.57	-0.44	1.53e-23	Prudent dietary pattern;
LGG	cis	rs12220238	0.915	rs11001027	chr10:76152655	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.52	0.37	2.28e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1467026	0.584	rs9880453	chr3:12804060	C/T	cg24848339	chr3:12840334	CAND2	0.38	8.36	0.36	7.39e-16	P wave duration;
LGG	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	7.02	0.31	7.7e-12	Resting heart rate;
LGG	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg13699009	chr12:122356056	WDR66	-0.55	-14.77	-0.57	1.04e-40	Mean corpuscular volume;
LGG	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg05623727	chr3:50126028	RBM5	0.39	8.51	0.37	2.39e-16	Body mass index;
LGG	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg26384229	chr12:38710491	ALG10B	1.05	27.9	0.79	3.32e-101	Heart rate;
LGG	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg19507638	chr5:93509721	C5orf36	0.66	9.42	0.4	2.11e-19	Diabetic retinopathy;
LGG	cis	rs7084402	0.565	rs4948522	chr10:60334575	T/C	cg07615347	chr10:60278583	BICC1	0.5	12.37	0.5	1.49e-30	Refractive error;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs1801251	1.000	rs56777991	chr2:233635388	A/C	cg08000102	chr2:233561755	GIGYF2	0.56	9.14	0.39	1.9e-18	Coronary artery disease;
LGG	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg15068132	chr12:102092402	CHPT1	-0.36	-6.7	-0.3	6.21e-11	Blood protein levels;
LGG	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg00579200	chr11:133705235	NA	-0.6	-11.59	-0.47	1.88e-27	Childhood ear infection;
LGG	cis	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg07460842	chr6:66804631	NA	-0.96	-17.65	-0.63	1.1e-53	Exhaled nitric oxide output;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.98	0.35	1.17e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs9944715	0.954	rs13381529	chr18:43747827	A/T	cg26436583	chr18:43649176	PSTPIP2	0.37	6.73	0.3	5e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg08621203	chr6:150244597	RAET1G	0.53	9.99	0.42	1.98e-21	Testicular germ cell tumor;
LGG	cis	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.08	0.72	2.62e-74	Bladder cancer;
LGG	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs9287719	0.967	rs6432116	chr2:10748615	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs4417704	0.551	rs4077132	chr2:241889937	A/G	cg26818257	chr2:241905806	NA	0.49	10.85	0.45	1.32e-24	Joint mobility (Beighton score);
LGG	cis	rs870825	0.698	rs2696046	chr4:185599972	G/A	cg04058563	chr4:185651563	MLF1IP	-1.01	-19.67	-0.67	4.57e-63	Blood protein levels;
LGG	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-9.58	-0.41	5.81e-20	Lung cancer in ever smokers;
LGG	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg21420622	chr7:105162941	PUS7	-0.44	-6.67	-0.3	7.09e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18621852	chr3:10150065	C3orf24	0.39	6.67	0.3	7.53e-11	Alzheimer's disease;
LGG	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.5	-0.37	2.61e-16	Retinal vascular caliber;
LGG	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.18	-0.39	1.45e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4363385	0.818	rs4452994	chr1:152986871	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.52e-17	Inflammatory skin disease;
LGG	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.69	0.37	6.4e-17	Fuchs's corneal dystrophy;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg05896524	chr21:47604654	C21orf56	0.47	8.16	0.35	3.1e-15	Testicular germ cell tumor;
LGG	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg20628663	chr10:43360327	NA	-0.41	-8.48	-0.37	2.95e-16	Blood protein levels;
LGG	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg03528353	chr17:61819722	STRADA	-0.41	-6.84	-0.3	2.47e-11	Prudent dietary pattern;
LGG	cis	rs10089	0.953	rs2016015	chr5:127527253	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.63	0.48	1.33e-27	Ileal carcinoids;
LGG	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg02487422	chr3:49467188	NICN1	0.4	6.86	0.3	2.24e-11	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs10751667	0.714	rs7395879	chr11:963855	G/C	cg22143635	chr11:980567	AP2A2	0.45	8.45	0.37	3.74e-16	Alzheimer's disease (late onset);
LGG	cis	rs7572644	0.640	rs4632296	chr2:28024984	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.88	0.3	1.95e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs6547631	0.622	rs1561285	chr2:85924384	C/G	cg19805943	chr2:85933069	NA	0.32	6.67	0.3	7.28e-11	Blood protein levels;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg19500098	chr13:21900506	NA	0.43	8.62	0.37	1.11e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.47e-20	Prudent dietary pattern;
LGG	cis	rs11874712	0.899	rs11664764	chr18:43675364	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.16e-14	Blood trace element (Cu levels);
LGG	cis	rs1595825	0.891	rs892512	chr2:198905910	C/A	cg00982548	chr2:198649783	BOLL	-0.53	-7.24	-0.32	1.83e-12	Ulcerative colitis;
LGG	cis	rs7412746	0.621	rs11204749	chr1:150929563	G/A	cg15448220	chr1:150897856	SETDB1	0.36	6.73	0.3	4.98e-11	Melanoma;
LGG	cis	rs9849248	0.627	rs56246133	chr3:88170569	G/A	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs972578	1.000	rs1546860	chr22:43400329	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.74	-0.3	4.67e-11	Mean platelet volume;
LGG	cis	rs10979	1.000	rs9399448	chr6:143896315	G/T	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg04731861	chr2:219085781	ARPC2	0.46	11.2	0.46	6.17e-26	Colorectal cancer;
LGG	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.71	-0.3	5.8200000000000003e-11	Iron status biomarkers;
LGG	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg06885757	chr1:42089581	HIVEP3	0.56	12.87	0.51	1.3e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.01	-0.39	5.46e-18	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07454192	chr8:74888262	TMEM70	0.51	7.68	0.34	9.48e-14	Gut microbiome composition (summer);
LGG	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg08648136	chr8:956695	NA	0.43	9.15	0.39	1.87e-18	Schizophrenia;
LGG	cis	rs9487094	0.553	rs11968891	chr6:109869850	C/T	cg01125227	chr6:109776195	MICAL1	0.47	7.41	0.33	5.97e-13	Height;
LGG	cis	rs9828933	0.832	rs3774723	chr3:63962339	G/A	cg17941049	chr3:63904683	ATXN7	0.66	7.9	0.34	2e-14	Type 2 diabetes;
LGG	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg03806693	chr22:41940476	POLR3H	0.91	15.98	0.6	4.41e-46	Vitiligo;
LGG	cis	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg19399532	chr1:178512495	C1orf220	-0.53	-10.56	-0.44	1.62e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4919694	1.000	rs58700372	chr10:104800205	T/C	cg04362960	chr10:104952993	NT5C2	1.07	14.88	0.57	3.26e-41	Arsenic metabolism;
LGG	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.13	0.35	3.87e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg26384229	chr12:38710491	ALG10B	0.76	15.33	0.58	3.45e-43	Morning vs. evening chronotype;
LGG	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	trans	rs9929218	0.817	rs3114400	chr16:68719430	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-17.29	-0.63	4.7e-52	Colorectal cancer;
LGG	cis	rs9487094	0.689	rs7754650	chr6:109726739	A/G	cg01125227	chr6:109776195	MICAL1	0.45	8.12	0.35	4.38e-15	Height;
LGG	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg08085267	chr17:45401833	C17orf57	0.51	9.58	0.41	5.73e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg17757837	chr7:157058334	UBE3C	0.78	15.99	0.6	3.83e-46	Body mass index;
LGG	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg05793240	chr7:2802953	GNA12	0.31	7.67	0.34	1.04e-13	Height;
LGG	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.95	0.57	1.63e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1878931	0.624	rs39728	chr16:3453076	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	12.44	0.5	7.83e-31	Body mass index (adult);
LGG	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg15268244	chr15:77196840	NA	0.32	7.09	0.31	5.09e-12	Blood metabolite levels;
LGG	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg02073558	chr3:44770973	ZNF501	0.87	19.6	0.67	9.94e-63	Depressive symptoms;
LGG	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg06219351	chr7:158114137	PTPRN2	0.69	13.67	0.54	5.86e-36	Calcium levels;
LGG	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	13.93	0.54	4.18e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg13395646	chr4:1353034	KIAA1530	0.52	8.9	0.38	1.23e-17	Obesity-related traits;
LGG	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg07148914	chr20:33460835	GGT7	0.54	9.06	0.39	3.68e-18	Height;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg19357499	chr8:144660631	NAPRT1	0.89	6.91	0.31	1.6e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs7129556	0.645	rs598071	chr11:77560652	G/T	cg12586386	chr11:77299805	AQP11	0.44	7.32	0.32	1.08e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg08461772	chr7:95026248	PON3	0.39	8.37	0.36	6.74e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10173297	0.686	rs1965733	chr2:3709129	T/C	cg17046650	chr2:3699563	NA	0.67	9.34	0.4	4.16e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs4917300	0.935	rs4917295	chr8:143119810	A/T	cg06573787	chr8:143070187	NA	0.48	8.77	0.38	3.35e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.45	-0.33	4.55e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg05804949	chr7:23719620	C7orf46	0.32	7.46	0.33	4.27e-13	Schizophrenia;
LGG	cis	rs1568889	0.838	rs11030187	chr11:28044391	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.88	19.95	0.68	2.26e-64	Bipolar disorder;
LGG	cis	rs4409675	0.576	rs3766396	chr1:28221554	C/T	cg23691781	chr1:28212827	C1orf38	-0.43	-11.31	-0.47	2.3e-26	Corneal astigmatism;
LGG	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg25358565	chr5:93447407	FAM172A	1.27	15.64	0.59	1.47e-44	Diabetic retinopathy;
LGG	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg24375607	chr4:120327624	NA	0.66	10.98	0.45	4.43e-25	Corneal astigmatism;
LGG	cis	rs6743226	0.840	rs6747036	chr2:242227054	T/C	cg10021735	chr2:242295487	FARP2	0.52	9.64	0.41	3.7e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.78	0.41	1.17e-20	Schizophrenia;
LGG	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg00717180	chr2:96193071	NA	-0.52	-9.71	-0.41	2.12e-20	Coronary artery disease;
LGG	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg07382826	chr16:28625726	SULT1A1	0.4	8.07	0.35	6e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg03036210	chr16:89904091	SPIRE2	-0.5	-7.22	-0.32	2.13e-12	Skin colour saturation;
LGG	cis	rs3762637	1.000	rs9836309	chr3:122135195	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-10.07	-0.42	1.05e-21	LDL cholesterol levels;
LGG	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.56	0.37	1.64e-16	Mood instability;
LGG	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg21775007	chr8:11205619	TDH	-0.53	-8.65	-0.37	8.22e-17	Retinal vascular caliber;
LGG	cis	rs262150	0.842	rs2657398	chr7:158784911	T/C	cg19418458	chr7:158789849	NA	-0.46	-9.5	-0.4	1.14e-19	Facial morphology (factor 20);
LGG	cis	rs7666738	0.830	rs10005173	chr4:98816062	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.79	0.34	4.56e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg06565975	chr8:143823917	SLURP1	-0.29	-7.07	-0.31	5.63e-12	Urinary tract infection frequency;
LGG	trans	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg01314568	chr7:57830625	NA	-0.52	-8.18	-0.36	2.67e-15	Obesity-related traits;
LGG	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg18446336	chr7:2847575	GNA12	0.38	10.03	0.42	1.51e-21	Height;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.41	-0.61	4.98e-48	Intelligence (multi-trait analysis);
LGG	cis	rs1003719	0.762	rs1015551	chr21:38449510	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs4696584	0.877	rs72725354	chr4:155399841	A/G	cg04517429	chr4:155413618	DCHS2	-0.32	-7.23	-0.32	1.98e-12	Folding of antihelix;
LGG	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs5015933	0.966	rs1965342	chr9:128133661	T/A	cg14078157	chr9:128172775	NA	-0.39	-7.45	-0.33	4.64e-13	Body mass index;
LGG	cis	rs3815700	0.844	rs444089	chr19:33106991	G/C	cg02997394	chr19:33096574	ANKRD27	0.88	12.89	0.51	1.04e-32	Eosinophilic esophagitis;
LGG	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg02836325	chr17:76403955	PGS1	-0.72	-14.45	-0.56	2.45e-39	HDL cholesterol levels;
LGG	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg15309053	chr8:964076	NA	0.42	8.24	0.36	1.84e-15	Schizophrenia;
LGG	cis	rs4075765	0.656	rs11029441	chr11:26279145	T/C	cg19182008	chr11:26298241	NA	0.63	6.74	0.3	4.64e-11	Cannabis dependence symptom count;
LGG	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg04267008	chr7:1944627	MAD1L1	0.66	11.18	0.46	7.75e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs887829	0.694	rs6749496	chr2:234624286	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-9.02	-0.39	5.01e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4812048	0.894	rs236729	chr20:57579975	T/C	cg23907860	chr20:57583709	CTSZ	0.51	7.34	0.32	9.96e-13	Mean platelet volume;
LGG	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg00198680	chr16:28758506	NA	0.28	6.81	0.3	3.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7614311	0.689	rs56329572	chr3:63846672	G/A	cg22134162	chr3:63841271	THOC7	-0.45	-7.92	-0.35	1.75e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg21775007	chr8:11205619	TDH	-0.53	-8.26	-0.36	1.54e-15	Neuroticism;
LGG	cis	rs12220238	0.822	rs10824193	chr10:76261759	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.18	0.36	2.83e-15	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1003719	0.708	rs2000417	chr21:38502868	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg10995359	chr2:30670170	LCLAT1	0.41	6.88	0.3	1.9e-11	Body mass index;
LGG	cis	rs4926611	0.966	rs6682763	chr1:54110300	C/A	cg23596471	chr1:54105337	GLIS1	0.41	8.51	0.37	2.52e-16	Hand grip strength;
LGG	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg24899294	chr7:1481343	MICALL2	-0.67	-8.24	-0.36	1.75e-15	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg16850897	chr7:100343110	ZAN	-0.59	-8.11	-0.35	4.61e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9948	0.655	rs61742095	chr2:97366088	T/C	cg01990225	chr2:97406019	LMAN2L	-0.74	-7.31	-0.32	1.15e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs503734	0.502	rs348879	chr3:100979826	A/T	cg27318481	chr3:100970896	IMPG2	-0.57	-12.78	-0.51	3.12e-32	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4478137	0.501	rs28477602	chr4:164230477	C/T	cg06758707	chr4:164254230	NPY1R	-0.52	-7.75	-0.34	6.05e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.96	-0.45	5.1e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg12011299	chr4:100065546	ADH4	0.4	8.64	0.37	9.02e-17	Alcohol dependence;
LGG	cis	rs9815354	1.000	rs9823254	chr3:41894768	G/C	cg03022575	chr3:42003672	ULK4	0.74	9.27	0.4	6.95e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	13.83	0.54	1.15e-36	Response to antipsychotic treatment;
LGG	cis	rs7666738	0.791	rs1426661	chr4:98874303	C/G	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3750450	0.718	rs4978775	chr9:111937507	A/T	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	trans	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.38	-0.32	7.39e-13	Educational attainment (years of education);
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg12395012	chr8:11607386	GATA4	0.38	6.85	0.3	2.35e-11	Neuroticism;
LGG	cis	rs6496932	0.802	rs67928464	chr15:85881766	C/G	cg19183879	chr15:85880815	NA	0.44	6.96	0.31	1.2e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-7.19	-0.32	2.68e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25978167	chr4:57301353	PAICS;PPAT	0.52	8.32	0.36	9.84e-16	Gut microbiome composition (summer);
LGG	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg07395648	chr5:131743802	NA	0.56	13.08	0.52	1.66e-33	Blood metabolite levels;
LGG	cis	rs7226408	0.857	rs74682538	chr18:34473572	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg25358565	chr5:93447407	FAM172A	1.29	16.09	0.6	1.34e-46	Diabetic retinopathy;
LGG	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg01864069	chr14:103024347	NA	0.46	7.87	0.34	2.56e-14	Platelet count;
LGG	cis	rs755249	0.567	rs4660690	chr1:39819503	G/A	cg18385671	chr1:39797026	MACF1	0.43	7.32	0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9644630	0.864	rs4339658	chr8:19347059	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.61	17.16	0.62	1.92e-51	Oropharynx cancer;
LGG	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08109568	chr15:31115862	NA	-0.54	-9.57	-0.41	6.48e-20	Huntington's disease progression;
LGG	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg08999081	chr20:33150536	PIGU	-0.41	-10.34	-0.43	1.08e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9811920	0.581	rs793468	chr3:99538346	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.75	-0.38	4.09e-17	Axial length;
LGG	trans	rs2018683	0.707	rs1021690	chr7:28974488	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.24	-0.39	8.65e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg08851530	chr6:28072375	NA	0.81	7.31	0.32	1.19e-12	Parkinson's disease;
LGG	cis	rs7301016	1.000	rs11613132	chr12:62856444	A/C	cg11441379	chr12:63026424	NA	0.65	8.62	0.37	1.05e-16	IgG glycosylation;
LGG	cis	rs4654899	0.714	rs12401630	chr1:21495049	G/A	cg05370193	chr1:21551575	ECE1	0.29	6.66	0.3	7.94e-11	Superior frontal gyrus grey matter volume;
LGG	cis	rs2154319	0.836	rs2013925	chr1:41560291	A/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.88	-0.38	1.49e-17	Height;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg26174226	chr8:58114915	NA	0.58	7.96	0.35	1.37e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs3206736	0.548	rs329229	chr7:35054029	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.05	0.31	6.61e-12	Diastolic blood pressure;
LGG	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg11887960	chr12:57824829	NA	0.59	7.24	0.32	1.88e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.26	-0.36	1.53e-15	Retinal vascular caliber;
LGG	cis	rs138249	1.000	rs138209	chr22:50539413	T/C	cg07310406	chr22:50524374	MLC1	0.4	7.93	0.35	1.63e-14	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08677398	chr8:58056175	NA	0.5	7.99	0.35	1.12e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.79	-0.38	3.03e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg01765077	chr12:122356316	WDR66	0.29	7.66	0.34	1.07e-13	Mean corpuscular volume;
LGG	cis	rs28595532	0.516	rs17594740	chr4:119246754	C/T	cg21605333	chr4:119757512	SEC24D	0.89	8.31	0.36	1.06e-15	Cannabis dependence symptom count;
LGG	trans	rs12579753	0.917	rs11612874	chr12:82212649	A/C	cg07923666	chr12:49932857	KCNH3	0.51	7.49	0.33	3.62e-13	Resting heart rate;
LGG	cis	rs929596	0.561	rs6431625	chr2:234637912	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-10.1	-0.42	8.42e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg24232236	chr22:38142998	TRIOBP	0.35	6.66	0.3	7.84e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs11083475	0.681	rs62121377	chr19:39257296	G/A	cg07403899	chr19:39283540	NA	-0.24	-6.87	-0.3	2.12e-11	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16403912	chr8:23104730	CHMP7	0.46	6.78	0.3	3.72e-11	Gut microbiome composition (summer);
LGG	cis	rs943437	0.877	rs633177	chr6:112272939	T/C	cg25325257	chr6:112272685	NA	-0.44	-6.66	-0.3	7.93e-11	Parkinson's disease;
LGG	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg26818010	chr10:134567672	INPP5A	-0.52	-8.27	-0.36	1.42e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00116688	chr5:159848696	PTTG1	0.48	7.13	0.31	3.79e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24420395	chr8:29206910	DUSP4	0.47	7.57	0.33	1.98e-13	Gut microbiome composition (summer);
LGG	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg18198730	chr1:247681584	NA	0.72	12.11	0.49	1.65e-29	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9355814	0.539	rs1830522	chr6:161078234	T/G	cg04181478	chr6:161122748	PLG	-0.41	-6.73	-0.3	5.13e-11	Lipoprotein (a) levels;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.45	0.53	4.88e-35	Prudent dietary pattern;
LGG	trans	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg02002194	chr4:3960332	NA	-0.38	-6.91	-0.31	1.61e-11	Joint mobility (Beighton score);
LGG	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg19761014	chr17:28927070	LRRC37B2	0.6	7.21	0.32	2.25e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6763768	0.606	rs11130367	chr3:53293373	G/A	cg16894138	chr3:53270350	TKT	0.41	7.93	0.35	1.71e-14	Bacterial meningitis;
LGG	cis	rs10220309	1.000	rs10220309	chr14:80587141	T/C	cg08183125	chr14:80678293	DIO2	0.47	6.68	0.3	7.02e-11	Lung function (FEV1);
LGG	cis	rs7666738	0.791	rs1426674	chr4:98924247	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.2	0.46	6.34e-26	Bone mineral density;
LGG	cis	rs35176054	0.730	rs11592750	chr10:105511601	G/C	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.9	-0.31	1.77e-11	Atrial fibrillation;
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg19901468	chr14:105411992	AHNAK2	-0.89	-18.71	-0.66	1.4e-58	Rheumatoid arthritis;
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.68	-0.34	9.56e-14	Obesity;
LGG	cis	rs10462794	0.853	rs6886143	chr5:4506748	T/C	cg18482690	chr5:4511582	NA	0.41	7.24	0.32	1.82e-12	DNA methylation (variation);
LGG	cis	rs5997397	0.934	rs6005864	chr22:29157487	A/G	cg02153584	chr22:29168773	CCDC117	-0.39	-6.66	-0.3	7.68e-11	Red cell distribution width;
LGG	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.21	0.36	2.16e-15	Fuchs's corneal dystrophy;
LGG	cis	rs12282928	0.959	rs713325	chr11:48285301	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.65e-12	Migraine - clinic-based;
LGG	cis	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg24375607	chr4:120327624	NA	0.68	11.04	0.46	2.61e-25	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18094902	chr2:71357089	MPHOSPH10;MCEE	0.43	7.08	0.31	5.51e-12	Cognitive performance;
LGG	cis	rs58365910	1	rs58365910	chr15:78849034	T/C	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.32	-0.32	1.08e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg00757033	chr12:89920650	WDR51B	0.63	9.12	0.39	2.25e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02743256	chr7:2109353	MAD1L1	-0.34	-6.97	-0.31	1.11e-11	Bipolar disorder;
LGG	cis	rs13064447	0.874	rs9310408	chr3:12757726	T/C	cg23032965	chr3:12705835	RAF1	0.51	7.74	0.34	6.28e-14	Major depression and alcohol dependence;
LGG	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.15	-0.32	3.46e-12	Alzheimer's disease (late onset);
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg16339924	chr4:17578868	LAP3	0.63	10.99	0.45	4.16e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs883565	0.569	rs784508	chr3:39166484	C/T	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs283228	0.754	rs407498	chr6:101721753	G/A	cg27451362	chr6:101846650	GRIK2	0.56	8.69	0.37	6.15e-17	Coenzyme Q10 levels;
LGG	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11987759	chr7:65425863	GUSB	0.4	7.79	0.34	4.49e-14	Calcium levels;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.4	-0.4	2.58e-19	Aortic root size;
LGG	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.65	-0.33	1.2e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg11878867	chr6:150167359	LRP11	-0.54	-11.25	-0.46	4.11e-26	Lung cancer;
LGG	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11890956	chr21:40555474	PSMG1	-0.95	-19.2	-0.67	6.92e-61	Cognitive function;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg18350739	chr11:68623251	NA	-0.84	-21.44	-0.71	2.4e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs701145	0.585	rs1727882	chr3:153837246	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg12016809	chr21:47604291	C21orf56	-0.46	-7.45	-0.33	4.52e-13	Testicular germ cell tumor;
LGG	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg25554036	chr4:6271136	WFS1	0.52	8.85	0.38	1.93e-17	Cisplatin-induced ototoxicity;
LGG	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg02269571	chr22:50332266	NA	-0.7	-10.35	-0.43	9.74e-23	Schizophrenia;
LGG	cis	rs7666738	0.830	rs7657179	chr4:98948569	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg23188684	chr11:67383651	NA	0.52	8.83	0.38	2.18e-17	Mean corpuscular volume;
LGG	cis	rs2470578	0.792	rs2470583	chr3:17280812	G/A	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs953387	0.910	rs16833170	chr2:136929076	A/G	cg07169764	chr2:136633963	MCM6	0.54	8.83	0.38	2.14e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs9878978	0.754	rs35669246	chr3:2437193	G/A	cg21928760	chr3:2462534	CNTN4	0.39	7.77	0.34	5.23e-14	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.2e-17	Lung cancer;
LGG	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg19761014	chr17:28927070	LRRC37B2	0.64	7.62	0.33	1.49e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.85e-16	Life satisfaction;
LGG	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg15269541	chr15:43626905	ADAL	-0.44	-7.1	-0.31	4.59e-12	Lung cancer in ever smokers;
LGG	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.53	0.33	2.75e-13	Bipolar disorder;
LGG	cis	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg06521331	chr12:34319734	NA	-0.43	-7.92	-0.35	1.75e-14	Morning vs. evening chronotype;
LGG	cis	rs11203032	0.831	rs9651495	chr10:90932381	G/A	cg16672925	chr10:90967113	CH25H	0.76	10.95	0.45	5.8e-25	Heart failure;
LGG	cis	rs3126085	0.935	rs11583524	chr1:152161657	T/C	cg26876637	chr1:152193138	HRNR	-0.5	-7.4	-0.33	6.33e-13	Atopic dermatitis;
LGG	cis	rs12472274	0.941	rs2880131	chr2:239089151	A/C	cg17459225	chr2:239074497	NA	0.8	13.87	0.54	8.28e-37	Phospholipid levels (plasma);
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg23034840	chr1:205782522	SLC41A1	0.49	7.85	0.34	2.96e-14	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg11494091	chr17:61959527	GH2	-0.51	-8.22	-0.36	2.09e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	10.99	0.45	4.01e-25	Prudent dietary pattern;
LGG	trans	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-17.06	-0.62	5.38e-51	Exhaled nitric oxide levels;
LGG	trans	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg25214090	chr10:38739885	LOC399744	0.57	10.4	0.44	6.55e-23	Corneal astigmatism;
LGG	trans	rs3960554	0.932	rs60717745	chr7:75846083	C/G	cg19862616	chr7:65841803	NCRNA00174	0.83	11.04	0.46	2.49e-25	Eotaxin levels;
LGG	cis	rs7766436	0.767	rs13215709	chr6:22604121	A/G	cg13666174	chr6:22585274	NA	-0.36	-8.67	-0.37	7.09e-17	Coronary artery disease;
LGG	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.71	-0.3	5.87e-11	Mood instability;
LGG	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg21174375	chr14:64681225	SYNE2	-0.36	-6.86	-0.3	2.2e-11	Atrial fibrillation;
LGG	trans	rs208520	0.690	rs851464	chr6:66839802	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.67	-0.63	8.49e-54	Exhaled nitric oxide output;
LGG	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg07005078	chr4:17578674	LAP3	0.36	6.74	0.3	4.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7546	0.504	rs2075637	chr16:4938280	T/C	cg04440724	chr16:4920505	UBN1	0.56	12.18	0.49	8.51e-30	Cancer;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.31	0.36	1.06e-15	Longevity;
LGG	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg11366901	chr6:160182831	ACAT2	1.03	15.92	0.59	8.16e-46	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04738309	chr5:111093624	C5orf13	0.43	6.92	0.31	1.48e-11	Gut microbiome composition (summer);
LGG	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg11317459	chr13:21872234	NA	-1.24	-20.64	-0.69	1.45e-67	White matter hyperintensity burden;
LGG	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs11700980	0.551	rs56165045	chr21:30114027	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs1018836	0.637	rs6471113	chr8:91519735	A/G	cg16814680	chr8:91681699	NA	-0.64	-10.55	-0.44	1.8e-23	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.53	0.63	4e-53	Obesity-related traits;
LGG	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg25986240	chr4:9926439	SLC2A9	-0.52	-9.51	-0.4	1.05e-19	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg11995313	chr8:8860691	ERI1	0.45	7.68	0.34	9.46e-14	Joint mobility (Beighton score);
LGG	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg18252515	chr7:66147081	NA	-1.44	-20.91	-0.7	7.19e-69	Diabetic kidney disease;
LGG	cis	rs4481887	0.861	rs6676061	chr1:248443887	G/C	cg00666640	chr1:248458726	OR2T12	0.57	8.94	0.38	9.24e-18	Common traits (Other);
LGG	cis	rs6735179	0.565	rs736869	chr2:1748463	G/A	cg20570797	chr2:1712800	PXDN	-0.46	-7.91	-0.34	1.94e-14	Response to antipsychotic treatment;
LGG	trans	rs8073060	0.586	rs226089	chr17:34016935	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs11018904	0.906	rs61903722	chr11:89967042	C/T	cg27158573	chr11:89632121	NA	-0.42	-7.28	-0.32	1.42e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10743315	0.732	rs16915327	chr12:19446916	C/G	cg02471346	chr12:19282374	PLEKHA5	0.6	6.84	0.3	2.48e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07916071	chr1:151227225	PSMD4	0.41	7.04	0.31	6.83e-12	Hip circumference;
LGG	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.29	0.32	1.33e-12	Myopia (pathological);
LGG	cis	rs4740619	0.967	rs10756687	chr9:15642191	A/C	cg14451791	chr9:16040625	NA	0.41	10.55	0.44	1.83e-23	Body mass index;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07132326	chr6:150258058	NA	0.38	8.03	0.35	7.91e-15	Lung cancer;
LGG	cis	rs10893109	0.517	rs7927385	chr11:123778031	A/G	cg12387464	chr11:123775935	OR8D4	-0.38	-8.24	-0.36	1.75e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg18200150	chr17:30822561	MYO1D	0.49	9.45	0.4	1.64e-19	Schizophrenia;
LGG	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg22705602	chr4:152727874	NA	0.31	7.51	0.33	3.03e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4959677	0.611	rs56543437	chr6:2474933	G/A	cg23817096	chr6:1620687	NA	-0.3	-7.31	-0.32	1.18e-12	Orthostatic hypotension;
LGG	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.64	15.75	0.59	4.61e-45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.59	0.53	1.23e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs787274	1.000	rs700122	chr9:115551847	A/G	cg13803584	chr9:115635662	SNX30	-0.59	-7.38	-0.32	7.19e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.33	-6.65	-0.3	8.15e-11	Aortic root size;
LGG	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg17077180	chr1:38461687	NA	0.37	8.16	0.35	3.17e-15	Coronary artery disease;
LGG	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg13073564	chr4:8508604	NA	-0.59	-11.87	-0.48	1.53e-28	Response to antineoplastic agents;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.09	0.46	1.67e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg26513180	chr16:89883248	FANCA	0.98	9.25	0.39	8.38e-19	Skin colour saturation;
LGG	cis	rs735539	0.521	rs9552282	chr13:21365721	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-7.13	-0.31	3.93e-12	Dental caries;
LGG	cis	rs757081	0.667	rs214933	chr11:17194584	C/T	cg15432903	chr11:17409602	KCNJ11	-0.47	-7.97	-0.35	1.21e-14	Systolic blood pressure;
LGG	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg19773385	chr1:10388646	KIF1B	-0.47	-10.31	-0.43	1.41e-22	Hepatocellular carcinoma;
LGG	cis	rs17767392	1.000	rs17178045	chr14:71756358	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.22e-18	Mitral valve prolapse;
LGG	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg03264133	chr6:25882463	NA	-0.45	-7.06	-0.31	6.05e-12	Iron status biomarkers;
LGG	cis	rs1003719	0.751	rs2835585	chr21:38460488	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs13177180	0.805	rs10041776	chr5:114854685	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.36	-7.84	-0.34	3.13e-14	Conotruncal heart defects (inherited effects);
LGG	cis	rs4799461	0.773	rs12969480	chr18:35147621	C/G	cg27332583	chr18:35150602	NA	-0.56	-11.22	-0.46	5.14e-26	Neuroticism;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13669465	chr10:99205343	ZDHHC16;EXOSC1	0.43	6.88	0.3	1.97e-11	Cognitive performance;
LGG	cis	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	cis	rs2470578	0.792	rs2596674	chr3:17315986	C/T	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06634786	chr22:41940651	POLR3H	-0.67	-11.1	-0.46	1.48e-25	Vitiligo;
LGG	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg16339924	chr4:17578868	LAP3	-0.68	-11.49	-0.47	4.85e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg16797656	chr11:68205561	LRP5	0.39	6.87	0.3	2.13e-11	Total body bone mineral density;
LGG	cis	rs2587949	0.550	rs80182329	chr3:4226282	A/T	cg16519197	chr3:4211558	NA	-0.32	-6.72	-0.3	5.3e-11	Periodontitis (DPAL);
LGG	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg12310025	chr6:25882481	NA	-0.43	-7.03	-0.31	7.47e-12	Iron status biomarkers;
LGG	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg27490568	chr2:178487706	NA	0.52	10.19	0.43	3.75e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.86	0.48	1.63e-28	Hip circumference adjusted for BMI;
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.59	-0.37	1.33e-16	Personality dimensions;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.83	0.45	1.56e-24	Personality dimensions;
LGG	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg07061783	chr6:25882402	NA	-0.45	-7.72	-0.34	7.37e-14	Intelligence (multi-trait analysis);
LGG	cis	rs42648	0.837	rs6970750	chr7:89938191	G/A	cg25739043	chr7:89950458	NA	-0.44	-9.27	-0.4	6.89e-19	Homocysteine levels;
LGG	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg06191203	chr2:152266755	RIF1	-0.49	-8.46	-0.37	3.58e-16	Lung cancer;
LGG	trans	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg16141378	chr3:129829833	LOC729375	0.32	6.88	0.3	1.96e-11	Recombination measurement;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.28	0.5	3.4e-30	Prudent dietary pattern;
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13012494	chr21:47604986	C21orf56	-0.64	-10.75	-0.45	3.18e-24	Testicular germ cell tumor;
LGG	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg26384229	chr12:38710491	ALG10B	0.64	12.32	0.5	2.41e-30	Bladder cancer;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg15971980	chr6:150254442	NA	-0.45	-8.32	-0.36	9.7e-16	Lung cancer;
LGG	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg12046867	chr14:103022105	NA	0.74	12.53	0.5	3.15e-31	Platelet count;
LGG	cis	rs12887734	0.524	rs4906364	chr14:104214342	C/G	cg26031613	chr14:104095156	KLC1	-0.56	-8.85	-0.38	1.88e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs1032833	0.732	rs17454164	chr2:179995839	T/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23248424	chr5:179741104	GFPT2	-0.58	-10.7	-0.45	4.88e-24	Height;
LGG	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg10523679	chr1:76189770	ACADM	-0.81	-13.11	-0.52	1.27e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.75	0.54	2.51e-36	Bladder cancer;
LGG	trans	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg26043149	chr18:55253948	FECH	-0.62	-10.29	-0.43	1.65e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg09537434	chr19:41945824	ATP5SL	0.93	22.31	0.72	2.11e-75	Height;
LGG	cis	rs6032067	0.636	rs6032092	chr20:43911886	A/C	cg10761708	chr20:43804764	PI3	0.54	8.22	0.36	2.03e-15	Blood protein levels;
LGG	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg10057126	chr4:77819792	ANKRD56	0.36	6.83	0.3	2.72e-11	Emphysema distribution in smoking;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg07005078	chr4:17578674	LAP3	0.38	6.9	0.31	1.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1015291	0.605	rs1388678	chr12:19994151	A/C	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.58	-0.37	1.5e-16	Kawasaki disease;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg09699651	chr6:150184138	LRP11	0.51	9.13	0.39	2.13e-18	Lung cancer;
LGG	trans	rs3942852	0.806	rs10769317	chr11:48150712	T/C	cg03929089	chr4:120376271	NA	-0.64	-8.93	-0.38	9.91e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21963583	chr11:68658836	MRPL21	0.59	10.19	0.43	3.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9354308	0.738	rs1938101	chr6:66600032	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg03806693	chr22:41940476	POLR3H	-0.92	-15.81	-0.59	2.43e-45	Vitiligo;
LGG	cis	rs11792861	0.926	rs17729523	chr9:111773317	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.24	0.39	8.8e-19	Menarche (age at onset);
LGG	trans	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.98	0.42	2.29e-21	Metabolite levels;
LGG	trans	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg16141378	chr3:129829833	LOC729375	0.3	6.68	0.3	7.07e-11	Recombination measurement;
LGG	cis	rs7666738	0.822	rs28512427	chr4:98919029	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.81	0.34	3.76e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.81	0.51	2.29e-32	Vitiligo;
LGG	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg11789530	chr4:8429930	ACOX3	-0.88	-17.53	-0.63	3.9e-53	Response to antineoplastic agents;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs919433	0.680	rs6710530	chr2:198277551	G/A	cg00792783	chr2:198669748	PLCL1	0.51	8.04	0.35	7.4e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg13206674	chr6:150067644	NUP43	0.66	14.83	0.57	5.72e-41	Lung cancer;
LGG	cis	rs2154319	0.836	rs2363097	chr1:41543807	A/G	cg02290550	chr1:41487317	SLFNL1	-0.5	-9.08	-0.39	3.16e-18	Height;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.43	-0.33	5.3e-13	Personality dimensions;
LGG	cis	rs72772090	0.539	rs72773991	chr5:96163775	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.48	-0.37	3.03e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg13699009	chr12:122356056	WDR66	0.56	14.97	0.57	1.31e-41	Mean corpuscular volume;
LGG	cis	rs975722	0.638	rs213971	chr7:117234176	C/T	cg10524701	chr7:117356490	CTTNBP2	0.47	10.45	0.44	4.39e-23	Coronary artery disease;
LGG	cis	rs42648	0.564	rs17863031	chr7:89805813	A/G	cg04070188	chr7:89809444	NA	-0.27	-6.66	-0.3	7.82e-11	Homocysteine levels;
LGG	cis	rs2154319	0.887	rs1015091	chr1:41518041	C/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.84	-0.38	2e-17	Height;
LGG	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg12633918	chr20:23549525	CST9L	-0.33	-6.73	-0.3	4.9e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg06115741	chr20:33292138	TP53INP2	0.52	8.59	0.37	1.29e-16	Coronary artery disease;
LGG	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg10402321	chr1:26617780	UBXN11	-0.36	-7.17	-0.32	3.07e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.98	0.38	7.08e-18	Lung cancer;
LGG	cis	rs10897473	0.573	rs2701543	chr11:63862123	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.53	-7.54	-0.33	2.55e-13	Immature fraction of reticulocytes;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.92	0.48	9.75e-29	Tonsillectomy;
LGG	cis	rs17162190	0.659	rs12024530	chr1:26812298	G/A	cg23229016	chr1:26872525	RPS6KA1	0.25	6.72	0.3	5.39e-11	Mean corpuscular volume;
LGG	cis	rs1144	0.537	rs2470948	chr7:104588533	A/G	cg03782966	chr7:104585482	NA	0.34	7.85	0.34	2.92e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00721468	chr6:8102731	EEF1E1	0.46	6.85	0.3	2.31e-11	Gut microbiome composition (summer);
LGG	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg06102954	chr21:42741788	MX2	-0.4	-7.46	-0.33	4.31e-13	Melanoma;
LGG	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg04935436	chr20:30431758	NA	0.44	7.3	0.32	1.25e-12	Mean corpuscular hemoglobin;
LGG	cis	rs986417	0.818	rs10148116	chr14:61101089	C/T	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.32e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg04632378	chr13:21900426	NA	0.4	8.37	0.36	6.74e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.9	18.06	0.64	1.45e-55	Hip circumference adjusted for BMI;
LGG	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg08648136	chr8:956695	NA	0.46	10.09	0.42	8.88e-22	Schizophrenia;
LGG	cis	rs62380364	0.557	rs663046	chr5:88036486	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg07192821	chr15:45003560	B2M	0.38	6.84	0.3	2.56e-11	Body mass index;
LGG	trans	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.65	-0.33	1.19e-13	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.17	-0.35	2.97e-15	Mean corpuscular volume;
LGG	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg09201001	chr11:18656081	SPTY2D1	0.92	18.2	0.65	3.05e-56	Breast cancer;
LGG	cis	rs7444	0.941	rs5754352	chr22:21964951	C/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.54	-0.33	2.53e-13	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.08e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.76e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03352830	chr11:487213	PTDSS2	0.83	10.01	0.42	1.78e-21	Body mass index;
LGG	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg02002194	chr4:3960332	NA	-0.52	-10.33	-0.43	1.18e-22	Neuroticism;
LGG	cis	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg24232236	chr22:38142998	TRIOBP	-0.33	-6.69	-0.3	6.59e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg15432903	chr11:17409602	KCNJ11	0.69	12.88	0.51	1.15e-32	Type 2 diabetes;
LGG	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg20673091	chr1:2541236	MMEL1	0.77	18.34	0.65	7.12e-57	Ulcerative colitis;
LGG	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg13114125	chr14:105738426	BRF1	-0.85	-15.71	-0.59	6.74e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9356171	0.539	rs11755754	chr6:164325492	A/G	cg25752492	chr6:164341247	NA	-0.46	-9.18	-0.39	1.42e-18	Diisocyanate-induced asthma;
LGG	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg26384229	chr12:38710491	ALG10B	-0.68	-12.42	-0.5	8.98e-31	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg19774624	chr17:42201019	HDAC5	-0.56	-9.96	-0.42	2.65e-21	Red cell distribution width;Reticulocyte count;
LGG	trans	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg23762105	chr12:34175262	ALG10	0.34	6.74	0.3	4.68e-11	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg02733842	chr7:1102375	C7orf50	0.62	9.61	0.41	4.64e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9487094	0.670	rs1476388	chr6:109839986	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.04	0.35	7.57e-15	Height;
LGG	cis	rs6489785	0.562	rs494632	chr12:121189116	C/T	cg02419362	chr12:121203948	SPPL3	0.55	9.36	0.4	3.55e-19	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7945705	0.791	rs4579928	chr11:8815704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.38	7.7	0.34	8.26e-14	Hemoglobin concentration;
LGG	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg19847130	chr8:10466454	RP1L1	0.32	6.89	0.3	1.82e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.92	0.38	1.11e-17	Lung cancer;
LGG	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.03	-0.31	7.33e-12	Bipolar disorder;
LGG	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.2	-0.32	2.47e-12	Blood metabolite levels;
LGG	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg24253500	chr15:84953950	NA	0.44	7.33	0.32	1.01e-12	Schizophrenia;
LGG	cis	rs17221829	0.733	rs11018681	chr11:89364443	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs2279817	0.735	rs71644063	chr1:17987274	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-9.26	-0.4	7.62e-19	Neuroticism;
LGG	cis	rs1007190	0.881	rs9915066	chr17:42962166	C/T	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	cis	rs4950322	0.542	rs56080828	chr1:146655026	G/A	cg22381352	chr1:146742008	CHD1L	-0.49	-8.09	-0.35	5.22e-15	Protein quantitative trait loci;
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.85	0.38	1.86e-17	Aortic root size;
LGG	cis	rs7267979	0.844	rs2474780	chr20:25285835	G/A	cg06421707	chr20:25228305	PYGB	0.43	9.0	0.39	5.82e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4780401	0.642	rs7194145	chr16:11764615	T/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.22	-0.32	2.15e-12	Rheumatoid arthritis;
LGG	cis	rs2991971	0.967	rs937291	chr1:45957039	G/T	cg24296786	chr1:45957014	TESK2	0.42	7.67	0.34	1.05e-13	High light scatter reticulocyte count;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg13453750	chr1:205783389	SLC41A1	0.37	7.6	0.33	1.65e-13	Monocyte percentage of white cells;
LGG	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg11247378	chr22:39784982	NA	-0.32	-9.09	-0.39	2.89e-18	Intelligence (multi-trait analysis);
LGG	cis	rs709400	0.567	rs1961600	chr14:103862144	G/A	cg26031613	chr14:104095156	KLC1	0.8	13.68	0.54	4.86e-36	Body mass index;
LGG	trans	rs459571	0.959	rs460888	chr9:136913123	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.93	-0.48	8.82e-29	Platelet distribution width;
LGG	cis	rs7849585	0.830	rs55679545	chr9:139122363	G/A	cg14094347	chr9:139131620	QSOX2	-0.48	-9.15	-0.39	1.77e-18	Height;
LGG	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.51	0.33	3.16e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg08779649	chr13:50194554	NA	0.37	9.27	0.4	7e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg03929089	chr4:120376271	NA	-0.62	-7.8	-0.34	4.22e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg10852096	chr15:79043040	NA	-0.29	-8.3	-0.36	1.11e-15	Coronary artery disease or large artery stroke;
LGG	trans	rs12579753	1.000	rs10862371	chr12:82249298	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.52	-0.33	2.84e-13	Resting heart rate;
LGG	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.38	0.47	1.21e-26	Mean platelet volume;
LGG	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg00012203	chr2:219082015	ARPC2	-0.67	-12.1	-0.49	1.74e-29	Colorectal cancer;
LGG	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.39	-0.53	8.93e-35	Colorectal cancer;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg18135555	chr8:22132992	PIWIL2	0.4	10.49	0.44	3.14e-23	Hypertriglyceridemia;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg18402987	chr7:1209562	NA	0.47	7.49	0.33	3.49e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.14	-0.46	1.04e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.48	-0.44	3.34e-23	Bipolar disorder;
LGG	cis	rs2114646	0.731	rs1469357	chr2:170638407	G/A	cg17598339	chr2:170624727	NA	0.35	6.76	0.3	4.29e-11	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-9.81	-0.41	9.29e-21	Pancreatic cancer;
LGG	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg00405596	chr8:11794950	NA	-0.65	-11.46	-0.47	6.24e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13519464	chr19:9938554	UBL5	0.43	7.1	0.31	4.76e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg26875233	chr11:93583750	C11orf90	-0.47	-8.73	-0.38	4.59e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.26	-0.32	1.68e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.12	0.31	4.14e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs283228	0.550	rs522650	chr6:101811685	C/T	cg02011392	chr6:101847541	GRIK2	0.54	7.3	0.32	1.3e-12	Coenzyme Q10 levels;
LGG	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg16230307	chr14:35515116	FAM177A1	0.95	13.74	0.54	2.73e-36	Psoriasis;
LGG	cis	rs2249694	0.520	rs7096321	chr10:135324536	A/G	cg20169779	chr10:135381914	SYCE1	-0.54	-7.42	-0.33	5.54e-13	Obesity-related traits;
LGG	cis	rs9362426	0.503	rs6454622	chr6:88134511	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.39	-7.58	-0.33	1.86e-13	Depressive episodes in bipolar disorder;
LGG	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg11764359	chr7:65958608	NA	0.64	9.73	0.41	1.7e-20	Aortic root size;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg09264619	chr17:80180166	NA	-0.41	-7.78	-0.34	4.68e-14	Life satisfaction;
LGG	cis	rs11971779	0.680	rs7801613	chr7:139039927	A/G	cg07862535	chr7:139043722	LUC7L2	-0.42	-6.92	-0.31	1.55e-11	Diisocyanate-induced asthma;
LGG	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2286885	1.000	rs1537987	chr9:129242112	T/C	cg14319473	chr9:129242481	FAM125B	0.45	8.42	0.36	4.88e-16	Intraocular pressure;
LGG	cis	rs9309473	0.950	rs7566364	chr2:73842889	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.68	-0.34	9.69e-14	Metabolite levels;
LGG	cis	rs7226408	0.857	rs997661	chr18:34703727	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg26528311	chr1:38462546	FHL3	0.28	7.45	0.33	4.68e-13	Coronary artery disease;
LGG	cis	rs17433780	0.897	rs12142922	chr1:89489915	A/G	cg09516651	chr1:89888402	LOC400759	0.76	17.64	0.63	1.23e-53	Carotid intima media thickness;
LGG	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg13271783	chr10:134563150	INPP5A	-0.54	-7.87	-0.34	2.56e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg09033563	chr22:24373618	LOC391322	-0.53	-8.88	-0.38	1.51e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07614371	chr15:38746870	FAM98B	0.43	7.28	0.32	1.47e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.77	0.3	3.89e-11	Bone mineral density;
LGG	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	11.08	0.46	1.8e-25	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.41	-0.63	1.36e-52	Skin colour saturation;
LGG	cis	rs7241530	0.569	rs12965699	chr18:75895741	C/A	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs2274273	0.805	rs7159808	chr14:55624327	G/T	cg04306507	chr14:55594613	LGALS3	0.65	18.42	0.65	2.99e-57	Protein biomarker;
LGG	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-8.99	-0.39	6.31e-18	Retinal vascular caliber;
LGG	cis	rs9992101	0.645	rs3849577	chr4:77286706	A/G	cg17010112	chr4:77227123	STBD1	-0.46	-9.58	-0.41	5.99e-20	Creatinine levels;
LGG	cis	rs13314892	0.728	rs55808455	chr3:69861423	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg02725872	chr8:58115012	NA	-0.76	-11.33	-0.47	1.96e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Educational attainment;
LGG	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	22.29	0.72	2.71e-75	Homoarginine levels;
LGG	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg13010199	chr12:38710504	ALG10B	0.7	14.62	0.56	4.55e-40	Heart rate;
LGG	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.54	0.33	2.54e-13	Colorectal cancer;
LGG	cis	rs4319547	0.637	rs61244464	chr12:123090565	T/G	cg23029597	chr12:123009494	RSRC2	-0.5	-8.7	-0.37	5.75e-17	Body mass index;
LGG	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg22307297	chr20:60903441	LAMA5	-0.42	-8.01	-0.35	9.48e-15	Colorectal cancer;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg13047869	chr3:10149882	C3orf24	0.46	7.48	0.33	3.74e-13	Alzheimer's disease;
LGG	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11890956	chr21:40555474	PSMG1	-0.98	-21.07	-0.7	1.27e-69	Cognitive function;
LGG	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg06917634	chr15:78832804	PSMA4	-0.64	-9.56	-0.41	6.99e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg15704280	chr7:45808275	SEPT13	0.88	9.18	0.39	1.45e-18	Myopia (pathological);
LGG	trans	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg18187862	chr3:45730750	SACM1L	-0.53	-8.39	-0.36	6.15e-16	Primary sclerosing cholangitis;
LGG	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg08807101	chr21:30365312	RNF160	-0.6	-8.25	-0.36	1.6e-15	Cognitive test performance;
LGG	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.31	-0.32	1.21e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg00745463	chr17:30367425	LRRC37B	-0.62	-8.89	-0.38	1.33e-17	Hip circumference adjusted for BMI;
LGG	cis	rs2013441	1.000	rs11654025	chr17:20198160	A/T	cg09818912	chr17:20140352	CYTSB	0.3	6.91	0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs11225247	0.772	rs11225222	chr11:102230129	T/A	cg06323957	chr11:102217781	BIRC2	0.8	7.53	0.33	2.69e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs73191547	0.782	rs11786117	chr8:10038474	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.53	0.33	2.72e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs77511414	chr22:32406941	A/T	cg00543991	chr22:32367038	NA	0.8	8.89	0.38	1.41e-17	Childhood ear infection;
LGG	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06850241	chr22:41845214	NA	-0.42	-6.74	-0.3	4.73e-11	Vitiligo;
LGG	cis	rs4771450	0.925	rs7333662	chr13:103986817	G/A	cg02987523	chr13:103978230	NA	-0.33	-7.2	-0.32	2.52e-12	Uric acid levels;
LGG	cis	rs963731	0.579	rs1377864	chr2:39246240	T/G	cg04010122	chr2:39346883	SOS1	-0.75	-7.66	-0.34	1.08e-13	Corticobasal degeneration;
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg11494091	chr17:61959527	GH2	0.51	8.19	0.36	2.51e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.53	-0.37	2.12e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg19847130	chr8:10466454	RP1L1	0.34	7.34	0.32	9.69e-13	Triglycerides;
LGG	cis	rs2241941	0.802	rs72927524	chr11:20629584	C/T	cg09136245	chr11:20631761	SLC6A5	-0.46	-8.18	-0.36	2.83e-15	Obesity-related traits;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6032067	0.777	rs62208382	chr20:43785549	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg10591111	chr5:226296	SDHA	0.54	6.83	0.3	2.62e-11	Breast cancer;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	21.17	0.7	4.33e-70	Homoarginine levels;
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg08222618	chr4:941054	TMEM175	0.8	19.55	0.67	1.69e-62	Sjögren's syndrome;
LGG	cis	rs7928758	0.887	rs55751035	chr11:134265723	C/T	cg15243474	chr11:134282918	B3GAT1	1.25	16.15	0.6	7.1500000000000005e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2076222	1.000	rs2076350	chr1:209800341	C/T	cg00257659	chr1:209800214	LAMB3	-1.21	-11.75	-0.48	4.6e-28	Fentanyl consumption in laparoscopic-assisted colectomy (first 24 hours);
LGG	cis	rs911119	1.000	rs34897231	chr20:23620268	A/G	cg16589663	chr20:23618590	CST3	0.47	6.75	0.3	4.46e-11	Chronic kidney disease;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg11416447	chr7:86781551	DMTF1	0.42	6.65	0.3	8.18e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg21153622	chr11:89784906	NA	-0.41	-6.97	-0.31	1.09e-11	HDL cholesterol;
LGG	cis	rs17301259	0.548	rs2519946	chr7:88397143	C/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.87	-0.3	2.04e-11	Heschl's gyrus morphology;
LGG	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11644478	chr21:40555479	PSMG1	0.92	18.0	0.64	2.65e-55	Cognitive function;
LGG	cis	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg24110177	chr3:50126178	RBM5	-0.41	-6.81	-0.3	3.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg00504896	chr12:9437009	LOC642846	-0.45	-8.24	-0.36	1.81e-15	Breast size;
LGG	cis	rs2074193	0.627	rs61929787	chr12:47768325	G/C	cg02516419	chr12:47771422	NA	0.72	10.6	0.44	1.16e-23	Migraine with aura;
LGG	cis	rs17221829	0.739	rs7945443	chr11:89372622	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.15	-0.39	1.83e-18	Anxiety in major depressive disorder;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg26354017	chr1:205819088	PM20D1	0.86	20.28	0.69	6.75e-66	Menarche (age at onset);
LGG	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg08250081	chr4:10125330	NA	0.66	12.22	0.49	5.75e-30	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg13852218	chr11:84431850	DLG2	0.41	6.9	0.31	1.76e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.39	-0.4	2.77e-19	Obesity-related traits;
LGG	cis	rs757978	0.810	rs34123564	chr2:242404437	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.62	-7.02	-0.31	8.2e-12	Chronic lymphocytic leukemia;
LGG	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg08916839	chr5:415575	AHRR	0.72	11.48	0.47	5e-27	Fat distribution (HIV);
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02018176	chr4:1364513	KIAA1530	0.49	11.88	0.48	1.34e-28	Longevity;
LGG	trans	rs6011368	0.792	rs6512309	chr20:62892584	A/G	cg13869341	chr1:15865	WASH5P	0.52	9.38	0.4	3e-19	Clozapine-induced cytotoxicity;
LGG	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg13010199	chr12:38710504	ALG10B	0.6	11.3	0.47	2.49e-26	Bladder cancer;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.18	-0.58	1.52e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.82	-16.83	-0.62	6.15e-50	Age at first birth;
LGG	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06677660	chr19:49140777	SEC1;DBP	0.76	12.36	0.5	1.65e-30	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs340630	0.967	rs13126334	chr4:87909890	A/G	cg01323104	chr4:87958903	AFF1	-0.24	-6.87	-0.3	2.05e-11	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-9.23	-0.39	9.37e-19	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17772490	chr12:57119086	NACA	0.45	6.68	0.3	6.66e-11	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.68e-12	Bipolar disorder;
LGG	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg00071950	chr4:10020882	SLC2A9	0.38	7.79	0.34	4.49e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2115536	0.730	rs4573897	chr15:80187225	G/A	cg11839771	chr15:80205821	ST20	-0.37	-7.85	-0.34	2.85e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg12923728	chr3:195709715	SDHAP1	-0.78	-14.64	-0.56	3.64e-40	Pancreatic cancer;
LGG	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14159747	chr11:113255604	NA	0.32	8.79	0.38	3.06e-17	Neuroticism;
LGG	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.86	-10.81	-0.45	1.86e-24	Lung cancer in ever smokers;
LGG	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg09222892	chr1:25734099	RHCE	0.45	9.55	0.41	7.6e-20	Erythrocyte sedimentation rate;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg15971980	chr6:150254442	NA	0.46	8.43	0.36	4.42e-16	Lung cancer;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg15537850	chr8:144661051	NAPRT1	1.0	7.51	0.33	3.1e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2370759	1.000	rs11597888	chr10:32635834	G/A	cg01819863	chr10:32635814	EPC1	1.09	15.51	0.58	5.66e-44	Sexual dysfunction (female);
LGG	cis	rs969413	0.535	rs8077394	chr17:79258787	A/G	cg25342872	chr17:79175132	AZI1	-0.49	-8.16	-0.35	3.21e-15	Frontotemporal dementia;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05371064	chr6:119671176	MAN1A1	0.45	6.78	0.3	3.75e-11	Hip circumference;
LGG	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.68	-0.34	9.31e-14	Mean corpuscular hemoglobin;
LGG	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg02631450	chr22:32366979	NA	1.01	9.71	0.41	2.14e-20	Childhood ear infection;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.63	-11.16	-0.46	8.76e-26	Obesity-related traits;
LGG	cis	rs6496932	0.770	rs4843040	chr15:85838636	C/T	cg19183879	chr15:85880815	NA	0.44	7.42	0.33	5.55e-13	Central corneal thickness;Corneal structure;
LGG	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg12773197	chr13:112238673	NA	0.38	7.74	0.34	6.41e-14	Hepatitis;
LGG	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs11229555	0.645	rs12295551	chr11:58188983	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs68170813	0.559	rs3823960	chr7:107009349	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.63e-22	Coronary artery disease;
LGG	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.32e-35	Corneal astigmatism;
LGG	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg00092383	chr7:157075207	NA	0.39	6.95	0.31	1.22e-11	Body mass index;
LGG	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg13482628	chr17:19912719	NA	0.63	12.46	0.5	6.09e-31	Schizophrenia;
LGG	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg26578617	chr4:90757533	SNCA	0.35	6.99	0.31	9.66e-12	Dementia with Lewy bodies;
LGG	cis	rs72781680	0.752	rs56343114	chr2:23900629	C/G	cg08917208	chr2:24149416	ATAD2B	0.77	8.53	0.37	2.13e-16	Lymphocyte counts;
LGG	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.27	-0.55	1.47e-38	Platelet distribution width;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.31e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg26875233	chr11:93583750	C11orf90	-0.44	-8.56	-0.37	1.66e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg12070911	chr6:150209640	RAET1E	0.28	7.0	0.31	9.17e-12	Testicular germ cell tumor;
LGG	cis	rs7666738	0.830	rs13138059	chr4:99050430	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs240764	0.817	rs240143	chr6:101080621	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg15704280	chr7:45808275	SEPT13	-0.67	-8.43	-0.36	4.36e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	12.15	0.49	1.12e-29	Lung cancer in ever smokers;
LGG	cis	rs4731207	0.698	rs10270784	chr7:124446208	A/T	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg19774624	chr17:42201019	HDAC5	-0.94	-20.13	-0.68	3.36e-65	Total body bone mineral density;
LGG	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.82	-0.3	2.94e-11	Aortic root size;
LGG	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.26	0.36	1.53e-15	Mood instability;
LGG	cis	rs240110	0.588	rs7738319	chr6:101195253	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.07	0.31	5.78e-12	Neuroticism;
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs79149102	0.522	rs74925675	chr15:74905756	A/C	cg02384859	chr15:74862662	ARID3B	-0.39	-6.81	-0.3	3.05e-11	Lung cancer;
LGG	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.39	0.36	6.08e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg25214090	chr10:38739885	LOC399744	0.53	9.61	0.41	4.49e-20	Corneal astigmatism;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03274991	chr11:120207803	ARHGEF12	-0.41	-6.87	-0.3	2.07e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg14541582	chr5:601475	NA	-0.48	-8.67	-0.37	7.51e-17	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg26677194	chr12:130822605	PIWIL1	0.56	9.99	0.42	1.98e-21	Menopause (age at onset);
LGG	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.16	0.35	3.27e-15	Colorectal cancer;
LGG	cis	rs10214930	0.697	rs7780431	chr7:27593368	G/A	cg22168087	chr7:27702803	HIBADH	0.46	6.8	0.3	3.14e-11	Hypospadias;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08677398	chr8:58056175	NA	0.47	7.76	0.34	5.6e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.81	-0.3	3.07e-11	Arsenic metabolism;
LGG	cis	rs2274273	0.682	rs7151224	chr14:55517262	G/A	cg04306507	chr14:55594613	LGALS3	0.44	10.83	0.45	1.68e-24	Protein biomarker;
LGG	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.31	-0.32	1.19e-12	Uric acid levels;
LGG	cis	rs6435862	0.500	rs6756902	chr2:215672827	C/T	cg04004882	chr2:215674386	BARD1	-0.61	-10.58	-0.44	1.36e-23	Neuroblastoma (high-risk);
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg18225595	chr11:63971243	STIP1	0.52	6.96	0.31	1.16e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg20887711	chr4:1340912	KIAA1530	0.63	12.71	0.51	5.61e-32	Longevity;
LGG	cis	rs6429082	0.818	rs291341	chr1:235663174	G/T	cg26050004	chr1:235667680	B3GALNT2	0.61	10.16	0.43	5.13e-22	Adiposity;
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg11764359	chr7:65958608	NA	0.72	12.99	0.52	3.9e-33	Aortic root size;
LGG	cis	rs12788925	1.000	rs12788925	chr11:102801847	A/G	cg19620758	chr11:102826565	MMP13	-0.37	-7.3	-0.32	1.27e-12	Coronary artery disease;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.72	10.47	0.44	3.67e-23	Lung function (FEV1/FVC);
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.85	-0.3	2.4e-11	Menopause (age at onset);
LGG	cis	rs1318772	0.932	rs7705255	chr5:112950169	C/A	cg12552261	chr5:112820674	MCC	0.68	7.67	0.34	1.05e-13	F-cell distribution;
LGG	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg12560992	chr17:57184187	TRIM37	0.53	8.51	0.37	2.5e-16	Testicular germ cell tumor;
LGG	cis	rs9296092	0.517	rs78978280	chr6:33520747	T/A	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7945718	0.621	rs10831894	chr11:12680733	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.17	0.32	2.94e-12	Educational attainment (years of education);
LGG	cis	rs7785730	0.652	rs10273399	chr7:28089047	C/T	cg17702455	chr7:28058989	JAZF1	-0.42	-7.63	-0.33	1.33e-13	Free thyroxine concentration;
LGG	cis	rs2235573	0.662	rs6000991	chr22:38460484	T/C	cg19171272	chr22:38449367	NA	-0.61	-12.0	-0.49	4.3e-29	Glioblastoma;Glioma;
LGG	cis	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg00188032	chr5:96141721	ERAP1	-0.52	-6.87	-0.3	2.1e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	8.0	0.35	9.86e-15	Neuroticism;
LGG	trans	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg06521331	chr12:34319734	NA	-0.5	-8.9	-0.38	1.31e-17	Bladder cancer;
LGG	cis	rs9880211	0.800	rs36109616	chr3:136492403	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs10463554	0.927	rs34811	chr5:102431821	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.46	-0.33	4.36e-13	Parkinson's disease;
LGG	trans	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.26	0.5	3.98e-30	Mean corpuscular volume;
LGG	cis	rs9902453	0.765	rs9890747	chr17:28007442	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.49	0.56	1.59e-39	Coffee consumption (cups per day);
LGG	cis	rs12621278	0.655	rs59454075	chr2:173301275	G/A	cg15021238	chr2:173305865	ITGA6	-0.81	-9.08	-0.39	3.07e-18	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg27587195	chr5:112824172	MCC	-0.46	-7.41	-0.33	5.96e-13	Type 2 diabetes;
LGG	cis	rs2718058	0.589	rs10258728	chr7:37792922	C/T	cg15028436	chr7:37888078	TXNDC3	-0.46	-7.5	-0.33	3.18e-13	Alzheimer's disease (late onset);
LGG	cis	rs7928758	0.767	rs7932600	chr11:134276142	A/G	cg25213107	chr11:134282864	B3GAT1	0.74	10.29	0.43	1.62e-22	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs67311347	0.668	rs73071710	chr3:40288587	A/G	cg13683864	chr3:40499215	RPL14	-0.85	-16.2	-0.6	4.38e-47	Renal cell carcinoma;
LGG	cis	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg20368463	chr18:77673604	PQLC1	0.48	7.36	0.32	8.69e-13	Opioid sensitivity;
LGG	cis	rs774359	0.797	rs1319236	chr9:27507209	G/A	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.35	-0.36	8.18e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg03433033	chr1:76189801	ACADM	-0.78	-13.04	-0.52	2.42e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg00319359	chr11:70116639	PPFIA1	0.64	6.96	0.31	1.15e-11	Coronary artery disease;
LGG	cis	rs7707921	0.522	rs10065463	chr5:81500280	A/G	cg15871215	chr5:81402204	ATG10	-0.3	-6.79	-0.3	3.45e-11	Breast cancer;
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.42e-27	Rheumatoid arthritis;
LGG	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05901451	chr6:126070800	HEY2	0.75	14.75	0.57	1.2e-40	Brugada syndrome;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.13	0.52	1.11e-33	Lung cancer;
LGG	cis	rs6840360	0.642	rs6843639	chr4:152416015	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.33	0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17106184	1.000	rs12065210	chr1:50942784	C/T	cg07174182	chr1:51127561	FAF1	0.56	8.44	0.37	4.16e-16	Type 2 diabetes;
LGG	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.24	-0.36	1.82e-15	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg11494091	chr17:61959527	GH2	0.55	9.0	0.39	6.09e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9297145	0.724	rs62473013	chr7:98762418	G/T	cg05967295	chr7:98741636	SMURF1	0.93	15.3	0.58	4.67e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.94	-0.42	3.17e-21	Bipolar disorder;
LGG	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.91e-19	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.34	-0.55	7.83e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs896854	0.738	rs2515226	chr8:95965743	G/A	cg16049864	chr8:95962084	TP53INP1	0.4	8.7	0.37	5.74e-17	Type 2 diabetes;
LGG	cis	rs9513627	1.000	rs7985908	chr13:100186218	T/C	cg15490075	chr13:100150979	NA	0.63	6.75	0.3	4.34e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05919661	chr12:49504308	LMBR1L	0.47	6.73	0.3	5.1e-11	Gut microbiome composition (summer);
LGG	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.08	0.55	1.03e-37	IgG glycosylation;
LGG	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-13.39	-0.53	8.65e-35	Chronic sinus infection;
LGG	cis	rs28374715	0.662	rs16971558	chr15:41458619	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-16.96	-0.62	1.58e-50	Ulcerative colitis;
LGG	cis	rs926938	0.618	rs360675	chr1:115490918	T/C	cg12756093	chr1:115239321	AMPD1	0.48	9.32	0.4	4.92e-19	Autism;
LGG	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.0	0.35	9.88e-15	Morning vs. evening chronotype;
LGG	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.74	13.93	0.54	4.26e-37	Colorectal cancer;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg10207240	chr12:122356781	WDR66	0.24	7.41	0.33	5.87e-13	Mean corpuscular volume;
LGG	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg26384229	chr12:38710491	ALG10B	0.79	14.41	0.56	3.8e-39	Resting heart rate;
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg09173681	chr1:183549694	NCF2	-0.37	-8.35	-0.36	7.81e-16	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.57	-0.37	1.5e-16	Retinal vascular caliber;
LGG	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg14829155	chr15:31115871	NA	-0.54	-8.73	-0.38	4.5e-17	Huntington's disease progression;
LGG	cis	rs7617773	0.784	rs9850672	chr3:48301172	C/A	cg11946769	chr3:48343235	NME6	0.63	10.44	0.44	4.68e-23	Coronary artery disease;
LGG	cis	rs4774899	1.000	rs12899187	chr15:57285255	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.25	-0.36	1.65e-15	Urinary tract infection frequency;
LGG	cis	rs981844	1.000	rs55792703	chr4:154668278	C/A	cg14289246	chr4:154710475	SFRP2	0.69	11.51	0.47	4.02e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg19628046	chr18:33552617	C18orf21	0.51	7.54	0.33	2.46e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4330281	0.669	rs6807020	chr3:17692815	C/G	cg20981856	chr3:17787350	NA	-0.38	-7.04	-0.31	6.8e-12	Schizophrenia;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.87	0.42	5.55e-21	Obesity-related traits;
LGG	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	10.97	0.45	4.96e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-9.27	-0.4	7.31e-19	Erythrocyte sedimentation rate;
LGG	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08109568	chr15:31115862	NA	-0.59	-10.02	-0.42	1.55e-21	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13245472	chr1:109234981	PRPF38B	0.49	7.37	0.32	7.66e-13	Gut microbiome composition (summer);
LGG	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg00405596	chr8:11794950	NA	0.41	6.98	0.31	9.97e-12	Monocyte count;
LGG	cis	rs9443645	0.901	rs9359354	chr6:79590385	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg10756647	chr7:56101905	PSPH	0.75	8.58	0.37	1.43e-16	Diabetic kidney disease;
LGG	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg12432903	chr7:1882776	MAD1L1	0.52	7.93	0.35	1.64e-14	Bipolar disorder;
LGG	cis	rs3126085	1.000	rs72697000	chr1:152276772	C/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.07	-0.31	5.74e-12	Atopic dermatitis;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.01	0.64	2.49e-55	Personality dimensions;
LGG	cis	rs12618769	0.597	rs3754884	chr2:99125376	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs975722	0.638	rs213973	chr7:117235886	A/G	cg10524701	chr7:117356490	CTTNBP2	0.49	10.54	0.44	1.98e-23	Coronary artery disease;
LGG	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.93	0.38	1.02e-17	Mood instability;
LGG	cis	rs9517320	0.935	rs9645891	chr13:99126800	A/G	cg07423050	chr13:99094983	FARP1	0.4	8.16	0.35	3.12e-15	Longevity;
LGG	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.7	0.34	8.21e-14	Homoarginine levels;
LGG	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg17467752	chr17:38218738	THRA	-0.43	-6.96	-0.31	1.18e-11	Self-reported allergy;
LGG	cis	rs6840360	1.000	rs6817586	chr4:152643184	G/A	cg22705602	chr4:152727874	NA	-0.27	-6.71	-0.3	5.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg12658982	chr7:29603541	PRR15	-0.4	-8.38	-0.36	6.58e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg00808730	chr14:93215038	LGMN	0.4	6.72	0.3	5.35e-11	Corneal astigmatism;
LGG	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg04469686	chr1:162760199	HSD17B7	0.45	6.72	0.3	5.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg24692254	chr21:30365293	RNF160	-0.57	-8.39	-0.36	5.82e-16	Cognitive test performance;
LGG	cis	rs6466055	0.666	rs12671047	chr7:104999535	C/A	cg04380332	chr7:105027541	SRPK2	-0.38	-7.05	-0.31	6.43e-12	Schizophrenia;
LGG	cis	rs35160687	0.623	rs718292	chr2:86473740	A/G	cg10973622	chr2:86423274	IMMT	0.42	7.48	0.33	3.83e-13	Night sleep phenotypes;
LGG	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26714650	chr12:56694279	CS	1.49	18.31	0.65	9.68e-57	Psoriasis vulgaris;
LGG	cis	rs4664308	0.935	rs4637057	chr2:160950161	G/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.87	-0.64	1.02e-54	Idiopathic membranous nephropathy;
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg13047869	chr3:10149882	C3orf24	0.48	7.95	0.35	1.41e-14	Alzheimer's disease;
LGG	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg11822372	chr1:151115635	SEMA6C	0.49	8.72	0.38	4.99e-17	Childhood ear infection;
LGG	cis	rs55665837	1.000	rs10832257	chr11:14443316	A/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.86e-17	Vitamin D levels;
LGG	cis	rs9341835	0.608	rs2076874	chr6:64153691	G/A	cg00787780	chr6:64151745	NA	0.45	8.28	0.36	1.3e-15	Schizophrenia;
LGG	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg09173681	chr1:183549694	NCF2	0.37	8.34	0.36	8.47e-16	Systemic lupus erythematosus;
LGG	cis	rs7444	0.941	rs59391722	chr22:21920817	G/C	cg15846791	chr22:21984385	YDJC	-0.47	-7.04	-0.31	6.77e-12	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06481639	chr22:41940642	POLR3H	0.64	9.16	0.39	1.65e-18	Vitiligo;
LGG	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg23335576	chr14:104009727	NA	0.42	7.05	0.31	6.4e-12	Reticulocyte count;
LGG	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg26116260	chr4:7069785	GRPEL1	-0.97	-8.66	-0.37	7.88e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.29	-0.32	1.36e-12	Life satisfaction;
LGG	cis	rs2290159	0.752	rs5746182	chr3:12672550	A/G	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.92	-0.42	3.78e-21	IgG glycosylation;
LGG	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg12856521	chr11:46389249	DGKZ	-0.39	-6.65	-0.3	8.35e-11	Leprosy;
LGG	cis	rs9863	0.861	rs3789967	chr12:124447339	T/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.22	-0.32	2.19e-12	White blood cell count;
LGG	cis	rs4356975	0.563	rs7666195	chr4:69979483	G/C	cg27372994	chr4:70080453	UGT2B11	0.37	6.81	0.3	3.09e-11	Obesity-related traits;
LGG	cis	rs9354308	0.714	rs2351714	chr6:66585731	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs4731207	0.698	rs4311608	chr7:124519707	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	cis	rs36093844	0.752	rs1445511	chr11:85548049	C/A	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg05896524	chr21:47604654	C21orf56	-0.6	-10.73	-0.45	3.79e-24	Testicular germ cell tumor;
LGG	cis	rs35740288	1.000	rs11637212	chr15:86293097	C/G	cg07943548	chr15:86304357	KLHL25	0.36	7.13	0.31	3.97e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17331151	0.573	rs11718060	chr3:52875546	G/A	cg04865290	chr3:52927548	TMEM110	-0.45	-7.7	-0.34	8.38e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10861342	0.892	rs12227605	chr12:105501100	G/A	cg23923672	chr12:105501055	KIAA1033	0.81	7.6	0.33	1.7e-13	IgG glycosylation;
LGG	cis	rs7177699	0.526	rs7165733	chr15:79123505	G/A	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2286885	0.896	rs62578061	chr9:129248219	C/T	cg14319473	chr9:129242481	FAM125B	0.45	8.44	0.36	4.25e-16	Intraocular pressure;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13012494	chr21:47604986	C21orf56	0.52	8.65	0.37	8.78e-17	Testicular germ cell tumor;
LGG	cis	rs990171	1.000	rs13015714	chr2:102971865	G/T	cg05295703	chr2:102895712	NA	-0.55	-9.6	-0.41	5.21e-20	Lymphocyte counts;
LGG	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24110177	chr3:50126178	RBM5	0.58	10.74	0.45	3.64e-24	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg26338869	chr17:61819248	STRADA	0.57	9.62	0.41	4.28e-20	Prudent dietary pattern;
LGG	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg12552261	chr5:112820674	MCC	0.75	14.29	0.55	1.21e-38	Type 2 diabetes;
LGG	trans	rs7777677	0.925	rs6960743	chr7:142369601	T/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg12560992	chr17:57184187	TRIM37	-0.87	-14.98	-0.57	1.14e-41	Intelligence (multi-trait analysis);
LGG	trans	rs9914544	0.545	rs4924945	chr17:18813160	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.63	-0.33	1.33e-13	Educational attainment (years of education);
LGG	cis	rs8005677	0.962	rs8003934	chr14:23401142	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.16	-0.32	3.17e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg21055462	chr7:100276975	NA	0.35	6.76	0.3	4.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs727505	0.954	rs68102397	chr7:124685315	C/T	cg23710748	chr7:124431027	NA	-0.51	-9.3	-0.4	5.52e-19	Lewy body disease;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg13395646	chr4:1353034	KIAA1530	0.52	8.87	0.38	1.55e-17	Obesity-related traits;
LGG	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg23740940	chr11:68924746	NA	0.43	6.95	0.31	1.29e-11	Blond vs. brown hair color;
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.44e-15	Alzheimer's disease;
LGG	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.98	-0.39	6.61e-18	Response to antipsychotic treatment;
LGG	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg25174290	chr11:3078921	CARS	-0.51	-9.28	-0.4	6.41e-19	Calcium levels;
LGG	cis	rs4132509	1.000	rs10927059	chr1:243852079	T/C	cg21452805	chr1:244014465	NA	0.63	7.69	0.34	8.78e-14	RR interval (heart rate);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03705042	chr17:34891475	PIGW;MYO19	-0.47	-7.74	-0.34	6.28e-14	Pancreatic cancer;
LGG	cis	rs151349	0.743	rs151353	chr20:57604343	A/C	cg23907860	chr20:57583709	CTSZ	-0.39	-7.7	-0.34	8.35e-14	Platelet distribution width;
LGG	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	cis	rs11785693	0.862	rs6995565	chr8:4990461	C/T	cg26367366	chr8:4980734	NA	-0.96	-15.19	-0.58	1.42e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.13	0.31	3.78e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-7.89	-0.34	2.16e-14	Lung cancer;
LGG	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg24375607	chr4:120327624	NA	0.6	10.07	0.42	1.05e-21	Corneal astigmatism;
LGG	cis	rs9902453	0.967	rs6505155	chr17:28372783	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg16606324	chr3:10149918	C3orf24	0.53	6.9	0.31	1.74e-11	Alzheimer's disease;
LGG	cis	rs209489	0.892	rs9474464	chr6:53109958	A/G	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg01631408	chr1:248437212	OR2T33	-0.5	-8.92	-0.38	1.07e-17	Common traits (Other);
LGG	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg13010199	chr12:38710504	ALG10B	-0.53	-9.83	-0.42	8.04e-21	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.774	rs10155672	chr6:66538447	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg02733842	chr7:1102375	C7orf50	0.43	7.48	0.33	3.69e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg08925882	chr11:67350491	GSTP1	-0.35	-6.87	-0.3	2.1e-11	Mean corpuscular volume;
LGG	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg25039879	chr17:56429692	SUPT4H1	0.59	7.79	0.34	4.35e-14	Cognitive test performance;
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg21017887	chr14:105400489	NA	0.44	8.67	0.37	7.28e-17	Rheumatoid arthritis;
LGG	cis	rs9300255	0.620	rs1727311	chr12:123660716	T/G	cg00376283	chr12:123451042	ABCB9	0.6	8.59	0.37	1.31e-16	Neutrophil percentage of white cells;
LGG	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg03929089	chr4:120376271	NA	0.86	17.37	0.63	2.14e-52	Coronary artery disease;
LGG	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg04568710	chr12:38710424	ALG10B	-0.39	-8.15	-0.35	3.37e-15	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg02158880	chr13:53174818	NA	-0.4	-8.02	-0.35	8.74e-15	Lewy body disease;
LGG	cis	rs9807989	0.507	rs1035129	chr2:103019785	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.85	-0.38	1.81e-17	Initial pursuit acceleration;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01601746	chr19:58038689	ZNF549	-0.43	-7.4	-0.33	6.36e-13	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg04111992	chr7:158790115	NA	-0.38	-7.52	-0.33	2.8e-13	Facial morphology (factor 20);
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg15971980	chr6:150254442	NA	0.46	8.58	0.37	1.5e-16	Lung cancer;
LGG	trans	rs12517041	1.000	rs34515966	chr5:23310388	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.8	-11.95	-0.49	7.15e-29	Calcium levels;
LGG	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.04	-0.35	7.69e-15	HDL cholesterol;
LGG	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg00717180	chr2:96193071	NA	0.41	7.28	0.32	1.49e-12	HDL cholesterol;
LGG	cis	rs2072732	0.821	rs10909864	chr1:2948178	T/C	cg08733933	chr1:2954429	NA	-0.39	-8.25	-0.36	1.63e-15	Plateletcrit;
LGG	cis	rs9354308	0.764	rs9354334	chr6:66607770	A/G	cg07460842	chr6:66804631	NA	-0.39	-6.72	-0.3	5.34e-11	Metabolite levels;
LGG	trans	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg06521331	chr12:34319734	NA	-0.51	-9.4	-0.4	2.49e-19	Bladder cancer;
LGG	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-17.2	-0.62	1.31e-51	Personality dimensions;
LGG	cis	rs1451375	0.698	rs11238214	chr7:50636018	A/G	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs4557202	0.509	rs12690576	chr3:160647912	G/A	cg04691961	chr3:161091175	C3orf57	-0.4	-7.88	-0.34	2.29e-14	Menarche (age at onset);
LGG	cis	rs7188861	0.681	rs6498184	chr16:11435990	A/G	cg01510278	chr16:11456238	NA	-0.29	-6.81	-0.3	3.03e-11	HDL cholesterol;
LGG	cis	rs988958	0.526	rs12712822	chr2:42238995	C/G	cg27428208	chr2:42229179	NA	0.5	7.61	0.33	1.51e-13	Hypospadias;
LGG	cis	rs11168854	0.930	rs10783302	chr12:49498130	A/C	cg24176009	chr12:49580217	TUBA1A	-0.54	-10.42	-0.44	5.73e-23	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05647208	chr19:18527971	NA	0.42	6.69	0.3	6.48e-11	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs9600832	0.574	rs4943303	chr13:36052726	T/C	cg20704442	chr13:36052768	MIR548F5;NBEA	0.43	12.46	0.5	6.04e-31	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg26446133	chr18:72167187	CNDP2	-0.67	-13.37	-0.53	1.08e-34	Refractive error;
LGG	cis	rs34845616	0.551	rs4936209	chr11:133686106	C/G	cg06067394	chr11:133789110	IGSF9B	0.41	7.09	0.31	4.97e-12	Hand grip strength;
LGG	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg09998033	chr7:158218633	PTPRN2	0.46	8.43	0.36	4.44e-16	Obesity-related traits;
LGG	cis	rs9815354	0.953	rs1717007	chr3:41942199	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs782590	0.967	rs782592	chr2:55843875	T/A	cg18811423	chr2:55921094	PNPT1	0.79	15.14	0.58	2.39e-42	Metabolic syndrome;
LGG	cis	rs3540	0.554	rs4244879	chr15:91066915	C/T	cg22089800	chr15:90895588	ZNF774	-0.67	-12.16	-0.49	1.06e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19720917	chr19:36606221	POLR2I;TBCB	0.45	7.47	0.33	3.95e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.89e-22	Cannabis dependence symptom count;
LGG	trans	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg16141378	chr3:129829833	LOC729375	-0.41	-9.56	-0.41	6.76e-20	Parkinson's disease;
LGG	cis	rs2797160	0.967	rs1739355	chr6:126018114	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.45	0.33	4.67e-13	Endometrial cancer;
LGG	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.28e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg15103426	chr22:29168792	CCDC117	0.66	7.65	0.34	1.17e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs74781061	0.929	rs6495115	chr15:74870463	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.09	-0.31	5.13e-12	Endometriosis;
LGG	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.09	0.49	2.02e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.38e-11	Blood metabolite levels;
LGG	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg12193833	chr17:30244370	NA	-0.28	-7.04	-0.31	7.15e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg06219351	chr7:158114137	PTPRN2	-0.83	-14.31	-0.55	9.67e-39	Response to amphetamines;
LGG	cis	rs13040088	0.872	rs13039291	chr20:61572760	C/T	cg23096297	chr20:61557774	DIDO1	0.87	12.02	0.49	3.71e-29	Menopause (age at onset);
LGG	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg10587741	chr22:38071170	LGALS1	0.63	12.32	0.5	2.39e-30	Fat distribution (HIV);
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00864171	chr11:67383662	NA	-0.52	-7.87	-0.34	2.53e-14	Mean corpuscular volume;
LGG	trans	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg08807101	chr21:30365312	RNF160	-0.81	-15.75	-0.59	4.45e-45	Dental caries;
LGG	cis	rs7312774	0.748	rs1861745	chr12:107301642	C/T	cg16260113	chr12:107380972	MTERFD3	0.72	7.51	0.33	3.08e-13	Severe influenza A (H1N1) infection;
LGG	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg17911788	chr17:44343683	NA	0.46	7.71	0.34	8e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg18240062	chr17:79603768	NPLOC4	-0.81	-15.4	-0.58	1.73e-43	Eye color traits;
LGG	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.04	-0.35	7.65e-15	Neuroticism;
LGG	trans	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.41	-0.33	5.85e-13	Menopause (age at onset);
LGG	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.96	-0.91	1.19e-174	Myeloid white cell count;
LGG	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg04317338	chr11:64019027	PLCB3	0.67	8.19	0.36	2.55e-15	Mean platelet volume;
LGG	cis	rs526231	0.543	rs158400	chr5:102413332	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg10756647	chr7:56101905	PSPH	-0.8	-9.31	-0.4	5.11e-19	Diabetic kidney disease;
LGG	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	cg07245641	chr1:182991651	LAMC1	-0.4	-9.09	-0.39	3e-18	Fuchs's corneal dystrophy;
LGG	cis	rs17030434	0.953	rs12639885	chr4:154700374	G/A	cg14289246	chr4:154710475	SFRP2	-0.76	-11.66	-0.48	9.66e-28	Electrocardiographic conduction measures;
LGG	trans	rs1997103	0.954	rs6953004	chr7:55411919	G/A	cg20935933	chr6:143382018	AIG1	0.55	8.54	0.37	1.9e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19723775	chr5:179050963	HNRNPH1	0.45	7.67	0.34	1.03e-13	Lung cancer;
LGG	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-14.99	-0.57	1.05e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg05484508	chr16:89589025	SPG7	0.46	7.39	0.32	6.82e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.6	10.43	0.44	4.91e-23	Birth weight;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg16507663	chr6:150244633	RAET1G	0.47	8.84	0.38	2.04e-17	Lung cancer;
LGG	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.89	-0.38	1.34e-17	Joint mobility (Beighton score);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14212634	chr20:3189677	ITPA	0.46	7.46	0.33	4.17e-13	Cognitive performance;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12016809	chr21:47604291	C21orf56	0.4	6.71	0.3	5.86e-11	Testicular germ cell tumor;
LGG	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.64	-0.54	7.68e-36	Response to antipsychotic treatment;
LGG	cis	rs4566357	0.557	rs2272201	chr2:227912551	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.05	-0.39	3.88e-18	Coronary artery disease;
LGG	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg08668359	chr10:1443807	ADARB2	0.65	12.29	0.5	3.11e-30	Radiation response;
LGG	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00689492	chr4:1303491	MAEA	0.51	8.94	0.38	9.13e-18	Obesity-related traits;
LGG	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg03342759	chr3:160939853	NMD3	-0.52	-8.71	-0.38	5.42e-17	Kawasaki disease;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg25725258	chr1:46597318	PIK3R3	0.39	6.83	0.3	2.66e-11	Apolipoprotein A-IV levels;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	8.76	0.38	3.77e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.83	-0.38	2.13e-17	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.53	0.84	5.72e-126	Prudent dietary pattern;
LGG	cis	rs2133450	0.526	rs10510356	chr3:7350877	C/G	cg19930620	chr3:7340148	GRM7	-0.4	-8.65	-0.37	8.23e-17	Early response to risperidone in schizophrenia;
LGG	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg00405596	chr8:11794950	NA	-0.39	-6.69	-0.3	6.39e-11	Triglycerides;
LGG	trans	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	16.99	0.62	1.16e-50	Exhaled nitric oxide levels;
LGG	cis	rs806215	0.547	rs59140894	chr7:127430797	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.1	-0.31	4.85e-12	Type 2 diabetes;
LGG	cis	rs2247341	0.965	rs2236787	chr4:1718883	A/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.97	-0.52	5.03e-33	Hip circumference adjusted for BMI;Height;
LGG	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.43	-0.36	4.31e-16	Neuroticism;
LGG	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg07549998	chr6:150325970	RAET1K	0.36	6.98	0.31	1.01e-11	Alopecia areata;
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs17767392	0.958	rs12433040	chr14:72030555	G/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.17	0.36	2.92e-15	Mitral valve prolapse;
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.41	0.4	2.38e-19	Monocyte count;
LGG	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.67	-0.3	7.49e-11	Triglycerides;
LGG	cis	rs6815814	0.950	rs5743556	chr4:38806851	A/G	cg06935464	chr4:38784597	TLR10	0.61	8.29	0.36	1.22e-15	Breast cancer;
LGG	cis	rs7580658	0.545	rs13006847	chr2:127952263	C/T	cg10021288	chr2:128175891	PROC	0.44	8.56	0.37	1.69e-16	Protein C levels;
LGG	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg14784868	chr12:69753453	YEATS4	0.9	19.53	0.67	2.22e-62	Blood protein levels;
LGG	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03264133	chr6:25882463	NA	-0.62	-11.26	-0.46	3.61e-26	Intelligence (multi-trait analysis);
LGG	cis	rs4132509	1.000	rs7534117	chr1:243964902	A/C	cg25706552	chr1:244017396	NA	-0.5	-8.17	-0.36	2.89e-15	RR interval (heart rate);
LGG	cis	rs7717393	1.000	rs1857769	chr5:155769363	A/G	cg04435420	chr5:155754009	SGCD	1.13	12.71	0.51	6.16e-32	Egg allergy;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg12458913	chr13:53173898	NA	0.58	10.34	0.43	1.07e-22	Lewy body disease;
LGG	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg06115741	chr20:33292138	TP53INP2	-0.47	-7.86	-0.34	2.73e-14	Coronary artery disease;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7216064	0.954	rs4790973	chr17:65951133	C/T	cg12091567	chr17:66097778	LOC651250	-0.62	-9.05	-0.39	3.89e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg15028436	chr7:37888078	TXNDC3	-0.8	-14.34	-0.55	7.61e-39	Alzheimer's disease (late onset);
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18252515	chr7:66147081	NA	0.41	6.91	0.31	1.65e-11	Aortic root size;
LGG	cis	rs9863	0.898	rs11057400	chr12:124425149	C/T	cg13487667	chr12:124434373	CCDC92	-0.39	-7.59	-0.33	1.76e-13	White blood cell count;
LGG	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.18	-0.49	8.8e-30	Response to antipsychotic treatment;
LGG	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.77	0.3	3.79e-11	Dupuytren's disease;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg02462569	chr6:150064036	NUP43	-0.39	-8.34	-0.36	8.73e-16	Lung cancer;
LGG	cis	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg06521331	chr12:34319734	NA	-0.43	-7.56	-0.33	2.22e-13	Morning vs. evening chronotype;
LGG	cis	rs6062302	0.522	rs6090476	chr20:62248001	G/A	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg00579200	chr11:133705235	NA	-0.56	-10.87	-0.45	1.18e-24	Childhood ear infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26020585	chr1:235491765	GGPS1;ARID4B	-0.46	-6.67	-0.3	7.12e-11	Systemic lupus erythematosus;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01585723	chr16:33734837	NA	0.46	8.13	0.35	3.85e-15	Menopause (age at onset);
LGG	cis	rs59901009	0.569	rs12280005	chr11:10228452	G/A	cg01453529	chr11:10209919	SBF2	-0.47	-7.7	-0.34	8.04e-14	Hematocrit;Hemoglobin concentration;
LGG	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg06636001	chr8:8085503	FLJ10661	0.39	7.17	0.32	3e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-17.83	-0.64	1.69e-54	Refractive error;
LGG	cis	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg07460842	chr6:66804631	NA	0.94	16.94	0.62	2.02e-50	Exhaled nitric oxide levels;
LGG	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg13647721	chr17:30228624	UTP6	0.62	8.02	0.35	8.85e-15	Hip circumference adjusted for BMI;
LGG	cis	rs10979	1.000	rs9386036	chr6:143890709	A/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.42	-0.5	9.26e-31	Hypospadias;
LGG	cis	rs1957429	0.901	rs6573583	chr14:65351211	G/T	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.76	0.45	3.07e-24	Lung cancer in ever smokers;
LGG	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.49	0.33	3.46e-13	Neuroticism;
LGG	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg01796438	chr3:11312864	ATG7	-0.54	-7.51	-0.33	3.07e-13	Circulating chemerin levels;
LGG	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Myopia (pathological);
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24429831	chr19:36120171	RBM42	0.44	7.3	0.32	1.26e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg08677398	chr8:58056175	NA	0.43	7.34	0.32	9.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg11812906	chr14:75593930	NEK9	-0.54	-10.07	-0.42	1.04e-21	Height;
LGG	cis	rs986417	1.000	rs1956557	chr14:60972569	G/A	cg27398547	chr14:60952738	C14orf39	0.69	6.81	0.3	3.02e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9649465	1.000	rs3807640	chr7:123338713	G/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.07e-18	Migraine;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02071572	chr4:1403502	NA	0.39	7.16	0.32	3.21e-12	Longevity;
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.58	-9.19	-0.39	1.32e-18	Tonsillectomy;
LGG	cis	rs56404409	0.911	rs12360751	chr11:123327366	G/A	cg04681489	chr11:123325084	NA	-0.46	-8.09	-0.35	5.36e-15	Ulcerative colitis;
LGG	cis	rs9815354	0.812	rs56183581	chr3:41848492	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg05084668	chr3:125655381	ALG1L	-0.84	-10.1	-0.42	8.23e-22	Blood pressure (smoking interaction);
LGG	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg27053975	chr1:166958233	MAEL	-0.48	-6.65	-0.3	8.37e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08219700	chr8:58056026	NA	0.45	6.86	0.3	2.23e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6466055	0.777	rs3801285	chr7:104837801	C/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.98	-0.31	9.97e-12	Schizophrenia;
LGG	trans	rs3960554	0.530	rs6954252	chr7:75859709	C/G	cg19862616	chr7:65841803	NCRNA00174	0.63	10.2	0.43	3.69e-22	Eotaxin levels;
LGG	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-15.8	-0.59	2.77e-45	Chronic sinus infection;
LGG	cis	rs36051895	0.623	rs10975033	chr9:5262567	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-13.48	-0.53	3.48e-35	Pediatric autoimmune diseases;
LGG	cis	rs10173297	0.686	rs13392120	chr2:3708685	C/T	cg14882966	chr2:3699353	NA	0.58	7.42	0.33	5.77e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13012494	chr21:47604986	C21orf56	0.55	9.67	0.41	2.88e-20	Testicular germ cell tumor;
LGG	cis	rs2718058	0.630	rs2722363	chr7:37835603	A/G	cg24998770	chr7:37888106	TXNDC3	0.45	7.26	0.32	1.66e-12	Alzheimer's disease (late onset);
LGG	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.52	-0.67	2.34e-62	Blood trace element (Zn levels);
LGG	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs2012796	0.957	rs8009083	chr14:81818289	A/G	cg02996355	chr14:81879375	NA	0.43	6.96	0.31	1.14e-11	Night sleep phenotypes;
LGG	cis	rs9905704	0.647	rs33922512	chr17:57114148	C/G	cg05425664	chr17:57184151	TRIM37	0.45	7.2	0.32	2.48e-12	Testicular germ cell tumor;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg08355456	chr11:67383691	NA	0.47	7.83	0.34	3.35e-14	Mean corpuscular volume;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg00149659	chr3:10157352	C3orf10	0.74	9.08	0.39	3.13e-18	Alzheimer's disease;
LGG	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs11748327	0.543	rs12653903	chr5:4086562	T/C	cg01025095	chr5:4101132	NA	-0.63	-10.22	-0.43	2.9e-22	Myocardial infarction;
LGG	trans	rs3960554	0.808	rs112372188	chr7:75723376	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.38	0.5	1.31e-30	Eotaxin levels;
LGG	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs1408799	0.579	rs1326780	chr9:12738034	T/C	cg05274944	chr9:12693694	TYRP1	-0.31	-6.79	-0.3	3.47e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs367943	0.666	rs10074214	chr5:112702214	A/G	cg12552261	chr5:112820674	MCC	0.57	10.19	0.43	3.75e-22	Type 2 diabetes;
LGG	cis	rs62238980	0.614	rs4821006	chr22:32370060	A/G	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	trans	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg18335740	chr13:41363409	SLC25A15	0.88	20.8	0.7	2.39e-68	Lewy body disease;
LGG	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg03161606	chr19:29218774	NA	-0.52	-6.7	-0.3	5.93e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23396286	chr10:99258505	UBTD1;MMS19	0.48	7.41	0.33	6.03e-13	Gut microbiome composition (summer);
LGG	cis	rs11158559	0.865	rs17102073	chr14:65242577	C/T	cg22797773	chr14:65239943	SPTB	-0.42	-6.87	-0.3	2.12e-11	Obesity-related traits;
LGG	cis	rs17401966	0.627	rs35859381	chr1:10466040	G/A	cg19773385	chr1:10388646	KIF1B	-0.43	-8.47	-0.37	3.37e-16	Hepatocellular carcinoma;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.98	0.39	6.77e-18	Bipolar disorder;
LGG	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg00666640	chr1:248458726	OR2T12	0.62	9.99	0.42	2.02e-21	Common traits (Other);
LGG	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.48	-7.19	-0.32	2.54e-12	Huntington's disease progression;
LGG	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg03929089	chr4:120376271	NA	-0.44	-6.99	-0.31	9.78e-12	HDL cholesterol;
LGG	cis	rs12980942	0.872	rs66724427	chr19:41776257	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.86	0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg06889755	chr6:150326021	RAET1K	-0.38	-7.63	-0.33	1.35e-13	Alopecia areata;
LGG	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg24812749	chr6:127587940	RNF146	0.53	8.74	0.38	4.25e-17	Breast cancer;
LGG	cis	rs4380275	1.000	rs4268954	chr2:772834	A/G	cg14072418	chr2:740025	NA	-0.4	-7.47	-0.33	3.96e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7296418	0.816	rs1790096	chr12:123710364	C/T	cg00376283	chr12:123451042	ABCB9	0.67	12.42	0.5	9.28e-31	Platelet count;
LGG	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg03433033	chr1:76189801	ACADM	-0.45	-7.03	-0.31	7.53e-12	Daytime sleep phenotypes;
LGG	cis	rs887829	0.570	rs10203266	chr2:234596368	G/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11623869	0.614	rs11627052	chr14:103863476	A/G	cg26031613	chr14:104095156	KLC1	-0.66	-9.25	-0.39	8.53e-19	Bone mineral density;
LGG	cis	rs7572733	0.515	rs700675	chr2:198700216	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.73e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2033732	0.826	rs2196617	chr8:85089394	G/A	cg05716166	chr8:85095498	RALYL	0.56	9.14	0.39	1.99e-18	Body mass index;
LGG	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg27211696	chr2:191398769	TMEM194B	0.39	9.11	0.39	2.4e-18	Pulse pressure;
LGG	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg00677455	chr12:58241039	CTDSP2	0.4	7.26	0.32	1.63e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg08677398	chr8:58056175	NA	0.4	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg23649088	chr2:200775458	C2orf69	-0.78	-15.68	-0.59	9.88e-45	Osteoporosis;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.31	0.32	1.18e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg12438819	chr7:158236134	PTPRN2	0.36	9.37	0.4	3.19e-19	Obesity-related traits;
LGG	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.4	0.36	5.45e-16	Systemic lupus erythematosus;
LGG	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.73	0.51	4.85e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs2236918	0.710	rs2797603	chr1:242029027	T/G	cg17736920	chr1:242011382	EXO1	0.38	6.92	0.31	1.48e-11	Menopause (age at onset);
LGG	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg07148914	chr20:33460835	GGT7	-0.55	-9.27	-0.4	7.23e-19	Height;
LGG	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.22e-18	Blood metabolite levels;
LGG	cis	rs3820068	0.603	rs6429768	chr1:15963531	G/A	cg05660106	chr1:15850417	CASP9	0.83	16.72	0.61	1.94e-49	Systolic blood pressure;
LGG	cis	rs3735485	0.738	rs3735489	chr7:45105459	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.58	-0.41	6.12e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4417704	0.525	rs12694990	chr2:241883621	C/G	cg14055004	chr2:241860995	NA	0.28	7.53	0.33	2.76e-13	Joint mobility (Beighton score);
LGG	cis	rs733592	0.507	rs10747529	chr12:48473369	G/A	cg24011408	chr12:48396354	COL2A1	-0.69	-12.22	-0.49	5.77e-30	Plateletcrit;
LGG	cis	rs773506	0.932	rs2482340	chr9:94037842	A/G	cg14446406	chr9:93919335	NA	-0.47	-8.37	-0.36	6.82e-16	Type 2 diabetes nephropathy;
LGG	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg07777115	chr5:623756	CEP72	-0.54	-7.46	-0.33	4.22e-13	Obesity-related traits;
LGG	cis	rs3735485	0.800	rs6943774	chr7:45045368	A/G	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg04935436	chr20:30431758	NA	0.39	6.85	0.3	2.4e-11	Mean corpuscular hemoglobin;
LGG	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg08048268	chr3:133502702	NA	-0.6	-11.15	-0.46	9.99e-26	Iron status biomarkers;
LGG	cis	rs10193935	0.901	rs1044562	chr2:42516884	C/G	cg27598129	chr2:42591480	NA	-0.63	-9.43	-0.4	2.05e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4700695	0.698	rs416369	chr5:65231058	C/T	cg21114390	chr5:65439923	SFRS12	0.59	7.46	0.33	4.37e-13	Facial morphology (factor 19);
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg00405596	chr8:11794950	NA	-0.43	-6.95	-0.31	1.28e-11	Neuroticism;
LGG	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.81	-0.38	2.63e-17	Lung cancer;
LGG	cis	rs7113850	0.541	rs7935630	chr11:24222206	A/C	ch.11.24196551F	chr11:24239977	NA	0.9	10.17	0.43	4.49e-22	Bone fracture in osteoporosis;
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.29	-0.36	1.19e-15	Testicular germ cell tumor;
LGG	cis	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg02023728	chr11:77925099	USP35	0.44	7.58	0.33	1.95e-13	Testicular germ cell tumor;
LGG	cis	rs11877825	0.826	rs9676146	chr18:10571489	A/T	cg07277756	chr18:10589357	NA	0.58	10.37	0.43	8.34e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs6450176	0.633	rs389525	chr5:53333075	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.23	-0.46	5e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg05368731	chr17:41323189	NBR1	0.96	19.1	0.66	2.23e-60	Menopause (age at onset);
LGG	cis	rs7927771	0.864	rs4752999	chr11:47428565	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-10.5	-0.44	2.73e-23	Subjective well-being;
LGG	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg08847533	chr14:75593920	NEK9	0.63	12.16	0.49	1.05e-29	Height;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg09346547	chr7:75189280	HIP1	0.32	7.07	0.31	5.7e-12	Migraine with aura;
LGG	cis	rs3816183	1.000	rs10196492	chr2:43018534	T/G	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs77741769	0.571	rs989986	chr12:121274178	A/C	cg02419362	chr12:121203948	SPPL3	0.54	9.36	0.4	3.6e-19	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02126950	chr14:48143384	MDGA2	0.44	7.59	0.33	1.82e-13	Gut microbiome composition (summer);
LGG	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.9	0.34	2.11e-14	Colorectal cancer;
LGG	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg13009111	chr11:71350975	NA	-0.33	-7.34	-0.32	9.51e-13	Monocyte count;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11792861	0.926	rs1051474	chr9:111881856	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.95	0.38	8.79e-18	Menarche (age at onset);
LGG	cis	rs6032067	0.704	rs62208374	chr20:43765628	C/T	cg10761708	chr20:43804764	PI3	0.74	11.11	0.46	1.4e-25	Blood protein levels;
LGG	cis	rs9815354	1.000	rs73069392	chr3:41787009	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.06	0.35	6.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22555675	chr19:17799230	UNC13A	0.45	7.03	0.31	7.62e-12	Gut microbiome composition (summer);
LGG	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg26597838	chr10:835615	NA	0.75	10.23	0.43	2.74e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg12501923	chr17:73937416	FBF1	-0.42	-6.67	-0.3	7.14e-11	Body fat percentage;
LGG	cis	rs2273669	0.915	rs2038542	chr6:109295293	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.51	-8.01	-0.35	9.53e-15	Menarche (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04856096	chr8:68255097	ARFGEF1	-0.45	-6.74	-0.3	4.69e-11	Systemic lupus erythematosus;
LGG	cis	rs9287719	0.935	rs61424402	chr2:10758371	T/A	cg02196655	chr2:10830764	NOL10	-0.45	-7.7	-0.34	8.57e-14	Prostate cancer;
LGG	cis	rs2594989	1.000	rs2594993	chr3:11360744	C/T	cg01796438	chr3:11312864	ATG7	-0.59	-7.96	-0.35	1.34e-14	Circulating chemerin levels;
LGG	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg25208724	chr1:156163844	SLC25A44	1.27	32.35	0.83	6.52e-121	Testicular germ cell tumor;
LGG	cis	rs7917772	0.582	rs4408249	chr10:104374653	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.53	0.47	3.34e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs138249	0.867	rs138226	chr22:50556787	A/G	cg07310406	chr22:50524374	MLC1	0.41	8.14	0.35	3.68e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg07511668	chr11:68622177	NA	0.48	9.33	0.4	4.43e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20840177	chr12:68042558	DYRK2	-0.41	-6.81	-0.3	2.95e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg15440763	chr7:158190612	PTPRN2	-0.43	-8.82	-0.38	2.4e-17	Obesity-related traits;
LGG	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.65	0.3	8.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.58	-7.33	-0.32	1.03e-12	HIV-1 control;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7766436	0.848	rs13200143	chr6:22586212	T/G	cg13666174	chr6:22585274	NA	-0.51	-11.54	-0.47	2.93e-27	Coronary artery disease;
LGG	cis	rs6912958	0.702	rs2300909	chr6:88212100	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.72e-16	Monocyte percentage of white cells;
LGG	cis	rs12135191	0.771	rs12729455	chr1:236501925	A/C	cg21399712	chr1:236511386	NA	-0.41	-7.72	-0.34	7.21e-14	Urate levels (BMI interaction);
LGG	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg06623630	chr22:50017776	C22orf34	-0.38	-8.03	-0.35	7.99e-15	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg20673091	chr1:2541236	MMEL1	-0.78	-18.09	-0.64	1.01e-55	Ulcerative colitis;
LGG	cis	rs12410462	0.591	rs67676707	chr1:227767165	A/C	cg23173402	chr1:227635558	NA	0.4	7.43	0.33	5.38e-13	Major depressive disorder;
LGG	cis	rs17039065	0.920	rs7688259	chr4:109435575	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.74	0.34	6.43e-14	Gut microbiome composition (summer);
LGG	cis	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05901451	chr6:126070800	HEY2	-0.54	-9.37	-0.4	3.27e-19	Migraine;
LGG	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg04455712	chr21:45112962	RRP1B	0.54	10.46	0.44	3.88e-23	Mean corpuscular volume;
LGG	cis	rs6963495	0.818	rs73190189	chr7:105164452	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05509352	chr5:142092851	NA	0.59	6.67	0.3	7.36e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06666157	chr19:4791552	FEM1A	0.51	8.12	0.35	4.19e-15	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19630841	chr15:70390368	TLE3	0.56	8.33	0.36	9.07e-16	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg16270222	chr17:41446396	NA	-0.31	-7.44	-0.33	4.84e-13	Menopause (age at onset);
LGG	cis	rs9783347	0.857	rs2124374	chr11:18313911	A/C	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.07	-0.31	5.93e-12	Pancreatic cancer;
LGG	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg19223190	chr17:80058835	NA	-0.48	-9.67	-0.41	2.86e-20	Life satisfaction;
LGG	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.07	-0.83	1.1e-119	Myeloid white cell count;
LGG	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg10661904	chr17:79619235	PDE6G	-0.49	-10.13	-0.43	6.5600000000000005e-22	Eye color traits;
LGG	cis	rs4566357	0.615	rs4675140	chr2:227908665	C/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.09	-0.39	3e-18	Coronary artery disease;
LGG	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg12310025	chr6:25882481	NA	-0.53	-10.21	-0.43	3.27e-22	Blood metabolite levels;
LGG	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.07	-0.52	1.84e-33	Response to antipsychotic treatment;
LGG	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg09417038	chr21:47716443	C21orf57	-0.37	-7.34	-0.32	9.61e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg24829409	chr8:58192753	C8orf71	-0.77	-10.37	-0.43	8.28e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.23	-0.36	1.86e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.43	-0.44	5.06e-23	Triglycerides;
LGG	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.35	-0.32	8.85e-13	Inflammatory bowel disease;
LGG	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.45e-22	Motion sickness;
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs300703	0.935	rs7568664	chr2:280939	A/G	cg24565620	chr2:194026	NA	-0.72	-9.05	-0.39	4.12e-18	Blood protein levels;
LGG	cis	rs7572263	0.528	rs6731294	chr2:209071325	G/A	cg00164906	chr2:209055251	C2orf80	-0.5	-7.78	-0.34	4.87e-14	Glioma;Non-glioblastoma glioma;
LGG	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg16096631	chr1:42092165	HIVEP3	0.47	10.99	0.45	4.06e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg11890956	chr21:40555474	PSMG1	1.17	29.97	0.81	1.75e-110	Cognitive function;
LGG	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg00850481	chr1:228891306	NA	-0.48	-7.56	-0.33	2.16e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg09085632	chr11:111637200	PPP2R1B	1.19	25.68	0.77	4.44e-91	Primary sclerosing cholangitis;
LGG	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg10326726	chr10:51549505	MSMB	-0.66	-13.64	-0.54	7.75e-36	Prostate-specific antigen levels;
LGG	cis	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg20913747	chr6:44695427	NA	-0.59	-9.88	-0.42	5.27e-21	Total body bone mineral density;
LGG	cis	rs990171	1.000	rs2110734	chr2:103052206	C/T	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs701145	0.938	rs355778	chr3:154030349	C/T	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs7072216	0.763	rs12259939	chr10:100169021	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.7e-12	Metabolite levels;
LGG	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2131877	0.956	rs12639008	chr3:194871007	C/G	cg07250128	chr3:194833983	C3orf21	0.41	7.64	0.33	1.3e-13	Non-small cell lung cancer;
LGG	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg12432903	chr7:1882776	MAD1L1	0.54	8.18	0.36	2.78e-15	Bipolar disorder;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.37e-17	Self-reported allergy;
LGG	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	7.34	0.32	9.41e-13	Schizophrenia;
LGG	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	18.15	0.64	5.16e-56	Multiple sclerosis;
LGG	cis	rs3796727	0.660	rs1050465	chr4:8621392	G/A	cg05284713	chr4:8621361	CPZ	-0.34	-6.72	-0.3	5.21e-11	Sporadic neuroblastoma;
LGG	cis	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.45	-0.37	3.92e-16	Tonsillectomy;
LGG	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg11812906	chr14:75593930	NEK9	-0.51	-9.35	-0.4	3.65e-19	Height;
LGG	trans	rs7939886	0.920	rs7933691	chr11:56046900	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16386425	chr10:429943	DIP2C	-0.47	-9.55	-0.41	7.51e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.81	8.8	0.38	2.81e-17	Diabetic retinopathy;
LGG	cis	rs1005224	0.963	rs2302592	chr14:76129287	C/G	cg25116370	chr14:76127843	TTLL5;C14orf1	0.41	6.78	0.3	3.7e-11	Large artery stroke;
LGG	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.48	-0.37	3.11e-16	Retinal vascular caliber;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg23625390	chr15:77176239	SCAPER	-0.58	-11.99	-0.49	4.78e-29	Blood metabolite levels;
LGG	cis	rs12638540	0.543	rs13433871	chr3:32559673	A/C	cg11605617	chr3:32612461	DYNC1LI1	1.04	10.38	0.43	7.71e-23	Mortality in heart failure;
LGG	trans	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.5	-0.33	3.37e-13	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13663190	chr2:73461428	CCT7;C2orf7	0.4	6.74	0.3	4.7e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17039065	1.000	rs78569046	chr4:109393475	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg01411142	chr8:19674711	INTS10	0.46	7.46	0.33	4.17e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs751728	0.597	rs767895	chr6:33791463	C/G	cg25922239	chr6:33757077	LEMD2	0.55	7.87	0.34	2.61e-14	Crohn's disease;
LGG	cis	rs365132	0.875	rs2454952	chr5:176376493	C/T	cg16309518	chr5:176445507	NA	-0.51	-11.11	-0.46	1.4e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.68	-0.59	9.69e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg12310025	chr6:25882481	NA	-0.55	-10.39	-0.43	7.29e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.594	rs59942091	chr6:161263402	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.55	-0.33	2.33e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00149659	chr3:10157352	C3orf10	0.79	9.92	0.42	3.83e-21	Alzheimer's disease;
LGG	cis	rs11168618	1.000	rs12815544	chr12:48949608	A/G	cg24011408	chr12:48396354	COL2A1	0.48	7.75	0.34	5.71e-14	Adiponectin levels;
LGG	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg07777115	chr5:623756	CEP72	-0.63	-8.04	-0.35	7.59e-15	Obesity-related traits;
LGG	cis	rs7582720	1.000	rs114393235	chr2:203795987	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg22105103	chr4:187893119	NA	0.58	11.25	0.46	3.92e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10979	0.597	rs9484776	chr6:143906325	T/C	cg25407410	chr6:143891975	LOC285740	-0.56	-8.28	-0.36	1.32e-15	Hypospadias;
LGG	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg24803719	chr17:45855879	NA	-0.3	-8.57	-0.37	1.58e-16	IgG glycosylation;
LGG	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg02228329	chr11:64053129	BAD;GPR137	-0.75	-14.49	-0.56	1.75e-39	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.45	-0.33	4.7e-13	Systemic lupus erythematosus;
LGG	cis	rs7916697	0.891	rs7897809	chr10:70000293	A/G	cg18338521	chr10:69995036	NA	-0.33	-7.34	-0.32	9.93e-13	Optic disc area;
LGG	cis	rs367943	0.712	rs26969	chr5:112742436	A/G	cg12552261	chr5:112820674	MCC	0.58	10.48	0.44	3.44e-23	Type 2 diabetes;
LGG	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.19	-0.32	2.6e-12	Morning vs. evening chronotype;
LGG	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg12473912	chr3:136751656	NA	0.43	7.63	0.33	1.34e-13	Neuroticism;
LGG	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg24375607	chr4:120327624	NA	-0.56	-9.36	-0.4	3.38e-19	Corneal astigmatism;
LGG	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg00376283	chr12:123451042	ABCB9	0.63	10.37	0.43	8.41e-23	Neutrophil percentage of white cells;
LGG	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg04935436	chr20:30431758	NA	0.41	7.21	0.32	2.24e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg11789530	chr4:8429930	ACOX3	-0.74	-14.56	-0.56	8.03e-40	Response to antineoplastic agents;
LGG	cis	rs368123	0.824	rs577261	chr6:160715564	G/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.21	-0.32	2.37e-12	Waist circumference;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12016809	chr21:47604291	C21orf56	-0.55	-9.86	-0.42	6.26e-21	Testicular germ cell tumor;
LGG	cis	rs4664308	0.875	rs7593593	chr2:160933811	C/T	cg03641300	chr2:160917029	PLA2R1	-0.87	-17.95	-0.64	4.34e-55	Idiopathic membranous nephropathy;
LGG	cis	rs7843479	0.562	rs6988010	chr8:21859084	G/A	cg17168535	chr8:21777572	XPO7	0.78	15.36	0.58	2.4e-43	Mean corpuscular volume;
LGG	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg16797656	chr11:68205561	LRP5	0.5	9.73	0.41	1.78e-20	Total body bone mineral density;
LGG	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg10167378	chr1:228756711	NA	0.56	7.98	0.35	1.2e-14	Chronic lymphocytic leukemia;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	10.45	0.44	4.46e-23	Obesity-related traits;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07167872	chr1:205819463	PM20D1	-0.48	-9.83	-0.42	7.68e-21	Monocyte percentage of white cells;
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg00976097	chr5:421733	AHRR	-0.48	-7.78	-0.34	4.7e-14	Cystic fibrosis severity;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03452623	chr4:187889614	NA	-1.04	-30.06	-0.81	6.67e-111	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9397585	0.857	rs1933263	chr6:153391358	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.36	0.56	6.11e-39	Body mass index;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs7212938	0.509	rs3893044	chr17:38103016	C/T	cg17467752	chr17:38218738	THRA	-0.46	-7.66	-0.34	1.13e-13	Asthma and hay fever;
LGG	cis	rs66716358	0.773	rs10769035	chr11:44318786	G/A	cg16977035	chr11:44330474	ALX4	0.3	7.39	0.32	7.1e-13	Monobrow;
LGG	cis	rs7580658	0.724	rs71414745	chr2:127992588	A/G	cg10021288	chr2:128175891	PROC	-0.6	-12.18	-0.49	8.56e-30	Protein C levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08677932	chr3:167967462	C3orf50	0.54	8.17	0.35	2.98e-15	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.75	-0.68	1.89e-63	Height;
LGG	cis	rs9649465	0.704	rs665867	chr7:123432329	A/G	cg03229431	chr7:123269106	ASB15	0.44	9.65	0.41	3.39e-20	Migraine;
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg02158880	chr13:53174818	NA	0.76	17.02	0.62	8.19e-51	Lewy body disease;
LGG	cis	rs963731	0.649	rs57378308	chr2:39348346	G/A	cg04010122	chr2:39346883	SOS1	0.78	7.24	0.32	1.89e-12	Corticobasal degeneration;
LGG	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-7.6	-0.33	1.65e-13	Blood metabolite levels;
LGG	cis	rs12519773	0.502	rs67862943	chr5:92529268	G/A	cg18783429	chr5:92414398	NA	0.31	7.55	0.33	2.3e-13	Migraine;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10856509	chr5:148737559	PCYOX1L	-0.42	-6.7	-0.3	6.12e-11	Pancreatic cancer;
LGG	trans	rs11088226	0.645	rs11702343	chr21:33937888	C/A	cg09050820	chr6:167586206	TCP10L2	0.89	12.53	0.5	3.15e-31	Gastritis;
LGG	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg16590910	chr6:42928470	GNMT	0.41	11.79	0.48	2.95e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs13102973	0.899	rs10213137	chr4:135900543	T/C	cg14419869	chr4:135874104	NA	-0.45	-8.22	-0.36	2.12e-15	Subjective well-being;
LGG	cis	rs4555082	0.874	rs10151638	chr14:105761592	T/C	cg27165867	chr14:105738592	BRF1	-0.46	-7.86	-0.34	2.72e-14	Mean platelet volume;Platelet distribution width;
LGG	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg26384229	chr12:38710491	ALG10B	-0.59	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg12856521	chr11:46389249	DGKZ	0.43	7.52	0.33	2.82e-13	Leprosy;
LGG	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg20608306	chr11:116969690	SIK3	-0.41	-10.79	-0.45	2.36e-24	Subjective well-being;
LGG	cis	rs7648466	0.915	rs3181077	chr3:46250652	C/T	cg12441928	chr3:46249985	CCR1	-0.55	-9.65	-0.41	3.39e-20	Eotaxin levels;
LGG	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg09462578	chr12:12878428	APOLD1	-1.04	-20.9	-0.7	8.15e-69	Lymphocyte counts;
LGG	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.91	0.54	5.15e-37	Colorectal cancer;
LGG	cis	rs9397585	0.857	rs1338071	chr6:153365834	G/C	cg17707550	chr6:153380415	RGS17	0.63	14.85	0.57	4.56e-41	Body mass index;
LGG	cis	rs13266463	0.830	rs6983790	chr8:143406575	A/G	cg16886403	chr8:143471632	TSNARE1	0.5	8.05	0.35	6.84e-15	Schizophrenia;
LGG	cis	rs4919087	0.620	rs793515	chr10:98988469	A/C	cg25902810	chr10:99078978	FRAT1	-0.41	-6.73	-0.3	5.08e-11	Monocyte count;
LGG	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg04362960	chr10:104952993	NT5C2	0.48	7.99	0.35	1.05e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.86	0.42	6.29e-21	Obesity-related traits;
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.59	0.37	1.37e-16	Prostate cancer;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	7.94	0.35	1.57e-14	Menarche (age at onset);
LGG	cis	rs6988985	0.728	rs10103405	chr8:143968631	T/C	cg10324643	chr8:143916377	GML	0.4	8.06	0.35	6.37e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-6.81	-0.3	3.06e-11	Lung cancer;
LGG	cis	rs807669	0.548	rs762522	chr22:19180575	C/T	cg02655711	chr22:19163373	SLC25A1	0.65	12.79	0.51	2.85e-32	Metabolite levels;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.76	-0.34	5.62e-14	IgG glycosylation;
LGG	cis	rs4622507	0.618	rs12923220	chr16:55070193	T/C	cg09947736	chr16:55091198	NA	0.77	11.65	0.48	1.12e-27	Social communication problems;
LGG	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.57	-9.55	-0.41	7.54e-20	Colorectal cancer;
LGG	cis	rs10744422	1.000	rs1587856	chr12:123342229	A/G	cg25930673	chr12:123319894	HIP1R	-0.75	-9.39	-0.4	2.8e-19	Schizophrenia;
LGG	cis	rs9807989	0.524	rs7594402	chr2:103021267	A/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.87	-0.54	7.99e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs2044029	0.504	rs7165378	chr15:71691504	C/T	cg19634315	chr15:71679485	THSD4	0.47	9.14	0.39	1.96e-18	Airflow obstruction;
LGG	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg10636054	chr15:40330586	SRP14	0.7	7.69	0.34	8.93e-14	Response to haloperidol in psychosis;
LGG	cis	rs16966142	0.579	rs62054562	chr16:90056564	A/G	cg08854185	chr16:90077956	DBNDD1	-0.67	-8.09	-0.35	5.15e-15	Caffeine consumption;
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg11494091	chr17:61959527	GH2	0.53	8.26	0.36	1.57e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs9287719	0.967	rs6721514	chr2:10751062	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg13683864	chr3:40499215	RPL14	-1.14	-26.77	-0.78	4.25e-96	Renal cell carcinoma;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg11584989	chr19:19387371	SF4	-0.4	-7.32	-0.32	1.09e-12	Tonsillectomy;
LGG	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.12e-14	Colorectal cancer;
LGG	cis	rs11203032	0.831	rs10887929	chr10:90948864	T/C	cg16672925	chr10:90967113	CH25H	0.77	11.08	0.46	1.8e-25	Heart failure;
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg02002194	chr4:3960332	NA	0.39	7.01	0.31	8.36e-12	Neuroticism;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg18829125	chr20:61273859	SLCO4A1	-0.38	-6.83	-0.3	2.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs972578	0.967	rs8138930	chr22:43336728	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.68	-0.3	6.76e-11	Mean platelet volume;
LGG	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.49	-0.63	5.63e-53	Chronic sinus infection;
LGG	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg01028140	chr2:1542097	TPO	-0.55	-8.5	-0.37	2.68e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21552867	chr2:84686507	SUCLG1	-0.48	-6.84	-0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg04691961	chr3:161091175	C3orf57	-0.47	-9.63	-0.41	3.97e-20	Parkinson's disease;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg17202724	chr17:61916730	SMARCD2	0.49	10.96	0.45	5.45e-25	Prudent dietary pattern;
LGG	cis	rs9815354	0.723	rs12152489	chr3:42060402	T/C	cg03022575	chr3:42003672	ULK4	0.72	8.09	0.35	5.26e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs36051895	0.664	rs3780369	chr9:5095095	A/C	cg02405213	chr9:5042618	JAK2	-0.81	-15.43	-0.58	1.2e-43	Pediatric autoimmune diseases;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.32	-0.53	1.73e-34	Aortic root size;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09699651	chr6:150184138	LRP11	0.57	11.07	0.46	1.93e-25	Testicular germ cell tumor;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.28	0.36	1.31e-15	Prudent dietary pattern;
LGG	cis	rs11920090	0.932	rs1499820	chr3:170711968	G/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.46	0.37	3.59e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.94	-0.52	6.47e-33	Obesity-related traits;
LGG	cis	rs782590	0.870	rs2586950	chr2:55868966	T/G	cg18811423	chr2:55921094	PNPT1	0.85	17.56	0.63	2.72e-53	Metabolic syndrome;
LGG	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg17077180	chr1:38461687	NA	0.41	8.76	0.38	3.6e-17	Coronary artery disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg17187048	chr2:122407283	CLASP1	0.38	6.79	0.3	3.55e-11	Body mass index;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.6e-12	Electroencephalogram traits;
LGG	cis	rs10905065	0.965	rs10795520	chr10:5764160	G/A	cg11519256	chr10:5708881	ASB13	0.41	7.19	0.32	2.68e-12	Menopause (age at onset);
LGG	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	8.0	0.35	9.96e-15	Height;
LGG	cis	rs13082711	0.640	rs35903173	chr3:27287751	T/C	cg02860705	chr3:27208620	NA	1.08	20.79	0.69	2.78e-68	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs57502260	0.790	rs7128942	chr11:68387984	C/T	cg01657329	chr11:68192670	LRP5	-0.53	-7.21	-0.32	2.37e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs7224668	0.647	rs2271090	chr17:79246605	A/G	cg03823431	chr17:79229385	SLC38A10	0.34	7.35	0.32	8.85e-13	IgG glycosylation;
LGG	cis	rs3087591	0.960	rs1124918	chr17:29492423	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.18	-0.55	3.6e-38	Hip circumference;
LGG	cis	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg15148918	chr7:75625777	STYXL1	-0.64	-7.33	-0.32	1.02e-12	Mononucleosis;
LGG	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.26	0.36	1.56e-15	Colorectal cancer;
LGG	cis	rs644148	0.836	rs2686770	chr19:44998773	A/G	cg15540054	chr19:45004280	ZNF180	-0.59	-11.03	-0.46	2.84e-25	Personality dimensions;
LGG	cis	rs11971779	0.680	rs73154134	chr7:139039951	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	7.83	0.34	3.29e-14	Diisocyanate-induced asthma;
LGG	cis	rs4740619	0.839	rs4740622	chr9:15665602	G/C	cg14451791	chr9:16040625	NA	-0.4	-10.44	-0.44	4.81e-23	Body mass index;
LGG	cis	rs62244186	0.659	rs4682745	chr3:44508967	T/C	cg02073558	chr3:44770973	ZNF501	0.65	11.79	0.48	2.99e-28	Depressive symptoms;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg22535103	chr8:58192502	C8orf71	-1.02	-16.12	-0.6	1.04e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-13.4	-0.53	7.83e-35	Menarche (age at onset);
LGG	cis	rs1957429	0.731	rs10144554	chr14:65321514	T/G	cg23373153	chr14:65346875	NA	1.02	13.14	0.52	9.55e-34	Pediatric areal bone mineral density (radius);
LGG	trans	rs3960554	0.660	rs55671363	chr7:75793405	T/C	cg19862616	chr7:65841803	NCRNA00174	0.94	16.13	0.6	8.78e-47	Eotaxin levels;
LGG	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg04568710	chr12:38710424	ALG10B	0.35	7.37	0.32	8.07e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7617773	0.780	rs34946886	chr3:48338487	A/G	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg21775007	chr8:11205619	TDH	-0.53	-8.3	-0.36	1.14e-15	Triglycerides;
LGG	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.27e-16	Response to antipsychotic treatment;
LGG	cis	rs10991814	0.688	rs17501728	chr9:93946219	A/G	cg14446406	chr9:93919335	NA	-0.84	-7.94	-0.35	1.58e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs7246760	0.867	rs73014087	chr19:9956366	A/G	cg16876255	chr19:9731953	ZNF561	0.84	7.07	0.31	5.63e-12	Pursuit maintenance gain;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg09165964	chr15:75287851	SCAMP5	0.68	12.89	0.51	1.05e-32	Breast cancer;
LGG	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.72	-0.41	1.87e-20	Height;
LGG	cis	rs3798221	0.618	rs6940254	chr6:161024171	C/G	cg04181478	chr6:161122748	PLG	0.43	7.08	0.31	5.39e-12	Lipoprotein (a) levels;
LGG	trans	rs56804039	1.000	rs58361948	chr8:8380995	C/T	cg02002194	chr4:3960332	NA	0.44	6.95	0.31	1.24e-11	Cervical cancer;
LGG	cis	rs11748327	0.580	rs10069086	chr5:4011747	G/C	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.27e-12	Myocardial infarction;
LGG	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg22437258	chr11:111473054	SIK2	-0.4	-6.69	-0.3	6.28e-11	Primary sclerosing cholangitis;
LGG	cis	rs3771570	0.892	rs59715783	chr2:242366262	C/T	cg21155796	chr2:242212141	HDLBP	0.75	9.95	0.42	2.8e-21	Prostate cancer;
LGG	cis	rs77741769	0.571	rs73415720	chr12:121344515	T/C	cg02419362	chr12:121203948	SPPL3	0.55	9.45	0.4	1.74e-19	Mean corpuscular volume;
LGG	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.82	-0.3	2.9e-11	Triglycerides;
LGG	cis	rs9487051	1.000	rs9480924	chr6:109617070	T/C	cg21918786	chr6:109611834	NA	-0.44	-8.31	-0.36	1.1e-15	Reticulocyte fraction of red cells;
LGG	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg16434002	chr17:42200994	HDAC5	0.44	8.55	0.37	1.87e-16	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg21617494	chr15:57618479	NA	0.42	6.82	0.3	2.85e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.05	-19.99	-0.68	1.54e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23598886	chr18:12777645	NA	0.74	10.35	0.43	9.7e-23	Inflammatory skin disease;
LGG	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.06	-0.35	6.5e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.57	0.37	1.56e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.35	-0.32	8.99e-13	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.06	-0.31	5.98e-12	Menopause (age at onset);
LGG	cis	rs4356203	0.792	rs620241	chr11:17196890	A/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.26	-0.32	1.67e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs11088226	0.681	rs2833903	chr21:33940819	C/T	cg09050820	chr6:167586206	TCP10L2	0.9	12.64	0.51	1.12e-31	Gastritis;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.78e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg04166393	chr7:2884313	GNA12	-0.42	-7.89	-0.34	2.25e-14	Height;
LGG	cis	rs7106204	0.534	rs113519220	chr11:24251432	T/C	ch.11.24196551F	chr11:24239977	NA	0.86	8.77	0.38	3.54e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.11	-0.31	4.4e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs780096	0.560	rs4665972	chr2:27598097	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-6.97	-0.31	1.07e-11	Total body bone mineral density;
LGG	cis	rs4423214	1.000	rs12790010	chr11:71170653	T/C	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26431298	chr1:156737036	PRCC	0.43	6.91	0.31	1.61e-11	Cognitive performance;
LGG	cis	rs4845570	1.000	rs7416415	chr1:151757798	C/T	cg07092448	chr1:151763213	TDRKH	1.11	17.38	0.63	1.9e-52	Coronary artery disease;
LGG	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg00031303	chr3:195681400	NA	0.6	9.13	0.39	2.09e-18	Pancreatic cancer;
LGG	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg27661571	chr11:113659931	NA	-0.47	-6.72	-0.3	5.2e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7010267	0.642	rs9969672	chr8:120006080	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.39	10.12	0.43	7.2e-22	Total body bone mineral density (age 45-60);
LGG	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg00543991	chr22:32367038	NA	0.8	8.78	0.38	3.08e-17	Childhood ear infection;
LGG	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg21775007	chr8:11205619	TDH	-0.6	-9.74	-0.41	1.65e-20	Retinal vascular caliber;
LGG	trans	rs7939886	0.920	rs74459856	chr11:56027689	G/A	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg07460842	chr6:66804631	NA	0.94	17.1	0.62	3.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.74	-0.41	1.57e-20	Mood instability;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.1	-0.31	4.68e-12	Dementia with Lewy bodies;
LGG	cis	rs10865541	1.000	rs11684337	chr2:3395287	A/G	cg11642891	chr2:3452563	TTC15	0.38	7.33	0.32	1.05e-12	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-8.95	-0.38	8.38e-18	Blood protein levels;
LGG	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg15823100	chr22:32027580	PISD	-0.69	-7.81	-0.34	3.94e-14	Age-related hearing impairment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02976543	chr2:239197607	PER2	0.42	7.07	0.31	5.67e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01880437	chr4:26321873	RBPJ	0.43	7.13	0.31	3.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg08847533	chr14:75593920	NEK9	-0.55	-10.09	-0.42	8.76e-22	Height;
LGG	cis	rs7617773	0.817	rs3731497	chr3:48226553	T/G	cg11946769	chr3:48343235	NME6	0.68	11.08	0.46	1.79e-25	Coronary artery disease;
LGG	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg06634786	chr22:41940651	POLR3H	-0.43	-6.84	-0.3	2.44e-11	Neuroticism;
LGG	cis	rs10876993	0.928	rs10877001	chr12:58083077	T/C	cg18357645	chr12:58087776	OS9	-0.68	-12.33	-0.5	2.1000000000000002e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg05665937	chr4:1216051	CTBP1	0.48	8.37	0.36	6.67e-16	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.68	0.3	6.67e-11	Homoarginine levels;
LGG	cis	rs7945718	0.621	rs10831888	chr11:12665604	T/C	cg25843174	chr11:12811716	TEAD1	0.33	6.99	0.31	9.68e-12	Educational attainment (years of education);
LGG	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.89	20.03	0.68	1.02e-64	Chronic sinus infection;
LGG	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.89	0.57	2.87e-41	Cannabis dependence symptom count;
LGG	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg21926883	chr2:100939477	LONRF2	-0.61	-12.32	-0.5	2.4e-30	Intelligence (multi-trait analysis);
LGG	trans	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg13565492	chr6:43139072	SRF	-0.73	-8.96	-0.38	7.9e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	cis	rs239198	0.602	rs11755579	chr6:101322469	A/C	cg09795085	chr6:101329169	ASCC3	0.44	7.16	0.32	3.21e-12	Menarche (age at onset);
LGG	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.47e-12	Hemoglobin concentration;
LGG	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.49e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.47	7.97	0.35	1.28e-14	Cognitive performance;
LGG	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-19.89	-0.68	4.25e-64	Cognitive function;
LGG	cis	rs9397585	0.824	rs9371276	chr6:153369161	T/C	cg17707550	chr6:153380415	RGS17	0.63	14.82	0.57	5.76e-41	Body mass index;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25072359	chr17:41440525	NA	0.51	10.0	0.42	1.86e-21	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg11846333	chr4:119757529	SEC24D	0.84	7.77	0.34	5.01e-14	Cannabis dependence symptom count;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg11360546	chr7:1094263	C7orf50	-0.41	-7.11	-0.31	4.3e-12	Longevity;Endometriosis;
LGG	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg02023728	chr11:77925099	USP35	-0.41	-7.34	-0.32	9.87e-13	Alzheimer's disease (survival time);
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg21171335	chr12:122356390	WDR66	-0.28	-7.94	-0.35	1.56e-14	Mean corpuscular volume;
LGG	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.94	0.31	1.31e-11	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg16339924	chr4:17578868	LAP3	0.63	10.57	0.44	1.57e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg13385794	chr1:248469461	NA	0.45	8.19	0.36	2.49e-15	Common traits (Other);
LGG	cis	rs36071027	0.615	rs13159303	chr5:158421063	A/G	cg23468002	chr5:158532401	NA	0.43	7.15	0.32	3.49e-12	Carotid intima media thickness;
LGG	cis	rs10463554	0.927	rs464720	chr5:102406887	C/T	cg23492399	chr5:102201601	PAM	-0.5	-7.45	-0.33	4.73e-13	Parkinson's disease;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18252515	chr7:66147081	NA	-0.43	-7.28	-0.32	1.4e-12	Aortic root size;
LGG	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.86	0.42	6.11e-21	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12016809	chr21:47604291	C21orf56	0.53	9.01	0.39	5.27e-18	Testicular germ cell tumor;
LGG	cis	rs722599	0.651	rs7159354	chr14:75253847	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	8.74	0.38	4.39e-17	IgG glycosylation;
LGG	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg06917763	chr7:130033247	NA	0.33	7.12	0.31	4.02e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08223748	chr5:88179260	MEF2C	0.41	6.97	0.31	1.12e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg02002194	chr4:3960332	NA	0.45	8.01	0.35	9.05e-15	Retinal vascular caliber;
LGG	cis	rs6142618	0.562	rs2295035	chr20:30702144	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.32e-15	Inflammatory bowel disease;
LGG	cis	rs7129556	0.690	rs588217	chr11:77583376	A/G	cg12586386	chr11:77299805	AQP11	-0.44	-7.28	-0.32	1.49e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg20607798	chr8:58055168	NA	0.59	7.14	0.31	3.72e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14019695	chr9:139328340	INPP5E	0.43	7.75	0.34	6.02e-14	Monocyte percentage of white cells;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg06074448	chr4:187884817	NA	-0.58	-12.83	-0.51	1.93e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.87	0.3	2.03e-11	Educational attainment;
LGG	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg07395648	chr5:131743802	NA	-0.39	-8.3	-0.36	1.12e-15	Blood metabolite levels;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.1e-19	Aortic root size;
LGG	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.89	0.51	1.04e-32	IgG glycosylation;
LGG	cis	rs3818285	0.679	rs2475275	chr10:111633979	C/T	cg00817464	chr10:111662876	XPNPEP1	0.49	10.12	0.43	6.72e-22	Superior crus of antihelix expression;
LGG	cis	rs2070488	0.775	rs762318	chr3:38516369	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.88	0.57	3.3e-41	Electrocardiographic conduction measures;
LGG	cis	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg24110177	chr3:50126178	RBM5	0.4	6.89	0.3	1.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1010254	0.559	rs115672114	chr5:151749774	G/T	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.86e-11	Optic nerve measurement (cup area);
LGG	cis	rs1568889	0.641	rs34857148	chr11:28481976	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	9.68	0.41	2.71e-20	Bipolar disorder;
LGG	cis	rs9463078	0.605	rs7763421	chr6:44877313	A/G	cg25276700	chr6:44698697	NA	0.34	7.12	0.31	4.25e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg15704280	chr7:45808275	SEPT13	-1.0	-21.55	-0.71	7.89e-72	Coronary artery disease;
LGG	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg06191203	chr2:152266755	RIF1	-0.47	-8.16	-0.35	3.22e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20390242	chr2:157291951	GPD2	0.46	7.03	0.31	7.67e-12	Gut microbiome composition (summer);
LGG	cis	rs2180341	1.000	rs7776136	chr6:127638348	A/T	cg27446573	chr6:127587934	RNF146	1.1	21.62	0.71	3.64e-72	Breast cancer;
LGG	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg27532318	chr7:32358331	NA	0.73	7.59	0.33	1.75e-13	Body mass index;
LGG	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg26818010	chr10:134567672	INPP5A	0.4	6.81	0.3	2.97e-11	Migraine;
LGG	cis	rs7769051	0.614	rs17061930	chr6:133223799	T/C	cg22852734	chr6:133119734	C6orf192	0.89	7.68	0.34	9.67e-14	Type 2 diabetes nephropathy;
LGG	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.27	0.32	1.58e-12	Homoarginine levels;
LGG	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.53e-18	Motion sickness;
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00864171	chr11:67383662	NA	0.55	9.47	0.4	1.39e-19	Mean corpuscular volume;
LGG	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg04398451	chr17:18023971	MYO15A	-0.58	-11.52	-0.47	3.55e-27	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.07	0.55	1.05e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6429082	0.871	rs6675944	chr1:235572669	C/T	cg26050004	chr1:235667680	B3GALNT2	0.47	7.76	0.34	5.47e-14	Adiposity;
LGG	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg10523679	chr1:76189770	ACADM	-0.73	-11.13	-0.46	1.13e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs362296	0.698	rs362283	chr4:3259558	T/C	cg06533319	chr4:3265114	C4orf44	0.51	9.94	0.42	3.21e-21	Parental longevity (mother's age at death);
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.83	-0.3	2.76e-11	Total body bone mineral density;
LGG	cis	rs963731	0.649	rs297143	chr2:39320067	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-8.03	-0.35	8.34e-15	Corticobasal degeneration;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15320075	chr8:145703422	NA	0.72	13.85	0.54	9.88e-37	Age at first birth;
LGG	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg00376283	chr12:123451042	ABCB9	0.63	10.05	0.42	1.23e-21	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs7246760	0.737	rs60584926	chr19:9797014	C/T	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs6546537	0.826	rs2704443	chr2:69889338	A/C	cg10773587	chr2:69614142	GFPT1	-0.45	-7.29	-0.32	1.32e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.02	0.31	8.09e-12	Height;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.8	0.41	1.03e-20	Longevity;
LGG	cis	rs7103648	0.669	rs11039332	chr11:47695840	G/A	cg20307385	chr11:47447363	PSMC3	0.82	16.72	0.61	1.87e-49	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.35	0.36	8.21e-16	Tonsillectomy;
LGG	trans	rs11088226	0.645	rs7281844	chr21:33932435	T/C	cg09050820	chr6:167586206	TCP10L2	0.89	12.62	0.51	1.33e-31	Gastritis;
LGG	cis	rs1953600	0.754	rs2573348	chr10:81925785	C/T	cg04850286	chr10:81895943	PLAC9	-0.43	-9.7	-0.41	2.34e-20	Sarcoidosis;
LGG	trans	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.52e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00933542	chr6:150070202	PCMT1	0.39	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.73	-0.34	6.81e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg01557791	chr16:72042693	DHODH	0.5	9.2	0.39	1.21e-18	Fibrinogen levels;
LGG	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg18850127	chr7:39170497	POU6F2	0.55	12.4	0.5	1.09e-30	IgG glycosylation;
LGG	cis	rs78487399	0.808	rs7599781	chr2:43678726	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg22906224	chr7:99728672	NA	-0.58	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.98	-0.31	1.02e-11	Longevity;Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07434579	chr4:39639626	C4orf34	-0.46	-6.77	-0.3	3.92e-11	Systemic lupus erythematosus;
LGG	cis	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg08807101	chr21:30365312	RNF160	-0.54	-8.94	-0.38	9.67e-18	Pancreatic cancer;
LGG	cis	rs9649465	1.000	rs10215473	chr7:123380681	C/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18099408	chr3:52552593	STAB1	-0.35	-7.13	-0.31	3.79e-12	Bipolar disorder;
LGG	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg27523141	chr10:43048294	ZNF37B	0.37	7.49	0.33	3.49e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs988958	0.530	rs12712818	chr2:42236321	C/T	cg27252766	chr2:42229092	NA	0.52	7.47	0.33	4.16e-13	Hypospadias;
LGG	cis	rs16854884	0.657	rs13078840	chr3:143700753	A/G	cg06585982	chr3:143692056	C3orf58	0.61	10.3	0.43	1.59e-22	Economic and political preferences (feminism/equality);
LGG	cis	rs4740619	0.755	rs3122702	chr9:15609961	T/G	cg14451791	chr9:16040625	NA	-0.34	-8.74	-0.38	4.38e-17	Body mass index;
LGG	cis	rs6547631	0.622	rs10187164	chr2:85928209	G/C	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.92	-0.31	1.48e-11	Parkinson's disease;
LGG	cis	rs2839186	0.632	rs17176110	chr21:47706535	C/A	cg12379764	chr21:47803548	PCNT	-0.5	-8.22	-0.36	2.12e-15	Testicular germ cell tumor;
LGG	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg26550872	chr12:69656319	CPSF6	0.58	6.81	0.3	3.06e-11	Airflow obstruction;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg19077165	chr18:44547161	KATNAL2	0.7	13.35	0.53	1.33e-34	Personality dimensions;
LGG	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.86	-0.54	8.45e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg17971929	chr21:40555470	PSMG1	0.83	15.37	0.58	2.35e-43	Cognitive function;
LGG	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19524238	chr7:2802976	GNA12	0.34	8.26	0.36	1.55e-15	Height;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	7.42	0.33	5.47e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07243736	chr16:783730	NARFL	-0.6	-10.33	-0.43	1.17e-22	Height;
LGG	cis	rs2470578	0.740	rs2470581	chr3:17244668	C/G	cg20981856	chr3:17787350	NA	0.36	6.96	0.31	1.14e-11	Schizophrenia;
LGG	cis	rs72901758	0.768	rs1567237	chr17:76246294	A/G	cg26068271	chr17:76253126	NA	-0.49	-10.83	-0.45	1.69e-24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.16	-0.35	3.14e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg21665744	chr7:39171113	POU6F2	0.39	8.03	0.35	8.35e-15	IgG glycosylation;
LGG	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg13334819	chr7:99746414	C7orf59	-0.54	-8.29	-0.36	1.28e-15	Coronary artery disease;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg04503457	chr17:41445688	NA	-0.4	-9.81	-0.41	9.47e-21	Menopause (age at onset);
LGG	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg15128208	chr22:42549153	NA	0.75	11.78	0.48	3.41e-28	Birth weight;
LGG	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg15704280	chr7:45808275	SEPT13	-0.65	-8.14	-0.35	3.82e-15	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg02002194	chr4:3960332	NA	-0.53	-10.54	-0.44	1.97e-23	Neuroticism;
LGG	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg26116260	chr4:7069785	GRPEL1	-0.82	-8.41	-0.36	5.05e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg24690094	chr11:67383802	NA	0.5	9.26	0.4	7.63e-19	Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg19455335	chr8:22457658	C8orf58	-0.38	-7.73	-0.34	6.77e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.6	0.41	5.03e-20	Height;
LGG	cis	rs9815354	0.812	rs17215183	chr3:41812334	T/C	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9828933	0.516	rs704371	chr3:63867528	G/A	cg17941049	chr3:63904683	ATXN7	-0.63	-7.83	-0.34	3.4e-14	Type 2 diabetes;
LGG	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg18081430	chr2:111878091	BCL2L11	-0.31	-6.74	-0.3	4.82e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg11062466	chr8:58055876	NA	0.5	8.11	0.35	4.69e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14159672	chr1:205819179	PM20D1	0.52	9.66	0.41	3.14e-20	Menarche (age at onset);
LGG	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg16434002	chr17:42200994	HDAC5	0.44	7.82	0.34	3.58e-14	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.25	0.32	1.75e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg00504896	chr12:9437009	LOC642846	-0.44	-8.07	-0.35	6.21e-15	Breast size;
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg05484376	chr2:27715224	FNDC4	0.47	10.15	0.43	5.56e-22	Total body bone mineral density;
LGG	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg22771759	chr13:24902376	NA	0.44	7.57	0.33	2.02e-13	Obesity-related traits;
LGG	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg09165964	chr15:75287851	SCAMP5	-0.55	-10.36	-0.43	9.02e-23	Caffeine consumption;
LGG	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg04234412	chr22:24373322	LOC391322	0.67	11.19	0.46	6.94e-26	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs7584262	0.653	rs10210654	chr2:42264686	G/A	cg27252766	chr2:42229092	NA	0.51	6.83	0.3	2.76e-11	Bone mineral density;
LGG	cis	rs7312774	0.618	rs7975954	chr12:107345750	C/T	cg16260113	chr12:107380972	MTERFD3	0.94	8.75	0.38	3.87e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs7927771	0.864	rs55927797	chr11:47446292	A/T	cg20307385	chr11:47447363	PSMC3	-0.58	-10.57	-0.44	1.53e-23	Subjective well-being;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg07701084	chr6:150067640	NUP43	0.68	13.25	0.52	3.25e-34	Lung cancer;
LGG	trans	rs12517041	1.000	rs995215	chr5:23285366	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.68	0.37	7.05e-17	Calcium levels;
LGG	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.77	-0.38	3.32e-17	Colorectal cancer;
LGG	cis	rs4417704	0.551	rs60677070	chr2:241900494	A/G	cg26818257	chr2:241905806	NA	0.5	10.57	0.44	1.52e-23	Joint mobility (Beighton score);
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg12419862	chr22:24373484	LOC391322	-0.9	-18.88	-0.66	2.23e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	trans	rs2235573	0.662	rs6000991	chr22:38460484	T/C	cg19894588	chr14:64061835	NA	0.43	6.92	0.31	1.51e-11	Glioblastoma;Glioma;
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg16208657	chr15:68119293	LBXCOR1	-0.35	-6.7	-0.3	6.12e-11	Obesity;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08182975	chr2:7164527	RNF144A	0.37	6.77	0.3	3.85e-11	Electrocardiographic conduction measures;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14940636	chr12:56498092	PA2G4	-0.49	-7.23	-0.32	2.05e-12	Systemic lupus erythematosus;
LGG	trans	rs1032833	0.732	rs79717491	chr2:180033844	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11890956	chr21:40555474	PSMG1	-0.75	-12.91	-0.51	8.95e-33	Menarche (age at onset);
LGG	cis	rs368123	1.000	rs452788	chr6:160735328	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.25	-0.32	1.77e-12	Waist circumference;
LGG	cis	rs12410462	0.551	rs2012432	chr1:227866157	T/G	cg23173402	chr1:227635558	NA	0.35	6.65	0.3	8.38e-11	Major depressive disorder;
LGG	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg01529538	chr14:23388837	RBM23	0.37	6.76	0.3	4.13e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg25338242	chr13:114786047	RASA3	0.42	7.46	0.33	4.23e-13	Schizophrenia;
LGG	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.64	-0.51	1.19e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs2016266	0.784	rs12424778	chr12:53737840	A/T	cg04065151	chr12:53682969	ESPL1	-0.52	-8.29	-0.36	1.24e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs367943	0.603	rs1864066	chr5:112997865	C/T	cg12552261	chr5:112820674	MCC	0.56	9.97	0.42	2.5e-21	Type 2 diabetes;
LGG	cis	rs6141769	0.542	rs6119939	chr20:31315153	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs17453880	0.929	rs4612055	chr5:151963332	C/T	cg10931792	chr5:152022470	NA	-0.38	-8.29	-0.36	1.25e-15	Subjective well-being;
LGG	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-7.04	-0.31	7.14e-12	Response to amphetamines;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20563098	chr10:64892887	NRBF2	0.39	6.7	0.3	5.97e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.65	-0.37	8.38e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg12011299	chr4:100065546	ADH4	0.41	7.98	0.35	1.14e-14	Smoking initiation;
LGG	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22455342	chr2:225449267	CUL3	0.86	15.23	0.58	9.85e-43	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg09307838	chr4:120376055	NA	0.79	13.29	0.53	2.17e-34	Corneal astigmatism;
LGG	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.26	-0.32	1.65e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.9	0.31	1.72e-11	Hip circumference adjusted for BMI;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg01988459	chr11:68622903	NA	-0.62	-12.43	-0.5	8.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg09855544	chr8:135498122	ZFAT	-0.45	-7.61	-0.33	1.52e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07701084	chr6:150067640	NUP43	-0.42	-7.83	-0.34	3.46e-14	Testicular germ cell tumor;
LGG	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg07636037	chr3:49044803	WDR6	0.6	10.41	0.44	5.86e-23	Resting heart rate;
LGG	cis	rs4788570	0.566	rs1804984	chr16:71481520	T/A	cg06353428	chr16:71660113	MARVELD3	-1.03	-13.86	-0.54	8.68e-37	Intelligence (multi-trait analysis);
LGG	cis	rs12468557	0.527	rs12694206	chr2:211499394	T/A	cg07063745	chr2:211341572	LANCL1;CPS1	-0.5	-8.73	-0.38	4.55e-17	Body mass index in asthmatics;
LGG	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.4e-17	Fuchs's corneal dystrophy;
LGG	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg13010199	chr12:38710504	ALG10B	0.49	9.23	0.39	9.72e-19	Morning vs. evening chronotype;
LGG	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg07636037	chr3:49044803	WDR6	-0.78	-13.51	-0.53	2.76e-35	Menarche (age at onset);
LGG	cis	rs240764	0.681	rs12209887	chr6:101156806	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-7.45	-0.33	4.49e-13	Neuroticism;
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs4950322	0.547	rs6660507	chr1:146620153	T/C	cg22381352	chr1:146742008	CHD1L	-0.44	-7.48	-0.33	3.81e-13	Protein quantitative trait loci;
LGG	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg01028140	chr2:1542097	TPO	-0.54	-8.62	-0.37	1.05e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs8070128	0.534	rs2955350	chr17:17953548	G/A	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs10463316	0.894	rs13361298	chr5:150765549	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.2800000000000002e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg17788362	chr6:86352627	SYNCRIP	0.53	9.21	0.39	1.11e-18	Smooth-surface caries;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg24575275	chr7:1094737	C7orf50	-0.39	-7.43	-0.33	5.28e-13	Longevity;Endometriosis;
LGG	trans	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg06521331	chr12:34319734	NA	0.39	6.8	0.3	3.3e-11	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.679	rs4768471	chr12:39325960	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.85	0.38	1.85e-17	Morning vs. evening chronotype;
LGG	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	2.93e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg19168338	chr16:4465731	CORO7	-0.78	-14.59	-0.56	6.1e-40	Schizophrenia;
LGG	cis	rs5758511	0.513	rs7292782	chr22:42200324	A/C	cg15128208	chr22:42549153	NA	-0.42	-7.15	-0.32	3.5e-12	Birth weight;
LGG	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg03315344	chr16:75512273	CHST6	0.52	10.45	0.44	4.36e-23	Dupuytren's disease;
LGG	cis	rs8064024	0.604	rs1049212	chr16:4932929	A/G	cg08329684	chr16:4932620	PPL	-0.57	-12.72	-0.51	5.31e-32	Cancer;
LGG	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Calcium levels;
LGG	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg10792982	chr14:105748885	BRF1	0.67	13.87	0.54	7.84e-37	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3771570	0.786	rs62186396	chr2:242221219	A/G	cg21155796	chr2:242212141	HDLBP	0.75	9.8	0.41	9.99e-21	Prostate cancer;
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.42	-6.97	-0.31	1.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.77	0.34	4.99e-14	Height;
LGG	cis	rs61935443	0.673	rs11107770	chr12:95275147	C/T	cg21533806	chr12:95267307	NA	-0.5	-6.81	-0.3	2.99e-11	Schizophrenia;
LGG	trans	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg22153745	chr1:153894579	GATAD2B	-0.63	-10.24	-0.43	2.66e-22	Total cholesterol levels;
LGG	cis	rs548181	0.611	rs609200	chr11:125383808	G/A	cg03464685	chr11:125439445	EI24	-1.45	-20.5	-0.69	6.54e-67	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7572733	0.935	rs10177758	chr2:198858917	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.26	0.36	1.55e-15	Dermatomyositis;
LGG	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.46	-0.37	3.57e-16	Retinal vascular caliber;
LGG	cis	rs7572263	0.874	rs9646836	chr2:209055610	C/A	cg00164906	chr2:209055251	C2orf80	-0.54	-8.37	-0.36	7.12e-16	Glioma;Non-glioblastoma glioma;
LGG	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11644478	chr21:40555479	PSMG1	-0.71	-12.51	-0.5	3.78e-31	Cognitive function;
LGG	cis	rs6960043	0.846	rs7781710	chr7:15056045	T/A	cg19272540	chr7:15055459	NA	0.32	7.2	0.32	2.49e-12	Type 2 diabetes;
LGG	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08045932	chr20:61659980	NA	-0.49	-8.71	-0.38	5.53e-17	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.98	-0.49	5.35e-29	Parkinson's disease;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg18402987	chr7:1209562	NA	0.72	7.75	0.34	6.05e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs713587	0.776	rs1172294	chr2:25169200	A/G	cg04586622	chr2:25135609	ADCY3	0.39	10.09	0.42	8.92e-22	Body mass index in non-asthmatics;
LGG	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.31	-0.5	2.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	15.13	0.58	2.49e-42	Tonsillectomy;
LGG	cis	rs35883536	0.588	rs114540631	chr1:101101249	A/G	cg06223162	chr1:101003688	GPR88	0.35	7.9	0.34	2.08e-14	Monocyte count;
LGG	cis	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.3e-25	Resting heart rate;
LGG	cis	rs6725041	0.740	rs4673654	chr2:213093403	C/A	cg20637307	chr2:213403960	ERBB4	-0.36	-6.94	-0.31	1.35e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	9.4	0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs1056053	0.514	rs3127334	chr6:166574246	G/A	cg11088901	chr6:166572345	T	-0.5	-9.59	-0.41	5.44e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs972578	0.715	rs8141176	chr22:43215692	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.75	-0.3	4.47e-11	Mean platelet volume;
LGG	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.99	0.42	2.04e-21	Height;
LGG	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg09307838	chr4:120376055	NA	0.71	11.7	0.48	6.94e-28	Corneal astigmatism;
LGG	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg10483660	chr13:112241077	NA	-0.34	-7.49	-0.33	3.61e-13	Hepatitis;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.35	0.55	7.03e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.83	0.3	2.61e-11	Lung cancer;
LGG	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.69e-30	Response to antipsychotic treatment;
LGG	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg02985381	chr13:37494744	SMAD9	0.73	12.89	0.51	1.03e-32	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12085660	chr19:44124104	ZNF428	-0.44	-7.1	-0.31	4.59e-12	Pancreatic cancer;
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.35	0.32	8.8e-13	Renal function-related traits (BUN);
LGG	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.27	0.43	1.94e-22	Height;
LGG	cis	rs1018836	0.575	rs17635255	chr8:91518135	A/T	cg16814680	chr8:91681699	NA	-0.66	-9.64	-0.41	3.73e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg08888203	chr3:10149979	C3orf24	0.36	6.89	0.31	1.8e-11	Alzheimer's disease;
LGG	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg08847533	chr14:75593920	NEK9	-0.59	-11.52	-0.47	3.48e-27	Height;
LGG	trans	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg20587970	chr11:113659929	NA	-1.36	-16.95	-0.62	1.69e-50	Height;
LGG	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg20570797	chr2:1712800	PXDN	-0.46	-8.34	-0.36	8.42e-16	Response to antipsychotic treatment;
LGG	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.96	0.49	6.44e-29	Response to antipsychotic treatment;
LGG	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg01557791	chr16:72042693	DHODH	-0.52	-8.19	-0.36	2.54e-15	Blood protein levels;
LGG	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg11764359	chr7:65958608	NA	-0.64	-9.87	-0.42	5.45e-21	Aortic root size;
LGG	trans	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.53e-18	Bladder cancer;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs3617	0.652	rs7630552	chr3:52891570	G/C	cg11645453	chr3:52864694	ITIH4	-0.45	-7.52	-0.33	2.87e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.65	0.59	1.26e-44	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg04861929	chr11:109293070	C11orf87	0.61	10.63	0.44	8.82e-24	Schizophrenia;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg05313129	chr8:58192883	C8orf71	-0.47	-8.06	-0.35	6.68e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.54	-0.33	2.42e-13	Prostate cancer;
LGG	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg14500267	chr11:67383377	NA	-0.39	-7.2	-0.32	2.51e-12	Mean corpuscular volume;
LGG	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg11764359	chr7:65958608	NA	-0.62	-8.62	-0.37	1.08e-16	Aortic root size;
LGG	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	5.91e-19	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.57	-0.41	6.32e-20	Life satisfaction;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.77	-0.3	3.94e-11	Personality dimensions;
LGG	cis	rs9547996	0.879	rs11618138	chr13:38195296	C/T	cg17979426	chr13:38220150	TRPC4	-0.37	-6.92	-0.31	1.56e-11	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg18032289	chr17:61959525	GH2	-0.41	-6.97	-0.31	1.11e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1707322	1.000	rs6671754	chr1:46433990	A/G	cg03146154	chr1:46216737	IPP	0.52	9.86	0.42	6.11e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg02002194	chr4:3960332	NA	0.49	9.3	0.4	5.49e-19	Neuroticism;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg05941027	chr17:61774174	LIMD2	0.37	9.19	0.39	1.36e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	11.12	0.46	1.27e-25	Ulcerative colitis;
LGG	trans	rs73198271	0.737	rs506960	chr8:8630269	A/C	cg16141378	chr3:129829833	LOC729375	0.33	6.69	0.3	6.65e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg21058520	chr6:100914733	NA	0.38	6.68	0.3	6.68e-11	Neuroticism;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg07930552	chr6:133119739	C6orf192	-0.87	-11.57	-0.47	2.18e-27	Type 2 diabetes nephropathy;
LGG	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs10882165	0.507	rs4326721	chr10:94958886	C/T	cg13743231	chr10:94958683	NA	-0.36	-7.15	-0.32	3.37e-12	Refractive error;
LGG	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg27129171	chr3:47204927	SETD2	-0.79	-15.36	-0.58	2.63e-43	Colorectal cancer;
LGG	cis	rs929596	0.556	rs35984508	chr2:234587852	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.4	-0.44	6.61e-23	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg27572855	chr1:25598939	RHD	0.53	11.75	0.48	4.51e-28	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg20503657	chr10:835505	NA	0.75	10.4	0.44	6.72e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.55	-8.0	-0.35	1e-14	Yeast infection;
LGG	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.92	-0.59	8.3e-46	Height;
LGG	trans	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.68	-0.41	2.58e-20	Bladder cancer;
LGG	cis	rs6589964	0.755	rs11828143	chr11:122876855	A/C	cg27398637	chr11:122830231	C11orf63	0.46	8.02	0.35	8.81e-15	Menarche (age at onset);
LGG	cis	rs727505	0.754	rs55905546	chr7:124783064	A/C	cg23710748	chr7:124431027	NA	-0.44	-8.62	-0.37	1.1e-16	Lewy body disease;
LGG	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.99	-0.57	1.07e-41	Aortic root size;
LGG	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg08999081	chr20:33150536	PIGU	0.4	10.13	0.43	6.35e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	trans	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg25214090	chr10:38739885	LOC399744	0.61	10.98	0.45	4.23e-25	Corneal astigmatism;
LGG	trans	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg13565492	chr6:43139072	SRF	-0.74	-9.0	-0.39	5.85e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg16141378	chr3:129829833	LOC729375	0.34	7.66	0.34	1.13e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg16434002	chr17:42200994	HDAC5	0.54	10.05	0.42	1.22e-21	Total body bone mineral density;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01341218	chr17:43662625	NA	0.94	16.27	0.6	2.17e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg19524238	chr7:2802976	GNA12	-0.41	-9.64	-0.41	3.69e-20	Height;
LGG	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg23649088	chr2:200775458	C2orf69	-0.57	-7.03	-0.31	7.36e-12	Schizophrenia;
LGG	cis	rs9462027	0.675	rs7755926	chr6:34722574	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.47	-0.47	5.82e-27	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.53	-0.53	2.29e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Body mass index;
LGG	cis	rs1372520	0.684	rs2619355	chr4:90748374	A/C	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs5742933	0.857	rs1437891	chr2:190562708	C/T	cg04003228	chr2:190539410	ANKAR	0.5	7.32	0.32	1.12e-12	Ferritin levels;
LGG	cis	rs994014	0.572	rs10034545	chr4:82289087	C/T	cg07938847	chr4:82126349	PRKG2	0.28	6.92	0.31	1.53e-11	Height;
LGG	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg08250081	chr4:10125330	NA	0.41	8.13	0.35	3.96e-15	Bone mineral density;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg04098458	chr2:149402448	EPC2	-0.38	-6.8	-0.3	3.2e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.53	-0.4	9.22e-20	Life satisfaction;
LGG	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg05163923	chr11:71159392	DHCR7	0.72	14.24	0.55	1.97e-38	Vitamin D levels;
LGG	cis	rs9828933	0.938	rs9809432	chr3:64002953	G/A	cg17941049	chr3:63904683	ATXN7	0.66	7.99	0.35	1.12e-14	Type 2 diabetes;
LGG	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg25706552	chr1:244017396	NA	0.52	8.36	0.36	7.66e-16	RR interval (heart rate);
LGG	cis	rs1014246	0.848	rs2420330	chr10:118457481	C/T	cg14919929	chr10:118506882	NA	0.62	12.05	0.49	2.79e-29	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.79	0.54	1.74e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg13385794	chr1:248469461	NA	0.49	8.21	0.36	2.28e-15	Common traits (Other);
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06112835	chr11:68658793	MRPL21	0.6	10.04	0.42	1.35e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1018836	0.595	rs2223010	chr8:91480068	A/G	cg16814680	chr8:91681699	NA	-0.67	-11.3	-0.47	2.53e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.25	0.49	4.6e-30	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25696485	chr21:38445943	PIGP;TTC3	0.43	7.1	0.31	4.84e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00142150	chr22:38071001	LGALS1	0.93	19.87	0.68	5.34e-64	Fat distribution (HIV);
LGG	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg17809284	chr5:56205270	C5orf35	-0.38	-7.25	-0.32	1.74e-12	Coronary artery disease;
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg11984989	chr7:158649758	WDR60	1.05	23.03	0.73	9.34e-79	Height;
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.28	-0.36	1.34e-15	Neuroticism;
LGG	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg24998981	chr18:77441810	CTDP1	0.36	7.99	0.35	1.05e-14	Monocyte count;
LGG	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.64	0.37	9.16e-17	Schizophrenia;
LGG	cis	rs9403521	1.000	rs116980222	chr6:143998987	C/T	cg18240653	chr6:144019428	PHACTR2	-0.64	-10.05	-0.42	1.26e-21	Obesity-related traits;
LGG	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg11789530	chr4:8429930	ACOX3	0.88	17.21	0.62	1.13e-51	Response to antineoplastic agents;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg24829409	chr8:58192753	C8orf71	-0.86	-12.97	-0.52	4.81e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg10792982	chr14:105748885	BRF1	0.56	10.88	0.45	1.06e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg27624424	chr6:160112604	SOD2	0.65	9.6	0.41	4.98e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.44	-0.4	1.86e-19	Lung cancer;
LGG	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg18478394	chr8:109455254	TTC35	0.43	8.63	0.37	1.02e-16	Dupuytren's disease;
LGG	cis	rs1358748	0.522	rs6588239	chr1:67572361	G/A	cg02640540	chr1:67518911	SLC35D1	0.55	6.69	0.3	6.43e-11	Tuberculosis;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06955919	chr8:110551796	EBAG9	-0.42	-6.87	-0.3	2.04e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg19418458	chr7:158789849	NA	-0.55	-11.5	-0.47	4.38e-27	Facial morphology (factor 20);
LGG	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg11502198	chr6:26597334	ABT1	0.58	10.05	0.42	1.3e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.51	-0.37	2.43e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.8	-0.3	3.18e-11	Menopause (age at onset);
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg07701084	chr6:150067640	NUP43	-0.46	-6.96	-0.31	1.15e-11	Lung cancer;
LGG	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg18129748	chr3:49941408	MST1R	-0.23	-7.36	-0.32	8.54e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg26384229	chr12:38710491	ALG10B	0.92	20.78	0.69	3.01e-68	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03230822	chr7:14029701	ETV1	-0.47	-6.95	-0.31	1.21e-11	Systemic lupus erythematosus;
LGG	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.13	-0.31	3.77e-12	Hemoglobin concentration;
LGG	cis	rs7267979	0.844	rs6083851	chr20:25401235	G/A	cg06421707	chr20:25228305	PYGB	-0.43	-9.08	-0.39	3.05e-18	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21711868	chr11:66886748	KDM2A	0.51	8.24	0.36	1.74e-15	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	17.72	0.64	5.08e-54	Smoking behavior;
LGG	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg12658694	chr1:38397304	INPP5B	0.47	9.54	0.41	8.28e-20	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.43	-0.33	5.24e-13	Uric acid levels;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.6	-0.37	1.26e-16	Lung cancer;
LGG	cis	rs988958	1.000	rs988958	chr2:42287306	A/G	cg27428208	chr2:42229179	NA	-0.38	-6.83	-0.3	2.71e-11	Hypospadias;
LGG	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.04	-0.31	6.79e-12	Systemic lupus erythematosus;
LGG	trans	rs1459104	0.929	rs35627018	chr11:55199639	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.3	7.25e-11	Body mass index;
LGG	trans	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg25214090	chr10:38739885	LOC399744	-0.57	-9.83	-0.42	7.73e-21	Corneal astigmatism;
LGG	cis	rs9398803	0.687	rs1269195	chr6:127031550	C/T	cg19875578	chr6:126661172	C6orf173	-0.53	-9.77	-0.41	1.3e-20	Male-pattern baldness;
LGG	cis	rs13082711	0.911	rs4973770	chr3:27425815	C/T	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.69e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21468634	chr8:41507844	NA	0.35	6.89	0.3	1.78e-11	Electrocardiographic conduction measures;
LGG	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg09339527	chr5:178322752	ZFP2	-0.4	-7.47	-0.33	4.04e-13	Sleep duration;
LGG	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-10.07	-0.42	1.07e-21	Response to antipsychotic treatment;
LGG	trans	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg25835954	chr13:50160062	RCBTB1	0.51	7.71	0.34	7.82e-14	Cortisol levels (saliva);
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.12	-0.35	4.13e-15	Educational attainment (college completion);
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.47	-0.44	3.62e-23	Longevity;Endometriosis;
LGG	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.06	0.42	1.11e-21	Iron status biomarkers;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg22535103	chr8:58192502	C8orf71	-0.58	-9.64	-0.41	3.64e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09476347	chr16:613343	C16orf11	-0.37	-6.67	-0.3	7.17e-11	Height;
LGG	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	9.65	0.41	3.29e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13732083	chr21:47605072	C21orf56	0.46	7.62	0.33	1.46e-13	Testicular germ cell tumor;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg27661571	chr11:113659931	NA	-0.7	-9.57	-0.41	6.42e-20	Hip circumference adjusted for BMI;
LGG	cis	rs72827839	0.802	rs4794321	chr17:46028844	T/C	cg02219949	chr17:45927392	SP6	-0.48	-7.46	-0.33	4.23e-13	Ease of getting up in the morning;
LGG	cis	rs9381107	0.932	rs9349096	chr6:9437004	C/T	cg14735645	chr6:9486422	NA	-0.42	-7.15	-0.32	3.49e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.91e-101	Cognitive ability;
LGG	cis	rs72781680	0.716	rs7564732	chr2:24034178	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	8.24	0.36	1.84e-15	Lymphocyte counts;
LGG	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03264133	chr6:25882463	NA	-0.68	-12.48	-0.5	5.24e-31	Intelligence (multi-trait analysis);
LGG	cis	rs653465	0.739	rs1402980	chr3:27123670	A/G	cg02860705	chr3:27208620	NA	0.4	7.71	0.34	7.86e-14	Breast cancer (early onset);
LGG	cis	rs11634851	0.844	rs12917526	chr15:81025457	G/C	cg03950166	chr15:80988613	FAM108C1	-0.38	-7.09	-0.31	5.12e-12	Systolic blood pressure;
LGG	cis	rs1322639	0.614	rs7751131	chr6:169578710	G/A	cg04662567	chr6:169592167	NA	-0.87	-11.89	-0.48	1.26e-28	Pulse pressure;
LGG	cis	rs7326068	0.610	rs2596150	chr13:21317048	C/T	cg04906043	chr13:21280425	IL17D	-0.44	-7.04	-0.31	7.08e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.52	-0.44	2.33e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4740619	0.688	rs10962225	chr9:15936528	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.17	-0.43	4.74e-22	Body mass index;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.11	-0.57	3.04e-42	Prudent dietary pattern;
LGG	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.56	9.49	0.4	1.24e-19	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg13565492	chr6:43139072	SRF	-0.79	-9.69	-0.41	2.4e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.1e-34	Heart rate;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.21	0.46	5.52e-26	Bipolar disorder;
LGG	cis	rs7216064	1.000	rs56148300	chr17:65892752	T/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.79	-0.38	3.05e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg04743876	chr7:130013617	NA	0.37	8.37	0.36	6.66e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06634786	chr22:41940651	POLR3H	-0.63	-10.77	-0.45	2.64e-24	Vitiligo;
LGG	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12826209	chr6:26865740	GUSBL1	0.59	7.3	0.32	1.27e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7412746	0.658	rs6677420	chr1:150946490	G/A	cg15448220	chr1:150897856	SETDB1	0.41	7.49	0.33	3.49e-13	Melanoma;
LGG	cis	rs644148	0.836	rs2571112	chr19:45000319	T/A	cg15540054	chr19:45004280	ZNF180	-0.57	-10.96	-0.45	5.2e-25	Personality dimensions;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg02158880	chr13:53174818	NA	0.5	10.28	0.43	1.79e-22	Lewy body disease;
LGG	cis	rs3806843	1.000	rs4151680	chr5:140186657	A/G	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg20503657	chr10:835505	NA	0.75	10.49	0.44	3.18e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg01221209	chr5:554886	NA	-0.47	-9.47	-0.4	1.42e-19	Ulcerative colitis;
LGG	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	cg15522984	chr1:182991683	LAMC1	0.48	9.85	0.42	6.6e-21	Colorectal cancer;
LGG	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg03929089	chr4:120376271	NA	0.7	9.53	0.4	9.1e-20	Axial length;
LGG	trans	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	trans	rs6787172	0.870	rs1714524	chr3:158273096	C/T	cg23275840	chr4:47708675	CORIN	-0.34	-7.19	-0.32	2.59e-12	Subjective well-being;
LGG	cis	rs1318772	1.000	rs34625553	chr5:112680073	C/A	cg12552261	chr5:112820674	MCC	0.71	8.35	0.36	8.12e-16	F-cell distribution;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.31	0.32	1.15e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg03433033	chr1:76189801	ACADM	0.81	14.47	0.56	2.04e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.89	8.95	0.38	8.74e-18	Schizophrenia;
LGG	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs3806843	1.000	rs10072015	chr5:140170655	A/T	cg19875535	chr5:140030758	IK	-0.51	-10.3	-0.43	1.49e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7766436	0.621	rs6903615	chr6:22602569	T/C	cg13666174	chr6:22585274	NA	-0.32	-7.72	-0.34	7.47e-14	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs9543976	0.623	rs7139740	chr13:76166942	C/T	cg12827798	chr13:76122768	UCHL3	-0.43	-6.7	-0.3	6.2e-11	Diabetic retinopathy;
LGG	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg18551225	chr6:44695536	NA	-0.61	-9.95	-0.42	2.9e-21	Total body bone mineral density;
LGG	cis	rs6912958	0.535	rs448580	chr6:88040399	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	13.22	0.52	4.35e-34	Monocyte percentage of white cells;
LGG	cis	rs7695597	0.708	rs7680050	chr4:185181276	C/T	cg12654155	chr4:185238627	NA	-0.36	-6.66	-0.3	7.84e-11	Night sleep phenotypes;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg21479132	chr6:26055353	NA	0.85	7.45	0.33	4.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg16194253	chr14:24768981	DHRS1;C14orf21	0.46	8.2	0.36	2.35e-15	Height;
LGG	cis	rs2235649	0.833	rs2011088	chr16:1850091	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.21e-11	Blood metabolite levels;
LGG	cis	rs4006360	0.606	rs11657468	chr17:39233876	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.45e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs8067545	0.750	rs4924803	chr17:19991806	C/T	cg13482628	chr17:19912719	NA	0.63	12.44	0.5	7.33e-31	Schizophrenia;
LGG	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg20503657	chr10:835505	NA	0.7	8.98	0.39	6.77e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg24642439	chr20:33292090	TP53INP2	0.83	15.38	0.58	2.08e-43	Coronary artery disease;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.64	-0.37	9.48e-17	Platelet distribution width;
LGG	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.13e-33	Aortic root size;
LGG	cis	rs8056893	0.842	rs3785119	chr16:68374434	G/T	cg07273125	chr16:68295692	NA	0.36	6.8	0.3	3.14e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs17767392	1.000	rs34057981	chr14:71823981	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.25	-0.39	8.45e-19	Mitral valve prolapse;
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.26	-0.52	2.92e-34	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs10875746	0.551	rs1471998	chr12:48712002	C/T	cg24011408	chr12:48396354	COL2A1	-0.56	-7.16	-0.32	3.28e-12	Longevity (90 years and older);
LGG	trans	rs28595532	0.623	rs11932674	chr4:119306807	A/C	cg26518628	chr1:97050305	NA	-0.91	-12.39	-0.5	1.24e-30	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg03806693	chr22:41940476	POLR3H	-0.86	-14.99	-0.57	1.05e-41	Vitiligo;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg08112188	chr17:47440006	ZNF652	1.28	14.98	0.57	1.2e-41	Prostate cancer;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg11878867	chr6:150167359	LRP11	-0.56	-12.05	-0.49	2.85e-29	Lung cancer;
LGG	cis	rs2916247	1.000	rs2916248	chr8:93013260	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23809679	chr4:71554125	UTP3	0.43	6.81	0.3	3.09e-11	Cognitive performance;
LGG	cis	rs4330281	0.692	rs13076724	chr3:17758473	A/G	cg20981856	chr3:17787350	NA	-0.37	-6.77	-0.3	3.99e-11	Schizophrenia;
LGG	cis	rs9816226	0.938	rs55742087	chr3:185830488	C/T	cg00760338	chr3:185826511	ETV5	-0.88	-12.91	-0.51	8.51e-33	Obesity;Body mass index;
LGG	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg20387954	chr3:183756860	HTR3D	0.69	14.03	0.55	1.66e-37	Anterior chamber depth;
LGG	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs1873147	0.569	rs12593573	chr15:63309919	G/A	cg12160578	chr15:63334699	TPM1	0.57	7.9	0.34	1.99e-14	Orofacial clefts;
LGG	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg12438819	chr7:158236134	PTPRN2	-0.31	-8.19	-0.36	2.48e-15	Obesity-related traits;
LGG	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-10.15	-0.43	5.53e-22	Diastolic blood pressure;
LGG	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.73	-0.34	6.56e-14	Triglycerides;
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.22	-0.32	2.12e-12	Neuroticism;
LGG	cis	rs4561483	0.667	rs3743590	chr16:11930337	A/C	cg08843971	chr16:11963173	GSPT1	-0.47	-10.8	-0.45	2.15e-24	Testicular germ cell tumor;
LGG	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg26597838	chr10:835615	NA	0.65	8.92	0.38	1.05e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs9810089	0.676	rs526574	chr3:136103349	A/G	cg21827317	chr3:136751795	NA	0.46	8.13	0.35	3.88e-15	Gestational age at birth (child effect);
LGG	cis	rs7017697	1.000	rs6980875	chr8:19685948	C/T	cg03894339	chr8:19674705	INTS10	-0.53	-8.75	-0.38	3.93e-17	Breast cancer;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg13010199	chr12:38710504	ALG10B	0.69	14.52	0.56	1.27e-39	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg01314568	chr7:57830625	NA	-0.45	-7.52	-0.33	2.87e-13	Obesity-related traits;
LGG	cis	rs7683537	0.692	rs56368159	chr4:185654827	T/G	cg04058563	chr4:185651563	MLF1IP	1.01	16.81	0.62	7.29e-50	Systemic lupus erythematosus;
LGG	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.97	0.31	1.12e-11	Bipolar disorder;
LGG	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg06917634	chr15:78832804	PSMA4	-0.65	-9.76	-0.41	1.33e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs877282	0.945	rs877280	chr10:771599	C/T	cg17470449	chr10:769945	NA	0.64	8.09	0.35	5.42e-15	Uric acid levels;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-13.19	-0.52	5.73e-34	Personality dimensions;
LGG	cis	rs4919694	0.901	rs113541728	chr10:104716771	A/T	cg04362960	chr10:104952993	NT5C2	1.06	15.11	0.57	3.18e-42	Arsenic metabolism;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.78e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg11905131	chr22:24372483	LOC391322	-0.4	-7.05	-0.31	6.4e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2859741	0.967	rs535876	chr1:37484052	C/G	cg09363841	chr1:37513479	NA	-0.66	-15.85	-0.59	1.72e-45	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.47	-0.61	2.54e-48	Height;
LGG	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg07636037	chr3:49044803	WDR6	1.1	28.03	0.79	8.03e-102	Parkinson's disease;
LGG	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg13256891	chr4:100009986	ADH5	0.53	9.53	0.4	8.97e-20	Alcohol dependence;
LGG	cis	rs1461503	0.534	rs7944405	chr11:122816099	A/G	cg27398637	chr11:122830231	C11orf63	-0.68	-13.09	-0.52	1.61e-33	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06734807	chr5:139936782	SRA1	0.49	7.33	0.32	1.06e-12	Gut microbiome composition (summer);
LGG	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg00409905	chr10:38381863	ZNF37A	0.5	8.2	0.36	2.36e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs892961	0.932	rs2170863	chr17:75415037	C/T	cg05865280	chr17:75406074	SEPT9	0.42	9.89	0.42	4.68e-21	Airflow obstruction;
LGG	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg11161011	chr14:65562177	MAX	-0.74	-14.72	-0.56	1.58e-40	Obesity-related traits;
LGG	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg14227996	chr4:17616232	MED28	0.73	8.93	0.38	1.02e-17	Opioid sensitivity;
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.33	-0.4	4.5e-19	Aortic root size;
LGG	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg07541023	chr7:19748670	TWISTNB	0.57	7.77	0.34	5.1e-14	Thyroid stimulating hormone;
LGG	cis	rs16854884	0.660	rs990320	chr3:143796305	T/C	cg06585982	chr3:143692056	C3orf58	0.51	8.38	0.36	6.52e-16	Economic and political preferences (feminism/equality);
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg23758822	chr17:41437982	NA	0.87	15.42	0.58	1.42e-43	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg06654118	chr4:1303317	MAEA	0.47	8.03	0.35	8.13e-15	Obesity-related traits;
LGG	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.56	0.37	1.64e-16	Mood instability;
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	10.67	0.44	6.45e-24	Bipolar disorder;
LGG	cis	rs9878978	0.964	rs11707598	chr3:2478957	T/C	cg21928760	chr3:2462534	CNTN4	0.41	8.99	0.39	6.18e-18	Blood pressure (smoking interaction);
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.0	-0.31	9.13e-12	Bipolar disorder;
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	8.81	0.38	2.55e-17	Lung function (FEV1/FVC);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14276619	chr12:117319577	HRK	0.42	7.51	0.33	3.03e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.83	0.57	5.34e-41	Platelet count;
LGG	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.6	0.33	1.62e-13	Coronary artery disease;
LGG	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15128208	chr22:42549153	NA	0.43	8.83	0.38	2.19e-17	Cognitive function;
LGG	cis	rs4262150	0.544	rs56097272	chr5:151899155	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.6	-0.47	1.75e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	cis	rs2354432	0.556	rs6593777	chr1:146884013	C/G	cg25205988	chr1:146714368	CHD1L	1.21	11.89	0.48	1.18e-28	Mitochondrial DNA levels;
LGG	cis	rs2286885	1.000	rs7851961	chr9:129249140	G/A	cg14319473	chr9:129242481	FAM125B	0.45	8.44	0.36	4.25e-16	Intraocular pressure;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.28	0.43	1.84e-22	Prudent dietary pattern;
LGG	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10908458	0.808	rs11264322	chr1:155087933	G/A	cg13808842	chr1:155066096	NA	-0.31	-7.83	-0.34	3.42e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504073	0.584	rs62507177	chr8:49937306	C/A	cg00325661	chr8:49890786	NA	0.79	15.49	0.58	6.81e-44	Blood metabolite ratios;
LGG	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.42	0.4	2.21e-19	Diabetic retinopathy;
LGG	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg03343631	chr13:114764489	RASA3	-0.58	-8.02	-0.35	8.85e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7666738	0.606	rs28625338	chr4:99076996	A/G	cg05340658	chr4:99064831	C4orf37	0.43	6.93	0.31	1.41e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.74	0.34	6.09e-14	Electroencephalogram traits;
LGG	cis	rs4750440	0.702	rs4750445	chr10:14030314	C/T	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.7	-0.54	4.26e-36	Adiponectin levels;
LGG	cis	rs1375194	0.582	rs13388224	chr2:33802902	T/C	cg04131969	chr2:33951647	MYADML	-0.58	-10.18	-0.43	4.21e-22	Response to antidepressants in depression;
LGG	cis	rs6539288	0.513	rs7977247	chr12:107259470	T/C	cg15890332	chr12:107067104	RFX4	0.36	10.06	0.42	1.14e-21	Total body bone mineral density;
LGG	cis	rs490234	0.783	rs2416967	chr9:128440014	T/C	cg14078157	chr9:128172775	NA	-0.48	-8.42	-0.36	4.91e-16	Mean arterial pressure;
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg15268244	chr15:77196840	NA	-0.33	-7.26	-0.32	1.64e-12	Blood metabolite levels;
LGG	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27286337	chr10:134555280	INPP5A	0.84	12.09	0.49	2e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6835098	0.961	rs2877748	chr4:174102397	G/A	cg08422745	chr4:174089978	GALNT7	-0.84	-14.8	-0.57	7.38e-41	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.24e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.65	-0.37	8.38e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg09307838	chr4:120376055	NA	0.82	13.9	0.54	5.81e-37	Corneal astigmatism;
LGG	cis	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs2070488	0.965	rs3749386	chr3:38496065	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	19.64	0.67	6.28e-63	Electrocardiographic conduction measures;
LGG	cis	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg19847130	chr8:10466454	RP1L1	0.34	7.06	0.31	6.24e-12	Neuroticism;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg18485729	chr3:113774958	QTRTD1;KIAA1407	-0.38	-6.83	-0.3	2.64e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.42	-0.33	5.59e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg13880726	chr7:1868755	MAD1L1	-0.52	-9.31	-0.4	5e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10489202	0.632	rs202265	chr1:167990231	G/C	cg24449463	chr1:168025552	DCAF6	-0.6	-10.6	-0.44	1.24e-23	Schizophrenia;
LGG	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14373873	chr11:113211441	TTC12	0.41	8.5	0.37	2.72e-16	Neuroticism;
LGG	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg18478394	chr8:109455254	TTC35	0.47	9.34	0.4	4.01e-19	Dupuytren's disease;
LGG	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg05623727	chr3:50126028	RBM5	-0.4	-8.72	-0.38	4.88e-17	Body mass index;
LGG	cis	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg05084668	chr3:125655381	ALG1L	-0.89	-11.38	-0.47	1.28e-26	Blood pressure (smoking interaction);
LGG	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.5	-0.37	2.64e-16	Subjective well-being;
LGG	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-9.08	-0.39	3.12e-18	Diabetic retinopathy;
LGG	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7103648	0.695	rs11039290	chr11:47572279	G/A	cg20307385	chr11:47447363	PSMC3	0.87	18.47	0.65	1.85e-57	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg02153584	chr22:29168773	CCDC117	-0.6	-9.63	-0.41	4.11e-20	Lymphocyte counts;
LGG	cis	rs2710642	0.849	rs4671450	chr2:62981869	C/A	cg17519650	chr2:63277830	OTX1	-0.47	-7.49	-0.33	3.47e-13	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg19628046	chr18:33552617	C18orf21	0.53	7.72	0.34	7.13e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.91	-0.35	1.86e-14	Neuroticism;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.35	-0.47	1.72e-26	Neuroticism;
LGG	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg10840412	chr1:235813424	GNG4	0.54	7.51	0.33	3.11e-13	Bipolar disorder;
LGG	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	cis	rs2735413	0.881	rs12921945	chr16:78080133	G/T	cg04733911	chr16:78082701	NA	-0.78	-18.92	-0.66	1.52e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2072732	0.950	rs55775305	chr1:2975119	C/G	cg08733933	chr1:2954429	NA	-0.44	-8.16	-0.35	3.09e-15	Plateletcrit;
LGG	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	9.92	0.42	3.82e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9399135	1.000	rs4475342	chr6:135283348	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.44	0.4	1.9e-19	Red blood cell count;
LGG	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.48	-0.44	3.3e-23	Hip circumference adjusted for BMI;
LGG	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs2213920	0.516	rs13301972	chr9:118158086	C/T	cg13918206	chr9:118159781	DEC1	-0.77	-10.54	-0.44	2e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.25	-0.6	2.68e-47	Intelligence (multi-trait analysis);
LGG	cis	rs6028335	0.577	rs16987738	chr20:37625015	G/T	cg16355469	chr20:37678765	NA	-0.6	-8.04	-0.35	7.55e-15	Alcohol and nicotine co-dependence;
LGG	trans	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg01620082	chr3:125678407	NA	-0.68	-6.68	-0.3	6.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.24	0.32	1.87e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs701145	0.585	rs2060622	chr3:153833862	A/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	8.17	0.35	2.95e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg26384229	chr12:38710491	ALG10B	0.8	15.87	0.59	1.31e-45	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.67	-0.54	5.8e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg18854424	chr1:2615690	NA	-0.33	-6.78	-0.3	3.61e-11	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs13256369	0.511	rs7012395	chr8:8538009	T/C	cg02002194	chr4:3960332	NA	0.45	8.01	0.35	9.51e-15	Obesity-related traits;
LGG	cis	rs926938	0.584	rs360607	chr1:115392401	C/A	cg12756093	chr1:115239321	AMPD1	0.47	8.9	0.38	1.24e-17	Autism;
LGG	cis	rs185694	1.000	rs613291	chr13:30894404	T/C	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.67	-0.3	7.36e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg16141378	chr3:129829833	LOC729375	0.42	9.38	0.4	2.94e-19	Neuroticism;
LGG	cis	rs10982213	0.830	rs10982212	chr9:117187976	C/G	cg00969271	chr9:117093052	ORM2	0.42	7.41	0.33	6.09e-13	Interleukin-6 levels;
LGG	cis	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg24375607	chr4:120327624	NA	0.62	10.19	0.43	4.02e-22	Corneal astigmatism;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.27e-25	Obesity-related traits;
LGG	cis	rs12681287	0.605	rs2976181	chr8:87344470	C/T	cg27223183	chr8:87520930	FAM82B	-0.42	-6.67	-0.3	7.25e-11	Caudate activity during reward;
LGG	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.64e-20	Hypertriglyceridemia;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg17644776	chr2:200775616	C2orf69	0.58	7.29	0.32	1.39e-12	Schizophrenia;
LGG	cis	rs2976388	0.507	rs1036385	chr8:143842901	T/C	cg06565975	chr8:143823917	SLURP1	0.34	8.27	0.36	1.42e-15	Urinary tract infection frequency;
LGG	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.49	0.4	1.25e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg26446133	chr18:72167187	CNDP2	-0.69	-13.89	-0.54	6.76e-37	Refractive error;
LGG	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg00543991	chr22:32367038	NA	0.81	8.95	0.38	8.83e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.91	0.35	1.88e-14	Longevity;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.76	-0.34	5.31e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg07636037	chr3:49044803	WDR6	0.91	17.54	0.63	3.64e-53	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.92	0.59	7.65e-46	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.58	0.33	1.86e-13	Rheumatoid arthritis;
LGG	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg27572855	chr1:25598939	RHD	0.49	10.84	0.45	1.53e-24	Erythrocyte sedimentation rate;
LGG	cis	rs870825	0.616	rs10428373	chr4:185639002	A/G	cg21366198	chr4:185655624	MLF1IP	-0.77	-11.66	-0.48	1.04e-27	Blood protein levels;
LGG	cis	rs9834373	0.922	rs9816855	chr3:78505950	C/G	cg06138941	chr3:78371609	NA	-0.5	-8.86	-0.38	1.77e-17	Protein quantitative trait loci;
LGG	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg00543991	chr22:32367038	NA	0.8	8.81	0.38	2.57e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7017914	0.935	rs35564237	chr8:71600474	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg15627072	chr1:2432621	PLCH2	0.37	8.28	0.36	1.3e-15	Ulcerative colitis;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02018176	chr4:1364513	KIAA1530	0.65	15.36	0.58	2.49e-43	Longevity;
LGG	cis	rs28655083	0.956	rs4088757	chr16:77071545	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.49	7.78	0.34	4.81e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7770628	0.653	rs113525646	chr6:161119901	G/A	cg04181478	chr6:161122748	PLG	-0.42	-8.17	-0.36	2.9e-15	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11644478	chr21:40555479	PSMG1	0.65	10.84	0.45	1.47e-24	Cognitive function;
LGG	cis	rs2303319	1.000	rs2194726	chr2:162245832	C/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg08621203	chr6:150244597	RAET1G	-0.46	-6.93	-0.31	1.45e-11	Lung cancer;
LGG	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg13385521	chr17:29058706	SUZ12P	0.82	9.99	0.42	2.15e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs28588043	0.877	rs72710570	chr1:170985995	A/C	cg03458344	chr1:170964477	C1orf129	-0.55	-7.44	-0.33	4.85e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg21095983	chr6:86352623	SYNCRIP	-0.57	-10.53	-0.44	2.13e-23	Smooth-surface caries;
LGG	cis	rs10744422	0.925	rs3825143	chr12:123352179	C/T	cg25930673	chr12:123319894	HIP1R	-0.68	-8.67	-0.37	7.22e-17	Schizophrenia;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs1982963	1.000	rs753051	chr14:52505360	A/G	cg05884192	chr14:52515736	NID2	-0.34	-7.55	-0.33	2.34e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg09855544	chr8:135498122	ZFAT	0.45	7.65	0.34	1.17e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs11225247	0.772	rs11501343	chr11:102227214	A/C	cg06323957	chr11:102217781	BIRC2	0.8	7.53	0.33	2.69e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs12195424	0.730	rs77221194	chr6:56307243	A/T	cg07152817	chr6:56299822	NA	-0.99	-9.95	-0.42	2.82e-21	Cerebrospinal fluid clusterin levels;
LGG	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.76	0.3	4.22e-11	Parkinson's disease;
LGG	trans	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.86	13.05	0.52	2.25e-33	Exhaled nitric oxide output;
LGG	cis	rs4629180	1.000	rs4851457	chr2:102091220	C/T	cg16435561	chr2:102091048	RFX8	-0.41	-6.85	-0.3	2.36e-11	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs62344088	0.590	rs62329989	chr5:300141	A/G	cg09048205	chr5:1608656	LOC728613	-0.47	-7.9	-0.34	2.04e-14	Asthma (childhood onset);
LGG	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27370558	chr19:13397515	CACNA1A	0.36	6.71	0.3	5.77e-11	Electrocardiographic conduction measures;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs9783347	1.000	rs4150610	chr11:18364140	A/G	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.18	-0.32	2.72e-12	Pancreatic cancer;
LGG	cis	rs1419980	0.586	rs10845548	chr12:7777657	T/A	cg10578777	chr12:7781093	NA	-0.59	-7.95	-0.35	1.42e-14	HDL cholesterol levels;
LGG	cis	rs9443645	0.869	rs9343827	chr6:79501036	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.4	-0.36	5.56e-16	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.99	-0.39	6.44e-18	Mean corpuscular volume;
LGG	cis	rs7192750	0.562	rs4788573	chr16:71921946	A/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4917300	0.606	rs4917278	chr8:143095603	A/T	cg26003909	chr8:143102224	NA	0.34	6.79	0.3	3.35e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7590720	0.851	rs13006614	chr2:216876204	C/T	cg12620499	chr2:216877984	MREG	0.8	16.07	0.6	1.62e-46	Alcohol dependence;
LGG	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.62	-0.41	4.16e-20	Aortic root size;
LGG	cis	rs4731207	0.596	rs1525614	chr7:124658600	C/G	cg05630886	chr7:124431682	NA	-0.31	-7.3	-0.32	1.28e-12	Cutaneous malignant melanoma;
LGG	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs60180747	1.000	rs74397736	chr15:66701500	G/A	cg07575407	chr15:66541975	MEGF11	0.35	7.03	0.31	7.52e-12	Testicular germ cell tumor;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	16.45	0.61	3.11e-48	Platelet count;
LGG	cis	rs2180341	0.960	rs7766802	chr6:127709871	T/G	cg27446573	chr6:127587934	RNF146	1.13	22.04	0.72	4e-74	Breast cancer;
LGG	cis	rs7945718	0.563	rs4525215	chr11:12664830	T/C	cg25843174	chr11:12811716	TEAD1	0.32	6.79	0.3	3.53e-11	Educational attainment (years of education);
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13126279	chr21:47581558	C21orf56	-0.47	-8.21	-0.36	2.29e-15	Testicular germ cell tumor;
LGG	cis	rs9921222	0.521	rs78867928	chr16:368986	C/T	cg07915516	chr16:377344	AXIN1	0.27	6.73	0.3	5e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-14.16	-0.55	4.55e-38	Asthma;
LGG	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.75	-0.48	4.41e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	9.4	0.4	2.43e-19	Height;
LGG	cis	rs4293296	0.525	rs28619304	chr14:54823270	A/G	cg11186706	chr14:54815745	NA	0.58	8.06	0.35	6.74e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs28830936	0.510	rs2412640	chr15:42124082	C/T	cg17847044	chr15:42102381	MAPKBP1	0.77	24.97	0.76	8.53e-88	Diastolic blood pressure;
LGG	cis	rs283228	0.517	rs661064	chr6:101801581	C/T	cg02011392	chr6:101847541	GRIK2	0.52	7.23	0.32	2e-12	Coenzyme Q10 levels;
LGG	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg03060546	chr3:49711283	APEH	-0.63	-10.39	-0.43	7.01e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.26	0.32	1.69e-12	Hair morphology;
LGG	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg05973401	chr12:123451056	ABCB9	-0.45	-7.71	-0.34	7.64e-14	Platelet count;
LGG	cis	rs10936602	0.527	rs7628572	chr3:169539649	T/A	cg08193579	chr3:169529701	LRRC34	0.37	7.56	0.33	2.19e-13	Renal cell carcinoma;
LGG	cis	rs6912958	0.712	rs2307379	chr6:88366771	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.38	-0.36	6.62e-16	Monocyte percentage of white cells;
LGG	cis	rs765787	1.000	rs765787	chr15:45500047	C/T	cg25801113	chr15:45476975	SHF	0.68	10.2	0.43	3.69e-22	Uric acid levels;
LGG	trans	rs12517041	1.000	rs2356716	chr5:23308496	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg02002194	chr4:3960332	NA	0.38	6.95	0.31	1.21e-11	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.65	0.34	1.16e-13	Cannabis dependence symptom count;
LGG	cis	rs11676348	0.904	rs10804264	chr2:218955809	T/C	cg00012203	chr2:219082015	ARPC2	-0.5	-8.82	-0.38	2.29e-17	Ulcerative colitis;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.97	0.49	5.98e-29	Prudent dietary pattern;
LGG	cis	rs7193541	0.684	rs8062783	chr16:74691264	C/T	cg01733217	chr16:74700730	RFWD3	-1.1	-34.02	-0.85	5e-128	Multiple myeloma;
LGG	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg23840854	chr1:161414152	NA	-0.71	-8.64	-0.37	9.2e-17	Rheumatoid arthritis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16423265	chr20:60697137	LSM14B	0.64	7.22	0.32	2.13e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.47	-0.5	5.69e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs686320	0.667	rs2904976	chr11:65185387	G/A	cg17392047	chr11:65247138	NA	-0.56	-7.17	-0.32	2.92e-12	Hip circumference adjusted for BMI;
LGG	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.94	0.45	6.27e-25	Morning vs. evening chronotype;
LGG	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg06026331	chr20:60912101	LAMA5	0.62	10.84	0.45	1.5e-24	Colorectal cancer;
LGG	cis	rs896543	0.515	rs62189825	chr2:237494954	C/T	cg25295825	chr2:237489920	CXCR7	0.85	10.49	0.44	3.07e-23	Alcohol dependence (age at onset);
LGG	cis	rs72827839	0.846	rs72823591	chr17:46122628	C/T	cg02219949	chr17:45927392	SP6	0.54	8.1	0.35	4.93e-15	Ease of getting up in the morning;
LGG	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg18937875	chr11:14930189	NA	-0.47	-7.69	-0.34	9e-14	Vitamin D levels;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.58	9.63	0.41	3.95e-20	Obesity-related traits;
LGG	cis	rs12410462	0.591	rs2819508	chr1:227704184	G/A	cg23173402	chr1:227635558	NA	0.38	7.11	0.31	4.56e-12	Major depressive disorder;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg04503457	chr17:41445688	NA	-0.39	-8.97	-0.38	7.22e-18	Menopause (age at onset);
LGG	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg20848291	chr7:100343083	ZAN	-0.66	-9.64	-0.41	3.65e-20	Other erythrocyte phenotypes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04854107	chr15:38544003	SPRED1	0.46	7.43	0.33	5.23e-13	Cognitive performance;
LGG	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg11494091	chr17:61959527	GH2	-0.56	-9.5	-0.4	1.16e-19	Height;
LGG	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.6	-0.33	1.63e-13	Total cholesterol levels;
LGG	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs5769707	0.667	rs4824069	chr22:50030325	T/C	cg06623630	chr22:50017776	C22orf34	-0.5	-10.23	-0.43	2.71e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.92	0.35	1.77e-14	Iron status biomarkers;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.24	0.36	1.73e-15	Schizophrenia;
LGG	cis	rs597583	0.664	rs10892133	chr11:117383694	C/T	cg27161313	chr11:117392002	DSCAML1	-0.56	-8.75	-0.38	4.09e-17	Putamen volume;
LGG	cis	rs28588043	1.000	rs28432360	chr1:170961822	G/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.41	-0.33	6.14e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs526231	0.543	rs6880911	chr5:102307471	T/C	cg23492399	chr5:102201601	PAM	-0.62	-9.4	-0.4	2.61e-19	Primary biliary cholangitis;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.25e-11	Alzheimer's disease;
LGG	cis	rs9814567	1.000	rs6802654	chr3:134217072	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.26	-0.52	2.93e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg24110177	chr3:50126178	RBM5	0.56	9.56	0.41	7.22e-20	Menarche (age at onset);
LGG	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg21479132	chr6:26055353	NA	0.77	7.8	0.34	4.18e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1034435	0.755	rs9615336	chr22:48893090	G/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.74	-0.61	1.49e-49	Late-onset Alzheimer's disease;
LGG	cis	rs7555523	0.887	rs2251768	chr1:165738311	A/T	cg24409356	chr1:165738333	TMCO1	0.76	9.2	0.39	1.2e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.85	-0.3	2.32e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2652834	0.851	rs4774475	chr15:63407357	T/C	cg05507819	chr15:63340323	TPM1	0.5	7.07	0.31	5.67e-12	HDL cholesterol;
LGG	cis	rs11064837	0.504	rs11064846	chr12:120054151	T/C	cg25937854	chr12:120150414	CIT	-0.59	-10.39	-0.43	7.22e-23	Schizophrenia;
LGG	cis	rs6087990	1.000	rs1007123	chr20:31345840	G/A	cg13636640	chr20:31349939	DNMT3B	1.01	22.11	0.72	1.88e-74	Ulcerative colitis;
LGG	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-8.31	-0.36	1.1e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.57	0.33	2.04e-13	Cystic fibrosis severity;
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg19168338	chr16:4465731	CORO7	1.17	26.77	0.78	4.64e-96	Schizophrenia;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg15971980	chr6:150254442	NA	0.44	8.24	0.36	1.74e-15	Lung cancer;
LGG	cis	rs12580194	0.593	rs61957878	chr12:55716754	G/T	cg19537932	chr12:55886519	OR6C68	-0.56	-9.79	-0.41	1.05e-20	Cancer;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.66	12.13	0.49	1.41e-29	Obesity-related traits;
LGG	cis	rs910187	0.678	rs6018328	chr20:45813180	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-8.95	-0.38	8.36e-18	Migraine;
LGG	cis	rs72772090	0.539	rs116360011	chr5:96117797	T/C	cg00188032	chr5:96141721	ERAP1	0.54	7.19	0.32	2.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg19761014	chr17:28927070	LRRC37B2	0.67	7.82	0.34	3.62e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4731207	0.596	rs7799518	chr7:124575684	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.53	-0.59	4.55e-44	Rheumatoid arthritis;
LGG	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.55e-15	Coronary artery disease;
LGG	trans	rs6601327	0.665	rs12543369	chr8:9655915	C/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.96	-0.31	1.17e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg09845145	chr15:78292470	TBC1D2B	0.69	14.02	0.55	1.88e-37	Coronary artery disease or large artery stroke;
LGG	cis	rs8179	0.589	rs12154498	chr7:92223518	A/C	cg15732164	chr7:92237376	CDK6	0.64	8.37	0.36	6.88e-16	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg16141378	chr3:129829833	LOC729375	0.35	7.72	0.34	7.23e-14	Retinal vascular caliber;
LGG	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs2084898	1.000	rs73004764	chr11:120055326	C/G	cg13907859	chr11:120009124	TRIM29	0.87	11.36	0.47	1.45e-26	Stroke (pediatric);
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17554472	chr22:41940697	POLR3H	-0.5	-7.11	-0.31	4.43e-12	Vitiligo;
LGG	cis	rs3087591	0.553	rs2854334	chr17:29715500	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.04	0.49	3.23e-29	Hip circumference;
LGG	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg15557168	chr22:42548783	NA	0.41	8.9	0.38	1.28e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10214930	0.671	rs2391449	chr7:27685146	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.74	0.3	4.79e-11	Hypospadias;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.34	-0.36	8.62e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg24692254	chr21:30365293	RNF160	-0.65	-11.85	-0.48	1.72e-28	Pancreatic cancer;
LGG	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.66	0.34	1.09e-13	Rheumatoid arthritis;
LGG	cis	rs12908161	0.959	rs34784022	chr15:85231906	T/C	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.85e-12	Schizophrenia;
LGG	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11644478	chr21:40555479	PSMG1	-0.81	-14.0	-0.55	2.13e-37	Cognitive function;
LGG	cis	rs11150038	0.826	rs9926583	chr16:78087730	C/T	cg04733911	chr16:78082701	NA	-0.66	-9.39	-0.4	2.78e-19	Colorectal or endometrial cancer;
LGG	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg24675658	chr1:53192096	ZYG11B	0.66	13.84	0.54	1.08e-36	Monocyte count;
LGG	cis	rs11229555	0.874	rs11605683	chr11:58350794	T/A	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	9.25e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.28	0.36	1.38e-15	Coronary artery disease;
LGG	cis	rs11971779	0.715	rs6467856	chr7:139127299	A/C	cg07862535	chr7:139043722	LUC7L2	0.46	7.59	0.33	1.8e-13	Diisocyanate-induced asthma;
LGG	cis	rs239198	0.568	rs34555037	chr6:101327153	G/C	cg09795085	chr6:101329169	ASCC3	0.43	7.01	0.31	8.61e-12	Menarche (age at onset);
LGG	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg23625390	chr15:77176239	SCAPER	-0.65	-12.88	-0.51	1.15e-32	Blood metabolite levels;
LGG	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-7.73	-0.34	6.87e-14	Vitiligo;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg01169559	chr10:831247	NA	0.43	6.67	0.3	7.51e-11	Uric acid levels;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.63	0.54	8.58e-36	Lung cancer;
LGG	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg07395648	chr5:131743802	NA	-0.43	-9.14	-0.39	1.93e-18	Blood metabolite levels;
LGG	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg25319279	chr11:5960081	NA	-0.54	-8.63	-0.37	9.62e-17	DNA methylation (variation);
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.13	0.43	6.19e-22	Height;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg13206674	chr6:150067644	NUP43	0.43	7.3	0.32	1.26e-12	Lung cancer;
LGG	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg14598338	chr9:96623480	NA	-0.58	-10.9	-0.45	8.88e-25	DNA methylation (variation);
LGG	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-14.88	-0.57	3.34e-41	Colorectal cancer;
LGG	cis	rs2415984	0.505	rs1389607	chr14:46957922	T/C	cg14871534	chr14:47121158	RPL10L	0.55	9.69	0.41	2.38e-20	Number of children ever born;
LGG	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg03511173	chr18:77590860	NA	-0.56	-6.9	-0.31	1.68e-11	Opioid sensitivity;
LGG	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs870825	0.616	rs28666955	chr4:185631338	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.46	8.04	0.35	7.57e-15	IgG glycosylation;
LGG	cis	rs3767633	0.748	rs6667896	chr1:161837407	G/A	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg03929089	chr4:120376271	NA	-0.44	-7.11	-0.31	4.47e-12	HDL cholesterol;
LGG	cis	rs6489785	0.687	rs3213567	chr12:121222556	T/C	cg02419362	chr12:121203948	SPPL3	0.58	9.95	0.42	2.99e-21	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs752010	0.967	rs752011	chr1:42092929	C/T	cg06885757	chr1:42089581	HIVEP3	0.58	12.97	0.52	5.06e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs36093844	0.706	rs75334800	chr11:85586581	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.31	-0.5	2.47e-30	Resting heart rate;
LGG	cis	rs7215564	0.908	rs35542453	chr17:78687242	T/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.08	-0.35	5.84e-15	Myopia (pathological);
LGG	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg24189917	chr7:1970923	MAD1L1	-0.48	-7.25	-0.32	1.76e-12	Bipolar disorder;
LGG	cis	rs10504130	0.666	rs7834181	chr8:52873130	A/G	cg22653915	chr8:52722023	PXDNL	-0.48	-7.9	-0.34	2.09e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.18	-0.36	2.86e-15	Mood instability;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg02018176	chr4:1364513	KIAA1530	0.46	10.18	0.43	4.1e-22	Obesity-related traits;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg11878867	chr6:150167359	LRP11	-0.47	-9.3	-0.4	5.57e-19	Lung cancer;
LGG	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11987759	chr7:65425863	GUSB	-0.41	-7.82	-0.34	3.72e-14	Aortic root size;
LGG	cis	rs2063714	0.967	rs1012534	chr6:157209663	A/G	cg23222435	chr6:157204239	ARID1B	-0.64	-12.39	-0.5	1.15e-30	Sitting height ratio;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg16270222	chr17:41446396	NA	0.31	7.47	0.33	4.14e-13	Menopause (age at onset);
LGG	cis	rs7638995	0.878	rs7644952	chr3:69181064	C/G	cg26574240	chr3:69171822	LMOD3	-0.57	-9.02	-0.39	5.2e-18	Alzheimer's disease (late onset);
LGG	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg09165964	chr15:75287851	SCAMP5	0.58	10.3	0.43	1.59e-22	Caffeine consumption;
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.35	-8.38	-0.36	6.18e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs9815354	0.516	rs75047809	chr3:42033437	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.52	0.33	2.95e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg24851651	chr11:66362959	CCS	-0.35	-6.65	-0.3	8.36e-11	HIV-1 susceptibility;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg15971980	chr6:150254442	NA	-0.43	-7.01	-0.31	8.43e-12	Lung cancer;
LGG	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04380228	chr2:47142555	MCFD2	0.5	7.58	0.33	1.84e-13	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg03609598	chr5:56110824	MAP3K1	-0.52	-7.68	-0.34	9.46e-14	Initial pursuit acceleration;
LGG	cis	rs600550	0.618	rs1443250	chr11:60102790	G/A	cg05040360	chr11:60102449	MS4A6E	0.37	8.12	0.35	4.2e-15	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.37e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6976053	0.846	rs15624	chr7:100482026	T/C	cg03098644	chr7:100410630	EPHB4	-0.43	-7.59	-0.33	1.83e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.6	0.37	1.22e-16	Mood instability;
LGG	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg11693508	chr17:37793320	STARD3	0.49	7.43	0.33	5.13e-13	Bipolar disorder;
LGG	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg03701759	chr13:99174930	STK24	-0.36	-6.98	-0.31	1.04e-11	Longevity;
LGG	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.37e-50	Platelet distribution width;
LGG	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.2	0.62	1.3e-51	Chronic sinus infection;
LGG	cis	rs4742903	0.967	rs10125661	chr9:106868443	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.51	0.37	2.51e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg09699651	chr6:150184138	LRP11	0.52	9.23	0.39	9.49e-19	Lung cancer;
LGG	cis	rs17253792	0.822	rs2274075	chr14:56096731	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs6700896	0.500	rs11208707	chr1:66139513	C/T	cg04111102	chr1:66153794	NA	0.33	6.86	0.3	2.15e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05901451	chr6:126070800	HEY2	0.61	11.11	0.46	1.4e-25	Endometrial cancer;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg19847130	chr8:10466454	RP1L1	0.3	6.75	0.3	4.49e-11	Joint mobility (Beighton score);
LGG	cis	rs1371867	0.846	rs959022	chr8:101295992	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg07701084	chr6:150067640	NUP43	0.71	13.9	0.54	5.92e-37	Lung cancer;
LGG	cis	rs2710642	0.886	rs10153716	chr2:63007059	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-7.32	-0.32	1.14e-12	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg06916706	chr16:4465613	CORO7	-0.69	-11.7	-0.48	6.73e-28	Schizophrenia;
LGG	cis	rs6800768	0.633	rs826374	chr3:24163921	A/C	cg10674438	chr3:24145617	LOC152024	-0.51	-9.28	-0.4	6.67e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08267002	chr2:74741573	TLX2	0.44	7.25	0.32	1.73e-12	Gut microbiome composition (summer);
LGG	cis	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg06521331	chr12:34319734	NA	-0.4	-7.0	-0.31	8.97e-12	Morning vs. evening chronotype;
LGG	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs7737355	0.947	rs39600	chr5:130828649	A/T	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	7.04e-18	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14329685	chr9:72288179	APBA1	0.51	7.88	0.34	2.43e-14	Gut microbiome composition (summer);
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg26354017	chr1:205819088	PM20D1	0.86	20.62	0.69	1.62e-67	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.14	-0.31	3.68e-12	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg02297831	chr4:17616191	MED28	0.51	9.6	0.41	5.21e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg13902645	chr11:5959945	NA	0.71	10.95	0.45	5.73e-25	DNA methylation (variation);
LGG	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg06221963	chr1:154839813	KCNN3	0.39	7.74	0.34	6.49e-14	Prostate cancer;
LGG	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg08085267	chr17:45401833	C17orf57	-0.72	-14.46	-0.56	2.3e-39	Glaucoma (primary open-angle);
LGG	trans	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg13565492	chr6:43139072	SRF	-0.87	-14.62	-0.56	4.37e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10463554	0.927	rs34799	chr5:102426202	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg26384229	chr12:38710491	ALG10B	0.89	19.94	0.68	2.51e-64	Bladder cancer;
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg26150922	chr2:100937072	LONRF2	-0.61	-11.93	-0.48	8.93e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg11764359	chr7:65958608	NA	-0.73	-13.02	-0.52	3.13e-33	Aortic root size;
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17376030	chr22:41985996	PMM1	0.59	9.25	0.39	8.46e-19	Vitiligo;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.71	0.3	5.59e-11	Schizophrenia;
LGG	cis	rs4974559	0.947	rs6847321	chr4:1347374	C/T	cg02980000	chr4:1222292	CTBP1	0.68	9.15	0.39	1.87e-18	Systolic blood pressure;
LGG	cis	rs701145	0.585	rs1727879	chr3:153835819	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-11.63	-0.48	1.28e-27	Schizophrenia;
LGG	cis	rs11877825	0.826	rs8082984	chr18:10571904	C/T	cg25239095	chr18:10589360	NA	0.47	8.65	0.37	8.66e-17	Gut microbiota (bacterial taxa);
LGG	trans	rs9348739	1	rs9348739	chr6:26923099	G/C	cg01620082	chr3:125678407	NA	-0.61	-7.31	-0.32	1.18e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.9	0.31	1.71e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg15971980	chr6:150254442	NA	-0.46	-9.18	-0.39	1.41e-18	Testicular germ cell tumor;
LGG	cis	rs61884328	0.733	rs57012996	chr11:47194924	T/G	cg03339077	chr11:47165057	C11orf49	0.62	6.72	0.3	5.37e-11	Total body bone mineral density (age over 60);
LGG	cis	rs4973397	0.765	rs2290130	chr2:232263127	G/A	cg06574960	chr2:232265084	B3GNT7	0.38	6.88	0.3	1.94e-11	Anti-saccade response;
LGG	cis	rs7202877	0.706	rs247443	chr16:75465073	G/C	cg03315344	chr16:75512273	CHST6	-0.51	-6.98	-0.31	1.03e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg18379455	chr17:41446167	NA	-0.32	-7.27	-0.32	1.53e-12	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg09448879	chr15:79043637	NA	0.51	12.89	0.51	1.06e-32	Coronary artery disease or large artery stroke;
LGG	cis	rs8032158	1.000	rs12232351	chr15:56140995	T/A	cg02198044	chr15:56286336	NEDD4	-0.69	-11.88	-0.48	1.32e-28	Keloid;
LGG	cis	rs2028299	0.879	rs4932262	chr15:90439597	A/C	cg23731826	chr15:90371692	NA	0.35	7.84	0.34	3.08e-14	Type 2 diabetes;
LGG	cis	rs12472274	0.941	rs4663861	chr2:239105203	C/T	cg17459225	chr2:239074497	NA	0.8	13.26	0.52	2.96e-34	Phospholipid levels (plasma);
LGG	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.47	-0.33	4.13e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg04863758	chr4:1303710	MAEA	0.4	6.83	0.3	2.71e-11	Obesity-related traits;
LGG	cis	rs704	0.790	rs13469	chr17:26676135	C/T	cg10342447	chr17:26645325	TMEM97	-0.4	-7.45	-0.33	4.76e-13	Osteoprotegerin levels;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.03e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg13147721	chr7:65941812	NA	-0.83	-10.28	-0.43	1.76e-22	Diabetic kidney disease;
LGG	cis	rs6871536	1.000	rs2301713	chr5:131951996	C/T	cg04303330	chr5:131992430	IL13	-0.29	-6.86	-0.3	2.17e-11	Asthma (childhood onset);
LGG	cis	rs3741151	1.000	rs79778136	chr11:73041339	T/C	cg17517138	chr11:73019481	ARHGEF17	1.02	10.48	0.44	3.24e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07659893	chr17:61819838	STRADA	-0.41	-6.66	-0.3	8.02e-11	Prudent dietary pattern;
LGG	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	7.2	0.32	2.4e-12	Height;
LGG	cis	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs2594989	1.000	rs346081	chr3:11329085	A/G	cg01796438	chr3:11312864	ATG7	-0.61	-8.18	-0.36	2.83e-15	Circulating chemerin levels;
LGG	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg24812749	chr6:127587940	RNF146	0.94	15.77	0.59	3.71e-45	Breast cancer;
LGG	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg21775007	chr8:11205619	TDH	0.41	6.85	0.3	2.3e-11	Mood instability;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg06719900	chr11:109292894	C11orf87	0.44	8.3	0.36	1.16e-15	Schizophrenia;
LGG	trans	rs12517041	1.000	rs16892316	chr5:23282819	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21803417	chr5:7868887	MTRR;FASTKD3	0.42	7.08	0.31	5.46e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.95	0.42	2.85e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg06968155	chr5:131705112	SLC22A5	0.68	7.81	0.34	3.99e-14	Rheumatoid arthritis;
LGG	trans	rs9354308	0.764	rs1938108	chr6:66570993	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs10463554	0.927	rs257306	chr5:102417474	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07659893	chr17:61819838	STRADA	-0.5	-8.46	-0.37	3.57e-16	Prudent dietary pattern;
LGG	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	17.05	0.62	5.89e-51	Smoking behavior;
LGG	cis	rs4700695	0.686	rs251710	chr5:65347357	G/C	cg21114390	chr5:65439923	SFRS12	0.58	7.04	0.31	7.18e-12	Facial morphology (factor 19);
LGG	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg21366198	chr4:185655624	MLF1IP	0.44	7.57	0.33	1.98e-13	Kawasaki disease;
LGG	cis	rs7000551	0.751	rs2461490	chr8:22370115	G/C	cg12081754	chr8:22256438	SLC39A14	0.69	13.41	0.53	7.27e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.39	-0.47	1.13e-26	Resting heart rate;
LGG	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.53	-0.33	2.68e-13	Retinal vascular caliber;
LGG	cis	rs926392	1.000	rs2867898	chr20:37690952	G/A	cg16355469	chr20:37678765	NA	0.42	6.91	0.31	1.58e-11	Dialysis-related mortality;
LGG	cis	rs889312	0.500	rs3099460	chr5:56133748	G/C	cg14703610	chr5:56206110	C5orf35	0.4	6.97	0.31	1.11e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs367615	0.918	rs10067984	chr5:108872684	C/T	cg17395555	chr5:108820864	NA	0.66	9.35	0.4	3.66e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7202877	0.706	rs247437	chr16:75431275	T/G	cg03315344	chr16:75512273	CHST6	-0.52	-7.26	-0.32	1.64e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs6456156	0.792	rs10946212	chr6:167515947	C/G	cg07741184	chr6:167504864	NA	0.39	8.77	0.38	3.35e-17	Primary biliary cholangitis;
LGG	cis	rs72781680	0.898	rs56315094	chr2:23941952	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.13e-18	Lymphocyte counts;
LGG	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.63	0.41	3.84e-20	Fuchs's corneal dystrophy;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg19884546	chr22:38082237	NOL12	0.48	7.09	0.31	5.11e-12	Breast cancer;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20887711	chr4:1340912	KIAA1530	0.94	21.33	0.7	8.07e-71	Longevity;
LGG	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs258892	0.846	rs266441	chr5:72197677	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.11e-11	Small cell lung carcinoma;
LGG	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg10845886	chr2:3471009	TTC15	-0.48	-9.47	-0.4	1.41e-19	Neurofibrillary tangles;
LGG	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.01	0.31	8.34e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg23782820	chr8:58130467	NA	0.43	6.64	0.3	8.62e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg12623918	chr2:306882	NA	0.38	7.12	0.31	4.09e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12477438	0.520	rs2309604	chr2:100090098	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	9.91	0.42	3.88e-21	Prudent dietary pattern;
LGG	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.47	-0.33	4.13e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.83	0.3	2.64e-11	Schizophrenia;
LGG	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11644478	chr21:40555479	PSMG1	0.93	17.71	0.64	6.02e-54	Cognitive function;
LGG	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.75	0.3	4.32e-11	Parkinson's disease;
LGG	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.51	-0.63	5e-53	Chronic sinus infection;
LGG	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.78	0.3	3.56e-11	Bipolar disorder;
LGG	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg04568710	chr12:38710424	ALG10B	0.35	6.97	0.31	1.08e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6554196	0.508	rs3819393	chr4:55526615	C/T	cg18836493	chr4:55524333	KIT	-0.44	-8.14	-0.35	3.62e-15	Monocyte count;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.8	-0.3	3.18e-11	Lung cancer;
LGG	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg02493740	chr2:85810744	VAMP5	-0.41	-7.39	-0.32	6.8e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs16976116	0.901	rs62020114	chr15:55501116	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg12773197	chr13:112238673	NA	-0.37	-7.61	-0.33	1.59e-13	Hepatitis;
LGG	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg27205649	chr11:78285834	NARS2	0.49	8.54	0.37	1.96e-16	Alzheimer's disease (survival time);
LGG	cis	rs6546550	0.901	rs4144081	chr2:70155482	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.02	-0.35	9e-15	Prevalent atrial fibrillation;
LGG	cis	rs362296	0.661	rs3121420	chr4:3264210	T/C	cg06533319	chr4:3265114	C4orf44	0.52	10.81	0.45	1.92e-24	Parental longevity (mother's age at death);
LGG	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22496380	chr5:211416	CCDC127	-1.23	-17.54	-0.63	3.54e-53	Breast cancer;
LGG	cis	rs735860	0.763	rs6458912	chr6:53147965	G/A	cg10236188	chr6:53219634	NA	-0.38	-7.52	-0.33	2.79e-13	Glaucoma;
LGG	cis	rs283228	0.570	rs546176	chr6:101720791	T/C	cg27451362	chr6:101846650	GRIK2	0.92	13.13	0.52	1.1e-33	Coenzyme Q10 levels;
LGG	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg07148914	chr20:33460835	GGT7	0.55	9.17	0.39	1.52e-18	Height;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg26318627	chr11:63887540	MACROD1	-0.47	-6.8	-0.3	3.22e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg26384229	chr12:38710491	ALG10B	1.07	28.86	0.8	1.57e-105	Heart rate;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1045714	0.895	rs4721866	chr7:2643341	G/A	cg14042143	chr7:2646782	IQCE	0.81	12.44	0.5	7.82e-31	Urate levels in lean individuals;
LGG	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg25358565	chr5:93447407	FAM172A	1.3	16.03	0.6	2.54e-46	Diabetic retinopathy;
LGG	cis	rs7927771	0.793	rs12803525	chr11:47413475	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.51	-0.44	2.53e-23	Subjective well-being;
LGG	cis	rs67133203	0.579	rs1984544	chr12:51535910	C/T	cg14688905	chr12:51403056	SLC11A2	-0.61	-10.16	-0.43	5.07e-22	Urinary tract infection frequency;
LGG	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.37	0.43	8.52e-23	Lung cancer in ever smokers;
LGG	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg03433033	chr1:76189801	ACADM	0.82	14.17	0.55	3.87e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg17809284	chr5:56205270	C5orf35	0.54	9.02	0.39	5.12e-18	Initial pursuit acceleration;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03183872	chr20:3140552	FASTKD5;UBOX5	0.39	7.02	0.31	8.04e-12	Obesity-related traits;
LGG	cis	rs503734	0.871	rs11706439	chr3:100928788	C/A	cg27318481	chr3:100970896	IMPG2	-0.38	-8.11	-0.35	4.61e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg08355456	chr11:67383691	NA	0.48	8.23	0.36	1.88e-15	Mean corpuscular volume;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.14	-0.46	1.09e-25	Obesity-related traits;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.87	0.48	1.47e-28	Lymphocyte counts;
LGG	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg11846333	chr4:119757529	SEC24D	0.83	7.79	0.34	4.45e-14	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-8.82	-0.38	2.37e-17	Lung cancer;
LGG	cis	rs1707322	0.752	rs6678444	chr1:46229847	A/G	cg03146154	chr1:46216737	IPP	0.58	10.59	0.44	1.27e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg07930552	chr6:133119739	C6orf192	0.77	8.51	0.37	2.49e-16	Type 2 diabetes nephropathy;
LGG	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg06640241	chr16:89574553	SPG7	0.67	11.45	0.47	6.65e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs2033732	0.706	rs12679039	chr8:85064095	G/A	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.48	0.33	3.71e-13	Schizophrenia;
LGG	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg03517284	chr6:25882590	NA	-0.43	-6.93	-0.31	1.42e-11	Iron status biomarkers;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs6867032	0.839	rs4314451	chr5:2001859	T/C	cg26168224	chr5:2018326	NA	-1.12	-20.38	-0.69	2.35e-66	Gut microbiome composition (winter);
LGG	trans	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg02002194	chr4:3960332	NA	0.51	8.14	0.35	3.8e-15	Myopia (pathological);
LGG	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg04025307	chr7:1156635	C7orf50	0.86	18.1	0.64	9.1e-56	Longevity;Endometriosis;
LGG	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg23173402	chr1:227635558	NA	0.63	10.42	0.44	5.76e-23	Major depressive disorder;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.73e-13	Rheumatoid arthritis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18481087	chr3:160474064	PPM1L	0.4	6.87	0.3	2.05e-11	Bipolar disorder;
LGG	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg13010199	chr12:38710504	ALG10B	0.36	6.81	0.3	3.06e-11	Morning vs. evening chronotype;
LGG	cis	rs55788414	0.932	rs7185658	chr16:81189336	A/G	cg06400318	chr16:81190750	PKD1L2	-1.07	-12.17	-0.49	9.51e-30	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg12463550	chr7:65579703	CRCP	0.5	8.69	0.37	6.36e-17	Aortic root size;
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00149659	chr3:10157352	C3orf10	1.14	12.6	0.51	1.61e-31	Alzheimer's disease;
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg23034840	chr1:205782522	SLC41A1	0.46	7.48	0.33	3.69e-13	Menarche (age at onset);
LGG	cis	rs28830936	0.966	rs3179542	chr15:42118123	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.23	-0.52	4.04e-34	Diastolic blood pressure;
LGG	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg04455712	chr21:45112962	RRP1B	0.51	9.65	0.41	3.38e-20	Mean corpuscular volume;
LGG	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-11.43	-0.47	7.72e-27	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.44	-6.92	-0.31	1.52e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg00383909	chr3:49044727	WDR6	0.44	7.27	0.32	1.51e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.72e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.21	-0.55	2.78e-38	Type 2 diabetes;
LGG	cis	rs1697139	0.528	rs7725332	chr5:66529458	T/C	cg11553311	chr5:66541588	NA	0.53	11.96	0.49	6.66e-29	Breast cancer;
LGG	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs60180747	1.000	rs11071896	chr15:66821250	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	11.06	0.46	2.09e-25	Testicular germ cell tumor;
LGG	cis	rs12731740	0.908	rs12568382	chr1:207966393	C/T	cg22525895	chr1:207977042	MIR29B2	-0.58	-6.9	-0.31	1.77e-11	Biomedical quantitative traits;
LGG	cis	rs2652822	0.967	rs4775633	chr15:63437746	G/A	cg02713581	chr15:63449717	RPS27L	0.49	8.4	0.36	5.4e-16	Metabolic traits;
LGG	cis	rs1497828	0.956	rs2818975	chr1:217550732	T/G	cg04411442	chr1:217543379	NA	0.47	7.96	0.35	1.3e-14	Dialysis-related mortality;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.65	0.54	6.57e-36	Lung cancer;
LGG	cis	rs6807915	0.603	rs7611617	chr3:12289142	C/T	cg22839075	chr3:12045461	SYN2	-0.4	-6.82	-0.3	2.78e-11	Leprosy;
LGG	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.76	0.54	2.31e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg23173402	chr1:227635558	NA	0.56	8.85	0.38	1.89e-17	Major depressive disorder;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg06026331	chr20:60912101	LAMA5	0.46	8.51	0.37	2.52e-16	Colorectal cancer;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	cis	rs727505	0.866	rs66650870	chr7:124713194	T/C	cg23710748	chr7:124431027	NA	-0.49	-9.19	-0.39	1.36e-18	Lewy body disease;
LGG	cis	rs975739	0.872	rs1279659	chr13:78369995	G/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.79	0.3	3.54e-11	Hair color;
LGG	cis	rs6708331	0.941	rs10173259	chr2:70367210	C/T	cg01613454	chr2:70366299	NA	0.51	9.04	0.39	4.4e-18	Obesity-related traits;
LGG	cis	rs7940866	0.801	rs10894300	chr11:130845943	A/G	cg12179176	chr11:130786555	SNX19	0.72	13.42	0.53	6.51e-35	Schizophrenia;
LGG	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.69	14.42	0.56	3.49e-39	Lymphocyte percentage of white cells;
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg11859384	chr17:80120422	CCDC57	0.45	7.88	0.34	2.4e-14	Life satisfaction;
LGG	cis	rs7241530	0.585	rs35569163	chr18:75890441	T/C	cg14642773	chr18:75888474	NA	0.46	8.98	0.39	7.05e-18	Educational attainment (years of education);
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg06558623	chr16:89946397	TCF25	1.07	12.68	0.51	7.95e-32	Skin colour saturation;
LGG	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs9399135	0.967	rs11755229	chr6:135369913	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg22732515	chr19:44031385	ETHE1	0.55	9.5	0.4	1.16e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs4704846	0.614	rs6555828	chr5:156493740	C/T	cg12943317	chr5:156479607	HAVCR1	-0.6	-8.11	-0.35	4.71e-15	Blood protein levels;
LGG	cis	rs7937612	0.965	rs12420378	chr11:120250699	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.81	-0.51	2.38e-32	Intraocular pressure;
LGG	cis	rs2235649	1.000	rs11643434	chr16:1838375	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.7	-0.3	6.19e-11	Blood metabolite levels;
LGG	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg11812906	chr14:75593930	NEK9	-0.51	-9.31	-0.4	5.14e-19	Height;
LGG	trans	rs2018683	0.834	rs733485	chr7:29026685	C/A	cg19402173	chr7:128379420	CALU	-0.66	-12.12	-0.49	1.53e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs4774899	0.966	rs11071305	chr15:57371178	A/G	cg08128148	chr15:57256372	TCF12	-0.33	-7.73	-0.34	6.94e-14	Urinary tract infection frequency;
LGG	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg03701759	chr13:99174930	STK24	-0.36	-6.97	-0.31	1.09e-11	Longevity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12460105	chr5:68665773	RAD17;TAF9	0.4	6.65	0.3	8.24e-11	Cognitive performance;
LGG	cis	rs2133450	0.745	rs7639597	chr3:7364047	T/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.2	-0.36	2.46e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs13314892	0.734	rs79366329	chr3:69854698	G/A	cg17445875	chr3:69859618	MITF	-0.39	-7.24	-0.32	1.91e-12	QRS complex (12-leadsum);
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg01657329	chr11:68192670	LRP5	0.6	10.59	0.44	1.29e-23	Bone mineral density (spine);
LGG	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg09754948	chr16:28834200	ATXN2L	0.45	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.39	-0.32	7.13e-13	Body mass index;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg09038676	chr11:67351608	GSTP1	-0.36	-7.18	-0.32	2.72e-12	Mean corpuscular volume;
LGG	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs6500395	0.584	rs1592570	chr16:48742466	G/A	cg16662043	chr16:48846231	NA	0.47	8.32	0.36	1.03e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.96e-21	Tonsillectomy;
LGG	cis	rs7584330	0.737	rs12469894	chr2:238365528	T/C	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg05182265	chr7:156933206	UBE3C	0.37	7.49	0.33	3.48e-13	Body mass index;
LGG	cis	rs9682041	0.668	rs6784631	chr3:170100476	T/C	cg11886554	chr3:170076028	SKIL	1.07	12.35	0.5	1.7e-30	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.66	-0.54	6.27e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg20913747	chr6:44695427	NA	-0.6	-10.22	-0.43	3.01e-22	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg01879757	chr17:41196368	BRCA1	-0.4	-8.09	-0.35	5.29e-15	Menopause (age at onset);
LGG	cis	rs10779751	0.960	rs4845860	chr1:11324193	A/G	cg08854313	chr1:11322531	MTOR	0.77	16.64	0.61	4.29e-49	Body mass index;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs7584330	0.744	rs10929234	chr2:238380034	C/G	cg16989719	chr2:238392110	NA	0.35	6.9	0.31	1.72e-11	Prostate cancer;
LGG	cis	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg00806126	chr19:22604979	ZNF98	0.64	9.56	0.41	7.05e-20	Pain;
LGG	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg17054900	chr3:154042577	DHX36	0.52	7.72	0.34	7.2e-14	Coronary artery disease;
LGG	cis	rs7932354	0.655	rs6485690	chr11:46798631	A/G	cg03339077	chr11:47165057	C11orf49	-0.43	-7.79	-0.34	4.55e-14	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs4948496	0.840	rs56140430	chr10:63806563	C/A	cg16389209	chr10:63809121	ARID5B	0.36	6.95	0.31	1.22e-11	Systemic lupus erythematosus;
LGG	cis	rs6840360	0.533	rs4696295	chr4:152717430	T/C	cg22705602	chr4:152727874	NA	0.37	9.01	0.39	5.63e-18	Intelligence (multi-trait analysis);
LGG	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.59e-14	Psoriasis;
LGG	trans	rs9929218	1.000	rs28660361	chr16:68800838	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.81	-0.51	2.22e-32	Colorectal cancer;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.91e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12886676	chr2:99224936	C2orf64;UNC50	0.37	6.66	0.3	7.87e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16925090	chr11:101785516	KIAA1377;ANGPTL5	0.43	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs1152591	1.000	rs2738413	chr14:64679960	A/G	cg23250157	chr14:64679961	SYNE2	0.46	8.86	0.38	1.67e-17	Atrial fibrillation;
LGG	cis	rs17604090	1.000	rs28420551	chr7:29685353	G/A	cg19413766	chr7:29689036	LOC646762	-0.63	-7.96	-0.35	1.32e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs28456	1	rs28456	chr11:61589481	A/G	cg19610905	chr11:61596333	FADS2	-0.75	-12.79	-0.51	2.63e-32	Bipolar disorder;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg14196790	chr5:131705035	SLC22A5	0.6	7.49	0.33	3.56e-13	Rheumatoid arthritis;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg02002194	chr4:3960332	NA	0.54	10.29	0.43	1.66e-22	Triglycerides;
LGG	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.29	0.32	1.36e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02743256	chr7:2109353	MAD1L1	-0.38	-6.89	-0.3	1.85e-11	Neuroticism;
LGG	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.79	0.38	3e-17	Schizophrenia;
LGG	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.3	0.36	1.15e-15	Aortic root size;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-15.97	-0.6	4.85e-46	Longevity;Endometriosis;
LGG	trans	rs7777677	0.925	rs6956269	chr7:142369136	T/G	cg18540325	chr9:33795118	PRSS3	-0.43	-7.29	-0.32	1.33e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg08603382	chr10:743973	NA	-0.62	-11.65	-0.48	1.12e-27	Psychosis in Alzheimer's disease;
LGG	cis	rs10779751	0.770	rs12097293	chr1:11197467	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-14.42	-0.56	3.22e-39	Body mass index;
LGG	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg06219351	chr7:158114137	PTPRN2	0.7	13.85	0.54	9.56e-37	Calcium levels;
LGG	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg02574844	chr11:5959923	NA	-0.57	-9.56	-0.41	6.71e-20	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10049880	chr9:130213948	LRSAM1;RPL12	0.41	6.86	0.3	2.19e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs13128441	0.528	rs4689200	chr4:5189645	G/A	cg26099876	chr8:141644609	EIF2C2	-0.57	-9.21	-0.39	1.16e-18	Celiac disease;
LGG	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.23	-0.32	1.97e-12	Colorectal cancer;
LGG	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs714031	0.934	rs2235342	chr22:40068853	T/C	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.54	-0.56	1.05e-39	Schizophrenia;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07132326	chr6:150258058	NA	0.38	8.08	0.35	5.55e-15	Testicular germ cell tumor;
LGG	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.25	-0.32	1.72e-12	Monocyte count;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg05368731	chr17:41323189	NBR1	-0.93	-18.66	-0.66	2.26e-58	Menopause (age at onset);
LGG	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg01152986	chr16:58549298	SETD6	0.84	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg00495681	chr13:53174319	NA	-0.75	-15.33	-0.58	3.57e-43	Lewy body disease;
LGG	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg18252515	chr7:66147081	NA	-0.75	-11.93	-0.48	8.4e-29	Corneal structure;
LGG	cis	rs9815354	0.680	rs115754309	chr3:42017246	A/G	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.07	0.31	5.86e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg01145232	chr6:150245071	RAET1G	-0.47	-8.73	-0.38	4.76e-17	Lung cancer;
LGG	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.54	-0.37	2.01e-16	Diabetic retinopathy;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg14338887	chr6:42928500	GNMT	0.26	8.54	0.37	1.89e-16	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg26384229	chr12:38710491	ALG10B	0.98	22.0	0.71	6.02e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs584438	0.837	rs35103116	chr17:38594806	C/T	cg09358481	chr17:38600305	IGFBP4	-0.46	-8.78	-0.38	3.12e-17	Height;
LGG	cis	rs9354308	0.727	rs9453466	chr6:66590654	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg27102117	chr16:15229624	NA	0.62	12.04	0.49	2.98e-29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.17	-0.43	4.63e-22	Neuroticism;
LGG	trans	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg17712092	chr4:129076599	LARP1B	0.55	9.18	0.39	1.44e-18	Breast cancer;
LGG	trans	rs2562456	0.833	rs62110416	chr19:21584726	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.75	-0.34	5.85e-14	Pain;
LGG	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg25237894	chr2:233734115	C2orf82	0.65	12.34	0.5	1.99e-30	Coronary artery disease;
LGG	cis	rs6815814	0.950	rs114719937	chr4:38808585	G/C	cg06935464	chr4:38784597	TLR10	0.6	8.31	0.36	1.08e-15	Breast cancer;
LGG	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	trans	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.92	-0.38	1.1e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg14541582	chr5:601475	NA	-0.71	-10.94	-0.45	6.18e-25	Obesity-related traits;
LGG	cis	rs638893	0.588	rs2508929	chr11:118641451	G/T	cg13782932	chr11:118662891	DDX6	0.37	6.8	0.3	3.25e-11	Vitiligo;
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.6	7.2	0.32	2.49e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs6565180	1.000	rs11646130	chr16:30376959	T/C	cg17640201	chr16:30407289	ZNF48	-0.86	-16.57	-0.61	9.4e-49	Tonsillectomy;
LGG	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg05313129	chr8:58192883	C8orf71	-0.46	-6.97	-0.31	1.11e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6764363	0.504	rs58516654	chr3:283267	G/T	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.83e-13	Sudden cardiac arrest;
LGG	cis	rs3750082	0.582	rs3750079	chr7:32969419	G/A	cg08946731	chr7:32981826	RP9P	0.54	8.67	0.37	7.18e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13732083	chr21:47605072	C21orf56	-0.53	-8.59	-0.37	1.31e-16	Testicular germ cell tumor;
LGG	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg20587970	chr11:113659929	NA	-1.4	-24.77	-0.75	7.12e-87	Hip circumference adjusted for BMI;
LGG	cis	rs975739	1.000	rs1766345	chr13:78387125	G/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs722599	0.748	rs55707505	chr14:75362552	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.63	-10.51	-0.44	2.55e-23	IgG glycosylation;
LGG	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg27523141	chr10:43048294	ZNF37B	0.38	7.48	0.33	3.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17030434	1.000	rs6853522	chr4:154706220	A/C	cg14289246	chr4:154710475	SFRP2	0.75	11.92	0.48	9.16e-29	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg15971980	chr6:150254442	NA	0.45	8.29	0.36	1.26e-15	Lung cancer;
LGG	cis	rs7917772	0.582	rs4919661	chr10:104358403	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.39e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.69	0.34	8.65e-14	Glycated hemoglobin levels;
LGG	cis	rs4865875	0.901	rs10045175	chr5:54120524	A/G	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs6450176	0.564	rs391470	chr5:53332338	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.23	-0.46	5e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9915657	0.595	rs10438697	chr17:70055734	A/G	cg09344028	chr17:70110421	NA	-0.54	-11.41	-0.47	9.34e-27	Thyroid hormone levels;
LGG	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg02002194	chr4:3960332	NA	-0.5	-10.14	-0.43	5.7e-22	Mood instability;
LGG	cis	rs920590	0.704	rs3866469	chr8:19658534	T/C	cg03894339	chr8:19674705	INTS10	0.45	7.69	0.34	8.85e-14	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg23782820	chr8:58130467	NA	0.43	6.67	0.3	7.15e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.547	rs338520	chr15:86214798	A/G	cg25843651	chr15:86329602	KLHL25	-0.54	-9.26	-0.4	7.95e-19	Idiopathic pulmonary fibrosis;
LGG	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg15704280	chr7:45808275	SEPT13	0.49	7.98	0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs77669868	0.810	rs11602830	chr11:114074286	C/A	cg01914181	chr11:114070210	ZBTB16	0.71	9.08	0.39	3.04e-18	Monocyte percentage of white cells;
LGG	trans	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg25214090	chr10:38739885	LOC399744	0.64	11.58	0.47	2.06e-27	Corneal astigmatism;
LGG	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.65	-0.41	3.47e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg15268244	chr15:77196840	NA	-0.34	-7.51	-0.33	3.02e-13	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg05368731	chr17:41323189	NBR1	0.97	18.97	0.66	8.96e-60	Menopause (age at onset);
LGG	trans	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg24247370	chr13:99142703	STK24	-0.38	-6.98	-0.31	1.04e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg26031613	chr14:104095156	KLC1	1.13	26.38	0.77	2.6e-94	Body mass index;
LGG	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg18105134	chr13:113819100	PROZ	-0.79	-13.87	-0.54	7.58e-37	Platelet distribution width;
LGG	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg26384229	chr12:38710491	ALG10B	0.74	14.96	0.57	1.46e-41	Morning vs. evening chronotype;
LGG	cis	rs6942756	1.000	rs12111832	chr7:128889025	G/C	cg02491457	chr7:128862824	NA	-0.77	-14.12	-0.55	6.64e-38	White matter hyperintensity burden;
LGG	cis	rs8051149	0.625	rs74039983	chr16:87882539	A/G	cg02614661	chr16:87878292	SLC7A5	-0.37	-7.03	-0.31	7.3e-12	Blood metabolite levels;
LGG	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.54	-0.37	1.94e-16	Initial pursuit acceleration;
LGG	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg04398451	chr17:18023971	MYO15A	-0.73	-14.83	-0.57	5.65e-41	Total body bone mineral density;
LGG	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs2073300	0.609	rs3827085	chr20:23356985	A/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17376030	chr22:41985996	PMM1	0.55	8.8	0.38	2.69e-17	Vitiligo;
LGG	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg00204512	chr16:28754710	NA	-0.26	-6.99	-0.31	9.73e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg27523141	chr10:43048294	ZNF37B	0.38	7.47	0.33	4.07e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg12856521	chr11:46389249	DGKZ	0.52	9.19	0.39	1.29e-18	Leprosy;
LGG	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg06606381	chr12:133084897	FBRSL1	-0.98	-10.21	-0.43	3.2e-22	Depression;
LGG	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg12458913	chr13:53173898	NA	-0.46	-7.83	-0.34	3.32e-14	Lewy body disease;
LGG	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs7666738	0.830	rs17558193	chr4:99049593	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10267417	0.603	rs4593428	chr7:19864061	T/A	cg05791153	chr7:19748676	TWISTNB	0.56	7.26	0.32	1.61e-12	Night sleep phenotypes;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg07414643	chr4:187882934	NA	0.52	10.8	0.45	2.15e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4846580	0.660	rs1338235	chr1:219906224	G/C	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	trans	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg02002194	chr4:3960332	NA	-0.57	-11.61	-0.47	1.62e-27	Neuroticism;
LGG	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg24232236	chr22:38142998	TRIOBP	0.37	7.23	0.32	2.05e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg24375607	chr4:120327624	NA	0.58	9.59	0.41	5.7e-20	Corneal astigmatism;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg27189623	chr16:705930	WDR90	0.4	7.62	0.33	1.44e-13	Height;
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.42	0.36	4.76e-16	Bipolar disorder;
LGG	cis	rs6540556	0.723	rs7539852	chr1:209898539	A/G	cg23920097	chr1:209922102	NA	-0.41	-6.7	-0.3	6.13e-11	Red blood cell count;
LGG	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg15103426	chr22:29168792	CCDC117	0.73	11.82	0.48	2.29e-28	Lymphocyte counts;
LGG	cis	rs9649465	0.905	rs3757504	chr7:123391750	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.72	-0.38	5.04e-17	Migraine;
LGG	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg10523679	chr1:76189770	ACADM	-0.73	-11.49	-0.47	4.89e-27	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8077889	0.703	rs231534	chr17:41945564	C/T	cg26893861	chr17:41843967	DUSP3	-0.72	-10.32	-0.43	1.33e-22	Triglycerides;
LGG	cis	rs7539542	0.556	rs6662413	chr1:202888496	C/T	cg19681188	chr1:202830198	LOC148709	-0.51	-8.48	-0.37	3.11e-16	Mean platelet volume;
LGG	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg19500275	chr17:80737654	TBCD	0.48	6.87	0.3	2.05e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs28588043	0.877	rs16863948	chr1:170992100	G/A	cg03458344	chr1:170964477	C1orf129	-0.5	-6.97	-0.31	1.12e-11	Number of children (6+ vs. 0 or 1);
LGG	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg20587970	chr11:113659929	NA	-1.21	-21.75	-0.71	8.76e-73	Hip circumference adjusted for BMI;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg02002194	chr4:3960332	NA	0.54	10.45	0.44	4.42e-23	Triglycerides;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs4774830	0.744	rs62046394	chr15:56316356	C/A	cg24530489	chr15:56299380	NA	-0.86	-7.72	-0.34	7.4e-14	Delta-5 desaturase activity;
LGG	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg16141378	chr3:129829833	LOC729375	0.38	8.35	0.36	7.72e-16	Neuroticism;
LGG	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.5	0.33	3.24e-13	Joint mobility (Beighton score);
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg11050988	chr7:1952600	MAD1L1	-0.39	-9.37	-0.4	3.33e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg20608306	chr11:116969690	SIK3	0.41	13.19	0.52	6.08e-34	Blood protein levels;
LGG	trans	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg20290983	chr6:43655470	MRPS18A	0.97	15.68	0.59	9.22e-45	IgG glycosylation;
LGG	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.01	-0.35	9.35e-15	Calcium levels;
LGG	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg10326726	chr10:51549505	MSMB	-0.69	-14.65	-0.56	3.36e-40	Prostate-specific antigen levels;
LGG	cis	rs9355814	0.539	rs13202636	chr6:161029728	A/G	cg04181478	chr6:161122748	PLG	0.44	7.3	0.32	1.23e-12	Lipoprotein (a) levels;
LGG	cis	rs3008870	1.000	rs2755245	chr1:67487964	C/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	21.49	0.71	1.38e-71	Lymphocyte percentage of white cells;
LGG	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg10523679	chr1:76189770	ACADM	0.72	10.78	0.45	2.43e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.17	-0.32	2.98e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg13147721	chr7:65941812	NA	0.84	10.16	0.43	4.94e-22	Diabetic kidney disease;
LGG	trans	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17712092	chr4:129076599	LARP1B	0.74	14.18	0.55	3.61e-38	Eosinophil percentage of white cells;
LGG	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg07519485	chr6:33762594	MLN	-0.3	-6.73	-0.3	4.98e-11	Crohn's disease;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.38	0.65	4.77e-57	Personality dimensions;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15320075	chr8:145703422	NA	-0.78	-15.24	-0.58	8.34e-43	Age at first birth;
LGG	cis	rs11225247	1.000	rs11547916	chr11:102267820	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.03	0.31	7.51e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg00745463	chr17:30367425	LRRC37B	-0.76	-8.86	-0.38	1.78e-17	Hip circumference adjusted for BMI;
LGG	cis	rs12681366	0.571	rs2930959	chr8:95474158	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1519814	0.956	rs6469900	chr8:121117378	C/T	cg22335954	chr8:121166405	COL14A1	-0.56	-11.41	-0.47	9.52e-27	Breast cancer;
LGG	cis	rs139371	0.713	rs139316	chr22:39499763	C/T	cg17972162	chr22:39496387	APOBEC3H	0.26	6.72	0.3	5.25e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs68170813	0.559	rs17427849	chr7:106864237	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.86	-0.45	1.21e-24	Coronary artery disease;
LGG	cis	rs7580658	0.963	rs62157555	chr2:128107176	C/T	cg10021288	chr2:128175891	PROC	-0.65	-13.4	-0.53	8.08e-35	Protein C levels;
LGG	cis	rs6426558	0.537	rs7512409	chr1:227484038	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.61	-10.12	-0.43	6.93e-22	Neutrophil percentage of white cells;
LGG	cis	rs975722	0.507	rs6978213	chr7:117395995	A/G	cg10524701	chr7:117356490	CTTNBP2	0.35	7.0	0.31	9.12e-12	Coronary artery disease;
LGG	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg03342759	chr3:160939853	NMD3	-0.7	-11.62	-0.48	1.45e-27	Parkinson's disease;
LGG	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg15103426	chr22:29168792	CCDC117	0.73	11.78	0.48	3.32e-28	Lymphocyte counts;
LGG	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.32	7.01e-13	Schizophrenia;
LGG	cis	rs9309473	0.898	rs10201159	chr2:73858965	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.18	-0.32	2.82e-12	Metabolite levels;
LGG	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg25356066	chr3:128598488	ACAD9	0.45	6.9	0.31	1.71e-11	IgG glycosylation;
LGG	cis	rs36051895	0.632	rs10974983	chr9:5149657	G/T	cg02405213	chr9:5042618	JAK2	-0.76	-13.85	-0.54	9.86e-37	Pediatric autoimmune diseases;
LGG	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg26655873	chr3:72818019	SHQ1	0.32	6.82	0.3	2.88e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9902453	1.000	rs9896062	chr17:28357047	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg05791153	chr7:19748676	TWISTNB	0.95	12.58	0.5	1.93e-31	Thyroid stimulating hormone;
LGG	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg26513180	chr16:89883248	FANCA	0.63	11.44	0.47	7.28e-27	Vitiligo;
LGG	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	13.32	0.53	1.68e-34	Psoriasis;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg13607699	chr17:42295918	UBTF	0.55	9.19	0.39	1.38e-18	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16904090	chr1:40997253	ZNF684	0.41	7.08	0.31	5.43e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3820928	0.904	rs4414671	chr2:227816200	T/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.16e-14	Pulmonary function;
LGG	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg27129171	chr3:47204927	SETD2	0.78	15.04	0.57	6.33e-42	Colorectal cancer;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.79e-31	Lymphocyte counts;
LGG	cis	rs1670533	1.000	rs10084888	chr4:1053814	G/T	cg27284194	chr4:1044797	NA	0.54	9.72	0.41	1.84e-20	Recombination rate (females);
LGG	cis	rs3806843	0.932	rs2563269	chr5:140136468	G/T	cg19875535	chr5:140030758	IK	-0.53	-11.02	-0.46	3.09e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg26031613	chr14:104095156	KLC1	-0.6	-9.62	-0.41	4.33e-20	Reticulocyte count;
LGG	cis	rs9811920	0.809	rs13059754	chr3:99678490	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-9.09	-0.39	2.98e-18	Axial length;
LGG	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.87	0.34	2.54e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	9.04	0.39	4.25e-18	Personality dimensions;
LGG	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.32	-0.53	1.75e-34	Response to antipsychotic treatment;
LGG	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg13902645	chr11:5959945	NA	-0.66	-11.36	-0.47	1.55e-26	DNA methylation (variation);
LGG	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.58	-0.41	5.82e-20	Common traits (Other);
LGG	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.63	-0.37	1.01e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	17.75	0.64	3.57e-54	Menopause (age at onset);
LGG	cis	rs1847505	0.609	rs17819716	chr13:61423429	C/T	cg25164009	chr13:61490935	NA	0.57	9.19	0.39	1.31e-18	Polychlorinated biphenyl levels;
LGG	cis	rs2451279	0.565	rs2485364	chr6:159512260	C/T	cg01046905	chr6:159515345	NA	0.33	6.93	0.31	1.46e-11	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs193541	0.632	rs154512	chr5:122195040	T/C	cg19412675	chr5:122181750	SNX24	0.53	8.51	0.37	2.52e-16	Glucose homeostasis traits;
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs968451	0.789	rs1003644	chr22:39676744	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	13.4	0.53	7.55e-35	Primary biliary cholangitis;
LGG	cis	rs6489785	0.745	rs11065345	chr12:121372696	T/C	cg02419362	chr12:121203948	SPPL3	0.46	7.11	0.31	4.31e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg13736514	chr6:26305472	NA	0.35	7.02	0.31	7.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg00290607	chr11:67383545	NA	-0.51	-9.08	-0.39	3.04e-18	Mean corpuscular volume;
LGG	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.77	-0.34	4.94e-14	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.7	0.54	4.2e-36	Lung cancer;
LGG	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg11247378	chr22:39784982	NA	-0.32	-8.16	-0.35	3.14e-15	IgG glycosylation;
LGG	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	10.52	0.44	2.28e-23	Mean platelet volume;
LGG	cis	rs2292096	0.850	rs6663728	chr1:200815179	G/A	cg07580975	chr1:200843333	NA	0.49	7.84	0.34	3.04e-14	Epilepsy;
LGG	cis	rs883565	0.740	rs9311203	chr3:39072079	T/C	cg01426195	chr3:39028469	NA	-0.71	-16.06	-0.6	1.87e-46	Handedness;
LGG	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs4356203	0.875	rs214935	chr11:17193122	T/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.35	-0.32	8.74e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1595825	0.786	rs79490184	chr2:198894219	T/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs9811920	0.965	rs9289981	chr3:99868104	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.42	0.36	4.58e-16	Axial length;
LGG	cis	rs8064024	0.625	rs960006	chr16:4911195	T/C	cg04440724	chr16:4920505	UBN1	-0.56	-12.45	-0.5	6.96e-31	Cancer;
LGG	cis	rs9596863	0.898	rs9568908	chr13:54336521	A/C	ch.13.53330881F	chr13:54432880	NA	0.54	7.32	0.32	1.09e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs977987	0.806	rs8057203	chr16:75404974	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs111547017	1	rs111547017	chr6:43341689	A/G	cg26312998	chr6:43337775	ZNF318	0.61	8.57	0.37	1.59e-16	Schizophrenia;
LGG	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg05784532	chr1:230284198	GALNT2	0.51	9.01	0.39	5.29e-18	Coronary artery disease;
LGG	cis	rs763121	0.819	rs5757237	chr22:39073835	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg05368731	chr17:41323189	NBR1	0.93	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.91	0.38	1.2e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6141769	0.518	rs6058834	chr20:31316862	C/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs60180747	0.544	rs11633808	chr15:66568111	C/T	cg07575407	chr15:66541975	MEGF11	0.63	13.73	0.54	3.24e-36	Testicular germ cell tumor;
LGG	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	7.94	0.35	1.56e-14	Thyroid stimulating hormone;
LGG	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg17294928	chr15:75287854	SCAMP5	0.65	12.12	0.49	1.44e-29	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.01	0.31	8.47e-12	Lung cancer;
LGG	cis	rs13421350	0.579	rs76837457	chr2:173303391	G/T	cg15021238	chr2:173305865	ITGA6	-0.81	-9.21	-0.39	1.16e-18	Diabetic kidney disease;
LGG	trans	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19894588	chr14:64061835	NA	-0.65	-10.96	-0.45	5.09e-25	Glioblastoma;Glioma;
LGG	cis	rs5756391	0.532	rs4820261	chr22:37316949	G/A	cg21209356	chr22:37319042	CSF2RB	0.42	9.55	0.41	7.64e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs877282	0.945	rs11253398	chr10:790012	T/C	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs4788570	0.537	rs56222754	chr16:71491806	G/A	cg06353428	chr16:71660113	MARVELD3	-0.99	-13.36	-0.53	1.2e-34	Intelligence (multi-trait analysis);
LGG	cis	rs9357271	1.000	rs9380743	chr6:38358802	G/C	cg07362130	chr6:38359646	BTBD9	-0.45	-10.25	-0.43	2.26e-22	Restless legs syndrome;
LGG	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12756686	chr19:29218302	NA	0.71	11.51	0.47	3.95e-27	Methadone dose in opioid dependence;
LGG	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg15704280	chr7:45808275	SEPT13	0.86	9.09	0.39	2.99e-18	Myopia (pathological);
LGG	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs9914988	0.943	rs1035989	chr17:27143810	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg06685724	chr7:23720386	C7orf46	0.45	10.75	0.45	3.18e-24	Schizophrenia;
LGG	cis	rs12997796	0.556	rs7558827	chr2:86923178	A/G	cg25203885	chr2:87302643	LOC285074	-0.55	-6.72	-0.3	5.23e-11	Schizophrenia;
LGG	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg14210321	chr2:106509881	NCK2	-0.53	-9.19	-0.39	1.38e-18	Addiction;
LGG	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13490244	chr10:67231801	NA	0.31	7.09	0.31	5.08e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg07157834	chr1:205819609	PM20D1	0.4	6.91	0.31	1.6e-11	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	cis	rs7551222	0.892	rs7539399	chr1:204590044	A/G	cg20240347	chr1:204465584	NA	0.39	7.38	0.32	7.64e-13	Schizophrenia;
LGG	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.92	0.31	1.56e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg24250549	chr1:154909240	PMVK	0.74	15.22	0.58	1.06e-42	Prostate cancer;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.89	0.3	1.87e-11	Schizophrenia;
LGG	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.36	-0.47	1.54e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg10150615	chr22:24372951	LOC391322	0.42	6.99	0.31	9.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg22875332	chr1:76189707	ACADM	0.62	10.3	0.43	1.57e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.02	0.39	5.07e-18	Diabetic retinopathy;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06719391	chr11:2554330	KCNQ1	0.41	6.84	0.3	2.56e-11	Bipolar disorder;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-11.04	-0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs10173297	0.686	rs12621171	chr2:3710463	A/G	cg16123090	chr2:3699210	NA	-0.55	-7.3	-0.32	1.26e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2050392	0.931	rs2265187	chr10:30690844	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.55	-0.44	1.78e-23	Inflammatory bowel disease;
LGG	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg05926928	chr17:57297772	GDPD1	0.95	15.1	0.57	3.49e-42	Opioid sensitivity;
LGG	cis	rs193541	0.632	rs154504	chr5:122204086	A/T	cg19412675	chr5:122181750	SNX24	0.54	8.73	0.38	4.49e-17	Glucose homeostasis traits;
LGG	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg27490568	chr2:178487706	NA	-0.81	-14.13	-0.55	6.04e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.7	-0.45	5.13e-24	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.18	0.65	3.76e-56	Personality dimensions;
LGG	cis	rs4959677	0.698	rs9503199	chr6:2485468	C/T	cg20147862	chr6:2634573	C6orf195	0.38	8.59	0.37	1.36e-16	Orthostatic hypotension;
LGG	cis	rs12915845	0.563	rs12592916	chr15:89092699	C/A	cg05013243	chr15:89149849	MIR1179	0.36	7.29	0.32	1.39e-12	Menarche (age at onset);
LGG	cis	rs745080	0.519	rs2357631	chr14:52967503	A/C	cg23333723	chr14:53022898	GPR137C	-0.4	-8.07	-0.35	6.04e-15	Orofacial clefts;
LGG	trans	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg23909802	chr19:49965263	ALDH16A1	-0.33	-6.69	-0.3	6.61e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7647973	0.925	rs6769821	chr3:49244657	G/A	cg07636037	chr3:49044803	WDR6	0.75	12.89	0.51	1.1e-32	Menarche (age at onset);
LGG	cis	rs1788820	0.957	rs1652340	chr18:21099831	A/C	cg14672496	chr18:21087552	C18orf8	0.39	7.32	0.32	1.11e-12	Body mass index;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg04911518	chr14:31353148	COCH	-0.42	-7.25	-0.32	1.77e-12	Apolipoprotein A-IV levels;
LGG	cis	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.11e-25	Morning vs. evening chronotype;
LGG	cis	rs1670533	1.000	rs6852850	chr4:1052857	C/G	cg27284194	chr4:1044797	NA	0.54	9.72	0.41	1.84e-20	Recombination rate (females);
LGG	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg20744362	chr22:50050164	C22orf34	0.4	7.14	0.31	3.75e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6942756	0.744	rs2718088	chr7:128927020	C/A	cg02491457	chr7:128862824	NA	0.63	11.7	0.48	7.03e-28	White matter hyperintensity burden;
LGG	cis	rs2133450	0.526	rs17047063	chr3:7343584	G/A	cg19930620	chr3:7340148	GRM7	-0.42	-9.46	-0.4	1.58e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs981844	0.890	rs56184506	chr4:154685889	G/T	cg14289246	chr4:154710475	SFRP2	0.74	12.16	0.49	1.05e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs362272	0.505	rs2857854	chr4:3043184	G/T	cg13731523	chr4:3047190	NA	-0.43	-9.79	-0.41	1.1e-20	Serum sulfate level;
LGG	cis	rs1062746	0.711	rs8056833	chr16:87378388	G/C	cg02258303	chr16:87377426	FBXO31	-0.59	-11.79	-0.48	2.97e-28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs28595532	0.720	rs72670228	chr4:119309516	T/C	cg21605333	chr4:119757512	SEC24D	0.89	8.39	0.36	6.15e-16	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.77	-0.3	3.82e-11	Obesity-related traits;
LGG	cis	rs12367572	0.601	rs10880730	chr12:45422443	G/A	cg03114573	chr12:45410052	DBX2	-0.67	-11.98	-0.49	5.35e-29	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.58e-49	Intelligence (multi-trait analysis);
LGG	cis	rs11677416	1.000	rs1516790	chr2:113531291	G/A	cg27083787	chr2:113543245	IL1A	0.52	8.73	0.38	4.55e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.37e-21	Bipolar disorder;
LGG	cis	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg21775007	chr8:11205619	TDH	-0.46	-7.01	-0.31	8.66e-12	Triglycerides;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01963240	chr14:54421117	BMP4	0.42	7.1	0.31	4.67e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg03929089	chr4:120376271	NA	-0.8	-15.37	-0.58	2.21e-43	Height;
LGG	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.82e-21	HDL cholesterol;
LGG	trans	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs11225247	1.000	rs11225247	chr11:102280751	A/C	cg06323957	chr11:102217781	BIRC2	0.78	6.9	0.31	1.72e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.07e-11	Total body bone mineral density;
LGG	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg06191203	chr2:152266755	RIF1	-0.46	-7.97	-0.35	1.25e-14	Lung cancer;
LGG	cis	rs2072732	0.861	rs10909866	chr1:2960372	C/T	cg08733933	chr1:2954429	NA	-0.44	-8.78	-0.38	3.25e-17	Plateletcrit;
LGG	cis	rs60843830	0.550	rs300751	chr2:209063	A/C	cg21211680	chr2:198530	NA	0.4	6.9	0.31	1.74e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.33	-0.4	4.54e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg23649088	chr2:200775458	C2orf69	0.6	7.92	0.35	1.75e-14	Schizophrenia;
LGG	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg25237894	chr2:233734115	C2orf82	0.66	12.65	0.51	1.04e-31	Coronary artery disease;
LGG	trans	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg07211511	chr3:129823064	LOC729375	-1.37	-22.16	-0.72	1.1e-74	Blood pressure (smoking interaction);
LGG	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.9	-0.34	2.11e-14	HDL cholesterol;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg12705353	chr12:122356852	WDR66	0.24	6.85	0.3	2.32e-11	Mean corpuscular volume;
LGG	cis	rs9814567	0.896	rs7653807	chr3:134345724	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.32	-0.5	2.33e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11150038	0.702	rs28631802	chr16:78100000	T/C	cg04733911	chr16:78082701	NA	0.62	8.69	0.37	6.36e-17	Colorectal or endometrial cancer;
LGG	cis	rs509477	0.690	rs273354	chr18:32598235	T/C	cg23791764	chr18:32556832	MAPRE2	0.43	7.2	0.32	2.49e-12	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg15556689	chr8:8085844	FLJ10661	0.46	8.41	0.36	5.25e-16	Mood instability;
LGG	cis	rs2820315	1.000	rs2644119	chr1:201807776	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.75	0.3	4.37e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs8133932	0.677	rs6518257	chr21:47210107	T/C	cg11214348	chr21:47283868	PCBP3	0.41	7.54	0.33	2.51e-13	Schizophrenia;
LGG	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15664640	chr17:80829946	TBCD	-0.67	-8.97	-0.38	7.48e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23480499	chr12:95867566	METAP2	-0.45	-6.65	-0.3	8.39e-11	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	8.0	0.35	9.96e-15	Height;
LGG	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.27	-0.58	5.98e-43	Chronic sinus infection;
LGG	cis	rs4740619	0.935	rs10756674	chr9:15584228	A/T	cg14451791	chr9:16040625	NA	0.4	10.03	0.42	1.46e-21	Body mass index;
LGG	cis	rs6708331	0.517	rs2028879	chr2:70354637	C/T	cg01613454	chr2:70366299	NA	0.53	10.85	0.45	1.41e-24	Obesity-related traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22315683	chr3:101280662	RG9MTD1	0.35	6.69	0.3	6.46e-11	Menarche (age at onset);
LGG	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.37e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4664308	0.618	rs35771982	chr2:160885418	G/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.64	-0.48	1.15e-27	Idiopathic membranous nephropathy;
LGG	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00631329	chr6:26305371	NA	-0.55	-9.76	-0.41	1.33e-20	Educational attainment;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-8.54	-0.37	1.89e-16	Prudent dietary pattern;
LGG	cis	rs4538187	1.000	rs13431781	chr2:64086372	A/G	cg02541582	chr2:64069798	UGP2	0.61	14.48	0.56	1.84e-39	Systolic blood pressure;
LGG	cis	rs1568889	1.000	rs12791341	chr11:28335452	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.69	0.56	2.2e-40	Bipolar disorder;
LGG	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.12	0.31	4.22e-12	Height;
LGG	cis	rs17001868	0.568	rs9611328	chr22:40791972	C/T	cg07138101	chr22:40742427	ADSL	0.69	9.04	0.39	4.3e-18	Mammographic density (dense area);
LGG	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.6	0.71	4.27e-72	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg10505658	chr17:80084571	CCDC57	0.34	6.76	0.3	4.16e-11	Life satisfaction;
LGG	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg05791153	chr7:19748676	TWISTNB	0.76	10.62	0.44	1.04e-23	Thyroid stimulating hormone;
LGG	trans	rs931812	0.895	rs7831714	chr8:101913987	C/T	cg20993868	chr7:22813445	NA	0.7	13.12	0.52	1.16e-33	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs4774899	0.966	rs35646942	chr15:57281336	T/C	cg08128148	chr15:57256372	TCF12	-0.34	-8.25	-0.36	1.63e-15	Urinary tract infection frequency;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	6.86	0.3	2.28e-11	Menopause (age at onset);
LGG	cis	rs8005677	0.828	rs8016027	chr14:23420153	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-7.07	-0.31	5.61e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg12856521	chr11:46389249	DGKZ	0.39	6.69	0.3	6.44e-11	Leprosy;
LGG	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.94	-0.42	3.03e-21	Response to antipsychotic treatment;
LGG	cis	rs4974559	0.739	rs28444605	chr4:1290281	C/A	cg02980000	chr4:1222292	CTBP1	0.82	9.37	0.4	3.22e-19	Systolic blood pressure;
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs8192917	0.614	rs8019426	chr14:25069836	C/A	cg01932691	chr14:25045625	CTSG	-0.4	-7.0	-0.31	9.15e-12	Vitiligo;
LGG	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg00376283	chr12:123451042	ABCB9	-0.61	-9.07	-0.39	3.5e-18	Neutrophil percentage of white cells;
LGG	trans	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg12575136	chr18:32820987	ZNF397	0.48	8.8	0.38	2.66e-17	White blood cell count;
LGG	cis	rs7648466	0.915	rs1491961	chr3:46250348	T/C	cg13144783	chr3:46249795	CCR1	-0.7	-13.25	-0.52	3.35e-34	Eotaxin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25636833	chr22:41864805	PHF5A;ACO2	0.5	8.06	0.35	6.45e-15	Cognitive performance;
LGG	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.71	-10.18	-0.43	4.25e-22	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg13206674	chr6:150067644	NUP43	-0.69	-15.95	-0.6	5.85e-46	Lung cancer;
LGG	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg26513180	chr16:89883248	FANCA	0.72	11.9	0.48	1.09e-28	Vitiligo;
LGG	cis	rs6993813	0.967	rs1872422	chr8:120048305	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.29	7.48	0.33	3.87e-13	Bone mineral density (hip);
LGG	cis	rs9487094	0.689	rs4636056	chr6:109730882	T/C	cg16315928	chr6:109776240	MICAL1	0.38	6.66	0.3	7.83e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23397278	chr11:64051699	GPR137;BAD	0.46	6.9	0.31	1.76e-11	Gut microbiome composition (summer);
LGG	cis	rs968451	1.000	rs971964	chr22:39702473	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	11.08	0.46	1.89e-25	Primary biliary cholangitis;
LGG	cis	rs3204270	0.714	rs8074828	chr17:79657136	G/C	cg18367735	chr17:79674897	NA	0.6	7.96	0.35	1.33e-14	Dental caries;
LGG	cis	rs10895140	0.756	rs7116889	chr11:101504590	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14470647	chr9:107690075	ABCA1	0.42	6.84	0.3	2.5e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs56804039	1.000	rs17616779	chr8:8382374	A/G	cg02002194	chr4:3960332	NA	-0.43	-6.87	-0.3	2.12e-11	Cervical cancer;
LGG	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg14191688	chr11:70257035	CTTN	0.6	8.56	0.37	1.66e-16	Coronary artery disease;
LGG	cis	rs11874712	0.932	rs8092674	chr18:43665982	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.06	0.39	3.62e-18	Cognitive test performance;
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	13.85	0.54	9.68e-37	Platelet count;
LGG	cis	rs2274273	0.840	rs28493647	chr14:55824463	T/C	cg04306507	chr14:55594613	LGALS3	0.61	16.97	0.62	1.45e-50	Protein biomarker;
LGG	cis	rs7192750	0.586	rs4788576	chr16:71934105	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6840360	0.901	rs1443094	chr4:152456724	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.21	0.32	2.26e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	0.515	rs10916192	chr1:227852584	A/G	cg23173402	chr1:227635558	NA	0.36	6.8	0.3	3.26e-11	Major depressive disorder;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg13880726	chr7:1868755	MAD1L1	0.38	6.7	0.3	6.12e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg21798802	chr22:38057573	PDXP	0.38	8.32	0.36	9.63e-16	Fat distribution (HIV);
LGG	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15534507	chr18:15165202	NA	0.38	7.48	0.33	3.88e-13	Menarche (age at onset);
LGG	cis	rs7517126	0.925	rs3766404	chr1:196651832	T/C	cg07209298	chr1:196795943	CFHR1	-0.5	-6.75	-0.3	4.39e-11	Blood protein levels;
LGG	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg15212455	chr7:39170539	POU6F2	0.42	9.46	0.4	1.51e-19	IgG glycosylation;
LGG	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg06219351	chr7:158114137	PTPRN2	-0.83	-14.32	-0.55	9.03e-39	Response to amphetamines;
LGG	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.33	6.7e-13	Schizophrenia;
LGG	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	cis	rs5742933	0.762	rs2033746	chr2:190599452	G/A	cg04003228	chr2:190539410	ANKAR	-0.5	-7.35	-0.32	9.27e-13	Ferritin levels;
LGG	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg05887092	chr17:76393375	PGS1	0.71	15.35	0.58	2.77e-43	HDL cholesterol levels;
LGG	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.62	-9.77	-0.41	1.22e-20	Chronic sinus infection;
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg16482183	chr6:26056742	HIST1H1C	0.53	9.39	0.4	2.66e-19	Height;
LGG	trans	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg13565492	chr6:43139072	SRF	-0.79	-10.35	-0.43	9.87e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-9.53	-0.4	8.93e-20	Longevity;Endometriosis;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs9611519	0.531	rs1967708	chr22:41444444	G/C	cg03806693	chr22:41940476	POLR3H	-0.48	-7.92	-0.35	1.73e-14	Neuroticism;
LGG	cis	rs42648	0.564	rs11563340	chr7:89809579	A/G	cg04070188	chr7:89809444	NA	-0.27	-6.66	-0.3	7.99e-11	Homocysteine levels;
LGG	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg05493394	chr6:133562035	EYA4	0.31	8.67	0.37	7.59e-17	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.36	0.5	1.59e-30	Obesity-related traits;
LGG	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg18876405	chr7:65276391	NA	0.6	11.0	0.46	3.64e-25	Aortic root size;
LGG	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.22	-0.36	2e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs892961	0.836	rs35077273	chr17:75412415	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs35146811	0.586	rs1076237	chr7:99585441	A/C	cg22906224	chr7:99728672	NA	0.53	8.55	0.37	1.85e-16	Coronary artery disease;
LGG	cis	rs9815354	0.812	rs4577439	chr3:41952540	T/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12210905	0.925	rs10456349	chr6:26975459	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg17809284	chr5:56205270	C5orf35	-0.35	-6.71	-0.3	5.66e-11	Coronary artery disease;
LGG	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg26384229	chr12:38710491	ALG10B	0.95	20.58	0.69	2.67e-67	Bladder cancer;
LGG	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-13.19	-0.52	5.84e-34	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.69	0.54	4.51e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00149659	chr3:10157352	C3orf10	0.76	9.65	0.41	3.37e-20	Alzheimer's disease;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00294572	chr6:26285232	NA	0.42	7.82	0.34	3.73e-14	Educational attainment;
LGG	cis	rs727505	1.000	rs10244817	chr7:124467470	T/C	cg23710748	chr7:124431027	NA	-0.53	-10.03	-0.42	1.43e-21	Lewy body disease;
LGG	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg21366198	chr4:185655624	MLF1IP	-0.41	-7.0	-0.31	9.05e-12	Kawasaki disease;
LGG	cis	rs76693355	0.512	rs11823264	chr11:120294004	C/T	cg15690696	chr11:120217718	ARHGEF12	-0.43	-6.84	-0.3	2.54e-11	Intraocular pressure;
LGG	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg04450456	chr4:17643702	FAM184B	0.31	6.81	0.3	2.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs763121	0.853	rs138713	chr22:39142615	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	16.62	0.61	5.25e-49	Menopause (age at onset);
LGG	cis	rs2458413	0.563	rs2458419	chr8:105337141	G/C	cg23108931	chr8:105342351	NA	-0.28	-7.3	-0.32	1.23e-12	Paget's disease;
LGG	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	12.32	0.5	2.21e-30	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg25019033	chr10:957182	NA	-0.6	-12.69	-0.51	7e-32	Eosinophil percentage of granulocytes;
LGG	trans	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg19694781	chr19:47549865	TMEM160	-0.42	-7.22	-0.32	2.11e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6912958	0.712	rs4587138	chr6:88356915	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.71	-0.38	5.36e-17	Monocyte percentage of white cells;
LGG	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.08	-0.42	9.64e-22	Aortic root size;
LGG	cis	rs3813359	0.545	rs2326948	chr6:130554442	G/A	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4740619	0.836	rs1891212	chr9:15900771	G/T	cg14451791	chr9:16040625	NA	-0.39	-9.71	-0.41	2.03e-20	Body mass index;
LGG	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-9.89	-0.42	4.79e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg14893161	chr1:205819251	PM20D1	-0.43	-7.17	-0.32	2.95e-12	Menarche (age at onset);
LGG	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg01130898	chr2:219473002	PLCD4	0.42	7.3	0.32	1.28e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.71	0.38	5.22e-17	Schizophrenia;
LGG	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg01620082	chr3:125678407	NA	0.61	7.51	0.33	2.98e-13	Depression;
LGG	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg00531865	chr16:30841666	NA	-0.48	-9.87	-0.42	5.46e-21	Dementia with Lewy bodies;
LGG	cis	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs283228	0.917	rs2518323	chr6:101809462	G/A	cg27451362	chr6:101846650	GRIK2	0.54	9.08	0.39	3.11e-18	Coenzyme Q10 levels;
LGG	cis	rs5758511	0.773	rs9623482	chr22:42360574	T/C	cg15128208	chr22:42549153	NA	0.58	9.13	0.39	2.18e-18	Birth weight;
LGG	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.49	8.54	0.37	2.01e-16	Longevity;
LGG	cis	rs847577	0.651	rs10464490	chr7:97715319	T/G	cg13397024	chr7:97797637	LMTK2	-0.37	-7.0	-0.31	9.11e-12	Breast cancer;
LGG	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.44	8.15	0.35	3.54e-15	Platelet count;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg04861929	chr11:109293070	C11orf87	0.52	9.73	0.41	1.74e-20	Schizophrenia;
LGG	cis	rs3742264	0.615	rs9534256	chr13:46517336	A/C	cg15192986	chr13:46630673	CPB2	-0.35	-6.88	-0.3	2e-11	Blood protein levels;
LGG	cis	rs3741151	0.773	rs79994237	chr11:73147974	T/C	cg17517138	chr11:73019481	ARHGEF17	0.88	8.75	0.38	3.89e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs3736594	0.513	rs62131882	chr2:27765480	T/C	cg27432699	chr2:27873401	GPN1	0.56	8.51	0.37	2.39e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4901869	0.966	rs12893803	chr14:59329655	T/C	cg02291164	chr14:59296302	NA	0.27	6.81	0.3	3.08e-11	Panic disorder;
LGG	cis	rs67133203	0.606	rs11169742	chr12:51574127	G/A	cg14688905	chr12:51403056	SLC11A2	0.6	8.98	0.39	6.88e-18	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04904834	chr1:179851103	TOR1AIP1	0.43	6.69	0.3	6.27e-11	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.39	0.32	6.75e-13	Bladder cancer;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg27305603	chr7:155059486	NA	0.35	6.84	0.3	2.52e-11	Body fat percentage;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.71	0.45	4.67e-24	Personality dimensions;
LGG	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-24.11	-0.75	8.15e-84	Dental caries;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-12.02	-0.49	3.77e-29	Parkinson's disease;
LGG	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.47	-0.44	3.59e-23	Migraine;Coronary artery disease;
LGG	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg21890820	chr11:65308645	LTBP3	0.69	7.14	0.32	3.54e-12	Height;
LGG	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs12543645	0.598	rs17767186	chr8:10277494	C/T	cg12940923	chr8:10282607	MSRA	0.3	7.11	0.31	4.47e-12	Schizophrenia;
LGG	cis	rs2274273	0.686	rs66842809	chr14:55630571	T/C	cg04306507	chr14:55594613	LGALS3	0.53	12.35	0.5	1.82e-30	Protein biomarker;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg04267008	chr7:1944627	MAD1L1	-0.75	-13.52	-0.53	2.54e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.95	-0.31	1.27e-11	Neuroticism;
LGG	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg16386425	chr10:429943	DIP2C	0.37	6.87	0.3	2.11e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.68	0.48	8.76e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.98	-0.52	4.59e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg07382826	chr16:28625726	SULT1A1	0.34	7.27	0.32	1.59e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs6840360	0.615	rs28659854	chr4:152607442	T/C	cg22705602	chr4:152727874	NA	-0.38	-9.23	-0.39	1e-18	Intelligence (multi-trait analysis);
LGG	cis	rs1003719	0.788	rs9977602	chr21:38450650	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.58	0.63	2.3e-53	Eye color traits;
LGG	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg02002194	chr4:3960332	NA	0.41	7.92	0.35	1.73e-14	Mood instability;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.6	-9.93	-0.42	3.36e-21	Longevity;
LGG	cis	rs4919694	0.572	rs12262258	chr10:104900272	G/A	cg04362960	chr10:104952993	NT5C2	0.88	13.41	0.53	7.14e-35	Arsenic metabolism;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25072359	chr17:41440525	NA	0.53	10.14	0.43	5.94e-22	Menopause (age at onset);
LGG	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg13010199	chr12:38710504	ALG10B	0.73	14.91	0.57	2.55e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.86	0.34	2.76e-14	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.03	-0.35	8.08e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02889418	chr18:77227672	NFATC1	-0.4	-6.81	-0.3	3e-11	Cognitive performance;
LGG	cis	rs10744422	0.925	rs2292132	chr12:123332834	T/C	cg22842854	chr12:123319900	HIP1R	-0.53	-6.65	-0.3	8.37e-11	Schizophrenia;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg02002194	chr4:3960332	NA	-0.5	-9.64	-0.41	3.63e-20	Neuroticism;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs17125944	0.615	rs17125798	chr14:53319905	G/A	cg00686598	chr14:53173677	PSMC6	0.81	8.17	0.35	3.07e-15	Alzheimer's disease (late onset);
LGG	cis	rs7166081	1.000	rs4432221	chr15:67634862	C/T	cg05925327	chr15:68127851	NA	0.32	6.72	0.3	5.28e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-9.49	-0.4	1.26e-19	Lung cancer in ever smokers;
LGG	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg16507663	chr6:150244633	RAET1G	0.42	8.04	0.35	7.55e-15	Lung cancer;
LGG	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg03806693	chr22:41940476	POLR3H	0.98	16.52	0.61	1.53e-48	Vitiligo;
LGG	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03264133	chr6:25882463	NA	0.71	13.69	0.54	4.41e-36	Blood metabolite levels;
LGG	cis	rs4731207	0.596	rs10081336	chr7:124575945	A/G	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.74e-13	Life satisfaction;
LGG	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.56	-0.67	1.56e-62	Height;
LGG	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.0	0.64	2.58e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7639513	0.767	rs7648488	chr3:12708946	T/C	cg23032965	chr3:12705835	RAF1	0.85	16.72	0.61	2.04e-49	Itch intensity from mosquito bite;
LGG	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg15309053	chr8:964076	NA	0.43	9.11	0.39	2.58e-18	Schizophrenia;
LGG	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.66	-0.69	1.07e-67	Systemic lupus erythematosus;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg06719900	chr11:109292894	C11orf87	0.44	8.3	0.36	1.14e-15	Schizophrenia;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.98	-0.39	6.69e-18	Obesity-related traits;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg09263875	chr16:632152	PIGQ	0.66	13.28	0.53	2.39e-34	Height;
LGG	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	trans	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19894588	chr14:64061835	NA	0.63	10.69	0.44	5.64e-24	Glioblastoma;Glioma;
LGG	cis	rs2274273	0.588	rs17675223	chr14:55862236	G/A	cg04306507	chr14:55594613	LGALS3	0.52	12.21	0.49	6.71e-30	Protein biomarker;
LGG	cis	rs2455799	0.613	rs11128762	chr3:15883439	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.84	-0.34	3.12e-14	Mean platelet volume;
LGG	cis	rs763121	0.889	rs9610971	chr22:38910810	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.41	0.63	1.35e-52	Menopause (age at onset);
LGG	cis	rs6754311	0.628	rs309811	chr2:136625602	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-12.91	-0.51	9.15e-33	Mosquito bite size;
LGG	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg14074117	chr16:1909714	C16orf73	0.49	7.03	0.31	7.61e-12	Insulin-like growth factors;
LGG	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg23594656	chr7:65796392	TPST1	-0.36	-8.08	-0.35	5.67e-15	Aortic root size;
LGG	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg02725872	chr8:58115012	NA	-0.53	-8.56	-0.37	1.63e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6450176	1.000	rs3776707	chr5:53304873	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg12856521	chr11:46389249	DGKZ	0.42	7.22	0.32	2.18e-12	Leprosy;
LGG	cis	rs17253792	0.598	rs35830444	chr14:56017350	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-1.03	-13.69	-0.54	4.59e-36	Lung cancer in ever smokers;
LGG	cis	rs9972944	0.756	rs6504353	chr17:63768013	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.03	0.35	8.25e-15	Schizophrenia;
LGG	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg15736062	chr7:158136485	PTPRN2	-0.37	-7.36	-0.32	8.72e-13	Calcium levels;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg09359103	chr1:154839909	KCNN3	-0.54	-11.21	-0.46	5.63e-26	Prostate cancer;
LGG	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg08297393	chr2:100937505	LONRF2	-0.53	-9.3	-0.4	5.46e-19	Intelligence (multi-trait analysis);
LGG	cis	rs965513	1.000	rs10739496	chr9:100552559	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.68	-0.41	2.57e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg07120314	chr15:79043507	NA	-0.38	-7.17	-0.32	2.94e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg10402321	chr1:26617780	UBXN11	-0.36	-7.05	-0.31	6.65e-12	Obesity-related traits;
LGG	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-12.77	-0.51	3.21e-32	Granulocyte count;Sum neutrophil eosinophil counts;
LGG	cis	rs3857067	0.806	rs72665608	chr4:95093501	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.98	-0.35	1.18e-14	QT interval;
LGG	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg08999081	chr20:33150536	PIGU	0.39	9.86	0.42	5.89e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg13699009	chr12:122356056	WDR66	0.56	14.53	0.56	1.14e-39	Mean corpuscular volume;
LGG	cis	rs1920116	0.778	rs11928433	chr3:169563450	T/C	cg08193579	chr3:169529701	LRRC34	0.42	7.36	0.32	8.71e-13	Glioma (high-grade);
LGG	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg20935368	chr5:178288625	ZNF354B	0.34	6.93	0.31	1.44e-11	Sleep duration;
LGG	trans	rs2975734	0.676	rs4841299	chr8:10112593	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.54	-0.33	2.46e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg26513180	chr16:89883248	FANCA	0.7	7.63	0.33	1.37e-13	Skin colour saturation;
LGG	cis	rs12711979	0.509	rs10205540	chr2:3827839	A/G	cg17052675	chr2:3827356	NA	-0.51	-9.92	-0.42	3.73e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.84	-0.34	3.22e-14	Blood metabolite levels;
LGG	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.96e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20887711	chr4:1340912	KIAA1530	0.94	21.04	0.7	1.75e-69	Longevity;
LGG	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg06360820	chr2:242988706	NA	-0.98	-12.61	-0.51	1.48e-31	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg25358565	chr5:93447407	FAM172A	1.39	17.13	0.62	2.67e-51	Diabetic retinopathy;
LGG	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg03929089	chr4:120376271	NA	-0.86	-13.4	-0.53	7.55e-35	Coronary artery disease;
LGG	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg09021430	chr5:549028	NA	-0.72	-10.02	-0.42	1.56e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs6912958	0.935	rs6454629	chr6:88165515	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-10.45	-0.44	4.25e-23	Monocyte percentage of white cells;
LGG	cis	rs36051895	0.589	rs62543574	chr9:5204090	A/T	cg02405213	chr9:5042618	JAK2	-0.73	-13.3	-0.53	2.07e-34	Pediatric autoimmune diseases;
LGG	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg27661571	chr11:113659931	NA	-0.57	-7.75	-0.34	5.78e-14	Hip circumference adjusted for BMI;
LGG	cis	rs10465746	0.935	rs6692233	chr1:84327214	A/G	cg10977910	chr1:84465055	TTLL7	-0.53	-9.94	-0.42	3.16e-21	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.15e-25	Homoarginine levels;
LGG	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg26585981	chr11:48327164	OR4S1	-0.4	-6.96	-0.31	1.19e-11	Migraine - clinic-based;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23221052	chr5:179740743	GFPT2	-0.63	-11.58	-0.47	2.08e-27	Height;
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	trans	rs9657904	0.774	rs6807382	chr3:105570345	A/G	cg14088669	chr1:158435396	OR10K1	0.43	8.16	0.35	3.12e-15	Multiple sclerosis;
LGG	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg10326726	chr10:51549505	MSMB	-0.69	-14.37	-0.56	5.66e-39	Prostate-specific antigen levels;
LGG	cis	rs6694672	0.702	rs6685259	chr1:197093098	A/T	cg13682187	chr1:196946512	CFHR5	0.54	7.08	0.31	5.32e-12	Asthma;
LGG	cis	rs1691799	0.899	rs1168358	chr12:66748664	A/G	cg16791601	chr12:66731901	HELB	-0.64	-14.78	-0.57	9.45e-41	White blood cell count (basophil);
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11905131	chr22:24372483	LOC391322	-0.43	-7.55	-0.33	2.39e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9358372	1.000	rs6902880	chr6:20809890	T/C	cg13405222	chr6:20811065	CDKAL1	-0.71	-15.71	-0.59	7.03e-45	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg07005078	chr4:17578674	LAP3	0.37	6.93	0.31	1.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35176054	0.730	rs7920154	chr10:105514473	C/A	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.91	-0.31	1.59e-11	Atrial fibrillation;
LGG	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2290402	0.536	rs56307842	chr4:854232	T/C	cg09237302	chr4:906077	GAK	-0.44	-7.55	-0.33	2.29e-13	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.58	-0.33	1.87e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs986417	0.818	rs7153263	chr14:61099261	G/A	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.78	-0.51	2.95e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.63e-15	Common traits (Other);
LGG	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg23173402	chr1:227635558	NA	0.57	9.03	0.39	4.56e-18	Major depressive disorder;
LGG	cis	rs4731207	0.698	rs7801140	chr7:124505761	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.74	-0.34	6.44e-14	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02548606	chr15:77363299	TSPAN3	0.48	7.01	0.31	8.34e-12	Gut microbiome composition (summer);
LGG	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.75	0.3	4.33e-11	Schizophrenia;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.06e-12	Aortic root size;
LGG	cis	rs7765175	0.698	rs9488155	chr6:113664985	T/C	cg26552650	chr6:113682475	NA	0.33	7.49	0.33	3.57e-13	Coronary artery calcification;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.32	3.6e-12	Lung cancer;
LGG	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg05163923	chr11:71159392	DHCR7	-0.65	-11.22	-0.46	5.43e-26	Vitamin D levels;
LGG	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg21775007	chr8:11205619	TDH	-0.44	-7.0	-0.31	9.33e-12	Joint mobility (Beighton score);
LGG	cis	rs1691799	0.899	rs1168308	chr12:66742183	A/G	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs6740322	0.895	rs6744746	chr2:43555805	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.59	9.15	0.39	1.78e-18	Coronary artery disease;
LGG	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.4	0.44	6.46e-23	Aortic root size;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00933542	chr6:150070202	PCMT1	0.37	6.72	0.3	5.48e-11	Lung cancer;
LGG	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.41	-0.33	5.89e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4713118	0.513	rs9368547	chr6:28028067	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.9	-0.31	1.69e-11	Parkinson's disease;
LGG	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg03433033	chr1:76189801	ACADM	0.63	9.11	0.39	2.57e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg10326726	chr10:51549505	MSMB	-0.69	-14.53	-0.56	1.09e-39	Prostate-specific antigen levels;
LGG	trans	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg26043149	chr18:55253948	FECH	0.69	12.06	0.49	2.47e-29	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs12517041	0.935	rs13152937	chr5:23304368	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22929808	chr12:58027113	B4GALNT1	0.5	7.47	0.33	3.98e-13	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15778350	chr1:163291775	NUF2	0.41	6.68	0.3	6.71e-11	Cognitive performance;
LGG	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg22044901	chr15:68126292	NA	-0.4	-6.86	-0.3	2.18e-11	Restless legs syndrome;
LGG	cis	rs3092073	0.669	rs11697323	chr20:44551579	C/T	cg27529037	chr20:44575021	PCIF1	0.4	7.64	0.33	1.27e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03264133	chr6:25882463	NA	-0.52	-9.64	-0.41	3.79e-20	Height;
LGG	cis	rs2693698	0.679	rs4905809	chr14:99692739	C/T	cg07440398	chr14:99712966	BCL11B	0.57	12.3	0.5	2.66e-30	Schizophrenia;
LGG	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg26655873	chr3:72818019	SHQ1	0.34	7.17	0.32	2.91e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.68	0.44	6.11e-24	Body mass index;
LGG	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg16141378	chr3:129829833	LOC729375	-0.56	-14.69	-0.56	2.22e-40	Systolic blood pressure;
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.52	-0.33	2.79e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs526231	0.511	rs158402	chr5:102415525	G/A	cg23492399	chr5:102201601	PAM	-0.56	-8.27	-0.36	1.4e-15	Primary biliary cholangitis;
LGG	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs7619833	0.935	rs6551196	chr3:27432206	T/C	cg02860705	chr3:27208620	NA	0.34	6.74	0.3	4.59e-11	Breast cancer;
LGG	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-6.99	-0.31	9.65e-12	Schizophrenia;
LGG	cis	rs1109114	0.816	rs998583	chr5:148612619	G/T	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.91	-0.59	8.69e-46	Body mass index;
LGG	cis	rs12210905	0.858	rs858992	chr6:27180827	G/C	cg23155468	chr6:27110703	HIST1H2BK	0.51	6.66	0.3	7.86e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.8	-0.3	3.3e-11	Body mass index;
LGG	cis	rs4900538	0.855	rs9788420	chr14:102839338	A/G	cg18135206	chr14:102964638	TECPR2	-0.7	-12.58	-0.5	2e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.82	-0.3	2.82e-11	Total body bone mineral density;
LGG	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	7.57	0.33	2.09e-13	Triglycerides;
LGG	cis	rs754423	0.622	rs730531	chr14:52518683	A/G	cg05884192	chr14:52515736	NID2	-0.33	-6.96	-0.31	1.19e-11	Craniofacial microsomia;
LGG	cis	rs4679904	0.960	rs73875290	chr3:160232240	G/A	cg20378687	chr3:160281681	KPNA4	-0.35	-6.69	-0.3	6.48e-11	Primary biliary cholangitis;
LGG	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.39	-0.79	6.66e-99	Primary sclerosing cholangitis;
LGG	cis	rs679087	1.000	rs436124	chr12:29916839	C/T	cg14258853	chr12:29935411	TMTC1	0.43	8.6	0.37	1.23e-16	Schizophrenia;
LGG	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs9398803	0.865	rs1538172	chr6:126748493	A/G	cg19875578	chr6:126661172	C6orf173	0.58	10.61	0.44	1.11e-23	Male-pattern baldness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25380868	chr2:217498826	IGFBP2	0.48	7.5	0.33	3.33e-13	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg15704280	chr7:45808275	SEPT13	0.79	12.6	0.51	1.73e-31	Coronary artery disease;
LGG	cis	rs9547996	1.000	rs9547998	chr13:38223134	T/G	cg17979426	chr13:38220150	TRPC4	-0.46	-8.89	-0.38	1.42e-17	Diastolic blood pressure;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg02524346	chr8:600233	NA	1.15	11.31	0.47	2.25e-26	IgG glycosylation;
LGG	cis	rs5753618	0.539	rs695438	chr22:31811876	G/C	cg02404636	chr22:31891804	SFI1	0.36	6.91	0.31	1.61e-11	Colorectal cancer;
LGG	cis	rs5762813	0.515	rs5762822	chr22:29219601	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg01943577	chr7:158741284	NA	-0.42	-7.67	-0.34	9.98e-14	Height;
LGG	cis	rs9880211	0.904	rs9857833	chr3:136404467	T/C	cg21827317	chr3:136751795	NA	-0.49	-7.29	-0.32	1.38e-12	Body mass index;Height;
LGG	cis	rs77972916	0.519	rs13411327	chr2:43515483	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.5	-0.33	3.24e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.32	-0.32	1.13e-12	Inflammatory bowel disease;
LGG	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.79	-0.34	4.36e-14	IgG glycosylation;
LGG	cis	rs6142618	0.562	rs6061197	chr20:30750346	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg16414030	chr3:133502952	NA	-0.48	-7.92	-0.35	1.81e-14	Iron status biomarkers;
LGG	cis	rs490647	0.652	rs504383	chr1:37254662	T/G	cg24672014	chr1:37203461	NA	0.35	7.41	0.33	5.9e-13	Neuroticism;
LGG	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg03689076	chr20:33865952	NA	0.65	9.18	0.39	1.39e-18	Attention deficit hyperactivity disorder;
LGG	cis	rs4363385	0.720	rs1970328	chr1:152975829	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	trans	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg17712092	chr4:129076599	LARP1B	0.63	10.69	0.44	5.64e-24	DNA methylation (variation);
LGG	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg01448562	chr3:133502909	NA	-0.72	-13.38	-0.53	9.24e-35	Iron status biomarkers;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.58	0.5	2.02e-31	IgG glycosylation;
LGG	cis	rs11203032	0.831	rs11203014	chr10:90940333	C/G	cg16672925	chr10:90967113	CH25H	0.78	11.12	0.46	1.29e-25	Heart failure;
LGG	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.28	0.32	1.45e-12	Menopause (age at onset);
LGG	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg24642844	chr7:1081250	C7orf50	-0.74	-13.23	-0.52	4.13e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.75	-8.84	-0.38	2.05e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01516881	chr6:292596	DUSP22	-0.53	-9.2	-0.39	1.22e-18	Menopause (age at onset);
LGG	cis	rs4950322	0.570	rs72692920	chr1:146780214	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08924488	chr3:113464993	ATP6V1A;NAA50	0.49	7.16	0.32	3.11e-12	Gut microbiome composition (summer);
LGG	cis	rs10927875	0.632	rs7535248	chr1:16129598	C/T	cg21385522	chr1:16154831	NA	-1.03	-25.72	-0.77	2.81e-91	Dilated cardiomyopathy;
LGG	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg11812906	chr14:75593930	NEK9	-0.51	-9.31	-0.4	5.14e-19	Height;
LGG	cis	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg08930214	chr7:62859557	LOC100287834	0.44	7.08	0.31	5.36e-12	Obesity-related traits;
LGG	cis	rs7937612	0.931	rs61898351	chr11:120199924	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.51	-11.98	-0.49	5.45e-29	Intraocular pressure;
LGG	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg20578329	chr17:80767326	TBCD	-0.77	-11.12	-0.46	1.32e-25	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4696584	0.816	rs4696587	chr4:155405655	C/T	cg04517429	chr4:155413618	DCHS2	0.32	7.63	0.33	1.31e-13	Folding of antihelix;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs2797160	0.967	rs1578793	chr6:126015057	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.09	-17.82	-0.64	1.72e-54	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.79	-0.51	2.68e-32	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg06558623	chr16:89946397	TCF25	1.02	12.76	0.51	3.69e-32	Skin colour saturation;
LGG	cis	rs9911578	0.967	rs9907940	chr17:56663842	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.81	0.59	2.59e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.66	-0.3	7.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7010267	0.773	rs4355801	chr8:119923873	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.78	-0.41	1.21e-20	Total body bone mineral density (age 45-60);
LGG	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg06092702	chr1:163392909	NA	-0.46	-8.08	-0.35	5.82e-15	Motion sickness;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg07332563	chr6:291687	DUSP22	-0.41	-6.88	-0.3	1.92e-11	Menopause (age at onset);
LGG	cis	rs11874712	0.933	rs8097521	chr18:43666952	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg05863683	chr7:1912471	MAD1L1	0.44	8.53	0.37	2.12e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2273669	0.915	rs67708237	chr6:109292058	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-7.42	-0.33	5.55e-13	Prostate cancer;
LGG	cis	rs9557207	0.901	rs913430	chr13:99788474	G/A	cg24509225	chr13:100037070	UBAC2	-0.64	-11.3	-0.47	2.52e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg14092988	chr3:52407081	DNAH1	0.31	8.14	0.35	3.68e-15	Bipolar disorder;
LGG	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.53	0.4	9.03e-20	Dupuytren's disease;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.9	-0.51	9.68e-33	Schizophrenia;
LGG	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg15556689	chr8:8085844	FLJ10661	0.5	9.42	0.4	2.07e-19	Mood instability;
LGG	trans	rs1997103	1.000	rs10278894	chr7:55404748	A/G	cg20935933	chr6:143382018	AIG1	0.56	8.64	0.37	8.99e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg05338066	chr1:7812865	CAMTA1	-0.47	-7.25	-0.32	1.74e-12	Inflammatory bowel disease;
LGG	cis	rs9388451	0.626	rs9385383	chr6:126086290	G/T	cg05901451	chr6:126070800	HEY2	-0.68	-12.96	-0.52	5.57e-33	Brugada syndrome;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg22535103	chr8:58192502	C8orf71	0.95	12.58	0.5	2.02e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg16339924	chr4:17578868	LAP3	0.62	10.53	0.44	2.13e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs747650	0.892	rs12291341	chr11:47242761	G/A	cg03339077	chr11:47165057	C11orf49	0.51	9.39	0.4	2.62e-19	Acne (severe);
LGG	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs68170813	0.559	rs6965001	chr7:106933196	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.58	-0.44	1.42e-23	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	1.000	rs4660896	chr1:46372416	A/G	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12643440	0.503	rs7699243	chr4:17159265	T/G	cg22650099	chr4:17144496	NA	-0.54	-9.18	-0.39	1.39e-18	Metabolite levels (Pyroglutamine);
LGG	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	cis	rs12474201	0.963	rs11676737	chr2:46929873	T/C	cg06386533	chr2:46925753	SOCS5	0.78	14.34	0.55	7.68e-39	Height;
LGG	cis	rs9487094	0.922	rs6916579	chr6:109851638	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.82	0.38	2.39e-17	Height;
LGG	cis	rs3106136	0.546	rs2664880	chr4:95144177	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.94	-0.45	6.4e-25	Capecitabine sensitivity;
LGG	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg24253500	chr15:84953950	NA	0.58	10.48	0.44	3.22e-23	Schizophrenia;
LGG	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg05775895	chr3:12838266	CAND2	0.69	12.67	0.51	8.53e-32	QRS complex (12-leadsum);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15781316	chr7:96339267	SHFM1	-0.49	-7.17	-0.32	2.92e-12	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.37	0.56	5.56e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg18252515	chr7:66147081	NA	-1.38	-18.81	-0.66	4.92e-59	Diabetic kidney disease;
LGG	cis	rs7666738	0.830	rs13129503	chr4:98987892	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg08975724	chr8:8085496	FLJ10661	0.49	9.24	0.39	8.84e-19	Myopia (pathological);
LGG	cis	rs6546537	0.550	rs12617329	chr2:69781530	C/A	cg10773587	chr2:69614142	GFPT1	-0.44	-7.64	-0.33	1.27e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs10892173	1.000	rs10892173	chr11:117672561	C/T	cg07621104	chr11:117668040	DSCAML1	0.46	6.87	0.3	2.13e-11	Myopia;
LGG	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg09818912	chr17:20140352	CYTSB	0.31	7.3	0.32	1.25e-12	Schizophrenia;
LGG	cis	rs12765878	0.756	rs6584579	chr10:105645725	A/G	cg11005552	chr10:105648138	OBFC1	-0.81	-16.16	-0.6	6.52e-47	Coronary artery disease;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.38	-0.32	7.6e-13	Height;
LGG	cis	rs7712401	0.607	rs246270	chr5:122258649	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.18	0.32	2.73e-12	Mean platelet volume;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.51	7.69	0.34	8.92e-14	Hip circumference adjusted for BMI;
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.06	0.39	3.72e-18	Bipolar disorder;
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg27329371	chr17:19651940	ALDH3A1	-0.9	-21.94	-0.71	1.18e-73	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs2108225	0.837	rs6466186	chr7:107446966	G/C	cg18560240	chr7:107437656	SLC26A3	-0.56	-9.99	-0.42	2.11e-21	Ulcerative colitis;
LGG	cis	rs2905347	0.895	rs2961283	chr7:22640498	A/G	cg18045685	chr7:22629474	NA	0.72	15.48	0.58	7.24e-44	Major depression and alcohol dependence;
LGG	cis	rs2274273	0.840	rs28568813	chr14:55794114	C/G	cg04306507	chr14:55594613	LGALS3	0.63	18.13	0.64	6.93e-56	Protein biomarker;
LGG	cis	rs1957429	0.901	rs7143661	chr14:65378981	G/A	cg23373153	chr14:65346875	NA	1.02	13.23	0.52	4.18e-34	Pediatric areal bone mineral density (radius);
LGG	cis	rs4262150	0.846	rs4958574	chr5:152091901	C/T	cg12297329	chr5:152029980	NA	-0.79	-14.85	-0.57	4.39e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs56399783	0.901	rs73033408	chr7:2879755	C/T	cg19731401	chr7:2775893	GNA12	0.36	6.83	0.3	2.66e-11	Childhood ear infection;
LGG	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg20568497	chr10:133558893	NA	0.32	6.91	0.31	1.63e-11	Survival in rectal cancer;
LGG	cis	rs847649	1.000	rs4620204	chr7:102594217	T/C	cg18108683	chr7:102477205	FBXL13	0.62	13.64	0.54	7.81e-36	Morning vs. evening chronotype;
LGG	cis	rs10992471	0.756	rs7043152	chr9:95138499	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.15	-0.32	3.43e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.13	0.39	2.15e-18	Schizophrenia;
LGG	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg24375607	chr4:120327624	NA	0.62	10.37	0.43	8.55e-23	Corneal astigmatism;
LGG	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.14	-0.49	1.26e-29	Intelligence (multi-trait analysis);
LGG	trans	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.15	31.99	0.83	2.5e-119	Exhaled nitric oxide output;
LGG	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.59e-15	Colorectal cancer;
LGG	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.04	-0.35	7.62e-15	Restless legs syndrome;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06787431	chr3:185827293	ETV5	-0.47	-6.82	-0.3	2.79e-11	Systemic lupus erythematosus;
LGG	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.1	-0.31	4.69e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg24250549	chr1:154909240	PMVK	0.76	15.52	0.58	5.01e-44	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19863630	chr1:156023942	ROBLD3;UBQLN4	0.53	7.7	0.34	8.48e-14	Gut microbiome composition (summer);
LGG	cis	rs459571	0.804	rs448918	chr9:136885979	G/A	cg13789015	chr9:136890014	NCRNA00094	0.59	11.01	0.46	3.23e-25	Platelet distribution width;
LGG	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg11693508	chr17:37793320	STARD3	0.63	9.37	0.4	3.18e-19	Bipolar disorder;
LGG	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg03078520	chr22:18463400	MICAL3	0.58	11.25	0.46	4.16e-26	Presence of antiphospholipid antibodies;
LGG	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	6.96	0.31	1.19e-11	Menarche (age at onset);
LGG	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg02753203	chr1:228287806	NA	-0.63	-11.73	-0.48	5.49e-28	Diastolic blood pressure;
LGG	trans	rs800082	0.668	rs7643301	chr3:144293612	G/A	cg24215973	chr2:240111563	HDAC4	-0.64	-12.66	-0.51	9.71e-32	Smoking behavior;
LGG	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg24692254	chr21:30365293	RNF160	0.57	10.12	0.43	6.91e-22	Pancreatic cancer;
LGG	cis	rs11229555	0.874	rs12800710	chr11:58314540	C/T	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	8.52e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg07395648	chr5:131743802	NA	0.55	13.07	0.52	1.84e-33	Blood metabolite levels;
LGG	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg11584989	chr19:19387371	SF4	0.75	12.48	0.5	4.98e-31	Bipolar disorder;
LGG	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg03929089	chr4:120376271	NA	0.68	8.07	0.35	6.23e-15	Intraocular pressure;
LGG	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg11266682	chr4:10021025	SLC2A9	0.56	11.22	0.46	5.44e-26	Bone mineral density;
LGG	cis	rs950169	0.545	rs4842841	chr15:84641125	G/A	cg24253500	chr15:84953950	NA	0.44	7.02	0.31	7.9e-12	Schizophrenia;
LGG	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg06886374	chr16:1844152	IGFALS	0.45	8.2	0.36	2.4e-15	Insulin-like growth factors;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg25173464	chr15:68126554	NA	-0.35	-7.28	-0.32	1.42e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.69	-0.34	9.01e-14	Neuroticism;
LGG	cis	rs11920090	0.858	rs11717435	chr3:170691812	G/A	cg09710316	chr3:170744871	SLC2A2	0.66	8.52	0.37	2.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6840360	0.642	rs2709828	chr4:152355268	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.81	-0.3	3.01e-11	Childhood ear infection;
LGG	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.56	-0.37	1.66e-16	Platelet distribution width;
LGG	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg15704280	chr7:45808275	SEPT13	-0.81	-13.62	-0.53	9.06e-36	Coronary artery disease;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg11584989	chr19:19387371	SF4	0.43	7.8	0.34	4.11e-14	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg18379455	chr17:41446167	NA	-0.32	-7.18	-0.32	2.77e-12	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg18379455	chr17:41446167	NA	-0.33	-7.37	-0.32	7.74e-13	Menopause (age at onset);
LGG	cis	rs17039065	0.920	rs72891080	chr4:109471522	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg19223190	chr17:80058835	NA	-0.48	-9.53	-0.4	9.06e-20	Life satisfaction;
LGG	cis	rs988958	0.526	rs2119171	chr2:42254637	T/G	cg27252766	chr2:42229092	NA	0.5	7.13	0.31	3.99e-12	Hypospadias;
LGG	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg21775007	chr8:11205619	TDH	-0.51	-8.31	-0.36	1.04e-15	Triglycerides;
LGG	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg00717180	chr2:96193071	NA	-0.47	-8.83	-0.38	2.11e-17	HDL cholesterol;
LGG	trans	rs7615952	0.512	rs2979351	chr3:125363599	C/T	cg07211511	chr3:129823064	LOC729375	-0.48	-7.13	-0.31	3.82e-12	Blood pressure (smoking interaction);
LGG	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.69	-0.48	7.81e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.05	0.42	1.31e-21	Lung cancer in ever smokers;
LGG	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg01620082	chr3:125678407	NA	-0.62	-7.68	-0.34	9.29e-14	Depression;
LGG	cis	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.88	-0.3	2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.8	0.38	2.76e-17	Colorectal cancer;
LGG	cis	rs4819388	0.915	rs7278940	chr21:45648992	C/T	cg01992765	chr21:45622493	NA	0.44	8.35	0.36	7.75e-16	Celiac disease;
LGG	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7226408	0.857	rs72887052	chr18:34487296	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	7.16	0.32	3.11e-12	Body mass index;
LGG	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.11	-0.39	2.57e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg07959490	chr17:80112427	CCDC57	0.39	7.56	0.33	2.15e-13	Life satisfaction;
LGG	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-10.39	-0.43	7.12e-23	Morning vs. evening chronotype;
LGG	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.45	-7.71	-0.34	7.9e-14	Coronary artery disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08215925	chr3:71633214	FOXP1	-0.48	-7.04	-0.31	7.08e-12	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs1318772	1.000	rs13177178	chr5:112625124	C/T	cg12552261	chr5:112820674	MCC	0.71	8.18	0.36	2.86e-15	F-cell distribution;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg19676328	chr12:49525230	TUBA1B	-0.62	-9.89	-0.42	4.66e-21	Total cholesterol levels;
LGG	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg27398817	chr8:82754497	SNX16	0.7	10.88	0.45	1.09e-24	Diastolic blood pressure;
LGG	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg24623649	chr8:11872141	NA	0.29	6.77	0.3	3.93e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs80033912	0.640	rs6785832	chr3:49224316	C/T	cg07636037	chr3:49044803	WDR6	0.47	7.6	0.33	1.71e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2522056	1.000	rs11242113	chr5:131777234	G/A	cg07395648	chr5:131743802	NA	0.41	7.12	0.31	4.08e-12	Lymphocyte counts;Fibrinogen;
LGG	cis	rs7503807	0.515	rs12948040	chr17:78678434	A/G	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.53e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07685180	chr8:600429	NA	1.04	10.7	0.45	5.17e-24	IgG glycosylation;
LGG	cis	rs422249	0.512	rs174577	chr11:61604814	A/C	cg19610905	chr11:61596333	FADS2	0.75	13.76	0.54	2.44e-36	Trans fatty acid levels;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg12419862	chr22:24373484	LOC391322	-0.87	-17.01	-0.62	9.35e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13082711	1.000	rs13082711	chr3:27537909	T/C	cg02860705	chr3:27208620	NA	0.84	14.83	0.57	5.73e-41	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4319547	1.000	rs10998	chr12:122989412	G/A	cg23029597	chr12:123009494	RSRC2	-0.95	-18.08	-0.64	1.11e-55	Body mass index;
LGG	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg09307838	chr4:120376055	NA	0.74	12.65	0.51	1.07e-31	Corneal astigmatism;
LGG	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.83	0.42	7.72e-21	Menarche (age at onset);
LGG	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs6834538	0.559	rs10434014	chr4:113401357	C/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	7.46	0.33	4.24e-13	Free thyroxine concentration;
LGG	cis	rs7246760	1.000	rs1592997	chr19:9900983	G/A	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.51e-11	Pursuit maintenance gain;
LGG	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.36	-0.32	8.53e-13	Body mass index;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.55	9.67	0.41	2.81e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00689492	chr4:1303491	MAEA	0.46	7.92	0.35	1.72e-14	Obesity-related traits;
LGG	cis	rs9818758	0.607	rs66991555	chr3:49228643	A/G	cg00383909	chr3:49044727	WDR6	0.97	12.29	0.5	3.02e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg19628046	chr18:33552617	C18orf21	0.52	7.56	0.33	2.22e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2798269	0.966	rs2761914	chr13:22137130	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs9397585	0.637	rs9384069	chr6:153370902	T/G	cg17707550	chr6:153380415	RGS17	0.63	14.84	0.57	4.84e-41	Body mass index;
LGG	cis	rs7503807	0.688	rs731452	chr17:78599052	G/T	cg18469159	chr17:78755841	RPTOR	-0.38	-6.95	-0.31	1.25e-11	Obesity;
LGG	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg22643751	chr7:855365	UNC84A	-0.44	-7.12	-0.31	4.07e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	12.44	0.5	7.24e-31	Neutrophil percentage of white cells;
LGG	trans	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.79	-0.45	2.29e-24	Pursuit maintenance gain;
LGG	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs13314892	0.843	rs57537586	chr3:69833100	C/T	cg17445875	chr3:69859618	MITF	-0.36	-7.45	-0.33	4.6e-13	QRS complex (12-leadsum);
LGG	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg05941027	chr17:61774174	LIMD2	-0.3	-7.12	-0.31	4.13e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7916697	0.593	rs7912895	chr10:70021498	A/G	cg04882175	chr6:131122610	NA	-0.43	-6.67	-0.3	7.13e-11	Optic disc area;
LGG	cis	rs10883723	0.738	rs715438	chr10:104258303	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	13.98	0.54	2.73e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg02462569	chr6:150064036	NUP43	0.43	9.23	0.39	9.94e-19	Lung cancer;
LGG	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg24450063	chr1:156163899	SLC25A44	1.25	32.46	0.83	2.22e-121	Testicular germ cell tumor;
LGG	cis	rs4237845	0.735	rs11172375	chr12:58291574	G/C	cg02175503	chr12:58329896	NA	0.61	10.76	0.45	3.12e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg11965913	chr1:205819406	PM20D1	0.45	7.14	0.31	3.65e-12	Parkinson's disease;
LGG	cis	rs3219090	0.962	rs2793380	chr1:226588977	C/G	cg17127702	chr1:226594323	PARP1	0.38	12.23	0.49	5.25e-30	Melanoma;
LGG	cis	rs4356932	0.967	rs28433437	chr4:76972653	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.71	-0.3	5.62e-11	Blood protein levels;
LGG	cis	rs4700695	0.841	rs957526	chr5:65345830	A/G	cg21114390	chr5:65439923	SFRS12	0.58	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9547996	0.836	rs61957483	chr13:38147504	T/C	cg13634560	chr13:38173852	POSTN	-0.36	-7.29	-0.32	1.37e-12	Diastolic blood pressure;
LGG	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg00325661	chr8:49890786	NA	-0.43	-7.22	-0.32	2.21e-12	Sudden cardiac arrest;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg16507663	chr6:150244633	RAET1G	0.43	7.99	0.35	1.08e-14	Lung cancer;
LGG	cis	rs8056064	0.739	rs12597383	chr16:82805803	A/G	cg08271366	chr16:82816457	CDH13	-0.46	-7.71	-0.34	7.61e-14	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs10851411	0.697	rs17766258	chr15:42785137	A/G	cg21293051	chr15:42870591	STARD9	-0.51	-7.19	-0.32	2.62e-12	Glucose homeostasis traits;
LGG	cis	rs9354308	0.764	rs1353875	chr6:66609751	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg03929089	chr4:120376271	NA	0.84	13.22	0.52	4.67e-34	Height;
LGG	cis	rs9733	0.650	rs4970923	chr1:150608300	A/G	cg13175981	chr1:150552382	MCL1	0.58	9.89	0.42	4.92e-21	Tonsillectomy;
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg13047869	chr3:10149882	C3orf24	0.54	7.88	0.34	2.29e-14	Alzheimer's disease;
LGG	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg20821713	chr7:1055600	C7orf50	-0.47	-6.8	-0.3	3.21e-11	Bronchopulmonary dysplasia;
LGG	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg08847533	chr14:75593920	NEK9	-0.62	-12.19	-0.49	7.71e-30	Height;
LGG	cis	rs17039065	0.920	rs7672020	chr4:109436064	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.74	0.34	6.43e-14	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg01244601	chr4:120671846	NA	-0.39	-7.5	-0.33	3.21e-13	Corneal astigmatism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13383235	chr7:7680321	RPA3	0.42	7.07	0.31	5.9e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs6825911	0.543	rs1487260	chr4:111354224	C/G	cg10580549	chr19:53101634	ZNF137	0.55	6.97	0.31	1.1e-11	Blood pressure;
LGG	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg04546413	chr19:29218101	NA	0.88	15.33	0.58	3.25e-43	Methadone dose in opioid dependence;
LGG	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg03258749	chr1:151040405	MLLT11	-0.47	-8.36	-0.36	7.2e-16	Childhood ear infection;
LGG	cis	rs2224391	0.628	rs2753236	chr6:5252214	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.33	-0.32	1.01e-12	Height;
LGG	cis	rs6908034	0.556	rs77486465	chr6:19803862	T/G	cg02682789	chr6:19804855	NA	0.91	8.25	0.36	1.6e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg10160682	chr2:1713001	PXDN	-0.56	-9.5	-0.4	1.16e-19	Response to antipsychotic treatment;
LGG	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg22920501	chr2:26401640	FAM59B	-0.46	-9.22	-0.39	1.07e-18	Gut microbiome composition (summer);
LGG	cis	rs477692	0.544	rs7894836	chr10:131442595	T/A	cg05714579	chr10:131428358	MGMT	-0.86	-20.23	-0.68	1.18e-65	Response to temozolomide;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.75	0.3	4.5e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.84	0.38	1.94e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10089	1.000	rs883074	chr5:127445823	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-11.81	-0.48	2.68e-28	Ileal carcinoids;
LGG	cis	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg24134504	chr18:76639479	NA	-0.62	-7.9	-0.34	2.07e-14	Obesity-related traits;
LGG	trans	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg24247370	chr13:99142703	STK24	-0.39	-6.92	-0.31	1.55e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4731207	0.698	rs11980925	chr7:124483707	T/A	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg02002194	chr4:3960332	NA	-0.51	-10.01	-0.42	1.71e-21	Mood instability;
LGG	trans	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg25214090	chr10:38739885	LOC399744	0.61	11.09	0.46	1.64e-25	Corneal astigmatism;
LGG	trans	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.06	0.46	2.16e-25	Corneal astigmatism;
LGG	cis	rs75920871	0.640	rs61903395	chr11:116931907	A/G	cg20608306	chr11:116969690	SIK3	-0.3	-6.66	-0.3	8e-11	Subjective well-being;
LGG	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg00405596	chr8:11794950	NA	-0.43	-7.32	-0.32	1.09e-12	Monocyte count;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg26174226	chr8:58114915	NA	-0.57	-7.6	-0.33	1.71e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16405210	chr4:1374714	KIAA1530	-0.67	-12.47	-0.5	5.46e-31	Longevity;
LGG	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs367943	0.673	rs7708084	chr5:112732692	G/T	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.58e-23	Type 2 diabetes;
LGG	cis	rs17001868	0.568	rs2075764	chr22:40758581	C/T	cg07138101	chr22:40742427	ADSL	0.69	8.9	0.38	1.29e-17	Mammographic density (dense area);
LGG	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg02002194	chr4:3960332	NA	-0.46	-8.75	-0.38	3.97e-17	Neuroticism;
LGG	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.38	0.32	7.22e-13	Bladder cancer;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.76	0.79	1.34e-100	Height;
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.19	-0.52	5.75e-34	Personality dimensions;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.01	-0.52	3.5e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs1957429	0.520	rs72625646	chr14:65343809	C/A	cg23373153	chr14:65346875	NA	-0.96	-9.42	-0.4	2.18e-19	Pediatric areal bone mineral density (radius);
LGG	cis	rs4363385	0.550	rs2050673	chr1:152923698	C/T	cg13444842	chr1:152974279	SPRR3	-0.46	-9.06	-0.39	3.62e-18	Inflammatory skin disease;
LGG	cis	rs17221829	0.965	rs11018751	chr11:89458909	G/T	cg02982614	chr11:89391479	FOLH1B	0.34	7.55	0.33	2.26e-13	Anxiety in major depressive disorder;
LGG	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg12463550	chr7:65579703	CRCP	0.75	7.94	0.35	1.53e-14	Diabetic kidney disease;
LGG	cis	rs16912285	0.748	rs7104694	chr11:24280281	A/C	ch.11.24196551F	chr11:24239977	NA	0.89	13.36	0.53	1.19e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2898279	0.801	rs2001463	chr8:11295511	A/G	cg26274995	chr8:11302983	FAM167A	0.49	9.4	0.4	2.51e-19	Small cell lung carcinoma;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs988958	0.636	rs7581391	chr2:42219967	G/C	cg27252766	chr2:42229092	NA	0.53	8.33	0.36	9.52e-16	Hypospadias;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.3	0.36	1.17e-15	Tonsillectomy;
LGG	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.89	0.31	1.82e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg08302650	chr8:145750040	LRRC24;LRRC14	-0.37	-8.25	-0.36	1.67e-15	Age at first birth;
LGG	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg12310025	chr6:25882481	NA	-0.62	-11.5	-0.47	4.12e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg18032289	chr17:61959525	GH2	-0.41	-6.75	-0.3	4.44e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9341808	0.718	rs2143887	chr6:80917287	T/C	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg07061783	chr6:25882402	NA	0.43	7.55	0.33	2.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.25	-0.36	1.66e-15	Lymphocyte counts;
LGG	cis	rs36051895	0.530	rs2093447	chr9:5230374	G/T	cg02405213	chr9:5042618	JAK2	-0.67	-11.66	-0.48	1.03e-27	Pediatric autoimmune diseases;
LGG	cis	rs9814567	1.000	rs62269547	chr3:134214042	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.3	-0.53	2.07e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7572733	0.773	rs970551	chr2:198497709	C/T	cg00792783	chr2:198669748	PLCL1	0.4	6.65	0.3	8.46e-11	Dermatomyositis;
LGG	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg21972741	chr5:435613	AHRR	0.49	8.92	0.38	1.07e-17	Cystic fibrosis severity;
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg05535760	chr7:792225	HEATR2	-0.79	-11.24	-0.46	4.55e-26	Cerebrospinal P-tau181p levels;
LGG	cis	rs6430585	0.528	rs75753154	chr2:136665711	T/C	cg07169764	chr2:136633963	MCM6	1.26	25.06	0.76	3.41e-88	Corneal structure;
LGG	cis	rs910316	0.687	rs11627442	chr14:75669649	A/G	cg08847533	chr14:75593920	NEK9	-0.5	-9.36	-0.4	3.46e-19	Height;
LGG	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg21699342	chr2:239360505	ASB1	0.39	7.45	0.33	4.54e-13	Multiple system atrophy;
LGG	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.87	0.34	2.59e-14	Mood instability;
LGG	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg03476357	chr21:30257390	N6AMT1	0.46	7.9	0.34	2.02e-14	Cognitive test performance;
LGG	cis	rs17125944	0.556	rs12588482	chr14:53311552	G/A	cg00686598	chr14:53173677	PSMC6	-0.71	-7.42	-0.33	5.54e-13	Alzheimer's disease (late onset);
LGG	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg08305652	chr11:111469057	NA	-0.43	-8.52	-0.37	2.26e-16	Primary sclerosing cholangitis;
LGG	cis	rs9457247	0.967	rs425039	chr6:167410527	C/T	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.67	-0.3	7.2e-11	Electroencephalogram traits;
LGG	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-21.27	-0.7	1.49e-70	Body mass index;
LGG	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs9649465	0.935	rs3807636	chr7:123368488	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17554472	chr22:41940697	POLR3H	0.47	6.73	0.3	5.14e-11	Vitiligo;
LGG	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.72	-0.34	7.15e-14	HDL cholesterol;
LGG	cis	rs9811920	0.683	rs10936003	chr3:99667565	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.43	-7.51	-0.33	3.11e-13	Axial length;
LGG	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.25	-0.4	8.09e-19	Menarche (age at onset);
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg20453264	chr5:131705742	SLC22A5	0.63	7.99	0.35	1.06e-14	Rheumatoid arthritis;
LGG	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg13010199	chr12:38710504	ALG10B	0.58	11.18	0.46	7.37e-26	Bladder cancer;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg23758822	chr17:41437982	NA	0.88	16.13	0.6	9.24e-47	Menopause (age at onset);
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17320237	chr2:71454500	PAIP2B	0.43	6.69	0.3	6.41e-11	Gut microbiome composition (summer);
LGG	cis	rs2421770	0.532	rs4459280	chr11:35343355	C/T	cg10331829	chr11:35343789	SLC1A2	-0.33	-7.38	-0.32	7.39e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs6032067	0.777	rs2868237	chr20:43794189	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs3764400	0.506	rs72827851	chr17:46452495	C/A	cg10706073	chr17:46328419	SKAP1	-0.46	-6.91	-0.31	1.59e-11	Body mass index;
LGG	cis	rs2976388	0.609	rs2717605	chr8:143801015	T/G	cg06565975	chr8:143823917	SLURP1	0.37	9.42	0.4	2.11e-19	Urinary tract infection frequency;
LGG	trans	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.78	-13.3	-0.53	2.05e-34	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg18032289	chr17:61959525	GH2	-0.4	-6.98	-0.31	1.04e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9487051	0.737	rs1260593	chr6:109521400	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.61	-0.37	1.19e-16	Lung cancer;
LGG	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Alcohol dependence;
LGG	cis	rs360798	0.512	rs2710637	chr2:63173450	G/A	cg17519650	chr2:63277830	OTX1	0.47	7.64	0.33	1.25e-13	Coronary artery disease;
LGG	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg24110177	chr3:50126178	RBM5	0.4	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.62	-0.37	1.09e-16	Response to antipsychotic treatment;
LGG	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg12081754	chr8:22256438	SLC39A14	-0.78	-15.94	-0.6	6.14e-46	Verbal declarative memory;
LGG	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg00666640	chr1:248458726	OR2T12	0.54	9.15	0.39	1.86e-18	Common traits (Other);
LGG	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.3	-0.32	1.25e-12	IgG glycosylation;
LGG	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg04317338	chr11:64019027	PLCB3	0.65	8.11	0.35	4.5e-15	Mean platelet volume;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg16606324	chr3:10149918	C3orf24	0.58	7.7	0.34	8.38e-14	Alzheimer's disease;
LGG	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-9.85	-0.42	6.77e-21	Chronic sinus infection;
LGG	trans	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg00129232	chr17:37814104	STARD3	-0.5	-9.55	-0.41	7.29e-20	Self-reported allergy;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg14926445	chr8:58193284	C8orf71	-0.77	-9.56	-0.41	7.27e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7695597	0.708	rs12503453	chr4:185179367	A/G	cg12654155	chr4:185238627	NA	-0.42	-7.5	-0.33	3.27e-13	Night sleep phenotypes;
LGG	cis	rs240764	0.658	rs6909880	chr6:101179354	A/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.78	-0.34	4.79e-14	Neuroticism;
LGG	trans	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg20587970	chr11:113659929	NA	-1.16	-19.76	-0.68	1.69e-63	Hip circumference adjusted for BMI;
LGG	trans	rs11875185	0.510	rs76418149	chr18:55596403	A/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2354432	0.607	rs894469	chr1:146672906	C/T	cg25205988	chr1:146714368	CHD1L	1.05	9.27	0.4	6.89e-19	Mitochondrial DNA levels;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg13939156	chr17:80058883	NA	-0.45	-8.88	-0.38	1.53e-17	Life satisfaction;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg27471124	chr11:109292789	C11orf87	0.48	9.54	0.41	7.91e-20	Schizophrenia;
LGG	cis	rs45430	0.665	rs431563	chr21:42740949	C/T	cg22778903	chr21:42741698	MX2	0.38	7.3	0.32	1.22e-12	Melanoma;
LGG	cis	rs2239547	0.522	rs2564947	chr3:53046216	C/T	cg11645453	chr3:52864694	ITIH4	-0.66	-10.21	-0.43	3.25e-22	Schizophrenia;
LGG	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg07148914	chr20:33460835	GGT7	-0.5	-8.17	-0.35	3.04e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.28	-0.36	1.32e-15	Triglycerides;
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg04911050	chr16:677664	RAB40C	0.35	6.96	0.31	1.17e-11	Height;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06028808	chr11:68637592	NA	0.73	12.78	0.51	3.08e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg01200585	chr1:228362443	C1orf69	-0.45	-8.06	-0.35	6.78e-15	Diastolic blood pressure;
LGG	cis	rs6542838	0.704	rs56125264	chr2:99516699	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.72	-0.3	5.44e-11	Fear of minor pain;
LGG	cis	rs2050392	0.931	rs2265189	chr10:30689316	C/T	cg25182066	chr10:30743637	MAP3K8	0.53	10.83	0.45	1.68e-24	Inflammatory bowel disease;
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.76	0.45	2.96e-24	Total body bone mineral density;
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.77	-0.54	2.06e-36	Alzheimer's disease;
LGG	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg18898632	chr2:242989856	NA	-0.74	-9.35	-0.4	3.83e-19	Obesity-related traits;
LGG	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg13072238	chr3:49761600	GMPPB	0.53	6.85	0.3	2.35e-11	Menarche (age at onset);
LGG	cis	rs4696584	0.816	rs1552638	chr4:155402365	A/G	cg13738195	chr4:155413469	DCHS2	0.37	7.19	0.32	2.54e-12	Folding of antihelix;
LGG	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg08344181	chr3:125677491	NA	-0.69	-7.3	-0.32	1.28e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11997175	0.550	rs10954943	chr8:33815972	A/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.44	0.33	4.99e-13	Body mass index;
LGG	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg26248373	chr2:1572462	NA	-0.72	-9.0	-0.39	5.94e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7666738	0.830	rs11935588	chr4:98979862	A/G	cg05340658	chr4:99064831	C4orf37	-0.5	-8.36	-0.36	7.28e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2386661	0.956	rs10905489	chr10:5670541	G/C	cg26603656	chr10:5671107	NA	-0.35	-7.33	-0.32	1.02e-12	Breast cancer;
LGG	cis	rs7188861	1.000	rs7188861	chr16:11454650	C/A	cg01510278	chr16:11456238	NA	0.36	8.45	0.37	3.87e-16	HDL cholesterol;
LGG	cis	rs9399135	0.967	rs6923765	chr6:135335176	C/G	cg24558204	chr6:135376177	HBS1L	-0.5	-8.83	-0.38	2.15e-17	Red blood cell count;
LGG	cis	rs8077889	0.645	rs1230396	chr17:41843029	A/C	cg26893861	chr17:41843967	DUSP3	-1.11	-26.21	-0.77	1.56e-93	Triglycerides;
LGG	trans	rs6787172	0.622	rs12632998	chr3:158096813	G/C	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs607541	0.850	rs673208	chr15:45936292	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	7.37	0.32	7.83e-13	Obesity-related traits;
LGG	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg08648136	chr8:956695	NA	0.44	9.39	0.4	2.76e-19	Schizophrenia;
LGG	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.45	-0.44	4.17e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00911551	chr12:8234647	NECAP1	0.47	7.24	0.32	1.91e-12	Gut microbiome composition (summer);
LGG	trans	rs3960554	0.808	rs3779419	chr7:75695081	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.8	0.51	2.58e-32	Eotaxin levels;
LGG	cis	rs12190007	0.517	rs3006183	chr6:169808263	T/C	cg15038512	chr6:170123185	PHF10	-0.44	-8.54	-0.37	2.01e-16	Obesity-related traits;
LGG	cis	rs2421770	0.532	rs2281633	chr11:35343767	G/T	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.4	-0.33	6.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.91	0.38	1.13e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs1920116	0.744	rs12492658	chr3:169562083	C/T	cg08193579	chr3:169529701	LRRC34	0.42	7.36	0.32	8.71e-13	Glioma (high-grade);
LGG	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12654349	chr5:56205094	C5orf35	0.8	12.27	0.5	3.54e-30	Initial pursuit acceleration;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16837525	chr21:38739074	DYRK1A	-0.46	-7.41	-0.33	6.05e-13	Pancreatic cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02083259	chr16:57220135	RSPRY1;FAM192A	0.49	8.35	0.36	7.87e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg13944838	chr5:179740914	GFPT2	-0.68	-12.88	-0.51	1.2e-32	Height;
LGG	cis	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg13010199	chr12:38710504	ALG10B	0.76	16.2	0.6	4.58e-47	Heart rate;
LGG	cis	rs11169552	0.510	rs11169507	chr12:51015509	A/G	cg12884762	chr12:50931848	DIP2B	0.41	7.64	0.33	1.24e-13	Colorectal cancer;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg17145862	chr1:211918768	LPGAT1	0.97	24.96	0.76	9.02e-88	Leprosy;
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg14912033	chr15:79043428	NA	-0.39	-9.26	-0.4	7.44e-19	Coronary artery disease or large artery stroke;
LGG	cis	rs2120243	0.653	rs3816527	chr3:157155314	C/A	cg24825693	chr3:157122686	VEPH1	-0.39	-8.28	-0.36	1.35e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg17911788	chr17:44343683	NA	0.62	9.47	0.4	1.47e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9381107	0.932	rs9380836	chr6:9441421	A/G	cg14735645	chr6:9486422	NA	-0.41	-7.17	-0.32	2.97e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg12560992	chr17:57184187	TRIM37	-0.87	-15.19	-0.58	1.41e-42	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-7.84	-0.34	3.1e-14	Lung cancer;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg00106254	chr7:1943704	MAD1L1	0.5	9.13	0.39	2.19e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg13206674	chr6:150067644	NUP43	0.68	15.79	0.59	2.93e-45	Lung cancer;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg20453264	chr5:131705742	SLC22A5	0.61	7.76	0.34	5.39e-14	Rheumatoid arthritis;
LGG	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-9.23	-0.39	9.36e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg00717180	chr2:96193071	NA	0.42	7.52	0.33	2.81e-13	HDL cholesterol;
LGG	cis	rs6719977	0.569	rs1016607	chr2:42971687	C/T	cg14631114	chr2:43023945	NA	0.45	9.25	0.39	8.26e-19	Hyperactive-impulsive symptoms;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg05556477	chr5:131705319	SLC22A5	0.85	10.22	0.43	2.95e-22	Rheumatoid arthritis;
LGG	trans	rs9409565	1.000	rs9409565	chr9:97251034	C/T	cg05679027	chr9:99775184	HIATL2	-0.49	-8.24	-0.36	1.8e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs11203032	0.901	rs7098394	chr10:90960906	T/A	cg16672925	chr10:90967113	CH25H	0.84	11.62	0.48	1.42e-27	Heart failure;
LGG	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg18551225	chr6:44695536	NA	-0.66	-11.84	-0.48	1.95e-28	Total body bone mineral density;
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs3820928	1.000	rs11692572	chr2:227774503	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.26	-0.32	1.68e-12	Pulmonary function;
LGG	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg20608306	chr11:116969690	SIK3	0.34	8.88	0.38	1.49e-17	Blood protein levels;
LGG	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07570687	chr10:102243282	WNT8B	0.4	7.27	0.32	1.57e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg21775007	chr8:11205619	TDH	-0.55	-9.05	-0.39	3.87e-18	Triglycerides;
LGG	cis	rs28374715	0.733	rs9568	chr15:41573612	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.24	-26.32	-0.77	5.03e-94	Ulcerative colitis;
LGG	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	6.76e-11	IgG glycosylation;
LGG	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg00647317	chr7:50633725	DDC	-0.33	-7.38	-0.32	7.33e-13	Malaria;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg08621203	chr6:150244597	RAET1G	0.41	6.98	0.31	1.03e-11	Lung cancer;
LGG	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03352830	chr11:487213	PTDSS2	0.83	10.01	0.42	1.78e-21	Body mass index;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg10295955	chr4:187884368	NA	1.14	30.58	0.82	3.55e-113	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg16141378	chr3:129829833	LOC729375	0.4	8.91	0.38	1.21e-17	Mood instability;
LGG	cis	rs981844	1.000	rs72731670	chr4:154662471	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	trans	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg06606381	chr12:133084897	FBRSL1	0.78	7.38	0.32	7.28e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.44	-0.33	4.78e-13	Educational attainment (years of education);
LGG	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.6e-22	Motion sickness;
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.23	-0.32	2.03e-12	Dementia with Lewy bodies;
LGG	trans	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.98	0.42	2.24e-21	Joint mobility (Beighton score);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	6.98	0.31	1.01e-11	Longevity;
LGG	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-18.91	-0.66	1.64e-59	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg04731861	chr2:219085781	ARPC2	-0.45	-11.06	-0.46	2.15e-25	Colorectal cancer;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.41	-0.5	1.02e-30	Depression;
LGG	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg25418670	chr11:30344373	C11orf46	0.57	7.86	0.34	2.7e-14	Morning vs. evening chronotype;
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg14689365	chr7:158441557	NCAPG2	0.62	10.54	0.44	1.91e-23	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17872999	chr7:104653783	MLL5;LOC100216545	-0.46	-6.81	-0.3	3.04e-11	Systemic lupus erythematosus;
LGG	cis	rs17221829	0.965	rs10830366	chr11:89459254	C/T	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.7	-0.34	8.32e-14	Anxiety in major depressive disorder;
LGG	cis	rs11229555	0.645	rs7945992	chr11:58187755	T/A	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7572263	0.724	rs6749281	chr2:209050696	C/A	cg00164906	chr2:209055251	C2orf80	0.72	9.65	0.41	3.45e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg00495681	chr13:53174319	NA	0.51	9.05	0.39	4.06e-18	Lewy body disease;
LGG	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg03862225	chr10:126850454	CTBP2	0.25	6.93	0.31	1.42e-11	Menarche (age at onset);
LGG	cis	rs1691799	0.867	rs1168344	chr12:66758213	G/A	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	cis	rs10870270	1.000	rs7898755	chr10:133777122	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.67	-0.54	5.85e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg25809561	chr17:30822961	MYO1D	0.34	7.81	0.34	3.96e-14	Schizophrenia;
LGG	cis	rs12493885	0.769	rs61791504	chr3:153745537	C/G	cg12800244	chr3:153838788	SGEF	-0.77	-9.28	-0.4	6.32e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg02023728	chr11:77925099	USP35	0.45	8.02	0.35	8.76e-15	Testicular germ cell tumor;
LGG	trans	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg07817883	chr1:32538562	TMEM39B	-0.69	-9.22	-0.39	1.03e-18	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03758392	chr3:184870408	C3orf70	0.42	7.11	0.31	4.53e-12	Gut microbiome composition (summer);
LGG	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg14186256	chr22:23484241	RTDR1	1.02	27.7	0.79	2.49e-100	Bone mineral density;
LGG	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.54	-0.33	2.52e-13	Testicular germ cell tumor;
LGG	cis	rs35306767	0.623	rs72760941	chr10:1141244	A/G	cg25019033	chr10:957182	NA	-0.49	-8.61	-0.37	1.13e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs2629540	0.508	rs12217633	chr10:126533872	A/G	cg08799069	chr10:126477246	METTL10	-0.63	-11.96	-0.49	6.23e-29	Cocaine dependence;
LGG	cis	rs8017423	0.967	rs2277517	chr14:90722778	G/A	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs7315438	0.512	rs1391712	chr12:115941419	G/A	cg18639984	chr12:115943877	NA	-0.4	-8.63	-0.37	9.7e-17	Colorectal cancer;
LGG	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg01324343	chr3:183735012	ABCC5	0.87	18.07	0.64	1.2e-55	Anterior chamber depth;
LGG	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg14186256	chr22:23484241	RTDR1	1.0	24.68	0.75	1.96e-86	Bone mineral density;
LGG	cis	rs7215564	0.908	rs8080789	chr17:78735202	A/G	cg06153925	chr17:78755379	RPTOR	-0.4	-7.11	-0.31	4.4e-12	Myopia (pathological);
LGG	cis	rs36051895	0.623	rs10120337	chr9:5243511	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-13.65	-0.54	6.71e-36	Pediatric autoimmune diseases;
LGG	cis	rs12476592	0.602	rs262485	chr2:63878413	T/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.88	-0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs7010267	0.935	rs4319131	chr8:119947651	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.39	-10.26	-0.43	2.19e-22	Total body bone mineral density (age 45-60);
LGG	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.48	-0.33	3.81e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs4799461	0.693	rs948537	chr18:35125161	C/T	cg27332583	chr18:35150602	NA	0.59	11.66	0.48	9.75e-28	Neuroticism;
LGG	cis	rs7580658	0.895	rs9636237	chr2:128076022	T/C	cg10021288	chr2:128175891	PROC	-0.62	-12.78	-0.51	3.16e-32	Protein C levels;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg22398616	chr13:53314203	LECT1	-0.46	-9.52	-0.4	9.38e-20	Lewy body disease;
LGG	cis	rs735539	1.000	rs6490605	chr13:21285009	C/T	cg04906043	chr13:21280425	IL17D	-0.58	-10.28	-0.43	1.81e-22	Dental caries;
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11644478	chr21:40555479	PSMG1	0.77	14.1	0.55	7.76e-38	Cognitive function;
LGG	cis	rs6817170	0.578	rs13105053	chr4:154369161	G/A	cg07229402	chr4:154369277	NA	0.33	6.67	0.3	7.51e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs12472274	0.617	rs7568705	chr2:239081808	C/T	cg17459225	chr2:239074497	NA	0.66	11.67	0.48	8.9e-28	Phospholipid levels (plasma);
LGG	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg21452805	chr1:244014465	NA	0.67	7.95	0.35	1.42e-14	RR interval (heart rate);
LGG	cis	rs4262150	0.883	rs72802868	chr5:152235215	G/T	cg12297329	chr5:152029980	NA	-0.64	-11.93	-0.49	8.18e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg12046867	chr14:103022105	NA	-0.81	-15.64	-0.59	1.47e-44	Platelet count;
LGG	cis	rs10249651	0.509	rs10264450	chr7:117059654	A/G	cg10524701	chr7:117356490	CTTNBP2	0.4	7.84	0.34	3.17e-14	Coronary artery disease;
LGG	cis	rs12210905	1.000	rs12210905	chr6:27151309	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.0	-0.35	9.97e-15	Hip circumference adjusted for BMI;
LGG	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg04149295	chr10:70884716	VPS26A	0.48	7.35	0.32	9.34e-13	Left atrial antero-posterior diameter;
LGG	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg07928641	chr1:182991847	LAMC1	0.49	10.04	0.42	1.36e-21	Colorectal cancer;
LGG	cis	rs35740288	0.929	rs11635081	chr15:86304260	G/A	cg04173714	chr15:86211321	AKAP13	0.41	7.16	0.32	3.1e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9796	0.870	rs2925346	chr15:41315695	G/A	cg18705301	chr15:41695430	NDUFAF1	0.49	8.39	0.36	5.87e-16	Menopause (age at onset);
LGG	trans	rs148734725	1	rs148734725	chr3:49406708	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-10.06	-0.42	1.17e-21	Educational attainment (college completion);
LGG	cis	rs12765878	0.603	rs10883944	chr10:105651657	G/T	cg11005552	chr10:105648138	OBFC1	-0.71	-12.79	-0.51	2.79e-32	Coronary artery disease;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.86	-0.54	8.41e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs12153243	1.000	rs17342419	chr5:142900260	T/G	cg13907255	chr5:142895549	NA	-0.4	-7.63	-0.33	1.36e-13	Migraine;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg17802220	chr15:77601643	NA	-0.54	-12.25	-0.49	4.31e-30	Type 2 diabetes;
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg05973401	chr12:123451056	ABCB9	0.49	7.32	0.32	1.14e-12	Neutrophil percentage of white cells;
LGG	cis	rs4689388	0.824	rs4580722	chr4:6306144	C/A	cg00701064	chr4:6280414	WFS1	0.68	14.57	0.56	7.8e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg02002194	chr4:3960332	NA	-0.55	-10.76	-0.45	3.1e-24	Neuroticism;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14446504	chr2:3291358	TSSC1	-0.3	-6.88	-0.3	1.92e-11	Bipolar disorder;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg02002194	chr4:3960332	NA	0.53	10.22	0.43	3.15e-22	Neuroticism;
LGG	cis	rs9788682	0.747	rs7174190	chr15:78763617	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.1	-0.35	4.78e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs62400317	0.826	rs11970496	chr6:45125833	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	cis	rs67478160	0.643	rs12880167	chr14:104300829	C/T	cg26031613	chr14:104095156	KLC1	-0.41	-6.73	-0.3	5.1e-11	Schizophrenia;
LGG	cis	rs9534288	0.797	rs718530	chr13:46563653	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.22	-0.52	4.31e-34	Blood protein levels;
LGG	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.41	-0.36	4.98e-16	Neurofibrillary tangles;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg05941027	chr17:61774174	LIMD2	0.36	9.35	0.4	3.63e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9807841	0.617	rs892087	chr19:10794793	C/T	cg17710535	chr19:10819994	QTRT1	0.52	8.39	0.36	5.91e-16	Inflammatory skin disease;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg16400903	chr5:693638	TPPP	0.44	6.72	0.3	5.19e-11	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23088430	chr8:144679052	EEF1D;TIGD5	0.4	6.7	0.3	6.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.27e-27	Type 2 diabetes;
LGG	cis	rs994014	0.572	rs7675510	chr4:82262861	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.77	-0.3	3.92e-11	Height;
LGG	cis	rs722599	0.748	rs929579	chr14:75330697	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-9.55	-0.41	7.54e-20	IgG glycosylation;
LGG	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg03733263	chr8:22462867	KIAA1967	-0.88	-18.53	-0.65	9.44e-58	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9517320	0.967	rs2274056	chr13:99134839	G/C	cg07423050	chr13:99094983	FARP1	0.4	8.17	0.35	3.07e-15	Longevity;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.7e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg12698349	chr2:225449008	CUL3	0.7	12.01	0.49	4.2e-29	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg09165964	chr15:75287851	SCAMP5	-1.01	-19.53	-0.67	2.05e-62	Blood trace element (Zn levels);
LGG	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.1	0.35	4.79e-15	Initial pursuit acceleration;
LGG	cis	rs9557207	1.000	rs9554577	chr13:99900707	G/A	cg24509225	chr13:100037070	UBAC2	0.7	12.49	0.5	4.63e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.33	-0.43	1.22e-22	Hip circumference adjusted for BMI;
LGG	cis	rs72781680	0.821	rs72796361	chr2:24160689	A/T	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.68e-17	Lymphocyte counts;
LGG	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg02753203	chr1:228287806	NA	-0.64	-11.95	-0.49	6.97e-29	Diastolic blood pressure;
LGG	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg11871910	chr12:69753446	YEATS4	0.43	6.77	0.3	3.82e-11	Response to diuretic therapy;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg16507663	chr6:150244633	RAET1G	0.45	8.39	0.36	5.93e-16	Lung cancer;
LGG	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg19920283	chr7:105172520	RINT1	0.59	8.08	0.35	5.58e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.96	-0.35	1.29e-14	Mood instability;
LGG	cis	rs8012	0.517	rs9384	chr19:13010643	G/T	cg11738485	chr19:12877000	HOOK2	-0.45	-7.28	-0.32	1.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs259282	0.524	rs11878322	chr19:33122886	C/T	cg02997394	chr19:33096574	ANKRD27	-0.37	-6.97	-0.31	1.12e-11	Schizophrenia;
LGG	cis	rs1829883	0.898	rs2688941	chr5:98769659	A/G	cg08333243	chr5:99726346	NA	0.37	6.94	0.31	1.29e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9341808	0.718	rs7740627	chr6:80916347	A/G	cg08355045	chr6:80787529	NA	0.41	7.85	0.34	2.84e-14	Sitting height ratio;
LGG	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg08999081	chr20:33150536	PIGU	0.31	7.35	0.32	9.13e-13	Coronary artery disease;
LGG	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg05044414	chr3:183734942	ABCC5	0.72	14.77	0.57	9.73e-41	Anterior chamber depth;
LGG	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-10.93	-0.45	6.76e-25	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07167872	chr1:205819463	PM20D1	0.37	6.87	0.3	2.05e-11	Menarche (age at onset);
LGG	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg19875535	chr5:140030758	IK	-0.56	-11.59	-0.47	1.84e-27	Depressive symptoms (multi-trait analysis);
LGG	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	7.19	0.32	2.56e-12	Initial pursuit acceleration;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg20110707	chr11:118481992	PHLDB1	-0.49	-9.64	-0.41	3.66e-20	Cholesterol, total;
LGG	trans	rs7178375	0.941	rs35497908	chr15:31224071	C/T	cg04373760	chr16:53404718	NA	0.55	8.4	0.36	5.41e-16	Hypertriglyceridemia;
LGG	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs7975161	0.572	rs7299669	chr12:104568919	C/T	cg25273343	chr12:104657179	TXNRD1	-0.83	-7.58	-0.33	1.9e-13	Toenail selenium levels;
LGG	cis	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg15148918	chr7:75625777	STYXL1	-0.69	-7.85	-0.34	2.94e-14	Mononucleosis;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.43	0.4	2.03e-19	Life satisfaction;
LGG	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.44	7.22	0.32	2.08e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg15133208	chr4:90757351	SNCA	-0.33	-7.45	-0.33	4.75e-13	Dementia with Lewy bodies;
LGG	cis	rs2693698	0.550	rs2793322	chr14:99686536	A/G	cg07440398	chr14:99712966	BCL11B	0.51	10.76	0.45	2.99e-24	Schizophrenia;
LGG	trans	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg25214090	chr10:38739885	LOC399744	0.45	8.21	0.36	2.26e-15	Diastolic blood pressure;
LGG	cis	rs11792861	0.816	rs11788336	chr9:111688387	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	10.55	0.44	1.76e-23	Menarche (age at onset);
LGG	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg18681998	chr4:17616180	MED28	0.82	16.81	0.62	7.9e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.87	-0.42	5.76e-21	Lung cancer;
LGG	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs62481355	0.963	rs1419410	chr7:127120497	C/G	cg25922125	chr7:127225783	GCC1	-0.49	-7.14	-0.31	3.73e-12	Type 2 diabetes;
LGG	cis	rs3742264	0.656	rs6561275	chr13:46518299	A/T	cg15192986	chr13:46630673	CPB2	-0.35	-6.87	-0.3	2.05e-11	Blood protein levels;
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.32	-0.53	1.72e-34	Aortic root size;
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg04287289	chr16:89883240	FANCA	0.84	7.98	0.35	1.17e-14	Skin colour saturation;
LGG	cis	rs7188873	1	rs7188873	chr16:24727064	A/G	cg02428538	chr16:24856791	SLC5A11	0.37	6.73	0.3	5.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg16386425	chr10:429943	DIP2C	-0.46	-9.47	-0.4	1.4e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg16230307	chr14:35515116	FAM177A1	0.92	13.57	0.53	1.55e-35	Psoriasis;
LGG	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg26384229	chr12:38710491	ALG10B	0.93	20.76	0.69	3.63e-68	Bladder cancer;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.39	-0.36	6.08e-16	Neuroticism;
LGG	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg18357526	chr6:26021779	HIST1H4A	0.92	18.08	0.64	1.08e-55	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.14	-0.39	2.02e-18	Coronary artery disease;
LGG	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg16070123	chr10:51489643	NA	-0.4	-7.33	-0.32	1.05e-12	Prostate-specific antigen levels;
LGG	cis	rs16937	0.662	rs10900464	chr1:205157100	T/C	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.58e-13	Schizophrenia;
LGG	cis	rs240764	0.717	rs1039032	chr6:101161931	T/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.47	-0.33	3.97e-13	Neuroticism;
LGG	cis	rs7666738	0.830	rs17026973	chr4:98680041	T/A	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.26e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg08847533	chr14:75593920	NEK9	-0.6	-11.21	-0.46	5.67e-26	Height;
LGG	cis	rs7666738	0.830	rs58696666	chr4:99006913	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg15997130	chr1:24165203	NA	0.47	12.68	0.51	7.5e-32	Immature fraction of reticulocytes;
LGG	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg25174290	chr11:3078921	CARS	-0.48	-8.37	-0.36	6.87e-16	Calcium levels;
LGG	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26734620	chr12:56694298	CS	0.77	6.87	0.3	2.13e-11	Psoriasis vulgaris;
LGG	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg00717180	chr2:96193071	NA	-0.41	-7.37	-0.32	8.16e-13	HDL cholesterol;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07659893	chr17:61819838	STRADA	0.49	8.27	0.36	1.4e-15	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg04450456	chr4:17643702	FAM184B	0.3	6.7	0.3	6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg13628971	chr7:2884303	GNA12	-0.33	-6.67	-0.3	7.13e-11	Loneliness (linear analysis);
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg13736514	chr6:26305472	NA	0.45	9.54	0.41	8.25e-20	Educational attainment;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg03709012	chr19:19516395	GATAD2A	0.83	16.71	0.61	2.14e-49	Tonsillectomy;
LGG	cis	rs45544231	0.569	rs4784224	chr16:52580247	C/A	cg09051775	chr16:52580266	TOX3	-0.44	-7.67	-0.34	1.02e-13	Restless legs syndrome;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs959260	0.557	rs12946365	chr17:73317644	C/T	cg14668889	chr17:73230827	NUP85	-0.52	-8.79	-0.38	2.92e-17	Systemic lupus erythematosus;
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg08302650	chr8:145750040	LRRC24;LRRC14	0.35	7.49	0.33	3.46e-13	Age at first birth;
LGG	cis	rs36051895	0.623	rs2181115	chr9:5263058	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-12.48	-0.5	5.29e-31	Pediatric autoimmune diseases;
LGG	cis	rs1109114	0.816	rs2918263	chr5:148616104	G/A	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.59	-0.59	2.39e-44	Body mass index;
LGG	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.23	-0.43	2.89e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg26441486	chr22:50317300	CRELD2	0.4	7.33	0.32	1.06e-12	Schizophrenia;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.76	0.38	3.57e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg16507663	chr6:150244633	RAET1G	0.45	8.47	0.37	3.32e-16	Lung cancer;
LGG	trans	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg12045294	chr17:78518616	RPTOR	-0.46	-7.01	-0.31	8.49e-12	Glycated hemoglobin levels;
LGG	cis	rs981844	0.714	rs2405202	chr4:154705132	A/G	cg14289246	chr4:154710475	SFRP2	-0.59	-10.47	-0.44	3.49e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs4771450	0.962	rs4772543	chr13:103973035	C/T	cg02987523	chr13:103978230	NA	-0.32	-6.77	-0.3	3.92e-11	Uric acid levels;
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.7	-0.41	2.16e-20	Menopause (age at onset);
LGG	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg05163923	chr11:71159392	DHCR7	0.73	14.14	0.55	5.25e-38	Vitamin D levels;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs11700980	0.636	rs11702742	chr21:30254022	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-7.4	-0.33	6.53e-13	QRS complex (12-leadsum);
LGG	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.26	0.36	1.54e-15	Initial pursuit acceleration;
LGG	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg24623649	chr8:11872141	NA	0.3	6.99	0.31	9.56e-12	Neuroticism;
LGG	cis	rs10979	1.000	rs1416206	chr6:143889385	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19717773	chr7:2847554	GNA12	-0.33	-7.51	-0.33	3.1e-13	Height;
LGG	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg03433033	chr1:76189801	ACADM	0.78	14.36	0.56	5.92e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17712092	chr4:129076599	LARP1B	0.74	14.4	0.56	4.13e-39	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.85	-7.34	-0.32	9.55e-13	Facial emotion recognition (sad faces);
LGG	cis	rs4843185	0.731	rs3815795	chr16:85712105	A/G	cg26571870	chr16:85723150	GINS2	0.42	7.48	0.33	3.82e-13	Platelet distribution width;
LGG	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.48	7.66	0.34	1.09e-13	Hip circumference adjusted for BMI;
LGG	trans	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg06636001	chr8:8085503	FLJ10661	0.4	6.7	0.3	5.95e-11	Systemic lupus erythematosus;
LGG	cis	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg19847130	chr8:10466454	RP1L1	0.32	6.71	0.3	5.6e-11	Neuroticism;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg01191920	chr7:158217561	PTPRN2	-0.92	-24.53	-0.75	9.47e-86	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg15103426	chr22:29168792	CCDC117	0.63	9.54	0.41	8.08e-20	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg13009111	chr11:71350975	NA	0.34	7.51	0.33	3.03e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10186029	0.509	rs1122846	chr2:213939354	C/G	cg08319019	chr2:214017104	IKZF2	0.39	6.65	0.3	8.42e-11	Systemic sclerosis;
LGG	cis	rs4684776	0.935	rs11714039	chr3:11365448	G/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.56	-0.37	1.64e-16	Small vessel stroke;
LGG	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg12654349	chr5:56205094	C5orf35	-0.4	-7.2	-0.32	2.49e-12	Coronary artery disease;
LGG	cis	rs10751667	0.621	rs7394681	chr11:952111	C/T	cg22143635	chr11:980567	AP2A2	0.43	7.87	0.34	2.53e-14	Alzheimer's disease (late onset);
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13732083	chr21:47605072	C21orf56	0.53	9.11	0.39	2.57e-18	Testicular germ cell tumor;
LGG	trans	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg06636001	chr8:8085503	FLJ10661	0.4	7.06	0.31	6.23e-12	Extraversion;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.39	0.36	5.82e-16	Schizophrenia;
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg02002194	chr4:3960332	NA	0.51	9.7	0.41	2.25e-20	Systolic blood pressure;
LGG	cis	rs258892	0.841	rs266427	chr5:72130751	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03576123	chr11:487126	PTDSS2	-1.21	-14.81	-0.57	6.4e-41	Body mass index;
LGG	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg20336341	chr7:50628841	DDC	0.37	7.06	0.31	6.01e-12	Malaria;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg21782813	chr7:2030301	MAD1L1	0.39	9.16	0.39	1.72e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10463554	0.857	rs34376	chr5:102401113	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07362569	chr17:61921086	SMARCD2	-0.47	-9.04	-0.39	4.36e-18	Prudent dietary pattern;
LGG	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg14768367	chr16:72042858	DHODH	0.82	9.01	0.39	5.54e-18	Cholesterol, total;LDL cholesterol;
LGG	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg06219351	chr7:158114137	PTPRN2	-0.83	-14.32	-0.55	9.03e-39	Response to amphetamines;
LGG	cis	rs2404602	1.000	rs6495206	chr15:76870963	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-6.74	-0.3	4.7e-11	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12243255	chr3:39194549	CSRNP1	0.45	6.98	0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs4750440	0.676	rs12779988	chr10:14020404	T/A	cg00551146	chr10:14014579	FRMD4A	0.29	6.93	0.31	1.44e-11	Adiponectin levels;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.08	0.52	1.72e-33	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7851660	0.527	rs7859751	chr9:100575888	C/T	cg13688889	chr9:100608707	NA	-0.88	-19.44	-0.67	5.71e-62	Strep throat;
LGG	cis	rs10779751	0.734	rs2791653	chr1:11129848	A/G	cg08854313	chr1:11322531	MTOR	0.73	14.98	0.57	1.15e-41	Body mass index;
LGG	cis	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg04990556	chr1:26633338	UBXN11	0.63	8.39	0.36	5.88e-16	Obesity-related traits;
LGG	cis	rs6840360	0.642	rs2709822	chr4:152351500	A/G	cg17217059	chr4:152329364	FAM160A1	0.19	6.79	0.3	3.51e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.33	0.5	2.04e-30	Total body bone mineral density;
LGG	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg23335576	chr14:104009727	NA	0.49	9.02	0.39	4.85e-18	Intelligence (multi-trait analysis);
LGG	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg12395012	chr8:11607386	GATA4	0.41	7.38	0.32	7.57e-13	Monocyte count;
LGG	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.02	-0.39	4.92e-18	Bone mineral density;
LGG	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg26248373	chr2:1572462	NA	-0.71	-8.83	-0.38	2.25e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg13010199	chr12:38710504	ALG10B	-0.53	-9.89	-0.42	4.78e-21	Morning vs. evening chronotype;
LGG	cis	rs2274273	0.870	rs17741831	chr14:55816715	T/A	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	4.92e-51	Protein biomarker;
LGG	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg25174290	chr11:3078921	CARS	0.75	16.08	0.6	1.45e-46	Longevity;
LGG	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg20848291	chr7:100343083	ZAN	-0.64	-9.26	-0.4	7.91e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1506636	0.646	rs805776	chr7:123212561	T/C	cg03229431	chr7:123269106	ASB15	-0.55	-11.87	-0.48	1.42e-28	Plateletcrit;Platelet count;
LGG	cis	rs9815354	1.000	rs9847975	chr3:41786904	A/G	cg03022575	chr3:42003672	ULK4	0.63	7.95	0.35	1.41e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.18	-0.32	2.87e-12	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.747	rs1577964	chr1:152961784	C/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.83e-18	Inflammatory skin disease;
LGG	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg09461388	chr22:46763229	CELSR1	-0.59	-6.66	-0.3	7.81e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg00686598	chr14:53173677	PSMC6	1.35	14.76	0.57	1.15e-40	Alzheimer's disease (late onset);
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.3e-14	Tonsillectomy;
LGG	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.8	-0.34	4.23e-14	Mood instability;
LGG	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.87	0.34	2.51e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg03929089	chr4:120376271	NA	0.9	18.02	0.64	2.06e-55	Coronary artery disease;
LGG	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.45	0.37	3.82e-16	Colorectal cancer;
LGG	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-12.71	-0.51	5.72e-32	Monocyte count;
LGG	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-10.9	-0.45	9.11e-25	HDL cholesterol;
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg23202291	chr11:1979235	NA	0.37	7.07	0.31	5.84e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4262150	0.672	rs6884140	chr5:152347678	C/A	cg12297329	chr5:152029980	NA	-0.56	-8.92	-0.38	1.07e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4631830	0.832	rs10825652	chr10:51510761	G/A	cg16070123	chr10:51489643	NA	0.4	7.09	0.31	5e-12	Prostate-specific antigen levels;
LGG	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg19680485	chr15:31195859	MTMR15	0.54	9.36	0.4	3.47e-19	Huntington's disease progression;
LGG	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg01528321	chr10:82214614	TSPAN14	0.67	11.99	0.49	4.89e-29	Post bronchodilator FEV1;
LGG	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.85	-0.3	2.36e-11	Blood metabolite levels;
LGG	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg11890956	chr21:40555474	PSMG1	1.01	21.81	0.71	4.68e-73	Cognitive function;
LGG	cis	rs12580194	0.593	rs12579408	chr12:55764348	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.16	-0.43	4.97e-22	Cancer;
LGG	cis	rs7192750	0.586	rs8058118	chr16:71959733	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs7246760	1.000	rs12462027	chr19:9926860	G/A	cg02900749	chr2:68251473	NA	-1.08	-11.66	-0.48	1.01e-27	Pursuit maintenance gain;
LGG	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg20821713	chr7:1055600	C7orf50	-0.5	-7.9	-0.34	2e-14	Bronchopulmonary dysplasia;
LGG	cis	rs9849248	0.627	rs55928667	chr3:88174395	C/A	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.45	-9.11	-0.39	2.57e-18	Fuchs's corneal dystrophy;
LGG	cis	rs17776563	0.768	rs1470108	chr15:89153744	G/T	cg05013243	chr15:89149849	MIR1179	-0.49	-10.24	-0.43	2.63e-22	Thyroid hormone levels;
LGG	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg23422044	chr7:1970798	MAD1L1	-0.47	-8.47	-0.37	3.33e-16	Neuroticism;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg08930214	chr7:62859557	LOC100287834	0.48	7.9	0.34	2.02e-14	Obesity-related traits;
LGG	trans	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg13770153	chr20:60521292	NA	-0.44	-7.41	-0.33	6.18e-13	Body mass index;
LGG	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg12573674	chr2:1569213	NA	-0.62	-9.58	-0.41	5.87e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs12517041	1.000	rs7736335	chr5:23288232	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.75	-10.31	-0.43	1.42e-22	Calcium levels;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg24642844	chr7:1081250	C7orf50	-0.64	-10.82	-0.45	1.7e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg07061783	chr6:25882402	NA	0.38	6.89	0.3	1.87e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7928758	0.887	rs74622686	chr11:134264227	A/G	cg22777979	chr11:134283252	B3GAT1	1.0	12.83	0.51	1.84e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg22681709	chr2:178499509	PDE11A	0.45	8.48	0.37	3.02e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24110177	chr3:50126178	RBM5	0.55	10.08	0.42	9.9700000000000009e-22	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04008888	chr11:68622739	NA	-0.57	-12.13	-0.49	1.4e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg08847533	chr14:75593920	NEK9	0.61	11.75	0.48	4.3e-28	Height;
LGG	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg18850127	chr7:39170497	POU6F2	0.51	11.65	0.48	1.05e-27	IgG glycosylation;
LGG	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs8005677	1.000	rs4981446	chr14:23381413	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.25	-0.32	1.8e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.16	0.32	3.1e-12	Skin colour saturation;
LGG	cis	rs1014246	0.784	rs4751610	chr10:118473730	T/C	cg14919929	chr10:118506882	NA	-0.61	-12.46	-0.5	6.16e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	9.27	0.4	6.81e-19	Mean corpuscular volume;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04025889	chr20:32891089	AHCY	0.42	7.42	0.33	5.66e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.46	-6.97	-0.31	1.08e-11	Parkinson's disease;
LGG	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.46	-0.37	3.56e-16	Bone mineral density;
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.34	-0.36	8.35e-16	Menopause (age at onset);
LGG	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14240646	chr10:27532245	ACBD5	-0.56	-8.39	-0.36	5.98e-16	Breast cancer;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.39	0.32	7.02e-13	Menopause (age at onset);
LGG	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg17376030	chr22:41985996	PMM1	0.56	9.21	0.39	1.15e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg22681709	chr2:178499509	PDE11A	-0.49	-7.6	-0.33	1.62e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.68	-0.48	8.64e-28	Intelligence (multi-trait analysis);
LGG	cis	rs16854884	1.000	rs2370171	chr3:143765177	C/T	cg06585982	chr3:143692056	C3orf58	0.53	8.3	0.36	1.18e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg18402987	chr7:1209562	NA	0.68	9.24	0.39	9.11e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12618769	0.652	rs4851145	chr2:99222916	A/G	cg18455616	chr2:99124870	INPP4A	-0.27	-7.58	-0.33	1.96e-13	Bipolar disorder;
LGG	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.4	6.68	0.3	6.75e-11	Carotid intima media thickness;
LGG	trans	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.28e-13	Type 2 diabetes;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.73	0.38	4.54e-17	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2274273	0.837	rs59871474	chr14:55779363	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.18	0.62	1.55e-51	Protein biomarker;
LGG	cis	rs7512552	0.839	rs11587575	chr1:150451863	T/C	cg15654264	chr1:150340011	RPRD2	0.45	9.28	0.4	6.41e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	trans	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg10756647	chr7:56101905	PSPH	0.82	9.9	0.42	4.42e-21	Diabetic kidney disease;
LGG	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg04398451	chr17:18023971	MYO15A	-0.74	-15.2	-0.58	1.24e-42	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05380793	chr13:73301995	C13orf37;C13orf34	0.46	7.49	0.33	3.61e-13	Cognitive performance;
LGG	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg26384229	chr12:38710491	ALG10B	0.59	8.71	0.38	5.29e-17	Morning vs. evening chronotype;
LGG	trans	rs55986470	0.646	rs79795396	chr2:239419181	T/C	cg01134436	chr17:81009848	B3GNTL1	0.76	7.81	0.34	3.88e-14	Chronotype;
LGG	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.7	0.3	6.05e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg04731861	chr2:219085781	ARPC2	0.52	13.59	0.53	1.19e-35	Colorectal cancer;
LGG	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.84	-0.34	3.04e-14	Mean platelet volume;
LGG	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg02151108	chr14:50098012	C14orf104	-0.41	-8.86	-0.38	1.72e-17	Carotid intima media thickness;
LGG	cis	rs34172651	0.545	rs9302428	chr16:24717600	C/G	cg02428538	chr16:24856791	SLC5A11	0.38	6.87	0.3	2.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.537	rs10772993	chr12:123644714	A/G	cg00376283	chr12:123451042	ABCB9	0.55	8.57	0.37	1.59e-16	Neutrophil percentage of white cells;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg20814179	chr4:940893	TMEM175	0.51	9.72	0.41	1.92e-20	Sjögren's syndrome;
LGG	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg04986931	chr22:39850128	NA	-0.33	-7.37	-0.32	7.92e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1719271	0.831	rs1719260	chr15:65174320	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.51	-7.15	-0.32	3.41e-12	Platelet count;
LGG	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.46	-0.47	6.29e-27	Hemoglobin concentration;
LGG	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg16141378	chr3:129829833	LOC729375	-0.44	-10.48	-0.44	3.35e-23	Mood instability;
LGG	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg26076054	chr5:421317	AHRR	-0.43	-6.88	-0.3	1.93e-11	Cystic fibrosis severity;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07308232	chr7:1071921	C7orf50	-0.52	-9.63	-0.41	4.03e-20	Longevity;Endometriosis;
LGG	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Vitiligo;
LGG	cis	rs9972944	0.756	rs7223214	chr17:63761473	C/T	cg07283582	chr17:63770753	CCDC46	-0.39	-7.65	-0.33	1.17e-13	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23155395	chr7:128045684	IMPDH1	0.47	7.13	0.31	3.77e-12	Gut microbiome composition (summer);
LGG	cis	rs1371867	0.875	rs2439456	chr8:101336874	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.91	-0.38	1.17e-17	Atrioventricular conduction;
LGG	cis	rs12210905	0.925	rs72838258	chr6:27007681	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg01043669	chr3:72786069	NA	-0.41	-6.93	-0.31	1.43e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg14416269	chr4:6271139	WFS1	0.5	9.28	0.4	6.45e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg04492858	chr10:133558786	NA	-0.43	-8.98	-0.39	7.05e-18	Survival in rectal cancer;
LGG	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-8.14	-0.35	3.72e-15	Self-reported allergy;
LGG	cis	rs4950322	0.547	rs17355509	chr1:146594721	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.67	-0.34	1.03e-13	Protein quantitative trait loci;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2249694	0.959	rs4129223	chr10:135403948	A/G	cg20169779	chr10:135381914	SYCE1	-0.49	-7.7	-0.34	8.6e-14	Obesity-related traits;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.74e-21	Prudent dietary pattern;
LGG	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.83	0.3	2.65e-11	Bipolar disorder;
LGG	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg20891283	chr12:69753455	YEATS4	0.46	7.06	0.31	6.28e-12	Response to diuretic therapy;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.55	-0.5	2.73e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06850241	chr22:41845214	NA	-0.43	-6.77	-0.3	3.83e-11	Vitiligo;
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.46	-0.33	4.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg18252515	chr7:66147081	NA	-0.76	-12.1	-0.49	1.84e-29	Corneal structure;
LGG	cis	rs9902453	0.845	rs3102556	chr17:28042542	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs79839061	0.563	rs55728587	chr4:843674	G/A	cg07828340	chr4:882639	GAK	0.89	9.46	0.4	1.53e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.43	-0.4	2.03e-19	Neuroticism;
LGG	cis	rs7113850	0.541	rs7107940	chr11:24233228	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	10.42	0.44	5.54e-23	Bone fracture in osteoporosis;
LGG	cis	rs4689642	0.507	rs904979	chr4:7220647	C/T	cg21353189	chr4:7228343	SORCS2	0.32	7.02	0.31	8.03e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs10824796	0.953	rs2384046	chr10:54535840	T/G	cg27418851	chr10:54531653	MBL2	0.47	8.98	0.39	6.82e-18	Blood protein levels;
LGG	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg06121193	chr1:90282411	NA	-0.37	-7.24	-0.32	1.91e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3010562	0.872	rs6938463	chr6:167757981	G/A	cg22772386	chr6:167763320	NA	-0.58	-11.87	-0.48	1.43e-28	Gut microbiome composition (summer and winter);
LGG	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs11239187	0.530	rs10793547	chr10:45064723	C/T	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00262122	chr8:11665843	FDFT1	0.42	6.65	0.3	8.26e-11	Myopia (pathological);
LGG	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg16586182	chr3:47516702	SCAP	-0.77	-15.15	-0.58	2.24e-42	Colorectal cancer;
LGG	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg25319279	chr11:5960081	NA	-0.44	-6.68	-0.3	6.73e-11	DNA methylation (variation);
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05665937	chr4:1216051	CTBP1	0.49	9.01	0.39	5.33e-18	Obesity-related traits;
LGG	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg27432699	chr2:27873401	GPN1	-0.76	-15.71	-0.59	6.74e-45	Oral cavity cancer;
LGG	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg18200150	chr17:30822561	MYO1D	0.81	18.9	0.66	1.83e-59	Schizophrenia;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.87	-0.3	2.14e-11	Lung cancer;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg08645402	chr16:4508243	NA	0.54	9.76	0.41	1.35e-20	Schizophrenia;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg05096777	chr10:104283225	SUFU	0.32	7.09	0.31	5.01e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2797369	0.713	rs1928066	chr6:101589701	G/A	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs4243971	0.537	rs6141697	chr20:30969606	C/T	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6598955	0.543	rs12125620	chr1:26552238	G/A	cg04990556	chr1:26633338	UBXN11	0.71	10.48	0.44	3.43e-23	Obesity-related traits;
LGG	cis	rs3816183	0.597	rs4953488	chr2:42821022	C/G	cg14631114	chr2:43023945	NA	0.33	6.67	0.3	7.25e-11	Hypospadias;
LGG	cis	rs6901004	0.803	rs354539	chr6:111517829	T/C	cg15721981	chr6:111408429	SLC16A10	-0.44	-7.84	-0.34	3.13e-14	Blood metabolite levels;
LGG	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg24110177	chr3:50126178	RBM5	0.48	8.2	0.36	2.37e-15	Menarche (age at onset);
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg05335186	chr13:53173507	NA	0.48	10.17	0.43	4.53e-22	Lewy body disease;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.07	0.55	1.06e-37	Obesity-related traits;
LGG	trans	rs7980799	0.935	rs10844582	chr12:33560873	A/G	cg13010199	chr12:38710504	ALG10B	-0.38	-6.7	-0.3	5.92e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg07959490	chr17:80112427	CCDC57	-0.45	-8.6	-0.37	1.24e-16	Life satisfaction;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg05793240	chr7:2802953	GNA12	0.37	9.0	0.39	5.98e-18	Height;
LGG	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg15309053	chr8:964076	NA	0.41	8.76	0.38	3.75e-17	Schizophrenia;
LGG	cis	rs2289583	0.544	rs1867153	chr15:75271229	C/T	cg10253484	chr15:75165896	SCAMP2	0.49	7.35	0.32	9.06e-13	Systemic lupus erythematosus;
LGG	cis	rs701145	0.537	rs1713832	chr3:153835833	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.21	-0.62	1.14e-51	Bladder cancer;
LGG	cis	rs72720396	0.803	rs114993052	chr1:91190855	T/A	cg13456504	chr1:91191583	NA	0.65	9.26	0.4	7.52e-19	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.21	-0.55	2.73e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12410462	0.551	rs6693348	chr1:227719467	C/G	cg04117972	chr1:227635322	NA	-0.4	-7.3	-0.32	1.26e-12	Major depressive disorder;
LGG	cis	rs2070488	0.804	rs6764551	chr3:38460305	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.42	0.56	3.2e-39	Electrocardiographic conduction measures;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg11905131	chr22:24372483	LOC391322	-0.46	-8.31	-0.36	1.08e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs546131	0.614	rs473885	chr11:34851961	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.35	0.32	9.09e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs4262150	0.810	rs72797213	chr5:151960514	A/T	cg12297329	chr5:152029980	NA	-0.8	-15.36	-0.58	2.47e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs7267979	0.873	rs6115093	chr20:25210730	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.21	0.43	3.18e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.21e-23	Total body bone mineral density;
LGG	cis	rs72802342	0.510	rs12932952	chr16:75365486	C/T	cg03315344	chr16:75512273	CHST6	0.54	7.46	0.33	4.43e-13	Advanced age-related macular degeneration;
LGG	cis	rs903263	0.582	rs11163898	chr1:84547271	C/T	cg10977910	chr1:84465055	TTLL7	0.44	7.69	0.34	8.62e-14	Breast cancer (male);
LGG	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg08847335	chr10:891726	LARP4B	-0.52	-9.36	-0.4	3.54e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg12463550	chr7:65579703	CRCP	0.49	8.19	0.36	2.5e-15	Aortic root size;
LGG	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg17644776	chr2:200775616	C2orf69	0.6	6.89	0.3	1.89e-11	Schizophrenia;
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-12.99	-0.52	4.02e-33	Vitiligo;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.85	17.84	0.64	1.44e-54	Personality dimensions;
LGG	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg04731861	chr2:219085781	ARPC2	-0.44	-10.9	-0.45	8.95e-25	Colorectal cancer;
LGG	cis	rs7928758	0.945	rs55986667	chr11:134280126	A/C	cg22777979	chr11:134283252	B3GAT1	0.85	10.98	0.45	4.42e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg13009111	chr11:71350975	NA	-0.3	-6.77	-0.3	4e-11	Systolic blood pressure;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg20887711	chr4:1340912	KIAA1530	0.51	9.37	0.4	3.18e-19	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs9815354	1.000	rs9856633	chr3:42013850	C/T	cg03022575	chr3:42003672	ULK4	0.63	8.28	0.36	1.29e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2131877	0.830	rs62285226	chr3:194880595	C/T	cg07250128	chr3:194833983	C3orf21	0.45	7.5	0.33	3.27e-13	Non-small cell lung cancer;
LGG	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	trans	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.08	-0.39	3.09e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9902453	0.808	rs76515799	chr17:28169491	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.85	0.54	9.72e-37	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg05313129	chr8:58192883	C8orf71	-0.6	-7.67	-0.34	9.95e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3741151	0.686	rs2298469	chr11:73133030	T/C	cg17517138	chr11:73019481	ARHGEF17	0.75	8.13	0.35	3.99e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7572644	0.699	rs7595847	chr2:28173043	T/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20414838	chr1:53704138	MAGOH	0.42	6.99	0.31	9.51e-12	Cognitive performance;
LGG	cis	rs4919694	0.901	rs10509763	chr10:104776391	G/A	cg04362960	chr10:104952993	NT5C2	1.05	14.53	0.56	1.13e-39	Arsenic metabolism;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg19182353	chr11:118479428	PHLDB1	0.56	11.83	0.48	2.2e-28	Cholesterol, total;
LGG	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg02753203	chr1:228287806	NA	0.92	18.72	0.66	1.3e-58	Diastolic blood pressure;
LGG	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.98	0.31	1.05e-11	Resting heart rate;
LGG	cis	rs11096990	0.964	rs3733280	chr4:39271541	A/G	cg24403649	chr4:39172243	NA	-0.4	-6.67	-0.3	7.18e-11	Cognitive function;
LGG	cis	rs35146811	0.695	rs1618851	chr7:99810643	T/G	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.79e-13	Coronary artery disease;
LGG	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.41	0.4	2.33e-19	Sudden cardiac arrest;
LGG	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg05784532	chr1:230284198	GALNT2	0.52	9.22	0.39	1.01e-18	Coronary artery disease;
LGG	cis	rs11168351	0.927	rs10875716	chr12:48389023	C/T	cg24011408	chr12:48396354	COL2A1	0.61	10.19	0.43	4.04e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9517320	0.515	rs4772101	chr13:99207554	G/A	cg03701759	chr13:99174930	STK24	-0.36	-7.03	-0.31	7.43e-12	Longevity;
LGG	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg10167378	chr1:228756711	NA	0.74	9.35	0.4	3.77e-19	Chronic lymphocytic leukemia;
LGG	cis	rs308971	0.563	rs2618404	chr3:12038665	A/C	cg15873301	chr3:12045459	SYN2	0.52	6.83	0.3	2.69e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs847649	0.804	rs4729866	chr7:102685561	A/C	cg18108683	chr7:102477205	FBXL13	0.57	12.1	0.49	1.85e-29	Morning vs. evening chronotype;
LGG	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg07052231	chr12:7363540	PEX5	0.38	6.67	0.3	7.09e-11	IgG glycosylation;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg25214090	chr10:38739885	LOC399744	0.37	6.86	0.3	2.25e-11	Diastolic blood pressure;
LGG	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-8.48	-0.37	3.15e-16	Blood metabolite levels;
LGG	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg25554036	chr4:6271136	WFS1	0.62	11.68	0.48	8.03e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.96	0.38	7.78e-18	Lung cancer in ever smokers;
LGG	cis	rs4919044	0.808	rs835274	chr10:94796534	A/G	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg26396452	chr14:65542826	MAX	0.49	10.1	0.42	8.25e-22	Obesity-related traits;
LGG	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg22232500	chr2:134024266	NCKAP5	0.56	7.89	0.34	2.24e-14	Bipolar disorder;
LGG	cis	rs12200560	0.505	rs2387378	chr6:97077504	C/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg24623649	chr8:11872141	NA	-0.29	-7.09	-0.31	4.97e-12	Neuroticism;
LGG	trans	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg12463550	chr7:65579703	CRCP	-0.44	-6.85	-0.3	2.32e-11	Aortic root size;
LGG	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.02e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg01043669	chr3:72786069	NA	0.43	6.99	0.31	9.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9815354	0.812	rs17218103	chr3:41943724	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3087591	0.960	rs2953012	chr17:29496486	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	cis	rs10463316	0.894	rs7727770	chr5:150767116	G/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs12775980	0.737	rs61623705	chr10:29844494	G/A	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg21171335	chr12:122356390	WDR66	0.29	8.4	0.36	5.42e-16	Mean corpuscular volume;
LGG	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg20476274	chr7:133979776	SLC35B4	0.66	11.83	0.48	2.2e-28	Mean platelet volume;
LGG	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg03528353	chr17:61819722	STRADA	0.44	7.42	0.33	5.57e-13	Prudent dietary pattern;
LGG	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg16586182	chr3:47516702	SCAP	-0.79	-15.24	-0.58	8.86e-43	Colorectal cancer;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.53	0.37	2.1e-16	Prudent dietary pattern;
LGG	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	11.01	0.46	3.5e-25	Breast cancer;
LGG	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg10792982	chr14:105748885	BRF1	-0.67	-13.84	-0.54	1.08e-36	Mean platelet volume;Platelet distribution width;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00022308	chr2:27851831	CCDC121;GPN1	0.47	7.51	0.33	3.08e-13	Cognitive performance;
LGG	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.71	0.51	6.03e-32	Coronary artery disease;
LGG	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03576123	chr11:487126	PTDSS2	-1.24	-16.56	-0.61	1.03e-48	Body mass index;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg04287289	chr16:89883240	FANCA	0.9	8.49	0.37	2.73e-16	Skin colour saturation;
LGG	cis	rs10937275	1.000	rs35461422	chr3:186649678	A/G	cg26193484	chr3:186648175	ST6GAL1	0.89	9.21	0.39	1.15e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06481639	chr22:41940642	POLR3H	0.54	7.54	0.33	2.55e-13	Vitiligo;
LGG	cis	rs9768139	0.935	rs6953748	chr7:158121184	G/A	cg25566285	chr7:158114605	PTPRN2	-0.97	-25.39	-0.76	9.32e-90	Calcium levels;
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.48	9.57	0.41	6.46e-20	Personality dimensions;
LGG	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg11366901	chr6:160182831	ACAT2	1.04	15.33	0.58	3.32e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1371867	0.875	rs1788178	chr8:101332518	A/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs2070433	0.851	rs8129793	chr21:47925719	T/C	cg12379764	chr21:47803548	PCNT	0.5	7.18	0.32	2.75e-12	Lymphocyte counts;
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9462027	1.000	rs9462027	chr6:34797241	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-8.38	-0.36	6.22e-16	Systemic lupus erythematosus;
LGG	cis	rs9814567	1.000	rs6772896	chr3:134203347	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.6	-0.51	1.62e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4950322	0.543	rs4950318	chr1:146787953	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.15e-21	Aortic root size;
LGG	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.42	0.4	2.22e-19	Fuchs's corneal dystrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06719391	chr11:2554330	KCNQ1	0.43	7.04	0.31	7.21e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09596336	chr2:145273297	ZEB2	0.53	8.67	0.37	7.2e-17	Gut microbiome composition (summer);
LGG	trans	rs6921919	0.945	rs61289879	chr6:28419162	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.35	-0.32	8.91e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg08621203	chr6:150244597	RAET1G	0.43	7.35	0.32	9.08e-13	Lung cancer;
LGG	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg23887609	chr12:130822674	PIWIL1	0.5	8.6	0.37	1.25e-16	Menopause (age at onset);
LGG	cis	rs1519814	0.696	rs7012522	chr8:121038044	A/G	cg22335954	chr8:121166405	COL14A1	-0.48	-8.67	-0.37	7.23e-17	Breast cancer;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	7.15e-21	Common traits (Other);
LGG	cis	rs503734	0.502	rs348876	chr3:100930989	A/G	cg27318481	chr3:100970896	IMPG2	-0.58	-13.33	-0.53	1.52e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2439831	1.000	rs2264239	chr15:43765533	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	12.66	0.51	9.84e-32	Lung cancer in ever smokers;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg23034840	chr1:205782522	SLC41A1	0.53	8.66	0.37	8.03e-17	Menarche (age at onset);
LGG	cis	rs4919087	0.748	rs701819	chr10:98986316	C/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.25	-0.32	1.8e-12	Monocyte count;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04772025	chr11:68637568	NA	0.67	11.81	0.48	2.49e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7572733	0.935	rs10048735	chr2:198742525	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.43	0.36	4.58e-16	Dermatomyositis;
LGG	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg13010199	chr12:38710504	ALG10B	0.47	8.92	0.38	1.08e-17	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.78	0.34	4.7e-14	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24341944	chr3:157827791	RSRC1	0.44	7.36	0.32	8.59e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02653800	chr10:60095305	UBE2D1	0.39	7.0	0.31	9.19e-12	Obesity-related traits;
LGG	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs2028299	1.000	rs2351707	chr15:90384045	C/T	cg23731826	chr15:90371692	NA	0.37	8.73	0.38	4.83e-17	Type 2 diabetes;
LGG	cis	rs7113874	0.524	rs10840083	chr11:8608636	C/T	cg23764900	chr11:8616102	STK33	0.39	6.82	0.3	2.85e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.74	-0.38	4.23e-17	Lung cancer;
LGG	cis	rs4631830	0.932	rs4581397	chr10:51532367	A/G	cg16070123	chr10:51489643	NA	-0.4	-7.29	-0.32	1.32e-12	Prostate-specific antigen levels;
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs7584262	0.736	rs10174871	chr2:42263018	G/A	cg19376973	chr2:42229025	NA	0.67	9.57	0.41	6.66e-20	Bone mineral density;
LGG	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.71	-0.34	7.73e-14	Iron status biomarkers;
LGG	cis	rs595018	0.505	rs11230501	chr11:60598075	G/A	cg07588442	chr11:60673866	PRPF19	0.51	6.69	0.3	6.28e-11	Wegener's granulomatosis;
LGG	cis	rs2346160	0.899	rs384974	chr6:167688418	C/T	cg20683250	chr6:167653907	NA	-0.41	-6.79	-0.3	3.41e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.1e-20	Bipolar disorder;
LGG	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg01221209	chr5:554886	NA	-0.51	-8.15	-0.35	3.39e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg01673284	chr16:4527211	HMOX2	0.35	7.07	0.31	5.92e-12	Schizophrenia;
LGG	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.36	6.65	0.3	8.22e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg20608306	chr11:116969690	SIK3	-0.41	-10.58	-0.44	1.42e-23	Subjective well-being;
LGG	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg02002194	chr4:3960332	NA	-0.45	-7.77	-0.34	4.96e-14	Systemic lupus erythematosus;
LGG	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.85	-16.41	-0.61	4.68e-48	Menarche (age at onset);
LGG	cis	rs477692	0.905	rs570967	chr10:131421330	T/G	cg05714579	chr10:131428358	MGMT	0.66	13.69	0.54	4.72e-36	Response to temozolomide;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg15971980	chr6:150254442	NA	0.45	8.42	0.36	4.59e-16	Lung cancer;
LGG	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg06915193	chr4:185205329	NA	-0.38	-6.98	-0.31	1.04e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs35079168	0.923	rs12115573	chr9:137288782	G/A	cg00753924	chr9:137298813	RXRA	-0.39	-7.29	-0.32	1.39e-12	Intelligence;
LGG	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg02503808	chr4:7069936	GRPEL1	-1.02	-8.75	-0.38	3.87e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	8.62	0.37	1.09e-16	Obesity-related traits;
LGG	cis	rs74781061	0.929	rs9635320	chr15:74885091	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.26	-0.32	1.66e-12	Endometriosis;
LGG	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg13010199	chr12:38710504	ALG10B	0.51	9.87	0.42	5.56e-21	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg01221209	chr5:554886	NA	0.47	7.02	0.31	8.02e-12	Obesity-related traits;
LGG	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.73	0.3	4.9e-11	Renal cell carcinoma;
LGG	trans	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs4788570	0.537	rs12149254	chr16:71458851	G/A	cg06353428	chr16:71660113	MARVELD3	-0.81	-10.98	-0.45	4.43e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17554472	chr22:41940697	POLR3H	-0.47	-6.66	-0.3	7.94e-11	Vitiligo;
LGG	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg02073558	chr3:44770973	ZNF501	0.84	17.99	0.64	3.09e-55	Depressive symptoms;
LGG	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs36051895	0.530	rs10114531	chr9:5229116	A/G	cg02405213	chr9:5042618	JAK2	-0.7	-12.94	-0.52	6.41e-33	Pediatric autoimmune diseases;
LGG	cis	rs9914988	0.943	rs2874253	chr17:27157863	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-6.66	-0.3	7.94e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9611519	1.000	rs9611520	chr22:41613303	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-8.47	-0.37	3.24e-16	Neuroticism;
LGG	cis	rs2735413	0.521	rs7192820	chr16:78041379	A/G	cg04733911	chr16:78082701	NA	0.48	6.74	0.3	4.61e-11	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10851411	0.688	rs11635041	chr15:42778347	T/C	cg21293051	chr15:42870591	STARD9	0.47	6.99	0.31	9.61e-12	Glucose homeostasis traits;
LGG	cis	rs240764	0.621	rs11155623	chr6:101184373	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.97	-0.35	1.24e-14	Neuroticism;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08925882	chr11:67350491	GSTP1	-0.34	-6.83	-0.3	2.72e-11	Mean corpuscular volume;
LGG	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.63	-10.51	-0.44	2.58e-23	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23451291	chr7:25891427	NA	0.41	6.7	0.3	5.9e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.57e-12	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs11157436	0.602	rs1894371	chr14:22634695	A/C	cg00994629	chr14:22694547	NA	-0.33	-7.23	-0.32	2.04e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-11.0	-0.46	3.83e-25	Personality dimensions;
LGG	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg25358565	chr5:93447407	FAM172A	1.4	17.18	0.62	1.52e-51	Diabetic retinopathy;
LGG	cis	rs75920871	0.925	rs4936360	chr11:116893769	C/G	cg20608306	chr11:116969690	SIK3	0.33	6.93	0.31	1.45e-11	Subjective well-being;
LGG	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg19507638	chr5:93509721	C5orf36	-0.73	-9.97	-0.42	2.42e-21	Diabetic retinopathy;
LGG	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21659725	chr3:3221576	CRBN	0.73	11.5	0.47	4.26e-27	Resting heart rate;
LGG	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg00631329	chr6:26305371	NA	-0.46	-8.52	-0.37	2.27e-16	Educational attainment;
LGG	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.74	0.38	4.38e-17	Retinal vascular caliber;
LGG	cis	rs8005677	0.828	rs35085068	chr14:23409909	C/A	cg25600027	chr14:23388339	RBM23	-0.42	-7.15	-0.32	3.34e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17554472	chr22:41940697	POLR3H	-0.5	-7.07	-0.31	5.6e-12	Vitiligo;
LGG	cis	rs1904096	0.506	rs2632412	chr4:95149319	A/C	cg11021082	chr4:95130006	SMARCAD1	0.56	10.49	0.44	2.94e-23	Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg04979063	chr2:113191202	RGPD5;RGPD8	0.76	9.85	0.42	6.53e-21	Yeast infection;
LGG	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.36	0.4	3.51e-19	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.52e-12	Schizophrenia;
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg02002194	chr4:3960332	NA	0.44	7.8	0.34	4.18e-14	Triglycerides;
LGG	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.68	-0.34	9.29e-14	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.1	-0.31	4.74e-12	Neuroticism;
LGG	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.13	-0.35	4e-15	IgG glycosylation;
LGG	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03264133	chr6:25882463	NA	-0.53	-10.0	-0.42	1.85e-21	Blood metabolite levels;
LGG	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg07382826	chr16:28625726	SULT1A1	0.42	8.89	0.38	1.33e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9616064	0.557	rs5767318	chr22:47048792	A/G	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.79	-0.3	3.54e-11	Urate levels in obese individuals;
LGG	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs1801251	0.727	rs35853577	chr2:233558879	T/C	cg08000102	chr2:233561755	GIGYF2	0.54	9.1	0.39	2.73e-18	Coronary artery disease;
LGG	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg00092383	chr7:157075207	NA	0.43	7.58	0.33	1.93e-13	Body mass index;
LGG	cis	rs2777491	1.000	rs1757455	chr15:41761332	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.14	-0.68	3.01e-65	Ulcerative colitis;
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg03264133	chr6:25882463	NA	-0.43	-7.55	-0.33	2.35e-13	Height;
LGG	cis	rs55665837	1.000	rs12287715	chr11:14444575	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.86e-17	Vitamin D levels;
LGG	cis	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg21775007	chr8:11205619	TDH	-0.47	-7.52	-0.33	2.88e-13	Neuroticism;
LGG	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg25418670	chr11:30344373	C11orf46	-0.57	-7.92	-0.35	1.72e-14	Morning vs. evening chronotype;
LGG	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.21	0.46	5.85e-26	Vitamin D levels;
LGG	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg21095983	chr6:86352623	SYNCRIP	0.61	11.31	0.47	2.35e-26	Smooth-surface caries;
LGG	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg06886374	chr16:1844152	IGFALS	0.43	7.8	0.34	4.27e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7726354	0.793	rs115302578	chr5:56006345	G/A	cg27303933	chr5:56029418	NA	0.48	6.77	0.3	4e-11	Breast cancer (early onset);
LGG	cis	rs4891159	0.790	rs72975930	chr18:74144645	G/A	cg24786174	chr18:74118243	ZNF516	-0.56	-13.0	-0.52	3.53e-33	Longevity;
LGG	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.99	0.57	1.07e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1408224	0.626	rs912434	chr13:47189928	G/T	cg24453118	chr13:47229927	LRCH1	-0.3	-6.95	-0.31	1.26e-11	QRS complex (12-leadsum);
LGG	cis	rs3780378	0.875	rs4372063	chr9:5003338	C/T	cg02405213	chr9:5042618	JAK2	-0.43	-7.35	-0.32	9.17e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17767392	0.834	rs17767380	chr14:71747031	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.92	-0.38	1.09e-17	Mitral valve prolapse;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg15971980	chr6:150254442	NA	0.44	8.29	0.36	1.2e-15	Lung cancer;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14159672	chr1:205819179	PM20D1	-0.5	-9.41	-0.4	2.29e-19	Menarche (age at onset);
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.1	0.43	8.05e-22	Tonsillectomy;
LGG	cis	rs4561483	0.771	rs12924398	chr16:11972948	T/A	cg08843971	chr16:11963173	GSPT1	-0.62	-15.32	-0.58	3.8e-43	Testicular germ cell tumor;
LGG	cis	rs2898279	0.902	rs1057750	chr8:11296091	G/A	cg26274995	chr8:11302983	FAM167A	0.49	9.42	0.4	2.2e-19	Small cell lung carcinoma;
LGG	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-9.87	-0.42	5.44e-21	HDL cholesterol;
LGG	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.33e-12	Retinal vascular caliber;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg05368731	chr17:41323189	NBR1	0.86	16.71	0.61	2.1e-49	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs1003719	0.715	rs2251952	chr21:38559711	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.1	-0.57	3.65e-42	Eye color traits;
LGG	cis	rs881375	0.502	rs4837811	chr9:123901594	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.62	0.37	1.07e-16	Rheumatoid arthritis;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs1788820	0.917	rs4800489	chr18:21125942	A/G	cg14672496	chr18:21087552	C18orf8	0.39	7.22	0.32	2.16e-12	Body mass index;
LGG	trans	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.85	-0.38	1.92e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1018836	0.828	rs756568	chr8:91557038	G/C	cg16814680	chr8:91681699	NA	-0.73	-13.21	-0.52	4.97e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs975739	0.695	rs1924937	chr13:78524431	G/T	cg07847733	chr13:78271382	SLAIN1	0.42	7.22	0.32	2.11e-12	Hair color;
LGG	cis	rs3816183	0.597	rs6544583	chr2:42876876	T/A	cg14631114	chr2:43023945	NA	0.34	6.74	0.3	4.78e-11	Hypospadias;
LGG	cis	rs1021993	0.545	rs17014370	chr1:209540091	C/T	cg24446417	chr1:209558027	NA	-0.71	-10.59	-0.44	1.34e-23	Gut microbiome composition (winter);
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg03806693	chr22:41940476	POLR3H	1.09	19.86	0.68	5.84e-64	Vitiligo;
LGG	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg11812906	chr14:75593930	NEK9	0.4	7.21	0.32	2.23e-12	Coronary artery disease;
LGG	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.59	-0.37	1.39e-16	Mood instability;
LGG	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg24812749	chr6:127587940	RNF146	0.96	15.87	0.59	1.28e-45	Breast cancer;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg21911579	chr5:131705225	SLC22A5	0.69	7.65	0.33	1.18e-13	Rheumatoid arthritis;
LGG	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg02187348	chr16:89574699	SPG7	0.47	7.73	0.34	6.8e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.4	6.71	0.3	5.61e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.53	-0.37	2.09e-16	Menarche (age at onset);
LGG	cis	rs6554196	0.508	rs10488849	chr4:55510862	C/T	cg18836493	chr4:55524333	KIT	-0.43	-8.02	-0.35	8.65e-15	Monocyte count;
LGG	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.41	0.58	1.58e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9911578	0.741	rs2611776	chr17:56819636	G/T	cg12560992	chr17:57184187	TRIM37	0.88	15.58	0.59	2.77e-44	Intelligence (multi-trait analysis);
LGG	cis	rs12474201	0.928	rs12998762	chr2:46938393	A/C	cg06386533	chr2:46925753	SOCS5	0.8	14.96	0.57	1.46e-41	Height;
LGG	cis	rs185694	1.000	rs202083	chr13:30881316	C/T	cg07600127	chr13:30881527	KATNAL1	-0.54	-7.04	-0.31	7.11e-12	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21659725	chr3:3221576	CRBN	-0.91	-20.26	-0.69	8.57e-66	Intelligence (multi-trait analysis);
LGG	cis	rs919433	0.680	rs6434934	chr2:198437386	C/G	cg00792783	chr2:198669748	PLCL1	0.5	7.8	0.34	4.28e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs57590327	0.503	rs13073613	chr3:81888512	C/A	cg07356753	chr3:81810745	GBE1	-0.45	-7.14	-0.31	3.75e-12	Extraversion;
LGG	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	7.09	0.31	4.89e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3812049	0.784	rs2250127	chr5:127388844	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.64	-10.22	-0.43	2.91e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	10.11	0.43	7.3e-22	Rheumatoid arthritis;
LGG	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs68170813	0.559	rs76020313	chr7:106877468	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.83	-0.45	1.63e-24	Coronary artery disease;
LGG	cis	rs367615	0.840	rs113540823	chr5:108879084	C/T	cg17395555	chr5:108820864	NA	0.65	9.03	0.39	4.69e-18	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22255354	chr7:934221	C7orf20	0.4	6.65	0.3	8.39e-11	Pancreatic cancer;
LGG	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg23845249	chr11:68861649	NA	0.45	8.09	0.35	5.36e-15	Blond vs. brown hair color;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07343612	chr16:622815	PIGQ	-0.77	-15.78	-0.59	3.46e-45	Height;
LGG	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.28	-0.4	6.58e-19	Calcium levels;
LGG	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg10636054	chr15:40330586	SRP14	0.82	8.49	0.37	2.81e-16	Response to haloperidol in psychosis;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg08677398	chr8:58056175	NA	0.4	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.19	0.32	2.64e-12	Longevity;
LGG	cis	rs10743315	0.643	rs16915128	chr12:19304286	G/T	cg02471346	chr12:19282374	PLEKHA5	-0.62	-7.06	-0.31	5.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg18681998	chr4:17616180	MED28	0.74	14.47	0.56	2.02e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6489882	0.607	rs4767033	chr12:113364382	T/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.38e-13	Chronic lymphocytic leukemia;
LGG	cis	rs2120243	0.533	rs34263112	chr3:157056048	A/G	cg24825693	chr3:157122686	VEPH1	-0.37	-8.16	-0.35	3.19e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	6.84	0.3	2.49e-11	Bone mineral density;
LGG	cis	rs9715521	0.589	rs11726451	chr4:59852381	A/C	cg11281224	chr4:60001000	NA	-0.52	-8.96	-0.38	8.04e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.14e-20	Mean corpuscular volume;
LGG	cis	rs10484885	0.775	rs62416027	chr6:90608054	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.68	-8.63	-0.37	9.55e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg04568710	chr12:38710424	ALG10B	0.36	7.48	0.33	3.87e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg12219531	chr12:120966889	COQ5	0.66	11.02	0.46	3.02e-25	High light scatter reticulocyte count;
LGG	cis	rs7106204	0.609	rs11825384	chr11:24285137	G/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.68	0.41	2.59e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7648466	1.000	rs2172246	chr3:46214685	C/A	cg13144783	chr3:46249795	CCR1	-0.66	-12.74	-0.51	4.58e-32	Eotaxin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00880079	chr19:37157318	ZNF461	0.42	7.16	0.32	3.13e-12	Cognitive performance;
LGG	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-9.66	-0.41	3.13e-20	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23213688	chr1:231473791	C1orf124;EXOC8	0.41	6.91	0.31	1.56e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.81	15.91	0.59	8.93e-46	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2249694	0.520	rs6537609	chr10:135323084	A/G	cg20169779	chr10:135381914	SYCE1	-0.55	-7.53	-0.33	2.7e-13	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg27572855	chr1:25598939	RHD	0.49	11.13	0.46	1.17e-25	Erythrocyte sedimentation rate;
LGG	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg13010199	chr12:38710504	ALG10B	0.7	13.74	0.54	2.94e-36	Bladder cancer;
LGG	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg07303275	chr16:75499416	TMEM170A	0.36	6.67	0.3	7.54e-11	Dupuytren's disease;
LGG	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg09998033	chr7:158218633	PTPRN2	-0.55	-10.15	-0.43	5.42e-22	Obesity-related traits;
LGG	cis	rs7584330	0.737	rs1390985	chr2:238367420	G/A	cg16989719	chr2:238392110	NA	-0.32	-6.84	-0.3	2.44e-11	Prostate cancer;
LGG	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.05	-0.46	2.27e-25	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.89e-13	Menopause (age at onset);
LGG	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.11	-0.52	1.27e-33	Gut microbiome composition (summer);
LGG	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg04398451	chr17:18023971	MYO15A	-0.86	-19.52	-0.67	2.3e-62	Total body bone mineral density;
LGG	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-13.46	-0.53	4.42e-35	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.49	-0.4	1.27e-19	Triglycerides;
LGG	cis	rs13102973	0.932	rs4130841	chr4:135869673	T/C	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg03264133	chr6:25882463	NA	0.43	7.0	0.31	9.01e-12	Iron status biomarkers;
LGG	trans	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg16006296	chr10:38738647	LOC399744	0.35	6.72	0.3	5.27e-11	Diastolic blood pressure;
LGG	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg04455712	chr21:45112962	RRP1B	0.56	10.64	0.44	8.18e-24	Mean corpuscular volume;
LGG	cis	rs2274273	0.638	rs9919921	chr14:55695505	A/G	cg04306507	chr14:55594613	LGALS3	0.51	11.83	0.48	2.21e-28	Protein biomarker;
LGG	cis	rs701145	0.585	rs1713843	chr3:153786394	C/G	cg17054900	chr3:154042577	DHX36	-0.68	-8.56	-0.37	1.62e-16	Coronary artery disease;
LGG	cis	rs9487051	0.676	rs6928622	chr6:109595112	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-16.61	-0.61	6.02e-49	Chronic sinus infection;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg25703541	chr22:24373054	LOC391322	-0.89	-17.69	-0.64	7.02e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12474201	0.928	rs12998753	chr2:46938385	A/G	cg06386533	chr2:46925753	SOCS5	0.8	14.96	0.57	1.46e-41	Height;
LGG	cis	rs4253772	0.591	rs12167567	chr22:46659942	G/C	cg24881330	chr22:46731750	TRMU	0.71	8.76	0.38	3.71e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.23	-0.36	1.89e-15	IgG glycosylation;
LGG	cis	rs1519814	0.659	rs7387672	chr8:121024511	A/G	cg22335954	chr8:121166405	COL14A1	-0.48	-8.63	-0.37	9.68e-17	Breast cancer;
LGG	cis	rs2227564	0.700	rs2688612	chr10:75653205	G/T	cg00564723	chr10:75632066	CAMK2G	-0.42	-8.92	-0.38	1.06e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7737355	0.812	rs12514547	chr5:130973304	C/G	cg06307176	chr5:131281290	NA	0.52	8.57	0.37	1.54e-16	Life satisfaction;
LGG	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.47	0.4	1.46e-19	Educational attainment;
LGG	cis	rs2708240	1.000	rs2538987	chr7:147580505	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.46e-11	QT interval (drug interaction);
LGG	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.37	-0.32	7.88e-13	Cognitive ability;
LGG	cis	rs8077889	0.750	rs231535	chr17:41944865	T/G	cg26893861	chr17:41843967	DUSP3	-0.83	-11.68	-0.48	8.44e-28	Triglycerides;
LGG	cis	rs2274273	0.870	rs11625001	chr14:55758160	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.05	0.62	6.35e-51	Protein biomarker;
LGG	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg11878867	chr6:150167359	LRP11	-0.55	-11.8	-0.48	2.89e-28	Lung cancer;
LGG	cis	rs7523273	0.597	rs6657476	chr1:207960104	G/T	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.68	-0.3	6.7e-11	Schizophrenia;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01641771	chr4:140476319	SETD7	-0.44	-7.39	-0.32	7.09e-13	Body fat percentage;
LGG	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.77	0.34	5.03e-14	Hepatocellular carcinoma;
LGG	cis	rs4948275	0.710	rs2787698	chr10:63297450	T/C	cg03237606	chr10:63212265	TMEM26	-0.39	-7.04	-0.31	6.83e-12	Night sleep phenotypes;
LGG	cis	rs34638952	0.577	rs11650356	chr17:27457136	G/A	cg27392559	chr17:27410759	MYO18A	-0.38	-7.11	-0.31	4.34e-12	Sitting height ratio;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08280861	chr8:58055591	NA	0.67	8.17	0.36	2.94e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg10661904	chr17:79619235	PDE6G	-0.46	-9.32	-0.4	4.73e-19	Eye color traits;
LGG	cis	rs1682825	0.505	rs2600066	chr3:10771817	G/T	cg25137700	chr3:10780651	NA	-0.48	-6.72	-0.3	5.28e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.4	-0.33	6.34e-13	Neuroticism;
LGG	cis	rs11700980	0.551	rs2832024	chr21:30113692	C/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs113835537	0.529	rs11227511	chr11:66281244	A/C	cg24851651	chr11:66362959	CCS	0.45	7.85	0.34	2.98e-14	Airway imaging phenotypes;
LGG	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.83	-0.3	2.71e-11	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.46	0.37	3.63e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9818758	0.607	rs56306491	chr3:49314960	G/A	cg00383909	chr3:49044727	WDR6	1.12	13.61	0.53	9.92e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14159672	chr1:205819179	PM20D1	0.75	16.0	0.6	3.46e-46	Menarche (age at onset);
LGG	cis	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05901451	chr6:126070800	HEY2	-0.69	-13.0	-0.52	3.8e-33	Brugada syndrome;
LGG	cis	rs7940866	0.874	rs10894306	chr11:130873882	A/C	cg12179176	chr11:130786555	SNX19	0.72	13.13	0.52	1.08e-33	Schizophrenia;
LGG	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg25706552	chr1:244017396	NA	0.55	6.97	0.31	1.08e-11	RR interval (heart rate);
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs209489	0.892	rs2294859	chr6:53159576	A/G	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg11752832	chr7:134001865	SLC35B4	0.62	11.45	0.47	6.69e-27	Mean platelet volume;
LGG	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg06028605	chr16:24865363	SLC5A11	-0.48	-7.8	-0.34	4.27e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs11941844	chr4:99042722	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13314892	0.764	rs57634646	chr3:69860488	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-10.4	-0.44	6.45e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.81e-34	Prudent dietary pattern;
LGG	cis	rs9487051	0.803	rs11153161	chr6:109541774	A/G	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5.04e-12	Reticulocyte fraction of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25858261	chr10:12085058	UPF2	0.47	7.01	0.31	8.74e-12	Gut microbiome composition (summer);
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg03517284	chr6:25882590	NA	-0.4	-7.26	-0.32	1.66e-12	Height;
LGG	cis	rs3820068	0.705	rs951225	chr1:15826292	G/A	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.88	-0.42	5.3e-21	Lung cancer;
LGG	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg06453172	chr10:134556979	INPP5A	-0.46	-7.26	-0.32	1.69e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2901460	0.509	rs12470090	chr2:62094367	T/C	cg02183531	chr2:62113199	CCT4	-0.45	-8.02	-0.35	8.94e-15	Mean corpuscular volume;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg02018176	chr4:1364513	KIAA1530	0.45	9.95	0.42	3e-21	Obesity-related traits;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg24378470	chr17:9478950	WDR16;STX8	-0.39	-6.68	-0.3	7.08e-11	Platelet count;
LGG	cis	rs2658782	1.000	rs2605583	chr11:93164957	T/A	cg15737290	chr11:93063684	CCDC67	0.58	8.48	0.37	2.99e-16	Pulmonary function decline;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg02002194	chr4:3960332	NA	0.44	7.7	0.34	8.19e-14	Neuroticism;
LGG	cis	rs7851660	0.809	rs3824495	chr9:100663700	A/C	cg13688889	chr9:100608707	NA	0.64	12.78	0.51	3.02e-32	Strep throat;
LGG	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.4	-0.36	5.6e-16	Calcium levels;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.53	-0.33	2.69e-13	Obesity-related traits;
LGG	cis	rs975722	0.542	rs39312	chr7:116954785	A/C	cg10524701	chr7:117356490	CTTNBP2	0.36	7.71	0.34	7.98e-14	Coronary artery disease;
LGG	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6032067	0.929	rs13043503	chr20:43805835	T/C	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.89	-0.34	2.26e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.93	-0.31	1.4e-11	Height;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-11.47	-0.47	5.41e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-7.01	-0.31	8.23e-12	Neuroticism;
LGG	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15557168	chr22:42548783	NA	-0.34	-7.66	-0.34	1.09e-13	Cognitive function;
LGG	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.79	-0.48	3.08e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.87e-16	Lung cancer;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg11814155	chr7:99998594	ZCWPW1	0.61	8.46	0.37	3.55e-16	Platelet count;
LGG	trans	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.53e-30	Corneal astigmatism;
LGG	cis	rs988958	0.565	rs35733689	chr2:42236778	G/C	cg19376973	chr2:42229025	NA	0.67	9.55	0.41	7.86e-20	Hypospadias;
LGG	cis	rs7917772	0.503	rs61871067	chr10:104295382	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.78	0.48	3.47e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-11.32	-0.47	2.18e-26	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs1109114	0.816	rs2918267	chr5:148608852	A/T	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.64	-0.59	1.5e-44	Body mass index;
LGG	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-10.32	-0.43	1.33e-22	Body mass index;
LGG	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.29	-0.32	1.33e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.74	0.57	1.35e-40	Platelet count;
LGG	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.73	-0.3	5.14e-11	Breast cancer;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.81	0.34	3.88e-14	Schizophrenia;
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.92	-0.31	1.49e-11	Monocyte percentage of white cells;
LGG	cis	rs3845702	0.800	rs6744281	chr2:180844382	G/A	cg01881094	chr2:180872142	CWC22	-1.25	-16.87	-0.62	3.8300000000000002e-50	Schizophrenia;
LGG	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg24375607	chr4:120327624	NA	0.66	10.66	0.44	7.37e-24	Corneal astigmatism;
LGG	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg23484912	chr5:273055	PDCD6	0.47	9.53	0.4	8.8e-20	Pancreatic cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06733736	chr16:3661771	BTBD12	0.42	6.9	0.31	1.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7937612	0.931	rs11823300	chr11:120199080	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.49	-11.35	-0.47	1.6e-26	Intraocular pressure;
LGG	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.83	9.49	0.4	1.22e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg09307838	chr4:120376055	NA	0.79	12.98	0.52	4.66e-33	Corneal astigmatism;
LGG	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22168489	chr12:122356033	WDR66	-0.37	-8.38	-0.36	6.24e-16	Mean corpuscular volume;
LGG	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17401966	0.931	rs4846205	chr1:10310214	A/T	cg19773385	chr1:10388646	KIF1B	-0.5	-10.98	-0.45	4.32e-25	Hepatocellular carcinoma;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18715511	chr12:1058965	RAD52	0.4	6.74	0.3	4.79e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.75	-0.41	1.45e-20	Blood metabolite levels;
LGG	cis	rs847577	0.630	rs3801294	chr7:97822210	G/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.77	-0.3	3.96e-11	Breast cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16449659	chr4:153701590	TIGD4;ARFIP1	0.43	6.92	0.31	1.53e-11	Menarche (age at onset);
LGG	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs6961069	0.806	rs4728183	chr7:80256003	A/G	cg04458919	chr7:80252533	CD36	0.28	6.85	0.3	2.36e-11	Platelet count;
LGG	cis	rs16866061	0.962	rs16866045	chr2:225413020	G/A	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs4780401	0.728	rs4781136	chr16:11767978	G/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.32	-0.32	1.13e-12	Rheumatoid arthritis;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	9.3	0.4	5.68e-19	Height;
LGG	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg04469686	chr1:162760199	HSD17B7	0.45	7.34	0.32	9.74e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	9.61	0.41	4.63e-20	Body mass index;
LGG	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg01221209	chr5:554886	NA	-0.46	-6.92	-0.31	1.54e-11	Obesity-related traits;
LGG	cis	rs9549260	0.755	rs2701869	chr13:41157372	G/A	cg21288729	chr13:41239152	FOXO1	0.33	6.75	0.3	4.56e-11	Red blood cell count;
LGG	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg07274523	chr3:49395745	GPX1	0.58	9.73	0.41	1.7e-20	Intelligence (multi-trait analysis);Educational attainment (years of education);
LGG	cis	rs9487051	0.802	rs6910696	chr6:109592329	A/T	cg21918786	chr6:109611834	NA	-0.42	-7.77	-0.34	4.96e-14	Reticulocyte fraction of red cells;
LGG	cis	rs17453880	0.929	rs10041415	chr5:152041409	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.59	-0.74	2.26e-81	Subjective well-being;
LGG	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.38	-0.36	6.18e-16	Neuroticism;
LGG	cis	rs4566357	1.000	rs6705989	chr2:227923320	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	cis	rs6963495	0.799	rs73190201	chr7:105165891	A/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs6840360	0.615	rs10021407	chr4:152465002	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg25358565	chr5:93447407	FAM172A	1.32	16.4	0.61	5.75e-48	Diabetic retinopathy;
LGG	cis	rs735860	0.700	rs209524	chr6:53213226	G/C	cg10236188	chr6:53219634	NA	0.35	6.85	0.3	2.41e-11	Glaucoma;
LGG	trans	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg25214090	chr10:38739885	LOC399744	0.65	11.57	0.47	2.27e-27	Corneal astigmatism;
LGG	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg07777115	chr5:623756	CEP72	-0.57	-7.29	-0.32	1.31e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.62	-0.44	9.73e-24	Lung cancer;
LGG	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg12165864	chr7:66369176	NA	-0.47	-7.68	-0.34	9.42e-14	Corneal structure;
LGG	cis	rs7524258	0.868	rs2157499	chr1:7271472	C/T	cg07173049	chr1:7289937	CAMTA1	0.69	16.0	0.6	3.48e-46	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	9.33e-30	Intelligence (multi-trait analysis);
LGG	trans	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.03	-0.31	7.25e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08564027	chr20:61660810	NA	1.04	25.83	0.77	8.84e-92	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9878978	1.000	rs9878978	chr3:2485969	C/T	cg21928760	chr3:2462534	CNTN4	0.36	7.73	0.34	6.53e-14	Blood pressure (smoking interaction);
LGG	cis	rs4936894	0.500	rs10790647	chr11:124075438	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-10.02	-0.42	1.6e-21	Aging (time to death);
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.33	-0.5	2.11e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg14664628	chr15:75095509	CSK	0.51	9.08	0.39	3.2e-18	Systemic lupus erythematosus;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.94	10.34	0.43	1.12e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.78	-0.3	3.73e-11	Blood metabolite levels;
LGG	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.46	0.61	3.03e-48	Hip circumference adjusted for BMI;
LGG	cis	rs9309473	0.898	rs10197755	chr2:73797623	T/A	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg26850624	chr5:429559	AHRR	-0.35	-7.72	-0.34	7.24e-14	Cystic fibrosis severity;
LGG	cis	rs7027203	0.828	rs7037960	chr9:96584028	G/A	cg13679303	chr9:96623674	NA	-0.39	-7.04	-0.31	7.02e-12	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23271606	chr7:92464891	CDK6	0.41	7.73	0.34	6.63e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.84	0.34	3.18e-14	Neuroticism;
LGG	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg10327440	chr1:227177885	CDC42BPA	-1.25	-38.64	-0.87	5.84e-147	Myeloid white cell count;
LGG	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg26248373	chr2:1572462	NA	-0.89	-14.25	-0.55	1.77e-38	IgG glycosylation;
LGG	cis	rs919433	0.679	rs10931787	chr2:198520615	A/G	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6489785	0.501	rs551125	chr12:121203427	C/T	cg02419362	chr12:121203948	SPPL3	0.43	6.86	0.3	2.25e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3106136	0.546	rs2276910	chr4:95129238	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.56	-10.31	-0.43	1.38e-22	Capecitabine sensitivity;
LGG	cis	rs2594989	0.943	rs346073	chr3:11298181	G/A	cg01796438	chr3:11312864	ATG7	-0.58	-7.92	-0.35	1.74e-14	Circulating chemerin levels;
LGG	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg00383909	chr3:49044727	WDR6	0.59	8.27	0.36	1.42e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.89	0.34	2.22e-14	Bipolar disorder;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg05091796	chr16:4465799	CORO7	-0.8	-13.22	-0.52	4.44e-34	Schizophrenia;
LGG	trans	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.38	8.12	0.35	4.14e-15	Obesity-related traits;
LGG	cis	rs12580194	0.593	rs4590978	chr12:55725086	G/T	cg19537932	chr12:55886519	OR6C68	-0.56	-9.89	-0.42	4.75e-21	Cancer;
LGG	cis	rs953387	1.000	rs12616955	chr2:136902666	C/T	cg07169764	chr2:136633963	MCM6	0.53	8.9	0.38	1.24e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.78	0.48	3.36e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg03806693	chr22:41940476	POLR3H	1.04	19.39	0.67	9.41e-62	Vitiligo;
LGG	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.73	-0.69	4.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2120243	0.782	rs7609926	chr3:157149160	T/C	cg24825693	chr3:157122686	VEPH1	-0.36	-7.72	-0.34	7.04e-14	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	12.43	0.5	7.92e-31	Parkinson's disease;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg00990874	chr7:1149470	C7orf50	-0.84	-15.33	-0.58	3.51e-43	Bronchopulmonary dysplasia;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.26	-0.46	3.77e-26	Neuroticism;
LGG	cis	rs1577917	1.000	rs12196411	chr6:86779762	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.02	-0.42	1.58e-21	Response to antipsychotic treatment;
LGG	trans	rs7819412	0.558	rs4841483	chr8:10908354	G/A	cg15556689	chr8:8085844	FLJ10661	0.43	7.06	0.31	6.32e-12	Triglycerides;
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.93	0.45	6.87e-25	Personality dimensions;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg11905131	chr22:24372483	LOC391322	-0.41	-7.04	-0.31	7.01e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg24812749	chr6:127587940	RNF146	0.64	10.77	0.45	2.73e-24	Breast cancer;
LGG	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg11366901	chr6:160182831	ACAT2	1.0	14.83	0.57	5.72e-41	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs7737355	0.812	rs548635	chr5:131055546	G/T	cg06307176	chr5:131281290	NA	-0.53	-8.82	-0.38	2.39e-17	Life satisfaction;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-6.91	-0.31	1.58e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg19357499	chr8:144660631	NAPRT1	0.89	7.04	0.31	6.76e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16529639	chr3:32726786	CNOT10	0.47	7.06	0.31	6.15e-12	Gut microbiome composition (summer);
LGG	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg10523679	chr1:76189770	ACADM	0.82	15.75	0.59	4.76e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg15557168	chr22:42548783	NA	-0.42	-8.82	-0.38	2.35e-17	Schizophrenia;
LGG	cis	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg06521331	chr12:34319734	NA	-0.47	-7.94	-0.35	1.58e-14	Resting heart rate;
LGG	cis	rs11608355	0.515	rs61941591	chr12:109919965	A/C	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs73086581	1.000	rs73088416	chr20:3995276	A/G	cg02187196	chr20:3869020	PANK2	0.8	11.22	0.46	5.33e-26	Response to antidepressants in depression;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.54	8.83	0.38	2.11e-17	Tonsillectomy;
LGG	trans	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.6	-0.41	4.94e-20	Monocyte percentage of white cells;
LGG	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg20302533	chr7:39170763	POU6F2	-0.34	-8.13	-0.35	3.9e-15	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.582	rs1304193	chr11:48688588	C/T	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	6.72e-22	Axial length;
LGG	cis	rs12980942	0.872	rs11879562	chr19:41804976	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.51	7.04	0.31	6.99e-12	Coronary artery disease;
LGG	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg15627072	chr1:2432621	PLCH2	-0.35	-7.85	-0.34	2.84e-14	Ulcerative colitis;
LGG	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg23625390	chr15:77176239	SCAPER	-0.76	-15.42	-0.58	1.42e-43	Blood metabolite levels;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.2	-0.49	6.95e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1035144	0.524	rs8009260	chr14:81408591	G/T	cg06600135	chr14:81408086	NA	0.53	10.58	0.44	1.42e-23	Male sexual orientation;
LGG	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg04731861	chr2:219085781	ARPC2	0.46	11.27	0.46	3.37e-26	Colorectal cancer;
LGG	cis	rs2371030	0.632	rs2887916	chr2:211570759	C/T	cg18417063	chr2:211583084	NA	0.51	8.31	0.36	1.03e-15	Non-small cell lung cancer;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-13.06	-0.52	1.99e-33	Menopause (age at onset);
LGG	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg04731861	chr2:219085781	ARPC2	0.31	7.37	0.32	7.85e-13	Ulcerative colitis;
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg19223190	chr17:80058835	NA	-0.45	-8.87	-0.38	1.55e-17	Life satisfaction;
LGG	cis	rs2230307	0.572	rs6677080	chr1:100633469	A/T	cg24955406	chr1:100503596	HIAT1	0.56	7.35	0.32	9.18e-13	Carotid intima media thickness;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg03188948	chr7:1209495	NA	0.48	7.49	0.33	3.4e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs68170813	0.617	rs6964395	chr7:107080667	G/C	cg02696742	chr7:106810147	HBP1	-0.7	-8.95	-0.38	8.77e-18	Coronary artery disease;
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg22072935	chr14:105399595	NA	0.52	10.11	0.43	7.82e-22	Rheumatoid arthritis;
LGG	cis	rs262150	0.566	rs2247275	chr7:158765812	A/G	cg13444538	chr7:158905317	VIPR2	-0.42	-6.91	-0.31	1.58e-11	Facial morphology (factor 20);
LGG	trans	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg18335740	chr13:41363409	SLC25A15	0.61	12.15	0.49	1.16e-29	Lewy body disease;
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.03	-0.31	7.52e-12	Bipolar disorder;
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06481639	chr22:41940642	POLR3H	-0.64	-9.25	-0.39	8.2e-19	Vitiligo;
LGG	trans	rs9354308	0.838	rs7769057	chr6:66540229	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.07e-11	Blood metabolite levels;
LGG	cis	rs4538187	0.585	rs34765999	chr2:64252793	G/A	cg02541582	chr2:64069798	UGP2	-0.58	-13.32	-0.53	1.7e-34	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	trans	rs3206736	0.548	rs1637676	chr7:35000559	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.91e-12	Diastolic blood pressure;
LGG	trans	rs10242455	1.000	rs73395547	chr7:98922746	C/A	cg09045935	chr12:6379348	NA	0.64	6.79	0.3	3.4e-11	Blood metabolite levels;
LGG	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg12751644	chr20:60527061	NA	-0.31	-7.07	-0.31	5.68e-12	Body mass index;
LGG	trans	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg06521331	chr12:34319734	NA	0.44	7.9	0.34	2.11e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg14912033	chr15:79043428	NA	-0.41	-10.33	-0.43	1.19e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg15103426	chr22:29168792	CCDC117	0.72	11.69	0.48	7.74e-28	Lymphocyte counts;
LGG	cis	rs2658782	0.789	rs2658775	chr11:93126799	C/T	cg15737290	chr11:93063684	CCDC67	0.51	7.73	0.34	6.85e-14	Pulmonary function decline;
LGG	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg14768367	chr16:72042858	DHODH	0.84	9.07	0.39	3.44e-18	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg06916706	chr16:4465613	CORO7	-0.7	-12.14	-0.49	1.22e-29	Schizophrenia;
LGG	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg25174290	chr11:3078921	CARS	-0.5	-8.71	-0.38	5.57e-17	Calcium levels;
LGG	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg18551225	chr6:44695536	NA	-0.72	-12.47	-0.5	5.74e-31	Total body bone mineral density;
LGG	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg09307838	chr4:120376055	NA	0.82	13.53	0.53	2.1e-35	Corneal astigmatism;
LGG	trans	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg05926928	chr17:57297772	GDPD1	-0.49	-7.75	-0.34	5.76e-14	Schizophrenia;
LGG	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.54	-0.33	2.48e-13	Gut microbiome composition (summer);
LGG	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.25	-0.46	4.07e-26	Lung cancer;
LGG	cis	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07988820	chr12:82153109	PPFIA2	-0.79	-11.43	-0.47	8.01e-27	Resting heart rate;
LGG	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-22.3	-0.72	2.34e-75	Blood trace element (Zn levels);
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11245990	chr11:68621969	NA	0.41	8.72	0.38	5.09e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg19554555	chr3:13937349	NA	-0.56	-10.22	-0.43	3.08e-22	Ovarian reserve;
LGG	trans	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg01620082	chr3:125678407	NA	-0.59	-6.69	-0.3	6.3e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg03517284	chr6:25882590	NA	-0.39	-6.99	-0.31	9.73e-12	Height;
LGG	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg19147804	chr7:1989927	MAD1L1	0.43	8.43	0.36	4.37e-16	Schizophrenia;
LGG	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.56	0.37	1.68e-16	Schizophrenia;
LGG	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg26354017	chr1:205819088	PM20D1	-0.53	-6.83	-0.3	2.69e-11	Prostate-specific antigen levels;
LGG	trans	rs8073060	0.544	rs225244	chr17:33946581	A/G	cg19694781	chr19:47549865	TMEM160	1.16	17.34	0.63	2.96e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs12579753	0.526	rs73359948	chr12:82322986	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-6.93	-0.31	1.42e-11	Resting heart rate;
LGG	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg04672837	chr16:48644449	N4BP1	0.51	8.4	0.36	5.53e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.35	0.7	6.59e-71	Bladder cancer;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07157834	chr1:205819609	PM20D1	0.82	20.08	0.68	5.48e-65	Menarche (age at onset);
LGG	cis	rs7103648	0.932	rs7104036	chr11:47462140	A/G	cg20307385	chr11:47447363	PSMC3	0.99	24.03	0.74	1.96e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs12618769	0.597	rs3754880	chr2:99132215	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs1010254	0.510	rs72808347	chr5:151760491	G/C	cg08593883	chr5:151785301	NMUR2	-0.45	-6.91	-0.31	1.58e-11	Optic nerve measurement (cup area);
LGG	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.33	0.32	1.06e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg05468953	chr4:100565104	NA	0.4	7.97	0.35	1.21e-14	Metabolite levels (MHPG);
LGG	trans	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg14227996	chr4:17616232	MED28	0.6	7.02	0.31	8.11e-12	Opioid sensitivity;
LGG	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.62e-17	Cognitive function;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg09690326	chr7:23720549	C7orf46	0.46	10.58	0.44	1.45e-23	Schizophrenia;
LGG	cis	rs4819388	0.789	rs4568033	chr21:45649778	A/G	cg01992765	chr21:45622493	NA	-0.43	-8.28	-0.36	1.28e-15	Celiac disease;
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	20.52	0.69	5.24e-67	Platelet count;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.64	0.33	1.28e-13	Lung cancer;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22037798	chr1:231473786	C1orf124;EXOC8	0.39	6.67	0.3	7.12e-11	Body mass index;
LGG	cis	rs4959677	0.698	rs9501850	chr6:2480110	C/T	cg20147862	chr6:2634573	C6orf195	0.39	8.58	0.37	1.45e-16	Orthostatic hypotension;
LGG	cis	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg26677194	chr12:130822605	PIWIL1	0.56	9.99	0.42	1.98e-21	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg02631450	chr22:32366979	NA	0.98	9.34	0.4	4e-19	Childhood ear infection;
LGG	trans	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg11693508	chr17:37793320	STARD3	0.52	8.43	0.36	4.54e-16	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg27129171	chr3:47204927	SETD2	-0.86	-16.05	-0.6	2.06e-46	Colorectal cancer;
LGG	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg24375607	chr4:120327624	NA	0.67	11.03	0.46	2.72e-25	Corneal astigmatism;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.9	-19.41	-0.67	7.36e-62	Personality dimensions;
LGG	cis	rs9596863	0.898	rs9596850	chr13:54371713	C/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4917300	0.606	rs6583566	chr8:143114541	G/A	cg06573787	chr8:143070187	NA	0.59	9.95	0.42	2.81e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.75	0.38	3.91e-17	Platelet count;
LGG	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg27661571	chr11:113659931	NA	-0.62	-8.71	-0.38	5.49e-17	Hip circumference adjusted for BMI;
LGG	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg13010199	chr12:38710504	ALG10B	0.74	15.62	0.59	1.72e-44	Heart rate;
LGG	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.71	-0.41	2.02e-20	Body mass index;
LGG	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg11502198	chr6:26597334	ABT1	0.7	12.68	0.51	7.73e-32	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg06521331	chr12:34319734	NA	-0.55	-9.42	-0.4	2.07e-19	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg24642844	chr7:1081250	C7orf50	-0.47	-8.76	-0.38	3.62e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2737618	0.698	rs2737681	chr1:200091864	C/T	cg21825944	chr1:200113062	NR5A2	-0.61	-11.96	-0.49	6.58e-29	Uric acid levels;
LGG	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg18851795	chr1:204543875	NA	-0.38	-7.04	-0.31	7.15e-12	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.8	0.59	2.76e-45	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07308232	chr7:1071921	C7orf50	-0.53	-9.86	-0.42	5.81e-21	Longevity;Endometriosis;
LGG	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.93	-0.48	8.42e-29	Parkinson's disease;
LGG	cis	rs9462027	0.628	rs9462009	chr6:34716330	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	cis	rs4639966	0.797	rs11217021	chr11:118640828	T/C	cg19182353	chr11:118479428	PHLDB1	-0.53	-8.65	-0.37	8.62e-17	Systemic lupus erythematosus;
LGG	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	9.39	0.4	2.66e-19	Height;
LGG	cis	rs72781680	1.000	rs56068891	chr2:24230633	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.62	0.41	4.16e-20	Lymphocyte counts;
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg27189623	chr16:705930	WDR90	0.4	7.62	0.33	1.44e-13	Height;
LGG	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg03929089	chr4:120376271	NA	-0.7	-9.53	-0.4	8.61e-20	Axial length;
LGG	cis	rs2694528	0.686	rs7723165	chr5:59876715	A/G	cg11474532	chr5:59995715	DEPDC1B	0.92	8.84	0.38	1.99e-17	Parkinson's disease;
LGG	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs2629540	0.580	rs2930796	chr10:126485684	A/G	cg08799069	chr10:126477246	METTL10	0.63	11.3	0.46	2.66e-26	Cocaine dependence;
LGG	cis	rs8072100	0.576	rs7216112	chr17:45406345	C/T	cg25173405	chr17:45401733	C17orf57	0.7	11.99	0.49	5.07e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg22778903	chr21:42741698	MX2	0.44	8.85	0.38	1.88e-17	Melanoma;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.67	0.37	7.6e-17	Mean platelet volume;
LGG	cis	rs2236918	1.000	rs2797605	chr1:242025245	A/T	cg17736920	chr1:242011382	EXO1	0.5	9.03	0.39	4.76e-18	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.83	0.73	7.6e-78	Homoarginine levels;
LGG	cis	rs17818399	0.620	rs3087822	chr2:46852033	C/T	cg26688816	chr2:46740690	ATP6V1E2	0.43	7.67	0.34	1.04e-13	Height;
LGG	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg12654349	chr5:56205094	C5orf35	0.58	9.97	0.42	2.5e-21	Initial pursuit acceleration;
LGG	cis	rs7617773	0.817	rs79310258	chr3:48259667	C/G	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg03929089	chr4:120376271	NA	0.49	7.85	0.34	2.98e-14	HDL cholesterol;
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg16885296	chr6:26284938	NA	0.39	8.51	0.37	2.35e-16	Educational attainment;
LGG	cis	rs10992471	0.756	rs10992319	chr9:95127895	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.09	-0.31	5.12e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2587949	0.615	rs2600114	chr3:4225064	G/A	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.77e-11	Periodontitis (DPAL);
LGG	cis	rs12249377	0.519	rs10785972	chr10:92593800	C/T	cg14313238	chr10:92632228	RPP30	0.4	7.06	0.31	6.24e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs3136516	0.772	rs7947747	chr11:46852839	A/G	cg03339077	chr11:47165057	C11orf49	-0.37	-6.72	-0.3	5.4e-11	Venous thromboembolism;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11912956	chr7:73588697	EIF4H	0.39	6.66	0.3	7.86e-11	Bipolar disorder;
LGG	cis	rs4538187	0.901	rs68117986	chr2:64239566	G/A	cg02541582	chr2:64069798	UGP2	-0.61	-14.36	-0.56	6.01e-39	Systolic blood pressure;
LGG	cis	rs7508	0.612	rs10112857	chr8:17917888	A/G	cg18067069	chr8:17937731	ASAH1	-0.33	-7.66	-0.34	1.06e-13	Atrial fibrillation;
LGG	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs433852	0.904	rs8102492	chr19:49140809	A/C	cg06530960	chr19:49140787	SEC1;DBP	0.67	10.69	0.45	5.34e-24	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg20978937	chr14:105399321	PLD4	0.47	10.38	0.43	7.95e-23	Rheumatoid arthritis;
LGG	cis	rs13108043	0.605	rs17702203	chr4:87961503	A/C	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs6450176	0.859	rs3776719	chr5:53298684	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.16	-0.46	8.79e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16405210	chr4:1374714	KIAA1530	-0.52	-8.99	-0.39	6.51e-18	Obesity-related traits;
LGG	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg04117972	chr1:227635322	NA	0.87	13.31	0.53	1.89e-34	Major depressive disorder;
LGG	cis	rs3784262	0.967	rs12148907	chr15:58296450	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.12	-0.35	4.36e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs12453935	0.640	rs17614124	chr17:59916024	C/T	cg14757157	chr17:59911755	BRIP1	0.34	6.71	0.3	5.86e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs2415984	0.622	rs12437018	chr14:46937149	A/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.26	-0.43	2.24e-22	Number of children ever born;
LGG	cis	rs17286411	0.750	rs8044004	chr16:71868168	A/C	cg03805757	chr16:71968109	PKD1L3	0.34	6.92	0.31	1.56e-11	Blood protein levels;
LGG	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.15	-0.39	1.87e-18	Systolic blood pressure;
LGG	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg05425664	chr17:57184151	TRIM37	-0.45	-7.15	-0.32	3.48e-12	Testicular germ cell tumor;
LGG	cis	rs6032067	0.929	rs55726011	chr20:43855229	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs17767392	0.881	rs35680546	chr14:71940619	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.05	0.39	3.89e-18	Mitral valve prolapse;
LGG	trans	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg06521331	chr12:34319734	NA	-0.55	-9.14	-0.39	1.95e-18	Bladder cancer;
LGG	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg11764359	chr7:65958608	NA	-0.71	-12.52	-0.5	3.41e-31	Aortic root size;
LGG	cis	rs4732038	1.000	rs4732038	chr7:134250322	A/C	cg06906464	chr7:134288099	NA	-0.52	-14.04	-0.55	1.53e-37	Longevity;
LGG	cis	rs11240074	0.516	rs2353953	chr1:146945434	G/A	cg25205988	chr1:146714368	CHD1L	-0.65	-6.71	-0.3	5.88e-11	Type 2 diabetes;
LGG	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg11441379	chr12:63026424	NA	0.69	9.65	0.41	3.45e-20	IgG glycosylation;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg11878867	chr6:150167359	LRP11	-0.4	-8.36	-0.36	7.45e-16	Testicular germ cell tumor;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg26338869	chr17:61819248	STRADA	0.6	9.95	0.42	2.95e-21	Prudent dietary pattern;
LGG	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.71e-11	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01078248	chr7:123197661	NDUFA5	0.52	8.28	0.36	1.33e-15	Gut microbiome composition (summer);
LGG	cis	rs4604732	0.574	rs111928142	chr1:247625229	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.69e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg11584989	chr19:19387371	SF4	-0.74	-12.12	-0.49	1.54e-29	Bipolar disorder;
LGG	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	8.18	0.36	2.72e-15	Nonalcoholic fatty liver disease;
LGG	cis	rs2952156	1.000	rs2934971	chr17:37854507	G/T	cg00129232	chr17:37814104	STARD3	-0.67	-13.21	-0.52	4.69e-34	Asthma;
LGG	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg04117972	chr1:227635322	NA	0.72	11.74	0.48	4.71e-28	Major depressive disorder;
LGG	cis	rs240764	0.658	rs11155618	chr6:101181811	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs11608355	1.000	rs10850135	chr12:109866528	C/A	cg19025524	chr12:109796872	NA	-0.49	-9.25	-0.4	8.14e-19	Neuroticism;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20887711	chr4:1340912	KIAA1530	-0.53	-9.73	-0.41	1.81e-20	Obesity-related traits;
LGG	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg11707556	chr5:10655725	ANKRD33B	0.66	11.26	0.46	3.74e-26	Height;
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg02002194	chr4:3960332	NA	0.45	8.55	0.37	1.78e-16	Neuroticism;
LGG	cis	rs7737355	0.947	rs58991576	chr5:130589540	T/C	cg06307176	chr5:131281290	NA	-0.49	-8.18	-0.36	2.77e-15	Life satisfaction;
LGG	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg10840412	chr1:235813424	GNG4	0.54	7.44	0.33	4.89e-13	Bipolar disorder;
LGG	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	trans	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg21775007	chr8:11205619	TDH	-0.45	-7.46	-0.33	4.18e-13	Morning vs. evening chronotype;
LGG	cis	rs17092148	0.887	rs2378199	chr20:33186480	T/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg09085632	chr11:111637200	PPP2R1B	0.9	17.94	0.64	4.78e-55	Primary sclerosing cholangitis;
LGG	cis	rs12765878	1.000	rs61277100	chr10:105643352	A/G	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg02023728	chr11:77925099	USP35	0.39	6.96	0.31	1.16e-11	Alzheimer's disease (survival time);
LGG	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg17211192	chr8:82754475	SNX16	0.71	11.89	0.48	1.19e-28	Diastolic blood pressure;
LGG	cis	rs12477438	0.520	rs11892441	chr2:100005318	G/A	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.59	-0.41	5.64e-20	Life satisfaction;
LGG	cis	rs7267979	0.966	rs6083818	chr20:25346082	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6831352	0.734	rs2602857	chr4:100030318	G/A	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs11239187	0.566	rs12244967	chr10:45077687	A/G	cg03916630	chr10:45065415	NA	0.34	8.28	0.36	1.37e-15	Body mass index;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.5	8.89	0.38	1.39e-17	Glycated hemoglobin levels;
LGG	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg03060546	chr3:49711283	APEH	-0.64	-8.39	-0.36	6e-16	Menarche (age at onset);
LGG	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg26248373	chr2:1572462	NA	-0.86	-14.99	-0.57	1.11e-41	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs1997103	1.000	rs2331067	chr7:55408232	A/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.61	-0.41	4.79e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg23533926	chr12:111358616	MYL2	0.4	6.65	0.3	8.4e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.65e-20	Aortic root size;
LGG	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg12856521	chr11:46389249	DGKZ	0.89	14.75	0.57	1.22e-40	Crohn's disease;
LGG	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.17	-0.49	9.63e-30	Chronic sinus infection;
LGG	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg20587970	chr11:113659929	NA	0.9	14.02	0.55	1.8e-37	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg20453264	chr5:131705742	SLC22A5	0.65	8.26	0.36	1.54e-15	Rheumatoid arthritis;
LGG	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg13393036	chr8:95962371	TP53INP1	-0.28	-7.24	-0.32	1.94e-12	Type 2 diabetes;
LGG	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11890956	chr21:40555474	PSMG1	-0.94	-19.05	-0.66	3.48e-60	Cognitive function;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg22756942	chr8:1746360	NA	-0.39	-6.75	-0.3	4.46e-11	Systolic blood pressure;
LGG	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-9.92	-0.42	3.65e-21	Hepatocellular carcinoma;
LGG	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-10.63	-0.44	9.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2694528	0.844	rs2169255	chr5:60062624	C/A	cg11474532	chr5:59995715	DEPDC1B	0.73	7.81	0.34	3.74e-14	Parkinson's disease;
LGG	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.08e-16	Platelet distribution width;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg01673284	chr16:4527211	HMOX2	0.32	6.67	0.3	7.42e-11	Schizophrenia;
LGG	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-6.79	-0.3	3.36e-11	Crohn's disease;
LGG	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg08344181	chr3:125677491	NA	-0.59	-6.91	-0.31	1.56e-11	Breast cancer;
LGG	cis	rs28374715	0.578	rs7165914	chr15:41632451	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.66	-0.84	1.68e-126	Ulcerative colitis;
LGG	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.24	0.36	1.79e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs28830936	0.509	rs6493004	chr15:41858687	A/G	cg17847044	chr15:42102381	MAPKBP1	0.38	7.8	0.34	4.27e-14	Diastolic blood pressure;
LGG	cis	rs7928758	0.943	rs11823810	chr11:134270070	A/G	cg15243474	chr11:134282918	B3GAT1	1.09	14.67	0.56	2.78e-40	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs1032833	0.732	rs74367571	chr2:179959890	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.68	0.37	6.76e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg05863683	chr7:1912471	MAD1L1	0.44	8.52	0.37	2.27e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg24247370	chr13:99142703	STK24	-0.38	-6.96	-0.31	1.14e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4731207	0.535	rs1351471	chr7:124672015	A/T	cg05630886	chr7:124431682	NA	-0.33	-7.5	-0.33	3.34e-13	Cutaneous malignant melanoma;
LGG	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs834603	0.541	rs1704965	chr7:47470215	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs295140	0.585	rs4233996	chr2:201131228	A/T	cg17644776	chr2:200775616	C2orf69	-0.46	-7.75	-0.34	6.03e-14	QT interval;
LGG	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg13147721	chr7:65941812	NA	-0.79	-9.54	-0.41	7.93e-20	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01855760	chr4:68567075	LOC550112;UBA6	0.49	7.77	0.34	5.09e-14	Gut microbiome composition (summer);
LGG	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.56	-0.47	2.56e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg13939156	chr17:80058883	NA	-0.46	-8.97	-0.38	7.18e-18	Life satisfaction;
LGG	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs1775715	0.707	rs2065443	chr10:32164236	C/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.77	0.3	3.83e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.81	-0.3	3.03e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg02153584	chr22:29168773	CCDC117	0.57	8.21	0.36	2.17e-15	Lymphocyte counts;
LGG	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	trans	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg18335740	chr13:41363409	SLC25A15	0.53	9.4	0.4	2.53e-19	Lewy body disease;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg08621203	chr6:150244597	RAET1G	0.46	8.0	0.35	1.03e-14	Lung cancer;
LGG	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.61	0.33	1.56e-13	Neuroticism;
LGG	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18876405	chr7:65276391	NA	-0.53	-9.54	-0.41	8.02e-20	Aortic root size;
LGG	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg18245976	chr7:158708271	WDR60	0.44	7.47	0.33	4.04e-13	Height;
LGG	cis	rs921968	0.643	rs483172	chr2:219428299	A/G	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.04	18.27	0.65	1.56e-56	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08295258	chr5:102455984	GIN1	0.44	7.26	0.32	1.64e-12	Cognitive performance;
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg18357526	chr6:26021779	HIST1H4A	0.8	12.74	0.51	4.56e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	1.000	rs439553	chr6:167391212	A/G	cg07741184	chr6:167504864	NA	0.32	7.1	0.31	4.86e-12	Crohn's disease;
LGG	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg07930552	chr6:133119739	C6orf192	1.11	9.67	0.41	2.76e-20	Type 2 diabetes nephropathy;
LGG	cis	rs433406	0.760	rs433443	chr11:131371202	A/G	cg27203895	chr11:131369037	NTM	-0.77	-17.72	-0.64	5.22e-54	Male fertility;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1461503	0.966	rs11218910	chr11:122842861	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs4478037	0.749	rs72856153	chr3:33111182	T/G	cg19404215	chr3:33155277	CRTAP	0.74	9.21	0.39	1.15e-18	Major depressive disorder;
LGG	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg07615347	chr10:60278583	BICC1	-0.61	-17.14	-0.62	2.37e-51	Refractive error;
LGG	cis	rs7711186	0.786	rs10051137	chr5:178038291	C/A	cg17371294	chr5:178012716	COL23A1	-0.68	-6.99	-0.31	9.42e-12	Urate levels in obese individuals;
LGG	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg12395012	chr8:11607386	GATA4	0.41	7.16	0.32	3.2e-12	Retinal vascular caliber;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.1	0.31	4.87e-12	Prudent dietary pattern;
LGG	cis	rs3740540	0.530	rs2362505	chr10:126290739	T/G	cg04949429	chr10:126290192	LHPP	0.6	11.36	0.47	1.53e-26	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.49e-15	Bipolar disorder;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg22907277	chr7:1156413	C7orf50	0.49	8.57	0.37	1.5e-16	Longevity;Endometriosis;
LGG	cis	rs7527798	0.637	rs7515149	chr1:207838352	T/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.9	-0.31	1.74e-11	Erythrocyte sedimentation rate;
LGG	cis	rs3738772	0.633	rs919958	chr1:110053148	C/G	cg17185401	chr1:110052093	AMIGO1	-0.41	-7.01	-0.31	8.6e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.51e-16	Obesity-related traits;
LGG	cis	rs2742417	1.000	rs2742390	chr3:45756722	A/G	cg04837898	chr3:45731254	SACM1L	0.38	7.52	0.33	2.88e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs11677416	1.000	rs2856836	chr2:113532083	A/G	cg27083787	chr2:113543245	IL1A	0.54	9.06	0.39	3.66e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg27624424	chr6:160112604	SOD2	0.65	9.27	0.4	6.84e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18252515	chr7:66147081	NA	0.46	7.59	0.33	1.76e-13	Aortic root size;
LGG	cis	rs3820928	0.874	rs2229812	chr2:227896886	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.46e-13	Pulmonary function;
LGG	cis	rs6142618	0.562	rs67703205	chr20:30762655	T/C	cg00028034	chr20:30779307	TSPYL3	0.36	7.87	0.34	2.44e-14	Inflammatory bowel disease;
LGG	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.47	0.4	1.41e-19	Bone mineral density;
LGG	cis	rs17253792	0.822	rs75995456	chr14:56073194	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs6960043	0.782	rs10228456	chr7:15063926	C/T	cg19272540	chr7:15055459	NA	-0.35	-7.76	-0.34	5.63e-14	Type 2 diabetes;
LGG	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.18	-0.43	4.3e-22	Response to antipsychotic treatment;
LGG	cis	rs7267979	0.808	rs84816	chr20:25459919	G/A	cg06421707	chr20:25228305	PYGB	0.46	9.8	0.41	9.68e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05491587	chr18:77659695	KCNG2	-0.53	-7.08	-0.31	5.26e-12	Opioid sensitivity;
LGG	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg24812749	chr6:127587940	RNF146	-0.88	-13.54	-0.53	2.08e-35	Breast cancer;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.58	-0.37	1.46e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg12165864	chr7:66369176	NA	-0.47	-7.84	-0.34	3.18e-14	Corneal structure;
LGG	cis	rs9457247	0.967	rs443570	chr6:167389925	G/A	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg19992207	chr2:111874495	ACOXL	-0.37	-6.69	-0.3	6.29e-11	Chronic lymphocytic leukemia;
LGG	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg21775007	chr8:11205619	TDH	-0.46	-7.52	-0.33	2.83e-13	Mood instability;
LGG	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.29	0.36	1.23e-15	Menopause (age at onset);
LGG	cis	rs2276314	0.857	rs28431958	chr18:33578401	T/G	cg05985134	chr18:33552581	C18orf21	0.63	9.79	0.41	1.03e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs225245	0.694	rs321616	chr17:33882720	C/T	cg19694781	chr19:47549865	TMEM160	-0.44	-7.57	-0.33	2.09e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2235649	0.833	rs4335769	chr16:1849376	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs7582720	1.000	rs72926782	chr2:203811628	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg14196790	chr5:131705035	SLC22A5	0.62	7.83	0.34	3.35e-14	Rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg13010199	chr12:38710504	ALG10B	0.63	12.63	0.51	1.28e-31	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg19168338	chr16:4465731	CORO7	-0.73	-13.38	-0.53	9.18e-35	Schizophrenia;
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg13699009	chr12:122356056	WDR66	0.56	15.6	0.59	2.09e-44	Mean corpuscular volume;
LGG	cis	rs8018808	1.000	rs4903577	chr14:77847258	C/T	cg20045696	chr14:77926864	AHSA1	-0.4	-6.76	-0.3	4.24e-11	Myeloid white cell count;
LGG	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	8.0	0.35	1e-14	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.66	-0.9	1.51e-173	Myeloid white cell count;
LGG	cis	rs548181	0.736	rs540436	chr11:125512619	A/G	cg03464685	chr11:125439445	EI24	1.3	19.65	0.67	5.62e-63	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2013441	1.000	rs2703794	chr17:20073338	T/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg26913058	chr16:419975	MRPL28	0.49	7.93	0.35	1.66e-14	Body mass index;
LGG	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.42	0.56	3.27e-39	Cognitive test performance;
LGG	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg04198125	chr7:157211777	NA	0.42	7.89	0.34	2.27e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-27.15	-0.78	8.19e-98	Height;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00933542	chr6:150070202	PCMT1	-0.39	-7.08	-0.31	5.52e-12	Lung cancer;
LGG	trans	rs11989744	0.500	rs7826517	chr8:23568841	G/A	cg03492747	chr16:86543808	FOXF1	-0.59	-10.8	-0.45	2.05e-24	Waist-hip ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15805921	chr6:42952109	PPP2R5D	0.45	6.71	0.3	5.53e-11	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.770	rs745191	chr15:86123170	G/T	cg04173714	chr15:86211321	AKAP13	0.47	8.48	0.37	3e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg06221963	chr1:154839813	KCNN3	0.52	10.64	0.44	8.25e-24	Prostate cancer;
LGG	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.26	-0.36	1.55e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg20587970	chr11:113659929	NA	1.06	15.99	0.6	3.68e-46	Hip circumference adjusted for BMI;
LGG	cis	rs9393777	0.588	rs11967935	chr6:26560672	A/C	cg12826209	chr6:26865740	GUSBL1	0.83	12.35	0.5	1.82e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21659725	chr3:3221576	CRBN	0.63	11.63	0.48	1.32e-27	Intelligence (multi-trait analysis);
LGG	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg01557791	chr16:72042693	DHODH	-0.45	-8.25	-0.36	1.69e-15	Fibrinogen levels;
LGG	cis	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg06521331	chr12:34319734	NA	-0.4	-7.27	-0.32	1.59e-12	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.32	-0.5	2.4e-30	Vitiligo;
LGG	cis	rs2415984	0.558	rs10220566	chr14:46965511	A/T	cg14871534	chr14:47121158	RPL10L	-0.59	-10.33	-0.43	1.24e-22	Number of children ever born;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.85	-0.34	2.87e-14	Neuroticism;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg14675211	chr2:100938903	LONRF2	0.64	11.46	0.47	6e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4696584	0.877	rs6819298	chr4:155397921	G/T	cg04517429	chr4:155413618	DCHS2	0.3	6.82	0.3	2.84e-11	Folding of antihelix;
LGG	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg01206211	chr2:36825736	FEZ2	0.43	8.18	0.36	2.72e-15	Height;
LGG	cis	rs11627756	0.957	rs12434778	chr14:103142135	G/T	cg12046867	chr14:103022105	NA	0.46	8.46	0.37	3.63e-16	Mean platelet volume;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs6496667	0.533	rs2074583	chr15:91009192	T/C	cg22089800	chr15:90895588	ZNF774	0.53	8.75	0.38	4.1e-17	Rheumatoid arthritis;
LGG	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18876405	chr7:65276391	NA	-0.6	-10.94	-0.45	5.95e-25	Aortic root size;
LGG	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06481639	chr22:41940642	POLR3H	0.58	8.44	0.37	4e-16	Vitiligo;
LGG	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg03264133	chr6:25882463	NA	-0.41	-7.24	-0.32	1.91e-12	Height;
LGG	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07570687	chr10:102243282	WNT8B	0.4	7.05	0.31	6.35e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.81e-52	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg02002194	chr4:3960332	NA	-0.53	-10.24	-0.43	2.59e-22	Mood instability;
LGG	cis	rs8051431	0.504	rs2335711	chr16:71907559	T/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	LDL cholesterol levels;
LGG	trans	rs75804782	0.520	rs34058921	chr2:239318665	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.92	0.38	1.11e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.0	-0.39	6.09e-18	Aortic root size;
LGG	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg11871910	chr12:69753446	YEATS4	0.78	13.16	0.52	8.03e-34	Response to diuretic therapy;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg18402987	chr7:1209562	NA	0.68	9.26	0.4	7.92e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Bladder cancer;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg23758822	chr17:41437982	NA	0.87	16.04	0.6	2.38e-46	Menopause (age at onset);
LGG	trans	rs2270927	0.510	rs6453214	chr5:75584423	A/G	cg13563193	chr19:33072644	PDCD5	0.85	10.15	0.43	5.58e-22	Mean corpuscular volume;
LGG	cis	rs7945718	0.934	rs10831907	chr11:12790875	C/T	cg25843174	chr11:12811716	TEAD1	-0.42	-8.62	-0.37	1.09e-16	Educational attainment (years of education);
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg07117364	chr1:16154769	NA	-0.48	-8.99	-0.39	6.3e-18	Dilated cardiomyopathy;
LGG	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg20744362	chr22:50050164	C22orf34	0.42	7.39	0.32	6.71e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7113874	0.524	rs4612809	chr11:8620038	T/C	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.69e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg27446573	chr6:127587934	RNF146	0.93	17.35	0.63	2.51e-52	Breast cancer;
LGG	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg12654349	chr5:56205094	C5orf35	-0.37	-6.72	-0.3	5.48e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	trans	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg07817883	chr1:32538562	TMEM39B	1.44	13.58	0.53	1.38e-35	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg20417195	chr1:21767127	NBPF3	0.42	7.62	0.33	1.49e-13	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg06606381	chr12:133084897	FBRSL1	-1.18	-10.64	-0.44	8.69e-24	Intelligence (multi-trait analysis);
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg04166393	chr7:2884313	GNA12	0.45	8.37	0.36	6.98e-16	Height;
LGG	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg01620082	chr3:125678407	NA	0.61	6.71	0.3	5.8e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg05552183	chr6:42928497	GNMT	0.44	12.86	0.51	1.45e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs721399	0.539	rs10103148	chr8:18267429	A/C	cg18736775	chr8:18248649	NAT2	-0.77	-11.71	-0.48	6.46e-28	Blood metabolite levels;
LGG	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg25114630	chr15:101792522	CHSY1	0.56	9.53	0.4	8.84e-20	Corneal structure;
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg23958373	chr8:599963	NA	1.38	13.31	0.53	1.93e-34	IgG glycosylation;
LGG	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs477692	0.792	rs12762024	chr10:131441055	G/C	cg05714579	chr10:131428358	MGMT	-0.7	-14.82	-0.57	6.08e-41	Response to temozolomide;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10979	1.000	rs3748072	chr6:143889757	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05025164	chr4:1340916	KIAA1530	0.56	9.89	0.42	4.64e-21	Obesity-related traits;
LGG	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs9487094	0.670	rs7767525	chr6:109967390	C/G	cg01125227	chr6:109776195	MICAL1	0.44	7.74	0.34	6.26e-14	Height;
LGG	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg04986931	chr22:39850128	NA	0.4	8.94	0.38	9.02e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg24642439	chr20:33292090	TP53INP2	-0.67	-12.2	-0.49	7.22e-30	Coronary artery disease;
LGG	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg24375607	chr4:120327624	NA	0.59	9.75	0.41	1.54e-20	Corneal astigmatism;
LGG	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.9	0.45	9e-25	Bone mineral density;
LGG	cis	rs113835537	0.529	rs11227525	chr11:66308065	T/G	cg24851651	chr11:66362959	CCS	0.46	7.8	0.34	4.22e-14	Airway imaging phenotypes;
LGG	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg23166289	chr1:210001082	C1orf107	0.32	6.68	0.3	7e-11	Orofacial clefts;
LGG	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg19455335	chr8:22457658	C8orf58	0.45	9.3	0.4	5.8e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs68170813	0.559	rs74745121	chr7:106958037	T/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.79	-0.45	2.3e-24	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs9649465	0.934	rs34030532	chr7:123274992	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-9.05	-0.39	4.1e-18	Migraine;
LGG	trans	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg24247370	chr13:99142703	STK24	-0.37	-6.87	-0.3	2.11e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03847052	chr16:89347724	ANKRD11	-0.38	-6.8	-0.3	3.33e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.65	0.44	7.42e-24	Lung cancer in ever smokers;
LGG	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg19717773	chr7:2847554	GNA12	-0.43	-10.04	-0.42	1.33e-21	Height;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.14e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg06697600	chr4:7070879	GRPEL1	0.51	7.7	0.34	8.48e-14	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12292205	chr6:26970375	C6orf41	-0.59	-9.34	-0.4	4.18e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35740288	0.770	rs12907126	chr15:86171357	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.35	0.36	7.72e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg06115741	chr20:33292138	TP53INP2	0.6	9.95	0.42	2.92e-21	Coronary artery disease;
LGG	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg13271783	chr10:134563150	INPP5A	-0.61	-9.23	-0.39	9.85e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg27147174	chr7:100797783	AP1S1	0.65	12.34	0.5	1.97e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs17253792	0.822	rs77250916	chr14:56042208	A/G	cg01858014	chr14:56050164	KTN1	-0.88	-11.04	-0.46	2.62e-25	Putamen volume;
LGG	cis	rs1707322	1.000	rs785517	chr1:46567535	A/T	cg03146154	chr1:46216737	IPP	-0.53	-9.59	-0.41	5.58e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3820928	0.839	rs13404750	chr2:227876129	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.61	-0.33	1.5e-13	Pulmonary function;
LGG	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg02297831	chr4:17616191	MED28	-0.44	-7.32	-0.32	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg05775895	chr3:12838266	CAND2	0.63	11.03	0.46	2.83e-25	QRS complex (12-leadsum);
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.47	2.48e-26	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs6028335	0.867	rs67490812	chr20:37716619	A/G	cg16355469	chr20:37678765	NA	0.56	7.08	0.31	5.49e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs4740619	0.669	rs6474967	chr9:15760988	G/T	cg14451791	chr9:16040625	NA	0.36	9.31	0.4	5.1e-19	Body mass index;
LGG	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg16141378	chr3:129829833	LOC729375	-0.41	-9.69	-0.41	2.53e-20	Mood instability;
LGG	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.94	-0.38	9.51e-18	Bipolar disorder;
LGG	cis	rs13082711	0.954	rs34348584	chr3:27532704	T/C	cg02860705	chr3:27208620	NA	0.81	14.4	0.56	4.17e-39	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg06528063	chr17:8532759	MYH10	0.48	7.2	0.32	2.42e-12	Apolipoprotein A-IV levels;
LGG	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg11887960	chr12:57824829	NA	0.6	7.38	0.32	7.58e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg08085267	chr17:45401833	C17orf57	0.74	13.77	0.54	2.14e-36	Coronary artery disease;
LGG	cis	rs9398803	0.965	rs6907898	chr6:126666416	C/T	cg19875578	chr6:126661172	C6orf173	0.56	10.29	0.43	1.65e-22	Male-pattern baldness;
LGG	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.79e-21	Platelet count;
LGG	cis	rs5742933	0.817	rs6738042	chr2:190641684	C/T	cg04003228	chr2:190539410	ANKAR	-0.49	-7.14	-0.32	3.58e-12	Ferritin levels;
LGG	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg09517075	chr8:22133004	PIWIL2	0.42	9.05	0.39	4.01e-18	Hypertriglyceridemia;
LGG	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg02297831	chr4:17616191	MED28	0.5	9.51	0.4	1.05e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.59	-10.47	-0.44	3.58e-23	Lymphocyte counts;
LGG	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg03929089	chr4:120376271	NA	0.44	7.18	0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg18479299	chr3:125709523	NA	-0.58	-7.28	-0.32	1.48e-12	Blood pressure (smoking interaction);
LGG	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.76	-0.48	3.94e-28	Mean platelet volume;
LGG	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg09307838	chr4:120376055	NA	0.68	11.8	0.48	2.73e-28	Corneal astigmatism;
LGG	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.55	-0.37	1.79e-16	Obesity-related traits;
LGG	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.53	-0.63	3.85e-53	Bladder cancer;
LGG	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.58	-0.69	2.5e-67	Diabetic kidney disease;
LGG	trans	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg02725872	chr8:58115012	NA	-0.76	-10.72	-0.45	4.25e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7444	0.941	rs181360	chr22:21928916	A/C	cg11654148	chr22:21984483	YDJC	-0.35	-6.88	-0.3	2e-11	Systemic lupus erythematosus;
LGG	cis	rs7216064	1.000	rs7224923	chr17:65842265	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg18032289	chr17:61959525	GH2	-0.41	-6.85	-0.3	2.42e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9937943	0.512	rs13335886	chr16:74577161	C/G	cg01733217	chr16:74700730	RFWD3	-0.66	-9.87	-0.42	5.41e-21	Neutrophil percentage of white cells;
LGG	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.09	0.31	4.92e-12	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02012445	chr14:57856758	NAA30	0.39	6.7	0.3	6.23e-11	Cognitive performance;
LGG	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.59	-0.41	5.61e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.9	-0.31	1.75e-11	Childhood ear infection;
LGG	cis	rs3820068	0.603	rs35509554	chr1:15993514	C/T	cg05660106	chr1:15850417	CASP9	0.82	15.71	0.59	6.95e-45	Systolic blood pressure;
LGG	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.03	0.31	7.63e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs283228	0.617	rs484819	chr6:101742101	A/G	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs4891159	0.790	rs77878087	chr18:74116337	G/A	cg24786174	chr18:74118243	ZNF516	-0.57	-13.29	-0.53	2.34e-34	Longevity;
LGG	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg24623649	chr8:11872141	NA	0.3	7.0	0.31	9.15e-12	Neuroticism;
LGG	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.45	-6.9	-0.31	1.71e-11	Parkinson's disease;
LGG	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg17211192	chr8:82754475	SNX16	-0.74	-12.44	-0.5	7.82e-31	Diastolic blood pressure;
LGG	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg13256891	chr4:100009986	ADH5	0.37	6.65	0.3	8.08e-11	Alcohol dependence;
LGG	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg14154082	chr13:112174009	NA	0.35	7.69	0.34	9.07e-14	Menarche (age at onset);
LGG	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg23173402	chr1:227635558	NA	0.6	9.93	0.42	3.49e-21	Major depressive disorder;
LGG	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	8.18	0.36	2.72e-15	Neuroticism;
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.46	8.27	0.36	1.39e-15	Total body bone mineral density;
LGG	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.68	0.3	6.86e-11	Homoarginine levels;
LGG	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg08824895	chr13:115047677	UPF3A	0.43	7.13	0.31	3.95e-12	Schizophrenia;
LGG	cis	rs5753037	0.585	rs5752962	chr22:30188245	A/C	cg01021169	chr22:30184971	ASCC2	-0.41	-8.26	-0.36	1.49e-15	Type 1 diabetes;
LGG	cis	rs858239	0.537	rs6942981	chr7:23231548	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.68	0.3	6.69e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs782590	0.694	rs2627775	chr2:55877113	C/T	cg18811423	chr2:55921094	PNPT1	0.84	17.52	0.63	4.37e-53	Metabolic syndrome;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg02733842	chr7:1102375	C7orf50	0.69	10.27	0.43	2.02e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11096990	0.572	rs35040563	chr4:39155882	G/A	cg24403649	chr4:39172243	NA	0.4	7.26	0.32	1.62e-12	Cognitive function;
LGG	cis	rs11676348	0.755	rs6436026	chr2:218951738	T/A	cg00012203	chr2:219082015	ARPC2	-0.56	-9.91	-0.42	4.13e-21	Ulcerative colitis;
LGG	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg21138405	chr5:131827807	IRF1	0.28	6.7	0.3	5.89e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg23750338	chr8:142222470	SLC45A4	0.6	12.48	0.5	4.92e-31	Immature fraction of reticulocytes;
LGG	trans	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg16141378	chr3:129829833	LOC729375	0.42	8.98	0.39	6.94e-18	Neuroticism;
LGG	cis	rs7236492	0.872	rs78536295	chr18:77229738	G/A	cg15532942	chr18:77220712	NFATC1	0.47	7.39	0.32	6.95e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg13207630	chr7:32358064	NA	-0.66	-7.06	-0.31	6.23e-12	Body mass index;
LGG	cis	rs977987	0.806	rs12917651	chr16:75466696	G/T	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs1620921	0.622	rs67876803	chr6:161268321	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs12230513	0.732	rs61957760	chr12:55859957	G/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.93	-0.45	6.76e-25	Contrast sensitivity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg20368377	chr13:23499360	NA	-0.6	-7.26	-0.32	1.65e-12	Intelligence (multi-trait analysis);
LGG	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg02002194	chr4:3960332	NA	0.38	6.72	0.3	5.31e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg00666640	chr1:248458726	OR2T12	0.57	9.19	0.39	1.32e-18	Common traits (Other);
LGG	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08109568	chr15:31115862	NA	-0.52	-8.52	-0.37	2.2e-16	Huntington's disease progression;
LGG	cis	rs1829883	0.689	rs2511979	chr5:98828142	A/T	cg08333243	chr5:99726346	NA	-0.37	-6.64	-0.3	8.6e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6988985	0.560	rs4418320	chr8:143944138	G/A	cg10324643	chr8:143916377	GML	0.44	9.11	0.39	2.58e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11690935	0.632	rs12052246	chr2:172895606	G/T	cg13550731	chr2:172543902	DYNC1I2	0.7	14.53	0.56	1.07e-39	Schizophrenia;
LGG	cis	rs8028182	0.636	rs4243034	chr15:75750969	G/A	cg20655648	chr15:75932815	IMP3	0.47	7.81	0.34	3.9e-14	Sudden cardiac arrest;
LGG	cis	rs28588043	1.000	rs2204792	chr1:170987278	T/C	cg03458344	chr1:170964477	C1orf129	-0.48	-7.2	-0.32	2.45e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg24253500	chr15:84953950	NA	-0.4	-7.42	-0.33	5.57e-13	P wave terminal force;
LGG	cis	rs10463316	0.963	rs4958450	chr5:150739932	A/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.07	-0.42	1.03e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg25173405	chr17:45401733	C17orf57	-0.47	-8.15	-0.35	3.47e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2769264	0.546	rs12071705	chr1:151430504	G/C	cg18801370	chr1:151430492	POGZ	1.04	17.05	0.62	6.18e-51	Blood trace element (Cu levels);
LGG	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.69	-0.3	6.31e-11	Neuroticism;
LGG	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg06347083	chr6:39282316	KCNK17	0.44	12.6	0.51	1.68e-31	Type 2 diabetes;
LGG	cis	rs7649275	0.882	rs2015263	chr3:53785540	C/T	cg21503701	chr3:53781065	CACNA1D	-0.46	-7.19	-0.32	2.61e-12	Trans fatty acid levels;
LGG	cis	rs2635047	0.756	rs28628143	chr18:44799028	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.13	0.31	3.84e-12	Educational attainment;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs11214589	0.905	rs12804573	chr11:113241726	G/A	cg14373873	chr11:113211441	TTC12	0.44	9.01	0.39	5.3e-18	Neuroticism;
LGG	cis	rs704	0.726	rs11080055	chr17:26649724	A/C	cg10342447	chr17:26645325	TMEM97	-0.39	-7.19	-0.32	2.65e-12	Osteoprotegerin levels;
LGG	cis	rs2562456	0.917	rs2650805	chr19:21687939	T/G	cg00806126	chr19:22604979	ZNF98	0.63	9.4	0.4	2.48e-19	Pain;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25698089	chr15:65321903	MTFMT	0.55	8.61	0.37	1.12e-16	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.54	-0.44	1.96e-23	Triglycerides;
LGG	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg14186256	chr22:23484241	RTDR1	-1.01	-25.34	-0.76	1.58e-89	Bone mineral density;
LGG	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.98	-0.35	1.18e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.39	0.32	7.02e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	8.08	0.35	5.57e-15	Platelet count;
LGG	cis	rs9435341	0.826	rs17496332	chr1:107546375	C/T	cg09367891	chr1:107599246	PRMT6	-0.56	-9.91	-0.42	4.11e-21	Facial morphology (factor 21, depth of nasal alae);
LGG	trans	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	trans	rs11227306	0.934	rs2234458	chr11:65639374	C/T	cg17712092	chr4:129076599	LARP1B	-0.6	-10.47	-0.44	3.68e-23	DNA methylation (variation);
LGG	cis	rs1707322	0.752	rs11211145	chr1:46108491	A/C	cg03146154	chr1:46216737	IPP	0.6	10.29	0.43	1.63e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs13095912	0.785	rs6791954	chr3:185335709	C/T	cg11274856	chr3:185301563	NA	-0.49	-7.93	-0.35	1.6e-14	Systolic blood pressure;
LGG	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	25.09	0.76	2.42e-88	IgG glycosylation;
LGG	cis	rs4704187	0.663	rs6897274	chr5:74426103	T/A	cg03227963	chr5:74354835	NA	0.31	6.71	0.3	5.75e-11	Response to amphetamines;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs2816316	1.000	rs2760528	chr1:192536785	G/A	cg02586212	chr1:192544902	RGS1	0.46	9.21	0.39	1.14e-18	Celiac disease;
LGG	cis	rs4538187	1.000	rs6546029	chr2:64069732	G/A	cg19915305	chr2:64069682	UGP2	0.68	15.15	0.58	2.17e-42	Systolic blood pressure;
LGG	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15128208	chr22:42549153	NA	-0.43	-8.58	-0.37	1.41e-16	Cognitive function;
LGG	cis	rs6430585	0.528	rs721765	chr2:136748779	C/A	cg07169764	chr2:136633963	MCM6	1.23	22.6	0.72	9.25e-77	Corneal structure;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg21605333	chr4:119757512	SEC24D	0.53	7.03	0.31	7.33e-12	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg08975724	chr8:8085496	FLJ10661	0.44	8.37	0.36	6.93e-16	Mood instability;
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-8.68	-0.37	6.82e-17	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.76	0.41	1.38e-20	Menarche (age at onset);
LGG	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.12	0.35	4.33e-15	Alzheimer's disease;
LGG	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg06481639	chr22:41940642	POLR3H	0.47	6.83	0.3	2.64e-11	Vitiligo;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg22907277	chr7:1156413	C7orf50	0.85	15.16	0.58	1.84e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.81	-0.38	2.53e-17	Post bronchodilator FEV1;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.46	0.4	1.54e-19	Longevity;
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg01262667	chr19:19385393	TM6SF2	0.43	10.74	0.45	3.46e-24	Tonsillectomy;
LGG	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg12310025	chr6:25882481	NA	-0.55	-10.37	-0.43	8.28e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg21724239	chr8:58056113	NA	0.46	7.08	0.31	5.43e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09699651	chr6:150184138	LRP11	0.55	10.41	0.44	6.11e-23	Testicular germ cell tumor;
LGG	cis	rs1801251	0.896	rs2305141	chr2:233684402	A/G	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.38	-0.36	6.32e-16	Coronary artery disease;
LGG	cis	rs4253772	0.530	rs6008662	chr22:46713917	G/A	cg24881330	chr22:46731750	TRMU	0.82	9.75	0.41	1.54e-20	LDL cholesterol;Cholesterol, total;
LGG	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.73	0.56	1.53e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg06640241	chr16:89574553	SPG7	-0.9	-17.02	-0.62	8.62e-51	Multiple myeloma (IgH translocation);
LGG	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg00531865	chr16:30841666	NA	-0.62	-13.2	-0.52	5.47e-34	Multiple myeloma;
LGG	cis	rs10779751	0.734	rs2748877	chr1:11129437	T/C	cg08854313	chr1:11322531	MTOR	0.75	16.61	0.61	6.26e-49	Body mass index;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg05863683	chr7:1912471	MAD1L1	0.44	8.45	0.37	3.85e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.67	0.34	1.06e-13	Lung cancer;
LGG	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg02073558	chr3:44770973	ZNF501	0.86	19.25	0.67	4.28e-61	Depressive symptoms;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05665937	chr4:1216051	CTBP1	-0.47	-8.55	-0.37	1.82e-16	Obesity-related traits;
LGG	trans	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg20587970	chr11:113659929	NA	-0.75	-11.82	-0.48	2.43e-28	Hip circumference adjusted for BMI;
LGG	cis	rs11585357	0.793	rs11587669	chr1:17616259	C/T	cg08277548	chr1:17600880	PADI3	-0.71	-7.93	-0.35	1.67e-14	Hair shape;
LGG	cis	rs58616815	0.857	rs4933183	chr10:92163334	A/G	cg17905462	chr10:92153495	NA	-0.25	-6.71	-0.3	5.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4774830	0.744	rs2288346	chr15:56139153	T/C	cg05129572	chr15:56138634	NEDD4	-0.92	-10.29	-0.43	1.72e-22	Delta-5 desaturase activity;
LGG	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.17	-0.7	4.74e-70	Leprosy;
LGG	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg16583315	chr14:65563665	MAX	-0.43	-8.64	-0.37	9.11e-17	Obesity-related traits;
LGG	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg15479754	chr10:1447082	ADARB2	-0.32	-6.7	-0.3	5.97e-11	Radiation response;
LGG	cis	rs6964587	1.000	rs7806184	chr7:91601978	A/G	cg17063962	chr7:91808500	NA	0.48	8.58	0.37	1.45e-16	Breast cancer;
LGG	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.45	-0.33	4.63e-13	Morning vs. evening chronotype;
LGG	trans	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-15.99	-0.6	3.75e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg09137382	chr11:130731461	NA	0.42	8.01	0.35	9.65e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.53	0.4	9.07e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.85	-0.3	2.29e-11	Menopause (age at onset);
LGG	cis	rs6750795	0.746	rs1667301	chr2:232423717	C/T	cg19187155	chr2:232395269	NMUR1	0.58	10.92	0.45	7.53e-25	Height;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-11.96	-0.49	6.22e-29	Prudent dietary pattern;
LGG	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg01145232	chr6:150245071	RAET1G	0.49	8.16	0.35	3.19e-15	Lung cancer;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.7e-18	Primary sclerosing cholangitis;
LGG	cis	rs11800820	0.536	rs61839815	chr1:246633791	T/C	cg16700716	chr1:246684329	NA	-0.41	-7.23	-0.32	2.03e-12	Obesity-related traits;
LGG	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.44	-7.78	-0.34	4.89e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs60180747	0.909	rs56913458	chr15:66702345	C/A	cg07575407	chr15:66541975	MEGF11	0.38	7.35	0.32	9.22e-13	Testicular germ cell tumor;
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.54	14.66	0.56	2.89e-40	Tonsillectomy;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.24	0.32	1.93e-12	Tonsillectomy;
LGG	cis	rs9473924	0.505	rs2223869	chr6:50904239	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs6032067	0.704	rs35009666	chr20:43786020	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs4788570	0.615	rs7190487	chr16:71648617	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	20.72	0.69	6.01e-68	Intelligence (multi-trait analysis);
LGG	cis	rs939658	0.805	rs11630571	chr15:79432992	C/A	cg17916960	chr15:79447300	NA	-0.67	-13.2	-0.52	5.57e-34	Refractive error;
LGG	cis	rs17428076	0.793	rs3765167	chr2:172693944	A/G	cg21435375	chr2:172878103	MAP1D	0.4	8.72	0.38	5.21e-17	Myopia;
LGG	cis	rs17767392	1.000	rs17178206	chr14:71880093	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.61	-0.33	1.55e-13	Lung cancer;
LGG	cis	rs7177699	0.557	rs34372090	chr15:79110735	C/T	cg00540400	chr15:79124168	NA	-0.54	-11.34	-0.47	1.74e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs35883536	0.967	rs2050471	chr1:101175651	C/T	cg06223162	chr1:101003688	GPR88	0.27	6.65	0.3	8.28e-11	Monocyte count;
LGG	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.47e-25	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06634786	chr22:41940651	POLR3H	0.79	13.0	0.52	3.6e-33	Vitiligo;
LGG	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg04824913	chr4:887549	GAK	-0.82	-16.42	-0.61	4.49e-48	Systemic sclerosis;
LGG	cis	rs3087591	0.683	rs757375	chr17:29717879	C/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.22	0.49	5.7e-30	Hip circumference;
LGG	cis	rs17428076	0.633	rs705870	chr2:172932283	C/T	cg21435375	chr2:172878103	MAP1D	0.34	7.54	0.33	2.56e-13	Myopia;
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.49	0.69	6.6e-67	Platelet count;
LGG	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg19500275	chr17:80737654	TBCD	0.52	7.32	0.32	1.13e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg19635926	chr16:89946313	TCF25	0.72	7.11	0.31	4.31e-12	Skin colour saturation;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00684032	chr4:1343700	KIAA1530	0.45	8.73	0.38	4.66e-17	Obesity-related traits;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.76	-0.59	4.21e-45	Height;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.4	-7.09	-0.31	4.9e-12	Longevity;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.41	-7.51	-0.33	3.02e-13	Schizophrenia;
LGG	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.27	0.72	3.09e-75	Breast cancer;
LGG	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03517284	chr6:25882590	NA	-0.68	-12.93	-0.52	7.06e-33	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg21475434	chr5:93447410	FAM172A	0.72	7.31	0.32	1.2e-12	Diabetic retinopathy;
LGG	cis	rs6840360	0.573	rs2407171	chr4:152256782	A/G	cg25486957	chr4:152246857	NA	-0.46	-8.09	-0.35	5.16e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg03264133	chr6:25882463	NA	-0.42	-7.27	-0.32	1.5e-12	Height;
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.24	-0.32	1.87e-12	Bipolar disorder;
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.7e-17	Bipolar disorder;
LGG	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg13385794	chr1:248469461	NA	0.44	8.06	0.35	6.69e-15	Common traits (Other);
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg17971929	chr21:40555470	PSMG1	0.86	15.73	0.59	5.82e-45	Cognitive function;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.545	rs1796219	chr7:66110964	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-10.47	-0.44	3.7e-23	Aortic root size;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11673391	chr1:10459052	PGD	0.38	6.67	0.3	7.09e-11	Obesity-related traits;
LGG	cis	rs13191362	0.507	rs13212746	chr6:163203092	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.52	7.19	0.32	2.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg27129171	chr3:47204927	SETD2	0.82	15.0	0.57	9.83e-42	Colorectal cancer;
LGG	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.31	0.55	1.02e-38	Morning vs. evening chronotype;
LGG	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg26818257	chr2:241905806	NA	0.41	7.84	0.34	3.2e-14	Urinary metabolites;
LGG	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg09021430	chr5:549028	NA	-0.73	-10.36	-0.43	9.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs11645898	0.687	rs6499558	chr16:72102813	G/C	cg14768367	chr16:72042858	DHODH	-0.68	-9.59	-0.41	5.7e-20	Blood protein levels;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg03347828	chr17:7739579	NA	0.43	6.75	0.3	4.5e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg05425664	chr17:57184151	TRIM37	0.62	9.84	0.42	7.19e-21	Intelligence (multi-trait analysis);
LGG	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg01169559	chr10:831247	NA	0.54	8.88	0.38	1.45e-17	Uric acid levels;
LGG	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg15309053	chr8:964076	NA	0.43	9.05	0.39	4.1e-18	Schizophrenia;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.41	0.61	4.94e-48	Platelet count;
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg19635926	chr16:89946313	TCF25	0.71	7.98	0.35	1.13e-14	Skin colour saturation;
LGG	cis	rs1185460	0.508	rs7942757	chr11:118903651	G/A	cg12636538	chr11:118901039	SLC37A4	-0.66	-13.82	-0.54	1.25e-36	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg07615347	chr10:60278583	BICC1	-0.64	-18.39	-0.65	4.36e-57	Refractive error;
LGG	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	9.92e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.04	-0.31	6.88e-12	Bipolar disorder;
LGG	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg03078520	chr22:18463400	MICAL3	-0.67	-14.59	-0.56	6.18e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg16325326	chr1:53192061	ZYG11B	0.84	23.11	0.73	3.78e-79	Monocyte count;
LGG	cis	rs8077889	0.672	rs1230397	chr17:41844689	A/G	cg26893861	chr17:41843967	DUSP3	1.12	26.49	0.78	8.54e-95	Triglycerides;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg11581979	chr11:66247464	DPP3	0.41	7.02	0.31	7.95e-12	Body mass index;
LGG	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.82	-0.34	3.55e-14	HDL cholesterol;
LGG	cis	rs9811920	0.609	rs7638900	chr3:99670773	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-9.03	-0.39	4.72e-18	Axial length;
LGG	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg16586182	chr3:47516702	SCAP	-0.81	-15.76	-0.59	4.16e-45	Colorectal cancer;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-10.01	-0.42	1.7e-21	Platelet count;
LGG	cis	rs4132509	0.649	rs12140040	chr1:243871922	G/A	cg21452805	chr1:244014465	NA	0.92	8.94	0.38	9.34e-18	RR interval (heart rate);
LGG	cis	rs490234	0.616	rs2841325	chr9:128163620	C/G	cg14078157	chr9:128172775	NA	0.45	8.64	0.37	9.45e-17	Mean arterial pressure;
LGG	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.72	0.41	1.8899999999999998e-20	Alcohol dependence;
LGG	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg00717180	chr2:96193071	NA	-0.44	-7.96	-0.35	1.3e-14	HDL cholesterol;
LGG	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg16414030	chr3:133502952	NA	-0.6	-10.33	-0.43	1.17e-22	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05987030	chr3:137834655	DZIP1L	0.47	7.64	0.33	1.28e-13	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg00938859	chr5:1591904	SDHAP3	0.92	13.45	0.53	4.96e-35	Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	0.4	6.71	0.3	5.54e-11	Bipolar disorder;
LGG	cis	rs17767392	0.871	rs34347034	chr14:71935513	G/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	trans	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-7.29	-0.32	1.35e-12	Neuroticism;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.59	0.69	2.31e-67	Alzheimer's disease;
LGG	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg22437258	chr11:111473054	SIK2	0.55	9.73	0.41	1.82e-20	Primary sclerosing cholangitis;
LGG	cis	rs4731207	0.565	rs12536146	chr7:124600631	T/A	cg05630886	chr7:124431682	NA	-0.32	-7.48	-0.33	3.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs877282	1.000	rs11253367	chr10:773389	G/A	cg17470449	chr10:769945	NA	0.63	8.05	0.35	7.11e-15	Uric acid levels;
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.45	0.33	4.57e-13	Tonsillectomy;
LGG	cis	rs4819852	0.752	rs9605043	chr22:19974344	A/G	cg07821417	chr22:19972146	ARVCF	0.51	10.96	0.45	5.13e-25	Pulse pressure;
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.91	0.42	3.88e-21	Neuroticism;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.69	-0.3	6.54e-11	Obesity-related traits;
LGG	cis	rs7737355	0.773	rs13154452	chr5:130623358	G/A	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg20295408	chr7:1910781	MAD1L1	-0.42	-7.0	-0.31	8.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1506403	0.945	rs58692831	chr7:142825366	T/C	cg11323483	chr7:142828068	PIP	-0.39	-7.08	-0.31	5.53e-12	Cancer;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	13.06	0.52	2.08e-33	Lymphocyte counts;
LGG	cis	rs7737355	0.853	rs1468453	chr5:130587459	A/C	cg06307176	chr5:131281290	NA	0.5	8.34	0.36	8.69e-16	Life satisfaction;
LGG	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.1e-14	Colorectal cancer;
LGG	cis	rs780094	0.500	rs7577311	chr2:27793921	G/T	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	5.1e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.38	7.18	0.32	2.87e-12	Schizophrenia;
LGG	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg20913747	chr6:44695427	NA	-0.66	-10.91	-0.45	8.16e-25	Total body bone mineral density;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4363385	1.000	rs4363385	chr1:152989321	A/G	cg07796016	chr1:152779584	LCE1C	-0.42	-7.18	-0.32	2.82e-12	Inflammatory skin disease;
LGG	cis	rs494459	0.838	rs581045	chr11:118632522	C/T	cg20110707	chr11:118481992	PHLDB1	0.31	6.72	0.3	5.5e-11	Height;
LGG	cis	rs926392	0.692	rs6028259	chr20:37696977	T/A	cg16355469	chr20:37678765	NA	0.56	8.95	0.38	8.56e-18	Dialysis-related mortality;
LGG	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs12230513	0.732	rs6581047	chr12:55832001	C/G	cg19537932	chr12:55886519	OR6C68	-0.61	-11.06	-0.46	2.23e-25	Contrast sensitivity;
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg02158880	chr13:53174818	NA	0.7	15.98	0.6	4.49e-46	Lewy body disease;
LGG	cis	rs787274	0.850	rs10739376	chr9:115616775	A/T	cg13803584	chr9:115635662	SNX30	-0.65	-7.87	-0.34	2.48e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.48	7.72	0.34	7.18e-14	Menopause (age at onset);
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.94e-21	Educational attainment;
LGG	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.17	0.55	4.26e-38	Cognitive test performance;
LGG	cis	rs2290159	0.800	rs6792773	chr3:12668726	C/T	cg23032965	chr3:12705835	RAF1	0.69	10.03	0.42	1.45e-21	Cholesterol, total;
LGG	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg18351406	chr4:77819688	ANKRD56	0.45	7.99	0.35	1.08e-14	Emphysema distribution in smoking;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10928925	chr10:81205554	ZCCHC24	0.46	6.89	0.3	1.82e-11	Gut microbiome composition (summer);
LGG	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg08344181	chr3:125677491	NA	-0.57	-7.42	-0.33	5.63e-13	Depression;
LGG	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg21226059	chr5:178986404	RUFY1	0.45	7.25	0.32	1.72e-12	Lung cancer;
LGG	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg00990874	chr7:1149470	C7orf50	-0.84	-14.89	-0.57	3.12e-41	Bronchopulmonary dysplasia;
LGG	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.91	-0.31	1.59e-11	Total body bone mineral density;
LGG	cis	rs66887589	0.934	rs6817317	chr4:120542827	A/G	cg09307838	chr4:120376055	NA	-0.48	-8.41	-0.36	5.27e-16	Diastolic blood pressure;
LGG	cis	rs9549367	0.789	rs2287250	chr13:113889474	C/T	cg18105134	chr13:113819100	PROZ	0.65	13.41	0.53	6.81e-35	Platelet distribution width;
LGG	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg12395012	chr8:11607386	GATA4	0.41	7.35	0.32	8.79e-13	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs1318772	1.000	rs36613	chr5:112758471	G/A	cg12552261	chr5:112820674	MCC	0.71	7.97	0.35	1.28e-14	F-cell distribution;
LGG	cis	rs9810089	0.934	rs696520	chr3:136056861	T/C	cg21827317	chr3:136751795	NA	0.43	7.51	0.33	3.16e-13	Gestational age at birth (child effect);
LGG	cis	rs4006360	0.574	rs6503592	chr17:39253010	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.35e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg01631408	chr1:248437212	OR2T33	-0.56	-9.92	-0.42	3.59e-21	Common traits (Other);
LGG	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.31	0.36	1.05e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	8.14	0.35	3.82e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.79	-14.65	-0.56	3.5e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg15268244	chr15:77196840	NA	0.43	9.36	0.4	3.41e-19	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.69	0.45	5.37e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2180341	0.842	rs9375492	chr6:127545492	C/T	cg27446573	chr6:127587934	RNF146	-1.06	-18.99	-0.66	6.75e-60	Breast cancer;
LGG	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.92	0.31	1.55e-11	Hemoglobin concentration;
LGG	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg02158880	chr13:53174818	NA	0.67	15.42	0.58	1.42e-43	Lewy body disease;
LGG	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.69	-13.75	-0.54	2.65e-36	Total body bone mineral density;
LGG	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.34	-0.4	4.11e-19	Bladder cancer;
LGG	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.68	-0.75	1.83e-86	Height;
LGG	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg07423050	chr13:99094983	FARP1	-0.56	-10.86	-0.45	1.21e-24	Longevity;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.15	-0.39	1.87e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg25356066	chr3:128598488	ACAD9	0.48	7.29	0.32	1.38e-12	IgG glycosylation;
LGG	cis	rs74054849	0.850	rs7546138	chr1:16015784	A/G	cg05660106	chr1:15850417	CASP9	-0.73	-7.11	-0.31	4.37e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-9.3	-0.4	5.78e-19	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1519814	0.654	rs2139438	chr8:121007717	T/C	cg22335954	chr8:121166405	COL14A1	-0.46	-8.06	-0.35	6.52e-15	Breast cancer;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.36	6.97	0.31	1.08e-11	Schizophrenia;
LGG	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg16325326	chr1:53192061	ZYG11B	0.61	13.17	0.52	7.31e-34	Monocyte count;
LGG	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg16751781	chr15:78858589	CHRNA5	0.42	7.97	0.35	1.26e-14	Sudden cardiac arrest;
LGG	cis	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg05084668	chr3:125655381	ALG1L	1.09	12.25	0.49	4.3e-30	Blood pressure (smoking interaction);
LGG	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg10621924	chr7:39171070	POU6F2	0.45	9.19	0.39	1.3e-18	IgG glycosylation;
LGG	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg07777115	chr5:623756	CEP72	-0.51	-6.72	-0.3	5.48e-11	Ulcerative colitis;
LGG	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.97	-0.35	1.28e-14	Mood instability;
LGG	cis	rs10865541	0.869	rs6711292	chr2:3422170	A/T	cg11642891	chr2:3452563	TTC15	-0.43	-8.48	-0.37	3.16e-16	Obesity-related traits;
LGG	cis	rs2274273	0.624	rs7152390	chr14:55811701	C/T	cg04306507	chr14:55594613	LGALS3	0.53	12.49	0.5	4.75e-31	Protein biomarker;
LGG	cis	rs4731207	0.596	rs9969187	chr7:124661472	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.1e-12	Cutaneous malignant melanoma;
LGG	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs963731	0.579	rs2168042	chr2:39273536	C/T	cg04010122	chr2:39346883	SOS1	-0.76	-7.39	-0.32	6.82e-13	Corticobasal degeneration;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4774899	0.932	rs1037956	chr15:57523883	A/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.17e-12	Urinary tract infection frequency;
LGG	cis	rs9815354	0.812	rs73077365	chr3:41851559	T/C	cg03022575	chr3:42003672	ULK4	0.82	9.61	0.41	4.77e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14159672	chr1:205819179	PM20D1	0.77	16.43	0.61	3.81e-48	Menarche (age at onset);
LGG	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg24331049	chr13:111365604	ING1	0.87	16.36	0.61	8.4e-48	Coronary artery disease;
LGG	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.53	-6.78	-0.3	3.57e-11	Smoking behavior;
LGG	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg26031613	chr14:104095156	KLC1	-0.67	-10.79	-0.45	2.32e-24	Reticulocyte count;
LGG	cis	rs8064024	0.870	rs930854	chr16:4864101	A/G	cg04440724	chr16:4920505	UBN1	-0.46	-10.11	-0.43	7.35e-22	Cancer;
LGG	cis	rs2587949	0.615	rs1444060	chr3:4230231	C/G	cg16519197	chr3:4211558	NA	0.32	6.68	0.3	6.82e-11	Periodontitis (DPAL);
LGG	cis	rs4926611	1.000	rs12753604	chr1:54106382	C/T	cg23596471	chr1:54105337	GLIS1	0.4	8.18	0.36	2.68e-15	Hand grip strength;
LGG	cis	rs1978968	0.717	rs13057517	chr22:18402669	G/T	cg03078520	chr22:18463400	MICAL3	-0.52	-10.02	-0.42	1.61e-21	Presence of antiphospholipid antibodies;
LGG	cis	rs4006360	0.575	rs67524820	chr17:39318208	T/C	cg16985667	chr17:39306289	KRTAP4-5	0.61	13.73	0.54	3.21e-36	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs7113874	0.524	rs11041990	chr11:8585615	G/T	cg23764900	chr11:8616102	STK33	-0.4	-7.2	-0.32	2.44e-12	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.11	-0.57	3.04e-42	Prudent dietary pattern;
LGG	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04530015	chr2:215796436	ABCA12	-0.46	-7.81	-0.34	3.86e-14	Neuroblastoma;
LGG	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-10.56	-0.44	1.66e-23	Morning vs. evening chronotype;
LGG	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg15128208	chr22:42549153	NA	0.76	11.55	0.47	2.77e-27	Birth weight;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05886006	chr1:161359784	NA	0.49	8.04	0.35	7.47e-15	Gut microbiome composition (summer);
LGG	trans	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.87	-0.3	2.1e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.83e-11	Personality dimensions;
LGG	cis	rs9463078	0.547	rs2038555	chr6:44744033	A/G	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.79e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg27284194	chr4:1044797	NA	0.56	11.37	0.47	1.4e-26	Recombination rate (males);
LGG	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.77	-0.45	2.68e-24	Aortic root size;
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.62e-16	Aortic root size;
LGG	cis	rs7512552	1.000	rs7512552	chr1:150265704	T/C	cg15654264	chr1:150340011	RPRD2	-0.42	-8.67	-0.37	7.23e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2249694	0.960	rs7084391	chr10:135412344	A/C	cg20169779	chr10:135381914	SYCE1	-0.51	-7.88	-0.34	2.37e-14	Obesity-related traits;
LGG	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs7808935	0.628	rs12666447	chr7:27937267	C/T	cg22168087	chr7:27702803	HIBADH	0.72	10.1	0.42	8.26e-22	Prostate cancer;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.4	7.97	0.35	1.25e-14	Schizophrenia;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.56	10.33	0.43	1.17e-22	Longevity;
LGG	cis	rs921968	0.643	rs579610	chr2:219327582	C/A	cg02985541	chr2:219472218	PLCD4	0.29	6.9	0.31	1.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg20637307	chr2:213403960	ERBB4	0.74	16.77	0.61	1.09e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.65	0.3	8.05e-11	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24091570	chr5:110428036	WDR36	0.44	6.99	0.31	9.79e-12	Cognitive performance;
LGG	cis	rs7853377	0.723	rs6559751	chr9:86551269	A/G	cg12437157	chr9:86433764	GKAP1	0.39	6.72	0.3	5.28e-11	Height;
LGG	cis	rs4936891	0.577	rs4935862	chr11:123921479	C/T	cg22125253	chr11:123886957	OR10G4	0.51	8.66	0.37	8.15e-17	Male fertility;
LGG	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27297192	chr10:134578999	INPP5A	0.29	7.28	0.32	1.47e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7928758	0.725	rs78751202	chr11:134286609	T/C	cg15243474	chr11:134282918	B3GAT1	1.34	15.68	0.59	9.17e-45	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.99	-0.49	4.97e-29	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.53	9.87	0.42	5.43e-21	Lymphocyte counts;
LGG	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-9.6	-0.41	5.22e-20	Hepatocellular carcinoma;
LGG	cis	rs9815354	0.537	rs73073272	chr3:42022446	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg16339924	chr4:17578868	LAP3	-0.6	-10.54	-0.44	1.94e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg26656751	chr17:43910226	CRHR1	0.35	7.05	0.31	6.63e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.13	0.43	6.6e-22	Lung cancer in ever smokers;
LGG	cis	rs1371867	0.846	rs2919469	chr8:101233896	C/T	cg06636551	chr8:101224915	SPAG1	-0.5	-9.24	-0.39	9.02e-19	Atrioventricular conduction;
LGG	cis	rs600550	0.519	rs7931525	chr11:60103826	G/A	cg05040360	chr11:60102449	MS4A6E	0.37	8.04	0.35	7.32e-15	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg00745248	chr2:20101788	TTC32	-0.4	-6.74	-0.3	4.77e-11	Leprosy;
LGG	cis	rs7781557	0.640	rs6968036	chr7:102555920	G/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.06	-0.35	6.34e-15	Colorectal adenoma (advanced);
LGG	cis	rs4780401	0.933	rs8058003	chr16:11815178	C/T	cg01061890	chr16:11836724	TXNDC11	-0.41	-7.0	-0.31	8.82e-12	Rheumatoid arthritis;
LGG	cis	rs6964587	1.000	rs1859114	chr7:91682848	T/C	cg17063962	chr7:91808500	NA	0.47	8.43	0.36	4.52e-16	Breast cancer;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00294572	chr6:26285232	NA	0.42	7.68	0.34	9.77e-14	Educational attainment;
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg19524238	chr7:2802976	GNA12	0.4	9.16	0.39	1.69e-18	Height;
LGG	cis	rs8179	0.645	rs6954221	chr7:92283262	A/G	cg15732164	chr7:92237376	CDK6	0.54	10.03	0.42	1.44e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg19413766	chr7:29689036	LOC646762	-0.53	-7.49	-0.33	3.44e-13	Facial emotion recognition (angry faces);
LGG	cis	rs981844	0.689	rs7666762	chr4:154684197	C/T	cg14289246	chr4:154710475	SFRP2	-0.6	-10.71	-0.45	4.47e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00166722	chr3:10149974	C3orf24	0.5	8.48	0.37	3.09e-16	Alzheimer's disease;
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.7	-9.42	-0.4	2.19e-19	Diabetic retinopathy;
LGG	cis	rs6456156	0.586	rs12528689	chr6:167461746	A/G	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.2	0.36	2.4e-15	Neuroticism;
LGG	cis	rs2777491	0.872	rs7163649	chr15:41586798	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.66	-0.66	2.44e-58	Ulcerative colitis;
LGG	trans	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.66	-0.34	1.09e-13	Life satisfaction;
LGG	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.42	-0.33	5.72e-13	Neuroticism;
LGG	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08645402	chr16:4508243	NA	0.5	9.09	0.39	2.99e-18	Schizophrenia;
LGG	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.85	-0.78	1.84e-96	Height;
LGG	cis	rs12908161	0.959	rs35557864	chr15:85331629	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.81e-12	Schizophrenia;
LGG	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.49	-8.71	-0.38	5.59e-17	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg22432760	chr17:80829718	TBCD	0.4	6.91	0.31	1.57e-11	Breast cancer;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	6.84	0.3	2.58e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9972944	0.729	rs7209787	chr17:63769896	G/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.39	-0.36	5.77e-16	Total body bone mineral density;
LGG	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg20991723	chr1:152506922	NA	-0.69	-14.08	-0.55	1.02e-37	Hair morphology;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg26174226	chr8:58114915	NA	-0.58	-8.39	-0.36	5.98e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg27129171	chr3:47204927	SETD2	0.81	15.59	0.59	2.41e-44	Colorectal cancer;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg00405596	chr8:11794950	NA	0.41	6.97	0.31	1.11e-11	Monocyte count;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg15991262	chr7:23720454	C7orf46	-0.46	-10.78	-0.45	2.47e-24	Schizophrenia;
LGG	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg12560992	chr17:57184187	TRIM37	0.88	15.64	0.59	1.36e-44	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9457247	0.534	rs12055488	chr6:167379570	A/G	cg18261144	chr6:167370276	RNASET2	-0.37	-7.55	-0.33	2.35e-13	Crohn's disease;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg04013166	chr16:89971882	TCF25	0.53	7.15	0.32	3.38e-12	Skin colour saturation;
LGG	cis	rs7226408	0.857	rs72887031	chr18:34472083	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs457717	0.730	rs2937415	chr5:75933097	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.65	0.3	8.51e-11	Hearing impairment;
LGG	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs11997175	0.575	rs56942690	chr8:33820308	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	7.34	0.32	9.54e-13	Body mass index;
LGG	cis	rs28588043	1.000	rs116494685	chr1:170990527	A/G	cg03458344	chr1:170964477	C1orf129	-0.55	-7.44	-0.33	4.85e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg20040747	chr15:74715105	SEMA7A	0.4	8.66	0.37	8.13e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs8014204	0.869	rs2070599	chr14:75361177	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.85	-16.96	-0.62	1.6e-50	Caffeine consumption;
LGG	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.58	-9.28	-0.4	6.57e-19	Height;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.61	10.09	0.42	9.06e-22	Obesity-related traits;
LGG	cis	rs7247513	0.790	rs17476839	chr19:12762783	C/T	cg01871581	chr19:12707946	ZNF490	0.36	7.13	0.31	3.86e-12	Bipolar disorder;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	7.3	0.32	1.27e-12	Schizophrenia;
LGG	cis	rs763121	0.853	rs2205802	chr22:39046327	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg00666640	chr1:248458726	OR2T12	-0.51	-8.09	-0.35	5.42e-15	Common traits (Other);
LGG	cis	rs4819388	0.709	rs4143384	chr21:45638684	C/T	cg01992765	chr21:45622493	NA	0.48	9.12	0.39	2.37e-18	Celiac disease;
LGG	cis	rs2862064	1.000	rs7715467	chr5:156468654	C/G	cg12943317	chr5:156479607	HAVCR1	-0.89	-11.08	-0.46	1.78e-25	Platelet count;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.13	-0.52	1.04e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.954	rs611861	chr1:209937251	C/G	cg23920097	chr1:209922102	NA	-0.42	-7.56	-0.33	2.16e-13	Red blood cell count;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.37	0.56	5.76e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg06917634	chr15:78832804	PSMA4	-0.66	-12.23	-0.49	5.1e-30	Sudden cardiac arrest;
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.97	0.31	1.08e-11	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25947998	chr8:42948467	SGK196	0.47	7.43	0.33	5.27e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg03929089	chr4:120376271	NA	0.79	8.19	0.36	2.51e-15	Myopia (pathological);
LGG	cis	rs8064024	0.619	rs9935080	chr16:4902207	A/G	cg04440724	chr16:4920505	UBN1	-0.57	-12.46	-0.5	6.13e-31	Cancer;
LGG	cis	rs1941023	0.503	rs894591	chr11:60132647	T/C	cg08716584	chr11:60157161	MS4A7	-0.42	-8.34	-0.36	8.66e-16	Congenital heart disease (maternal effect);
LGG	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg17108064	chr15:78857060	CHRNA5	0.45	9.64	0.41	3.65e-20	Sudden cardiac arrest;
LGG	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg20673091	chr1:2541236	MMEL1	0.6	13.76	0.54	2.39e-36	Ulcerative colitis;
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19524238	chr7:2802976	GNA12	0.37	8.93	0.38	9.88e-18	Height;
LGG	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg13072238	chr3:49761600	GMPPB	-0.55	-7.62	-0.33	1.48e-13	Menarche (age at onset);
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs4700695	0.841	rs251305	chr5:65249859	C/T	cg21114390	chr5:65439923	SFRS12	0.59	7.53	0.33	2.65e-13	Facial morphology (factor 19);
LGG	cis	rs9868809	0.772	rs13070798	chr3:48705934	C/T	cg00383909	chr3:49044727	WDR6	-0.74	-9.14	-0.39	2.04e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11776272	0.927	rs11135789	chr8:21878607	C/T	cg17168535	chr8:21777572	XPO7	-0.5	-8.07	-0.35	6.02e-15	Obesity-related traits;
LGG	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	8.46	0.37	3.65e-16	HDL cholesterol;
LGG	cis	rs7572733	0.555	rs2341778	chr2:198776546	G/A	cg00792783	chr2:198669748	PLCL1	-0.69	-11.11	-0.46	1.36e-25	Dermatomyositis;
LGG	cis	rs9815354	0.812	rs17215883	chr3:41841873	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17122278	0.613	rs572126	chr11:118359161	C/T	cg19182353	chr11:118479428	PHLDB1	0.42	6.69	0.3	6.33e-11	Total cholesterol levels;
LGG	cis	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg06521331	chr12:34319734	NA	0.55	9.38	0.4	2.95e-19	Morning vs. evening chronotype;
LGG	cis	rs2587949	0.540	rs2600129	chr3:4216660	G/T	cg16519197	chr3:4211558	NA	0.32	6.7	0.3	5.91e-11	Periodontitis (DPAL);
LGG	cis	rs9287719	0.699	rs4669602	chr2:10787967	C/T	cg02196655	chr2:10830764	NOL10	-0.42	-7.48	-0.33	3.77e-13	Prostate cancer;
LGG	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.43e-38	IgG glycosylation;
LGG	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg13852791	chr20:30311386	BCL2L1	0.98	19.55	0.67	1.76e-62	Mean corpuscular hemoglobin;
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg13047869	chr3:10149882	C3orf24	0.6	8.46	0.37	3.53e-16	Alzheimer's disease;
LGG	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs2470578	0.792	rs2060627	chr3:17339381	C/G	cg20981856	chr3:17787350	NA	0.35	6.73	0.3	4.92e-11	Schizophrenia;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19692165	chr12:24716640	SOX5	0.44	6.98	0.31	1.05e-11	Cognitive performance;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.96	-0.38	7.74e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg00198680	chr16:28758506	NA	0.3	7.51	0.33	3.02e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs58649573	0.509	rs2055029	chr9:126789678	T/C	cg14112217	chr9:126806003	NA	0.39	7.53	0.33	2.67e-13	Post-traumatic stress disorder;
LGG	cis	rs12980942	0.872	rs12985339	chr19:41801756	A/T	cg25627403	chr19:41769009	HNRNPUL1	-0.61	-7.75	-0.34	5.69e-14	Coronary artery disease;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.83	-0.51	1.85e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.32	0.5	2.37e-30	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23570261	chr2:128284252	IWS1	0.46	7.43	0.33	5.34e-13	Cognitive performance;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg25358565	chr5:93447407	FAM172A	-0.68	-9.85	-0.42	6.55e-21	Diabetic retinopathy;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg24250549	chr1:154909240	PMVK	0.7	13.48	0.53	3.75e-35	Prostate cancer;
LGG	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg05163923	chr11:71159392	DHCR7	0.51	9.33	0.4	4.24e-19	Vitamin D levels;
LGG	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg24375607	chr4:120327624	NA	0.64	10.57	0.44	1.6e-23	Corneal astigmatism;
LGG	cis	rs11074306	0.561	rs17674163	chr15:28071208	A/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.4	-0.36	5.6e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.72	-0.34	7.4e-14	HDL cholesterol;
LGG	cis	rs3735485	0.723	rs10264842	chr7:45087382	A/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.41	-0.4	2.35e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.52	-0.33	2.78e-13	Personality dimensions;
LGG	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg25319279	chr11:5960081	NA	-0.54	-8.74	-0.38	4.33e-17	DNA methylation (variation);
LGG	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg00666640	chr1:248458726	OR2T12	0.6	9.72	0.41	1.8899999999999998e-20	Common traits (Other);
LGG	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg15596359	chr8:11213517	TDH	-0.43	-8.82	-0.38	2.43e-17	Retinal vascular caliber;
LGG	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.57	-7.67	-0.34	9.92e-14	Smoking behavior;
LGG	cis	rs9902453	0.934	rs8079028	chr17:28484234	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.14	0.52	9.8e-34	Coffee consumption (cups per day);
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg16103275	chr6:290800	DUSP22	0.39	6.76	0.3	4.2e-11	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs8017423	0.935	rs17188598	chr14:90722473	A/T	cg04374321	chr14:90722782	PSMC1	0.88	18.98	0.66	8.01e-60	Mortality in heart failure;
LGG	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg11584989	chr19:19387371	SF4	0.74	12.07	0.49	2.37e-29	Bipolar disorder;
LGG	cis	rs4262150	0.883	rs56286804	chr5:152150366	G/A	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg10661904	chr17:79619235	PDE6G	-0.42	-8.56	-0.37	1.62e-16	Eye color traits;
LGG	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06108461	chr20:60628389	TAF4	0.91	15.67	0.59	9.97e-45	Body mass index;
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.77	-14.36	-0.56	5.98e-39	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.17	0.39	1.6e-18	Obesity-related traits;
LGG	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg27476859	chr7:2772710	GNA12	0.54	10.52	0.44	2.3e-23	Height;
LGG	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg05308233	chr10:104796373	CNNM2	-0.33	-6.65	-0.3	8.13e-11	Arsenic metabolism;
LGG	cis	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs10046574	0.519	rs7781819	chr7:135205700	A/T	cg27474649	chr7:135195673	CNOT4	0.74	9.36	0.4	3.49e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs2227564	0.761	rs2227552	chr10:75669319	C/T	cg00564723	chr10:75632066	CAMK2G	-0.44	-9.02	-0.39	5.13e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs926392	0.533	rs6129162	chr20:37683195	G/A	cg16355469	chr20:37678765	NA	0.63	10.03	0.42	1.44e-21	Dialysis-related mortality;
LGG	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg15320455	chr10:103880129	LDB1	0.69	9.34	0.4	4.19e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9470366	0.527	rs4711456	chr6:36632482	C/T	cg08179530	chr6:36648295	CDKN1A	-0.66	-11.51	-0.47	3.88e-27	QRS duration;
LGG	cis	rs4363385	0.776	rs1415957	chr1:152948909	A/G	cg07796016	chr1:152779584	LCE1C	-0.42	-6.76	-0.3	4.12e-11	Inflammatory skin disease;
LGG	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.85	-0.57	4.35e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs6032067	0.929	rs17424868	chr20:43818519	T/G	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg05091796	chr16:4465799	CORO7	-0.83	-14.14	-0.55	5.66e-38	Schizophrenia;
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg00814883	chr7:100076585	TSC22D4	0.72	10.67	0.44	6.44e-24	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26300613	chr20:42839365	C20orf111	0.45	6.73	0.3	4.95e-11	Gut microbiome composition (summer);
LGG	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg01420254	chr6:26195488	NA	0.93	12.48	0.5	5.1e-31	Gout;Renal underexcretion gout;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.02	0.62	7.97e-51	Tonsillectomy;
LGG	cis	rs7766436	0.885	rs7773749	chr6:22587190	C/G	cg13666174	chr6:22585274	NA	-0.51	-11.83	-0.48	2.07e-28	Coronary artery disease;
LGG	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg13271783	chr10:134563150	INPP5A	-0.59	-8.67	-0.37	7.24e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2841233	0.558	rs10145270	chr14:105349891	G/A	cg16576083	chr14:105354267	KIAA0284	0.36	7.31	0.32	1.18e-12	IgG glycosylation;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg18402987	chr7:1209562	NA	-0.38	-6.7	-0.3	5.89e-11	Longevity;Endometriosis;
LGG	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg03433033	chr1:76189801	ACADM	-0.62	-9.12	-0.39	2.39e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg04861929	chr11:109293070	C11orf87	0.56	10.13	0.43	6.6e-22	Schizophrenia;
LGG	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg04568710	chr12:38710424	ALG10B	0.36	7.72	0.34	7.33e-14	Heart rate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14928991	chr14:61448281	TRMT5;SLC38A6	0.4	6.88	0.3	1.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs975739	0.657	rs7993712	chr13:78609250	T/A	cg07847733	chr13:78271382	SLAIN1	0.46	7.89	0.34	2.14e-14	Hair color;
LGG	cis	rs4629180	0.586	rs2048252	chr2:102138384	C/T	cg16435561	chr2:102091048	RFX8	0.49	9.09	0.39	2.83e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.41	-0.33	6.07e-13	Hemoglobin concentration;
LGG	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.75	-0.45	3.34e-24	Triglycerides;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.91	0.66	1.61e-59	Menopause (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15513227	chr14:50330101	NA	-0.48	-7.1	-0.31	4.59e-12	Systemic lupus erythematosus;
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.9	-0.42	4.36e-21	Neuroticism;
LGG	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.52	0.37	2.31e-16	Bipolar disorder;
LGG	cis	rs7633770	0.643	rs1581325	chr3:46691866	T/C	cg11219411	chr3:46661640	NA	-0.5	-10.89	-0.45	9.42e-25	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.06e-43	Menopause (age at onset);
LGG	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.66	-0.44	7.08e-24	Initial pursuit acceleration;
LGG	cis	rs209489	0.892	rs732647	chr6:53122053	G/A	cg15607103	chr6:53167650	ELOVL5	0.71	8.58	0.37	1.46e-16	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs12765878	0.580	rs11191833	chr10:105619678	G/A	cg11005552	chr10:105648138	OBFC1	-0.71	-12.41	-0.5	9.83e-31	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18876405	chr7:65276391	NA	-0.59	-10.86	-0.45	1.28e-24	Aortic root size;
LGG	cis	rs7107174	0.901	rs7941639	chr11:78116959	A/G	cg02023728	chr11:77925099	USP35	-0.44	-7.7	-0.34	8.08e-14	Testicular germ cell tumor;
LGG	cis	rs1729951	0.575	rs168635	chr3:136699078	A/G	cg21827317	chr3:136751795	NA	0.53	10.07	0.42	1.04e-21	Neuroticism;
LGG	cis	rs1953600	0.870	rs12770550	chr10:81953451	G/T	cg04850286	chr10:81895943	PLAC9	0.44	9.85	0.42	6.33e-21	Sarcoidosis;
LGG	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11644478	chr21:40555479	PSMG1	0.9	17.28	0.63	5.47e-52	Cognitive function;
LGG	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg03342759	chr3:160939853	NMD3	-0.59	-9.97	-0.42	2.43e-21	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	trans	rs3960554	0.808	rs112962015	chr7:75659303	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.32	0.5	2.4e-30	Eotaxin levels;
LGG	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg04287289	chr16:89883240	FANCA	-0.54	-9.73	-0.41	1.82e-20	Vitiligo;
LGG	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs6489882	0.867	rs4766674	chr12:113365201	A/C	cg25319449	chr12:113376135	OAS3	0.41	7.54	0.33	2.54e-13	Chronic lymphocytic leukemia;
LGG	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.97e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg23034840	chr1:205782522	SLC41A1	0.49	7.85	0.34	2.88e-14	Menarche (age at onset);
LGG	cis	rs9581857	0.725	rs9581853	chr13:28016236	T/C	cg01674679	chr13:27998804	GTF3A	-0.66	-7.72	-0.34	7.35e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg14789911	chr21:47582049	C21orf56	-0.49	-8.69	-0.37	6.27e-17	Testicular germ cell tumor;
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg02002194	chr4:3960332	NA	0.46	8.99	0.39	6.29e-18	Systolic blood pressure;
LGG	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg06374794	chr16:88002281	BANP	0.45	8.33	0.36	9.21e-16	Menopause (age at onset);
LGG	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg04731861	chr2:219085781	ARPC2	-0.44	-10.53	-0.44	2.21e-23	Colorectal cancer;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg23262073	chr20:60523788	NA	0.61	9.43	0.4	1.97e-19	Obesity-related traits;
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg12454169	chr2:30669597	LCLAT1	-0.52	-7.49	-0.33	3.55e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs2692947	0.644	rs772178	chr2:96963684	C/T	cg22654517	chr2:96458247	NA	-0.36	-7.35	-0.32	8.85e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.44	0.36	4.24e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg02158880	chr13:53174818	NA	0.47	9.72	0.41	1.95e-20	Lewy body disease;
LGG	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg05863683	chr7:1912471	MAD1L1	0.4	7.81	0.34	3.98e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.753	rs7659724	chr4:98944063	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11892836	chr11:64410564	NRXN2	0.61	6.84	0.3	2.48e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.26e-19	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00290607	chr11:67383545	NA	0.65	12.53	0.5	3.37e-31	Mean corpuscular volume;
LGG	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg17691542	chr6:26056736	HIST1H1C	0.74	12.04	0.49	3.01e-29	Iron status biomarkers;
LGG	cis	rs11074306	0.561	rs4778121	chr15:28065086	A/G	cg26402630	chr15:28053930	OCA2	-0.36	-7.34	-0.32	9.61e-13	Uveal melanoma;
LGG	cis	rs77972916	0.518	rs55877805	chr2:43557597	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.06	-0.31	6.04e-12	Granulocyte percentage of myeloid white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01943813	chr6:24495061	ALDH5A1	0.46	7.52	0.33	2.78e-13	Cognitive performance;
LGG	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg11279151	chr3:101281821	RG9MTD1	0.4	7.13	0.31	3.78e-12	Colorectal cancer;
LGG	cis	rs3087591	0.708	rs2854320	chr17:29694063	C/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.54	0.5	2.82e-31	Hip circumference;
LGG	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.5	0.4	1.13e-19	Mean corpuscular volume;
LGG	cis	rs16912285	0.688	rs59797575	chr11:24315536	A/T	ch.11.24196551F	chr11:24239977	NA	0.88	12.73	0.51	4.84e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.3	0.4	5.57e-19	Rheumatoid arthritis;
LGG	cis	rs1109114	0.899	rs13156539	chr5:148606052	A/C	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.33	-0.58	3.49e-43	Body mass index;
LGG	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg25319279	chr11:5960081	NA	-0.45	-6.96	-0.31	1.14e-11	DNA methylation (variation);
LGG	cis	rs977987	0.806	rs4887818	chr16:75361995	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.09	0.42	8.64e-22	Dupuytren's disease;
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg23302884	chr18:44338147	ST8SIA5	-0.43	-8.48	-0.37	3e-16	Personality dimensions;
LGG	cis	rs5756391	0.568	rs4821567	chr22:37316388	T/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.55	0.41	7.4e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4356203	0.905	rs545773	chr11:17213636	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12292205	chr6:26970375	C6orf41	-0.62	-8.19	-0.36	2.61e-15	Intelligence (multi-trait analysis);
LGG	trans	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg26043149	chr18:55253948	FECH	-0.46	-7.84	-0.34	3.02e-14	Bone mineral density;
LGG	cis	rs75059851	0.756	rs11223658	chr11:133843216	G/A	cg20042908	chr11:133852938	NA	-0.76	-13.92	-0.54	4.8e-37	Schizophrenia;
LGG	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg25457927	chr22:38595422	NA	-0.41	-10.54	-0.44	1.99e-23	Cutaneous nevi;
LGG	cis	rs2421770	0.532	rs7119430	chr11:35345085	C/T	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.4	-0.33	6.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs6867032	0.527	rs13190594	chr5:2012474	T/C	cg26168224	chr5:2018326	NA	0.95	18.44	0.65	2.45e-57	Gut microbiome composition (winter);
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg13880726	chr7:1868755	MAD1L1	0.46	8.07	0.35	6.04e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg14092988	chr3:52407081	DNAH1	0.3	8.09	0.35	5.33e-15	Bipolar disorder;
LGG	cis	rs1451375	0.785	rs10278338	chr7:50630270	C/T	cg00647317	chr7:50633725	DDC	-0.34	-7.59	-0.33	1.74e-13	Malaria;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07655025	chr19:12835001	TNPO2	0.45	6.78	0.3	3.72e-11	Gut microbiome composition (summer);
LGG	cis	rs3736594	0.918	rs9967838	chr2:27968454	A/C	cg27432699	chr2:27873401	GPN1	-0.57	-9.28	-0.4	6.75e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.84	12.51	0.5	3.99e-31	Schizophrenia;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs7010267	0.692	rs3102732	chr8:119960547	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.96	0.35	1.38e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg04772025	chr11:68637568	NA	0.75	12.45	0.5	6.92e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17221829	0.669	rs7128681	chr11:89383644	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.13e-18	Anxiety in major depressive disorder;
LGG	cis	rs4891159	0.790	rs9950025	chr18:74113596	C/G	cg24786174	chr18:74118243	ZNF516	0.57	13.34	0.53	1.38e-34	Longevity;
LGG	cis	rs6665290	0.669	rs3768423	chr1:227177293	G/A	cg05696931	chr1:227175867	NA	-0.42	-8.39	-0.36	5.78e-16	Myeloid white cell count;
LGG	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19524238	chr7:2802976	GNA12	0.34	8.26	0.36	1.55e-15	Height;
LGG	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg19336497	chr11:14380999	RRAS2	-0.36	-6.81	-0.3	3.11e-11	Mitochondrial DNA levels;
LGG	cis	rs9828933	0.938	rs831691	chr3:64007214	C/G	cg17941049	chr3:63904683	ATXN7	0.62	7.79	0.34	4.29e-14	Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.37	-0.36	6.78e-16	Personality dimensions;
LGG	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg15490075	chr13:100150979	NA	0.69	8.75	0.38	4.1e-17	Obesity-related traits;
LGG	trans	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg16141378	chr3:129829833	LOC729375	0.39	7.15	0.32	3.42e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07173100	chr2:3606140	RNASEH1	0.45	6.96	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	cis	rs3743104	0.510	rs16973303	chr15:33020928	A/C	cg07179000	chr15:33023586	GREM1	-0.46	-8.5	-0.37	2.63e-16	Hypospadias;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06850241	chr22:41845214	NA	-0.44	-6.81	-0.3	2.99e-11	Vitiligo;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg06558623	chr16:89946397	TCF25	1.11	12.33	0.5	2.15e-30	Skin colour saturation;
LGG	cis	rs12479064	0.666	rs11887935	chr2:100127570	G/A	cg08885076	chr2:99613938	TSGA10	-0.44	-7.9	-0.34	2.01e-14	Chronic sinus infection;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.69	-0.3	6.54e-11	Obesity-related traits;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00495681	chr13:53174319	NA	0.61	11.57	0.47	2.2e-27	Lewy body disease;
LGG	cis	rs4363385	0.740	rs1338181	chr1:153010301	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.5	-0.37	2.63e-16	Inflammatory skin disease;
LGG	cis	rs6964587	0.869	rs2023784	chr7:91524677	A/G	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg12310025	chr6:25882481	NA	-0.4	-7.16	-0.32	3.28e-12	Height;
LGG	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-6.65	-0.3	8.04e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg07930552	chr6:133119739	C6orf192	1.1	9.46	0.4	1.55e-19	Type 2 diabetes nephropathy;
LGG	cis	rs7572263	0.959	rs7583625	chr2:209048739	A/G	cg00164906	chr2:209055251	C2orf80	0.53	8.67	0.37	7.51e-17	Glioma;Non-glioblastoma glioma;
LGG	cis	rs3764563	0.935	rs1654592	chr19:15690296	T/A	cg20725493	chr19:15740067	CYP4F8	0.57	6.76	0.3	4.17e-11	Inflammatory biomarkers;
LGG	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg08250081	chr4:10125330	NA	-0.38	-7.45	-0.33	4.48e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs778371	0.676	rs2293780	chr2:233635213	T/C	cg08000102	chr2:233561755	GIGYF2	0.73	12.46	0.5	6.38e-31	Schizophrenia;
LGG	cis	rs10766496	1.000	rs4341511	chr11:18736627	C/T	cg02515468	chr11:18743222	IGSF22	-0.46	-7.56	-0.33	2.17e-13	Diabetic kidney disease;
LGG	cis	rs16867321	0.639	rs12466770	chr2:181441312	C/G	cg23363182	chr2:181467187	NA	0.43	8.52	0.37	2.21e-16	Obesity;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg09739081	chr7:23719861	C7orf46	0.38	8.26	0.36	1.5e-15	Schizophrenia;
LGG	cis	rs4901869	0.902	rs10149194	chr14:59308198	A/G	cg02291164	chr14:59296302	NA	-0.28	-7.41	-0.33	6.04e-13	Panic disorder;
LGG	cis	rs12431410	0.584	rs11844804	chr14:60242773	C/G	cg07950296	chr14:60194823	RTN1	-0.4	-7.68	-0.34	9.82e-14	Schizophrenia;
LGG	cis	rs4650994	0.593	rs6676155	chr1:178508360	C/A	cg12486710	chr1:178512616	C1orf220	-0.34	-6.71	-0.3	5.72e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.01e-42	Menopause (age at onset);
LGG	cis	rs4684776	0.935	rs6772675	chr3:11376080	C/G	cg24705426	chr3:11550659	ATG7	-0.47	-8.77	-0.38	3.44e-17	Small vessel stroke;
LGG	cis	rs2066819	1.000	rs77853814	chr12:56687572	G/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs523522	0.962	rs9788155	chr12:120938408	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.65	0.79	4.42e-100	Parkinson's disease;
LGG	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23598886	chr18:12777645	NA	0.74	10.35	0.43	9.7e-23	Inflammatory skin disease;
LGG	trans	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg08344181	chr3:125677491	NA	-0.81	-7.9	-0.34	2.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg12463550	chr7:65579703	CRCP	0.51	8.41	0.36	4.94e-16	Aortic root size;
LGG	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6918586	0.658	rs198844	chr6:26108282	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.55	-0.41	7.4e-20	Schizophrenia;
LGG	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-7.51	-0.33	3.1e-13	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs6942756	1.000	rs6971917	chr7:128976919	G/A	cg02491457	chr7:128862824	NA	-0.73	-13.17	-0.52	7.19e-34	White matter hyperintensity burden;
LGG	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg21058520	chr6:100914733	NA	0.39	6.83	0.3	2.68e-11	Neuroticism;
LGG	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg20503657	chr10:835505	NA	0.75	10.17	0.43	4.43e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9880211	0.948	rs17298525	chr3:136193025	G/C	cg21827317	chr3:136751795	NA	-0.49	-7.21	-0.32	2.34e-12	Body mass index;Height;
LGG	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg16325326	chr1:53192061	ZYG11B	-0.74	-16.93	-0.62	2.05e-50	Monocyte count;
LGG	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg00717180	chr2:96193071	NA	-0.46	-8.3	-0.36	1.12e-15	HDL cholesterol;
LGG	cis	rs283228	0.583	rs808952	chr6:101735606	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.44	0.53	5.39e-35	Coenzyme Q10 levels;
LGG	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg03806693	chr22:41940476	POLR3H	1.08	19.59	0.67	1.06e-62	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12367572	0.501	rs3990143	chr12:45465042	A/G	cg03114573	chr12:45410052	DBX2	-0.51	-8.53	-0.37	2.17e-16	Gut microbiome composition (summer);
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs12220238	0.722	rs10740441	chr10:76410225	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.5	-6.74	-0.3	4.63e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg15242686	chr22:24348715	GSTTP1	0.44	8.17	0.35	3e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg24690094	chr11:67383802	NA	-0.4	-7.02	-0.31	7.76e-12	Mean corpuscular volume;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg05639522	chr1:247681581	NA	0.62	10.36	0.43	9.31e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17604090	1.000	rs10272065	chr7:29694236	A/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.21	-0.32	2.37e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs6993813	0.843	rs7013722	chr8:120047621	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.84	0.3	2.56e-11	Bone mineral density (hip);
LGG	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.93	-0.31	1.42e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg26076054	chr5:421317	AHRR	-0.46	-7.74	-0.34	6.44e-14	Cystic fibrosis severity;
LGG	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.15	0.43	5.44e-22	Dupuytren's disease;
LGG	cis	rs7586879	0.765	rs10171663	chr2:25086431	T/C	cg04586622	chr2:25135609	ADCY3	0.38	9.12	0.39	2.3e-18	Body mass index;
LGG	cis	rs9604529	0.557	rs74406200	chr13:114741208	C/T	cg04826882	chr13:114838756	RASA3	-0.64	-9.53	-0.4	8.85e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9815354	1.000	rs1717031	chr3:41905791	G/T	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg03806693	chr22:41940476	POLR3H	-0.93	-16.3	-0.6	1.51e-47	Vitiligo;
LGG	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg26248373	chr2:1572462	NA	-0.72	-9.27	-0.4	7.27e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7586879	0.616	rs6545813	chr2:25131287	C/T	cg04586622	chr2:25135609	ADCY3	0.48	13.13	0.52	1.08e-33	Body mass index;
LGG	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg02002194	chr4:3960332	NA	0.39	6.86	0.3	2.28e-11	Triglycerides;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23030894	chr19:37701637	ZNF585B	-0.46	-6.74	-0.3	4.84e-11	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03264133	chr6:25882463	NA	-0.51	-9.4	-0.4	2.51e-19	Height;
LGG	cis	rs7100689	0.753	rs1856773	chr10:82060484	T/A	cg01528321	chr10:82214614	TSPAN14	0.88	15.9	0.59	9.5e-46	Post bronchodilator FEV1;
LGG	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg08885076	chr2:99613938	TSGA10	-0.32	-6.7	-0.3	5.99e-11	Fear of minor pain;
LGG	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg06885757	chr1:42089581	HIVEP3	0.5	10.98	0.45	4.2e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs11920090	0.932	rs16855595	chr3:170694060	G/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.12	-0.52	1.19e-33	Schizophrenia;
LGG	cis	rs6882716	0.636	rs10043680	chr5:10804522	A/G	cg14521931	chr5:10832172	NA	1.07	18.7	0.66	1.49e-58	Alcohol consumption (maxi-drinks);
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.26	0.69	7.94e-66	Alzheimer's disease;
LGG	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.56	11.49	0.47	4.6e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs9354308	0.714	rs9363481	chr6:66606649	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg18551225	chr6:44695536	NA	-0.66	-10.92	-0.45	7.57e-25	Total body bone mineral density;
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-6.97	-0.31	1.08e-11	Bipolar disorder;
LGG	cis	rs11753937	0.774	rs569833	chr6:133527935	T/C	cg02446647	chr6:133562101	EYA4	0.31	7.3	0.32	1.3e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03517284	chr6:25882590	NA	-0.68	-12.94	-0.52	6.43e-33	Intelligence (multi-trait analysis);
LGG	cis	rs10940138	0.501	rs11950162	chr5:67243415	C/T	ch.5.1281357F	chr5:67228439	NA	-0.46	-8.55	-0.37	1.77e-16	Menarche (age at onset);
LGG	cis	rs7237497	0.532	rs515151	chr18:12860934	G/C	cg23598886	chr18:12777645	NA	0.53	7.34	0.32	9.92e-13	Inflammatory skin disease;
LGG	cis	rs6840360	0.667	rs2709829	chr4:152355390	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg21659725	chr3:3221576	CRBN	0.56	7.51	0.33	3.05e-13	Menarche (age at onset);
LGG	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg24375607	chr4:120327624	NA	0.61	10.07	0.42	1.07e-21	Corneal astigmatism;
LGG	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg12310025	chr6:25882481	NA	-0.66	-12.18	-0.49	8.55e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.94	0.54	3.78e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg03315344	chr16:75512273	CHST6	0.54	10.81	0.45	1.87e-24	Dupuytren's disease;
LGG	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-10.96	-0.45	5.39e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.86	-0.45	1.21e-24	Prostate cancer;
LGG	cis	rs611744	0.647	rs7015240	chr8:109262204	G/A	cg21045802	chr8:109455806	TTC35	0.49	9.21	0.39	1.16e-18	Dupuytren's disease;
LGG	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs9584850	0.522	rs9517299	chr13:99095031	C/T	cg20487152	chr13:99095054	FARP1	0.46	9.42	0.4	2.07e-19	Neuroticism;
LGG	cis	rs737008	0.500	rs7189239	chr16:11402515	T/C	cg00044050	chr16:11439710	C16orf75	0.65	11.41	0.47	9.25e-27	Obesity-related traits;
LGG	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg19761014	chr17:28927070	LRRC37B2	0.53	6.67	0.3	7.46e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2077654	0.822	rs12280242	chr11:17433737	C/T	cg25308976	chr11:17434268	ABCC8	0.84	10.0	0.42	1.97e-21	Gout;
LGG	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	8.55	0.37	1.82e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs13082711	0.596	rs683503	chr3:27348094	C/T	cg02860705	chr3:27208620	NA	0.65	12.7	0.51	6.65e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4865875	1.000	rs13180287	chr5:54107119	T/A	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.08	0.31	5.23e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg21724239	chr8:58056113	NA	0.47	7.03	0.31	7.54e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00745248	chr2:20101788	TTC32	0.44	7.32	0.32	1.09e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.76	-0.3	4.18e-11	Breast cancer;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.21	-0.46	5.52e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg25809561	chr17:30822961	MYO1D	0.34	7.84	0.34	3.09e-14	Schizophrenia;
LGG	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg08508325	chr11:3079039	CARS	-0.61	-12.97	-0.52	4.75e-33	Longevity;
LGG	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.38	-0.32	7.32e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs113835537	0.529	rs11227499	chr11:66272824	A/G	cg24851651	chr11:66362959	CCS	0.39	7.29	0.32	1.36e-12	Airway imaging phenotypes;
LGG	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg03433033	chr1:76189801	ACADM	-0.8	-15.79	-0.59	2.96e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3733418	0.860	rs13124015	chr4:165930282	G/A	cg10852876	chr4:165953100	TRIM60	-0.48	-6.64	-0.3	8.57e-11	Obesity-related traits;
LGG	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg22482690	chr17:47019901	SNF8	0.36	6.99	0.31	9.53e-12	Type 2 diabetes;
LGG	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg11812906	chr14:75593930	NEK9	0.52	9.54	0.41	8.16e-20	Height;
LGG	cis	rs2030401	0.604	rs2682427	chr12:123656809	C/T	cg06742321	chr12:123595122	PITPNM2	0.44	7.86	0.34	2.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg05973401	chr12:123451056	ABCB9	0.51	7.36	0.32	8.25e-13	Neutrophil percentage of white cells;
LGG	cis	rs2370759	1.000	rs7910776	chr10:32639093	C/T	cg01819863	chr10:32635814	EPC1	0.98	13.2	0.52	5.56e-34	Sexual dysfunction (female);
LGG	cis	rs9457247	1.000	rs408040	chr6:167398903	A/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg08677398	chr8:58056175	NA	0.46	7.11	0.31	4.54e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	trans	rs8002861	0.754	rs4053664	chr13:44429172	A/C	cg17145862	chr1:211918768	LPGAT1	0.96	24.56	0.75	7.04e-86	Leprosy;
LGG	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg17971929	chr21:40555470	PSMG1	0.59	10.2	0.43	3.54e-22	Cognitive function;
LGG	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.71	0.79	2.38e-100	Height;
LGG	cis	rs9487094	0.961	rs12206928	chr6:109679111	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.91	0.38	1.18e-17	Height;
LGG	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.6	-0.33	1.64e-13	Psoriasis;
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg00990874	chr7:1149470	C7orf50	-0.47	-8.22	-0.36	2.12e-15	Bronchopulmonary dysplasia;
LGG	cis	rs11741688	0.557	rs2004503	chr5:178337122	C/T	cg20935368	chr5:178288625	ZNF354B	0.33	6.78	0.3	3.74e-11	Sleep duration;
LGG	cis	rs926938	0.606	rs6537844	chr1:115289295	G/A	cg12756093	chr1:115239321	AMPD1	-0.5	-8.99	-0.39	6.12e-18	Autism;
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.12	-0.31	4.05e-12	Electroencephalogram traits;
LGG	cis	rs6728642	0.908	rs6576996	chr2:97623312	T/C	cg26665480	chr2:98280029	ACTR1B	-0.76	-9.12	-0.39	2.34e-18	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg18681998	chr4:17616180	MED28	0.85	18.83	0.66	3.67e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4699052	0.787	rs2169508	chr4:104066890	T/A	cg16532752	chr4:104119610	CENPE	-0.39	-6.82	-0.3	2.82e-11	Testicular germ cell tumor;
LGG	cis	rs7091068	0.671	rs604489	chr10:95405408	T/C	cg20715218	chr10:95462985	C10orf4	-0.6	-9.49	-0.4	1.24e-19	Urinary tract infection frequency;
LGG	cis	rs12230513	1.000	rs12230513	chr12:55916780	A/G	cg19537932	chr12:55886519	OR6C68	-0.48	-7.62	-0.33	1.43e-13	Contrast sensitivity;
LGG	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg18681998	chr4:17616180	MED28	0.81	18.1	0.64	9.22e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.07	-0.31	5.63e-12	Common traits (Other);
LGG	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg07303275	chr16:75499416	TMEM170A	-0.43	-7.63	-0.33	1.39e-13	Dupuytren's disease;
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	2.06e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs17288257	chr6:45193076	T/C	cg20913747	chr6:44695427	NA	-0.63	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs4799461	0.778	rs62081464	chr18:35142133	C/T	cg27332583	chr18:35150602	NA	0.64	13.29	0.53	2.29e-34	Neuroticism;
LGG	cis	rs1620921	0.563	rs28533078	chr6:161268730	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.86e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1355223	0.872	rs12802798	chr11:34747434	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.95	-0.31	1.25e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg04608330	chr12:45269318	NELL2	-0.42	-6.86	-0.3	2.15e-11	Gut microbiome composition (summer);
LGG	cis	rs2562456	0.833	rs2562416	chr19:21613411	A/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.66	-0.34	1.12e-13	Pain;
LGG	cis	rs12540874	0.542	rs4947581	chr7:50565967	G/A	cg04490037	chr7:50633773	DDC	0.31	6.89	0.31	1.78e-11	Systemic sclerosis;
LGG	cis	rs72781680	0.848	rs56021814	chr2:24073437	T/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.67e-20	Lymphocyte counts;
LGG	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg21055462	chr7:100276975	NA	0.36	7.36	0.32	8.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg11473876	chr11:109292803	C11orf87	0.55	10.28	0.43	1.88e-22	Schizophrenia;
LGG	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs4478137	0.931	rs12509756	chr4:164237464	A/T	cg06758707	chr4:164254230	NPY1R	0.72	12.86	0.51	1.47e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg05368731	chr17:41323189	NBR1	0.94	18.76	0.66	8.18e-59	Menopause (age at onset);
LGG	cis	rs9300255	0.602	rs10846486	chr12:123709927	G/A	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs3813359	0.545	rs2152193	chr6:130553794	A/G	cg23281432	chr6:130554730	NA	0.49	6.74	0.3	4.83e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs503734	0.666	rs2433031	chr3:101066717	T/A	cg27318481	chr3:100970896	IMPG2	-0.36	-7.3	-0.32	1.27e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.42	7.15	0.32	3.45e-12	Depressive symptoms;
LGG	cis	rs921968	0.643	rs10187066	chr2:219514759	A/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.2	-0.32	2.39e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4742903	0.935	rs6479228	chr9:106980912	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.23	0.36	1.97e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.69	-0.3	6.45e-11	Menopause (age at onset);
LGG	cis	rs7586879	1.000	rs12713419	chr2:25121853	G/A	cg04586622	chr2:25135609	ADCY3	0.38	9.42	0.4	2.22e-19	Body mass index;
LGG	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.14	-0.62	2.38e-51	Breast cancer;
LGG	cis	rs1185460	0.967	rs1784302	chr11:118940957	C/G	cg23280166	chr11:118938394	VPS11	0.61	11.31	0.47	2.39e-26	Coronary artery disease;
LGG	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	trans	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg13565492	chr6:43139072	SRF	-0.75	-9.06	-0.39	3.55e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg13902645	chr11:5959945	NA	-0.73	-11.43	-0.47	7.87e-27	DNA methylation (variation);
LGG	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	cis	rs773506	0.933	rs298723	chr9:94023342	C/T	cg14446406	chr9:93919335	NA	-0.44	-8.28	-0.36	1.38e-15	Type 2 diabetes nephropathy;
LGG	trans	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.97	-0.35	1.26e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg17218041	chr13:113365319	ATP11A	-0.46	-7.82	-0.34	3.61e-14	Glycated hemoglobin levels;
LGG	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg21100191	chr22:23484243	RTDR1	0.98	22.72	0.73	2.48e-77	Bone mineral density;
LGG	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg05973401	chr12:123451056	ABCB9	-0.45	-6.69	-0.3	6.31e-11	Neutrophil percentage of white cells;
LGG	trans	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg26119090	chr2:26468346	HADHA;HADHB	0.87	13.06	0.52	2.07e-33	Gut microbiome composition (summer);
LGG	cis	rs9972944	0.651	rs9897920	chr17:63832286	C/T	cg07283582	chr17:63770753	CCDC46	-0.38	-6.91	-0.31	1.57e-11	Total body bone mineral density;
LGG	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg23173402	chr1:227635558	NA	0.56	9.58	0.41	6.16e-20	Major depressive disorder;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg23782820	chr8:58130467	NA	0.56	8.33	0.36	9.21e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.65	-0.63	1.07e-53	Exhaled nitric oxide output;
LGG	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-9.64	-0.41	3.75e-20	Hepatocellular carcinoma;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7216064	1.000	rs12451707	chr17:65871598	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.76	-0.38	3.83e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg26248373	chr2:1572462	NA	-0.7	-8.42	-0.36	4.67e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-16.66	-0.61	3.79e-49	Vitiligo;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	1.01e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg13047869	chr3:10149882	C3orf24	0.44	7.18	0.32	2.84e-12	Alzheimer's disease;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.34	-7.19	-0.32	2.66e-12	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21087160	chr19:2269166	OAZ1	0.47	7.16	0.32	3.22e-12	Gut microbiome composition (summer);
LGG	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.71	0.3	5.6e-11	Vitiligo;
LGG	cis	rs6952809	0.532	rs10227362	chr7:2456799	A/G	cg23289794	chr7:2394357	EIF3B	-0.75	-9.87	-0.42	5.77e-21	Multiple sclerosis;
LGG	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg00717180	chr2:96193071	NA	-0.44	-8.02	-0.35	8.57e-15	Height;
LGG	cis	rs858239	0.539	rs6461694	chr7:23187779	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.49e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs9858542	0.537	rs2304442	chr3:49322027	A/T	cg00383909	chr3:49044727	WDR6	-0.56	-8.0	-0.35	9.93e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs6787172	0.593	rs4680433	chr3:158136848	A/G	cg23275840	chr4:47708675	CORIN	0.35	7.34	0.32	9.85e-13	Subjective well-being;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-7.93	-0.35	1.68e-14	IgG glycosylation;
LGG	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg06890432	chr16:12997467	SHISA9	-0.32	-7.0	-0.31	9.3e-12	Positive affect;Subjective well-being;
LGG	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg18105134	chr13:113819100	PROZ	-0.7	-14.18	-0.55	3.73e-38	Platelet distribution width;
LGG	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.18e-95	Breast cancer;
LGG	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg24130564	chr14:104152367	KLC1	-0.38	-6.8	-0.3	3.28e-11	Reticulocyte count;
LGG	cis	rs2236918	0.710	rs1776138	chr1:242027075	G/A	cg17736920	chr1:242011382	EXO1	0.39	7.19	0.32	2.55e-12	Menopause (age at onset);
LGG	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg12310025	chr6:25882481	NA	0.72	14.36	0.56	6.26e-39	Blood metabolite levels;
LGG	cis	rs28530618	0.580	rs4607010	chr20:31255271	G/C	cg13636640	chr20:31349939	DNMT3B	-0.47	-7.38	-0.32	7.57e-13	Birth weight;
LGG	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg16339924	chr4:17578868	LAP3	0.65	10.91	0.45	8.09e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-12.25	-0.49	4.24e-30	Menarche (age at onset);
LGG	trans	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.52	8.68	0.37	6.92e-17	Cognitive test performance;
LGG	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-12.91	-0.51	8.56e-33	Extrinsic epigenetic age acceleration;
LGG	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.32e-14	Retinal vascular caliber;
LGG	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg15162869	chr22:32027605	PISD	-0.68	-7.27	-0.32	1.57e-12	Age-related hearing impairment;
LGG	cis	rs3806843	0.576	rs246011	chr5:140336405	G/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.64	-0.56	3.74e-40	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19531713	chr17:41277059	BRCA1;NBR2	0.54	8.84	0.38	1.97e-17	Gut microbiome composition (summer);
LGG	cis	rs7927771	0.542	rs7102205	chr11:47745374	C/T	cg20307385	chr11:47447363	PSMC3	0.56	11.01	0.46	3.46e-25	Subjective well-being;
LGG	cis	rs607541	0.850	rs74009657	chr15:45935021	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	7.4	0.33	6.58e-13	Obesity-related traits;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.45	-0.44	4.21e-23	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09163801	chr7:75157515	PMS2L3	0.43	7.1	0.31	4.86e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg01988459	chr11:68622903	NA	-0.62	-12.54	-0.5	2.86e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg04287289	chr16:89883240	FANCA	-0.46	-8.16	-0.35	3.2e-15	Vitiligo;
LGG	cis	rs7089973	0.604	rs17663387	chr10:116588060	C/G	cg03647239	chr10:116582469	FAM160B1	0.41	7.43	0.33	5.41e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg12856521	chr11:46389249	DGKZ	-0.45	-7.87	-0.34	2.46e-14	Leprosy;
LGG	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg13802316	chr11:70253460	CTTN	-0.61	-7.57	-0.33	1.97e-13	Coronary artery disease;
LGG	cis	rs457717	0.730	rs1423605	chr5:75945849	G/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs9463078	0.900	rs1555681	chr6:45086367	A/G	cg25276700	chr6:44698697	NA	-0.39	-8.15	-0.35	3.47e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.87	0.42	5.56e-21	Colorectal cancer;
LGG	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg07061783	chr6:25882402	NA	-0.46	-8.01	-0.35	9.68e-15	Blood metabolite levels;
LGG	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	13.06	0.52	2.01e-33	Cognitive test performance;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6460942	1.000	rs62448565	chr7:12400458	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.66	-0.3	7.86e-11	Coronary artery disease;
LGG	cis	rs8067545	0.641	rs397969	chr17:19804247	T/C	cg13482628	chr17:19912719	NA	0.53	9.76	0.41	1.34e-20	Schizophrenia;
LGG	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.96	0.49	6.7e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.36e-21	Colorectal cancer;
LGG	cis	rs4901847	0.967	rs4901846	chr14:58553582	G/C	cg15908186	chr14:58618357	C14orf37	0.54	9.49	0.4	1.25e-19	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16680214	chr1:154839983	KCNN3	-0.51	-10.17	-0.43	4.46e-22	Prostate cancer;
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg05484376	chr2:27715224	FNDC4	0.46	9.81	0.41	8.9e-21	Total body bone mineral density;
LGG	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.44	-0.33	4.96e-13	Iron status biomarkers;
LGG	cis	rs7107174	1.000	rs10899491	chr11:78106305	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs7572733	0.534	rs1401095	chr2:198779867	C/T	cg00792783	chr2:198669748	PLCL1	-0.69	-11.11	-0.46	1.36e-25	Dermatomyositis;
LGG	trans	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg25214090	chr10:38739885	LOC399744	0.55	10.24	0.43	2.58e-22	Corneal astigmatism;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19717773	chr7:2847554	GNA12	-0.38	-8.86	-0.38	1.68e-17	Height;
LGG	cis	rs4788570	0.585	rs7499576	chr16:71789553	T/G	cg06353428	chr16:71660113	MARVELD3	1.26	20.24	0.69	1.04e-65	Intelligence (multi-trait analysis);
LGG	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-8.03	-0.35	8.1e-15	Mean platelet volume;
LGG	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs9460578	0.537	rs7752310	chr6:20813917	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.66	0.63	9.4e-54	Breast cancer;
LGG	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg06917634	chr15:78832804	PSMA4	0.75	14.24	0.55	2.03e-38	Sudden cardiac arrest;
LGG	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg01028140	chr2:1542097	TPO	-0.53	-8.3	-0.36	1.16e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.49	7.51	0.33	3.08e-13	Height;
LGG	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg05696931	chr1:227175867	NA	-0.39	-7.52	-0.33	2.79e-13	Myeloid white cell count;
LGG	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg13347044	chr2:232276743	NA	0.44	9.44	0.4	1.81e-19	Anti-saccade response;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27189623	chr16:705930	WDR90	0.42	8.14	0.35	3.64e-15	Height;
LGG	cis	rs7119	0.651	rs34829483	chr15:77835986	C/T	cg10437265	chr15:77819839	NA	0.24	6.72	0.3	5.26e-11	Type 2 diabetes;
LGG	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg00717180	chr2:96193071	NA	-0.49	-9.1	-0.39	2.72e-18	HDL cholesterol;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg27661571	chr11:113659931	NA	-0.69	-9.57	-0.41	6.32e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.34	0.36	8.78e-16	Platelet count;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg00495681	chr13:53174319	NA	-0.56	-10.4	-0.44	6.51e-23	Lewy body disease;
LGG	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg21605333	chr4:119757512	SEC24D	1.33	12.6	0.51	1.65e-31	Cannabis dependence symptom count;
LGG	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg04455712	chr21:45112962	RRP1B	0.54	10.07	0.42	1.06e-21	Mean corpuscular volume;
LGG	cis	rs314370	0.818	rs12705091	chr7:100472380	C/T	cg10426581	chr7:100472382	SRRT	0.5	6.72	0.3	5.2e-11	Resting heart rate;
LGG	cis	rs7113850	0.541	rs75347910	chr11:24213815	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	10.01	0.42	1.71e-21	Bone fracture in osteoporosis;
LGG	cis	rs9534288	0.699	rs1409432	chr13:46668302	C/T	cg15192986	chr13:46630673	CPB2	-0.67	-14.12	-0.55	6.43e-38	Blood protein levels;
LGG	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg09264619	chr17:80180166	NA	0.53	10.0	0.42	1.9e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7312774	0.618	rs3759317	chr12:107370252	T/C	cg16260113	chr12:107380972	MTERFD3	0.96	8.84	0.38	2.04e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg21545522	chr1:205238299	TMCC2	0.44	8.38	0.36	6.56e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2635047	0.638	rs2571010	chr18:44652130	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.12	0.31	4.22e-12	Educational attainment;
LGG	trans	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg16011800	chr17:1958478	HIC1	-0.63	-9.64	-0.41	3.56e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg22307297	chr20:60903441	LAMA5	-0.39	-7.82	-0.34	3.73e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg16301924	chr13:53314226	LECT1	-0.48	-9.98	-0.42	2.2e-21	Lewy body disease;
LGG	cis	rs9473924	0.505	rs7753025	chr6:50858352	A/C	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	trans	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.81	-0.38	2.53e-17	Bladder cancer;
LGG	cis	rs4780401	0.933	rs7203803	chr16:11812291	A/G	cg01061890	chr16:11836724	TXNDC11	0.4	6.95	0.31	1.25e-11	Rheumatoid arthritis;
LGG	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.2	-0.43	3.52e-22	Glycated hemoglobin levels;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg07511668	chr11:68622177	NA	0.48	9.03	0.39	4.64e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg01262667	chr19:19385393	TM6SF2	0.45	11.32	0.47	2.15e-26	Tonsillectomy;
LGG	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.12	0.7	8.14e-70	Morning vs. evening chronotype;
LGG	cis	rs7010267	0.773	rs4876869	chr8:119941277	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.72	-0.41	1.85e-20	Total body bone mineral density (age 45-60);
LGG	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg27661571	chr11:113659931	NA	-0.71	-9.57	-0.41	6.18e-20	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg08847335	chr10:891726	LARP4B	-0.53	-9.11	-0.39	2.45e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg11441553	chr12:57614120	NXPH4	0.63	7.93	0.35	1.62e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg03806693	chr22:41940476	POLR3H	0.98	17.55	0.63	3.05e-53	Vitiligo;
LGG	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg03098644	chr7:100410630	EPHB4	0.52	7.84	0.34	3.15e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17219203	chr10:38645113	HSD17B7P2	0.45	7.09	0.31	4.96e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs8180040	0.932	rs62248599	chr3:47516728	G/A	cg16586182	chr3:47516702	SCAP	0.77	15.38	0.58	2.06e-43	Colorectal cancer;
LGG	cis	rs6450176	0.625	rs3776726	chr5:53290052	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-13.62	-0.53	9.21e-36	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs832540	0.552	rs252924	chr5:56205643	A/G	cg12654349	chr5:56205094	C5orf35	-0.45	-7.88	-0.34	2.29e-14	Coronary artery disease;
LGG	cis	rs793571	0.523	rs7163162	chr15:58983588	T/A	cg05156742	chr15:59063176	FAM63B	0.57	9.64	0.41	3.53e-20	Schizophrenia;
LGG	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.89	-0.42	4.59e-21	Response to antipsychotic treatment;
LGG	cis	rs6696846	0.515	rs12739846	chr1:205096895	T/C	cg00889227	chr1:205173544	DSTYK	-0.3	-7.48	-0.33	3.81e-13	Red blood cell count;
LGG	cis	rs13088318	0.557	rs28460520	chr3:101270494	A/G	cg27318481	chr3:100970896	IMPG2	0.37	7.45	0.33	4.55e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3845702	0.736	rs259811	chr2:180787801	C/T	cg01881094	chr2:180872142	CWC22	-1.26	-15.96	-0.6	5.49e-46	Schizophrenia;
LGG	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg00701064	chr4:6280414	WFS1	0.74	16.42	0.61	4.4e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs13403149	0.617	rs62107065	chr2:2846345	T/G	cg02105481	chr2:2853515	NA	0.33	7.26	0.32	1.68e-12	Smoking initiation;
LGG	trans	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.68	0.63	7.72e-54	Exhaled nitric oxide output;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20707008	chr6:160210612	MRPL18;TCP1	0.38	6.68	0.3	6.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6460942	0.915	rs62448598	chr7:12453762	T/C	cg06484146	chr7:12443880	VWDE	-0.4	-7.04	-0.31	6.98e-12	Coronary artery disease;
LGG	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg22563815	chr15:78856949	CHRNA5	0.29	7.27	0.32	1.54e-12	Sudden cardiac arrest;
LGG	cis	rs17534004	1.000	rs17599764	chr13:31469580	G/A	cg00367615	chr13:31480979	C13orf33	0.36	7.25	0.32	1.77e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg07211511	chr3:129823064	LOC729375	-0.65	-8.96	-0.38	8.1e-18	Blood pressure (smoking interaction);
LGG	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg09818912	chr17:20140352	CYTSB	0.32	7.57	0.33	2.06e-13	Schizophrenia;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21862992	chr11:68658383	NA	0.5	8.38	0.36	6.43e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-7.87	-0.34	2.49e-14	Schizophrenia;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.26	-0.43	2.13e-22	Lung cancer;
LGG	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg05623727	chr3:50126028	RBM5	-0.4	-8.72	-0.38	4.88e-17	Body mass index;
LGG	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg06637938	chr14:75390232	RPS6KL1	0.57	10.73	0.45	3.78e-24	Height;
LGG	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	7.66	0.34	1.11e-13	HIV-1 control;
LGG	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg03254818	chr6:169586852	NA	0.53	8.23	0.36	1.93e-15	Pulse pressure;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.43	-0.61	3.83e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.62	6.97	0.31	1.12e-11	Schizophrenia;
LGG	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.21	-0.46	5.97e-26	Neuroticism;
LGG	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg12473912	chr3:136751656	NA	0.44	7.66	0.34	1.1e-13	Neuroticism;
LGG	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg25237894	chr2:233734115	C2orf82	-0.56	-10.43	-0.44	5e-23	Coronary artery disease;
LGG	cis	rs4077515	0.743	rs3812571	chr9:139275294	G/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.44	0.33	5e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9487051	0.735	rs1146246	chr6:109519741	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.65e-13	Reticulocyte fraction of red cells;
LGG	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	13.83	0.54	1.22e-36	Total body bone mineral density;
LGG	trans	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg05926928	chr17:57297772	GDPD1	0.62	10.79	0.45	2.39e-24	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	trans	rs1422110	0.513	rs1363264	chr5:85450380	G/C	cg01787110	chr1:109008453	NBPF6	0.55	9.58	0.41	5.94e-20	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg08344181	chr3:125677491	NA	-0.87	-8.58	-0.37	1.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg27532560	chr4:187881888	NA	-0.6	-13.17	-0.52	7.03e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs926938	0.584	rs869990	chr1:115379614	A/G	cg12756093	chr1:115239321	AMPD1	-0.48	-9.08	-0.39	3.06e-18	Autism;
LGG	cis	rs10089	0.951	rs1864923	chr5:127420843	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.97	0.49	5.84e-29	Ileal carcinoids;
LGG	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg17757837	chr7:157058334	UBE3C	0.91	20.47	0.69	8.51e-67	Body mass index;
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-8.57	-0.37	1.61e-16	Tonsillectomy;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06028808	chr11:68637592	NA	0.71	12.09	0.49	1.97e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13418717	0.793	rs10180994	chr2:127660075	C/G	cg25501666	chr2:127640322	NA	1.13	8.91	0.38	1.2e-17	Heart failure;
LGG	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.0	-0.31	8.76e-12	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg06925179	chr17:43578568	NA	0.3	7.88	0.34	2.37e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg01200585	chr1:228362443	C1orf69	0.49	8.65	0.37	8.35e-17	Diastolic blood pressure;
LGG	cis	rs7173389	0.530	rs6495063	chr15:73682708	G/T	cg01796676	chr15:73680284	NA	0.49	9.29	0.4	5.92e-19	Resting heart rate;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg20607798	chr8:58055168	NA	0.59	6.79	0.3	3.38e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs4363385	0.755	rs516198	chr1:153026196	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.88	-0.38	1.46e-17	Inflammatory skin disease;
LGG	cis	rs6028335	0.674	rs66486072	chr20:37647882	G/A	cg16355469	chr20:37678765	NA	0.58	7.66	0.34	1.12e-13	Alcohol and nicotine co-dependence;
LGG	trans	rs877282	0.700	rs816311	chr10:796490	C/A	cg22713356	chr15:30763199	NA	0.5	7.89	0.34	2.17e-14	Uric acid levels;
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg13282195	chr8:144660772	NAPRT1	0.92	7.37	0.32	7.7e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2652834	0.851	rs4238370	chr15:63347363	T/G	cg05507819	chr15:63340323	TPM1	0.6	8.02	0.35	8.46e-15	HDL cholesterol;
LGG	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg11584989	chr19:19387371	SF4	0.74	12.12	0.49	1.54e-29	Bipolar disorder;
LGG	cis	rs3741151	1.000	rs60924672	chr11:73098724	A/C	cg17517138	chr11:73019481	ARHGEF17	0.95	9.16	0.39	1.73e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs877282	0.945	rs12776447	chr10:790625	A/G	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg23302884	chr18:44338147	ST8SIA5	0.48	9.78	0.41	1.13e-20	Personality dimensions;
LGG	cis	rs12519773	0.501	rs10428523	chr5:92536365	G/A	cg18783429	chr5:92414398	NA	0.31	7.66	0.34	1.06e-13	Migraine;
LGG	cis	rs1957429	0.901	rs8009996	chr14:65351582	A/G	cg23373153	chr14:65346875	NA	1.11	15.49	0.58	6.68e-44	Pediatric areal bone mineral density (radius);
LGG	cis	rs4666002	0.789	rs6727388	chr2:27932587	A/G	cg27432699	chr2:27873401	GPN1	0.56	7.76	0.34	5.29e-14	Phospholipid levels (plasma);
LGG	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg20608306	chr11:116969690	SIK3	0.42	13.31	0.53	1.92e-34	Blood protein levels;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.78	-0.34	4.79e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg06521331	chr12:34319734	NA	-0.54	-9.21	-0.39	1.18e-18	Bladder cancer;
LGG	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg25319279	chr11:5960081	NA	-0.55	-8.62	-0.37	1.1e-16	DNA methylation (variation);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14191109	chr10:70287438	SLC25A16	0.4	6.8	0.3	3.21e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg05926928	chr17:57297772	GDPD1	1.39	22.61	0.72	8.41e-77	Opioid sensitivity;
LGG	cis	rs367943	1.000	rs168366	chr5:112818587	C/T	cg12552261	chr5:112820674	MCC	0.75	14.3	0.55	1.07e-38	Type 2 diabetes;
LGG	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.65	-0.3	8.09e-11	Sudden cardiac arrest;
LGG	trans	rs3206736	0.548	rs329242	chr7:35059667	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.29	0.32	1.32e-12	Diastolic blood pressure;
LGG	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg23250157	chr14:64679961	SYNE2	0.44	7.91	0.35	1.85e-14	Atrial fibrillation;
LGG	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.77	-0.3	3.94e-11	Blood metabolite levels;
LGG	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.48	-0.37	3.01e-16	Aortic root size;
LGG	cis	rs4804815	1.000	rs4804815	chr19:7842669	C/G	cg09310891	chr19:7854403	CLEC4GP1	0.59	9.45	0.4	1.7e-19	Neutrophil count;
LGG	cis	rs2734839	0.929	rs7131627	chr11:113299829	G/A	cg14159747	chr11:113255604	NA	0.26	7.03	0.31	7.65e-12	Information processing speed;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.36	-0.4	3.35e-19	Life satisfaction;
LGG	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg22875332	chr1:76189707	ACADM	0.62	11.13	0.46	1.21e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2108225	1.000	rs6466191	chr7:107453511	A/T	cg18560240	chr7:107437656	SLC26A3	-0.54	-9.61	-0.41	4.67e-20	Ulcerative colitis;
LGG	cis	rs9814567	1.000	rs9864346	chr3:134312352	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.42	0.5	9.08e-31	Lung cancer;
LGG	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07570687	chr10:102243282	WNT8B	0.4	7.07	0.31	5.61e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19171272	chr22:38449367	NA	0.4	6.79	0.3	3.37e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.49	-0.33	3.62e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12862611	chr4:147443109	SLC10A7	0.48	8.26	0.36	1.57e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs12579753	1.000	rs12579753	chr12:82219376	C/T	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.23	-0.46	5e-26	Resting heart rate;
LGG	cis	rs1957429	0.808	rs7149922	chr14:65334541	C/T	cg23373153	chr14:65346875	NA	1.05	13.12	0.52	1.16e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.65	-0.41	3.25e-20	Lung cancer;
LGG	cis	rs2289125	0.556	rs514981	chr11:89221089	C/T	cg01436723	chr11:89220647	NOX4	-0.52	-7.43	-0.33	5.45e-13	Pulse pressure;
LGG	trans	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.92	-0.35	1.8e-14	Depression;
LGG	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs6840360	0.615	rs12503677	chr4:152610543	A/G	cg22705602	chr4:152727874	NA	-0.39	-9.7	-0.41	2.34e-20	Intelligence (multi-trait analysis);
LGG	trans	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg21659725	chr3:3221576	CRBN	-0.67	-7.34	-0.32	9.54e-13	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg00745463	chr17:30367425	LRRC37B	0.57	6.95	0.31	1.26e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2737618	0.630	rs2821324	chr1:200078006	G/A	cg21825944	chr1:200113062	NR5A2	-0.59	-11.32	-0.47	2.07e-26	Uric acid levels;
LGG	cis	rs11169552	0.510	rs55877451	chr12:50987378	G/A	cg12884762	chr12:50931848	DIP2B	-0.41	-7.72	-0.34	7.25e-14	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10841076	chr16:3174662	NA	0.49	7.56	0.33	2.13e-13	Gut microbiome composition (summer);
LGG	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg26897989	chr16:1907736	C16orf73	-0.81	-12.85	-0.51	1.54e-32	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08109568	chr15:31115862	NA	0.59	10.03	0.42	1.49e-21	Huntington's disease progression;
LGG	cis	rs7011049	0.841	rs66467113	chr8:53873613	C/T	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg04731861	chr2:219085781	ARPC2	-0.49	-12.54	-0.5	2.87e-31	Colorectal cancer;
LGG	trans	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.73e-12	Morning vs. evening chronotype;
LGG	cis	rs6963495	0.745	rs75805443	chr7:105162828	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg05163923	chr11:71159392	DHCR7	0.7	13.66	0.54	6.47e-36	Vitamin D levels;
LGG	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.08	-0.42	9.99e-22	Joint mobility (Beighton score);
LGG	cis	rs12210905	0.925	rs7753123	chr6:26991540	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;
LGG	cis	rs4704187	0.553	rs116188801	chr5:74398141	A/G	cg03227963	chr5:74354835	NA	0.31	6.71	0.3	5.64e-11	Response to amphetamines;
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg22398616	chr13:53314203	LECT1	-0.45	-9.39	-0.4	2.79e-19	Lewy body disease;
LGG	cis	rs12220238	1.000	rs10824098	chr10:75943579	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.51	0.47	3.95e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg02574844	chr11:5959923	NA	-0.57	-8.86	-0.38	1.74e-17	DNA methylation (variation);
LGG	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.23	-0.6	3.27e-47	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg20283391	chr11:68216788	NA	-0.54	-8.81	-0.38	2.59e-17	Total body bone mineral density;
LGG	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Vitiligo;
LGG	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg07541023	chr7:19748670	TWISTNB	0.49	7.49	0.33	3.6e-13	Thyroid stimulating hormone;
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg12705353	chr12:122356852	WDR66	0.24	6.75	0.3	4.49e-11	Mean corpuscular volume;
LGG	cis	rs7927592	0.913	rs3758643	chr11:68367193	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg23649088	chr2:200775458	C2orf69	-0.64	-9.19	-0.39	1.28e-18	Schizophrenia;
LGG	trans	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.66	-0.3	7.98e-11	Neuroticism;
LGG	cis	rs11096990	0.613	rs9997015	chr4:39224297	A/G	cg24403649	chr4:39172243	NA	-0.4	-7.19	-0.32	2.59e-12	Cognitive function;
LGG	cis	rs7173743	0.756	rs8035039	chr15:79129823	A/G	cg00540400	chr15:79124168	NA	0.39	7.96	0.35	1.32e-14	Coronary artery disease;
LGG	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22633769	chr20:60982531	CABLES2	0.48	6.71	0.3	5.75e-11	Colorectal cancer;
LGG	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg01528321	chr10:82214614	TSPAN14	0.67	12.02	0.49	3.73e-29	Post bronchodilator FEV1;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg05555928	chr11:63887634	MACROD1	-0.79	-10.84	-0.45	1.5e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1550582	1.000	rs1550582	chr8:135542084	A/G	cg17885191	chr8:135476712	NA	-0.69	-10.89	-0.45	9.34e-25	Educational attainment;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.11	0.35	4.62e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00419759	chr1:114301964	PHTF1	0.44	7.4	0.33	6.64e-13	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05647660	chr4:76439704	RCHY1;THAP6	0.51	7.87	0.34	2.53e-14	Gut microbiome composition (summer);
LGG	cis	rs6504108	0.647	rs3805370	chr17:46259093	A/C	cg02219949	chr17:45927392	SP6	0.43	8.06	0.35	6.72e-15	Body mass index;
LGG	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg18196295	chr10:418757	DIP2C	0.64	12.99	0.52	3.94e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs60180747	0.865	rs11639144	chr15:66600096	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.53	8.85	0.38	1.8e-17	Testicular germ cell tumor;
LGG	cis	rs2692947	0.800	rs2692936	chr2:96745729	G/A	cg22654517	chr2:96458247	NA	0.37	7.28	0.32	1.47e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1185460	0.804	rs13929	chr11:118915755	G/C	cg23280166	chr11:118938394	VPS11	0.52	9.33	0.4	4.55e-19	Coronary artery disease;
LGG	cis	rs4750440	0.642	rs7921741	chr10:14030776	G/A	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.66	-0.54	6.03e-36	Adiponectin levels;
LGG	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	cis	rs6988985	0.765	rs10096393	chr8:143984315	T/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs28647808	0.881	rs28625799	chr9:136264557	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg04450456	chr4:17643702	FAM184B	0.32	6.92	0.31	1.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1371867	0.846	rs1660324	chr8:101281271	C/T	cg06636551	chr8:101224915	SPAG1	-0.49	-9.03	-0.39	4.51e-18	Atrioventricular conduction;
LGG	cis	rs9487094	0.961	rs12206928	chr6:109679111	C/T	cg16315928	chr6:109776240	MICAL1	0.53	9.05	0.39	4.07e-18	Height;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.24	-0.43	2.56e-22	Obesity-related traits;
LGG	cis	rs6688613	0.685	rs10918600	chr1:166919342	C/T	ch.1.3259774R	chr1:166827647	TADA1	-0.46	-6.78	-0.3	3.71e-11	Refractive astigmatism;
LGG	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-16.63	-0.61	5.05e-49	Body mass index;
LGG	cis	rs4538187	0.662	rs66980330	chr2:64125978	C/G	cg02541582	chr2:64069798	UGP2	-0.59	-13.23	-0.52	4.11e-34	Systolic blood pressure;
LGG	cis	rs11169552	0.510	rs10876056	chr12:50948517	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-7.85	-0.34	2.95e-14	Colorectal cancer;
LGG	cis	rs13088645	0.532	rs9857134	chr3:134161607	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	8.38	0.36	6.55e-16	Coronary artery disease;
LGG	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg13010199	chr12:38710504	ALG10B	0.48	8.59	0.37	1.34e-16	Morning vs. evening chronotype;
LGG	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg06197492	chr11:2016605	H19	0.48	10.07	0.42	1.03e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs17767392	0.958	rs2109276	chr14:71889767	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7577696	0.962	rs13022197	chr2:32343167	A/T	cg02381751	chr2:32503542	YIPF4	-0.4	-6.89	-0.31	1.78e-11	Inflammatory biomarkers;
LGG	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.55e-17	Aortic root size;
LGG	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07570687	chr10:102243282	WNT8B	0.42	6.8	0.3	3.15e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs981844	0.857	rs62325142	chr4:154717790	A/G	cg14289246	chr4:154710475	SFRP2	0.72	11.89	0.48	1.18e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs17021463	0.673	rs12646467	chr4:95288819	G/A	cg11021082	chr4:95130006	SMARCAD1	0.4	6.81	0.3	3.03e-11	Testicular germ cell tumor;
LGG	cis	rs10937275	0.826	rs62294593	chr3:186642111	T/G	cg13419791	chr3:186648285	ST6GAL1	0.79	7.97	0.35	1.23e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg20387954	chr3:183756860	HTR3D	0.66	13.4	0.53	7.88e-35	Anterior chamber depth;
LGG	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg27131176	chr22:46450114	C22orf26;LOC150381	-0.39	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7129220	0.512	rs2119991	chr11:10226268	A/G	cg01453529	chr11:10209919	SBF2	-0.47	-7.66	-0.34	1.08e-13	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7215564	0.730	rs7214653	chr17:78581450	A/G	cg16980736	chr17:78789706	RPTOR	0.56	7.27	0.32	1.55e-12	Myopia (pathological);
LGG	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.94	-0.38	9.35e-18	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22975147	chr17:8021903	ALOXE3	0.48	7.16	0.32	3.26e-12	Gut microbiome composition (summer);
LGG	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg01620082	chr3:125678407	NA	-0.75	-8.38	-0.36	6.62e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6601327	0.641	rs10111376	chr8:9615470	A/G	cg12395012	chr8:11607386	GATA4	-0.39	-7.03	-0.31	7.48e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6700896	0.500	rs4655754	chr1:66114747	C/T	cg04111102	chr1:66153794	NA	-0.37	-7.68	-0.34	9.37e-14	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg00086871	chr4:6988644	TBC1D14	0.81	7.97	0.35	1.23e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14159672	chr1:205819179	PM20D1	0.44	7.87	0.34	2.54e-14	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.72	-0.34	7.1e-14	Menopause (age at onset);
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg09264619	chr17:80180166	NA	0.36	7.3	0.32	1.27e-12	Life satisfaction;
LGG	cis	rs9487094	0.885	rs11153214	chr6:110015323	A/G	cg16315928	chr6:109776240	MICAL1	0.53	8.81	0.38	2.6e-17	Height;
LGG	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14373873	chr11:113211441	TTC12	0.42	8.66	0.37	7.63e-17	Neuroticism;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	trans	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg21659725	chr3:3221576	CRBN	0.55	7.47	0.33	3.9e-13	Menarche (age at onset);
LGG	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg24998770	chr7:37888106	TXNDC3	-0.49	-7.97	-0.35	1.22e-14	Alzheimer's disease (late onset);
LGG	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.53	0.33	2.74e-13	Educational attainment;
LGG	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg24375607	chr4:120327624	NA	0.61	10.2	0.43	3.61e-22	Corneal astigmatism;
LGG	cis	rs7572733	0.534	rs700670	chr2:198687284	T/C	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.19e-26	Dermatomyositis;
LGG	trans	rs73191547	0.771	rs11787363	chr8:10043355	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.62	0.33	1.43e-13	Schizophrenia;
LGG	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg19761014	chr17:28927070	LRRC37B2	0.67	7.82	0.34	3.62e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs262150	0.819	rs6956589	chr7:158769301	C/T	cg19418458	chr7:158789849	NA	-0.45	-9.11	-0.39	2.56e-18	Facial morphology (factor 20);
LGG	cis	rs72772090	0.539	rs72775818	chr5:96193215	A/G	cg00188032	chr5:96141721	ERAP1	0.55	7.24	0.32	1.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs67478160	0.644	rs7159810	chr14:104294117	T/G	cg26031613	chr14:104095156	KLC1	-0.43	-6.98	-0.31	1.01e-11	Schizophrenia;
LGG	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.13e-42	Aortic root size;
LGG	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.45	-0.33	4.74e-13	Triglycerides;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	6.71	0.3	5.53e-11	Schizophrenia;
LGG	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	7.07	0.31	5.64e-12	Total cholesterol levels;
LGG	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg26384229	chr12:38710491	ALG10B	-0.62	-12.09	-0.49	1.98e-29	Morning vs. evening chronotype;
LGG	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17221829	0.965	rs11018753	chr11:89459064	T/C	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.77	-0.34	4.95e-14	Anxiety in major depressive disorder;
LGG	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-11.62	-0.48	1.45e-27	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg25726756	chr21:47582351	C21orf56	0.31	6.76	0.3	4.22e-11	Testicular germ cell tumor;
LGG	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg08754478	chr10:133766260	PPP2R2D	0.69	12.71	0.51	5.87e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs28374715	0.532	rs28477406	chr15:41642036	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.82	-0.84	3.49e-127	Ulcerative colitis;
LGG	cis	rs2735413	0.563	rs11647117	chr16:78058062	G/T	cg04733911	chr16:78082701	NA	0.57	7.65	0.34	1.17e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08280861	chr8:58055591	NA	0.63	7.84	0.34	3.22e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg00031303	chr3:195681400	NA	-0.45	-6.88	-0.3	1.97e-11	Mean corpuscular volume;
LGG	cis	rs3770081	1.000	rs76081054	chr2:86285037	T/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-8.66	-0.37	7.63e-17	Facial emotion recognition (sad faces);
LGG	cis	rs6580649	1.000	rs10783227	chr12:48400617	C/T	cg24011408	chr12:48396354	COL2A1	0.64	7.93	0.35	1.64e-14	Lung cancer;
LGG	cis	rs6558174	0.802	rs6558170	chr8:22487388	C/G	cg03733263	chr8:22462867	KIAA1967	0.63	10.24	0.43	2.51e-22	Breast cancer;
LGG	cis	rs9308731	0.644	rs3789064	chr2:111915322	T/C	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.07	-0.31	5.73e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.65	-0.37	8.59e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg03806693	chr22:41940476	POLR3H	-0.76	-12.75	-0.51	3.91e-32	Vitiligo;
LGG	trans	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs896543	1.000	rs896543	chr2:237509207	A/G	cg25295825	chr2:237489920	CXCR7	-0.65	-9.24	-0.39	9.05e-19	Alcohol dependence (age at onset);
LGG	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.64	-0.54	7.77e-36	Response to antipsychotic treatment;
LGG	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg11189052	chr15:85197271	WDR73	-0.51	-8.32	-0.36	1.01e-15	P wave terminal force;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg05861140	chr6:150128134	PCMT1	-0.3	-6.94	-0.31	1.29e-11	Testicular germ cell tumor;
LGG	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.15	0.39	1.85e-18	Myopia (pathological);
LGG	cis	rs8112449	0.861	rs3760650	chr19:10515804	T/C	cg21868191	chr19:10515988	NA	-0.48	-8.27	-0.36	1.48e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.43	-6.86	-0.3	2.17e-11	Resting heart rate;
LGG	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.73	0.34	6.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.89	0.34	2.19e-14	Height;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs2274273	0.624	rs78205412	chr14:55781250	G/A	cg04306507	chr14:55594613	LGALS3	0.53	12.33	0.5	2.16e-30	Protein biomarker;
LGG	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg07395648	chr5:131743802	NA	0.55	13.18	0.52	6.39e-34	Blood metabolite levels;
LGG	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg12856521	chr11:46389249	DGKZ	-0.42	-7.23	-0.32	2.03e-12	Leprosy;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.68	-12.38	-0.5	1.35e-30	Obesity-related traits;
LGG	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	5.17e-45	Intelligence (multi-trait analysis);
LGG	trans	rs7246760	0.867	rs73014056	chr19:9914120	G/A	cg02900749	chr2:68251473	NA	-1.05	-10.39	-0.43	7.02e-23	Pursuit maintenance gain;
LGG	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg00666640	chr1:248458726	OR2T12	0.55	8.98	0.39	6.98e-18	Common traits (Other);
LGG	cis	rs9487094	0.670	rs114261376	chr6:109923358	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.97e-14	Height;
LGG	cis	rs2531992	0.686	rs2041247	chr16:4032581	A/G	cg05927578	chr16:4029543	ADCY9	0.71	10.2	0.43	3.65e-22	Waist circumference;
LGG	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg02725872	chr8:58115012	NA	1.04	15.37	0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-7.75	-0.34	6e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.39	0.5	1.16e-30	Obesity-related traits;
LGG	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg03258749	chr1:151040405	MLLT11	-0.56	-9.73	-0.41	1.81e-20	Childhood ear infection;
LGG	cis	rs2964802	0.505	rs7447014	chr5:10814212	T/C	cg14521931	chr5:10832172	NA	-0.74	-16.12	-0.6	9.53e-47	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg05313129	chr8:58192883	C8orf71	-0.61	-8.51	-0.37	2.48e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15369054	chr17:80825471	TBCD	0.51	7.16	0.32	3.27e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs72781680	0.752	rs72780185	chr2:24003967	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.58	0.37	1.47e-16	Lung cancer;
LGG	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.34e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11064837	0.504	rs2393522	chr12:120055357	A/G	cg25937854	chr12:120150414	CIT	-0.58	-10.1	-0.43	8.04e-22	Schizophrenia;
LGG	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.09	-0.49	1.94e-29	Height;
LGG	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.49	6.71	0.3	5.59e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg03511173	chr18:77590860	NA	0.43	7.2	0.32	2.41e-12	Schizophrenia;
LGG	cis	rs17039065	1.000	rs72889379	chr4:109390266	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.86	0.3	2.25e-11	Gut microbiome composition (summer);
LGG	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg06627557	chr7:32535165	LSM5;AVL9	0.99	21.34	0.7	7.35e-71	Cognitive ability;
LGG	cis	rs911263	0.961	rs2208397	chr14:68753287	T/G	cg18825221	chr14:68749962	RAD51L1	0.51	10.77	0.45	2.82e-24	Primary biliary cholangitis;
LGG	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4819852	0.723	rs2238790	chr22:19983014	G/A	cg07821417	chr22:19972146	ARVCF	-0.48	-10.42	-0.44	5.37e-23	Pulse pressure;
LGG	cis	rs7715811	0.913	rs1910091	chr5:13781535	G/A	cg07548982	chr5:13769939	DNAH5	-0.45	-8.97	-0.38	7.56e-18	Subclinical atherosclerosis traits (other);
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg19635926	chr16:89946313	TCF25	0.71	7.61	0.33	1.59e-13	Skin colour saturation;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg15991262	chr7:23720454	C7orf46	0.44	10.21	0.43	3.27e-22	Schizophrenia;
LGG	trans	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg11693508	chr17:37793320	STARD3	0.61	8.52	0.37	2.31e-16	Bipolar disorder;
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00761968	chr13:53314142	LECT1	-0.38	-7.9	-0.34	2.12e-14	Lewy body disease;
LGG	trans	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg06521331	chr12:34319734	NA	0.52	9.55	0.41	7.6e-20	Bladder cancer;
LGG	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg11279151	chr3:101281821	RG9MTD1	0.64	10.7	0.45	4.97e-24	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6787172	0.622	rs4680431	chr3:158098919	T/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg11812906	chr14:75593930	NEK9	0.55	10.26	0.43	2.1e-22	Height;
LGG	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg15704280	chr7:45808275	SEPT13	-1.05	-23.98	-0.74	3.42e-83	Height;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.68	-11.76	-0.48	4.22e-28	Longevity;Endometriosis;
LGG	cis	rs4684776	1.000	rs7616608	chr3:11429793	C/T	cg24705426	chr3:11550659	ATG7	-0.42	-7.62	-0.33	1.4e-13	Small vessel stroke;
LGG	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg02466173	chr16:30829666	NA	0.46	8.24	0.36	1.79e-15	Dementia with Lewy bodies;
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01341218	chr17:43662625	NA	-0.88	-14.83	-0.57	5.36e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs477692	0.870	rs532248	chr10:131414156	T/A	cg05714579	chr10:131428358	MGMT	0.66	14.05	0.55	1.4e-37	Response to temozolomide;
LGG	cis	rs526231	0.511	rs10434792	chr5:102389602	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.83	-0.3	2.74e-11	Neuroticism;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg25703541	chr22:24373054	LOC391322	-0.87	-17.27	-0.63	6.18e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.08	-0.31	5.41e-12	Morning vs. evening chronotype;
LGG	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.24	0.43	2.48e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs870825	0.872	rs12507711	chr4:185571776	C/T	cg04058563	chr4:185651563	MLF1IP	1.0	17.51	0.63	4.84e-53	Blood protein levels;
LGG	cis	rs2213920	1.000	rs9409169	chr9:118273407	A/G	cg13918206	chr9:118159781	DEC1	-0.48	-6.66	-0.3	7.57e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7737355	1.000	rs2551036	chr5:130648994	G/A	cg06307176	chr5:131281290	NA	0.5	8.42	0.36	4.75e-16	Life satisfaction;
LGG	cis	rs11150038	0.793	rs2204891	chr16:78062219	C/T	cg04733911	chr16:78082701	NA	-0.67	-8.48	-0.37	3.03e-16	Colorectal or endometrial cancer;
LGG	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4356203	0.905	rs9919540	chr11:17080333	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.33	-0.32	1.06e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs4595586	0.655	rs4142847	chr12:39395128	C/T	cg26384229	chr12:38710491	ALG10B	0.46	8.38	0.36	6.59e-16	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07831432	chr5:179125659	CANX	0.42	6.99	0.31	9.45e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8078723	0.714	rs12940405	chr17:38143768	C/T	cg17467752	chr17:38218738	THRA	-0.62	-11.29	-0.46	2.91e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs3818285	0.504	rs7100154	chr10:111650150	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.55	-10.13	-0.43	6.17e-22	Superior crus of antihelix expression;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-9.12	-0.39	2.39e-18	Menopause (age at onset);
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg21775007	chr8:11205619	TDH	-0.55	-8.98	-0.39	6.75e-18	Triglycerides;
LGG	cis	rs77741769	0.529	rs10849791	chr12:121235280	T/C	cg02419362	chr12:121203948	SPPL3	0.55	9.47	0.4	1.4e-19	Mean corpuscular volume;
LGG	cis	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg07460842	chr6:66804631	NA	0.94	16.94	0.62	2.02e-50	Exhaled nitric oxide levels;
LGG	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg07777115	chr5:623756	CEP72	-0.5	-6.84	-0.3	2.51e-11	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.06e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2120243	0.539	rs9990136	chr3:157075834	C/T	cg24825693	chr3:157122686	VEPH1	-0.5	-11.14	-0.46	1.09e-25	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg20573242	chr4:122745356	CCNA2	0.45	8.35	0.36	8.23e-16	Type 2 diabetes;
LGG	trans	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24308560	chr3:49941425	MST1R	-0.23	-7.18	-0.32	2.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.75e-22	Motion sickness;
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg19357499	chr8:144660631	NAPRT1	0.85	6.96	0.31	1.17e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs11748327	0.959	rs57592121	chr5:4051072	T/C	cg01025095	chr5:4101132	NA	-0.58	-9.35	-0.4	3.82e-19	Myocardial infarction;
LGG	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.47	-0.33	3.9e-13	Joint mobility (Beighton score);
LGG	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg23594656	chr7:65796392	TPST1	-0.36	-8.03	-0.35	8.18e-15	Aortic root size;
LGG	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg22437258	chr11:111473054	SIK2	0.57	10.07	0.42	1.07e-21	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.0	-0.49	4.63e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25172604	chr17:41446521	NA	-0.3	-7.1	-0.31	4.59e-12	Menopause (age at onset);
LGG	cis	rs3790455	0.833	rs12038396	chr1:156459535	C/T	cg14087168	chr1:156450669	MEF2D	0.47	7.72	0.34	7.35e-14	Migraine;
LGG	cis	rs5756813	0.688	rs12484064	chr22:38126746	C/A	cg19171272	chr22:38449367	NA	0.41	7.03	0.31	7.65e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12681288	0.676	rs7459467	chr8:999359	C/T	cg15309053	chr8:964076	NA	0.37	7.34	0.32	9.54e-13	Schizophrenia;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.632	rs7177107	chr15:86123364	G/A	cg25843651	chr15:86329602	KLHL25	0.55	8.13	0.35	4.05e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg05623727	chr3:50126028	RBM5	0.44	9.49	0.4	1.24e-19	Body mass index;
LGG	cis	rs7580658	0.676	rs4150407	chr2:128049631	C/T	cg10021288	chr2:128175891	PROC	0.58	11.96	0.49	6.2e-29	Protein C levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00251738	chr7:77428046	PHTF2;TMEM60	0.46	7.1	0.31	4.82e-12	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg02023728	chr11:77925099	USP35	0.46	7.92	0.35	1.79e-14	Testicular germ cell tumor;
LGG	cis	rs11785693	0.862	rs17435835	chr8:5000713	C/T	cg26367366	chr8:4980734	NA	-1.0	-15.27	-0.58	5.99e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.85	-0.34	2.93e-14	Life satisfaction;
LGG	cis	rs11785693	0.862	rs11786657	chr8:5001792	T/C	cg26367366	chr8:4980734	NA	1.0	14.93	0.57	1.94e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg05861140	chr6:150128134	PCMT1	0.43	9.78	0.41	1.18e-20	Lung cancer;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.46	-0.33	4.45e-13	Menopause (age at onset);
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21028326	chr22:50683188	TUBGCP6	-0.52	-7.63	-0.33	1.31e-13	Systemic lupus erythematosus;
LGG	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.76	0.48	3.89e-28	Rheumatoid arthritis;
LGG	cis	rs9815354	0.680	rs61646756	chr3:42029352	A/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.22	-0.32	2.1e-12	Coronary artery disease;
LGG	cis	rs4262150	0.672	rs113147549	chr5:152356818	G/A	cg12297329	chr5:152029980	NA	-0.55	-8.43	-0.36	4.54e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs910187	0.605	rs62201430	chr20:45808227	A/T	cg27589058	chr20:45804311	EYA2	-0.36	-9.4	-0.4	2.58e-19	Migraine;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22433210	chr17:43662623	NA	0.64	11.11	0.46	1.42e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg15596359	chr8:11213517	TDH	-0.42	-8.89	-0.38	1.35e-17	Retinal vascular caliber;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00166722	chr3:10149974	C3orf24	0.56	8.1	0.35	4.75e-15	Alzheimer's disease;
LGG	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.21	-0.55	2.68e-38	Platelet distribution width;
LGG	cis	rs13095912	0.785	rs35637544	chr3:185329958	A/G	cg11274856	chr3:185301563	NA	0.49	7.9	0.34	2.03e-14	Systolic blood pressure;
LGG	cis	rs12479064	0.694	rs1823569	chr2:100113764	G/A	cg08885076	chr2:99613938	TSGA10	-0.46	-8.41	-0.36	5.17e-16	Chronic sinus infection;
LGG	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.5	8.3	0.36	1.14e-15	Cognitive test performance;
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg16141378	chr3:129829833	LOC729375	-0.35	-8.06	-0.35	6.45e-15	Monocyte count;
LGG	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg15017067	chr4:17643749	FAM184B	0.32	7.45	0.33	4.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3796352	1.000	rs13074524	chr3:52974184	A/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7166081	1.000	rs78553942	chr15:67521810	C/A	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.33e-17	Self-reported allergy;
LGG	cis	rs524281	0.692	rs2254388	chr11:65837599	C/T	cg16950941	chr11:66035639	RAB1B	0.5	8.13	0.35	4.02e-15	Electroencephalogram traits;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00294572	chr6:26285232	NA	0.44	7.85	0.34	3.02e-14	Educational attainment;
LGG	cis	rs2070997	0.702	rs3780284	chr9:133733961	A/G	cg13397898	chr9:133768931	QRFP	0.36	7.59	0.33	1.76e-13	Response to amphetamines;
LGG	cis	rs258892	0.947	rs34955	chr5:72203628	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.68	0.3	7.07e-11	Small cell lung carcinoma;
LGG	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg15704280	chr7:45808275	SEPT13	0.49	8.03	0.35	8.14e-15	HDL cholesterol;
LGG	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg00647317	chr7:50633725	DDC	0.37	8.8	0.38	2.8e-17	Systemic sclerosis;
LGG	cis	rs7020830	0.861	rs6476622	chr9:37308049	T/A	cg14294708	chr9:37120828	ZCCHC7	1.16	33.66	0.84	1.74e-126	Schizophrenia;
LGG	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg23750338	chr8:142222470	SLC45A4	0.48	10.04	0.42	1.33e-21	Immature fraction of reticulocytes;
LGG	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg03060546	chr3:49711283	APEH	-0.62	-10.27	-0.43	2.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg22705602	chr4:152727874	NA	-0.32	-7.73	-0.34	6.86e-14	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.22	0.52	4.46e-34	Colorectal cancer;
LGG	cis	rs367615	1.000	rs367615	chr5:108948937	C/T	cg17395555	chr5:108820864	NA	-0.58	-8.24	-0.36	1.84e-15	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg12800244	chr3:153838788	SGEF	0.79	8.35	0.36	8.27e-16	Coronary artery disease;
LGG	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.17	-0.35	2.91e-15	Neuroticism;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.67	-0.34	1.02e-13	HDL cholesterol;
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-8.25	-0.36	1.69e-15	Menopause (age at onset);
LGG	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.94	0.42	3.08e-21	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg05714926	chr2:166810417	TTC21B	-0.37	-7.04	-0.31	7.02e-12	Iris color (L* coordinate);
LGG	cis	rs5769707	0.935	rs1109320	chr22:49989106	G/A	cg20744362	chr22:50050164	C22orf34	0.37	7.15	0.32	3.3e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07988820	chr12:82153109	PPFIA2	-0.79	-11.45	-0.47	6.54e-27	Resting heart rate;
LGG	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg02269571	chr22:50332266	NA	-0.63	-10.12	-0.43	7.22e-22	Schizophrenia;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg14675211	chr2:100938903	LONRF2	0.61	10.88	0.45	1.09e-24	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	16.62	0.61	5.55e-49	Obesity-related traits;
LGG	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2013441	1.000	rs2107566	chr17:20103252	C/T	cg13482628	chr17:19912719	NA	-0.5	-9.27	-0.4	7.15e-19	Obesity-related traits;
LGG	cis	rs74781061	0.929	rs7176095	chr15:74886411	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.26	-0.32	1.66e-12	Endometriosis;
LGG	cis	rs7444	0.660	rs11089637	chr22:21979096	A/G	cg15846791	chr22:21984385	YDJC	-0.46	-6.8	-0.3	3.2e-11	Systemic lupus erythematosus;
LGG	cis	rs12617721	0.681	rs10190015	chr2:99018717	A/G	cg18455616	chr2:99124870	INPP4A	0.31	8.09	0.35	5.11e-15	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg12813108	chr7:99719912	CNPY4	-0.58	-8.64	-0.37	8.92e-17	Lung function (FEV1/FVC);
LGG	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg08999081	chr20:33150536	PIGU	-0.39	-9.85	-0.42	6.84e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs7177699	0.557	rs8035093	chr15:79120670	T/C	cg00540400	chr15:79124168	NA	0.54	11.53	0.47	3.34e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs8141529	0.529	rs28458474	chr22:29213034	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Lymphocyte counts;
LGG	cis	rs9649465	1.000	rs6950659	chr7:123361910	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	trans	rs3812049	0.826	rs17764730	chr5:127357526	A/G	cg16011800	chr17:1958478	HIC1	-0.61	-9.22	-0.39	1.02e-18	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.88	0.34	2.41e-14	Bipolar disorder;
LGG	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.25	0.43	2.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	trans	rs11875185	0.510	rs79726302	chr18:55618665	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg05673287	chr15:77411982	SGK269	-0.44	-9.67	-0.41	2.9e-20	Type 2 diabetes;
LGG	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg12561776	chr17:30844705	MYO1D	-0.28	-7.18	-0.32	2.83e-12	Schizophrenia;
LGG	cis	rs2952156	0.876	rs903501	chr17:37839493	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-14.27	-0.55	1.5e-38	Asthma;
LGG	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.72	0.3	5.25e-11	Bipolar disorder;
LGG	cis	rs4760636	0.512	rs12809264	chr12:48013316	T/C	cg12761788	chr12:48120090	P11	0.48	7.67	0.34	1.03e-13	Urate levels;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14893161	chr1:205819251	PM20D1	0.88	20.41	0.69	1.63e-66	Menarche (age at onset);
LGG	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg13256891	chr4:100009986	ADH5	0.57	9.92	0.42	3.8e-21	Alcohol dependence;
LGG	cis	rs4629710	0.592	rs67399092	chr6:131582936	G/A	cg12606694	chr6:131520996	AKAP7	0.52	8.51	0.37	2.51e-16	Multiple myeloma (IgH translocation);
LGG	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21659725	chr3:3221576	CRBN	-0.64	-10.29	-0.43	1.71e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg14926445	chr8:58193284	C8orf71	-0.72	-8.56	-0.37	1.73e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg17971929	chr21:40555470	PSMG1	0.85	16.54	0.61	1.34e-48	Cognitive function;
LGG	cis	rs3767633	0.925	rs4656335	chr1:161822078	A/G	cg09175582	chr1:161736000	ATF6	0.73	8.92	0.38	1.07e-17	IgG glycosylation;
LGG	cis	rs11203032	0.831	rs11203018	chr10:90948783	T/C	cg16672925	chr10:90967113	CH25H	0.77	11.08	0.46	1.8e-25	Heart failure;
LGG	cis	rs7766436	0.553	rs72833230	chr6:22618417	T/A	cg13666174	chr6:22585274	NA	-0.4	-7.15	-0.32	3.51e-12	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg00551146	chr10:14014579	FRMD4A	0.3	7.22	0.32	2.21e-12	Adiponectin levels;
LGG	cis	rs1318772	1.000	rs182988	chr5:112813566	T/A	cg12552261	chr5:112820674	MCC	-0.68	-8.13	-0.35	3.88e-15	F-cell distribution;
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs9515201	0.627	rs11838637	chr13:111029923	G/A	cg06243866	chr13:111019493	COL4A2	-0.7	-13.54	-0.53	2.01e-35	White matter hyperintensity burden;
LGG	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg21926883	chr2:100939477	LONRF2	-0.59	-12.34	-0.5	1.92e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2952156	0.920	rs1565920	chr17:37831613	G/A	cg00129232	chr17:37814104	STARD3	-0.75	-16.24	-0.6	2.94e-47	Asthma;
LGG	cis	rs1062177	0.724	rs2915828	chr5:151118121	G/A	cg00977110	chr5:151150581	G3BP1	-0.47	-7.46	-0.33	4.27e-13	Preschool internalizing problems;
LGG	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg19761014	chr17:28927070	LRRC37B2	0.58	6.93	0.31	1.38e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2692947	0.644	rs1030864	chr2:96822373	A/G	cg22654517	chr2:96458247	NA	0.37	7.47	0.33	3.91e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg08297393	chr2:100937505	LONRF2	0.54	10.08	0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.933	rs980573	chr12:39127811	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs9636252	0.847	rs13415264	chr2:9267564	T/C	cg20341998	chr2:9276514	NA	0.38	7.2	0.32	2.46e-12	IgG glycosylation;
LGG	trans	rs3857536	0.813	rs9294688	chr6:66945904	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.37	-0.32	7.65e-13	Bipolar disorder;
LGG	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.64	-0.37	9.51e-17	Lung cancer;
LGG	cis	rs6445975	0.915	rs11130633	chr3:58370792	A/G	cg24175188	chr3:58374923	PXK	-0.47	-8.45	-0.37	3.84e-16	Systemic lupus erythematosus;
LGG	cis	rs8017423	0.900	rs11625870	chr14:90693396	C/T	cg04374321	chr14:90722782	PSMC1	-0.91	-18.81	-0.66	4.66e-59	Mortality in heart failure;
LGG	trans	rs73198271	0.920	rs11781542	chr8:8617181	G/T	cg16141378	chr3:129829833	LOC729375	0.38	7.03	0.31	7.49e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs4942242	0.663	rs9525817	chr13:44225189	C/T	cg19169023	chr15:41853346	TYRO3	0.46	9.05	0.39	3.97e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs800082	1.000	rs7613909	chr3:144308606	A/G	cg24215973	chr2:240111563	HDAC4	0.5	8.86	0.38	1.73e-17	Smoking behavior;
LGG	cis	rs782590	0.967	rs782588	chr2:55841640	T/C	cg18811423	chr2:55921094	PNPT1	0.88	20.33	0.69	3.81e-66	Metabolic syndrome;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05575046	chr16:58163367	C16orf80	-0.39	-6.73	-0.3	5.11e-11	Brain structure;
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.1	-0.31	4.57e-12	Aortic root size;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg18379455	chr17:41446167	NA	-0.31	-7.05	-0.31	6.44e-12	Menopause (age at onset);
LGG	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg26811252	chr16:29126840	RRN3P2	0.69	11.01	0.46	3.38e-25	Menopause (age at onset);
LGG	trans	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg06521331	chr12:34319734	NA	-0.41	-7.12	-0.31	4.24e-12	Heart rate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26521562	chr19:41732468	AXL	0.36	6.66	0.3	7.62e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4787491	0.729	rs4238960	chr16:30038648	G/C	cg06326092	chr16:30034487	C16orf92	0.42	8.45	0.37	3.73e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.69e-15	Retinal vascular caliber;
LGG	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg13010199	chr12:38710504	ALG10B	0.6	11.86	0.48	1.66e-28	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg08250081	chr4:10125330	NA	-0.48	-9.49	-0.4	1.23e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.0	-0.39	5.95e-18	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg07148914	chr20:33460835	GGT7	0.41	6.73	0.3	5.01e-11	Coronary artery disease;
LGG	cis	rs9467711	0.559	rs3799383	chr6:26510748	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	8.99	0.39	6.55e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7681423	1.000	rs7654093	chr4:155545072	A/T	cg20735720	chr4:155535218	FGG	-0.56	-10.39	-0.43	6.96e-23	Fibrinogen;
LGG	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg14675211	chr2:100938903	LONRF2	0.5	8.2	0.36	2.46e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg01864069	chr14:103024347	NA	-0.73	-12.15	-0.49	1.17e-29	Platelet count;
LGG	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.02e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs3779273	0.965	rs3779274	chr7:77828739	G/A	cg05596911	chr5:118502651	DMXL1	0.44	9.28	0.4	6.73e-19	Body mass index;
LGG	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg20026190	chr17:76395443	PGS1	0.57	10.08	0.42	9.6e-22	HDL cholesterol levels;
LGG	cis	rs727505	1.000	rs28844358	chr7:124562695	A/C	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg05084668	chr3:125655381	ALG1L	-1.06	-11.97	-0.49	6.17e-29	Blood pressure (smoking interaction);
LGG	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-6.94	-0.31	1.32e-11	Crohn's disease;
LGG	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg04851639	chr8:1020857	NA	-0.32	-6.79	-0.3	3.36e-11	Schizophrenia;
LGG	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg05535760	chr7:792225	HEATR2	-0.77	-10.87	-0.45	1.1e-24	Cerebrospinal P-tau181p levels;
LGG	cis	rs17776563	0.593	rs11635389	chr15:89140294	G/A	cg05013243	chr15:89149849	MIR1179	-0.34	-7.07	-0.31	5.84e-12	Thyroid hormone levels;
LGG	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-9.01	-0.39	5.47e-18	Aortic root size;
LGG	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg02153584	chr22:29168773	CCDC117	0.6	9.5	0.4	1.14e-19	Lymphocyte counts;
LGG	cis	rs9457247	1.000	rs422694	chr6:167406074	G/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.29	-0.4	5.94e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg08807101	chr21:30365312	RNF160	0.77	13.9	0.54	5.71e-37	Selective IgA deficiency;
LGG	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	7.55	0.33	2.28e-13	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg13009111	chr11:71350975	NA	-0.33	-7.23	-0.32	1.95e-12	Monocyte count;
LGG	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg00277334	chr10:82204260	NA	-0.35	-7.71	-0.34	7.74e-14	Post bronchodilator FEV1;
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg04450456	chr4:17643702	FAM184B	0.32	6.94	0.31	1.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg12292205	chr6:26970375	C6orf41	0.73	14.22	0.55	2.36e-38	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10186029	0.708	rs4672673	chr2:213981463	A/G	cg08319019	chr2:214017104	IKZF2	0.46	8.04	0.35	7.32e-15	Systemic sclerosis;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.26	-0.52	2.92e-34	Alzheimer's disease;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.24	0.55	2.05e-38	Obesity-related traits;
LGG	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg05484508	chr16:89589025	SPG7	0.42	6.78	0.3	3.66e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg08470875	chr2:26401718	FAM59B	-0.39	-7.62	-0.33	1.45e-13	Gut microbiome composition (summer);
LGG	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg18357526	chr6:26021779	HIST1H4A	0.89	17.16	0.62	1.93e-51	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.46	7.38	0.32	7.45e-13	Height;
LGG	cis	rs2013441	0.965	rs2703820	chr17:20121479	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.5	-0.4	1.15e-19	Obesity-related traits;
LGG	trans	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.82	-0.34	3.71e-14	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10828337	chr14:29236476	FOXG1	0.41	6.87	0.3	2.08e-11	Cognitive performance;
LGG	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg13009111	chr11:71350975	NA	-0.34	-7.48	-0.33	3.66e-13	Monocyte count;
LGG	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg25019033	chr10:957182	NA	-0.49	-9.19	-0.39	1.31e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.4	-0.36	5.39e-16	Bone mineral density;
LGG	cis	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg06521331	chr12:34319734	NA	0.43	7.62	0.33	1.49e-13	Morning vs. evening chronotype;
LGG	cis	rs9796	0.621	rs2899013	chr15:41492283	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.74	-0.41	1.64e-20	Menopause (age at onset);
LGG	cis	rs700590	0.532	rs17558396	chr5:88102281	T/G	cg22951263	chr5:87985283	NA	-0.42	-7.55	-0.33	2.27e-13	Educational attainment (years of education);
LGG	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg20991723	chr1:152506922	NA	-0.73	-14.73	-0.56	1.55e-40	Hair morphology;
LGG	trans	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg23484912	chr5:273055	PDCD6	-0.4	-7.93	-0.35	1.66e-14	Mean corpuscular volume;
LGG	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.05	0.49	2.92e-29	Height;
LGG	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg08733933	chr1:2954429	NA	-0.39	-8.67	-0.37	7.5e-17	Plateletcrit;
LGG	cis	rs2067615	0.542	rs4964184	chr12:107070425	A/T	cg15890332	chr12:107067104	RFX4	0.44	12.82	0.51	2.05e-32	Heart rate;
LGG	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.67	-0.34	1.02e-13	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.13	-0.6	9.48e-47	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21862992	chr11:68658383	NA	0.5	8.44	0.37	4.12e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.66	0.44	7.01e-24	Personality dimensions;
LGG	trans	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg20290983	chr6:43655470	MRPS18A	1.12	24.95	0.76	1.02e-87	IgG glycosylation;
LGG	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg12654349	chr5:56205094	C5orf35	-0.63	-9.81	-0.41	9.25e-21	Initial pursuit acceleration;
LGG	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg00343986	chr7:65444356	GUSB	0.4	6.72	0.3	5.21e-11	Aortic root size;
LGG	cis	rs2594989	0.895	rs2594980	chr3:11381387	C/T	cg01796438	chr3:11312864	ATG7	-0.43	-6.74	-0.3	4.69e-11	Circulating chemerin levels;
LGG	cis	rs6594713	0.570	rs35926701	chr5:112898969	A/G	cg12552261	chr5:112820674	MCC	0.64	7.87	0.34	2.54e-14	Brain cytoarchitecture;
LGG	cis	rs1707322	0.686	rs2991986	chr1:46081282	A/G	cg03146154	chr1:46216737	IPP	-0.57	-11.02	-0.46	3.18e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg11764359	chr7:65958608	NA	-0.79	-14.76	-0.57	1.1e-40	Aortic root size;
LGG	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	8.2	0.36	2.32e-15	Schizophrenia;
LGG	cis	rs4820539	0.966	rs5996470	chr22:23483255	G/A	cg21100191	chr22:23484243	RTDR1	1.02	24.74	0.75	9.64e-87	Bone mineral density;
LGG	cis	rs12618769	0.597	rs17446058	chr2:99164160	A/G	cg18455616	chr2:99124870	INPP4A	0.24	6.85	0.3	2.39e-11	Bipolar disorder;
LGG	cis	rs787274	0.543	rs10739377	chr9:115631598	A/G	cg13803584	chr9:115635662	SNX30	0.65	9.93	0.42	3.42e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7432375	0.901	rs4521165	chr3:136369710	T/C	cg21827317	chr3:136751795	NA	-0.47	-8.55	-0.37	1.76e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.49	-0.4	1.2e-19	Retinal vascular caliber;
LGG	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg26384229	chr12:38710491	ALG10B	0.7	14.34	0.55	7.42e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.18	-0.32	2.78e-12	Triglycerides;
LGG	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	7.98	0.35	1.14e-14	Menarche (age at onset);
LGG	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg13385794	chr1:248469461	NA	0.46	7.77	0.34	5.06e-14	Common traits (Other);
LGG	cis	rs988958	0.675	rs7597889	chr2:42220091	T/C	cg27428208	chr2:42229179	NA	0.52	9.15	0.39	1.87e-18	Hypospadias;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07677032	chr17:61819896	STRADA	0.67	12.52	0.5	3.45e-31	Prudent dietary pattern;
LGG	trans	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.71	-0.51	5.79e-32	Obesity-related traits;
LGG	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs4743820	0.651	rs73494914	chr9:93923108	G/A	cg14446406	chr9:93919335	NA	-0.91	-15.45	-0.58	1e-43	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg15145296	chr3:125709740	NA	-0.6	-7.75	-0.34	5.96e-14	Blood pressure (smoking interaction);
LGG	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.66	11.32	0.47	2.17e-26	Parkinson's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21885650	chr3:186284968	TBCCD1	0.43	7.12	0.31	4.16e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg04490037	chr7:50633773	DDC	0.32	7.04	0.31	7.2e-12	Systemic sclerosis;
LGG	cis	rs13418717	0.793	rs3795874	chr2:127656383	A/G	cg25501666	chr2:127640322	NA	1.23	9.31	0.4	5.28e-19	Heart failure;
LGG	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9457247	1.000	rs389946	chr6:167407268	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs36051895	0.632	rs72701654	chr9:5161453	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-13.69	-0.54	4.8e-36	Pediatric autoimmune diseases;
LGG	cis	rs9515201	0.859	rs9521735	chr13:111037328	G/C	cg06243866	chr13:111019493	COL4A2	-0.59	-11.08	-0.46	1.74e-25	White matter hyperintensity burden;
LGG	cis	rs240764	0.619	rs9399652	chr6:101120006	C/T	cg09795085	chr6:101329169	ASCC3	-0.4	-6.65	-0.3	8.09e-11	Neuroticism;
LGG	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22022881	chr2:105853494	NA	-0.36	-7.49	-0.33	3.53e-13	Type 2 diabetes;
LGG	cis	rs4901847	0.716	rs10483696	chr14:58552645	G/A	cg15908186	chr14:58618357	C14orf37	0.41	7.1	0.31	4.75e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg18850127	chr7:39170497	POU6F2	0.63	16.07	0.6	1.72e-46	IgG glycosylation;
LGG	cis	rs35740288	0.520	rs56183577	chr15:86319706	A/G	cg04173714	chr15:86211321	AKAP13	0.44	7.22	0.32	2.15e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg02151108	chr14:50098012	C14orf104	-0.44	-9.21	-0.39	1.17e-18	Carotid intima media thickness;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg07511668	chr11:68622177	NA	0.51	9.86	0.42	6.01e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg17108064	chr15:78857060	CHRNA5	-0.44	-9.38	-0.4	3.02e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.71e-27	Schizophrenia;
LGG	cis	rs9790314	1.000	rs336589	chr3:161080358	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.11	-0.46	1.39e-25	Morning vs. evening chronotype;
LGG	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.8	0.64	2.2e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17767392	0.681	rs4902922	chr14:71688207	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.94	-0.31	1.3e-11	Mitral valve prolapse;
LGG	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg17644776	chr2:200775616	C2orf69	0.48	7.84	0.34	3.12e-14	QT interval;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs3857067	1.000	rs1588381	chr4:95017558	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.49	-0.33	3.53e-13	QT interval;
LGG	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.65	-0.51	1.03e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg10596483	chr8:143751796	JRK	-0.59	-9.52	-0.4	9.48e-20	Schizophrenia;
LGG	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.44	-0.4	1.83e-19	Triglycerides;
LGG	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.38	-0.32	7.61e-13	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23965022	chr3:183892590	AP2M1	0.45	6.88	0.3	1.94e-11	Gut microbiome composition (summer);
LGG	cis	rs1125355	0.690	rs62183016	chr2:159620530	T/C	cg02251393	chr2:159651559	DAPL1	0.42	8.21	0.36	2.18e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.7e-18	Motion sickness;
LGG	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.68	11.84	0.48	1.97e-28	Colorectal cancer;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.35	-0.47	1.59e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg06640241	chr16:89574553	SPG7	0.85	16.0	0.6	3.64e-46	Multiple myeloma (IgH translocation);
LGG	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.12	-0.31	4.17e-12	Hemoglobin concentration;
LGG	cis	rs4788570	0.566	rs72795881	chr16:71500229	A/G	cg06353428	chr16:71660113	MARVELD3	-1.02	-13.84	-0.54	1.05e-36	Intelligence (multi-trait analysis);
LGG	cis	rs732765	0.734	rs17183132	chr14:75153818	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.76	-0.3	4.16e-11	Non-small cell lung cancer;
LGG	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg09754948	chr16:28834200	ATXN2L	0.42	6.74	0.3	4.69e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg00571178	chr13:114841904	RASA3	-0.56	-10.11	-0.43	7.65e-22	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs73198271	0.562	rs76960788	chr8:8674049	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.0	0.35	9.92e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7928758	0.943	rs75842822	chr11:134265236	C/T	cg25213107	chr11:134282864	B3GAT1	1.19	14.23	0.55	2.21e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg23978390	chr7:1156363	C7orf50	0.49	7.84	0.34	3.11e-14	Bronchopulmonary dysplasia;
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg00495681	chr13:53174319	NA	0.75	15.37	0.58	2.35e-43	Lewy body disease;
LGG	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	trans	rs1997103	0.954	rs56030000	chr7:55405750	A/G	cg20935933	chr6:143382018	AIG1	0.56	8.84	0.38	2.04e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg15522984	chr1:182991683	LAMC1	0.49	10.08	0.42	9.76e-22	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.5e-77	Homoarginine levels;
LGG	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg21132104	chr15:45694354	SPATA5L1	0.7	10.41	0.44	5.98e-23	Homoarginine levels;
LGG	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg26384229	chr12:38710491	ALG10B	0.63	12.13	0.49	1.39e-29	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg22105103	chr4:187893119	NA	0.57	10.84	0.45	1.49e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg06115741	chr20:33292138	TP53INP2	0.56	9.0	0.39	5.86e-18	Coronary artery disease;
LGG	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg25457927	chr22:38595422	NA	-0.41	-9.61	-0.41	4.58e-20	Cutaneous nevi;
LGG	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.47	-0.5	5.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21862992	chr11:68658383	NA	0.5	8.35	0.36	7.85e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-14.09	-0.55	9.31e-38	Response to antipsychotic treatment;
LGG	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg13073564	chr4:8508604	NA	0.42	7.59	0.33	1.79e-13	Response to antineoplastic agents;
LGG	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg14228332	chr4:119757509	SEC24D	0.99	10.14	0.43	6.09e-22	Cannabis dependence symptom count;
LGG	cis	rs7737355	0.947	rs2021774	chr5:130920831	G/A	cg06307176	chr5:131281290	NA	0.55	9.14	0.39	1.99e-18	Life satisfaction;
LGG	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg08999081	chr20:33150536	PIGU	0.31	7.35	0.32	9.13e-13	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06185204	chr15:80351985	ZFAND6	0.46	7.35	0.32	9.04e-13	Gut microbiome composition (summer);
LGG	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg26384229	chr12:38710491	ALG10B	0.85	16.46	0.61	2.99e-48	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs2916247	0.909	rs11785983	chr8:93049466	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg02002194	chr4:3960332	NA	0.38	7.05	0.31	6.44e-12	Joint mobility (Beighton score);
LGG	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07570687	chr10:102243282	WNT8B	0.42	7.05	0.31	6.72e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.65	0.37	8.72e-17	Prudent dietary pattern;
LGG	cis	rs4849845	0.573	rs33971369	chr2:121024987	A/G	cg15425061	chr2:121036351	RALB	0.37	6.74	0.3	4.84e-11	Mean platelet volume;
LGG	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg21238619	chr17:78079768	GAA	-0.54	-10.3	-0.43	1.52e-22	Yeast infection;
LGG	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	cis	rs72925845	0.519	rs692632	chr17:76426627	T/A	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg11984989	chr7:158649758	WDR60	0.97	14.0	0.55	2.16e-37	Height;
LGG	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.26e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6665290	0.901	rs61834005	chr1:227202789	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.26	-42.04	-0.89	3.48e-160	Myeloid white cell count;
LGG	cis	rs6752107	1.000	rs6708373	chr2:234172846	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.61	0.53	9.84e-36	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.08e-23	Prudent dietary pattern;
LGG	cis	rs6558174	0.714	rs17674754	chr8:22533388	A/G	cg03733263	chr8:22462867	KIAA1967	0.62	9.09	0.39	2.85e-18	Breast cancer;
LGG	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg00599393	chr8:22457479	C8orf58	0.42	7.56	0.33	2.23e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg00938859	chr5:1591904	SDHAP3	0.89	13.16	0.52	7.66e-34	Breast cancer;
LGG	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg08847533	chr14:75593920	NEK9	-0.6	-11.51	-0.47	3.75e-27	Height;
LGG	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg06026331	chr20:60912101	LAMA5	0.37	6.83	0.3	2.68e-11	Colorectal cancer;
LGG	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg08085267	chr17:45401833	C17orf57	-0.62	-12.79	-0.51	2.69e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17253792	0.915	rs78089630	chr14:56178584	G/C	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs12431410	0.550	rs10136152	chr14:60196153	A/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.14	-0.31	3.65e-12	Schizophrenia;
LGG	cis	rs11608355	0.545	rs6606724	chr12:109905179	T/C	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07677032	chr17:61819896	STRADA	-0.67	-12.26	-0.49	4.23e-30	Prudent dietary pattern;
LGG	cis	rs209489	0.892	rs74705698	chr6:53171621	C/T	cg15607103	chr6:53167650	ELOVL5	0.72	9.01	0.39	5.41e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4595586	0.525	rs4768531	chr12:39417754	T/A	cg26384229	chr12:38710491	ALG10B	0.69	12.77	0.51	3.25e-32	Morning vs. evening chronotype;
LGG	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg20387954	chr3:183756860	HTR3D	0.57	10.75	0.45	3.24e-24	Anterior chamber depth;
LGG	cis	rs1550582	0.917	rs7831961	chr8:135507060	C/G	cg17885191	chr8:135476712	NA	-0.7	-11.89	-0.48	1.2e-28	Educational attainment;
LGG	cis	rs1595825	0.945	rs76877032	chr2:198840000	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.87	-0.3	2.1e-11	Ulcerative colitis;
LGG	cis	rs6835098	1.000	rs6835098	chr4:174089238	T/C	cg08422745	chr4:174089978	GALNT7	-0.87	-15.51	-0.58	5.32e-44	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg03606772	chr1:152487856	CRCT1	-0.29	-6.86	-0.3	2.15e-11	Hair morphology;
LGG	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	trans	rs877282	0.891	rs11253355	chr10:768367	C/G	cg22713356	chr15:30763199	NA	0.54	8.19	0.36	2.54e-15	Uric acid levels;
LGG	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs10979	1.000	rs9376763	chr6:143887386	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.47	-0.5	5.47e-31	Hypospadias;
LGG	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg13385794	chr1:248469461	NA	0.49	8.36	0.36	7.33e-16	Common traits (Other);
LGG	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg22875332	chr1:76189707	ACADM	-0.54	-8.44	-0.37	4.09e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4144743	1.000	rs2037150	chr17:45328718	G/A	cg18085866	chr17:45331354	ITGB3	-0.81	-9.67	-0.41	2.85e-20	Body mass index;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg04703951	chr17:43578652	NA	0.39	7.92	0.35	1.81e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs5769765	0.779	rs12170530	chr22:50318422	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.99	-0.52	4.18e-33	Schizophrenia;
LGG	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg06606381	chr12:133084897	FBRSL1	-1.27	-11.76	-0.48	4.24e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-13.93	-0.54	4.2e-37	Alzheimer's disease;
LGG	cis	rs74781061	0.860	rs4887150	chr15:74737024	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-6.97	-0.31	1.09e-11	Endometriosis;
LGG	cis	rs4660214	0.666	rs636156	chr1:39821737	A/G	cg18385671	chr1:39797026	MACF1	0.47	9.87	0.42	5.37e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4731207	0.596	rs1011722	chr7:124605207	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.6	0.37	1.26e-16	Oral cavity cancer;
LGG	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.55	-0.37	1.75e-16	Retinal vascular caliber;
LGG	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg24112000	chr20:60950667	NA	-0.37	-7.47	-0.33	3.89e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs12956009	0.518	rs71352652	chr18:44869536	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.32	0.32	1.1e-12	Educational attainment (years of education);
LGG	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg01028140	chr2:1542097	TPO	-0.54	-9.87	-0.42	5.57e-21	IgG glycosylation;
LGG	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg07777115	chr5:623756	CEP72	-0.56	-6.8	-0.3	3.31e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4764487	0.735	rs11612258	chr12:6360683	G/T	cg08284733	chr12:6341482	CD9	0.38	10.29	0.43	1.68e-22	Mean platelet volume;
LGG	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg12310025	chr6:25882481	NA	-0.46	-7.48	-0.33	3.74e-13	Iron status biomarkers;
LGG	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.39	-0.36	5.74e-16	Neuroticism;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.25	-0.32	1.7e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.36	-0.36	7.62e-16	Height;
LGG	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg21211680	chr2:198530	NA	-1.16	-18.8	-0.66	5.27e-59	Blood protein levels;
LGG	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.21	0.36	2.2e-15	HIV-1 control;
LGG	cis	rs12431410	0.550	rs10151833	chr14:60178934	A/C	cg07950296	chr14:60194823	RTN1	-0.39	-7.56	-0.33	2.11e-13	Schizophrenia;
LGG	cis	rs244731	0.919	rs12652509	chr5:176626441	A/G	cg17509989	chr5:176798049	RGS14	-0.59	-8.37	-0.36	6.9e-16	Urate levels in lean individuals;
LGG	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg26874164	chr19:58962979	ZNF324B	0.36	7.17	0.32	2.9e-12	Uric acid clearance;
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg11360546	chr7:1094263	C7orf50	-0.41	-7.37	-0.32	8.07e-13	Longevity;Endometriosis;
LGG	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg13647721	chr17:30228624	UTP6	0.63	7.87	0.34	2.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.812	rs30735	chr5:130709422	G/A	cg06307176	chr5:131281290	NA	-0.49	-8.21	-0.36	2.18e-15	Life satisfaction;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg18245976	chr7:158708271	WDR60	-0.56	-9.75	-0.41	1.55e-20	Height;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07308232	chr7:1071921	C7orf50	-0.56	-10.37	-0.43	8.65e-23	Longevity;Endometriosis;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg12070911	chr6:150209640	RAET1E	0.27	6.83	0.3	2.72e-11	Testicular germ cell tumor;
LGG	cis	rs1506636	1.000	rs676755	chr7:123439082	A/G	cg03229431	chr7:123269106	ASB15	-0.7	-16.55	-0.61	1.11e-48	Plateletcrit;Platelet count;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg03517284	chr6:25882590	NA	-0.38	-6.79	-0.3	3.53e-11	Height;
LGG	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.27	-0.4	7.12e-19	Mean corpuscular volume;
LGG	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg26396452	chr14:65542826	MAX	0.52	10.99	0.45	3.88e-25	Obesity-related traits;
LGG	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg01557791	chr16:72042693	DHODH	-0.46	-8.42	-0.36	4.71e-16	Fibrinogen levels;
LGG	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg01620082	chr3:125678407	NA	-1.08	-10.72	-0.45	4.18e-24	Depression;
LGG	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg18131467	chr2:239335373	ASB1	1.01	23.43	0.74	1.16e-80	Multiple system atrophy;
LGG	cis	rs259282	0.605	rs3760937	chr19:33106893	A/G	cg02997394	chr19:33096574	ANKRD27	-0.35	-6.69	-0.3	6.57e-11	Schizophrenia;
LGG	cis	rs9513627	1.000	rs73556165	chr13:100120317	C/T	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg22903471	chr2:27725779	GCKR	0.36	8.11	0.35	4.54e-15	Oral cavity cancer;
LGG	cis	rs10865541	0.869	rs4318418	chr2:3393289	A/C	cg13173536	chr2:3403300	TTC15	-0.33	-6.78	-0.3	3.75e-11	Obesity-related traits;
LGG	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.54	-0.37	1.93e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.18	-0.36	2.76e-15	Neuroticism;
LGG	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.63	-10.88	-0.45	1.1e-24	Mean platelet volume;
LGG	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6684428	1.000	rs12145137	chr1:56370557	A/T	cg11651538	chr1:56320950	NA	-0.75	-12.82	-0.51	2.04e-32	Airflow obstruction;
LGG	cis	rs79839061	0.610	rs11726280	chr4:864077	C/T	cg07828340	chr4:882639	GAK	0.89	9.41	0.4	2.31e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1335587	0.550	rs9518401	chr13:102082068	C/T	cg13538571	chr13:102108074	ITGBL1	0.35	6.75	0.3	4.53e-11	Obesity-related traits;
LGG	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	trans	rs4714291	0.832	rs2984431	chr6:39980900	T/A	cg02267698	chr19:7991119	CTXN1	-0.59	-9.48	-0.4	1.28e-19	Strep throat;
LGG	cis	rs6964587	0.610	rs4729008	chr7:91457054	G/T	cg17063962	chr7:91808500	NA	0.39	7.07	0.31	5.73e-12	Breast cancer;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg11062466	chr8:58055876	NA	0.48	8.08	0.35	5.82e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.75	0.34	5.9e-14	Educational attainment;
LGG	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg02175503	chr12:58329896	NA	0.48	7.62	0.33	1.42e-13	Multiple sclerosis;
LGG	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg15704280	chr7:45808275	SEPT13	0.78	9.03	0.39	4.79e-18	Axial length;
LGG	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg17971929	chr21:40555470	PSMG1	0.84	15.57	0.59	3.06e-44	Cognitive function;
LGG	cis	rs972578	1.000	rs2267482	chr22:43380548	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.82	-0.3	2.82e-11	Mean platelet volume;
LGG	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg07777115	chr5:623756	CEP72	-0.62	-7.75	-0.34	5.69e-14	Lung disease severity in cystic fibrosis;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.16	0.43	4.83e-22	Myopia (pathological);
LGG	cis	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg07460842	chr6:66804631	NA	0.57	9.44	0.4	1.84e-19	Metabolite levels;
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg22907277	chr7:1156413	C7orf50	0.77	10.89	0.45	9.66e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg16141378	chr3:129829833	LOC729375	0.43	10.14	0.43	5.91e-22	Mood instability;
LGG	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs721917	0.525	rs1054053	chr10:81682645	A/G	cg25562619	chr10:81652821	NA	-0.35	-7.92	-0.35	1.83e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.02	0.35	9.01e-15	Prudent dietary pattern;
LGG	cis	rs10991814	0.920	rs3827826	chr9:94030185	G/A	cg14446406	chr9:93919335	NA	-0.74	-8.29	-0.36	1.21e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg23034840	chr1:205782522	SLC41A1	0.53	8.65	0.37	8.69e-17	Menarche (age at onset);
LGG	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg05784532	chr1:230284198	GALNT2	0.52	9.23	0.39	9.66e-19	Coronary artery disease;
LGG	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.61	-0.41	4.75e-20	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs2371030	1.000	rs2371026	chr2:211565999	G/T	cg18417063	chr2:211583084	NA	-0.63	-12.23	-0.49	5.43e-30	Non-small cell lung cancer;
LGG	cis	rs6732160	0.574	rs1991612	chr2:73480501	G/C	cg01422370	chr2:73384389	NA	0.48	9.03	0.39	4.54e-18	Intelligence (multi-trait analysis);
LGG	cis	rs240768	0.511	rs61289570	chr6:101403098	C/T	cg12253828	chr6:101329408	ASCC3	1.12	9.68	0.41	2.62e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.95	-0.49	7.13e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg21427119	chr20:30132790	HM13	-0.58	-9.02	-0.39	5.15e-18	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg18551225	chr6:44695536	NA	-0.61	-10.03	-0.42	1.43e-21	Total body bone mineral density;
LGG	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-11.41	-0.47	9.43e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11683229	0.925	rs34781199	chr2:63481266	T/G	cg19915305	chr2:64069682	UGP2	-0.46	-6.98	-0.31	1.06e-11	Protein quantitative trait loci;
LGG	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg24623649	chr8:11872141	NA	-0.29	-6.96	-0.31	1.2e-11	Systolic blood pressure;
LGG	cis	rs986417	1.000	rs8004736	chr14:61053061	T/C	cg27398547	chr14:60952738	C14orf39	0.75	6.9	0.31	1.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg05491587	chr18:77659695	KCNG2	-0.41	-7.34	-0.32	9.52e-13	Schizophrenia;
LGG	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06108461	chr20:60628389	TAF4	-1.0	-20.0	-0.68	1.41e-64	Body mass index;
LGG	cis	rs9399135	0.933	rs4559100	chr6:135324085	T/C	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Red blood cell count;
LGG	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.41	-0.36	4.97e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.56	0.53	1.72e-35	Lung cancer;
LGG	cis	rs11700980	0.636	rs117634508	chr21:30224652	G/A	cg24692254	chr21:30365293	RNF160	-0.62	-7.14	-0.32	3.53e-12	QRS complex (12-leadsum);
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.24	-0.43	2.64e-22	Bipolar disorder;
LGG	cis	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg09307838	chr4:120376055	NA	0.64	10.31	0.43	1.45e-22	Corneal astigmatism;
LGG	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02498218	chr4:26361371	RBPJ	0.39	6.65	0.3	8.17e-11	Gut microbiome composition (summer);
LGG	cis	rs4474465	0.920	rs4945285	chr11:78221698	C/T	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.36e-11	Lung cancer;
LGG	cis	rs7586879	0.609	rs7608976	chr2:25075281	G/A	cg04586622	chr2:25135609	ADCY3	0.4	10.47	0.44	3.51e-23	Body mass index;
LGG	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg02891314	chr5:179741120	GFPT2	-0.58	-9.99	-0.42	2.09e-21	Height;
LGG	cis	rs758324	0.812	rs6893070	chr5:131237599	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.66	-0.37	8.05e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.49	-7.46	-0.33	4.34e-13	Parkinson's disease;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg05863683	chr7:1912471	MAD1L1	0.47	9.03	0.39	4.72e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs4262150	0.883	rs72802874	chr5:152240163	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.27	-0.5	3.53e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs459571	0.959	rs467379	chr9:136905474	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.85	-0.48	1.75e-28	Platelet distribution width;
LGG	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg18357526	chr6:26021779	HIST1H4A	0.56	9.68	0.41	2.73e-20	Blood metabolite levels;
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg17328964	chr8:145687451	CYHR1	0.61	11.26	0.46	3.52e-26	Age at first birth;
LGG	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg24397884	chr7:158709396	WDR60	1.1	16.42	0.61	4.35e-48	Height;
LGG	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg00206168	chr11:65308501	LTBP3	0.73	8.21	0.36	2.23e-15	Height;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.79	-0.45	2.23e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg06191203	chr2:152266755	RIF1	-0.48	-8.79	-0.38	3.05e-17	Lung cancer;
LGG	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs7639513	0.545	rs12714874	chr3:12719928	C/T	cg23032965	chr3:12705835	RAF1	0.73	11.72	0.48	5.99e-28	Itch intensity from mosquito bite;
LGG	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs2766692	0.788	rs2281892	chr14:100769938	G/A	cg14866419	chr14:100704911	YY1	0.54	8.4	0.36	5.35e-16	Electroencephalographic traits in alcoholism;
LGG	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.2	0.39	1.19e-18	Rheumatoid arthritis;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06873352	chr17:61820015	STRADA	0.73	13.78	0.54	1.94e-36	Prudent dietary pattern;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg14668632	chr7:2872130	GNA12	0.38	7.74	0.34	6.28e-14	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22195011	chr5:125759262	GRAMD3	-0.44	-6.87	-0.3	2.08e-11	Pancreatic cancer;
LGG	cis	rs910187	0.572	rs6018325	chr20:45810335	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.22	-0.39	1.09e-18	Migraine;
LGG	cis	rs7927771	0.931	rs12361256	chr11:47910823	A/C	cg20307385	chr11:47447363	PSMC3	-0.51	-9.17	-0.39	1.59e-18	Subjective well-being;
LGG	cis	rs1670533	1.000	rs6821725	chr4:1060360	C/G	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.4e-21	Recombination rate (females);
LGG	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg01043669	chr3:72786069	NA	0.42	7.04	0.31	6.82e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2916247	1.000	rs6992515	chr8:93042269	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	trans	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.68	-0.34	9.63e-14	Heart rate;
LGG	cis	rs9807989	0.507	rs2293224	chr2:103035779	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg15017067	chr4:17643749	FAM184B	-0.29	-6.65	-0.3	8.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.17	0.32	3.03e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14154082	chr13:112174009	NA	0.42	9.23	0.39	9.85e-19	Menarche (age at onset);
LGG	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg26384229	chr12:38710491	ALG10B	0.64	11.78	0.48	3.5e-28	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.55	-0.53	1.76e-35	Retinal vascular caliber;
LGG	cis	rs11645898	0.745	rs72787062	chr16:72105844	G/A	cg14768367	chr16:72042858	DHODH	-0.83	-11.25	-0.46	4.12e-26	Blood protein levels;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg09033563	chr22:24373618	LOC391322	0.52	8.52	0.37	2.2e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-8.32	-0.36	1.03e-15	Neuroticism;
LGG	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg21130718	chr4:1044621	NA	0.39	7.52	0.33	2.86e-13	Recombination rate (males);
LGG	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.98	0.54	2.68e-37	Colorectal cancer;
LGG	cis	rs10739695	0.548	rs2241167	chr9:130430116	A/G	cg13643465	chr9:130375613	STXBP1	0.5	8.63	0.37	9.55e-17	Monocyte percentage of white cells;
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg18446336	chr7:2847575	GNA12	-0.28	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs10193935	0.901	rs12622153	chr2:42598386	C/A	cg27598129	chr2:42591480	NA	-0.64	-9.66	-0.41	3.05e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg02187348	chr16:89574699	SPG7	0.52	7.95	0.35	1.45e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs2074585	0.839	rs11638780	chr15:91041896	G/T	cg22089800	chr15:90895588	ZNF774	-0.68	-12.65	-0.51	1.07e-31	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs72781680	0.898	rs72788212	chr2:24087385	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.34e-18	Lymphocyte counts;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg20607798	chr8:58055168	NA	0.57	6.87	0.3	2.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.78e-25	Aortic root size;
LGG	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg14541582	chr5:601475	NA	-0.7	-11.02	-0.46	3.05e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs4731207	0.698	rs4731214	chr7:124442905	A/G	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg04842962	chr6:43655489	MRPS18A	1.01	16.44	0.61	3.61e-48	IgG glycosylation;
LGG	cis	rs708547	0.874	rs1315006	chr4:57858193	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	9.74	0.41	1.61e-20	Response to bleomycin (chromatid breaks);
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1927790	0.727	rs7323056	chr13:96956200	C/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.96	-0.31	1.19e-11	Body mass index;
LGG	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.68	0.63	7.79e-54	Chronic sinus infection;
LGG	cis	rs2964802	0.505	rs7729989	chr5:10822246	A/G	cg14521931	chr5:10832172	NA	-0.74	-16.16	-0.6	6.57e-47	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.43	-0.44	4.94e-23	Bipolar disorder;
LGG	cis	rs2694528	0.544	rs6449481	chr5:59911179	G/C	cg11474532	chr5:59995715	DEPDC1B	0.84	8.51	0.37	2.46e-16	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12352820	chr6:13616043	NOL7	0.42	6.92	0.31	1.47e-11	Cognitive performance;
LGG	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.33	0.43	1.2e-22	Diabetic retinopathy;
LGG	cis	rs60695258	0.963	rs3775228	chr4:87985166	C/T	cg11209507	chr4:87813803	C4orf36	0.45	7.18	0.32	2.87e-12	Hematocrit;
LGG	trans	rs61931739	0.577	rs78671000	chr12:33648835	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-8.33	-0.36	9.57e-16	Morning vs. evening chronotype;
LGG	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.4	-0.36	5.4e-16	Restless legs syndrome;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16448525	chr5:92918072	FLJ42709;NR2F1	0.46	8.48	0.37	3.12e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.81	0.41	9.51e-21	Mean corpuscular volume;
LGG	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg00784671	chr22:46762841	CELSR1	-0.61	-7.26	-0.32	1.63e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg07636037	chr3:49044803	WDR6	0.54	7.32	0.32	1.07e-12	Menarche (age at onset);
LGG	cis	rs10865541	1.000	rs11692425	chr2:3395383	A/G	cg11642891	chr2:3452563	TTC15	-0.4	-7.7	-0.34	8.52e-14	Obesity-related traits;
LGG	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-10.61	-0.44	1.14e-23	Pancreatic cancer;
LGG	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs1519814	0.696	rs7386139	chr8:121027419	C/T	cg22335954	chr8:121166405	COL14A1	-0.48	-8.65	-0.37	8.28e-17	Breast cancer;
LGG	cis	rs1318772	0.932	rs7703186	chr5:112907867	C/A	cg12552261	chr5:112820674	MCC	0.68	7.7	0.34	8.16e-14	F-cell distribution;
LGG	cis	rs1185460	0.967	rs4454730	chr11:118937444	G/A	cg23280166	chr11:118938394	VPS11	0.61	11.3	0.47	2.5e-26	Coronary artery disease;
LGG	cis	rs185694	1.000	rs846495	chr13:30894250	T/C	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.67	-0.3	7.36e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3806843	0.900	rs2563286	chr5:140125199	T/A	cg19875535	chr5:140030758	IK	-0.54	-11.24	-0.46	4.55e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg08000102	chr2:233561755	GIGYF2	0.58	9.39	0.4	2.75e-19	Coronary artery disease;
LGG	trans	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.94	0.49	7.71e-29	Mean corpuscular volume;
LGG	cis	rs9596863	1.000	rs7318666	chr13:54418960	C/G	ch.13.53330881F	chr13:54432880	NA	-0.5	-7.12	-0.31	4.15e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg02903104	chr8:1507517	DLGAP2	0.32	6.7	0.3	5.89e-11	Lung cancer;
LGG	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg06640241	chr16:89574553	SPG7	0.85	15.36	0.58	2.57e-43	Multiple myeloma (IgH translocation);
LGG	cis	rs2688608	0.647	rs2633319	chr10:75691247	A/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.02	-0.31	7.79e-12	Inflammatory bowel disease;
LGG	cis	rs4959677	0.935	rs4355649	chr6:2492381	A/G	cg23817096	chr6:1620687	NA	-0.31	-7.27	-0.32	1.53e-12	Orthostatic hypotension;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10663408	chr7:130021651	CPA1	0.36	6.86	0.3	2.28e-11	Menarche (age at onset);
LGG	cis	rs2860975	0.542	rs1926705	chr10:96818418	C/T	cg09036531	chr10:96991505	NA	-0.49	-8.56	-0.37	1.69e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-12.94	-0.52	6.86e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.508	rs6666148	chr1:248402758	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-7.16	-0.32	3.23e-12	Common traits (Other);
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.7	-0.41	2.27e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	cis	rs2802728	0.881	rs56394517	chr1:243582753	A/G	cg05593162	chr1:243577377	SDCCAG8	0.51	6.91	0.31	1.61e-11	Toenail selenium levels;
LGG	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg08773314	chr2:239334832	ASB1	0.42	8.0	0.35	1.04e-14	Multiple system atrophy;
LGG	cis	rs2637030	0.559	rs376566	chr5:53005420	G/A	cg06476337	chr5:52856530	NDUFS4	0.44	6.84	0.3	2.56e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.31e-12	Refractive error;
LGG	cis	rs61906588	0.961	rs10891982	chr11:116357955	C/T	cg12564567	chr11:116371188	NA	-0.35	-7.04	-0.31	6.8e-12	Post bronchodilator FEV1 in COPD;
LGG	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06045225	chr5:65892993	MAST4	0.4	6.88	0.3	2.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.49	-9.15	-0.39	1.78e-18	Myopia;
LGG	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg13482628	chr17:19912719	NA	0.62	12.41	0.5	9.76e-31	Schizophrenia;
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.25	0.39	8.59e-19	Neuroticism;
LGG	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg02023728	chr11:77925099	USP35	0.45	7.99	0.35	1.08e-14	Testicular germ cell tumor;
LGG	trans	rs3858145	0.588	rs115455464	chr10:70038498	T/C	cg04882175	chr6:131122610	NA	-0.56	-8.0	-0.35	1.04e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg15485101	chr11:133734466	NA	0.61	10.68	0.44	6e-24	Childhood ear infection;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.43	0.56	3.03e-39	Tonsillectomy;
LGG	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg00976097	chr5:421733	AHRR	-0.43	-7.18	-0.32	2.83e-12	Cystic fibrosis severity;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.42	-0.36	4.76e-16	Personality dimensions;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25064146	chr11:111957872	TIMM8B;SDHD	-0.48	-7.07	-0.31	5.91e-12	Systemic lupus erythematosus;
LGG	cis	rs17428076	0.793	rs3765166	chr2:172693780	G/A	cg21435375	chr2:172878103	MAP1D	0.42	9.02	0.39	5e-18	Myopia;
LGG	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.28	0.4	6.75e-19	Diabetic retinopathy;
LGG	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg11362935	chr11:111250201	POU2AF1	0.31	7.05	0.31	6.53e-12	Primary biliary cholangitis;
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18252515	chr7:66147081	NA	0.41	6.89	0.31	1.79e-11	Aortic root size;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg14500267	chr11:67383377	NA	0.47	8.68	0.37	6.72e-17	Mean corpuscular volume;
LGG	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg07777115	chr5:623756	CEP72	-0.57	-7.22	-0.32	2.13e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.38e-16	Aortic root size;
LGG	cis	rs13394619	0.875	rs9287734	chr2:11724475	A/G	cg07314298	chr2:11723111	GREB1	-0.48	-9.85	-0.42	6.44e-21	Endometriosis;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	11.75	0.48	4.41e-28	Personality dimensions;
LGG	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg15627072	chr1:2432621	PLCH2	0.39	8.36	0.36	7.49e-16	Ulcerative colitis;
LGG	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg10621924	chr7:39171070	POU6F2	0.43	8.76	0.38	3.7e-17	IgG glycosylation;
LGG	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg21132104	chr15:45694354	SPATA5L1	-0.71	-10.19	-0.43	3.79e-22	Homoarginine levels;
LGG	cis	rs35661897	0.920	rs12463838	chr2:227310093	G/A	cg03426602	chr2:227312417	NA	-0.43	-6.94	-0.31	1.32e-11	Urinary tract infection frequency;
LGG	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs10884984	0.874	rs10884986	chr10:112277340	C/T	cg18756771	chr10:112261994	DUSP5	-0.65	-10.97	-0.45	4.7e-25	Facial morphology (factor 22);
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.34	-0.32	9.62e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg09873164	chr1:152488093	CRCT1	0.61	15.0	0.57	9.52e-42	Hair morphology;
LGG	cis	rs4595586	0.545	rs7308161	chr12:39363459	A/G	cg13010199	chr12:38710504	ALG10B	0.4	7.23	0.32	2.02e-12	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg13047869	chr3:10149882	C3orf24	0.57	9.65	0.41	3.34e-20	Alzheimer's disease;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg11584989	chr19:19387371	SF4	-0.39	-7.1	-0.31	4.81e-12	Tonsillectomy;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg26554054	chr8:600488	NA	1.05	10.89	0.45	9.94e-25	IgG glycosylation;
LGG	cis	rs6580649	0.843	rs3803184	chr12:48398002	G/C	cg24011408	chr12:48396354	COL2A1	0.66	8.29	0.36	1.23e-15	Lung cancer;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02071572	chr4:1403502	NA	0.4	6.91	0.31	1.66e-11	Longevity;
LGG	cis	rs41271473	0.607	rs6692032	chr1:228853984	G/C	cg00850481	chr1:228891306	NA	-0.53	-11.22	-0.46	5.46e-26	Chronic lymphocytic leukemia;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05025164	chr4:1340916	KIAA1530	0.64	12.02	0.49	3.61e-29	Longevity;
LGG	trans	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.38	-0.32	7.44e-13	Triglycerides;
LGG	cis	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.62	-0.41	4.41e-20	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg09264619	chr17:80180166	NA	-0.39	-7.77	-0.34	5.03e-14	Life satisfaction;
LGG	cis	rs4774899	0.752	rs2733177	chr15:57344581	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.95	-0.31	1.25e-11	Urinary tract infection frequency;
LGG	cis	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg19399532	chr1:178512495	C1orf220	-0.54	-10.87	-0.45	1.18e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7607369	0.609	rs13391398	chr2:219282429	A/G	cg10223061	chr2:219282414	VIL1	-0.34	-7.55	-0.33	2.42e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11890956	chr21:40555474	PSMG1	-0.73	-12.76	-0.51	3.76e-32	Menarche (age at onset);
LGG	cis	rs4730250	0.655	rs75243311	chr7:106890791	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.51	-0.44	2.58e-23	Osteoarthritis;
LGG	cis	rs35740288	0.571	rs11633790	chr15:86326370	G/A	cg04173714	chr15:86211321	AKAP13	0.44	7.14	0.32	3.57e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg05973401	chr12:123451056	ABCB9	0.44	7.47	0.33	4.01e-13	Platelet count;
LGG	cis	rs3740909	1.000	rs77611445	chr11:125883765	A/C	cg24940576	chr11:125904314	CDON	-0.46	-6.91	-0.31	1.65e-11	Blood protein levels;
LGG	cis	rs1957429	0.901	rs1957432	chr14:65352796	A/G	cg23373153	chr14:65346875	NA	0.99	13.49	0.53	3.27e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19524238	chr7:2802976	GNA12	0.33	8.03	0.35	8.16e-15	Height;
LGG	cis	rs1318772	1.000	rs421515	chr5:112808643	C/A	cg12552261	chr5:112820674	MCC	-0.71	-7.93	-0.35	1.69e-14	F-cell distribution;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.29e-28	Gout;Renal underexcretion gout;
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10802521	chr3:52805072	NEK4	0.42	7.37	0.32	7.73e-13	Bipolar disorder;
LGG	trans	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-9.52	-0.4	9.3e-20	Neuroticism;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-8.83	-0.38	2.15e-17	Renal function-related traits (BUN);
LGG	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.19	-0.32	2.55e-12	Mood instability;
LGG	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.31	0.32	1.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs9837602	0.507	rs6803204	chr3:99680874	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.02	-0.39	4.97e-18	Breast cancer;
LGG	cis	rs17122278	1.000	rs17842763	chr11:118454177	A/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14139511	chr9:86238119	C9orf103	0.42	6.65	0.3	8.19e-11	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.817	rs72888915	chr18:34521261	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg18131467	chr2:239335373	ASB1	-0.62	-6.68	-0.3	6.71e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25072359	chr17:41440525	NA	0.53	9.99	0.42	2.02e-21	Menopause (age at onset);
LGG	cis	rs12956009	0.583	rs11663646	chr18:44862895	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.41	-6.73	-0.3	4.91e-11	Educational attainment (years of education);
LGG	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.58	-0.33	1.86e-13	Initial pursuit acceleration;
LGG	cis	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg25173405	chr17:45401733	C17orf57	0.47	8.06	0.35	6.79e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs72772090	0.908	rs6864233	chr5:96044681	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.44	7.06	0.31	6e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07648498	chr16:89883185	FANCA	0.4	6.83	0.3	2.71e-11	Vitiligo;
LGG	cis	rs12519773	0.526	rs4264926	chr5:92518686	C/T	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg24375607	chr4:120327624	NA	0.66	10.98	0.45	4.53e-25	Corneal astigmatism;
LGG	trans	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.01e-18	Bladder cancer;
LGG	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg11871910	chr12:69753446	YEATS4	0.85	15.93	0.59	7.35e-46	Response to diuretic therapy;
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg06848047	chr4:90757629	SNCA	-0.4	-7.55	-0.33	2.32e-13	Dementia with Lewy bodies;
LGG	cis	rs151997	0.671	rs3991902	chr5:50203749	A/T	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg21435375	chr2:172878103	MAP1D	-0.33	-7.31	-0.32	1.19e-12	Schizophrenia;
LGG	cis	rs4713118	0.513	rs149897	chr6:28006650	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.46	-6.68	-0.3	7.04e-11	Parkinson's disease;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs780094	0.500	rs6760250	chr2:27812252	G/A	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.3	5.3e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	2e-82	Dental caries;
LGG	cis	rs9596863	0.898	rs68039282	chr13:54389435	C/A	ch.13.53330881F	chr13:54432880	NA	0.52	6.9	0.31	1.67e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg13736514	chr6:26305472	NA	-0.47	-9.38	-0.4	2.97e-19	Educational attainment;
LGG	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27532318	chr7:32358331	NA	0.88	8.55	0.37	1.85e-16	Body mass index;
LGG	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.42	0.4	2.07e-19	Longevity;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg02002194	chr4:3960332	NA	0.44	8.16	0.35	3.15e-15	Neuroticism;
LGG	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg04691961	chr3:161091175	C3orf57	-0.59	-13.39	-0.53	8.3e-35	Morning vs. evening chronotype;
LGG	cis	rs13053817	1.000	rs13055707	chr22:29851172	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.45	-6.83	-0.3	2.69e-11	Carotid atherosclerosis in HIV infection;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.5	0.37	2.71e-16	Neuroticism;
LGG	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg08125733	chr17:73851984	WBP2	-0.43	-7.03	-0.31	7.49e-12	White matter hyperintensity burden;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.05	-0.35	7.05e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6997458	0.813	rs3758078	chr8:86374664	A/G	cg02393479	chr8:86352350	CA3	-0.31	-6.87	-0.3	2.13e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg02524346	chr8:600233	NA	-1.33	-11.22	-0.46	5.24e-26	IgG glycosylation;
LGG	cis	rs11514810	1.000	rs7812242	chr7:1431747	C/T	cg01003211	chr7:1472830	NA	-0.6	-8.17	-0.36	2.88e-15	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg13010199	chr12:38710504	ALG10B	0.65	13.38	0.53	9.09e-35	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg02725872	chr8:58115012	NA	-1.03	-14.08	-0.55	9.84e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs2602381	0.599	rs2741047	chr2:234581654	A/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.65e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg12011299	chr4:100065546	ADH4	0.4	8.63	0.37	1.01e-16	Alcohol dependence;
LGG	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg25457927	chr22:38595422	NA	-0.32	-7.83	-0.34	3.36e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs8017423	0.967	rs11159956	chr14:90715890	C/T	cg04374321	chr14:90722782	PSMC1	-0.89	-19.05	-0.66	3.81e-60	Mortality in heart failure;
LGG	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.55	-0.44	1.82e-23	Hepatocellular carcinoma;
LGG	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg17467752	chr17:38218738	THRA	-0.45	-7.15	-0.32	3.49e-12	Self-reported allergy;
LGG	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	7.26e-22	Axial length;
LGG	cis	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.12	-0.35	4.41e-15	Triglycerides;
LGG	cis	rs9309473	0.904	rs62149783	chr2:73821384	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-7.95	-0.35	1.44e-14	Metabolite levels;
LGG	cis	rs61192259	0.659	rs9349087	chr6:38454433	A/G	cg07362130	chr6:38359646	BTBD9	-0.33	-7.09	-0.31	5.04e-12	Restless legs syndrome;
LGG	cis	rs4740619	0.619	rs4740631	chr9:16030126	G/C	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.91e-26	Body mass index;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg27532318	chr7:32358331	NA	0.65	6.88	0.3	1.92e-11	Body mass index;
LGG	cis	rs10751667	0.643	rs10751671	chr11:944479	T/G	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-6.99	-0.31	9.48e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs853679	0.517	rs9380065	chr6:28144751	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	8.61e-14	Depression;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.49	7.89	0.34	2.2e-14	Longevity;
LGG	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg21211680	chr2:198530	NA	1.27	21.96	0.71	8.89e-74	Blood protein levels;
LGG	cis	rs4363385	0.510	rs6673356	chr1:153041903	C/T	cg13444842	chr1:152974279	SPRR3	0.47	9.44	0.4	1.83e-19	Inflammatory skin disease;
LGG	trans	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.52e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs988958	0.567	rs13409420	chr2:42233150	C/T	cg27428208	chr2:42229179	NA	-0.5	-8.76	-0.38	3.65e-17	Hypospadias;
LGG	cis	rs10463316	0.823	rs7700340	chr5:150776320	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.14	-0.43	5.91e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs3206736	0.583	rs1649233	chr7:35000459	T/C	cg13400248	chr7:35225412	NA	0.53	9.15	0.39	1.79e-18	Diastolic blood pressure;
LGG	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.14	-0.32	3.53e-12	Pancreatic cancer;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg12862611	chr4:147443109	SLC10A7	0.47	6.79	0.3	3.49e-11	Breast cancer;
LGG	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg18850127	chr7:39170497	POU6F2	0.55	12.4	0.5	1.09e-30	IgG glycosylation;
LGG	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19171272	chr22:38449367	NA	0.41	6.96	0.31	1.17e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12519773	0.501	rs4293897	chr5:92500822	T/G	cg18783429	chr5:92414398	NA	0.31	7.49	0.33	3.4e-13	Migraine;
LGG	cis	rs12479064	0.694	rs1823569	chr2:100113764	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.48	-0.44	3.36e-23	Chronic sinus infection;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19717773	chr7:2847554	GNA12	-0.31	-6.7	-0.3	6.03e-11	Height;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09435090	chr4:17513980	QDPR	-0.4	-6.82	-0.3	2.86e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg06558623	chr16:89946397	TCF25	1.07	11.27	0.46	3.25e-26	Skin colour saturation;
LGG	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.29e-11	Cognitive ability;
LGG	cis	rs2798269	1.000	rs12428749	chr13:22097630	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.02	-0.31	7.74e-12	PR segment;
LGG	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg09307838	chr4:120376055	NA	0.73	12.58	0.5	1.99e-31	Corneal astigmatism;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	trans	rs1422110	0.543	rs10035841	chr5:85419597	T/C	cg01787110	chr1:109008453	NBPF6	0.79	13.46	0.53	4.49e-35	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg23762105	chr12:34175262	ALG10	-0.34	-6.89	-0.3	1.86e-11	Morning vs. evening chronotype;
LGG	cis	rs12134245	0.874	rs35115044	chr1:92021650	A/G	cg25838465	chr1:92012736	NA	-0.41	-7.49	-0.33	3.63e-13	Breast cancer;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg10150615	chr22:24372951	LOC391322	-0.41	-6.98	-0.31	1.01e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg03929089	chr4:120376271	NA	0.73	7.82	0.34	3.67e-14	Axial length;
LGG	cis	rs10979	0.557	rs9390120	chr6:143909411	A/G	cg25407410	chr6:143891975	LOC285740	-0.56	-8.24	-0.36	1.8e-15	Hypospadias;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11905131	chr22:24372483	LOC391322	-0.45	-7.7	-0.34	8.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7712401	0.601	rs385547	chr5:122321833	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	trans	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.25	0.49	4.56e-30	Mean corpuscular volume;
LGG	trans	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.12	-0.31	4.18e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7939886	0.920	rs74962317	chr11:56036589	C/T	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs7923452	1.000	rs7923452	chr10:30751171	T/C	cg25182066	chr10:30743637	MAP3K8	0.46	7.23	0.32	1.99e-12	Itch intensity from mosquito bite;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.65	0.54	6.72e-36	Lung cancer;
LGG	cis	rs7607369	0.648	rs7582193	chr2:219652532	T/C	cg01130898	chr2:219473002	PLCD4	0.41	6.86	0.3	2.17e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.42	-8.19	-0.36	2.61e-15	Schizophrenia;
LGG	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg20891558	chr2:74357851	NA	0.45	8.18	0.36	2.79e-15	Gestational age at birth (maternal effect);
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg09699651	chr6:150184138	LRP11	0.47	8.34	0.36	8.47e-16	Lung cancer;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg19182353	chr11:118479428	PHLDB1	0.57	11.24	0.46	4.22e-26	Cholesterol, total;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg14926445	chr8:58193284	C8orf71	-0.73	-9.19	-0.39	1.33e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.55	0.59	3.66e-44	Headache;
LGG	cis	rs243505	0.767	rs243518	chr7:148425028	A/G	cg18940274	chr7:148469757	CUL1	0.37	7.01	0.31	8.54e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg22358067	chr17:16797159	NA	-0.47	-6.7	-0.3	6.13e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.11	-0.43	7.71e-22	Response to antipsychotic treatment;
LGG	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs4363385	0.719	rs2066005	chr1:152923113	G/C	cg13444842	chr1:152974279	SPRR3	-0.4	-7.42	-0.33	5.53e-13	Inflammatory skin disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21740146	chr1:247171252	ZNF695	0.4	7.33	0.32	1.05e-12	Cognitive performance;
LGG	cis	rs10876993	0.928	rs1689587	chr12:58075398	A/G	cg18357645	chr12:58087776	OS9	0.71	13.07	0.52	1.9e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg24006582	chr15:45444508	DUOX1	0.66	12.25	0.49	4.4e-30	Uric acid levels;
LGG	cis	rs422249	0.512	rs174566	chr11:61592362	A/G	cg19610905	chr11:61596333	FADS2	-0.78	-14.18	-0.55	3.72e-38	Trans fatty acid levels;
LGG	cis	rs11098499	0.954	rs6849171	chr4:120409549	G/A	cg09307838	chr4:120376055	NA	0.81	13.83	0.54	1.12e-36	Corneal astigmatism;
LGG	cis	rs4684776	1.000	rs2454490	chr3:11516534	T/A	cg24705426	chr3:11550659	ATG7	-0.47	-8.68	-0.37	6.7e-17	Small vessel stroke;
LGG	cis	rs36093844	0.752	rs7943104	chr11:85545180	A/C	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg22496339	chr2:162101262	NA	-0.53	-11.63	-0.48	1.34e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs7326068	0.647	rs2818978	chr13:21319537	C/G	cg04906043	chr13:21280425	IL17D	-0.5	-7.95	-0.35	1.44e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs35079168	0.661	rs3118529	chr9:137304915	C/T	cg00753924	chr9:137298813	RXRA	-0.47	-8.45	-0.37	3.78e-16	Intelligence;
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06634786	chr22:41940651	POLR3H	0.73	12.38	0.5	1.29e-30	Vitiligo;
LGG	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg21926883	chr2:100939477	LONRF2	-0.65	-15.21	-0.58	1.13e-42	Intelligence (multi-trait analysis);
LGG	cis	rs2408955	0.522	rs4760612	chr12:48421856	C/T	cg24011408	chr12:48396354	COL2A1	-0.6	-9.9	-0.42	4.31e-21	Glycated hemoglobin levels;
LGG	cis	rs1018836	0.923	rs4735260	chr8:91617157	C/G	cg16814680	chr8:91681699	NA	0.85	15.88	0.59	1.14e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg00071950	chr4:10020882	SLC2A9	0.35	6.91	0.31	1.64e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6904897	0.563	rs9321479	chr6:135233909	A/G	cg22676075	chr6:135203613	NA	-0.58	-10.45	-0.44	4.19e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	7.64	0.33	1.24e-13	HIV-1 control;
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg24375607	chr4:120327624	NA	0.55	8.28	0.36	1.35e-15	Corneal astigmatism;
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg26554054	chr8:600488	NA	-0.94	-9.91	-0.42	3.92e-21	IgG glycosylation;
LGG	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg24692254	chr21:30365293	RNF160	-0.87	-20.0	-0.68	1.32e-64	Dental caries;
LGG	cis	rs7572733	0.901	rs13011918	chr2:198779083	T/C	cg00792783	chr2:198669748	PLCL1	-0.48	-8.17	-0.35	3.03e-15	Dermatomyositis;
LGG	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg09021430	chr5:549028	NA	-0.75	-10.41	-0.44	5.88e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg22980697	chr10:16874865	CUBN	0.6	9.82	0.42	8.55e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg22433210	chr17:43662623	NA	-0.63	-10.96	-0.45	5.02e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11890956	chr21:40555474	PSMG1	-0.72	-12.47	-0.5	5.43e-31	Menarche (age at onset);
LGG	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.39	-7.18	-0.32	2.75e-12	Personality dimensions;
LGG	cis	rs3099143	1.000	rs3102709	chr15:77072260	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-10.28	-0.43	1.88e-22	Recalcitrant atopic dermatitis;
LGG	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.91	-0.78	1.05e-96	Height;
LGG	cis	rs490234	0.783	rs10986848	chr9:128461889	T/C	cg14078157	chr9:128172775	NA	-0.48	-8.39	-0.36	6.05e-16	Mean arterial pressure;
LGG	cis	rs36715	0.953	rs185177	chr5:127547810	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.66	0.34	1.13e-13	Breast cancer;
LGG	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg14675211	chr2:100938903	LONRF2	-0.6	-10.38	-0.43	8.08e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg07245641	chr1:182991651	LAMC1	0.41	9.27	0.4	7.34e-19	Hypertriglyceridemia;
LGG	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg06618935	chr21:46677482	NA	-0.52	-9.16	-0.39	1.62e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23752086	chr12:20522177	PDE3A	0.42	7.22	0.32	2.17e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg09427745	chr16:71932006	KIAA0174	-0.5	-7.29	-0.32	1.35e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.59	0.41	5.29e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19524238	chr7:2802976	GNA12	0.33	8.03	0.35	7.92e-15	Height;
LGG	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg16230307	chr14:35515116	FAM177A1	0.61	9.09	0.39	2.85e-18	Psoriasis;
LGG	cis	rs66569888	0.789	rs66826026	chr2:106732879	C/T	cg16099169	chr2:106886729	NA	-0.3	-6.65	-0.3	8.1e-11	Facial morphology (factor 23);
LGG	cis	rs2120243	0.539	rs35218020	chr3:157115416	G/A	cg24825693	chr3:157122686	VEPH1	-0.58	-13.56	-0.53	1.69e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	9.79	0.41	1.07e-20	Triglycerides;
LGG	cis	rs1867631	0.585	rs9787219	chr1:67080159	G/C	cg13052034	chr1:66999238	SGIP1	0.33	6.77	0.3	3.82e-11	Menopause (age at onset);
LGG	cis	rs1185460	1.000	rs7127212	chr11:118953202	A/G	cg23280166	chr11:118938394	VPS11	-0.53	-9.46	-0.4	1.59e-19	Coronary artery disease;
LGG	cis	rs8077889	0.672	rs2074143	chr17:41856622	A/G	cg26893861	chr17:41843967	DUSP3	1.07	24.7	0.75	1.5e-86	Triglycerides;
LGG	cis	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg07460842	chr6:66804631	NA	0.55	8.83	0.38	2.21e-17	Metabolite levels;
LGG	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-10.48	-0.44	3.29e-23	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.83	-0.38	2.24e-17	Bladder cancer;
LGG	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg16724585	chr3:197361211	NA	-0.48	-8.36	-0.36	7.52e-16	Pancreatic cancer;
LGG	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg13770153	chr20:60521292	NA	0.48	7.99	0.35	1.11e-14	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27211781	chr16:85045293	ZDHHC7	0.46	6.82	0.3	2.89e-11	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.45	0.53	4.96e-35	Breast cancer;
LGG	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06634786	chr22:41940651	POLR3H	0.75	11.91	0.48	1.03e-28	Vitiligo;
LGG	cis	rs3126085	0.935	rs7537637	chr1:152223335	T/A	cg26876637	chr1:152193138	HRNR	0.55	8.98	0.39	6.85e-18	Atopic dermatitis;
LGG	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg13647721	chr17:30228624	UTP6	0.63	8.23	0.36	1.94e-15	Hip circumference adjusted for BMI;
LGG	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.41	-7.32	-0.32	1.11e-12	Colorectal cancer;
LGG	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg16586182	chr3:47516702	SCAP	-0.77	-15.3	-0.58	4.73e-43	Colorectal cancer;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7945718	0.592	rs10765985	chr11:12676468	G/A	cg25843174	chr11:12811716	TEAD1	0.34	7.2	0.32	2.46e-12	Educational attainment (years of education);
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg13607699	chr17:42295918	UBTF	-0.56	-9.34	-0.4	4.05e-19	Total body bone mineral density;
LGG	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg05926928	chr17:57297772	GDPD1	1.25	18.45	0.65	2.29e-57	Opioid sensitivity;
LGG	cis	rs1894633	0.574	rs61806074	chr1:172311199	A/G	cg01573306	chr1:172330400	DNM3	-0.42	-7.37	-0.32	7.86e-13	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6598955	0.543	rs4585968	chr1:26535146	G/A	cg04990556	chr1:26633338	UBXN11	0.72	10.56	0.44	1.73e-23	Obesity-related traits;
LGG	cis	rs9658691	0.607	rs983751	chr10:90746693	A/C	cg03111039	chr10:90751583	FAS;ACTA2	0.93	10.01	0.42	1.75e-21	Mosquito bite size;
LGG	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg04455712	chr21:45112962	RRP1B	0.48	8.78	0.38	3.24e-17	Mean corpuscular volume;
LGG	cis	rs10979	1.000	rs10979	chr6:143890039	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.7	-0.41	2.16e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg08621203	chr6:150244597	RAET1G	0.45	7.67	0.34	1.03e-13	Lung cancer;
LGG	cis	rs13382275	0.632	rs13384065	chr2:940126	T/G	cg10902693	chr2:875509	NA	0.43	7.8	0.34	4.01e-14	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg08621203	chr6:150244597	RAET1G	0.4	6.82	0.3	2.84e-11	Lung cancer;
LGG	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24838063	chr12:130822603	PIWIL1	-0.7	-13.16	-0.52	7.63e-34	Menopause (age at onset);
LGG	cis	rs2067615	0.524	rs4964483	chr12:107099057	T/C	cg15890332	chr12:107067104	RFX4	0.44	12.96	0.52	5.61e-33	Heart rate;
LGG	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg03477792	chr4:77819574	ANKRD56	-0.52	-9.38	-0.4	2.94e-19	Emphysema distribution in smoking;
LGG	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.27	-0.55	1.49e-38	Platelet distribution width;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg04025307	chr7:1156635	C7orf50	0.81	14.75	0.57	1.17e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	15.02	0.57	8.33e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg23625390	chr15:77176239	SCAPER	-0.71	-14.32	-0.55	9.05e-39	Blood metabolite levels;
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	1.12	31.37	0.82	1.17e-116	Birth weight;
LGG	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04492929	chr16:2155436	PKD1	-0.54	-9.88	-0.42	4.96e-21	Metabolite levels (lipid measures);
LGG	cis	rs7119	0.717	rs12916682	chr15:77807937	A/T	cg10437265	chr15:77819839	NA	0.25	6.89	0.3	1.87e-11	Type 2 diabetes;
LGG	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.59	-0.41	5.63e-20	Body mass index;
LGG	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg13852791	chr20:30311386	BCL2L1	0.7	10.34	0.43	1.07e-22	Mean corpuscular hemoglobin;
LGG	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs67133203	0.632	rs829022	chr12:51374748	G/T	cg14688905	chr12:51403056	SLC11A2	-0.6	-10.31	-0.43	1.41e-22	Urinary tract infection frequency;
LGG	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg07777115	chr5:623756	CEP72	-0.61	-7.7	-0.34	8.51e-14	Obesity-related traits;
LGG	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.8	-0.34	4.05e-14	Blood metabolite levels;
LGG	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.17	0.32	3e-12	Systemic lupus erythematosus;
LGG	cis	rs6840360	0.615	rs6535816	chr4:152614264	T/C	cg22705602	chr4:152727874	NA	-0.4	-9.97	-0.42	2.34e-21	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	0.692	rs1822205	chr15:58284657	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.73	-0.3	4.96e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.45	0.33	4.75e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs55665837	1.000	rs11023223	chr11:14457112	A/G	cg19336497	chr11:14380999	RRAS2	-0.44	-8.72	-0.38	4.94e-17	Vitamin D levels;
LGG	cis	rs11969893	0.850	rs12664068	chr6:101362098	G/T	cg12253828	chr6:101329408	ASCC3	1.16	8.64	0.37	9.01e-17	Economic and political preferences (immigration/crime);
LGG	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg12011299	chr4:100065546	ADH4	0.41	7.97	0.35	1.23e-14	Alcohol dependence;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg23782820	chr8:58130467	NA	0.57	8.37	0.36	6.67e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg01620082	chr3:125678407	NA	-0.85	-9.41	-0.4	2.41e-19	Depression;
LGG	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg13147721	chr7:65941812	NA	-0.8	-9.15	-0.39	1.82e-18	Diabetic kidney disease;
LGG	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg13010199	chr12:38710504	ALG10B	0.56	11.12	0.46	1.24e-25	Heart rate;
LGG	cis	rs35771425	0.600	rs12752670	chr1:211530480	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.26	-0.36	1.52e-15	Educational attainment (years of education);
LGG	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs6708331	0.941	rs12989076	chr2:70403407	T/C	cg01613454	chr2:70366299	NA	0.53	9.31	0.4	5.06e-19	Obesity-related traits;
LGG	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.16	-0.35	3.28e-15	HDL cholesterol;
LGG	cis	rs55788414	0.932	rs12102293	chr16:81181607	T/C	cg06400318	chr16:81190750	PKD1L2	-0.79	-9.75	-0.41	1.5e-20	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.47	0.33	3.96e-13	Renal function-related traits (BUN);
LGG	cis	rs7224668	0.564	rs7223939	chr17:79241521	A/G	cg03823431	chr17:79229385	SLC38A10	0.39	8.31	0.36	1.07e-15	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg11062466	chr8:58055876	NA	0.46	7.57	0.33	2.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12980942	0.872	rs12976536	chr19:41799886	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.61	7.67	0.34	9.89e-14	Coronary artery disease;
LGG	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-11.9	-0.48	1.16e-28	Morning vs. evening chronotype;
LGG	cis	rs1783925	0.881	rs643446	chr11:125306472	T/C	cg03464685	chr11:125439445	EI24	-0.59	-9.38	-0.4	2.9e-19	Formal thought disorder in schizophrenia;
LGG	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03352830	chr11:487213	PTDSS2	0.85	10.77	0.45	2.72e-24	Body mass index;
LGG	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg18446336	chr7:2847575	GNA12	-0.32	-8.52	-0.37	2.22e-16	Height;
LGG	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg08847533	chr14:75593920	NEK9	-0.54	-9.83	-0.42	7.82e-21	Height;
LGG	cis	rs4740619	0.901	rs433849	chr9:15570319	C/T	cg14451791	chr9:16040625	NA	-0.32	-8.23	-0.36	1.93e-15	Body mass index;
LGG	cis	rs4478858	0.698	rs4949385	chr1:31793256	C/T	cg19084893	chr1:31688959	NA	0.31	6.71	0.3	5.76e-11	Alcohol dependence;
LGG	cis	rs7159888	0.727	rs11847263	chr14:65775695	A/C	cg15999311	chr14:65749247	NA	0.42	7.61	0.33	1.55e-13	IgG glycosylation;N-glycan levels;
LGG	cis	rs11018904	0.608	rs35700249	chr11:89931927	A/C	cg16626580	chr11:89713163	NA	-0.4	-6.67	-0.3	7.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4730250	0.707	rs4730222	chr7:106810293	G/C	cg02696742	chr7:106810147	HBP1	-0.84	-11.72	-0.48	5.69e-28	Osteoarthritis;
LGG	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.55e-15	Coronary artery disease;
LGG	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00204512	chr16:28754710	NA	0.25	6.92	0.31	1.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs68170813	0.559	rs11764448	chr7:106924928	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.54	-0.44	2e-23	Coronary artery disease;
LGG	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg11812906	chr14:75593930	NEK9	-0.53	-9.78	-0.41	1.14e-20	Height;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	9.97	0.42	2.35e-21	Longevity;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.24	0.84	1.06e-124	Prudent dietary pattern;
LGG	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.84	0.34	3.03e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs34421088	0.506	rs7813424	chr8:11144517	G/A	cg16141378	chr3:129829833	LOC729375	-0.31	-6.68	-0.3	6.98e-11	Neuroticism;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.58	-0.33	1.85e-13	Joint mobility (Beighton score);
LGG	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.0	-0.52	3.72e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg13206674	chr6:150067644	NUP43	0.59	12.7	0.51	6.45e-32	Lung cancer;
LGG	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.61	0.51	1.55e-31	IgG glycosylation;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs847851	0.917	rs6912327	chr6:34764922	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.48	-8.19	-0.36	2.63e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg02227867	chr8:22457446	C8orf58	-0.42	-7.9	-0.34	2.02e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9457247	0.508	rs2285147	chr6:167505548	G/A	cg07741184	chr6:167504864	NA	0.37	8.61	0.37	1.18e-16	Crohn's disease;
LGG	cis	rs10751667	0.666	rs4074233	chr11:977685	G/A	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs4417704	0.551	rs60677070	chr2:241900494	A/G	cg05025159	chr2:241905733	NA	0.52	10.38	0.43	7.8e-23	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21815882	chr7:26241064	CBX3;HNRNPA2B1	0.57	8.96	0.38	8.14e-18	Gut microbiome composition (summer);
LGG	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg00864171	chr11:67383662	NA	-0.41	-6.65	-0.3	8.07e-11	Mean corpuscular volume;
LGG	cis	rs7267979	0.966	rs2424714	chr20:25418681	T/G	cg06421707	chr20:25228305	PYGB	0.48	10.38	0.43	8.06e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs75804782	0.630	rs57435966	chr2:239311369	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	6.77	0.3	4.03e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.44	-0.33	5.08e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-9.6	-0.41	4.98e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.31	0.43	1.39e-22	Longevity;
LGG	cis	rs10791097	0.547	rs12365680	chr11:130749059	C/T	cg12179176	chr11:130786555	SNX19	0.88	17.97	0.64	3.6e-55	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.59	13.7	0.54	4.04e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10465746	0.967	rs4907191	chr1:84444165	A/G	cg10977910	chr1:84465055	TTLL7	-0.55	-10.3	-0.43	1.51e-22	Obesity-related traits;
LGG	cis	rs2486288	0.656	rs11639420	chr15:45559268	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.23	-0.43	2.7e-22	Glomerular filtration rate;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.38	-0.47	1.26e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05165339	chr4:1420672	NA	-0.35	-8.93	-0.38	1.04e-17	Longevity;
LGG	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	10.36	0.43	9.03e-23	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg19980929	chr12:42632907	YAF2	0.35	7.77	0.34	5.19e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg09324608	chr17:30823087	MYO1D	0.34	8.25	0.36	1.62e-15	Schizophrenia;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.51	-8.87	-0.38	1.6e-17	Obesity-related traits;
LGG	cis	rs8064024	0.599	rs882235	chr16:4931651	C/T	cg08329684	chr16:4932620	PPL	0.48	9.88	0.42	5.31e-21	Cancer;
LGG	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg08344181	chr3:125677491	NA	-0.45	-6.83	-0.3	2.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs571497	0.583	rs4804809	chr19:7835977	G/A	cg09310891	chr19:7854403	CLEC4GP1	0.61	7.14	0.32	3.53e-12	Monocyte count;
LGG	cis	rs7945718	0.905	rs6486032	chr11:12723693	G/A	cg25843174	chr11:12811716	TEAD1	0.39	7.87	0.34	2.46e-14	Educational attainment (years of education);
LGG	cis	rs1697139	0.501	rs16896422	chr5:66519431	G/A	cg11553311	chr5:66541588	NA	0.53	11.81	0.48	2.46e-28	Breast cancer;
LGG	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg02151108	chr14:50098012	C14orf104	-0.43	-9.16	-0.39	1.64e-18	Carotid intima media thickness;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.588	rs11158037	chr14:55832152	C/A	cg04306507	chr14:55594613	LGALS3	0.51	12.08	0.49	2.17e-29	Protein biomarker;
LGG	cis	rs4740619	0.745	rs10810485	chr9:15941175	T/A	cg14451791	chr9:16040625	NA	-0.39	-9.62	-0.41	4.44e-20	Body mass index;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.13	-0.46	1.19e-25	IgG glycosylation;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.88	-0.34	2.31e-14	Myopia (pathological);
LGG	cis	rs17767294	0.612	rs9461424	chr6:27919401	G/A	cg15325629	chr6:28072465	NA	0.73	7.23	0.32	2.03e-12	Parkinson's disease;
LGG	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg18681998	chr4:17616180	MED28	0.73	14.67	0.56	2.74e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1065852	0.526	rs8138080	chr22:42396371	A/G	cg15128208	chr22:42549153	NA	-0.43	-7.5	-0.33	3.31e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg26150922	chr2:100937072	LONRF2	-0.57	-9.84	-0.42	6.86e-21	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.64	-0.41	3.7799999999999997e-20	Neuroticism;
LGG	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.44	-0.44	4.54e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.52e-27	Personality dimensions;
LGG	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg04851639	chr8:1020857	NA	-0.33	-6.9	-0.31	1.72e-11	Schizophrenia;
LGG	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg03959625	chr15:84868606	LOC388152	0.55	8.6	0.37	1.22e-16	Schizophrenia;
LGG	cis	rs1256061	0.646	rs1152588	chr14:64688175	G/C	cg23250157	chr14:64679961	SYNE2	0.39	6.98	0.31	9.96e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs74781061	0.929	rs79534854	chr15:74786598	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.24	-0.36	1.84e-15	Total body bone mineral density;
LGG	cis	rs2370759	1.000	rs75984055	chr10:32591276	T/C	cg01819863	chr10:32635814	EPC1	1.12	15.72	0.59	6.19e-45	Sexual dysfunction (female);
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg13628971	chr7:2884303	GNA12	0.51	10.24	0.43	2.59e-22	Height;
LGG	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg12654349	chr5:56205094	C5orf35	0.41	7.33	0.32	1.02e-12	Coronary artery disease;
LGG	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.25	-0.49	4.36e-30	Cognitive function;
LGG	cis	rs3916	0.911	rs2239758	chr12:121162637	A/G	cg21892295	chr12:121157589	UNC119B	-0.42	-7.32	-0.32	1.1e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs6076065	0.963	rs6048797	chr20:23422621	G/A	cg11657817	chr20:23433608	CST11	0.38	7.54	0.33	2.44e-13	Facial morphology (factor 15, philtrum width);
LGG	trans	rs61931739	0.620	rs61927757	chr12:33710109	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-8.51	-0.37	2.39e-16	Morning vs. evening chronotype;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13076329	chr4:114682704	CAMK2D	0.61	7.24	0.32	1.92e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17433780	0.523	rs6701673	chr1:89525812	C/G	cg09516651	chr1:89888402	LOC400759	0.8	19.42	0.67	7.15e-62	Carotid intima media thickness;
LGG	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-12.82	-0.51	2.01e-32	Bladder cancer;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.61e-13	Lung cancer;
LGG	cis	rs10893109	0.517	rs10790609	chr11:123775334	T/C	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg03351412	chr1:154909251	PMVK	0.65	12.53	0.5	3.3e-31	Prostate cancer;
LGG	cis	rs4716602	0.862	rs10257343	chr7:156162378	A/G	cg16983916	chr7:156159713	NA	-0.38	-6.83	-0.3	2.74e-11	Anti-saccade response;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1801251	0.963	rs35395584	chr2:233573698	G/C	cg25237894	chr2:233734115	C2orf82	0.65	12.43	0.5	8.15e-31	Coronary artery disease;
LGG	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.3	0.32	1.29e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9807989	0.507	rs1833174	chr2:103034843	T/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg13385521	chr17:29058706	SUZ12P	0.69	8.18	0.36	2.83e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.74e-14	Neuroticism;
LGG	trans	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg18187862	chr3:45730750	SACM1L	-0.57	-9.57	-0.41	6.69e-20	Primary sclerosing cholangitis;
LGG	cis	rs2120243	0.874	rs2316708	chr3:157150299	G/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	6.93	0.31	1.37e-11	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs1497828	0.956	rs2646802	chr1:217522359	G/A	cg04411442	chr1:217543379	NA	-0.49	-8.18	-0.36	2.83e-15	Dialysis-related mortality;
LGG	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg13334819	chr7:99746414	C7orf59	-0.47	-7.32	-0.32	1.11e-12	Coronary artery disease;
LGG	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg03258749	chr1:151040405	MLLT11	-0.45	-8.04	-0.35	7.6e-15	Childhood ear infection;
LGG	cis	rs7937890	0.559	rs2597201	chr11:14485404	T/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs3806843	0.551	rs184996	chr5:140323773	T/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg12654349	chr5:56205094	C5orf35	-0.42	-7.51	-0.33	3.1e-13	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg04287289	chr16:89883240	FANCA	0.89	8.64	0.37	9.26e-17	Skin colour saturation;
LGG	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.64	-0.51	1.15e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11758351	0.500	rs76607472	chr6:26191557	C/T	cg01420254	chr6:26195488	NA	0.97	7.39	0.32	6.97e-13	Gout;Renal underexcretion gout;
LGG	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-7.58	-0.33	1.87e-13	Schizophrenia;
LGG	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.71	-0.41	2.12e-20	Height;
LGG	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg23752985	chr2:85803571	VAMP8	0.4	7.67	0.34	1.02e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6764363	0.527	rs13078683	chr3:275511	T/G	cg02057681	chr3:285234	CHL1	-0.44	-7.75	-0.34	5.93e-14	Sudden cardiac arrest;
LGG	cis	rs10754283	0.901	rs10922684	chr1:90117934	T/C	cg06121193	chr1:90282411	NA	-0.38	-7.26	-0.32	1.63e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7945718	0.840	rs10741601	chr11:12735873	T/C	cg25843174	chr11:12811716	TEAD1	0.42	8.46	0.37	3.42e-16	Educational attainment (years of education);
LGG	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.35	0.43	1.04e-22	Aortic root size;
LGG	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.19e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs2797160	1.000	rs1777226	chr6:126017691	C/A	cg05901451	chr6:126070800	HEY2	0.45	7.6	0.33	1.64e-13	Endometrial cancer;
LGG	cis	rs1127311	1.000	rs9427094	chr1:154557685	C/T	cg11650704	chr1:154556575	ADAR	-0.5	-9.91	-0.42	3.98e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg27446573	chr6:127587934	RNF146	1.13	22.33	0.72	1.64e-75	Breast cancer;
LGG	cis	rs7851660	0.809	rs10739526	chr9:100662671	T/C	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg26384229	chr12:38710491	ALG10B	0.93	20.93	0.7	6.32e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6456042	1.000	rs4343903	chr6:166539594	T/A	cg11088901	chr6:166572345	T	-0.35	-7.39	-0.32	6.77e-13	Asthma;
LGG	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.95	0.57	1.56e-41	Cognitive test performance;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg07511668	chr11:68622177	NA	0.51	9.79	0.41	1.05e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108043	0.511	rs34881728	chr4:87759088	G/C	cg11209507	chr4:87813803	C4orf36	0.62	8.08	0.35	5.88e-15	Red blood cell count;
LGG	trans	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg26043149	chr18:55253948	FECH	-0.48	-8.3	-0.36	1.17e-15	Bone mineral density;
LGG	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg04850017	chr11:63683019	RCOR2	0.3	7.67	0.34	1.04e-13	Pulse pressure;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg01238044	chr22:24384105	GSTT1	-0.54	-9.22	-0.39	1.04e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg22903471	chr2:27725779	GCKR	-0.57	-13.32	-0.53	1.73e-34	Total body bone mineral density;
LGG	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg09339527	chr5:178322752	ZFP2	-0.41	-7.31	-0.32	1.16e-12	Sleep duration;
LGG	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg26818010	chr10:134567672	INPP5A	-0.59	-9.47	-0.4	1.48e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg03806693	chr22:41940476	POLR3H	-0.9	-15.12	-0.57	2.93e-42	Vitiligo;
LGG	cis	rs870825	0.616	rs7678616	chr4:185648714	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	trans	rs2562456	0.833	rs11670815	chr19:21539317	T/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.6e-13	Pain;
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg13397359	chr6:42928475	GNMT	0.64	18.98	0.66	7.39e-60	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg19168338	chr16:4465731	CORO7	-0.98	-17.37	-0.63	2.08e-52	Schizophrenia;
LGG	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg24253500	chr15:84953950	NA	0.57	10.29	0.43	1.7e-22	Schizophrenia;
LGG	cis	rs6908034	0.607	rs75110577	chr6:19814523	C/T	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg21095983	chr6:86352623	SYNCRIP	0.61	11.38	0.47	1.24e-26	Smooth-surface caries;
LGG	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg15268244	chr15:77196840	NA	0.48	10.25	0.43	2.42e-22	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg08621203	chr6:150244597	RAET1G	0.47	8.22	0.36	2.12e-15	Lung cancer;
LGG	cis	rs6489785	0.775	rs1168954	chr12:121323985	C/T	cg02419362	chr12:121203948	SPPL3	0.44	6.82	0.3	2.81e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9436747	0.626	rs17412723	chr1:65952741	A/G	cg14976592	chr1:65886160	LEPROT;LEPR	-0.45	-7.68	-0.34	9.23e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.71	0.3	5.64e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24232171	chr10:81205543	ZCCHC24	0.45	7.24	0.32	1.94e-12	Gut microbiome composition (summer);
LGG	cis	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg06521331	chr12:34319734	NA	0.41	6.93	0.31	1.46e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg11871910	chr12:69753446	YEATS4	0.46	7.32	0.32	1.13e-12	Response to diuretic therapy;
LGG	trans	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.14	0.49	1.23e-29	Mean corpuscular volume;
LGG	cis	rs4704187	0.687	rs4447963	chr5:74376309	A/C	cg03227963	chr5:74354835	NA	0.31	6.72	0.3	5.21e-11	Response to amphetamines;
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg07460842	chr6:66804631	NA	-0.97	-18.02	-0.64	2.04e-55	Exhaled nitric oxide output;
LGG	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg09165964	chr15:75287851	SCAMP5	0.53	9.56	0.41	7.2e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6840360	0.681	rs9968292	chr4:152297368	T/C	cg17217059	chr4:152329364	FAM160A1	0.22	7.62	0.33	1.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	12.74	0.51	4.28e-32	Lung cancer in ever smokers;
LGG	cis	rs73086581	1.000	rs6052218	chr20:3970212	A/G	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	cis	rs1007190	1.000	rs3024275	chr17:43043353	G/C	cg15406952	chr17:42872593	NA	0.64	7.41	0.33	5.91e-13	DNA methylation (variation);
LGG	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs4679904	0.960	rs12630956	chr3:160207385	T/C	cg20378687	chr3:160281681	KPNA4	-0.35	-6.68	-0.3	6.7e-11	Primary biliary cholangitis;
LGG	cis	rs9972944	0.729	rs10083877	chr17:63773623	T/C	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs72781680	0.898	rs113522526	chr2:24018476	C/T	cg08917208	chr2:24149416	ATAD2B	0.78	8.84	0.38	2.02e-17	Lymphocyte counts;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs2858942	0.602	rs1211375	chr16:240280	G/T	cg08400316	chr16:204221	HBZ	-0.53	-8.55	-0.37	1.79e-16	Mean corpuscular hemoglobin;
LGG	cis	rs60180747	1.000	rs112981358	chr15:66653446	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.55	9.8	0.41	1.01e-20	Testicular germ cell tumor;
LGG	cis	rs11758351	0.660	rs1997768	chr6:26217728	C/T	cg23601095	chr6:26197514	HIST1H3D	-0.7	-8.89	-0.38	1.35e-17	Gout;Renal underexcretion gout;
LGG	cis	rs988958	0.958	rs13419707	chr2:42280927	C/T	cg27252766	chr2:42229092	NA	0.46	7.53	0.33	2.76e-13	Hypospadias;
LGG	cis	rs10504073	0.584	rs10957337	chr8:49959027	G/T	cg00325661	chr8:49890786	NA	0.78	15.34	0.58	3.15e-43	Blood metabolite ratios;
LGG	cis	rs17270561	1.000	rs79867288	chr6:25828416	A/G	cg16482183	chr6:26056742	HIST1H1C	0.79	11.08	0.46	1.82e-25	Iron status biomarkers;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg05313129	chr8:58192883	C8orf71	-0.61	-7.99	-0.35	1.09e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-9.98	-0.42	2.29e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9543976	0.623	rs8192764	chr13:76179215	G/C	cg01531495	chr13:76123901	UCHL3	0.51	6.67	0.3	7.46e-11	Diabetic retinopathy;
LGG	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg26656751	chr17:43910226	CRHR1	0.41	7.93	0.35	1.65e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2070488	0.896	rs11914389	chr3:38527215	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.86	0.64	1.2e-54	Electrocardiographic conduction measures;
LGG	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.29	38.91	0.88	4.96e-148	Chronic sinus infection;
LGG	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg20744362	chr22:50050164	C22orf34	0.38	7.45	0.33	4.77e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.32	0.43	1.35e-22	Motion sickness;
LGG	cis	rs2276314	0.802	rs4799838	chr18:33597530	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.72	0.41	1.97e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg15971980	chr6:150254442	NA	0.46	8.98	0.39	6.94e-18	Testicular germ cell tumor;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	9.69	0.41	2.47e-20	Personality dimensions;
LGG	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.94	-0.31	1.35e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3784262	0.631	rs4646625	chr15:58256296	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.12e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.02	0.52	2.99e-33	Obesity-related traits;
LGG	trans	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg25214090	chr10:38739885	LOC399744	0.57	10.37	0.43	8.75e-23	Corneal astigmatism;
LGG	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.57e-16	Neuroticism;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg11062466	chr8:58055876	NA	0.61	14.0	0.55	2.19e-37	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.748	rs57204407	chr14:71704261	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.25	-0.32	1.74e-12	Mitral valve prolapse;
LGG	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg19500275	chr17:80737654	TBCD	0.52	7.36	0.32	8.57e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9902453	0.967	rs9900911	chr17:28330280	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	8.1e-35	Coffee consumption (cups per day);
LGG	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg05444541	chr17:17804740	TOM1L2	-0.68	-16.25	-0.6	2.74e-47	Total body bone mineral density;
LGG	cis	rs1318772	0.800	rs17332053	chr5:112916596	A/G	cg12552261	chr5:112820674	MCC	-0.7	-7.47	-0.33	4.06e-13	F-cell distribution;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs8068544	0.818	rs7209012	chr17:40161323	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.45	-0.56	2.5e-39	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs2072732	0.861	rs72629498	chr1:2954203	C/T	cg08733933	chr1:2954429	NA	-0.42	-8.75	-0.38	4.05e-17	Plateletcrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17990871	chr1:1677678	SLC35E2	0.41	6.96	0.31	1.2e-11	Gut microbiome composition (summer);
LGG	cis	rs4731207	0.698	rs4731223	chr7:124483272	A/T	cg05630886	chr7:124431682	NA	0.34	7.99	0.35	1.11e-14	Cutaneous malignant melanoma;
LGG	cis	rs17689437	0.647	rs1177647	chr16:68603756	G/C	cg02972257	chr16:68554789	NA	-0.43	-7.19	-0.32	2.69e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs11229555	0.645	rs7117080	chr11:58178677	C/G	cg15696309	chr11:58395628	NA	-0.93	-15.14	-0.58	2.48e-42	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg23625390	chr15:77176239	SCAPER	-0.73	-14.66	-0.56	2.89e-40	Blood metabolite levels;
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.7	-0.48	7.24e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg25947184	chr8:1697459	NA	-0.42	-7.34	-0.32	9.51e-13	Systolic blood pressure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26354759	chr5:72861182	UTP15;ANKRA2	0.4	6.77	0.3	3.93e-11	Bipolar disorder;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs7937840	0.501	rs4963459	chr11:61877137	G/A	cg01969543	chr11:61895209	INCENP	-0.44	-9.26	-0.4	7.79e-19	Breast cancer;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg11062466	chr8:58055876	NA	0.71	9.82	0.42	8.23e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1904096	0.506	rs6841121	chr4:95222995	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.39	-0.47	1.1e-26	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.12e-34	Heart rate;
LGG	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg16583315	chr14:65563665	MAX	-0.36	-6.7	-0.3	5.93e-11	Obesity-related traits;
LGG	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.47	-0.33	4.05e-13	Height;
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	trans	rs11875185	0.510	rs4572490	chr18:55611497	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg10160682	chr2:1713001	PXDN	-0.54	-9.76	-0.41	1.37e-20	Response to antipsychotic treatment;
LGG	cis	rs4788570	0.566	rs16973112	chr16:71501274	T/C	cg06353428	chr16:71660113	MARVELD3	-1.02	-13.84	-0.54	1.05e-36	Intelligence (multi-trait analysis);
LGG	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg00850481	chr1:228891306	NA	-0.5	-8.64	-0.37	9.09e-17	Chronic lymphocytic leukemia;
LGG	cis	rs11885103	0.652	rs2724921	chr2:559020	T/C	cg21195176	chr2:593345	NA	0.39	7.2	0.32	2.38e-12	Heschl's gyrus morphology;
LGG	cis	rs6430585	0.528	rs309151	chr2:136661150	C/T	cg07169764	chr2:136633963	MCM6	1.22	22.35	0.72	1.4e-75	Corneal structure;
LGG	cis	rs2013441	1.000	rs2703787	chr17:20158665	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.24e-19	Obesity-related traits;
LGG	trans	rs1941687	0.764	rs1493918	chr18:31381845	C/G	cg27147174	chr7:100797783	AP1S1	-0.56	-9.45	-0.4	1.66e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67311347	0.544	rs13097602	chr3:40339247	T/C	cg13683864	chr3:40499215	RPL14	0.82	16.74	0.61	1.53e-49	Renal cell carcinoma;
LGG	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.74	-0.38	4.41e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.05	0.39	3.88e-18	Neuroticism;
LGG	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg09696939	chr10:60272079	BICC1	-0.36	-6.84	-0.3	2.52e-11	Refractive error;
LGG	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg20892847	chr12:58011875	NA	0.36	7.53	0.33	2.64e-13	Multiple sclerosis;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg23782820	chr8:58130467	NA	0.54	7.36	0.32	8.52e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	trans	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-12.94	-0.52	6.8e-33	Obesity-related traits;
LGG	cis	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg07460842	chr6:66804631	NA	0.96	17.9	0.64	7.68e-55	Exhaled nitric oxide output;
LGG	cis	rs1682825	0.615	rs350661	chr3:10779703	G/C	cg25137700	chr3:10780651	NA	-0.48	-6.79	-0.3	3.55e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg11360546	chr7:1094263	C7orf50	-0.39	-6.82	-0.3	2.78e-11	Longevity;Endometriosis;
LGG	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg20368463	chr18:77673604	PQLC1	0.57	7.47	0.33	3.89e-13	Opioid sensitivity;
LGG	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg25382214	chr1:3105252	PRDM16	0.4	7.21	0.32	2.25e-12	Migraine;
LGG	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	cg07245641	chr1:182991651	LAMC1	-0.41	-9.57	-0.41	6.49e-20	Colorectal cancer;
LGG	cis	rs17030434	0.784	rs17370965	chr4:154650948	C/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.5	-0.4	1.16e-19	Electrocardiographic conduction measures;
LGG	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00292662	chr22:38071168	LGALS1	0.65	14.83	0.57	5.52e-41	Fat distribution (HIV);
LGG	cis	rs8016982	1.000	rs8016982	chr14:81707057	C/T	cg01989461	chr14:81687754	GTF2A1	0.64	12.33	0.5	2.08e-30	Schizophrenia;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg01238044	chr22:24384105	GSTT1	-0.44	-7.36	-0.32	8.44e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs68170813	0.605	rs10464620	chr7:107135653	A/G	cg02696742	chr7:106810147	HBP1	0.73	9.94	0.42	3.02e-21	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg06916706	chr16:4465613	CORO7	-0.71	-12.09	-0.49	1.88e-29	Schizophrenia;
LGG	cis	rs17767392	0.595	rs17177822	chr14:71656209	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.21	-0.32	2.32e-12	Mitral valve prolapse;
LGG	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg00647317	chr7:50633725	DDC	0.38	9.11	0.39	2.41e-18	Systemic sclerosis;
LGG	cis	rs7917772	0.582	rs10786687	chr10:104336994	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg27432699	chr2:27873401	GPN1	-0.49	-8.62	-0.37	1.04e-16	Total body bone mineral density;
LGG	cis	rs9916302	0.904	rs4795359	chr17:37573146	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg21775007	chr8:11205619	TDH	0.49	8.11	0.35	4.61e-15	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06545950	chr7:155605005	SHH	0.47	6.72	0.3	5.27e-11	Gut microbiome composition (summer);
LGG	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg19680485	chr15:31195859	MTMR15	-0.44	-6.73	-0.3	5.18e-11	Huntington's disease progression;
LGG	cis	rs7169223	0.653	rs12905740	chr15:79082364	C/T	cg03762349	chr15:79060523	ADAMTS7	0.37	7.07	0.31	5.76e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg07701084	chr6:150067640	NUP43	0.69	13.44	0.53	5.49e-35	Lung cancer;
LGG	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg11752832	chr7:134001865	SLC35B4	0.69	12.81	0.51	2.22e-32	Mean platelet volume;
LGG	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg10503236	chr1:231470652	EXOC8	-0.36	-6.98	-0.31	1.05e-11	Hemoglobin concentration;
LGG	cis	rs10751667	0.666	rs6597957	chr11:982294	T/A	cg22143635	chr11:980567	AP2A2	0.44	7.93	0.35	1.72e-14	Alzheimer's disease (late onset);
LGG	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg11764359	chr7:65958608	NA	0.63	10.77	0.45	2.69e-24	Aortic root size;
LGG	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg07243736	chr16:783730	NARFL	0.66	11.09	0.46	1.65e-25	Height;
LGG	trans	rs3960554	0.709	rs73138006	chr7:75769990	T/C	cg19862616	chr7:65841803	NCRNA00174	0.86	12.52	0.5	3.51e-31	Eotaxin levels;
LGG	cis	rs2067615	0.560	rs12298717	chr12:107099883	C/T	cg15890332	chr12:107067104	RFX4	-0.41	-11.94	-0.49	7.92e-29	Heart rate;
LGG	trans	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg10756647	chr7:56101905	PSPH	0.8	9.44	0.4	1.83e-19	Diabetic kidney disease;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.52	-0.53	2.52e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-15.01	-0.57	8.76e-42	Response to antipsychotic treatment;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg01879757	chr17:41196368	BRCA1	-0.42	-8.73	-0.38	4.77e-17	Menopause (age at onset);
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12016809	chr21:47604291	C21orf56	0.55	9.71	0.41	2.07e-20	Testicular germ cell tumor;
LGG	cis	rs9326248	0.520	rs2735183	chr11:117015195	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.76	13.72	0.54	3.53e-36	Blood protein levels;
LGG	trans	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg08344181	chr3:125677491	NA	-0.58	-7.18	-0.32	2.77e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9810089	0.903	rs711975	chr3:136235908	T/C	cg12473912	chr3:136751656	NA	0.4	6.77	0.3	4.03e-11	Gestational age at birth (child effect);
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.08	-0.35	5.52e-15	IgG glycosylation;
LGG	cis	rs2988277	0.737	rs1723015	chr1:167432894	T/C	cg09179987	chr1:167433047	CD247	0.33	7.28	0.32	1.44e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1010254	0.510	rs72808345	chr5:151759695	G/A	cg12297329	chr5:152029980	NA	-0.51	-7.24	-0.32	1.91e-12	Optic nerve measurement (cup area);
LGG	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.74	0.3	4.58e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg12419862	chr22:24373484	LOC391322	-0.93	-18.61	-0.65	3.98e-58	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27148665	chr15:40697782	IVD	0.45	7.17	0.32	2.93e-12	Cognitive performance;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.569	rs1600746	chr7:124585095	T/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs72781680	0.716	rs2551325	chr2:23979729	C/T	cg08917208	chr2:24149416	ATAD2B	0.65	8.48	0.37	3.12e-16	Lymphocyte counts;
LGG	cis	rs1650123	0.645	rs831684	chr12:104020461	T/C	cg23227824	chr12:103980017	STAB2	0.36	8.47	0.37	3.38e-16	IgG glycosylation;
LGG	cis	rs1878931	0.567	rs7196196	chr16:3411855	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	20.67	0.69	1.01e-67	Body mass index (adult);
LGG	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.39e-16	Aortic root size;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18418962	chr18:2571633	METTL4;NDC80	-0.48	-6.97	-0.31	1.08e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.8e-17	Lung cancer;
LGG	trans	rs59574136	1	rs59574136	chr7:2036460	T/C	cg24247370	chr13:99142703	STK24	-0.37	-6.93	-0.31	1.41e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.67	0.34	1.06e-13	Lung cancer;
LGG	cis	rs7523273	0.925	rs12132780	chr1:207999605	C/T	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.33	-0.47	2.06e-26	Schizophrenia;
LGG	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.31	-0.43	1.46e-22	Total body bone mineral density;
LGG	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg01864069	chr14:103024347	NA	-0.45	-8.01	-0.35	9.35e-15	Platelet count;
LGG	cis	rs1670533	0.932	rs9992925	chr4:1050909	A/T	cg27284194	chr4:1044797	NA	0.54	9.82	0.42	8.6e-21	Recombination rate (females);
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg26513180	chr16:89883248	FANCA	0.88	8.51	0.37	2.5e-16	Skin colour saturation;
LGG	cis	rs4363385	0.530	rs58298199	chr1:152908814	A/C	cg13444842	chr1:152974279	SPRR3	-0.44	-8.78	-0.38	3.15e-17	Inflammatory skin disease;
LGG	cis	rs4731207	0.596	rs7810643	chr7:124611410	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs3820068	0.705	rs57971278	chr1:15838604	G/A	cg05660106	chr1:15850417	CASP9	1.1	27.19	0.78	5.39e-98	Systolic blood pressure;
LGG	cis	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg06521331	chr12:34319734	NA	0.55	9.79	0.41	1.08e-20	Morning vs. evening chronotype;
LGG	cis	rs2729354	0.953	rs2649663	chr11:57357305	C/T	cg24343310	chr11:57249947	NA	0.36	6.83	0.3	2.67e-11	Blood protein levels;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01341218	chr17:43662625	NA	0.96	17.04	0.62	6.63e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg00319359	chr11:70116639	PPFIA1	0.62	6.81	0.3	2.97e-11	Coronary artery disease;
LGG	cis	rs3771570	0.901	rs55764424	chr2:242407467	C/T	cg21155796	chr2:242212141	HDLBP	0.68	9.01	0.39	5.32e-18	Prostate cancer;
LGG	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.2	-0.32	2.52e-12	Morning vs. evening chronotype;
LGG	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-10.31	-0.43	1.46e-22	Aortic root size;
LGG	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg20503657	chr10:835505	NA	0.57	7.49	0.33	3.56e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs1904096	0.506	rs6532476	chr4:95192461	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.35	-0.47	1.6e-26	Type 2 diabetes;
LGG	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg16105309	chr15:79090380	ADAMTS7	0.42	7.36	0.32	8.66e-13	Schizophrenia;
LGG	cis	rs3812831	0.669	rs7327370	chr13:114946858	A/G	cg22348356	chr13:114891224	RASA3	0.42	8.07	0.35	6.03e-15	Schizophrenia;
LGG	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg02227867	chr8:22457446	C8orf58	-0.41	-7.94	-0.35	1.51e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.5	-0.44	2.82e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg07142201	chr11:109293216	C11orf87	0.54	9.69	0.41	2.42e-20	Schizophrenia;
LGG	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg14101638	chr12:121416612	HNF1A	0.39	7.94	0.35	1.54e-14	N-glycan levels;
LGG	cis	rs1015291	0.671	rs1352904	chr12:19995014	C/T	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg05313129	chr8:58192883	C8orf71	-0.74	-9.78	-0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg16230307	chr14:35515116	FAM177A1	-0.4	-7.0	-0.31	8.86e-12	Psoriasis;
LGG	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg25554036	chr4:6271136	WFS1	0.57	10.68	0.44	5.73e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4888262	0.564	rs8062404	chr16:74611675	T/C	cg01733217	chr16:74700730	RFWD3	0.85	16.9	0.62	2.92e-50	Testicular germ cell tumor;
LGG	cis	rs6693567	0.545	rs1313568	chr1:150344180	C/G	cg15654264	chr1:150340011	RPRD2	0.33	6.78	0.3	3.61e-11	Migraine;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10335659	chr2:99757356	C2orf15;TSGA10	0.46	7.74	0.34	6.27e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg26384229	chr12:38710491	ALG10B	-0.84	-19.79	-0.68	1.25e-63	Heart rate;
LGG	cis	rs12362504	0.532	rs12796169	chr11:9930529	C/T	cg07197493	chr11:9884649	SBF2	-0.35	-6.65	-0.3	8.24e-11	Survival in pancreatic cancer;
LGG	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg17809284	chr5:56205270	C5orf35	-0.67	-10.63	-0.44	9.32e-24	Initial pursuit acceleration;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10802521	chr3:52805072	NEK4	0.41	6.88	0.3	1.91e-11	Bipolar disorder;
LGG	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg13736514	chr6:26305472	NA	-0.44	-9.08	-0.39	3.25e-18	Educational attainment;
LGG	cis	rs7192750	0.586	rs4788581	chr16:71967695	T/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.56	0.44	1.69e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4789452	0.742	rs751633	chr17:75385775	C/A	cg06761530	chr17:75373219	SEPT9	-0.36	-6.87	-0.3	2.04e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00761968	chr13:53314142	LECT1	-0.38	-7.95	-0.35	1.39e-14	Lewy body disease;
LGG	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg02023728	chr11:77925099	USP35	-0.44	-7.88	-0.34	2.39e-14	Testicular germ cell tumor;
LGG	cis	rs9814567	1.000	rs9850015	chr3:134269541	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.08	-0.52	1.75e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg16507663	chr6:150244633	RAET1G	0.45	8.42	0.36	4.84e-16	Lung cancer;
LGG	cis	rs892961	1.000	rs11653743	chr17:75401923	C/A	cg05865280	chr17:75406074	SEPT9	0.42	9.65	0.41	3.29e-20	Airflow obstruction;
LGG	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.55	12.01	0.49	4.04e-29	Hemoglobin concentration;
LGG	cis	rs9522267	1.000	rs9522267	chr13:112196367	C/T	cg10483660	chr13:112241077	NA	-0.36	-7.36	-0.32	8.52e-13	Hepatitis;
LGG	cis	rs9912468	0.933	rs12944131	chr17:64307611	C/A	cg19474267	chr17:64306194	PRKCA	0.94	25.41	0.76	8.14e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.23	0.55	2.25e-38	Obesity-related traits;
LGG	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg12560992	chr17:57184187	TRIM37	0.53	8.42	0.36	4.78e-16	Cognitive test performance;
LGG	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg17108064	chr15:78857060	CHRNA5	-0.43	-9.04	-0.39	4.27e-18	Sudden cardiac arrest;
LGG	cis	rs6748734	0.519	rs9973362	chr2:241898198	T/C	cg05025159	chr2:241905733	NA	0.52	10.22	0.43	2.95e-22	Urinary metabolites;
LGG	cis	rs3820928	0.874	rs13383070	chr2:227904939	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.54	-0.33	2.58e-13	Pulmonary function;
LGG	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg12046867	chr14:103022105	NA	0.74	14.58	0.56	6.64e-40	Platelet count;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg06558623	chr16:89946397	TCF25	1.04	13.26	0.52	3.07e-34	Skin colour saturation;
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg11494091	chr17:61959527	GH2	0.51	8.13	0.35	3.83e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6693567	0.586	rs12031973	chr1:150485566	T/G	cg15654264	chr1:150340011	RPRD2	0.32	6.66	0.3	7.87e-11	Migraine;
LGG	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.88	-0.3	1.89e-11	Joint mobility (Beighton score);
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.1e-17	Aortic root size;
LGG	cis	rs4919087	1.000	rs10786326	chr10:99070377	G/A	cg25902810	chr10:99078978	FRAT1	0.52	9.79	0.41	1.08e-20	Monocyte count;
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.05	0.57	5.95e-42	Alzheimer's disease;
LGG	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg21100191	chr22:23484243	RTDR1	0.95	21.05	0.7	1.7e-69	Bone mineral density;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.49	0.5	4.6e-31	Prudent dietary pattern;
LGG	cis	rs244731	0.959	rs918459	chr5:176669030	C/T	cg17509989	chr5:176798049	RGS14	-0.57	-8.25	-0.36	1.72e-15	Urate levels in lean individuals;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03476370	chr11:77791237	NDUFC2	0.45	6.75	0.3	4.46e-11	Gut microbiome composition (summer);
LGG	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs793571	0.502	rs395601	chr15:59063196	G/C	cg05156742	chr15:59063176	FAM63B	0.66	12.29	0.5	2.97e-30	Schizophrenia;
LGG	cis	rs17767392	0.829	rs35796129	chr14:71758598	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.11	0.39	2.43e-18	Mitral valve prolapse;
LGG	cis	rs11748327	0.580	rs17717616	chr5:4017960	T/G	cg01025095	chr5:4101132	NA	-0.44	-7.23	-0.32	2.03e-12	Myocardial infarction;
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.53	-0.4	8.89e-20	Neuroticism;
LGG	cis	rs4918072	0.667	rs11191874	chr10:105711107	T/C	cg11005552	chr10:105648138	OBFC1	0.44	7.98	0.35	1.14e-14	Coronary artery disease;
LGG	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.41	-8.8	-0.38	2.64e-17	Restless legs syndrome;
LGG	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg04672837	chr16:48644449	N4BP1	0.55	9.13	0.39	2.16e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg17178900	chr1:205818956	PM20D1	0.58	13.06	0.52	2.03e-33	Menarche (age at onset);
LGG	cis	rs6976053	0.935	rs7801015	chr7:100476497	T/C	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.84e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9549260	0.709	rs4943795	chr13:41173433	C/T	cg21288729	chr13:41239152	FOXO1	-0.36	-6.95	-0.31	1.25e-11	Red blood cell count;
LGG	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg27624424	chr6:160112604	SOD2	0.57	9.16	0.39	1.74e-18	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg19077165	chr18:44547161	KATNAL2	0.43	7.26	0.32	1.68e-12	Educational attainment;
LGG	cis	rs6977660	1.000	rs2892940	chr7:19794750	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.66	0.37	7.67e-17	Thyroid stimulating hormone;
LGG	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg09873164	chr1:152488093	CRCT1	-0.64	-15.64	-0.59	1.44e-44	Hair morphology;
LGG	cis	rs2816316	0.945	rs1359062	chr1:192541472	C/G	cg02586212	chr1:192544902	RGS1	0.43	8.92	0.38	1.12e-17	Celiac disease;
LGG	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.2	-0.39	1.22e-18	Mean corpuscular volume;
LGG	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11890956	chr21:40555474	PSMG1	-0.71	-12.35	-0.5	1.79e-30	Menarche (age at onset);
LGG	cis	rs128738	0.500	rs743563	chr5:131569406	C/T	cg05556477	chr5:131705319	SLC22A5	0.45	6.66	0.3	7.88e-11	Giant cell arteritis;
LGG	cis	rs6988636	1.000	rs57322232	chr8:124193532	A/G	cg23067535	chr8:124195133	FAM83A	-0.57	-6.94	-0.31	1.35e-11	Urinary uromodulin levels;
LGG	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg19507638	chr5:93509721	C5orf36	0.39	7.0	0.31	9.14e-12	Diabetic retinopathy;
LGG	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg18240062	chr17:79603768	NPLOC4	0.75	13.9	0.54	5.8e-37	Eye color traits;
LGG	cis	rs7928758	1.000	rs56134226	chr11:134279882	T/C	cg22777979	chr11:134283252	B3GAT1	0.85	10.98	0.45	4.42e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg07460842	chr6:66804631	NA	0.9	14.76	0.57	1.13e-40	Exhaled nitric oxide output;
LGG	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg27129171	chr3:47204927	SETD2	-0.77	-14.74	-0.57	1.35e-40	Colorectal cancer;
LGG	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	8.0	0.35	9.96e-15	Mood instability;
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg14675211	chr2:100938903	LONRF2	0.69	12.47	0.5	5.64e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg13072238	chr3:49761600	GMPPB	0.52	6.91	0.31	1.58e-11	Menarche (age at onset);
LGG	cis	rs757081	0.667	rs615424	chr11:17210481	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.91	-0.38	1.17e-17	Systolic blood pressure;
LGG	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.39	-0.4	2.78e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.76	-0.34	5.64e-14	Psoriasis;
LGG	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-14.85	-0.57	4.42e-41	Headache;
LGG	cis	rs4262150	0.810	rs4557395	chr5:151963272	G/T	cg12297329	chr5:152029980	NA	-0.8	-15.29	-0.58	5.35e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs9660992	0.662	rs12092492	chr1:205251880	T/C	cg21545522	chr1:205238299	TMCC2	0.45	8.26	0.36	1.52e-15	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg00129232	chr17:37814104	STARD3	0.56	8.45	0.37	3.92e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.49	-0.4	1.19e-19	Lung cancer;
LGG	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.79	-0.38	3.06e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7267979	0.527	rs6076369	chr20:25576783	G/A	cg06421707	chr20:25228305	PYGB	-0.37	-7.72	-0.34	7.41e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg04440724	chr16:4920505	UBN1	0.56	11.92	0.48	9.54e-29	Cancer;
LGG	cis	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg05299278	chr17:33885742	SLFN14	0.42	8.11	0.35	4.52e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs36051895	0.589	rs7869015	chr9:5199750	C/T	cg02405213	chr9:5042618	JAK2	-0.79	-14.37	-0.56	5.6e-39	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg08621203	chr6:150244597	RAET1G	0.46	8.08	0.35	5.64e-15	Lung cancer;
LGG	trans	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg06521331	chr12:34319734	NA	0.54	9.74	0.41	1.58e-20	Bladder cancer;
LGG	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18876405	chr7:65276391	NA	0.49	8.85	0.38	1.84e-17	Aortic root size;
LGG	cis	rs6580649	0.943	rs9651993	chr12:48404692	G/A	cg24011408	chr12:48396354	COL2A1	0.61	7.55	0.33	2.29e-13	Lung cancer;
LGG	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg00012203	chr2:219082015	ARPC2	-0.69	-12.34	-0.5	1.93e-30	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg14019146	chr3:50243930	SLC38A3	0.32	6.81	0.3	3.11e-11	Body mass index;
LGG	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg11789530	chr4:8429930	ACOX3	-0.66	-10.78	-0.45	2.52e-24	Response to antineoplastic agents;
LGG	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.55	-0.44	1.79e-23	Height;
LGG	cis	rs2708240	0.577	rs1186173	chr7:147546603	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.33	-0.32	1.05e-12	QT interval (drug interaction);
LGG	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs1568889	0.592	rs17652117	chr11:28483645	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.59	-9.14	-0.39	1.99e-18	Bipolar disorder;
LGG	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.36	-0.47	1.5e-26	Lung cancer;
LGG	cis	rs3735485	0.800	rs17451462	chr7:45084525	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7737355	0.812	rs11242083	chr5:130927526	A/T	cg06307176	chr5:131281290	NA	0.53	8.65	0.37	8.69e-17	Life satisfaction;
LGG	cis	rs9309473	0.583	rs11899517	chr2:73573261	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-8.15	-0.35	3.48e-15	Metabolite levels;
LGG	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.42	-0.33	5.8e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.29	-0.32	1.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05901451	chr6:126070800	HEY2	-0.59	-10.63	-0.44	8.89e-24	Endometrial cancer;
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.81	0.64	2.07e-54	Alzheimer's disease;
LGG	cis	rs4774830	0.744	rs62045229	chr15:56280869	G/C	cg05129572	chr15:56138634	NEDD4	0.77	7.31	0.32	1.19e-12	Delta-5 desaturase activity;
LGG	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg23752985	chr2:85803571	VAMP8	-0.42	-8.42	-0.36	4.69e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs209489	1.000	rs209486	chr6:53175237	T/C	cg15607103	chr6:53167650	ELOVL5	-0.5	-6.65	-0.3	8.45e-11	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs11650494	0.516	rs117384420	chr17:47505383	G/C	cg08112188	chr17:47440006	ZNF652	0.95	10.78	0.45	2.56e-24	Prostate cancer;
LGG	cis	rs266717	0.751	rs266733	chr3:186493313	A/C	cg00373256	chr3:186519153	RFC4	-0.34	-6.92	-0.31	1.49e-11	Adiponectin levels;
LGG	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs1595825	0.838	rs73058878	chr2:198895078	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.83	-0.3	2.73e-11	Ulcerative colitis;
LGG	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-11.94	-0.49	8.16e-29	Height;
LGG	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg13010199	chr12:38710504	ALG10B	0.68	13.59	0.53	1.24e-35	Bladder cancer;
LGG	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg19913688	chr11:428466	ANO9	-0.64	-8.1	-0.35	5.03e-15	Body mass index;
LGG	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11644478	chr21:40555479	PSMG1	0.92	18.03	0.64	1.88e-55	Cognitive function;
LGG	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg04164538	chr19:48867262	TMEM143;SYNGR4	0.43	6.84	0.3	2.46e-11	Hip circumference;
LGG	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.7	0.34	8.22e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.68	-0.61	2.9e-49	Blood trace element (Zn levels);
LGG	cis	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg05084668	chr3:125655381	ALG1L	-0.67	-8.49	-0.37	2.88e-16	Blood pressure (smoking interaction);
LGG	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.0	-0.31	8.89e-12	Iron status biomarkers;
LGG	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.79	12.18	0.49	8.16e-30	Cognitive test performance;
LGG	cis	rs193541	0.530	rs2125857	chr5:122083156	G/A	cg19412675	chr5:122181750	SNX24	0.52	8.26	0.36	1.55e-15	Glucose homeostasis traits;
LGG	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg18681998	chr4:17616180	MED28	0.81	16.77	0.61	1.21e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg05973401	chr12:123451056	ABCB9	0.5	8.08	0.35	5.77e-15	Height;Educational attainment;Head circumference (infant);
LGG	trans	rs7939886	0.844	rs2512784	chr11:55894186	G/A	cg15704280	chr7:45808275	SEPT13	-0.77	-8.02	-0.35	8.76e-15	Myopia (pathological);
LGG	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	8.79	0.38	2.94e-17	Neuroticism;
LGG	cis	rs7580658	0.963	rs12479003	chr2:128118553	C/T	cg10021288	chr2:128175891	PROC	-0.65	-13.43	-0.53	5.59e-35	Protein C levels;
LGG	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg23250157	chr14:64679961	SYNE2	0.38	6.72	0.3	5.39e-11	Atrial fibrillation;
LGG	cis	rs1620921	0.711	rs2489942	chr6:161257961	G/A	cg01280913	chr6:161186852	NA	-0.35	-7.16	-0.32	3.19e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg21100191	chr22:23484243	RTDR1	0.54	8.11	0.35	4.7e-15	Serum parathyroid hormone levels;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.46	-0.53	4.27e-35	Personality dimensions;
LGG	cis	rs490234	0.812	rs13288963	chr9:128295198	G/A	cg14078157	chr9:128172775	NA	-0.48	-9.15	-0.39	1.83e-18	Mean arterial pressure;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg06558623	chr16:89946397	TCF25	1.19	12.93	0.52	7.08e-33	Skin colour saturation;
LGG	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg20608306	chr11:116969690	SIK3	0.42	13.57	0.53	1.43e-35	Blood protein levels;
LGG	cis	rs10861661	0.856	rs4964190	chr12:107216359	C/T	cg15890332	chr12:107067104	RFX4	0.28	6.74	0.3	4.82e-11	Triglyceride levels;
LGG	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg08079166	chr15:68083412	MAP2K5	0.36	8.34	0.36	8.5e-16	Restless legs syndrome;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.41	0.36	5.14e-16	Platelet count;
LGG	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.54	-8.65	-0.37	8.8e-17	Menarche (age at onset);
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg18379455	chr17:41446167	NA	-0.32	-7.57	-0.33	1.98e-13	Menopause (age at onset);
LGG	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg06353428	chr16:71660113	MARVELD3	0.42	7.16	0.32	3.17e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg19678392	chr7:94953810	PON1	-0.49	-13.49	-0.53	3.29e-35	Paraoxonase activity;
LGG	trans	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg11441553	chr12:57614120	NXPH4	-0.62	-7.77	-0.34	5.22e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.07	-0.35	5.91e-15	Height;
LGG	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg12395012	chr8:11607386	GATA4	-0.38	-6.95	-0.31	1.25e-11	Retinal vascular caliber;
LGG	cis	rs4824093	0.610	rs58671506	chr22:50288983	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.11	-0.31	4.51e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs11064837	0.523	rs1978108	chr12:120102253	T/C	cg25937854	chr12:120150414	CIT	-0.68	-11.35	-0.47	1.65e-26	Schizophrenia;
LGG	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.56	8.15	0.35	3.41e-15	Renal function-related traits (BUN);
LGG	cis	rs477692	0.935	rs557158	chr10:131420534	C/T	cg05714579	chr10:131428358	MGMT	0.56	11.56	0.47	2.58e-27	Response to temozolomide;
LGG	cis	rs72799341	1.000	rs7200879	chr16:30947572	A/G	cg00531865	chr16:30841666	NA	-0.5	-8.9	-0.38	1.23e-17	Diastolic blood pressure;
LGG	cis	rs4774830	0.744	rs17819312	chr15:56297427	G/A	cg24530489	chr15:56299380	NA	-0.84	-7.53	-0.33	2.63e-13	Delta-5 desaturase activity;
LGG	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.92	-0.38	1.11e-17	Kawasaki disease;
LGG	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg21153622	chr11:89784906	NA	-0.67	-8.78	-0.38	3.13e-17	White blood cell types;
LGG	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg27478167	chr7:817139	HEATR2	-0.44	-6.99	-0.31	9.55e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05665937	chr4:1216051	CTBP1	0.54	9.91	0.42	3.88e-21	Obesity-related traits;
LGG	trans	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg07211511	chr3:129823064	LOC729375	-0.65	-9.0	-0.39	5.87e-18	Blood pressure (smoking interaction);
LGG	cis	rs9460578	0.537	rs4712554	chr6:20825396	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.56	0.63	2.69e-53	Breast cancer;
LGG	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg03929089	chr4:120376271	NA	0.73	8.49	0.37	2.76e-16	Axial length;
LGG	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg23815491	chr16:72088622	HP	0.35	7.34	0.32	9.97e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.48e-20	Bipolar disorder;
LGG	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg14228332	chr4:119757509	SEC24D	1.01	9.58	0.41	5.76e-20	Cannabis dependence symptom count;
LGG	cis	rs60871478	0.735	rs62432241	chr7:795360	G/A	cg05535760	chr7:792225	HEATR2	0.97	12.81	0.51	2.34e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs9611565	0.506	rs2024566	chr22:41697338	A/G	cg06634786	chr22:41940651	POLR3H	-0.56	-9.26	-0.4	7.71e-19	Vitiligo;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg05793240	chr7:2802953	GNA12	0.37	8.21	0.36	2.27e-15	Height;
LGG	cis	rs2297441	0.550	rs6011097	chr20:62398825	G/A	cg14758556	chr20:62440591	NA	-0.55	-6.65	-0.3	8.35e-11	Ulcerative colitis;
LGG	cis	rs7666738	0.606	rs4699611	chr4:99097492	T/G	cg05340658	chr4:99064831	C4orf37	0.42	6.74	0.3	4.68e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12086130	0.892	rs3176466	chr1:51438365	A/G	cg07174182	chr1:51127561	FAF1	-0.51	-7.65	-0.34	1.15e-13	Hip circumference adjusted for BMI;Hip circumference;
LGG	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15533453	chr10:2542242	NA	0.28	6.7	0.3	6.2e-11	Age-related hearing impairment;
LGG	cis	rs4774899	1.000	rs12906936	chr15:57298553	A/C	cg08128148	chr15:57256372	TCF12	-0.34	-8.12	-0.35	4.32e-15	Urinary tract infection frequency;
LGG	cis	rs17208368	0.723	rs72802762	chr16:55091684	A/G	cg09947736	chr16:55091198	NA	0.72	12.35	0.5	1.7e-30	Hypospadias;
LGG	cis	rs1707322	0.963	rs10890371	chr1:46390897	T/G	cg03146154	chr1:46216737	IPP	0.54	10.12	0.43	6.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.11	-0.43	7.55e-22	Colorectal cancer;
LGG	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.7e-13	Refractive error;
LGG	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg04455712	chr21:45112962	RRP1B	0.53	10.08	0.42	9.81e-22	Mean corpuscular volume;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.06	0.6	1.83e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg01134436	chr17:81009848	B3GNTL1	0.84	8.82	0.38	2.31e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.37	-0.32	7.9e-13	Life satisfaction;
LGG	cis	rs17767392	0.794	rs61991247	chr14:71860318	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.67e-18	Mitral valve prolapse;
LGG	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg00254258	chr1:3105189	PRDM16	-0.69	-13.98	-0.54	2.66e-37	Migraine;
LGG	cis	rs9362426	0.943	rs7744338	chr6:88101999	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.5	9.41	0.4	2.33e-19	Depressive episodes in bipolar disorder;
LGG	cis	rs2718058	0.589	rs10258880	chr7:37793033	C/T	cg15028436	chr7:37888078	TXNDC3	-0.46	-7.44	-0.33	4.93e-13	Alzheimer's disease (late onset);
LGG	cis	rs457717	0.798	rs3797412	chr5:75927954	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.4	-7.68	-0.34	9.71e-14	Hearing impairment;
LGG	cis	rs9636202	1.000	rs17724992	chr19:18454825	A/G	cg02383626	chr19:18455508	PGPEP1	0.91	17.94	0.64	5.06e-55	Life satisfaction;
LGG	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.63	-0.33	1.39e-13	Testicular germ cell tumor;
LGG	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg18225595	chr11:63971243	STIP1	0.57	7.66	0.34	1.12e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs7084402	0.565	rs1982173	chr10:60334002	G/T	cg07615347	chr10:60278583	BICC1	0.5	12.37	0.5	1.49e-30	Refractive error;
LGG	cis	rs7147624	0.882	rs1956008	chr14:66085429	G/T	cg03016385	chr14:66212404	NA	-0.8	-9.84	-0.42	7.2e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg13939156	chr17:80058883	NA	0.49	9.72	0.41	1.92e-20	Life satisfaction;
LGG	trans	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg11430096	chr6:110968061	CDK19	0.65	6.84	0.3	2.49e-11	Prostate cancer;
LGG	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19413766	chr7:29689036	LOC646762	-0.53	-7.6	-0.33	1.71e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07677032	chr17:61819896	STRADA	-0.61	-11.07	-0.46	1.99e-25	Prudent dietary pattern;
LGG	cis	rs12579753	0.692	rs9943807	chr12:82279404	T/A	cg07988820	chr12:82153109	PPFIA2	-0.54	-7.77	-0.34	5.16e-14	Resting heart rate;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg12288994	chr5:1860383	NA	0.78	15.59	0.59	2.27e-44	Cardiovascular disease risk factors;
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18099408	chr3:52552593	STAB1	-0.34	-7.07	-0.31	5.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	12.14	0.49	1.28e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03352830	chr11:487213	PTDSS2	-0.63	-9.02	-0.39	4.99e-18	Body mass index;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13012494	chr21:47604986	C21orf56	0.41	6.94	0.31	1.35e-11	Testicular germ cell tumor;
LGG	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg16434002	chr17:42200994	HDAC5	0.43	7.79	0.34	4.56e-14	Total body bone mineral density;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg22605799	chr17:65374541	PITPNC1	-0.4	-6.9	-0.31	1.7e-11	Iris color (L* coordinate);
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg18335740	chr13:41363409	SLC25A15	0.88	21.32	0.7	8.64e-71	Lewy body disease;
LGG	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg11494091	chr17:61959527	GH2	0.64	10.88	0.45	1.06e-24	Height;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs12724450	0.793	rs11802612	chr1:150427279	G/A	cg03818307	chr1:150480534	ECM1	0.49	7.19	0.32	2.61e-12	Blood protein levels;
LGG	cis	rs8017423	0.647	rs12590712	chr14:90822481	T/C	cg04374321	chr14:90722782	PSMC1	-0.64	-12.83	-0.51	1.91e-32	Mortality in heart failure;
LGG	cis	rs10892173	0.716	rs12792357	chr11:117666595	C/T	cg21640587	chr11:117668038	DSCAML1	0.5	8.33	0.36	8.91e-16	Myopia;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg24503407	chr1:205819492	PM20D1	0.84	20.37	0.69	2.5e-66	Menarche (age at onset);
LGG	cis	rs7726354	0.793	rs73756780	chr5:56013798	T/A	cg27303933	chr5:56029418	NA	0.5	7.56	0.33	2.18e-13	Breast cancer (early onset);
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg05091796	chr16:4465799	CORO7	-0.73	-11.95	-0.49	7.25e-29	Schizophrenia;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg02725872	chr8:58115012	NA	-0.91	-12.76	-0.51	3.5e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.37	-0.36	6.97e-16	Total body bone mineral density;
LGG	cis	rs9297145	0.565	rs941001	chr7:98735185	A/T	cg05967295	chr7:98741636	SMURF1	-0.65	-11.63	-0.48	1.34e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg03701759	chr13:99174930	STK24	-0.37	-7.05	-0.31	6.75e-12	Neuroticism;
LGG	cis	rs7155454	0.935	rs11620955	chr14:65491255	C/T	cg26396452	chr14:65542826	MAX	-0.35	-6.66	-0.3	7.81e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs3806843	1.000	rs3733708	chr5:140181734	A/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg00647317	chr7:50633725	DDC	0.37	8.85	0.38	1.84e-17	Body mass index;
LGG	cis	rs4684776	1.000	rs2442779	chr3:11483005	C/T	cg24705426	chr3:11550659	ATG7	-0.45	-7.99	-0.35	1.08e-14	Small vessel stroke;
LGG	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs35176054	0.730	rs7093473	chr10:105535331	C/T	cg00730670	chr10:105510713	SH3PXD2A	0.48	6.96	0.31	1.18e-11	Atrial fibrillation;
LGG	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-9.06	-0.39	3.55e-18	Headache;
LGG	cis	rs12477438	0.520	rs12464785	chr2:99938942	A/G	cg23527387	chr2:100056660	REV1	0.44	9.81	0.41	9.41e-21	Chronic sinus infection;
LGG	cis	rs11696845	0.966	rs1467473	chr20:43371978	A/G	cg25301532	chr20:43378953	KCNK15	-0.35	-7.81	-0.34	3.95e-14	Obesity-related traits;
LGG	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.21e-21	Hypertriglyceridemia;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg13047869	chr3:10149882	C3orf24	0.53	8.91	0.38	1.21e-17	Alzheimer's disease;
LGG	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19671926	chr4:122722719	EXOSC9	0.48	7.32	0.32	1.11e-12	Type 2 diabetes;
LGG	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg07148914	chr20:33460835	GGT7	0.5	8.28	0.36	1.32e-15	Height;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg24596788	chr1:163392923	NA	-0.65	-12.05	-0.49	2.86e-29	Motion sickness;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02071572	chr4:1403502	NA	0.4	6.84	0.3	2.59e-11	Longevity;
LGG	cis	rs7166081	1.000	rs35722009	chr15:67625533	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	3.05e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.23	-0.39	1e-18	Schizophrenia;
LGG	cis	rs2439831	0.681	rs7168940	chr15:43633334	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.5	-0.33	3.2e-13	Lung cancer in ever smokers;
LGG	trans	rs1997103	0.863	rs4480062	chr7:55401299	T/C	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.59	0.37	1.32e-16	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg14646974	chr10:38645378	HSD17B7P2	0.46	7.33	0.32	1.02e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg24596788	chr1:163392923	NA	-0.73	-13.83	-0.54	1.13e-36	Motion sickness;
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs9296092	0.521	rs6929165	chr6:33515958	T/G	cg13560919	chr6:33536144	NA	-0.99	-19.45	-0.67	4.82e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12681366	0.708	rs12680213	chr8:95399816	T/C	cg13257157	chr8:95487014	RAD54B	0.38	6.71	0.3	5.62e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.41	-0.5	1.02e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.91	-0.51	8.65e-33	Gut microbiome composition (summer);
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg05793240	chr7:2802953	GNA12	0.29	7.18	0.32	2.73e-12	Height;
LGG	trans	rs1997103	0.911	rs17777	chr7:55380765	T/C	cg20935933	chr6:143382018	AIG1	0.58	8.94	0.38	9.26e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg03315344	chr16:75512273	CHST6	0.49	9.67	0.41	2.87e-20	Dupuytren's disease;
LGG	cis	rs10936602	0.520	rs3732451	chr3:169558025	C/T	cg00832555	chr3:169529716	LRRC34	0.36	7.21	0.32	2.31e-12	Renal cell carcinoma;
LGG	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.61	0.33	1.59e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.67e-44	Prostate cancer;
LGG	cis	rs9912468	0.933	rs35433169	chr17:64322135	C/G	cg19474267	chr17:64306194	PRKCA	0.94	25.49	0.76	3.45e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg11502198	chr6:26597334	ABT1	-0.92	-7.86	-0.34	2.77e-14	Small cell lung carcinoma;
LGG	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.21	0.39	1.1e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg16507663	chr6:150244633	RAET1G	0.41	7.6	0.33	1.65e-13	Lung cancer;
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg18225595	chr11:63971243	STIP1	0.56	7.54	0.33	2.43e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1707322	0.835	rs946525	chr1:46487277	A/T	cg03146154	chr1:46216737	IPP	-0.52	-9.93	-0.42	3.33e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1459104	1.000	rs2903534	chr11:55054044	A/G	cg15704280	chr7:45808275	SEPT13	0.73	7.1	0.31	4.78e-12	Body mass index;
LGG	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.94e-13	Neuroticism;
LGG	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.2	-0.32	2.38e-12	Coronary artery disease;
LGG	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.28	-0.43	1.85e-22	Menarche (age at onset);
LGG	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg20302533	chr7:39170763	POU6F2	0.59	14.97	0.57	1.38e-41	IgG glycosylation;
LGG	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7582720	1.000	rs76461893	chr2:203865515	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.87	-0.3	2.13e-11	Neuroticism;
LGG	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg20026190	chr17:76395443	PGS1	0.58	10.13	0.43	6.36e-22	HDL cholesterol levels;
LGG	cis	rs2294693	0.945	rs13216361	chr6:41007046	C/T	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.83	-0.3	2.7e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs3806843	1.000	rs6579987	chr5:140183659	T/C	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg21775007	chr8:11205619	TDH	-0.75	-12.93	-0.52	7.4e-33	Retinal vascular caliber;
LGG	cis	rs3820928	0.874	rs4675132	chr2:227841792	A/C	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.94	-0.35	1.58e-14	Pulmonary function;
LGG	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg21775007	chr8:11205619	TDH	0.47	7.82	0.34	3.71e-14	Mood instability;
LGG	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg19980929	chr12:42632907	YAF2	0.38	8.51	0.37	2.46e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6460942	0.778	rs76030612	chr7:12462937	C/A	cg06484146	chr7:12443880	VWDE	-0.35	-6.82	-0.3	2.86e-11	Coronary artery disease;
LGG	cis	rs9309473	0.653	rs6718843	chr2:73852505	C/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.22	-0.32	2.15e-12	Metabolite levels;
LGG	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg03929089	chr4:120376271	NA	-0.88	-15.59	-0.59	2.37e-44	Coronary artery disease;
LGG	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	cg07928641	chr1:182991847	LAMC1	0.45	8.73	0.38	4.81e-17	Fuchs's corneal dystrophy;
LGG	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg20026190	chr17:76395443	PGS1	0.57	10.14	0.43	5.94e-22	HDL cholesterol levels;
LGG	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg16512390	chr1:228756714	NA	0.48	6.72	0.3	5.35e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg16386425	chr10:429943	DIP2C	-0.42	-8.56	-0.37	1.69e-16	Psychosis in Alzheimer's disease;
LGG	trans	rs1997103	1.000	rs10270618	chr7:55396712	T/A	cg20935933	chr6:143382018	AIG1	0.59	9.1	0.39	2.74e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg12046867	chr14:103022105	NA	-0.74	-12.44	-0.5	7.33e-31	Platelet count;
LGG	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-9.74	-0.41	1.66e-20	Educational attainment (years of education);
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.84	-0.34	3.13e-14	Personality dimensions;
LGG	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg08470875	chr2:26401718	FAM59B	-0.41	-8.02	-0.35	8.94e-15	Gut microbiome composition (summer);
LGG	cis	rs7106204	0.534	rs77761450	chr11:24338593	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	8.6	0.37	1.28e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg04863758	chr4:1303710	MAEA	0.45	7.6	0.33	1.7e-13	Obesity-related traits;
LGG	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg15704280	chr7:45808275	SEPT13	0.45	7.27	0.32	1.58e-12	HDL cholesterol;
LGG	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.03	-0.42	1.47e-21	Schizophrenia;
LGG	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg24253500	chr15:84953950	NA	-0.56	-10.25	-0.43	2.31e-22	Schizophrenia;
LGG	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.62e-28	Lymphocyte counts;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg04305134	chr10:75173374	ANXA7	-0.43	-7.08	-0.31	5.38e-12	Height;
LGG	cis	rs16854884	0.657	rs13086088	chr3:143723942	G/A	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs11700980	0.551	rs11701783	chr21:30115629	C/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg14675211	chr2:100938903	LONRF2	-0.63	-11.04	-0.46	2.56e-25	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-12.99	-0.52	3.92e-33	Obesity-related traits;
LGG	cis	rs7444	0.882	rs140492	chr22:21923144	A/C	cg05046821	chr22:21984468	YDJC	-0.38	-7.11	-0.31	4.33e-12	Systemic lupus erythematosus;
LGG	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg03806693	chr22:41940476	POLR3H	-0.67	-11.04	-0.46	2.59e-25	Neuroticism;
LGG	cis	rs42648	0.596	rs194520	chr7:89854446	T/G	cg25739043	chr7:89950458	NA	-0.34	-7.02	-0.31	7.72e-12	Homocysteine levels;
LGG	cis	rs4604732	0.536	rs12074913	chr1:247631607	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.22	0.39	1.05e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs11585357	0.895	rs112208664	chr1:17632010	G/A	cg08277548	chr1:17600880	PADI3	-0.74	-8.42	-0.36	4.87e-16	Hair shape;
LGG	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg16414030	chr3:133502952	NA	-0.64	-11.41	-0.47	9.59e-27	Iron status biomarkers;
LGG	cis	rs6065	0.618	rs16942630	chr17:4878437	C/G	cg03443944	chr17:4872326	CAMTA2;SPAG7	-0.52	-6.88	-0.3	1.99e-11	Platelet count;
LGG	cis	rs11711311	0.824	rs9876528	chr3:113357196	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.88	-0.3	1.92e-11	IgG glycosylation;
LGG	trans	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg19894588	chr14:64061835	NA	-0.6	-9.39	-0.4	2.75e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7582720	1.000	rs72926791	chr2:203822891	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg00405596	chr8:11794950	NA	0.42	7.14	0.31	3.54e-12	Mood instability;
LGG	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.36	0.58	2.62e-43	Chronic sinus infection;
LGG	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.31	-0.32	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4604732	0.631	rs80319072	chr1:247626835	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12447804	0.822	rs9926705	chr16:58081989	C/G	cg03859792	chr16:58121049	NA	0.47	7.28	0.32	1.43e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.03	-0.49	3.41e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg13647721	chr17:30228624	UTP6	0.61	7.91	0.35	1.85e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg08621203	chr6:150244597	RAET1G	0.41	6.91	0.31	1.61e-11	Lung cancer;
LGG	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg04234412	chr22:24373322	LOC391322	0.68	11.34	0.47	1.83e-26	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2120243	0.539	rs1456108	chr3:157119054	A/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg22535103	chr8:58192502	C8orf71	-0.45	-7.14	-0.31	3.71e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg18245976	chr7:158708271	WDR60	0.61	8.13	0.35	3.87e-15	Height;
LGG	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs4936894	0.500	rs11219560	chr11:124159965	C/T	cg27160556	chr11:124181099	OR8D1	-0.46	-10.77	-0.45	2.83e-24	Aging (time to death);
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs876084	0.505	rs12680859	chr8:121118968	A/G	cg06265175	chr8:121136014	COL14A1	0.46	9.3	0.4	5.77e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2270450	0.765	rs12528857	chr6:46669936	G/T	cg10156739	chr6:46714674	LOC100287718	-0.4	-8.58	-0.37	1.42e-16	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.38	-0.36	6.42e-16	Restless legs syndrome;
LGG	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	8.06	0.35	6.34e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg19507638	chr5:93509721	C5orf36	-0.73	-9.97	-0.42	2.42e-21	Diabetic retinopathy;
LGG	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg24375607	chr4:120327624	NA	-0.55	-9.17	-0.39	1.6e-18	Corneal astigmatism;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02018176	chr4:1364513	KIAA1530	0.64	15.85	0.59	1.64e-45	Longevity;
LGG	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg02985381	chr13:37494744	SMAD9	0.71	12.45	0.5	6.86e-31	Coronary artery disease;
LGG	cis	rs6519955	0.866	rs9626920	chr22:46428993	A/G	cg05468064	chr22:46423449	NA	-0.41	-7.85	-0.34	2.99e-14	Dupuytren's disease;
LGG	cis	rs757278	0.552	rs10441245	chr7:117311066	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.53	0.33	2.72e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs1707322	0.721	rs11211157	chr1:46132844	T/C	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs643506	1.000	rs647080	chr11:111609174	A/G	cg18187862	chr3:45730750	SACM1L	-0.43	-6.77	-0.3	3.97e-11	Breast cancer;
LGG	cis	rs6714710	0.603	rs2305143	chr2:98413781	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg03060546	chr3:49711283	APEH	0.47	7.36	0.32	8.61e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs7843479	0.543	rs10866823	chr8:21781629	C/T	cg17168535	chr8:21777572	XPO7	0.82	15.68	0.59	9.77e-45	Mean corpuscular volume;
LGG	cis	rs7566780	0.630	rs4364023	chr2:16687496	A/G	cg09580478	chr2:16689509	NA	0.49	7.56	0.33	2.11e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg00976097	chr5:421733	AHRR	-0.41	-6.94	-0.31	1.33e-11	Cystic fibrosis severity;
LGG	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-7.04	-0.31	6.8e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg00035636	chr13:21900591	NA	0.39	8.43	0.36	4.5e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2710642	0.962	rs2058567	chr2:63091426	T/C	cg17519650	chr2:63277830	OTX1	0.46	7.63	0.33	1.33e-13	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.16	-0.32	3.28e-12	Lung cancer;
LGG	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg00012203	chr2:219082015	ARPC2	0.75	13.93	0.54	4.27e-37	Colorectal cancer;
LGG	trans	rs17685	0.884	rs3823882	chr7:75631913	T/C	cg19862616	chr7:65841803	NCRNA00174	-0.95	-19.78	-0.68	1.49e-63	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg08807101	chr21:30365312	RNF160	-0.85	-17.21	-0.62	1.08e-51	Dental caries;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.28	0.32	1.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.36	0.63	2.36e-52	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs2692947	0.727	rs749459	chr2:96795714	G/A	cg22654517	chr2:96458247	NA	0.37	7.9	0.34	1.99e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg25457927	chr22:38595422	NA	-0.37	-8.82	-0.38	2.3e-17	Cutaneous nevi;
LGG	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg06885757	chr1:42089581	HIVEP3	0.51	10.96	0.45	5.11e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg06654118	chr4:1303317	MAEA	0.45	7.85	0.34	2.95e-14	Obesity-related traits;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.44	8.2e-24	Neuroticism;
LGG	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	11.0	0.46	3.66e-25	Lung cancer in ever smokers;
LGG	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	7.18	0.32	2.72e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs41271473	0.948	rs72750016	chr1:228816786	G/C	cg10167378	chr1:228756711	NA	0.55	7.6	0.33	1.67e-13	Chronic lymphocytic leukemia;
LGG	cis	rs4740619	0.740	rs10962152	chr9:15775208	G/A	cg14451791	chr9:16040625	NA	0.35	8.83	0.38	2.16e-17	Body mass index;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.02	-0.39	5.15e-18	Life satisfaction;
LGG	cis	rs12431410	0.550	rs8014898	chr14:60201014	T/C	cg07950296	chr14:60194823	RTN1	-0.38	-7.31	-0.32	1.2e-12	Schizophrenia;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg04025307	chr7:1156635	C7orf50	0.81	14.72	0.56	1.59e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23955431	chr14:42076492	LRFN5	-0.46	-7.17	-0.32	3e-12	Systemic lupus erythematosus;
LGG	cis	rs2050392	0.517	rs602097	chr10:30747546	C/T	cg25182066	chr10:30743637	MAP3K8	-0.7	-15.01	-0.57	9.17e-42	Inflammatory bowel disease;
LGG	cis	rs4006360	0.646	rs4890158	chr17:39295805	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.14	-0.46	1.03e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg27478167	chr7:817139	HEATR2	0.46	7.46	0.33	4.45e-13	Cerebrospinal P-tau181p levels;
LGG	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg15103426	chr22:29168792	CCDC117	0.67	7.83	0.34	3.37e-14	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg24397884	chr7:158709396	WDR60	0.93	20.17	0.68	2.21e-65	Height;
LGG	cis	rs9397585	0.819	rs1415890	chr6:153372681	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.69	0.56	2.25e-40	Body mass index;
LGG	cis	rs11096990	0.634	rs6531702	chr4:39275394	C/T	cg24403649	chr4:39172243	NA	0.38	6.75	0.3	4.37e-11	Cognitive function;
LGG	trans	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg25482853	chr8:67687455	SGK3	-0.41	-6.67	-0.3	7.32e-11	Obesity-related traits;
LGG	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg08999081	chr20:33150536	PIGU	0.31	7.41	0.33	5.87e-13	Coronary artery disease;
LGG	cis	rs6918586	0.658	rs198838	chr6:26113340	C/T	cg18357526	chr6:26021779	HIST1H4A	0.55	9.64	0.41	3.68e-20	Schizophrenia;
LGG	cis	rs2224391	0.911	rs9504368	chr6:5261460	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.18	-0.36	2.69e-15	Height;
LGG	cis	rs4788570	0.615	rs1058750	chr16:71679057	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	21.23	0.7	2.48e-70	Intelligence (multi-trait analysis);
LGG	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-10.03	-0.42	1.44e-21	Body mass index;
LGG	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg27490568	chr2:178487706	NA	-0.82	-13.49	-0.53	3.32e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01724336	chr1:111992067	WDR77;ATP5F1	0.43	7.09	0.31	5.06e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.65	0.3	8.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7215564	0.730	rs36075755	chr17:78719099	G/A	cg16980736	chr17:78789706	RPTOR	-0.66	-6.96	-0.31	1.14e-11	Myopia (pathological);
LGG	cis	rs367615	0.918	rs72797472	chr5:108881343	C/T	cg17395555	chr5:108820864	NA	0.65	9.02	0.39	5.1e-18	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg14829155	chr15:31115871	NA	-0.56	-9.81	-0.41	9.13e-21	Huntington's disease progression;
LGG	cis	rs9921222	0.521	rs757460	chr16:367174	G/C	cg07915516	chr16:377344	AXIN1	0.27	6.87	0.3	2.07e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	cis	rs504918	0.556	rs56140315	chr3:124013819	C/T	cg05766129	chr3:123988013	KALRN	-0.58	-10.26	-0.43	2.07e-22	Schizophrenia;
LGG	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg12432903	chr7:1882776	MAD1L1	0.48	7.15	0.32	3.48e-12	Bipolar disorder;
LGG	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.15	-0.39	1.85e-18	Educational attainment;
LGG	cis	rs6693567	0.507	rs9436120	chr1:150473084	T/C	cg15654264	chr1:150340011	RPRD2	0.33	6.67	0.3	7.4e-11	Migraine;
LGG	trans	rs1997103	1.000	rs12532070	chr7:55407698	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12220238	1.000	rs12359456	chr10:75937994	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.5e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.71	0.48	6.62e-28	Corneal astigmatism;
LGG	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.44e-13	IgG glycosylation;
LGG	cis	rs9419702	0.614	rs59573564	chr10:133532158	T/G	cg20568497	chr10:133558893	NA	0.34	7.26	0.32	1.63e-12	Survival in rectal cancer;
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7928758	0.778	rs1866767	chr11:134274763	A/G	cg22777979	chr11:134283252	B3GAT1	-0.96	-12.77	-0.51	3.29e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11239187	0.586	rs7083920	chr10:45071890	C/T	cg03916630	chr10:45065415	NA	0.36	8.77	0.38	3.4e-17	Body mass index;
LGG	cis	rs7666738	0.716	rs11721453	chr4:99045485	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs283228	0.583	rs283186	chr6:101744172	G/A	cg27451362	chr6:101846650	GRIK2	0.86	13.44	0.53	5.55e-35	Coenzyme Q10 levels;
LGG	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg15704280	chr7:45808275	SEPT13	0.72	8.75	0.38	3.89e-17	Intraocular pressure;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg06916706	chr16:4465613	CORO7	-0.7	-12.22	-0.49	5.85e-30	Schizophrenia;
LGG	cis	rs13319406	0.546	rs16865077	chr3:189830554	C/T	cg03343083	chr3:189718843	LEPREL1	-0.55	-6.82	-0.3	2.82e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08322747	chr16:2347298	ABCA3	0.4	7.06	0.31	5.97e-12	Menarche (age at onset);
LGG	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.78	-0.3	3.65e-11	Alzheimer's disease (survival time);
LGG	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg04691961	chr3:161091175	C3orf57	-0.37	-7.76	-0.34	5.38e-14	Morning vs. evening chronotype;
LGG	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg14835575	chr10:16859367	RSU1	0.37	7.15	0.32	3.5e-12	Platelet distribution width;
LGG	cis	rs9815354	0.767	rs17281609	chr3:41833432	G/A	cg03022575	chr3:42003672	ULK4	0.79	9.28	0.4	6.68e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2692947	0.702	rs7604842	chr2:96777340	C/T	cg22654517	chr2:96458247	NA	-0.36	-7.58	-0.33	1.96e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07132326	chr6:150258058	NA	0.37	7.76	0.34	5.62e-14	Lung cancer;
LGG	cis	rs11602339	1	rs11602339	chr11:47761471	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Body mass index;
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg13699009	chr12:122356056	WDR66	0.56	14.85	0.57	4.6e-41	Mean corpuscular volume;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg06221963	chr1:154839813	KCNN3	-0.52	-11.0	-0.46	3.79e-25	Prostate cancer;
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg27532560	chr4:187881888	NA	-0.6	-13.06	-0.52	2.02e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17286411	0.814	rs12708919	chr16:71986995	A/G	cg06353428	chr16:71660113	MARVELD3	-0.41	-7.33	-0.32	1.05e-12	Blood protein levels;
LGG	cis	rs3740909	1.000	rs76286021	chr11:125884134	G/A	cg24940576	chr11:125904314	CDON	-0.47	-7.27	-0.32	1.55e-12	Blood protein levels;
LGG	trans	rs7615952	0.673	rs16834637	chr3:125605471	C/T	cg07211511	chr3:129823064	LOC729375	-1.34	-16.88	-0.62	3.5e-50	Blood pressure (smoking interaction);
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg19077165	chr18:44547161	KATNAL2	0.68	13.04	0.52	2.59e-33	Personality dimensions;
LGG	trans	rs9409565	0.559	rs62581187	chr9:97242284	T/G	cg05679027	chr9:99775184	HIATL2	-0.45	-6.7	-0.3	6.18e-11	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs7747724	0.692	rs6926436	chr6:20768475	C/T	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Bladder cancer;
LGG	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg25174290	chr11:3078921	CARS	-0.52	-9.54	-0.41	8.27e-20	Calcium levels;
LGG	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg12438819	chr7:158236134	PTPRN2	-0.32	-8.17	-0.35	3.02e-15	Obesity-related traits;
LGG	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.92	-0.31	1.51e-11	Systolic blood pressure;
LGG	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg22852734	chr6:133119734	C6orf192	1.16	15.8	0.59	2.82e-45	Type 2 diabetes nephropathy;
LGG	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.06	-0.31	6.11e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg24011408	chr12:48396354	COL2A1	0.5	8.02	0.35	8.68e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg07817883	chr1:32538562	TMEM39B	1.43	13.57	0.53	1.56e-35	Granulocyte percentage of myeloid white cells;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg21862992	chr11:68658383	NA	0.51	8.64	0.37	9.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg11584989	chr19:19387371	SF4	-0.39	-6.69	-0.3	6.4e-11	Tonsillectomy;
LGG	cis	rs34599045	0.522	rs12724858	chr1:152915631	C/T	cg07796016	chr1:152779584	LCE1C	-0.86	-8.03	-0.35	7.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6940638	1.000	rs12215241	chr6:27023081	G/A	cg09904177	chr6:26538194	HMGN4	-0.58	-7.91	-0.35	1.87e-14	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg12193833	chr17:30244370	NA	-0.27	-6.66	-0.3	7.9e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.44	7.21	0.32	2.24e-12	Cognitive test performance;
LGG	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg18196295	chr10:418757	DIP2C	-0.47	-8.95	-0.38	8.58e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.8	0.54	1.53e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg11247378	chr22:39784982	NA	-0.3	-7.86	-0.34	2.77e-14	IgG glycosylation;
LGG	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs701145	0.585	rs1713853	chr3:153795595	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.52	-9.71	-0.41	2.07e-20	Colorectal cancer;
LGG	cis	rs1594829	0.553	rs11135933	chr8:26162364	A/G	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs6540556	0.608	rs2205985	chr1:209912100	A/G	cg23920097	chr1:209922102	NA	-0.41	-7.51	-0.33	3.02e-13	Red blood cell count;
LGG	cis	rs1018836	0.812	rs10808619	chr8:91622916	A/T	cg16814680	chr8:91681699	NA	-0.84	-16.07	-0.6	1.65e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08280861	chr8:58055591	NA	0.64	7.98	0.35	1.18e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.32	-0.4	4.93e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9937943	0.667	rs12934000	chr16:74623420	T/G	cg01733217	chr16:74700730	RFWD3	0.65	8.93	0.38	9.96e-18	Neutrophil percentage of white cells;
LGG	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.27e-23	Aortic root size;
LGG	cis	rs72949976	0.646	rs1441171	chr2:214033637	G/T	cg08319019	chr2:214017104	IKZF2	0.65	12.21	0.49	6.73e-30	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs919433	0.617	rs700638	chr2:198588950	A/C	cg00792783	chr2:198669748	PLCL1	0.6	9.75	0.41	1.44e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg02002194	chr4:3960332	NA	0.54	10.41	0.44	6.03e-23	Triglycerides;
LGG	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	-0.46	-7.65	-0.34	1.14e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs17453880	0.929	rs62398709	chr5:152055235	A/T	cg10931792	chr5:152022470	NA	0.39	8.52	0.37	2.3e-16	Subjective well-being;
LGG	cis	rs6138458	0.626	rs6050259	chr20:25011423	A/G	cg26195577	chr20:24973756	C20orf3	0.9	16.14	0.6	8.42e-47	Blood protein levels;
LGG	cis	rs2046867	0.862	rs6788139	chr3:72835630	A/G	cg25664220	chr3:72788482	NA	0.32	9.17	0.39	1.57e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg04013166	chr16:89971882	TCF25	0.51	6.8	0.3	3.31e-11	Skin colour saturation;
LGG	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg10253484	chr15:75165896	SCAMP2	-0.4	-6.71	-0.3	5.55e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07577957	chr10:98803188	SLIT1	0.42	7.35	0.32	8.96e-13	Pancreatic cancer;
LGG	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs9486719	1.000	rs11152969	chr6:96908712	A/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg08975724	chr8:8085496	FLJ10661	0.46	8.85	0.38	1.86e-17	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02523844	chr7:79083507	MAGI2	0.46	6.67	0.3	7.5e-11	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.75	-0.48	4.28e-28	Response to antipsychotic treatment;
LGG	cis	rs6912958	0.781	rs9450739	chr6:88268271	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.59	-0.37	1.38e-16	Monocyte percentage of white cells;
LGG	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg05082376	chr22:42548792	NA	0.37	7.72	0.34	7.43e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg27476859	chr7:2772710	GNA12	0.39	6.66	0.3	7.71e-11	Height;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg16359550	chr11:109292809	C11orf87	0.42	8.19	0.36	2.58e-15	Schizophrenia;
LGG	cis	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg22496380	chr5:211416	CCDC127	-1.34	-18.64	-0.65	3e-58	Breast cancer;
LGG	cis	rs2455799	0.613	rs2470542	chr3:15724133	A/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.02e-14	Mean platelet volume;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg11814155	chr7:99998594	ZCWPW1	0.59	9.2	0.39	1.2e-18	Platelet count;
LGG	cis	rs9463078	0.764	rs3799968	chr6:44805377	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.58	-0.37	1.39e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12563480	chr17:46184629	SNX11	-0.48	-7.1	-0.31	4.75e-12	Systemic lupus erythematosus;
LGG	cis	rs7572733	0.935	rs1518364	chr2:198809975	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.19	0.36	2.62e-15	Dermatomyositis;
LGG	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.09	-0.31	5.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg00006948	chr4:1768889	NA	-0.5	-6.86	-0.3	2.24e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs3803915	0.925	rs2240128	chr19:2187276	T/C	cg27073066	chr19:2169160	DOT1L	1.04	12.71	0.51	5.74e-32	Body mass index;Myocardial infarction;
LGG	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg26578617	chr4:90757533	SNCA	-0.41	-8.31	-0.36	1.09e-15	Dementia with Lewy bodies;
LGG	cis	rs1776421	0.950	rs6678150	chr1:53900967	A/G	cg10892335	chr1:53966318	NA	-0.68	-10.42	-0.44	5.8e-23	PR interval in Tripanosoma cruzi seropositivity;
LGG	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg22044901	chr15:68126292	NA	-0.41	-6.94	-0.31	1.34e-11	Restless legs syndrome;
LGG	cis	rs657075	0.595	rs35719560	chr5:131584395	T/C	cg06968155	chr5:131705112	SLC22A5	0.53	6.65	0.3	8.07e-11	Rheumatoid arthritis;
LGG	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.74	-0.41	1.67e-20	Life satisfaction;
LGG	cis	rs9309473	1.000	rs6546835	chr2:73664715	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.47	-0.33	4.07e-13	Metabolite levels;
LGG	cis	rs72772090	0.710	rs11745122	chr5:96060738	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.47	-7.06	-0.31	5.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg19761014	chr17:28927070	LRRC37B2	-0.6	-7.3	-0.32	1.28e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs68170813	0.559	rs6967638	chr7:106929356	T/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.41	-0.44	5.81e-23	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.42	-8.58	-0.37	1.43e-16	Schizophrenia;
LGG	cis	rs10895140	0.709	rs2508244	chr11:101491322	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs994014	0.525	rs4282164	chr4:82289547	G/A	cg07938847	chr4:82126349	PRKG2	-0.28	-6.65	-0.3	8.04e-11	Height;
LGG	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg11764359	chr7:65958608	NA	0.71	12.92	0.51	7.77e-33	Aortic root size;
LGG	cis	rs7827545	1.000	rs6578234	chr8:135566363	A/G	cg17885191	chr8:135476712	NA	0.43	6.84	0.3	2.46e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs377457	0.893	rs451871	chr16:85736429	A/G	cg08768472	chr16:85689701	KIAA0182	0.42	8.11	0.35	4.73e-15	Type 2 diabetes;
LGG	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg08847335	chr10:891726	LARP4B	-0.49	-8.83	-0.38	2.23e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg01028140	chr2:1542097	TPO	-0.52	-9.5	-0.4	1.16e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.46e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg13770153	chr20:60521292	NA	-0.53	-8.46	-0.37	3.45e-16	Body mass index;
LGG	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.52	-7.81	-0.34	3.97e-14	Total cholesterol levels;
LGG	cis	rs12153243	0.714	rs17341992	chr5:142893637	T/C	cg13907255	chr5:142895549	NA	-0.49	-8.69	-0.37	6.26e-17	Migraine;
LGG	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-12.36	-0.5	1.62e-30	Schizophrenia;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.05	-0.46	2.4e-25	Prostate cancer;
LGG	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg15704280	chr7:45808275	SEPT13	0.83	14.87	0.57	3.54e-41	Coronary artery disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16590151	chr6:86352636	SYNCRIP	0.36	6.83	0.3	2.64e-11	Menarche (age at onset);
LGG	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-8.11	-0.35	4.51e-15	Vitiligo;
LGG	cis	rs943466	1.000	rs61394483	chr6:33751945	G/A	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	1.99e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs9462027	0.628	rs2477508	chr6:34703695	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.54	10.94	0.45	6.01e-25	Systemic lupus erythematosus;
LGG	cis	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-13.22	-0.52	4.33e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.19	0.39	1.34e-18	Blood protein levels;
LGG	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg22920501	chr2:26401640	FAM59B	-0.41	-8.61	-0.37	1.12e-16	Gut microbiome composition (summer);
LGG	trans	rs800082	1.000	rs1007564	chr3:144311843	C/T	cg24215973	chr2:240111563	HDAC4	-0.5	-8.67	-0.37	7.24e-17	Smoking behavior;
LGG	trans	rs2562456	0.833	rs8102783	chr19:21538553	T/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs12431410	0.550	rs12432408	chr14:60195141	C/A	cg07950296	chr14:60194823	RTN1	-0.39	-7.39	-0.32	6.81e-13	Schizophrenia;
LGG	cis	rs742614	0.533	rs2092737	chr20:32428135	A/C	cg06304546	chr20:32448765	NA	-0.7	-14.12	-0.55	6.88e-38	Stearic acid (18:0) levels;
LGG	cis	rs2229238	0.911	rs73023346	chr1:154512077	C/T	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs8032158	0.502	rs2136385	chr15:56235245	C/A	cg05129572	chr15:56138634	NEDD4	-0.54	-9.51	-0.4	1.08e-19	Keloid;
LGG	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg12219531	chr12:120966889	COQ5	0.66	10.95	0.45	5.86e-25	High light scatter reticulocyte count;
LGG	cis	rs820430	0.535	rs7617094	chr3:27403453	T/C	cg02860705	chr3:27208620	NA	-0.38	-7.03	-0.31	7.65e-12	Hypertension;Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs10785877	0.570	rs7043538	chr9:137109051	A/G	cg21243944	chr9:137118148	NA	0.29	7.31	0.32	1.18e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	trans	rs61931739	0.577	rs7313428	chr12:33672325	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-8.73	-0.38	4.64e-17	Morning vs. evening chronotype;
LGG	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.65	-0.33	1.2e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.91	0.42	3.86e-21	Height;
LGG	cis	rs3820068	0.581	rs16851876	chr1:15950628	A/T	cg05660106	chr1:15850417	CASP9	-0.89	-17.47	-0.63	7.58e-53	Systolic blood pressure;
LGG	cis	rs9976767	0.932	rs11910048	chr21:43822576	C/T	cg23042151	chr21:43824109	UBASH3A	-0.48	-10.02	-0.42	1.64e-21	Type 1 diabetes;
LGG	cis	rs6669919	0.622	rs10863907	chr1:211685066	G/A	cg10512769	chr1:211675356	NA	-0.69	-14.45	-0.56	2.56e-39	Intelligence (multi-trait analysis);
LGG	cis	rs13202913	0.518	rs13205543	chr6:151813779	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	7.67	0.34	9.98e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg13010199	chr12:38710504	ALG10B	0.72	14.58	0.56	6.76e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11225247	0.881	rs7113906	chr11:102253670	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.06	0.31	5.94e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.69	13.16	0.52	7.61e-34	Total body bone mineral density;
LGG	cis	rs2764208	0.510	rs4618513	chr6:34601825	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.49	-0.33	3.54e-13	Systemic lupus erythematosus;
LGG	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg16662043	chr16:48846231	NA	0.38	7.38	0.32	7.22e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	18.45	0.65	2.31e-57	Menopause (age at onset);
LGG	cis	rs4660214	0.666	rs683135	chr1:39895460	G/A	cg18385671	chr1:39797026	MACF1	0.48	9.96	0.42	2.65e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.33	0.53	1.59e-34	Obesity-related traits;
LGG	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg17830980	chr10:43048298	ZNF37B	0.38	7.95	0.35	1.41e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs72781680	0.898	rs12612492	chr2:24093756	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.39	0.4	2.8e-19	Lymphocyte counts;
LGG	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-12.07	-0.49	2.36e-29	Vitiligo;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.09	-0.42	9.17e-22	Lung cancer;
LGG	cis	rs698833	0.926	rs698835	chr2:44737089	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.86	0.3	2.28e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9810089	0.835	rs6791611	chr3:136160590	C/G	cg21827317	chr3:136751795	NA	-0.44	-7.61	-0.33	1.52e-13	Gestational age at birth (child effect);
LGG	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15128208	chr22:42549153	NA	0.48	9.76	0.41	1.34e-20	Cognitive function;
LGG	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg02753203	chr1:228287806	NA	0.94	20.64	0.69	1.38e-67	Diastolic blood pressure;
LGG	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg13770153	chr20:60521292	NA	-0.42	-6.85	-0.3	2.33e-11	Body mass index;
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.75e-17	Bipolar disorder;
LGG	cis	rs2797369	0.882	rs1222375	chr6:101607252	A/G	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg04248312	chr19:17393744	ANKLE1	-0.65	-10.69	-0.44	5.64e-24	Systemic lupus erythematosus;
LGG	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03576123	chr11:487126	PTDSS2	-1.21	-15.58	-0.59	2.5e-44	Body mass index;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg04025307	chr7:1156635	C7orf50	0.82	14.75	0.57	1.26e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13177180	0.705	rs256965	chr5:114937967	G/C	cg22173752	chr5:114937919	TMED7-TICAM2;TICAM2	0.26	6.95	0.31	1.24e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg26039829	chr8:22132926	PIWIL2	-0.55	-12.65	-0.51	1.04e-31	Hypertriglyceridemia;
LGG	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs10504130	0.569	rs11775587	chr8:52820165	C/T	cg22653915	chr8:52722023	PXDNL	0.43	6.87	0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg08470875	chr2:26401718	FAM59B	0.41	7.96	0.35	1.32e-14	Gut microbiome composition (summer);
LGG	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg18477163	chr1:228402036	OBSCN	0.25	6.67	0.3	7.44e-11	Diastolic blood pressure;
LGG	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg04117972	chr1:227635322	NA	0.57	9.4	0.4	2.62e-19	Major depressive disorder;
LGG	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06108461	chr20:60628389	TAF4	-1.05	-21.06	-0.7	1.55e-69	Body mass index;
LGG	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg23625390	chr15:77176239	SCAPER	0.59	11.97	0.49	6.04e-29	Blood metabolite levels;
LGG	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg21138405	chr5:131827807	IRF1	-0.39	-10.25	-0.43	2.34e-22	Asthma (sex interaction);
LGG	cis	rs74781061	0.929	rs4887163	chr15:74872746	G/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.53e-12	Endometriosis;
LGG	cis	rs17125944	0.615	rs7151643	chr14:53313661	G/C	cg00686598	chr14:53173677	PSMC6	-0.75	-7.78	-0.34	4.77e-14	Alzheimer's disease (late onset);
LGG	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg00887848	chr4:3482507	DOK7	-0.47	-9.48	-0.4	1.3e-19	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.13	-0.31	3.87e-12	Bipolar disorder;
LGG	cis	rs1568889	0.838	rs7952717	chr11:28261658	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.2	0.67	7.09e-61	Bipolar disorder;
LGG	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.21	-0.49	6.71e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06558623	chr16:89946397	TCF25	1.19	13.53	0.53	2.18e-35	Skin colour saturation;
LGG	cis	rs362272	0.524	rs881816	chr4:3365366	A/G	cg06533319	chr4:3265114	C4orf44	-0.35	-6.87	-0.3	2.08e-11	Serum sulfate level;
LGG	cis	rs3925075	0.903	rs36100148	chr16:31345023	C/T	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.07e-14	IgA nephropathy;
LGG	cis	rs7267979	1.000	rs6050590	chr20:25384994	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.11	-0.46	1.4e-25	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14315863	chr3:160283655	KPNA4	0.44	7.04	0.31	7.04e-12	Cognitive performance;
LGG	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg06606381	chr12:133084897	FBRSL1	-1.03	-8.44	-0.37	4.16e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg03929089	chr4:120376271	NA	-0.53	-8.79	-0.38	2.97e-17	HDL cholesterol;
LGG	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg13010199	chr12:38710504	ALG10B	0.69	13.75	0.54	2.54e-36	Bladder cancer;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.68	-0.37	6.91e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.46	9.12	0.39	2.31e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs9467160	1.000	rs7762901	chr6:24449639	G/A	cg20631270	chr6:24437470	GPLD1	0.52	7.4	0.33	6.48e-13	Liver enzyme levels;
LGG	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg02153584	chr22:29168773	CCDC117	0.59	7.15	0.32	3.37e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03199721	chr4:75023540	MTHFD2L	0.51	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	cis	rs2013441	1.000	rs2080673	chr17:20062395	C/A	cg13482628	chr17:19912719	NA	0.5	9.35	0.4	3.73e-19	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.2	0.36	2.36e-15	Iron status biomarkers;
LGG	cis	rs877282	0.945	rs12767287	chr10:787310	A/G	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg22729335	chr19:2427816	TIMM13	1.19	26.26	0.77	9.27e-94	Cortisol levels (saliva);
LGG	cis	rs17092148	0.945	rs6142237	chr20:33340993	C/T	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.79	-0.34	4.42e-14	Neuroticism;
LGG	cis	rs7949566	0.833	rs6590203	chr11:126274197	A/G	cg05055844	chr11:126275997	ST3GAL4	0.43	9.49	0.4	1.23e-19	Platelet distribution width;Mean platelet volume;
LGG	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg22168489	chr12:122356033	WDR66	-0.37	-8.35	-0.36	8.01e-16	Mean corpuscular volume;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg26150922	chr2:100937072	LONRF2	-0.61	-11.95	-0.49	7.24e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2976388	0.590	rs7828042	chr8:143819383	A/G	cg06565975	chr8:143823917	SLURP1	-0.53	-13.45	-0.53	4.75e-35	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12654349	chr5:56205094	C5orf35	-0.76	-11.47	-0.47	5.7e-27	Type 2 diabetes;
LGG	cis	rs113835537	0.529	rs3816492	chr11:66297363	C/T	cg24851651	chr11:66362959	CCS	0.45	7.69	0.34	8.9e-14	Airway imaging phenotypes;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg19168338	chr16:4465731	CORO7	-0.9	-17.2	-0.62	1.27e-51	Schizophrenia;
LGG	cis	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg10402321	chr1:26617780	UBXN11	-0.43	-7.75	-0.34	5.77e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.25	0.52	3.36e-34	HIV-1 control;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.98	-0.42	2.28e-21	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs72781680	1.000	rs72781649	chr2:24210864	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.61e-20	Lymphocyte counts;
LGG	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4804815	0.780	rs4804814	chr19:7840310	A/G	cg00371453	chr19:7854482	CLEC4GP1	-0.68	-10.29	-0.43	1.71e-22	Neutrophil count;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.01	-0.35	9.45e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	13.04	0.52	2.5e-33	Alzheimer's disease;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.05e-21	Electroencephalogram traits;
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.89	-0.34	2.28e-14	Menopause (age at onset);
LGG	cis	rs1506636	1.000	rs635072	chr7:123403255	G/A	cg03229431	chr7:123269106	ASB15	0.73	18.05	0.64	1.51e-55	Plateletcrit;Platelet count;
LGG	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg21827317	chr3:136751795	NA	0.53	9.9	0.42	4.31e-21	Neuroticism;
LGG	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg02269571	chr22:50332266	NA	-0.7	-10.35	-0.43	1e-22	Schizophrenia;
LGG	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg13628971	chr7:2884303	GNA12	-0.55	-11.49	-0.47	4.79e-27	Height;
LGG	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs7503807	0.688	rs12942347	chr17:78587942	C/T	cg16980736	chr17:78789706	RPTOR	-0.36	-6.68	-0.3	6.97e-11	Obesity;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.78e-26	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	1.000	rs10204105	chr2:43017520	A/G	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs490234	0.588	rs35278449	chr9:128172963	C/G	cg14078157	chr9:128172775	NA	-0.61	-11.43	-0.47	7.97e-27	Mean arterial pressure;
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs9810089	1.000	rs1278493	chr3:135814009	G/A	cg21827317	chr3:136751795	NA	-0.39	-6.86	-0.3	2.15e-11	Gestational age at birth (child effect);
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg03709012	chr19:19516395	GATAD2A	-0.83	-16.11	-0.6	1.09e-46	Tonsillectomy;
LGG	cis	rs7215564	0.818	rs35638109	chr17:78657367	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.32	-0.36	9.89e-16	Myopia (pathological);
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.74	-0.41	1.61e-20	Aortic root size;
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs7619833	0.620	rs1445111	chr3:27253971	C/T	cg02860705	chr3:27208620	NA	0.4	7.88	0.34	2.36e-14	Breast cancer;
LGG	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23598886	chr18:12777645	NA	0.74	10.35	0.43	1.02e-22	Inflammatory skin disease;
LGG	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.83	-0.34	3.37e-14	HDL cholesterol;
LGG	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg21775007	chr8:11205619	TDH	-0.52	-8.35	-0.36	8.05e-16	Neuroticism;
LGG	cis	rs2933343	0.679	rs1091938	chr3:128637025	T/C	cg25356066	chr3:128598488	ACAD9	0.46	6.84	0.3	2.51e-11	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.08	-0.64	1.15e-55	Refractive error;
LGG	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg23166289	chr1:210001082	C1orf107	0.32	6.81	0.3	3e-11	Orofacial clefts;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.49	7.9	0.34	2.08e-14	Longevity;
LGG	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg15028436	chr7:37888078	TXNDC3	0.88	15.91	0.59	8.45e-46	Alzheimer's disease (late onset);
LGG	trans	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg25214090	chr10:38739885	LOC399744	0.57	10.42	0.44	5.63e-23	Corneal astigmatism;
LGG	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.37	0.32	7.82e-13	Total cholesterol levels;
LGG	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs67311347	1.000	rs12630072	chr3:40517190	T/G	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs7432375	0.519	rs34799319	chr3:136586618	G/A	cg21827317	chr3:136751795	NA	0.54	9.46	0.4	1.58e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.5	-0.37	2.65e-16	Lung cancer;
LGG	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs6138458	1.000	rs227629	chr20:24913551	G/T	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg10189774	chr4:17578691	LAP3	0.43	7.58	0.33	1.88e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs988958	0.565	rs1440095	chr2:42289666	T/C	cg27252766	chr2:42229092	NA	0.39	7.03	0.31	7.35e-12	Hypospadias;
LGG	cis	rs6466055	0.777	rs10953470	chr7:104871892	G/T	cg04380332	chr7:105027541	SRPK2	0.37	6.95	0.31	1.21e-11	Schizophrenia;
LGG	cis	rs8077889	1.000	rs8077889	chr17:41878166	G/T	cg26893861	chr17:41843967	DUSP3	-0.88	-15.27	-0.58	6.09e-43	Triglycerides;
LGG	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg22437258	chr11:111473054	SIK2	-0.58	-9.68	-0.41	2.62e-20	Primary sclerosing cholangitis;
LGG	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg04149295	chr10:70884716	VPS26A	0.49	7.54	0.33	2.51e-13	Left atrial antero-posterior diameter;
LGG	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg00666640	chr1:248458726	OR2T12	0.55	8.99	0.39	6.49e-18	Common traits (Other);
LGG	cis	rs701145	0.938	rs1515653	chr3:154076654	A/G	cg17054900	chr3:154042577	DHX36	0.98	12.3	0.5	2.69e-30	Coronary artery disease;
LGG	cis	rs4650994	0.593	rs12033086	chr1:178540925	C/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.32	-0.32	1.1e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4731207	0.672	rs66823127	chr7:124472329	G/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg23029597	chr12:123009494	RSRC2	-0.94	-17.2	-0.62	1.24e-51	Body mass index;
LGG	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs10924309	0.737	rs4658797	chr1:245854862	G/A	cg00036263	chr1:245852353	KIF26B	-0.44	-6.96	-0.31	1.17e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs754466	0.580	rs2579178	chr10:79529215	A/G	cg17075019	chr10:79541650	NA	0.98	21.6	0.71	4.52e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08109568	chr15:31115862	NA	-0.59	-10.02	-0.42	1.55e-21	Huntington's disease progression;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06112835	chr11:68658793	MRPL21	0.62	10.5	0.44	2.84e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27286337	chr10:134555280	INPP5A	0.83	14.36	0.56	5.95e-39	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg18825076	chr15:78729989	IREB2	-0.42	-6.65	-0.3	8.09e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg03517284	chr6:25882590	NA	-0.4	-7.26	-0.32	1.66e-12	Height;
LGG	trans	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-9.82	-0.42	8.17e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.22	-0.46	5.34e-26	Morning vs. evening chronotype;
LGG	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg24231037	chr15:68117551	LBXCOR1	0.32	7.79	0.34	4.57e-14	Restless legs syndrome;
LGG	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg24558204	chr6:135376177	HBS1L	0.53	9.7	0.41	2.22e-20	Red blood cell count;
LGG	trans	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg02002194	chr4:3960332	NA	-0.46	-8.42	-0.36	4.59e-16	Systolic blood pressure;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs36093844	0.800	rs75605851	chr11:85580031	T/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.11	-0.31	4.53e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg26043149	chr18:55253948	FECH	0.43	7.23	0.32	2.06e-12	Bone mineral density;
LGG	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.46	0.56	2.22e-39	Cognitive test performance;
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg23985595	chr17:80112537	CCDC57	0.39	7.8	0.34	4.2e-14	Life satisfaction;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg19182353	chr11:118479428	PHLDB1	0.56	11.91	0.48	1.07e-28	Cholesterol, total;
LGG	cis	rs7209395	0.959	rs6504399	chr17:64138088	T/C	cg19474267	chr17:64306194	PRKCA	0.52	8.09	0.35	5.4e-15	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.12	-0.35	4.33e-15	Aortic root size;
LGG	cis	rs11753937	0.774	rs569833	chr6:133527935	T/C	cg05493394	chr6:133562035	EYA4	0.31	8.29	0.36	1.2e-15	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9914988	0.943	rs11652272	chr17:27167973	C/G	cg20469991	chr17:27169893	C17orf63	-0.6	-7.14	-0.31	3.63e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs5758511	0.514	rs5758580	chr22:42493875	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.23	0.36	1.87e-15	Birth weight;
LGG	cis	rs4737010	0.644	rs777870	chr8:41610234	G/A	cg17182837	chr8:41585554	ANK1	0.44	6.84	0.3	2.49e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg06521331	chr12:34319734	NA	-0.52	-9.04	-0.39	4.43e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs806215	1.000	rs698406	chr7:127255285	C/G	cg25922125	chr7:127225783	GCC1	0.73	10.02	0.42	1.65e-21	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.45	-0.33	4.72e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg25319279	chr11:5960081	NA	-0.53	-8.5	-0.37	2.68e-16	DNA methylation (variation);
LGG	cis	rs17604090	0.793	rs10241305	chr7:29689929	T/C	cg19413766	chr7:29689036	LOC646762	-0.54	-7.31	-0.32	1.21e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2802728	0.881	rs56179302	chr1:243582806	G/C	cg05593162	chr1:243577377	SDCCAG8	0.52	7.16	0.32	3.18e-12	Toenail selenium levels;
LGG	cis	rs12643440	0.538	rs1357233	chr4:17143376	A/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg04455712	chr21:45112962	RRP1B	-0.52	-9.54	-0.41	8.38e-20	Mean corpuscular volume;
LGG	cis	rs9557207	0.724	rs9557201	chr13:99989538	C/T	cg24509225	chr13:100037070	UBAC2	-0.46	-9.13	-0.39	2.09e-18	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg26818010	chr10:134567672	INPP5A	-0.6	-9.36	-0.4	3.38e-19	Migraine;
LGG	cis	rs834603	0.575	rs834595	chr7:47472276	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.77	0.34	5e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.51	-0.37	2.47e-16	Retinal vascular caliber;
LGG	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg22643751	chr7:855365	UNC84A	-0.55	-13.89	-0.54	6.26e-37	Perceived unattractiveness to mosquitoes;
LGG	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg18478394	chr8:109455254	TTC35	0.48	10.04	0.42	1.38e-21	Dupuytren's disease;
LGG	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg16797656	chr11:68205561	LRP5	0.39	6.97	0.31	1.08e-11	Total body bone mineral density;
LGG	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg16473166	chr22:50639996	SELO	0.75	11.65	0.48	1.08e-27	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02508567	chr2:85361184	TCF7L1	0.4	6.75	0.3	4.43e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.72	-13.14	-0.52	9.85e-34	Lymphocyte counts;
LGG	cis	rs9880211	0.948	rs13316214	chr3:136158221	A/G	cg21827317	chr3:136751795	NA	-0.47	-6.94	-0.31	1.29e-11	Body mass index;Height;
LGG	trans	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.24	-0.32	1.89e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg00599393	chr8:22457479	C8orf58	-0.44	-7.97	-0.35	1.24e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg16597345	chr16:4466593	CORO7	0.42	7.12	0.31	4.23e-12	Corneal astigmatism;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg21775007	chr8:11205619	TDH	-0.51	-7.87	-0.34	2.59e-14	Neuroticism;
LGG	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg23166289	chr1:210001082	C1orf107	0.32	6.78	0.3	3.71e-11	Orofacial clefts;
LGG	cis	rs2274273	0.624	rs11848456	chr14:55755392	A/G	cg04306507	chr14:55594613	LGALS3	0.54	12.45	0.5	7.07e-31	Protein biomarker;
LGG	cis	rs11168618	0.626	rs2731097	chr12:48883311	T/C	cg24011408	chr12:48396354	COL2A1	-0.42	-6.69	-0.3	6.6e-11	Adiponectin levels;
LGG	cis	rs9463078	0.809	rs9357469	chr6:45049811	C/T	cg25276700	chr6:44698697	NA	-0.39	-8.27	-0.36	1.44e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg18187862	chr3:45730750	SACM1L	0.65	10.83	0.45	1.63e-24	Primary sclerosing cholangitis;
LGG	cis	rs2299587	0.622	rs12334522	chr8:17889773	G/C	cg18067069	chr8:17937731	ASAH1	-0.33	-7.65	-0.33	1.18e-13	Economic and political preferences;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08677398	chr8:58056175	NA	0.57	8.72	0.38	4.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.3	0.43	1.49e-22	Diabetic retinopathy;
LGG	cis	rs7914558	1.000	rs4917996	chr10:104925829	A/C	cg04362960	chr10:104952993	NT5C2	0.55	10.6	0.44	1.18e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.41	0.58	1.58e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4748857	0.947	rs7082900	chr10:23595533	G/A	cg18853376	chr10:23633759	C10orf67	0.37	7.04	0.31	7.02e-12	Systemic lupus erythematosus;
LGG	cis	rs9640161	0.789	rs2373751	chr7:150021599	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.8	-16.58	-0.61	8.2e-49	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.06	0.52	2.1e-33	Tonsillectomy;
LGG	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06634786	chr22:41940651	POLR3H	0.67	11.27	0.46	3.41e-26	Vitiligo;
LGG	cis	rs9596863	0.898	rs9596847	chr13:54322250	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.19	0.32	2.55e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-12.44	-0.5	7.58e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3859192	0.599	rs12451897	chr17:38179275	G/T	cg17467752	chr17:38218738	THRA	-0.58	-9.81	-0.41	9.03e-21	White blood cell count;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.08	-0.42	9.48e-22	Platelet count;
LGG	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg06108461	chr20:60628389	TAF4	-0.72	-13.1	-0.52	1.38e-33	Body mass index;
LGG	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg00666640	chr1:248458726	OR2T12	0.45	6.76	0.3	4.3e-11	Common traits (Other);
LGG	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg24881330	chr22:46731750	TRMU	0.71	7.21	0.32	2.27e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg15395560	chr15:45543142	SLC28A2	0.42	7.04	0.31	7.08e-12	Glomerular filtration rate;
LGG	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg12042659	chr19:58951599	ZNF132	0.34	6.88	0.3	1.97e-11	Uric acid clearance;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	17.12	0.62	2.85e-51	Personality dimensions;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg02158880	chr13:53174818	NA	0.43	7.7	0.34	8.52e-14	Lewy body disease;
LGG	cis	rs11039131	0.754	rs2291119	chr11:47298201	C/T	cg20307385	chr11:47447363	PSMC3	-0.46	-7.68	-0.34	9.85e-14	Schizophrenia;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.83	-0.3	2.67e-11	Retinal vascular caliber;
LGG	cis	rs6456156	0.792	rs4710178	chr6:167513532	G/A	cg07741184	chr6:167504864	NA	0.4	8.9	0.38	1.28e-17	Primary biliary cholangitis;
LGG	cis	rs9814567	1.000	rs7433991	chr3:134312292	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs4363385	0.747	rs3753454	chr1:152973776	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.34	-0.4	4.09e-19	Inflammatory skin disease;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-6.96	-0.31	1.13e-11	Bipolar disorder;
LGG	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.26	-0.32	1.66e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.3	-7.22	-0.32	2.21e-12	Restless legs syndrome;
LGG	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.75	-0.48	4.51e-28	Intelligence (multi-trait analysis);
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.31	-0.43	1.46e-22	Tonsillectomy;
LGG	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.55	-7.27	-0.32	1.5e-12	Smoking behavior;
LGG	cis	rs6723226	0.806	rs2710606	chr2:32811909	A/G	cg02381751	chr2:32503542	YIPF4	0.73	11.81	0.48	2.48e-28	Intelligence (multi-trait analysis);
LGG	cis	rs17384381	0.700	rs11161617	chr1:85913538	A/G	cg16011679	chr1:85725395	C1orf52	0.48	8.57	0.37	1.57e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.7	-13.25	-0.52	3.31e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs668210	0.793	rs540584	chr11:65765866	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-9.26	-0.4	7.56e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.67	-0.48	8.93e-28	Life satisfaction;
LGG	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg19442545	chr10:75533431	FUT11	-0.44	-7.37	-0.32	7.93e-13	Inflammatory bowel disease;
LGG	cis	rs17253792	0.822	rs79807559	chr14:56108117	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg05791153	chr7:19748676	TWISTNB	0.77	10.2	0.43	3.57e-22	Thyroid stimulating hormone;
LGG	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg14541582	chr5:601475	NA	-0.57	-9.1	-0.39	2.67e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.74	-0.3	4.6e-11	Triglycerides;
LGG	cis	rs11785693	0.730	rs62489549	chr8:4954185	G/C	cg26367366	chr8:4980734	NA	0.77	10.34	0.43	1.11e-22	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2802728	1.000	rs2970547	chr1:243521042	C/T	cg05593162	chr1:243577377	SDCCAG8	-0.48	-6.87	-0.3	2.13e-11	Toenail selenium levels;
LGG	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	Neuroticism;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg11764359	chr7:65958608	NA	-0.74	-13.32	-0.53	1.73e-34	Aortic root size;
LGG	cis	rs10982213	0.830	rs10081697	chr9:117182605	C/G	cg00969271	chr9:117093052	ORM2	0.43	7.38	0.32	7.27e-13	Interleukin-6 levels;
LGG	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.25	0.4	8.09e-19	Blood metabolite levels;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-9.0	-0.39	5.69e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg03733263	chr8:22462867	KIAA1967	1.04	26.99	0.78	4.63e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs638893	0.636	rs583213	chr11:118669178	G/T	cg22253036	chr11:118662786	DDX6	0.48	7.29	0.32	1.37e-12	Vitiligo;
LGG	cis	rs6466055	0.720	rs4730082	chr7:105027509	A/G	cg04380332	chr7:105027541	SRPK2	-0.41	-7.69	-0.34	8.76e-14	Schizophrenia;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.02	-0.39	4.85e-18	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.35	-0.4	3.82e-19	Coronary artery disease;
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg05484376	chr2:27715224	FNDC4	-0.46	-10.09	-0.42	8.9e-22	Total body bone mineral density;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.56	9.71	0.41	2.04e-20	Prudent dietary pattern;
LGG	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg10518543	chr12:38710700	ALG10B	-0.43	-6.95	-0.31	1.23e-11	Morning vs. evening chronotype;
LGG	cis	rs4493873	0.869	rs4501550	chr8:92088212	A/G	cg16814680	chr8:91681699	NA	0.45	6.96	0.31	1.14e-11	Migraine - clinic-based;
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg14675211	chr2:100938903	LONRF2	0.62	10.79	0.45	2.27e-24	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg13482628	chr17:19912719	NA	0.62	12.28	0.5	3.41e-30	Schizophrenia;
LGG	trans	rs61931739	0.649	rs1093031	chr12:33722730	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.64	-0.44	8.71e-24	Hip circumference adjusted for BMI;
LGG	cis	rs6964587	0.935	rs9770444	chr7:91783162	T/G	cg17063962	chr7:91808500	NA	0.53	9.85	0.42	6.47e-21	Breast cancer;
LGG	trans	rs12579753	0.879	rs35087297	chr12:82133398	C/T	cg07923666	chr12:49932857	KCNH3	-0.51	-7.92	-0.35	1.78e-14	Resting heart rate;
LGG	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg25866889	chr13:114914595	NA	-0.35	-6.95	-0.31	1.21e-11	Schizophrenia;
LGG	cis	rs4478858	0.735	rs10798843	chr1:31797094	A/G	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05149425	chr12:129308602	SLC15A4	0.46	6.66	0.3	7.83e-11	Hip circumference;
LGG	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg09904177	chr6:26538194	HMGN4	0.64	12.84	0.51	1.76e-32	Intelligence (multi-trait analysis);
LGG	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08677398	chr8:58056175	NA	0.48	7.95	0.35	1.39e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg18129748	chr3:49941408	MST1R	-0.22	-6.87	-0.3	2.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg11812906	chr14:75593930	NEK9	-0.44	-7.91	-0.35	1.87e-14	Height;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg06654118	chr4:1303317	MAEA	0.42	7.27	0.32	1.55e-12	Obesity-related traits;
LGG	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.61	-11.84	-0.48	2.03e-28	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18621852	chr3:10150065	C3orf24	0.4	6.8	0.3	3.15e-11	Alzheimer's disease;
LGG	cis	rs3106136	0.903	rs35361491	chr4:95202492	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.2	-0.36	2.42e-15	Capecitabine sensitivity;
LGG	cis	rs1881396	0.947	rs77350364	chr2:27866139	A/G	cg27432699	chr2:27873401	GPN1	0.59	9.06	0.39	3.69e-18	Nonalcoholic fatty liver disease;
LGG	trans	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg11693508	chr17:37793320	STARD3	0.46	7.1	0.31	4.63e-12	Neuroticism;
LGG	cis	rs11967485	0.609	rs11969332	chr6:157143703	A/C	cg23222435	chr6:157204239	ARID1B	-0.78	-7.29	-0.32	1.35e-12	Calcium levels;
LGG	cis	rs7512552	0.582	rs834233	chr1:150354276	G/A	cg15654264	chr1:150340011	RPRD2	0.42	8.3	0.36	1.17e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7107356	1	rs7107356	chr11:47676170	A/G	cg20307385	chr11:47447363	PSMC3	0.6	11.89	0.48	1.28e-28	Neuroticism;Neuroticism (multi-trait analysis);
LGG	cis	rs10876993	0.928	rs10082911	chr12:58104104	C/A	cg18357645	chr12:58087776	OS9	0.71	12.69	0.51	7.24e-32	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg12046867	chr14:103022105	NA	-0.78	-12.93	-0.52	6.96e-33	Platelet count;
LGG	trans	rs629535	0.814	rs674429	chr8:70069942	G/A	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg15627072	chr1:2432621	PLCH2	-0.38	-8.28	-0.36	1.28e-15	Ulcerative colitis;
LGG	cis	rs35740288	0.514	rs2455561	chr15:86326348	T/G	cg25843651	chr15:86329602	KLHL25	0.38	6.84	0.3	2.53e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.97	0.49	5.85e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.26e-12	HDL cholesterol;
LGG	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04226364	chr17:47865990	MYST2	0.42	6.96	0.31	1.15e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	cg07245641	chr1:182991651	LAMC1	0.4	9.28	0.4	6.56e-19	Colorectal cancer;
LGG	cis	rs7481584	0.624	rs451060	chr11:3056389	G/A	cg08508325	chr11:3079039	CARS	0.43	8.43	0.36	4.37e-16	Calcium levels;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg20607798	chr8:58055168	NA	0.68	7.67	0.34	1.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03647317	chr4:187891568	NA	-0.41	-8.7	-0.37	5.76e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11245990	chr11:68621969	NA	0.44	9.19	0.39	1.37e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7166081	1.000	rs35011221	chr15:67645013	G/C	cg05925327	chr15:68127851	NA	-0.34	-7.14	-0.31	3.67e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg00339695	chr16:24857497	SLC5A11	0.4	6.84	0.3	2.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	0.821	rs56064672	chr2:24156769	G/T	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.68e-17	Lymphocyte counts;
LGG	cis	rs8180040	0.800	rs62248905	chr3:47274082	A/G	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6e-39	Colorectal cancer;
LGG	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.03	-0.31	7.56e-12	Rheumatoid arthritis;
LGG	trans	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg02002194	chr4:3960332	NA	0.41	7.12	0.31	4.19e-12	Mood instability;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05764766	chr1:19638718	PQLC2;AKR7A2	-0.38	-6.8	-0.3	3.34e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs17253792	0.822	rs75897560	chr14:56090965	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg06713675	chr4:122721982	EXOSC9	-0.44	-6.98	-0.31	1.02e-11	Type 2 diabetes;
LGG	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.17	-0.7	4.77e-70	Leprosy;
LGG	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02071572	chr4:1403502	NA	0.38	6.83	0.3	2.65e-11	Longevity;
LGG	cis	rs2131877	0.645	rs4677663	chr3:194874605	A/G	cg07250128	chr3:194833983	C3orf21	-0.32	-7.09	-0.31	4.89e-12	Non-small cell lung cancer;
LGG	cis	rs1881396	0.531	rs4665385	chr2:27930837	C/T	cg27432699	chr2:27873401	GPN1	0.58	7.48	0.33	3.89e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs1669338	0.646	rs3792415	chr3:3201780	C/G	cg16797762	chr3:3221439	CRBN	0.59	8.55	0.37	1.74e-16	White matter integrity;
LGG	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4474465	0.688	rs7945812	chr11:78280509	T/C	cg27205649	chr11:78285834	NARS2	0.61	11.43	0.47	8.16e-27	Alzheimer's disease (survival time);
LGG	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.47	-0.44	3.55e-23	Total body bone mineral density;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg16507663	chr6:150244633	RAET1G	0.45	8.34	0.36	8.38e-16	Lung cancer;
LGG	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg12560992	chr17:57184187	TRIM37	0.53	8.57	0.37	1.53e-16	Testicular germ cell tumor;
LGG	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg23205692	chr1:25664452	TMEM50A	0.44	9.05	0.39	4.01e-18	Erythrocyte sedimentation rate;
LGG	cis	rs6500395	1.000	rs871902	chr16:48593779	A/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs73071352	0.588	rs55744136	chr3:41812293	A/C	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Multiple myeloma and monoclonal gammopathy;Multiple myeloma;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.25	0.32	1.79e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg00571178	chr13:114841904	RASA3	-0.56	-10.09	-0.42	8.96e-22	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs17683430	0.681	rs9606899	chr22:32447811	T/C	cg02631450	chr22:32366979	NA	0.55	6.8	0.3	3.19e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9341808	0.754	rs9294173	chr6:80991630	T/A	cg08355045	chr6:80787529	NA	0.38	7.36	0.32	8.52e-13	Sitting height ratio;
LGG	cis	rs2073300	0.609	rs6137941	chr20:23400848	G/A	cg12062639	chr20:23401060	NAPB	0.92	8.93	0.38	9.82e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg00071950	chr4:10020882	SLC2A9	0.4	8.34	0.36	8.59e-16	Bone mineral density;
LGG	cis	rs4006360	0.522	rs72625953	chr17:39237157	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.45	-0.47	6.94e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.23	0.46	4.67e-26	Alzheimer's disease;
LGG	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg06138931	chr13:21896616	NA	-0.44	-7.19	-0.32	2.64e-12	White matter hyperintensity burden;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10053473	chr17:62856997	LRRC37A3	0.79	13.85	0.54	9.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11239187	0.553	rs34539511	chr10:45078466	T/C	cg03916630	chr10:45065415	NA	0.42	7.62	0.33	1.42e-13	Body mass index;
LGG	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg15704280	chr7:45808275	SEPT13	-0.91	-14.84	-0.57	4.96e-41	Height;
LGG	cis	rs7011049	1.000	rs78977297	chr8:53858902	T/C	cg26025543	chr8:53854495	NA	0.75	9.68	0.41	2.58e-20	Systolic blood pressure;
LGG	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.4	6.79	0.3	3.37e-11	Depressive symptoms;
LGG	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.56	14.81	0.57	6.4e-41	Oropharynx cancer;
LGG	cis	rs4144027	0.875	rs6576010	chr14:104349602	A/G	cg26031613	chr14:104095156	KLC1	0.43	7.02	0.31	8.02e-12	Blood metabolite levels;
LGG	cis	rs13132184	0.507	rs12649018	chr4:38060085	A/G	cg24826020	chr4:38070998	TBC1D1	0.5	8.5	0.37	2.54e-16	Verbal declarative memory;
LGG	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg27366882	chr3:133540807	NA	-0.46	-9.55	-0.41	7.55e-20	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.42	-0.47	8.48e-27	Autism spectrum disorder or schizophrenia;
LGG	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg25482853	chr8:67687455	SGK3	1.01	13.09	0.52	1.53e-33	Lung disease severity in cystic fibrosis;
LGG	trans	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.44	7.47	0.33	3.96e-13	Blood trace element (Cu levels);
LGG	cis	rs988958	0.526	rs13024096	chr2:42252950	A/G	cg27252766	chr2:42229092	NA	0.49	7.14	0.31	3.75e-12	Hypospadias;
LGG	cis	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg07460842	chr6:66804631	NA	0.57	9.58	0.41	6.14e-20	Metabolite levels;
LGG	cis	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg12486710	chr1:178512616	C1orf220	-0.39	-7.9	-0.34	2.11e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.43	-0.33	5.2e-13	Total cholesterol levels;
LGG	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg00071950	chr4:10020882	SLC2A9	0.39	7.71	0.34	7.75e-14	Bone mineral density;
LGG	trans	rs9929218	1.000	rs9282650	chr16:68809640	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.85	-0.51	1.59e-32	Colorectal cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22901322	chr4:100815570	MAPKSP1	0.39	6.95	0.31	1.27e-11	Obesity-related traits;
LGG	cis	rs3087591	0.708	rs3815154	chr17:29654974	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.2	0.49	7.27e-30	Hip circumference;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg11502198	chr6:26597334	ABT1	-0.54	-9.29	-0.4	6.16e-19	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.83	-0.42	8.03e-21	Mean corpuscular volume;
LGG	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.78	-0.57	8.88e-41	Calcium levels;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.17e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg07537917	chr2:241836409	C2orf54	-0.42	-8.19	-0.36	2.52e-15	Urinary metabolites;
LGG	cis	rs10789491	0.953	rs11211337	chr1:47133811	T/C	cg15501359	chr1:47185051	KIAA0494	0.75	14.56	0.56	8.4e-40	Response to hepatitis C treatment;
LGG	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg27446573	chr6:127587934	RNF146	0.72	12.98	0.52	4.37e-33	Breast cancer;
LGG	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg16070123	chr10:51489643	NA	-0.43	-7.88	-0.34	2.32e-14	Prostate-specific antigen levels;
LGG	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg21926883	chr2:100939477	LONRF2	-0.48	-9.25	-0.39	8.44e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.29	0.32	1.38e-12	Retinal vascular caliber;
LGG	cis	rs754466	0.605	rs10824578	chr10:79578244	G/C	cg17075019	chr10:79541650	NA	-0.99	-22.54	-0.72	1.73e-76	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg18187862	chr3:45730750	SACM1L	-0.68	-11.2	-0.46	6.55e-26	Primary sclerosing cholangitis;
LGG	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg05335186	chr13:53173507	NA	0.53	11.37	0.47	1.35e-26	Lewy body disease;
LGG	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg02023728	chr11:77925099	USP35	0.46	8.31	0.36	1.07e-15	Testicular germ cell tumor;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg11584989	chr19:19387371	SF4	-0.41	-7.28	-0.32	1.44e-12	Tonsillectomy;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.27	0.55	1.47e-38	Platelet count;
LGG	cis	rs3771570	1.000	rs73020143	chr2:242261240	T/A	cg21155796	chr2:242212141	HDLBP	0.73	9.31	0.4	5.02e-19	Prostate cancer;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07157834	chr1:205819609	PM20D1	-0.71	-15.6	-0.59	2.17e-44	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22800332	chr5:138775207	DNAJC18	0.45	6.83	0.3	2.62e-11	Gut microbiome composition (summer);
LGG	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg05793240	chr7:2802953	GNA12	0.31	7.77	0.34	4.94e-14	Height;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.62	0.37	1.03e-16	Personality dimensions;
LGG	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg21775007	chr8:11205619	TDH	0.81	14.17	0.55	4.03e-38	Retinal vascular caliber;
LGG	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	14.18	0.55	3.6e-38	Cognitive test performance;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08358671	chr1:185286807	IVNS1ABP	-0.46	-6.87	-0.3	2.11e-11	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9357271	0.652	rs78054489	chr6:38401926	C/T	cg07362130	chr6:38359646	BTBD9	-0.41	-8.37	-0.36	6.79e-16	Restless legs syndrome;
LGG	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg17376030	chr22:41985996	PMM1	-0.51	-8.25	-0.36	1.67e-15	Vitiligo;
LGG	cis	rs3784262	0.565	rs3784264	chr15:58250246	T/G	cg12031962	chr15:58353849	ALDH1A2	0.33	6.81	0.3	3e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg11871910	chr12:69753446	YEATS4	0.7	13.41	0.53	6.83e-35	Blood protein levels;
LGG	cis	rs28374715	0.617	rs16971733	chr15:41562030	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.83	-14.56	-0.56	7.95e-40	Ulcerative colitis;
LGG	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg12395012	chr8:11607386	GATA4	0.41	7.85	0.34	3e-14	Neuroticism;
LGG	cis	rs78366141	0.649	rs112818517	chr4:89653103	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.55	0.37	1.87e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg03517284	chr6:25882590	NA	-0.43	-6.98	-0.31	1.05e-11	Iron status biomarkers;
LGG	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg11764359	chr7:65958608	NA	-0.61	-10.26	-0.43	2.16e-22	Aortic root size;
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.62	-0.33	1.41e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.76	-0.38	3.71e-17	Neuroticism;
LGG	cis	rs12580194	0.593	rs7487895	chr12:55796720	T/C	cg19537932	chr12:55886519	OR6C68	-0.58	-10.49	-0.44	3.03e-23	Cancer;
LGG	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg04568710	chr12:38710424	ALG10B	-0.34	-7.14	-0.31	3.74e-12	Bladder cancer;
LGG	trans	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg27411982	chr8:10470053	RP1L1	-0.46	-8.0	-0.35	9.89e-15	Joint mobility (Beighton score);
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08645402	chr16:4508243	NA	0.52	9.41	0.4	2.26e-19	Schizophrenia;
LGG	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.98	0.35	1.17e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2070488	1.000	rs3792528	chr3:38493303	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.06	0.64	1.47e-55	Electrocardiographic conduction measures;
LGG	cis	rs7914558	0.966	rs746293	chr10:104897254	G/T	cg04362960	chr10:104952993	NT5C2	0.54	10.41	0.44	6.01e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.3	0.47	2.49e-26	Vitamin D levels;
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.77	-0.48	3.79e-28	Tonsillectomy;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg14092988	chr3:52407081	DNAH1	-0.29	-7.45	-0.33	4.68e-13	Bipolar disorder;
LGG	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg18898632	chr2:242989856	NA	-0.8	-9.76	-0.41	1.36e-20	Obesity-related traits;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.27	0.55	1.43e-38	Obesity-related traits;
LGG	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg22437258	chr11:111473054	SIK2	0.55	9.74	0.41	1.57e-20	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.01	-0.31	8.43e-12	Longevity;
LGG	trans	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg25214090	chr10:38739885	LOC399744	-0.6	-10.99	-0.45	4.13e-25	Corneal astigmatism;
LGG	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg11764359	chr7:65958608	NA	0.8	14.9	0.57	2.68e-41	Aortic root size;
LGG	cis	rs11229555	0.645	rs11229450	chr11:58201629	G/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02788857	chr8:22132959	PIWIL2	0.5	11.79	0.48	3.07e-28	Hypertriglyceridemia;
LGG	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg13073564	chr4:8508604	NA	-0.53	-10.92	-0.45	7.35e-25	Response to antineoplastic agents;
LGG	cis	rs2307022	0.586	rs4783623	chr16:68390113	A/G	cg07273125	chr16:68295692	NA	0.45	10.07	0.42	1.04e-21	Body mass index;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs4730779	0.571	rs10258791	chr7:117070582	C/A	cg10524701	chr7:117356490	CTTNBP2	0.4	7.85	0.34	2.84e-14	Waist circumference;
LGG	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs67478160	0.619	rs3742365	chr14:104198251	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-8.99	-0.39	6.2e-18	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17290332	chr10:14880008	CDNF;HSPA14	0.41	6.83	0.3	2.73e-11	Cognitive performance;
LGG	trans	rs7246760	0.609	rs12459250	chr19:9909543	C/T	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs477692	0.692	rs7905095	chr10:131448143	C/T	cg05714579	chr10:131428358	MGMT	-0.7	-15.67	-0.59	1.08e-44	Response to temozolomide;
LGG	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.3	-0.4	5.37e-19	Bone mineral density;
LGG	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.5	-0.44	2.88e-23	Hepatocellular carcinoma;
LGG	cis	rs12200560	0.505	rs927271	chr6:97075910	T/G	cg06623918	chr6:96969491	KIAA0776	0.43	7.18	0.32	2.79e-12	Coronary heart disease;
LGG	cis	rs2247341	0.965	rs11730727	chr4:1738313	T/C	cg05026014	chr4:1749153	NA	-0.34	-9.32	-0.4	4.59e-19	Hip circumference adjusted for BMI;Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14582546	chr20:61427684	C20orf20	0.55	8.89	0.38	1.39e-17	Gut microbiome composition (summer);
LGG	cis	rs7572644	0.679	rs12986980	chr2:28030437	A/G	cg27432699	chr2:27873401	GPN1	0.48	7.09	0.31	5.08e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7226408	0.600	rs12963071	chr18:34543990	G/A	cg15022739	chr18:34823045	BRUNOL4	0.42	9.05	0.39	3.97e-18	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg00383909	chr3:49044727	WDR6	0.45	7.46	0.33	4.27e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3925075	0.584	rs12600286	chr16:31360679	G/C	cg02846316	chr16:31340340	ITGAM	0.4	7.93	0.35	1.69e-14	IgA nephropathy;
LGG	cis	rs4233802	0.530	rs11894267	chr2:151155568	A/G	cg25300694	chr2:151184358	NA	0.43	6.96	0.31	1.14e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg11502198	chr6:26597334	ABT1	0.69	12.09	0.49	2.01e-29	Intelligence (multi-trait analysis);
LGG	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg22862003	chr21:42797588	MX1	-0.34	-8.6	-0.37	1.23e-16	IgG glycosylation;
LGG	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg16070123	chr10:51489643	NA	-0.4	-7.42	-0.33	5.81e-13	Prostate-specific antigen levels;
LGG	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.8	0.3	3.21e-11	Educational attainment;
LGG	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.08e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14754491	chr12:50677585	LIMA1	-0.45	-6.79	-0.3	3.56e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg08677398	chr8:58056175	NA	0.44	6.96	0.31	1.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10463554	0.963	rs34828	chr5:102442913	C/A	cg23492399	chr5:102201601	PAM	-0.51	-7.57	-0.33	2.04e-13	Parkinson's disease;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg12016809	chr21:47604291	C21orf56	0.49	8.22	0.36	2.12e-15	Testicular germ cell tumor;
LGG	cis	rs12220238	0.908	rs11000893	chr10:75905996	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.86	0.45	1.29e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg02002194	chr4:3960332	NA	-0.39	-6.93	-0.31	1.43e-11	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10904849	chr6:161695321	AGPAT4	0.55	8.4	0.36	5.54e-16	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.672	rs7846476	chr8:22479461	T/C	cg00599393	chr8:22457479	C8orf58	-0.42	-7.68	-0.34	9.79e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg21970626	chr13:21893289	NA	-0.41	-6.68	-0.3	6.98e-11	White matter hyperintensity burden;
LGG	cis	rs2070488	0.775	rs1073506	chr3:38566235	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.69	-13.16	-0.52	7.62e-34	Electrocardiographic conduction measures;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12281049	chr4:186990315	TLR3	0.38	6.67	0.3	7.27e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg11789530	chr4:8429930	ACOX3	-0.88	-17.52	-0.63	4.5e-53	Response to antineoplastic agents;
LGG	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg16096631	chr1:42092165	HIVEP3	0.76	22.62	0.72	7.3e-77	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-15.03	-0.57	6.96e-42	Response to antipsychotic treatment;
LGG	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03264133	chr6:25882463	NA	0.53	9.65	0.41	3.24e-20	Blood metabolite levels;
LGG	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg01657329	chr11:68192670	LRP5	0.63	10.4	0.44	6.62e-23	Bone mineral density (spine);
LGG	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.04	-0.35	7.36e-15	Retinal vascular caliber;
LGG	cis	rs72781680	0.898	rs72786279	chr2:24063266	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg04317338	chr11:64019027	PLCB3	0.59	6.67	0.3	7.47e-11	Mean platelet volume;
LGG	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07098314	chr17:39823360	NA	0.58	9.07	0.39	3.31e-18	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg04568710	chr12:38710424	ALG10B	0.4	8.46	0.37	3.65e-16	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.792	rs276436	chr9:15614370	A/T	cg14451791	chr9:16040625	NA	-0.34	-8.44	-0.36	4.24e-16	Body mass index;
LGG	cis	rs7215564	0.908	rs34932625	chr17:78653155	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs870825	0.616	rs4519834	chr4:185633865	A/G	cg04058563	chr4:185651563	MLF1IP	-1.0	-21.33	-0.7	8.48e-71	Blood protein levels;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.01e-23	Lymphocyte counts;
LGG	trans	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg07211511	chr3:129823064	LOC729375	-0.66	-9.1	-0.39	2.77e-18	Blood pressure (smoking interaction);
LGG	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg22681709	chr2:178499509	PDE11A	0.52	7.77	0.34	5.17e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg00666640	chr1:248458726	OR2T12	0.51	8.84	0.38	1.97e-17	Common traits (Other);
LGG	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg09427745	chr16:71932006	KIAA0174	-0.52	-7.63	-0.33	1.37e-13	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg19336497	chr11:14380999	RRAS2	0.38	7.22	0.32	2.19e-12	Mitochondrial DNA levels;
LGG	cis	rs2832191	0.720	rs2832194	chr21:30494250	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.91	-0.62	2.67e-50	Dental caries;
LGG	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg21130718	chr4:1044621	NA	0.39	7.62	0.33	1.46e-13	Recombination rate (males);
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg05896524	chr21:47604654	C21orf56	0.54	9.12	0.39	2.3e-18	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05457941	chr1:149858211	HIST2H2BE;HIST2H2AC	0.42	6.76	0.3	4.08e-11	Cognitive performance;
LGG	cis	rs9902453	0.765	rs62068653	chr17:28212663	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.11	0.55	7.09e-38	Coffee consumption (cups per day);
LGG	trans	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg17830980	chr10:43048298	ZNF37B	-0.35	-7.21	-0.32	2.3e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.68	-0.54	4.93e-36	Personality dimensions;
LGG	cis	rs17125944	0.615	rs12587286	chr14:53304751	C/T	cg00686598	chr14:53173677	PSMC6	0.92	8.93	0.38	9.99e-18	Alzheimer's disease (late onset);
LGG	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg24250549	chr1:154909240	PMVK	-0.53	-9.36	-0.4	3.4e-19	Prostate cancer;
LGG	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg00543991	chr22:32367038	NA	0.76	8.69	0.37	6.51e-17	Childhood ear infection;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg05091796	chr16:4465799	CORO7	-0.63	-10.42	-0.44	5.75e-23	Schizophrenia;
LGG	cis	rs988958	0.601	rs11887745	chr2:42238054	C/T	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs55986470	0.763	rs2280034	chr2:239438298	C/T	cg18131467	chr2:239335373	ASB1	-0.56	-6.98	-0.31	1.04e-11	Chronotype;
LGG	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg21775007	chr8:11205619	TDH	-0.5	-8.02	-0.35	8.89e-15	Triglycerides;
LGG	cis	rs59197085	0.636	rs60324735	chr7:128465450	A/G	cg00734629	chr7:128471146	FLNC	0.36	7.22	0.32	2.17e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs61192259	1.000	rs61192259	chr6:38453962	C/A	cg07362130	chr6:38359646	BTBD9	0.28	6.75	0.3	4.34e-11	Restless legs syndrome;
LGG	cis	rs700651	0.753	rs10207232	chr2:198893813	A/G	cg00792783	chr2:198669748	PLCL1	0.66	10.65	0.44	7.93e-24	Intracranial aneurysm;
LGG	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.86	0.34	2.74e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg25986240	chr4:9926439	SLC2A9	-0.59	-11.4	-0.47	1.06e-26	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg26695010	chr11:65641043	EFEMP2	0.57	9.86	0.42	6.28e-21	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg25457927	chr22:38595422	NA	-0.37	-8.76	-0.38	3.69e-17	Breast cancer;
LGG	cis	rs9487094	0.670	rs11754340	chr6:109905992	A/C	cg01125227	chr6:109776195	MICAL1	0.44	7.7	0.34	8.1e-14	Height;
LGG	cis	rs919433	0.680	rs788023	chr2:198283305	T/C	cg00792783	chr2:198669748	PLCL1	0.51	8.04	0.35	7.4e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg25174290	chr11:3078921	CARS	-0.49	-8.53	-0.37	2.11e-16	Calcium levels;
LGG	trans	rs877282	0.898	rs12357016	chr10:765675	C/T	cg22713356	chr15:30763199	NA	0.51	7.51	0.33	3.17e-13	Uric acid levels;
LGG	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg25801113	chr15:45476975	SHF	0.88	20.26	0.69	8.23e-66	Uric acid levels;
LGG	cis	rs4417704	0.551	rs12620108	chr2:241874076	G/A	cg26818257	chr2:241905806	NA	-0.48	-10.56	-0.44	1.62e-23	Joint mobility (Beighton score);
LGG	cis	rs6120849	0.707	rs6120798	chr20:33610822	T/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs11649743	0.701	rs7223387	chr17:36082473	A/C	cg21250756	chr17:36077300	HNF1B	0.29	7.8	0.34	4.01e-14	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg23188588	chr14:78226832	SNW1;C14orf178	-0.54	-6.81	-0.3	3.08e-11	Fibroblast growth factor basic levels;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.73	0.38	4.69e-17	Schizophrenia;
LGG	cis	rs4740619	0.967	rs10810428	chr9:15689759	C/G	cg14451791	chr9:16040625	NA	-0.37	-9.46	-0.4	1.56e-19	Body mass index;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs17767392	0.871	rs34347034	chr14:71935513	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.11e-25	Morning vs. evening chronotype;
LGG	cis	rs3008870	1.000	rs2815352	chr1:67482104	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.99	23.16	0.73	2.23e-79	Lymphocyte percentage of white cells;
LGG	trans	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Neuroticism;
LGG	cis	rs13095912	0.638	rs6791369	chr3:185289989	C/A	cg11274856	chr3:185301563	NA	0.49	7.87	0.34	2.45e-14	Systolic blood pressure;
LGG	cis	rs10489202	0.608	rs10918826	chr1:168075316	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.14	-0.43	6.03e-22	Schizophrenia;
LGG	cis	rs2710642	0.777	rs2539987	chr2:63142864	A/G	cg17519650	chr2:63277830	OTX1	0.5	8.22	0.36	2.01e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs7666738	0.830	rs113999196	chr4:99041961	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.8	0.59	2.72e-45	HDL cholesterol levels;
LGG	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg01620082	chr3:125678407	NA	-0.83	-9.45	-0.4	1.74e-19	Depression;
LGG	cis	rs2346160	0.932	rs2026993	chr6:167661034	T/C	cg20683250	chr6:167653907	NA	0.44	7.17	0.32	3.04e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg05335186	chr13:53173507	NA	0.68	16.62	0.61	5.26e-49	Lewy body disease;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1793639	0.902	rs1790165	chr11:131928971	C/A	cg13908476	chr11:131942942	NTM	0.43	8.9	0.38	1.23e-17	Myopia;
LGG	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07362569	chr17:61921086	SMARCD2	0.49	9.55	0.41	7.31e-20	Prudent dietary pattern;
LGG	cis	rs9487094	1.000	rs9487094	chr6:109742015	G/A	cg01125227	chr6:109776195	MICAL1	0.46	7.87	0.34	2.51e-14	Height;
LGG	cis	rs3820928	0.874	rs12614648	chr2:227785535	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.83	-0.34	3.47e-14	Pulmonary function;
LGG	cis	rs12893597	0.715	rs12892786	chr14:76833888	C/T	cg20290672	chr14:76816747	NA	-0.48	-7.3	-0.32	1.3e-12	Maximal oxygen uptake response;
LGG	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg13263323	chr15:86062960	AKAP13	-0.36	-7.32	-0.32	1.07e-12	Coronary artery disease;
LGG	cis	rs6032067	0.704	rs62208390	chr20:43794844	A/C	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg07701084	chr6:150067640	NUP43	-0.7	-13.34	-0.53	1.43e-34	Lung cancer;
LGG	cis	rs1506636	1.000	rs7357252	chr7:123369856	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.49	-0.65	1.39e-57	Plateletcrit;Platelet count;
LGG	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg15327641	chr2:3715039	ALLC	0.34	7.36	0.32	8.32e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3806843	0.676	rs2569159	chr5:140030710	C/T	cg19875535	chr5:140030758	IK	-0.59	-12.41	-0.5	9.79e-31	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg02900749	chr2:68251473	NA	-1.01	-10.63	-0.44	9.43e-24	Pursuit maintenance gain;
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg06618935	chr21:46677482	NA	-0.49	-9.64	-0.41	3.75e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4731207	0.596	rs10264766	chr7:124572916	T/A	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	cis	rs6723108	0.660	rs655472	chr2:135290221	A/G	cg20854539	chr2:135475426	TMEM163	-0.41	-6.65	-0.3	8.41e-11	Type 2 diabetes;
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.15	-0.32	3.44e-12	Neuroticism;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg03528353	chr17:61819722	STRADA	-0.42	-7.02	-0.31	7.94e-12	Prudent dietary pattern;
LGG	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.52	-0.33	2.79e-13	Refractive error;
LGG	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.72	0.41	1.8899999999999998e-20	Mood instability;
LGG	cis	rs883115	0.686	rs12730234	chr1:224863428	C/T	cg01808320	chr1:224927238	CNIH3	0.41	7.36	0.32	8.26e-13	Cancer;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.04	-0.31	6.76e-12	Longevity;Endometriosis;
LGG	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg08048268	chr3:133502702	NA	-0.61	-11.38	-0.47	1.22e-26	Iron status biomarkers;
LGG	cis	rs12410462	0.591	rs12082414	chr1:227786257	T/C	cg04117972	chr1:227635322	NA	0.46	8.39	0.36	5.84e-16	Major depressive disorder;
LGG	cis	rs1957429	0.808	rs1957436	chr14:65348207	T/G	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.34	-0.32	9.39e-13	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.07	0.42	1.03e-21	Motion sickness;
LGG	cis	rs6062302	0.549	rs4809586	chr20:62249402	C/T	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg08344181	chr3:125677491	NA	-0.58	-7.48	-0.33	3.73e-13	Depression;
LGG	cis	rs6964587	1.000	rs10274756	chr7:91740796	G/A	cg17063962	chr7:91808500	NA	0.5	9.12	0.39	2.39e-18	Breast cancer;
LGG	trans	rs9929218	1.000	rs12443730	chr16:68804342	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.86	-0.51	1.37e-32	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04132851	chr1:85155548	SSX2IP	0.52	8.2	0.36	2.44e-15	Gut microbiome composition (summer);
LGG	cis	rs72827839	0.793	rs112296021	chr17:46101460	G/A	cg02219949	chr17:45927392	SP6	0.52	7.91	0.35	1.88e-14	Ease of getting up in the morning;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07377662	chr17:81037199	METRNL	0.45	6.74	0.3	4.65e-11	Gut microbiome composition (summer);
LGG	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg03060546	chr3:49711283	APEH	0.73	13.06	0.52	2.15e-33	Resting heart rate;
LGG	cis	rs7572733	0.935	rs771016	chr2:198665520	C/T	cg00792783	chr2:198669748	PLCL1	0.48	8.13	0.35	3.95e-15	Dermatomyositis;
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.76	-0.3	4.16e-11	Bipolar disorder;
LGG	cis	rs11690935	1.000	rs312924	chr2:172564021	A/T	cg13550731	chr2:172543902	DYNC1I2	1.05	26.72	0.78	7.25e-96	Schizophrenia;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg27068330	chr11:65405492	SIPA1	0.48	7.55	0.33	2.37e-13	Blood pressure (age interaction);
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18876405	chr7:65276391	NA	-0.53	-9.08	-0.39	3.24e-18	Aortic root size;
LGG	cis	rs9487094	0.744	rs13220304	chr6:109652236	C/T	cg16315928	chr6:109776240	MICAL1	0.46	7.51	0.33	3.03e-13	Height;
LGG	cis	rs2274273	0.870	rs7158768	chr14:55763612	A/C	cg04306507	chr14:55594613	LGALS3	0.64	18.06	0.64	1.37e-55	Protein biomarker;
LGG	trans	rs61931739	0.574	rs12578378	chr12:33669639	C/G	cg26384229	chr12:38710491	ALG10B	-0.48	-8.41	-0.36	5.26e-16	Morning vs. evening chronotype;
LGG	cis	rs4787491	0.704	rs11644459	chr16:30095236	C/T	cg06326092	chr16:30034487	C16orf92	0.43	8.56	0.37	1.71e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg15704280	chr7:45808275	SEPT13	0.85	8.87	0.38	1.62e-17	Myopia (pathological);
LGG	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.68	-0.34	9.84e-14	Testicular germ cell tumor;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg11168104	chr5:1857477	NA	-0.4	-7.1	-0.31	4.59e-12	Cardiovascular disease risk factors;
LGG	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.86	-0.3	2.15e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09217309	chr6:150244204	RAET1G	0.44	8.13	0.35	3.96e-15	Testicular germ cell tumor;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg13939156	chr17:80058883	NA	-0.46	-8.89	-0.38	1.42e-17	Life satisfaction;
LGG	cis	rs4148660	0.719	rs1517272	chr12:22097301	T/C	cg14669847	chr12:22099120	NA	-0.39	-7.11	-0.31	4.5e-12	Gout;
LGG	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.81	-0.34	3.99e-14	HDL cholesterol;
LGG	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.25	-0.43	2.42e-22	Lymphocyte counts;
LGG	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg06565975	chr8:143823917	SLURP1	-0.28	-6.8	-0.3	3.17e-11	Urinary tract infection frequency;
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg21911579	chr5:131705225	SLC22A5	-0.68	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs35110281	0.807	rs1598206	chr21:45058776	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.05	-0.39	3.92e-18	Mean corpuscular volume;
LGG	cis	rs4430311	0.688	rs12143602	chr1:243744904	G/A	cg25706552	chr1:244017396	NA	-0.64	-15.51	-0.58	5.4e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10189230	0.546	rs6727259	chr2:222358292	C/G	cg14652038	chr2:222343519	EPHA4	-0.41	-8.05	-0.35	7.27e-15	Urate levels in lean individuals;
LGG	cis	rs7106204	0.668	rs7951530	chr11:24246904	T/C	ch.11.24196551F	chr11:24239977	NA	1.02	16.41	0.61	5.11e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg18196295	chr10:418757	DIP2C	-0.61	-11.72	-0.48	5.87e-28	Psychosis in Alzheimer's disease;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.19	0.32	2.65e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.71	-0.34	7.58e-14	Heart rate;
LGG	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg05555928	chr11:63887634	MACROD1	-0.58	-9.69	-0.41	2.34e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4423214	0.879	rs1792264	chr11:71150247	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-11.11	-0.46	1.43e-25	Vitamin D levels;
LGG	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.2	0.36	2.3e-15	Headache;
LGG	cis	rs7617773	0.817	rs13068265	chr3:48301614	A/C	cg11946769	chr3:48343235	NME6	0.69	11.34	0.47	1.75e-26	Coronary artery disease;
LGG	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg11252792	chr3:125932053	NA	-0.85	-17.62	-0.63	1.52e-53	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs787274	1.000	rs787286	chr9:115534336	T/C	cg13803584	chr9:115635662	SNX30	-0.59	-7.31	-0.32	1.16e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg27129171	chr3:47204927	SETD2	0.72	12.67	0.51	8.75e-32	Birth weight;
LGG	cis	rs71403859	0.502	rs12708914	chr16:71470636	G/A	cg08717414	chr16:71523259	ZNF19	-1.22	-16.42	-0.61	4.53e-48	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.23	-0.32	2.05e-12	Lung cancer;
LGG	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg13334819	chr7:99746414	C7orf59	0.52	8.13	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs17453880	0.890	rs12515178	chr5:152039638	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.59	-0.74	2.26e-81	Subjective well-being;
LGG	cis	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.46	-0.37	3.63e-16	Neuroticism;
LGG	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-12.47	-0.5	5.52e-31	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg05335186	chr13:53173507	NA	0.4	8.1	0.35	4.9e-15	Lewy body disease;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.47	-0.33	3.96e-13	Bipolar disorder;
LGG	trans	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg06521331	chr12:34319734	NA	0.5	9.34	0.4	3.94e-19	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg11301795	chr4:187892539	NA	-0.95	-24.9	-0.76	1.76e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2304069	0.954	rs2276983	chr5:149424966	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.78	11.56	0.47	2.56e-27	HIV-1 control;
LGG	cis	rs4731207	0.596	rs7779244	chr7:124652930	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg01864069	chr14:103024347	NA	0.47	8.1	0.35	4.85e-15	Platelet count;
LGG	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.31	0.36	1.11e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-7.26	-0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg24558204	chr6:135376177	HBS1L	-0.57	-9.58	-0.41	6.17e-20	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs12949688	0.601	rs11079327	chr17:55837375	C/T	cg12582317	chr17:55822272	NA	0.47	10.78	0.45	2.54e-24	Schizophrenia;
LGG	cis	rs6430585	0.527	rs76622824	chr2:136411879	A/G	cg07169764	chr2:136633963	MCM6	1.0	16.81	0.62	7.4e-50	Corneal structure;
LGG	cis	rs67311347	1.000	rs7625736	chr3:40441345	C/G	cg24209194	chr3:40518798	ZNF619	-0.41	-6.7	-0.3	6.14e-11	Renal cell carcinoma;
LGG	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg19507638	chr5:93509721	C5orf36	-0.69	-9.5	-0.4	1.1e-19	Diabetic retinopathy;
LGG	cis	rs6579956	0.517	rs4318765	chr5:152046544	G/C	cg12297329	chr5:152029980	NA	-0.5	-9.27	-0.4	7.13e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3789045	0.774	rs12029692	chr1:204532323	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.47	-9.33	-0.4	4.45e-19	Educational attainment (college completion);
LGG	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11890956	chr21:40555474	PSMG1	1.17	29.85	0.81	5.75e-110	Cognitive function;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25993851	chr11:46722334	ARHGAP1;ZNF408	0.42	7.15	0.32	3.3e-12	Bipolar disorder;
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1109114	0.934	rs10036768	chr5:148617988	A/T	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.27	-0.58	6.01e-43	Body mass index;
LGG	cis	rs935334	1.000	rs4903386	chr14:76669658	A/G	cg14073839	chr14:76668648	C14orf118	-0.41	-6.93	-0.31	1.43e-11	Blood pressure;
LGG	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg09085632	chr11:111637200	PPP2R1B	0.99	19.1	0.66	2.17e-60	Primary sclerosing cholangitis;
LGG	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.88	-0.34	2.37e-14	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.64	0.54	7.83e-36	Lung cancer;
LGG	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg14186256	chr22:23484241	RTDR1	0.53	8.32	0.36	9.72e-16	Serum parathyroid hormone levels;
LGG	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg12310025	chr6:25882481	NA	0.47	8.52	0.37	2.32e-16	Height;
LGG	cis	rs892961	0.932	rs312853	chr17:75406045	T/G	cg05865280	chr17:75406074	SEPT9	0.42	9.78	0.41	1.14e-20	Airflow obstruction;
LGG	cis	rs11096990	0.855	rs2566168	chr4:39151673	G/A	cg24403649	chr4:39172243	NA	-0.49	-7.93	-0.35	1.63e-14	Cognitive function;
LGG	cis	rs1790761	0.777	rs917570	chr11:67196544	C/G	cg00290607	chr11:67383545	NA	-0.48	-8.27	-0.36	1.45e-15	Mean corpuscular volume;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg18032289	chr17:61959525	GH2	-0.41	-7.0	-0.31	8.87e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg01244601	chr4:120671846	NA	0.36	6.64	0.3	8.6e-11	Corneal astigmatism;
LGG	cis	rs7246865	0.954	rs1060367	chr19:17215202	G/A	cg19418318	chr19:17219073	MYO9B	0.35	9.49	0.4	1.27e-19	Reticulocyte fraction of red cells;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg03528353	chr17:61819722	STRADA	0.45	7.63	0.33	1.35e-13	Prudent dietary pattern;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.37	0.32	7.95e-13	Prudent dietary pattern;
LGG	cis	rs6456156	0.565	rs12529238	chr6:167465576	G/A	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs9513627	1.000	rs2390278	chr13:100159712	G/A	cg15490075	chr13:100150979	NA	0.62	6.69	0.3	6.54e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.57e-19	Red blood cell count;
LGG	cis	rs9636252	0.810	rs13412683	chr2:9267605	A/G	cg20341998	chr2:9276514	NA	0.38	7.23	0.32	2.03e-12	IgG glycosylation;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg07332563	chr6:291687	DUSP22	-0.58	-9.48	-0.4	1.32e-19	Menopause (age at onset);
LGG	cis	rs968451	0.951	rs5757622	chr22:39728861	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	11.42	0.47	8.41e-27	Primary biliary cholangitis;
LGG	cis	rs12200560	0.505	rs172425	chr6:97075299	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs9863	0.828	rs11057409	chr12:124479331	A/G	cg13487667	chr12:124434373	CCDC92	0.35	7.04	0.31	7.13e-12	White blood cell count;
LGG	cis	rs9387478	0.500	rs34059490	chr6:117791260	T/G	cg14611402	chr6:117803162	DCBLD1	0.29	8.57	0.37	1.6e-16	Lung cancer;
LGG	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg25482853	chr8:67687455	SGK3	1.05	13.21	0.52	4.95e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs432925	0.600	rs214249	chr16:348687	T/G	cg06233593	chr16:337645	AXIN1	0.44	8.2	0.36	2.46e-15	Morning vs. evening chronotype;
LGG	cis	rs975739	0.657	rs9544679	chr13:78611819	C/T	cg07847733	chr13:78271382	SLAIN1	0.47	8.08	0.35	5.6e-15	Hair color;
LGG	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-11.82	-0.48	2.35e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs67311347	0.955	rs6764102	chr3:40378153	C/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.23	-0.68	1.17e-65	Renal cell carcinoma;
LGG	cis	rs738321	0.756	rs11089863	chr22:38512402	G/A	cg03162506	chr22:38580953	NA	0.36	8.59	0.37	1.32e-16	Breast cancer;
LGG	cis	rs9815354	1.000	rs1025646	chr3:41754422	A/T	cg03022575	chr3:42003672	ULK4	0.62	7.8	0.34	4.17e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.72	-0.41	1.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg13660082	chr14:53194042	PSMC6	-0.56	-7.95	-0.35	1.43e-14	Alzheimer's disease (late onset);
LGG	cis	rs2239547	0.563	rs6797399	chr3:52905917	G/A	cg11645453	chr3:52864694	ITIH4	0.71	10.95	0.45	5.49e-25	Schizophrenia;
LGG	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-8.38	-0.36	6.17e-16	Educational attainment;
LGG	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.62e-13	Platelet count;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg04234412	chr22:24373322	LOC391322	-0.86	-18.86	-0.66	2.69e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs113835537	0.529	rs10896125	chr11:66288733	G/C	cg24851651	chr11:66362959	CCS	0.45	7.75	0.34	5.82e-14	Airway imaging phenotypes;
LGG	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.32	0.55	8.72e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg05775895	chr3:12838266	CAND2	0.64	11.44	0.47	7.62e-27	QRS complex (12-leadsum);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05525867	chr15:75661090	MAN2C1	0.42	6.68	0.3	7.03e-11	Cognitive performance;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20104243	chr12:133060347	NA	0.4	6.95	0.31	1.21e-11	Pancreatic cancer;
LGG	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.19	-0.32	2.63e-12	Restless legs syndrome;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg26150922	chr2:100937072	LONRF2	0.52	8.34	0.36	8.9e-16	Intelligence (multi-trait analysis);
LGG	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.31	0.36	1.07e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg25237894	chr2:233734115	C2orf82	-0.71	-15.01	-0.57	9.25e-42	Coronary artery disease;
LGG	cis	rs975722	0.507	rs757278	chr7:117377645	G/T	cg10524701	chr7:117356490	CTTNBP2	0.44	8.88	0.38	1.52e-17	Coronary artery disease;
LGG	cis	rs8017423	0.967	rs57793584	chr14:90714833	G/A	cg04374321	chr14:90722782	PSMC1	0.88	18.67	0.66	2.02e-58	Mortality in heart failure;
LGG	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.9	-0.48	1.12e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.11	-0.49	1.63e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14159672	chr1:205819179	PM20D1	0.9	21.79	0.71	5.65e-73	Menarche (age at onset);
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs7172677	0.961	rs4421941	chr15:75400740	A/G	cg14664628	chr15:75095509	CSK	0.54	8.3	0.36	1.19e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11112613	0.713	rs58066965	chr12:105952505	C/G	cg03607813	chr12:105948248	NA	0.59	10.85	0.45	1.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg13736514	chr6:26305472	NA	-0.46	-9.54	-0.41	8.29e-20	Educational attainment;
LGG	trans	rs9650657	0.623	rs6601514	chr8:10601281	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.37	-0.32	7.85e-13	Neuroticism;
LGG	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg23231163	chr10:75533350	FUT11	-0.4	-6.91	-0.31	1.56e-11	Inflammatory bowel disease;
LGG	cis	rs4363385	0.791	rs10788855	chr1:153002359	A/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.76	-0.38	3.61e-17	Inflammatory skin disease;
LGG	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.33	-0.36	9.11e-16	Triglycerides;
LGG	cis	rs17776563	0.887	rs28773595	chr15:89128232	A/G	cg05013243	chr15:89149849	MIR1179	-0.5	-10.43	-0.44	5.32e-23	Thyroid hormone levels;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg11764359	chr7:65958608	NA	-0.73	-12.96	-0.52	5.43e-33	Aortic root size;
LGG	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-12.89	-0.51	1.01e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg06654118	chr4:1303317	MAEA	0.48	7.94	0.35	1.59e-14	Obesity-related traits;
LGG	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg26384229	chr12:38710491	ALG10B	-0.73	-14.11	-0.55	7.51e-38	Morning vs. evening chronotype;
LGG	cis	rs4975616	0.869	rs370348	chr5:1331219	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.36	-0.65	5.97e-57	Lung cancer;
LGG	cis	rs832540	0.629	rs3309	chr5:56092779	A/T	cg12654349	chr5:56205094	C5orf35	0.4	6.96	0.31	1.14e-11	Coronary artery disease;
LGG	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg25554036	chr4:6271136	WFS1	-0.54	-9.58	-0.41	5.94e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg24848339	chr3:12840334	CAND2	0.45	10.8	0.45	2.07e-24	QRS complex (12-leadsum);
LGG	cis	rs1371867	0.846	rs1788206	chr8:101306966	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs6735179	0.607	rs10202812	chr2:1746468	A/T	cg20570797	chr2:1712800	PXDN	-0.46	-7.73	-0.34	6.84e-14	Response to antipsychotic treatment;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg03160526	chr17:80928410	B3GNTL1	0.47	7.61	0.33	1.58e-13	Glycated hemoglobin levels;
LGG	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.46	-0.33	4.44e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.89e-21	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2708240	0.577	rs10246256	chr7:147554807	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.32	-0.32	1.09e-12	QT interval (drug interaction);
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg08621203	chr6:150244597	RAET1G	0.41	6.9	0.31	1.77e-11	Lung cancer;
LGG	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.98	-0.39	6.96e-18	Response to antipsychotic treatment;
LGG	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg01557791	chr16:72042693	DHODH	-0.56	-10.26	-0.43	2.22e-22	Fibrinogen levels;
LGG	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.64	-8.15	-0.35	3.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-8.68	-0.37	6.76e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.55e-19	Colorectal cancer;
LGG	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27297192	chr10:134578999	INPP5A	0.32	7.2	0.32	2.48e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08704250	chr15:31115839	NA	-0.43	-7.82	-0.34	3.51e-14	Huntington's disease progression;
LGG	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg25706552	chr1:244017396	NA	0.52	8.46	0.37	3.46e-16	RR interval (heart rate);
LGG	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg24189917	chr7:1970923	MAD1L1	-0.61	-8.92	-0.38	1.07e-17	Bipolar disorder;
LGG	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg03806693	chr22:41940476	POLR3H	0.88	15.51	0.58	5.26e-44	Vitiligo;
LGG	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg00198680	chr16:28758506	NA	0.3	7.64	0.33	1.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg11062466	chr8:58055876	NA	0.6	13.86	0.54	8.86e-37	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg16339924	chr4:17578868	LAP3	0.5	8.39	0.36	5.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg14505434	chr11:89522851	NA	0.63	8.98	0.39	6.98e-18	White blood cell types;
LGG	cis	rs975739	0.695	rs1924938	chr13:78524430	G/C	cg07847733	chr13:78271382	SLAIN1	0.42	7.22	0.32	2.11e-12	Hair color;
LGG	cis	rs1847505	1.000	rs1847505	chr13:61532597	G/C	cg25164009	chr13:61490935	NA	-0.61	-9.72	-0.41	1.85e-20	Polychlorinated biphenyl levels;
LGG	cis	rs2236918	1.000	rs2236919	chr1:242017731	A/G	cg17736920	chr1:242011382	EXO1	0.52	9.42	0.4	2.08e-19	Menopause (age at onset);
LGG	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs7010267	0.805	rs2062375	chr8:119977792	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.45	0.44	4.37e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs79387448	0.638	rs78123896	chr2:103075417	T/C	cg20060108	chr2:102954350	IL1RL1	-0.45	-6.84	-0.3	2.47e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg00717180	chr2:96193071	NA	0.41	7.3	0.32	1.24e-12	HDL cholesterol;
LGG	cis	rs67311347	1.000	rs962847	chr3:40495156	A/G	cg13683864	chr3:40499215	RPL14	1.16	29.23	0.81	3.37e-107	Renal cell carcinoma;
LGG	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.31	0.36	1.04e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12493885	0.818	rs10935972	chr3:153774029	G/A	cg12800244	chr3:153838788	SGEF	-0.82	-9.08	-0.39	3.03e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs6601327	0.602	rs35431433	chr8:9660621	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.96	-0.31	1.14e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.59	0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs11229555	0.645	rs10896785	chr11:58233395	G/A	cg15696309	chr11:58395628	NA	-0.97	-15.79	-0.59	3e-45	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07988820	chr12:82153109	PPFIA2	-0.72	-11.34	-0.47	1.75e-26	Resting heart rate;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs113835537	0.529	rs11227500	chr11:66273233	T/C	cg24851651	chr11:66362959	CCS	0.45	7.77	0.34	5.26e-14	Airway imaging phenotypes;
LGG	cis	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg10911889	chr6:126070802	HEY2	-0.41	-6.79	-0.3	3.55e-11	Brugada syndrome;
LGG	cis	rs72772090	0.908	rs17086588	chr5:96044914	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.44	7.06	0.31	6e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs524281	0.861	rs10791854	chr11:65963543	A/T	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs61931739	0.649	rs12424046	chr12:33714374	C/T	cg06521331	chr12:34319734	NA	0.39	6.8	0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.24e-13	Schizophrenia;
LGG	cis	rs10779751	0.734	rs1034528	chr1:11249132	G/C	cg08854313	chr1:11322531	MTOR	-0.71	-15.38	-0.58	2e-43	Body mass index;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.69	-0.34	8.98e-14	Lung cancer;
LGG	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg05527609	chr1:210001259	C1orf107	-0.5	-6.99	-0.31	9.71e-12	Red blood cell count;
LGG	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-7.97	-0.35	1.23e-14	Breast cancer;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg01879757	chr17:41196368	BRCA1	0.44	8.84	0.38	2.01e-17	Menopause (age at onset);
LGG	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg18187862	chr3:45730750	SACM1L	-0.43	-7.1	-0.31	4.64e-12	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.23	-0.39	9.71e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.03	0.57	7.02e-42	Cognitive test performance;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg13397359	chr6:42928475	GNMT	0.57	15.4	0.58	1.63e-43	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.74	0.3	4.86e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.37	-0.5	1.48e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05491587	chr18:77659695	KCNG2	-0.53	-7.06	-0.31	6.06e-12	Opioid sensitivity;
LGG	cis	rs1915146	1.000	rs1915146	chr10:126846214	A/G	cg23000734	chr10:126850823	CTBP2	0.3	9.18	0.39	1.48e-18	Menarche (age at onset);
LGG	trans	rs61931739	0.507	rs1352393	chr12:33815820	A/G	cg26384229	chr12:38710491	ALG10B	0.46	8.2	0.36	2.36e-15	Morning vs. evening chronotype;
LGG	cis	rs537930	0.925	rs674464	chr5:134349392	T/C	cg24576358	chr5:134350122	NA	0.49	10.32	0.43	1.33e-22	Height;
LGG	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg15704280	chr7:45808275	SEPT13	0.78	8.98	0.39	7.05e-18	Axial length;
LGG	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg06637938	chr14:75390232	RPS6KL1	0.52	9.16	0.39	1.65e-18	Height;
LGG	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg00204512	chr16:28754710	NA	0.25	7.05	0.31	6.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Vitiligo;
LGG	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.74	0.45	3.65e-24	Lung cancer in ever smokers;
LGG	cis	rs7188861	0.603	rs2113260	chr16:11455993	C/T	cg00044050	chr16:11439710	C16orf75	0.44	6.8	0.3	3.15e-11	HDL cholesterol;
LGG	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg13010199	chr12:38710504	ALG10B	0.58	10.92	0.45	7.43e-25	Morning vs. evening chronotype;
LGG	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg05025159	chr2:241905733	NA	-0.46	-9.39	-0.4	2.63e-19	Joint mobility (Beighton score);
LGG	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg00599393	chr8:22457479	C8orf58	0.46	8.4	0.36	5.69e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3806843	1.000	rs12055222	chr5:140165568	T/C	cg19875535	chr5:140030758	IK	0.51	10.67	0.44	6.5e-24	Depressive symptoms (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21160472	chr1:212782112	ATF3	0.44	6.89	0.3	1.79e-11	Cognitive performance;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	7.69e-17	Lung cancer;
LGG	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg10167378	chr1:228756711	NA	0.7	9.48	0.4	1.29e-19	Chronic lymphocytic leukemia;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.5	-0.33	3.4e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg07636037	chr3:49044803	WDR6	0.46	7.01	0.31	8.39e-12	Resting heart rate;
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg18404041	chr3:52824283	ITIH1	0.57	11.0	0.46	3.6e-25	Bipolar disorder;
LGG	cis	rs2629540	0.847	rs12247543	chr10:126419743	G/C	cg08799069	chr10:126477246	METTL10	0.67	13.65	0.54	6.66e-36	Cocaine dependence;
LGG	cis	rs36051895	0.664	rs17425637	chr9:5110000	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.19	-0.58	1.45e-42	Pediatric autoimmune diseases;
LGG	cis	rs1506636	1.000	rs646753	chr7:123401237	G/T	cg03229431	chr7:123269106	ASB15	0.73	18.22	0.65	2.5e-56	Plateletcrit;Platelet count;
LGG	cis	rs2658782	0.789	rs1456238	chr11:93117370	G/C	cg15737290	chr11:93063684	CCDC67	0.52	7.78	0.34	4.67e-14	Pulmonary function decline;
LGG	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg08250081	chr4:10125330	NA	-0.49	-9.77	-0.41	1.25e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.2	0.49	6.75e-30	Hip circumference adjusted for BMI;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04696559	chr5:36152378	SKP2;LMBRD2	-0.46	-6.8	-0.3	3.21e-11	Systemic lupus erythematosus;
LGG	cis	rs4538187	0.737	rs36033991	chr2:64150441	A/G	cg19915305	chr2:64069682	UGP2	-0.69	-15.34	-0.58	2.94e-43	Systolic blood pressure;
LGG	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg03806693	chr22:41940476	POLR3H	0.94	16.91	0.62	2.72e-50	Vitiligo;
LGG	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.4	-0.47	1.06e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13082711	0.554	rs35840701	chr3:27334231	A/C	cg02860705	chr3:27208620	NA	0.93	17.44	0.63	1.02e-52	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.95	-0.31	1.25e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6840360	0.593	rs10013612	chr4:152693622	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.26	-0.43	2.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs17030434	0.784	rs4696486	chr4:154651354	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.51	-0.4	1e-19	Electrocardiographic conduction measures;
LGG	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg05234568	chr11:5960015	NA	-0.64	-10.2	-0.43	3.54e-22	DNA methylation (variation);
LGG	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.57	-0.71	6.1e-72	Heart rate;
LGG	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg22432760	chr17:80829718	TBCD	-0.4	-6.95	-0.31	1.28e-11	Breast cancer;
LGG	cis	rs7289126	1.000	rs7290372	chr22:38628388	T/G	cg03162506	chr22:38580953	NA	0.27	6.74	0.3	4.67e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs921968	0.612	rs4674323	chr2:219517088	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.14	-0.31	3.69e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.21	0.39	1.17e-18	Neuroticism;
LGG	trans	rs7944735	0.817	rs2305983	chr11:47858755	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.79	0.34	4.46e-14	Intraocular pressure;
LGG	cis	rs9486719	0.947	rs2472893	chr6:96870048	G/C	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs963731	0.649	rs297159	chr2:39328827	C/T	cg04010122	chr2:39346883	SOS1	-0.94	-8.19	-0.36	2.53e-15	Corticobasal degeneration;
LGG	cis	rs7623687	0.579	rs78807522	chr3:49056150	C/A	cg19401529	chr3:49056140	DALRD3	0.74	8.19	0.36	2.52e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg13385521	chr17:29058706	SUZ12P	0.7	8.28	0.36	1.32e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17125944	0.773	rs1952089	chr14:53339777	C/T	cg00686598	chr14:53173677	PSMC6	-0.72	-7.72	-0.34	7.21e-14	Alzheimer's disease (late onset);
LGG	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg27661571	chr11:113659931	NA	-0.69	-9.43	-0.4	1.95e-19	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg05941027	chr17:61774174	LIMD2	0.36	9.02	0.39	5.21e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg10160682	chr2:1713001	PXDN	-0.54	-9.75	-0.41	1.47e-20	Response to antipsychotic treatment;
LGG	cis	rs1007190	0.881	rs12937256	chr17:42981499	C/T	cg15406952	chr17:42872593	NA	1.1	14.01	0.55	1.94e-37	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16854052	chr11:14542106	PSMA1	0.45	7.37	0.32	7.82e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07080220	chr10:102295463	HIF1AN	0.7	12.05	0.49	2.88e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.61	-0.37	1.15e-16	Menopause (age at onset);
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7727544	0.582	rs3828675	chr5:131546868	G/A	cg07395648	chr5:131743802	NA	-0.39	-8.5	-0.37	2.69e-16	Blood metabolite levels;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.72e-18	Aortic root size;
LGG	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg04362960	chr10:104952993	NT5C2	0.54	9.57	0.41	6.19e-20	Arsenic metabolism;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg10207240	chr12:122356781	WDR66	0.24	7.42	0.33	5.74e-13	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25820220	chr8:107282481	OXR1	0.5	7.35	0.32	8.76e-13	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.66	-7.89	-0.34	2.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg12633918	chr20:23549525	CST9L	-0.32	-6.65	-0.3	8.22e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	trans	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg17712092	chr4:129076599	LARP1B	-0.57	-9.57	-0.41	6.45e-20	Breast cancer;
LGG	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg26597838	chr10:835615	NA	0.69	8.78	0.38	3.19e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs7226408	0.857	rs2007524	chr18:34450142	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23598886	chr18:12777645	NA	0.74	10.36	0.43	9.15e-23	Inflammatory skin disease;
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg13628971	chr7:2884303	GNA12	0.53	10.67	0.44	6.43e-24	Height;
LGG	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg20637307	chr2:213403960	ERBB4	0.55	10.68	0.44	6.01e-24	Symmetrical dimethylarginine levels;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18876405	chr7:65276391	NA	0.53	9.48	0.4	1.36e-19	Aortic root size;
LGG	cis	rs7666738	0.830	rs62321598	chr4:99014237	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.19e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg26879891	chr1:152191343	HRNR	-0.32	-6.72	-0.3	5.25e-11	Inflammatory skin disease;
LGG	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg24503407	chr1:205819492	PM20D1	-0.4	-7.14	-0.32	3.56e-12	Menarche (age at onset);
LGG	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs17106184	1.000	rs12078434	chr1:51393645	C/G	cg07174182	chr1:51127561	FAF1	0.57	8.43	0.36	4.36e-16	Type 2 diabetes;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg11708118	chr12:6862968	MLF2	0.38	7.2	0.32	2.42e-12	Corneal astigmatism;
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg01069141	chr11:67398826	TBX10;NUDT8	-0.36	-6.68	-0.3	6.81e-11	Mean corpuscular volume;
LGG	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.81	-0.34	3.99e-14	Myeloid white cell count;
LGG	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg04691961	chr3:161091175	C3orf57	0.42	8.86	0.38	1.75e-17	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.84e-14	Height;
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg13736514	chr6:26305472	NA	-0.34	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs7663924	chr4:99037679	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-8.27	-0.36	1.45e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01212965	chr4:106630041	GSTCD;INTS12	0.45	7.82	0.34	3.63e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg07061783	chr6:25882402	NA	-0.45	-7.93	-0.35	1.64e-14	Blood metabolite levels;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.75	-0.3	4.37e-11	Height;
LGG	cis	rs3747547	0.710	rs7864512	chr9:37949638	G/A	cg13774184	chr9:37916125	SHB	-0.72	-8.02	-0.35	8.98e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.49	9.49	0.4	1.24e-19	Prostate cancer;
LGG	cis	rs1163251	0.869	rs487884	chr1:120217330	C/T	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs6489882	0.836	rs7967461	chr12:113369759	G/C	cg25319449	chr12:113376135	OAS3	-0.41	-7.6	-0.33	1.64e-13	Chronic lymphocytic leukemia;
LGG	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.53	-0.33	2.6e-13	HDL cholesterol;
LGG	cis	rs8028182	0.636	rs28783769	chr15:75849009	C/A	cg20655648	chr15:75932815	IMP3	0.44	7.31	0.32	1.19e-12	Sudden cardiac arrest;
LGG	cis	rs977987	0.868	rs10871313	chr16:75507094	C/T	cg03315344	chr16:75512273	CHST6	0.57	10.94	0.45	6.19e-25	Dupuytren's disease;
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg19223190	chr17:80058835	NA	-0.47	-9.07	-0.39	3.33e-18	Life satisfaction;
LGG	trans	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg19676328	chr12:49525230	TUBA1B	-0.63	-10.29	-0.43	1.7e-22	Total cholesterol levels;
LGG	cis	rs4936894	0.500	rs10790649	chr11:124080360	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.11	-0.43	7.56e-22	Aging (time to death);
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg19077165	chr18:44547161	KATNAL2	0.69	13.36	0.53	1.12e-34	Personality dimensions;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg19168338	chr16:4465731	CORO7	0.83	15.09	0.57	3.76e-42	Schizophrenia;
LGG	cis	rs7928758	0.943	rs878987	chr11:134266372	A/G	cg22777979	chr11:134283252	B3GAT1	0.83	10.79	0.45	2.38e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg09048205	chr5:1608656	LOC728613	-0.5	-8.44	-0.37	4.05e-16	Breast cancer;
LGG	cis	rs7660883	0.866	rs1674999	chr4:88027650	G/A	cg21988461	chr4:88008667	AFF1	0.34	9.77	0.41	1.23e-20	HDL cholesterol levels;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg11965913	chr1:205819406	PM20D1	-0.8	-16.62	-0.61	5.56e-49	Menarche (age at onset);
LGG	cis	rs1904096	0.506	rs17021463	chr4:95224812	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.09	-0.46	1.7e-25	Type 2 diabetes;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.01	0.49	4.02e-29	Prudent dietary pattern;
LGG	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg27432699	chr2:27873401	GPN1	0.72	14.94	0.57	1.76e-41	Oral cavity cancer;
LGG	cis	rs6860806	0.507	rs273915	chr5:131660119	G/C	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Breast cancer;
LGG	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg12419862	chr22:24373484	LOC391322	-0.65	-9.98	-0.42	2.25e-21	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg20978937	chr14:105399321	PLD4	-0.39	-8.42	-0.36	4.87e-16	Rheumatoid arthritis;
LGG	cis	rs11627756	0.958	rs10131189	chr14:103091440	C/G	cg12046867	chr14:103022105	NA	-0.44	-8.16	-0.35	3.14e-15	Mean platelet volume;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.63e-12	Lung cancer;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.64	11.21	0.46	5.76e-26	Obesity-related traits;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07308232	chr7:1071921	C7orf50	-0.71	-14.05	-0.55	1.35e-37	Longevity;Endometriosis;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.51	-9.85	-0.42	6.77e-21	Prudent dietary pattern;
LGG	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.16e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg21699342	chr2:239360505	ASB1	0.38	7.25	0.32	1.79e-12	Multiple system atrophy;
LGG	cis	rs9309473	0.950	rs6726694	chr2:73847230	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.86	-0.34	2.72e-14	Metabolite levels;
LGG	cis	rs3206736	0.593	rs328923	chr7:35035695	G/A	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.63e-19	Diastolic blood pressure;
LGG	cis	rs7312774	0.618	rs4964195	chr12:107392778	T/C	cg16260113	chr12:107380972	MTERFD3	0.72	7.0	0.31	9.24e-12	Severe influenza A (H1N1) infection;
LGG	cis	rs10991814	0.844	rs7860510	chr9:94128796	C/G	cg14446406	chr9:93919335	NA	-0.7	-7.77	-0.34	5.14e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.07	-20.07	-0.68	6.7e-65	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg21545522	chr1:205238299	TMCC2	0.41	7.86	0.34	2.63e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg14092988	chr3:52407081	DNAH1	0.25	6.84	0.3	2.5e-11	Electroencephalogram traits;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs1670533	1.000	rs1670533	chr4:1078187	G/A	cg27284194	chr4:1044797	NA	0.54	9.92	0.42	3.6e-21	Recombination rate (females);
LGG	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg03511173	chr18:77590860	NA	0.62	7.79	0.34	4.41e-14	Opioid sensitivity;
LGG	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	trans	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg05926928	chr17:57297772	GDPD1	-0.51	-7.68	-0.34	9.24e-14	Schizophrenia;
LGG	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg21452805	chr1:244014465	NA	0.59	6.98	0.31	1.01e-11	RR interval (heart rate);
LGG	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	7.75	0.34	5.83e-14	Cognitive test performance;
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.19e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.96	-0.31	1.2e-11	Fear of minor pain;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg05252892	chr5:154320678	MRPL22	0.46	6.93	0.31	1.39e-11	Breast cancer;
LGG	cis	rs754466	0.580	rs10824575	chr10:79549047	A/G	cg17075019	chr10:79541650	NA	-0.98	-22.16	-0.72	1.1e-74	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg21775007	chr8:11205619	TDH	0.51	8.08	0.35	5.59e-15	Retinal vascular caliber;
LGG	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03352830	chr11:487213	PTDSS2	0.86	10.85	0.45	1.33e-24	Body mass index;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10783050	chr4:185377277	IRF2	0.33	6.74	0.3	4.63e-11	Electrocardiographic conduction measures;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.7	-0.3	5.9e-11	Longevity;Endometriosis;
LGG	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg07274523	chr3:49395745	GPX1	0.55	8.98	0.39	6.62e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg00953403	chr17:74099816	EXOC7	-0.41	-6.76	-0.3	4.09e-11	Psychosis in Alzheimer's disease;
LGG	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.88	0.57	3.22e-41	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg19635926	chr16:89946313	TCF25	0.67	8.05	0.35	6.99e-15	Skin colour saturation;
LGG	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7166081	1.000	rs12592400	chr15:67558010	C/A	cg05925327	chr15:68127851	NA	-0.33	-6.94	-0.31	1.35e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs981844	0.816	rs56413502	chr4:154721784	T/A	cg14289246	chr4:154710475	SFRP2	0.71	11.63	0.48	1.34e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.32	0.55	8.78e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6942756	0.955	rs55638303	chr7:128885770	C/T	cg02491457	chr7:128862824	NA	-0.77	-13.92	-0.54	4.69e-37	White matter hyperintensity burden;
LGG	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg06634786	chr22:41940651	POLR3H	0.66	10.69	0.44	5.56e-24	Vitiligo;
LGG	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg13010199	chr12:38710504	ALG10B	0.47	8.57	0.37	1.54e-16	Resting heart rate;
LGG	trans	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.45e-27	Corneal astigmatism;
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07685180	chr8:600429	NA	1.0	9.55	0.41	7.47e-20	IgG glycosylation;
LGG	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg21775007	chr8:11205619	TDH	-0.44	-6.95	-0.31	1.24e-11	Neuroticism;
LGG	cis	rs17001868	0.568	rs9611325	chr22:40782490	G/A	cg07138101	chr22:40742427	ADSL	0.69	9.05	0.39	3.85e-18	Mammographic density (dense area);
LGG	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-7.41	-0.33	6.12e-13	Vitamin D levels;
LGG	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.45e-13	HDL cholesterol;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg20120463	chr17:44301886	NA	-0.48	-7.41	-0.33	6.15e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.34	0.55	7.15e-39	Obesity-related traits;
LGG	cis	rs926392	0.572	rs6129157	chr20:37672247	G/T	cg16355469	chr20:37678765	NA	0.6	9.45	0.4	1.72e-19	Dialysis-related mortality;
LGG	cis	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	10.65	0.44	7.74e-24	Longevity;
LGG	cis	rs727505	0.954	rs28638102	chr7:124499480	A/C	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg01557791	chr16:72042693	DHODH	-0.48	-6.97	-0.31	1.08e-11	Blood protein levels;
LGG	cis	rs7619833	0.685	rs1899997	chr3:27307196	A/G	cg02860705	chr3:27208620	NA	0.4	7.58	0.33	1.85e-13	Breast cancer;
LGG	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg05234568	chr11:5960015	NA	-0.63	-9.98	-0.42	2.26e-21	DNA methylation (variation);
LGG	cis	rs35160687	0.623	rs11127021	chr2:86474919	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	7.06	0.31	6.16e-12	Night sleep phenotypes;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs7173389	1.000	rs8038766	chr15:73663314	A/G	cg01796676	chr15:73680284	NA	0.48	8.23	0.36	1.89e-15	Resting heart rate;
LGG	cis	rs7210086	0.606	rs72849437	chr17:70631124	T/C	cg04206342	chr17:70636940	NA	-0.34	-6.73	-0.3	5.16e-11	Ulcerative colitis;
LGG	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs4900538	0.819	rs72698595	chr14:102863099	G/A	cg18135206	chr14:102964638	TECPR2	-0.69	-12.62	-0.51	1.34e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs67385638	0.862	rs11036641	chr11:5310578	A/G	cg12559170	chr11:5275217	HBG2	0.53	11.94	0.49	8.05e-29	Hemoglobin levels;
LGG	cis	rs4740619	0.875	rs9886731	chr9:15804297	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.12	-0.43	7.1e-22	Body mass index;
LGG	cis	rs9583531	0.550	rs7985098	chr13:111386416	G/A	cg24331049	chr13:111365604	ING1	0.84	15.12	0.57	2.89e-42	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg18032289	chr17:61959525	GH2	-0.39	-6.84	-0.3	2.53e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg01028140	chr2:1542097	TPO	-0.54	-8.55	-0.37	1.74e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg02733842	chr7:1102375	C7orf50	0.72	8.37	0.36	6.65e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00166722	chr3:10149974	C3orf24	0.5	8.36	0.36	7.58e-16	Alzheimer's disease;
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.83	0.68	8.3e-64	Platelet count;
LGG	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.5	0.33	3.32e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-9.97	-0.42	2.41e-21	Chronic sinus infection;
LGG	cis	rs12137294	0.761	rs1172150	chr1:205221861	A/G	cg00889227	chr1:205173544	DSTYK	-0.27	-6.75	-0.3	4.34e-11	Red cell distribution width;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg13880726	chr7:1868755	MAD1L1	0.42	7.4	0.33	6.2800000000000005e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3820928	0.874	rs56324594	chr2:227868854	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.46	-0.33	4.37e-13	Pulmonary function;
LGG	cis	rs8064024	0.538	rs12446456	chr16:4922201	C/T	cg08329684	chr16:4932620	PPL	0.55	12.57	0.5	2.24e-31	Cancer;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.75	0.34	5.83e-14	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs12618769	0.652	rs1516085	chr2:99232312	G/A	cg18455616	chr2:99124870	INPP4A	0.27	7.66	0.34	1.11e-13	Bipolar disorder;
LGG	trans	rs3960554	1.000	rs3960554	chr7:75845597	G/T	cg19862616	chr7:65841803	NCRNA00174	0.82	11.78	0.48	3.3e-28	Eotaxin levels;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs28647808	0.881	rs7029256	chr9:136263655	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs6429082	0.783	rs291364	chr1:235687179	A/G	cg26050004	chr1:235667680	B3GALNT2	0.69	11.93	0.48	8.66e-29	Adiposity;
LGG	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-7.94	-0.35	1.58e-14	Alzheimer's disease (late onset);
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg21911579	chr5:131705225	SLC22A5	0.67	7.44	0.33	4.97e-13	Rheumatoid arthritis;
LGG	cis	rs6834538	0.597	rs9307383	chr4:113529834	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.52	8.69	0.37	6.53e-17	Free thyroxine concentration;
LGG	cis	rs10940138	0.501	rs6872437	chr5:67239886	C/T	ch.5.1281357F	chr5:67228439	NA	0.47	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg07936489	chr17:37558343	FBXL20	1.03	17.88	0.64	9.33e-55	Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg00666640	chr1:248458726	OR2T12	0.53	8.9	0.38	1.24e-17	Common traits (Other);
LGG	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.02	-0.31	7.75e-12	Neuroticism;
LGG	cis	rs12143943	0.866	rs4252726	chr1:204513402	G/A	cg20240347	chr1:204465584	NA	-0.34	-7.41	-0.33	5.96e-13	Cognitive performance;
LGG	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg13263691	chr18:77568018	NA	-0.82	-14.51	-0.56	1.39e-39	Schizophrenia;
LGG	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22857025	chr5:266934	NA	-1.55	-25.44	-0.76	5.97e-90	Breast cancer;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg15344914	chr12:54567476	NA	-0.39	-6.7	-0.3	5.94e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23223544	chr13:114807760	RASA3	-0.36	-6.67	-0.3	7.16e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7226408	0.532	rs323299	chr18:34668147	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.29	-0.36	1.28e-15	Obesity-related traits;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.52	-8.63	-0.37	9.58e-17	Renal function-related traits (BUN);
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.63	-11.03	-0.46	2.7e-25	Obesity-related traits;
LGG	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg03929089	chr4:120376271	NA	0.45	7.39	0.32	6.87e-13	HDL cholesterol;
LGG	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.7e-13	Refractive error;
LGG	cis	rs6743376	0.556	rs1530550	chr2:113817513	A/T	cg05949173	chr2:113825882	IL1F10	0.48	9.17	0.39	1.5e-18	Inflammatory biomarkers;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg01200585	chr1:228362443	C1orf69	-0.45	-7.79	-0.34	4.36e-14	Diastolic blood pressure;
LGG	cis	rs365132	1.000	rs35977534	chr5:176335231	T/C	cg16309518	chr5:176445507	NA	-0.55	-12.22	-0.49	5.86e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs67311347	1.000	rs6795475	chr3:40489281	A/G	cg13683864	chr3:40499215	RPL14	-0.97	-19.83	-0.68	8.14e-64	Renal cell carcinoma;
LGG	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.27	-0.32	1.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.77	-0.3	3.8e-11	Triglycerides;
LGG	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs1461503	0.966	rs11218905	chr11:122840303	A/G	cg27398637	chr11:122830231	C11orf63	0.71	13.91	0.54	5.55e-37	Menarche (age at onset);
LGG	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg24011408	chr12:48396354	COL2A1	0.5	7.92	0.35	1.78e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.49	-0.4	1.23e-19	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00652727	chr1:235812198	GNG4	0.43	6.99	0.31	9.41e-12	Cognitive performance;
LGG	cis	rs12681287	0.752	rs4641037	chr8:87268379	A/G	cg27223183	chr8:87520930	FAM82B	-0.45	-6.84	-0.3	2.52e-11	Caudate activity during reward;
LGG	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11644478	chr21:40555479	PSMG1	-0.58	-9.51	-0.4	1.01e-19	Menarche (age at onset);
LGG	cis	rs870825	0.587	rs35845099	chr4:185639762	A/G	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs12143943	0.866	rs3789051	chr1:204494436	C/T	cg20240347	chr1:204465584	NA	-0.35	-7.54	-0.33	2.51e-13	Cognitive performance;
LGG	cis	rs4950322	0.580	rs2014106	chr1:146590081	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-7.42	-0.33	5.84e-13	Protein quantitative trait loci;
LGG	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg21995147	chr19:1064017	ABCA7	-0.48	-7.66	-0.34	1.11e-13	Alzheimer's disease (late onset);
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.84	-16.46	-0.61	2.83e-48	Lymphocyte counts;
LGG	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg04826882	chr13:114838756	RASA3	-0.64	-9.52	-0.4	9.27e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4950322	0.748	rs56392137	chr1:146824196	A/G	cg22381352	chr1:146742008	CHD1L	-0.48	-7.7	-0.34	8.31e-14	Protein quantitative trait loci;
LGG	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.4	-0.36	5.49e-16	Hemoglobin concentration;
LGG	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg08885076	chr2:99613938	TSGA10	0.42	8.89	0.38	1.4e-17	Chronic sinus infection;
LGG	cis	rs12286929	0.609	rs11602686	chr11:115100638	G/A	cg04055981	chr11:115044050	NA	0.36	6.65	0.3	8.17e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg04117972	chr1:227635322	NA	0.72	11.25	0.46	4.13e-26	Major depressive disorder;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg25703541	chr22:24373054	LOC391322	0.81	14.09	0.55	9.34e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2688608	0.780	rs2688619	chr10:75682176	A/G	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.2	-0.32	2.39e-12	Inflammatory bowel disease;
LGG	cis	rs941764	1.000	rs941764	chr14:91841069	C/T	cg10511902	chr14:91842949	CCDC88C	-0.65	-14.9	-0.57	2.58e-41	Breast cancer;
LGG	cis	rs193541	0.632	rs34714850	chr5:122332695	A/G	cg19412675	chr5:122181750	SNX24	-0.52	-8.36	-0.36	7.61e-16	Glucose homeostasis traits;
LGG	cis	rs193541	0.621	rs898391	chr5:122082166	T/C	cg19412675	chr5:122181750	SNX24	0.51	8.06	0.35	6.71e-15	Glucose homeostasis traits;
LGG	cis	rs9868809	0.505	rs9882549	chr3:48749358	C/T	cg00383909	chr3:49044727	WDR6	0.9	11.22	0.46	5.15e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1185460	0.967	rs1168568	chr11:118949799	G/A	cg23280166	chr11:118938394	VPS11	0.6	10.88	0.45	1.04e-24	Coronary artery disease;
LGG	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg21435375	chr2:172878103	MAP1D	-0.32	-6.91	-0.31	1.6e-11	Schizophrenia;
LGG	cis	rs2562456	0.833	rs62110429	chr19:21613786	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.62	-0.33	1.42e-13	Pain;
LGG	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg19077165	chr18:44547161	KATNAL2	0.52	9.27	0.4	7.36e-19	Personality dimensions;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.72	-0.3	5.33e-11	Longevity;Endometriosis;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg26384229	chr12:38710491	ALG10B	-0.68	-13.52	-0.53	2.43e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg21699342	chr2:239360505	ASB1	0.39	7.44	0.33	4.84e-13	Multiple system atrophy;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	14.42	0.56	3.4e-39	Menarche (age at onset);
LGG	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs7246760	1.000	rs112124298	chr19:9923154	T/C	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.8	9.88	0.42	5.27e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.15	0.49	1.07e-29	Rheumatoid arthritis;
LGG	cis	rs10089	1.000	rs13355233	chr5:127425350	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.78	-12.15	-0.49	1.11e-29	Ileal carcinoids;
LGG	cis	rs7267979	0.899	rs6115213	chr20:25550372	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.03	0.42	1.44e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3767633	0.925	rs2298019	chr1:161736035	A/G	cg09175582	chr1:161736000	ATF6	0.74	8.88	0.38	1.48e-17	IgG glycosylation;
LGG	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs7084402	0.967	rs2438182	chr10:60314815	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs11971779	0.680	rs6467846	chr7:139079385	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21862992	chr11:68658383	NA	0.51	8.64	0.37	9.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07677032	chr17:61819896	STRADA	-0.66	-12.34	-0.5	1.93e-30	Prudent dietary pattern;
LGG	cis	rs6942756	0.737	rs61570833	chr7:128933492	C/A	cg02491457	chr7:128862824	NA	-0.76	-13.73	-0.54	3.2e-36	White matter hyperintensity burden;
LGG	cis	rs3099143	0.901	rs3764244	chr15:77223740	T/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.08	-0.39	3.18e-18	Recalcitrant atopic dermatitis;
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg20978937	chr14:105399321	PLD4	0.49	11.11	0.46	1.34e-25	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-9.72	-0.41	1.85e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	10.34	0.43	1.07e-22	Educational attainment;
LGG	cis	rs4662750	0.580	rs4662743	chr2:128350808	A/G	cg10021288	chr2:128175891	PROC	-0.38	-6.97	-0.31	1.1e-11	Renal cell carcinoma;
LGG	cis	rs892961	0.777	rs747483	chr17:75412091	C/T	cg05865280	chr17:75406074	SEPT9	0.44	10.38	0.43	7.61e-23	Airflow obstruction;
LGG	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg16797656	chr11:68205561	LRP5	0.52	9.88	0.42	5.03e-21	Total body bone mineral density;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.34	-0.43	1.06e-22	Bipolar disorder;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00631329	chr6:26305371	NA	-0.52	-9.66	-0.41	3.06e-20	Educational attainment;
LGG	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-7.28	-0.32	1.48e-12	Testicular germ cell tumor;
LGG	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg04672837	chr16:48644449	N4BP1	0.56	9.32	0.4	4.8e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9915657	0.803	rs12449851	chr17:70099002	C/T	cg09344028	chr17:70110421	NA	-0.59	-13.99	-0.54	2.51e-37	Thyroid hormone levels;
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg07414643	chr4:187882934	NA	-0.48	-9.27	-0.4	6.85e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22857025	chr5:266934	NA	-1.54	-24.79	-0.76	5.65e-87	Breast cancer;
LGG	cis	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.49	-0.33	3.58e-13	Triglycerides;
LGG	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3e-13	Schizophrenia;
LGG	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg11494091	chr17:61959527	GH2	0.48	7.33	0.32	1.04e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg20336341	chr7:50628841	DDC	-0.41	-7.1	-0.31	4.75e-12	Malaria;
LGG	cis	rs9463078	0.739	rs6941169	chr6:45173552	A/C	cg25276700	chr6:44698697	NA	-0.38	-7.87	-0.34	2.57e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1355223	1.000	rs11601923	chr11:34764354	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.29	-0.32	1.35e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg26597838	chr10:835615	NA	0.75	10.41	0.44	5.93e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg11901034	chr3:128598214	ACAD9	-0.46	-6.95	-0.31	1.25e-11	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18099408	chr3:52552593	STAB1	-0.37	-7.16	-0.32	3.17e-12	Bipolar disorder;
LGG	cis	rs4478037	0.558	rs60462824	chr3:33085929	T/C	cg19404215	chr3:33155277	CRTAP	0.79	6.91	0.31	1.57e-11	Major depressive disorder;
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.05	0.31	6.36e-12	Neuroticism;
LGG	cis	rs3814113	0.586	rs10962662	chr9:16889937	C/A	cg13173848	chr9:16870893	BNC2	-0.52	-7.55	-0.33	2.27e-13	Epithelial ovarian cancer;Ovarian cancer in BRCA1 mutation carriers;Ovarian cancer;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg18926786	chr6:150244388	RAET1G	0.32	6.84	0.3	2.45e-11	Lung cancer;
LGG	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-13.92	-0.54	4.7e-37	Platelet distribution width;
LGG	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg16885296	chr6:26284938	NA	0.36	7.36	0.32	8.19e-13	Mosquito bite size;
LGG	cis	rs757978	0.733	rs11689496	chr2:242426399	G/A	cg10173475	chr2:242152697	ANO7	-0.52	-6.81	-0.3	3.08e-11	Chronic lymphocytic leukemia;
LGG	cis	rs3806843	0.868	rs2563291	chr5:140119599	T/A	cg19875535	chr5:140030758	IK	-0.53	-11.16	-0.46	8.81e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.66	-0.34	1.12e-13	Total cholesterol levels;
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg15948088	chr11:109293068	C11orf87	0.54	8.71	0.38	5.56e-17	Schizophrenia;
LGG	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg25986240	chr4:9926439	SLC2A9	0.36	7.04	0.31	6.76e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.66	-0.51	9.87e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg18357526	chr6:26021779	HIST1H4A	0.84	15.42	0.58	1.29e-43	Intelligence (multi-trait analysis);
LGG	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg18479299	chr3:125709523	NA	-0.58	-7.39	-0.32	6.93e-13	Blood pressure (smoking interaction);
LGG	cis	rs1878931	1.000	rs1878931	chr16:3450907	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	18.81	0.66	4.55e-59	Body mass index (adult);
LGG	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg25358565	chr5:93447407	FAM172A	1.28	15.67	0.59	1.08e-44	Diabetic retinopathy;
LGG	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.01	0.31	8.45e-12	Height;
LGG	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg24253500	chr15:84953950	NA	0.59	10.91	0.45	8.4e-25	Schizophrenia;
LGG	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg13770153	chr20:60521292	NA	-0.44	-7.29	-0.32	1.39e-12	Body mass index;
LGG	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	cis	rs3857067	0.839	rs12505694	chr4:95042940	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.95	-0.35	1.49e-14	QT interval;
LGG	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg09085632	chr11:111637200	PPP2R1B	1.05	22.07	0.72	2.71e-74	Primary sclerosing cholangitis;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg16359550	chr11:109292809	C11orf87	0.42	8.28	0.36	1.31e-15	Schizophrenia;
LGG	cis	rs55728055	0.661	rs55673702	chr22:32035518	G/A	cg01338084	chr22:32026380	PISD	1.45	12.25	0.49	4.33e-30	Age-related hearing impairment;
LGG	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.84	0.45	1.51e-24	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg05313129	chr8:58192883	C8orf71	-0.82	-12.3	-0.5	2.71e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9357271	0.910	rs9357272	chr6:38370352	A/G	cg07362130	chr6:38359646	BTBD9	-0.43	-9.8	-0.41	1.02e-20	Restless legs syndrome;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-9.7	-0.41	2.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg07395648	chr5:131743802	NA	-0.43	-9.15	-0.39	1.84e-18	Blood metabolite levels;
LGG	cis	rs3785574	1.000	rs2955245	chr17:61979845	T/C	cg11494091	chr17:61959527	GH2	-0.63	-10.19	-0.43	3.94e-22	Height;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg16507663	chr6:150244633	RAET1G	0.45	7.21	0.32	2.36e-12	Lung cancer;
LGG	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.65	-0.3	8.31e-11	Height;
LGG	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.5	-0.33	3.33e-13	Morning vs. evening chronotype;
LGG	trans	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.71e-11	Depression;
LGG	cis	rs6032067	0.929	rs6032055	chr20:43833336	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	12.79	0.51	2.78e-32	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg19147804	chr7:1989927	MAD1L1	0.57	11.59	0.47	1.89e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg25885449	chr18:77638415	KCNG2	0.35	6.68	0.3	6.83e-11	Schizophrenia;
LGG	cis	rs755249	0.567	rs61779279	chr1:39837102	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.62	0.33	1.46e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17253792	0.545	rs12879564	chr14:56017694	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg06481639	chr22:41940642	POLR3H	0.56	7.9	0.34	2.03e-14	Vitiligo;
LGG	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.92	-0.54	4.73e-37	Response to antipsychotic treatment;
LGG	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg25019033	chr10:957182	NA	-0.55	-9.89	-0.42	4.6e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs972578	1.000	rs9611984	chr22:43408562	C/T	cg01576275	chr22:43409880	NA	-0.24	-6.89	-0.31	1.81e-11	Mean platelet volume;
LGG	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.61e-25	Bone mineral density;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg13206674	chr6:150067644	NUP43	0.67	15.46	0.58	9.32e-44	Lung cancer;
LGG	cis	rs7020830	0.898	rs7846747	chr9:37167539	A/C	cg14294708	chr9:37120828	ZCCHC7	1.2	35.48	0.86	3.78e-134	Schizophrenia;
LGG	cis	rs7000551	0.751	rs1116085	chr8:22394920	A/G	cg12081754	chr8:22256438	SLC39A14	0.63	11.94	0.49	8e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7843479	1.000	rs1032094	chr8:21820479	A/T	cg17168535	chr8:21777572	XPO7	0.61	9.93	0.42	3.45e-21	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.93	-0.52	7.35e-33	Alzheimer's disease;
LGG	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg19628046	chr18:33552617	C18orf21	0.53	7.73	0.34	6.95e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.51	0.61	1.73e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.04	-0.39	4.26e-18	Bladder cancer;
LGG	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg09904177	chr6:26538194	HMGN4	0.68	14.02	0.55	1.8e-37	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg25358565	chr5:93447407	FAM172A	0.74	10.45	0.44	4.44e-23	Diabetic retinopathy;
LGG	cis	rs13202913	0.639	rs9383892	chr6:151747152	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	6.92	0.31	1.5e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.67	-0.3	7.48e-11	Bipolar disorder;
LGG	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.93	10.31	0.43	1.43e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.58	-0.41	5.83e-20	Neuroticism;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.99e-17	Platelet count;
LGG	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg10596483	chr8:143751796	JRK	0.52	8.14	0.35	3.65e-15	Schizophrenia;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg23758822	chr17:41437982	NA	0.87	15.4	0.58	1.61e-43	Menopause (age at onset);
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.16e-14	Total body bone mineral density;
LGG	cis	rs1670533	1.000	rs688785	chr4:1082707	G/C	cg27284194	chr4:1044797	NA	0.55	9.9	0.42	4.21e-21	Recombination rate (females);
LGG	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg00012203	chr2:219082015	ARPC2	0.65	11.5	0.47	4.45e-27	Colorectal cancer;
LGG	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.06	-0.52	2.07e-33	Gut microbiome composition (summer);
LGG	cis	rs4243830	0.850	rs7540913	chr1:6581877	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.43	-6.79	-0.3	3.39e-11	Body mass index;
LGG	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.91	0.31	1.58e-11	Sudden cardiac arrest;
LGG	cis	rs7927997	0.615	rs7931483	chr11:76302067	C/A	cg17647271	chr11:76299819	NA	-0.43	-7.52	-0.33	2.95e-13	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.32e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg13206674	chr6:150067644	NUP43	0.68	15.82	0.59	2.22e-45	Lung cancer;
LGG	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.47	-0.33	4.06e-13	Monocyte count;
LGG	cis	rs13314892	0.764	rs7647742	chr3:69857303	A/C	cg17445875	chr3:69859618	MITF	-0.4	-7.82	-0.34	3.65e-14	QRS complex (12-leadsum);
LGG	cis	rs7717393	0.786	rs9313900	chr5:155800253	C/T	cg04435420	chr5:155754009	SGCD	-0.75	-9.37	-0.4	3.12e-19	Egg allergy;
LGG	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.39	0.47	1.11e-26	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	8.92	0.38	1.09e-17	Neuroticism;
LGG	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.16	0.35	3.28e-15	Gut microbiome composition (summer);
LGG	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg00129232	chr17:37814104	STARD3	0.61	11.43	0.47	7.83e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs11166927	0.901	rs7827091	chr8:140812044	G/C	cg16909799	chr8:140841666	TRAPPC9	0.55	11.67	0.48	8.92e-28	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg03909863	chr11:638404	DRD4	-0.41	-6.98	-0.31	1.02e-11	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg25986240	chr4:9926439	SLC2A9	0.51	11.25	0.46	4.18e-26	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg12379764	chr21:47803548	PCNT	-0.42	-7.28	-0.32	1.46e-12	Testicular germ cell tumor;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08645402	chr16:4508243	NA	-0.47	-9.01	-0.39	5.52e-18	Schizophrenia;
LGG	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.41	0.33	5.9e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-10.71	-0.45	4.53e-24	Platelet count;
LGG	cis	rs7020830	0.830	rs12554976	chr9:37244505	G/T	cg14294708	chr9:37120828	ZCCHC7	1.14	31.63	0.83	8.68e-118	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4330281	0.608	rs283935	chr3:17367357	A/T	cg20981856	chr3:17787350	NA	-0.36	-6.9	-0.31	1.71e-11	Schizophrenia;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg04025307	chr7:1156635	C7orf50	0.66	12.28	0.5	3.32e-30	Longevity;Endometriosis;
LGG	cis	rs2282802	0.685	rs11750229	chr5:139559014	T/G	cg26211634	chr5:139558579	C5orf32	-0.35	-7.73	-0.34	6.75e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.74	-0.41	1.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg20607798	chr8:58055168	NA	0.57	6.87	0.3	2.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6546550	0.935	rs7563062	chr2:70050725	G/A	cg02498382	chr2:70120550	SNRNP27	-0.4	-7.58	-0.33	1.89e-13	Prevalent atrial fibrillation;
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg25309564	chr22:51001381	C22orf41	0.43	6.98	0.31	1.02e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg22681709	chr2:178499509	PDE11A	0.43	7.79	0.34	4.43e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.39	0.43	7.42e-23	Arsenic metabolism;
LGG	trans	rs7939886	0.920	rs11227729	chr11:56039901	G/A	cg03929089	chr4:120376271	NA	0.72	6.7	0.3	5.99e-11	Myopia (pathological);
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg24829409	chr8:58192753	C8orf71	0.77	11.02	0.46	3.08e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg10840412	chr1:235813424	GNG4	0.51	6.87	0.3	2.04e-11	Bipolar disorder;
LGG	cis	rs13082711	0.558	rs640912	chr3:27364092	C/A	cg02860705	chr3:27208620	NA	0.58	11.0	0.46	3.7e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg04851639	chr8:1020857	NA	0.42	8.65	0.37	8.75e-17	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24675879	chr17:28444056	MIR423;CCDC55	0.43	7.08	0.31	5.43e-12	Cognitive performance;
LGG	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg04149295	chr10:70884716	VPS26A	0.48	7.16	0.32	3.29e-12	Left atrial antero-posterior diameter;
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg01516881	chr6:292596	DUSP22	-0.48	-8.33	-0.36	9.33e-16	Menopause (age at onset);
LGG	cis	rs3741151	0.686	rs7927344	chr11:73207517	T/C	cg17517138	chr11:73019481	ARHGEF17	0.7	7.31	0.32	1.16e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13934093	chr19:4458039	UBXN6	0.4	6.73	0.3	5.1e-11	Bipolar disorder;
LGG	cis	rs7255045	0.788	rs6511843	chr19:12955544	A/C	cg07955356	chr19:12992479	DNASE2	0.41	6.84	0.3	2.59e-11	Mean corpuscular volume;
LGG	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-14.5	-0.56	1.58e-39	Morning vs. evening chronotype;
LGG	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.8	0.57	7.69e-41	Cognitive test performance;
LGG	trans	rs8073060	0.586	rs3859284	chr17:34012792	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs3736594	0.643	rs2384655	chr2:27952235	A/T	cg27432699	chr2:27873401	GPN1	-0.58	-9.44	-0.4	1.89e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6912958	0.754	rs6918909	chr6:88247251	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.44	-0.37	4.17e-16	Monocyte percentage of white cells;
LGG	trans	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.04	-0.39	4.26e-18	Bladder cancer;
LGG	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.93	-0.31	1.4e-11	Retinal vascular caliber;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg08621203	chr6:150244597	RAET1G	0.45	7.62	0.33	1.4e-13	Lung cancer;
LGG	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg11764359	chr7:65958608	NA	0.8	14.91	0.57	2.46e-41	Aortic root size;
LGG	cis	rs17453880	0.929	rs6860209	chr5:152049547	A/G	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.24	0.32	1.93e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg23978390	chr7:1156363	C7orf50	0.4	6.77	0.3	3.96e-11	Longevity;Endometriosis;
LGG	cis	rs10193935	0.579	rs62142594	chr2:42524531	G/A	cg27598129	chr2:42591480	NA	-0.59	-7.2	-0.32	2.48e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.77e-15	Obesity-related traits;
LGG	cis	rs9815354	0.812	rs17284472	chr3:41996304	A/G	cg03022575	chr3:42003672	ULK4	-0.79	-9.13	-0.39	2.07e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg13010199	chr12:38710504	ALG10B	-0.61	-12.77	-0.51	3.26e-32	Morning vs. evening chronotype;
LGG	cis	rs11645898	0.810	rs72787060	chr16:72105371	T/C	cg14768367	chr16:72042858	DHODH	-0.94	-12.09	-0.49	1.88e-29	Blood protein levels;
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.67	-0.34	1.01e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg24848339	chr3:12840334	CAND2	0.42	9.63	0.41	3.82e-20	QRS complex (12-leadsum);
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg00495681	chr13:53174319	NA	0.57	10.21	0.43	3.31e-22	Lewy body disease;
LGG	cis	rs4430311	0.723	rs12739344	chr1:243791312	C/G	cg25706552	chr1:244017396	NA	0.64	15.74	0.59	5.26e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg23506143	chr5:55761274	NA	0.34	7.15	0.32	3.34e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3857067	0.806	rs9996975	chr4:95101338	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.98	-0.35	1.16e-14	QT interval;
LGG	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.05	-0.39	3.9e-18	Primary sclerosing cholangitis;
LGG	cis	rs3820928	1.000	rs7579961	chr2:227776976	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.29	-0.32	1.35e-12	Pulmonary function;
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.32	-0.36	9.99e-16	IgG glycosylation;
LGG	cis	rs16976116	0.901	rs1061874	chr15:55496287	A/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11671005	0.735	rs34152946	chr19:58923263	C/T	cg11952622	chr19:58962976	ZNF324B	-0.43	-6.68	-0.3	6.94e-11	Mean platelet volume;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs7100689	0.646	rs7919380	chr10:82133380	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.82	17.73	0.64	4.81e-54	Menarche (age at onset);
LGG	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg15128208	chr22:42549153	NA	0.4	7.91	0.34	1.96e-14	Cognitive function;
LGG	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg13010199	chr12:38710504	ALG10B	0.68	13.58	0.53	1.41e-35	Morning vs. evening chronotype;
LGG	cis	rs4493873	1.000	rs4568579	chr8:92072144	T/C	cg16814680	chr8:91681699	NA	0.47	7.14	0.32	3.58e-12	Migraine - clinic-based;
LGG	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.15e-15	Monocyte count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22956410	chr19:58281117	ZNF586	0.58	6.67	0.3	7.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.78	0.3	3.58e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs412658	0.776	rs12460025	chr19:22318230	A/G	cg25360861	chr19:22235199	ZNF257	-0.39	-6.72	-0.3	5.29e-11	Telomere length;
LGG	cis	rs7192380	0.756	rs12596945	chr16:69780819	C/A	cg00738113	chr16:70207722	CLEC18C	0.35	10.05	0.42	1.21e-21	Sjögren's syndrome;
LGG	cis	rs2797369	0.665	rs2749130	chr6:101460674	G/A	cg27451362	chr6:101846650	GRIK2	0.79	10.45	0.44	4.17e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg03959625	chr15:84868606	LOC388152	0.54	8.58	0.37	1.49e-16	Schizophrenia;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.93	-0.42	3.41e-21	Bipolar disorder;
LGG	cis	rs887829	0.570	rs6724485	chr2:234592816	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.09	-0.35	5.3e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg00666640	chr1:248458726	OR2T12	-0.51	-8.34	-0.36	8.72e-16	Common traits (Other);
LGG	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15305172	chr6:116892775	RWDD1	0.48	7.92	0.35	1.81e-14	Cognitive performance;
LGG	cis	rs2274273	0.662	rs67215571	chr14:55673723	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.87	0.48	1.51e-28	Protein biomarker;
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg07870479	chr16:1813987	MAPK8IP3	-0.44	-6.84	-0.3	2.45e-11	Insulin-like growth factors;
LGG	cis	rs283228	0.535	rs525685	chr6:101723692	A/G	cg27451362	chr6:101846650	GRIK2	0.91	12.84	0.51	1.63e-32	Coenzyme Q10 levels;
LGG	cis	rs6456156	0.586	rs12203510	chr6:167473006	C/T	cg07741184	chr6:167504864	NA	0.39	9.08	0.39	3.07e-18	Primary biliary cholangitis;
LGG	cis	rs2718058	0.565	rs2598078	chr7:37864078	G/C	cg15028436	chr7:37888078	TXNDC3	0.52	8.2	0.36	2.31e-15	Alzheimer's disease (late onset);
LGG	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg00990874	chr7:1149470	C7orf50	-0.79	-11.84	-0.48	1.88e-28	Bronchopulmonary dysplasia;
LGG	trans	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.23	-0.32	2.01e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9393813	0.509	rs10946915	chr6:27377830	A/G	cg18711553	chr6:27366782	ZNF391	-0.49	-9.47	-0.4	1.42e-19	Bipolar disorder;
LGG	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg14191688	chr11:70257035	CTTN	0.55	7.99	0.35	1.07e-14	Coronary artery disease;
LGG	cis	rs12220238	0.908	rs10824124	chr10:75997360	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.73	0.48	5.15e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg08048268	chr3:133502702	NA	0.68	13.46	0.53	4.44e-35	Iron status biomarkers;
LGG	cis	rs504918	0.556	rs4678105	chr3:124000265	A/G	cg05766129	chr3:123988013	KALRN	-0.59	-10.73	-0.45	3.9e-24	Schizophrenia;
LGG	cis	rs12476592	0.602	rs10865339	chr2:63811884	G/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.77	-0.3	3.85e-11	Childhood ear infection;
LGG	cis	rs4731207	0.698	rs10250911	chr7:124473034	G/A	cg05630886	chr7:124431682	NA	0.33	7.85	0.34	3.01e-14	Cutaneous malignant melanoma;
LGG	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg18479299	chr3:125709523	NA	-0.58	-7.51	-0.33	3.07e-13	Blood pressure (smoking interaction);
LGG	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg25809561	chr17:30822961	MYO1D	0.4	9.67	0.41	2.87e-20	Schizophrenia;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg18446336	chr7:2847575	GNA12	-0.29	-6.96	-0.31	1.18e-11	Height;
LGG	cis	rs11700980	0.551	rs2832023	chr21:30112996	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-7.41	-0.33	5.92e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.67	0.3	7.13e-11	Neuroticism;
LGG	trans	rs10238623	0.503	rs6964001	chr7:28833479	G/T	cg06315995	chr11:1283037	MUC5B	-0.39	-6.72	-0.3	5.43e-11	Anxiety in major depressive disorder;
LGG	cis	rs6450176	0.564	rs401449	chr5:53326735	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.4	-0.47	1.07e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg25919922	chr13:100150906	NA	-0.65	-6.67	-0.3	7.25e-11	Obesity-related traits;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.51	0.33	3.11e-13	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.1	0.43	7.95e-22	Motion sickness;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.86	-0.3	2.27e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-8.15	-0.35	3.34e-15	Renal function-related traits (BUN);
LGG	cis	rs71403859	0.803	rs8063455	chr16:71599977	G/A	cg08717414	chr16:71523259	ZNF19	-1.15	-15.16	-0.58	1.89e-42	Post bronchodilator FEV1;
LGG	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg12310025	chr6:25882481	NA	0.52	9.64	0.41	3.6e-20	Blood metabolite levels;
LGG	cis	rs12618769	0.625	rs4850880	chr2:99212417	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11803077	chr1:11120633	SRM	0.46	6.93	0.31	1.42e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2377585	0.653	rs73053860	chr12:8844774	C/T	cg03761649	chr12:8850719	RIMKLB	0.49	8.14	0.35	3.57e-15	Reticulocyte fraction of red cells;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.86	0.57	3.89e-41	Platelet count;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg09166659	chr1:861177	SAMD11	0.34	6.85	0.3	2.4e-11	Coronary artery disease;
LGG	cis	rs1040555	0.516	rs242547	chr20:31418581	T/C	cg13636640	chr20:31349939	DNMT3B	0.63	11.62	0.48	1.42e-27	Lymphocyte percentage of white cells;
LGG	cis	rs17208368	0.723	rs1386266	chr16:55088588	C/A	cg09947736	chr16:55091198	NA	0.78	13.95	0.54	3.68e-37	Hypospadias;
LGG	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg06640241	chr16:89574553	SPG7	0.69	12.02	0.49	3.63e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.09	-0.42	8.64e-22	Mood instability;
LGG	cis	rs34172651	0.917	rs6497756	chr16:24798291	G/T	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.66	-0.34	1.08e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11585357	0.895	rs72633812	chr1:17623140	T/C	cg08277548	chr1:17600880	PADI3	-0.73	-7.96	-0.35	1.36e-14	Hair shape;
LGG	trans	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.76	0.41	1.38e-20	Mean corpuscular volume;
LGG	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg24375607	chr4:120327624	NA	-0.56	-9.37	-0.4	3.28e-19	Corneal astigmatism;
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg25338242	chr13:114786047	RASA3	-0.4	-7.35	-0.32	9.3e-13	Schizophrenia;
LGG	cis	rs3740540	0.507	rs942014	chr10:126290070	C/T	cg04949429	chr10:126290192	LHPP	0.64	12.23	0.49	5.1e-30	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg16141378	chr3:129829833	LOC729375	0.36	7.92	0.35	1.78e-14	Morning vs. evening chronotype;
LGG	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs2073300	1.000	rs6114098	chr20:23444276	G/A	cg12062639	chr20:23401060	NAPB	0.82	6.73	0.3	5.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00105470	chr1:228290868	C1orf35	0.48	7.25	0.32	1.78e-12	Gut microbiome composition (summer);
LGG	trans	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.79	0.51	2.68e-32	Prudent dietary pattern;
LGG	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg11477892	chr4:106580295	NA	-0.43	-7.6	-0.33	1.63e-13	Post bronchodilator FEV1;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22044216	chr19:58361147	ZNF587	0.48	7.16	0.32	3.11e-12	Gut microbiome composition (summer);
LGG	cis	rs17209837	1.000	rs17149640	chr7:87086039	A/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg01145232	chr6:150245071	RAET1G	-0.53	-9.54	-0.41	8.15e-20	Lung cancer;
LGG	cis	rs4930561	0.714	rs7950452	chr11:67962407	C/A	cg16338278	chr11:67432957	ALDH3B2	0.42	7.84	0.34	3.13e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.17	-0.36	2.94e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24415082	chr16:74700811	RFWD3	0.53	8.24	0.36	1.73e-15	Gut microbiome composition (summer);
LGG	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg02187348	chr16:89574699	SPG7	0.49	7.48	0.33	3.8e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg06521331	chr12:34319734	NA	-0.51	-8.2	-0.36	2.31e-15	Resting heart rate;
LGG	trans	rs637571	0.565	rs633800	chr11:65638719	G/A	cg17712092	chr4:129076599	LARP1B	-0.76	-14.7	-0.56	2.07e-40	Eosinophil percentage of white cells;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17824933	0.778	rs17752099	chr11:60760794	G/C	cg16817237	chr11:60793675	NA	0.37	6.94	0.31	1.29e-11	Multiple sclerosis;
LGG	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs10155981	0.510	rs4722157	chr7:22583941	G/A	cg06110297	chr7:22589830	NA	-0.64	-6.95	-0.31	1.28e-11	Bilirubin levels;
LGG	cis	rs4742903	0.935	rs1413341	chr9:106973013	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.04	0.35	7.4e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs7712401	0.601	rs35256179	chr5:122334255	C/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs7091068	0.550	rs7079013	chr10:95487878	A/C	cg20715218	chr10:95462985	C10orf4	0.76	13.36	0.53	1.17e-34	Urinary tract infection frequency;
LGG	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.34	0.36	8.3e-16	Morning vs. evening chronotype;
LGG	cis	rs1580019	0.922	rs59938271	chr7:32484844	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.95	0.6	5.84e-46	Cognitive ability;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.3	-0.32	1.26e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.52	-0.33	2.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs721917	0.525	rs2250473	chr10:81664395	G/C	cg25562619	chr10:81652821	NA	-0.34	-7.85	-0.34	2.91e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg24687335	chr11:118901407	SLC37A4	-0.54	-9.92	-0.42	3.68e-21	Coronary artery disease;
LGG	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg06885757	chr1:42089581	HIVEP3	0.62	14.5	0.56	1.51e-39	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg19774624	chr17:42201019	HDAC5	0.59	10.43	0.44	5.24e-23	Total body bone mineral density;
LGG	cis	rs3816183	0.958	rs1439644	chr2:43021749	C/T	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.1e-18	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08466320	chr2:70121048	SNRNP27	0.45	7.64	0.33	1.27e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg15948088	chr11:109293068	C11orf87	0.8	15.07	0.57	4.72e-42	Schizophrenia;
LGG	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg18196295	chr10:418757	DIP2C	0.49	9.24	0.39	8.89e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.81	0.45	1.97e-24	Arsenic metabolism;
LGG	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg22431228	chr1:16359049	CLCNKA	-0.47	-8.37	-0.36	7e-16	Dilated cardiomyopathy;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.35	-8.45	-0.37	3.89e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs12517041	1.000	rs10805750	chr5:23300753	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.04e-25	Calcium levels;
LGG	trans	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg00938859	chr5:1591904	SDHAP3	0.75	7.5	0.33	3.36e-13	Asthma (childhood onset);
LGG	cis	rs1633360	1	rs1633360	chr12:58108052	C/T	cg18357645	chr12:58087776	OS9	0.55	9.87	0.42	5.71e-21	Rheumatoid arthritis;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07677032	chr17:61819896	STRADA	0.66	12.17	0.49	9.63e-30	Prudent dietary pattern;
LGG	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18876405	chr7:65276391	NA	0.58	10.87	0.45	1.16e-24	Aortic root size;
LGG	cis	rs28655083	0.509	rs679263	chr16:77103829	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.43	7.38	0.32	7.35e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs10892173	1.000	rs10892173	chr11:117672561	C/T	cg21640587	chr11:117668038	DSCAML1	0.6	9.79	0.41	1.07e-20	Myopia;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs7747724	0.715	rs9465884	chr6:20761679	C/T	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.41	-0.4	2.33e-19	Bladder cancer;
LGG	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg10621924	chr7:39171070	POU6F2	0.44	8.55	0.37	1.77e-16	IgG glycosylation;
LGG	cis	rs34311866	0.808	rs11728344	chr4:963755	T/C	cg07828340	chr4:882639	GAK	0.84	9.1	0.39	2.73e-18	Parkinson's disease;
LGG	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs755249	0.567	rs16826000	chr1:39713860	G/T	cg18385671	chr1:39797026	MACF1	0.45	7.47	0.33	4.11e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg13385521	chr17:29058706	SUZ12P	-0.77	-8.7	-0.37	5.72e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg00666640	chr1:248458726	OR2T12	0.55	8.93	0.38	1.03e-17	Common traits (Other);
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg10207240	chr12:122356781	WDR66	0.24	7.42	0.33	5.56e-13	Mean corpuscular volume;
LGG	trans	rs11088226	0.681	rs1015048	chr21:33949306	T/C	cg09050820	chr6:167586206	TCP10L2	0.93	13.56	0.53	1.59e-35	Gastritis;
LGG	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.67	0.51	8.42e-32	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-9.3	-0.4	5.38e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03517284	chr6:25882590	NA	0.51	9.43	0.4	1.93e-19	Intelligence (multi-trait analysis);
LGG	cis	rs912057	0.526	rs737449	chr6:6733729	A/G	cg06612196	chr6:6737390	NA	-0.51	-11.52	-0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs2862064	0.745	rs2902133	chr5:156445687	G/A	cg12943317	chr5:156479607	HAVCR1	-0.81	-10.56	-0.44	1.64e-23	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21452766	chr1:70877088	CTH	0.41	6.92	0.31	1.51e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg15596359	chr8:11213517	TDH	-0.39	-7.97	-0.35	1.22e-14	Retinal vascular caliber;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.35	-0.32	9.21e-13	Menopause (age at onset);
LGG	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg01028140	chr2:1542097	TPO	-0.55	-8.54	-0.37	1.89e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg21452805	chr1:244014465	NA	0.78	9.06	0.39	3.71e-18	RR interval (heart rate);
LGG	cis	rs11229555	0.598	rs4519112	chr11:58176386	C/T	cg15696309	chr11:58395628	NA	-0.92	-14.96	-0.57	1.4e-41	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg08975724	chr8:8085496	FLJ10661	0.47	8.95	0.38	8.77e-18	Neuroticism;
LGG	cis	rs9902453	0.833	rs7216631	chr17:28495112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.01	0.52	3.27e-33	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26519745	chr21:43639879	ABCG1	0.49	7.94	0.35	1.51e-14	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.43	-6.81	-0.3	2.95e-11	Menarche (age at onset);
LGG	cis	rs6466055	0.604	rs1204078	chr7:104986644	A/T	cg04380332	chr7:105027541	SRPK2	0.39	7.27	0.32	1.57e-12	Schizophrenia;
LGG	cis	rs774359	0.789	rs2477520	chr9:27509870	G/A	cg21249376	chr9:27528432	MOBKL2B	0.45	8.63	0.37	9.69e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg01529538	chr14:23388837	RBM23	-0.37	-6.86	-0.3	2.21e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg05335186	chr13:53173507	NA	0.37	6.9	0.31	1.71e-11	Lewy body disease;
LGG	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.19	0.36	2.63e-15	Retinal vascular caliber;
LGG	cis	rs9487094	0.922	rs9487098	chr6:109743392	A/T	cg01125227	chr6:109776195	MICAL1	0.48	8.09	0.35	5.11e-15	Height;
LGG	cis	rs11644362	0.966	rs1433747	chr16:12992147	C/A	cg08528231	chr16:12997261	SHISA9	-0.36	-7.13	-0.31	3.78e-12	Positive affect;Subjective well-being;
LGG	cis	rs7020830	0.898	rs13284651	chr9:37222681	G/T	cg14294708	chr9:37120828	ZCCHC7	-1.14	-30.66	-0.82	1.59e-113	Schizophrenia;
LGG	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.25	0.36	1.6e-15	Mood instability;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg07511668	chr11:68622177	NA	0.48	9.09	0.39	2.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg20887711	chr4:1340912	KIAA1530	0.49	8.59	0.37	1.29e-16	Obesity-related traits;
LGG	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg17971929	chr21:40555470	PSMG1	0.87	16.82	0.62	6.5e-50	Cognitive function;
LGG	cis	rs11123610	0.520	rs12996655	chr2:3720900	G/A	cg26344334	chr2:3718215	ALLC	-0.49	-8.34	-0.36	8.55e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3816183	0.793	rs1347928	chr2:43049644	G/A	cg14631114	chr2:43023945	NA	0.46	8.59	0.37	1.3e-16	Hypospadias;
LGG	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg22676075	chr6:135203613	NA	-0.43	-7.43	-0.33	5.27e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.62	-0.33	1.43e-13	Life satisfaction;
LGG	cis	rs10861342	0.892	rs2044307	chr12:105531171	G/T	cg23923672	chr12:105501055	KIAA1033	0.81	7.24	0.32	1.87e-12	IgG glycosylation;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.87	-0.45	1.18e-24	Prostate cancer;
LGG	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs113835537	0.559	rs11227498	chr11:66269714	A/G	cg24851651	chr11:66362959	CCS	0.45	7.8	0.34	4.23e-14	Airway imaging phenotypes;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs12410462	0.585	rs2644143	chr1:227731157	T/C	cg04117972	chr1:227635322	NA	0.46	8.68	0.37	6.93e-17	Major depressive disorder;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.34	-0.32	9.71e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11239187	0.530	rs10900071	chr10:45066120	G/A	cg03916630	chr10:45065415	NA	0.36	8.91	0.38	1.19e-17	Body mass index;
LGG	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.02	0.57	8.19e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg10511902	chr14:91842949	CCDC88C	0.45	6.67	0.3	7.36e-11	Alzheimer disease and age of onset;
LGG	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg22348356	chr13:114891224	RASA3	0.41	7.88	0.34	2.39e-14	Schizophrenia;
LGG	cis	rs2290159	0.800	rs57884385	chr3:12673551	G/C	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg27400746	chr16:89904261	SPIRE2	-1.1	-16.63	-0.61	5.13e-49	Skin colour saturation;
LGG	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11890956	chr21:40555474	PSMG1	-0.69	-11.36	-0.47	1.57e-26	Menarche (age at onset);
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg03036210	chr16:89904091	SPIRE2	-0.64	-7.54	-0.33	2.57e-13	Skin colour saturation;
LGG	trans	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg14191688	chr11:70257035	CTTN	0.56	8.21	0.36	2.19e-15	Coronary artery disease;
LGG	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14373873	chr11:113211441	TTC12	0.41	8.59	0.37	1.33e-16	Neuroticism;
LGG	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.7	-0.54	4.06e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg20283391	chr11:68216788	NA	-0.49	-8.07	-0.35	5.94e-15	Total body bone mineral density;
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.2e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg08888203	chr3:10149979	C3orf24	0.36	6.77	0.3	3.94e-11	Alzheimer's disease;
LGG	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg23306229	chr2:178417860	TTC30B	0.72	8.65	0.37	8.6e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg00292662	chr22:38071168	LGALS1	-0.36	-6.8	-0.3	3.21e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg00157179	chr1:2383687	NA	-0.78	-14.9	-0.57	2.72e-41	Non-obstructive azoospermia;
LGG	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg15208524	chr1:10270712	KIF1B	0.43	7.37	0.32	7.7e-13	Hepatocellular carcinoma;
LGG	cis	rs757110	0.524	rs214095	chr11:17293462	T/A	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.45	-0.33	4.75e-13	Type 2 diabetes;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg09699651	chr6:150184138	LRP11	0.53	10.16	0.43	5.05e-22	Testicular germ cell tumor;
LGG	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg11645453	chr3:52864694	ITIH4	0.45	7.22	0.32	2.17e-12	Bipolar disorder;
LGG	cis	rs2735413	0.875	rs11649082	chr16:78082256	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9814567	0.806	rs4955526	chr3:134317337	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.17	-0.46	8.41e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08564027	chr20:61660810	NA	1.02	25.21	0.76	6.33e-89	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.4	-0.36	5.4e-16	Joint mobility (Beighton score);
LGG	cis	rs9354308	0.764	rs9345702	chr6:66578835	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.06e-11	Metabolite levels;
LGG	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg18681998	chr4:17616180	MED28	0.83	17.41	0.63	1.42e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs727505	0.954	rs1525613	chr7:124658636	A/G	cg23710748	chr7:124431027	NA	-0.51	-9.47	-0.4	1.41e-19	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14932796	chr17:55038330	COIL	0.49	7.58	0.33	1.96e-13	Gut microbiome composition (summer);
LGG	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg24189917	chr7:1970923	MAD1L1	0.59	8.79	0.38	2.88e-17	Bipolar disorder;
LGG	cis	rs2486288	0.656	rs8039153	chr15:45579813	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.73	-0.45	3.89e-24	Glomerular filtration rate;
LGG	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.84e-14	Height;
LGG	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2e-21	Height;
LGG	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.87	-0.51	1.26e-32	Chronic sinus infection;
LGG	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.86	-0.51	1.42e-32	Morning vs. evening chronotype;
LGG	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg12636538	chr11:118901039	SLC37A4	-0.61	-12.76	-0.51	3.78e-32	Coronary artery disease;
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs283228	0.583	rs594870	chr6:101735356	A/C	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs72781680	0.678	rs56145919	chr2:24088489	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	8.27	0.36	1.42e-15	Lymphocyte counts;
LGG	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.16	-0.32	3.15e-12	Total cholesterol levels;
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00166722	chr3:10149974	C3orf24	0.53	8.96	0.38	8.06e-18	Alzheimer's disease;
LGG	cis	rs9341808	0.718	rs4437429	chr6:80828592	A/G	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.77e-14	Sitting height ratio;
LGG	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg27129171	chr3:47204927	SETD2	0.8	14.78	0.57	9.42e-41	Colorectal cancer;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg26656751	chr17:43910226	CRHR1	0.49	8.91	0.38	1.2e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1506636	0.886	rs4731112	chr7:123269118	C/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.55	-0.65	7.5e-58	Plateletcrit;Platelet count;
LGG	trans	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.43	-0.4	2.05e-19	Brugada syndrome;
LGG	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg15485101	chr11:133734466	NA	0.62	10.71	0.45	4.71e-24	Childhood ear infection;
LGG	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.42	-0.33	5.59e-13	Restless legs syndrome;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg14668632	chr7:2872130	GNA12	-0.37	-7.61	-0.33	1.5e-13	Height;
LGG	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg05665937	chr4:1216051	CTBP1	0.53	9.28	0.4	6.46e-19	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg12458913	chr13:53173898	NA	0.76	15.83	0.59	2.1e-45	Lewy body disease;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg15971980	chr6:150254442	NA	-0.46	-8.68	-0.37	6.94e-17	Lung cancer;
LGG	cis	rs1003719	0.715	rs2835642	chr21:38539066	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.31	-0.58	4.35e-43	Eye color traits;
LGG	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.14e-14	HDL cholesterol;
LGG	cis	rs2439831	0.850	rs28524541	chr15:44124831	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.15	0.39	1.88e-18	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg15971980	chr6:150254442	NA	0.44	8.41	0.36	5.1e-16	Lung cancer;
LGG	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg03128945	chr5:622914	CEP72	-0.44	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	cis	rs77372450	0.636	rs11748443	chr5:157029457	C/T	cg25387487	chr5:157003181	ADAM19	-0.57	-7.22	-0.32	2.11e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg20302533	chr7:39170763	POU6F2	0.5	11.55	0.47	2.78e-27	IgG glycosylation;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg12458913	chr13:53173898	NA	0.54	9.72	0.41	1.83e-20	Lewy body disease;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.02	-0.31	8.2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg27624424	chr6:160112604	SOD2	0.67	9.93	0.42	3.29e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg04450456	chr4:17643702	FAM184B	0.33	7.47	0.33	4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg23985595	chr17:80112537	CCDC57	-0.39	-7.61	-0.33	1.59e-13	Life satisfaction;
LGG	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.87	-0.64	1.11e-54	Refractive error;
LGG	cis	rs11785693	0.789	rs11776268	chr8:4985852	C/T	cg26367366	chr8:4980734	NA	-0.49	-7.37	-0.32	8.03e-13	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2820315	0.964	rs2644109	chr1:201797535	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.82	0.3	2.86e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg10756647	chr7:56101905	PSPH	-0.46	-6.99	-0.31	9.59e-12	Corneal structure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13467399	chr9:133588111	ABL1	0.43	6.89	0.3	1.81e-11	Cognitive performance;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.35	-0.32	8.82e-13	Bipolar disorder;
LGG	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.22	-0.46	5.11e-26	Coronary artery disease;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.36e-23	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12539128	chr2:71222296	TEX261	0.48	7.66	0.34	1.12e-13	Gut microbiome composition (summer);
LGG	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.14	-0.35	3.74e-15	Morning vs. evening chronotype;
LGG	cis	rs4038782	0.503	rs11862351	chr16:4903583	G/A	cg04440724	chr16:4920505	UBN1	-0.64	-9.95	-0.42	3e-21	Cancer;
LGG	cis	rs7432375	0.610	rs28458819	chr3:136522314	A/G	cg21827317	chr3:136751795	NA	0.44	7.92	0.35	1.76e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4330281	0.608	rs4589965	chr3:17709985	C/T	cg20981856	chr3:17787350	NA	-0.41	-7.68	-0.34	9.65e-14	Schizophrenia;
LGG	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg09163369	chr1:210001066	C1orf107	0.38	6.74	0.3	4.58e-11	Orofacial clefts;
LGG	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.85	-16.55	-0.61	1.1e-48	Hip circumference adjusted for BMI;
LGG	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg27205649	chr11:78285834	NARS2	-0.49	-8.46	-0.37	3.62e-16	Alzheimer's disease (survival time);
LGG	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.67	0.37	7.12e-17	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg27471124	chr11:109292789	C11orf87	0.5	9.82	0.42	8.11e-21	Schizophrenia;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.97	0.49	5.87e-29	Tonsillectomy;
LGG	cis	rs2115630	0.967	rs8028490	chr15:85277888	G/A	cg12501888	chr15:85177176	SCAND2	-0.41	-6.86	-0.3	2.23e-11	P wave terminal force;
LGG	cis	rs2463822	0.858	rs2463836	chr11:62126494	A/G	cg06239285	chr11:62104954	ASRGL1	1.15	15.87	0.59	1.39e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.97	0.31	1.07e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs7918232	0.596	rs7902540	chr10:27304693	C/T	cg14240646	chr10:27532245	ACBD5	-0.49	-8.12	-0.35	4.3e-15	Breast cancer;
LGG	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg08999081	chr20:33150536	PIGU	0.3	6.9	0.31	1.77e-11	Coronary artery disease;
LGG	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg03342759	chr3:160939853	NMD3	-0.61	-10.76	-0.45	3.1e-24	Morning vs. evening chronotype;
LGG	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.78	0.34	4.68e-14	Electroencephalogram traits;
LGG	cis	rs755249	0.529	rs604316	chr1:39879366	T/C	cg18385671	chr1:39797026	MACF1	0.46	9.52	0.4	9.93e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.7	0.34	8.16e-14	Renal function-related traits (BUN);
LGG	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg21230503	chr5:139085173	NA	0.36	8.44	0.37	4.21e-16	Schizophrenia;
LGG	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg02297831	chr4:17616191	MED28	-0.42	-7.33	-0.32	1.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs67311347	0.544	rs4974047	chr3:40339653	G/T	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.9e-45	Renal cell carcinoma;
LGG	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg09048205	chr5:1608656	LOC728613	-0.44	-7.95	-0.35	1.46e-14	Breast cancer;
LGG	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	10.91	0.45	7.88e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg13010199	chr12:38710504	ALG10B	0.68	13.28	0.53	2.42e-34	Morning vs. evening chronotype;
LGG	cis	rs7566780	0.597	rs4389335	chr2:16688159	G/T	cg09580478	chr2:16689509	NA	-0.49	-7.49	-0.33	3.49e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg03511173	chr18:77590860	NA	0.66	8.41	0.36	5.09e-16	Opioid sensitivity;
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg13607699	chr17:42295918	UBTF	0.75	12.55	0.5	2.63e-31	Total body bone mineral density;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00933542	chr6:150070202	PCMT1	0.38	6.89	0.3	1.88e-11	Lung cancer;
LGG	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.83	0.38	2.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1030877	0.515	rs3828300	chr2:105901107	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.62	-9.03	-0.39	4.83e-18	Obesity-related traits;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg16141378	chr3:129829833	LOC729375	0.4	9.05	0.39	4.12e-18	Neuroticism;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg05941027	chr17:61774174	LIMD2	0.35	8.75	0.38	3.91e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21659725	chr3:3221576	CRBN	0.55	9.68	0.41	2.59e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	trans	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg19635926	chr16:89946313	TCF25	0.81	9.19	0.39	1.35e-18	Skin colour saturation;
LGG	cis	rs6444746	0.935	rs904882	chr3:193506326	A/G	cg22553634	chr3:193489233	NA	-0.69	-7.94	-0.35	1.53e-14	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-8.45	-0.37	3.78e-16	Height;
LGG	trans	rs1459104	0.925	rs35473011	chr11:54881353	G/A	cg03929089	chr4:120376271	NA	0.71	6.96	0.31	1.16e-11	Body mass index;
LGG	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.9	0.38	1.29e-17	Bipolar disorder;
LGG	cis	rs2294693	0.945	rs9381023	chr6:40983281	C/T	cg14769373	chr6:40998127	UNC5CL	0.41	6.81	0.3	2.95e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs7524258	0.868	rs10779678	chr1:7300573	A/G	cg07173049	chr1:7289937	CAMTA1	0.78	18.36	0.65	6.01e-57	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06470251	chr20:60548479	NA	0.47	7.98	0.35	1.18e-14	Body mass index;
LGG	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12229367	chr17:55822335	NA	0.45	8.67	0.37	7.25e-17	Schizophrenia;
LGG	cis	rs1793639	0.667	rs1625427	chr11:131957293	A/G	cg13908476	chr11:131942942	NTM	0.57	11.76	0.48	4.09e-28	Myopia;
LGG	cis	rs7667	0.881	rs12036866	chr1:19751333	T/C	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.38	-6.69	-0.3	6.38e-11	Crohn's disease and psoriasis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11765430	chr4:331396	ZNF141	0.41	6.75	0.3	4.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs6964587	1.000	rs2157747	chr7:91750578	A/G	cg17063962	chr7:91808500	NA	0.5	9.12	0.39	2.39e-18	Breast cancer;
LGG	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs240764	0.782	rs239235	chr6:101100528	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.31e-14	Neuroticism;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.4	-0.36	5.41e-16	Longevity;Endometriosis;
LGG	cis	rs7927771	1.000	rs2290850	chr11:47807774	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs11168618	1.000	rs11168618	chr12:48933233	C/T	cg24011408	chr12:48396354	COL2A1	0.46	7.49	0.33	3.43e-13	Adiponectin levels;
LGG	cis	rs2173063	1.000	rs74029122	chr15:93130716	G/A	cg07052004	chr15:93132129	NA	0.65	7.36	0.32	8.71e-13	Subcutaneous adipose tissue;
LGG	cis	rs4655582	0.527	rs4655794	chr1:66159301	T/C	cg04111102	chr1:66153794	NA	0.27	6.96	0.31	1.14e-11	Fibrinogen levels;
LGG	cis	rs12410462	0.551	rs12070539	chr1:227865316	C/T	cg04117972	chr1:227635322	NA	0.44	8.11	0.35	4.54e-15	Major depressive disorder;
LGG	cis	rs703842	1.000	rs11172351	chr12:58213485	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.05	0.35	7.03e-15	Multiple sclerosis;
LGG	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg27490568	chr2:178487706	NA	0.85	15.25	0.58	7.89e-43	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22649991	chr20:49547243	ADNP	0.47	7.24	0.32	1.85e-12	Hip circumference;
LGG	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg14675211	chr2:100938903	LONRF2	-0.46	-6.94	-0.31	1.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7538876	1.000	rs2526829	chr1:17728231	A/G	cg10329579	chr1:17754830	RCC2	-0.47	-9.21	-0.39	1.18e-18	Basal cell carcinoma;
LGG	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg16850897	chr7:100343110	ZAN	0.44	7.02	0.31	8.13e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs16912285	0.688	rs7929701	chr11:24357964	A/C	ch.11.24196551F	chr11:24239977	NA	0.92	12.7	0.51	6.21e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.1	-0.31	4.63e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.48	-0.33	3.81e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg02269571	chr22:50332266	NA	-0.64	-10.2	-0.43	3.67e-22	Schizophrenia;
LGG	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg16339924	chr4:17578868	LAP3	-0.54	-8.88	-0.38	1.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17453880	0.929	rs6897983	chr5:151994224	T/C	cg12297329	chr5:152029980	NA	-0.86	-22.14	-0.72	1.32e-74	Subjective well-being;
LGG	cis	rs1007190	0.570	rs12185253	chr17:42867957	C/T	cg15406952	chr17:42872593	NA	-1.1	-13.04	-0.52	2.62e-33	DNA methylation (variation);
LGG	cis	rs7011049	0.778	rs117805592	chr8:53865778	A/G	cg26025543	chr8:53854495	NA	0.61	8.59	0.37	1.32e-16	Systolic blood pressure;
LGG	cis	rs12908161	0.683	rs12903256	chr15:85308141	G/T	cg03959625	chr15:84868606	LOC388152	0.43	6.64	0.3	8.58e-11	Schizophrenia;
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg22753661	chr15:79092743	ADAMTS7	0.4	6.84	0.3	2.44e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs7129220	0.512	rs7936409	chr11:10086260	A/C	cg01453529	chr11:10209919	SBF2	-0.42	-6.88	-0.3	1.93e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3762637	0.882	rs9818537	chr3:122086457	G/T	cg24169773	chr3:122142474	KPNA1	-0.55	-8.9	-0.38	1.28e-17	LDL cholesterol levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.44	7.41	0.33	5.9e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs6500395	1.000	rs7187513	chr16:48591638	T/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.72e-13	Height;
LGG	cis	rs9811920	0.609	rs6809988	chr3:99656615	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.54	-9.24	-0.39	9.18e-19	Axial length;
LGG	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.18e-34	Blood metabolite levels;
LGG	cis	rs9549367	0.713	rs9549352	chr13:113833221	A/G	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.37e-50	Platelet distribution width;
LGG	cis	rs4262150	0.810	rs72797284	chr5:152031650	A/G	cg12297329	chr5:152029980	NA	-0.82	-15.97	-0.6	4.59e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg22437258	chr11:111473054	SIK2	-0.55	-9.64	-0.41	3.59e-20	Primary sclerosing cholangitis;
LGG	cis	rs7113850	0.541	rs11820983	chr11:24211705	T/C	ch.11.24196551F	chr11:24239977	NA	0.92	10.91	0.45	8.07e-25	Bone fracture in osteoporosis;
LGG	cis	rs240764	0.817	rs239245	chr6:101090377	C/A	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs79146658	0.688	rs56345539	chr2:179727315	A/C	cg17765952	chr2:179737173	CCDC141	0.59	8.62	0.37	1.1e-16	Diastolic blood pressure;
LGG	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06627557	chr7:32535165	LSM5;AVL9	1.09	26.75	0.78	5.54e-96	Cognitive ability;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05665937	chr4:1216051	CTBP1	-0.41	-7.22	-0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.2	0.52	5.63e-34	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs6138458	0.701	rs6050255	chr20:25007089	A/G	cg26195577	chr20:24973756	C20orf3	0.9	16.24	0.6	2.8e-47	Blood protein levels;
LGG	trans	rs634534	0.622	rs624273	chr11:65712413	A/G	cg17712092	chr4:129076599	LARP1B	0.71	13.35	0.53	1.33e-34	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg10621924	chr7:39171070	POU6F2	0.44	8.55	0.37	1.75e-16	IgG glycosylation;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00166722	chr3:10149974	C3orf24	-0.55	-9.21	-0.39	1.15e-18	Alzheimer's disease;
LGG	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg19507638	chr5:93509721	C5orf36	0.4	7.18	0.32	2.79e-12	Diabetic retinopathy;
LGG	cis	rs240764	0.817	rs239237	chr6:101094940	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs1707322	1.000	rs10890350	chr1:46262378	G/A	cg03146154	chr1:46216737	IPP	0.55	10.38	0.43	7.68e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg25457927	chr22:38595422	NA	-0.42	-10.72	-0.45	4.28e-24	Cutaneous nevi;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg19635926	chr16:89946313	TCF25	0.72	7.09	0.31	5.12e-12	Skin colour saturation;
LGG	trans	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.69	-0.34	9.11e-14	Blood trace element (Cu levels);
LGG	cis	rs6840360	0.693	rs28622593	chr4:152374080	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.16	0.32	3.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9314323	0.798	rs12682345	chr8:26218332	A/G	cg11498726	chr8:26250323	BNIP3L	0.52	10.99	0.45	4.18e-25	Red cell distribution width;
LGG	trans	rs2018683	0.523	rs4513881	chr7:29025410	C/T	cg19402173	chr7:128379420	CALU	0.58	9.65	0.41	3.37e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs700590	0.532	rs10462335	chr5:88088204	G/A	cg22951263	chr5:87985283	NA	-0.43	-7.64	-0.33	1.23e-13	Educational attainment (years of education);
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.28	-0.32	1.43e-12	Bipolar disorder;
LGG	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-10.38	-0.43	8.08e-23	Personality dimensions;
LGG	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg16325326	chr1:53192061	ZYG11B	0.84	22.73	0.73	2.33e-77	Monocyte count;
LGG	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.67	-0.37	7.31e-17	Mood instability;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.16	-0.32	3.27e-12	Lung cancer;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.77e-13	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.37	0.53	1.03e-34	Lung cancer;
LGG	cis	rs10463316	0.894	rs869196	chr5:150746287	G/T	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.32	-0.43	1.27e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08533424	chr17:37009973	RPL23;SNORA21	0.44	7.42	0.33	5.51e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12444795	0.675	rs74003567	chr16:4953055	G/T	cg04440724	chr16:4920505	UBN1	-0.56	-7.65	-0.34	1.16e-13	Cancer;
LGG	cis	rs9534288	0.577	rs2897029	chr13:46682821	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.2	-0.55	2.98e-38	Blood protein levels;
LGG	cis	rs4851254	0.660	rs4851250	chr2:100729293	T/C	cg17356467	chr2:100759845	AFF3	0.47	7.27	0.32	1.59e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19671926	chr4:122722719	EXOSC9	0.48	7.26	0.32	1.64e-12	Type 2 diabetes;
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06481639	chr22:41940642	POLR3H	0.59	8.65	0.37	8.58e-17	Vitiligo;
LGG	cis	rs9916302	0.707	rs11078903	chr17:37631924	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.54	-0.59	4.16e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.78	0.57	8.84e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg25919922	chr13:100150906	NA	-0.71	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	cis	rs12190007	0.547	rs3006178	chr6:169823936	G/A	cg15038512	chr6:170123185	PHF10	-0.45	-8.57	-0.37	1.54e-16	Obesity-related traits;
LGG	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.36	0.32	8.71e-13	Neuroticism;
LGG	cis	rs9863	0.861	rs7958691	chr12:124440743	G/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.04	-0.31	7.17e-12	White blood cell count;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.34	0.32	9.94e-13	Schizophrenia;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.87	-19.71	-0.68	3.02e-63	Birth weight;
LGG	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg16482183	chr6:26056742	HIST1H1C	-0.46	-7.48	-0.33	3.73e-13	Iron status biomarkers;
LGG	cis	rs9399135	0.967	rs6908512	chr6:135367757	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg09303159	chr6:26284866	NA	0.32	7.24	0.32	1.85e-12	Educational attainment;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.27	0.69	7.14e-66	Alzheimer's disease;
LGG	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg25237894	chr2:233734115	C2orf82	-0.67	-12.61	-0.51	1.54e-31	Coronary artery disease;
LGG	cis	rs7538876	1.000	rs4920603	chr1:17727379	C/G	cg10329579	chr1:17754830	RCC2	0.48	9.6	0.41	5.25e-20	Basal cell carcinoma;
LGG	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg20503657	chr10:835505	NA	0.75	10.48	0.44	3.28e-23	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12727795	chr5:149535695	PDGFRB	0.4	6.83	0.3	2.67e-11	Gut microbiome composition (summer);
LGG	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg01657329	chr11:68192670	LRP5	0.57	10.58	0.44	1.45e-23	Total body bone mineral density;
LGG	cis	rs1577917	0.687	rs34618171	chr6:86811165	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-11.73	-0.48	5.44e-28	Response to antipsychotic treatment;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.07	-0.35	6.19e-15	Lewy body disease;
LGG	cis	rs736801	0.569	rs12517950	chr5:131731326	A/G	cg07395648	chr5:131743802	NA	-0.59	-12.9	-0.51	1e-32	Breast cancer;Mosquito bite size;
LGG	trans	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg11441553	chr12:57614120	NXPH4	-0.58	-7.2	-0.32	2.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg06074448	chr4:187884817	NA	-0.59	-12.6	-0.51	1.73e-31	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg20891558	chr2:74357851	NA	0.49	9.6	0.41	4.9e-20	Gestational age at birth (maternal effect);
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg09307838	chr4:120376055	NA	0.81	13.47	0.53	3.79e-35	Corneal astigmatism;
LGG	cis	rs1568889	0.938	rs11601602	chr11:28233768	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	13.75	0.54	2.69e-36	Bipolar disorder;
LGG	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg13010199	chr12:38710504	ALG10B	0.72	14.8	0.57	7.53e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2066819	1.000	rs77447765	chr12:56690662	G/A	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.3	-0.36	1.16e-15	Calcium levels;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22433210	chr17:43662623	NA	0.91	15.04	0.57	6.65e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4356932	1.000	rs6850515	chr4:76973751	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs4380275	1.000	rs7562792	chr2:774469	T/C	cg14072418	chr2:740025	NA	-0.41	-7.67	-0.34	1.04e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs1062746	0.683	rs891094	chr16:87378001	C/G	cg02258303	chr16:87377426	FBXO31	0.6	11.92	0.48	9.51e-29	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.8	-0.34	4.08e-14	Restless legs syndrome;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg20387954	chr3:183756860	HTR3D	0.66	13.36	0.53	1.17e-34	Anterior chamber depth;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg15971980	chr6:150254442	NA	0.44	8.9	0.38	1.29e-17	Testicular germ cell tumor;
LGG	cis	rs11229555	1.000	rs8373	chr11:58378424	A/G	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4664308	0.967	rs34248629	chr2:160902497	C/T	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.25	-0.63	7.68e-52	Idiopathic membranous nephropathy;
LGG	trans	rs6787172	0.728	rs7430565	chr3:158107180	G/A	cg23275840	chr4:47708675	CORIN	-0.4	-8.51	-0.37	2.41e-16	Subjective well-being;
LGG	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg02227867	chr8:22457446	C8orf58	-0.4	-7.66	-0.34	1.13e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg00290607	chr11:67383545	NA	-0.47	-8.41	-0.36	5.03e-16	Mean corpuscular volume;
LGG	trans	rs6787172	0.702	rs1730020	chr3:158003849	G/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs72827839	0.802	rs16953382	chr17:46252906	C/T	cg02219949	chr17:45927392	SP6	0.54	8.11	0.35	4.67e-15	Ease of getting up in the morning;
LGG	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg20503657	chr10:835505	NA	0.75	10.23	0.43	2.85e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.23	-0.32	1.95e-12	Refractive error;
LGG	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.49	-0.4	1.21e-19	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg25214090	chr10:38739885	LOC399744	0.68	12.2	0.49	7.22e-30	Corneal astigmatism;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg10360139	chr7:1886902	MAD1L1	-0.4	-7.06	-0.31	6.04e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.19	0.49	8.07e-30	Type 2 diabetes;
LGG	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg02187348	chr16:89574699	SPG7	0.43	6.96	0.31	1.19e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg13939156	chr17:80058883	NA	0.47	8.18	0.36	2.79e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.78e-25	Aortic root size;
LGG	cis	rs6445975	0.666	rs9311674	chr3:58390702	C/G	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs3748022	1.000	rs12124627	chr1:206687263	C/G	cg11166312	chr1:206654246	IKBKE	-0.4	-6.79	-0.3	3.4e-11	Lymphocyte counts;
LGG	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg11764359	chr7:65958608	NA	0.63	9.79	0.41	1.09e-20	Aortic root size;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg03351412	chr1:154909251	PMVK	0.66	12.82	0.51	2.14e-32	Prostate cancer;
LGG	cis	rs6942756	0.531	rs9649530	chr7:128927406	G/A	cg02491457	chr7:128862824	NA	0.49	9.11	0.39	2.53e-18	White matter hyperintensity burden;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg18379455	chr17:41446167	NA	0.3	7.15	0.32	3.51e-12	Menopause (age at onset);
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-12.69	-0.51	6.84e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg17971929	chr21:40555470	PSMG1	0.87	17.06	0.62	5.58e-51	Cognitive function;
LGG	cis	rs367943	0.634	rs2195377	chr5:112973620	G/A	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.39	0.43	7.45e-23	Aortic root size;
LGG	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.19	0.32	2.64e-12	Facial emotion recognition (sad faces);
LGG	cis	rs10824796	1.000	rs2384044	chr10:54536083	C/G	cg27418851	chr10:54531653	MBL2	-0.45	-8.61	-0.37	1.15e-16	Blood protein levels;
LGG	cis	rs6728642	1.000	rs73959416	chr2:97604518	A/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.98	-0.31	1.01e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs1109114	0.816	rs2963497	chr5:148597684	A/G	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.8	-0.59	2.82e-45	Body mass index;
LGG	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg02002194	chr4:3960332	NA	0.39	6.96	0.31	1.17e-11	Myopia (pathological);
LGG	cis	rs7940866	0.803	rs1865296	chr11:130882944	C/T	cg12179176	chr11:130786555	SNX19	-0.71	-13.37	-0.53	1.04e-34	Schizophrenia;
LGG	cis	rs4700695	0.668	rs253212	chr5:65497553	C/T	cg21114390	chr5:65439923	SFRS12	-0.67	-9.77	-0.41	1.25e-20	Facial morphology (factor 19);
LGG	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs10504073	0.584	rs17642664	chr8:49942945	A/G	cg00325661	chr8:49890786	NA	0.79	15.57	0.59	3.06e-44	Blood metabolite ratios;
LGG	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.72	0.3	5.48e-11	Homoarginine levels;
LGG	cis	rs7660883	0.897	rs342466	chr4:88053085	C/T	cg21988461	chr4:88008667	AFF1	0.36	10.19	0.43	3.91e-22	HDL cholesterol levels;
LGG	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg02297831	chr4:17616191	MED28	-0.48	-9.03	-0.39	4.68e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg01620082	chr3:125678407	NA	-0.6	-6.76	-0.3	4.2e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7572733	0.875	rs7587043	chr2:198841729	A/C	cg00792783	chr2:198669748	PLCL1	0.46	7.65	0.34	1.14e-13	Dermatomyositis;
LGG	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg10560079	chr2:191398806	TMEM194B	0.36	7.91	0.35	1.87e-14	Pulse pressure;
LGG	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg12219531	chr12:120966889	COQ5	0.62	10.13	0.43	6.5e-22	High light scatter reticulocyte count;
LGG	cis	rs11168618	0.626	rs11609074	chr12:48819335	C/A	cg24011408	chr12:48396354	COL2A1	0.48	7.72	0.34	7.39e-14	Adiponectin levels;
LGG	cis	rs11585357	0.895	rs72646797	chr1:17613838	C/G	cg08277548	chr1:17600880	PADI3	-0.74	-8.21	-0.36	2.19e-15	Hair shape;
LGG	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg19766460	chr21:43528205	UMODL1;C21orf128	0.47	9.08	0.39	3.1e-18	IgG glycosylation;
LGG	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg14036092	chr11:66035641	RAB1B	0.46	8.0	0.35	9.81e-15	Gout;
LGG	cis	rs7937612	1.000	rs10790380	chr11:120233158	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.76	-0.51	3.8e-32	Intraocular pressure;
LGG	cis	rs11264213	0.901	rs79303353	chr1:36402056	G/A	cg27506609	chr1:36549197	TEKT2	0.77	7.64	0.33	1.3e-13	Schizophrenia;
LGG	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg11586189	chr1:201857591	SHISA4	0.37	8.3	0.36	1.13e-15	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg27490568	chr2:178487706	NA	0.51	10.11	0.43	7.9e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2797369	0.550	rs1408771	chr6:101650474	T/G	cg27451362	chr6:101846650	GRIK2	-0.47	-7.46	-0.33	4.26e-13	Renal function-related traits (eGRFcrea);
LGG	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs1965732	0.563	rs13409104	chr2:3718692	C/T	cg15327641	chr2:3715039	ALLC	0.34	7.37	0.32	7.95e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg02187348	chr16:89574699	SPG7	-0.5	-8.22	-0.36	2.12e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.3	-0.32	1.25e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg03342759	chr3:160939853	NMD3	0.66	10.8	0.45	2.06e-24	Parkinson's disease;
LGG	cis	rs4776059	1.000	rs11857150	chr15:52922216	G/A	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.79	-0.34	4.33e-14	Schizophrenia;
LGG	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg13607699	chr17:42295918	UBTF	-0.42	-6.69	-0.3	6.36e-11	Total body bone mineral density;
LGG	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg03060546	chr3:49711283	APEH	-0.53	-7.13	-0.31	3.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7666738	0.753	rs13111199	chr4:98953705	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.74	-0.34	6.12e-14	Obesity-related traits;
LGG	cis	rs4566357	0.557	rs6707158	chr2:227911269	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.11	-0.39	2.48e-18	Coronary artery disease;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.74	0.41	1.59e-20	Longevity;
LGG	trans	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg18335740	chr13:41363409	SLC25A15	0.56	10.37	0.43	8.66e-23	Lewy body disease;
LGG	cis	rs151234	0.565	rs9924471	chr16:28591530	G/A	cg01378222	chr16:28622494	SULT1A1	-0.63	-9.68	-0.41	2.67e-20	Platelet distribution width;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg14675211	chr2:100938903	LONRF2	0.49	7.01	0.31	8.41e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg08470875	chr2:26401718	FAM59B	-0.41	-8.11	-0.35	4.58e-15	Gut microbiome composition (summer);
LGG	cis	rs911263	0.603	rs1956524	chr14:68800393	G/A	cg18825221	chr14:68749962	RAD51L1	0.37	8.11	0.35	4.49e-15	Primary biliary cholangitis;
LGG	cis	rs2597513	0.745	rs2655229	chr3:13567729	G/C	cg24006715	chr3:13568212	NA	0.63	10.3	0.43	1.55e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1030877	0.889	rs2576746	chr2:105909559	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.74	15.02	0.57	8.27e-42	Obesity-related traits;
LGG	cis	rs6450176	1.000	rs4311394	chr5:53300662	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.49	-0.47	4.79e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00166722	chr3:10149974	C3orf24	0.35	6.86	0.3	2.15e-11	Alzheimer's disease;
LGG	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.72	0.41	1.84e-20	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg12310025	chr6:25882481	NA	-0.43	-7.1	-0.31	4.59e-12	Iron status biomarkers;
LGG	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg00343986	chr7:65444356	GUSB	-0.43	-7.29	-0.32	1.39e-12	Aortic root size;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	18.89	0.66	1.91e-59	Platelet count;
LGG	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-9.9	-0.42	4.49e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs2274273	0.624	rs10132453	chr14:55840851	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.42	0.5	8.93e-31	Protein biomarker;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg20848291	chr7:100343083	ZAN	-0.66	-9.83	-0.42	7.62e-21	Other erythrocyte phenotypes;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg08925882	chr11:67350491	GSTP1	-0.35	-6.9	-0.31	1.72e-11	Mean corpuscular volume;
LGG	cis	rs607541	1.000	rs8036075	chr15:45934921	A/C	cg26924012	chr15:45694286	SPATA5L1	0.54	7.5	0.33	3.22e-13	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.11	0.46	1.43e-25	Homoarginine levels;
LGG	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg15596359	chr8:11213517	TDH	0.41	8.23	0.36	1.87e-15	Retinal vascular caliber;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.82	0.3	2.84e-11	Schizophrenia;
LGG	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg16141378	chr3:129829833	LOC729375	0.4	9.64	0.41	3.68e-20	Joint mobility (Beighton score);
LGG	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg02002194	chr4:3960332	NA	-0.5	-9.58	-0.41	5.84e-20	Mood instability;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.63	0.37	9.81e-17	Lung cancer;
LGG	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg01191920	chr7:158217561	PTPRN2	-0.72	-16.1	-0.6	1.21e-46	Obesity-related traits;
LGG	cis	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg25427524	chr10:38739819	LOC399744	0.46	8.7	0.37	5.9e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg04398451	chr17:18023971	MYO15A	-0.61	-12.33	-0.5	2.05e-30	Total body bone mineral density;
LGG	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg07440826	chr16:89882328	FANCA	-0.26	-6.85	-0.3	2.41e-11	Vitiligo;
LGG	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	12.53	0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg00531865	chr16:30841666	NA	0.56	11.73	0.48	5.34e-28	Dementia with Lewy bodies;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg11473876	chr11:109292803	C11orf87	0.48	9.48	0.4	1.34e-19	Schizophrenia;
LGG	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg26248373	chr2:1572462	NA	-0.69	-8.91	-0.38	1.16e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6032067	0.929	rs2267864	chr20:43805279	C/G	cg10761708	chr20:43804764	PI3	0.66	10.27	0.43	1.98e-22	Blood protein levels;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.52	0.4	9.66e-20	Height;
LGG	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg05335186	chr13:53173507	NA	0.74	18.89	0.66	1.99e-59	Lewy body disease;
LGG	cis	rs571497	0.877	rs868878	chr19:7831047	A/G	cg00371453	chr19:7854482	CLEC4GP1	-0.62	-7.04	-0.31	7.16e-12	Monocyte count;
LGG	cis	rs3126085	0.778	rs10788828	chr1:152191879	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.38e-17	Atopic dermatitis;
LGG	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.6	-0.37	1.21e-16	Aortic root size;
LGG	trans	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.3	-0.4	5.47e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1018836	0.923	rs4734266	chr8:91628147	C/T	cg16814680	chr8:91681699	NA	-0.84	-15.66	-0.59	1.19e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.68e-14	Lung cancer;
LGG	cis	rs9341835	0.772	rs9344090	chr6:64135830	G/A	cg00787780	chr6:64151745	NA	0.42	7.68	0.34	9.46e-14	Schizophrenia;
LGG	cis	rs11157436	0.602	rs12588757	chr14:22639997	T/G	cg00994629	chr14:22694547	NA	0.33	7.17	0.32	2.96e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00149659	chr3:10157352	C3orf10	0.84	10.76	0.45	3.01e-24	Alzheimer's disease;
LGG	cis	rs8049040	0.967	rs8050135	chr16:71472571	T/C	cg08717414	chr16:71523259	ZNF19	-0.4	-6.65	-0.3	8.09e-11	Blood protein levels;
LGG	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	10.05	0.42	1.25e-21	Retinal vascular caliber;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22433210	chr17:43662623	NA	-0.63	-10.83	-0.45	1.62e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.35	-0.32	9.3e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg02462569	chr6:150064036	NUP43	-0.37	-7.92	-0.35	1.8e-14	Lung cancer;
LGG	cis	rs113835537	0.529	rs61561111	chr11:66275923	T/C	cg24851651	chr11:66362959	CCS	0.45	7.74	0.34	6.37e-14	Airway imaging phenotypes;
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg21926883	chr2:100939477	LONRF2	-0.7	-16.81	-0.62	7.73e-50	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg22920501	chr2:26401640	FAM59B	-0.41	-7.97	-0.35	1.29e-14	Gut microbiome composition (summer);
LGG	cis	rs12618769	0.652	rs6736755	chr2:99204428	A/G	cg18455616	chr2:99124870	INPP4A	-0.27	-7.77	-0.34	5.1e-14	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg15309053	chr8:964076	NA	0.43	9.2	0.39	1.2e-18	Schizophrenia;
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.89	19.27	0.67	3.37e-61	Birth weight;
LGG	cis	rs4689642	1.000	rs1875338	chr4:7215300	C/G	cg21353189	chr4:7228343	SORCS2	-0.3	-7.33	-0.32	1.05e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.1	-0.31	4.82e-12	Joint mobility (Beighton score);
LGG	cis	rs7143963	0.636	rs11160705	chr14:103354184	G/A	cg23020514	chr14:103360112	TRAF3	0.39	8.17	0.35	3.01e-15	Body mass index;
LGG	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg07274523	chr3:49395745	GPX1	0.55	9.09	0.39	3.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg25358565	chr5:93447407	FAM172A	1.37	14.95	0.57	1.65e-41	Diabetic retinopathy;
LGG	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.55	0.37	1.78e-16	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06634786	chr22:41940651	POLR3H	-0.75	-12.39	-0.5	1.21e-30	Vitiligo;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21482837	chr2:85581528	ELMOD3;RETSAT	0.39	7.02	0.31	7.79e-12	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs1465370	0.692	rs2402996	chr7:130017003	C/T	cg06917763	chr7:130033247	NA	0.33	7.23	0.32	2.02e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg20703242	chr1:230279135	GALNT2	0.35	7.02	0.31	8.01e-12	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg03188948	chr7:1209495	NA	0.67	8.66	0.37	8.16e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2764208	0.535	rs2744967	chr6:34585344	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.72	-0.34	6.99e-14	Systemic lupus erythematosus;
LGG	cis	rs12367572	0.965	rs1506676	chr12:45237401	T/C	cg04608330	chr12:45269318	NELL2	-0.61	-10.82	-0.45	1.79e-24	Gut microbiome composition (summer);
LGG	cis	rs360798	0.512	rs1420018	chr2:63112500	A/G	cg17519650	chr2:63277830	OTX1	0.48	7.75	0.34	5.97e-14	Coronary artery disease;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg13010199	chr12:38710504	ALG10B	0.65	13.45	0.53	5.01e-35	Bladder cancer;
LGG	cis	rs11039389	1	rs11039389	chr11:47796062	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.7	-0.37	5.98e-17	Neuroticism;
LGG	cis	rs231513	0.954	rs11654245	chr17:41992650	T/C	cg26893861	chr17:41843967	DUSP3	0.6	6.71	0.3	5.74e-11	Cognitive function;
LGG	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg20913747	chr6:44695427	NA	-0.62	-10.08	-0.42	1.01e-21	Total body bone mineral density;
LGG	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4824093	0.610	rs4141437	chr22:50243719	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.81	7.06	0.31	6.15e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs240764	0.658	rs12212435	chr6:101196080	T/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg16268157	chr7:99778414	STAG3	-0.46	-7.59	-0.33	1.74e-13	Lung function (FEV1/FVC);
LGG	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg22906224	chr7:99728672	NA	-0.55	-9.26	-0.4	7.48e-19	Coronary artery disease;
LGG	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg04546413	chr19:29218101	NA	0.75	12.74	0.51	4.35e-32	Methadone dose in opioid dependence;
LGG	cis	rs9880211	0.898	rs73230099	chr3:136552627	A/G	cg21827317	chr3:136751795	NA	-0.51	-7.44	-0.33	4.97e-13	Body mass index;Height;
LGG	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg25486957	chr4:152246857	NA	-0.37	-6.65	-0.3	8.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.95	-0.45	5.8e-25	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21292152	chr19:37406949	ZNF829;ZNF568	0.41	7.32	0.32	1.09e-12	Obesity-related traits;
LGG	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg16586182	chr3:47516702	SCAP	0.75	13.56	0.53	1.68e-35	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07222113	chr8:104427719	DCAF13;SLC25A32	0.43	7.04	0.31	7.08e-12	Cognitive performance;
LGG	cis	rs3820068	0.608	rs12740492	chr1:16048951	A/T	cg05660106	chr1:15850417	CASP9	0.75	13.54	0.53	1.97e-35	Systolic blood pressure;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.87e-12	Prudent dietary pattern;
LGG	cis	rs9964724	0.559	rs7243439	chr18:35156196	A/G	cg27332583	chr18:35150602	NA	0.62	12.14	0.49	1.18e-29	Educational attainment (years of education);
LGG	cis	rs1941023	0.584	rs4938941	chr11:60173360	C/T	cg08716584	chr11:60157161	MS4A7	0.43	8.52	0.37	2.21e-16	Congenital heart disease (maternal effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19552494	chr11:60674271	PRPF19	0.52	8.17	0.35	2.98e-15	Gut microbiome composition (summer);
LGG	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg17201900	chr20:34330562	RBM39	0.5	6.72	0.3	5.52e-11	Total cholesterol levels;
LGG	trans	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg18187862	chr3:45730750	SACM1L	0.58	9.39	0.4	2.68e-19	Primary sclerosing cholangitis;
LGG	cis	rs2276314	0.857	rs7237599	chr18:33639396	T/C	cg05985134	chr18:33552581	C18orf21	0.61	9.73	0.41	1.81e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs950169	0.920	rs12915390	chr15:84792069	T/C	cg24253500	chr15:84953950	NA	0.59	10.93	0.45	6.58e-25	Schizophrenia;
LGG	cis	rs889398	0.641	rs9936589	chr16:69884817	C/T	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.62	-0.33	1.43e-13	Body mass index;
LGG	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg10940203	chr5:177434438	FAM153C	0.37	7.77	0.34	5.27e-14	Methadone dose in opioid dependence;
LGG	cis	rs1978968	0.956	rs2017932	chr22:18439190	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.2	-0.49	6.82e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1829883	0.898	rs2460686	chr5:98770831	T/C	cg08333243	chr5:99726346	NA	-0.36	-6.7	-0.3	6.26e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.2e-17	Menopause (age at onset);
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg19774624	chr17:42201019	HDAC5	-0.81	-14.37	-0.56	5.59e-39	Total body bone mineral density;
LGG	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg12560992	chr17:57184187	TRIM37	-0.47	-6.99	-0.31	9.57e-12	Cognitive test performance;
LGG	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.48	-7.71	-0.34	7.68e-14	Longevity;
LGG	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg24585782	chr17:78113791	EIF4A3	-0.51	-8.48	-0.37	3.05e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs4481887	0.516	rs11204613	chr1:248379155	A/G	cg00666640	chr1:248458726	OR2T12	-0.41	-6.7	-0.3	6.05e-11	Common traits (Other);
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg08742575	chr21:47604166	C21orf56	-0.56	-10.22	-0.43	3.05e-22	Testicular germ cell tumor;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs896854	0.654	rs16893776	chr8:95973604	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.99	-0.39	6.5e-18	Type 2 diabetes;
LGG	cis	rs503734	0.629	rs4287896	chr3:101261559	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.18	0.32	2.85e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4538187	0.707	rs67308158	chr2:64129453	G/A	cg14150252	chr2:64069583	UGP2	-0.5	-9.07	-0.39	3.34e-18	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.44	-0.33	5.01e-13	Menopause (age at onset);
LGG	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.24e-17	Height;
LGG	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11758351	0.500	rs79697629	chr6:26196512	A/G	cg01420254	chr6:26195488	NA	0.97	7.36	0.32	8.35e-13	Gout;Renal underexcretion gout;
LGG	cis	rs2373794	0.961	rs2110927	chr2:40354688	C/T	cg17740179	chr2:40377776	SLC8A1	0.95	20.16	0.68	2.4e-65	Asthma;
LGG	cis	rs1018836	0.923	rs7007102	chr8:91629730	T/A	cg16814680	chr8:91681699	NA	-0.84	-15.67	-0.59	1.07e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2976388	0.609	rs2572909	chr8:143806464	C/G	cg06565975	chr8:143823917	SLURP1	0.36	9.28	0.4	6.73e-19	Urinary tract infection frequency;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4959677	0.725	rs1680829	chr6:2503120	A/G	cg23817096	chr6:1620687	NA	-0.33	-8.14	-0.35	3.61e-15	Orthostatic hypotension;
LGG	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg01221209	chr5:554886	NA	-0.46	-6.86	-0.3	2.23e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	12.44	0.5	7.66e-31	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg26597838	chr10:835615	NA	0.7	9.86	0.42	6.11e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs2249625	0.584	rs2463744	chr6:72875936	C/T	cg27608224	chr6:72922399	RIMS1	0.32	7.27	0.32	1.58e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs3859192	0.599	rs2227319	chr17:38170845	G/A	cg17467752	chr17:38218738	THRA	-0.58	-9.62	-0.41	4.46e-20	White blood cell count;
LGG	cis	rs12200782	0.790	rs72840194	chr6:26361369	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.2	-0.32	2.46e-12	Small cell lung carcinoma;
LGG	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.85	-0.45	1.37e-24	Hemoglobin concentration;
LGG	cis	rs6578185	0.782	rs10099726	chr8:142448896	G/T	cg07762003	chr8:142452454	FLJ43860	-0.64	-13.14	-0.52	9.77e-34	Endometriosis;
LGG	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.95	0.38	8.79e-18	Educational attainment;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs1357245	0.534	rs6766181	chr3:27100290	A/G	cg02860705	chr3:27208620	NA	-0.37	-7.29	-0.32	1.35e-12	Breast cancer;
LGG	cis	rs516946	0.797	rs13266210	chr8:41533514	A/G	cg01678292	chr8:41522873	ANK1	0.35	7.47	0.33	4e-13	Type 2 diabetes;
LGG	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-8.01	-0.35	9.37e-15	Lung cancer in ever smokers;
LGG	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg15501526	chr10:2543763	NA	0.68	14.1	0.55	8.11e-38	Age-related hearing impairment;
LGG	cis	rs6784615	0.744	rs4687617	chr3:52509277	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	-0.62	-7.24	-0.32	1.9e-12	Waist-hip ratio;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg27286069	chr11:118481882	PHLDB1	-0.53	-9.74	-0.41	1.57e-20	Cholesterol, total;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg26554054	chr8:600488	NA	1.08	11.15	0.46	9.59e-26	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.33	0.36	8.92e-16	Monocyte count;
LGG	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs11229555	0.645	rs12285111	chr11:58208385	T/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg08645402	chr16:4508243	NA	0.47	8.87	0.38	1.54e-17	Schizophrenia;
LGG	cis	rs887829	0.570	rs6736508	chr2:234595747	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.25	-0.36	1.65e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06108461	chr20:60628389	TAF4	0.67	11.97	0.49	6.13e-29	Body mass index;
LGG	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.1	-0.35	5.06e-15	Calcium levels;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg19635926	chr16:89946313	TCF25	0.75	7.32	0.32	1.14e-12	Skin colour saturation;
LGG	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg06872548	chr17:78716983	RPTOR	-0.45	-11.1	-0.46	1.58e-25	Obesity;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	1.000	rs17078916	chr3:40445438	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-26.03	-0.77	1.12e-92	Renal cell carcinoma;
LGG	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.41	0.58	1.46e-43	Body mass index;
LGG	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.25	-0.32	1.73e-12	Mood instability;
LGG	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	13.76	0.54	2.23e-36	Total body bone mineral density;
LGG	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg21948465	chr5:131705150	SLC22A5	0.68	7.58	0.33	1.88e-13	Rheumatoid arthritis;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	7.81	0.34	3.98e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs593982	0.843	rs552312	chr11:65477349	C/T	cg08755490	chr11:65554678	OVOL1	0.7	8.61	0.37	1.19e-16	Atopic dermatitis;
LGG	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg00042356	chr1:8021962	PARK7	0.63	7.24	0.32	1.83e-12	Inflammatory bowel disease;
LGG	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg09021430	chr5:549028	NA	-0.65	-9.1	-0.39	2.62e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg00012203	chr2:219082015	ARPC2	-0.75	-14.39	-0.56	4.47e-39	Colorectal cancer;
LGG	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg09222892	chr1:25734099	RHCE	-0.45	-9.37	-0.4	3.22e-19	Erythrocyte sedimentation rate;
LGG	cis	rs9879311	0.966	rs4684684	chr3:10411344	C/T	cg21387009	chr3:10280255	IRAK2	-0.36	-6.77	-0.3	3.83e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg15704280	chr7:45808275	SEPT13	0.78	9.04	0.39	4.17e-18	Axial length;
LGG	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.46	7.75	0.34	5.68e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-13.02	-0.52	2.95e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs709400	0.930	rs28513222	chr14:104028069	A/T	cg24130564	chr14:104152367	KLC1	-0.4	-7.39	-0.32	6.83e-13	Body mass index;
LGG	cis	rs2077654	0.556	rs2299640	chr11:17441228	A/G	cg25308976	chr11:17434268	ABCC8	0.59	7.85	0.34	2.92e-14	Gout;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg18402987	chr7:1209562	NA	0.67	9.04	0.39	4.43e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg17971929	chr21:40555470	PSMG1	0.87	17.32	0.63	3.49e-52	Cognitive function;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22168489	chr12:122356033	WDR66	0.45	11.03	0.46	2.73e-25	Mean corpuscular volume;
LGG	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	-0.49	-6.97	-0.31	1.12e-11	Birth weight;
LGG	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg22437258	chr11:111473054	SIK2	0.55	9.74	0.41	1.57e-20	Primary sclerosing cholangitis;
LGG	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg01324343	chr3:183735012	ABCC5	0.65	12.42	0.5	8.76e-31	Anterior chamber depth;
LGG	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg24375607	chr4:120327624	NA	0.66	10.64	0.44	8.18e-24	Corneal astigmatism;
LGG	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00142150	chr22:38071001	LGALS1	0.69	13.34	0.53	1.42e-34	Fat distribution (HIV);
LGG	cis	rs3789045	0.826	rs12040520	chr1:204564762	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.85	-0.38	1.85e-17	Educational attainment (college completion);
LGG	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.56e-22	Motion sickness;
LGG	cis	rs8078723	0.738	rs3816472	chr17:38142677	A/C	cg17467752	chr17:38218738	THRA	-0.62	-11.11	-0.46	1.34e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs2430307	0.556	rs3905501	chr7:76542080	C/T	cg15770687	chr7:76625569	PMS2L11	-0.51	-7.14	-0.32	3.56e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs12286929	0.609	rs12791813	chr11:115091510	G/A	cg04055981	chr11:115044050	NA	0.36	6.69	0.3	6.56e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.85	15.24	0.58	8.62e-43	Chronic sinus infection;
LGG	cis	rs78487399	0.808	rs7578597	chr2:43732823	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs968451	1.000	rs968451	chr22:39670851	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	11.05	0.46	2.27e-25	Primary biliary cholangitis;
LGG	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg25947184	chr8:1697459	NA	0.42	7.34	0.32	9.66e-13	Systolic blood pressure;
LGG	cis	rs9944715	0.954	rs62096525	chr18:43743820	G/A	cg26436583	chr18:43649176	PSTPIP2	0.41	7.52	0.33	2.81e-13	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs4363385	0.720	rs1611754	chr1:152956415	A/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.19	-0.39	1.31e-18	Inflammatory skin disease;
LGG	cis	rs7106204	0.534	rs75423384	chr11:24273691	A/T	ch.11.24196551F	chr11:24239977	NA	0.84	8.62	0.37	1.06e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg04824913	chr4:887549	GAK	0.49	9.12	0.39	2.36e-18	Systemic sclerosis;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg26668828	chr6:292823	DUSP22	-0.7	-12.21	-0.49	6.46e-30	Menopause (age at onset);
LGG	trans	rs6011368	0.740	rs6062679	chr20:62889991	T/C	cg13869341	chr1:15865	WASH5P	0.53	9.48	0.4	1.36e-19	Clozapine-induced cytotoxicity;
LGG	cis	rs9867325	1.000	rs9867325	chr3:136618909	G/C	cg21827317	chr3:136751795	NA	-0.51	-7.41	-0.33	5.85e-13	Body mass index;
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03264133	chr6:25882463	NA	0.5	9.16	0.39	1.73e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg19539972	chr4:7069911	GRPEL1	-0.77	-10.24	-0.43	2.56e-22	Monocyte percentage of white cells;
LGG	trans	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	7.64	0.33	1.27e-13	Mononucleosis;
LGG	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.68	-0.3	6.88e-11	Parkinson's disease;
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs55871839	0.643	rs10109566	chr8:59800446	A/G	cg07426533	chr8:59803705	TOX	-0.57	-12.91	-0.51	8.45e-33	Pneumonia;
LGG	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg16576597	chr16:28551801	NUPR1	0.37	8.64	0.37	9.08e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.03	0.46	2.79e-25	Corneal astigmatism;
LGG	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg14541582	chr5:601475	NA	-0.68	-10.7	-0.45	5.09e-24	Obesity-related traits;
LGG	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg07777115	chr5:623756	CEP72	-0.52	-7.0	-0.31	9.08e-12	Obesity-related traits;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg24623649	chr8:11872141	NA	-0.3	-6.78	-0.3	3.58e-11	Neuroticism;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg10295955	chr4:187884368	NA	-1.13	-31.6	-0.83	1.19e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	8.85e-13	Lung cancer;
LGG	cis	rs12949688	1.000	rs12949688	chr17:55825701	C/T	cg12582317	chr17:55822272	NA	-0.64	-16.57	-0.61	9.08e-49	Schizophrenia;
LGG	cis	rs9596863	0.851	rs1379832	chr13:54429818	C/T	ch.13.53330881F	chr13:54432880	NA	0.51	6.98	0.31	1.03e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs8064024	0.681	rs7189135	chr16:4884368	G/C	cg04440724	chr16:4920505	UBN1	-0.55	-11.95	-0.49	6.86e-29	Cancer;
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.68	-0.41	2.61e-20	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01337508	chr17:40540572	STAT3	0.5	7.6	0.33	1.68e-13	Gut microbiome composition (summer);
LGG	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg01236616	chr12:121019343	POP5	-1.19	-19.3	-0.67	2.6e-61	Type 1 diabetes nephropathy;
LGG	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg02886208	chr11:14281011	SPON1	0.41	8.27	0.36	1.47e-15	Mitochondrial DNA levels;
LGG	trans	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg05926928	chr17:57297772	GDPD1	-0.71	-12.8	-0.51	2.49e-32	Schizophrenia;
LGG	cis	rs12946454	0.621	rs11651809	chr17:43255681	C/G	cg10701640	chr17:43249399	NA	0.39	7.15	0.32	3.3e-12	Systolic blood pressure;
LGG	cis	rs4780401	0.609	rs9923954	chr16:11816855	G/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.87	-0.51	1.27e-32	Rheumatoid arthritis;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.545	rs10074490	chr5:131340032	C/T	cg07395648	chr5:131743802	NA	-0.41	-8.88	-0.38	1.45e-17	Blood metabolite levels;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.58	0.41	5.96e-20	Bipolar disorder;
LGG	cis	rs11630290	0.592	rs12232336	chr15:64153357	T/C	cg12036633	chr15:63758958	NA	0.5	7.19	0.32	2.6e-12	Iris characteristics;
LGG	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg10167378	chr1:228756711	NA	0.7	9.37	0.4	3.08e-19	Chronic lymphocytic leukemia;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.48e-12	Height;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00166722	chr3:10149974	C3orf24	0.53	8.84	0.38	2.04e-17	Alzheimer's disease;
LGG	cis	rs9831754	0.704	rs1512492	chr3:78471190	A/C	cg06138941	chr3:78371609	NA	-0.79	-15.64	-0.59	1.37e-44	Calcium levels;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg11301795	chr4:187892539	NA	-0.94	-24.89	-0.76	1.9e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8056064	0.790	rs36047343	chr16:82803959	G/A	cg08271366	chr16:82816457	CDH13	-0.43	-7.14	-0.31	3.65e-12	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg02753203	chr1:228287806	NA	0.76	14.73	0.56	1.53e-40	Diastolic blood pressure;
LGG	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg09904177	chr6:26538194	HMGN4	0.59	11.7	0.48	6.86e-28	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05665937	chr4:1216051	CTBP1	-0.5	-9.01	-0.39	5.46e-18	Obesity-related traits;
LGG	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15557168	chr22:42548783	NA	-0.34	-7.51	-0.33	3.13e-13	Cognitive function;
LGG	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.12	-0.35	4.17e-15	Huntington's disease progression;
LGG	cis	rs10901296	0.660	rs2855199	chr9:133765044	T/C	cg13397898	chr9:133768931	QRFP	0.42	8.4	0.36	5.46e-16	Bilirubin levels;
LGG	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg18154014	chr19:37997991	ZNF793	0.45	7.63	0.33	1.33e-13	Coronary artery calcification;
LGG	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg15028436	chr7:37888078	TXNDC3	0.89	16.37	0.61	7.59e-48	Alzheimer's disease (late onset);
LGG	cis	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg13443165	chr9:33130375	B4GALT1	-0.61	-12.21	-0.49	6.17e-30	IgG glycosylation;
LGG	cis	rs1670533	1.000	rs34956924	chr4:1047270	T/C	cg27284194	chr4:1044797	NA	0.53	9.47	0.4	1.39e-19	Recombination rate (females);
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.67	-0.3	7.42e-11	Lung cancer;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.81e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg12724942	chr10:75457680	AGAP5	-0.52	-6.7	-0.3	6.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs939658	0.805	rs36068099	chr15:79438598	G/C	cg17916960	chr15:79447300	NA	-0.66	-12.9	-0.51	9.39e-33	Refractive error;
LGG	cis	rs490234	0.702	rs10986788	chr9:128303942	G/C	cg14078157	chr9:128172775	NA	-0.55	-10.35	-0.43	9.74e-23	Mean arterial pressure;
LGG	cis	rs4950322	0.580	rs17355419	chr1:146581676	T/C	cg22381352	chr1:146742008	CHD1L	-0.43	-7.29	-0.32	1.32e-12	Protein quantitative trait loci;
LGG	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg19628046	chr18:33552617	C18orf21	0.55	7.88	0.34	2.36e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs988958	0.565	rs6758382	chr2:42231733	G/A	cg27252766	chr2:42229092	NA	0.54	7.63	0.33	1.35e-13	Hypospadias;
LGG	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg02227867	chr8:22457446	C8orf58	0.4	7.54	0.33	2.48e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2270431	1	rs2270431	chr14:75270635	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	9.02	0.39	5.04e-18	Neuroticism;
LGG	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg09754948	chr16:28834200	ATXN2L	0.47	7.35	0.32	9.13e-13	Tonsillectomy;Mean corpuscular volume;
LGG	trans	rs970548	0.730	rs61854092	chr10:45934795	G/A	cg20477318	chr10:51623047	TIMM23	0.65	7.79	0.34	4.39e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs72848980	0.512	rs61151381	chr10:105370496	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.79	13.05	0.52	2.38e-33	White matter hyperintensity burden;
LGG	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg01620082	chr3:125678407	NA	-1.01	-9.68	-0.41	2.75e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2708240	0.599	rs1613285	chr7:147520530	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.3	-6.8	-0.3	3.26e-11	QT interval (drug interaction);
LGG	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg04986931	chr22:39850128	NA	0.4	8.93	0.38	1.02e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg02023728	chr11:77925099	USP35	0.44	7.57	0.33	2.04e-13	Testicular germ cell tumor;
LGG	cis	rs17092148	1.000	rs6058112	chr20:33322006	G/C	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.79	-0.34	4.39e-14	Neuroticism;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg13010199	chr12:38710504	ALG10B	0.36	6.79	0.3	3.45e-11	Morning vs. evening chronotype;
LGG	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs11608355	0.515	rs7310945	chr12:109946012	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs2587949	0.615	rs2686697	chr3:4199267	G/C	cg16519197	chr3:4211558	NA	0.33	6.77	0.3	3.83e-11	Periodontitis (DPAL);
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg13395646	chr4:1353034	KIAA1530	-0.63	-10.92	-0.45	7.16e-25	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg08344181	chr3:125677491	NA	-0.62	-7.11	-0.31	4.46e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg24642439	chr20:33292090	TP53INP2	0.63	10.94	0.45	6.09e-25	Coronary artery disease;
LGG	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12292205	chr6:26970375	C6orf41	-0.63	-8.43	-0.36	4.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.69	0.3	6.27e-11	Longevity;
LGG	trans	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.7	-0.41	2.25e-20	Triglycerides;
LGG	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.46	0.33	4.32e-13	Systemic lupus erythematosus;
LGG	cis	rs10875746	0.551	rs11168536	chr12:48745051	C/T	cg24011408	chr12:48396354	COL2A1	-0.56	-7.14	-0.32	3.57e-12	Longevity (90 years and older);
LGG	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg27422857	chr2:105853526	NA	-0.36	-6.7	-0.3	6.16e-11	Type 2 diabetes;
LGG	cis	rs2084898	1.000	rs7116650	chr11:120041917	C/T	cg13907859	chr11:120009124	TRIM29	0.86	11.74	0.48	4.91e-28	Stroke (pediatric);
LGG	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00989323	chr10:49864621	NA	0.43	6.78	0.3	3.6e-11	Cognitive performance;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg02297831	chr4:17616191	MED28	0.51	9.49	0.4	1.25e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg10057126	chr4:77819792	ANKRD56	0.36	6.98	0.31	1.06e-11	Emphysema distribution in smoking;
LGG	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs7539542	0.556	rs1042990	chr1:202861566	C/T	cg19681188	chr1:202830198	LOC148709	-0.52	-8.79	-0.38	2.9e-17	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg15432903	chr11:17409602	KCNJ11	0.86	16.56	0.61	9.93e-49	Type 2 diabetes;
LGG	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg24631222	chr15:78858424	CHRNA5	0.42	6.68	0.3	6.96e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg02002194	chr4:3960332	NA	0.41	7.32	0.32	1.13e-12	Joint mobility (Beighton score);
LGG	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11081185	chr11:208423	RIC8A;BET1L	0.47	7.9	0.34	2.09e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg14789911	chr21:47582049	C21orf56	-0.41	-7.04	-0.31	6.93e-12	Testicular germ cell tumor;
LGG	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg07142201	chr11:109293216	C11orf87	-0.53	-9.44	-0.4	1.82e-19	Schizophrenia;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.57	9.98	0.42	2.31e-21	Longevity;
LGG	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg11502198	chr6:26597334	ABT1	0.54	9.34	0.4	3.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg03528353	chr17:61819722	STRADA	-0.44	-7.38	-0.32	7.23e-13	Prudent dietary pattern;
LGG	cis	rs77972916	0.505	rs34247383	chr2:43532780	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-9.4	-0.4	2.45e-19	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs1065852	0.526	rs7290655	chr22:42390225	C/G	cg15128208	chr22:42549153	NA	0.41	7.09	0.31	4.97e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg06360820	chr2:242988706	NA	-0.9	-11.52	-0.47	3.6e-27	Obesity-related traits;
LGG	cis	rs4704846	1.000	rs6896579	chr5:156541376	C/T	cg12943317	chr5:156479607	HAVCR1	-0.58	-7.63	-0.33	1.37e-13	Blood protein levels;
LGG	cis	rs79146658	1.000	rs55844607	chr2:179770998	A/G	cg17765952	chr2:179737173	CCDC141	0.65	7.36	0.32	8.42e-13	Diastolic blood pressure;
LGG	cis	rs727505	0.607	rs67673811	chr7:124802694	C/G	cg23710748	chr7:124431027	NA	-0.44	-8.4	-0.36	5.34e-16	Lewy body disease;
LGG	cis	rs4780401	0.632	rs8055462	chr16:11834821	T/C	cg01061890	chr16:11836724	TXNDC11	-0.7	-12.94	-0.52	6.77e-33	Rheumatoid arthritis;
LGG	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg06532163	chr17:45867833	NA	0.55	9.26	0.4	7.54e-19	IgG glycosylation;
LGG	cis	rs763121	0.853	rs5757141	chr22:38957483	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	16.96	0.62	1.56e-50	Menopause (age at onset);
LGG	cis	rs9914988	0.887	rs4795463	chr17:27146389	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs6787172	0.702	rs864877	chr3:157920326	T/A	cg23275840	chr4:47708675	CORIN	0.41	8.71	0.38	5.27e-17	Subjective well-being;
LGG	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg04492858	chr10:133558786	NA	0.43	8.93	0.38	1.04e-17	Survival in rectal cancer;
LGG	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg11752832	chr7:134001865	SLC35B4	0.57	10.04	0.42	1.34e-21	Mean platelet volume;
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	7.17	0.32	2.91e-12	Multiple sclerosis;
LGG	cis	rs6500395	0.775	rs4471681	chr16:48665946	C/T	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg25457927	chr22:38595422	NA	-0.41	-10.51	-0.44	2.6e-23	Cutaneous nevi;
LGG	cis	rs77372450	0.636	rs6865742	chr5:157023262	A/T	cg25387487	chr5:157003181	ADAM19	-0.56	-7.08	-0.31	5.44e-12	Bipolar disorder (body mass index interaction);
LGG	trans	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.27e-14	Heart rate;
LGG	cis	rs3857067	0.806	rs4693375	chr4:95133241	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.23	-0.36	1.88e-15	QT interval;
LGG	trans	rs2018683	0.707	rs1021689	chr7:28974223	G/T	cg19402173	chr7:128379420	CALU	-0.53	-9.24	-0.39	8.65e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2242663	0.798	rs607736	chr11:66328877	G/A	cg01599099	chr11:66649832	PC	0.4	7.9	0.34	2.04e-14	Bipolar disorder;
LGG	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-10.97	-0.45	4.88e-25	Morning vs. evening chronotype;
LGG	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg05484376	chr2:27715224	FNDC4	0.44	9.44	0.4	1.85e-19	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs9460578	0.537	rs9465909	chr6:20824421	C/T	cg13405222	chr6:20811065	CDKAL1	-0.79	-18.32	-0.65	8.52e-57	Breast cancer;
LGG	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg01493522	chr13:37497338	NA	-0.5	-8.47	-0.37	3.37e-16	Coronary artery disease;
LGG	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03878208	chr11:72483293	STARD10	0.52	7.22	0.32	2.19e-12	Type 2 diabetes;
LGG	cis	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg25866889	chr13:114914595	NA	-0.34	-6.66	-0.3	7.55e-11	Schizophrenia;
LGG	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg09307838	chr4:120376055	NA	0.77	12.64	0.51	1.11e-31	Corneal astigmatism;
LGG	cis	rs975722	0.700	rs213984	chr7:117258529	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	9.17	0.39	1.61e-18	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg18379455	chr17:41446167	NA	-0.32	-7.36	-0.32	8.25e-13	Menopause (age at onset);
LGG	trans	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg25214090	chr10:38739885	LOC399744	0.66	11.61	0.47	1.52e-27	Corneal astigmatism;
LGG	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg00006948	chr4:1768889	NA	0.48	6.71	0.3	5.54e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg03528353	chr17:61819722	STRADA	-0.44	-7.5	-0.33	3.39e-13	Prudent dietary pattern;
LGG	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg01631408	chr1:248437212	OR2T33	-0.37	-6.8	-0.3	3.28e-11	Common traits (Other);
LGG	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg09818912	chr17:20140352	CYTSB	-0.32	-7.54	-0.33	2.49e-13	Schizophrenia;
LGG	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg03213289	chr20:61660250	NA	0.66	14.53	0.56	1.14e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg13628971	chr7:2884303	GNA12	0.5	9.65	0.41	3.35e-20	Height;
LGG	cis	rs4538187	0.760	rs35697586	chr2:64181216	A/T	cg02541582	chr2:64069798	UGP2	-0.59	-10.89	-0.45	9.66e-25	Systolic blood pressure;
LGG	cis	rs4262150	0.883	rs72804786	chr5:152317799	G/A	cg12297329	chr5:152029980	NA	-0.61	-11.08	-0.46	1.88e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg13482628	chr17:19912719	NA	0.53	9.68	0.41	2.7e-20	Schizophrenia;
LGG	cis	rs73086581	1.000	rs73086505	chr20:3921571	A/G	cg02187196	chr20:3869020	PANK2	0.82	11.46	0.47	6.39e-27	Response to antidepressants in depression;
LGG	cis	rs4684776	0.800	rs7640358	chr3:11614969	T/C	cg24705426	chr3:11550659	ATG7	-0.42	-7.3	-0.32	1.28e-12	Small vessel stroke;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.24	-0.32	1.92e-12	Height;
LGG	cis	rs9814567	0.806	rs13076825	chr3:134317239	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	10.87	0.45	1.13e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11877825	0.826	rs4121954	chr18:10569713	T/C	cg07277756	chr18:10589357	NA	0.58	10.72	0.45	4.34e-24	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg20913747	chr6:44695427	NA	-0.63	-10.49	-0.44	2.98e-23	Total body bone mineral density;
LGG	cis	rs7226408	0.857	rs55917307	chr18:34503664	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg02421172	chr7:1938701	MAD1L1	0.39	6.67	0.3	7.1e-11	Bipolar disorder;
LGG	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg19223190	chr17:80058835	NA	0.44	8.63	0.37	1e-16	Life satisfaction;
LGG	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg13010199	chr12:38710504	ALG10B	-0.55	-10.63	-0.44	9.57e-24	Bladder cancer;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.27	-0.32	1.5e-12	Longevity;Endometriosis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06784845	chr3:133614993	RAB6B	0.41	7.29	0.32	1.32e-12	Bilirubin levels;
LGG	trans	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.2	-0.32	2.43e-12	Heart rate;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.58	0.37	1.5e-16	Personality dimensions;
LGG	cis	rs3790455	0.610	rs3790458	chr1:156459699	A/T	cg14087168	chr1:156450669	MEF2D	-0.67	-10.23	-0.43	2.85e-22	Migraine;
LGG	cis	rs7149337	0.869	rs10137445	chr14:51694416	G/A	cg23942311	chr14:51606299	NA	0.32	7.15	0.32	3.36e-12	Cancer;
LGG	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg02002194	chr4:3960332	NA	0.6	11.94	0.49	7.7e-29	Schizophrenia;
LGG	cis	rs3206736	0.648	rs76733486	chr7:35231725	G/A	cg13400248	chr7:35225412	NA	0.45	7.86	0.34	2.69e-14	Diastolic blood pressure;
LGG	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg11693508	chr17:37793320	STARD3	0.52	7.4	0.33	6.2800000000000005e-13	Bipolar disorder;
LGG	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4918072	0.834	rs7079220	chr10:105710147	A/G	cg11005552	chr10:105648138	OBFC1	0.43	7.53	0.33	2.59e-13	Coronary artery disease;
LGG	cis	rs977987	0.778	rs35214308	chr16:75476088	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.22	0.43	3e-22	Dupuytren's disease;
LGG	cis	rs7503807	0.515	rs12601001	chr17:78681084	T/C	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs9447004	0.584	rs56093139	chr6:74432923	C/T	cg03006477	chr6:74432658	CD109	0.29	7.67	0.34	1.04e-13	Blood protein levels;Calcium levels;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08677398	chr8:58056175	NA	-0.57	-9.19	-0.39	1.34e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg26384229	chr12:38710491	ALG10B	-0.7	-13.2	-0.52	5.25e-34	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg18681998	chr4:17616180	MED28	0.73	14.4	0.56	4.24e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6586163	1.000	rs6586163	chr10:90752018	A/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.92	-0.31	1.5e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.93e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs741702	0.928	rs2009222	chr19:13034543	T/C	cg04657146	chr19:12876947	HOOK2	0.43	7.12	0.31	4.16e-12	Red blood cell traits;
LGG	cis	rs2188561	0.697	rs6956243	chr7:107388911	T/C	cg16793755	chr7:107334138	SLC26A4	0.41	7.2	0.32	2.53e-12	Alcohol consumption;
LGG	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	17.23	0.62	9.53e-52	Smoking behavior;
LGG	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg03806693	chr22:41940476	POLR3H	-1.1	-18.96	-0.66	9.99e-60	Vitiligo;
LGG	cis	rs78366141	0.536	rs76432068	chr4:89624219	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.49	0.37	2.9e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg04672837	chr16:48644449	N4BP1	0.56	9.31	0.4	5.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-9.44	-0.4	1.84e-19	Body mass index;
LGG	cis	rs2239547	0.563	rs6445547	chr3:52908577	T/C	cg11645453	chr3:52864694	ITIH4	0.7	10.89	0.45	9.46e-25	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24648061	chr7:107114615	COG5;GPR22	0.32	6.71	0.3	5.6e-11	Gut microbiome composition (summer);
LGG	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg02428538	chr16:24856791	SLC5A11	-0.72	-11.18	-0.46	7.73e-26	Intelligence (multi-trait analysis);
LGG	cis	rs35164067	1.000	rs73923215	chr19:10514842	A/C	cg21868191	chr19:10515988	NA	-0.49	-7.37	-0.32	7.66e-13	Inflammatory bowel disease;
LGG	cis	rs4262150	0.726	rs9324734	chr5:152012795	G/A	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs13082711	0.911	rs35904501	chr3:27443317	T/C	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs35146811	0.555	rs1981549	chr7:99541636	A/G	cg22906224	chr7:99728672	NA	0.44	6.86	0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg16586182	chr3:47516702	SCAP	0.74	13.44	0.53	5.4e-35	Colorectal cancer;
LGG	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18252515	chr7:66147081	NA	-0.41	-6.87	-0.3	2.12e-11	Aortic root size;
LGG	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.53	-8.97	-0.38	7.48e-18	IgG glycosylation;
LGG	trans	rs1997103	0.954	rs940880	chr7:55392619	C/G	cg20935933	chr6:143382018	AIG1	0.58	9.08	0.39	3.1e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg06848047	chr4:90757629	SNCA	0.37	7.08	0.31	5.23e-12	Dementia with Lewy bodies;
LGG	cis	rs968567	0.638	rs7943728	chr11:61547068	G/A	cg19610905	chr11:61596333	FADS2	-0.68	-8.15	-0.35	3.53e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg00198680	chr16:28758506	NA	0.28	6.93	0.31	1.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg12658694	chr1:38397304	INPP5B	-0.51	-11.54	-0.47	3.08e-27	Coronary artery disease;
LGG	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg11941060	chr3:133502564	NA	-0.53	-9.19	-0.39	1.29e-18	Iron status biomarkers;
LGG	cis	rs1953600	0.870	rs2236557	chr10:81923961	A/G	cg04850286	chr10:81895943	PLAC9	0.41	9.06	0.39	3.78e-18	Sarcoidosis;
LGG	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg05623727	chr3:50126028	RBM5	-0.38	-8.38	-0.36	6.48e-16	Intelligence (multi-trait analysis);
LGG	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg08079166	chr15:68083412	MAP2K5	0.34	7.61	0.33	1.58e-13	Restless legs syndrome;
LGG	cis	rs701145	0.585	rs921318	chr3:153856775	T/G	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs8005677	1.000	rs1043209	chr14:23373986	A/G	cg25600027	chr14:23388339	RBM23	0.43	7.07	0.31	5.72e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs2760061	0.819	rs708114	chr1:228197496	G/A	cg01200585	chr1:228362443	C1orf69	0.47	8.18	0.36	2.75e-15	Diastolic blood pressure;
LGG	cis	rs273218	1.000	rs273217	chr5:53380938	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.65	8.99	0.39	6.25e-18	Migraine;
LGG	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-27.0	-0.78	4.03e-97	Height;
LGG	cis	rs787274	0.867	rs4978507	chr9:115609376	G/A	cg13803584	chr9:115635662	SNX30	-0.61	-7.55	-0.33	2.38e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg16512390	chr1:228756714	NA	0.46	7.98	0.35	1.16e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-10.12	-0.43	7.08e-22	Systemic lupus erythematosus;
LGG	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.53	0.44	2.14e-23	Aortic root size;
LGG	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg02403541	chr12:121454288	C12orf43	0.41	7.01	0.31	8.32e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9487094	0.885	rs3799839	chr6:109702193	T/C	cg01125227	chr6:109776195	MICAL1	0.52	9.06	0.39	3.63e-18	Height;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.55e-15	Electroencephalogram traits;
LGG	cis	rs1707322	1.000	rs10890365	chr1:46359348	C/T	cg03146154	chr1:46216737	IPP	0.54	10.02	0.42	1.61e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs13102973	0.965	rs11735381	chr4:135850474	T/C	cg14419869	chr4:135874104	NA	0.56	10.7	0.45	5.24e-24	Subjective well-being;
LGG	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg00149659	chr3:10157352	C3orf10	0.59	8.35	0.36	7.89e-16	Alzheimer's disease;
LGG	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg27490568	chr2:178487706	NA	0.51	9.75	0.41	1.52e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg14210321	chr2:106509881	NCK2	-0.51	-8.81	-0.38	2.47e-17	Addiction;
LGG	cis	rs227833	0.837	rs679769	chr6:44674860	C/T	cg20913747	chr6:44695427	NA	0.46	7.87	0.34	2.5e-14	Monobrow;
LGG	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg25457927	chr22:38595422	NA	-0.32	-7.68	-0.34	9.83e-14	Triglycerides;
LGG	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg13512537	chr8:22265999	SLC39A14	-0.47	-7.62	-0.33	1.47e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11644478	chr21:40555479	PSMG1	0.84	14.82	0.57	5.93e-41	Cognitive function;
LGG	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.09	-0.31	5.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg01043669	chr3:72786069	NA	0.4	7.24	0.32	1.91e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs34734847	0.777	rs555404	chr12:121175984	T/C	cg21892295	chr12:121157589	UNC119B	-0.38	-7.26	-0.32	1.62e-12	Mean corpuscular volume;
LGG	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg12573674	chr2:1569213	NA	-0.59	-8.63	-0.37	9.64e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs735539	0.521	rs2585895	chr13:21396967	A/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.02	-0.35	8.74e-15	Dental caries;
LGG	cis	rs78366141	0.649	rs17747350	chr4:89727562	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.07	8.91	0.38	1.18e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg11987759	chr7:65425863	GUSB	0.39	7.65	0.33	1.19e-13	Aortic root size;
LGG	cis	rs4262150	0.508	rs72795366	chr5:151920076	T/A	cg12297329	chr5:152029980	NA	-0.67	-11.99	-0.49	5.02e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs10861661	1.000	rs4964491	chr12:107222515	G/A	cg15890332	chr12:107067104	RFX4	0.32	7.63	0.33	1.35e-13	Triglyceride levels;
LGG	cis	rs6430585	0.528	rs2278682	chr2:136743143	G/C	cg07169764	chr2:136633963	MCM6	1.15	20.28	0.69	6.35e-66	Corneal structure;
LGG	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.53	-12.6	-0.51	1.66e-31	Oropharynx cancer;
LGG	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg23594656	chr7:65796392	TPST1	0.4	8.85	0.38	1.86e-17	Aortic root size;
LGG	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg13770153	chr20:60521292	NA	-0.5	-8.14	-0.35	3.78e-15	Body mass index;
LGG	cis	rs4132509	0.895	rs12045787	chr1:244011843	T/A	cg25706552	chr1:244017396	NA	0.56	8.85	0.38	1.89e-17	RR interval (heart rate);
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg27476859	chr7:2772710	GNA12	0.41	6.85	0.3	2.37e-11	Height;
LGG	cis	rs12318506	0.826	rs13377894	chr12:75661825	A/G	cg04728562	chr12:75699417	CAPS2	-1.12	-9.67	-0.41	2.91e-20	Coronary artery calcification;
LGG	cis	rs4671458	1.000	rs4671460	chr2:63397203	T/C	cg17519650	chr2:63277830	OTX1	-0.65	-8.05	-0.35	7.14e-15	Subjective well-being;
LGG	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg26384229	chr12:38710491	ALG10B	-0.82	-17.63	-0.63	1.33e-53	Morning vs. evening chronotype;
LGG	cis	rs10861342	1.000	rs12320123	chr12:105492167	C/T	cg23923672	chr12:105501055	KIAA1033	0.76	6.72	0.3	5.4e-11	IgG glycosylation;
LGG	cis	rs939658	0.776	rs4778925	chr15:79443791	C/T	cg17916960	chr15:79447300	NA	-0.67	-12.95	-0.52	6.06e-33	Refractive error;
LGG	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	11.8	0.48	2.84e-28	Mean corpuscular hemoglobin;
LGG	cis	rs4075765	0.881	rs10501039	chr11:26174403	T/C	cg19182008	chr11:26298241	NA	0.78	7.44	0.33	4.94e-13	Cannabis dependence symptom count;
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	1.1	30.8	0.82	3.85e-114	Birth weight;
LGG	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.46	-0.4	1.59e-19	Extrinsic epigenetic age acceleration;
LGG	cis	rs2285947	1.000	rs6970985	chr7:21583597	G/T	cg04471919	chr7:21584483	DNAH11	0.49	13.84	0.54	1.02e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg15269541	chr15:43626905	ADAL	-0.44	-7.62	-0.33	1.45e-13	Lung cancer in ever smokers;
LGG	cis	rs6835098	1.000	rs10027708	chr4:174083116	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-15.22	-0.58	1.06e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.28	-0.36	1.37e-15	Life satisfaction;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg04824913	chr4:887549	GAK	0.57	9.6	0.41	5.21e-20	Sjögren's syndrome;
LGG	cis	rs7215564	0.908	rs4889783	chr17:78667160	C/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.16	-0.35	3.11e-15	Myopia (pathological);
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg13628971	chr7:2884303	GNA12	-0.5	-9.65	-0.41	3.35e-20	Height;
LGG	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg03162506	chr22:38580953	NA	-0.28	-7.01	-0.31	8.38e-12	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.79	0.45	2.31e-24	Personality dimensions;
LGG	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.5	-0.5	4.09e-31	Vitiligo;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg16301924	chr13:53314226	LECT1	0.47	9.73	0.41	1.79e-20	Lewy body disease;
LGG	cis	rs11190604	0.767	rs74869390	chr10:102189385	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.86e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17504614	0.597	rs75882045	chr2:51082996	C/T	cg08066024	chr2:51057548	NRXN1	0.59	9.06	0.39	3.75e-18	Educational attainment (years of education);
LGG	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.06	-0.31	6e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7444	0.941	rs5998672	chr22:21966442	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	cg15522984	chr1:182991683	LAMC1	-0.44	-8.79	-0.38	2.88e-17	Fuchs's corneal dystrophy;
LGG	cis	rs10744422	0.800	rs2649902	chr12:123243687	G/A	cg25930673	chr12:123319894	HIP1R	-0.68	-8.12	-0.35	4.29e-15	Schizophrenia;
LGG	cis	rs7027203	0.663	rs4428726	chr9:96623559	T/G	cg13679303	chr9:96623674	NA	-0.38	-7.01	-0.31	8.71e-12	DNA methylation (variation);
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11168618	1.000	rs11168637	chr12:48953504	G/A	cg24011408	chr12:48396354	COL2A1	0.48	7.76	0.34	5.62e-14	Adiponectin levels;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg13628971	chr7:2884303	GNA12	0.51	10.21	0.43	3.18e-22	Height;
LGG	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg24253500	chr15:84953950	NA	0.42	6.92	0.31	1.53e-11	Schizophrenia;
LGG	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg02269571	chr22:50332266	NA	-0.54	-8.5	-0.37	2.68e-16	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10176457	chr19:797221	PTBP1	-0.43	-6.91	-0.31	1.62e-11	Pancreatic cancer;
LGG	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	11.97	0.49	5.75e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4974559	1.000	rs4974559	chr4:1380848	C/T	cg02980000	chr4:1222292	CTBP1	-0.67	-10.45	-0.44	4.36e-23	Systolic blood pressure;
LGG	cis	rs9462027	0.606	rs3777752	chr6:34772212	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	Cognitive function;
LGG	cis	rs2173063	1.000	rs16947098	chr15:93142624	T/C	cg07052004	chr15:93132129	NA	0.69	7.21	0.32	2.27e-12	Subcutaneous adipose tissue;
LGG	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg08344181	chr3:125677491	NA	-0.91	-9.21	-0.39	1.11e-18	Depression;
LGG	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg00092383	chr7:157075207	NA	0.43	7.71	0.34	7.71e-14	Body mass index;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs11169552	0.510	rs4768912	chr12:51135940	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.48	-0.33	3.74e-13	Colorectal cancer;
LGG	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg15506890	chr2:3487001	NA	0.44	8.23	0.36	1.97e-15	Neurofibrillary tangles;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.46	0.37	3.54e-16	Personality dimensions;
LGG	cis	rs1776883	0.502	rs4713758	chr6:34145361	A/G	cg10661734	chr6:34122502	NA	-0.46	-7.62	-0.33	1.46e-13	Asthma;Asthma (childhood onset);
LGG	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs6867032	0.958	rs4463207	chr5:2017118	G/T	cg26168224	chr5:2018326	NA	1.29	31.13	0.82	1.41e-115	Gut microbiome composition (winter);
LGG	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.46	6.9	0.31	1.75e-11	Cystic fibrosis severity;
LGG	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg03342759	chr3:160939853	NMD3	-0.77	-13.84	-0.54	1.04e-36	Parkinson's disease;
LGG	trans	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg06521331	chr12:34319734	NA	-0.52	-8.89	-0.38	1.4e-17	Bladder cancer;
LGG	cis	rs2274273	0.967	rs2340931	chr14:55616937	T/G	cg04306507	chr14:55594613	LGALS3	0.65	18.51	0.65	1.13e-57	Protein biomarker;
LGG	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.33	0.65	7.89e-57	Refractive error;
LGG	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26306683	chr17:18585705	ZNF286B	0.5	9.46	0.4	1.54e-19	Educational attainment (years of education);
LGG	cis	rs9486719	1.000	rs4262195	chr6:96929475	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.7e-23	Migraine;Coronary artery disease;
LGG	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs8133932	0.667	rs3788218	chr21:47287332	A/G	cg11214348	chr21:47283868	PCBP3	0.44	7.99	0.35	1.1e-14	Schizophrenia;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	11.3	0.46	2.61e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs1459104	1.000	rs12791192	chr11:55049986	C/A	cg15704280	chr7:45808275	SEPT13	0.7	6.93	0.31	1.41e-11	Body mass index;
LGG	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg23202291	chr11:1979235	NA	0.4	7.6	0.33	1.67e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs28595532	0.920	rs115084148	chr4:119739290	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.77	0.34	5.06e-14	Cannabis dependence symptom count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00922025	chr5:134734559	H2AFY	0.62	7.08	0.31	5.45e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3820068	0.603	rs56032936	chr1:15970953	T/C	cg05660106	chr1:15850417	CASP9	0.84	17.19	0.62	1.39e-51	Systolic blood pressure;
LGG	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg15556689	chr8:8085844	FLJ10661	0.38	6.72	0.3	5.32e-11	Neuroticism;
LGG	cis	rs240764	0.817	rs239238	chr6:101094880	G/T	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	4.99e-14	Neuroticism;
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.78	-13.7	-0.54	4.33e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7737355	0.738	rs55955246	chr5:131078498	C/G	cg06307176	chr5:131281290	NA	0.53	8.73	0.38	4.51e-17	Life satisfaction;
LGG	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg10760299	chr15:45669010	GATM	0.41	7.95	0.35	1.47e-14	Homoarginine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24319545	chr7:44887278	H2AFV	0.5	7.62	0.33	1.47e-13	Gut microbiome composition (summer);
LGG	cis	rs1580019	1.000	rs1580019	chr7:32493169	A/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.81	-15.29	-0.58	5.02e-43	Cognitive ability;
LGG	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg21045802	chr8:109455806	TTC35	0.52	9.81	0.41	8.85e-21	Dupuytren's disease;
LGG	cis	rs1775715	0.678	rs2105360	chr10:32210198	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.8	0.3	3.29e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg10189774	chr4:17578691	LAP3	0.42	7.54	0.33	2.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.04	-0.42	1.35e-21	Lung cancer;
LGG	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg14784868	chr12:69753453	YEATS4	1.0	24.03	0.74	1.96e-83	Cerebrospinal fluid biomarker levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg05557255	chr11:2422385	TSSC4	0.42	6.98	0.31	1e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs4684776	1.000	rs62245866	chr3:11434292	G/T	cg24705426	chr3:11550659	ATG7	-0.41	-7.45	-0.33	4.75e-13	Small vessel stroke;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg07511668	chr11:68622177	NA	0.5	9.66	0.41	3.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg16301924	chr13:53314226	LECT1	-0.44	-9.03	-0.39	4.65e-18	Lewy body disease;
LGG	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg08400814	chr5:56204995	C5orf35	-0.43	-6.91	-0.31	1.58e-11	Initial pursuit acceleration;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg17178900	chr1:205818956	PM20D1	0.58	13.09	0.52	1.59e-33	Menarche (age at onset);
LGG	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg14132834	chr19:41945861	ATP5SL	-0.5	-9.62	-0.41	4.39e-20	Height;
LGG	cis	rs12928939	0.815	rs11648483	chr16:71707398	T/C	cg03805757	chr16:71968109	PKD1L3	-0.48	-9.04	-0.39	4.43e-18	Post bronchodilator FEV1;
LGG	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-9.62	-0.41	4.33e-20	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1577917	1.000	rs12665321	chr6:86769289	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.41	-0.53	7.07e-35	Response to antipsychotic treatment;
LGG	cis	rs16854884	0.657	rs1867608	chr3:143752938	G/A	cg06585982	chr3:143692056	C3orf58	0.61	10.54	0.44	1.92e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg18479299	chr3:125709523	NA	-0.56	-7.19	-0.32	2.57e-12	Blood pressure (smoking interaction);
LGG	cis	rs6456156	0.586	rs2017338	chr6:167471714	G/A	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Primary biliary cholangitis;
LGG	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg24812749	chr6:127587940	RNF146	0.96	15.74	0.59	4.98e-45	Breast cancer;
LGG	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.78	-0.3	3.57e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg15971980	chr6:150254442	NA	0.43	8.05	0.35	6.89e-15	Lung cancer;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg21171335	chr12:122356390	WDR66	0.29	8.48	0.37	3.04e-16	Mean corpuscular volume;
LGG	cis	rs7493	0.950	rs6961624	chr7:95037661	T/C	cg08461772	chr7:95026248	PON3	0.37	8.26	0.36	1.52e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg03576123	chr11:487126	PTDSS2	-1.21	-14.81	-0.57	6.4e-41	Body mass index;
LGG	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-14.68	-0.56	2.54e-40	Height;
LGG	cis	rs7633787	0.571	rs7636994	chr3:23145106	A/C	cg00327796	chr3:23032191	NA	-0.4	-7.48	-0.33	3.64e-13	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs4356975	0.563	rs4274916	chr4:69988378	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.78	0.3	3.75e-11	Obesity-related traits;
LGG	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.67	0.34	1.05e-13	Glycated hemoglobin levels;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6960043	0.714	rs6976086	chr7:15048611	T/G	cg19272540	chr7:15055459	NA	0.35	7.86	0.34	2.66e-14	Type 2 diabetes;
LGG	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg01028140	chr2:1542097	TPO	-0.59	-8.76	-0.38	3.66e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg00376283	chr12:123451042	ABCB9	0.62	11.45	0.47	7e-27	Platelet count;
LGG	cis	rs9807841	0.592	rs3810154	chr19:10764914	G/A	cg17710535	chr19:10819994	QTRT1	0.48	7.79	0.34	4.45e-14	Inflammatory skin disease;
LGG	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg08344181	chr3:125677491	NA	-0.79	-8.29	-0.36	1.26e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	0.791	rs2729451	chr17:28131334	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.88	-0.54	6.98e-37	Coffee consumption (cups per day);
LGG	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.04	0.62	6.91e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1568889	1.000	rs9783281	chr11:28033786	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	15.08	0.57	4.18e-42	Bipolar disorder;
LGG	cis	rs758324	0.812	rs6893957	chr5:131198780	T/C	cg06307176	chr5:131281290	NA	0.53	8.87	0.38	1.58e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs10463316	0.894	rs6875014	chr5:150754345	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.29	-0.43	1.6400000000000001e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg21782813	chr7:2030301	MAD1L1	0.39	9.1	0.39	2.65e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.34	0.55	7.5e-39	Obesity-related traits;
LGG	trans	rs479844	1.000	rs479844	chr11:65551957	A/G	cg17712092	chr4:129076599	LARP1B	-0.45	-7.67	-0.34	1.01e-13	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
LGG	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg00204512	chr16:28754710	NA	0.24	6.65	0.3	8.27e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01773306	chr2:85555458	TGOLN2	0.44	7.27	0.32	1.58e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15128208	chr22:42549153	NA	-0.44	-8.61	-0.37	1.15e-16	Cognitive function;
LGG	cis	rs16837677	1.000	rs4661219	chr1:156767888	A/G	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs701145	0.585	rs1629659	chr3:153798731	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs4660214	0.666	rs11205839	chr1:39733733	G/A	cg18385671	chr1:39797026	MACF1	-0.47	-9.66	-0.41	3.22e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs963731	0.522	rs297128	chr2:39298403	C/G	cg04010122	chr2:39346883	SOS1	-0.82	-7.62	-0.33	1.49e-13	Corticobasal degeneration;
LGG	trans	rs11165623	0.543	rs6656866	chr1:97002238	T/C	cg10631902	chr5:14652156	NA	-0.45	-9.4	-0.4	2.49e-19	Hip circumference;Waist circumference;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg06917634	chr15:78832804	PSMA4	0.83	17.34	0.63	2.85e-52	Sudden cardiac arrest;
LGG	cis	rs4330281	0.692	rs8179891	chr3:17727378	T/G	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	trans	rs12339094	0.929	rs9410970	chr9:90415220	A/C	cg24436365	chr6:63940138	NA	-0.4	-6.77	-0.3	3.98e-11	Smoking quantity;
LGG	cis	rs9547996	0.879	rs11619443	chr13:38169715	C/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.89	-0.3	1.85e-11	Diastolic blood pressure;
LGG	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg15268244	chr15:77196840	NA	0.32	7.1	0.31	4.72e-12	Blood metabolite levels;
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg15556689	chr8:8085844	FLJ10661	0.39	6.79	0.3	3.52e-11	Monocyte count;
LGG	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.25e-13	Hemoglobin concentration;
LGG	cis	rs12220238	1.000	rs11000925	chr10:75972601	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.06e-12	Aortic root size;
LGG	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg14541582	chr5:601475	NA	-0.71	-10.61	-0.44	1.05e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.23	-0.43	2.85e-22	Body mass index;
LGG	cis	rs3768617	0.811	rs12563494	chr1:183039698	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.83	0.3	2.76e-11	Fuchs's corneal dystrophy;
LGG	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg13802316	chr11:70253460	CTTN	-0.57	-7.31	-0.32	1.18e-12	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	8.97e-12	Lung cancer;
LGG	cis	rs258892	0.895	rs34155124	chr5:72060249	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.68	-0.3	6.75e-11	Small cell lung carcinoma;
LGG	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	13.04	0.52	2.54e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.67	0.34	1.04e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg06470251	chr20:60548479	NA	0.42	7.46	0.33	4.34e-13	Body mass index;
LGG	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg11812906	chr14:75593930	NEK9	0.54	10.07	0.42	1.05e-21	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22466812	chr17:113827	RPH3AL	-0.36	-6.9	-0.31	1.75e-11	Cognitive performance;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Bipolar disorder;
LGG	cis	rs537930	0.734	rs4976261	chr5:134374108	G/C	cg24576358	chr5:134350122	NA	0.38	7.16	0.32	3.1e-12	Height;
LGG	cis	rs17092148	0.652	rs7269526	chr20:33053293	G/C	cg12302830	chr20:33297742	TP53INP2	0.42	6.95	0.31	1.28e-11	Neuroticism;
LGG	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg20026190	chr17:76395443	PGS1	0.57	10.04	0.42	1.31e-21	HDL cholesterol levels;
LGG	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg22232500	chr2:134024266	NCKAP5	0.55	7.94	0.35	1.55e-14	Bipolar disorder;
LGG	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg05333889	chr7:157238977	NA	-0.5	-9.71	-0.41	2.08e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs12791968	0.917	rs11038239	chr11:45002012	A/G	cg11846598	chr11:44996168	LOC221122	-0.67	-12.57	-0.5	2.26e-31	Inhibitory control;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg15971980	chr6:150254442	NA	0.44	8.29	0.36	1.26e-15	Lung cancer;
LGG	cis	rs10876993	0.890	rs1082502	chr12:58035706	C/T	cg18357645	chr12:58087776	OS9	0.66	11.91	0.48	1.06e-28	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg12573674	chr2:1569213	NA	-0.64	-10.13	-0.43	6.39e-22	IgG glycosylation;
LGG	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.38	-0.32	7.29e-13	Body mass index;
LGG	cis	rs4409675	0.576	rs2474470	chr1:28234999	C/T	cg23691781	chr1:28212827	C1orf38	0.42	10.9	0.45	8.74e-25	Corneal astigmatism;
LGG	cis	rs4363385	0.775	rs427470	chr1:153017353	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-8.88	-0.38	1.46e-17	Inflammatory skin disease;
LGG	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg27478167	chr7:817139	HEATR2	-0.48	-6.91	-0.31	1.58e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4262150	0.508	rs55696164	chr5:151890623	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.59	-0.47	1.88e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Electroencephalogram traits;
LGG	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg14835575	chr10:16859367	RSU1	0.72	13.16	0.52	7.99e-34	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg20892847	chr12:58011875	NA	0.36	7.42	0.33	5.64e-13	Multiple sclerosis;
LGG	trans	rs11976180	1.000	rs67239267	chr7:143745116	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.37	-6.7	-0.3	6.23e-11	Obesity-related traits;
LGG	cis	rs963731	0.649	rs59732351	chr2:39336981	C/T	cg04010122	chr2:39346883	SOS1	0.75	7.05	0.31	6.63e-12	Corticobasal degeneration;
LGG	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg02631450	chr22:32366979	NA	1.05	9.9	0.42	4.18e-21	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18471160	chr1:201083459	NA	0.48	7.02	0.31	8.06e-12	Gut microbiome composition (summer);
LGG	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.88e-11	Type 2 diabetes;
LGG	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11764359	chr7:65958608	NA	0.56	9.52	0.4	9.61e-20	Aortic root size;
LGG	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg18357526	chr6:26021779	HIST1H4A	0.5	8.35	0.36	8.03e-16	Height;
LGG	cis	rs17209837	1.000	rs66869391	chr7:87119069	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-11.62	-0.48	1.51e-27	Gallbladder cancer;
LGG	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg13010199	chr12:38710504	ALG10B	-0.64	-13.44	-0.53	5.38e-35	Bladder cancer;
LGG	cis	rs10089	1.000	rs6887847	chr5:127473807	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.8	0.48	2.82e-28	Ileal carcinoids;
LGG	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.75	-11.22	-0.46	5.14e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7000551	0.725	rs2249098	chr8:22400098	T/C	cg12081754	chr8:22256438	SLC39A14	0.65	12.23	0.49	5.21e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6694672	0.867	rs4915337	chr1:197091537	A/T	cg13682187	chr1:196946512	CFHR5	0.5	6.96	0.31	1.19e-11	Asthma;
LGG	cis	rs12410462	0.591	rs68186506	chr1:227826788	C/T	cg04117972	chr1:227635322	NA	0.43	7.96	0.35	1.31e-14	Major depressive disorder;
LGG	cis	rs4330281	0.669	rs4908987	chr3:17688490	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.47	-0.33	3.9e-13	Schizophrenia;
LGG	cis	rs9400467	0.537	rs10457232	chr6:111434407	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.72	0.3	5.29e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs56146971	0.763	rs45490092	chr14:91845143	A/G	cg14409461	chr14:91925021	SMEK1	-0.42	-6.67	-0.3	7.31e-11	Alzheimer disease and age of onset;
LGG	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg16414030	chr3:133502952	NA	-0.58	-9.94	-0.42	3.16e-21	Iron status biomarkers;
LGG	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.52	-0.44	2.31e-23	Hepatocellular carcinoma;
LGG	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg08975724	chr8:8085496	FLJ10661	0.43	7.84	0.34	3.1e-14	Retinal vascular caliber;
LGG	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06481639	chr22:41940642	POLR3H	0.59	8.53	0.37	2.09e-16	Vitiligo;
LGG	cis	rs9397585	0.637	rs595832	chr6:153409368	A/T	cg17707550	chr6:153380415	RGS17	0.44	9.86	0.42	5.91e-21	Body mass index;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg05091796	chr16:4465799	CORO7	-0.61	-10.07	-0.42	1.03e-21	Schizophrenia;
LGG	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg20503657	chr10:835505	NA	0.95	12.51	0.5	3.8e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs10743315	0.599	rs11044451	chr12:19365798	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.63	-8.23	-0.36	1.92e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2230307	0.536	rs560659	chr1:100523536	A/G	cg24955406	chr1:100503596	HIAT1	-0.55	-7.8	-0.34	4.2e-14	Carotid intima media thickness;
LGG	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg26384229	chr12:38710491	ALG10B	0.75	14.9	0.57	2.7e-41	Morning vs. evening chronotype;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.35e-11	Aortic root size;
LGG	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.48	-0.4	1.34e-19	Response to amphetamines;
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.96	0.31	1.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.06	0.42	1.2e-21	Motion sickness;
LGG	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.21	-0.49	6.29e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7789940	0.951	rs7787526	chr7:75947553	C/T	cg10167463	chr7:75959203	YWHAG	-0.47	-7.64	-0.33	1.24e-13	Multiple sclerosis;
LGG	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6032067	0.571	rs6017536	chr20:43907369	G/T	cg10761708	chr20:43804764	PI3	0.58	8.96	0.38	7.96e-18	Blood protein levels;
LGG	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg19676328	chr12:49525230	TUBA1B	-0.54	-7.97	-0.35	1.23e-14	Total cholesterol levels;
LGG	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg21475434	chr5:93447410	FAM172A	0.7	7.18	0.32	2.73e-12	Diabetic retinopathy;
LGG	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg19784903	chr17:45786737	TBKBP1	0.32	6.88	0.3	1.94e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03647317	chr4:187891568	NA	-0.41	-8.73	-0.38	4.58e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg05673287	chr15:77411982	SGK269	-0.44	-9.49	-0.4	1.2e-19	Type 2 diabetes;
LGG	cis	rs7617773	0.780	rs4479622	chr3:48338173	C/T	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs6993813	0.843	rs1905779	chr8:120041165	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg06606381	chr12:133084897	FBRSL1	-0.94	-10.14	-0.43	6.01e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs6839277	chr4:99015563	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg19913688	chr11:428466	ANO9	0.64	8.42	0.36	4.62e-16	Body mass index;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg10911889	chr6:126070802	HEY2	-0.47	-8.15	-0.35	3.52e-15	Brugada syndrome;
LGG	cis	rs9733	0.650	rs1971378	chr1:150597261	C/T	cg13175981	chr1:150552382	MCL1	0.59	10.2	0.43	3.47e-22	Tonsillectomy;
LGG	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg23205692	chr1:25664452	TMEM50A	0.49	10.17	0.43	4.49e-22	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg24375607	chr4:120327624	NA	0.66	10.66	0.44	7.37e-24	Corneal astigmatism;
LGG	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs4774899	0.966	rs11853331	chr15:57431471	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.44	-0.33	5.05e-13	Urinary tract infection frequency;
LGG	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	trans	rs6787172	0.622	rs6414390	chr3:158108144	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg23939001	chr4:940644	TMEM175	0.63	13.23	0.52	4.12e-34	Sjögren's syndrome;
LGG	cis	rs12447804	0.911	rs12924451	chr16:58093669	G/T	cg03859792	chr16:58121049	NA	0.48	7.3	0.32	1.25e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9399135	0.967	rs9389261	chr6:135371148	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg20308403	chr7:2120281	MAD1L1	0.32	7.0	0.31	8.99e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs700651	0.624	rs12105927	chr2:198937258	G/A	cg00792783	chr2:198669748	PLCL1	0.6	9.52	0.4	9.79e-20	Intracranial aneurysm;
LGG	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg11812906	chr14:75593930	NEK9	0.54	10.06	0.42	1.11e-21	Height;
LGG	cis	rs6594499	0.872	rs10038058	chr5:110443281	A/G	cg04022379	chr5:110408740	TSLP	0.39	7.0	0.31	9.23e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg03606772	chr1:152487856	CRCT1	0.29	6.85	0.3	2.3e-11	Hair morphology;
LGG	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg10935138	chr17:73851978	WBP2	0.69	9.1	0.39	2.77e-18	Psoriasis;
LGG	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg25566285	chr7:158114605	PTPRN2	-0.96	-24.94	-0.76	1.16e-87	Calcium levels;
LGG	cis	rs397969	0.646	rs1638527	chr17:19845393	A/G	cg13482628	chr17:19912719	NA	-0.51	-8.3	-0.36	1.12e-15	Platelet count;
LGG	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg08461772	chr7:95026248	PON3	0.37	8.01	0.35	9.32e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg02002194	chr4:3960332	NA	-0.48	-8.86	-0.38	1.77e-17	Myopia (pathological);
LGG	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2270875	0.660	rs6982719	chr8:132930163	G/T	cg24184792	chr8:132919238	EFR3A	-0.44	-7.61	-0.33	1.52e-13	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs9457247	0.565	rs2038580	chr6:167456490	A/T	cg07741184	chr6:167504864	NA	0.45	10.13	0.43	6.6e-22	Crohn's disease;
LGG	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg16325326	chr1:53192061	ZYG11B	0.77	18.01	0.64	2.49e-55	Monocyte count;
LGG	cis	rs6066825	0.532	rs6012506	chr20:47285637	A/G	cg18078177	chr20:47281410	PREX1	0.52	8.67	0.37	7.25e-17	Colorectal cancer;
LGG	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg06046430	chr4:77819534	ANKRD56	0.54	11.2	0.46	6.25e-26	Emphysema distribution in smoking;
LGG	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs975722	0.638	rs17452984	chr7:117324588	C/T	cg10524701	chr7:117356490	CTTNBP2	0.46	9.61	0.41	4.59e-20	Coronary artery disease;
LGG	cis	rs7147624	1.000	rs7147624	chr14:65865625	G/T	cg03016385	chr14:66212404	NA	0.71	9.51	0.4	1.06e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7914558	1.000	rs7896547	chr10:104866958	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.38	0.43	8.11e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.45	0.37	3.93e-16	Schizophrenia;
LGG	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg03474202	chr17:45855739	NA	-0.27	-7.75	-0.34	5.9e-14	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.25	-0.52	3.44e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg24623649	chr8:11872141	NA	-0.3	-7.03	-0.31	7.3e-12	Triglycerides;
LGG	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	7.74	0.34	6.29e-14	Initial pursuit acceleration;
LGG	cis	rs11096990	0.819	rs2381225	chr4:39160535	G/A	cg24403649	chr4:39172243	NA	-0.49	-7.88	-0.34	2.38e-14	Cognitive function;
LGG	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg19455335	chr8:22457658	C8orf58	-0.39	-8.11	-0.35	4.6e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs412658	0.668	rs7253490	chr19:22293706	A/C	cg25360861	chr19:22235199	ZNF257	0.39	6.87	0.3	2.08e-11	Telomere length;
LGG	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg23129478	chr18:44337922	ST8SIA5	0.38	7.42	0.33	5.48e-13	Personality dimensions;
LGG	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg27411982	chr8:10470053	RP1L1	-0.47	-7.84	-0.34	3.21e-14	Triglycerides;
LGG	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.02	-0.35	9e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs643506	0.874	rs645411	chr11:111694490	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.94	0.31	1.36e-11	Breast cancer;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.41	-0.33	5.87e-13	Longevity;Endometriosis;
LGG	cis	rs4774899	1.000	rs4774899	chr15:57201548	C/T	cg08128148	chr15:57256372	TCF12	-0.34	-7.99	-0.35	1.08e-14	Urinary tract infection frequency;
LGG	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg15047889	chr8:124780837	FAM91A1	-0.48	-7.08	-0.31	5.4e-12	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00166722	chr3:10149974	C3orf24	0.52	8.83	0.38	2.21e-17	Alzheimer's disease;
LGG	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg26150922	chr2:100937072	LONRF2	-0.62	-12.07	-0.49	2.27e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.615	rs12641438	chr4:152607586	A/G	cg22705602	chr4:152727874	NA	-0.38	-9.23	-0.39	9.98e-19	Intelligence (multi-trait analysis);
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.41	-0.36	5.25e-16	Obesity;
LGG	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg25809561	chr17:30822961	MYO1D	0.37	8.93	0.38	9.82e-18	Schizophrenia;
LGG	trans	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg25214090	chr10:38739885	LOC399744	0.71	12.64	0.51	1.1e-31	Corneal astigmatism;
LGG	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg00149659	chr3:10157352	C3orf10	0.56	7.91	0.35	1.85e-14	Alzheimer's disease;
LGG	cis	rs6964587	1.000	rs12530646	chr7:91588036	A/G	cg17063962	chr7:91808500	NA	-0.48	-8.6	-0.37	1.21e-16	Breast cancer;
LGG	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg23422044	chr7:1970798	MAD1L1	-0.79	-13.57	-0.53	1.56e-35	Bipolar disorder;
LGG	cis	rs2073300	0.609	rs74809795	chr20:23372383	A/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7226408	0.600	rs322650	chr18:34614913	T/C	cg15022739	chr18:34823045	BRUNOL4	0.43	9.33	0.4	4.45e-19	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21582582	chr3:182698605	DCUN1D1	0.51	9.52	0.4	9.42e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.74	0.3	4.62e-11	Vitiligo;
LGG	cis	rs12681287	0.640	rs6992944	chr8:87419308	G/T	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg05623727	chr3:50126028	RBM5	0.38	7.99	0.35	1.05e-14	Body mass index;
LGG	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg06766960	chr11:133703094	NA	-0.59	-12.02	-0.49	3.86e-29	Childhood ear infection;
LGG	cis	rs68170813	0.559	rs2107318	chr7:106845969	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-10.99	-0.45	3.96e-25	Coronary artery disease;
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg13009111	chr11:71350975	NA	0.38	8.7	0.37	6.03e-17	Monocyte count;
LGG	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.1	0.55	8.18e-38	IgG glycosylation;
LGG	cis	rs8038465	0.550	rs11072431	chr15:73987642	T/A	cg15420318	chr15:73925796	NPTN	0.41	6.97	0.31	1.1e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8028182	0.549	rs10775209	chr15:75634759	G/A	cg20655648	chr15:75932815	IMP3	-0.46	-7.58	-0.33	1.88e-13	Sudden cardiac arrest;
LGG	cis	rs9902453	0.935	rs9898424	chr17:28392946	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.36	-0.53	1.11e-34	Coffee consumption (cups per day);
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.58	0.37	1.42e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg02886208	chr11:14281011	SPON1	0.37	7.19	0.32	2.68e-12	Sense of smell;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg26338869	chr17:61819248	STRADA	0.58	9.76	0.41	1.34e-20	Prudent dietary pattern;
LGG	cis	rs2594989	0.895	rs2606739	chr3:11394611	C/A	cg01796438	chr3:11312864	ATG7	-0.53	-6.99	-0.31	9.58e-12	Circulating chemerin levels;
LGG	cis	rs9912468	0.594	rs11079645	chr17:64228090	G/T	cg19474267	chr17:64306194	PRKCA	-0.69	-14.16	-0.55	4.4e-38	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg14761175	chr22:17898020	NA	-0.37	-6.76	-0.3	4.06e-11	Iris color (L* coordinate);
LGG	trans	rs9784649	0.882	rs72753879	chr5:24947395	C/T	cg08600765	chr20:34638493	LOC647979	-0.61	-7.69	-0.34	8.95e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4774899	0.966	rs62022237	chr15:57513613	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.08	-0.31	5.35e-12	Urinary tract infection frequency;
LGG	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs12618769	0.597	rs2278214	chr2:99135738	A/G	cg18455616	chr2:99124870	INPP4A	-0.28	-8.03	-0.35	7.94e-15	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg24642844	chr7:1081250	C7orf50	-0.87	-14.18	-0.55	3.68e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg12698349	chr2:225449008	CUL3	-0.7	-11.78	-0.48	3.53e-28	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.21	-0.39	1.14e-18	Neuroticism;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg06636001	chr8:8085503	FLJ10661	0.58	10.97	0.45	4.57e-25	Retinal vascular caliber;
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg05335186	chr13:53173507	NA	0.38	7.08	0.31	5.28e-12	Lewy body disease;
LGG	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.41	0.33	5.95e-13	Hemoglobin concentration;
LGG	trans	rs7944735	0.817	rs7942031	chr11:47868474	T/C	cg15704280	chr7:45808275	SEPT13	0.62	7.79	0.34	4.46e-14	Intraocular pressure;
LGG	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.57	0.41	6.32e-20	Menarche (age at onset);
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg05082376	chr22:42548792	NA	0.37	7.73	0.34	6.9e-14	Schizophrenia;
LGG	cis	rs7216064	0.954	rs8079291	chr17:65887622	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg14500267	chr11:67383377	NA	-0.39	-7.34	-0.32	9.53e-13	Mean corpuscular volume;
LGG	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.03e-18	Motion sickness;
LGG	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg03188948	chr7:1209495	NA	0.65	8.47	0.37	3.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7646881	0.812	rs75107964	chr3:158458751	G/A	cg19483011	chr3:158453295	NA	-0.62	-8.17	-0.36	2.92e-15	Tetralogy of Fallot;
LGG	cis	rs12580194	1.000	rs4262806	chr12:55711562	T/A	cg19537932	chr12:55886519	OR6C68	-0.37	-6.67	-0.3	7.18e-11	Cancer;
LGG	cis	rs2415984	0.622	rs61993294	chr14:46932466	C/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.16	-0.43	4.89e-22	Number of children ever born;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	trans	rs62458065	0.513	rs10265319	chr7:32571564	A/C	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.67	-0.34	1.01e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg13385794	chr1:248469461	NA	0.5	8.34	0.36	8.83e-16	Common traits (Other);
LGG	cis	rs5743618	0.537	rs11096957	chr4:38776491	A/C	cg06935464	chr4:38784597	TLR10	0.39	7.0	0.31	9.31e-12	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2916247	0.954	rs990746	chr8:93173405	C/G	cg10183463	chr8:93005414	RUNX1T1	0.35	6.99	0.31	9.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12493885	0.818	rs61791541	chr3:153758155	G/T	cg17054900	chr3:154042577	DHX36	-0.69	-8.62	-0.37	1.04e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1620921	0.711	rs2802354	chr6:161245752	G/C	cg01280913	chr6:161186852	NA	-0.34	-6.94	-0.31	1.32e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.47	0.4	1.43e-19	Longevity;
LGG	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg03162506	chr22:38580953	NA	0.38	9.72	0.41	1.8899999999999998e-20	Cutaneous nevi;
LGG	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.37	0.47	1.39e-26	Ovarian reserve;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.06	0.52	2.01e-33	Tonsillectomy;
LGG	cis	rs6920372	0.731	rs2357124	chr6:109872263	T/G	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18099408	chr3:52552593	STAB1	0.35	6.7	0.3	5.88e-11	Bipolar disorder;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00495681	chr13:53174319	NA	0.47	8.13	0.35	4.07e-15	Lewy body disease;
LGG	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg08999081	chr20:33150536	PIGU	0.39	9.86	0.42	5.89e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs6087990	0.735	rs1003522	chr20:31368560	T/C	cg13636640	chr20:31349939	DNMT3B	0.84	17.56	0.63	2.73e-53	Ulcerative colitis;
LGG	cis	rs9419702	0.614	rs59573564	chr10:133532158	T/G	cg04492858	chr10:133558786	NA	0.43	8.5	0.37	2.65e-16	Survival in rectal cancer;
LGG	trans	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17712092	chr4:129076599	LARP1B	0.74	14.27	0.55	1.53e-38	Breast cancer;
LGG	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04362095	chr11:63592001	C11orf84	-0.55	-10.72	-0.45	4.38e-24	Pulse pressure;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg27189623	chr16:705930	WDR90	0.4	7.67	0.34	1.01e-13	Height;
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	8.92e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg24692254	chr21:30365293	RNF160	-0.46	-7.8	-0.34	4.21e-14	Selective IgA deficiency;
LGG	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg24848339	chr3:12840334	CAND2	0.36	8.04	0.35	7.48e-15	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.02	0.52	3.1e-33	Lung cancer;
LGG	cis	rs9314323	0.557	rs3779916	chr8:26250906	C/A	cg11498726	chr8:26250323	BNIP3L	-0.46	-10.31	-0.43	1.4e-22	Red cell distribution width;
LGG	cis	rs77633900	0.772	rs79181196	chr15:76656281	G/T	cg21673338	chr15:77095150	SCAPER	-0.61	-7.92	-0.35	1.84e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg23009067	chr7:2775923	GNA12	0.26	7.12	0.31	4.14e-12	Height;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg20978937	chr14:105399321	PLD4	0.48	10.75	0.45	3.14e-24	Rheumatoid arthritis;
LGG	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10462794	0.853	rs17678610	chr5:4509088	G/C	cg18482690	chr5:4511582	NA	-0.43	-7.24	-0.32	1.91e-12	DNA methylation (variation);
LGG	cis	rs6598955	0.950	rs6700455	chr1:26545864	T/C	cg04990556	chr1:26633338	UBXN11	0.75	14.44	0.56	2.8e-39	Obesity-related traits;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg11905131	chr22:24372483	LOC391322	-0.41	-7.05	-0.31	6.56e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7091068	0.616	rs1409336	chr10:95479674	T/G	cg20715218	chr10:95462985	C10orf4	0.7	10.94	0.45	6.37e-25	Urinary tract infection frequency;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg03036210	chr16:89904091	SPIRE2	-0.5	-7.18	-0.32	2.74e-12	Interleukin-17 levels;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.27	-0.36	1.39e-15	Joint mobility (Beighton score);
LGG	cis	rs422249	0.819	rs174605	chr11:61626921	G/T	cg19610905	chr11:61596333	FADS2	-0.52	-7.54	-0.33	2.56e-13	Trans fatty acid levels;
LGG	trans	rs75804782	0.625	rs72984528	chr2:239469373	T/C	cg01134436	chr17:81009848	B3GNTL1	0.69	7.44	0.33	5.01e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7572733	0.534	rs700678	chr2:198705820	T/C	cg00792783	chr2:198669748	PLCL1	0.69	11.25	0.46	4.16e-26	Dermatomyositis;
LGG	cis	rs9487094	0.558	rs10457194	chr6:109828569	T/A	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.04e-14	Height;
LGG	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.23	-0.32	2.04e-12	Common traits (Other);
LGG	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.32	-20.95	-0.7	4.84e-69	Hemostatic factors and hematological phenotypes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02146966	chr17:18967117	NA	0.51	8.57	0.37	1.54e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.18	0.32	2.77e-12	Lung cancer;
LGG	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg11040518	chr10:102331378	NA	-0.36	-6.73	-0.3	5.03e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg25214090	chr10:38739885	LOC399744	0.61	10.71	0.45	4.48e-24	Corneal astigmatism;
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg22398616	chr13:53314203	LECT1	-0.4	-7.56	-0.33	2.24e-13	Lewy body disease;
LGG	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.68	-0.75	1.83e-86	Height;
LGG	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg12643083	chr1:161476548	FCGR2A	-0.67	-10.0	-0.42	1.95e-21	Rheumatoid arthritis;
LGG	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg02002194	chr4:3960332	NA	0.38	6.98	0.31	1.03e-11	Neuroticism;
LGG	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs1395	0.744	rs11126934	chr2:27476613	T/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg25482853	chr8:67687455	SGK3	0.94	11.79	0.48	3.19e-28	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.23	-0.32	1.98e-12	Menopause (age at onset);
LGG	cis	rs9462027	0.628	rs9380455	chr6:34690778	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.52	10.68	0.44	6.08e-24	Systemic lupus erythematosus;
LGG	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg18252515	chr7:66147081	NA	-1.4	-20.12	-0.68	3.71e-65	Gout;
LGG	cis	rs7020830	0.825	rs10973248	chr9:37197768	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	34.82	0.85	2.15e-131	Schizophrenia;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg13047869	chr3:10149882	C3orf24	0.53	8.93	0.38	1.02e-17	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg21230503	chr5:139085173	NA	0.37	8.47	0.37	3.38e-16	Schizophrenia;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg21535247	chr6:8435926	SLC35B3	0.61	10.3	0.43	1.57e-22	Motion sickness;
LGG	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.5	-0.4	1.13e-19	Life satisfaction;
LGG	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg18551225	chr6:44695536	NA	-0.59	-8.7	-0.37	5.72e-17	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4948496	1.000	rs6479781	chr10:63805735	G/A	cg16389209	chr10:63809121	ARID5B	-0.36	-6.98	-0.31	1.01e-11	Systemic lupus erythematosus;
LGG	cis	rs718857	0.508	rs747029	chr9:106719165	G/T	cg14250997	chr9:106856677	SMC2	0.35	6.65	0.3	8.48e-11	Breast cancer;
LGG	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg25809561	chr17:30822961	MYO1D	0.34	7.77	0.34	5.05e-14	Schizophrenia;
LGG	cis	rs3820928	0.874	rs1917122	chr2:227835681	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.52e-14	Pulmonary function;
LGG	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15664640	chr17:80829946	TBCD	0.57	11.26	0.46	3.56e-26	Breast cancer;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2227564	0.620	rs11000765	chr10:75512452	G/C	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.82	-0.42	8.56e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1878931	0.513	rs35160989	chr16:3405506	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	19.95	0.68	2.29e-64	Body mass index (adult);
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.01	-0.39	5.58e-18	Life satisfaction;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	1.000	rs35648189	chr15:84740748	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	cis	rs4696584	0.816	rs61270934	chr4:155400949	T/C	cg13738195	chr4:155413469	DCHS2	-0.36	-7.17	-0.32	2.95e-12	Folding of antihelix;
LGG	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs6062302	0.522	rs13038448	chr20:62218453	C/T	cg16989086	chr20:62203971	PRIC285	0.5	7.3	0.32	1.29e-12	Glioblastoma;
LGG	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg11502198	chr6:26597334	ABT1	0.89	12.88	0.51	1.17e-32	Small cell lung carcinoma;
LGG	cis	rs16854884	0.657	rs7637912	chr3:143749777	G/A	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg03929089	chr4:120376271	NA	0.62	8.6	0.37	1.21e-16	Intraocular pressure;
LGG	cis	rs17875496	0.912	rs4778889	chr15:81588995	C/T	cg19620333	chr15:81596332	IL16	-0.5	-9.74	-0.41	1.62e-20	Number of common colds;
LGG	cis	rs7674212	0.541	rs2251322	chr4:104079424	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-7.34	-0.32	9.77e-13	Type 2 diabetes;
LGG	trans	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg25214090	chr10:38739885	LOC399744	0.62	11.23	0.46	4.67e-26	Corneal astigmatism;
LGG	cis	rs9902453	0.933	rs8080343	chr17:28456758	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.83	0.51	1.8e-32	Coffee consumption (cups per day);
LGG	cis	rs7666738	0.830	rs28451001	chr4:98924544	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg00339695	chr16:24857497	SLC5A11	-0.41	-7.0	-0.31	9.19e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg09201001	chr11:18656081	SPTY2D1	0.97	21.16	0.7	4.8e-70	Breast cancer;
LGG	cis	rs7614311	0.594	rs58473894	chr3:63857208	G/C	cg22134162	chr3:63841271	THOC7	-0.36	-6.9	-0.31	1.7e-11	Lung function (FVC);Lung function (FEV1);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06642177	chr6:134496341	SGK1	-0.49	-7.13	-0.31	3.98e-12	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13732083	chr21:47605072	C21orf56	0.46	7.73	0.34	6.85e-14	Testicular germ cell tumor;
LGG	cis	rs7236492	0.688	rs73494217	chr18:77186200	G/A	cg15532942	chr18:77220712	NFATC1	0.45	7.27	0.32	1.54e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6912958	0.781	rs2325064	chr6:88224467	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.85e-16	Monocyte percentage of white cells;
LGG	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.27	0.36	1.38e-15	Diabetic kidney disease;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg18258770	chr4:90757814	SNCA	-0.4	-7.25	-0.32	1.81e-12	Dementia with Lewy bodies;
LGG	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.7e-21	Corneal astigmatism;
LGG	cis	rs6754311	0.544	rs11693502	chr2:136808949	C/T	cg07169764	chr2:136633963	MCM6	-0.66	-10.85	-0.45	1.4e-24	Mosquito bite size;
LGG	cis	rs968451	1.000	rs12628705	chr22:39693518	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	11.14	0.46	1.09e-25	Primary biliary cholangitis;
LGG	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg07395648	chr5:131743802	NA	-0.51	-10.7	-0.45	5.07e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs10463554	0.963	rs32850	chr5:102470029	G/C	cg23492399	chr5:102201601	PAM	-0.5	-7.42	-0.33	5.72e-13	Parkinson's disease;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg07870213	chr5:140052090	DND1	0.89	16.16	0.6	6.4e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.14	0.46	1.11e-25	Corneal astigmatism;
LGG	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg00339695	chr16:24857497	SLC5A11	0.34	6.74	0.3	4.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12615966	1.000	rs882424	chr2:105370336	C/A	cg16465502	chr2:105461796	NA	0.89	10.3	0.43	1.49e-22	Pancreatic cancer;
LGG	cis	rs7267979	0.816	rs443009	chr20:25499817	A/G	cg06421707	chr20:25228305	PYGB	-0.44	-9.06	-0.39	3.79e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10883723	0.773	rs2296587	chr10:104245588	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.89	0.48	1.22e-28	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.97	0.35	1.24e-14	Lung cancer;
LGG	cis	rs17767392	0.670	rs11845249	chr14:71723237	G/T	cg02058870	chr14:72053146	SIPA1L1	0.38	8.24	0.36	1.8e-15	Mitral valve prolapse;
LGG	cis	rs4321325	0.733	rs4510165	chr2:127936284	C/T	cg11380483	chr2:127933992	NA	0.67	9.3	0.4	5.62e-19	Protein C levels;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg24189917	chr7:1970923	MAD1L1	-0.47	-7.04	-0.31	6.84e-12	Bipolar disorder;
LGG	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.75	-0.3	4.35e-11	Bone mineral density;
LGG	cis	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg07460842	chr6:66804631	NA	0.73	12.56	0.5	2.52e-31	Type 2 diabetes;
LGG	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg02297831	chr4:17616191	MED28	-0.47	-8.54	-0.37	1.88e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.14e-11	Neuroticism;
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg04503457	chr17:41445688	NA	-0.37	-8.82	-0.38	2.35e-17	Menopause (age at onset);
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.32	-8.39	-0.36	5.91e-16	IgG glycosylation;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg01988459	chr11:68622903	NA	-0.61	-12.44	-0.5	7.25e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg05082376	chr22:42548792	NA	-0.4	-8.13	-0.35	4.01e-15	Schizophrenia;
LGG	cis	rs7512552	0.839	rs2264418	chr1:150368579	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg24812749	chr6:127587940	RNF146	0.97	16.18	0.6	5.22e-47	Breast cancer;
LGG	cis	rs60180747	0.543	rs1871006	chr15:66547641	G/A	cg07575407	chr15:66541975	MEGF11	0.64	13.6	0.53	1.1e-35	Testicular germ cell tumor;
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.66	0.34	1.09e-13	Bipolar disorder;
LGG	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs9296092	0.517	rs76662639	chr6:33508476	G/A	cg13560919	chr6:33536144	NA	-0.99	-18.9	-0.66	1.78e-59	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg12070911	chr6:150209640	RAET1E	0.27	6.98	0.31	1.05e-11	Testicular germ cell tumor;
LGG	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg02811702	chr13:24901961	NA	0.39	7.3	0.32	1.25e-12	Obesity-related traits;
LGG	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg03160526	chr17:80928410	B3GNTL1	0.5	7.97	0.35	1.24e-14	Glycated hemoglobin levels;
LGG	cis	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg16454426	chr8:49984564	C8orf22	-0.33	-6.65	-0.3	8.04e-11	Blood metabolite levels;
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg09997372	chr17:61989759	CSHL1	-0.33	-6.72	-0.3	5.35e-11	Height;
LGG	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg21045802	chr8:109455806	TTC35	0.53	10.06	0.42	1.16e-21	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2559856	0.967	rs2695297	chr12:102082218	T/C	cg12924262	chr12:102091054	CHPT1	0.64	12.8	0.51	2.44e-32	Blood protein levels;
LGG	cis	rs55871839	0.559	rs4737526	chr8:59823372	A/G	cg07426533	chr8:59803705	TOX	0.59	12.47	0.5	5.77e-31	Pneumonia;
LGG	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg01043669	chr3:72786069	NA	0.4	7.23	0.32	2.01e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6499188	0.510	rs9923262	chr16:68613106	A/G	cg02972257	chr16:68554789	NA	-0.55	-7.56	-0.33	2.22e-13	Ulcerative colitis;
LGG	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg12395012	chr8:11607386	GATA4	-0.39	-7.2	-0.32	2.41e-12	Mood instability;
LGG	cis	rs17039065	0.920	rs59773923	chr4:109467489	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs3806843	0.576	rs246041	chr5:140331128	C/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg18654377	chr3:49208889	KLHDC8B	0.53	8.43	0.36	4.42e-16	Menarche (age at onset);
LGG	cis	rs5742933	0.857	rs13021611	chr2:190564764	A/T	cg10453823	chr2:190539512	ANKAR	-0.46	-6.72	-0.3	5.51e-11	Ferritin levels;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg09033563	chr22:24373618	LOC391322	-0.59	-9.65	-0.41	3.42e-20	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2708240	0.936	rs2708241	chr7:147578931	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	3.04e-11	QT interval (drug interaction);
LGG	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg26116260	chr4:7069785	GRPEL1	0.47	8.2	0.36	2.4e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-14.78	-0.57	8.99e-41	Colorectal cancer;
LGG	cis	rs9814567	0.752	rs7623567	chr3:134330976	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs870825	0.616	rs4594761	chr4:185643002	A/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	7.15	0.32	3.48e-12	Coronary artery disease;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg04234412	chr22:24373322	LOC391322	-0.73	-14.79	-0.57	8.09e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg04455712	chr21:45112962	RRP1B	0.51	9.69	0.41	2.52e-20	Mean corpuscular volume;
LGG	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.63	18.15	0.64	5.35e-56	Oropharynx cancer;
LGG	cis	rs3845702	0.736	rs6433821	chr2:180837806	T/A	cg01881094	chr2:180872142	CWC22	-1.25	-16.87	-0.62	3.8300000000000002e-50	Schizophrenia;
LGG	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-9.22	-0.39	1.03e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.75	14.16	0.55	4.36e-38	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg01028140	chr2:1542097	TPO	-0.48	-8.68	-0.37	6.56e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08564027	chr20:61660810	NA	1.02	25.57	0.77	1.49e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg03175030	chr11:2018143	H19;MIR675	0.57	10.66	0.44	7.21e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7818345	0.845	rs17407039	chr8:19268056	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.71	0.3	5.79e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg14689365	chr7:158441557	NCAPG2	0.59	7.26	0.32	1.65e-12	Height;
LGG	cis	rs10462794	0.686	rs12652129	chr5:4494822	C/T	cg18482690	chr5:4511582	NA	0.37	6.68	0.3	7.02e-11	DNA methylation (variation);
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg02503808	chr4:7069936	GRPEL1	0.9	14.17	0.55	4.16e-38	Monocyte percentage of white cells;
LGG	cis	rs1793639	0.654	rs1793626	chr11:131957811	C/T	cg13908476	chr11:131942942	NTM	0.65	13.21	0.52	4.76e-34	Myopia;
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07440826	chr16:89882328	FANCA	-0.26	-6.76	-0.3	4.09e-11	Vitiligo;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg15948088	chr11:109293068	C11orf87	0.42	7.05	0.31	6.47e-12	Schizophrenia;
LGG	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg05985134	chr18:33552581	C18orf21	0.63	9.9	0.42	4.46e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg19399532	chr1:178512495	C1orf220	-0.53	-10.7	-0.45	5.14e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs42648	0.869	rs2027965	chr7:89912513	C/T	cg25739043	chr7:89950458	NA	-0.44	-9.23	-0.39	9.38e-19	Homocysteine levels;
LGG	cis	rs709400	0.627	rs62007686	chr14:103899344	A/G	cg26031613	chr14:104095156	KLC1	0.78	13.53	0.53	2.21e-35	Body mass index;
LGG	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg03929089	chr4:120376271	NA	-0.53	-8.98	-0.39	6.99e-18	HDL cholesterol;
LGG	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-9.98	-0.42	2.24e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10463554	0.963	rs154355	chr5:102498881	G/T	cg23492399	chr5:102201601	PAM	-0.52	-7.82	-0.34	3.49e-14	Parkinson's disease;
LGG	cis	rs1982963	1.000	rs753050	chr14:52505375	A/G	cg05884192	chr14:52515736	NID2	-0.34	-7.55	-0.33	2.38e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11718455	0.881	rs17076257	chr3:44006787	C/T	cg21419209	chr3:44054225	NA	-0.41	-6.74	-0.3	4.86e-11	Coronary artery disease;
LGG	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg06618935	chr21:46677482	NA	-0.48	-9.34	-0.4	3.99e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9300255	0.550	rs10772997	chr12:123719880	C/A	cg05973401	chr12:123451056	ABCB9	0.51	8.22	0.36	2.13e-15	Neutrophil percentage of white cells;
LGG	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg02153584	chr22:29168773	CCDC117	0.62	9.77	0.41	1.27e-20	Lymphocyte counts;
LGG	cis	rs7766436	0.885	rs11759879	chr6:22587130	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.54	-0.47	2.93e-27	Coronary artery disease;
LGG	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg05169099	chr5:481640	SLC9A3	0.47	6.9	0.31	1.76e-11	Fat distribution (HIV);
LGG	cis	rs11971779	0.625	rs2355784	chr7:139072493	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg22643751	chr7:855365	UNC84A	0.36	6.98	0.31	1.05e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg00405596	chr8:11794950	NA	-0.6	-10.68	-0.44	5.8e-24	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00337957	chr19:8547807	HNRNPM	0.41	7.12	0.31	4.26e-12	Gut microbiome composition (summer);
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg21548813	chr6:291882	DUSP22	-0.74	-13.06	-0.52	2.09e-33	Menopause (age at onset);
LGG	cis	rs4774899	0.966	rs11635440	chr15:57573834	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg22120825	chr2:201024476	NA	-0.49	-6.82	-0.3	2.81e-11	Schizophrenia;
LGG	cis	rs7666738	0.791	rs1896155	chr4:99020948	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7712401	0.562	rs364723	chr5:122326464	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs12135191	0.900	rs7552075	chr1:236474892	A/G	cg21399712	chr1:236511386	NA	-0.41	-7.92	-0.35	1.74e-14	Urate levels (BMI interaction);
LGG	cis	rs9811920	0.809	rs793476	chr3:99541747	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.66	-0.37	7.62e-17	Axial length;
LGG	cis	rs12431410	0.892	rs12717467	chr14:60168672	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.05	0.31	6.62e-12	Schizophrenia;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.59	8.92	0.38	1.12e-17	Renal function-related traits (BUN);
LGG	cis	rs2066819	1.000	rs57137641	chr12:56741228	G/A	cg26714650	chr12:56694279	CS	-1.59	-16.49	-0.61	2.05e-48	Psoriasis vulgaris;
LGG	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg23335576	chr14:104009727	NA	-0.47	-7.97	-0.35	1.23e-14	Reticulocyte count;
LGG	trans	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.12	-0.39	2.26e-18	Bladder cancer;
LGG	cis	rs7267979	1.000	rs6107033	chr20:25363591	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.37	-0.43	8.77e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.61	-0.41	4.71e-20	Mean corpuscular volume;
LGG	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.56	10.62	0.44	1.02e-23	HDL cholesterol;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg21724239	chr8:58056113	NA	0.44	7.03	0.31	7.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg02697781	chr21:44492131	CBS	-0.43	-7.17	-0.32	2.95e-12	Emphysema imaging phenotypes;
LGG	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	trans	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.71	0.3	5.54e-11	Renal cell carcinoma;
LGG	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg23625390	chr15:77176239	SCAPER	-0.71	-13.91	-0.54	5.35e-37	Blood metabolite levels;
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg24675658	chr1:53192096	ZYG11B	0.49	9.75	0.41	1.44e-20	Monocyte count;
LGG	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.41	-0.44	6.05e-23	Response to antipsychotic treatment;
LGG	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-10.69	-0.44	5.56e-24	Longevity;
LGG	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.48e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7940866	0.804	rs6590540	chr11:130805444	T/C	cg12179176	chr11:130786555	SNX19	0.77	14.76	0.57	1.13e-40	Schizophrenia;
LGG	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg22906224	chr7:99728672	NA	-0.52	-8.62	-0.37	1.08e-16	Coronary artery disease;
LGG	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	12.44	0.5	7.76e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.9	19.49	0.67	3.41e-62	Birth weight;
LGG	cis	rs10850519	0.751	rs11615738	chr12:115944636	T/A	cg18639984	chr12:115943877	NA	-0.42	-8.98	-0.39	6.92e-18	Diastolic blood pressure;
LGG	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg26695010	chr11:65641043	EFEMP2	-0.55	-6.95	-0.31	1.28e-11	Crohn's disease;
LGG	trans	rs629535	0.725	rs639127	chr8:70073251	A/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs2299587	0.897	rs3850745	chr8:17784277	G/A	cg18067069	chr8:17937731	ASAH1	-0.29	-6.78	-0.3	3.62e-11	Economic and political preferences;
LGG	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	-0.69	-7.52	-0.33	2.8e-13	Initial pursuit acceleration;
LGG	trans	rs28595532	0.547	rs1913576	chr4:119297789	C/T	cg26518628	chr1:97050305	NA	-0.8	-6.86	-0.3	2.23e-11	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.66e-11	Personality dimensions;
LGG	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.59	-0.51	1.76e-31	Vitiligo;
LGG	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg09696939	chr10:60272079	BICC1	0.35	6.85	0.3	2.43e-11	Refractive error;
LGG	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.01e-13	Schizophrenia;
LGG	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.41e-12	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg26174226	chr8:58114915	NA	-0.51	-6.69	-0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7911264	0.739	rs10882094	chr10:94387676	T/A	cg25093409	chr10:94429542	NA	0.48	9.54	0.41	7.99e-20	Inflammatory bowel disease;
LGG	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg00405596	chr8:11794950	NA	0.65	11.47	0.47	5.75e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs897984	0.722	rs12445568	chr16:31004812	T/C	cg00531865	chr16:30841666	NA	-0.56	-11.29	-0.46	2.9e-26	Dementia with Lewy bodies;
LGG	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg05623727	chr3:50126028	RBM5	0.33	7.18	0.32	2.72e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs17253792	0.822	rs78261053	chr14:56061784	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg00106254	chr7:1943704	MAD1L1	0.41	7.05	0.31	6.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs4774899	0.867	rs978274	chr15:57528500	C/T	cg08128148	chr15:57256372	TCF12	-0.32	-7.3	-0.32	1.26e-12	Urinary tract infection frequency;
LGG	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	9.0	0.39	5.9e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.76	-0.41	1.34e-20	Body mass index;
LGG	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg15704280	chr7:45808275	SEPT13	0.77	8.92	0.38	1.08e-17	Axial length;
LGG	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg19131313	chr8:1704013	NA	-0.31	-6.8	-0.3	3.27e-11	Systolic blood pressure;
LGG	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.46	0.53	4.41e-35	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22496380	chr5:211416	CCDC127	1.22	17.72	0.64	5.42e-54	Breast cancer;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.96	-0.35	1.38e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.4	0.36	5.45e-16	Skin colour saturation;
LGG	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg12011299	chr4:100065546	ADH4	0.43	8.61	0.37	1.15e-16	Alcohol dependence;
LGG	trans	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg07211511	chr3:129823064	LOC729375	-0.64	-8.84	-0.38	2.03e-17	Blood pressure (smoking interaction);
LGG	cis	rs858239	0.539	rs6949363	chr7:23192394	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.87	0.3	2.13e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2075371	1.000	rs2598292	chr7:133988584	C/G	cg11752832	chr7:134001865	SLC35B4	0.63	11.54	0.47	3.11e-27	Mean platelet volume;
LGG	cis	rs1566085	0.766	rs4342639	chr8:142654228	G/A	cg26331504	chr8:142652174	NA	0.32	7.64	0.33	1.26e-13	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg06654118	chr4:1303317	MAEA	0.42	6.8	0.3	3.16e-11	Obesity-related traits;
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg23594656	chr7:65796392	TPST1	-0.4	-8.91	-0.38	1.17e-17	Aortic root size;
LGG	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg03806693	chr22:41940476	POLR3H	0.99	16.35	0.6	9.46e-48	Vitiligo;
LGG	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg13073564	chr4:8508604	NA	-0.51	-10.22	-0.43	2.94e-22	Response to antineoplastic agents;
LGG	cis	rs4566357	0.595	rs1320406	chr2:227920474	C/T	cg11843606	chr2:227700838	RHBDD1	-0.49	-8.82	-0.38	2.41e-17	Coronary artery disease;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-9.05	-0.39	3.99e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs17321999	1.000	rs17321999	chr2:30479857	A/C	cg05247661	chr2:30472410	LBH	-0.56	-9.1	-0.39	2.74e-18	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03288419	chr19:35225464	ZNF181	0.52	8.09	0.35	5.2e-15	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00820581	chr1:174969299	CACYBP	0.44	7.35	0.32	9.14e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9443189	0.615	rs618239	chr6:76350038	A/G	cg01950844	chr6:76311363	SENP6	0.77	10.16	0.43	4.88e-22	Prostate cancer;
LGG	cis	rs3857747	0.827	rs10241646	chr7:40473750	C/T	cg00420559	chr7:40367873	C7orf10	0.37	7.47	0.33	4.02e-13	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7095944	0.614	rs7898003	chr10:126451385	G/A	cg08799069	chr10:126477246	METTL10	-0.49	-11.44	-0.47	7.21e-27	Asthma;
LGG	trans	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg18335740	chr13:41363409	SLC25A15	-0.58	-11.22	-0.46	5.13e-26	Lewy body disease;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.68	-0.41	2.64e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs6714710	0.603	rs956039	chr2:98416848	C/A	cg26665480	chr2:98280029	ACTR1B	0.64	10.35	0.43	9.74e-23	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg12386194	chr3:101231763	SENP7	0.47	8.33	0.36	9.55e-16	Colorectal cancer;
LGG	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg18854424	chr1:2615690	NA	0.35	7.78	0.34	4.88e-14	Ulcerative colitis;
LGG	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg04065151	chr12:53682969	ESPL1	-0.57	-9.34	-0.4	4.1e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4740619	0.661	rs10810483	chr9:15932052	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.17	-0.43	4.47e-22	Body mass index;
LGG	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs12249377	0.519	rs4520504	chr10:92602373	T/C	cg14313238	chr10:92632228	RPP30	0.41	7.4	0.33	6.3e-13	White matter microstructure (global fractional anisotropy);
LGG	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg02403541	chr12:121454288	C12orf43	0.65	10.44	0.44	4.61e-23	N-glycan levels;
LGG	cis	rs514024	0.665	rs534652	chr9:130494667	G/A	cg13643465	chr9:130375613	STXBP1	0.58	10.54	0.44	2.07e-23	Eating disorders (purging via substances);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04945388	chr2:232573881	PTMA	0.48	7.49	0.33	3.45e-13	Gut microbiome composition (summer);
LGG	cis	rs3735485	0.760	rs10232306	chr7:45026736	G/C	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4771450	0.925	rs3916931	chr13:103986357	A/T	cg02987523	chr13:103978230	NA	0.32	7.02	0.31	8.2e-12	Uric acid levels;
LGG	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.84	-0.51	1.66e-32	Uric acid levels;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22968622	chr17:43663579	NA	0.8	15.54	0.59	4.03e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6964587	0.967	rs10280620	chr7:91582183	C/G	cg17063962	chr7:91808500	NA	-0.48	-8.62	-0.37	1.09e-16	Breast cancer;
LGG	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg14664628	chr15:75095509	CSK	-0.5	-8.6	-0.37	1.23e-16	Systemic lupus erythematosus;
LGG	cis	rs7017914	0.934	rs62530826	chr8:71641643	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs1109114	0.934	rs4295373	chr5:148615987	C/T	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.52	-0.58	4.94e-44	Body mass index;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.65	0.37	8.27e-17	Aortic root size;
LGG	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg16482183	chr6:26056742	HIST1H1C	0.68	9.26	0.4	7.54e-19	Iron status biomarkers;
LGG	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05491587	chr18:77659695	KCNG2	-0.52	-6.77	-0.3	3.98e-11	Opioid sensitivity;
LGG	cis	rs12282928	1.000	rs4436574	chr11:48334788	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.04	0.57	6.42e-42	Cognitive test performance;
LGG	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg10792982	chr14:105748885	BRF1	0.67	13.73	0.54	3.04e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.31	0.81	1.44e-107	Dental caries;
LGG	cis	rs9296092	0.538	rs80012910	chr6:33519542	G/A	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg01043669	chr3:72786069	NA	0.43	7.05	0.31	6.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg02353165	chr6:42928485	GNMT	0.39	10.73	0.45	4e-24	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg16141378	chr3:129829833	LOC729375	0.33	6.93	0.31	1.42e-11	Neuroticism;
LGG	cis	rs9914544	0.602	rs4924929	chr17:18714241	G/A	cg26378065	chr17:18585709	ZNF286B	0.41	7.67	0.34	1.01e-13	Educational attainment (years of education);
LGG	cis	rs1971762	0.527	rs6580953	chr12:54021138	T/C	cg06632207	chr12:54070931	ATP5G2	0.23	7.08	0.31	5.44e-12	Height;
LGG	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg11161011	chr14:65562177	MAX	-0.61	-12.09	-0.49	1.99e-29	Obesity-related traits;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.96	-0.38	7.96e-18	Schizophrenia;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs9880211	0.706	rs35716521	chr3:136494670	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.85	-0.3	2.33e-11	Body mass index;Height;
LGG	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.54	-0.33	2.51e-13	Schizophrenia;
LGG	cis	rs727505	0.866	rs67724276	chr7:124719719	G/A	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.06e-18	Lewy body disease;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg20309703	chr11:118481025	PHLDB1	0.58	10.58	0.44	1.36e-23	Cholesterol, total;
LGG	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.86e-66	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16308101	chr1:67895914	SERBP1	-0.38	-6.86	-0.3	2.25e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06128509	chr10:91461539	KIF20B	0.36	7.05	0.31	6.39e-12	Bilirubin levels;
LGG	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.03	-0.31	7.5e-12	Iron status biomarkers;
LGG	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08704250	chr15:31115839	NA	0.49	8.85	0.38	1.88e-17	Huntington's disease progression;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.78	0.38	3.27e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.62	-10.87	-0.45	1.18e-24	Obesity-related traits;
LGG	cis	rs753778	0.628	rs11579	chr8:142205132	G/A	cg18755752	chr8:142205143	DENND3	-0.51	-10.59	-0.44	1.33e-23	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg08621203	chr6:150244597	RAET1G	0.46	6.66	0.3	7.79e-11	Lung cancer;
LGG	cis	rs497273	0.517	rs580240	chr12:121199903	T/G	cg02419362	chr12:121203948	SPPL3	0.52	8.86	0.38	1.72e-17	Systemic lupus erythematosus;
LGG	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg08610935	chr16:1836813	NUBP2	-0.55	-9.63	-0.41	4.07e-20	Insulin-like growth factors;
LGG	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.82	-0.48	2.26e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3740909	1.000	rs75691635	chr11:125888896	A/C	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs1670533	0.932	rs610218	chr4:1080083	C/G	cg27284194	chr4:1044797	NA	0.54	9.92	0.42	3.6e-21	Recombination rate (females);
LGG	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg04935436	chr20:30431758	NA	0.44	7.36	0.32	8.7e-13	Mean corpuscular hemoglobin;
LGG	cis	rs2354432	0.607	rs7516430	chr1:146767062	A/G	cg25205988	chr1:146714368	CHD1L	-1.32	-15.4	-0.58	1.75e-43	Mitochondrial DNA levels;
LGG	trans	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg02002194	chr4:3960332	NA	0.48	9.24	0.39	9.07e-19	Mood instability;
LGG	cis	rs9443189	0.855	rs1321161	chr6:76454182	G/A	cg01950844	chr6:76311363	SENP6	-0.55	-7.31	-0.32	1.17e-12	Prostate cancer;
LGG	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg04935436	chr20:30431758	NA	0.41	7.24	0.32	1.93e-12	Mean corpuscular hemoglobin;
LGG	trans	rs9929218	1.000	rs13334326	chr16:68809207	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.85	-0.51	1.59e-32	Colorectal cancer;
LGG	cis	rs7166081	0.951	rs34590589	chr15:67514190	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg06618935	chr21:46677482	NA	-0.47	-9.13	-0.39	2.19e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9547996	0.842	rs9547965	chr13:38153888	G/A	cg13634560	chr13:38173852	POSTN	-0.35	-7.13	-0.31	3.95e-12	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06296570	chr7:130792605	FLJ43663	0.6	9.4	0.4	2.52e-19	Gut microbiome composition (summer);
LGG	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg02002194	chr4:3960332	NA	-0.49	-9.14	-0.39	1.93e-18	Neuroticism;
LGG	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg11901034	chr3:128598214	ACAD9	-0.46	-6.99	-0.31	9.49e-12	IgG glycosylation;
LGG	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.19	-0.32	2.68e-12	Total cholesterol levels;
LGG	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg05973401	chr12:123451056	ABCB9	0.48	8.02	0.35	8.74e-15	Platelet count;
LGG	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13080904	chr7:143534545	LOC154761	0.47	7.24	0.32	1.9e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg13902645	chr11:5959945	NA	0.73	11.36	0.47	1.51e-26	DNA methylation (variation);
LGG	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs903263	0.601	rs72711192	chr1:84562805	A/G	cg10977910	chr1:84465055	TTLL7	0.42	7.42	0.33	5.75e-13	Breast cancer (male);
LGG	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg03605463	chr16:89740564	NA	-0.41	-6.81	-0.3	3.08e-11	Vitiligo;
LGG	trans	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg09264619	chr17:80180166	NA	-0.48	-9.67	-0.41	2.98e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs651907	0.588	rs9881690	chr3:101663317	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.41	7.56	0.33	2.14e-13	Colorectal cancer;
LGG	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg03806693	chr22:41940476	POLR3H	1.08	19.39	0.67	9.63e-62	Vitiligo;
LGG	cis	rs5762813	0.561	rs5752811	chr22:29225592	C/G	cg15103426	chr22:29168792	CCDC117	-0.66	-7.03	-0.31	7.61e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs774359	0.797	rs2814708	chr9:27513716	G/C	cg14173147	chr9:27528300	MOBKL2B	0.42	8.7	0.37	5.92e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.11	-0.46	1.36e-25	Blood trace element (Zn levels);
LGG	cis	rs367943	0.712	rs1366393	chr5:112729472	A/G	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.29e-23	Type 2 diabetes;
LGG	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg25801113	chr15:45476975	SHF	-0.88	-19.27	-0.67	3.5e-61	Uric acid levels;
LGG	cis	rs8077889	0.719	rs2079006	chr17:41865745	C/G	cg26893861	chr17:41843967	DUSP3	1.04	23.68	0.74	8.67e-82	Triglycerides;
LGG	cis	rs3771570	0.901	rs35496488	chr2:242434316	G/A	cg21155796	chr2:242212141	HDLBP	0.71	9.1	0.39	2.64e-18	Prostate cancer;
LGG	cis	rs807029	0.577	rs3740489	chr10:102754238	A/G	cg04662943	chr10:102668895	NA	0.47	6.86	0.3	2.15e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-8.61	-0.37	1.17e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.56	-6.72	-0.3	5.34e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg24375607	chr4:120327624	NA	0.59	9.8	0.41	9.81e-21	Corneal astigmatism;
LGG	cis	rs3087591	0.960	rs4795593	chr17:29613600	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.57	-0.56	7.72e-40	Hip circumference;
LGG	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg13385794	chr1:248469461	NA	0.48	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg08648136	chr8:956695	NA	0.46	10.02	0.42	1.56e-21	Schizophrenia;
LGG	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg06951627	chr6:26196580	NA	0.48	7.19	0.32	2.7e-12	Gout;Renal underexcretion gout;
LGG	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9462027	0.561	rs2814972	chr6:34566975	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.55	-0.44	1.85e-23	Systemic lupus erythematosus;
LGG	cis	rs7737355	0.947	rs31585	chr5:130999082	A/G	cg06307176	chr5:131281290	NA	0.57	9.42	0.4	2.13e-19	Life satisfaction;
LGG	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.24e-12	Iron status biomarkers;
LGG	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg01657329	chr11:68192670	LRP5	-0.6	-10.73	-0.45	3.95e-24	Total body bone mineral density;
LGG	cis	rs2797369	0.570	rs2813647	chr6:101582214	G/A	cg27451362	chr6:101846650	GRIK2	0.56	8.32	0.36	1e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs1739378	chr6:126012262	C/A	cg05901451	chr6:126070800	HEY2	0.44	7.42	0.33	5.7e-13	Endometrial cancer;
LGG	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-6.92	-0.31	1.53e-11	Coronary artery disease;
LGG	cis	rs9443645	0.901	rs9352670	chr6:79584433	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg06916706	chr16:4465613	CORO7	-0.81	-14.55	-0.56	8.95e-40	Schizophrenia;
LGG	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs701145	0.585	rs1727919	chr3:153788757	G/A	cg17054900	chr3:154042577	DHX36	0.79	9.38	0.4	2.9e-19	Coronary artery disease;
LGG	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	8.04	0.35	7.51e-15	Retinal vascular caliber;
LGG	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg09699651	chr6:150184138	LRP11	0.47	8.04	0.35	7.6e-15	Lung cancer;
LGG	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg14829360	chr17:73884958	NA	-0.8	-14.45	-0.56	2.61e-39	Psoriasis;
LGG	cis	rs1978968	0.717	rs34740481	chr22:18401620	G/C	cg03078520	chr22:18463400	MICAL3	-0.51	-9.81	-0.41	9.39e-21	Presence of antiphospholipid antibodies;
LGG	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg08508325	chr11:3079039	CARS	0.42	8.06	0.35	6.55e-15	Calcium levels;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.06	-0.31	6.08e-12	Prostate cancer;
LGG	cis	rs7188861	0.768	rs12922733	chr16:11380670	C/G	cg01510278	chr16:11456238	NA	0.3	7.3	0.32	1.27e-12	HDL cholesterol;
LGG	cis	rs41005	1.000	rs12692349	chr2:8114312	G/A	cg03155496	chr2:8117019	LOC339788	-0.89	-20.08	-0.68	5.86e-65	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs11748327	0.959	rs59774773	chr5:4033785	G/C	cg01025095	chr5:4101132	NA	-0.56	-8.94	-0.38	9.63e-18	Myocardial infarction;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04564312	chr5:102456179	GIN1	-0.51	-7.46	-0.33	4.4e-13	Systemic lupus erythematosus;
LGG	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg03929089	chr4:120376271	NA	0.7	9.74	0.41	1.62e-20	Axial length;
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg06656553	chr16:89960601	TCF25	-0.71	-6.88	-0.3	1.91e-11	Skin colour saturation;
LGG	cis	rs6976053	0.541	rs314359	chr7:100411278	T/C	cg03098644	chr7:100410630	EPHB4	-0.6	-11.34	-0.47	1.73e-26	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs4330281	0.647	rs6577619	chr3:17715678	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.5	-0.33	3.25e-13	Schizophrenia;
LGG	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg06640241	chr16:89574553	SPG7	0.91	17.24	0.63	8.29e-52	Multiple myeloma (IgH translocation);
LGG	cis	rs7100689	0.646	rs7903701	chr10:82129268	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs1620921	0.511	rs2489931	chr6:161273628	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg19980929	chr12:42632907	YAF2	0.38	8.57	0.37	1.57e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs17209837	1.000	rs4148814	chr7:87091543	T/C	cg00919237	chr7:87102261	ABCB4	-0.68	-11.12	-0.46	1.24e-25	Gallbladder cancer;
LGG	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg13010199	chr12:38710504	ALG10B	-0.44	-7.88	-0.34	2.41e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6504108	0.624	rs1860862	chr17:46204836	A/C	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg13607699	chr17:42295918	UBTF	0.94	19.02	0.66	5.23e-60	Red cell distribution width;Reticulocyte count;
LGG	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg17971929	chr21:40555470	PSMG1	0.86	16.85	0.62	5.21e-50	Cognitive function;
LGG	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg03606772	chr1:152487856	CRCT1	0.29	6.72	0.3	5.29e-11	Hair morphology;
LGG	cis	rs4746818	1.000	rs10823313	chr10:70952115	G/A	cg11621586	chr10:70884670	VPS26A	1.14	20.33	0.69	4.04e-66	Left atrial antero-posterior diameter;
LGG	cis	rs7215564	0.818	rs36034584	chr17:78671478	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.08	-0.35	5.76e-15	Myopia (pathological);
LGG	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs55692411	0.537	rs62262118	chr3:50003586	G/A	cg24110177	chr3:50126178	RBM5	-0.54	-8.22	-0.36	2.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs2324843	chr6:86617501	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-14.06	-0.55	1.24e-37	Response to antipsychotic treatment;
LGG	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg14703610	chr5:56206110	C5orf35	0.42	7.15	0.32	3.45e-12	Coronary artery disease;
LGG	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg07148914	chr20:33460835	GGT7	0.57	9.44	0.4	1.87e-19	Height;
LGG	trans	rs9929218	0.954	rs2059254	chr16:68817439	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.37	-0.5	1.43e-30	Colorectal cancer;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg04529724	chr6:150244392	RAET1G	0.33	6.77	0.3	3.83e-11	Lung cancer;
LGG	cis	rs250677	1.000	rs250676	chr5:148425518	A/T	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.73	-0.34	6.53e-14	Breast cancer;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg08344181	chr3:125677491	NA	-0.69	-7.3	-0.32	1.28e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg08400814	chr5:56204995	C5orf35	0.54	7.87	0.34	2.52e-14	Initial pursuit acceleration;
LGG	cis	rs7742824	0.917	rs12526930	chr6:44104818	C/T	cg04074908	chr6:44101190	TMEM63B	0.65	13.63	0.54	8.48e-36	Major depressive disorder;
LGG	cis	rs17208368	0.574	rs72802767	chr16:55093956	T/A	cg09947736	chr16:55091198	NA	0.67	12.81	0.51	2.35e-32	Hypospadias;
LGG	cis	rs9790314	0.586	rs73021449	chr3:161128941	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-11.25	-0.46	4.05e-26	Morning vs. evening chronotype;
LGG	cis	rs5762813	0.566	rs16987027	chr22:29215703	G/A	cg15103426	chr22:29168792	CCDC117	0.67	7.2	0.32	2.52e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs258892	0.895	rs394274	chr5:72135955	C/T	cg21869765	chr5:72125136	TNPO1	0.42	6.68	0.3	7.01e-11	Small cell lung carcinoma;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg01988459	chr11:68622903	NA	-0.62	-12.63	-0.51	1.27e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg26513180	chr16:89883248	FANCA	-0.53	-9.37	-0.4	3.21e-19	Vitiligo;
LGG	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg07541023	chr7:19748670	TWISTNB	0.5	7.47	0.33	3.98e-13	Thyroid stimulating hormone;
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.33e-11	Aortic root size;
LGG	trans	rs4657015	1.000	rs4657015	chr1:161272441	A/G	cg18430411	chr8:144873183	SCRIB	-0.62	-13.36	-0.53	1.16e-34	Visceral adipose tissue adjusted for BMI;
LGG	trans	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	12.44	0.5	7.18e-31	Breast cancer;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg11494091	chr17:61959527	GH2	0.51	8.01	0.35	9.5e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg25214090	chr10:38739885	LOC399744	0.61	10.99	0.45	3.87e-25	Corneal astigmatism;
LGG	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.85	0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs7241530	0.662	rs9951456	chr18:75888704	A/G	cg14642773	chr18:75888474	NA	0.47	9.87	0.42	5.62e-21	Educational attainment (years of education);
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.33	-0.32	1.05e-12	Dementia with Lewy bodies;
LGG	cis	rs1020064	0.636	rs1529975	chr2:105929901	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.44	7.16	0.32	3.27e-12	AIDS;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23027509	chr22:50964208	TYMP;SCO2	0.46	6.83	0.3	2.61e-11	Gut microbiome composition (summer);
LGG	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg12623918	chr2:306882	NA	0.54	10.12	0.43	7e-22	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg26818257	chr2:241905806	NA	0.51	11.56	0.47	2.58e-27	Joint mobility (Beighton score);
LGG	cis	rs68170813	0.652	rs763386	chr7:107196723	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.42	-0.36	4.92e-16	Coronary artery disease;
LGG	cis	rs910187	0.678	rs6066231	chr20:45818895	C/T	cg27589058	chr20:45804311	EYA2	-0.36	-9.16	-0.39	1.64e-18	Migraine;
LGG	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg04455712	chr21:45112962	RRP1B	0.52	9.79	0.41	1.07e-20	Mean corpuscular volume;
LGG	cis	rs9522267	0.966	rs9515443	chr13:112197387	T/C	cg14952266	chr13:112191215	NA	0.36	6.68	0.3	7.02e-11	Hepatitis;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.35e-16	Testicular germ cell tumor;
LGG	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.05	-0.35	6.84e-15	HDL cholesterol;
LGG	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.73	-0.48	5.31e-28	Response to antipsychotic treatment;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg22907277	chr7:1156413	C7orf50	0.66	8.56	0.37	1.65e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg02002194	chr4:3960332	NA	0.44	8.29	0.36	1.26e-15	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg00934597	chr7:893267	UNC84A	-0.52	-8.57	-0.37	1.56e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs6460942	0.915	rs10267801	chr7:12451931	G/A	cg06484146	chr7:12443880	VWDE	-0.38	-6.78	-0.3	3.68e-11	Coronary artery disease;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.6	-0.37	1.21e-16	Personality dimensions;
LGG	cis	rs4809627	1	rs4809627	chr20:45757655	C/T	cg27589058	chr20:45804311	EYA2	-0.28	-7.24	-0.32	1.82e-12	Type 2 diabetes;
LGG	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg21401794	chr1:90099060	LRRC8C	-0.57	-11.87	-0.48	1.53e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.63	0.41	4.1e-20	Bipolar disorder;
LGG	trans	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg07393940	chr7:158741817	NA	0.56	10.42	0.44	5.67e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg08344181	chr3:125677491	NA	-0.74	-7.69	-0.34	9.11e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs889398	0.770	rs8052225	chr16:69883653	G/A	cg00738113	chr16:70207722	CLEC18C	-0.25	-6.96	-0.31	1.19e-11	Body mass index;
LGG	cis	rs9807989	0.507	rs10200952	chr2:103027651	A/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.4e-19	Asthma;
LGG	trans	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg26043149	chr18:55253948	FECH	0.4	6.75	0.3	4.31e-11	Bone mineral density;
LGG	trans	rs7507204	0.723	rs12979645	chr19:3414688	A/T	cg08382705	chr11:45687319	CHST1	-0.51	-6.75	-0.3	4.5e-11	Height;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18732869	chr19:6739680	TRIP10	0.56	6.73	0.3	5.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9913711	1.000	rs9913711	chr17:70098161	C/G	cg09344028	chr17:70110421	NA	0.42	8.18	0.36	2.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.98	-0.39	6.86e-18	HDL cholesterol;
LGG	cis	rs6882076	0.961	rs55776147	chr5:156400808	A/G	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.73	-0.48	5.3e-28	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	trans	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.49	0.4	1.25e-19	Mean corpuscular volume;
LGG	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.93e-21	Aortic root size;
LGG	trans	rs2548003	0.965	rs967079	chr5:28755993	T/C	cg12623145	chr2:97778927	ANKRD36	0.44	6.81	0.3	3.03e-11	Hip geometry;
LGG	cis	rs11971779	0.585	rs3922848	chr7:139046210	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg12651540	chr15:90191926	KIF7	-0.37	-6.82	-0.3	2.77e-11	Migraine with aura;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg14789911	chr21:47582049	C21orf56	0.45	7.35	0.32	8.98e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03517284	chr6:25882590	NA	-0.69	-13.22	-0.52	4.55e-34	Intelligence (multi-trait analysis);
LGG	cis	rs6456156	0.774	rs6930998	chr6:167526940	A/C	cg07741184	chr6:167504864	NA	-0.32	-7.17	-0.32	3.01e-12	Primary biliary cholangitis;
LGG	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg21926883	chr2:100939477	LONRF2	-0.66	-14.58	-0.56	6.49e-40	Intelligence (multi-trait analysis);
LGG	cis	rs28374715	0.578	rs13313520	chr15:41629127	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.66	-0.84	1.68e-126	Ulcerative colitis;
LGG	cis	rs745080	0.674	rs6572850	chr14:53018461	C/T	cg23333723	chr14:53022898	GPR137C	-0.31	-7.14	-0.31	3.64e-12	Orofacial clefts;
LGG	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.3	-7.02	-0.31	8.16e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4650994	0.789	rs2476559	chr1:178592919	A/G	cg19399532	chr1:178512495	C1orf220	-0.36	-6.92	-0.31	1.5e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8027181	0.617	rs28827493	chr15:73083121	G/A	cg01955962	chr15:73089536	NA	-0.4	-6.68	-0.3	6.77e-11	Triglyceride levels;
LGG	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg23034840	chr1:205782522	SLC41A1	-0.75	-8.73	-0.38	4.55e-17	Prostate-specific antigen levels;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05165339	chr4:1420672	NA	-0.29	-7.59	-0.33	1.79e-13	Longevity;
LGG	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg01169559	chr10:831247	NA	0.54	8.88	0.38	1.45e-17	Uric acid levels;
LGG	cis	rs748404	0.534	rs489509	chr15:43586907	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	7.83	0.34	3.43e-14	Lung cancer;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.24e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.07e-25	Resting heart rate;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.41	7.92	0.35	1.77e-14	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13790879	chr2:239336104	ASB1	-0.49	-7.1	-0.31	4.63e-12	Systemic lupus erythematosus;
LGG	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.7	13.75	0.54	2.62e-36	Lymphocyte percentage of white cells;
LGG	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg13482628	chr17:19912719	NA	-0.54	-10.28	-0.43	1.88e-22	Schizophrenia;
LGG	cis	rs2133450	0.679	rs28578967	chr3:7365088	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.31	-0.36	1.08e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs12615966	0.929	rs9941698	chr2:105384717	G/A	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg23335576	chr14:104009727	NA	0.42	7.15	0.32	3.33e-12	Reticulocyte count;
LGG	cis	rs11700980	0.551	rs2832033	chr21:30114841	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08280861	chr8:58055591	NA	0.56	7.02	0.31	7.94e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg14191688	chr11:70257035	CTTN	0.55	7.95	0.35	1.42e-14	Coronary artery disease;
LGG	trans	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg06606381	chr12:133084897	FBRSL1	-0.49	-6.81	-0.3	3.07e-11	Depression;
LGG	cis	rs9581857	0.685	rs17808758	chr13:28036412	C/T	cg01674679	chr13:27998804	GTF3A	-0.64	-7.29	-0.32	1.36e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs6912958	0.712	rs2787927	chr6:88412786	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.45	-7.74	-0.34	6.18e-14	Monocyte percentage of white cells;
LGG	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg17644776	chr2:200775616	C2orf69	0.58	7.17	0.32	3.05e-12	Schizophrenia;
LGG	cis	rs953492	0.672	rs1766030	chr1:243314577	C/T	cg02356786	chr1:243265016	LOC731275	-0.38	-6.79	-0.3	3.52e-11	Diastolic blood pressure;
LGG	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.93	-0.48	8.81e-29	Alzheimer's disease;
LGG	cis	rs2735413	0.875	rs12925138	chr16:78083923	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg20573242	chr4:122745356	CCNA2	0.6	11.68	0.48	8.59e-28	Type 2 diabetes;
LGG	cis	rs12893597	0.821	rs12896434	chr14:76816746	C/T	cg20290672	chr14:76816747	NA	-0.51	-7.93	-0.35	1.66e-14	Maximal oxygen uptake response;
LGG	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg09461388	chr22:46763229	CELSR1	-0.7	-7.23	-0.32	1.99e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.99	-0.42	2.07e-21	Mean corpuscular volume;
LGG	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00142150	chr22:38071001	LGALS1	0.68	10.66	0.44	6.94e-24	Fat distribution (HIV);
LGG	cis	rs1010254	0.559	rs114626875	chr5:151740939	G/A	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.73e-11	Optic nerve measurement (cup area);
LGG	cis	rs6694672	0.867	rs6679189	chr1:197100556	C/A	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.74e-12	Asthma;
LGG	cis	rs9814567	1.000	rs7356093	chr3:134238753	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.09	-0.52	1.57e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.49	-0.4	1.27e-19	Monocyte percentage of white cells;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg16359550	chr11:109292809	C11orf87	0.39	7.82	0.34	3.71e-14	Schizophrenia;
LGG	cis	rs11690935	0.550	rs55653103	chr2:172861816	T/C	cg13550731	chr2:172543902	DYNC1I2	0.64	12.37	0.5	1.5e-30	Schizophrenia;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.67	0.48	9.27e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg10560079	chr2:191398806	TMEM194B	-0.37	-8.33	-0.36	8.99e-16	Pulse pressure;
LGG	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.18	0.46	7.33e-26	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24520871	chr10:73074265	NA	0.44	6.69	0.3	6.26e-11	Gut microbiome composition (summer);
LGG	cis	rs13082711	0.595	rs17317435	chr3:27339326	A/G	cg02860705	chr3:27208620	NA	0.93	17.05	0.62	6.06e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg27490568	chr2:178487706	NA	-0.87	-15.47	-0.58	8.28e-44	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6735179	0.641	rs2382558	chr2:1752229	A/G	cg10160682	chr2:1713001	PXDN	-0.54	-9.25	-0.39	8.35e-19	Response to antipsychotic treatment;
LGG	cis	rs4639966	0.836	rs7110526	chr11:118633533	T/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.96	-0.31	1.2e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21640587	chr11:117668038	DSCAML1	0.92	15.31	0.58	4.36e-43	Myopia;
LGG	cis	rs34929064	0.536	rs2961278	chr7:22634779	C/G	cg23521230	chr7:22704884	NA	0.53	9.43	0.4	2.03e-19	Major depression and alcohol dependence;
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Electroencephalogram traits;
LGG	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs888194	0.738	rs731178	chr12:109981678	C/T	cg19025524	chr12:109796872	NA	-0.35	-6.93	-0.31	1.44e-11	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22704520	chr2:200820451	C2orf60;C2orf47	0.51	8.45	0.37	3.78e-16	Cognitive performance;
LGG	cis	rs9972944	0.729	rs7211481	chr17:63766434	A/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.27	-0.36	1.46e-15	Total body bone mineral density;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.65	0.48	1.08e-27	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg11366901	chr6:160182831	ACAT2	1.08	16.69	0.61	2.52e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg14926445	chr8:58193284	C8orf71	-0.87	-13.12	-0.52	1.19e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9393777	0.513	rs7759969	chr6:26663096	T/A	cg12826209	chr6:26865740	GUSBL1	0.82	12.34	0.5	1.9e-30	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	1.000	rs76889265	chr6:27008835	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08663953	chr5:72804550	NA	0.36	6.72	0.3	5.42e-11	Menarche (age at onset);
LGG	trans	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg25214090	chr10:38739885	LOC399744	0.42	7.76	0.34	5.36e-14	Diastolic blood pressure;
LGG	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg06618935	chr21:46677482	NA	-0.46	-8.99	-0.39	6.24e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg01238044	chr22:24384105	GSTT1	0.58	10.04	0.42	1.38e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs5756813	0.646	rs875300	chr22:38157805	A/G	cg19894588	chr14:64061835	NA	0.44	7.37	0.32	7.72e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.18	-0.32	2.8e-12	Pancreatic cancer;
LGG	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.79	0.34	4.49e-14	Homoarginine levels;
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.47	0.37	3.26e-16	Bipolar disorder;
LGG	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg07661805	chr8:143867942	LY6D	0.3	8.0	0.35	1e-14	Urinary tract infection frequency;
LGG	trans	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg13565492	chr6:43139072	SRF	-0.74	-9.0	-0.39	5.85e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg15557168	chr22:42548783	NA	-0.39	-8.43	-0.36	4.28e-16	Schizophrenia;
LGG	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg21775007	chr8:11205619	TDH	-0.79	-13.61	-0.53	1.04e-35	Retinal vascular caliber;
LGG	trans	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.71	0.41	2.11e-20	Mean corpuscular volume;
LGG	cis	rs2652834	0.851	rs2652820	chr15:63430901	T/C	cg05507819	chr15:63340323	TPM1	0.5	7.12	0.31	4.24e-12	HDL cholesterol;
LGG	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg02187348	chr16:89574699	SPG7	-0.46	-7.48	-0.33	3.85e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7927771	0.832	rs10769262	chr11:47411581	G/A	cg20307385	chr11:47447363	PSMC3	0.57	10.36	0.43	9.33e-23	Subjective well-being;
LGG	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg10847948	chr11:71163743	NADSYN1	-0.56	-9.81	-0.41	9.24e-21	Vitamin D levels;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.75	-12.71	-0.51	5.83e-32	Alzheimer's disease;
LGG	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg22907277	chr7:1156413	C7orf50	0.82	11.83	0.48	2.18e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6456156	0.792	rs7775443	chr6:167513252	A/C	cg07741184	chr6:167504864	NA	-0.4	-8.86	-0.38	1.67e-17	Primary biliary cholangitis;
LGG	cis	rs747650	0.892	rs2029298	chr11:47234718	C/T	cg03339077	chr11:47165057	C11orf49	-0.53	-10.14	-0.43	6.11e-22	Acne (severe);
LGG	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27511599	chr7:32358540	NA	0.64	7.12	0.31	4.18e-12	Body mass index;
LGG	cis	rs12543645	0.609	rs35112858	chr8:10277269	C/T	cg12940923	chr8:10282607	MSRA	0.3	7.18	0.32	2.88e-12	Schizophrenia;
LGG	cis	rs2239547	0.657	rs4687672	chr3:52880543	G/A	cg11645453	chr3:52864694	ITIH4	0.72	11.19	0.46	6.64e-26	Schizophrenia;
LGG	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.38	0.43	7.63e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.93	-0.31	1.44e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06873352	chr17:61820015	STRADA	-0.74	-13.88	-0.54	7.36e-37	Prudent dietary pattern;
LGG	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.61	0.37	1.12e-16	Systemic lupus erythematosus;
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.87	-0.34	2.46e-14	Total body bone mineral density;
LGG	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26734620	chr12:56694298	CS	-0.83	-7.88	-0.34	2.34e-14	Psoriasis vulgaris;
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.34	-0.36	8.75e-16	Bipolar disorder;
LGG	cis	rs73086581	1.000	rs6052220	chr20:3970594	C/T	cg02187196	chr20:3869020	PANK2	0.78	10.99	0.46	3.85e-25	Response to antidepressants in depression;
LGG	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg05985134	chr18:33552581	C18orf21	0.63	9.99	0.42	1.99e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs11748327	0.580	rs10068959	chr5:4011549	G/A	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.01e-12	Myocardial infarction;
LGG	cis	rs1035144	0.785	rs12323356	chr14:81464279	A/G	cg06600135	chr14:81408086	NA	0.37	6.91	0.31	1.58e-11	Male sexual orientation;
LGG	cis	rs12410462	0.636	rs7413796	chr1:227741423	A/G	cg04117972	chr1:227635322	NA	0.48	8.68	0.37	6.55e-17	Major depressive disorder;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg21782813	chr7:2030301	MAD1L1	0.4	9.23	0.39	9.98e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg01324343	chr3:183735012	ABCC5	0.66	12.73	0.51	4.92e-32	Anterior chamber depth;
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.4	-0.36	5.6e-16	Aortic root size;
LGG	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg08297393	chr2:100937505	LONRF2	-0.59	-10.21	-0.43	3.41e-22	Intelligence (multi-trait analysis);
LGG	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg01620082	chr3:125678407	NA	-0.65	-7.08	-0.31	5.28e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2373794	0.961	rs2160365	chr2:40354571	C/G	cg17740179	chr2:40377776	SLC8A1	0.94	20.0	0.68	1.41e-64	Asthma;
LGG	cis	rs7928758	0.945	rs56330625	chr11:134280067	G/A	cg25213107	chr11:134282864	B3GAT1	0.99	11.76	0.48	4.08e-28	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs7666738	0.830	rs9307218	chr4:99024885	T/C	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.39e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg14668632	chr7:2872130	GNA12	0.34	7.11	0.31	4.52e-12	Height;
LGG	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg04568710	chr12:38710424	ALG10B	0.39	8.3	0.36	1.14e-15	Morning vs. evening chronotype;
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg06916706	chr16:4465613	CORO7	-0.72	-12.39	-0.5	1.22e-30	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.84	-0.42	7.33e-21	Lung cancer;
LGG	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg27411982	chr8:10470053	RP1L1	0.42	7.12	0.31	4.16e-12	Mood instability;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.41	6.66	0.3	7.75e-11	Prudent dietary pattern;
LGG	cis	rs7188861	0.813	rs1974882	chr16:11446480	T/G	cg01510278	chr16:11456238	NA	-0.34	-7.9	-0.34	2.12e-14	HDL cholesterol;
LGG	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg21435375	chr2:172878103	MAP1D	-0.31	-7.06	-0.31	6.3e-12	Schizophrenia;
LGG	cis	rs9815354	1.000	rs17063584	chr3:41861463	A/G	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05665937	chr4:1216051	CTBP1	0.54	10.03	0.42	1.51e-21	Obesity-related traits;
LGG	cis	rs6909430	0.901	rs7766224	chr6:98744693	A/T	cg12860156	chr6:98744658	NA	-0.48	-7.93	-0.35	1.6e-14	Quantitative traits;
LGG	cis	rs2050392	0.590	rs685319	chr10:30719331	G/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.32	-0.5	2.26e-30	Inflammatory bowel disease;
LGG	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg08704250	chr15:31115839	NA	0.51	9.16	0.39	1.73e-18	Huntington's disease progression;
LGG	cis	rs4740619	0.619	rs943789	chr9:16031951	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.83e-26	Body mass index;
LGG	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg25801113	chr15:45476975	SHF	0.86	19.6	0.67	1.04e-62	Uric acid levels;
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg02002194	chr4:3960332	NA	0.42	7.75	0.34	5.94e-14	Neuroticism;
LGG	cis	rs308971	0.656	rs307582	chr3:12085149	T/C	cg15873301	chr3:12045459	SYN2	0.54	7.86	0.34	2.76e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg15733309	chr7:157513707	PTPRN2	0.62	15.02	0.57	7.93e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs7011049	1.000	rs72643576	chr8:53845016	A/T	cg26025543	chr8:53854495	NA	0.74	9.89	0.42	4.69e-21	Systolic blood pressure;
LGG	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg15704280	chr7:45808275	SEPT13	0.81	13.16	0.52	8.32e-34	Coronary artery disease;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg18032289	chr17:61959525	GH2	-0.42	-7.24	-0.32	1.88e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12210905	1.000	rs5030955	chr6:27213867	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.62	-7.11	-0.31	4.5e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg03788504	chr6:150331562	NA	-0.56	-12.54	-0.5	3.06e-31	Alopecia areata;
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg16301924	chr13:53314226	LECT1	-0.48	-10.0	-0.42	1.84e-21	Lewy body disease;
LGG	cis	rs13082711	0.911	rs66694067	chr3:27477337	C/T	cg02860705	chr3:27208620	NA	0.73	13.17	0.52	7.03e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs72960926	0.744	rs9360792	chr6:75128956	G/C	cg03266952	chr6:74778945	NA	-0.63	-6.72	-0.3	5.52e-11	Metabolite levels (MHPG);
LGG	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg25358565	chr5:93447407	FAM172A	1.36	14.49	0.56	1.6e-39	Diabetic retinopathy;
LGG	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg24623649	chr8:11872141	NA	-0.28	-6.72	-0.3	5.46e-11	Systolic blood pressure;
LGG	cis	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.46	3.63e-26	Morning vs. evening chronotype;
LGG	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.8	0.54	1.58e-36	IgG glycosylation;
LGG	cis	rs9460578	0.537	rs6938757	chr6:20823506	A/G	cg13405222	chr6:20811065	CDKAL1	0.75	17.0	0.62	1e-50	Breast cancer;
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg18404041	chr3:52824283	ITIH1	0.55	10.35	0.43	9.96e-23	Bipolar disorder;
LGG	cis	rs9309473	0.528	rs10191517	chr2:73558403	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-8.08	-0.35	5.52e-15	Metabolite levels;
LGG	trans	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg11441553	chr12:57614120	NXPH4	-0.62	-7.77	-0.34	5.22e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7129556	0.520	rs4944164	chr11:77275849	G/A	cg12586386	chr11:77299805	AQP11	0.39	6.87	0.3	2.1e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg00034003	chr16:88779146	CTU2	0.46	7.62	0.33	1.49e-13	Autism spectrum disorder-related traits;
LGG	cis	rs7808935	0.581	rs6968704	chr7:27966984	C/T	cg22168087	chr7:27702803	HIBADH	0.54	8.9	0.38	1.25e-17	Prostate cancer;
LGG	cis	rs7241530	0.717	rs28445036	chr18:75889191	G/A	cg14642773	chr18:75888474	NA	0.46	9.38	0.4	2.9e-19	Educational attainment (years of education);
LGG	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg11984989	chr7:158649758	WDR60	1.01	14.02	0.55	1.78e-37	Height;
LGG	trans	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg22358067	chr17:16797159	NA	0.51	7.17	0.32	3.06e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00166722	chr3:10149974	C3orf24	0.56	9.39	0.4	2.71e-19	Alzheimer's disease;
LGG	trans	rs140364877	1	rs140364877	chr7:1885178	C/T	cg24247370	chr13:99142703	STK24	-0.43	-7.85	-0.34	2.94e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg06917634	chr15:78832804	PSMA4	-0.64	-9.7	-0.41	2.24e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg23758822	chr17:41437982	NA	0.89	15.7	0.59	7.44e-45	Menopause (age at onset);
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs41271951	0.512	rs6664387	chr1:151021509	A/G	cg11822372	chr1:151115635	SEMA6C	-0.68	-7.04	-0.31	6.96e-12	Blood protein levels;
LGG	trans	rs9354308	0.764	rs9345712	chr6:66591479	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs10207628	0.941	rs17014923	chr2:127841930	A/G	cg06223080	chr2:127868745	NA	0.72	13.11	0.52	1.32e-33	Psychosis and Alzheimer's disease;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.89	-0.34	2.13e-14	Neuroticism;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.39	0.63	1.64e-52	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg01206211	chr2:36825736	FEZ2	0.46	8.36	0.36	7.3e-16	Height;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg02951883	chr7:2050386	MAD1L1	-0.78	-16.07	-0.6	1.61e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs8028182	0.636	rs6495182	chr15:75814388	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.48	0.33	3.71e-13	Sudden cardiac arrest;
LGG	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg14088196	chr11:70211408	PPFIA1	0.96	12.94	0.52	6.62e-33	Coronary artery disease;
LGG	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg15394860	chr11:2017084	H19	0.57	11.98	0.49	5.3e-29	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1669338	0.588	rs62228634	chr3:3184985	A/G	cg16797762	chr3:3221439	CRBN	-0.91	-12.17	-0.49	9.12e-30	White matter integrity;
LGG	cis	rs1372520	1.000	rs1372520	chr4:90757505	T/C	cg15133208	chr4:90757351	SNCA	-0.42	-8.43	-0.36	4.41e-16	Neuroticism;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg11584989	chr19:19387371	SF4	0.4	7.25	0.32	1.81e-12	Tonsillectomy;
LGG	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.36	-0.5	1.65e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg09307838	chr4:120376055	NA	0.8	13.51	0.53	2.7900000000000003e-35	Corneal astigmatism;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07659893	chr17:61819838	STRADA	-0.47	-7.75	-0.34	5.82e-14	Prudent dietary pattern;
LGG	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.56	-0.5	2.32e-31	Colorectal cancer;
LGG	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg04989706	chr14:50066350	PPIL5	-0.53	-8.14	-0.35	3.57e-15	Carotid intima media thickness;
LGG	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.68e-19	Menarche (age at onset);
LGG	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg07636037	chr3:49044803	WDR6	0.45	6.84	0.3	2.55e-11	Resting heart rate;
LGG	cis	rs10421328	0.848	rs10423449	chr19:19755946	G/A	cg11584989	chr19:19387371	SF4	0.51	7.43	0.33	5.35e-13	Parental longevity (combined parental age at death);
LGG	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg13010199	chr12:38710504	ALG10B	-0.6	-11.54	-0.47	3.03e-27	Morning vs. evening chronotype;
LGG	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg26384229	chr12:38710491	ALG10B	-0.88	-19.85	-0.68	6.78e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg02733842	chr7:1102375	C7orf50	0.62	9.68	0.41	2.61e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg16662043	chr16:48846231	NA	-0.35	-6.96	-0.31	1.16e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg02772935	chr3:125709198	NA	-0.53	-6.71	-0.3	5.55e-11	Blood pressure (smoking interaction);
LGG	cis	rs4356932	1.000	rs7688306	chr4:76982046	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.91	-0.31	1.62e-11	Blood protein levels;
LGG	cis	rs2251666	0.630	rs4786555	chr16:4951463	T/G	cg08329684	chr16:4932620	PPL	-0.42	-6.99	-0.31	9.45e-12	Cancer;
LGG	cis	rs721399	0.719	rs4646254	chr8:18262059	A/G	cg18736775	chr8:18248649	NAT2	-0.77	-12.31	-0.5	2.63e-30	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg13385521	chr17:29058706	SUZ12P	0.91	10.65	0.44	7.56e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35883536	0.588	rs10465764	chr1:101105030	A/G	cg06223162	chr1:101003688	GPR88	0.34	7.86	0.34	2.76e-14	Monocyte count;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg03395511	chr6:291903	DUSP22	-0.67	-11.48	-0.47	5.13e-27	Menopause (age at onset);
LGG	cis	rs12410462	0.591	rs2819508	chr1:227704184	G/A	cg04117972	chr1:227635322	NA	0.46	8.4	0.36	5.32e-16	Major depressive disorder;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs7267979	0.739	rs6138555	chr20:25242910	G/A	cg08601574	chr20:25228251	PYGB	0.37	7.72	0.34	7.43e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6764363	0.683	rs6798880	chr3:298819	A/C	cg02057681	chr3:285234	CHL1	0.39	6.92	0.31	1.52e-11	Sudden cardiac arrest;
LGG	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg06495924	chr8:145149574	CYC1	-0.87	-7.08	-0.31	5.54e-12	Blood metabolite levels;
LGG	cis	rs7927771	0.698	rs34467936	chr11:47915299	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-9.08	-0.39	3.15e-18	Subjective well-being;
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg16141378	chr3:129829833	LOC729375	0.43	10.09	0.42	8.85e-22	Neuroticism;
LGG	cis	rs9513627	1.000	rs9517758	chr13:100179397	T/A	cg25919922	chr13:100150906	NA	0.73	7.72	0.34	7.28e-14	Obesity-related traits;
LGG	cis	rs4959677	0.935	rs2325965	chr6:2493314	A/T	cg20147862	chr6:2634573	C6orf195	-0.4	-8.6	-0.37	1.28e-16	Orthostatic hypotension;
LGG	cis	rs7209395	1.000	rs7209395	chr17:64133726	T/C	cg19474267	chr17:64306194	PRKCA	0.51	7.97	0.35	1.25e-14	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg01988459	chr11:68622903	NA	-0.6	-12.39	-0.5	1.23e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg11764359	chr7:65958608	NA	-0.6	-9.04	-0.39	4.45e-18	Aortic root size;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg19318889	chr4:1322082	MAEA	0.48	8.29	0.36	1.2e-15	Longevity;
LGG	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg10503236	chr1:231470652	EXOC8	-0.35	-6.71	-0.3	5.7e-11	Hemoglobin concentration;
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg24623649	chr8:11872141	NA	-0.32	-7.55	-0.33	2.37e-13	Triglycerides;
LGG	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.71	0.41	2e-20	Height;
LGG	cis	rs7095944	0.614	rs11245354	chr10:126450125	C/A	cg08799069	chr10:126477246	METTL10	-0.5	-11.51	-0.47	3.9e-27	Asthma;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.31	0.47	2.29e-26	Tonsillectomy;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.47	-0.33	4.15e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7523273	0.627	rs2724389	chr1:207933648	T/C	cg22525895	chr1:207977042	MIR29B2	0.6	11.88	0.48	1.33e-28	Schizophrenia;
LGG	cis	rs11718455	0.960	rs13081767	chr3:44004468	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.73	-0.3	4.95e-11	Coronary artery disease;
LGG	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg13939156	chr17:80058883	NA	-0.41	-7.2	-0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg00646200	chr1:148855367	NA	0.56	10.95	0.45	5.79e-25	Hip geometry;
LGG	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg08885076	chr2:99613938	TSGA10	0.39	8.37	0.36	6.9e-16	Chronic sinus infection;
LGG	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg15038512	chr6:170123185	PHF10	0.59	10.36	0.43	9.21e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.85	0.38	1.83e-17	Neuroticism;
LGG	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg25319279	chr11:5960081	NA	-0.46	-7.17	-0.32	2.96e-12	DNA methylation (variation);
LGG	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg06766960	chr11:133703094	NA	-0.55	-11.06	-0.46	2.14e-25	Childhood ear infection;
LGG	cis	rs4774899	0.966	rs12904189	chr15:57549515	C/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.42	-0.33	5.79e-13	Urinary tract infection frequency;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg11494091	chr17:61959527	GH2	0.51	7.75	0.34	5.99e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07701084	chr6:150067640	NUP43	0.62	11.7	0.48	7.22e-28	Lung cancer;
LGG	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg26384229	chr12:38710491	ALG10B	0.8	15.53	0.59	4.27e-44	Morning vs. evening chronotype;
LGG	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg25486957	chr4:152246857	NA	-0.52	-8.62	-0.37	1.1e-16	Intelligence (multi-trait analysis);
LGG	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg11812906	chr14:75593930	NEK9	0.53	10.14	0.43	6.03e-22	Height;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.27	0.32	1.53e-12	Schizophrenia;
LGG	cis	rs977987	0.843	rs10514396	chr16:75422903	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.35	0.43	9.81e-23	Dupuytren's disease;
LGG	cis	rs11608355	0.545	rs9943724	chr12:109902903	G/A	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.03	16.24	0.6	2.81e-47	Platelet count;
LGG	cis	rs68170813	0.559	rs58319984	chr7:106965794	G/A	cg02696742	chr7:106810147	HBP1	-0.71	-10.3	-0.43	1.54e-22	Coronary artery disease;
LGG	cis	rs6909430	0.901	rs2505065	chr6:98597809	G/A	cg12860156	chr6:98744658	NA	-0.45	-7.54	-0.33	2.47e-13	Quantitative traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03602124	chr1:113258101	PPM1J	0.59	6.78	0.3	3.75e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.28	0.5	3.32e-30	Corneal astigmatism;
LGG	cis	rs1790761	0.505	rs34721562	chr11:67312708	T/C	cg09038676	chr11:67351608	GSTP1	0.34	6.74	0.3	4.84e-11	Mean corpuscular volume;
LGG	cis	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg08930214	chr7:62859557	LOC100287834	0.44	7.08	0.31	5.36e-12	Obesity-related traits;
LGG	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.11	0.72	1.75e-74	Bladder cancer;
LGG	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.89	-0.3	1.86e-11	Blood metabolite levels;
LGG	cis	rs17023223	0.581	rs12064109	chr1:119642296	T/C	cg05756136	chr1:119680316	WARS2	-0.42	-7.76	-0.34	5.62e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg06521331	chr12:34319734	NA	0.51	9.36	0.4	3.4e-19	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg16507663	chr6:150244633	RAET1G	0.41	7.62	0.33	1.4e-13	Lung cancer;
LGG	cis	rs4969178	0.965	rs938351	chr17:76399404	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.42	-0.56	3.2e-39	HDL cholesterol levels;
LGG	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-7.73	-0.34	6.98e-14	Subjective well-being;
LGG	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg25358565	chr5:93447407	FAM172A	1.35	16.44	0.61	3.48e-48	Diabetic retinopathy;
LGG	trans	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg06521331	chr12:34319734	NA	0.49	8.42	0.36	4.79e-16	Bladder cancer;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04008888	chr11:68622739	NA	-0.57	-11.82	-0.48	2.28e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7551222	0.749	rs11240764	chr1:204569376	A/G	cg20240347	chr1:204465584	NA	-0.45	-8.59	-0.37	1.36e-16	Schizophrenia;
LGG	cis	rs6800768	0.633	rs826372	chr3:24163705	T/C	cg10674438	chr3:24145617	LOC152024	-0.51	-9.36	-0.4	3.56e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4888262	0.545	rs4072450	chr16:74666634	G/C	cg01733217	chr16:74700730	RFWD3	0.9	18.26	0.65	1.63e-56	Testicular germ cell tumor;
LGG	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.81	-0.41	9.26e-21	Joint mobility (Beighton score);
LGG	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	11.1	0.46	1.5e-25	Lung cancer in ever smokers;
LGG	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg03806693	chr22:41940476	POLR3H	-0.99	-17.66	-0.63	9.64e-54	Vitiligo;
LGG	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06470251	chr20:60548479	NA	0.42	7.31	0.32	1.22e-12	Body mass index;
LGG	cis	rs11785693	0.602	rs73190403	chr8:4954798	T/C	cg26367366	chr8:4980734	NA	0.77	10.37	0.43	8.4e-23	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs12286929	0.639	rs10891802	chr11:115043888	C/A	cg04055981	chr11:115044050	NA	0.37	6.77	0.3	3.81e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.11	-0.43	7.67e-22	Morning vs. evening chronotype;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20188282	chr9:135906200	GTF3C5	0.41	7.36	0.32	8.37e-13	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs757278	0.526	rs1366912	chr7:117316601	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.57	0.33	1.99e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7444	0.941	rs5754422	chr22:21980257	A/G	cg05046821	chr22:21984468	YDJC	-0.37	-6.67	-0.3	7.45e-11	Systemic lupus erythematosus;
LGG	cis	rs7226408	0.749	rs72892525	chr18:34670741	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.14	-0.31	3.71e-12	Obesity-related traits;
LGG	cis	rs172166	0.694	rs203893	chr6:28062066	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.13	-0.31	3.98e-12	Cardiac Troponin-T levels;
LGG	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs9297145	0.585	rs10953283	chr7:98782750	A/G	cg05967295	chr7:98741636	SMURF1	0.63	11.38	0.47	1.29e-26	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-10.84	-0.45	1.46e-24	Parkinson's disease;
LGG	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg23335576	chr14:104009727	NA	0.52	9.21	0.39	1.18e-18	Reticulocyte count;
LGG	cis	rs742614	0.533	rs2747536	chr20:32404128	C/G	cg06304546	chr20:32448765	NA	-0.7	-13.97	-0.54	2.98e-37	Stearic acid (18:0) levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07609388	chr8:89341103	MMP16	0.54	8.53	0.37	2.07e-16	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.34	0.36	8.81e-16	Bipolar disorder;
LGG	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	15.22	0.58	1.06e-42	Menarche (age at onset);
LGG	cis	rs3845702	0.866	rs818659	chr2:180870893	G/A	cg01881094	chr2:180872142	CWC22	0.93	14.33	0.55	8.35e-39	Schizophrenia;
LGG	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.36	0.32	8.25e-13	Neutrophil percentage of white cells;
LGG	trans	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.88	0.34	2.44e-14	Mood instability;
LGG	cis	rs7193541	0.694	rs8061942	chr16:74691362	C/T	cg01733217	chr16:74700730	RFWD3	1.1	35.2	0.85	5.69e-133	Multiple myeloma;
LGG	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg21772509	chr8:41503840	NKX6-3	0.87	19.6	0.67	9.99e-63	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.14	-0.31	3.6e-12	Schizophrenia;
LGG	cis	rs9393813	1.000	rs13220817	chr6:27356527	T/C	cg18711553	chr6:27366782	ZNF391	-0.51	-9.32	-0.4	4.66e-19	Bipolar disorder;
LGG	cis	rs6686643	0.762	rs6672982	chr1:165612815	T/A	cg19407955	chr1:165599744	MGST3	-0.62	-8.93	-0.38	1.03e-17	Total ventricular volume;
LGG	trans	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.4	0.4	2.49e-19	Neuroticism;
LGG	cis	rs11168618	1.000	rs10875833	chr12:48953368	C/T	cg24011408	chr12:48396354	COL2A1	0.48	7.74	0.34	6.11e-14	Adiponectin levels;
LGG	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.94	0.49	7.81e-29	Rheumatoid arthritis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16513467	chr10:28822500	WAC	0.4	6.66	0.3	7.65e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs8018967	0.622	rs2041073	chr14:73972535	C/T	cg10076968	chr14:74006090	HEATR4;ACOT1	-0.29	-6.98	-0.31	1.02e-11	Blood metabolite ratios;
LGG	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.28	-39.18	-0.88	3.95e-149	Chronic sinus infection;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg23958373	chr8:599963	NA	1.18	11.85	0.48	1.85e-28	IgG glycosylation;
LGG	trans	rs1032833	0.732	rs16866673	chr2:180048294	G/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs13033859	0.655	rs10171965	chr2:199144	G/A	cg21211680	chr2:198530	NA	0.45	7.19	0.32	2.57e-12	Mitochondrial DNA levels;
LGG	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	13.3	0.53	2.09e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.83	0.34	3.25e-14	Depressive symptoms;
LGG	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg02503808	chr4:7069936	GRPEL1	0.91	12.85	0.51	1.59e-32	Monocyte percentage of white cells;
LGG	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg05425664	chr17:57184151	TRIM37	0.71	11.55	0.47	2.63e-27	Intelligence (multi-trait analysis);
LGG	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.35	-0.32	8.78e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg14668632	chr7:2872130	GNA12	-0.37	-7.58	-0.33	1.92e-13	Height;
LGG	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg00277334	chr10:82204260	NA	-0.38	-8.34	-0.36	8.75e-16	Post bronchodilator FEV1;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg03351412	chr1:154909251	PMVK	0.66	12.31	0.5	2.63e-30	Prostate cancer;
LGG	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.23	0.32	2.06e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.48	-0.33	3.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg25173405	chr17:45401733	C17orf57	-0.5	-8.58	-0.37	1.45e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg16141378	chr3:129829833	LOC729375	-0.48	-10.9	-0.45	8.82e-25	Red cell distribution width;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg02462569	chr6:150064036	NUP43	-0.39	-8.45	-0.37	3.91e-16	Lung cancer;
LGG	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg24675658	chr1:53192096	ZYG11B	0.51	10.4	0.44	6.53e-23	Monocyte count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05452345	chr5:102455768	GIN1	-0.48	-7.32	-0.32	1.09e-12	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs478881	0.510	rs573929	chr11:134106675	A/G	cg23319012	chr11:134007935	JAM3	0.47	7.33	0.32	1.02e-12	Obesity-related traits;
LGG	trans	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg05926928	chr17:57297772	GDPD1	0.57	9.34	0.4	4.16e-19	Schizophrenia;
LGG	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg15557168	chr22:42548783	NA	0.41	8.9	0.38	1.28e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9354308	0.764	rs9453471	chr6:66598984	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.4	6.89	0.3	1.78e-11	Metabolite levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01013600	chr19:49141177	DBP;SEC1	0.39	6.66	0.3	7.91e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg27411982	chr8:10470053	RP1L1	0.46	7.9	0.34	1.98e-14	Retinal vascular caliber;
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg24250549	chr1:154909240	PMVK	0.7	13.81	0.54	1.37e-36	Prostate cancer;
LGG	cis	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.65	-0.37	8.83e-17	Triglycerides;
LGG	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg25358565	chr5:93447407	FAM172A	1.36	16.55	0.61	1.17e-48	Diabetic retinopathy;
LGG	cis	rs11920090	0.722	rs5404	chr3:170724955	A/G	cg09710316	chr3:170744871	SLC2A2	-0.67	-8.9	-0.38	1.28e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.77	-0.38	3.5e-17	Aortic root size;
LGG	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg07243736	chr16:783730	NARFL	0.61	10.38	0.43	7.68e-23	Height;
LGG	cis	rs1805008	0.568	rs118174802	chr16:90143567	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.94	-7.13	-0.31	3.78e-12	Skin colour saturation;
LGG	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg21827317	chr3:136751795	NA	0.47	8.42	0.36	4.76e-16	Gestational age at birth (child effect);
LGG	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg25866889	chr13:114914595	NA	-0.35	-6.98	-0.31	1.02e-11	Schizophrenia;
LGG	cis	rs11785693	0.862	rs17351027	chr8:4987098	A/G	cg26367366	chr8:4980734	NA	-0.97	-15.46	-0.58	8.68e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg17133734	chr15:86042851	AKAP13	-0.28	-6.79	-0.3	3.44e-11	Coronary artery disease;
LGG	cis	rs9796	0.870	rs28501589	chr15:41282534	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.1	-0.35	4.97e-15	Menopause (age at onset);
LGG	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg03733263	chr8:22462867	KIAA1967	1.05	27.06	0.78	2.07e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg18898632	chr2:242989856	NA	-0.81	-10.05	-0.42	1.23e-21	Obesity-related traits;
LGG	cis	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg07460842	chr6:66804631	NA	0.57	9.47	0.4	1.41e-19	Metabolite levels;
LGG	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg08344181	chr3:125677491	NA	0.61	7.15	0.32	3.51e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.05	-0.42	1.24e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.83e-11	Aortic root size;
LGG	cis	rs151234	0.676	rs508022	chr16:28573963	C/T	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.94	-0.42	3.01e-21	Platelet distribution width;
LGG	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg25811766	chr13:21894605	NA	-0.57	-7.48	-0.33	3.78e-13	White matter hyperintensity burden;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.49	-0.33	3.62e-13	Neuroticism;
LGG	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg01631408	chr1:248437212	OR2T33	-0.56	-10.12	-0.43	7.09e-22	Common traits (Other);
LGG	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.22	-0.39	1.01e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg05484508	chr16:89589025	SPG7	0.53	8.37	0.36	6.66e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg15309053	chr8:964076	NA	0.33	6.79	0.3	3.49e-11	Schizophrenia;
LGG	trans	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg06521331	chr12:34319734	NA	-0.44	-8.0	-0.35	9.9e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2236267	0.693	rs2755080	chr14:88595886	A/G	cg02175263	chr14:88627849	NA	0.31	7.03	0.31	7.4e-12	Food antigen IgG levels;
LGG	cis	rs3789045	0.560	rs1008833	chr1:204426295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.58	-10.4	-0.44	6.71e-23	Educational attainment (college completion);
LGG	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg07922204	chr17:28395674	EFCAB5	0.64	6.75	0.3	4.55e-11	Airflow obstruction;
LGG	cis	rs713587	0.571	rs564667	chr2:25310860	A/T	cg04586622	chr2:25135609	ADCY3	-0.27	-6.94	-0.31	1.36e-11	Body mass index in non-asthmatics;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg04861929	chr11:109293070	C11orf87	0.49	8.26	0.36	1.58e-15	Schizophrenia;
LGG	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.67	0.48	9.62e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.52	0.63	4.35e-53	Platelet count;
LGG	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg01864069	chr14:103024347	NA	0.46	8.06	0.35	6.63e-15	Platelet count;
LGG	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg03606772	chr1:152487856	CRCT1	0.31	7.35	0.32	9.01e-13	Hair morphology;
LGG	cis	rs9341835	0.518	rs9361816	chr6:64174439	T/A	cg00787780	chr6:64151745	NA	0.41	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs975722	0.569	rs2188556	chr7:116978741	C/T	cg10524701	chr7:117356490	CTTNBP2	0.37	8.04	0.35	7.72e-15	Coronary artery disease;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02825527	chr7:2087843	MAD1L1	-0.41	-7.98	-0.35	1.17e-14	Neuroticism;
LGG	trans	rs12545912	0.909	rs12676827	chr8:9581432	C/G	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg18681998	chr4:17616180	MED28	0.83	18.39	0.65	4.19e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs721917	0.506	rs2758539	chr10:81654436	G/A	cg25562619	chr10:81652821	NA	-0.35	-8.1	-0.35	4.92e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg04672837	chr16:48644449	N4BP1	-0.53	-8.82	-0.38	2.26e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4356203	0.905	rs615358	chr11:17210432	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-6.99	-0.31	9.92e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg06521331	chr12:34319734	NA	-0.5	-8.87	-0.38	1.54e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2769264	0.505	rs11801791	chr1:151387508	C/T	cg18801370	chr1:151430492	POGZ	0.85	14.19	0.55	3.47e-38	Blood trace element (Cu levels);
LGG	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg06138931	chr13:21896616	NA	-0.47	-7.62	-0.33	1.4e-13	White matter hyperintensity burden;
LGG	cis	rs9534288	0.797	rs2148414	chr13:46582368	G/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.52e-12	Schizophrenia;
LGG	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg08344181	chr3:125677491	NA	-0.79	-8.22	-0.36	2.13e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.81	-0.38	2.5e-17	HDL cholesterol;
LGG	cis	rs2117029	0.586	rs7957998	chr12:49574023	A/C	cg24176009	chr12:49580217	TUBA1A	0.66	12.78	0.51	3.07e-32	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs897117	chr3:40437294	C/T	cg13683864	chr3:40499215	RPL14	0.97	20.23	0.69	1.11e-65	Renal cell carcinoma;
LGG	trans	rs4942242	0.663	rs34595450	chr13:44221245	A/G	cg19169023	chr15:41853346	TYRO3	-0.44	-8.8	-0.38	2.67e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Electroencephalogram traits;
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg27121462	chr16:89883253	FANCA	0.62	11.2	0.46	6.46e-26	Vitiligo;
LGG	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg08344181	chr3:125677491	NA	-0.67	-7.56	-0.33	2.13e-13	Depression;
LGG	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg02428538	chr16:24856791	SLC5A11	-0.7	-10.81	-0.45	1.98e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg13880726	chr7:1868755	MAD1L1	0.39	6.99	0.31	9.6e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00149659	chr3:10157352	C3orf10	0.83	10.68	0.44	5.84e-24	Alzheimer's disease;
LGG	trans	rs1941687	0.797	rs1493917	chr18:31392833	G/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg08888203	chr3:10149979	C3orf24	0.55	8.04	0.35	7.6e-15	Alzheimer's disease;
LGG	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.43	-0.61	3.87e-48	Height;
LGG	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg00262122	chr8:11665843	FDFT1	-0.42	-6.74	-0.3	4.73e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7463659	1.000	rs7463659	chr8:135432140	T/C	cg09855544	chr8:135498122	ZFAT	-0.44	-7.88	-0.34	2.44e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg18357526	chr6:26021779	HIST1H4A	0.83	15.93	0.6	6.83e-46	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.958	rs35051046	chr14:71849308	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.9	-0.38	1.28e-17	Mitral valve prolapse;
LGG	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg03806693	chr22:41940476	POLR3H	1.01	17.78	0.64	2.66e-54	Vitiligo;
LGG	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg13010199	chr12:38710504	ALG10B	0.42	7.61	0.33	1.55e-13	Morning vs. evening chronotype;
LGG	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg18446336	chr7:2847575	GNA12	-0.3	-7.92	-0.35	1.78e-14	Height;
LGG	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg02002194	chr4:3960332	NA	0.42	7.97	0.35	1.28e-14	Neuroticism;
LGG	cis	rs13102973	0.899	rs7438900	chr4:135909921	T/A	cg14419869	chr4:135874104	NA	0.45	8.04	0.35	7.42e-15	Subjective well-being;
LGG	cis	rs10979	1.000	rs7774497	chr6:143889033	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs4851266	0.966	rs4851270	chr2:100832656	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.15	-0.35	3.38e-15	Educational attainment;
LGG	cis	rs4974559	0.947	rs28509315	chr4:1358107	C/T	cg02980000	chr4:1222292	CTBP1	0.65	7.91	0.34	1.96e-14	Systolic blood pressure;
LGG	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg12310025	chr6:25882481	NA	-0.42	-6.73	-0.3	4.98e-11	Iron status biomarkers;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.06e-13	Bipolar disorder;
LGG	cis	rs988958	0.567	rs11892988	chr2:42246149	C/G	cg19376973	chr2:42229025	NA	0.62	10.13	0.43	6.68e-22	Hypospadias;
LGG	cis	rs17321999	0.904	rs13386353	chr2:30480756	A/G	cg05247661	chr2:30472410	LBH	0.56	9.19	0.39	1.37e-18	Systemic lupus erythematosus;
LGG	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.48e-14	Bone mineral density;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.32	0.67	2.12e-61	Platelet count;
LGG	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg08700190	chr5:6636046	SRD5A1	-0.31	-6.75	-0.3	4.33e-11	Response to amphetamines;
LGG	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg03161606	chr19:29218774	NA	0.69	10.55	0.44	1.85e-23	Methadone dose in opioid dependence;
LGG	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg16096631	chr1:42092165	HIVEP3	0.76	21.36	0.7	5.95e-71	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	6.99	0.31	9.55e-12	Schizophrenia;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg17514608	chr6:28193279	ZNF193	0.43	6.7	0.3	6.03e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.79	-12.74	-0.51	4.56e-32	Chronic sinus infection;
LGG	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27511599	chr7:32358540	NA	0.58	6.66	0.3	7.57e-11	Body mass index;
LGG	trans	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg19862616	chr7:65841803	NCRNA00174	0.74	7.68	0.34	9.68e-14	Mononucleosis;
LGG	cis	rs9771228	0.835	rs6950141	chr7:32368718	T/C	cg27532318	chr7:32358331	NA	0.43	6.84	0.3	2.48e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg18709589	chr6:96969512	KIAA0776	0.46	6.67	0.3	7.1e-11	Migraine;Coronary artery disease;
LGG	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.77	0.3	3.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg13770153	chr20:60521292	NA	-0.48	-7.76	-0.34	5.59e-14	Body mass index;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.87	-0.3	2.11e-11	Total body bone mineral density;
LGG	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg04132472	chr17:19861366	AKAP10	0.26	7.12	0.31	4.15e-12	Schizophrenia;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg25004347	chr4:1352787	KIAA1530	-0.4	-7.07	-0.31	5.92e-12	Obesity-related traits;
LGG	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg18198730	chr1:247681584	NA	0.73	12.3	0.5	2.69e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg22906224	chr7:99728672	NA	-0.57	-9.29	-0.4	5.94e-19	Coronary artery disease;
LGG	cis	rs6568686	0.730	rs4947120	chr6:111819044	G/A	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	trans	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.65	-0.33	1.18e-13	Blood trace element (Cu levels);
LGG	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg10596483	chr8:143751796	JRK	0.56	9.04	0.39	4.19e-18	Schizophrenia;
LGG	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg23894439	chr1:183413866	NA	0.49	9.11	0.39	2.5e-18	Systemic lupus erythematosus;
LGG	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.4	-0.33	6.54e-13	Triglycerides;
LGG	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs757081	0.648	rs11024223	chr11:17277693	A/T	cg15432903	chr11:17409602	KCNJ11	0.42	7.81	0.34	3.99e-14	Systolic blood pressure;
LGG	cis	rs57927100	0.578	rs7221079	chr17:75345027	T/C	cg18271897	chr17:75316784	SEPT9	0.38	8.51	0.37	2.43e-16	Systolic blood pressure;
LGG	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.54	-9.07	-0.39	3.41e-18	IgG glycosylation;
LGG	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg20336341	chr7:50628841	DDC	-0.42	-7.22	-0.32	2.2e-12	Malaria;
LGG	cis	rs6815814	0.731	rs11734342	chr4:38773109	A/G	cg06935464	chr4:38784597	TLR10	0.44	6.82	0.3	2.92e-11	Breast cancer;
LGG	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg21427119	chr20:30132790	HM13	-0.41	-7.05	-0.31	6.73e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2018055	0.618	rs35002781	chr6:117794774	T/C	cg14611402	chr6:117803162	DCBLD1	0.3	8.9	0.38	1.24e-17	Diastolic blood pressure;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07494248	chr2:198365610	HSPD1;HSPE1	0.38	6.65	0.3	8.41e-11	Obesity-related traits;
LGG	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg00405596	chr8:11794950	NA	-0.45	-7.79	-0.34	4.34e-14	Mood instability;
LGG	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg16141378	chr3:129829833	LOC729375	0.36	8.61	0.37	1.15e-16	Neuroticism;
LGG	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg22705602	chr4:152727874	NA	-0.32	-7.77	-0.34	5.08e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg05335186	chr13:53173507	NA	0.48	10.16	0.43	4.91e-22	Lewy body disease;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12042938	0.935	rs823167	chr1:231767230	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	11.23	0.46	4.69e-26	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs7011049	1.000	rs72640848	chr8:53836225	A/G	cg26025543	chr8:53854495	NA	0.74	9.8	0.41	9.87e-21	Systolic blood pressure;
LGG	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-11.12	-0.46	1.24e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs889398	0.771	rs8048550	chr16:69891759	T/G	cg00738113	chr16:70207722	CLEC18C	-0.25	-6.87	-0.3	2.02e-11	Body mass index;
LGG	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg08250081	chr4:10125330	NA	-0.36	-6.92	-0.31	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13314892	0.728	rs62252174	chr3:69874383	T/A	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs113835537	0.597	rs2305534	chr11:66313203	T/C	cg24851651	chr11:66362959	CCS	0.46	7.83	0.34	3.32e-14	Airway imaging phenotypes;
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.01	-0.31	8.53e-12	Testicular germ cell tumor;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07157834	chr1:205819609	PM20D1	0.74	16.79	0.62	9.58e-50	Menarche (age at onset);
LGG	cis	rs3540	0.960	rs2238327	chr15:91012949	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.01	0.35	9.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs9487051	0.872	rs1521908	chr6:109613986	T/C	cg21918786	chr6:109611834	NA	-0.49	-9.1	-0.39	2.64e-18	Reticulocyte fraction of red cells;
LGG	trans	rs11875185	0.510	rs75426711	chr18:55633962	G/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs17092148	0.836	rs6059910	chr20:33142107	T/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.77	-0.3	3.93e-11	Neuroticism;
LGG	cis	rs11690935	1.000	rs2138348	chr2:172558172	A/C	cg13550731	chr2:172543902	DYNC1I2	1.07	27.16	0.78	7.75e-98	Schizophrenia;
LGG	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.66	0.3	7.73e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.73	13.84	0.54	1.06e-36	Mean corpuscular volume;
LGG	cis	rs151997	0.853	rs3846498	chr5:50253625	A/C	cg06027927	chr5:50259733	NA	-0.67	-11.54	-0.47	2.89e-27	Callous-unemotional behaviour;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13476336	chr17:38255694	NR1D1	0.53	8.34	0.36	8.82e-16	Gut microbiome composition (summer);
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg23188684	chr11:67383651	NA	0.53	8.98	0.39	6.85e-18	Mean corpuscular volume;
LGG	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg02975922	chr3:195473998	MUC4	0.45	7.15	0.32	3.36e-12	Mean corpuscular volume;
LGG	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg04705435	chr11:17411270	KCNJ11	0.43	8.39	0.36	6.12e-16	Type 2 diabetes;
LGG	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.69	-0.44	5.62e-24	Vitiligo;
LGG	cis	rs6764363	0.527	rs7650973	chr3:276196	A/G	cg02057681	chr3:285234	CHL1	-0.42	-7.46	-0.33	4.42e-13	Sudden cardiac arrest;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg14926445	chr8:58193284	C8orf71	-0.8	-10.53	-0.44	2.23e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs12980942	0.810	rs8103839	chr19:41781493	C/G	cg25627403	chr19:41769009	HNRNPUL1	0.56	7.61	0.33	1.56e-13	Coronary artery disease;
LGG	trans	rs61931739	0.534	rs1490113	chr12:34132394	A/G	cg26384229	chr12:38710491	ALG10B	0.81	16.35	0.61	9.5e-48	Morning vs. evening chronotype;
LGG	cis	rs643506	0.817	rs1940392	chr11:111776846	G/A	cg09085632	chr11:111637200	PPP2R1B	0.43	6.86	0.3	2.19e-11	Breast cancer;
LGG	cis	rs11874712	1.000	rs1800640	chr18:43671400	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.92	-0.45	7.27e-25	Migraine - clinic-based;
LGG	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg13114125	chr14:105738426	BRF1	-0.85	-16.92	-0.62	2.31e-50	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg11764359	chr7:65958608	NA	-0.72	-12.88	-0.51	1.13e-32	Aortic root size;
LGG	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.36	-0.58	2.56e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7695597	0.668	rs1217946	chr4:185170597	T/A	cg12654155	chr4:185238627	NA	0.4	7.14	0.31	3.74e-12	Night sleep phenotypes;
LGG	cis	rs3767633	0.925	rs1553444	chr1:161813515	C/T	cg09175582	chr1:161736000	ATF6	0.69	8.72	0.38	5.06e-17	IgG glycosylation;
LGG	cis	rs7226408	0.901	rs17568091	chr18:34739590	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.42	-6.75	-0.3	4.56e-11	Obesity-related traits;
LGG	cis	rs11018904	0.861	rs12787117	chr11:89943681	A/G	cg27158573	chr11:89632121	NA	-0.42	-7.66	-0.34	1.07e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6580649	0.941	rs60681522	chr12:48464195	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	trans	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.83	0.48	2.1e-28	Lewy body disease;
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg02158880	chr13:53174818	NA	0.77	17.34	0.63	2.91e-52	Lewy body disease;
LGG	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg24585782	chr17:78113791	EIF4A3	-0.48	-7.98	-0.35	1.13e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs4900538	0.855	rs72698602	chr14:102880454	T/C	cg18135206	chr14:102964638	TECPR2	-0.69	-12.45	-0.5	7.05e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs516946	0.797	rs13266210	chr8:41533514	A/G	cg12439423	chr8:41522721	ANK1	0.42	7.16	0.32	3.29e-12	Type 2 diabetes;
LGG	cis	rs36093844	0.660	rs12274717	chr11:85577714	A/C	cg16165120	chr11:85566439	CCDC83	-0.44	-7.13	-0.31	3.92e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.13	-0.43	6.24e-22	Lung cancer;
LGG	cis	rs11159840	0.587	rs1940533	chr14:88612052	T/C	cg18078958	chr14:88630771	NA	-0.3	-7.28	-0.32	1.44e-12	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg21171335	chr12:122356390	WDR66	0.29	8.49	0.37	2.9e-16	Mean corpuscular volume;
LGG	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.92	0.31	1.49e-11	Retinal vascular caliber;
LGG	cis	rs11785400	0.793	rs2976400	chr8:143743611	G/A	cg24634471	chr8:143751801	JRK	0.5	7.66	0.34	1.1e-13	Schizophrenia;
LGG	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg01420254	chr6:26195488	NA	0.83	10.67	0.44	6.28e-24	Gout;Renal underexcretion gout;
LGG	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.42	-0.33	5.66e-13	Morning vs. evening chronotype;
LGG	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.9e-13	Uric acid levels;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg16405210	chr4:1374714	KIAA1530	0.5	8.43	0.36	4.26e-16	Obesity-related traits;
LGG	cis	rs795544	0.554	rs12186615	chr5:13783861	T/C	cg07548982	chr5:13769939	DNAH5	-0.43	-8.34	-0.36	8.75e-16	Corneal astigmatism;
LGG	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs571497	0.697	rs657855	chr19:7833408	C/T	cg00371453	chr19:7854482	CLEC4GP1	0.69	7.78	0.34	4.93e-14	Monocyte count;
LGG	cis	rs7412746	0.658	rs6660845	chr1:150841066	G/A	cg15448220	chr1:150897856	SETDB1	0.39	7.16	0.32	3.11e-12	Melanoma;
LGG	trans	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg06521331	chr12:34319734	NA	-0.52	-8.96	-0.38	8.22e-18	Bladder cancer;
LGG	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	6.69	0.3	6.58e-11	Homoarginine levels;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.84e-21	Prudent dietary pattern;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg00908189	chr16:619842	PIGQ	0.87	16.76	0.61	1.24e-49	Height;
LGG	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.11	-0.39	2.47e-18	Mosquito bite size;
LGG	cis	rs9902453	0.904	rs7219456	chr17:28374112	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg18165381	chr3:44552316	NA	-0.39	-6.67	-0.3	7.19e-11	Depressive symptoms;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.24	-0.32	1.86e-12	Menopause (age at onset);
LGG	cis	rs12190007	0.573	rs13202383	chr6:169826544	A/G	cg15038512	chr6:170123185	PHF10	-0.45	-8.54	-0.37	1.96e-16	Obesity-related traits;
LGG	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg02466173	chr16:30829666	NA	-0.42	-7.67	-0.34	1.03e-13	Dementia with Lewy bodies;
LGG	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	10.03	0.42	1.51e-21	Retinal vascular caliber;
LGG	cis	rs7577696	0.524	rs805831	chr2:32484228	C/G	cg02381751	chr2:32503542	YIPF4	0.45	6.65	0.3	8.09e-11	Inflammatory biomarkers;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.09	-0.31	5.07e-12	Menopause (age at onset);
LGG	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.22	0.32	2.2e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.04	-0.46	2.48e-25	Lung cancer;
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg02002194	chr4:3960332	NA	0.43	7.82	0.34	3.71e-14	Neuroticism;
LGG	cis	rs9503598	0.778	rs10155771	chr6:3465930	G/A	cg00476032	chr6:3446245	SLC22A23	0.65	14.07	0.55	1.1e-37	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	7.95	0.35	1.49e-14	Longevity;
LGG	cis	rs3784262	0.669	rs12594082	chr15:58267779	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.96	-0.31	1.16e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.27	0.32	1.52e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10492096	0.947	rs11064227	chr12:6598043	A/G	cg13857086	chr12:6580257	VAMP1	0.51	7.47	0.33	4.06e-13	Hip geometry;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.95	0.68	2.36e-64	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.21e-13	Heart rate;
LGG	cis	rs804292	0.724	rs8191518	chr8:11627261	C/G	cg26752888	chr8:11627280	NEIL2	1.09	17.06	0.62	5.74e-51	Alcohol dependence;Nicotine use;
LGG	cis	rs6692729	0.933	rs2236914	chr1:227078721	A/T	cg08708961	chr1:227070630	PSEN2	-0.31	-7.84	-0.34	3.16e-14	Electrodermal activity;
LGG	trans	rs2562456	0.833	rs17680605	chr19:21562448	C/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.75	-0.34	5.85e-14	Pain;
LGG	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg13334819	chr7:99746414	C7orf59	-0.46	-7.2	-0.32	2.53e-12	Coronary artery disease;
LGG	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.0	0.7	2.88e-69	Bladder cancer;
LGG	cis	rs6032067	0.527	rs6017490	chr20:43736369	C/A	cg10761708	chr20:43804764	PI3	0.55	8.46	0.37	3.58e-16	Blood protein levels;
LGG	cis	rs17366136	1.000	rs17366136	chr7:22601127	A/C	cg18045685	chr7:22629474	NA	-0.42	-7.27	-0.32	1.54e-12	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
LGG	cis	rs7737355	0.947	rs1422871	chr5:130942481	G/A	cg06307176	chr5:131281290	NA	0.57	9.24	0.39	8.89e-19	Life satisfaction;
LGG	cis	rs6784615	0.744	rs758803	chr3:52515533	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.49	-0.33	3.44e-13	Waist-hip ratio;
LGG	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	8.01e-23	Blood metabolite levels;
LGG	cis	rs4653767	1.000	rs708775	chr1:226923264	G/A	cg00279406	chr1:226924739	ITPKB	0.27	7.08	0.31	5.22e-12	Parkinson's disease;
LGG	trans	rs330048	0.644	rs10102807	chr8:9104590	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.17	-0.32	3.07e-12	Systemic lupus erythematosus;
LGG	cis	rs11225247	1.000	rs79991976	chr11:102321434	T/C	cg06323957	chr11:102217781	BIRC2	0.77	6.72	0.3	5.38e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	1e-15	Response to antipsychotic treatment;
LGG	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg08344181	chr3:125677491	NA	-0.85	-8.27	-0.36	1.39e-15	Depression;
LGG	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg07636037	chr3:49044803	WDR6	-0.72	-11.74	-0.48	4.79e-28	Menarche (age at onset);
LGG	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	8.09	0.35	5.11e-15	Iron status biomarkers;
LGG	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg15665833	chr6:26285013	NA	0.37	6.77	0.3	4e-11	Educational attainment;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.92	-0.45	7.54e-25	Lung cancer;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	1.97e-12	Bipolar disorder;
LGG	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg17646820	chr3:66848679	NA	-0.48	-7.54	-0.33	2.49e-13	Type 2 diabetes;
LGG	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg05623727	chr3:50126028	RBM5	0.34	7.36	0.32	8.38e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg03060546	chr3:49711283	APEH	0.6	7.58	0.33	1.96e-13	Menarche (age at onset);
LGG	cis	rs4919044	0.674	rs9419766	chr10:94800788	G/A	cg05127821	chr10:94822908	CYP26C1	-0.44	-8.01	-0.35	9.7e-15	Coronary artery disease;
LGG	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.86	0.51	1.36e-32	IgG glycosylation;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg22907277	chr7:1156413	C7orf50	0.61	11.26	0.46	3.65e-26	Longevity;Endometriosis;
LGG	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg20336341	chr7:50628841	DDC	0.43	7.56	0.33	2.11e-13	Malaria;
LGG	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg16141378	chr3:129829833	LOC729375	0.37	8.78	0.38	3.2e-17	Joint mobility (Beighton score);
LGG	trans	rs9354308	0.764	rs2351717	chr6:66585982	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs972578	0.668	rs4820490	chr22:43243204	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.79	-0.3	3.4e-11	Mean platelet volume;
LGG	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg12573674	chr2:1569213	NA	-0.62	-9.66	-0.41	3.03e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg22771759	chr13:24902376	NA	0.41	7.01	0.31	8.54e-12	Obesity-related traits;
LGG	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg27490568	chr2:178487706	NA	0.84	15.58	0.59	2.65e-44	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17428076	0.751	rs788168	chr2:172917799	A/G	cg21435375	chr2:172878103	MAP1D	0.45	9.55	0.41	7.3e-20	Myopia;
LGG	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg07001201	chr5:642380	CEP72	-0.4	-6.74	-0.3	4.76e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs4478137	0.931	rs4057797	chr4:164245053	T/A	cg06758707	chr4:164254230	NPY1R	0.71	12.67	0.51	8.73e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg03036210	chr16:89904091	SPIRE2	-0.5	-7.24	-0.32	1.9e-12	Skin colour saturation;
LGG	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg12419862	chr22:24373484	LOC391322	0.83	14.82	0.57	6.32e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13177180	0.602	rs12187973	chr5:114858437	G/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.32	6.84	0.3	2.57e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs7572733	0.514	rs700686	chr2:198721054	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs2742417	1.000	rs2673033	chr3:45756350	C/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.12e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs10479542	0.544	rs7706275	chr5:178990305	A/G	cg14851468	chr5:179071604	C5orf60	0.46	7.81	0.34	3.89e-14	Lung cancer;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.2	0.32	2.49e-12	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12809842	chr3:196438875	PIGX;C3orf34	0.44	7.12	0.31	4.14e-12	Cognitive performance;
LGG	cis	rs3735485	0.843	rs1476617	chr7:45037734	C/T	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs972578	0.967	rs6002985	chr22:43333427	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.79	-0.3	3.35e-11	Mean platelet volume;
LGG	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg15327641	chr2:3715039	ALLC	0.33	7.23	0.32	2.06e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6784615	0.744	rs35130772	chr3:52325106	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.65	0.33	1.21e-13	Waist-hip ratio;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.78e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg18379455	chr17:41446167	NA	0.32	7.39	0.32	6.85e-13	Menopause (age at onset);
LGG	trans	rs12517041	0.872	rs6887084	chr5:23307439	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	trans	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg25214090	chr10:38739885	LOC399744	0.68	11.92	0.48	9.31e-29	Corneal astigmatism;
LGG	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.57e-12	Mean corpuscular hemoglobin;
LGG	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.77	-0.38	3.34e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.28	-0.32	1.43e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6815814	0.950	rs11722813	chr4:38810769	C/T	cg06935464	chr4:38784597	TLR10	0.62	8.37	0.36	6.96e-16	Breast cancer;
LGG	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.63	6.88	0.3	2.01e-11	Facial emotion recognition (sad faces);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12445461	chr9:6681608	NA	0.47	7.72	0.34	7.35e-14	Gut microbiome composition (summer);
LGG	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg16583315	chr14:65563665	MAX	-0.43	-8.62	-0.37	1.11e-16	Obesity-related traits;
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg11859384	chr17:80120422	CCDC57	0.39	6.79	0.3	3.51e-11	Life satisfaction;
LGG	cis	rs1568889	0.887	rs7102237	chr11:28344296	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	19.45	0.67	5.25e-62	Bipolar disorder;
LGG	cis	rs2797160	0.651	rs1268093	chr6:126029235	C/T	cg05901451	chr6:126070800	HEY2	0.58	10.37	0.43	8.45e-23	Endometrial cancer;
LGG	cis	rs368123	1.000	rs422292	chr6:160719491	T/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs7226408	0.857	rs72888997	chr18:34580216	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.62	0.41	4.13e-20	Total body bone mineral density;
LGG	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg12661370	chr5:149340060	SLC26A2	0.51	8.59	0.37	1.36e-16	HIV-1 control;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.98	-0.31	1.01e-11	Longevity;Endometriosis;
LGG	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg25019033	chr10:957182	NA	-0.58	-10.93	-0.45	6.73e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg04025307	chr7:1156635	C7orf50	0.52	9.7	0.41	2.22e-20	Longevity;Endometriosis;
LGG	cis	rs939658	0.683	rs11634726	chr15:79465894	A/G	cg17916960	chr15:79447300	NA	-0.52	-10.01	-0.42	1.72e-21	Refractive error;
LGG	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg23625390	chr15:77176239	SCAPER	0.55	11.09	0.46	1.66e-25	Blood metabolite levels;
LGG	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg04826882	chr13:114838756	RASA3	-0.6	-9.06	-0.39	3.68e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9796	0.870	rs8042088	chr15:41337487	C/T	cg18705301	chr15:41695430	NDUFAF1	0.49	8.52	0.37	2.22e-16	Menopause (age at onset);
LGG	trans	rs9914544	0.583	rs35783872	chr17:18748820	A/C	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.75	-0.34	6.02e-14	Educational attainment (years of education);
LGG	cis	rs988958	0.958	rs13001171	chr2:42279071	C/T	cg19376973	chr2:42229025	NA	0.46	7.5	0.33	3.27e-13	Hypospadias;
LGG	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg00666640	chr1:248458726	OR2T12	0.47	7.11	0.31	4.4e-12	Common traits (Other);
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06028808	chr11:68637592	NA	0.69	11.86	0.48	1.56e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.91	-0.35	1.88e-14	Life satisfaction;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.34	0.32	9.64e-13	Schizophrenia;
LGG	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24308560	chr3:49941425	MST1R	0.22	6.88	0.3	1.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06634786	chr22:41940651	POLR3H	0.74	12.31	0.5	2.54e-30	Vitiligo;
LGG	cis	rs986417	0.901	rs1955688	chr14:60989237	G/A	cg27398547	chr14:60952738	C14orf39	0.71	6.82	0.3	2.93e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg01411142	chr8:19674711	INTS10	0.48	7.37	0.32	7.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg02733842	chr7:1102375	C7orf50	-0.47	-7.64	-0.33	1.28e-13	Bronchopulmonary dysplasia;
LGG	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.74	13.74	0.54	2.97e-36	IgG glycosylation;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	cis	rs6963495	0.818	rs56055535	chr7:105163574	C/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11966931	0.711	rs11964340	chr6:108111651	G/T	cg04749840	chr6:108095067	SCML4	0.46	9.4	0.4	2.58e-19	Neutrophil percentage of white cells;
LGG	cis	rs3087591	1.000	rs2953015	chr17:29495341	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	14.29	0.55	1.19e-38	Hip circumference;
LGG	trans	rs1459104	0.636	rs12577480	chr11:54986004	A/C	cg15704280	chr7:45808275	SEPT13	0.76	7.29	0.32	1.39e-12	Body mass index;
LGG	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg09307838	chr4:120376055	NA	0.8	13.41	0.53	7.15e-35	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg23978390	chr7:1156363	C7orf50	0.54	9.26	0.4	7.73e-19	Longevity;Endometriosis;
LGG	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03713592	chr11:72463424	ARAP1	-0.38	-7.45	-0.33	4.48e-13	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.81	0.3	2.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg00599393	chr8:22457479	C8orf58	-0.46	-8.38	-0.36	6.32e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs911555	0.723	rs11160751	chr14:103925740	T/C	cg24130564	chr14:104152367	KLC1	-0.39	-7.19	-0.32	2.62e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg02725872	chr8:58115012	NA	-1.04	-14.06	-0.55	1.23e-37	Developmental language disorder (linguistic errors);
LGG	trans	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.18	-0.32	2.8e-12	Mood instability;
LGG	cis	rs7267979	1.000	rs6083805	chr20:25317356	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.86e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg03805757	chr16:71968109	PKD1L3	-0.51	-9.27	-0.4	7.28e-19	Post bronchodilator FEV1;
LGG	cis	rs896854	0.608	rs7004862	chr8:95876963	T/G	cg16049864	chr8:95962084	TP53INP1	-0.34	-7.49	-0.33	3.52e-13	Type 2 diabetes;
LGG	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.84	0.42	7.18e-21	Height;
LGG	cis	rs138055607	1	rs138055607	chr10:75450901	C/G	cg07699608	chr10:75541558	CHCHD1	0.53	7.07	0.31	5.72e-12	Initial pursuit acceleration;
LGG	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg04117972	chr1:227635322	NA	0.72	11.07	0.46	2.06e-25	Major depressive disorder;
LGG	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg24375607	chr4:120327624	NA	0.68	10.86	0.45	1.25e-24	Corneal astigmatism;
LGG	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg09137382	chr11:130731461	NA	0.43	8.38	0.36	6.36e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg01620082	chr3:125678407	NA	-0.97	-9.36	-0.4	3.6e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6787391	0.933	rs4510365	chr3:4745531	C/T	cg11584376	chr3:4789075	ITPR1	-0.34	-6.98	-0.31	1.04e-11	Breast cancer;
LGG	cis	rs9486719	1.000	rs2472897	chr6:96870569	G/T	cg18709589	chr6:96969512	KIAA0776	0.46	6.81	0.3	3.11e-11	Migraine;Coronary artery disease;
LGG	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.45e-16	Aortic root size;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg08621203	chr6:150244597	RAET1G	0.44	7.63	0.33	1.31e-13	Lung cancer;
LGG	cis	rs6784615	0.744	rs1011062	chr3:52506903	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.63	-7.57	-0.33	2.1e-13	Waist-hip ratio;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg05804949	chr7:23719620	C7orf46	-0.34	-7.86	-0.34	2.69e-14	Schizophrenia;
LGG	cis	rs1665650	0.874	rs73385592	chr10:118492298	G/A	cg14919929	chr10:118506882	NA	-0.49	-8.62	-0.37	1.04e-16	Colorectal cancer;
LGG	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg26031613	chr14:104095156	KLC1	-0.68	-10.81	-0.45	1.97e-24	Reticulocyte count;
LGG	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg19168338	chr16:4465731	CORO7	-0.97	-17.42	-0.63	1.29e-52	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs877282	0.898	rs12356709	chr10:763365	A/G	cg22713356	chr15:30763199	NA	0.52	7.7	0.34	8.12e-14	Uric acid levels;
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22618164	chr12:122356400	WDR66	0.4	12.17	0.49	9.12e-30	Mean corpuscular volume;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg18402987	chr7:1209562	NA	0.73	11.14	0.46	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.38	0.4	3.07e-19	Lung cancer;
LGG	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg26384229	chr12:38710491	ALG10B	0.74	15.21	0.58	1.1e-42	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	12.07	0.49	2.25e-29	Response to antipsychotic treatment;
LGG	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg13770153	chr20:60521292	NA	-0.49	-7.97	-0.35	1.26e-14	Body mass index;
LGG	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg01028140	chr2:1542097	TPO	-0.53	-8.59	-0.37	1.3e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg02903104	chr8:1507517	DLGAP2	0.33	6.82	0.3	2.92e-11	Lung cancer;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.61	-0.41	4.5e-20	Lung cancer;
LGG	cis	rs3806843	0.868	rs2531342	chr5:140130612	C/T	cg19875535	chr5:140030758	IK	-0.52	-10.69	-0.44	5.62e-24	Depressive symptoms (multi-trait analysis);
LGG	trans	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg11693508	chr17:37793320	STARD3	0.61	8.52	0.37	2.31e-16	Bipolar disorder;
LGG	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg09873164	chr1:152488093	CRCT1	0.63	15.75	0.59	4.75e-45	Hair morphology;
LGG	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg17971929	chr21:40555470	PSMG1	-0.49	-8.0	-0.35	1.04e-14	Menarche (age at onset);
LGG	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg19761014	chr17:28927070	LRRC37B2	0.63	7.49	0.33	3.49e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12912251	1.000	rs35024396	chr15:38989770	G/A	cg01338139	chr15:38987640	C15orf53	-0.53	-8.2	-0.36	2.44e-15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg06951627	chr6:26196580	NA	0.53	8.13	0.35	3.94e-15	Gout;Renal underexcretion gout;
LGG	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg07747251	chr5:1868357	NA	0.46	8.03	0.35	7.85e-15	Cardiovascular disease risk factors;
LGG	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.66	0.54	5.93e-36	Morning vs. evening chronotype;
LGG	cis	rs36051895	0.632	rs12337481	chr9:5134599	T/G	cg02405213	chr9:5042618	JAK2	-0.79	-15.43	-0.58	1.23e-43	Pediatric autoimmune diseases;
LGG	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg02297831	chr4:17616191	MED28	0.5	9.41	0.4	2.4e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg12165864	chr7:66369176	NA	-0.45	-7.68	-0.34	9.68e-14	Corneal structure;
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.04	-0.42	1.34e-21	Total body bone mineral density;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-10.15	-0.43	5.34e-22	Schizophrenia;
LGG	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	10.99	0.45	4.11e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg06718696	chr17:78121285	EIF4A3	-0.91	-14.83	-0.57	5.55e-41	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.35	-0.32	9.16e-13	Blood metabolite levels;
LGG	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg21775007	chr8:11205619	TDH	-0.44	-7.22	-0.32	2.16e-12	Neuroticism;
LGG	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg08188268	chr10:116634841	FAM160B1	0.31	6.86	0.3	2.28e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1568889	1.000	rs12790932	chr11:28046189	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	15.04	0.57	6.5e-42	Bipolar disorder;
LGG	cis	rs7681440	0.647	rs6814221	chr4:90805501	C/T	cg26578617	chr4:90757533	SNCA	-0.36	-7.09	-0.31	5.08e-12	Dementia with Lewy bodies;
LGG	cis	rs2274273	0.712	rs1002054	chr14:55528913	A/C	cg04306507	chr14:55594613	LGALS3	0.43	10.8	0.45	2.14e-24	Protein biomarker;
LGG	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-15.57	-0.59	2.89e-44	Total body bone mineral density;
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg15352829	chr14:105391018	PLD4	0.48	11.52	0.47	3.45e-27	Rheumatoid arthritis;
LGG	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg13010199	chr12:38710504	ALG10B	0.56	10.55	0.44	1.81e-23	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.913	rs6591344	chr11:68360873	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06133097	chr7:32552212	AVL9	-0.38	-7.13	-0.31	3.8e-12	Cognitive ability;
LGG	cis	rs6964587	0.869	rs34791781	chr7:91532720	C/T	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg00689492	chr4:1303491	MAEA	0.46	8.04	0.35	7.44e-15	Obesity-related traits;
LGG	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.79	-0.41	1.05e-20	Schizophrenia;
LGG	cis	rs9783347	0.600	rs2403254	chr11:18325146	A/G	cg15585147	chr11:18324498	HPS5	-0.31	-6.98	-0.31	1.04e-11	Pancreatic cancer;
LGG	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs78487399	0.808	rs13405776	chr2:43739121	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06952910	chr4:122744652	CCNA2	0.43	7.18	0.32	2.84e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs999943	0.846	rs9366826	chr6:33619184	C/G	cg14003231	chr6:33640908	ITPR3	0.6	14.11	0.55	7.43e-38	Obesity (extreme);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23627909	chr14:60337760	RTN1	-0.48	-7.12	-0.31	4.03e-12	Systemic lupus erythematosus;
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25427524	chr10:38739819	LOC399744	-0.73	-14.87	-0.57	3.48e-41	Breast cancer;
LGG	cis	rs6963495	0.818	rs73192105	chr7:105167945	T/C	cg19920283	chr7:105172520	RINT1	0.61	7.93	0.35	1.65e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.68	-0.3	6.75e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11877270	chr2:65658583	SPRED2	-0.51	-7.58	-0.33	1.92e-13	Systemic lupus erythematosus;
LGG	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-9.8	-0.41	9.6e-21	Schizophrenia;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg00908189	chr16:619842	PIGQ	0.86	16.15	0.6	7.43e-47	Height;
LGG	cis	rs740474	0.831	rs10477148	chr5:140989242	C/T	cg00076195	chr5:140892677	NA	0.5	8.95	0.38	8.5e-18	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg26818257	chr2:241905806	NA	0.5	11.31	0.47	2.33e-26	Joint mobility (Beighton score);
LGG	trans	rs1973993	0.603	rs2391799	chr1:97024329	A/G	cg10631902	chr5:14652156	NA	0.37	6.76	0.3	4.25e-11	Weight;
LGG	cis	rs2594989	0.887	rs4684071	chr3:11443084	C/G	cg01796438	chr3:11312864	ATG7	-0.54	-7.28	-0.32	1.45e-12	Circulating chemerin levels;
LGG	cis	rs7166081	1.000	rs12324222	chr15:67581282	G/A	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg08807101	chr21:30365312	RNF160	-0.83	-16.92	-0.62	2.35e-50	Dental caries;
LGG	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg08975724	chr8:8085496	FLJ10661	0.42	8.16	0.35	3.22e-15	Mood instability;
LGG	cis	rs6547741	0.935	rs6749426	chr2:27847606	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.54	0.56	9.67e-40	Oral cavity cancer;
LGG	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg15596359	chr8:11213517	TDH	-0.39	-8.1	-0.35	5.01e-15	Retinal vascular caliber;
LGG	cis	rs2455799	0.634	rs13085226	chr3:15923750	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.62	-0.33	1.43e-13	Mean platelet volume;
LGG	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg13902645	chr11:5959945	NA	-0.64	-10.02	-0.42	1.59e-21	DNA methylation (variation);
LGG	cis	rs11700980	0.636	rs61735765	chr21:30255347	C/A	cg24692254	chr21:30365293	RNF160	-0.61	-7.4	-0.33	6.53e-13	QRS complex (12-leadsum);
LGG	cis	rs9467160	0.834	rs17247566	chr6:24450404	A/C	cg20631270	chr6:24437470	GPLD1	-0.54	-8.09	-0.35	5.43e-15	Liver enzyme levels;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03452623	chr4:187889614	NA	1.03	27.02	0.78	3.37e-97	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg27624424	chr6:160112604	SOD2	0.66	9.73	0.41	1.69e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg00292662	chr22:38071168	LGALS1	0.65	14.94	0.57	1.88e-41	Fat distribution (HIV);
LGG	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.06	0.31	6.01e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg14926445	chr8:58193284	C8orf71	-0.91	-13.29	-0.53	2.3e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.81	-0.34	3.84e-14	Life satisfaction;
LGG	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.14	-0.35	3.58e-15	Monocyte count;
LGG	cis	rs17428076	0.710	rs56049564	chr2:172648680	T/C	cg21435375	chr2:172878103	MAP1D	0.4	7.23	0.32	1.97e-12	Myopia;
LGG	cis	rs7000551	0.715	rs34649162	chr8:22314730	T/C	cg12081754	chr8:22256438	SLC39A14	0.67	13.08	0.52	1.78e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg25173405	chr17:45401733	C17orf57	0.47	8.06	0.35	6.55e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13082711	0.680	rs7647818	chr3:27418896	T/C	cg02860705	chr3:27208620	NA	0.76	13.96	0.54	3.37e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg26043149	chr18:55253948	FECH	1.01	18.95	0.66	1.09e-59	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg13147721	chr7:65941812	NA	-0.79	-9.54	-0.41	7.93e-20	Diabetic kidney disease;
LGG	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.34	-0.32	9.78e-13	Depression;
LGG	cis	rs7394190	0.748	rs4746151	chr10:75578720	G/T	cg07699608	chr10:75541558	CHCHD1	0.54	7.05	0.31	6.47e-12	Incident atrial fibrillation;
LGG	cis	rs1790761	0.803	rs2302264	chr11:67207426	G/A	cg00290607	chr11:67383545	NA	-0.47	-8.36	-0.36	7.57e-16	Mean corpuscular volume;
LGG	cis	rs13126513	0.519	rs7659550	chr4:100554402	G/T	cg05468953	chr4:100565104	NA	0.41	8.07	0.35	5.96e-15	Metabolite levels (MHPG);
LGG	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.84	-0.42	7.2e-21	Chronic sinus infection;
LGG	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg03735888	chr19:58951602	ZNF132	0.38	6.83	0.3	2.76e-11	Uric acid clearance;
LGG	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg11166453	chr1:247681781	NA	0.63	9.91	0.42	4.14e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.79	-0.45	2.34e-24	Body mass index;
LGG	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg14631276	chr8:145163102	KIAA1875	-1.22	-11.38	-0.47	1.23e-26	Blood metabolite levels;
LGG	cis	rs6809651	0.524	rs79262908	chr3:185803594	C/T	cg00760338	chr3:185826511	ETV5	-0.91	-15.26	-0.58	7.23e-43	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs2115630	0.905	rs6496401	chr15:85297793	A/T	cg12501888	chr15:85177176	SCAND2	-0.42	-7.02	-0.31	8.08e-12	P wave terminal force;
LGG	cis	rs11671005	0.779	rs11670125	chr19:58987390	G/T	cg13877915	chr19:58951672	ZNF132	0.6	7.82	0.34	3.67e-14	Mean platelet volume;
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg24250549	chr1:154909240	PMVK	0.75	14.9	0.57	2.57e-41	Prostate cancer;
LGG	cis	rs240764	0.717	rs183566	chr6:101142605	A/T	cg09795085	chr6:101329169	ASCC3	0.45	7.85	0.34	2.86e-14	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25390349	chr10:13570521	NA	0.48	7.33	0.32	1.05e-12	Gut microbiome composition (summer);
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg06925179	chr17:43578568	NA	0.42	9.96	0.42	2.69e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.25	-0.39	8.56e-19	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05189008	chr12:49582177	TUBA1A	0.45	6.9	0.31	1.67e-11	Gut microbiome composition (summer);
LGG	cis	rs9549260	0.755	rs2701863	chr13:41170140	C/T	cg21288729	chr13:41239152	FOXO1	0.33	6.67	0.3	7.3e-11	Red blood cell count;
LGG	cis	rs782590	0.764	rs2586969	chr2:55829392	G/C	cg18811423	chr2:55921094	PNPT1	0.82	17.71	0.64	5.94e-54	Metabolic syndrome;
LGG	cis	rs4774899	1.000	rs4774898	chr15:57199662	G/C	cg08128148	chr15:57256372	TCF12	-0.34	-7.98	-0.35	1.16e-14	Urinary tract infection frequency;
LGG	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg09696939	chr10:60272079	BICC1	0.35	6.87	0.3	2.1e-11	Refractive error;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg11360546	chr7:1094263	C7orf50	-0.4	-7.03	-0.31	7.57e-12	Longevity;Endometriosis;
LGG	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg08250081	chr4:10125330	NA	0.37	7.06	0.31	6.3e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg11995313	chr8:8860691	ERI1	0.45	7.62	0.33	1.48e-13	Joint mobility (Beighton score);
LGG	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg08344181	chr3:125677491	NA	0.56	7.49	0.33	3.61e-13	Depression;
LGG	cis	rs11997175	0.846	rs11776207	chr8:33765126	G/T	ch.8.33884649F	chr8:33765107	NA	-0.36	-7.11	-0.31	4.48e-12	Body mass index;
LGG	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.7	0.34	8.14e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.01	-0.31	8.68e-12	Lung cancer;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg03575189	chr17:44344142	NA	0.48	7.09	0.31	5.12e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg14926445	chr8:58193284	C8orf71	-0.45	-7.02	-0.31	7.84e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7246760	1.000	rs56357664	chr19:9903399	C/T	cg02900749	chr2:68251473	NA	-1.04	-11.35	-0.47	1.63e-26	Pursuit maintenance gain;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg09858108	chr8:58055024	NA	0.42	6.69	0.3	6.64e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.15e-12	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7727544	0.735	rs273914	chr5:131660431	A/T	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.63	-0.37	9.83e-17	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.69e-18	Life satisfaction;
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	18.25	0.65	1.81e-56	Platelet count;
LGG	cis	rs2905347	0.520	rs1858936	chr7:22647553	G/C	cg23521230	chr7:22704884	NA	0.54	9.97	0.42	2.45e-21	Major depression and alcohol dependence;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.06	0.42	1.14e-21	Longevity;
LGG	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.9	-0.38	1.28e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6912958	0.781	rs9450732	chr6:88249826	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.59	-0.37	1.36e-16	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.22	-0.43	3.02e-22	Obesity-related traits;
LGG	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg13385794	chr1:248469461	NA	0.45	8.0	0.35	1.02e-14	Common traits (Other);
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg01943577	chr7:158741284	NA	-0.44	-7.93	-0.35	1.64e-14	Height;
LGG	cis	rs2865126	0.818	rs8087370	chr18:10764174	C/T	cg21165219	chr18:10698044	FAM38B	-0.45	-7.34	-0.32	9.43e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs972578	0.715	rs17409550	chr22:43214400	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.88	-0.3	1.97e-11	Mean platelet volume;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.57	9.45	0.4	1.63e-19	Longevity;
LGG	cis	rs36051895	0.664	rs4593605	chr9:5107278	C/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.15	-0.58	2.18e-42	Pediatric autoimmune diseases;
LGG	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg08250081	chr4:10125330	NA	-0.48	-9.25	-0.39	8.2e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.56e-18	Bladder cancer;
LGG	cis	rs2798269	0.867	rs11840168	chr13:22118302	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.92	-0.31	1.54e-11	PR segment;
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	0.56	6.91	0.31	1.59e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9443189	0.570	rs775075	chr6:76380035	A/C	cg01950844	chr6:76311363	SENP6	-0.76	-10.07	-0.42	1.07e-21	Prostate cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10025462	chr17:27046956	SNORD42B;RPL23A	0.38	6.84	0.3	2.52e-11	Obesity-related traits;
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.7	0.34	8.11e-14	Rheumatoid arthritis;
LGG	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg25019033	chr10:957182	NA	-0.57	-10.46	-0.44	3.83e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg19554555	chr3:13937349	NA	-0.57	-10.28	-0.43	1.82e-22	Ovarian reserve;
LGG	cis	rs4561483	0.619	rs12597429	chr16:12062396	A/G	cg08843971	chr16:11963173	GSPT1	-0.51	-11.82	-0.48	2.3e-28	Testicular germ cell tumor;
LGG	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	10.42	0.44	5.63e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4566357	0.930	rs12621916	chr2:227923564	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.29	0.32	1.39e-12	Mood instability;
LGG	cis	rs17253792	0.822	rs77676035	chr14:56096229	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs7408868	0.520	rs1043994	chr19:15302844	T/C	cg14696996	chr19:15285081	NOTCH3	0.86	10.98	0.45	4.52e-25	Pulse pressure;
LGG	cis	rs9399135	0.967	rs2297340	chr6:135376058	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.48	0.4	1.32e-19	Red blood cell count;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.56	0.33	2.2e-13	Lung cancer;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg08975724	chr8:8085496	FLJ10661	0.47	8.92	0.38	1.1e-17	Neuroticism;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg11494091	chr17:61959527	GH2	0.99	24.14	0.75	6.1e-84	Prudent dietary pattern;
LGG	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.41e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4253772	0.701	rs9627280	chr22:46643964	T/C	cg24881330	chr22:46731750	TRMU	0.57	7.38	0.32	7.63e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1030877	0.515	rs2576736	chr2:105890971	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	10.34	0.43	1.12e-22	Obesity-related traits;
LGG	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg04691961	chr3:161091175	C3orf57	-0.42	-8.76	-0.38	3.63e-17	Kawasaki disease;
LGG	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg18105134	chr13:113819100	PROZ	-0.65	-13.8	-0.54	1.55e-36	Platelet distribution width;
LGG	cis	rs7100689	0.646	rs1538815	chr10:82137670	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.37	0.58	2.15e-43	Post bronchodilator FEV1;
LGG	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.37	-0.4	3.11e-19	Breast cancer;
LGG	trans	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg27661571	chr11:113659931	NA	-0.65	-7.37	-0.32	8.1e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.74	0.3	4.69e-11	Schizophrenia;
LGG	trans	rs9929218	0.954	rs12599393	chr16:68829021	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-11.79	-0.48	2.99e-28	Colorectal cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14209299	chr2:107502793	ST6GAL2	-0.41	-6.67	-0.3	7.23e-11	Brain structure;
LGG	cis	rs1355223	1.000	rs1355221	chr11:34758609	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.33	-0.32	1.06e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.64	0.48	1.22e-27	Coronary artery disease;
LGG	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.71	-0.3	5.74e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg01324343	chr3:183735012	ABCC5	0.56	10.2	0.43	3.61e-22	Anterior chamber depth;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13012494	chr21:47604986	C21orf56	0.62	10.4	0.44	6.54e-23	Testicular germ cell tumor;
LGG	cis	rs73086581	1.000	rs6052217	chr20:3970211	A/G	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.28	-0.32	1.4e-12	Life satisfaction;
LGG	cis	rs4262150	0.721	rs11167603	chr5:152282386	C/T	cg12297329	chr5:152029980	NA	-0.58	-11.29	-0.46	2.85e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg00579200	chr11:133705235	NA	-0.6	-11.37	-0.47	1.4e-26	Childhood ear infection;
LGG	cis	rs283228	0.798	rs426243	chr6:101748442	T/G	cg27451362	chr6:101846650	GRIK2	0.63	10.46	0.44	3.84e-23	Coenzyme Q10 levels;
LGG	cis	rs1878931	0.507	rs1218762	chr16:3405986	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-10.53	-0.44	2.13e-23	Body mass index (adult);
LGG	trans	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg19894588	chr14:64061835	NA	-0.6	-9.41	-0.4	2.31e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg02711726	chr17:80685570	FN3KRP	-0.45	-8.5	-0.37	2.63e-16	Glycated hemoglobin levels;
LGG	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg17376030	chr22:41985996	PMM1	0.67	10.87	0.45	1.18e-24	Vitiligo;
LGG	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg24375607	chr4:120327624	NA	0.6	10.38	0.43	7.92e-23	Corneal astigmatism;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02249930	chr10:70166207	RUFY2	0.44	7.68	0.34	9.37e-14	Bipolar disorder;
LGG	cis	rs13082711	0.911	rs7625337	chr3:27516853	G/T	cg02860705	chr3:27208620	NA	0.69	12.23	0.49	5.37e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg08733933	chr1:2954429	NA	-0.44	-8.73	-0.38	4.7e-17	Plateletcrit;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg07701084	chr6:150067640	NUP43	0.41	7.49	0.33	3.63e-13	Testicular germ cell tumor;
LGG	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg20503657	chr10:835505	NA	0.75	10.22	0.43	2.98e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs758324	0.947	rs9327622	chr5:131125080	T/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1707322	0.964	rs785509	chr1:46527300	G/A	cg03146154	chr1:46216737	IPP	-0.55	-10.14	-0.43	5.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4132509	0.793	rs6694738	chr1:243715210	C/A	cg21452805	chr1:244014465	NA	0.84	8.05	0.35	7.21e-15	RR interval (heart rate);
LGG	cis	rs6546550	0.867	rs4852349	chr2:70076954	A/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.86	-0.34	2.68e-14	Prevalent atrial fibrillation;
LGG	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	2.98e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17227506	0.529	rs13263378	chr8:13471193	A/G	cg03566418	chr8:13424080	C8orf48	-0.56	-8.54	-0.37	1.91e-16	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg10546459	chr2:36825355	FEZ2	0.49	7.43	0.33	5.24e-13	Height;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.73	-0.41	1.69e-20	Personality dimensions;
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.7	0.37	5.79e-17	Bipolar disorder;
LGG	cis	rs1941023	0.584	rs6591578	chr11:60158649	G/A	cg08716584	chr11:60157161	MS4A7	-0.4	-7.87	-0.34	2.51e-14	Congenital heart disease (maternal effect);
LGG	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg17809284	chr5:56205270	C5orf35	0.67	10.78	0.45	2.42e-24	Initial pursuit acceleration;
LGG	trans	rs7777677	1.000	rs7796160	chr7:142371453	A/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.17	-0.32	3.02e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.68	0.37	6.57e-17	Platelet count;
LGG	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg01221209	chr5:554886	NA	-0.48	-7.09	-0.31	4.97e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9902453	0.900	rs56195309	chr17:28453753	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.85e-34	Coffee consumption (cups per day);
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg07701084	chr6:150067640	NUP43	0.7	13.65	0.54	6.72e-36	Lung cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06837242	chr1:19578761	MRTO4;KIAA0090	0.41	6.78	0.3	3.63e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.53	-9.41	-0.4	2.26e-19	Response to antipsychotic treatment;
LGG	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg03511173	chr18:77590860	NA	0.62	7.71	0.34	7.78e-14	Opioid sensitivity;
LGG	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.3	-0.53	2.15e-34	Response to antipsychotic treatment;
LGG	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.75	-0.34	6.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2798269	1.000	rs12877509	chr13:22124028	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.85	-0.3	2.4e-11	PR segment;
LGG	cis	rs711245	0.899	rs848603	chr2:36773868	C/T	cg01206211	chr2:36825736	FEZ2	0.41	7.79	0.34	4.36e-14	Height;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.16e-13	Obesity-related traits;
LGG	cis	rs1497828	1.000	rs1032598	chr1:217548508	A/G	cg04411442	chr1:217543379	NA	0.47	8.09	0.35	5.42e-15	Dialysis-related mortality;
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.47	-0.4	1.49e-19	Triglycerides;
LGG	cis	rs7765175	0.598	rs6929486	chr6:113656016	T/C	cg26552650	chr6:113682475	NA	0.33	7.32	0.32	1.09e-12	Coronary artery calcification;
LGG	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg26384229	chr12:38710491	ALG10B	0.8	17.62	0.63	1.54e-53	Bladder cancer;
LGG	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.17	-0.32	3.07e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	21.4	0.71	3.69e-71	Homoarginine levels;
LGG	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg06637938	chr14:75390232	RPS6KL1	0.56	10.05	0.42	1.21e-21	Height;
LGG	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg26769984	chr7:1090371	C7orf50	0.53	9.49	0.4	1.22e-19	Bronchopulmonary dysplasia;
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.7	-0.3	6.24e-11	Monocyte count;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	14.74	0.57	1.32e-40	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg18032289	chr17:61959525	GH2	-0.39	-6.8	-0.3	3.34e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.11	-0.39	2.53e-18	Retinal vascular caliber;
LGG	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-15.33	-0.58	3.28e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg07636037	chr3:49044803	WDR6	0.75	13.06	0.52	2.01e-33	Menarche (age at onset);
LGG	cis	rs7766436	0.885	rs13200219	chr6:22595428	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.54	-0.47	2.93e-27	Coronary artery disease;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.61	-0.37	1.16e-16	Neuroticism;
LGG	cis	rs2594989	0.831	rs6803125	chr3:11583228	A/G	cg01796438	chr3:11312864	ATG7	0.54	7.15	0.32	3.3e-12	Circulating chemerin levels;
LGG	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-8.23	-0.36	1.89e-15	Cognitive test performance;
LGG	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg04503457	chr17:41445688	NA	-0.39	-8.09	-0.35	5.15e-15	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg17376030	chr22:41985996	PMM1	-0.59	-9.61	-0.41	4.79e-20	Vitiligo;
LGG	cis	rs939658	0.805	rs8036435	chr15:79420031	T/C	cg17916960	chr15:79447300	NA	-0.67	-13.23	-0.52	3.91e-34	Refractive error;
LGG	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg09699651	chr6:150184138	LRP11	0.51	8.69	0.37	6.26e-17	Lung cancer;
LGG	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg13010199	chr12:38710504	ALG10B	0.52	10.28	0.43	1.87e-22	Morning vs. evening chronotype;
LGG	cis	rs6912958	0.703	rs6903219	chr6:88096498	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.06	0.46	2.25e-25	Monocyte percentage of white cells;
LGG	cis	rs4919087	1.000	rs4919091	chr10:99088682	A/T	cg25902810	chr10:99078978	FRAT1	-0.48	-8.8	-0.38	2.77e-17	Monocyte count;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11203670	chr7:100026453	MEPCE;ZCWPW1	-0.36	-6.69	-0.3	6.53e-11	Brain structure;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	6.85	0.3	2.42e-11	Tonsillectomy;
LGG	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg13271783	chr10:134563150	INPP5A	-0.53	-8.13	-0.35	4.07e-15	Migraine;
LGG	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg17809284	chr5:56205270	C5orf35	0.66	10.55	0.44	1.84e-23	Initial pursuit acceleration;
LGG	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg02297831	chr4:17616191	MED28	0.51	9.66	0.41	3.13e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg24623649	chr8:11872141	NA	0.29	6.74	0.3	4.7e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg27446573	chr6:127587934	RNF146	1.13	22.38	0.72	1e-75	Breast cancer;
LGG	cis	rs3106136	0.527	rs2664894	chr4:95153831	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.01	-0.46	3.26e-25	Capecitabine sensitivity;
LGG	cis	rs921968	0.643	rs590771	chr2:219369851	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.89	0.3	1.84e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs1867631	1.000	rs10889640	chr1:67127851	G/A	cg13052034	chr1:66999238	SGIP1	0.45	8.67	0.37	7.22e-17	Menopause (age at onset);
LGG	cis	rs4253772	0.550	rs9615953	chr22:46731024	C/G	cg09461388	chr22:46763229	CELSR1	-0.67	-6.95	-0.31	1.24e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11645898	0.935	rs72787078	chr16:72158493	C/T	cg14768367	chr16:72042858	DHODH	-0.83	-11.32	-0.47	2.11e-26	Blood protein levels;
LGG	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg01960748	chr1:24522592	NA	-0.51	-7.73	-0.34	6.86e-14	Psoriasis vulgaris;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.92	-0.38	1.05e-17	Longevity;
LGG	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg17545662	chr6:170176663	C6orf70	0.69	8.68	0.37	6.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7100689	0.646	rs1340375	chr10:82129039	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.85	0.38	1.82e-17	Schizophrenia;
LGG	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg22546130	chr22:19950026	COMT	-0.45	-10.58	-0.44	1.47e-23	Blood metabolite levels;
LGG	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.94	0.42	3.01e-21	Coronary artery disease;
LGG	cis	rs3925075	1.000	rs12923297	chr16:31360944	T/C	cg02846316	chr16:31340340	ITGAM	0.4	7.9	0.34	2.1e-14	IgA nephropathy;
LGG	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg02002194	chr4:3960332	NA	0.44	7.82	0.34	3.71e-14	Retinal vascular caliber;
LGG	cis	rs701145	0.537	rs1713819	chr3:153864474	A/G	cg17054900	chr3:154042577	DHX36	0.63	7.86	0.34	2.64e-14	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.48	-0.33	3.72e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs735539	0.645	rs6490600	chr13:21208189	G/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.31	-0.36	1.08e-15	Dental caries;
LGG	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.4	0.81	5.7e-108	Chronic sinus infection;
LGG	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18252515	chr7:66147081	NA	-0.41	-6.92	-0.31	1.52e-11	Aortic root size;
LGG	cis	rs62238980	0.614	rs117017176	chr22:32400725	T/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05464172	chr8:97247954	UQCRB	0.42	7.61	0.33	1.6e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.67	0.54	5.51e-36	Morning vs. evening chronotype;
LGG	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg03788504	chr6:150331562	NA	-0.61	-13.98	-0.54	2.74e-37	Alopecia areata;
LGG	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg05623727	chr3:50126028	RBM5	0.44	9.59	0.41	5.58e-20	Body mass index;
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg13397359	chr6:42928475	GNMT	0.64	18.91	0.66	1.64e-59	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10220309	0.628	rs10138520	chr14:80572248	T/C	cg08183125	chr14:80678293	DIO2	0.47	7.35	0.32	9.2e-13	Lung function (FEV1);
LGG	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg23625390	chr15:77176239	SCAPER	-0.49	-9.63	-0.41	4.05e-20	Blood metabolite levels;
LGG	cis	rs972578	0.715	rs4822205	chr22:43246818	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.78	-0.3	3.73e-11	Mean platelet volume;
LGG	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1018836	0.851	rs10808620	chr8:91622940	T/C	cg16814680	chr8:91681699	NA	-0.84	-16.1	-0.6	1.2e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg25237894	chr2:233734115	C2orf82	-0.72	-15.28	-0.58	5.63e-43	Coronary artery disease;
LGG	cis	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg11984989	chr7:158649758	WDR60	-0.96	-19.86	-0.68	6.08e-64	Height;
LGG	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.63	-0.37	9.81e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7226408	0.857	rs57901563	chr18:34453207	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.51	9.53	0.4	9.04e-20	Brugada syndrome;
LGG	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg13607699	chr17:42295918	UBTF	0.66	11.41	0.47	9.55e-27	Total body bone mineral density;
LGG	cis	rs7267979	0.933	rs11699203	chr20:25435169	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12210905	0.925	rs12212317	chr6:26986553	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.773	rs184949	chr5:130815593	A/G	cg06307176	chr5:131281290	NA	-0.49	-8.15	-0.35	3.37e-15	Life satisfaction;
LGG	cis	rs7122539	0.770	rs10160758	chr11:66673079	C/T	cg01599099	chr11:66649832	PC	-0.45	-9.09	-0.39	2.9e-18	HIV-1 susceptibility;
LGG	trans	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.78e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4780805	0.564	rs8045821	chr16:19397943	C/T	cg03088525	chr16:19421907	TMC5	0.5	7.99	0.35	1.06e-14	Sleep duration;
LGG	cis	rs2280018	1.000	rs2280017	chr16:15151361	A/G	cg07549590	chr16:15018862	NA	0.44	7.96	0.35	1.31e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10979	1.000	rs9390104	chr6:143890978	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.42	-0.5	9.26e-31	Hypospadias;
LGG	cis	rs4356932	0.967	rs28505472	chr4:76972727	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.07e-11	Blood protein levels;
LGG	cis	rs17030434	0.654	rs10021631	chr4:154646675	A/G	cg14289246	chr4:154710475	SFRP2	-0.6	-9.07	-0.39	3.3e-18	Electrocardiographic conduction measures;
LGG	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg15704280	chr7:45808275	SEPT13	0.88	12.43	0.5	8.41e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1707322	1.000	rs785467	chr1:46521559	A/T	cg03146154	chr1:46216737	IPP	-0.53	-10.0	-0.42	1.85e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg03342759	chr3:160939853	NMD3	-0.46	-7.66	-0.34	1.13e-13	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg05091796	chr16:4465799	CORO7	0.62	10.24	0.43	2.59e-22	Schizophrenia;
LGG	cis	rs7737355	0.645	rs184950	chr5:130852847	G/A	cg06307176	chr5:131281290	NA	0.53	8.99	0.39	6.53e-18	Life satisfaction;
LGG	cis	rs2494938	1.000	rs2473584	chr6:40536482	C/T	cg14084896	chr6:40530702	LRFN2	-0.3	-7.06	-0.31	6.22e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg11584989	chr19:19387371	SF4	0.43	7.82	0.34	3.68e-14	Tonsillectomy;
LGG	cis	rs151997	0.777	rs6870880	chr5:50256207	G/A	cg06027927	chr5:50259733	NA	0.65	11.35	0.47	1.62e-26	Callous-unemotional behaviour;
LGG	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg20744362	chr22:50050164	C22orf34	0.41	7.13	0.31	3.82e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.71e-12	Lung cancer;
LGG	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	10.94	0.45	6.45e-25	Parkinson's disease;
LGG	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg18357526	chr6:26021779	HIST1H4A	0.84	15.48	0.58	7.01e-44	Intelligence (multi-trait analysis);
LGG	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg15557168	chr22:42548783	NA	-0.4	-8.64	-0.37	9.24e-17	Schizophrenia;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg02725872	chr8:58115012	NA	-1.03	-14.08	-0.55	9.84e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg18402987	chr7:1209562	NA	0.39	7.02	0.31	7.8e-12	Longevity;Endometriosis;
LGG	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.76	-0.34	5.57e-14	Triglycerides;
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg05941027	chr17:61774174	LIMD2	0.37	9.54	0.41	8.01e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10940138	0.501	rs6877828	chr5:67249904	A/G	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.01	-0.35	9.08e-15	Menarche (age at onset);
LGG	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	8.06	0.35	6.56e-15	Parkinson's disease;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.34	0.5	1.97e-30	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs13160562	0.522	rs26502	chr5:96099958	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.17	0.32	2.94e-12	Alcohol dependence;
LGG	cis	rs6450176	1.000	rs10805455	chr5:53302302	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.54	-0.47	2.91e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg08677398	chr8:58056175	NA	0.44	7.32	0.32	1.13e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg11764359	chr7:65958608	NA	0.64	9.76	0.41	1.41e-20	Aortic root size;
LGG	cis	rs10489202	0.608	rs3753934	chr1:168074677	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-10.01	-0.42	1.77e-21	Schizophrenia;
LGG	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03264133	chr6:25882463	NA	-0.53	-9.99	-0.42	2.04e-21	Blood metabolite levels;
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg02002194	chr4:3960332	NA	-0.47	-8.92	-0.38	1.13e-17	Monocyte count;
LGG	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg25457927	chr22:38595422	NA	-0.35	-8.31	-0.36	1.04e-15	Cutaneous nevi;
LGG	cis	rs590121	0.876	rs653724	chr11:75276467	G/A	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.6	-0.37	1.23e-16	Coronary artery disease;
LGG	cis	rs1256061	0.624	rs1760988	chr14:64696813	A/G	cg23250157	chr14:64679961	SYNE2	0.38	6.87	0.3	2.01e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4650994	0.623	rs35854525	chr1:178618604	C/T	cg19399532	chr1:178512495	C1orf220	-0.36	-6.74	-0.3	4.84e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2798269	1.000	rs1200046	chr13:22131160	C/A	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg05692746	chr2:100937584	LONRF2	-0.53	-8.81	-0.38	2.56e-17	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.6	-0.37	1.27e-16	Mean corpuscular volume;
LGG	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg07636037	chr3:49044803	WDR6	0.98	22.04	0.72	3.83e-74	Parkinson's disease;
LGG	cis	rs6573604	1.000	rs17102587	chr14:65774477	T/C	cg15999311	chr14:65749247	NA	0.46	6.69	0.3	6.26e-11	N-glycan levels;
LGG	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	cis	rs1007190	0.881	rs9900293	chr17:42936003	G/C	cg15406952	chr17:42872593	NA	1.11	14.41	0.56	3.75e-39	DNA methylation (variation);
LGG	cis	rs11264213	0.901	rs72661631	chr1:36417453	A/G	cg27506609	chr1:36549197	TEKT2	0.74	7.71	0.34	7.88e-14	Schizophrenia;
LGG	cis	rs238295	0.805	rs6053527	chr20:5582457	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.43	-6.73	-0.3	5.01e-11	Occipital cortical area (total cortical area interaction);
LGG	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.43	-0.36	4.26e-16	Cognitive test performance;
LGG	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-8.34	-0.36	8.63e-16	Morning vs. evening chronotype;
LGG	cis	rs6541297	1.000	rs6682741	chr1:230279090	T/C	cg20703242	chr1:230279135	GALNT2	0.36	7.48	0.33	3.84e-13	Coronary artery disease;
LGG	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06634786	chr22:41940651	POLR3H	-0.7	-11.62	-0.48	1.46e-27	Vitiligo;
LGG	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg16230307	chr14:35515116	FAM177A1	0.58	9.09	0.39	2.99e-18	Psoriasis;
LGG	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-11.02	-0.46	3.21e-25	Chronic sinus infection;
LGG	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg23649088	chr2:200775458	C2orf69	0.53	7.65	0.34	1.17e-13	Schizophrenia;
LGG	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg07148914	chr20:33460835	GGT7	0.57	9.32	0.4	4.66e-19	Height;
LGG	cis	rs735539	0.874	rs9579927	chr13:21270201	C/T	cg04906043	chr13:21280425	IL17D	0.54	9.31	0.4	5.31e-19	Dental caries;
LGG	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg03959625	chr15:84868606	LOC388152	0.57	9.05	0.39	4.11e-18	Schizophrenia;
LGG	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg01200585	chr1:228362443	C1orf69	0.47	7.97	0.35	1.25e-14	Diastolic blood pressure;
LGG	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.16	-0.35	3.16e-15	Aortic root size;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.33e-16	Lung cancer;
LGG	cis	rs7937612	0.965	rs7932658	chr11:120211212	A/G	cg24566217	chr11:120254723	ARHGEF12	0.51	12.36	0.5	1.6e-30	Intraocular pressure;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.05	-0.35	7.26e-15	Total body bone mineral density;
LGG	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.01e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7267979	0.966	rs2482923	chr20:25308981	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.1	-0.42	8.25e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17879804	chr3:44752500	NA	0.42	7.35	0.32	8.81e-13	Menarche (age at onset);
LGG	trans	rs9354308	0.714	rs1846566	chr6:66615707	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.89	-0.3	1.89e-11	Metabolite levels;
LGG	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg22862634	chr11:62369728	EML3;MTA2	-0.55	-12.2	-0.49	7.35e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg19773385	chr1:10388646	KIF1B	-0.46	-9.84	-0.42	7.24e-21	Hepatocellular carcinoma;
LGG	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg06970220	chr1:156163860	SLC25A44	0.45	6.76	0.3	4.29e-11	Testicular germ cell tumor;
LGG	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs1372520	0.873	rs2583990	chr4:90771499	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.16	-0.35	3.21e-15	Neuroticism;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02475777	chr4:1388615	CRIPAK	0.41	7.44	0.33	4.93e-13	Longevity;
LGG	cis	rs7945718	0.621	rs61879826	chr11:12684486	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg09818912	chr17:20140352	CYTSB	0.32	7.62	0.33	1.42e-13	Schizophrenia;
LGG	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	trans	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg06875740	chr19:51307921	C19orf48	0.65	8.26	0.36	1.56e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.07e-33	Response to antipsychotic treatment;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg16301924	chr13:53314226	LECT1	0.5	9.74	0.41	1.62e-20	Lewy body disease;
LGG	cis	rs9682041	0.932	rs6782252	chr3:170133639	C/T	cg11886554	chr3:170076028	SKIL	0.97	11.12	0.46	1.24e-25	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs12681366	0.762	rs7831073	chr8:95354366	C/G	cg13257157	chr8:95487014	RAD54B	0.39	6.73	0.3	5.12e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs62400317	0.762	rs10484626	chr6:44882271	A/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg20387954	chr3:183756860	HTR3D	0.48	9.21	0.39	1.15e-18	Anterior chamber depth;
LGG	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg07549998	chr6:150325970	RAET1K	-0.36	-6.91	-0.31	1.62e-11	Alopecia areata;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07423838	chr7:73062350	NA	0.47	7.16	0.32	3.21e-12	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg16359550	chr11:109292809	C11orf87	0.7	14.61	0.56	4.82e-40	Schizophrenia;
LGG	cis	rs10861342	1.000	rs11112380	chr12:105526695	C/T	cg23923672	chr12:105501055	KIAA1033	0.84	7.43	0.33	5.43e-13	IgG glycosylation;
LGG	cis	rs2735413	0.918	rs11643649	chr16:78081199	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.06	-0.49	2.53e-29	HDL cholesterol;
LGG	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg13010199	chr12:38710504	ALG10B	-0.57	-10.76	-0.45	2.97e-24	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24695828	chr19:36980257	ZNF566	0.41	6.82	0.3	2.78e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18481087	chr3:160474064	PPM1L	0.46	7.53	0.33	2.6e-13	Cognitive performance;
LGG	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs9649213	0.614	rs62479858	chr7:97924226	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-7.85	-0.34	2.89e-14	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.84	0.45	1.51e-24	Lung cancer in ever smokers;
LGG	cis	rs1669338	0.588	rs3804783	chr3:3184442	C/T	cg16797762	chr3:3221439	CRBN	-0.95	-12.74	-0.51	4.33e-32	White matter integrity;
LGG	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg15704280	chr7:45808275	SEPT13	-0.51	-8.34	-0.36	8.63e-16	HDL cholesterol;
LGG	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg19336497	chr11:14380999	RRAS2	-0.56	-11.56	-0.47	2.53e-27	Sense of smell;
LGG	cis	rs1124376	1.000	rs12488369	chr3:20154059	G/T	cg05072819	chr3:20081367	KAT2B	-0.61	-8.13	-0.35	4.07e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	17.98	0.64	3.14e-55	Chronic sinus infection;
LGG	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.09	-0.6	1.38e-46	Height;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.12	0.31	4.08e-12	Lung cancer;
LGG	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7523273	0.565	rs4081159	chr1:207885479	G/A	cg22525895	chr1:207977042	MIR29B2	0.46	8.65	0.37	8.6e-17	Schizophrenia;
LGG	cis	rs11628318	0.614	rs4906254	chr14:103209153	C/T	cg12046867	chr14:103022105	NA	-0.44	-8.67	-0.37	7.23e-17	Platelet count;
LGG	cis	rs4862307	0.808	rs7666346	chr4:185000657	G/A	cg06737308	chr4:185021514	ENPP6	-0.4	-6.92	-0.31	1.49e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.01	-0.31	8.67e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6831256	0.899	rs36205397	chr4:3470604	A/G	cg23495837	chr4:3480318	DOK7	-0.5	-9.33	-0.4	4.31e-19	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg06697600	chr4:7070879	GRPEL1	-0.53	-9.07	-0.39	3.28e-18	Monocyte percentage of white cells;
LGG	trans	rs6956675	1.000	rs10229492	chr7:62580546	G/A	cg01314568	chr7:57830625	NA	-0.51	-8.07	-0.35	6.27e-15	Obesity-related traits;
LGG	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	7.52	0.33	2.93e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4363385	0.654	rs1129654	chr1:152958238	A/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg09222892	chr1:25734099	RHCE	0.48	10.31	0.43	1.36e-22	Erythrocyte sedimentation rate;
LGG	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.18	-0.46	7.28e-26	Urinary metabolites;
LGG	cis	rs7527798	0.545	rs6696228	chr1:207846830	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-7.01	-0.31	8.35e-12	Erythrocyte sedimentation rate;
LGG	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg02002194	chr4:3960332	NA	0.44	8.1	0.35	4.84e-15	Triglycerides;
LGG	cis	rs7973719	1.000	rs1839622	chr12:7334534	G/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.73	-0.34	6.61e-14	IgG glycosylation;
LGG	cis	rs7241530	0.636	rs4799273	chr18:75898963	C/T	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	cis	rs7811528	0.656	rs58091069	chr7:2705879	C/T	cg11411865	chr7:2701802	TTYH3	0.53	7.39	0.32	6.88e-13	Schizophrenia;
LGG	cis	rs4774899	0.932	rs1867641	chr15:57527722	A/G	cg08128148	chr15:57256372	TCF12	-0.3	-7.07	-0.31	5.75e-12	Urinary tract infection frequency;
LGG	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs2282802	0.685	rs2116790	chr5:139654115	G/A	cg26211634	chr5:139558579	C5orf32	0.34	7.37	0.32	7.85e-13	Intelligence (multi-trait analysis);
LGG	cis	rs16944613	0.541	rs10852135	chr15:91106412	T/C	cg26821196	chr15:91095069	CRTC3	0.59	9.07	0.39	3.46e-18	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg09307838	chr4:120376055	NA	0.59	9.56	0.41	7.16e-20	Corneal astigmatism;
LGG	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg26384229	chr12:38710491	ALG10B	0.92	21.42	0.71	3.21e-71	Bladder cancer;
LGG	cis	rs10463316	0.928	rs4958267	chr5:150752643	A/T	cg03212797	chr5:150827313	SLC36A1	-0.62	-10.86	-0.45	1.23e-24	Metabolite levels (Pyroglutamine);
LGG	cis	rs9399135	0.967	rs6909975	chr6:135315570	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs7089973	0.872	rs35010779	chr10:116631816	A/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg03162506	chr22:38580953	NA	0.39	9.64	0.41	3.55e-20	Breast cancer;
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.35	-0.47	1.65e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg26384229	chr12:38710491	ALG10B	0.84	18.79	0.66	5.82e-59	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg21911579	chr5:131705225	SLC22A5	0.7	7.74	0.34	6.13e-14	Rheumatoid arthritis;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.74	-14.0	-0.55	2.12e-37	Longevity;Endometriosis;
LGG	cis	rs4740619	0.619	rs10738425	chr9:16041576	T/C	cg14451791	chr9:16040625	NA	-0.43	-11.57	-0.47	2.18e-27	Body mass index;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg24565620	chr2:194026	NA	0.68	9.83	0.42	7.44e-21	Blood protein levels;
LGG	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg00666640	chr1:248458726	OR2T12	0.53	8.95	0.38	8.65e-18	Common traits (Other);
LGG	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg02297831	chr4:17616191	MED28	0.46	8.22	0.36	2.1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs9733	0.818	rs4970926	chr1:150673684	T/C	cg13175981	chr1:150552382	MCL1	0.54	9.12	0.39	2.24e-18	Tonsillectomy;
LGG	cis	rs2718058	0.769	rs12155159	chr7:37800529	G/A	cg15028436	chr7:37888078	TXNDC3	-0.47	-8.6	-0.37	1.25e-16	Alzheimer's disease (late onset);
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg11951692	chr20:3761938	SPEF1	0.44	6.65	0.3	8.38e-11	Hepatitis;
LGG	cis	rs61989804	0.590	rs10498517	chr14:65762781	A/G	cg15999311	chr14:65749247	NA	0.67	7.29	0.32	1.33e-12	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.73	-0.34	6.65e-14	Testicular germ cell tumor;
LGG	cis	rs4776059	1.000	rs34431049	chr15:52940538	G/C	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.81	-0.34	3.98e-14	Schizophrenia;
LGG	cis	rs742614	0.935	rs736264	chr20:32482386	C/T	cg06304546	chr20:32448765	NA	0.48	8.74	0.38	4.27e-17	Stearic acid (18:0) levels;
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.75	0.41	1.48e-20	Bipolar disorder;
LGG	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg04863758	chr4:1303710	MAEA	0.43	7.35	0.32	9.16e-13	Obesity-related traits;
LGG	cis	rs999943	0.774	rs10947421	chr6:33611278	G/T	cg14003231	chr6:33640908	ITPR3	0.61	14.29	0.55	1.29e-38	Obesity (extreme);
LGG	cis	rs11966931	0.657	rs12198472	chr6:108151637	G/C	cg04749840	chr6:108095067	SCML4	-0.39	-7.77	-0.34	5.22e-14	Neutrophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02182114	chr7:139876578	LOC100134229;JHDM1D	0.45	7.44	0.33	4.95e-13	Cognitive performance;
LGG	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg09237302	chr4:906077	GAK	-0.51	-10.8	-0.45	2.16e-24	Parkinson's disease;
LGG	cis	rs7551222	0.749	rs11240761	chr1:204566700	C/A	cg20240347	chr1:204465584	NA	-0.45	-8.61	-0.37	1.14e-16	Schizophrenia;
LGG	cis	rs7765175	0.598	rs2842838	chr6:113627471	C/T	cg26552650	chr6:113682475	NA	0.32	7.04	0.31	7.06e-12	Coronary artery calcification;
LGG	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14019695	chr9:139328340	INPP5E	0.42	7.57	0.33	2.01e-13	Monocyte percentage of white cells;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg07414643	chr4:187882934	NA	0.55	11.4	0.47	1.1e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6763768	0.819	rs17788344	chr3:53535098	A/T	cg16894138	chr3:53270350	TKT	0.41	7.18	0.32	2.71e-12	Bacterial meningitis;
LGG	cis	rs883115	0.791	rs10799589	chr1:224819278	C/T	cg01808320	chr1:224927238	CNIH3	0.44	8.2	0.36	2.45e-15	Cancer;
LGG	cis	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.3	0.36	1.12e-15	Diabetic kidney disease;
LGG	trans	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg16006296	chr10:38738647	LOC399744	0.35	6.85	0.3	2.35e-11	Diastolic blood pressure;
LGG	cis	rs7648466	1.000	rs2172246	chr3:46214685	C/A	cg12441928	chr3:46249985	CCR1	-0.55	-10.05	-0.42	1.25e-21	Eotaxin levels;
LGG	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg02631450	chr22:32366979	NA	1.0	9.65	0.41	3.47e-20	Childhood ear infection;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.29	-0.36	1.21e-15	Menopause (age at onset);
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.4	-6.83	-0.3	2.73e-11	Longevity;Endometriosis;
LGG	cis	rs17641971	1.000	rs73579360	chr8:49920586	C/T	cg00325661	chr8:49890786	NA	-0.43	-6.98	-0.31	1.02e-11	Blood metabolite levels;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19524238	chr7:2802976	GNA12	0.41	9.33	0.4	4.42e-19	Height;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg26597838	chr10:835615	NA	-0.75	-10.33	-0.43	1.2e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg04851639	chr8:1020857	NA	-0.42	-8.7	-0.37	5.78e-17	Schizophrenia;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.27	-0.36	1.4e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs593982	0.777	rs534414	chr11:65475515	A/G	cg08755490	chr11:65554678	OVOL1	0.7	8.61	0.37	1.19e-16	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08875180	chr17:21454528	C17orf51	0.48	7.4	0.33	6.59e-13	Gut microbiome composition (summer);
LGG	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg15208524	chr1:10270712	KIF1B	0.44	7.51	0.33	3.03e-13	Hepatocellular carcinoma;
LGG	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.29	0.32	1.38e-12	Neuroticism;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.15	-0.43	5.3e-22	Total body bone mineral density;
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.79	-0.3	3.45e-11	Total body bone mineral density;
LGG	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg08000102	chr2:233561755	GIGYF2	-0.43	-7.11	-0.31	4.34e-12	Coronary artery disease;
LGG	cis	rs283228	0.502	rs2787573	chr6:101847505	C/A	cg02011392	chr6:101847541	GRIK2	0.56	7.44	0.33	4.95e-13	Coenzyme Q10 levels;
LGG	cis	rs7584330	0.910	rs66509917	chr2:238395394	T/G	cg16989719	chr2:238392110	NA	-0.34	-7.56	-0.33	2.19e-13	Prostate cancer;
LGG	cis	rs7503807	0.515	rs34863264	chr17:78655312	C/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.39	-0.47	1.14e-26	Obesity;
LGG	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg18252515	chr7:66147081	NA	-0.41	-6.92	-0.31	1.47e-11	Aortic root size;
LGG	cis	rs8114671	0.935	rs6142313	chr20:33780427	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.47	-0.33	4.03e-13	Height;
LGG	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg10122326	chr6:28072925	NA	0.8	6.65	0.3	8.42e-11	Hip circumference adjusted for BMI;
LGG	cis	rs17253792	0.822	rs74720318	chr14:56099828	G/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs9636252	0.962	rs34462073	chr2:9264793	G/A	cg20341998	chr2:9276514	NA	0.37	7.32	0.32	1.12e-12	IgG glycosylation;
LGG	cis	rs9815354	0.680	rs112310714	chr3:42024797	A/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs5758511	0.573	rs1569451	chr22:42232291	C/T	cg15128208	chr22:42549153	NA	-0.42	-7.23	-0.32	1.98e-12	Birth weight;
LGG	cis	rs7914558	0.966	rs11191518	chr10:104782853	C/G	cg04362960	chr10:104952993	NT5C2	0.53	10.14	0.43	6e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.89	-0.59	1.12e-45	Chronic sinus infection;
LGG	cis	rs483180	0.511	rs496198	chr1:120207177	A/G	cg19096424	chr1:120255104	PHGDH	-0.57	-10.24	-0.43	2.52e-22	Macular telangiectasia type 2;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg00953403	chr17:74099816	EXOC7	-0.4	-6.7	-0.3	6.07e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg03788504	chr6:150331562	NA	-0.54	-12.21	-0.49	6.17e-30	Alopecia areata;
LGG	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg03806693	chr22:41940476	POLR3H	1.05	17.66	0.63	9.32e-54	Vitiligo;
LGG	cis	rs11874712	0.966	rs8094902	chr18:43666774	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs6754311	0.773	rs309180	chr2:136614255	A/G	cg07169764	chr2:136633963	MCM6	0.76	12.99	0.52	4.21e-33	Mosquito bite size;
LGG	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg04733989	chr22:42467013	NAGA	0.57	10.18	0.43	4.26e-22	Schizophrenia;
LGG	cis	rs911555	0.755	rs10144051	chr14:103885931	A/C	cg24130564	chr14:104152367	KLC1	-0.38	-7.16	-0.32	3.23e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2736345	0.788	rs2736336	chr8:11341870	G/T	cg06636001	chr8:8085503	FLJ10661	0.43	6.69	0.3	6.34e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg17376030	chr22:41985996	PMM1	0.5	8.18	0.36	2.71e-15	Vitiligo;
LGG	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg14055004	chr2:241860995	NA	-0.28	-7.63	-0.33	1.32e-13	Joint mobility (Beighton score);
LGG	cis	rs1003719	0.646	rs2032063	chr21:38576657	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	cis	rs709400	0.663	rs17617941	chr14:103953032	T/C	cg26031613	chr14:104095156	KLC1	0.8	13.84	0.54	1.03e-36	Body mass index;
LGG	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.79	-0.41	1.1e-20	Common traits (Other);
LGG	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg17211192	chr8:82754475	SNX16	-0.75	-11.98	-0.49	5.36e-29	Diastolic blood pressure;
LGG	cis	rs139371	0.742	rs139332	chr22:39504602	C/A	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.69	-0.3	6.54e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.31	-0.43	1.38e-22	Longevity;Endometriosis;
LGG	cis	rs7072216	0.763	rs6584202	chr10:100170383	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.28	-0.32	1.44e-12	Metabolite levels;
LGG	cis	rs2050392	0.858	rs306583	chr10:30710057	C/T	cg25182066	chr10:30743637	MAP3K8	0.51	10.5	0.44	2.72e-23	Inflammatory bowel disease;
LGG	cis	rs457717	0.730	rs461187	chr5:75947836	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.3	6.66	0.3	7.99e-11	Hearing impairment;
LGG	cis	rs7202877	0.656	rs37596	chr16:75498320	C/A	cg03315344	chr16:75512273	CHST6	-0.51	-7.06	-0.31	6.26e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.14e-11	Type 2 diabetes;
LGG	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg19507638	chr5:93509721	C5orf36	0.67	9.37	0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg15147215	chr3:52552868	STAB1	-0.45	-9.09	-0.39	2.97e-18	Electroencephalogram traits;
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs977987	0.669	rs1001861	chr16:75306455	G/A	cg03315344	chr16:75512273	CHST6	0.51	9.7	0.41	2.31e-20	Dupuytren's disease;
LGG	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22496380	chr5:211416	CCDC127	-1.29	-18.35	-0.65	6.61e-57	Breast cancer;
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18876405	chr7:65276391	NA	-0.53	-9.08	-0.39	3.24e-18	Aortic root size;
LGG	cis	rs7084783	0.600	rs11191738	chr10:105345984	A/T	cg00126946	chr10:105363258	SH3PXD2A	-0.5	-9.14	-0.39	2.05e-18	Fear of pain;
LGG	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg26655873	chr3:72818019	SHQ1	0.34	6.77	0.3	3.9e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg03970086	chr16:88974840	CBFA2T3	0.4	8.03	0.35	8.02e-15	Social autistic-like traits;
LGG	cis	rs17401966	0.964	rs6674843	chr1:10458378	A/T	cg19773385	chr1:10388646	KIF1B	-0.47	-9.03	-0.39	4.58e-18	Hepatocellular carcinoma;
LGG	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg17644776	chr2:200775616	C2orf69	0.57	8.92	0.38	1.1e-17	Schizophrenia;
LGG	cis	rs12476592	0.602	rs1255	chr2:63825934	T/C	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg22907277	chr7:1156413	C7orf50	0.54	7.4	0.33	6.29e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2692947	0.795	rs2252697	chr2:96778190	G/C	cg22654517	chr2:96458247	NA	-0.38	-8.43	-0.36	4.26e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.19	-0.36	2.63e-15	Aortic root size;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.67e-16	Axial length;
LGG	cis	rs2777491	0.957	rs8026197	chr15:41711447	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.06	-0.68	7e-65	Ulcerative colitis;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg17178900	chr1:205818956	PM20D1	0.59	13.38	0.53	9.17e-35	Menarche (age at onset);
LGG	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg06115741	chr20:33292138	TP53INP2	-0.53	-8.77	-0.38	3.51e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg04990556	chr1:26633338	UBXN11	-0.69	-13.78	-0.54	1.9e-36	Obesity-related traits;
LGG	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-9.2	-0.39	1.21e-18	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.26	-0.36	1.58e-15	Personality dimensions;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	trans	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg27411982	chr8:10470053	RP1L1	-0.45	-8.2	-0.36	2.32e-15	Mood instability;
LGG	trans	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg18187862	chr3:45730750	SACM1L	0.58	9.54	0.41	8.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-9.28	-0.4	6.76e-19	Body mass index;
LGG	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg09307838	chr4:120376055	NA	0.73	12.1	0.49	1.78e-29	Corneal astigmatism;
LGG	cis	rs4664304	0.934	rs72957586	chr2:160762687	G/A	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.36	-0.32	8.37e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.72	0.48	5.77e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9948	0.655	rs17119591	chr2:97435557	G/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.55e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.01	-0.52	3.29e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs774359	0.789	rs2440620	chr9:27497621	T/C	cg14173147	chr9:27528300	MOBKL2B	0.46	8.82	0.38	2.29e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs4430311	0.655	rs12138753	chr1:243795607	G/A	cg25706552	chr1:244017396	NA	-0.64	-15.65	-0.59	1.35e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg25664220	chr3:72788482	NA	0.32	9.24	0.39	9.11e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg14675211	chr2:100938903	LONRF2	0.48	7.38	0.32	7.21e-13	Intelligence (multi-trait analysis);
LGG	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg18551225	chr6:44695536	NA	0.57	8.51	0.37	2.48e-16	Total body bone mineral density;
LGG	cis	rs2798269	0.510	rs7985023	chr13:22123600	A/G	cg18095732	chr13:22033692	ZDHHC20	0.47	8.3	0.36	1.13e-15	PR segment;
LGG	cis	rs713587	0.520	rs488817	chr2:25332696	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-7.73	-0.34	6.86e-14	Body mass index in non-asthmatics;
LGG	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg04398451	chr17:18023971	MYO15A	0.74	15.56	0.59	3.33e-44	Total body bone mineral density;
LGG	cis	rs73787773	0.668	rs56092269	chr5:111479053	T/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.57	-7.5	-0.33	3.2e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg07701084	chr6:150067640	NUP43	0.68	12.77	0.51	3.33e-32	Lung cancer;
LGG	cis	rs3820928	0.869	rs2396436	chr2:227795464	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.71	-0.34	7.97e-14	Pulmonary function;
LGG	cis	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg00383909	chr3:49044727	WDR6	1.13	13.69	0.54	4.85e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4132509	0.744	rs58594024	chr1:243862702	C/A	cg21452805	chr1:244014465	NA	0.94	10.28	0.43	1.81e-22	RR interval (heart rate);
LGG	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12200782	1.000	rs12201802	chr6:26398664	G/A	cg11502198	chr6:26597334	ABT1	-0.85	-6.97	-0.31	1.12e-11	Small cell lung carcinoma;
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg04450456	chr4:17643702	FAM184B	0.31	6.74	0.3	4.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.95	-0.42	2.99e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2694528	0.841	rs77691613	chr5:60417118	C/T	cg11474532	chr5:59995715	DEPDC1B	0.73	7.08	0.31	5.4e-12	Parkinson's disease;
LGG	cis	rs12643440	0.538	rs1522079	chr4:17134960	A/G	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.38	-0.32	7.21e-13	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg18357526	chr6:26021779	HIST1H4A	0.54	9.33	0.4	4.33e-19	Blood metabolite levels;
LGG	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg17230874	chr3:125932073	NA	0.77	16.27	0.6	2.02e-47	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26076054	chr5:421317	AHRR	-0.44	-8.12	-0.35	4.23e-15	Cystic fibrosis severity;
LGG	cis	rs3736594	0.546	rs6719960	chr2:27830067	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.57	-0.37	1.59e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg07606381	chr6:8435919	SLC35B3	-0.67	-12.11	-0.49	1.57e-29	Motion sickness;
LGG	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg01194073	chr14:101175302	NA	0.44	7.02	0.31	8.08e-12	Plateletcrit;
LGG	cis	rs17227506	0.507	rs7840294	chr8:13418513	A/G	cg03566418	chr8:13424080	C8orf48	0.48	7.3	0.32	1.25e-12	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.67	0.34	1.01e-13	Retinal vascular caliber;
LGG	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg13736514	chr6:26305472	NA	-0.48	-8.87	-0.38	1.65e-17	Educational attainment;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg08621203	chr6:150244597	RAET1G	0.47	7.11	0.31	4.38e-12	Lung cancer;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg05091796	chr16:4465799	CORO7	-1.03	-18.97	-0.66	8.41e-60	Schizophrenia;
LGG	cis	rs7241530	0.636	rs12456531	chr18:75899668	G/C	cg14642773	chr18:75888474	NA	0.47	8.99	0.39	6.21e-18	Educational attainment (years of education);
LGG	trans	rs656319	0.535	rs654132	chr8:9808336	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.91	-0.31	1.61e-11	Myopia (pathological);
LGG	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.86	-0.54	8.45e-37	Presence of antiphospholipid antibodies;
LGG	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.82e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2455601	0.882	rs11042105	chr11:8894510	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-11.8	-0.48	2.93e-28	Schizophrenia;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.04	-15.15	-0.58	2.07e-42	Platelet count;
LGG	cis	rs7648466	0.592	rs4683184	chr3:46187707	G/A	cg12441928	chr3:46249985	CCR1	-0.44	-8.62	-0.37	1.03e-16	Eotaxin levels;
LGG	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06634786	chr22:41940651	POLR3H	0.65	10.91	0.45	8.07e-25	Vitiligo;
LGG	cis	rs17253792	0.822	rs10083303	chr14:56068521	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs10426930	0.607	rs2613768	chr19:5074637	G/A	cg15621731	chr19:5074616	KDM4B	0.3	7.3	0.32	1.25e-12	Monocyte percentage of white cells;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14928532	chr9:133454630	LOC100272217;FUBP3	0.42	7.12	0.31	4.02e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg15664640	chr17:80829946	TBCD	-0.65	-9.07	-0.39	3.47e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs283228	0.550	rs675259	chr6:101830113	A/T	cg02011392	chr6:101847541	GRIK2	0.5	6.85	0.3	2.38e-11	Coenzyme Q10 levels;
LGG	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.72	9.98	0.42	2.26e-21	Inflammatory bowel disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20731804	chr6:42858765	C6orf226	0.38	6.78	0.3	3.78e-11	Obesity-related traits;
LGG	cis	rs8032158	1.000	rs11633313	chr15:56135709	A/G	cg02198044	chr15:56286336	NEDD4	-0.69	-11.81	-0.48	2.58e-28	Keloid;
LGG	trans	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.44	0.44	4.71e-23	Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.7e-21	Aortic root size;
LGG	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.41	0.33	6.08e-13	Triglycerides;
LGG	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg01864069	chr14:103024347	NA	0.68	9.73	0.41	1.78e-20	Platelet count;
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.0	0.42	1.91e-21	Height;
LGG	cis	rs2075371	0.897	rs1643102	chr7:133999983	T/A	cg11752832	chr7:134001865	SLC35B4	0.6	11.0	0.46	3.67e-25	Mean platelet volume;
LGG	cis	rs911263	0.961	rs10131490	chr14:68743307	A/G	cg18825221	chr14:68749962	RAD51L1	-0.51	-10.76	-0.45	2.87e-24	Primary biliary cholangitis;
LGG	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-8.71	-0.38	5.39e-17	Headache;
LGG	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg17376030	chr22:41985996	PMM1	0.64	10.34	0.43	1.13e-22	Vitiligo;
LGG	cis	rs2708240	0.905	rs2080154	chr7:147571529	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg26150922	chr2:100937072	LONRF2	-0.55	-9.63	-0.41	4.11e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg04374321	chr14:90722782	PSMC1	0.49	8.1	0.35	4.96e-15	Longevity;
LGG	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	11.63	0.48	1.36e-27	Response to antipsychotic treatment;
LGG	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.99	-0.31	9.43e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs1538970	0.851	rs2055145	chr1:45926495	C/G	cg05343316	chr1:45956843	TESK2	0.74	12.38	0.5	1.28e-30	Platelet count;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg18538332	chr22:24372958	LOC391322	-0.5	-8.56	-0.37	1.66e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs9399135	0.967	rs4451151	chr6:135310546	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.5	0.4	1.1e-19	Red blood cell count;
LGG	cis	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg04990556	chr1:26633338	UBXN11	0.59	8.0	0.35	1.02e-14	Obesity-related traits;
LGG	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg15440763	chr7:158190612	PTPRN2	0.36	7.35	0.32	8.79e-13	Obesity-related traits;
LGG	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.81	-0.38	2.44e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6540556	0.736	rs2076152	chr1:209936060	A/G	cg23920097	chr1:209922102	NA	-0.42	-7.65	-0.33	1.19e-13	Red blood cell count;
LGG	cis	rs12410462	0.681	rs79461024	chr1:227568783	G/T	cg04117972	chr1:227635322	NA	0.72	11.07	0.46	1.96e-25	Major depressive disorder;
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg06719900	chr11:109292894	C11orf87	0.73	14.95	0.57	1.68e-41	Schizophrenia;
LGG	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9354308	0.764	rs9342506	chr6:66581774	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.06e-11	Metabolite levels;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs7072216	0.763	rs10736129	chr10:100171571	C/T	cg26618903	chr10:100175079	PYROXD2	0.28	6.9	0.31	1.77e-11	Metabolite levels;
LGG	cis	rs5769707	0.521	rs6009810	chr22:50059540	A/G	cg06623630	chr22:50017776	C22orf34	-0.44	-8.62	-0.37	1.05e-16	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2795502	1.000	rs3121278	chr10:43375646	G/T	cg20628663	chr10:43360327	NA	0.4	7.7	0.34	8.11e-14	Blood protein levels;
LGG	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg14541582	chr5:601475	NA	-0.56	-8.95	-0.38	8.67e-18	Obesity-related traits;
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.38e-28	Alzheimer's disease;
LGG	cis	rs870825	0.860	rs60022249	chr4:185600772	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	19.83	0.68	8.12e-64	Blood protein levels;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.81	-0.34	3.96e-14	Menopause (age at onset);
LGG	cis	rs1729951	0.575	rs361239	chr3:136701295	G/T	cg21827317	chr3:136751795	NA	0.53	9.8	0.41	1.02e-20	Neuroticism;
LGG	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs9443645	0.527	rs10943596	chr6:79575292	C/T	cg18132916	chr6:79620363	NA	-0.27	-7.14	-0.31	3.63e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg16662043	chr16:48846231	NA	0.33	6.66	0.3	7.91e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13732083	chr21:47605072	C21orf56	-0.5	-8.58	-0.37	1.49e-16	Testicular germ cell tumor;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.44	-0.47	7.4e-27	Tonsillectomy;
LGG	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg21640587	chr11:117668038	DSCAML1	0.6	9.84	0.42	7.42e-21	Myopia;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.86	0.54	8.38e-37	Prudent dietary pattern;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19717773	chr7:2847554	GNA12	-0.31	-6.73	-0.3	4.94e-11	Height;
LGG	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2e-21	Height;
LGG	cis	rs16854884	0.770	rs6782024	chr3:143816936	G/C	cg06585982	chr3:143692056	C3orf58	0.55	8.93	0.38	1.02e-17	Economic and political preferences (feminism/equality);
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.63	-11.18	-0.46	7.27e-26	Obesity-related traits;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.39e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg00908189	chr16:619842	PIGQ	0.87	16.74	0.61	1.61e-49	Height;
LGG	cis	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs3820928	0.904	rs10933161	chr2:227764872	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.42	-0.33	5.59e-13	Pulmonary function;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.17e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg15596359	chr8:11213517	TDH	0.41	8.43	0.36	4.55e-16	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27304813	chr3:120068385	LRRC58	0.49	7.67	0.34	1.03e-13	Gut microbiome composition (summer);
LGG	cis	rs10861342	1.000	rs7968711	chr12:105447921	G/A	cg23923672	chr12:105501055	KIAA1033	0.76	6.7	0.3	6.22e-11	IgG glycosylation;
LGG	cis	rs7766436	0.845	rs1342207	chr6:22587762	G/A	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs7166081	1.000	rs1444935	chr15:67635420	A/G	cg05925327	chr15:68127851	NA	-0.33	-7.11	-0.31	4.37e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg24060327	chr5:131705240	SLC22A5	0.49	8.53	0.37	2.12e-16	Blood metabolite levels;
LGG	cis	rs13401104	0.716	rs11687393	chr2:237143805	G/C	cg15742758	chr2:237126235	ASB18	0.49	7.87	0.34	2.49e-14	Educational attainment;
LGG	cis	rs7715811	1.000	rs2896103	chr5:13764419	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.84	-0.42	7.13e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.33	0.58	3.48e-43	Lymphocyte percentage of white cells;
LGG	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg20476274	chr7:133979776	SLC35B4	0.5	8.94	0.38	9.66e-18	Mean platelet volume;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.19	-0.32	2.62e-12	Prostate cancer;
LGG	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg26384229	chr12:38710491	ALG10B	-0.89	-20.64	-0.69	1.36e-67	Heart rate;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.8	-0.45	2.08e-24	Lung cancer;
LGG	trans	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg24634471	chr8:143751801	JRK	0.52	8.35	0.36	8.24e-16	Schizophrenia;
LGG	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.28	0.4	6.75e-19	Diabetic retinopathy;
LGG	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg16325326	chr1:53192061	ZYG11B	0.71	14.34	0.55	7.51e-39	Monocyte count;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-12.74	-0.51	4.34e-32	Colorectal cancer;
LGG	cis	rs7178909	0.872	rs3784387	chr15:90437370	G/A	cg19708238	chr15:90437601	AP3S2	0.41	6.82	0.3	2.92e-11	Common traits (Other);
LGG	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.99	0.39	6.15e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.76	0.34	5.3e-14	Neuroticism;
LGG	cis	rs12618769	0.543	rs3769728	chr2:99103001	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.53	0.37	2.15e-16	Bipolar disorder;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.74	-0.59	5.09e-45	Skin colour saturation;
LGG	cis	rs736408	0.608	rs2239547	chr3:52855229	T/C	cg11645453	chr3:52864694	ITIH4	0.63	10.05	0.42	1.3e-21	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.4	0.36	5.36e-16	Lung cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17928916	chr17:80041824	FASN	0.39	6.86	0.3	2.19e-11	Menarche (age at onset);
LGG	cis	rs2455601	0.529	rs2653569	chr11:8986978	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-10.64	-0.44	8.22e-24	Schizophrenia;
LGG	cis	rs2380220	0.541	rs72928273	chr6:96079360	C/T	cg04719120	chr6:96025338	MANEA	-0.55	-7.76	-0.34	5.36e-14	Behavioural disinhibition (generation interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00085830	chr1:182808254	DHX9	0.42	6.72	0.3	5.49e-11	Cognitive performance;
LGG	cis	rs7666738	0.753	rs35146453	chr4:98902278	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.04e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg04568710	chr12:38710424	ALG10B	0.41	8.73	0.38	4.68e-17	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg01338084	chr22:32026380	PISD	1.51	12.81	0.51	2.35e-32	Age-related hearing impairment;
LGG	trans	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-7.67	-0.34	1.02e-13	Menarche (age at onset);
LGG	cis	rs490234	0.934	rs571675	chr9:128297692	C/T	cg14078157	chr9:128172775	NA	0.4	7.56	0.33	2.24e-13	Mean arterial pressure;
LGG	cis	rs11711311	0.910	rs62265549	chr3:113396234	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.8	0.54	1.58e-36	IgG glycosylation;
LGG	cis	rs35883536	0.545	rs56674564	chr1:101097718	T/C	cg06223162	chr1:101003688	GPR88	0.34	7.8	0.34	4.07e-14	Monocyte count;
LGG	cis	rs701145	0.640	rs896016	chr3:153929902	C/T	cg17054900	chr3:154042577	DHX36	0.83	9.26	0.4	7.38e-19	Coronary artery disease;
LGG	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg05091796	chr16:4465799	CORO7	-0.85	-13.18	-0.52	6.62e-34	Schizophrenia;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs668210	0.793	rs522553	chr11:65771669	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.74	9.91	0.42	4.04e-21	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.15	-0.52	9.1e-34	Colorectal cancer;
LGG	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.32	0.32	1.11e-12	Morning vs. evening chronotype;
LGG	cis	rs2964802	0.505	rs6872243	chr5:10818337	C/T	cg14521931	chr5:10832172	NA	-0.74	-16.04	-0.6	2.39e-46	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-7.13	-0.31	3.79e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg15627072	chr1:2432621	PLCH2	-0.39	-8.53	-0.37	2.15e-16	Ulcerative colitis;
LGG	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg23461800	chr14:103021989	NA	0.52	8.21	0.36	2.29e-15	Platelet count;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22555675	chr19:17799230	UNC13A	0.47	7.15	0.32	3.37e-12	Hip circumference;
LGG	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg03060546	chr3:49711283	APEH	-0.69	-11.56	-0.47	2.48e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg13385794	chr1:248469461	NA	0.49	8.36	0.36	7.35e-16	Common traits (Other);
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg18357526	chr6:26021779	HIST1H4A	0.43	7.04	0.31	7.08e-12	Height;
LGG	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg18681998	chr4:17616180	MED28	0.87	20.23	0.69	1.1000000000000001e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs516946	0.797	rs10106563	chr8:41533200	C/A	cg12439423	chr8:41522721	ANK1	0.42	7.19	0.32	2.67e-12	Type 2 diabetes;
LGG	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg17330251	chr7:94953956	PON1	-0.42	-8.35	-0.36	8.26e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7236492	0.572	rs7242868	chr18:77179564	G/A	cg15532942	chr18:77220712	NFATC1	0.52	7.48	0.33	3.77e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9287719	0.967	rs6432114	chr2:10744930	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg04455712	chr21:45112962	RRP1B	0.54	10.01	0.42	1.79e-21	Mean corpuscular volume;
LGG	cis	rs889398	0.616	rs35808754	chr16:69771710	G/T	cg00738113	chr16:70207722	CLEC18C	0.24	6.67	0.3	7.19e-11	Body mass index;
LGG	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.22	0.32	2.08e-12	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07504864	chr6:88412167	NCRNA00120;AKIRIN2	0.46	7.73	0.34	6.89e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2088885	0.967	rs11917336	chr3:170970130	G/T	cg18052528	chr3:170975382	TNIK	0.28	7.03	0.31	7.42e-12	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs6580649	0.771	rs1635535	chr12:48386241	A/G	cg24011408	chr12:48396354	COL2A1	0.6	7.06	0.31	6.07e-12	Lung cancer;
LGG	cis	rs75920871	1.000	rs61905705	chr11:116883776	A/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.99e-12	Subjective well-being;
LGG	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg06627628	chr2:24431161	ITSN2	-0.67	-10.58	-0.44	1.37e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs5742933	0.725	rs1132360	chr2:190526224	C/T	cg10453823	chr2:190539512	ANKAR	-0.46	-6.72	-0.3	5.31e-11	Ferritin levels;
LGG	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-11.49	-0.47	4.89e-27	Hemoglobin concentration;
LGG	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg12165864	chr7:66369176	NA	-0.58	-9.27	-0.4	7.13e-19	Corneal structure;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	2.98e-13	Schizophrenia;
LGG	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg14893161	chr1:205819251	PM20D1	-0.44	-7.57	-0.33	2.06e-13	Menarche (age at onset);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09781932	chr11:117651301	DSCAML1	-0.34	-6.88	-0.3	1.96e-11	Bipolar disorder;
LGG	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg03060546	chr3:49711283	APEH	0.73	13.18	0.52	6.83e-34	Resting heart rate;
LGG	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-6.72	-0.3	5.25e-11	Type 2 diabetes;
LGG	cis	rs9814567	0.752	rs1534030	chr3:134330083	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.6	-0.44	1.2e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs9487094	0.885	rs13212766	chr6:109705431	C/A	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.15e-18	Height;
LGG	cis	rs9393813	0.626	rs2393926	chr6:27320744	G/C	cg18711553	chr6:27366782	ZNF391	0.5	9.71	0.41	2.14e-20	Bipolar disorder;
LGG	cis	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.74	0.3	4.83e-11	Systolic blood pressure;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg01988459	chr11:68622903	NA	-0.62	-12.72	-0.51	5.14e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.52	-0.53	2.34e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs751728	0.717	rs3763258	chr6:33773744	A/G	cg25922239	chr6:33757077	LEMD2	0.65	10.09	0.42	8.62e-22	Crohn's disease;
LGG	trans	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg21385522	chr1:16154831	NA	0.54	9.63	0.41	3.9e-20	Systolic blood pressure;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg26513180	chr16:89883248	FANCA	1.0	9.57	0.41	6.29e-20	Skin colour saturation;
LGG	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21659725	chr3:3221576	CRBN	0.92	20.33	0.69	4e-66	Intelligence (multi-trait analysis);
LGG	cis	rs2764208	0.576	rs2492862	chr6:34603303	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.52	-0.33	2.86e-13	Systemic lupus erythematosus;
LGG	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg05585630	chr7:157510462	PTPRN2	-0.66	-13.71	-0.54	3.97e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13012494	chr21:47604986	C21orf56	0.5	8.56	0.37	1.64e-16	Testicular germ cell tumor;
LGG	cis	rs1015291	0.680	rs1388677	chr12:19994112	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-9.68	-0.41	2.64e-20	IgG glycosylation;
LGG	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.52	-8.94	-0.38	9.63e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17125944	0.615	rs2357944	chr14:53305573	T/G	cg00686598	chr14:53173677	PSMC6	-0.79	-7.99	-0.35	1.06e-14	Alzheimer's disease (late onset);
LGG	cis	rs910187	0.678	rs6018329	chr20:45813184	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-8.95	-0.38	8.36e-18	Migraine;
LGG	cis	rs10875746	0.669	rs11168510	chr12:48685555	A/G	cg24011408	chr12:48396354	COL2A1	-0.59	-7.51	-0.33	2.98e-13	Longevity (90 years and older);
LGG	cis	rs2797369	0.546	rs11963911	chr6:101308421	T/C	cg27451362	chr6:101846650	GRIK2	0.56	8.64	0.37	9.07e-17	Renal function-related traits (eGRFcrea);
LGG	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg20991723	chr1:152506922	NA	-0.71	-14.38	-0.56	4.83e-39	Hair morphology;
LGG	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg20307385	chr11:47447363	PSMC3	-0.43	-6.97	-0.31	1.12e-11	Migraine - clinic-based;
LGG	cis	rs7582720	1.000	rs72932767	chr2:203679306	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.79e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7712401	0.601	rs2910136	chr5:122254017	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.82	-0.3	2.88e-11	Mean platelet volume;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg06654118	chr4:1303317	MAEA	0.44	7.77	0.34	5.06e-14	Obesity-related traits;
LGG	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg11502198	chr6:26597334	ABT1	0.71	12.84	0.51	1.66e-32	Intelligence (multi-trait analysis);
LGG	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.94	0.52	6.37e-33	Cognitive test performance;
LGG	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg08824895	chr13:115047677	UPF3A	0.42	7.1	0.31	4.87e-12	Schizophrenia;
LGG	cis	rs3849046	0.781	rs11745065	chr5:137939170	G/C	cg10920316	chr5:137946599	NA	-0.46	-7.27	-0.32	1.53e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7937612	1.000	rs7117063	chr11:120238824	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.33e-32	Intraocular pressure;
LGG	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg09596252	chr17:78655493	RPTOR	-0.44	-7.69	-0.34	8.84e-14	Obesity;
LGG	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.9	0.31	1.76e-11	Total cholesterol levels;
LGG	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg00292662	chr22:38071168	LGALS1	-0.37	-6.91	-0.31	1.62e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg08603382	chr10:743973	NA	0.42	7.78	0.34	4.86e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs972578	1.000	rs6002997	chr22:43392264	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.56e-11	Mean platelet volume;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg04568710	chr12:38710424	ALG10B	0.38	8.03	0.35	7.99e-15	Bladder cancer;
LGG	cis	rs7226408	0.640	rs1968334	chr18:34343634	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.79	-0.3	3.46e-11	Obesity-related traits;
LGG	cis	rs7301826	0.610	rs7957899	chr12:131279076	T/C	cg11011512	chr12:131303247	STX2	0.41	8.79	0.38	2.95e-17	Plasma plasminogen activator levels;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs653465	0.739	rs66506821	chr3:27121942	G/A	cg02860705	chr3:27208620	NA	-0.38	-7.35	-0.32	9.12e-13	Breast cancer (early onset);
LGG	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg04608330	chr12:45269318	NELL2	0.63	11.14	0.46	1.09e-25	Gut microbiome composition (summer);
LGG	cis	rs11608355	0.515	rs1045582	chr12:109915727	G/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs9649465	0.967	rs12538876	chr7:123296320	C/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.21e-17	Migraine;
LGG	trans	rs9929218	0.581	rs4783676	chr16:68801077	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	18.49	0.65	1.52e-57	Colorectal cancer;
LGG	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.43e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs71403859	0.502	rs8053720	chr16:71456142	C/G	cg08717414	chr16:71523259	ZNF19	-1.14	-13.56	-0.53	1.66e-35	Post bronchodilator FEV1;
LGG	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg19761014	chr17:28927070	LRRC37B2	0.7	8.88	0.38	1.53e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.05	-0.42	1.24e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2018055	1.000	rs2018055	chr6:117814167	T/C	cg14611402	chr6:117803162	DCBLD1	0.3	8.18	0.36	2.69e-15	Diastolic blood pressure;
LGG	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	6.12e-13	HDL cholesterol;
LGG	cis	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.86	0.34	2.64e-14	Pursuit maintenance gain;
LGG	cis	rs2718058	0.583	rs2722248	chr7:37845286	G/T	cg24998770	chr7:37888106	TXNDC3	0.45	7.25	0.32	1.72e-12	Alzheimer's disease (late onset);
LGG	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.38	0.36	6.43e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg16325326	chr1:53192061	ZYG11B	0.74	16.19	0.6	5.1e-47	Monocyte count;
LGG	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.22	-0.32	2.12e-12	Menarche (age at onset);
LGG	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg10523679	chr1:76189770	ACADM	0.79	15.21	0.58	1.16e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg26111184	chr2:27255694	TMEM214	-0.47	-6.98	-0.31	1.04e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs981844	0.740	rs6815202	chr4:154682440	A/G	cg14289246	chr4:154710475	SFRP2	-0.6	-10.75	-0.45	3.4e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.28	0.36	1.3e-15	Schizophrenia;
LGG	cis	rs6693567	0.565	rs12736375	chr1:150411912	T/C	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg25486957	chr4:152246857	NA	-0.37	-6.65	-0.3	8.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1568889	0.730	rs6484350	chr11:28113658	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.86	-19.36	-0.67	1.24e-61	Bipolar disorder;
LGG	cis	rs7814319	0.870	rs2292836	chr8:97239613	A/C	cg20787634	chr8:97240163	UQCRB	-0.77	-18.32	-0.65	9.1e-57	Lung function (FVC);
LGG	cis	rs12367572	0.620	rs2643140	chr12:45418311	C/T	cg03114573	chr12:45410052	DBX2	-0.69	-12.73	-0.51	4.98e-32	Gut microbiome composition (summer);
LGG	cis	rs4731207	0.564	rs10954060	chr7:124626037	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg04374321	chr14:90722782	PSMC1	0.42	6.66	0.3	7.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6694672	1.000	rs1576877	chr1:197047639	A/G	cg13682187	chr1:196946512	CFHR5	0.51	7.23	0.32	2.04e-12	Asthma;
LGG	cis	rs77372450	0.636	rs6556089	chr5:157000854	C/G	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg25554036	chr4:6271136	WFS1	0.62	11.72	0.48	5.78e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg02002194	chr4:3960332	NA	0.47	8.9	0.38	1.28e-17	Joint mobility (Beighton score);
LGG	cis	rs7851660	0.809	rs10115216	chr9:100657119	G/T	cg13688889	chr9:100608707	NA	0.63	12.63	0.51	1.28e-31	Strep throat;
LGG	cis	rs6963495	0.818	rs818619	chr7:105172505	A/T	cg21420622	chr7:105162941	PUS7	-0.45	-7.05	-0.31	6.48e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs876084	0.505	rs10738134	chr8:121168145	T/C	cg06265175	chr8:121136014	COL14A1	0.46	9.14	0.39	1.95e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16524936	chr4:1340807	KIAA1530	-0.45	-6.87	-0.3	2.04e-11	Obesity-related traits;
LGG	cis	rs2658782	0.704	rs2605614	chr11:93232745	A/G	cg15737290	chr11:93063684	CCDC67	0.47	7.0	0.31	9.03e-12	Pulmonary function decline;
LGG	cis	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg24110177	chr3:50126178	RBM5	0.54	8.71	0.38	5.45e-17	Intelligence (multi-trait analysis);
LGG	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg02463440	chr8:22132932	PIWIL2	0.49	10.94	0.45	5.97e-25	Hypertriglyceridemia;
LGG	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27286337	chr10:134555280	INPP5A	0.83	12.34	0.5	2e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1682825	0.505	rs2600066	chr3:10771817	G/T	cg23512531	chr3:10780469	NA	-0.58	-9.31	-0.4	5.25e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg02461776	chr11:598696	PHRF1	0.42	6.96	0.31	1.16e-11	Systemic lupus erythematosus;
LGG	cis	rs9796	0.689	rs72737758	chr15:41449778	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.56	-0.41	6.83e-20	Menopause (age at onset);
LGG	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.43	-0.53	5.7e-35	Retinal vascular caliber;
LGG	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg06889755	chr6:150326021	RAET1K	-0.39	-8.12	-0.35	4.33e-15	Alopecia areata;
LGG	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg03433033	chr1:76189801	ACADM	0.82	15.07	0.57	4.86e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg21548813	chr6:291882	DUSP22	-0.73	-12.88	-0.51	1.15e-32	Menopause (age at onset);
LGG	cis	rs4799461	0.643	rs1941951	chr18:35128263	T/C	cg27332583	chr18:35150602	NA	0.58	10.58	0.44	1.42e-23	Neuroticism;
LGG	cis	rs3796727	0.607	rs4696865	chr4:8618239	C/T	cg05284713	chr4:8621361	CPZ	-0.33	-6.73	-0.3	5.14e-11	Sporadic neuroblastoma;
LGG	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg02649063	chr16:55794731	CES4	0.48	8.21	0.36	2.17e-15	Response to dabigatran etexilate treatment;
LGG	cis	rs61931739	0.500	rs2389269	chr12:34034179	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.19e-26	Morning vs. evening chronotype;
LGG	cis	rs7010267	0.570	rs2326194	chr8:120043960	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs17122278	1.000	rs11216922	chr11:118465295	A/G	cg27286069	chr11:118481882	PHLDB1	-0.55	-6.72	-0.3	5.25e-11	Total cholesterol levels;
LGG	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg23029597	chr12:123009494	RSRC2	-0.91	-16.78	-0.61	1.05e-49	Body mass index;
LGG	cis	rs2274273	0.638	rs3759667	chr14:55658421	A/G	cg04306507	chr14:55594613	LGALS3	0.52	11.84	0.48	1.88e-28	Protein biomarker;
LGG	cis	rs10193935	0.792	rs13423729	chr2:42492874	C/T	cg27598129	chr2:42591480	NA	-0.56	-8.49	-0.37	2.92e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62064224	0.738	rs2344972	chr17:30633671	G/C	cg18200150	chr17:30822561	MYO1D	0.55	10.68	0.44	5.75e-24	Schizophrenia;
LGG	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg12573674	chr2:1569213	NA	-0.61	-9.06	-0.39	3.6e-18	IgG glycosylation;
LGG	trans	rs11134654	1.000	rs11134654	chr5:170240423	A/C	cg20034712	chr19:52675470	ZNF836	-0.47	-7.72	-0.34	7.44e-14	Smooth-surface caries;
LGG	cis	rs7202877	0.610	rs3844219	chr16:75370230	G/T	cg03315344	chr16:75512273	CHST6	0.55	7.58	0.33	1.89e-13	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12016809	chr21:47604291	C21orf56	0.58	10.1	0.42	8.5e-22	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.6	0.33	1.66e-13	Tonsillectomy;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-7.53	-0.33	2.61e-13	Morning vs. evening chronotype;
LGG	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg20891558	chr2:74357851	NA	0.47	9.28	0.4	6.67e-19	Gestational age at birth (maternal effect);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg10490147	chr1:11120546	SRM	-0.31	-7.12	-0.31	4.06e-12	Iris color (L* coordinate);
LGG	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.11e-11	Blood metabolite levels;
LGG	trans	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.38	8.07	0.35	6.04e-15	Obesity-related traits;
LGG	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.99	-0.42	2.07e-21	Mean corpuscular volume;
LGG	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg16230307	chr14:35515116	FAM177A1	0.42	7.44	0.33	5e-13	Psoriasis;
LGG	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.7	-0.3	6.06e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg11247378	chr22:39784982	NA	-0.31	-9.15	-0.39	1.86e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.0	-0.52	3.57e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00294572	chr6:26285232	NA	0.39	6.85	0.3	2.41e-11	Educational attainment;
LGG	cis	rs11690935	0.959	rs6759575	chr2:172689068	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.37	-0.77	3.13e-94	Schizophrenia;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg01200585	chr1:228362443	C1orf69	-0.45	-7.91	-0.34	1.93e-14	Diastolic blood pressure;
LGG	trans	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg10523679	chr1:76189770	ACADM	0.77	14.61	0.56	4.92e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg17644776	chr2:200775616	C2orf69	0.59	8.34	0.36	8.88e-16	Schizophrenia;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.68	0.3	6.86e-11	Rheumatoid arthritis;
LGG	trans	rs6560039	1	rs6560039	chr9:90474946	C/T	cg24436365	chr6:63940138	NA	0.86	17.96	0.64	3.95e-55	Gait variability;
LGG	cis	rs7572644	0.760	rs10190494	chr2:28131243	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.69	-0.3	6.33e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg19418458	chr7:158789849	NA	-0.56	-11.19	-0.46	6.6e-26	Facial morphology (factor 20);
LGG	trans	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	8.67	0.37	7.45e-17	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-11.03	-0.46	2.7e-25	Neuroticism;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.36	0.4	3.5e-19	Alzheimer's disease;
LGG	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.25	-0.36	1.69e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7119	0.717	rs12911854	chr15:77817288	T/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg26513180	chr16:89883248	FANCA	0.83	8.72	0.38	5.12e-17	Skin colour saturation;
LGG	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.05	0.42	1.22e-21	Motion sickness;
LGG	cis	rs9534288	0.700	rs4942466	chr13:46597190	A/G	cg15192986	chr13:46630673	CPB2	-0.57	-12.37	-0.5	1.43e-30	Blood protein levels;
LGG	cis	rs28374715	0.681	rs7165396	chr15:41586947	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.27	-29.5	-0.81	2.1e-108	Ulcerative colitis;
LGG	cis	rs7927771	0.864	rs11600581	chr11:47448497	T/C	cg20307385	chr11:47447363	PSMC3	-0.58	-10.61	-0.44	1.14e-23	Subjective well-being;
LGG	cis	rs806215	0.547	rs12540484	chr7:127370040	G/A	cg25922125	chr7:127225783	GCC1	-0.5	-7.29	-0.32	1.34e-12	Type 2 diabetes;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	11.27	0.46	3.36e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12229367	chr17:55822335	NA	0.45	8.72	0.38	5.02e-17	Schizophrenia;
LGG	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	16.85	0.62	5.15e-50	Smoking behavior;
LGG	cis	rs12482904	0.895	rs2839509	chr21:43846729	C/T	cg23042151	chr21:43824109	UBASH3A	0.51	9.57	0.41	6.42e-20	Vitiligo;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.5	-0.61	1.98e-48	Skin colour saturation;
LGG	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00424166	chr6:150045504	NUP43	-0.33	-6.84	-0.3	2.52e-11	Lung cancer;
LGG	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.77	15.41	0.58	1.46e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14442939	chr10:27389572	ANKRD26	0.76	11.89	0.48	1.22e-28	Breast cancer;
LGG	trans	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg25214090	chr10:38739885	LOC399744	0.69	12.38	0.5	1.34e-30	Corneal astigmatism;
LGG	cis	rs9583531	0.657	rs9521915	chr13:111384528	C/T	cg24331049	chr13:111365604	ING1	0.84	14.6	0.56	5.33e-40	Coronary artery disease;
LGG	cis	rs7166081	1.000	rs4776350	chr15:67542179	C/G	cg05925327	chr15:68127851	NA	-0.33	-6.82	-0.3	2.9e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.57	10.98	0.45	4.3e-25	Total body bone mineral density;
LGG	cis	rs1707322	0.717	rs1972410	chr1:46080947	G/T	cg03146154	chr1:46216737	IPP	0.53	10.35	0.43	1.05e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg22232500	chr2:134024266	NCKAP5	-0.62	-8.67	-0.37	7.53e-17	Bipolar disorder;
LGG	cis	rs9463078	0.764	rs7754698	chr6:44782717	A/G	cg25276700	chr6:44698697	NA	-0.4	-8.52	-0.37	2.32e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.93	0.35	1.61e-14	Height;
LGG	cis	rs4629710	0.592	rs3777476	chr6:131533821	A/C	cg12606694	chr6:131520996	AKAP7	0.51	8.35	0.36	8.12e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg04743876	chr7:130013617	NA	-0.35	-8.05	-0.35	7.17e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs8114671	0.562	rs6087643	chr20:33474462	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.91	0.38	1.17e-17	Height;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg19635926	chr16:89946313	TCF25	0.72	7.11	0.31	4.48e-12	Skin colour saturation;
LGG	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.97	0.42	2.39e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg03929089	chr4:120376271	NA	0.83	13.83	0.54	1.12e-36	Coronary artery disease;
LGG	trans	rs56346965	1.000	rs2192008	chr2:191545147	C/T	cg26081003	chr17:41323112	NBR1	0.33	6.83	0.3	2.71e-11	Bone mineral density (Ward's triangle area);
LGG	cis	rs80282103	0.618	rs74117831	chr10:1145707	A/C	cg08668510	chr10:1095578	IDI1	0.77	7.63	0.33	1.32e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs9640161	0.830	rs35635199	chr7:150063342	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-10.1	-0.43	8.08e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs12476592	0.602	rs959195	chr2:63804125	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg24687543	chr11:63912206	MACROD1	-0.61	-8.73	-0.38	4.57e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4843185	0.699	rs11865	chr16:85709316	A/G	cg26571870	chr16:85723150	GINS2	-0.4	-7.3	-0.32	1.27e-12	Platelet distribution width;
LGG	cis	rs17776563	0.614	rs6496502	chr15:89127460	A/G	cg05013243	chr15:89149849	MIR1179	-0.33	-6.87	-0.3	2.03e-11	Thyroid hormone levels;
LGG	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.43	-0.75	2.68e-85	Height;
LGG	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg16141378	chr3:129829833	LOC729375	-0.49	-12.55	-0.5	2.73e-31	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10392504	chr7:5464594	TNRC18	0.45	6.66	0.3	7.66e-11	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg25486957	chr4:152246857	NA	-0.4	-7.0	-0.31	9.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1372520	0.748	rs2737002	chr4:90753180	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.1	-0.35	4.76e-15	Neuroticism;
LGG	cis	rs5753037	0.665	rs1961926	chr22:30223813	C/T	cg01021169	chr22:30184971	ASCC2	-0.41	-7.95	-0.35	1.39e-14	Type 1 diabetes;
LGG	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg15208524	chr1:10270712	KIF1B	0.41	6.69	0.3	6.47e-11	Hepatocellular carcinoma;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg19635926	chr16:89946313	TCF25	0.73	7.2	0.32	2.49e-12	Skin colour saturation;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg01879757	chr17:41196368	BRCA1	-0.46	-9.07	-0.39	3.51e-18	Menopause (age at onset);
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.75	-0.34	5.98e-14	Total body bone mineral density;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.51	-8.0	-0.35	9.73e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs7927771	0.756	rs10742803	chr11:47439938	A/G	cg20307385	chr11:47447363	PSMC3	0.59	10.76	0.45	3e-24	Subjective well-being;
LGG	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.32	-0.32	1.14e-12	Retinal vascular caliber;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg07211511	chr3:129823064	LOC729375	-0.51	-7.57	-0.33	2.06e-13	Blood pressure (smoking interaction);
LGG	cis	rs9900972	0.877	rs8064344	chr17:76876974	C/T	cg00961940	chr17:76876995	TIMP2	0.46	8.48	0.37	3.04e-16	Obesity-related traits;
LGG	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs807029	0.533	rs12571302	chr10:102742763	C/A	cg04662943	chr10:102668895	NA	0.48	7.0	0.31	9.01e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.02	0.31	8.13e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7178909	0.902	rs3853638	chr15:90443140	C/T	cg19708238	chr15:90437601	AP3S2	-0.43	-7.28	-0.32	1.41e-12	Common traits (Other);
LGG	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.0	0.39	6.01e-18	Motion sickness;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05665937	chr4:1216051	CTBP1	0.56	10.63	0.44	9.46e-24	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.66	0.37	8.06e-17	Platelet count;
LGG	cis	rs10871290	0.650	rs3760055	chr16:74490529	G/A	cg01733217	chr16:74700730	RFWD3	0.71	12.59	0.5	1.86e-31	Breast cancer;
LGG	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.88	-0.3	1.92e-11	Hip circumference adjusted for BMI;
LGG	trans	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.94	-0.35	1.57e-14	Joint mobility (Beighton score);
LGG	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg05887092	chr17:76393375	PGS1	0.8	19.07	0.66	2.97e-60	HDL cholesterol levels;
LGG	cis	rs28588043	0.938	rs41310903	chr1:170983976	C/T	cg03458344	chr1:170964477	C1orf129	-0.55	-7.45	-0.33	4.7e-13	Number of children (6+ vs. 0 or 1);
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg15556689	chr8:8085844	FLJ10661	0.39	6.84	0.3	2.52e-11	Monocyte count;
LGG	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.73	-0.51	4.76e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg08975724	chr8:8085496	FLJ10661	0.37	6.72	0.3	5.45e-11	Retinal vascular caliber;
LGG	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs17767392	0.756	rs61991195	chr14:71747223	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.92	-0.38	1.09e-17	Mitral valve prolapse;
LGG	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs7000551	0.688	rs2948145	chr8:22367792	T/C	cg12081754	chr8:22256438	SLC39A14	0.66	12.43	0.5	8.58e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg06360820	chr2:242988706	NA	-1.11	-13.2	-0.52	5.28e-34	Obesity-related traits;
LGG	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg05072819	chr3:20081367	KAT2B	0.45	7.84	0.34	3.15e-14	Post-traumatic stress disorder;
LGG	cis	rs9296092	0.517	rs56069946	chr6:33511136	G/A	cg13560919	chr6:33536144	NA	-0.99	-19.2	-0.67	7.21e-61	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs17767392	0.781	rs2108057	chr14:72022750	G/A	cg13720639	chr14:72061746	SIPA1L1	0.36	8.35	0.36	7.94e-16	Mitral valve prolapse;
LGG	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs9911578	1.000	rs2531732	chr17:56548420	T/A	cg05425664	chr17:57184151	TRIM37	0.61	9.68	0.41	2.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg04990556	chr1:26633338	UBXN11	-0.56	-7.65	-0.33	1.22e-13	Obesity-related traits;
LGG	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg11584989	chr19:19387371	SF4	0.43	7.32	0.32	1.07e-12	Perceived unattractiveness to mosquitoes;
LGG	trans	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.92e-30	Corneal astigmatism;
LGG	cis	rs990171	1.000	rs7559479	chr2:103068787	C/T	cg05295703	chr2:102895712	NA	-0.52	-8.97	-0.38	7.15e-18	Lymphocyte counts;
LGG	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg24692254	chr21:30365293	RNF160	-0.7	-13.1	-0.52	1.45e-33	Cognitive test performance;
LGG	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.74	-0.45	3.45e-24	Chronic sinus infection;
LGG	cis	rs6840360	0.642	rs7676059	chr4:152393267	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02189925	chr1:205091232	RBBP5	0.42	7.29	0.32	1.37e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10397009	chr20:62284737	STMN3	0.47	6.76	0.3	4.17e-11	Gut microbiome composition (summer);
LGG	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg12661370	chr5:149340060	SLC26A2	0.5	7.79	0.34	4.42e-14	HIV-1 control;
LGG	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.42	0.4	2.15e-19	Aortic root size;
LGG	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.75	-0.3	4.45e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs72781680	0.898	rs72796158	chr2:23935727	T/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.3	0.4	5.55e-19	Lymphocyte counts;
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.43	-0.47	7.74e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7584330	0.868	rs7571898	chr2:238383028	T/C	cg16989719	chr2:238392110	NA	-0.33	-6.76	-0.3	4.1e-11	Prostate cancer;
LGG	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.34	6.66	0.3	7.83e-11	Oropharynx cancer;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs11168618	0.904	rs7136845	chr12:48907029	C/T	cg24011408	chr12:48396354	COL2A1	0.46	7.47	0.33	4.08e-13	Adiponectin levels;
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg14675211	chr2:100938903	LONRF2	0.67	12.08	0.49	2.08e-29	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.08	0.42	9.59e-22	Diabetic retinopathy;
LGG	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.48	-0.44	3.47e-23	Chronic sinus infection;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03647317	chr4:187891568	NA	-0.4	-8.86	-0.38	1.7e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs4787491	0.729	rs3814878	chr16:30041966	A/G	cg06326092	chr16:30034487	C16orf92	0.42	8.44	0.37	4.1e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg03342759	chr3:160939853	NMD3	-0.47	-7.87	-0.34	2.47e-14	Kawasaki disease;
LGG	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg14664628	chr15:75095509	CSK	-0.78	-16.0	-0.6	3.5e-46	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9462027	0.628	rs2814971	chr6:34714209	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.55	11.51	0.47	3.79e-27	Systemic lupus erythematosus;
LGG	cis	rs3857536	0.704	rs7775899	chr6:66969860	C/A	cg07460842	chr6:66804631	NA	-0.43	-7.2	-0.32	2.49e-12	Blood trace element (Cu levels);
LGG	cis	rs9443645	0.869	rs4706747	chr6:79722639	A/G	cg18132916	chr6:79620363	NA	-0.3	-8.37	-0.36	7.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg01236616	chr12:121019343	POP5	1.26	22.2	0.72	6.81e-75	Type 1 diabetes nephropathy;
LGG	cis	rs4460629	0.742	rs4625273	chr1:155076043	C/T	cg13808842	chr1:155066096	NA	-0.29	-6.99	-0.31	9.43e-12	Serum magnesium levels;
LGG	cis	rs9399135	0.967	rs17638970	chr6:135320063	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Red blood cell count;
LGG	cis	rs897080	0.515	rs698767	chr2:44576417	A/G	cg00619915	chr2:44497795	NA	-0.5	-6.94	-0.31	1.34e-11	Height;
LGG	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg03929089	chr4:120376271	NA	0.57	6.91	0.31	1.66e-11	Intraocular pressure;
LGG	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.46e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg13010199	chr12:38710504	ALG10B	0.56	10.44	0.44	4.76e-23	Morning vs. evening chronotype;
LGG	cis	rs62380364	0.602	rs665324	chr5:88055517	T/C	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.49e-23	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs7916697	0.947	rs56238729	chr10:70001640	T/C	cg18338521	chr10:69995036	NA	-0.33	-7.31	-0.32	1.2e-12	Optic disc area;
LGG	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg11040518	chr10:102331378	NA	-0.38	-6.68	-0.3	6.84e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg17376030	chr22:41985996	PMM1	0.67	10.76	0.45	2.93e-24	Vitiligo;
LGG	cis	rs41271473	0.800	rs12133951	chr1:228791179	A/C	cg00850481	chr1:228891306	NA	-0.51	-7.84	-0.34	3.1e-14	Chronic lymphocytic leukemia;
LGG	cis	rs7923452	0.938	rs34930615	chr10:30761051	G/A	cg25182066	chr10:30743637	MAP3K8	0.45	6.99	0.31	9.42e-12	Itch intensity from mosquito bite;
LGG	trans	rs1459104	1.000	rs35756956	chr11:55323627	C/A	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.62e-11	Body mass index;
LGG	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg17376030	chr22:41985996	PMM1	0.46	7.51	0.33	3.1400000000000003e-13	Vitiligo;
LGG	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg25039879	chr17:56429692	SUPT4H1	-0.62	-8.78	-0.38	3.11e-17	Cognitive test performance;
LGG	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg24634471	chr8:143751801	JRK	0.53	8.41	0.36	5.21e-16	Schizophrenia;
LGG	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-16.0	-0.6	3.33e-46	Chronic sinus infection;
LGG	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg22875332	chr1:76189707	ACADM	0.58	10.29	0.43	1.65e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4764487	0.901	rs3181295	chr12:6344174	A/G	cg08284733	chr12:6341482	CD9	0.36	8.93	0.38	1.01e-17	Mean platelet volume;
LGG	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg23029597	chr12:123009494	RSRC2	-0.93	-17.36	-0.63	2.41e-52	Body mass index;
LGG	trans	rs2562456	0.833	rs2061916	chr19:21541708	A/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.22	-0.32	2.12e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs4950322	0.518	rs61838936	chr1:146570006	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.69	-0.34	8.69e-14	Protein quantitative trait loci;
LGG	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg12310025	chr6:25882481	NA	-0.52	-10.04	-0.42	1.37e-21	Blood metabolite levels;
LGG	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg22044901	chr15:68126292	NA	-0.42	-7.02	-0.31	8.06e-12	Restless legs syndrome;
LGG	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.71	0.41	2e-20	Height;
LGG	trans	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.34	0.55	7.44e-39	Exhaled nitric oxide output;
LGG	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg08603382	chr10:743973	NA	0.39	7.18	0.32	2.75e-12	Psychosis in Alzheimer's disease;
LGG	trans	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19019321	chr2:159826400	TANC1	0.41	6.73	0.3	4.95e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1832871	0.599	rs1539312	chr6:158743188	G/A	cg07215822	chr6:158701037	NA	0.47	9.28	0.4	6.3e-19	Height;
LGG	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg25174290	chr11:3078921	CARS	0.72	14.69	0.56	2.21e-40	Longevity;
LGG	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg12855166	chr17:30846586	MYO1D	0.42	7.18	0.32	2.8e-12	Schizophrenia;
LGG	trans	rs2548003	0.565	rs2554894	chr5:28762951	A/G	cg12623145	chr2:97778927	ANKRD36	0.47	6.65	0.3	8.5e-11	Hip geometry;
LGG	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg08125733	chr17:73851984	WBP2	0.44	7.24	0.32	1.94e-12	White matter hyperintensity burden;
LGG	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg17054900	chr3:154042577	DHX36	0.47	7.1	0.31	4.72e-12	Coronary artery disease;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.53	-0.47	3.26e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7937612	0.965	rs12361632	chr11:120215843	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.51	-11.91	-0.48	1.03e-28	Intraocular pressure;
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.48	-0.33	3.72e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg17467752	chr17:38218738	THRA	-0.44	-7.09	-0.31	5.04e-12	Self-reported allergy;
LGG	cis	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-9.94	-0.42	3e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs10940138	0.779	rs62370675	chr5:67247975	G/A	ch.5.1281357F	chr5:67228439	NA	0.74	12.62	0.51	1.4e-31	Menarche (age at onset);
LGG	cis	rs4851250	0.559	rs13023088	chr2:100576304	A/G	cg17356467	chr2:100759845	AFF3	-0.44	-7.07	-0.31	5.65e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2444240	1.000	rs573211	chr11:120044762	G/A	cg16005559	chr11:120040616	NA	-0.33	-7.52	-0.33	2.88e-13	Corneal curvature;
LGG	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg02297831	chr4:17616191	MED28	0.4	6.97	0.31	1.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-12.93	-0.51	7.54e-33	Menarche (age at onset);
LGG	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg08079166	chr15:68083412	MAP2K5	0.34	7.61	0.33	1.51e-13	Restless legs syndrome;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg19147804	chr7:1989927	MAD1L1	0.52	10.37	0.43	8.29e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg08859206	chr1:53392774	SCP2	0.34	6.84	0.3	2.47e-11	Monocyte count;
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg02002194	chr4:3960332	NA	0.44	8.14	0.35	3.63e-15	Neuroticism;
LGG	cis	rs7394190	0.748	rs4746146	chr10:75527197	C/T	cg07699608	chr10:75541558	CHCHD1	0.56	7.44	0.33	5.05e-13	Incident atrial fibrillation;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg10360139	chr7:1886902	MAD1L1	-0.46	-8.15	-0.35	3.33e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	trans	rs6601327	0.602	rs35431433	chr8:9660621	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.98	0.35	1.12e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg07936489	chr17:37558343	FBXL20	-0.47	-7.79	-0.34	4.49e-14	Asthma;
LGG	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	cis	rs2486288	0.656	rs11639349	chr15:45568260	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-11.04	-0.46	2.6e-25	Glomerular filtration rate;
LGG	cis	rs7617773	0.817	rs11707606	chr3:48237087	A/C	cg11946769	chr3:48343235	NME6	0.68	11.19	0.46	6.83e-26	Coronary artery disease;
LGG	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.23	-0.32	1.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs503734	0.846	rs6803747	chr3:100913309	G/C	cg27318481	chr3:100970896	IMPG2	-0.43	-9.7	-0.41	2.2e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg17328964	chr8:145687451	CYHR1	-0.68	-13.27	-0.52	2.73e-34	Age at first birth;
LGG	trans	rs9650657	0.746	rs4841441	chr8:10630898	C/A	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.73	-0.3	4.97e-11	Neuroticism;
LGG	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg13010199	chr12:38710504	ALG10B	0.46	8.8	0.38	2.63e-17	Morning vs. evening chronotype;
LGG	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs7267979	1.000	rs6115168	chr20:25372891	C/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10743315	0.778	rs1586843	chr12:19354550	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.57	-8.04	-0.35	7.74e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg18963800	chr10:38644991	HSD17B7P2	0.47	7.11	0.31	4.56e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg27211696	chr2:191398769	TMEM194B	0.4	9.48	0.4	1.36e-19	Pulse pressure;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02475777	chr4:1388615	CRIPAK	-0.47	-8.51	-0.37	2.37e-16	Obesity-related traits;
LGG	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg13072238	chr3:49761600	GMPPB	0.52	7.1	0.31	4.86e-12	Menarche (age at onset);
LGG	cis	rs6546550	0.901	rs6736408	chr2:70137774	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07243736	chr16:783730	NARFL	0.41	7.15	0.32	3.35e-12	Height;
LGG	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.34	-0.36	8.73e-16	Mood instability;
LGG	cis	rs2073300	0.609	rs2277765	chr20:23425163	C/T	cg12062639	chr20:23401060	NAPB	0.89	8.19	0.36	2.58e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg01988459	chr11:68622903	NA	0.58	11.95	0.49	7.41e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg23422044	chr7:1970798	MAD1L1	-0.66	-11.36	-0.47	1.53e-26	Bipolar disorder;
LGG	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg18252515	chr7:66147081	NA	-1.41	-20.28	-0.69	6.73e-66	Diabetic kidney disease;
LGG	cis	rs60180747	0.909	rs41277720	chr15:66773975	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.6	10.01	0.42	1.79e-21	Testicular germ cell tumor;
LGG	cis	rs7098414	0.531	rs3844126	chr10:82019997	T/G	cg01528321	chr10:82214614	TSPAN14	0.64	11.07	0.46	2.03e-25	Post bronchodilator FEV1;
LGG	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg25019033	chr10:957182	NA	-0.56	-9.28	-0.4	6.62e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg20637307	chr2:213403960	ERBB4	0.74	16.8	0.62	8.08e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.81	-0.34	3.94e-14	Neuroticism;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-20.49	-0.69	7.12e-67	Prudent dietary pattern;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.18	-0.39	1.46e-18	Life satisfaction;
LGG	cis	rs6723226	0.765	rs12612824	chr2:32579759	C/T	cg02381751	chr2:32503542	YIPF4	-0.75	-12.3	-0.5	2.66e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08564027	chr20:61660810	NA	1.02	25.63	0.77	7.65e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs208520	0.690	rs1233103	chr6:66855943	T/G	cg07460842	chr6:66804631	NA	-0.97	-18.11	-0.64	8.1e-56	Exhaled nitric oxide output;
LGG	cis	rs7100689	0.577	rs10749560	chr10:82092801	G/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.59	0.56	6.02e-40	Post bronchodilator FEV1;
LGG	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.7	-0.34	8.43e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10870270	1.000	rs10870271	chr10:133754807	A/G	cg17892150	chr10:133769511	PPP2R2D	0.7	14.42	0.56	3.39e-39	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg27432699	chr2:27873401	GPN1	0.69	13.9	0.54	5.93e-37	Oral cavity cancer;
LGG	cis	rs2249694	0.919	rs2987794	chr10:135378612	G/T	cg20169779	chr10:135381914	SYCE1	0.49	7.3	0.32	1.28e-12	Obesity-related traits;
LGG	cis	rs10937275	0.793	rs35376159	chr3:186648929	T/A	cg24050613	chr3:186648279	ST6GAL1	0.86	8.88	0.38	1.44e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg26384229	chr12:38710491	ALG10B	0.73	15.0	0.57	9.53e-42	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg11062466	chr8:58055876	NA	0.5	8.1	0.35	4.77e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg21459583	chr1:227974177	NA	0.44	6.77	0.3	3.98e-11	Major depressive disorder;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07156296	chr4:108911347	HADH	-0.45	-6.81	-0.3	3.02e-11	Systemic lupus erythematosus;
LGG	cis	rs9879311	1.000	rs9879311	chr3:10415343	C/T	cg21387009	chr3:10280255	IRAK2	-0.37	-6.86	-0.3	2.22e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg05194412	chr2:137003533	NA	0.37	7.98	0.35	1.2e-14	Colorectal cancer;
LGG	cis	rs2777491	0.872	rs7176588	chr15:41588872	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.93	-18.71	-0.66	1.31e-58	Ulcerative colitis;
LGG	trans	rs1459104	0.714	rs1851614	chr11:54836269	C/T	cg03929089	chr4:120376271	NA	0.74	6.83	0.3	2.6e-11	Body mass index;
LGG	cis	rs17125944	0.615	rs7145392	chr14:53321016	G/A	cg00686598	chr14:53173677	PSMC6	-0.67	-6.97	-0.31	1.09e-11	Alzheimer's disease (late onset);
LGG	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg12223502	chr10:5658492	NA	-0.38	-7.34	-0.32	9.99e-13	Breast cancer;
LGG	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-7.23	-0.32	2.07e-12	Neuroticism;
LGG	cis	rs990171	0.954	rs6543137	chr2:103065908	T/G	cg05295703	chr2:102895712	NA	-0.53	-9.23	-0.39	9.98e-19	Lymphocyte counts;
LGG	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.47	-0.33	4.05e-13	Obesity (extreme);
LGG	cis	rs9788682	0.747	rs2656073	chr15:78742276	G/T	cg06917634	chr15:78832804	PSMA4	-0.52	-8.1	-0.35	4.82e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.07	0.42	1.07e-21	Metabolite levels;
LGG	cis	rs12580194	0.554	rs12578577	chr12:55716443	C/T	cg19537932	chr12:55886519	OR6C68	-0.55	-9.7	-0.41	2.33e-20	Cancer;
LGG	cis	rs7103648	0.966	rs1377416	chr11:47416746	C/T	cg20307385	chr11:47447363	PSMC3	0.96	23.21	0.73	1.31e-79	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07234876	chr8:600039	NA	1.17	11.7	0.48	6.98e-28	IgG glycosylation;
LGG	cis	rs9633740	1.000	rs1870137	chr10:82269848	C/G	cg01528321	chr10:82214614	TSPAN14	1.07	16.56	0.61	1.04e-48	Post bronchodilator FEV1;
LGG	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.02	0.35	8.83e-15	Resting heart rate;
LGG	cis	rs9457247	1.000	rs2149090	chr6:167372764	T/C	cg07741184	chr6:167504864	NA	-0.32	-7.01	-0.31	8.29e-12	Crohn's disease;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs4722166	0.695	rs4722177	chr7:22798531	T/C	cg05265849	chr7:22767390	IL6	0.38	7.27	0.32	1.56e-12	Lung cancer;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.98	0.31	1.04e-11	Lung cancer;
LGG	cis	rs209489	0.892	rs2294853	chr6:53158052	G/A	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg02527881	chr3:46936655	PTH1R	-0.34	-8.36	-0.36	7.56e-16	Birth weight;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg01673284	chr16:4527211	HMOX2	0.34	6.78	0.3	3.7e-11	Schizophrenia;
LGG	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg07741184	chr6:167504864	NA	-0.31	-6.72	-0.3	5.52e-11	Crohn's disease;
LGG	cis	rs10504073	0.584	rs7820270	chr8:49971395	G/T	cg00325661	chr8:49890786	NA	0.76	14.92	0.57	2.18e-41	Blood metabolite ratios;
LGG	cis	rs9860250	0.562	rs72930292	chr3:100704413	C/T	cg23634451	chr3:100713646	ABI3BP	-0.36	-7.01	-0.31	8.61e-12	Optic disc area;
LGG	cis	rs1790761	0.868	rs872375	chr11:67205978	G/A	cg00290607	chr11:67383545	NA	-0.48	-8.5	-0.37	2.67e-16	Mean corpuscular volume;
LGG	cis	rs9309473	0.950	rs1918863	chr2:73644481	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-7.2	-0.32	2.51e-12	Metabolite levels;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg20003494	chr4:90757398	SNCA	-0.43	-8.5	-0.37	2.69e-16	Dementia with Lewy bodies;
LGG	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg27422857	chr2:105853526	NA	-0.41	-7.5	-0.33	3.25e-13	Type 2 diabetes;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.49	0.37	2.76e-16	Schizophrenia;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs4474465	1.000	rs2063727	chr11:78183882	T/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.73	-0.38	4.56e-17	Alzheimer's disease (survival time);
LGG	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg00717180	chr2:96193071	NA	-0.47	-8.6	-0.37	1.28e-16	Height;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg15971980	chr6:150254442	NA	0.46	8.67	0.37	7.59e-17	Lung cancer;
LGG	trans	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg25482853	chr8:67687455	SGK3	0.94	11.96	0.49	6.3e-29	Obesity-related traits;
LGG	trans	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg06521331	chr12:34319734	NA	0.52	9.53	0.4	8.82e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg05863683	chr7:1912471	MAD1L1	0.42	8.09	0.35	5.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.35e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05977259	chr2:48133053	FBXO11	0.62	7.02	0.31	7.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs7805077	chr7:91644553	A/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs6762644	0.507	rs9823748	chr3:4765955	G/A	cg11584376	chr3:4789075	ITPR1	-0.39	-8.36	-0.36	7.63e-16	Breast cancer;
LGG	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg22654517	chr2:96458247	NA	0.34	6.74	0.3	4.6e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs11920090	0.722	rs66768945	chr3:170672740	A/G	cg09710316	chr3:170744871	SLC2A2	0.61	7.5	0.33	3.28e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9358372	0.574	rs4712551	chr6:20805130	T/C	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.23	-0.39	9.94e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8044868	0.530	rs2288000	chr16:72058881	A/G	cg23815491	chr16:72088622	HP	0.34	7.16	0.32	3.17e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs67311347	1.000	rs9829800	chr3:40443927	T/C	cg13683864	chr3:40499215	RPL14	-0.96	-19.68	-0.67	4.38e-63	Renal cell carcinoma;
LGG	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	12.31	0.5	2.48e-30	Hip circumference adjusted for BMI;
LGG	cis	rs6815814	0.950	rs73236632	chr4:38836071	G/A	cg06935464	chr4:38784597	TLR10	0.58	8.1	0.35	4.98e-15	Breast cancer;
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10802521	chr3:52805072	NEK4	-0.4	-6.68	-0.3	6.75e-11	Bipolar disorder;
LGG	cis	rs2236267	0.726	rs4341685	chr14:88575161	G/A	cg18078958	chr14:88630771	NA	0.31	6.95	0.31	1.23e-11	Food antigen IgG levels;
LGG	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg23231163	chr10:75533350	FUT11	-0.4	-6.67	-0.3	7.46e-11	Inflammatory bowel disease;
LGG	cis	rs9321453	1.000	rs9399101	chr6:134768282	A/G	cg08754004	chr6:134775465	NA	-0.45	-6.66	-0.3	7.84e-11	Urate levels;
LGG	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.2	0.32	2.42e-12	Hemoglobin concentration;
LGG	cis	rs3796352	0.892	rs9756317	chr3:53088815	T/C	cg12962167	chr3:53033115	SFMBT1	-0.7	-7.14	-0.32	3.58e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18252515	chr7:66147081	NA	0.44	7.46	0.33	4.29e-13	Aortic root size;
LGG	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg11502198	chr6:26597334	ABT1	0.73	13.16	0.52	7.99e-34	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg07511668	chr11:68622177	NA	0.5	9.64	0.41	3.64e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.4	0.36	5.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg24825693	chr3:157122686	VEPH1	-0.35	-7.55	-0.33	2.38e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-13.09	-0.52	1.6e-33	Menarche (age at onset);
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.09	0.31	5.07e-12	Schizophrenia;
LGG	cis	rs7085104	0.700	rs3740397	chr10:104592675	G/C	cg04362960	chr10:104952993	NT5C2	0.52	9.79	0.41	1.1e-20	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg01631408	chr1:248437212	OR2T33	-0.5	-9.14	-0.39	1.95e-18	Common traits (Other);
LGG	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg14500267	chr11:67383377	NA	-0.41	-7.48	-0.33	3.82e-13	Mean corpuscular volume;
LGG	cis	rs17122278	1.000	rs11216911	chr11:118451901	C/T	cg19182353	chr11:118479428	PHLDB1	0.52	6.75	0.3	4.33e-11	Total cholesterol levels;
LGG	cis	rs4774899	1.000	rs62022986	chr15:57278894	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.19	-0.36	2.51e-15	Urinary tract infection frequency;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00495681	chr13:53174319	NA	0.6	11.21	0.46	5.85e-26	Lewy body disease;
LGG	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg24634471	chr8:143751801	JRK	-0.5	-7.63	-0.33	1.39e-13	Schizophrenia;
LGG	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.5	0.37	2.58e-16	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14037413	chr11:9482594	ZNF143	0.45	7.25	0.32	1.75e-12	Cognitive performance;
LGG	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7301016	0.948	rs12369985	chr12:62918780	A/G	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01893041	chr5:67583972	PIK3R1	0.53	8.91	0.38	1.21e-17	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg17809284	chr5:56205270	C5orf35	-0.54	-8.81	-0.38	2.53e-17	Initial pursuit acceleration;
LGG	cis	rs911555	0.723	rs6575982	chr14:103862681	G/A	cg24130564	chr14:104152367	KLC1	0.37	6.85	0.3	2.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.601	rs1981665	chr7:23167969	T/C	cg23682824	chr7:23144976	KLHL7	0.42	7.08	0.31	5.24e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1707322	1.000	rs4660328	chr1:46444831	G/T	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg15479754	chr10:1447082	ADARB2	-0.34	-7.01	-0.31	8.48e-12	Radiation response;
LGG	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-9.29	-0.4	6.27e-19	HDL cholesterol;
LGG	cis	rs7474896	0.537	rs2505255	chr10:38359642	C/A	cg25427524	chr10:38739819	LOC399744	-0.53	-7.86	-0.34	2.68e-14	Obesity (extreme);
LGG	cis	rs994014	0.572	rs11732106	chr4:82322678	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.74	-0.3	4.66e-11	Height;
LGG	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	9.73	0.41	1.82e-20	Aortic root size;
LGG	cis	rs10276381	0.786	rs10281102	chr7:28243473	A/G	cg23620719	chr7:28220237	JAZF1	0.79	9.83	0.42	7.6e-21	Crohn's disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03464378	chr2:75427699	TACR1	0.37	6.69	0.3	6.4e-11	Bilirubin levels;
LGG	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg01620082	chr3:125678407	NA	-0.99	-9.14	-0.39	1.98e-18	Intelligence (multi-trait analysis);
LGG	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg11887960	chr12:57824829	NA	0.54	6.67	0.3	7.13e-11	Obesity-related traits;
LGG	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg08807101	chr21:30365312	RNF160	-0.59	-8.17	-0.35	2.96e-15	Cognitive test performance;
LGG	cis	rs929596	0.606	rs7604115	chr2:234658116	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.91	-0.45	7.79e-25	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg18876405	chr7:65276391	NA	0.63	11.79	0.48	3.17e-28	Aortic root size;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.91e-18	Menopause (age at onset);
LGG	cis	rs7402982	0.625	rs12905392	chr15:99199212	G/A	cg03437748	chr15:99193247	IGF1R	0.79	13.27	0.52	2.77e-34	Birth weight;
LGG	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg09173681	chr1:183549694	NCF2	0.36	8.29	0.36	1.25e-15	Systemic lupus erythematosus;
LGG	cis	rs13031619	0.517	rs10183413	chr2:3684342	T/C	cg01268866	chr2:3683757	COLEC11	-0.58	-11.64	-0.48	1.17e-27	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg03474202	chr17:45855739	NA	-0.27	-7.95	-0.35	1.45e-14	IgG glycosylation;
LGG	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg01324343	chr3:183735012	ABCC5	0.77	13.64	0.54	7.47e-36	Anterior chamber depth;
LGG	cis	rs7227917	0.536	rs72916034	chr18:45514650	T/G	cg22195133	chr18:45534586	NA	0.77	7.0	0.31	9.17e-12	Lung cancer in ever smokers;
LGG	cis	rs6784615	0.744	rs6771558	chr3:52497254	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	7.33	0.32	1.02e-12	Educational attainment;
LGG	trans	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs9308433	0.529	rs3767842	chr1:214498306	C/T	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.13e-14	IgG glycosylation;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.56	-0.47	2.6e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.97	-0.31	1.1e-11	Bipolar disorder;
LGG	cis	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg06521331	chr12:34319734	NA	-0.42	-7.65	-0.34	1.15e-13	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	trans	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg06521331	chr12:34319734	NA	0.46	8.06	0.35	6.38e-15	Bladder cancer;
LGG	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.68	0.3	6.87e-11	Total cholesterol levels;
LGG	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.88	0.3	1.9e-11	Resting heart rate;
LGG	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.66	-0.48	1.03e-27	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00610228	chr6:35695934	FKBP5;LOC285847	0.48	6.95	0.31	1.26e-11	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08645402	chr16:4508243	NA	0.49	9.29	0.4	6.26e-19	Schizophrenia;
LGG	cis	rs1062177	0.826	rs2053063	chr5:151166764	T/C	cg00977110	chr5:151150581	G3BP1	0.48	7.59	0.33	1.73e-13	Preschool internalizing problems;
LGG	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.2	-0.49	6.88e-30	Chronic sinus infection;
LGG	cis	rs735539	0.521	rs2763002	chr13:21369982	T/C	cg04906043	chr13:21280425	IL17D	-0.5	-7.85	-0.34	2.83e-14	Dental caries;
LGG	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs7192750	0.586	rs8054111	chr16:71990651	A/G	cg06353428	chr16:71660113	MARVELD3	0.66	10.75	0.45	3.31e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs9611519	1.000	rs5758264	chr22:41616284	T/G	cg03806693	chr22:41940476	POLR3H	-0.5	-8.03	-0.35	8e-15	Neuroticism;
LGG	cis	rs10089	1.000	rs10064357	chr5:127417272	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.81	0.48	2.66e-28	Ileal carcinoids;
LGG	cis	rs3784262	0.669	rs4646579	chr15:58329528	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.99	-0.31	9.6e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.44	0.47	7.41e-27	Coronary artery disease;
LGG	cis	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-11.38	-0.47	1.27e-26	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg21427119	chr20:30132790	HM13	-0.5	-8.25	-0.36	1.71e-15	Mean corpuscular hemoglobin;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11688874	chr10:28822482	WAC	0.59	9.76	0.41	1.37e-20	Gut microbiome composition (summer);
LGG	cis	rs240764	0.817	rs12193960	chr6:101150326	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.64	-0.33	1.27e-13	Neuroticism;
LGG	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg13482628	chr17:19912719	NA	-0.53	-10.1	-0.42	8.58e-22	Schizophrenia;
LGG	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg10818794	chr15:86012489	AKAP13	-0.36	-7.58	-0.33	1.84e-13	Coronary artery disease;
LGG	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg08528231	chr16:12997261	SHISA9	-0.33	-6.73	-0.3	5.08e-11	Positive affect;Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02488887	chr5:176830915	F12	0.46	7.18	0.32	2.73e-12	Gut microbiome composition (summer);
LGG	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg01338139	chr15:38987640	C15orf53	-0.53	-8.25	-0.36	1.68e-15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	11.69	0.48	7.8e-28	Lung cancer in ever smokers;
LGG	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg12800244	chr3:153838788	SGEF	0.59	8.31	0.36	1.06e-15	Coronary artery disease;
LGG	cis	rs4988958	0.548	rs6543127	chr2:103028301	A/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25072359	chr17:41440525	NA	0.51	9.86	0.42	6.29e-21	Menopause (age at onset);
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.7	0.54	4e-36	Lung cancer;
LGG	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg06618935	chr21:46677482	NA	-0.43	-8.44	-0.37	4.1e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg12163867	chr12:51592794	POU6F1	-0.54	-11.76	-0.48	3.96e-28	Cisplatin-induced ototoxicity;
LGG	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.37	0.4	3.1400000000000002e-19	Educational attainment;
LGG	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-10.01	-0.42	1.79e-21	Coronary artery disease;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.21	0.32	2.28e-12	Renal function-related traits (BUN);
LGG	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg05091796	chr16:4465799	CORO7	-0.9	-14.43	-0.56	2.94e-39	Schizophrenia;
LGG	cis	rs4954585	0.708	rs10200263	chr2:137007429	C/T	cg07169764	chr2:136633963	MCM6	-0.45	-7.24	-0.32	1.92e-12	Colorectal cancer;
LGG	cis	rs2117029	0.554	rs2334931	chr12:49567913	G/T	cg24176009	chr12:49580217	TUBA1A	0.66	12.79	0.51	2.83e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2304069	0.729	rs2066934	chr5:149433596	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	11.53	0.47	3.25e-27	HIV-1 control;
LGG	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg03477792	chr4:77819574	ANKRD56	0.52	9.08	0.39	3.2e-18	Emphysema distribution in smoking;
LGG	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg03060546	chr3:49711283	APEH	-0.64	-10.55	-0.44	1.89e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4764487	0.760	rs10849421	chr12:6327008	A/G	cg08284733	chr12:6341482	CD9	0.33	8.45	0.37	3.94e-16	Mean platelet volume;
LGG	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg17211192	chr8:82754475	SNX16	0.7	11.53	0.47	3.35e-27	Diastolic blood pressure;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg13934093	chr19:4458039	UBXN6	-0.41	-6.87	-0.3	2.13e-11	Platelet count;
LGG	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.38	0.32	7.16e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.34	-0.36	8.63e-16	Glycated hemoglobin levels;
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg02018176	chr4:1364513	KIAA1530	0.39	8.65	0.37	8.42e-17	Obesity-related traits;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.31e-14	Tonsillectomy;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05025164	chr4:1340916	KIAA1530	0.55	10.02	0.42	1.64e-21	Longevity;
LGG	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg26384229	chr12:38710491	ALG10B	0.94	20.88	0.7	1.02e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28374715	0.532	rs28463309	chr15:41666716	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.33	-34.26	-0.85	4.94e-129	Ulcerative colitis;
LGG	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	6.2e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03264133	chr6:25882463	NA	-0.72	-13.45	-0.53	4.99e-35	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.22	0.83	2.46e-120	Chronic sinus infection;
LGG	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	9.68	0.41	2.6e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.43	7.78	0.34	4.92e-14	Obesity-related traits;
LGG	cis	rs4722166	0.603	rs7801406	chr7:22788274	A/G	cg05265849	chr7:22767390	IL6	0.43	7.97	0.35	1.26e-14	Lung cancer;
LGG	cis	rs72949976	0.606	rs11898263	chr2:214030649	A/G	cg08319019	chr2:214017104	IKZF2	0.63	11.91	0.48	1.01e-28	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.55	12.2	0.49	6.89e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7020830	0.898	rs6476617	chr9:37200103	G/A	cg14294708	chr9:37120828	ZCCHC7	1.14	31.09	0.82	1.95e-115	Schizophrenia;
LGG	cis	rs9660992	0.573	rs1172147	chr1:205225457	G/A	cg00857998	chr1:205179979	DSTYK	0.49	7.63	0.33	1.34e-13	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6466055	0.669	rs7797912	chr7:104769415	C/T	cg04380332	chr7:105027541	SRPK2	0.38	7.2	0.32	2.43e-12	Schizophrenia;
LGG	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg11161011	chr14:65562177	MAX	-0.66	-12.24	-0.49	4.91e-30	Obesity-related traits;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.19	-0.49	8.05e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.32	-7.11	-0.31	4.29e-12	Personality dimensions;
LGG	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.27	-0.46	3.31e-26	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.5	0.53	2.93e-35	Bladder cancer;
LGG	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.14	0.35	3.72e-15	Multiple myeloma (hyperdiploidy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11287521	chr10:124134015	PLEKHA1	0.46	6.9	0.31	1.75e-11	Gut microbiome composition (summer);
LGG	cis	rs9581857	0.685	rs12585587	chr13:28024694	G/A	cg01674679	chr13:27998804	GTF3A	-0.62	-7.45	-0.33	4.58e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs4764487	0.735	rs2159521	chr12:6349328	A/G	cg08284733	chr12:6341482	CD9	0.36	9.77	0.41	1.3e-20	Mean platelet volume;
LGG	trans	rs3857536	0.704	rs7753493	chr6:66963871	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.19e-12	Blood trace element (Cu levels);
LGG	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg09448879	chr15:79043637	NA	0.41	7.19	0.32	2.56e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7301826	0.580	rs12821464	chr12:131322719	T/G	cg11011512	chr12:131303247	STX2	-0.4	-8.46	-0.37	3.51e-16	Plasma plasminogen activator levels;
LGG	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.67	-0.41	2.82e-20	Alcohol dependence;
LGG	trans	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg06521331	chr12:34319734	NA	0.43	7.24	0.32	1.89e-12	Morning vs. evening chronotype;
LGG	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg00031303	chr3:195681400	NA	-0.44	-6.83	-0.3	2.73e-11	Mean corpuscular volume;
LGG	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg05791153	chr7:19748676	TWISTNB	0.63	8.05	0.35	6.86e-15	Night sleep phenotypes;
LGG	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg22980697	chr10:16874865	CUBN	0.59	9.48	0.4	1.38e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6565189	1.000	rs6565189	chr16:30507265	A/C	cg17640201	chr16:30407289	ZNF48	0.42	6.75	0.3	4.46e-11	Tonsillectomy;
LGG	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.97	0.45	4.82e-25	Morning vs. evening chronotype;
LGG	cis	rs3824867	0.879	rs10769267	chr11:47460098	C/T	cg20307385	chr11:47447363	PSMC3	0.47	7.55	0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs4262150	0.511	rs72795339	chr5:151904788	A/C	cg12297329	chr5:152029980	NA	-0.65	-11.8	-0.48	2.84e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs73787773	0.799	rs7730334	chr5:111495150	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.68	-8.15	-0.35	3.34e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs67385638	1.000	rs11036474	chr11:5275178	T/C	cg12559170	chr11:5275217	HBG2	0.57	13.14	0.52	9.31e-34	Hemoglobin levels;
LGG	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg11247378	chr22:39784982	NA	-0.32	-9.02	-0.39	4.83e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9358372	0.637	rs6926335	chr6:20886230	G/T	cg13405222	chr6:20811065	CDKAL1	-0.6	-12.56	-0.5	2.32e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.45e-15	Common traits (Other);
LGG	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.94	0.35	1.59e-14	Menarche (age at onset);
LGG	cis	rs9463078	0.834	rs7770401	chr6:45320500	A/G	cg25276700	chr6:44698697	NA	0.39	8.25	0.36	1.64e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9649465	0.967	rs11769381	chr7:123264804	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-9.03	-0.39	4.54e-18	Migraine;
LGG	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	trans	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg27661571	chr11:113659931	NA	-0.65	-7.37	-0.32	7.66e-13	Hip circumference adjusted for BMI;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs367943	0.712	rs26967	chr5:112741467	C/G	cg12552261	chr5:112820674	MCC	0.58	10.47	0.44	3.64e-23	Type 2 diabetes;
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg22398616	chr13:53314203	LECT1	0.44	9.03	0.39	4.58e-18	Lewy body disease;
LGG	cis	rs3767633	1.000	rs3767633	chr1:161826615	T/A	cg09175582	chr1:161736000	ATF6	0.74	9.01	0.39	5.4e-18	IgG glycosylation;
LGG	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11987759	chr7:65425863	GUSB	-0.4	-7.91	-0.35	1.91e-14	Aortic root size;
LGG	trans	rs2727020	0.718	rs1404366	chr11:49415899	T/A	cg15704280	chr7:45808275	SEPT13	-0.9	-15.93	-0.6	7.45e-46	Coronary artery disease;
LGG	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.73	0.34	6.81e-14	Response to antipsychotic treatment;
LGG	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg06238570	chr21:40685208	BRWD1	0.43	6.75	0.3	4.35e-11	Cognitive function;
LGG	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg08847335	chr10:891726	LARP4B	-0.47	-8.55	-0.37	1.8e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs1109114	0.844	rs2963493	chr5:148596041	C/T	cg06539116	chr5:148597365	ABLIM3	-0.62	-16.52	-0.61	1.6e-48	Body mass index;
LGG	cis	rs858239	0.600	rs6960001	chr7:23130876	T/C	cg23682824	chr7:23144976	KLHL7	0.44	7.66	0.34	1.08e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg16301924	chr13:53314226	LECT1	-0.44	-8.54	-0.37	1.99e-16	Lewy body disease;
LGG	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-14.94	-0.57	1.78e-41	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	8.81	0.38	2.49e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.03	0.39	4.82e-18	Lung cancer;
LGG	cis	rs12220238	0.841	rs11001001	chr10:76097678	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.93	0.38	9.91e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7635838	0.684	rs2606762	chr3:11343889	G/C	cg00170343	chr3:11313890	ATG7	0.49	8.52	0.37	2.34e-16	HDL cholesterol;
LGG	cis	rs10876993	0.890	rs810204	chr12:58075733	T/C	cg18357645	chr12:58087776	OS9	0.68	12.33	0.5	2.16e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs368123	0.960	rs366719	chr6:160716480	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.13e-12	Waist circumference;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg15971980	chr6:150254442	NA	0.44	8.0	0.35	9.98e-15	Lung cancer;
LGG	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.9	0.54	5.92e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.2	0.58	1.22e-42	Coronary artery disease;
LGG	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-8.7	-0.37	5.94e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs525304	0.750	rs11237165	chr11:70523008	A/G	cg07091154	chr11:70562728	SHANK2	0.37	6.98	0.31	1.02e-11	Response to fenofibrate (adiponectin levels);
LGG	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.7	0.37	6.01e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs115344852	0.557	rs2859351	chr6:28456195	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.52	-6.8	-0.3	3.32e-11	Epithelial ovarian cancer;
LGG	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg27661571	chr11:113659931	NA	-0.68	-9.73	-0.41	1.69e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.08	-0.46	1.75e-25	Migraine;Coronary artery disease;
LGG	cis	rs78579285	0.584	rs34908386	chr16:88800913	C/T	cg06225923	chr16:88797506	FAM38A	-0.48	-6.73	-0.3	5.12e-11	Joint mobility (Beighton score);
LGG	cis	rs6496932	0.802	rs56306166	chr15:85870079	G/A	cg19183879	chr15:85880815	NA	0.42	6.71	0.3	5.59e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg08847533	chr14:75593920	NEK9	0.63	12.13	0.49	1.29e-29	Height;
LGG	cis	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.6	9.57	0.41	6.31e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs1788820	0.917	rs1788826	chr18:21154024	G/A	cg14672496	chr18:21087552	C18orf8	0.39	7.17	0.32	2.97e-12	Body mass index;
LGG	cis	rs2769264	1.000	rs6684085	chr1:151357333	C/T	cg18801370	chr1:151430492	POGZ	-0.83	-13.61	-0.53	1.04e-35	Blood trace element (Cu levels);
LGG	cis	rs4865875	1.000	rs4464652	chr5:54121153	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs4409675	0.576	rs2295367	chr1:28224312	C/T	cg23691781	chr1:28212827	C1orf38	0.38	10.09	0.42	9.04e-22	Corneal astigmatism;
LGG	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.69	-0.59	8.14e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9948	0.655	rs56913233	chr2:97405896	A/G	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs6867032	1.000	rs16902318	chr5:2013568	A/G	cg26168224	chr5:2018326	NA	1.26	28.43	0.8	1.33e-103	Gut microbiome composition (winter);
LGG	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg06766960	chr11:133703094	NA	-0.58	-11.37	-0.47	1.39e-26	Childhood ear infection;
LGG	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.52	0.5	3.46e-31	Motion sickness;
LGG	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.7	-0.37	5.68e-17	Platelet distribution width;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.71	-0.41	2.04e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs208515	0.525	rs12215007	chr6:66671008	C/T	cg07460842	chr6:66804631	NA	-0.94	-16.97	-0.62	1.37e-50	Exhaled nitric oxide levels;
LGG	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg16511985	chr3:153974050	SGEF	0.49	8.32	0.36	1.01e-15	Coronary artery disease;
LGG	trans	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg07393940	chr7:158741817	NA	0.48	8.7	0.37	5.76e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg23625390	chr15:77176239	SCAPER	0.49	9.69	0.41	2.35e-20	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06117184	chr2:113522207	CKAP2L	0.44	6.94	0.31	1.31e-11	Cognitive performance;
LGG	trans	rs9354308	0.764	rs7764095	chr6:66569923	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg17328964	chr8:145687451	CYHR1	0.66	12.66	0.51	9.4e-32	Age at first birth;
LGG	cis	rs17092148	0.945	rs6058115	chr20:33358397	T/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg13206674	chr6:150067644	NUP43	0.6	13.23	0.52	4.05e-34	Lung cancer;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.49	-0.4	1.18e-19	Lung cancer;
LGG	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.75	0.34	5.85e-14	Total cholesterol levels;
LGG	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg25754956	chr12:51612065	POU6F1	0.56	9.22	0.39	1.02e-18	Cisplatin-induced ototoxicity;
LGG	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.53	0.37	2.08e-16	Lung cancer in ever smokers;
LGG	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00367659	chr17:33288544	CCT6B;ZNF830	0.51	8.75	0.38	4.01e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg06889755	chr6:150326021	RAET1K	-0.4	-8.2	-0.36	2.35e-15	Alopecia areata;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.01	-0.31	8.25e-12	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.55	0.37	1.87e-16	Alzheimer's disease;
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg13628971	chr7:2884303	GNA12	0.53	10.82	0.45	1.74e-24	Height;
LGG	cis	rs888194	0.738	rs1543897	chr12:109975211	A/T	cg19025524	chr12:109796872	NA	-0.36	-7.15	-0.32	3.31e-12	Neuroticism;
LGG	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg26354017	chr1:205819088	PM20D1	-0.42	-7.41	-0.33	5.84e-13	Menarche (age at onset);
LGG	cis	rs11997175	0.574	rs10954931	chr8:33631066	A/T	ch.8.33884649F	chr8:33765107	NA	0.37	6.9	0.31	1.67e-11	Body mass index;
LGG	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3106136	0.901	rs17376488	chr4:95226548	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.03	-0.35	8.3e-15	Capecitabine sensitivity;
LGG	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7572733	1.000	rs10184227	chr2:198894305	C/T	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs17453880	0.963	rs4304072	chr5:151953465	G/C	cg10931792	chr5:152022470	NA	0.38	8.22	0.36	2.07e-15	Subjective well-being;
LGG	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.23e-17	Response to antipsychotic treatment;
LGG	trans	rs3206736	0.521	rs2057819	chr7:34944871	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.39	6.82	0.3	2.83e-11	Diastolic blood pressure;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19717773	chr7:2847554	GNA12	-0.34	-7.16	-0.32	3.21e-12	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13968953	chr3:97483466	ARL6	0.45	7.33	0.32	1.03e-12	Cognitive performance;
LGG	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg08600765	chr20:34638493	LOC647979	-0.61	-7.69	-0.34	9.1e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7402982	0.625	rs4966008	chr15:99203445	A/G	cg03437748	chr15:99193247	IGF1R	-0.81	-14.2	-0.55	3.06e-38	Birth weight;
LGG	cis	rs28595532	0.920	rs115797971	chr4:119779620	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs15676	0.947	rs2977994	chr9:131585216	G/T	cg04621255	chr9:131581398	ENDOG	-0.39	-6.92	-0.31	1.47e-11	Blood metabolite levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04902851	chr8:59572557	NSMAF	0.38	6.83	0.3	2.7e-11	Menarche (age at onset);
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.3	0.32	1.3e-12	Schizophrenia;
LGG	trans	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.83	-0.3	2.72e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.16e-36	Corneal astigmatism;
LGG	cis	rs4740619	0.869	rs1341732	chr9:15901875	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.01	-0.42	1.69e-21	Body mass index;
LGG	cis	rs1461503	0.966	rs4936764	chr11:122844492	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs4747241	0.562	rs9416018	chr10:74100642	G/A	cg25082487	chr10:74091975	NA	0.36	6.88	0.3	1.91e-11	Heschl's gyrus morphology;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.01	0.35	9.43e-15	Prudent dietary pattern;
LGG	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	cis	rs7236492	0.688	rs77069608	chr18:77186319	C/T	cg15532942	chr18:77220712	NFATC1	0.45	7.27	0.32	1.54e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs644799	0.760	rs7114555	chr11:95648242	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	9.71	0.41	2.09e-20	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs698833	1.000	rs1067352	chr2:44669724	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	7.47	0.33	4.15e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs11677416	1.000	rs1878319	chr2:113544826	G/A	cg27083787	chr2:113543245	IL1A	0.53	8.78	0.38	3.07e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs1620921	0.594	rs9347451	chr6:161270100	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.53	0.63	3.74e-53	Sudden cardiac arrest;
LGG	cis	rs2247341	0.965	rs2854913	chr4:1723137	A/T	cg08629884	chr4:1719983	TMEM129	-0.58	-11.31	-0.47	2.28e-26	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6942756	0.806	rs10248810	chr7:128993806	G/A	cg02491457	chr7:128862824	NA	-0.62	-11.46	-0.47	6.38e-27	White matter hyperintensity burden;
LGG	cis	rs4356932	1.000	rs6532114	chr4:76957974	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	6.77e-11	Blood protein levels;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	5.84e-17	IgG glycosylation;
LGG	cis	rs10991814	0.588	rs1751800	chr9:93943920	C/G	cg14446406	chr9:93919335	NA	0.79	11.32	0.47	2.21e-26	Neutrophil percentage of granulocytes;
LGG	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg19507638	chr5:93509721	C5orf36	0.41	7.0	0.31	9.11e-12	Diabetic retinopathy;
LGG	cis	rs477692	0.699	rs471390	chr10:131382825	A/G	cg05714579	chr10:131428358	MGMT	-0.43	-8.22	-0.36	2.08e-15	Response to temozolomide;
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg06848047	chr4:90757629	SNCA	-0.43	-8.05	-0.35	6.83e-15	Dementia with Lewy bodies;
LGG	cis	rs9964724	0.559	rs72893192	chr18:35174836	T/G	cg27332583	chr18:35150602	NA	0.62	11.93	0.48	8.51e-29	Educational attainment (years of education);
LGG	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.47	-0.4	1.48e-19	Neuroticism;
LGG	trans	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg25214090	chr10:38739885	LOC399744	0.65	11.55	0.47	2.85e-27	Corneal astigmatism;
LGG	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg02733842	chr7:1102375	C7orf50	0.43	7.26	0.32	1.63e-12	Bronchopulmonary dysplasia;
LGG	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-12.75	-0.51	3.96e-32	Morning vs. evening chronotype;
LGG	trans	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.65	-0.33	1.18e-13	Blood trace element (Cu levels);
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg08024992	chr7:2133441	MAD1L1	0.37	6.91	0.31	1.64e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.27	-0.4	6.97e-19	Height;
LGG	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.1	-0.31	4.61e-12	Caffeine consumption;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	13.53	0.53	2.21e-35	Initial pursuit acceleration in psychotic disorders;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13610241	chr3:184032169	EIF4G1	0.47	7.54	0.33	2.42e-13	Cognitive performance;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.652	rs853961	chr6:127003464	G/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.53	-0.41	8.68e-20	Male-pattern baldness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20443138	chr2:183943496	DUSP19	0.43	6.78	0.3	3.59e-11	Cognitive performance;
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg15971980	chr6:150254442	NA	-0.44	-7.1	-0.31	4.84e-12	Lung cancer;
LGG	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg08807101	chr21:30365312	RNF160	0.77	13.96	0.54	3.29e-37	Selective IgA deficiency;
LGG	cis	rs57221529	0.546	rs72707044	chr5:677239	T/C	cg09021430	chr5:549028	NA	-0.7	-8.99	-0.39	6.54e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs16866061	1.000	rs11681451	chr2:225334104	T/C	cg12698349	chr2:225449008	CUL3	0.92	19.09	0.66	2.48e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.55	0.33	2.29e-13	Obesity-related traits;
LGG	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.94	-0.45	6.06e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.51	-9.87	-0.42	5.53e-21	Prudent dietary pattern;
LGG	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs11608355	0.515	rs4766476	chr12:109934700	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	16.22	0.6	3.54e-47	Personality dimensions;
LGG	cis	rs12580194	1.000	rs58332180	chr12:55711353	C/A	cg19537932	chr12:55886519	OR6C68	-0.37	-6.67	-0.3	7.18e-11	Cancer;
LGG	trans	rs73198271	0.737	rs535094	chr8:8633928	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.99	0.31	9.59e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6546537	0.714	rs17036759	chr2:69767029	C/T	cg10773587	chr2:69614142	GFPT1	-0.54	-9.19	-0.39	1.34e-18	Serum thyroid-stimulating hormone levels;
LGG	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg08534653	chr2:1747700	PXDN	0.49	7.25	0.32	1.77e-12	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.06e-15	Life satisfaction;
LGG	cis	rs4746818	1.000	rs4746818	chr10:70884687	G/T	cg11621586	chr10:70884670	VPS26A	1.18	22.69	0.73	3.66e-77	Left atrial antero-posterior diameter;
LGG	cis	rs72772090	0.908	rs72772091	chr5:96040122	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.44	-7.03	-0.31	7.48e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7315438	0.581	rs10850526	chr12:115934758	C/T	cg18639984	chr12:115943877	NA	-0.36	-7.46	-0.33	4.23e-13	Colorectal cancer;
LGG	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg01221209	chr5:554886	NA	-0.51	-8.18	-0.36	2.75e-15	Obesity-related traits;
LGG	cis	rs6504108	0.624	rs17681336	chr17:46249792	A/G	cg02219949	chr17:45927392	SP6	0.43	8.07	0.35	6.18e-15	Body mass index;
LGG	trans	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	trans	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.62e-25	Corneal astigmatism;
LGG	cis	rs9814567	1.000	rs62271514	chr3:134298554	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	12.84	0.51	1.73e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7927592	0.546	rs554734	chr11:68192518	T/G	cg16797656	chr11:68205561	LRP5	0.55	10.27	0.43	1.91e-22	Total body bone mineral density;
LGG	cis	rs7617773	0.817	rs13059037	chr3:48287879	A/G	cg11946769	chr3:48343235	NME6	0.69	11.37	0.47	1.33e-26	Coronary artery disease;
LGG	cis	rs9487051	0.933	rs5005289	chr6:109617673	C/G	cg21918786	chr6:109611834	NA	-0.44	-8.24	-0.36	1.77e-15	Reticulocyte fraction of red cells;
LGG	trans	rs9354308	0.838	rs9445595	chr6:66537559	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-8.83	-0.38	2.12e-17	Metabolite levels;
LGG	cis	rs422249	0.547	rs174536	chr11:61551927	A/C	cg19610905	chr11:61596333	FADS2	-0.81	-14.78	-0.57	9.43e-41	Trans fatty acid levels;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg05665937	chr4:1216051	CTBP1	0.5	8.74	0.38	4.47e-17	Obesity-related traits;
LGG	cis	rs11168618	0.967	rs10875831	chr12:48938380	G/A	cg24011408	chr12:48396354	COL2A1	0.48	7.85	0.34	2.82e-14	Adiponectin levels;
LGG	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg12552261	chr5:112820674	MCC	0.75	14.17	0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs738321	0.725	rs9622738	chr22:38542346	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.49	-0.4	1.24e-19	Breast cancer;
LGG	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg17971929	chr21:40555470	PSMG1	0.72	13.51	0.53	2.77e-35	Cognitive function;
LGG	cis	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg08112188	chr17:47440006	ZNF652	0.4	6.65	0.3	8.37e-11	Cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.5	7.8	0.34	4.18e-14	Gut microbiome composition (summer);
LGG	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg17145862	chr1:211918768	LPGAT1	-0.71	-14.67	-0.56	2.83e-40	Leprosy;
LGG	cis	rs4950322	0.580	rs4950371	chr1:146585825	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.82	-0.34	3.63e-14	Protein quantitative trait loci;
LGG	cis	rs727505	0.564	rs67745021	chr7:124868018	T/C	cg23710748	chr7:124431027	NA	-0.44	-8.18	-0.36	2.68e-15	Lewy body disease;
LGG	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.43	-7.96	-0.35	1.33e-14	Homoarginine levels;
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-12.74	-0.51	4.29e-32	Vitiligo;
LGG	trans	rs937213	0.596	rs4924406	chr15:40309704	A/T	cg22705835	chr10:65332833	REEP3	0.42	7.44	0.33	4.77e-13	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs2953174	0.786	rs2953146	chr2:241515252	A/G	cg07929629	chr2:241523174	NA	-0.55	-7.79	-0.34	4.36e-14	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.44	0.44	4.58e-23	Prudent dietary pattern;
LGG	cis	rs6032067	0.673	rs2301366	chr20:43836173	T/A	cg10761708	chr20:43804764	PI3	0.58	8.93	0.38	9.74e-18	Blood protein levels;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	trans	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg07393940	chr7:158741817	NA	-0.57	-10.5	-0.44	2.74e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs877282	0.898	rs11253338	chr10:759559	C/T	cg22713356	chr15:30763199	NA	0.48	7.53	0.33	2.67e-13	Uric acid levels;
LGG	cis	rs9300255	0.602	rs1727294	chr12:123616514	A/G	cg05973401	chr12:123451056	ABCB9	0.49	7.54	0.33	2.52e-13	Neutrophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01358551	chr19:47353761	AP2S1	0.46	7.48	0.33	3.84e-13	Cognitive performance;
LGG	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg23173402	chr1:227635558	NA	0.69	11.13	0.46	1.2e-25	Major depressive disorder;
LGG	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg03060546	chr3:49711283	APEH	0.74	13.39	0.53	8.55e-35	Resting heart rate;
LGG	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.99	0.31	9.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg02389323	chr16:88786976	FAM38A	1.06	12.93	0.52	7.27e-33	Plateletcrit;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs7649275	0.938	rs1809282	chr3:53781957	A/G	cg21503701	chr3:53781065	CACNA1D	-0.42	-6.81	-0.3	3.01e-11	Trans fatty acid levels;
LGG	cis	rs4535700	0.501	rs2135116	chr7:55991144	A/G	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	4.01e-11	Macular telangiectasia type 2;
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg01765077	chr12:122356316	WDR66	0.28	7.45	0.33	4.52e-13	Mean corpuscular volume;
LGG	cis	rs17824933	0.943	rs11230562	chr11:60776186	C/T	cg16817237	chr11:60793675	NA	0.36	6.75	0.3	4.57e-11	Multiple sclerosis;
LGG	cis	rs11239187	0.606	rs989077	chr10:45074117	C/A	cg03916630	chr10:45065415	NA	0.35	8.46	0.37	3.6e-16	Body mass index;
LGG	cis	rs9341808	0.754	rs6907729	chr6:81004922	A/T	cg08355045	chr6:80787529	NA	-0.39	-7.66	-0.34	1.13e-13	Sitting height ratio;
LGG	cis	rs2797369	0.570	rs2813642	chr6:101574489	T/A	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.86e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg17737146	chr3:169530037	LRRC34	0.35	6.67	0.3	7.53e-11	Renal cell carcinoma;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg12070911	chr6:150209640	RAET1E	0.33	8.09	0.35	5.17e-15	Lung cancer;
LGG	cis	rs7264396	0.790	rs6579255	chr20:34219496	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.47	0.33	4.07e-13	Total cholesterol levels;
LGG	cis	rs10979	1.000	rs12212011	chr6:143894694	C/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg20913747	chr6:44695427	NA	-0.6	-10.23	-0.43	2.7e-22	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13664964	chr2:43454185	ZFP36L2;LOC100129726	0.48	7.35	0.32	9.18e-13	Gut microbiome composition (summer);
LGG	cis	rs10463316	0.817	rs7709507	chr5:150783349	C/T	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.64	-0.41	3.7e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg13939156	chr17:80058883	NA	-0.46	-9.01	-0.39	5.4e-18	Life satisfaction;
LGG	cis	rs2693698	0.651	rs11160506	chr14:99683297	A/C	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.72e-28	Schizophrenia;
LGG	cis	rs9297145	0.916	rs6969140	chr7:98753900	G/A	cg05967295	chr7:98741636	SMURF1	-0.97	-19.09	-0.66	2.38e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.84	-10.4	-0.44	6.55e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.62	0.33	1.49e-13	Coronary artery disease;
LGG	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs7914558	0.933	rs10883814	chr10:104737404	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.5	0.44	2.71e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg24829409	chr8:58192753	C8orf71	-0.73	-10.34	-0.43	1.11e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27332243	chr1:154842767	KCNN3	0.47	7.37	0.32	7.93e-13	Cognitive performance;
LGG	cis	rs12410462	0.591	rs59149651	chr1:227877251	T/C	cg23173402	chr1:227635558	NA	0.35	6.83	0.3	2.74e-11	Major depressive disorder;
LGG	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg21659725	chr3:3221576	CRBN	0.52	7.8	0.34	4.04e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06741594	chr7:132260475	PLXNA4	0.44	7.36	0.32	8.43e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg17470184	chr11:118478236	PHLDB1	-0.42	-7.22	-0.32	2.14e-12	Cholesterol, total;
LGG	cis	rs8114671	0.562	rs6088636	chr20:33469746	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.15	0.32	3.49e-12	Height;
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg05313129	chr8:58192883	C8orf71	-0.82	-12.2	-0.49	7.22e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg05082376	chr22:42548792	NA	0.38	8.06	0.35	6.74e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg04602081	chr1:16498086	NA	0.34	7.48	0.33	3.71e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs988958	0.526	rs13024096	chr2:42252950	A/G	cg19376973	chr2:42229025	NA	0.63	9.48	0.4	1.28e-19	Hypospadias;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.75e-15	IgG glycosylation;
LGG	cis	rs6988985	0.667	rs7818953	chr8:143959289	T/C	cg10324643	chr8:143916377	GML	0.42	8.14	0.35	3.58e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21582582	chr3:182698605	DCUN1D1	0.38	6.71	0.3	5.85e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.64	-0.44	8.52e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7264396	0.790	rs3787166	chr20:34229072	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-6.8	-0.3	3.33e-11	Total cholesterol levels;
LGG	trans	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.44	0.5	7.6e-31	Corneal astigmatism;
LGG	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg20220242	chr21:30392188	RWDD2B	0.69	8.13	0.35	3.9e-15	Cognitive test performance;
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00149659	chr3:10157352	C3orf10	0.76	9.69	0.41	2.51e-20	Alzheimer's disease;
LGG	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg08847533	chr14:75593920	NEK9	0.62	11.76	0.48	4.11e-28	Height;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg12070911	chr6:150209640	RAET1E	0.28	6.87	0.3	2.07e-11	Lung cancer;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.67	12.23	0.49	5.44e-30	Obesity-related traits;
LGG	cis	rs77972916	0.505	rs11899984	chr2:43578246	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.32	-0.4	4.61e-19	Granulocyte percentage of myeloid white cells;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg05556477	chr5:131705319	SLC22A5	-0.75	-9.26	-0.4	7.84e-19	Rheumatoid arthritis;
LGG	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11245990	chr11:68621969	NA	0.41	8.74	0.38	4.35e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs747650	0.859	rs4567413	chr11:47232184	A/G	cg03339077	chr11:47165057	C11orf49	-0.55	-10.7	-0.45	4.86e-24	Acne (severe);
LGG	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg19680485	chr15:31195859	MTMR15	-0.45	-7.39	-0.32	6.82e-13	Huntington's disease progression;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg27471124	chr11:109292789	C11orf87	0.47	9.48	0.4	1.35e-19	Schizophrenia;
LGG	trans	rs75804782	0.521	rs55988884	chr2:239396930	G/A	cg01134436	chr17:81009848	B3GNTL1	0.81	8.72	0.38	4.86e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3784262	0.967	rs35511675	chr15:58266978	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.15	-0.35	3.35e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7166081	1.000	rs8025621	chr15:67556726	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.7	-0.3	6.06e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg00666640	chr1:248458726	OR2T12	0.49	7.35	0.32	9.17e-13	Common traits (Other);
LGG	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg13334819	chr7:99746414	C7orf59	0.51	7.83	0.34	3.45e-14	Coronary artery disease;
LGG	cis	rs362296	0.698	rs3135172	chr4:3258735	A/G	cg06533319	chr4:3265114	C4orf44	0.5	9.76	0.41	1.34e-20	Parental longevity (mother's age at death);
LGG	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg05623727	chr3:50126028	RBM5	0.39	8.32	0.36	1.03e-15	Body mass index;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.7	0.38	5.64e-17	Longevity;
LGG	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg10818794	chr15:86012489	AKAP13	0.37	7.66	0.34	1.08e-13	Coronary artery disease;
LGG	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg01620082	chr3:125678407	NA	-0.66	-7.06	-0.31	6.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9902453	0.619	rs2617866	chr17:28076217	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-14.01	-0.55	2.01e-37	Coffee consumption (cups per day);
LGG	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg14829360	chr17:73884958	NA	-0.7	-8.16	-0.35	3.13e-15	Psoriasis;
LGG	cis	rs300774	0.925	rs300707	chr2:141324	G/T	cg04617936	chr2:214353	NA	-0.5	-7.72	-0.34	7.02e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	9.11	0.39	2.52e-18	Bipolar disorder;
LGG	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.73	0.34	6.93e-14	Mood instability;
LGG	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg06808227	chr14:105710500	BRF1	-0.61	-11.09	-0.46	1.66e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	5.07e-34	Prudent dietary pattern;
LGG	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.51	-9.8	-0.41	1.02e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg08975724	chr8:8085496	FLJ10661	0.42	7.64	0.33	1.29e-13	Retinal vascular caliber;
LGG	cis	rs7294478	0.563	rs7962714	chr12:7262797	A/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.45	-11.85	-0.48	1.86e-28	Neuritic plaque;
LGG	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.89	-10.49	-0.44	2.98e-23	Lung cancer in ever smokers;
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg16885296	chr6:26284938	NA	-0.39	-8.54	-0.37	2.01e-16	Educational attainment;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg18632102	chr5:154238496	CNOT8	-0.45	-6.99	-0.31	9.64e-12	Coronary artery disease;
LGG	cis	rs8049634	0.764	rs11864937	chr16:84228199	G/T	cg26466773	chr16:84211947	TAF1C	0.42	7.0	0.31	9.05e-12	Small cell lung carcinoma;
LGG	cis	rs910187	0.678	rs6066229	chr20:45815341	A/G	cg27589058	chr20:45804311	EYA2	0.35	9.08	0.39	3.12e-18	Migraine;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16405210	chr4:1374714	KIAA1530	0.66	11.89	0.48	1.21e-28	Obesity-related traits;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg14598950	chr3:37035355	MLH1;EPM2AIP1	-0.43	-6.78	-0.3	3.75e-11	Coronary artery disease;
LGG	trans	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg25214090	chr10:38739885	LOC399744	0.38	6.96	0.31	1.15e-11	Diastolic blood pressure;
LGG	cis	rs758324	0.947	rs2896961	chr5:131165006	C/T	cg06307176	chr5:131281290	NA	0.57	9.45	0.4	1.68e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg08344181	chr3:125677491	NA	-0.77	-7.42	-0.33	5.53e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24475210	chr4:6642433	MRFAP1	0.45	7.56	0.33	2.15e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg08499158	chr17:42289980	UBTF	-0.39	-7.21	-0.32	2.34e-12	Total body bone mineral density;
LGG	cis	rs6456156	0.526	rs1854853	chr6:167533062	A/G	cg07741184	chr6:167504864	NA	-0.33	-7.59	-0.33	1.74e-13	Primary biliary cholangitis;
LGG	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg23625390	chr15:77176239	SCAPER	-0.63	-11.13	-0.46	1.13e-25	Blood metabolite levels;
LGG	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs78545713	0.649	rs79759076	chr6:26223694	C/G	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs4727027	0.933	rs10277119	chr7:148849942	T/C	cg23583168	chr7:148888333	NA	-0.87	-16.95	-0.62	1.65e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg15103426	chr22:29168792	CCDC117	0.59	8.96	0.38	7.86e-18	Lymphocyte counts;
LGG	trans	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.82	0.64	1.86e-54	Exhaled nitric oxide output;
LGG	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg02487422	chr3:49467188	NICN1	0.45	7.28	0.32	1.48e-12	Resting heart rate;
LGG	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg00405596	chr8:11794950	NA	-0.42	-7.01	-0.31	8.74e-12	Neuroticism;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg07701084	chr6:150067640	NUP43	0.7	13.64	0.54	7.3e-36	Lung cancer;
LGG	cis	rs10463554	0.927	rs40061	chr5:102403116	G/A	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg14703610	chr5:56206110	C5orf35	0.44	7.59	0.33	1.82e-13	Coronary artery disease;
LGG	trans	rs17685	0.753	rs6465000	chr7:75787417	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs3741151	0.764	rs7101561	chr11:73264219	G/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs7246760	0.500	rs66490745	chr19:9999841	G/A	cg02900749	chr2:68251473	NA	-0.6	-6.79	-0.3	3.48e-11	Pursuit maintenance gain;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.18	-0.36	2.77e-15	IgG glycosylation;
LGG	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg13010199	chr12:38710504	ALG10B	0.55	9.7	0.41	2.29e-20	Resting heart rate;
LGG	cis	rs7666738	0.830	rs17484890	chr4:99013778	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.91	0.35	1.87e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12269901	0.516	rs4938316	chr11:116764582	A/G	cg20608306	chr11:116969690	SIK3	0.37	8.21	0.36	2.17e-15	HDL cholesterol;
LGG	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.6	-0.75	4.41e-86	Height;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg08621203	chr6:150244597	RAET1G	0.46	8.08	0.35	5.64e-15	Lung cancer;
LGG	cis	rs9818758	0.607	rs4855860	chr3:49526044	A/T	cg00383909	chr3:49044727	WDR6	-1.01	-10.89	-0.45	9.57e-25	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg21659725	chr3:3221576	CRBN	0.66	12.43	0.5	8.47e-31	Intelligence (multi-trait analysis);
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg22072935	chr14:105399595	NA	0.54	10.46	0.44	3.83e-23	Rheumatoid arthritis;
LGG	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-8.89	-0.38	1.39e-17	Chronic sinus infection;
LGG	cis	rs10805346	1.000	rs10805346	chr4:9920347	T/C	cg25986240	chr4:9926439	SLC2A9	0.47	10.43	0.44	5.02e-23	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg03929089	chr4:120376271	NA	0.7	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs2816316	1.000	rs2760528	chr1:192536785	G/A	cg10861751	chr1:192544716	RGS1	0.34	6.85	0.3	2.41e-11	Celiac disease;
LGG	cis	rs12286929	0.637	rs34138164	chr11:115050127	A/G	cg04055981	chr11:115044050	NA	0.37	7.04	0.31	7.15e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6964587	1.000	rs9690208	chr7:91735613	T/A	cg17063962	chr7:91808500	NA	0.5	9.04	0.39	4.45e-18	Breast cancer;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg16060761	chr17:80687452	NA	0.56	10.18	0.43	4.21e-22	Glycated hemoglobin levels;
LGG	cis	rs7291412	0.540	rs9627391	chr22:46447097	C/T	cg23564243	chr22:46441127	LOC100271722	-0.4	-7.1	-0.31	4.63e-12	Dupuytren's disease;Subjective well-being;
LGG	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.08	0.77	6.26e-93	Chronic sinus infection;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg18258770	chr4:90757814	SNCA	-0.42	-7.69	-0.34	9.11e-14	Dementia with Lewy bodies;
LGG	cis	rs17767392	0.958	rs34169215	chr14:72011148	C/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.41	0.4	2.35e-19	Mitral valve prolapse;
LGG	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.86	0.34	2.79e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg19338460	chr6:170058176	WDR27	-0.85	-9.98	-0.42	2.24e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg05729581	chr11:3078854	CARS	-0.54	-9.62	-0.41	4.42e-20	Longevity;
LGG	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg16141378	chr3:129829833	LOC729375	-0.33	-7.09	-0.31	5.14e-12	Multiple myeloma (hyperdiploidy);
LGG	trans	rs853679	0.723	rs1736904	chr6:28219270	G/A	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.22	-0.32	2.14e-12	Depression;
LGG	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg14689365	chr7:158441557	NCAPG2	0.61	10.64	0.44	8.8e-24	Height;
LGG	cis	rs526231	0.575	rs12652973	chr5:102306322	G/A	cg23492399	chr5:102201601	PAM	-0.62	-9.34	-0.4	4.14e-19	Primary biliary cholangitis;
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg19774624	chr17:42201019	HDAC5	-0.96	-20.38	-0.69	2.34e-66	Total body bone mineral density;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.48	-0.47	5.2e-27	Personality dimensions;
LGG	cis	rs3784262	0.669	rs12914455	chr15:58312096	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.91	-0.31	1.63e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg08704250	chr15:31115839	NA	-0.48	-8.64	-0.37	8.95e-17	Huntington's disease progression;
LGG	cis	rs4664304	0.531	rs11691616	chr2:160758680	G/C	cg06856378	chr2:160759118	LY75	0.41	7.64	0.33	1.29e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg14137381	chr5:502291	SLC9A3	-0.32	-6.67	-0.3	7.1e-11	Cystic fibrosis severity;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs943466	1.000	rs11753083	chr6:33761111	C/G	cg07519485	chr6:33762594	MLN	0.55	11.22	0.46	5.18e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.19	-0.58	1.39e-42	Prudent dietary pattern;
LGG	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg12654349	chr5:56205094	C5orf35	-0.4	-7.11	-0.31	4.33e-12	Breast cancer;Breast cancer (early onset);
LGG	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.69	0.34	8.93e-14	Cystic fibrosis severity;
LGG	cis	rs6120849	0.662	rs6060300	chr20:33780970	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	7.03	0.31	7.32e-12	Protein C levels;
LGG	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.64	-0.41	3.62e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	25.25	0.76	4.12e-89	IgG glycosylation;
LGG	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.72	-0.38	5e-17	Neuroticism;
LGG	cis	rs9972944	0.756	rs9894298	chr17:63769225	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.17	0.39	1.51e-18	Bipolar disorder;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	16.02	0.6	2.81e-46	Personality dimensions;
LGG	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg22875332	chr1:76189707	ACADM	-0.55	-8.44	-0.37	3.98e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3784262	0.740	rs1441829	chr15:58289739	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.1	-0.31	4.61e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7010267	0.740	rs6993910	chr8:119950781	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.32	-7.96	-0.35	1.36e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.44	6.92	0.31	1.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg04731861	chr2:219085781	ARPC2	-0.48	-12.17	-0.49	9.6e-30	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.22	-0.32	2.12e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9358372	0.711	rs9350297	chr6:20880280	G/A	cg13405222	chr6:20811065	CDKAL1	-0.59	-12.43	-0.5	8.42e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg09307838	chr4:120376055	NA	-0.8	-12.99	-0.52	3.93e-33	Corneal astigmatism;
LGG	cis	rs11150038	0.623	rs7192427	chr16:78020544	A/G	cg04733911	chr16:78082701	NA	-0.55	-7.24	-0.32	1.87e-12	Colorectal or endometrial cancer;
LGG	cis	rs7113850	0.541	rs79932281	chr11:24231839	T/G	ch.11.24196551F	chr11:24239977	NA	0.89	10.14	0.43	5.8e-22	Bone fracture in osteoporosis;
LGG	cis	rs498079	0.544	rs509685	chr6:133517005	A/G	cg14017655	chr6:133562193	EYA4	0.41	7.52	0.33	2.82e-13	Total body bone mineral density;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	cis	rs4430311	0.688	rs12142652	chr1:243953583	A/G	cg25706552	chr1:244017396	NA	-0.65	-15.93	-0.6	6.95e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs4356203	0.870	rs10741724	chr11:17253151	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-1.0	-20.38	-0.69	2.16e-66	Height;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.49	-0.37	2.74e-16	Personality dimensions;
LGG	cis	rs73086581	1.000	rs56069856	chr20:3965709	A/C	cg02187196	chr20:3869020	PANK2	0.83	11.65	0.48	1.14e-27	Response to antidepressants in depression;
LGG	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.88	0.48	1.38e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg05896524	chr21:47604654	C21orf56	-0.52	-8.51	-0.37	2.52e-16	Testicular germ cell tumor;
LGG	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.25	-0.36	1.67e-15	Mood instability;
LGG	cis	rs6960043	0.905	rs2215381	chr7:15054935	G/T	cg19272540	chr7:15055459	NA	0.34	7.78	0.34	4.73e-14	Type 2 diabetes;
LGG	cis	rs10851478	0.558	rs4389093	chr15:49743069	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.42	7.44	0.33	4.83e-13	Oral cavity cancer;
LGG	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.67	-0.34	1.03e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg16507663	chr6:150244633	RAET1G	0.44	7.16	0.32	3.11e-12	Lung cancer;
LGG	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10850197	chr6:106773227	ATG5	0.43	7.15	0.32	3.51e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg00800038	chr16:89945340	TCF25	-0.57	-7.96	-0.35	1.3e-14	Skin colour saturation;
LGG	cis	rs17818399	0.620	rs1598517	chr2:46857401	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-7.98	-0.35	1.15e-14	Height;
LGG	cis	rs7737355	0.812	rs13158295	chr5:130629392	G/A	cg06307176	chr5:131281290	NA	0.49	8.1	0.35	4.8e-15	Life satisfaction;
LGG	cis	rs68170813	0.559	rs74925723	chr7:106954536	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.68	-0.44	5.93e-24	Coronary artery disease;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.71	-13.29	-0.53	2.32e-34	Longevity;Endometriosis;
LGG	cis	rs7216064	1.000	rs7209675	chr17:65831258	A/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.83	-0.38	2.13e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6032067	0.714	rs2206887	chr20:43856024	A/G	cg10761708	chr20:43804764	PI3	0.58	8.87	0.38	1.6e-17	Blood protein levels;
LGG	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg19168338	chr16:4465731	CORO7	-0.99	-18.34	-0.65	6.79e-57	Schizophrenia;
LGG	cis	rs8072100	0.701	rs6503807	chr17:45772932	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-9.93	-0.42	3.39e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg22681709	chr2:178499509	PDE11A	-0.52	-7.74	-0.34	6.11e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.39	-0.36	5.92e-16	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9649465	1.000	rs2109724	chr7:123325391	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs7928758	0.767	rs10894810	chr11:134273559	C/T	cg15243474	chr11:134282918	B3GAT1	0.79	12.31	0.5	2.56e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	0.4	6.87	0.3	2.09e-11	Bipolar disorder;
LGG	cis	rs11229555	0.645	rs11229430	chr11:58181104	G/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2133450	0.689	rs9829495	chr3:7268094	A/C	cg19930620	chr3:7340148	GRM7	0.34	7.45	0.33	4.7e-13	Early response to risperidone in schizophrenia;
LGG	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.6	7.98	0.35	1.15e-14	HIV-1 control;
LGG	cis	rs7444	0.941	rs5998672	chr22:21966442	G/A	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.34	0.36	8.45e-16	Schizophrenia;
LGG	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.78	0.66	6.45e-59	Smoking behavior;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg15971980	chr6:150254442	NA	0.44	7.62	0.33	1.43e-13	Lung cancer;
LGG	cis	rs266717	0.816	rs187868	chr3:186509517	G/A	cg00373256	chr3:186519153	RFC4	-0.41	-8.45	-0.37	3.85e-16	Adiponectin levels;
LGG	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.45	-0.33	4.73e-13	Joint mobility (Beighton score);
LGG	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg08344181	chr3:125677491	NA	-0.84	-8.16	-0.35	3.28e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg02985381	chr13:37494744	SMAD9	0.69	12.55	0.5	2.69e-31	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02793854	chr16:67867809	CENPT	-0.46	-7.25	-0.32	1.75e-12	Pancreatic cancer;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.38	0.36	6.21e-16	Life satisfaction;
LGG	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-10.79	-0.45	2.28e-24	Morning vs. evening chronotype;
LGG	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg25801113	chr15:45476975	SHF	-0.86	-18.89	-0.66	2.07e-59	Uric acid levels;
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg25145360	chr17:19651881	ALDH3A1	-0.91	-22.04	-0.72	3.65e-74	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs7580658	0.750	rs6731176	chr2:128071003	C/T	cg10021288	chr2:128175891	PROC	-0.61	-12.55	-0.5	2.62e-31	Protein C levels;
LGG	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg10523679	chr1:76189770	ACADM	-0.71	-11.06	-0.46	2.1e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs986417	0.901	rs1015119	chr14:61027510	G/T	cg27398547	chr14:60952738	C14orf39	0.75	7.05	0.31	6.63e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg15128208	chr22:42549153	NA	0.74	11.38	0.47	1.21e-26	Birth weight;
LGG	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.58e-35	Anterior chamber depth;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs7017914	0.967	rs34558600	chr8:71586152	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	cis	rs6809651	0.524	rs6444106	chr3:185811495	C/T	cg00760338	chr3:185826511	ETV5	-0.9	-15.33	-0.58	3.32e-43	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs4771450	0.925	rs7320440	chr13:103984998	A/G	cg02987523	chr13:103978230	NA	-0.33	-7.08	-0.31	5.53e-12	Uric acid levels;
LGG	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.69	0.41	2.49e-20	Menopause (age at onset);
LGG	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg18876405	chr7:65276391	NA	-0.55	-9.61	-0.41	4.84e-20	Aortic root size;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.62	-0.37	1.1e-16	Alzheimer's disease (survival time);
LGG	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.5	-7.1	-0.31	4.72e-12	Birth weight;
LGG	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-15.48	-0.58	7.65e-44	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.37	-7.04	-0.31	7e-12	Schizophrenia;
LGG	cis	rs11967485	0.614	rs62434272	chr6:157219482	G/A	cg23222435	chr6:157204239	ARID1B	-0.86	-7.17	-0.32	2.98e-12	Calcium levels;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8141529	0.529	rs5762767	chr22:29141241	C/T	cg02153584	chr22:29168773	CCDC117	0.6	6.71	0.3	5.8e-11	Lymphocyte counts;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06481639	chr22:41940642	POLR3H	0.51	7.8	0.34	4.28e-14	Vitiligo;
LGG	cis	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg06521331	chr12:34319734	NA	-0.59	-10.98	-0.45	4.49e-25	Morning vs. evening chronotype;
LGG	cis	rs12493885	0.769	rs61791510	chr3:153754666	G/T	cg12800244	chr3:153838788	SGEF	-0.76	-8.54	-0.37	1.88e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.11	0.39	2.54e-18	Lung cancer in ever smokers;
LGG	cis	rs12153243	0.714	rs1946237	chr5:142895450	A/T	cg13907255	chr5:142895549	NA	-0.49	-8.76	-0.38	3.78e-17	Migraine;
LGG	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg11502198	chr6:26597334	ABT1	-0.54	-9.45	-0.4	1.66e-19	Intelligence (multi-trait analysis);
LGG	cis	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg12292205	chr6:26970375	C6orf41	-0.62	-8.19	-0.36	2.61e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9902453	0.542	rs3809789	chr17:27955761	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	11.29	0.46	2.9e-26	Coffee consumption (cups per day);
LGG	cis	rs7727544	0.735	rs2569266	chr5:131706791	T/C	cg07395648	chr5:131743802	NA	0.56	13.26	0.52	3.07e-34	Blood metabolite levels;
LGG	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.35	-0.32	9.14e-13	Mean corpuscular volume;
LGG	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.69	-0.34	9.08e-14	Psoriasis;
LGG	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg10596483	chr8:143751796	JRK	0.52	8.12	0.35	4.16e-15	Schizophrenia;
LGG	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22496380	chr5:211416	CCDC127	-1.29	-11.54	-0.47	2.89e-27	Breast cancer;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs3790455	0.896	rs1050316	chr1:156434703	G/T	cg14087168	chr1:156450669	MEF2D	0.48	7.97	0.35	1.25e-14	Migraine;
LGG	cis	rs892961	0.932	rs8066646	chr17:75414192	C/T	cg05865280	chr17:75406074	SEPT9	0.43	10.19	0.43	3.85e-22	Airflow obstruction;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.57	-0.37	1.56e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7000551	0.700	rs2461491	chr8:22361252	C/T	cg12081754	chr8:22256438	SLC39A14	-0.63	-11.89	-0.48	1.27e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg12692727	chr7:1102344	C7orf50	0.48	6.71	0.3	5.8200000000000003e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs847851	0.630	rs9462021	chr6:34758640	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4742903	1.000	rs7854630	chr9:106875277	A/C	cg14250997	chr9:106856677	SMC2	-0.4	-8.24	-0.36	1.76e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg23758822	chr17:41437982	NA	0.87	15.43	0.58	1.29e-43	Menopause (age at onset);
LGG	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.48e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg26174226	chr8:58114915	NA	-0.52	-7.22	-0.32	2.11e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg21972741	chr5:435613	AHRR	0.5	8.98	0.39	6.77e-18	Cystic fibrosis severity;
LGG	cis	rs9467160	0.871	rs13191455	chr6:24448459	T/C	cg20631270	chr6:24437470	GPLD1	0.51	7.68	0.34	9.4e-14	Liver enzyme levels;
LGG	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg08508325	chr11:3079039	CARS	0.41	7.91	0.34	1.93e-14	Calcium levels;
LGG	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	-0.56	-8.94	-0.38	8.98e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9287719	0.810	rs7601748	chr2:10785446	A/G	cg02196655	chr2:10830764	NOL10	-0.47	-8.23	-0.36	1.98e-15	Prostate cancer;
LGG	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg20744362	chr22:50050164	C22orf34	0.4	7.08	0.31	5.29e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.69e-24	Alzheimer's disease;
LGG	cis	rs10274279	0.688	rs7459356	chr7:157398852	G/C	cg09270525	chr7:157391030	PTPRN2	0.84	11.06	0.46	2.11e-25	Myopia (pathological);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg21350283	chr14:69445743	ACTN1	0.41	6.95	0.31	1.22e-11	Bipolar disorder;
LGG	cis	rs929596	0.564	rs2741034	chr2:234548814	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.27	-0.4	7.3e-19	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg27411982	chr8:10470053	RP1L1	0.4	7.05	0.31	6.66e-12	Neuroticism;
LGG	cis	rs2289125	0.597	rs664472	chr11:89217735	T/C	cg01436723	chr11:89220647	NOX4	-0.54	-7.65	-0.34	1.14e-13	Pulse pressure;
LGG	cis	rs10461617	0.617	rs1423623	chr5:56065575	A/G	cg12654349	chr5:56205094	C5orf35	0.38	6.85	0.3	2.43e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg07701084	chr6:150067640	NUP43	0.69	12.97	0.52	4.81e-33	Lung cancer;
LGG	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.66	-0.51	9.87e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg04166393	chr7:2884313	GNA12	0.47	9.01	0.39	5.4e-18	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16898493	chr22:50946451	LMF2;NCAPH2	0.51	7.97	0.35	1.29e-14	Gut microbiome composition (summer);
LGG	cis	rs8028182	0.636	rs8034317	chr15:75764343	G/A	cg20655648	chr15:75932815	IMP3	0.47	7.89	0.34	2.14e-14	Sudden cardiac arrest;
LGG	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.71	-0.34	7.95e-14	Neuroticism;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.73e-33	Prudent dietary pattern;
LGG	trans	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-13.04	-0.52	2.54e-33	Obesity-related traits;
LGG	cis	rs17767392	0.881	rs7142343	chr14:72023489	T/C	cg02058870	chr14:72053146	SIPA1L1	-0.46	-9.52	-0.4	9.36e-20	Mitral valve prolapse;
LGG	cis	rs12681287	0.604	rs28378899	chr8:87434500	G/C	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg09307838	chr4:120376055	NA	0.81	13.25	0.52	3.49e-34	Corneal astigmatism;
LGG	cis	rs11203032	0.634	rs2154255	chr10:90942967	A/T	cg16672925	chr10:90967113	CH25H	-0.71	-10.32	-0.43	1.36e-22	Heart failure;
LGG	cis	rs3735485	0.738	rs28603332	chr7:45089956	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7246760	1.000	rs2287839	chr19:9940814	C/G	cg16876255	chr19:9731953	ZNF561	0.76	7.02	0.31	7.9e-12	Pursuit maintenance gain;
LGG	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg27489772	chr12:121021490	NA	0.55	7.22	0.32	2.17e-12	Type 1 diabetes nephropathy;
LGG	cis	rs1018836	0.637	rs7843684	chr8:91470035	G/C	cg16814680	chr8:91681699	NA	-0.59	-9.85	-0.42	6.61e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-7.2	-0.32	2.4e-12	Blood metabolite levels;
LGG	cis	rs258892	0.895	rs2338792	chr5:72066860	G/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg21095983	chr6:86352623	SYNCRIP	0.6	11.29	0.46	2.86e-26	Smooth-surface caries;
LGG	cis	rs4727027	0.704	rs13221837	chr7:148903597	C/T	cg23583168	chr7:148888333	NA	-0.94	-19.2	-0.67	7.01e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg08621203	chr6:150244597	RAET1G	0.46	8.14	0.35	3.71e-15	Lung cancer;
LGG	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg25356066	chr3:128598488	ACAD9	0.45	6.86	0.3	2.27e-11	IgG glycosylation;
LGG	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs11264213	0.591	rs408986	chr1:36551895	C/T	cg27506609	chr1:36549197	TEKT2	0.69	8.77	0.38	3.46e-17	Schizophrenia;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg20978937	chr14:105399321	PLD4	0.46	10.13	0.43	6.65e-22	Rheumatoid arthritis;
LGG	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg00409905	chr10:38381863	ZNF37A	-0.49	-7.78	-0.34	4.62e-14	Obesity (extreme);
LGG	cis	rs34467563	0.872	rs6981275	chr8:97363684	A/G	cg22138393	chr8:97340270	PTDSS1	0.3	6.65	0.3	8.24e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-8.54	-0.37	1.9e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg23758822	chr17:41437982	NA	0.9	15.99	0.6	3.77e-46	Menopause (age at onset);
LGG	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05491587	chr18:77659695	KCNG2	-0.52	-7.02	-0.31	8.06e-12	Opioid sensitivity;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.59	-0.41	5.32e-20	Lung cancer;
LGG	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg21665744	chr7:39171113	POU6F2	0.4	7.95	0.35	1.41e-14	IgG glycosylation;
LGG	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg05527609	chr1:210001259	C1orf107	0.6	9.63	0.41	4.03e-20	Orofacial clefts;
LGG	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-9.17	-0.39	1.62e-18	Blood protein levels;
LGG	cis	rs4959677	0.935	rs9503208	chr6:2499191	C/T	cg23817096	chr6:1620687	NA	-0.31	-7.34	-0.32	9.83e-13	Orthostatic hypotension;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg15971980	chr6:150254442	NA	0.42	6.76	0.3	4.1e-11	Lung cancer;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg01238044	chr22:24384105	GSTT1	-0.4	-6.81	-0.3	2.96e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg13207630	chr7:32358064	NA	0.67	7.24	0.32	1.86e-12	Body mass index;
LGG	cis	rs755249	0.567	rs41270821	chr1:39923732	T/C	cg18385671	chr1:39797026	MACF1	0.45	7.55	0.33	2.29e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg09222892	chr1:25734099	RHCE	0.46	9.81	0.41	8.79e-21	Erythrocyte sedimentation rate;
LGG	trans	rs17685	0.753	rs6464999	chr7:75787315	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg07701084	chr6:150067640	NUP43	0.66	12.59	0.5	1.89e-31	Lung cancer;
LGG	trans	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg01620082	chr3:125678407	NA	-0.66	-8.18	-0.36	2.69e-15	Lung cancer in ever smokers;
LGG	cis	rs7216064	1.000	rs62084248	chr17:65874541	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs360798	0.512	rs2710640	chr2:63144305	A/G	cg17519650	chr2:63277830	OTX1	0.5	8.15	0.35	3.51e-15	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.3	1.85e-11	Lung cancer;
LGG	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg23815491	chr16:72088622	HP	0.5	11.38	0.47	1.21e-26	Fibrinogen levels;
LGG	cis	rs754466	0.957	rs61854183	chr10:79698077	T/C	cg17075019	chr10:79541650	NA	-0.8	-13.21	-0.52	4.85e-34	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6960043	0.738	rs7798360	chr7:15055972	A/G	cg19272540	chr7:15055459	NA	0.35	7.7	0.34	8.28e-14	Type 2 diabetes;
LGG	cis	rs7927771	0.524	rs7110300	chr11:47848442	T/G	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg12826209	chr6:26865740	GUSBL1	0.8	8.29	0.36	1.27e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.75	0.51	4.02e-32	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg16482183	chr6:26056742	HIST1H1C	0.52	9.34	0.4	3.99e-19	Height;
LGG	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.0	-0.35	1.02e-14	Subjective well-being;
LGG	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	cis	rs7617773	0.780	rs4511915	chr3:48343858	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg21171335	chr12:122356390	WDR66	0.28	7.88	0.34	2.38e-14	Mean corpuscular volume;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.65	-0.34	1.14e-13	Rheumatoid arthritis;
LGG	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg27400746	chr16:89904261	SPIRE2	-0.79	-12.77	-0.51	3.18e-32	Skin colour saturation;
LGG	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12826209	chr6:26865740	GUSBL1	0.62	9.51	0.4	1.05e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7523273	0.565	rs1998538	chr1:207886487	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.67	-0.37	7.36e-17	Schizophrenia;
LGG	cis	rs4742903	0.904	rs1507512	chr9:107004948	A/G	cg14250997	chr9:106856677	SMC2	0.37	7.7	0.34	8.52e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg06532163	chr17:45867833	NA	0.54	9.13	0.39	2.19e-18	IgG glycosylation;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.84e-12	Bipolar disorder;
LGG	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs12493885	0.818	rs62276828	chr3:153775941	C/T	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs3784262	0.935	rs4646636	chr15:58251034	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.17	-0.35	3.02e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9814567	1.000	rs4309773	chr3:134277301	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg24692254	chr21:30365293	RNF160	-0.84	-18.64	-0.65	2.95e-58	Dental caries;
LGG	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg20283391	chr11:68216788	NA	0.51	8.33	0.36	8.95e-16	Total body bone mineral density;
LGG	cis	rs1650123	0.617	rs703618	chr12:104021263	G/A	cg23227824	chr12:103980017	STAB2	0.36	8.27	0.36	1.42e-15	IgG glycosylation;
LGG	cis	rs4417704	0.551	rs6735127	chr2:241885932	G/T	cg14055004	chr2:241860995	NA	0.29	7.57	0.33	2.04e-13	Joint mobility (Beighton score);
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs2247341	0.894	rs61675353	chr4:1720794	T/G	cg08446824	chr4:1720184	TMEM129	-0.68	-13.09	-0.52	1.57e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4363385	0.818	rs11205166	chr1:152988627	C/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.71	-0.38	5.38e-17	Inflammatory skin disease;
LGG	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs17221829	0.965	rs3881252	chr11:89445186	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.68	-0.34	9.5e-14	Anxiety in major depressive disorder;
LGG	cis	rs1009647	0.592	rs1045004	chr14:55819791	G/A	cg04306507	chr14:55594613	LGALS3	0.45	8.0	0.35	1.04e-14	Testicular germ cell tumor;
LGG	cis	rs877426	0.681	rs877425	chr13:114833726	G/C	cg00571178	chr13:114841904	RASA3	-0.54	-9.44	-0.4	1.84e-19	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs138665726	1	rs138665726	chr22:21917859	A/C	cg05046821	chr22:21984468	YDJC	-0.4	-7.13	-0.31	3.8e-12	Mean corpuscular volume;Red cell distribution width;
LGG	cis	rs701145	0.585	rs959376	chr3:153866707	A/T	cg12800244	chr3:153838788	SGEF	0.77	8.47	0.37	3.18e-16	Coronary artery disease;
LGG	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg26769984	chr7:1090371	C7orf50	0.39	6.67	0.3	7.13e-11	Bronchopulmonary dysplasia;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03452623	chr4:187889614	NA	-1.04	-30.04	-0.81	8.44e-111	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs10267417	0.535	rs10281472	chr7:19915443	A/G	cg05791153	chr7:19748676	TWISTNB	0.56	7.19	0.32	2.6e-12	Night sleep phenotypes;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08280861	chr8:58055591	NA	-0.6	-7.76	-0.34	5.53e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10991814	1.000	rs76953614	chr9:93985979	G/C	cg14446406	chr9:93919335	NA	-0.78	-8.78	-0.38	3.29e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-8.19	-0.36	2.56e-15	Skin colour saturation;
LGG	cis	rs12101261	0.556	rs2300516	chr14:81446908	A/G	cg06600135	chr14:81408086	NA	0.38	7.28	0.32	1.44e-12	Graves' disease;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs7226408	0.857	rs56217642	chr18:34687844	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.05	-0.31	6.35e-12	Obesity-related traits;
LGG	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg18252515	chr7:66147081	NA	-1.33	-18.75	-0.66	8.82e-59	Diabetic kidney disease;
LGG	cis	rs11225247	0.772	rs35569122	chr11:102232348	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.34	0.32	9.89e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg20887711	chr4:1340912	KIAA1530	0.71	14.89	0.57	3.13e-41	Longevity;
LGG	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.84	-10.53	-0.44	2.14e-23	Lung cancer in ever smokers;
LGG	cis	rs9462027	0.606	rs4624858	chr6:34802301	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.33	-0.47	1.92e-26	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg13206674	chr6:150067644	NUP43	0.67	15.51	0.58	5.46e-44	Lung cancer;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06558623	chr16:89946397	TCF25	1.15	14.72	0.56	1.72e-40	Skin colour saturation;
LGG	cis	rs867371	1.000	rs1174543	chr15:82448073	C/T	cg00614314	chr15:82944287	LOC80154	-0.6	-10.14	-0.43	5.83e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg24189917	chr7:1970923	MAD1L1	-0.52	-7.57	-0.33	1.97e-13	Bipolar disorder;
LGG	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg15557168	chr22:42548783	NA	-0.39	-8.31	-0.36	1.04e-15	Schizophrenia;
LGG	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21659725	chr3:3221576	CRBN	0.92	20.43	0.69	1.29e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7274811	0.688	rs6141400	chr20:32056087	C/T	cg21523528	chr20:32077966	CBFA2T2	0.4	6.7	0.3	6.25e-11	Height;
LGG	cis	rs6993813	0.843	rs6999463	chr8:120023302	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.95e-11	Bone mineral density (hip);
LGG	cis	rs7133214	0.771	rs11049136	chr12:27926784	T/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.9	-0.31	1.72e-11	Gut microbiota (functional units);
LGG	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg08461772	chr7:95026248	PON3	0.37	8.16	0.35	3.2e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7017914	0.967	rs59992214	chr8:71599545	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.5	-0.4	1.09e-19	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-11.29	-0.46	2.72e-26	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg04503457	chr17:41445688	NA	-0.4	-9.87	-0.42	5.35e-21	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.15	0.52	8.95e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg27275811	chr11:74457193	NA	-0.58	-6.67	-0.3	7.24e-11	Type 2 diabetes nephropathy;
LGG	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg14683738	chr19:37701593	ZNF585B	-0.41	-6.75	-0.3	4.52e-11	Coronary artery calcification;
LGG	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs4481887	0.636	rs6672981	chr1:248407200	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-7.49	-0.33	3.49e-13	Common traits (Other);
LGG	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.5	-0.33	3.24e-13	Blood protein levels;
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07243736	chr16:783730	NARFL	0.42	7.21	0.32	2.22e-12	Height;
LGG	cis	rs9878978	0.722	rs35717117	chr3:2436950	A/G	cg21928760	chr3:2462534	CNTN4	0.38	7.49	0.33	3.53e-13	Blood pressure (smoking interaction);
LGG	cis	rs12464559	0.522	rs1916301	chr2:152640498	G/A	cg01189475	chr2:152685088	ARL5A	0.77	7.66	0.34	1.12e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6840360	0.667	rs9994482	chr4:152391230	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27189623	chr16:705930	WDR90	0.4	7.73	0.34	6.78e-14	Height;
LGG	cis	rs832540	0.931	rs2591960	chr5:56238811	A/T	cg12654349	chr5:56205094	C5orf35	0.48	8.28	0.36	1.32e-15	Coronary artery disease;
LGG	trans	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg17830980	chr10:43048298	ZNF37B	0.39	8.9	0.38	1.23e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27568321	chr4:113152709	AP1AR	0.48	7.72	0.34	7.46e-14	Cognitive performance;
LGG	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg14993813	chr1:46806288	NSUN4	-0.55	-8.99	-0.39	6.49e-18	Menopause (age at onset);
LGG	cis	rs9487051	0.768	rs351729	chr6:109511668	T/C	cg21918786	chr6:109611834	NA	0.41	7.68	0.34	9.62e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7089973	0.604	rs10885618	chr10:116617718	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.47	0.33	3.97e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2668423	0.922	rs2668418	chr19:1366422	C/G	cg02639931	chr19:1387894	NDUFS7	-0.83	-14.18	-0.55	3.8e-38	Nonalcoholic fatty liver disease;
LGG	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26236440	chr2:113341947	CHCHD5	0.47	7.86	0.34	2.69e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg06453172	chr10:134556979	INPP5A	-0.47	-7.39	-0.32	6.72e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-8.76	-0.38	3.84e-17	Diabetic retinopathy;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg24687543	chr11:63912206	MACROD1	0.62	8.58	0.37	1.45e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17001868	0.527	rs11913132	chr22:40778778	A/G	cg07138101	chr22:40742427	ADSL	0.64	8.42	0.36	4.72e-16	Mammographic density (dense area);
LGG	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg02254774	chr11:50257496	LOC441601	0.57	6.76	0.3	4.15e-11	Myopia (pathological);
LGG	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg08344181	chr3:125677491	NA	-0.65	-6.77	-0.3	3.89e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs853679	0.546	rs200953	chr6:27837267	T/C	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.54	-0.44	2.0500000000000001e-23	Depression;
LGG	cis	rs7166081	1.000	rs10152973	chr15:67647218	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.23	-0.32	2.02e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg18196295	chr10:418757	DIP2C	-0.54	-10.03	-0.42	1.51e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg19635926	chr16:89946313	TCF25	0.69	8.34	0.36	8.55e-16	Skin colour saturation;
LGG	cis	rs7216064	1.000	rs56404791	chr17:65893019	T/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.12	-0.39	2.26e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg22398616	chr13:53314203	LECT1	-0.48	-9.97	-0.42	2.54e-21	Lewy body disease;
LGG	cis	rs7077256	0.564	rs12770482	chr10:65260161	C/T	cg02276361	chr10:65351566	REEP3	-0.33	-6.82	-0.3	2.93e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg02002194	chr4:3960332	NA	0.5	9.13	0.39	2.14e-18	Triglycerides;
LGG	cis	rs2535633	0.661	rs4515041	chr3:52996032	T/A	cg11645453	chr3:52864694	ITIH4	-0.48	-7.98	-0.35	1.15e-14	Body mass index;
LGG	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	13.99	0.54	2.53e-37	Cognitive test performance;
LGG	cis	rs72781680	0.898	rs72780118	chr2:23994431	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg06916706	chr16:4465613	CORO7	-0.91	-17.16	-0.62	1.84e-51	Schizophrenia;
LGG	cis	rs7249698	1	rs7249698	chr19:17210615	G/A	cg19418318	chr19:17219073	MYO9B	0.27	7.5	0.33	3.28e-13	Breast cancer;
LGG	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.76	0.34	5.3e-14	Hepatocellular carcinoma;
LGG	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg23788917	chr6:8435910	SLC35B3	0.51	8.8	0.38	2.74e-17	Motion sickness;
LGG	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg19455335	chr8:22457658	C8orf58	0.4	8.25	0.36	1.65e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.73	-0.3	5.11e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01438737	chr20:42086396	SFRS6	-0.47	-6.83	-0.3	2.65e-11	Systemic lupus erythematosus;
LGG	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg16586182	chr3:47516702	SCAP	0.75	13.49	0.53	3.18e-35	Colorectal cancer;
LGG	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.36	0.4	3.51e-19	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10927271	chr22:46610313	PPARA	-0.37	-6.8	-0.3	3.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg02631450	chr22:32366979	NA	0.98	9.2	0.39	1.19e-18	Childhood ear infection;
LGG	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg08355456	chr11:67383691	NA	0.49	8.36	0.36	7.47e-16	Mean corpuscular volume;
LGG	cis	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs2201728	0.935	rs1497378	chr4:100158023	T/G	cg07219303	chr4:100140905	ADH6	-0.42	-8.35	-0.36	8.24e-16	Cardiac Troponin-T levels;
LGG	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg14983838	chr19:29218262	NA	0.78	12.61	0.51	1.57e-31	Methadone dose in opioid dependence;
LGG	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.7	10.38	0.43	7.59e-23	Homoarginine levels;
LGG	cis	rs7106204	0.764	rs11821644	chr11:24212686	T/C	ch.11.24196551F	chr11:24239977	NA	0.94	11.22	0.46	5.19e-26	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs9354308	0.764	rs9283825	chr6:66598457	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.68	-0.3	6.84e-11	Metabolite levels;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.59	0.37	1.31e-16	Lung cancer;
LGG	trans	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg16011800	chr17:1958478	HIC1	-0.65	-9.73	-0.41	1.78e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg00012203	chr2:219082015	ARPC2	0.57	10.16	0.43	4.98e-22	Ulcerative colitis;
LGG	trans	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.14e-14	Bladder cancer;
LGG	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg16141378	chr3:129829833	LOC729375	0.44	10.54	0.44	1.97e-23	Mood instability;
LGG	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg12310025	chr6:25882481	NA	-0.59	-11.59	-0.47	1.86e-27	Blood metabolite levels;
LGG	cis	rs1580019	0.961	rs4460271	chr7:32496503	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	cis	rs6424115	0.931	rs2473377	chr1:24148260	T/C	cg15997130	chr1:24165203	NA	0.5	13.65	0.54	6.83e-36	Immature fraction of reticulocytes;
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg16797656	chr11:68205561	LRP5	-0.52	-10.08	-0.42	1.01e-21	Total body bone mineral density;
LGG	cis	rs9860250	0.661	rs35157452	chr3:100710139	C/T	cg23634451	chr3:100713646	ABI3BP	-0.38	-7.6	-0.33	1.68e-13	Optic disc area;
LGG	cis	rs9912468	0.647	rs9895261	chr17:64240436	A/G	cg19474267	chr17:64306194	PRKCA	-0.78	-16.91	-0.62	2.59e-50	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs6735179	0.641	rs2382558	chr2:1752229	A/G	cg20570797	chr2:1712800	PXDN	-0.47	-8.11	-0.35	4.59e-15	Response to antipsychotic treatment;
LGG	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.82	-0.45	1.75e-24	Total body bone mineral density;
LGG	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.68	-0.48	8.58e-28	Type 2 diabetes;
LGG	cis	rs7444	0.941	rs140491	chr22:21922364	T/C	cg05046821	chr22:21984468	YDJC	-0.39	-7.08	-0.31	5.48e-12	Systemic lupus erythematosus;
LGG	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs9457247	1.000	rs439237	chr6:167391392	A/G	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg03188948	chr7:1209495	NA	0.54	7.14	0.31	3.68e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg24375607	chr4:120327624	NA	0.68	11.26	0.46	3.72e-26	Corneal astigmatism;
LGG	cis	rs9814567	1.000	rs2373865	chr3:134291556	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs611744	0.967	rs635219	chr8:109229243	C/T	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.04e-11	Dupuytren's disease;
LGG	cis	rs17689437	0.671	rs1728793	chr16:68602693	T/A	cg02972257	chr16:68554789	NA	-0.42	-6.96	-0.31	1.19e-11	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs3540	0.513	rs2601182	chr15:90925430	A/T	cg22089800	chr15:90895588	ZNF774	0.76	14.29	0.55	1.26e-38	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs963731	0.649	rs4670272	chr2:39260468	A/C	cg04010122	chr2:39346883	SOS1	-0.86	-7.52	-0.33	2.96e-13	Corticobasal degeneration;
LGG	cis	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg21724239	chr8:58056113	NA	0.61	9.03	0.39	4.51e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.62	-0.41	4.2e-20	Blood metabolite levels;
LGG	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg12560992	chr17:57184187	TRIM37	0.87	15.17	0.58	1.81e-42	Intelligence (multi-trait analysis);
LGG	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg05090351	chr10:126851162	NA	0.28	6.77	0.3	3.93e-11	Menarche (age at onset);
LGG	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg06374794	chr16:88002281	BANP	0.45	8.4	0.36	5.45e-16	Menopause (age at onset);
LGG	cis	rs3762637	1.000	rs6777596	chr3:122133321	C/T	cg24169773	chr3:122142474	KPNA1	-0.59	-9.87	-0.42	5.6e-21	LDL cholesterol levels;
LGG	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg01557791	chr16:72042693	DHODH	-0.62	-11.31	-0.47	2.43e-26	Fibrinogen levels;
LGG	cis	rs6840360	0.642	rs7698816	chr4:152352972	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.08	0.31	5.49e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.27	-0.69	7.69e-66	Diabetic kidney disease;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg11965913	chr1:205819406	PM20D1	0.85	18.52	0.65	1.1e-57	Menarche (age at onset);
LGG	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.71	0.51	5.87e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3747547	0.818	rs16934639	chr9:37943092	T/C	cg13774184	chr9:37916125	SHB	-0.73	-8.24	-0.36	1.74e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.1	0.52	1.38e-33	Obesity-related traits;
LGG	cis	rs921968	0.643	rs611203	chr2:219472325	G/A	cg01130898	chr2:219473002	PLCD4	-0.39	-6.8	-0.3	3.29e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1032833	0.732	rs75805674	chr2:180059711	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.37e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg07615347	chr10:60278583	BICC1	0.63	17.36	0.63	2.22e-52	Refractive error;
LGG	cis	rs7769051	0.522	rs6930703	chr6:133111266	C/T	cg22852734	chr6:133119734	C6orf192	1.32	10.47	0.44	3.75e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7113850	0.541	rs77699762	chr11:24236448	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.45	0.44	4.38e-23	Bone fracture in osteoporosis;
LGG	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg26818010	chr10:134567672	INPP5A	-0.56	-8.56	-0.37	1.64e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg22676075	chr6:135203613	NA	0.43	7.51	0.33	2.99e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs6758382	chr2:42231733	G/A	cg19376973	chr2:42229025	NA	0.62	9.08	0.39	3.18e-18	Hypospadias;
LGG	cis	rs1943345	0.642	rs11233500	chr11:82881407	C/T	cg07047830	chr11:82868014	PCF11	-0.58	-11.05	-0.46	2.27e-25	Obesity-related traits;
LGG	cis	rs3806843	0.838	rs2563289	chr5:140122766	T/A	cg19875535	chr5:140030758	IK	-0.53	-11.12	-0.46	1.29e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg07075840	chr7:29603327	PRR15	-0.28	-6.65	-0.3	8.54e-11	Facial emotion recognition (angry faces);
LGG	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-7.03	-0.31	7.35e-12	Aortic root size;
LGG	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg24851651	chr11:66362959	CCS	0.35	6.67	0.3	7.22e-11	HIV-1 susceptibility;
LGG	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg06697600	chr4:7070879	GRPEL1	0.49	8.08	0.35	5.71e-15	Monocyte percentage of white cells;
LGG	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg15268244	chr15:77196840	NA	0.41	8.83	0.38	2.11e-17	Blood metabolite levels;
LGG	cis	rs853679	0.517	rs3757187	chr6:28107654	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.72	-0.34	7.41e-14	Depression;
LGG	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.06	-0.31	6.3e-12	Mood instability;
LGG	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14240646	chr10:27532245	ACBD5	0.74	8.93	0.38	1e-17	Breast cancer;
LGG	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg23815491	chr16:72088622	HP	0.36	7.62	0.33	1.46e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11694433	chr15:63796712	USP3	0.43	6.84	0.3	2.57e-11	Cognitive performance;
LGG	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg06606381	chr12:133084897	FBRSL1	0.83	8.64	0.37	9.37e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg03060546	chr3:49711283	APEH	-0.69	-11.51	-0.47	3.88e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7998202	0.720	rs2274773	chr13:113343171	A/G	cg17218041	chr13:113365319	ATP11A	0.44	7.46	0.33	4.32e-13	Glycated hemoglobin levels;
LGG	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg25566285	chr7:158114605	PTPRN2	-0.74	-13.81	-0.54	1.38e-36	Calcium levels;
LGG	cis	rs9649465	1.000	rs10215466	chr7:123326044	G/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs4919087	1.000	rs10786329	chr10:99074621	G/A	cg25902810	chr10:99078978	FRAT1	0.52	9.75	0.41	1.47e-20	Monocyte count;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg06558623	chr16:89946397	TCF25	0.91	11.81	0.48	2.63e-28	Skin colour saturation;
LGG	cis	rs12410462	0.591	rs2814061	chr1:227735114	C/T	cg23173402	chr1:227635558	NA	0.37	7.11	0.31	4.33e-12	Major depressive disorder;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg05863683	chr7:1912471	MAD1L1	0.42	7.92	0.35	1.77e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.57e-31	Motion sickness;
LGG	cis	rs17767392	0.918	rs17178234	chr14:71900364	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.88	-0.38	1.48e-17	Mitral valve prolapse;
LGG	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.59	-0.37	1.32e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg04986931	chr22:39850128	NA	0.41	9.02	0.39	5e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg12560992	chr17:57184187	TRIM37	0.53	8.53	0.37	2.06e-16	Testicular germ cell tumor;
LGG	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs6901004	0.803	rs1150083	chr6:111510767	C/T	cg15721981	chr6:111408429	SLC16A10	-0.41	-7.47	-0.33	4.12e-13	Blood metabolite levels;
LGG	cis	rs6580649	0.769	rs60629297	chr12:48438290	T/A	cg24011408	chr12:48396354	COL2A1	-0.55	-6.71	-0.3	5.63e-11	Lung cancer;
LGG	cis	rs113835537	0.559	rs11227497	chr11:66269464	T/C	cg24851651	chr11:66362959	CCS	0.46	8.01	0.35	9.47e-15	Airway imaging phenotypes;
LGG	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Neuroticism;
LGG	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg18252515	chr7:66147081	NA	-1.42	-20.69	-0.69	7.75e-68	Diabetic kidney disease;
LGG	cis	rs883565	0.527	rs11715262	chr3:39003853	A/T	cg01426195	chr3:39028469	NA	-0.61	-12.94	-0.52	6.89e-33	Handedness;
LGG	cis	rs6740322	0.895	rs9309098	chr2:43554972	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.63	9.62	0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs2997447	0.655	rs2275950	chr1:26385003	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-8.26	-0.36	1.55e-15	QRS complex (12-leadsum);
LGG	cis	rs2154319	0.887	rs2064740	chr1:41514150	C/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.02	-0.39	5.03e-18	Height;
LGG	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg21475434	chr5:93447410	FAM172A	0.72	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.8	-0.34	4.13e-14	Neuroticism;
LGG	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg18200150	chr17:30822561	MYO1D	-0.48	-8.89	-0.38	1.35e-17	Schizophrenia;
LGG	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg07636037	chr3:49044803	WDR6	0.59	10.4	0.44	6.54e-23	Resting heart rate;
LGG	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.48	-0.33	3.69e-13	Morning vs. evening chronotype;
LGG	cis	rs919433	0.617	rs4850809	chr2:198583403	C/T	cg00792783	chr2:198669748	PLCL1	-0.62	-10.08	-0.42	1.01e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg09596252	chr17:78655493	RPTOR	-0.44	-8.0	-0.35	1.01e-14	Obesity;
LGG	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08045932	chr20:61659980	NA	0.6	13.02	0.52	3.16e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.92	-0.35	1.78e-14	IgG glycosylation;
LGG	cis	rs13065560	0.594	rs7620018	chr3:38886649	C/T	cg01426195	chr3:39028469	NA	-0.46	-9.52	-0.4	9.49e-20	Interleukin-18 levels;
LGG	cis	rs1003719	1.000	rs2835608	chr21:38493455	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.79	15.51	0.58	5.56e-44	Eye color traits;
LGG	cis	rs2133450	0.526	rs56174360	chr3:7349316	T/C	cg19930620	chr3:7340148	GRM7	-0.42	-9.41	-0.4	2.24e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs12453935	0.708	rs72843735	chr17:59934862	A/G	cg14757157	chr17:59911755	BRIP1	0.34	6.73	0.3	5e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.11	-0.43	7.32e-22	Lung cancer;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg05025164	chr4:1340916	KIAA1530	0.52	9.36	0.4	3.51e-19	Longevity;
LGG	cis	rs7017914	0.934	rs17760050	chr8:71574251	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg16141378	chr3:129829833	LOC729375	-0.34	-6.96	-0.31	1.17e-11	Neuroticism;
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06850241	chr22:41845214	NA	-0.45	-7.03	-0.31	7.65e-12	Vitiligo;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg08009458	chr12:31738811	DENND5B	-0.38	-6.87	-0.3	2.02e-11	Apolipoprotein A-IV levels;
LGG	cis	rs2247341	0.894	rs2592831	chr4:1711404	T/C	cg05026014	chr4:1749153	NA	-0.3	-8.28	-0.36	1.33e-15	Hip circumference adjusted for BMI;Height;
LGG	cis	rs774359	0.789	rs17769038	chr9:27489693	G/A	cg14173147	chr9:27528300	MOBKL2B	0.48	8.77	0.38	3.31e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg09307838	chr4:120376055	NA	0.48	7.84	0.34	3.22e-14	Diastolic blood pressure;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg08742575	chr21:47604166	C21orf56	0.54	9.83	0.42	7.56e-21	Testicular germ cell tumor;
LGG	cis	rs1982963	1.000	rs4901186	chr14:52509484	G/A	cg05884192	chr14:52515736	NID2	-0.33	-7.28	-0.32	1.45e-12	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.49	10.55	0.44	1.8e-23	Hemoglobin concentration;
LGG	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.53	-8.2	-0.36	2.38e-15	Menarche (age at onset);
LGG	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg00701064	chr4:6280414	WFS1	0.74	16.32	0.6	1.24e-47	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9341808	0.617	rs9294170	chr6:80814080	A/G	cg08355045	chr6:80787529	NA	0.46	9.3	0.4	5.52e-19	Sitting height ratio;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg05863683	chr7:1912471	MAD1L1	0.42	7.92	0.35	1.77e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.97	-0.35	1.21e-14	Resting heart rate;
LGG	trans	rs75804782	0.641	rs72983834	chr2:239319895	G/A	cg01134436	chr17:81009848	B3GNTL1	0.85	8.97	0.38	7.27e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.07e-25	Resting heart rate;
LGG	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.83	-0.3	2.63e-11	Parkinson's disease;
LGG	cis	rs9457247	0.663	rs9459845	chr6:167440501	C/G	cg07741184	chr6:167504864	NA	0.39	8.68	0.37	7.05e-17	Crohn's disease;
LGG	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg25554036	chr4:6271136	WFS1	-0.62	-11.51	-0.47	3.74e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13129662	chr17:48227708	PPP1R9B	0.41	7.35	0.32	9.17e-13	Obesity-related traits;
LGG	cis	rs4330281	0.647	rs12487248	chr3:17697696	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.54	-0.33	2.46e-13	Schizophrenia;
LGG	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.37	-0.4	3.13e-19	Height;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.25	-0.43	2.37e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg12070911	chr6:150209640	RAET1E	0.27	6.74	0.3	4.66e-11	Testicular germ cell tumor;
LGG	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08468577	chr11:2973342	NAP1L4	-0.34	-6.82	-0.3	2.83e-11	Calcium levels;
LGG	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg14055004	chr2:241860995	NA	0.28	7.58	0.33	1.96e-13	Joint mobility (Beighton score);
LGG	trans	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg05059571	chr16:84539110	KIAA1609	0.52	9.85	0.42	6.58e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg02187348	chr16:89574699	SPG7	0.63	10.56	0.44	1.71e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg18446336	chr7:2847575	GNA12	0.39	9.37	0.4	3.15e-19	Loneliness (linear analysis);
LGG	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg18165381	chr3:44552316	NA	-0.41	-6.72	-0.3	5.52e-11	Depressive symptoms;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07875825	chr17:7210680	EIF5A	0.42	6.98	0.31	1.05e-11	Hepatitis;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.77	-14.35	-0.55	6.81e-39	Longevity;Endometriosis;
LGG	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.38	0.43	8.1e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg14416269	chr4:6271139	WFS1	0.51	9.4	0.4	2.57e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6964587	0.869	rs10242792	chr7:91492103	A/C	cg17063962	chr7:91808500	NA	0.39	6.8	0.3	3.18e-11	Breast cancer;
LGG	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg24397884	chr7:158709396	WDR60	-1.14	-18.22	-0.65	2.68e-56	Height;
LGG	cis	rs4388249	0.659	rs10065099	chr5:109177378	C/T	cg17395555	chr5:108820864	NA	0.42	6.66	0.3	7.89e-11	Schizophrenia;
LGG	cis	rs2729354	0.953	rs2649650	chr11:57327567	C/T	cg24343310	chr11:57249947	NA	0.38	7.15	0.32	3.45e-12	Blood protein levels;
LGG	cis	rs10864907	0.553	rs7578034	chr2:113718077	C/T	cg06156847	chr2:113672199	IL1F7	-0.35	-6.94	-0.31	1.31e-11	Pulmonary function;
LGG	cis	rs9398803	0.865	rs9398809	chr6:126789144	C/T	cg19875578	chr6:126661172	C6orf173	0.58	10.51	0.44	2.48e-23	Male-pattern baldness;
LGG	cis	rs7100689	0.646	rs12253992	chr10:82158710	G/A	cg01528321	chr10:82214614	TSPAN14	0.88	16.52	0.61	1.54e-48	Post bronchodilator FEV1;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.82	-16.88	-0.62	3.49e-50	Longevity;Endometriosis;
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.67	-0.3	7.22e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg05333889	chr7:157238977	NA	-0.5	-9.54	-0.41	8.28e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs9549260	0.755	rs4429172	chr13:41189143	C/A	cg21288729	chr13:41239152	FOXO1	0.33	6.7	0.3	5.99e-11	Red blood cell count;
LGG	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs9902453	0.765	rs6505143	chr17:28150585	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.14	0.55	5.37e-38	Coffee consumption (cups per day);
LGG	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.46	2.66e-26	Total body bone mineral density;
LGG	trans	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs13177180	0.777	rs9326964	chr5:114839203	C/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.35	-7.76	-0.34	5.64e-14	Conotruncal heart defects (inherited effects);
LGG	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg23422044	chr7:1970798	MAD1L1	-0.51	-9.15	-0.39	1.82e-18	Neuroticism;
LGG	cis	rs950027	0.584	rs1145086	chr15:45654327	A/G	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg18854424	chr1:2615690	NA	0.34	7.42	0.33	5.5e-13	Ulcerative colitis;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.12	-0.35	4.36e-15	Triglycerides;
LGG	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-14.01	-0.55	1.95e-37	Response to amphetamines;
LGG	cis	rs12786942	0.569	rs12276736	chr11:101315197	A/T	cg03942599	chr11:101341554	TRPC6	0.49	7.36	0.32	8.27e-13	Facial depth;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13244804	chr8:128749511	MYC	0.41	6.67	0.3	7.17e-11	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg15704280	chr7:45808275	SEPT13	0.94	19.45	0.67	4.99e-62	Coronary artery disease;
LGG	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.47	-0.44	3.7e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs12980942	0.872	rs3752705	chr19:41798111	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.51	6.73	0.3	5.09e-11	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg05084668	chr3:125655381	ALG1L	-0.86	-10.56	-0.44	1.68e-23	Blood pressure (smoking interaction);
LGG	cis	rs883565	0.569	rs1274973	chr3:39160441	G/A	cg01426195	chr3:39028469	NA	-0.65	-14.08	-0.55	1.02e-37	Handedness;
LGG	cis	rs6964587	1.000	rs57816416	chr7:91736078	A/C	cg17063962	chr7:91808500	NA	0.5	9.09	0.39	2.81e-18	Breast cancer;
LGG	cis	rs745080	0.519	rs11849480	chr14:52978412	C/G	cg23333723	chr14:53022898	GPR137C	-0.4	-8.08	-0.35	5.58e-15	Orofacial clefts;
LGG	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.01	-0.39	5.47e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-9.43	-0.4	2.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6558174	0.965	rs2404655	chr8:22490209	T/C	cg03733263	chr8:22462867	KIAA1967	0.65	11.04	0.46	2.53e-25	Breast cancer;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg23131131	chr22:24373011	LOC391322	-0.49	-8.11	-0.35	4.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.25	-0.49	4.26e-30	Obesity-related traits;
LGG	cis	rs12765878	0.557	rs2984133	chr10:105670848	T/A	cg11005552	chr10:105648138	OBFC1	-0.73	-12.97	-0.52	5.16e-33	Coronary artery disease;
LGG	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03878208	chr11:72483293	STARD10	0.51	7.18	0.32	2.74e-12	Type 2 diabetes;
LGG	cis	rs78905543	1.000	rs4872049	chr8:22931779	C/T	cg13462030	chr8:22926911	TNFRSF10B	-0.42	-7.99	-0.35	1.05e-14	Mean corpuscular volume;
LGG	cis	rs7945718	0.810	rs7930282	chr11:12835941	C/T	cg25843174	chr11:12811716	TEAD1	0.38	7.59	0.33	1.74e-13	Educational attainment (years of education);
LGG	cis	rs72901758	0.768	rs72901762	chr17:76244926	A/G	cg26068271	chr17:76253126	NA	0.5	10.89	0.45	9.71e-25	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9473924	0.542	rs9463665	chr6:50928520	G/T	cg14470998	chr6:50812995	TFAP2B	0.66	7.72	0.34	7.35e-14	Body mass index;
LGG	cis	rs66561647	0.661	rs7835090	chr8:128940177	A/C	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	6.76	0.3	4.26e-11	Hemoglobin concentration;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.48e-16	Obesity-related traits;
LGG	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.68	7.47	0.33	4.01e-13	Initial pursuit acceleration;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.17	-0.46	8.12e-26	Obesity-related traits;
LGG	cis	rs4148087	1.000	rs4148092	chr21:43635162	T/C	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg15485101	chr11:133734466	NA	0.61	10.78	0.45	2.45e-24	Childhood ear infection;
LGG	cis	rs10193935	0.901	rs222463	chr2:42644080	A/G	cg27598129	chr2:42591480	NA	-0.65	-9.65	-0.41	3.43e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4959677	0.586	rs55732532	chr6:2474874	A/G	cg20147862	chr6:2634573	C6orf195	-0.34	-7.35	-0.32	9.03e-13	Orthostatic hypotension;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg16141378	chr3:129829833	LOC729375	0.38	8.85	0.38	1.9e-17	Neuroticism;
LGG	cis	rs17534004	1.000	rs12876002	chr13:31467467	A/G	cg00367615	chr13:31480979	C13orf33	0.35	6.95	0.31	1.22e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.08	-0.42	9.92e-22	Platelet count;
LGG	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg16691251	chr5:66510806	NA	-0.34	-6.82	-0.3	2.78e-11	Breast cancer;
LGG	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	9.64	0.41	3.55e-20	Aortic root size;
LGG	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.19	-0.39	1.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg06636001	chr8:8085503	FLJ10661	0.73	15.44	0.58	1.15e-43	Schizophrenia;
LGG	cis	rs8077889	1.000	rs2342310	chr17:41866199	T/C	cg26893861	chr17:41843967	DUSP3	0.96	16.42	0.61	4.22e-48	Triglycerides;
LGG	cis	rs4687717	0.717	rs13101181	chr3:53288224	G/A	cg16894138	chr3:53270350	TKT	0.41	7.82	0.34	3.58e-14	Blood metabolite levels;Blood metabolite ratios;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg16507663	chr6:150244633	RAET1G	0.45	8.6	0.37	1.24e-16	Lung cancer;
LGG	cis	rs7166081	0.951	rs16950805	chr15:67560677	T/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.75	-0.3	4.5e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12753569	0.748	rs1340689	chr1:76506409	T/A	cg00791851	chr1:76518896	NA	0.42	9.7	0.41	2.19e-20	Personality dimensions;
LGG	trans	rs6956675	0.915	rs6965334	chr7:62645446	A/G	cg01314568	chr7:57830625	NA	-0.46	-7.5	-0.33	3.19e-13	Obesity-related traits;
LGG	trans	rs9914544	0.545	rs9914914	chr17:18787780	G/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg13264159	chr8:625131	ERICH1	-1.04	-12.13	-0.49	1.39e-29	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.76	-0.41	1.37e-20	Lung cancer;
LGG	cis	rs367943	0.730	rs2914174	chr5:112978531	C/T	cg12552261	chr5:112820674	MCC	-0.55	-9.7	-0.41	2.18e-20	Type 2 diabetes;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg22963979	chr7:1858916	MAD1L1	-0.52	-10.36	-0.43	9.52e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.15	-0.32	3.51e-12	Bipolar disorder;
LGG	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg10556349	chr10:835070	NA	-0.34	-8.85	-0.38	1.9e-17	Survival in rectal cancer;
LGG	cis	rs8028182	0.609	rs8038760	chr15:75742095	A/C	cg20655648	chr15:75932815	IMP3	0.47	7.85	0.34	2.81e-14	Sudden cardiac arrest;
LGG	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg11693508	chr17:37793320	STARD3	0.52	7.47	0.33	3.96e-13	Neuroticism;
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg02353165	chr6:42928485	GNMT	0.47	14.22	0.55	2.4e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs2735413	0.564	rs78375430	chr16:78084813	C/G	cg04733911	chr16:78082701	NA	0.62	8.66	0.37	7.71e-17	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02164462	chr16:57769538	KATNB1	-0.49	-7.45	-0.33	4.6e-13	Pancreatic cancer;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg13453750	chr1:205783389	SLC41A1	-0.39	-7.63	-0.33	1.32e-13	Menarche (age at onset);
LGG	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg24829409	chr8:58192753	C8orf71	-0.49	-7.47	-0.33	4.06e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs939658	0.776	rs11631411	chr15:79445816	C/T	cg17916960	chr15:79447300	NA	-0.67	-13.16	-0.52	7.99e-34	Refractive error;
LGG	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06873352	chr17:61820015	STRADA	0.47	7.4	0.33	6.3e-13	Height;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg07538946	chr5:131705188	SLC22A5	0.6	7.03	0.31	7.65e-12	Rheumatoid arthritis;
LGG	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg07303275	chr16:75499416	TMEM170A	0.45	7.93	0.35	1.64e-14	Dupuytren's disease;
LGG	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg03469862	chr11:68924853	NA	0.44	6.66	0.3	7.64e-11	Blond vs. brown hair color;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg06848047	chr4:90757629	SNCA	-0.42	-8.02	-0.35	8.54e-15	Dementia with Lewy bodies;
LGG	cis	rs28595532	0.920	rs56302493	chr4:119772382	A/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg14673194	chr17:80132900	CCDC57	0.47	8.52	0.37	2.25e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.02	-0.31	8.2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.17	0.52	7.05e-34	Lung cancer in ever smokers;
LGG	cis	rs7666738	0.830	rs7659593	chr4:98934823	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg02466173	chr16:30829666	NA	-0.59	-11.7	-0.48	7.3e-28	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.89	0.42	4.55e-21	Obesity-related traits;
LGG	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.51	7.05	0.31	6.71e-12	Crohn's disease;
LGG	cis	rs6496667	0.509	rs57962570	chr15:90985596	C/G	cg22089800	chr15:90895588	ZNF774	0.51	8.42	0.36	4.72e-16	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.42	-0.58	1.3e-43	Prudent dietary pattern;
LGG	cis	rs6594713	0.642	rs17389165	chr5:112796598	A/C	cg12552261	chr5:112820674	MCC	-0.63	-8.03	-0.35	8.02e-15	Brain cytoarchitecture;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.29	-0.32	1.36e-12	Life satisfaction;
LGG	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.67	0.41	2.83e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.63	-0.33	1.31e-13	Neuroticism;
LGG	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9515201	0.627	rs4773173	chr13:111025118	A/G	cg06243866	chr13:111019493	COL4A2	-0.73	-13.99	-0.55	2.41e-37	White matter hyperintensity burden;
LGG	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg14784868	chr12:69753453	YEATS4	0.73	13.96	0.54	3.26e-37	Blood protein levels;
LGG	trans	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.34	0.5	1.84e-30	Mean corpuscular volume;
LGG	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.44	6.96	0.31	1.21e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.77	-0.38	3.5e-17	Joint mobility (Beighton score);
LGG	cis	rs12493885	0.725	rs4680113	chr3:153727337	C/T	cg12800244	chr3:153838788	SGEF	-0.75	-9.18	-0.39	1.42e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg09263875	chr16:632152	PIGQ	0.65	12.72	0.51	5.27e-32	Height;
LGG	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.32	0.43	1.31e-22	Motion sickness;
LGG	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-9.6	-0.41	5.13e-20	Type 2 diabetes;
LGG	trans	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	10.28	0.43	1.89e-22	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.47	-0.37	3.19e-16	Skin colour saturation;
LGG	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.88	0.3	1.96e-11	Educational attainment;
LGG	cis	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg20368463	chr18:77673604	PQLC1	-0.5	-6.66	-0.3	7.73e-11	Opioid sensitivity;
LGG	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg25427524	chr10:38739819	LOC399744	-0.47	-7.17	-0.32	2.9e-12	Obesity (extreme);
LGG	cis	rs4731207	0.596	rs12537431	chr7:124586556	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.91	-0.31	1.66e-11	Cutaneous malignant melanoma;
LGG	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.62	-0.37	1.04e-16	Morning vs. evening chronotype;
LGG	cis	rs10992471	0.756	rs7027595	chr9:95131553	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.09	-0.31	5.12e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg23505145	chr19:12996616	KLF1	0.41	7.35	0.32	9.09e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4973397	0.643	rs2369271	chr2:232289244	C/T	cg13347044	chr2:232276743	NA	-0.35	-6.7	-0.3	6.15e-11	Anti-saccade response;
LGG	cis	rs17227506	0.704	rs34621320	chr8:13434824	A/C	cg03566418	chr8:13424080	C8orf48	0.63	9.72	0.41	1.97e-20	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs10463554	1.000	rs1593842	chr5:102334722	A/C	cg23492399	chr5:102201601	PAM	-0.53	-8.21	-0.36	2.17e-15	Parkinson's disease;
LGG	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg02002194	chr4:3960332	NA	0.5	9.27	0.4	7.3e-19	Retinal vascular caliber;
LGG	cis	rs7586879	0.964	rs4077680	chr2:25122942	A/G	cg04586622	chr2:25135609	ADCY3	0.39	9.92	0.42	3.81e-21	Body mass index;
LGG	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg25173405	chr17:45401733	C17orf57	0.52	8.8	0.38	2.83e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6933660	0.512	rs13202634	chr6:151800630	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	7.6	0.33	1.64e-13	Menarche (age at onset);
LGG	cis	rs6964587	1.000	rs1859037	chr7:91568272	A/G	cg17063962	chr7:91808500	NA	-0.49	-8.68	-0.37	6.57e-17	Breast cancer;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.18e-21	Prudent dietary pattern;
LGG	trans	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg05059571	chr16:84539110	KIAA1609	0.5	9.43	0.4	2.04e-19	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg17788362	chr6:86352627	SYNCRIP	0.47	7.84	0.34	3.08e-14	Smooth-surface caries;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.67	-0.37	7.22e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11630290	0.604	rs17775820	chr15:64168582	G/A	cg12036633	chr15:63758958	NA	-0.56	-7.37	-0.32	7.92e-13	Iris characteristics;
LGG	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.42	0.4	2.23e-19	Diabetic retinopathy;
LGG	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.09	-0.42	9e-22	Colorectal cancer;
LGG	cis	rs17433780	0.612	rs7911	chr1:89518120	A/G	cg09516651	chr1:89888402	LOC400759	0.72	17.63	0.63	1.39e-53	Carotid intima media thickness;
LGG	cis	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg27411982	chr8:10470053	RP1L1	0.44	6.9	0.31	1.71e-11	Neuroticism;
LGG	cis	rs2273669	0.667	rs12197912	chr6:109338147	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs6568686	0.786	rs3851226	chr6:111826295	A/G	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs9398803	0.713	rs1387916	chr6:126886731	G/C	cg19875578	chr6:126661172	C6orf173	0.52	9.58	0.41	5.79e-20	Male-pattern baldness;
LGG	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg27129171	chr3:47204927	SETD2	0.78	15.03	0.57	6.87e-42	Colorectal cancer;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg19774624	chr17:42201019	HDAC5	-0.52	-8.76	-0.38	3.58e-17	Total body bone mineral density;
LGG	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs968567	0.906	rs61897793	chr11:61599347	G/A	cg19610905	chr11:61596333	FADS2	-0.67	-8.21	-0.36	2.27e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs7000551	0.638	rs2469771	chr8:22376627	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	11.99	0.49	5.01e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11123610	0.520	rs7576701	chr2:3718227	T/C	cg26344334	chr2:3718215	ALLC	-0.49	-8.53	-0.37	2.05e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg22907277	chr7:1156413	C7orf50	0.62	11.42	0.47	8.86e-27	Longevity;Endometriosis;
LGG	cis	rs368123	1.000	rs316163	chr6:160752478	G/A	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.24	-0.52	3.81e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs7717393	0.786	rs17053484	chr5:155794624	A/G	cg04435420	chr5:155754009	SGCD	0.71	9.15	0.39	1.83e-18	Egg allergy;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.25	-0.52	3.45e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs7444	0.941	rs1034329	chr22:21943938	T/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.7	-0.34	8.36e-14	Systemic lupus erythematosus;
LGG	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.48	-0.44	3.4e-23	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg17202724	chr17:61916730	SMARCD2	-0.46	-8.63	-0.37	9.95e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4676380	0.855	rs1583261	chr2:241644740	T/C	cg21930842	chr2:241631663	AQP12A	0.34	7.16	0.32	3.21e-12	Response to metformin (IC50);
LGG	trans	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg06521331	chr12:34319734	NA	0.46	8.03	0.35	8.34e-15	Bladder cancer;
LGG	cis	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg01579765	chr21:45077557	HSF2BP	0.4	9.23	0.39	9.44e-19	Mean corpuscular volume;
LGG	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.6	-0.47	1.78e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.47	-0.33	3.96e-13	Bipolar disorder;
LGG	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	15.9	0.59	1e-45	Headache;
LGG	cis	rs6693567	0.565	rs10888584	chr1:150476406	C/G	cg15654264	chr1:150340011	RPRD2	0.33	6.69	0.3	6.45e-11	Migraine;
LGG	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg12379764	chr21:47803548	PCNT	0.67	9.36	0.4	3.47e-19	Lymphocyte counts;
LGG	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-8.18	-0.36	2.86e-15	Schizophrenia;
LGG	trans	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg23484912	chr5:273055	PDCD6	0.43	8.78	0.38	3.23e-17	Pancreatic cancer;
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg01874867	chr7:94954059	PON1	-0.31	-6.87	-0.3	2.02e-11	Paraoxonase activity;
LGG	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg12856521	chr11:46389249	DGKZ	0.52	9.3	0.4	5.71e-19	Leprosy;
LGG	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg11887960	chr12:57824829	NA	0.57	6.93	0.31	1.45e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg13259177	chr13:114761607	RASA3	-0.75	-10.6	-0.44	1.16e-23	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg14593290	chr7:50529359	DDC	0.51	8.94	0.38	9.31e-18	Malaria;
LGG	cis	rs6840360	0.571	rs4696110	chr4:152671325	G/A	cg22705602	chr4:152727874	NA	-0.4	-9.96	-0.42	2.64e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.812	rs73071242	chr3:41993011	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg11062466	chr8:58055876	NA	0.58	9.14	0.39	1.91e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs61931739	0.534	rs11053005	chr12:34091626	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.1	-0.46	1.57e-25	Morning vs. evening chronotype;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.09	0.57	3.93e-42	Platelet count;
LGG	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg16691251	chr5:66510806	NA	0.35	7.19	0.32	2.61e-12	Breast cancer;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.44	-0.37	4.02e-16	Aortic root size;
LGG	trans	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg06521331	chr12:34319734	NA	-0.44	-7.56	-0.33	2.15e-13	Heart rate;
LGG	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg18196295	chr10:418757	DIP2C	0.63	12.11	0.49	1.56e-29	Psychosis in Alzheimer's disease;
LGG	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg02002194	chr4:3960332	NA	-0.38	-6.76	-0.3	4.29e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.6	0.53	1.16e-35	Lung cancer;
LGG	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg27205649	chr11:78285834	NARS2	0.47	8.07	0.35	6.06e-15	Alzheimer's disease (survival time);
LGG	trans	rs9409565	0.826	rs9409564	chr9:97248166	C/T	cg05679027	chr9:99775184	HIATL2	-0.5	-8.21	-0.36	2.17e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9863	0.827	rs6488913	chr12:124445569	C/G	cg13487667	chr12:124434373	CCDC92	0.35	7.01	0.31	8.3e-12	White blood cell count;
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.92	0.31	1.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg17802220	chr15:77601643	NA	0.5	10.12	0.43	6.78e-22	Type 2 diabetes;
LGG	trans	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.25	0.32	1.72e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg01620082	chr3:125678407	NA	-0.67	-7.82	-0.34	3.66e-14	Depression;
LGG	cis	rs3219090	0.512	rs3219023	chr1:226591056	T/C	cg17127702	chr1:226594323	PARP1	0.28	6.75	0.3	4.43e-11	Melanoma;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg19635926	chr16:89946313	TCF25	0.72	7.11	0.31	4.48e-12	Skin colour saturation;
LGG	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg21045802	chr8:109455806	TTC35	0.53	10.06	0.42	1.14e-21	Dupuytren's disease;
LGG	cis	rs10197940	0.571	rs13393021	chr2:152413258	A/C	cg19508488	chr2:152266495	RIF1	0.6	10.7	0.45	5.05e-24	Lung cancer;
LGG	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg24812749	chr6:127587940	RNF146	0.95	15.92	0.59	7.75e-46	Breast cancer;
LGG	cis	rs11785693	0.661	rs6982652	chr8:4977252	T/C	cg26367366	chr8:4980734	NA	0.48	7.36	0.32	8.21e-13	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs9868809	0.505	rs35064573	chr3:48740280	C/A	cg00383909	chr3:49044727	WDR6	0.92	11.43	0.47	8.27e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg16301924	chr13:53314226	LECT1	-0.43	-8.68	-0.37	6.92e-17	Lewy body disease;
LGG	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg11766577	chr21:47581405	C21orf56	-0.41	-6.79	-0.3	3.44e-11	Testicular germ cell tumor;
LGG	cis	rs367943	0.666	rs7703503	chr5:112962334	A/C	cg12552261	chr5:112820674	MCC	0.53	9.5	0.4	1.15e-19	Type 2 diabetes;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.55	9.41	0.4	2.36e-19	Longevity;
LGG	cis	rs7011049	0.778	rs66556025	chr8:53866055	A/C	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg13271783	chr10:134563150	INPP5A	-0.45	-7.21	-0.32	2.22e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.6	-0.37	1.26e-16	Alcohol dependence;
LGG	cis	rs6714710	0.580	rs11680018	chr2:98479581	C/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.92	0.42	3.71e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.34	-0.43	1.1e-22	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7824557	0.806	rs11777002	chr8:11096153	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.43	0.33	5.19e-13	Retinal vascular caliber;
LGG	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg15479754	chr10:1447082	ADARB2	-0.34	-7.01	-0.31	8.48e-12	Radiation response;
LGG	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg11764359	chr7:65958608	NA	0.63	10.94	0.45	6.37e-25	Aortic root size;
LGG	cis	rs17767392	0.958	rs3784064	chr14:72059551	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.48	-0.4	1.37e-19	Mitral valve prolapse;
LGG	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg14092571	chr14:90743983	NA	0.43	7.65	0.33	1.18e-13	Longevity;
LGG	cis	rs3768617	0.811	rs4366285	chr1:183013672	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.77	0.3	3.93e-11	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-7.06	-0.31	6.05e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.06	-0.42	1.17e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	9.82	0.42	8.25e-21	Obesity-related traits;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg16590910	chr6:42928470	GNMT	0.42	11.95	0.49	7.09e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg10546459	chr2:36825355	FEZ2	0.5	7.53	0.33	2.64e-13	Height;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-8.72	-0.38	4.99e-17	Prudent dietary pattern;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg23556447	chr6:90529595	MDN1	0.42	7.24	0.32	1.93e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg16230307	chr14:35515116	FAM177A1	0.92	13.43	0.53	5.81e-35	Psoriasis;
LGG	cis	rs2074193	0.569	rs11183912	chr12:47769306	A/G	cg02516419	chr12:47771422	NA	0.57	8.67	0.37	7.38e-17	Migraine with aura;
LGG	cis	rs2071403	0.933	rs12329063	chr2:1400686	G/A	cg06500727	chr2:1417164	TPO	-0.5	-9.61	-0.41	4.49e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs2074193	0.569	rs215395	chr12:47766064	A/G	cg02516419	chr12:47771422	NA	-0.58	-8.61	-0.37	1.18e-16	Migraine with aura;
LGG	cis	rs10743315	0.732	rs16915309	chr12:19430632	G/A	cg02471346	chr12:19282374	PLEKHA5	0.64	7.43	0.33	5.3e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09083178	chr16:1016463	LMF1	0.35	6.87	0.3	2.03e-11	Electrocardiographic conduction measures;
LGG	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg22732515	chr19:44031385	ETHE1	0.54	9.37	0.4	3.1e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs763121	0.925	rs17032	chr22:39130843	C/G	cg06022373	chr22:39101656	GTPBP1	0.85	17.07	0.62	4.87e-51	Menopause (age at onset);
LGG	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg09044154	chr16:88155775	NA	0.5	7.62	0.33	1.45e-13	Menopause (age at onset);
LGG	cis	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg12826209	chr6:26865740	GUSBL1	0.83	12.12	0.49	1.43e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4740619	0.740	rs2382540	chr9:15784496	C/G	cg14451791	chr9:16040625	NA	0.32	8.21	0.36	2.29e-15	Body mass index;
LGG	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg13271783	chr10:134563150	INPP5A	-0.56	-8.28	-0.36	1.37e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7932354	0.528	rs12224096	chr11:47174361	C/T	cg03339077	chr11:47165057	C11orf49	0.55	10.46	0.44	3.92e-23	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg02002194	chr4:3960332	NA	0.49	9.48	0.4	1.35e-19	Systolic blood pressure;
LGG	cis	rs9457247	1.000	rs394522	chr6:167398071	A/C	cg07741184	chr6:167504864	NA	0.31	6.93	0.31	1.41e-11	Crohn's disease;
LGG	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg13802316	chr11:70253460	CTTN	-0.65	-8.97	-0.38	7.21e-18	Coronary artery disease;
LGG	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg13147721	chr7:65941812	NA	-0.83	-10.19	-0.43	4.05e-22	Diabetic kidney disease;
LGG	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.25	0.32	1.82e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.44	0.33	5.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg21775007	chr8:11205619	TDH	-0.77	-13.31	-0.53	1.87e-34	Retinal vascular caliber;
LGG	cis	rs4740619	0.619	rs1328276	chr9:16029036	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.48	-0.47	5.21e-27	Body mass index;
LGG	cis	rs975739	0.657	rs7997143	chr13:78591827	T/G	cg07847733	chr13:78271382	SLAIN1	0.45	7.8	0.34	4.27e-14	Hair color;
LGG	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg03264133	chr6:25882463	NA	-0.47	-7.56	-0.33	2.14e-13	Iron status biomarkers;
LGG	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg08344181	chr3:125677491	NA	0.61	7.08	0.31	5.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10850519	0.827	rs7965876	chr12:115948900	T/A	cg18639984	chr12:115943877	NA	-0.41	-8.92	-0.38	1.07e-17	Diastolic blood pressure;
LGG	cis	rs2067615	0.579	rs4964492	chr12:107222774	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.15	0.49	1.11e-29	Heart rate;
LGG	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg24308560	chr3:49941425	MST1R	0.22	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg00689492	chr4:1303491	MAEA	-0.47	-8.07	-0.35	6.16e-15	Obesity-related traits;
LGG	trans	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs42648	0.837	rs10262603	chr7:89909442	G/A	cg25739043	chr7:89950458	NA	-0.44	-9.33	-0.4	4.32e-19	Homocysteine levels;
LGG	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-8.55	-0.37	1.8e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg02023728	chr11:77925099	USP35	0.45	7.81	0.34	3.84e-14	Testicular germ cell tumor;
LGG	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg12751644	chr20:60527061	NA	-0.32	-7.12	-0.31	4.16e-12	Body mass index;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg18538332	chr22:24372958	LOC391322	-0.45	-7.41	-0.33	6.19e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2224391	0.910	rs2875979	chr6:5275243	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.52	7.68	0.34	9.23e-14	Height;
LGG	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.41	0.44	6.3e-23	Arsenic metabolism;
LGG	cis	rs9818758	0.607	rs67060340	chr3:48915321	C/T	cg00383909	chr3:49044727	WDR6	1.04	12.61	0.51	1.54e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg00278107	chr5:1061253	SLC12A7	-0.91	-20.4	-0.69	1.87e-66	QT interval;
LGG	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg05169160	chr2:178484487	TTC30A	0.35	6.89	0.3	1.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	8.14	0.35	3.57e-15	Joint mobility (Beighton score);
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg25986240	chr4:9926439	SLC2A9	-0.5	-11.03	-0.46	2.85e-25	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.45	-0.37	3.68e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg07395648	chr5:131743802	NA	0.42	9.02	0.39	4.92e-18	Blood metabolite levels;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg20887711	chr4:1340912	KIAA1530	0.85	18.23	0.65	2.19e-56	Longevity;
LGG	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg26769984	chr7:1090371	C7orf50	0.45	7.35	0.32	8.87e-13	Bronchopulmonary dysplasia;
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs7215564	0.818	rs112155856	chr17:78594573	A/T	cg16980736	chr17:78789706	RPTOR	-0.67	-8.58	-0.37	1.49e-16	Myopia (pathological);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19693284	chr19:2783607	SGTA	0.46	6.89	0.3	1.81e-11	Gut microbiome composition (summer);
LGG	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg07777115	chr5:623756	CEP72	-0.57	-7.13	-0.31	3.95e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg08847533	chr14:75593920	NEK9	-0.53	-9.87	-0.42	5.69e-21	Height;
LGG	cis	rs4148087	0.929	rs4148084	chr21:43620250	A/C	cg08841829	chr21:43638893	ABCG1	-0.61	-8.4	-0.36	5.56e-16	Eating disorder in bipolar disorder;
LGG	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.87e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23633679	chr1:173793655	CENPL;DARS2	0.45	7.53	0.33	2.76e-13	Cognitive performance;
LGG	cis	rs244899	0.967	rs2445785	chr5:167924928	A/G	cg06604206	chr5:167912465	RARS	0.53	11.69	0.48	7.85e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.25e-14	Life satisfaction;
LGG	cis	rs9815354	1.000	rs1717011	chr3:41980199	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6121246	0.609	rs4453755	chr20:30331047	G/A	cg13852791	chr20:30311386	BCL2L1	0.93	17.86	0.64	1.13e-54	Mean corpuscular hemoglobin;
LGG	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs2479724	0.840	rs6925777	chr6:41750822	C/T	cg17623882	chr6:41773611	USP49	0.51	8.95	0.38	8.54e-18	Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg10760299	chr15:45669010	GATM	0.41	8.13	0.35	4.04e-15	Homoarginine levels;
LGG	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg04608330	chr12:45269318	NELL2	-0.65	-11.61	-0.47	1.54e-27	Gut microbiome composition (summer);
LGG	cis	rs9810089	0.527	rs3957816	chr3:135955852	C/T	cg12473912	chr3:136751656	NA	0.49	8.69	0.37	6.26e-17	Gestational age at birth (child effect);
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-9.84	-0.42	6.97e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs34734847	0.750	rs3915	chr12:121176679	C/T	cg21892295	chr12:121157589	UNC119B	-0.39	-7.32	-0.32	1.09e-12	Mean corpuscular volume;
LGG	cis	rs11700980	0.551	rs2832008	chr21:30109998	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12016809	chr21:47604291	C21orf56	0.54	9.65	0.41	3.43e-20	Testicular germ cell tumor;
LGG	cis	rs7246760	1.000	rs12460571	chr19:9881746	C/A	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.51e-11	Pursuit maintenance gain;
LGG	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.17	-0.49	9.27e-30	Hemoglobin concentration;
LGG	cis	rs74781061	0.929	rs11072493	chr15:74829222	G/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.34	-0.32	9.81e-13	Endometriosis;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg16070123	chr10:51489643	NA	-0.4	-7.18	-0.32	2.84e-12	Prostate-specific antigen levels;
LGG	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg18867708	chr6:26865862	GUSBL1	0.46	7.73	0.34	6.69e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-7.31	-0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg26138144	chr22:38071188	LGALS1	0.68	15.35	0.58	2.81e-43	Fat distribution (HIV);
LGG	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg01191920	chr7:158217561	PTPRN2	-0.79	-17.75	-0.64	3.85e-54	Obesity-related traits;
LGG	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg17085576	chr10:5658249	NA	-0.4	-7.58	-0.33	1.88e-13	Breast cancer;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg07511668	chr11:68622177	NA	0.5	9.25	0.39	8.19e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1869026	0.967	rs11122802	chr2:121335866	C/A	cg13274077	chr2:121334614	NA	0.33	7.69	0.34	8.83e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.08	0.39	3.18e-18	Lung cancer;
LGG	cis	rs11920090	0.872	rs7628514	chr3:170697051	A/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2247341	1.000	rs2247341	chr4:1701317	C/T	cg05026014	chr4:1749153	NA	-0.3	-8.42	-0.36	4.71e-16	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg14092988	chr3:52407081	DNAH1	0.3	7.84	0.34	3.09e-14	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.623	rs719973	chr7:124631727	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7927592	0.913	rs12285993	chr11:68302538	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg04568710	chr12:38710424	ALG10B	0.35	7.37	0.32	8.14e-13	Morning vs. evening chronotype;
LGG	cis	rs9513627	0.915	rs4539436	chr13:100122802	C/G	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.42	-0.33	5.81e-13	Coronary artery disease;
LGG	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg25866889	chr13:114914595	NA	-0.35	-7.12	-0.31	4.02e-12	Schizophrenia;
LGG	cis	rs6867032	0.527	rs4975720	chr5:2010455	C/G	cg26168224	chr5:2018326	NA	0.92	17.26	0.63	7.01e-52	Gut microbiome composition (winter);
LGG	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg02002194	chr4:3960332	NA	-0.43	-8.2	-0.36	2.37e-15	Mood instability;
LGG	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg25237894	chr2:233734115	C2orf82	0.65	12.5	0.5	4.4e-31	Coronary artery disease;
LGG	cis	rs754466	0.580	rs11002294	chr10:79540588	T/C	cg17075019	chr10:79541650	NA	-0.98	-21.72	-0.71	1.21e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg16141378	chr3:129829833	LOC729375	0.37	7.88	0.34	2.28e-14	Retinal vascular caliber;
LGG	trans	rs931812	1.000	rs4734494	chr8:101917721	T/C	cg20993868	chr7:22813445	NA	0.66	12.5	0.5	4.3e-31	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1867631	0.585	rs6694782	chr1:67126762	C/T	cg13052034	chr1:66999238	SGIP1	-0.33	-6.78	-0.3	3.74e-11	Menopause (age at onset);
LGG	cis	rs35740288	1.000	rs11637212	chr15:86293097	C/G	cg04173714	chr15:86211321	AKAP13	-0.41	-7.07	-0.31	5.59e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs981844	0.712	rs11099915	chr4:154743624	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18252515	chr7:66147081	NA	0.49	7.79	0.34	4.39e-14	Aortic root size;
LGG	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26714650	chr12:56694279	CS	1.5	18.25	0.65	1.81e-56	Psoriasis vulgaris;
LGG	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.48	0.4	1.37e-19	Mood instability;
LGG	cis	rs377457	0.623	rs4565	chr16:85711411	C/G	cg08768472	chr16:85689701	KIAA0182	0.47	9.04	0.39	4.27e-18	Type 2 diabetes;
LGG	cis	rs753955	0.567	rs767378	chr13:24364565	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	7.53	0.33	2.65e-13	Lung cancer;
LGG	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg02574844	chr11:5959923	NA	-0.56	-8.8	-0.38	2.65e-17	DNA methylation (variation);
LGG	cis	rs12282928	0.959	rs2101185	chr11:48319573	G/T	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.24	-0.32	1.89e-12	Bipolar disorder;
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs72827839	0.894	rs112306902	chr17:46191032	C/T	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.54	-0.33	2.59e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6489882	0.836	rs10850099	chr12:113364504	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.52	-0.33	2.83e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.3	-0.36	1.17e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2797369	0.571	rs2749132	chr6:101485092	C/T	cg27451362	chr6:101846650	GRIK2	0.7	10.15	0.43	5.64e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs62400317	0.762	rs1329711	chr6:44963401	A/G	cg20913747	chr6:44695427	NA	-0.66	-11.29	-0.46	2.78e-26	Total body bone mineral density;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg03804240	chr11:118481350	PHLDB1	0.39	7.62	0.33	1.49e-13	Cholesterol, total;
LGG	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg13647721	chr17:30228624	UTP6	0.78	12.38	0.5	1.27e-30	Height;
LGG	cis	rs7586879	0.575	rs6721750	chr2:25128719	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg03929089	chr4:120376271	NA	-0.8	-13.28	-0.53	2.54e-34	Coronary artery disease;
LGG	cis	rs1878931	0.559	rs2106863	chr16:3391330	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	14.58	0.56	6.8e-40	Body mass index (adult);
LGG	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.34	-0.5	1.93e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.88	-0.38	1.43e-17	Bone mineral density;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.18	-0.6	5.38e-47	Platelet count;
LGG	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg21174375	chr14:64681225	SYNE2	0.37	7.0	0.31	9.24e-12	Atrial fibrillation;
LGG	cis	rs922692	0.744	rs12899147	chr15:79079512	A/G	cg00540400	chr15:79124168	NA	-0.38	-7.27	-0.32	1.51e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9487051	0.676	rs6568567	chr6:109596993	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.38e-14	Reticulocyte fraction of red cells;
LGG	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg05163923	chr11:71159392	DHCR7	-0.61	-10.56	-0.44	1.75e-23	Vitamin D levels;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg03709012	chr19:19516395	GATAD2A	0.85	17.08	0.62	4.45e-51	Tonsillectomy;
LGG	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg16751781	chr15:78858589	CHRNA5	-0.39	-7.12	-0.31	4.14e-12	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-11.76	-0.48	3.91e-28	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05380793	chr13:73301995	C13orf37;C13orf34	0.42	7.03	0.31	7.31e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg02297831	chr4:17616191	MED28	0.5	9.42	0.4	2.1e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg02002194	chr4:3960332	NA	-0.47	-9.17	-0.39	1.54e-18	Neuroticism;
LGG	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.77	-0.45	2.84e-24	Lung cancer;
LGG	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00294572	chr6:26285232	NA	0.41	7.24	0.32	1.87e-12	Educational attainment;
LGG	cis	rs1920116	0.744	rs9833035	chr3:169553498	G/T	cg08193579	chr3:169529701	LRRC34	0.42	7.34	0.32	9.92e-13	Glioma (high-grade);
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg21856205	chr7:94953877	PON1	-0.42	-10.32	-0.43	1.27e-22	Paraoxonase activity;
LGG	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg08717414	chr16:71523259	ZNF19	-0.48	-7.31	-0.32	1.18e-12	Blood protein levels;
LGG	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg10935138	chr17:73851978	WBP2	0.63	8.84	0.38	1.94e-17	Psoriasis;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg04863758	chr4:1303710	MAEA	0.42	7.16	0.32	3.09e-12	Obesity-related traits;
LGG	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-7.77	-0.34	5.29e-14	Mood instability;
LGG	cis	rs877282	0.947	rs4133015	chr10:774131	T/C	cg17470449	chr10:769945	NA	0.63	8.14	0.35	3.79e-15	Uric acid levels;
LGG	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg12623918	chr2:306882	NA	0.38	7.12	0.31	4.09e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1843834	0.838	rs6436506	chr2:225558242	T/C	cg22455342	chr2:225449267	CUL3	0.56	9.55	0.41	7.39e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	12.01	0.49	4.16e-29	Response to antipsychotic treatment;
LGG	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg24375607	chr4:120327624	NA	0.67	11.16	0.46	9.18e-26	Corneal astigmatism;
LGG	cis	rs1971762	0.545	rs3864905	chr12:54058324	C/T	cg06632207	chr12:54070931	ATP5G2	0.24	7.58	0.33	1.92e-13	Height;
LGG	cis	rs911186	0.730	rs2393911	chr6:27057079	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-8.8	-0.38	2.7e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs240764	0.541	rs9390693	chr6:101239935	T/C	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs3219090	0.962	rs2793655	chr1:226602814	T/A	cg17127702	chr1:226594323	PARP1	0.39	12.42	0.5	8.68e-31	Melanoma;
LGG	cis	rs897984	0.683	rs9932572	chr16:30841642	A/G	cg02466173	chr16:30829666	NA	-0.6	-12.08	-0.49	2.07e-29	Dementia with Lewy bodies;
LGG	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg26031613	chr14:104095156	KLC1	-0.68	-10.81	-0.45	1.97e-24	Reticulocyte count;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.12	-0.35	4.21e-15	Life satisfaction;
LGG	cis	rs4561483	0.864	rs190461	chr16:12005745	A/G	cg08843971	chr16:11963173	GSPT1	-0.64	-15.81	-0.59	2.56e-45	Testicular germ cell tumor;
LGG	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg08847533	chr14:75593920	NEK9	-0.59	-11.34	-0.47	1.79e-26	Height;
LGG	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.39	-8.63	-0.37	1.03e-16	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs11039798	0.764	rs1121450	chr11:48897476	C/T	cg03929089	chr4:120376271	NA	0.73	8.39	0.36	5.99e-16	Axial length;
LGG	cis	rs2235642	0.826	rs8048410	chr16:1614097	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.4	9.36	0.4	3.38e-19	Coronary artery disease;
LGG	cis	rs10861342	1.000	rs10861357	chr12:105544254	C/T	cg23923672	chr12:105501055	KIAA1033	0.8	7.12	0.31	4.23e-12	IgG glycosylation;
LGG	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg06623630	chr22:50017776	C22orf34	-0.36	-7.71	-0.34	7.9e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg14541582	chr5:601475	NA	-0.69	-10.69	-0.44	5.59e-24	Obesity-related traits;
LGG	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.52	-0.33	2.8e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg04111992	chr7:158790115	NA	-0.36	-7.33	-0.32	1.06e-12	Facial morphology (factor 20);
LGG	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg20503657	chr10:835505	NA	0.8	11.27	0.46	3.31e-26	Eosinophil percentage of granulocytes;
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18876405	chr7:65276391	NA	0.49	8.8	0.38	2.81e-17	Aortic root size;
LGG	cis	rs3862030	0.839	rs7078511	chr10:104283874	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-10.33	-0.43	1.25e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.54	9.85	0.42	6.72e-21	Multiple sclerosis;
LGG	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs7674212	0.570	rs6841136	chr4:104103509	A/C	cg16532752	chr4:104119610	CENPE	-0.42	-7.24	-0.32	1.85e-12	Type 2 diabetes;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04008888	chr11:68622739	NA	-0.52	-11.2	-0.46	6.41e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-8.57	-0.37	1.56e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4363385	0.719	rs6664411	chr1:152932857	T/C	cg07796016	chr1:152779584	LCE1C	-0.48	-7.66	-0.34	1.13e-13	Inflammatory skin disease;
LGG	trans	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg11430096	chr6:110968061	CDK19	0.64	6.8	0.3	3.3e-11	Prostate cancer;
LGG	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg13647721	chr17:30228624	UTP6	0.63	7.5	0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1018836	0.608	rs2205150	chr8:91483232	G/A	cg16814680	chr8:91681699	NA	-0.58	-9.55	-0.41	7.28e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11190604	1.000	rs4919468	chr10:102288343	G/C	cg07570687	chr10:102243282	WNT8B	0.44	7.34	0.32	9.71e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg16060761	chr17:80687452	NA	-0.54	-9.9	-0.42	4.51e-21	Glycated hemoglobin levels;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg26043149	chr18:55253948	FECH	0.93	15.77	0.59	3.88e-45	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4780401	0.573	rs8045673	chr16:11804385	C/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.88	-0.51	1.19e-32	Rheumatoid arthritis;
LGG	cis	rs3820928	0.839	rs10197773	chr2:227824835	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.83	-0.34	3.31e-14	Pulmonary function;
LGG	cis	rs7917772	0.536	rs17783771	chr10:104410736	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.67	0.48	9.17e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2236918	1.000	rs2526704	chr1:242015820	A/G	cg17736920	chr1:242011382	EXO1	0.5	9.05	0.39	3.98e-18	Menopause (age at onset);
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg08888203	chr3:10149979	C3orf24	0.56	9.49	0.4	1.27e-19	Alzheimer's disease;
LGG	cis	rs2860975	0.620	rs7095531	chr10:96811841	A/G	cg09036531	chr10:96991505	NA	-0.47	-8.2	-0.36	2.44e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg03188948	chr7:1209495	NA	0.65	8.47	0.37	3.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs774359	0.830	rs2477523	chr9:27536894	T/A	cg14173147	chr9:27528300	MOBKL2B	0.46	8.69	0.37	6.23e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2270450	0.650	rs13210554	chr6:46704339	C/T	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.53e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs16944613	0.541	rs13313427	chr15:91090768	G/A	cg22089800	chr15:90895588	ZNF774	-0.55	-6.65	-0.3	8.24e-11	Colorectal cancer;
LGG	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg26248373	chr2:1572462	NA	-0.69	-9.0	-0.39	5.76e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.65e-54	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs10017201	chr4:98983561	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg18357526	chr6:26021779	HIST1H4A	0.51	8.36	0.36	7.46e-16	Blood metabolite levels;
LGG	cis	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.01	-0.35	9.2e-15	Ulcerative colitis;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg09699651	chr6:150184138	LRP11	0.53	9.51	0.4	1.04e-19	Lung cancer;
LGG	cis	rs1784581	0.722	rs1619122	chr6:162400198	G/T	cg17173639	chr6:162384350	PARK2	-0.74	-16.43	-0.61	3.97e-48	Itch intensity from mosquito bite;
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-7.01	-0.31	8.64e-12	Daytime sleep phenotypes;
LGG	cis	rs300774	1.000	rs300777	chr2:112026	T/C	cg04617936	chr2:214353	NA	-0.49	-7.29	-0.32	1.35e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs12195424	0.730	rs76732986	chr6:56305341	C/T	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4409675	0.556	rs2064710	chr1:28231154	G/A	cg23691781	chr1:28212827	C1orf38	0.4	10.59	0.44	1.27e-23	Corneal astigmatism;
LGG	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.02	0.39	4.92e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03264133	chr6:25882463	NA	-0.55	-10.25	-0.43	2.3e-22	Blood metabolite levels;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00495681	chr13:53174319	NA	0.58	10.33	0.43	1.24e-22	Lewy body disease;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg08621203	chr6:150244597	RAET1G	0.42	7.05	0.31	6.51e-12	Lung cancer;
LGG	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg05147244	chr20:61493195	TCFL5	0.72	7.19	0.32	2.6e-12	Obesity-related traits;
LGG	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg25801113	chr15:45476975	SHF	0.87	19.78	0.68	1.5e-63	Uric acid levels;
LGG	cis	rs9814567	0.964	rs6776203	chr3:134234345	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.35	-0.53	1.28e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11690935	0.918	rs12692978	chr2:172725981	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-25.83	-0.77	8.89e-92	Schizophrenia;
LGG	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg12458913	chr13:53173898	NA	0.88	20.57	0.69	2.85e-67	Lewy body disease;
LGG	cis	rs17451754	0.762	rs34002054	chr7:117355267	A/G	cg10524701	chr7:117356490	CTTNBP2	0.46	6.79	0.3	3.37e-11	Barrett's esophagus  or Esophageal adenocarcinoma;
LGG	cis	rs11920090	0.858	rs73167792	chr3:170690375	A/C	cg09710316	chr3:170744871	SLC2A2	0.66	8.52	0.37	2.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04498971	chr17:56084468	SFRS1	0.45	6.97	0.31	1.1e-11	Gut microbiome composition (summer);
LGG	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.34	-0.36	8.78e-16	Body mass index;
LGG	cis	rs6032067	0.866	rs2233901	chr20:43851094	A/G	cg10761708	chr20:43804764	PI3	-0.76	-11.8	-0.48	2.72e-28	Blood protein levels;
LGG	trans	rs2975734	0.674	rs6983870	chr8:10111294	G/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.81	-0.3	3.07e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7113874	0.524	rs10769926	chr11:8623674	C/A	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.71e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs858239	0.539	rs10280815	chr7:23188370	A/C	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.46e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs36051895	0.632	rs12349918	chr9:5125250	A/G	cg02405213	chr9:5042618	JAK2	-0.8	-14.98	-0.57	1.17e-41	Pediatric autoimmune diseases;
LGG	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg09085632	chr11:111637200	PPP2R1B	1.02	19.69	0.68	3.65e-63	Primary sclerosing cholangitis;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.57e-13	Menopause (age at onset);
LGG	cis	rs2239547	0.563	rs4687560	chr3:52898121	T/G	cg11645453	chr3:52864694	ITIH4	0.69	10.71	0.45	4.53e-24	Schizophrenia;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg20003494	chr4:90757398	SNCA	0.41	8.12	0.35	4.13e-15	Dementia with Lewy bodies;
LGG	cis	rs80282103	0.867	rs7098169	chr10:1078601	G/A	cg08668510	chr10:1095578	IDI1	0.76	7.78	0.34	4.75e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-7.12	-0.31	4.16e-12	Reticulocyte count;
LGG	cis	rs1843834	0.721	rs1434057	chr2:225606389	T/G	cg22455342	chr2:225449267	CUL3	0.46	7.8	0.34	4.21e-14	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg23302884	chr18:44338147	ST8SIA5	0.35	6.9	0.31	1.72e-11	Personality dimensions;
LGG	cis	rs3816183	0.716	rs10176547	chr2:43083279	A/G	cg14631114	chr2:43023945	NA	0.47	8.32	0.36	1.03e-15	Hypospadias;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg25338242	chr13:114786047	RASA3	0.4	7.15	0.32	3.39e-12	Schizophrenia;
LGG	cis	rs9868809	0.505	rs28567949	chr3:48744560	G/A	cg00383909	chr3:49044727	WDR6	0.92	11.38	0.47	1.31e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs806794	0.810	rs62396185	chr6:26180634	G/C	cg13736514	chr6:26305472	NA	-0.39	-7.06	-0.31	6.21e-12	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs11750568	1.000	rs2059776	chr5:178539400	C/T	cg10208897	chr5:178548229	ADAMTS2	-0.42	-6.85	-0.3	2.39e-11	Height;
LGG	cis	rs559928	0.524	rs4963222	chr11:64184735	T/C	cg05555928	chr11:63887634	MACROD1	-0.59	-9.79	-0.41	1.1e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-8.73	-0.38	4.72e-17	Diabetic retinopathy;
LGG	cis	rs3735485	0.738	rs56334845	chr7:45092975	T/C	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7580658	0.926	rs79789049	chr2:128145472	G/A	cg10021288	chr2:128175891	PROC	-0.66	-13.48	-0.53	3.7e-35	Protein C levels;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg13206674	chr6:150067644	NUP43	0.66	15.12	0.57	2.82e-42	Lung cancer;
LGG	trans	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs60180747	0.909	rs11629783	chr15:66741387	C/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	-0.56	-9.47	-0.4	1.44e-19	Testicular germ cell tumor;
LGG	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg04398451	chr17:18023971	MYO15A	0.74	15.75	0.59	4.77e-45	Total body bone mineral density;
LGG	cis	rs68170813	0.559	rs78610616	chr7:106951369	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	9.64e-24	Coronary artery disease;
LGG	trans	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.52	-0.33	2.8e-13	Joint mobility (Beighton score);
LGG	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.86	-17.43	-0.63	1.09e-52	Lung cancer;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.04	-0.39	4.16e-18	Life satisfaction;
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg15145296	chr3:125709740	NA	-0.62	-8.14	-0.35	3.82e-15	Blood pressure (smoking interaction);
LGG	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.47e-22	Motion sickness;
LGG	trans	rs17685	0.712	rs7785025	chr7:75628101	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.03	-24.55	-0.75	7.5e-86	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs28830936	0.841	rs4923914	chr15:42119603	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.56	-12.69	-0.51	7.08e-32	Diastolic blood pressure;
LGG	cis	rs10849893	0.595	rs10444490	chr12:121876385	G/C	cg01154721	chr12:121881891	KDM2B	-0.41	-7.24	-0.32	1.93e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs1032833	0.732	rs1048026	chr2:179973467	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs963731	0.579	rs1454226	chr2:39246862	A/G	cg04010122	chr2:39346883	SOS1	-0.83	-7.43	-0.33	5.31e-13	Corticobasal degeneration;
LGG	cis	rs157093	1.000	rs157093	chr20:56252956	C/T	cg04055238	chr20:56251166	PMEPA1	0.45	8.0	0.35	9.75e-15	Verbal declarative memory;
LGG	cis	rs2294693	0.945	rs742494	chr6:41007835	A/T	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.71	-0.3	5.56e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs17301259	0.548	rs2718338	chr7:88322046	C/T	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.73	-0.3	5.09e-11	Heschl's gyrus morphology;
LGG	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07080220	chr10:102295463	HIF1AN	0.58	10.13	0.43	6.4e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg07460842	chr6:66804631	NA	0.94	17.1	0.62	3.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.02	0.31	7.96e-12	Height;
LGG	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.88	-0.34	2.44e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7177699	0.557	rs8027833	chr15:79112837	T/C	cg00540400	chr15:79124168	NA	0.53	11.24	0.46	4.37e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg14019146	chr3:50243930	SLC38A3	-0.47	-9.5	-0.4	1.13e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg01200585	chr1:228362443	C1orf69	0.47	8.18	0.36	2.8e-15	Diastolic blood pressure;
LGG	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg08807101	chr21:30365312	RNF160	0.61	9.65	0.41	3.31e-20	Cognitive test performance;
LGG	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.48e-13	HDL cholesterol;
LGG	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg10857441	chr5:6722123	POLS	-0.27	-6.84	-0.3	2.56e-11	Menopause (age at onset);
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11514810	1.000	rs7812242	chr7:1431747	C/T	cg24899294	chr7:1481343	MICALL2	-0.76	-8.51	-0.37	2.5e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.8	0.3	3.34e-11	Longevity;
LGG	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg25664220	chr3:72788482	NA	-0.32	-8.81	-0.38	2.47e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg15704280	chr7:45808275	SEPT13	-0.69	-10.93	-0.45	6.83e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg03162506	chr22:38580953	NA	0.41	10.0	0.42	1.88e-21	Breast cancer;
LGG	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	8.07e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.4	-0.4	2.58e-19	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22945462	chr14:102829122	TECPR2;CINP	0.45	6.77	0.3	3.93e-11	Gut microbiome composition (summer);
LGG	cis	rs2665103	0.715	rs11639440	chr15:82571046	G/A	cg00614314	chr15:82944287	LOC80154	0.45	7.64	0.33	1.28e-13	Intelligence (multi-trait analysis);
LGG	cis	rs56775891	0.959	rs7238071	chr18:77579812	C/T	cg02536541	chr18:77568900	NA	0.5	7.99	0.35	1.11e-14	Schizophrenia;
LGG	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg24848339	chr3:12840334	CAND2	0.46	11.13	0.46	1.21e-25	P wave duration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02429035	chr17:27348666	NA	-0.57	-6.81	-0.3	2.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg21995147	chr19:1064017	ABCA7	-0.47	-7.38	-0.32	7.55e-13	Alzheimer's disease (late onset);
LGG	cis	rs7924176	0.549	rs2395076	chr10:75931839	T/A	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.87	-0.3	2.06e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs2764208	0.576	rs6906500	chr6:34692585	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.47	8.38	0.36	6.37e-16	Systemic lupus erythematosus;
LGG	cis	rs6815814	0.950	rs5743565	chr4:38805983	T/C	cg06935464	chr4:38784597	TLR10	0.6	8.24	0.36	1.76e-15	Breast cancer;
LGG	cis	rs754423	0.515	rs12587906	chr14:52553959	T/G	cg12071775	chr14:52591786	NA	-0.42	-6.85	-0.3	2.36e-11	Craniofacial microsomia;
LGG	cis	rs11018904	0.906	rs55685917	chr11:89964365	T/C	cg27158573	chr11:89632121	NA	-0.41	-7.31	-0.32	1.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg18316613	chr7:23719636	C7orf46	0.36	8.39	0.36	5.76e-16	Schizophrenia;
LGG	trans	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.71	-0.51	5.79e-32	Obesity-related traits;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg18538332	chr22:24372958	LOC391322	-0.5	-8.33	-0.36	9.53e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg02574844	chr11:5959923	NA	-0.54	-8.72	-0.38	5.2e-17	DNA methylation (variation);
LGG	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.67	-0.41	2.88e-20	Height;
LGG	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg03477792	chr4:77819574	ANKRD56	0.53	9.25	0.39	8.6e-19	Emphysema distribution in smoking;
LGG	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg02428538	chr16:24856791	SLC5A11	-0.7	-10.75	-0.45	3.24e-24	Intelligence (multi-trait analysis);
LGG	trans	rs13256369	0.826	rs12678414	chr8:8586016	G/T	cg02002194	chr4:3960332	NA	-0.43	-7.52	-0.33	2.85e-13	Obesity-related traits;
LGG	cis	rs9473924	0.542	rs9463650	chr6:50822081	C/T	cg14470998	chr6:50812995	TFAP2B	0.66	7.89	0.34	2.2e-14	Body mass index;
LGG	cis	rs12195424	0.558	rs76569072	chr6:56299479	G/T	cg07152817	chr6:56299822	NA	-0.98	-10.57	-0.44	1.54e-23	Cerebrospinal fluid clusterin levels;
LGG	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg11887960	chr12:57824829	NA	0.56	6.84	0.3	2.58e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg20913747	chr6:44695427	NA	-0.61	-10.31	-0.43	1.43e-22	Total body bone mineral density;
LGG	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.54	-0.41	8.48e-20	Diabetic retinopathy;
LGG	cis	rs7666738	1.000	rs880471	chr4:98922541	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.71	0.3	5.67e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4776059	1.000	rs2288271	chr15:52886466	A/G	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.14	-0.35	3.82e-15	Schizophrenia;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.68	0.37	6.75e-17	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg07701084	chr6:150067640	NUP43	0.7	13.63	0.54	8.19e-36	Lung cancer;
LGG	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.53	-0.37	2.12e-16	Total body bone mineral density;
LGG	cis	rs701145	0.585	rs357487	chr3:153885199	G/C	cg17054900	chr3:154042577	DHX36	0.85	10.0	0.42	1.83e-21	Coronary artery disease;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.04	-0.39	4.38e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.84	-0.38	1.99e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27580026	chr2:27717965	FNDC4	0.46	7.02	0.31	8.06e-12	Hip circumference;
LGG	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg00666640	chr1:248458726	OR2T12	0.58	9.4	0.4	2.5e-19	Common traits (Other);
LGG	cis	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-8.08	-0.35	5.48e-15	Extrinsic epigenetic age acceleration;
LGG	trans	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.45	-0.33	4.76e-13	Resting heart rate;
LGG	trans	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-12.13	-0.49	1.34e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg14675211	chr2:100938903	LONRF2	0.64	11.28	0.46	2.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg20887711	chr4:1340912	KIAA1530	0.44	7.83	0.34	3.36e-14	Obesity-related traits;
LGG	cis	rs9326248	0.559	rs609177	chr11:116770517	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.59	0.44	1.31e-23	Blood protein levels;
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg14403583	chr14:105418241	AHNAK2	-0.78	-15.14	-0.58	2.45e-42	Rheumatoid arthritis;
LGG	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg03959625	chr15:84868606	LOC388152	0.56	8.69	0.37	6.32e-17	Schizophrenia;
LGG	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg04691961	chr3:161091175	C3orf57	0.44	9.41	0.4	2.35e-19	Morning vs. evening chronotype;
LGG	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.53	0.47	3.2e-27	Obesity-related traits;
LGG	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.89e-22	Arsenic metabolism;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg03876184	chr2:27886755	SUPT7L;SLC4A1AP	0.71	6.71	0.3	5.55e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs12210905	1.000	rs72843633	chr6:27182949	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.08	-0.31	5.26e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12431204	1.000	rs12431204	chr13:38450235	T/A	cg23307680	chr13:38443104	TRPC4	0.42	7.34	0.32	9.37e-13	Schizophrenia;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.16e-12	Bipolar disorder;
LGG	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs3735485	0.738	rs10272689	chr7:45094847	A/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9596863	0.750	rs1971924	chr13:54432432	T/G	ch.13.53330881F	chr13:54432880	NA	-0.5	-6.99	-0.31	9.74e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg21782813	chr7:2030301	MAD1L1	0.54	14.31	0.55	1.01e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs9398803	0.687	rs4243491	chr6:126938536	T/C	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.58e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg08344181	chr3:125677491	NA	-0.92	-9.23	-0.39	9.45e-19	Depression;
LGG	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.24	-0.49	4.84e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg14926445	chr8:58193284	C8orf71	-0.72	-9.24	-0.39	8.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg26578617	chr4:90757533	SNCA	-0.45	-9.11	-0.39	2.58e-18	Dementia with Lewy bodies;
LGG	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs151997	0.925	rs27570	chr5:50191974	G/A	cg06027927	chr5:50259733	NA	0.68	11.11	0.46	1.38e-25	Callous-unemotional behaviour;
LGG	cis	rs9399135	0.967	rs6915770	chr6:135369214	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.08e-19	Red blood cell count;
LGG	cis	rs72843166	0.545	rs1107041	chr17:61005950	C/G	cg06641342	chr17:61514920	CYB561	0.45	6.94	0.31	1.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7799006	0.527	rs6967286	chr7:2212758	C/A	cg21782813	chr7:2030301	MAD1L1	0.34	7.99	0.35	1.11e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg07636037	chr3:49044803	WDR6	0.9	16.29	0.6	1.68e-47	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg06219351	chr7:158114137	PTPRN2	0.71	14.07	0.55	1.06e-37	Calcium levels;
LGG	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg25019033	chr10:957182	NA	-0.53	-9.62	-0.41	4.31e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs11700980	0.551	rs2832032	chr21:30114790	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs1062177	0.774	rs2964574	chr5:151155711	G/A	cg00977110	chr5:151150581	G3BP1	0.48	7.59	0.33	1.73e-13	Preschool internalizing problems;
LGG	cis	rs7264396	0.528	rs7273880	chr20:34551507	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.9	-0.31	1.7e-11	Total cholesterol levels;
LGG	cis	rs9815354	0.638	rs12634670	chr3:41875299	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs758324	0.947	rs422291	chr5:131320942	A/T	cg06307176	chr5:131281290	NA	-0.6	-9.39	-0.4	2.75e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7010267	0.542	rs4618726	chr8:120009385	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.36	9.05	0.39	3.9e-18	Total body bone mineral density (age 45-60);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03290755	chr11:62559514	TMEM223	-0.43	-6.94	-0.31	1.33e-11	Pancreatic cancer;
LGG	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg16141378	chr3:129829833	LOC729375	-0.48	-12.3	-0.5	2.89e-30	Mood instability;
LGG	cis	rs8133932	0.701	rs2839035	chr21:47308281	A/G	cg13695288	chr21:47294981	PCBP3	-0.37	-7.43	-0.33	5.43e-13	Schizophrenia;
LGG	cis	rs763121	0.888	rs2235229	chr22:39124912	A/G	cg06022373	chr22:39101656	GTPBP1	0.74	14.78	0.57	8.64e-41	Menopause (age at onset);
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.68	-0.34	9.69e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg04568710	chr12:38710424	ALG10B	0.4	8.71	0.38	5.24e-17	Morning vs. evening chronotype;
LGG	trans	rs7246760	0.867	rs67539464	chr19:9832424	C/G	cg02900749	chr2:68251473	NA	-0.97	-10.52	-0.44	2.34e-23	Pursuit maintenance gain;
LGG	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.89	0.34	2.17e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.93	0.42	3.5e-21	Coronary artery disease;
LGG	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg18137308	chr11:63775436	MACROD1	0.29	6.76	0.3	4.21e-11	Pulse pressure;
LGG	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg25703541	chr22:24373054	LOC391322	-0.88	-17.4	-0.63	1.46e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2916247	0.909	rs7004147	chr8:93024405	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.62	-0.37	1.05e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.670	rs2024852	chr6:109819789	G/C	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	6.9e-15	Height;
LGG	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg13385521	chr17:29058706	SUZ12P	0.9	10.22	0.43	2.96e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-9.31	-0.4	4.98e-19	Vitiligo;
LGG	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg12395012	chr8:11607386	GATA4	0.39	6.9	0.31	1.77e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	12.5	0.5	4.41e-31	Lung cancer in ever smokers;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.5	-8.15	-0.35	3.54e-15	Iron status biomarkers;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs6032067	0.714	rs6104065	chr20:43848079	C/G	cg10761708	chr20:43804764	PI3	0.57	8.74	0.38	4.3e-17	Blood protein levels;
LGG	cis	rs300774	0.925	rs409572	chr2:153302	A/G	cg04617936	chr2:214353	NA	-0.5	-7.49	-0.33	3.48e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12600695	chr5:137513806	BRD8;KIF20A	0.44	6.85	0.3	2.39e-11	Gut microbiome composition (summer);
LGG	trans	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.28	-0.65	1.33e-56	Exhaled nitric oxide output;
LGG	cis	rs6784615	1.000	rs164636	chr3:52265259	G/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.72	7.7	0.34	8.05e-14	Waist-hip ratio;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg21782813	chr7:2030301	MAD1L1	0.48	12.05	0.49	2.77e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg14664628	chr15:75095509	CSK	1.14	27.87	0.79	4.35e-101	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4959677	0.901	rs2185659	chr6:2486398	C/T	cg20147862	chr6:2634573	C6orf195	-0.39	-8.59	-0.37	1.35e-16	Orthostatic hypotension;
LGG	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	cis	rs2236267	0.693	rs11626612	chr14:88610244	C/T	cg02175263	chr14:88627849	NA	0.33	7.46	0.33	4.39e-13	Food antigen IgG levels;
LGG	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg18154014	chr19:37997991	ZNF793	-0.42	-7.76	-0.34	5.52e-14	Coronary artery calcification;
LGG	cis	rs17641971	0.662	rs1828495	chr8:49945281	C/T	cg00325661	chr8:49890786	NA	0.54	10.25	0.43	2.29e-22	Blood metabolite levels;
LGG	cis	rs6694672	1.000	rs1576879	chr1:196992318	C/G	cg13682187	chr1:196946512	CFHR5	0.5	6.84	0.3	2.53e-11	Asthma;
LGG	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg13147721	chr7:65941812	NA	-0.76	-8.96	-0.38	8.06e-18	Gout;
LGG	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.84	0.42	7.09e-21	Menarche (age at onset);
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg11965913	chr1:205819406	PM20D1	-0.56	-10.51	-0.44	2.5e-23	Menarche (age at onset);
LGG	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.45	8.27	0.36	1.38e-15	Colorectal cancer;
LGG	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.99	0.39	6.12e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg05791153	chr7:19748676	TWISTNB	0.77	10.09	0.42	8.95e-22	Thyroid stimulating hormone;
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22618164	chr12:122356400	WDR66	0.38	11.12	0.46	1.3e-25	Mean corpuscular volume;
LGG	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg02187348	chr16:89574699	SPG7	0.45	7.15	0.32	3.45e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg10818794	chr15:86012489	AKAP13	-0.55	-12.33	-0.5	2.12e-30	Coronary artery disease;
LGG	cis	rs4417704	0.551	rs56237031	chr2:241875360	C/A	cg14055004	chr2:241860995	NA	-0.28	-7.41	-0.33	6.11e-13	Joint mobility (Beighton score);
LGG	cis	rs4144743	1.000	rs4144744	chr17:45323262	A/G	cg18085866	chr17:45331354	ITGB3	-0.78	-9.87	-0.42	5.56e-21	Body mass index;
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg06494592	chr3:125709126	NA	-0.56	-7.09	-0.31	5.02e-12	Blood pressure (smoking interaction);
LGG	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg06115741	chr20:33292138	TP53INP2	0.6	9.86	0.42	6.21e-21	Coronary artery disease;
LGG	cis	rs9914988	0.943	rs9908881	chr17:27100924	T/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18110333	chr6:292329	DUSP22	-0.69	-11.78	-0.48	3.46e-28	Menopause (age at onset);
LGG	cis	rs7616330	0.887	rs1947150	chr3:71113096	A/G	cg23830205	chr3:71127516	FOXP1	0.5	7.28	0.32	1.4e-12	QT interval;
LGG	cis	rs3818285	0.679	rs552419	chr10:111630883	G/T	cg00817464	chr10:111662876	XPNPEP1	0.49	10.19	0.43	3.94e-22	Superior crus of antihelix expression;
LGG	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.29	-0.4	6.15e-19	Ovarian reserve;
LGG	cis	rs2996428	0.667	rs7545274	chr1:3744261	G/T	cg10555106	chr1:3691387	LOC388588	0.39	8.24	0.36	1.73e-15	Red cell distribution width;
LGG	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg19507638	chr5:93509721	C5orf36	0.7	9.7	0.41	2.16e-20	Diabetic retinopathy;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg06074448	chr4:187884817	NA	-0.59	-12.99	-0.52	3.96e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg14088196	chr11:70211408	PPFIA1	0.81	10.84	0.45	1.52e-24	Coronary artery disease;
LGG	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.37	-0.53	1.08e-34	Heart rate;
LGG	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg09085632	chr11:111637200	PPP2R1B	1.18	25.8	0.77	1.29e-91	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	7.23	0.32	1.96e-12	Longevity;
LGG	cis	rs7143963	0.666	rs8017944	chr14:103320048	T/G	cg23020514	chr14:103360112	TRAF3	0.4	8.21	0.36	2.22e-15	Body mass index;
LGG	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg19920283	chr7:105172520	RINT1	0.59	7.75	0.34	5.87e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg04267008	chr7:1944627	MAD1L1	-0.52	-8.66	-0.37	7.69e-17	Schizophrenia;
LGG	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.43	0.44	5.04e-23	Thyroid stimulating hormone;
LGG	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg12310025	chr6:25882481	NA	-0.37	-6.67	-0.3	7.3e-11	Height;
LGG	cis	rs3889237	0.896	rs3803818	chr17:64786250	A/G	cg09655520	chr17:64786064	PRKCA	-0.42	-8.83	-0.38	2.13e-17	Height;
LGG	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg04727924	chr7:799746	HEATR2	-0.48	-7.65	-0.33	1.18e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-11.79	-0.48	3.09e-28	Schizophrenia;
LGG	cis	rs74781061	0.860	rs6495103	chr15:74762848	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.27	-0.32	1.56e-12	Endometriosis;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg19168338	chr16:4465731	CORO7	-0.98	-19.19	-0.67	7.95e-61	Schizophrenia;
LGG	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg23950597	chr19:37808831	NA	0.55	8.28	0.36	1.33e-15	Coronary artery calcification;
LGG	cis	rs758324	0.898	rs6877358	chr5:131111360	G/A	cg06307176	chr5:131281290	NA	0.57	9.47	0.4	1.47e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12923728	chr3:195709715	SDHAP1	-0.8	-14.82	-0.57	5.93e-41	Pancreatic cancer;
LGG	cis	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg21775007	chr8:11205619	TDH	0.85	15.28	0.58	5.39e-43	Retinal vascular caliber;
LGG	cis	rs7000551	0.725	rs2249102	chr8:22400193	C/G	cg12081754	chr8:22256438	SLC39A14	0.63	11.79	0.48	3.06e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg03060546	chr3:49711283	APEH	0.61	9.23	0.39	9.82e-19	Resting heart rate;
LGG	cis	rs990171	0.572	rs951774	chr2:102912664	A/C	cg05295703	chr2:102895712	NA	-1.03	-18.34	-0.65	7.06e-57	Lymphocyte counts;
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg21171335	chr12:122356390	WDR66	0.28	7.58	0.33	1.89e-13	Mean corpuscular volume;
LGG	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg25486957	chr4:152246857	NA	-0.49	-8.09	-0.35	5.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs77106637	0.530	rs7122044	chr11:72462634	A/G	cg04827223	chr11:72435913	ARAP1	-0.45	-7.58	-0.33	1.84e-13	Type 2 diabetes;
LGG	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.62e-14	Testicular germ cell tumor;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-12.26	-0.49	4.11e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	cis	rs17221829	0.549	rs7114659	chr11:89383424	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.12	-0.39	2.38e-18	Anxiety in major depressive disorder;
LGG	cis	rs7928758	0.830	rs11223780	chr11:134261150	C/T	cg22777979	chr11:134283252	B3GAT1	-0.83	-11.94	-0.49	8.07e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25072359	chr17:41440525	NA	0.52	9.82	0.42	8.29e-21	Menopause (age at onset);
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs2033732	0.643	rs10101396	chr8:85060125	A/G	cg05716166	chr8:85095498	RALYL	0.43	6.95	0.31	1.24e-11	Body mass index;
LGG	cis	rs9815354	0.680	rs73073294	chr3:42028053	A/G	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03647317	chr4:187891568	NA	-0.42	-9.0	-0.39	5.73e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.97	-0.49	6.19e-29	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.23	-0.32	2.01e-12	Bone mineral density;
LGG	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.09	0.31	4.92e-12	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.76	0.66	7.74e-59	Menopause (age at onset);
LGG	cis	rs2066819	1.000	rs59626664	chr12:56636975	C/G	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.51	13.06	0.52	2.09e-33	Tonsillectomy;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg16606324	chr3:10149918	C3orf24	0.56	7.39	0.32	7.12e-13	Alzheimer's disease;
LGG	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg26513180	chr16:89883248	FANCA	0.93	20.42	0.69	1.47e-66	Vitiligo;
LGG	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg16141378	chr3:129829833	LOC729375	0.33	7.15	0.32	3.38e-12	Triglycerides;
LGG	cis	rs7193541	0.684	rs9929496	chr16:74668473	G/A	cg01733217	chr16:74700730	RFWD3	1.09	34.3	0.85	3.15e-129	Multiple myeloma;
LGG	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg03342759	chr3:160939853	NMD3	0.62	11.1	0.46	1.57e-25	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg11663600	chr3:49941416	MST1R	-0.24	-6.65	-0.3	8.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg03264133	chr6:25882463	NA	-0.47	-7.57	-0.33	2.06e-13	Iron status biomarkers;
LGG	cis	rs2334880	0.638	rs35166226	chr16:71443219	T/C	cg06353428	chr16:71660113	MARVELD3	-0.77	-10.51	-0.44	2.58e-23	Malaria;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.44	0.58	1.09e-43	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16876829	chr4:925652	GAK;TMEM175	0.49	7.11	0.31	4.55e-12	Gut microbiome composition (summer);
LGG	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg02158880	chr13:53174818	NA	0.67	15.47	0.58	8.09e-44	Lewy body disease;
LGG	cis	rs16912285	0.748	rs7104550	chr11:24345162	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	12.42	0.5	9.23e-31	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs78456975	1.000	rs13431491	chr2:1553808	T/A	cg01028140	chr2:1542097	TPO	-0.54	-8.36	-0.36	7.44e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs477692	0.673	rs511361	chr10:131365052	C/T	cg05714579	chr10:131428358	MGMT	0.47	8.97	0.38	7.13e-18	Response to temozolomide;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg13880726	chr7:1868755	MAD1L1	0.39	7.02	0.31	8.04e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.864	rs1566823	chr2:128018192	A/G	cg10021288	chr2:128175891	PROC	-0.61	-12.63	-0.51	1.21e-31	Protein C levels;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.64	0.44	8.77e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.4	-0.65	3.66e-57	Blood trace element (Zn levels);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg15971980	chr6:150254442	NA	0.43	8.13	0.35	4.07e-15	Lung cancer;
LGG	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	cis	rs7267979	1.000	rs7268053	chr20:25328286	A/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.49	-0.44	3.04e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs4740619	0.901	rs6474953	chr9:15714456	A/C	cg14451791	chr9:16040625	NA	-0.37	-9.46	-0.4	1.52e-19	Body mass index;
LGG	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06634786	chr22:41940651	POLR3H	0.7	11.23	0.46	4.95e-26	Vitiligo;
LGG	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg19143629	chr17:61920732	SMARCD2	0.43	7.36	0.32	8.2e-13	Prudent dietary pattern;
LGG	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg05666200	chr11:89790683	NA	-0.52	-7.0	-0.31	8.77e-12	White blood cell types;
LGG	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg05985134	chr18:33552581	C18orf21	0.62	9.7	0.41	2.21e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	cis	rs7119038	0.509	rs10892258	chr11:118579865	A/G	cg19182353	chr11:118479428	PHLDB1	-0.38	-6.99	-0.31	9.38e-12	Sjögren's syndrome;
LGG	cis	rs3126085	0.877	rs57597406	chr1:152246619	C/G	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg19847130	chr8:10466454	RP1L1	0.32	6.95	0.31	1.23e-11	Neuroticism;
LGG	cis	rs11203032	0.831	rs10887928	chr10:90945861	A/T	cg16672925	chr10:90967113	CH25H	0.76	11.29	0.46	2.93e-26	Heart failure;
LGG	cis	rs1806153	0.611	rs1805270	chr11:31845332	G/T	cg11990419	chr11:31841155	NA	0.34	7.97	0.35	1.22e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs73086581	1.000	rs73084575	chr20:3906768	G/T	cg02187196	chr20:3869020	PANK2	0.9	12.52	0.5	3.51e-31	Response to antidepressants in depression;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23221605	chr17:48171917	PDK2	0.41	7.26	0.32	1.66e-12	Obesity-related traits;
LGG	cis	rs9880211	0.752	rs9838884	chr3:136455704	C/T	cg21827317	chr3:136751795	NA	-0.48	-6.97	-0.31	1.13e-11	Body mass index;Height;
LGG	cis	rs4474465	0.850	rs11237537	chr11:78248397	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.66	-0.37	8e-17	Alzheimer's disease (survival time);
LGG	cis	rs741702	0.819	rs62108438	chr19:13000247	T/C	cg06417478	chr19:12876846	HOOK2	-0.4	-6.75	-0.3	4.37e-11	Red blood cell traits;
LGG	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08704250	chr15:31115839	NA	-0.41	-7.43	-0.33	5.13e-13	Huntington's disease progression;
LGG	cis	rs990171	1.000	rs6543134	chr2:103050458	T/G	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.33	-0.43	1.15e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs2016266	0.502	rs7398676	chr12:53630558	A/C	cg04065151	chr12:53682969	ESPL1	0.81	16.01	0.6	3.12e-46	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs1372356	0.780	rs11159839	chr14:88552409	A/G	cg18078958	chr14:88630771	NA	0.33	7.67	0.34	1.02e-13	Food antigen IgG levels;
LGG	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg17489451	chr12:28410104	CCDC91	-0.3	-6.93	-0.31	1.38e-11	Asthma;
LGG	trans	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	8.15e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.71	0.51	5.79e-32	Colorectal cancer;
LGG	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg21827317	chr3:136751795	NA	0.52	9.71	0.41	2.01e-20	Neuroticism;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.28	-0.4	6.47e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.75e-25	Prostate cancer;
LGG	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg08875078	chr22:50639485	SELO	-0.52	-7.63	-0.33	1.39e-13	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs1620921	0.505	rs1344730	chr6:161204995	G/A	cg01280913	chr6:161186852	NA	-0.53	-11.03	-0.46	2.83e-25	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg05623727	chr3:50126028	RBM5	-0.38	-8.26	-0.36	1.51e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.83	-0.3	2.73e-11	Multiple myeloma (IgH translocation);
LGG	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg20673091	chr1:2541236	MMEL1	0.76	17.18	0.62	1.53e-51	Multiple sclerosis;
LGG	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg24375607	chr4:120327624	NA	0.63	9.86	0.42	5.94e-21	Corneal astigmatism;
LGG	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.42e-21	HDL cholesterol;
LGG	cis	rs7615952	0.546	rs2979350	chr3:125362215	T/C	cg21696256	chr3:125484277	NA	-0.45	-6.99	-0.31	9.64e-12	Blood pressure (smoking interaction);
LGG	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	12.97	0.52	5.1e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.68	0.34	9.66e-14	Educational attainment;
LGG	cis	rs9815354	1.000	rs56121764	chr3:41883975	T/C	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9942416	0.660	rs194137	chr5:74978857	G/A	cg19683494	chr5:74908142	NA	-0.44	-6.84	-0.3	2.47e-11	Age-related disease endophenotypes;
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg18681998	chr4:17616180	MED28	0.85	18.9	0.66	1.81e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.16	0.58	1.9e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg02733842	chr7:1102375	C7orf50	-0.46	-7.03	-0.31	7.4e-12	Bronchopulmonary dysplasia;
LGG	cis	rs1062177	0.855	rs919263	chr5:151265853	A/G	cg00977110	chr5:151150581	G3BP1	0.42	6.72	0.3	5.37e-11	Preschool internalizing problems;
LGG	cis	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg21775007	chr8:11205619	TDH	-0.43	-6.7	-0.3	6.09e-11	Neuroticism;
LGG	cis	rs11650494	0.710	rs73987294	chr17:47474730	T/C	cg08112188	chr17:47440006	ZNF652	1.13	12.68	0.51	8.14e-32	Prostate cancer;
LGG	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg24253500	chr15:84953950	NA	0.59	10.91	0.45	8.37e-25	Schizophrenia;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg07332563	chr6:291687	DUSP22	-0.44	-7.45	-0.33	4.7e-13	Menopause (age at onset);
LGG	cis	rs9443645	0.901	rs1960542	chr6:79566643	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.56	-0.37	1.72e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12496657	chr2:105488809	NA	0.41	6.91	0.31	1.62e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2692947	0.644	rs1168976	chr2:96813480	G/A	cg22654517	chr2:96458247	NA	0.36	7.28	0.32	1.47e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs41271473	0.649	rs72751952	chr1:228901715	G/T	cg10167378	chr1:228756711	NA	0.5	6.99	0.31	9.64e-12	Chronic lymphocytic leukemia;
LGG	cis	rs9547996	0.765	rs9547977	chr13:38185811	G/C	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.65e-11	Diastolic blood pressure;
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg07440826	chr16:89882328	FANCA	-0.25	-6.75	-0.3	4.36e-11	Vitiligo;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18591973	chr12:50478751	SMARCD1	0.4	6.67	0.3	7.39e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg06219351	chr7:158114137	PTPRN2	0.7	13.77	0.54	2.04e-36	Calcium levels;
LGG	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg04672837	chr16:48644449	N4BP1	-0.52	-8.51	-0.37	2.51e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg03433033	chr1:76189801	ACADM	-0.64	-9.21	-0.39	1.11e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg21775007	chr8:11205619	TDH	0.53	8.83	0.38	2.1e-17	Neuroticism;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.92	-16.87	-0.62	3.94e-50	Platelet count;
LGG	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.26	-0.43	2.22e-22	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg11657817	chr20:23433608	CST11	0.44	8.97	0.38	7.37e-18	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg04691961	chr3:161091175	C3orf57	0.43	9.12	0.39	2.34e-18	Morning vs. evening chronotype;
LGG	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg24375607	chr4:120327624	NA	0.4	6.74	0.3	4.86e-11	Educational attainment;
LGG	cis	rs4253772	0.591	rs6007740	chr22:46654323	A/G	cg24881330	chr22:46731750	TRMU	-0.7	-8.76	-0.38	3.75e-17	LDL cholesterol;Cholesterol, total;
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg00405596	chr8:11794950	NA	-0.4	-6.95	-0.31	1.28e-11	Mood instability;
LGG	cis	rs400736	0.930	rs226249	chr1:8021778	A/G	cg25007680	chr1:8021821	PARK7	0.46	8.15	0.35	3.45e-15	Response to antidepressants and depression;
LGG	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.41	-0.33	6e-13	Restless legs syndrome;
LGG	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.24	-0.6	2.87e-47	Calcium levels;
LGG	cis	rs6032067	0.516	rs16989916	chr20:43899514	C/T	cg10761708	chr20:43804764	PI3	0.47	7.44	0.33	5.1e-13	Blood protein levels;
LGG	cis	rs2070488	1.000	rs2268753	chr3:38500189	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.23	0.65	2.28e-56	Electrocardiographic conduction measures;
LGG	cis	rs3862030	0.694	rs1984795	chr10:104226830	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.14e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs17253792	0.822	rs77761669	chr14:56034216	G/A	cg01858014	chr14:56050164	KTN1	-0.87	-11.22	-0.46	5.26e-26	Putamen volume;
LGG	cis	rs10979	1.000	rs9386038	chr6:143896358	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs1506636	0.539	rs17701547	chr7:123383461	A/G	cg03229431	chr7:123269106	ASB15	-0.61	-11.76	-0.48	4.22e-28	Plateletcrit;Platelet count;
LGG	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg24675658	chr1:53192096	ZYG11B	-0.61	-12.62	-0.51	1.39e-31	Monocyte count;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg13047869	chr3:10149882	C3orf24	0.54	9.31	0.4	5.26e-19	Alzheimer's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04099264	chr1:44435507	DPH2	0.36	6.75	0.3	4.57e-11	Obesity-related traits;
LGG	cis	rs427394	0.659	rs274693	chr5:6734162	G/A	cg15145174	chr5:6755386	POLS	-0.43	-8.02	-0.35	8.6e-15	Menopause (age at onset);
LGG	cis	rs8067545	0.611	rs1373146	chr17:20206675	G/A	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.42e-22	Schizophrenia;
LGG	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.87	13.81	0.54	1.47e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg07414643	chr4:187882934	NA	0.56	11.43	0.47	8.12e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs701145	0.585	rs1727945	chr3:153882865	G/A	cg12800244	chr3:153838788	SGEF	0.78	8.34	0.36	8.54e-16	Coronary artery disease;
LGG	cis	rs7444	0.882	rs5749495	chr22:21940310	A/G	cg05046821	chr22:21984468	YDJC	-0.39	-7.1	-0.31	4.65e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	1.01e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg02227867	chr8:22457446	C8orf58	-0.38	-7.27	-0.32	1.5e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2470578	0.766	rs2060626	chr3:17339260	T/A	cg20981856	chr3:17787350	NA	0.36	6.87	0.3	2.11e-11	Schizophrenia;
LGG	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg02023728	chr11:77925099	USP35	-0.42	-7.52	-0.33	2.94e-13	Testicular germ cell tumor;
LGG	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg24825693	chr3:157122686	VEPH1	-0.34	-7.28	-0.32	1.4e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg17595323	chr11:93583763	C11orf90	-0.44	-7.87	-0.34	2.46e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.51	0.5	4.04e-31	Coronary artery disease;
LGG	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg03929089	chr4:120376271	NA	0.82	8.62	0.37	1.05e-16	Myopia (pathological);
LGG	cis	rs72827839	0.793	rs72825512	chr17:46155069	C/T	cg02219949	chr17:45927392	SP6	0.54	8.06	0.35	6.51e-15	Ease of getting up in the morning;
LGG	cis	rs9911578	1.000	rs8076121	chr17:57041699	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03330867	chr16:1543988	TELO2	0.43	7.12	0.31	4.18e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs240764	0.658	rs705584	chr6:101261553	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.56	0.33	2.12e-13	Neuroticism;
LGG	trans	rs1032833	0.732	rs112452546	chr2:179958681	T/A	cg23654767	chr2:101192981	PDCL3	0.72	8.68	0.37	6.76e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15557168	chr22:42548783	NA	-0.33	-7.52	-0.33	2.88e-13	Cognitive function;
LGG	cis	rs9715521	0.677	rs17493148	chr4:59861895	T/C	cg11281224	chr4:60001000	NA	-0.56	-9.97	-0.42	2.38e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg02725872	chr8:58115012	NA	-0.94	-12.99	-0.52	3.94e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6087990	0.735	rs2889703	chr20:31379184	C/A	cg13636640	chr20:31349939	DNMT3B	0.79	16.01	0.6	3.14e-46	Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg07930552	chr6:133119739	C6orf192	0.87	11.51	0.47	3.87e-27	Type 2 diabetes nephropathy;
LGG	trans	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.15	-0.32	3.37e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11716531	0.574	rs62256311	chr3:27271505	G/A	cg02860705	chr3:27208620	NA	0.82	14.96	0.57	1.43e-41	Diastolic blood pressure;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.86	-0.42	6.09e-21	Platelet count;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09709060	chr11:95522957	CEP57;FAM76B	0.42	7.14	0.31	3.71e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg16325326	chr1:53192061	ZYG11B	-0.76	-18.31	-0.65	9.77e-57	Monocyte count;
LGG	cis	rs7928758	0.945	rs56330625	chr11:134280067	G/A	cg15243474	chr11:134282918	B3GAT1	1.06	13.7	0.54	4.38e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.22e-29	Aortic root size;
LGG	cis	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg13010199	chr12:38710504	ALG10B	0.69	14.07	0.55	1.07e-37	Bladder cancer;
LGG	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.13	-0.35	4.09e-15	Triglycerides;
LGG	cis	rs12765878	1.000	rs12765878	chr10:105669622	C/T	cg11005552	chr10:105648138	OBFC1	-1.03	-27.28	-0.79	2.17e-98	Coronary artery disease;
LGG	cis	rs4589502	1.000	rs4589502	chr15:67155069	C/T	cg09911534	chr15:67153556	NA	-0.6	-7.57	-0.33	2.09e-13	Lung cancer (smoking interaction);
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	13.84	0.54	1.06e-36	Obesity-related traits;
LGG	cis	rs7635838	0.826	rs9867963	chr3:11469126	C/T	cg00170343	chr3:11313890	ATG7	0.43	6.96	0.31	1.18e-11	HDL cholesterol;
LGG	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg06885757	chr1:42089581	HIVEP3	-0.49	-11.01	-0.46	3.45e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.76	-0.48	4.11e-28	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9640161	0.711	rs10259796	chr7:150050427	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.63	-11.57	-0.47	2.32e-27	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg02030672	chr11:45687055	CHST1	0.56	10.14	0.43	6.01e-22	Obesity-related traits;
LGG	cis	rs2463822	0.844	rs72923263	chr11:62161170	C/G	cg06239285	chr11:62104954	ASRGL1	-1.15	-15.08	-0.57	4.48e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6964587	1.000	rs2237568	chr7:91622676	G/A	cg17063962	chr7:91808500	NA	0.48	8.57	0.37	1.6e-16	Breast cancer;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs894344	0.650	rs66669000	chr8:135582895	A/G	cg09855544	chr8:135498122	ZFAT	0.42	7.56	0.33	2.12e-13	Systolic blood pressure;
LGG	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17376030	chr22:41985996	PMM1	0.58	9.16	0.39	1.64e-18	Vitiligo;
LGG	trans	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg21659725	chr3:3221576	CRBN	-0.44	-7.29	-0.32	1.33e-12	Menarche (age at onset);
LGG	cis	rs12738007	0.901	rs61783694	chr1:29510934	C/T	cg01115565	chr1:29584222	PTPRU	-0.27	-7.26	-0.32	1.66e-12	Schizophrenia;
LGG	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	6.99e-21	Common traits (Other);
LGG	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg00531865	chr16:30841666	NA	-0.49	-9.82	-0.42	8.74e-21	Dementia with Lewy bodies;
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.52	-0.37	2.26e-16	Triglycerides;
LGG	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.99	0.35	1.07e-14	Mean platelet volume;
LGG	cis	rs1707322	1.000	rs785493	chr1:46584859	A/G	cg03146154	chr1:46216737	IPP	-0.54	-9.41	-0.4	2.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2249694	0.960	rs11101890	chr10:135421321	G/A	cg20169779	chr10:135381914	SYCE1	-0.51	-7.88	-0.34	2.4e-14	Obesity-related traits;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg13990905	chr1:179846837	TOR1AIP2	0.5	8.05	0.35	6.95e-15	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg23978390	chr7:1156363	C7orf50	0.49	7.74	0.34	6.33e-14	Bronchopulmonary dysplasia;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs9790314	0.902	rs9863590	chr3:161116445	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-13.17	-0.52	7.45e-34	Morning vs. evening chronotype;
LGG	trans	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6032067	0.602	rs2741523	chr20:43920446	C/T	cg10761708	chr20:43804764	PI3	0.56	8.54	0.37	1.96e-16	Blood protein levels;
LGG	cis	rs2717559	0.522	rs2572922	chr8:143871652	G/A	cg07661805	chr8:143867942	LY6D	0.3	8.06	0.35	6.77e-15	Urinary tract infection frequency;
LGG	cis	rs9894429	0.646	rs12948797	chr17:79617384	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	10.2	0.43	3.43e-22	Eye color traits;
LGG	cis	rs6840360	0.550	rs6836343	chr4:152497564	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs1938065	chr6:66608617	A/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.27e-11	Metabolite levels;
LGG	cis	rs2302729	0.929	rs7306298	chr12:2777311	G/A	cg19945202	chr12:2788847	CACNA1C	-0.78	-11.94	-0.49	8.15e-29	Sleep quality;
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg16141378	chr3:129829833	LOC729375	0.42	9.42	0.4	2.24e-19	Neuroticism;
LGG	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg03315344	chr16:75512273	CHST6	0.52	10.45	0.44	4.26e-23	Dupuytren's disease;
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.52e-12	Menopause (age at onset);
LGG	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Vitiligo;
LGG	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg17971929	chr21:40555470	PSMG1	-0.69	-13.0	-0.52	3.68e-33	Cognitive function;
LGG	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.5	-0.5	4.19e-31	Chronic sinus infection;
LGG	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.44e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.65	-12.98	-0.52	4.37e-33	Prudent dietary pattern;
LGG	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg01221209	chr5:554886	NA	-0.45	-6.72	-0.3	5.51e-11	Obesity-related traits;
LGG	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs45544231	0.544	rs4783780	chr16:52571436	G/T	cg09051775	chr16:52580266	TOX3	0.42	7.24	0.32	1.82e-12	Restless legs syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06941879	chr19:45971137	FOSB	0.5	7.5	0.33	3.21e-13	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20295040	chr1:192778396	RGS2	0.45	7.08	0.31	5.5e-12	Cognitive performance;
LGG	cis	rs9596863	0.749	rs11148280	chr13:54309804	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	6.95	0.31	1.26e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2153535	0.935	rs11243254	chr6:8381242	C/T	cg07606381	chr6:8435919	SLC35B3	-0.43	-7.42	-0.33	5.6e-13	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03169527	chr3:11888582	C3orf31	0.43	7.38	0.32	7.59e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg03806693	chr22:41940476	POLR3H	-1.14	-21.55	-0.71	7.83e-72	Vitiligo;
LGG	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.24	-0.46	4.32e-26	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21092834	chr11:107462721	LOC643923;ELMOD1	0.44	7.17	0.32	2.9e-12	Cognitive performance;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg23958373	chr8:599963	NA	0.98	9.91	0.42	4.14e-21	IgG glycosylation;
LGG	cis	rs7432375	1.000	rs940174	chr3:136309710	T/C	cg12473912	chr3:136751656	NA	0.4	6.82	0.3	2.86e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.29	-0.32	1.36e-12	Life satisfaction;
LGG	cis	rs17767392	0.918	rs12894016	chr14:71883088	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.1	-0.35	4.94e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg03474202	chr17:45855739	NA	-0.27	-8.0	-0.35	9.89e-15	IgG glycosylation;
LGG	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg03929089	chr4:120376271	NA	-0.88	-14.29	-0.55	1.19e-38	Height;
LGG	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-7.86	-0.34	2.63e-14	Self-reported allergy;
LGG	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg04743876	chr7:130013617	NA	0.38	8.61	0.37	1.12e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg22437258	chr11:111473054	SIK2	-0.52	-8.87	-0.38	1.62e-17	Primary sclerosing cholangitis;
LGG	cis	rs7216064	1.000	rs12451511	chr17:65874861	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg03160526	chr17:80928410	B3GNTL1	0.5	7.97	0.35	1.24e-14	Glycated hemoglobin levels;
LGG	cis	rs778371	0.874	rs938575	chr2:233768788	G/A	cg08000102	chr2:233561755	GIGYF2	-0.58	-8.56	-0.37	1.65e-16	Schizophrenia;
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs12545109	0.800	rs990301	chr8:57406021	G/C	cg19413350	chr8:57351067	NA	-0.43	-6.92	-0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg04861929	chr11:109293070	C11orf87	0.55	10.09	0.42	9.03e-22	Schizophrenia;
LGG	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg11752832	chr7:134001865	SLC35B4	0.6	10.76	0.45	2.98e-24	Mean platelet volume;
LGG	trans	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg06521331	chr12:34319734	NA	-0.47	-8.36	-0.36	7.25e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg16070123	chr10:51489643	NA	-0.4	-7.23	-0.32	2.03e-12	Prostate-specific antigen levels;
LGG	cis	rs3540	1.000	rs7173724	chr15:91036855	A/G	cg22089800	chr15:90895588	ZNF774	0.52	8.39	0.36	5.89e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.91	-0.35	1.92e-14	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.02	0.46	3.18e-25	Personality dimensions;
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg15105011	chr4:940614	TMEM175	0.42	8.07	0.35	6.07e-15	Sjögren's syndrome;
LGG	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.68e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs13260300	0.745	rs11995479	chr8:75478740	C/G	cg22993706	chr8:75542856	NA	-0.37	-7.79	-0.34	4.54e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.04	0.35	7.54e-15	Bipolar disorder;
LGG	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg23461800	chr14:103021989	NA	-0.57	-8.93	-0.38	1.04e-17	Platelet count;
LGG	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg16586182	chr3:47516702	SCAP	0.73	12.76	0.51	3.57e-32	Colorectal cancer;
LGG	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.52	-10.37	-0.43	8.73e-23	DNA methylation (variation);
LGG	cis	rs6732160	0.624	rs10865397	chr2:73358292	C/T	cg01422370	chr2:73384389	NA	0.43	8.15	0.35	3.34e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.33	0.4	4.53e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs36051895	0.632	rs117896567	chr9:5141281	C/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.33	-0.55	7.94e-39	Pediatric autoimmune diseases;
LGG	cis	rs8180040	0.701	rs7617689	chr3:46996442	C/T	cg16586182	chr3:47516702	SCAP	0.75	14.04	0.55	1.42e-37	Colorectal cancer;
LGG	cis	rs6840360	0.642	rs2724574	chr4:152381800	A/T	cg17217059	chr4:152329364	FAM160A1	-0.2	-7.13	-0.31	3.89e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.45	-0.44	4.33e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs11711311	1.000	rs12631232	chr3:113497386	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.07	0.55	1.13e-37	IgG glycosylation;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20887711	chr4:1340912	KIAA1530	0.56	10.8	0.45	2.1e-24	Longevity;
LGG	cis	rs7503807	0.688	rs12942347	chr17:78587942	C/T	cg06872548	chr17:78716983	RPTOR	0.39	8.48	0.37	3.11e-16	Obesity;
LGG	cis	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg03469862	chr11:68924853	NA	0.44	6.66	0.3	7.64e-11	Blond vs. brown hair color;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg20578329	chr17:80767326	TBCD	-0.4	-7.38	-0.32	7.48e-13	Glycated hemoglobin levels;
LGG	cis	rs4321325	0.733	rs78593261	chr2:127947044	G/A	cg11380483	chr2:127933992	NA	0.64	8.74	0.38	4.35e-17	Protein C levels;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg05234568	chr11:5960015	NA	-0.68	-12.18	-0.49	8.6e-30	DNA methylation (variation);
LGG	cis	rs10214930	0.697	rs6462025	chr7:27562341	A/C	cg22168087	chr7:27702803	HIBADH	0.45	6.7	0.3	6.14e-11	Hypospadias;
LGG	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.69	-9.47	-0.4	1.48e-19	Diabetic retinopathy;
LGG	cis	rs12210905	1.000	rs72838266	chr6:27015052	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6835098	0.923	rs9997477	chr4:174112543	C/T	cg08422745	chr4:174089978	GALNT7	-0.85	-15.02	-0.57	7.84e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg11494091	chr17:61959527	GH2	-0.99	-24.68	-0.75	1.81e-86	Prudent dietary pattern;
LGG	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	6.86	0.3	2.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs6909430	1.000	rs7770988	chr6:98737183	C/T	cg12860156	chr6:98744658	NA	-0.48	-8.15	-0.35	3.54e-15	Quantitative traits;
LGG	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg09173681	chr1:183549694	NCF2	0.35	7.85	0.34	3e-14	Systemic lupus erythematosus;
LGG	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.23e-15	Monocyte count;
LGG	cis	rs2869548	1	rs2869548	chr15:78922638	G/A	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.48	-0.33	3.77e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00636124	chr16:27215281	JMJD5	0.43	7.03	0.31	7.56e-12	Cognitive performance;
LGG	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg09021430	chr5:549028	NA	-0.69	-9.63	-0.41	4.05e-20	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg25019033	chr10:957182	NA	-0.55	-10.17	-0.43	4.47e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg06532163	chr17:45867833	NA	0.52	8.15	0.35	3.37e-15	IgG glycosylation;
LGG	cis	rs7917772	0.536	rs3961456	chr10:104425304	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.67	-12.32	-0.5	2.2e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg02002194	chr4:3960332	NA	-0.39	-7.15	-0.32	3.3e-12	Morning vs. evening chronotype;
LGG	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs7635838	0.596	rs13353463	chr3:11260221	T/C	cg00170343	chr3:11313890	ATG7	0.43	7.39	0.32	6.88e-13	HDL cholesterol;
LGG	cis	rs7119038	0.509	rs10892256	chr11:118578705	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.95	0.31	1.23e-11	Sjögren's syndrome;
LGG	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg22676075	chr6:135203613	NA	0.36	6.66	0.3	7.71e-11	Red blood cell count;
LGG	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg00745463	chr17:30367425	LRRC37B	0.53	7.13	0.31	3.99e-12	Hip circumference adjusted for BMI;
LGG	cis	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs9354308	0.753	rs1938103	chr6:66600308	A/T	cg07460842	chr6:66804631	NA	0.43	7.15	0.32	3.35e-12	Metabolite levels;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	8.02e-17	Menopause (age at onset);
LGG	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.44	0.44	4.57e-23	Blood protein levels;
LGG	cis	rs1018836	0.847	rs4735226	chr8:91569238	T/A	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	5.12e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs35110281	0.774	rs1003280	chr21:44997322	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.95	0.42	2.78e-21	Mean corpuscular volume;
LGG	trans	rs1941687	0.797	rs12967889	chr18:31399371	G/A	cg27147174	chr7:100797783	AP1S1	-0.54	-9.03	-0.39	4.68e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.27	0.55	1.47e-38	Platelet count;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.84	0.42	7.17e-21	Prudent dietary pattern;
LGG	cis	rs8170	0.603	rs8109328	chr19:17417955	C/T	cg04749549	chr19:17459798	NA	-0.37	-6.85	-0.3	2.35e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg20302533	chr7:39170763	POU6F2	0.5	11.52	0.47	3.69e-27	IgG glycosylation;
LGG	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.18	-0.32	2.88e-12	Neuroticism;
LGG	cis	rs72781680	0.848	rs2339926	chr2:24045734	C/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.71e-18	Lymphocyte counts;
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg13770153	chr20:60521292	NA	-1.13	-21.21	-0.7	2.91e-70	Obesity-related traits;
LGG	trans	rs7178375	1.000	rs4779797	chr15:31208425	C/T	cg04373760	chr16:53404718	NA	-0.5	-7.74	-0.34	6.1e-14	Hypertriglyceridemia;
LGG	cis	rs368123	1.000	rs410569	chr6:160735746	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.32	-0.32	1.07e-12	Waist circumference;
LGG	cis	rs2916247	0.954	rs991871	chr8:93164505	T/A	cg10183463	chr8:93005414	RUNX1T1	0.35	7.07	0.31	5.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.05	0.83	1.37e-119	Prudent dietary pattern;
LGG	cis	rs6499255	1.000	rs4464069	chr16:69816284	C/T	cg00738113	chr16:70207722	CLEC18C	-0.3	-6.67	-0.3	7.53e-11	IgE levels;
LGG	cis	rs13314892	0.840	rs62250976	chr3:69835405	T/G	cg17445875	chr3:69859618	MITF	-0.37	-7.48	-0.33	3.74e-13	QRS complex (12-leadsum);
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg05552183	chr6:42928497	GNMT	0.44	12.8	0.51	2.57e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3741151	0.773	rs7925226	chr11:73137362	A/G	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7264396	0.623	rs6060507	chr20:34198334	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.14	0.31	3.61e-12	Total cholesterol levels;
LGG	cis	rs12478296	1.000	rs56387669	chr2:243043889	T/C	cg18898632	chr2:242989856	NA	-0.8	-9.95	-0.42	2.8e-21	Obesity-related traits;
LGG	cis	rs16957091	0.909	rs16957104	chr15:43021628	C/T	cg07484255	chr15:43025164	CDAN1	-0.51	-7.33	-0.32	1.01e-12	MGMT methylation in smokers;
LGG	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg20026190	chr17:76395443	PGS1	0.58	10.13	0.43	6.36e-22	HDL cholesterol levels;
LGG	cis	rs2540226	0.539	rs10170462	chr2:39911538	A/G	cg02886589	chr2:39892450	TMEM178	0.29	8.17	0.36	2.92e-15	Personality dimensions;
LGG	cis	rs939658	0.805	rs11634679	chr15:79432475	T/C	cg17916960	chr15:79447300	NA	-0.67	-13.22	-0.52	4.43e-34	Refractive error;
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.58	0.33	1.84e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	10.41	0.44	6.07e-23	Hypertriglyceridemia;
LGG	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.12e-14	IgG glycosylation;
LGG	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg17644776	chr2:200775616	C2orf69	0.54	8.69	0.37	6.36e-17	Osteoporosis;
LGG	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.24	-0.36	1.81e-15	Total body bone mineral density (age 0-15);
LGG	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.04	0.31	7.13e-12	Educational attainment;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg02048412	chr16:4421654	VASN;CORO7	0.28	6.93	0.31	1.4e-11	Schizophrenia;
LGG	cis	rs12431410	0.584	rs12893956	chr14:60244447	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.2	0.32	2.5e-12	Schizophrenia;
LGG	trans	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg01620082	chr3:125678407	NA	-0.59	-6.77	-0.3	3.94e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8056893	0.634	rs4783610	chr16:68310457	G/C	cg07273125	chr16:68295692	NA	0.4	8.37	0.36	6.84e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-11.06	-0.46	2.13e-25	HDL cholesterol;
LGG	cis	rs7100689	0.555	rs1934146	chr10:82062121	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	14.5	0.56	1.55e-39	Post bronchodilator FEV1;
LGG	cis	rs11074306	0.561	rs62003764	chr15:28071911	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.34	0.32	9.64e-13	Uveal melanoma;
LGG	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.65e-22	Motion sickness;
LGG	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.84	-18.13	-0.64	6.42e-56	Multiple sclerosis;
LGG	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	8.99	0.39	6.29e-18	Mood instability;
LGG	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.59	-0.33	1.76e-13	Response to antipsychotic treatment;
LGG	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg26818257	chr2:241905806	NA	0.5	11.55	0.47	2.78e-27	Joint mobility (Beighton score);
LGG	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg25174290	chr11:3078921	CARS	0.68	13.74	0.54	2.77e-36	Longevity;
LGG	cis	rs66716358	0.744	rs10769036	chr11:44321508	C/A	cg16977035	chr11:44330474	ALX4	0.37	9.63	0.41	3.97e-20	Monobrow;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg15490075	chr13:100150979	NA	-0.68	-7.07	-0.31	5.58e-12	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07661836	chr12:53688940	PFDN5	0.5	7.83	0.34	3.31e-14	Gut microbiome composition (summer);
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.89	0.31	1.81e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg05090351	chr10:126851162	NA	0.33	8.23	0.36	1.89e-15	Menarche (age at onset);
LGG	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.71	0.3	5.59e-11	Cognitive function;
LGG	cis	rs60180747	0.818	rs2414902	chr15:66636518	C/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.53	8.9	0.38	1.26e-17	Testicular germ cell tumor;
LGG	cis	rs7481584	0.581	rs420127	chr11:3077990	C/T	cg08508325	chr11:3079039	CARS	0.42	8.17	0.35	2.98e-15	Calcium levels;
LGG	cis	rs877282	0.891	rs10904557	chr10:797490	C/T	cg17470449	chr10:769945	NA	-0.61	-7.76	-0.34	5.3e-14	Uric acid levels;
LGG	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg05973401	chr12:123451056	ABCB9	-0.5	-8.31	-0.36	1.03e-15	Platelet count;
LGG	cis	rs4330281	0.692	rs6577644	chr3:17766733	A/G	cg20981856	chr3:17787350	NA	-0.41	-7.69	-0.34	8.98e-14	Schizophrenia;
LGG	cis	rs6456042	1.000	rs3099355	chr6:166534826	T/C	cg11088901	chr6:166572345	T	-0.35	-7.31	-0.32	1.15e-12	Asthma;
LGG	cis	rs7555523	0.887	rs6696454	chr1:165707923	T/C	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs2011503	1.000	rs1560687	chr19:19562902	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs11096990	0.634	rs2086752	chr4:39282106	A/G	cg24403649	chr4:39172243	NA	-0.4	-7.17	-0.32	3.03e-12	Cognitive function;
LGG	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.0	-0.46	3.73e-25	Bipolar disorder;
LGG	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg07541023	chr7:19748670	TWISTNB	0.59	8.57	0.37	1.5e-16	Thyroid stimulating hormone;
LGG	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.24	0.36	1.85e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.24	0.32	1.86e-12	Neuroticism;
LGG	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg16586182	chr3:47516702	SCAP	-0.57	-9.7	-0.41	2.31e-20	Birth weight;
LGG	cis	rs2708240	0.617	rs2710107	chr7:147593314	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-7.86	-0.34	2.8e-14	QT interval (drug interaction);
LGG	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.07	-0.35	6e-15	Aortic root size;
LGG	trans	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.72	-0.38	5.13e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09805055	chr2:208634004	FZD5	0.4	6.83	0.3	2.65e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7666738	0.830	rs10009943	chr4:99021475	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs61990749	0.597	rs6574391	chr14:78208121	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.02	0.31	7.73e-12	Fibroblast growth factor basic levels;
LGG	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg08997352	chr12:9597637	DDX12	-0.67	-12.8	-0.51	2.57e-32	Breast size;
LGG	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg11502198	chr6:26597334	ABT1	0.54	9.35	0.4	3.64e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.29	0.43	1.62e-22	Longevity;
LGG	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs4926611	0.736	rs11206186	chr1:54117985	G/T	cg23596471	chr1:54105337	GLIS1	0.31	6.64	0.3	8.56e-11	Hand grip strength;
LGG	cis	rs9513627	0.831	rs7319727	chr13:100125541	A/T	cg15490075	chr13:100150979	NA	-0.66	-6.92	-0.31	1.52e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08231274	chr14:57735852	MUDENG;EXOC5	0.47	6.83	0.3	2.67e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg16606324	chr3:10149918	C3orf24	0.6	6.87	0.3	2.07e-11	Alzheimer's disease;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.77e-14	Lung cancer;
LGG	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg20891283	chr12:69753455	YEATS4	0.71	12.93	0.52	7.31e-33	Response to diuretic therapy;
LGG	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.95	-0.38	8.69e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg07606381	chr6:8435919	SLC35B3	0.66	12.06	0.49	2.48e-29	Motion sickness;
LGG	cis	rs7106204	0.609	rs55751762	chr11:24296146	C/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.66	-0.44	7.18e-24	Primary sclerosing cholangitis;
LGG	trans	rs7777677	0.888	rs9655574	chr7:142370244	G/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs1669338	0.588	rs3931974	chr3:3186894	A/G	cg16797762	chr3:3221439	CRBN	0.94	12.46	0.5	6.23e-31	White matter integrity;
LGG	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg20578329	chr17:80767326	TBCD	-0.74	-11.49	-0.47	4.78e-27	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.76e-34	Prudent dietary pattern;
LGG	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg02487422	chr3:49467188	NICN1	0.57	10.55	0.44	1.88e-23	Resting heart rate;
LGG	cis	rs922692	0.710	rs1994016	chr15:79080234	C/T	cg00540400	chr15:79124168	NA	-0.38	-7.47	-0.33	4.11e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26549029	chr12:133286883	PGAM5	-0.46	-6.72	-0.3	5.41e-11	Systemic lupus erythematosus;
LGG	cis	rs2235649	0.833	rs9933168	chr16:1848361	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs2241941	0.840	rs11600101	chr11:20628072	T/G	cg18855426	chr11:20631935	SLC6A5	-0.44	-7.24	-0.32	1.89e-12	Obesity-related traits;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.596	rs1600737	chr7:124639547	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.69	-0.3	6.28e-11	Cutaneous malignant melanoma;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg09487611	chr12:5019311	KCNA1	0.38	6.71	0.3	5.79e-11	Body mass index;
LGG	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.74	0.3	4.69e-11	IgG glycosylation;
LGG	cis	rs8064024	0.538	rs12596053	chr16:4946794	A/C	cg04440724	chr16:4920505	UBN1	0.56	12.17	0.49	9.45e-30	Cancer;
LGG	cis	rs6704644	0.527	rs72980361	chr2:234359375	A/G	cg27060346	chr2:234359958	DGKD	-0.6	-7.07	-0.31	5.76e-12	Bilirubin levels;
LGG	cis	rs6772849	0.931	rs60825080	chr3:128384834	G/T	cg08795948	chr3:128337044	NA	0.65	10.87	0.45	1.11e-24	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4664308	1.000	rs62175515	chr2:160909524	A/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs2594989	0.832	rs13325556	chr3:11566961	T/G	cg01796438	chr3:11312864	ATG7	0.54	7.38	0.32	7.41e-13	Circulating chemerin levels;
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.16e-12	Bipolar disorder;
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg05484376	chr2:27715224	FNDC4	0.46	9.9	0.42	4.26e-21	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15688767	chr3:125093330	ZNF148	0.47	7.38	0.32	7.63e-13	Gut microbiome composition (summer);
LGG	cis	rs2643217	0.953	rs2624262	chr15:38999331	G/C	cg10631289	chr15:39006617	NA	-0.43	-7.34	-0.32	9.81e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg10189774	chr4:17578691	LAP3	0.41	6.97	0.31	1.13e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6964587	0.732	rs12539523	chr7:91710836	G/A	cg17063962	chr7:91808500	NA	0.49	8.56	0.37	1.63e-16	Breast cancer;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	trans	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg02002194	chr4:3960332	NA	0.49	9.07	0.39	3.45e-18	Mood instability;
LGG	cis	rs9443645	0.869	rs9443621	chr6:79576499	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.71	-0.38	5.4e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.48	-0.4	1.33e-19	Cotinine glucuronidation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12092708	chr1:19229145	ALDH4A1	0.4	6.68	0.3	6.96e-11	Gut microbiome composition (summer);
LGG	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg06453172	chr10:134556979	INPP5A	-0.58	-8.65	-0.37	8.54e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9517320	0.633	rs35368417	chr13:99121347	T/C	cg07423050	chr13:99094983	FARP1	0.35	7.08	0.31	5.51e-12	Longevity;
LGG	cis	rs7737355	0.812	rs11242084	chr5:130935777	T/C	cg06307176	chr5:131281290	NA	0.53	8.77	0.38	3.48e-17	Life satisfaction;
LGG	cis	rs4363385	0.818	rs9659389	chr1:152989844	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.94	-0.38	9.64e-18	Inflammatory skin disease;
LGG	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19748678	chr4:122722346	EXOSC9	-0.54	-9.76	-0.41	1.34e-20	Type 2 diabetes;
LGG	cis	rs10214930	0.697	rs1014373	chr7:27571093	G/A	cg22168087	chr7:27702803	HIBADH	0.46	7.0	0.31	8.99e-12	Hypospadias;
LGG	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs41271473	0.898	rs17352535	chr1:228822284	C/G	cg00850481	chr1:228891306	NA	-0.49	-7.99	-0.35	1.05e-14	Chronic lymphocytic leukemia;
LGG	cis	rs9287719	0.967	rs11674433	chr2:10730839	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg24829409	chr8:58192753	C8orf71	-0.58	-7.91	-0.35	1.84e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg08461772	chr7:95026248	PON3	0.36	7.63	0.33	1.39e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.35	-0.32	9.23e-13	Menopause (age at onset);
LGG	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg21479132	chr6:26055353	NA	0.81	8.15	0.35	3.34e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17767392	0.767	rs61989382	chr14:71983638	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.7	-0.37	6e-17	Mitral valve prolapse;
LGG	cis	rs12765878	0.565	rs11191818	chr10:105591779	A/C	cg11005552	chr10:105648138	OBFC1	0.63	11.88	0.48	1.33e-28	Coronary artery disease;
LGG	cis	rs42648	0.905	rs42641	chr7:89972764	T/C	cg25739043	chr7:89950458	NA	-0.42	-8.97	-0.38	7.37e-18	Homocysteine levels;
LGG	cis	rs2531992	0.800	rs1045476	chr16:4015313	A/G	cg05927578	chr16:4029543	ADCY9	0.68	10.44	0.44	4.55e-23	Waist circumference;
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.01	0.42	1.75e-21	Height;
LGG	cis	rs4262150	0.689	rs4958566	chr5:152014061	C/T	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	12.2	0.49	7.26e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg10523679	chr1:76189770	ACADM	0.71	11.06	0.46	2.09e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg19468946	chr17:37922297	IKZF3	-0.43	-7.73	-0.34	6.88e-14	Self-reported allergy;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg24829409	chr8:58192753	C8orf71	-0.68	-9.32	-0.4	4.63e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg04025307	chr7:1156635	C7orf50	0.66	8.5	0.37	2.58e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs9359856	0.510	rs6454775	chr6:90465000	A/T	cg13799429	chr6:90582589	CASP8AP2	0.86	13.54	0.53	2.04e-35	Bipolar disorder;
LGG	cis	rs9341835	0.772	rs9294197	chr6:64135648	A/G	cg00787780	chr6:64151745	NA	0.4	7.35	0.32	9.28e-13	Schizophrenia;
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg19901468	chr14:105411992	AHNAK2	0.88	18.14	0.64	5.99e-56	Rheumatoid arthritis;
LGG	cis	rs3206736	0.521	rs6948899	chr7:35232802	G/A	cg13400248	chr7:35225412	NA	0.45	7.86	0.34	2.69e-14	Diastolic blood pressure;
LGG	cis	rs72781680	0.898	rs72796154	chr2:23933839	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	9.15	0.39	1.84e-18	Lymphocyte counts;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.77	0.41	1.3e-20	Schizophrenia;
LGG	cis	rs7928758	0.943	rs11826381	chr11:134273304	A/G	cg22777979	chr11:134283252	B3GAT1	0.83	11.7	0.48	7.26e-28	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Myopia (pathological);
LGG	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg14228332	chr4:119757509	SEC24D	0.67	7.31	0.32	1.22e-12	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05665937	chr4:1216051	CTBP1	-0.51	-9.19	-0.39	1.35e-18	Obesity-related traits;
LGG	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg03060546	chr3:49711283	APEH	0.61	9.33	0.4	4.4e-19	Resting heart rate;
LGG	cis	rs16912285	0.688	rs12284649	chr11:24316260	T/A	ch.11.24196551F	chr11:24239977	NA	0.88	12.73	0.51	4.84e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg10483660	chr13:112241077	NA	-0.36	-7.82	-0.34	3.54e-14	Hepatitis;
LGG	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2070677	0.935	rs11812637	chr10:135413418	A/G	cg20169779	chr10:135381914	SYCE1	-0.98	-12.85	-0.51	1.58e-32	Gout;
LGG	cis	rs7236492	0.872	rs74569193	chr18:77232698	C/T	cg15644404	chr18:77186268	NFATC1	-0.79	-9.62	-0.41	4.14e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7666738	0.830	rs116103936	chr4:98954531	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9976767	0.932	rs7283281	chr21:43825519	C/G	cg23042151	chr21:43824109	UBASH3A	-0.48	-10.04	-0.42	1.38e-21	Type 1 diabetes;
LGG	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.53	-0.33	2.76e-13	Bone mineral density;
LGG	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg13647721	chr17:30228624	UTP6	-0.71	-8.03	-0.35	8.34e-15	Hip circumference adjusted for BMI;
LGG	cis	rs13082711	0.911	rs13097178	chr3:27527920	T/C	cg02860705	chr3:27208620	NA	0.72	12.69	0.51	6.8e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7914558	0.966	rs7908280	chr10:104816947	C/G	cg04362960	chr10:104952993	NT5C2	0.56	10.78	0.45	2.51e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg14092988	chr3:52407081	DNAH1	0.3	7.85	0.34	2.92e-14	Bipolar disorder;
LGG	cis	rs17030434	1.000	rs952211	chr4:154717816	A/G	cg14289246	chr4:154710475	SFRP2	-0.62	-8.6	-0.37	1.26e-16	Electrocardiographic conduction measures;
LGG	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs946099	chr1:152971618	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.12	-0.39	2.26e-18	Inflammatory skin disease;
LGG	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg00864171	chr11:67383662	NA	-0.42	-7.04	-0.31	6.98e-12	Mean corpuscular volume;
LGG	cis	rs10991814	1.000	rs76260934	chr9:93969276	G/C	cg14446406	chr9:93919335	NA	-0.75	-8.29	-0.36	1.25e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg03162506	chr22:38580953	NA	0.41	10.71	0.45	4.79e-24	Cutaneous nevi;
LGG	cis	rs2342371	0.641	rs4916427	chr3:196094213	C/T	cg15048948	chr3:196158458	UBXN7	0.62	10.56	0.44	1.69e-23	Fat distribution (HIV);
LGG	cis	rs7166081	1.000	rs34221449	chr15:67644263	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.85	-0.3	2.39e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.32	-0.63	3.4e-52	Refractive error;
LGG	cis	rs2303319	0.901	rs62188141	chr2:162273891	G/A	cg13806767	chr2:162164127	PSMD14	-0.67	-7.72	-0.34	7.07e-14	Cognitive function;
LGG	cis	rs774359	0.753	rs7036117	chr9:27507836	C/T	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.29	-0.36	1.24e-15	Amyotrophic lateral sclerosis;
LGG	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	8.94	0.38	9.46e-18	Retinal vascular caliber;
LGG	cis	rs6121246	0.559	rs12479491	chr20:30265450	T/C	cg13852791	chr20:30311386	BCL2L1	0.93	18.46	0.65	2.05e-57	Mean corpuscular hemoglobin;
LGG	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs757081	0.671	rs214090	chr11:17297161	C/T	cg15432903	chr11:17409602	KCNJ11	-0.55	-8.33	-0.36	8.9e-16	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.93	-0.31	1.44e-11	Menopause (age at onset);
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg12990844	chr2:170655321	SSB	-0.5	-6.88	-0.3	1.96e-11	Educational attainment (years of education);
LGG	cis	rs8077889	0.917	rs28694735	chr17:41912144	A/G	cg26893861	chr17:41843967	DUSP3	0.91	15.57	0.59	2.95e-44	Triglycerides;
LGG	cis	rs17001868	0.568	rs12484697	chr22:40736472	A/G	cg07138101	chr22:40742427	ADSL	-0.67	-8.8	-0.38	2.8e-17	Mammographic density (dense area);
LGG	cis	rs4750440	0.614	rs7921866	chr10:14030161	C/T	cg00551146	chr10:14014579	FRMD4A	0.3	7.13	0.31	3.9e-12	Adiponectin levels;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg04450456	chr4:17643702	FAM184B	0.33	7.15	0.32	3.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6547631	0.594	rs7585576	chr2:85937785	G/A	cg24620635	chr2:85921963	GNLY	0.49	9.48	0.4	1.33e-19	Blood protein levels;
LGG	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg01324343	chr3:183735012	ABCC5	0.86	18.23	0.65	2.2e-56	Anterior chamber depth;
LGG	cis	rs2916247	0.954	rs66579130	chr8:93054332	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62238980	0.614	rs76348022	chr22:32412186	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	trans	rs9650657	0.655	rs1991651	chr8:10706411	C/G	cg06636001	chr8:8085503	FLJ10661	0.46	8.02	0.35	8.79e-15	Neuroticism;
LGG	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25517755	chr10:38738941	LOC399744	-0.38	-6.87	-0.3	2.03e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2820315	0.867	rs2820323	chr1:201883160	G/A	cg10061532	chr1:201886748	LMOD1	0.34	7.28	0.32	1.44e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs12220238	0.908	rs4746179	chr10:75940169	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.51	0.47	3.95e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg05025164	chr4:1340916	KIAA1530	0.56	10.34	0.43	1.13e-22	Longevity;
LGG	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg27411982	chr8:10470053	RP1L1	0.42	7.14	0.31	3.55e-12	Mood instability;
LGG	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg16400903	chr5:693638	TPPP	0.46	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg26003909	chr8:143102224	NA	-0.4	-8.68	-0.37	6.67e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg23202291	chr11:1979235	NA	0.51	10.7	0.45	4.9299999999999996e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2594989	0.943	rs4580536	chr3:11422319	A/G	cg01796438	chr3:11312864	ATG7	-0.51	-7.0	-0.31	9.09e-12	Circulating chemerin levels;
LGG	cis	rs9815354	0.812	rs73073234	chr3:42012071	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.2	0.39	1.18e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.8	-0.51	2.49e-32	Total body bone mineral density;
LGG	cis	rs1049296	0.583	rs17376019	chr3:133540883	C/T	cg27366882	chr3:133540807	NA	-0.49	-7.73	-0.34	6.9e-14	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs6908034	0.607	rs74573060	chr6:19806032	T/A	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg09904177	chr6:26538194	HMGN4	0.79	18.14	0.64	6.05e-56	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.94	-0.38	9.63e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg03114573	chr12:45410052	DBX2	-0.52	-9.0	-0.39	5.85e-18	Gut microbiome composition (summer);
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg13607699	chr17:42295918	UBTF	0.54	9.03	0.39	4.69e-18	Total body bone mineral density;
LGG	cis	rs4330281	0.692	rs4908969	chr3:17779407	T/C	cg20981856	chr3:17787350	NA	-0.41	-7.56	-0.33	2.25e-13	Schizophrenia;
LGG	cis	rs7267979	0.565	rs6076364	chr20:25556801	T/C	cg06421707	chr20:25228305	PYGB	-0.36	-7.62	-0.33	1.41e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg21017887	chr14:105400489	NA	0.43	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.58	0.44	1.45e-23	Arsenic metabolism;
LGG	cis	rs6496044	0.634	rs4843066	chr15:86062911	C/T	cg13263323	chr15:86062960	AKAP13	-0.39	-8.47	-0.37	3.23e-16	Interstitial lung disease;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg08048268	chr3:133502702	NA	-0.46	-7.94	-0.35	1.54e-14	Iron status biomarkers;
LGG	cis	rs4604732	0.631	rs60311891	chr1:247623127	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.21	0.39	1.17e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg27398817	chr8:82754497	SNX16	-0.72	-11.23	-0.46	4.81e-26	Diastolic blood pressure;
LGG	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.55	-0.53	1.85e-35	Response to antipsychotic treatment;
LGG	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg13444538	chr7:158905317	VIPR2	-0.48	-7.6	-0.33	1.67e-13	Facial morphology (factor 20);
LGG	cis	rs9354308	0.838	rs9360156	chr6:66553074	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.76	-0.34	5.51e-14	Metabolite levels;
LGG	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg27661571	chr11:113659931	NA	-0.65	-9.29	-0.4	6.14e-19	Hip circumference adjusted for BMI;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-11.02	-0.46	3.05e-25	Neuroticism;
LGG	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg21775007	chr8:11205619	TDH	-0.5	-8.13	-0.35	4.03e-15	Neuroticism;
LGG	cis	rs3815700	1.000	rs8108840	chr19:33094452	A/C	cg02997394	chr19:33096574	ANKRD27	0.92	12.61	0.51	1.46e-31	Eosinophilic esophagitis;
LGG	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.52	0.33	2.92e-13	Colorectal cancer;
LGG	cis	rs718433	0.616	rs2222916	chr14:22212602	C/G	cg18200828	chr14:22236018	NA	-0.55	-7.3	-0.32	1.28e-12	Intraocular pressure;
LGG	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.4	-0.4	2.59e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.15	0.35	3.43e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18599117	chr14:89021229	PTPN21	0.62	6.8	0.3	3.15e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg11707556	chr5:10655725	ANKRD33B	0.49	9.41	0.4	2.29e-19	Coronary artery disease;
LGG	cis	rs5753618	0.539	rs5753596	chr22:31787472	C/T	cg02404636	chr22:31891804	SFI1	-0.35	-6.77	-0.3	4.01e-11	Colorectal cancer;
LGG	trans	rs877282	1.000	rs12763443	chr10:771941	G/A	cg22713356	chr15:30763199	NA	0.57	8.59	0.37	1.34e-16	Uric acid levels;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs7267979	1.000	rs2258719	chr20:25275843	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.27	0.43	2e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.8	-0.45	2.07e-24	Vitiligo;
LGG	cis	rs1371867	1.000	rs1371867	chr8:101330209	A/C	cg06636551	chr8:101224915	SPAG1	-0.43	-7.82	-0.34	3.62e-14	Atrioventricular conduction;
LGG	cis	rs9810089	0.814	rs696518	chr3:136120300	A/C	cg21827317	chr3:136751795	NA	0.45	7.94	0.35	1.56e-14	Gestational age at birth (child effect);
LGG	cis	rs72772090	0.539	rs11740375	chr5:96112897	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.87	-0.38	1.56e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.33	0.55	8.11e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.54	0.33	2.47e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.88	-0.42	5.05e-21	Lung cancer;
LGG	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg24596788	chr1:163392923	NA	-0.67	-12.65	-0.51	1.07e-31	Motion sickness;
LGG	cis	rs4650994	0.593	rs28445692	chr1:178511892	G/C	cg19399532	chr1:178512495	C1orf220	-0.39	-7.33	-0.32	1.06e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17001868	0.568	rs3788579	chr22:40742989	T/C	cg07138101	chr22:40742427	ADSL	0.68	8.82	0.38	2.32e-17	Mammographic density (dense area);
LGG	cis	rs17023223	0.537	rs12085616	chr1:119689148	A/C	cg05756136	chr1:119680316	WARS2	-0.44	-9.24	-0.39	8.89e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21582582	chr3:182698605	DCUN1D1	0.42	6.96	0.31	1.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7568458	0.870	rs1972297	chr2:85808573	T/C	cg23752985	chr2:85803571	VAMP8	0.42	8.31	0.36	1.04e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg12708336	chr17:41446283	NA	0.33	8.03	0.35	7.95e-15	Menopause (age at onset);
LGG	trans	rs2548003	0.966	rs2161537	chr5:28725359	T/C	cg23224356	chr2:98206733	ANKRD36B	0.45	6.7	0.3	5.95e-11	Hip geometry;
LGG	cis	rs1209950	0.966	rs1209948	chr21:40170078	C/T	cg01359822	chr21:40176597	ETS2	0.33	7.52	0.33	2.88e-13	Non-small cell lung cancer (survival);
LGG	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg13147721	chr7:65941812	NA	-0.82	-10.07	-0.42	1.09e-21	Diabetic kidney disease;
LGG	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg19507638	chr5:93509721	C5orf36	0.72	9.96	0.42	2.64e-21	Diabetic retinopathy;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg21775007	chr8:11205619	TDH	0.51	8.53	0.37	2.13e-16	Neuroticism;
LGG	cis	rs7188861	0.724	rs443299	chr16:11372656	G/A	cg01510278	chr16:11456238	NA	0.29	7.07	0.31	5.7e-12	HDL cholesterol;
LGG	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-21.94	-0.71	1.08e-73	Vitiligo;
LGG	cis	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg12486710	chr1:178512616	C1orf220	0.52	10.63	0.44	9.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg14664628	chr15:75095509	CSK	-0.51	-9.06	-0.39	3.65e-18	Caffeine consumption;
LGG	trans	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg24247370	chr13:99142703	STK24	-0.4	-7.46	-0.33	4.25e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6960043	1.000	rs6960043	chr7:15052860	C/T	cg19272540	chr7:15055459	NA	0.34	7.66	0.34	1.09e-13	Type 2 diabetes;
LGG	trans	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Educational attainment;
LGG	cis	rs1497828	0.956	rs2818965	chr1:217569776	T/A	cg04411442	chr1:217543379	NA	0.47	7.8	0.34	4.03e-14	Dialysis-related mortality;
LGG	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24110177	chr3:50126178	RBM5	0.57	10.49	0.44	3.04e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10267417	0.603	rs4236297	chr7:19910884	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	7.57	0.33	2.06e-13	Night sleep phenotypes;
LGG	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg21420622	chr7:105162941	PUS7	-0.45	-7.05	-0.31	6.48e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs116139393	0.505	rs3801033	chr7:6734103	A/G	cg09896999	chr7:6746977	ZNF12	0.49	7.35	0.32	8.94e-13	Alzheimer's disease (APOE e4 interaction);
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.24	-0.46	4.43e-26	Personality dimensions;
LGG	cis	rs3741151	0.686	rs11235809	chr11:73290163	A/G	cg17517138	chr11:73019481	ARHGEF17	0.71	7.5	0.33	3.31e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1506636	0.512	rs1035015	chr7:123309842	G/C	cg03229431	chr7:123269106	ASB15	0.64	11.93	0.49	8.19e-29	Plateletcrit;Platelet count;
LGG	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg07621104	chr11:117668040	DSCAML1	0.66	9.24	0.39	8.71e-19	Myopia;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-10.47	-0.44	3.74e-23	Obesity-related traits;
LGG	cis	rs9487051	0.735	rs1260595	chr6:109519873	T/G	cg21918786	chr6:109611834	NA	-0.41	-7.57	-0.33	2.06e-13	Reticulocyte fraction of red cells;
LGG	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg05096777	chr10:104283225	SUFU	0.31	6.69	0.3	6.45e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg07460842	chr6:66804631	NA	0.72	12.6	0.51	1.62e-31	Type 2 diabetes;
LGG	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg07157834	chr1:205819609	PM20D1	0.45	7.68	0.34	9.72e-14	White blood cell count (basophil);Basophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09223439	chr15:65282374	SPG21	0.5	8.2	0.36	2.47e-15	Cognitive performance;
LGG	cis	rs721399	0.719	rs4646257	chr8:18262546	A/G	cg18736775	chr8:18248649	NAT2	0.73	11.72	0.48	5.8e-28	Blood metabolite levels;
LGG	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg04455712	chr21:45112962	RRP1B	-0.45	-7.55	-0.33	2.31e-13	Mean corpuscular hemoglobin;
LGG	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg10224037	chr5:178157518	ZNF354A	0.78	12.7	0.51	6.35e-32	Neutrophil percentage of white cells;
LGG	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-12.24	-0.49	4.7e-30	Menarche (age at onset);
LGG	cis	rs2274273	0.870	rs1109170	chr14:55785788	A/C	cg04306507	chr14:55594613	LGALS3	0.64	18.05	0.64	1.53e-55	Protein biomarker;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs11971779	0.616	rs7779314	chr7:139112696	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg18200150	chr17:30822561	MYO1D	0.48	9.15	0.39	1.76e-18	Schizophrenia;
LGG	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg18404041	chr3:52824283	ITIH1	-0.46	-8.29	-0.36	1.24e-15	Bipolar disorder;
LGG	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.61	0.37	1.14e-16	Neuroticism;
LGG	cis	rs11792861	0.855	rs116127510	chr9:111868344	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-10.48	-0.44	3.28e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.71	-0.38	5.24e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24441022	chr1:154946677	SHC1;CKS1B	0.43	6.79	0.3	3.49e-11	Gut microbiome composition (summer);
LGG	cis	rs17767392	0.834	rs61991193	chr14:71743789	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.8	-0.38	2.71e-17	Mitral valve prolapse;
LGG	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.52	-0.33	2.9e-13	Personality dimensions;
LGG	trans	rs1459104	0.866	rs28822225	chr11:54818606	C/G	cg15704280	chr7:45808275	SEPT13	0.73	7.37	0.32	7.65e-13	Body mass index;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg06558623	chr16:89946397	TCF25	1.19	13.01	0.52	3.29e-33	Skin colour saturation;
LGG	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs12464559	0.649	rs4306714	chr2:152611351	G/A	cg01189475	chr2:152685088	ARL5A	0.75	6.71	0.3	5.77e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg03806693	chr22:41940476	POLR3H	0.96	16.28	0.6	1.88e-47	Vitiligo;
LGG	cis	rs7917772	0.582	rs10748826	chr10:104354804	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.39e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.38	2.31e-17	Eosinophil percentage of white cells;
LGG	cis	rs708547	1.000	rs2412770	chr4:57794660	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	8.75	0.38	3.98e-17	Response to bleomycin (chromatid breaks);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	0.49	8.05	0.35	6.91e-15	Cognitive performance;
LGG	cis	rs9381040	0.655	rs9381029	chr6:41026453	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.71	-0.3	5.7e-11	Alzheimer's disease (late onset);
LGG	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg04842962	chr6:43655489	MRPS18A	0.81	15.13	0.58	2.59e-42	IgG glycosylation;
LGG	cis	rs733592	0.507	rs7304428	chr12:48494275	T/G	cg24011408	chr12:48396354	COL2A1	-0.68	-11.86	-0.48	1.63e-28	Plateletcrit;
LGG	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg27624424	chr6:160112604	SOD2	0.69	10.12	0.43	7.04e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4262150	0.693	rs9285647	chr5:152279502	A/G	cg12297329	chr5:152029980	NA	0.59	11.59	0.47	1.91e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2594989	0.831	rs7651886	chr3:11572728	A/G	cg01796438	chr3:11312864	ATG7	-0.52	-7.18	-0.32	2.73e-12	Circulating chemerin levels;
LGG	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.79	0.45	2.31e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6909279	0.678	rs11155795	chr6:151851339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.4	-6.77	-0.3	3.83e-11	Bone mineral density;
LGG	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.02	-0.35	8.6e-15	Height;
LGG	cis	rs2247341	0.965	rs2854921	chr4:1715250	C/T	cg05026014	chr4:1749153	NA	-0.32	-9.01	-0.39	5.42e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.6	-0.33	1.71e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4430311	0.656	rs12744297	chr1:243734296	G/A	cg25706552	chr1:244017396	NA	-0.64	-15.73	-0.59	5.62e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs16854884	0.657	rs35796781	chr3:143731662	T/C	cg06585982	chr3:143692056	C3orf58	0.56	9.6	0.41	5.16e-20	Economic and political preferences (feminism/equality);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01678788	chr7:151012255	NA	-0.45	-7.31	-0.32	1.19e-12	Body fat percentage;
LGG	cis	rs757978	1.000	rs757978	chr2:242371101	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.84	-9.05	-0.39	3.89e-18	Chronic lymphocytic leukemia;
LGG	cis	rs240764	0.782	rs239223	chr6:101112345	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	trans	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-8.09	-0.35	5.3e-15	Resting heart rate;
LGG	cis	rs7226408	0.842	rs2033117	chr18:34349962	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.72	-0.3	5.35e-11	Obesity-related traits;
LGG	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.23	-0.36	1.88e-15	Alzheimer's disease (survival time);
LGG	cis	rs12431410	0.857	rs12434368	chr14:60162843	G/A	cg07950296	chr14:60194823	RTN1	0.38	7.25	0.32	1.77e-12	Schizophrenia;
LGG	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg21427119	chr20:30132790	HM13	-0.49	-7.55	-0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs10463554	0.927	rs34798	chr5:102425751	C/G	cg23492399	chr5:102201601	PAM	-0.58	-8.13	-0.35	4.11e-15	Parkinson's disease;
LGG	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.53	-7.1	-0.31	4.86e-12	Schizophrenia;
LGG	cis	rs7572733	0.515	rs12619300	chr2:198786490	A/C	cg00792783	chr2:198669748	PLCL1	-0.68	-11.05	-0.46	2.39e-25	Dermatomyositis;
LGG	cis	rs804292	0.800	rs8191589	chr8:11634194	T/A	cg12395012	chr8:11607386	GATA4	0.54	7.68	0.34	9.89e-14	Alcohol dependence;Nicotine use;
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg21926883	chr2:100939477	LONRF2	-0.68	-16.19	-0.6	4.85e-47	Intelligence (multi-trait analysis);
LGG	cis	rs9894429	0.869	rs9748184	chr17:79596280	A/G	cg18240062	chr17:79603768	NPLOC4	0.75	13.81	0.54	1.46e-36	Eye color traits;
LGG	cis	rs6868223	0.617	rs13355124	chr5:33641578	T/G	cg10594543	chr5:33649717	ADAMTS12	0.66	15.64	0.59	1.43e-44	Mortality in heart failure;
LGG	cis	rs7091068	0.616	rs7093903	chr10:95484010	C/T	cg20715218	chr10:95462985	C10orf4	-0.71	-11.25	-0.46	4.12e-26	Urinary tract infection frequency;
LGG	cis	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg06521331	chr12:34319734	NA	0.41	6.87	0.3	2.08e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs12200560	0.505	rs211164	chr6:97068140	G/T	cg06623918	chr6:96969491	KIAA0776	0.46	7.79	0.34	4.41e-14	Coronary heart disease;
LGG	cis	rs6909430	0.901	rs6939063	chr6:98567343	G/A	cg12860156	chr6:98744658	NA	-0.44	-7.34	-0.32	9.62e-13	Quantitative traits;
LGG	cis	rs9443645	0.901	rs4706079	chr6:79615208	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.93e-17	Intelligence (multi-trait analysis);
LGG	cis	rs8067287	1.000	rs8067287	chr17:16816656	A/T	cg26910001	chr17:16838321	NA	-0.35	-6.66	-0.3	8e-11	Diabetic kidney disease;
LGG	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg07061783	chr6:25882402	NA	0.48	8.21	0.36	2.21e-15	Blood metabolite levels;
LGG	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg24110177	chr3:50126178	RBM5	-0.59	-10.61	-0.44	1.07e-23	Body mass index;
LGG	cis	rs1568889	1.000	rs12802157	chr11:28060285	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-9.64	-0.41	3.64e-20	Schizophrenia;
LGG	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg26655873	chr3:72818019	SHQ1	0.35	6.92	0.31	1.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg14926445	chr8:58193284	C8orf71	-0.73	-9.11	-0.39	2.46e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs209489	0.892	rs78936977	chr6:53123958	C/T	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs57221529	0.654	rs72707041	chr5:677152	G/A	cg16400903	chr5:693638	TPPP	0.48	6.73	0.3	5.01e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg23649088	chr2:200775458	C2orf69	0.61	8.01	0.35	9.43e-15	Schizophrenia;
LGG	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4639966	0.836	rs11217016	chr11:118627149	A/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.54	-0.37	1.94e-16	Systemic lupus erythematosus;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02671751	chr10:88281576	WAPAL	-0.38	-6.79	-0.3	3.35e-11	Brain structure;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.11	0.52	1.33e-33	Obesity-related traits;
LGG	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg22044901	chr15:68126292	NA	-0.4	-6.86	-0.3	2.28e-11	Restless legs syndrome;
LGG	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.91	18.64	0.65	2.98e-58	Hip circumference adjusted for BMI;
LGG	cis	rs1371867	0.846	rs1788194	chr8:101277916	T/C	cg06636551	chr8:101224915	SPAG1	-0.49	-8.94	-0.38	9.65e-18	Atrioventricular conduction;
LGG	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.41	-7.06	-0.31	6.04e-12	Longevity;Endometriosis;
LGG	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.9	-17.69	-0.64	7.14e-54	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg11266682	chr4:10021025	SLC2A9	0.55	10.75	0.45	3.3e-24	Bone mineral density;
LGG	cis	rs9849248	0.627	rs4859003	chr3:88247645	T/C	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.49	-0.33	3.43e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs12791968	0.765	rs12794751	chr11:44998769	C/G	cg11846598	chr11:44996168	LOC221122	-0.59	-10.03	-0.42	1.54e-21	Inhibitory control;
LGG	cis	rs41271951	0.512	rs7537292	chr1:151071038	C/G	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	cis	rs6976053	0.726	rs1799806	chr7:100488658	G/C	cg03098644	chr7:100410630	EPHB4	0.43	7.55	0.33	2.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs763121	0.853	rs6001214	chr22:39149155	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.27	0.63	5.9e-52	Menopause (age at onset);
LGG	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg26874229	chr2:105853672	NA	0.32	6.77	0.3	3.8e-11	Type 2 diabetes;
LGG	cis	rs6740322	0.793	rs9808360	chr2:43546835	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.62	-0.41	4.32e-20	Coronary artery disease;
LGG	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg08885076	chr2:99613938	TSGA10	0.43	9.14	0.39	1.96e-18	Chronic sinus infection;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg24503407	chr1:205819492	PM20D1	0.96	27.11	0.78	1.29e-97	Menarche (age at onset);
LGG	cis	rs7122539	0.603	rs508443	chr11:66509369	C/T	cg01599099	chr11:66649832	PC	-0.37	-7.5	-0.33	3.29e-13	HIV-1 susceptibility;
LGG	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.23	0.43	2.84e-22	Diabetic retinopathy;
LGG	cis	rs6988985	0.765	rs4736359	chr8:143987427	T/G	cg10324643	chr8:143916377	GML	0.39	7.8	0.34	4.28e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7666738	0.830	rs115712871	chr4:98954535	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg26384229	chr12:38710491	ALG10B	0.98	23.25	0.73	8.47e-80	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.84	-0.42	7.06e-21	Response to antipsychotic treatment;
LGG	cis	rs41271473	0.950	rs72750042	chr1:228854138	T/C	cg16512390	chr1:228756714	NA	0.5	7.11	0.31	4.5e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs7267979	0.899	rs2104734	chr20:25526668	A/G	cg06421707	chr20:25228305	PYGB	0.47	9.93	0.42	3.45e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.9	0.45	8.89e-25	Morning vs. evening chronotype;
LGG	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.92	-0.38	1.1e-17	Lung cancer;
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs7712401	0.601	rs30072	chr5:122292220	C/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg13147721	chr7:65941812	NA	-0.82	-9.68	-0.41	2.57e-20	Diabetic kidney disease;
LGG	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs701145	0.537	rs357471	chr3:153896403	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.55	0.37	1.8e-16	Coronary artery disease;
LGG	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.44	-0.33	4.98e-13	Myopia (pathological);
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.65	0.48	1.08e-27	Obesity-related traits;
LGG	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg18137308	chr11:63775436	MACROD1	0.29	6.9	0.31	1.74e-11	Pulse pressure;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg00405596	chr8:11794950	NA	-0.42	-6.88	-0.3	1.94e-11	Neuroticism;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg14926445	chr8:58193284	C8orf71	-0.68	-9.02	-0.39	4.92e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs9287719	0.967	rs10203664	chr2:10752377	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg05941027	chr17:61774174	LIMD2	0.33	8.24	0.36	1.77e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.14	0.39	1.97e-18	Rheumatoid arthritis;
LGG	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.46	-7.74	-0.34	6.35e-14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.56	11.12	0.46	1.25e-25	Obesity-related traits;
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg07538946	chr5:131705188	SLC22A5	0.64	7.53	0.33	2.68e-13	Rheumatoid arthritis;
LGG	trans	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg11441553	chr12:57614120	NXPH4	-0.45	-6.9	-0.31	1.74e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.39	0.43	6.92e-23	Motion sickness;
LGG	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs757081	0.648	rs10832752	chr11:17285487	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.71	-0.34	7.5e-14	Systolic blood pressure;
LGG	cis	rs4629180	0.675	rs10183203	chr2:102095080	C/T	cg16435561	chr2:102091048	RFX8	-0.48	-8.97	-0.38	7.23e-18	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21217426	chr17:58042342	RNFT1	0.41	6.89	0.3	1.79e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3771570	0.901	rs62190413	chr2:242417950	G/A	cg21155796	chr2:242212141	HDLBP	0.7	9.33	0.4	4.41e-19	Prostate cancer;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs3087591	0.810	rs2269856	chr17:29482701	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs10220309	0.501	rs12588985	chr14:80635104	A/G	cg08183125	chr14:80678293	DIO2	-0.43	-6.86	-0.3	2.23e-11	Lung function (FEV1);
LGG	cis	rs10851411	0.697	rs56069741	chr15:42855057	G/A	cg21293051	chr15:42870591	STARD9	0.5	7.09	0.31	5.14e-12	Glucose homeostasis traits;
LGG	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg03036210	chr16:89904091	SPIRE2	-0.64	-7.08	-0.31	5.29e-12	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-13.17	-0.52	7.3e-34	Prudent dietary pattern;
LGG	cis	rs13082711	0.911	rs35605663	chr3:27515754	C/T	cg02860705	chr3:27208620	NA	0.69	12.23	0.49	5.37e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.58e-23	Lung cancer;
LGG	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg10818794	chr15:86012489	AKAP13	-0.31	-6.73	-0.3	5.13e-11	Interstitial lung disease;
LGG	cis	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19171272	chr22:38449367	NA	-0.5	-9.35	-0.4	3.81e-19	Glioblastoma;Glioma;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.46e-13	Lung cancer;
LGG	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg12310025	chr6:25882481	NA	-0.68	-12.97	-0.52	5.12e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2133450	0.712	rs9867566	chr3:7368673	C/T	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.68e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg10513866	chr5:139070639	NA	0.4	7.82	0.34	3.69e-14	Schizophrenia;
LGG	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2617583	0.967	rs2652510	chr5:1447860	C/T	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.01	-0.31	8.61e-12	Breast cancer;
LGG	trans	rs1422110	0.796	rs2909865	chr5:85507394	T/C	cg01787110	chr1:109008453	NBPF6	0.61	9.66	0.41	3.13e-20	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs8005677	0.926	rs34344888	chr14:23387585	A/G	cg01529538	chr14:23388837	RBM23	0.37	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.57	0.33	1.99e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17227506	0.772	rs1871800	chr8:13439699	C/G	cg03566418	chr8:13424080	C8orf48	0.45	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg13699009	chr12:122356056	WDR66	-0.54	-14.63	-0.56	4.16e-40	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09747578	chr1:46769076	LRRC41;UQCRH	0.48	7.96	0.35	1.36e-14	Cognitive performance;
LGG	cis	rs1062746	0.528	rs11646030	chr16:87339278	T/C	cg02258303	chr16:87377426	FBXO31	-0.43	-7.96	-0.35	1.37e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg16876255	chr19:9731953	ZNF561	0.84	7.83	0.34	3.26e-14	Pursuit maintenance gain;
LGG	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg08885076	chr2:99613938	TSGA10	0.41	8.71	0.38	5.22e-17	Chronic sinus infection;
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.66	-0.44	7.34e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs4689642	1.000	rs4689642	chr4:7215322	A/G	cg21353189	chr4:7228343	SORCS2	0.28	7.11	0.31	4.38e-12	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg15704280	chr7:45808275	SEPT13	-0.93	-18.99	-0.66	6.69e-60	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16436509	chr12:120875898	COX6A1	0.51	8.56	0.37	1.67e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs2236267	0.518	rs12878664	chr14:88549799	G/T	cg18078958	chr14:88630771	NA	0.32	7.58	0.33	1.87e-13	Food antigen IgG levels;
LGG	cis	rs13065560	0.594	rs9858516	chr3:38891548	C/T	cg01426195	chr3:39028469	NA	-0.46	-9.53	-0.41	8.78e-20	Interleukin-18 levels;
LGG	cis	rs986417	1.000	rs1254270	chr14:60843134	G/T	cg27398547	chr14:60952738	C14orf39	-0.7	-6.76	-0.3	4.25e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg04691961	chr3:161091175	C3orf57	-0.52	-11.08	-0.46	1.84e-25	Morning vs. evening chronotype;
LGG	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg19748678	chr4:122722346	EXOSC9	0.64	12.83	0.51	1.86e-32	Type 2 diabetes;
LGG	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg10483660	chr13:112241077	NA	-0.42	-8.59	-0.37	1.38e-16	Menarche (age at onset);
LGG	trans	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.5	-0.37	2.59e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg00864171	chr11:67383662	NA	-0.43	-7.1	-0.31	4.85e-12	Mean corpuscular volume;
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg05868516	chr6:26286170	HIST1H4H	0.4	6.68	0.3	6.99e-11	Educational attainment;
LGG	cis	rs11225247	1.000	rs17350205	chr11:102296024	A/G	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg20477318	chr10:51623047	TIMM23	0.63	7.53	0.33	2.64e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg01472538	chr16:58549086	SETD6	0.98	8.78	0.38	3.23e-17	Schizophrenia;
LGG	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.24	0.36	1.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg18000306	chr6:288505	NA	0.58	10.22	0.43	2.95e-22	Menopause (age at onset);
LGG	cis	rs2742417	1.000	rs2742369	chr3:45754487	C/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4356932	1.000	rs6532093	chr4:76948032	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs9487051	0.768	rs386696	chr6:109520166	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.2e-11	Reticulocyte fraction of red cells;
LGG	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02788857	chr8:22132959	PIWIL2	0.51	11.8	0.48	2.69e-28	Hypertriglyceridemia;
LGG	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg13385794	chr1:248469461	NA	0.45	8.04	0.35	7.4e-15	Common traits (Other);
LGG	cis	rs11677416	1.000	rs2856841	chr2:113537339	A/G	cg27083787	chr2:113543245	IL1A	0.54	8.88	0.38	1.53e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.9	0.38	1.31e-17	Hypertriglyceridemia;
LGG	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg21132104	chr15:45694354	SPATA5L1	0.7	10.38	0.43	7.59e-23	Homoarginine levels;
LGG	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg26384229	chr12:38710491	ALG10B	0.98	22.14	0.72	1.26e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.44	-0.33	5e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs5744897	1.000	rs36118826	chr12:133223685	A/C	cg16945633	chr12:133170342	NA	0.67	7.07	0.31	5.66e-12	Urate levels in overweight individuals;
LGG	cis	rs7808935	0.768	rs757138	chr7:27989403	T/G	cg22168087	chr7:27702803	HIBADH	0.61	9.91	0.42	3.89e-21	Prostate cancer;
LGG	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg24764310	chr7:157512201	PTPRN2	0.35	6.89	0.3	1.82e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7928758	0.943	rs75842822	chr11:134265236	C/T	cg15243474	chr11:134282918	B3GAT1	1.19	15.37	0.58	2.23e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14486921	chr8:114449226	CSMD3	-0.5	-7.49	-0.33	3.59e-13	Systemic lupus erythematosus;
LGG	cis	rs7524258	0.900	rs7514988	chr1:7271651	C/T	cg07173049	chr1:7289937	CAMTA1	0.62	14.61	0.56	5.02e-40	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs6964587	1.000	rs2888851	chr7:91648341	G/A	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00049323	chr5:472564	LOC25845	0.39	8.73	0.38	4.65e-17	Cystic fibrosis severity;
LGG	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.48	0.37	3.15e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg03060546	chr3:49711283	APEH	-0.53	-7.11	-0.31	4.31e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13603859	chr5:145827007	TCERG1	0.44	7.17	0.32	2.93e-12	Menarche (age at onset);
LGG	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13893634	chr17:48229117	PPP1R9B	-0.56	-9.66	-0.41	3.05e-20	Temporomandibular joint disorder;
LGG	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.74	0.71	9.56e-73	Bladder cancer;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.35	-0.36	8.08e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26076054	chr5:421317	AHRR	-0.45	-7.57	-0.33	2.07e-13	Cystic fibrosis severity;
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg22398616	chr13:53314203	LECT1	-0.46	-8.86	-0.38	1.74e-17	Lewy body disease;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg08302650	chr8:145750040	LRRC24;LRRC14	-0.37	-7.84	-0.34	3.06e-14	Age at first birth;
LGG	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.38e-12	HDL cholesterol;
LGG	cis	rs367615	0.506	rs246102	chr5:108699695	C/G	cg17395555	chr5:108820864	NA	-0.71	-11.58	-0.47	2.01e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.63	-0.37	9.83e-17	Blood metabolite levels;
LGG	cis	rs7760949	0.852	rs9349847	chr6:13927711	T/C	cg27413430	chr6:13925136	RNF182	0.48	7.38	0.32	7.23e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs911263	0.961	rs3784099	chr14:68749927	A/G	cg18825221	chr14:68749962	RAD51L1	0.51	10.69	0.44	5.39e-24	Primary biliary cholangitis;
LGG	cis	rs476633	0.573	rs2099652	chr15:41528745	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.78	-13.35	-0.53	1.21e-34	Glomerular filtration rate (creatinine);
LGG	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs6960043	0.714	rs7784091	chr7:15047637	A/G	cg19272540	chr7:15055459	NA	-0.38	-8.43	-0.36	4.58e-16	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg19223190	chr17:80058835	NA	0.45	8.72	0.38	5.17e-17	Life satisfaction;
LGG	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg00129232	chr17:37814104	STARD3	0.57	8.58	0.37	1.42e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.01	-0.31	8.75e-12	Bone mineral density;
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs6466055	0.720	rs35757884	chr7:105020534	G/T	cg04380332	chr7:105027541	SRPK2	-0.4	-7.41	-0.33	6.2e-13	Schizophrenia;
LGG	trans	rs2898857	0.504	rs12937923	chr17:47408475	G/A	cg11430096	chr6:110968061	CDK19	-0.48	-8.28	-0.36	1.29e-15	Cancer;
LGG	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg04568710	chr12:38710424	ALG10B	0.34	6.95	0.31	1.28e-11	Bladder cancer;
LGG	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg25664220	chr3:72788482	NA	0.32	8.79	0.38	2.91e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-10.56	-0.44	1.75e-23	Dental caries;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs4639966	0.836	rs11217014	chr11:118626286	T/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.41	-0.33	5.86e-13	Systemic lupus erythematosus;
LGG	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg00012203	chr2:219082015	ARPC2	0.77	14.59	0.56	6.17e-40	Colorectal cancer;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.75	-0.3	4.52e-11	Total body bone mineral density;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg06074448	chr4:187884817	NA	-0.61	-14.18	-0.55	3.77e-38	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg01221209	chr5:554886	NA	-0.46	-6.98	-0.31	1.01e-11	Obesity-related traits;
LGG	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs9486719	1.000	rs2472888	chr6:96865501	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	Cognitive function;
LGG	cis	rs908922	0.887	rs4845783	chr1:152492559	G/A	cg20991723	chr1:152506922	NA	-0.57	-9.64	-0.41	3.8e-20	Hair morphology;
LGG	cis	rs7017914	0.967	rs1838393	chr8:71702591	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs4481887	0.597	rs6587475	chr1:248578622	C/T	cg00666640	chr1:248458726	OR2T12	0.48	6.85	0.3	2.41e-11	Common traits (Other);
LGG	cis	rs4950322	0.570	rs4950315	chr1:146736092	A/G	cg22381352	chr1:146742008	CHD1L	0.51	8.43	0.36	4.37e-16	Protein quantitative trait loci;
LGG	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.96	0.42	2.68e-21	Lung cancer in ever smokers;
LGG	cis	rs12580194	0.593	rs7960719	chr12:55722035	G/A	cg19537932	chr12:55886519	OR6C68	-0.53	-9.37	-0.4	3.22e-19	Cancer;
LGG	trans	rs629535	0.814	rs62513381	chr8:70110991	T/C	cg21567404	chr3:27674614	NA	-0.4	-6.73	-0.3	4.94e-11	Dupuytren's disease;
LGG	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.2	-0.32	2.49e-12	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg07117364	chr1:16154769	NA	-0.5	-9.46	-0.4	1.58e-19	Dilated cardiomyopathy;
LGG	cis	rs6988985	0.728	rs10093618	chr8:143952214	A/G	cg10324643	chr8:143916377	GML	-0.39	-7.78	-0.34	4.71e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs300774	0.925	rs300727	chr2:132469	C/A	cg04617936	chr2:214353	NA	-0.51	-7.77	-0.34	5.08e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs16854884	0.632	rs35362423	chr3:143687441	C/A	cg06585982	chr3:143692056	C3orf58	0.62	10.63	0.44	9.45e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.93	-0.45	6.91e-25	Resting heart rate;
LGG	cis	rs944722	0.621	rs9904749	chr17:26034262	C/T	cg07704981	chr17:26127537	NOS2	-0.4	-6.85	-0.3	2.38e-11	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg11494091	chr17:61959527	GH2	1.0	24.51	0.75	1.11e-85	Prudent dietary pattern;
LGG	cis	rs7100689	0.622	rs7090351	chr10:82142047	T/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.54	0.59	3.91e-44	Post bronchodilator FEV1;
LGG	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg26597838	chr10:835615	NA	0.93	12.3	0.5	2.82e-30	Eosinophil percentage of granulocytes;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg16359550	chr11:109292809	C11orf87	0.44	8.19	0.36	2.55e-15	Schizophrenia;
LGG	cis	rs4262150	0.544	rs72795340	chr5:151905013	G/C	cg12297329	chr5:152029980	NA	-0.65	-11.8	-0.48	2.85e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg11752832	chr7:134001865	SLC35B4	0.56	10.05	0.42	1.24e-21	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6750047	0.546	rs985257	chr2:38283228	A/T	cg07380506	chr2:38303506	CYP1B1	-0.49	-7.92	-0.35	1.81e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs4740619	0.689	rs1590749	chr9:15953344	G/A	cg14451791	chr9:16040625	NA	-0.4	-9.92	-0.42	3.73e-21	Body mass index;
LGG	cis	rs9611519	0.761	rs35445172	chr22:41660301	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-8.65	-0.37	8.55e-17	Neuroticism;
LGG	cis	rs55788414	1.000	rs55788414	chr16:81184939	C/T	cg06400318	chr16:81190750	PKD1L2	-1.04	-11.24	-0.46	4.39e-26	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.39	0.43	7.13e-23	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00192856	chr16:71446866	NA	0.48	7.1	0.31	4.8e-12	Gut microbiome composition (summer);
LGG	cis	rs4774899	0.752	rs2951898	chr15:57383139	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.87	-0.3	2.04e-11	Urinary tract infection frequency;
LGG	cis	rs3845702	0.736	rs72962517	chr2:180861452	G/A	cg01881094	chr2:180872142	CWC22	1.28	16.5	0.61	1.84e-48	Schizophrenia;
LGG	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.82	-0.38	2.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs2011503	1.000	rs78010159	chr19:19615905	C/T	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.65	-0.37	8.71e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.55e-15	Coronary artery disease;
LGG	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.45	0.33	4.66e-13	Morning vs. evening chronotype;
LGG	cis	rs7929679	0.602	rs10501135	chr11:34811180	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.5e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25172604	chr17:41446521	NA	-0.3	-6.84	-0.3	2.5e-11	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg07061783	chr6:25882402	NA	0.39	6.94	0.31	1.36e-11	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.664	rs10815157	chr9:5108771	C/G	cg02405213	chr9:5042618	JAK2	-0.8	-15.43	-0.58	1.28e-43	Pediatric autoimmune diseases;
LGG	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg27129171	chr3:47204927	SETD2	-0.81	-15.64	-0.59	1.41e-44	Colorectal cancer;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	9.92	0.42	3.79e-21	Obesity-related traits;
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg21058520	chr6:100914733	NA	0.4	6.94	0.31	1.35e-11	Neuroticism;
LGG	cis	rs7582720	1.000	rs72932763	chr2:203678658	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.39e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7000551	0.779	rs2443507	chr8:22373231	G/A	cg12081754	chr8:22256438	SLC39A14	0.66	12.35	0.5	1.72e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg25338242	chr13:114786047	RASA3	-0.39	-7.35	-0.32	8.76e-13	Schizophrenia;
LGG	cis	rs1881509	0.623	rs7101802	chr11:1437782	T/C	cg07067744	chr11:1421172	BRSK2	0.34	6.74	0.3	4.79e-11	Heroin dependence;
LGG	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.71	12.9	0.51	1e-32	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	17.55	0.63	3.11e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg09021430	chr5:549028	NA	-0.53	-10.27	-0.43	2.01e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.45e-15	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	18.07	0.64	1.26e-55	Menopause (age at onset);
LGG	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg24634471	chr8:143751801	JRK	0.47	7.12	0.31	4.25e-12	Schizophrenia;
LGG	cis	rs11885103	0.791	rs2685249	chr2:593554	A/G	cg21195176	chr2:593345	NA	0.43	8.16	0.35	3.15e-15	Heschl's gyrus morphology;
LGG	cis	rs6993813	0.620	rs6984675	chr8:120045227	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.8	0.34	4.05e-14	Bone mineral density (hip);
LGG	cis	rs10492096	1.000	rs12427239	chr12:6590626	C/T	cg13857086	chr12:6580257	VAMP1	0.52	7.53	0.33	2.59e-13	Hip geometry;
LGG	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs7143963	1.000	rs4906267	chr14:103305077	G/T	cg23020514	chr14:103360112	TRAF3	0.52	10.02	0.42	1.55e-21	Body mass index;
LGG	cis	rs9649465	1.000	rs55633050	chr7:123388474	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.52e-17	Migraine;
LGG	cis	rs9487094	0.670	rs11754455	chr6:109817883	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg10327440	chr1:227177885	CDC42BPA	1.25	40.35	0.88	1.07e-153	Myeloid white cell count;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg03528353	chr17:61819722	STRADA	0.44	7.42	0.33	5.67e-13	Prudent dietary pattern;
LGG	cis	rs4740619	0.905	rs2105318	chr9:15799406	T/C	cg14451791	chr9:16040625	NA	-0.39	-10.02	-0.42	1.65e-21	Body mass index;
LGG	trans	rs9784649	0.574	rs7702369	chr5:25026602	A/G	cg08600765	chr20:34638493	LOC647979	-0.47	-6.72	-0.3	5.22e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg24642439	chr20:33292090	TP53INP2	0.42	6.64	0.3	8.6e-11	Height;
LGG	cis	rs7711186	0.618	rs4441888	chr5:178010528	G/A	cg17371294	chr5:178012716	COL23A1	-0.92	-8.89	-0.38	1.38e-17	Urate levels in obese individuals;
LGG	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg07308232	chr7:1071921	C7orf50	-0.62	-11.8	-0.48	2.75e-28	Longevity;Endometriosis;
LGG	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg05775895	chr3:12838266	CAND2	0.65	11.67	0.48	9.59e-28	QRS complex (12-leadsum);
LGG	cis	rs73001065	0.901	rs8107974	chr19:19388500	A/T	cg03709012	chr19:19516395	GATAD2A	0.89	8.18	0.36	2.67e-15	LDL cholesterol;
LGG	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.16	0.39	1.69e-18	Resting heart rate;
LGG	cis	rs10979	1.000	rs9403504	chr6:143885430	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.51	-0.5	3.85e-31	Hypospadias;
LGG	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg12193833	chr17:30244370	NA	-0.28	-7.02	-0.31	7.79e-12	Hip circumference adjusted for BMI;
LGG	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08704250	chr15:31115839	NA	-0.41	-7.18	-0.32	2.78e-12	Huntington's disease progression;
LGG	cis	rs950027	1.000	rs950027	chr15:45801035	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-7.44	-0.33	5e-13	Response to fenofibrate (adiponectin levels);
LGG	cis	rs6942756	0.876	rs6953598	chr7:129033741	A/G	cg02491457	chr7:128862824	NA	0.66	12.01	0.49	4.27e-29	White matter hyperintensity burden;
LGG	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg11693508	chr17:37793320	STARD3	0.51	7.35	0.32	8.75e-13	Bipolar disorder;
LGG	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	12.86	0.51	1.41e-32	Hip circumference adjusted for BMI;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10041390	chr10:89623018	PTEN;KILLIN	0.44	7.2	0.32	2.38e-12	Cognitive performance;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.26	-0.32	1.68e-12	Myopia (pathological);
LGG	cis	rs11649743	1.000	rs11649743	chr17:36074979	C/T	cg21250756	chr17:36077300	HNF1B	0.36	9.33	0.4	4.55e-19	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13304665	chr22:22862802	ZNF280B	0.46	6.83	0.3	2.7e-11	Gut microbiome composition (summer);
LGG	cis	rs7937612	0.501	rs4245212	chr11:120273353	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.37	-8.61	-0.37	1.15e-16	Intraocular pressure;
LGG	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.46	-8.8	-0.38	2.76e-17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.49	8.63	0.37	9.63e-17	Glycated hemoglobin levels;
LGG	cis	rs300703	0.542	rs376385	chr2:190245	G/A	cg24565620	chr2:194026	NA	-0.67	-10.57	-0.44	1.52e-23	Blood protein levels;
LGG	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg01631408	chr1:248437212	OR2T33	-0.56	-10.08	-0.42	9.62e-22	Common traits (Other);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16701467	chr17:7475727	EIF4A1	0.4	6.77	0.3	3.86e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2274273	0.840	rs2341622	chr14:55737243	C/A	cg04306507	chr14:55594613	LGALS3	0.63	17.82	0.64	1.85e-54	Protein biomarker;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04772025	chr11:68637568	NA	0.77	13.8	0.54	1.59e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17739794	0.517	rs34109064	chr8:772796	T/C	cg11667643	chr8:748456	NA	-0.43	-8.08	-0.35	5.58e-15	Clozapine-induced cytotoxicity;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg14789911	chr21:47582049	C21orf56	0.45	7.35	0.32	8.98e-13	Testicular germ cell tumor;
LGG	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg21279865	chr17:18430908	FAM106A	0.41	8.33	0.36	9.02e-16	Multiple sclerosis;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	11.54	0.47	2.89e-27	Obesity-related traits;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.86	-16.89	-0.62	3.37e-50	Age at first birth;
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07648498	chr16:89883185	FANCA	0.41	7.01	0.31	8.68e-12	Vitiligo;
LGG	cis	rs7241530	0.662	rs8096274	chr18:75909734	T/C	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	8.11e-17	Educational attainment (years of education);
LGG	cis	rs4266144	0.563	rs61124401	chr3:156840919	A/G	cg14969094	chr3:156848003	NA	-0.27	-6.75	-0.3	4.54e-11	Coronary artery disease;
LGG	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.23	0.36	1.96e-15	Neuroticism;
LGG	trans	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.37	-0.32	8.03e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg23166289	chr1:210001082	C1orf107	0.32	6.67	0.3	7.13e-11	Orofacial clefts;
LGG	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs10463554	0.963	rs158254	chr5:102394883	G/A	cg23492399	chr5:102201601	PAM	-0.53	-7.83	-0.34	3.42e-14	Parkinson's disease;
LGG	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg20336341	chr7:50628841	DDC	0.36	7.01	0.31	8.75e-12	Malaria;
LGG	cis	rs2067615	0.826	rs2731359	chr12:107255547	T/C	cg15890332	chr12:107067104	RFX4	0.28	7.58	0.33	1.89e-13	Heart rate;
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08927260	chr10:15254823	FAM171A1	0.38	7.32	0.32	1.08e-12	Pancreatic cancer;
LGG	cis	rs4363385	0.818	rs946095	chr1:153006470	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.09e-16	Inflammatory skin disease;
LGG	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.84	0.38	1.97e-17	Eosinophil percentage of white cells;
LGG	cis	rs477895	0.941	rs71456309	chr11:64108262	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	7.69	0.34	8.76e-14	Mean platelet volume;
LGG	cis	rs10915437	0.516	rs12409803	chr1:4193426	G/A	cg27165836	chr1:4193882	NA	0.49	9.82	0.42	8.41e-21	Migraine - clinic-based;
LGG	cis	rs6714710	0.603	rs895438	chr2:98382886	G/A	cg26665480	chr2:98280029	ACTR1B	0.64	10.27	0.43	1.92e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg14456004	chr13:21872349	NA	1.36	23.94	0.74	5.36e-83	White matter hyperintensity burden;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Electroencephalogram traits;
LGG	cis	rs9311474	0.967	rs610060	chr3:52273421	G/A	cg14092988	chr3:52407081	DNAH1	-0.29	-7.68	-0.34	9.48e-14	Electroencephalogram traits;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.6	0.53	1.09e-35	Obesity-related traits;
LGG	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.07	-0.35	6.22e-15	Monocyte count;
LGG	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.67	0.41	2.97e-20	Red blood cell count;
LGG	trans	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs208520	0.874	rs208514	chr6:66945520	G/A	cg07460842	chr6:66804631	NA	-0.89	-15.32	-0.58	3.93e-43	Exhaled nitric oxide output;
LGG	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.2	-0.32	2.46e-12	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24568646	chr21:30446238	CCT8	0.46	7.52	0.33	2.96e-13	Cognitive performance;
LGG	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.83	-0.45	1.59e-24	Height;
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg14500267	chr11:67383377	NA	-0.4	-7.33	-0.32	1.06e-12	Mean corpuscular volume;
LGG	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg09448879	chr15:79043637	NA	-0.53	-13.49	-0.53	3.22e-35	Coronary artery disease or large artery stroke;
LGG	cis	rs7247513	0.759	rs8110545	chr19:12754898	C/T	cg01871581	chr19:12707946	ZNF490	-0.42	-8.45	-0.37	3.8e-16	Bipolar disorder;
LGG	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg10402321	chr1:26617780	UBXN11	-0.36	-7.05	-0.31	6.74e-12	Obesity-related traits;
LGG	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06634786	chr22:41940651	POLR3H	0.7	11.25	0.46	4.01e-26	Vitiligo;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24270624	chr10:95721318	PIPSL	0.36	6.71	0.3	5.8200000000000003e-11	Menarche (age at onset);
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs9393777	0.557	rs9358949	chr6:26485717	A/C	cg12826209	chr6:26865740	GUSBL1	0.76	9.52	0.4	1e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg21226059	chr5:178986404	RUFY1	-0.51	-8.64	-0.37	9.41e-17	Lung cancer;
LGG	cis	rs2229238	0.868	rs72999419	chr1:154514092	T/C	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs698833	0.892	rs1067403	chr2:44675851	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	7.45	0.33	4.6e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-10.11	-0.43	7.56e-22	Fibrinogen levels;
LGG	cis	rs1109114	0.934	rs1465850	chr5:148611207	C/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.22	-0.58	1.03e-42	Body mass index;
LGG	cis	rs929596	0.793	rs13009407	chr2:234652347	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-12.4	-0.5	1.1e-30	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.48	-9.24	-0.39	9.32e-19	Myopia;
LGG	cis	rs9811920	0.809	rs793464	chr3:99626028	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	9.04	0.39	4.28e-18	Axial length;
LGG	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg17644776	chr2:200775616	C2orf69	0.5	8.34	0.36	8.3e-16	QT interval;
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg21972741	chr5:435613	AHRR	0.49	8.22	0.36	2.1e-15	Cystic fibrosis severity;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg06654118	chr4:1303317	MAEA	-0.44	-7.45	-0.33	4.5e-13	Obesity-related traits;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15749322	chr11:82905199	ANKRD42	0.39	6.75	0.3	4.44e-11	Lung adenocarcinoma;
LGG	cis	rs9341808	0.754	rs9343973	chr6:80913216	A/G	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg15595755	chr5:1867978	NA	0.44	7.43	0.33	5.25e-13	Cardiovascular disease risk factors;
LGG	trans	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg06875740	chr19:51307921	C19orf48	-0.67	-8.37	-0.36	6.89e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.54e-21	Lung cancer;
LGG	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.03	0.46	2.85e-25	Morning vs. evening chronotype;
LGG	cis	rs11628318	0.515	rs4906248	chr14:103126570	A/T	cg12046867	chr14:103022105	NA	0.42	7.95	0.35	1.42e-14	Platelet count;
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.63	-0.44	8.95e-24	Prostate cancer;
LGG	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg05444541	chr17:17804740	TOM1L2	0.79	22.21	0.72	6.17e-75	Total body bone mineral density;
LGG	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.55	-0.37	1.79e-16	Obesity-related traits;
LGG	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg20336341	chr7:50628841	DDC	-0.38	-7.25	-0.32	1.74e-12	Malaria;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22857025	chr5:266934	NA	-1.49	-26.17	-0.77	2.46e-93	Breast cancer;
LGG	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg07382826	chr16:28625726	SULT1A1	0.37	7.75	0.34	5.77e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7312774	0.618	rs73385161	chr12:107300164	G/A	cg16260113	chr12:107380972	MTERFD3	0.65	6.89	0.3	1.85e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs9815354	1.000	rs1716644	chr3:41968028	A/G	cg03022575	chr3:42003672	ULK4	-0.67	-8.54	-0.37	1.89e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg08461772	chr7:95026248	PON3	0.36	7.63	0.33	1.31e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.51	-0.33	3.08e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	9.62	0.41	4.39e-20	Multiple sclerosis;
LGG	cis	rs6719977	0.543	rs6713059	chr2:42977280	C/A	cg14631114	chr2:43023945	NA	0.48	10.05	0.42	1.29e-21	Hyperactive-impulsive symptoms;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15664640	chr17:80829946	TBCD	0.48	9.48	0.4	1.31e-19	Breast cancer;
LGG	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg20573242	chr4:122745356	CCNA2	0.49	8.92	0.38	1.1e-17	Type 2 diabetes;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.16	0.32	3.13e-12	Birth weight;
LGG	cis	rs4268898	0.527	rs72789910	chr2:24388609	T/G	cg06627628	chr2:24431161	ITSN2	-0.77	-12.36	-0.5	1.66e-30	Asthma;
LGG	cis	rs7928758	0.832	rs75190711	chr11:134269772	G/C	cg25213107	chr11:134282864	B3GAT1	1.16	14.12	0.55	6.67e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg08621203	chr6:150244597	RAET1G	0.46	8.03	0.35	7.86e-15	Lung cancer;
LGG	cis	rs870825	0.616	rs28607131	chr4:185651617	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.85	0.48	1.79e-28	Tonsillectomy;
LGG	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg16583315	chr14:65563665	MAX	-0.4	-8.1	-0.35	4.81e-15	Obesity-related traits;
LGG	cis	rs9952991	0.582	rs658158	chr18:12823402	T/G	cg23598886	chr18:12777645	NA	0.51	7.43	0.33	5.24e-13	Inflammatory skin disease;
LGG	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.57	0.44	1.54e-23	Personality dimensions;
LGG	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg10483660	chr13:112241077	NA	-0.36	-7.78	-0.34	4.63e-14	Hepatitis;
LGG	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg03894339	chr8:19674705	INTS10	0.63	10.33	0.43	1.17e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.07e-38	Tonsillectomy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08557188	chr13:113420371	ATP11A	-0.4	-7.04	-0.31	7.2e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg21775007	chr8:11205619	TDH	-0.77	-13.35	-0.53	1.32e-34	Neuroticism;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.05	-0.35	7.04e-15	Lewy body disease;
LGG	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg09818912	chr17:20140352	CYTSB	0.31	7.26	0.32	1.61e-12	Schizophrenia;
LGG	trans	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg20477318	chr10:51623047	TIMM23	0.6	7.3	0.32	1.28e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg03433033	chr1:76189801	ACADM	-0.78	-13.97	-0.54	2.88e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg18681998	chr4:17616180	MED28	-0.81	-18.14	-0.64	6.12e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg23173402	chr1:227635558	NA	0.61	10.06	0.42	1.12e-21	Major depressive disorder;
LGG	cis	rs17253792	0.915	rs77252471	chr14:56178075	C/T	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs7666738	0.830	rs7664169	chr4:99037859	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-8.4	-0.36	5.41e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg22681709	chr2:178499509	PDE11A	0.42	7.51	0.33	2.97e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg13207630	chr7:32358064	NA	0.68	7.21	0.32	2.33e-12	Body mass index;
LGG	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg26116260	chr4:7069785	GRPEL1	0.48	8.18	0.36	2.67e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg20891283	chr12:69753455	YEATS4	0.73	13.64	0.54	7.88e-36	Blood protein levels;
LGG	cis	rs1707322	1.000	rs11211228	chr1:46399840	G/A	cg03146154	chr1:46216737	IPP	0.54	10.15	0.43	5.47e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.58	0.44	1.46e-23	Testicular germ cell tumor;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg06640241	chr16:89574553	SPG7	0.97	20.51	0.69	5.48e-67	Multiple myeloma (IgH translocation);
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08045932	chr20:61659980	NA	0.59	12.8	0.51	2.56e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.61	-12.33	-0.5	2.1000000000000002e-30	Prudent dietary pattern;
LGG	cis	rs16976116	0.901	rs73409851	chr15:55502516	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.26	0.32	1.68e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2074193	0.627	rs215383	chr12:47758032	A/G	cg02516419	chr12:47771422	NA	-0.71	-10.34	-0.43	1.08e-22	Migraine with aura;
LGG	cis	rs9815354	1.000	rs2683696	chr3:41914898	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.3	0.36	1.14e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg25174290	chr11:3078921	CARS	-0.76	-16.63	-0.61	4.9e-49	Longevity;
LGG	cis	rs6964587	1.000	rs6969536	chr7:91689351	C/G	cg17063962	chr7:91808500	NA	0.47	8.4	0.36	5.34e-16	Breast cancer;
LGG	cis	rs2456568	0.802	rs7115629	chr11:93635477	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9831754	0.704	rs9882111	chr3:78470746	A/G	cg06138941	chr3:78371609	NA	-0.8	-15.59	-0.59	2.28e-44	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21844450	chr20:8112956	PLCB1	0.53	7.85	0.34	2.99e-14	Gut microbiome composition (summer);
LGG	cis	rs990171	1.000	rs2160232	chr2:103046880	G/A	cg05295703	chr2:102895712	NA	-0.53	-9.06	-0.39	3.57e-18	Lymphocyte counts;
LGG	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg25208724	chr1:156163844	SLC25A44	1.06	17.89	0.64	8.61e-55	Testicular germ cell tumor;
LGG	trans	rs6787172	0.622	rs9873426	chr3:158099782	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg07777115	chr5:623756	CEP72	-0.63	-8.25	-0.36	1.69e-15	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08431062	chr19:16607243	C19orf44;CALR3	0.52	7.74	0.34	6.24e-14	Gut microbiome composition (summer);
LGG	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg25427524	chr10:38739819	LOC399744	-0.7	-13.86	-0.54	8.9e-37	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-8.03	-0.35	8.25e-15	Neuroticism;
LGG	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg07120314	chr15:79043507	NA	0.58	9.46	0.4	1.55e-19	Post bronchodilator FEV1;
LGG	cis	rs977987	0.806	rs4888420	chr16:75462998	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.93	0.42	3.42e-21	Dupuytren's disease;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg18446336	chr7:2847575	GNA12	-0.29	-6.88	-0.3	1.9e-11	Height;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg23649088	chr2:200775458	C2orf69	-0.43	-7.44	-0.33	4.79e-13	QT interval;
LGG	cis	rs17767392	0.881	rs9672060	chr14:72010126	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.59	-0.37	1.3e-16	Mitral valve prolapse;
LGG	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-18.46	-0.65	1.89e-57	Coronary artery disease;
LGG	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg11502198	chr6:26597334	ABT1	0.53	9.34	0.4	3.96e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg08534653	chr2:1747700	PXDN	0.45	6.97	0.31	1.1e-11	Response to antipsychotic treatment;
LGG	cis	rs4262150	0.883	rs72804789	chr5:152322621	C/T	cg12297329	chr5:152029980	NA	-0.62	-11.28	-0.46	3.07e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10352719	chr14:24769404	DHRS1;C14orf21	0.56	9.07	0.39	3.44e-18	Gut microbiome composition (summer);
LGG	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg21775007	chr8:11205619	TDH	-0.58	-9.59	-0.41	5.48e-20	Neuroticism;
LGG	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.28	-0.32	1.4e-12	Colorectal cancer;
LGG	cis	rs10744422	0.920	rs897393	chr12:123312051	A/G	cg25930673	chr12:123319894	HIP1R	0.68	8.78	0.38	3.21e-17	Schizophrenia;
LGG	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.07	-0.31	5.86e-12	IgG glycosylation;
LGG	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg02811702	chr13:24901961	NA	0.38	7.23	0.32	1.96e-12	Obesity-related traits;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg05091796	chr16:4465799	CORO7	-0.6	-9.88	-0.42	4.97e-21	Schizophrenia;
LGG	cis	rs7818345	0.967	rs12543061	chr8:19286181	G/T	cg11303988	chr8:19266685	CSGALNACT1	-0.38	-6.67	-0.3	7.24e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg12081754	chr8:22256438	SLC39A14	0.98	20.95	0.7	4.88e-69	Verbal declarative memory;
LGG	trans	rs6787172	0.692	rs1656370	chr3:158276050	A/G	cg23275840	chr4:47708675	CORIN	0.32	6.65	0.3	8.42e-11	Subjective well-being;
LGG	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs55882075	0.723	rs56227602	chr5:179179472	A/G	cg14593053	chr5:179126677	CANX	0.39	6.78	0.3	3.77e-11	Monocyte percentage of white cells;
LGG	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg24110177	chr3:50126178	RBM5	0.56	10.17	0.43	4.8e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg24110177	chr3:50126178	RBM5	0.4	6.89	0.3	1.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-6.83	-0.3	2.67e-11	Height;
LGG	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs10876993	0.928	rs7136269	chr12:58075937	G/A	cg18357645	chr12:58087776	OS9	0.68	12.4	0.5	1.1e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-7.83	-0.34	3.4e-14	Total body bone mineral density;
LGG	cis	rs2916247	1.000	rs11776021	chr8:93025183	A/G	cg10183463	chr8:93005414	RUNX1T1	0.4	8.46	0.37	3.52e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg16851482	chr4:6955953	TBC1D14	0.26	6.71	0.3	5.6e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs11229555	0.574	rs12292024	chr11:58186716	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg21775007	chr8:11205619	TDH	-0.55	-8.43	-0.36	4.35e-16	Triglycerides;
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.61	-0.33	1.55e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg19894588	chr14:64061835	NA	-0.64	-10.24	-0.43	2.53e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg26441486	chr22:50317300	CRELD2	0.41	7.12	0.31	4.26e-12	Schizophrenia;
LGG	cis	rs36071027	0.577	rs12109219	chr5:158393842	T/G	cg18496440	chr5:158532302	NA	0.41	6.85	0.3	2.36e-11	Carotid intima media thickness;
LGG	cis	rs11158026	0.757	rs10150110	chr14:55462010	G/T	cg04306507	chr14:55594613	LGALS3	0.31	7.12	0.31	4.09e-12	Parkinson's disease;
LGG	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg18898632	chr2:242989856	NA	-0.8	-9.91	-0.42	4.01e-21	Obesity-related traits;
LGG	cis	rs877426	0.681	rs41291225	chr13:114839462	T/C	cg27119904	chr13:114814333	RASA3	0.35	7.15	0.32	3.43e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.84	0.38	1.97e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.75	-0.48	4.51e-28	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.58	0.61	8.44e-49	Obesity-related traits;
LGG	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg23825213	chr18:77623475	KCNG2	-0.4	-7.14	-0.31	3.74e-12	Schizophrenia;
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg13628971	chr7:2884303	GNA12	0.48	9.52	0.4	9.48e-20	Height;
LGG	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.42e-22	Iron status biomarkers;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg06558623	chr16:89946397	TCF25	0.98	11.86	0.48	1.62e-28	Skin colour saturation;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg09448879	chr15:79043637	NA	-0.56	-14.49	-0.56	1.72e-39	Coronary artery disease or large artery stroke;
LGG	cis	rs12681287	0.604	rs71502657	chr8:87478781	T/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.71	-0.34	7.73e-14	Caudate activity during reward;
LGG	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg23188684	chr11:67383651	NA	-0.42	-6.91	-0.31	1.6e-11	Mean corpuscular volume;
LGG	cis	rs62209	0.800	rs201078	chr10:11002752	A/G	cg26901096	chr10:10994189	LOC254312	0.56	8.82	0.38	2.33e-17	Alzheimer's disease (late onset);
LGG	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.96	-0.31	1.14e-11	Arsenic metabolism;
LGG	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.13	0.31	3.78e-12	Retinal vascular caliber;
LGG	cis	rs79247733	0.786	rs2286442	chr22:30772686	C/T	cg03868770	chr22:30783737	RNF215	-0.65	-7.61	-0.33	1.5e-13	Tonsillectomy;
LGG	cis	rs7808935	0.914	rs11982766	chr7:27983781	C/T	cg22168087	chr7:27702803	HIBADH	0.65	8.97	0.38	7.31e-18	Prostate cancer;
LGG	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.74	-0.41	1.61e-20	Body mass index;
LGG	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg08807101	chr21:30365312	RNF160	0.91	19.24	0.67	4.63e-61	Dental caries;
LGG	cis	rs11718455	0.960	rs11929518	chr3:44016874	A/G	cg21419209	chr3:44054225	NA	-0.44	-7.14	-0.31	3.68e-12	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg15971980	chr6:150254442	NA	0.46	8.61	0.37	1.12e-16	Lung cancer;
LGG	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg20368463	chr18:77673604	PQLC1	-0.47	-8.47	-0.37	3.37e-16	Schizophrenia;
LGG	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.46	-0.37	3.56e-16	Bone mineral density;
LGG	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg22437258	chr11:111473054	SIK2	-0.58	-9.68	-0.41	2.62e-20	Primary sclerosing cholangitis;
LGG	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg20573242	chr4:122745356	CCNA2	0.55	10.29	0.43	1.65e-22	Type 2 diabetes;
LGG	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.66	0.3	7.97e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg26248373	chr2:1572462	NA	-0.71	-9.4	-0.4	2.47e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7923837	0.687	rs2185756	chr10:94430497	A/C	cg25093409	chr10:94429542	NA	0.51	10.0	0.42	1.98e-21	Body mass index;Multiple sclerosis;
LGG	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg15208524	chr1:10270712	KIF1B	0.41	7.15	0.32	3.48e-12	Hepatocellular carcinoma;
LGG	cis	rs4690686	0.500	rs4690429	chr4:177263983	G/A	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	9.95	0.42	2.84e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7555523	0.778	rs4233408	chr1:165712960	G/A	cg24409356	chr1:165738333	TMCO1	0.68	8.52	0.37	2.28e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.11	-0.31	4.5e-12	Neuroticism;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg12708336	chr17:41446283	NA	-0.31	-7.25	-0.32	1.71e-12	Menopause (age at onset);
LGG	cis	rs56152251	0.515	rs9635753	chr17:64329197	T/G	cg19474267	chr17:64306194	PRKCA	0.76	16.56	0.61	1.06e-48	QT interval;
LGG	cis	rs1395	0.744	rs4665962	chr2:27515105	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.04	-0.31	6.76e-12	Blood metabolite levels;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-10.58	-0.44	1.45e-23	Obesity-related traits;
LGG	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.56	0.41	6.94e-20	Lung cancer in ever smokers;
LGG	cis	rs55788414	0.860	rs9929059	chr16:81182117	G/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.03	-0.42	1.48e-21	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg18379455	chr17:41446167	NA	-0.32	-7.59	-0.33	1.78e-13	Menopause (age at onset);
LGG	cis	rs854037	0.512	rs35694981	chr5:57125280	A/G	cg08523694	chr5:57076192	NA	0.53	7.0	0.31	8.75e-12	Birth weight;
LGG	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg04000281	chr11:63949212	NA	-0.43	-8.28	-0.36	1.3e-15	Platelet count;
LGG	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg02269571	chr22:50332266	NA	0.64	10.17	0.43	4.62e-22	Schizophrenia;
LGG	cis	rs883565	0.569	rs7613766	chr3:39152248	C/G	cg01426195	chr3:39028469	NA	-0.65	-14.06	-0.55	1.22e-37	Handedness;
LGG	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	cis	rs2916247	1.000	rs13250170	chr8:93035331	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.39	-8.2	-0.36	2.34e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg26769984	chr7:1090371	C7orf50	0.43	7.69	0.34	8.88e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2342371	0.848	rs9864836	chr3:196200737	C/T	cg15048948	chr3:196158458	UBXN7	0.41	6.85	0.3	2.41e-11	Fat distribution (HIV);
LGG	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.55e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.8	-0.34	4.16e-14	Retinal vascular caliber;
LGG	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg01493522	chr13:37497338	NA	-0.5	-8.46	-0.37	3.49e-16	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.42e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.64	-8.79	-0.38	2.97e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.9e-22	Diabetic retinopathy;
LGG	trans	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg01314568	chr7:57830625	NA	-0.51	-8.15	-0.35	3.45e-15	Obesity-related traits;
LGG	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg24642439	chr20:33292090	TP53INP2	0.79	13.66	0.54	6.43e-36	Coronary artery disease;
LGG	trans	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg06521331	chr12:34319734	NA	0.42	7.16	0.32	3.27e-12	Morning vs. evening chronotype;
LGG	cis	rs7173389	1.000	rs8040533	chr15:73664741	T/G	cg01796676	chr15:73680284	NA	0.52	8.69	0.37	6.33e-17	Resting heart rate;
LGG	cis	rs6743226	0.934	rs7604465	chr2:242249828	C/T	cg10021735	chr2:242295487	FARP2	0.53	9.64	0.41	3.6e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6032067	0.543	rs13045693	chr20:43911817	T/C	cg10761708	chr20:43804764	PI3	0.49	7.9	0.34	2.11e-14	Blood protein levels;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg08888203	chr3:10149979	C3orf24	0.55	9.37	0.4	3.21e-19	Alzheimer's disease;
LGG	cis	rs11229555	0.645	rs11229428	chr11:58180382	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.38	-0.58	2.13e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.22	0.36	2.09e-15	Colorectal cancer;
LGG	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-7.29	-0.32	1.32e-12	Electroencephalogram traits;
LGG	cis	rs4073582	0.595	rs1151540	chr11:66041807	A/C	cg14036092	chr11:66035641	RAB1B	0.46	7.89	0.34	2.23e-14	Gout;
LGG	cis	rs6547631	0.594	rs7908	chr2:85925756	C/G	cg24620635	chr2:85921963	GNLY	0.5	9.99	0.42	2.02e-21	Blood protein levels;
LGG	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.53	-0.5	3.26e-31	Chronic sinus infection;
LGG	cis	rs6032067	0.925	rs35751129	chr20:43847658	C/A	cg10761708	chr20:43804764	PI3	0.76	11.56	0.47	2.48e-27	Blood protein levels;
LGG	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.91	0.38	1.15e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2613964	0.504	rs1903431	chr3:112852657	C/T	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	6.12e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs963731	0.649	rs378698	chr2:39316301	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-8.03	-0.35	8.34e-15	Corticobasal degeneration;
LGG	trans	rs7939886	0.920	rs11227463	chr11:55955447	C/T	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg08085267	chr17:45401833	C17orf57	0.59	11.69	0.48	7.82e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.94	0.31	1.31e-11	Systemic lupus erythematosus;
LGG	cis	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg12826209	chr6:26865740	GUSBL1	0.82	11.62	0.48	1.45e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1975974	0.574	rs17052370	chr17:21736353	A/G	cg18423549	chr17:21743878	NA	0.54	8.6	0.37	1.28e-16	Psoriasis;
LGG	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs17227506	0.868	rs7817022	chr8:13440596	G/A	cg03566418	chr8:13424080	C8orf48	0.48	7.42	0.33	5.61e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg11366901	chr6:160182831	ACAT2	1.09	17.1	0.62	3.67e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg13385794	chr1:248469461	NA	0.45	8.0	0.35	1.02e-14	Common traits (Other);
LGG	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.74e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.97	0.31	1.11e-11	Aortic root size;
LGG	cis	rs637571	0.676	rs634534	chr11:65665256	A/G	cg26695010	chr11:65641043	EFEMP2	0.64	11.5	0.47	4.33e-27	Eosinophil percentage of white cells;
LGG	cis	rs698833	0.532	rs2616444	chr2:44605518	C/T	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	3.95e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs2285947	1.000	rs6970597	chr7:21583519	C/A	cg23045935	chr7:21583304	DNAH11	0.43	9.36	0.4	3.57e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.67	0.41	2.98e-20	Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg20503657	chr10:835505	NA	0.75	10.18	0.43	4.11e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs79349575	0.721	rs4794004	chr17:47038471	C/T	cg16584676	chr17:46985605	UBE2Z	0.44	7.71	0.34	7.89e-14	Type 2 diabetes;
LGG	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg00092383	chr7:157075207	NA	-0.38	-6.66	-0.3	7.95e-11	Body mass index;
LGG	cis	rs5758511	0.573	rs2267438	chr22:42237565	C/T	cg15128208	chr22:42549153	NA	-0.43	-7.33	-0.32	1.07e-12	Birth weight;
LGG	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.79	0.48	3.1e-28	Hip circumference adjusted for BMI;
LGG	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.07	-0.6	1.76e-46	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6542838	0.641	rs13005124	chr2:99527680	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-6.81	-0.3	3.05e-11	Fear of minor pain;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21862992	chr11:68658383	NA	0.52	8.76	0.38	3.57e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1997103	1.000	rs6953494	chr7:55412157	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.54	0.37	1.94e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg18402987	chr7:1209562	NA	0.68	9.17	0.39	1.53e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg03528353	chr17:61819722	STRADA	-0.42	-7.02	-0.31	8.07e-12	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20878095	chr19:49298744	BCAT2	0.4	6.79	0.3	3.49e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4716602	0.596	rs10275400	chr7:156161550	A/G	cg16983916	chr7:156159713	NA	-0.5	-9.57	-0.41	6.38e-20	Anti-saccade response;
LGG	cis	rs7552167	0.925	rs7546025	chr1:24510252	T/C	cg01960748	chr1:24522592	NA	-0.52	-7.84	-0.34	3.12e-14	Psoriasis vulgaris;
LGG	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg14952266	chr13:112191215	NA	-0.41	-7.5	-0.33	3.18e-13	Menarche (age at onset);
LGG	trans	rs4942242	1.000	rs7331003	chr13:44230253	C/T	cg19169023	chr15:41853346	TYRO3	-0.33	-6.86	-0.3	2.16e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3087591	0.708	rs2525568	chr17:29675878	T/G	cg24425628	chr17:29625626	OMG;NF1	0.61	12.74	0.51	4.39e-32	Hip circumference;
LGG	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.16	0.52	8.03e-34	Coronary artery disease;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00294572	chr6:26285232	NA	0.42	7.72	0.34	7.01e-14	Educational attainment;
LGG	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg02297831	chr4:17616191	MED28	0.45	8.2	0.36	2.44e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg06092702	chr1:163392909	NA	-0.41	-7.11	-0.31	4.41e-12	Motion sickness;
LGG	trans	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.59	-0.33	1.72e-13	Prostate cancer;
LGG	cis	rs9902453	0.904	rs4375718	chr17:28363642	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.64	-0.54	7.79e-36	Coffee consumption (cups per day);
LGG	cis	rs12980942	0.872	rs7256416	chr19:41787931	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.51	6.97	0.31	1.07e-11	Coronary artery disease;
LGG	cis	rs7617773	0.780	rs34630841	chr3:48343261	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg27400746	chr16:89904261	SPIRE2	-0.92	-14.6	-0.56	5.27e-40	Skin colour saturation;
LGG	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg26384229	chr12:38710491	ALG10B	0.77	14.28	0.55	1.37e-38	Resting heart rate;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg04503457	chr17:41445688	NA	-0.38	-8.77	-0.38	3.41e-17	Menopause (age at onset);
LGG	cis	rs782590	0.764	rs2586970	chr2:55829967	A/G	cg18811423	chr2:55921094	PNPT1	0.82	17.7	0.64	6.39e-54	Metabolic syndrome;
LGG	cis	rs2737618	0.680	rs2737686	chr1:200094347	C/T	cg21825944	chr1:200113062	NR5A2	-0.6	-11.56	-0.47	2.47e-27	Uric acid levels;
LGG	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1577917	0.959	rs34258068	chr6:86679449	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs6840360	0.571	rs62327272	chr4:152545090	A/C	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.85e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-11.0	-0.46	3.72e-25	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.09	0.31	5.2e-12	Lung cancer;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs3925075	1.000	rs3925075	chr16:31347748	C/T	cg02846316	chr16:31340340	ITGAM	-0.4	-7.91	-0.35	1.87e-14	IgA nephropathy;
LGG	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg13010199	chr12:38710504	ALG10B	-0.65	-13.88	-0.54	7.38e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg00376283	chr12:123451042	ABCB9	0.65	10.33	0.43	1.17e-22	Neutrophil percentage of white cells;
LGG	cis	rs208520	0.690	rs851458	chr6:66813279	T/G	cg07460842	chr6:66804631	NA	-0.98	-18.64	-0.65	2.97e-58	Exhaled nitric oxide output;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.77	-0.34	5.24e-14	Skin colour saturation;
LGG	cis	rs72827839	0.846	rs16954204	chr17:46315198	T/C	cg02219949	chr17:45927392	SP6	0.52	7.74	0.34	6.08e-14	Ease of getting up in the morning;
LGG	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg15208524	chr1:10270712	KIF1B	0.45	8.07	0.35	5.92e-15	Hepatocellular carcinoma;
LGG	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.48	-7.47	-0.33	3.91e-13	Intraocular pressure;
LGG	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg05585630	chr7:157510462	PTPRN2	-0.67	-14.07	-0.55	1.13e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.84	-0.45	1.51e-24	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs10802346	0.545	rs1361408	chr1:246410054	T/G	cg13514129	chr1:39547527	MACF1	0.69	12.73	0.51	4.99e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs3126085	1.000	rs72696989	chr1:152248674	A/C	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg25554036	chr4:6271136	WFS1	0.61	11.74	0.48	5.06e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg11764359	chr7:65958608	NA	0.63	10.77	0.45	2.69e-24	Aortic root size;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.4e-21	Lymphocyte counts;
LGG	cis	rs737693	0.564	rs72983568	chr11:102773998	T/G	cg19620758	chr11:102826565	MMP13	0.59	8.02	0.35	8.95e-15	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9547692	0.938	rs12020196	chr13:37469191	G/C	cg02985381	chr13:37494744	SMAD9	0.7	12.24	0.49	4.71e-30	Coronary artery disease;
LGG	cis	rs9783347	0.643	rs2305565	chr11:18317699	C/T	cg03595886	chr11:18357587	GTF2H1	-0.46	-11.18	-0.46	7.76e-26	Pancreatic cancer;
LGG	cis	rs7523273	0.526	rs733177	chr1:208046384	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	8.61	0.37	1.14e-16	Schizophrenia;
LGG	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-11.93	-0.48	8.61e-29	Bladder cancer;
LGG	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.29	-0.43	1.63e-22	Chronic sinus infection;
LGG	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg08949735	chr16:89699720	DPEP1	-0.48	-9.96	-0.42	2.66e-21	Vitiligo;
LGG	cis	rs1021993	0.597	rs1395753	chr1:209490527	A/T	cg24446417	chr1:209558027	NA	-0.68	-10.05	-0.42	1.22e-21	Gut microbiome composition (winter);
LGG	cis	rs16976116	0.951	rs13733	chr15:55489104	A/G	cg11288833	chr15:55489084	RSL24D1	0.56	7.64	0.33	1.27e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3762637	0.941	rs28679619	chr3:122100349	C/A	cg24169773	chr3:122142474	KPNA1	-0.57	-9.11	-0.39	2.52e-18	LDL cholesterol levels;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03639675	chr16:46723204	ORC6L;VPS35	0.41	6.98	0.31	1.03e-11	Lung adenocarcinoma;
LGG	cis	rs9534288	0.699	rs9534321	chr13:46669032	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-13.87	-0.54	8.12e-37	Blood protein levels;
LGG	cis	rs2456568	0.503	rs11020603	chr11:93667439	A/G	cg26875233	chr11:93583750	C11orf90	0.47	8.67	0.37	7.38e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-13.04	-0.52	2.63e-33	Multiple sclerosis;
LGG	cis	rs1243572	0.617	rs10484049	chr14:95362271	C/T	cg13737829	chr14:95358161	NA	0.41	6.95	0.31	1.22e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg09461388	chr22:46763229	CELSR1	-0.67	-6.82	-0.3	2.87e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg14456004	chr13:21872349	NA	-1.16	-18.27	-0.65	1.52e-56	White matter hyperintensity burden;
LGG	trans	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg21775007	chr8:11205619	TDH	0.46	7.65	0.33	1.21e-13	Neuroticism;
LGG	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg06917634	chr15:78832804	PSMA4	-0.68	-13.4	-0.53	7.45e-35	Sudden cardiac arrest;
LGG	cis	rs972578	0.715	rs738535	chr22:43203137	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.88e-11	Mean platelet volume;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.7	-0.34	8.27e-14	Menopause (age at onset);
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	8.14	0.35	3.78e-15	Schizophrenia;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg22907277	chr7:1156413	C7orf50	0.81	11.69	0.48	7.65e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06634786	chr22:41940651	POLR3H	-0.75	-12.09	-0.49	2.04e-29	Vitiligo;
LGG	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg11342453	chr6:26196699	NA	0.5	6.84	0.3	2.44e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg20712883	chr12:51590929	POU6F1	0.64	10.89	0.45	9.61e-25	Cisplatin-induced ototoxicity;
LGG	cis	rs283228	1.000	rs189739	chr6:101746374	A/T	cg27451362	chr6:101846650	GRIK2	0.54	9.08	0.39	3.15e-18	Coenzyme Q10 levels;
LGG	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg15128208	chr22:42549153	NA	0.75	11.85	0.48	1.72e-28	Birth weight;
LGG	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg24232236	chr22:38142998	TRIOBP	0.37	7.19	0.32	2.68e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg10636054	chr15:40330586	SRP14	1.16	13.2	0.52	5.31e-34	Corneal curvature;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg02353165	chr6:42928485	GNMT	0.54	17.03	0.62	7.35e-51	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7127900	0.614	rs72853920	chr11:2206429	T/C	cg04484994	chr11:2181039	INS-IGF2;INS	0.46	7.58	0.33	1.95e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg08742575	chr21:47604166	C21orf56	-0.55	-9.9	-0.42	4.47e-21	Testicular germ cell tumor;
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.78	-0.38	3.08e-17	Joint mobility (Beighton score);
LGG	cis	rs8064024	0.619	rs4141486	chr16:4896780	A/C	cg04440724	chr16:4920505	UBN1	-0.56	-12.43	-0.5	8.38e-31	Cancer;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg24503407	chr1:205819492	PM20D1	0.82	19.53	0.67	2.16e-62	Menarche (age at onset);
LGG	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15596359	chr8:11213517	TDH	0.42	8.77	0.38	3.45e-17	Retinal vascular caliber;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	17.02	0.62	7.97e-51	Tonsillectomy;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-10.88	-0.45	1.07e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.77	0.34	5.24e-14	Vitiligo;
LGG	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.3	-0.32	1.24e-12	Sudden cardiac arrest;
LGG	cis	rs3087591	0.537	rs75847291	chr17:29717854	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.66	-9.35	-0.4	3.7e-19	Hip circumference;
LGG	cis	rs793571	0.650	rs12899638	chr15:58920275	G/A	cg05156742	chr15:59063176	FAM63B	0.57	9.98	0.42	2.34e-21	Schizophrenia;
LGG	cis	rs4919694	0.536	rs12256506	chr10:104963618	T/A	cg04362960	chr10:104952993	NT5C2	0.88	13.02	0.52	3.06e-33	Arsenic metabolism;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.45	7.4	0.33	6.56e-13	Longevity;
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg24503407	chr1:205819492	PM20D1	-0.53	-10.46	-0.44	4.09e-23	Menarche (age at onset);
LGG	trans	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.76	0.41	1.35e-20	Mean corpuscular volume;
LGG	cis	rs13126513	0.768	rs6822162	chr4:100472583	A/G	cg05468953	chr4:100565104	NA	0.38	7.62	0.33	1.48e-13	Metabolite levels (MHPG);
LGG	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg25706552	chr1:244017396	NA	-0.51	-8.34	-0.36	8.39e-16	RR interval (heart rate);
LGG	cis	rs2173063	1.000	rs4453419	chr15:93132361	A/C	cg07052004	chr15:93132129	NA	0.64	7.39	0.32	6.82e-13	Subcutaneous adipose tissue;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	0.43	7.7	0.34	8.53e-14	Obesity-related traits;
LGG	cis	rs11662586	0.517	rs11662894	chr18:77713591	G/A	cg20368463	chr18:77673604	PQLC1	0.65	13.19	0.52	6.01e-34	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs457717	0.706	rs2455214	chr5:75945476	G/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.87	0.3	2.12e-11	Hearing impairment;
LGG	cis	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg22857025	chr5:266934	NA	-1.5	-26.08	-0.77	6.7e-93	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22156867	chr6:37467762	C6orf129	0.53	7.95	0.35	1.47e-14	Gut microbiome composition (summer);
LGG	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.94	0.35	1.59e-14	Birth weight;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.21	0.36	2.2e-15	HIV-1 control;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.16	-0.32	3.16e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg05639522	chr1:247681581	NA	0.61	10.28	0.43	1.77e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg18681998	chr4:17616180	MED28	0.88	20.21	0.68	1.39e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4740619	0.711	rs10756730	chr9:15975069	T/C	cg14451791	chr9:16040625	NA	-0.41	-10.68	-0.44	5.79e-24	Body mass index;
LGG	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.79	-0.3	3.54e-11	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.31	-0.5	2.48e-30	Alzheimer's disease;
LGG	cis	rs6692729	0.965	rs1289395	chr1:227042462	T/C	cg08708961	chr1:227070630	PSEN2	-0.28	-7.05	-0.31	6.62e-12	Electrodermal activity;
LGG	cis	rs283228	0.605	rs643101	chr6:101726103	G/T	cg02011392	chr6:101847541	GRIK2	0.54	7.39	0.32	7.1e-13	Coenzyme Q10 levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14616479	chr3:155588124	GMPS	0.49	7.28	0.32	1.47e-12	Gut microbiome composition (summer);
LGG	cis	rs9457247	0.663	rs12526548	chr6:167431147	C/T	cg07741184	chr6:167504864	NA	0.39	8.69	0.37	6.11e-17	Crohn's disease;
LGG	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.12	-0.35	4.41e-15	Joint mobility (Beighton score);
LGG	cis	rs11809207	0.953	rs17163666	chr1:26525383	A/G	cg23602478	chr1:26503979	CNKSR1	0.38	7.91	0.35	1.88e-14	Height;
LGG	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.21	-0.32	2.35e-12	Initial pursuit acceleration;
LGG	trans	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg26043149	chr18:55253948	FECH	0.41	6.81	0.3	2.95e-11	Bone mineral density;
LGG	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	cg07928641	chr1:182991847	LAMC1	0.44	8.66	0.37	8.02e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.92	0.59	7.65e-46	Morning vs. evening chronotype;
LGG	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg24675658	chr1:53192096	ZYG11B	-0.68	-15.56	-0.59	3.08e-44	Monocyte count;
LGG	cis	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	11.53	0.47	3.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7428	0.527	rs1053560	chr2:85546192	C/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.9	-0.54	5.86e-37	Ear protrusion;
LGG	cis	rs6704644	0.722	rs72980338	chr2:234325023	C/T	cg27060346	chr2:234359958	DGKD	-0.61	-6.93	-0.31	1.4e-11	Bilirubin levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05557255	chr11:2422385	TSSC4	-0.42	-6.89	-0.3	1.89e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg07061783	chr6:25882402	NA	-0.38	-6.9	-0.31	1.75e-11	Blood metabolite levels;
LGG	cis	rs13064447	0.845	rs73022960	chr3:12775803	C/T	cg23032965	chr3:12705835	RAF1	-0.46	-7.04	-0.31	6.98e-12	Major depression and alcohol dependence;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg18032289	chr17:61959525	GH2	-0.41	-7.12	-0.31	4.27e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1953600	0.715	rs1079242	chr10:81917708	C/T	cg04850286	chr10:81895943	PLAC9	0.37	7.97	0.35	1.24e-14	Sarcoidosis;
LGG	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg01191920	chr7:158217561	PTPRN2	-0.73	-16.16	-0.6	6.88e-47	Obesity-related traits;
LGG	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg00490583	chr16:1843685	IGFALS	-0.43	-7.13	-0.31	3.94e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.57	-0.37	1.5e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg26043149	chr18:55253948	FECH	0.95	16.33	0.6	1.08e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-12.12	-0.49	1.42e-29	Prudent dietary pattern;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs61906588	0.553	rs7104494	chr11:116361589	G/A	cg12564567	chr11:116371188	NA	-0.38	-7.07	-0.31	5.85e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs7177699	0.557	rs12898578	chr15:79112574	G/A	cg00540400	chr15:79124168	NA	0.53	11.0	0.46	3.79e-25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9287719	0.967	rs7593496	chr2:10738176	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.15	-0.52	9.06e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.16	-0.78	7.4e-98	Height;
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	5.99e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg17202724	chr17:61916730	SMARCD2	-0.41	-8.27	-0.36	1.46e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12474201	0.589	rs76089707	chr2:47013899	G/A	cg06386533	chr2:46925753	SOCS5	0.61	10.25	0.43	2.26e-22	Height;
LGG	cis	rs1712517	0.588	rs12220267	chr10:105075712	C/T	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.48e-15	Migraine;
LGG	cis	rs559555	0.512	rs655548	chr2:31836658	A/C	cg02381751	chr2:32503542	YIPF4	0.44	6.67	0.3	7.54e-11	Blood metabolite ratios;Blood metabolite levels;
LGG	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg13263323	chr15:86062960	AKAP13	-0.36	-7.48	-0.33	3.66e-13	Coronary artery disease;
LGG	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg04568710	chr12:38710424	ALG10B	-0.41	-9.13	-0.39	2.13e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.85	-0.38	1.93e-17	Mood instability;
LGG	cis	rs554111	0.963	rs601329	chr1:21044161	A/G	cg15613048	chr1:21044031	KIF17	-0.35	-7.1	-0.31	4.77e-12	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.38	-7.63	-0.33	1.32e-13	Colorectal cancer;
LGG	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg25237894	chr2:233734115	C2orf82	-0.57	-11.05	-0.46	2.29e-25	Coronary artery disease;
LGG	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.82	0.45	1.8e-24	Diabetic retinopathy;
LGG	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.48	-0.37	3.09e-16	Headache;
LGG	cis	rs2486288	0.586	rs12909625	chr15:45572053	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.64	-11.08	-0.46	1.88e-25	Glomerular filtration rate;
LGG	cis	rs7226408	0.600	rs323303	chr18:34707916	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.1	-0.39	2.77e-18	Obesity-related traits;
LGG	cis	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg04455712	chr21:45112962	RRP1B	0.52	9.72	0.41	1.93e-20	Mean corpuscular volume;
LGG	cis	rs7927771	0.524	rs7936948	chr11:47704200	T/G	cg20307385	chr11:47447363	PSMC3	0.57	11.18	0.46	7.26e-26	Subjective well-being;
LGG	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg12560992	chr17:57184187	TRIM37	0.62	10.02	0.42	1.68e-21	Cognitive function;
LGG	cis	rs1904096	0.506	rs10028613	chr4:95223698	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.6	-11.23	-0.46	4.62e-26	Type 2 diabetes;
LGG	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs16976116	0.803	rs9920136	chr15:55504102	A/G	cg11288833	chr15:55489084	RSL24D1	0.57	7.65	0.33	1.19e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1670533	0.746	rs688008	chr4:1082829	T/C	cg27284194	chr4:1044797	NA	0.55	9.9	0.42	4.21e-21	Recombination rate (females);
LGG	trans	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.47	-0.37	3.33e-16	Bladder cancer;
LGG	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg13114125	chr14:105738426	BRF1	-0.83	-16.25	-0.6	2.53e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.6	0.37	1.23e-16	Calcium levels;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13600149	chr9:98079129	FANCC	0.38	6.75	0.3	4.31e-11	Bilirubin levels;
LGG	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg01950434	chr2:97203154	ARID5A	-0.6	-9.5	-0.4	1.17e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.7	-0.34	8.23e-14	Lung cancer;
LGG	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg02153584	chr22:29168773	CCDC117	0.7	11.81	0.48	2.6e-28	Lymphocyte counts;
LGG	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg03162506	chr22:38580953	NA	0.36	8.6	0.37	1.27e-16	Breast cancer;
LGG	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.3	-0.4	5.51e-19	Height;
LGG	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg08344181	chr3:125677491	NA	-0.9	-9.02	-0.39	5.1e-18	Depression;
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.02	-0.46	3.21e-25	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg23782820	chr8:58130467	NA	0.54	8.1	0.35	4.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg06421707	chr20:25228305	PYGB	0.48	10.77	0.45	2.65e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg05552183	chr6:42928497	GNMT	0.48	14.48	0.56	1.77e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11213987	chr17:4607616	PELP1	-0.45	-7.22	-0.32	2.15e-12	Pancreatic cancer;
LGG	cis	rs757978	0.929	rs115271170	chr2:242347614	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-8.59	-0.37	1.37e-16	Chronic lymphocytic leukemia;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.5	0.65	1.3e-57	Personality dimensions;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg19635926	chr16:89946313	TCF25	0.71	8.01	0.35	9.07e-15	Skin colour saturation;
LGG	cis	rs1707322	0.827	rs10890347	chr1:46242332	A/T	cg03146154	chr1:46216737	IPP	-0.59	-9.93	-0.42	3.5e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.38	0.47	1.26e-26	Schizophrenia;
LGG	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.6	0.33	1.61e-13	Neuroticism;
LGG	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg22676075	chr6:135203613	NA	0.36	6.66	0.3	7.78e-11	Red blood cell count;
LGG	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg06718696	chr17:78121285	EIF4A3	0.43	7.16	0.32	3.09e-12	Yeast infection;
LGG	cis	rs870825	0.616	rs10013562	chr4:185610486	A/G	cg04058563	chr4:185651563	MLF1IP	1.0	21.41	0.71	3.59e-71	Blood protein levels;
LGG	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg13802316	chr11:70253460	CTTN	-0.69	-9.24	-0.39	9.03e-19	Coronary artery disease;
LGG	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg02187348	chr16:89574699	SPG7	0.47	7.52	0.33	2.95e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg13263323	chr15:86062960	AKAP13	-0.38	-8.38	-0.36	6.56e-16	Interstitial lung disease;
LGG	cis	rs258892	0.793	rs6452682	chr5:72082390	T/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs61990749	0.597	rs12887606	chr14:78200620	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs7412746	0.611	rs752376	chr1:150941381	C/T	cg15448220	chr1:150897856	SETDB1	0.36	6.68	0.3	7.05e-11	Melanoma;
LGG	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg23173402	chr1:227635558	NA	0.48	7.16	0.32	3.24e-12	Major depressive disorder;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.75e-26	Bipolar disorder;
LGG	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg00717180	chr2:96193071	NA	0.4	7.16	0.32	3.17e-12	Coronary artery disease;
LGG	cis	rs7666738	0.791	rs13111960	chr4:98976851	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg02733842	chr7:1102375	C7orf50	0.46	8.41	0.36	5.25e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.63	0.44	9.47e-24	Blood protein levels;
LGG	cis	rs4538187	1.000	rs6546030	chr2:64071651	G/A	cg14150252	chr2:64069583	UGP2	0.49	9.72	0.41	1.9e-20	Systolic blood pressure;
LGG	cis	rs7100689	0.646	rs1934692	chr10:82125734	C/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs3820068	0.581	rs1547033	chr1:15918988	T/C	cg05660106	chr1:15850417	CASP9	0.84	17.3	0.63	4.57e-52	Systolic blood pressure;
LGG	cis	rs12477438	0.520	rs2290261	chr2:100021184	A/G	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs2268241	0.938	rs17878783	chr21:34779185	G/A	cg14850771	chr21:34775459	IFNGR2	0.76	9.2	0.39	1.24e-18	Obesity-related traits;
LGG	cis	rs4417704	0.551	rs4675789	chr2:241875481	A/G	cg26818257	chr2:241905806	NA	-0.49	-11.21	-0.46	5.59e-26	Joint mobility (Beighton score);
LGG	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg12082025	chr19:1064218	ABCA7	-0.46	-7.08	-0.31	5.49e-12	Alzheimer's disease (late onset);
LGG	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg05835009	chr4:710272	PCGF3	0.48	8.18	0.36	2.68e-15	White blood cell count;
LGG	cis	rs6032067	0.641	rs34622539	chr20:43756548	A/T	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg22920501	chr2:26401640	FAM59B	0.46	9.48	0.4	1.38e-19	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg21775007	chr8:11205619	TDH	0.5	8.15	0.35	3.35e-15	Neuroticism;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14295842	chr14:50234897	KLHDC2	-0.44	-7.28	-0.32	1.48e-12	Brain structure;
LGG	cis	rs1595825	1.000	rs56765024	chr2:198876286	G/T	cg00982548	chr2:198649783	BOLL	-0.48	-6.68	-0.3	7e-11	Ulcerative colitis;
LGG	cis	rs1847505	0.957	rs2134869	chr13:61523637	A/G	cg25164009	chr13:61490935	NA	-0.61	-9.72	-0.41	1.85e-20	Polychlorinated biphenyl levels;
LGG	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg19468946	chr17:37922297	IKZF3	-0.37	-6.66	-0.3	8.02e-11	Self-reported allergy;
LGG	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg02975922	chr3:195473998	MUC4	0.46	7.33	0.32	1e-12	Mean corpuscular volume;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.34e-18	Obesity-related traits;
LGG	cis	rs1107366	0.722	rs2364368	chr3:125905080	A/T	cg01346077	chr3:125931526	NA	0.4	9.81	0.41	9.21e-21	Metabolite levels;
LGG	cis	rs10186029	0.582	rs1441165	chr2:214009831	A/G	cg08319019	chr2:214017104	IKZF2	0.43	7.5	0.33	3.36e-13	Systemic sclerosis;
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.19	0.36	2.59e-15	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg25019033	chr10:957182	NA	0.55	10.1	0.42	8.12e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7660883	0.897	rs1037814	chr4:88049850	T/C	cg21988461	chr4:88008667	AFF1	0.35	9.97	0.42	2.38e-21	HDL cholesterol levels;
LGG	cis	rs3206736	0.729	rs1052355	chr7:35119776	A/T	cg13400248	chr7:35225412	NA	0.44	8.09	0.35	5.29e-15	Diastolic blood pressure;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg12379764	chr21:47803548	PCNT	-0.46	-7.9	-0.34	2.04e-14	Testicular germ cell tumor;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.4	-7.72	-0.34	7.11e-14	Schizophrenia;
LGG	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.95	-0.42	2.87e-21	Blood metabolite levels;
LGG	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg11764359	chr7:65958608	NA	0.73	13.13	0.52	1.06e-33	Aortic root size;
LGG	cis	rs4642101	0.824	rs11717013	chr3:12843862	A/C	cg24848339	chr3:12840334	CAND2	0.38	8.61	0.37	1.18e-16	QRS complex (12-leadsum);
LGG	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg09021430	chr5:549028	NA	-0.69	-9.86	-0.42	6.16e-21	Obesity-related traits;
LGG	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.73	0.59	5.41e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.92	-0.42	3.68e-21	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg00319359	chr11:70116639	PPFIA1	0.71	7.45	0.33	4.62e-13	Coronary artery disease;
LGG	cis	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg18131467	chr2:239335373	ASB1	-0.7	-8.26	-0.36	1.54e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg04025307	chr7:1156635	C7orf50	0.58	9.1	0.39	2.71e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17286411	0.750	rs4788575	chr16:71931126	T/G	cg03805757	chr16:71968109	PKD1L3	0.34	7.07	0.31	5.83e-12	Blood protein levels;
LGG	cis	rs477692	0.517	rs871026	chr10:131293145	A/G	cg05714579	chr10:131428358	MGMT	-0.54	-10.58	-0.44	1.38e-23	Response to temozolomide;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs10463554	0.963	rs7721530	chr5:102362192	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.71	-0.34	7.88e-14	Parkinson's disease;
LGG	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg23730037	chr7:158596552	ESYT2	0.4	6.77	0.3	4.02e-11	Height;
LGG	cis	rs12135191	0.935	rs7550202	chr1:236471558	G/A	cg21399712	chr1:236511386	NA	-0.41	-7.85	-0.34	2.93e-14	Urate levels (BMI interaction);
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg15383120	chr6:291909	DUSP22	-0.54	-8.83	-0.38	2.17e-17	Menopause (age at onset);
LGG	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.49	0.33	3.57e-13	Intelligence (multi-trait analysis);Educational attainment (years of education);
LGG	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg08250081	chr4:10125330	NA	-0.46	-9.2	-0.39	1.23e-18	Bone mineral density;
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.95	0.38	8.46e-18	Aortic root size;
LGG	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.02	-0.46	3.07e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.79	-0.38	2.93e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg22705602	chr4:152727874	NA	-0.38	-9.51	-0.4	1.06e-19	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.960	rs11857092	chr15:90960115	T/C	cg22089800	chr15:90895588	ZNF774	0.5	7.82	0.34	3.67e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.82	-0.42	8.37e-21	Primary sclerosing cholangitis;
LGG	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg03929089	chr4:120376271	NA	-0.87	-17.67	-0.63	9.22e-54	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09217309	chr6:150244204	RAET1G	0.41	7.36	0.32	8.37e-13	Testicular germ cell tumor;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg27532560	chr4:187881888	NA	-0.59	-12.94	-0.52	6.87e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3106136	1.000	rs2664871	chr4:95146281	A/G	cg11021082	chr4:95130006	SMARCAD1	0.46	8.2	0.36	2.43e-15	Capecitabine sensitivity;
LGG	cis	rs7017697	0.507	rs10112790	chr8:19684414	A/T	cg03894339	chr8:19674705	INTS10	-0.65	-9.41	-0.4	2.31e-19	Breast cancer;
LGG	cis	rs9814567	0.727	rs4543053	chr3:134351724	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.94	-0.45	6.09e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9815354	0.812	rs73083333	chr3:41927505	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.5	0.4	1.11e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg27446573	chr6:127587934	RNF146	0.71	12.57	0.5	2.25e-31	Breast cancer;
LGG	cis	rs7917772	0.582	rs4919663	chr10:104363293	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.49e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg12219531	chr12:120966889	COQ5	0.68	11.19	0.46	7.07e-26	High light scatter reticulocyte count;
LGG	cis	rs490234	0.729	rs10819050	chr9:128237178	G/T	cg14078157	chr9:128172775	NA	-0.43	-8.05	-0.35	6.86e-15	Mean arterial pressure;
LGG	cis	rs17253792	0.822	rs80321745	chr14:56162947	T/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.05	-0.49	2.88e-29	Putamen volume;
LGG	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-11.91	-0.48	1.01e-28	Pancreatic cancer;
LGG	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg02487422	chr3:49467188	NICN1	0.47	8.28	0.36	1.32e-15	Red cell distribution width;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg01262667	chr19:19385393	TM6SF2	0.45	11.45	0.47	6.54e-27	Tonsillectomy;
LGG	cis	rs922107	0.846	rs4486433	chr1:90007316	G/T	cg01128109	chr1:89989507	LRRC8B	-0.35	-7.91	-0.34	1.96e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03264133	chr6:25882463	NA	0.53	9.75	0.41	1.53e-20	Blood metabolite levels;
LGG	cis	rs17767392	1.000	rs34528131	chr14:71861278	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.07	0.39	3.33e-18	Mitral valve prolapse;
LGG	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.18e-13	Lung cancer in ever smokers;
LGG	trans	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.84	0.3	2.45e-11	Retinal vascular caliber;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.56	0.37	1.73e-16	Lung cancer;
LGG	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg04374321	chr14:90722782	PSMC1	0.43	6.76	0.3	4.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg12591125	chr7:1885375	MAD1L1	0.43	7.2	0.32	2.47e-12	Bipolar disorder;
LGG	cis	rs34599045	0.522	rs34974823	chr1:153017026	A/T	cg07796016	chr1:152779584	LCE1C	-0.88	-7.86	-0.34	2.67e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11679564	0.714	rs4670638	chr2:37164911	C/G	cg14987922	chr2:37194071	STRN	0.49	8.01	0.35	9.7e-15	Immature fraction of reticulocytes;
LGG	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg16386425	chr10:429943	DIP2C	-0.45	-8.92	-0.38	1.06e-17	Psychosis in Alzheimer's disease;
LGG	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.3	0.43	1.58e-22	Motion sickness;
LGG	cis	rs9381107	1.000	rs9381212	chr6:9476532	C/T	cg14735645	chr6:9486422	NA	-0.49	-8.03	-0.35	7.94e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg20503657	chr10:835505	NA	0.75	10.34	0.43	1.12e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7085104	0.513	rs192569	chr10:104577915	T/C	cg04362960	chr10:104952993	NT5C2	-0.44	-7.88	-0.34	2.43e-14	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs67311347	1.000	rs6599094	chr3:40399593	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.26	-0.69	8.47e-66	Renal cell carcinoma;
LGG	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.23	0.63	9.09e-52	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Bladder cancer;
LGG	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.85	0.34	3e-14	Cannabis dependence symptom count;
LGG	cis	rs9357271	0.736	rs9380753	chr6:38416590	G/A	cg07362130	chr6:38359646	BTBD9	-0.4	-8.4	-0.36	5.67e-16	Restless legs syndrome;
LGG	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg08999081	chr20:33150536	PIGU	0.32	7.47	0.33	3.95e-13	Coronary artery disease;
LGG	cis	rs938554	0.806	rs4447862	chr4:9931645	C/G	cg25986240	chr4:9926439	SLC2A9	0.41	8.17	0.36	2.89e-15	Blood metabolite levels;
LGG	trans	rs6561151	0.957	rs2121034	chr13:44473866	G/T	cg12856521	chr11:46389249	DGKZ	0.74	12.85	0.51	1.55e-32	Crohn's disease;
LGG	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs977987	0.864	rs37594	chr16:75496943	T/C	cg07303275	chr16:75499416	TMEM170A	-0.43	-7.63	-0.33	1.39e-13	Dupuytren's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04777683	chr1:185286462	IVNS1ABP	0.41	6.66	0.3	7.97e-11	Gut microbiome composition (summer);
LGG	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.45	0.44	4.28e-23	Arsenic metabolism;
LGG	cis	rs7523273	0.564	rs1977265	chr1:207880683	G/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.77	-0.38	3.38e-17	Schizophrenia;
LGG	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg16339924	chr4:17578868	LAP3	0.52	8.7	0.37	5.75e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.34	0.32	9.5e-13	Schizophrenia;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg11062466	chr8:58055876	NA	0.59	9.9	0.42	4.29e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.49	0.37	2.87e-16	Schizophrenia;
LGG	cis	rs6448317	0.863	rs2695228	chr4:24901985	C/T	cg21108841	chr4:24914750	CCDC149	0.52	7.22	0.32	2.09e-12	Heschl's gyrus morphology;
LGG	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.64	0.48	1.16e-27	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg02002194	chr4:3960332	NA	-0.49	-8.97	-0.38	7.17e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06214220	chr9:36400252	RNF38	0.5	8.13	0.35	3.95e-15	Cognitive performance;
LGG	cis	rs8017423	0.935	rs11159960	chr14:90740012	C/T	cg04374321	chr14:90722782	PSMC1	-0.87	-17.81	-0.64	1.92e-54	Mortality in heart failure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14466961	chr4:493368	ZNF721;PIGG	0.41	6.9	0.31	1.74e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9914544	0.545	rs35911764	chr17:18782582	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg07061783	chr6:25882402	NA	-0.46	-7.74	-0.34	6.43e-14	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10193935	1.000	rs72796507	chr2:42409840	A/G	cg27598129	chr2:42591480	NA	-0.62	-9.1	-0.39	2.66e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg08250081	chr4:10125330	NA	0.42	8.15	0.35	3.43e-15	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20087917	chr14:77924039	C14orf133;AHSA1	0.5	7.85	0.34	3e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg16507663	chr6:150244633	RAET1G	0.41	7.4	0.33	6.34e-13	Lung cancer;
LGG	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg02023728	chr11:77925099	USP35	-0.38	-6.84	-0.3	2.48e-11	Alzheimer's disease (survival time);
LGG	cis	rs4731207	0.698	rs2286173	chr7:124465951	A/C	cg05630886	chr7:124431682	NA	0.34	7.83	0.34	3.31e-14	Cutaneous malignant melanoma;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.29	-0.32	1.39e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.39	-0.32	7.09e-13	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12517041	0.515	rs17312807	chr5:23325432	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-9.0	-0.39	5.86e-18	Calcium levels;
LGG	cis	rs2652834	0.851	rs2652824	chr15:63420001	C/T	cg05507819	chr15:63340323	TPM1	0.5	7.02	0.31	7.76e-12	HDL cholesterol;
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg23796481	chr11:64053134	BAD;GPR137	0.75	13.89	0.54	6.32e-37	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg15736062	chr7:158136485	PTPRN2	-0.41	-7.92	-0.35	1.83e-14	Calcium levels;
LGG	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg08446824	chr4:1720184	TMEM129	0.65	11.87	0.48	1.51e-28	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg26838691	chr2:24397539	C2orf84	-0.48	-6.79	-0.3	3.4e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg19894588	chr14:64061835	NA	-0.57	-9.04	-0.39	4.14e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg11657817	chr20:23433608	CST11	0.4	8.08	0.35	5.56e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04004882	chr2:215674386	BARD1	0.51	7.08	0.31	5.45e-12	Neuroblastoma;
LGG	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11890956	chr21:40555474	PSMG1	0.75	12.88	0.51	1.13e-32	Cognitive function;
LGG	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg06640241	chr16:89574553	SPG7	0.92	17.87	0.64	1.01e-54	Multiple myeloma (IgH translocation);
LGG	cis	rs1620921	0.653	rs62435277	chr6:161265332	C/T	cg01280913	chr6:161186852	NA	-0.37	-7.5	-0.33	3.24e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg14092988	chr3:52407081	DNAH1	0.3	7.9	0.34	2e-14	Electroencephalogram traits;
LGG	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg16482183	chr6:26056742	HIST1H1C	0.92	13.8	0.54	1.52e-36	Iron status biomarkers;
LGG	cis	rs8017423	0.935	rs17260827	chr14:90732703	G/A	cg04374321	chr14:90722782	PSMC1	-0.9	-18.46	-0.65	1.97e-57	Mortality in heart failure;
LGG	cis	rs4716602	0.596	rs1996994	chr7:156159694	A/G	cg16983916	chr7:156159713	NA	0.5	9.71	0.41	2.07e-20	Anti-saccade response;
LGG	trans	rs11088226	1.000	rs2833889	chr21:33927768	G/T	cg09050820	chr6:167586206	TCP10L2	-0.68	-9.95	-0.42	3e-21	Gastritis;
LGG	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg07661805	chr8:143867942	LY6D	-0.3	-8.05	-0.35	7.22e-15	Urinary tract infection frequency;
LGG	cis	rs7523273	0.526	rs677715	chr1:208047284	A/G	cg22525895	chr1:207977042	MIR29B2	0.47	8.66	0.37	8.05e-17	Schizophrenia;
LGG	cis	rs4851254	0.921	rs11679078	chr2:100757881	C/G	cg17356467	chr2:100759845	AFF3	0.42	7.33	0.32	1.05e-12	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.853	rs5757187	chr22:39021522	A/G	cg06022373	chr22:39101656	GTPBP1	-0.88	-17.63	-0.63	1.4e-53	Menopause (age at onset);
LGG	trans	rs629535	0.783	rs538832	chr8:70033817	A/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.28	0.43	1.75e-22	Height;
LGG	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.81	-0.34	3.89e-14	Myeloid white cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18193109	chr2:179345747	MIR548N;PLEKHA3	0.46	6.84	0.3	2.48e-11	Gut microbiome composition (summer);
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.68	0.34	9.3e-14	Prostate cancer;
LGG	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.52	0.33	2.89e-13	Triglycerides;
LGG	cis	rs6087990	0.735	rs2424907	chr20:31359819	C/T	cg13636640	chr20:31349939	DNMT3B	0.84	17.33	0.63	3.25e-52	Ulcerative colitis;
LGG	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg04455712	chr21:45112962	RRP1B	0.5	9.4	0.4	2.56e-19	Mean corpuscular volume;
LGG	cis	rs11966931	1.000	rs11966931	chr6:108131298	G/A	cg04749840	chr6:108095067	SCML4	0.44	7.48	0.33	3.72e-13	Neutrophil percentage of white cells;
LGG	trans	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-8.99	-0.39	6.44e-18	Brugada syndrome;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg02127607	chr17:61920694	SMARCD2	0.46	8.19	0.36	2.6e-15	Prudent dietary pattern;
LGG	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg21466736	chr12:48725269	NA	-0.39	-7.78	-0.34	4.78e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-15.14	-0.58	2.4e-42	Response to antipsychotic treatment;
LGG	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg12654349	chr5:56205094	C5orf35	0.76	11.13	0.46	1.15e-25	Initial pursuit acceleration;
LGG	cis	rs736408	0.632	rs2240919	chr3:52831701	C/G	cg18404041	chr3:52824283	ITIH1	-0.57	-10.35	-0.43	1.04e-22	Bipolar disorder;
LGG	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.86	-0.62	4.39e-50	Height;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs357618	1.000	rs165353	chr5:150856757	C/T	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.77	-0.3	3.81e-11	Basophil percentage of white cells;
LGG	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs73086581	1.000	rs73086549	chr20:3954662	C/A	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg23306229	chr2:178417860	TTC30B	-0.69	-9.16	-0.39	1.65e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	trans	rs9929218	1.000	rs13334294	chr16:68809278	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.85	-0.51	1.59e-32	Colorectal cancer;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs11122272	0.735	rs2790897	chr1:231491712	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.18	-0.32	2.75e-12	Hemoglobin concentration;
LGG	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg11941060	chr3:133502564	NA	-0.48	-8.04	-0.35	7.71e-15	Iron status biomarkers;
LGG	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg03929089	chr4:120376271	NA	0.69	7.59	0.33	1.75e-13	Intraocular pressure;
LGG	trans	rs7939886	0.920	rs11227507	chr11:55972274	G/A	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs787274	1.000	rs787294	chr9:115540424	T/C	cg13803584	chr9:115635662	SNX30	-0.59	-7.31	-0.32	1.16e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg07701084	chr6:150067640	NUP43	0.68	12.81	0.51	2.34e-32	Lung cancer;
LGG	cis	rs4742903	0.526	rs12341282	chr9:106913250	T/C	cg14250997	chr9:106856677	SMC2	-0.37	-7.42	-0.33	5.69e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg05692746	chr2:100937584	LONRF2	0.59	9.65	0.41	3.47e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg15971980	chr6:150254442	NA	0.44	8.31	0.36	1.09e-15	Lung cancer;
LGG	cis	rs1707322	1.000	rs7538978	chr1:46505054	C/T	cg03146154	chr1:46216737	IPP	-0.51	-9.88	-0.42	5.3e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02512021	chr16:88966376	CBFA2T3	0.37	6.77	0.3	3.93e-11	Pancreatic cancer;
LGG	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.79	-0.78	3.74e-96	Height;
LGG	cis	rs17504614	0.634	rs67134957	chr2:51052060	A/C	cg23851515	chr2:51057218	NRXN1	0.48	7.86	0.34	2.77e-14	Educational attainment (years of education);
LGG	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg08885076	chr2:99613938	TSGA10	0.42	8.97	0.38	7.48e-18	Chronic sinus infection;
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg13628971	chr7:2884303	GNA12	0.51	9.81	0.41	9.28e-21	Height;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.81	-0.45	1.98e-24	Lung cancer;
LGG	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg11890956	chr21:40555474	PSMG1	1.19	27.97	0.79	1.57e-101	Cognitive function;
LGG	cis	rs806215	1.000	rs806216	chr7:127237862	C/A	cg25922125	chr7:127225783	GCC1	-0.78	-10.49	-0.44	3.02e-23	Type 2 diabetes;
LGG	cis	rs10504073	0.647	rs6997703	chr8:49998364	T/C	cg00325661	chr8:49890786	NA	0.74	14.23	0.55	2.2e-38	Blood metabolite ratios;
LGG	cis	rs9517320	0.935	rs56294784	chr13:99123198	C/T	cg07423050	chr13:99094983	FARP1	0.39	7.86	0.34	2.71e-14	Longevity;
LGG	cis	rs504918	0.506	rs73188196	chr3:124028519	A/T	cg05766129	chr3:123988013	KALRN	-0.57	-10.13	-0.43	6.53e-22	Schizophrenia;
LGG	cis	rs10197940	0.578	rs2045025	chr2:152317531	T/C	cg06191203	chr2:152266755	RIF1	-0.38	-6.73	-0.3	4.88e-11	Lung cancer;
LGG	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.13	-0.43	6.39e-22	Triglycerides;
LGG	trans	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-7.59	-0.33	1.75e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg12560992	chr17:57184187	TRIM37	-0.89	-15.79	-0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg23758822	chr17:41437982	NA	0.87	15.43	0.58	1.29e-43	Menopause (age at onset);
LGG	cis	rs17767392	0.958	rs12892512	chr14:71983296	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.21	-0.39	1.11e-18	Mitral valve prolapse;
LGG	cis	rs7666738	0.830	rs11725477	chr4:98803266	G/T	cg05340658	chr4:99064831	C4orf37	0.46	7.36	0.32	8.41e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13596200	chr2:26257549	RAB10	0.55	8.01	0.35	9.51e-15	Gut microbiome composition (summer);
LGG	trans	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg23762105	chr12:34175262	ALG10	0.35	6.9	0.31	1.77e-11	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.22	-0.43	3.04e-22	Response to antipsychotic treatment;
LGG	cis	rs1519814	1.000	rs6983133	chr8:121166682	T/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.25	-0.46	4.05e-26	Breast cancer;
LGG	cis	rs71403859	0.730	rs12922775	chr16:71584354	C/T	cg08717414	chr16:71523259	ZNF19	-1.18	-16.23	-0.6	3.21e-47	Post bronchodilator FEV1;
LGG	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.46	-0.47	6e-27	Response to antipsychotic treatment;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg20999797	chr1:1681921	NA	0.33	7.21	0.32	2.3e-12	Body mass index;
LGG	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg07395648	chr5:131743802	NA	-0.55	-13.18	-0.52	6.52e-34	Blood metabolite levels;
LGG	cis	rs11225247	0.881	rs10895292	chr11:102245718	G/C	cg06323957	chr11:102217781	BIRC2	0.83	7.21	0.32	2.26e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.16e-17	Cognitive test performance;
LGG	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg03929089	chr4:120376271	NA	0.81	11.17	0.46	7.87e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg16606324	chr3:10149918	C3orf24	0.53	6.98	0.31	1.04e-11	Alzheimer's disease;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg15704280	chr7:45808275	SEPT13	-0.54	-9.0	-0.39	5.77e-18	Height;
LGG	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg14664628	chr15:75095509	CSK	-0.8	-16.48	-0.61	2.38e-48	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.51	-0.67	2.48e-62	Rheumatoid arthritis;
LGG	trans	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.58	-0.33	1.85e-13	Menarche (age at onset);
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg13010199	chr12:38710504	ALG10B	0.74	15.19	0.58	1.43e-42	Heart rate;
LGG	cis	rs7737355	0.812	rs251012	chr5:131030295	A/G	cg06307176	chr5:131281290	NA	-0.53	-8.82	-0.38	2.31e-17	Life satisfaction;
LGG	trans	rs2548003	0.871	rs2433288	chr5:28730106	C/G	cg12623145	chr2:97778927	ANKRD36	0.44	6.82	0.3	2.8e-11	Hip geometry;
LGG	cis	rs1620921	0.902	rs1406890	chr6:161187335	C/T	cg01280913	chr6:161186852	NA	-0.33	-6.96	-0.31	1.17e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.27	0.32	1.52e-12	Total cholesterol levels;
LGG	cis	rs2694528	0.841	rs75979228	chr5:60228016	A/C	cg11474532	chr5:59995715	DEPDC1B	0.72	6.92	0.31	1.47e-11	Parkinson's disease;
LGG	cis	rs539514	0.627	rs9544034	chr13:76293764	G/A	cg04757411	chr13:76259545	LMO7	-0.27	-7.07	-0.31	5.71e-12	Type 1 diabetes;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs969413	0.535	rs61698755	chr17:79257880	T/C	cg25342872	chr17:79175132	AZI1	-0.48	-7.84	-0.34	3.12e-14	Frontotemporal dementia;
LGG	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg18898632	chr2:242989856	NA	-0.81	-10.1	-0.43	7.95e-22	Obesity-related traits;
LGG	cis	rs2665103	0.589	rs3858953	chr15:82530390	A/G	cg00614314	chr15:82944287	LOC80154	0.46	7.67	0.34	1.05e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-6.98	-0.31	1.01e-11	Daytime sleep phenotypes;
LGG	trans	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.12e-19	Gout;
LGG	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg21775007	chr8:11205619	TDH	-0.75	-12.93	-0.52	7.4e-33	Retinal vascular caliber;
LGG	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21659725	chr3:3221576	CRBN	0.63	10.5	0.44	2.92e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9912468	1.000	rs9912468	chr17:64318357	C/G	cg19474267	chr17:64306194	PRKCA	0.97	28.4	0.8	1.77e-103	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.21	0.55	2.62e-38	IgG glycosylation;
LGG	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.75	0.45	3.27e-24	Arsenic metabolism;
LGG	cis	rs10206020	0.885	rs13411553	chr2:1574018	A/G	cg26248373	chr2:1572462	NA	-0.87	-15.59	-0.59	2.41e-44	IgG glycosylation;
LGG	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg26695010	chr11:65641043	EFEMP2	0.46	7.13	0.31	3.79e-12	Breast cancer;
LGG	trans	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg12705353	chr12:122356852	WDR66	0.24	6.75	0.3	4.49e-11	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg16606324	chr3:10149918	C3orf24	0.52	6.78	0.3	3.6e-11	Alzheimer's disease;
LGG	cis	rs12447804	0.645	rs35033732	chr16:58108191	G/A	cg03859792	chr16:58121049	NA	0.63	9.76	0.41	1.42e-20	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.72	0.34	7.32e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7551222	0.789	rs2290855	chr1:204515863	C/T	cg20240347	chr1:204465584	NA	-0.54	-10.65	-0.44	7.74e-24	Schizophrenia;
LGG	cis	rs836589	0.517	rs7590282	chr2:173534873	C/T	cg06468108	chr2:173539091	NA	-0.37	-6.79	-0.3	3.41e-11	Erectile dysfunction in type 1 diabetes;
LGG	cis	rs7914558	0.966	rs1971589	chr10:104744406	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.51	0.44	2.62e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2120243	0.621	rs7634847	chr3:157159145	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.35	7.51	0.33	2.98e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3936840	0.861	rs1044502	chr14:102965897	G/A	cg18135206	chr14:102964638	TECPR2	0.5	8.43	0.36	4.36e-16	Plateletcrit;
LGG	cis	rs974417	0.529	rs7771745	chr6:97345233	G/A	cg10979063	chr6:97285822	GPR63	0.4	6.71	0.3	5.68e-11	Body mass index;
LGG	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg04568710	chr12:38710424	ALG10B	0.34	6.8	0.3	3.26e-11	Bladder cancer;
LGG	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg04398451	chr17:18023971	MYO15A	0.73	14.64	0.56	3.71e-40	Total body bone mineral density;
LGG	cis	rs7551222	0.680	rs2169137	chr1:204497913	G/C	cg20240347	chr1:204465584	NA	-0.45	-7.94	-0.35	1.56e-14	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg16507663	chr6:150244633	RAET1G	0.46	8.53	0.37	2.07e-16	Lung cancer;
LGG	cis	rs4846580	0.622	rs12026289	chr1:219876281	C/T	cg08034750	chr1:219919793	NA	0.41	7.33	0.32	1.01e-12	Total body bone mineral density;
LGG	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg20673091	chr1:2541236	MMEL1	0.78	18.3	0.65	1.14e-56	Ulcerative colitis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06024111	chr6:43597558	MAD2L1BP;GTPBP2	0.4	6.91	0.31	1.56e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs787274	0.850	rs7873289	chr9:115638386	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-8.93	-0.38	1.03e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27574168	chr18:54318782	WDR7	0.45	7.6	0.33	1.68e-13	Cognitive performance;
LGG	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg14416269	chr4:6271139	WFS1	0.52	9.48	0.4	1.35e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg00409905	chr10:38381863	ZNF37A	0.48	7.08	0.31	5.36e-12	Obesity (extreme);
LGG	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg08400814	chr5:56204995	C5orf35	-0.42	-6.87	-0.3	2.05e-11	Initial pursuit acceleration;
LGG	cis	rs4240897	0.935	rs1474868	chr1:12044164	A/G	cg07603449	chr1:11986842	KIAA2013	0.24	6.66	0.3	7.73e-11	Tuberculosis;
LGG	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg09324608	chr17:30823087	MYO1D	0.31	7.45	0.33	4.74e-13	Schizophrenia;
LGG	cis	rs2173063	1.000	rs2173063	chr15:93131632	G/A	cg07052004	chr15:93132129	NA	0.64	7.39	0.32	6.82e-13	Subcutaneous adipose tissue;
LGG	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg03959625	chr15:84868606	LOC388152	0.47	7.06	0.31	5.94e-12	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.66	-0.3	7.88e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg16606324	chr3:10149918	C3orf24	0.53	6.97	0.31	1.13e-11	Alzheimer's disease;
LGG	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg03213289	chr20:61660250	NA	0.66	14.44	0.56	2.77e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18402987	chr7:1209562	NA	0.4	7.17	0.32	2.93e-12	Longevity;Endometriosis;
LGG	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg24675658	chr1:53192096	ZYG11B	0.62	13.32	0.53	1.78e-34	Monocyte count;
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06481639	chr22:41940642	POLR3H	-0.63	-9.21	-0.39	1.17e-18	Vitiligo;
LGG	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.61e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs858239	0.539	rs4295546	chr7:23191021	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.67	0.3	7.45e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.27	0.4	7.36e-19	Red blood cell count;
LGG	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg08807101	chr21:30365312	RNF160	0.85	17.39	0.63	1.72e-52	Dental caries;
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.53e-11	Bipolar disorder;
LGG	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg04398451	chr17:18023971	MYO15A	-0.63	-13.07	-0.52	1.82e-33	Total body bone mineral density;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg25427524	chr10:38739819	LOC399744	0.51	7.47	0.33	4e-13	Obesity (extreme);
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg12813108	chr7:99719912	CNPY4	-0.57	-9.05	-0.39	4.06e-18	Lung function (FEV1/FVC);
LGG	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg03563238	chr19:33554763	RHPN2	0.4	6.97	0.31	1.13e-11	Bone properties (heel);
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.26e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg06346307	chr22:19949965	COMT	-0.35	-9.32	-0.4	4.94e-19	Blood metabolite levels;
LGG	cis	rs357618	1.000	rs357618	chr5:150846612	A/G	cg03212797	chr5:150827313	SLC36A1	-0.41	-6.72	-0.3	5.31e-11	Basophil percentage of white cells;
LGG	cis	rs2273669	0.667	rs7767882	chr6:109334971	C/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg19399532	chr1:178512495	C1orf220	-0.54	-10.96	-0.45	5.19e-25	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	6.66	0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs8017423	0.967	rs11849641	chr14:90727647	T/C	cg04374321	chr14:90722782	PSMC1	0.9	18.94	0.66	1.2e-59	Mortality in heart failure;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13012494	chr21:47604986	C21orf56	-0.6	-10.61	-0.44	1.05e-23	Testicular germ cell tumor;
LGG	trans	rs2161208	0.585	rs2974101	chr5:85337276	C/A	cg01787110	chr1:109008453	NBPF6	0.45	6.68	0.3	6.68e-11	Daytime sleep phenotypes;
LGG	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	7.77	0.34	5.1e-14	Thyroid stimulating hormone;
LGG	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.52	0.33	2.88e-13	Systolic blood pressure;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.81	-0.3	3.04e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4268898	0.662	rs12052954	chr2:24425620	C/T	cg06627628	chr2:24431161	ITSN2	0.76	11.95	0.49	7.43e-29	Asthma;
LGG	trans	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.65	-0.37	8.77e-17	Lung cancer in ever smokers;
LGG	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg24881330	chr22:46731750	TRMU	0.7	7.19	0.32	2.6e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg24692254	chr21:30365293	RNF160	0.65	11.86	0.48	1.62e-28	Pancreatic cancer;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6976053	0.710	rs3757870	chr7:100496012	T/C	cg03098644	chr7:100410630	EPHB4	-0.41	-7.42	-0.33	5.66e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg26818257	chr2:241905806	NA	0.38	7.19	0.32	2.59e-12	Urinary metabolites;
LGG	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg16077055	chr2:106428750	NCK2	0.29	7.48	0.33	3.72e-13	Addiction;
LGG	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-9.08	-0.39	3.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg15017067	chr4:17643749	FAM184B	0.3	6.89	0.3	1.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.83	-0.38	2.13e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6121246	0.567	rs2811	chr20:30194248	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs7572733	0.534	rs1401092	chr2:198792320	C/A	cg00792783	chr2:198669748	PLCL1	-0.68	-11.08	-0.46	1.85e-25	Dermatomyositis;
LGG	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.45	-0.44	4.15e-23	Retinal vascular caliber;
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs10861342	1.000	rs10861356	chr12:105526965	G/T	cg23923672	chr12:105501055	KIAA1033	0.78	7.38	0.32	7.35e-13	IgG glycosylation;
LGG	cis	rs7020830	0.894	rs13300951	chr9:37146627	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	35.37	0.85	1.1e-133	Schizophrenia;
LGG	cis	rs7928758	0.887	rs76956658	chr11:134272144	G/A	cg22777979	chr11:134283252	B3GAT1	1.04	13.64	0.54	7.4e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg16586182	chr3:47516702	SCAP	-0.75	-14.02	-0.55	1.73e-37	Colorectal cancer;
LGG	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg03060546	chr3:49711283	APEH	0.75	13.34	0.53	1.38e-34	Resting heart rate;
LGG	cis	rs9596863	0.898	rs7995039	chr13:54382214	G/A	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	10.93	0.45	6.72e-25	Schizophrenia;
LGG	trans	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.1	0.42	8.2e-22	Mean corpuscular volume;
LGG	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg04450456	chr4:17643702	FAM184B	0.32	7.06	0.31	5.98e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg20913747	chr6:44695427	NA	-0.65	-10.84	-0.45	1.55e-24	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.89	0.54	6.56e-37	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00777555	chr3:57583074	ARF4	0.49	7.62	0.33	1.49e-13	Gut microbiome composition (summer);
LGG	cis	rs2802728	0.748	rs72759846	chr1:243537921	A/G	cg05593162	chr1:243577377	SDCCAG8	0.53	7.05	0.31	6.35e-12	Toenail selenium levels;
LGG	trans	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg06521331	chr12:34319734	NA	-0.54	-9.45	-0.4	1.72e-19	Bladder cancer;
LGG	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.967	rs4473252	chr17:28454423	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.59	0.53	1.2e-35	Coffee consumption (cups per day);
LGG	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg11941060	chr3:133502564	NA	-0.53	-9.16	-0.39	1.71e-18	Iron status biomarkers;
LGG	trans	rs208515	0.525	rs12193034	chr6:66677866	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.12	0.62	3.03e-51	Exhaled nitric oxide levels;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg19635926	chr16:89946313	TCF25	0.67	8.0	0.35	1.04e-14	Skin colour saturation;
LGG	cis	rs6499165	0.560	rs3743741	chr16:68344945	G/C	cg07273125	chr16:68295692	NA	0.46	10.42	0.44	5.64e-23	Metabolic traits;
LGG	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg17425144	chr1:10567563	PEX14	-0.63	-17.36	-0.63	2.44e-52	Prostate cancer;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12602172	1	rs12602172	chr17:38163567	G/A	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	Neutrophil percentage of white cells;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg05368731	chr17:41323189	NBR1	0.96	18.01	0.64	2.3e-55	Menopause (age at onset);
LGG	cis	rs11690935	0.632	rs6737308	chr2:172872042	G/A	cg13550731	chr2:172543902	DYNC1I2	0.66	12.64	0.51	1.12e-31	Schizophrenia;
LGG	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg20336341	chr7:50628841	DDC	0.5	9.44	0.4	1.9e-19	Malaria;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg11608241	chr8:8085544	FLJ10661	0.34	7.89	0.34	2.13e-14	Neuroticism;
LGG	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.92	-0.31	1.47e-11	Blood metabolite levels;
LGG	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg12081754	chr8:22256438	SLC39A14	1.18	26.42	0.78	1.74e-94	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10170846	0.924	rs3768973	chr2:223436402	C/T	cg25565276	chr2:223520875	FARSB	0.78	13.5	0.53	2.96e-35	Schizophrenia (inflammation and infection response interaction);
LGG	trans	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg00953403	chr17:74099816	EXOC7	0.45	7.52	0.33	2.83e-13	Psychosis in Alzheimer's disease;
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.91	-0.31	1.61e-11	Retinal vascular caliber;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg22105103	chr4:187893119	NA	0.56	10.68	0.44	6.13e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7666738	0.830	rs34892904	chr4:98938097	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg06046430	chr4:77819534	ANKRD56	0.55	11.22	0.46	5.17e-26	Emphysema distribution in smoking;
LGG	cis	rs10267417	0.603	rs10278800	chr7:19909594	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	7.49	0.33	3.55e-13	Night sleep phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00171983	chr16:9185448	C16orf72	0.53	8.09	0.35	5.46e-15	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2718058	0.613	rs1562767	chr7:37758187	G/A	cg24998770	chr7:37888106	TXNDC3	-0.5	-8.46	-0.37	3.41e-16	Alzheimer's disease (late onset);
LGG	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-9.87	-0.42	5.45e-21	Aortic root size;
LGG	cis	rs2070433	0.556	rs8129460	chr21:47822544	C/T	cg12379764	chr21:47803548	PCNT	0.67	9.67	0.41	2.91e-20	Lymphocyte counts;
LGG	trans	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg06875740	chr19:51307921	C19orf48	-0.66	-6.83	-0.3	2.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16281248	chr11:64014554	PPP1R14B	0.44	7.37	0.32	8.03e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg05793240	chr7:2802953	GNA12	0.36	8.23	0.36	1.98e-15	Height;
LGG	cis	rs66731853	0.771	rs541244	chr1:20889380	G/A	cg04087271	chr1:20915334	CDA	-0.43	-7.03	-0.31	7.43e-12	Mean corpuscular volume;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.41	-0.4	2.29e-19	Lung cancer;
LGG	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.18e-13	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs894734	0.535	rs10783613	chr12:54321966	G/T	cg12374095	chr12:54320830	NA	-0.41	-7.34	-0.32	9.82e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg08085267	chr17:45401833	C17orf57	-0.59	-11.8	-0.48	2.86e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg00857998	chr1:205179979	DSTYK	0.58	9.24	0.39	9.15e-19	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13126279	chr21:47581558	C21orf56	-0.49	-8.39	-0.36	6.06e-16	Testicular germ cell tumor;
LGG	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.55e-19	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03647317	chr4:187891568	NA	-0.41	-8.76	-0.38	3.77e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	12.98	0.52	4.5e-33	Lung cancer in ever smokers;
LGG	cis	rs9549367	0.577	rs3024718	chr13:113813853	C/T	cg18105134	chr13:113819100	PROZ	0.77	14.12	0.55	6.62e-38	Platelet distribution width;
LGG	cis	rs6594713	0.604	rs34324763	chr5:112937355	T/C	cg12552261	chr5:112820674	MCC	0.61	7.76	0.34	5.64e-14	Brain cytoarchitecture;
LGG	cis	rs1267303	0.642	rs11588450	chr1:47000996	C/T	cg25110126	chr1:46999211	NA	-0.57	-9.28	-0.4	6.55e-19	Monobrow;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21076271	chr14:32546633	ARHGAP5;C14orf128	0.45	7.58	0.33	1.84e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg25457927	chr22:38595422	NA	-0.4	-9.58	-0.41	5.98e-20	Cutaneous nevi;
LGG	cis	rs1707322	1.000	rs10890377	chr1:46406594	G/A	cg03146154	chr1:46216737	IPP	0.54	10.23	0.43	2.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.64	-0.37	8.91e-17	Menopause (age at onset);
LGG	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.94	-0.42	3.09e-21	Axial length;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg27476859	chr7:2772710	GNA12	0.44	7.43	0.33	5.42e-13	Height;
LGG	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg18196295	chr10:418757	DIP2C	0.48	9.15	0.39	1.84e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.31	-0.36	1.1e-15	Height;
LGG	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg12219531	chr12:120966889	COQ5	-0.66	-11.06	-0.46	2.23e-25	High light scatter reticulocyte count;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg08621203	chr6:150244597	RAET1G	0.41	6.96	0.31	1.19e-11	Lung cancer;
LGG	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg15736062	chr7:158136485	PTPRN2	-0.52	-9.1	-0.39	2.77e-18	Response to amphetamines;
LGG	cis	rs1256061	0.603	rs1256036	chr14:64743332	C/T	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg21427119	chr20:30132790	HM13	-0.48	-8.12	-0.35	4.22e-15	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Myopia (pathological);
LGG	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-11.12	-0.46	1.26e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg10950524	chr7:2139216	MAD1L1	0.33	7.0	0.31	8.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9611519	1.000	rs2057070	chr22:41564287	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-8.41	-0.36	4.99e-16	Neuroticism;
LGG	cis	rs514024	0.801	rs522328	chr9:130475011	A/G	cg13643465	chr9:130375613	STXBP1	0.6	11.56	0.47	2.5e-27	Eating disorders (purging via substances);
LGG	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg12432903	chr7:1882776	MAD1L1	-0.43	-6.71	-0.3	5.66e-11	Bipolar disorder;
LGG	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg25309564	chr22:51001381	C22orf41	0.62	9.79	0.41	1.05e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	10.03	0.42	1.54e-21	Longevity;
LGG	cis	rs6087990	0.899	rs998382	chr20:31384136	C/T	cg13636640	chr20:31349939	DNMT3B	-0.94	-20.27	-0.69	7.25e-66	Ulcerative colitis;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.92	-0.31	1.48e-11	Lung cancer;
LGG	cis	rs12928939	0.517	rs71384782	chr16:71978591	A/G	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.57	-0.53	1.51e-35	Post bronchodilator FEV1;
LGG	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg13798912	chr7:905769	UNC84A	0.57	7.06	0.31	6.09e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg16586182	chr3:47516702	SCAP	0.42	7.01	0.31	8.21e-12	Birth weight;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg12070911	chr6:150209640	RAET1E	0.31	7.32	0.32	1.08e-12	Lung cancer;
LGG	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.22	0.65	2.5e-56	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg12458913	chr13:53173898	NA	0.63	12.21	0.49	6.36e-30	Lewy body disease;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4974559	0.739	rs28429103	chr4:1320023	G/A	cg02980000	chr4:1222292	CTBP1	0.81	8.99	0.39	6.54e-18	Systolic blood pressure;
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg03264133	chr6:25882463	NA	0.5	8.86	0.38	1.68e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3857747	0.931	rs10227645	chr7:40364609	G/C	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs71403859	0.730	rs17347255	chr16:71587225	C/T	cg08717414	chr16:71523259	ZNF19	-1.18	-16.21	-0.6	3.94e-47	Post bronchodilator FEV1;
LGG	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg05484508	chr16:89589025	SPG7	0.42	6.85	0.3	2.39e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs11605924	0.901	rs11607883	chr11:45839709	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.46	-7.92	-0.35	1.77e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg04727924	chr7:799746	HEATR2	-0.48	-7.59	-0.33	1.83e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg26150922	chr2:100937072	LONRF2	-0.57	-10.87	-0.45	1.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg12463550	chr7:65579703	CRCP	0.51	8.5	0.37	2.65e-16	Aortic root size;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.41	-7.97	-0.35	1.29e-14	Personality dimensions;
LGG	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.06	0.35	6.74e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg06028605	chr16:24865363	SLC5A11	-0.47	-7.82	-0.34	3.6e-14	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.837	rs2518320	chr6:101800400	G/A	cg27451362	chr6:101846650	GRIK2	0.71	11.33	0.47	1.97e-26	Coenzyme Q10 levels;
LGG	trans	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg10756647	chr7:56101905	PSPH	-0.79	-9.19	-0.39	1.36e-18	Diabetic kidney disease;
LGG	cis	rs7911264	0.791	rs9420589	chr10:94450233	G/T	cg25093409	chr10:94429542	NA	-0.57	-11.17	-0.46	8.24e-26	Inflammatory bowel disease;
LGG	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	cis	rs7586879	0.593	rs10198356	chr2:25130592	A/G	cg04586622	chr2:25135609	ADCY3	0.48	13.13	0.52	1.08e-33	Body mass index;
LGG	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg05163923	chr11:71159392	DHCR7	0.51	9.32	0.4	4.85e-19	Vitamin D levels;
LGG	cis	rs1109114	1.000	rs13161048	chr5:148615269	A/G	cg06539116	chr5:148597365	ABLIM3	0.55	12.95	0.52	6.26e-33	Body mass index;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04709771	chr16:646395	RAB40C	0.36	6.72	0.3	5.38e-11	Height;
LGG	cis	rs12477438	0.539	rs1839667	chr2:100064264	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.96	-0.31	1.19e-11	Chronic sinus infection;
LGG	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg03959625	chr15:84868606	LOC388152	0.56	8.69	0.37	6.32e-17	Schizophrenia;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.3	-0.43	1.56e-22	Platelet count;
LGG	cis	rs7737355	0.773	rs1019122	chr5:131099227	C/T	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.41e-17	Life satisfaction;
LGG	cis	rs6988985	0.791	rs13257680	chr8:143997309	C/T	cg10324643	chr8:143916377	GML	-0.38	-7.5	-0.33	3.22e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03264133	chr6:25882463	NA	-0.51	-9.22	-0.39	1.07e-18	Height;
LGG	cis	rs73081554	0.611	rs13071861	chr3:58371332	C/G	cg24175188	chr3:58374923	PXK	0.55	7.42	0.33	5.73e-13	Rheumatoid arthritis;
LGG	trans	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.3	-0.36	1.16e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1040	0.690	rs9393165	chr6:169620247	T/C	cg04662567	chr6:169592167	NA	-0.46	-8.02	-0.35	9.02e-15	Joint mobility (Beighton score);
LGG	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24838063	chr12:130822603	PIWIL1	0.71	13.09	0.52	1.52e-33	Menopause (age at onset);
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg14668821	chr17:77704760	ENPP7	0.42	8.28	0.36	1.33e-15	Menopause (age at onset);
LGG	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg04851639	chr8:1020857	NA	-0.43	-9.11	-0.39	2.52e-18	Schizophrenia;
LGG	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg12856521	chr11:46389249	DGKZ	-0.5	-9.06	-0.39	3.82e-18	Leprosy;
LGG	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11890956	chr21:40555474	PSMG1	1.0	21.47	0.71	1.74e-71	Cognitive function;
LGG	cis	rs643506	1.000	rs647080	chr11:111609174	A/G	cg09085632	chr11:111637200	PPP2R1B	0.57	9.2	0.39	1.21e-18	Breast cancer;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.83	-0.3	2.64e-11	Total body bone mineral density;
LGG	cis	rs28374715	0.532	rs28703570	chr15:41679492	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.36	-36.2	-0.86	4.25e-137	Ulcerative colitis;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	7.42	0.33	5.47e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg21545522	chr1:205238299	TMCC2	0.49	8.98	0.39	6.64e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.83	0.34	3.28e-14	Tonsillectomy;
LGG	cis	rs12731740	1.000	rs36074690	chr1:208032537	C/T	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.06	-0.31	6.29e-12	Biomedical quantitative traits;
LGG	cis	rs7582720	0.945	rs72932707	chr2:203639395	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.28	0.4	6.56e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs8038465	0.592	rs58443257	chr15:73930707	A/T	cg15420318	chr15:73925796	NPTN	0.49	8.23	0.36	1.92e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Myopia (pathological);
LGG	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg11707556	chr5:10655725	ANKRD33B	0.64	11.02	0.46	3e-25	Coronary artery disease;
LGG	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg18240062	chr17:79603768	NPLOC4	0.81	15.28	0.58	5.74e-43	Eye color traits;
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg18479299	chr3:125709523	NA	-0.58	-7.43	-0.33	5.24e-13	Blood pressure (smoking interaction);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13112249	chr22:32870603	FBXO7	0.41	7.04	0.31	6.84e-12	Bilirubin levels;
LGG	cis	rs4959677	0.901	rs10458143	chr6:2479086	C/A	cg23817096	chr6:1620687	NA	-0.32	-7.44	-0.33	5.03e-13	Orthostatic hypotension;
LGG	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg08499158	chr17:42289980	UBTF	-0.39	-7.21	-0.32	2.22e-12	Total body bone mineral density;
LGG	cis	rs774359	0.789	rs9969707	chr9:27491104	A/G	cg21249376	chr9:27528432	MOBKL2B	0.48	8.51	0.37	2.48e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.64	0.37	9.42e-17	Platelet count;
LGG	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg00543991	chr22:32367038	NA	0.79	8.54	0.37	1.97e-16	Childhood ear infection;
LGG	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg00717180	chr2:96193071	NA	0.41	7.41	0.33	6.03e-13	HDL cholesterol;
LGG	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg04733989	chr22:42467013	NAGA	-0.59	-10.65	-0.44	7.45e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.85e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	17.07	0.62	5.13e-51	Smoking behavior;
LGG	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg04455712	chr21:45112962	RRP1B	0.55	10.33	0.43	1.16e-22	Mean corpuscular volume;
LGG	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20814179	chr4:940893	TMEM175	0.39	6.88	0.3	1.99e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs4953318	0.619	rs13406773	chr2:46362868	T/C	cg12428440	chr2:46370979	PRKCE	0.5	9.24	0.39	8.91e-19	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs10106298	0.935	rs3191333	chr8:103662219	G/A	cg10187029	chr8:103597600	NA	0.42	6.74	0.3	4.74e-11	Schizophrenia;
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg22903471	chr2:27725779	GCKR	0.58	13.45	0.53	4.65e-35	Total body bone mineral density;
LGG	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg22852734	chr6:133119734	C6orf192	1.39	11.7	0.48	7.25e-28	Type 2 diabetes nephropathy;
LGG	cis	rs9796	0.553	rs2925343	chr15:41306493	T/C	cg18705301	chr15:41695430	NDUFAF1	0.59	10.44	0.44	4.55e-23	Menopause (age at onset);
LGG	cis	rs13064447	0.817	rs55907913	chr3:12761887	T/C	cg23032965	chr3:12705835	RAF1	-0.49	-7.3	-0.32	1.25e-12	Major depression and alcohol dependence;
LGG	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.47e-12	Total cholesterol levels;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg11965913	chr1:205819406	PM20D1	0.52	9.25	0.39	8.37e-19	Prostate cancer;
LGG	cis	rs16837677	1.000	rs78365002	chr1:156716689	G/A	cg14991358	chr1:156767203	PRCC	0.77	8.3	0.36	1.12e-15	Sjögren's syndrome;
LGG	cis	rs9311474	1.000	rs6445358	chr3:52308845	C/G	cg14092988	chr3:52407081	DNAH1	0.27	7.01	0.31	8.36e-12	Electroencephalogram traits;
LGG	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg00717180	chr2:96193071	NA	-0.42	-7.78	-0.34	4.61e-14	Coronary artery disease;
LGG	cis	rs8017423	0.935	rs11624890	chr14:90738165	T/A	cg04374321	chr14:90722782	PSMC1	-0.87	-17.89	-0.64	8.31e-55	Mortality in heart failure;
LGG	cis	rs7928758	0.887	rs11822935	chr11:134271771	T/C	cg25213107	chr11:134282864	B3GAT1	1.12	14.0	0.55	2.11e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	10.83	0.45	1.66e-24	Migraine;Coronary artery disease;
LGG	cis	rs9487094	0.626	rs12192776	chr6:109955353	C/T	cg16315928	chr6:109776240	MICAL1	0.47	8.18	0.36	2.72e-15	Height;
LGG	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.21	0.7	2.97e-70	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.81	-0.41	9.24e-21	Lung cancer;
LGG	cis	rs7923609	0.561	rs12257409	chr10:65302699	C/T	cg02276361	chr10:65351566	REEP3	-0.3	-6.65	-0.3	8.16e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.76	-0.38	3.65e-17	Retinal vascular caliber;
LGG	cis	rs9581857	0.579	rs9581843	chr13:27980507	T/G	cg01674679	chr13:27998804	GTF3A	-0.75	-8.61	-0.37	1.16e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs12220238	1.000	rs10824085	chr10:75911984	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.52	0.47	3.65e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.19	0.32	2.67e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs73198271	0.681	rs35457364	chr8:8649790	T/A	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg22232500	chr2:134024266	NCKAP5	-0.55	-7.9	-0.34	2e-14	Bipolar disorder;
LGG	cis	rs6871536	1.000	rs2706372	chr5:131935477	C/T	cg04303330	chr5:131992430	IL13	0.28	6.77	0.3	3.96e-11	Asthma (childhood onset);
LGG	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg00319359	chr11:70116639	PPFIA1	0.63	6.91	0.31	1.57e-11	Coronary artery disease;
LGG	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	9.49	0.4	1.23e-19	Multiple sclerosis;
LGG	cis	rs9287719	0.967	rs728281	chr2:10750355	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs3857747	0.931	rs10256660	chr7:40364588	A/G	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7084783	0.538	rs11191734	chr10:105338128	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.49	8.5	0.37	2.66e-16	Fear of pain;
LGG	cis	rs11679564	1.000	rs11679564	chr2:37158384	G/T	cg14987922	chr2:37194071	STRN	0.47	7.52	0.33	2.8e-13	Immature fraction of reticulocytes;
LGG	cis	rs4906332	1.000	rs12879663	chr14:103874215	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-7.87	-0.34	2.59e-14	Coronary artery disease;
LGG	cis	rs6692729	0.966	rs1794035	chr1:227048758	T/C	cg08708961	chr1:227070630	PSEN2	-0.29	-7.3	-0.32	1.26e-12	Electrodermal activity;
LGG	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.89e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg12654349	chr5:56205094	C5orf35	-0.66	-10.48	-0.44	3.31e-23	Initial pursuit acceleration;
LGG	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg17108064	chr15:78857060	CHRNA5	-0.48	-10.73	-0.45	3.99e-24	Sudden cardiac arrest;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.48	0.33	3.82e-13	Prudent dietary pattern;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.9	-0.38	1.27e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4742903	0.967	rs3739737	chr9:106858192	A/G	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg13385794	chr1:248469461	NA	0.44	7.81	0.34	3.91e-14	Common traits (Other);
LGG	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg21211680	chr2:198530	NA	-1.24	-18.9	-0.66	1.74e-59	Blood protein levels;
LGG	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg06640241	chr16:89574553	SPG7	0.67	10.42	0.44	5.43e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs8103771	0.826	rs3865481	chr19:54352596	A/G	cg06697294	chr19:54385412	PRKCG	-0.81	-7.62	-0.33	1.41e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.97e-41	Skin colour saturation;
LGG	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Bladder cancer;
LGG	trans	rs783540	0.843	rs9652567	chr15:83368514	T/G	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.29	-0.32	1.38e-12	Schizophrenia;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.44e-15	Alzheimer's disease;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg07100595	chr3:56503840	ERC2	-0.49	-6.81	-0.3	3.02e-11	Apolipoprotein A-IV levels;
LGG	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16344026	chr5:149109979	PPARGC1B	0.43	7.24	0.32	1.92e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06550102	chr3:142720758	SR140	0.51	7.83	0.34	3.27e-14	Gut microbiome composition (summer);
LGG	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.91	-0.31	1.66e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs7666738	0.830	rs13108422	chr4:99059267	G/A	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.18e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4132509	1.000	rs10927051	chr1:243805936	G/C	cg25706552	chr1:244017396	NA	0.51	8.34	0.36	8.64e-16	RR interval (heart rate);
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08677398	chr8:58056175	NA	0.48	6.95	0.31	1.29e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06850241	chr22:41845214	NA	-0.42	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg26384229	chr12:38710491	ALG10B	0.94	21.79	0.71	5.52e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6835098	0.924	rs13138282	chr4:174120906	C/T	cg08422745	chr4:174089978	GALNT7	0.85	14.63	0.56	4.03e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	7.05	0.31	6.74e-12	Height;
LGG	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-8.98	-0.39	6.97e-18	Educational attainment;
LGG	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg26248373	chr2:1572462	NA	-0.86	-14.27	-0.55	1.45e-38	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs1003719	0.762	rs8130846	chr21:38480242	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.84	17.01	0.62	8.84e-51	Eye color traits;
LGG	cis	rs11252926	0.574	rs4881313	chr10:487973	C/T	cg18196295	chr10:418757	DIP2C	-0.57	-10.88	-0.45	1.07e-24	Psychosis in Alzheimer's disease;
LGG	cis	rs13418717	0.793	rs7425345	chr2:127640396	C/T	cg25501666	chr2:127640322	NA	1.24	10.03	0.42	1.49e-21	Heart failure;
LGG	cis	rs8064024	0.538	rs11076854	chr16:4929269	A/G	cg04440724	chr16:4920505	UBN1	0.56	12.17	0.49	9.08e-30	Cancer;
LGG	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.05	-0.35	7.08e-15	Neuroticism;
LGG	cis	rs300774	0.858	rs1829220	chr2:118383	A/C	cg04617936	chr2:214353	NA	-0.48	-7.07	-0.31	5.59e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs782590	0.967	rs10496050	chr2:55806313	C/T	cg18811423	chr2:55921094	PNPT1	0.89	20.4	0.69	1.75e-66	Metabolic syndrome;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.12	-0.35	4.33e-15	IgG glycosylation;
LGG	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.14	-0.39	1.94e-18	Bone mineral density;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg05556477	chr5:131705319	SLC22A5	0.84	10.03	0.42	1.5e-21	Rheumatoid arthritis;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs2976388	0.609	rs1469811	chr8:143787999	C/T	cg06565975	chr8:143823917	SLURP1	0.35	8.99	0.39	6.38e-18	Urinary tract infection frequency;
LGG	cis	rs10050311	0.746	rs72665791	chr4:87678787	C/T	cg11209507	chr4:87813803	C4orf36	0.54	6.99	0.31	9.43e-12	Insulin-related traits;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg11764359	chr7:65958608	NA	-0.74	-13.45	-0.53	4.98e-35	Aortic root size;
LGG	cis	rs6496667	0.533	rs7172909	chr15:90991416	C/T	cg22089800	chr15:90895588	ZNF774	0.51	8.36	0.36	7.39e-16	Rheumatoid arthritis;
LGG	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-13.23	-0.52	4.16e-34	Bladder cancer;
LGG	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg23815491	chr16:72088622	HP	0.5	9.25	0.39	8.46e-19	Blood protein levels;
LGG	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs897984	0.683	rs12447534	chr16:30804257	C/T	cg00531865	chr16:30841666	NA	0.66	15.58	0.59	2.67e-44	Dementia with Lewy bodies;
LGG	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg09222892	chr1:25734099	RHCE	0.45	9.25	0.4	8.14e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	3.99e-13	Schizophrenia;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg11584989	chr19:19387371	SF4	-0.42	-7.68	-0.34	9.48e-14	Tonsillectomy;
LGG	cis	rs9311474	1.000	rs7629072	chr3:52305633	C/T	cg14092988	chr3:52407081	DNAH1	0.28	7.45	0.33	4.58e-13	Electroencephalogram traits;
LGG	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.46	-0.33	4.32e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2692947	0.740	rs60452119	chr2:96420050	T/C	cg22654517	chr2:96458247	NA	0.37	7.88	0.34	2.44e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-7.72	-0.34	7.04e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.9	-0.38	1.23e-17	Life satisfaction;
LGG	trans	rs4713118	0.699	rs573179	chr6:27849676	C/A	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.69	-0.3	6.58e-11	Parkinson's disease;
LGG	cis	rs3820068	0.734	rs6669156	chr1:15905206	T/A	cg05660106	chr1:15850417	CASP9	1.13	23.72	0.74	5.59e-82	Systolic blood pressure;
LGG	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg11764359	chr7:65958608	NA	-0.7	-12.06	-0.49	2.57e-29	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19853927	chr3:153839743	SGEF	0.44	7.14	0.31	3.66e-12	Cognitive performance;
LGG	trans	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.34	-0.5	1.89e-30	Obesity-related traits;
LGG	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.8	-0.51	2.58e-32	Response to antipsychotic treatment;
LGG	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07570687	chr10:102243282	WNT8B	0.44	7.5	0.33	3.32e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg04617936	chr2:214353	NA	-0.4	-7.37	-0.32	7.93e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05665937	chr4:1216051	CTBP1	-0.49	-8.85	-0.38	1.87e-17	Obesity-related traits;
LGG	cis	rs3806843	0.521	rs246061	chr5:140324656	C/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.37	-0.53	1.01e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6807915	0.504	rs167467	chr3:12281183	A/G	cg22839075	chr3:12045461	SYN2	0.4	7.07	0.31	5.86e-12	Leprosy;
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg14689365	chr7:158441557	NCAPG2	0.6	10.33	0.43	1.15e-22	Height;
LGG	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg20587970	chr11:113659929	NA	-1.34	-23.66	-0.74	1.08e-81	Hip circumference adjusted for BMI;
LGG	cis	rs929596	0.564	rs2741042	chr2:234565917	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.12	-0.39	2.34e-18	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg04450456	chr4:17643702	FAM184B	0.34	7.52	0.33	2.85e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs208520	0.690	rs6929762	chr6:66709277	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.54	0.63	3.6e-53	Exhaled nitric oxide output;
LGG	cis	rs6430585	0.702	rs746857	chr2:136554890	G/A	cg07169764	chr2:136633963	MCM6	-1.27	-23.8	-0.74	2.29e-82	Corneal structure;
LGG	cis	rs12956009	0.583	rs4331415	chr18:44885048	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.11	0.31	4.29e-12	Educational attainment (years of education);
LGG	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg19554555	chr3:13937349	NA	-0.55	-9.85	-0.42	6.49e-21	Ovarian reserve;
LGG	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	16.94	0.62	1.95e-50	Smoking behavior;
LGG	trans	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg21775007	chr8:11205619	TDH	0.41	6.7	0.3	5.96e-11	Mood instability;
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg00277334	chr10:82204260	NA	-0.35	-7.7	-0.34	8.59e-14	Post bronchodilator FEV1;
LGG	cis	rs9880211	0.752	rs35428413	chr3:136380698	T/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg23625390	chr15:77176239	SCAPER	0.66	13.38	0.53	9.56e-35	Blood metabolite levels;
LGG	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg03788504	chr6:150331562	NA	-0.59	-13.39	-0.53	8.96e-35	Alopecia areata;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg18106800	chr5:94890715	ARSK;TTC37	-0.4	-6.81	-0.3	2.96e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg19508488	chr2:152266495	RIF1	0.58	10.4	0.44	6.36e-23	Lung cancer;
LGG	cis	rs283228	0.793	rs1234740	chr6:101718226	A/C	cg27451362	chr6:101846650	GRIK2	0.57	8.76	0.38	3.66e-17	Coenzyme Q10 levels;
LGG	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.21	-0.36	2.27e-15	Glycated hemoglobin levels;
LGG	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg23029597	chr12:123009494	RSRC2	0.94	17.37	0.63	2.11e-52	Body mass index;
LGG	cis	rs6445975	0.726	rs6764512	chr3:58468236	T/G	cg24175188	chr3:58374923	PXK	-0.44	-8.01	-0.35	9.29e-15	Systemic lupus erythematosus;
LGG	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.82	-9.53	-0.4	9.22e-20	Response to haloperidol in psychosis;
LGG	cis	rs11649743	0.748	rs4794758	chr17:36080428	C/T	cg21250756	chr17:36077300	HNF1B	0.29	8.1	0.35	4.94e-15	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7945705	0.934	rs1988709	chr11:8882890	A/T	cg00186954	chr11:8933980	ST5;C11orf17	0.37	7.51	0.33	3.02e-13	Hemoglobin concentration;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.45	-0.53	4.88e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.39	-7.0	-0.31	8.93e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs477692	0.699	rs557311	chr10:131389484	A/G	cg05714579	chr10:131428358	MGMT	0.47	9.24	0.39	9.07e-19	Response to temozolomide;
LGG	cis	rs7572733	0.935	rs11679040	chr2:198806829	T/C	cg00792783	chr2:198669748	PLCL1	0.48	7.97	0.35	1.23e-14	Dermatomyositis;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.08	-0.31	5.23e-12	Obesity-related traits;
LGG	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg20568497	chr10:133558893	NA	0.35	7.4	0.33	6.52e-13	Survival in rectal cancer;
LGG	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg17211192	chr8:82754475	SNX16	-0.73	-11.24	-0.46	4.23e-26	Diastolic blood pressure;
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg11062466	chr8:58055876	NA	0.49	8.09	0.35	5.38e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg03528353	chr17:61819722	STRADA	0.44	7.45	0.33	4.58e-13	Prudent dietary pattern;
LGG	cis	rs208520	0.690	rs864314	chr6:66814830	G/A	cg07460842	chr6:66804631	NA	-1.15	-31.84	-0.83	1.05e-118	Exhaled nitric oxide output;
LGG	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg15704280	chr7:45808275	SEPT13	-1.0	-21.41	-0.71	3.45e-71	Coronary artery disease;
LGG	cis	rs2115536	1.000	rs2115540	chr15:80190308	A/G	cg11839771	chr15:80205821	ST20	-0.34	-7.24	-0.32	1.89e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6754311	0.593	rs2034276	chr2:136422171	A/T	cg07169764	chr2:136633963	MCM6	0.75	13.19	0.52	6.03e-34	Mosquito bite size;
LGG	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg18478394	chr8:109455254	TTC35	0.43	8.71	0.38	5.35e-17	Dupuytren's disease;
LGG	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg15212455	chr7:39170539	POU6F2	0.47	10.76	0.45	2.98e-24	IgG glycosylation;
LGG	cis	rs7914558	0.966	rs7921574	chr10:104840970	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.73	0.45	3.79e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1620921	0.619	rs7381975	chr6:161275254	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg12310025	chr6:25882481	NA	-0.37	-6.68	-0.3	6.69e-11	Height;
LGG	cis	rs7010267	0.602	rs4313185	chr8:120052549	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.8	0.38	2.7e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07320819	chr13:48877957	RB1	-0.42	-7.35	-0.32	9.08e-13	Brain structure;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg14789911	chr21:47582049	C21orf56	0.48	8.58	0.37	1.44e-16	Testicular germ cell tumor;
LGG	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg00405596	chr8:11794950	NA	-0.41	-7.02	-0.31	8.07e-12	Mood instability;
LGG	cis	rs16976116	0.901	rs1061875	chr15:55496278	C/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26378065	chr17:18585709	ZNF286B	0.51	9.56	0.41	6.94e-20	Educational attainment (years of education);
LGG	cis	rs6831256	0.899	rs36205397	chr4:3470604	A/G	cg13455623	chr4:3480656	DOK7	-0.68	-14.02	-0.55	1.77e-37	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg26769984	chr7:1090371	C7orf50	0.53	9.31	0.4	5.36e-19	Bronchopulmonary dysplasia;
LGG	cis	rs72634258	0.945	rs1883679	chr1:8100451	T/G	cg00042356	chr1:8021962	PARK7	0.84	10.95	0.45	5.76e-25	Inflammatory bowel disease;
LGG	cis	rs4888262	0.545	rs7342732	chr16:74698716	A/C	cg01733217	chr16:74700730	RFWD3	0.94	19.85	0.68	6.77e-64	Testicular germ cell tumor;
LGG	trans	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg02002194	chr4:3960332	NA	0.46	7.5	0.33	3.21e-13	Myopia (pathological);
LGG	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg25457927	chr22:38595422	NA	-0.41	-9.47	-0.4	1.38e-19	Breast cancer;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	8.18	0.36	2.73e-15	Obesity-related traits;
LGG	cis	rs9534338	0.520	rs9534341	chr13:46717047	T/C	cg11274337	chr13:46717068	LCP1	-0.36	-8.14	-0.35	3.71e-15	Blood protein levels;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7737355	0.842	rs30733	chr5:130704956	T/A	cg06307176	chr5:131281290	NA	-0.49	-8.14	-0.35	3.7e-15	Life satisfaction;
LGG	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg14983838	chr19:29218262	NA	0.55	7.27	0.32	1.55e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7106204	0.800	rs6484026	chr11:24214633	G/A	ch.11.24196551F	chr11:24239977	NA	1.05	16.53	0.61	1.46e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06656553	chr16:89960601	TCF25	-0.73	-7.14	-0.32	3.57e-12	Skin colour saturation;
LGG	cis	rs10463316	0.817	rs1318783	chr5:150814807	T/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.25	-0.43	2.29e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.55	-0.41	7.37e-20	Retinal vascular caliber;
LGG	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg11845111	chr2:191398756	TMEM194B	0.36	7.96	0.35	1.37e-14	Pulse pressure;
LGG	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg27490568	chr2:178487706	NA	0.47	9.41	0.4	2.29e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.27	0.58	6.07e-43	Coronary artery disease;
LGG	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03517284	chr6:25882590	NA	-0.49	-9.32	-0.4	4.79e-19	Blood metabolite levels;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06028808	chr11:68637592	NA	0.73	12.18	0.49	8.32e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11169552	0.510	rs10876076	chr12:51049083	G/C	cg12884762	chr12:50931848	DIP2B	-0.39	-7.21	-0.32	2.22e-12	Colorectal cancer;
LGG	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	-0.89	-17.27	-0.63	5.78e-52	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg21724239	chr8:58056113	NA	0.63	9.64	0.41	3.68e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.13	-0.31	3.79e-12	Neuroticism;
LGG	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.84	0.54	1.11e-36	Colorectal cancer;
LGG	cis	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.1	-0.39	2.78e-18	Morning vs. evening chronotype;
LGG	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg03315344	chr16:75512273	CHST6	-0.51	-10.0	-0.42	1.9e-21	Dupuytren's disease;
LGG	cis	rs1007190	0.881	rs3816275	chr17:42957327	G/A	cg15406952	chr17:42872593	NA	1.05	13.86	0.54	8.36e-37	DNA methylation (variation);
LGG	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg23625390	chr15:77176239	SCAPER	-0.47	-9.1	-0.39	2.63e-18	Blood metabolite levels;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00495681	chr13:53174319	NA	0.68	13.11	0.52	1.26e-33	Lewy body disease;
LGG	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg10760299	chr15:45669010	GATM	0.41	8.13	0.35	4.04e-15	Homoarginine levels;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg10150615	chr22:24372951	LOC391322	-0.41	-6.77	-0.3	3.84e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9886651	0.776	rs12155669	chr8:128779931	A/G	cg24514600	chr8:128805414	PVT1	0.51	11.21	0.46	5.49e-26	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	7.76	0.34	5.51e-14	Schizophrenia;
LGG	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg24112000	chr20:60950667	NA	-0.39	-7.88	-0.34	2.29e-14	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs7765175	0.775	rs7766390	chr6:113682732	G/A	cg26552650	chr6:113682475	NA	0.33	7.21	0.32	2.27e-12	Coronary artery calcification;
LGG	cis	rs2354432	0.607	rs10900350	chr1:146828017	T/G	cg25205988	chr1:146714368	CHD1L	1.21	12.45	0.5	7.04e-31	Mitochondrial DNA levels;
LGG	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	7.75	0.34	5.85e-14	Menarche (age at onset);
LGG	cis	rs7639513	0.520	rs79141906	chr3:12711977	A/C	cg23032965	chr3:12705835	RAF1	0.84	15.44	0.58	1.15e-43	Itch intensity from mosquito bite;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.32	-0.32	1.12e-12	Body mass index;
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.36	-0.4	3.35e-19	Life satisfaction;
LGG	cis	rs1843834	0.734	rs1908251	chr2:225487865	T/C	cg22455342	chr2:225449267	CUL3	0.62	10.75	0.45	3.19e-24	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg20991723	chr1:152506922	NA	0.56	9.5	0.4	1.17e-19	Hair morphology;
LGG	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.35e-12	Total cholesterol levels;
LGG	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg03160526	chr17:80928410	B3GNTL1	0.5	8.01	0.35	9.64e-15	Glycated hemoglobin levels;
LGG	cis	rs12210905	0.688	rs9368509	chr6:27379422	A/G	cg15325629	chr6:28072465	NA	-0.95	-7.07	-0.31	5.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4918072	0.637	rs61861138	chr10:105613417	G/A	cg11005552	chr10:105648138	OBFC1	0.68	10.26	0.43	2.19e-22	Coronary artery disease;
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg04013166	chr16:89971882	TCF25	0.54	7.26	0.32	1.64e-12	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10158674	chr1:51426069	FAF1	0.47	7.01	0.31	8.64e-12	Gut microbiome composition (summer);
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg11766577	chr21:47581405	C21orf56	-0.48	-8.42	-0.36	4.79e-16	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.09	0.52	1.57e-33	Prudent dietary pattern;
LGG	cis	rs6988985	0.685	rs7003379	chr8:143931898	T/G	cg10324643	chr8:143916377	GML	0.39	7.75	0.34	6.07e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg00462492	chr3:157827761	RSRC1	0.48	7.03	0.31	7.32e-12	Breast cancer;
LGG	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg14979609	chr8:8086686	FLJ10661	-0.32	-8.11	-0.35	4.67e-15	Neuroticism;
LGG	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg10756647	chr7:56101905	PSPH	0.75	8.6	0.37	1.25e-16	Diabetic kidney disease;
LGG	cis	rs10929925	0.966	rs2609195	chr2:6152005	A/C	cg00493617	chr2:6141445	NA	0.32	7.38	0.32	7.3e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs12431410	0.550	rs11847592	chr14:60209878	A/G	cg07950296	chr14:60194823	RTN1	0.37	7.17	0.32	2.91e-12	Schizophrenia;
LGG	cis	rs6460942	1.000	rs7791634	chr7:12401482	A/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.87	-0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs6430585	0.702	rs2304601	chr2:136528034	C/A	cg07169764	chr2:136633963	MCM6	1.27	24.09	0.75	1e-83	Corneal structure;
LGG	cis	rs4740619	0.810	rs10733301	chr9:15764178	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.34	-0.43	1.08e-22	Body mass index;
LGG	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs7572733	0.935	rs6434942	chr2:198756688	G/A	cg00792783	chr2:198669748	PLCL1	0.52	8.78	0.38	3.16e-17	Dermatomyositis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01874871	chr20:2644800	IDH3B	0.45	7.01	0.31	8.5e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08280861	chr8:58055591	NA	-0.6	-7.7	-0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.684	rs274560	chr5:131719450	T/C	cg24060327	chr5:131705240	SLC22A5	0.48	8.27	0.36	1.47e-15	Blood metabolite levels;
LGG	cis	rs5750830	0.594	rs1010169	chr22:39778167	C/T	cg11247378	chr22:39784982	NA	0.3	8.69	0.37	6.53e-17	Intelligence (multi-trait analysis);
LGG	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.68	11.7	0.48	6.94e-28	Colorectal cancer;
LGG	cis	rs6867032	0.527	rs13153217	chr5:2012788	G/T	cg26168224	chr5:2018326	NA	-0.8	-14.98	-0.57	1.16e-41	Gut microbiome composition (winter);
LGG	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.94	-0.38	9.56e-18	Coronary artery disease;
LGG	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg25173405	chr17:45401733	C17orf57	-0.53	-9.05	-0.39	3.93e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg23576260	chr20:44600978	ZNF335	0.41	6.94	0.31	1.33e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg17150306	chr7:855575	UNC84A	-0.33	-6.82	-0.3	2.86e-11	Perceived unattractiveness to mosquitoes;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg02725872	chr8:58115012	NA	-1.05	-15.36	-0.58	2.39e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg00278107	chr5:1061253	SLC12A7	-0.73	-14.71	-0.56	1.8e-40	QT interval;
LGG	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.01	0.31	8.37e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg02487422	chr3:49467188	NICN1	0.42	7.01	0.31	8.59e-12	Parkinson's disease;
LGG	cis	rs7666738	0.606	rs4577589	chr4:99087858	A/G	cg05340658	chr4:99064831	C4orf37	0.42	6.84	0.3	2.56e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7100689	0.646	rs2486302	chr10:82076600	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.69	0.56	2.33e-40	Post bronchodilator FEV1;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg22105103	chr4:187893119	NA	0.54	10.54	0.44	1.97e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9308433	0.529	rs867444	chr1:214502160	T/C	cg06198575	chr1:214491504	SMYD2	0.51	7.62	0.33	1.44e-13	IgG glycosylation;
LGG	cis	rs17818399	0.675	rs35949012	chr2:46860401	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.18	-0.39	1.39e-18	Height;
LGG	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.65	-0.3	8.08e-11	Arsenic metabolism;
LGG	trans	rs7939886	0.920	rs7107736	chr11:55987980	C/G	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.62	-0.33	1.48e-13	HDL cholesterol;
LGG	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg26655873	chr3:72818019	SHQ1	0.35	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4561483	0.583	rs9925010	chr16:11956668	A/G	cg08843971	chr16:11963173	GSPT1	0.56	13.66	0.54	6.21e-36	Testicular germ cell tumor;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg17506739	chr13:50159779	RCBTB1	0.46	6.93	0.31	1.4e-11	Hip circumference;
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.48	0.4	1.3e-19	Monocyte count;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg13206674	chr6:150067644	NUP43	0.65	14.64	0.56	3.8e-40	Lung cancer;
LGG	trans	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.24	0.55	2.01e-38	Exhaled nitric oxide output;
LGG	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg15454534	chr1:248569605	OR2T1	0.38	6.9	0.31	1.72e-11	Common traits (Other);
LGG	cis	rs4538187	1.000	rs4538187	chr2:64103741	C/T	cg02541582	chr2:64069798	UGP2	0.62	14.75	0.57	1.25e-40	Systolic blood pressure;
LGG	cis	rs4776059	0.798	rs10851520	chr15:52912978	C/G	cg22715398	chr15:52968154	KIAA1370	0.45	6.79	0.3	3.46e-11	Schizophrenia;
LGG	trans	rs971891	1.000	rs971891	chr5:129573666	C/T	cg07395648	chr5:131743802	NA	-0.39	-7.24	-0.32	1.86e-12	Itch intensity from mosquito bite;Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs11229555	0.645	rs12794534	chr11:58179568	C/A	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7747724	0.715	rs2820000	chr6:20758704	C/T	cg13405222	chr6:20811065	CDKAL1	0.47	9.48	0.4	1.37e-19	Bladder cancer;
LGG	cis	rs977987	0.835	rs3863445	chr16:75371744	C/G	cg03315344	chr16:75512273	CHST6	0.51	10.28	0.43	1.87e-22	Dupuytren's disease;
LGG	cis	rs4716602	0.542	rs35137250	chr7:156161066	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.43	-0.4	1.92e-19	Anti-saccade response;
LGG	cis	rs7666738	1.000	rs1426673	chr4:98924024	G/A	cg05340658	chr4:99064831	C4orf37	0.42	6.71	0.3	5.67e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg01579765	chr21:45077557	HSF2BP	0.37	8.42	0.36	4.64e-16	Mean corpuscular volume;
LGG	cis	rs362296	0.698	rs3095072	chr4:3263325	G/A	cg06533319	chr4:3265114	C4orf44	0.5	10.31	0.43	1.39e-22	Parental longevity (mother's age at death);
LGG	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	8.34	0.36	8.4e-16	Mood instability;
LGG	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.49	-0.37	2.79e-16	Hemoglobin concentration;
LGG	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg16486109	chr11:613632	IRF7	0.42	7.18	0.32	2.85e-12	Systemic lupus erythematosus;
LGG	cis	rs17169635	0.840	rs3800746	chr7:134550086	G/C	cg02516134	chr7:134575187	CALD1	-0.39	-7.8	-0.34	4.07e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg19223190	chr17:80058835	NA	0.44	8.57	0.37	1.51e-16	Life satisfaction;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.91e-60	Menopause (age at onset);
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg11168104	chr5:1857477	NA	-0.38	-6.64	-0.3	8.56e-11	Cardiovascular disease risk factors;
LGG	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg02389323	chr16:88786976	FAM38A	0.93	12.21	0.49	6.38e-30	Plateletcrit;
LGG	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg24112000	chr20:60950667	NA	-0.37	-7.48	-0.33	3.84e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg03605463	chr16:89740564	NA	0.61	11.04	0.46	2.57e-25	Vitiligo;
LGG	cis	rs629922	0.507	rs633767	chr11:114053886	T/A	cg01914181	chr11:114070210	ZBTB16	-0.53	-6.72	-0.3	5.41e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.81	15.43	0.58	1.2e-43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.32	0.32	1.12e-12	Total cholesterol levels;
LGG	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg04851639	chr8:1020857	NA	-0.44	-9.04	-0.39	4.17e-18	Schizophrenia;
LGG	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg12463550	chr7:65579703	CRCP	0.78	8.63	0.37	9.63e-17	Diabetic kidney disease;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg00933542	chr6:150070202	PCMT1	0.4	7.18	0.32	2.85e-12	Lung cancer;
LGG	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21659725	chr3:3221576	CRBN	0.64	11.97	0.49	5.8e-29	Intelligence (multi-trait analysis);
LGG	cis	rs853679	0.517	rs9283884	chr6:28135660	C/G	cg18032046	chr6:28092343	ZSCAN16	0.57	7.46	0.33	4.3e-13	Depression;
LGG	cis	rs9487051	0.604	rs9320282	chr6:109619377	A/G	cg21918786	chr6:109611834	NA	-0.5	-9.34	-0.4	4.03e-19	Reticulocyte fraction of red cells;
LGG	trans	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg07120314	chr15:79043507	NA	-0.72	-17.27	-0.63	6.33e-52	Coronary artery disease or large artery stroke;
LGG	cis	rs9398803	0.687	rs1340953	chr6:126951748	A/G	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.89e-20	Male-pattern baldness;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs1256531	0.661	rs61987779	chr14:66192754	G/A	cg15999311	chr14:65749247	NA	0.83	6.91	0.31	1.65e-11	Conduct disorder (symptom count);
LGG	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg24692254	chr21:30365293	RNF160	-1.02	-27.9	-0.79	3.34e-101	Dental caries;
LGG	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg22916017	chr11:64110731	CCDC88B	-0.48	-6.99	-0.31	9.95e-12	Mean platelet volume;
LGG	cis	rs9902453	0.765	rs3102555	chr17:28044101	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.49	0.56	1.6e-39	Coffee consumption (cups per day);
LGG	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg07303275	chr16:75499416	TMEM170A	0.38	6.74	0.3	4.71e-11	Dupuytren's disease;
LGG	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs754423	0.558	rs10498441	chr14:52544224	C/T	cg12071775	chr14:52591786	NA	0.46	8.18	0.36	2.77e-15	Craniofacial microsomia;
LGG	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg19847130	chr8:10466454	RP1L1	-0.32	-7.24	-0.32	1.83e-12	Mood instability;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6708331	0.517	rs13017427	chr2:70381531	G/A	cg01613454	chr2:70366299	NA	0.53	10.77	0.45	2.77e-24	Obesity-related traits;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg11764359	chr7:65958608	NA	0.73	13.2	0.52	5.46e-34	Aortic root size;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7944735	0.628	rs4752879	chr11:47897772	C/T	cg03929089	chr4:120376271	NA	0.55	6.92	0.31	1.5e-11	Intraocular pressure;
LGG	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06481639	chr22:41940642	POLR3H	0.58	8.05	0.35	6.85e-15	Vitiligo;
LGG	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.0	-0.31	9.06e-12	Morning vs. evening chronotype;
LGG	trans	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg00953403	chr17:74099816	EXOC7	0.42	7.01	0.31	8.47e-12	Psychosis in Alzheimer's disease;
LGG	trans	rs459571	1.000	rs467387	chr9:136907005	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.88	-0.48	1.35e-28	Platelet distribution width;
LGG	cis	rs758324	0.812	rs10045303	chr5:131202801	C/T	cg06307176	chr5:131281290	NA	-0.53	-8.8	-0.38	2.71e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs701145	0.585	rs62276840	chr3:153783622	G/C	cg12800244	chr3:153838788	SGEF	-0.81	-9.0	-0.39	6.07e-18	Coronary artery disease;
LGG	cis	rs2274273	0.624	rs7140628	chr14:55760681	A/C	cg04306507	chr14:55594613	LGALS3	0.54	12.57	0.5	2.2e-31	Protein biomarker;
LGG	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg15145296	chr3:125709740	NA	-0.6	-8.72	-0.38	4.95e-17	Blood pressure (smoking interaction);
LGG	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.54	-0.37	2e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7182946	1.000	rs4779820	chr15:31394810	A/T	cg18085517	chr15:31394285	TRPM1	-0.3	-6.7	-0.3	6.02e-11	Advanced age-related macular degeneration;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.92	-0.48	9.03e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg02023728	chr11:77925099	USP35	0.38	6.72	0.3	5.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	6.87	0.3	2.05e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs367615	0.552	rs2963022	chr5:108727185	A/G	cg17395555	chr5:108820864	NA	-0.71	-11.56	-0.47	2.54e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	9.2	0.39	1.27e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg00543991	chr22:32367038	NA	0.74	9.19	0.39	1.29e-18	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17267835	chr6:161413433	MAP3K4	0.54	8.18	0.36	2.76e-15	Gut microbiome composition (summer);
LGG	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.66	0.34	1.07e-13	Bipolar disorder;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.68	-0.34	9.24e-14	Neuroticism;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg00157179	chr1:2383687	NA	-0.79	-14.84	-0.57	4.82e-41	Non-obstructive azoospermia;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.72e-18	Lung cancer;
LGG	trans	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg26043149	chr18:55253948	FECH	0.4	6.67	0.3	7.1e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg19507638	chr5:93509721	C5orf36	-0.66	-9.17	-0.39	1.61e-18	Diabetic retinopathy;
LGG	cis	rs2071403	0.933	rs10183226	chr2:1404756	T/G	cg06500727	chr2:1417164	TPO	-0.5	-9.53	-0.41	8.61e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg08250081	chr4:10125330	NA	0.41	8.06	0.35	6.43e-15	Bone mineral density;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00689492	chr4:1303491	MAEA	0.5	8.5	0.37	2.64e-16	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg08000102	chr2:233561755	GIGYF2	0.58	9.47	0.4	1.46e-19	Coronary artery disease;
LGG	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg08999081	chr20:33150536	PIGU	-0.31	-7.16	-0.32	3.15e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg11846333	chr4:119757529	SEC24D	0.85	7.36	0.32	8.48e-13	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.67	0.3	7.16e-11	Schizophrenia;
LGG	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg15268244	chr15:77196840	NA	0.44	8.37	0.36	6.68e-16	Blood metabolite levels;
LGG	cis	rs7666738	0.819	rs62318904	chr4:99036101	A/T	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21747090	chr2:27597821	SNX17	-0.38	-6.8	-0.3	3.26e-11	Total body bone mineral density;
LGG	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg26384229	chr12:38710491	ALG10B	1.05	27.9	0.79	3.32e-101	Heart rate;
LGG	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs4789294	0.702	rs445683	chr17:74401522	C/T	cg27112972	chr17:74378252	NA	-0.25	-6.7	-0.3	6.05e-11	Lymphocyte percentage of white cells;
LGG	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg02002194	chr4:3960332	NA	-0.52	-9.77	-0.41	1.22e-20	Retinal vascular caliber;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg02002194	chr4:3960332	NA	0.44	8.06	0.35	6.78e-15	Triglycerides;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.6	0.53	1.09e-35	Obesity-related traits;
LGG	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21659725	chr3:3221576	CRBN	-0.63	-9.91	-0.42	4.13e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.66e-13	Testicular germ cell tumor;
LGG	cis	rs9972944	0.729	rs10083875	chr17:63773303	T/C	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.6	0.61	7.08e-49	Obesity-related traits;
LGG	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg08198773	chr8:1697536	NA	0.47	8.3	0.36	1.11e-15	Systolic blood pressure;
LGG	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.26	0.32	1.63e-12	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg13010199	chr12:38710504	ALG10B	0.51	9.84	0.42	7.11e-21	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs2692947	0.589	rs810057	chr2:97015073	T/C	cg22654517	chr2:96458247	NA	0.36	7.44	0.33	4.78e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.18	-0.43	4.16e-22	Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09782300	chr19:14640092	MIR639;TECR	0.44	6.74	0.3	4.59e-11	Gut microbiome composition (summer);
LGG	cis	rs2307022	0.541	rs10775303	chr16:68360914	G/T	cg07273125	chr16:68295692	NA	0.43	9.37	0.4	3.25e-19	Body mass index;
LGG	cis	rs12493885	0.818	rs60023390	chr3:153771056	C/T	cg12800244	chr3:153838788	SGEF	-0.78	-9.45	-0.4	1.7e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4740619	0.619	rs943787	chr9:16031796	T/C	cg14451791	chr9:16040625	NA	-0.44	-11.61	-0.47	1.57e-27	Body mass index;
LGG	cis	rs16937	0.711	rs10900470	chr1:205168614	C/T	cg00889227	chr1:205173544	DSTYK	-0.3	-7.43	-0.33	5.35e-13	Schizophrenia;
LGG	cis	rs9815354	0.812	rs58360908	chr3:41839837	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.51	0.4	1.03e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs68170813	0.652	rs7807154	chr7:107161391	T/G	cg02696742	chr7:106810147	HBP1	-0.68	-8.71	-0.38	5.49e-17	Coronary artery disease;
LGG	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg17127132	chr2:85788382	GGCX	0.48	8.26	0.36	1.54e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs882632	0.668	rs57505815	chr2:29286364	C/T	cg23429306	chr2:29287725	C2orf71	0.4	8.33	0.36	9.27e-16	Major depressive disorder;
LGG	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.49	0.71	1.49e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg11360546	chr7:1094263	C7orf50	-0.41	-7.33	-0.32	1.04e-12	Longevity;Endometriosis;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.78	0.38	3.13e-17	Lung cancer;
LGG	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08468577	chr11:2973342	NAP1L4	-0.32	-6.71	-0.3	5.85e-11	Calcium levels;
LGG	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg03264133	chr6:25882463	NA	-0.41	-7.18	-0.32	2.86e-12	Height;
LGG	cis	rs4789378	1.000	rs1562087	chr17:74931626	A/G	cg02841895	chr17:74942714	MGAT5B	-0.34	-7.18	-0.32	2.85e-12	Colorectal or endometrial cancer;
LGG	cis	rs6960043	0.818	rs10228796	chr7:15064190	C/G	cg19272540	chr7:15055459	NA	-0.35	-7.77	-0.34	5.1e-14	Type 2 diabetes;
LGG	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg24812749	chr6:127587940	RNF146	0.5	7.91	0.35	1.85e-14	Breast cancer;
LGG	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg23625390	chr15:77176239	SCAPER	0.41	7.61	0.33	1.6e-13	Blood metabolite levels;
LGG	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.65	-0.41	3.5e-20	Aortic root size;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg18357526	chr6:26021779	HIST1H4A	0.49	8.27	0.36	1.49e-15	Height;
LGG	cis	rs2470578	0.792	rs2596657	chr3:17238673	G/A	cg20981856	chr3:17787350	NA	0.37	7.02	0.31	7.86e-12	Schizophrenia;
LGG	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.69	-0.34	8.63e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs13102973	0.965	rs13103954	chr4:135844189	A/G	cg14419869	chr4:135874104	NA	0.57	10.7	0.45	4.91e-24	Subjective well-being;
LGG	cis	rs4774899	0.934	rs12903578	chr15:57452681	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.21	-0.32	2.26e-12	Urinary tract infection frequency;
LGG	cis	rs6840360	0.642	rs7657747	chr4:152394254	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs16976116	0.901	rs113679855	chr15:55502428	C/T	cg11288833	chr15:55489084	RSL24D1	0.54	7.35	0.32	9.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.58	-7.87	-0.34	2.57e-14	Diabetic retinopathy;
LGG	cis	rs4731207	0.596	rs10275296	chr7:124681292	T/A	cg05630886	chr7:124431682	NA	-0.33	-7.52	-0.33	2.85e-13	Cutaneous malignant melanoma;
LGG	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.65	-0.34	1.16e-13	Testicular germ cell tumor;
LGG	cis	rs2342371	0.756	rs28712197	chr3:196107214	T/C	cg15048948	chr3:196158458	UBXN7	0.62	10.61	0.44	1.14e-23	Fat distribution (HIV);
LGG	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26629188	chr21:47878281	DIP2A	0.46	6.89	0.3	1.85e-11	Gut microbiome composition (summer);
LGG	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg13010199	chr12:38710504	ALG10B	0.42	7.64	0.33	1.23e-13	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.647	rs9792412	chr9:16025889	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.18	-0.46	7.29e-26	Body mass index;
LGG	trans	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.16e-27	Corneal astigmatism;
LGG	cis	rs174601	0.864	rs174545	chr11:61569306	C/G	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg26597838	chr10:835615	NA	0.75	10.3	0.43	1.57e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs867371	0.892	rs4344697	chr15:82545214	A/T	cg00614314	chr15:82944287	LOC80154	0.62	10.35	0.43	9.67e-23	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg17202724	chr17:61916730	SMARCD2	-0.63	-15.43	-0.58	1.26e-43	Prudent dietary pattern;
LGG	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg13114125	chr14:105738426	BRF1	-0.87	-15.47	-0.58	8.34e-44	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.01e-14	HDL cholesterol;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.73	-0.38	4.51e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg24006582	chr15:45444508	DUOX1	0.63	11.84	0.48	1.99e-28	Uric acid levels;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03452623	chr4:187889614	NA	-1.05	-33.01	-0.84	1.01e-123	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs59197085	0.636	rs60894155	chr7:128465755	G/A	cg00734629	chr7:128471146	FLNC	0.34	6.96	0.31	1.19e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.64e-12	Lung cancer;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.65	-0.3	8.2e-11	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs13148913	chr4:99009732	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9460578	0.537	rs9465898	chr6:20806696	T/G	cg13405222	chr6:20811065	CDKAL1	0.78	17.67	0.63	9.26e-54	Breast cancer;
LGG	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg00129232	chr17:37814104	STARD3	0.61	11.39	0.47	1.19e-26	Glomerular filtration rate (creatinine);
LGG	trans	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.37e-14	Blood trace element (Cu levels);
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.62	0.37	1.05e-16	Schizophrenia;
LGG	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.96	0.35	1.33e-14	Intelligence (multi-trait analysis);
LGG	cis	rs546131	0.642	rs2915186	chr11:34851183	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.38	0.32	7.5e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg12698349	chr2:225449008	CUL3	0.69	11.82	0.48	2.36e-28	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23088430	chr8:144679052	EEF1D;TIGD5	0.4	7.31	0.32	1.15e-12	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22754176	chr5:95066806	RHOBTB3	0.44	6.8	0.3	3.28e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00149659	chr3:10157352	C3orf10	0.72	8.82	0.38	2.41e-17	Alzheimer's disease;
LGG	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg26441486	chr22:50317300	CRELD2	-0.37	-6.89	-0.31	1.78e-11	Schizophrenia;
LGG	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	cis	rs4973397	0.643	rs2369271	chr2:232289244	C/T	cg18859089	chr2:232277014	NA	-0.43	-6.69	-0.3	6.28e-11	Anti-saccade response;
LGG	cis	rs6912958	0.514	rs7767449	chr6:87887985	A/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.32	-6.67	-0.3	7.16e-11	Monocyte percentage of white cells;
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	10.95	0.45	5.89e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg13009111	chr11:71350975	NA	-0.33	-6.92	-0.31	1.53e-11	Neuroticism;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.75	-0.41	1.47e-20	Personality dimensions;
LGG	cis	rs67133203	0.579	rs2730648	chr12:51537196	C/T	cg14688905	chr12:51403056	SLC11A2	-0.59	-10.1	-0.42	8.36e-22	Urinary tract infection frequency;
LGG	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg04979063	chr2:113191202	RGPD5;RGPD8	0.74	9.35	0.4	3.81e-19	Yeast infection;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg01673284	chr16:4527211	HMOX2	-0.37	-7.32	-0.32	1.14e-12	Schizophrenia;
LGG	cis	rs7412746	0.658	rs3843843	chr1:150918084	C/T	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	trans	rs72991	0.607	rs4936625	chr11:121237245	C/T	cg27192990	chr6:129479024	LAMA2	0.53	8.11	0.35	4.6e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7465272	1.000	rs7465272	chr8:143691838	A/T	cg10104451	chr8:143696006	ARC	-0.75	-11.16	-0.46	8.97e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs12618769	0.597	rs17502889	chr2:99031745	A/G	cg18455616	chr2:99124870	INPP4A	0.3	8.76	0.38	3.8e-17	Bipolar disorder;
LGG	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	7.78	0.34	4.69e-14	Thyroid stimulating hormone;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08645402	chr16:4508243	NA	0.5	9.56	0.41	6.78e-20	Schizophrenia;
LGG	cis	rs208520	0.874	rs208491	chr6:66928459	C/G	cg07460842	chr6:66804631	NA	-0.93	-16.11	-0.6	1.13e-46	Exhaled nitric oxide output;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09063787	chr12:2921766	ITFG2	0.59	7.01	0.31	8.65e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg03060546	chr3:49711283	APEH	-0.63	-10.44	-0.44	4.61e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.84	-0.34	3.23e-14	Neuroticism;
LGG	cis	rs6963495	0.872	rs1569134	chr7:105158228	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.6	-0.44	1.24e-23	Glomerular filtration rate;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs990171	0.770	rs1420103	chr2:102948632	A/C	cg05295703	chr2:102895712	NA	-0.63	-11.39	-0.47	1.17e-26	Lymphocyte counts;
LGG	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-10.17	-0.43	4.5e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs12517041	1.000	rs16892312	chr5:23279764	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.99	-0.45	4e-25	Calcium levels;
LGG	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.29	0.36	1.25e-15	Mood instability;
LGG	cis	rs12908161	1.000	rs36033486	chr15:85319692	A/G	cg24253500	chr15:84953950	NA	0.41	6.76	0.3	4.28e-11	Schizophrenia;
LGG	cis	rs12282928	1.000	rs1905287	chr11:48322153	A/C	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg06494592	chr3:125709126	NA	-0.54	-6.92	-0.31	1.53e-11	Blood pressure (smoking interaction);
LGG	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.69	-0.34	8.71e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12476592	0.602	rs4671508	chr2:63654140	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.99	-0.31	9.64e-12	Childhood ear infection;
LGG	cis	rs1109114	0.816	rs1866375	chr5:148601446	A/C	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.64	-0.59	1.39e-44	Body mass index;
LGG	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-8.57	-0.37	1.61e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs17767392	0.958	rs34957192	chr14:71752336	G/A	cg02058870	chr14:72053146	SIPA1L1	0.47	9.44	0.4	1.8e-19	Mitral valve prolapse;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09248148	chr21:15755608	HSPA13	0.49	7.13	0.31	3.95e-12	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.71	-0.38	5.33e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.47	0.47	5.54e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6028335	0.674	rs68173814	chr20:37621180	A/G	cg16355469	chr20:37678765	NA	0.59	7.92	0.35	1.81e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg03351412	chr1:154909251	PMVK	0.58	10.17	0.43	4.63e-22	Prostate cancer;
LGG	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg20913747	chr6:44695427	NA	-0.67	-11.46	-0.47	5.93e-27	Total body bone mineral density;
LGG	trans	rs9409565	0.826	rs9409546	chr9:97209066	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-8.15	-0.35	3.39e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg15627072	chr1:2432621	PLCH2	0.37	8.59	0.37	1.34e-16	Ulcerative colitis;
LGG	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg07928641	chr1:182991847	LAMC1	0.49	10.0	0.42	1.86e-21	Colorectal cancer;
LGG	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg15268244	chr15:77196840	NA	-0.35	-7.8	-0.34	4.26e-14	Blood metabolite levels;
LGG	trans	rs11875185	0.510	rs112843798	chr18:55596968	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.94	-0.31	1.36e-11	Prostate cancer;
LGG	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg27532318	chr7:32358331	NA	0.73	7.43	0.33	5.29e-13	Body mass index;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg00149659	chr3:10157352	C3orf10	0.73	9.11	0.39	2.41e-18	Alzheimer's disease;
LGG	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg07148914	chr20:33460835	GGT7	0.43	6.85	0.3	2.32e-11	Height;
LGG	cis	rs17321999	1.000	rs10171296	chr2:30481309	A/G	cg05247661	chr2:30472410	LBH	0.54	8.49	0.37	2.79e-16	Systemic lupus erythematosus;
LGG	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg14664628	chr15:75095509	CSK	-0.55	-10.45	-0.44	4.37e-23	Breast cancer;
LGG	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.96	0.31	1.15e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9549260	0.755	rs9549252	chr13:41230141	A/G	cg21288729	chr13:41239152	FOXO1	0.33	6.75	0.3	4.44e-11	Red blood cell count;
LGG	cis	rs12762955	0.561	rs1904671	chr10:1014603	G/A	cg25019033	chr10:957182	NA	0.33	6.93	0.31	1.41e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.48	-0.4	1.35e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg07636037	chr3:49044803	WDR6	0.78	13.89	0.54	6.59e-37	Menarche (age at onset);
LGG	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06481639	chr22:41940642	POLR3H	-0.55	-7.78	-0.34	4.8e-14	Vitiligo;
LGG	cis	rs9463078	0.691	rs6938177	chr6:45271834	T/C	cg25276700	chr6:44698697	NA	-0.32	-6.73	-0.3	4.88e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg00495681	chr13:53174319	NA	0.85	18.92	0.66	1.51e-59	Lewy body disease;
LGG	cis	rs9807989	0.507	rs2110659	chr2:103043867	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.58	0.41	5.74e-20	Asthma;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg18926786	chr6:150244388	RAET1G	0.31	6.81	0.3	3.06e-11	Testicular germ cell tumor;
LGG	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs5771242	0.518	rs5771258	chr22:50675648	C/A	cg08875078	chr22:50639485	SELO	0.56	8.27	0.36	1.45e-15	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg00071950	chr4:10020882	SLC2A9	0.36	7.27	0.32	1.51e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7927592	0.630	rs510772	chr11:68218731	T/C	cg01657329	chr11:68192670	LRP5	-0.56	-10.45	-0.44	4.48e-23	Total body bone mineral density;
LGG	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg02153584	chr22:29168773	CCDC117	0.59	7.19	0.32	2.69e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg02640540	chr1:67518911	SLC35D1	0.37	7.36	0.32	8.28e-13	Lymphocyte percentage of white cells;
LGG	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08862035	chr2:2617432	NA	0.42	6.8	0.3	3.31e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg13512537	chr8:22265999	SLC39A14	-0.47	-8.35	-0.36	7.88e-16	Verbal declarative memory;
LGG	cis	rs267939	0.521	rs267954	chr5:10740624	A/T	cg14521931	chr5:10832172	NA	-0.38	-6.97	-0.31	1.12e-11	Gut microbiota (functional units);Ulcerative colitis;
LGG	cis	rs7582720	1.000	rs72936842	chr2:203773686	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.72	0.41	1.98e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg10560079	chr2:191398806	TMEM194B	-0.37	-8.34	-0.36	8.74e-16	Pulse pressure;
LGG	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg08999081	chr20:33150536	PIGU	-0.4	-9.87	-0.42	5.53e-21	Glomerular filtration rate (creatinine);
LGG	trans	rs4713118	0.699	rs200978	chr6:27853168	C/G	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.67	-0.3	7.44e-11	Parkinson's disease;
LGG	cis	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.2	-0.36	2.47e-15	Triglycerides;
LGG	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg12046867	chr14:103022105	NA	-0.79	-15.58	-0.59	2.63e-44	Platelet count;
LGG	cis	rs9399135	0.967	rs6919862	chr6:135352443	C/A	cg22676075	chr6:135203613	NA	0.36	6.7	0.3	6.2e-11	Red blood cell count;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg22105103	chr4:187893119	NA	0.57	10.81	0.45	1.99e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2304069	0.954	rs2340463	chr5:149409294	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.61	7.85	0.34	2.91e-14	HIV-1 control;
LGG	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	5.03e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.26	-0.36	1.5e-15	Height;
LGG	cis	rs3862435	0.518	rs2601166	chr15:90911179	G/A	cg22089800	chr15:90895588	ZNF774	0.53	6.69	0.3	6.58e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg01765077	chr12:122356316	WDR66	0.29	7.91	0.35	1.91e-14	Mean corpuscular volume;
LGG	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs745080	0.569	rs2104568	chr14:52915128	T/C	cg23333723	chr14:53022898	GPR137C	-0.3	-6.74	-0.3	4.75e-11	Orofacial clefts;
LGG	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.72	-0.54	3.61e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg04000281	chr11:63949212	NA	-0.44	-8.39	-0.36	5.93e-16	Platelet count;
LGG	cis	rs6032067	0.777	rs2868236	chr20:43794070	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs11771526	0.901	rs62456036	chr7:32266182	C/T	cg27532318	chr7:32358331	NA	0.67	6.93	0.31	1.42e-11	Body mass index;
LGG	cis	rs6732160	0.691	rs2007191	chr2:73421463	T/G	cg01422370	chr2:73384389	NA	0.47	9.05	0.39	4.04e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg13385794	chr1:248469461	NA	0.44	7.67	0.34	1e-13	Common traits (Other);
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg24764310	chr7:157512201	PTPRN2	-0.46	-10.13	-0.43	6.48e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg11494091	chr17:61959527	GH2	-1.03	-26.1	-0.77	5.33e-93	Prudent dietary pattern;
LGG	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.45	0.53	5.01e-35	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02461956	chr11:134093940	NCAPD3;VPS26B	0.5	8.2	0.36	2.33e-15	Cognitive performance;
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg10189774	chr4:17578691	LAP3	0.38	6.73	0.3	4.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3849046	0.846	rs256014	chr5:137903084	A/G	cg10920316	chr5:137946599	NA	0.47	7.65	0.33	1.19e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-9.58	-0.41	5.97e-20	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs477692	0.624	rs880300	chr10:131329486	G/A	cg05714579	chr10:131428358	MGMT	0.47	8.85	0.38	1.87e-17	Response to temozolomide;
LGG	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	9.02	0.39	4.95e-18	Neuroticism;
LGG	cis	rs9463078	0.683	rs911524	chr6:44747204	G/A	cg25276700	chr6:44698697	NA	0.44	9.03	0.39	4.53e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg14004847	chr7:1930337	MAD1L1	0.54	9.2	0.39	1.2e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.13	0.52	1.09e-33	Prudent dietary pattern;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.36	6.83	0.3	2.75e-11	Schizophrenia;
LGG	cis	rs3008870	0.959	rs56707923	chr1:67388016	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.35	0.72	1.41e-75	Lymphocyte percentage of white cells;
LGG	cis	rs9863	0.896	rs12311114	chr12:124460703	A/C	cg13487667	chr12:124434373	CCDC92	0.36	7.25	0.32	1.73e-12	White blood cell count;
LGG	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.8	-0.41	9.81e-21	Diabetic retinopathy;
LGG	cis	rs2729354	0.909	rs2729374	chr11:57326927	C/T	cg24343310	chr11:57249947	NA	0.38	7.22	0.32	2.16e-12	Blood protein levels;
LGG	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg27532318	chr7:32358331	NA	0.8	6.71	0.3	5.73e-11	Body mass index;
LGG	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg10518543	chr12:38710700	ALG10B	0.42	6.76	0.3	4.25e-11	Morning vs. evening chronotype;
LGG	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg13683864	chr3:40499215	RPL14	-1.14	-25.97	-0.77	2.03e-92	Renal cell carcinoma;
LGG	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg09462578	chr12:12878428	APOLD1	-0.56	-7.67	-0.34	1.01e-13	Systemic lupus erythematosus;
LGG	cis	rs61906588	0.961	rs7934455	chr11:116359851	T/C	cg12564567	chr11:116371188	NA	-0.37	-7.2	-0.32	2.41e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg13628971	chr7:2884303	GNA12	0.34	6.98	0.31	1.03e-11	Height;
LGG	trans	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.6	0.53	1.14e-35	Obesity-related traits;
LGG	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg27661571	chr11:113659931	NA	-0.69	-9.47	-0.4	1.4e-19	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.47	-0.37	3.22e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09593402	chr5:96270297	LNPEP	0.44	7.38	0.32	7.26e-13	Cognitive performance;
LGG	cis	rs6754311	0.689	rs191079	chr2:136633771	T/C	cg07169764	chr2:136633963	MCM6	0.76	12.92	0.51	8.31e-33	Mosquito bite size;
LGG	trans	rs6956675	0.831	rs10268923	chr7:62652624	C/G	cg01314568	chr7:57830625	NA	-0.48	-7.79	-0.34	4.52e-14	Obesity-related traits;
LGG	cis	rs2067615	0.599	rs1579808	chr12:107239947	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-11.62	-0.48	1.4e-27	Heart rate;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg21724239	chr8:58056113	NA	0.42	6.72	0.3	5.32e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg20607798	chr8:58055168	NA	0.65	7.57	0.33	2.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg18479299	chr3:125709523	NA	-0.56	-7.2	-0.32	2.42e-12	Blood pressure (smoking interaction);
LGG	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg16586182	chr3:47516702	SCAP	-0.77	-15.56	-0.59	3.13e-44	Colorectal cancer;
LGG	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg07930552	chr6:133119739	C6orf192	0.86	12.07	0.49	2.36e-29	Type 2 diabetes nephropathy;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	9.79	0.41	1.04e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	cis	rs3741151	0.686	rs7118982	chr11:73110668	T/C	cg17517138	chr11:73019481	ARHGEF17	0.76	8.15	0.35	3.37e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg18681998	chr4:17616180	MED28	0.84	18.72	0.66	1.24e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2274273	0.967	rs11622740	chr14:55617844	G/A	cg04306507	chr14:55594613	LGALS3	0.61	17.21	0.62	1.11e-51	Protein biomarker;
LGG	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg19847130	chr8:10466454	RP1L1	0.3	6.69	0.3	6.36e-11	Joint mobility (Beighton score);
LGG	cis	rs6466055	0.639	rs11760317	chr7:104711711	T/C	cg03782966	chr7:104585482	NA	0.31	6.72	0.3	5.49e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Alcohol dependence;
LGG	cis	rs60180747	1.000	rs76428668	chr15:66839282	T/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.64	11.44	0.47	7.52e-27	Testicular germ cell tumor;
LGG	cis	rs2797369	0.882	rs2254178	chr6:101652860	C/T	cg27451362	chr6:101846650	GRIK2	-0.82	-10.92	-0.45	7.72e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.73	-0.34	6.56e-14	Initial pursuit acceleration;
LGG	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg13852791	chr20:30311386	BCL2L1	0.73	11.53	0.47	3.35e-27	Mean corpuscular hemoglobin;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.46e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.7	-0.37	5.75e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26330133	chr20:35089838	DLGAP4	-0.4	-6.65	-0.3	8.17e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07856758	chr19:37861652	ZNF527	0.5	8.26	0.36	1.6e-15	Cognitive performance;
LGG	cis	rs11229555	0.645	rs12269928	chr11:58184358	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	cis	rs2415984	0.519	rs2642102	chr14:46965502	A/G	cg14871534	chr14:47121158	RPL10L	0.58	10.26	0.43	2.2e-22	Number of children ever born;
LGG	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.51	-8.01	-0.35	9.59e-15	Menarche (age at onset);
LGG	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg07636037	chr3:49044803	WDR6	0.7	11.0	0.46	3.62e-25	Menarche (age at onset);
LGG	cis	rs6577655	0.517	rs9693237	chr8:135578218	G/A	cg17885191	chr8:135476712	NA	0.59	8.83	0.38	2.24e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs7444	0.825	rs738129	chr22:21971041	C/T	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg18478394	chr8:109455254	TTC35	0.45	8.92	0.38	1.12e-17	Dupuytren's disease;
LGG	cis	rs13082711	0.911	rs36101969	chr3:27438181	G/A	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg15971980	chr6:150254442	NA	0.43	8.5	0.37	2.62e-16	Testicular germ cell tumor;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg11766577	chr21:47581405	C21orf56	-0.5	-8.33	-0.36	9.4e-16	Testicular germ cell tumor;
LGG	cis	rs15676	0.947	rs2977999	chr9:131579807	G/A	cg04621255	chr9:131581398	ENDOG	-0.38	-6.83	-0.3	2.67e-11	Blood metabolite levels;
LGG	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.49e-13	Type 2 diabetes;
LGG	cis	rs6456156	0.792	rs4710181	chr6:167513998	T/C	cg07741184	chr6:167504864	NA	0.4	8.92	0.38	1.06e-17	Primary biliary cholangitis;
LGG	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg09264619	chr17:80180166	NA	0.52	10.4	0.44	6.74e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7011049	0.722	rs11985689	chr8:53832615	G/A	cg26025543	chr8:53854495	NA	0.69	9.19	0.39	1.36e-18	Systolic blood pressure;
LGG	cis	rs2063714	0.532	rs2063713	chr6:157196299	G/T	cg23222435	chr6:157204239	ARID1B	-0.87	-16.26	-0.6	2.25e-47	Sitting height ratio;
LGG	cis	rs9287719	0.967	rs3815521	chr2:10743654	G/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.28	-0.53	2.45e-34	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg21724239	chr8:58056113	NA	0.51	7.69	0.34	8.72e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.29	0.4	6.12e-19	Obesity-related traits;
LGG	cis	rs2072499	0.767	rs3001789	chr1:156197614	T/G	cg25208724	chr1:156163844	SLC25A44	1.11	22.9	0.73	3.47e-78	Testicular germ cell tumor;
LGG	cis	rs78487399	0.808	rs6717636	chr2:43703684	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.72	-0.3	5.43e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg23730037	chr7:158596552	ESYT2	-0.47	-8.51	-0.37	2.51e-16	Height;
LGG	cis	rs73086581	1.000	rs11906274	chr20:3945536	G/A	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg08677398	chr8:58056175	NA	0.44	7.4	0.33	6.46e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7944735	0.817	rs6485774	chr11:47773226	C/T	cg15704280	chr7:45808275	SEPT13	0.63	7.87	0.34	2.59e-14	Intraocular pressure;
LGG	cis	rs9557207	1.000	rs3181718	chr13:99946853	C/T	cg24509225	chr13:100037070	UBAC2	0.69	12.33	0.5	2.07e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.37	0.36	7.07e-16	Tonsillectomy;
LGG	cis	rs9677476	0.909	rs10181602	chr2:232121642	G/C	cg23338755	chr2:231921595	PSMD1	0.47	7.18	0.32	2.88e-12	Food antigen IgG levels;
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg27219399	chr15:67835830	MAP2K5	0.32	7.04	0.31	6.84e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2239547	0.522	rs6770957	chr3:52995416	T/C	cg11645453	chr3:52864694	ITIH4	0.69	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs2070433	0.904	rs8130209	chr21:47925984	T/C	cg12379764	chr21:47803548	PCNT	0.5	7.16	0.32	3.17e-12	Lymphocyte counts;
LGG	cis	rs60695258	0.726	rs1471251	chr4:87976359	A/T	cg11209507	chr4:87813803	C4orf36	-0.55	-9.75	-0.41	1.54e-20	Hematocrit;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08280861	chr8:58055591	NA	0.62	7.72	0.34	7.24e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg06035437	chr8:1398411	NA	-0.51	-8.32	-0.36	1.01e-15	Triglycerides;
LGG	cis	rs2011503	1.000	rs75525243	chr19:19638218	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs3824867	0.770	rs11820680	chr11:47452744	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-7.16	-0.32	3.19e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2742417	1.000	rs2742418	chr3:45731920	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.48	-0.33	3.81e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-15.44	-0.58	1.14e-43	Chronic sinus infection;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg11494091	chr17:61959527	GH2	0.58	9.04	0.39	4.39e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12220238	0.558	rs76330316	chr10:76002291	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.92	0.48	9.35e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg27476859	chr7:2772710	GNA12	0.43	7.33	0.32	1.03e-12	Height;
LGG	trans	rs1973993	0.603	rs1967769	chr1:96993449	C/T	cg10631902	chr5:14652156	NA	0.38	7.3	0.32	1.3e-12	Weight;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.79	-0.34	4.41e-14	Systolic blood pressure;
LGG	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg20503657	chr10:835505	NA	0.53	6.94	0.31	1.34e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.41	-0.5	1.04e-30	Resting heart rate;
LGG	cis	rs908922	0.676	rs3753451	chr1:152485227	T/G	cg20991723	chr1:152506922	NA	-0.7	-14.48	-0.56	1.93e-39	Hair morphology;
LGG	cis	rs9470366	0.509	rs4714001	chr6:36638175	G/A	cg08179530	chr6:36648295	CDKN1A	-0.68	-11.93	-0.49	8.17e-29	QRS duration;
LGG	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.45	0.5	6.62e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg05775895	chr3:12838266	CAND2	0.72	13.92	0.54	4.99e-37	QRS complex (12-leadsum);
LGG	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg00647317	chr7:50633725	DDC	0.49	12.39	0.5	1.19e-30	Systemic sclerosis;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg12458913	chr13:53173898	NA	0.75	15.52	0.59	4.7e-44	Lewy body disease;
LGG	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.05	-0.31	6.71e-12	Crohn's disease;
LGG	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-7.31	-0.32	1.19e-12	Height;
LGG	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg08250081	chr4:10125330	NA	0.41	8.14	0.35	3.65e-15	Bone mineral density;
LGG	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.92	-15.19	-0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs9399135	0.838	rs4896126	chr6:135342786	C/A	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.92e-20	Red blood cell count;
LGG	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs7695597	0.643	rs2665730	chr4:185172104	G/T	cg12654155	chr4:185238627	NA	0.43	7.91	0.35	1.87e-14	Night sleep phenotypes;
LGG	cis	rs8016982	0.674	rs11159494	chr14:81667611	G/C	cg01989461	chr14:81687754	GTF2A1	0.79	19.71	0.68	2.99e-63	Schizophrenia;
LGG	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg18200150	chr17:30822561	MYO1D	0.47	8.96	0.38	8.23e-18	Schizophrenia;
LGG	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg16386425	chr10:429943	DIP2C	-0.36	-6.81	-0.3	3.02e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2070488	0.745	rs9838792	chr3:38546726	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.34	-0.55	7.45e-39	Electrocardiographic conduction measures;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.8e-16	Tonsillectomy;
LGG	cis	rs4774899	0.966	rs4238322	chr15:57573365	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg06640241	chr16:89574553	SPG7	-0.69	-12.06	-0.49	2.54e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.63e-17	Bipolar disorder;
LGG	cis	rs7188861	0.768	rs1794025	chr16:11380945	C/T	cg01510278	chr16:11456238	NA	0.3	7.15	0.32	3.37e-12	HDL cholesterol;
LGG	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.59	-0.67	1.16e-62	Blood trace element (Zn levels);
LGG	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.27e-14	Huntington's disease progression;
LGG	cis	rs6430585	0.646	rs12476116	chr2:136497199	A/G	cg07169764	chr2:136633963	MCM6	1.27	22.67	0.73	4.13e-77	Corneal structure;
LGG	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg22681709	chr2:178499509	PDE11A	0.49	7.16	0.32	3.27e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg23173402	chr1:227635558	NA	0.6	9.89	0.42	4.82e-21	Major depressive disorder;
LGG	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2073300	0.609	rs6137915	chr20:23358509	A/G	cg12062639	chr20:23401060	NAPB	-0.88	-8.68	-0.37	6.94e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7674212	0.539	rs6533056	chr4:104120997	T/C	cg16532752	chr4:104119610	CENPE	-0.41	-7.09	-0.31	5.05e-12	Type 2 diabetes;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg02187348	chr16:89574699	SPG7	0.45	7.32	0.32	1.11e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2658782	0.724	rs1869914	chr11:93112492	C/G	cg15737290	chr11:93063684	CCDC67	0.51	7.73	0.34	6.58e-14	Pulmonary function decline;
LGG	cis	rs1355223	0.902	rs61881050	chr11:34719749	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.7	-0.3	6.05e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs362296	0.590	rs4690081	chr4:3262105	T/G	cg06533319	chr4:3265114	C4orf44	0.51	10.57	0.44	1.55e-23	Parental longevity (mother's age at death);
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.09	0.39	2.84e-18	Aortic root size;
LGG	cis	rs965513	0.512	rs10983655	chr9:100524322	T/C	cg13688889	chr9:100608707	NA	-0.38	-6.75	-0.3	4.34e-11	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs17321999	0.904	rs6708792	chr2:30468860	C/T	cg05247661	chr2:30472410	LBH	0.62	9.72	0.41	1.94e-20	Systemic lupus erythematosus;
LGG	cis	rs13401104	0.716	rs11677595	chr2:237140651	A/G	cg15742758	chr2:237126235	ASB18	0.49	7.89	0.34	2.26e-14	Educational attainment;
LGG	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.43	-0.36	4.36e-16	Schizophrenia;
LGG	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg03342759	chr3:160939853	NMD3	-0.59	-9.91	-0.42	4.11e-21	Morning vs. evening chronotype;
LGG	trans	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	25.08	0.76	2.5e-88	IgG glycosylation;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs74781061	0.932	rs7161903	chr15:74940270	A/G	cg02384859	chr15:74862662	ARID3B	-0.33	-6.96	-0.31	1.16e-11	Endometriosis;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.94	-0.38	9.07e-18	Lung cancer;
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg06494592	chr3:125709126	NA	-0.55	-7.02	-0.31	8.14e-12	Blood pressure (smoking interaction);
LGG	cis	rs7923837	0.663	rs5015480	chr10:94465559	C/T	cg25093409	chr10:94429542	NA	0.41	8.36	0.36	7.44e-16	Body mass index;Multiple sclerosis;
LGG	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg24699146	chr1:24152579	HMGCL	-0.25	-7.46	-0.33	4.41e-13	Immature fraction of reticulocytes;
LGG	cis	rs2415984	0.579	rs2100337	chr14:46966088	T/C	cg14871534	chr14:47121158	RPL10L	-0.58	-10.21	-0.43	3.3e-22	Number of children ever born;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11169552	0.510	rs10431486	chr12:50941025	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.77	-0.34	5.15e-14	Colorectal cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11674773	chr1:54518492	TMEM59;C1orf83	-0.46	-6.67	-0.3	7.29e-11	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg18681998	chr4:17616180	MED28	0.85	18.8	0.66	5.39e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg06521331	chr12:34319734	NA	0.51	9.43	0.4	1.97e-19	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00369126	chr16:4674642	MGRN1	0.49	7.67	0.34	1.06e-13	Gut microbiome composition (summer);
LGG	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.12	0.49	1.45e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7106204	0.748	rs11820336	chr11:24219701	G/A	ch.11.24196551F	chr11:24239977	NA	1.04	16.5	0.61	1.98e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6942756	0.806	rs2718093	chr7:128939582	G/A	cg02491457	chr7:128862824	NA	-0.63	-11.79	-0.48	3.07e-28	White matter hyperintensity burden;
LGG	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg19812747	chr11:111475976	SIK2	0.47	9.52	0.4	9.58e-20	Primary sclerosing cholangitis;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.47	7.91	0.34	1.94e-14	Lymphocyte counts;
LGG	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg17859187	chr1:168147929	TIPRL	0.42	6.86	0.3	2.17e-11	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12230513	0.732	rs61956331	chr12:55840856	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-11.16	-0.46	9.03e-26	Contrast sensitivity;
LGG	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.76	0.3	4.21e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs701145	0.938	rs1086106	chr3:154084032	C/T	cg17054900	chr3:154042577	DHX36	0.98	12.27	0.5	3.69e-30	Coronary artery disease;
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00149659	chr3:10157352	C3orf10	0.8	9.66	0.41	3.17e-20	Alzheimer's disease;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg05313129	chr8:58192883	C8orf71	-0.79	-11.97	-0.49	6.17e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg13206674	chr6:150067644	NUP43	0.66	15.28	0.58	5.57e-43	Lung cancer;
LGG	cis	rs2016266	0.787	rs61928080	chr12:53752204	G/A	cg04065151	chr12:53682969	ESPL1	0.54	8.26	0.36	1.56e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9397585	0.857	rs2295231	chr6:153365348	G/A	cg17707550	chr6:153380415	RGS17	0.61	14.43	0.56	3.11e-39	Body mass index;
LGG	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02788857	chr8:22132959	PIWIL2	0.5	11.63	0.48	1.29e-27	Hypertriglyceridemia;
LGG	cis	rs77106637	0.769	rs11603313	chr11:72588177	G/A	cg03878208	chr11:72483293	STARD10	0.48	6.9	0.31	1.69e-11	Type 2 diabetes;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.71	-0.34	7.96e-14	Longevity;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9831754	0.906	rs1588650	chr3:78410750	T/G	cg06138941	chr3:78371609	NA	-0.86	-17.47	-0.63	6.93e-53	Calcium levels;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14893161	chr1:205819251	PM20D1	-0.41	-7.97	-0.35	1.28e-14	Prostate-specific antigen levels;
LGG	cis	rs7241530	0.636	rs11873523	chr18:75897751	G/A	cg14642773	chr18:75888474	NA	0.47	8.99	0.39	6.4e-18	Educational attainment (years of education);
LGG	cis	rs3735485	0.800	rs1866578	chr7:45085634	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs13108043	0.605	rs33983129	chr4:87939330	C/T	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07080220	chr10:102295463	HIF1AN	0.69	11.88	0.48	1.41e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg11366901	chr6:160182831	ACAT2	0.99	15.11	0.57	3.26e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03352830	chr11:487213	PTDSS2	0.83	10.01	0.42	1.78e-21	Body mass index;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg12708336	chr17:41446283	NA	-0.31	-7.21	-0.32	2.36e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.05	0.49	2.92e-29	Prudent dietary pattern;
LGG	cis	rs3796352	0.571	rs71301816	chr3:53142071	G/A	cg12962167	chr3:53033115	SFMBT1	0.74	7.45	0.33	4.54e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7236492	0.688	rs35455644	chr18:77184282	A/G	cg15532942	chr18:77220712	NFATC1	0.45	7.09	0.31	5.13e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg05091796	chr16:4465799	CORO7	-0.84	-14.31	-0.55	9.75e-39	Schizophrenia;
LGG	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.03	-0.83	1.67e-119	Myeloid white cell count;
LGG	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg18240062	chr17:79603768	NPLOC4	0.81	15.47	0.58	8.3500000000000005e-44	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15235185	chr1:193028809	TROVE2;UCHL5	0.46	7.08	0.31	5.33e-12	Gut microbiome composition (summer);
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg13628971	chr7:2884303	GNA12	0.5	10.1	0.43	7.96e-22	Height;
LGG	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg20302533	chr7:39170763	POU6F2	0.53	13.06	0.52	2.01e-33	IgG glycosylation;
LGG	trans	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.86	-0.38	1.74e-17	Response to antipsychotic treatment;
LGG	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg20387954	chr3:183756860	HTR3D	0.65	13.31	0.53	1.79e-34	Anterior chamber depth;
LGG	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.39	7.79	0.34	4.34e-14	Insulin-like growth factors;
LGG	cis	rs1034435	1.000	rs6007867	chr22:48889170	T/G	cg05992904	chr22:48892994	FAM19A5	-0.78	-14.98	-0.57	1.15e-41	Late-onset Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.22	-0.58	1.08e-42	Prudent dietary pattern;
LGG	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03576123	chr11:487126	PTDSS2	1.23	17.08	0.62	4.27e-51	Body mass index;
LGG	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.46	8.09	0.35	5.15e-15	Glycated hemoglobin levels;
LGG	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.52e-22	Height;
LGG	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg20848291	chr7:100343083	ZAN	-0.66	-9.46	-0.4	1.54e-19	Other erythrocyte phenotypes;
LGG	cis	rs7927771	0.839	rs7124681	chr11:47529947	C/A	cg20307385	chr11:47447363	PSMC3	-0.42	-7.58	-0.33	1.84e-13	Subjective well-being;
LGG	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg24375607	chr4:120327624	NA	0.67	11.0	0.46	3.52e-25	Corneal astigmatism;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.79	-0.34	4.52e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg06654118	chr4:1303317	MAEA	0.48	8.12	0.35	4.19e-15	Obesity-related traits;
LGG	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg17545662	chr6:170176663	C6orf70	0.67	8.66	0.37	7.96e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg13271783	chr10:134563150	INPP5A	-0.43	-6.82	-0.3	2.88e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.18e-66	Intelligence (multi-trait analysis);
LGG	cis	rs1519814	1.000	rs4871037	chr8:121124042	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.56	-0.47	2.58e-27	Breast cancer;
LGG	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg23517279	chr6:96025343	MANEA	0.49	6.77	0.3	3.9e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs2354432	0.556	rs66501488	chr1:146853992	T/C	cg25205988	chr1:146714368	CHD1L	-1.23	-11.75	-0.48	4.62e-28	Mitochondrial DNA levels;
LGG	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-10.93	-0.45	7.08e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs701145	0.585	rs17817774	chr3:153779868	A/G	cg17054900	chr3:154042577	DHX36	-0.65	-8.22	-0.36	2.07e-15	Coronary artery disease;
LGG	cis	rs7712401	0.562	rs30073	chr5:122290509	A/T	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg02733842	chr7:1102375	C7orf50	-0.47	-7.25	-0.32	1.73e-12	Bronchopulmonary dysplasia;
LGG	cis	rs4740619	0.933	rs10756694	chr9:15710636	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.32	-0.43	1.31e-22	Body mass index;
LGG	trans	rs11088226	0.681	rs8131384	chr21:33944127	C/T	cg09050820	chr6:167586206	TCP10L2	0.93	13.2	0.52	5.34e-34	Gastritis;
LGG	cis	rs6450176	1.000	rs3776716	chr5:53298923	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-15.34	-0.58	2.95e-43	Total body bone mineral density;
LGG	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg05484376	chr2:27715224	FNDC4	0.43	9.33	0.4	4.46e-19	Total body bone mineral density;
LGG	cis	rs13126513	0.708	rs4699383	chr4:100467011	G/T	cg05468953	chr4:100565104	NA	-0.39	-7.85	-0.34	2.93e-14	Metabolite levels (MHPG);
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04275707	chr20:20033092	CRNKL1;C20orf26	0.43	7.39	0.32	7.09e-13	Lung adenocarcinoma;
LGG	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg12395012	chr8:11607386	GATA4	-0.39	-7.32	-0.32	1.11e-12	Monocyte count;
LGG	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg15704280	chr7:45808275	SEPT13	0.77	8.89	0.38	1.35e-17	Axial length;
LGG	trans	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.57	-0.33	2.08e-13	Resting heart rate;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg13750949	chr14:105293957	NA	0.53	8.75	0.38	3.92e-17	IgG glycosylation;
LGG	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg26396452	chr14:65542826	MAX	0.41	7.99	0.35	1.06e-14	Obesity-related traits;
LGG	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.07	-0.31	5.74e-12	Monocyte count;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg07747251	chr5:1868357	NA	0.45	9.04	0.39	4.27e-18	Cardiovascular disease risk factors;
LGG	cis	rs1372520	0.684	rs2197120	chr4:90729602	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	cis	rs7737355	0.812	rs994453	chr5:130872520	G/T	cg06307176	chr5:131281290	NA	-0.52	-8.61	-0.37	1.13e-16	Life satisfaction;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00689492	chr4:1303491	MAEA	0.47	8.05	0.35	6.95e-15	Obesity-related traits;
LGG	cis	rs1003719	0.667	rs3753073	chr21:38466615	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.71	13.08	0.52	1.71e-33	Eye color traits;
LGG	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg13560919	chr6:33536144	NA	0.41	7.59	0.33	1.76e-13	Crohn's disease;
LGG	cis	rs73416724	1.000	rs75473868	chr6:43352623	A/G	cg26312998	chr6:43337775	ZNF318	0.59	8.26	0.36	1.51e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4740619	0.901	rs10810401	chr9:15584485	A/T	cg14451791	chr9:16040625	NA	-0.4	-10.51	-0.44	2.57e-23	Body mass index;
LGG	trans	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg18335740	chr13:41363409	SLC25A15	0.86	20.67	0.69	9.51e-68	Lewy body disease;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg05368731	chr17:41323189	NBR1	0.96	18.01	0.64	2.3e-55	Menopause (age at onset);
LGG	cis	rs7226408	0.802	rs11081969	chr18:34483191	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.0	-0.31	8.97e-12	Obesity-related traits;
LGG	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.87	-0.34	2.52e-14	HDL cholesterol;
LGG	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg18105134	chr13:113819100	PROZ	-0.7	-14.03	-0.55	1.71e-37	Platelet distribution width;
LGG	cis	rs4731207	0.564	rs12531844	chr7:124603900	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs56283067	0.887	rs10948172	chr6:44777691	A/G	cg18551225	chr6:44695536	NA	-0.66	-10.69	-0.45	5.25e-24	Total body bone mineral density;
LGG	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg17085576	chr10:5658249	NA	-0.39	-7.41	-0.33	5.86e-13	Breast cancer;
LGG	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.66	-0.51	9.57e-32	Total body bone mineral density;
LGG	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg12395012	chr8:11607386	GATA4	0.4	7.32	0.32	1.09e-12	Neuroticism;
LGG	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg25237894	chr2:233734115	C2orf82	0.48	9.02	0.39	4.99e-18	Coronary artery disease;
LGG	cis	rs4409675	0.956	rs4072743	chr1:28270934	T/C	cg23691781	chr1:28212827	C1orf38	-0.31	-7.13	-0.31	3.91e-12	Corneal astigmatism;
LGG	trans	rs643955	0.611	rs35044612	chr8:9864980	T/G	cg16141378	chr3:129829833	LOC729375	0.3	6.65	0.3	8.05e-11	Systemic lupus erythematosus;
LGG	cis	rs4566357	1.000	rs1917129	chr2:227927951	A/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.74	-0.3	4.62e-11	Coronary artery disease;
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg02825527	chr7:2087843	MAD1L1	-0.44	-7.78	-0.34	4.83e-14	Bipolar disorder;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.75	-0.3	4.5e-11	Aortic root size;
LGG	cis	rs834603	0.547	rs834599	chr7:47463842	T/G	cg23694490	chr7:47445681	TNS3	-0.43	-12.28	-0.5	3.35e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.37	0.47	1.39e-26	Schizophrenia;
LGG	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs7927771	0.524	rs1056387	chr11:47681370	A/C	cg20307385	chr11:47447363	PSMC3	0.41	7.34	0.32	9.48e-13	Subjective well-being;
LGG	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg22491629	chr6:157744540	C6orf35	-0.96	-13.59	-0.53	1.26e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs3740909	1.000	rs7935585	chr11:125896365	T/C	cg24940576	chr11:125904314	CDON	-0.49	-7.32	-0.32	1.14e-12	Blood protein levels;
LGG	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	4.12e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1862618	0.671	rs2591958	chr5:56239369	C/G	cg17809284	chr5:56205270	C5orf35	0.55	10.25	0.43	2.32e-22	Initial pursuit acceleration;
LGG	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg24692254	chr21:30365293	RNF160	-0.73	-14.21	-0.55	2.77e-38	Dental caries;
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs7326068	0.576	rs9552273	chr13:21333750	A/C	cg04906043	chr13:21280425	IL17D	-0.44	-7.15	-0.32	3.46e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg23815491	chr16:72088622	HP	0.51	9.73	0.41	1.82e-20	Blood protein levels;
LGG	cis	rs9863	0.896	rs77112003	chr12:124487543	C/T	cg13487667	chr12:124434373	CCDC92	-0.37	-7.37	-0.32	7.99e-13	White blood cell count;
LGG	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg00383909	chr3:49044727	WDR6	0.45	7.3	0.32	1.26e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs3942852	0.524	rs7118665	chr11:48078427	C/A	cg15704280	chr7:45808275	SEPT13	0.71	11.07	0.46	1.91e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10489202	0.632	rs275137	chr1:168051266	A/C	cg24449463	chr1:168025552	DCAF6	0.6	10.66	0.44	6.84e-24	Schizophrenia;
LGG	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-7.09	-0.31	5.05e-12	Aortic root size;
LGG	cis	rs2236918	0.901	rs1776135	chr1:242025530	A/G	cg17736920	chr1:242011382	EXO1	0.53	9.55	0.41	7.29e-20	Menopause (age at onset);
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.79	-0.45	2.31e-24	Bipolar disorder;
LGG	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg08085267	chr17:45401833	C17orf57	0.62	12.99	0.52	4.04e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg08677398	chr8:58056175	NA	0.44	6.69	0.3	6.37e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg05313129	chr8:58192883	C8orf71	-0.62	-8.5	-0.37	2.66e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2708977	0.637	rs687950	chr2:97069612	C/G	cg01950434	chr2:97203154	ARID5A	0.45	6.86	0.3	2.26e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.73e-33	Prudent dietary pattern;
LGG	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg04287289	chr16:89883240	FANCA	-0.52	-9.37	-0.4	3.1400000000000002e-19	Vitiligo;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.57	0.37	1.5e-16	Personality dimensions;
LGG	cis	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg07460842	chr6:66804631	NA	0.96	17.95	0.64	4.53e-55	Exhaled nitric oxide output;
LGG	cis	rs943466	0.955	rs2281819	chr6:33771673	T/A	cg07519485	chr6:33762594	MLN	0.53	10.53	0.44	2.09e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	trans	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg11764359	chr7:65958608	NA	0.62	9.58	0.41	5.89e-20	Aortic root size;
LGG	cis	rs3741151	0.773	rs79915238	chr11:73272947	C/T	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9393777	0.557	rs36034627	chr6:27237363	G/T	cg12292205	chr6:26970375	C6orf41	-0.64	-9.21	-0.39	1.15e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg24631222	chr15:78858424	CHRNA5	-0.42	-6.68	-0.3	7.03e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg03098644	chr7:100410630	EPHB4	0.49	7.27	0.32	1.54e-12	Other erythrocyte phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19794490	chr20:33412943	NCOA6	0.48	7.02	0.31	7.99e-12	Gut microbiome composition (summer);
LGG	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg27572855	chr1:25598939	RHD	0.49	11.15	0.46	9.42e-26	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs209489	1.000	rs209491	chr6:53181861	C/G	cg15607103	chr6:53167650	ELOVL5	-0.52	-7.44	-0.33	5.08e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22455342	chr2:225449267	CUL3	0.85	14.9	0.57	2.64e-41	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg04503457	chr17:41445688	NA	-0.38	-9.31	-0.4	5.21e-19	Menopause (age at onset);
LGG	cis	rs6032067	1.000	rs6032067	chr20:43864809	G/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-12.01	-0.49	4.24e-29	Total body bone mineral density;
LGG	cis	rs4906332	0.899	rs12888042	chr14:103891709	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.76e-14	Coronary artery disease;
LGG	cis	rs2587949	0.615	rs2587950	chr3:4225251	A/G	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg09038676	chr11:67351608	GSTP1	-0.36	-7.24	-0.32	1.87e-12	Mean corpuscular volume;
LGG	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12591125	chr7:1885375	MAD1L1	0.47	7.35	0.32	9.27e-13	Bipolar disorder;
LGG	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs10779751	0.770	rs1057079	chr1:11205058	A/G	cg08854313	chr1:11322531	MTOR	-0.75	-16.61	-0.61	5.9e-49	Body mass index;
LGG	cis	rs704	0.522	rs12947270	chr17:26739127	A/G	cg10342447	chr17:26645325	TMEM97	0.51	9.37	0.4	3.1400000000000002e-19	Osteoprotegerin levels;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06112835	chr11:68658793	MRPL21	0.59	9.75	0.41	1.54e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg20744362	chr22:50050164	C22orf34	0.38	7.47	0.33	4.04e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.06	-0.31	6.08e-12	Blood metabolite levels;
LGG	cis	rs897080	0.515	rs1085486	chr2:44617324	T/A	cg00619915	chr2:44497795	NA	-0.47	-6.71	-0.3	5.69e-11	Height;
LGG	cis	rs2213920	0.679	rs4979534	chr9:118211159	T/C	cg13918206	chr9:118159781	DEC1	0.61	8.68	0.37	6.99e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.97e-26	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg25660036	chr4:7070649	GRPEL1	-0.46	-6.92	-0.31	1.47e-11	Monocyte percentage of white cells;
LGG	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-7.0	-0.31	9.19e-12	Lung cancer in ever smokers;
LGG	cis	rs4666002	0.956	rs13020949	chr2:27836605	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.3	2.38e-11	Phospholipid levels (plasma);
LGG	cis	rs72634258	0.553	rs112697022	chr1:7949253	G/A	cg26816564	chr1:7831052	VAMP3	0.6	7.83	0.34	3.26e-14	Inflammatory bowel disease;
LGG	cis	rs1879553	0.527	rs56160739	chr3:118655746	G/T	cg11869695	chr3:118686312	IGSF11	-0.36	-6.68	-0.3	6.88e-11	Parkinson's disease;
LGG	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg08773314	chr2:239334832	ASB1	0.42	8.06	0.35	6.4e-15	Multiple system atrophy;
LGG	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.66	-0.44	7.08e-24	Initial pursuit acceleration;
LGG	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg02023728	chr11:77925099	USP35	0.46	8.22	0.36	2e-15	Testicular germ cell tumor;
LGG	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.21	-0.55	2.68e-38	Platelet distribution width;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.22	-0.32	2.2e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg02002194	chr4:3960332	NA	-0.39	-7.16	-0.32	3.11e-12	Mood instability;
LGG	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15644404	chr18:77186268	NFATC1	-0.82	-8.78	-0.38	3.08e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg23845249	chr11:68861649	NA	0.45	8.03	0.35	8.14e-15	Blond vs. brown hair color;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13732083	chr21:47605072	C21orf56	0.52	8.5	0.37	2.63e-16	Testicular germ cell tumor;
LGG	cis	rs2797369	0.600	rs705595	chr6:101295392	A/T	cg27451362	chr6:101846650	GRIK2	0.67	9.13	0.39	2.08e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.14	-0.58	2.28e-42	Skin colour saturation;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1318772	1.000	rs26962	chr5:112737010	C/A	cg12552261	chr5:112820674	MCC	0.7	7.99	0.35	1.11e-14	F-cell distribution;
LGG	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8067545	0.532	rs56371654	chr17:19960362	G/T	cg13482628	chr17:19912719	NA	0.53	8.75	0.38	3.85e-17	Schizophrenia;
LGG	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg22601191	chr20:60968625	CABLES2	0.37	7.16	0.32	3.21e-12	Colorectal cancer;
LGG	cis	rs9863	0.861	rs3802999	chr12:124414098	C/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.15	-0.32	3.3e-12	White blood cell count;
LGG	trans	rs853679	0.723	rs9366718	chr6:28205502	A/T	cg01620082	chr3:125678407	NA	-0.51	-6.96	-0.31	1.13e-11	Depression;
LGG	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.78	0.38	3.29e-17	Fuchs's corneal dystrophy;
LGG	cis	rs11074306	0.561	rs6497244	chr15:28072600	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg17545662	chr6:170176663	C6orf70	0.7	8.95	0.38	8.96e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4481887	0.927	rs4523548	chr1:248472399	G/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.99	-0.42	2.07e-21	Joint mobility (Beighton score);
LGG	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg18551225	chr6:44695536	NA	-0.68	-11.26	-0.46	3.76e-26	Total body bone mineral density;
LGG	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg18424134	chr6:126068038	NA	0.21	6.82	0.3	2.85e-11	Brugada syndrome;
LGG	cis	rs9513627	0.915	rs4324006	chr13:100122545	A/G	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg09033563	chr22:24373618	LOC391322	-0.51	-8.4	-0.36	5.32e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10186029	0.548	rs4673728	chr2:214001997	C/G	cg08319019	chr2:214017104	IKZF2	0.4	7.12	0.31	4.12e-12	Systemic sclerosis;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg04824913	chr4:887549	GAK	0.44	7.03	0.31	7.51e-12	Sjögren's syndrome;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg24204643	chr3:107243096	BBX	0.48	7.1	0.31	4.58e-12	Apolipoprotein A-IV levels;
LGG	cis	rs12318506	0.826	rs11180434	chr12:75662128	T/C	cg04728562	chr12:75699417	CAPS2	-1.12	-9.42	-0.4	2.1e-19	Coronary artery calcification;
LGG	cis	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05901451	chr6:126070800	HEY2	0.45	7.51	0.33	3.1400000000000003e-13	Endometrial cancer;
LGG	cis	rs2708240	1.000	rs2538974	chr7:147587753	A/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.28	-7.11	-0.31	4.56e-12	QT interval (drug interaction);
LGG	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs1775715	0.675	rs2808085	chr10:32148599	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.83	0.3	2.69e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg18131467	chr2:239335373	ASB1	1.03	23.71	0.74	5.9e-82	Multiple system atrophy;
LGG	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg00717180	chr2:96193071	NA	-0.47	-8.86	-0.38	1.71e-17	Coronary artery disease;
LGG	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Bladder cancer;
LGG	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.79	-0.41	1.09e-20	Rheumatoid arthritis;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.68	-0.3	6.94e-11	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg18245976	chr7:158708271	WDR60	-0.55	-9.52	-0.4	9.77e-20	Height;
LGG	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs12447804	0.911	rs12918521	chr16:58096284	C/G	cg03859792	chr16:58121049	NA	0.48	7.3	0.32	1.25e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg09339527	chr5:178322752	ZFP2	-0.4	-7.4	-0.33	6.47e-13	Sleep duration;
LGG	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg22437258	chr11:111473054	SIK2	0.57	9.96	0.42	2.76e-21	Primary sclerosing cholangitis;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg24623649	chr8:11872141	NA	-0.3	-6.99	-0.31	9.65e-12	Neuroticism;
LGG	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.73	-0.34	6.55e-14	Neuroticism;
LGG	cis	rs7191439	0.584	rs11076698	chr16:88752693	T/G	cg27087555	chr16:88793112	FAM38A	-1.29	-12.72	-0.51	5.41e-32	Plateletcrit;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg13385794	chr1:248469461	NA	0.49	8.31	0.36	1.07e-15	Common traits (Other);
LGG	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-9.87	-0.42	5.66e-21	Parkinson's disease;
LGG	cis	rs3816183	1.000	rs920390	chr2:43019144	A/G	cg14631114	chr2:43023945	NA	-0.49	-9.32	-0.4	4.6e-19	Hypospadias;
LGG	cis	rs727505	1.000	rs722560	chr7:124488035	T/C	cg23710748	chr7:124431027	NA	-0.53	-10.0	-0.42	1.83e-21	Lewy body disease;
LGG	cis	rs477692	0.669	rs12265939	chr10:131445398	A/G	cg05714579	chr10:131428358	MGMT	-0.7	-15.62	-0.59	1.74e-44	Response to temozolomide;
LGG	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Body mass index;
LGG	cis	rs2404602	0.684	rs11072602	chr15:76873467	T/C	cg15268244	chr15:77196840	NA	0.47	9.91	0.42	4.07e-21	Blood metabolite levels;
LGG	cis	rs754466	0.580	rs2579176	chr10:79529350	A/G	cg17075019	chr10:79541650	NA	-0.99	-21.72	-0.71	1.25e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg26174226	chr8:58114915	NA	-0.57	-7.67	-0.34	1.03e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg15017067	chr4:17643749	FAM184B	0.3	6.89	0.3	1.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg08017756	chr2:100939284	LONRF2	-0.29	-7.02	-0.31	8.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg09699651	chr6:150184138	LRP11	0.54	9.72	0.41	1.88e-20	Lung cancer;
LGG	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg06917634	chr15:78832804	PSMA4	0.82	17.17	0.62	1.78e-51	Sudden cardiac arrest;
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13012494	chr21:47604986	C21orf56	-0.56	-9.82	-0.42	8.5e-21	Testicular germ cell tumor;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21963583	chr11:68658836	MRPL21	-0.6	-10.21	-0.43	3.25e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.87	-0.38	1.57e-17	Colorectal cancer;
LGG	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg16346588	chr10:242978	ZMYND11	-0.46	-7.12	-0.31	4.16e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs4919694	1.000	rs11191525	chr10:104793435	G/C	cg04362960	chr10:104952993	NT5C2	1.07	14.76	0.57	1.09e-40	Arsenic metabolism;
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg26354017	chr1:205819088	PM20D1	0.86	20.43	0.69	1.3e-66	Menarche (age at onset);
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.77	-0.34	5.29e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	8.1	0.35	4.94e-15	Iron status biomarkers;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg05091796	chr16:4465799	CORO7	-0.79	-13.23	-0.52	4.03e-34	Schizophrenia;
LGG	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg19168338	chr16:4465731	CORO7	0.72	12.65	0.51	9.98e-32	Schizophrenia;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.8e-14	Lung cancer;
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02825527	chr7:2087843	MAD1L1	-0.44	-7.86	-0.34	2.71e-14	Bipolar disorder;
LGG	cis	rs8017423	0.626	rs8003363	chr14:90826840	T/C	cg04374321	chr14:90722782	PSMC1	-0.63	-12.32	-0.5	2.35e-30	Mortality in heart failure;
LGG	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg08807101	chr21:30365312	RNF160	-0.83	-16.91	-0.62	2.67e-50	Dental caries;
LGG	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg21366198	chr4:185655624	MLF1IP	-0.42	-7.25	-0.32	1.76e-12	Kawasaki disease;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.46	7.73	0.34	6.86e-14	Longevity;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg07120314	chr15:79043507	NA	-0.77	-19.5	-0.67	2.84e-62	Coronary artery disease or large artery stroke;
LGG	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.6	0.51	1.7e-31	Motion sickness;
LGG	cis	rs13102973	0.965	rs4437307	chr4:135861598	C/T	cg14419869	chr4:135874104	NA	-0.57	-10.97	-0.45	4.84e-25	Subjective well-being;
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00294572	chr6:26285232	NA	0.42	7.68	0.34	9.71e-14	Educational attainment;
LGG	trans	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs1816854	1.000	rs10880569	chr12:44201636	C/G	cg00106942	chr12:44200524	TWF1	0.45	7.02	0.31	8.14e-12	Inflammatory bowel disease;
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg11062466	chr8:58055876	NA	0.46	7.01	0.31	8.31e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.06	-0.52	2.09e-33	Vitamin D levels;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg05313129	chr8:58192883	C8orf71	-0.84	-12.5	-0.5	4.31e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.52e-12	Schizophrenia;
LGG	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg00405596	chr8:11794950	NA	-0.44	-7.28	-0.32	1.43e-12	Neuroticism;
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg20493526	chr2:3714936	ALLC	0.37	7.81	0.34	3.96e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4262150	0.883	rs72799173	chr5:152149398	A/G	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs2652834	0.851	rs6494392	chr15:63406863	A/G	cg05507819	chr15:63340323	TPM1	-0.5	-7.05	-0.31	6.38e-12	HDL cholesterol;
LGG	cis	rs7766436	0.848	rs2294828	chr6:22598018	G/A	cg13666174	chr6:22585274	NA	-0.52	-12.22	-0.49	5.78e-30	Coronary artery disease;
LGG	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg13010199	chr12:38710504	ALG10B	0.68	14.21	0.55	2.71e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg06212747	chr3:49208901	KLHDC8B	0.46	6.85	0.3	2.39e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs2494938	0.716	rs846509	chr6:40530612	T/C	cg14084896	chr6:40530702	LRFN2	-0.33	-7.13	-0.31	3.96e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03264133	chr6:25882463	NA	0.5	9.19	0.39	1.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4789693	0.518	rs6502108	chr17:80374899	A/C	cg19579500	chr17:80346614	NA	-0.46	-8.27	-0.36	1.41e-15	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs17767392	0.836	rs61989383	chr14:71983644	T/C	cg02058870	chr14:72053146	SIPA1L1	0.44	8.99	0.39	6.24e-18	Mitral valve prolapse;
LGG	cis	rs3762637	0.941	rs77599736	chr3:122179509	A/T	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.27	-0.32	1.51e-12	Schizophrenia;
LGG	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg23933602	chr10:16859644	RSU1	0.68	10.25	0.43	2.26e-22	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg04287289	chr16:89883240	FANCA	0.52	9.54	0.41	8.04e-20	Vitiligo;
LGG	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.17	0.35	3.03e-15	Colorectal cancer;
LGG	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg19729930	chr2:74357872	NA	0.6	11.97	0.49	6.05e-29	Gestational age at birth (maternal effect);
LGG	cis	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg19847130	chr8:10466454	RP1L1	-0.32	-6.91	-0.31	1.62e-11	Neuroticism;
LGG	cis	rs6795744	0.634	rs17290567	chr3:14042447	A/T	cg19554555	chr3:13937349	NA	0.57	7.4	0.33	6.67e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs981844	0.753	rs62325149	chr4:154728006	G/C	cg14289246	chr4:154710475	SFRP2	0.64	10.66	0.44	6.8e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.05	-0.31	6.33e-12	Menopause (age at onset);
LGG	cis	rs2342371	0.756	rs3973	chr3:196124278	A/G	cg15048948	chr3:196158458	UBXN7	-0.63	-10.85	-0.45	1.4e-24	Fat distribution (HIV);
LGG	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-13.46	-0.53	4.29e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs700651	0.789	rs6715070	chr2:198898265	A/G	cg00792783	chr2:198669748	PLCL1	-0.64	-10.35	-0.43	1.01e-22	Intracranial aneurysm;
LGG	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg11584989	chr19:19387371	SF4	-0.7	-11.5	-0.47	4.37e-27	Bipolar disorder;
LGG	cis	rs7737355	0.812	rs250888	chr5:131015346	C/T	cg06307176	chr5:131281290	NA	-0.53	-8.74	-0.38	4.2e-17	Life satisfaction;
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg27400746	chr16:89904261	SPIRE2	-1.08	-16.33	-0.6	1.19e-47	Skin colour saturation;
LGG	trans	rs10877945	0.702	rs12820630	chr12:63400179	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.38	-7.21	-0.32	2.29e-12	Obesity-related traits;
LGG	trans	rs9914544	0.545	rs8071783	chr17:18807939	C/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.81	-0.34	3.78e-14	Educational attainment (years of education);
LGG	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg21014159	chr11:117668035	DSCAML1	0.48	7.36	0.32	8.72e-13	Myopia;
LGG	cis	rs7523273	0.526	rs1204708	chr1:208024062	G/C	cg22525895	chr1:207977042	MIR29B2	-0.63	-11.99	-0.49	5.12e-29	Schizophrenia;
LGG	cis	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg07460842	chr6:66804631	NA	-0.97	-18.14	-0.64	6.14e-56	Exhaled nitric oxide output;
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.64	-0.33	1.26e-13	Dementia with Lewy bodies;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg22105103	chr4:187893119	NA	0.59	11.37	0.47	1.33e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3770081	1.000	rs1036554	chr2:86236099	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-6.95	-0.31	1.25e-11	Facial emotion recognition (sad faces);
LGG	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg26655873	chr3:72818019	SHQ1	0.36	7.36	0.32	8.41e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9309473	1.000	rs11899902	chr2:73631564	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.04	-0.35	7.59e-15	Metabolite levels;
LGG	trans	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg16011800	chr17:1958478	HIC1	-0.66	-9.99	-0.42	2.13e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs3806843	0.545	rs251375	chr5:140252960	T/G	cg19875535	chr5:140030758	IK	-0.38	-7.5	-0.33	3.39e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2731664	0.756	rs335433	chr5:176867207	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-12.48	-0.5	5.35e-31	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs1003719	0.751	rs7280371	chr21:38450008	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.4	-0.33	6.32e-13	Cognitive ability;
LGG	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg07005078	chr4:17578674	LAP3	-0.38	-6.81	-0.3	3.11e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.56	0.47	2.48e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7703051	0.585	rs918623	chr5:74596682	A/C	cg19683494	chr5:74908142	NA	0.5	7.52	0.33	2.88e-13	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LGG	cis	rs11169225	0.756	rs3759124	chr12:50343166	G/A	cg04450003	chr12:50355995	AQP5	0.34	6.72	0.3	5.49e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.6	-0.33	1.69e-13	Neuroticism;
LGG	cis	rs6723226	0.610	rs458628	chr2:32515398	G/A	cg02381751	chr2:32503542	YIPF4	0.72	12.34	0.5	1.85e-30	Intelligence (multi-trait analysis);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg23556447	chr6:90529595	MDN1	0.41	7.16	0.32	3.15e-12	Body mass index;
LGG	cis	rs2131877	0.871	rs59361541	chr3:194869939	T/C	cg07250128	chr3:194833983	C3orf21	0.4	6.71	0.3	5.68e-11	Non-small cell lung cancer;
LGG	cis	rs9287719	0.967	rs10454738	chr2:10742049	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs17384381	0.861	rs12736004	chr1:85901367	G/A	cg16011679	chr1:85725395	C1orf52	0.62	10.64	0.44	8.33e-24	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.3	0.53	1.99e-34	Morning vs. evening chronotype;
LGG	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg10523679	chr1:76189770	ACADM	-0.64	-10.45	-0.44	4.25e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4851254	0.660	rs34714421	chr2:100692175	T/C	cg17356467	chr2:100759845	AFF3	0.46	7.37	0.32	7.94e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17641971	0.662	rs13268440	chr8:50000873	C/T	cg00325661	chr8:49890786	NA	0.55	10.5	0.44	2.85e-23	Blood metabolite levels;
LGG	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg21238619	chr17:78079768	GAA	-0.32	-6.78	-0.3	3.69e-11	Yeast infection;
LGG	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.24	0.43	2.65e-22	Colorectal cancer;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.42	0.4	2.09e-19	Schizophrenia;
LGG	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg04731861	chr2:219085781	ARPC2	-0.32	-7.61	-0.33	1.59e-13	Ulcerative colitis;
LGG	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg24253500	chr15:84953950	NA	0.56	10.29	0.43	1.65e-22	Schizophrenia;
LGG	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg27490568	chr2:178487706	NA	0.52	10.22	0.43	3.15e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7940866	0.834	rs10894302	chr11:130861994	C/T	cg12179176	chr11:130786555	SNX19	0.73	13.4	0.53	7.66e-35	Schizophrenia;
LGG	trans	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg11430096	chr6:110968061	CDK19	0.68	7.1	0.31	4.76e-12	Prostate cancer;
LGG	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg27129171	chr3:47204927	SETD2	-0.85	-15.8	-0.59	2.88e-45	Colorectal cancer;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg22398616	chr13:53314203	LECT1	-0.49	-10.04	-0.42	1.42e-21	Lewy body disease;
LGG	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg16105309	chr15:79090380	ADAMTS7	0.39	6.93	0.31	1.38e-11	Schizophrenia;
LGG	trans	rs9929218	0.954	rs7199991	chr16:68818245	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-12.15	-0.49	1.14e-29	Colorectal cancer;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.32	-0.43	1.27e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg13902645	chr11:5959945	NA	-0.7	-11.02	-0.46	3.02e-25	DNA methylation (variation);
LGG	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.28	-0.53	2.59e-34	Vitamin D levels;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg21017887	chr14:105400489	NA	0.43	8.56	0.37	1.72e-16	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.16	0.39	1.62e-18	Alzheimer's disease;
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg16268157	chr7:99778414	STAG3	-0.49	-7.77	-0.34	5.19e-14	Lung function (FEV1/FVC);
LGG	cis	rs2640806	0.505	rs7837495	chr8:97359508	T/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.17	0.32	2.99e-12	Obesity-related traits;
LGG	cis	rs4851254	0.618	rs35300735	chr2:100667829	G/A	cg17356467	chr2:100759845	AFF3	0.44	7.27	0.32	1.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.81	-0.38	2.49e-17	Lung cancer;
LGG	cis	rs4330281	0.608	rs11713917	chr3:17382262	G/A	cg20981856	chr3:17787350	NA	0.36	6.81	0.3	3.03e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17101748	chr1:224517614	NVL	0.45	6.98	0.31	1.01e-11	Gut microbiome composition (summer);
LGG	cis	rs10262624	1.000	rs2390847	chr7:23911701	G/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg03237606	chr10:63212265	TMEM26	0.48	8.72	0.38	5.17e-17	Night sleep phenotypes;
LGG	cis	rs701145	0.585	rs1713828	chr3:153838553	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs12681287	0.571	rs13254675	chr8:87353594	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.05e-13	Caudate activity during reward;
LGG	cis	rs9811920	0.529	rs793442	chr3:99581062	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-8.79	-0.38	2.9e-17	Axial length;
LGG	cis	rs4262150	0.883	rs72799183	chr5:152173815	G/A	cg12297329	chr5:152029980	NA	-0.69	-12.55	-0.5	2.69e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs2011503	0.782	rs8113006	chr19:19669441	C/G	cg11584989	chr19:19387371	SF4	-0.63	-9.98	-0.42	2.2e-21	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg08621203	chr6:150244597	RAET1G	0.45	7.78	0.34	4.88e-14	Lung cancer;
LGG	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-12.07	-0.49	2.29e-29	Menarche (age at onset);
LGG	cis	rs4891159	0.824	rs17059362	chr18:74144307	G/A	cg24786174	chr18:74118243	ZNF516	-0.56	-13.0	-0.52	3.53e-33	Longevity;
LGG	trans	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.9	0.34	2.03e-14	Joint mobility (Beighton score);
LGG	cis	rs10929925	0.966	rs7599874	chr2:6157718	A/C	cg00493617	chr2:6141445	NA	0.32	7.2	0.32	2.39e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15128208	chr22:42549153	NA	-0.36	-7.21	-0.32	2.27e-12	Cognitive function;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg15971980	chr6:150254442	NA	0.44	8.36	0.36	7.59e-16	Lung cancer;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg08621203	chr6:150244597	RAET1G	0.52	9.53	0.4	9.24e-20	Testicular germ cell tumor;
LGG	cis	rs9788721	0.836	rs2656065	chr15:78750549	G/A	cg18825076	chr15:78729989	IREB2	-0.53	-8.81	-0.38	2.61e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg24764310	chr7:157512201	PTPRN2	-0.48	-10.33	-0.43	1.15e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9948	0.655	rs62156228	chr2:97420335	A/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.62e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg13010199	chr12:38710504	ALG10B	0.58	11.3	0.47	2.52e-26	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg08017756	chr2:100939284	LONRF2	-0.3	-6.97	-0.31	1.13e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.12	-0.43	6.92e-22	Type 2 diabetes;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.62	-0.33	1.4e-13	Lung cancer;
LGG	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg23840854	chr1:161414152	NA	0.73	8.88	0.38	1.53e-17	Rheumatoid arthritis;
LGG	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg27490568	chr2:178487706	NA	0.7	13.09	0.52	1.55e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg01221209	chr5:554886	NA	-0.46	-7.0	-0.31	9.12e-12	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03352830	chr11:487213	PTDSS2	0.86	10.9	0.45	8.63e-25	Body mass index;
LGG	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs77106637	0.929	rs77464186	chr11:72460398	A/C	cg03713592	chr11:72463424	ARAP1	0.43	7.38	0.32	7.46e-13	Type 2 diabetes;
LGG	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18876405	chr7:65276391	NA	0.55	9.73	0.41	1.8e-20	Aortic root size;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg04632378	chr13:21900426	NA	0.43	9.39	0.4	2.8e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.28e-17	Schizophrenia;
LGG	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg11995313	chr8:8860691	ERI1	0.44	7.63	0.33	1.36e-13	Joint mobility (Beighton score);
LGG	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg17145862	chr1:211918768	LPGAT1	-0.78	-16.88	-0.62	3.67e-50	Leprosy;
LGG	cis	rs9788682	0.747	rs16969894	chr15:78776456	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-7.84	-0.34	3.15e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4716602	0.622	rs59109406	chr7:156167344	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.44	-0.4	1.79e-19	Anti-saccade response;
LGG	trans	rs8073060	0.586	rs225307	chr17:33918311	A/G	cg19694781	chr19:47549865	TMEM160	1.11	16.31	0.6	1.34e-47	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg18350739	chr11:68623251	NA	-0.87	-22.1	-0.72	2.07e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	cis	rs1124376	0.688	rs11715447	chr3:20140129	A/C	cg05072819	chr3:20081367	KAT2B	0.89	10.75	0.45	3.16e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-11.08	-0.46	1.75e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572644	0.640	rs4666024	chr2:28072979	C/G	cg27432699	chr2:27873401	GPN1	-0.45	-6.89	-0.3	1.82e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg20308403	chr7:2120281	MAD1L1	0.34	7.21	0.32	2.34e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs5769707	0.642	rs4824070	chr22:50031521	T/C	cg06623630	chr22:50017776	C22orf34	-0.5	-10.11	-0.43	7.68e-22	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg23762105	chr12:34175262	ALG10	-0.33	-6.75	-0.3	4.45e-11	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19556208	chr14:24630405	IRF9	0.42	7.0	0.31	8.96e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg18551225	chr6:44695536	NA	-0.7	-12.46	-0.5	6.19e-31	Total body bone mineral density;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.97	-0.35	1.26e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs10791097	0.667	rs4937585	chr11:130741940	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.75	0.64	3.65e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs523522	0.962	rs2235218	chr12:120888619	A/C	cg27279351	chr12:120934652	DYNLL1	0.78	12.28	0.5	3.31e-30	High light scatter reticulocyte count;
LGG	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg23057051	chr16:89984268	MC1R	-0.37	-6.92	-0.31	1.53e-11	Vitiligo;
LGG	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg16576597	chr16:28551801	NUPR1	0.3	6.75	0.3	4.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1953600	1.000	rs1953600	chr10:81911725	A/G	cg04850286	chr10:81895943	PLAC9	0.44	9.9	0.42	4.31e-21	Sarcoidosis;
LGG	cis	rs3008870	1.000	rs2815357	chr1:67491854	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.98	22.36	0.72	1.27e-75	Lymphocyte percentage of white cells;
LGG	cis	rs3126085	0.935	rs114825811	chr1:152231877	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg00666640	chr1:248458726	OR2T12	0.6	9.76	0.41	1.39e-20	Common traits (Other);
LGG	cis	rs12410462	0.551	rs67511833	chr1:227838514	G/A	cg04117972	chr1:227635322	NA	0.44	8.15	0.35	3.31e-15	Major depressive disorder;
LGG	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg21747090	chr2:27597821	SNX17	0.39	6.92	0.31	1.52e-11	Total body bone mineral density;
LGG	cis	rs4671458	0.948	rs10496101	chr2:63454114	T/C	cg17519650	chr2:63277830	OTX1	-0.65	-8.35	-0.36	8.07e-16	Subjective well-being;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg27471124	chr11:109292789	C11orf87	0.48	9.59	0.41	5.27e-20	Schizophrenia;
LGG	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs62238980	0.614	rs4821001	chr22:32344403	T/C	cg02631450	chr22:32366979	NA	0.98	9.32	0.4	4.81e-19	Childhood ear infection;
LGG	cis	rs61990749	0.597	rs2032781	chr14:78214875	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.02	0.31	7.73e-12	Fibroblast growth factor basic levels;
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg16141378	chr3:129829833	LOC729375	0.4	9.39	0.4	2.78e-19	Systolic blood pressure;
LGG	cis	rs4824093	0.535	rs73443931	chr22:50291603	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.11	-0.31	4.51e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg11050988	chr7:1952600	MAD1L1	-0.41	-10.03	-0.42	1.45e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs6669919	0.553	rs1122745	chr1:211663261	C/T	cg10512769	chr1:211675356	NA	-0.79	-18.32	-0.65	8.83e-57	Intelligence (multi-trait analysis);
LGG	cis	rs9399135	0.904	rs4895438	chr6:135317665	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs6087990	0.735	rs6057647	chr20:31381690	A/T	cg13636640	chr20:31349939	DNMT3B	0.81	16.81	0.62	7.49e-50	Ulcerative colitis;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.93	-0.35	1.68e-14	Mood instability;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg05552183	chr6:42928497	GNMT	0.44	13.13	0.52	1.11e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg26384229	chr12:38710491	ALG10B	0.65	11.71	0.48	6.57e-28	Morning vs. evening chronotype;
LGG	cis	rs504918	0.554	rs4234217	chr3:123961088	T/A	cg05766129	chr3:123988013	KALRN	-0.43	-7.27	-0.32	1.51e-12	Schizophrenia;
LGG	trans	rs9929218	1.000	rs12599517	chr16:68814590	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.82	-0.51	2e-32	Colorectal cancer;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg24812749	chr6:127587940	RNF146	0.71	11.39	0.47	1.14e-26	Breast cancer;
LGG	trans	rs877282	0.945	rs12767287	chr10:787310	A/G	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1682825	0.547	rs17028925	chr3:10777632	A/G	cg25137700	chr3:10780651	NA	0.47	6.79	0.3	3.5e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg02503808	chr4:7069936	GRPEL1	1.01	15.99	0.6	3.73e-46	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.31	0.47	2.34e-26	Obesity-related traits;
LGG	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg19847130	chr8:10466454	RP1L1	0.34	7.29	0.32	1.34e-12	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25352856	chr1:180472145	ACBD6	0.41	6.79	0.3	3.46e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9914544	0.564	rs4334348	chr17:18787004	G/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg05775895	chr3:12838266	CAND2	0.63	11.11	0.46	1.35e-25	QRS complex (12-leadsum);
LGG	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11644478	chr21:40555479	PSMG1	0.9	16.81	0.62	7.71e-50	Cognitive function;
LGG	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.24e-14	HDL cholesterol;
LGG	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.05	-0.31	6.34e-12	Iron status biomarkers;
LGG	cis	rs1003719	0.762	rs11701556	chr21:38455153	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg26513180	chr16:89883248	FANCA	0.89	8.7	0.37	6.04e-17	Skin colour saturation;
LGG	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.4	0.33	6.25e-13	Bitter taste perception;
LGG	cis	rs9504361	0.838	rs11242985	chr6:554776	A/G	cg13471009	chr6:564609	EXOC2	-0.39	-8.43	-0.36	4.58e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LGG	cis	rs8077059	1.000	rs8076475	chr17:55814749	C/T	cg12582317	chr17:55822272	NA	0.39	7.15	0.32	3.41e-12	Sex hormone-binding globulin levels;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.63	0.63	1.37e-53	Obesity-related traits;
LGG	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg27432699	chr2:27873401	GPN1	0.69	13.74	0.54	2.73e-36	Oral cavity cancer;
LGG	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.23	0.32	2.03e-12	Retinal vascular caliber;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg13880726	chr7:1868755	MAD1L1	0.49	8.49	0.37	2.85e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9487094	1.000	rs35056702	chr6:109736326	C/T	cg01125227	chr6:109776195	MICAL1	0.46	7.88	0.34	2.32e-14	Height;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	6.13e-37	Prudent dietary pattern;
LGG	cis	rs2594989	0.943	rs7622627	chr3:11357419	T/C	cg01796438	chr3:11312864	ATG7	-0.59	-7.96	-0.35	1.34e-14	Circulating chemerin levels;
LGG	cis	rs11700980	0.551	rs2832047	chr21:30117970	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs11644362	0.966	rs36056252	chr16:12994672	T/G	cg08528231	chr16:12997261	SHISA9	-0.37	-7.3	-0.32	1.27e-12	Positive affect;Subjective well-being;
LGG	cis	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg04990556	chr1:26633338	UBXN11	-0.7	-13.97	-0.54	3.07e-37	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09894072	chr16:68279486	PLA2G15	0.59	9.17	0.39	1.55e-18	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg03929089	chr4:120376271	NA	-0.95	-19.94	-0.68	2.55e-64	Height;
LGG	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg09163369	chr1:210001066	C1orf107	0.39	6.97	0.31	1.1e-11	Orofacial clefts;
LGG	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg25919922	chr13:100150906	NA	0.69	7.12	0.31	4.1e-12	Obesity-related traits;
LGG	cis	rs751728	1.000	rs3806108	chr6:33767579	C/G	cg25922239	chr6:33757077	LEMD2	0.71	12.49	0.5	4.72e-31	Crohn's disease;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04772025	chr11:68637568	NA	0.73	12.8	0.51	2.49e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg07537917	chr2:241836409	C2orf54	-0.39	-7.38	-0.32	7.47e-13	Urinary metabolites;
LGG	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg00784671	chr22:46762841	CELSR1	-0.69	-7.55	-0.33	2.41e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs3820068	0.532	rs72647105	chr1:15935238	C/G	cg05660106	chr1:15850417	CASP9	0.86	17.4	0.63	1.53e-52	Systolic blood pressure;
LGG	cis	rs3126085	1.000	rs2338555	chr1:152309380	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.95	-0.35	1.47e-14	Atopic dermatitis;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg02002194	chr4:3960332	NA	0.48	9.15	0.39	1.82e-18	Mood instability;
LGG	cis	rs4650994	0.593	rs2811302	chr1:178552875	C/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.39	-0.32	6.96e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs240764	0.658	rs9404054	chr6:101256597	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg27165867	chr14:105738592	BRF1	-0.45	-7.4	-0.33	6.54e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1021993	0.545	rs80311419	chr1:209547418	T/G	cg24446417	chr1:209558027	NA	-0.74	-11.08	-0.46	1.86e-25	Gut microbiome composition (winter);
LGG	cis	rs3740909	1.000	rs7930483	chr11:125886573	C/A	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs2479724	0.935	rs2025951	chr6:41827193	C/T	cg17623882	chr6:41773611	USP49	0.52	9.28	0.4	6.38e-19	Menarche (age at onset);
LGG	cis	rs11166927	0.934	rs7015426	chr8:140802688	C/G	cg16909799	chr8:140841666	TRAPPC9	0.58	12.1	0.49	1.81e-29	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs7814319	0.674	rs2292835	chr8:97243720	G/A	cg20787634	chr8:97240163	UQCRB	-0.67	-13.65	-0.54	6.71e-36	Lung function (FVC);
LGG	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg16096631	chr1:42092165	HIVEP3	0.57	13.56	0.53	1.7000000000000001e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.39	0.4	2.68e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg00383909	chr3:49044727	WDR6	0.45	7.35	0.32	9.2e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg06521331	chr12:34319734	NA	0.45	8.07	0.35	5.89e-15	Bladder cancer;
LGG	cis	rs17253792	0.822	rs76267907	chr14:56066969	C/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.38e-23	Bipolar disorder;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.53	0.33	2.6e-13	Rheumatoid arthritis;
LGG	cis	rs12360000	0.770	rs12573442	chr10:1910626	T/C	cg26364871	chr10:1889757	NA	-0.7	-13.46	-0.53	4.25e-35	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg08847533	chr14:75593920	NEK9	-0.6	-11.52	-0.47	3.5e-27	Height;
LGG	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg23335576	chr14:104009727	NA	0.49	8.63	0.37	9.97e-17	Reticulocyte count;
LGG	cis	rs7928758	0.767	rs1866769	chr11:134274676	C/T	cg15243474	chr11:134282918	B3GAT1	-0.77	-11.99	-0.49	4.77e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg25703541	chr22:24373054	LOC391322	0.92	13.99	0.55	2.44e-37	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg24397884	chr7:158709396	WDR60	1.11	16.67	0.61	3.31e-49	Height;
LGG	cis	rs10463316	0.894	rs7727926	chr5:150767216	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg25554036	chr4:6271136	WFS1	0.56	9.7	0.41	2.3e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11785693	0.862	rs73183633	chr8:4994543	G/A	cg26367366	chr8:4980734	NA	1.03	15.68	0.59	9.06e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg05925327	chr15:68127851	NA	-0.43	-8.73	-0.38	4.7e-17	Restless legs syndrome;
LGG	cis	rs944722	1.000	rs2248814	chr17:26100321	A/G	cg07704981	chr17:26127537	NOS2	-0.51	-8.74	-0.38	4.22e-17	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs10979	1.000	rs9399447	chr6:143896163	T/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.55	-0.5	2.76e-31	Hypospadias;
LGG	cis	rs6489882	0.966	rs10735079	chr12:113380008	A/G	cg25319449	chr12:113376135	OAS3	0.37	6.91	0.31	1.59e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.43e-38	IgG glycosylation;
LGG	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg08250081	chr4:10125330	NA	-0.36	-6.97	-0.31	1.12e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg08847533	chr14:75593920	NEK9	0.63	11.98	0.49	5.43e-29	Height;
LGG	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg14675211	chr2:100938903	LONRF2	0.47	7.38	0.32	7.61e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4722166	0.630	rs1829927	chr7:22779918	G/A	cg05265849	chr7:22767390	IL6	0.44	8.26	0.36	1.57e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12148919	chr6:128841705	PTPRK	0.49	7.01	0.31	8.59e-12	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4.2e-19	Life satisfaction;
LGG	trans	rs9784649	0.882	rs72753879	chr5:24947395	C/T	cg11038491	chr20:34638489	LOC647979	-0.58	-7.4	-0.33	6.39e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.58	-0.33	1.89e-13	HDL cholesterol;
LGG	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg12463550	chr7:65579703	CRCP	0.52	8.2	0.36	2.44e-15	Aortic root size;
LGG	trans	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg02002194	chr4:3960332	NA	0.39	7.33	0.32	1.06e-12	Joint mobility (Beighton score);
LGG	cis	rs9443645	0.869	rs9361489	chr6:79816785	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.33	-0.36	9.56e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3764563	0.935	rs623700	chr19:15698544	C/T	cg20725493	chr19:15740067	CYP4F8	0.58	6.82	0.3	2.77e-11	Inflammatory biomarkers;
LGG	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg12623918	chr2:306882	NA	0.53	9.86	0.42	6.02e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.65	11.67	0.48	8.96e-28	Obesity-related traits;
LGG	cis	rs9443189	0.762	rs2748955	chr6:76464302	C/G	cg01950844	chr6:76311363	SENP6	-0.54	-6.96	-0.31	1.16e-11	Prostate cancer;
LGG	cis	rs806215	1.000	rs712704	chr7:127258208	A/G	cg25922125	chr7:127225783	GCC1	-0.8	-10.84	-0.45	1.43e-24	Type 2 diabetes;
LGG	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg15212455	chr7:39170539	POU6F2	0.51	11.84	0.48	1.9e-28	IgG glycosylation;
LGG	cis	rs3849570	1.000	rs9817181	chr3:81827765	A/C	cg07356753	chr3:81810745	GBE1	-0.48	-7.81	-0.34	3.75e-14	Waist circumference;Body mass index;
LGG	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.86	0.3	2.24e-11	Bipolar disorder;
LGG	cis	rs7737355	0.898	rs6864413	chr5:130637868	G/T	cg06307176	chr5:131281290	NA	0.51	8.62	0.37	1.06e-16	Life satisfaction;
LGG	cis	rs9811920	0.609	rs13317017	chr3:99665521	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.05	-0.39	4.03e-18	Axial length;
LGG	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg08125733	chr17:73851984	WBP2	-0.43	-7.14	-0.31	3.61e-12	White matter hyperintensity burden;
LGG	cis	rs13088318	0.504	rs9828111	chr3:101197777	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-7.35	-0.32	9.12e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg04861929	chr11:109293070	C11orf87	0.56	10.07	0.42	1.05e-21	Schizophrenia;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.3	-0.5	2.73e-30	Alzheimer's disease;
LGG	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg04568710	chr12:38710424	ALG10B	-0.36	-7.45	-0.33	4.71e-13	Morning vs. evening chronotype;
LGG	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg26874164	chr19:58962979	ZNF324B	0.38	7.37	0.32	7.92e-13	Uric acid clearance;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-7.81	-0.34	3.82e-14	Life satisfaction;
LGG	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg02811702	chr13:24901961	NA	0.4	7.54	0.33	2.48e-13	Obesity-related traits;
LGG	cis	rs981844	1.000	rs2579916	chr4:154659972	G/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs2797369	0.882	rs1342801	chr6:101615452	A/G	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs2865126	0.761	rs1881089	chr18:10765806	A/C	cg21165219	chr18:10698044	FAM38B	-0.45	-7.31	-0.32	1.17e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs7106204	0.534	rs76997388	chr11:24272878	C/G	ch.11.24196551F	chr11:24239977	NA	0.84	8.62	0.37	1.06e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2688419	0.545	rs1849478	chr3:23067010	C/G	cg00327796	chr3:23032191	NA	-0.35	-6.83	-0.3	2.65e-11	Type 2 diabetes;
LGG	cis	rs4356975	0.545	rs35297888	chr4:69949573	G/A	cg27372994	chr4:70080453	UGT2B11	0.37	6.69	0.3	6.51e-11	Obesity-related traits;
LGG	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.87	-0.45	1.19e-24	Aortic root size;
LGG	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg25554036	chr4:6271136	WFS1	0.48	7.81	0.34	3.95e-14	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7633770	0.664	rs34000414	chr3:46689958	G/A	cg11219411	chr3:46661640	NA	-0.5	-10.8	-0.45	2.15e-24	Coronary artery disease;
LGG	cis	rs7927997	0.757	rs2212434	chr11:76281593	C/T	cg17647271	chr11:76299819	NA	-0.39	-7.05	-0.31	6.47e-12	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs1185460	0.508	rs7942757	chr11:118903651	G/A	cg23280166	chr11:118938394	VPS11	-0.46	-7.81	-0.34	3.74e-14	Coronary artery disease;
LGG	cis	rs10751667	0.666	rs7483273	chr11:951127	T/C	cg22143635	chr11:980567	AP2A2	0.42	7.81	0.34	4e-14	Alzheimer's disease (late onset);
LGG	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg09754948	chr16:28834200	ATXN2L	0.42	6.8	0.3	3.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg13207630	chr7:32358064	NA	0.8	7.92	0.35	1.74e-14	Body mass index;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.39	0.36	5.8e-16	Mood instability;
LGG	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21014159	chr11:117668035	DSCAML1	0.47	7.27	0.32	1.59e-12	Myopia;
LGG	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.52	-0.37	2.2e-16	Platelet distribution width;
LGG	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg16486109	chr11:613632	IRF7	0.43	7.35	0.32	9.02e-13	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg15596359	chr8:11213517	TDH	-0.39	-7.93	-0.35	1.61e-14	Retinal vascular caliber;
LGG	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg26031613	chr14:104095156	KLC1	-0.6	-9.63	-0.41	3.88e-20	Reticulocyte count;
LGG	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.93	0.35	1.65e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg24623649	chr8:11872141	NA	-0.31	-7.36	-0.32	8.74e-13	Neuroticism;
LGG	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.56	-0.33	2.16e-13	Body mass index;
LGG	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg06917634	chr15:78832804	PSMA4	-0.81	-16.99	-0.62	1.1e-50	Sudden cardiac arrest;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08219700	chr8:58056026	NA	0.45	6.86	0.3	2.23e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12517041	1.000	rs7720974	chr5:23300191	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.1	-0.46	1.46e-25	Calcium levels;
LGG	cis	rs6728642	0.519	rs6721921	chr2:97566501	G/A	cg26665480	chr2:98280029	ACTR1B	-0.65	-8.3	-0.36	1.16e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs1506636	0.720	rs2456552	chr7:123441400	A/G	cg03229431	chr7:123269106	ASB15	0.58	13.69	0.54	4.7e-36	Plateletcrit;Platelet count;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.35	0.36	8.06e-16	Aortic root size;
LGG	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	11.08	0.46	1.74e-25	Parkinson's disease;
LGG	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22496380	chr5:211416	CCDC127	-1.09	-10.41	-0.44	6.07e-23	Breast cancer;
LGG	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.22	-0.36	2.07e-15	Mood instability;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.54	0.47	3.01e-27	Bipolar disorder;
LGG	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.71	0.34	7.67e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg00700412	chr12:58011837	NA	0.4	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg02725872	chr8:58115012	NA	-0.78	-10.69	-0.44	5.41e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.91e-15	Obesity-related traits;
LGG	cis	rs9878978	0.519	rs1502570	chr3:2477066	G/A	cg21928760	chr3:2462534	CNTN4	-0.46	-11.02	-0.46	3.16e-25	Blood pressure (smoking interaction);
LGG	cis	rs834603	0.965	rs700755	chr7:47445641	A/G	cg23694490	chr7:47445681	TNS3	-0.52	-16.15	-0.6	7.06e-47	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1806153	0.673	rs608293	chr11:31808280	A/G	cg11990419	chr11:31841155	NA	0.33	7.34	0.32	9.61e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs965513	0.524	rs1443432	chr9:100583195	C/T	cg13688889	chr9:100608707	NA	-0.57	-11.06	-0.46	2.07e-25	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	trans	rs7178375	0.678	rs34678577	chr15:31177465	A/C	cg04373760	chr16:53404718	NA	0.59	8.87	0.38	1.59e-17	Hypertriglyceridemia;
LGG	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg11693508	chr17:37793320	STARD3	0.59	8.19	0.36	2.63e-15	Bipolar disorder;
LGG	cis	rs9329289	0.510	rs12359941	chr10:2547015	G/A	cg15501526	chr10:2543763	NA	0.48	9.2	0.39	1.19e-18	Age-related hearing impairment;
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg14782152	chr13:114913410	NA	0.33	6.78	0.3	3.76e-11	Schizophrenia;
LGG	cis	rs4262150	0.544	rs4613693	chr5:151898365	G/T	cg12297329	chr5:152029980	NA	-0.64	-11.6	-0.47	1.75e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs17767392	0.834	rs11626886	chr14:71727155	C/T	cg02058870	chr14:72053146	SIPA1L1	0.42	8.09	0.35	5.4e-15	Mitral valve prolapse;
LGG	cis	rs2280630	0.529	rs784495	chr3:39178899	C/T	cg01426195	chr3:39028469	NA	0.7	15.27	0.58	6.11e-43	Verbal declarative memory;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.58	-0.47	2.1e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg22771759	chr13:24902376	NA	0.42	7.18	0.32	2.72e-12	Obesity-related traits;
LGG	cis	rs17162190	0.698	rs4659444	chr1:26825116	C/T	cg23229016	chr1:26872525	RPS6KA1	0.25	6.73	0.3	5.06e-11	Mean corpuscular volume;
LGG	cis	rs67133203	0.799	rs7959082	chr12:51361222	A/G	cg14688905	chr12:51403056	SLC11A2	0.78	11.86	0.48	1.62e-28	Urinary tract infection frequency;
LGG	cis	rs4262150	0.810	rs12188715	chr5:151973884	T/A	cg12297329	chr5:152029980	NA	-0.81	-15.84	-0.59	1.83e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg24375607	chr4:120327624	NA	0.61	10.16	0.43	4.94e-22	Corneal astigmatism;
LGG	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg17545662	chr6:170176663	C6orf70	0.67	8.03	0.35	7.92e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs35425515	0.706	rs17112405	chr10:98862817	C/A	cg09122387	chr10:98855762	SLIT1	0.68	8.72	0.38	4.93e-17	Bipolar disorder;
LGG	cis	rs1577917	1.000	rs12215903	chr6:86675028	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.76	-0.41	1.36e-20	Response to antipsychotic treatment;
LGG	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg18252515	chr7:66147081	NA	-1.44	-20.91	-0.7	7.19e-69	Diabetic kidney disease;
LGG	trans	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg11441553	chr12:57614120	NXPH4	-0.57	-7.3	-0.32	1.3e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg23740940	chr11:68924746	NA	0.43	6.93	0.31	1.44e-11	Blond vs. brown hair color;
LGG	cis	rs10858096	0.608	rs4970843	chr1:109887191	A/G	cg08367326	chr1:110052010	AMIGO1	0.45	10.46	0.44	3.9e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg13010199	chr12:38710504	ALG10B	-0.49	-9.19	-0.39	1.33e-18	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.764	rs1938099	chr6:66599750	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs34638952	0.577	rs11650356	chr17:27457136	G/A	cg13672501	chr17:27410685	MYO18A	-0.4	-7.23	-0.32	2.02e-12	Sitting height ratio;
LGG	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg26384229	chr12:38710491	ALG10B	-0.76	-15.47	-0.58	8.28e-44	Morning vs. evening chronotype;
LGG	cis	rs75059851	1.000	rs73036062	chr11:133828187	G/A	cg17703048	chr11:133852993	NA	-0.79	-13.62	-0.53	9.34e-36	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20273774	chr5:180671298	GNB2L1;SNORD95	0.43	7.63	0.33	1.33e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.02	-0.39	4.87e-18	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs1559859	chr4:99024325	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6825911	0.597	rs2129564	chr4:111358688	C/G	cg10580549	chr19:53101634	ZNF137	0.55	6.95	0.31	1.28e-11	Blood pressure;
LGG	cis	rs2070488	0.775	rs13098946	chr3:38517784	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.78	0.57	8.79e-41	Electrocardiographic conduction measures;
LGG	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg10560079	chr2:191398806	TMEM194B	0.37	8.29	0.36	1.21e-15	Pulse pressure;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.53	-0.47	3.16e-27	Obesity-related traits;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.02	-0.42	1.6e-21	Bipolar disorder;
LGG	cis	rs13102973	0.897	rs10434068	chr4:135840331	A/G	cg14419869	chr4:135874104	NA	0.56	10.59	0.44	1.33e-23	Subjective well-being;
LGG	cis	rs12980942	0.872	rs2053086	chr19:41799475	C/T	cg25627403	chr19:41769009	HNRNPUL1	-0.61	-7.93	-0.35	1.63e-14	Coronary artery disease;
LGG	cis	rs6430585	0.583	rs78364332	chr2:136640101	T/C	cg07169764	chr2:136633963	MCM6	1.31	27.7	0.79	2.67e-100	Corneal structure;
LGG	cis	rs11191205	0.644	rs10883667	chr10:103384849	A/T	cg15320455	chr10:103880129	LDB1	0.48	6.95	0.31	1.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7312933	0.703	rs10459290	chr12:42613290	T/G	cg19980929	chr12:42632907	YAF2	0.37	8.31	0.36	1.07e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1962073	0.529	rs13258627	chr8:10274578	T/C	cg12940923	chr8:10282607	MSRA	0.3	6.94	0.31	1.29e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs300774	0.925	rs12233125	chr2:118611	A/T	cg04617936	chr2:214353	NA	-0.5	-7.37	-0.32	7.96e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg06221963	chr1:154839813	KCNN3	-0.5	-9.89	-0.42	4.84e-21	Prostate cancer;
LGG	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.57	-0.41	6.23e-20	Retinal vascular caliber;
LGG	trans	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg25482853	chr8:67687455	SGK3	1.04	13.42	0.53	6.24e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.28	0.32	1.43e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg12591125	chr7:1885375	MAD1L1	0.47	6.84	0.3	2.45e-11	Bipolar disorder;
LGG	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg25986240	chr4:9926439	SLC2A9	0.37	7.62	0.33	1.49e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6681460	0.625	rs6696812	chr1:67100309	T/C	cg20812318	chr1:67072952	SGIP1	-0.31	-7.26	-0.32	1.63e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.66	-0.37	7.97e-17	Mean corpuscular volume;
LGG	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.35	-0.36	7.91e-16	Depression;
LGG	cis	rs16937	0.521	rs78176224	chr1:205178609	G/A	cg00889227	chr1:205173544	DSTYK	-0.31	-7.64	-0.33	1.29e-13	Schizophrenia;
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	9.97	0.42	2.37e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.37	-0.36	6.8e-16	Life satisfaction;
LGG	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.69e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg02002194	chr4:3960332	NA	0.43	8.01	0.35	9.7e-15	Triglycerides;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.81e-34	Prudent dietary pattern;
LGG	cis	rs7264396	0.676	rs6060723	chr20:34549947	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.81	0.3	3.12e-11	Total cholesterol levels;
LGG	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs7444	0.941	rs4821124	chr22:21979289	T/C	cg05046821	chr22:21984468	YDJC	-0.38	-6.78	-0.3	3.73e-11	Systemic lupus erythematosus;
LGG	cis	rs4743820	0.651	rs10114465	chr9:93936592	C/T	cg14446406	chr9:93919335	NA	-0.82	-13.81	-0.54	1.4e-36	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg15971980	chr6:150254442	NA	0.45	8.57	0.37	1.6e-16	Lung cancer;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg02018176	chr4:1364513	KIAA1530	0.48	11.62	0.48	1.46e-27	Longevity;
LGG	cis	rs653465	0.739	rs1013673	chr3:27206003	A/C	cg02860705	chr3:27208620	NA	-0.42	-8.14	-0.35	3.64e-15	Breast cancer (early onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23360000	chr19:39421712	SARS2;MRPS12	-0.46	-6.77	-0.3	4e-11	Systemic lupus erythematosus;
LGG	trans	rs12517041	1.000	rs10059818	chr5:23292940	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs2289583	0.503	rs12050494	chr15:75260896	G/A	cg14664628	chr15:75095509	CSK	0.6	10.1	0.43	7.96e-22	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	cis	rs7717393	1.000	rs7725121	chr5:155753983	A/T	cg12904904	chr5:155754151	SGCD	0.88	8.39	0.36	6.02e-16	Egg allergy;
LGG	cis	rs4731207	0.844	rs2299903	chr7:124397342	A/G	cg05630886	chr7:124431682	NA	0.31	6.84	0.3	2.48e-11	Cutaneous malignant melanoma;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg03188948	chr7:1209495	NA	0.45	6.91	0.31	1.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.66	0.3	7.72e-11	Schizophrenia;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.26	0.32	1.66e-12	Alzheimer's disease;
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg11494091	chr17:61959527	GH2	0.63	10.47	0.44	3.64e-23	Height;
LGG	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg02297831	chr4:17616191	MED28	0.51	9.5	0.4	1.1e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg08027265	chr7:2291960	NA	0.39	6.92	0.31	1.53e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-7.12	-0.31	4.1e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg12856521	chr11:46389249	DGKZ	0.51	9.23	0.39	9.61e-19	Leprosy;
LGG	cis	rs922107	0.967	rs922104	chr1:90041899	C/T	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.49	-0.33	3.62e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs151997	0.925	rs27286	chr5:50196324	G/T	cg06027927	chr5:50259733	NA	0.67	10.94	0.45	6.22e-25	Callous-unemotional behaviour;
LGG	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg25358565	chr5:93447407	FAM172A	1.26	15.46	0.58	9.02e-44	Diabetic retinopathy;
LGG	cis	rs4917300	0.606	rs7832653	chr8:143111932	A/G	cg26003909	chr8:143102224	NA	-0.34	-6.71	-0.3	5.66e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg20578329	chr17:80767326	TBCD	-0.46	-8.07	-0.35	5.92e-15	Breast cancer;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg06558623	chr16:89946397	TCF25	1.12	12.22	0.49	6.01e-30	Skin colour saturation;
LGG	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.91	0.64	6.87e-55	Cognitive function;
LGG	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.11e-31	Motion sickness;
LGG	cis	rs34102591	0.744	rs35981630	chr12:124463278	G/A	cg13487667	chr12:124434373	CCDC92	-0.55	-6.95	-0.31	1.21e-11	Schizophrenia;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg00960700	chr17:80709150	TBCD	0.49	9.42	0.4	2.14e-19	Glycated hemoglobin levels;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.45e-14	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.54	-0.44	1.91e-23	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.13	-0.58	2.51e-42	Prudent dietary pattern;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	19.37	0.67	1.23e-61	Smoking behavior;
LGG	cis	rs42648	0.935	rs7803012	chr7:90026166	A/T	cg25739043	chr7:89950458	NA	0.38	8.07	0.35	6.23e-15	Homocysteine levels;
LGG	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg20790798	chr5:1857306	NA	-0.44	-7.18	-0.32	2.86e-12	Cardiovascular disease risk factors;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.26e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2286885	1.000	rs10733677	chr9:129242209	A/G	cg14319473	chr9:129242481	FAM125B	0.45	8.45	0.37	3.92e-16	Intraocular pressure;
LGG	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06133097	chr7:32552212	AVL9	-0.38	-7.24	-0.32	1.83e-12	Cognitive ability;
LGG	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg02002194	chr4:3960332	NA	-0.44	-8.02	-0.35	8.69e-15	Monocyte count;
LGG	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs4363385	0.747	rs6704105	chr1:152964397	C/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.32	-0.4	4.89e-19	Inflammatory skin disease;
LGG	cis	rs861020	0.630	rs656566	chr1:210006603	C/T	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg02836325	chr17:76403955	PGS1	-0.72	-14.45	-0.56	2.45e-39	HDL cholesterol levels;
LGG	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg26384229	chr12:38710491	ALG10B	0.63	12.42	0.5	8.99e-31	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.04	-0.49	3.23e-29	Response to antipsychotic treatment;
LGG	cis	rs1665650	0.874	rs7906171	chr10:118485062	G/T	cg14919929	chr10:118506882	NA	-0.46	-7.9	-0.34	2.01e-14	Colorectal cancer;
LGG	cis	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-6.81	-0.3	3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	16.67	0.61	3.14e-49	Personality dimensions;
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.86e-21	Educational attainment;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.68	-0.3	6.94e-11	Menopause (age at onset);
LGG	trans	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19894588	chr14:64061835	NA	0.51	8.55	0.37	1.8e-16	Glioblastoma;Glioma;
LGG	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7945705	0.875	rs10769955	chr11:8784647	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.42	8.5	0.37	2.69e-16	Hemoglobin concentration;
LGG	cis	rs209489	1.000	rs209492	chr6:53181881	C/T	cg15607103	chr6:53167650	ELOVL5	-0.54	-7.63	-0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06634786	chr22:41940651	POLR3H	-0.74	-12.41	-0.5	9.88e-31	Vitiligo;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg06219351	chr7:158114137	PTPRN2	0.7	13.67	0.54	5.46e-36	Calcium levels;
LGG	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg02631450	chr22:32366979	NA	1.04	9.9	0.42	4.42e-21	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4959677	0.586	rs9501846	chr6:2477056	A/C	cg20147862	chr6:2634573	C6orf195	-0.36	-7.76	-0.34	5.45e-14	Orthostatic hypotension;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.16	-0.32	3.09e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs262150	0.625	rs55974535	chr7:158769145	C/G	cg13444538	chr7:158905317	VIPR2	-0.47	-7.0	-0.31	8.88e-12	Facial morphology (factor 20);
LGG	cis	rs787274	1.000	rs4979154	chr9:115555031	A/G	cg13803584	chr9:115635662	SNX30	-0.6	-7.48	-0.33	3.66e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg08250081	chr4:10125330	NA	0.37	7.23	0.32	2.05e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg23594656	chr7:65796392	TPST1	-0.32	-6.77	-0.3	3.84e-11	Aortic root size;
LGG	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg13595904	chr3:137834489	DZIP1L	0.39	6.68	0.3	6.93e-11	Eye color traits;
LGG	cis	rs6960043	1.000	rs6962498	chr7:15050305	C/G	cg19272540	chr7:15055459	NA	-0.36	-8.09	-0.35	5.36e-15	Type 2 diabetes;
LGG	cis	rs6138458	1.000	rs6114981	chr20:24974401	C/T	cg26195577	chr20:24973756	C20orf3	-1.23	-26.05	-0.77	9.03e-93	Blood protein levels;
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs12586317	0.508	rs10134914	chr14:35425012	T/G	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.13	-0.43	6.3e-22	Psoriasis;
LGG	cis	rs7843479	0.601	rs4872207	chr8:21842751	C/G	cg17168535	chr8:21777572	XPO7	-0.81	-15.6	-0.59	2.07e-44	Mean corpuscular volume;
LGG	cis	rs3806933	0.522	rs13153937	chr5:110434307	C/T	cg04022379	chr5:110408740	TSLP	0.48	8.22	0.36	2.04e-15	Eosinophilic esophagitis;
LGG	cis	rs283228	0.617	rs662916	chr6:101741122	A/G	cg27451362	chr6:101846650	GRIK2	0.84	13.16	0.52	8.32e-34	Coenzyme Q10 levels;
LGG	cis	rs9828933	0.752	rs13434089	chr3:63948566	C/T	cg17941049	chr3:63904683	ATXN7	-0.67	-7.28	-0.32	1.44e-12	Type 2 diabetes;
LGG	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.87	-0.62	3.93e-50	Dental caries;
LGG	cis	rs4742903	0.875	rs1857980	chr9:106992265	G/T	cg14250997	chr9:106856677	SMC2	0.38	7.81	0.34	3.98e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg24623649	chr8:11872141	NA	-0.29	-6.74	-0.3	4.79e-11	Triglycerides;
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.8e-14	Personality dimensions;
LGG	cis	rs2285947	1.000	rs2285950	chr7:21584432	C/T	cg03697024	chr7:21583438	DNAH11	-0.36	-8.9	-0.38	1.29e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9612	0.950	rs11351	chr19:44271066	A/C	cg08581076	chr19:44259116	C19orf61	0.54	9.27	0.4	7.04e-19	Exhaled nitric oxide output;
LGG	cis	rs34599045	1.000	rs12240158	chr1:152879103	C/T	cg07796016	chr1:152779584	LCE1C	-0.74	-7.79	-0.34	4.29e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7011049	0.915	rs12375408	chr8:53868662	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg22875332	chr1:76189707	ACADM	0.62	10.91	0.45	8.44e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1904096	0.506	rs28522293	chr4:95167087	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.55	-0.44	1.83e-23	Type 2 diabetes;
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.48	0.33	3.7e-13	Systolic blood pressure;
LGG	trans	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	17.09	0.62	4.15e-51	Exhaled nitric oxide levels;
LGG	cis	rs9649465	0.967	rs9641717	chr7:123350060	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.88	-0.38	1.45e-17	Migraine;
LGG	cis	rs7737355	0.812	rs6868007	chr5:130824810	T/C	cg06307176	chr5:131281290	NA	0.51	8.55	0.37	1.87e-16	Life satisfaction;
LGG	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg26318627	chr11:63887540	MACROD1	0.36	6.78	0.3	3.77e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13190036	1.000	rs59737888	chr5:176587375	C/T	cg06733329	chr5:176740039	MXD3	0.49	6.79	0.3	3.4e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs1003719	0.715	rs8126941	chr21:38551542	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.15	-0.58	2.2e-42	Eye color traits;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg21620608	chr2:139259466	SPOPL	-0.4	-7.05	-0.31	6.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg21138405	chr5:131827807	IRF1	-0.38	-10.19	-0.43	4.03e-22	Asthma (sex interaction);
LGG	cis	rs9398803	0.678	rs9375448	chr6:126896782	A/T	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.69e-20	Male-pattern baldness;
LGG	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg02389323	chr16:88786976	FAM38A	1.08	13.29	0.53	2.23e-34	Plateletcrit;
LGG	cis	rs988958	0.600	rs34917148	chr2:42217721	G/T	cg27252766	chr2:42229092	NA	0.57	8.34	0.36	8.79e-16	Hypospadias;
LGG	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg00012203	chr2:219082015	ARPC2	-0.78	-15.55	-0.59	3.51e-44	Colorectal cancer;
LGG	cis	rs9354308	0.764	rs6927734	chr6:66613917	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.74	-0.3	4.71e-11	Metabolite levels;
LGG	cis	rs9487051	0.676	rs9400267	chr6:109600164	T/C	cg21918786	chr6:109611834	NA	-0.44	-8.05	-0.35	7.06e-15	Reticulocyte fraction of red cells;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20887711	chr4:1340912	KIAA1530	0.94	21.14	0.7	5.98e-70	Longevity;
LGG	cis	rs8049040	0.500	rs7188475	chr16:71446358	C/T	cg08717414	chr16:71523259	ZNF19	-0.45	-7.16	-0.32	3.2e-12	Blood protein levels;
LGG	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg06951627	chr6:26196580	NA	0.53	8.06	0.35	6.43e-15	Gout;Renal underexcretion gout;
LGG	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs1670533	1.000	rs6852155	chr4:1067638	T/G	cg27284194	chr4:1044797	NA	0.55	9.92	0.42	3.74e-21	Recombination rate (females);
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg12486710	chr1:178512616	C1orf220	0.5	10.22	0.43	3.13e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4604732	0.642	rs4489599	chr1:247635213	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.52	-8.5	-0.37	2.68e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.31	-0.43	1.39e-22	Hepatocellular carcinoma;
LGG	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-7.45	-0.33	4.68e-13	Obesity (extreme);
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07234876	chr8:600039	NA	1.18	11.6	0.47	1.81e-27	IgG glycosylation;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg01262667	chr19:19385393	TM6SF2	0.47	12.04	0.49	2.98e-29	Tonsillectomy;
LGG	cis	rs41005	1.000	rs35398717	chr2:8115041	A/T	cg03155496	chr2:8117019	LOC339788	-0.9	-19.97	-0.68	1.86e-64	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg10523679	chr1:76189770	ACADM	0.69	11.08	0.46	1.84e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg24209194	chr3:40518798	ZNF619	0.41	6.8	0.3	3.34e-11	Renal cell carcinoma;
LGG	cis	rs9400467	0.537	rs12192695	chr6:111453046	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.19	0.32	2.58e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.69	-0.37	6.07e-17	Menopause (age at onset);
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg04025307	chr7:1156635	C7orf50	0.62	11.29	0.46	2.75e-26	Longevity;Endometriosis;
LGG	trans	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs7312774	0.618	rs10861680	chr12:107323730	T/C	cg16260113	chr12:107380972	MTERFD3	0.89	8.35	0.36	7.89e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs17428076	0.681	rs62183776	chr2:172858117	C/T	cg21435375	chr2:172878103	MAP1D	0.43	7.81	0.34	3.95e-14	Myopia;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg20308403	chr7:2120281	MAD1L1	0.35	7.37	0.32	7.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11890956	chr21:40555474	PSMG1	1.0	21.47	0.71	1.74e-71	Cognitive function;
LGG	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00292662	chr22:38071168	LGALS1	0.68	13.03	0.52	2.89e-33	Fat distribution (HIV);
LGG	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg05901451	chr6:126070800	HEY2	-0.81	-16.82	-0.62	6.83e-50	Brugada syndrome;
LGG	cis	rs1355223	0.902	rs35032224	chr11:34698154	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.3	-0.32	1.27e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg25706552	chr1:244017396	NA	0.52	7.93	0.35	1.68e-14	RR interval (heart rate);
LGG	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.39	0.32	6.78e-13	Cannabis dependence symptom count;
LGG	cis	rs4750440	0.712	rs11258776	chr10:14031709	G/T	cg00551146	chr10:14014579	FRMD4A	0.27	6.69	0.3	6.44e-11	Adiponectin levels;
LGG	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg26384229	chr12:38710491	ALG10B	0.73	14.49	0.56	1.65e-39	Morning vs. evening chronotype;
LGG	cis	rs72772090	0.539	rs72773923	chr5:96117579	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg02023728	chr11:77925099	USP35	0.4	6.89	0.3	1.85e-11	Testicular germ cell tumor;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.77	0.41	1.3e-20	Prudent dietary pattern;
LGG	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.15	-0.32	3.48e-12	Joint mobility (Beighton score);
LGG	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg26384229	chr12:38710491	ALG10B	1.07	28.94	0.8	6.99e-106	Heart rate;
LGG	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg06640241	chr16:89574553	SPG7	0.72	12.64	0.51	1.19e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg08773314	chr2:239334832	ASB1	0.41	7.81	0.34	3.9e-14	Multiple system atrophy;
LGG	cis	rs9397585	0.857	rs9371278	chr6:153377229	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg07777115	chr5:623756	CEP72	-0.57	-7.29	-0.32	1.31e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.6	-0.41	4.94e-20	Monocyte percentage of white cells;
LGG	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.64	-0.54	7.22e-36	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg06453172	chr10:134556979	INPP5A	-0.57	-8.44	-0.37	4.06e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg14784868	chr12:69753453	YEATS4	0.75	12.76	0.51	3.52e-32	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4919087	1.000	rs10786330	chr10:99074959	C/A	cg25902810	chr10:99078978	FRAT1	0.52	9.72	0.41	1.94e-20	Monocyte count;
LGG	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg01262667	chr19:19385393	TM6SF2	0.35	7.76	0.34	5.32e-14	Tonsillectomy;
LGG	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs9658691	0.607	rs9658750	chr10:90766596	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.74	-8.95	-0.38	8.64e-18	Mosquito bite size;
LGG	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.52	8.93	0.38	9.99e-18	Menarche (age at onset);
LGG	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg25919922	chr13:100150906	NA	-0.71	-7.58	-0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.85	-0.3	2.42e-11	Mood instability;
LGG	cis	rs68170813	0.641	rs6979368	chr7:107089009	C/G	cg02696742	chr7:106810147	HBP1	-0.73	-9.86	-0.42	5.98e-21	Coronary artery disease;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.56	9.9	0.42	4.19e-21	Longevity;
LGG	cis	rs2463822	0.583	rs72919462	chr11:62035663	G/A	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.22	-0.49	5.64e-30	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2342371	0.701	rs4916498	chr3:196202961	G/C	cg15048948	chr3:196158458	UBXN7	-0.42	-7.02	-0.31	7.93e-12	Fat distribution (HIV);
LGG	cis	rs7402982	0.625	rs4966011	chr15:99204006	G/A	cg03437748	chr15:99193247	IGF1R	0.81	14.48	0.56	1.93e-39	Birth weight;
LGG	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg24692254	chr21:30365293	RNF160	0.94	24.0	0.74	2.84e-83	Dental caries;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg09033563	chr22:24373618	LOC391322	-0.61	-10.28	-0.43	1.75e-22	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.69	-11.61	-0.47	1.54e-27	Height;
LGG	cis	rs10791323	0.575	rs4489760	chr11:133732265	A/T	cg15485101	chr11:133734466	NA	0.57	10.19	0.43	3.92e-22	Childhood ear infection;
LGG	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs12643440	0.538	rs16894433	chr4:17143112	A/C	cg22650099	chr4:17144496	NA	-0.5	-8.64	-0.37	9.13e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00689492	chr4:1303491	MAEA	0.47	8.07	0.35	6.28e-15	Obesity-related traits;
LGG	cis	rs9403521	0.898	rs3924969	chr6:143979399	C/G	cg18240653	chr6:144019428	PHACTR2	-0.65	-10.11	-0.43	7.47e-22	Obesity-related traits;
LGG	cis	rs709400	0.659	rs3825566	chr14:103852725	C/T	cg26031613	chr14:104095156	KLC1	-0.81	-14.17	-0.55	4.24e-38	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17675125	chr8:61590787	CHD7	0.5	7.5	0.33	3.24e-13	Gut microbiome composition (summer);
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	7.59	0.33	1.75e-13	Renal function-related traits (BUN);
LGG	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg19455335	chr8:22457658	C8orf58	-0.37	-7.49	-0.33	3.43e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs154659	1.000	rs154659	chr16:89667337	C/T	cg01710450	chr16:89662404	CPNE7	0.61	10.88	0.45	1.03e-24	Tanning;
LGG	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg02269571	chr22:50332266	NA	0.58	9.02	0.39	5.01e-18	Schizophrenia;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg18357526	chr6:26021779	HIST1H4A	0.67	10.8	0.45	2.05e-24	Urate levels;
LGG	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg06766960	chr11:133703094	NA	-0.58	-11.56	-0.47	2.53e-27	Childhood ear infection;
LGG	cis	rs236352	0.515	rs9380610	chr6:36805885	A/C	cg03410223	chr6:36853544	C6orf89	0.36	6.92	0.31	1.56e-11	Heart rate;
LGG	cis	rs11096990	0.552	rs7655170	chr4:39173604	T/G	cg24403649	chr4:39172243	NA	0.4	7.27	0.32	1.52e-12	Cognitive function;
LGG	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	8.09	0.35	5.11e-15	Iron status biomarkers;
LGG	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.31	6.64e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg24110177	chr3:50126178	RBM5	-0.4	-6.96	-0.31	1.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.65	0.33	1.18e-13	Schizophrenia;
LGG	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg17971929	chr21:40555470	PSMG1	0.7	9.94	0.42	3.01e-21	Cognitive function;
LGG	cis	rs10895140	0.756	rs7107018	chr11:101507687	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg00717180	chr2:96193071	NA	-0.45	-8.32	-0.36	9.75e-16	HDL cholesterol;
LGG	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg12379764	chr21:47803548	PCNT	0.7	12.15	0.49	1.15e-29	Lymphocyte counts;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg18857889	chr7:23719661	C7orf46	0.34	6.84	0.3	2.57e-11	Schizophrenia;
LGG	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg07075026	chr17:47091521	IGF2BP1	0.42	7.53	0.33	2.6e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15664640	chr17:80829946	TBCD	0.75	14.47	0.56	2.04e-39	Breast cancer;
LGG	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.04	0.49	3.09e-29	Rheumatoid arthritis;
LGG	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg15704280	chr7:45808275	SEPT13	0.73	7.77	0.34	5.11e-14	Axial length;
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg05941027	chr17:61774174	LIMD2	0.35	8.93	0.38	1.01e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4764124	0.576	rs7963212	chr12:14966165	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.38	7.08	0.31	5.4e-12	Pubertal anthropometrics;
LGG	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg24375607	chr4:120327624	NA	0.67	11.0	0.46	3.52e-25	Corneal astigmatism;
LGG	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.36	-0.47	1.53e-26	Hemoglobin concentration;
LGG	cis	rs4660306	0.677	rs1006215	chr1:45909945	T/A	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.44	6.67	0.3	7.24e-11	Homocysteine levels;
LGG	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg13385521	chr17:29058706	SUZ12P	0.8	9.61	0.41	4.48e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.46	-0.33	4.42e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-8.1	-0.35	4.76e-15	Menarche (age at onset);
LGG	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg25554036	chr4:6271136	WFS1	0.56	10.3	0.43	1.56e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg08600765	chr20:34638493	LOC647979	-0.62	-7.9	-0.34	2.09e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.97	-0.52	4.72e-33	Intelligence (multi-trait analysis);
LGG	cis	rs4944092	0.960	rs10400322	chr11:75910913	C/T	cg04588336	chr11:75916460	WNT11	0.42	9.69	0.41	2.37e-20	PR interval;
LGG	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg06618935	chr21:46677482	NA	-0.35	-6.86	-0.3	2.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg09873164	chr1:152488093	CRCT1	-0.61	-15.04	-0.57	6.77e-42	Hair morphology;
LGG	cis	rs7727544	0.548	rs35696821	chr5:131508017	C/T	cg07395648	chr5:131743802	NA	-0.4	-8.78	-0.38	3.2e-17	Blood metabolite levels;
LGG	cis	rs8170	0.603	rs10259	chr19:17430915	G/A	cg04749549	chr19:17459798	NA	-0.41	-7.49	-0.33	3.43e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.1	0.31	4.84e-12	Lung cancer;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7119	0.643	rs12904384	chr15:77410878	T/G	cg05673287	chr15:77411982	SGK269	-0.34	-7.4	-0.33	6.52e-13	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.53	-0.53	2.13e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg17202724	chr17:61916730	SMARCD2	-0.45	-9.08	-0.39	3.25e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504073	0.584	rs56068225	chr8:49923988	A/G	cg00325661	chr8:49890786	NA	0.81	16.34	0.6	1.07e-47	Blood metabolite ratios;
LGG	cis	rs490234	0.902	rs12351538	chr9:128281503	A/G	cg14078157	chr9:128172775	NA	-0.4	-7.51	-0.33	3.02e-13	Mean arterial pressure;
LGG	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg22961513	chr11:14280813	SPON1	-0.29	-6.65	-0.3	8.06e-11	Sense of smell;
LGG	cis	rs1003719	0.680	rs7275984	chr21:38505696	C/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs67478160	0.643	rs8004408	chr14:104203938	G/A	cg26031613	chr14:104095156	KLC1	-0.43	-7.2	-0.32	2.52e-12	Schizophrenia;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04016957	chr4:1044486	NA	-0.39	-7.61	-0.33	1.58e-13	Recombination rate (males);
LGG	cis	rs2227564	0.830	rs2675667	chr10:75683832	G/A	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.9	-0.38	1.29e-17	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg13009111	chr11:71350975	NA	0.35	7.76	0.34	5.52e-14	Neuroticism;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg24253500	chr15:84953950	NA	0.57	10.29	0.43	1.7e-22	Schizophrenia;
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg13013644	chr5:502571	SLC9A3	0.33	7.3	0.32	1.27e-12	Cystic fibrosis severity;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.48	-0.37	3.01e-16	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg23601416	chr22:19950040	COMT	-0.45	-11.17	-0.46	8.44e-26	Blood metabolite levels;
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03517284	chr6:25882590	NA	-0.38	-6.79	-0.3	3.41e-11	Height;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.44	-0.5	7.76e-31	Lymphocyte counts;
LGG	cis	rs10937275	0.590	rs116050195	chr3:186672937	G/A	cg13419791	chr3:186648285	ST6GAL1	0.76	8.06	0.35	6.69e-15	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs4774899	0.898	rs11634352	chr15:57576475	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.24	-0.32	1.83e-12	Urinary tract infection frequency;
LGG	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg18196295	chr10:418757	DIP2C	-0.4	-7.16	-0.32	3.16e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs9463078	0.656	rs227838	chr6:44684621	C/A	cg25276700	chr6:44698697	NA	0.42	8.74	0.38	4.38e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.49	0.4	1.26e-19	Lung cancer in ever smokers;
LGG	cis	rs1957429	0.614	rs73279812	chr14:65348012	G/A	cg23373153	chr14:65346875	NA	-1.08	-12.1	-0.49	1.76e-29	Pediatric areal bone mineral density (radius);
LGG	cis	rs6732160	0.932	rs6546802	chr2:73379564	G/A	cg01422370	chr2:73384389	NA	0.53	10.16	0.43	5.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs2018055	0.692	rs929058	chr6:117819198	A/G	cg14611402	chr6:117803162	DCBLD1	0.26	7.38	0.32	7.28e-13	Diastolic blood pressure;
LGG	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg17218041	chr13:113365319	ATP11A	-0.47	-7.74	-0.34	6.49e-14	Glycated hemoglobin levels;
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg14019146	chr3:50243930	SLC38A3	-0.32	-6.86	-0.3	2.18e-11	Body mass index;
LGG	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg02002194	chr4:3960332	NA	0.38	6.88	0.3	1.97e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3750450	0.718	rs10119430	chr9:111938268	G/A	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.53	-0.47	3.18e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.38	-0.53	9.28e-35	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs4714291	0.963	rs1721409	chr6:40112439	A/T	cg02267698	chr19:7991119	CTXN1	0.6	9.56	0.41	7.23e-20	Strep throat;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.56	-8.4	-0.36	5.37e-16	Platelet count;
LGG	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg17927777	chr20:33865990	NA	0.74	9.91	0.42	4.17e-21	Attention deficit hyperactivity disorder;
LGG	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4919044	0.799	rs56024810	chr10:94753313	G/A	cg05127821	chr10:94822908	CYP26C1	-0.4	-7.0	-0.31	9.23e-12	Coronary artery disease;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg13206674	chr6:150067644	NUP43	0.4	8.6	0.37	1.24e-16	Testicular germ cell tumor;
LGG	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-6.96	-0.31	1.18e-11	Blood metabolite levels;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.59	0.41	5.38e-20	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.44	-0.33	4.82e-13	Lung cancer;
LGG	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.36	-0.4	3.57e-19	Neuroticism;
LGG	cis	rs2298450	0.550	rs2070517	chr21:37650235	T/C	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.71	-0.38	5.22e-17	Schizophrenia;
LGG	cis	rs6547631	0.622	rs11127	chr2:85924729	C/T	cg19805943	chr2:85933069	NA	0.32	6.73	0.3	4.92e-11	Blood protein levels;
LGG	cis	rs870825	0.587	rs7682995	chr4:185640684	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00149659	chr3:10157352	C3orf10	0.76	9.69	0.41	2.51e-20	Alzheimer's disease;
LGG	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg02187348	chr16:89574699	SPG7	0.65	11.09	0.46	1.68e-25	Multiple myeloma (IgH translocation);
LGG	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg03605463	chr16:89740564	NA	0.61	11.08	0.46	1.85e-25	Vitiligo;
LGG	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg16339924	chr4:17578868	LAP3	-0.66	-11.39	-0.47	1.13e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2067615	0.579	rs10861665	chr12:107193836	T/C	cg15890332	chr12:107067104	RFX4	0.4	11.69	0.48	7.89e-28	Heart rate;
LGG	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-7.11	-0.31	4.43e-12	Reticulocyte count;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg02158880	chr13:53174818	NA	0.5	10.28	0.43	1.79e-22	Lewy body disease;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg07701084	chr6:150067640	NUP43	0.7	13.81	0.54	1.46e-36	Lung cancer;
LGG	cis	rs738321	0.762	rs5995543	chr22:38579026	G/A	cg03162506	chr22:38580953	NA	0.38	9.23	0.39	9.91e-19	Breast cancer;
LGG	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs1957429	0.520	rs72625645	chr14:65343431	G/C	cg23373153	chr14:65346875	NA	-0.96	-9.58	-0.41	6.12e-20	Pediatric areal bone mineral density (radius);
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	6.8	0.3	3.21e-11	Prudent dietary pattern;
LGG	cis	rs975722	0.638	rs213966	chr7:117229819	A/G	cg10524701	chr7:117356490	CTTNBP2	0.47	10.44	0.44	4.61e-23	Coronary artery disease;
LGG	trans	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg03929089	chr4:120376271	NA	-0.48	-7.85	-0.34	2.91e-14	HDL cholesterol;
LGG	trans	rs34421088	0.506	rs2572428	chr8:11146672	T/A	cg02002194	chr4:3960332	NA	-0.39	-6.95	-0.31	1.23e-11	Neuroticism;
LGG	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-27.4	-0.79	5.85e-99	Schizophrenia;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg07685180	chr8:600429	NA	1.04	10.7	0.45	5.17e-24	IgG glycosylation;
LGG	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg03959625	chr15:84868606	LOC388152	-0.55	-8.71	-0.38	5.36e-17	Schizophrenia;
LGG	cis	rs17683430	0.702	rs61742196	chr22:32369435	C/T	cg02631450	chr22:32366979	NA	1.03	9.84	0.42	7.15e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg19455335	chr8:22457658	C8orf58	-0.39	-8.02	-0.35	8.64e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6141769	0.569	rs6057617	chr20:31259367	A/G	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.24	-0.32	1.89e-12	Subjective well-being;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg26354017	chr1:205819088	PM20D1	0.85	20.24	0.69	1.07e-65	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12604982	chr17:1394479	MYO1C	0.46	6.77	0.3	3.87e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	6.89	0.3	1.83e-11	Menopause (age at onset);
LGG	cis	rs12220238	0.554	rs11001029	chr10:76154777	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.54	0.37	1.88e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.95	-8.52	-0.37	2.2e-16	Facial emotion recognition (sad faces);
LGG	cis	rs4731207	0.596	rs1531716	chr7:124638538	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.86	-0.42	6.14e-21	Mean corpuscular volume;
LGG	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.99	-0.35	1.05e-14	Neuroticism;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	12.75	0.51	4.2e-32	Prudent dietary pattern;
LGG	cis	rs735539	0.645	rs1411038	chr13:21248431	A/G	cg04906043	chr13:21280425	IL17D	-0.52	-8.54	-0.37	1.95e-16	Dental caries;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.93	-0.45	6.52e-25	Lung cancer;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg13010199	chr12:38710504	ALG10B	0.64	13.45	0.53	4.81e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21963583	chr11:68658836	MRPL21	0.6	10.37	0.43	8.16e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6032067	0.929	rs1997892	chr20:43810961	A/T	cg10761708	chr20:43804764	PI3	0.74	11.68	0.48	8.63e-28	Blood protein levels;
LGG	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg21459583	chr1:227974177	NA	0.43	6.79	0.3	3.55e-11	Major depressive disorder;
LGG	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg03733263	chr8:22462867	KIAA1967	0.96	22.4	0.72	8.09e-76	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08976451	chr10:92631876	RPP30	0.39	6.74	0.3	4.62e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17227506	0.679	rs34216318	chr8:13444780	T/C	cg03566418	chr8:13424080	C8orf48	0.64	10.1	0.42	8.61e-22	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.16	0.39	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7863010	0.579	rs12336101	chr9:112143287	C/A	cg14235574	chr9:112080226	EPB41L4B	-0.32	-6.65	-0.3	8.51e-11	HIV-associated neurocognitive disorder;
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg00490583	chr16:1843685	IGFALS	0.49	8.5	0.37	2.7e-16	Insulin-like growth factors;
LGG	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg12310025	chr6:25882481	NA	0.42	6.98	0.31	1.01e-11	Iron status biomarkers;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	0.960	rs2952976	chr17:29486152	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.61	0.56	5.01e-40	Hip circumference;
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.24	0.32	1.85e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg14893161	chr1:205819251	PM20D1	0.47	7.54	0.33	2.56e-13	Parkinson's disease;
LGG	cis	rs9894429	0.646	rs8079963	chr17:79603285	C/T	cg18240062	chr17:79603768	NPLOC4	0.62	10.44	0.44	4.88e-23	Eye color traits;
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg18402987	chr7:1209562	NA	0.67	7.35	0.32	9.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10229583	0.527	rs73450923	chr7:127305809	G/C	cg25855768	chr7:127472121	SND1	-0.38	-6.74	-0.3	4.85e-11	Type 2 diabetes;
LGG	cis	rs3126085	0.935	rs11204934	chr1:152176848	C/A	cg26876637	chr1:152193138	HRNR	-0.52	-8.05	-0.35	6.8e-15	Atopic dermatitis;
LGG	cis	rs3796352	1.000	rs59583591	chr3:53119581	T/C	cg12962167	chr3:53033115	SFMBT1	0.65	7.19	0.32	2.58e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9944715	0.954	rs12457740	chr18:43741742	G/A	cg26436583	chr18:43649176	PSTPIP2	0.39	7.29	0.32	1.34e-12	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7577696	0.525	rs2366547	chr2:32251109	G/A	cg02381751	chr2:32503542	YIPF4	-0.46	-6.66	-0.3	7.93e-11	Inflammatory biomarkers;
LGG	cis	rs787274	1.000	rs2796028	chr9:115528755	T/C	cg13803584	chr9:115635662	SNX30	-0.57	-7.2	-0.32	2.51e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs763121	0.962	rs909564	chr22:39126508	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	16.04	0.6	2.41e-46	Menopause (age at onset);
LGG	cis	rs11677416	1.000	rs1800794	chr2:113543273	G/A	cg27083787	chr2:113543245	IL1A	0.55	8.92	0.38	1.07e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg07511668	chr11:68622177	NA	0.51	9.64	0.41	3.71e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg04025307	chr7:1156635	C7orf50	0.62	11.29	0.46	2.75e-26	Longevity;Endometriosis;
LGG	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.18	0.36	2.86e-15	Iron status biomarkers;
LGG	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg09307838	chr4:120376055	NA	0.74	12.63	0.51	1.25e-31	Corneal astigmatism;
LGG	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs3779273	1.000	rs3807649	chr7:77828340	G/A	cg05596911	chr5:118502651	DMXL1	-0.43	-9.03	-0.39	4.59e-18	Body mass index;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg11965913	chr1:205819406	PM20D1	0.69	14.64	0.56	3.83e-40	Monocyte percentage of white cells;
LGG	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs11792861	0.926	rs56899598	chr9:111867271	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.34	0.4	3.91e-19	Menarche (age at onset);
LGG	trans	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.91	0.48	1.04e-28	Lung disease severity in cystic fibrosis;
LGG	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.65	0.44	8.08e-24	Aortic root size;
LGG	cis	rs10489202	1.000	rs2272911	chr1:167936302	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg08621203	chr6:150244597	RAET1G	0.47	8.03	0.35	7.99e-15	Lung cancer;
LGG	cis	rs11608355	0.545	rs33997929	chr12:109912064	C/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg05692746	chr2:100937584	LONRF2	0.59	10.49	0.44	2.96e-23	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.41	0.5	9.78e-31	Colorectal cancer;
LGG	cis	rs28655083	0.957	rs7185514	chr16:77070129	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-9.27	-0.4	7.09e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4466137	0.909	rs4466136	chr5:82985576	T/G	cg16102102	chr5:83017553	HAPLN1	-0.61	-11.2	-0.46	6.16e-26	Prostate cancer;
LGG	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.2	0.52	5.53e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg01236616	chr12:121019343	POP5	1.27	22.78	0.73	1.36e-77	Type 1 diabetes nephropathy;
LGG	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg05234568	chr11:5960015	NA	-0.66	-10.59	-0.44	1.35e-23	DNA methylation (variation);
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg12419862	chr22:24373484	LOC391322	-0.97	-20.33	-0.69	3.69e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12220238	0.915	rs10824164	chr10:76137032	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.73	0.38	4.55e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs250677	0.641	rs2915807	chr5:148450950	A/G	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.92	-0.31	1.5e-11	Breast cancer;
LGG	cis	rs3820928	0.874	rs7594505	chr2:227878562	C/G	cg11843606	chr2:227700838	RHBDD1	-0.47	-8.05	-0.35	6.93e-15	Pulmonary function;
LGG	cis	rs989128	0.572	rs6504674	chr17:48630814	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	6.92	0.31	1.48e-11	Type 2 diabetes;
LGG	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg09408571	chr1:101003634	GPR88	-0.32	-8.29	-0.36	1.21e-15	Breast cancer;
LGG	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg00898013	chr13:113819073	PROZ	-0.51	-10.02	-0.42	1.55e-21	Platelet distribution width;
LGG	cis	rs11677416	1.000	rs11677416	chr2:113529240	A/G	cg27083787	chr2:113543245	IL1A	0.53	8.87	0.38	1.55e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05025164	chr4:1340916	KIAA1530	0.44	7.37	0.32	7.9e-13	Obesity-related traits;
LGG	cis	rs7084402	0.515	rs12262629	chr10:60265656	G/A	cg07615347	chr10:60278583	BICC1	-0.51	-12.16	-0.49	9.82e-30	Refractive error;
LGG	cis	rs17092148	0.652	rs6088515	chr20:33110042	C/T	cg12302830	chr20:33297742	TP53INP2	-0.41	-6.69	-0.3	6.58e-11	Neuroticism;
LGG	cis	rs11074306	0.561	rs6497241	chr15:28072330	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg25811766	chr13:21894605	NA	-0.55	-7.37	-0.32	7.84e-13	White matter hyperintensity burden;
LGG	cis	rs7747724	0.573	rs9348443	chr6:20785165	A/G	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.31	-0.4	5.05e-19	Bladder cancer;
LGG	cis	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg12826209	chr6:26865740	GUSBL1	0.78	7.45	0.33	4.77e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg08621203	chr6:150244597	RAET1G	0.46	7.96	0.35	1.31e-14	Lung cancer;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00292662	chr22:38071168	LGALS1	0.89	24.24	0.75	2.1e-84	Fat distribution (HIV);
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.63	0.61	4.9e-49	Obesity-related traits;
LGG	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg20608306	chr11:116969690	SIK3	0.42	13.44	0.53	5.08e-35	Blood protein levels;
LGG	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.23	0.43	2.84e-22	Diabetic retinopathy;
LGG	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.48	-0.33	3.87e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg08733933	chr1:2954429	NA	-0.41	-9.1	-0.39	2.63e-18	Plateletcrit;
LGG	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg03433033	chr1:76189801	ACADM	0.79	13.62	0.53	9.22e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg24375607	chr4:120327624	NA	0.59	10.12	0.43	7.28e-22	Corneal astigmatism;
LGG	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.1	-0.49	1.82e-29	HDL cholesterol;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg16359550	chr11:109292809	C11orf87	0.44	8.38	0.36	6.48e-16	Schizophrenia;
LGG	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg08198773	chr8:1697536	NA	0.45	7.84	0.34	3.13e-14	Systolic blood pressure;
LGG	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.36	-0.43	8.98e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg19980929	chr12:42632907	YAF2	0.37	8.17	0.35	2.99e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg14668632	chr7:2872130	GNA12	-0.37	-7.54	-0.33	2.45e-13	Height;
LGG	cis	rs9534288	0.659	rs7996394	chr13:46653503	A/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.72	-0.56	1.68e-40	Blood protein levels;
LGG	cis	rs72781680	0.898	rs72786298	chr2:24083011	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	9.57	0.41	6.46e-20	Lymphocyte counts;
LGG	cis	rs7614311	0.636	rs73117047	chr3:63910779	G/A	cg22134162	chr3:63841271	THOC7	-0.44	-7.69	-0.34	8.92e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs77861329	1.000	rs893056	chr3:52109564	G/A	cg08692210	chr3:52188851	WDR51A	0.74	6.74	0.3	4.67e-11	Macrophage inflammatory protein 1b levels;
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.72e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg14500267	chr11:67383377	NA	0.42	7.65	0.34	1.14e-13	Mean corpuscular volume;
LGG	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.34e-18	Rheumatoid arthritis;
LGG	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6032067	1.000	rs6032052	chr20:43829883	C/A	cg10761708	chr20:43804764	PI3	0.76	11.83	0.48	2.1e-28	Blood protein levels;
LGG	cis	rs7940866	0.801	rs10894296	chr11:130840433	T/G	cg12179176	chr11:130786555	SNX19	0.73	13.51	0.53	2.8e-35	Schizophrenia;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg11878867	chr6:150167359	LRP11	-0.6	-12.89	-0.51	1.07e-32	Lung cancer;
LGG	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	12.26	0.5	4.08e-30	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.82	0.38	2.36e-17	Fuchs's corneal dystrophy;
LGG	cis	rs3126085	0.935	rs1552995	chr1:152171427	A/G	cg26876637	chr1:152193138	HRNR	0.55	9.08	0.39	3.06e-18	Atopic dermatitis;
LGG	cis	rs698833	0.892	rs2603257	chr2:44731588	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	7.32	0.32	1.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg07308232	chr7:1071921	C7orf50	-0.67	-13.37	-0.53	1.04e-34	Longevity;Endometriosis;
LGG	cis	rs7267979	1.000	rs12428	chr20:25433821	G/T	cg06421707	chr20:25228305	PYGB	-0.49	-10.52	-0.44	2.35e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs57244997	1.000	rs73026551	chr6:162393642	A/C	cg17173639	chr6:162384350	PARK2	-0.6	-7.59	-0.33	1.82e-13	Mosquito bite size;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg26338869	chr17:61819248	STRADA	0.62	9.93	0.42	3.4e-21	Prudent dietary pattern;
LGG	cis	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg04455712	chr21:45112962	RRP1B	0.52	10.08	0.42	9.47e-22	Mean corpuscular volume;
LGG	cis	rs67478160	0.643	rs8003653	chr14:104298836	A/G	cg26031613	chr14:104095156	KLC1	-0.44	-7.3	-0.32	1.28e-12	Schizophrenia;
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg26513180	chr16:89883248	FANCA	0.95	9.93	0.42	3.52e-21	Skin colour saturation;
LGG	trans	rs225245	0.817	rs225273	chr17:33970935	A/T	cg19694781	chr19:47549865	TMEM160	-0.42	-7.14	-0.31	3.61e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs4776059	0.798	rs7167494	chr15:52928453	C/G	cg22715398	chr15:52968154	KIAA1370	0.46	6.91	0.31	1.66e-11	Schizophrenia;
LGG	cis	rs3764563	1.000	rs623675	chr19:15705115	G/A	cg20725493	chr19:15740067	CYP4F8	0.68	7.9	0.34	2.12e-14	Inflammatory biomarkers;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg04503457	chr17:41445688	NA	-0.37	-8.55	-0.37	1.87e-16	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14209549	chr10:3215073	PITRM1	0.44	7.16	0.32	3.11e-12	Cognitive performance;
LGG	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg16386425	chr10:429943	DIP2C	0.42	8.33	0.36	9.25e-16	Psychosis in Alzheimer's disease;
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22168489	chr12:122356033	WDR66	0.42	10.1	0.42	8.43e-22	Mean corpuscular volume;
LGG	cis	rs6142618	0.562	rs4911197	chr20:30718293	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs7712401	0.601	rs62377424	chr5:122332322	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.66	-13.0	-0.52	3.58e-33	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.48	-7.86	-0.34	2.67e-14	Mean platelet volume;
LGG	trans	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Bladder cancer;
LGG	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.05e-54	Refractive error;
LGG	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg09197432	chr4:183729176	NA	0.59	7.82	0.34	3.54e-14	Pediatric autoimmune diseases;
LGG	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.21	-0.32	2.31e-12	Menarche (age at onset);
LGG	cis	rs1011108	0.561	rs1053807	chr2:26800422	G/A	cg18742855	chr2:26800399	C2orf70	0.43	7.97	0.35	1.2e-14	Periodontal microbiota;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.4	-0.58	1.66e-43	Platelet count;
LGG	cis	rs9916302	0.861	rs11078913	chr17:37671714	G/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.36	-0.47	1.56e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2976388	0.967	rs2585183	chr8:143766059	C/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.31	-0.43	1.46e-22	Urinary tract infection frequency;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg02951883	chr7:2050386	MAD1L1	-0.73	-14.49	-0.56	1.7e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs2286885	1.000	rs1537989	chr9:129241824	C/T	cg14319473	chr9:129242481	FAM125B	0.46	8.7	0.37	5.84e-17	Intraocular pressure;
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg11062466	chr8:58055876	NA	0.44	7.16	0.32	3.2e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12711979	0.509	rs12711972	chr2:3823786	T/C	cg17052675	chr2:3827356	NA	-0.49	-9.64	-0.41	3.74e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.43	-6.67	-0.3	7.52e-11	Tonsillectomy;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.69	0.48	7.87e-28	Obesity-related traits;
LGG	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg09818912	chr17:20140352	CYTSB	-0.32	-7.53	-0.33	2.71e-13	Schizophrenia;
LGG	cis	rs6430585	0.528	rs12476127	chr2:136763242	A/G	cg07169764	chr2:136633963	MCM6	1.26	25.13	0.76	1.6e-88	Corneal structure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27658640	chr17:4843839	RNF167;SLC25A11	0.52	8.2	0.36	2.33e-15	Gut microbiome composition (summer);
LGG	cis	rs7264396	0.676	rs6058383	chr20:34556005	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.76	0.54	2.26e-36	IgG glycosylation;
LGG	cis	rs7953249	0.618	rs7954331	chr12:121398657	G/T	cg02403541	chr12:121454288	C12orf43	-0.54	-8.93	-0.38	1.04e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14431266	chr11:67057003	ANKRD13D	0.46	7.17	0.32	3.08e-12	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.34	-0.36	8.3e-16	Breast cancer;
LGG	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.93e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg25358565	chr5:93447407	FAM172A	1.4	17.18	0.62	1.52e-51	Diabetic retinopathy;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.17	0.32	2.99e-12	Alzheimer's disease;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg23782820	chr8:58130467	NA	0.49	7.53	0.33	2.75e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg08621203	chr6:150244597	RAET1G	0.5	9.29	0.4	6.23e-19	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26872706	chr19:12551931	ZNF443	0.46	6.68	0.3	6.86e-11	Gut microbiome composition (summer);
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg10295955	chr4:187884368	NA	-1.15	-30.83	-0.82	2.79e-114	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg27624424	chr6:160112604	SOD2	0.67	9.91	0.42	3.99e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-8.68	-0.37	6.65e-17	Height;
LGG	cis	rs2463822	0.547	rs72917373	chr11:62024403	C/A	cg06239285	chr11:62104954	ASRGL1	-1.0	-11.91	-0.48	1.07e-28	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.44	7.4	0.33	6.39e-13	Longevity;
LGG	cis	rs8028182	0.636	rs62027209	chr15:75871626	A/G	cg20655648	chr15:75932815	IMP3	0.47	7.79	0.34	4.29e-14	Sudden cardiac arrest;
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17376030	chr22:41985996	PMM1	0.54	8.54	0.37	1.93e-16	Vitiligo;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04958252	chr8:87517638	FAM82B	-0.57	-6.67	-0.3	7.49e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg07308232	chr7:1071921	C7orf50	-0.72	-14.31	-0.55	1e-38	Longevity;Endometriosis;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09217309	chr6:150244204	RAET1G	0.41	7.47	0.33	4.09e-13	Testicular germ cell tumor;
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg26924012	chr15:45694286	SPATA5L1	-1.06	-23.28	-0.73	6.32e-80	Homoarginine levels;
LGG	cis	rs9487094	0.670	rs13203587	chr6:109820962	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.67	0.34	1.05e-13	Height;
LGG	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg21665744	chr7:39171113	POU6F2	0.34	6.67	0.3	7.42e-11	IgG glycosylation;
LGG	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg04691961	chr3:161091175	C3orf57	0.43	9.0	0.39	5.82e-18	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg02002194	chr4:3960332	NA	-0.52	-9.73	-0.41	1.8e-20	Retinal vascular caliber;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04772025	chr11:68637568	NA	0.77	13.85	0.54	9.8e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12431410	0.584	rs2350013	chr14:60222781	A/G	cg07950296	chr14:60194823	RTN1	-0.37	-7.08	-0.31	5.4e-12	Schizophrenia;
LGG	cis	rs422249	0.547	rs174537	chr11:61552680	G/T	cg19610905	chr11:61596333	FADS2	-0.81	-14.74	-0.57	1.36e-40	Trans fatty acid levels;
LGG	cis	rs9818758	0.545	rs55921200	chr3:49189316	T/C	cg00383909	chr3:49044727	WDR6	1.1	11.7	0.48	7.25e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26279152	chr13:20356101	PSPC1	0.43	7.13	0.31	3.88e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.28	0.53	2.42e-34	Morning vs. evening chronotype;
LGG	cis	rs11605275	1.000	rs78687006	chr11:20032176	G/A	cg14835545	chr11:20032148	NAV2	-0.96	-11.38	-0.47	1.26e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6445975	0.715	rs3773007	chr3:58269566	G/T	cg24175188	chr3:58374923	PXK	0.39	7.45	0.33	4.71e-13	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.39	0.36	6.09e-16	Obesity-related traits;
LGG	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg25566285	chr7:158114605	PTPRN2	0.89	19.73	0.68	2.39e-63	Calcium levels;
LGG	trans	rs970548	0.643	rs7080474	chr10:45931899	C/T	cg20477318	chr10:51623047	TIMM23	0.56	6.97	0.31	1.13e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs9463078	0.625	rs3799986	chr6:44900253	C/T	cg25276700	chr6:44698697	NA	0.33	6.96	0.31	1.19e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7465272	1.000	rs13259747	chr8:143683567	A/C	cg10104451	chr8:143696006	ARC	-0.74	-10.95	-0.45	5.57e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs5769707	0.632	rs6009782	chr22:50010812	C/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.76	-0.41	1.43e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg11845111	chr2:191398756	TMEM194B	-0.37	-8.24	-0.36	1.84e-15	Pulse pressure;
LGG	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg03433033	chr1:76189801	ACADM	0.67	9.9	0.42	4.35e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.46	-0.4	1.52e-19	Neuroticism;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg12692727	chr7:1102344	C7orf50	0.49	6.86	0.3	2.2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11081185	chr11:208423	RIC8A;BET1L	0.44	6.97	0.31	1.11e-11	Cognitive performance;
LGG	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg19875535	chr5:140030758	IK	0.55	11.29	0.46	2.91e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs9358372	0.574	rs9368247	chr6:20875727	G/T	cg13405222	chr6:20811065	CDKAL1	-0.45	-9.04	-0.39	4.2e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg07636037	chr3:49044803	WDR6	0.95	20.36	0.69	2.81e-66	Menarche (age at onset);
LGG	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg05444541	chr17:17804740	TOM1L2	0.69	16.47	0.61	2.56e-48	Total body bone mineral density;
LGG	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.51	-0.33	3.06e-13	Mean corpuscular volume;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg21970626	chr13:21893289	NA	-0.46	-10.18	-0.43	4.29e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg05044414	chr3:183734942	ABCC5	0.78	17.19	0.62	1.39e-51	Anterior chamber depth;
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg13047869	chr3:10149882	C3orf24	-0.47	-7.71	-0.34	7.87e-14	Alzheimer's disease;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg20453264	chr5:131705742	SLC22A5	0.66	8.36	0.36	7.42e-16	Rheumatoid arthritis;
LGG	cis	rs7851660	0.809	rs7031386	chr9:100665669	G/T	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.86	0.38	1.73e-17	Platelet count;
LGG	trans	rs28735056	0.904	rs9967107	chr18:77633343	C/T	cg05926928	chr17:57297772	GDPD1	0.56	8.89	0.38	1.38e-17	Schizophrenia;
LGG	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.27	0.52	2.89e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.99	-0.49	4.92e-29	Alzheimer's disease;
LGG	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg23920097	chr1:209922102	NA	-0.47	-7.97	-0.35	1.25e-14	Red blood cell count;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.16e-21	Prudent dietary pattern;
LGG	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg05425664	chr17:57184151	TRIM37	0.68	11.04	0.46	2.67e-25	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.76	-0.41	1.33e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	7.11	0.31	4.45e-12	Longevity;
LGG	cis	rs9902453	0.874	rs7213517	chr17:28401740	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-13.81	-0.54	1.44e-36	Coffee consumption (cups per day);
LGG	cis	rs2346177	1.000	rs11125074	chr2:46655260	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.58	-0.44	1.42e-23	HDL cholesterol;
LGG	cis	rs9457247	1.000	rs1794693	chr6:167405670	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	trans	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.55	-0.33	2.32e-13	Joint mobility (Beighton score);
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.39e-49	Obesity-related traits;
LGG	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg22903471	chr2:27725779	GCKR	0.39	8.76	0.38	3.65e-17	Oral cavity cancer;
LGG	cis	rs7923837	0.687	rs1111875	chr10:94462882	C/T	cg25093409	chr10:94429542	NA	0.5	10.14	0.43	5.79e-22	Body mass index;Multiple sclerosis;
LGG	cis	rs1018836	0.923	rs4734269	chr8:91635474	G/C	cg16814680	chr8:91681699	NA	-0.82	-15.03	-0.57	6.96e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11245990	chr11:68621969	NA	0.41	8.63	0.37	1.02e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2905347	0.531	rs2961289	chr7:22677755	C/T	cg18045685	chr7:22629474	NA	-0.73	-15.8	-0.59	2.62e-45	Major depression and alcohol dependence;
LGG	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg16662043	chr16:48846231	NA	0.36	7.0	0.31	8.99e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-13.93	-0.54	4.46e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg15971980	chr6:150254442	NA	0.45	8.39	0.36	6.11e-16	Lung cancer;
LGG	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg23730037	chr7:158596552	ESYT2	0.39	6.69	0.3	6.48e-11	Height;
LGG	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-24.3	-0.75	1.05e-84	Monocyte count;
LGG	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg04672837	chr16:48644449	N4BP1	-0.53	-8.65	-0.37	8.46e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.81	0.38	2.54e-17	Obesity-related traits;
LGG	cis	rs9905704	0.624	rs6503891	chr17:57065924	A/C	cg12560992	chr17:57184187	TRIM37	0.55	8.76	0.38	3.84e-17	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04590931	chr5:133861743	PHF15	0.45	6.72	0.3	5.5e-11	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.99	-0.39	6.13e-18	Mean corpuscular hemoglobin;
LGG	cis	rs757081	0.658	rs105290	chr11:17292068	T/C	cg15432903	chr11:17409602	KCNJ11	-0.4	-7.39	-0.32	7.1e-13	Systolic blood pressure;
LGG	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.64	-0.41	3.67e-20	Height;
LGG	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg02466173	chr16:30829666	NA	-0.43	-7.68	-0.34	9.27e-14	Dementia with Lewy bodies;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg05335186	chr13:53173507	NA	0.59	13.28	0.53	2.61e-34	Lewy body disease;
LGG	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Vitiligo;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.8	0.62	8.48e-50	Platelet count;
LGG	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.73	0.34	6.77e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.79	-0.3	3.38e-11	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18299363	chr10:103816089	C10orf76	0.4	6.74	0.3	4.62e-11	Bipolar disorder;
LGG	cis	rs2354432	0.556	rs7525622	chr1:146774116	G/A	cg25205988	chr1:146714368	CHD1L	-1.43	-14.63	-0.56	4.12e-40	Mitochondrial DNA levels;
LGG	cis	rs4740619	0.933	rs4741534	chr9:15715215	G/A	cg14451791	chr9:16040625	NA	-0.37	-9.57	-0.41	6.37e-20	Body mass index;
LGG	cis	rs2860975	0.501	rs602941	chr10:96961184	G/A	cg09036531	chr10:96991505	NA	-0.75	-17.8	-0.64	2.11e-54	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg08648136	chr8:956695	NA	0.39	7.79	0.34	4.54e-14	Schizophrenia;
LGG	cis	rs787274	1.000	rs1965335	chr9:115504483	C/T	cg13803584	chr9:115635662	SNX30	0.57	7.66	0.34	1.11e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg27129171	chr3:47204927	SETD2	0.87	16.87	0.62	4.23e-50	Colorectal cancer;
LGG	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg06212747	chr3:49208901	KLHDC8B	0.6	10.06	0.42	1.17e-21	Parkinson's disease;
LGG	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.83	-8.81	-0.38	2.47e-17	Corneal curvature;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg06637938	chr14:75390232	RPS6KL1	0.6	10.98	0.45	4.27e-25	Height;
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg15133208	chr4:90757351	SNCA	-0.35	-7.77	-0.34	5.19e-14	Dementia with Lewy bodies;
LGG	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg13147721	chr7:65941812	NA	-0.82	-9.91	-0.42	4.13e-21	Diabetic kidney disease;
LGG	cis	rs2180341	0.920	rs6916990	chr6:127698759	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.92	0.59	8.29e-46	Breast cancer;
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg18357526	chr6:26021779	HIST1H4A	0.86	15.76	0.59	4.25e-45	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-9.82	-0.42	8.75e-21	Diabetic retinopathy;
LGG	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-9.06	-0.39	3.58e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	10.84	0.45	1.53e-24	Hemoglobin concentration;
LGG	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg02251663	chr11:14281053	SPON1	-0.3	-6.9	-0.31	1.74e-11	Mitochondrial DNA levels;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-15.42	-0.58	1.36e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.12e-14	Colorectal cancer;
LGG	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg13695288	chr21:47294981	PCBP3	-0.36	-7.18	-0.32	2.88e-12	Schizophrenia;
LGG	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg16301924	chr13:53314226	LECT1	-0.45	-9.17	-0.39	1.54e-18	Lewy body disease;
LGG	trans	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.45e-15	Bladder cancer;
LGG	cis	rs7192750	0.563	rs11649672	chr16:71952614	G/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	9.93e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg02002194	chr4:3960332	NA	-0.42	-7.9	-0.34	2e-14	Neuroticism;
LGG	cis	rs921968	0.643	rs559722	chr2:219398159	A/G	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	trans	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs2742417	1.000	rs2742423	chr3:45733430	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-7.14	-0.32	3.53e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.36e-16	Aortic root size;
LGG	cis	rs4774899	0.934	rs11636201	chr15:57470533	A/G	cg08128148	chr15:57256372	TCF12	-0.3	-7.05	-0.31	6.37e-12	Urinary tract infection frequency;
LGG	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.51	-0.37	2.39e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg06558623	chr16:89946397	TCF25	1.05	12.15	0.49	1.08e-29	Skin colour saturation;
LGG	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.78	-0.34	4.91e-14	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.22e-12	Lung cancer;
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	6.15e-38	Bladder cancer;
LGG	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06108461	chr20:60628389	TAF4	-0.85	-14.22	-0.55	2.52e-38	Body mass index;
LGG	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg20891558	chr2:74357851	NA	0.49	9.29	0.4	6.01e-19	Gestational age at birth (maternal effect);
LGG	cis	rs6504108	0.624	rs2278868	chr17:46262171	C/T	cg02219949	chr17:45927392	SP6	0.43	8.05	0.35	7.15e-15	Body mass index;
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.51e-12	Alzheimer's disease;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	9.89	0.42	4.7e-21	Obesity-related traits;
LGG	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg20368463	chr18:77673604	PQLC1	0.57	7.47	0.33	3.89e-13	Opioid sensitivity;
LGG	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg02002194	chr4:3960332	NA	0.5	9.76	0.41	1.39e-20	Mood instability;
LGG	cis	rs2249625	0.545	rs2496495	chr6:72882414	G/A	cg27608224	chr6:72922399	RIMS1	0.32	7.23	0.32	2.05e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg05279229	chr7:1896384	MAD1L1	-0.38	-6.94	-0.31	1.31e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg02269571	chr22:50332266	NA	0.68	10.66	0.44	6.92e-24	Schizophrenia;
LGG	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg02461776	chr11:598696	PHRF1	0.52	8.07	0.35	6.09e-15	Systemic lupus erythematosus;
LGG	cis	rs472402	0.560	rs10065299	chr5:6654489	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.82	-0.3	2.81e-11	Response to amphetamines;
LGG	cis	rs7463659	0.904	rs7826572	chr8:135433805	G/T	cg09855544	chr8:135498122	ZFAT	-0.43	-8.03	-0.35	8e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg11473876	chr11:109292803	C11orf87	0.49	9.56	0.41	6.79e-20	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02993943	chr7:39605861	C7orf36	0.46	7.46	0.33	4.38e-13	Cognitive performance;
LGG	trans	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.16	0.43	4.9e-22	Mean corpuscular volume;
LGG	trans	rs1459104	1.000	rs35449391	chr11:55330401	G/A	cg15704280	chr7:45808275	SEPT13	0.66	6.69	0.3	6.33e-11	Body mass index;
LGG	cis	rs7216064	0.531	rs6504573	chr17:66015963	C/T	cg12091567	chr17:66097778	LOC651250	-0.58	-9.86	-0.42	6.02e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4380275	0.782	rs11691064	chr2:755718	T/G	cg14072418	chr2:740025	NA	-0.36	-7.18	-0.32	2.84e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs709400	0.663	rs28444993	chr14:103930564	T/C	cg26031613	chr14:104095156	KLC1	0.78	14.0	0.55	2.16e-37	Body mass index;
LGG	cis	rs7444	0.941	rs5754344	chr22:21963786	A/G	cg05046821	chr22:21984468	YDJC	-0.39	-7.06	-0.31	6.13e-12	Systemic lupus erythematosus;
LGG	cis	rs11112613	0.713	rs11112591	chr12:105951620	C/T	cg03607813	chr12:105948248	NA	0.58	10.68	0.44	6.23e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs35740288	0.822	rs11630549	chr15:86275796	C/T	cg04173714	chr15:86211321	AKAP13	0.42	7.18	0.32	2.76e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2652834	1.000	rs2134265	chr15:63398196	G/A	cg05507819	chr15:63340323	TPM1	0.58	7.83	0.34	3.24e-14	HDL cholesterol;
LGG	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.17	0.32	3.06e-12	Total cholesterol levels;
LGG	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg19847130	chr8:10466454	RP1L1	0.34	7.56	0.33	2.21e-13	Neuroticism;
LGG	cis	rs12144094	0.873	rs12127605	chr1:120228184	A/G	cg20995928	chr1:120229863	NA	-0.44	-7.5	-0.33	3.39e-13	Height;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg11814155	chr7:99998594	ZCWPW1	0.58	9.0	0.39	5.81e-18	Platelet count;
LGG	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	7.85	0.34	2.98e-14	Retinal vascular caliber;
LGG	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.85e-66	Intelligence (multi-trait analysis);
LGG	cis	rs3798221	0.590	rs12175867	chr6:161019138	T/C	cg04181478	chr6:161122748	PLG	0.46	7.36	0.32	8.48e-13	Lipoprotein (a) levels;
LGG	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg00701064	chr4:6280414	WFS1	0.74	16.99	0.62	1.19e-50	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg21972741	chr5:435613	AHRR	0.48	8.37	0.36	6.73e-16	Cystic fibrosis severity;
LGG	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.91e-19	Obesity-related traits;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg18402987	chr7:1209562	NA	0.37	6.71	0.3	5.77e-11	Longevity;Endometriosis;
LGG	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9596863	1.000	rs9596866	chr13:54459385	A/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.13	0.31	3.91e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg16885296	chr6:26284938	NA	0.39	8.51	0.37	2.35e-16	Educational attainment;
LGG	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg06636001	chr8:8085503	FLJ10661	0.54	10.32	0.43	1.3e-22	Neuroticism;
LGG	cis	rs875971	0.545	rs313830	chr7:65551931	T/C	cg11764359	chr7:65958608	NA	-0.61	-8.98	-0.39	6.95e-18	Aortic root size;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg11494091	chr17:61959527	GH2	0.5	8.02	0.35	8.63e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03347722	chr19:13134771	NFIX	0.4	6.82	0.3	2.9100000000000002e-11	Gut microbiome composition (summer);
LGG	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg23601095	chr6:26197514	HIST1H3D	0.46	6.65	0.3	8.14e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10802521	chr3:52805072	NEK4	0.42	7.47	0.33	3.99e-13	Bipolar disorder;
LGG	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg03929089	chr4:120376271	NA	0.71	9.87	0.42	5.42e-21	Axial length;
LGG	cis	rs2304069	0.954	rs6861548	chr5:149384680	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	13.89	0.54	6.5e-37	HIV-1 control;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg20887711	chr4:1340912	KIAA1530	0.61	12.11	0.49	1.59e-29	Longevity;
LGG	cis	rs4731207	0.596	rs11761669	chr7:124586301	C/T	cg05630886	chr7:124431682	NA	0.3	6.92	0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs7100689	0.754	rs1934695	chr10:82125230	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	16.77	0.61	1.15e-49	Post bronchodilator FEV1;
LGG	cis	rs5742933	0.750	rs10197331	chr2:190632838	A/C	cg10453823	chr2:190539512	ANKAR	-0.47	-6.82	-0.3	2.83e-11	Ferritin levels;
LGG	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg04000281	chr11:63949212	NA	-0.43	-8.3	-0.36	1.18e-15	Platelet count;
LGG	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.27	-0.79	2.28e-98	Height;
LGG	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg19338460	chr6:170058176	WDR27	-0.6	-8.12	-0.35	4.17e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs16937	0.557	rs11240386	chr1:205175401	G/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.77	-0.34	5.09e-14	Schizophrenia;
LGG	cis	rs16837677	1.000	rs79536139	chr1:156751164	G/A	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg00350519	chr1:53905742	FLJ40434	0.37	7.76	0.34	5.46e-14	Menarche (age at onset);
LGG	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg11965913	chr1:205819406	PM20D1	0.45	7.02	0.31	7.98e-12	Parkinson's disease;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	9.7	0.41	2.32e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg02023728	chr11:77925099	USP35	0.44	7.78	0.34	4.76e-14	Testicular germ cell tumor;
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg00864171	chr11:67383662	NA	0.45	7.36	0.32	8.33e-13	Mean corpuscular volume;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.32	0.32	1.11e-12	Tonsillectomy;
LGG	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg16339924	chr4:17578868	LAP3	0.56	9.37	0.4	3.16e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06850241	chr22:41845214	NA	0.43	6.87	0.3	2.06e-11	Vitiligo;
LGG	cis	rs17102423	0.615	rs7147987	chr14:65538131	A/G	cg26396452	chr14:65542826	MAX	0.51	10.6	0.44	1.18e-23	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.82	0.42	8.25e-21	Primary sclerosing cholangitis;
LGG	cis	rs4917300	0.632	rs7813106	chr8:143107922	A/T	cg26003909	chr8:143102224	NA	-0.33	-6.69	-0.3	6.59e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.32	-0.32	1.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg09021430	chr5:549028	NA	-0.8	-12.76	-0.51	3.56e-32	Obesity-related traits;
LGG	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg21775007	chr8:11205619	TDH	-0.57	-9.41	-0.4	2.34e-19	Neuroticism;
LGG	trans	rs6499188	0.510	rs9923262	chr16:68613106	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.73	10.54	0.44	1.98e-23	Ulcerative colitis;
LGG	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.93	-0.42	3.49e-21	Depression;
LGG	cis	rs7558370	1.000	rs55792518	chr2:3717387	C/T	cg17046650	chr2:3699563	NA	0.78	7.89	0.34	2.22e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	2.11e-13	Menarche (age at onset);
LGG	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg04568710	chr12:38710424	ALG10B	0.4	8.45	0.37	3.95e-16	Morning vs. evening chronotype;
LGG	cis	rs6912958	0.781	rs7742965	chr6:88278196	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs870825	0.616	rs67641203	chr4:185623845	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs9457247	1.000	rs422094	chr6:167397033	C/G	cg07741184	chr6:167504864	NA	0.32	7.05	0.31	6.68e-12	Crohn's disease;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg15242686	chr22:24348715	GSTTP1	0.49	9.36	0.4	3.55e-19	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg10523679	chr1:76189770	ACADM	0.84	14.32	0.55	8.77e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04640194	chr12:56754023	STAT2	0.45	6.91	0.31	1.62e-11	Gut microbiome composition (summer);
LGG	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg14227996	chr4:17616232	MED28	0.54	7.58	0.33	1.91e-13	Opioid sensitivity;
LGG	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.74	0.48	4.67e-28	Rheumatoid arthritis;
LGG	cis	rs2050392	0.544	rs598672	chr10:30742388	C/T	cg25182066	chr10:30743637	MAP3K8	-0.66	-14.21	-0.55	2.82e-38	Inflammatory bowel disease;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg04731861	chr2:219085781	ARPC2	0.28	6.79	0.3	3.41e-11	Ulcerative colitis;
LGG	cis	rs988958	0.675	rs34863191	chr2:42217615	G/A	cg27252766	chr2:42229092	NA	0.58	9.0	0.39	5.83e-18	Hypospadias;
LGG	cis	rs7766436	0.648	rs3734214	chr6:22571414	C/G	cg13666174	chr6:22585274	NA	-0.4	-9.75	-0.41	1.44e-20	Coronary artery disease;
LGG	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.76	0.3	4.17e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg22358067	chr17:16797159	NA	-0.52	-7.22	-0.32	2.21e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg25482853	chr8:67687455	SGK3	0.94	11.98	0.49	5.31e-29	Obesity-related traits;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg26597838	chr10:835615	NA	0.64	9.54	0.41	8.19e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.32	0.36	9.68e-16	Mood instability;
LGG	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg08297393	chr2:100937505	LONRF2	-0.56	-9.75	-0.41	1.53e-20	Intelligence (multi-trait analysis);
LGG	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg14664628	chr15:75095509	CSK	-0.95	-18.07	-0.64	1.25e-55	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-8.26	-0.36	1.58e-15	IgG glycosylation;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.12	-0.43	7.15e-22	Neuroticism;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.8	0.38	2.66e-17	Bipolar disorder;
LGG	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.19	0.68	1.83e-65	Bladder cancer;
LGG	cis	rs4696584	0.816	rs1490666	chr4:155403285	G/T	cg04517429	chr4:155413618	DCHS2	0.31	7.05	0.31	6.54e-12	Folding of antihelix;
LGG	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg02187348	chr16:89574699	SPG7	0.67	11.39	0.47	1.19e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs2273669	0.588	rs11153158	chr6:109376118	T/C	cg05315195	chr6:109294784	ARMC2	-0.56	-6.91	-0.31	1.56e-11	Prostate cancer;
LGG	cis	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg12395012	chr8:11607386	GATA4	0.43	7.72	0.34	7.16e-14	Monocyte count;
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg00800038	chr16:89945340	TCF25	0.61	8.55	0.37	1.77e-16	Skin colour saturation;
LGG	cis	rs4604732	0.754	rs12080212	chr1:247631606	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.48	7.74	0.34	6.23e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg19418458	chr7:158789849	NA	-0.52	-10.67	-0.44	6.48e-24	Facial morphology (factor 20);
LGG	cis	rs8067545	0.750	rs28603224	chr17:19985052	G/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.74	-0.3	4.62e-11	Schizophrenia;
LGG	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg18867708	chr6:26865862	GUSBL1	0.44	7.17	0.32	3e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.88	-0.38	1.51e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15596359	chr8:11213517	TDH	0.42	8.77	0.38	3.45e-17	Retinal vascular caliber;
LGG	cis	rs9814567	0.964	rs9815983	chr3:134222507	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.29	-0.53	2.3e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs883565	0.682	rs35219579	chr3:39044665	A/T	cg01426195	chr3:39028469	NA	-0.74	-16.9	-0.62	2.96e-50	Handedness;
LGG	cis	rs708547	0.647	rs781666	chr4:57830981	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	8.97	0.38	7.22e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07701084	chr6:150067640	NUP43	0.43	7.86	0.34	2.64e-14	Testicular germ cell tumor;
LGG	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg20573242	chr4:122745356	CCNA2	0.54	9.89	0.42	4.67e-21	Type 2 diabetes;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.13	0.35	4.06e-15	Schizophrenia;
LGG	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg10847948	chr11:71163743	NADSYN1	0.59	8.88	0.38	1.47e-17	Vitamin D levels;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.7e-13	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg02297831	chr4:17616191	MED28	0.51	9.67	0.41	2.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg03970086	chr16:88974840	CBFA2T3	0.41	7.65	0.33	1.18e-13	Social autistic-like traits;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.76	-0.54	2.35e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs2131877	0.913	rs1874099	chr3:194848766	G/T	cg07250128	chr3:194833983	C3orf21	0.39	7.21	0.32	2.23e-12	Non-small cell lung cancer;
LGG	cis	rs2294693	0.947	rs9369254	chr6:40989408	T/C	cg14769373	chr6:40998127	UNC5CL	-0.43	-7.58	-0.33	1.91e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.47	7.15	0.32	3.49e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4891159	0.790	rs7241485	chr18:74122325	C/T	cg24786174	chr18:74118243	ZNF516	-0.58	-13.61	-0.53	9.71e-36	Longevity;
LGG	cis	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg13010199	chr12:38710504	ALG10B	0.77	16.53	0.61	1.4e-48	Heart rate;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.83	-0.48	2.18e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg25237894	chr2:233734115	C2orf82	-0.65	-12.45	-0.5	6.93e-31	Coronary artery disease;
LGG	trans	rs11976180	1.000	rs1320893	chr7:143752112	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.89	-0.3	1.85e-11	Obesity-related traits;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08120226	chr3:195531633	MUC4	0.52	8.55	0.37	1.78e-16	Lung disease severity in cystic fibrosis;
LGG	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.78	-0.3	3.58e-11	Bipolar disorder;
LGG	cis	rs75920871	0.925	rs7112191	chr11:116902056	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.01	-0.31	8.29e-12	Subjective well-being;
LGG	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg08885076	chr2:99613938	TSGA10	-0.44	-8.14	-0.35	3.79e-15	Chronic sinus infection;
LGG	cis	rs1670533	1.000	rs10031302	chr4:1059664	G/A	cg27284194	chr4:1044797	NA	0.57	10.22	0.43	2.97e-22	Recombination rate (females);
LGG	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg21017887	chr14:105400489	NA	0.43	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs71403859	0.570	rs77809998	chr16:71430687	C/T	cg08717414	chr16:71523259	ZNF19	-1.18	-12.87	-0.51	1.22e-32	Post bronchodilator FEV1;
LGG	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg23188684	chr11:67383651	NA	-0.42	-6.91	-0.31	1.6e-11	Mean corpuscular volume;
LGG	trans	rs6787172	0.622	rs6797629	chr3:158065671	T/A	cg23275840	chr4:47708675	CORIN	-0.36	-7.28	-0.32	1.44e-12	Subjective well-being;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.65	0.33	1.19e-13	Prostate cancer;
LGG	cis	rs1124376	0.935	rs9855900	chr3:20147172	C/T	cg05072819	chr3:20081367	KAT2B	0.63	8.42	0.36	4.65e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	0.812	rs59146151	chr3:41949301	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg26513180	chr16:89883248	FANCA	0.81	8.5	0.37	2.66e-16	Skin colour saturation;
LGG	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg03929089	chr4:120376271	NA	0.43	7.02	0.31	7.75e-12	HDL cholesterol;
LGG	cis	rs17428076	0.836	rs12053046	chr2:172673399	A/G	cg21435375	chr2:172878103	MAP1D	0.4	8.67	0.37	7.56e-17	Myopia;
LGG	cis	rs17286411	0.750	rs11075910	chr16:71936733	A/G	cg06353428	chr16:71660113	MARVELD3	0.41	7.36	0.32	8.24e-13	Blood protein levels;
LGG	cis	rs748404	0.578	rs512628	chr15:43618734	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.51	7.53	0.33	2.62e-13	Lung cancer;
LGG	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg15103426	chr22:29168792	CCDC117	0.72	11.31	0.47	2.45e-26	Lymphocyte counts;
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg02002194	chr4:3960332	NA	-0.43	-7.99	-0.35	1.09e-14	Neuroticism;
LGG	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg12395012	chr8:11607386	GATA4	-0.38	-7.05	-0.31	6.49e-12	Neuroticism;
LGG	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg26384229	chr12:38710491	ALG10B	0.74	14.88	0.57	3.22e-41	Morning vs. evening chronotype;
LGG	cis	rs9362426	0.503	rs6454609	chr6:88106028	T/C	cg22010963	chr6:88119922	C6orf165	0.3	6.7	0.3	6.1e-11	Depressive episodes in bipolar disorder;
LGG	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg03517284	chr6:25882590	NA	0.55	10.45	0.44	4.22e-23	Blood metabolite levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03473125	chr7:157550806	PTPRN2	0.42	7.06	0.31	6.25e-12	Pancreatic cancer;
LGG	cis	rs17445240	1.000	rs78506209	chr2:3699715	G/A	cg13452994	chr2:3699195	NA	0.68	7.3	0.32	1.27e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	13.68	0.54	5.13e-36	Alzheimer's disease;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.29	0.46	2.81e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs6489882	0.966	rs7311182	chr12:113379123	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.63	-0.33	1.33e-13	Total cholesterol levels;
LGG	cis	rs1971762	0.504	rs1843318	chr12:53958077	C/T	cg06632207	chr12:54070931	ATP5G2	0.22	6.89	0.31	1.78e-11	Height;
LGG	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg13385794	chr1:248469461	NA	0.49	8.45	0.37	3.81e-16	Common traits (Other);
LGG	cis	rs66569888	0.789	rs17213078	chr2:106734065	G/A	cg16099169	chr2:106886729	NA	-0.3	-6.65	-0.3	8.31e-11	Facial morphology (factor 23);
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.93e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg05091796	chr16:4465799	CORO7	0.63	10.48	0.44	3.48e-23	Schizophrenia;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08564027	chr20:61660810	NA	1.02	25.59	0.77	1.18e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg11764359	chr7:65958608	NA	-0.72	-12.89	-0.51	1.09e-32	Aortic root size;
LGG	trans	rs208520	0.802	rs851600	chr6:66893754	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-16.64	-0.61	4.44e-49	Exhaled nitric oxide output;
LGG	cis	rs4728302	0.583	rs58955798	chr7:133158420	C/T	cg10665199	chr7:133106180	EXOC4	0.6	10.28	0.43	1.86e-22	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.16	-0.32	3.25e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.83	-0.3	2.71e-11	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.87	9.25	0.4	8.05e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24423099	chr22:42466851	NAGA	0.53	8.14	0.35	3.63e-15	Gut microbiome composition (summer);
LGG	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg05234568	chr11:5960015	NA	-0.66	-10.59	-0.44	1.35e-23	DNA methylation (variation);
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg08508337	chr8:144660607	NAPRT1	0.9	7.22	0.32	2.22e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs975739	0.657	rs9544672	chr13:78590073	C/T	cg07847733	chr13:78271382	SLAIN1	0.45	7.88	0.34	2.4e-14	Hair color;
LGG	cis	rs6430585	0.527	rs60966546	chr2:136401843	C/T	cg07169764	chr2:136633963	MCM6	1.0	16.81	0.62	7.4e-50	Corneal structure;
LGG	cis	rs2286885	1.000	rs10819171	chr9:129253074	G/A	cg14319473	chr9:129242481	FAM125B	0.46	8.63	0.37	9.93e-17	Intraocular pressure;
LGG	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.43	7.09	0.31	5.1e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg18681998	chr4:17616180	MED28	0.87	20.02	0.68	1.11e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.24	0.36	1.78e-15	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.12	-0.31	4.1e-12	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18721605	chr18:44676421	HDHD2	0.43	7.21	0.32	2.34e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9815354	0.812	rs17215498	chr3:41829679	G/C	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg11905131	chr22:24372483	LOC391322	0.4	6.97	0.31	1.06e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg07460842	chr6:66804631	NA	-0.5	-8.4	-0.36	5.51e-16	Metabolite levels;
LGG	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg11161011	chr14:65562177	MAX	-0.65	-12.58	-0.5	1.99e-31	Obesity-related traits;
LGG	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-9.04	-0.39	4.24e-18	Height;
LGG	cis	rs10489202	1.000	rs7535138	chr1:167931462	T/G	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs774359	0.797	rs7046653	chr9:27490967	A/G	cg21249376	chr9:27528432	MOBKL2B	-0.4	-8.21	-0.36	2.18e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	15.19	0.58	1.35e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg10503236	chr1:231470652	EXOC8	-0.35	-6.87	-0.3	2.07e-11	Hemoglobin concentration;
LGG	cis	rs2659678	0.538	rs17127839	chr8:18973808	C/T	cg15587955	chr8:19026658	NA	-0.48	-8.3	-0.36	1.16e-15	Bone ultrasound measurement (velocity of sound);
LGG	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.45	0.4	1.73e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg18258770	chr4:90757814	SNCA	-0.4	-7.42	-0.33	5.67e-13	Dementia with Lewy bodies;
LGG	cis	rs71403859	0.730	rs17356206	chr16:71736359	G/C	cg08717414	chr16:71523259	ZNF19	-1.05	-13.22	-0.52	4.56e-34	Post bronchodilator FEV1;
LGG	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg20991723	chr1:152506922	NA	-0.45	-7.26	-0.32	1.62e-12	Hair morphology;
LGG	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg12219531	chr12:120966889	COQ5	0.66	10.94	0.45	6.08e-25	High light scatter reticulocyte count;
LGG	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg27165867	chr14:105738592	BRF1	-0.44	-7.13	-0.31	3.89e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg11584989	chr19:19387371	SF4	0.75	12.54	0.5	2.96e-31	Bipolar disorder;
LGG	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	cis	rs17767392	1.000	rs34674149	chr14:71777093	C/A	cg02058870	chr14:72053146	SIPA1L1	0.47	9.52	0.4	9.68e-20	Mitral valve prolapse;
LGG	cis	rs2285947	1.000	rs2285949	chr7:21584243	G/A	cg04471919	chr7:21584483	DNAH11	0.5	13.88	0.54	6.95e-37	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.86	-16.58	-0.61	8.81e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.7	-0.34	8.57e-14	Hepatitis;
LGG	cis	rs12210905	0.925	rs115182402	chr6:26980110	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-7.56	-0.33	2.24e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg08193579	chr3:169529701	LRRC34	0.37	7.61	0.33	1.59e-13	Renal cell carcinoma;
LGG	cis	rs42648	0.935	rs42660	chr7:89982522	C/T	cg25739043	chr7:89950458	NA	-0.38	-7.96	-0.35	1.34e-14	Homocysteine levels;
LGG	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg05973401	chr12:123451056	ABCB9	0.48	8.08	0.35	5.79e-15	Platelet count;
LGG	cis	rs3857067	0.736	rs2865333	chr4:95019964	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.12	-0.46	1.23e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1018836	0.923	rs6999898	chr8:91650549	G/A	cg16814680	chr8:91681699	NA	-0.86	-16.52	-0.61	1.54e-48	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs975739	1.000	rs1279396	chr13:78378593	G/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.75	0.3	4.51e-11	Hair color;
LGG	cis	rs62400317	0.859	rs10948217	chr6:45187618	A/C	cg20913747	chr6:44695427	NA	-0.64	-10.35	-0.43	1e-22	Total body bone mineral density;
LGG	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg16262614	chr3:133464971	TF	0.47	8.72	0.38	4.88e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02951883	chr7:2050386	MAD1L1	0.45	7.11	0.31	4.39e-12	Neuroticism;
LGG	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg04398451	chr17:18023971	MYO15A	-0.83	-17.48	-0.63	6.66e-53	Total body bone mineral density;
LGG	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-21.57	-0.71	5.91e-72	Hemostatic factors and hematological phenotypes;
LGG	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.37e-19	Height;
LGG	cis	rs3820928	0.967	rs4675113	chr2:227766339	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.38	-0.32	7.47e-13	Pulmonary function;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.44	7.48	0.33	3.75e-13	Obesity-related traits;
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.79	0.3	3.55e-11	Vitiligo;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg02725872	chr8:58115012	NA	0.83	11.5	0.47	4.14e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-8.26	-0.36	1.59e-15	Vitamin D levels;
LGG	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19671926	chr4:122722719	EXOSC9	0.52	8.1	0.35	5.1e-15	Type 2 diabetes;
LGG	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.92	0.35	1.76e-14	Birth weight;
LGG	trans	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg02002194	chr4:3960332	NA	0.39	7.0	0.31	9.23e-12	Joint mobility (Beighton score);
LGG	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg26441486	chr22:50317300	CRELD2	0.4	7.39	0.32	6.87e-13	Schizophrenia;
LGG	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27286337	chr10:134555280	INPP5A	0.85	12.34	0.5	1.86e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.73	-0.34	6.65e-14	Neuroticism;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg19168338	chr16:4465731	CORO7	-0.91	-17.39	-0.63	1.7e-52	Schizophrenia;
LGG	cis	rs2613964	0.504	rs9838253	chr3:112850525	A/T	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	5.83e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs2249694	0.878	rs2480257	chr10:135352509	T/A	cg20169779	chr10:135381914	SYCE1	0.51	7.75	0.34	5.71e-14	Obesity-related traits;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06916706	chr16:4465613	CORO7	-0.89	-15.84	-0.59	1.76e-45	Schizophrenia;
LGG	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg07777115	chr5:623756	CEP72	-0.59	-8.05	-0.35	7e-15	Obesity-related traits;
LGG	cis	rs11229555	0.834	rs7925560	chr11:58263036	G/A	cg15696309	chr11:58395628	NA	-1.0	-17.49	-0.63	5.82e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7179456	0.545	rs507801	chr15:59053345	T/G	cg05156742	chr15:59063176	FAM63B	0.59	9.59	0.41	5.52e-20	Asperger disorder;
LGG	trans	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg20587970	chr11:113659929	NA	0.72	10.5	0.44	2.87e-23	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	trans	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.8e-30	Corneal astigmatism;
LGG	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.82	0.38	2.39e-17	Eosinophil percentage of white cells;
LGG	cis	rs4604732	0.631	rs12038880	chr1:247624603	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.62	9.07	0.39	3.34e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.24	0.32	1.9e-12	Renal function-related traits (BUN);
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg04234412	chr22:24373322	LOC391322	-0.76	-16.06	-0.6	1.9e-46	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs17767392	0.881	rs12880188	chr14:72009745	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.87	-0.34	2.51e-14	Mitral valve prolapse;
LGG	cis	rs1519814	0.696	rs2326434	chr8:121047798	A/C	cg22335954	chr8:121166405	COL14A1	-0.53	-10.23	-0.43	2.87e-22	Breast cancer;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.8e-13	Life satisfaction;
LGG	cis	rs17221829	0.965	rs12278734	chr11:89461172	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.47	-0.33	4.07e-13	Anxiety in major depressive disorder;
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg06494592	chr3:125709126	NA	-0.53	-6.75	-0.3	4.32e-11	Blood pressure (smoking interaction);
LGG	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg09537434	chr19:41945824	ATP5SL	-0.87	-22.74	-0.73	1.93e-77	Height;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.02	-0.46	3.21e-25	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.617	rs504408	chr6:101739046	T/G	cg27451362	chr6:101846650	GRIK2	0.84	13.16	0.52	8.32e-34	Coenzyme Q10 levels;
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18876405	chr7:65276391	NA	-0.54	-9.58	-0.41	6.13e-20	Aortic root size;
LGG	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg08885076	chr2:99613938	TSGA10	0.38	8.11	0.35	4.72e-15	Chronic sinus infection;
LGG	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	7.89	0.34	2.21e-14	Schizophrenia;
LGG	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.74	0.3	4.65e-11	Menopause (age at onset);
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg26656751	chr17:43910226	CRHR1	-0.43	-7.82	-0.34	3.66e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7312774	0.618	rs4964518	chr12:107466217	C/T	cg16260113	chr12:107380972	MTERFD3	0.69	6.91	0.31	1.61e-11	Severe influenza A (H1N1) infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00586367	chr8:74790437	UBE2W	0.52	8.98	0.39	6.99e-18	Cognitive performance;
LGG	cis	rs7215564	0.730	rs34579757	chr17:78700077	G/A	cg16980736	chr17:78789706	RPTOR	-0.71	-9.07	-0.39	3.47e-18	Myopia (pathological);
LGG	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg21775007	chr8:11205619	TDH	0.46	7.51	0.33	3.09e-13	Mood instability;
LGG	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg18446336	chr7:2847575	GNA12	-0.33	-8.37	-0.36	6.66e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg18681998	chr4:17616180	MED28	0.85	18.86	0.66	2.89e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	4.17e-44	Lung cancer;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg19507638	chr5:93509721	C5orf36	0.39	6.99	0.31	9.47e-12	Diabetic retinopathy;
LGG	cis	rs9487094	0.961	rs3757234	chr6:109706290	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.75e-18	Height;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg22535103	chr8:58192502	C8orf71	-0.96	-12.73	-0.51	4.84e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs4919694	1.000	rs17727044	chr10:104821256	A/T	cg04362960	chr10:104952993	NT5C2	1.07	14.31	0.55	9.83e-39	Arsenic metabolism;
LGG	cis	rs7408868	0.764	rs45504393	chr19:15277010	A/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg05925327	chr15:68127851	NA	0.39	7.95	0.35	1.45e-14	Restless legs syndrome;
LGG	cis	rs2371030	0.900	rs10932350	chr2:211565772	G/A	cg18417063	chr2:211583084	NA	-0.64	-12.32	-0.5	2.28e-30	Non-small cell lung cancer;
LGG	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg20244327	chr10:3283946	NA	-0.32	-8.73	-0.38	4.57e-17	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg27523141	chr10:43048294	ZNF37B	0.41	8.1	0.35	4.88e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg20283391	chr11:68216788	NA	-0.48	-7.71	-0.34	7.73e-14	Total body bone mineral density;
LGG	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg17545662	chr6:170176663	C6orf70	0.67	8.56	0.37	1.65e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6743226	0.870	rs67652230	chr2:242235446	A/T	cg10021735	chr2:242295487	FARP2	0.52	9.49	0.4	1.26e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20524308	chr17:7358945	CHRNB1	0.38	6.88	0.3	1.96e-11	Bilirubin levels;
LGG	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.5	8.82	0.38	2.28e-17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs478222	0.930	rs510107	chr2:25319471	G/A	cg04586622	chr2:25135609	ADCY3	-0.31	-7.88	-0.34	2.44e-14	Type 1 diabetes;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg01943577	chr7:158741284	NA	-0.44	-8.22	-0.36	2.12e-15	Height;
LGG	cis	rs77372450	0.636	rs6879751	chr5:157007406	T/C	cg25387487	chr5:157003181	ADAM19	-0.58	-7.29	-0.32	1.37e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs9487051	0.735	rs1260596	chr6:109519847	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.65e-13	Reticulocyte fraction of red cells;
LGG	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg02151108	chr14:50098012	C14orf104	-0.43	-9.14	-0.39	2e-18	Carotid intima media thickness;
LGG	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg15268244	chr15:77196840	NA	0.47	10.01	0.42	1.75e-21	Blood metabolite levels;
LGG	cis	rs755249	0.567	rs41270803	chr1:39766041	A/G	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.1	-0.31	4.63e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4639966	0.758	rs11217013	chr11:118624919	G/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.56	-0.37	1.66e-16	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg00689492	chr4:1303491	MAEA	0.51	8.97	0.38	7.32e-18	Obesity-related traits;
LGG	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.19e-13	White matter hyperintensity burden;
LGG	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg23335576	chr14:104009727	NA	0.4	6.81	0.3	3.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs754423	0.515	rs768021	chr14:52553563	G/A	cg12071775	chr14:52591786	NA	0.41	6.84	0.3	2.46e-11	Craniofacial microsomia;
LGG	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg06115741	chr20:33292138	TP53INP2	0.57	9.01	0.39	5.54e-18	Coronary artery disease;
LGG	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg06026331	chr20:60912101	LAMA5	0.7	10.57	0.44	1.54e-23	Colorectal cancer;
LGG	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.25	-0.32	1.73e-12	Inflammatory bowel disease;
LGG	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.77	-8.51	-0.37	2.53e-16	Lung cancer in ever smokers;
LGG	cis	rs11971779	0.711	rs6961204	chr7:139047399	T/G	cg07862535	chr7:139043722	LUC7L2	0.64	9.88	0.42	5.16e-21	Diisocyanate-induced asthma;
LGG	cis	rs208520	0.661	rs704519	chr6:66801136	T/C	cg07460842	chr6:66804631	NA	-0.98	-18.71	-0.66	1.43e-58	Exhaled nitric oxide output;
LGG	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg23625390	chr15:77176239	SCAPER	0.71	14.33	0.55	8.62e-39	Blood metabolite levels;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-11.88	-0.48	1.36e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg26309987	chr1:37940113	ZC3H12A	-0.39	-6.99	-0.31	9.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.54e-12	Bipolar disorder;
LGG	cis	rs62025270	0.632	rs17571078	chr15:86140479	A/G	cg25843651	chr15:86329602	KLHL25	0.55	8.26	0.36	1.53e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg14338887	chr6:42928500	GNMT	-0.23	-7.38	-0.32	7.16e-13	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9944715	0.911	rs718513	chr18:43856267	C/G	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.69	-0.3	6.29e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg22044901	chr15:68126292	NA	-0.41	-6.91	-0.31	1.6e-11	Restless legs syndrome;
LGG	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs7267979	0.789	rs6076347	chr20:25398790	C/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.79	-0.34	4.47e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg22903471	chr2:27725779	GCKR	-0.54	-12.3	-0.5	2.83e-30	Total body bone mineral density;
LGG	cis	rs1185460	0.967	rs3825061	chr11:118944675	C/T	cg23280166	chr11:118938394	VPS11	0.57	10.16	0.43	5.2e-22	Coronary artery disease;
LGG	cis	rs9309473	0.950	rs10206899	chr2:73900900	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.43	-0.33	5.18e-13	Metabolite levels;
LGG	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg27426351	chr10:43362370	NA	-0.53	-7.44	-0.33	5.09e-13	Blood protein levels;
LGG	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg07382826	chr16:28625726	SULT1A1	0.42	8.54	0.37	1.95e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs11650494	0.516	rs4640235	chr17:47502352	T/C	cg08112188	chr17:47440006	ZNF652	0.84	9.6	0.41	4.87e-20	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07693037	chr3:128216748	NA	0.52	7.88	0.34	2.36e-14	Gut microbiome composition (summer);
LGG	trans	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-11.09	-0.46	1.61e-25	Ulcerative colitis;
LGG	cis	rs12282928	0.917	rs7942804	chr11:48297076	C/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.65e-12	Migraine - clinic-based;
LGG	cis	rs4732038	0.510	rs28817066	chr7:134277491	G/A	cg06906464	chr7:134288099	NA	-0.67	-17.35	-0.63	2.46e-52	Longevity;
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg11301795	chr4:187892539	NA	-0.95	-25.14	-0.76	1.45e-88	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4727027	0.645	rs12704072	chr7:148904888	G/A	cg23583168	chr7:148888333	NA	-0.94	-18.79	-0.66	5.89e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.77	-0.38	3.47e-17	Triglycerides;
LGG	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg06453172	chr10:134556979	INPP5A	-0.57	-8.65	-0.37	8.51e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	trans	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.25	-0.36	1.64e-15	Blood trace element (Cu levels);
LGG	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.29	0.32	1.35e-12	Red blood cell count;
LGG	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg06453172	chr10:134556979	INPP5A	-0.48	-7.43	-0.33	5.44e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.19	-0.36	2.54e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9308731	0.966	rs4849442	chr2:111934219	C/T	cg19992207	chr2:111874495	ACOXL	-0.39	-7.02	-0.31	7.97e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg11380483	chr2:127933992	NA	-0.37	-7.26	-0.32	1.66e-12	Self-rated health;
LGG	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.72	-0.34	7.45e-14	Mean corpuscular volume;
LGG	cis	rs977987	0.806	rs12449170	chr16:75463012	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.93	0.42	3.42e-21	Dupuytren's disease;
LGG	cis	rs6723226	0.772	rs2366894	chr2:32713706	A/T	cg02381751	chr2:32503542	YIPF4	0.69	11.86	0.48	1.56e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.15	-0.35	3.4e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg19223190	chr17:80058835	NA	0.43	8.37	0.36	6.83e-16	Life satisfaction;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg26187166	chr20:56884786	RAB22A;PPP4R1L	-0.4	-6.77	-0.3	3.89e-11	Brain structure;
LGG	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg13902645	chr11:5959945	NA	0.61	10.46	0.44	4.01e-23	DNA methylation (variation);
LGG	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg26384229	chr12:38710491	ALG10B	0.48	8.81	0.38	2.54e-17	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg15212455	chr7:39170539	POU6F2	0.51	11.99	0.49	4.93e-29	IgG glycosylation;
LGG	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.95	-0.57	1.55e-41	Hair morphology;
LGG	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg10818794	chr15:86012489	AKAP13	-0.54	-12.08	-0.49	2.25e-29	Coronary artery disease;
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg06719900	chr11:109292894	C11orf87	0.44	8.33	0.36	9.32e-16	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.01	0.46	3.34e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs497273	0.534	rs9431	chr12:121202664	A/C	cg02419362	chr12:121203948	SPPL3	0.5	8.64	0.37	8.95e-17	Systemic lupus erythematosus;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.78	-0.41	1.16e-20	Systolic blood pressure;
LGG	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-11.56	-0.47	2.56e-27	Parkinson's disease;
LGG	cis	rs6963495	0.818	rs55794529	chr7:105165747	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs877282	0.945	rs10904550	chr10:774177	C/T	cg17470449	chr10:769945	NA	0.63	8.1	0.35	4.91e-15	Uric acid levels;
LGG	cis	rs539514	0.690	rs607095	chr13:76316165	A/T	cg04757411	chr13:76259545	LMO7	-0.27	-6.92	-0.31	1.51e-11	Type 1 diabetes;
LGG	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg07959490	chr17:80112427	CCDC57	-0.37	-7.17	-0.32	3.05e-12	Life satisfaction;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.21	0.43	3.31e-22	Tonsillectomy;
LGG	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg15704280	chr7:45808275	SEPT13	-1.04	-23.12	-0.73	3.56e-79	Height;
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.9	-0.31	1.71e-11	Vitiligo;
LGG	trans	rs2055729	0.961	rs9918834	chr8:9790551	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-6.99	-0.31	9.39e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg06521331	chr12:34319734	NA	0.41	6.93	0.31	1.46e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00567749	chr5:82767908	VCAN	-0.46	-6.82	-0.3	2.89e-11	Systemic lupus erythematosus;
LGG	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg07936489	chr17:37558343	FBXL20	-0.77	-10.88	-0.45	1.02e-24	Glomerular filtration rate (creatinine);
LGG	cis	rs11628318	0.515	rs10144272	chr14:103086289	T/G	cg12046867	chr14:103022105	NA	-0.4	-7.56	-0.33	2.2e-13	Platelet count;
LGG	cis	rs4704187	0.687	rs9763362	chr5:74406316	T/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs17453880	0.853	rs60025184	chr5:151965130	G/A	cg10931792	chr5:152022470	NA	0.38	8.29	0.36	1.25e-15	Subjective well-being;
LGG	trans	rs4427176	0.507	rs7462115	chr8:9578675	C/T	cg16141378	chr3:129829833	LOC729375	0.34	6.76	0.3	4.07e-11	Mosquito bite size;
LGG	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg15841412	chr13:111365552	ING1	0.43	6.82	0.3	2.82e-11	Coronary artery disease;
LGG	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg16662043	chr16:48846231	NA	0.37	7.31	0.32	1.17e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.4	0.36	5.55e-16	Schizophrenia;
LGG	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs9828933	0.882	rs3816156	chr3:63999712	A/T	cg17941049	chr3:63904683	ATXN7	0.67	8.33	0.36	9.28e-16	Type 2 diabetes;
LGG	cis	rs73198271	0.562	rs964772	chr8:8651306	A/G	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01341218	chr17:43662625	NA	-0.67	-12.06	-0.49	2.51e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg15112475	chr7:1198522	ZFAND2A	-0.38	-6.78	-0.3	3.62e-11	Longevity;Endometriosis;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.72	0.34	7.02e-14	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18093693	chr15:72668265	HEXA;C15orf34	0.5	7.99	0.35	1.11e-14	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.18	0.32	2.83e-12	Longevity;
LGG	cis	rs7166081	0.950	rs8043060	chr15:67661784	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.25	-0.32	1.81e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg12395012	chr8:11607386	GATA4	-0.39	-7.31	-0.32	1.19e-12	Neuroticism;
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg27400746	chr16:89904261	SPIRE2	-1.09	-16.53	-0.61	1.41e-48	Skin colour saturation;
LGG	cis	rs138491296	1	rs138491296	chr17:27961561	GATTATT/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-12.11	-0.49	1.56e-29	White blood cell count;
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg16141378	chr3:129829833	LOC729375	0.46	11.11	0.46	1.42e-25	Retinal vascular caliber;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg12436631	chr1:155007014	DCST1;DCST2	-0.4	-8.12	-0.35	4.14e-15	Prostate cancer;
LGG	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15664640	chr17:80829946	TBCD	-0.8	-15.74	-0.59	5.18e-45	Breast cancer;
LGG	cis	rs10895140	0.609	rs10219398	chr11:101431740	G/A	cg23650423	chr11:101454676	TRPC6	0.43	6.68	0.3	6.86e-11	Menarche (age at onset);
LGG	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg14088196	chr11:70211408	PPFIA1	0.81	10.84	0.45	1.52e-24	Coronary artery disease;
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs7633770	0.735	rs12491294	chr3:46688498	G/T	cg11219411	chr3:46661640	NA	-0.54	-12.25	-0.49	4.61e-30	Coronary artery disease;
LGG	cis	rs701145	0.585	rs1629659	chr3:153798731	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg03929089	chr4:120376271	NA	-0.84	-13.41	-0.53	7.38e-35	Coronary artery disease;
LGG	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg05444541	chr17:17804740	TOM1L2	-0.67	-14.93	-0.57	1.94e-41	Total body bone mineral density;
LGG	cis	rs9356171	0.540	rs2207441	chr6:164325217	G/A	cg25752492	chr6:164341247	NA	-0.47	-9.27	-0.4	7.14e-19	Diisocyanate-induced asthma;
LGG	cis	rs12190007	0.547	rs2981944	chr6:169801753	T/G	cg15038512	chr6:170123185	PHF10	-0.44	-8.54	-0.37	2.01e-16	Obesity-related traits;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22878388	chr2:105853796	NA	-0.46	-8.39	-0.36	5.81e-16	Type 2 diabetes;
LGG	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg25008857	chr14:105974488	NA	0.58	9.6	0.41	5.08e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.81	0.34	3.96e-14	Schizophrenia;
LGG	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg00078996	chr12:132293329	NA	-0.34	-7.0	-0.31	8.8e-12	Migraine;
LGG	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg08754478	chr10:133766260	PPP2R2D	0.62	11.65	0.48	1.11e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.48	9.05	0.39	3.85e-18	Longevity;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg05793240	chr7:2802953	GNA12	0.36	8.2	0.36	2.43e-15	Height;
LGG	cis	rs7572733	0.555	rs6434953	chr2:198929693	A/G	cg00792783	chr2:198669748	PLCL1	0.6	9.5	0.4	1.14e-19	Dermatomyositis;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08280861	chr8:58055591	NA	0.61	7.47	0.33	4.16e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9463078	0.809	rs10948195	chr6:44957965	T/C	cg25276700	chr6:44698697	NA	-0.38	-7.85	-0.34	2.89e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4538187	0.853	rs2439183	chr2:64287632	C/T	cg02541582	chr2:64069798	UGP2	-0.62	-13.77	-0.54	2.02e-36	Systolic blood pressure;
LGG	cis	rs6912958	0.728	rs6923230	chr6:88213949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.8e-16	Monocyte percentage of white cells;
LGG	cis	rs2413583	0.591	rs117385880	chr22:39721299	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.69	7.78	0.34	4.66e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs372883	0.530	rs2832302	chr21:30749793	G/T	cg24692254	chr21:30365293	RNF160	-0.58	-10.42	-0.44	5.41e-23	Pancreatic cancer;
LGG	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21659725	chr3:3221576	CRBN	-0.61	-10.13	-0.43	6.26e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6909430	1.000	rs10223664	chr6:98677699	G/A	cg12860156	chr6:98744658	NA	-0.45	-7.53	-0.33	2.64e-13	Quantitative traits;
LGG	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg15133208	chr4:90757351	SNCA	-0.31	-7.02	-0.31	8e-12	Dementia with Lewy bodies;
LGG	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.5	0.65	1.25e-57	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg18721089	chr20:30220636	NA	-0.53	-7.77	-0.34	5.27e-14	Mean corpuscular hemoglobin;
LGG	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg22681709	chr2:178499509	PDE11A	-0.39	-7.56	-0.33	2.11e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7666738	0.830	rs62321569	chr4:98984250	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.44	-0.4	1.8e-19	Educational attainment;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg19853927	chr3:153839743	SGEF	0.4	6.85	0.3	2.36e-11	Bipolar disorder;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg24690094	chr11:67383802	NA	0.43	8.01	0.35	9.55e-15	Mean corpuscular volume;
LGG	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg24829409	chr8:58192753	C8orf71	-0.73	-9.62	-0.41	4.37e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg11878867	chr6:150167359	LRP11	-0.54	-11.07	-0.46	2.04e-25	Lung cancer;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	4.95e-12	Prudent dietary pattern;
LGG	cis	rs847851	1.000	rs847859	chr6:34937472	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-6.76	-0.3	4.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4849975	0.510	rs13432750	chr2:3708503	G/A	cg17046650	chr2:3699563	NA	0.68	9.49	0.4	1.21e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3806843	0.966	rs10036519	chr5:140151701	C/T	cg19875535	chr5:140030758	IK	-0.51	-10.53	-0.44	2.14e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	3.9e-11	Cognitive function;
LGG	cis	rs36051895	0.530	rs4142064	chr9:5221818	C/T	cg02405213	chr9:5042618	JAK2	-0.69	-12.55	-0.5	2.63e-31	Pediatric autoimmune diseases;
LGG	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg07460842	chr6:66804631	NA	-0.62	-10.93	-0.45	6.94e-25	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs12571093	0.773	rs10762197	chr10:70009255	A/G	cg06988349	chr10:69991859	ATOH7	-0.35	-6.66	-0.3	7.74e-11	Optic nerve measurement (disc area);
LGG	cis	rs9733	0.621	rs12746899	chr1:150579678	A/T	cg13175981	chr1:150552382	MCL1	0.59	10.23	0.43	2.75e-22	Tonsillectomy;
LGG	trans	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.5	-9.5	-0.4	1.13e-19	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1568889	0.838	rs12273631	chr11:28042135	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.5	0.67	2.81e-62	Bipolar disorder;
LGG	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg24101359	chr6:42928495	GNMT	0.54	15.2	0.58	1.32e-42	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05025164	chr4:1340916	KIAA1530	0.88	16.74	0.61	1.59e-49	Longevity;
LGG	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	10.99	0.45	4.11e-25	Blood metabolite levels;
LGG	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-10.01	-0.42	1.68e-21	Common traits (Other);
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg18032289	chr17:61959525	GH2	-0.4	-6.88	-0.3	1.97e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg11764359	chr7:65958608	NA	0.63	9.87	0.42	5.39e-21	Aortic root size;
LGG	cis	rs9902453	0.904	rs11654983	chr17:28370042	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg17545662	chr6:170176663	C6orf70	0.66	8.68	0.37	6.64e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs7444	0.825	rs5994638	chr22:21953276	A/G	cg22858872	chr22:21984481	YDJC	-0.35	-6.8	-0.3	3.27e-11	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00166722	chr3:10149974	C3orf24	0.52	8.58	0.37	1.4e-16	Alzheimer's disease;
LGG	cis	rs7666738	0.747	rs2865955	chr4:99040518	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg08999081	chr20:33150536	PIGU	0.31	7.05	0.31	6.53e-12	Coronary artery disease;
LGG	cis	rs2114646	0.672	rs4614899	chr2:170639019	C/T	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.23e-11	Obesity-related traits;
LGG	cis	rs4664308	0.618	rs17830755	chr2:160888835	T/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.66	-0.48	9.84e-28	Idiopathic membranous nephropathy;
LGG	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg03342759	chr3:160939853	NMD3	-0.54	-9.18	-0.39	1.43e-18	Educational attainment (years of education);
LGG	trans	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg19894588	chr14:64061835	NA	-0.59	-9.28	-0.4	6.34e-19	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20745568	chr17:40321545	KCNH4	0.4	7.06	0.31	6.29e-12	Pancreatic cancer;
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs11168351	1.000	rs11168351	chr12:48403765	C/T	cg24011408	chr12:48396354	COL2A1	0.61	10.53	0.44	2.21e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg15684481	chr3:111698265	ABHD10	-0.42	-6.66	-0.3	7.99e-11	Educational attainment (years of education);
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.32e-11	Lung cancer;
LGG	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg10847948	chr11:71163743	NADSYN1	0.59	8.63	0.37	9.63e-17	Vitamin D levels;
LGG	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.42	-0.33	5.54e-13	Triglycerides;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.29	-0.5	3.03e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3762637	0.882	rs56074178	chr3:122180011	C/G	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.43	-7.9	-0.34	2.04e-14	Schizophrenia;
LGG	trans	rs62458065	0.640	rs10271491	chr7:32530665	C/A	cg00845942	chr12:64062724	DPY19L2	-0.6	-7.65	-0.33	1.19e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs7582720	0.945	rs72932720	chr2:203646934	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.35	0.4	3.9e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00873521	chr9:95056130	IARS;SNORA84	0.5	7.55	0.33	2.36e-13	Gut microbiome composition (summer);
LGG	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.32	-0.47	2.16e-26	Lung cancer;
LGG	trans	rs2048656	0.561	rs12544371	chr8:9542071	T/G	cg16141378	chr3:129829833	LOC729375	0.32	6.85	0.3	2.35e-11	Schizophrenia;
LGG	cis	rs8064024	0.870	rs6500635	chr16:4867565	A/G	cg04440724	chr16:4920505	UBN1	-0.47	-10.17	-0.43	4.77e-22	Cancer;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg15921436	chr17:44337874	NA	0.6	12.92	0.51	8.01e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01423820	chr14:77228690	VASH1	-0.42	-6.87	-0.3	2.06e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg03929089	chr4:120376271	NA	0.44	7.26	0.32	1.62e-12	HDL cholesterol;
LGG	cis	rs2016266	0.855	rs1056692	chr12:53687387	A/G	cg04065151	chr12:53682969	ESPL1	0.63	10.09	0.42	9e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg26396452	chr14:65542826	MAX	0.55	11.84	0.48	1.99e-28	Obesity-related traits;
LGG	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.14	-0.35	3.81e-15	Coronary artery disease;
LGG	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.49	0.47	4.55e-27	Bone mineral density;
LGG	cis	rs17092148	0.945	rs6087622	chr20:33310471	A/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs9324022	0.790	rs56349439	chr14:101168739	G/A	cg18089426	chr14:101175970	NA	0.71	10.91	0.45	8.06e-25	Plateletcrit;
LGG	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.82e-22	Diabetic retinopathy;
LGG	cis	rs7432375	0.579	rs10935199	chr3:136563535	G/C	cg21827317	chr3:136751795	NA	0.53	9.24	0.39	9.2e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7215564	0.730	rs9901550	chr17:78584464	T/C	cg16980736	chr17:78789706	RPTOR	-0.53	-7.07	-0.31	5.72e-12	Myopia (pathological);
LGG	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg02975922	chr3:195473998	MUC4	-0.54	-8.98	-0.39	6.82e-18	Pancreatic cancer;
LGG	trans	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg06521331	chr12:34319734	NA	-0.52	-9.08	-0.39	3.18e-18	Bladder cancer;
LGG	trans	rs9467711	0.591	rs6903228	chr6:25903047	A/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.02	-0.31	7.79e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9906944	0.585	rs11650936	chr17:47072261	C/G	cg09029085	chr17:47094198	IGF2BP1	-0.25	-6.7	-0.3	6.17e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.38e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs57994353	0.508	rs7874956	chr9:139336813	T/G	cg14019695	chr9:139328340	INPP5E	0.4	7.09	0.31	4.98e-12	Eosinophil counts;Cutaneous squamous cell carcinoma;
LGG	cis	rs2253017	0.767	rs4770070	chr13:21330776	G/A	cg04906043	chr13:21280425	IL17D	-0.5	-7.94	-0.35	1.52e-14	PR segment;
LGG	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg14019146	chr3:50243930	SLC38A3	0.31	6.77	0.3	4.03e-11	Body mass index;
LGG	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs9815354	0.762	rs794899	chr3:42028722	T/C	cg03022575	chr3:42003672	ULK4	-0.61	-7.52	-0.33	2.77e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-8.96	-0.38	8.08e-18	Menarche (age at onset);
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.03	-0.39	4.74e-18	Obesity-related traits;
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg19357499	chr8:144660631	NAPRT1	0.89	6.91	0.31	1.6e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg05793240	chr7:2802953	GNA12	0.34	8.64	0.37	9.01e-17	Height;
LGG	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.79	0.3	3.51e-11	Parkinson's disease;
LGG	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg01403660	chr11:68851641	TPCN2	0.53	7.36	0.32	8.49e-13	Blond vs. brown hair color;
LGG	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06108461	chr20:60628389	TAF4	0.85	14.21	0.55	2.84e-38	Body mass index;
LGG	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg12654349	chr5:56205094	C5orf35	0.57	9.82	0.42	8.6e-21	Initial pursuit acceleration;
LGG	cis	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs79839061	0.610	rs11731387	chr4:851357	C/T	cg07828340	chr4:882639	GAK	0.83	8.94	0.38	9.09e-18	Intelligence (multi-trait analysis);
LGG	cis	rs3849046	0.817	rs2304057	chr5:137897174	C/T	cg10920316	chr5:137946599	NA	0.43	6.99	0.31	9.45e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9534288	0.742	rs1977395	chr13:46638131	C/T	cg15192986	chr13:46630673	CPB2	-0.72	-15.32	-0.58	3.78e-43	Blood protein levels;
LGG	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg16482183	chr6:26056742	HIST1H1C	0.58	9.24	0.39	8.71e-19	Iron status biomarkers;
LGG	cis	rs3741151	0.773	rs7945825	chr11:73287140	G/C	cg17517138	chr11:73019481	ARHGEF17	0.84	8.02	0.35	8.93e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg00166722	chr3:10149974	C3orf24	0.53	8.88	0.38	1.47e-17	Alzheimer's disease;
LGG	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	cg15522984	chr1:182991683	LAMC1	0.44	8.88	0.38	1.51e-17	Colorectal cancer;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg26668828	chr6:292823	DUSP22	-0.51	-9.07	-0.39	3.5e-18	Menopause (age at onset);
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.39	7.56	0.33	2.24e-13	Schizophrenia;
LGG	trans	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.78	-0.38	3.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17102423	0.559	rs4899160	chr14:65481212	C/T	cg11161011	chr14:65562177	MAX	-0.76	-12.3	-0.5	2.9e-30	Obesity-related traits;
LGG	cis	rs2901460	0.509	rs11125898	chr2:62079895	T/C	cg02183531	chr2:62113199	CCT4	-0.46	-8.09	-0.35	5.42e-15	Mean corpuscular volume;
LGG	cis	rs55871839	0.684	rs10108037	chr8:59812337	A/C	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs6728642	1.000	rs7593754	chr2:97607544	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-7.07	-0.31	5.6e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg23306229	chr2:178417860	TTC30B	0.71	8.6	0.37	1.24e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17683430	0.681	rs12157575	chr22:32543338	T/C	cg00543991	chr22:32367038	NA	0.51	6.91	0.31	1.66e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs10193935	0.901	rs10196091	chr2:42541591	T/C	cg27598129	chr2:42591480	NA	-0.64	-9.6	-0.41	5.19e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9880211	1.000	rs9828976	chr3:136536835	C/G	cg21827317	chr3:136751795	NA	-0.5	-7.35	-0.32	9.28e-13	Body mass index;Height;
LGG	cis	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg15145296	chr3:125709740	NA	-0.6	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs4660214	0.666	rs625384	chr1:39893093	C/T	cg18385671	chr1:39797026	MACF1	0.47	9.56	0.41	6.89e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg25214090	chr10:38739885	LOC399744	0.68	11.92	0.48	9.31e-29	Corneal astigmatism;
LGG	cis	rs36093844	0.800	rs79276445	chr11:85587827	G/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg13699009	chr12:122356056	WDR66	0.56	14.93	0.57	1.94e-41	Mean corpuscular volume;
LGG	cis	rs17209837	1.000	rs59934297	chr7:87116469	T/G	cg00919237	chr7:87102261	ABCB4	-0.74	-12.08	-0.49	2.19e-29	Gallbladder cancer;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.65	-0.33	1.18e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs42648	0.633	rs11563909	chr7:89935704	A/G	cg25739043	chr7:89950458	NA	-0.36	-7.4	-0.33	6.56e-13	Homocysteine levels;
LGG	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	Neuroticism;
LGG	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg25208724	chr1:156163844	SLC25A44	1.09	19.12	0.66	1.63e-60	Testicular germ cell tumor;
LGG	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg21775007	chr8:11205619	TDH	0.41	6.75	0.3	4.39e-11	Mood instability;
LGG	cis	rs7394190	0.630	rs78845904	chr10:75517249	C/A	cg07699608	chr10:75541558	CHCHD1	0.54	7.05	0.31	6.43e-12	Incident atrial fibrillation;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.79	-12.65	-0.51	1.04e-31	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-9.26	-0.4	7.52e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	6.97	0.31	1.12e-11	Schizophrenia;
LGG	cis	rs4740619	0.967	rs7036172	chr9:15653593	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.86	-0.45	1.29e-24	Body mass index;
LGG	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.26e-22	Dupuytren's disease;
LGG	cis	rs1003719	0.715	rs2835658	chr21:38565201	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.3	-0.58	4.4e-43	Eye color traits;
LGG	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg13073564	chr4:8508604	NA	-0.6	-11.74	-0.48	5.09e-28	Response to antineoplastic agents;
LGG	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	13.04	0.52	2.52e-33	Total body bone mineral density;
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg14403583	chr14:105418241	AHNAK2	-0.76	-15.37	-0.58	2.15e-43	Rheumatoid arthritis;
LGG	cis	rs4788570	0.615	rs4788822	chr16:71681515	A/G	cg06353428	chr16:71660113	MARVELD3	1.25	20.87	0.7	1.11e-68	Intelligence (multi-trait analysis);
LGG	cis	rs2249694	0.960	rs4556495	chr10:135422209	C/T	cg20169779	chr10:135381914	SYCE1	-0.51	-7.86	-0.34	2.69e-14	Obesity-related traits;
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg01145232	chr6:150245071	RAET1G	0.4	7.39	0.32	6.97e-13	Lung cancer;
LGG	cis	rs6704644	0.656	rs11681704	chr2:234338402	G/A	cg27060346	chr2:234359958	DGKD	-0.6	-7.45	-0.33	4.52e-13	Bilirubin levels;
LGG	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs4380275	1.000	rs6548253	chr2:773655	A/G	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg00717180	chr2:96193071	NA	0.41	7.41	0.33	6.03e-13	HDL cholesterol;
LGG	cis	rs963731	0.649	rs4670905	chr2:39266134	A/T	cg04010122	chr2:39346883	SOS1	-0.83	-7.22	-0.32	2.17e-12	Corticobasal degeneration;
LGG	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.85	-0.54	9.74e-37	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg09699651	chr6:150184138	LRP11	0.47	8.3	0.36	1.15e-15	Lung cancer;
LGG	trans	rs970548	0.779	rs752059	chr10:45942423	A/T	cg20477318	chr10:51623047	TIMM23	0.62	7.41	0.33	5.99e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs9929218	0.551	rs2274240	chr16:68725486	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.09	28.26	0.8	7.68e-103	Colorectal cancer;
LGG	cis	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg13789015	chr9:136890014	NCRNA00094	0.47	7.04	0.31	6.81e-12	Mosquito bite size;
LGG	cis	rs7267979	0.714	rs1555329	chr20:25231858	G/A	cg08601574	chr20:25228251	PYGB	0.39	7.9	0.34	2.08e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20134190	chr8:99129593	POP1;HRSP12	0.49	7.59	0.33	1.74e-13	Gut microbiome composition (summer);
LGG	cis	rs7192750	0.586	rs8050651	chr16:71881444	C/G	cg06353428	chr16:71660113	MARVELD3	0.66	10.63	0.44	9.27e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs8064029	1.000	rs1610232	chr16:4914516	A/G	cg04440724	chr16:4920505	UBN1	-0.64	-7.83	-0.34	3.24e-14	Cancer;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg12708336	chr17:41446283	NA	0.31	7.38	0.32	7.56e-13	Menopause (age at onset);
LGG	cis	rs6141769	0.569	rs6058799	chr20:31257732	A/G	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.23	-0.32	2.03e-12	Subjective well-being;
LGG	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-8.99	-0.39	6.53e-18	Blood metabolite levels;
LGG	cis	rs9583531	0.891	rs9521911	chr13:111370615	A/G	cg24331049	chr13:111365604	ING1	-0.85	-11.91	-0.48	9.84e-29	Coronary artery disease;
LGG	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-13.07	-0.52	1.86e-33	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg19223190	chr17:80058835	NA	0.44	8.56	0.37	1.62e-16	Life satisfaction;
LGG	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg27205649	chr11:78285834	NARS2	0.5	8.52	0.37	2.33e-16	Alzheimer's disease (survival time);
LGG	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg03576123	chr11:487126	PTDSS2	-1.21	-14.81	-0.57	6.4e-41	Body mass index;
LGG	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.73	-0.41	1.79e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs131777	0.508	rs140518	chr22:50999182	C/T	cg25309564	chr22:51001381	C22orf41	0.74	12.5	0.5	4.43e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg12463550	chr7:65579703	CRCP	0.81	9.03	0.39	4.51e-18	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25225968	chr3:8543159	LMCD1	0.5	7.73	0.34	6.54e-14	Gut microbiome composition (summer);
LGG	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg20578329	chr17:80767326	TBCD	-0.47	-8.18	-0.36	2.84e-15	Breast cancer;
LGG	cis	rs4740619	0.905	rs10756690	chr9:15683562	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.95	-0.42	2.9e-21	Body mass index;
LGG	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.9	15.22	0.58	1.05e-42	Gut microbiome composition (summer);
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.05	-0.42	1.23e-21	Total body bone mineral density;
LGG	cis	rs9443645	0.527	rs12196485	chr6:79556871	A/G	cg18132916	chr6:79620363	NA	-0.26	-7.0	-0.31	9.24e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs11971779	0.680	rs4732370	chr7:139077240	A/C	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.04	-0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg20503657	chr10:835505	NA	0.75	10.48	0.44	3.28e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg07414643	chr4:187882934	NA	0.56	11.49	0.47	4.74e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg12591125	chr7:1885375	MAD1L1	0.45	6.97	0.31	1.08e-11	Bipolar disorder;
LGG	cis	rs2066819	1.000	rs75598973	chr12:56746558	C/T	cg26714650	chr12:56694279	CS	-1.58	-15.38	-0.58	1.95e-43	Psoriasis vulgaris;
LGG	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.76	-0.48	3.97e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.67	-11.63	-0.48	1.32e-27	Longevity;Endometriosis;
LGG	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg04731861	chr2:219085781	ARPC2	0.45	11.04	0.46	2.55e-25	Colorectal cancer;
LGG	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg25986240	chr4:9926439	SLC2A9	-0.71	-15.95	-0.6	5.89e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs17433780	0.666	rs2624	chr1:89518623	C/T	cg09516651	chr1:89888402	LOC400759	-0.71	-17.71	-0.64	5.52e-54	Carotid intima media thickness;
LGG	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg08079166	chr15:68083412	MAP2K5	0.36	8.1	0.35	4.89e-15	Restless legs syndrome;
LGG	cis	rs2455601	0.882	rs11042106	chr11:8896083	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.7	11.72	0.48	6.07e-28	Schizophrenia;
LGG	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg18942110	chr15:91072797	CRTC3	-0.29	-6.66	-0.3	8e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.49	-0.4	1.19e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4077515	0.967	rs4567159	chr9:139277059	G/A	cg21253087	chr9:139290292	SNAPC4	0.36	7.25	0.32	1.73e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7173743	0.935	rs12232282	chr15:79136525	T/C	cg00540400	chr15:79124168	NA	-0.43	-8.68	-0.37	6.73e-17	Coronary artery disease;
LGG	cis	rs7944584	0.632	rs11606683	chr11:47302733	C/T	cg20307385	chr11:47447363	PSMC3	0.63	12.11	0.49	1.59e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.09	0.68	5.23e-65	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg07701084	chr6:150067640	NUP43	0.49	7.38	0.32	7.62e-13	Lung cancer;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05306587	chr14:20881602	TEP1	-0.37	-6.67	-0.3	7.13e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7091068	0.706	rs1147644	chr10:95400947	A/G	cg20715218	chr10:95462985	C10orf4	-0.55	-7.67	-0.34	1.02e-13	Urinary tract infection frequency;
LGG	cis	rs7785730	0.600	rs62449882	chr7:28076343	T/C	cg17702455	chr7:28058989	JAZF1	-0.43	-7.64	-0.33	1.28e-13	Free thyroxine concentration;
LGG	cis	rs7773004	0.905	rs3778279	chr6:26325463	T/C	cg13736514	chr6:26305472	NA	-0.41	-8.36	-0.36	7.45e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs2070677	0.799	rs11101854	chr10:135394430	G/A	cg20169779	chr10:135381914	SYCE1	-0.99	-12.64	-0.51	1.15e-31	Gout;
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.1	-0.43	8.08e-22	Electroencephalogram traits;
LGG	cis	rs7089973	0.872	rs17092497	chr10:116612628	G/A	cg08188268	chr10:116634841	FAM160B1	0.35	7.73	0.34	6.74e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.75	-0.38	4.09e-17	Cognitive function;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.94	14.08	0.55	9.75e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.5	-0.4	1.09e-19	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11003645	chr6:143382007	AIG1	0.6	6.68	0.3	6.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg02725872	chr8:58115012	NA	-0.78	-11.14	-0.46	1.1e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9457247	1.000	rs436707	chr6:167388843	T/C	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs36051895	0.659	rs1575285	chr9:5267440	A/G	cg02405213	chr9:5042618	JAK2	-0.71	-11.76	-0.48	4.09e-28	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7927771	0.689	rs10734557	chr11:47380061	A/C	cg20307385	chr11:47447363	PSMC3	0.55	9.96	0.42	2.7e-21	Subjective well-being;
LGG	cis	rs10214930	0.697	rs4719898	chr7:27563661	G/A	cg22168087	chr7:27702803	HIBADH	0.45	6.7	0.3	6.14e-11	Hypospadias;
LGG	cis	rs7267979	0.816	rs374701	chr20:25483616	A/G	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.69e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27144592	chr16:783916	NARFL	0.42	7.0	0.31	8.83e-12	Height;
LGG	cis	rs17767392	0.958	rs61989377	chr14:71957362	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.24e-18	Mitral valve prolapse;
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg00405596	chr8:11794950	NA	0.45	7.68	0.34	9.47e-14	Mood instability;
LGG	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg04362960	chr10:104952993	NT5C2	0.48	8.05	0.35	7.05e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg19507638	chr5:93509721	C5orf36	-0.69	-9.56	-0.41	6.95e-20	Diabetic retinopathy;
LGG	cis	rs12493885	0.585	rs787812	chr3:153622217	A/G	cg17054900	chr3:154042577	DHX36	0.54	6.72	0.3	5.36e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg07382826	chr16:28625726	SULT1A1	0.42	8.88	0.38	1.51e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.52	7.58	0.33	1.94e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6668534	0.679	rs10753610	chr1:161663823	C/G	cg01550473	chr1:161493932	HSPA6	0.53	7.26	0.32	1.66e-12	Blood protein levels;
LGG	cis	rs74781061	0.858	rs12592493	chr15:74759340	T/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.27	-0.32	1.56e-12	Endometriosis;
LGG	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg03433033	chr1:76189801	ACADM	0.64	9.45	0.4	1.7e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg05368731	chr17:41323189	NBR1	0.95	18.88	0.66	2.12e-59	Menopause (age at onset);
LGG	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.91	0.48	1.07e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg04398451	chr17:18023971	MYO15A	0.74	15.69	0.59	8.74e-45	Schizophrenia;
LGG	trans	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05926928	chr17:57297772	GDPD1	0.56	9.24	0.39	9.17e-19	Schizophrenia;
LGG	cis	rs4731207	0.596	rs1404898	chr7:124694339	G/T	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.87e-12	Cutaneous malignant melanoma;
LGG	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg06191203	chr2:152266755	RIF1	0.43	7.52	0.33	2.87e-13	Lung cancer;
LGG	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.72	8.67	0.37	7.33e-17	Yeast infection;
LGG	cis	rs1707322	0.721	rs56255771	chr1:46224319	C/T	cg03146154	chr1:46216737	IPP	0.58	10.91	0.45	8.36e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11987759	chr7:65425863	GUSB	-0.4	-7.93	-0.35	1.63e-14	Aortic root size;
LGG	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.32	-0.7	8.66e-71	Monocyte count;
LGG	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg15212455	chr7:39170539	POU6F2	0.37	8.02	0.35	9.02e-15	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	8.84e-19	Life satisfaction;
LGG	cis	rs9583531	0.689	rs1061386	chr13:111373368	G/C	cg24331049	chr13:111365604	ING1	0.8	13.7	0.54	4.27e-36	Coronary artery disease;
LGG	cis	rs12681287	0.511	rs7839601	chr8:87503839	G/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs926938	0.608	rs360612	chr1:115394747	G/A	cg12756093	chr1:115239321	AMPD1	0.48	9.21	0.39	1.1e-18	Autism;
LGG	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg16077055	chr2:106428750	NCK2	0.33	8.75	0.38	3.99e-17	Addiction;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	9.98	0.42	2.31e-21	Schizophrenia;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg19147804	chr7:1989927	MAD1L1	0.54	11.24	0.46	4.28e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg18850127	chr7:39170497	POU6F2	0.55	12.35	0.5	1.75e-30	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg18681998	chr4:17616180	MED28	-0.71	-14.14	-0.55	5.64e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg12654349	chr5:56205094	C5orf35	0.57	9.94	0.42	3.15e-21	Initial pursuit acceleration;
LGG	cis	rs9397585	0.759	rs6920313	chr6:153402841	T/C	cg17707550	chr6:153380415	RGS17	0.41	8.49	0.37	2.77e-16	Body mass index;
LGG	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.11	0.52	1.23e-33	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-12.57	-0.5	2.22e-31	Morning vs. evening chronotype;
LGG	cis	rs78905543	0.555	rs11135693	chr8:22925154	A/C	cg13462030	chr8:22926911	TNFRSF10B	-0.42	-7.13	-0.31	3.79e-12	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24664689	chr8:11058690	XKR6	0.4	6.65	0.3	8.37e-11	Gut microbiome composition (summer);
LGG	cis	rs4727027	0.866	rs3927307	chr7:148774869	C/T	cg23583168	chr7:148888333	NA	-0.82	-15.54	-0.59	3.87e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.83	0.34	3.24e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.533	rs4932342	chr15:90982923	C/T	cg22089800	chr15:90895588	ZNF774	0.69	12.63	0.51	1.2e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs11700980	0.551	rs12481819	chr21:30113901	G/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs67478160	0.608	rs4906368	chr14:104242397	A/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.33	-0.32	1.05e-12	Schizophrenia;
LGG	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.22	0.52	4.41e-34	Mean platelet volume;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.1	-0.35	4.94e-15	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg03517284	chr6:25882590	NA	-0.7	-13.41	-0.53	7.4e-35	Intelligence (multi-trait analysis);
LGG	cis	rs4356932	1.000	rs6828596	chr4:76961373	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg19182353	chr11:118479428	PHLDB1	0.56	11.91	0.48	1.03e-28	Cholesterol, total;
LGG	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg17376030	chr22:41985996	PMM1	-0.55	-9.08	-0.39	3.08e-18	Cannabis dependence symptom count;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.61	-10.93	-0.45	6.83e-25	Lymphocyte counts;
LGG	cis	rs1009647	1.000	rs1009647	chr14:55880047	G/A	cg04306507	chr14:55594613	LGALS3	0.43	8.46	0.37	3.47e-16	Testicular germ cell tumor;
LGG	cis	rs9912468	1.000	rs9909004	chr17:64306133	C/T	cg19474267	chr17:64306194	PRKCA	-0.96	-28.09	-0.79	4.66e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.36	0.32	8.18e-13	Homoarginine levels;
LGG	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg14993813	chr1:46806288	NSUN4	-0.47	-6.71	-0.3	5.56e-11	Menopause (age at onset);
LGG	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg02836325	chr17:76403955	PGS1	-0.72	-14.5	-0.56	1.46e-39	HDL cholesterol levels;
LGG	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg21665744	chr7:39171113	POU6F2	0.43	8.77	0.38	3.38e-17	IgG glycosylation;
LGG	cis	rs2221894	0.506	rs77261575	chr8:28894579	C/T	cg07962641	chr8:28805897	HMBOX1	-0.55	-8.01	-0.35	9.39e-15	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg05863683	chr7:1912471	MAD1L1	0.49	9.4	0.4	2.6e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg16507663	chr6:150244633	RAET1G	0.43	7.75	0.34	5.79e-14	Lung cancer;
LGG	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg00071950	chr4:10020882	SLC2A9	0.43	8.84	0.38	2.05e-17	Bone mineral density;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.14	-0.46	1.04e-25	Lung cancer;
LGG	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg05194412	chr2:137003533	NA	0.37	8.09	0.35	5.33e-15	Colorectal cancer;
LGG	cis	rs2916247	0.954	rs10808644	chr8:93127873	C/T	cg10183463	chr8:93005414	RUNX1T1	0.36	7.55	0.33	2.36e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg26578617	chr4:90757533	SNCA	-0.47	-9.53	-0.4	8.91e-20	Dementia with Lewy bodies;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23924007	chr4:140099401	NA	-0.41	-6.73	-0.3	4.88e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11792861	0.591	rs11791855	chr9:111684139	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	11.42	0.47	8.95e-27	Menarche (age at onset);
LGG	cis	rs6912958	0.781	rs9450712	chr6:88193175	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.5	-0.37	2.57e-16	Monocyte percentage of white cells;
LGG	cis	rs17253792	0.822	rs17685078	chr14:56127202	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.62	-0.37	1.05e-16	Systolic blood pressure;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg04156016	chr5:1868137	NA	0.32	6.78	0.3	3.71e-11	Cardiovascular disease risk factors;
LGG	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg02975922	chr3:195473998	MUC4	-0.54	-8.8	-0.38	2.75e-17	Pancreatic cancer;
LGG	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg07930552	chr6:133119739	C6orf192	0.88	12.01	0.49	4.01e-29	Type 2 diabetes nephropathy;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.06	-0.42	1.13e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs12643440	0.538	rs981886	chr4:17136883	T/C	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg17545662	chr6:170176663	C6orf70	0.68	8.58	0.37	1.49e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg02269571	chr22:50332266	NA	-0.75	-10.95	-0.45	5.57e-25	Schizophrenia;
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.77	0.38	3.49e-17	Eosinophil percentage of white cells;
LGG	cis	rs362296	0.597	rs3129320	chr4:3265130	G/C	cg06533319	chr4:3265114	C4orf44	0.55	12.17	0.49	9.03e-30	Parental longevity (mother's age at death);
LGG	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg19748678	chr4:122722346	EXOSC9	0.51	9.63	0.41	4.09e-20	Type 2 diabetes;
LGG	cis	rs1691799	0.899	rs1168325	chr12:66728234	C/G	cg16791601	chr12:66731901	HELB	-0.65	-15.38	-0.58	2.04e-43	White blood cell count (basophil);
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.39	-0.32	6.76e-13	Life satisfaction;
LGG	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg05985134	chr18:33552581	C18orf21	0.64	9.85	0.42	6.34e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs11989744	0.500	rs7844903	chr8:23568464	T/C	cg03492747	chr16:86543808	FOXF1	-0.59	-10.79	-0.45	2.22e-24	Waist-hip ratio;
LGG	cis	rs11696845	0.626	rs4810439	chr20:43377870	C/G	cg25301532	chr20:43378953	KCNK15	-0.49	-12.42	-0.5	9.34e-31	Obesity-related traits;
LGG	cis	rs7851660	0.809	rs7036589	chr9:100657720	A/T	cg13688889	chr9:100608707	NA	0.63	12.64	0.51	1.12e-31	Strep throat;
LGG	cis	rs7617773	0.817	rs3729577	chr3:48228994	A/C	cg11946769	chr3:48343235	NME6	0.68	11.09	0.46	1.72e-25	Coronary artery disease;
LGG	cis	rs4926611	0.830	rs1879735	chr1:54055693	A/G	cg23596471	chr1:54105337	GLIS1	-0.39	-8.38	-0.36	6.25e-16	Hand grip strength;
LGG	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg04989706	chr14:50066350	PPIL5	-0.53	-8.31	-0.36	1.04e-15	Carotid intima media thickness;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.67e-11	Testicular germ cell tumor;
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	9.87	0.42	5.37e-21	Neuroticism;
LGG	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg21399703	chr1:247681439	NA	-0.66	-11.91	-0.48	1e-28	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.21	-0.43	3.34e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg11965913	chr1:205819406	PM20D1	0.6	11.22	0.46	5.37e-26	Menarche (age at onset);
LGG	cis	rs2797369	0.600	rs596601	chr6:101380020	A/C	cg27451362	chr6:101846650	GRIK2	-0.74	-9.97	-0.42	2.42e-21	Renal function-related traits (eGRFcrea);
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg11965913	chr1:205819406	PM20D1	0.78	16.38	0.61	6.51e-48	Menarche (age at onset);
LGG	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg11871910	chr12:69753446	YEATS4	1.05	28.86	0.8	1.55e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg05335186	chr13:53173507	NA	0.48	10.25	0.43	2.3e-22	Lewy body disease;
LGG	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg13647721	chr17:30228624	UTP6	0.63	7.97	0.35	1.26e-14	Hip circumference adjusted for BMI;
LGG	cis	rs920590	0.500	rs7819535	chr8:19689058	A/G	cg03894339	chr8:19674705	INTS10	1.07	15.01	0.57	8.92e-42	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs701145	0.585	rs1727946	chr3:153826470	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg03605463	chr16:89740564	NA	0.41	7.01	0.31	8.49e-12	Vitiligo;
LGG	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.71	0.3	5.67e-11	Bladder cancer;
LGG	cis	rs926392	0.589	rs2019032	chr20:37680326	C/A	cg16355469	chr20:37678765	NA	0.63	10.15	0.43	5.42e-22	Dialysis-related mortality;
LGG	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg16751781	chr15:78858589	CHRNA5	-0.39	-7.36	-0.32	8.51e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2236293	0.724	rs11791889	chr9:35860942	G/A	cg12876594	chr9:35791798	NPR2	0.41	7.82	0.34	3.57e-14	Blood protein levels;
LGG	cis	rs514406	0.861	rs7518390	chr1:53233374	A/G	cg24675658	chr1:53192096	ZYG11B	0.47	9.06	0.39	3.63e-18	Monocyte count;
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg10295955	chr4:187884368	NA	-0.96	-20.67	-0.69	9.66e-68	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9398803	0.865	rs4565329	chr6:126752798	A/G	cg19875578	chr6:126661172	C6orf173	-0.56	-10.18	-0.43	4.35e-22	Male-pattern baldness;
LGG	cis	rs12210905	0.841	rs12206996	chr6:27066415	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.07	0.57	4.63e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg08470875	chr2:26401718	FAM59B	-0.37	-6.84	-0.3	2.45e-11	Gut microbiome composition (summer);
LGG	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	6.88	0.3	2e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14761175	chr22:17898020	NA	0.37	6.72	0.3	5.31e-11	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs9640161	0.742	rs2108854	chr7:150017408	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.74	15.55	0.59	3.48e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg26446133	chr18:72167187	CNDP2	-0.7	-14.21	-0.55	2.79e-38	Refractive error;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg08648136	chr8:956695	NA	0.36	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs4466137	0.953	rs974023	chr5:83014848	T/C	cg16102102	chr5:83017553	HAPLN1	-0.6	-11.01	-0.46	3.22e-25	Prostate cancer;
LGG	cis	rs12291225	0.883	rs1864658	chr11:14256444	C/T	cg19336497	chr11:14380999	RRAS2	0.45	8.55	0.37	1.8e-16	Sense of smell;
LGG	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg12654349	chr5:56205094	C5orf35	0.38	6.8	0.3	3.2e-11	Coronary artery disease;
LGG	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.98	-0.42	2.18e-21	Body mass index;
LGG	cis	rs6840360	0.554	rs4643789	chr4:152726691	C/T	cg22705602	chr4:152727874	NA	-0.38	-9.16	-0.39	1.69e-18	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.88	-0.38	1.43e-17	Bladder cancer;
LGG	cis	rs75229567	0.717	rs77874289	chr12:70234203	A/G	cg10114359	chr12:70132523	RAB3IP	1.21	10.38	0.43	7.57e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs10911457	0.701	rs4328036	chr1:183895178	C/T	cg18131582	chr1:183912305	GLT25D2	0.26	6.65	0.3	8.44e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7914558	1.000	rs7094843	chr10:104806654	A/C	cg04362960	chr10:104952993	NT5C2	0.55	10.78	0.45	2.54e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1348850	0.872	rs7559521	chr2:178452328	A/G	cg27490568	chr2:178487706	NA	-0.48	-9.28	-0.4	6.45e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg23167307	chr17:36981148	CCDC49	0.53	7.85	0.34	2.96e-14	Apolipoprotein A-IV levels;
LGG	cis	rs3771570	0.901	rs62190407	chr2:242405772	G/A	cg21155796	chr2:242212141	HDLBP	0.6	8.22	0.36	2.07e-15	Prostate cancer;
LGG	cis	rs3812049	0.784	rs6889311	chr5:127431285	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.23	0.43	2.84e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs7975161	0.630	rs7138317	chr12:104650271	G/A	cg25273343	chr12:104657179	TXNRD1	-0.75	-7.34	-0.32	9.4e-13	Toenail selenium levels;
LGG	cis	rs3849570	1.000	rs4411908	chr3:81802418	A/C	cg07356753	chr3:81810745	GBE1	-0.41	-7.04	-0.31	6.88e-12	Waist circumference;Body mass index;
LGG	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg18876405	chr7:65276391	NA	0.52	9.13	0.39	2.1e-18	Aortic root size;
LGG	cis	rs8064024	0.901	rs930855	chr16:4864179	A/G	cg04440724	chr16:4920505	UBN1	-0.47	-10.27	-0.43	2.04e-22	Cancer;
LGG	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs4919694	1.000	rs111622998	chr10:104953021	C/A	cg04362960	chr10:104952993	NT5C2	1.05	14.48	0.56	1.88e-39	Arsenic metabolism;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.79	-0.41	1.08e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs6960043	0.738	rs6461153	chr7:15059796	G/C	cg19272540	chr7:15055459	NA	-0.38	-8.32	-0.36	9.96e-16	Type 2 diabetes;
LGG	cis	rs911263	0.603	rs1956525	chr14:68799859	G/A	cg18825221	chr14:68749962	RAD51L1	0.35	7.66	0.34	1.13e-13	Primary biliary cholangitis;
LGG	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.44	0.71	2.55e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2302729	0.545	rs10161275	chr12:2771018	A/G	cg19945202	chr12:2788847	CACNA1C	-0.64	-10.27	-0.43	1.98e-22	Sleep quality;
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	13.29	0.53	2.33e-34	Total body bone mineral density;
LGG	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg23601095	chr6:26197514	HIST1H3D	0.68	8.66	0.37	8.1e-17	Gout;Renal underexcretion gout;
LGG	cis	rs2070488	0.804	rs35463537	chr3:38498248	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.71	0.56	1.75e-40	Electrocardiographic conduction measures;
LGG	cis	rs4942783	0.647	rs9590972	chr13:31583488	A/G	cg22761482	chr13:31579400	NA	-0.43	-8.05	-0.35	7.04e-15	Subjective well-being;
LGG	cis	rs6918586	0.658	rs198856	chr6:26102708	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.62	-0.41	4.37e-20	Schizophrenia;
LGG	cis	rs4509693	0.782	rs7897782	chr10:102495856	C/A	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.22e-11	Alzheimer's disease;
LGG	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs4604732	0.527	rs77361748	chr1:247626475	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg10295955	chr4:187884368	NA	-1.15	-31.3	-0.82	2.5e-116	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.72	-0.51	5.46e-32	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11896211	chr11:820192	PNPLA2	0.48	7.14	0.31	3.59e-12	Gut microbiome composition (summer);
LGG	cis	rs922107	0.935	rs1077539	chr1:90013144	T/G	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.56	-0.33	2.13e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs13082711	0.911	rs73050094	chr3:27519552	T/A	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.24e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4740619	0.716	rs10962146	chr9:15767899	T/A	cg14451791	chr9:16040625	NA	0.33	8.57	0.37	1.61e-16	Body mass index;
LGG	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.76	-0.34	5.59e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2050392	0.624	rs303447	chr10:30728464	T/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.33	-0.5	2.07e-30	Inflammatory bowel disease;
LGG	trans	rs1829883	0.776	rs2511923	chr5:98721641	C/T	cg08333243	chr5:99726346	NA	0.35	6.92	0.31	1.55e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.63	0.63	1.33e-53	Cognitive function;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.82	0.34	3.54e-14	Lung cancer;
LGG	cis	rs9460578	0.563	rs10806923	chr6:20790477	C/T	cg13405222	chr6:20811065	CDKAL1	0.62	11.27	0.46	3.36e-26	Breast cancer;
LGG	cis	rs9796	0.866	rs516156	chr15:41381257	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.06	-0.39	3.65e-18	Menopause (age at onset);
LGG	cis	rs11644362	0.966	rs4781348	chr16:12986742	A/C	cg08528231	chr16:12997261	SHISA9	-0.36	-7.29	-0.32	1.34e-12	Positive affect;Subjective well-being;
LGG	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.63	7.57	0.33	1.99e-13	Schizophrenia;
LGG	cis	rs4926298	1.000	rs10423745	chr19:13176815	T/C	cg04657146	chr19:12876947	HOOK2	-0.41	-6.88	-0.3	1.96e-11	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.63	0.37	9.7e-17	Lung cancer;
LGG	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg13010199	chr12:38710504	ALG10B	0.54	10.39	0.43	6.9e-23	Bladder cancer;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.32	-6.67	-0.3	7.16e-11	Monocyte percentage of white cells;
LGG	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg11764359	chr7:65958608	NA	-0.8	-14.91	-0.57	2.47e-41	Aortic root size;
LGG	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04492929	chr16:2155436	PKD1	-0.57	-11.66	-0.48	9.64e-28	Triglycerides;
LGG	cis	rs6764363	0.527	rs13072907	chr3:279924	G/A	cg02057681	chr3:285234	CHL1	-0.43	-7.65	-0.33	1.21e-13	Sudden cardiac arrest;
LGG	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-7.08	-0.31	5.51e-12	Vitiligo;
LGG	cis	rs2247341	0.965	rs11248074	chr4:1743754	C/T	cg07465881	chr4:1713556	SLBP	-0.44	-6.92	-0.31	1.49e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.7	-0.3	5.96e-11	Coronary artery disease;
LGG	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg25174290	chr11:3078921	CARS	0.75	16.36	0.61	8.43e-48	Longevity;
LGG	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg07541023	chr7:19748670	TWISTNB	-0.56	-7.88	-0.34	2.34e-14	Thyroid stimulating hormone;
LGG	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.52	-0.5	3.58e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg09307838	chr4:120376055	NA	0.73	12.27	0.5	3.63e-30	Corneal astigmatism;
LGG	cis	rs8060686	0.565	rs8044328	chr16:68146859	G/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.05	-0.31	6.37e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg25427524	chr10:38739819	LOC399744	-0.45	-7.05	-0.31	6.67e-12	Obesity (extreme);
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg19223190	chr17:80058835	NA	-0.44	-8.46	-0.37	3.56e-16	Life satisfaction;
LGG	trans	rs75804782	0.581	rs3191996	chr2:239344412	A/G	cg01134436	chr17:81009848	B3GNTL1	-0.81	-8.74	-0.38	4.34e-17	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs3960554	0.740	rs10216079	chr7:75690988	A/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.46	0.5	6.43e-31	Eotaxin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15254786	chr2:207630414	MDH1B;FASTKD2	0.46	7.25	0.32	1.79e-12	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg18551225	chr6:44695536	NA	-0.61	-10.05	-0.42	1.29e-21	Total body bone mineral density;
LGG	cis	rs4237845	0.742	rs3751330	chr12:58290226	T/C	cg02175503	chr12:58329896	NA	0.67	12.55	0.5	2.72e-31	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.54	-0.37	1.97e-16	Personality dimensions;
LGG	cis	rs12731740	1.000	rs2724392	chr1:208010077	T/C	cg22525895	chr1:207977042	MIR29B2	-0.57	-6.69	-0.3	6.61e-11	Biomedical quantitative traits;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.81	0.34	3.78e-14	Longevity;
LGG	cis	rs16912285	0.688	rs12805482	chr11:24346955	C/A	ch.11.24196551F	chr11:24239977	NA	0.92	12.69	0.51	7.24e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	8.97e-12	Lung cancer;
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.19	-0.43	3.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.07	-0.31	5.74e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25072359	chr17:41440525	NA	0.52	9.87	0.42	5.38e-21	Menopause (age at onset);
LGG	cis	rs283228	0.876	rs512464	chr6:101733360	C/T	cg27451362	chr6:101846650	GRIK2	0.59	8.97	0.38	7.29e-18	Coenzyme Q10 levels;
LGG	cis	rs7444	0.941	rs5749493	chr22:21939687	C/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.88	-0.51	1.19e-32	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09925621	chr16:84178555	HSDL1;LRRC50	-0.48	-7.69	-0.34	9.18e-14	Pancreatic cancer;
LGG	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.24	-0.32	1.92e-12	Schizophrenia;
LGG	cis	rs10949834	0.504	rs77541100	chr7:73555605	C/T	cg07137043	chr7:73588983	EIF4H	-0.56	-8.34	-0.36	8.65e-16	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg12373951	chr3:133503437	NA	0.4	7.19	0.32	2.64e-12	Iron status biomarkers;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg02462569	chr6:150064036	NUP43	-0.39	-8.14	-0.35	3.81e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06617136	chr1:145470297	ANKRD34A;POLR3GL	0.54	8.65	0.37	8.5e-17	Gut microbiome composition (summer);
LGG	cis	rs757278	0.591	rs10266116	chr7:117304459	T/C	cg10524701	chr7:117356490	CTTNBP2	0.42	7.53	0.33	2.72e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02886208	chr11:14281011	SPON1	-0.47	-9.76	-0.41	1.38e-20	Mitochondrial DNA levels;
LGG	cis	rs34172651	0.917	rs12599173	chr16:24823619	T/C	cg02428538	chr16:24856791	SLC5A11	-0.42	-7.05	-0.31	6.49e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg22676075	chr6:135203613	NA	0.4	6.96	0.31	1.16e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs2652834	0.808	rs28583444	chr15:63357852	T/G	cg05507819	chr15:63340323	TPM1	0.6	8.04	0.35	7.46e-15	HDL cholesterol;
LGG	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.7	-0.3	6.23e-11	Aortic root size;
LGG	cis	rs13102973	0.835	rs4280795	chr4:135857246	T/A	cg14419869	chr4:135874104	NA	0.57	10.85	0.45	1.35e-24	Subjective well-being;
LGG	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.23	-0.43	2.76e-22	Aortic root size;
LGG	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg15268244	chr15:77196840	NA	0.32	7.15	0.32	3.42e-12	Blood metabolite levels;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg05861140	chr6:150128134	PCMT1	-0.31	-7.14	-0.32	3.56e-12	Lung cancer;
LGG	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs7614311	0.731	rs6445387	chr3:63962678	C/G	cg22134162	chr3:63841271	THOC7	-0.4	-7.61	-0.33	1.59e-13	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.53	-0.37	2.07e-16	Joint mobility (Beighton score);
LGG	trans	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg17712092	chr4:129076599	LARP1B	-0.76	-14.84	-0.57	4.74e-41	Eosinophil percentage of white cells;
LGG	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg23939001	chr4:940644	TMEM175	0.56	10.21	0.43	3.42e-22	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg12751644	chr20:60527061	NA	-0.32	-7.22	-0.32	2.11e-12	Body mass index;
LGG	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg00006032	chr14:66974439	GPHN	0.59	6.67	0.3	7.32e-11	Kashin-Beck disease;
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg14456004	chr13:21872349	NA	1.37	24.71	0.75	1.42e-86	White matter hyperintensity burden;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg14773178	chr5:1868261	NA	0.35	7.68	0.34	9.6e-14	Cardiovascular disease risk factors;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.41	-0.53	7.22e-35	Alzheimer's disease;
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.47	9.27	0.4	7.01e-19	Prostate cancer;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.22	0.32	2.1e-12	Longevity;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg11141652	chr22:24348549	GSTTP1	0.44	7.55	0.33	2.31e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs139371	0.742	rs139336	chr22:39505393	T/C	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.71	-0.3	5.55e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17058777	chr11:71814579	LRTOMT;C11orf59	0.41	7.06	0.31	6.22e-12	Bipolar disorder;
LGG	trans	rs28573326	0.629	rs1438119	chr4:166348346	T/C	cg13437084	chr2:26467494	HADHB;HADHA	-0.69	-9.62	-0.41	4.16e-20	Pelvic organ prolapse (moderate/severe);
LGG	cis	rs8179	0.645	rs10264916	chr7:92286376	A/G	cg15732164	chr7:92237376	CDK6	-0.54	-10.34	-0.43	1.11e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7916410	0.512	rs1900003	chr10:70004551	A/C	cg18338521	chr10:69995036	NA	-0.33	-7.17	-0.32	3.05e-12	Optic disc area;
LGG	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg06637938	chr14:75390232	RPS6KL1	0.47	8.21	0.36	2.25e-15	Height;
LGG	cis	rs17767392	0.881	rs8017775	chr14:72029436	A/G	cg13720639	chr14:72061746	SIPA1L1	0.37	8.09	0.35	5.22e-15	Mitral valve prolapse;
LGG	cis	rs9543976	1.000	rs73223984	chr13:76181141	G/A	cg01531495	chr13:76123901	UCHL3	-0.68	-7.87	-0.34	2.45e-14	Diabetic retinopathy;
LGG	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg10621924	chr7:39171070	POU6F2	0.45	9.1	0.39	2.6e-18	IgG glycosylation;
LGG	cis	rs62400317	0.821	rs12202232	chr6:45208345	G/A	cg20913747	chr6:44695427	NA	-0.63	-10.26	-0.43	2.11e-22	Total body bone mineral density;
LGG	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg02175503	chr12:58329896	NA	0.54	8.89	0.38	1.32e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6445975	0.688	rs2271633	chr3:58260073	A/G	cg24175188	chr3:58374923	PXK	0.39	7.29	0.32	1.31e-12	Systemic lupus erythematosus;
LGG	cis	rs17321999	1.000	rs13386455	chr2:30480865	A/G	cg05247661	chr2:30472410	LBH	0.55	9.02	0.39	5.19e-18	Systemic lupus erythematosus;
LGG	cis	rs4684776	1.000	rs13081460	chr3:11534409	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.4	-0.36	5.59e-16	Small vessel stroke;
LGG	cis	rs9811920	0.569	rs793445	chr3:99576644	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-8.96	-0.38	7.83e-18	Axial length;
LGG	cis	rs4363385	0.818	rs678960	chr1:153011621	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs4731207	0.596	rs10081226	chr7:124575529	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs490234	0.683	rs2841326	chr9:128161768	G/A	cg14078157	chr9:128172775	NA	-0.51	-9.48	-0.4	1.37e-19	Mean arterial pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11502736	chr1:179923845	CEP350	0.43	6.69	0.3	6.28e-11	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg16141378	chr3:129829833	LOC729375	0.42	9.46	0.4	1.62e-19	Neuroticism;
LGG	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	10.79	0.45	2.3e-24	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05491587	chr18:77659695	KCNG2	0.39	7.36	0.32	8.24e-13	Schizophrenia;
LGG	cis	rs834603	1.000	rs834603	chr7:47447921	A/G	cg09696706	chr7:47479511	TNS3	0.32	6.79	0.3	3.55e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg24687543	chr11:63912206	MACROD1	0.54	7.71	0.34	7.98e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg24247370	chr13:99142703	STK24	-0.45	-8.18	-0.36	2.82e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg00990874	chr7:1149470	C7orf50	-0.66	-9.99	-0.42	2.1e-21	Bronchopulmonary dysplasia;
LGG	cis	rs7267979	1.000	rs1046073	chr20:25281333	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.92	-0.54	4.95e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs1062753	0.731	rs11090065	chr22:42384171	T/C	cg15128208	chr22:42549153	NA	0.38	6.73	0.3	4.9e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg12552261	chr5:112820674	MCC	-0.78	-13.92	-0.54	4.88e-37	Type 2 diabetes;
LGG	cis	rs10504073	0.584	rs7818507	chr8:49918423	G/T	cg00325661	chr8:49890786	NA	0.8	16.1	0.6	1.21e-46	Blood metabolite ratios;
LGG	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.05	-0.49	2.72e-29	Morning vs. evening chronotype;
LGG	cis	rs10225163	0.590	rs10266923	chr7:27918229	C/T	cg22168087	chr7:27702803	HIBADH	-0.45	-7.64	-0.33	1.3e-13	Gout;
LGG	cis	rs6429082	0.749	rs291362	chr1:235686690	T/A	cg26050004	chr1:235667680	B3GALNT2	0.69	11.93	0.48	8.66e-29	Adiposity;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg12708336	chr17:41446283	NA	-0.32	-7.42	-0.33	5.6e-13	Menopause (age at onset);
LGG	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs2479724	0.905	rs2149274	chr6:41839092	T/C	cg17623882	chr6:41773611	USP49	-0.52	-9.28	-0.4	6.38e-19	Menarche (age at onset);
LGG	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg04851639	chr8:1020857	NA	-0.36	-7.35	-0.32	8.93e-13	Schizophrenia;
LGG	cis	rs3806843	0.966	rs11958868	chr5:140201420	T/C	cg19875535	chr5:140030758	IK	0.5	10.24	0.43	2.66e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4740619	0.661	rs769151	chr9:15947240	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.51	-0.44	2.52e-23	Body mass index;
LGG	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.93	0.38	9.93e-18	Common traits (Other);
LGG	cis	rs7666738	0.830	rs732299	chr4:98995389	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.88	0.34	2.36e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg27147174	chr7:100797783	AP1S1	-0.69	-12.87	-0.51	1.28e-32	Life satisfaction;
LGG	cis	rs774359	0.789	rs868857	chr9:27488906	G/A	cg22262168	chr9:27528999	MOBKL2B	0.44	6.76	0.3	4.23e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg05863683	chr7:1912471	MAD1L1	0.48	9.23	0.39	9.45e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs34172651	0.917	rs11074651	chr16:24778409	A/G	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.48	-0.33	3.88e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	1.000	rs12220238	chr10:75952670	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	10.96	0.45	5.05e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9992101	0.680	rs4266316	chr4:77319743	C/T	cg17010112	chr4:77227123	STBD1	-0.46	-9.4	-0.4	2.56e-19	Creatinine levels;
LGG	cis	rs2304069	0.659	rs216141	chr5:149443994	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.48	-7.57	-0.33	2.06e-13	HIV-1 control;
LGG	trans	rs61931739	0.613	rs6488174	chr12:33756569	T/C	cg26384229	chr12:38710491	ALG10B	0.47	8.38	0.36	6.63e-16	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg15971980	chr6:150254442	NA	0.45	8.25	0.36	1.66e-15	Lung cancer;
LGG	cis	rs721917	0.569	rs2247820	chr10:81722879	C/G	cg25562619	chr10:81652821	NA	-0.31	-6.84	-0.3	2.47e-11	Chronic obstructive pulmonary disease;
LGG	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg00717180	chr2:96193071	NA	-0.5	-9.53	-0.4	8.95e-20	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs1851853	chr11:49953434	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs1044826	0.642	rs4607068	chr3:139162994	A/G	cg15131784	chr3:139108705	COPB2	0.43	7.05	0.31	6.58e-12	Obesity-related traits;
LGG	cis	rs9814567	0.806	rs11927540	chr3:134319455	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg27572855	chr1:25598939	RHD	-0.49	-10.88	-0.45	1.08e-24	Erythrocyte sedimentation rate;
LGG	cis	rs2299587	0.582	rs7844023	chr8:17909471	C/T	cg18067069	chr8:17937731	ASAH1	-0.33	-7.95	-0.35	1.46e-14	Economic and political preferences;
LGG	cis	rs8014204	0.781	rs10143492	chr14:75212114	G/C	cg06637938	chr14:75390232	RPS6KL1	0.63	11.26	0.46	3.65e-26	Caffeine consumption;
LGG	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.08	-0.42	9.44e-22	Retinal vascular caliber;
LGG	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.05	0.31	6.7e-12	Aortic root size;
LGG	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg24231037	chr15:68117551	LBXCOR1	0.33	7.52	0.33	2.81e-13	Motion sickness;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg15212455	chr7:39170539	POU6F2	0.51	12.02	0.49	3.73e-29	IgG glycosylation;
LGG	cis	rs9487094	0.677	rs13203636	chr6:110062288	G/C	cg16315928	chr6:109776240	MICAL1	0.48	7.37	0.32	7.72e-13	Height;
LGG	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg05082376	chr22:42548792	NA	-0.4	-8.38	-0.36	6.23e-16	Schizophrenia;
LGG	cis	rs9457247	0.624	rs17524252	chr6:167466978	T/G	cg07741184	chr6:167504864	NA	0.44	10.07	0.42	1.03e-21	Crohn's disease;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.21e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7523273	0.925	rs10863593	chr1:208018074	C/T	cg22525895	chr1:207977042	MIR29B2	0.58	10.36	0.43	8.97e-23	Schizophrenia;
LGG	cis	rs13088645	0.532	rs12695613	chr3:134166572	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	8.0	0.35	1.02e-14	Coronary artery disease;
LGG	cis	rs896854	0.654	rs4735339	chr8:95974373	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs981844	0.848	rs72731652	chr4:154641123	A/T	cg14289246	chr4:154710475	SFRP2	0.68	10.89	0.45	9.51e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07648498	chr16:89883185	FANCA	0.39	6.8	0.3	3.24e-11	Vitiligo;
LGG	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg27147174	chr7:100797783	AP1S1	-0.7	-13.33	-0.53	1.47e-34	Life satisfaction;
LGG	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg13232821	chr7:50628718	DDC	-0.37	-7.29	-0.32	1.33e-12	Malaria;
LGG	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg17108064	chr15:78857060	CHRNA5	0.45	9.55	0.41	7.73e-20	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.28	0.36	1.37e-15	Lung cancer;
LGG	cis	rs6456042	1.000	rs4709098	chr6:166534145	G/A	cg11088901	chr6:166572345	T	-0.35	-7.28	-0.32	1.44e-12	Asthma;
LGG	cis	rs72772090	0.710	rs17400741	chr5:96066576	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.52	-8.01	-0.35	9.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.46	0.33	4.31e-13	HDL cholesterol;
LGG	cis	rs10089	0.552	rs1351141	chr5:127550055	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.54	-8.18	-0.36	2.67e-15	Ileal carcinoids;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08219700	chr8:58056026	NA	0.45	6.91	0.31	1.62e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs721399	0.924	rs1961456	chr8:18255709	A/G	cg18736775	chr8:18248649	NAT2	-0.48	-8.23	-0.36	1.89e-15	Blood metabolite levels;
LGG	trans	rs617791	0.530	rs735942	chr11:65749337	A/G	cg17712092	chr4:129076599	LARP1B	-0.58	-9.64	-0.41	3.67e-20	Breast cancer;
LGG	cis	rs7737355	1.000	rs12719444	chr5:130607378	C/T	cg06307176	chr5:131281290	NA	0.5	8.43	0.36	4.57e-16	Life satisfaction;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.23e-15	Rheumatoid arthritis;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-8.19	-0.36	2.59e-15	Lung cancer;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07659893	chr17:61819838	STRADA	0.49	8.16	0.35	3.17e-15	Prudent dietary pattern;
LGG	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg05784532	chr1:230284198	GALNT2	0.54	8.01	0.35	9.36e-15	Coronary artery disease;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.79	0.41	1.04e-20	Longevity;
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.79e-15	HDL cholesterol;
LGG	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg10167378	chr1:228756711	NA	0.52	8.92	0.38	1.09e-17	Chronic lymphocytic leukemia;
LGG	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg24812749	chr6:127587940	RNF146	0.82	13.66	0.54	6.51e-36	Breast cancer;
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.85	-0.3	2.4e-11	Menopause (age at onset);
LGG	cis	rs5742933	0.857	rs7571089	chr2:190561793	G/A	cg10453823	chr2:190539512	ANKAR	-0.46	-6.72	-0.3	5.4e-11	Ferritin levels;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.61e-12	Life satisfaction;
LGG	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg26384229	chr12:38710491	ALG10B	0.63	12.19	0.49	8.1e-30	Morning vs. evening chronotype;
LGG	cis	rs4481887	0.741	rs11488135	chr1:248568961	G/A	cg01631408	chr1:248437212	OR2T33	-0.4	-7.12	-0.31	4.26e-12	Common traits (Other);
LGG	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg23815491	chr16:72088622	HP	0.53	11.74	0.48	4.66e-28	Fibrinogen levels;
LGG	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg00531865	chr16:30841666	NA	-0.56	-11.37	-0.47	1.37e-26	Multiple myeloma;
LGG	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg06623918	chr6:96969491	KIAA0776	0.72	10.66	0.44	7.08e-24	Migraine;Coronary artery disease;
LGG	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.53	-0.4	9.2e-20	Educational attainment (years of education);
LGG	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg06027949	chr8:82754900	SNX16	0.55	8.58	0.37	1.42e-16	Diastolic blood pressure;
LGG	cis	rs2354432	0.607	rs12404113	chr1:146750343	C/A	cg25205988	chr1:146714368	CHD1L	-1.47	-15.13	-0.58	2.57e-42	Mitochondrial DNA levels;
LGG	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03264133	chr6:25882463	NA	-0.58	-11.08	-0.46	1.77e-25	Blood metabolite levels;
LGG	cis	rs17102423	0.623	rs2898862	chr14:65612144	G/A	cg11161011	chr14:65562177	MAX	-0.66	-12.06	-0.49	2.47e-29	Obesity-related traits;
LGG	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg11764359	chr7:65958608	NA	-0.55	-9.45	-0.4	1.74e-19	Aortic root size;
LGG	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.08	-0.39	3.12e-18	Triglycerides;
LGG	cis	rs6993813	0.678	rs4416847	chr8:120009258	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.84	0.34	3.04e-14	Bone mineral density (hip);
LGG	cis	rs60695258	1.000	rs60695258	chr4:88022709	C/T	cg11209507	chr4:87813803	C4orf36	0.42	6.73	0.3	5.09e-11	Hematocrit;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7666738	0.962	rs2865950	chr4:99040061	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.77	0.3	3.82e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22455342	chr2:225449267	CUL3	-0.87	-15.54	-0.59	3.86e-44	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs2018683	0.683	rs12538606	chr7:28969408	T/C	cg19402173	chr7:128379420	CALU	-0.53	-9.21	-0.39	1.14e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9815354	0.597	rs60690674	chr3:41997811	G/C	cg03022575	chr3:42003672	ULK4	0.78	9.11	0.39	2.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2201728	0.702	rs35235194	chr4:100176832	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg01620082	chr3:125678407	NA	-0.7	-6.9	-0.31	1.77e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.55	0.41	7.87e-20	Menarche (age at onset);
LGG	cis	rs9467160	0.644	rs3846833	chr6:24462367	C/T	cg20631270	chr6:24437470	GPLD1	0.55	7.82	0.34	3.63e-14	Liver enzyme levels;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg08621203	chr6:150244597	RAET1G	0.45	7.52	0.33	2.86e-13	Lung cancer;
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03452623	chr4:187889614	NA	-1.04	-29.79	-0.81	1.04e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg21211680	chr2:198530	NA	-1.22	-18.94	-0.66	1.17e-59	Blood protein levels;
LGG	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7084402	0.565	rs7912792	chr10:60335179	C/T	cg07615347	chr10:60278583	BICC1	0.5	12.37	0.5	1.5e-30	Refractive error;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.29	0.6	1.65e-47	Platelet count;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg03073431	chr7:44887862	H2AFV	0.38	6.71	0.3	5.78e-11	Eye color traits;
LGG	cis	rs972578	0.765	rs713717	chr22:43396109	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.19	-0.32	2.61e-12	Mean platelet volume;
LGG	trans	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg18335740	chr13:41363409	SLC25A15	0.65	12.84	0.51	1.63e-32	Lewy body disease;
LGG	cis	rs4460629	0.742	rs6427158	chr1:155074903	G/T	cg13808842	chr1:155066096	NA	-0.29	-6.9	-0.31	1.7e-11	Serum magnesium levels;
LGG	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.24	0.43	2.54e-22	Lung cancer in ever smokers;
LGG	cis	rs12681288	0.823	rs2701905	chr8:1003482	T/C	cg04851639	chr8:1020857	NA	-0.42	-9.2	-0.39	1.21e-18	Schizophrenia;
LGG	cis	rs4918072	0.755	rs35168839	chr10:105706259	G/T	cg11005552	chr10:105648138	OBFC1	0.43	7.07	0.31	5.69e-12	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.36	-0.63	2.33e-52	Skin colour saturation;
LGG	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg21545522	chr1:205238299	TMCC2	0.37	7.19	0.32	2.68e-12	Red blood cell count;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.92	0.31	1.53e-11	Lung cancer;
LGG	cis	rs4356932	0.967	rs6837830	chr4:76980179	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg23654821	chr3:39188656	CSRNP1	0.27	6.96	0.31	1.17e-11	Verbal declarative memory;
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.67	0.34	9.99e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg13147721	chr7:65941812	NA	-0.81	-9.61	-0.41	4.53e-20	Diabetic kidney disease;
LGG	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.35	0.43	1.02e-22	Iron status biomarkers;
LGG	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg00717180	chr2:96193071	NA	0.42	7.55	0.33	2.39e-13	HDL cholesterol;
LGG	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs115118317	chr4:119736613	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs7808935	0.768	rs757137	chr7:27989343	T/C	cg22168087	chr7:27702803	HIBADH	0.61	9.88	0.42	5.11e-21	Prostate cancer;
LGG	trans	rs2018683	0.649	rs221171	chr7:29006139	C/G	cg19402173	chr7:128379420	CALU	0.63	10.28	0.43	1.79e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg09237302	chr4:906077	GAK	-0.46	-7.84	-0.34	3.21e-14	Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	17.12	0.62	2.87e-51	Personality dimensions;
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.19	-0.32	2.56e-12	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg09264619	chr17:80180166	NA	-0.39	-7.44	-0.33	4.84e-13	Life satisfaction;
LGG	trans	rs75804782	0.521	rs60779166	chr2:239433943	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.45	0.37	3.82e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10089	1.000	rs4836368	chr5:127486330	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.78	0.48	3.23e-28	Ileal carcinoids;
LGG	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.6	-0.33	1.65e-13	IgG glycosylation;
LGG	cis	rs28595532	0.545	rs17516526	chr4:119259199	C/G	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs11792861	0.816	rs28361186	chr9:111704064	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	10.11	0.43	7.62e-22	Menarche (age at onset);
LGG	cis	rs758324	0.891	rs652839	chr5:131281106	G/C	cg06307176	chr5:131281290	NA	-0.56	-9.29	-0.4	5.82e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg19774624	chr17:42201019	HDAC5	-0.92	-19.37	-0.67	1.2e-61	Total body bone mineral density;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00149659	chr3:10157352	C3orf10	0.82	10.46	0.44	3.84e-23	Alzheimer's disease;
LGG	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg21435375	chr2:172878103	MAP1D	-0.3	-6.69	-0.3	6.38e-11	Schizophrenia;
LGG	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07570687	chr10:102243282	WNT8B	0.43	7.33	0.32	1.06e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg16400903	chr5:693638	TPPP	0.45	6.87	0.3	2.05e-11	Obesity-related traits;
LGG	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs7666738	0.830	rs6832209	chr4:98994120	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.88	0.34	2.37e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4944092	1.000	rs7125695	chr11:75908131	A/G	cg04588336	chr11:75916460	WNT11	0.41	9.35	0.4	3.89e-19	PR interval;
LGG	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	9.59	0.41	5.37e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12367572	0.930	rs10880695	chr12:45233261	T/C	cg04608330	chr12:45269318	NELL2	-0.61	-10.8	-0.45	2.13e-24	Gut microbiome composition (summer);
LGG	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg04181038	chr4:183730758	NA	0.53	7.21	0.32	2.33e-12	Pediatric autoimmune diseases;
LGG	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg20503657	chr10:835505	NA	0.56	7.43	0.33	5.41e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs11677416	1.000	rs7570215	chr2:113527660	G/T	cg27083787	chr2:113543245	IL1A	0.53	8.71	0.38	5.32e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg15049968	chr18:44337910	ST8SIA5	-0.36	-6.7	-0.3	6.04e-11	Personality dimensions;
LGG	cis	rs73086581	0.787	rs67633417	chr20:3868257	C/G	cg02187196	chr20:3869020	PANK2	0.93	13.04	0.52	2.61e-33	Response to antidepressants in depression;
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg20003494	chr4:90757398	SNCA	-0.43	-8.63	-0.37	1.01e-16	Dementia with Lewy bodies;
LGG	cis	rs6840360	1.000	rs12331037	chr4:152663971	G/A	cg22705602	chr4:152727874	NA	-0.27	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg23730037	chr7:158596552	ESYT2	-0.4	-6.83	-0.3	2.68e-11	Height;
LGG	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg24375607	chr4:120327624	NA	0.62	10.4	0.44	6.52e-23	Corneal astigmatism;
LGG	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.5	0.33	3.32e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg19147804	chr7:1989927	MAD1L1	-0.46	-9.17	-0.39	1.51e-18	Schizophrenia;
LGG	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.36	-0.4	3.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4690686	0.500	rs4690431	chr4:177264251	G/A	cg17059388	chr4:177262070	NA	1.03	24.21	0.75	2.86e-84	Essential tremor;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.2	-0.32	2.44e-12	Skin colour saturation;
LGG	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg18825119	chr6:163149453	PACRG;PARK2	-0.46	-7.79	-0.34	4.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg03929089	chr4:120376271	NA	-1.04	-24.47	-0.75	1.77e-85	Height;
LGG	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.53	-0.61	1.4e-48	Total body bone mineral density;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg14092988	chr3:52407081	DNAH1	0.32	8.42	0.36	4.87e-16	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16978263	chr3:160118452	SMC4;IFT80	0.43	6.73	0.3	5.11e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.34e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg10845886	chr2:3471009	TTC15	-0.44	-8.67	-0.37	7.46e-17	Neurofibrillary tangles;
LGG	cis	rs2415984	0.622	rs1761025	chr14:46930439	T/C	cg14871534	chr14:47121158	RPL10L	0.57	10.11	0.43	7.92e-22	Number of children ever born;
LGG	cis	rs228437	0.913	rs1467434	chr6:134925349	C/T	cg24504307	chr6:134963096	NA	0.35	6.87	0.3	2.12e-11	Melanoma;
LGG	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19671926	chr4:122722719	EXOSC9	0.48	7.32	0.32	1.11e-12	Type 2 diabetes;
LGG	trans	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg02002194	chr4:3960332	NA	0.41	7.48	0.33	3.67e-13	Joint mobility (Beighton score);
LGG	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg26818257	chr2:241905806	NA	-0.38	-7.28	-0.32	1.42e-12	Urinary metabolites;
LGG	cis	rs62238980	0.522	rs74748244	chr22:32497724	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1065656	0.553	rs344359	chr16:1838640	T/C	cg00490583	chr16:1843685	IGFALS	0.51	8.84	0.38	2.03e-17	Insulin-like growth factors;
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.8e-18	Dementia with Lewy bodies;
LGG	cis	rs17039065	0.920	rs72889360	chr4:109379840	T/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.0	0.31	9.09e-12	Gut microbiome composition (summer);
LGG	cis	rs782590	0.774	rs782630	chr2:55899425	T/C	cg18811423	chr2:55921094	PNPT1	0.92	22.13	0.72	1.52e-74	Metabolic syndrome;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.67	12.06	0.49	2.57e-29	Obesity-related traits;
LGG	cis	rs11792861	0.888	rs72607168	chr9:111832192	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.48	0.4	1.38e-19	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06154860	chr7:14029085	ETV1	0.53	8.18	0.36	2.68e-15	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2114646	0.731	rs58732945	chr2:170635304	G/A	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg14675211	chr2:100938903	LONRF2	0.48	7.41	0.33	5.86e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17286411	0.814	rs12708918	chr16:71984941	C/G	cg06353428	chr16:71660113	MARVELD3	0.41	7.31	0.32	1.21e-12	Blood protein levels;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg10852096	chr15:79043040	NA	-0.28	-7.75	-0.34	6.07e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs2235649	0.663	rs6600167	chr16:1848912	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.91	-0.31	1.65e-11	Blood metabolite levels;
LGG	cis	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.43	0.33	5.11e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs340849	0.703	rs12130674	chr1:214121995	T/C	cg05052969	chr1:214156842	NA	0.38	6.86	0.3	2.23e-11	Alzheimer's disease;
LGG	cis	rs17641971	0.708	rs1511363	chr8:49901023	C/T	cg00325661	chr8:49890786	NA	0.54	9.7	0.41	2.28e-20	Blood metabolite levels;
LGG	cis	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg02972257	chr16:68554789	NA	-0.55	-8.19	-0.36	2.49e-15	Ulcerative colitis;
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.12	25.27	0.76	3.54e-89	Height;
LGG	cis	rs4660214	0.614	rs1537815	chr1:39744618	A/G	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04798930	chr2:37193060	STRN	0.47	7.65	0.33	1.18e-13	Cognitive performance;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14694896	chr8:104427370	SLC25A32;DCAF13	0.39	6.67	0.3	7.31e-11	Bipolar disorder;
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-10.21	-0.43	3.36e-22	Electroencephalogram traits;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00684032	chr4:1343700	KIAA1530	0.66	13.56	0.53	1.7000000000000001e-35	Obesity-related traits;
LGG	cis	rs1790761	0.967	rs4930427	chr11:67200819	C/T	cg14500267	chr11:67383377	NA	-0.38	-6.94	-0.31	1.34e-11	Mean corpuscular volume;
LGG	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg02002194	chr4:3960332	NA	0.44	8.01	0.35	9.64e-15	Retinal vascular caliber;
LGG	cis	rs4700695	0.668	rs20768	chr5:65484805	C/T	cg21114390	chr5:65439923	SFRS12	-0.68	-9.92	-0.42	3.71e-21	Facial morphology (factor 19);
LGG	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg12615879	chr12:58013172	SLC26A10	0.39	8.93	0.38	1.02e-17	Multiple sclerosis;
LGG	cis	rs10979	1.000	rs9386037	chr6:143891950	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.26	-0.5	3.99e-30	Hypospadias;
LGG	cis	rs7106204	0.513	rs2165784	chr11:24249360	C/A	ch.11.24196551F	chr11:24239977	NA	0.96	15.19	0.58	1.48e-42	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.11	0.46	1.37e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg03162506	chr22:38580953	NA	0.39	9.63	0.41	4.04e-20	Cutaneous nevi;
LGG	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.24e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.33e-12	Obesity-related traits;
LGG	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg11738485	chr19:12877000	HOOK2	0.44	7.06	0.31	6.09e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs8067545	0.586	rs2703770	chr17:20123928	A/G	cg13482628	chr17:19912719	NA	-0.55	-9.82	-0.42	8.46e-21	Schizophrenia;
LGG	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15664640	chr17:80829946	TBCD	-0.8	-15.91	-0.59	9.21e-46	Breast cancer;
LGG	cis	rs17453880	1.000	rs17453880	chr5:151977841	G/A	cg12297329	chr5:152029980	NA	-0.84	-20.1	-0.68	4.36e-65	Subjective well-being;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.04	0.57	6.41e-42	Platelet count;
LGG	cis	rs7572733	0.536	rs6732517	chr2:198912902	G/C	cg00792783	chr2:198669748	PLCL1	0.57	8.85	0.38	1.91e-17	Dermatomyositis;
LGG	trans	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg13565492	chr6:43139072	SRF	-0.79	-10.7	-0.45	4.9e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9462027	0.606	rs4513788	chr6:34694779	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.74	-0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg18240062	chr17:79603768	NPLOC4	0.81	15.31	0.58	4.3e-43	Eye color traits;
LGG	cis	rs1707322	0.691	rs61784803	chr1:46179271	C/A	cg03146154	chr1:46216737	IPP	-0.56	-11.02	-0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4771122	0.500	rs1049302	chr13:27998769	T/C	cg01674679	chr13:27998804	GTF3A	0.72	10.13	0.43	6.71e-22	Body mass index;
LGG	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	12.25	0.49	4.29e-30	Hip circumference adjusted for BMI;
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.3	0.36	1.15e-15	Prostate cancer;
LGG	cis	rs6964587	0.677	rs62467839	chr7:91967371	A/G	cg17063962	chr7:91808500	NA	0.46	7.85	0.34	2.96e-14	Breast cancer;
LGG	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.47	-0.37	3.29e-16	Lung cancer;
LGG	cis	rs6807915	0.647	rs310756	chr3:12277612	C/T	cg15873301	chr3:12045459	SYN2	0.43	7.3	0.32	1.3e-12	Leprosy;
LGG	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.31	0.32	1.19e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.93	0.31	1.37e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg13660082	chr14:53194042	PSMC6	-0.55	-7.51	-0.33	3.13e-13	Alzheimer's disease (late onset);
LGG	cis	rs877282	0.945	rs35342920	chr10:790484	T/C	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs6982240	0.569	rs6992286	chr8:142279412	G/A	cg20799268	chr8:142275649	NA	-0.25	-7.18	-0.32	2.83e-12	Tonsillectomy;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7219021	0.705	rs962273	chr17:46978353	T/C	cg16584676	chr17:46985605	UBE2Z	0.44	7.41	0.33	6.19e-13	Schizophrenia or bipolar disorder;
LGG	cis	rs8064024	0.620	rs8048709	chr16:4913761	A/C	cg08329684	chr16:4932620	PPL	0.52	11.85	0.48	1.77e-28	Cancer;
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg27411982	chr8:10470053	RP1L1	0.4	7.03	0.31	7.41e-12	Systolic blood pressure;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.12	0.6	1.04e-46	Lymphocyte counts;
LGG	cis	rs2071403	0.966	rs11682968	chr2:1412230	C/T	cg06500727	chr2:1417164	TPO	-0.51	-9.65	-0.41	3.44e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs6708331	0.540	rs9679269	chr2:70381828	C/T	cg01613454	chr2:70366299	NA	0.53	10.77	0.45	2.77e-24	Obesity-related traits;
LGG	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.62	-0.37	1.03e-16	Alzheimer's disease (survival time);
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg16724585	chr3:197361211	NA	-0.48	-8.24	-0.36	1.74e-15	Pancreatic cancer;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg13736514	chr6:26305472	NA	-0.45	-9.3	-0.4	5.54e-19	Educational attainment;
LGG	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg13550731	chr2:172543902	DYNC1I2	1.06	27.13	0.78	1.02e-97	Schizophrenia;
LGG	cis	rs7590720	0.731	rs1864253	chr2:216878008	C/G	cg12620499	chr2:216877984	MREG	0.89	19.71	0.68	3.21e-63	Alcohol dependence;
LGG	cis	rs7582720	0.943	rs72934762	chr2:203756677	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.82	-0.3	2.9100000000000002e-11	Alzheimer's disease (survival time);
LGG	cis	rs2451279	0.902	rs2485363	chr6:159506121	T/G	cg01046905	chr6:159515345	NA	0.42	8.13	0.35	3.87e-15	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.76	-0.3	4.09e-11	Neuroticism;
LGG	trans	rs3858145	0.588	rs7081284	chr10:70044792	C/G	cg04882175	chr6:131122610	NA	-0.57	-8.11	-0.35	4.55e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs4363385	0.818	rs532743	chr1:153011758	T/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg03342759	chr3:160939853	NMD3	0.44	7.46	0.33	4.3e-13	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg02297831	chr4:17616191	MED28	-0.47	-8.67	-0.37	7.18e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11626933	1.000	rs3742669	chr14:90767746	C/A	cg14092571	chr14:90743983	NA	0.77	15.99	0.6	3.83e-46	Gut microbiota (bacterial taxa);
LGG	cis	rs7566780	0.541	rs4645016	chr2:16664292	G/A	cg09580478	chr2:16689509	NA	0.43	6.7	0.3	6.06e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs12738007	0.933	rs6426352	chr1:29470843	G/C	cg11747820	chr1:29584023	PTPRU	-0.31	-7.27	-0.32	1.53e-12	Schizophrenia;
LGG	cis	rs9902453	0.726	rs3110494	chr17:27976597	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.14	0.52	1.01e-33	Coffee consumption (cups per day);
LGG	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg25922239	chr6:33757077	LEMD2	0.42	7.32	0.32	1.13e-12	Crohn's disease;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg02018176	chr4:1364513	KIAA1530	0.49	11.88	0.48	1.4e-28	Longevity;
LGG	cis	rs1506636	0.646	rs805778	chr7:123214655	C/T	cg03229431	chr7:123269106	ASB15	-0.55	-12.18	-0.49	8.48e-30	Plateletcrit;Platelet count;
LGG	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg13385794	chr1:248469461	NA	0.48	8.14	0.35	3.74e-15	Common traits (Other);
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.47	7.84	0.34	3.08e-14	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25072359	chr17:41440525	NA	0.54	10.23	0.43	2.85e-22	Menopause (age at onset);
LGG	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg09359103	chr1:154839909	KCNN3	0.39	7.61	0.33	1.6e-13	Prostate cancer;
LGG	cis	rs919433	0.617	rs12619333	chr2:198567638	C/G	cg00792783	chr2:198669748	PLCL1	-0.61	-9.89	-0.42	4.82e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg08822215	chr16:89438651	ANKRD11	-0.37	-6.99	-0.31	9.8e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.61	0.44	1.13e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.94	-0.38	9.31e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14442939	chr10:27389572	ANKRD26	0.74	11.05	0.46	2.34e-25	Breast cancer;
LGG	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-10.47	-0.44	3.53e-23	Response to antipsychotic treatment;
LGG	cis	rs1111571	0.597	rs2863976	chr16:68378884	A/T	cg07273125	chr16:68295692	NA	0.39	8.43	0.36	4.41e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg23231163	chr10:75533350	FUT11	-0.42	-7.18	-0.32	2.79e-12	Inflammatory bowel disease;
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg08499158	chr17:42289980	UBTF	-0.55	-10.1	-0.42	8.53e-22	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	8.95e-13	Lung cancer;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs12586317	0.620	rs79832710	chr14:35547434	G/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.51	0.53	2.75e-35	Psoriasis;
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs4742903	0.935	rs10991168	chr9:106974902	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.34	0.36	8.42e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg02725872	chr8:58115012	NA	-0.53	-8.55	-0.37	1.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9976767	0.637	rs2156309	chr21:43824529	G/A	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.42	-0.53	6.45e-35	Type 1 diabetes;
LGG	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg17108064	chr15:78857060	CHRNA5	0.45	9.64	0.41	3.6e-20	Sudden cardiac arrest;
LGG	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	cis	rs9815354	0.812	rs73071315	chr3:41805887	T/C	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg07636037	chr3:49044803	WDR6	1.12	27.35	0.79	9.95e-99	Parkinson's disease;
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	7.14	0.31	3.71e-12	Menopause (age at onset);
LGG	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg03806693	chr22:41940476	POLR3H	-0.85	-14.75	-0.57	1.22e-40	Vitiligo;
LGG	cis	rs807669	0.505	rs2236759	chr22:19187427	C/G	cg02655711	chr22:19163373	SLC25A1	0.5	8.88	0.38	1.5e-17	Metabolite levels;
LGG	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.83	-0.38	2.09e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4662945	0.525	rs28625431	chr2:130303333	A/G	cg05962382	chr2:130345044	NA	-0.44	-7.83	-0.34	3.43e-14	Response to cytidine analogues (gemcitabine);
LGG	cis	rs9649213	0.614	rs2240348	chr7:97984077	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.39	-0.36	5.9e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.25	-0.36	1.68e-15	Total body bone mineral density;
LGG	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg17294928	chr15:75287854	SCAMP5	-0.77	-8.34	-0.36	8.52e-16	Lung cancer;
LGG	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg06197492	chr11:2016605	H19	0.48	9.93	0.42	3.43e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg03929089	chr4:120376271	NA	0.66	7.93	0.35	1.64e-14	Intraocular pressure;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.28	0.32	1.46e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg03213289	chr20:61660250	NA	-0.61	-13.41	-0.53	7.25e-35	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2067615	0.560	rs10431462	chr12:107106546	G/A	cg15890332	chr12:107067104	RFX4	0.41	11.88	0.48	1.31e-28	Heart rate;
LGG	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.4	-0.4	2.5e-19	Sudden cardiac arrest;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.47	0.56	2.07e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg26150922	chr2:100937072	LONRF2	0.57	10.89	0.45	9.24e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs1362636	chr16:48712779	T/C	cg16662043	chr16:48846231	NA	-0.37	-7.34	-0.32	9.71e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg03806693	chr22:41940476	POLR3H	-0.96	-16.34	-0.6	9.8e-48	Vitiligo;
LGG	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-16.02	-0.6	2.78e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-11.95	-0.49	6.86e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.91	-0.35	1.85e-14	Obesity (extreme);
LGG	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-10.59	-0.44	1.34e-23	Total body bone mineral density;
LGG	cis	rs4780401	0.728	rs8191290	chr16:11765954	C/A	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.32	-0.32	1.12e-12	Rheumatoid arthritis;
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.85	0.38	1.92e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg14664628	chr15:75095509	CSK	-0.56	-10.57	-0.44	1.53e-23	Breast cancer;
LGG	cis	rs1595825	0.786	rs16826740	chr2:198893927	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs6909430	0.901	rs9385327	chr6:98708623	C/T	cg12860156	chr6:98744658	NA	-0.45	-7.67	-0.34	1.04e-13	Quantitative traits;
LGG	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg07274523	chr3:49395745	GPX1	0.57	9.68	0.41	2.65e-20	Educational attainment (college completion);
LGG	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15541040	chr2:3486749	NA	-0.45	-8.07	-0.35	6.2e-15	Neurofibrillary tangles;
LGG	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.77	-0.34	4.97e-14	Iron status biomarkers;
LGG	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02711726	chr17:80685570	FN3KRP	-0.57	-10.12	-0.43	6.98e-22	Glycated hemoglobin levels;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.51	-0.37	2.5e-16	Neuroticism;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.43	0.33	5.13e-13	Schizophrenia;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.99	-0.31	9.8e-12	Lung cancer;
LGG	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.65e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-10.0	-0.42	1.98e-21	Electroencephalogram traits;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6772849	0.804	rs9832430	chr3:128412897	C/T	cg08795948	chr3:128337044	NA	0.62	9.54	0.41	8.45e-20	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs3820928	0.874	rs1917123	chr2:227889783	T/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.41	-0.33	6.2e-13	Pulmonary function;
LGG	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg10523679	chr1:76189770	ACADM	0.75	12.28	0.5	3.24e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4595586	0.545	rs7486598	chr12:39371159	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.64	0.44	8.19e-24	Morning vs. evening chronotype;
LGG	cis	rs7523273	1.000	rs7523273	chr1:207977083	A/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-12.06	-0.49	2.6e-29	Schizophrenia;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg09359103	chr1:154839909	KCNN3	-0.48	-9.49	-0.4	1.25e-19	Prostate cancer;
LGG	cis	rs17039065	1.000	rs59695652	chr4:109377151	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.75	0.3	4.35e-11	Gut microbiome composition (summer);
LGG	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg07148914	chr20:33460835	GGT7	-0.41	-6.87	-0.3	2.02e-11	Coronary artery disease;
LGG	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	cg07928641	chr1:182991847	LAMC1	0.45	8.73	0.38	4.81e-17	Fuchs's corneal dystrophy;
LGG	cis	rs11064837	0.550	rs11064849	chr12:120054587	C/T	cg25937854	chr12:120150414	CIT	-0.63	-10.19	-0.43	3.99e-22	Schizophrenia;
LGG	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg18709589	chr6:96969512	KIAA0776	0.45	7.12	0.31	4.06e-12	Migraine;Coronary artery disease;
LGG	cis	rs9487094	0.567	rs13198879	chr6:110091064	G/C	cg01125227	chr6:109776195	MICAL1	0.47	7.64	0.33	1.22e-13	Height;
LGG	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg08975724	chr8:8085496	FLJ10661	0.39	7.51	0.33	3.15e-13	Systolic blood pressure;
LGG	cis	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg08975724	chr8:8085496	FLJ10661	0.35	6.65	0.3	8.1e-11	Parkinson's disease;
LGG	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg05775895	chr3:12838266	CAND2	0.79	15.92	0.59	7.93e-46	QRS complex (12-leadsum);
LGG	cis	rs9398803	0.713	rs3861455	chr6:126897969	A/C	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.69e-20	Male-pattern baldness;
LGG	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg16230307	chr14:35515116	FAM177A1	0.57	8.77	0.38	3.4e-17	Psoriasis;
LGG	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg13010199	chr12:38710504	ALG10B	0.64	13.37	0.53	1.06e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8053891	0.756	rs12708921	chr16:71999589	G/A	cg09427745	chr16:71932006	KIAA0174	-0.37	-6.84	-0.3	2.53e-11	Coronary artery disease;
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg26752003	chr8:145688521	CYHR1	0.54	11.69	0.48	7.87e-28	Age at first birth;
LGG	cis	rs1497406	0.744	rs12057222	chr1:16508534	A/G	cg20430773	chr1:16534157	ARHGEF19	0.3	8.4	0.36	5.62e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12410462	0.591	rs1495851	chr1:227711073	C/A	cg04117972	chr1:227635322	NA	0.46	8.35	0.36	7.99e-16	Major depressive disorder;
LGG	trans	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.83	-0.34	3.45e-14	Resting heart rate;
LGG	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.45	-0.33	4.58e-13	Refractive error;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	9.18	0.39	1.44e-18	Personality dimensions;
LGG	cis	rs12681287	0.640	rs67123356	chr8:87453992	A/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.7	-0.34	8.59e-14	Caudate activity during reward;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.48e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg18252515	chr7:66147081	NA	-1.41	-20.58	-0.69	2.5e-67	Diabetic kidney disease;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg07511668	chr11:68622177	NA	0.47	9.11	0.39	2.44e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9972944	0.756	rs9907969	chr17:63754860	G/T	cg07283582	chr17:63770753	CCDC46	-0.39	-7.6	-0.33	1.7e-13	Total body bone mineral density;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.32	0.32	1.13e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs3731896	0.752	rs2292604	chr2:220161306	C/T	cg14987769	chr2:220197576	RESP18	0.48	6.93	0.31	1.44e-11	Educational attainment;
LGG	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg08344181	chr3:125677491	NA	-0.6	-7.02	-0.31	8.17e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.23	-0.43	2.75e-22	Colorectal cancer;
LGG	cis	rs6840360	0.642	rs6855845	chr4:152417380	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	8.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04008888	chr11:68622739	NA	-0.54	-11.6	-0.47	1.7e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.57e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2070433	0.539	rs56157650	chr21:47957959	T/C	cg02959939	chr21:47813025	PCNT	-0.32	-7.14	-0.32	3.56e-12	Lymphocyte counts;
LGG	trans	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg25214090	chr10:38739885	LOC399744	0.45	8.07	0.35	6.04e-15	Diastolic blood pressure;
LGG	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.06	-0.35	6.6e-15	Systolic blood pressure;
LGG	trans	rs208520	0.690	rs207091	chr6:66799847	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg04503457	chr17:41445688	NA	-0.41	-8.41	-0.36	5.27e-16	Menopause (age at onset);
LGG	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg02023728	chr11:77925099	USP35	0.45	7.62	0.33	1.43e-13	Testicular germ cell tumor;
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs9457247	0.561	rs916331	chr6:167470559	T/G	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Crohn's disease;
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	9.32	0.4	4.91e-19	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04436714	chr1:90309218	LRRC8D	0.4	6.95	0.31	1.23e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.93	-0.42	3.35e-21	Mean corpuscular volume;
LGG	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.05	-0.31	6.62e-12	Schizophrenia;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg06221963	chr1:154839813	KCNN3	0.52	11.0	0.46	3.79e-25	Prostate cancer;
LGG	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg04455712	chr21:45112962	RRP1B	0.49	9.23	0.39	1.01e-18	Mean corpuscular volume;
LGG	cis	rs1557765	0.527	rs2018218	chr11:17390855	A/G	cg15432903	chr11:17409602	KCNJ11	0.49	9.05	0.39	4.11e-18	Body mass index;Social communication problems;
LGG	cis	rs11711311	0.955	rs3796254	chr3:113380332	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.76	0.54	2.33e-36	IgG glycosylation;
LGG	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg11752832	chr7:134001865	SLC35B4	0.68	12.72	0.51	5.19e-32	Mean platelet volume;
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg08297393	chr2:100937505	LONRF2	-0.52	-9.68	-0.41	2.57e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9399137	0.507	rs11154791	chr6:135379148	A/G	cg22676075	chr6:135203613	NA	0.41	7.01	0.31	8.55e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-7.73	-0.34	6.88e-14	Self-reported allergy;
LGG	cis	rs1982963	1.000	rs1982963	chr14:52509101	C/T	cg05884192	chr14:52515736	NID2	-0.34	-7.34	-0.32	9.46e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg16339924	chr4:17578868	LAP3	0.65	11.18	0.46	7.3e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg01236616	chr12:121019343	POP5	-1.22	-22.21	-0.72	5.83e-75	Type 1 diabetes nephropathy;
LGG	cis	rs73198271	0.531	rs112930476	chr8:8671551	G/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.02	0.35	8.67e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.56	-0.72	1.44e-76	Height;
LGG	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-6.73	-0.3	4.98e-11	Huntington's disease progression;
LGG	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.69e-30	Response to antipsychotic treatment;
LGG	cis	rs9783347	0.643	rs10741743	chr11:18347994	G/C	cg15585147	chr11:18324498	HPS5	0.31	6.99	0.31	9.81e-12	Pancreatic cancer;
LGG	cis	rs13082711	0.522	rs608374	chr3:27345397	G/A	cg02860705	chr3:27208620	NA	0.59	11.14	0.46	1.02e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg20283391	chr11:68216788	NA	-0.5	-8.3	-0.36	1.19e-15	Total body bone mineral density;
LGG	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg15596359	chr8:11213517	TDH	-0.36	-7.43	-0.33	5.43e-13	Retinal vascular caliber;
LGG	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06850241	chr22:41845214	NA	-0.42	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs17253792	0.822	rs58589065	chr14:56152478	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.54	-0.5	2.8e-31	Putamen volume;
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg03351412	chr1:154909251	PMVK	0.67	13.01	0.52	3.47e-33	Prostate cancer;
LGG	cis	rs11239187	0.586	rs1999774	chr10:45081394	A/T	cg03916630	chr10:45065415	NA	0.36	8.6	0.37	1.28e-16	Body mass index;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg27471124	chr11:109292789	C11orf87	0.49	9.45	0.4	1.66e-19	Schizophrenia;
LGG	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-9.59	-0.41	5.49e-20	HDL cholesterol;
LGG	cis	rs9287719	0.967	rs7592691	chr2:10737426	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg26528311	chr1:38462546	FHL3	-0.35	-9.45	-0.4	1.66e-19	Coronary artery disease;
LGG	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.82	0.34	3.51e-14	Mood instability;
LGG	cis	rs6738485	0.507	rs72819611	chr2:106845912	G/A	cg16099169	chr2:106886729	NA	-0.38	-7.71	-0.34	7.73e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LGG	cis	rs11112613	0.713	rs10507192	chr12:105948247	A/G	cg03607813	chr12:105948248	NA	0.7	13.36	0.53	1.18e-34	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs9733	0.818	rs12130363	chr1:150688596	T/C	cg13175981	chr1:150552382	MCL1	0.54	9.12	0.39	2.24e-18	Tonsillectomy;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg07936489	chr17:37558343	FBXL20	0.85	16.0	0.6	3.49e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs2120243	0.935	rs9681270	chr3:157143996	A/G	cg24825693	chr3:157122686	VEPH1	-0.41	-8.63	-0.37	1.01e-16	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg08949735	chr16:89699720	DPEP1	-0.47	-9.72	-0.41	1.98e-20	Vitiligo;
LGG	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg19500275	chr17:80737654	TBCD	0.49	6.72	0.3	5.44e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4262150	0.810	rs72797217	chr5:151961639	C/T	cg12297329	chr5:152029980	NA	-0.8	-15.36	-0.58	2.47e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg13852791	chr20:30311386	BCL2L1	0.74	11.76	0.48	4.11e-28	Mean corpuscular hemoglobin;
LGG	cis	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.62	-0.41	4.27e-20	Morning vs. evening chronotype;
LGG	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.41	-0.58	1.48e-43	Colorectal cancer;
LGG	cis	rs6120849	0.663	rs11698868	chr20:33549946	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.91	0.31	1.63e-11	Protein C levels;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22509189	chr2:225307070	NA	-0.59	-9.6	-0.41	5.07e-20	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg20296188	chr17:77397067	HRNBP3	0.44	7.37	0.32	8.01e-13	Prudent dietary pattern;
LGG	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg08392591	chr16:89556376	ANKRD11	0.54	8.46	0.37	3.44e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg26150922	chr2:100937072	LONRF2	-0.53	-9.39	-0.4	2.82e-19	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05678191	chr18:76753238	SALL3	-0.4	-6.92	-0.31	1.56e-11	Cognitive performance;
LGG	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-12.17	-0.49	9.7e-30	Schizophrenia;
LGG	cis	rs7617773	0.539	rs13069884	chr3:48381148	T/A	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs7508	0.597	rs383499	chr8:17912375	T/A	cg18067069	chr8:17937731	ASAH1	-0.3	-6.92	-0.31	1.5e-11	Atrial fibrillation;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg15558759	chr11:118478939	PHLDB1	0.38	6.65	0.3	8.05e-11	Cholesterol, total;
LGG	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.88	-0.42	5.16e-21	Primary sclerosing cholangitis;
LGG	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg22906224	chr7:99728672	NA	0.55	8.94	0.38	9.47e-18	Coronary artery disease;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06850241	chr22:41845214	NA	0.46	7.17	0.32	2.93e-12	Vitiligo;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs701145	0.585	rs6789213	chr3:153792795	T/C	cg12800244	chr3:153838788	SGEF	0.84	9.15	0.39	1.77e-18	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs9994346	chr4:99037986	A/G	cg05340658	chr4:99064831	C4orf37	0.48	8.07	0.35	6.31e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25072359	chr17:41440525	NA	0.53	10.2	0.43	3.57e-22	Menopause (age at onset);
LGG	cis	rs4804815	0.780	rs62125168	chr19:7840521	T/G	cg09310891	chr19:7854403	CLEC4GP1	0.54	8.36	0.36	7.51e-16	Neutrophil count;
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.37	-0.58	2.32e-43	Height;
LGG	cis	rs9914988	0.943	rs2043031	chr17:27085564	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.75	-0.3	4.35e-11	Height;
LGG	cis	rs709400	0.633	rs10143247	chr14:103920927	G/A	cg26031613	chr14:104095156	KLC1	0.78	13.99	0.55	2.38e-37	Body mass index;
LGG	cis	rs3862435	0.572	rs2601163	chr15:90908200	A/G	cg22089800	chr15:90895588	ZNF774	-0.55	-6.79	-0.3	3.42e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg00898013	chr13:113819073	PROZ	-0.42	-8.64	-0.37	8.97e-17	Platelet distribution width;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg01765077	chr12:122356316	WDR66	0.28	7.75	0.34	6.06e-14	Mean corpuscular volume;
LGG	cis	rs7166081	0.688	rs12903168	chr15:67680209	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.71	-0.34	7.71e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs11165623	0.564	rs7523597	chr1:97000989	A/G	cg10631902	chr5:14652156	NA	-0.45	-9.38	-0.4	2.86e-19	Hip circumference;Waist circumference;
LGG	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.25	-0.46	4.09e-26	Total body bone mineral density;
LGG	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg15083037	chr5:83017644	HAPLN1	-0.35	-6.98	-0.31	1.04e-11	Prostate cancer;
LGG	cis	rs2467099	0.504	rs2666005	chr17:73944596	T/G	cg23806715	chr17:73775811	H3F3B	0.46	6.98	0.31	9.97e-12	Systolic blood pressure;
LGG	cis	rs17767392	0.958	rs2332641	chr14:72044728	T/G	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.8	-0.41	9.79e-21	Mitral valve prolapse;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg01570182	chr17:44337453	NA	0.73	12.37	0.5	1.46e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	trans	rs61931739	0.926	rs1995966	chr12:34095420	G/A	cg13010199	chr12:38710504	ALG10B	-0.46	-8.36	-0.36	7.29e-16	Morning vs. evening chronotype;
LGG	trans	rs6787172	0.622	rs74808906	chr3:158067362	A/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.27	-0.32	1.49e-12	Subjective well-being;
LGG	cis	rs2587949	0.593	rs795288	chr3:4204455	T/C	cg16519197	chr3:4211558	NA	-0.33	-6.89	-0.31	1.78e-11	Periodontitis (DPAL);
LGG	cis	rs686320	0.748	rs550894	chr11:65211940	C/A	cg17392047	chr11:65247138	NA	0.51	6.86	0.3	2.15e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.12	0.39	2.25e-18	Motion sickness;
LGG	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.23	0.75	2.25e-84	Chronic sinus infection;
LGG	cis	rs7523273	0.548	rs2724381	chr1:207949017	T/C	cg22525895	chr1:207977042	MIR29B2	0.62	12.1	0.49	1.81e-29	Schizophrenia;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.94	0.42	3.17e-21	Prudent dietary pattern;
LGG	cis	rs6912958	0.781	rs2300906	chr6:88207155	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.58	-0.37	1.43e-16	Monocyte percentage of white cells;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03284175	chr1:146643471	PRKAB2	0.41	6.78	0.3	3.69e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg05793240	chr7:2802953	GNA12	0.33	7.33	0.32	1.01e-12	Height;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.47	-0.53	3.9e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2067615	0.965	rs4964484	chr12:107113024	A/C	cg15890332	chr12:107067104	RFX4	-0.31	-8.68	-0.37	7e-17	Heart rate;
LGG	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg18681998	chr4:17616180	MED28	0.82	18.3	0.65	1.09e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg07460842	chr6:66804631	NA	0.96	17.9	0.64	7.68e-55	Exhaled nitric oxide output;
LGG	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.95	0.35	1.4e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.3	5.18e-11	Aortic root size;
LGG	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs2201728	0.967	rs28914783	chr4:100231602	C/T	cg07219303	chr4:100140905	ADH6	-0.4	-8.23	-0.36	1.85e-15	Cardiac Troponin-T levels;
LGG	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.83	0.34	3.39e-14	Electroencephalogram traits;
LGG	cis	rs7241530	0.610	rs12454279	chr18:75893785	C/A	cg14642773	chr18:75888474	NA	0.48	9.13	0.39	2.11e-18	Educational attainment (years of education);
LGG	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg16386425	chr10:429943	DIP2C	0.45	9.11	0.39	2.44e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs72781680	0.716	rs2551326	chr2:23982378	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	8.53	0.37	2.09e-16	Lymphocyte counts;
LGG	cis	rs1451375	0.657	rs12665904	chr7:50635399	A/G	cg20336341	chr7:50628841	DDC	0.34	6.68	0.3	6.75e-11	Malaria;
LGG	cis	rs7523273	0.606	rs2724391	chr1:207953244	T/C	cg22525895	chr1:207977042	MIR29B2	0.62	12.07	0.49	2.32e-29	Schizophrenia;
LGG	cis	rs9309473	0.607	rs7573719	chr2:73582986	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-8.85	-0.38	1.87e-17	Metabolite levels;
LGG	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg16662043	chr16:48846231	NA	0.37	7.29	0.32	1.33e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg23609528	chr2:113191194	RGPD5;RGPD8	0.6	7.2	0.32	2.44e-12	Yeast infection;
LGG	cis	rs6964587	1.000	rs7784248	chr7:91758111	A/G	cg17063962	chr7:91808500	NA	0.5	9.01	0.39	5.63e-18	Breast cancer;
LGG	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg02187348	chr16:89574699	SPG7	0.56	9.11	0.39	2.47e-18	Multiple myeloma (IgH translocation);
LGG	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-8.52	-0.37	2.32e-16	Thyroid stimulating hormone;
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg10189774	chr4:17578691	LAP3	0.37	6.7	0.3	5.99e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg13047869	chr3:10149882	C3orf24	0.54	9.09	0.39	2.95e-18	Alzheimer's disease;
LGG	cis	rs9487094	0.922	rs9885646	chr6:109742460	C/T	cg16315928	chr6:109776240	MICAL1	0.48	8.07	0.35	6.08e-15	Height;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg26513180	chr16:89883248	FANCA	0.7	7.63	0.33	1.37e-13	Skin colour saturation;
LGG	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg20891283	chr12:69753455	YEATS4	0.83	16.67	0.61	3.1e-49	Cerebrospinal fluid biomarker levels;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	trans	rs9944715	1.000	rs3744858	chr18:43845269	C/T	cg01718231	chr17:29326311	RNF135	-0.42	-6.8	-0.3	3.23e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg26076054	chr5:421317	AHRR	-0.47	-7.76	-0.34	5.5e-14	Cystic fibrosis severity;
LGG	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg24565620	chr2:194026	NA	0.68	10.52	0.44	2.46e-23	Blood protein levels;
LGG	cis	rs75059851	1.000	rs73036063	chr11:133828758	G/A	cg17703048	chr11:133852993	NA	-0.79	-13.67	-0.54	5.43e-36	Schizophrenia;
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11645453	chr3:52864694	ITIH4	0.43	7.03	0.31	7.27e-12	Bipolar disorder;
LGG	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.85e-33	Intelligence (multi-trait analysis);
LGG	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.0	0.35	1.02e-14	Neuroticism;
LGG	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg02297831	chr4:17616191	MED28	0.51	9.56	0.41	6.72e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.35	-0.77	3.84e-94	Schizophrenia;
LGG	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg02403541	chr12:121454288	C12orf43	-0.41	-7.0	-0.31	8.81e-12	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg25019033	chr10:957182	NA	-0.56	-10.28	-0.43	1.88e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg16359550	chr11:109292809	C11orf87	0.41	8.09	0.35	5.34e-15	Schizophrenia;
LGG	cis	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg21775007	chr8:11205619	TDH	0.61	9.95	0.42	2.82e-21	Retinal vascular caliber;
LGG	cis	rs12431410	0.550	rs12896125	chr14:60202416	T/C	cg07950296	chr14:60194823	RTN1	-0.41	-7.73	-0.34	6.69e-14	Schizophrenia;
LGG	cis	rs600231	0.708	rs661403	chr11:65242478	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.2	-0.39	1.27e-18	Bone mineral density;
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15320075	chr8:145703422	NA	-0.72	-14.04	-0.55	1.45e-37	Age at first birth;
LGG	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.54	0.71	8.24e-72	Bladder cancer;
LGG	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	8.02e-12	Obesity-related traits;
LGG	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg22903471	chr2:27725779	GCKR	0.6	13.88	0.54	7.32e-37	Total body bone mineral density;
LGG	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg11317459	chr13:21872234	NA	-1.18	-19.38	-0.67	1.1e-61	White matter hyperintensity burden;
LGG	cis	rs7113874	0.524	rs4929944	chr11:8625441	C/T	cg23764900	chr11:8616102	STK33	0.4	6.89	0.3	1.83e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs977987	0.806	rs12448947	chr16:75462954	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.93	0.42	3.42e-21	Dupuytren's disease;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.85	-0.38	1.81e-17	Initial pursuit acceleration;
LGG	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.23	-0.39	9.46e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg16434002	chr17:42200994	HDAC5	-0.51	-9.37	-0.4	3.31e-19	Total body bone mineral density;
LGG	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.62	0.63	1.53e-53	Refractive error;
LGG	cis	rs2273669	0.667	rs76747161	chr6:109305456	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg00806245	chr18:76673096	NA	0.69	9.31	0.4	5.13e-19	Obesity-related traits;
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.54	-10.05	-0.42	1.28e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs62238980	0.522	rs117215349	chr22:32412642	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs9309473	0.948	rs2421577	chr2:73840998	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.71	-0.34	7.8500000000000006e-14	Metabolite levels;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7129556	0.690	rs648601	chr11:77586910	A/G	cg12586386	chr11:77299805	AQP11	0.44	7.23	0.32	1.95e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs6076065	0.748	rs2281431	chr20:23399304	C/G	cg11657817	chr20:23433608	CST11	0.41	8.39	0.36	6.11e-16	Facial morphology (factor 15, philtrum width);
LGG	trans	rs6601327	0.665	rs10113186	chr8:9655426	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.78e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg25457927	chr22:38595422	NA	-0.31	-7.33	-0.32	1.05e-12	Cutaneous nevi;
LGG	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg15704280	chr7:45808275	SEPT13	0.98	20.66	0.69	1.11e-67	Height;
LGG	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg14675211	chr2:100938903	LONRF2	0.65	11.28	0.46	2.99e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2797160	0.904	rs1777197	chr6:126007401	G/A	cg05901451	chr6:126070800	HEY2	0.44	7.25	0.32	1.74e-12	Endometrial cancer;
LGG	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg11317459	chr13:21872234	NA	1.3	21.15	0.7	5.7e-70	White matter hyperintensity burden;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06873352	chr17:61820015	STRADA	0.74	13.85	0.54	1e-36	Prudent dietary pattern;
LGG	cis	rs6445975	0.956	rs7631010	chr3:58446010	A/T	cg24175188	chr3:58374923	PXK	-0.52	-9.42	-0.4	2.18e-19	Systemic lupus erythematosus;
LGG	trans	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg07211511	chr3:129823064	LOC729375	-0.66	-9.12	-0.39	2.38e-18	Blood pressure (smoking interaction);
LGG	cis	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg07460842	chr6:66804631	NA	1.1	28.89	0.8	1.17e-105	Exhaled nitric oxide output;
LGG	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.57	-9.4	-0.4	2.44e-19	Iron status biomarkers;
LGG	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.52	0.4	9.76e-20	Diabetic retinopathy;
LGG	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.81	-0.3	3.08e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs4702718	0.616	rs9312742	chr5:10734772	C/T	cg14521931	chr5:10832172	NA	-0.43	-8.14	-0.35	3.78e-15	Obesity-related traits;
LGG	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-14.85	-0.57	4.68e-41	Headache;
LGG	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06634786	chr22:41940651	POLR3H	0.71	11.04	0.46	2.54e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.49	-0.4	1.23e-19	Body mass index;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg03452623	chr4:187889614	NA	-1.04	-29.44	-0.81	3.74e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2559856	1.000	rs2695291	chr12:102087543	G/A	cg12924262	chr12:102091054	CHPT1	0.64	12.45	0.5	6.55e-31	Blood protein levels;
LGG	cis	rs4478137	0.931	rs56233753	chr4:164249023	A/G	cg06758707	chr4:164254230	NPY1R	0.7	12.5	0.5	4.16e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs703842	1.000	rs1599932	chr12:58177943	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.36	0.36	7.48e-16	Multiple sclerosis;
LGG	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	6.91e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg14338887	chr6:42928500	GNMT	-0.28	-9.17	-0.39	1.6e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg04568710	chr12:38710424	ALG10B	0.37	8.1	0.35	5.1e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.71	-10.32	-0.43	1.3e-22	Schizophrenia;
LGG	cis	rs59197085	0.636	rs4731517	chr7:128458649	A/C	cg00734629	chr7:128471146	FLNC	-0.35	-7.27	-0.32	1.53e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs735539	0.645	rs9550663	chr13:21174053	C/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.36	-0.36	7.29e-16	Dental caries;
LGG	trans	rs11875185	0.510	rs75419830	chr18:55621161	A/G	cg15513957	chr14:69354734	ACTN1	-0.89	-9.04	-0.39	4.15e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.95	-0.31	1.27e-11	Longevity;Endometriosis;
LGG	trans	rs877282	0.945	rs10904550	chr10:774177	C/T	cg22713356	chr15:30763199	NA	0.56	8.73	0.38	4.69e-17	Uric acid levels;
LGG	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg08648136	chr8:956695	NA	0.44	9.39	0.4	2.76e-19	Schizophrenia;
LGG	cis	rs3780378	0.967	rs7023146	chr9:5040163	G/A	cg02405213	chr9:5042618	JAK2	-0.54	-9.73	-0.41	1.77e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12731740	1.000	rs55797717	chr1:208018961	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.45	-0.33	4.67e-13	Biomedical quantitative traits;
LGG	cis	rs17683430	0.681	rs12159823	chr22:32563229	A/G	cg00543991	chr22:32367038	NA	0.57	7.61	0.33	1.52e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg08470875	chr2:26401718	FAM59B	-0.41	-7.89	-0.34	2.14e-14	Gut microbiome composition (summer);
LGG	cis	rs877282	0.898	rs11253353	chr10:766862	C/A	cg17470449	chr10:769945	NA	0.61	7.46	0.33	4.23e-13	Uric acid levels;
LGG	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg14773178	chr5:1868261	NA	0.37	7.07	0.31	5.89e-12	Cardiovascular disease risk factors;
LGG	cis	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg20368463	chr18:77673604	PQLC1	-0.56	-7.46	-0.33	4.37e-13	Opioid sensitivity;
LGG	trans	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg02030672	chr11:45687055	CHST1	0.57	10.33	0.43	1.16e-22	Obesity-related traits;
LGG	cis	rs2832191	0.791	rs2832181	chr21:30481371	G/T	cg24692254	chr21:30365293	RNF160	-0.96	-24.74	-0.75	9.56e-87	Dental caries;
LGG	trans	rs8129326	0.754	rs9974541	chr21:35806004	C/T	cg07474852	chr4:123073612	NA	-0.44	-7.39	-0.32	6.87e-13	Cancer;
LGG	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.65	0.48	1.15e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9357271	1.000	rs9357271	chr6:38365873	A/G	cg07362130	chr6:38359646	BTBD9	-0.48	-11.05	-0.46	2.28e-25	Restless legs syndrome;
LGG	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg26031613	chr14:104095156	KLC1	-0.67	-10.61	-0.44	1.08e-23	Reticulocyte count;
LGG	cis	rs7766436	0.885	rs12662891	chr6:22575096	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.94	-0.49	7.48e-29	Coronary artery disease;
LGG	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg12756686	chr19:29218302	NA	0.62	8.41	0.36	5.3e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs36051895	0.564	rs7874624	chr9:5179865	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-14.55	-0.56	9.23e-40	Pediatric autoimmune diseases;
LGG	cis	rs57590327	0.503	rs12152272	chr3:81911684	G/A	cg07356753	chr3:81810745	GBE1	-0.45	-7.19	-0.32	2.64e-12	Extraversion;
LGG	cis	rs757081	0.648	rs10832750	chr11:17260918	A/T	cg15432903	chr11:17409602	KCNJ11	0.41	7.71	0.34	7.81e-14	Systolic blood pressure;
LGG	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.61	0.37	1.14e-16	Hypertriglyceridemia;
LGG	cis	rs11240408	1	rs11240408	chr1:205264536	A/T	cg21545522	chr1:205238299	TMCC2	-0.42	-7.57	-0.33	2.02e-13	Platelet count;
LGG	cis	rs3816183	1.000	rs893729	chr2:43015224	A/G	cg14631114	chr2:43023945	NA	0.51	9.68	0.41	2.68e-20	Hypospadias;
LGG	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.03	-0.35	7.86e-15	Joint mobility (Beighton score);
LGG	cis	rs8020289	0.957	rs741858	chr14:77284079	G/C	cg23436960	chr14:77239540	VASH1	-0.27	-6.97	-0.31	1.13e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg13010199	chr12:38710504	ALG10B	0.4	7.59	0.33	1.72e-13	Morning vs. evening chronotype;
LGG	cis	rs56283067	0.847	rs2128543	chr6:44685552	G/A	cg20913747	chr6:44695427	NA	-0.66	-12.14	-0.49	1.22e-29	Total body bone mineral density;
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18876405	chr7:65276391	NA	-0.52	-9.25	-0.39	8.55e-19	Aortic root size;
LGG	cis	rs708547	0.578	rs781665	chr4:57831461	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.55	9.03	0.39	4.5e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg09699651	chr6:150184138	LRP11	0.54	9.65	0.41	3.51e-20	Lung cancer;
LGG	cis	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg06521331	chr12:34319734	NA	-0.55	-9.38	-0.4	2.95e-19	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.41	0.33	6e-13	Lung cancer;
LGG	cis	rs2354432	0.546	rs7539416	chr1:146881586	C/T	cg25205988	chr1:146714368	CHD1L	1.22	14.22	0.55	2.54e-38	Mitochondrial DNA levels;
LGG	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg03735888	chr19:58951602	ZNF132	0.43	8.66	0.37	7.75e-17	Uric acid clearance;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg17328964	chr8:145687451	CYHR1	0.69	12.33	0.5	2.15e-30	Age at first birth;
LGG	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-8.48	-0.37	2.97e-16	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.74	0.38	4.21e-17	Alzheimer's disease;
LGG	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg13073564	chr4:8508604	NA	0.4	7.13	0.31	3.93e-12	Response to antineoplastic agents;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.55	0.41	7.5e-20	Longevity;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.04	-19.74	-0.68	2.26e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.85e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.13	-0.31	3.94e-12	Life satisfaction;
LGG	trans	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg00953403	chr17:74099816	EXOC7	0.44	7.11	0.31	4.53e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg14598338	chr9:96623480	NA	0.54	9.77	0.41	1.22e-20	DNA methylation (variation);
LGG	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	7.57	0.33	2.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.07e-15	Aortic root size;
LGG	cis	rs9815354	1.000	rs1716688	chr3:41926546	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	trans	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.11	-0.39	2.58e-18	Bladder cancer;
LGG	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg08773314	chr2:239334832	ASB1	-0.42	-8.15	-0.35	3.41e-15	Multiple system atrophy;
LGG	cis	rs7166081	1.000	rs7166081	chr15:67492301	G/A	cg24231037	chr15:68117551	LBXCOR1	0.3	6.7	0.3	5.92e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9309473	0.528	rs11898362	chr2:73565293	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.69	-0.34	9.22e-14	Metabolite levels;
LGG	trans	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg21659725	chr3:3221576	CRBN	0.63	11.73	0.48	5.16e-28	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg14668632	chr7:2872130	GNA12	-0.35	-7.13	-0.31	3.77e-12	Height;
LGG	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs1125355	0.622	rs17203501	chr2:159613637	G/A	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg00409905	chr10:38381863	ZNF37A	0.52	10.34	0.43	1.06e-22	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg04455712	chr21:45112962	RRP1B	0.52	9.83	0.42	7.61e-21	Mean corpuscular volume;
LGG	cis	rs3820928	0.804	rs4675125	chr2:227802499	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	2.93e-14	Pulmonary function;
LGG	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.0	-0.77	1.45e-92	Height;
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg19077165	chr18:44547161	KATNAL2	0.55	10.1	0.43	7.97e-22	Personality dimensions;
LGG	cis	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg05084668	chr3:125655381	ALG1L	-0.91	-11.1	-0.46	1.47e-25	Blood pressure (smoking interaction);
LGG	cis	rs9879311	0.522	rs7627223	chr3:10422406	C/G	cg21387009	chr3:10280255	IRAK2	-0.4	-6.74	-0.3	4.74e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1568889	1.000	rs34140872	chr11:28335872	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.69	0.56	2.2e-40	Bipolar disorder;
LGG	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg07541023	chr7:19748670	TWISTNB	-0.49	-7.58	-0.33	1.96e-13	Thyroid stimulating hormone;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg03929089	chr4:120376271	NA	0.84	9.11	0.39	2.42e-18	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.04e-45	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13275176	chr2:97534450	SEMA4C	0.45	7.15	0.32	3.4e-12	Hip circumference;
LGG	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11644478	chr21:40555479	PSMG1	-0.75	-14.01	-0.55	1.92e-37	Cognitive function;
LGG	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg08975724	chr8:8085496	FLJ10661	0.38	6.99	0.31	9.62e-12	Monocyte count;
LGG	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.57e-19	Red blood cell count;
LGG	cis	rs9911578	1.000	rs7342903	chr17:56914588	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.45	-9.19	-0.39	1.33e-18	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg21475434	chr5:93447410	FAM172A	0.7	7.18	0.32	2.73e-12	Diabetic retinopathy;
LGG	cis	rs12049351	0.725	rs1328219	chr1:229596260	A/G	cg13547644	chr1:229569608	ACTA1	0.35	7.64	0.33	1.23e-13	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs2270450	0.715	rs9381472	chr6:46658905	C/G	cg10156739	chr6:46714674	LOC100287718	-0.34	-8.18	-0.36	2.72e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg23302884	chr18:44338147	ST8SIA5	0.44	8.91	0.38	1.17e-17	Personality dimensions;
LGG	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg09873164	chr1:152488093	CRCT1	0.64	15.81	0.59	2.57e-45	Hair morphology;
LGG	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg13385794	chr1:248469461	NA	0.5	8.3	0.36	1.14e-15	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19015582	chr11:75946767	NA	0.43	7.05	0.31	6.34e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9287719	0.745	rs4997809	chr2:10755542	G/A	cg02196655	chr2:10830764	NOL10	-0.41	-6.91	-0.31	1.59e-11	Prostate cancer;
LGG	cis	rs875971	0.502	rs2946580	chr7:65531842	G/A	cg11764359	chr7:65958608	NA	-0.61	-8.88	-0.38	1.46e-17	Aortic root size;
LGG	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.4e-17	Fuchs's corneal dystrophy;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.53	0.44	2.12e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs11711311	1.000	rs9811746	chr3:113515060	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.13e-34	IgG glycosylation;
LGG	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs9398803	0.713	rs3861457	chr6:126902245	T/C	cg19875578	chr6:126661172	C6orf173	0.51	9.39	0.4	2.68e-19	Male-pattern baldness;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.37	-7.04	-0.31	7.19e-12	Schizophrenia;
LGG	cis	rs3741151	0.656	rs10501411	chr11:73292085	A/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.94	0.35	1.56e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.17e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16127845	chr7:1126423	GPER;C7orf50	-0.28	-7.04	-0.31	6.76e-12	Longevity;Endometriosis;
LGG	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg03342759	chr3:160939853	NMD3	0.65	10.44	0.44	4.56e-23	Parkinson's disease;
LGG	cis	rs9660992	0.649	rs12128254	chr1:205268097	C/T	cg21545522	chr1:205238299	TMCC2	0.45	7.95	0.35	1.42e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg03806693	chr22:41940476	POLR3H	-1.07	-17.82	-0.64	1.84e-54	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27537053	chr1:44069790	PTPRF	0.42	6.87	0.3	2.05e-11	Gut microbiome composition (summer);
LGG	cis	rs9309473	0.950	rs13431529	chr2:73876041	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.19	-0.32	2.7e-12	Metabolite levels;
LGG	cis	rs3204270	0.714	rs79243595	chr17:79681220	T/C	cg18367735	chr17:79674897	NA	0.61	8.0	0.35	9.87e-15	Dental caries;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00689492	chr4:1303491	MAEA	-0.47	-7.96	-0.35	1.29e-14	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.74	-0.34	6.38e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18696692	chr7:140771827	NA	0.48	7.39	0.32	6.87e-13	Gut microbiome composition (summer);
LGG	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs8032158	1.000	rs11632096	chr15:56210499	A/G	cg02198044	chr15:56286336	NEDD4	-0.7	-12.39	-0.5	1.14e-30	Keloid;
LGG	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	9.0	0.39	5.9e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9287719	0.967	rs6759100	chr2:10746710	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.11	0.43	7.75e-22	Mean corpuscular volume;
LGG	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.97	0.31	1.1e-11	Parkinson's disease;
LGG	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg19717773	chr7:2847554	GNA12	-0.43	-9.93	-0.42	3.52e-21	Height;
LGG	cis	rs7580658	0.521	rs2404535	chr2:127947709	A/G	cg10021288	chr2:128175891	PROC	0.45	8.64	0.37	9.32e-17	Protein C levels;
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.52	-9.3	-0.4	5.51e-19	Height;
LGG	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg09307838	chr4:120376055	NA	0.8	13.23	0.52	4.2e-34	Corneal astigmatism;
LGG	trans	rs877282	0.898	rs11253344	chr10:765162	C/T	cg22713356	chr15:30763199	NA	0.52	7.6	0.33	1.71e-13	Uric acid levels;
LGG	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg20891558	chr2:74357851	NA	0.47	8.47	0.37	3.37e-16	Gestational age at birth (maternal effect);
LGG	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg10596483	chr8:143751796	JRK	-0.52	-8.01	-0.35	9.15e-15	Schizophrenia;
LGG	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.23	-0.36	1.94e-15	Body mass index;
LGG	cis	rs9503598	0.636	rs6596977	chr6:3466254	G/A	cg00476032	chr6:3446245	SLC22A23	0.54	11.05	0.46	2.41e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg00666640	chr1:248458726	OR2T12	0.61	9.97	0.42	2.54e-21	Common traits (Other);
LGG	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg24803719	chr17:45855879	NA	-0.29	-8.16	-0.35	3.27e-15	IgG glycosylation;
LGG	cis	rs6430585	0.527	rs7592050	chr2:136459227	C/T	cg07169764	chr2:136633963	MCM6	-0.99	-16.84	-0.62	5.4e-50	Corneal structure;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg16507663	chr6:150244633	RAET1G	0.45	8.51	0.37	2.49e-16	Lung cancer;
LGG	cis	rs68170813	0.559	rs7779062	chr7:106880195	T/A	cg02696742	chr7:106810147	HBP1	-0.71	-10.62	-0.44	1.01e-23	Coronary artery disease;
LGG	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.55	11.61	0.47	1.64e-27	Hemoglobin concentration;
LGG	cis	rs7000551	0.663	rs11778844	chr8:22335170	C/T	cg12081754	chr8:22256438	SLC39A14	0.69	13.34	0.53	1.42e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05665937	chr4:1216051	CTBP1	0.49	9.12	0.39	2.36e-18	Obesity-related traits;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.8	-0.3	3.28e-11	Total body bone mineral density;
LGG	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.28	0.36	1.36e-15	Diabetic kidney disease;
LGG	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg09873164	chr1:152488093	CRCT1	0.63	15.34	0.58	3.23e-43	Hair morphology;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg02227867	chr8:22457446	C8orf58	0.43	8.17	0.36	2.88e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.94	0.54	4.07e-37	IgG glycosylation;
LGG	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.51	-0.63	5e-53	Chronic sinus infection;
LGG	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.32	0.43	1.35e-22	Motion sickness;
LGG	cis	rs4363385	0.747	rs11205151	chr1:152961496	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.91	-0.38	1.16e-17	Inflammatory skin disease;
LGG	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg02640540	chr1:67518911	SLC35D1	0.57	11.39	0.47	1.16e-26	Lymphocyte percentage of white cells;
LGG	cis	rs7666738	0.830	rs28761309	chr4:98867393	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	trans	rs75804782	0.521	rs56387296	chr2:239426298	A/G	cg01134436	chr17:81009848	B3GNTL1	0.79	8.68	0.37	6.71e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg00531865	chr16:30841666	NA	-0.57	-11.68	-0.48	8.33e-28	Multiple myeloma;
LGG	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.43	-0.33	5.27e-13	Bone mineral density;
LGG	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg19748678	chr4:122722346	EXOSC9	0.5	9.5	0.4	1.1e-19	Type 2 diabetes;
LGG	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.57	-7.34	-0.32	9.96e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7444	0.941	rs12484550	chr22:21941915	C/T	cg22858872	chr22:21984481	YDJC	-0.37	-6.81	-0.3	3.08e-11	Systemic lupus erythematosus;
LGG	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg17211192	chr8:82754475	SNX16	-0.72	-12.01	-0.49	3.92e-29	Diastolic blood pressure;
LGG	cis	rs7503807	0.515	rs12452916	chr17:78664655	C/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.4	-0.47	1.1e-26	Obesity;
LGG	trans	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	12.04	0.49	3.15e-29	Type 2 diabetes;
LGG	cis	rs61884328	0.777	rs61897776	chr11:47133419	C/G	cg03339077	chr11:47165057	C11orf49	0.63	6.79	0.3	3.49e-11	Total body bone mineral density (age over 60);
LGG	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg01200585	chr1:228362443	C1orf69	-0.45	-8.06	-0.35	6.41e-15	Diastolic blood pressure;
LGG	cis	rs490234	0.651	rs13301073	chr9:128284378	G/A	cg14078157	chr9:128172775	NA	-0.55	-10.45	-0.44	4.34e-23	Mean arterial pressure;
LGG	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg21045802	chr8:109455806	TTC35	0.6	11.13	0.46	1.2e-25	Dupuytren's disease;
LGG	cis	rs9815354	0.904	rs73073368	chr3:41843391	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2797369	0.600	rs2813645	chr6:101580327	T/C	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs459571	0.959	rs456205	chr9:136911146	G/A	cg13789015	chr9:136890014	NCRNA00094	0.57	10.77	0.45	2.81e-24	Platelet distribution width;
LGG	cis	rs75920871	0.925	rs4936362	chr11:116952200	C/T	cg20608306	chr11:116969690	SIK3	-0.35	-7.15	-0.32	3.37e-12	Subjective well-being;
LGG	cis	rs17401966	1.000	rs7520651	chr1:10329872	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-9.93	-0.42	3.44e-21	Hepatocellular carcinoma;
LGG	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.4	0.65	3.62e-57	Refractive error;
LGG	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.17	-0.58	1.82e-42	Colorectal cancer;
LGG	cis	rs12410462	0.591	rs67676707	chr1:227767165	A/C	cg04117972	chr1:227635322	NA	0.48	8.74	0.38	4.24e-17	Major depressive disorder;
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.69	-0.45	5.36e-24	IgG glycosylation;
LGG	cis	rs858239	0.509	rs57611130	chr7:23184552	C/A	cg23682824	chr7:23144976	KLHL7	0.42	6.85	0.3	2.36e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-12.89	-0.51	1.07e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg11317459	chr13:21872234	NA	-1.18	-19.43	-0.67	6.16e-62	White matter hyperintensity burden;
LGG	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg07796016	chr1:152779584	LCE1C	0.46	7.36	0.32	8.49e-13	Inflammatory skin disease;
LGG	cis	rs2777491	0.957	rs16971798	chr15:41657144	A/T	cg18705301	chr15:41695430	NDUFAF1	0.94	18.84	0.66	3.47e-59	Ulcerative colitis;
LGG	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg10167378	chr1:228756711	NA	0.7	9.54	0.41	8.09e-20	Chronic lymphocytic leukemia;
LGG	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-6.65	-0.3	8.37e-11	Blood metabolite levels;
LGG	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	12.04	0.49	3.05e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg24642844	chr7:1081250	C7orf50	-0.62	-10.34	-0.43	1.05e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg11871910	chr12:69753446	YEATS4	1.05	28.86	0.8	1.55e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11167764	0.945	rs891991	chr5:141484977	A/T	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.73	-0.3	4.93e-11	Crohn's disease;
LGG	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	11.61	0.47	1.6e-27	Mean corpuscular hemoglobin;
LGG	cis	rs17321999	0.516	rs72787745	chr2:30506543	T/C	cg05247661	chr2:30472410	LBH	0.65	7.96	0.35	1.37e-14	Systemic lupus erythematosus;
LGG	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	12.07	0.49	2.45e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs5769765	0.913	rs28670284	chr22:50221973	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-10.09	-0.42	9.03e-22	Schizophrenia;
LGG	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07098151	chr1:229762071	URB2;TAF5L	0.42	7.13	0.31	3.9e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs56146971	0.670	rs12590074	chr14:91867390	T/G	cg14409461	chr14:91925021	SMEK1	-0.41	-6.81	-0.3	3.03e-11	Alzheimer disease and age of onset;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.02	-0.39	5.11e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7582720	1.000	rs72934512	chr2:203926271	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.34	0.4	3.94e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12360000	0.797	rs11250853	chr10:1909770	A/G	cg26364871	chr10:1889757	NA	-0.7	-13.46	-0.53	4.25e-35	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg00579200	chr11:133705235	NA	-0.55	-10.69	-0.45	5.3e-24	Childhood ear infection;
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16779626	chr15:41709933	RTF1	0.48	7.34	0.32	9.62e-13	Gut microbiome composition (summer);
LGG	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg22834771	chr12:69754056	YEATS4	0.5	8.63	0.37	9.68e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2016266	0.855	rs6580941	chr12:53662199	T/C	cg04065151	chr12:53682969	ESPL1	-0.61	-9.93	-0.42	3.33e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg23131131	chr22:24373011	LOC391322	0.47	7.75	0.34	5.92e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4716602	0.674	rs4997807	chr7:156158672	C/T	cg16983916	chr7:156159713	NA	0.43	8.23	0.36	1.91e-15	Anti-saccade response;
LGG	cis	rs12618769	0.597	rs72821951	chr2:99157009	A/C	cg18455616	chr2:99124870	INPP4A	0.27	7.75	0.34	5.74e-14	Bipolar disorder;
LGG	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.4	0.53	7.47e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	cg15522984	chr1:182991683	LAMC1	0.42	8.3	0.36	1.12e-15	Fuchs's corneal dystrophy;
LGG	cis	rs4740619	0.689	rs10756726	chr9:15958680	A/C	cg14451791	chr9:16040625	NA	-0.41	-10.32	-0.43	1.25e-22	Body mass index;
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg16208657	chr15:68119293	LBXCOR1	-0.37	-7.24	-0.32	1.91e-12	Obesity;
LGG	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg18876405	chr7:65276391	NA	-0.65	-12.34	-0.5	1.83e-30	Aortic root size;
LGG	cis	rs17604090	0.938	rs10253264	chr7:29692543	T/C	cg19413766	chr7:29689036	LOC646762	-0.59	-7.23	-0.32	2e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.89	0.34	2.28e-14	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04918265	chr1:228353294	C1orf69	0.47	6.65	0.3	8.21e-11	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg16141378	chr3:129829833	LOC729375	0.32	6.76	0.3	4.09e-11	Triglycerides;
LGG	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.21	-0.46	5.9e-26	Total body bone mineral density;
LGG	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.47	4.6e-27	Morning vs. evening chronotype;
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg12310025	chr6:25882481	NA	0.49	9.08	0.39	3.09e-18	Intelligence (multi-trait analysis);
LGG	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	9.19	0.39	1.3e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg11642891	chr2:3452563	TTC15	-0.45	-9.03	-0.39	4.78e-18	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg23306229	chr2:178417860	TTC30B	0.6	7.55	0.33	2.29e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg13010199	chr12:38710504	ALG10B	0.55	9.75	0.41	1.51e-20	Resting heart rate;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-7.29	-0.32	1.35e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg26161368	chr5:91018691	NA	0.33	6.71	0.3	5.73e-11	Pancreatic cancer;
LGG	cis	rs9811920	0.609	rs793463	chr3:99620252	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.01	0.39	5.36e-18	Axial length;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26082856	chr14:23503928	PSMB5	0.44	7.36	0.32	8.52e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs877282	0.891	rs11253355	chr10:768367	C/G	cg17470449	chr10:769945	NA	0.61	7.62	0.33	1.46e-13	Uric acid levels;
LGG	cis	rs7707921	0.541	rs10066167	chr5:81495445	C/T	cg15871215	chr5:81402204	ATG10	0.31	6.94	0.31	1.3e-11	Breast cancer;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7975161	0.832	rs11111955	chr12:104650735	T/C	cg25273343	chr12:104657179	TXNRD1	-0.79	-10.49	-0.44	3.16e-23	Toenail selenium levels;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.12	0.35	4.19e-15	Prudent dietary pattern;
LGG	cis	rs6565180	1.000	rs11863150	chr16:30385503	C/T	cg17640201	chr16:30407289	ZNF48	0.88	18.28	0.65	1.38e-56	Tonsillectomy;
LGG	cis	rs55871839	0.708	rs13263261	chr8:59814688	T/G	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.75e-34	Pneumonia;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg15665833	chr6:26285013	NA	0.39	7.64	0.33	1.22e-13	Educational attainment;
LGG	cis	rs62400317	0.762	rs17423748	chr6:44943982	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.39	-0.47	1.1e-26	Total body bone mineral density;
LGG	cis	rs2236267	0.661	rs2245688	chr14:88595873	G/A	cg18078958	chr14:88630771	NA	-0.29	-6.76	-0.3	4.05e-11	Food antigen IgG levels;
LGG	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.53	-12.57	-0.5	2.15e-31	Oropharynx cancer;
LGG	cis	rs3816183	0.626	rs6716721	chr2:42835932	A/G	cg14631114	chr2:43023945	NA	0.34	6.65	0.3	8.13e-11	Hypospadias;
LGG	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.13e-34	IgG glycosylation;
LGG	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg14210321	chr2:106509881	NCK2	-0.49	-8.4	-0.36	5.38e-16	Addiction;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.56	-0.44	1.7e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.66	11.7	0.48	6.95e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7914558	0.966	rs12569617	chr10:104729996	T/C	cg04362960	chr10:104952993	NT5C2	0.54	10.3	0.43	1.57e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	13.33	0.53	1.56e-34	Psoriasis;
LGG	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.14	-0.35	3.65e-15	Bone mineral density;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08253463	chr7:65579941	CRCP	-0.41	-6.65	-0.3	8.11e-11	Pancreatic cancer;
LGG	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg03701759	chr13:99174930	STK24	-0.37	-7.17	-0.32	3.08e-12	Neuroticism;
LGG	trans	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.52e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg09448879	chr15:79043637	NA	0.4	7.1	0.31	4.65e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.47e-15	Breast cancer;
LGG	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22601191	chr20:60968625	CABLES2	0.56	9.72	0.41	1.9e-20	Colorectal cancer;
LGG	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg05163923	chr11:71159392	DHCR7	-0.58	-8.45	-0.37	3.74e-16	Vitamin D levels;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.779	rs208446	chr6:66903515	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-14.32	-0.55	8.83e-39	Exhaled nitric oxide output;
LGG	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg05623727	chr3:50126028	RBM5	-0.37	-8.11	-0.35	4.45e-15	Intelligence (multi-trait analysis);
LGG	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	11.01	0.46	3.47e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.65	0.37	8.34e-17	Aortic root size;
LGG	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg19554555	chr3:13937349	NA	-0.76	-14.48	-0.56	1.85e-39	Ovarian reserve;
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg10056627	chr6:42928773	GNMT	0.26	7.12	0.31	4.04e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs870825	0.616	rs1401358	chr4:185640057	C/T	cg04058563	chr4:185651563	MLF1IP	1.01	22.47	0.72	3.88e-76	Blood protein levels;
LGG	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg16751781	chr15:78858589	CHRNA5	-0.39	-7.22	-0.32	2.14e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	18.88	0.66	2.18e-59	Platelet count;
LGG	cis	rs2658782	1.000	rs2658782	chr11:93166731	T/G	cg15737290	chr11:93063684	CCDC67	0.58	8.54	0.37	1.99e-16	Pulmonary function decline;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10445487	chr16:75599896	GABARAPL2	0.44	7.45	0.33	4.67e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.65	-0.51	1.01e-31	Total body bone mineral density;
LGG	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg19524238	chr7:2802976	GNA12	0.32	7.74	0.34	6.39e-14	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13129662	chr17:48227708	PPP1R9B	0.51	8.69	0.37	6.32e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18621852	chr3:10150065	C3orf24	-0.41	-6.69	-0.3	6.28e-11	Alzheimer's disease;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-15.11	-0.57	3.1e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13928594	chr12:110562699	IFT81	0.48	7.09	0.31	5.13e-12	Gut microbiome composition (summer);
LGG	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.21	-0.36	2.22e-15	Retinal vascular caliber;
LGG	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg06872548	chr17:78716983	RPTOR	-0.45	-11.03	-0.46	2.78e-25	Obesity;
LGG	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06634786	chr22:41940651	POLR3H	-0.62	-10.58	-0.44	1.4e-23	Vitiligo;
LGG	cis	rs2070997	0.756	rs2987903	chr9:133711263	G/A	cg13397898	chr9:133768931	QRFP	0.38	7.7	0.34	8.4e-14	Response to amphetamines;
LGG	cis	rs4639966	0.836	rs11217018	chr11:118635364	T/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.45	-0.33	4.73e-13	Systemic lupus erythematosus;
LGG	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-9.14	-0.39	2.01e-18	Neuroticism;
LGG	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg06565975	chr8:143823917	SLURP1	0.34	8.56	0.37	1.67e-16	Urinary tract infection frequency;
LGG	trans	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19894588	chr14:64061835	NA	-0.57	-9.08	-0.39	3.21e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs17767392	0.958	rs7145755	chr14:71848110	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	8.99	0.39	6.11e-18	Mitral valve prolapse;
LGG	cis	rs72781680	0.898	rs72780125	chr2:24000145	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.41	0.4	2.28e-19	Lymphocyte counts;
LGG	cis	rs735539	0.521	rs9550672	chr13:21428380	G/T	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg26384229	chr12:38710491	ALG10B	0.81	16.23	0.6	3.24e-47	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.588	rs12079087	chr1:153023888	T/C	cg13444842	chr1:152974279	SPRR3	-0.48	-9.72	-0.41	1.97e-20	Inflammatory skin disease;
LGG	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	trans	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg23484912	chr5:273055	PDCD6	0.4	7.74	0.34	6.25e-14	Mean corpuscular volume;
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.13	-0.35	4.1e-15	Total body bone mineral density;
LGG	cis	rs62400317	0.762	rs11961316	chr6:45029598	T/C	cg18551225	chr6:44695536	NA	-0.58	-8.51	-0.37	2.45e-16	Total body bone mineral density;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.24	-0.32	1.92e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7113850	0.541	rs7131336	chr11:24219418	C/T	ch.11.24196551F	chr11:24239977	NA	0.92	11.17	0.46	7.84e-26	Bone fracture in osteoporosis;
LGG	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg27490568	chr2:178487706	NA	0.47	9.21	0.39	1.15e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg04657146	chr19:12876947	HOOK2	0.46	7.65	0.33	1.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg07148914	chr20:33460835	GGT7	0.53	8.95	0.38	8.36e-18	Height;
LGG	cis	rs4917300	0.572	rs7814797	chr8:143114963	C/T	cg26003909	chr8:143102224	NA	-0.35	-6.89	-0.3	1.85e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2171564	0.791	rs4682420	chr3:112440692	C/T	cg06685282	chr3:112453648	NA	-0.47	-8.91	-0.38	1.2e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs34599045	0.522	rs71626738	chr1:152906086	G/A	cg07796016	chr1:152779584	LCE1C	-0.85	-7.82	-0.34	3.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7927771	0.524	rs11039431	chr11:47872012	G/T	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	1.92e-25	Subjective well-being;
LGG	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.62	-0.67	7.91e-63	Height;
LGG	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg15971980	chr6:150254442	NA	0.45	8.84	0.38	1.99e-17	Lung cancer;
LGG	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.7	-17.39	-0.63	1.7e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg02574844	chr11:5959923	NA	-0.59	-10.25	-0.43	2.39e-22	DNA methylation (variation);
LGG	cis	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg02972257	chr16:68554789	NA	-0.56	-8.38	-0.36	6.4e-16	Ulcerative colitis;
LGG	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg05163923	chr11:71159392	DHCR7	0.72	14.24	0.55	1.97e-38	Vitamin D levels;
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg13264159	chr8:625131	ERICH1	-0.97	-9.97	-0.42	2.38e-21	IgG glycosylation;
LGG	cis	rs17227506	0.543	rs13282808	chr8:13416650	A/G	cg03566418	chr8:13424080	C8orf48	0.55	8.34	0.36	8.36e-16	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-14.71	-0.56	1.76e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11122272	0.705	rs1416914	chr1:231533196	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.51	-0.47	3.83e-27	Hemoglobin concentration;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg01238044	chr22:24384105	GSTT1	-0.41	-6.97	-0.31	1.07e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7122539	0.500	rs2242663	chr11:66335308	A/G	cg01599099	chr11:66649832	PC	0.43	8.31	0.36	1.06e-15	HIV-1 susceptibility;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22174410	chr3:42641766	NKTR	0.39	6.82	0.3	2.92e-11	Bilirubin levels;
LGG	cis	rs12893597	0.580	rs2360999	chr14:76818989	A/C	cg20290672	chr14:76816747	NA	-0.42	-6.92	-0.31	1.51e-11	Maximal oxygen uptake response;
LGG	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg10818794	chr15:86012489	AKAP13	-0.38	-8.0	-0.35	9.94e-15	Coronary artery disease;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.83	-0.34	3.29e-14	Personality dimensions;
LGG	cis	rs1873147	0.569	rs12593531	chr15:63309936	C/G	cg12160578	chr15:63334699	TPM1	0.57	7.9	0.34	1.99e-14	Orofacial clefts;
LGG	cis	rs71636213	0.527	rs9293816	chr5:79664437	A/T	cg12576332	chr5:79646847	LOC441089	-0.5	-7.85	-0.34	2.99e-14	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9467160	0.734	rs9467170	chr6:24452754	G/A	cg20631270	chr6:24437470	GPLD1	0.54	8.48	0.37	3.13e-16	Liver enzyme levels;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg18446336	chr7:2847575	GNA12	-0.29	-6.89	-0.31	1.78e-11	Height;
LGG	cis	rs1015291	0.708	rs12310169	chr12:20005949	C/T	cg25401612	chr12:20009446	NA	-0.34	-7.3	-0.32	1.26e-12	Diastolic blood pressure;
LGG	cis	rs2649	0.518	rs7162745	chr15:63878889	T/A	cg22599514	chr15:63798201	USP3	0.44	7.28	0.32	1.4e-12	Aortic root size;
LGG	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg00071950	chr4:10020882	SLC2A9	-0.38	-7.69	-0.34	8.64e-14	Bone mineral density;
LGG	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg08885076	chr2:99613938	TSGA10	-0.37	-8.13	-0.35	4.08e-15	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06748848	chr17:49197978	SPAG9	0.47	6.73	0.3	4.9e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00166722	chr3:10149974	C3orf24	0.5	8.57	0.37	1.52e-16	Alzheimer's disease;
LGG	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg12292205	chr6:26970375	C6orf41	0.55	10.83	0.45	1.66e-24	Schizophrenia;
LGG	cis	rs17221829	0.703	rs17818747	chr11:89373690	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.84e-12	Bipolar disorder;
LGG	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	17.97	0.64	3.56e-55	Smoking behavior;
LGG	cis	rs7695597	0.708	rs6813607	chr4:185166734	G/C	cg12654155	chr4:185238627	NA	-0.41	-7.23	-0.32	1.96e-12	Night sleep phenotypes;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg03804240	chr11:118481350	PHLDB1	0.39	7.57	0.33	1.98e-13	Cholesterol, total;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10016835	chr1:29557393	MECR	0.5	7.72	0.34	7.19e-14	Gut microbiome composition (summer);
LGG	cis	rs4959677	0.934	rs11242779	chr6:2507901	T/C	cg20147862	chr6:2634573	C6orf195	-0.39	-8.53	-0.37	2.07e-16	Orthostatic hypotension;
LGG	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg27129171	chr3:47204927	SETD2	0.82	14.92	0.57	2.3e-41	Colorectal cancer;
LGG	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg12463550	chr7:65579703	CRCP	0.78	8.81	0.38	2.46e-17	Diabetic kidney disease;
LGG	cis	rs7853377	0.739	rs296884	chr9:86582923	G/T	cg12437157	chr9:86433764	GKAP1	0.4	6.85	0.3	2.36e-11	Height;
LGG	cis	rs75920871	0.702	rs59511712	chr11:116945762	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-7.95	-0.35	1.45e-14	Subjective well-being;
LGG	cis	rs4713118	0.516	rs6931858	chr6:28078411	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.51	-6.82	-0.3	2.86e-11	Parkinson's disease;
LGG	cis	rs8141529	0.584	rs58004020	chr22:29257050	A/T	cg02153584	chr22:29168773	CCDC117	0.69	11.42	0.47	8.63e-27	Lymphocyte counts;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05025164	chr4:1340916	KIAA1530	-0.57	-9.96	-0.42	2.63e-21	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg12070911	chr6:150209640	RAET1E	0.27	7.02	0.31	7.9e-12	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg13607699	chr17:42295918	UBTF	0.91	18.91	0.66	1.69e-59	Total body bone mineral density;
LGG	cis	rs57590327	0.503	rs13080520	chr3:81850742	T/C	cg07356753	chr3:81810745	GBE1	-0.43	-7.39	-0.32	6.94e-13	Extraversion;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3859192	0.599	rs34342173	chr17:38161507	T/C	cg17467752	chr17:38218738	THRA	-0.58	-9.62	-0.41	4.25e-20	White blood cell count;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.09	0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs295140	1.000	rs1367857	chr2:201160765	T/C	cg25099087	chr2:201172481	SPATS2L	0.27	6.67	0.3	7.32e-11	QT interval;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02689023	chr2:169104449	STK39	0.53	8.32	0.36	1.02e-15	Gut microbiome composition (summer);
LGG	trans	rs9354308	0.868	rs6923994	chr6:66555665	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-8.54	-0.37	1.91e-16	Metabolite levels;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.3	0.36	1.16e-15	Life satisfaction;
LGG	cis	rs11225247	1.000	rs75000494	chr11:102288962	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg19628046	chr18:33552617	C18orf21	-0.51	-7.35	-0.32	8.79e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9902453	0.838	rs3110495	chr17:27978455	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-13.14	-0.52	9.37e-34	Coffee consumption (cups per day);
LGG	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs713587	0.713	rs12466350	chr2:25239969	A/G	cg04586622	chr2:25135609	ADCY3	0.36	9.34	0.4	3.99e-19	Body mass index in non-asthmatics;
LGG	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.32	-0.32	1.08e-12	Bone mineral density;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg22901322	chr4:100815570	MAPKSP1	0.47	6.72	0.3	5.25e-11	Breast cancer;
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16680214	chr1:154839983	KCNN3	-0.51	-10.15	-0.43	5.53e-22	Prostate cancer;
LGG	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg03030879	chr14:75389066	RPS6KL1	0.37	6.89	0.3	1.84e-11	Caffeine consumption;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.93	-0.31	1.4e-11	Obesity-related traits;
LGG	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.32	0.43	1.25e-22	Colorectal cancer;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.18	-0.52	6.81e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs62209	1.000	rs62209	chr10:11000339	G/T	cg26901096	chr10:10994189	LOC254312	0.5	8.22	0.36	2.01e-15	Alzheimer's disease (late onset);
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg14789911	chr21:47582049	C21orf56	-0.41	-7.09	-0.31	4.91e-12	Testicular germ cell tumor;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg10950524	chr7:2139216	MAD1L1	0.33	7.17	0.32	3.08e-12	Schizophrenia;
LGG	cis	rs8068544	0.818	rs79892925	chr17:40171819	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.32	-0.55	9.52e-39	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg25008857	chr14:105974488	NA	0.58	10.16	0.43	4.9e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.39	-0.32	6.84e-13	Tonsillectomy;
LGG	cis	rs7077164	0.846	rs1227773	chr10:71579347	C/A	cg20696214	chr10:71583771	COL13A1	-0.39	-7.65	-0.34	1.14e-13	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg09307838	chr4:120376055	NA	0.73	12.11	0.49	1.57e-29	Corneal astigmatism;
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.09	0.42	8.65e-22	Neuroticism;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.33	-0.32	1.06e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.77	-0.34	5.17e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7765175	0.775	rs9398341	chr6:113682160	A/C	cg26552650	chr6:113682475	NA	0.31	6.73	0.3	5.09e-11	Coronary artery calcification;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.33	0.47	1.9e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg11520003	chr13:113540631	ATP11A	-0.39	-7.84	-0.34	3.08e-14	Interstitial lung disease;
LGG	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg24006582	chr15:45444508	DUOX1	-0.66	-12.61	-0.51	1.53e-31	Uric acid levels;
LGG	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25517755	chr10:38738941	LOC399744	-0.35	-6.69	-0.3	6.39e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2018055	0.644	rs4946258	chr6:117803538	C/T	cg14611402	chr6:117803162	DCBLD1	0.29	8.54	0.37	1.95e-16	Diastolic blood pressure;
LGG	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs11645898	0.935	rs4788615	chr16:72192372	G/A	cg14768367	chr16:72042858	DHODH	-0.8	-10.94	-0.45	6.38e-25	Blood protein levels;
LGG	cis	rs432925	0.625	rs2685119	chr16:341476	T/C	cg06233593	chr16:337645	AXIN1	0.42	7.66	0.34	1.12e-13	Morning vs. evening chronotype;
LGG	cis	rs9815354	1.000	rs6783001	chr3:41862232	C/A	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg05535760	chr7:792225	HEATR2	0.94	14.49	0.56	1.61e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-8.28	-0.36	1.3e-15	Neuroticism;
LGG	cis	rs1719271	0.908	rs1684052	chr15:65198511	T/C	cg11671771	chr15:65133392	PLEKHO2	-0.51	-7.07	-0.31	5.63e-12	Platelet count;
LGG	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.53	-12.57	-0.5	2.18e-31	Oropharynx cancer;
LGG	cis	rs3741151	0.773	rs73542967	chr11:73123512	C/T	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1927790	0.759	rs9554345	chr13:96997133	A/C	cg02571835	chr13:96230311	CLDN10	-0.34	-6.82	-0.3	2.9e-11	Body mass index;
LGG	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg07928641	chr1:182991847	LAMC1	0.49	10.0	0.42	1.92e-21	Colorectal cancer;
LGG	cis	rs4731207	0.698	rs12666427	chr7:124479352	A/G	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs4302748	0.862	rs11981777	chr7:36184753	G/A	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs9463078	0.804	rs9463081	chr6:45233108	G/A	cg25276700	chr6:44698697	NA	-0.39	-7.99	-0.35	1.05e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs439731	0.628	rs384344	chr16:1078084	C/T	cg09274344	chr16:1078689	NA	0.43	7.64	0.33	1.23e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7928758	0.887	rs75373472	chr11:134264506	T/G	cg25213107	chr11:134282864	B3GAT1	1.26	14.92	0.57	2.29e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg21100191	chr22:23484243	RTDR1	1.0	22.95	0.73	2.04e-78	Bone mineral density;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.84e-17	Lung cancer;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.13	-0.31	3.77e-12	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00711711	chr7:137687007	CREB3L2	0.45	6.81	0.3	3.01e-11	Gut microbiome composition (summer);
LGG	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.84	-0.34	3.1e-14	Systemic lupus erythematosus;
LGG	cis	rs9457247	0.765	rs1322077	chr6:167424293	T/C	cg07741184	chr6:167504864	NA	0.42	9.26	0.4	7.94e-19	Crohn's disease;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18110333	chr6:292329	DUSP22	-0.57	-10.07	-0.42	1.04e-21	Menopause (age at onset);
LGG	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg01411142	chr8:19674711	INTS10	0.44	7.07	0.31	5.61e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7927771	0.524	rs10838782	chr11:47877800	A/G	cg20307385	chr11:47447363	PSMC3	0.59	11.42	0.47	9.15e-27	Subjective well-being;
LGG	cis	rs4849845	0.637	rs2028147	chr2:121058412	C/T	cg15425061	chr2:121036351	RALB	-0.37	-6.83	-0.3	2.69e-11	Mean platelet volume;
LGG	cis	rs2991971	0.901	rs11211122	chr1:45954650	C/T	cg24296786	chr1:45957014	TESK2	0.41	7.49	0.33	3.57e-13	High light scatter reticulocyte count;
LGG	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg08250081	chr4:10125330	NA	0.44	8.55	0.37	1.76e-16	Bone mineral density;
LGG	cis	rs17818399	0.781	rs6746598	chr2:46865773	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-9.11	-0.39	2.44e-18	Height;
LGG	cis	rs755249	0.567	rs1126313	chr1:39639744	A/C	cg18385671	chr1:39797026	MACF1	-0.45	-8.17	-0.35	2.99e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27112264	chr19:58400504	ZNF814	0.44	7.39	0.32	6.82e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg21724239	chr8:58056113	NA	0.56	8.18	0.36	2.78e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12756686	chr19:29218302	NA	0.79	11.18	0.46	7.75e-26	Methadone dose in opioid dependence;
LGG	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	10.15	0.43	5.37e-22	Bone mineral density;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg11878867	chr6:150167359	LRP11	-0.49	-10.13	-0.43	6.67e-22	Lung cancer;
LGG	cis	rs701145	0.585	rs436852	chr3:153913403	G/A	cg17054900	chr3:154042577	DHX36	0.86	9.67	0.41	2.9e-20	Coronary artery disease;
LGG	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg11812906	chr14:75593930	NEK9	0.47	8.34	0.36	8.34e-16	Height;
LGG	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.48	7.89	0.34	2.2e-14	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9462027	0.527	rs11755393	chr6:34824636	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-10.98	-0.45	4.51e-25	Systemic lupus erythematosus;
LGG	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07648498	chr16:89883185	FANCA	0.4	6.87	0.3	2.14e-11	Vitiligo;
LGG	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg20892847	chr12:58011875	NA	-0.4	-8.52	-0.37	2.29e-16	Multiple sclerosis;
LGG	cis	rs72781680	0.821	rs72796369	chr2:24162663	G/T	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.68e-17	Lymphocyte counts;
LGG	cis	rs9486715	1.000	rs6902835	chr6:97063005	C/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-8.83	-0.38	2.18e-17	Headache;
LGG	trans	rs2018683	0.768	rs10282015	chr7:29022138	G/A	cg19402173	chr7:128379420	CALU	-0.69	-12.37	-0.5	1.4e-30	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg03806693	chr22:41940476	POLR3H	1.09	19.76	0.68	1.71e-63	Vitiligo;
LGG	cis	rs7923609	0.500	rs6479909	chr10:65333946	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-7.49	-0.33	3.51e-13	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg15596359	chr8:11213517	TDH	-0.41	-8.49	-0.37	2.79e-16	Retinal vascular caliber;
LGG	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg25019033	chr10:957182	NA	-0.6	-12.68	-0.51	7.58e-32	Eosinophil percentage of granulocytes;
LGG	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg00405596	chr8:11794950	NA	0.4	6.66	0.3	7.97e-11	Joint mobility (Beighton score);
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg17749961	chr2:30669863	LCLAT1	-0.71	-10.13	-0.43	6.23e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs10876993	0.680	rs2277322	chr12:58009202	T/C	cg18357645	chr12:58087776	OS9	-0.64	-10.76	-0.45	3.11e-24	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg18402987	chr7:1209562	NA	0.43	7.98	0.35	1.13e-14	Longevity;Endometriosis;
LGG	cis	rs6754311	0.731	rs745500	chr2:136583192	G/A	cg07169764	chr2:136633963	MCM6	-0.76	-12.97	-0.52	4.78e-33	Mosquito bite size;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.06	-0.31	6.05e-12	Lung cancer;
LGG	cis	rs2836974	0.897	rs2836973	chr21:40654928	A/G	cg17971929	chr21:40555470	PSMG1	0.87	17.4	0.63	1.47e-52	Cognitive function;
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.41	-0.4	2.28e-19	Triglycerides;
LGG	cis	rs1318772	0.866	rs348923	chr5:112836838	C/T	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.29	0.43	1.71e-22	Colorectal cancer;
LGG	cis	rs758324	0.947	rs804059	chr5:131270136	T/C	cg06307176	chr5:131281290	NA	-0.56	-9.21	-0.39	1.15e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg06968155	chr5:131705112	SLC22A5	0.72	8.32	0.36	9.6e-16	Rheumatoid arthritis;
LGG	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.27e-22	Height;
LGG	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.58	10.39	0.43	7.24e-23	Alzheimer's disease;
LGG	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg24642439	chr20:33292090	TP53INP2	0.83	14.58	0.56	7.1e-40	Coronary artery disease;
LGG	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg20573242	chr4:122745356	CCNA2	0.41	7.35	0.32	8.75e-13	Type 2 diabetes;
LGG	trans	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg00938859	chr5:1591904	SDHAP3	-0.7	-10.21	-0.43	3.15e-22	Breast cancer;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13126279	chr21:47581558	C21orf56	-0.48	-7.54	-0.33	2.54e-13	Testicular germ cell tumor;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06233552	chr17:5322836	RPAIN;NUP88	0.44	7.22	0.32	2.19e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg20587970	chr11:113659929	NA	-1.35	-17.99	-0.64	3.09e-55	Hip circumference adjusted for BMI;
LGG	trans	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg25214090	chr10:38739885	LOC399744	0.7	12.5	0.5	4.37e-31	Corneal astigmatism;
LGG	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg08997352	chr12:9597637	DDX12	-0.49	-8.06	-0.35	6.69e-15	IgG glycosylation;
LGG	trans	rs7939886	0.920	rs74459856	chr11:56027689	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	6.25e-64	Height;
LGG	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg13939156	chr17:80058883	NA	-0.39	-7.08	-0.31	5.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg03929089	chr4:120376271	NA	-0.45	-7.25	-0.32	1.75e-12	HDL cholesterol;
LGG	trans	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.39	-0.32	6.82e-13	Triglycerides;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00021576	chr1:244211966	NA	0.62	7.36	0.32	8.49e-13	Intelligence (multi-trait analysis);
LGG	cis	rs55665837	0.540	rs3206554	chr11:14797945	A/T	cg19336497	chr11:14380999	RRAS2	-0.4	-7.64	-0.33	1.25e-13	Vitamin D levels;
LGG	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg00631329	chr6:26305371	NA	-0.46	-8.52	-0.37	2.33e-16	Educational attainment;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.77	0.38	3.42e-17	Motion sickness;
LGG	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg23231163	chr10:75533350	FUT11	-0.4	-6.76	-0.3	4.24e-11	Inflammatory bowel disease;
LGG	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs986417	1.000	rs6573318	chr14:61087985	A/G	cg27398547	chr14:60952738	C14orf39	0.76	7.08	0.31	5.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.13	0.31	3.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.64	-0.63	1.25e-53	Refractive error;
LGG	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15664640	chr17:80829946	TBCD	0.55	10.62	0.44	1.01e-23	Breast cancer;
LGG	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.82e-22	Diabetic retinopathy;
LGG	cis	rs9814567	1.000	rs7611611	chr3:134307877	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg02574844	chr11:5959923	NA	-0.56	-8.83	-0.38	2.25e-17	DNA methylation (variation);
LGG	trans	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg06521331	chr12:34319734	NA	0.42	7.68	0.34	9.7e-14	Bladder cancer;
LGG	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg03929089	chr4:120376271	NA	-0.46	-7.44	-0.33	4.95e-13	HDL cholesterol;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg11301795	chr4:187892539	NA	-0.95	-27.15	-0.78	8.47e-98	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4731207	0.565	rs7811203	chr7:124653374	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs8049040	0.500	rs7188475	chr16:71446358	C/T	cg06353428	chr16:71660113	MARVELD3	-0.49	-7.8	-0.34	4.19e-14	Blood protein levels;
LGG	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg05887092	chr17:76393375	PGS1	0.78	18.66	0.66	2.26e-58	HDL cholesterol;
LGG	cis	rs9460578	0.537	rs12661606	chr6:20815260	A/G	cg13405222	chr6:20811065	CDKAL1	-0.77	-17.63	-0.63	1.37e-53	Breast cancer;
LGG	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.7	-0.3	5.96e-11	Coronary artery disease;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg17178900	chr1:205818956	PM20D1	-0.56	-12.62	-0.51	1.36e-31	Menarche (age at onset);
LGG	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg16584290	chr5:462447	EXOC3	0.46	9.45	0.4	1.67e-19	Cystic fibrosis severity;
LGG	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.33	4.17e-13	Height;
LGG	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg23625390	chr15:77176239	SCAPER	-0.73	-14.04	-0.55	1.5e-37	Blood metabolite levels;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.49	-0.37	2.78e-16	Obesity-related traits;
LGG	cis	rs10463554	0.890	rs26428	chr5:102366484	C/T	cg23492399	chr5:102201601	PAM	0.47	7.05	0.31	6.37e-12	Parkinson's disease;
LGG	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg02297831	chr4:17616191	MED28	0.49	9.27	0.4	7.22e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3768617	0.782	rs10911211	chr1:183022299	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.81	0.3	2.96e-11	Fuchs's corneal dystrophy;
LGG	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.63	6.95	0.31	1.21e-11	Initial pursuit acceleration;
LGG	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg07636037	chr3:49044803	WDR6	1.09	25.5	0.76	2.93e-90	Parkinson's disease;
LGG	cis	rs4851250	0.559	rs13032879	chr2:100602759	C/T	cg17356467	chr2:100759845	AFF3	0.45	7.01	0.31	8.22e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg08344181	chr3:125677491	NA	-0.61	-6.76	-0.3	4.12e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.740	rs34653170	chr8:10676542	G/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.48	-0.33	3.88e-13	Neuroticism;
LGG	cis	rs1670533	1.000	rs935970	chr4:1045323	C/G	cg27284194	chr4:1044797	NA	-0.54	-9.66	-0.41	3.14e-20	Recombination rate (females);
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs834603	0.575	rs1799370	chr7:47467864	C/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9636252	0.887	rs4552159	chr2:9267874	G/A	cg20341998	chr2:9276514	NA	0.38	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.7	-0.34	8.34e-14	Prudent dietary pattern;
LGG	trans	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-12.68	-0.51	7.5e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09138267	chr7:150102791	LOC728743	0.45	6.84	0.3	2.44e-11	Gut microbiome composition (summer);
LGG	cis	rs10484885	0.818	rs117562849	chr6:90249804	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.67	-8.09	-0.35	5.35e-15	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg10792982	chr14:105748885	BRF1	0.65	13.39	0.53	8.96e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg17809284	chr5:56205270	C5orf35	0.68	10.41	0.44	5.95e-23	Initial pursuit acceleration;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.79	-15.64	-0.59	1.35e-44	Obesity-related traits;
LGG	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.41	7.08	0.31	5.29e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.2e-20	Aortic root size;
LGG	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg05091796	chr16:4465799	CORO7	-0.9	-14.51	-0.56	1.32e-39	Schizophrenia;
LGG	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg22920501	chr2:26401640	FAM59B	0.44	8.88	0.38	1.43e-17	Gut microbiome composition (summer);
LGG	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07080220	chr10:102295463	HIF1AN	-0.64	-11.04	-0.46	2.63e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg21535247	chr6:8435926	SLC35B3	0.61	10.6	0.44	1.15e-23	Motion sickness;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08468577	chr11:2973342	NAP1L4	-0.32	-6.72	-0.3	5.52e-11	Calcium levels;
LGG	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg09324608	chr17:30823087	MYO1D	0.32	7.8	0.34	4.14e-14	Schizophrenia;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.7	-0.37	5.91e-17	Initial pursuit acceleration;
LGG	cis	rs11785693	0.862	rs62491200	chr8:4998001	A/C	cg26367366	chr8:4980734	NA	1.02	15.47	0.58	8.05e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg22496339	chr2:162101262	NA	-0.53	-11.71	-0.48	6.13e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	trans	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.47	-0.33	4.02e-13	Triglycerides;
LGG	cis	rs28374715	0.532	rs28897479	chr15:41690851	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.35	-31.61	-0.83	1.13e-117	Ulcerative colitis;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	8.01	0.35	9.18e-15	Renal function-related traits (BUN);
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg13009111	chr11:71350975	NA	-0.31	-7.02	-0.31	7.85e-12	Neuroticism;
LGG	cis	rs1975974	0.511	rs66461325	chr17:21755430	A/G	cg18423549	chr17:21743878	NA	-0.52	-8.04	-0.35	7.66e-15	Psoriasis;
LGG	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg09904177	chr6:26538194	HMGN4	0.77	17.17	0.62	1.64e-51	Intelligence (multi-trait analysis);
LGG	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.83	-0.3	2.64e-11	Alzheimer's disease (late onset);
LGG	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.28	-0.32	1.44e-12	Refractive error;
LGG	cis	rs9462027	0.651	rs9469885	chr6:34758716	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.42	-0.47	9.16e-27	Systemic lupus erythematosus;
LGG	trans	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg24247370	chr13:99142703	STK24	-0.43	-7.95	-0.35	1.47e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs422249	0.512	rs174578	chr11:61605499	T/A	cg19610905	chr11:61596333	FADS2	-0.75	-13.66	-0.54	6.35e-36	Trans fatty acid levels;
LGG	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg18681998	chr4:17616180	MED28	0.85	17.6	0.63	1.88e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.74	0.48	4.89e-28	Prudent dietary pattern;
LGG	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg26384229	chr12:38710491	ALG10B	-0.74	-13.99	-0.55	2.46e-37	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg07308232	chr7:1071921	C7orf50	-0.52	-9.34	-0.4	4.03e-19	Longevity;Endometriosis;
LGG	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg22431228	chr1:16359049	CLCNKA	0.37	6.74	0.3	4.86e-11	Systolic blood pressure;
LGG	cis	rs10463316	0.894	rs3846712	chr5:150759813	C/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2597513	0.860	rs2731340	chr3:13559829	C/T	cg24006715	chr3:13568212	NA	0.62	10.2	0.43	3.56e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg15557168	chr22:42548783	NA	0.33	7.25	0.32	1.75e-12	Cognitive function;
LGG	cis	rs208520	0.874	rs208470	chr6:66916402	G/A	cg07460842	chr6:66804631	NA	-0.93	-16.08	-0.6	1.52e-46	Exhaled nitric oxide output;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg04772025	chr11:68637568	NA	0.76	13.31	0.53	1.89e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-9.0	-0.39	6.03e-18	Educational attainment;
LGG	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg10167378	chr1:228756711	NA	0.56	7.98	0.35	1.2e-14	Chronic lymphocytic leukemia;
LGG	cis	rs11605924	0.766	rs12419690	chr11:45858584	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.49	-8.3	-0.36	1.15e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg18681998	chr4:17616180	MED28	0.85	18.77	0.66	7.61e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs877282	0.891	rs34652870	chr10:772218	T/C	cg17470449	chr10:769945	NA	0.65	8.11	0.35	4.44e-15	Uric acid levels;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg16885296	chr6:26284938	NA	0.36	6.65	0.3	8.19e-11	Gout;Renal underexcretion gout;
LGG	cis	rs4950322	0.857	rs72694703	chr1:146830138	C/A	cg22381352	chr1:146742008	CHD1L	-0.48	-7.98	-0.35	1.14e-14	Protein quantitative trait loci;
LGG	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	9.78e-21	Common traits (Other);
LGG	cis	rs12791968	1.000	rs10838397	chr11:45009133	A/G	cg11846598	chr11:44996168	LOC221122	0.61	11.3	0.47	2.47e-26	Inhibitory control;
LGG	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg13207630	chr7:32358064	NA	0.67	7.08	0.31	5.35e-12	Body mass index;
LGG	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg13010199	chr12:38710504	ALG10B	0.7	14.13	0.55	5.9e-38	Bladder cancer;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg17340268	chr14:105411764	AHNAK2	0.39	7.21	0.32	2.28e-12	Rheumatoid arthritis;
LGG	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.21	0.32	2.35e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.86	-0.42	6.1e-21	Body mass index;
LGG	trans	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.91	-0.51	8.82e-33	Obesity-related traits;
LGG	cis	rs9460578	0.634	rs9465912	chr6:20826011	G/A	cg13405222	chr6:20811065	CDKAL1	0.66	11.66	0.48	9.67e-28	Breast cancer;
LGG	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg13010199	chr12:38710504	ALG10B	0.73	14.89	0.57	2.91e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.86	0.38	1.67e-17	Platelet count;
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	2.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9487051	0.714	rs7774390	chr6:109602461	C/G	cg21918786	chr6:109611834	NA	0.48	8.94	0.38	9.36e-18	Reticulocyte fraction of red cells;
LGG	cis	rs4911259	0.513	rs6057665	chr20:31463460	A/G	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.91	-0.48	1.01e-28	Inflammatory bowel disease;
LGG	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg26150922	chr2:100937072	LONRF2	-0.5	-8.4	-0.36	5.68e-16	Intelligence (multi-trait analysis);
LGG	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg12454169	chr2:30669597	LCLAT1	0.88	9.01	0.39	5.24e-18	Midgestational circulating levels of PBDEs (fetal genetic effect);
LGG	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg03929089	chr4:120376271	NA	0.44	7.14	0.31	3.59e-12	HDL cholesterol;
LGG	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg20290983	chr6:43655470	MRPS18A	1.1	24.85	0.76	2.97e-87	IgG glycosylation;
LGG	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg13010199	chr12:38710504	ALG10B	0.7	14.31	0.55	9.98e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg06452013	chr16:1006166	LMF1	-0.52	-8.91	-0.38	1.19e-17	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.46	-0.47	6e-27	Response to antipsychotic treatment;
LGG	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14442939	chr10:27389572	ANKRD26	0.74	11.19	0.46	6.67e-26	Breast cancer;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.06	-0.55	1.23e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9972944	0.756	rs7222229	chr17:63765025	T/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs67311347	1.000	rs28871903	chr3:40511094	T/G	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11245990	chr11:68621969	NA	0.39	8.29	0.36	1.22e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.31	-0.58	4.11e-43	Chronic sinus infection;
LGG	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.31	-0.4	5.01e-19	Coronary artery disease;
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg16482183	chr6:26056742	HIST1H1C	0.4	6.84	0.3	2.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg23758822	chr17:41437982	NA	0.87	16.04	0.6	2.2e-46	Menopause (age at onset);
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	3.92e-21	Bipolar disorder;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg04503457	chr17:41445688	NA	-0.4	-9.94	-0.42	3.03e-21	Menopause (age at onset);
LGG	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg00990874	chr7:1149470	C7orf50	-0.84	-15.25	-0.58	8.03e-43	Bronchopulmonary dysplasia;
LGG	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg18105134	chr13:113819100	PROZ	-0.68	-13.87	-0.54	8.02e-37	Platelet distribution width;
LGG	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.41	0.44	6.3e-23	Arsenic metabolism;
LGG	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21659725	chr3:3221576	CRBN	-0.56	-9.76	-0.41	1.34e-20	Body mass index;
LGG	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg23625390	chr15:77176239	SCAPER	0.41	7.69	0.34	8.7e-14	Blood metabolite levels;
LGG	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg26446133	chr18:72167187	CNDP2	-0.69	-13.86	-0.54	8.65e-37	Refractive error;
LGG	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	trans	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	12.97	0.52	5.16e-33	Exhaled nitric oxide output;
LGG	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg00339695	chr16:24857497	SLC5A11	0.35	6.95	0.31	1.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg13010199	chr12:38710504	ALG10B	0.38	6.78	0.3	3.78e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg15162869	chr22:32027605	PISD	-0.7	-7.35	-0.32	9.02e-13	Age-related hearing impairment;
LGG	cis	rs757978	0.733	rs41342147	chr2:242407588	C/T	cg10173475	chr2:242152697	ANO7	-0.53	-6.81	-0.3	2.96e-11	Chronic lymphocytic leukemia;
LGG	cis	rs742614	0.533	rs6120395	chr20:32451693	A/G	cg06304546	chr20:32448765	NA	-0.7	-13.69	-0.54	4.55e-36	Stearic acid (18:0) levels;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.76	-0.38	3.83e-17	Menopause (age at onset);
LGG	cis	rs528418	0.592	rs9390305	chr6:145674158	G/C	cg03642472	chr6:145670687	NA	0.54	7.05	0.31	6.45e-12	Methadone dose in opioid dependence;
LGG	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg07599136	chr5:415885	AHRR	0.85	11.58	0.47	2.06e-27	Fat distribution (HIV);
LGG	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.42e-31	Motion sickness;
LGG	cis	rs7917772	0.582	rs4917975	chr10:104358407	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.39e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs77633900	0.892	rs2469216	chr15:76613477	C/T	cg21673338	chr15:77095150	SCAPER	-0.45	-6.7	-0.3	6.13e-11	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg13114125	chr14:105738426	BRF1	-0.85	-15.77	-0.59	3.73e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg01043669	chr3:72786069	NA	-0.44	-7.2	-0.32	2.39e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9381107	0.932	rs11756620	chr6:9423799	T/C	cg14735645	chr6:9486422	NA	-0.41	-6.8	-0.3	3.24e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs528418	0.540	rs7775733	chr6:145692352	G/T	cg03642472	chr6:145670687	NA	0.57	7.63	0.33	1.35e-13	Methadone dose in opioid dependence;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg09359103	chr1:154839909	KCNN3	-0.51	-10.6	-0.44	1.19e-23	Prostate cancer;
LGG	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg15704280	chr7:45808275	SEPT13	0.77	7.62	0.33	1.43e-13	Body mass index;
LGG	trans	rs2389217	0.509	rs2389219	chr12:33722185	T/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg13298116	chr11:62369859	EML3;MTA2	-0.59	-12.62	-0.51	1.33e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	trans	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.32	-0.32	1.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Mean corpuscular hemoglobin;
LGG	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.78	0.71	6.28e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2124969	0.548	rs72979963	chr2:161014483	A/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.18	-0.39	1.39e-18	Waist circumference adjusted for body mass index;
LGG	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg11541897	chr5:78281793	ARSB	0.44	7.34	0.32	9.62e-13	Blood and toenail selenium levels;Blood trace element (Se levels);
LGG	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.48	-7.15	-0.32	3.35e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg07817883	chr1:32538562	TMEM39B	-0.67	-8.48	-0.37	3e-16	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07677032	chr17:61819896	STRADA	-0.61	-10.98	-0.45	4.39e-25	Prudent dietary pattern;
LGG	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.91	-0.38	1.21e-17	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12862611	chr4:147443109	SLC10A7	0.47	7.69	0.34	8.71e-14	Cognitive performance;
LGG	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg16586182	chr3:47516702	SCAP	0.72	13.03	0.52	2.9e-33	Colorectal cancer;
LGG	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg14664628	chr15:75095509	CSK	-0.55	-10.45	-0.44	4.22e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg23306229	chr2:178417860	TTC30B	0.72	8.66	0.37	7.96e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.83	0.48	2.17e-28	Lewy body disease;
LGG	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.35	0.5	1.69e-30	Lung cancer in ever smokers;
LGG	cis	rs2562456	0.917	rs6511253	chr19:21678798	A/G	cg00806126	chr19:22604979	ZNF98	0.61	9.1	0.39	2.7e-18	Pain;
LGG	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.57	-0.71	6.1e-72	Heart rate;
LGG	trans	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg02002194	chr4:3960332	NA	0.47	8.89	0.38	1.33e-17	Mood instability;
LGG	cis	rs9649465	0.967	rs598115	chr7:123402603	C/G	cg03229431	chr7:123269106	ASB15	0.4	8.7	0.37	5.95e-17	Migraine;
LGG	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.76	13.53	0.53	2.24e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.89	0.45	9.64e-25	Mean platelet volume;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.78	-0.54	1.83e-36	Alzheimer's disease;
LGG	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg27129171	chr3:47204927	SETD2	-0.81	-14.98	-0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	7.2	0.32	2.49e-12	Resting heart rate;
LGG	cis	rs12200560	0.505	rs211175	chr6:97073320	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.73	0.34	6.78e-14	Coronary heart disease;
LGG	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg13647721	chr17:30228624	UTP6	0.66	8.98	0.39	6.91e-18	Hip circumference adjusted for BMI;
LGG	cis	rs477692	0.544	rs7904404	chr10:131447612	G/A	cg05714579	chr10:131428358	MGMT	-0.86	-20.14	-0.68	3e-65	Response to temozolomide;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs782590	0.837	rs782584	chr2:55921116	C/G	cg18811423	chr2:55921094	PNPT1	-0.95	-23.5	-0.74	5.87e-81	Metabolic syndrome;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg03351412	chr1:154909251	PMVK	0.67	12.9	0.51	9.59e-33	Prostate cancer;
LGG	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.34	0.32	9.64e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.34	-7.43	-0.33	5.36e-13	Schizophrenia;
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg21775007	chr8:11205619	TDH	0.5	8.4	0.36	5.4e-16	Systolic blood pressure;
LGG	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.78	0.71	6.28e-73	Bladder cancer;
LGG	cis	rs13394619	0.605	rs12476319	chr2:11748406	A/G	cg07314298	chr2:11723111	GREB1	0.34	7.09	0.31	5.14e-12	Endometriosis;
LGG	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Breast cancer;
LGG	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.52	-8.48	-0.37	3.03e-16	Cognitive test performance;
LGG	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.68	0.37	6.66e-17	Aortic root size;
LGG	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.16e-16	Aortic root size;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg23129478	chr18:44337922	ST8SIA5	0.35	6.76	0.3	4.17e-11	Personality dimensions;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07157834	chr1:205819609	PM20D1	0.82	19.87	0.68	5.65e-64	Menarche (age at onset);
LGG	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg26470479	chr17:40805923	NA	0.32	6.79	0.3	3.44e-11	Colorectal or endometrial cancer;
LGG	cis	rs36051895	0.659	rs62541539	chr9:5038180	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.68	-0.59	9.15e-45	Pediatric autoimmune diseases;
LGG	cis	rs6723226	0.750	rs3769597	chr2:32691400	T/G	cg02381751	chr2:32503542	YIPF4	0.62	10.74	0.45	3.49e-24	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114789346	chr4:119748652	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04665180	chr9:132934972	FREQ	0.45	7.27	0.32	1.52e-12	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15921240	chr4:331448	ZNF141	0.49	7.49	0.33	3.64e-13	Gut microbiome composition (summer);
LGG	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg18351406	chr4:77819688	ANKRD56	0.45	7.77	0.34	5.23e-14	Emphysema distribution in smoking;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.75	0.54	2.54e-36	Prudent dietary pattern;
LGG	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.42	-0.33	5.79e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg04058563	chr4:185651563	MLF1IP	-0.46	-9.76	-0.41	1.35e-20	Kawasaki disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11643848	chr6:36561834	SFRS3	0.54	8.25	0.36	1.62e-15	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg13010199	chr12:38710504	ALG10B	0.44	8.41	0.36	4.95e-16	Morning vs. evening chronotype;
LGG	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-9.82	-0.42	8.54e-21	Colorectal cancer;
LGG	cis	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07988820	chr12:82153109	PPFIA2	0.77	11.21	0.46	5.5e-26	Resting heart rate;
LGG	cis	rs17453880	0.929	rs4473762	chr5:152065361	T/C	cg10931792	chr5:152022470	NA	0.4	8.53	0.37	2.14e-16	Subjective well-being;
LGG	cis	rs10937275	0.826	rs62294593	chr3:186642111	T/G	cg24050613	chr3:186648279	ST6GAL1	0.86	8.77	0.38	3.35e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg13385521	chr17:29058706	SUZ12P	-0.78	-8.97	-0.38	7.66e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.56	0.37	1.7e-16	Platelet count;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.27	0.36	1.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-8.01	-0.35	9.33e-15	Vitiligo;
LGG	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11890956	chr21:40555474	PSMG1	-1.0	-21.4	-0.71	3.89e-71	Cognitive function;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.56	0.37	1.68e-16	Bipolar disorder;
LGG	cis	rs477692	1.000	rs4750759	chr10:131436603	G/A	cg05714579	chr10:131428358	MGMT	-0.52	-10.53	-0.44	2.19e-23	Response to temozolomide;
LGG	cis	rs4774899	0.966	rs4238321	chr15:57560777	C/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.3	-0.32	1.24e-12	Urinary tract infection frequency;
LGG	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg13263323	chr15:86062960	AKAP13	-0.36	-7.48	-0.33	3.66e-13	Coronary artery disease;
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg16434002	chr17:42200994	HDAC5	0.55	10.36	0.43	9.14e-23	Total body bone mineral density;
LGG	cis	rs9814567	0.778	rs4955546	chr3:134334738	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-11.0	-0.46	3.69e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs8073060	0.586	rs225298	chr17:33923946	T/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.07	-0.64	1.31e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg11764359	chr7:65958608	NA	0.75	13.54	0.53	2.08e-35	Aortic root size;
LGG	trans	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.76	11.01	0.46	3.33e-25	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs9816226	0.590	rs872602	chr3:185826028	A/G	cg00760338	chr3:185826511	ETV5	0.97	18.1	0.64	9.08e-56	Obesity;Body mass index;
LGG	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	7.02e-11	IgG glycosylation;
LGG	cis	rs4731207	0.596	rs6961441	chr7:124590871	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6669919	0.647	rs10863900	chr1:211675597	A/G	cg10512769	chr1:211675356	NA	-0.58	-12.32	-0.5	2.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9467773	0.620	rs2504567	chr6:26662920	C/G	cg09904177	chr6:26538194	HMGN4	0.67	13.9	0.54	5.81e-37	Intelligence (multi-trait analysis);
LGG	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg11845111	chr2:191398756	TMEM194B	-0.37	-8.3	-0.36	1.15e-15	Pulse pressure;
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	9.58	0.41	5.78e-20	Tonsillectomy;
LGG	cis	rs9487094	0.689	rs4636056	chr6:109730882	T/C	cg01125227	chr6:109776195	MICAL1	0.39	6.89	0.3	1.83e-11	Height;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25427524	chr10:38739819	LOC399744	-0.68	-12.92	-0.51	8.06e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.36	-0.32	8.28e-13	Bipolar disorder;
LGG	cis	rs2239547	0.657	rs12488303	chr3:52862003	G/A	cg11645453	chr3:52864694	ITIH4	0.72	11.24	0.46	4.56e-26	Schizophrenia;
LGG	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg05887092	chr17:76393375	PGS1	0.79	18.55	0.65	7.24e-58	HDL cholesterol levels;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.63	-0.33	1.31e-13	Lung cancer;
LGG	cis	rs6088590	0.561	rs6088527	chr20:33155841	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.69	0.37	6.18e-17	Coronary artery disease;
LGG	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg02002194	chr4:3960332	NA	0.42	7.24	0.32	1.93e-12	Triglycerides;
LGG	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg12011299	chr4:100065546	ADH4	0.41	8.02	0.35	8.94e-15	Smoking initiation;
LGG	cis	rs7017914	0.934	rs17689585	chr8:71818801	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.8	-0.3	3.21e-11	Bone mineral density;
LGG	cis	rs6800768	0.633	rs826371	chr3:24163645	C/G	cg10674438	chr3:24145617	LOC152024	-0.51	-9.36	-0.4	3.56e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8017423	0.967	rs11159958	chr14:90716051	T/C	cg04374321	chr14:90722782	PSMC1	0.86	18.08	0.64	1.08e-55	Mortality in heart failure;
LGG	cis	rs7072216	0.763	rs7911036	chr10:100167015	A/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg22875332	chr1:76189707	ACADM	0.61	10.29	0.43	1.65e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17453880	0.963	rs4304072	chr5:151953465	G/C	cg12297329	chr5:152029980	NA	-0.86	-21.92	-0.71	1.35e-73	Subjective well-being;
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg21918786	chr6:109611834	NA	-0.47	-8.66	-0.37	8.14e-17	Reticulocyte fraction of red cells;
LGG	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg02002194	chr4:3960332	NA	0.42	7.42	0.33	5.81e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.62	-0.37	1.06e-16	Lung cancer;
LGG	cis	rs9733	0.744	rs11204737	chr1:150847647	C/T	cg13175981	chr1:150552382	MCL1	0.53	8.58	0.37	1.45e-16	Tonsillectomy;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg27400746	chr16:89904261	SPIRE2	-1.11	-16.37	-0.61	7.1e-48	Skin colour saturation;
LGG	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg03517284	chr6:25882590	NA	0.66	12.84	0.51	1.77e-32	Blood metabolite levels;
LGG	cis	rs17221829	0.673	rs56004718	chr11:89413190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.58	-0.37	1.49e-16	Anxiety in major depressive disorder;
LGG	cis	rs2229238	0.868	rs41308419	chr1:154507197	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.88	0.3	1.99e-11	Coronary heart disease;
LGG	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.28e-14	Dementia with Lewy bodies;
LGG	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg02640540	chr1:67518911	SLC35D1	0.36	7.02	0.31	7.83e-12	Lymphocyte percentage of white cells;
LGG	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg02023728	chr11:77925099	USP35	0.45	7.69	0.34	9.01e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.33	-6.87	-0.3	2.14e-11	Schizophrenia;
LGG	cis	rs806215	0.526	rs4728079	chr7:127480364	A/G	cg25922125	chr7:127225783	GCC1	-0.47	-6.9	-0.31	1.74e-11	Type 2 diabetes;
LGG	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg17150306	chr7:855575	UNC84A	-0.34	-7.02	-0.31	7.78e-12	Perceived unattractiveness to mosquitoes;
LGG	cis	rs758324	0.797	rs247004	chr5:131344358	A/G	cg06307176	chr5:131281290	NA	0.49	7.22	0.32	2.15e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4731207	0.596	rs12111658	chr7:124584768	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs7572644	0.640	rs11127126	chr2:28023284	C/T	cg27432699	chr2:27873401	GPN1	0.47	6.86	0.3	2.21e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	10.65	0.44	7.55e-24	Menopause (age at onset);
LGG	trans	rs3960554	0.569	rs11973658	chr7:75882026	A/C	cg19862616	chr7:65841803	NCRNA00174	0.62	10.16	0.43	4.93e-22	Eotaxin levels;
LGG	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.6e-12	Mean corpuscular hemoglobin;
LGG	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.46e-22	Iron status biomarkers;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.8e-22	Neutrophil percentage of white cells;
LGG	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.68	-0.51	7.86e-32	Vitiligo;
LGG	cis	rs3735485	0.800	rs4724350	chr7:45059339	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11890956	chr21:40555474	PSMG1	-0.73	-12.7	-0.51	6.26e-32	Menarche (age at onset);
LGG	cis	rs7849585	0.830	rs10858250	chr9:139119215	A/G	cg14094347	chr9:139131620	QSOX2	-0.48	-9.2	-0.39	1.21e-18	Height;
LGG	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.81	-15.45	-0.58	1.05e-43	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	15.97	0.6	4.63e-46	Platelet count;
LGG	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg17376030	chr22:41985996	PMM1	-0.48	-7.86	-0.34	2.78e-14	Vitiligo;
LGG	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.05e-19	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg11062466	chr8:58055876	NA	0.57	9.02	0.39	4.97e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg13607699	chr17:42295918	UBTF	0.54	9.11	0.39	2.55e-18	Total body bone mineral density;
LGG	cis	rs1691799	0.867	rs1168341	chr12:66759080	G/C	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-7.26	-0.32	1.69e-12	Height;
LGG	cis	rs7523273	0.597	rs56075814	chr1:207975949	T/C	cg22525895	chr1:207977042	MIR29B2	-0.45	-6.77	-0.3	4.02e-11	Schizophrenia;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20832137	chr6:71667105	B3GAT2	-0.4	-6.66	-0.3	7.63e-11	Electrocardiographic conduction measures;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg18402987	chr7:1209562	NA	0.5	8.29	0.36	1.22e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9318086	0.648	rs7331047	chr13:24467342	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	9.53	0.41	8.58e-20	Myopia (pathological);
LGG	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.25	-0.4	8.12e-19	Educational attainment;
LGG	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.44	0.4	1.81e-19	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	0.784	rs13326389	chr3:40459724	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.66	0.3	7.97e-11	Renal cell carcinoma;
LGG	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg11062466	chr8:58055876	NA	0.48	8.39	0.36	5.93e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg26818257	chr2:241905806	NA	0.5	11.43	0.47	8.12e-27	Joint mobility (Beighton score);
LGG	cis	rs1497828	0.956	rs2646832	chr1:217544979	A/G	cg04411442	chr1:217543379	NA	0.48	8.22	0.36	1.99e-15	Dialysis-related mortality;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg15128208	chr22:42549153	NA	0.74	11.04	0.46	2.49e-25	Birth weight;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	6.92	0.31	1.51e-11	Longevity;
LGG	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg13010199	chr12:38710504	ALG10B	0.59	11.24	0.46	4.34e-26	Morning vs. evening chronotype;
LGG	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg13902645	chr11:5959945	NA	-0.66	-10.6	-0.44	1.14e-23	DNA methylation (variation);
LGG	cis	rs7119038	0.509	rs10892260	chr11:118583525	A/C	cg20309703	chr11:118481025	PHLDB1	0.4	6.76	0.3	4.27e-11	Sjögren's syndrome;
LGG	cis	rs283228	0.617	rs473846	chr6:101738038	G/A	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg13206674	chr6:150067644	NUP43	0.61	13.82	0.54	1.31e-36	Lung cancer;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg11494091	chr17:61959527	GH2	-1.03	-26.1	-0.77	5.33e-93	Prudent dietary pattern;
LGG	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg27572855	chr1:25598939	RHD	0.48	11.15	0.46	9.92e-26	Erythrocyte sedimentation rate;
LGG	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.79	0.38	3.04e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9543976	0.925	rs2876706	chr13:76186305	T/G	cg01531495	chr13:76123901	UCHL3	0.64	7.71	0.34	7.75e-14	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16312414	chr1:109633444	TMEM167B	0.45	6.74	0.3	4.71e-11	Gut microbiome composition (summer);
LGG	cis	rs7927771	0.524	rs4539273	chr11:47694699	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-10.99	-0.45	3.98e-25	Subjective well-being;
LGG	cis	rs9943753	0.508	rs11066422	chr12:109807153	A/G	cg19025524	chr12:109796872	NA	-0.53	-11.28	-0.46	3.14e-26	HDL cholesterol;
LGG	cis	rs59197085	0.636	rs2270593	chr7:128456234	C/T	cg00734629	chr7:128471146	FLNC	0.34	6.89	0.3	1.87e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.77	-0.38	3.54e-17	Colorectal cancer;
LGG	trans	rs853679	0.567	rs13196606	chr6:28370078	C/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.65	-0.3	8.14e-11	Depression;
LGG	cis	rs4788570	0.697	rs11075904	chr16:71816899	G/A	cg06353428	chr16:71660113	MARVELD3	1.27	20.46	0.69	9.34e-67	Intelligence (multi-trait analysis);
LGG	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg11901034	chr3:128598214	ACAD9	0.47	7.04	0.31	6.79e-12	IgG glycosylation;
LGG	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.84	-0.51	1.72e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.0	0.49	4.4e-29	Prudent dietary pattern;
LGG	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.27	-0.32	1.5e-12	HDL cholesterol;
LGG	cis	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.45	-0.37	3.69e-16	Triglycerides;
LGG	cis	rs1971256	0.500	rs3912291	chr6:151818210	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.64	-6.7	-0.3	5.9e-11	Endometriosis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg24021652	chr19:16296192	FAM32A	0.42	6.92	0.31	1.55e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10744422	0.858	rs12426809	chr12:123327143	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-9.28	-0.4	6.3e-19	Schizophrenia;
LGG	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg08601574	chr20:25228251	PYGB	0.37	7.54	0.33	2.43e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.17	0.49	9.25e-30	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	0.821	rs55948613	chr2:24094787	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.75	0.38	3.98e-17	Lymphocyte counts;
LGG	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.7	-0.41	2.3e-20	Educational attainment;
LGG	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg08250081	chr4:10125330	NA	0.67	12.27	0.5	3.69e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08677398	chr8:58056175	NA	0.6	9.02	0.39	5e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7742824	0.917	rs2015676	chr6:44075124	G/A	cg04074908	chr6:44101190	TMEM63B	0.6	12.19	0.49	7.87e-30	Major depressive disorder;
LGG	trans	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg14227996	chr4:17616232	MED28	0.72	8.65	0.37	8.43e-17	Opioid sensitivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19406736	chr19:37096010	ZNF529;ZNF382	0.44	6.89	0.3	1.78e-11	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.26	0.32	1.69e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.03	-0.42	1.5e-21	Lung cancer;
LGG	trans	rs2362965	0.565	rs77879537	chr3:158149065	T/G	cg23275840	chr4:47708675	CORIN	-0.39	-8.23	-0.36	1.88e-15	Height;
LGG	cis	rs6997458	0.716	rs1845253	chr8:86402196	C/T	cg02393479	chr8:86352350	CA3	-0.32	-6.98	-0.31	1.03e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2797369	0.713	rs2749133	chr6:101485805	T/C	cg27451362	chr6:101846650	GRIK2	0.85	11.39	0.47	1.19e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.23	-0.39	9.61e-19	Menopause (age at onset);
LGG	cis	rs2798269	0.528	rs9509802	chr13:22148698	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.44	-7.8	-0.34	4.14e-14	PR segment;
LGG	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg13010199	chr12:38710504	ALG10B	0.63	12.63	0.51	1.28e-31	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.967	rs55744550	chr17:28475729	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.59	0.53	1.2e-35	Coffee consumption (cups per day);
LGG	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-10.31	-0.43	1.36e-22	Body mass index;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-15.38	-0.58	1.94e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg12486710	chr1:178512616	C1orf220	0.52	10.67	0.44	6.43e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7586879	0.593	rs10198275	chr2:25130542	A/C	cg04586622	chr2:25135609	ADCY3	0.48	13.13	0.52	1.08e-33	Body mass index;
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.69e-14	Height;
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg04911050	chr16:677664	RAB40C	0.35	6.94	0.31	1.33e-11	Height;
LGG	cis	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg07460842	chr6:66804631	NA	0.93	17.19	0.62	1.42e-51	Exhaled nitric oxide levels;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg03188948	chr7:1209495	NA	0.71	10.2	0.43	3.7e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.77e-17	Aortic root size;
LGG	cis	rs11264213	0.892	rs16822339	chr1:36220558	A/C	cg27506609	chr1:36549197	TEKT2	-0.64	-7.4	-0.33	6.49e-13	Schizophrenia;
LGG	cis	rs4731207	0.672	rs2896360	chr7:124448516	T/C	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs2282802	0.685	rs11748023	chr5:139558584	C/T	cg26211634	chr5:139558579	C5orf32	-0.35	-7.73	-0.34	6.75e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg06640241	chr16:89574553	SPG7	0.68	11.4	0.47	1.03e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs8017423	0.967	rs60548738	chr14:90724399	G/A	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.74e-60	Mortality in heart failure;
LGG	cis	rs17039065	0.920	rs58451659	chr4:109446003	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	cis	rs9354308	0.764	rs9345716	chr6:66607782	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.72	-0.3	5.34e-11	Metabolite levels;
LGG	cis	rs6840360	0.642	rs1443089	chr4:152450300	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.33	0.32	1.05e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	7.31	0.32	1.16e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4566357	0.615	rs10198406	chr2:227913539	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.06	-0.39	3.55e-18	Coronary artery disease;
LGG	cis	rs9902453	0.838	rs8064689	chr17:28217053	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.64	0.54	7.57e-36	Coffee consumption (cups per day);
LGG	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg05887092	chr17:76393375	PGS1	0.72	15.84	0.59	1.89e-45	HDL cholesterol levels;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.813	rs8003478	chr14:72120363	C/G	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.18	-0.39	1.45e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-8.48	-0.37	3.05e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25072359	chr17:41440525	NA	0.48	9.37	0.4	3.15e-19	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15749322	chr11:82905199	ANKRD42	0.46	7.85	0.34	2.83e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19671926	chr4:122722719	EXOSC9	0.48	7.33	0.32	1.03e-12	Type 2 diabetes;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg04990556	chr1:26633338	UBXN11	0.63	8.32	0.36	9.6e-16	Obesity-related traits;
LGG	cis	rs9815354	0.767	rs73081335	chr3:41895177	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.95	-0.31	1.22e-11	Myopia (pathological);
LGG	cis	rs13421350	0.579	rs16860426	chr2:173319112	A/T	cg15021238	chr2:173305865	ITGA6	-0.84	-9.62	-0.41	4.2e-20	Diabetic kidney disease;
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg01059449	chr18:44338099	ST8SIA5	-0.36	-7.72	-0.34	7.26e-14	Personality dimensions;
LGG	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.02	-0.55	1.79e-37	Hair morphology;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.45	0.53	4.9e-35	Obesity-related traits;
LGG	cis	rs9522267	0.643	rs9522280	chr13:112221334	G/C	cg14952266	chr13:112191215	NA	0.44	8.52	0.37	2.31e-16	Hepatitis;
LGG	cis	rs9549367	0.713	rs3024746	chr13:113821777	G/A	cg18105134	chr13:113819100	PROZ	-0.76	-15.87	-0.59	1.34e-45	Platelet distribution width;
LGG	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.74	-0.3	4.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2074193	0.627	rs11183922	chr12:47774732	C/A	cg02516419	chr12:47771422	NA	0.73	10.74	0.45	3.46e-24	Migraine with aura;
LGG	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg06431347	chr2:235935754	SH3BP4	-0.49	-11.62	-0.48	1.47e-27	Dialysis-related mortality;
LGG	cis	rs72945132	0.507	rs34612166	chr11:70244400	C/T	cg14088196	chr11:70211408	PPFIA1	0.8	10.54	0.44	1.92e-23	Coronary artery disease;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.65	0.37	8.39e-17	Longevity;
LGG	cis	rs7020830	0.931	rs13288178	chr9:37107799	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	33.39	0.84	2.24e-125	Schizophrenia;
LGG	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.75	0.34	6.06e-14	Eosinophil percentage of white cells;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	16.26	0.6	2.3e-47	Platelet count;
LGG	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg26446133	chr18:72167187	CNDP2	-0.7	-14.95	-0.57	1.55e-41	Refractive error;
LGG	cis	rs4740619	0.745	rs10733305	chr9:15866759	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.79	-0.41	1.07e-20	Body mass index;
LGG	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg01244601	chr4:120671846	NA	-0.35	-6.65	-0.3	8.53e-11	Corneal astigmatism;
LGG	cis	rs4732038	0.967	rs10261532	chr7:134248045	A/G	cg06906464	chr7:134288099	NA	-0.5	-12.6	-0.51	1.71e-31	Longevity;
LGG	trans	rs9929218	1.000	rs4783570	chr16:68806539	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.82	-0.51	2e-32	Colorectal cancer;
LGG	cis	rs78366141	0.649	rs73842243	chr4:89738899	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.83	7.3	0.32	1.28e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.12	-0.31	4.17e-12	Bipolar disorder;
LGG	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg07661805	chr8:143867942	LY6D	0.3	8.0	0.35	1e-14	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1784581	0.569	rs9365357	chr6:162414913	A/G	cg17173639	chr6:162384350	PARK2	0.64	13.52	0.53	2.5e-35	Itch intensity from mosquito bite;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.21	0.6	4.15e-47	Lymphocyte counts;
LGG	cis	rs10864907	0.614	rs7557537	chr2:113702530	T/C	cg06156847	chr2:113672199	IL1F7	-0.37	-7.39	-0.32	6.99e-13	Pulmonary function;
LGG	cis	rs4684776	0.867	rs1499119	chr3:11333291	G/T	cg24705426	chr3:11550659	ATG7	-0.47	-8.79	-0.38	3.04e-17	Small vessel stroke;
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg08742575	chr21:47604166	C21orf56	0.47	8.15	0.35	3.5e-15	Testicular germ cell tumor;
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg16301924	chr13:53314226	LECT1	-0.36	-7.04	-0.31	7.17e-12	Lewy body disease;
LGG	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.0	0.35	9.88e-15	Morning vs. evening chronotype;
LGG	cis	rs7717393	0.786	rs6860183	chr5:155788183	C/T	cg04435420	chr5:155754009	SGCD	0.75	9.66	0.41	3.12e-20	Egg allergy;
LGG	trans	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg06521331	chr12:34319734	NA	0.46	8.33	0.36	9.16e-16	Bladder cancer;
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.54	-0.33	2.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg13047869	chr3:10149882	C3orf24	0.58	8.28	0.36	1.31e-15	Alzheimer's disease;
LGG	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.08	-0.49	2.05e-29	Urinary tract infection frequency;
LGG	cis	rs9467160	0.834	rs7766620	chr6:24455543	G/C	cg20631270	chr6:24437470	GPLD1	0.54	7.95	0.35	1.43e-14	Liver enzyme levels;
LGG	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	7.13	0.31	3.9e-12	Morning vs. evening chronotype;
LGG	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg23950597	chr19:37808831	NA	0.55	8.04	0.35	7.56e-15	Coronary artery calcification;
LGG	trans	rs73191547	0.771	rs11777161	chr8:10043145	A/T	cg16141378	chr3:129829833	LOC729375	-0.3	-6.74	-0.3	4.79e-11	Schizophrenia;
LGG	cis	rs10504130	0.660	rs6473666	chr8:52838295	A/G	cg24946253	chr8:52722146	PXDNL	-0.5	-7.94	-0.35	1.51e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9831754	0.906	rs9840031	chr3:78396140	C/T	cg06138941	chr3:78371609	NA	0.9	19.13	0.66	1.51e-60	Calcium levels;
LGG	trans	rs3206736	0.548	rs1649224	chr7:34990996	G/C	cg14337134	chr7:102920323	DPY19L2P2	0.4	6.9	0.31	1.69e-11	Diastolic blood pressure;
LGG	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg15268244	chr15:77196840	NA	0.43	8.34	0.36	8.9e-16	Blood metabolite levels;
LGG	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg12310025	chr6:25882481	NA	0.45	7.55	0.33	2.32e-13	Iron status biomarkers;
LGG	trans	rs9354308	0.691	rs9445610	chr6:66598938	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.67	-0.3	7.49e-11	Metabolite levels;
LGG	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg25664220	chr3:72788482	NA	-0.31	-8.96	-0.38	7.73e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg14541582	chr5:601475	NA	-0.68	-10.65	-0.44	7.51e-24	Obesity-related traits;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01245787	chr4:71859630	DCK	0.41	7.36	0.32	8.56e-13	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.71	-0.3	5.87e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.44	-0.37	4.03e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07237946	chr1:155904327	KIAA0907	0.42	6.96	0.31	1.16e-11	Cognitive performance;
LGG	cis	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05901451	chr6:126070800	HEY2	-0.81	-17.27	-0.63	6.32e-52	Brugada syndrome;
LGG	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg16070123	chr10:51489643	NA	0.4	7.01	0.31	8.51e-12	Prostate-specific antigen levels;
LGG	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg01631408	chr1:248437212	OR2T33	0.52	9.5	0.4	1.12e-19	Common traits (Other);
LGG	cis	rs8078723	0.966	rs7021	chr17:38153875	T/A	cg17467752	chr17:38218738	THRA	0.73	13.8	0.54	1.5e-36	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs35425515	0.706	rs12770870	chr10:98863561	A/G	cg09122387	chr10:98855762	SLIT1	-0.68	-8.77	-0.38	3.53e-17	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	6.13e-37	Prudent dietary pattern;
LGG	trans	rs8073060	0.586	rs225250	chr17:33941963	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.3	-0.65	1.09e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7444	0.556	rs5754100	chr22:21916166	T/C	cg11654148	chr22:21984483	YDJC	-0.4	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.67	-0.34	1.04e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2777491	0.915	rs7180418	chr15:41629502	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.42	-0.67	6.91e-62	Ulcerative colitis;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg02127607	chr17:61920694	SMARCD2	-0.38	-6.68	-0.3	6.91e-11	Prudent dietary pattern;
LGG	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg16400903	chr5:693638	TPPP	0.47	6.84	0.3	2.48e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg13010199	chr12:38710504	ALG10B	0.72	14.23	0.55	2.25e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.01	-0.39	5.47e-18	Vitiligo;
LGG	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg23422044	chr7:1970798	MAD1L1	-0.63	-10.87	-0.45	1.17e-24	Bipolar disorder;
LGG	cis	rs1620921	0.594	rs9355843	chr6:161268805	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.86e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-12.9	-0.51	9.35e-33	Life satisfaction;
LGG	cis	rs11229555	0.574	rs12271501	chr11:58214969	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg26897989	chr16:1907736	C16orf73	-0.48	-8.73	-0.38	4.82e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg05091796	chr16:4465799	CORO7	-0.97	-16.83	-0.62	6.45e-50	Schizophrenia;
LGG	cis	rs1318772	0.932	rs13187776	chr5:112910850	G/A	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg11878867	chr6:150167359	LRP11	0.53	11.06	0.46	2.21e-25	Lung cancer;
LGG	trans	rs7786808	0.760	rs10259321	chr7:158221038	G/A	cg02030672	chr11:45687055	CHST1	-0.42	-7.47	-0.33	3.93e-13	Obesity-related traits;
LGG	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg14541582	chr5:601475	NA	-0.69	-10.98	-0.45	4.26e-25	Obesity-related traits;
LGG	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg24450063	chr1:156163899	SLC25A44	1.01	20.78	0.69	3.1e-68	Testicular germ cell tumor;
LGG	cis	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg24110177	chr3:50126178	RBM5	-0.41	-7.11	-0.31	4.46e-12	Intelligence (multi-trait analysis);
LGG	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27286337	chr10:134555280	INPP5A	0.89	13.01	0.52	3.28e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	7.28	0.32	1.45e-12	Height;
LGG	cis	rs60180747	0.865	rs11639073	chr15:66600097	C/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.53	8.85	0.38	1.8e-17	Testicular germ cell tumor;
LGG	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg02640540	chr1:67518911	SLC35D1	0.38	7.38	0.32	7.54e-13	Lymphocyte percentage of white cells;
LGG	cis	rs3771570	0.901	rs4075818	chr2:242432142	T/C	cg21155796	chr2:242212141	HDLBP	0.7	9.17	0.39	1.55e-18	Prostate cancer;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs2916247	0.909	rs7009009	chr8:93170665	T/A	cg10183463	chr8:93005414	RUNX1T1	0.34	6.9	0.31	1.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.662	rs2094436	chr14:55661495	C/G	cg04306507	chr14:55594613	LGALS3	0.51	11.86	0.48	1.69e-28	Protein biomarker;
LGG	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg05791153	chr7:19748676	TWISTNB	-0.65	-9.78	-0.41	1.16e-20	Thyroid stimulating hormone;
LGG	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.1	0.35	4.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg20637307	chr2:213403960	ERBB4	0.61	10.71	0.45	4.62e-24	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7568458	0.684	rs67988001	chr2:85787123	C/T	cg17127132	chr2:85788382	GGCX	0.52	8.31	0.36	1.07e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg00292662	chr22:38071168	LGALS1	0.7	13.43	0.53	5.91e-35	Fat distribution (HIV);
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-7.04	-0.31	6.92e-12	Longevity;Endometriosis;
LGG	cis	rs12928939	0.727	rs8053623	chr16:71647529	A/G	cg08717414	chr16:71523259	ZNF19	-0.48	-7.49	-0.33	3.44e-13	Post bronchodilator FEV1;
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00149659	chr3:10157352	C3orf10	-0.86	-10.78	-0.45	2.6e-24	Alzheimer's disease;
LGG	cis	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-6.94	-0.31	1.32e-11	Triglycerides;
LGG	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg11861562	chr11:117069780	TAGLN	-0.26	-7.03	-0.31	7.67e-12	Blood protein levels;
LGG	cis	rs8018808	1.000	rs4903580	chr14:77850978	C/T	cg20045696	chr14:77926864	AHSA1	-0.4	-6.69	-0.3	6.51e-11	Myeloid white cell count;
LGG	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.97	0.38	7.19e-18	Rheumatoid arthritis;
LGG	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg13010199	chr12:38710504	ALG10B	0.47	8.53	0.37	2.08e-16	Morning vs. evening chronotype;
LGG	cis	rs10461617	0.541	rs860581	chr5:56150537	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-8.98	-0.39	6.63e-18	Type 2 diabetes;
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	16.85	0.62	5.03e-50	Alzheimer's disease;
LGG	cis	rs4253772	0.591	rs6008538	chr22:46685963	G/A	cg24881330	chr22:46731750	TRMU	0.78	9.49	0.4	1.18e-19	LDL cholesterol;Cholesterol, total;
LGG	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg02002194	chr4:3960332	NA	-0.5	-9.69	-0.41	2.42e-20	Parkinson's disease;
LGG	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.16	-0.43	4.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.89	18.44	0.65	2.58e-57	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.83e-12	Menopause (age at onset);
LGG	cis	rs2070488	1.000	rs17733640	chr3:38446742	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.39	0.63	1.73e-52	Electrocardiographic conduction measures;
LGG	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	13.31	0.53	1.84e-34	Total body bone mineral density;
LGG	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg06766960	chr11:133703094	NA	-0.54	-10.81	-0.45	1.91e-24	Childhood ear infection;
LGG	cis	rs1003719	0.715	rs2835640	chr21:38537380	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg25427524	chr10:38739819	LOC399744	-0.51	-7.48	-0.33	3.84e-13	Obesity (extreme);
LGG	trans	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Colorectal cancer;
LGG	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg16486109	chr11:613632	IRF7	0.41	7.31	0.32	1.14e-12	Systemic lupus erythematosus;
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.53	9.13	0.39	2.09e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.19	-0.43	3.81e-22	Lung cancer;
LGG	cis	rs34599045	0.522	rs12744709	chr1:153002303	G/A	cg07796016	chr1:152779584	LCE1C	-0.88	-7.88	-0.34	2.32e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4740619	0.846	rs10810416	chr9:15638471	T/C	cg14451791	chr9:16040625	NA	0.35	8.85	0.38	1.86e-17	Body mass index;
LGG	cis	rs4936894	0.519	rs10893194	chr11:124142531	T/C	cg27160556	chr11:124181099	OR8D1	-0.48	-11.13	-0.46	1.19e-25	Aging (time to death);
LGG	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg22980697	chr10:16874865	CUBN	0.6	9.78	0.41	1.17e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24148025	chr15:52264263	LEO1	-0.45	-6.67	-0.3	7.21e-11	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17027046	chr20:3190012	ITPA	0.46	7.75	0.34	5.72e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs3540	0.960	rs6496675	chr15:90982756	C/T	cg22089800	chr15:90895588	ZNF774	0.53	8.46	0.37	3.56e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg14191688	chr11:70257035	CTTN	0.56	8.16	0.35	3.24e-15	Coronary artery disease;
LGG	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg24375607	chr4:120327624	NA	0.55	9.34	0.4	4.1e-19	Corneal astigmatism;
LGG	cis	rs2282802	0.685	rs6870103	chr5:139692515	G/T	cg26211634	chr5:139558579	C5orf32	-0.34	-7.48	-0.33	3.79e-13	Intelligence (multi-trait analysis);
LGG	cis	rs71403859	0.502	rs35394108	chr16:71540639	T/C	cg08717414	chr16:71523259	ZNF19	-1.3	-17.74	-0.64	4.11e-54	Post bronchodilator FEV1;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.45	-0.33	4.58e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7582720	0.945	rs72934583	chr2:204009057	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.29	0.4	6.08e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7666738	0.830	rs4699592	chr4:98974202	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3805663	1.000	rs3805663	chr5:134366200	A/G	cg24576358	chr5:134350122	NA	0.35	7.36	0.32	8.61e-13	Testicular germ cell tumor;
LGG	cis	rs300774	0.925	rs437409	chr2:142137	G/A	cg04617936	chr2:214353	NA	-0.5	-7.67	-0.34	1.05e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg06623630	chr22:50017776	C22orf34	-0.44	-9.01	-0.39	5.26e-18	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05901451	chr6:126070800	HEY2	0.76	14.96	0.57	1.4e-41	Brugada syndrome;
LGG	cis	rs11750568	0.967	rs6864287	chr5:178515091	T/C	cg10208897	chr5:178548229	ADAMTS2	0.42	6.88	0.3	1.89e-11	Height;
LGG	trans	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg16141378	chr3:129829833	LOC729375	-0.31	-6.76	-0.3	4.2e-11	Neuroticism;
LGG	cis	rs4665809	1.000	rs2384322	chr2:26291146	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.96	-0.54	3.35e-37	Gut microbiome composition (summer);
LGG	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg20255370	chr15:40268687	EIF2AK4	0.86	9.02	0.39	5.04e-18	Corneal curvature;
LGG	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.62	0.37	1.04e-16	Mood instability;
LGG	cis	rs35771425	0.564	rs11803005	chr1:211425492	C/T	cg10512769	chr1:211675356	NA	-0.62	-8.23	-0.36	1.9e-15	Educational attainment (years of education);
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg14346243	chr4:90757452	SNCA	0.34	6.75	0.3	4.31e-11	Dementia with Lewy bodies;
LGG	cis	rs2865126	0.818	rs7227167	chr18:10763007	A/G	cg21165219	chr18:10698044	FAM38B	-0.45	-7.34	-0.32	9.64e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs8180040	0.966	rs6792461	chr3:47473168	C/T	cg16586182	chr3:47516702	SCAP	0.78	15.57	0.59	2.98e-44	Colorectal cancer;
LGG	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg27147174	chr7:100797783	AP1S1	-0.7	-13.18	-0.52	6.56e-34	Life satisfaction;
LGG	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg12402800	chr5:56204917	C5orf35	-0.42	-6.66	-0.3	7.74e-11	Type 2 diabetes;
LGG	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg03605463	chr16:89740564	NA	-0.49	-8.53	-0.37	2.12e-16	Hemoglobin concentration;
LGG	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg10503236	chr1:231470652	EXOC8	0.37	7.16	0.32	3.17e-12	Hemoglobin concentration;
LGG	cis	rs1847505	0.874	rs1394314	chr13:61521491	A/G	cg25164009	chr13:61490935	NA	-0.61	-9.75	-0.41	1.48e-20	Polychlorinated biphenyl levels;
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg22903471	chr2:27725779	GCKR	-0.59	-13.48	-0.53	3.62e-35	Total body bone mineral density;
LGG	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg05091796	chr16:4465799	CORO7	-0.89	-14.52	-0.56	1.27e-39	Schizophrenia;
LGG	cis	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg08112188	chr17:47440006	ZNF652	1.33	15.72	0.59	6.2e-45	Prostate cancer;
LGG	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg04733989	chr22:42467013	NAGA	0.52	9.18	0.39	1.39e-18	Schizophrenia;
LGG	cis	rs1318772	0.932	rs17324474	chr5:112591838	A/T	cg12552261	chr5:112820674	MCC	0.7	8.15	0.35	3.37e-15	F-cell distribution;
LGG	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg20503657	chr10:835505	NA	0.96	12.71	0.51	5.94e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs8008758	0.963	rs10132271	chr14:101688874	C/T	cg26224664	chr14:101693935	NA	-0.56	-9.32	-0.4	4.79e-19	Body mass index (alcohol intake interaction);
LGG	cis	rs9902453	0.765	rs3115087	chr17:28030267	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.93	0.54	4.35e-37	Coffee consumption (cups per day);
LGG	cis	rs7503807	0.515	rs34388940	chr17:78663350	G/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.17	-0.39	1.58e-18	Obesity;
LGG	cis	rs7264396	0.690	rs2425180	chr20:34447160	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.41	-0.33	6.14e-13	Total cholesterol levels;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg09217309	chr6:150244204	RAET1G	0.43	7.71	0.34	7.79e-14	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg19507638	chr5:93509721	C5orf36	-0.75	-10.09	-0.42	9.15e-22	Diabetic retinopathy;
LGG	cis	rs9964724	0.929	rs7504262	chr18:35160143	C/T	cg27332583	chr18:35150602	NA	0.44	9.41	0.4	2.41e-19	Educational attainment (years of education);
LGG	cis	rs972578	1.000	rs5759086	chr22:43404929	C/G	cg01576275	chr22:43409880	NA	-0.23	-6.89	-0.31	1.8e-11	Mean platelet volume;
LGG	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg04842962	chr6:43655489	MRPS18A	0.83	15.75	0.59	4.64e-45	IgG glycosylation;
LGG	cis	rs9902453	0.791	rs2628166	chr17:28113123	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.79	-0.54	1.67e-36	Coffee consumption (cups per day);
LGG	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17767392	0.958	rs61989377	chr14:71957362	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.61e-18	Mitral valve prolapse;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg16606324	chr3:10149918	C3orf24	0.54	7.17	0.32	2.99e-12	Alzheimer's disease;
LGG	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg16301924	chr13:53314226	LECT1	-0.35	-6.94	-0.31	1.34e-11	Lewy body disease;
LGG	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg13010199	chr12:38710504	ALG10B	0.46	8.75	0.38	3.94e-17	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg27411982	chr8:10470053	RP1L1	-0.48	-8.32	-0.36	9.86e-16	Retinal vascular caliber;
LGG	cis	rs8067287	0.634	rs11652811	chr17:16843171	A/G	cg26910001	chr17:16838321	NA	-0.44	-8.6	-0.37	1.21e-16	Diabetic kidney disease;
LGG	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.28	-0.55	1.32e-38	Heart rate;
LGG	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.85	0.48	1.83e-28	Hip circumference adjusted for BMI;
LGG	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg16586182	chr3:47516702	SCAP	0.76	15.03	0.57	7.39e-42	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg06917634	chr15:78832804	PSMA4	0.5	8.24	0.36	1.8e-15	Sudden cardiac arrest;
LGG	cis	rs3617	0.522	rs6773650	chr3:52897095	A/T	cg11645453	chr3:52864694	ITIH4	0.45	7.51	0.33	2.99e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4959677	0.935	rs4355649	chr6:2492381	A/G	cg20147862	chr6:2634573	C6orf195	-0.39	-8.37	-0.36	6.69e-16	Orthostatic hypotension;
LGG	cis	rs9952991	0.566	rs514000	chr18:12854072	C/T	cg23598886	chr18:12777645	NA	0.51	7.19	0.32	2.67e-12	Inflammatory skin disease;
LGG	cis	rs7828089	0.582	rs13259873	chr8:22266292	C/T	cg12081754	chr8:22256438	SLC39A14	0.97	20.93	0.7	6.2e-69	Verbal declarative memory;
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg09303159	chr6:26284866	NA	0.39	8.77	0.38	3.41e-17	Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27367512	chr5:126405711	FLJ44606	0.34	6.66	0.3	7.75e-11	Gut microbiome composition (summer);
LGG	cis	rs524281	1.000	rs489337	chr11:65854561	A/G	cg16950941	chr11:66035639	RAB1B	0.51	7.87	0.34	2.45e-14	Electroencephalogram traits;
LGG	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg06916706	chr16:4465613	CORO7	-0.86	-15.09	-0.57	3.79e-42	Schizophrenia;
LGG	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg10760299	chr15:45669010	GATM	-0.4	-7.5	-0.33	3.28e-13	Homoarginine levels;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg19168338	chr16:4465731	CORO7	-0.76	-14.27	-0.55	1.57e-38	Schizophrenia;
LGG	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg21772509	chr8:41503840	NKX6-3	0.87	19.72	0.68	2.81e-63	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs3767633	0.925	rs2499856	chr1:161926637	C/T	cg09175582	chr1:161736000	ATF6	-0.7	-8.64	-0.37	9.06e-17	IgG glycosylation;
LGG	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs1461503	0.932	rs10892934	chr11:122837950	C/T	cg27398637	chr11:122830231	C11orf63	-0.72	-14.33	-0.55	7.93e-39	Menarche (age at onset);
LGG	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg22920501	chr2:26401640	FAM59B	-0.43	-9.08	-0.39	3.22e-18	Gut microbiome composition (summer);
LGG	cis	rs12431410	0.584	rs2350012	chr14:60222753	A/C	cg07950296	chr14:60194823	RTN1	-0.37	-7.08	-0.31	5.4e-12	Schizophrenia;
LGG	cis	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg24134504	chr18:76639479	NA	-0.45	-7.99	-0.35	1.11e-14	Obesity-related traits;
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.13	-0.31	3.95e-12	Monocyte percentage of white cells;
LGG	cis	rs7085104	0.700	rs10883785	chr10:104603588	A/G	cg04362960	chr10:104952993	NT5C2	0.48	8.89	0.38	1.37e-17	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs1003719	0.679	rs1133001	chr21:38512956	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.34	-0.58	3.19e-43	Eye color traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25846302	chr15:102501640	WASH3P	0.34	6.7	0.3	6.06e-11	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.26e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg17182837	chr8:41585554	ANK1	-0.54	-7.9	-0.34	2.11e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.84	-0.38	1.99e-17	Bone mineral density;
LGG	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.36	0.36	7.46e-16	Joint mobility (Beighton score);
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs12912251	1.000	rs71403553	chr15:38989121	C/A	cg01338139	chr15:38987640	C15orf53	-0.54	-8.65	-0.37	8.34e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg27121462	chr16:89883253	FANCA	0.63	11.78	0.48	3.25e-28	Vitiligo;
LGG	cis	rs7793919	0.726	rs10261971	chr7:4776547	A/G	cg09789173	chr7:4769017	FOXK1	0.81	18.5	0.65	1.34e-57	Mosquito bite size;
LGG	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg26031613	chr14:104095156	KLC1	0.6	9.44	0.4	1.87e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.818	rs3181787	chr1:153004809	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	trans	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg07817883	chr1:32538562	TMEM39B	-0.66	-9.46	-0.4	1.52e-19	Monocyte percentage of white cells;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.71	-0.38	5.56e-17	Lung cancer;
LGG	trans	rs9657904	0.865	rs4894962	chr3:105600699	G/A	cg14088669	chr1:158435396	OR10K1	0.43	7.99	0.35	1.1e-14	Multiple sclerosis;
LGG	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.63	0.59	1.51e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.34	-0.32	9.39e-13	Total cholesterol levels;
LGG	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg02023728	chr11:77925099	USP35	0.43	7.62	0.33	1.42e-13	Testicular germ cell tumor;
LGG	trans	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.2	-0.32	2.5e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.37	6.71	0.3	5.78e-11	Total body bone mineral density;
LGG	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.82	-0.34	3.63e-14	Height;
LGG	cis	rs787274	0.557	rs4979184	chr9:115667362	G/A	cg13803584	chr9:115635662	SNX30	-0.68	-7.47	-0.33	4.14e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.62	9.15	0.39	1.84e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00636124	chr16:27215281	JMJD5	0.44	7.47	0.33	4.15e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg22535103	chr8:58192502	C8orf71	-1.02	-16.12	-0.6	1.04e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs10927875	0.619	rs1806991	chr1:16129441	T/C	cg21385522	chr1:16154831	NA	-0.74	-15.34	-0.58	3.15e-43	Dilated cardiomyopathy;
LGG	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg13607699	chr17:42295918	UBTF	-0.43	-6.8	-0.3	3.21e-11	Total body bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06118578	chr18:67872897	RTTN	-0.52	-7.81	-0.34	3.89e-14	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.84e-19	Testicular germ cell tumor;
LGG	cis	rs7551222	0.752	rs2290854	chr1:204516025	A/G	cg20240347	chr1:204465584	NA	-0.55	-11.13	-0.46	1.12e-25	Schizophrenia;
LGG	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs11920090	0.858	rs16855591	chr3:170693708	A/G	cg09710316	chr3:170744871	SLC2A2	0.66	8.49	0.37	2.93e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg12292205	chr6:26970375	C6orf41	0.67	12.49	0.5	4.5e-31	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.96	0.35	1.33e-14	Colorectal cancer;
LGG	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.71	-0.38	5.3e-17	Mean corpuscular volume;
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg08888203	chr3:10149979	C3orf24	0.57	7.85	0.34	2.85e-14	Alzheimer's disease;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.46	-0.44	3.83e-23	Longevity;Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07623022	chr16:18801545	RPS15A	-0.49	-7.05	-0.31	6.59e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg21724239	chr8:58056113	NA	0.43	6.78	0.3	3.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.791	rs1593571	chr4:98963763	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg27205649	chr11:78285834	NARS2	0.51	8.79	0.38	2.91e-17	Alzheimer's disease (survival time);
LGG	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.54	-0.37	1.88e-16	Retinal vascular caliber;
LGG	cis	rs7619833	0.512	rs7634574	chr3:27223319	C/A	cg02860705	chr3:27208620	NA	0.42	8.13	0.35	3.86e-15	Breast cancer;
LGG	cis	rs12136530	0.774	rs12137162	chr1:19763396	G/T	cg17081867	chr1:19768096	CAPZB	-0.38	-8.65	-0.37	8.37e-17	Lead levels in blood;
LGG	cis	rs9487094	0.670	rs11153183	chr6:109817276	T/G	cg01125227	chr6:109776195	MICAL1	0.44	7.67	0.34	1.05e-13	Height;
LGG	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03264133	chr6:25882463	NA	-0.52	-9.59	-0.41	5.45e-20	Intelligence (multi-trait analysis);
LGG	cis	rs60180747	1.000	rs35510028	chr15:66612079	C/G	cg07575407	chr15:66541975	MEGF11	0.36	7.43	0.33	5.26e-13	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg18258770	chr4:90757814	SNCA	0.39	7.07	0.31	5.8e-12	Dementia with Lewy bodies;
LGG	trans	rs488400	0.676	rs165581	chr4:152789786	A/G	cg09532503	chr4:119711185	SEC24D	-0.44	-6.65	-0.3	8.06e-11	Trans fatty acid levels;
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.13e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg09904177	chr6:26538194	HMGN4	-0.62	-12.2	-0.49	7.09e-30	Intelligence (multi-trait analysis);
LGG	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg24846343	chr22:24311635	DDTL	-0.45	-7.24	-0.32	1.87e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg11040518	chr10:102331378	NA	-0.37	-6.85	-0.3	2.3e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2898279	0.872	rs7830445	chr8:11302061	A/G	cg26274995	chr8:11302983	FAM167A	0.53	10.42	0.44	5.78e-23	Small cell lung carcinoma;
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg24250549	chr1:154909240	PMVK	-0.7	-13.63	-0.54	8.35e-36	Prostate cancer;
LGG	cis	rs16957091	1.000	rs16957091	chr15:43017426	G/T	cg07484255	chr15:43025164	CDAN1	0.48	7.03	0.31	7.5e-12	MGMT methylation in smokers;
LGG	cis	rs4664304	0.652	rs2221808	chr2:160870944	T/C	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.74	-0.3	4.78e-11	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.07	-0.35	6.23e-15	Systemic lupus erythematosus;
LGG	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.6	-0.51	1.66e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.78	-0.51	2.95e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs13053817	1.000	rs13057815	chr22:29853526	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.45	-6.83	-0.3	2.69e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs13102973	0.720	rs7687641	chr4:135885739	C/T	cg14419869	chr4:135874104	NA	0.46	7.96	0.35	1.33e-14	Subjective well-being;
LGG	trans	rs17685	0.671	rs60303271	chr7:75760008	A/G	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg10483660	chr13:112241077	NA	0.35	6.94	0.31	1.33e-11	Menarche (age at onset);
LGG	cis	rs4604732	0.631	rs76761880	chr1:247626377	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs3768617	0.811	rs34721094	chr1:183051521	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.82	0.3	2.83e-11	Fuchs's corneal dystrophy;
LGG	trans	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg02800362	chr5:177631904	HNRNPAB	0.77	13.59	0.53	1.2e-35	Obesity-related traits;
LGG	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg08085267	chr17:45401833	C17orf57	-0.53	-10.38	-0.43	7.59e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10197940	0.638	rs2288193	chr2:152348842	T/A	cg19508488	chr2:152266495	RIF1	0.59	10.33	0.43	1.22e-22	Lung cancer;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg08888203	chr3:10149979	C3orf24	0.57	9.72	0.41	1.84e-20	Alzheimer's disease;
LGG	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg09307838	chr4:120376055	NA	0.81	13.25	0.52	3.25e-34	Corneal astigmatism;
LGG	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.65	0.37	8.63e-17	Colorectal cancer;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13126279	chr21:47581558	C21orf56	-0.47	-8.21	-0.36	2.29e-15	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.28	0.4	6.75e-19	Diabetic retinopathy;
LGG	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg24812749	chr6:127587940	RNF146	0.95	15.73	0.59	5.44e-45	Breast cancer;
LGG	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.1e-100	Height;
LGG	cis	rs1983891	1.000	rs1983891	chr6:41536427	A/G	cg20194872	chr6:41519635	FOXP4	-0.59	-10.21	-0.43	3.31e-22	Prostate cancer;
LGG	cis	rs7666738	0.822	rs11097599	chr4:98959562	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs736408	0.608	rs4687657	chr3:52852538	G/T	cg11645453	chr3:52864694	ITIH4	0.63	9.95	0.42	3e-21	Bipolar disorder;
LGG	cis	rs10504073	0.669	rs62507251	chr8:50028524	T/G	cg00325661	chr8:49890786	NA	0.74	13.97	0.54	2.91e-37	Blood metabolite ratios;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg13902069	chr21:47551987	COL6A2	-0.38	-6.69	-0.3	6.31e-11	Corneal astigmatism;
LGG	cis	rs6964587	0.967	rs410	chr7:91557425	C/G	cg17063962	chr7:91808500	NA	-0.49	-8.6	-0.37	1.24e-16	Breast cancer;
LGG	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg14952266	chr13:112191215	NA	0.42	8.17	0.36	2.9e-15	Hepatitis;
LGG	trans	rs11875185	0.510	rs60383544	chr18:55620350	G/A	cg15513957	chr14:69354734	ACTN1	-0.89	-9.04	-0.39	4.15e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg18200150	chr17:30822561	MYO1D	0.66	13.88	0.54	7.15e-37	Schizophrenia;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10802521	chr3:52805072	NEK4	-0.41	-7.35	-0.32	8.81e-13	Bipolar disorder;
LGG	trans	rs6073597	1.000	rs6031980	chr20:43714384	C/T	cg09081385	chr12:120972070	RNF10	0.38	6.94	0.31	1.29e-11	Positive affect;
LGG	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg12379764	chr21:47803548	PCNT	0.7	12.14	0.49	1.2e-29	Lymphocyte counts;
LGG	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08109568	chr15:31115862	NA	0.6	10.65	0.44	7.78e-24	Huntington's disease progression;
LGG	cis	rs858239	0.508	rs7805071	chr7:23190212	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.49e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-13.64	-0.54	7.79e-36	Heart rate;
LGG	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21659725	chr3:3221576	CRBN	0.55	9.6	0.41	5.21e-20	Body mass index;
LGG	cis	rs892961	0.932	rs7222170	chr17:75413096	G/A	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.12	-0.31	4.01e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg04861929	chr11:109293070	C11orf87	0.52	9.16	0.39	1.72e-18	Schizophrenia;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12016809	chr21:47604291	C21orf56	0.51	8.58	0.37	1.43e-16	Testicular germ cell tumor;
LGG	trans	rs1997103	0.705	rs56301138	chr7:55396555	G/T	cg20935933	chr6:143382018	AIG1	0.59	9.1	0.39	2.74e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg06951627	chr6:26196580	NA	0.46	6.78	0.3	3.57e-11	Gout;Renal underexcretion gout;
LGG	cis	rs36093844	0.706	rs75217143	chr11:85562270	T/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.35	-0.32	9.27e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6496667	0.533	rs886491	chr15:90993215	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.37	0.36	6.68e-16	Rheumatoid arthritis;
LGG	cis	rs6495367	1.000	rs4778634	chr15:79380822	C/T	cg17916960	chr15:79447300	NA	0.52	8.98	0.39	6.98e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9397585	0.599	rs626671	chr6:153407175	G/A	cg17707550	chr6:153380415	RGS17	-0.44	-9.77	-0.41	1.3e-20	Body mass index;
LGG	cis	rs5769707	0.904	rs7288869	chr22:50015327	C/T	cg20744362	chr22:50050164	C22orf34	0.39	7.63	0.33	1.33e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs367943	0.712	rs27567	chr5:112741798	C/T	cg12552261	chr5:112820674	MCC	0.58	10.47	0.44	3.64e-23	Type 2 diabetes;
LGG	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.93	-0.31	1.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.69	-0.34	8.95e-14	Testicular germ cell tumor;
LGG	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs921968	0.541	rs642520	chr2:219423605	A/G	cg01130898	chr2:219473002	PLCD4	0.41	7.14	0.31	3.68e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4930561	0.739	rs12225316	chr11:67976003	T/C	cg16338278	chr11:67432957	ALDH3B2	0.41	7.6	0.33	1.62e-13	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg24623649	chr8:11872141	NA	0.31	7.11	0.31	4.46e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg26174226	chr8:58114915	NA	-0.52	-7.65	-0.33	1.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.5	0.5	4.31e-31	Motion sickness;
LGG	cis	rs655029	0.837	rs647316	chr2:31464829	A/G	cg14018959	chr2:31480232	EHD3	-0.35	-6.93	-0.31	1.45e-11	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
LGG	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs4319547	0.876	rs10846978	chr12:122964708	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-10.31	-0.43	1.47e-22	Body mass index;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12016809	chr21:47604291	C21orf56	0.5	8.45	0.37	3.68e-16	Testicular germ cell tumor;
LGG	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg08305652	chr11:111469057	NA	0.44	8.44	0.37	3.97e-16	Primary sclerosing cholangitis;
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-15.63	-0.59	1.52e-44	Age at first birth;
LGG	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	cis	rs6429082	0.668	rs291395	chr1:235652049	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.76	-13.39	-0.53	8.76e-35	Adiposity;
LGG	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.29	-0.36	1.24e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg08198773	chr8:1697536	NA	0.36	6.93	0.31	1.42e-11	Systolic blood pressure;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04921814	chr1:145575587	PIAS3	0.42	7.19	0.32	2.58e-12	Parental extreme longevity (95 years and older);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01839850	chr22:38240395	ANKRD54;MIR658	0.47	7.45	0.33	4.54e-13	Gut microbiome composition (summer);
LGG	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.71	14.67	0.56	2.8e-40	Lymphocyte percentage of white cells;
LGG	cis	rs1691799	0.831	rs6581678	chr12:66776656	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.5	-0.58	6.18e-44	White blood cell count (basophil);
LGG	cis	rs9831754	1.000	rs3946823	chr3:78353052	G/A	cg06138941	chr3:78371609	NA	-0.97	-20.61	-0.69	1.82e-67	Calcium levels;
LGG	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg19773385	chr1:10388646	KIF1B	-0.48	-9.93	-0.42	3.45e-21	Hepatocellular carcinoma;
LGG	cis	rs12618769	0.520	rs72821904	chr2:99084882	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.32	0.32	1.07e-12	Retinal vascular caliber;
LGG	cis	rs2115630	1.000	rs6496452	chr15:85372645	A/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.7	-0.3	6.11e-11	P wave terminal force;
LGG	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg22875332	chr1:76189707	ACADM	-0.64	-10.66	-0.44	7.09e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg16583315	chr14:65563665	MAX	-0.39	-7.65	-0.33	1.21e-13	Obesity-related traits;
LGG	cis	rs7503807	0.515	rs34863264	chr17:78655312	C/T	cg22878693	chr17:78755604	RPTOR	-0.55	-9.08	-0.39	3.05e-18	Obesity;
LGG	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.53	-7.58	-0.33	1.92e-13	Diabetic retinopathy;
LGG	cis	rs4851254	0.920	rs11689956	chr2:100795329	T/C	cg17356467	chr2:100759845	AFF3	0.4	7.02	0.31	8.02e-12	Intelligence (multi-trait analysis);
LGG	cis	rs55665837	0.961	rs11023237	chr11:14500334	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.81	-0.38	2.53e-17	Vitamin D levels;
LGG	cis	rs6908034	0.607	rs113894708	chr6:19806066	G/T	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2640806	0.544	rs11997526	chr8:97365919	C/A	cg22138393	chr8:97340270	PTDSS1	0.28	7.27	0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs7122539	0.722	rs2380759	chr11:66647430	T/G	cg01599099	chr11:66649832	PC	0.45	9.14	0.39	1.93e-18	HIV-1 susceptibility;
LGG	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6754311	0.593	rs10186843	chr2:136586958	C/A	cg07169764	chr2:136633963	MCM6	-0.78	-13.3	-0.53	2.06e-34	Mosquito bite size;
LGG	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg16141378	chr3:129829833	LOC729375	0.34	7.79	0.34	4.4e-14	Mood instability;
LGG	cis	rs7808935	0.914	rs10807843	chr7:27992390	T/C	cg22168087	chr7:27702803	HIBADH	0.65	8.95	0.38	8.69e-18	Prostate cancer;
LGG	cis	rs834811	0.796	rs2349456	chr7:135901545	G/T	cg01726295	chr7:135938950	NA	-0.33	-6.65	-0.3	8.45e-11	Post-traumatic stress disorder;
LGG	trans	rs7395662	0.892	rs11040010	chr11:48776929	G/T	cg00717180	chr2:96193071	NA	0.41	7.23	0.32	1.99e-12	HDL cholesterol;
LGG	cis	rs4262150	0.960	rs4463219	chr5:152288557	G/T	cg12297329	chr5:152029980	NA	0.59	11.35	0.47	1.67e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs3741151	0.687	rs7933355	chr11:73236817	G/C	cg17517138	chr11:73019481	ARHGEF17	0.8	7.79	0.34	4.54e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.23	-0.39	9.66e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg16576597	chr16:28551801	NUPR1	0.37	8.61	0.37	1.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg04568710	chr12:38710424	ALG10B	-0.38	-8.14	-0.35	3.76e-15	Morning vs. evening chronotype;
LGG	cis	rs67478160	0.643	rs8005225	chr14:104300151	C/T	cg26031613	chr14:104095156	KLC1	0.44	7.26	0.32	1.66e-12	Schizophrenia;
LGG	cis	rs9972944	0.756	rs7221131	chr17:63764848	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03576123	chr11:487126	PTDSS2	-1.23	-16.45	-0.61	3.41e-48	Body mass index;
LGG	cis	rs9309473	1.000	rs1114380	chr2:73804708	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.62	-0.33	1.43e-13	Metabolite levels;
LGG	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg20476274	chr7:133979776	SLC35B4	0.66	11.69	0.48	7.97e-28	Mean platelet volume;
LGG	cis	rs9831754	1.000	rs9831754	chr3:78353591	A/C	cg06138941	chr3:78371609	NA	-0.96	-20.49	-0.69	7.28e-67	Calcium levels;
LGG	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg17644776	chr2:200775616	C2orf69	0.61	8.49	0.37	2.8e-16	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg15971980	chr6:150254442	NA	0.43	8.12	0.35	4.27e-15	Lung cancer;
LGG	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg01416317	chr19:45737208	EXOC3L2	0.47	10.26	0.43	2.14e-22	Monocyte percentage of white cells;
LGG	cis	rs5758511	0.773	rs62240997	chr22:42354567	T/G	cg15128208	chr22:42549153	NA	0.57	8.92	0.38	1.07e-17	Birth weight;
LGG	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg18137308	chr11:63775436	MACROD1	0.29	6.85	0.3	2.33e-11	Pulse pressure;
LGG	cis	rs9513627	1.000	rs7334844	chr13:100121047	G/C	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs12580194	0.593	rs7314118	chr12:55737403	A/C	cg19537932	chr12:55886519	OR6C68	-0.51	-9.31	-0.4	5.05e-19	Cancer;
LGG	cis	rs7166081	0.951	rs12594065	chr15:67518001	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg13256891	chr4:100009986	ADH5	0.38	6.75	0.3	4.55e-11	Alcohol dependence;
LGG	cis	rs3087591	0.920	rs7225014	chr17:29572973	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.69	-0.56	2.2e-40	Hip circumference;
LGG	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg03576123	chr11:487126	PTDSS2	-0.49	-6.71	-0.3	5.75e-11	Systemic lupus erythematosus;
LGG	cis	rs9557207	1.000	rs9554568	chr13:99840875	G/A	cg24509225	chr13:100037070	UBAC2	0.72	12.86	0.51	1.43e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21582582	chr3:182698605	DCUN1D1	0.5	9.28	0.4	6.32e-19	Intelligence (multi-trait analysis);
LGG	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg20891283	chr12:69753455	YEATS4	0.83	14.89	0.57	2.84e-41	Response to diuretic therapy;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.17	-0.46	8.47e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1015291	0.708	rs1492115	chr12:19995164	T/C	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg05194412	chr2:137003533	NA	0.38	8.09	0.35	5.2e-15	Colorectal cancer;
LGG	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg05890377	chr2:74357713	NA	0.53	9.84	0.42	6.86e-21	Gestational age at birth (maternal effect);
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.37	-0.36	6.98e-16	Tonsillectomy;
LGG	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg25986240	chr4:9926439	SLC2A9	0.72	16.59	0.61	7.26e-49	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-7.5	-0.33	3.19e-13	Myopia (pathological);
LGG	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.3	-0.32	1.25e-12	Testicular germ cell tumor;
LGG	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg17644776	chr2:200775616	C2orf69	0.59	7.34	0.32	9.99e-13	Schizophrenia;
LGG	cis	rs4690686	0.500	rs7657249	chr4:177275198	A/G	cg17059388	chr4:177262070	NA	1.03	24.3	0.75	1.07e-84	Essential tremor;
LGG	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg19748678	chr4:122722346	EXOSC9	0.7	14.25	0.55	1.91e-38	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg05793240	chr7:2802953	GNA12	0.31	7.17	0.32	2.94e-12	Height;
LGG	cis	rs1009647	0.677	rs11851870	chr14:55815982	A/C	cg04306507	chr14:55594613	LGALS3	0.47	7.77	0.34	5e-14	Testicular germ cell tumor;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg02002194	chr4:3960332	NA	0.45	8.3	0.36	1.12e-15	Neuroticism;
LGG	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.72	-0.3	5.23e-11	Educational attainment;
LGG	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg05425664	chr17:57184151	TRIM37	-0.64	-10.11	-0.43	7.71e-22	Intelligence (multi-trait analysis);
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11220663	chr2:70994863	ADD2	0.39	6.67	0.3	7.28e-11	Lung adenocarcinoma;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14159672	chr1:205819179	PM20D1	-0.48	-7.63	-0.33	1.31e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.19	-0.32	2.64e-12	Neuroticism;
LGG	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg22920501	chr2:26401640	FAM59B	0.38	7.56	0.33	2.16e-13	Gut microbiome composition (summer);
LGG	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg12310025	chr6:25882481	NA	-0.64	-11.8	-0.48	2.71e-28	Intelligence (multi-trait analysis);
LGG	cis	rs975722	0.632	rs213961	chr7:117224724	C/A	cg10524701	chr7:117356490	CTTNBP2	0.47	10.43	0.44	4.98e-23	Coronary artery disease;
LGG	cis	rs3540	0.553	rs2158406	chr15:90994499	T/C	cg22089800	chr15:90895588	ZNF774	0.69	12.83	0.51	1.87e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg24110177	chr3:50126178	RBM5	-0.4	-6.81	-0.3	3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.649	rs1318348	chr1:11130418	A/G	cg08854313	chr1:11322531	MTOR	0.76	16.68	0.61	2.85e-49	Body mass index;
LGG	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs9296092	0.538	rs9469491	chr6:33521545	A/G	cg13560919	chr6:33536144	NA	1.03	21.39	0.7	4.43e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9296092	0.538	rs62407565	chr6:33535739	A/G	cg13560919	chr6:33536144	NA	-1.06	-22.23	-0.72	5e-75	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19437060	chr12:110434204	GIT2	0.46	6.92	0.31	1.48e-11	Gut microbiome composition (summer);
LGG	cis	rs8060686	0.545	rs3826164	chr16:68280317	A/G	cg27539214	chr16:67997921	SLC12A4	0.5	7.46	0.33	4.33e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.78e-31	Motion sickness;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg20607798	chr8:58055168	NA	0.65	7.54	0.33	2.58e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg09307838	chr4:120376055	NA	0.68	11.74	0.48	4.89e-28	Educational attainment;
LGG	cis	rs17092148	0.887	rs4302281	chr20:33171645	C/T	cg12302830	chr20:33297742	TP53INP2	0.43	6.91	0.31	1.63e-11	Neuroticism;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04772025	chr11:68637568	NA	0.75	12.5	0.5	4.13e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg03477792	chr4:77819574	ANKRD56	0.53	9.25	0.39	8.6e-19	Emphysema distribution in smoking;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11980791	chr9:131084797	COQ4;TRUB2	0.46	7.85	0.34	2.82e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg06697600	chr4:7070879	GRPEL1	-0.53	-8.64	-0.37	9.23e-17	Monocyte percentage of white cells;
LGG	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-7.27	-0.32	1.53e-12	Menarche (age at onset);
LGG	cis	rs2249694	1.000	rs8192781	chr10:135354251	T/G	cg20169779	chr10:135381914	SYCE1	0.5	7.69	0.34	9.12e-14	Obesity-related traits;
LGG	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.28	0.4	6.7e-19	Blood metabolite levels;
LGG	cis	rs11074306	0.561	rs931665	chr15:28069897	A/G	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs9549367	0.865	rs9549366	chr13:113907644	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-13.96	-0.54	3.19e-37	Platelet distribution width;
LGG	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg26396452	chr14:65542826	MAX	0.42	8.41	0.36	5.14e-16	Obesity-related traits;
LGG	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg25358565	chr5:93447407	FAM172A	1.36	16.52	0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs6500395	0.588	rs4479221	chr16:48680835	G/C	cg04672837	chr16:48644449	N4BP1	0.48	8.4	0.36	5.55e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg13866156	chr1:1669148	SLC35E2	0.67	13.28	0.53	2.45e-34	Body mass index;
LGG	cis	rs8078723	1.000	rs7214085	chr17:38169095	T/C	cg17467752	chr17:38218738	THRA	0.74	13.92	0.54	5.02e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.55	-0.41	7.52e-20	Diabetic retinopathy;
LGG	cis	rs4901847	0.577	rs10782436	chr14:58574964	T/C	cg15908186	chr14:58618357	C14orf37	0.66	11.86	0.48	1.63e-28	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.87	-9.75	-0.41	1.44e-20	Diabetic retinopathy;
LGG	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.3	-0.32	1.24e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs529866	0.519	rs4451969	chr16:11383519	A/G	cg00044050	chr16:11439710	C16orf75	-0.45	-7.12	-0.31	4.17e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg16096631	chr1:42092165	HIVEP3	0.54	12.84	0.51	1.72e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs4919694	1.000	rs17881215	chr10:104629236	G/C	cg04362960	chr10:104952993	NT5C2	1.03	14.39	0.56	4.54e-39	Arsenic metabolism;
LGG	cis	rs988958	0.675	rs67312072	chr2:42230670	T/C	cg27428208	chr2:42229179	NA	0.52	9.06	0.39	3.61e-18	Hypospadias;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.37	6.77	0.3	3.96e-11	Schizophrenia;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg16507663	chr6:150244633	RAET1G	-0.44	-8.2	-0.36	2.46e-15	Lung cancer;
LGG	trans	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg18335740	chr13:41363409	SLC25A15	0.58	11.2	0.46	6.02e-26	Lewy body disease;
LGG	cis	rs1707322	0.686	rs2275085	chr1:46085852	C/T	cg03146154	chr1:46216737	IPP	-0.57	-11.05	-0.46	2.33e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-7.13	-0.31	3.93e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg17202724	chr17:61916730	SMARCD2	-0.37	-6.83	-0.3	2.64e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs701145	0.938	rs355788	chr3:154000612	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg26174226	chr8:58114915	NA	-0.5	-7.42	-0.33	5.75e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4851254	0.961	rs7596385	chr2:100796598	A/T	cg17356467	chr2:100759845	AFF3	0.41	7.1	0.31	4.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17504614	0.608	rs17570033	chr2:51079664	G/T	cg23851515	chr2:51057218	NRXN1	0.67	8.19	0.36	2.6e-15	Educational attainment (years of education);
LGG	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg01620082	chr3:125678407	NA	-0.82	-9.5	-0.4	1.09e-19	Depression;
LGG	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	trans	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg18187862	chr3:45730750	SACM1L	-0.59	-9.51	-0.4	1.05e-19	Primary sclerosing cholangitis;
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-9.44	-0.4	1.87e-19	Dementia with Lewy bodies;
LGG	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.55	7.64	0.33	1.3e-13	Schizophrenia;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs13421350	0.579	rs75888567	chr2:173324256	G/A	cg15021238	chr2:173305865	ITGA6	-0.82	-9.32	-0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.6	0.41	4.97e-20	Obesity-related traits;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.46	-0.53	4.17e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs3845702	1.000	rs259808	chr2:180791419	T/G	cg01881094	chr2:180872142	CWC22	-0.9	-14.0	-0.55	2.14e-37	Schizophrenia;
LGG	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.67	-0.34	1.02e-13	HDL cholesterol;
LGG	cis	rs727505	1.000	rs67552763	chr7:124517857	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.49	-0.61	2.04e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11976180	1.000	rs2961134	chr7:143771062	A/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-7.04	-0.31	7.03e-12	Obesity-related traits;
LGG	cis	rs6547631	0.622	rs10180391	chr2:85926345	C/T	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.68e-11	Blood protein levels;
LGG	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.72	-9.09	-0.39	2.86e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg21171335	chr12:122356390	WDR66	-0.24	-6.81	-0.3	3.12e-11	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7503807	0.688	rs7503186	chr17:78590472	G/C	cg16980736	chr17:78789706	RPTOR	-0.36	-6.66	-0.3	7.7e-11	Obesity;
LGG	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.18	0.49	8.75e-30	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg02127607	chr17:61920694	SMARCD2	-0.44	-7.92	-0.35	1.8e-14	Prudent dietary pattern;
LGG	cis	rs4689642	1.000	rs12643248	chr4:7215934	T/C	cg21353189	chr4:7228343	SORCS2	0.3	7.54	0.33	2.57e-13	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs561341	0.609	rs739800	chr17:30190083	T/A	cg20587970	chr11:113659929	NA	0.93	12.95	0.52	5.99e-33	Hip circumference adjusted for BMI;
LGG	cis	rs528418	0.540	rs7743055	chr6:145677229	C/T	cg03642472	chr6:145670687	NA	-0.52	-6.95	-0.31	1.24e-11	Methadone dose in opioid dependence;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg05941027	chr17:61774174	LIMD2	0.37	9.2	0.39	1.27e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.2	-0.36	2.3e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7172689	1.000	rs7163931	chr15:81551842	C/G	cg11808699	chr15:81528661	IL16	-0.51	-10.59	-0.44	1.24e-23	Inattentive symptoms;
LGG	cis	rs1355223	0.902	rs2226113	chr11:34746289	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg26518628	chr1:97050305	NA	-0.83	-6.82	-0.3	2.85e-11	Cannabis dependence symptom count;
LGG	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg11752832	chr7:134001865	SLC35B4	0.58	10.38	0.43	8.02e-23	Mean platelet volume;
LGG	cis	rs6142618	0.562	rs6061185	chr20:30731472	G/T	cg00028034	chr20:30779307	TSPYL3	-0.36	-7.73	-0.34	6.76e-14	Inflammatory bowel disease;
LGG	cis	rs2282300	0.653	rs12800124	chr11:30239865	A/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.92	-0.35	1.8e-14	Morning vs. evening chronotype;
LGG	trans	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.75e-14	Joint mobility (Beighton score);
LGG	trans	rs7395662	1.000	rs12366208	chr11:48563128	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.43e-13	HDL cholesterol;
LGG	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg12658694	chr1:38397304	INPP5B	-0.52	-9.74	-0.41	1.56e-20	Coronary artery disease;
LGG	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg03894339	chr8:19674705	INTS10	0.64	10.4	0.44	6.35e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs926938	0.527	rs360666	chr1:115481290	C/T	cg12756093	chr1:115239321	AMPD1	0.44	8.14	0.35	3.63e-15	Autism;
LGG	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	11.51	0.47	3.76e-27	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg23102388	chr7:1867652	MAD1L1	0.36	6.87	0.3	2.12e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07623022	chr16:18801545	RPS15A	0.43	7.18	0.32	2.85e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg06532163	chr17:45867833	NA	0.55	9.33	0.4	4.58e-19	IgG glycosylation;
LGG	cis	rs13424612	1.000	rs34849118	chr2:240919912	T/C	cg01812947	chr2:240904978	NDUFA10	0.41	6.8	0.3	3.32e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs3806843	1.000	rs3806845	chr5:140180737	C/T	cg19875535	chr5:140030758	IK	0.51	10.4	0.44	6.34e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs526231	0.511	rs45518833	chr5:102342990	T/C	cg23492399	chr5:102201601	PAM	-0.56	-8.38	-0.36	6.59e-16	Primary biliary cholangitis;
LGG	cis	rs11971779	0.648	rs10085708	chr7:139110954	A/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg03929089	chr4:120376271	NA	-0.93	-19.77	-0.68	1.59e-63	Height;
LGG	cis	rs4474465	0.850	rs4597089	chr11:78262244	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.51	0.37	2.48e-16	Alzheimer's disease (survival time);
LGG	cis	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg00614314	chr15:82944287	LOC80154	0.65	10.91	0.45	7.83e-25	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2273669	0.915	rs6929070	chr6:109294322	G/T	cg05315195	chr6:109294784	ARMC2	-0.51	-7.31	-0.32	1.17e-12	Prostate cancer;
LGG	cis	rs7493	0.853	rs11770901	chr7:95054480	T/C	cg17330251	chr7:94953956	PON1	-0.44	-8.36	-0.36	7.15e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs12517041	1.000	rs34157151	chr5:23289755	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg05535760	chr7:792225	HEATR2	0.93	13.69	0.54	4.49e-36	Cerebrospinal P-tau181p levels;
LGG	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg21100191	chr22:23484243	RTDR1	0.54	8.19	0.36	2.64e-15	Serum parathyroid hormone levels;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg26513180	chr16:89883248	FANCA	0.81	8.82	0.38	2.38e-17	Skin colour saturation;
LGG	cis	rs9878978	0.660	rs62245710	chr3:2452312	G/A	cg21928760	chr3:2462534	CNTN4	0.47	8.96	0.38	7.96e-18	Blood pressure (smoking interaction);
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	3.2e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2692947	0.673	rs584811	chr2:97069879	A/G	cg22654517	chr2:96458247	NA	-0.34	-7.16	-0.32	3.13e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.42	-0.4	2.15e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.17	-0.36	2.88e-15	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs11785693	0.819	rs6994891	chr8:4989856	T/A	cg26367366	chr8:4980734	NA	1.0	15.67	0.59	1.05e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs11096990	0.593	rs6531700	chr4:39270885	T/G	cg24403649	chr4:39172243	NA	-0.38	-6.78	-0.3	3.66e-11	Cognitive function;
LGG	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg24375607	chr4:120327624	NA	0.41	7.09	0.31	4.95e-12	Diastolic blood pressure;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06112835	chr11:68658793	MRPL21	0.62	10.24	0.43	2.47e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4601790	0.601	rs66864335	chr11:65390803	G/A	cg01640437	chr11:65405484	SIPA1	0.4	6.84	0.3	2.57e-11	Blood pressure (age interaction);
LGG	cis	rs3106136	0.872	rs2059605	chr4:95255212	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-6.82	-0.3	2.79e-11	Capecitabine sensitivity;
LGG	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	11.3	0.47	2.46e-26	Lung cancer in ever smokers;
LGG	cis	rs6456042	0.824	rs3127423	chr6:166539088	G/A	cg11088901	chr6:166572345	T	-0.36	-7.54	-0.33	2.56e-13	Asthma;
LGG	trans	rs937213	0.573	rs2412464	chr15:40303842	G/A	cg22705835	chr10:65332833	REEP3	0.41	7.2	0.32	2.46e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	trans	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg06521331	chr12:34319734	NA	-0.54	-10.03	-0.42	1.51e-21	Bladder cancer;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.4	-0.33	6.5e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.26	-0.58	6.79e-43	Colorectal cancer;
LGG	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg19847130	chr8:10466454	RP1L1	-0.32	-7.23	-0.32	2e-12	Mood instability;
LGG	cis	rs9354308	0.866	rs2814092	chr6:66547346	C/G	cg07460842	chr6:66804631	NA	0.57	9.55	0.41	7.54e-20	Metabolite levels;
LGG	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg03929089	chr4:120376271	NA	-0.44	-7.13	-0.31	3.76e-12	HDL cholesterol;
LGG	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg02002194	chr4:3960332	NA	-0.52	-9.85	-0.42	6.74e-21	Retinal vascular caliber;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03286391	chr6:163661641	PACRG	0.38	7.3	0.32	1.25e-12	Electrocardiographic conduction measures;
LGG	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.58e-12	Schizophrenia;
LGG	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.16e-16	Aortic root size;
LGG	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg09307838	chr4:120376055	NA	-0.58	-9.38	-0.4	2.94e-19	Corneal astigmatism;
LGG	cis	rs1420338	1.000	rs4723351	chr7:34155813	T/G	cg01275685	chr7:34179230	BMPER	-0.47	-8.5	-0.37	2.53e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.27	-0.4	6.84e-19	Aortic root size;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg16359550	chr11:109292809	C11orf87	0.42	8.23	0.36	1.9e-15	Schizophrenia;
LGG	cis	rs877282	0.898	rs11253352	chr10:766598	C/A	cg17470449	chr10:769945	NA	0.59	7.33	0.32	1.06e-12	Uric acid levels;
LGG	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1788820	0.843	rs1788821	chr18:21120869	A/G	cg14672496	chr18:21087552	C18orf8	0.38	6.93	0.31	1.39e-11	Body mass index;
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.35	-0.32	8.93e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	10.28	0.43	1.81e-22	Lung cancer in ever smokers;
LGG	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg07061783	chr6:25882402	NA	-0.46	-7.97	-0.35	1.29e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg11502198	chr6:26597334	ABT1	0.55	9.4	0.4	2.52e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	7.88	0.34	2.39e-14	Obesity-related traits;
LGG	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.76	0.38	3.63e-17	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg13206674	chr6:150067644	NUP43	0.66	15.01	0.57	9.11e-42	Lung cancer;
LGG	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	trans	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.55	-0.33	2.28e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg07701084	chr6:150067640	NUP43	0.68	12.47	0.5	5.84e-31	Lung cancer;
LGG	cis	rs4851254	0.660	rs56037757	chr2:100690130	A/G	cg17356467	chr2:100759845	AFF3	0.45	7.27	0.32	1.54e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	9.09e-16	Personality dimensions;
LGG	cis	rs10089	1.000	rs10478796	chr5:127436187	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.97	0.49	5.87e-29	Ileal carcinoids;
LGG	cis	rs6573604	1.000	rs6573602	chr14:65784610	C/G	cg15999311	chr14:65749247	NA	0.48	6.81	0.3	3.13e-11	N-glycan levels;
LGG	cis	rs3762637	1.000	rs10934602	chr3:122223182	A/C	cg24169773	chr3:122142474	KPNA1	0.62	10.6	0.44	1.15e-23	LDL cholesterol levels;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg04503457	chr17:41445688	NA	-0.41	-10.0	-0.42	1.92e-21	Menopause (age at onset);
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.92	-0.31	1.49e-11	Monocyte percentage of white cells;
LGG	cis	rs36051895	0.623	rs2208685	chr9:5251758	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-11.87	-0.48	1.49e-28	Pediatric autoimmune diseases;
LGG	cis	rs2859741	0.967	rs522481	chr1:37488337	C/T	cg09363841	chr1:37513479	NA	-0.65	-16.36	-0.61	8.37e-48	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs12615966	0.932	rs60065121	chr2:105368305	T/C	cg16465502	chr2:105461796	NA	0.88	10.18	0.43	4.32e-22	Pancreatic cancer;
LGG	cis	rs9796	0.870	rs7181816	chr15:41358720	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.55	-0.37	1.85e-16	Menopause (age at onset);
LGG	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.21	0.43	3.16e-22	Iron status biomarkers;
LGG	cis	rs1966248	0.537	rs1414670	chr6:134114096	C/T	cg25632230	chr6:134101081	NA	-0.35	-7.63	-0.33	1.38e-13	Coronary artery disease;
LGG	cis	rs9902453	0.874	rs7220004	chr17:28369548	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.51e-11	Self-reported allergy;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg15971980	chr6:150254442	NA	0.45	8.97	0.38	7.13e-18	Lung cancer;
LGG	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26076054	chr5:421317	AHRR	-0.44	-7.13	-0.31	3.89e-12	Cystic fibrosis severity;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19752602	chr5:153039227	GRIA1	0.4	6.72	0.3	5.23e-11	Pancreatic cancer;
LGG	cis	rs9660992	0.508	rs113817010	chr1:205104581	C/A	cg21545522	chr1:205238299	TMCC2	0.38	7.02	0.31	7.9e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs13090388	1	rs13090388	chr3:49391082	C/T	cg03060546	chr3:49711283	APEH	-0.62	-10.22	-0.43	3.12e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);
LGG	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	cis	rs209489	0.892	rs2163013	chr6:53110301	A/G	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4750440	0.702	rs7917296	chr10:14029639	G/A	cg27542038	chr10:14027202	FRMD4A	-0.7	-14.19	-0.55	3.48e-38	Adiponectin levels;
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03517284	chr6:25882590	NA	-0.51	-9.39	-0.4	2.76e-19	Height;
LGG	cis	rs988958	0.526	rs10195970	chr2:42249643	C/T	cg19376973	chr2:42229025	NA	0.62	9.3	0.4	5.8e-19	Hypospadias;
LGG	cis	rs2236521	0.714	rs6062210	chr20:60890375	A/G	cg06026331	chr20:60912101	LAMA5	0.41	7.68	0.34	9.75e-14	Pelvic organ prolapse;
LGG	cis	rs68170813	0.652	rs12533694	chr7:107102817	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-8.64	-0.37	8.86e-17	Coronary artery disease;
LGG	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg22920501	chr2:26401640	FAM59B	0.45	9.35	0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs4728302	0.608	rs10254118	chr7:133158353	T/A	cg10665199	chr7:133106180	EXOC4	0.59	10.14	0.43	5.99e-22	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.63	-0.37	1.02e-16	Response to antipsychotic treatment;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06656553	chr16:89960601	TCF25	-0.73	-7.09	-0.31	4.99e-12	Skin colour saturation;
LGG	cis	rs151997	1.000	rs26063	chr5:50216718	G/A	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg12438819	chr7:158236134	PTPRN2	-0.31	-8.11	-0.35	4.74e-15	Obesity-related traits;
LGG	cis	rs3859192	0.561	rs9916158	chr17:38182229	G/T	cg17467752	chr17:38218738	THRA	-0.59	-9.9	-0.42	4.49e-21	White blood cell count;
LGG	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.38	-0.32	7.54e-13	Refractive error;
LGG	cis	rs36051895	0.659	rs12351277	chr9:5061405	A/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.11	-0.57	3.21e-42	Pediatric autoimmune diseases;
LGG	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05901451	chr6:126070800	HEY2	-0.81	-17.3	-0.63	4.21e-52	Brugada syndrome;
LGG	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.61	-0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs1125355	0.661	rs62183017	chr2:159622852	G/A	cg02251393	chr2:159651559	DAPL1	0.41	8.14	0.35	3.75e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	4.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg24642439	chr20:33292090	TP53INP2	0.56	9.5	0.4	1.16e-19	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05165339	chr4:1420672	NA	-0.26	-6.86	-0.3	2.22e-11	Obesity-related traits;
LGG	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22857025	chr5:266934	NA	-1.56	-25.53	-0.76	2.21e-90	Breast cancer;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg00933542	chr6:150070202	PCMT1	0.38	7.02	0.31	7.72e-12	Lung cancer;
LGG	cis	rs924043	0.636	rs74954452	chr6:170396846	T/C	cg00389036	chr6:170409598	NA	0.55	7.03	0.31	7.68e-12	Type 1 diabetes;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg07142201	chr11:109293216	C11orf87	0.48	8.36	0.36	7.49e-16	Schizophrenia;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg06558623	chr16:89946397	TCF25	1.11	12.14	0.49	1.21e-29	Skin colour saturation;
LGG	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	trans	rs13128441	0.637	rs6823878	chr4:5153750	C/G	cg26099876	chr8:141644609	EIF2C2	0.53	8.31	0.36	1.07e-15	Celiac disease;
LGG	cis	rs6580649	0.941	rs4760615	chr12:48428150	A/G	cg24011408	chr12:48396354	COL2A1	0.58	7.21	0.32	2.27e-12	Lung cancer;
LGG	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg12310025	chr6:25882481	NA	-0.37	-6.72	-0.3	5.48e-11	Height;
LGG	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.08e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2737618	0.722	rs1986405	chr1:200095935	C/G	cg21825944	chr1:200113062	NR5A2	-0.59	-11.47	-0.47	5.81e-27	Uric acid levels;
LGG	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg16576597	chr16:28551801	NUPR1	0.43	9.99	0.42	2.14e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg02187348	chr16:89574699	SPG7	0.65	11.18	0.46	7.63e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg21605333	chr4:119757512	SEC24D	0.72	7.74	0.34	6.41e-14	Cannabis dependence symptom count;
LGG	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.33	0.55	7.88e-39	Colorectal cancer;
LGG	cis	rs2235649	0.798	rs9932875	chr16:1848012	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-7.13	-0.31	3.86e-12	Blood metabolite levels;
LGG	cis	rs62400317	0.859	rs12214885	chr6:45197731	C/G	cg18551225	chr6:44695536	NA	-0.62	-9.88	-0.42	5.25e-21	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14309743	chr22:50312258	ALG12;CRELD2	0.45	6.65	0.3	8.37e-11	Gut microbiome composition (summer);
LGG	cis	rs12956009	0.583	rs16951972	chr18:44898600	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.4e-12	Educational attainment (years of education);
LGG	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07080220	chr10:102295463	HIF1AN	0.7	12.05	0.49	2.88e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6997458	0.806	rs1496532	chr8:86253982	A/G	cg02393479	chr8:86352350	CA3	0.31	6.78	0.3	3.67e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6942756	0.531	rs7811141	chr7:128908273	C/G	cg02491457	chr7:128862824	NA	0.51	9.64	0.41	3.74e-20	White matter hyperintensity burden;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01171360	chr6:293285	DUSP22	0.57	9.53	0.4	9.21e-20	Menopause (age at onset);
LGG	cis	rs1044826	0.642	rs186103	chr3:139211942	C/A	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6504108	0.624	rs7220768	chr17:46224829	A/G	cg02219949	chr17:45927392	SP6	0.44	8.3	0.36	1.18e-15	Body mass index;
LGG	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg22484793	chr3:52261325	TLR9	0.31	7.29	0.32	1.33e-12	Bipolar disorder;
LGG	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11644478	chr21:40555479	PSMG1	-0.55	-8.83	-0.38	2.23e-17	Menarche (age at onset);
LGG	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg11477892	chr4:106580295	NA	-0.4	-6.67	-0.3	7.34e-11	Post bronchodilator FEV1;
LGG	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.58	0.47	2.02e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-6.68	-0.3	6.76e-11	Blood metabolite levels;
LGG	cis	rs11750568	1.000	rs931617	chr5:178514893	A/C	cg10208897	chr5:178548229	ADAMTS2	0.42	6.91	0.31	1.56e-11	Height;
LGG	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg23505145	chr19:12996616	KLF1	0.41	7.34	0.32	9.6e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg07959490	chr17:80112427	CCDC57	0.47	9.34	0.4	4.12e-19	Life satisfaction;
LGG	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg09473613	chr1:24152604	HMGCL	0.27	6.83	0.3	2.75e-11	Immature fraction of reticulocytes;
LGG	cis	rs6719977	0.905	rs2278584	chr2:42989744	G/C	cg14631114	chr2:43023945	NA	0.46	9.78	0.41	1.13e-20	Hyperactive-impulsive symptoms;
LGG	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg16339924	chr4:17578868	LAP3	-0.51	-8.5	-0.37	2.65e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg00405596	chr8:11794950	NA	-0.4	-6.73	-0.3	5.16e-11	Triglycerides;
LGG	trans	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.04	0.39	4.35e-18	Iron status biomarkers;
LGG	cis	rs9487094	0.961	rs9487100	chr6:109750410	C/T	cg16315928	chr6:109776240	MICAL1	0.55	9.21	0.39	1.1e-18	Height;
LGG	cis	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.23	-0.46	4.79e-26	Morning vs. evening chronotype;
LGG	cis	rs7267979	0.702	rs449801	chr20:25491847	C/T	cg06421707	chr20:25228305	PYGB	0.37	7.69	0.34	8.71e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs677665	0.918	rs11590326	chr1:9339205	A/G	cg25755851	chr1:9335794	NA	-0.23	-6.86	-0.3	2.18e-11	Eosinophil percentage of white cells;
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-10.77	-0.45	2.73e-24	Prostate cancer;
LGG	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.2	-0.32	2.45e-12	Neuroticism;
LGG	cis	rs12791968	1.000	rs1005935	chr11:45002498	A/C	cg11846598	chr11:44996168	LOC221122	-0.67	-12.45	-0.5	6.6e-31	Inhibitory control;
LGG	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg15557168	chr22:42548783	NA	-0.4	-8.25	-0.36	1.64e-15	Schizophrenia;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg05279229	chr7:1896384	MAD1L1	-0.38	-6.81	-0.3	3e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs172166	0.694	rs1631552	chr6:28089699	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.12	-0.31	4.2e-12	Cardiac Troponin-T levels;
LGG	cis	rs12367572	0.623	rs10880718	chr12:45362806	G/C	cg03114573	chr12:45410052	DBX2	-0.66	-11.9	-0.48	1.16e-28	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg20607798	chr8:58055168	NA	0.58	8.93	0.38	9.77e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7215564	0.730	rs34484282	chr17:78684663	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07570687	chr10:102243282	WNT8B	-0.4	-7.26	-0.32	1.61e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg12698349	chr2:225449008	CUL3	0.7	11.81	0.48	2.47e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.49	0.47	4.55e-27	Bone mineral density;
LGG	cis	rs12410462	0.591	rs72748074	chr1:227763286	G/A	cg23173402	chr1:227635558	NA	0.39	7.38	0.32	7.32e-13	Major depressive disorder;
LGG	cis	rs7011049	0.778	rs6995569	chr8:53866259	C/T	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs600231	0.623	rs587080	chr11:65253800	A/C	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.18	-0.39	1.4e-18	Bone mineral density;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg11766577	chr21:47581405	C21orf56	-0.43	-7.61	-0.33	1.52e-13	Testicular germ cell tumor;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg22753661	chr15:79092743	ADAMTS7	0.41	7.04	0.31	6.92e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	12.43	0.5	8.13e-31	Total body bone mineral density;
LGG	cis	rs17767392	0.813	rs8013161	chr14:72021499	G/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.56	0.37	1.65e-16	Mitral valve prolapse;
LGG	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.79	-0.34	4.39e-14	Retinal vascular caliber;
LGG	cis	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg06521331	chr12:34319734	NA	-0.38	-6.76	-0.3	4.12e-11	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	10.3	0.43	1.57e-22	Motion sickness;
LGG	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg07061783	chr6:25882402	NA	0.38	6.86	0.3	2.22e-11	Blood metabolite levels;
LGG	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11520985	chr6:7313314	SSR1	0.41	6.66	0.3	7.59e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg20587970	chr11:113659929	NA	1.06	16.2	0.6	4.56e-47	Hip circumference adjusted for BMI;
LGG	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg21045802	chr8:109455806	TTC35	0.55	10.45	0.44	4.23e-23	Dupuytren's disease;
LGG	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg06494592	chr3:125709126	NA	-0.54	-6.8	-0.3	3.26e-11	Blood pressure (smoking interaction);
LGG	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg07936489	chr17:37558343	FBXL20	-0.84	-15.7	-0.59	8.07e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.12	-0.43	7.27e-22	Lung cancer;
LGG	cis	rs2073300	1.000	rs6137957	chr20:23437384	G/A	cg12062639	chr20:23401060	NAPB	0.86	7.0	0.31	8.82e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.68	-0.41	2.59e-20	Lung cancer;
LGG	cis	rs41271473	0.706	rs72763990	chr1:228719071	A/T	cg16512390	chr1:228756714	NA	0.65	8.07	0.35	5.95e-15	Chronic lymphocytic leukemia;
LGG	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg24505687	chr6:33548425	BAK1	0.56	9.2	0.39	1.21e-18	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LGG	trans	rs7939886	0.920	rs7113835	chr11:55947007	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs7762018	0.607	rs78941587	chr6:170061157	G/C	cg19338460	chr6:170058176	WDR27	-0.85	-10.08	-0.42	9.81e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg11693508	chr17:37793320	STARD3	0.5	7.18	0.32	2.79e-12	Bipolar disorder;
LGG	cis	rs1318772	0.932	rs13171273	chr5:112907809	A/G	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	cis	rs9902453	0.845	rs2321493	chr17:28230359	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.64	0.54	7.54e-36	Coffee consumption (cups per day);
LGG	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.97	0.38	7.52e-18	Neuroticism;
LGG	cis	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-8.57	-0.37	1.51e-16	Resting heart rate;
LGG	cis	rs35570576	0.585	rs7216806	chr17:77538517	C/T	cg08506369	chr17:77610316	NA	-0.45	-6.71	-0.3	5.69e-11	Photic sneeze reflex;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18788524	chr1:145096602	SEC22B	0.61	6.92	0.31	1.56e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.32	-0.5	2.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11677416	1.000	rs3783514	chr2:113547425	A/G	cg27083787	chr2:113543245	IL1A	0.53	8.97	0.38	7.25e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg23950597	chr19:37808831	NA	-0.74	-10.2	-0.43	3.69e-22	Coronary artery calcification;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg13129662	chr17:48227708	PPP1R9B	-0.42	-7.24	-0.32	1.86e-12	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs368123	1.000	rs435542	chr6:160723324	T/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.25e-12	Waist circumference;
LGG	cis	rs3820068	0.705	rs72645803	chr1:15868232	G/A	cg05660106	chr1:15850417	CASP9	1.14	27.09	0.78	1.6e-97	Systolic blood pressure;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	11.6	0.47	1.67e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.5	-0.44	2.88e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.59	-0.33	1.77e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs457717	0.730	rs463973	chr5:75948025	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.3	6.66	0.3	7.74e-11	Hearing impairment;
LGG	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg21401794	chr1:90099060	LRRC8C	-0.56	-11.97	-0.49	5.81e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs6011368	0.765	rs7270745	chr20:62892756	C/G	cg13869341	chr1:15865	WASH5P	-0.51	-9.21	-0.39	1.15e-18	Clozapine-induced cytotoxicity;
LGG	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.61	-0.51	1.58e-31	Total body bone mineral density;
LGG	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg00188032	chr5:96141721	ERAP1	0.53	7.23	0.32	2.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2018683	0.707	rs10279610	chr7:28975696	C/G	cg19402173	chr7:128379420	CALU	0.54	9.41	0.4	2.26e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg09173681	chr1:183549694	NCF2	0.36	8.28	0.36	1.36e-15	Systemic lupus erythematosus;
LGG	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg03576123	chr11:487126	PTDSS2	0.97	14.28	0.55	1.31e-38	Body mass index;
LGG	cis	rs806215	0.547	rs765971	chr7:127420642	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.09	-0.31	5.14e-12	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg10189774	chr4:17578691	LAP3	0.37	6.66	0.3	7.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2562456	0.833	rs2154302	chr19:21490411	G/A	cg00806126	chr19:22604979	ZNF98	-0.56	-7.46	-0.33	4.29e-13	Pain;
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.03	-0.39	4.82e-18	Prostate cancer;
LGG	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg00898013	chr13:113819073	PROZ	-0.48	-9.57	-0.41	6.68e-20	Platelet distribution width;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00761968	chr13:53314142	LECT1	-0.34	-7.22	-0.32	2.13e-12	Lewy body disease;
LGG	cis	rs2862064	1.000	rs1910053	chr5:156463063	G/A	cg12943317	chr5:156479607	HAVCR1	-0.88	-10.96	-0.45	5.22e-25	Platelet count;
LGG	cis	rs6580649	0.883	rs879242	chr12:48503301	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.4e-11	Lung cancer;
LGG	cis	rs7267979	0.789	rs6083810	chr20:25329759	T/A	cg06421707	chr20:25228305	PYGB	-0.37	-7.84	-0.34	3.19e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	0.872	rs12785367	chr11:34715269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.88	-0.3	2e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7937612	1.000	rs7478880	chr11:120261791	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.79	-0.51	2.82e-32	Intraocular pressure;
LGG	cis	rs9811920	0.609	rs793465	chr3:99627750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs1109114	0.844	rs12153240	chr5:148622329	A/G	cg06539116	chr5:148597365	ABLIM3	-0.44	-10.06	-0.42	1.12e-21	Body mass index;
LGG	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Body mass index;
LGG	cis	rs4843185	0.699	rs2029	chr16:85708846	C/A	cg26571870	chr16:85723150	GINS2	-0.42	-7.53	-0.33	2.72e-13	Platelet distribution width;
LGG	cis	rs12681287	0.640	rs34794500	chr8:87449995	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg19147804	chr7:1989927	MAD1L1	-0.55	-11.38	-0.47	1.23e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg00405596	chr8:11794950	NA	-0.43	-7.35	-0.32	9.12e-13	Neuroticism;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.44	0.44	4.82e-23	Personality dimensions;
LGG	cis	rs4740619	0.933	rs6474955	chr9:15715526	C/T	cg14451791	chr9:16040625	NA	-0.37	-9.58	-0.41	5.79e-20	Body mass index;
LGG	trans	rs11088226	0.681	rs2833901	chr21:33939318	T/C	cg09050820	chr6:167586206	TCP10L2	0.9	12.68	0.51	7.79e-32	Gastritis;
LGG	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs10193935	0.901	rs7605782	chr2:42502332	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.37	-0.4	3.25e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08142263	chr19:17420206	DDA1	0.43	7.37	0.32	8.05e-13	Bipolar disorder;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs35079168	0.923	rs10858277	chr9:137287959	G/A	cg00753924	chr9:137298813	RXRA	-0.38	-7.18	-0.32	2.77e-12	Intelligence;
LGG	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg16751781	chr15:78858589	CHRNA5	-0.43	-8.49	-0.37	2.74e-16	Sudden cardiac arrest;
LGG	cis	rs8067287	0.597	rs4985735	chr17:16866164	C/T	cg26910001	chr17:16838321	NA	0.37	7.33	0.32	1.07e-12	Diabetic kidney disease;
LGG	trans	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.0	0.42	1.88e-21	Mean corpuscular volume;
LGG	cis	rs3780486	0.846	rs7849148	chr9:33138352	A/T	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.76	-0.57	1.13e-40	IgG glycosylation;
LGG	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg04025307	chr7:1156635	C7orf50	0.46	6.72	0.3	5.26e-11	Bronchopulmonary dysplasia;
LGG	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13012494	chr21:47604986	C21orf56	-0.63	-10.46	-0.44	4.03e-23	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg18379455	chr17:41446167	NA	-0.31	-7.08	-0.31	5.54e-12	Menopause (age at onset);
LGG	cis	rs7604693	0.507	rs329502	chr2:64316687	G/A	cg02541582	chr2:64069798	UGP2	0.27	7.18	0.32	2.89e-12	Kawasaki disease;
LGG	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg02002194	chr4:3960332	NA	0.45	8.21	0.36	2.16e-15	Neuroticism;
LGG	cis	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg26384229	chr12:38710491	ALG10B	1.0	25.1	0.76	2.2e-88	Heart rate;
LGG	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg07395648	chr5:131743802	NA	0.56	13.07	0.52	1.81e-33	Blood metabolite levels;
LGG	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg10556349	chr10:835070	NA	-0.29	-7.26	-0.32	1.61e-12	Survival in rectal cancer;
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.47	-0.37	3.37e-16	Aortic root size;
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg13397359	chr6:42928475	GNMT	0.63	18.69	0.66	1.8e-58	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs4740619	0.819	rs276455	chr9:15584809	G/C	cg14451791	chr9:16040625	NA	-0.34	-8.83	-0.38	2.15e-17	Body mass index;
LGG	cis	rs1125355	0.690	rs72939206	chr2:159642311	T/A	cg02251393	chr2:159651559	DAPL1	0.42	8.72	0.38	4.88e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg00711542	chr16:29343894	RUNDC2C	0.43	7.16	0.32	3.13e-12	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4363385	0.747	rs1413849	chr1:152970233	C/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.86e-18	Inflammatory skin disease;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	8.7	0.37	5.83e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs7927592	0.913	rs4316515	chr11:68308840	A/T	cg01657329	chr11:68192670	LRP5	0.47	8.03	0.35	8.01e-15	Total body bone mineral density;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs61897795	0.628	rs93923	chr11:61613745	C/T	cg19610905	chr11:61596333	FADS2	-0.67	-9.43	-0.4	1.93e-19	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.43e-16	Total body bone mineral density;
LGG	cis	rs7916697	0.947	rs9783176	chr10:70002393	A/T	cg18338521	chr10:69995036	NA	-0.33	-7.34	-0.32	9.93e-13	Optic disc area;
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.0	-0.52	3.62e-33	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7010267	0.543	rs6469803	chr8:120040538	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.78	0.38	3.3e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs228437	1.000	rs9376050	chr6:134910136	A/G	cg24504307	chr6:134963096	NA	0.41	7.66	0.34	1.06e-13	Melanoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15624725	chr16:30381887	TBC1D10B	0.44	7.03	0.31	7.53e-12	Cognitive performance;
LGG	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.85	9.89	0.42	4.87e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.2	0.46	6.04e-26	High light scatter reticulocyte count;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg06873352	chr17:61820015	STRADA	0.75	13.97	0.54	2.97e-37	Prudent dietary pattern;
LGG	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg15823100	chr22:32027580	PISD	-0.73	-8.34	-0.36	8.9e-16	Age-related hearing impairment;
LGG	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg20503657	chr10:835505	NA	0.75	10.44	0.44	4.84e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.95e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs751728	1.000	rs2296748	chr6:33745071	C/T	cg25922239	chr6:33757077	LEMD2	0.69	12.24	0.49	4.84e-30	Crohn's disease;
LGG	cis	rs6735179	0.549	rs56066419	chr2:1755649	G/A	cg20570797	chr2:1712800	PXDN	-0.45	-8.15	-0.35	3.35e-15	Response to antipsychotic treatment;
LGG	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg02836325	chr17:76403955	PGS1	-0.71	-14.37	-0.56	5.6e-39	HDL cholesterol levels;
LGG	cis	rs6997458	0.806	rs12544332	chr8:86256210	C/A	cg02393479	chr8:86352350	CA3	-0.32	-6.94	-0.31	1.35e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.55	-0.53	1.85e-35	Response to antipsychotic treatment;
LGG	cis	rs62025270	0.522	rs16943120	chr15:86226297	A/G	cg25843651	chr15:86329602	KLHL25	0.56	8.52	0.37	2.19e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg13628971	chr7:2884303	GNA12	0.54	11.48	0.47	4.93e-27	Height;
LGG	cis	rs6684428	1.000	rs7540772	chr1:56375368	C/G	cg11651538	chr1:56320950	NA	-0.75	-13.03	-0.52	2.77e-33	Airflow obstruction;
LGG	cis	rs782590	0.935	rs10460508	chr2:55882565	A/C	cg18811423	chr2:55921094	PNPT1	0.91	21.05	0.7	1.62e-69	Metabolic syndrome;
LGG	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg13010199	chr12:38710504	ALG10B	0.58	11.44	0.47	7.34e-27	Heart rate;
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.54e-23	Bipolar disorder;
LGG	cis	rs10193935	0.901	rs17029411	chr2:42479149	G/A	cg27598129	chr2:42591480	NA	-0.58	-8.99	-0.39	6.58e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2905347	0.726	rs2905321	chr7:22704587	A/G	cg23521230	chr7:22704884	NA	-0.41	-7.56	-0.33	2.12e-13	Major depression and alcohol dependence;
LGG	trans	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg03929089	chr4:120376271	NA	0.72	7.88	0.34	2.41e-14	Axial length;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.82	-0.34	3.67e-14	Obesity;
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.1e-17	Aortic root size;
LGG	cis	rs73086581	0.838	rs73088426	chr20:4003283	A/T	cg02187196	chr20:3869020	PANK2	0.71	9.7	0.41	2.21e-20	Response to antidepressants in depression;
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs745821	0.660	rs9962245	chr18:48100138	T/A	cg18923635	chr18:48083994	NA	0.42	7.57	0.33	2.02e-13	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2070677	0.736	rs7895560	chr10:135431038	G/A	cg20169779	chr10:135381914	SYCE1	-1.04	-11.41	-0.47	9.91e-27	Gout;
LGG	trans	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.02	-0.31	8.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10849893	0.557	rs7976840	chr12:121829972	T/C	cg01154721	chr12:121881891	KDM2B	-0.39	-6.73	-0.3	4.92e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs15676	0.947	rs2997913	chr9:131589033	C/T	cg04621255	chr9:131581398	ENDOG	-0.39	-6.87	-0.3	2.09e-11	Blood metabolite levels;
LGG	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.68	-0.3	6.75e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13948710	chr19:53970754	ZNF813	0.53	8.42	0.36	4.75e-16	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.29	0.4	5.89e-19	Lung cancer;
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.49	-0.47	4.68e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg07061783	chr6:25882402	NA	-0.46	-7.85	-0.34	2.89e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg03689076	chr20:33865952	NA	0.65	8.38	0.36	6.53e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs526231	0.543	rs246901	chr5:102584178	G/A	cg23492399	chr5:102201601	PAM	-0.62	-8.91	-0.38	1.16e-17	Primary biliary cholangitis;
LGG	cis	rs1345301	0.518	rs12468355	chr2:102861250	T/G	cg05295703	chr2:102895712	NA	0.48	9.54	0.41	8.1e-20	Waist circumference;
LGG	cis	rs3857747	0.931	rs17171685	chr7:40368882	C/T	cg00420559	chr7:40367873	C7orf10	0.42	8.58	0.37	1.49e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs9487051	0.768	rs12176068	chr6:109521629	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs4950322	0.570	rs4950399	chr1:146791020	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	trans	rs2727020	0.521	rs7101761	chr11:49598178	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.78	-0.54	1.93e-36	Coronary artery disease;
LGG	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg18196295	chr10:418757	DIP2C	0.48	9.15	0.39	1.84e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00149659	chr3:10157352	C3orf10	-0.73	-9.37	-0.4	3.19e-19	Alzheimer's disease;
LGG	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06672317	chr19:20150232	ZNF682	0.51	7.71	0.34	7.77e-14	Gut microbiome composition (summer);
LGG	cis	rs6141769	0.569	rs11905501	chr20:31270962	C/A	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.11	-0.31	4.32e-12	Subjective well-being;
LGG	cis	rs941873	0.835	rs10762859	chr10:81103370	T/A	cg09469691	chr10:81107165	PPIF	0.63	11.4	0.47	1.08e-26	Height;
LGG	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.42	-0.33	5.8e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg21926883	chr2:100939477	LONRF2	0.66	15.16	0.58	1.9e-42	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg22398616	chr13:53314203	LECT1	-0.46	-9.76	-0.41	1.38e-20	Lewy body disease;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.32e-17	Lung cancer;
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06634786	chr22:41940651	POLR3H	-0.8	-12.97	-0.52	5.13e-33	Vitiligo;
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs4740619	0.792	rs442549	chr9:15616508	T/G	cg14451791	chr9:16040625	NA	-0.34	-8.69	-0.37	6.16e-17	Body mass index;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.91	-0.31	1.62e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg01059449	chr18:44338099	ST8SIA5	0.33	7.25	0.32	1.81e-12	Personality dimensions;
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg07959490	chr17:80112427	CCDC57	0.47	9.3	0.4	5.57e-19	Life satisfaction;
LGG	cis	rs11169552	0.510	rs10783370	chr12:50937149	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.87	-0.34	2.51e-14	Colorectal cancer;
LGG	cis	rs10484885	0.763	rs56401039	chr6:90522486	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.85	-10.83	-0.45	1.69e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg01557791	chr16:72042693	DHODH	-0.52	-9.68	-0.41	2.6e-20	Fibrinogen levels;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.33	-0.36	9.45e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6740322	0.895	rs9309097	chr2:43554397	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.62	-0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.49e-11	Coronary artery disease;
LGG	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg24231037	chr15:68117551	LBXCOR1	0.3	7.3	0.32	1.22e-12	Restless legs syndrome;
LGG	cis	rs377457	0.823	rs72803037	chr16:85740078	C/T	cg08768472	chr16:85689701	KIAA0182	0.42	7.57	0.33	2e-13	Type 2 diabetes;
LGG	cis	rs56399783	0.614	rs73047368	chr7:2766396	G/T	cg19731401	chr7:2775893	GNA12	0.38	7.45	0.33	4.53e-13	Childhood ear infection;
LGG	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.89	0.51	1.06e-32	High light scatter reticulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06148375	chr16:12070864	RUNDC2A	0.47	6.92	0.31	1.52e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg08888203	chr3:10149979	C3orf24	0.53	9.0	0.39	5.86e-18	Alzheimer's disease;
LGG	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg00919237	chr7:87102261	ABCB4	-0.79	-16.07	-0.6	1.62e-46	Gallbladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03500798	chr12:124068866	TMED2	0.56	8.61	0.37	1.15e-16	Gut microbiome composition (summer);
LGG	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg12463550	chr7:65579703	CRCP	0.75	8.41	0.36	5.13e-16	Gout;
LGG	cis	rs929354	0.685	rs7807856	chr7:156934498	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg04287289	chr16:89883240	FANCA	0.81	17.41	0.63	1.38e-52	Vitiligo;
LGG	cis	rs965513	0.901	rs1877431	chr9:100534147	C/T	cg13688889	chr9:100608707	NA	0.45	8.12	0.35	4.31e-15	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg11040518	chr10:102331378	NA	-0.38	-7.04	-0.31	7.04e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg27490568	chr2:178487706	NA	0.49	9.72	0.41	1.93e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1371867	0.846	rs1613453	chr8:101244215	G/T	cg06636551	chr8:101224915	SPAG1	0.49	9.09	0.39	2.89e-18	Atrioventricular conduction;
LGG	cis	rs41005	1.000	rs41004	chr2:8111580	C/T	cg03155496	chr2:8117019	LOC339788	0.89	20.08	0.68	5.91e-65	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.2	-0.36	2.32e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg22842854	chr12:123319900	HIP1R	-0.53	-6.65	-0.3	8.37e-11	Schizophrenia;
LGG	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	14.94	0.57	1.78e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	7.81	0.34	3.88e-14	Thyroid stimulating hormone;
LGG	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs17453880	0.632	rs2964243	chr5:151921873	C/T	cg12297329	chr5:152029980	NA	-0.59	-12.42	-0.5	9.33e-31	Subjective well-being;
LGG	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg13010199	chr12:38710504	ALG10B	-0.53	-10.48	-0.44	3.46e-23	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-6.95	-0.31	1.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs877282	0.853	rs10904545	chr10:757100	G/A	cg22713356	chr15:30763199	NA	0.48	7.18	0.32	2.78e-12	Uric acid levels;
LGG	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg04568710	chr12:38710424	ALG10B	-0.4	-8.73	-0.38	4.61e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7091068	0.706	rs4919398	chr10:95429162	C/T	cg20715218	chr10:95462985	C10orf4	0.65	9.59	0.41	5.32e-20	Urinary tract infection frequency;
LGG	cis	rs3204270	0.639	rs7215738	chr17:79659847	C/T	cg18367735	chr17:79674897	NA	0.6	7.93	0.35	1.67e-14	Dental caries;
LGG	cis	rs7223966	0.621	rs35819807	chr17:61623052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.59	0.33	1.76e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	13.53	0.53	2.31e-35	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-7.48	-0.33	3.83e-13	Coronary artery disease;
LGG	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg19508488	chr2:152266495	RIF1	0.63	11.69	0.48	7.51e-28	Lung cancer;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.44	0.5	7.33e-31	Prudent dietary pattern;
LGG	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11890956	chr21:40555474	PSMG1	1.2	27.94	0.79	2.1e-101	Cognitive function;
LGG	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03647317	chr4:187891568	NA	0.41	8.92	0.38	1.13e-17	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22776125	chr6:167041314	RPS6KA2	0.52	8.08	0.35	5.51e-15	Gut microbiome composition (summer);
LGG	cis	rs2905347	0.895	rs2961280	chr7:22639717	A/G	cg18045685	chr7:22629474	NA	-0.74	-15.86	-0.59	1.47e-45	Major depression and alcohol dependence;
LGG	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.31	0.43	1.46e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4776059	0.876	rs2414163	chr15:52897478	T/C	cg22715398	chr15:52968154	KIAA1370	-0.49	-7.84	-0.34	3.21e-14	Schizophrenia;
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg15133208	chr4:90757351	SNCA	0.34	7.72	0.34	7.24e-14	Dementia with Lewy bodies;
LGG	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.39	-0.36	5.8e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg26850624	chr5:429559	AHRR	-0.38	-8.39	-0.36	5.81e-16	Cystic fibrosis severity;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg02002194	chr4:3960332	NA	0.44	7.77	0.34	5.12e-14	Myopia (pathological);
LGG	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12826209	chr6:26865740	GUSBL1	0.59	7.3	0.32	1.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.36e-16	Aortic root size;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.49	-8.29	-0.36	1.28e-15	Personality dimensions;
LGG	cis	rs6120849	0.707	rs6120826	chr20:33671831	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.37	-0.47	1.4e-26	Intelligence (multi-trait analysis);
LGG	trans	rs11875185	0.510	rs113845577	chr18:55593893	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.42	-0.33	5.74e-13	Joint mobility (Beighton score);
LGG	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.5	0.33	3.21e-13	Joint mobility (Beighton score);
LGG	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-12.48	-0.5	5.22e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.56e-19	Diabetic retinopathy;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.21	-0.32	2.33e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-27.16	-0.78	7.18e-98	Primary sclerosing cholangitis;
LGG	cis	rs4950322	0.542	rs17159914	chr1:146654805	C/T	cg22381352	chr1:146742008	CHD1L	0.45	7.65	0.34	1.14e-13	Protein quantitative trait loci;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	7.61	0.33	1.59e-13	Obesity-related traits;
LGG	trans	rs7944735	0.817	rs747782	chr11:47940925	A/G	cg15704280	chr7:45808275	SEPT13	0.62	7.6	0.33	1.68e-13	Intraocular pressure;
LGG	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg20026190	chr17:76395443	PGS1	0.57	10.0	0.42	1.9e-21	HDL cholesterol levels;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21862992	chr11:68658383	NA	0.48	8.15	0.35	3.53e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs185694	1.000	rs595449	chr13:30896852	T/C	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.71	-0.3	5.7e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07167872	chr1:205819463	PM20D1	0.51	10.13	0.43	6.66e-22	Menarche (age at onset);
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg22907277	chr7:1156413	C7orf50	0.69	12.36	0.5	1.58e-30	Longevity;Endometriosis;
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg16434002	chr17:42200994	HDAC5	-0.55	-10.21	-0.43	3.26e-22	Total body bone mineral density;
LGG	cis	rs55665837	1.000	rs12276938	chr11:14463488	C/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.7	-0.37	5.8e-17	Vitamin D levels;
LGG	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg02631450	chr22:32366979	NA	0.8	8.42	0.36	4.64e-16	Childhood ear infection;
LGG	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg12179176	chr11:130786555	SNX19	0.84	17.58	0.63	2.17e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg13565492	chr6:43139072	SRF	-0.72	-8.78	-0.38	3.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg25214090	chr10:38739885	LOC399744	0.56	9.75	0.41	1.54e-20	Corneal astigmatism;
LGG	cis	rs9420907	0.579	rs2487999	chr10:105659826	T/C	cg11005552	chr10:105648138	OBFC1	0.66	7.09	0.31	4.97e-12	Telomere length;
LGG	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg14664628	chr15:75095509	CSK	-0.56	-10.43	-0.44	5.02e-23	Breast cancer;
LGG	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg24699146	chr1:24152579	HMGCL	-0.27	-7.88	-0.34	2.34e-14	Immature fraction of reticulocytes;
LGG	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.65	-11.25	-0.46	3.91e-26	Mean platelet volume;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.39	-7.65	-0.33	1.19e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg25486957	chr4:152246857	NA	-0.48	-8.06	-0.35	6.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg11062466	chr8:58055876	NA	0.44	7.78	0.34	4.82e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg12292205	chr6:26970375	C6orf41	0.72	13.86	0.54	9.01e-37	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9290877	0.580	rs13314127	chr3:188469964	C/T	cg17392043	chr3:188495102	LPP	-0.46	-8.11	-0.35	4.6e-15	IgE levels;
LGG	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg03929089	chr4:120376271	NA	-0.53	-8.97	-0.38	7.18e-18	HDL cholesterol;
LGG	cis	rs9400467	0.537	rs73530977	chr6:111504819	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.11	0.31	4.29e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs28655083	0.879	rs1502444	chr16:77059172	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.54	-8.68	-0.37	6.7e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03576123	chr11:487126	PTDSS2	-1.25	-16.79	-0.62	9.04e-50	Body mass index;
LGG	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.75	-0.38	4.05e-17	HDL cholesterol;
LGG	cis	rs12493885	0.818	rs60023390	chr3:153771056	C/T	cg17054900	chr3:154042577	DHX36	-0.62	-7.88	-0.34	2.3e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10739695	0.635	rs7033913	chr9:130561067	C/T	cg13492245	chr9:130566157	FPGS	0.39	6.81	0.3	3.04e-11	Monocyte percentage of white cells;
LGG	cis	rs17253792	0.822	rs28478195	chr14:56047851	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.54	-0.5	2.91e-31	Putamen volume;
LGG	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg26248373	chr2:1572462	NA	-0.84	-13.15	-0.52	8.97e-34	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.31	-0.32	1.19e-12	Joint mobility (Beighton score);
LGG	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg24110177	chr3:50126178	RBM5	0.63	11.51	0.47	4.08e-27	Body mass index;
LGG	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg13009111	chr11:71350975	NA	-0.32	-6.89	-0.3	1.77e-11	Monocyte count;
LGG	cis	rs7717393	0.881	rs10056289	chr5:155776066	A/T	cg12904904	chr5:155754151	SGCD	-0.61	-6.86	-0.3	2.16e-11	Egg allergy;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.28	0.4	6.65e-19	Obesity-related traits;
LGG	cis	rs2688608	0.672	rs4065	chr10:75676464	C/T	cg10168709	chr10:75599394	CAMK2G	-0.35	-6.94	-0.31	1.31e-11	Inflammatory bowel disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03671748	chr4:2965203	GRK4;NOP14	-0.44	-6.82	-0.3	2.87e-11	Pancreatic cancer;
LGG	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg06640241	chr16:89574553	SPG7	0.58	9.76	0.41	1.43e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs11166927	0.548	rs4736099	chr8:140828745	T/C	cg16909799	chr8:140841666	TRAPPC9	-0.65	-14.25	-0.55	1.87e-38	Pediatric non-alcoholic fatty liver disease activity score;
LGG	trans	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg26043149	chr18:55253948	FECH	0.41	6.83	0.3	2.75e-11	Bone mineral density;
LGG	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg07599136	chr5:415885	AHRR	0.85	11.55	0.47	2.73e-27	Fat distribution (HIV);
LGG	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg08847533	chr14:75593920	NEK9	-0.51	-9.16	-0.39	1.73e-18	Height;
LGG	cis	rs7638995	1.000	rs7638995	chr3:69173375	A/C	cg26574240	chr3:69171822	LMOD3	0.52	8.21	0.36	2.18e-15	Alzheimer's disease (late onset);
LGG	cis	rs935334	1.000	rs2121075	chr14:76675540	G/C	cg14073839	chr14:76668648	C14orf118	-0.42	-7.01	-0.31	8.22e-12	Blood pressure;
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg16359550	chr11:109292809	C11orf87	0.4	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs9397585	0.599	rs583665	chr6:153408950	T/C	cg17707550	chr6:153380415	RGS17	-0.45	-10.19	-0.43	3.92e-22	Body mass index;
LGG	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg16662043	chr16:48846231	NA	0.37	7.11	0.31	4.29e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27339505	chr5:140998609	DIAPH1	0.45	6.78	0.3	3.59e-11	Gut microbiome composition (summer);
LGG	cis	rs1185460	0.565	rs1043314	chr11:118915944	A/G	cg23280166	chr11:118938394	VPS11	-0.45	-7.67	-0.34	1.01e-13	Coronary artery disease;
LGG	cis	rs972578	0.765	rs5759029	chr22:43308526	G/T	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.12e-11	Mean platelet volume;
LGG	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.29	0.32	1.37e-12	Systolic blood pressure;
LGG	cis	rs6504108	0.602	rs3944039	chr17:46205070	T/C	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg00206168	chr11:65308501	LTBP3	0.71	7.78	0.34	4.78e-14	Height;
LGG	cis	rs10463554	0.927	rs39666	chr5:102447127	C/T	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs7945718	0.533	rs10765987	chr11:12705743	C/T	cg25843174	chr11:12811716	TEAD1	0.33	6.9	0.31	1.7e-11	Educational attainment (years of education);
LGG	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg02811702	chr13:24901961	NA	0.41	7.34	0.32	9.91e-13	Obesity-related traits;
LGG	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg27411982	chr8:10470053	RP1L1	0.42	7.22	0.32	2.19e-12	Mood instability;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg06558623	chr16:89946397	TCF25	1.07	13.12	0.52	1.16e-33	Skin colour saturation;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.59	0.41	5.29e-20	Height;
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.22	-0.32	2.21e-12	Testicular germ cell tumor;
LGG	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.41	-6.68	-0.3	7.07e-11	Eosinophil percentage of white cells;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg01673284	chr16:4527211	HMOX2	0.35	6.98	0.31	1.04e-11	Schizophrenia;
LGG	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03264133	chr6:25882463	NA	-0.63	-11.58	-0.47	2.06e-27	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.600	rs7341483	chr7:23127657	G/T	cg23682824	chr7:23144976	KLHL7	-0.43	-7.4	-0.33	6.63e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.46e-14	Bone mineral density;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22111038	chr5:57879168	RAB3C	0.38	6.75	0.3	4.51e-11	Obesity-related traits;
LGG	cis	rs815815	0.583	rs11125126	chr2:47395379	C/T	cg27223769	chr2:47403360	CALM2	-0.52	-8.08	-0.35	5.86e-15	Dialysis-related mortality;
LGG	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg08250081	chr4:10125330	NA	-0.48	-9.25	-0.39	8.2e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg13207630	chr7:32358064	NA	0.61	6.8	0.3	3.16e-11	Body mass index;
LGG	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg05163923	chr11:71159392	DHCR7	0.72	14.02	0.55	1.77e-37	Vitamin D levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13603859	chr5:145827007	TCERG1	-0.49	-7.25	-0.32	1.8e-12	Systemic lupus erythematosus;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg15948088	chr11:109293068	C11orf87	0.47	8.29	0.36	1.24e-15	Schizophrenia;
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg06636001	chr8:8085503	FLJ10661	0.57	10.85	0.45	1.42e-24	Triglycerides;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.47	-8.45	-0.37	3.73e-16	Obesity-related traits;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23634478	chr14:75348573	DLST	-0.4	-6.74	-0.3	4.84e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs10504073	0.647	rs12549138	chr8:50007203	C/T	cg00325661	chr8:49890786	NA	0.74	14.34	0.55	7.46e-39	Blood metabolite ratios;
LGG	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11890956	chr21:40555474	PSMG1	0.75	12.95	0.52	5.81e-33	Cognitive function;
LGG	cis	rs7524258	0.867	rs916392	chr1:7271930	T/C	cg07173049	chr1:7289937	CAMTA1	0.77	18.37	0.65	5.37e-57	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg00898013	chr13:113819073	PROZ	0.44	8.58	0.37	1.5e-16	Platelet distribution width;
LGG	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg05696931	chr1:227175867	NA	-0.39	-7.53	-0.33	2.7e-13	Myeloid white cell count;
LGG	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg18252515	chr7:66147081	NA	1.43	20.72	0.69	5.87e-68	Diabetic kidney disease;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg16339924	chr4:17578868	LAP3	-0.51	-8.55	-0.37	1.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg21100191	chr22:23484243	RTDR1	0.99	22.67	0.73	4.33e-77	Bone mineral density;
LGG	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg05925327	chr15:68127851	NA	-0.37	-8.71	-0.38	5.61e-17	Restless legs syndrome;
LGG	cis	rs17453880	0.929	rs6886482	chr5:152031320	G/C	cg10931792	chr5:152022470	NA	0.41	8.95	0.38	8.35e-18	Subjective well-being;
LGG	cis	rs2797160	0.837	rs1739364	chr6:126022383	A/G	cg05901451	chr6:126070800	HEY2	-0.5	-8.25	-0.36	1.72e-15	Endometrial cancer;
LGG	cis	rs9427116	0.740	rs11264230	chr1:154608418	G/T	cg11650704	chr1:154556575	ADAR	-0.44	-8.45	-0.37	3.84e-16	Blood protein levels;
LGG	cis	rs9457247	0.602	rs12209395	chr6:167463914	C/T	cg07741184	chr6:167504864	NA	0.43	9.89	0.42	4.55e-21	Crohn's disease;
LGG	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg17330251	chr7:94953956	PON1	0.44	8.3	0.36	1.17e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.02	0.35	8.65e-15	Iron status biomarkers;
LGG	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.32	0.72	1.9e-75	Homoarginine levels;
LGG	trans	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg17712092	chr4:129076599	LARP1B	-0.58	-9.72	-0.41	1.91e-20	Breast cancer;
LGG	cis	rs4742903	0.904	rs7028408	chr9:106859811	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.5e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1883415	0.750	rs2076317	chr6:24490147	A/G	cg20631270	chr6:24437470	GPLD1	0.43	6.96	0.31	1.17e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2694528	1.000	rs973304	chr5:60145817	G/A	cg11474532	chr5:59995715	DEPDC1B	0.72	7.63	0.33	1.33e-13	Parkinson's disease;
LGG	cis	rs1847505	0.574	rs17822177	chr13:61491537	G/C	cg25164009	chr13:61490935	NA	0.59	9.1	0.39	2.76e-18	Polychlorinated biphenyl levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01989157	chr22:40742702	ADSL	0.5	7.82	0.34	3.49e-14	Gut microbiome composition (summer);
LGG	cis	rs10754283	1.000	rs10754283	chr1:90112431	G/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg00631329	chr6:26305371	NA	-0.52	-9.66	-0.41	3.06e-20	Educational attainment;
LGG	cis	rs4684776	0.867	rs13081232	chr3:11342271	T/G	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg04132472	chr17:19861366	AKAP10	0.26	7.27	0.32	1.59e-12	Schizophrenia;
LGG	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg22643751	chr7:855365	UNC84A	0.44	7.5	0.33	3.27e-13	Cerebrospinal P-tau181p levels;
LGG	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.55	0.37	1.74e-16	Retinal vascular caliber;
LGG	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.75	0.3	4.37e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7568458	0.660	rs6547623	chr2:85801964	T/A	cg17127132	chr2:85788382	GGCX	0.51	8.52	0.37	2.33e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4253772	0.745	rs78023664	chr22:46647844	G/A	cg00784671	chr22:46762841	CELSR1	-0.63	-6.89	-0.31	1.78e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4363385	0.747	rs4255332	chr1:152958745	G/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs8078723	0.966	rs2227322	chr17:38171668	C/G	cg17467752	chr17:38218738	THRA	0.73	13.76	0.54	2.22e-36	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg01403660	chr11:68851641	TPCN2	0.53	7.45	0.33	4.57e-13	Blond vs. brown hair color;
LGG	cis	rs9649465	1.000	rs13224762	chr7:123370710	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg18681998	chr4:17616180	MED28	-0.81	-17.74	-0.64	4.23e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.76	0.41	1.34e-20	Bipolar disorder;
LGG	cis	rs6500637	0.931	rs79338890	chr16:4905127	T/G	cg08329684	chr16:4932620	PPL	0.52	10.96	0.45	5.03e-25	Cancer;
LGG	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12654349	chr5:56205094	C5orf35	0.8	12.21	0.49	6.22e-30	Initial pursuit acceleration;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg04851935	chr6:46703193	PLA2G7	-0.41	-7.19	-0.32	2.69e-12	Iris color (L* coordinate);
LGG	cis	rs4561483	0.673	rs28279	chr16:11968555	A/C	cg08843971	chr16:11963173	GSPT1	0.64	16.54	0.61	1.26e-48	Testicular germ cell tumor;
LGG	cis	rs15676	0.947	rs2997922	chr9:131580744	C/T	cg04621255	chr9:131581398	ENDOG	-0.38	-6.84	-0.3	2.53e-11	Blood metabolite levels;
LGG	cis	rs11645898	0.748	rs56387295	chr16:72055336	C/A	cg14768367	chr16:72042858	DHODH	-0.9	-11.72	-0.48	5.85e-28	Blood protein levels;
LGG	cis	rs12618769	0.625	rs3769717	chr2:99124817	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg03929089	chr4:120376271	NA	-0.72	-13.0	-0.52	3.57e-33	Coronary artery disease;
LGG	cis	rs402219	0.533	rs510586	chr6:160738478	A/G	cg04181478	chr6:161122748	PLG	-0.39	-6.67	-0.3	7.41e-11	Monocyte early outgrowth colony forming units;
LGG	cis	rs8028182	0.636	rs4299117	chr15:75789444	C/T	cg20655648	chr15:75932815	IMP3	0.47	7.79	0.34	4.31e-14	Sudden cardiac arrest;
LGG	trans	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg24247370	chr13:99142703	STK24	-0.4	-7.07	-0.31	5.78e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.13	-0.35	3.85e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2070488	0.965	rs9829192	chr3:38569463	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.57	-0.63	2.55e-53	Electrocardiographic conduction measures;
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg01194073	chr14:101175302	NA	0.46	7.01	0.31	8.67e-12	Plateletcrit;
LGG	cis	rs2274273	0.901	rs8011288	chr14:55735112	C/T	cg04306507	chr14:55594613	LGALS3	0.61	16.78	0.62	1e-49	Protein biomarker;
LGG	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg04450456	chr4:17643702	FAM184B	0.34	7.51	0.33	3.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg23461800	chr14:103021989	NA	-0.53	-8.32	-0.36	9.770000000000001e-16	Platelet count;
LGG	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg24011408	chr12:48396354	COL2A1	0.48	7.42	0.33	5.82e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg19168338	chr16:4465731	CORO7	-0.87	-16.03	-0.6	2.59e-46	Schizophrenia;
LGG	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs7267979	0.873	rs6037062	chr20:25202892	G/A	cg06421707	chr20:25228305	PYGB	0.46	9.75	0.41	1.43e-20	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.18	-0.6	5.53e-47	Intelligence (multi-trait analysis);
LGG	cis	rs752092	0.894	rs8043243	chr15:101771453	C/T	cg19997662	chr15:101784653	CHSY1	-0.82	-17.02	-0.62	8.41e-51	Corneal structure;
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg05335186	chr13:53173507	NA	0.43	8.48	0.37	3.07e-16	Lewy body disease;
LGG	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg11644478	chr21:40555479	PSMG1	-0.61	-10.01	-0.42	1.78e-21	Menarche (age at onset);
LGG	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg26783146	chr16:4423632	VASN;CORO7	-0.39	-7.16	-0.32	3.22e-12	Schizophrenia;
LGG	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg11757124	chr7:157526947	PTPRN2	-0.52	-9.35	-0.4	3.86e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26100149	chr5:173315151	CPEB4	0.41	6.69	0.3	6.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4262150	0.693	rs4304124	chr5:152260774	A/C	cg12297329	chr5:152029980	NA	0.59	11.54	0.47	2.92e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.72	0.34	7.41e-14	Schizophrenia;
LGG	cis	rs2051773	0.567	rs58047221	chr11:17056634	G/T	cg15432903	chr11:17409602	KCNJ11	-0.52	-7.73	-0.34	6.53e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs7614311	0.636	rs77639204	chr3:64005452	C/T	cg22134162	chr3:63841271	THOC7	-0.38	-6.84	-0.3	2.57e-11	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	9.0	0.39	5.69e-18	Cognitive function;
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.54e-23	Bipolar disorder;
LGG	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.95	-0.35	1.44e-14	Neuroticism;
LGG	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs1506403	0.945	rs315284	chr7:142827954	A/G	cg11323483	chr7:142828068	PIP	0.39	7.17	0.32	3.04e-12	Cancer;
LGG	cis	rs1965732	0.588	rs4849976	chr2:3717567	A/C	cg20493526	chr2:3714936	ALLC	0.46	9.99	0.42	2.11e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12200560	0.505	rs211173	chr6:97070804	C/T	cg06623918	chr6:96969491	KIAA0776	0.46	7.85	0.34	2.87e-14	Coronary heart disease;
LGG	cis	rs2652834	1.000	rs2652835	chr15:63396408	T/C	cg05507819	chr15:63340323	TPM1	0.57	7.75	0.34	6.06e-14	HDL cholesterol;
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg02002194	chr4:3960332	NA	-0.44	-8.32	-0.36	1.03e-15	Mood instability;
LGG	cis	rs963731	0.579	rs6739568	chr2:39287550	G/T	cg04010122	chr2:39346883	SOS1	-0.79	-7.67	-0.34	1.05e-13	Corticobasal degeneration;
LGG	trans	rs7181230	1.000	rs11638521	chr15:40360314	T/C	cg22705835	chr10:65332833	REEP3	0.61	10.81	0.45	1.87e-24	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	9.34	0.4	3.92e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg19507638	chr5:93509721	C5orf36	-0.73	-9.9	-0.42	4.24e-21	Diabetic retinopathy;
LGG	cis	rs6430585	0.583	rs7581814	chr2:136641593	C/G	cg07169764	chr2:136633963	MCM6	-1.31	-27.33	-0.79	1.29e-98	Corneal structure;
LGG	cis	rs988958	0.567	rs11887431	chr2:42267462	C/T	cg27252766	chr2:42229092	NA	0.46	7.41	0.33	6.16e-13	Hypospadias;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.69	-0.34	8.92e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg23958373	chr8:599963	NA	1.22	12.34	0.5	1.92e-30	IgG glycosylation;
LGG	cis	rs2820315	0.867	rs2819349	chr1:201885026	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.88	0.3	1.92e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg26384229	chr12:38710491	ALG10B	-0.9	-18.76	-0.66	8.21e-59	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs13102973	0.682	rs6535054	chr4:135886055	A/C	cg14419869	chr4:135874104	NA	0.46	7.9	0.34	2.06e-14	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26164735	chr4:71768712	MOBKL1A	0.5	8.14	0.35	3.75e-15	Gut microbiome composition (summer);
LGG	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg23484912	chr5:273055	PDCD6	0.45	9.14	0.39	1.99e-18	Pancreatic cancer;
LGG	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg17108064	chr15:78857060	CHRNA5	0.37	7.38	0.32	7.29e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs3806843	0.966	rs6891559	chr5:140145206	G/A	cg19875535	chr5:140030758	IK	0.53	11.2	0.46	6.25e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4660214	0.756	rs11205823	chr1:39714238	T/A	cg18385671	chr1:39797026	MACF1	-0.44	-8.81	-0.38	2.5e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7267979	0.933	rs6138571	chr20:25435388	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg03929089	chr4:120376271	NA	-0.78	-11.59	-0.47	1.95e-27	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01458420	chr20:48532416	SPATA2	0.44	7.36	0.32	8.19e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg08888203	chr3:10149979	C3orf24	0.52	8.83	0.38	2.14e-17	Alzheimer's disease;
LGG	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg00080972	chr5:178986291	RUFY1	0.46	7.22	0.32	2.08e-12	Lung cancer;
LGG	cis	rs2133450	0.712	rs10510357	chr3:7367528	C/T	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.64e-14	Early response to risperidone in schizophrenia;
LGG	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg15704280	chr7:45808275	SEPT13	0.87	13.67	0.54	5.43e-36	Coronary artery disease;
LGG	cis	rs7267979	1.000	rs2259837	chr20:25280205	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg21138405	chr5:131827807	IRF1	0.28	6.73	0.3	5.12e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs9878978	0.722	rs11717961	chr3:2513869	C/T	cg21928760	chr3:2462534	CNTN4	0.35	6.86	0.3	2.27e-11	Blood pressure (smoking interaction);
LGG	cis	rs7928758	0.708	rs11223785	chr11:134275986	G/A	cg25213107	chr11:134282864	B3GAT1	0.83	11.25	0.46	3.98e-26	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.97	-0.31	1.11e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9863	0.896	rs12829951	chr12:124425841	A/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.27	-0.32	1.58e-12	White blood cell count;
LGG	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg22232500	chr2:134024266	NCKAP5	0.56	7.96	0.35	1.31e-14	Bipolar disorder;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg11766577	chr21:47581405	C21orf56	-0.56	-10.36	-0.43	9.29e-23	Testicular germ cell tumor;
LGG	cis	rs1408799	0.665	rs10809836	chr9:12758843	A/C	cg05274944	chr9:12693694	TYRP1	0.34	7.95	0.35	1.42e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg08112188	chr17:47440006	ZNF652	1.29	15.27	0.58	6.14e-43	Prostate cancer;
LGG	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg19847130	chr8:10466454	RP1L1	-0.32	-7.23	-0.32	2e-12	Mood instability;
LGG	cis	rs17767392	0.958	rs1981588	chr14:72039689	G/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.16	0.35	3.29e-15	Mitral valve prolapse;
LGG	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg17219203	chr10:38645113	HSD17B7P2	-0.5	-7.91	-0.35	1.87e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.1	0.84	3.94e-124	Chronic sinus infection;
LGG	cis	rs4740619	0.774	rs2182936	chr9:15918922	A/G	cg14451791	chr9:16040625	NA	-0.37	-9.47	-0.4	1.48e-19	Body mass index;
LGG	cis	rs4356932	1.000	rs6814012	chr4:76950778	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.62e-11	Blood protein levels;
LGG	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg20026190	chr17:76395443	PGS1	0.57	9.94	0.42	3.09e-21	HDL cholesterol levels;
LGG	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.76e-44	Lymphocyte percentage of white cells;
LGG	cis	rs3859192	0.537	rs12309	chr17:38175462	C/T	cg17467752	chr17:38218738	THRA	-0.58	-9.73	-0.41	1.69e-20	White blood cell count;
LGG	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.46	7.6	0.33	1.71e-13	Osteoporosis;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg08888203	chr3:10149979	C3orf24	0.56	9.57	0.41	6.42e-20	Alzheimer's disease;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.05	0.42	1.24e-21	Longevity;
LGG	cis	rs7762018	0.607	rs3800544	chr6:170058374	C/T	cg19338460	chr6:170058176	WDR27	-0.83	-10.2	-0.43	3.66e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.65	-0.41	3.28e-20	Bladder cancer;
LGG	cis	rs7808935	1.000	rs7808935	chr7:27977363	T/C	cg22168087	chr7:27702803	HIBADH	0.62	9.33	0.4	4.26e-19	Prostate cancer;
LGG	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg21545522	chr1:205238299	TMCC2	-0.39	-7.49	-0.33	3.54e-13	Red blood cell count;
LGG	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02251663	chr11:14281053	SPON1	-0.31	-7.55	-0.33	2.33e-13	Mitochondrial DNA levels;
LGG	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.62	0.51	1.43e-31	Motion sickness;
LGG	trans	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.06	-0.39	3.72e-18	Bladder cancer;
LGG	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg25427524	chr10:38739819	LOC399744	0.52	7.74	0.34	6.45e-14	Obesity (extreme);
LGG	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg02631450	chr22:32366979	NA	1.01	9.67	0.41	2.84e-20	Childhood ear infection;
LGG	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.53	-0.72	1.94e-76	Schizophrenia;
LGG	cis	rs477692	0.673	rs579952	chr10:131356084	A/T	cg05714579	chr10:131428358	MGMT	-0.41	-7.78	-0.34	4.78e-14	Response to temozolomide;
LGG	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg20608306	chr11:116969690	SIK3	-0.41	-12.83	-0.51	1.81e-32	Blood protein levels;
LGG	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg13010199	chr12:38710504	ALG10B	-0.58	-11.32	-0.47	2.11e-26	Morning vs. evening chronotype;
LGG	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg02023728	chr11:77925099	USP35	0.44	7.53	0.33	2.62e-13	Testicular germ cell tumor;
LGG	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.86	-0.34	2.63e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9549328	0.921	rs9549623	chr13:113640293	G/A	cg08528486	chr13:113648767	MCF2L	-0.33	-6.79	-0.3	3.47e-11	Systolic blood pressure;
LGG	cis	rs11758351	0.500	rs74660303	chr6:26183710	C/T	cg01420254	chr6:26195488	NA	0.97	7.39	0.32	6.97e-13	Gout;Renal underexcretion gout;
LGG	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs4740619	0.525	rs13296360	chr9:15810787	G/C	cg14451791	chr9:16040625	NA	0.3	7.54	0.33	2.59e-13	Body mass index;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.01e-42	Menopause (age at onset);
LGG	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg23461800	chr14:103021989	NA	0.52	8.21	0.36	2.29e-15	Platelet count;
LGG	cis	rs1816854	0.938	rs10880571	chr12:44207279	T/C	cg00106942	chr12:44200524	TWF1	0.42	6.72	0.3	5.24e-11	Inflammatory bowel disease;
LGG	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg22455342	chr2:225449267	CUL3	0.85	15.05	0.57	5.9e-42	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs11674184	0.714	rs9789525	chr2:11724580	G/T	cg07314298	chr2:11723111	GREB1	-0.81	-19.09	-0.66	2.36e-60	Endometriosis;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9581943	0.967	rs11618581	chr13:28476911	C/T	cg16302790	chr13:28498334	PDX1	0.48	8.2	0.36	2.33e-15	Pancreatic cancer;
LGG	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.21e-66	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs10220309	0.501	rs4903904	chr14:80649565	G/A	cg08183125	chr14:80678293	DIO2	-0.44	-6.88	-0.3	1.91e-11	Lung function (FEV1);
LGG	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs2303319	1.000	rs62188137	chr2:162257548	T/C	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg27490568	chr2:178487706	NA	0.45	8.7	0.37	5.7e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11191270	0.554	rs77616533	chr10:104055983	A/G	cg15320455	chr10:103880129	LDB1	0.65	8.45	0.37	3.74e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg06215416	chr1:2383473	NA	-0.5	-11.63	-0.48	1.3e-27	Non-obstructive azoospermia;
LGG	cis	rs6598955	0.543	rs6698557	chr1:26561220	G/C	cg04990556	chr1:26633338	UBXN11	0.71	10.6	0.44	1.16e-23	Obesity-related traits;
LGG	cis	rs7617773	0.817	rs3731513	chr3:48219537	A/G	cg11946769	chr3:48343235	NME6	0.68	11.09	0.46	1.72e-25	Coronary artery disease;
LGG	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.41	-0.33	6.21e-13	Neuroticism;
LGG	cis	rs67311347	0.568	rs57287242	chr3:40335538	T/C	cg13683864	chr3:40499215	RPL14	-0.81	-16.11	-0.6	1.14e-46	Renal cell carcinoma;
LGG	cis	rs7666738	0.830	rs6823718	chr4:99063202	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs7336332	0.662	rs9581862	chr13:28039993	T/G	cg01674679	chr13:27998804	GTF3A	-0.59	-8.11	-0.35	4.72e-15	Weight;
LGG	cis	rs5743618	0.537	rs11734337	chr4:38773067	A/G	cg06935464	chr4:38784597	TLR10	0.37	6.65	0.3	8.03e-11	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg17077180	chr1:38461687	NA	-0.41	-8.64	-0.37	8.98e-17	Coronary artery disease;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg03188948	chr7:1209495	NA	0.4	7.17	0.32	3.08e-12	Longevity;Endometriosis;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13126279	chr21:47581558	C21orf56	-0.47	-8.04	-0.35	7.44e-15	Testicular germ cell tumor;
LGG	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg08807101	chr21:30365312	RNF160	0.76	13.86	0.54	8.31e-37	Selective IgA deficiency;
LGG	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg13482628	chr17:19912719	NA	0.59	11.67	0.48	9.46e-28	Schizophrenia;
LGG	cis	rs9462027	0.628	rs2477507	chr6:34703599	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.91	-0.45	8.27e-25	Systemic lupus erythematosus;
LGG	cis	rs7226408	0.802	rs1445529	chr18:34512757	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg01967586	chr1:228894546	NA	0.38	7.95	0.35	1.39e-14	Chronic lymphocytic leukemia;
LGG	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg22676075	chr6:135203613	NA	0.43	7.45	0.33	4.73e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.64e-24	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.32	-0.36	9.61e-16	Breast cancer;
LGG	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg24812749	chr6:127587940	RNF146	0.78	13.26	0.52	3e-34	Breast cancer;
LGG	cis	rs6489882	0.867	rs4766672	chr12:113365148	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.35	-0.32	9.18e-13	Chronic lymphocytic leukemia;
LGG	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.65	0.41	3.27e-20	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs1806153	0.673	rs1894620	chr11:31834516	C/G	cg11990419	chr11:31841155	NA	0.32	6.81	0.3	3.06e-11	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg05973401	chr12:123451056	ABCB9	0.5	7.56	0.33	2.18e-13	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14347670	chr6:41908995	CCND3	0.57	9.32	0.4	4.72e-19	Gut microbiome composition (summer);
LGG	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.35	0.32	8.97e-13	Body mass index;
LGG	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.42	0.36	4.78e-16	Oral cavity cancer;
LGG	trans	rs7944735	0.508	rs11820480	chr11:47779470	T/G	cg15704280	chr7:45808275	SEPT13	0.63	6.89	0.3	1.81e-11	Intraocular pressure;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25815124	chr19:18434238	LSM4	-0.44	-6.74	-0.3	4.78e-11	Pancreatic cancer;
LGG	cis	rs7715811	0.913	rs4368727	chr5:13770248	C/T	cg07548982	chr5:13769939	DNAH5	-0.48	-10.14	-0.43	6.01e-22	Subclinical atherosclerosis traits (other);
LGG	cis	rs4148087	1.000	rs9975740	chr21:43620485	A/T	cg08841829	chr21:43638893	ABCG1	-0.62	-8.56	-0.37	1.67e-16	Eating disorder in bipolar disorder;
LGG	cis	rs6772849	0.768	rs9820741	chr3:128416080	G/A	cg08795948	chr3:128337044	NA	0.63	9.82	0.42	8.33e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4740619	0.619	rs10810523	chr9:16034642	T/G	cg14451791	chr9:16040625	NA	-0.44	-11.72	-0.48	5.79e-28	Body mass index;
LGG	cis	rs3820928	0.874	rs116652884	chr2:227902285	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.33	-0.32	1.05e-12	Pulmonary function;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11792281	chr17:26443366	NLK	-0.6	-6.92	-0.31	1.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1015291	0.708	rs2417811	chr12:20009432	A/T	cg25401612	chr12:20009446	NA	-0.34	-7.38	-0.32	7.32e-13	Diastolic blood pressure;
LGG	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg19920283	chr7:105172520	RINT1	0.59	8.09	0.35	5.2e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg11366901	chr6:160182831	ACAT2	0.99	14.87	0.57	3.5e-41	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg12800244	chr3:153838788	SGEF	0.58	8.27	0.36	1.43e-15	Coronary artery disease;
LGG	cis	rs12477438	0.501	rs1011633	chr2:100094799	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg04287289	chr16:89883240	FANCA	0.81	16.86	0.62	4.31e-50	Vitiligo;
LGG	cis	rs741702	0.928	rs2965214	chr19:13029188	G/A	cg11738485	chr19:12877000	HOOK2	0.43	6.84	0.3	2.44e-11	Red blood cell traits;
LGG	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg01043669	chr3:72786069	NA	0.41	6.93	0.31	1.44e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Educational attainment;
LGG	cis	rs12908161	1.000	rs12912388	chr15:85344550	T/A	cg03959625	chr15:84868606	LOC388152	0.48	7.03	0.31	7.38e-12	Schizophrenia;
LGG	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg15268244	chr15:77196840	NA	-0.34	-7.51	-0.33	3.16e-13	Blood metabolite levels;
LGG	trans	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg06521331	chr12:34319734	NA	0.41	6.76	0.3	4.14e-11	Morning vs. evening chronotype;
LGG	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg13385794	chr1:248469461	NA	-0.48	-8.07	-0.35	5.93e-15	Common traits (Other);
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg15556689	chr8:8085844	FLJ10661	0.38	6.73	0.3	4.97e-11	Monocyte count;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.38	-0.4	2.92e-19	Aortic root size;
LGG	cis	rs7554547	0.667	rs2336377	chr1:11949970	A/G	cg07603449	chr1:11986842	KIAA2013	0.3	8.05	0.35	7.26e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.18e-11	Schizophrenia;
LGG	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.67	-0.41	2.88e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9527	0.501	rs12244388	chr10:104640052	G/A	cg04362960	chr10:104952993	NT5C2	0.55	10.0	0.42	1.86e-21	Arsenic metabolism;
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg02002194	chr4:3960332	NA	0.42	7.59	0.33	1.77e-13	Neuroticism;
LGG	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.86	-0.3	2.27e-11	Educational attainment;
LGG	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-7.2	-0.32	2.38e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.37	7.0	0.31	8.87e-12	Schizophrenia;
LGG	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9287719	0.967	rs6432118	chr2:10749441	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7188861	0.861	rs7197188	chr16:11443424	C/A	cg01510278	chr16:11456238	NA	-0.32	-7.65	-0.33	1.2e-13	HDL cholesterol;
LGG	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg09904177	chr6:26538194	HMGN4	0.59	11.7	0.48	6.86e-28	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.2	0.46	6.41e-26	Corneal astigmatism;
LGG	cis	rs12367572	0.641	rs7964973	chr12:45402893	T/C	cg03114573	chr12:45410052	DBX2	-0.67	-12.06	-0.49	2.48e-29	Gut microbiome composition (summer);
LGG	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg05926928	chr17:57297772	GDPD1	1.36	21.89	0.71	1.99e-73	Opioid sensitivity;
LGG	cis	rs11105298	0.891	rs10777184	chr12:89919568	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2415984	0.538	rs4595715	chr14:46967541	C/T	cg14871534	chr14:47121158	RPL10L	-0.58	-10.22	-0.43	2.99e-22	Number of children ever born;
LGG	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03264133	chr6:25882463	NA	0.54	10.0	0.42	1.9e-21	Blood metabolite levels;
LGG	cis	rs67460515	0.563	rs11713441	chr3:160906855	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.96	-0.49	6.23e-29	Parkinson's disease;
LGG	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg23920097	chr1:209922102	NA	-0.49	-8.7	-0.37	5.66e-17	Red blood cell count;
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.4	0.4	2.43e-19	Height;
LGG	cis	rs751728	1.000	rs4713682	chr6:33757047	G/C	cg25922239	chr6:33757077	LEMD2	0.69	12.31	0.5	2.57e-30	Crohn's disease;
LGG	cis	rs4950322	0.570	rs72691093	chr1:146769662	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg02493740	chr2:85810744	VAMP5	-0.39	-7.16	-0.32	3.28e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2963155	0.518	rs852978	chr5:142690596	T/C	cg17617527	chr5:142782415	NR3C1	1.0	13.42	0.53	6.67e-35	Breast cancer;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03517284	chr6:25882590	NA	-0.43	-7.8	-0.34	4.09e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.09	-0.31	5.07e-12	Blood metabolite levels;
LGG	cis	rs2377058	0.961	rs16965913	chr16:89734788	C/T	cg03605463	chr16:89740564	NA	-0.43	-6.67	-0.3	7.43e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg04851639	chr8:1020857	NA	-0.43	-8.53	-0.37	2.03e-16	Schizophrenia;
LGG	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	7.89	0.34	2.16e-14	Menarche (age at onset);
LGG	cis	rs4253772	0.530	rs113258957	chr22:46663678	G/C	cg00784671	chr22:46762841	CELSR1	-0.58	-7.0	-0.31	9.12e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7089973	0.564	rs55671354	chr10:116571281	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.03	0.31	7.45e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.53	9.63	0.41	3.97e-20	Multiple sclerosis;
LGG	cis	rs4363385	0.818	rs10788854	chr1:153002320	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.76	-0.38	3.61e-17	Inflammatory skin disease;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.1	-0.62	3.66e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg09307838	chr4:120376055	NA	0.8	13.51	0.53	2.73e-35	Corneal astigmatism;
LGG	cis	rs7851660	0.874	rs925487	chr9:100636398	C/T	cg13688889	chr9:100608707	NA	-0.59	-11.59	-0.47	1.85e-27	Strep throat;
LGG	cis	rs3008870	1.000	rs6673462	chr1:67461857	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	8.39	0.36	6.04e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9650657	0.707	rs6984744	chr8:10616265	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.78	-0.34	4.69e-14	Neuroticism;
LGG	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg11890956	chr21:40555474	PSMG1	-0.95	-19.14	-0.66	1.37e-60	Cognitive function;
LGG	cis	rs11971779	0.618	rs9640925	chr7:139085288	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.38	0.43	7.9e-23	Retinal vascular caliber;
LGG	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg25986240	chr4:9926439	SLC2A9	0.52	11.37	0.47	1.35e-26	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.65	8.93	0.38	9.9e-18	Lung function (FEV1/FVC);
LGG	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22496380	chr5:211416	CCDC127	-1.36	-18.04	-0.64	1.69e-55	Breast cancer;
LGG	cis	rs593982	0.777	rs72941015	chr11:65457514	A/C	cg08755490	chr11:65554678	OVOL1	-0.63	-7.26	-0.32	1.6e-12	Atopic dermatitis;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg16270222	chr17:41446396	NA	-0.3	-7.21	-0.32	2.26e-12	Menopause (age at onset);
LGG	cis	rs3741151	0.892	rs7107905	chr11:73061232	A/T	cg17517138	chr11:73019481	ARHGEF17	0.88	9.61	0.41	4.65e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs73787773	0.668	rs57673629	chr5:111472541	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.4	-0.33	6.54e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg18196295	chr10:418757	DIP2C	0.52	9.75	0.41	1.45e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs16837677	1.000	rs79696810	chr1:156772988	G/A	cg14991358	chr1:156767203	PRCC	0.77	7.88	0.34	2.31e-14	Sjögren's syndrome;
LGG	cis	rs9828933	1.000	rs9828933	chr3:64002897	T/C	cg17941049	chr3:63904683	ATXN7	0.62	7.8	0.34	4.13e-14	Type 2 diabetes;
LGG	cis	rs6963495	0.818	rs117887993	chr7:105193837	T/G	cg19920283	chr7:105172520	RINT1	0.63	8.33	0.36	9.3e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06028808	chr11:68637592	NA	0.73	12.25	0.49	4.41e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg22920501	chr2:26401640	FAM59B	0.46	9.5	0.4	1.16e-19	Gut microbiome composition (summer);
LGG	trans	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.41	0.44	6.22e-23	Ulcerative colitis;
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg24189917	chr7:1970923	MAD1L1	-0.46	-6.78	-0.3	3.76e-11	Bipolar disorder;
LGG	cis	rs9581857	0.556	rs9581864	chr13:28041567	T/C	cg01674679	chr13:27998804	GTF3A	-0.62	-8.51	-0.37	2.41e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg27432699	chr2:27873401	GPN1	0.71	14.34	0.55	7.38e-39	Oral cavity cancer;
LGG	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg00578828	chr5:131826934	IRF1	0.41	7.38	0.32	7.32e-13	Asthma (sex interaction);
LGG	cis	rs2916247	1.000	rs2011093	chr8:92982608	A/G	cg10183463	chr8:93005414	RUNX1T1	0.4	8.22	0.36	2.09e-15	Intelligence (multi-trait analysis);
LGG	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.04	0.49	3.08e-29	Height;
LGG	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg02023728	chr11:77925099	USP35	0.46	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs8017423	0.607	rs10142482	chr14:90848280	G/T	cg04374321	chr14:90722782	PSMC1	-0.6	-11.27	-0.46	3.31e-26	Mortality in heart failure;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg10295955	chr4:187884368	NA	-1.16	-31.63	-0.83	8.47e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs55788414	0.932	rs9929066	chr16:81182157	G/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2288073	0.965	rs10185445	chr2:24410976	A/C	cg06627628	chr2:24431161	ITSN2	0.66	10.47	0.44	3.76e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg04369109	chr6:150039330	LATS1	0.41	6.87	0.3	2.07e-11	Lung cancer;
LGG	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg02023728	chr11:77925099	USP35	0.41	7.11	0.31	4.36e-12	Alzheimer's disease (survival time);
LGG	cis	rs11971779	0.774	rs6467838	chr7:139043501	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05025164	chr4:1340916	KIAA1530	0.42	7.16	0.32	3.27e-12	Obesity-related traits;
LGG	cis	rs9942416	0.601	rs40059	chr5:74964582	A/G	cg19683494	chr5:74908142	NA	-0.47	-7.42	-0.33	5.51e-13	Age-related disease endophenotypes;
LGG	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg21775007	chr8:11205619	TDH	0.43	6.69	0.3	6.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg02151108	chr14:50098012	C14orf104	-0.48	-10.23	-0.43	2.83e-22	Carotid intima media thickness;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-13.32	-0.53	1.68e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs1014246	0.826	rs4752004	chr10:118473209	A/G	cg14919929	chr10:118506882	NA	0.63	13.22	0.52	4.67e-34	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs2048656	0.578	rs10095236	chr8:9684925	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.48	0.33	3.78e-13	Schizophrenia;
LGG	cis	rs2288073	0.965	rs36101491	chr2:24387532	C/T	cg26838691	chr2:24397539	C2orf84	-0.48	-6.7	-0.3	6.08e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04004882	chr2:215674386	BARD1	0.51	7.03	0.31	7.58e-12	Neuroblastoma;
LGG	cis	rs67478160	0.643	rs3818085	chr14:104215985	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.27	-0.32	1.55e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg15971980	chr6:150254442	NA	0.45	8.57	0.37	1.51e-16	Lung cancer;
LGG	cis	rs910316	0.967	rs4899551	chr14:75660246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.68	-0.41	2.65e-20	Height;
LGG	cis	rs6815814	0.861	rs6843043	chr4:38843136	A/G	cg06935464	chr4:38784597	TLR10	0.43	6.83	0.3	2.62e-11	Breast cancer;
LGG	cis	rs6456156	0.819	rs9457273	chr6:167520749	A/T	cg07741184	chr6:167504864	NA	-0.39	-8.46	-0.37	3.57e-16	Primary biliary cholangitis;
LGG	cis	rs7017914	0.967	rs34508469	chr8:71628463	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.35	-0.53	1.23e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg05555928	chr11:63887634	MACROD1	-0.77	-10.33	-0.43	1.15e-22	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19568834	chr20:34252926	CPNE1;RBM12	0.41	6.71	0.3	5.56e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7412746	0.658	rs12090215	chr1:150893660	C/A	cg15448220	chr1:150897856	SETDB1	0.4	7.35	0.32	8.79e-13	Melanoma;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs1784581	0.894	rs1626020	chr6:162383379	G/A	cg17173639	chr6:162384350	PARK2	-0.88	-22.47	-0.72	3.61e-76	Itch intensity from mosquito bite;
LGG	cis	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg02972257	chr16:68554789	NA	0.56	8.27	0.36	1.43e-15	Ulcerative colitis;
LGG	cis	rs9358372	0.502	rs2745932	chr6:20753750	T/C	cg13405222	chr6:20811065	CDKAL1	0.47	9.37	0.4	3.09e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6752107	0.967	rs6431661	chr2:234167421	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	8.04	0.35	7.81e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg20913747	chr6:44695427	NA	-0.61	-10.35	-0.43	9.68e-23	Total body bone mineral density;
LGG	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.48	-0.37	2.96e-16	Retinal vascular caliber;
LGG	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg08508325	chr11:3079039	CARS	0.39	7.32	0.32	1.1e-12	Calcium levels;
LGG	cis	rs1712517	0.524	rs1712509	chr10:105013870	G/T	cg04362960	chr10:104952993	NT5C2	-0.48	-7.95	-0.35	1.4e-14	Migraine;
LGG	cis	rs6750795	0.569	rs1667305	chr2:232403829	A/G	cg19187155	chr2:232395269	NMUR1	0.51	9.59	0.41	5.52e-20	Height;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.66e-28	Obesity-related traits;
LGG	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg22153745	chr1:153894579	GATAD2B	-0.68	-10.73	-0.45	3.88e-24	Total cholesterol levels;
LGG	trans	rs208515	0.592	rs10944862	chr6:66674215	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.12	0.62	3.03e-51	Exhaled nitric oxide levels;
LGG	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.4	-0.33	6.59e-13	Initial pursuit acceleration;
LGG	cis	rs72781680	1.000	rs17712391	chr2:24245659	C/T	cg08917208	chr2:24149416	ATAD2B	0.89	9.51	0.4	1.06e-19	Lymphocyte counts;
LGG	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg26384229	chr12:38710491	ALG10B	0.62	11.53	0.47	3.14e-27	Morning vs. evening chronotype;
LGG	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg05985134	chr18:33552581	C18orf21	0.63	9.85	0.42	6.54e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.73	0.34	6.56e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.26	-0.5	4.01e-30	Height;
LGG	cis	rs10504073	0.669	rs11779189	chr8:50030592	C/G	cg00325661	chr8:49890786	NA	-0.67	-13.18	-0.52	6.54e-34	Blood metabolite ratios;
LGG	cis	rs3816183	0.585	rs2272447	chr2:42870975	A/G	cg14631114	chr2:43023945	NA	-0.35	-6.82	-0.3	2.82e-11	Hypospadias;
LGG	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg18850127	chr7:39170497	POU6F2	0.37	8.43	0.36	4.35e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.3	-0.32	1.31e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg21775007	chr8:11205619	TDH	0.47	7.76	0.34	5.36e-14	Neuroticism;
LGG	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg15394860	chr11:2017084	H19	0.58	12.54	0.5	3.06e-31	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16318349	chr1:154917307	PBXIP1	-0.29	-7.45	-0.33	4.62e-13	Prostate cancer;
LGG	cis	rs747650	0.798	rs11039086	chr11:47116033	G/C	cg03339077	chr11:47165057	C11orf49	-0.54	-10.22	-0.43	2.93e-22	Acne (severe);
LGG	cis	rs4740619	0.587	rs4740632	chr9:16030208	T/G	cg14451791	chr9:16040625	NA	-0.42	-11.22	-0.46	5.23e-26	Body mass index;
LGG	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg19773385	chr1:10388646	KIF1B	-0.46	-9.85	-0.42	6.82e-21	Hepatocellular carcinoma;
LGG	cis	rs3741151	0.686	rs7112924	chr11:73106408	C/T	cg17517138	chr11:73019481	ARHGEF17	0.85	8.89	0.38	1.39e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg13647721	chr17:30228624	UTP6	0.63	7.83	0.34	3.34e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg00409905	chr10:38381863	ZNF37A	0.5	7.41	0.33	6.14e-13	Obesity (extreme);
LGG	cis	rs4851266	1.000	rs1160543	chr2:100832182	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.22	-0.36	2.08e-15	Educational attainment;
LGG	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-8.91	-0.38	1.16e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	12.41	0.5	9.48e-31	Colorectal cancer;
LGG	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg13010199	chr12:38710504	ALG10B	0.53	10.44	0.44	4.75e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg14952266	chr13:112191215	NA	0.36	6.7	0.3	6.09e-11	Menarche (age at onset);
LGG	trans	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.49	0.5	4.6e-31	Corneal astigmatism;
LGG	cis	rs4787491	0.704	rs67218159	chr16:30050505	C/T	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	2.97e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.23	-0.36	1.92e-15	Neuroticism;
LGG	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	cis	rs7945718	0.806	rs11022507	chr11:12829753	A/T	cg25843174	chr11:12811716	TEAD1	0.38	7.56	0.33	2.18e-13	Educational attainment (years of education);
LGG	cis	rs9948	0.655	rs62156213	chr2:97399100	T/C	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg14541582	chr5:601475	NA	-0.7	-10.85	-0.45	1.38e-24	Obesity-related traits;
LGG	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.63	-0.44	8.85e-24	Breast cancer;
LGG	cis	rs2549003	0.870	rs10053046	chr5:131821558	A/G	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg07936489	chr17:37558343	FBXL20	0.83	15.33	0.58	3.28e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs701145	0.585	rs1470663	chr3:153870883	A/G	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.45	-0.56	2.37e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs4363385	0.747	rs1415970	chr1:152965741	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.3e-18	Inflammatory skin disease;
LGG	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg22431228	chr1:16359049	CLCNKA	-0.49	-9.08	-0.39	3.2e-18	Dilated cardiomyopathy;
LGG	cis	rs28830936	0.625	rs8038764	chr15:41907905	A/C	cg17847044	chr15:42102381	MAPKBP1	0.76	24.24	0.75	2.15e-84	Diastolic blood pressure;
LGG	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.6	-0.44	1.2e-23	Bladder cancer;
LGG	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.43	6.96	0.31	1.2e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg03517284	chr6:25882590	NA	0.51	9.27	0.4	6.96e-19	Blood metabolite levels;
LGG	cis	rs7106204	0.514	rs1443044	chr11:24255575	C/G	ch.11.24196551F	chr11:24239977	NA	-0.96	-14.55	-0.56	8.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs113835537	0.559	rs57045447	chr11:66339683	A/G	cg24851651	chr11:66362959	CCS	0.49	8.35	0.36	7.83e-16	Airway imaging phenotypes;
LGG	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg03060546	chr3:49711283	APEH	-0.67	-11.17	-0.46	8.17e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg03433033	chr1:76189801	ACADM	-0.43	-6.78	-0.3	3.63e-11	Daytime sleep phenotypes;
LGG	cis	rs7927771	0.839	rs11039308	chr11:47622412	G/A	cg20307385	chr11:47447363	PSMC3	-0.42	-7.54	-0.33	2.48e-13	Subjective well-being;
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg21775007	chr8:11205619	TDH	-0.45	-7.49	-0.33	3.57e-13	Neuroticism;
LGG	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18876405	chr7:65276391	NA	0.49	8.84	0.38	2.03e-17	Aortic root size;
LGG	cis	rs10936602	0.527	rs7628572	chr3:169539649	T/A	cg17737146	chr3:169530037	LRRC34	0.36	6.7	0.3	5.91e-11	Renal cell carcinoma;
LGG	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg10840412	chr1:235813424	GNG4	0.59	7.83	0.34	3.25e-14	Bipolar disorder;
LGG	cis	rs31872	0.526	rs810277	chr5:140452494	A/G	cg19884223	chr5:140554610	PCDHB7	-0.3	-6.73	-0.3	5.09e-11	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.43e-40	Retinal vascular caliber;
LGG	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.43	-0.36	4.3e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1346	0.552	rs4326800	chr11:65367253	C/T	cg17120908	chr11:65337727	SSSCA1	-0.44	-6.66	-0.3	7.9e-11	Vertical cup-disc ratio;Optic cup area;
LGG	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs2732480	0.577	rs2634691	chr12:48708259	G/T	cg21466736	chr12:48725269	NA	-0.39	-7.73	-0.34	6.9e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg17691542	chr6:26056736	HIST1H1C	0.88	14.09	0.55	9.24e-38	Iron status biomarkers;
LGG	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg19773385	chr1:10388646	KIF1B	-0.45	-9.61	-0.41	4.84e-20	Hepatocellular carcinoma;
LGG	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.19	-0.32	2.67e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg23985595	chr17:80112537	CCDC57	0.39	7.73	0.34	6.98e-14	Life satisfaction;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	cis	rs1881396	0.945	rs1881395	chr2:27838549	G/A	cg27432699	chr2:27873401	GPN1	0.57	8.64	0.37	8.94e-17	Nonalcoholic fatty liver disease;
LGG	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg05425664	chr17:57184151	TRIM37	0.71	11.62	0.48	1.41e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	0.866	rs12941200	chr17:20011561	C/A	cg13482628	chr17:19912719	NA	0.41	7.02	0.31	8.01e-12	Obesity-related traits;
LGG	cis	rs11250098	0.583	rs36030755	chr8:10816771	G/C	cg21775007	chr8:11205619	TDH	-0.55	-8.39	-0.36	5.72e-16	Morning vs. evening chronotype;
LGG	cis	rs7444	0.882	rs5754217	chr22:21939675	G/T	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs6504108	0.624	rs3792692	chr17:46255092	C/T	cg02219949	chr17:45927392	SP6	0.43	8.1	0.35	5.04e-15	Body mass index;
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	cis	rs9987353	0.519	rs2929465	chr8:9064002	C/G	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.75	-0.3	4.37e-11	Recombination measurement;
LGG	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg12223502	chr10:5658492	NA	-0.37	-7.15	-0.32	3.52e-12	Breast cancer;
LGG	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg06640241	chr16:89574553	SPG7	0.85	15.43	0.58	1.27e-43	Multiple myeloma (IgH translocation);
LGG	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	14.72	0.56	1.6e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg20503657	chr10:835505	NA	0.63	9.04	0.39	4.25e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs10876993	0.890	rs774887	chr12:58034835	A/G	cg18357645	chr12:58087776	OS9	0.68	12.19	0.49	7.44e-30	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg02002194	chr4:3960332	NA	0.43	7.93	0.35	1.67e-14	Neuroticism;
LGG	cis	rs4740619	0.653	rs4741553	chr9:15963999	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.19	-0.43	3.8e-22	Body mass index;
LGG	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.9	-0.31	1.68e-11	Bipolar disorder;
LGG	cis	rs4774899	0.902	rs12910109	chr15:57572148	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs774359	0.797	rs1537712	chr9:27508489	C/T	cg21249376	chr9:27528432	MOBKL2B	0.42	8.64	0.37	9.06e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs975722	0.516	rs994996	chr7:117052915	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	8.5	0.37	2.66e-16	Coronary artery disease;
LGG	cis	rs4595586	0.967	rs56149694	chr12:39263771	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.96	-0.35	1.39e-14	Morning vs. evening chronotype;
LGG	cis	rs4727027	0.901	rs1137432	chr7:148801658	C/T	cg23583168	chr7:148888333	NA	-0.86	-16.27	-0.6	2.14e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12519773	0.526	rs4869415	chr5:92522764	A/G	cg18783429	chr5:92414398	NA	0.32	7.65	0.33	1.18e-13	Migraine;
LGG	cis	rs3762637	1.000	rs9833415	chr3:122159840	G/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs1961637	0.514	rs1440073	chr2:223891324	A/G	cg02552189	chr2:223891284	NA	-0.46	-8.77	-0.38	3.38e-17	Oropharynx cancer;
LGG	trans	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-7.42	-0.33	5.79e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg08677398	chr8:58056175	NA	0.43	7.11	0.31	4.38e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.779	rs12493960	chr3:160899772	T/C	cg04691961	chr3:161091175	C3orf57	-0.6	-13.33	-0.53	1.49e-34	Morning vs. evening chronotype;
LGG	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21659725	chr3:3221576	CRBN	0.92	20.59	0.69	2.48e-67	Intelligence (multi-trait analysis);
LGG	trans	rs3858145	0.588	rs61854837	chr10:70042370	C/G	cg04882175	chr6:131122610	NA	-0.57	-7.72	-0.34	7.16e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	trans	rs17685	0.753	rs2302438	chr7:75677065	C/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.81	0.77	1.1e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6728642	1.000	rs11890407	chr2:97621647	G/C	cg26665480	chr2:98280029	ACTR1B	-0.7	-7.4	-0.33	6.6e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs4566357	0.615	rs6436644	chr2:227914275	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.07	-0.39	3.51e-18	Coronary artery disease;
LGG	cis	rs9333075	0.507	rs10508493	chr10:15752181	A/G	cg14364212	chr10:15760690	ITGA8	0.47	9.58	0.41	5.92e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg00012203	chr2:219082015	ARPC2	0.85	17.53	0.63	3.87e-53	Colorectal cancer;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg19147804	chr7:1989927	MAD1L1	-0.6	-11.85	-0.48	1.83e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg16850897	chr7:100343110	ZAN	-0.63	-9.1	-0.39	2.67e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-6.84	-0.3	2.51e-11	Platelet count;Platelet distribution width;Mean platelet volume;
LGG	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg12292205	chr6:26970375	C6orf41	-0.77	-15.68	-0.59	9.57e-45	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2688608	0.623	rs2633318	chr10:75690434	T/C	cg10168709	chr10:75599394	CAMK2G	-0.37	-7.13	-0.31	4e-12	Inflammatory bowel disease;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.73	0.3	4.9e-11	Bipolar disorder;
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg04013166	chr16:89971882	TCF25	0.51	6.9	0.31	1.69e-11	Skin colour saturation;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	trans	rs6787172	0.622	rs10936135	chr3:158091774	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg19554555	chr3:13937349	NA	-0.54	-9.77	-0.41	1.28e-20	Ovarian reserve;
LGG	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg00543991	chr22:32367038	NA	0.74	8.83	0.38	2.14e-17	Childhood ear infection;
LGG	cis	rs9358372	0.635	rs11968853	chr6:20798072	G/C	cg13405222	chr6:20811065	CDKAL1	0.63	13.44	0.53	5.39e-35	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.25	-0.32	1.77e-12	HDL cholesterol;
LGG	cis	rs10463554	0.963	rs72785733	chr5:102374192	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Parkinson's disease;
LGG	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	trans	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.3	-0.43	1.57e-22	Total cholesterol levels;
LGG	cis	rs57590327	0.503	rs13075250	chr3:81907952	T/C	cg07356753	chr3:81810745	GBE1	-0.44	-7.03	-0.31	7.37e-12	Extraversion;
LGG	cis	rs4148087	1.000	rs73225405	chr21:43613428	C/T	cg08841829	chr21:43638893	ABCG1	-0.6	-7.94	-0.35	1.53e-14	Eating disorder in bipolar disorder;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg09845145	chr15:78292470	TBC1D2B	0.69	14.09	0.55	8.84e-38	Coronary artery disease or large artery stroke;
LGG	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg24375607	chr4:120327624	NA	0.67	11.12	0.46	1.24e-25	Corneal astigmatism;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg09426994	chr11:118478258	PHLDB1	-0.43	-7.34	-0.32	9.97e-13	Cholesterol, total;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg07022442	chr13:21864356	NA	-0.39	-6.82	-0.3	2.93e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg24848339	chr3:12840334	CAND2	0.46	11.04	0.46	2.68e-25	P wave duration;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg18252515	chr7:66147081	NA	0.42	7.07	0.31	5.62e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10107186	chr12:53689090	PFDN5	0.47	7.0	0.31	8.84e-12	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	trans	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	cis	rs12786942	0.569	rs4271356	chr11:101313984	T/C	cg03942599	chr11:101341554	TRPC6	0.48	7.31	0.32	1.21e-12	Facial depth;
LGG	trans	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg18335740	chr13:41363409	SLC25A15	0.97	23.48	0.74	7.11e-81	Lewy body disease;
LGG	cis	rs6754311	0.773	rs309137	chr2:136765951	A/G	cg07169764	chr2:136633963	MCM6	0.73	12.24	0.49	4.75e-30	Mosquito bite size;
LGG	trans	rs2235573	0.662	rs2076369	chr22:38463652	T/G	cg19894588	chr14:64061835	NA	0.43	6.86	0.3	2.17e-11	Glioblastoma;Glioma;
LGG	cis	rs11096990	0.892	rs11931354	chr4:39231476	A/G	cg24403649	chr4:39172243	NA	-0.44	-7.26	-0.32	1.63e-12	Cognitive function;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg21045802	chr8:109455806	TTC35	0.56	10.67	0.44	6.51e-24	Dupuytren's disease;
LGG	trans	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg06521331	chr12:34319734	NA	-0.5	-8.72	-0.38	5.05e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.14	0.31	3.63e-12	Triglycerides;
LGG	trans	rs941408	0.515	rs878893	chr19:2781325	A/G	cg22153745	chr1:153894579	GATAD2B	-0.56	-8.37	-0.36	6.92e-16	Total cholesterol levels;
LGG	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.32	-0.4	4.64e-19	Blood metabolite levels;
LGG	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-12.91	-0.51	8.5e-33	Chronic sinus infection;
LGG	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg08508325	chr11:3079039	CARS	0.42	8.07	0.35	5.94e-15	Calcium levels;
LGG	cis	rs9914988	0.943	rs12453504	chr17:27119524	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg01059449	chr18:44338099	ST8SIA5	-0.36	-7.85	-0.34	2.84e-14	Personality dimensions;
LGG	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.66	-0.44	7.02e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06771106	chr2:113671356	IL1F7	0.36	7.03	0.31	7.44e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.29	-0.63	5.07e-52	Skin colour saturation;
LGG	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg21453758	chr17:80185943	SLC16A3	0.34	7.46	0.33	4.42e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07414097	chr2:232646663	PDE6D	-0.51	-7.57	-0.33	2.01e-13	Systemic lupus erythematosus;
LGG	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg15128208	chr22:42549153	NA	0.75	11.57	0.47	2.28e-27	Birth weight;
LGG	cis	rs1555895	0.576	rs10904571	chr10:850762	A/G	cg09361094	chr10:834503	NA	-0.3	-7.87	-0.34	2.59e-14	Survival in rectal cancer;
LGG	cis	rs3806843	0.900	rs2337983	chr5:140136808	G/A	cg19875535	chr5:140030758	IK	-0.54	-11.03	-0.46	2.8e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.5e-11	Alzheimer's disease (survival time);
LGG	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg09137382	chr11:130731461	NA	0.35	6.81	0.3	3.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9420907	0.579	rs2475215	chr10:105660702	T/C	cg11005552	chr10:105648138	OBFC1	0.66	7.09	0.31	4.97e-12	Telomere length;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg11608241	chr8:8085544	FLJ10661	-0.29	-6.81	-0.3	2.95e-11	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.8	0.45	2.05e-24	Bladder cancer;
LGG	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg22437258	chr11:111473054	SIK2	-0.48	-8.11	-0.35	4.62e-15	Primary sclerosing cholangitis;
LGG	cis	rs2463822	0.669	rs72919484	chr11:62043430	T/C	cg06239285	chr11:62104954	ASRGL1	-1.13	-13.73	-0.54	3.01e-36	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs4851254	0.961	rs6713524	chr2:100747357	A/G	cg17356467	chr2:100759845	AFF3	0.4	6.97	0.31	1.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	7.03	0.31	7.54e-12	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg00647317	chr7:50633725	DDC	0.33	7.46	0.33	4.28e-13	Malaria;
LGG	cis	rs17209837	0.607	rs2109505	chr7:87079406	T/A	cg00919237	chr7:87102261	ABCB4	-0.75	-14.14	-0.55	5.61e-38	Gallbladder cancer;
LGG	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.02	-0.31	8.02e-12	Blood metabolite levels;
LGG	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg25566285	chr7:158114605	PTPRN2	0.89	19.57	0.67	1.3e-62	Calcium levels;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.7	-0.45	4.87e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.24	-0.32	1.91e-12	Bipolar disorder;
LGG	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg18196295	chr10:418757	DIP2C	-0.68	-13.86	-0.54	8.57e-37	Psychosis in Alzheimer's disease;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	8.45	0.37	3.88e-16	Lung function (FEV1/FVC);
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg02353165	chr6:42928485	GNMT	0.51	15.87	0.59	1.32e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-8.37	-0.36	6.69e-16	Breast cancer;
LGG	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg12927641	chr6:109611667	NA	-0.38	-7.18	-0.32	2.77e-12	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12200782	0.929	rs72836460	chr6:26351890	T/A	cg11502198	chr6:26597334	ABT1	-0.78	-6.75	-0.3	4.49e-11	Small cell lung carcinoma;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.62	-10.86	-0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs225245	1.000	rs225245	chr17:33946107	A/G	cg05299278	chr17:33885742	SLFN14	0.4	7.47	0.33	4.09e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4788570	0.615	rs2032918	chr16:71703436	T/G	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Intelligence (multi-trait analysis);
LGG	cis	rs6429082	0.818	rs291383	chr1:235643100	G/A	cg26050004	chr1:235667680	B3GALNT2	0.61	10.21	0.43	3.41e-22	Adiposity;
LGG	trans	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg02030672	chr11:45687055	CHST1	-0.5	-9.24	-0.39	8.94e-19	Obesity-related traits;
LGG	cis	rs9400467	0.506	rs12209969	chr6:111668167	G/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-8.42	-0.36	4.93e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg19812747	chr11:111475976	SIK2	0.41	8.48	0.37	2.96e-16	Primary sclerosing cholangitis;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.36	-6.96	-0.31	1.14e-11	Schizophrenia;
LGG	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.24e-17	Retinal vascular caliber;
LGG	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.44	0.47	7.47e-27	Schizophrenia;
LGG	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.24	0.32	1.91e-12	Neuroticism;
LGG	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg25482853	chr8:67687455	SGK3	1.04	13.42	0.53	6.24e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg07148914	chr20:33460835	GGT7	-0.5	-8.17	-0.35	3.04e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg24879335	chr3:133465180	TF	0.44	7.33	0.32	1.06e-12	Iron status biomarkers (transferrin levels);
LGG	cis	rs10504073	0.584	rs55908480	chr8:49923431	G/A	cg00325661	chr8:49890786	NA	0.8	16.25	0.6	2.62e-47	Blood metabolite ratios;
LGG	cis	rs9463078	0.753	rs3778507	chr6:44896803	G/A	cg25276700	chr6:44698697	NA	-0.39	-8.18	-0.36	2.81e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7077256	0.564	rs72835357	chr10:65096434	A/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.91	-0.31	1.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4917300	0.606	rs6583565	chr8:143114379	C/T	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.32e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.56	-9.31	-0.4	5.21e-19	Height;
LGG	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.44	-0.37	4.19e-16	Neuroticism;
LGG	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.25e-12	Arsenic metabolism;
LGG	cis	rs943466	1.000	rs943466	chr6:33731787	A/G	cg07519485	chr6:33762594	MLN	-0.51	-10.44	-0.44	4.5e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs6456042	0.893	rs3099312	chr6:166557339	T/C	cg11088901	chr6:166572345	T	-0.38	-7.87	-0.34	2.61e-14	Asthma;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7191700	0.644	rs12149160	chr16:11439303	G/T	cg00044050	chr16:11439710	C16orf75	-0.64	-11.2	-0.46	6.5e-26	Multiple sclerosis;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	12.06	0.49	2.64e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7017914	0.967	rs6998786	chr8:71694630	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg07395648	chr5:131743802	NA	-0.45	-9.75	-0.41	1.55e-20	Blood metabolite levels;
LGG	cis	rs4742903	0.904	rs10124553	chr9:106993898	G/A	cg14250997	chr9:106856677	SMC2	0.38	7.85	0.34	2.91e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs10895140	0.756	rs12280648	chr11:101428328	A/G	cg23650423	chr11:101454676	TRPC6	0.43	6.67	0.3	7.54e-11	Menarche (age at onset);
LGG	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08109568	chr15:31115862	NA	-0.54	-9.53	-0.41	8.56e-20	Huntington's disease progression;
LGG	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg22676075	chr6:135203613	NA	-0.48	-8.42	-0.36	4.77e-16	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg00405596	chr8:11794950	NA	-0.6	-10.67	-0.44	6.56e-24	Monocyte count;
LGG	cis	rs787274	1.000	rs4979150	chr9:115553502	T/A	cg13803584	chr9:115635662	SNX30	-0.57	-7.86	-0.34	2.71e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg16586182	chr3:47516702	SCAP	0.76	14.99	0.57	1.11e-41	Colorectal cancer;
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg09303159	chr6:26284866	NA	0.32	7.04	0.31	6.98e-12	Educational attainment;
LGG	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	10.93	0.45	6.83e-25	Height;
LGG	cis	rs963731	0.579	rs6726833	chr2:39351569	A/C	cg04010122	chr2:39346883	SOS1	0.74	7.51	0.33	3.15e-13	Corticobasal degeneration;
LGG	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12923728	chr3:195709715	SDHAP1	0.76	14.21	0.55	2.62e-38	Pancreatic cancer;
LGG	cis	rs2070433	0.800	rs11702190	chr21:47877367	C/T	cg12379764	chr21:47803548	PCNT	0.65	9.27	0.4	7e-19	Lymphocyte counts;
LGG	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg27532318	chr7:32358331	NA	0.65	6.9	0.31	1.74e-11	Body mass index;
LGG	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg09307838	chr4:120376055	NA	-0.79	-12.99	-0.52	4.06e-33	Corneal astigmatism;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.91	-0.48	1e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg09307838	chr4:120376055	NA	0.66	11.32	0.47	2.19e-26	Corneal astigmatism;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.43	-0.47	7.81e-27	Personality dimensions;
LGG	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg20637307	chr2:213403960	ERBB4	0.73	16.63	0.61	4.93e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.36	-0.32	8.55e-13	Total cholesterol levels;
LGG	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.62	0.41	4.16e-20	Menarche (age at onset);
LGG	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg01657329	chr11:68192670	LRP5	-0.57	-10.64	-0.44	8.2e-24	Total body bone mineral density;
LGG	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg26513180	chr16:89883248	FANCA	-0.53	-9.37	-0.4	3.31e-19	Vitiligo;
LGG	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.73	0.56	1.45e-40	Cognitive test performance;
LGG	cis	rs17030434	0.654	rs10021447	chr4:154646459	A/C	cg14289246	chr4:154710475	SFRP2	-0.61	-9.5	-0.4	1.16e-19	Electrocardiographic conduction measures;
LGG	cis	rs72781680	0.898	rs7589440	chr2:24038595	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.21e-18	Lymphocyte counts;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg01114163	chr5:1856713	NA	-0.4	-6.83	-0.3	2.71e-11	Cardiovascular disease risk factors;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25072359	chr17:41440525	NA	0.54	10.19	0.43	4.05e-22	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg12070911	chr6:150209640	RAET1E	0.28	6.72	0.3	5.29e-11	Lung cancer;
LGG	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04530015	chr2:215796436	ABCA12	0.45	7.7	0.34	8.48e-14	Neuroblastoma;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg11494091	chr17:61959527	GH2	0.59	9.59	0.41	5.61e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs758324	0.947	rs58016983	chr5:131235275	T/C	cg06307176	chr5:131281290	NA	-0.56	-9.45	-0.4	1.76e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	18.28	0.65	1.33e-56	Obesity-related traits;
LGG	cis	rs892961	0.932	rs7208336	chr17:75412932	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	trans	rs3206736	0.548	rs328929	chr7:35040038	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.87	9.25	0.4	8.05e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg01448562	chr3:133502909	NA	-0.74	-13.75	-0.54	2.52e-36	Iron status biomarkers;
LGG	cis	rs9397585	0.857	rs9397129	chr6:153378570	C/A	cg17707550	chr6:153380415	RGS17	0.62	14.51	0.56	1.32e-39	Body mass index;
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg13013644	chr5:502571	SLC9A3	-0.35	-6.81	-0.3	3.11e-11	Cystic fibrosis severity;
LGG	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs10743315	0.778	rs9805106	chr12:19372357	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.53	-7.54	-0.33	2.53e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4330281	0.647	rs4908958	chr3:17728043	G/A	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs9818758	0.607	rs11552724	chr3:49156473	C/G	cg00383909	chr3:49044727	WDR6	1.05	12.73	0.51	5.07e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.68e-19	Diabetic retinopathy;
LGG	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.17e-13	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.88	0.54	7.05e-37	Lung cancer;
LGG	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	-0.51	-7.36	-0.32	8.44e-13	Birth weight;
LGG	cis	rs607541	0.850	rs642328	chr15:45935350	T/A	cg26924012	chr15:45694286	SPATA5L1	0.53	7.39	0.32	7e-13	Obesity-related traits;
LGG	cis	rs989128	0.600	rs9913430	chr17:48628470	A/T	cg20467136	chr17:48638190	CACNA1G	0.46	6.87	0.3	2.04e-11	Type 2 diabetes;
LGG	cis	rs6693295	0.816	rs12404559	chr1:246313321	G/A	cg11798871	chr1:246315928	SMYD3	-0.47	-6.88	-0.3	1.97e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.62	-9.06	-0.39	3.64e-18	Body mass index;
LGG	cis	rs3820928	0.874	rs4675128	chr2:227814757	T/C	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.95	-0.35	1.48e-14	Pulmonary function;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg25214090	chr10:38739885	LOC399744	0.48	9.05	0.39	3.95e-18	Corneal astigmatism;
LGG	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.09	0.42	9.09e-22	Motion sickness;
LGG	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg12395012	chr8:11607386	GATA4	0.37	6.94	0.31	1.31e-11	Neuroticism;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.62	0.33	1.4e-13	Rheumatoid arthritis;
LGG	cis	rs3741151	0.892	rs7105681	chr11:73059341	G/A	cg17517138	chr11:73019481	ARHGEF17	0.91	9.54	0.41	7.89e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs853679	0.538	rs13199081	chr6:28331834	T/C	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.96	-0.31	1.19e-11	Depression;
LGG	trans	rs561341	0.882	rs504887	chr17:30322881	T/A	cg27661571	chr11:113659931	NA	-0.68	-9.68	-0.41	2.71e-20	Hip circumference adjusted for BMI;
LGG	cis	rs981844	0.583	rs62325060	chr4:154630501	G/A	cg14289246	chr4:154710475	SFRP2	0.62	8.9	0.38	1.25e-17	Response to statins (LDL cholesterol change);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14037413	chr11:9482594	ZNF143	0.47	7.92	0.35	1.81e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.91	0.48	1.03e-28	Rheumatoid arthritis;
LGG	cis	rs2692947	0.763	rs7570074	chr2:96407037	T/C	cg22654517	chr2:96458247	NA	0.37	7.87	0.34	2.49e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.3e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7582720	1.000	rs75166090	chr2:203692760	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs3796352	1.000	rs11714876	chr3:53101640	C/G	cg12962167	chr3:53033115	SFMBT1	-0.74	-7.84	-0.34	3.06e-14	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10053473	chr17:62856997	LRRC37A3	0.89	14.01	0.55	2.02e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg16339924	chr4:17578868	LAP3	0.5	8.36	0.36	7.54e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-16.71	-0.61	2.15e-49	Chronic sinus infection;
LGG	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs3087591	0.922	rs2905805	chr17:29502856	C/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs68170813	0.522	rs12535814	chr7:107038432	A/T	cg02696742	chr7:106810147	HBP1	-0.7	-9.95	-0.42	2.84e-21	Coronary artery disease;
LGG	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11644478	chr21:40555479	PSMG1	-0.6	-10.13	-0.43	6.57e-22	Menarche (age at onset);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16232504	chr1:99127707	SNX7	0.41	6.88	0.3	2.01e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9302635	0.513	rs12444701	chr16:72155240	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-8.95	-0.38	8.38e-18	Blood protein levels;
LGG	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.7	-0.56	2.09e-40	Leprosy;
LGG	cis	rs9916302	0.904	rs10221223	chr17:37489100	T/G	cg00129232	chr17:37814104	STARD3	0.61	11.53	0.47	3.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9650657	0.871	rs7814142	chr8:10637552	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.72	-0.3	5.39e-11	Neuroticism;
LGG	cis	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.96	-0.31	1.14e-11	Morning vs. evening chronotype;
LGG	cis	rs78905543	1.000	rs4872049	chr8:22931779	C/T	cg16861508	chr8:22926909	TNFRSF10B	-0.37	-7.13	-0.31	3.8e-12	Mean corpuscular volume;
LGG	trans	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg10756647	chr7:56101905	PSPH	0.83	9.55	0.41	7.4e-20	Diabetic kidney disease;
LGG	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg11584989	chr19:19387371	SF4	0.76	12.77	0.51	3.47e-32	Bipolar disorder;
LGG	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06634786	chr22:41940651	POLR3H	-0.78	-11.6	-0.47	1.8e-27	Vitiligo;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18252515	chr7:66147081	NA	0.44	7.35	0.32	9.03e-13	Aortic root size;
LGG	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.82	-0.51	2.06e-32	Response to antipsychotic treatment;
LGG	cis	rs17301259	0.509	rs3915188	chr7:88415956	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-7.16	-0.32	3.28e-12	Heschl's gyrus morphology;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17739167	0.550	rs2665213	chr15:42234265	T/G	cg20935245	chr15:42234343	EHD4	-0.44	-8.41	-0.36	4.98e-16	Monocyte count;
LGG	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02788857	chr8:22132959	PIWIL2	0.5	11.72	0.48	5.82e-28	Hypertriglyceridemia;
LGG	cis	rs72781680	0.898	rs72780121	chr2:23995918	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs2573652	0.722	rs12914180	chr15:100544416	T/C	cg14911520	chr15:100542628	ADAMTS17	-0.29	-7.14	-0.32	3.53e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25356086	chr21:33764900	C21orf119;URB1	0.49	7.76	0.34	5.5e-14	Gut microbiome composition (summer);
LGG	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg18709589	chr6:96969512	KIAA0776	-0.37	-7.15	-0.32	3.48e-12	Headache;
LGG	trans	rs9409565	0.826	rs4744345	chr9:97207669	G/A	cg05679027	chr9:99775184	HIATL2	-0.49	-8.15	-0.35	3.39e-15	Colorectal cancer (alcohol consumption interaction);
LGG	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.51	-0.47	3.79e-27	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs9944715	0.954	rs11082514	chr18:43770207	C/T	cg01718231	chr17:29326311	RNF135	-0.41	-6.65	-0.3	8.44e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.67	0.44	6.29e-24	Mean platelet volume;
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	15.24	0.58	8.5e-43	Tonsillectomy;
LGG	trans	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.52e-15	Morning vs. evening chronotype;
LGG	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg05590025	chr7:65112418	INTS4L2	-0.75	-6.79	-0.3	3.46e-11	Diabetic kidney disease;
LGG	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg14186256	chr22:23484241	RTDR1	1.0	25.57	0.77	1.43e-90	Bone mineral density;
LGG	cis	rs7017914	0.967	rs13258584	chr8:71671579	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg08085267	chr17:45401833	C17orf57	-0.57	-11.47	-0.47	5.57e-27	Multiple sclerosis;Ankylosing spondylitis;
LGG	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.1	0.35	5.06e-15	Myopia (pathological);
LGG	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg12395012	chr8:11607386	GATA4	-0.39	-7.08	-0.31	5.23e-12	Monocyte count;
LGG	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg15103426	chr22:29168792	CCDC117	0.62	9.5	0.4	1.09e-19	Lymphocyte counts;
LGG	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg21475434	chr5:93447410	FAM172A	-0.71	-7.25	-0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs9783347	0.714	rs11024622	chr11:18352685	C/G	cg15585147	chr11:18324498	HPS5	0.32	7.29	0.32	1.31e-12	Pancreatic cancer;
LGG	cis	rs11150038	0.826	rs9934062	chr16:78087287	C/T	cg04733911	chr16:78082701	NA	0.66	9.25	0.4	8.09e-19	Colorectal or endometrial cancer;
LGG	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.3	0.32	1.23e-12	Retinal vascular caliber;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg07120314	chr15:79043507	NA	0.67	14.34	0.55	7.31e-39	Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.57e-12	Lung cancer;
LGG	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.16	-0.32	3.09e-12	Bipolar disorder;
LGG	cis	rs972578	0.791	rs5759003	chr22:43264851	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.89	-0.3	1.83e-11	Mean platelet volume;
LGG	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.24e-20	Diabetic kidney disease;
LGG	cis	rs6547741	0.935	rs12714204	chr2:27787540	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.66	0.37	8.19e-17	Oral cavity cancer;
LGG	cis	rs10106298	1.000	rs17773903	chr8:103685172	A/G	cg10187029	chr8:103597600	NA	0.41	6.76	0.3	4.08e-11	Schizophrenia;
LGG	cis	rs6831352	0.744	rs2602847	chr4:100025963	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Alcohol dependence;
LGG	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg25174290	chr11:3078921	CARS	-0.61	-12.42	-0.5	8.73e-31	Longevity;
LGG	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.54e-21	HDL cholesterol;
LGG	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg18252515	chr7:66147081	NA	-1.4	-18.43	-0.65	2.71e-57	Diabetic kidney disease;
LGG	cis	rs2629540	0.765	rs4962687	chr10:126404141	G/A	cg08799069	chr10:126477246	METTL10	-0.55	-11.52	-0.47	3.65e-27	Cocaine dependence;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.58	0.65	5.77e-58	Personality dimensions;
LGG	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg21699342	chr2:239360505	ASB1	0.4	7.87	0.34	2.54e-14	Multiple system atrophy;
LGG	cis	rs6693567	0.507	rs4970964	chr1:150458029	A/G	cg15654264	chr1:150340011	RPRD2	0.33	6.78	0.3	3.71e-11	Migraine;
LGG	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.51	8.49	0.37	2.72e-16	Response to antipsychotic treatment;
LGG	cis	rs13294100	0.861	rs2754341	chr9:17572069	A/G	cg11213383	chr9:17579734	SH3GL2	-0.58	-10.83	-0.45	1.6e-24	Parkinson's disease;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03452623	chr4:187889614	NA	-1.04	-30.5	-0.82	8.16e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7584262	0.740	rs13401161	chr2:42245267	C/T	cg27252766	chr2:42229092	NA	0.48	6.87	0.3	2.06e-11	Bone mineral density;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg23758822	chr17:41437982	NA	0.91	15.99	0.6	3.7e-46	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05596135	chr16:72128010	TXNL4B;DHX38	0.43	7.02	0.31	8.19e-12	Cognitive performance;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	4.85e-22	Menopause (age at onset);
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg12310025	chr6:25882481	NA	-0.53	-9.97	-0.42	2.41e-21	Height;
LGG	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14169450	chr9:139327907	INPP5E	0.39	7.08	0.31	5.52e-12	Monocyte percentage of white cells;
LGG	cis	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg08975724	chr8:8085496	FLJ10661	0.38	6.96	0.31	1.18e-11	Mood instability;
LGG	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg23706161	chr2:109336669	RANBP2	-0.38	-6.91	-0.31	1.63e-11	Mean platelet volume;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg25742201	chr17:35306863	AATF	0.4	6.71	0.3	5.81e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg02297831	chr4:17616191	MED28	0.46	8.26	0.36	1.54e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg05526886	chr2:227700861	RHBDD1	-0.42	-7.47	-0.33	3.91e-13	Pulmonary function;
LGG	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.22	0.39	1.04e-18	Cannabis dependence symptom count;
LGG	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.92	-0.42	3.65e-21	Joint mobility (Beighton score);
LGG	trans	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg19508488	chr2:152266495	RIF1	0.61	11.11	0.46	1.42e-25	Lung cancer;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg02975922	chr3:195473998	MUC4	-0.54	-8.92	-0.38	1.12e-17	Pancreatic cancer;
LGG	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg13939156	chr17:80058883	NA	0.46	8.22	0.36	2.08e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7326068	0.610	rs4769128	chr13:21322682	A/G	cg04906043	chr13:21280425	IL17D	0.5	8.02	0.35	8.85e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.22	0.46	5.45e-26	Morning vs. evening chronotype;
LGG	cis	rs2154319	0.887	rs1740610	chr1:41502680	C/A	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.91	-0.38	1.14e-17	Height;
LGG	cis	rs4740619	1.000	rs4740621	chr9:15640404	C/T	cg14451791	chr9:16040625	NA	-0.39	-9.7	-0.41	2.2e-20	Body mass index;
LGG	cis	rs11601602	0.576	rs12576396	chr11:28555952	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	9.94	0.42	3.11e-21	Obesity-related traits;
LGG	cis	rs9902453	0.868	rs9890075	chr17:28470464	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.15	0.52	9.16e-34	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02838143	chr10:126606107	NA	0.44	6.85	0.3	2.43e-11	Gut microbiome composition (summer);
LGG	cis	rs17221829	0.733	rs12421371	chr11:89381008	T/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	trans	rs9650657	0.707	rs1115867	chr8:10638750	T/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.85	-0.3	2.33e-11	Neuroticism;
LGG	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.0	0.31	8.8e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg24110177	chr3:50126178	RBM5	-0.6	-11.01	-0.46	3.45e-25	Body mass index;
LGG	cis	rs67311347	0.549	rs60249586	chr3:40246659	G/A	cg13683864	chr3:40499215	RPL14	-0.71	-13.4	-0.53	7.48e-35	Renal cell carcinoma;
LGG	cis	rs490234	0.812	rs4838286	chr9:128460057	G/A	cg14078157	chr9:128172775	NA	-0.48	-8.39	-0.36	6.05e-16	Mean arterial pressure;
LGG	cis	rs4417704	0.551	rs10169006	chr2:241898824	A/G	cg26818257	chr2:241905806	NA	0.48	10.6	0.44	1.15e-23	Joint mobility (Beighton score);
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg04267008	chr7:1944627	MAD1L1	-0.62	-10.31	-0.43	1.47e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg02002194	chr4:3960332	NA	0.4	7.13	0.31	3.77e-12	Neuroticism;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.01	-0.31	8.67e-12	Personality dimensions;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg07395648	chr5:131743802	NA	-0.41	-8.86	-0.38	1.69e-17	Blood metabolite levels;
LGG	cis	rs2285947	1.000	rs6970597	chr7:21583519	C/A	cg03697024	chr7:21583438	DNAH11	0.35	8.66	0.37	7.97e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg10523679	chr1:76189770	ACADM	0.84	16.45	0.61	3.22e-48	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs61931739	0.649	rs815028	chr12:33718591	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.77	-0.3	3.99e-11	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25072359	chr17:41440525	NA	0.53	10.14	0.43	6.1e-22	Menopause (age at onset);
LGG	cis	rs11690935	0.798	rs13018768	chr2:172598592	A/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.82	-0.3	2.77e-11	Schizophrenia;
LGG	trans	rs6601327	0.602	rs12678014	chr8:9649165	T/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.8	-0.34	4.14e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.19	-0.32	2.66e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs858239	0.539	rs2141306	chr7:23191664	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.88	0.3	1.98e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21659725	chr3:3221576	CRBN	0.75	11.97	0.49	5.79e-29	Resting heart rate;
LGG	cis	rs9290877	0.580	rs9865310	chr3:188466638	G/A	cg17392043	chr3:188495102	LPP	-0.46	-7.98	-0.35	1.15e-14	IgE levels;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg13628971	chr7:2884303	GNA12	0.5	9.7	0.41	2.19e-20	Height;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg09699651	chr6:150184138	LRP11	0.51	9.07	0.39	3.42e-18	Lung cancer;
LGG	cis	rs4690686	0.500	rs72623908	chr4:177261971	A/G	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs7100689	0.646	rs1934696	chr10:82124966	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg23788917	chr6:8435910	SLC35B3	0.51	8.8	0.38	2.74e-17	Motion sickness;
LGG	cis	rs61931739	0.620	rs61927757	chr12:33710109	A/G	cg06521331	chr12:34319734	NA	0.39	6.76	0.3	4.06e-11	Morning vs. evening chronotype;
LGG	cis	rs2742417	1.000	rs2742386	chr3:45756310	A/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.45	-0.33	4.69e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg00129232	chr17:37814104	STARD3	-0.45	-8.52	-0.37	2.29e-16	Self-reported allergy;
LGG	trans	rs12517041	1.000	rs4701219	chr5:23284067	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs4731207	0.596	rs719972	chr7:124631797	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg10224037	chr5:178157518	ZNF354A	0.56	8.01	0.35	9.43e-15	Neutrophil percentage of white cells;
LGG	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.29	0.58	5.05e-43	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg06875740	chr19:51307921	C19orf48	-0.63	-7.89	-0.34	2.28e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg00383909	chr3:49044727	WDR6	0.44	7.27	0.32	1.51e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.29	-0.36	1.2e-15	Parkinson's disease;
LGG	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.41	0.33	6.24e-13	Refractive error;
LGG	cis	rs2247341	0.965	rs2854913	chr4:1723137	A/T	cg07465881	chr4:1713556	SLBP	-0.45	-7.11	-0.31	4.4e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.52e-23	Aortic root size;
LGG	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.7	-0.3	5.96e-11	Coronary artery disease;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-13.27	-0.52	2.82e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg17470184	chr11:118478236	PHLDB1	0.43	7.8	0.34	4.22e-14	Cholesterol, total;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.68e-14	Lung cancer;
LGG	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg19761014	chr17:28927070	LRRC37B2	0.64	7.55	0.33	2.38e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg14186256	chr22:23484241	RTDR1	0.93	22.69	0.73	3.55e-77	Bone mineral density;
LGG	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg04156418	chr7:157293606	NA	0.63	14.89	0.57	3.11e-41	Inattentive symptoms;
LGG	cis	rs11719291	0.833	rs11713694	chr3:48833615	G/T	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	Cognitive function;
LGG	cis	rs8049040	0.547	rs12929335	chr16:71435752	G/A	cg06353428	chr16:71660113	MARVELD3	-0.47	-7.37	-0.32	7.65e-13	Blood protein levels;
LGG	cis	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.22e-14	Blood trace element (Cu levels);
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg16141378	chr3:129829833	LOC729375	0.41	9.5	0.4	1.09e-19	Neuroticism;
LGG	cis	rs7538876	1.000	rs2526828	chr1:17729903	G/A	cg10329579	chr1:17754830	RCC2	-0.48	-9.23	-0.39	9.85e-19	Basal cell carcinoma;
LGG	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg02023728	chr11:77925099	USP35	0.46	7.91	0.34	1.97e-14	Testicular germ cell tumor;
LGG	cis	rs7226408	0.846	rs2121024	chr18:34488206	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs8064029	0.892	rs77213183	chr16:4902110	A/G	cg04440724	chr16:4920505	UBN1	-0.62	-7.52	-0.33	2.84e-13	Cancer;
LGG	cis	rs4740619	0.619	rs10738427	chr9:16041822	C/T	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19717773	chr7:2847554	GNA12	-0.33	-7.06	-0.31	5.98e-12	Height;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg02297831	chr4:17616191	MED28	0.51	9.29	0.4	5.92e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1497828	0.956	rs2646817	chr1:217525251	T/G	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg12395012	chr8:11607386	GATA4	-0.36	-6.75	-0.3	4.53e-11	Systolic blood pressure;
LGG	cis	rs972578	0.765	rs4822208	chr22:43261223	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.88	-0.3	1.89e-11	Mean platelet volume;
LGG	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg10621924	chr7:39171070	POU6F2	0.48	10.06	0.42	1.15e-21	IgG glycosylation;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs7103648	0.618	rs11039284	chr11:47564785	A/G	cg20307385	chr11:47447363	PSMC3	0.85	16.93	0.62	2.08e-50	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.6	-0.41	4.94e-20	Monocyte percentage of white cells;
LGG	cis	rs3770081	1.000	rs74607112	chr2:86305534	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.68	7.24	0.32	1.92e-12	Facial emotion recognition (sad faces);
LGG	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg00290607	chr11:67383545	NA	-0.5	-8.88	-0.38	1.48e-17	Mean corpuscular volume;
LGG	cis	rs243505	0.767	rs243530	chr7:148412618	T/C	cg18940274	chr7:148469757	CUL1	0.38	7.25	0.32	1.76e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg13009111	chr11:71350975	NA	0.33	7.16	0.32	3.12e-12	Monocyte count;
LGG	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs9517302	0.544	rs2281766	chr13:99098882	A/C	cg24044564	chr13:99115944	STK24	0.48	6.81	0.3	3.11e-11	Obesity-related traits;
LGG	cis	rs4696584	0.755	rs56390496	chr4:155407940	A/T	cg04517429	chr4:155413618	DCHS2	-0.33	-7.45	-0.33	4.47e-13	Folding of antihelix;
LGG	cis	rs11608355	0.573	rs7970666	chr12:109793495	T/G	cg19025524	chr12:109796872	NA	-0.6	-13.1	-0.52	1.44e-33	Neuroticism;
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.51	0.37	2.44e-16	Alzheimer's disease;
LGG	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.58	10.12	0.43	6.73e-22	Alzheimer's disease;
LGG	cis	rs7192750	0.562	rs2335709	chr16:71938442	G/A	cg06353428	chr16:71660113	MARVELD3	0.66	10.65	0.44	7.5e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg12070911	chr6:150209640	RAET1E	0.27	6.79	0.3	3.47e-11	Lung cancer;
LGG	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg23806715	chr17:73775811	H3F3B	0.93	10.17	0.43	4.47e-22	Psoriasis;
LGG	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg12924262	chr12:102091054	CHPT1	0.64	12.67	0.51	8.27e-32	Blood protein levels;
LGG	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.24	-0.36	1.82e-15	Total body bone mineral density;
LGG	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.29e-11	Parkinson's disease;
LGG	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg06532163	chr17:45867833	NA	0.55	9.31	0.4	5.3e-19	IgG glycosylation;
LGG	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg24110177	chr3:50126178	RBM5	0.65	11.9	0.48	1.13e-28	Body mass index;
LGG	cis	rs4906332	1.000	rs12885762	chr14:103882200	C/A	cg26031613	chr14:104095156	KLC1	-0.52	-7.89	-0.34	2.22e-14	Coronary artery disease;
LGG	cis	rs7589342	1.000	rs7589342	chr2:106433478	C/T	cg16077055	chr2:106428750	NCK2	0.33	8.75	0.38	3.99e-17	Addiction;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs3816183	0.626	rs4953529	chr2:42870440	C/T	cg14631114	chr2:43023945	NA	0.34	6.76	0.3	4.12e-11	Hypospadias;
LGG	cis	rs2067615	0.831	rs1922437	chr12:107058045	C/T	cg15890332	chr12:107067104	RFX4	0.32	8.91	0.38	1.14e-17	Heart rate;
LGG	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg18245976	chr7:158708271	WDR60	-0.57	-7.3	-0.32	1.29e-12	Height;
LGG	trans	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg06521331	chr12:34319734	NA	0.44	7.95	0.35	1.42e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg27426351	chr10:43362370	NA	-0.55	-7.85	-0.34	2.83e-14	Blood protein levels;
LGG	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.82	-0.59	2.29e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6142618	0.583	rs2281364	chr20:30752152	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs7737355	0.812	rs13158215	chr5:130629543	C/A	cg06307176	chr5:131281290	NA	0.48	8.05	0.35	6.83e-15	Life satisfaction;
LGG	trans	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.37	-0.4	3.09e-19	Brugada syndrome;
LGG	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg13647721	chr17:30228624	UTP6	0.63	7.59	0.33	1.82e-13	Hip circumference adjusted for BMI;
LGG	cis	rs4696584	0.877	rs72725345	chr4:155387524	G/A	cg04517429	chr4:155413618	DCHS2	-0.33	-7.13	-0.31	3.99e-12	Folding of antihelix;
LGG	cis	rs3735485	0.738	rs3735493	chr7:45122324	C/A	cg03440944	chr7:45023329	C7orf40	-0.55	-8.98	-0.39	6.9e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.12	0.39	2.25e-18	Motion sickness;
LGG	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg06889755	chr6:150326021	RAET1K	-0.39	-7.87	-0.34	2.45e-14	Alopecia areata;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.932	rs6115214	chr20:25557426	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.08	-0.42	9.53e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11245990	chr11:68621969	NA	0.44	9.15	0.39	1.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs990171	0.770	rs4577297	chr2:102918018	G/A	cg05295703	chr2:102895712	NA	-0.65	-11.96	-0.49	6.75e-29	Lymphocyte counts;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02475777	chr4:1388615	CRIPAK	0.43	8.08	0.35	5.72e-15	Longevity;
LGG	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.38	0.47	1.26e-26	Schizophrenia;
LGG	cis	rs7814319	0.966	rs10095443	chr8:97269738	C/T	cg20787634	chr8:97240163	UQCRB	-0.78	-18.56	-0.65	7.09e-58	Lung function (FVC);
LGG	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg00938859	chr5:1591904	SDHAP3	0.85	12.68	0.51	7.48e-32	Breast cancer;
LGG	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg00204512	chr16:28754710	NA	0.26	7.16	0.32	3.13e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7843479	1.000	rs17615788	chr8:21814739	C/T	cg17168535	chr8:21777572	XPO7	0.61	10.03	0.42	1.47e-21	Mean corpuscular volume;
LGG	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg08847335	chr10:891726	LARP4B	-0.51	-7.7	-0.34	8.08e-14	Eosinophil percentage of granulocytes;
LGG	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg07005078	chr4:17578674	LAP3	0.37	6.92	0.31	1.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.7	0.54	4.12e-36	IgG glycosylation;
LGG	cis	rs4731207	0.651	rs1525619	chr7:124654541	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-11.24	-0.46	4.21e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.87	-0.51	1.31e-32	Morning vs. evening chronotype;
LGG	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-7.96	-0.35	1.35e-14	Menarche (age at onset);
LGG	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg18351406	chr4:77819688	ANKRD56	0.46	8.09	0.35	5.19e-15	Emphysema distribution in smoking;
LGG	cis	rs9463078	0.565	rs3799973	chr6:44823727	G/A	cg25276700	chr6:44698697	NA	0.33	6.73	0.3	5.18e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.9	-0.31	1.69e-11	Neuroticism;
LGG	cis	rs773506	0.898	rs1995933	chr9:94042707	A/G	cg14446406	chr9:93919335	NA	0.44	8.3	0.36	1.14e-15	Type 2 diabetes nephropathy;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08219700	chr8:58056026	NA	0.43	6.83	0.3	2.68e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs713587	0.563	rs7591460	chr2:25103967	A/C	cg04586622	chr2:25135609	ADCY3	0.43	11.49	0.47	4.76e-27	Body mass index in non-asthmatics;
LGG	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.53	0.5	3.16e-31	Lung cancer in ever smokers;
LGG	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg21545522	chr1:205238299	TMCC2	0.48	8.59	0.37	1.37e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08983490	chr16:1876867	HAGH;FAHD1	0.45	6.76	0.3	4.23e-11	Gut microbiome composition (summer);
LGG	cis	rs977987	0.843	rs12443904	chr16:75438770	C/T	cg03315344	chr16:75512273	CHST6	0.52	10.41	0.44	6.23e-23	Dupuytren's disease;
LGG	cis	rs6867032	1.000	rs4975802	chr5:2019750	T/C	cg26168224	chr5:2018326	NA	1.29	31.04	0.82	3.25e-115	Gut microbiome composition (winter);
LGG	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.71e-11	Red blood cell count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11886014	chr5:41904500	C5orf51	0.44	7.4	0.33	6.37e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7590368	0.673	rs17455708	chr2:10926767	A/G	cg15705551	chr2:10952987	PDIA6	0.57	7.34	0.32	9.39e-13	Educational attainment (years of education);
LGG	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg05425664	chr17:57184151	TRIM37	0.58	9.3	0.4	5.73e-19	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.36e-22	Total body bone mineral density;
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	8.62	0.37	1.07e-16	Bipolar disorder;
LGG	cis	rs539514	0.932	rs625755	chr13:76326701	G/A	cg04757411	chr13:76259545	LMO7	-0.26	-6.81	-0.3	3.05e-11	Type 1 diabetes;
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09476347	chr16:613343	C16orf11	-0.37	-6.85	-0.3	2.35e-11	Height;
LGG	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.87	-0.51	1.31e-32	Morning vs. evening chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23213688	chr1:231473791	C1orf124;EXOC8	0.43	7.1	0.31	4.63e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11169552	0.510	rs12231309	chr12:51041062	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.82	-0.34	3.65e-14	Colorectal cancer;
LGG	cis	rs1878931	0.580	rs7204571	chr16:3402444	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.93	19.24	0.67	4.92e-61	Body mass index (adult);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02881625	chr7:14030255	ETV1	0.38	6.77	0.3	3.84e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg24829409	chr8:58192753	C8orf71	-0.49	-7.47	-0.33	4.06e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg21659725	chr3:3221576	CRBN	-0.73	-6.71	-0.3	5.75e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9359856	0.564	rs72915944	chr6:90447226	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.68	-0.41	2.75e-20	Bipolar disorder;
LGG	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.31	0.43	1.47e-22	Lung cancer in ever smokers;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.84	0.64	1.53e-54	Platelet count;
LGG	trans	rs225245	0.782	rs225293	chr17:33925906	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.08	-0.31	5.24e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs3925075	0.966	rs11645917	chr16:31359826	C/T	cg02846316	chr16:31340340	ITGAM	0.42	8.2	0.36	2.32e-15	IgA nephropathy;
LGG	cis	rs870825	0.616	rs56844261	chr4:185632478	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	trans	rs7939886	0.841	rs79902631	chr11:55995241	A/C	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg06028605	chr16:24865363	SLC5A11	0.5	8.34	0.36	8.42e-16	Intelligence (multi-trait analysis);
LGG	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg08600765	chr20:34638493	LOC647979	-0.85	-11.35	-0.47	1.64e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	7.33e-43	Height;
LGG	cis	rs9636252	0.605	rs35267306	chr2:9276541	G/A	cg20341998	chr2:9276514	NA	0.41	8.12	0.35	4.28e-15	IgG glycosylation;
LGG	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg04986931	chr22:39850128	NA	0.34	7.66	0.34	1.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.1	0.31	4.85e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2742417	1.000	rs2742397	chr3:45758946	C/G	cg04837898	chr3:45731254	SACM1L	0.36	7.34	0.32	9.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13012494	chr21:47604986	C21orf56	0.49	8.31	0.36	1.06e-15	Testicular germ cell tumor;
LGG	cis	rs698833	0.562	rs13402006	chr2:44726040	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.41	6.65	0.3	8.44e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg01657329	chr11:68192670	LRP5	0.6	10.59	0.44	1.29e-23	Bone mineral density (spine);
LGG	cis	rs807669	0.548	rs5748028	chr22:19172281	G/A	cg02655711	chr22:19163373	SLC25A1	0.65	12.72	0.51	5.37e-32	Metabolite levels;
LGG	cis	rs4356932	1.000	rs12502834	chr4:76980499	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs7818345	1.000	rs4392916	chr8:19309355	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.73	0.3	5.13e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg13770153	chr20:60521292	NA	-0.59	-9.13	-0.39	2.12e-18	Body mass index;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.54e-22	Motion sickness;
LGG	cis	rs4262150	0.544	rs4958555	chr5:151903379	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.76	-0.48	4.13e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg15454534	chr1:248569605	OR2T1	0.38	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs7077256	0.564	rs34568091	chr10:65017242	T/C	cg02276361	chr10:65351566	REEP3	-0.33	-6.75	-0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	trans	rs4427176	0.507	rs11785987	chr8:9587894	G/A	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Mosquito bite size;
LGG	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg21605333	chr4:119757512	SEC24D	-1.44	-13.94	-0.54	3.84e-37	Cannabis dependence symptom count;
LGG	cis	rs4561483	0.831	rs2018199	chr16:11940968	C/T	cg08843971	chr16:11963173	GSPT1	-0.61	-14.42	-0.56	3.29e-39	Testicular germ cell tumor;
LGG	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg18709589	chr6:96969512	KIAA0776	-0.44	-8.69	-0.37	6.43e-17	Headache;
LGG	cis	rs9305556	0.857	rs13052028	chr21:36022287	C/T	cg24523685	chr21:36062813	CLIC6	-0.36	-6.88	-0.3	1.97e-11	Psoriasis;
LGG	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg12573674	chr2:1569213	NA	-0.56	-7.61	-0.33	1.52e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg21452805	chr1:244014465	NA	0.65	7.74	0.34	6.25e-14	RR interval (heart rate);
LGG	cis	rs2120243	0.641	rs7639254	chr3:157141041	A/G	cg24825693	chr3:157122686	VEPH1	-0.58	-13.15	-0.52	9.02e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs875971	0.545	rs12670811	chr7:65823019	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.15	0.43	5.38e-22	Aortic root size;
LGG	cis	rs10985070	0.507	rs12551347	chr9:123936594	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.04	0.35	7.8e-15	Rheumatoid arthritis;
LGG	cis	rs66716358	0.800	rs10838255	chr11:44320172	C/T	cg16977035	chr11:44330474	ALX4	-0.3	-7.33	-0.32	1.01e-12	Monobrow;
LGG	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg02269571	chr22:50332266	NA	-0.65	-9.71	-0.41	2.12e-20	Schizophrenia;
LGG	cis	rs564799	0.931	rs1651081	chr3:159732502	A/T	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg04568710	chr12:38710424	ALG10B	0.36	7.52	0.33	2.85e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.78	0.3	3.78e-11	Bladder cancer;
LGG	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-7.95	-0.35	1.41e-14	Neuroticism;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.58	-0.56	6.85e-40	Prudent dietary pattern;
LGG	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg16586182	chr3:47516702	SCAP	-0.78	-15.27	-0.58	6.04e-43	Colorectal cancer;
LGG	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg19980929	chr12:42632907	YAF2	0.38	8.57	0.37	1.57e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4906332	1.000	rs3783397	chr14:103947289	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.79e-14	Coronary artery disease;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	17.2	0.62	1.27e-51	Personality dimensions;
LGG	cis	rs41271473	0.687	rs4391637	chr1:228878379	A/C	cg16512390	chr1:228756714	NA	0.44	7.03	0.31	7.65e-12	Chronic lymphocytic leukemia;
LGG	cis	rs6719977	0.905	rs4953641	chr2:42983004	T/C	cg14631114	chr2:43023945	NA	0.41	8.64	0.37	9.09e-17	Hyperactive-impulsive symptoms;
LGG	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg07245641	chr1:182991651	LAMC1	-0.39	-8.85	-0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.14e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.83	-0.34	3.36e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.57e-13	Refractive error;
LGG	cis	rs7408868	1.000	rs7254735	chr19:15263385	A/G	cg14696996	chr19:15285081	NOTCH3	1.05	12.73	0.51	5.06e-32	Pulse pressure;
LGG	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg15208524	chr1:10270712	KIF1B	0.42	7.3	0.32	1.27e-12	Hepatocellular carcinoma;
LGG	cis	rs4704846	0.950	rs378529	chr5:156547031	A/G	cg12943317	chr5:156479607	HAVCR1	-0.52	-6.97	-0.31	1.07e-11	Blood protein levels;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.56	0.37	1.64e-16	Lung cancer;
LGG	cis	rs17253792	0.822	rs76612185	chr14:56037706	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	trans	rs853679	0.567	rs7774981	chr6:28346910	T/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.78	-0.3	3.78e-11	Depression;
LGG	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg00717180	chr2:96193071	NA	-0.41	-7.35	-0.32	8.94e-13	HDL cholesterol;
LGG	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15644404	chr18:77186268	NFATC1	-0.83	-8.93	-0.38	1.03e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg26924012	chr15:45694286	SPATA5L1	1.06	22.03	0.72	4.12e-74	Homoarginine levels;
LGG	trans	rs783540	0.967	rs2567635	chr15:83262181	T/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.38	0.32	7.6e-13	Schizophrenia;
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12034167	chr7:91875362	KRIT1;ANKIB1	0.46	7.02	0.31	7.88e-12	Gut microbiome composition (summer);
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18110333	chr6:292329	DUSP22	-0.53	-9.42	-0.4	2.2e-19	Menopause (age at onset);
LGG	cis	rs72781680	0.898	rs55761273	chr2:23957849	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.01	0.39	5.52e-18	Lymphocyte counts;
LGG	cis	rs10861342	1.000	rs10861337	chr12:105452442	G/A	cg23923672	chr12:105501055	KIAA1033	0.78	6.96	0.31	1.15e-11	IgG glycosylation;
LGG	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	cg15522984	chr1:182991683	LAMC1	0.43	8.74	0.38	4.32e-17	Colorectal cancer;
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg16301924	chr13:53314226	LECT1	-0.49	-10.08	-0.42	9.71e-22	Lewy body disease;
LGG	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.28	0.4	6.7e-19	Blood metabolite levels;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg05941027	chr17:61774174	LIMD2	0.36	8.97	0.38	7.66e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09962298	chr15:40763199	CHST14	0.45	6.78	0.3	3.77e-11	Gut microbiome composition (summer);
LGG	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg22106847	chr5:118584299	DMXL1	-0.29	-6.81	-0.3	2.95e-11	Asthma;
LGG	cis	rs1620921	0.967	rs1406891	chr6:161187080	C/T	cg01280913	chr6:161186852	NA	0.34	7.15	0.32	3.4e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.61e-21	Neuroticism;
LGG	cis	rs3771570	0.901	rs3821285	chr2:242421314	A/G	cg21155796	chr2:242212141	HDLBP	-0.58	-8.05	-0.35	7.2e-15	Prostate cancer;
LGG	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs4926611	0.798	rs4634849	chr1:54043110	C/T	cg23596471	chr1:54105337	GLIS1	0.36	7.39	0.32	7.08e-13	Hand grip strength;
LGG	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.2	-0.43	3.49e-22	Morning vs. evening chronotype;
LGG	cis	rs372883	0.967	rs2832292	chr21:30738760	C/A	cg24692254	chr21:30365293	RNF160	0.44	7.48	0.33	3.83e-13	Pancreatic cancer;
LGG	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg15208524	chr1:10270712	KIF1B	-0.4	-7.0	-0.31	9.33e-12	Hepatocellular carcinoma;
LGG	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.39	8.06	0.35	6.56e-15	Colorectal cancer;
LGG	cis	rs4664308	0.905	rs62175518	chr2:160915149	C/T	cg03641300	chr2:160917029	PLA2R1	-0.8	-16.7	-0.61	2.4e-49	Idiopathic membranous nephropathy;
LGG	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.02	0.39	4.98e-18	Neuroticism;
LGG	cis	rs7666738	0.830	rs11940273	chr4:98979965	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26842315	chr11:66036614	RAB1B	0.42	7.17	0.32	2.99e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs6728642	0.908	rs17842456	chr2:98014319	C/T	cg26665480	chr2:98280029	ACTR1B	0.73	8.38	0.36	6.34e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg02733842	chr7:1102375	C7orf50	0.66	7.76	0.34	5.37e-14	Longevity;Endometriosis;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	18.21	0.65	2.89e-56	Obesity-related traits;
LGG	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.19	-0.36	2.58e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg08222618	chr4:941054	TMEM175	0.81	19.35	0.67	1.51e-61	Sjögren's syndrome;
LGG	cis	rs6964587	0.869	rs406	chr7:91546526	C/A	cg17063962	chr7:91808500	NA	-0.45	-7.84	-0.34	3.11e-14	Breast cancer;
LGG	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg11707556	chr5:10655725	ANKRD33B	0.51	9.72	0.41	1.86e-20	Coronary artery disease;
LGG	cis	rs16837677	0.737	rs2150906	chr1:156785356	C/T	cg14991358	chr1:156767203	PRCC	0.64	6.89	0.31	1.79e-11	Sjögren's syndrome;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.51	13.38	0.53	9.91e-35	Tonsillectomy;
LGG	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg09873164	chr1:152488093	CRCT1	-0.56	-11.62	-0.48	1.51e-27	Hair morphology;
LGG	cis	rs3219090	0.962	rs2249844	chr1:226601135	A/G	cg17127702	chr1:226594323	PARP1	0.39	12.41	0.5	9.66e-31	Melanoma;
LGG	cis	rs2303319	1.000	rs75552514	chr2:162116323	A/T	cg13806767	chr2:162164127	PSMD14	-0.65	-7.54	-0.33	2.43e-13	Cognitive function;
LGG	trans	rs2574985	0.739	rs3011794	chr10:52316590	C/G	cg18558237	chr10:81444220	LOC650623	0.44	6.81	0.3	3.13e-11	Subjective well-being;
LGG	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg03433033	chr1:76189801	ACADM	0.76	13.98	0.54	2.7e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9457247	1.000	rs2769354	chr6:167379771	G/T	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.17	0.32	3e-12	Refractive error;
LGG	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-17.49	-0.63	5.95e-53	Response to antipsychotic treatment;
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.08	-0.31	5.44e-12	Bipolar disorder;
LGG	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg14154082	chr13:112174009	NA	-0.37	-8.11	-0.35	4.67e-15	Menarche (age at onset);
LGG	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.39e-34	Obesity-related traits;
LGG	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg26818010	chr10:134567672	INPP5A	0.71	11.62	0.48	1.46e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7106204	0.514	rs34587986	chr11:24253053	T/C	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.45	9.35	0.4	3.7e-19	Schizophrenia;
LGG	trans	rs9929218	1.000	rs7200690	chr16:68778457	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.53	-0.56	1.08e-39	Colorectal cancer;
LGG	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg19773385	chr1:10388646	KIF1B	-0.43	-8.46	-0.37	3.56e-16	Hepatocellular carcinoma;
LGG	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.43	-0.36	4.32e-16	Total body bone mineral density;
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg06916706	chr16:4465613	CORO7	-1.12	-22.62	-0.72	7.5e-77	Schizophrenia;
LGG	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg17201900	chr20:34330562	RBM39	0.5	6.78	0.3	3.67e-11	Total cholesterol levels;
LGG	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.98	0.35	1.19e-14	Neuroticism;
LGG	cis	rs240764	0.658	rs9399694	chr6:101257877	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	trans	rs10838798	0.504	rs7121133	chr11:48156131	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.65	-0.3	8.05e-11	Height;
LGG	cis	rs2239547	0.522	rs2581823	chr3:53022076	C/G	cg11645453	chr3:52864694	ITIH4	-0.65	-10.22	-0.43	3.06e-22	Schizophrenia;
LGG	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.39	0.36	5.83e-16	Life satisfaction;
LGG	cis	rs6815814	0.904	rs3924113	chr4:38796255	G/T	cg06935464	chr4:38784597	TLR10	0.62	8.4	0.36	5.47e-16	Breast cancer;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.7	-0.37	5.98e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9462027	0.959	rs205262	chr6:34563164	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-7.77	-0.34	5.15e-14	Systemic lupus erythematosus;
LGG	trans	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg12310025	chr6:25882481	NA	-0.37	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00149659	chr3:10157352	C3orf10	1.18	13.99	0.55	2.35e-37	Alzheimer's disease;
LGG	cis	rs6121246	0.609	rs6060843	chr20:30297047	G/C	cg13852791	chr20:30311386	BCL2L1	0.92	17.72	0.64	5.01e-54	Mean corpuscular hemoglobin;
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.07	0.39	3.35e-18	Triglycerides;
LGG	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg26384229	chr12:38710491	ALG10B	0.96	20.9	0.7	8.12e-69	Bladder cancer;
LGG	cis	rs9682041	0.866	rs6444926	chr3:170133235	T/C	cg11886554	chr3:170076028	SKIL	0.99	11.12	0.46	1.27e-25	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs11018904	0.768	rs56160356	chr11:89987280	G/C	cg27158573	chr11:89632121	NA	-0.5	-7.8	-0.34	4.19e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4789693	0.938	rs4789694	chr17:80428099	A/C	cg04308225	chr17:80449738	NA	-0.63	-9.36	-0.4	3.6e-19	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-11.98	-0.49	5.17e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.72	-0.45	4.18e-24	Longevity;Endometriosis;
LGG	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg00745463	chr17:30367425	LRRC37B	0.74	10.15	0.43	5.42e-22	Hip circumference adjusted for BMI;
LGG	cis	rs6466055	0.720	rs4730072	chr7:104832260	A/T	cg04380332	chr7:105027541	SRPK2	-0.37	-6.97	-0.31	1.13e-11	Schizophrenia;
LGG	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.01	0.42	1.8e-21	Height;
LGG	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg23029597	chr12:123009494	RSRC2	-0.92	-17.13	-0.62	2.76e-51	Body mass index;
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07685180	chr8:600429	NA	1.01	10.47	0.44	3.63e-23	IgG glycosylation;
LGG	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.29	-0.53	2.31e-34	Personality dimensions;
LGG	cis	rs7741085	0.967	rs4711795	chr6:44635929	G/A	cg18551225	chr6:44695536	NA	0.44	7.31	0.32	1.19e-12	Total body bone mineral density;
LGG	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg04731861	chr2:219085781	ARPC2	-0.49	-12.61	-0.51	1.53e-31	Colorectal cancer;
LGG	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.28	-0.43	1.84e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.75	-0.41	1.5e-20	Lung cancer;
LGG	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg20587970	chr11:113659929	NA	-1.29	-24.04	-0.75	1.77e-83	Hip circumference adjusted for BMI;
LGG	cis	rs2562456	0.833	rs2968078	chr19:21641744	A/G	cg00806126	chr19:22604979	ZNF98	0.57	8.09	0.35	5.19e-15	Pain;
LGG	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs476633	0.573	rs6492995	chr15:41529712	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-13.46	-0.53	4.31e-35	Glomerular filtration rate (creatinine);
LGG	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-22.92	-0.73	3e-78	Coronary artery disease;
LGG	cis	rs911555	0.755	rs11620897	chr14:103944861	T/G	cg24130564	chr14:104152367	KLC1	-0.39	-7.13	-0.31	3.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06850241	chr22:41845214	NA	-0.45	-6.84	-0.3	2.48e-11	Vitiligo;
LGG	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs11700980	0.636	rs116954706	chr21:30219404	T/A	cg24692254	chr21:30365293	RNF160	-0.61	-6.98	-0.31	9.99e-12	QRS complex (12-leadsum);
LGG	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-9.73	-0.41	1.83e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs490234	0.586	rs3122934	chr9:128154100	C/G	cg14078157	chr9:128172775	NA	0.43	8.14	0.35	3.6e-15	Mean arterial pressure;
LGG	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7647973	0.560	rs62262671	chr3:49649873	A/G	cg03060546	chr3:49711283	APEH	-0.64	-7.62	-0.33	1.46e-13	Menarche (age at onset);
LGG	trans	rs6787172	0.622	rs10936134	chr3:158090123	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs988958	0.567	rs11887431	chr2:42267462	C/T	cg27428208	chr2:42229179	NA	0.49	8.77	0.38	3.53e-17	Hypospadias;
LGG	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg05973401	chr12:123451056	ABCB9	0.51	7.65	0.33	1.2e-13	Neutrophil percentage of white cells;
LGG	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg02466173	chr16:30829666	NA	-0.49	-8.22	-0.36	2.12e-15	Dementia with Lewy bodies;
LGG	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg25358565	chr5:93447407	FAM172A	1.27	15.64	0.59	1.47e-44	Diabetic retinopathy;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs11112613	0.713	rs11112589	chr12:105951226	C/G	cg03607813	chr12:105948248	NA	-0.57	-10.64	-0.44	8.16e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs7267979	0.934	rs2500399	chr20:25354694	T/G	cg06421707	chr20:25228305	PYGB	-0.46	-9.97	-0.42	2.49e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4824093	0.545	rs58876234	chr22:50258868	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.94	-0.31	1.35e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3219090	0.586	rs878366	chr1:226537868	C/T	cg17127702	chr1:226594323	PARP1	-0.33	-10.29	-0.43	1.74e-22	Melanoma;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.72	0.38	5.03e-17	Lung cancer;
LGG	cis	rs6964587	0.967	rs10231350	chr7:91808499	G/T	cg17063962	chr7:91808500	NA	0.54	9.94	0.42	3.23e-21	Breast cancer;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.86	13.96	0.54	3.27e-37	Alzheimer's disease;
LGG	cis	rs6835098	0.962	rs4377567	chr4:174083590	C/G	cg08422745	chr4:174089978	GALNT7	0.85	15.48	0.58	7.06e-44	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs10504073	0.584	rs62507210	chr8:49946601	C/T	cg00325661	chr8:49890786	NA	0.78	15.22	0.58	1.07e-42	Blood metabolite ratios;
LGG	cis	rs12190007	0.508	rs7452203	chr6:169741858	C/T	cg16388071	chr6:169726476	NA	-0.51	-10.26	-0.43	2.21e-22	Obesity-related traits;
LGG	cis	rs6735179	0.729	rs2382560	chr2:1762828	A/G	cg20570797	chr2:1712800	PXDN	-0.45	-8.23	-0.36	1.92e-15	Response to antipsychotic treatment;
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg14074117	chr16:1909714	C16orf73	-0.54	-8.02	-0.35	8.53e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg05234568	chr11:5960015	NA	-0.66	-11.17	-0.46	8.04e-26	DNA methylation (variation);
LGG	cis	rs12681288	0.676	rs17740799	chr8:1014327	C/T	cg15309053	chr8:964076	NA	-0.42	-8.48	-0.37	3.01e-16	Schizophrenia;
LGG	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.83	0.34	3.36e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.37	7.25	0.32	1.81e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4356932	1.000	rs7664354	chr4:76982068	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg08888203	chr3:10149979	C3orf24	0.56	8.01	0.35	9.23e-15	Alzheimer's disease;
LGG	cis	rs11225247	1.000	rs75093003	chr11:102321675	T/C	cg06323957	chr11:102217781	BIRC2	0.77	6.72	0.3	5.38e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs2562456	0.833	rs11666525	chr19:21599305	G/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.68	-0.34	9.62e-14	Pain;
LGG	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg15704280	chr7:45808275	SEPT13	0.89	12.63	0.51	1.23e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.54	0.59	4.12e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs58616815	0.746	rs11186156	chr10:92157259	T/A	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg10792982	chr14:105748885	BRF1	0.67	13.73	0.54	3.16e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1417569	0.517	rs3006596	chr10:31181876	C/T	cg00428179	chr10:31322131	ZNF438	-0.37	-8.68	-0.37	6.76e-17	Tuberculosis;
LGG	cis	rs7168592	1.000	rs34969439	chr15:101743688	A/G	cg24254196	chr15:101719523	CHSY1	-0.64	-7.16	-0.32	3.11e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs3784262	1.000	rs3784262	chr15:58253106	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.37	-0.36	6.74e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.11	-0.31	4.52e-12	Intelligence (multi-trait analysis);
LGG	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg19418458	chr7:158789849	NA	0.45	7.1	0.31	4.68e-12	Facial morphology (factor 20);
LGG	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg14101638	chr12:121416612	HNF1A	-0.44	-9.4	-0.4	2.51e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg09361094	chr10:834503	NA	-0.28	-7.32	-0.32	1.09e-12	Survival in rectal cancer;
LGG	cis	rs4330281	0.594	rs6577618	chr3:17715648	A/T	cg20981856	chr3:17787350	NA	-0.38	-6.95	-0.31	1.27e-11	Schizophrenia;
LGG	cis	rs2933343	0.700	rs1683787	chr3:128627021	C/T	cg11901034	chr3:128598214	ACAD9	0.46	6.75	0.3	4.3e-11	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.03e-21	HDL cholesterol levels;
LGG	cis	rs7727544	0.669	rs113823725	chr5:131563501	C/G	cg07395648	chr5:131743802	NA	-0.41	-8.76	-0.38	3.79e-17	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18917495	chr2:74006961	DUSP11	0.51	8.75	0.38	4.06e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12615966	1.000	rs17030308	chr2:105385872	T/C	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg17217059	chr4:152329364	FAM160A1	0.22	7.35	0.32	9.07e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.18e-26	Personality dimensions;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg16507663	chr6:150244633	RAET1G	0.44	8.35	0.36	7.76e-16	Lung cancer;
LGG	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg18551225	chr6:44695536	NA	-0.63	-9.95	-0.42	2.79e-21	Total body bone mineral density;
LGG	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	13.96	0.54	3.29e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.5	0.33	3.35e-13	Eosinophil percentage of white cells;
LGG	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27286337	chr10:134555280	INPP5A	0.86	12.71	0.51	6.08e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.48	-0.33	3.71e-13	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs75920871	1.000	rs61905680	chr11:116836031	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.04e-12	Subjective well-being;
LGG	trans	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.94	-0.35	1.53e-14	Heart rate;
LGG	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.15e-84	Height;
LGG	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg10596483	chr8:143751796	JRK	0.51	7.88	0.34	2.32e-14	Schizophrenia;
LGG	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg12623918	chr2:306882	NA	0.38	7.1	0.31	4.67e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12220238	0.722	rs6480742	chr10:76398466	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.51	6.85	0.3	2.33e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22159483	chr17:1588198	PRPF8	0.38	6.98	0.31	1e-11	Body mass index;
LGG	cis	rs977987	0.806	rs35787595	chr16:75466847	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs745821	0.701	rs59538792	chr18:48092547	A/T	cg18923635	chr18:48083994	NA	0.44	7.8	0.34	4.09e-14	Diastolic blood pressure;
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg16339924	chr4:17578868	LAP3	0.61	10.58	0.44	1.46e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	11.0	0.46	3.81e-25	Personality dimensions;
LGG	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.63	0.37	9.71e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs67478160	0.572	rs8016014	chr14:104293798	G/C	cg26031613	chr14:104095156	KLC1	-0.43	-7.03	-0.31	7.62e-12	Schizophrenia;
LGG	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg12654349	chr5:56205094	C5orf35	-0.63	-9.95	-0.42	2.85e-21	Initial pursuit acceleration;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.93	-0.38	9.86e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg07061783	chr6:25882402	NA	-0.39	-7.01	-0.31	8.65e-12	Blood metabolite levels;
LGG	cis	rs9326248	0.813	rs7115562	chr11:117020470	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.87	0.34	2.61e-14	Blood protein levels;
LGG	cis	rs4764487	0.735	rs2072370	chr12:6345080	A/G	cg08284733	chr12:6341482	CD9	-0.37	-10.1	-0.43	8e-22	Mean platelet volume;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg11494091	chr17:61959527	GH2	0.51	8.24	0.36	1.81e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg13679303	chr9:96623674	NA	-0.39	-6.86	-0.3	2.21e-11	DNA methylation (variation);
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg18538332	chr22:24372958	LOC391322	-0.49	-7.98	-0.35	1.15e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7555523	0.887	rs2814471	chr1:165739598	C/T	cg24409356	chr1:165738333	TMCO1	0.76	9.05	0.39	3.88e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg15432903	chr11:17409602	KCNJ11	0.81	16.66	0.61	3.51e-49	Type 2 diabetes;
LGG	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	13.04	0.52	2.52e-33	Total body bone mineral density;
LGG	cis	rs4889911	0.544	rs1285273	chr17:77830885	A/G	cg07923794	chr17:77834237	NA	-0.82	-12.52	-0.5	3.54e-31	Electroencephalogram traits;
LGG	cis	rs708547	0.581	rs10020462	chr4:57825593	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.48	-7.99	-0.35	1.06e-14	Response to bleomycin (chromatid breaks);
LGG	cis	rs9463078	0.739	rs6910749	chr6:44773892	A/G	cg25276700	chr6:44698697	NA	-0.43	-9.26	-0.4	7.96e-19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg23752985	chr2:85803571	VAMP8	0.45	8.69	0.37	6.18e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg13902645	chr11:5959945	NA	-0.66	-10.33	-0.43	1.18e-22	DNA methylation (variation);
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.32	0.36	1.02e-15	Prostate cancer;
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.42	-0.4	2.07e-19	Neuroticism;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs9796	0.558	rs7166205	chr15:41514733	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-10.16	-0.43	4.85e-22	Menopause (age at onset);
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.49	-0.4	1.23e-19	IgG glycosylation;
LGG	trans	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.16	-0.32	3.15e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.29	-0.32	1.31e-12	IgG glycosylation;
LGG	cis	rs9503598	0.517	rs11242860	chr6:3463536	A/C	cg00476032	chr6:3446245	SLC22A23	0.5	9.87	0.42	5.79e-21	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg11380483	chr2:127933992	NA	0.35	6.86	0.3	2.2e-11	Self-rated health;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg14500267	chr11:67383377	NA	0.46	8.55	0.37	1.84e-16	Mean corpuscular volume;
LGG	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg12384639	chr17:618140	VPS53	0.46	8.49	0.37	2.73e-16	Prostate cancer;
LGG	cis	rs1949733	1.000	rs2631745	chr4:8490530	T/C	cg13073564	chr4:8508604	NA	0.6	12.07	0.49	2.32e-29	Response to antineoplastic agents;
LGG	trans	rs440932	1.000	rs378974	chr8:9026639	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.07	-0.31	5.76e-12	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6429082	0.633	rs1416473	chr1:235563259	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-9.03	-0.39	4.68e-18	Adiposity;
LGG	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg22509179	chr1:25234806	RUNX3	-0.66	-14.15	-0.55	4.83e-38	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17504614	0.637	rs67206190	chr2:51092192	G/A	cg23851515	chr2:51057218	NRXN1	0.41	6.7	0.3	6.19e-11	Educational attainment (years of education);
LGG	cis	rs921968	0.541	rs581013	chr2:219432040	G/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.28	-0.32	1.41e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg13256891	chr4:100009986	ADH5	0.55	9.28	0.4	6.53e-19	Smoking initiation;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg14668632	chr7:2872130	GNA12	-0.33	-7.08	-0.31	5.29e-12	Height;
LGG	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg26513180	chr16:89883248	FANCA	-0.53	-9.25	-0.39	8.42e-19	Vitiligo;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg17999865	chr3:72004944	NA	0.4	6.93	0.31	1.46e-11	Migraine with aura;
LGG	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.21e-18	Corneal astigmatism;
LGG	cis	rs975739	0.657	rs7322216	chr13:78608243	A/T	cg07847733	chr13:78271382	SLAIN1	0.47	8.12	0.35	4.15e-15	Hair color;
LGG	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg04989706	chr14:50066350	PPIL5	-0.61	-10.09	-0.42	9.07e-22	Carotid intima media thickness;
LGG	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.63	-0.44	9.3e-24	Depression;
LGG	cis	rs7843479	0.601	rs10866837	chr8:21861663	G/C	cg17168535	chr8:21777572	XPO7	0.8	15.6	0.59	2.11e-44	Mean corpuscular volume;
LGG	cis	rs2735413	0.709	rs1319049	chr16:78084610	T/G	cg04733911	chr16:78082701	NA	0.75	15.95	0.6	5.6e-46	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg08975724	chr8:8085496	FLJ10661	0.47	8.38	0.36	6.33e-16	Triglycerides;
LGG	cis	rs36051895	0.695	rs59384377	chr9:5005034	A/T	cg02405213	chr9:5042618	JAK2	-0.79	-14.23	-0.55	2.28e-38	Pediatric autoimmune diseases;
LGG	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg17644776	chr2:200775616	C2orf69	-0.65	-8.85	-0.38	1.82e-17	Schizophrenia;
LGG	cis	rs2764208	0.535	rs7751664	chr6:34681188	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.47	8.31	0.36	1.04e-15	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.54	-8.68	-0.37	7.05e-17	Bipolar disorder;
LGG	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.87	-13.59	-0.53	1.2e-35	HIV-1 control;
LGG	cis	rs17428076	0.837	rs62182430	chr2:172772837	G/A	cg21435375	chr2:172878103	MAP1D	0.42	9.47	0.4	1.49e-19	Myopia;
LGG	trans	rs2270927	0.510	rs1995381	chr5:75570658	C/T	cg13563193	chr19:33072644	PDCD5	-0.74	-9.28	-0.4	6.37e-19	Mean corpuscular volume;
LGG	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.21	-0.36	2.29e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3087591	0.683	rs10512434	chr17:29639590	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.58	-12.07	-0.49	2.36e-29	Hip circumference;
LGG	cis	rs10779751	1.000	rs2016559	chr1:11269917	G/T	cg08854313	chr1:11322531	MTOR	0.73	16.5	0.61	1.99e-48	Body mass index;
LGG	cis	rs6503525	0.628	rs62068171	chr17:38103242	G/A	cg17467752	chr17:38218738	THRA	0.47	7.83	0.34	3.47e-14	Asthma;
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs9815354	0.812	rs73073364	chr3:41843058	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg22916017	chr11:64110731	CCDC88B	0.46	9.37	0.4	3.19e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25072359	chr17:41440525	NA	0.51	9.77	0.41	1.24e-20	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23117447	chr6:34394069	RPS10	0.51	7.8	0.34	4.28e-14	Gut microbiome composition (summer);
LGG	cis	rs1371867	0.875	rs1660319	chr8:101337530	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.62	-0.37	1.07e-16	Atrioventricular conduction;
LGG	cis	rs7155454	1.000	rs8006419	chr14:65500735	C/T	cg11161011	chr14:65562177	MAX	0.42	6.87	0.3	2.14e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg15490075	chr13:100150979	NA	-0.68	-7.07	-0.31	5.58e-12	Obesity-related traits;
LGG	cis	rs1124376	1.000	rs6774367	chr3:20163077	G/A	cg05072819	chr3:20081367	KAT2B	0.6	8.12	0.35	4.35e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg06598544	chr20:61472147	COL9A3	-0.92	-10.31	-0.43	1.39e-22	Obesity-related traits;
LGG	cis	rs4262150	0.764	rs10155517	chr5:151937958	G/T	cg12297329	chr5:152029980	NA	-0.72	-13.8	-0.54	1.62e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs10875746	0.729	rs11168357	chr12:48412138	G/A	cg24011408	chr12:48396354	COL2A1	-0.51	-6.87	-0.3	2.08e-11	Longevity (90 years and older);
LGG	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.46	0.5	6.47e-31	Morning vs. evening chronotype;
LGG	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg18898632	chr2:242989856	NA	-0.72	-8.57	-0.37	1.55e-16	Obesity-related traits;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02475777	chr4:1388615	CRIPAK	0.61	10.83	0.45	1.69e-24	Longevity;
LGG	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.05e-56	Refractive error;
LGG	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-7.27	-0.32	1.55e-12	Neuroticism;
LGG	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.74e-14	Neuroticism;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg09081385	chr12:120972070	RNF10	-0.41	-7.32	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg15557168	chr22:42548783	NA	-0.34	-7.47	-0.33	4.01e-13	Cognitive function;
LGG	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg07395648	chr5:131743802	NA	-0.41	-8.8	-0.38	2.79e-17	Blood metabolite levels;
LGG	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.78	0.54	1.94e-36	Bladder cancer;
LGG	cis	rs3096299	0.585	rs3114881	chr16:89422632	T/C	cg06640241	chr16:89574553	SPG7	0.62	10.18	0.43	4.25e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg07636037	chr3:49044803	WDR6	0.6	10.27	0.43	1.99e-22	Resting heart rate;
LGG	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.48	-0.4	1.34e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.12	0.62	3e-51	Obesity-related traits;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs10046574	0.561	rs17481974	chr7:135195701	A/G	cg27474649	chr7:135195673	CNOT4	0.75	8.93	0.38	9.73e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs16854884	0.657	rs1025984	chr3:143756187	C/G	cg06585982	chr3:143692056	C3orf58	-0.61	-10.49	-0.44	3.06e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg00666640	chr1:248458726	OR2T12	0.57	9.25	0.39	8.43e-19	Common traits (Other);
LGG	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-23.89	-0.74	8.61e-83	Dental caries;
LGG	cis	rs3956705	0.762	rs13311608	chr7:32999601	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.51	-8.41	-0.36	5.08e-16	Red cell distribution width;
LGG	cis	rs6960043	0.818	rs10487796	chr7:15063430	T/A	cg19272540	chr7:15055459	NA	0.35	7.7	0.34	8.36e-14	Type 2 diabetes;
LGG	cis	rs73198271	0.515	rs11906	chr8:8641259	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	7.11	0.31	4.3e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11190604	1.000	rs3793771	chr10:102222957	C/G	cg07570687	chr10:102243282	WNT8B	0.44	7.7	0.34	8.38e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.0	0.7	2.88e-69	Bladder cancer;
LGG	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg06353428	chr16:71660113	MARVELD3	-0.56	-8.86	-0.38	1.76e-17	Blood protein levels;
LGG	cis	rs981844	0.735	rs17371573	chr4:154765216	G/A	cg14289246	chr4:154710475	SFRP2	0.67	10.91	0.45	8.1e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs752092	0.775	rs4965806	chr15:101752435	G/A	cg25114630	chr15:101792522	CHSY1	0.53	8.9	0.38	1.23e-17	Corneal structure;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01570182	chr17:44337453	NA	0.72	11.95	0.49	7.09e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10937275	0.826	rs62294592	chr3:186635584	C/T	cg24050613	chr3:186648279	ST6GAL1	0.85	8.61	0.37	1.14e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs68170813	0.523	rs7781947	chr7:106902219	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.56	-0.44	1.67e-23	Coronary artery disease;
LGG	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg26384229	chr12:38710491	ALG10B	0.74	14.83	0.57	5.44e-41	Morning vs. evening chronotype;
LGG	cis	rs2070433	0.948	rs2839304	chr21:47952650	C/G	cg12379764	chr21:47803548	PCNT	-0.61	-8.65	-0.37	8.41e-17	Lymphocyte counts;
LGG	cis	rs17453880	0.963	rs57358310	chr5:151948242	A/T	cg10931792	chr5:152022470	NA	0.38	8.02	0.35	8.75e-15	Subjective well-being;
LGG	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg06191203	chr2:152266755	RIF1	-0.47	-8.23	-0.36	1.94e-15	Lung cancer;
LGG	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg08847335	chr10:891726	LARP4B	-0.52	-9.39	-0.4	2.73e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-8.46	-0.37	3.57e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.42e-12	Total cholesterol levels;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.44	8.61	0.37	1.12e-16	Schizophrenia;
LGG	cis	rs1003719	0.715	rs9981715	chr21:38499610	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg13263323	chr15:86062960	AKAP13	-0.34	-6.91	-0.31	1.64e-11	Coronary artery disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg21325941	chr15:85923618	AKAP13	0.39	6.75	0.3	4.57e-11	Body mass index;
LGG	cis	rs2797369	0.600	rs612459	chr6:101337975	T/G	cg27451362	chr6:101846650	GRIK2	0.68	9.12	0.39	2.25e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg19168338	chr16:4465731	CORO7	-0.92	-17.76	-0.64	3.47e-54	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23088430	chr8:144679052	EEF1D;TIGD5	0.45	7.35	0.32	9.12e-13	Cognitive performance;
LGG	cis	rs3008870	0.755	rs11208974	chr1:67398119	A/T	cg02640540	chr1:67518911	SLC35D1	0.38	7.4	0.33	6.26e-13	Lymphocyte percentage of white cells;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16611736	chr16:25123254	LCMT1	0.45	7.82	0.34	3.52e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg18850127	chr7:39170497	POU6F2	0.6	14.6	0.56	5.64e-40	IgG glycosylation;
LGG	trans	rs747782	0.646	rs4752839	chr11:47495202	G/A	cg15704280	chr7:45808275	SEPT13	0.64	6.96	0.31	1.19e-11	Intraocular pressure;
LGG	cis	rs1519814	0.740	rs2326433	chr8:121043723	T/A	cg22335954	chr8:121166405	COL14A1	-0.49	-9.64	-0.41	3.8e-20	Breast cancer;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg05768032	chr16:30646687	NA	0.41	6.95	0.31	1.22e-11	Multiple myeloma;
LGG	cis	rs7095944	0.614	rs10901816	chr10:126440395	G/A	cg08799069	chr10:126477246	METTL10	-0.48	-10.78	-0.45	2.43e-24	Asthma;
LGG	trans	rs12517041	0.786	rs62342671	chr5:23246743	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-7.75	-0.34	6.03e-14	Calcium levels;
LGG	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-19.67	-0.67	4.83e-63	Heart rate;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.58	-0.37	1.46e-16	Personality dimensions;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.65	-13.3	-0.53	2.11e-34	Prudent dietary pattern;
LGG	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.59e-22	Height;
LGG	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg12463550	chr7:65579703	CRCP	-0.78	-8.38	-0.36	6.34e-16	Diabetic kidney disease;
LGG	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg23649088	chr2:200775458	C2orf69	0.58	6.83	0.3	2.71e-11	Schizophrenia;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg08916839	chr5:415575	AHRR	0.99	14.14	0.55	5.35e-38	Fat distribution (HIV);
LGG	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg12386194	chr3:101231763	SENP7	-0.56	-9.89	-0.42	4.69e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.28	0.46	3.11e-26	Mean platelet volume;
LGG	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg13010199	chr12:38710504	ALG10B	0.46	8.1	0.35	4.87e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-9.01	-0.39	5.48e-18	Total body bone mineral density;
LGG	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	11.89	0.48	1.24e-28	IgG glycosylation;
LGG	trans	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg21775007	chr8:11205619	TDH	0.44	6.91	0.31	1.63e-11	Joint mobility (Beighton score);
LGG	cis	rs1754541	0.956	rs552777	chr1:101625231	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-6.78	-0.3	3.77e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg17691542	chr6:26056736	HIST1H1C	-0.55	-9.14	-0.39	1.91e-18	Iron status biomarkers;
LGG	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.49	0.83	1.63e-121	Chronic sinus infection;
LGG	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg08461772	chr7:95026248	PON3	0.39	8.2	0.36	2.31e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg23594656	chr7:65796392	TPST1	-0.32	-6.84	-0.3	2.52e-11	Aortic root size;
LGG	trans	rs9944715	1.000	rs9944836	chr18:43831380	C/T	cg01718231	chr17:29326311	RNF135	0.42	6.7	0.3	6.2e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg27624424	chr6:160112604	SOD2	0.65	9.72	0.41	1.83e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg15971980	chr6:150254442	NA	0.45	8.5	0.37	2.62e-16	Lung cancer;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	trans	rs12517041	1.000	rs35753092	chr5:23277623	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.91	-0.45	7.8e-25	Calcium levels;
LGG	cis	rs34638952	0.577	rs11080078	chr17:27456255	C/G	cg27392559	chr17:27410759	MYO18A	0.38	7.2	0.32	2.48e-12	Sitting height ratio;
LGG	cis	rs250677	0.617	rs166106	chr5:148447061	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.92	-0.31	1.55e-11	Breast cancer;
LGG	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.02	0.42	1.56e-21	Cognitive ability;
LGG	cis	rs6882076	1.000	rs9715911	chr5:156394441	G/A	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.42	-0.47	8.79e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	3.9e-20	Schizophrenia;
LGG	trans	rs9354308	0.714	rs4710541	chr6:66584320	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg14664628	chr15:75095509	CSK	-0.56	-10.46	-0.44	3.84e-23	Breast cancer;
LGG	cis	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.43	-6.91	-0.31	1.66e-11	Educational attainment;
LGG	cis	rs12496230	1.000	rs4856828	chr3:66868008	A/T	cg17646820	chr3:66848679	NA	0.51	7.98	0.35	1.16e-14	Type 2 diabetes;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.34	0.84	3.69e-125	Prudent dietary pattern;
LGG	cis	rs1408799	0.665	rs10960779	chr9:12758881	A/G	cg05274944	chr9:12693694	TYRP1	0.34	7.94	0.35	1.54e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	15.08	0.57	4.12e-42	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7503807	0.515	rs12946206	chr17:78687270	G/T	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15097968	chr15:63449935	RPS27L	0.51	7.86	0.34	2.63e-14	Gut microbiome composition (summer);
LGG	cis	rs4631830	0.747	rs745180	chr10:51504493	A/C	cg10326726	chr10:51549505	MSMB	0.62	12.55	0.5	2.64e-31	Prostate-specific antigen levels;
LGG	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg00339695	chr16:24857497	SLC5A11	0.42	7.26	0.32	1.61e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.66	-0.69	1.07e-67	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.39	0.36	5.75e-16	Schizophrenia;
LGG	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-10.43	-0.44	4.9e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs1816752	0.905	rs4770666	chr13:24989029	T/C	cg22771759	chr13:24902376	NA	0.42	7.2	0.32	2.41e-12	Obesity-related traits;
LGG	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg06885757	chr1:42089581	HIVEP3	0.65	14.81	0.57	6.75e-41	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs2840044	1.000	rs9900378	chr17:33911302	C/T	cg19694781	chr19:47549865	TMEM160	0.55	9.06	0.39	3.55e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs12476592	0.602	rs10168545	chr2:63734284	C/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.85	-0.3	2.43e-11	Childhood ear infection;
LGG	trans	rs208520	0.874	rs208481	chr6:66922636	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.24	-0.58	8.91e-43	Exhaled nitric oxide output;
LGG	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.96	-0.35	1.35e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.57e-15	Coronary artery disease;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.18	-0.46	7.29e-26	IgG glycosylation;
LGG	trans	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs1318772	1.000	rs1318772	chr5:112723567	A/G	cg12552261	chr5:112820674	MCC	0.65	7.93	0.35	1.66e-14	F-cell distribution;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07791516	chr6:150247246	NA	0.33	6.84	0.3	2.44e-11	Lung cancer;
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg20607798	chr8:58055168	NA	-0.65	-7.64	-0.33	1.26e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	1.000	rs9876960	chr3:41985812	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10940138	0.830	rs6867554	chr5:67207725	A/G	ch.5.1281357F	chr5:67228439	NA	0.77	13.9	0.54	5.91e-37	Menarche (age at onset);
LGG	cis	rs13102973	0.640	rs10434071	chr4:135842080	C/G	cg14419869	chr4:135874104	NA	0.51	9.5	0.4	1.14e-19	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19282889	chr15:86338423	KLHL25	0.44	7.21	0.32	2.24e-12	Cognitive performance;
LGG	cis	rs8133932	0.654	rs379501	chr21:47360784	T/C	cg11214348	chr21:47283868	PCBP3	-0.4	-7.08	-0.31	5.39e-12	Schizophrenia;
LGG	cis	rs11229555	0.645	rs35735990	chr11:58187371	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7219021	0.705	rs67174000	chr17:46982380	G/A	cg16584676	chr17:46985605	UBE2Z	-0.43	-7.12	-0.31	4.21e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs4737010	0.501	rs55694640	chr8:41649439	T/G	cg17182837	chr8:41585554	ANK1	-0.54	-7.78	-0.34	4.87e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6754311	0.731	rs2322660	chr2:136557319	A/G	cg07169764	chr2:136633963	MCM6	0.74	12.56	0.5	2.46e-31	Mosquito bite size;
LGG	cis	rs17106184	1.000	rs17106235	chr1:50943370	C/G	cg07174182	chr1:51127561	FAF1	0.6	8.64	0.37	9.36e-17	Type 2 diabetes;
LGG	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.26	0.43	2.1e-22	Morning vs. evening chronotype;
LGG	cis	rs9309711	0.883	rs13429373	chr2:3477014	G/A	cg10845886	chr2:3471009	TTC15	-0.72	-14.14	-0.55	5.25e-38	Neurofibrillary tangles;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-15.59	-0.59	2.42e-44	Age at first birth;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.28	0.32	1.42e-12	Tonsillectomy;
LGG	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg15432903	chr11:17409602	KCNJ11	0.84	17.57	0.63	2.53e-53	Type 2 diabetes;
LGG	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg17202724	chr17:61916730	SMARCD2	-0.36	-7.0	-0.31	9.15e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg16141378	chr3:129829833	LOC729375	0.45	10.86	0.45	1.22e-24	Mood instability;
LGG	trans	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17763188	chr8:6692148	XKR5	0.41	6.92	0.31	1.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4919694	1.000	rs12245343	chr10:104774050	A/G	cg04362960	chr10:104952993	NT5C2	1.05	14.51	0.56	1.3e-39	Arsenic metabolism;
LGG	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs10895140	0.645	rs10750612	chr11:101519826	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.87	-0.3	2.13e-11	Menarche (age at onset);
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.68	0.37	6.9e-17	Height;
LGG	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg02002194	chr4:3960332	NA	-0.51	-10.17	-0.43	4.77e-22	Mood instability;
LGG	cis	rs12618769	0.543	rs72819980	chr2:99040522	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	1.97e-16	Bipolar disorder;
LGG	cis	rs2735413	0.918	rs12918409	chr16:78082681	G/A	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Bone mineral density;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg23758822	chr17:41437982	NA	0.9	15.27	0.58	5.98e-43	Menopause (age at onset);
LGG	cis	rs1003719	0.788	rs2835595	chr21:38466203	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg10792982	chr14:105748885	BRF1	0.67	13.91	0.54	5.22e-37	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg06521331	chr12:34319734	NA	-0.4	-7.05	-0.31	6.5e-12	Morning vs. evening chronotype;
LGG	cis	rs73416724	1.000	rs112472472	chr6:43279276	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg27129171	chr3:47204927	SETD2	0.78	15.31	0.58	4.09e-43	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23291098	chr14:68283748	ZFYVE26	0.45	7.62	0.33	1.44e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg07493874	chr5:1342172	CLPTM1L	-0.78	-14.69	-0.56	2.35e-40	Lung cancer;
LGG	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg19524238	chr7:2802976	GNA12	0.32	7.73	0.34	6.95e-14	Height;
LGG	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg25019033	chr10:957182	NA	-0.55	-10.08	-0.42	9.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg26617929	chr16:1858877	NA	0.55	7.59	0.33	1.73e-13	Insulin-like growth factors;
LGG	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg23752985	chr2:85803571	VAMP8	0.4	7.67	0.34	1.02e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.55	-0.33	2.33e-13	Total body bone mineral density;
LGG	trans	rs1422110	0.616	rs1862230	chr5:85444868	C/T	cg01787110	chr1:109008453	NBPF6	-0.69	-11.91	-0.48	9.83e-29	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg16414030	chr3:133502952	NA	0.59	10.27	0.43	1.94e-22	Iron status biomarkers;
LGG	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg06611532	chr13:114900021	NA	0.28	7.07	0.31	5.93e-12	Schizophrenia;
LGG	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.22	0.49	6.04e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs73086581	0.838	rs6052265	chr20:4026835	C/T	cg02187196	chr20:3869020	PANK2	0.66	9.52	0.4	9.96e-20	Response to antidepressants in depression;
LGG	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-19.87	-0.68	5.43e-64	Vitiligo;
LGG	trans	rs8073060	0.586	rs225291	chr17:33927126	A/G	cg19694781	chr19:47549865	TMEM160	-0.97	-15.05	-0.57	5.72e-42	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.94	0.82	8.7e-115	Cognitive function;
LGG	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg06153925	chr17:78755379	RPTOR	0.39	6.82	0.3	2.85e-11	Myopia (pathological);
LGG	cis	rs883565	0.655	rs7629839	chr3:39115294	G/A	cg01426195	chr3:39028469	NA	-0.73	-17.09	-0.62	4.21e-51	Handedness;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg07343612	chr16:622815	PIGQ	-0.76	-15.92	-0.59	8.31e-46	Height;
LGG	cis	rs13191362	0.507	rs6907151	chr6:163200701	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.64	9.22	0.39	1.05e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs526231	0.543	rs8488	chr5:102538752	T/C	cg23492399	chr5:102201601	PAM	-0.56	-8.19	-0.36	2.51e-15	Primary biliary cholangitis;
LGG	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.11	0.43	7.93e-22	Thyroid stimulating hormone;
LGG	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.17	0.39	1.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1348850	0.914	rs1453370	chr2:178327727	C/T	cg27490568	chr2:178487706	NA	0.51	10.04	0.42	1.4e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23006223	chr4:57843834	C4orf14;POLR2B	-0.4	-6.66	-0.3	7.6e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg20637307	chr2:213403960	ERBB4	0.6	10.54	0.44	2.04e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg12165864	chr7:66369176	NA	-0.46	-7.68	-0.34	9.29e-14	Corneal structure;
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg03235661	chr20:60525775	NA	0.31	7.11	0.31	4.49e-12	Obesity-related traits;
LGG	cis	rs7928758	0.848	rs56766695	chr11:134276302	A/G	cg25213107	chr11:134282864	B3GAT1	0.77	10.67	0.44	6.45e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg05527609	chr1:210001259	C1orf107	-0.54	-7.04	-0.31	7e-12	Red blood cell count;
LGG	cis	rs3741151	1.000	rs75007932	chr11:73080336	G/A	cg17517138	chr11:73019481	ARHGEF17	1.02	10.33	0.43	1.16e-22	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg04733989	chr22:42467013	NAGA	0.59	10.35	0.43	1.05e-22	Schizophrenia;
LGG	cis	rs12618769	0.597	rs72821956	chr2:99159966	G/T	cg18455616	chr2:99124870	INPP4A	0.27	7.71	0.34	7.61e-14	Bipolar disorder;
LGG	cis	rs2735413	0.599	rs79414963	chr16:78077029	T/C	cg04733911	chr16:78082701	NA	0.57	7.81	0.34	3.88e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg26384229	chr12:38710491	ALG10B	0.99	23.59	0.74	2.22e-81	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg16270222	chr17:41446396	NA	-0.29	-6.78	-0.3	3.68e-11	Menopause (age at onset);
LGG	cis	rs4789452	0.744	rs1105409	chr17:75383940	T/C	cg06761530	chr17:75373219	SEPT9	-0.36	-6.9	-0.31	1.7e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs9902453	0.780	rs62068621	chr17:28170382	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.71	0.54	3.89e-36	Coffee consumption (cups per day);
LGG	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg25718383	chr7:130020096	CPA1	0.32	8.29	0.36	1.2e-15	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs72700829	0.507	rs11204766	chr1:151018060	G/C	cg11822372	chr1:151115635	SEMA6C	-0.67	-6.99	-0.31	9.57e-12	Schizophrenia;
LGG	cis	rs597583	0.575	rs11216435	chr11:117388932	C/T	cg27161313	chr11:117392002	DSCAML1	-0.49	-8.03	-0.35	8.1e-15	Putamen volume;
LGG	cis	rs2404602	0.735	rs62028423	chr15:76754514	G/A	cg23625390	chr15:77176239	SCAPER	-0.69	-14.07	-0.55	1.1e-37	Blood metabolite levels;
LGG	trans	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg01620082	chr3:125678407	NA	-0.68	-6.84	-0.3	2.47e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg06558623	chr16:89946397	TCF25	1.13	12.3	0.5	2.8e-30	Skin colour saturation;
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07234876	chr8:600039	NA	1.39	13.2	0.52	5.38e-34	IgG glycosylation;
LGG	trans	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg00953403	chr17:74099816	EXOC7	-0.43	-7.07	-0.31	5.92e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.87	0.3	2.14e-11	Longevity;
LGG	trans	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.18	0.43	4.26e-22	Mean corpuscular volume;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07791516	chr6:150247246	NA	0.32	6.9	0.31	1.71e-11	Lung cancer;
LGG	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg07211511	chr3:129823064	LOC729375	-1.37	-22.16	-0.72	1.1e-74	Blood pressure (smoking interaction);
LGG	cis	rs6998277	0.830	rs6468836	chr8:103602630	A/G	cg10187029	chr8:103597600	NA	1.01	19.26	0.67	3.69e-61	Migraine;
LGG	cis	rs283228	1.000	rs2518176	chr6:101814160	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.82	0.38	2.36e-17	Coenzyme Q10 levels;
LGG	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg19635926	chr16:89946313	TCF25	0.7	6.71	0.3	5.73e-11	Skin colour saturation;
LGG	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg15212455	chr7:39170539	POU6F2	0.48	10.98	0.45	4.34e-25	IgG glycosylation;
LGG	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg05791153	chr7:19748676	TWISTNB	0.65	9.48	0.4	1.31e-19	Thyroid stimulating hormone;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01087382	chr6:91297190	MAP3K7	-0.46	-6.8	-0.3	3.24e-11	Systemic lupus erythematosus;
LGG	cis	rs3820068	0.705	rs2042369	chr1:15843244	A/G	cg05660106	chr1:15850417	CASP9	-1.03	-24.44	-0.75	2.52e-85	Systolic blood pressure;
LGG	cis	rs3820068	0.608	rs12091644	chr1:16044945	G/A	cg05660106	chr1:15850417	CASP9	0.75	13.74	0.54	2.76e-36	Systolic blood pressure;
LGG	cis	rs6460942	0.915	rs62448620	chr7:12458170	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.88	17.08	0.62	4.32e-51	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.82	-0.34	3.67e-14	HDL cholesterol;
LGG	cis	rs1620921	0.711	rs1652471	chr6:161254403	T/C	cg01280913	chr6:161186852	NA	-0.34	-6.96	-0.31	1.18e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg17127132	chr2:85788382	GGCX	0.48	8.37	0.36	6.68e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg10513866	chr5:139070639	NA	0.4	7.86	0.34	2.71e-14	Schizophrenia;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.79	-0.3	3.42e-11	Electroencephalogram traits;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg14346243	chr4:90757452	SNCA	-0.39	-7.89	-0.34	2.24e-14	Dementia with Lewy bodies;
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.65	-0.3	8.48e-11	Total body bone mineral density;
LGG	cis	rs11122272	0.735	rs2808601	chr1:231536571	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.71	-0.45	4.67e-24	Hemoglobin concentration;
LGG	cis	rs7726354	0.793	rs79488097	chr5:56022251	T/C	cg27303933	chr5:56029418	NA	0.53	7.55	0.33	2.33e-13	Breast cancer (early onset);
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs4330281	0.740	rs4611850	chr3:17798649	A/C	cg20981856	chr3:17787350	NA	-0.39	-7.27	-0.32	1.57e-12	Schizophrenia;
LGG	cis	rs4535700	0.504	rs66528253	chr7:55996763	C/T	cg17215666	chr7:56131930	SUMF2	-0.44	-6.75	-0.3	4.5e-11	Macular telangiectasia type 2;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24205140	chr17:41910734	MPP3	0.47	6.93	0.31	1.39e-11	Gut microbiome composition (summer);
LGG	cis	rs72781680	1.000	rs72781648	chr2:24210333	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.61e-20	Lymphocyte counts;
LGG	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	10.46	0.44	4.04e-23	Pancreatic cancer;
LGG	cis	rs2963155	0.518	rs853176	chr5:142636456	A/G	cg17617527	chr5:142782415	NR3C1	-1.0	-13.8	-0.54	1.56e-36	Breast cancer;
LGG	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg03188948	chr7:1209495	NA	0.71	9.94	0.42	3.2e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7818345	0.569	rs4317590	chr8:19357642	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.4	-8.89	-0.38	1.4e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg01943577	chr7:158741284	NA	-0.45	-8.06	-0.35	6.67e-15	Height;
LGG	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg03060546	chr3:49711283	APEH	-0.62	-8.17	-0.36	2.93e-15	Menarche (age at onset);
LGG	cis	rs7168592	1.000	rs2012387	chr15:101734080	C/T	cg24254196	chr15:101719523	CHSY1	-0.65	-7.36	-0.32	8.49e-13	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.65	-0.33	1.18e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs75804782	0.625	rs13430702	chr2:239467349	G/A	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg04000281	chr11:63949212	NA	0.34	6.77	0.3	3.87e-11	Platelet count;
LGG	cis	rs722599	0.683	rs2058918	chr14:75288518	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	8.96	0.38	8.2e-18	IgG glycosylation;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02475777	chr4:1388615	CRIPAK	0.39	7.02	0.31	8.07e-12	Longevity;
LGG	cis	rs2455799	0.634	rs1584326	chr3:15903951	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.73	-0.34	6.94e-14	Mean platelet volume;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-16.08	-0.6	1.54e-46	Platelet count;
LGG	cis	rs3806843	1.000	rs7710794	chr5:140209467	T/G	cg19875535	chr5:140030758	IK	0.5	10.33	0.43	1.17e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg13628971	chr7:2884303	GNA12	0.51	10.24	0.43	2.62e-22	Height;
LGG	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	cg15522984	chr1:182991683	LAMC1	-0.46	-9.15	-0.39	1.86e-18	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00405232	chr1:94311802	MIR760	0.43	6.72	0.3	5.32e-11	Gut microbiome composition (summer);
LGG	cis	rs12681366	0.663	rs2043987	chr8:95469693	G/C	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs2574985	0.739	rs3011789	chr10:52309404	A/C	cg18558237	chr10:81444220	LOC650623	0.43	6.69	0.3	6.64e-11	Subjective well-being;
LGG	cis	rs41271951	0.512	rs16832976	chr1:151038135	T/C	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	9.26	0.4	7.57e-19	Mood instability;
LGG	cis	rs2072732	0.861	rs1890338	chr1:2949028	C/T	cg08733933	chr1:2954429	NA	-0.42	-8.59	-0.37	1.3e-16	Plateletcrit;
LGG	cis	rs1707322	0.717	rs3014249	chr1:46079493	A/G	cg03146154	chr1:46216737	IPP	-0.56	-10.65	-0.44	8.07e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00873186	chr2:96987921	NA	0.42	6.76	0.3	4.26e-11	Cognitive performance;
LGG	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg19336497	chr11:14380999	RRAS2	0.39	7.63	0.33	1.31e-13	Mitochondrial DNA levels;
LGG	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg23517279	chr6:96025343	MANEA	0.5	6.89	0.3	1.84e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19671926	chr4:122722719	EXOSC9	0.55	8.62	0.37	1.05e-16	Type 2 diabetes;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg23758822	chr17:41437982	NA	-0.88	-16.32	-0.6	1.27e-47	Menopause (age at onset);
LGG	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06873352	chr17:61820015	STRADA	0.47	7.39	0.32	6.94e-13	Height;
LGG	cis	rs1975991	0.597	rs715790	chr3:187985004	A/G	cg17585528	chr3:187988060	LPP	0.39	7.17	0.32	3.08e-12	White matter integrity (bipolar disorder risk interaction);
LGG	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.84	-0.3	2.53e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4740619	0.716	rs1410444	chr9:15942632	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.6	-0.41	4.87e-20	Body mass index;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1.05e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.05	0.39	3.93e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.95	-0.38	8.97e-18	Aortic root size;
LGG	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg08305652	chr11:111469057	NA	0.44	8.35	0.36	7.99e-16	Primary sclerosing cholangitis;
LGG	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.92	-0.31	1.49e-11	Diastolic blood pressure;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.45	8.13	0.35	4.08e-15	Schizophrenia;
LGG	cis	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg13443165	chr9:33130375	B4GALT1	-0.6	-12.02	-0.49	3.77e-29	IgG glycosylation;
LGG	cis	rs6429082	0.875	rs2291688	chr1:235594250	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.46	-7.62	-0.33	1.44e-13	Adiposity;
LGG	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.82e-13	Restless legs syndrome;
LGG	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg18252515	chr7:66147081	NA	-1.43	-20.57	-0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs13082711	0.911	rs7644466	chr3:27515271	C/G	cg02860705	chr3:27208620	NA	0.69	12.3	0.5	2.66e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.52	-0.67	2.31e-62	Rheumatoid arthritis;
LGG	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg24375607	chr4:120327624	NA	0.59	9.99	0.42	2.09e-21	Educational attainment;
LGG	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.04	-0.31	6.92e-12	Blood metabolite levels;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.08	-0.35	5.82e-15	IgG glycosylation;
LGG	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.4	0.36	5.43e-16	Educational attainment;
LGG	cis	rs1832871	0.599	rs661857	chr6:158658788	T/C	cg07215822	chr6:158701037	NA	-0.49	-9.72	-0.41	1.96e-20	Height;
LGG	cis	rs6500395	0.926	rs1120275	chr16:48598737	T/G	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.25	-0.52	3.42e-34	Personality dimensions;
LGG	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.52e-13	Testicular germ cell tumor;
LGG	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.82	-0.38	2.29e-17	Response to antipsychotic treatment;
LGG	cis	rs3820068	0.581	rs58567918	chr1:15925823	A/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg07393940	chr7:158741817	NA	0.61	10.99	0.45	3.84e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg00857998	chr1:205179979	DSTYK	0.51	7.98	0.35	1.13e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg19700328	chr14:106028568	NA	-0.6	-10.12	-0.43	7.28e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03264133	chr6:25882463	NA	-0.95	-20.11	-0.68	4.07e-65	Urate levels;
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	8.06	0.35	6.56e-15	Personality dimensions;
LGG	cis	rs9783347	1.000	rs4150615	chr11:18365028	A/G	cg15585147	chr11:18324498	HPS5	-0.42	-8.67	-0.37	7.08e-17	Pancreatic cancer;
LGG	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg06623630	chr22:50017776	C22orf34	-0.35	-7.32	-0.32	1.11e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs3741151	0.686	rs11544310	chr11:73107592	A/G	cg17517138	chr11:73019481	ARHGEF17	0.82	8.58	0.37	1.47e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg00405596	chr8:11794950	NA	0.43	7.36	0.32	8.19e-13	Mood instability;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg09303159	chr6:26284866	NA	0.35	7.91	0.35	1.87e-14	Educational attainment;
LGG	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg03929089	chr4:120376271	NA	0.7	9.59	0.41	5.7e-20	Axial length;
LGG	cis	rs490234	0.812	rs13300639	chr9:128407298	A/G	cg14078157	chr9:128172775	NA	-0.49	-9.1	-0.39	2.59e-18	Mean arterial pressure;
LGG	cis	rs7646881	0.812	rs7636023	chr3:158460059	T/C	cg19483011	chr3:158453295	NA	-0.62	-8.34	-0.36	8.53e-16	Tetralogy of Fallot;
LGG	cis	rs8060686	0.641	rs9674047	chr16:68045046	G/A	cg27539214	chr16:67997921	SLC12A4	-0.43	-6.89	-0.3	1.88e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	trans	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg07211511	chr3:129823064	LOC729375	-0.63	-8.69	-0.37	6.13e-17	Blood pressure (smoking interaction);
LGG	cis	rs9807989	0.708	rs6543124	chr2:102987459	T/A	cg03938978	chr2:103052716	IL18RAP	0.33	7.18	0.32	2.73e-12	Asthma;
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs9783347	0.826	rs4757645	chr11:18393845	C/G	cg15585147	chr11:18324498	HPS5	-0.37	-7.78	-0.34	4.63e-14	Pancreatic cancer;
LGG	cis	rs11758351	0.500	rs17533076	chr6:26183816	G/A	cg01420254	chr6:26195488	NA	0.97	7.39	0.32	6.97e-13	Gout;Renal underexcretion gout;
LGG	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.92	0.35	1.81e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg11584989	chr19:19387371	SF4	-0.42	-7.67	-0.34	1.02e-13	Tonsillectomy;
LGG	cis	rs3733585	0.673	rs7376948	chr4:9954708	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.01	-0.35	9.25e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg08847533	chr14:75593920	NEK9	0.62	11.78	0.48	3.3e-28	Height;
LGG	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg07661805	chr8:143867942	LY6D	0.3	8.07	0.35	6.15e-15	Urinary tract infection frequency;
LGG	cis	rs9341808	0.718	rs9443734	chr6:80820293	C/T	cg08355045	chr6:80787529	NA	0.42	8.11	0.35	4.49e-15	Sitting height ratio;
LGG	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg21420622	chr7:105162941	PUS7	-0.45	-7.17	-0.32	3.02e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg06636001	chr8:8085503	FLJ10661	0.49	8.79	0.38	2.86e-17	Mood instability;
LGG	trans	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.77	-0.34	5.22e-14	Resting heart rate;
LGG	cis	rs12681366	0.636	rs1580498	chr8:95425554	C/G	cg13257157	chr8:95487014	RAD54B	-0.38	-6.88	-0.3	1.96e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4843185	0.769	rs12149168	chr16:85705611	A/C	cg26571870	chr16:85723150	GINS2	0.38	6.65	0.3	8.44e-11	Platelet distribution width;
LGG	cis	rs6445975	0.617	rs11130641	chr3:58417929	T/C	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	4.07e-17	Systemic lupus erythematosus;
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg26850624	chr5:429559	AHRR	-0.38	-7.94	-0.35	1.57e-14	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00230302	chr9:21802598	MTAP	0.42	6.93	0.31	1.42e-11	Gut microbiome composition (summer);
LGG	cis	rs151234	0.741	rs10521145	chr16:28596884	A/G	cg01378222	chr16:28622494	SULT1A1	0.71	9.88	0.42	5.16e-21	Platelet distribution width;
LGG	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.26	-0.43	2.25e-22	Total body bone mineral density;
LGG	cis	rs526231	0.543	rs34789	chr5:102460739	A/T	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg06027949	chr8:82754900	SNX16	-0.48	-7.54	-0.33	2.53e-13	Diastolic blood pressure;
LGG	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.8	0.45	2.13e-24	Rheumatoid arthritis;
LGG	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.73	0.3	4.99e-11	Depression;
LGG	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg17376030	chr22:41985996	PMM1	-0.55	-8.89	-0.38	1.41e-17	Vitiligo;
LGG	cis	rs10779751	0.960	rs1883965	chr1:11322156	A/G	cg08854313	chr1:11322531	MTOR	0.76	16.77	0.61	1.17e-49	Body mass index;
LGG	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11890956	chr21:40555474	PSMG1	-0.7	-11.63	-0.48	1.29e-27	Menarche (age at onset);
LGG	cis	rs1691799	0.899	rs1183272	chr12:66735421	T/C	cg16791601	chr12:66731901	HELB	-0.66	-15.82	-0.59	2.27e-45	White blood cell count (basophil);
LGG	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg08733933	chr1:2954429	NA	-0.41	-8.62	-0.37	1.1e-16	Plateletcrit;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs2239815	0.515	rs5762839	chr22:29231447	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.15	0.32	3.42e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs2188554	0.675	rs6963669	chr7:116990048	A/G	cg10524701	chr7:117356490	CTTNBP2	0.36	7.28	0.32	1.47e-12	Esophageal adenocarcinoma;
LGG	cis	rs1044826	0.597	rs6803593	chr3:139193987	T/C	cg15131784	chr3:139108705	COPB2	0.42	6.85	0.3	2.32e-11	Obesity-related traits;
LGG	cis	rs3206736	0.576	rs17205723	chr7:35116436	A/G	cg13400248	chr7:35225412	NA	-0.55	-9.58	-0.41	5.97e-20	Diastolic blood pressure;
LGG	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg24812749	chr6:127587940	RNF146	0.65	10.27	0.43	2e-22	Breast cancer;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	2.98e-16	Personality dimensions;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03627896	chr16:30934334	NCRNA00095	0.41	6.89	0.3	1.88e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25072359	chr17:41440525	NA	0.5	9.9	0.42	4.35e-21	Menopause (age at onset);
LGG	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs8180040	0.620	rs6442055	chr3:47110722	A/G	cg27129171	chr3:47204927	SETD2	0.82	15.13	0.58	2.57e-42	Colorectal cancer;
LGG	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg01657329	chr11:68192670	LRP5	-0.61	-10.95	-0.45	5.9e-25	Total body bone mineral density;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg03188948	chr7:1209495	NA	0.45	8.3	0.36	1.15e-15	Longevity;Endometriosis;
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg26513180	chr16:89883248	FANCA	0.62	6.73	0.3	4.92e-11	Skin colour saturation;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00689492	chr4:1303491	MAEA	-0.47	-8.09	-0.35	5.41e-15	Obesity-related traits;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg22044901	chr15:68126292	NA	-0.43	-7.91	-0.34	1.94e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg11995313	chr8:8860691	ERI1	0.45	7.45	0.33	4.52e-13	Joint mobility (Beighton score);
LGG	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg26384229	chr12:38710491	ALG10B	0.91	20.21	0.68	1.41e-65	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03576123	chr11:487126	PTDSS2	-1.33	-17.1	-0.62	3.48e-51	Body mass index;
LGG	cis	rs1829883	0.739	rs2461969	chr5:98728440	G/A	cg08333243	chr5:99726346	NA	0.34	6.69	0.3	6.33e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs8133932	0.727	rs2150453	chr21:47253215	C/T	cg11214348	chr21:47283868	PCBP3	-0.43	-7.39	-0.32	7.12e-13	Schizophrenia;
LGG	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg25019033	chr10:957182	NA	-0.54	-9.84	-0.42	6.96e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs17253792	0.545	rs34446601	chr14:56010586	A/G	cg01858014	chr14:56050164	KTN1	-0.75	-9.0	-0.39	6.05e-18	Putamen volume;
LGG	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg05234568	chr11:5960015	NA	-0.65	-10.43	-0.44	5.24e-23	DNA methylation (variation);
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.89	0.45	9.46e-25	Diabetic retinopathy;
LGG	cis	rs6456156	0.755	rs4710182	chr6:167514061	G/A	cg07741184	chr6:167504864	NA	0.4	8.92	0.38	1.06e-17	Primary biliary cholangitis;
LGG	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg17971929	chr21:40555470	PSMG1	0.7	13.07	0.52	1.85e-33	Cognitive function;
LGG	cis	rs2270450	0.959	rs6899519	chr6:46681900	T/G	cg10156739	chr6:46714674	LOC100287718	-0.36	-8.24	-0.36	1.73e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs17023223	0.581	rs2765529	chr1:119581900	C/T	cg05756136	chr1:119680316	WARS2	-0.39	-8.09	-0.35	5.28e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg13147721	chr7:65941812	NA	0.84	10.16	0.43	4.94e-22	Diabetic kidney disease;
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg19913688	chr11:428466	ANO9	-0.66	-8.46	-0.37	3.61e-16	Body mass index;
LGG	cis	rs9952991	0.566	rs579052	chr18:12858610	T/C	cg23598886	chr18:12777645	NA	0.52	7.26	0.32	1.64e-12	Inflammatory skin disease;
LGG	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26378065	chr17:18585709	ZNF286B	0.49	9.23	0.39	9.81e-19	Educational attainment (years of education);
LGG	cis	rs758324	0.812	rs13165154	chr5:131155020	C/T	cg06307176	chr5:131281290	NA	0.53	8.83	0.38	2.23e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg07052231	chr12:7363540	PEX5	0.4	7.04	0.31	7.08e-12	IgG glycosylation;
LGG	cis	rs3093024	0.904	rs3093017	chr6:167541258	C/G	cg07741184	chr6:167504864	NA	-0.36	-7.72	-0.34	7.08e-14	Rheumatoid arthritis;
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03517284	chr6:25882590	NA	-0.5	-9.35	-0.4	3.7e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-11.21	-0.46	5.6e-26	Vitamin D levels;
LGG	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08219700	chr8:58056026	NA	0.44	7.01	0.31	8.49e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.655	rs6465351	chr7:91773213	T/C	cg17063962	chr7:91808500	NA	0.55	10.53	0.44	2.1e-23	Breast cancer;
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg12395012	chr8:11607386	GATA4	0.4	6.99	0.31	9.84e-12	Myopia (pathological);
LGG	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg20578329	chr17:80767326	TBCD	-0.45	-7.76	-0.34	5.57e-14	Breast cancer;
LGG	cis	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs228437	0.913	rs73554512	chr6:134941513	G/A	cg24504307	chr6:134963096	NA	-0.41	-7.74	-0.34	6.42e-14	Melanoma;
LGG	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs944722	0.628	rs4795051	chr17:26079497	G/C	cg07704981	chr17:26127537	NOS2	-0.46	-8.11	-0.35	4.61e-15	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs17767392	0.958	rs2108049	chr14:71962394	G/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.08	0.39	3.08e-18	Mitral valve prolapse;
LGG	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.25	0.36	1.65e-15	Triglycerides;
LGG	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg08305652	chr11:111469057	NA	0.43	8.58	0.37	1.44e-16	Primary sclerosing cholangitis;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg12708336	chr17:41446283	NA	-0.3	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	13.3	0.53	2.14e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07132326	chr6:150258058	NA	0.39	8.29	0.36	1.21e-15	Testicular germ cell tumor;
LGG	cis	rs7072216	0.691	rs7910973	chr10:100166732	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.06	-0.31	6.14e-12	Metabolite levels;
LGG	cis	rs10769966	0.515	rs2568069	chr11:8977707	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.52	11.18	0.46	7.72e-26	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.49	-0.33	3.47e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9964724	0.865	rs11082011	chr18:35145122	C/T	cg27332583	chr18:35150602	NA	-0.41	-8.44	-0.37	4.11e-16	Educational attainment (years of education);
LGG	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg27587195	chr5:112824172	MCC	0.45	7.34	0.32	9.67e-13	Type 2 diabetes;
LGG	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg11764359	chr7:65958608	NA	-0.8	-14.95	-0.57	1.66e-41	Aortic root size;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg27411982	chr8:10470053	RP1L1	0.42	7.3	0.32	1.27e-12	Morning vs. evening chronotype;
LGG	cis	rs6489882	0.763	rs1859329	chr12:113376452	C/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs17125944	0.615	rs1998777	chr14:53295706	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-8.08	-0.35	5.85e-15	Alzheimer's disease (late onset);
LGG	cis	rs9611519	0.507	rs12484525	chr22:41443877	G/C	cg03806693	chr22:41940476	POLR3H	-0.48	-7.94	-0.35	1.51e-14	Neuroticism;
LGG	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-11.69	-0.48	7.57e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7911264	0.765	rs7092522	chr10:94342983	T/C	cg25093409	chr10:94429542	NA	0.46	8.84	0.38	2.03e-17	Inflammatory bowel disease;
LGG	cis	rs6445975	0.666	rs9867320	chr3:58355273	G/C	cg24175188	chr3:58374923	PXK	-0.55	-8.89	-0.38	1.35e-17	Systemic lupus erythematosus;
LGG	cis	rs8064029	0.892	rs2660226	chr16:4926726	A/G	cg04440724	chr16:4920505	UBN1	0.56	6.81	0.3	2.97e-11	Cancer;
LGG	cis	rs698813	0.703	rs2053457	chr2:44572164	C/T	cg00619915	chr2:44497795	NA	-0.5	-6.94	-0.31	1.34e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg01420254	chr6:26195488	NA	0.92	12.41	0.5	1.03e-30	Gout;Renal underexcretion gout;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.79	0.41	1.1e-20	Longevity;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg11473876	chr11:109292803	C11orf87	0.48	9.13	0.39	2.07e-18	Schizophrenia;
LGG	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg00277334	chr10:82204260	NA	-0.53	-12.58	-0.5	2.04e-31	Post bronchodilator FEV1;
LGG	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg11441379	chr12:63026424	NA	0.69	9.72	0.41	1.91e-20	IgG glycosylation;
LGG	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg15736062	chr7:158136485	PTPRN2	0.36	7.16	0.32	3.14e-12	Calcium levels;
LGG	cis	rs858239	0.632	rs7811903	chr7:23119056	A/G	cg23682824	chr7:23144976	KLHL7	0.46	7.94	0.35	1.51e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg21699342	chr2:239360505	ASB1	0.38	7.38	0.32	7.52e-13	Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg11812906	chr14:75593930	NEK9	0.47	8.67	0.37	7.38e-17	Height;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13732083	chr21:47605072	C21orf56	0.46	7.63	0.33	1.35e-13	Testicular germ cell tumor;
LGG	cis	rs7572644	0.664	rs12473340	chr2:28023797	G/A	cg27432699	chr2:27873401	GPN1	0.48	6.85	0.3	2.4e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg03576123	chr11:487126	PTDSS2	-0.51	-6.97	-0.31	1.08e-11	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.04	-0.39	4.17e-18	Life satisfaction;
LGG	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.7	0.45	5.23e-24	Blood protein levels;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.97e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg23758822	chr17:41437982	NA	0.86	15.71	0.59	7.19e-45	Menopause (age at onset);
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg03188948	chr7:1209495	NA	0.48	7.75	0.34	5.9e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21659725	chr3:3221576	CRBN	0.74	11.84	0.48	1.9e-28	Resting heart rate;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs308971	0.656	rs2648347	chr3:12057200	T/G	cg15873301	chr3:12045459	SYN2	0.54	7.92	0.35	1.79e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-6.99	-0.31	9.46e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11914070	0.860	rs62229144	chr22:18963205	C/T	cg12798833	chr22:18958832	DGCR5	-0.57	-9.4	-0.4	2.54e-19	Gait variability;
LGG	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg22852734	chr6:133119734	C6orf192	0.97	11.0	0.46	3.75e-25	Type 2 diabetes nephropathy;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05665937	chr4:1216051	CTBP1	-0.57	-10.59	-0.44	1.31e-23	Obesity-related traits;
LGG	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg18478394	chr8:109455254	TTC35	-0.39	-7.52	-0.33	2.84e-13	Dupuytren's disease;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.38e-29	Tonsillectomy;
LGG	cis	rs4664304	1.000	rs57771571	chr2:160767804	G/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.6	-0.33	1.65e-13	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09690659	chr20:33680871	TRPC4AP	0.43	6.83	0.3	2.71e-11	Cognitive performance;
LGG	trans	rs208520	0.802	rs208499	chr6:66932146	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.21	-0.58	1.14e-42	Exhaled nitric oxide output;
LGG	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg02640540	chr1:67518911	SLC35D1	-0.4	-7.12	-0.31	4.19e-12	Lymphocyte percentage of white cells;
LGG	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23598886	chr18:12777645	NA	0.75	10.48	0.44	3.41e-23	Inflammatory skin disease;
LGG	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg18064842	chr5:14874549	NA	0.36	8.22	0.36	2.14e-15	Blood metabolite levels;
LGG	trans	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg16141378	chr3:129829833	LOC729375	-0.42	-10.08	-0.42	9.5e-22	Systolic blood pressure;
LGG	cis	rs9300255	0.602	rs1569068	chr12:123632276	A/G	cg00376283	chr12:123451042	ABCB9	-0.58	-8.66	-0.37	7.66e-17	Neutrophil percentage of white cells;
LGG	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg14036092	chr11:66035641	RAB1B	0.45	7.69	0.34	8.73e-14	Gout;
LGG	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-13.19	-0.52	5.88e-34	Schizophrenia;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg12458913	chr13:53173898	NA	0.72	14.74	0.57	1.39e-40	Lewy body disease;
LGG	trans	rs9467603	1.000	rs9467600	chr6:25792768	C/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.82	-0.3	2.84e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg06606381	chr12:133084897	FBRSL1	-0.85	-7.42	-0.33	5.79e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.27	-0.4	7.26e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg20476274	chr7:133979776	SLC35B4	0.68	12.92	0.51	8.29e-33	Mean platelet volume;
LGG	cis	rs7301826	0.585	rs6486600	chr12:131292977	C/T	cg11011512	chr12:131303247	STX2	0.39	8.45	0.37	3.77e-16	Plasma plasminogen activator levels;
LGG	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08704250	chr15:31115839	NA	-0.45	-7.89	-0.34	2.17e-14	Huntington's disease progression;
LGG	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg21665744	chr7:39171113	POU6F2	0.43	8.84	0.38	1.98e-17	IgG glycosylation;
LGG	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg05768032	chr16:30646687	NA	0.41	6.89	0.3	1.84e-11	Multiple myeloma;
LGG	cis	rs6142618	0.543	rs2295036	chr20:30703596	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.28e-15	Inflammatory bowel disease;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg03709012	chr19:19516395	GATAD2A	-0.84	-16.98	-0.62	1.22e-50	Tonsillectomy;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.81	-0.41	8.98e-21	Carotid intima media thickness;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.6	-10.41	-0.44	6.27e-23	Obesity-related traits;
LGG	cis	rs5742933	0.817	rs1233299	chr2:190664638	A/C	cg04003228	chr2:190539410	ANKAR	0.47	6.93	0.31	1.39e-11	Ferritin levels;
LGG	cis	rs11514810	1.000	rs4385385	chr7:1431125	T/C	cg01003211	chr7:1472830	NA	-0.59	-8.26	-0.36	1.57e-15	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs9549367	0.756	rs9603814	chr13:113900782	C/T	cg18105134	chr13:113819100	PROZ	0.66	13.64	0.54	7.83e-36	Platelet distribution width;
LGG	cis	rs7100689	0.784	rs3802638	chr10:82179689	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	20.4	0.69	1.9e-66	Post bronchodilator FEV1;
LGG	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.49e-24	Diabetic retinopathy;
LGG	cis	rs2274273	1.000	rs6573006	chr14:55610432	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.06	0.62	5.65e-51	Protein biomarker;
LGG	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27297192	chr10:134578999	INPP5A	0.32	7.61	0.33	1.54e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg05868516	chr6:26286170	HIST1H4H	-0.46	-7.84	-0.34	3.19e-14	Educational attainment;
LGG	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg08885076	chr2:99613938	TSGA10	0.41	8.63	0.37	1.01e-16	Chronic sinus infection;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs2797369	0.609	rs645369	chr6:101413752	A/T	cg27451362	chr6:101846650	GRIK2	0.77	10.33	0.43	1.24e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs727505	1.000	rs727505	chr7:124462081	C/T	cg23710748	chr7:124431027	NA	-0.52	-10.1	-0.42	8.17e-22	Lewy body disease;
LGG	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.49e-18	Myopia (pathological);
LGG	cis	rs2798269	0.528	rs7322862	chr13:22108134	C/T	cg18095732	chr13:22033692	ZDHHC20	0.48	8.42	0.36	4.91e-16	PR segment;
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg02297831	chr4:17616191	MED28	0.5	9.24	0.39	8.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg03909863	chr11:638404	DRD4	-0.41	-6.75	-0.3	4.55e-11	Systemic lupus erythematosus;
LGG	cis	rs9976767	0.714	rs35940194	chr21:43835090	C/T	cg23042151	chr21:43824109	UBASH3A	-0.49	-9.42	-0.4	2.13e-19	Type 1 diabetes;
LGG	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.99	0.35	1.09e-14	Mean platelet volume;
LGG	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-18.75	-0.66	8.91e-59	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.73	-0.51	4.66e-32	Bipolar disorder and schizophrenia;
LGG	trans	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.03	0.39	4.49e-18	Resting heart rate;
LGG	trans	rs11875185	0.510	rs35836562	chr18:55634420	G/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg09699651	chr6:150184138	LRP11	-0.52	-9.25	-0.39	8.47e-19	Lung cancer;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg14789911	chr21:47582049	C21orf56	0.49	8.74	0.38	4.35e-17	Testicular germ cell tumor;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12862611	chr4:147443109	SLC10A7	0.4	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs36093844	0.706	rs76407487	chr11:85550632	T/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.4	-0.33	6.47e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg24642844	chr7:1081250	C7orf50	-0.46	-8.57	-0.37	1.51e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg25214090	chr10:38739885	LOC399744	0.65	11.68	0.48	8.63e-28	Corneal astigmatism;
LGG	trans	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg18187862	chr3:45730750	SACM1L	-0.43	-6.97	-0.31	1.13e-11	Primary sclerosing cholangitis;
LGG	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg20578329	chr17:80767326	TBCD	0.84	12.8	0.51	2.45e-32	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs6011368	0.840	rs6062361	chr20:62904542	C/T	cg13869341	chr1:15865	WASH5P	-0.6	-10.77	-0.45	2.76e-24	Clozapine-induced cytotoxicity;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.66	0.34	1.08e-13	Lung cancer;
LGG	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg24253500	chr15:84953950	NA	0.59	10.82	0.45	1.8e-24	Schizophrenia;
LGG	cis	rs9457247	0.529	rs6907666	chr6:167523395	A/G	cg07741184	chr6:167504864	NA	-0.4	-8.97	-0.38	7.56e-18	Crohn's disease;
LGG	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg18551225	chr6:44695536	NA	-0.71	-12.37	-0.5	1.51e-30	Total body bone mineral density;
LGG	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.29	-0.5	3.08e-30	Vitiligo;
LGG	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg04546413	chr19:29218101	NA	0.63	9.6	0.41	5.07e-20	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs12681366	0.614	rs935052	chr8:95461946	T/C	cg13257157	chr8:95487014	RAD54B	0.38	7.02	0.31	8.02e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7911264	0.739	rs6583827	chr10:94358023	A/T	cg25093409	chr10:94429542	NA	0.49	9.6	0.41	5.13e-20	Inflammatory bowel disease;
LGG	cis	rs2346177	1.000	rs2346177	chr2:46642249	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.39	-6.67	-0.3	7.24e-11	HDL cholesterol;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07400328	chr6:8064096	MUTED	0.4	6.86	0.3	2.27e-11	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24315188	chr7:77428849	PHTF2;TMEM60	0.46	7.73	0.34	6.76e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg18252515	chr7:66147081	NA	-1.41	-20.58	-0.69	2.7e-67	Diabetic kidney disease;
LGG	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg09197432	chr4:183729176	NA	0.59	7.8	0.34	4.09e-14	Pediatric autoimmune diseases;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg02951883	chr7:2050386	MAD1L1	-0.8	-17.89	-0.64	8.33e-55	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg24803719	chr17:45855879	NA	0.29	8.28	0.36	1.31e-15	IgG glycosylation;
LGG	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg26248373	chr2:1572462	NA	-0.71	-9.02	-0.39	5.2e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg26017709	chr1:43824711	CDC20	-0.34	-6.87	-0.3	2.05e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg00204512	chr16:28754710	NA	0.24	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4148087	1.000	rs4148094	chr21:43635381	C/T	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	cis	rs9372253	1.000	rs9386894	chr6:110718853	A/G	cg01119278	chr6:110721349	DDO	-0.3	-7.16	-0.32	3.11e-12	Platelet distribution width;
LGG	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg06453172	chr10:134556979	INPP5A	-0.47	-7.41	-0.33	5.84e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg24253500	chr15:84953950	NA	0.58	10.37	0.43	8.65e-23	Schizophrenia;
LGG	cis	rs2235573	0.527	rs139883	chr22:38369027	C/T	cg19171272	chr22:38449367	NA	-0.49	-8.86	-0.38	1.68e-17	Glioblastoma;Glioma;
LGG	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06634786	chr22:41940651	POLR3H	0.68	10.99	0.45	4e-25	Vitiligo;
LGG	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg18825076	chr15:78729989	IREB2	-0.48	-7.67	-0.34	1.04e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06028808	chr11:68637592	NA	0.73	12.53	0.5	3.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12464559	0.522	rs4300824	chr2:152581866	T/C	cg01189475	chr2:152685088	ARL5A	0.66	6.97	0.31	1.13e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-12.32	-0.5	2.28e-30	Menarche (age at onset);
LGG	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg01631408	chr1:248437212	OR2T33	-0.56	-10.09	-0.42	8.84e-22	Common traits (Other);
LGG	cis	rs8114671	0.967	rs9574	chr20:33764632	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.18	0.32	2.87e-12	Height;
LGG	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg24331049	chr13:111365604	ING1	0.93	17.28	0.63	5.2e-52	Coronary artery disease;
LGG	cis	rs17253792	0.822	rs78824140	chr14:56042715	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-11.44	-0.47	7.15e-27	Putamen volume;
LGG	trans	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-11.86	-0.48	1.68e-28	Neuroticism;
LGG	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.67	-0.48	9.24e-28	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14189758	chr20:36156486	BLCAP	0.46	7.78	0.34	4.66e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.66	0.3	7.59e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9309473	1.000	rs11899740	chr2:73631212	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-8.22	-0.36	2.09e-15	Metabolite levels;
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.05	-0.35	7.18e-15	Morning vs. evening chronotype;
LGG	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.52	0.47	3.48e-27	Mean platelet volume;
LGG	cis	rs4148087	0.929	rs915845	chr21:43635438	T/G	cg08841829	chr21:43638893	ABCG1	-0.65	-9.36	-0.4	3.5e-19	Eating disorder in bipolar disorder;
LGG	cis	rs2721811	0.570	rs2721803	chr7:24781532	C/T	cg06301139	chr7:24798175	DFNA5	-0.45	-8.42	-0.36	4.92e-16	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg26384229	chr12:38710491	ALG10B	-0.72	-13.66	-0.54	6.3e-36	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.929	rs12366252	chr11:48542318	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.48	-0.33	3.8e-13	HDL cholesterol;
LGG	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.2e-22	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4730250	0.707	rs257373	chr7:106798290	G/A	cg02696742	chr7:106810147	HBP1	-0.82	-11.56	-0.47	2.59e-27	Osteoarthritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26446827	chr20:18268978	ZNF133	-0.5	-7.36	-0.32	8.54e-13	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13131034	chr6:7590591	SNRNP48	0.43	6.8	0.3	3.3e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg13206674	chr6:150067644	NUP43	0.65	14.64	0.56	3.8e-40	Lung cancer;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.41	6.81	0.3	3.01e-11	Prudent dietary pattern;
LGG	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs11190604	1.000	rs12219158	chr10:102302923	T/C	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg04617936	chr2:214353	NA	0.73	10.63	0.44	9.48e-24	Suicide attempts in bipolar disorder;
LGG	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg27532318	chr7:32358331	NA	0.62	6.8	0.3	3.22e-11	Body mass index;
LGG	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg12386194	chr3:101231763	SENP7	-0.74	-12.88	-0.51	1.15e-32	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12282928	0.625	rs12276188	chr11:48350692	G/A	cg26585981	chr11:48327164	OR4S1	0.46	7.4	0.33	6.55e-13	Migraine - clinic-based;
LGG	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg15103426	chr22:29168792	CCDC117	0.41	6.68	0.3	6.8e-11	Red cell distribution width;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05857979	chr16:1031653	SOX8	0.48	7.01	0.31	8.66e-12	Hip circumference;
LGG	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg27205649	chr11:78285834	NARS2	0.49	8.46	0.37	3.47e-16	Alzheimer's disease (survival time);
LGG	cis	rs7666738	0.791	rs1115615	chr4:99006614	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg05535760	chr7:792225	HEATR2	0.81	13.13	0.52	1.08e-33	Cerebrospinal P-tau181p levels;
LGG	cis	rs8060686	0.591	rs80346622	chr16:68074419	C/T	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7928758	0.943	rs11826381	chr11:134273304	A/G	cg15243474	chr11:134282918	B3GAT1	1.03	14.53	0.56	1.17e-39	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17582259	chr17:33288330	ZNF830;CCT6B	0.47	7.2	0.32	2.48e-12	Gut microbiome composition (summer);
LGG	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg03929089	chr4:120376271	NA	-0.65	-8.16	-0.35	3.26e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs854037	0.670	rs1972768	chr5:57140067	C/T	cg08523694	chr5:57076192	NA	0.54	7.78	0.34	4.67e-14	Birth weight;
LGG	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.73	-0.38	4.57e-17	Mood instability;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg26554054	chr8:600488	NA	0.94	9.87	0.42	5.75e-21	IgG glycosylation;
LGG	trans	rs12439619	1.000	rs12439619	chr15:82546946	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-9.28	-0.4	6.8e-19	Intelligence (multi-trait analysis);
LGG	cis	rs975739	1.000	rs1279675	chr13:78389693	C/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.73	0.3	5.13e-11	Hair color;
LGG	cis	rs2075371	0.933	rs1901214	chr7:133945108	C/T	cg11752832	chr7:134001865	SLC35B4	-0.57	-10.2	-0.43	3.47e-22	Mean platelet volume;
LGG	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg14703610	chr5:56206110	C5orf35	-0.42	-7.18	-0.32	2.84e-12	Coronary artery disease;
LGG	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.21	-0.62	1.19e-51	Response to antipsychotic treatment;
LGG	trans	rs1728785	0.901	rs1103286	chr16:68578625	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg01620082	chr3:125678407	NA	-0.67	-7.12	-0.31	4.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2235642	0.821	rs2281236	chr16:1603576	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.4	0.4	2.55e-19	Coronary artery disease;
LGG	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg11764359	chr7:65958608	NA	0.81	15.05	0.57	6e-42	Aortic root size;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg00830817	chr11:109293614	C11orf87	0.42	6.94	0.31	1.35e-11	Schizophrenia;
LGG	trans	rs1997103	1.000	rs1965556	chr7:55403584	C/G	cg20935933	chr6:143382018	AIG1	0.58	9.03	0.39	4.74e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12210905	0.920	rs77380818	chr6:27305498	G/A	cg15325629	chr6:28072465	NA	0.92	7.08	0.31	5.38e-12	Hip circumference adjusted for BMI;
LGG	cis	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg06609049	chr19:2785107	THOP1	0.61	9.64	0.41	3.52e-20	Total cholesterol levels;
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.61e-12	Bipolar disorder;
LGG	cis	rs2635047	0.811	rs17785419	chr18:44765469	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.5	-8.4	-0.36	5.53e-16	Educational attainment;
LGG	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg15979348	chr13:112237479	NA	0.41	6.7	0.3	5.92e-11	Menarche (age at onset);
LGG	cis	rs36051895	0.659	rs59225790	chr9:5042757	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-15.54	-0.59	4.12e-44	Pediatric autoimmune diseases;
LGG	cis	rs283228	0.583	rs504324	chr6:101772092	A/T	cg02011392	chr6:101847541	GRIK2	0.53	7.28	0.32	1.46e-12	Coenzyme Q10 levels;
LGG	trans	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg07460842	chr6:66804631	NA	0.96	17.81	0.64	2.08e-54	Exhaled nitric oxide output;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.25	-0.32	1.76e-12	Neuroticism;
LGG	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg25823085	chr7:87105416	ABCB4	0.3	7.56	0.33	2.24e-13	Gallbladder cancer;
LGG	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg07636037	chr3:49044803	WDR6	0.93	17.79	0.64	2.48e-54	Menarche (age at onset);
LGG	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg01620082	chr3:125678407	NA	-0.82	-8.96	-0.38	8.16e-18	Depression;
LGG	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.41	0.44	5.87e-23	Arsenic metabolism;
LGG	cis	rs853679	0.517	rs17774663	chr6:28120898	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg18200150	chr17:30822561	MYO1D	0.78	17.93	0.64	5.44e-55	Schizophrenia;
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.95	-0.31	1.25e-11	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12361925	chr2:220043530	FAM134A	0.39	6.83	0.3	2.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7077256	0.564	rs12770873	chr10:65248507	A/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs57590327	0.516	rs66665538	chr3:81796391	T/A	cg07356753	chr3:81810745	GBE1	-0.5	-6.77	-0.3	3.89e-11	Extraversion;
LGG	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.55e-20	Depression;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.15	0.46	1e-25	Personality dimensions;
LGG	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg09361094	chr10:834503	NA	-0.29	-7.99	-0.35	1.11e-14	Survival in rectal cancer;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg00106254	chr7:1943704	MAD1L1	0.42	7.34	0.32	9.73e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4639966	0.836	rs7943039	chr11:118603030	G/A	cg19182353	chr11:118479428	PHLDB1	-0.57	-9.18	-0.39	1.41e-18	Systemic lupus erythematosus;
LGG	cis	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg21775007	chr8:11205619	TDH	-0.54	-7.98	-0.35	1.19e-14	Triglycerides;
LGG	trans	rs11875185	0.510	rs77043323	chr18:55593441	A/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4731207	0.698	rs7782327	chr7:124505951	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.06	0.35	6.67e-15	Diabetic kidney disease;
LGG	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg21459583	chr1:227974177	NA	0.55	7.93	0.35	1.69e-14	Major depressive disorder;
LGG	cis	rs2298450	0.550	rs7280997	chr21:37658509	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.9	-0.38	1.32e-17	Schizophrenia;
LGG	cis	rs113601626	1	rs113601626	chr2:24239189	T/TCCTGGC	cg08917208	chr2:24149416	ATAD2B	0.9	9.62	0.41	4.16e-20	Lymphocyte percentage of white cells;
LGG	cis	rs2455601	0.679	rs2653559	chr11:8900394	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-8.77	-0.38	3.43e-17	Schizophrenia;
LGG	cis	rs12618769	0.652	rs3754872	chr2:99223925	A/T	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs7143963	0.636	rs12588339	chr14:103349176	G/A	cg23020514	chr14:103360112	TRAF3	0.4	8.4	0.36	5.32e-16	Body mass index;
LGG	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.86	-0.38	1.7e-17	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09823679	chr13:53425813	NA	0.46	7.61	0.33	1.55e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7899547	0.840	rs2384045	chr10:54535862	A/G	cg27418851	chr10:54531653	MBL2	0.3	6.75	0.3	4.39e-11	Blood protein levels;
LGG	cis	rs6868223	0.531	rs12187134	chr5:33646096	G/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg10606797	chr8:23315301	ENTPD4	-0.4	-6.84	-0.3	2.54e-11	Brain structure;
LGG	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Vitiligo;
LGG	cis	rs6500395	1.000	rs904818	chr16:48622582	T/C	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.6e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs972578	1.000	rs926351	chr22:43371176	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg06521331	chr12:34319734	NA	0.5	9.32	0.4	4.92e-19	Bladder cancer;
LGG	cis	rs45544231	0.544	rs2193094	chr16:52566454	G/T	cg09051775	chr16:52580266	TOX3	0.43	7.19	0.32	2.58e-12	Restless legs syndrome;
LGG	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg21775007	chr8:11205619	TDH	-0.43	-6.98	-0.31	1.05e-11	Neuroticism;
LGG	cis	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg09264619	chr17:80180166	NA	-0.53	-10.21	-0.43	3.38e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2224391	0.628	rs2773314	chr6:5253800	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.41	-0.33	6.23e-13	Height;
LGG	cis	rs546131	0.642	rs566798	chr11:34852277	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.43	-6.88	-0.3	1.98e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs1784581	0.928	rs1789995	chr6:162396518	C/T	cg17173639	chr6:162384350	PARK2	-0.85	-21.85	-0.71	2.87e-73	Itch intensity from mosquito bite;
LGG	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00495681	chr13:53174319	NA	0.64	12.34	0.5	1.99e-30	Lewy body disease;
LGG	cis	rs2070488	0.699	rs6599205	chr3:38529440	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.57	0.56	7.23e-40	Electrocardiographic conduction measures;
LGG	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.06	-0.31	6e-12	Primary sclerosing cholangitis;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg26513180	chr16:89883248	FANCA	0.74	8.28	0.36	1.29e-15	Interleukin-17 levels;
LGG	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg01017244	chr2:74357527	NA	0.46	8.6	0.37	1.24e-16	Gestational age at birth (maternal effect);
LGG	cis	rs7517126	0.614	rs7530627	chr1:197044480	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Blood protein levels;
LGG	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg15268244	chr15:77196840	NA	-0.31	-6.92	-0.31	1.49e-11	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03826535	chr12:113659136	TPCN1;IQCD	0.42	6.7	0.3	6.03e-11	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04686994	chr5:61700164	DIMT1L	0.45	7.72	0.34	7.01e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02215898	chr6:24721656	NA	0.44	7.23	0.32	1.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg19680485	chr15:31195859	MTMR15	-0.45	-7.31	-0.32	1.21e-12	Huntington's disease progression;
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg03036210	chr16:89904091	SPIRE2	-0.6	-7.45	-0.33	4.71e-13	Skin colour saturation;
LGG	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg26818010	chr10:134567672	INPP5A	-0.71	-10.74	-0.45	3.58e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg26597838	chr10:835615	NA	0.72	10.05	0.42	1.25e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs4788570	0.566	rs8053992	chr16:71505495	G/A	cg06353428	chr16:71660113	MARVELD3	-0.86	-12.0	-0.49	4.57e-29	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.23	-0.36	1.87e-15	Triglycerides;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg12708336	chr17:41446283	NA	-0.32	-7.42	-0.33	5.6e-13	Menopause (age at onset);
LGG	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.49	0.71	1.49e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg24375607	chr4:120327624	NA	0.6	10.19	0.43	3.98e-22	Corneal astigmatism;
LGG	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-11.82	-0.48	2.35e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg04568710	chr12:38710424	ALG10B	-0.42	-8.81	-0.38	2.58e-17	Morning vs. evening chronotype;
LGG	trans	rs56804039	1.000	rs6986470	chr8:8381430	A/G	cg02002194	chr4:3960332	NA	0.43	6.93	0.31	1.38e-11	Cervical cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14733031	chr19:17904427	B3GNT3	-0.31	-6.89	-0.3	1.83e-11	Pancreatic cancer;
LGG	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg26248373	chr2:1572462	NA	-0.71	-8.56	-0.37	1.69e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg17971929	chr21:40555470	PSMG1	0.86	17.1	0.62	3.7700000000000003e-51	Cognitive function;
LGG	trans	rs6076960	0.564	rs3844457	chr20:6143379	A/G	cg17788362	chr6:86352627	SYNCRIP	0.48	8.04	0.35	7.77e-15	Smooth-surface caries;
LGG	cis	rs8141529	0.702	rs469991	chr22:29307859	G/C	cg15103426	chr22:29168792	CCDC117	-0.6	-9.16	-0.39	1.7e-18	Lymphocyte counts;
LGG	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg09252315	chr15:63414802	LACTB	-0.34	-6.72	-0.3	5.45e-11	Metabolic traits;
LGG	cis	rs4077515	0.901	rs34826348	chr9:139281570	A/C	cg21253087	chr9:139290292	SNAPC4	0.35	7.07	0.31	5.76e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg20503657	chr10:835505	NA	0.63	9.08	0.39	3.24e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16579347	chr3:155572233	SLC33A1	0.41	6.86	0.3	2.15e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1015291	0.708	rs1565592	chr12:19997502	T/G	cg25401612	chr12:20009446	NA	-0.34	-7.17	-0.32	2.94e-12	Diastolic blood pressure;
LGG	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.04	-0.31	7.07e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs1707322	0.752	rs28623463	chr1:46170758	A/C	cg03146154	chr1:46216737	IPP	0.56	10.67	0.44	6.72e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg11502198	chr6:26597334	ABT1	0.57	9.88	0.42	5.14e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.07e-17	Lung cancer;
LGG	cis	rs4911259	0.593	rs6058924	chr20:31464467	G/A	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.66	-0.48	9.88e-28	Inflammatory bowel disease;
LGG	cis	rs7572733	0.935	rs7571869	chr2:198841615	A/G	cg00792783	chr2:198669748	PLCL1	0.5	8.24	0.36	1.78e-15	Dermatomyositis;
LGG	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg02023728	chr11:77925099	USP35	0.46	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs2282802	0.660	rs6873248	chr5:139683762	A/G	cg26211634	chr5:139558579	C5orf32	-0.34	-7.63	-0.33	1.39e-13	Intelligence (multi-trait analysis);
LGG	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg20578329	chr17:80767326	TBCD	-0.46	-7.93	-0.35	1.63e-14	Breast cancer;
LGG	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg06636001	chr8:8085503	FLJ10661	0.55	9.9	0.42	4.26e-21	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13072611	chr3:133524485	SRPRB	0.42	6.83	0.3	2.63e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4742903	0.904	rs7047747	chr9:106939922	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs13082711	0.911	rs4973769	chr3:27425746	T/C	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.69e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.31	-0.32	1.15e-12	Triglycerides;
LGG	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.42	7.08	0.31	5.35e-12	HIV-1 control;
LGG	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg14416269	chr4:6271139	WFS1	0.52	9.41	0.4	2.33e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs35110281	0.693	rs3819161	chr21:45092653	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-7.49	-0.33	3.41e-13	Mean corpuscular volume;
LGG	cis	rs1832871	0.619	rs262823	chr6:158676149	G/C	cg07215822	chr6:158701037	NA	-0.5	-9.85	-0.42	6.47e-21	Height;
LGG	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg04546413	chr19:29218101	NA	0.75	12.69	0.51	7.24e-32	Methadone dose in opioid dependence;
LGG	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00294572	chr6:26285232	NA	0.42	7.47	0.33	4.01e-13	Educational attainment;
LGG	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg03342759	chr3:160939853	NMD3	0.43	7.29	0.32	1.39e-12	Morning vs. evening chronotype;
LGG	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg10253484	chr15:75165896	SCAMP2	0.49	7.9	0.34	1.98e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7226408	0.857	rs72887017	chr18:34464233	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4901847	0.967	rs12433262	chr14:58552899	T/C	cg15908186	chr14:58618357	C14orf37	0.56	9.95	0.42	2.8e-21	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg23306229	chr2:178417860	TTC30B	-0.71	-8.08	-0.35	5.76e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg14092988	chr3:52407081	DNAH1	0.24	6.66	0.3	7.92e-11	Bipolar disorder;
LGG	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.15	12.68	0.51	7.84e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.83	0.54	1.14e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4132509	1.000	rs10927067	chr1:243923244	C/T	cg21452805	chr1:244014465	NA	0.65	7.83	0.34	3.26e-14	RR interval (heart rate);
LGG	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg03060546	chr3:49711283	APEH	-0.62	-10.31	-0.43	1.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg02725872	chr8:58115012	NA	-0.9	-11.42	-0.47	9.02e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs10979	0.965	rs7754452	chr6:143889028	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs7215564	0.818	rs78905718	chr17:78604278	G/A	cg16980736	chr17:78789706	RPTOR	-0.65	-8.49	-0.37	2.76e-16	Myopia (pathological);
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg10505658	chr17:80084571	CCDC57	0.34	6.8	0.3	3.33e-11	Life satisfaction;
LGG	cis	rs6539288	0.803	rs7307895	chr12:107332126	A/C	cg26297688	chr12:107349093	C12orf23	-0.36	-6.96	-0.31	1.15e-11	Total body bone mineral density;
LGG	cis	rs2916247	1.000	rs2976512	chr8:93013459	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.523	rs10253172	chr7:106786474	C/T	cg02696742	chr7:106810147	HBP1	0.78	10.89	0.45	9.83e-25	Coronary artery disease;
LGG	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg04455712	chr21:45112962	RRP1B	-0.52	-9.5	-0.4	1.11e-19	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg07701084	chr6:150067640	NUP43	0.71	13.77	0.54	2.13e-36	Lung cancer;
LGG	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs9815354	0.812	rs73071330	chr3:41810553	T/G	cg03022575	chr3:42003672	ULK4	0.8	9.22	0.39	1.08e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.93	-0.52	7.28e-33	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.715	rs4908973	chr3:17800423	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.36	-0.32	8.24e-13	Schizophrenia;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg00993799	chr7:104653126	LOC100216545	0.52	6.66	0.3	7.78e-11	Colorectal cancer;
LGG	cis	rs1927702	0.577	rs9407656	chr9:15832086	T/A	cg14451791	chr9:16040625	NA	0.32	7.68	0.34	9.58e-14	Body mass index;
LGG	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	10.11	0.43	7.63e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7444	0.941	rs4821112	chr22:21964761	G/A	cg15846791	chr22:21984385	YDJC	-0.44	-6.73	-0.3	5.15e-11	Systemic lupus erythematosus;
LGG	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.89	-0.38	1.34e-17	Mood instability;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg13939156	chr17:80058883	NA	-0.46	-8.97	-0.38	7.18e-18	Life satisfaction;
LGG	cis	rs877426	0.681	rs877425	chr13:114833726	G/C	cg27119904	chr13:114814333	RASA3	0.36	7.36	0.32	8.32e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg05368731	chr17:41323189	NBR1	0.94	18.64	0.65	2.85e-58	Menopause (age at onset);
LGG	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.45	-0.4	1.71e-19	NT-proBNP levels in acute coronary syndrome;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg00376283	chr12:123451042	ABCB9	-0.66	-11.48	-0.47	4.96e-27	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08371160	chr22:39152076	UNC84B	0.48	7.2	0.32	2.45e-12	Gut microbiome composition (summer);
LGG	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08673615	chr1:24151775	HMGCL	0.53	7.9	0.34	2.12e-14	Gut microbiome composition (summer);
LGG	cis	rs10489167	1.000	rs589609	chr1:41137121	G/A	cg11417323	chr1:41160271	NFYC	-0.52	-7.02	-0.31	7.95e-12	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg15208524	chr1:10270712	KIF1B	0.45	8.0	0.35	9.93e-15	Hepatocellular carcinoma;
LGG	cis	rs1620921	0.594	rs2465863	chr6:161260969	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4727443	1.000	rs6974373	chr7:99590893	C/G	cg12813108	chr7:99719912	CNPY4	-0.48	-9.09	-0.39	2.84e-18	Interstitial lung disease;
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg26513180	chr16:89883248	FANCA	-0.95	-21.81	-0.71	4.35e-73	Vitiligo;
LGG	cis	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg06521331	chr12:34319734	NA	-0.59	-11.02	-0.46	3.03e-25	Morning vs. evening chronotype;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg21862992	chr11:68658383	NA	0.49	8.36	0.36	7.52e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17767392	0.881	rs35054229	chr14:71785202	T/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.12	0.39	2.39e-18	Mitral valve prolapse;
LGG	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg07636037	chr3:49044803	WDR6	-0.77	-13.2	-0.52	5.63e-34	Menarche (age at onset);
LGG	cis	rs240764	0.817	rs151573	chr6:101086333	T/C	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	4.99e-14	Neuroticism;
LGG	cis	rs5742933	0.857	rs11685425	chr2:190612703	C/T	cg10453823	chr2:190539512	ANKAR	-0.49	-7.12	-0.31	4.23e-12	Ferritin levels;
LGG	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg15490075	chr13:100150979	NA	-0.66	-6.97	-0.31	1.13e-11	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10185519	chr16:30621987	ZNF689	0.49	8.07	0.35	5.99e-15	Cognitive performance;
LGG	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg23625390	chr15:77176239	SCAPER	-0.61	-11.52	-0.47	3.42e-27	Blood metabolite levels;
LGG	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg18165381	chr3:44552316	NA	-0.41	-6.79	-0.3	3.4e-11	Depressive symptoms;
LGG	cis	rs9358372	0.555	rs11752772	chr6:20791511	A/G	cg13405222	chr6:20811065	CDKAL1	-0.45	-9.0	-0.39	5.69e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs210143	1	rs210143	chr6:33546930	T/C	cg24505687	chr6:33548425	BAK1	0.57	9.06	0.39	3.77e-18	Neutrophil percentage of granulocytes;B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);Chronic lymphocytic leukemia;
LGG	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.3	-0.36	1.15e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs870825	0.616	rs1401359	chr4:185640216	T/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs2370759	1.000	rs77165999	chr10:32577131	T/C	cg01819863	chr10:32635814	EPC1	1.12	15.69	0.59	8.92e-45	Sexual dysfunction (female);
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg13939156	chr17:80058883	NA	0.5	9.96	0.42	2.59e-21	Life satisfaction;
LGG	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.9	-0.38	1.24e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2013441	1.000	rs9905493	chr17:20188581	C/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg05535760	chr7:792225	HEATR2	0.78	12.49	0.5	4.91e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs74781061	0.929	rs1821847	chr15:74809214	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs7106204	0.668	rs7119198	chr11:24218267	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	16.5	0.61	1.98e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg02476566	chr12:106696527	TCP11L2	-0.5	-7.15	-0.32	3.4e-12	Tourette syndrome;
LGG	cis	rs7129220	0.545	rs61520995	chr11:10139467	C/T	cg01453529	chr11:10209919	SBF2	-0.42	-6.78	-0.3	3.67e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg17294928	chr15:75287854	SCAMP5	0.7	13.02	0.52	2.92e-33	Breast cancer;
LGG	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs2028299	1.000	rs3960018	chr15:90383307	A/G	cg23731826	chr15:90371692	NA	0.38	8.92	0.38	1.06e-17	Type 2 diabetes;
LGG	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.42	8.78	0.38	3.29e-17	Tonsillectomy;
LGG	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs1997103	0.906	rs6593231	chr7:55402914	T/A	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9868809	0.505	rs13316551	chr3:48745167	A/C	cg00383909	chr3:49044727	WDR6	0.92	11.38	0.47	1.31e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4538187	0.813	rs2302808	chr2:64139834	A/T	cg02541582	chr2:64069798	UGP2	-0.56	-13.13	-0.52	1.04e-33	Systolic blood pressure;
LGG	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.15	0.46	9.51e-26	Hemoglobin concentration;
LGG	cis	rs9462027	0.628	rs6942040	chr6:34761809	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs6921919	0.887	rs7766356	chr6:28400538	T/C	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.45	-0.33	4.65e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs11255291	0.668	rs6602265	chr10:7732939	A/G	cg13340899	chr10:7670827	ITIH5	0.41	7.17	0.32	2.99e-12	Ovarian reserve;
LGG	trans	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg06606381	chr12:133084897	FBRSL1	0.54	6.88	0.3	1.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg25358565	chr5:93447407	FAM172A	1.27	15.62	0.59	1.67e-44	Diabetic retinopathy;
LGG	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg20307385	chr11:47447363	PSMC3	-0.42	-6.9	-0.31	1.67e-11	Migraine - clinic-based;
LGG	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg07928641	chr1:182991847	LAMC1	-0.49	-10.13	-0.43	6.23e-22	Colorectal cancer;
LGG	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg23306229	chr2:178417860	TTC30B	0.71	8.55	0.37	1.84e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04109349	chr1:245317172	KIF26B	0.49	7.49	0.33	3.51e-13	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg03264133	chr6:25882463	NA	-0.45	-7.42	-0.33	5.56e-13	Iron status biomarkers;
LGG	cis	rs3820928	0.874	rs2272198	chr2:227893017	A/G	cg11843606	chr2:227700838	RHBDD1	0.42	7.28	0.32	1.41e-12	Pulmonary function;
LGG	cis	rs6977660	1.000	rs5017191	chr7:19820158	C/A	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg23802518	chr10:80827482	ZMIZ1;LOC283050	0.53	6.73	0.3	5.08e-11	Colorectal cancer;
LGG	cis	rs2247341	0.928	rs2854916	chr4:1721348	G/A	cg07465881	chr4:1713556	SLBP	-0.46	-7.28	-0.32	1.43e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs113835537	0.529	rs7950407	chr11:66258006	A/G	cg24851651	chr11:66362959	CCS	0.46	8.05	0.35	6.87e-15	Airway imaging phenotypes;
LGG	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05901451	chr6:126070800	HEY2	0.71	14.08	0.55	9.92e-38	Brugada syndrome;
LGG	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.34	-0.32	9.77e-13	Retinal vascular caliber;
LGG	cis	rs2797160	0.904	rs1739366	chr6:126007409	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.25	0.32	1.74e-12	Endometrial cancer;
LGG	trans	rs9409565	0.762	rs60964095	chr9:97175774	G/T	cg05679027	chr9:99775184	HIATL2	-0.49	-8.13	-0.35	3.98e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.75	0.38	4.06e-17	Educational attainment;
LGG	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	8.94	0.38	9.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg02725872	chr8:58115012	NA	-0.95	-14.1	-0.55	7.75e-38	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg15704280	chr7:45808275	SEPT13	-1.04	-23.03	-0.73	8.75e-79	Height;
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.11	-0.35	4.54e-15	Mood instability;
LGG	cis	rs6860806	0.507	rs272868	chr5:131680751	C/G	cg07395648	chr5:131743802	NA	-0.49	-9.95	-0.42	2.86e-21	Breast cancer;
LGG	cis	rs926938	0.520	rs2007231	chr1:115266306	C/T	cg12756093	chr1:115239321	AMPD1	-0.49	-8.51	-0.37	2.36e-16	Autism;
LGG	cis	rs3768617	0.811	rs11590958	chr1:183023636	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.81	0.3	2.96e-11	Fuchs's corneal dystrophy;
LGG	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg00343986	chr7:65444356	GUSB	0.39	6.69	0.3	6.49e-11	Aortic root size;
LGG	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg13232821	chr7:50628718	DDC	0.36	7.13	0.31	3.91e-12	Malaria;
LGG	cis	rs10751667	0.666	rs7123912	chr11:963936	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.45	0.37	3.74e-16	Alzheimer's disease (late onset);
LGG	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.07	0.55	1.14e-37	Colorectal cancer;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.72	-0.54	3.56e-36	Alzheimer's disease;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg24623649	chr8:11872141	NA	-0.29	-6.87	-0.3	2.06e-11	Systolic blood pressure;
LGG	cis	rs62400317	0.731	rs17288320	chr6:45338703	T/C	cg20913747	chr6:44695427	NA	-0.55	-8.32	-0.36	1e-15	Total body bone mineral density;
LGG	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg03511173	chr18:77590860	NA	0.43	7.2	0.32	2.41e-12	Schizophrenia;
LGG	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg20978937	chr14:105399321	PLD4	0.48	10.78	0.45	2.56e-24	Rheumatoid arthritis;
LGG	cis	rs13202913	0.779	rs9383896	chr6:151768495	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	6.87	0.3	2.06e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1015291	0.670	rs1492114	chr12:19995128	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs9815354	1.000	rs9866092	chr3:41895967	A/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7582720	0.943	rs72932560	chr2:203847417	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg23815491	chr16:72088622	HP	0.51	11.63	0.48	1.34e-27	Fibrinogen levels;
LGG	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg01324343	chr3:183735012	ABCC5	0.64	12.63	0.51	1.31e-31	Anterior chamber depth;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.0	-0.52	3.62e-33	Alzheimer's disease;
LGG	cis	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg04455712	chr21:45112962	RRP1B	0.51	9.59	0.41	5.34e-20	Mean corpuscular volume;
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg05484376	chr2:27715224	FNDC4	0.47	10.15	0.43	5.56e-22	Total body bone mineral density;
LGG	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg14882966	chr2:3699353	NA	0.85	8.84	0.38	1.99e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg18681998	chr4:17616180	MED28	0.84	17.71	0.64	5.92e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg05775895	chr3:12838266	CAND2	0.76	14.4	0.56	4.21e-39	QRS complex (12-leadsum);
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.52	0.47	3.51e-27	Bone mineral density;
LGG	cis	rs7717393	1.000	rs17053447	chr5:155769694	A/T	cg04435420	chr5:155754009	SGCD	-1.14	-12.82	-0.51	2.02e-32	Egg allergy;
LGG	cis	rs2991971	0.967	rs12133294	chr1:45988764	C/T	cg24296786	chr1:45957014	TESK2	0.4	7.22	0.32	2.14e-12	High light scatter reticulocyte count;
LGG	cis	rs67311347	0.544	rs6762121	chr3:40355313	G/A	cg13683864	chr3:40499215	RPL14	-0.8	-15.74	-0.59	4.83e-45	Renal cell carcinoma;
LGG	cis	rs963731	0.579	rs6758330	chr2:39288183	C/T	cg04010122	chr2:39346883	SOS1	0.67	7.38	0.32	7.63e-13	Corticobasal degeneration;
LGG	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg13009111	chr11:71350975	NA	0.4	9.18	0.39	1.46e-18	Monocyte count;
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26617929	chr16:1858877	NA	-0.61	-8.6	-0.37	1.24e-16	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg15704280	chr7:45808275	SEPT13	-0.58	-9.98	-0.42	2.23e-21	HDL cholesterol;
LGG	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg22903471	chr2:27725779	GCKR	-0.36	-8.19	-0.36	2.55e-15	Oral cavity cancer;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.52	0.37	2.21e-16	Obesity-related traits;
LGG	cis	rs988958	0.565	rs12995780	chr2:42218610	C/T	cg19376973	chr2:42229025	NA	0.65	9.31	0.4	5.08e-19	Hypospadias;
LGG	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg16339924	chr4:17578868	LAP3	-0.66	-11.36	-0.47	1.49e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg05890377	chr2:74357713	NA	0.49	9.39	0.4	2.69e-19	Gestational age at birth (maternal effect);
LGG	trans	rs6828577	0.732	rs34983100	chr4:119454442	C/T	cg26518628	chr1:97050305	NA	-0.54	-8.64	-0.37	9.26e-17	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg07930552	chr6:133119739	C6orf192	0.85	11.81	0.48	2.5e-28	Type 2 diabetes nephropathy;
LGG	cis	rs6450176	0.564	rs34360866	chr5:53332737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.23	-0.46	5e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26306683	chr17:18585705	ZNF286B	-0.43	-7.88	-0.34	2.43e-14	Pancreatic cancer;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg14668632	chr7:2872130	GNA12	-0.33	-6.92	-0.31	1.51e-11	Height;
LGG	trans	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg10756647	chr7:56101905	PSPH	0.82	9.8	0.41	9.84e-21	Diabetic kidney disease;
LGG	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg00857998	chr1:205179979	DSTYK	0.47	6.89	0.31	1.79e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg15268244	chr15:77196840	NA	0.49	10.59	0.44	1.34e-23	Blood metabolite levels;
LGG	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.53	0.72	1.89e-76	Breast cancer;
LGG	cis	rs7226408	0.857	rs11665085	chr18:34469465	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.42	-6.88	-0.3	1.95e-11	Obesity-related traits;
LGG	cis	rs6141769	0.518	rs6057620	chr20:31265165	A/G	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.05	-0.31	6.61e-12	Subjective well-being;
LGG	cis	rs4906332	0.966	rs17679729	chr14:103924312	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.99	-0.35	1.05e-14	Coronary artery disease;
LGG	cis	rs9549367	0.577	rs7335409	chr13:113810186	T/C	cg00898013	chr13:113819073	PROZ	0.43	7.54	0.33	2.54e-13	Platelet distribution width;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg08621203	chr6:150244597	RAET1G	0.4	6.8	0.3	3.2e-11	Lung cancer;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg18709589	chr6:96969512	KIAA0776	0.42	8.34	0.36	8.65e-16	Headache;
LGG	cis	rs4474465	0.915	rs10899503	chr11:78149961	C/T	cg02023728	chr11:77925099	USP35	0.4	7.1	0.31	4.63e-12	Alzheimer's disease (survival time);
LGG	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.64	0.37	9.02e-17	Alcohol dependence;
LGG	cis	rs883115	0.846	rs1566387	chr1:224803787	C/T	cg01808320	chr1:224927238	CNIH3	-0.41	-7.6	-0.33	1.72e-13	Cancer;
LGG	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11644478	chr21:40555479	PSMG1	-0.72	-12.73	-0.51	4.99e-32	Cognitive function;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.51	0.33	2.99e-13	Rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg11764359	chr7:65958608	NA	0.63	9.74	0.41	1.64e-20	Aortic root size;
LGG	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.73	0.38	4.69e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6540556	0.678	rs11119330	chr1:209889659	A/G	cg23920097	chr1:209922102	NA	-0.43	-6.95	-0.31	1.24e-11	Red blood cell count;
LGG	cis	rs17776563	0.593	rs28434391	chr15:89144730	A/G	cg05013243	chr15:89149849	MIR1179	-0.33	-6.79	-0.3	3.46e-11	Thyroid hormone levels;
LGG	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-12.76	-0.51	3.56e-32	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.3	0.47	2.5e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	6.99	0.31	9.65e-12	Longevity;
LGG	trans	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg20628663	chr10:43360327	NA	0.42	8.61	0.37	1.17e-16	Blood protein levels;
LGG	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.18e-17	Axial length;
LGG	cis	rs1650123	0.645	rs1427798	chr12:104022683	G/T	cg23227824	chr12:103980017	STAB2	0.44	7.11	0.31	4.49e-12	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05477027	chr19:46295590	DMWD	0.48	7.72	0.34	7.05e-14	Gut microbiome composition (summer);
LGG	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg18876405	chr7:65276391	NA	0.54	9.75	0.41	1.55e-20	Aortic root size;
LGG	cis	rs9733	0.680	rs3738484	chr1:150552330	G/T	cg13175981	chr1:150552382	MCL1	0.61	10.58	0.44	1.45e-23	Tonsillectomy;
LGG	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg03929089	chr4:120376271	NA	-1.03	-24.55	-0.75	7.19e-86	Height;
LGG	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg09873164	chr1:152488093	CRCT1	-0.56	-11.62	-0.48	1.47e-27	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25302936	chr8:67579596	VCPIP1	0.48	7.71	0.34	7.51e-14	Cognitive performance;
LGG	cis	rs9868809	0.505	rs11706203	chr3:48746239	T/A	cg00383909	chr3:49044727	WDR6	0.92	11.38	0.47	1.31e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7172689	1.000	rs59545248	chr15:81540430	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.11	-0.43	7.8e-22	Inattentive symptoms;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.5	-9.62	-0.41	4.3e-20	Obesity-related traits;
LGG	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg16576597	chr16:28551801	NUPR1	0.44	10.47	0.44	3.55e-23	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg11050988	chr7:1952600	MAD1L1	-0.41	-10.06	-0.42	1.17e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7010267	0.740	rs1872426	chr8:119949756	A/C	cg17171407	chr8:119960777	TNFRSF11B	-0.33	-8.19	-0.36	2.57e-15	Total body bone mineral density (age 45-60);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07031532	chr15:64995684	OAZ2	0.4	6.73	0.3	5.1e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1079204	0.536	rs10175470	chr2:219037597	T/C	cg05728596	chr2:219128475	GPBAR1	-0.63	-7.36	-0.32	8.49e-13	Smooth-surface caries;
LGG	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.25	0.36	1.63e-15	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.94e-13	Menopause (age at onset);
LGG	cis	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg21775007	chr8:11205619	TDH	-0.5	-8.03	-0.35	8.36e-15	Neuroticism;
LGG	cis	rs4799461	0.773	rs9953231	chr18:35150526	G/A	cg27332583	chr18:35150602	NA	0.66	13.49	0.53	3.35e-35	Neuroticism;
LGG	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.45	-7.13	-0.31	3.91e-12	Hip circumference adjusted for BMI;
LGG	cis	rs975722	0.564	rs34374846	chr7:117331712	G/C	cg10524701	chr7:117356490	CTTNBP2	0.5	10.23	0.43	2.78e-22	Coronary artery disease;
LGG	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg12091567	chr17:66097778	LOC651250	0.76	12.59	0.5	1.84e-31	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9636252	0.923	rs13424404	chr2:9267775	G/C	cg20341998	chr2:9276514	NA	0.38	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	cis	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg15596359	chr8:11213517	TDH	0.41	8.46	0.37	3.65e-16	Retinal vascular caliber;
LGG	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg26446133	chr18:72167187	CNDP2	-0.66	-13.52	-0.53	2.38e-35	Refractive error;
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.05	-0.31	6.48e-12	Aortic root size;
LGG	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg17077180	chr1:38461687	NA	-0.37	-7.31	-0.32	1.21e-12	Coronary artery disease;
LGG	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg14703610	chr5:56206110	C5orf35	0.42	7.24	0.32	1.88e-12	Coronary artery disease;
LGG	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg26384229	chr12:38710491	ALG10B	0.92	20.93	0.7	5.87e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.17e-19	Blood metabolite levels;
LGG	cis	rs11239187	0.530	rs10900065	chr10:45060530	C/G	cg03916630	chr10:45065415	NA	0.36	8.68	0.37	6.65e-17	Body mass index;
LGG	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.7	0.34	8.17e-14	Response to antipsychotic treatment;
LGG	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg22875332	chr1:76189707	ACADM	0.6	9.61	0.41	4.84e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg24503407	chr1:205819492	PM20D1	0.52	10.37	0.43	8.84e-23	Menarche (age at onset);
LGG	cis	rs735539	0.521	rs2031353	chr13:21380474	C/A	cg04906043	chr13:21280425	IL17D	-0.51	-8.01	-0.35	9.44e-15	Dental caries;
LGG	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg23029597	chr12:123009494	RSRC2	-0.88	-16.8	-0.62	8.29e-50	Body mass index;
LGG	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg12395012	chr8:11607386	GATA4	0.41	7.16	0.32	3.09e-12	Myopia (pathological);
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.59	9.79	0.41	1.07e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9527	0.590	rs3781282	chr10:104852419	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-10.81	-0.45	1.87e-24	Arsenic metabolism;
LGG	cis	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.1	0.39	2.6e-18	Obesity-related traits;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.44	0.33	4.79e-13	Tonsillectomy;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.85e-44	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg07382826	chr16:28625726	SULT1A1	0.36	7.34	0.32	9.62e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.78	-0.48	3.27e-28	Intelligence (multi-trait analysis);
LGG	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg15103426	chr22:29168792	CCDC117	-0.62	-8.93	-0.38	9.94e-18	Lymphocyte counts;
LGG	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.17	-0.36	2.94e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7100689	0.646	rs10749573	chr10:82136839	T/A	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.84	0.48	1.99e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.36	0.4	3.41e-19	Fuchs's corneal dystrophy;
LGG	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg15704280	chr7:45808275	SEPT13	0.94	19.39	0.67	9.59e-62	Coronary artery disease;
LGG	cis	rs4731207	0.596	rs6466963	chr7:124572288	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.24	-0.32	1.93e-12	Personality dimensions;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.9	0.34	2.11e-14	Colorectal cancer;
LGG	cis	rs6968355	0.872	rs10262447	chr7:104605104	C/G	cg03782966	chr7:104585482	NA	0.46	8.78	0.38	3.1e-17	Myopia (pathological);
LGG	cis	rs17655565	0.636	rs59951029	chr12:52716607	G/T	cg08257133	chr12:52711352	KRT83	0.56	8.42	0.36	4.88e-16	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.87	-0.45	1.12e-24	Alzheimer's disease;
LGG	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg25566285	chr7:158114605	PTPRN2	-0.96	-25.17	-0.76	9.65e-89	Calcium levels;
LGG	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg24664470	chr2:208976933	NA	0.46	8.58	0.37	1.44e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs3126085	0.877	rs4415568	chr1:152181207	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.36	-0.32	8.47e-13	Iron status biomarkers;
LGG	cis	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg22857025	chr5:266934	NA	-1.5	-25.66	-0.77	5.3e-91	Breast cancer;
LGG	cis	rs7000551	0.560	rs4872483	chr8:22255684	C/T	cg12081754	chr8:22256438	SLC39A14	1.08	25.65	0.77	5.88e-91	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7408868	1.000	rs7254269	chr19:15277429	A/T	cg14696996	chr19:15285081	NOTCH3	-1.08	-13.11	-0.52	1.35e-33	Pulse pressure;
LGG	trans	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg25825726	chr19:6230459	MLLT1	0.63	6.7	0.3	5.92e-11	Airflow obstruction;
LGG	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.4	-0.36	5.66e-16	Depression;
LGG	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-22.29	-0.72	2.7e-75	Blood trace element (Zn levels);
LGG	cis	rs765787	0.530	rs12440321	chr15:45529385	G/A	cg25801113	chr15:45476975	SHF	-0.88	-18.85	-0.66	3e-59	Uric acid levels;
LGG	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg12419862	chr22:24373484	LOC391322	-0.91	-19.61	-0.67	9.04e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg08999081	chr20:33150536	PIGU	-0.28	-6.67	-0.3	7.4e-11	Height;
LGG	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg22348356	chr13:114891224	RASA3	0.4	7.72	0.34	7.26e-14	Schizophrenia;
LGG	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg05091796	chr16:4465799	CORO7	-0.6	-9.75	-0.41	1.44e-20	Schizophrenia;
LGG	cis	rs959260	0.588	rs12938183	chr17:73320433	G/C	cg14668889	chr17:73230827	NUP85	-0.52	-8.75	-0.38	3.99e-17	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	trans	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs9398803	0.965	rs2326387	chr6:126680489	G/A	cg19875578	chr6:126661172	C6orf173	0.55	9.98	0.42	2.18e-21	Male-pattern baldness;
LGG	cis	rs10908907	0.955	rs1360200	chr9:92253118	T/C	cg01515543	chr9:92254510	LOC100129066	0.42	7.61	0.33	1.54e-13	Alcoholism (heaviness of drinking);
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg18279126	chr7:2041391	MAD1L1	0.32	6.65	0.3	8.36e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01353569	chr7:106810328	HBP1	0.47	7.6	0.33	1.61e-13	Gut microbiome composition (summer);
LGG	cis	rs4774899	1.000	rs2414490	chr15:57244711	T/C	cg08128148	chr15:57256372	TCF12	-0.33	-7.83	-0.34	3.26e-14	Urinary tract infection frequency;
LGG	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg00701064	chr4:6280414	WFS1	-0.73	-16.34	-0.6	9.72e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg22916017	chr11:64110731	CCDC88B	-0.45	-6.7	-0.3	5.99e-11	Mean platelet volume;
LGG	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg01017244	chr2:74357527	NA	0.46	8.62	0.37	1.06e-16	Gestational age at birth (maternal effect);
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg03188948	chr7:1209495	NA	0.45	8.22	0.36	2.08e-15	Longevity;Endometriosis;
LGG	cis	rs778371	0.659	rs2289911	chr2:233704252	A/G	cg08000102	chr2:233561755	GIGYF2	-0.67	-10.85	-0.45	1.38e-24	Schizophrenia;
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs3816183	1.000	rs13026205	chr2:43018087	A/C	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	9.41	0.4	2.25e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1816752	0.905	rs9511262	chr13:25012023	C/T	cg02811702	chr13:24901961	NA	0.4	7.54	0.33	2.48e-13	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.15	-0.35	3.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.69	-0.34	8.97e-14	Testicular germ cell tumor;
LGG	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18876405	chr7:65276391	NA	0.59	10.83	0.45	1.69e-24	Aortic root size;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.35	-0.32	8.9e-13	Life satisfaction;
LGG	cis	rs1670533	1.000	rs13107058	chr4:1054379	G/A	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	cis	rs41271473	0.687	rs35637401	chr1:228883578	T/C	cg00850481	chr1:228891306	NA	-0.57	-11.55	-0.47	2.75e-27	Chronic lymphocytic leukemia;
LGG	cis	rs854765	0.893	rs712265	chr17:18008447	G/A	cg04398451	chr17:18023971	MYO15A	0.66	13.79	0.54	1.69e-36	Total body bone mineral density;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg27532560	chr4:187881888	NA	-0.61	-13.82	-0.54	1.24e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1372520	0.684	rs2737010	chr4:90746466	G/A	cg15133208	chr4:90757351	SNCA	-0.4	-8.14	-0.35	3.68e-15	Neuroticism;
LGG	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21659725	chr3:3221576	CRBN	0.55	9.58	0.41	5.74e-20	Intelligence (multi-trait analysis);
LGG	trans	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg25482853	chr8:67687455	SGK3	1.06	12.58	0.5	2.08e-31	Lung disease severity in cystic fibrosis;
LGG	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg15823100	chr22:32027580	PISD	-0.65	-7.93	-0.35	1.69e-14	Age-related hearing impairment;
LGG	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg25566285	chr7:158114605	PTPRN2	0.7	11.74	0.48	4.91e-28	Response to amphetamines;
LGG	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg17809284	chr5:56205270	C5orf35	-0.66	-10.04	-0.42	1.4e-21	Initial pursuit acceleration;
LGG	cis	rs11700980	0.551	rs2832041	chr21:30116018	C/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs12458462	0.892	rs2242175	chr18:77464406	G/A	cg11879182	chr18:77439856	CTDP1	0.8	14.93	0.57	1.94e-41	Monocyte count;
LGG	cis	rs2273669	0.667	rs12195728	chr6:109278873	A/G	cg05315195	chr6:109294784	ARMC2	-0.59	-7.64	-0.33	1.25e-13	Prostate cancer;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg26554054	chr8:600488	NA	0.94	9.87	0.42	5.57e-21	IgG glycosylation;
LGG	cis	rs490234	0.702	rs4838279	chr9:128411726	G/A	cg14078157	chr9:128172775	NA	-0.54	-9.94	-0.42	3.1e-21	Mean arterial pressure;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.05e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg04287289	chr16:89883240	FANCA	0.89	8.67	0.37	7.41e-17	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg18252515	chr7:66147081	NA	-1.44	-20.46	-0.69	9.75e-67	Diabetic kidney disease;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.48	-0.37	3.01e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15532942	chr18:77220712	NFATC1	0.47	7.67	0.34	1.03e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg07234876	chr8:600039	NA	1.17	11.7	0.48	6.98e-28	IgG glycosylation;
LGG	cis	rs7267979	1.000	rs2500424	chr20:25391969	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.09	-0.42	9.01e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9393777	0.513	rs9393741	chr6:26654189	A/G	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	8.61	0.37	1.14e-16	Thyroid stimulating hormone;
LGG	cis	rs11168187	0.843	rs2239188	chr12:48117535	A/C	cg12761788	chr12:48120090	P11	-0.5	-8.68	-0.37	7.06e-17	Vertical cup-disc ratio;
LGG	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.58	-9.19	-0.39	1.36e-18	Yeast infection;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.28	0.36	1.35e-15	Longevity;
LGG	cis	rs3733585	0.673	rs10018204	chr4:9964570	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2274273	0.870	rs10149420	chr14:55854257	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.94	0.64	5.2e-55	Protein biomarker;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg04861929	chr11:109293070	C11orf87	0.84	16.62	0.61	5.39e-49	Schizophrenia;
LGG	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-8.4	-0.36	5.45e-16	Height;
LGG	cis	rs713587	0.571	rs2438679	chr2:25317653	C/T	cg04586622	chr2:25135609	ADCY3	-0.27	-6.87	-0.3	2.14e-11	Body mass index in non-asthmatics;
LGG	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg05527609	chr1:210001259	C1orf107	0.6	9.63	0.41	4.03e-20	Orofacial clefts;
LGG	cis	rs12493885	0.628	rs11925052	chr3:153645195	A/C	cg17054900	chr3:154042577	DHX36	0.51	6.65	0.3	8.14e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9948	0.881	rs7594727	chr2:97489870	A/C	cg01990225	chr2:97406019	LMAN2L	0.69	7.9	0.34	2.01e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-11.0	-0.46	3.58e-25	Schizophrenia;
LGG	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg15268244	chr15:77196840	NA	-0.31	-6.74	-0.3	4.65e-11	Blood metabolite levels;
LGG	cis	rs8056893	0.569	rs7195944	chr16:68346250	C/T	cg07273125	chr16:68295692	NA	0.4	8.61	0.37	1.12e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg01206211	chr2:36825736	FEZ2	-0.43	-8.07	-0.35	5.91e-15	Height;
LGG	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.2	-0.43	3.68e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs6942756	1.000	rs66864889	chr7:128952560	G/A	cg02491457	chr7:128862824	NA	-0.75	-13.66	-0.54	6.15e-36	White matter hyperintensity burden;
LGG	cis	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	cis	rs2798269	0.604	rs2488803	chr13:22159277	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.32	-0.32	1.12e-12	PR segment;
LGG	cis	rs2013441	1.000	rs4924810	chr17:20071819	T/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs9595066	0.712	rs4391951	chr13:44755071	C/T	cg04068111	chr13:44716778	NA	0.53	8.33	0.36	9.02e-16	Schizophrenia;
LGG	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Calcium levels;
LGG	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg16586182	chr3:47516702	SCAP	-0.58	-9.18	-0.39	1.43e-18	Birth weight;
LGG	cis	rs722599	0.683	rs11848876	chr14:75224626	C/G	cg06637938	chr14:75390232	RPS6KL1	0.54	8.75	0.38	3.92e-17	IgG glycosylation;
LGG	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg20336341	chr7:50628841	DDC	0.38	7.23	0.32	1.96e-12	Malaria;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.2	0.39	1.23e-18	Life satisfaction;
LGG	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg18681998	chr4:17616180	MED28	-0.72	-14.67	-0.56	2.68e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg16141378	chr3:129829833	LOC729375	-0.42	-10.05	-0.42	1.24e-21	Neuroticism;
LGG	cis	rs1707322	0.752	rs12027622	chr1:46130252	A/C	cg03146154	chr1:46216737	IPP	0.55	10.76	0.45	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs231513	0.871	rs231522	chr17:41954602	A/G	cg26893861	chr17:41843967	DUSP3	-0.58	-6.81	-0.3	3.03e-11	Cognitive function;
LGG	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs7112043	0.838	rs11032839	chr11:34777725	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.41	6.83	0.3	2.74e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg07636037	chr3:49044803	WDR6	0.94	20.22	0.68	1.32e-65	Menarche (age at onset);
LGG	cis	rs2285947	1.000	rs2285946	chr7:21583329	T/C	cg23045935	chr7:21583304	DNAH11	0.43	9.43	0.4	1.96e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11608355	0.618	rs2075435	chr12:109796832	C/T	cg19025524	chr12:109796872	NA	-0.6	-13.08	-0.52	1.78e-33	Neuroticism;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg15017067	chr4:17643749	FAM184B	0.31	6.97	0.31	1.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	14.01	0.55	1.97e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12681287	0.640	rs7832493	chr8:87371533	A/C	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg14993813	chr1:46806288	NSUN4	0.53	8.86	0.38	1.69e-17	Menopause (age at onset);
LGG	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg07243736	chr16:783730	NARFL	0.4	6.88	0.3	1.96e-11	Height;
LGG	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg04034577	chr2:241836375	C2orf54	-0.53	-11.12	-0.46	1.25e-25	Urinary metabolites;
LGG	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	11.59	0.47	1.93e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.84	-14.54	-0.56	1.05e-39	Gut microbiome composition (summer);
LGG	cis	rs61990749	0.597	rs1006039	chr14:78263196	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.59	-7.02	-0.31	8e-12	Fibroblast growth factor basic levels;
LGG	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg05368731	chr17:41323189	NBR1	0.89	14.07	0.55	1.05e-37	Menopause (age at onset);
LGG	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg05696931	chr1:227175867	NA	-0.42	-8.16	-0.35	3.17e-15	Myeloid white cell count;
LGG	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg25338242	chr13:114786047	RASA3	0.45	6.9	0.31	1.71e-11	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg12756686	chr19:29218302	NA	-0.71	-10.01	-0.42	1.78e-21	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg18245976	chr7:158708271	WDR60	-0.55	-9.72	-0.41	1.98e-20	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17791867	chr7:112579927	C7orf60	0.51	7.82	0.34	3.51e-14	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg03188948	chr7:1209495	NA	0.62	8.27	0.36	1.47e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-11.96	-0.49	6.41e-29	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs12282928	0.959	rs1503181	chr11:48265379	G/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.15	-0.32	3.34e-12	Migraine - clinic-based;
LGG	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg08305652	chr11:111469057	NA	0.43	8.17	0.36	2.9e-15	Primary sclerosing cholangitis;
LGG	cis	rs9296092	0.538	rs9469488	chr6:33517117	G/T	cg13560919	chr6:33536144	NA	-1.03	-20.82	-0.7	2.08e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs4629710	0.592	rs13206776	chr6:131576679	T/G	cg12606694	chr6:131520996	AKAP7	0.51	8.31	0.36	1.04e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg14541582	chr5:601475	NA	-0.56	-9.18	-0.39	1.41e-18	Obesity-related traits;
LGG	cis	rs12617721	0.874	rs3754890	chr2:99088624	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs4321325	0.733	rs4284779	chr2:127946500	T/C	cg11380483	chr2:127933992	NA	0.64	8.94	0.38	9.18e-18	Protein C levels;
LGG	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg18196295	chr10:418757	DIP2C	0.62	12.44	0.5	7.54e-31	Psychosis in Alzheimer's disease;
LGG	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs3820928	1.000	rs2163041	chr2:227772480	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.72e-12	Pulmonary function;
LGG	cis	rs208520	0.690	rs866452	chr6:66849936	A/T	cg07460842	chr6:66804631	NA	-0.97	-17.98	-0.64	3.43e-55	Exhaled nitric oxide output;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00864171	chr11:67383662	NA	0.61	10.87	0.45	1.12e-24	Mean corpuscular volume;
LGG	cis	rs9912468	0.595	rs8064837	chr17:64242703	C/G	cg19474267	chr17:64306194	PRKCA	0.69	14.36	0.56	5.89e-39	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4774830	0.590	rs62045210	chr15:56249542	A/G	cg05129572	chr15:56138634	NEDD4	0.87	7.99	0.35	1.05e-14	Delta-5 desaturase activity;
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg02002194	chr4:3960332	NA	-0.44	-8.52	-0.37	2.25e-16	Monocyte count;
LGG	cis	rs9300255	0.602	rs4372492	chr12:123697357	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg19168338	chr16:4465731	CORO7	0.89	16.36	0.61	7.94e-48	Schizophrenia;
LGG	cis	rs9583531	0.689	rs9521913	chr13:111382058	C/T	cg24331049	chr13:111365604	ING1	-0.85	-14.75	-0.57	1.25e-40	Coronary artery disease;
LGG	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.57	-0.44	1.58e-23	Depression;
LGG	cis	rs8192917	0.667	rs34037718	chr14:25066728	A/T	cg01932691	chr14:25045625	CTSG	-0.39	-6.94	-0.31	1.35e-11	Vitiligo;
LGG	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.77	-0.34	5.16e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1691799	0.899	rs1168322	chr12:66743769	C/T	cg16791601	chr12:66731901	HELB	-0.66	-15.75	-0.59	4.71e-45	White blood cell count (basophil);
LGG	cis	rs26232	0.521	rs40508	chr5:102443938	A/T	cg23492399	chr5:102201601	PAM	-0.57	-8.38	-0.36	6.2e-16	Rheumatoid arthritis;
LGG	trans	rs17685	0.725	rs6467993	chr7:75719350	G/A	cg19862616	chr7:65841803	NCRNA00174	1.08	26.08	0.77	6.23e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	7e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs397969	0.646	rs6813	chr17:19808445	C/T	cg13482628	chr17:19912719	NA	-0.48	-7.62	-0.33	1.48e-13	Platelet count;
LGG	cis	rs55883249	1.000	rs55883249	chr2:9741535	C/A	cg23886495	chr2:9695866	ADAM17	0.6	8.49	0.37	2.82e-16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs42648	0.869	rs6970376	chr7:89938086	A/G	cg25739043	chr7:89950458	NA	0.43	9.26	0.4	7.68e-19	Homocysteine levels;
LGG	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg11494091	chr17:61959527	GH2	0.6	10.18	0.43	4.39e-22	Height;
LGG	trans	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.82	-0.34	3.57e-14	Blood trace element (Cu levels);
LGG	cis	rs240764	0.658	rs12664626	chr6:101195720	A/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg07936489	chr17:37558343	FBXL20	0.97	15.04	0.57	6.28e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg22643751	chr7:855365	UNC84A	0.54	13.73	0.54	3.06e-36	Perceived unattractiveness to mosquitoes;
LGG	cis	rs504918	0.527	rs78896894	chr3:124013360	T/G	cg05766129	chr3:123988013	KALRN	-0.57	-10.23	-0.43	2.87e-22	Schizophrenia;
LGG	cis	rs12135062	1.000	rs12135062	chr1:3103312	A/C	cg00254258	chr1:3105189	PRDM16	0.66	12.13	0.49	1.37e-29	Migraine;
LGG	cis	rs4253772	0.591	rs8143066	chr22:46656607	C/T	cg24881330	chr22:46731750	TRMU	0.69	8.61	0.37	1.18e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.11	0.31	4.3e-12	Height;
LGG	cis	rs9816226	0.591	rs75135487	chr3:185805294	C/G	cg00760338	chr3:185826511	ETV5	-0.82	-10.15	-0.43	5.4e-22	Obesity;Body mass index;
LGG	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg00012203	chr2:219082015	ARPC2	0.64	11.45	0.47	6.59e-27	Colorectal cancer;
LGG	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg15596359	chr8:11213517	TDH	0.41	8.32	0.36	1.02e-15	Retinal vascular caliber;
LGG	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-8.66	-0.37	7.63e-17	Facial emotion recognition (sad faces);
LGG	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9341808	0.683	rs9359409	chr6:80826897	C/G	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.41	-0.44	5.81e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9309473	1.000	rs6736866	chr2:73661986	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.88	-0.34	2.44e-14	Metabolite levels;
LGG	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1707322	0.963	rs6666763	chr1:46436451	C/A	cg03146154	chr1:46216737	IPP	0.52	9.86	0.42	6.11e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs701145	0.585	rs1960241	chr3:153858398	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.25	0.39	8.52e-19	Mean corpuscular volume;
LGG	cis	rs1355223	0.902	rs836466	chr11:34737366	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.11	-0.31	4.51e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg13010199	chr12:38710504	ALG10B	0.61	12.74	0.51	4.46e-32	Bladder cancer;
LGG	cis	rs4148087	1.000	rs9975154	chr21:43639741	C/G	cg08841829	chr21:43638893	ABCG1	-0.67	-9.73	-0.41	1.73e-20	Eating disorder in bipolar disorder;
LGG	cis	rs225245	0.755	rs226441	chr17:34033072	C/T	cg05299278	chr17:33885742	SLFN14	0.42	8.07	0.35	6.27e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	19.98	0.68	1.68e-64	Alzheimer's disease;
LGG	cis	rs755249	0.567	rs61779300	chr1:39885763	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.45	0.33	4.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.29	-0.32	1.35e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs4622507	0.566	rs17208368	chr16:55072007	G/T	cg09947736	chr16:55091198	NA	0.76	11.51	0.47	3.91e-27	Social communication problems;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10905876	chr6:56716656	DST	0.44	7.37	0.32	8.04e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg26597838	chr10:835615	NA	0.64	9.4	0.4	2.44e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs6028335	0.867	rs58919932	chr20:37714935	T/C	cg16355469	chr20:37678765	NA	0.56	7.01	0.31	8.24e-12	Alcohol and nicotine co-dependence;
LGG	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg16141378	chr3:129829833	LOC729375	0.36	7.85	0.34	2.86e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4604732	0.631	rs56704806	chr1:247626148	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.89	0.38	1.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg07936489	chr17:37558343	FBXL20	-0.83	-15.22	-0.58	1.04e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs9831754	1.000	rs1028024	chr3:78371577	A/C	cg06138941	chr3:78371609	NA	-0.98	-20.66	-0.69	1.06e-67	Calcium levels;
LGG	cis	rs10751667	0.666	rs11246357	chr11:963980	A/C	cg22143635	chr11:980567	AP2A2	0.44	8.09	0.35	5.4e-15	Alzheimer's disease (late onset);
LGG	cis	rs4812048	0.895	rs236691	chr20:57583536	G/C	cg23907860	chr20:57583709	CTSZ	0.5	7.32	0.32	1.08e-12	Mean platelet volume;
LGG	cis	rs975722	0.638	rs2237722	chr7:117147500	C/G	cg10524701	chr7:117356490	CTTNBP2	0.45	9.74	0.41	1.65e-20	Coronary artery disease;
LGG	cis	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.74	0.41	1.64e-20	Mood instability;
LGG	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg16077055	chr2:106428750	NCK2	0.33	8.75	0.38	3.99e-17	Addiction;
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.83	0.34	3.35e-14	Rheumatoid arthritis;
LGG	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.21	-0.32	2.28e-12	Iron status biomarkers;
LGG	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg00012203	chr2:219082015	ARPC2	0.78	14.9	0.57	2.76e-41	Colorectal cancer;
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg15147215	chr3:52552868	STAB1	-0.4	-7.92	-0.35	1.78e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg17802220	chr15:77601643	NA	-0.38	-8.26	-0.36	1.5e-15	Type 2 diabetes;
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg17328964	chr8:145687451	CYHR1	0.43	7.63	0.33	1.34e-13	Age at first birth;
LGG	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg27427491	chr17:78079615	GAA	-0.28	-6.69	-0.3	6.49e-11	Yeast infection;
LGG	cis	rs2797369	0.571	rs9498487	chr6:101523663	G/A	cg27451362	chr6:101846650	GRIK2	-0.72	-10.56	-0.44	1.69e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs1707322	0.752	rs28890893	chr1:46186576	T/G	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.89	0.34	2.28e-14	Life satisfaction;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00149659	chr3:10157352	C3orf10	0.84	10.75	0.45	3.25e-24	Alzheimer's disease;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg15145174	chr5:6755386	POLS	-0.39	-7.07	-0.31	5.78e-12	Menopause (age at onset);
LGG	cis	rs9811920	0.809	rs4928235	chr3:99706870	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-8.9	-0.38	1.29e-17	Axial length;
LGG	cis	rs10773046	0.740	rs1882489	chr12:124364441	T/A	cg18594669	chr12:124364423	DNAH10	0.34	6.8	0.3	3.28e-11	Osteoarthritis (hip);
LGG	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg14088196	chr11:70211408	PPFIA1	0.84	11.72	0.48	5.97e-28	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.91e-15	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.33e-18	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.33e-17	Lung cancer;
LGG	cis	rs6964587	1.000	rs17164275	chr7:91590408	A/G	cg17063962	chr7:91808500	NA	0.48	8.63	0.37	9.93e-17	Breast cancer;
LGG	cis	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg19399532	chr1:178512495	C1orf220	0.42	8.18	0.36	2.76e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs17021463	0.673	rs4699459	chr4:95292702	G/A	cg11021082	chr4:95130006	SMARCAD1	0.39	6.81	0.3	3.07e-11	Testicular germ cell tumor;
LGG	cis	rs3087591	0.960	rs2905869	chr17:29519016	C/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.37	0.56	5.69e-39	Hip circumference;
LGG	cis	rs1519814	0.654	rs6469882	chr8:121010471	A/G	cg22335954	chr8:121166405	COL14A1	-0.47	-8.37	-0.36	7.12e-16	Breast cancer;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs7166081	1.000	rs12915085	chr15:67522138	C/G	cg18050959	chr15:68126178	NA	-0.37	-6.75	-0.3	4.54e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.43	-0.33	5.41e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg04181038	chr4:183730758	NA	0.59	8.52	0.37	2.19e-16	Pediatric autoimmune diseases;
LGG	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-14.45	-0.56	2.49e-39	Headache;
LGG	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.61	10.33	0.43	1.19e-22	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17996757	chr7:131013207	MKLN1	0.46	7.76	0.34	5.67e-14	Cognitive performance;
LGG	cis	rs9487094	0.670	rs114261376	chr6:109923358	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.02	0.35	8.96e-15	Height;
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg18258770	chr4:90757814	SNCA	-0.41	-7.46	-0.33	4.36e-13	Dementia with Lewy bodies;
LGG	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.61e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14240646	chr10:27532245	ACBD5	-0.68	-10.61	-0.44	1.12e-23	Breast cancer;
LGG	cis	rs3540	0.512	rs17263706	chr15:91078803	G/T	cg22089800	chr15:90895588	ZNF774	0.66	12.18	0.49	8.54e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs72827839	0.779	rs72823592	chr17:46123004	G/A	cg02219949	chr17:45927392	SP6	0.45	7.17	0.32	3.06e-12	Ease of getting up in the morning;
LGG	cis	rs7552404	0.889	rs1250874	chr1:76190978	A/G	cg22875332	chr1:76189707	ACADM	0.61	10.91	0.45	7.86e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.69	0.34	9.11e-14	Depressive symptoms;
LGG	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg15736062	chr7:158136485	PTPRN2	0.38	7.42	0.33	5.52e-13	Calcium levels;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg21724239	chr8:58056113	NA	0.44	6.83	0.3	2.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.53	-0.4	9.21e-20	Life satisfaction;
LGG	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.66	-0.48	1.01e-27	Mean platelet volume;
LGG	cis	rs3741151	0.773	rs73542960	chr11:73115946	T/C	cg17517138	chr11:73019481	ARHGEF17	0.87	8.66	0.37	8.08e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg13010199	chr12:38710504	ALG10B	0.66	13.73	0.54	3.02e-36	Bladder cancer;
LGG	cis	rs6489882	0.779	rs57484342	chr12:113371973	A/G	cg25319449	chr12:113376135	OAS3	-0.39	-7.26	-0.32	1.67e-12	Chronic lymphocytic leukemia;
LGG	cis	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg07460842	chr6:66804631	NA	-1.13	-30.96	-0.82	7.58e-115	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.613	rs34297047	chr3:160631478	A/G	cg04691961	chr3:161091175	C3orf57	0.41	8.79	0.38	2.99e-17	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.73e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg07460842	chr6:66804631	NA	0.95	17.27	0.63	5.79e-52	Exhaled nitric oxide levels;
LGG	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg12310025	chr6:25882481	NA	-0.37	-6.71	-0.3	5.7e-11	Height;
LGG	trans	rs6575793	0.553	rs7140556	chr14:101036458	G/T	cg09399377	chr6:136611038	BCLAF1	0.48	7.42	0.33	5.5e-13	Menarche (age at onset);
LGG	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.53	0.37	2.04e-16	Alzheimer's disease (survival time);
LGG	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Iron status biomarkers;
LGG	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.41	-0.33	6.23e-13	Monocyte count;
LGG	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg05484376	chr2:27715224	FNDC4	0.47	10.15	0.43	5.56e-22	Total body bone mineral density;
LGG	cis	rs4417704	0.551	rs55978049	chr2:241890228	A/C	cg26818257	chr2:241905806	NA	0.48	10.83	0.45	1.57e-24	Joint mobility (Beighton score);
LGG	cis	rs9547996	0.842	rs1028728	chr13:38173816	A/T	cg13634560	chr13:38173852	POSTN	-0.35	-6.93	-0.31	1.43e-11	Diastolic blood pressure;
LGG	trans	rs7939886	0.920	rs7936219	chr11:55977335	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg16511870	chr7:6145057	USP42	-0.4	-7.07	-0.31	5.63e-12	Blood metabolite levels;
LGG	trans	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg25214090	chr10:38739885	LOC399744	0.68	12.12	0.49	1.48e-29	Corneal astigmatism;
LGG	cis	rs9902453	0.834	rs9901694	chr17:28271645	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.16	0.55	4.35e-38	Coffee consumption (cups per day);
LGG	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg12856521	chr11:46389249	DGKZ	0.43	7.44	0.33	4.81e-13	Leprosy;
LGG	cis	rs3741151	0.686	rs1002127	chr11:73103835	G/C	cg17517138	chr11:73019481	ARHGEF17	0.85	8.64	0.37	8.97e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg27490568	chr2:178487706	NA	0.52	10.07	0.42	1.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7666738	0.830	rs35865860	chr4:98968822	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7241530	0.560	rs35463811	chr18:75912516	G/C	cg14642773	chr18:75888474	NA	0.42	8.08	0.35	5.82e-15	Educational attainment (years of education);
LGG	cis	rs12724450	0.793	rs71622688	chr1:150278669	T/G	cg03818307	chr1:150480534	ECM1	0.5	6.76	0.3	4.18e-11	Blood protein levels;
LGG	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg18252515	chr7:66147081	NA	1.41	20.63	0.69	1.54e-67	Gout;
LGG	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.84	-0.3	2.51e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.55	0.37	1.79e-16	Obesity-related traits;
LGG	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg03469862	chr11:68924853	NA	0.43	6.81	0.3	3.12e-11	Blond vs. brown hair color;
LGG	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.14e-36	Corneal astigmatism;
LGG	cis	rs2013441	0.508	rs8068484	chr17:19976394	C/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.34	-0.32	9.92e-13	Coronary artery disease;
LGG	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg06636001	chr8:8085503	FLJ10661	0.59	11.55	0.47	2.65e-27	Mood instability;
LGG	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.71	0.41	2.09e-20	Coronary artery disease;
LGG	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs7998202	0.667	rs2104789	chr13:113365398	G/A	cg17218041	chr13:113365319	ATP11A	-0.41	-6.76	-0.3	4.12e-11	Glycated hemoglobin levels;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs12476592	0.602	rs1446563	chr2:63898124	T/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg12463550	chr7:65579703	CRCP	0.53	8.85	0.38	1.91e-17	Aortic root size;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.97	-0.42	2.42e-21	Lung cancer;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.55	-9.88	-0.42	5.33e-21	Lymphocyte counts;
LGG	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg16662043	chr16:48846231	NA	0.37	7.16	0.32	3.26e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs698833	0.962	rs1065785	chr2:44660699	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.47	7.1	0.31	4.83e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs73001065	0.901	rs73004951	chr19:19695228	C/T	cg03709012	chr19:19516395	GATAD2A	0.78	6.85	0.3	2.32e-11	LDL cholesterol;
LGG	cis	rs4149577	0.630	rs4149570	chr12:6451590	A/C	cg00556515	chr12:6442607	TNFRSF1A	0.38	8.18	0.36	2.83e-15	Monocyte count;
LGG	cis	rs17039065	1.000	rs72889355	chr4:109377863	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	6.95	0.31	1.28e-11	Gut microbiome composition (summer);
LGG	cis	rs7166081	1.000	rs4776909	chr15:67542349	T/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.78	-0.3	3.76e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.24e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.650	rs3815358	chr17:62010270	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-7.34	-0.32	9.71e-13	Height;
LGG	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14019695	chr9:139328340	INPP5E	0.42	7.51	0.33	3.1e-13	Monocyte percentage of white cells;
LGG	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg03959625	chr15:84868606	LOC388152	0.5	7.41	0.33	6.23e-13	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06319327	chr1:28415113	EYA3	0.43	7.15	0.32	3.41e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9880211	0.800	rs66509730	chr3:136504258	A/C	cg21827317	chr3:136751795	NA	-0.47	-6.9	-0.31	1.76e-11	Body mass index;Height;
LGG	cis	rs6580649	0.941	rs1793933	chr12:48396450	G/T	cg24011408	chr12:48396354	COL2A1	0.68	8.51	0.37	2.37e-16	Lung cancer;
LGG	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.34	-0.32	9.79e-13	Morning vs. evening chronotype;
LGG	cis	rs6076065	0.748	rs6048784	chr20:23382652	A/T	cg11657817	chr20:23433608	CST11	0.4	8.2	0.36	2.39e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.4	0.5	1.06e-30	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.15	-0.43	5.47e-22	Lung cancer;
LGG	cis	rs2071403	0.509	rs17786733	chr2:1410929	T/A	cg06500727	chr2:1417164	TPO	-0.61	-12.44	-0.5	7.84e-31	Thyroid peroxidase antibody positivity;
LGG	cis	rs8028182	0.636	rs7163907	chr15:75845097	T/C	cg20655648	chr15:75932815	IMP3	0.44	7.26	0.32	1.68e-12	Sudden cardiac arrest;
LGG	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.03	-0.31	7.26e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-8.36	-0.36	7.47e-16	Depression;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg05793240	chr7:2802953	GNA12	0.33	7.69	0.34	8.9e-14	Height;
LGG	cis	rs7071206	0.947	rs10509391	chr10:79422369	G/A	cg07817648	chr10:79422355	NA	-0.79	-15.08	-0.57	4.34e-42	Bone mineral density;
LGG	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg14784868	chr12:69753453	YEATS4	0.89	19.77	0.68	1.52e-63	Blood protein levels;
LGG	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	9.66	0.41	3.05e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-13.76	-0.54	2.39e-36	Body mass index;
LGG	cis	rs11229555	0.645	rs7116847	chr11:58178478	C/A	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13102973	0.932	rs13149380	chr4:135866539	A/C	cg14419869	chr4:135874104	NA	0.58	11.08	0.46	1.8e-25	Subjective well-being;
LGG	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg06108461	chr20:60628389	TAF4	-0.72	-12.94	-0.52	6.74e-33	Body mass index;
LGG	cis	rs36071027	0.577	rs11740411	chr5:158396215	C/T	cg23468002	chr5:158532401	NA	0.41	6.91	0.31	1.62e-11	Carotid intima media thickness;
LGG	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg20848291	chr7:100343083	ZAN	-0.66	-9.64	-0.41	3.65e-20	Other erythrocyte phenotypes;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-9.94	-0.42	3.13e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13762774	chr10:32048991	NA	0.44	6.74	0.3	4.74e-11	Gut microbiome composition (summer);
LGG	trans	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg23484912	chr5:273055	PDCD6	0.52	10.12	0.43	6.92e-22	Pancreatic cancer;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.42	-0.47	8.68e-27	Lung cancer;
LGG	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg06138931	chr13:21896616	NA	-0.44	-7.22	-0.32	2.17e-12	White matter hyperintensity burden;
LGG	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-11.09	-0.46	1.59e-25	Chronic sinus infection;
LGG	cis	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg25885449	chr18:77638415	KCNG2	0.37	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs4629710	0.592	rs13200165	chr6:131549167	G/C	cg12606694	chr6:131520996	AKAP7	0.51	8.39	0.36	5.83e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.89e-14	Common traits (Other);
LGG	cis	rs883565	0.582	rs7623343	chr3:39146792	A/C	cg01426195	chr3:39028469	NA	-0.69	-15.63	-0.59	1.51e-44	Handedness;
LGG	cis	rs9487051	0.676	rs2884013	chr6:109599952	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.31e-14	Reticulocyte fraction of red cells;
LGG	cis	rs67311347	0.911	rs6775936	chr3:40377399	T/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.31	-0.69	4.58e-66	Renal cell carcinoma;
LGG	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs6920965	0.507	rs7754833	chr6:126190894	A/G	cg05901451	chr6:126070800	HEY2	-0.49	-8.79	-0.38	3.05e-17	High light scatter reticulocyte count;
LGG	cis	rs1030877	0.924	rs2250658	chr2:105889683	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.74	14.83	0.57	5.61e-41	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Vitiligo;
LGG	cis	rs7301826	0.651	rs2037789	chr12:131288292	C/T	cg11011512	chr12:131303247	STX2	-0.42	-8.95	-0.38	8.38e-18	Plasma plasminogen activator levels;
LGG	cis	rs1942	0.837	rs12440045	chr15:41782684	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.39	-0.36	5.88e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg06028605	chr16:24865363	SLC5A11	-0.5	-8.2	-0.36	2.32e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.48	-0.37	3.14e-16	Morning vs. evening chronotype;
LGG	cis	rs12474201	0.507	rs6714451	chr2:47017743	G/C	cg06386533	chr2:46925753	SOCS5	0.42	6.99	0.31	9.56e-12	Height;
LGG	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg21775007	chr8:11205619	TDH	-0.44	-6.98	-0.31	1.06e-11	Morning vs. evening chronotype;
LGG	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg01236616	chr12:121019343	POP5	1.25	23.25	0.73	8.41e-80	Type 1 diabetes nephropathy;
LGG	cis	rs61021925	1	rs61021925	chr12:122863659	T/C	cg23029597	chr12:123009494	RSRC2	0.72	13.79	0.54	1.72e-36	Schizophrenia;
LGG	cis	rs2013441	0.508	rs4346259	chr17:19977414	C/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg16325326	chr1:53192061	ZYG11B	-0.67	-13.35	-0.53	1.24e-34	Monocyte count;
LGG	trans	rs6787172	0.653	rs7610691	chr3:158150843	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.01	-0.39	5.5e-18	Mean corpuscular volume;
LGG	cis	rs9814567	0.806	rs6806810	chr3:134323522	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-12.65	-0.51	9.95e-32	Schizophrenia;
LGG	trans	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.03	0.39	4.49e-18	Resting heart rate;
LGG	cis	rs11096990	0.634	rs11096988	chr4:39265701	G/A	cg24403649	chr4:39172243	NA	0.39	6.91	0.31	1.64e-11	Cognitive function;
LGG	trans	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.67	-12.13	-0.49	1.32e-29	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs4262150	0.883	rs72802891	chr5:152255602	C/G	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs4148087	1.000	rs4148092	chr21:43635162	T/C	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg03060546	chr3:49711283	APEH	-0.53	-8.08	-0.35	5.74e-15	Resting heart rate;
LGG	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.81	0.3	2.95e-11	Dupuytren's disease;
LGG	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg08999081	chr20:33150536	PIGU	0.38	9.6	0.41	5e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs12517041	1.000	rs74322845	chr5:23293404	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs8179	0.645	rs66939011	chr7:92265798	T/C	cg15732164	chr7:92237376	CDK6	-0.47	-9.03	-0.39	4.62e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7085104	0.552	rs11191414	chr10:104601565	A/T	cg04362960	chr10:104952993	NT5C2	0.49	9.16	0.39	1.63e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs73086581	1.000	rs73086595	chr20:3983448	A/G	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.43e-26	Response to antidepressants in depression;
LGG	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg13453750	chr1:205783389	SLC41A1	-0.37	-7.57	-0.33	2.07e-13	Monocyte percentage of white cells;
LGG	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-15.03	-0.57	7.1e-42	Morning vs. evening chronotype;
LGG	cis	rs17253792	0.822	rs78820104	chr14:56068854	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	trans	rs66887589	0.616	rs1052633	chr4:120215314	A/G	cg25214090	chr10:38739885	LOC399744	0.45	8.07	0.35	6.03e-15	Diastolic blood pressure;
LGG	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.86	0.34	2.74e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1459104	1.000	rs35005109	chr11:55117074	G/A	cg15704280	chr7:45808275	SEPT13	0.71	7.06	0.31	6.23e-12	Body mass index;
LGG	cis	rs2077654	0.556	rs11024284	chr11:17444590	C/T	cg25308976	chr11:17434268	ABCC8	0.57	7.19	0.32	2.62e-12	Gout;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.86	-0.3	2.28e-11	Monocyte percentage of white cells;
LGG	trans	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.22e-18	Bladder cancer;
LGG	cis	rs12476592	0.571	rs190519	chr2:63858425	T/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.69	-0.3	6.47e-11	Childhood ear infection;
LGG	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs504918	0.802	rs3755659	chr3:124054964	A/G	cg05766129	chr3:123988013	KALRN	0.38	6.73	0.3	5.03e-11	Schizophrenia;
LGG	cis	rs72928364	0.872	rs13064121	chr3:100710713	C/A	cg23634451	chr3:100713646	ABI3BP	-0.42	-7.5	-0.33	3.23e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg06360820	chr2:242988706	NA	-0.91	-11.82	-0.48	2.44e-28	Obesity-related traits;
LGG	cis	rs12410462	0.551	rs2814087	chr1:227632334	C/T	cg04117972	chr1:227635322	NA	-0.39	-6.99	-0.31	9.88e-12	Major depressive disorder;
LGG	cis	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg19399532	chr1:178512495	C1orf220	-0.54	-10.96	-0.45	5.19e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1109114	0.738	rs10067047	chr5:148623098	A/G	cg06539116	chr5:148597365	ABLIM3	-0.5	-12.16	-0.49	1.05e-29	Body mass index;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg15971980	chr6:150254442	NA	0.43	8.08	0.35	5.77e-15	Lung cancer;
LGG	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.94	0.35	1.59e-14	Birth weight;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	14.88	0.57	3.34e-41	Obesity-related traits;
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs73193808	0.639	rs9976274	chr21:30553936	A/C	cg03476357	chr21:30257390	N6AMT1	0.4	6.71	0.3	5.84e-11	Coronary artery disease;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs1888998	chr20:25291826	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.41	-0.5	9.52e-31	Response to antipsychotic treatment;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	6.85	0.3	2.43e-11	Schizophrenia;
LGG	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.67	-0.41	2.79e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2486288	0.554	rs1719235	chr15:45576108	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.8	-0.45	2.05e-24	Glomerular filtration rate;
LGG	cis	rs4731207	0.592	rs6967988	chr7:124570472	T/A	cg05630886	chr7:124431682	NA	-0.32	-7.25	-0.32	1.77e-12	Cutaneous malignant melanoma;
LGG	cis	rs1451375	1.000	rs921451	chr7:50623285	A/G	cg00647317	chr7:50633725	DDC	-0.34	-7.66	-0.34	1.11e-13	Malaria;
LGG	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.89	-0.59	1.03e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg20713898	chr8:124780851	FAM91A1	0.51	7.55	0.33	2.37e-13	Pancreatic cancer;
LGG	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg16386425	chr10:429943	DIP2C	-0.4	-7.53	-0.33	2.62e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.95e-17	Menopause (age at onset);
LGG	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg02002194	chr4:3960332	NA	-0.38	-6.85	-0.3	2.34e-11	Retinal vascular caliber;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg00761968	chr13:53314142	LECT1	-0.38	-7.82	-0.34	3.5e-14	Lewy body disease;
LGG	cis	rs4722166	0.630	rs1581497	chr7:22779503	C/A	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	8.91e-16	Lung cancer;
LGG	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-8.46	-0.37	3.46e-16	Morning vs. evening chronotype;
LGG	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs7766436	0.885	rs1418311	chr6:22594964	T/G	cg13666174	chr6:22585274	NA	-0.51	-12.03	-0.49	3.42e-29	Coronary artery disease;
LGG	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.87	-9.67	-0.41	2.98e-20	Smoking behavior;
LGG	cis	rs7551222	0.614	rs4951385	chr1:204454165	C/T	cg20240347	chr1:204465584	NA	-0.49	-9.14	-0.39	1.96e-18	Schizophrenia;
LGG	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.84	-0.34	3.21e-14	Bladder cancer;
LGG	cis	rs12220238	0.841	rs10824146	chr10:76076779	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.69	8.86	0.38	1.71e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg27661571	chr11:113659931	NA	-0.66	-9.53	-0.4	9.25e-20	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.52	0.83	1.28e-121	Prudent dietary pattern;
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.97	0.38	7.28e-18	Total body bone mineral density;
LGG	cis	rs525304	0.903	rs11237113	chr11:70511624	A/G	cg07091154	chr11:70562728	SHANK2	0.37	7.14	0.31	3.71e-12	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1829883	0.835	rs2511961	chr5:98878673	A/G	cg08333243	chr5:99726346	NA	0.37	7.17	0.32	3.01e-12	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg10150615	chr22:24372951	LOC391322	-0.4	-6.84	-0.3	2.53e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10819861	0.679	rs4623574	chr9:98849624	C/T	cg14508093	chr9:98862825	NA	0.3	7.09	0.31	5.16e-12	Electrocardiographic traits;
LGG	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs55871839	0.559	rs4737527	chr8:59823491	A/G	cg07426533	chr8:59803705	TOX	0.62	12.94	0.52	6.82e-33	Pneumonia;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.48e-12	Lung cancer;
LGG	trans	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.29	0.5	3.13e-30	Type 2 diabetes;
LGG	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg13010199	chr12:38710504	ALG10B	0.72	14.96	0.57	1.44e-41	Heart rate;
LGG	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs459571	0.715	rs401826	chr9:136890591	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-11.4	-0.47	1.01e-26	Platelet distribution width;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.9	-0.31	1.76e-11	Total body bone mineral density;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.45	-0.33	4.59e-13	Testicular germ cell tumor;
LGG	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.16	0.46	8.73e-26	Morning vs. evening chronotype;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg11328140	chr12:108079443	PWP1	0.48	6.99	0.31	9.47e-12	Breast cancer;
LGG	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg07382826	chr16:28625726	SULT1A1	0.4	8.12	0.35	4.22e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg16141378	chr3:129829833	LOC729375	0.43	10.14	0.43	6.15e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3760982	0.565	rs3786956	chr19:44286829	C/T	cg11993925	chr19:44307056	LYPD5	0.4	8.27	0.36	1.38e-15	Breast cancer (estrogen-receptor negative);Breast cancer;
LGG	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg09339527	chr5:178322752	ZFP2	-0.41	-7.54	-0.33	2.49e-13	Sleep duration;
LGG	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg00204512	chr16:28754710	NA	0.26	7.06	0.31	6.18e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08280861	chr8:58055591	NA	0.64	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.01e-23	Lymphocyte counts;
LGG	cis	rs7572644	0.699	rs2337374	chr2:28200152	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg26384229	chr12:38710491	ALG10B	0.71	14.22	0.55	2.41e-38	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.581	rs75219436	chr1:227546617	C/T	cg23173402	chr1:227635558	NA	0.5	8.44	0.37	3.99e-16	Major depressive disorder;
LGG	trans	rs11039798	1.000	rs7131020	chr11:48642132	A/G	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.63e-16	Axial length;
LGG	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.58	0.37	1.41e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg10756647	chr7:56101905	PSPH	0.46	6.8	0.3	3.29e-11	Corneal structure;
LGG	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.24	0.52	3.54e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs516946	0.797	rs11995075	chr8:41534068	T/C	cg12439423	chr8:41522721	ANK1	0.42	7.07	0.31	5.86e-12	Type 2 diabetes;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg15971980	chr6:150254442	NA	0.44	8.19	0.36	2.58e-15	Lung cancer;
LGG	cis	rs9443645	0.527	rs9359362	chr6:79723756	T/C	cg18132916	chr6:79620363	NA	-0.27	-7.0	-0.31	8.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.78	0.57	9.41e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg13880726	chr7:1868755	MAD1L1	0.45	7.9	0.34	1.99e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg06521331	chr12:34319734	NA	-0.65	-11.85	-0.48	1.7e-28	Morning vs. evening chronotype;
LGG	cis	rs11792861	0.926	rs75128146	chr9:111833791	G/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.55	0.41	7.29e-20	Menarche (age at onset);
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg26513180	chr16:89883248	FANCA	0.7	7.63	0.33	1.37e-13	Skin colour saturation;
LGG	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.41	-7.36	-0.32	8.4e-13	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs4363385	0.818	rs559236	chr1:153010510	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27532318	chr7:32358331	NA	0.88	8.29	0.36	1.26e-15	Body mass index;
LGG	cis	rs10799590	1.000	rs2648746	chr1:224838006	G/A	cg01808320	chr1:224927238	CNIH3	-0.4	-7.13	-0.31	3.78e-12	Opioid dependence;
LGG	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg21798802	chr22:38057573	PDXP	0.4	8.64	0.37	9.07e-17	Fat distribution (HIV);
LGG	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg09307838	chr4:120376055	NA	0.8	13.18	0.52	6.3e-34	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24654547	chr16:68057165	DUS2L;DDX28	0.46	7.31	0.32	1.14e-12	Cognitive performance;
LGG	cis	rs1018836	0.699	rs13271657	chr8:91474599	C/G	cg16814680	chr8:91681699	NA	-0.7	-11.68	-0.48	8.17e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg08975724	chr8:8085496	FLJ10661	0.47	9.07	0.39	3.45e-18	Retinal vascular caliber;
LGG	cis	rs7580658	0.929	rs13029237	chr2:128147854	C/T	cg10021288	chr2:128175891	PROC	-0.68	-13.85	-0.54	9.27e-37	Protein C levels;
LGG	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg20336341	chr7:50628841	DDC	-0.51	-9.6	-0.41	4.89e-20	Malaria;
LGG	cis	rs727505	0.954	rs1383748	chr7:124638201	A/T	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs1682825	0.615	rs5026889	chr3:10777448	C/G	cg23512531	chr3:10780469	NA	0.57	9.23	0.39	1.01e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs1707322	1.000	rs1613296	chr1:46546852	A/C	cg03146154	chr1:46216737	IPP	-0.46	-8.0	-0.35	9.75e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8133932	0.637	rs7283688	chr21:47301354	T/A	cg13695288	chr21:47294981	PCBP3	-0.36	-7.24	-0.32	1.89e-12	Schizophrenia;
LGG	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.94	-0.38	9.21e-18	Bone mineral density;
LGG	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	cis	rs239198	0.568	rs9404059	chr6:101331497	T/C	cg09795085	chr6:101329169	ASCC3	0.43	6.95	0.31	1.23e-11	Menarche (age at onset);
LGG	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.17	-0.43	4.6e-22	Total body bone mineral density;
LGG	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg11861562	chr11:117069780	TAGLN	0.26	6.89	0.3	1.88e-11	Blood protein levels;
LGG	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs972578	0.668	rs2413726	chr22:43202340	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.84	-0.3	2.58e-11	Mean platelet volume;
LGG	cis	rs9581857	0.579	rs75872792	chr13:27996064	G/T	cg01674679	chr13:27998804	GTF3A	-0.74	-8.71	-0.38	5.43e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.46	-0.4	1.5700000000000001e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg06618935	chr21:46677482	NA	-0.46	-8.96	-0.38	7.8e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg04267008	chr7:1944627	MAD1L1	-0.6	-10.25	-0.43	2.44e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6772849	1.000	rs6772849	chr3:128306418	T/C	cg08795948	chr3:128337044	NA	0.53	8.8	0.38	2.66e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6725041	0.547	rs4672645	chr2:213204955	C/T	cg16329650	chr2:213403929	ERBB4	-0.38	-6.71	-0.3	5.83e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg25600027	chr14:23388339	RBM23	-0.45	-7.53	-0.33	2.62e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs1062753	0.527	rs62240998	chr22:42354701	T/A	cg15128208	chr22:42549153	NA	0.38	6.99	0.31	9.71e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.43	-0.44	5.02e-23	Total cholesterol levels;
LGG	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.53	-0.44	2.17e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.46	0.37	3.63e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7178909	0.902	rs2043881	chr15:90439960	G/A	cg19708238	chr15:90437601	AP3S2	0.4	6.68	0.3	6.97e-11	Common traits (Other);
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg20607798	chr8:58055168	NA	0.59	6.66	0.3	7.6e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg11642891	chr2:3452563	TTC15	-0.47	-9.44	-0.4	1.8e-19	Obesity-related traits;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.89	0.3	1.83e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4849975	0.510	rs28548099	chr2:3710938	G/A	cg20720597	chr2:3699334	NA	0.56	6.98	0.31	1.01e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg05985134	chr18:33552581	C18orf21	0.65	10.26	0.43	2.24e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.43	0.53	5.81e-35	Psoriasis;
LGG	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg23601416	chr22:19950040	COMT	0.35	8.87	0.38	1.65e-17	Blood metabolite levels;
LGG	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg09044154	chr16:88155775	NA	-0.51	-7.75	-0.34	5.81e-14	Menopause (age at onset);
LGG	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.31	0.36	1.09e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg09307838	chr4:120376055	NA	0.77	12.67	0.51	8.34e-32	Corneal astigmatism;
LGG	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.92	-0.35	1.79e-14	Morning vs. evening chronotype;
LGG	cis	rs7219021	0.705	rs11079842	chr17:47002762	G/A	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.86	-0.3	2.22e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs7103648	0.838	rs11039244	chr11:47466442	G/A	cg20307385	chr11:47447363	PSMC3	0.92	20.7	0.69	7.19e-68	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg02753203	chr1:228287806	NA	-0.64	-11.74	-0.48	4.84e-28	Diastolic blood pressure;
LGG	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.2	0.43	3.58e-22	Diabetic retinopathy;
LGG	cis	rs968451	0.756	rs1007117	chr22:39675770	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	13.7	0.54	4.06e-36	Primary biliary cholangitis;
LGG	trans	rs9354308	0.738	rs1938117	chr6:66593480	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.85	-0.3	2.41e-11	Metabolite levels;
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	18.26	0.65	1.66e-56	Alzheimer's disease;
LGG	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.79	0.54	1.73e-36	Colorectal cancer;
LGG	cis	rs7932354	0.528	rs11039112	chr11:47174296	C/T	cg03339077	chr11:47165057	C11orf49	0.51	9.6	0.41	4.89e-20	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg06121193	chr1:90282411	NA	-0.37	-7.12	-0.31	4.03e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg04132472	chr17:19861366	AKAP10	-0.25	-7.1	-0.31	4.84e-12	Schizophrenia;
LGG	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg00383909	chr3:49044727	WDR6	0.44	7.22	0.32	2.08e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg06521331	chr12:34319734	NA	-0.64	-11.54	-0.47	2.99e-27	Morning vs. evening chronotype;
LGG	cis	rs77741769	0.571	rs1696357	chr12:121348649	A/G	cg02419362	chr12:121203948	SPPL3	0.5	8.61	0.37	1.15e-16	Mean corpuscular volume;
LGG	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.76	-0.68	1.78e-63	Height;
LGG	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.51	0.61	1.77e-48	Obesity-related traits;
LGG	cis	rs763121	0.853	rs138704	chr22:39133410	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	17.83	0.64	1.64e-54	Menopause (age at onset);
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg14074117	chr16:1909714	C16orf73	-0.53	-7.83	-0.34	3.36e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg19997662	chr15:101784653	CHSY1	-0.83	-17.38	-0.63	1.82e-52	Corneal structure;
LGG	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg15479754	chr10:1447082	ADARB2	0.33	6.84	0.3	2.59e-11	Radiation response;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg07414643	chr4:187882934	NA	0.56	11.7	0.48	7.09e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg13736514	chr6:26305472	NA	-0.49	-9.86	-0.42	6.05e-21	Educational attainment;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg04703951	chr17:43578652	NA	0.29	6.67	0.3	7.48e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs9650657	0.805	rs6982210	chr8:10599994	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.8	-0.34	4.09e-14	Neuroticism;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.57e-22	Menopause (age at onset);
LGG	cis	rs17221829	0.931	rs10160803	chr11:89461859	C/T	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.5	-0.33	3.18e-13	Anxiety in major depressive disorder;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-13.19	-0.52	5.73e-34	Personality dimensions;
LGG	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs2798269	0.763	rs11148172	chr13:22170275	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.44	-7.63	-0.33	1.39e-13	PR segment;
LGG	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.61	-0.37	1.11e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg16576597	chr16:28551801	NUPR1	0.32	7.19	0.32	2.56e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13126279	chr21:47581558	C21orf56	-0.46	-8.08	-0.35	5.56e-15	Testicular germ cell tumor;
LGG	cis	rs3741151	0.773	rs57354084	chr11:73139376	A/T	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7727544	0.716	rs72793278	chr5:131561372	C/A	cg24060327	chr5:131705240	SLC22A5	-0.45	-7.6	-0.33	1.68e-13	Blood metabolite levels;
LGG	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.18	-0.43	4.1e-22	Response to antipsychotic treatment;
LGG	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.24	-0.39	8.95e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11997175	0.574	rs4236733	chr8:33655582	G/A	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	cis	rs10463554	0.889	rs246912	chr5:102560841	A/C	cg23492399	chr5:102201601	PAM	-0.53	-7.81	-0.34	3.92e-14	Parkinson's disease;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs6426558	0.537	rs7523167	chr1:227365304	G/A	cg10327440	chr1:227177885	CDC42BPA	-0.63	-10.46	-0.44	3.93e-23	Neutrophil percentage of white cells;
LGG	cis	rs11039131	0.787	rs326217	chr11:47303275	T/C	cg20307385	chr11:47447363	PSMC3	-0.44	-7.4	-0.33	6.26e-13	Schizophrenia;
LGG	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg06421707	chr20:25228305	PYGB	0.45	8.67	0.37	7.3e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg24699146	chr1:24152579	HMGCL	-0.26	-7.84	-0.34	3.09e-14	Immature fraction of reticulocytes;
LGG	cis	rs1577917	0.771	rs2475790	chr6:86368068	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.17	-0.62	1.68e-51	Response to antipsychotic treatment;
LGG	cis	rs2658782	0.666	rs2925361	chr11:93098823	G/A	cg15737290	chr11:93063684	CCDC67	0.52	7.94	0.35	1.54e-14	Pulmonary function decline;
LGG	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.33	0.7	8.15e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.57e-11	Bladder cancer;
LGG	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg04450456	chr4:17643702	FAM184B	0.33	7.25	0.32	1.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7727544	0.716	rs3844312	chr5:131582356	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.22	-0.32	2.13e-12	Blood metabolite levels;
LGG	trans	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg07701084	chr6:150067640	NUP43	-0.46	-6.86	-0.3	2.26e-11	Lung cancer;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg07402800	chr8:145582003	FBXL6;GPR172A	0.43	6.79	0.3	3.41e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg08925882	chr11:67350491	GSTP1	-0.34	-6.64	-0.3	8.61e-11	Mean corpuscular volume;
LGG	cis	rs12580194	0.593	rs55898514	chr12:55736238	G/A	cg19537932	chr12:55886519	OR6C68	-0.51	-9.33	-0.4	4.53e-19	Cancer;
LGG	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.72	-0.3	5.45e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6565180	1.000	rs68051857	chr16:30360011	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-17.46	-0.63	8.29e-53	Tonsillectomy;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	16.56	0.61	1.08e-48	Alzheimer's disease;
LGG	cis	rs2415984	0.579	rs10140977	chr14:46955156	T/A	cg14871534	chr14:47121158	RPL10L	-0.56	-9.89	-0.42	4.73e-21	Number of children ever born;
LGG	cis	rs138249	0.966	rs138238	chr22:50563140	T/C	cg07310406	chr22:50524374	MLC1	0.45	9.05	0.39	4.12e-18	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs36051895	0.664	rs9695933	chr9:5153104	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-15.1	-0.57	3.72e-42	Pediatric autoimmune diseases;
LGG	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg26248373	chr2:1572462	NA	-0.88	-14.14	-0.55	5.42e-38	IgG glycosylation;
LGG	cis	rs12410462	0.636	rs1495849	chr1:227736363	G/A	cg21459583	chr1:227974177	NA	0.36	6.77	0.3	3.91e-11	Major depressive disorder;
LGG	cis	rs12724450	0.793	rs35762205	chr1:150297918	G/C	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	cis	rs1062746	0.557	rs35441225	chr16:87335498	C/A	cg02258303	chr16:87377426	FBXO31	-0.41	-7.6	-0.33	1.62e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs6964587	0.869	rs2374519	chr7:91541481	T/C	cg17063962	chr7:91808500	NA	-0.42	-7.41	-0.33	5.99e-13	Breast cancer;
LGG	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.2	-0.6	4.33e-47	Calcium levels;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg11235426	chr6:292522	DUSP22	-0.6	-10.13	-0.43	6.69e-22	Menopause (age at onset);
LGG	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg14088196	chr11:70211408	PPFIA1	-0.94	-13.24	-0.52	3.56e-34	Coronary artery disease;
LGG	cis	rs62025270	0.632	rs62022942	chr15:86258568	A/T	cg25843651	chr15:86329602	KLHL25	0.59	9.09	0.39	2.89e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg09696939	chr10:60272079	BICC1	0.39	7.58	0.33	1.96e-13	Refractive error;
LGG	cis	rs9394152	0.817	rs4428487	chr6:33468394	G/A	cg13560919	chr6:33536144	NA	0.68	12.57	0.5	2.14e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg16405210	chr4:1374714	KIAA1530	0.86	16.13	0.6	8.6e-47	Longevity;
LGG	cis	rs12190007	0.846	rs9505962	chr6:169726667	A/G	cg16388071	chr6:169726476	NA	0.43	8.31	0.36	1.09e-15	Obesity-related traits;
LGG	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-8.12	-0.35	4.17e-15	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs6028335	0.674	rs66513266	chr20:37597410	G/T	cg16355469	chr20:37678765	NA	0.6	7.92	0.35	1.77e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs9810259	0.508	rs9853146	chr3:12299313	C/T	cg22839075	chr3:12045461	SYN2	0.41	6.92	0.31	1.47e-11	Platelet count;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.79e-11	Personality dimensions;
LGG	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg05985134	chr18:33552581	C18orf21	0.62	9.68	0.41	2.65e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg17691542	chr6:26056736	HIST1H1C	1.11	17.93	0.64	5.46e-55	Iron status biomarkers;
LGG	cis	rs6693567	0.545	rs7553647	chr1:150472666	C/T	cg15654264	chr1:150340011	RPRD2	0.33	6.7	0.3	6.2e-11	Migraine;
LGG	cis	rs3784262	0.669	rs12905608	chr15:58314139	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.19	-0.32	2.68e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1568889	1.000	rs7931847	chr11:28175245	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	14.27	0.55	1.51e-38	Bipolar disorder;
LGG	cis	rs2692947	0.800	rs4332959	chr2:96549121	C/T	cg22654517	chr2:96458247	NA	0.38	7.79	0.34	4.36e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg18850127	chr7:39170497	POU6F2	0.61	14.53	0.56	1.08e-39	IgG glycosylation;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11573308	chr7:2025483	MAD1L1	0.39	6.77	0.3	3.9e-11	Pancreatic cancer;
LGG	cis	rs7923609	0.967	rs7085621	chr10:65208926	T/C	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-6.79	-0.3	3.51e-11	Blood metabolite levels;
LGG	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg01221209	chr5:554886	NA	-0.46	-6.81	-0.3	3e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs10276381	0.579	rs73072543	chr7:28146850	A/G	cg23620719	chr7:28220237	JAZF1	0.72	7.71	0.34	7.5e-14	Crohn's disease;
LGG	cis	rs1707322	0.963	rs4553121	chr1:46375253	G/A	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.84e-13	Menopause (age at onset);
LGG	cis	rs6546550	0.901	rs897120	chr2:70160982	C/T	cg02498382	chr2:70120550	SNRNP27	0.43	8.14	0.35	3.63e-15	Prevalent atrial fibrillation;
LGG	cis	rs7582720	1.000	rs76890136	chr2:203850011	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg27532318	chr7:32358331	NA	0.75	7.55	0.33	2.32e-13	Body mass index;
LGG	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg16797656	chr11:68205561	LRP5	0.41	7.27	0.32	1.53e-12	Total body bone mineral density;
LGG	cis	rs12410462	0.681	rs78978081	chr1:227571619	G/A	cg23173402	chr1:227635558	NA	0.57	9.01	0.39	5.53e-18	Major depressive disorder;
LGG	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-8.37	-0.36	6.81e-16	Aortic root size;
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg19539972	chr4:7069911	GRPEL1	0.68	10.12	0.43	7.01e-22	Monocyte percentage of white cells;
LGG	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2.01e-19	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12095067	chr19:9929835	FBXL12	0.45	6.85	0.3	2.42e-11	Gut microbiome composition (summer);
LGG	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg26528311	chr1:38462546	FHL3	0.31	7.83	0.34	3.44e-14	Coronary artery disease;
LGG	cis	rs4906332	0.868	rs4900578	chr14:103926010	A/T	cg26031613	chr14:104095156	KLC1	-0.53	-7.99	-0.35	1.06e-14	Coronary artery disease;
LGG	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.05	0.31	6.35e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05025164	chr4:1340916	KIAA1530	0.43	7.24	0.32	1.82e-12	Obesity-related traits;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg13009111	chr11:71350975	NA	0.32	7.18	0.32	2.87e-12	Neuroticism;
LGG	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg06951627	chr6:26196580	NA	0.51	7.83	0.34	3.45e-14	Gout;Renal underexcretion gout;
LGG	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg16512390	chr1:228756714	NA	0.47	6.65	0.3	8.46e-11	Chronic lymphocytic leukemia;
LGG	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	12.22	0.49	6.06e-30	Total body bone mineral density;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.44	8.87	0.38	1.62e-17	Prostate cancer;
LGG	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg10224037	chr5:178157518	ZNF354A	0.77	12.71	0.51	5.69e-32	Neutrophil percentage of white cells;
LGG	cis	rs3741151	0.773	rs11235770	chr11:73184002	C/T	cg17517138	chr11:73019481	ARHGEF17	0.75	8.06	0.35	6.54e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.53	0.37	2.17e-16	Bipolar disorder;
LGG	cis	rs6901004	0.935	rs9487602	chr6:111560946	C/T	cg15721981	chr6:111408429	SLC16A10	0.44	8.14	0.35	3.77e-15	Blood metabolite levels;
LGG	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg13256891	chr4:100009986	ADH5	0.55	9.28	0.4	6.53e-19	Smoking initiation;
LGG	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs2652834	0.851	rs2652796	chr15:63408042	T/A	cg05507819	chr15:63340323	TPM1	0.5	7.03	0.31	7.23e-12	HDL cholesterol;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg05313129	chr8:58192883	C8orf71	-0.77	-10.57	-0.44	1.53e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg22732515	chr19:44031385	ETHE1	0.55	9.38	0.4	3.01e-19	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20257096	chr14:21851954	SUPT16H	0.43	7.18	0.32	2.79e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2735413	0.564	rs79006334	chr16:78124954	A/G	cg04733911	chr16:78082701	NA	0.57	7.99	0.35	1.1e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.32	0.36	9.64e-16	Tonsillectomy;
LGG	cis	rs2072732	0.861	rs72630909	chr1:2968979	C/T	cg08733933	chr1:2954429	NA	-0.46	-8.54	-0.37	1.92e-16	Plateletcrit;
LGG	cis	rs3126085	0.935	rs10888483	chr1:152252789	T/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.7	-0.3	6.09e-11	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg26924012	chr15:45694286	SPATA5L1	-1.05	-22.47	-0.72	3.78e-76	Homoarginine levels;
LGG	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.77	0.3	3.98e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1371867	0.839	rs1660313	chr8:101332712	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs704	0.523	rs11080054	chr17:26645991	G/A	cg10342447	chr17:26645325	TMEM97	-0.52	-9.83	-0.42	7.88e-21	Osteoprotegerin levels;
LGG	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-8.39	-0.36	5.95e-16	Cognitive test performance;
LGG	cis	rs7129556	0.954	rs11512896	chr11:77275718	A/G	cg12586386	chr11:77299805	AQP11	0.51	8.58	0.37	1.43e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.84	-0.34	3.22e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs3126085	0.935	rs1390487	chr1:152194601	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.97	0.38	7.31e-18	Atopic dermatitis;
LGG	cis	rs858239	0.600	rs6967419	chr7:23136310	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.35	0.32	9.24e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg04705435	chr11:17411270	KCNJ11	0.49	9.38	0.4	2.91e-19	Type 2 diabetes;
LGG	cis	rs911263	0.561	rs7160221	chr14:68798110	T/C	cg18825221	chr14:68749962	RAD51L1	0.43	7.34	0.32	9.41e-13	Primary biliary cholangitis;
LGG	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.07	-0.31	5.81e-12	Chronic lymphocytic leukemia;
LGG	cis	rs67133203	0.808	rs11834746	chr12:51509487	G/A	cg14688905	chr12:51403056	SLC11A2	0.64	9.72	0.41	1.86e-20	Urinary tract infection frequency;
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg00800038	chr16:89945340	TCF25	-0.68	-7.87	-0.34	2.58e-14	Skin colour saturation;
LGG	cis	rs55871839	0.619	rs6471756	chr8:59802159	A/G	cg07426533	chr8:59803705	TOX	-0.57	-12.74	-0.51	4.29e-32	Pneumonia;
LGG	cis	rs881375	0.967	rs1930780	chr9:123686219	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.44	0.4	1.82e-19	Rheumatoid arthritis;
LGG	cis	rs7089973	0.604	rs11196937	chr10:116589500	G/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg17294928	chr15:75287854	SCAMP5	0.53	9.3	0.4	5.59e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2229238	0.911	rs11490956	chr1:154487258	G/T	cg10237817	chr1:154519846	TDRD10	0.33	6.74	0.3	4.59e-11	Coronary heart disease;
LGG	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg22517653	chr1:2918612	NA	-0.44	-6.99	-0.31	9.87e-12	Plateletcrit;
LGG	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg01864069	chr14:103024347	NA	0.42	6.8	0.3	3.34e-11	Platelet count;
LGG	trans	rs57046232	0.511	rs6054143	chr20:6334697	C/T	cg21095983	chr6:86352623	SYNCRIP	0.42	7.01	0.31	8.41e-12	Colorectal cancer;
LGG	cis	rs11064837	0.504	rs7973772	chr12:120086737	C/T	cg25937854	chr12:120150414	CIT	0.63	11.21	0.46	5.56e-26	Schizophrenia;
LGG	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-11.98	-0.49	5.57e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs754466	0.580	rs11002289	chr10:79532580	G/A	cg17075019	chr10:79541650	NA	-0.98	-21.62	-0.71	3.68e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.644	rs13201430	chr6:109956050	C/T	cg16315928	chr6:109776240	MICAL1	0.44	7.57	0.33	2.03e-13	Height;
LGG	cis	rs7572733	0.840	rs12472359	chr2:198587865	T/C	cg00792783	chr2:198669748	PLCL1	-0.44	-7.44	-0.33	4.95e-13	Dermatomyositis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15984612	chr8:145514624	BOP1;HSF1	0.41	6.97	0.31	1.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1497828	0.871	rs2646842	chr1:217555946	G/A	cg04411442	chr1:217543379	NA	0.47	7.97	0.35	1.22e-14	Dialysis-related mortality;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14283194	chr7:91763737	CYP51A1	0.38	6.79	0.3	3.47e-11	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18162528	chr11:133826660	IGSF9B	0.47	7.78	0.34	4.7e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.02	-0.39	5.13e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg21775007	chr8:11205619	TDH	0.83	14.71	0.56	1.84e-40	Retinal vascular caliber;
LGG	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg27411982	chr8:10470053	RP1L1	0.4	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs6838801	0.892	rs12647024	chr4:77575503	T/C	cg17476223	chr4:77663285	SHROOM3	0.37	6.8	0.3	3.18e-11	Cleft lip with or without cleft palate;
LGG	cis	rs9399137	0.507	rs11759062	chr6:135381248	A/C	cg24558204	chr6:135376177	HBS1L	0.62	10.79	0.45	2.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs2708240	1.000	rs2538989	chr7:147580154	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.94	-0.31	1.36e-11	QT interval (drug interaction);
LGG	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.74	0.34	6.23e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg03258749	chr1:151040405	MLLT11	-0.45	-8.04	-0.35	7.6e-15	Childhood ear infection;
LGG	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg21100191	chr22:23484243	RTDR1	0.99	22.51	0.72	2.33e-76	Bone mineral density;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-14.6	-0.56	5.77e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3768617	0.528	rs10911240	chr1:183062948	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.7	-0.37	5.86e-17	Life satisfaction;
LGG	cis	rs7584330	0.737	rs7568588	chr2:238364342	G/T	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.21e-11	Prostate cancer;
LGG	cis	rs7712401	0.601	rs371604	chr5:122318432	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg10326726	chr10:51549505	MSMB	-0.6	-12.18	-0.49	8.13e-30	Prostate-specific antigen levels;
LGG	cis	rs870825	0.655	rs28555435	chr4:185647300	C/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01880404	chr19:44079527	XRCC1	0.44	6.67	0.3	7.2e-11	Gut microbiome composition (summer);
LGG	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.33	0.32	1.06e-12	Hip circumference adjusted for BMI;
LGG	cis	rs13033859	0.602	rs7605004	chr2:199502	G/T	cg04617936	chr2:214353	NA	-0.39	-7.03	-0.31	7.47e-12	Mitochondrial DNA levels;
LGG	cis	rs72960926	1.000	rs72956942	chr6:75093037	G/A	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg00686598	chr14:53173677	PSMC6	1.4	15.42	0.58	1.33e-43	Alzheimer's disease (late onset);
LGG	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg15208524	chr1:10270712	KIF1B	0.42	7.29	0.32	1.33e-12	Hepatocellular carcinoma;
LGG	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg24812749	chr6:127587940	RNF146	0.72	11.8	0.48	2.9e-28	Breast cancer;
LGG	cis	rs2013441	1.000	rs2703772	chr17:20131453	C/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.24e-19	Obesity-related traits;
LGG	cis	rs1620921	0.624	rs13216274	chr6:161275309	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs7412746	0.658	rs7521719	chr1:150913134	G/A	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg07541023	chr7:19748670	TWISTNB	-0.63	-8.81	-0.38	2.52e-17	Thyroid stimulating hormone;
LGG	cis	rs3820928	0.874	rs1054413	chr2:227867719	A/G	cg11843606	chr2:227700838	RHBDD1	0.45	7.76	0.34	5.63e-14	Pulmonary function;
LGG	cis	rs12282928	1.000	rs10838850	chr11:48285856	C/T	cg26585981	chr11:48327164	OR4S1	-0.45	-7.28	-0.32	1.43e-12	Migraine - clinic-based;
LGG	cis	rs11748327	0.959	rs1911908	chr5:4064371	C/G	cg01025095	chr5:4101132	NA	0.57	9.32	0.4	4.87e-19	Myocardial infarction;
LGG	trans	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.65	0.37	8.82e-17	Mood instability;
LGG	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	cg15522984	chr1:182991683	LAMC1	0.45	9.04	0.39	4.34e-18	Fuchs's corneal dystrophy;
LGG	trans	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg06521331	chr12:34319734	NA	0.44	7.64	0.33	1.24e-13	Bladder cancer;
LGG	cis	rs6960043	0.818	rs2215383	chr7:15062983	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.82	-0.34	3.67e-14	Type 2 diabetes;
LGG	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg27189623	chr16:705930	WDR90	0.39	7.52	0.33	2.81e-13	Height;
LGG	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.58	-0.53	1.33e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11792861	0.962	rs11789624	chr9:111796231	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.59	0.41	5.32e-20	Menarche (age at onset);
LGG	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg26384229	chr12:38710491	ALG10B	0.67	12.11	0.49	1.57e-29	Resting heart rate;
LGG	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg15325629	chr6:28072465	NA	-0.89	-6.94	-0.31	1.3e-11	Parkinson's disease;
LGG	cis	rs6735179	0.607	rs10188708	chr2:1746032	G/C	cg20570797	chr2:1712800	PXDN	-0.46	-7.76	-0.34	5.53e-14	Response to antipsychotic treatment;
LGG	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.16e-13	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg11494091	chr17:61959527	GH2	0.55	8.95	0.38	8.68e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg18681998	chr4:17616180	MED28	0.81	16.66	0.61	3.65e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs7617773	0.817	rs3731555	chr3:48206102	G/A	cg11946769	chr3:48343235	NME6	0.69	11.3	0.46	2.69e-26	Coronary artery disease;
LGG	cis	rs861020	0.606	rs689210	chr1:210013723	A/C	cg05527609	chr1:210001259	C1orf107	0.6	9.62	0.41	4.3e-20	Orofacial clefts;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.52	-0.53	2.34e-35	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.41e-11	Intelligence (multi-trait analysis);
LGG	cis	rs757278	0.552	rs11764070	chr7:117312350	T/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.47	0.33	4.08e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg07549998	chr6:150325970	RAET1K	0.37	7.03	0.31	7.51e-12	Alopecia areata;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18402987	chr7:1209562	NA	0.39	7.17	0.32	2.95e-12	Longevity;Endometriosis;
LGG	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg09021430	chr5:549028	NA	-0.68	-11.66	-0.48	1.03e-27	Obesity-related traits;
LGG	cis	rs1568889	1.000	rs7945367	chr11:28166272	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.78	0.57	8.72e-41	Bipolar disorder;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	6.67	0.3	7.14e-11	IgG glycosylation;
LGG	cis	rs6032067	0.714	rs16989820	chr20:43837659	G/T	cg10761708	chr20:43804764	PI3	0.58	8.93	0.38	9.74e-18	Blood protein levels;
LGG	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.3	-0.43	1.52e-22	Intelligence (multi-trait analysis);
LGG	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg09165964	chr15:75287851	SCAMP5	-0.7	-7.37	-0.32	7.8e-13	Lung cancer;
LGG	cis	rs4356932	1.000	rs6532111	chr4:76955914	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs11976180	1.000	rs1540894	chr7:143767676	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.4	-7.18	-0.32	2.81e-12	Obesity-related traits;
LGG	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg11871910	chr12:69753446	YEATS4	1.04	28.71	0.8	6.95e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1519814	0.956	rs4871040	chr8:121131611	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.16e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.2	-0.49	6.94e-30	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.853	rs6001188	chr22:39062194	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.5	0.63	5.56e-53	Menopause (age at onset);
LGG	cis	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg08112188	chr17:47440006	ZNF652	1.29	15.39	0.58	1.8e-43	Prostate cancer;
LGG	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg01221209	chr5:554886	NA	-0.51	-8.18	-0.36	2.75e-15	Ulcerative colitis;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.85	-0.34	2.96e-14	Life satisfaction;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	8.93	0.38	1.05e-17	Personality dimensions;
LGG	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg08344181	chr3:125677491	NA	-0.66	-7.75	-0.34	6.08e-14	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07659893	chr17:61819838	STRADA	0.49	8.19	0.36	2.54e-15	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg23758822	chr17:41437982	NA	0.85	14.97	0.57	1.29e-41	Menopause (age at onset);
LGG	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg27129171	chr3:47204927	SETD2	0.81	15.48	0.58	7.37e-44	Colorectal cancer;
LGG	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg02975922	chr3:195473998	MUC4	-0.46	-7.33	-0.32	1.03e-12	Pancreatic cancer;
LGG	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.93	0.31	1.43e-11	Educational attainment;
LGG	cis	rs2290159	0.800	rs73132351	chr3:12688284	A/G	cg23032965	chr3:12705835	RAF1	0.66	9.53	0.4	9.25e-20	Cholesterol, total;
LGG	cis	rs7681423	0.906	rs56010410	chr4:155502869	T/C	cg20735720	chr4:155535218	FGG	-0.52	-8.59	-0.37	1.39e-16	Fibrinogen;
LGG	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.32	-0.43	1.31e-22	Alzheimer's disease;
LGG	cis	rs9487094	1.000	rs9480953	chr6:109739144	A/G	cg01125227	chr6:109776195	MICAL1	0.46	7.87	0.34	2.51e-14	Height;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07701084	chr6:150067640	NUP43	0.42	7.65	0.34	1.16e-13	Lung cancer;
LGG	cis	rs4629710	0.592	rs13205441	chr6:131575069	G/A	cg12606694	chr6:131520996	AKAP7	0.51	8.28	0.36	1.35e-15	Multiple myeloma (IgH translocation);
LGG	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg12633918	chr20:23549525	CST9L	-0.33	-6.75	-0.3	4.55e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.93	-0.52	6.96e-33	Gut microbiome composition (summer);
LGG	cis	rs2410601	0.562	rs7846416	chr8:18913273	C/G	cg19414122	chr8:18896631	NA	0.41	7.18	0.32	2.78e-12	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs3820068	0.705	rs72643694	chr1:15860185	C/T	cg05660106	chr1:15850417	CASP9	1.12	27.24	0.78	3.33e-98	Systolic blood pressure;
LGG	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.97	-0.74	3.67e-83	Height;
LGG	cis	rs10262624	0.564	rs58051142	chr7:23905666	G/A	cg09690326	chr7:23720549	C7orf46	-0.33	-6.87	-0.3	2.06e-11	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.63e-12	Menopause (age at onset);
LGG	trans	rs55986470	0.646	rs112559043	chr2:239446187	A/G	cg01134436	chr17:81009848	B3GNTL1	0.73	7.69	0.34	8.9e-14	Chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18122802	chr7:66459960	SBDS	0.46	7.06	0.31	6.18e-12	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03264133	chr6:25882463	NA	0.73	13.91	0.54	5.56e-37	Blood metabolite levels;
LGG	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg17971929	chr21:40555470	PSMG1	0.89	17.42	0.63	1.28e-52	Cognitive function;
LGG	cis	rs16854884	0.837	rs6767236	chr3:143758399	A/C	cg06585982	chr3:143692056	C3orf58	0.51	8.16	0.35	3.16e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs72792276	1.000	rs72794386	chr5:127479278	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.77	0.3	3.91e-11	Red cell distribution width;
LGG	cis	rs2712184	0.721	rs2541401	chr2:217641006	T/C	cg05032264	chr2:217675019	NA	-0.43	-9.11	-0.39	2.44e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs9354308	0.868	rs2351729	chr6:66537291	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.84	-0.34	3.13e-14	Metabolite levels;
LGG	cis	rs10751667	0.643	rs11246362	chr11:969818	C/T	cg22143635	chr11:980567	AP2A2	0.44	8.16	0.35	3.24e-15	Alzheimer's disease (late onset);
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs17767392	0.918	rs2108707	chr14:71791170	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.2	-0.39	1.22e-18	Mitral valve prolapse;
LGG	cis	rs11690935	0.571	rs13020884	chr2:172901699	T/G	cg13550731	chr2:172543902	DYNC1I2	0.7	13.83	0.54	1.21e-36	Schizophrenia;
LGG	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07570687	chr10:102243282	WNT8B	0.44	7.5	0.33	3.32e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg06470251	chr20:60548479	NA	0.52	8.33	0.36	9.16e-16	Body mass index;
LGG	cis	rs7762018	0.607	rs75999653	chr6:170066927	A/G	cg17545662	chr6:170176663	C6orf70	0.64	6.7	0.3	6.22e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9557207	0.570	rs1410285	chr13:99783505	A/G	cg24509225	chr13:100037070	UBAC2	0.57	10.46	0.44	3.98e-23	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs6032067	0.636	rs6032093	chr20:43912167	A/G	cg10761708	chr20:43804764	PI3	0.58	8.98	0.38	7.08e-18	Blood protein levels;
LGG	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg18105134	chr13:113819100	PROZ	-0.79	-13.63	-0.54	8.43e-36	Platelet distribution width;
LGG	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg02269571	chr22:50332266	NA	0.65	10.3	0.43	1.49e-22	Schizophrenia;
LGG	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.75	-8.7	-0.37	5.67e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg20578329	chr17:80767326	TBCD	-0.73	-10.74	-0.45	3.71e-24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs17039065	1.000	rs719786	chr4:109396732	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.78	0.3	3.56e-11	Gut microbiome composition (summer);
LGG	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.96	0.35	1.36e-14	Restless legs syndrome;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg00106254	chr7:1943704	MAD1L1	0.41	7.05	0.31	6.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.42	-0.33	5.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg20503657	chr10:835505	NA	0.75	10.27	0.43	1.95e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9811920	0.609	rs9817005	chr3:99682692	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.02	-0.39	4.97e-18	Axial length;
LGG	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.98	0.42	2.33e-21	Height;
LGG	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05491587	chr18:77659695	KCNG2	-0.52	-7.03	-0.31	7.57e-12	Opioid sensitivity;
LGG	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.27	-0.36	1.43e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg19554555	chr3:13937349	NA	-0.57	-10.28	-0.43	1.82e-22	Ovarian reserve;
LGG	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg25342872	chr17:79175132	AZI1	0.49	8.8	0.38	2.84e-17	Frontotemporal dementia;
LGG	cis	rs9308433	0.529	rs4655243	chr1:214497291	A/G	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.13e-14	IgG glycosylation;
LGG	cis	rs7523273	0.565	rs2985104	chr1:207892012	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.71	-0.38	5.42e-17	Schizophrenia;
LGG	cis	rs4363385	0.747	rs1055935	chr1:152975941	C/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.39	-0.4	2.63e-19	Inflammatory skin disease;
LGG	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.19	-0.32	2.64e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1577917	1.000	rs1415753	chr6:86753074	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.65	-0.41	3.42e-20	Response to antipsychotic treatment;
LGG	trans	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg25214090	chr10:38739885	LOC399744	0.39	7.15	0.32	3.44e-12	Diastolic blood pressure;
LGG	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg08861369	chr16:85671714	KIAA0182	0.45	6.99	0.31	9.53e-12	Platelet distribution width;
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-6.96	-0.31	1.15e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18784586	chr12:13044401	GPRC5A	0.43	6.71	0.3	5.6e-11	Gut microbiome composition (summer);
LGG	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.1	-0.49	1.75e-29	Breast cancer;
LGG	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg00204512	chr16:28754710	NA	0.27	7.56	0.33	2.21e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2652834	0.851	rs2729815	chr15:63412843	A/G	cg05507819	chr15:63340323	TPM1	0.5	7.1	0.31	4.63e-12	HDL cholesterol;
LGG	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg01620082	chr3:125678407	NA	-0.61	-7.51	-0.33	2.98e-13	Depression;
LGG	trans	rs9354308	0.764	rs9360164	chr6:66584033	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.5	-0.5	4.16e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg04990556	chr1:26633338	UBXN11	-0.69	-13.78	-0.54	1.9e-36	Obesity-related traits;
LGG	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-7.96	-0.35	1.37e-14	Body mass index;
LGG	trans	rs11976180	1.000	rs2961125	chr7:143761770	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg11878867	chr6:150167359	LRP11	-0.54	-10.86	-0.45	1.26e-24	Lung cancer;
LGG	cis	rs8014204	0.762	rs12889665	chr14:75234830	T/G	cg06637938	chr14:75390232	RPS6KL1	0.64	11.59	0.47	1.86e-27	Caffeine consumption;
LGG	cis	rs4891159	0.790	rs72973773	chr18:74115176	T/C	cg24786174	chr18:74118243	ZNF516	-0.57	-13.29	-0.53	2.34e-34	Longevity;
LGG	cis	rs67311347	0.568	rs9864544	chr3:40336204	T/C	cg13683864	chr3:40499215	RPL14	-0.8	-15.82	-0.59	2.21e-45	Renal cell carcinoma;
LGG	cis	rs807669	0.835	rs698423	chr22:19197896	T/C	cg02655711	chr22:19163373	SLC25A1	0.78	15.45	0.58	1.01e-43	Metabolite levels;
LGG	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	7.51	0.33	3e-13	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg09307838	chr4:120376055	NA	0.81	13.09	0.52	1.5e-33	Corneal astigmatism;
LGG	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg00092383	chr7:157075207	NA	0.42	7.33	0.32	1.03e-12	Body mass index;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg11494091	chr17:61959527	GH2	0.51	8.11	0.35	4.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13424612	0.860	rs34277046	chr2:240897331	G/A	cg01812947	chr2:240904978	NDUFA10	0.44	7.4	0.33	6.66e-13	Odorant perception (isobutyraldehyde);
LGG	trans	rs877282	0.898	rs12357995	chr10:765739	T/C	cg22713356	chr15:30763199	NA	0.51	7.51	0.33	3.17e-13	Uric acid levels;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.95	0.57	1.67e-41	Platelet count;
LGG	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.74	-0.3	4.72e-11	Coronary artery disease;
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg00290607	chr11:67383545	NA	-0.65	-11.09	-0.46	1.64e-25	Mean corpuscular volume;
LGG	cis	rs12580194	0.593	rs61957933	chr12:55744710	T/G	cg19537932	chr12:55886519	OR6C68	-0.52	-9.31	-0.4	4.99e-19	Cancer;
LGG	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23598886	chr18:12777645	NA	-0.68	-9.15	-0.39	1.89e-18	Inflammatory skin disease;
LGG	cis	rs4478858	0.684	rs12725881	chr1:31736123	C/T	cg19084893	chr1:31688959	NA	-0.32	-6.7	-0.3	6.02e-11	Alcohol dependence;
LGG	cis	rs988958	0.675	rs56140445	chr2:42230317	G/C	cg19376973	chr2:42229025	NA	0.61	9.78	0.41	1.21e-20	Hypospadias;
LGG	cis	rs12282928	1.000	rs7949513	chr11:48329713	T/C	cg26585981	chr11:48327164	OR4S1	0.44	7.15	0.32	3.49e-12	Migraine - clinic-based;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg24503407	chr1:205819492	PM20D1	-0.52	-8.6	-0.37	1.2e-16	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	3.81e-44	Lung cancer;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4774899	0.934	rs12904561	chr15:57510974	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.21	-0.32	2.24e-12	Urinary tract infection frequency;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14654948	chr6:36164803	BRPF3	0.59	6.7	0.3	5.91e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03100196	chr7:143077761	ZYX	0.41	6.66	0.3	7.56e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.9	0.51	9.98e-33	High light scatter reticulocyte count;
LGG	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg17971929	chr21:40555470	PSMG1	0.86	15.71	0.59	6.8e-45	Cognitive function;
LGG	cis	rs807029	0.533	rs67813203	chr10:102738551	A/G	cg04662943	chr10:102668895	NA	0.48	7.06	0.31	6.25e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg12751644	chr20:60527061	NA	-0.3	-6.84	-0.3	2.46e-11	Body mass index;
LGG	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg25237894	chr2:233734115	C2orf82	0.63	11.88	0.48	1.3e-28	Coronary artery disease;
LGG	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg00206168	chr11:65308501	LTBP3	0.58	7.23	0.32	2.02e-12	Height;
LGG	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg18252515	chr7:66147081	NA	-1.4	-19.23	-0.67	5.22e-61	Diabetic kidney disease;
LGG	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg19748678	chr4:122722346	EXOSC9	0.53	10.34	0.43	1.06e-22	Type 2 diabetes;
LGG	cis	rs5753618	0.583	rs5753639	chr22:31870400	A/G	cg02404636	chr22:31891804	SFI1	-0.39	-7.26	-0.32	1.63e-12	Colorectal cancer;
LGG	cis	rs9462027	0.628	rs9462030	chr6:34831280	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.26	-0.46	3.68e-26	Systemic lupus erythematosus;
LGG	cis	rs3790515	0.826	rs2280471	chr1:151783736	A/G	cg07092448	chr1:151763213	TDRKH	0.88	10.27	0.43	1.96e-22	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-11.36	-0.47	1.46e-26	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03452623	chr4:187889614	NA	1.03	27.87	0.79	4.4e-101	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06656553	chr16:89960601	TCF25	-0.7	-6.93	-0.31	1.42e-11	Skin colour saturation;
LGG	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.42	0.5	8.89e-31	Alzheimer's disease;
LGG	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg19508488	chr2:152266495	RIF1	0.61	10.83	0.45	1.64e-24	Lung cancer;
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.72e-13	Height;
LGG	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg02221750	chr19:17393354	ANKLE1	-0.64	-9.5	-0.4	1.15e-19	Systemic lupus erythematosus;
LGG	cis	rs1927702	0.609	rs7848880	chr9:16028693	A/G	cg14451791	chr9:16040625	NA	0.32	7.59	0.33	1.82e-13	Body mass index;
LGG	trans	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg17712092	chr4:129076599	LARP1B	-0.58	-9.62	-0.41	4.27e-20	Breast cancer;
LGG	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.51	-8.47	-0.37	3.35e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs36093844	0.752	rs113529766	chr11:85583401	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg07148914	chr20:33460835	GGT7	0.54	9.06	0.39	3.68e-18	Height;
LGG	cis	rs7106204	0.534	rs75335266	chr11:24256395	G/T	ch.11.24196551F	chr11:24239977	NA	0.83	9.32	0.4	4.68e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg03433033	chr1:76189801	ACADM	0.81	14.15	0.55	5.12e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg06875740	chr19:51307921	C19orf48	-0.63	-8.01	-0.35	9.38e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10463316	0.817	rs10040628	chr5:150821027	T/G	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.87	-0.42	5.73e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.69	0.37	6.28e-17	Alzheimer's disease;
LGG	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg04727924	chr7:799746	HEATR2	-0.5	-7.11	-0.31	4.39e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg00012203	chr2:219082015	ARPC2	-0.84	-16.84	-0.62	5.59e-50	Colorectal cancer;
LGG	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg12386194	chr3:101231763	SENP7	0.47	8.46	0.37	3.57e-16	Colorectal cancer;
LGG	cis	rs9894429	0.646	rs6565612	chr17:79602820	C/T	cg18240062	chr17:79603768	NPLOC4	-0.62	-10.41	-0.44	5.91e-23	Eye color traits;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg08742575	chr21:47604166	C21orf56	0.49	8.34	0.36	8.72e-16	Testicular germ cell tumor;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05930166	chr1:222884917	AIDA;C1orf58	0.39	6.65	0.3	8.32e-11	Bipolar disorder;
LGG	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg16141378	chr3:129829833	LOC729375	-0.48	-12.4	-0.5	1.07e-30	Mood instability;
LGG	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.2	0.52	5.19e-34	Colorectal cancer;
LGG	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg17644776	chr2:200775616	C2orf69	0.6	6.89	0.3	1.89e-11	Schizophrenia;
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg11608241	chr8:8085544	FLJ10661	0.33	7.51	0.33	3.06e-13	Neuroticism;
LGG	cis	rs34929064	1.000	rs34775303	chr7:22720089	G/A	cg18045685	chr7:22629474	NA	0.57	9.05	0.39	4.05e-18	Major depression and alcohol dependence;
LGG	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg16797656	chr11:68205561	LRP5	0.4	6.99	0.31	9.55e-12	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg08280861	chr8:58055591	NA	0.53	6.78	0.3	3.68e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs7166081	1.000	rs3743342	chr15:67485667	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.87	-0.3	2.06e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.92	-0.35	1.73e-14	Monocyte count;
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg08461457	chr11:2027003	NA	0.4	7.72	0.34	7.37e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg08436684	chr16:88034427	BANP	-0.67	-6.79	-0.3	3.46e-11	Airflow obstruction;
LGG	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg19680485	chr15:31195859	MTMR15	-0.45	-7.39	-0.32	6.82e-13	Huntington's disease progression;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.5	-9.02	-0.39	4.96e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7666738	0.830	rs6832568	chr4:98994061	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg09222892	chr1:25734099	RHCE	0.45	9.31	0.4	5.17e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11644478	chr21:40555479	PSMG1	-0.72	-12.76	-0.51	3.64e-32	Cognitive function;
LGG	cis	rs9863	0.861	rs75321546	chr12:124447465	T/A	cg13487667	chr12:124434373	CCDC92	-0.38	-7.49	-0.33	3.44e-13	White blood cell count;
LGG	cis	rs1669338	0.588	rs55959448	chr3:3204000	C/T	cg16797762	chr3:3221439	CRBN	-0.97	-12.62	-0.51	1.33e-31	White matter integrity;
LGG	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg26513180	chr16:89883248	FANCA	1.0	9.64	0.41	3.56e-20	Skin colour saturation;
LGG	cis	rs11711311	0.955	rs11715350	chr3:113418376	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.17	0.55	4.11e-38	IgG glycosylation;
LGG	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg13147721	chr7:65941812	NA	-0.83	-10.22	-0.43	3.1e-22	Diabetic kidney disease;
LGG	cis	rs2188561	0.638	rs3735609	chr7:107383744	C/G	cg16793755	chr7:107334138	SLC26A4	0.41	7.2	0.32	2.53e-12	Alcohol consumption;
LGG	cis	rs3087591	1.000	rs9904169	chr17:29572518	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.82	-0.57	5.98e-41	Hip circumference;
LGG	cis	rs7666738	0.830	rs28516388	chr4:98987449	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7737355	1.000	rs11242077	chr5:130771037	G/A	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.81e-19	Life satisfaction;
LGG	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.15	0.32	3.43e-12	Birth weight;
LGG	cis	rs9992101	1.000	rs10023335	chr4:77358987	C/T	cg17010112	chr4:77227123	STBD1	0.37	7.19	0.32	2.6e-12	Creatinine levels;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.2	-0.6	4.3e-47	Longevity;
LGG	cis	rs3816183	1.000	rs920391	chr2:43019347	C/G	cg14631114	chr2:43023945	NA	0.5	9.04	0.39	4.25e-18	Hypospadias;
LGG	cis	rs6754311	0.773	rs309176	chr2:136622216	T/C	cg07169764	chr2:136633963	MCM6	-0.77	-13.12	-0.52	1.22e-33	Mosquito bite size;
LGG	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg19468946	chr17:37922297	IKZF3	-0.44	-7.89	-0.34	2.19e-14	Self-reported allergy;
LGG	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg13334819	chr7:99746414	C7orf59	-0.45	-6.93	-0.31	1.46e-11	Coronary artery disease;
LGG	cis	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg13443165	chr9:33130375	B4GALT1	-0.6	-9.25	-0.4	8.17e-19	IgG glycosylation;
LGG	cis	rs2011503	0.941	rs2315023	chr19:19413393	C/T	cg11584989	chr19:19387371	SF4	0.79	13.15	0.52	8.98e-34	Bipolar disorder;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg19717773	chr7:2847554	GNA12	-0.34	-7.0	-0.31	8.99e-12	Height;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg02725872	chr8:58115012	NA	-0.86	-12.4	-0.5	1.12e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1386478	0.853	rs13071100	chr3:113801965	T/C	cg14431476	chr3:113822413	NA	-0.45	-7.13	-0.31	3.81e-12	Crohn's disease and psoriasis;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg13453750	chr1:205783389	SLC41A1	0.37	6.95	0.31	1.25e-11	Menarche (age at onset);
LGG	cis	rs2737618	1.000	rs2737618	chr1:200107425	C/T	cg21825944	chr1:200113062	NR5A2	-0.51	-8.56	-0.37	1.66e-16	Uric acid levels;
LGG	cis	rs8010715	0.596	rs12435995	chr14:24589464	A/C	cg06429887	chr14:24600500	FITM1	0.35	7.27	0.32	1.58e-12	IgG glycosylation;
LGG	cis	rs11514810	1.000	rs4385385	chr7:1431125	T/C	cg22426938	chr7:1423890	NA	-0.61	-7.78	-0.34	4.64e-14	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg02002194	chr4:3960332	NA	0.41	7.32	0.32	1.13e-12	Joint mobility (Beighton score);
LGG	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg13147721	chr7:65941812	NA	-0.79	-9.56	-0.41	7.18e-20	Diabetic kidney disease;
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg10207240	chr12:122356781	WDR66	0.27	8.06	0.35	6.77e-15	Mean corpuscular volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17156531	chr1:212781873	ATF3	-0.47	-7.44	-0.33	4.81e-13	Pancreatic cancer;
LGG	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg15522984	chr1:182991683	LAMC1	0.45	8.83	0.38	2.25e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9611519	1.000	rs9611505	chr22:41540279	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-8.46	-0.37	3.59e-16	Neuroticism;
LGG	trans	rs11875185	0.510	rs11872150	chr18:55628114	C/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.85	-0.38	1.91e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg05368731	chr17:41323189	NBR1	0.96	18.75	0.66	8.88e-59	Menopause (age at onset);
LGG	cis	rs704	0.739	rs2027993	chr17:26706946	G/T	cg10342447	chr17:26645325	TMEM97	-0.37	-6.76	-0.3	4.09e-11	Osteoprotegerin levels;
LGG	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg13114125	chr14:105738426	BRF1	-0.85	-16.43	-0.61	3.8e-48	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg14689365	chr7:158441557	NCAPG2	0.63	10.7	0.45	5.24e-24	Height;
LGG	cis	rs7715806	0.500	rs77544433	chr5:75001025	C/A	cg19683494	chr5:74908142	NA	0.49	6.7	0.3	5.95e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20791839	chr3:53926047	SELK	0.47	7.67	0.34	1.02e-13	Cognitive performance;
LGG	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.05	0.39	3.83e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg12193833	chr17:30244370	NA	0.28	6.99	0.31	9.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2154319	0.836	rs9326087	chr1:41504195	G/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.98	-0.39	7.04e-18	Height;
LGG	cis	rs60180747	0.909	rs79981875	chr15:66801662	T/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.38	0.43	8.13e-23	Testicular germ cell tumor;
LGG	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg06421707	chr20:25228305	PYGB	0.48	10.66	0.44	6.87e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.67	9.67	0.41	2.87e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg13944838	chr5:179740914	GFPT2	0.69	12.98	0.52	4.58e-33	Height;
LGG	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg23740940	chr11:68924746	NA	0.44	6.98	0.31	1e-11	Blond vs. brown hair color;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1270639	0.778	rs1465250	chr7:157439075	C/G	cg13357408	chr7:157437802	PTPRN2	0.66	10.66	0.44	7.13e-24	Colorectal cancer;
LGG	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg03264133	chr6:25882463	NA	-0.45	-7.18	-0.32	2.84e-12	Iron status biomarkers;
LGG	cis	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg06609049	chr19:2785107	THOP1	0.94	15.81	0.59	2.52e-45	Total cholesterol levels;
LGG	cis	rs4959677	0.868	rs1010762	chr6:2476867	C/T	cg20147862	chr6:2634573	C6orf195	-0.37	-8.04	-0.35	7.45e-15	Orthostatic hypotension;
LGG	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg24110177	chr3:50126178	RBM5	0.57	10.31	0.43	1.45e-22	Intelligence (multi-trait analysis);
LGG	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg20578329	chr17:80767326	TBCD	-0.46	-8.09	-0.35	5.23e-15	Breast cancer;
LGG	cis	rs7503807	0.967	rs12939549	chr17:78611724	C/T	cg06872548	chr17:78716983	RPTOR	-0.44	-10.63	-0.44	9.58e-24	Obesity;
LGG	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg15105969	chr2:36825350	FEZ2	0.48	7.02	0.31	8.12e-12	Height;
LGG	cis	rs4481887	0.927	rs12039929	chr1:248482018	G/A	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs17208368	0.657	rs12448373	chr16:55094232	T/C	cg11181171	chr16:55090946	NA	0.46	7.71	0.34	7.7e-14	Hypospadias;
LGG	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.17	-0.35	3.01e-15	Myopia (pathological);
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg24829409	chr8:58192753	C8orf71	0.63	9.04	0.39	4.46e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs11608355	0.846	rs61934479	chr12:109855111	A/G	cg19025524	chr12:109796872	NA	-0.4	-6.7	-0.3	6.04e-11	Neuroticism;
LGG	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-15.35	-0.58	2.78e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9815354	0.638	rs75687617	chr3:42044664	C/T	cg03022575	chr3:42003672	ULK4	0.75	8.3	0.36	1.12e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg00339695	chr16:24857497	SLC5A11	-0.4	-6.87	-0.3	2.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg22398616	chr13:53314203	LECT1	-0.45	-9.3	-0.4	5.54e-19	Lewy body disease;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07362569	chr17:61921086	SMARCD2	0.49	9.33	0.4	4.31e-19	Prudent dietary pattern;
LGG	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.43	0.33	5.46e-13	Cystic fibrosis severity;
LGG	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-10.45	-0.44	4.17e-23	Chronic sinus infection;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg19318889	chr4:1322082	MAEA	0.46	7.9	0.34	2.03e-14	Longevity;
LGG	cis	rs6997458	0.774	rs6984619	chr8:86331378	C/G	cg02393479	chr8:86352350	CA3	-0.3	-6.74	-0.3	4.64e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9357271	1.000	rs4711541	chr6:38342122	A/G	cg07362130	chr6:38359646	BTBD9	-0.47	-10.76	-0.45	2.98e-24	Restless legs syndrome;
LGG	cis	rs737693	1.000	rs72981675	chr11:102721251	C/T	cg19620758	chr11:102826565	MMP13	0.53	6.73	0.3	5.02e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs240764	0.507	rs2101814	chr6:101202822	T/A	cg09795085	chr6:101329169	ASCC3	0.44	7.07	0.31	5.81e-12	Neuroticism;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07362569	chr17:61921086	SMARCD2	0.49	9.24	0.39	8.72e-19	Prudent dietary pattern;
LGG	cis	rs9534288	0.843	rs4362286	chr13:46566514	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.22	-0.52	4.31e-34	Blood protein levels;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.8	0.34	4.27e-14	Schizophrenia;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg11965913	chr1:205819406	PM20D1	0.85	18.77	0.66	7.48e-59	Menarche (age at onset);
LGG	cis	rs7209395	0.840	rs57343195	chr17:64151738	A/C	cg19474267	chr17:64306194	PRKCA	0.51	7.99	0.35	1.1e-14	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22968622	chr17:43663579	NA	1.07	20.93	0.7	5.82e-69	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg01028140	chr2:1542097	TPO	-0.54	-8.62	-0.37	1.05e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2455799	0.552	rs2470519	chr3:15762847	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.07	-0.35	5.93e-15	Mean platelet volume;
LGG	cis	rs896854	0.684	rs10099059	chr8:95986972	G/C	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.5	-0.37	2.56e-16	Type 2 diabetes;
LGG	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg18854424	chr1:2615690	NA	-0.33	-6.8	-0.3	3.26e-11	Ulcerative colitis;
LGG	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18110333	chr6:292329	DUSP22	-0.55	-9.64	-0.41	3.7799999999999997e-20	Menopause (age at onset);
LGG	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg21130718	chr4:1044621	NA	-0.39	-7.53	-0.33	2.71e-13	Recombination rate (males);
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.69e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs9814567	0.865	rs9834981	chr3:134282279	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.07	-0.52	1.98e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg02187348	chr16:89574699	SPG7	0.45	7.41	0.33	6.16e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	trans	rs12310956	0.532	rs11052920	chr12:33955891	T/G	cg13010199	chr12:38710504	ALG10B	0.5	9.65	0.41	3.3e-20	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs4821108	chr22:21959038	G/C	cg05046821	chr22:21984468	YDJC	-0.38	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	cis	rs908922	0.676	rs1572533	chr1:152509742	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.32	-0.55	8.93e-39	Hair morphology;
LGG	cis	rs10895140	0.666	rs4439481	chr11:101511019	A/G	cg23650423	chr11:101454676	TRPC6	-0.42	-6.8	-0.3	3.16e-11	Menarche (age at onset);
LGG	cis	rs7586879	1.000	rs7603153	chr2:25116966	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs250677	0.687	rs36044	chr5:148441128	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.67e-12	Breast cancer;
LGG	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg03060546	chr3:49711283	APEH	-0.74	-13.43	-0.53	5.73e-35	Resting heart rate;
LGG	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg23173402	chr1:227635558	NA	0.6	10.2	0.43	3.64e-22	Major depressive disorder;
LGG	cis	rs7267979	0.933	rs2261109	chr20:25259200	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	2.96e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg03929089	chr4:120376271	NA	0.69	7.56	0.33	2.24e-13	Intraocular pressure;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02018176	chr4:1364513	KIAA1530	0.47	11.37	0.47	1.38e-26	Longevity;
LGG	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg15556689	chr8:8085844	FLJ10661	0.57	10.93	0.45	6.71e-25	Neuroticism;
LGG	cis	rs61897795	0.657	rs174587	chr11:61612830	C/T	cg19610905	chr11:61596333	FADS2	-0.68	-9.51	-0.4	1.06e-19	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs12153243	0.686	rs768010	chr5:142934382	C/T	cg13907255	chr5:142895549	NA	-0.47	-8.16	-0.35	3.25e-15	Migraine;
LGG	cis	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.42	-0.33	5.51e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.89	0.57	2.93e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.52	-0.33	2.9e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.6	0.33	1.69e-13	Neuroticism;
LGG	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg27426351	chr10:43362370	NA	-0.55	-7.83	-0.34	3.42e-14	Blood protein levels;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09699651	chr6:150184138	LRP11	0.57	11.13	0.46	1.17e-25	Lung cancer;
LGG	cis	rs17504614	0.634	rs17041069	chr2:51069156	A/T	cg23851515	chr2:51057218	NRXN1	0.45	7.38	0.32	7.4e-13	Educational attainment (years of education);
LGG	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg04117972	chr1:227635322	NA	0.73	11.81	0.48	2.51e-28	Major depressive disorder;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7192380	0.965	rs9938213	chr16:69640590	T/C	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.71	-0.34	7.8e-14	Sjögren's syndrome;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg06848047	chr4:90757629	SNCA	-0.4	-7.5	-0.33	3.37e-13	Dementia with Lewy bodies;
LGG	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21659725	chr3:3221576	CRBN	0.73	11.68	0.48	8.47e-28	Resting heart rate;
LGG	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs783540	0.746	rs7165125	chr15:83297936	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.81	-0.3	3.08e-11	Schizophrenia;
LGG	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg07061783	chr6:25882402	NA	-0.39	-6.91	-0.31	1.63e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12887734	0.546	rs66676135	chr14:104271504	G/A	cg26031613	chr14:104095156	KLC1	-0.55	-8.68	-0.37	6.59e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg03647239	chr10:116582469	FAM160B1	0.41	7.52	0.33	2.95e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs853679	0.517	rs3757185	chr6:28107776	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.72	-0.34	7.41e-14	Depression;
LGG	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg19524238	chr7:2802976	GNA12	0.36	7.73	0.34	6.74e-14	Height;
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-11.92	-0.48	9.71e-29	Personality dimensions;
LGG	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-16.77	-0.61	1.13e-49	Dental caries;
LGG	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg13010199	chr12:38710504	ALG10B	0.67	13.34	0.53	1.45e-34	Bladder cancer;
LGG	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg25486957	chr4:152246857	NA	-0.51	-8.34	-0.36	8.35e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4696584	0.877	rs1490677	chr4:155380037	C/A	cg13738195	chr4:155413469	DCHS2	-0.38	-7.11	-0.31	4.43e-12	Folding of antihelix;
LGG	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.48	-0.4	1.31e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	9.67	0.41	2.8e-20	Height;
LGG	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg00700412	chr12:58011837	NA	0.47	9.59	0.41	5.27e-20	Multiple sclerosis;
LGG	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg12633918	chr20:23549525	CST9L	-0.34	-6.92	-0.31	1.55e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4788570	0.538	rs16973260	chr16:71534853	A/G	cg06353428	chr16:71660113	MARVELD3	0.97	12.91	0.51	8.7e-33	Intelligence (multi-trait analysis);
LGG	cis	rs748404	0.578	rs4547312	chr15:43632138	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	7.25	0.32	1.81e-12	Lung cancer;
LGG	cis	rs4819852	0.752	rs4819526	chr22:19974032	T/C	cg07821417	chr22:19972146	ARVCF	0.51	10.96	0.45	5.13e-25	Pulse pressure;
LGG	cis	rs9443645	0.901	rs1890229	chr6:79695029	C/T	cg18132916	chr6:79620363	NA	-0.3	-8.44	-0.37	4e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg07599136	chr5:415885	AHRR	0.85	11.49	0.47	4.85e-27	Fat distribution (HIV);
LGG	cis	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg21775007	chr8:11205619	TDH	-0.52	-8.13	-0.35	3.99e-15	Triglycerides;
LGG	cis	rs7412746	0.611	rs11204747	chr1:150927152	A/G	cg15448220	chr1:150897856	SETDB1	-0.37	-6.75	-0.3	4.48e-11	Melanoma;
LGG	cis	rs11574514	1.000	rs14178	chr16:67969531	A/G	cg09738193	chr16:67926317	PSKH1	-0.75	-6.97	-0.31	1.07e-11	Crohn's disease;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg18350739	chr11:68623251	NA	-0.89	-22.78	-0.73	1.28e-77	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7226408	0.576	rs7244564	chr18:34621204	C/T	cg15022739	chr18:34823045	BRUNOL4	0.43	9.33	0.4	4.45e-19	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.36	9.93	0.42	3.29e-21	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	trans	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg16011800	chr17:1958478	HIC1	-0.67	-10.03	-0.42	1.5e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs4731207	0.596	rs6466971	chr7:124596007	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg09699651	chr6:150184138	LRP11	0.51	9.2	0.39	1.28e-18	Lung cancer;
LGG	cis	rs7444	0.941	rs181359	chr22:21928641	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.94	-0.31	1.33e-11	Systemic lupus erythematosus;
LGG	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg02023728	chr11:77925099	USP35	0.42	7.52	0.33	2.92e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-15.94	-0.6	6.71e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg18681998	chr4:17616180	MED28	0.89	20.64	0.69	1.39e-67	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg03060546	chr3:49711283	APEH	-0.7	-11.74	-0.48	4.88e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.55e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg19168338	chr16:4465731	CORO7	-1.14	-25.35	-0.76	1.44e-89	Schizophrenia;
LGG	cis	rs838721	0.740	rs838718	chr2:234296650	G/A	cg17212304	chr2:234394541	USP40	0.35	7.16	0.32	3.25e-12	Total body bone mineral density;
LGG	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg07274523	chr3:49395745	GPX1	0.57	9.64	0.41	3.69e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.19	-0.43	3.88e-22	Neuroticism;
LGG	trans	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.5	8.26	0.36	1.56e-15	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg16576597	chr16:28551801	NUPR1	0.37	8.64	0.37	9.14e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.88	0.34	2.3e-14	Red cell distribution width;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	7.1	0.31	4.59e-12	Platelet count;
LGG	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg15596359	chr8:11213517	TDH	0.4	8.15	0.35	3.39e-15	Retinal vascular caliber;
LGG	cis	rs457717	1.000	rs1697845	chr5:75922504	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.36	7.37	0.32	7.65e-13	Hearing impairment;
LGG	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.45	0.33	4.56e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22433210	chr17:43662623	NA	0.9	14.73	0.56	1.5e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.17	-0.32	2.92e-12	Blood metabolite levels;
LGG	cis	rs4148087	0.725	rs1378577	chr21:43619665	T/G	cg08841829	chr21:43638893	ABCG1	-0.44	-7.54	-0.33	2.42e-13	Eating disorder in bipolar disorder;
LGG	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	cg07245641	chr1:182991651	LAMC1	0.32	6.74	0.3	4.84e-11	Fuchs's corneal dystrophy;
LGG	cis	rs7202877	0.706	rs4993971	chr16:75411634	C/G	cg03315344	chr16:75512273	CHST6	-0.53	-7.13	-0.31	3.93e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg03036210	chr16:89904091	SPIRE2	-0.49	-6.97	-0.31	1.08e-11	Skin colour saturation;
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.36	0.4	3.58e-19	Systolic blood pressure;
LGG	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg17646820	chr3:66848679	NA	0.5	7.94	0.35	1.5e-14	Type 2 diabetes;
LGG	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.58	-0.41	5.92e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.76	0.34	5.51e-14	Systolic blood pressure;
LGG	cis	rs2273669	0.915	rs2145766	chr6:109296261	G/C	cg05315195	chr6:109294784	ARMC2	-0.52	-7.34	-0.32	9.41e-13	Prostate cancer;
LGG	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg13393036	chr8:95962371	TP53INP1	-0.26	-7.04	-0.31	6.84e-12	Type 2 diabetes;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-8.57	-0.37	1.53e-16	Renal function-related traits (BUN);
LGG	cis	rs2816316	0.697	rs2209014	chr1:192506082	G/A	cg02586212	chr1:192544902	RGS1	0.32	6.72	0.3	5.41e-11	Celiac disease;
LGG	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg10503236	chr1:231470652	EXOC8	-0.36	-7.03	-0.31	7.37e-12	Hemoglobin concentration;
LGG	cis	rs7917772	0.502	rs10748827	chr10:104368336	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.48	0.56	1.77e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg21775007	chr8:11205619	TDH	0.49	8.2	0.36	2.47e-15	Systolic blood pressure;
LGG	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.04	0.35	7.82e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs9534288	0.731	rs2404730	chr13:46617381	G/A	cg15192986	chr13:46630673	CPB2	-0.59	-12.97	-0.52	4.79e-33	Blood protein levels;
LGG	trans	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.38	-0.32	7.28e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.12	-0.31	4.21e-12	Triglycerides;
LGG	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	8.2	0.36	2.46e-15	Menarche (age at onset);
LGG	cis	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg24375607	chr4:120327624	NA	0.61	10.18	0.43	4.23e-22	Corneal astigmatism;
LGG	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg24692254	chr21:30365293	RNF160	-0.64	-11.2	-0.46	6.18e-26	Cognitive test performance;
LGG	cis	rs12282928	0.885	rs4472898	chr11:48260983	T/A	cg26585981	chr11:48327164	OR4S1	-0.42	-6.93	-0.31	1.39e-11	Migraine - clinic-based;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg04234412	chr22:24373322	LOC391322	-0.91	-20.3	-0.69	5.24e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11971779	0.680	rs10242419	chr7:139089380	A/G	cg07862535	chr7:139043722	LUC7L2	-0.43	-7.17	-0.32	2.93e-12	Diisocyanate-induced asthma;
LGG	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.18	0.36	2.67e-15	Prudent dietary pattern;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg02487422	chr3:49467188	NICN1	0.57	10.57	0.44	1.56e-23	Resting heart rate;
LGG	cis	rs17162190	0.590	rs7524421	chr1:26810612	C/G	cg23229016	chr1:26872525	RPS6KA1	0.26	6.84	0.3	2.44e-11	Mean corpuscular volume;
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg22618164	chr12:122356400	WDR66	-0.37	-10.92	-0.45	7.65e-25	Mean corpuscular volume;
LGG	cis	rs10865541	0.869	rs6548162	chr2:3434332	C/T	cg11642891	chr2:3452563	TTC15	-0.39	-7.47	-0.33	3.98e-13	Obesity-related traits;
LGG	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.35	0.7	6.47e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.31	0.5	2.61e-30	Intelligence (multi-trait analysis);
LGG	cis	rs477692	1.000	rs477692	chr10:131426022	T/C	cg05714579	chr10:131428358	MGMT	0.59	12.26	0.5	4.07e-30	Response to temozolomide;
LGG	cis	rs60180747	0.909	rs11639266	chr15:66600417	G/A	cg07575407	chr15:66541975	MEGF11	0.4	7.83	0.34	3.46e-14	Testicular germ cell tumor;
LGG	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs7945718	0.592	rs6416153	chr11:12684263	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg08250081	chr4:10125330	NA	-0.52	-10.2	-0.43	3.56e-22	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02018176	chr4:1364513	KIAA1530	0.61	14.89	0.57	2.88e-41	Longevity;
LGG	trans	rs3857536	0.740	rs9354390	chr6:66890162	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.47	8.08	0.35	5.68e-15	Blood trace element (Cu levels);
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg25338242	chr13:114786047	RASA3	0.39	7.16	0.32	3.18e-12	Schizophrenia;
LGG	cis	rs11674184	0.659	rs59129126	chr2:11728388	T/C	cg07314298	chr2:11723111	GREB1	-0.85	-20.36	-0.69	2.85e-66	Endometriosis;
LGG	cis	rs847649	0.731	rs10808120	chr7:102672234	A/G	cg18108683	chr7:102477205	FBXL13	-0.53	-10.89	-0.45	9.62e-25	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg17376030	chr22:41985996	PMM1	-0.57	-9.05	-0.39	4.06e-18	Vitiligo;
LGG	cis	rs3784262	0.669	rs4646635	chr15:58252277	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.21e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.07	0.31	5.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg20913747	chr6:44695427	NA	-0.61	-10.42	-0.44	5.68e-23	Total body bone mineral density;
LGG	cis	rs6866614	0.605	rs5029422	chr5:131390614	G/C	cg07395648	chr5:131743802	NA	-0.38	-6.98	-0.31	9.97e-12	Perceived unattractiveness to mosquitoes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00771170	chr19:3971184	DAPK3	0.45	6.72	0.3	5.22e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.45	0.37	3.79e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4804815	0.780	rs4804231	chr19:7839803	C/A	cg00371453	chr19:7854482	CLEC4GP1	0.7	10.52	0.44	2.44e-23	Neutrophil count;
LGG	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	7.65	0.34	1.14e-13	Blood protein levels;
LGG	trans	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.51	-8.29	-0.36	1.21e-15	Mean corpuscular volume;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg24634471	chr8:143751801	JRK	0.48	7.28	0.32	1.48e-12	Schizophrenia;
LGG	trans	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg25214090	chr10:38739885	LOC399744	0.7	12.18	0.49	8.78e-30	Corneal astigmatism;
LGG	cis	rs2415984	0.570	rs28674745	chr14:46924415	G/C	cg14871534	chr14:47121158	RPL10L	-0.6	-10.44	-0.44	4.89e-23	Number of children ever born;
LGG	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs6088580	0.506	rs6058096	chr20:33243184	C/T	cg12302830	chr20:33297742	TP53INP2	-0.45	-7.23	-0.32	2.05e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6426558	0.537	rs6685823	chr1:227270835	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26714650	chr12:56694279	CS	1.48	18.03	0.64	1.97e-55	Psoriasis vulgaris;
LGG	trans	rs3206736	0.548	rs57315957	chr7:35062819	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.3	0.32	1.24e-12	Diastolic blood pressure;
LGG	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg19673125	chr6:150240577	RAET1G	0.36	8.79	0.38	3.06e-17	Testicular germ cell tumor;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06719391	chr11:2554330	KCNQ1	0.41	7.27	0.32	1.52e-12	Obesity-related traits;
LGG	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg22875332	chr1:76189707	ACADM	-0.62	-9.31	-0.4	5.32e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg26769984	chr7:1090371	C7orf50	0.53	9.3	0.4	5.75e-19	Bronchopulmonary dysplasia;
LGG	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.13	0.31	3.88e-12	Type 2 diabetes;
LGG	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	trans	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg25214090	chr10:38739885	LOC399744	0.7	12.64	0.51	1.12e-31	Corneal astigmatism;
LGG	cis	rs17227506	0.900	rs7836004	chr8:13440683	A/G	cg03566418	chr8:13424080	C8orf48	0.47	7.36	0.32	8.71e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs12447804	0.645	rs12920639	chr16:58114140	G/T	cg03859792	chr16:58121049	NA	-0.62	-9.73	-0.41	1.69e-20	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs3857536	0.730	rs7766281	chr6:66988573	T/G	cg07460842	chr6:66804631	NA	-0.43	-7.08	-0.31	5.56e-12	Blood trace element (Cu levels);
LGG	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.49	-0.71	1.42e-71	Coronary artery disease;
LGG	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.44	-6.98	-0.31	1e-11	Schizophrenia;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg02733842	chr7:1102375	C7orf50	0.58	8.74	0.38	4.23e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs4622507	0.566	rs34435075	chr16:55072356	G/C	cg09947736	chr16:55091198	NA	0.77	11.66	0.48	1.05e-27	Social communication problems;
LGG	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg10402321	chr1:26617780	UBXN11	-0.36	-7.07	-0.31	5.63e-12	Obesity-related traits;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg06558623	chr16:89946397	TCF25	1.03	12.53	0.5	3.16e-31	Skin colour saturation;
LGG	cis	rs7737355	0.947	rs13174006	chr5:130963473	A/G	cg06307176	chr5:131281290	NA	0.58	9.49	0.4	1.2e-19	Life satisfaction;
LGG	trans	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg24247370	chr13:99142703	STK24	-0.37	-6.82	-0.3	2.85e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs62027291	0.654	rs56402836	chr15:77081967	A/C	cg23625390	chr15:77176239	SCAPER	-0.64	-7.16	-0.32	3.27e-12	Plateletcrit;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.68	-0.54	5.2e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs2133450	1.000	rs62234959	chr3:7345896	G/C	cg19930620	chr3:7340148	GRM7	-0.38	-8.46	-0.37	3.47e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs490234	0.871	rs4837019	chr9:128276081	C/G	cg14078157	chr9:128172775	NA	-0.46	-8.98	-0.38	7.06e-18	Mean arterial pressure;
LGG	trans	rs10751647	0.804	rs3809112	chr11:307036	C/T	cg04456547	chr11:69071124	NA	0.25	7.08	0.31	5.36e-12	Monocyte count;
LGG	cis	rs1451882	0.698	rs1376786	chr8:1061074	A/G	cg07395941	chr8:1078200	NA	-0.48	-6.67	-0.3	7.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10895140	0.756	rs4393286	chr11:101519215	T/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.75	-0.3	4.57e-11	Menarche (age at onset);
LGG	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg08250081	chr4:10125330	NA	0.36	7.08	0.31	5.24e-12	Bone mineral density;
LGG	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg11693508	chr17:37793320	STARD3	0.73	10.43	0.44	5.05e-23	Bipolar disorder;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg01145232	chr6:150245071	RAET1G	0.47	8.73	0.38	4.54e-17	Lung cancer;
LGG	cis	rs7159888	0.577	rs1256540	chr14:65764069	A/G	cg15999311	chr14:65749247	NA	0.46	8.07	0.35	6.2e-15	IgG glycosylation;N-glycan levels;
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg27476859	chr7:2772710	GNA12	0.44	7.42	0.33	5.76e-13	Height;
LGG	cis	rs2629540	0.781	rs11245362	chr10:126458649	T/C	cg08799069	chr10:126477246	METTL10	-0.68	-14.5	-0.56	1.53e-39	Cocaine dependence;
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.02	0.35	8.75e-15	Prostate cancer;
LGG	cis	rs2463822	0.688	rs7121684	chr11:62162389	T/C	cg06239285	chr11:62104954	ASRGL1	-1.15	-15.03	-0.57	6.88e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg26396452	chr14:65542826	MAX	-0.43	-8.64	-0.37	8.93e-17	Obesity-related traits;
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg16141378	chr3:129829833	LOC729375	-0.47	-11.51	-0.47	3.89e-27	Mood instability;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.22	0.43	3.02e-22	Tonsillectomy;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg13206674	chr6:150067644	NUP43	0.66	14.76	0.57	1.16e-40	Lung cancer;
LGG	cis	rs6716455	0.713	rs72871230	chr2:151004347	G/C	cg24691911	chr2:150991316	NA	0.47	7.19	0.32	2.61e-12	Alcoholism (alcohol use disorder factor score);Alcoholism (alcohol dependence factor score);
LGG	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-9.6	-0.41	5.05e-20	Body mass index;
LGG	cis	rs2131877	0.830	rs62290329	chr3:194843634	G/A	cg07250128	chr3:194833983	C3orf21	0.4	6.69	0.3	6.62e-11	Non-small cell lung cancer;
LGG	cis	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg04990556	chr1:26633338	UBXN11	-0.69	-14.0	-0.55	2.09e-37	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg16662043	chr16:48846231	NA	0.38	7.41	0.33	5.96e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg15522984	chr1:182991683	LAMC1	0.49	10.06	0.42	1.17e-21	Colorectal cancer;
LGG	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.41e-31	Motion sickness;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9341808	0.556	rs1474791	chr6:81033097	A/G	cg08355045	chr6:80787529	NA	0.35	6.91	0.31	1.63e-11	Sitting height ratio;
LGG	cis	rs8077059	0.959	rs3883322	chr17:55820399	G/A	cg12582317	chr17:55822272	NA	0.4	7.2	0.32	2.48e-12	Sex hormone-binding globulin levels;
LGG	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg06565975	chr8:143823917	SLURP1	0.34	8.51	0.37	2.4e-16	Urinary tract infection frequency;
LGG	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06634786	chr22:41940651	POLR3H	0.67	11.17	0.46	8.19e-26	Vitiligo;
LGG	cis	rs4804815	0.780	rs4804814	chr19:7840310	A/G	cg00970558	chr19:7854469	CLEC4GP1	-0.62	-9.42	-0.4	2.15e-19	Neutrophil count;
LGG	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs1062746	0.558	rs889608	chr16:87337543	A/G	cg02258303	chr16:87377426	FBXO31	-0.42	-7.82	-0.34	3.67e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs28374715	1.000	rs28374715	chr15:41563950	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.07	-20.18	-0.68	1.95e-65	Ulcerative colitis;
LGG	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg25986240	chr4:9926439	SLC2A9	0.49	10.76	0.45	2.93e-24	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs193541	0.564	rs62377434	chr5:122340569	C/A	cg19412675	chr5:122181750	SNX24	-0.52	-8.03	-0.35	7.92e-15	Glucose homeostasis traits;
LGG	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs11628318	0.515	rs60573537	chr14:103150407	A/G	cg12046867	chr14:103022105	NA	0.42	7.87	0.34	2.54e-14	Platelet count;
LGG	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.13	-0.43	6.51e-22	Colorectal cancer;
LGG	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.16	-0.49	1.03e-29	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.87	-0.42	5.69e-21	Triglycerides;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg14926445	chr8:58193284	C8orf71	-0.94	-13.0	-0.52	3.6e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg27432699	chr2:27873401	GPN1	-0.72	-14.65	-0.56	3.28e-40	Oral cavity cancer;
LGG	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27511599	chr7:32358540	NA	0.63	6.74	0.3	4.61e-11	Body mass index;
LGG	cis	rs56283067	0.847	rs10456536	chr6:44692995	G/C	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.3e-29	Total body bone mineral density;
LGG	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg22963979	chr7:1858916	MAD1L1	-0.49	-9.61	-0.41	4.72e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs67478160	0.634	rs7141928	chr14:104219949	C/T	cg26031613	chr14:104095156	KLC1	-0.43	-7.08	-0.31	5.51e-12	Schizophrenia;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg04986931	chr22:39850128	NA	-0.33	-7.61	-0.33	1.54e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.82	0.59	2.21e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	7.52	0.33	2.88e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	8.56	0.37	1.72e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg00850481	chr1:228891306	NA	-0.5	-8.61	-0.37	1.18e-16	Chronic lymphocytic leukemia;
LGG	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs17125944	0.556	rs7152229	chr14:53313405	T/C	cg00686598	chr14:53173677	PSMC6	-0.77	-8.03	-0.35	7.94e-15	Alzheimer's disease (late onset);
LGG	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09418493	chr15:93426002	NA	-0.39	-6.65	-0.3	8.14e-11	Brain structure;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.58	0.33	1.9e-13	Homoarginine levels;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.57	-0.44	1.55e-23	Prostate cancer;
LGG	cis	rs10884984	0.739	rs3793892	chr10:112265135	G/T	cg18756771	chr10:112261994	DUSP5	-0.69	-13.17	-0.52	7.17e-34	Facial morphology (factor 22);
LGG	cis	rs4906332	1.000	rs4906327	chr14:103929039	C/T	cg26031613	chr14:104095156	KLC1	-0.52	-7.85	-0.34	2.97e-14	Coronary artery disease;
LGG	cis	rs6500395	0.708	rs28449353	chr16:48555134	T/A	cg04672837	chr16:48644449	N4BP1	0.48	7.83	0.34	3.42e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11875185	0.510	rs113518744	chr18:55607180	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.79	-0.38	3.01e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg19143629	chr17:61920732	SMARCD2	0.39	6.66	0.3	7.61e-11	Prudent dietary pattern;
LGG	cis	rs6942756	0.747	rs598412	chr7:129127736	C/T	cg02491457	chr7:128862824	NA	0.64	11.28	0.46	3.07e-26	White matter hyperintensity burden;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7568458	0.870	rs2366639	chr2:85809955	A/G	cg23752985	chr2:85803571	VAMP8	0.42	8.32	0.36	1.02e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2033908	0.588	rs1899068	chr11:12872156	A/T	cg25843174	chr11:12811716	TEAD1	0.32	6.83	0.3	2.69e-11	Sitting height ratio;
LGG	cis	rs11718455	0.960	rs4682713	chr3:44013191	G/C	cg21419209	chr3:44054225	NA	-0.43	-6.93	-0.31	1.39e-11	Coronary artery disease;
LGG	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg08975724	chr8:8085496	FLJ10661	0.38	6.83	0.3	2.74e-11	Monocyte count;
LGG	cis	rs10929925	0.832	rs7591364	chr2:6157176	C/T	cg00493617	chr2:6141445	NA	0.32	7.14	0.31	3.69e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs9733	0.791	rs11204693	chr1:150647987	C/T	cg13175981	chr1:150552382	MCL1	0.53	9.04	0.39	4.19e-18	Tonsillectomy;
LGG	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg24687335	chr11:118901407	SLC37A4	-0.58	-10.42	-0.44	5.75e-23	Coronary artery disease;
LGG	cis	rs7091068	1.000	rs7091068	chr10:95420385	G/T	cg20715218	chr10:95462985	C10orf4	0.64	9.26	0.4	7.45e-19	Urinary tract infection frequency;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.48	0.4	1.3e-19	Longevity;
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.24	-0.36	1.82e-15	Skin colour saturation;
LGG	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.16	-0.83	4.32e-120	Myeloid white cell count;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg13282195	chr8:144660772	NAPRT1	0.97	7.46	0.33	4.28e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs17209837	1.000	rs60541816	chr7:87127861	G/A	cg00919237	chr7:87102261	ABCB4	-0.71	-11.06	-0.46	2.14e-25	Gallbladder cancer;
LGG	cis	rs2455799	0.593	rs2047852	chr3:15732539	T/G	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	8.4e-15	Mean platelet volume;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.33	-0.36	9.54e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg25894440	chr7:65020034	NA	-0.78	-7.09	-0.31	5e-12	Gout;
LGG	cis	rs73086581	1.000	rs14047	chr20:3914215	G/A	cg02187196	chr20:3869020	PANK2	0.84	11.66	0.48	9.99e-28	Response to antidepressants in depression;
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg14092988	chr3:52407081	DNAH1	0.29	7.84	0.34	3.07e-14	Bipolar disorder;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg21724239	chr8:58056113	NA	0.46	7.08	0.31	5.43e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6065	0.618	rs16954342	chr17:4907103	G/A	cg03443944	chr17:4872326	CAMTA2;SPAG7	-0.59	-7.47	-0.33	4.1e-13	Platelet count;
LGG	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg13010199	chr12:38710504	ALG10B	0.57	11.14	0.46	1.07e-25	Heart rate;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.27	0.36	1.49e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.32e-14	Bone mineral density;
LGG	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.87	0.3	2.11e-11	Bipolar disorder;
LGG	cis	rs4356203	0.870	rs214909	chr11:17243278	T/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs12282928	1.000	rs10838860	chr11:48307374	T/C	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs909674	0.690	rs5750823	chr22:39829973	C/T	cg11247378	chr22:39784982	NA	-0.31	-8.55	-0.37	1.82e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg11812906	chr14:75593930	NEK9	0.55	10.22	0.43	2.92e-22	Height;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg16920238	chr17:80076378	CCDC57	0.35	8.12	0.35	4.11e-15	Life satisfaction;
LGG	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.73	-0.3	4.9e-11	Schizophrenia;
LGG	cis	rs4946717	0.716	rs4478446	chr6:106472120	T/A	cg02270332	chr6:106475062	NA	0.38	7.9	0.34	2.12e-14	Inflammatory bowel disease;
LGG	cis	rs61990749	0.544	rs8003979	chr14:78211290	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	6.96	0.31	1.2e-11	Fibroblast growth factor basic levels;
LGG	cis	rs77741769	0.571	rs3897746	chr12:121324727	A/G	cg02419362	chr12:121203948	SPPL3	0.53	9.22	0.39	1.07e-18	Mean corpuscular volume;
LGG	cis	rs368123	0.961	rs368134	chr6:160745513	A/G	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.49	-0.33	3.54e-13	Waist circumference;
LGG	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg26513180	chr16:89883248	FANCA	0.62	11.34	0.47	1.8e-26	Vitiligo;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg19524238	chr7:2802976	GNA12	0.34	8.45	0.37	3.76e-16	Height;
LGG	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.76	0.59	3.95e-45	Colorectal cancer;
LGG	cis	rs2050392	1.000	rs2250714	chr10:30697396	G/C	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.66	-0.44	6.9e-24	Inflammatory bowel disease;
LGG	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg09795085	chr6:101329169	ASCC3	0.43	7.1	0.31	4.7e-12	Neuroticism;
LGG	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg15532942	chr18:77220712	NFATC1	0.51	7.37	0.32	7.89e-13	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01516881	chr6:292596	DUSP22	-0.69	-11.8	-0.48	2.9e-28	Menopause (age at onset);
LGG	trans	rs6076960	0.744	rs6516125	chr20:6165320	G/C	cg17788362	chr6:86352627	SYNCRIP	0.5	8.58	0.37	1.49e-16	Smooth-surface caries;
LGG	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg06634786	chr22:41940651	POLR3H	-0.56	-9.26	-0.4	7.71e-19	Vitiligo;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs4737010	0.501	rs1579274	chr8:41658923	T/G	cg08923054	chr8:41654455	ANK1	0.83	14.6	0.56	5.79e-40	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.76	-0.38	3.79e-17	Body mass index;
LGG	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.44	-0.4	1.87e-19	Common traits (Other);
LGG	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs45544231	0.544	rs1420535	chr16:52578215	C/A	cg09051775	chr16:52580266	TOX3	-0.44	-7.48	-0.33	3.68e-13	Restless legs syndrome;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06028808	chr11:68637592	NA	0.73	12.21	0.49	6.7e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.41	-0.36	5.02e-16	Personality dimensions;
LGG	cis	rs2766692	1.000	rs2766690	chr14:100682154	A/G	cg14866419	chr14:100704911	YY1	-0.62	-9.55	-0.41	7.66e-20	Electroencephalographic traits in alcoholism;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg08925882	chr11:67350491	GSTP1	-0.35	-6.9	-0.31	1.72e-11	Mean corpuscular volume;
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg00409905	chr10:38381863	ZNF37A	-0.55	-10.67	-0.44	6.28e-24	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg03733263	chr8:22462867	KIAA1967	1.12	32.75	0.84	1.26e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg15522984	chr1:182991683	LAMC1	-0.45	-9.09	-0.39	2.81e-18	Hypertriglyceridemia;
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	8.86	0.38	1.76e-17	Bipolar disorder;
LGG	trans	rs9354308	0.727	rs9354309	chr6:66566694	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.88	-0.3	1.98e-11	Metabolite levels;
LGG	cis	rs11112613	0.713	rs2374502	chr12:105938939	T/C	cg03607813	chr12:105948248	NA	0.62	10.61	0.44	1.09e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs11074306	0.561	rs4778187	chr15:28066862	T/C	cg26402630	chr15:28053930	OCA2	0.36	7.29	0.32	1.34e-12	Uveal melanoma;
LGG	cis	rs2718058	0.630	rs2722290	chr7:37820403	C/G	cg15028436	chr7:37888078	TXNDC3	0.52	8.25	0.36	1.66e-15	Alzheimer's disease (late onset);
LGG	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.12	-0.49	1.5e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.82	0.38	2.36e-17	Alzheimer's disease;
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18404041	chr3:52824283	ITIH1	-0.4	-7.72	-0.34	7.14e-14	Bipolar disorder;
LGG	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg25883020	chr8:41504993	NKX6-3	0.33	7.21	0.32	2.24e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs9487094	0.666	rs6920372	chr6:109723939	G/A	cg16315928	chr6:109776240	MICAL1	0.39	6.73	0.3	5.11e-11	Height;
LGG	cis	rs7107174	1.000	rs10899478	chr11:78052238	C/T	cg02023728	chr11:77925099	USP35	0.47	8.27	0.36	1.44e-15	Testicular germ cell tumor;
LGG	cis	rs208520	0.661	rs207111	chr6:66792513	C/T	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg10792982	chr14:105748885	BRF1	0.66	13.08	0.52	1.73e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.45	7.49	0.33	3.59e-13	Osteoporosis;
LGG	cis	rs7408868	0.706	rs7257550	chr19:15292088	C/G	cg14696996	chr19:15285081	NOTCH3	0.89	11.66	0.48	1.01e-27	Pulse pressure;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.84	0.48	1.91e-28	Obesity-related traits;
LGG	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg05527609	chr1:210001259	C1orf107	-0.53	-6.96	-0.31	1.16e-11	Red blood cell count;
LGG	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg24692254	chr21:30365293	RNF160	-0.57	-8.32	-0.36	9.76e-16	Cognitive test performance;
LGG	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg14664628	chr15:75095509	CSK	-1.12	-23.41	-0.74	1.56e-80	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg02951883	chr7:2050386	MAD1L1	-0.79	-16.23	-0.6	3.29e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs12493885	0.725	rs61791468	chr3:153739520	G/C	cg12800244	chr3:153838788	SGEF	-0.78	-8.78	-0.38	3.27e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs672413	0.739	rs500390	chr5:78283656	C/T	cg04677158	chr5:78279841	ARSB	0.35	6.7	0.3	6.06e-11	Blood and toenail selenium levels;Blood protein levels;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17376030	chr22:41985996	PMM1	0.54	8.58	0.37	1.43e-16	Vitiligo;
LGG	cis	rs9503598	0.636	rs6596975	chr6:3465925	G/A	cg00476032	chr6:3446245	SLC22A23	0.54	11.05	0.46	2.36e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs877282	0.755	rs2486579	chr10:785647	G/A	cg17470449	chr10:769945	NA	0.52	6.78	0.3	3.66e-11	Uric acid levels;
LGG	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg16576597	chr16:28551801	NUPR1	0.37	8.67	0.37	7.34e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg15212455	chr7:39170539	POU6F2	0.39	8.74	0.38	4.22e-17	IgG glycosylation;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1595825	0.891	rs2293255	chr2:198621506	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg26384229	chr12:38710491	ALG10B	1.0	25.1	0.76	2.2e-88	Heart rate;
LGG	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.49	-8.05	-0.35	7.19e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg02733842	chr7:1102375	C7orf50	0.68	8.15	0.35	3.32e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg12046867	chr14:103022105	NA	0.73	12.03	0.49	3.39e-29	Platelet count;
LGG	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg13114125	chr14:105738426	BRF1	-0.85	-16.53	-0.61	1.47e-48	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg22875332	chr1:76189707	ACADM	-0.61	-9.3	-0.4	5.77e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.42	0.36	4.9e-16	Skin colour saturation;
LGG	cis	rs11239187	0.512	rs11239136	chr10:45062251	C/A	cg03916630	chr10:45065415	NA	0.37	9.0	0.39	5.85e-18	Body mass index;
LGG	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg13256891	chr4:100009986	ADH5	0.55	9.49	0.4	1.2e-19	Smoking initiation;
LGG	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg02002194	chr4:3960332	NA	-0.46	-8.64	-0.37	9.21e-17	Joint mobility (Beighton score);
LGG	cis	rs497273	0.553	rs508595	chr12:121198891	C/G	cg02419362	chr12:121203948	SPPL3	0.51	8.81	0.38	2.44e-17	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	6.98	0.31	1.03e-11	Personality dimensions;
LGG	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19171272	chr22:38449367	NA	-0.39	-6.67	-0.3	7.1e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9287719	0.674	rs6432130	chr2:10821557	T/C	cg02196655	chr2:10830764	NOL10	0.5	8.79	0.38	2.96e-17	Prostate cancer;
LGG	cis	rs1035144	0.505	rs10145099	chr14:81456694	C/T	cg06600135	chr14:81408086	NA	-0.47	-9.13	-0.39	2.2e-18	Male sexual orientation;
LGG	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	4.85e-24	Aortic root size;
LGG	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.08	-0.46	1.88e-25	Hemoglobin concentration;
LGG	cis	rs972578	0.818	rs4820493	chr22:43281581	G/C	cg01576275	chr22:43409880	NA	-0.23	-7.06	-0.31	6.15e-12	Mean platelet volume;
LGG	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.57	-0.44	1.48e-23	Chronic sinus infection;
LGG	cis	rs9325144	0.560	rs1843910	chr12:38677408	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-12.81	-0.51	2.22e-32	Morning vs. evening chronotype;
LGG	cis	rs71403859	0.730	rs35390364	chr16:71740049	A/G	cg08717414	chr16:71523259	ZNF19	-1.05	-12.96	-0.52	5.29e-33	Post bronchodilator FEV1;
LGG	cis	rs9457247	0.934	rs2345571	chr6:167403400	T/G	cg07741184	chr6:167504864	NA	0.32	7.03	0.31	7.57e-12	Crohn's disease;
LGG	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.25	0.55	1.79e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.43	-8.6	-0.37	1.2e-16	Personality dimensions;
LGG	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg16950941	chr11:66035639	RAB1B	0.47	7.37	0.32	7.9e-13	Electroencephalogram traits;
LGG	cis	rs11628318	0.591	rs8010679	chr14:103155637	T/G	cg12046867	chr14:103022105	NA	0.46	8.91	0.38	1.22e-17	Platelet count;
LGG	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.36	0.47	1.54e-26	Alzheimer's disease;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.97	-0.31	1.08e-11	Height;
LGG	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg00531865	chr16:30841666	NA	-0.5	-9.92	-0.42	3.8e-21	Dementia with Lewy bodies;
LGG	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.87	-0.38	1.57e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7551222	0.749	rs6594018	chr1:204568152	A/G	cg20240347	chr1:204465584	NA	-0.46	-8.94	-0.38	9.26e-18	Schizophrenia;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	9.13e-13	Lung cancer;
LGG	trans	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs2154319	0.887	rs2024859	chr1:41562285	T/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.99	-0.39	6.39e-18	Height;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg16507663	chr6:150244633	RAET1G	0.47	9.09	0.39	2.8e-18	Lung cancer;
LGG	cis	rs28595532	1.000	rs114682099	chr4:119702004	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.38	0.4	3.08e-19	Cannabis dependence symptom count;
LGG	cis	rs17655565	1.000	rs17126647	chr12:52706194	C/T	cg02645295	chr12:52705424	NA	-0.66	-9.2	-0.39	1.22e-18	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs1408224	0.657	rs7986104	chr13:47206196	C/G	cg24453118	chr13:47229927	LRCH1	-0.29	-6.82	-0.3	2.79e-11	QRS complex (12-leadsum);
LGG	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg22771759	chr13:24902376	NA	0.41	6.89	0.3	1.86e-11	Obesity-related traits;
LGG	cis	rs2236267	0.693	rs11626612	chr14:88610244	C/T	cg18078958	chr14:88630771	NA	-0.34	-7.83	-0.34	3.31e-14	Food antigen IgG levels;
LGG	cis	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs920590	0.796	rs7820505	chr8:19634829	A/G	cg03894339	chr8:19674705	INTS10	-0.54	-8.68	-0.37	6.69e-17	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7246760	0.748	rs28384439	chr19:9731965	G/A	cg02900749	chr2:68251473	NA	-0.98	-9.86	-0.42	6.13e-21	Pursuit maintenance gain;
LGG	cis	rs7717393	1.000	rs72813881	chr5:155760241	C/T	cg01474424	chr5:155754231	SGCD	0.82	7.76	0.34	5.65e-14	Egg allergy;
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00149659	chr3:10157352	C3orf10	0.76	9.65	0.41	3.37e-20	Alzheimer's disease;
LGG	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	0.47	8.19	0.36	2.49e-15	Resistin levels;
LGG	cis	rs2073300	0.609	rs6137929	chr20:23376357	G/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg21724239	chr8:58056113	NA	0.61	9.06	0.39	3.61e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs34421088	0.532	rs11782742	chr8:11165009	C/T	cg06636001	chr8:8085503	FLJ10661	0.39	6.8	0.3	3.29e-11	Neuroticism;
LGG	cis	rs17453880	0.929	rs6869129	chr5:152028136	G/A	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05776084	chr3:133293427	CDV3	-0.6	-9.04	-0.39	4.2e-18	Systemic lupus erythematosus;
LGG	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg08916839	chr5:415575	AHRR	0.99	14.1	0.55	8.28e-38	Fat distribution (HIV);
LGG	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg19847130	chr8:10466454	RP1L1	0.31	7.09	0.31	4.95e-12	Neuroticism;
LGG	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg06212747	chr3:49208901	KLHDC8B	-0.5	-7.82	-0.34	3.6e-14	Menarche (age at onset);
LGG	cis	rs9807989	0.507	rs6710528	chr2:103016142	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.45	-0.4	1.66e-19	Asthma;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11245990	chr11:68621969	NA	0.41	8.7	0.37	5.75e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg18225595	chr11:63971243	STIP1	0.47	6.78	0.3	3.69e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg20573242	chr4:122745356	CCNA2	0.51	9.37	0.4	3.19e-19	Type 2 diabetes;
LGG	cis	rs11096990	0.634	rs12651217	chr4:39273584	C/T	cg24403649	chr4:39172243	NA	0.38	6.84	0.3	2.44e-11	Cognitive function;
LGG	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs4356203	0.875	rs7939614	chr11:17079620	C/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.12	0.52	1.13e-33	Coronary artery disease;
LGG	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg24130564	chr14:104152367	KLC1	-0.39	-7.12	-0.31	4.23e-12	Reticulocyte count;
LGG	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14154082	chr13:112174009	NA	0.39	8.82	0.38	2.39e-17	Menarche (age at onset);
LGG	cis	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg22729335	chr19:2427816	TIMM13	1.18	26.52	0.78	5.91e-95	Cortisol levels (saliva);
LGG	cis	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg12395012	chr8:11607386	GATA4	-0.39	-7.05	-0.31	6.56e-12	Monocyte count;
LGG	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-7.3	-0.32	1.29e-12	Colonoscopy-negative controls vs population controls;
LGG	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg24623649	chr8:11872141	NA	-0.3	-7.1	-0.31	4.6e-12	Systolic blood pressure;
LGG	cis	rs870825	0.550	rs10000507	chr4:185619281	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	22.07	0.72	2.83e-74	Blood protein levels;
LGG	trans	rs6787172	0.702	rs827178	chr3:157965315	C/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg18854424	chr1:2615690	NA	0.35	7.11	0.31	4.34e-12	Ulcerative colitis;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.32	-0.32	1.12e-12	Lung cancer;
LGG	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg27102117	chr16:15229624	NA	0.49	9.6	0.41	5.03e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02018176	chr4:1364513	KIAA1530	0.64	15.86	0.59	1.55e-45	Longevity;
LGG	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg04733989	chr22:42467013	NAGA	0.59	10.7	0.45	5.21e-24	Schizophrenia;
LGG	cis	rs13177180	0.545	rs256976	chr5:114890507	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.38	-0.32	7.4e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs11679564	0.714	rs4016031	chr2:37184754	C/T	cg14987922	chr2:37194071	STRN	0.5	8.04	0.35	7.58e-15	Immature fraction of reticulocytes;
LGG	cis	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.59	7.04	0.31	6.96e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11608355	0.545	rs12822891	chr12:109896002	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-9.13	-0.39	2.14e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg18876405	chr7:65276391	NA	-0.55	-9.83	-0.42	7.76e-21	Aortic root size;
LGG	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3206736	0.548	rs1649238	chr7:35004517	C/T	cg13400248	chr7:35225412	NA	-0.53	-9.41	-0.4	2.38e-19	Diastolic blood pressure;
LGG	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg04398451	chr17:18023971	MYO15A	-0.6	-12.06	-0.49	2.58e-29	Total body bone mineral density;
LGG	cis	rs854037	0.595	rs12516650	chr5:57149357	T/G	cg08523694	chr5:57076192	NA	0.52	6.91	0.31	1.58e-11	Birth weight;
LGG	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18252515	chr7:66147081	NA	0.46	7.59	0.33	1.76e-13	Aortic root size;
LGG	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.86	-0.54	8.45e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs17169635	0.765	rs1015350	chr7:134575255	C/T	cg13549461	chr7:134575145	CALD1	0.35	7.06	0.31	5.99e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.53e-21	Morning vs. evening chronotype;
LGG	cis	rs2346177	0.605	rs7598712	chr2:46660452	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.82	0.34	3.72e-14	HDL cholesterol;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	13.98	0.54	2.77e-37	Alzheimer's disease;
LGG	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.4	-0.36	5.46e-16	Total body bone mineral density;
LGG	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg00129232	chr17:37814104	STARD3	0.61	11.48	0.47	5.32e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs72781680	0.821	rs17038360	chr2:24095798	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.62e-17	Lymphocyte counts;
LGG	cis	rs755249	0.567	rs4660214	chr1:39731550	T/C	cg18385671	chr1:39797026	MACF1	0.43	7.25	0.32	1.79e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7666738	0.830	rs1405767	chr4:98965295	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.92	-0.38	1.13e-17	Menopause (age at onset);
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg21724239	chr8:58056113	NA	-0.59	-9.2	-0.39	1.26e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4776059	0.916	rs4774636	chr15:52968193	A/C	cg22715398	chr15:52968154	KIAA1370	-0.54	-8.92	-0.38	1.08e-17	Schizophrenia;
LGG	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg21452805	chr1:244014465	NA	0.7	8.42	0.36	4.59e-16	RR interval (heart rate);
LGG	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg25039879	chr17:56429692	SUPT4H1	0.56	8.04	0.35	7.82e-15	Cognitive test performance;
LGG	trans	rs9929218	0.953	rs34909703	chr16:68740097	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.85	-0.59	1.58e-45	Colorectal cancer;
LGG	cis	rs3126085	0.935	rs10749669	chr1:152177289	A/C	cg26876637	chr1:152193138	HRNR	-0.55	-9.07	-0.39	3.35e-18	Atopic dermatitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22563043	chr16:84853713	CRISPLD2	0.51	8.52	0.37	2.3e-16	Cognitive performance;
LGG	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	15.39	0.58	1.76e-43	Total body bone mineral density;
LGG	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	26.82	0.78	2.52e-96	Height;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.17	-0.62	1.68e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg16301924	chr13:53314226	LECT1	-0.45	-8.98	-0.39	6.77e-18	Lewy body disease;
LGG	cis	rs4865169	0.623	rs6838975	chr4:57739816	G/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.43	-6.93	-0.31	1.42e-11	Breast cancer;
LGG	cis	rs2456568	0.802	rs1395386	chr11:93639331	A/G	cg26875233	chr11:93583750	C11orf90	0.34	6.79	0.3	3.54e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs295140	1.000	rs11696001	chr2:201162433	G/A	cg25099087	chr2:201172481	SPATS2L	0.28	6.93	0.31	1.39e-11	QT interval;
LGG	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-7.12	-0.31	4.25e-12	Height;
LGG	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg09517075	chr8:22133004	PIWIL2	0.4	8.52	0.37	2.2e-16	Hypertriglyceridemia;
LGG	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03352830	chr11:487213	PTDSS2	0.9	10.97	0.45	4.61e-25	Body mass index;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.57e-12	Lung cancer;
LGG	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.34	-0.32	9.85e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.39e-49	Obesity-related traits;
LGG	cis	rs75059851	0.756	rs7106806	chr11:133838837	G/C	cg17703048	chr11:133852993	NA	-0.87	-15.97	-0.6	4.75e-46	Schizophrenia;
LGG	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg06417478	chr19:12876846	HOOK2	0.41	6.79	0.3	3.49e-11	Red blood cell traits;
LGG	cis	rs7188861	0.681	rs12922409	chr16:11415289	C/T	cg01510278	chr16:11456238	NA	0.29	6.65	0.3	8.19e-11	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05793409	chr1:35658810	SFPQ	0.62	9.88	0.42	5.32e-21	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.34e-12	Coronary artery disease;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg05793240	chr7:2802953	GNA12	0.33	7.73	0.34	6.54e-14	Height;
LGG	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.38	-0.53	9.82e-35	Response to antipsychotic treatment;
LGG	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg17201900	chr20:34330562	RBM39	0.51	6.89	0.3	1.82e-11	Total cholesterol levels;
LGG	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg05082376	chr22:42548792	NA	-0.4	-8.38	-0.36	6.2e-16	Schizophrenia;
LGG	trans	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05926928	chr17:57297772	GDPD1	1.36	21.68	0.71	1.93e-72	Opioid sensitivity;
LGG	cis	rs12140703	0.510	rs1572993	chr1:205045087	G/A	cg00857998	chr1:205179979	DSTYK	-0.42	-6.67	-0.3	7.24e-11	Reticulocyte count;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.75	-0.3	4.35e-11	Personality dimensions;
LGG	cis	rs7027203	1.000	rs7027203	chr9:96562563	A/C	cg14598338	chr9:96623480	NA	0.5	8.72	0.38	5.04e-17	DNA methylation (variation);
LGG	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg00777063	chr17:45855553	NA	-0.32	-6.71	-0.3	5.72e-11	IgG glycosylation;
LGG	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg18473234	chr19:5097819	KDM4B	0.42	7.29	0.32	1.38e-12	Monocyte percentage of white cells;
LGG	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs568617	0.768	rs12225345	chr11:65647105	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.66	8.65	0.37	8.69e-17	Crohn's disease;
LGG	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg10402321	chr1:26617780	UBXN11	-0.43	-7.75	-0.34	5.77e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9460578	0.537	rs9460559	chr6:20806005	A/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.68	0.63	8.23e-54	Breast cancer;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg07187585	chr17:10600923	C17orf48;SCO1	0.73	6.89	0.3	1.82e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs2735413	0.563	rs72800906	chr16:78046327	G/A	cg04733911	chr16:78082701	NA	0.57	7.47	0.33	4.16e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg04568710	chr12:38710424	ALG10B	0.34	6.83	0.3	2.67e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15698568	chr12:131200725	NA	0.48	7.18	0.32	2.83e-12	Gut microbiome composition (summer);
LGG	trans	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg10185519	chr16:30621987	ZNF689	0.39	6.65	0.3	8.13e-11	Prudent dietary pattern;
LGG	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg12751644	chr20:60527061	NA	-0.31	-7.09	-0.31	5.14e-12	Body mass index;
LGG	cis	rs8031584	0.678	rs36047941	chr15:31159235	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.12	-0.35	4.17e-15	Huntington's disease progression;
LGG	trans	rs947612	0.576	rs9359011	chr6:73706941	C/T	cg13494037	chr12:24737079	C12orf67	0.34	6.88	0.3	1.95e-11	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.0	-0.42	1.95e-21	Tonsillectomy;
LGG	cis	rs12586317	0.547	rs10142667	chr14:35445090	A/G	cg16230307	chr14:35515116	FAM177A1	0.88	12.56	0.5	2.43e-31	Psoriasis;
LGG	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg22839075	chr3:12045461	SYN2	-0.43	-7.33	-0.32	1.04e-12	Platelet count;
LGG	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg09165964	chr15:75287851	SCAMP5	-0.54	-9.96	-0.42	2.7e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs8180040	0.620	rs6767907	chr3:47162661	C/T	cg27129171	chr3:47204927	SETD2	-0.82	-14.97	-0.57	1.26e-41	Colorectal cancer;
LGG	cis	rs28647808	0.881	rs4962139	chr9:136267869	C/T	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	-0.78	-8.02	-0.35	8.55e-15	Blood protein levels;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.55	10.0	0.42	1.89e-21	Longevity;
LGG	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg14664628	chr15:75095509	CSK	-0.65	-13.15	-0.52	8.91e-34	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.44	0.33	5.03e-13	Height;
LGG	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg03653399	chr8:142233436	SLC45A4	-0.42	-8.16	-0.35	3.27e-15	Immature fraction of reticulocytes;
LGG	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg21775007	chr8:11205619	TDH	-0.61	-10.09	-0.42	8.68e-22	Retinal vascular caliber;
LGG	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg09085632	chr11:111637200	PPP2R1B	1.08	23.1	0.73	4.46e-79	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25339552	chr19:33165499	ANKRD27;RGS9BP	0.44	7.9	0.34	1.99e-14	Gut microbiome composition (summer);
LGG	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg19773385	chr1:10388646	KIF1B	-0.48	-9.97	-0.42	2.41e-21	Hepatocellular carcinoma;
LGG	cis	rs8114671	0.586	rs6087634	chr20:33413809	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	6.72	0.3	5.39e-11	Height;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06873352	chr17:61820015	STRADA	0.75	13.95	0.54	3.44e-37	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.2.155158194R	chr2:155449948	NA	-0.44	-6.85	-0.3	2.33e-11	Systemic lupus erythematosus;
LGG	cis	rs35160687	0.623	rs4832263	chr2:86485157	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	7.09	0.31	4.97e-12	Night sleep phenotypes;
LGG	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11711311	1.000	rs7622403	chr3:113472434	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.68	-14.16	-0.55	4.59e-38	IgG glycosylation;
LGG	cis	rs981844	0.735	rs111822747	chr4:154734629	G/C	cg14289246	chr4:154710475	SFRP2	0.68	11.15	0.46	9.68e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-7.81	-0.34	3.89e-14	Schizophrenia;
LGG	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg01864069	chr14:103024347	NA	-0.68	-9.57	-0.41	6.59e-20	Platelet count;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg16359550	chr11:109292809	C11orf87	0.42	8.23	0.36	1.9e-15	Schizophrenia;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-9.15	-0.39	1.84e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4746818	1.000	rs7918066	chr10:70913116	C/T	cg11621586	chr10:70884670	VPS26A	1.19	21.96	0.71	9.17e-74	Left atrial antero-posterior diameter;
LGG	cis	rs7503807	0.515	rs12450876	chr17:78682630	A/G	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs6142618	0.562	rs2235899	chr20:30719535	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.04	0.31	6.94e-12	Neuroticism;
LGG	cis	rs68170813	0.559	rs76534758	chr7:106963262	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-10.26	-0.43	2.21e-22	Coronary artery disease;
LGG	cis	rs457717	0.730	rs458573	chr5:75947651	T/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg00631329	chr6:26305371	NA	-0.53	-9.87	-0.42	5.74e-21	Educational attainment;
LGG	cis	rs9549367	0.789	rs9549701	chr13:113881752	G/C	cg00898013	chr13:113819073	PROZ	-0.44	-8.58	-0.37	1.42e-16	Platelet distribution width;
LGG	cis	rs4841097	0.876	rs11774267	chr8:8947722	T/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.19	-0.32	2.64e-12	Platelet distribution width;
LGG	trans	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.59	-0.37	1.36e-16	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.4	0.58	1.6700000000000001e-43	Lung cancer;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	8.36	0.36	7.38e-16	Obesity-related traits;
LGG	cis	rs6694672	1.000	rs1170883	chr1:196951471	C/T	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.8e-11	Asthma;
LGG	cis	rs3735485	0.678	rs3757574	chr7:45148019	C/T	cg03440944	chr7:45023329	C7orf40	-0.51	-8.76	-0.38	3.79e-17	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs12318506	0.826	rs34128238	chr12:75731819	T/C	cg04728562	chr12:75699417	CAPS2	-1.37	-12.5	-0.5	4.24e-31	Coronary artery calcification;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg08219700	chr8:58056026	NA	0.53	11.57	0.47	2.36e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs17818399	0.962	rs7565274	chr2:46841861	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.94	0.35	1.52e-14	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02836487	chr3:128206457	GATA2	0.42	6.67	0.3	7.53e-11	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.62	8.37	0.36	6.66e-16	Diabetic retinopathy;
LGG	cis	rs7100689	0.646	rs1340380	chr10:82115619	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	14.75	0.57	1.2e-40	Post bronchodilator FEV1;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg17911788	chr17:44343683	NA	0.62	9.38	0.4	3.02e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs9581857	0.725	rs117947621	chr13:28022267	T/C	cg01674679	chr13:27998804	GTF3A	-0.66	-7.69	-0.34	8.71e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg14500267	chr11:67383377	NA	-0.39	-7.24	-0.32	1.91e-12	Mean corpuscular volume;
LGG	cis	rs4698433	0.925	rs4698430	chr4:15958701	G/T	cg15380744	chr4:15964812	FGFBP2	-0.24	-6.68	-0.3	6.79e-11	QT interval;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.31	-0.4	5.09e-19	Menopause (age at onset);
LGG	cis	rs2470578	0.792	rs2733526	chr3:17238792	C/T	cg20981856	chr3:17787350	NA	-0.37	-7.02	-0.31	7.86e-12	Schizophrenia;
LGG	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg02725872	chr8:58115012	NA	-0.85	-12.22	-0.49	6.06e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7129556	0.737	rs623173	chr11:77529528	C/T	cg12586386	chr11:77299805	AQP11	-0.46	-7.43	-0.33	5.23e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg17182837	chr8:41585554	ANK1	-0.53	-7.64	-0.33	1.23e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs919433	0.783	rs3097383	chr2:198236887	A/G	cg00792783	chr2:198669748	PLCL1	0.46	7.34	0.32	9.4e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2224391	0.554	rs114825667	chr6:5242618	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-6.95	-0.31	1.22e-11	Height;
LGG	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg04935436	chr20:30431758	NA	0.41	7.0	0.31	9.1e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.51e-22	Motion sickness;
LGG	cis	rs1061377	0.513	rs2566166	chr4:39150024	C/A	cg24403649	chr4:39172243	NA	-0.46	-7.09	-0.31	4.92e-12	Uric acid levels;
LGG	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.62	0.59	1.74e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg05625103	chr10:2543513	NA	0.52	9.19	0.39	1.3e-18	Age-related hearing impairment;
LGG	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg18681998	chr4:17616180	MED28	0.78	15.04	0.57	6.81e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.6e-35	Resting heart rate;
LGG	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-13.23	-0.52	4.07e-34	Monocyte count;
LGG	cis	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-7.22	-0.32	2.15e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.7	0.51	6.62e-32	Coronary artery disease;
LGG	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.75	0.54	2.5e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg17127132	chr2:85788382	GGCX	0.46	7.88	0.34	2.33e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25798409	chr2:213402815	ERBB4	0.44	7.27	0.32	1.51e-12	Gut microbiome composition (summer);
LGG	cis	rs721917	0.525	rs2250652	chr10:81662649	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.91	-0.34	1.97e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg00850481	chr1:228891306	NA	0.66	15.34	0.58	3.13e-43	Chronic lymphocytic leukemia;
LGG	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg27476859	chr7:2772710	GNA12	0.54	10.42	0.44	5.78e-23	Height;
LGG	cis	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg21479132	chr6:26055353	NA	0.79	7.6	0.33	1.67e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.08	-0.35	5.51e-15	IgG glycosylation;
LGG	cis	rs79349575	0.783	rs62078370	chr17:47026836	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg04986931	chr22:39850128	NA	-0.39	-8.93	-0.38	1.02e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7166081	1.000	rs58074225	chr15:67545892	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.78	-0.3	3.76e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg08400814	chr5:56204995	C5orf35	0.4	7.19	0.32	2.55e-12	Initial pursuit acceleration;
LGG	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg05973401	chr12:123451056	ABCB9	-0.45	-6.69	-0.3	6.31e-11	Neutrophil percentage of white cells;
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.82	-0.3	2.87e-11	Aortic root size;
LGG	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg00129232	chr17:37814104	STARD3	0.61	11.16	0.46	8.91e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs793571	0.614	rs347117	chr15:59000957	C/T	cg05156742	chr15:59063176	FAM63B	0.57	9.66	0.41	3.11e-20	Schizophrenia;
LGG	trans	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.71	0.48	6.55e-28	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.9	-0.31	1.7e-11	Lung cancer;
LGG	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19748678	chr4:122722346	EXOSC9	-0.43	-7.45	-0.33	4.49e-13	Type 2 diabetes;
LGG	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.73	0.45	3.87e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg24253500	chr15:84953950	NA	0.42	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00292662	chr22:38071168	LGALS1	0.65	14.72	0.56	1.63e-40	Fat distribution (HIV);
LGG	cis	rs6028335	0.610	rs67343649	chr20:37557894	A/G	cg16355469	chr20:37678765	NA	0.53	7.05	0.31	6.44e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg10483660	chr13:112241077	NA	-0.36	-7.82	-0.34	3.54e-14	Hepatitis;
LGG	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg02931644	chr1:25747376	RHCE	0.44	9.65	0.41	3.28e-20	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs807669	0.777	rs9605972	chr22:19253274	C/T	cg02655711	chr22:19163373	SLC25A1	0.58	11.44	0.47	7.53e-27	Metabolite levels;
LGG	cis	rs11920090	0.790	rs11721319	chr3:170710808	G/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.44	0.37	4.12e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs11064837	0.504	rs7311445	chr12:120054097	C/T	cg25937854	chr12:120150414	CIT	-0.59	-10.32	-0.43	1.33e-22	Schizophrenia;
LGG	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg00343986	chr7:65444356	GUSB	0.49	8.66	0.37	7.84e-17	Calcium levels;
LGG	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-22.3	-0.72	2.34e-75	Blood trace element (Zn levels);
LGG	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg22398616	chr13:53314203	LECT1	0.4	7.63	0.33	1.36e-13	Lewy body disease;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.41	-0.36	5.22e-16	Menopause (age at onset);
LGG	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.64	0.37	8.98e-17	Colorectal cancer;
LGG	cis	rs1555322	1.000	rs2425031	chr20:33855284	T/C	cg17927777	chr20:33865990	NA	0.66	7.5	0.33	3.28e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs7241530	0.662	rs12961616	chr18:75908142	T/G	cg14642773	chr18:75888474	NA	0.45	8.72	0.38	4.88e-17	Educational attainment (years of education);
LGG	cis	rs7089973	0.872	rs12773943	chr10:116631184	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2239547	0.522	rs7652131	chr3:52997154	C/T	cg11645453	chr3:52864694	ITIH4	0.69	10.84	0.45	1.46e-24	Schizophrenia;
LGG	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg05163923	chr11:71159392	DHCR7	0.59	10.02	0.42	1.55e-21	Vitamin D levels;
LGG	cis	rs2652834	0.851	rs1126312	chr15:63427638	C/T	cg05507819	chr15:63340323	TPM1	-0.5	-7.12	-0.31	4.27e-12	HDL cholesterol;
LGG	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.6	-0.44	1.16e-23	Alzheimer's disease;
LGG	trans	rs208520	0.690	rs12192851	chr6:66705862	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.56	0.63	2.86e-53	Exhaled nitric oxide output;
LGG	cis	rs9463078	0.770	rs9296453	chr6:45227432	C/T	cg25276700	chr6:44698697	NA	-0.39	-8.02	-0.35	8.71e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2455799	0.613	rs1976479	chr3:15729714	C/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.14e-14	Mean platelet volume;
LGG	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg09165964	chr15:75287851	SCAMP5	-0.79	-8.93	-0.38	1.04e-17	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03703833	chr11:10773290	CTR9	0.5	8.22	0.36	2.09e-15	Cognitive performance;
LGG	cis	rs2346177	0.519	rs2121698	chr2:46709571	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.14	0.39	2.04e-18	HDL cholesterol;
LGG	cis	rs1044826	0.642	rs1580642	chr3:139132203	A/C	cg15131784	chr3:139108705	COPB2	-0.42	-6.9	-0.31	1.75e-11	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25154432	chr5:79703725	ZFYVE16	0.4	6.9	0.31	1.69e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg24848339	chr3:12840334	CAND2	-0.34	-7.59	-0.33	1.74e-13	P wave duration;
LGG	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg04248312	chr19:17393744	ANKLE1	-0.66	-10.92	-0.45	7.1e-25	Systemic lupus erythematosus;
LGG	trans	rs4698048	0.506	rs2080072	chr4:10235622	G/C	cg26043149	chr18:55253948	FECH	-0.41	-7.11	-0.31	4.36e-12	Skin aging (microtopography measurement);
LGG	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg01620082	chr3:125678407	NA	-0.84	-9.24	-0.39	9.18e-19	Squamous cell lung carcinoma;
LGG	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg27490568	chr2:178487706	NA	0.54	10.44	0.44	4.74e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4006360	0.579	rs6416910	chr17:39235562	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.31	-0.47	2.42e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg11766577	chr21:47581405	C21orf56	-0.59	-10.65	-0.44	7.69e-24	Testicular germ cell tumor;
LGG	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg26597838	chr10:835615	NA	0.74	10.23	0.43	2.74e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs919433	0.963	rs13033821	chr2:198173536	T/G	cg00792783	chr2:198669748	PLCL1	-0.45	-7.07	-0.31	5.92e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs439731	0.628	rs384344	chr16:1078084	C/T	cg09791621	chr16:1078722	NA	0.34	6.98	0.31	1.03e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2302729	0.545	rs216050	chr12:2766825	G/C	cg19945202	chr12:2788847	CACNA1C	0.74	12.59	0.5	1.88e-31	Sleep quality;
LGG	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg09307838	chr4:120376055	NA	0.82	13.68	0.54	5.19e-36	Corneal astigmatism;
LGG	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.31	0.32	1.15e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.31	0.5	2.61e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4356203	0.905	rs11024159	chr11:17127342	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.35	-0.32	8.99e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg06719900	chr11:109292894	C11orf87	0.44	8.33	0.36	9.32e-16	Schizophrenia;
LGG	trans	rs826838	0.967	rs826870	chr12:39120250	G/A	cg06521331	chr12:34319734	NA	0.43	7.69	0.34	8.85e-14	Heart rate;
LGG	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg25809561	chr17:30822961	MYO1D	0.37	8.68	0.37	6.59e-17	Schizophrenia;
LGG	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg19680485	chr15:31195859	MTMR15	-0.47	-8.28	-0.36	1.38e-15	Huntington's disease progression;
LGG	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg18200150	chr17:30822561	MYO1D	0.48	9.15	0.39	1.89e-18	Schizophrenia;
LGG	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-12.64	-0.51	1.15e-31	Menarche (age at onset);
LGG	cis	rs4144743	0.941	rs7222617	chr17:45324080	G/T	cg18085866	chr17:45331354	ITGB3	-0.77	-9.76	-0.41	1.36e-20	Body mass index;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg11494091	chr17:61959527	GH2	-0.99	-24.35	-0.75	6.71e-85	Prudent dietary pattern;
LGG	cis	rs7580658	0.724	rs6712446	chr2:127998399	G/T	cg10021288	chr2:128175891	PROC	-0.62	-12.56	-0.5	2.53e-31	Protein C levels;
LGG	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.18	-0.36	2.7e-15	HDL cholesterol;
LGG	cis	rs25645	0.502	rs17609240	chr17:38110689	T/G	cg17467752	chr17:38218738	THRA	0.46	6.96	0.31	1.2e-11	Myeloid white cell count;
LGG	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg20573242	chr4:122745356	CCNA2	0.53	9.73	0.41	1.83e-20	Type 2 diabetes;
LGG	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg13010199	chr12:38710504	ALG10B	0.68	14.03	0.55	1.66e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3008870	1.000	rs2755244	chr1:67484470	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.95	-22.39	-0.72	9.27e-76	Lymphocyte percentage of white cells;
LGG	cis	rs3206736	0.548	rs59505449	chr7:35065852	T/C	cg13400248	chr7:35225412	NA	0.55	9.59	0.41	5.65e-20	Diastolic blood pressure;
LGG	cis	rs1650123	0.932	rs703624	chr12:104035804	A/G	cg23227824	chr12:103980017	STAB2	-0.32	-7.23	-0.32	2.05e-12	IgG glycosylation;
LGG	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.86	0.34	2.67e-14	Educational attainment;
LGG	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	11.09	0.46	1.72e-25	Lung cancer in ever smokers;
LGG	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg08085267	chr17:45401833	C17orf57	0.63	13.04	0.52	2.46e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.26	-0.4	7.7e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.1	-0.31	4.81e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs883565	0.740	rs10510698	chr3:39107993	A/C	cg01426195	chr3:39028469	NA	-0.71	-16.37	-0.61	7.46e-48	Handedness;
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg13047869	chr3:10149882	C3orf24	0.44	7.4	0.33	6.38e-13	Alzheimer's disease;
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg15537850	chr8:144661051	NAPRT1	0.96	7.48	0.33	3.81e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg03433033	chr1:76189801	ACADM	-0.65	-9.54	-0.41	7.95e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4076764	0.830	rs10917770	chr1:163442214	G/C	cg06092702	chr1:163392909	NA	-0.45	-8.08	-0.35	5.82e-15	Motion sickness;
LGG	trans	rs6787172	0.622	rs6414388	chr3:158108089	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.36	-0.43	9.54e-23	Lung cancer;
LGG	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2239547	0.603	rs12489490	chr3:53064022	C/A	cg11645453	chr3:52864694	ITIH4	0.65	9.52	0.4	9.99e-20	Schizophrenia;
LGG	trans	rs9409565	0.821	rs7858082	chr9:97063929	T/A	cg05679027	chr9:99775184	HIATL2	0.5	8.23	0.36	1.94e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs68170813	0.652	rs6958969	chr7:107197755	A/T	cg02696742	chr7:106810147	HBP1	-0.66	-8.42	-0.36	4.92e-16	Coronary artery disease;
LGG	cis	rs3780486	0.846	rs10813960	chr9:33180362	C/T	cg13443165	chr9:33130375	B4GALT1	-0.63	-10.16	-0.43	4.97e-22	IgG glycosylation;
LGG	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg24110177	chr3:50126178	RBM5	-0.55	-8.69	-0.37	6.33e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg00531865	chr16:30841666	NA	0.39	8.19	0.36	2.55e-15	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12230513	0.732	rs7957446	chr12:55839631	G/C	cg19537932	chr12:55886519	OR6C68	-0.61	-11.14	-0.46	1.11e-25	Contrast sensitivity;
LGG	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2617583	0.935	rs2975223	chr5:1443603	T/C	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.13	-0.31	3.76e-12	Breast cancer;
LGG	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.6	-0.33	1.71e-13	Personality dimensions;
LGG	cis	rs2249694	0.960	rs4133041	chr10:135408387	G/A	cg20169779	chr10:135381914	SYCE1	-0.51	-7.97	-0.35	1.23e-14	Obesity-related traits;
LGG	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg08949735	chr16:89699720	DPEP1	-0.48	-10.02	-0.42	1.64e-21	Vitiligo;
LGG	cis	rs1806153	0.551	rs1806152	chr11:31851040	C/T	cg11990419	chr11:31841155	NA	0.33	7.53	0.33	2.6e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04098458	chr2:149402448	EPC2	-0.41	-6.69	-0.3	6.5500000000000006e-11	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.41	-0.33	6.11e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.91	0.38	1.13e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11587400	0.593	rs2336365	chr1:115175415	G/T	cg12756093	chr1:115239321	AMPD1	-0.39	-6.71	-0.3	5.67e-11	Autism;
LGG	cis	rs1843834	0.755	rs11898692	chr2:225575173	T/C	cg22455342	chr2:225449267	CUL3	0.49	8.35	0.36	8.21e-16	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg10326726	chr10:51549505	MSMB	-0.7	-14.51	-0.56	1.31e-39	Prostate-specific antigen levels;
LGG	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.84	-0.3	2.55e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08280861	chr8:58055591	NA	0.64	11.07	0.46	2.02e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs981844	0.816	rs74549610	chr4:154710464	C/G	cg14289246	chr4:154710475	SFRP2	0.74	12.39	0.5	1.25e-30	Response to statins (LDL cholesterol change);
LGG	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg15704280	chr7:45808275	SEPT13	-0.46	-7.46	-0.33	4.29e-13	HDL cholesterol;
LGG	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs2282802	0.685	rs6893253	chr5:139661279	T/C	cg26211634	chr5:139558579	C5orf32	0.35	7.65	0.34	1.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg19847130	chr8:10466454	RP1L1	0.33	6.89	0.31	1.79e-11	Neuroticism;
LGG	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.99	0.57	1.07e-41	Heart rate;
LGG	cis	rs10463554	0.892	rs6872442	chr5:102266522	A/T	cg23492399	chr5:102201601	PAM	-0.55	-8.53	-0.37	2.17e-16	Parkinson's disease;
LGG	cis	rs7267979	1.000	rs884613	chr20:25288505	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19832172	chr22:39916374	ATF4	-0.49	-7.09	-0.31	5.1e-12	Systemic lupus erythematosus;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.64	-0.37	8.97e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.99	0.39	6.1e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs9309711	0.961	rs11686236	chr2:3471549	G/A	cg10845886	chr2:3471009	TTC15	-0.76	-14.95	-0.57	1.66e-41	Neurofibrillary tangles;
LGG	cis	rs36051895	0.632	rs10115962	chr9:5140841	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-14.77	-0.57	9.86e-41	Pediatric autoimmune diseases;
LGG	cis	rs910316	1.000	rs175436	chr14:75608683	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.49	-0.44	2.99e-23	Height;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg11062466	chr8:58055876	NA	-0.61	-9.95	-0.42	2.9e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg19507638	chr5:93509721	C5orf36	0.39	7.13	0.31	3.76e-12	Diabetic retinopathy;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.79	-0.3	3.53e-11	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09699651	chr6:150184138	LRP11	0.58	11.02	0.46	3.15e-25	Testicular germ cell tumor;
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	9.0	0.39	5.64e-18	Bipolar disorder;
LGG	cis	rs6968355	0.799	rs6961188	chr7:104596755	A/G	cg03782966	chr7:104585482	NA	-0.48	-8.92	-0.38	1.12e-17	Myopia (pathological);
LGG	cis	rs12410462	0.585	rs2644143	chr1:227731157	T/C	cg23173402	chr1:227635558	NA	0.36	6.91	0.31	1.63e-11	Major depressive disorder;
LGG	cis	rs9534288	0.797	rs4142548	chr13:46535350	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-12.92	-0.51	7.82e-33	Blood protein levels;
LGG	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg24623649	chr8:11872141	NA	-0.35	-8.42	-0.36	4.61e-16	Neuroticism;
LGG	cis	rs910873	0.505	rs7261964	chr20:33205011	C/T	cg12302830	chr20:33297742	TP53INP2	-0.44	-6.99	-0.31	9.41e-12	Melanoma;
LGG	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	cis	rs6540556	0.723	rs11487866	chr1:209892046	G/A	cg23920097	chr1:209922102	NA	-0.42	-7.01	-0.31	8.51e-12	Red blood cell count;
LGG	cis	rs13314892	0.764	rs6802804	chr3:69862105	A/C	cg17445875	chr3:69859618	MITF	-0.4	-7.73	-0.34	6.83e-14	QRS complex (12-leadsum);
LGG	cis	rs12821008	1	rs12821008	chr12:49474605	C/T	cg24176009	chr12:49580217	TUBA1A	0.44	7.95	0.35	1.48e-14	Bone mineral density;
LGG	cis	rs6693567	0.565	rs698921	chr1:150379517	G/A	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg13259177	chr13:114761607	RASA3	-0.78	-11.68	-0.48	8.51e-28	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg12573674	chr2:1569213	NA	-0.65	-10.37	-0.43	8.53e-23	IgG glycosylation;
LGG	trans	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg06521331	chr12:34319734	NA	0.44	7.68	0.34	9.66e-14	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.850	rs3816792	chr15:44116986	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.81	-9.09	-0.39	2.95e-18	Lung cancer in ever smokers;
LGG	cis	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.57	-0.33	2.04e-13	Mean corpuscular volume;
LGG	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg19336497	chr11:14380999	RRAS2	-0.37	-6.9	-0.31	1.71e-11	Vitamin D levels;
LGG	cis	rs57502260	0.704	rs55975204	chr11:68249124	C/T	cg01657329	chr11:68192670	LRP5	-0.57	-7.15	-0.32	3.31e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-9.99	-0.42	2.07e-21	Morning vs. evening chronotype;
LGG	cis	rs6964587	0.692	rs4729025	chr7:91847504	C/T	cg17063962	chr7:91808500	NA	0.53	10.37	0.43	8.72e-23	Breast cancer;
LGG	cis	rs780094	0.500	rs12473139	chr2:27765587	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	4.88e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	trans	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg08733933	chr1:2954429	NA	-0.39	-8.46	-0.37	3.65e-16	Plateletcrit;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19147129	chr2:74230310	NA	0.37	6.86	0.3	2.24e-11	Menarche (age at onset);
LGG	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg19336497	chr11:14380999	RRAS2	-0.58	-11.87	-0.48	1.42e-28	Sense of smell;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg16434002	chr17:42200994	HDAC5	-0.54	-10.04	-0.42	1.34e-21	Total body bone mineral density;
LGG	trans	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg06521331	chr12:34319734	NA	0.46	8.13	0.35	3.94e-15	Bladder cancer;
LGG	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07523904	chr9:131799192	FAM73B	0.45	7.07	0.31	5.92e-12	Gut microbiome composition (summer);
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg11905131	chr22:24372483	LOC391322	-0.45	-7.75	-0.34	5.98e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9341835	0.740	rs7763834	chr6:64149357	T/C	cg00787780	chr6:64151745	NA	0.42	7.62	0.33	1.45e-13	Schizophrenia;
LGG	cis	rs4363385	0.720	rs6704498	chr1:152964740	C/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.08	-0.39	3.1e-18	Inflammatory skin disease;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.31	-0.47	2.35e-26	Tonsillectomy;
LGG	cis	rs2075466	0.514	rs75588955	chr16:4899394	G/T	cg04440724	chr16:4920505	UBN1	-0.62	-8.95	-0.38	8.95e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs926392	1.000	rs926391	chr20:37690485	A/G	cg16355469	chr20:37678765	NA	0.43	7.2	0.32	2.38e-12	Dialysis-related mortality;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.8	0.38	2.63e-17	Schizophrenia;
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.75	0.3	4.47e-11	Alzheimer's disease;
LGG	cis	rs7074356	0.522	rs1591958	chr10:82062661	G/A	cg27171509	chr10:82033454	MAT1A	-0.33	-6.85	-0.3	2.41e-11	Borderline personality disorder;
LGG	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.87e-16	Asthma;
LGG	cis	rs10493773	0.862	rs12075929	chr1:86248138	A/C	cg17807903	chr1:86174739	ZNHIT6	0.64	11.96	0.49	6.28e-29	Urate levels in overweight individuals;
LGG	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg16325326	chr1:53192061	ZYG11B	0.84	23.22	0.73	1.19e-79	Monocyte count;
LGG	trans	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.75	15.42	0.58	1.32e-43	Lymphocyte percentage of white cells;
LGG	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08564027	chr20:61660810	NA	1.04	25.82	0.77	9.94e-92	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs62400317	0.859	rs12193720	chr6:45103362	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.49	-0.44	2.97e-23	Total body bone mineral density;
LGG	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg09137382	chr11:130731461	NA	0.41	7.82	0.34	3.6e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg15674680	chr20:60982522	CABLES2	0.52	8.16	0.35	3.09e-15	Colorectal cancer;
LGG	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.1	-0.49	1.72e-29	Height;
LGG	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.18	0.43	4.37e-22	Motion sickness;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01148728	chr11:117198424	CEP164	-0.43	-7.35	-0.32	9.19e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	2.97e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs300774	0.925	rs300706	chr2:141540	A/C	cg04617936	chr2:214353	NA	-0.49	-7.55	-0.33	2.36e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08677398	chr8:58056175	NA	0.46	7.74	0.34	6.21e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs36093844	0.800	rs2044390	chr11:85569834	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.18	-0.32	2.76e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs3820068	0.581	rs6692461	chr1:15928449	A/G	cg05660106	chr1:15850417	CASP9	0.83	16.87	0.62	4.12e-50	Systolic blood pressure;
LGG	cis	rs564799	0.966	rs2914116	chr3:159731300	A/T	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.63	0.44	8.97e-24	Lung cancer in ever smokers;
LGG	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg04845185	chr20:61696220	NA	-0.4	-8.04	-0.35	7.74e-15	Body mass index;
LGG	cis	rs6800768	0.604	rs75990679	chr3:24155774	G/C	cg10674438	chr3:24145617	LOC152024	-0.52	-9.06	-0.39	3.82e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01184560	chr5:60627852	ZSWIM6	0.46	6.68	0.3	6.9e-11	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.05	0.52	2.37e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12580194	0.593	rs58709231	chr12:55719090	T/C	cg19537932	chr12:55886519	OR6C68	-0.54	-9.42	-0.4	2.15e-19	Cancer;
LGG	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.91	-0.38	1.14e-17	Depression;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg26174226	chr8:58114915	NA	-0.5	-7.43	-0.33	5.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12431204	0.932	rs2323637	chr13:38447640	T/A	cg23307680	chr13:38443104	TRPC4	0.42	7.41	0.33	6.18e-13	Schizophrenia;
LGG	cis	rs559928	0.553	rs508326	chr11:64176029	C/T	cg05555928	chr11:63887634	MACROD1	0.55	9.43	0.4	2e-19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg06221963	chr1:154839813	KCNN3	-0.53	-11.15	-0.46	1e-25	Prostate cancer;
LGG	cis	rs3126085	0.825	rs11204933	chr1:152172185	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.75	0.38	3.88e-17	Atopic dermatitis;
LGG	cis	rs6735179	0.588	rs6726313	chr2:1756908	C/T	cg10160682	chr2:1713001	PXDN	-0.53	-9.54	-0.41	8.3e-20	Response to antipsychotic treatment;
LGG	trans	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.16	-0.32	3.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.897	rs68090597	chr21:40535633	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.85	0.64	1.32e-54	Cognitive function;
LGG	cis	rs490234	0.702	rs35237975	chr9:128313867	A/G	cg14078157	chr9:128172775	NA	-0.55	-10.35	-0.43	9.74e-23	Mean arterial pressure;
LGG	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg08499158	chr17:42289980	UBTF	-0.43	-7.7	-0.34	8.08e-14	Total body bone mineral density;
LGG	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg08250081	chr4:10125330	NA	0.39	7.53	0.33	2.69e-13	Bone mineral density;
LGG	cis	rs4891159	0.790	rs7237974	chr18:74108860	A/G	cg24786174	chr18:74118243	ZNF516	-0.57	-13.04	-0.52	2.54e-33	Longevity;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.62	-0.33	1.48e-13	Schizophrenia;
LGG	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg08589960	chr16:83986755	OSGIN1	-0.43	-6.94	-0.31	1.3e-11	Pursuit maintenance gain;
LGG	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs35740288	0.577	rs11634361	chr15:86194281	A/G	cg04173714	chr15:86211321	AKAP13	0.38	7.38	0.32	7.49e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg19748678	chr4:122722346	EXOSC9	0.66	13.34	0.53	1.43e-34	Type 2 diabetes;
LGG	cis	rs36093844	0.706	rs116940726	chr11:85584052	A/C	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg05793240	chr7:2802953	GNA12	0.31	7.66	0.34	1.07e-13	Height;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg18350739	chr11:68623251	NA	-0.89	-22.59	-0.72	1.07e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24110177	chr3:50126178	RBM5	-0.54	-9.84	-0.42	6.92e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.686	rs57033289	chr14:55623317	C/A	cg04306507	chr14:55594613	LGALS3	0.52	12.11	0.49	1.56e-29	Protein biomarker;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg21132649	chr13:46626913	ZC3H13	-0.43	-6.67	-0.3	7.38e-11	Coronary artery disease;
LGG	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.41	0.5	1.02e-30	Colorectal cancer;
LGG	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.74	0.3	4.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.61	-12.05	-0.49	2.93e-29	Prudent dietary pattern;
LGG	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.61	0.33	1.54e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06481639	chr22:41940642	POLR3H	-0.49	-7.26	-0.32	1.65e-12	Vitiligo;
LGG	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-13.93	-0.54	4.48e-37	Extrinsic epigenetic age acceleration;
LGG	trans	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg07393940	chr7:158741817	NA	0.57	10.28	0.43	1.89e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10193935	0.792	rs6735571	chr2:42491951	C/T	cg27598129	chr2:42591480	NA	-0.58	-8.83	-0.38	2.21e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg23594656	chr7:65796392	TPST1	0.43	9.41	0.4	2.29e-19	Aortic root size;
LGG	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	trans	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg01620082	chr3:125678407	NA	-0.66	-8.24	-0.36	1.76e-15	Lung cancer in ever smokers;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5015933	1.000	rs4289914	chr9:128135805	A/C	cg14078157	chr9:128172775	NA	-0.36	-6.81	-0.3	3e-11	Body mass index;
LGG	cis	rs1555895	0.566	rs1000278	chr10:852629	C/T	cg10556349	chr10:835070	NA	-0.29	-7.18	-0.32	2.78e-12	Survival in rectal cancer;
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg26752003	chr8:145688521	CYHR1	0.56	12.28	0.5	3.35e-30	Age at first birth;
LGG	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.21	-0.36	2.29e-15	Joint mobility (Beighton score);
LGG	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-8.09	-0.35	5.47e-15	Oral cavity cancer;
LGG	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg24642439	chr20:33292090	TP53INP2	0.82	14.59	0.56	6.15e-40	Coronary artery disease;
LGG	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg10122326	chr6:28072925	NA	0.93	7.1	0.31	4.69e-12	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.22	0.36	2.14e-15	Aortic root size;
LGG	cis	rs6831352	0.765	rs35361391	chr4:100069281	A/T	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs13082711	0.554	rs73055750	chr3:27401505	C/G	cg02860705	chr3:27208620	NA	0.92	16.77	0.61	1.16e-49	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs17672112	0.667	rs12205870	chr6:101218216	A/G	cg27451362	chr6:101846650	GRIK2	0.69	8.75	0.38	3.92e-17	Putamen volume;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.32	-0.63	3.4e-52	Refractive error;
LGG	cis	rs1949733	0.958	rs2631731	chr4:8429817	A/G	cg13073564	chr4:8508604	NA	-0.58	-11.22	-0.46	5.42e-26	Response to antineoplastic agents;
LGG	cis	rs283228	1.000	rs386552	chr6:101735112	C/G	cg27451362	chr6:101846650	GRIK2	-0.54	-9.08	-0.39	3.13e-18	Coenzyme Q10 levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08981532	chr16:2264875	PGP	0.48	7.0	0.31	9.14e-12	Hip circumference;
LGG	cis	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg06609049	chr19:2785107	THOP1	0.66	10.02	0.42	1.6e-21	Total cholesterol levels;
LGG	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.73	16.95	0.62	1.73e-50	Multiple sclerosis;
LGG	cis	rs1707322	1.000	rs4660903	chr1:46457601	A/G	cg03146154	chr1:46216737	IPP	0.53	9.95	0.42	2.96e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.43e-11	Depression;
LGG	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs17453880	0.929	rs59126622	chr5:151999934	G/T	cg10931792	chr5:152022470	NA	0.38	8.18	0.36	2.69e-15	Subjective well-being;
LGG	cis	rs4237845	0.844	rs7306124	chr12:58303349	A/T	cg02175503	chr12:58329896	NA	0.7	13.21	0.52	5.14e-34	Intelligence (multi-trait analysis);
LGG	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.37	0.32	7.71e-13	Total cholesterol levels;
LGG	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.07	-0.31	5.69e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg06636001	chr8:8085503	FLJ10661	0.54	9.97	0.42	2.37e-21	Retinal vascular caliber;
LGG	cis	rs539514	0.690	rs504273	chr13:76310850	C/T	cg04757411	chr13:76259545	LMO7	-0.27	-7.04	-0.31	6.98e-12	Type 1 diabetes;
LGG	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.35	-0.43	9.7e-23	Intelligence (multi-trait analysis);
LGG	cis	rs943466	0.955	rs3763253	chr6:33772761	C/T	cg07519485	chr6:33762594	MLN	-0.51	-10.26	-0.43	2.09e-22	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.07	-0.39	3.5e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14159747	chr11:113255604	NA	0.29	7.88	0.34	2.42e-14	Neuroticism;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.68	-0.37	6.99e-17	IgG glycosylation;
LGG	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg01804193	chr12:63026212	NA	0.55	7.15	0.32	3.3e-12	IgG glycosylation;
LGG	cis	rs6952809	0.561	rs1548598	chr7:2438912	T/C	cg23289794	chr7:2394357	EIF3B	-0.76	-9.75	-0.41	1.46e-20	Multiple sclerosis;
LGG	cis	rs17641971	0.684	rs4873095	chr8:49990166	A/T	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg18681998	chr4:17616180	MED28	0.72	14.83	0.57	5.35e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg15133208	chr4:90757351	SNCA	-0.34	-7.67	-0.34	1.04e-13	Dementia with Lewy bodies;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03264133	chr6:25882463	NA	0.5	9.19	0.39	1.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6882046	0.513	rs639725	chr5:88001969	A/G	cg22951263	chr5:87985283	NA	-0.55	-10.29	-0.43	1.61e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26604901	chr18:43684385	HAUS1;ATP5A1	0.47	6.74	0.3	4.66e-11	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg05941027	chr17:61774174	LIMD2	0.35	8.27	0.36	1.4e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg04455712	chr21:45112962	RRP1B	0.56	10.93	0.45	6.76e-25	Mean corpuscular volume;
LGG	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.11	0.43	7.54e-22	Height;
LGG	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg23248424	chr5:179741104	GFPT2	-0.59	-10.69	-0.44	5.44e-24	Height;
LGG	cis	rs17030434	0.954	rs79908936	chr4:154749305	C/T	cg14289246	chr4:154710475	SFRP2	-0.71	-11.25	-0.46	3.85e-26	Electrocardiographic conduction measures;
LGG	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg24209194	chr3:40518798	ZNF619	0.44	7.05	0.31	6.34e-12	Renal cell carcinoma;
LGG	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg04842962	chr6:43655489	MRPS18A	1.03	16.23	0.6	3.08e-47	IgG glycosylation;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.09	-0.35	5.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.85e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4363385	0.765	rs1094409	chr1:153021040	T/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.91	-0.38	1.16e-17	Inflammatory skin disease;
LGG	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg13010199	chr12:38710504	ALG10B	0.64	12.98	0.52	4.57e-33	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg05863683	chr7:1912471	MAD1L1	0.44	8.81	0.38	2.57e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04850017	chr11:63683019	RCOR2	0.32	8.1	0.35	5.09e-15	Pulse pressure;
LGG	trans	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg21659725	chr3:3221576	CRBN	-0.66	-6.95	-0.31	1.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11064837	0.523	rs6490266	chr12:120105740	C/A	cg25937854	chr12:120150414	CIT	-0.69	-11.51	-0.47	3.92e-27	Schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04696559	chr5:36152378	SKP2;LMBRD2	0.42	7.12	0.31	4.03e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.19	-0.43	3.74e-22	Lymphocyte counts;
LGG	cis	rs11229555	0.645	rs11229463	chr11:58210147	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2287838	0.704	rs1862471	chr19:10000322	C/G	cg00846166	chr19:10022875	OLFM2	0.33	7.49	0.33	3.46e-13	Sleep duration;
LGG	cis	rs1620921	0.625	rs67998011	chr6:161273327	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.44e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg10661904	chr17:79619235	PDE6G	-0.42	-8.68	-0.37	6.61e-17	Eye color traits;
LGG	cis	rs2241941	0.840	rs11600101	chr11:20628072	T/G	cg05572763	chr11:20631898	SLC6A5	-0.48	-8.67	-0.37	7.36e-17	Obesity-related traits;
LGG	cis	rs7071206	0.947	rs10824560	chr10:79416901	C/T	cg07817648	chr10:79422355	NA	-0.77	-14.5	-0.56	1.5e-39	Bone mineral density;
LGG	cis	rs7666738	0.830	rs7672901	chr4:98938781	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.48e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72781680	0.898	rs72798064	chr2:23982832	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg08847335	chr10:891726	LARP4B	-0.48	-8.71	-0.38	5.27e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs1707322	1.000	rs6429588	chr1:46454058	T/G	cg03146154	chr1:46216737	IPP	0.54	9.99	0.42	2.07e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6743226	0.557	rs62186420	chr2:242246875	T/C	cg10021735	chr2:242295487	FARP2	0.4	7.07	0.31	5.63e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15644404	chr18:77186268	NFATC1	-0.82	-8.82	-0.38	2.34e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7666738	0.830	rs36047842	chr4:99004902	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	16.37	0.61	7.49e-48	Smoking behavior;
LGG	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22496380	chr5:211416	CCDC127	-1.25	-9.83	-0.42	7.65e-21	Asthma (childhood onset);
LGG	cis	rs11308613	1	rs11308613	chr13:38558010	GT/G	cg26068090	chr13:38518217	NA	-0.59	-10.11	-0.43	7.5e-22	Mild influenza (H1N1) infection;
LGG	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg16576597	chr16:28551801	NUPR1	0.43	10.08	0.42	1e-21	Mosquito bite size;
LGG	cis	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.28	-0.46	3e-26	Morning vs. evening chronotype;
LGG	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	trans	rs28595532	0.641	rs72670220	chr4:119300053	A/G	cg26518628	chr1:97050305	NA	-0.87	-8.98	-0.39	6.62e-18	Cannabis dependence symptom count;
LGG	cis	rs12410462	0.551	rs4384237	chr1:227868554	G/T	cg04117972	chr1:227635322	NA	0.44	8.11	0.35	4.54e-15	Major depressive disorder;
LGG	cis	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.04	0.42	1.33e-21	Height;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg22618164	chr12:122356400	WDR66	0.42	13.4	0.53	7.45e-35	Mean corpuscular volume;
LGG	cis	rs1451375	0.698	rs56766899	chr7:50648938	T/C	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs4443293	chr4:99063120	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6450176	0.564	rs390420	chr5:53326731	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.32	-0.47	2.2e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.29	0.46	2.74e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg05863683	chr7:1912471	MAD1L1	-0.44	-8.58	-0.37	1.41e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.98e-11	Alzheimer's disease (survival time);
LGG	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	8.0	0.35	1.02e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.15	0.32	3.31e-12	Height;
LGG	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg03959625	chr15:84868606	LOC388152	0.53	8.17	0.35	2.99e-15	Schizophrenia;
LGG	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg02466173	chr16:30829666	NA	0.51	8.53	0.37	2.12e-16	Dementia with Lewy bodies;
LGG	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg11608241	chr8:8085544	FLJ10661	0.29	6.7	0.3	6.08e-11	Schizophrenia;
LGG	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.45	0.37	3.69e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02788857	chr8:22132959	PIWIL2	-0.52	-12.21	-0.49	6.26e-30	Hypertriglyceridemia;
LGG	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg05147244	chr20:61493195	TCFL5	0.77	7.44	0.33	5.04e-13	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs17682583	chr22:32401495	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05165339	chr4:1420672	NA	-0.3	-8.16	-0.35	3.12e-15	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11786005	chr6:170863399	PSMB1;TBP	0.48	8.03	0.35	8.2e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4731207	0.596	rs10256218	chr7:124609982	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs7301826	0.651	rs7295705	chr12:131301885	C/T	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs4684776	0.800	rs730178	chr3:11610729	G/A	cg24705426	chr3:11550659	ATG7	-0.42	-7.33	-0.32	1.04e-12	Small vessel stroke;
LGG	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg12179176	chr11:130786555	SNX19	0.77	14.74	0.57	1.36e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6540556	0.954	rs6696463	chr1:209933757	G/C	cg23920097	chr1:209922102	NA	-0.45	-8.01	-0.35	9.37e-15	Red blood cell count;
LGG	cis	rs8114671	0.836	rs62213676	chr20:33612676	T/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22168489	chr12:122356033	WDR66	0.4	9.22	0.39	1.03e-18	Mean corpuscular volume;
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg01114163	chr5:1856713	NA	-0.4	-6.85	-0.3	2.43e-11	Cardiovascular disease risk factors;
LGG	cis	rs12210905	0.920	rs9348763	chr6:27302919	G/C	cg15325629	chr6:28072465	NA	0.91	7.02	0.31	7.87e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08280861	chr8:58055591	NA	0.6	7.76	0.34	5.43e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17125944	0.686	rs7144029	chr14:53333616	G/T	cg00686598	chr14:53173677	PSMC6	-0.69	-7.6	-0.33	1.7e-13	Alzheimer's disease (late onset);
LGG	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg03213289	chr20:61660250	NA	0.66	14.45	0.56	2.43e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.46e-12	Total cholesterol levels;
LGG	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg14019146	chr3:50243930	SLC38A3	0.46	9.94	0.42	3.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg12310025	chr6:25882481	NA	-0.38	-6.73	-0.3	5.1e-11	Height;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00149659	chr3:10157352	C3orf10	0.89	11.37	0.47	1.32e-26	Alzheimer's disease;
LGG	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg08085267	chr17:45401833	C17orf57	0.62	12.79	0.51	2.66e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6964587	0.692	rs10271430	chr7:91710466	G/C	cg17063962	chr7:91808500	NA	0.48	8.93	0.38	1.04e-17	Breast cancer;
LGG	cis	rs972578	0.765	rs6519351	chr22:43296474	A/T	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	3.03e-11	Mean platelet volume;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.74	-0.3	4.69e-11	Aortic root size;
LGG	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.54	0.33	2.54e-13	Colorectal cancer;
LGG	cis	rs9487051	0.802	rs6568558	chr6:109592701	A/T	cg21918786	chr6:109611834	NA	-0.42	-7.77	-0.34	4.96e-14	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.18	-0.52	6.81e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-8.49	-0.37	2.89e-16	Hip circumference adjusted for BMI;
LGG	cis	rs6430585	0.527	rs57530667	chr2:136444338	A/G	cg07169764	chr2:136633963	MCM6	1.0	16.85	0.62	4.88e-50	Corneal structure;
LGG	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg25358565	chr5:93447407	FAM172A	1.36	16.52	0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg22044901	chr15:68126292	NA	-0.41	-7.21	-0.32	2.31e-12	Obesity;
LGG	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	6.84	0.3	2.48e-11	Endometriosis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02525666	chr16:71845903	NA	0.36	7.04	0.31	7.08e-12	Electrocardiographic conduction measures;
LGG	cis	rs870825	0.616	rs1401361	chr4:185643742	G/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.71	0.61	2.23e-49	Hip circumference adjusted for BMI;
LGG	trans	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg05059571	chr16:84539110	KIAA1609	0.57	10.85	0.45	1.39e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.21	-0.39	1.11e-18	Neuroticism;
LGG	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.19	-0.46	6.72e-26	Response to antipsychotic treatment;
LGG	cis	rs735539	0.517	rs9552240	chr13:21126497	T/C	cg04906043	chr13:21280425	IL17D	-0.48	-8.03	-0.35	8.14e-15	Dental caries;
LGG	cis	rs35146811	0.735	rs6465766	chr7:99785671	A/G	cg22906224	chr7:99728672	NA	0.58	9.48	0.4	1.37e-19	Coronary artery disease;
LGG	cis	rs4865875	0.892	rs4282277	chr5:54074693	T/C	cg22421804	chr5:54100067	NA	0.47	6.66	0.3	7.88e-11	Sense of smell;
LGG	cis	rs6500395	1.000	rs4785535	chr16:48707659	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.96	0.42	2.55e-21	Height;
LGG	cis	rs2274273	0.870	rs10145203	chr14:55784458	A/C	cg04306507	chr14:55594613	LGALS3	0.62	16.92	0.62	2.42e-50	Protein biomarker;
LGG	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg26913058	chr16:419975	MRPL28	-0.48	-7.58	-0.33	1.9e-13	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg06916706	chr16:4465613	CORO7	0.87	14.83	0.57	5.57e-41	Schizophrenia;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg23758822	chr17:41437982	NA	0.84	15.29	0.58	5.02e-43	Menopause (age at onset);
LGG	cis	rs11264213	0.892	rs12037102	chr1:36261733	T/G	cg27506609	chr1:36549197	TEKT2	0.61	7.02	0.31	8.18e-12	Schizophrenia;
LGG	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.94	-0.35	1.57e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4363385	0.747	rs10788850	chr1:152963932	A/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.16	-0.39	1.72e-18	Inflammatory skin disease;
LGG	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg25986240	chr4:9926439	SLC2A9	0.37	7.63	0.33	1.35e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg00334542	chr7:100209784	MOSPD3	-0.61	-8.48	-0.37	3.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.89	0.57	3.06e-41	Post bronchodilator FEV1;
LGG	trans	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg07211511	chr3:129823064	LOC729375	-1.31	-16.28	-0.6	1.86e-47	Blood pressure (smoking interaction);
LGG	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg23335576	chr14:104009727	NA	0.5	8.64	0.37	9.01e-17	Reticulocyte count;
LGG	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.9	-0.45	9.11e-25	Chronic sinus infection;
LGG	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg13207630	chr7:32358064	NA	0.66	7.17	0.32	3.06e-12	Body mass index;
LGG	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-7.53	-0.33	2.61e-13	Morning vs. evening chronotype;
LGG	cis	rs4535700	0.501	rs11765531	chr7:56010287	C/G	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	3.81e-11	Macular telangiectasia type 2;
LGG	cis	rs9976767	0.932	rs9978717	chr21:43827765	A/G	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.88	-0.42	5.02e-21	Type 1 diabetes;
LGG	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs698813	0.674	rs11680456	chr2:44497544	C/G	cg00619915	chr2:44497795	NA	-0.61	-8.56	-0.37	1.74e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs1670533	1.000	rs2045069	chr4:1052206	T/C	cg27284194	chr4:1044797	NA	0.55	9.93	0.42	3.37e-21	Recombination rate (females);
LGG	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15557168	chr22:42548783	NA	-0.34	-7.64	-0.33	1.23e-13	Cognitive function;
LGG	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg15485101	chr11:133734466	NA	0.59	10.52	0.44	2.45e-23	Childhood ear infection;
LGG	cis	rs17208368	0.628	rs4784472	chr16:55092857	T/C	cg09947736	chr16:55091198	NA	0.68	12.97	0.52	5.03e-33	Hypospadias;
LGG	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg27478167	chr7:817139	HEATR2	-0.43	-6.88	-0.3	1.93e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg02023728	chr11:77925099	USP35	0.4	6.95	0.31	1.27e-11	Alzheimer's disease (survival time);
LGG	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	5.9e-49	Hip circumference adjusted for BMI;
LGG	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg05096777	chr10:104283225	SUFU	0.31	6.85	0.3	2.42e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.54	-0.41	8.34e-20	Primary sclerosing cholangitis;
LGG	cis	rs6728861	1	rs6728861	chr2:203873743	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease;
LGG	cis	rs4430311	0.965	rs3008660	chr1:244024703	T/G	cg25706552	chr1:244017396	NA	-0.68	-17.56	-0.63	2.84e-53	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg07395648	chr5:131743802	NA	0.51	10.68	0.44	6.22e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	9.83	0.42	7.49e-21	Lung cancer in ever smokers;
LGG	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg22517653	chr1:2918612	NA	-0.48	-7.43	-0.33	5.29e-13	Plateletcrit;
LGG	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg13385794	chr1:248469461	NA	0.49	8.35	0.36	8.06e-16	Common traits (Other);
LGG	cis	rs35123781	1.000	rs682164	chr5:139058589	A/G	cg21230503	chr5:139085173	NA	0.3	7.27	0.32	1.57e-12	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18078305	chr2:65215753	SLC1A4	-0.52	-7.86	-0.34	2.63e-14	Systemic lupus erythematosus;
LGG	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.76	-0.34	5.4e-14	Mood instability;
LGG	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.96	-0.31	1.14e-11	Triglycerides;
LGG	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg13683864	chr3:40499215	RPL14	-1.13	-26.17	-0.77	2.5e-93	Renal cell carcinoma;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.41e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg08847533	chr14:75593920	NEK9	0.63	12.28	0.5	3.42e-30	Height;
LGG	cis	rs9354308	0.774	rs10155672	chr6:66538447	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg16141378	chr3:129829833	LOC729375	-0.42	-10.01	-0.42	1.69e-21	Mood instability;
LGG	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.7e-30	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.26	0.32	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9359856	0.564	rs72913954	chr6:90361589	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.74	-0.41	1.65e-20	Bipolar disorder;
LGG	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg07636037	chr3:49044803	WDR6	0.77	13.6	0.53	1.13e-35	Menarche (age at onset);
LGG	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.04	0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.12	-0.31	4.14e-12	Alzheimer's disease (late onset);
LGG	cis	rs774359	0.797	rs2484314	chr9:27511284	T/G	cg21249376	chr9:27528432	MOBKL2B	0.43	8.85	0.38	1.85e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg24764310	chr7:157512201	PTPRN2	-0.48	-10.64	-0.44	8.35e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg20026190	chr17:76395443	PGS1	0.44	7.57	0.33	2.05e-13	HDL cholesterol levels;
LGG	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.81	-0.45	1.91e-24	Migraine;Coronary artery disease;
LGG	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.23	-0.32	1.96e-12	Blood metabolite levels;
LGG	cis	rs35740288	0.822	rs17636864	chr15:86234589	A/C	cg07943548	chr15:86304357	KLHL25	-0.36	-6.92	-0.31	1.47e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22496380	chr5:211416	CCDC127	-1.33	-18.47	-0.65	1.75e-57	Breast cancer;
LGG	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.98	0.35	1.13e-14	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13989810	chr7:154179786	DPP6	-0.34	-6.88	-0.3	2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg12633918	chr20:23549525	CST9L	-0.33	-6.78	-0.3	3.7e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.77	0.38	3.41e-17	Coronary artery disease;
LGG	cis	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg06521331	chr12:34319734	NA	0.39	6.72	0.3	5.21e-11	Morning vs. evening chronotype;
LGG	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.48e-12	Neuroticism;
LGG	cis	rs1385374	1.000	rs12311303	chr12:129301592	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	6.73	0.3	5.04e-11	Systemic lupus erythematosus;
LGG	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.95	-0.31	1.23e-11	Joint mobility (Beighton score);
LGG	cis	rs9354308	0.764	rs3960019	chr6:66586066	T/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	14.06	0.55	1.23e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.92	-0.38	1.06e-17	Lymphocyte counts;
LGG	cis	rs367615	0.552	rs2963025	chr5:108733256	A/C	cg17395555	chr5:108820864	NA	-0.71	-11.61	-0.47	1.62e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.35	0.47	1.72e-26	Tonsillectomy;
LGG	cis	rs4474465	0.850	rs7127028	chr11:78262324	A/G	cg02023728	chr11:77925099	USP35	-0.39	-6.82	-0.3	2.9100000000000002e-11	Alzheimer's disease (survival time);
LGG	cis	rs12476592	0.602	rs989527	chr2:63726791	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.3	-0.32	1.23e-12	Mood instability;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	cis	rs2816062	0.965	rs2816061	chr1:18903819	A/G	cg18795169	chr1:18902165	NA	1.01	27.95	0.79	2.02e-101	Urate levels in lean individuals;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg20978937	chr14:105399321	PLD4	0.48	10.75	0.45	3.22e-24	Rheumatoid arthritis;
LGG	cis	rs74781061	0.860	rs7169985	chr15:74745778	G/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs367943	0.660	rs9632462	chr5:112697801	T/C	cg12552261	chr5:112820674	MCC	0.58	10.43	0.44	5.16e-23	Type 2 diabetes;
LGG	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg26924012	chr15:45694286	SPATA5L1	1.02	20.88	0.7	1.01e-68	Homoarginine levels;
LGG	cis	rs782590	0.738	rs4312532	chr2:55812061	A/G	cg18811423	chr2:55921094	PNPT1	-0.75	-15.01	-0.57	8.93e-42	Metabolic syndrome;
LGG	cis	rs36093844	0.752	rs57534090	chr11:85573020	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.17	-0.32	3.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs41271473	0.526	rs10916339	chr1:228716894	C/T	cg16512390	chr1:228756714	NA	0.61	8.12	0.35	4.15e-15	Chronic lymphocytic leukemia;
LGG	cis	rs11168187	0.843	rs7976708	chr12:48116255	A/G	cg12761788	chr12:48120090	P11	0.5	8.72	0.38	4.91e-17	Vertical cup-disc ratio;
LGG	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg06640241	chr16:89574553	SPG7	0.84	15.45	0.58	9.5e-44	Multiple myeloma (IgH translocation);
LGG	cis	rs1983891	0.643	rs3800284	chr6:41558365	G/C	cg20194872	chr6:41519635	FOXP4	0.51	8.8	0.38	2.67e-17	Prostate cancer;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.41	7.56	0.33	2.13e-13	Bilirubin levels;
LGG	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg18188782	chr20:61659543	NA	-0.41	-6.85	-0.3	2.4e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg13607699	chr17:42295918	UBTF	0.54	9.02	0.39	5.08e-18	Total body bone mineral density;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg15971980	chr6:150254442	NA	0.44	8.66	0.37	7.99e-17	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg13047869	chr3:10149882	C3orf24	0.54	8.98	0.38	7.1e-18	Alzheimer's disease;
LGG	cis	rs12220238	0.908	rs10824086	chr10:75912668	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.87	0.45	1.13e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs4714291	0.775	rs2949019	chr6:40051200	C/T	cg02267698	chr19:7991119	CTXN1	-0.61	-10.08	-0.42	1e-21	Strep throat;
LGG	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.92	0.42	3.82e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg03453431	chr7:157225567	NA	-0.49	-8.4	-0.36	5.5e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg12386194	chr3:101231763	SENP7	0.47	8.27	0.36	1.4e-15	Colorectal cancer;
LGG	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg09754948	chr16:28834200	ATXN2L	0.42	6.74	0.3	4.7e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs6764363	0.587	rs459980	chr3:285569	A/G	cg02057681	chr3:285234	CHL1	0.4	7.58	0.33	1.86e-13	Sudden cardiac arrest;
LGG	trans	rs877282	0.898	rs11253339	chr10:759640	C/T	cg22713356	chr15:30763199	NA	0.49	7.34	0.32	9.59e-13	Uric acid levels;
LGG	cis	rs919433	0.680	rs11680291	chr2:198409884	A/G	cg00792783	chr2:198669748	PLCL1	0.5	7.87	0.34	2.55e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg21475434	chr5:93447410	FAM172A	0.71	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs6076065	0.707	rs12349	chr20:23352480	A/G	cg11657817	chr20:23433608	CST11	0.41	8.29	0.36	1.26e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs11885103	0.669	rs1317823	chr2:550873	C/G	cg21195176	chr2:593345	NA	0.4	7.34	0.32	9.89e-13	Heschl's gyrus morphology;
LGG	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.93	0.31	1.38e-11	Educational attainment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05489143	chr3:40498640	RPL14	0.46	7.76	0.34	5.42e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg04025307	chr7:1156635	C7orf50	0.64	8.29	0.36	1.21e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.69	-0.37	6.28e-17	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg15971980	chr6:150254442	NA	0.47	9.42	0.4	2.17e-19	Testicular germ cell tumor;
LGG	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg12219531	chr12:120966889	COQ5	0.66	11.13	0.46	1.2e-25	High light scatter reticulocyte count;
LGG	trans	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.79	-0.34	4.47e-14	Resting heart rate;
LGG	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg06153925	chr17:78755379	RPTOR	0.4	6.82	0.3	2.92e-11	Myopia (pathological);
LGG	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs6435862	0.517	rs6757091	chr2:215672793	G/C	cg04530015	chr2:215796436	ABCA12	0.49	9.86	0.42	6.16e-21	Neuroblastoma (high-risk);
LGG	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg03806693	chr22:41940476	POLR3H	1.01	17.78	0.64	2.66e-54	Vitiligo;
LGG	cis	rs17604090	0.793	rs73687726	chr7:29688773	T/C	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	12.04	0.49	3.13e-29	Type 2 diabetes;
LGG	cis	rs2587949	0.615	rs2600113	chr3:4225734	T/G	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.57e-11	Periodontitis (DPAL);
LGG	cis	rs1461503	0.900	rs7119398	chr11:122832492	C/A	cg27398637	chr11:122830231	C11orf63	-0.69	-14.07	-0.55	1.12e-37	Menarche (age at onset);
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.6e-22	Menopause (age at onset);
LGG	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00495681	chr13:53174319	NA	0.47	7.97	0.35	1.23e-14	Lewy body disease;
LGG	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg07636037	chr3:49044803	WDR6	-0.76	-13.57	-0.53	1.48e-35	Menarche (age at onset);
LGG	cis	rs113835537	0.529	rs11821155	chr11:66246337	C/T	cg24851651	chr11:66362959	CCS	-0.44	-7.7	-0.34	8.23e-14	Airway imaging phenotypes;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg23131131	chr22:24373011	LOC391322	-0.49	-8.22	-0.36	2.03e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	19.33	0.67	1.77e-61	Platelet count;
LGG	cis	rs17321999	0.516	rs7574911	chr2:30500715	G/A	cg05247661	chr2:30472410	LBH	0.51	6.66	0.3	7.92e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.14	-0.43	5.97e-22	Lung cancer;
LGG	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg19717773	chr7:2847554	GNA12	-0.39	-8.93	-0.38	9.83e-18	Height;
LGG	cis	rs4730250	0.654	rs6947857	chr7:106787266	T/G	cg02696742	chr7:106810147	HBP1	0.78	10.89	0.45	9.83e-25	Osteoarthritis;
LGG	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.46	-0.53	4.24e-35	Response to antipsychotic treatment;
LGG	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg10483660	chr13:112241077	NA	0.42	8.69	0.37	6.42e-17	Menarche (age at onset);
LGG	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg13902645	chr11:5959945	NA	-0.66	-11.02	-0.46	3.08e-25	DNA methylation (variation);
LGG	cis	rs9556958	0.527	rs9517313	chr13:99105892	C/G	cg07423050	chr13:99094983	FARP1	0.59	12.07	0.49	2.25e-29	Educational attainment (years of education);
LGG	cis	rs2235642	0.505	rs56359342	chr16:1654948	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.97	0.31	1.11e-11	Coronary artery disease;
LGG	cis	rs34734847	1.000	rs2948149	chr12:121162854	T/G	cg21892295	chr12:121157589	UNC119B	-0.45	-8.5	-0.37	2.59e-16	Mean corpuscular volume;
LGG	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg09824328	chr1:43425412	SLC2A1	-0.34	-7.2	-0.32	2.39e-12	Red cell distribution width;
LGG	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg11252792	chr3:125932053	NA	0.56	11.68	0.48	8.57e-28	Metabolite levels;
LGG	trans	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.5	-0.4	1.12e-19	Bladder cancer;
LGG	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.1	0.35	4.77e-15	Iron status biomarkers;
LGG	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.51	-0.4	1.02e-19	Depression;
LGG	cis	rs9863	0.861	rs10846580	chr12:124415453	T/C	cg13487667	chr12:124434373	CCDC92	-0.34	-6.77	-0.3	3.95e-11	White blood cell count;
LGG	cis	rs3008870	0.755	rs2815355	chr1:67485034	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.69	0.59	8.28e-45	Lymphocyte percentage of white cells;
LGG	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.85	-0.42	6.75e-21	Body mass index;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.39e-13	Prudent dietary pattern;
LGG	cis	rs282587	0.569	rs166865	chr13:113384879	A/G	cg04656015	chr13:113407548	ATP11A	0.42	6.75	0.3	4.31e-11	Glycated hemoglobin levels;
LGG	trans	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.46	-0.33	4.19e-13	Red cell distribution width;
LGG	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.94	-0.38	9.44e-18	Morning vs. evening chronotype;
LGG	cis	rs2737618	0.551	rs2816989	chr1:200070765	G/T	cg21825944	chr1:200113062	NR5A2	0.49	9.24	0.39	8.77e-19	Uric acid levels;
LGG	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg24692254	chr21:30365293	RNF160	1.04	29.93	0.81	2.68e-110	Dental caries;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25882709	chr1:224517832	NVL	0.41	6.7	0.3	6.02e-11	Cognitive performance;
LGG	cis	rs921968	0.643	rs3770218	chr2:219525335	C/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.1	-0.31	4.69e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2274273	0.624	rs8014540	chr14:55841688	C/A	cg04306507	chr14:55594613	LGALS3	0.53	12.45	0.5	7.06e-31	Protein biomarker;
LGG	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.9	0.34	2.02e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg00717180	chr2:96193071	NA	-0.41	-7.36	-0.32	8.18e-13	HDL cholesterol;
LGG	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.63	-0.33	1.39e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg21665744	chr7:39171113	POU6F2	0.32	6.66	0.3	7.88e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg22398616	chr13:53314203	LECT1	-0.48	-9.79	-0.41	1.05e-20	Lewy body disease;
LGG	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs13314892	0.764	rs56927902	chr3:69863476	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs10895140	0.666	rs4366455	chr11:101511001	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.89	-0.3	1.82e-11	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18951187	chr15:72524237	PKM2	0.41	6.92	0.31	1.53e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.13	0.31	3.85e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11088226	0.692	rs2833863	chr21:33886986	A/G	cg09050820	chr6:167586206	TCP10L2	0.48	7.48	0.33	3.87e-13	Gastritis;
LGG	cis	rs1829883	0.626	rs2548089	chr5:98910440	A/C	cg08333243	chr5:99726346	NA	0.37	6.81	0.3	3.09e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg02023728	chr11:77925099	USP35	0.44	7.35	0.32	8.78e-13	Testicular germ cell tumor;
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.45	-6.86	-0.3	2.18e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7741085	0.967	rs11752730	chr6:44639100	C/G	cg18551225	chr6:44695536	NA	-0.43	-7.28	-0.32	1.48e-12	Total body bone mineral density;
LGG	cis	rs6142618	0.562	rs6142617	chr20:30715762	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.88	0.34	2.38e-14	Inflammatory bowel disease;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.07e-38	Tonsillectomy;
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg05091796	chr16:4465799	CORO7	-0.65	-10.9	-0.45	9.05e-25	Schizophrenia;
LGG	trans	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs1125355	0.655	rs1515924	chr2:159649340	A/G	cg02251393	chr2:159651559	DAPL1	-0.44	-9.02	-0.39	4.92e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7666738	0.830	rs114722517	chr4:99042061	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg25457927	chr22:38595422	NA	0.47	12.22	0.49	5.79e-30	Cutaneous nevi;
LGG	cis	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg19847130	chr8:10466454	RP1L1	0.34	6.97	0.31	1.09e-11	Neuroticism;
LGG	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.89	0.31	1.82e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs151997	0.671	rs395557	chr5:50215832	G/T	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs9811920	0.928	rs9865713	chr3:99870299	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	7.8	0.34	4.08e-14	Axial length;
LGG	cis	rs804280	0.525	rs17153755	chr8:11611500	C/G	cg12395012	chr8:11607386	GATA4	-0.53	-9.95	-0.42	2.95e-21	Myopia (pathological);
LGG	cis	rs7432375	0.966	rs6808312	chr3:136371504	C/T	cg21827317	chr3:136751795	NA	-0.48	-8.66	-0.37	7.69e-17	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07440826	chr16:89882328	FANCA	-0.26	-6.84	-0.3	2.47e-11	Vitiligo;
LGG	cis	rs12681288	0.782	rs2600500	chr8:1029031	G/C	cg04851639	chr8:1020857	NA	-0.41	-8.07	-0.35	6.21e-15	Schizophrenia;
LGG	cis	rs7666738	0.830	rs11944035	chr4:98931618	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg06634786	chr22:41940651	POLR3H	-0.52	-8.69	-0.37	6.42e-17	Neuroticism;
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg16141378	chr3:129829833	LOC729375	0.38	8.79	0.38	2.95e-17	Triglycerides;
LGG	trans	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg26043149	chr18:55253948	FECH	-0.41	-6.92	-0.31	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.39	0.4	2.67e-19	Neuroticism;
LGG	cis	rs3796352	1.000	rs13076033	chr3:52898427	T/C	cg12962167	chr3:53033115	SFMBT1	0.73	7.74	0.34	6.09e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7107174	1.000	rs10899477	chr11:78052104	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.47	-0.33	4.06e-13	Testicular germ cell tumor;
LGG	cis	rs1163251	0.902	rs639761	chr1:120217558	G/A	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg00666640	chr1:248458726	OR2T12	0.53	8.95	0.38	8.65e-18	Common traits (Other);
LGG	cis	rs1420338	0.967	rs1014581	chr7:34164677	T/G	cg01275685	chr7:34179230	BMPER	-0.5	-8.91	-0.38	1.15e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs3096299	0.646	rs918722	chr16:89415081	C/G	cg06640241	chr16:89574553	SPG7	0.62	10.09	0.42	8.92e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg20607798	chr8:58055168	NA	0.77	8.51	0.37	2.43e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs78487399	0.808	rs7559842	chr2:43673442	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.83	-0.3	2.72e-11	Response to amphetamines;
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg03806693	chr22:41940476	POLR3H	-1.15	-20.7	-0.69	7.07e-68	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12977448	chr10:14920832	SUV39H2	0.46	7.2	0.32	2.45e-12	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg05368731	chr17:41323189	NBR1	-0.87	-17.28	-0.63	5.53e-52	Menopause (age at onset);
LGG	cis	rs763121	1.000	rs138457	chr22:38898051	T/C	cg06022373	chr22:39101656	GTPBP1	-0.8	-15.84	-0.59	1.87e-45	Menopause (age at onset);
LGG	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.03e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg04166393	chr7:2884313	GNA12	0.46	8.44	0.36	4.23e-16	Height;
LGG	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-16.48	-0.61	2.38e-48	Morning vs. evening chronotype;
LGG	cis	rs7914558	0.966	rs3977751	chr10:104920232	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.35	0.43	9.85e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2932538	1.000	rs2932538	chr1:113216543	A/G	cg22162597	chr1:113214053	CAPZA1	-0.63	-11.59	-0.47	1.89e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg10596483	chr8:143751796	JRK	0.57	9.52	0.4	1e-19	Schizophrenia;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.54	0.67	1.86e-62	Platelet count;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg18538332	chr22:24372958	LOC391322	-0.46	-7.45	-0.33	4.5e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9486719	1.000	rs28623445	chr6:96899116	G/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.18e-13	Dupuytren's disease;
LGG	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg15627072	chr1:2432621	PLCH2	-0.36	-8.15	-0.35	3.37e-15	Ulcerative colitis;
LGG	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.27	-0.36	1.42e-15	Schizophrenia;
LGG	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg12091567	chr17:66097778	LOC651250	0.75	12.38	0.5	1.36e-30	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.3	0.36	1.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs3820068	0.603	rs6429753	chr1:15900537	A/G	cg05660106	chr1:15850417	CASP9	0.83	14.5	0.56	1.47e-39	Systolic blood pressure;
LGG	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	9.57	0.41	6.27e-20	Menarche (age at onset);
LGG	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg12623918	chr2:306882	NA	0.52	9.61	0.41	4.82e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12410462	0.551	rs2814091	chr1:227636367	G/T	cg04117972	chr1:227635322	NA	0.37	6.68	0.3	6.89e-11	Major depressive disorder;
LGG	cis	rs8064299	0.967	rs3744208	chr17:72767565	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.67	12.88	0.51	1.15e-32	Monocyte count;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.57e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13732083	chr21:47605072	C21orf56	0.47	7.64	0.33	1.25e-13	Testicular germ cell tumor;
LGG	cis	rs911263	0.603	rs2180769	chr14:68799102	A/T	cg18825221	chr14:68749962	RAD51L1	0.37	8.01	0.35	9.7e-15	Primary biliary cholangitis;
LGG	cis	rs12612619	0.579	rs13029206	chr2:27077610	G/A	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.94	-0.31	1.3e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs3740909	1.000	rs11826465	chr11:125889469	G/A	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.56	-0.37	1.7e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2718058	0.630	rs2722228	chr7:37859818	G/A	cg24998770	chr7:37888106	TXNDC3	0.45	7.25	0.32	1.72e-12	Alzheimer's disease (late onset);
LGG	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg01244601	chr4:120671846	NA	-0.39	-7.58	-0.33	1.89e-13	Corneal astigmatism;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02234820	chr1:85358327	LPAR3	0.36	6.67	0.3	7.4e-11	Bilirubin levels;
LGG	cis	rs72781680	1.000	rs7581107	chr2:24173565	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Cannabis dependence symptom count;
LGG	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg23752985	chr2:85803571	VAMP8	0.4	7.81	0.34	3.84e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg06212747	chr3:49208901	KLHDC8B	0.46	6.76	0.3	4.17e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15557168	chr22:42548783	NA	-0.34	-7.63	-0.33	1.3e-13	Cognitive function;
LGG	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-9.2	-0.39	1.27e-18	Vitiligo;
LGG	cis	rs698813	0.756	rs2592196	chr2:44605522	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	3.95e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12431410	0.584	rs8015726	chr14:60247284	C/T	cg07950296	chr14:60194823	RTN1	0.39	7.42	0.33	5.66e-13	Schizophrenia;
LGG	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.2	-0.39	1.26e-18	Schizophrenia;
LGG	trans	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg14791747	chr16:20752902	THUMPD1	0.49	8.4	0.36	5.41e-16	Cognitive test performance;
LGG	cis	rs78545713	0.649	rs11751062	chr6:26216165	C/T	cg01420254	chr6:26195488	NA	0.78	7.45	0.33	4.59e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg21775007	chr8:11205619	TDH	0.48	7.86	0.34	2.74e-14	Neuroticism;
LGG	cis	rs9611565	0.765	rs132907	chr22:41801268	A/C	cg06481639	chr22:41940642	POLR3H	0.54	7.86	0.34	2.7e-14	Vitiligo;
LGG	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11890956	chr21:40555474	PSMG1	1.21	30.39	0.82	2.32e-112	Cognitive function;
LGG	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.25	-0.43	2.38e-22	Type 2 diabetes;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.69	0.34	8.85e-14	Tonsillectomy;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.64	-0.37	9.34e-17	Personality dimensions;
LGG	cis	rs11225247	0.772	rs12270109	chr11:102229310	G/C	cg06323957	chr11:102217781	BIRC2	0.81	7.68	0.34	9.23e-14	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.37	-0.4	3.09e-19	Response to antipsychotic treatment;
LGG	trans	rs877282	0.898	rs12358966	chr10:758703	A/G	cg22713356	chr15:30763199	NA	0.47	7.24	0.32	1.87e-12	Uric acid levels;
LGG	trans	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg12045294	chr17:78518616	RPTOR	-0.46	-7.07	-0.31	5.8e-12	Glycated hemoglobin levels;
LGG	trans	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg10756647	chr7:56101905	PSPH	0.47	7.06	0.31	6.23e-12	Corneal structure;
LGG	cis	rs4689642	0.507	rs4689654	chr4:7223348	C/T	cg21353189	chr4:7228343	SORCS2	0.33	7.07	0.31	5.69e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.13	18.65	0.66	2.54e-58	Platelet count;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg18538332	chr22:24372958	LOC391322	-0.44	-7.3	-0.32	1.3e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs700651	0.789	rs62277902	chr2:198879443	T/A	cg00792783	chr2:198669748	PLCL1	-0.66	-10.39	-0.43	6.96e-23	Intracranial aneurysm;
LGG	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg03929089	chr4:120376271	NA	-0.9	-18.01	-0.64	2.49e-55	Coronary artery disease;
LGG	cis	rs11785400	0.963	rs4579507	chr8:143733663	C/G	cg10596483	chr8:143751796	JRK	0.58	9.58	0.41	5.98e-20	Schizophrenia;
LGG	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-12.85	-0.51	1.5e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs10504073	0.647	rs10435612	chr8:49993696	A/T	cg00325661	chr8:49890786	NA	0.75	14.62	0.56	4.51e-40	Blood metabolite ratios;
LGG	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg16339924	chr4:17578868	LAP3	-0.59	-10.35	-0.43	9.84e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7633770	0.769	rs2385858	chr3:46660436	T/C	cg11219411	chr3:46661640	NA	0.65	16.19	0.6	4.86e-47	Coronary artery disease;
LGG	cis	rs6901004	0.803	rs354544	chr6:111531159	T/C	cg15721981	chr6:111408429	SLC16A10	-0.41	-7.37	-0.32	7.67e-13	Blood metabolite levels;
LGG	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.25e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg26384229	chr12:38710491	ALG10B	0.94	22.22	0.72	5.52e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.73	-0.45	3.95e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg21475434	chr5:93447410	FAM172A	0.67	6.78	0.3	3.59e-11	Diabetic retinopathy;
LGG	cis	rs476633	0.708	rs28629856	chr15:41446950	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.71	-11.62	-0.48	1.44e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4731207	0.596	rs900047	chr7:124673373	A/G	cg05630886	chr7:124431682	NA	0.31	7.21	0.32	2.29e-12	Cutaneous malignant melanoma;
LGG	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs7084402	0.870	rs1896245	chr10:60276083	T/G	cg07615347	chr10:60278583	BICC1	-0.64	-18.24	-0.65	2.15e-56	Refractive error;
LGG	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg01620082	chr3:125678407	NA	-0.64	-7.1	-0.31	4.68e-12	Depression;
LGG	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg13271783	chr10:134563150	INPP5A	-0.5	-7.78	-0.34	4.6e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.23	-0.32	2e-12	Longevity;Endometriosis;
LGG	cis	rs11696845	0.666	rs6073533	chr20:43361082	G/T	cg25301532	chr20:43378953	KCNK15	-0.48	-12.01	-0.49	4.03e-29	Obesity-related traits;
LGG	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs9814567	1.000	rs6766897	chr3:134191303	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.01	-0.49	3.96e-29	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	8.05	0.35	7.18e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.25e-13	Educational attainment;
LGG	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg17201900	chr20:34330562	RBM39	0.54	7.23	0.32	2.02e-12	Total cholesterol levels;
LGG	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg24375607	chr4:120327624	NA	0.6	10.09	0.42	8.88e-22	Corneal astigmatism;
LGG	cis	rs10237118	0.822	rs6976066	chr7:140228605	T/C	cg09787580	chr7:140227335	DENND2A	0.76	9.01	0.39	5.54e-18	Optic nerve measurement (cup area);
LGG	trans	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg02002194	chr4:3960332	NA	-0.47	-8.98	-0.39	6.71e-18	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.68e-19	Diabetic retinopathy;
LGG	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg26441486	chr22:50317300	CRELD2	0.42	7.86	0.34	2.64e-14	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03314080	chr2:178129903	NFE2L2	0.47	7.72	0.34	7.03e-14	Cognitive performance;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.01	-0.49	3.96e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg16885296	chr6:26284938	NA	0.37	7.75	0.34	6.01e-14	Educational attainment;
LGG	cis	rs60695258	1.000	rs17605615	chr4:87996745	G/A	cg21988461	chr4:88008667	AFF1	0.25	6.69	0.3	6.44e-11	Hematocrit;
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.69	0.48	7.84e-28	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg05335186	chr13:53173507	NA	-0.42	-8.49	-0.37	2.77e-16	Lewy body disease;
LGG	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg20336341	chr7:50628841	DDC	-0.44	-7.81	-0.34	3.99e-14	Malaria;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg16359550	chr11:109292809	C11orf87	0.48	9.01	0.39	5.32e-18	Schizophrenia;
LGG	cis	rs72781680	1.000	rs56205282	chr2:24221317	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.83	0.42	7.88e-21	Lymphocyte counts;
LGG	cis	rs2354432	0.607	rs6593751	chr1:146726023	A/G	cg25205988	chr1:146714368	CHD1L	-1.47	-15.07	-0.57	4.59e-42	Mitochondrial DNA levels;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.55	-0.53	1.9e-35	Personality dimensions;
LGG	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg14689365	chr7:158441557	NCAPG2	0.54	6.69	0.3	6.39e-11	Height;
LGG	trans	rs61931739	0.578	rs74627697	chr12:33628193	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-8.25	-0.36	1.71e-15	Morning vs. evening chronotype;
LGG	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg08000102	chr2:233561755	GIGYF2	-0.62	-9.72	-0.41	1.8899999999999998e-20	Schizophrenia;
LGG	cis	rs1385374	0.858	rs10847696	chr12:129297153	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	6.68	0.3	7.04e-11	Systemic lupus erythematosus;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.73	-0.41	1.75e-20	Pancreatic cancer;
LGG	cis	rs10186029	0.676	rs12614406	chr2:213955803	A/G	cg08319019	chr2:214017104	IKZF2	-0.48	-8.46	-0.37	3.51e-16	Systemic sclerosis;
LGG	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg08188268	chr10:116634841	FAM160B1	0.31	6.86	0.3	2.28e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs72781680	0.716	rs6718631	chr2:24036086	A/G	cg08917208	chr2:24149416	ATAD2B	-0.64	-8.24	-0.36	1.79e-15	Lymphocyte counts;
LGG	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg24848339	chr3:12840334	CAND2	0.44	10.2	0.43	3.63e-22	QRS complex (12-leadsum);
LGG	cis	rs4144743	1.000	rs72823473	chr17:45321775	A/T	cg18085866	chr17:45331354	ITGB3	-0.78	-9.88	-0.42	5.33e-21	Body mass index;
LGG	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.98	0.49	5.27e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	12.6	0.51	1.65e-31	Lung cancer in ever smokers;
LGG	cis	rs12476592	0.571	rs185499	chr2:63867523	G/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.92	-0.31	1.56e-11	Childhood ear infection;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg21045802	chr8:109455806	TTC35	0.49	9.21	0.39	1.13e-18	Dupuytren's disease;
LGG	cis	rs12474201	0.832	rs11695058	chr2:46978349	A/G	cg06386533	chr2:46925753	SOCS5	0.75	13.24	0.52	3.54e-34	Height;
LGG	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg08645402	chr16:4508243	NA	0.42	6.97	0.31	1.1e-11	Schizophrenia;
LGG	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg05973401	chr12:123451056	ABCB9	-0.45	-6.66	-0.3	8.02e-11	Neutrophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00101895	chr6:108279135	SEC63	0.43	7.16	0.32	3.12e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11018904	0.817	rs11606060	chr11:89928597	T/C	cg27158573	chr11:89632121	NA	-0.42	-7.54	-0.33	2.5e-13	Intelligence (multi-trait analysis);
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg09306365	chr3:61547944	PTPRG	-0.53	-7.62	-0.33	1.4e-13	Beard thickness;
LGG	cis	rs9972944	0.676	rs9303489	chr17:63784817	T/C	cg07283582	chr17:63770753	CCDC46	0.39	7.17	0.32	3.01e-12	Total body bone mineral density;
LGG	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg09307838	chr4:120376055	NA	0.72	12.45	0.5	7.1e-31	Corneal astigmatism;
LGG	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg08305652	chr11:111469057	NA	-0.37	-7.51	-0.33	3.01e-13	Primary sclerosing cholangitis;
LGG	trans	rs3206736	0.548	rs17793929	chr7:35068980	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.26	0.32	1.64e-12	Diastolic blood pressure;
LGG	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg01529538	chr14:23388837	RBM23	0.37	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.93	0.35	1.61e-14	Height;
LGG	cis	rs7084783	0.519	rs10883885	chr10:105333852	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.47	7.95	0.35	1.45e-14	Fear of pain;
LGG	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg23609528	chr2:113191194	RGPD5;RGPD8	0.56	6.73	0.3	5.06e-11	Yeast infection;
LGG	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg05692746	chr2:100937584	LONRF2	-0.63	-11.64	-0.48	1.2100000000000001e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg08250081	chr4:10125330	NA	0.41	8.12	0.35	4.12e-15	Bone mineral density;
LGG	cis	rs7552167	0.925	rs4489498	chr1:24512055	A/G	cg01960748	chr1:24522592	NA	0.45	7.38	0.32	7.55e-13	Psoriasis vulgaris;
LGG	cis	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg06521331	chr12:34319734	NA	-0.4	-7.05	-0.31	6.5e-12	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg22105103	chr4:187893119	NA	0.58	11.23	0.46	4.65e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg06951627	chr6:26196580	NA	0.48	7.11	0.31	4.51e-12	Gout;Renal underexcretion gout;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1941023	0.568	rs1373064	chr11:60168200	C/T	cg08716584	chr11:60157161	MS4A7	-0.43	-8.58	-0.37	1.46e-16	Congenital heart disease (maternal effect);
LGG	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg27165867	chr14:105738592	BRF1	-0.46	-7.33	-0.32	1.03e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-7.26	-0.32	1.6e-12	Educational attainment;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg01988459	chr11:68622903	NA	-0.4	-8.41	-0.36	5.08e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg08392591	chr16:89556376	ANKRD11	0.56	8.64	0.37	9.51e-17	Multiple myeloma (IgH translocation);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09469663	chr15:74908191	CLK3	0.61	6.84	0.3	2.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25517755	chr10:38738941	LOC399744	-0.38	-6.87	-0.3	2.03e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg05444541	chr17:17804740	TOM1L2	0.61	14.29	0.55	1.25e-38	Total body bone mineral density;
LGG	trans	rs9657904	1.000	rs4894840	chr3:105600399	A/G	cg14088669	chr1:158435396	OR10K1	0.39	6.66	0.3	7.75e-11	Multiple sclerosis;
LGG	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg04362960	chr10:104952993	NT5C2	0.57	10.85	0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs807029	0.533	rs3824783	chr10:102750851	C/T	cg04662943	chr10:102668895	NA	0.47	6.87	0.3	2.06e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs17539620	0.628	rs62432730	chr6:154830717	G/A	cg17771515	chr6:154831774	CNKSR3	0.69	9.01	0.39	5.26e-18	Lipoprotein (a) levels;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs68170813	0.652	rs17482543	chr7:107169174	C/G	cg02696742	chr7:106810147	HBP1	-0.66	-8.41	-0.36	5.19e-16	Coronary artery disease;
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg05692746	chr2:100937584	LONRF2	-0.65	-11.84	-0.48	1.89e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.03	0.39	4.51e-18	Blood metabolite levels;
LGG	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.36	7.01	0.31	8.47e-12	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg26384229	chr12:38710491	ALG10B	0.94	20.94	0.7	5.19e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.42	-0.53	6.18e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs4938330	0.608	rs3882897	chr11:117091227	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.63	-0.33	1.39e-13	Blood protein levels;
LGG	cis	rs17428076	0.681	rs62183817	chr2:172899868	C/T	cg21435375	chr2:172878103	MAP1D	0.43	7.68	0.34	9.35e-14	Myopia;
LGG	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg14983838	chr19:29218262	NA	0.55	7.16	0.32	3.28e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.7	17.8	0.64	2.21e-54	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg09155575	chr17:38084037	ORMDL3	0.41	7.19	0.32	2.61e-12	Body mass index;
LGG	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs926392	0.965	rs714108	chr20:37687838	G/A	cg16355469	chr20:37678765	NA	0.42	6.91	0.31	1.6e-11	Dialysis-related mortality;
LGG	trans	rs4427176	0.507	rs6983608	chr8:9581327	C/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg16797656	chr11:68205561	LRP5	-0.46	-7.49	-0.33	3.42e-13	Bone mineral density (spine);
LGG	cis	rs751728	1.000	rs4713684	chr6:33766488	T/C	cg25922239	chr6:33757077	LEMD2	0.71	12.58	0.5	1.92e-31	Crohn's disease;
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg07870213	chr5:140052090	DND1	0.93	17.29	0.63	4.69e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.42	-0.33	5.78e-13	Joint mobility (Beighton score);
LGG	cis	rs17106184	1.000	rs12076604	chr1:50906366	A/G	cg07174182	chr1:51127561	FAF1	0.55	8.38	0.36	6.41e-16	Type 2 diabetes;
LGG	cis	rs2286885	0.965	rs10987301	chr9:129250688	T/C	cg14319473	chr9:129242481	FAM125B	-0.44	-8.11	-0.35	4.57e-15	Intraocular pressure;
LGG	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg03342759	chr3:160939853	NMD3	-0.7	-13.44	-0.53	5.15e-35	Morning vs. evening chronotype;
LGG	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.31	-0.53	1.82e-34	Vitamin D levels;
LGG	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg12386194	chr3:101231763	SENP7	0.67	11.22	0.46	5.36e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.58	-0.41	6.07e-20	Response to amphetamines;
LGG	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.37	0.32	7.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg06521331	chr12:34319734	NA	0.4	6.75	0.3	4.33e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs28588043	0.938	rs7892078	chr1:170995055	C/A	cg03458344	chr1:170964477	C1orf129	-0.49	-7.12	-0.31	4.16e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg07511668	chr11:68622177	NA	0.51	9.81	0.41	9.24e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg03060546	chr3:49711283	APEH	-0.61	-8.33	-0.36	9.1e-16	Menarche (age at onset);
LGG	cis	rs6141769	0.542	rs28612490	chr20:31297568	G/A	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.8	-0.3	3.26e-11	Subjective well-being;
LGG	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg13010199	chr12:38710504	ALG10B	-0.46	-8.45	-0.37	3.72e-16	Morning vs. evening chronotype;
LGG	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.95	0.42	2.82e-21	Diabetic retinopathy;
LGG	cis	rs7107174	0.892	rs4945273	chr11:78096977	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs1535500	0.967	rs11756070	chr6:39282748	G/A	cg06347083	chr6:39282316	KCNK17	0.44	12.54	0.5	2.85e-31	Type 2 diabetes;
LGG	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg03517284	chr6:25882590	NA	-0.43	-6.88	-0.3	1.93e-11	Iron status biomarkers;
LGG	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg07303275	chr16:75499416	TMEM170A	-0.36	-6.71	-0.3	5.69e-11	Dupuytren's disease;
LGG	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg00701064	chr4:6280414	WFS1	-0.72	-15.79	-0.59	3.1e-45	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3219090	0.962	rs2793376	chr1:226602921	A/G	cg17127702	chr1:226594323	PARP1	0.39	12.42	0.5	8.68e-31	Melanoma;
LGG	cis	rs9527	0.641	rs10786732	chr10:104762535	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.27	0.43	1.93e-22	Arsenic metabolism;
LGG	cis	rs7937612	1.000	rs10790383	chr11:120344526	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.63	-0.51	1.22e-31	Intraocular pressure;
LGG	cis	rs735539	0.593	rs2818997	chr13:21369315	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-7.16	-0.32	3.18e-12	Dental caries;
LGG	cis	rs6868223	0.836	rs10052473	chr5:33654160	C/T	cg10594543	chr5:33649717	ADAMTS12	0.62	14.29	0.55	1.2e-38	Mortality in heart failure;
LGG	cis	rs9354308	0.764	rs9363486	chr6:66615551	A/G	cg07460842	chr6:66804631	NA	0.4	6.81	0.3	3.13e-11	Metabolite levels;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.02	0.68	1.09e-64	Alzheimer's disease;
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.24	0.36	1.82e-15	Aortic root size;
LGG	cis	rs774359	0.789	rs2764326	chr9:27535342	T/C	cg21249376	chr9:27528432	MOBKL2B	0.44	8.13	0.35	4.05e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs1021993	0.545	rs1507336	chr1:209548925	C/G	cg24446417	chr1:209558027	NA	-0.74	-10.49	-0.44	2.95e-23	Gut microbiome composition (winter);
LGG	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg02158880	chr13:53174818	NA	0.44	8.71	0.38	5.46e-17	Lewy body disease;
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg08859206	chr1:53392774	SCP2	-0.45	-9.23	-0.39	9.95e-19	Monocyte count;
LGG	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg00795024	chr1:214157026	NA	-0.26	-7.38	-0.32	7.28e-13	Schizophrenia;
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-12.9	-0.51	9.69e-33	Vitiligo;
LGG	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.24	-0.52	3.85e-34	Life satisfaction;
LGG	cis	rs2120243	0.539	rs10936086	chr3:157099859	A/C	cg24825693	chr3:157122686	VEPH1	-0.57	-13.24	-0.52	3.68e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.38	7.65	0.34	1.15e-13	Hemoglobin concentration;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg23978390	chr7:1156363	C7orf50	0.43	7.26	0.32	1.61e-12	Longevity;Endometriosis;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.66	-13.8	-0.54	1.51e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs16854884	0.802	rs6786460	chr3:143805895	A/G	cg06585982	chr3:143692056	C3orf58	0.58	9.81	0.41	9.15e-21	Economic and political preferences (feminism/equality);
LGG	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg03929089	chr4:120376271	NA	-0.81	-15.5	-0.58	5.96e-44	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10217445	chr21:34397784	OLIG2	0.42	6.83	0.3	2.64e-11	Gut microbiome composition (summer);
LGG	cis	rs12476592	0.602	rs1356390	chr2:63669625	C/T	cg17519650	chr2:63277830	OTX1	0.44	6.92	0.31	1.51e-11	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-6.9	-0.31	1.77e-11	Height;
LGG	trans	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg06521331	chr12:34319734	NA	-0.45	-7.69	-0.34	8.88e-14	Heart rate;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg02018176	chr4:1364513	KIAA1530	0.35	7.58	0.33	1.87e-13	Obesity-related traits;
LGG	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg24812749	chr6:127587940	RNF146	0.7	11.08	0.46	1.74e-25	Breast cancer;
LGG	cis	rs7166081	1.000	rs1444935	chr15:67635420	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.26	-0.32	1.6e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg22907277	chr7:1156413	C7orf50	0.83	14.72	0.56	1.68e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.08	-0.39	3.09e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs34929064	0.718	rs60783174	chr7:22725889	A/G	cg18045685	chr7:22629474	NA	0.59	8.53	0.37	2.15e-16	Major depression and alcohol dependence;
LGG	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg26384229	chr12:38710491	ALG10B	0.99	24.42	0.75	2.95e-85	Heart rate;
LGG	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg05973401	chr12:123451056	ABCB9	0.44	7.4	0.33	6.41e-13	Platelet count;
LGG	cis	rs151997	1.000	rs27249	chr5:50232678	A/G	cg06027927	chr5:50259733	NA	0.64	10.57	0.44	1.48e-23	Callous-unemotional behaviour;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.59	0.37	1.39e-16	Obesity-related traits;
LGG	cis	rs7928758	0.887	rs7945585	chr11:134272451	G/A	cg22777979	chr11:134283252	B3GAT1	0.98	13.25	0.52	3.39e-34	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09692335	chr3:48507596	TREX1	0.47	6.91	0.31	1.64e-11	Gut microbiome composition (summer);
LGG	cis	rs60695258	0.550	rs340648	chr4:87940940	A/G	cg11209507	chr4:87813803	C4orf36	-0.47	-7.99	-0.35	1.08e-14	Hematocrit;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.63e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg11473876	chr11:109292803	C11orf87	0.46	9.19	0.39	1.35e-18	Schizophrenia;
LGG	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg20387954	chr3:183756860	HTR3D	0.47	9.01	0.39	5.41e-18	Anterior chamber depth;
LGG	cis	rs4748857	0.782	rs4748848	chr10:23531244	C/T	cg18853376	chr10:23633759	C10orf67	0.36	6.75	0.3	4.57e-11	Systemic lupus erythematosus;
LGG	cis	rs2629540	0.847	rs10901807	chr10:126384610	G/A	cg08799069	chr10:126477246	METTL10	0.63	12.75	0.51	4.04e-32	Cocaine dependence;
LGG	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg04851639	chr8:1020857	NA	-0.45	-8.97	-0.38	7.65e-18	Schizophrenia;
LGG	cis	rs4319547	0.615	rs2341439	chr12:122848096	C/G	cg23029597	chr12:123009494	RSRC2	-0.92	-17.18	-0.62	1.54e-51	Body mass index;
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	12.97	0.52	4.71e-33	Lymphocyte counts;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg06916706	chr16:4465613	CORO7	-0.71	-12.13	-0.49	1.41e-29	Schizophrenia;
LGG	cis	rs774359	0.797	rs2484314	chr9:27511284	T/G	cg14173147	chr9:27528300	MOBKL2B	0.42	8.73	0.38	4.69e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs11785400	1.000	rs6995314	chr8:143749718	A/G	cg24634471	chr8:143751801	JRK	-0.51	-8.1	-0.35	5.08e-15	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.22	-0.52	4.42e-34	Vitamin D levels;
LGG	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.69	-0.3	6.4e-11	Longevity;Endometriosis;
LGG	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg20476274	chr7:133979776	SLC35B4	0.76	15.03	0.57	7.33e-42	Mean platelet volume;
LGG	cis	rs9583531	0.891	rs7999536	chr13:111382199	G/A	cg24331049	chr13:111365604	ING1	0.87	12.45	0.5	6.72e-31	Coronary artery disease;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08645402	chr16:4508243	NA	0.54	9.87	0.42	5.41e-21	Schizophrenia;
LGG	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg22852734	chr6:133119734	C6orf192	1.15	14.68	0.56	2.55e-40	Type 2 diabetes nephropathy;
LGG	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg05639522	chr1:247681581	NA	0.59	10.26	0.43	2.08e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg25664220	chr3:72788482	NA	-0.32	-8.98	-0.39	6.74e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg09998033	chr7:158218633	PTPRN2	-0.48	-8.5	-0.37	2.57e-16	Obesity-related traits;
LGG	cis	rs10849893	0.557	rs61955091	chr12:121833975	A/G	cg01154721	chr12:121881891	KDM2B	-0.41	-6.98	-0.31	1.06e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg19147804	chr7:1989927	MAD1L1	-0.6	-12.12	-0.49	1.54e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs8113308	0.810	rs8105110	chr19:52452116	C/T	cg25782003	chr19:52490127	ZNF350	0.5	7.43	0.33	5.27e-13	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg23029597	chr12:123009494	RSRC2	0.86	15.96	0.6	5.3e-46	Body mass index;
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg05793240	chr7:2802953	GNA12	0.31	7.54	0.33	2.58e-13	Height;
LGG	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs4889911	0.544	rs1294081	chr17:77829864	T/C	cg07923794	chr17:77834237	NA	-0.83	-12.68	-0.51	7.94e-32	Electroencephalogram traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11368578	chr7:150754936	CDK5	0.47	7.6	0.33	1.61e-13	Cognitive performance;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	7.51e-24	Lung cancer;
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg11764359	chr7:65958608	NA	-0.73	-13.02	-0.52	3.13e-33	Aortic root size;
LGG	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06133097	chr7:32552212	AVL9	-0.39	-7.33	-0.32	1.03e-12	Cognitive ability;
LGG	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg27490568	chr2:178487706	NA	0.55	10.86	0.45	1.24e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg16141378	chr3:129829833	LOC729375	0.38	8.69	0.37	6.52e-17	Retinal vascular caliber;
LGG	cis	rs8064024	0.676	rs9926458	chr16:4872628	G/A	cg04440724	chr16:4920505	UBN1	-0.44	-9.29	-0.4	6.25e-19	Cancer;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.18e-31	Prudent dietary pattern;
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.12e-11	Menopause (age at onset);
LGG	cis	rs2302729	0.789	rs876503	chr12:2797179	A/G	cg19945202	chr12:2788847	CACNA1C	-0.79	-9.45	-0.4	1.64e-19	Sleep quality;
LGG	cis	rs62238980	0.522	rs76859275	chr22:32515891	G/A	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.02	0.35	8.61e-15	Prudent dietary pattern;
LGG	cis	rs3126085	0.935	rs12401851	chr1:152259022	T/C	cg26876637	chr1:152193138	HRNR	-0.54	-8.6	-0.37	1.21e-16	Atopic dermatitis;
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.51	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.7	0.51	6.39e-32	Coronary artery disease;
LGG	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg19992207	chr2:111874495	ACOXL	-0.36	-6.69	-0.3	6.59e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08280861	chr8:58055591	NA	0.64	8.09	0.35	5.11e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg16850897	chr7:100343110	ZAN	-0.65	-9.73	-0.41	1.79e-20	Other erythrocyte phenotypes;
LGG	cis	rs2033732	0.706	rs10958208	chr8:85070836	A/C	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.84e-12	Body mass index;
LGG	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.41	-0.33	6.12e-13	Vitamin D levels;
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.79	0.38	3.05e-17	Bipolar disorder;
LGG	cis	rs9814567	1.000	rs1357762	chr3:134264859	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.38	-0.53	9.07e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.55	-0.37	1.76e-16	Alzheimer's disease (survival time);
LGG	cis	rs4704187	0.687	rs4704176	chr5:74420596	G/C	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.24e-12	Menopause (age at onset);
LGG	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg15268244	chr15:77196840	NA	0.49	10.46	0.44	3.94e-23	Blood metabolite levels;
LGG	cis	rs13082711	0.522	rs864241	chr3:27332674	T/C	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg15268244	chr15:77196840	NA	0.49	10.45	0.44	4.31e-23	Blood metabolite levels;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06850241	chr22:41845214	NA	-0.46	-7.05	-0.31	6.35e-12	Vitiligo;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg19635926	chr16:89946313	TCF25	0.79	8.03	0.35	7.92e-15	Skin colour saturation;
LGG	cis	rs10504130	0.666	rs7834181	chr8:52873130	A/G	cg13492337	chr8:52722140	PXDNL	-0.52	-7.46	-0.33	4.45e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg03161606	chr19:29218774	NA	0.69	10.56	0.44	1.73e-23	Methadone dose in opioid dependence;
LGG	cis	rs1062177	0.756	rs2964591	chr5:151117397	A/G	cg00977110	chr5:151150581	G3BP1	-0.45	-7.34	-0.32	9.92e-13	Preschool internalizing problems;
LGG	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg17182837	chr8:41585554	ANK1	-0.65	-9.6	-0.41	5.08e-20	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg16590910	chr6:42928470	GNMT	0.42	12.07	0.49	2.3e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg14186256	chr22:23484241	RTDR1	1.04	28.59	0.8	2.49e-104	Bone mineral density;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg11814155	chr7:99998594	ZCWPW1	0.62	9.69	0.41	2.39e-20	Platelet count;
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs17169635	0.579	rs10954474	chr7:134567368	G/A	cg02516134	chr7:134575187	CALD1	-0.36	-7.75	-0.34	6.06e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg08677398	chr8:58056175	NA	0.44	7.32	0.32	1.1e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-10.48	-0.44	3.4e-23	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1497828	0.956	rs1497835	chr1:217562287	C/T	cg04411442	chr1:217543379	NA	0.45	7.52	0.33	2.82e-13	Dialysis-related mortality;
LGG	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg26384229	chr12:38710491	ALG10B	0.94	20.68	0.69	9e-68	Bladder cancer;
LGG	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg23029597	chr12:123009494	RSRC2	-0.94	-17.17	-0.62	1.76e-51	Body mass index;
LGG	trans	rs1459104	0.571	rs10459012	chr11:55091574	C/A	cg15704280	chr7:45808275	SEPT13	0.53	7.43	0.33	5.18e-13	Body mass index;
LGG	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg26513180	chr16:89883248	FANCA	-0.62	-11.12	-0.46	1.24e-25	Vitiligo;
LGG	cis	rs9815354	0.951	rs9864331	chr3:41762217	G/A	cg03022575	chr3:42003672	ULK4	0.67	8.47	0.37	3.21e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg16011800	chr17:1958478	HIC1	-0.63	-9.34	-0.4	4.15e-19	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg12463550	chr7:65579703	CRCP	0.79	8.45	0.37	3.67e-16	Diabetic kidney disease;
LGG	cis	rs2734839	0.964	rs4938017	chr11:113303929	C/T	cg14159747	chr11:113255604	NA	-0.28	-7.38	-0.32	7.29e-13	Information processing speed;
LGG	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg18357526	chr6:26021779	HIST1H4A	0.75	13.97	0.54	2.93e-37	Intelligence (multi-trait analysis);
LGG	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg21385522	chr1:16154831	NA	0.63	10.43	0.44	5.25e-23	Dilated cardiomyopathy;
LGG	cis	rs10461617	0.512	rs7715746	chr5:56048837	C/T	cg12654349	chr5:56205094	C5orf35	-0.43	-7.32	-0.32	1.14e-12	Type 2 diabetes;
LGG	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.64e-19	Diabetic retinopathy;
LGG	cis	rs4740619	0.619	rs1887666	chr9:16032313	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.83e-26	Body mass index;
LGG	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg15921436	chr17:44337874	NA	0.45	10.58	0.44	1.37e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg17294928	chr15:75287854	SCAMP5	0.79	11.0	0.46	3.72e-25	Blood trace element (Zn levels);
LGG	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-10.21	-0.43	3.24e-22	Morning vs. evening chronotype;
LGG	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg21827317	chr3:136751795	NA	0.47	8.44	0.37	4.11e-16	Gestational age at birth (child effect);
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg00531865	chr16:30841666	NA	-0.55	-11.1	-0.46	1.5e-25	Multiple myeloma;
LGG	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.92e-16	Total body bone mineral density;
LGG	trans	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg18187862	chr3:45730750	SACM1L	0.53	8.62	0.37	1.09e-16	Primary sclerosing cholangitis;
LGG	cis	rs9487094	0.689	rs2884037	chr6:109675295	C/T	cg01125227	chr6:109776195	MICAL1	0.38	6.68	0.3	6.72e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21515243	chr18:21033072	RIOK3	0.54	8.89	0.38	1.4e-17	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25172604	chr17:41446521	NA	-0.29	-6.9	-0.31	1.73e-11	Menopause (age at onset);
LGG	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg09696939	chr10:60272079	BICC1	0.38	7.49	0.33	3.47e-13	Refractive error;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	7.03e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg03188948	chr7:1209495	NA	0.72	9.9	0.42	4.54e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2011503	1.000	rs11085264	chr19:19621780	A/G	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs10193935	0.901	rs10200353	chr2:42509554	A/G	cg27598129	chr2:42591480	NA	-0.65	-9.6	-0.41	4.95e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg11062466	chr8:58055876	NA	0.43	7.26	0.32	1.67e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs300703	0.654	rs435733	chr2:121222	A/G	cg24565620	chr2:194026	NA	0.68	9.8	0.41	9.58e-21	Blood protein levels;
LGG	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-8.69	-0.37	6.19e-17	Aortic root size;
LGG	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg08923054	chr8:41654455	ANK1	0.74	12.86	0.51	1.41e-32	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg00024416	chr22:24240387	NA	-0.36	-6.79	-0.3	3.53e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg10580341	chr11:889148	CHID1	-0.38	-6.86	-0.3	2.25e-11	Mean platelet volume;
LGG	cis	rs9487094	0.670	rs12194157	chr6:109961344	G/A	cg16315928	chr6:109776240	MICAL1	0.47	8.2	0.36	2.36e-15	Height;
LGG	cis	rs4917300	0.659	rs11167110	chr8:143097423	A/G	cg06573787	chr8:143070187	NA	0.58	9.71	0.41	2.01e-20	Amyotrophic lateral sclerosis;
LGG	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.59	0.44	1.3e-23	Lung cancer in ever smokers;
LGG	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg13010199	chr12:38710504	ALG10B	-0.47	-8.37	-0.36	6.99e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7945718	0.621	rs12281511	chr11:12677295	A/C	cg25843174	chr11:12811716	TEAD1	0.34	7.2	0.32	2.46e-12	Educational attainment (years of education);
LGG	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg04398451	chr17:18023971	MYO15A	-0.83	-18.31	-0.65	9.8e-57	Total body bone mineral density;
LGG	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg12560992	chr17:57184187	TRIM37	0.47	7.02	0.31	7.73e-12	Cognitive test performance;
LGG	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg10518543	chr12:38710700	ALG10B	0.42	6.77	0.3	3.81e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.14	-0.35	3.69e-15	IgG glycosylation;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.6	-0.37	1.21e-16	Lung cancer;
LGG	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg02151108	chr14:50098012	C14orf104	-0.42	-8.86	-0.38	1.72e-17	Carotid intima media thickness;
LGG	trans	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg02002194	chr4:3960332	NA	-0.38	-6.95	-0.31	1.21e-11	Neuroticism;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg07959490	chr17:80112427	CCDC57	0.42	8.08	0.35	5.52e-15	Life satisfaction;
LGG	cis	rs2071403	0.966	rs9677074	chr2:1409353	G/C	cg06500727	chr2:1417164	TPO	-0.51	-9.74	-0.41	1.58e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg12310025	chr6:25882481	NA	-0.55	-10.69	-0.45	5.36e-24	Blood metabolite levels;
LGG	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg07148914	chr20:33460835	GGT7	-0.51	-8.47	-0.37	3.39e-16	Height;
LGG	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg20587970	chr11:113659929	NA	-1.25	-21.42	-0.71	3.09e-71	Hip circumference adjusted for BMI;
LGG	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg13647721	chr17:30228624	UTP6	0.63	7.71	0.34	7.7e-14	Hip circumference adjusted for BMI;
LGG	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg14088196	chr11:70211408	PPFIA1	0.83	11.73	0.48	5.43e-28	Coronary artery disease;
LGG	cis	rs75059851	0.932	rs73034295	chr11:133822133	G/A	cg20042908	chr11:133852938	NA	-0.66	-11.27	-0.46	3.39e-26	Schizophrenia;
LGG	cis	rs11608355	0.545	rs35590455	chr12:109893514	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg18721089	chr20:30220636	NA	-0.52	-7.85	-0.34	2.94e-14	Mean corpuscular hemoglobin;
LGG	cis	rs7512552	0.809	rs1694377	chr1:150293153	A/G	cg15654264	chr1:150340011	RPRD2	0.46	9.38	0.4	2.91e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs503734	1.000	rs348869	chr3:100987978	A/G	cg27318481	chr3:100970896	IMPG2	-0.36	-7.78	-0.34	4.86e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.11	0.43	7.51e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2067615	0.579	rs10507214	chr12:107194461	G/A	cg15890332	chr12:107067104	RFX4	0.4	11.69	0.48	7.89e-28	Heart rate;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-12.39	-0.5	1.19e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs28830936	0.966	rs28373318	chr15:42126725	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.28	-0.53	2.44e-34	Diastolic blood pressure;
LGG	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg05887092	chr17:76393375	PGS1	0.71	15.46	0.58	9.28e-44	HDL cholesterol levels;
LGG	cis	rs793571	0.544	rs383902	chr15:59034174	C/T	cg05156742	chr15:59063176	FAM63B	0.59	10.15	0.43	5.52e-22	Schizophrenia;
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg08677398	chr8:58056175	NA	0.44	7.33	0.32	1.02e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs911119	0.955	rs35610040	chr20:23616469	T/C	cg16589663	chr20:23618590	CST3	0.47	6.72	0.3	5.39e-11	Chronic kidney disease;
LGG	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg02023728	chr11:77925099	USP35	0.47	8.38	0.36	6.3e-16	Testicular germ cell tumor;
LGG	cis	rs2016266	0.964	rs2272313	chr12:53671549	A/G	cg04065151	chr12:53682969	ESPL1	-0.58	-9.89	-0.42	4.78e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs62244186	0.748	rs6441861	chr3:44652287	A/G	cg02073558	chr3:44770973	ZNF501	0.7	13.11	0.52	1.3e-33	Depressive symptoms;
LGG	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg09303159	chr6:26284866	NA	0.31	7.06	0.31	5.98e-12	Educational attainment;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs6840360	0.571	rs62329101	chr4:152512239	G/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs112998813	0.571	rs9590394	chr13:114926891	C/T	cg14782152	chr13:114913410	NA	-0.56	-7.06	-0.31	6.31e-12	Nodular sclerosis Hodgkin lymphoma;
LGG	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.65	-0.41	3.49e-20	Lung cancer;
LGG	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg02002194	chr4:3960332	NA	0.4	7.18	0.32	2.75e-12	Morning vs. evening chronotype;
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg12395012	chr8:11607386	GATA4	0.38	7.04	0.31	6.99e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg24596788	chr1:163392923	NA	-0.7	-13.28	-0.53	2.4e-34	Motion sickness;
LGG	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.33e-17	Self-reported allergy;
LGG	cis	rs6694672	1.000	rs4915315	chr1:197059878	G/A	cg13682187	chr1:196946512	CFHR5	0.49	6.9	0.31	1.74e-11	Asthma;
LGG	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg02811702	chr13:24901961	NA	0.38	7.23	0.32	1.96e-12	Obesity-related traits;
LGG	cis	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg06521331	chr12:34319734	NA	-0.42	-7.49	-0.33	3.47e-13	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21160472	chr1:212782112	ATF3	0.42	6.84	0.3	2.52e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg03806693	chr22:41940476	POLR3H	0.89	14.9	0.57	2.66e-41	Vitiligo;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.65	0.37	8.69e-17	Longevity;
LGG	cis	rs981844	0.714	rs6853529	chr4:154706267	C/T	cg14289246	chr4:154710475	SFRP2	0.62	10.87	0.45	1.17e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg12654349	chr5:56205094	C5orf35	-0.66	-10.24	-0.43	2.48e-22	Initial pursuit acceleration;
LGG	cis	rs13257813	0.686	rs596532	chr8:19029144	T/C	cg15587955	chr8:19026658	NA	-0.48	-7.12	-0.31	4.08e-12	Mean platelet volume;
LGG	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg14664628	chr15:75095509	CSK	-0.51	-9.05	-0.39	3.88e-18	Caffeine consumption;
LGG	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg07636037	chr3:49044803	WDR6	-1.11	-28.33	-0.8	3.62e-103	Parkinson's disease;
LGG	cis	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg24596788	chr1:163392923	NA	0.61	11.37	0.47	1.35e-26	Motion sickness;
LGG	trans	rs116095464	0.558	rs6962	chr5:256509	G/A	cg00938859	chr5:1591904	SDHAP3	0.89	12.17	0.49	9.71e-30	Breast cancer;
LGG	cis	rs10736390	1.000	rs10736390	chr1:55103945	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.54	-11.58	-0.47	2.06e-27	Survival in pancreatic cancer;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs36051895	0.622	rs13440043	chr9:5268264	A/G	cg02405213	chr9:5042618	JAK2	-0.74	-11.79	-0.48	3.15e-28	Pediatric autoimmune diseases;
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg25172604	chr17:41446521	NA	-0.31	-7.38	-0.32	7.19e-13	Menopause (age at onset);
LGG	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-16.19	-0.6	4.94e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9783347	0.600	rs10766468	chr11:18321943	C/T	cg15585147	chr11:18324498	HPS5	0.31	6.95	0.31	1.23e-11	Pancreatic cancer;
LGG	cis	rs8005677	0.828	rs3794452	chr14:23386682	T/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.44	-0.33	5.05e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.62	12.54	0.5	2.97e-31	Obesity-related traits;
LGG	cis	rs57024841	0.562	rs2071006	chr9:139839904	G/T	cg00693599	chr9:139836323	FBXW5	-0.4	-7.22	-0.32	2.19e-12	Beta-trace protein levels;
LGG	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.31	-0.36	1.09e-15	Mood instability;
LGG	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg03264133	chr6:25882463	NA	-0.38	-6.74	-0.3	4.69e-11	Iron status biomarkers;
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg19223190	chr17:80058835	NA	0.44	8.49	0.37	2.89e-16	Life satisfaction;
LGG	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.03	-0.78	2.89e-97	Height;
LGG	cis	rs4948102	0.731	rs4543497	chr7:56047215	T/C	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-10.26	-0.43	2.12e-22	Menarche (age at onset);
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.86	-0.38	1.68e-17	Longevity;Endometriosis;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-6.98	-0.31	1.01e-11	Prostate cancer;
LGG	cis	rs9381107	0.932	rs9357302	chr6:9442605	A/C	cg14735645	chr6:9486422	NA	-0.42	-7.21	-0.32	2.32e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg12042659	chr19:58951599	ZNF132	0.38	7.55	0.33	2.39e-13	Uric acid clearance;
LGG	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg04181038	chr4:183730758	NA	0.56	7.71	0.34	7.77e-14	Pediatric autoimmune diseases;
LGG	cis	rs7100689	0.725	rs10736340	chr10:82061071	C/T	cg01528321	chr10:82214614	TSPAN14	0.88	15.9	0.59	9.5e-46	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg05313129	chr8:58192883	C8orf71	-0.59	-7.44	-0.33	4.88e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg18357526	chr6:26021779	HIST1H4A	0.83	15.99	0.6	4.01e-46	Intelligence (multi-trait analysis);
LGG	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg08949735	chr16:89699720	DPEP1	0.36	7.13	0.31	3.77e-12	Hemoglobin concentration;
LGG	cis	rs34734847	0.787	rs658521	chr12:121162414	G/T	cg21892295	chr12:121157589	UNC119B	-0.4	-7.45	-0.33	4.53e-13	Mean corpuscular volume;
LGG	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs9487094	0.885	rs2208209	chr6:109903003	C/T	cg16315928	chr6:109776240	MICAL1	0.54	9.03	0.39	4.75e-18	Height;
LGG	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs9443645	0.869	rs6913028	chr6:79513590	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.43	-0.36	4.44e-16	Intelligence (multi-trait analysis);
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg00830817	chr11:109293614	C11orf87	0.42	6.73	0.3	5.16e-11	Schizophrenia;
LGG	cis	rs57590327	0.555	rs13088603	chr3:81791167	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.18	-0.36	2.74e-15	Extraversion;
LGG	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23446375	chr19:39322544	ECH1	0.43	6.68	0.3	6.96e-11	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.697	rs6088856	chr20:30226543	C/G	cg13852791	chr20:30311386	BCL2L1	0.7	10.23	0.43	2.72e-22	Mean corpuscular hemoglobin;
LGG	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.07e-37	Bladder cancer;
LGG	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg01191920	chr7:158217561	PTPRN2	0.71	15.48	0.58	7.38e-44	Obesity-related traits;
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg22398616	chr13:53314203	LECT1	-0.49	-9.99	-0.42	2.09e-21	Lewy body disease;
LGG	cis	rs11578119	0.872	rs114909548	chr1:170542820	G/A	cg09767346	chr1:170501363	GORAB	0.37	6.68	0.3	7.02e-11	Male-pattern baldness;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20887711	chr4:1340912	KIAA1530	0.52	9.67	0.41	2.9e-20	Obesity-related traits;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22968622	chr17:43663579	NA	1.09	21.69	0.71	1.6e-72	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg16329650	chr2:213403929	ERBB4	0.5	8.09	0.35	5.1e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs523522	0.962	rs2233676	chr12:120933607	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs1198872	0.558	rs10929699	chr2:10918209	C/T	cg15705551	chr2:10952987	PDIA6	0.52	7.9	0.34	2.05e-14	Cardiac Troponin-T levels;
LGG	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg13849552	chr18:42260056	SETBP1	-0.33	-6.86	-0.3	2.16e-11	Iris color (L* coordinate);
LGG	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg19131313	chr8:1704013	NA	0.3	6.79	0.3	3.48e-11	Systolic blood pressure;
LGG	cis	rs4604732	0.642	rs4472786	chr1:247636518	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.46	0.37	3.51e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg17340268	chr14:105411764	AHNAK2	-0.42	-7.71	-0.34	7.79e-14	Rheumatoid arthritis;
LGG	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03324837	chr17:61044407	NA	-0.48	-7.03	-0.31	7.55e-12	Systemic lupus erythematosus;
LGG	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.56	-0.37	1.69e-16	Headache;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18482367	chr14:101458500	SNORD114-31	0.29	6.67	0.3	7.38e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs3764563	0.799	rs7249233	chr19:15723591	T/C	cg20725493	chr19:15740067	CYP4F8	-0.65	-7.76	-0.34	5.39e-14	Inflammatory biomarkers;
LGG	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18644191	chr1:99730224	LPPR4	0.43	7.68	0.34	9.74e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg05169160	chr2:178484487	TTC30A	0.35	6.89	0.3	1.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs701145	0.938	rs355769	chr3:154042550	T/C	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	cis	rs8014204	0.836	rs888413	chr14:75267396	C/T	cg06637938	chr14:75390232	RPS6KL1	0.77	15.73	0.59	5.37e-45	Caffeine consumption;
LGG	cis	rs988958	0.567	rs13409420	chr2:42233150	C/T	cg27252766	chr2:42229092	NA	-0.49	-7.77	-0.34	5.14e-14	Hypospadias;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.54	-0.53	2.07e-35	Alzheimer's disease;
LGG	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg08994789	chr17:28903642	LRRC37B2	0.72	9.13	0.39	2.15e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17227506	0.583	rs13281503	chr8:13434166	G/A	cg03566418	chr8:13424080	C8orf48	0.59	8.79	0.38	2.98e-17	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.3	-0.32	1.29e-12	HDL cholesterol;
LGG	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg10840412	chr1:235813424	GNG4	0.53	7.37	0.32	8.02e-13	Bipolar disorder;
LGG	cis	rs7666738	0.830	rs7663438	chr4:99014582	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.1e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2415984	0.622	rs12435397	chr14:46940867	G/A	cg14871534	chr14:47121158	RPL10L	-0.58	-10.23	-0.43	2.8e-22	Number of children ever born;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg23958373	chr8:599963	NA	-1.35	-11.52	-0.47	3.6e-27	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs7215564	0.908	rs901066	chr17:78659617	C/G	cg16980736	chr17:78789706	RPTOR	-0.59	-7.78	-0.34	4.73e-14	Myopia (pathological);
LGG	cis	rs67311347	1.000	rs1466236	chr3:40462162	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-21.46	-0.71	1.89e-71	Renal cell carcinoma;
LGG	cis	rs2274273	0.588	rs9323285	chr14:55863829	A/C	cg04306507	chr14:55594613	LGALS3	-0.51	-11.83	-0.48	2.15e-28	Protein biomarker;
LGG	cis	rs1003719	0.680	rs2257091	chr21:38522618	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-14.77	-0.57	1.02e-40	Eye color traits;
LGG	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs8017423	1.000	rs4904644	chr14:90665689	A/G	cg04374321	chr14:90722782	PSMC1	-0.88	-17.84	-0.64	1.49e-54	Mortality in heart failure;
LGG	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	trans	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.16	0.46	8.72e-26	Corneal astigmatism;
LGG	cis	rs11239187	0.530	rs10900067	chr10:45062673	G/A	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.24e-18	Body mass index;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.86	-0.38	1.76e-17	Lung cancer;
LGG	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05491587	chr18:77659695	KCNG2	-0.52	-6.84	-0.3	2.58e-11	Opioid sensitivity;
LGG	cis	rs1975974	0.511	rs56935892	chr17:21754089	A/G	cg18423549	chr17:21743878	NA	-0.52	-8.03	-0.35	8.18e-15	Psoriasis;
LGG	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg22307297	chr20:60903441	LAMA5	0.42	8.32	0.36	9.93e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg00531865	chr16:30841666	NA	-0.51	-10.41	-0.44	6.28e-23	Dementia with Lewy bodies;
LGG	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.25	-0.73	8.43e-80	Primary sclerosing cholangitis;
LGG	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4493873	0.840	rs11786324	chr8:92090573	G/C	cg16814680	chr8:91681699	NA	0.45	6.99	0.31	9.63e-12	Migraine - clinic-based;
LGG	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg03098644	chr7:100410630	EPHB4	0.47	6.99	0.31	9.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg04025307	chr7:1156635	C7orf50	0.61	11.2	0.46	6.52e-26	Longevity;Endometriosis;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08645402	chr16:4508243	NA	0.51	9.79	0.41	1.09e-20	Schizophrenia;
LGG	cis	rs4629710	0.592	rs35017713	chr6:131581212	G/A	cg12606694	chr6:131520996	AKAP7	0.52	8.48	0.37	3.1e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs782590	0.967	rs62165173	chr2:55741666	T/C	cg18811423	chr2:55921094	PNPT1	0.87	19.83	0.68	7.97e-64	Metabolic syndrome;
LGG	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg13010199	chr12:38710504	ALG10B	0.71	14.73	0.56	1.44e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg16507663	chr6:150244633	RAET1G	0.44	8.0	0.35	1.03e-14	Lung cancer;
LGG	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-11.85	-0.48	1.86e-28	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-10.79	-0.45	2.28e-24	Morning vs. evening chronotype;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg19147804	chr7:1989927	MAD1L1	-0.42	-8.2	-0.36	2.46e-15	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs1519814	0.956	rs11774123	chr8:121119274	C/T	cg22335954	chr8:121166405	COL14A1	0.55	11.18	0.46	7.73e-26	Breast cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22251124	chr3:140950598	ACPL2	0.61	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1461503	0.932	rs11218909	chr11:122842613	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs11608355	0.545	rs4766474	chr12:109908084	G/C	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg00666640	chr1:248458726	OR2T12	0.61	9.57	0.41	6.27e-20	Common traits (Other);
LGG	cis	rs10929925	0.897	rs12104582	chr2:6157812	C/T	cg00493617	chr2:6141445	NA	0.32	7.15	0.32	3.38e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg00204512	chr16:28754710	NA	0.25	7.06	0.31	6.27e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11711121	chr8:97247942	UQCRB	0.41	7.41	0.33	6.1e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.3	-0.32	1.24e-12	Sudden cardiac arrest;
LGG	cis	rs11748327	0.543	rs72731458	chr5:4087760	T/C	cg01025095	chr5:4101132	NA	-0.63	-10.13	-0.43	6.68e-22	Myocardial infarction;
LGG	cis	rs11971779	0.584	rs17613864	chr7:139095587	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00761968	chr13:53314142	LECT1	-0.44	-9.7	-0.41	2.19e-20	Lewy body disease;
LGG	cis	rs1707322	1.000	rs4660906	chr1:46470860	C/T	cg03146154	chr1:46216737	IPP	0.55	10.26	0.43	2.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg11965913	chr1:205819406	PM20D1	0.85	18.66	0.66	2.35e-58	Menarche (age at onset);
LGG	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.75e-23	Hip circumference adjusted for BMI;
LGG	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg15309053	chr8:964076	NA	0.33	6.83	0.3	2.61e-11	Schizophrenia;
LGG	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.84	-0.45	1.54e-24	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03532005	chr7:56119028	CCT6A;PSPH	0.45	7.28	0.32	1.49e-12	Cognitive performance;
LGG	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg21775007	chr8:11205619	TDH	-0.78	-13.65	-0.54	7.09e-36	Retinal vascular caliber;
LGG	cis	rs4595586	0.545	rs12819061	chr12:39386976	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs1030877	0.515	rs2679895	chr2:105906480	C/G	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.45	0.44	4.15e-23	Obesity-related traits;
LGG	cis	rs11209002	0.956	rs11209000	chr1:67578514	C/G	cg02640540	chr1:67518911	SLC35D1	0.46	6.89	0.3	1.86e-11	Crohn's disease;
LGG	trans	rs2530545	0.703	rs1023555	chr7:34696379	A/T	cg22832407	chr4:169931373	CBR4	-0.43	-6.66	-0.3	7.86e-11	IgG glycosylation;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg24607181	chr17:41446203	NA	-0.3	-7.0	-0.31	9.07e-12	Menopause (age at onset);
LGG	cis	rs804292	0.800	rs8191542	chr8:11629809	C/G	cg26752888	chr8:11627280	NEIL2	1.07	16.72	0.61	2.01e-49	Alcohol dependence;Nicotine use;
LGG	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg09307838	chr4:120376055	NA	0.7	11.43	0.47	8.12e-27	Corneal astigmatism;
LGG	cis	rs12282928	0.918	rs11039656	chr11:48320705	T/G	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs35362007	0.530	rs79171925	chr14:96003075	T/C	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.89	10.58	0.44	1.45e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.43e-20	Aortic root size;
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07362569	chr17:61921086	SMARCD2	-0.48	-9.33	-0.4	4.33e-19	Prudent dietary pattern;
LGG	cis	rs78487399	0.634	rs77881454	chr2:43757293	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.81	-0.3	3.13e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11453347	chr10:127512288	UROS;BCCIP	0.41	7.09	0.31	4.91e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.35	0.32	8.91e-13	Neuroticism;
LGG	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg20673091	chr1:2541236	MMEL1	-0.77	-17.94	-0.64	4.78e-55	Ulcerative colitis;
LGG	cis	rs6800768	0.593	rs11129139	chr3:24146298	C/G	cg10674438	chr3:24145617	LOC152024	-0.53	-9.47	-0.4	1.46e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12519773	0.555	rs2009416	chr5:92415111	C/T	cg18783429	chr5:92414398	NA	0.31	7.4	0.33	6.68e-13	Migraine;
LGG	cis	rs17767392	0.881	rs12880611	chr14:71923349	G/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	cis	rs7017914	0.967	rs3954897	chr8:71635955	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.6	0.37	1.2e-16	Myopia (pathological);
LGG	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.27e-12	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.56	0.53	1.7000000000000001e-35	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs3771570	1.000	rs41266959	chr2:242275579	G/A	cg21155796	chr2:242212141	HDLBP	0.71	8.86	0.38	1.78e-17	Prostate cancer;
LGG	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg26248373	chr2:1572462	NA	-0.89	-15.04	-0.57	6.36e-42	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.76	0.38	3.69e-17	Obesity-related traits;
LGG	cis	rs4517514	0.509	rs10765252	chr11:89875664	C/T	cg14505434	chr11:89522851	NA	0.63	8.0	0.35	9.73e-15	Trans fatty acid levels;
LGG	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg13009111	chr11:71350975	NA	0.35	7.76	0.34	5.42e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12431204	0.874	rs1538145	chr13:38445304	A/T	cg23307680	chr13:38443104	TRPC4	0.41	7.25	0.32	1.78e-12	Schizophrenia;
LGG	cis	rs11168351	0.864	rs12228750	chr12:48496997	G/A	cg24011408	chr12:48396354	COL2A1	-0.57	-9.58	-0.41	5.9e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21178548	chr17:48207167	SAMD14	0.54	8.45	0.37	3.69e-16	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.78	0.38	3.23e-17	Mood instability;
LGG	cis	rs6032067	0.777	rs34855539	chr20:43799036	T/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg18551225	chr6:44695536	NA	-0.61	-9.84	-0.42	7.26e-21	Total body bone mineral density;
LGG	cis	rs6840360	0.571	rs11939356	chr4:152505234	G/C	cg22705602	chr4:152727874	NA	-0.33	-7.72	-0.34	7.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs317689	0.690	rs604168	chr12:69671158	C/T	cg20891283	chr12:69753455	YEATS4	0.47	7.2	0.32	2.49e-12	Response to diuretic therapy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05312574	chr15:65281963	SPG21	0.46	6.89	0.3	1.8e-11	Gut microbiome composition (summer);
LGG	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1873147	0.861	rs2899687	chr15:63325548	C/T	cg12160578	chr15:63334699	TPM1	-0.43	-6.74	-0.3	4.61e-11	Orofacial clefts;
LGG	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg03929089	chr4:120376271	NA	-0.95	-19.87	-0.68	5.4e-64	Height;
LGG	cis	rs6663390	0.831	rs3754171	chr1:208086939	T/C	cg03990033	chr1:208084030	CD34	0.56	7.82	0.34	3.49e-14	Facial morphology (factor 18);
LGG	cis	rs9815354	0.951	rs6768438	chr3:41865355	G/A	cg03022575	chr3:42003672	ULK4	0.65	8.36	0.36	7.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10268125	chr7:120590544	ING3	-0.45	-6.78	-0.3	3.65e-11	Pancreatic cancer;
LGG	cis	rs977987	0.771	rs4888387	chr16:75389755	T/G	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg15522984	chr1:182991683	LAMC1	-0.48	-10.0	-0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.58	-0.44	1.43e-23	Alzheimer's disease;
LGG	cis	rs11158026	0.757	rs72715573	chr14:55459571	C/T	cg04306507	chr14:55594613	LGALS3	0.31	7.12	0.31	4.09e-12	Parkinson's disease;
LGG	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.2	0.32	2.52e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg09537434	chr19:41945824	ATP5SL	-0.6	-11.81	-0.48	2.55e-28	Migraine;Coronary artery disease;
LGG	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.73e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs970548	0.643	rs7068039	chr10:45932264	T/C	cg20477318	chr10:51623047	TIMM23	0.56	7.0	0.31	8.8e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg01620082	chr3:125678407	NA	-1.03	-9.58	-0.41	5.76e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	1.000	rs2482919	chr20:25299756	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.13	-0.43	6.65e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6988985	0.693	rs7822986	chr8:143957856	G/A	cg10324643	chr8:143916377	GML	0.4	7.97	0.35	1.29e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg11161011	chr14:65562177	MAX	-0.79	-16.07	-0.6	1.63e-46	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg26513180	chr16:89883248	FANCA	0.98	9.5	0.4	1.15e-19	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25533547	chr2:73053217	EXOC6B	0.46	7.6	0.33	1.68e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg02725872	chr8:58115012	NA	0.77	10.45	0.44	4.3e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.32	0.32	1.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1018836	0.700	rs7824511	chr8:91521545	T/C	cg16814680	chr8:91681699	NA	-0.74	-12.66	-0.51	9.42e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg21545522	chr1:205238299	TMCC2	0.5	9.55	0.41	7.41e-20	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg05044414	chr3:183734942	ABCC5	0.77	17.09	0.62	3.98e-51	Anterior chamber depth;
LGG	trans	rs3118233	1	rs3118233	chr16:68733646	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.8	-14.09	-0.55	8.61e-38	Red cell distribution width;
LGG	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4731207	0.596	rs12113765	chr7:124589684	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2798269	0.604	rs2798275	chr13:22159035	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.32	-0.32	1.12e-12	PR segment;
LGG	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg21798802	chr22:38057573	PDXP	0.61	14.1	0.55	8.08e-38	Fat distribution (HIV);
LGG	cis	rs2070488	0.775	rs9838614	chr3:38537671	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.4	-0.56	3.96e-39	Electrocardiographic conduction measures;
LGG	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs6062302	0.522	rs11696202	chr20:62246292	G/C	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg08048268	chr3:133502702	NA	0.6	11.22	0.46	5.2e-26	Iron status biomarkers;
LGG	trans	rs5744897	0.708	rs5744769	chr12:133250734	C/G	cg04991071	chr3:71615924	FOXP1	0.64	7.31	0.32	1.19e-12	Urate levels in overweight individuals;
LGG	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg08344181	chr3:125677491	NA	-0.54	-7.09	-0.31	5.14e-12	Lung cancer in ever smokers;
LGG	cis	rs9834373	0.811	rs9822678	chr3:78496448	C/T	cg06138941	chr3:78371609	NA	-0.51	-9.17	-0.39	1.54e-18	Protein quantitative trait loci;
LGG	cis	rs17539620	0.624	rs62432752	chr6:154841074	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	7.53	0.33	2.69e-13	Lipoprotein (a) levels;
LGG	cis	rs2274273	0.837	rs8008119	chr14:55831228	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.05	0.62	6.32e-51	Protein biomarker;
LGG	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.54	0.33	2.5e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg08717414	chr16:71523259	ZNF19	-0.47	-6.74	-0.3	4.63e-11	Blood protein levels;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	7.28	0.32	1.42e-12	Schizophrenia;
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg20607798	chr8:58055168	NA	0.55	6.72	0.3	5.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Gut microbiome composition (summer);
LGG	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg26248373	chr2:1572462	NA	-0.88	-14.78	-0.57	9.11e-41	IgG glycosylation;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16680214	chr1:154839983	KCNN3	0.5	10.01	0.42	1.77e-21	Prostate cancer;
LGG	cis	rs2201728	0.739	rs7439160	chr4:100161654	A/T	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs5742933	0.762	rs12992061	chr2:190600752	G/A	cg10453823	chr2:190539512	ANKAR	-0.46	-6.79	-0.3	3.35e-11	Ferritin levels;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs921968	0.509	rs655441	chr2:219357545	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg27205649	chr11:78285834	NARS2	-0.49	-8.32	-0.36	9.87e-16	Alzheimer's disease (survival time);
LGG	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg15704280	chr7:45808275	SEPT13	0.72	9.81	0.41	9.39e-21	Axial length;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	8.01	0.35	9.26e-15	Longevity;
LGG	cis	rs55665837	1.000	rs11023215	chr11:14436970	C/T	cg19336497	chr11:14380999	RRAS2	-0.47	-8.94	-0.38	9.19e-18	Vitamin D levels;
LGG	cis	rs6764363	0.527	rs13060510	chr3:279638	T/A	cg02057681	chr3:285234	CHL1	-0.43	-7.73	-0.34	6.67e-14	Sudden cardiac arrest;
LGG	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.07	-0.42	1.06e-21	Sudden cardiac arrest;
LGG	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg20503657	chr10:835505	NA	0.73	10.05	0.42	1.26e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg09238746	chr17:78121135	EIF4A3	-0.55	-10.09	-0.42	9.13e-22	Yeast infection;
LGG	cis	rs8044995	0.706	rs73612697	chr16:68162016	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.47	-0.33	3.91e-13	Schizophrenia;
LGG	trans	rs8073060	0.586	rs225265	chr17:33961972	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9902453	0.619	rs1038088	chr17:28074563	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-14.04	-0.55	1.47e-37	Coffee consumption (cups per day);
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.58	0.59	2.62e-44	Lung cancer;
LGG	cis	rs2991971	0.933	rs12568144	chr1:45965307	G/A	cg24296786	chr1:45957014	TESK2	0.41	7.44	0.33	4.98e-13	High light scatter reticulocyte count;
LGG	cis	rs7666738	0.830	rs4345191	chr4:98945408	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2797369	0.609	rs626411	chr6:101395577	A/C	cg27451362	chr6:101846650	GRIK2	0.78	10.47	0.44	3.5e-23	Renal function-related traits (eGRFcrea);
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.39	-0.32	7.11e-13	Morning vs. evening chronotype;
LGG	cis	rs7799006	1.000	rs7787274	chr7:2275993	G/A	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.86	-0.34	2.67e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs427394	0.802	rs200841	chr5:6737134	A/G	cg15145174	chr5:6755386	POLS	-0.4	-7.6	-0.33	1.7e-13	Menopause (age at onset);
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.54	-0.33	2.52e-13	Refractive error;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11750756	chr12:50135418	TMBIM6	0.43	6.97	0.31	1.07e-11	Cognitive performance;
LGG	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg04287289	chr16:89883240	FANCA	0.54	10.13	0.43	6.19e-22	Vitiligo;
LGG	cis	rs11690935	0.550	rs11676438	chr2:172826668	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	12.24	0.49	4.79e-30	Schizophrenia;
LGG	cis	rs72781680	1.000	rs12623496	chr2:24181583	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	9.54	0.41	8.09e-20	Lymphocyte counts;
LGG	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10489202	0.954	rs12403023	chr1:168086999	A/G	cg24449463	chr1:168025552	DCAF6	-0.64	-10.31	-0.43	1.36e-22	Schizophrenia;
LGG	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg11812906	chr14:75593930	NEK9	-0.51	-9.6	-0.41	4.89e-20	Height;
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.46e-22	Iron status biomarkers;
LGG	cis	rs7940866	0.903	rs10791109	chr11:130850377	A/C	cg12179176	chr11:130786555	SNX19	0.7	12.99	0.52	3.98e-33	Schizophrenia;
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.02	-0.31	7.7e-12	Bipolar disorder;
LGG	cis	rs4302748	0.862	rs11772400	chr7:36186371	G/C	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs7027203	1.000	rs13288708	chr9:96509653	T/C	cg14598338	chr9:96623480	NA	0.48	8.17	0.36	2.91e-15	DNA methylation (variation);
LGG	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg00976097	chr5:421733	AHRR	-0.44	-7.16	-0.32	3.16e-12	Cystic fibrosis severity;
LGG	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg16576597	chr16:28551801	NUPR1	0.31	7.03	0.31	7.44e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17780086	0.527	rs17182651	chr17:30547537	G/A	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.19	-0.36	2.66e-15	Height;
LGG	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg15394860	chr11:2017084	H19	0.59	12.64	0.51	1.1e-31	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	14.32	0.55	9.52e-39	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs2602381	0.570	rs2602378	chr2:234582504	A/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.65e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.8	0.3	3.31e-11	Longevity;
LGG	cis	rs67133203	0.808	rs12826153	chr12:51510234	C/A	cg14688905	chr12:51403056	SLC11A2	0.69	10.05	0.42	1.26e-21	Urinary tract infection frequency;
LGG	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg13453750	chr1:205783389	SLC41A1	-0.46	-8.78	-0.38	3.1e-17	Menarche (age at onset);
LGG	cis	rs3816183	0.958	rs4953663	chr2:43023658	C/T	cg14631114	chr2:43023945	NA	0.49	9.21	0.39	1.18e-18	Hypospadias;
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg15394860	chr11:2017084	H19	0.65	14.27	0.55	1.51e-38	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2798269	0.668	rs1044021	chr13:22067236	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.45	-7.92	-0.35	1.73e-14	PR segment;
LGG	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.83	-0.42	7.66e-21	Body mass index;
LGG	trans	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg05729581	chr11:3078854	CARS	-0.52	-8.81	-0.38	2.52e-17	Longevity;
LGG	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg04226714	chr8:49833948	SNAI2	-0.46	-8.29	-0.36	1.22e-15	Life satisfaction;
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs4253772	0.591	rs8135363	chr22:46651713	T/C	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.84	0.3	2.45e-11	Glycated hemoglobin levels;
LGG	cis	rs9487094	1.000	rs9320287	chr6:109744690	T/C	cg01125227	chr6:109776195	MICAL1	0.46	7.78	0.34	4.77e-14	Height;
LGG	cis	rs3106136	0.527	rs2865345	chr4:95156565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.91	-0.45	8.4e-25	Capecitabine sensitivity;
LGG	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg05775895	chr3:12838266	CAND2	0.73	14.0	0.55	2.1e-37	QRS complex (12-leadsum);
LGG	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg26354017	chr1:205819088	PM20D1	-0.42	-7.17	-0.32	3e-12	Menarche (age at onset);
LGG	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg00376283	chr12:123451042	ABCB9	0.66	12.34	0.5	1.88e-30	Platelet count;
LGG	cis	rs2377058	1.000	rs2377058	chr16:89734831	A/G	cg07835443	chr16:89734986	C16orf55	-0.47	-7.94	-0.35	1.5e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg18402987	chr7:1209562	NA	0.66	9.24	0.39	8.83e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg08600765	chr20:34638493	LOC647979	-0.75	-10.84	-0.45	1.55e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg05926928	chr17:57297772	GDPD1	-0.49	-7.73	-0.34	6.78e-14	Schizophrenia;
LGG	cis	rs9879311	1.000	rs9879311	chr3:10415343	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	7.16	0.32	3.2e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10736390	1.000	rs11206402	chr1:55104317	G/C	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.54	-11.4	-0.47	1.09e-26	Survival in pancreatic cancer;
LGG	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg27523141	chr10:43048294	ZNF37B	-0.38	-7.92	-0.35	1.81e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg18479299	chr3:125709523	NA	-0.57	-7.25	-0.32	1.77e-12	Blood pressure (smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08573313	chr7:94139369	CASD1	0.46	6.81	0.3	3.12e-11	Gut microbiome composition (summer);
LGG	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.4	-0.33	6.55e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	10.59	0.44	1.32e-23	Menopause (age at onset);
LGG	cis	rs10186029	0.582	rs10497995	chr2:213995346	G/A	cg08319019	chr2:214017104	IKZF2	0.4	7.12	0.31	4.12e-12	Systemic sclerosis;
LGG	cis	rs9815354	0.812	rs17217536	chr3:41923300	A/C	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.27	-0.43	1.94e-22	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.501	rs6761390	chr2:100106797	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.88	-0.3	1.99e-11	Chronic sinus infection;
LGG	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7166081	1.000	rs3743347	chr15:67547301	C/A	cg05925327	chr15:68127851	NA	-0.34	-7.1	-0.31	4.64e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg03264133	chr6:25882463	NA	0.49	7.86	0.34	2.78e-14	Iron status biomarkers;
LGG	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg22232500	chr2:134024266	NCKAP5	0.55	7.86	0.34	2.75e-14	Bipolar disorder;
LGG	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg15832292	chr6:96025679	MANEA	0.53	7.48	0.33	3.67e-13	Behavioural disinhibition (generation interaction);
LGG	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.32	0.32	1.09e-12	Total cholesterol levels;
LGG	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg27490568	chr2:178487706	NA	0.51	10.07	0.42	1.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs981844	0.743	rs17371461	chr4:154759220	C/T	cg14289246	chr4:154710475	SFRP2	0.68	11.09	0.46	1.62e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg09165964	chr15:75287851	SCAMP5	0.58	10.85	0.45	1.42e-24	Breast cancer;
LGG	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg16583315	chr14:65563665	MAX	-0.43	-8.75	-0.38	4.14e-17	Obesity-related traits;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg21911579	chr5:131705225	SLC22A5	0.68	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg16876255	chr19:9731953	ZNF561	0.83	7.72	0.34	7.47e-14	Pursuit maintenance gain;
LGG	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.75	-9.16	-0.39	1.72e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11650494	0.831	rs73324348	chr17:47455752	G/A	cg08112188	chr17:47440006	ZNF652	1.24	14.99	0.57	1.03e-41	Prostate cancer;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg20607798	chr8:58055168	NA	0.65	7.16	0.32	3.28e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4478858	0.735	rs34960310	chr1:31816197	A/G	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	cg07245641	chr1:182991651	LAMC1	0.41	9.08	0.39	3.17e-18	Colorectal cancer;
LGG	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7635838	0.596	rs4684765	chr3:11261085	G/C	cg00170343	chr3:11313890	ATG7	0.44	7.48	0.33	3.76e-13	HDL cholesterol;
LGG	cis	rs490647	0.681	rs479714	chr1:37240038	C/T	cg24672014	chr1:37203461	NA	-0.36	-7.5	-0.33	3.31e-13	Neuroticism;
LGG	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg16576597	chr16:28551801	NUPR1	-0.35	-7.53	-0.33	2.76e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.51e-24	Aortic root size;
LGG	cis	rs2075466	0.514	rs76214824	chr16:4900239	A/G	cg04440724	chr16:4920505	UBN1	-0.62	-8.95	-0.38	8.95e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg24253500	chr15:84953950	NA	0.42	7.78	0.34	4.74e-14	P wave terminal force;
LGG	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1143633	0.566	rs2708932	chr2:113690675	C/A	cg06156847	chr2:113672199	IL1F7	0.37	7.41	0.33	6.09e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg08200770	chr17:80723486	TBCD	0.4	8.0	0.35	9.99e-15	Glycated hemoglobin levels;
LGG	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18252515	chr7:66147081	NA	0.4	6.89	0.3	1.84e-11	Aortic root size;
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07234876	chr8:600039	NA	0.99	9.9	0.42	4.42e-21	IgG glycosylation;
LGG	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg08975724	chr8:8085496	FLJ10661	0.58	11.87	0.48	1.51e-28	Neuroticism;
LGG	cis	rs7829975	0.509	rs7838674	chr8:8797073	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.97	-0.35	1.28e-14	Mood instability;
LGG	cis	rs6542838	0.609	rs12712043	chr2:99541494	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.95	-0.31	1.24e-11	Fear of minor pain;
LGG	cis	rs9487094	0.813	rs3799840	chr6:109702646	A/T	cg01125227	chr6:109776195	MICAL1	0.54	9.06	0.39	3.68e-18	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11232610	chr5:140027381	NDUFA2;IK	0.44	7.36	0.32	8.18e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.92	0.35	1.75e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg23173402	chr1:227635558	NA	-0.61	-9.99	-0.42	2.13e-21	Major depressive disorder;
LGG	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.75e-34	Corneal astigmatism;
LGG	cis	rs1018836	0.608	rs12679836	chr8:91465287	A/G	cg16814680	chr8:91681699	NA	-0.59	-9.98	-0.42	2.23e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7949030	0.635	rs1801144	chr11:62381808	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.63	13.98	0.54	2.74e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9398803	0.723	rs1101556	chr6:127067803	T/G	cg19875578	chr6:126661172	C6orf173	-0.49	-8.99	-0.39	6.1e-18	Male-pattern baldness;
LGG	cis	rs7444	0.941	rs181359	chr22:21928641	C/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.68	-0.34	9.41e-14	Systemic lupus erythematosus;
LGG	trans	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg25214090	chr10:38739885	LOC399744	0.68	12.0	0.49	4.52e-29	Corneal astigmatism;
LGG	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg18225595	chr11:63971243	STIP1	0.48	9.35	0.4	3.65e-19	Platelet count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23812325	chr4:56915719	NA	0.43	7.18	0.32	2.81e-12	Cognitive performance;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.5	-7.34	-0.32	9.95e-13	Total cholesterol levels;
LGG	cis	rs6740322	0.748	rs13402621	chr2:43458611	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.51	-0.4	1.01e-19	Coronary artery disease;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11645453	chr3:52864694	ITIH4	-0.4	-6.96	-0.31	1.17e-11	Bipolar disorder;
LGG	cis	rs16866061	1.000	rs2047134	chr2:225347713	A/C	cg12698349	chr2:225449008	CUL3	0.92	19.09	0.66	2.47e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	trans	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17712092	chr4:129076599	LARP1B	-0.72	-13.87	-0.54	8.13e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.48	0.61	2.48e-48	Hip circumference adjusted for BMI;
LGG	cis	rs250677	1.000	rs36082	chr5:148428844	C/G	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.15	-0.32	3.38e-12	Breast cancer;
LGG	cis	rs2239547	0.657	rs6445538	chr3:52874288	T/C	cg11645453	chr3:52864694	ITIH4	0.72	11.09	0.46	1.62e-25	Schizophrenia;
LGG	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.45	-0.44	4.14e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg12756686	chr19:29218302	NA	0.61	9.06	0.39	3.77e-18	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-7.27	-0.32	1.54e-12	Systemic lupus erythematosus;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.09	-0.35	5.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg00031303	chr3:195681400	NA	0.54	8.39	0.36	6.09e-16	Pancreatic cancer;
LGG	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.31	6.66e-12	Intelligence (multi-trait analysis);
LGG	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg07777115	chr5:623756	CEP72	-0.54	-6.9	-0.31	1.7e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	7.21	0.32	2.28e-12	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15259947	chr6:151187339	MTHFD1L	0.44	6.74	0.3	4.73e-11	Gut microbiome composition (summer);
LGG	cis	rs4650994	0.550	rs11581618	chr1:178572720	G/A	cg19399532	chr1:178512495	C1orf220	-0.4	-7.45	-0.33	4.75e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27297192	chr10:134578999	INPP5A	0.31	7.47	0.33	3.89e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.16	-0.58	1.87e-42	Chronic sinus infection;
LGG	cis	rs2274273	0.744	rs8011808	chr14:55823344	A/T	cg04306507	chr14:55594613	LGALS3	0.63	17.74	0.64	4.03e-54	Protein biomarker;
LGG	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg11266682	chr4:10021025	SLC2A9	-0.36	-6.67	-0.3	7.44e-11	Bone mineral density;
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.68	-0.3	6.79e-11	Menopause (age at onset);
LGG	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.34	-0.32	9.97e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9596863	0.898	rs9591536	chr13:54377682	A/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.19	0.32	2.58e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg14055004	chr2:241860995	NA	0.28	7.52	0.33	2.86e-13	Joint mobility (Beighton score);
LGG	cis	rs1318772	0.932	rs11953034	chr5:112909921	C/T	cg12552261	chr5:112820674	MCC	0.69	7.85	0.34	2.89e-14	F-cell distribution;
LGG	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.61	0.33	1.6e-13	Homoarginine levels;
LGG	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg00405596	chr8:11794950	NA	-0.43	-7.26	-0.32	1.65e-12	Neuroticism;
LGG	cis	rs875971	0.502	rs2465121	chr7:65621004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.56	-0.44	1.73e-23	Aortic root size;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.77	-0.34	5.07e-14	Skin colour saturation;
LGG	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.84	0.42	7.18e-21	Height;
LGG	trans	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg10840412	chr1:235813424	GNG4	0.63	8.23	0.36	1.89e-15	Bipolar disorder;
LGG	trans	rs11039798	1.000	rs3902927	chr11:48581457	C/T	cg03929089	chr4:120376271	NA	0.74	8.62	0.37	1.06e-16	Axial length;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg09038676	chr11:67351608	GSTP1	0.35	7.17	0.32	2.96e-12	Mean corpuscular volume;
LGG	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg27523141	chr10:43048294	ZNF37B	0.36	7.55	0.33	2.27e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10751667	0.666	rs10902239	chr11:946484	A/G	cg22143635	chr11:980567	AP2A2	-0.43	-7.86	-0.34	2.74e-14	Alzheimer's disease (late onset);
LGG	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.2e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3796352	1.000	rs13091844	chr3:53010271	C/T	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	trans	rs7395662	0.759	rs4347397	chr11:48895946	T/C	cg03929089	chr4:120376271	NA	0.44	7.16	0.32	3.21e-12	HDL cholesterol;
LGG	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.73	-0.45	3.83e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-11.69	-0.48	7.47e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-8.68	-0.37	6.96e-17	Morning vs. evening chronotype;
LGG	cis	rs365132	0.967	rs353471	chr5:176363429	T/C	cg16309518	chr5:176445507	NA	-0.54	-11.7	-0.48	6.84e-28	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504073	0.584	rs62507182	chr8:49942500	C/A	cg00325661	chr8:49890786	NA	0.79	15.59	0.59	2.4e-44	Blood metabolite ratios;
LGG	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg11247378	chr22:39784982	NA	-0.31	-8.49	-0.37	2.91e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg11494091	chr17:61959527	GH2	0.54	8.66	0.37	7.73e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4696584	0.816	rs6536014	chr4:155403068	C/T	cg13738195	chr4:155413469	DCHS2	0.38	7.86	0.34	2.77e-14	Folding of antihelix;
LGG	cis	rs12476592	0.571	rs10171223	chr2:63687700	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-7.0	-0.31	9.1e-12	Childhood ear infection;
LGG	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg11738485	chr19:12877000	HOOK2	0.46	7.37	0.32	8.02e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs6976053	0.875	rs1054391	chr7:100468284	A/G	cg03098644	chr7:100410630	EPHB4	-0.43	-7.66	-0.34	1.08e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs13062095	0.505	rs2553425	chr3:101103623	C/G	cg11279151	chr3:101281821	RG9MTD1	0.39	7.53	0.33	2.69e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6912958	0.559	rs369674	chr6:88043402	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-13.06	-0.52	2.1e-33	Monocyte percentage of white cells;
LGG	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg14191688	chr11:70257035	CTTN	0.59	8.53	0.37	2.02e-16	Coronary artery disease;
LGG	cis	rs7301016	1.000	rs10877856	chr12:62870536	C/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs6912958	0.514	rs1980792	chr6:87889917	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-12.35	-0.5	1.71e-30	Monocyte percentage of white cells;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg04353095	chr3:140770588	SPSB4	-0.44	-7.78	-0.34	4.64e-14	Brain structure;
LGG	cis	rs16912285	0.688	rs7109312	chr11:24338974	G/A	ch.11.24196551F	chr11:24239977	NA	0.96	12.69	0.51	7.41e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg07303275	chr16:75499416	TMEM170A	0.42	7.4	0.33	6.61e-13	Dupuytren's disease;
LGG	cis	rs36071027	0.554	rs9918118	chr5:158394846	C/T	cg18496440	chr5:158532302	NA	0.41	6.85	0.3	2.36e-11	Carotid intima media thickness;
LGG	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.77	14.56	0.56	8e-40	Response to antipsychotic treatment;
LGG	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.89	-0.51	1.04e-32	Response to antipsychotic treatment;
LGG	cis	rs1451375	0.698	rs11489736	chr7:50645372	G/A	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg19847130	chr8:10466454	RP1L1	0.32	7.09	0.31	4.99e-12	Neuroticism;
LGG	cis	rs2764208	0.535	rs2744968	chr6:34584951	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.36	-0.32	8.56e-13	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.41	0.63	1.42e-52	Obesity-related traits;
LGG	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.25	0.52	3.34e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.81e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs12912251	0.591	rs2643216	chr15:39003809	C/G	cg10631289	chr15:39006617	NA	-0.4	-7.05	-0.31	6.51e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs9398803	0.713	rs9375447	chr6:126874091	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.58	0.41	5.79e-20	Male-pattern baldness;
LGG	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.93	-0.31	1.39e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg14829155	chr15:31115871	NA	-0.56	-9.59	-0.41	5.59e-20	Huntington's disease progression;
LGG	cis	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg00383909	chr3:49044727	WDR6	0.97	12.32	0.5	2.34e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9398803	0.723	rs853982	chr6:127046121	C/T	cg19875578	chr6:126661172	C6orf173	-0.5	-9.06	-0.39	3.62e-18	Male-pattern baldness;
LGG	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.89	0.45	9.96e-25	Aortic root size;
LGG	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.19	-0.36	2.59e-15	Glycated hemoglobin levels;
LGG	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15128208	chr22:42549153	NA	-0.46	-8.89	-0.38	1.33e-17	Cognitive function;
LGG	cis	rs6032067	0.714	rs3761192	chr20:43885764	C/G	cg10761708	chr20:43804764	PI3	0.57	8.77	0.38	3.5e-17	Blood protein levels;
LGG	cis	rs11608355	1.000	rs11066523	chr12:109851899	A/G	cg19025524	chr12:109796872	NA	0.49	9.34	0.4	3.99e-19	Neuroticism;
LGG	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.93	0.52	6.93e-33	Alzheimer's disease;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg00599393	chr8:22457479	C8orf58	0.41	7.3	0.32	1.29e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	6.72	0.3	5.45e-11	Body mass index;
LGG	cis	rs7633787	0.571	rs9817819	chr3:23143518	A/G	cg00327796	chr3:23032191	NA	0.37	6.96	0.31	1.19e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-6.66	-0.3	7.64e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg10295955	chr4:187884368	NA	1.15	31.07	0.82	2.57e-115	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	8.21	0.36	2.18e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.12	0.31	4.24e-12	Neuroticism;
LGG	cis	rs10979	1.000	rs9386033	chr6:143888520	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.41	-0.5	9.83e-31	Hypospadias;
LGG	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg01631408	chr1:248437212	OR2T33	-0.39	-7.07	-0.31	5.8e-12	Common traits (Other);
LGG	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.67e-12	Neuroticism;
LGG	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg07928641	chr1:182991847	LAMC1	0.44	8.69	0.37	6.08e-17	Fuchs's corneal dystrophy;
LGG	cis	rs7241530	0.610	rs57729653	chr18:75891593	C/A	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.61e-18	Educational attainment (years of education);
LGG	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg01017244	chr2:74357527	NA	0.47	8.9	0.38	1.29e-17	Gestational age at birth (maternal effect);
LGG	cis	rs1568889	1.000	rs7934085	chr11:28369660	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	14.78	0.57	9.01e-41	Bipolar disorder;
LGG	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.27e-18	Blood metabolite levels;
LGG	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg08109568	chr15:31115862	NA	-0.41	-7.43	-0.33	5.15e-13	Huntington's disease progression;
LGG	trans	rs9951602	0.512	rs9946115	chr18:76654531	A/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.17	-0.32	3e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12200782	0.929	rs72836460	chr6:26351890	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.53	-6.81	-0.3	3.13e-11	Small cell lung carcinoma;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18000306	chr6:288505	NA	0.61	10.94	0.45	6.07e-25	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.24	-0.36	1.82e-15	Skin colour saturation;
LGG	cis	rs7465272	1.000	rs13258638	chr8:143683582	C/T	cg10104451	chr8:143696006	ARC	-0.74	-10.79	-0.45	2.22e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9902453	0.740	rs2617867	chr17:28049399	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.17	-0.55	3.93e-38	Coffee consumption (cups per day);
LGG	cis	rs17767392	0.957	rs7140354	chr14:71759616	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.21e-18	Mitral valve prolapse;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg14657458	chr10:134469026	INPP5A	0.62	6.65	0.3	8.35e-11	Airflow obstruction;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12232852	chr3:69129018	UBA3	0.49	8.01	0.35	9.25e-15	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs7084783	0.500	rs4918024	chr10:105341860	G/C	cg00126946	chr10:105363258	SH3PXD2A	0.49	8.54	0.37	1.98e-16	Fear of pain;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg13047869	chr3:10149882	C3orf24	0.57	9.6	0.41	4.96e-20	Alzheimer's disease;
LGG	cis	rs6763768	0.752	rs36029422	chr3:53534200	C/T	cg16894138	chr3:53270350	TKT	0.4	7.04	0.31	6.87e-12	Bacterial meningitis;
LGG	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.65	-0.3	8.24e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3916	0.911	rs12829722	chr12:121155622	C/T	cg21892295	chr12:121157589	UNC119B	-0.41	-7.08	-0.31	5.48e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs68170813	0.559	rs3801958	chr7:106961139	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1.04e-23	Coronary artery disease;
LGG	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.81	-0.45	2e-24	Height;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-9.36	-0.4	3.33e-19	Aortic root size;
LGG	cis	rs1707322	0.682	rs28508523	chr1:46189625	G/A	cg03146154	chr1:46216737	IPP	0.56	11.09	0.46	1.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg19680485	chr15:31195859	MTMR15	-0.46	-7.58	-0.33	1.93e-13	Huntington's disease progression;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.51	0.56	1.33e-39	Platelet count;
LGG	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11748327	0.554	rs10058448	chr5:4013385	C/T	cg01025095	chr5:4101132	NA	-0.43	-6.97	-0.31	1.06e-11	Myocardial infarction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13897145	chr3:113557582	GRAMD1C	0.44	7.49	0.33	3.61e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg02297831	chr4:17616191	MED28	-0.44	-7.81	-0.34	3.8e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4740619	0.544	rs9406539	chr9:15823173	G/A	cg14451791	chr9:16040625	NA	0.32	8.01	0.35	9.48e-15	Body mass index;
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.69	-0.37	6.22e-17	Systolic blood pressure;
LGG	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21862992	chr11:68658383	NA	0.5	8.33	0.36	9.42e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3820928	0.935	rs10203363	chr2:227896976	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.35	-0.32	8.98e-13	Pulmonary function;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03647317	chr4:187891568	NA	-0.41	-9.02	-0.39	5.12e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg27476859	chr7:2772710	GNA12	0.46	8.59	0.37	1.32e-16	Height;
LGG	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.51	-6.65	-0.3	8.12e-11	Smoking behavior;
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.87e-14	Bipolar disorder;
LGG	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg04287289	chr16:89883240	FANCA	-0.53	-9.73	-0.41	1.81e-20	Vitiligo;
LGG	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg00012203	chr2:219082015	ARPC2	0.7	13.1	0.52	1.36e-33	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg13385794	chr1:248469461	NA	0.42	7.58	0.33	1.86e-13	Common traits (Other);
LGG	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg17145862	chr1:211918768	LPGAT1	0.71	10.75	0.45	3.28e-24	Crohn's disease;
LGG	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg24253500	chr15:84953950	NA	0.58	10.35	0.43	1.04e-22	Schizophrenia;
LGG	cis	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-12.01	-0.49	4.06e-29	Resting heart rate;
LGG	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.37	0.32	7.79e-13	Neuroticism;
LGG	trans	rs1829883	0.841	rs2948730	chr5:98723663	G/A	cg08333243	chr5:99726346	NA	0.34	6.77	0.3	4.03e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg25019033	chr10:957182	NA	-0.58	-11.24	-0.46	4.34e-26	Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.04	-0.31	7.21e-12	Bipolar disorder;
LGG	cis	rs2415984	0.783	rs61993306	chr14:46951186	G/A	cg14871534	chr14:47121158	RPL10L	-0.39	-6.7	-0.3	6.23e-11	Number of children ever born;
LGG	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg14228332	chr4:119757509	SEC24D	1.0	9.68	0.41	2.68e-20	Cannabis dependence symptom count;
LGG	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg25019033	chr10:957182	NA	-0.58	-10.57	-0.44	1.57e-23	Eosinophil percentage of granulocytes;
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.45	0.4	1.67e-19	Systolic blood pressure;
LGG	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.76	0.3	4.28e-11	Carotid intima media thickness;
LGG	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.33	-0.36	9.17e-16	Diabetic kidney disease;
LGG	trans	rs6787172	0.702	rs1213048	chr3:157989979	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.44	-0.37	4.02e-16	Aortic root size;
LGG	cis	rs7020830	0.898	rs7857936	chr9:37078491	T/C	cg14294708	chr9:37120828	ZCCHC7	1.11	28.69	0.8	8.59e-105	Schizophrenia;
LGG	cis	rs774359	0.830	rs2453554	chr9:27561800	C/T	cg21249376	chr9:27528432	MOBKL2B	0.42	7.51	0.33	3.15e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg26031613	chr14:104095156	KLC1	1.18	29.15	0.8	7.99e-107	Body mass index;
LGG	trans	rs61931739	0.578	rs61927700	chr12:33612348	T/C	cg26384229	chr12:38710491	ALG10B	-0.45	-7.87	-0.34	2.51e-14	Morning vs. evening chronotype;
LGG	cis	rs5742933	0.817	rs1233297	chr2:190694175	C/T	cg10453823	chr2:190539512	ANKAR	0.46	6.82	0.3	2.89e-11	Ferritin levels;
LGG	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	16.97	0.62	1.35e-50	Nonalcoholic fatty liver disease;
LGG	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-8.37	-0.36	6.87e-16	Aortic root size;
LGG	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-17.07	-0.62	4.9e-51	Skin colour saturation;
LGG	cis	rs2734839	0.964	rs2587548	chr11:113292212	G/C	cg14159747	chr11:113255604	NA	0.27	7.25	0.32	1.77e-12	Information processing speed;
LGG	cis	rs4319547	0.741	rs4758644	chr12:122943915	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.56	-8.51	-0.37	2.5e-16	Body mass index;
LGG	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg00376283	chr12:123451042	ABCB9	0.66	11.6	0.47	1.79e-27	Neutrophil percentage of white cells;
LGG	cis	rs7241530	0.662	rs55752151	chr18:75901986	T/C	cg14642773	chr18:75888474	NA	0.46	8.94	0.38	9.6e-18	Educational attainment (years of education);
LGG	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	10.91	0.45	7.9e-25	Blood metabolite levels;
LGG	cis	rs7727544	0.582	rs7703009	chr5:131552385	C/G	cg07395648	chr5:131743802	NA	-0.4	-8.62	-0.37	1.05e-16	Blood metabolite levels;
LGG	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg09222892	chr1:25734099	RHCE	0.45	9.31	0.4	5.03e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg26039829	chr8:22132926	PIWIL2	0.53	12.05	0.49	2.91e-29	Hypertriglyceridemia;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04772025	chr11:68637568	NA	0.76	13.04	0.52	2.47e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7106204	0.609	rs12804374	chr11:24338016	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	10.36	0.43	9.49e-23	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg05625103	chr10:2543513	NA	0.52	9.29	0.4	5.91e-19	Age-related hearing impairment;
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.18	-0.32	2.72e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9358372	0.555	rs9368237	chr6:20790808	C/T	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.18	-0.39	1.46e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6430585	0.941	rs10496737	chr2:136540083	A/G	cg07169764	chr2:136633963	MCM6	1.0	19.1	0.66	2.2e-60	Corneal structure;
LGG	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg00857998	chr1:205179979	DSTYK	0.58	9.41	0.4	2.32e-19	Red blood cell count;
LGG	cis	rs7017697	1.000	rs7017697	chr8:19685909	G/T	cg03894339	chr8:19674705	INTS10	-0.53	-8.73	-0.38	4.8e-17	Breast cancer;
LGG	cis	rs2180341	0.782	rs6569490	chr6:127729615	C/T	cg24812749	chr6:127587940	RNF146	0.7	11.18	0.46	7.77e-26	Breast cancer;
LGG	cis	rs7853377	0.723	rs4147132	chr9:86559213	T/C	cg12437157	chr9:86433764	GKAP1	0.39	6.8	0.3	3.32e-11	Height;
LGG	cis	rs9473924	0.618	rs61236902	chr6:50813055	C/G	cg14470998	chr6:50812995	TFAP2B	0.67	8.04	0.35	7.71e-15	Body mass index;
LGG	cis	rs4148087	1.000	rs4148091	chr21:43635126	C/T	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	cis	rs4750440	0.706	rs11258767	chr10:14016565	C/T	cg27542038	chr10:14027202	FRMD4A	-0.66	-12.77	-0.51	3.19e-32	Adiponectin levels;
LGG	cis	rs2117029	0.555	rs10783304	chr12:49500398	G/A	cg24176009	chr12:49580217	TUBA1A	0.56	10.56	0.44	1.69e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.13	-0.43	6.5e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07362569	chr17:61921086	SMARCD2	-0.48	-9.13	-0.39	2.19e-18	Prudent dietary pattern;
LGG	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.92	-0.38	1.09e-17	Retinal vascular caliber;
LGG	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg19336497	chr11:14380999	RRAS2	-0.39	-7.69	-0.34	8.98e-14	Mitochondrial DNA levels;
LGG	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.83	-0.34	3.44e-14	Response to antipsychotic treatment;
LGG	cis	rs6430585	0.941	rs60963894	chr2:136539670	T/G	cg07169764	chr2:136633963	MCM6	1.0	19.1	0.66	2.2e-60	Corneal structure;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.92	-0.38	1.13e-17	Life satisfaction;
LGG	trans	rs2898857	0.524	rs11652146	chr17:47422363	G/A	cg11430096	chr6:110968061	CDK19	-0.48	-8.22	-0.36	2.12e-15	Cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02657244	chr4:99183198	RAP1GDS1	-0.47	-6.88	-0.3	1.98e-11	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.65	-0.44	7.99e-24	Alzheimer's disease;
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg23188684	chr11:67383651	NA	0.5	8.49	0.37	2.82e-16	Mean corpuscular volume;
LGG	cis	rs1595825	0.945	rs76510735	chr2:198823095	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.78	-0.3	3.65e-11	Ulcerative colitis;
LGG	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-11.12	-0.46	1.24e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1505368	0.505	rs2135156	chr2:213259226	C/T	cg16329650	chr2:213403929	ERBB4	0.46	8.06	0.35	6.77e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs910187	0.624	rs6063077	chr20:45787261	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.8	-0.34	4.04e-14	Migraine;
LGG	cis	rs9815354	1.000	rs1717001	chr3:41934949	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.63	0.61	4.83e-49	Hip circumference adjusted for BMI;
LGG	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	7.08	0.31	5.53e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg10207240	chr12:122356781	WDR66	0.26	7.77	0.34	5.07e-14	Mean corpuscular volume;
LGG	cis	rs2133450	0.712	rs17697928	chr3:7367771	A/G	cg19930620	chr3:7340148	GRM7	-0.37	-8.09	-0.35	5.19e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg05941027	chr17:61774174	LIMD2	0.36	9.02	0.39	5.21e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg20387954	chr3:183756860	HTR3D	0.71	14.45	0.56	2.39e-39	Anterior chamber depth;
LGG	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.33e-17	Self-reported allergy;
LGG	cis	rs62244186	0.659	rs9855433	chr3:44468065	C/A	cg02073558	chr3:44770973	ZNF501	0.65	11.7	0.48	6.91e-28	Depressive symptoms;
LGG	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg04568710	chr12:38710424	ALG10B	-0.34	-7.39	-0.32	7.1e-13	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09883264	chr5:141489170	NDFIP1	0.48	7.69	0.34	8.9e-14	Cognitive performance;
LGG	cis	rs9487051	0.735	rs352837	chr6:109521806	C/T	cg21918786	chr6:109611834	NA	0.41	7.62	0.33	1.46e-13	Reticulocyte fraction of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16333535	chr22:24093440	ZNF70	0.52	7.78	0.34	4.74e-14	Gut microbiome composition (summer);
LGG	cis	rs274567	0.501	rs272856	chr5:131687081	G/C	cg07395648	chr5:131743802	NA	-0.49	-9.93	-0.42	3.46e-21	Blood metabolite levels;
LGG	cis	rs9636252	0.887	rs13412487	chr2:9267452	A/G	cg20341998	chr2:9276514	NA	0.37	7.1	0.31	4.62e-12	IgG glycosylation;
LGG	cis	rs7818345	0.967	rs12678336	chr8:19280552	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.72	0.3	5.46e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg04287289	chr16:89883240	FANCA	0.75	8.17	0.35	3.05e-15	Skin colour saturation;
LGG	cis	rs4742903	0.904	rs28658011	chr9:107006925	G/A	cg14250997	chr9:106856677	SMC2	0.38	7.76	0.34	5.35e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4926611	1.000	rs2037739	chr1:54115023	G/T	cg23596471	chr1:54105337	GLIS1	0.41	8.47	0.37	3.26e-16	Hand grip strength;
LGG	cis	rs3845702	0.673	rs12468986	chr2:180862320	T/G	cg01881094	chr2:180872142	CWC22	1.28	16.5	0.61	1.84e-48	Schizophrenia;
LGG	cis	rs9815354	1.000	rs3774372	chr3:41877414	A/G	cg03022575	chr3:42003672	ULK4	0.73	9.26	0.4	7.84e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg06654118	chr4:1303317	MAEA	0.46	7.99	0.35	1.04e-14	Obesity-related traits;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg03188948	chr7:1209495	NA	0.61	8.14	0.35	3.58e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs17685	0.735	rs11763339	chr7:75761541	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg12617538	chr9:69786570	NA	-0.4	-6.86	-0.3	2.15e-11	Alzheimer's disease (survival time);
LGG	cis	rs11792861	0.781	rs28361106	chr9:111762385	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.05	0.42	1.28e-21	Menarche (age at onset);
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg04863758	chr4:1303710	MAEA	0.42	7.16	0.32	3.09e-12	Obesity-related traits;
LGG	cis	rs7143963	0.636	rs10149939	chr14:103345467	G/A	cg23020514	chr14:103360112	TRAF3	0.39	7.97	0.35	1.23e-14	Body mass index;
LGG	cis	rs9636252	0.887	rs6743450	chr2:9269554	A/G	cg20341998	chr2:9276514	NA	0.4	7.52	0.33	2.79e-13	IgG glycosylation;
LGG	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.69	-9.37	-0.4	3.27e-19	Diabetic retinopathy;
LGG	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22509189	chr2:225307070	NA	-0.62	-9.95	-0.42	2.9e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs919433	0.927	rs6759834	chr2:198204860	C/T	cg00792783	chr2:198669748	PLCL1	-0.45	-7.02	-0.31	8.09e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9309473	1.000	rs60844734	chr2:73623205	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.04	-0.35	7.36e-15	Metabolite levels;
LGG	cis	rs853679	0.517	rs9393894	chr6:28112562	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.71	-0.34	7.87e-14	Depression;
LGG	cis	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-7.55	-0.33	2.36e-13	Triglycerides;
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.32	-8.12	-0.35	4.19e-15	IgG glycosylation;
LGG	cis	rs9942416	0.660	rs4704231	chr5:74986576	G/A	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs7666738	0.830	rs13139024	chr4:99020700	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs57590327	0.555	rs3772909	chr3:81707264	T/C	cg07356753	chr3:81810745	GBE1	-0.49	-7.63	-0.33	1.35e-13	Extraversion;
LGG	trans	rs9354308	0.764	rs9351534	chr6:66603183	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs9397585	0.857	rs6925834	chr6:153379593	A/T	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.43e-39	Body mass index;
LGG	cis	rs11608355	1.000	rs10850134	chr12:109861454	G/C	cg19025524	chr12:109796872	NA	-0.49	-9.29	-0.4	6.26e-19	Neuroticism;
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.38	-0.32	7.41e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	8.05	0.35	6.87e-15	Schizophrenia;
LGG	cis	rs9943753	0.525	rs7952909	chr12:109808573	A/T	cg19025524	chr12:109796872	NA	0.53	11.38	0.47	1.26e-26	HDL cholesterol;
LGG	trans	rs931812	0.895	rs965625	chr8:101909749	T/C	cg20993868	chr7:22813445	NA	0.71	13.55	0.53	1.75e-35	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs8056893	0.610	rs3803650	chr16:68344696	C/T	cg07273125	chr16:68295692	NA	0.37	8.0	0.35	9.97e-15	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg21459583	chr1:227974177	NA	0.68	10.37	0.43	8.59e-23	Major depressive disorder;
LGG	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-6.84	-0.3	2.52e-11	Coronary artery disease;
LGG	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs9911578	0.967	rs7222789	chr17:56819853	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.91e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs806215	0.526	rs62481419	chr7:127488007	A/G	cg25922125	chr7:127225783	GCC1	-0.48	-7.05	-0.31	6.7e-12	Type 2 diabetes;
LGG	cis	rs4771450	0.925	rs9284201	chr13:103986774	T/C	cg02987523	chr13:103978230	NA	-0.33	-7.2	-0.32	2.52e-12	Uric acid levels;
LGG	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg15971980	chr6:150254442	NA	0.45	8.32	0.36	1.02e-15	Lung cancer;
LGG	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg11161011	chr14:65562177	MAX	-0.76	-14.75	-0.57	1.24e-40	Obesity-related traits;
LGG	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg22980697	chr10:16874865	CUBN	0.61	9.94	0.42	3.12e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg19774624	chr17:42201019	HDAC5	-0.94	-20.22	-0.68	1.24e-65	Total body bone mineral density;
LGG	cis	rs7119	0.717	rs11629652	chr15:77779951	C/A	cg17802220	chr15:77601643	NA	-0.54	-12.25	-0.49	4.31e-30	Type 2 diabetes;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg04450456	chr4:17643702	FAM184B	0.32	6.87	0.3	2.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.16	0.32	3.22e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg00405596	chr8:11794950	NA	-0.41	-6.88	-0.3	1.95e-11	Mood instability;
LGG	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.37	0.43	8.74e-23	Mood instability;
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.97	-0.38	7.17e-18	Vitiligo;
LGG	cis	rs9972944	0.756	rs6416945	chr17:63763942	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.44	-0.37	4.1e-16	Total body bone mineral density;
LGG	cis	rs870825	0.616	rs57271221	chr4:185627198	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	21.66	0.71	2.39e-72	Blood protein levels;
LGG	cis	rs7737355	0.947	rs7706785	chr5:130954860	T/C	cg06307176	chr5:131281290	NA	0.58	9.58	0.41	5.89e-20	Life satisfaction;
LGG	cis	rs2952156	0.959	rs907087	chr17:37828787	G/A	cg00129232	chr17:37814104	STARD3	-0.7	-14.49	-0.56	1.66e-39	Asthma;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04080417	chr5:1859792	NA	-0.54	-8.97	-0.38	7.47e-18	Cardiovascular disease risk factors;
LGG	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg03315344	chr16:75512273	CHST6	-0.59	-11.82	-0.48	2.29e-28	Dupuytren's disease;
LGG	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg25418670	chr11:30344373	C11orf46	-0.53	-7.5	-0.33	3.37e-13	Morning vs. evening chronotype;
LGG	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14169450	chr9:139327907	INPP5E	0.39	7.02	0.31	8e-12	Monocyte percentage of white cells;
LGG	cis	rs7236492	0.935	rs11659416	chr18:77226973	C/T	cg15644404	chr18:77186268	NFATC1	-0.83	-10.0	-0.42	1.84e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.37	0.47	1.39e-26	Ovarian reserve;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg12070911	chr6:150209640	RAET1E	0.3	7.25	0.32	1.79e-12	Lung cancer;
LGG	cis	rs36071027	0.554	rs9918118	chr5:158394846	C/T	cg04248271	chr5:158524404	EBF1	0.41	7.24	0.32	1.89e-12	Carotid intima media thickness;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.13	-0.43	6.5e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs1034435	0.723	rs713946	chr22:48891376	T/C	cg05992904	chr22:48892994	FAM19A5	-0.82	-16.93	-0.62	2.04e-50	Late-onset Alzheimer's disease;
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg06115741	chr20:33292138	TP53INP2	0.6	9.85	0.42	6.71e-21	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.01	-0.42	1.8e-21	Bipolar disorder;
LGG	cis	rs1348850	0.874	rs2166558	chr2:178373652	G/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.53	-0.37	2.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.47	-0.33	3.99e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs877282	0.853	rs11253332	chr10:755262	G/C	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg19442545	chr10:75533431	FUT11	-0.43	-6.96	-0.31	1.16e-11	Inflammatory bowel disease;
LGG	cis	rs4690686	0.808	rs6553945	chr4:177270965	T/C	cg17059388	chr4:177262070	NA	0.76	16.37	0.61	7.12e-48	Essential tremor;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg15971980	chr6:150254442	NA	-0.43	-7.98	-0.35	1.16e-14	Lung cancer;
LGG	cis	rs7717393	1.000	rs1857770	chr5:155769455	T/G	cg01474424	chr5:155754231	SGCD	0.82	7.82	0.34	3.7e-14	Egg allergy;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs526231	0.543	rs62362544	chr5:102334247	C/T	cg23492399	chr5:102201601	PAM	-0.6	-9.18	-0.39	1.39e-18	Primary biliary cholangitis;
LGG	cis	rs587080	0.624	rs512715	chr11:65191208	C/G	cg17120908	chr11:65337727	SSSCA1	0.41	6.74	0.3	4.58e-11	Plateletcrit;
LGG	cis	rs7552167	1.000	rs59960858	chr1:24519437	C/A	cg01960748	chr1:24522592	NA	0.54	8.05	0.35	7.09e-15	Psoriasis vulgaris;
LGG	cis	rs1904096	0.506	rs114312933	chr4:95216802	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.6	-11.48	-0.47	5.04e-27	Type 2 diabetes;
LGG	cis	rs1869026	1.000	rs1880542	chr2:121338584	C/T	cg22272644	chr2:121334640	NA	0.3	7.17	0.32	2.94e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6489785	0.745	rs628771	chr12:121303539	T/C	cg02419362	chr12:121203948	SPPL3	-0.44	-6.83	-0.3	2.69e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs503734	0.714	rs2553430	chr3:101089262	T/C	cg27318481	chr3:100970896	IMPG2	-0.36	-7.22	-0.32	2.11e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg03609598	chr5:56110824	MAP3K1	-0.56	-8.09	-0.35	5.45e-15	Initial pursuit acceleration;
LGG	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.77	0.54	2.18e-36	Type 2 diabetes;
LGG	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	12.92	0.51	8.28e-33	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2274273	0.840	rs7159144	chr14:55821324	G/A	cg04306507	chr14:55594613	LGALS3	0.63	18.12	0.64	7.48e-56	Protein biomarker;
LGG	cis	rs7173743	0.934	rs7168915	chr15:79128889	C/T	cg00540400	chr15:79124168	NA	0.41	8.67	0.37	7.28e-17	Coronary artery disease;
LGG	cis	rs7017914	0.967	rs10448014	chr8:71688165	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	trans	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.54	-9.35	-0.4	3.62e-19	Metabolite levels;
LGG	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg03929089	chr4:120376271	NA	-1.03	-24.55	-0.75	7.19e-86	Height;
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg08508337	chr8:144660607	NAPRT1	0.9	7.24	0.32	1.9e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs1570884	0.539	rs3794377	chr13:50111135	T/C	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.71	-0.3	5.65e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs11168618	0.567	rs7314569	chr12:48816981	G/T	cg24011408	chr12:48396354	COL2A1	0.49	8.03	0.35	8.09e-15	Adiponectin levels;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2117029	0.521	rs58336603	chr12:49556888	C/T	cg24176009	chr12:49580217	TUBA1A	0.63	12.16	0.49	1.02e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	1.000	rs11039390	chr11:47796295	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs113835537	0.529	rs4542420	chr11:66277610	G/C	cg24851651	chr11:66362959	CCS	0.45	7.76	0.34	5.46e-14	Airway imaging phenotypes;
LGG	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.78	-0.38	3.26e-17	Post bronchodilator FEV1;
LGG	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs858239	0.600	rs2003555	chr7:23122915	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.49	0.33	3.57e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-14.74	-0.57	1.33e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs4700695	0.841	rs402100	chr5:65266125	A/G	cg21114390	chr5:65439923	SFRS12	0.58	7.1	0.31	4.63e-12	Facial morphology (factor 19);
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.84	11.82	0.48	2.43e-28	Lung function (FEV1/FVC);
LGG	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg22961513	chr11:14280813	SPON1	0.35	8.15	0.35	3.44e-15	Mitochondrial DNA levels;
LGG	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	cg07928641	chr1:182991847	LAMC1	0.47	9.31	0.4	5.31e-19	Colorectal cancer;
LGG	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg07382826	chr16:28625726	SULT1A1	0.34	7.27	0.32	1.59e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2617583	0.868	rs2617596	chr5:1446719	C/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-7.13	-0.31	3.77e-12	Breast cancer;
LGG	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.36	-0.43	9.24e-23	Hemoglobin concentration;
LGG	trans	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg13010199	chr12:38710504	ALG10B	-0.47	-9.22	-0.39	1.09e-18	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg11266682	chr4:10021025	SLC2A9	0.51	10.21	0.43	3.19e-22	Bone mineral density;
LGG	cis	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.33	-0.36	9.25e-16	Ulcerative colitis;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.67e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg08344181	chr3:125677491	NA	-0.76	-7.93	-0.35	1.6e-14	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs75059851	0.778	rs73034263	chr11:133808038	C/G	cg20042908	chr11:133852938	NA	-0.65	-10.96	-0.45	5e-25	Schizophrenia;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10802521	chr3:52805072	NEK4	0.41	6.99	0.31	9.43e-12	Bipolar disorder;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg11766577	chr21:47581405	C21orf56	0.57	10.39	0.43	7.28e-23	Testicular germ cell tumor;
LGG	trans	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg20587970	chr11:113659929	NA	-0.9	-13.81	-0.54	1.47e-36	Hip circumference adjusted for BMI;
LGG	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.73	-0.48	5.33e-28	Mean platelet volume;
LGG	trans	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg26518628	chr1:97050305	NA	-0.88	-9.03	-0.39	4.54e-18	Cannabis dependence symptom count;
LGG	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22857025	chr5:266934	NA	-1.12	-9.11	-0.39	2.57e-18	Asthma (childhood onset);
LGG	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg15704280	chr7:45808275	SEPT13	-0.96	-19.43	-0.67	6.01e-62	Height;
LGG	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg02733842	chr7:1102375	C7orf50	-0.45	-7.4	-0.33	6.51e-13	Bronchopulmonary dysplasia;
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.85e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg15309053	chr8:964076	NA	0.43	9.2	0.39	1.2e-18	Schizophrenia;
LGG	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg15269541	chr15:43626905	ADAL	-0.45	-8.1	-0.35	4.77e-15	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.61	-0.44	1.09e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.58	-9.9	-0.42	4.28e-21	Longevity;Endometriosis;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg08621203	chr6:150244597	RAET1G	0.45	7.7	0.34	8.04e-14	Lung cancer;
LGG	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg27205649	chr11:78285834	NARS2	0.5	8.44	0.37	4.14e-16	Alzheimer's disease (survival time);
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.66	0.37	7.7e-17	Bipolar disorder;
LGG	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg21775007	chr8:11205619	TDH	-0.77	-13.0	-0.52	3.58e-33	Retinal vascular caliber;
LGG	cis	rs2016266	0.859	rs4759061	chr12:53738214	C/T	cg04065151	chr12:53682969	ESPL1	0.57	9.01	0.39	5.55e-18	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.45	0.33	4.63e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7202877	0.706	rs247436	chr16:75445971	T/G	cg03315344	chr16:75512273	CHST6	-0.52	-6.98	-0.31	1.04e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs17125944	0.686	rs55685925	chr14:53334546	A/G	cg00686598	chr14:53173677	PSMC6	-0.74	-7.89	-0.34	2.25e-14	Alzheimer's disease (late onset);
LGG	cis	rs6750047	0.585	rs4670808	chr2:38267794	A/G	cg07380506	chr2:38303506	CYP1B1	0.43	7.09	0.31	5.09e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11039808	chr5:77591002	AP3B1	0.4	6.91	0.31	1.57e-11	Bilirubin levels;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg00830817	chr11:109293614	C11orf87	0.41	6.81	0.3	3.06e-11	Schizophrenia;
LGG	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg20608306	chr11:116969690	SIK3	0.43	13.7	0.54	4.09e-36	Blood protein levels;
LGG	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg18876405	chr7:65276391	NA	0.46	8.17	0.36	2.9e-15	Calcium levels;
LGG	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg05623727	chr3:50126028	RBM5	-0.34	-7.33	-0.32	1.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg17376030	chr22:41985996	PMM1	0.67	10.91	0.45	7.96e-25	Vitiligo;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg16270222	chr17:41446396	NA	0.29	6.81	0.3	2.99e-11	Menopause (age at onset);
LGG	cis	rs11800820	0.615	rs7513288	chr1:246661679	A/G	cg16700716	chr1:246684329	NA	-0.43	-7.72	-0.34	7.31e-14	Obesity-related traits;
LGG	cis	rs10046574	0.561	rs9656457	chr7:135202254	T/A	cg27474649	chr7:135195673	CNOT4	0.75	9.07	0.39	3.46e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4865875	1.000	rs4242045	chr5:54106378	A/G	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg04861929	chr11:109293070	C11orf87	0.84	16.9	0.62	3.07e-50	Schizophrenia;
LGG	cis	rs701145	0.585	rs1713822	chr3:153863505	A/G	cg12800244	chr3:153838788	SGEF	0.8	8.71	0.38	5.32e-17	Coronary artery disease;
LGG	cis	rs4740619	0.677	rs13283620	chr9:15771859	G/T	cg14451791	chr9:16040625	NA	0.35	8.81	0.38	2.55e-17	Body mass index;
LGG	cis	rs308971	0.656	rs307578	chr3:12084158	A/G	cg15873301	chr3:12045459	SYN2	0.54	7.82	0.34	3.56e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg13010199	chr12:38710504	ALG10B	-0.58	-11.47	-0.47	5.46e-27	Morning vs. evening chronotype;
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg19357499	chr8:144660631	NAPRT1	0.87	6.98	0.31	1.01e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg00551146	chr10:14014579	FRMD4A	0.33	7.82	0.34	3.61e-14	Adiponectin levels;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg22907277	chr7:1156413	C7orf50	0.45	7.78	0.34	4.68e-14	Longevity;Endometriosis;
LGG	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.56	-9.8	-0.41	1e-20	Hemoglobin concentration;
LGG	cis	rs2073300	0.609	rs6132617	chr20:23420151	G/C	cg12062639	chr20:23401060	NAPB	0.83	8.0	0.35	9.96e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.83	-0.51	1.85e-32	Total body bone mineral density;
LGG	trans	rs12517041	1.000	rs16892388	chr5:23306240	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg04117972	chr1:227635322	NA	0.91	14.11	0.55	7.19e-38	Major depressive disorder;
LGG	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.25	-0.43	2.41e-22	Subjective well-being;
LGG	cis	rs4788570	0.697	rs9930015	chr16:71801092	C/G	cg06353428	chr16:71660113	MARVELD3	1.24	20.04	0.68	8.43e-65	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg05941027	chr17:61774174	LIMD2	0.36	9.06	0.39	3.66e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06634786	chr22:41940651	POLR3H	0.68	11.34	0.47	1.81e-26	Vitiligo;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg18402987	chr7:1209562	NA	0.43	8.04	0.35	7.36e-15	Longevity;Endometriosis;
LGG	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg01221209	chr5:554886	NA	-0.46	-7.0	-0.31	9.12e-12	Obesity-related traits;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07659893	chr17:61819838	STRADA	-0.44	-7.32	-0.32	1.1e-12	Prudent dietary pattern;
LGG	cis	rs9457247	0.602	rs6456152	chr6:167472062	A/G	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Crohn's disease;
LGG	cis	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg24375607	chr4:120327624	NA	0.69	11.3	0.46	2.64e-26	Corneal astigmatism;
LGG	trans	rs7246760	1.000	rs10418248	chr19:9938214	T/A	cg02900749	chr2:68251473	NA	-0.96	-10.72	-0.45	4.27e-24	Pursuit maintenance gain;
LGG	cis	rs7326068	0.610	rs9552265	chr13:21311695	C/T	cg04906043	chr13:21280425	IL17D	-0.44	-7.04	-0.31	6.88e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs708547	0.647	rs1718831	chr4:57886946	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.3	-0.43	1.52e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.61	-0.37	1.17e-16	Mood instability;
LGG	trans	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.11	-0.46	1.43e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg02273617	chr15:68117586	LBXCOR1	0.31	6.84	0.3	2.53e-11	Restless legs syndrome;
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg26354017	chr1:205819088	PM20D1	-0.56	-9.22	-0.39	1.06e-18	Parkinson's disease;
LGG	cis	rs7267979	1.000	rs4815420	chr20:25383979	C/T	cg06421707	chr20:25228305	PYGB	-0.49	-10.52	-0.44	2.4e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg04503457	chr17:41445688	NA	-0.37	-8.63	-0.37	1.02e-16	Menopause (age at onset);
LGG	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.75	0.3	4.32e-11	Parkinson's disease;
LGG	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Bone mineral density;
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg03351412	chr1:154909251	PMVK	0.67	13.07	0.52	1.91e-33	Prostate cancer;
LGG	cis	rs4417704	0.551	rs7585067	chr2:241893465	T/C	cg26818257	chr2:241905806	NA	0.49	10.94	0.45	6.02e-25	Joint mobility (Beighton score);
LGG	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg24209194	chr3:40518798	ZNF619	-0.43	-6.71	-0.3	5.74e-11	Renal cell carcinoma;
LGG	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg03733263	chr8:22462867	KIAA1967	0.99	24.05	0.75	1.62e-83	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.68	-0.3	6.79e-11	Menopause (age at onset);
LGG	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07344492	chr5:132947192	FSTL4	0.39	6.84	0.3	2.53e-11	Cognitive performance;
LGG	cis	rs12927351	1.000	rs36026517	chr16:74597758	G/C	cg01733217	chr16:74700730	RFWD3	0.51	6.85	0.3	2.36e-11	Granulocyte percentage of myeloid white cells;
LGG	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg02002194	chr4:3960332	NA	-0.48	-9.04	-0.39	4.42e-18	Neuroticism;
LGG	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg24675658	chr1:53192096	ZYG11B	0.49	10.19	0.43	3.96e-22	Monocyte count;
LGG	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg20991723	chr1:152506922	NA	-0.73	-14.95	-0.57	1.55e-41	Hair morphology;
LGG	cis	rs5742933	0.803	rs1233262	chr2:190657833	A/G	cg04003228	chr2:190539410	ANKAR	0.47	6.75	0.3	4.31e-11	Ferritin levels;
LGG	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.94	-0.31	1.32e-11	Colorectal cancer;
LGG	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.71	0.3	5.64e-11	Parkinson's disease;
LGG	cis	rs9517320	1.000	rs9513430	chr13:99127252	C/G	cg07423050	chr13:99094983	FARP1	0.4	8.16	0.35	3.23e-15	Longevity;
LGG	cis	rs6032067	0.673	rs991048	chr20:43898227	C/T	cg10761708	chr20:43804764	PI3	-0.59	-9.0	-0.39	5.84e-18	Blood protein levels;
LGG	cis	rs6964587	1.000	rs2075881	chr7:91734552	T/C	cg17063962	chr7:91808500	NA	0.51	9.24	0.39	8.85e-19	Breast cancer;
LGG	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.64e-21	Diabetic retinopathy;
LGG	cis	rs6963495	0.818	rs6973974	chr7:105170629	C/T	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg01988459	chr11:68622903	NA	-0.63	-12.64	-0.51	1.14e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg03264133	chr6:25882463	NA	-0.43	-7.68	-0.34	9.66e-14	Height;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.57	0.53	1.53e-35	Prudent dietary pattern;
LGG	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg14664628	chr15:75095509	CSK	0.62	10.18	0.43	4.16e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.55	0.33	2.34e-13	Colorectal cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.42	7.73	0.34	6.69e-14	Obesity-related traits;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg13880726	chr7:1868755	MAD1L1	0.46	8.06	0.35	6.79e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7020830	0.858	rs7856690	chr9:37127545	A/T	cg14294708	chr9:37120828	ZCCHC7	1.14	28.32	0.8	4.23e-103	Schizophrenia;
LGG	cis	rs9815354	1.000	rs1607908	chr3:41905196	T/G	cg03022575	chr3:42003672	ULK4	0.64	8.19	0.36	2.53e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9397585	0.791	rs7750497	chr6:153376417	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.01e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07461318	chr12:96184965	NTN4	0.39	6.67	0.3	7.12e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg10847948	chr11:71163743	NADSYN1	-0.63	-11.48	-0.47	5.06e-27	Vitamin D levels;
LGG	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg24623649	chr8:11872141	NA	-0.31	-7.26	-0.32	1.66e-12	Neuroticism;
LGG	cis	rs75920871	1.000	rs61907591	chr11:116796855	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.0	-0.31	8.94e-12	Subjective well-being;
LGG	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg21699342	chr2:239360505	ASB1	0.35	6.74	0.3	4.8e-11	Multiple system atrophy;
LGG	cis	rs17767392	0.813	rs12878989	chr14:71856184	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.67	-0.37	7.29e-17	Mitral valve prolapse;
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.38	-7.7	-0.34	8.46e-14	Personality dimensions;
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	1.97e-12	Bipolar disorder;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08280861	chr8:58055591	NA	0.56	7.02	0.31	7.94e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.75	-0.57	1.22e-40	Schizophrenia;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg12708336	chr17:41446283	NA	-0.31	-7.08	-0.31	5.41e-12	Menopause (age at onset);
LGG	trans	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6956675	1.000	rs6968327	chr7:62574489	A/G	cg08930214	chr7:62859557	LOC100287834	0.43	7.01	0.31	8.35e-12	Obesity-related traits;
LGG	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.62	0.33	1.49e-13	Coronary artery disease;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg03188948	chr7:1209495	NA	0.68	8.89	0.38	1.42e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00631329	chr6:26305371	NA	-0.54	-9.91	-0.42	3.94e-21	Educational attainment;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs35740288	0.822	rs11630179	chr15:86282934	G/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.02	-0.31	7.74e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	23.66	0.74	1.01e-81	Chronic sinus infection;
LGG	cis	rs2617583	0.967	rs2617595	chr5:1448246	C/T	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.1	-0.31	4.74e-12	Breast cancer;
LGG	cis	rs9677476	0.779	rs10173555	chr2:232108769	C/G	cg23338755	chr2:231921595	PSMD1	0.49	6.77	0.3	4.03e-11	Food antigen IgG levels;
LGG	trans	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	12.44	0.5	7.18e-31	Breast cancer;
LGG	cis	rs4731207	0.565	rs1904972	chr7:124669687	T/C	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.81e-12	Cutaneous malignant melanoma;
LGG	cis	rs28588043	0.818	rs7052350	chr1:170989932	T/G	cg03458344	chr1:170964477	C1orf129	-0.47	-7.04	-0.31	7.19e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg24881330	chr22:46731750	TRMU	0.7	7.03	0.31	7.23e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2286885	0.965	rs10760440	chr9:129250831	C/T	cg14319473	chr9:129242481	FAM125B	0.44	7.97	0.35	1.25e-14	Intraocular pressure;
LGG	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg13010199	chr12:38710504	ALG10B	0.55	10.95	0.45	5.68e-25	Heart rate;
LGG	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.84	-17.64	-0.63	1.23e-53	Caffeine consumption;
LGG	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg23583168	chr7:148888333	NA	-0.87	-16.93	-0.62	2.2e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.82	-0.34	3.53e-14	Neuroticism;
LGG	cis	rs4538187	0.951	rs17562177	chr2:64160385	A/G	cg02541582	chr2:64069798	UGP2	-0.6	-13.87	-0.54	8.22e-37	Systolic blood pressure;
LGG	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg04374321	chr14:90722782	PSMC1	0.44	7.09	0.31	5.08e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.84	0.45	1.51e-24	Personality dimensions;
LGG	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.18	-0.52	6.86e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6960043	0.818	rs6947830	chr7:15064984	A/G	cg19272540	chr7:15055459	NA	0.36	7.85	0.34	2.88e-14	Type 2 diabetes;
LGG	cis	rs112591243	0.685	rs2839338	chr21:47987984	C/T	cg10657630	chr21:48055338	PRMT2	0.79	7.23	0.32	2.06e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.49	-0.47	4.69e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg08885076	chr2:99613938	TSGA10	0.43	9.22	0.39	1.06e-18	Chronic sinus infection;
LGG	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg14664628	chr15:75095509	CSK	-0.47	-9.11	-0.39	2.41e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs72792276	0.908	rs10478797	chr5:127442066	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.67	7.17	0.32	3.07e-12	Red cell distribution width;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg19727166	chr6:117804670	DCBLD1	0.39	6.75	0.3	4.46e-11	Body mass index;
LGG	cis	rs7503807	0.688	rs11150745	chr17:78757626	A/G	cg08454507	chr17:78755406	RPTOR	-0.36	-7.58	-0.33	1.91e-13	Obesity;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg06654118	chr4:1303317	MAEA	0.46	7.96	0.35	1.3e-14	Obesity-related traits;
LGG	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg25174290	chr11:3078921	CARS	0.72	14.74	0.57	1.35e-40	Longevity;
LGG	cis	rs12999616	0.817	rs35530168	chr2:98328477	C/G	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.35	3.7e-15	Colorectal cancer;
LGG	cis	rs2247341	0.893	rs743569	chr4:1719620	T/G	cg05026014	chr4:1749153	NA	-0.33	-9.16	-0.39	1.63e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7255045	0.788	rs2290688	chr19:12958697	T/C	cg07955356	chr19:12992479	DNASE2	0.43	7.25	0.32	1.74e-12	Mean corpuscular volume;
LGG	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	25.54	0.76	1.88e-90	Height;
LGG	cis	rs1355223	0.844	rs12809046	chr11:34748261	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.77	-0.3	4.03e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12282928	0.876	rs1158898	chr11:48273246	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.14	-0.31	3.61e-12	Migraine - clinic-based;
LGG	cis	rs963731	0.579	rs12471731	chr2:39225171	A/G	cg04010122	chr2:39346883	SOS1	-0.69	-7.29	-0.32	1.39e-12	Corticobasal degeneration;
LGG	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg18551225	chr6:44695536	NA	-0.68	-10.79	-0.45	2.32e-24	Total body bone mineral density;
LGG	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.54	-0.33	2.47e-13	Height;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.04	0.55	1.42e-37	Tonsillectomy;
LGG	cis	rs4308124	0.708	rs2137168	chr2:111986509	C/T	cg04571233	chr2:111982156	NA	-0.58	-9.23	-0.39	1.01e-18	Vitiligo;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.29	0.36	1.22e-15	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02938130	chr5:150460100	TNIP1	0.48	7.34	0.32	9.79e-13	Gut microbiome composition (summer);
LGG	cis	rs758324	0.812	rs30159	chr5:131306535	T/C	cg06307176	chr5:131281290	NA	-0.54	-8.86	-0.38	1.74e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg09517075	chr8:22133004	PIWIL2	0.43	9.5	0.4	1.14e-19	Hypertriglyceridemia;
LGG	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.25	0.7	1.97e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2224391	0.628	rs2753243	chr6:5256261	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-7.25	-0.32	1.73e-12	Height;
LGG	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9443645	0.901	rs2050659	chr6:79734369	A/C	cg18132916	chr6:79620363	NA	-0.31	-8.41	-0.36	4.95e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.71	-12.53	-0.5	3.34e-31	Obesity-related traits;
LGG	cis	rs4788570	0.615	rs10852503	chr16:71652227	G/C	cg06353428	chr16:71660113	MARVELD3	1.27	21.66	0.71	2.36e-72	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg11846333	chr4:119757529	SEC24D	-0.67	-7.08	-0.31	5.25e-12	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.3	-0.4	5.62e-19	Type 2 diabetes;
LGG	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg24110177	chr3:50126178	RBM5	0.61	11.1	0.46	1.5e-25	Body mass index;
LGG	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg10224037	chr5:178157518	ZNF354A	0.78	13.04	0.52	2.5e-33	Neutrophil percentage of white cells;
LGG	cis	rs4819852	0.752	rs2012714	chr22:19977647	C/T	cg06346307	chr22:19949965	COMT	0.29	6.83	0.3	2.69e-11	Pulse pressure;
LGG	cis	rs56775891	0.559	rs11664298	chr18:77578986	G/A	cg13263691	chr18:77568018	NA	0.52	6.97	0.31	1.12e-11	Schizophrenia;
LGG	cis	rs10267417	0.522	rs117382719	chr7:19944660	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12580194	0.556	rs73119000	chr12:55736662	G/A	cg19537932	chr12:55886519	OR6C68	-0.52	-9.38	-0.4	2.85e-19	Cancer;
LGG	cis	rs10864907	0.614	rs12711745	chr2:113700355	T/C	cg06156847	chr2:113672199	IL1F7	-0.37	-7.39	-0.32	6.8e-13	Pulmonary function;
LGG	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.77	0.34	5.24e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-10.68	-0.44	6.03e-24	Height;
LGG	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg04691961	chr3:161091175	C3orf57	0.43	9.14	0.39	2e-18	Morning vs. evening chronotype;
LGG	cis	rs6546550	0.933	rs6546554	chr2:70135706	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg14675211	chr2:100938903	LONRF2	0.68	12.18	0.49	8.52e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg01620082	chr3:125678407	NA	-0.64	-7.03	-0.31	7.22e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg02733842	chr7:1102375	C7orf50	0.73	10.84	0.45	1.54e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-7.37	-0.32	7.75e-13	Blood trace element (Cu levels);
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.11	-0.35	4.68e-15	Schizophrenia;
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Electroencephalogram traits;
LGG	cis	rs56404409	0.823	rs12788072	chr11:123334298	A/G	cg04681489	chr11:123325084	NA	-0.4	-7.58	-0.33	1.88e-13	Ulcerative colitis;
LGG	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg04568710	chr12:38710424	ALG10B	-0.41	-8.88	-0.38	1.44e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6433857	0.657	rs10209994	chr2:181514955	A/C	cg23363182	chr2:181467187	NA	-0.35	-7.01	-0.31	8.4e-12	Body mass index;
LGG	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.04	-0.31	7.19e-12	Iron status biomarkers;
LGG	cis	rs701145	0.643	rs7647694	chr3:153851535	C/G	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs36051895	0.659	rs1576271	chr9:5039652	A/C	cg02405213	chr9:5042618	JAK2	-0.83	-15.23	-0.58	9.36e-43	Pediatric autoimmune diseases;
LGG	cis	rs9810089	0.814	rs1279424	chr3:136007333	A/G	cg21827317	chr3:136751795	NA	0.45	7.82	0.34	3.51e-14	Gestational age at birth (child effect);
LGG	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.65	-0.71	2.64e-72	Height;
LGG	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg04989706	chr14:50066350	PPIL5	-0.6	-9.83	-0.42	7.93e-21	Carotid intima media thickness;
LGG	cis	rs72901758	0.768	rs72901766	chr17:76245203	G/C	cg26068271	chr17:76253126	NA	0.54	11.26	0.46	3.52e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg03929089	chr4:120376271	NA	0.66	6.77	0.3	3.9e-11	Intraocular pressure;
LGG	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg04743876	chr7:130013617	NA	-0.36	-8.25	-0.36	1.67e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06108461	chr20:60628389	TAF4	-0.92	-17.57	-0.63	2.41e-53	Body mass index;
LGG	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	7.74	0.34	6.23e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.84	0.57	4.96e-41	Platelet count;
LGG	cis	rs7582720	1.000	rs72936872	chr2:203790889	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.74e-14	Homoarginine levels;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg11965913	chr1:205819406	PM20D1	0.94	22.78	0.73	1.27e-77	Menarche (age at onset);
LGG	cis	rs75920871	1.000	rs61905677	chr11:116833655	T/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.04e-12	Subjective well-being;
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.03	-0.31	7.61e-12	Bipolar disorder;
LGG	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg11707556	chr5:10655725	ANKRD33B	0.74	15.9	0.59	9.99e-46	Height;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg16270222	chr17:41446396	NA	-0.29	-6.68	-0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.56	0.33	2.19e-13	Glycated hemoglobin levels;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg11050988	chr7:1952600	MAD1L1	-0.4	-9.87	-0.42	5.73e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs6489882	0.934	rs1859331	chr12:113376331	C/A	cg25319449	chr12:113376135	OAS3	-0.38	-7.1	-0.31	4.78e-12	Chronic lymphocytic leukemia;
LGG	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg07507251	chr3:52567010	NT5DC2	-0.35	-6.99	-0.31	9.55e-12	Electroencephalogram traits;
LGG	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg25809561	chr17:30822961	MYO1D	0.37	8.9	0.38	1.22e-17	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.72	0.41	1.91e-20	Prudent dietary pattern;
LGG	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg15212455	chr7:39170539	POU6F2	0.51	12.02	0.49	3.73e-29	IgG glycosylation;
LGG	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg02461776	chr11:598696	PHRF1	0.42	6.97	0.31	1.13e-11	Systemic lupus erythematosus;
LGG	cis	rs7555523	0.887	rs10918274	chr1:165714416	T/C	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg08188268	chr10:116634841	FAM160B1	0.32	7.01	0.31	8.36e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg18129748	chr3:49941408	MST1R	-0.21	-6.75	-0.3	4.43e-11	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.98	-0.42	2.22e-21	Mean corpuscular volume;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg04234412	chr22:24373322	LOC391322	-0.78	-16.31	-0.6	1.41e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.79	-0.3	3.4e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg08392591	chr16:89556376	ANKRD11	0.45	7.03	0.31	7.41e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.5	0.33	3.29e-13	Coronary artery disease;
LGG	cis	rs9467773	0.595	rs3799379	chr6:26404694	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-7.68	-0.34	9.84e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7020830	0.898	rs495863	chr9:37346955	T/C	cg14294708	chr9:37120828	ZCCHC7	1.13	30.78	0.82	4.44e-114	Schizophrenia;
LGG	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	trans	rs56114371	0.530	rs169262	chr6:27770890	C/T	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.86	-0.3	2.26e-11	Breast cancer;
LGG	cis	rs7483296	0.705	rs1000400	chr11:115410621	A/G	cg02820646	chr11:115398838	NA	0.42	7.37	0.32	7.98e-13	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg19694781	chr19:47549865	TMEM160	-0.42	-7.2	-0.32	2.5e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg08847533	chr14:75593920	NEK9	-0.55	-10.1	-0.42	8.42e-22	Height;
LGG	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg20368463	chr18:77673604	PQLC1	0.57	7.48	0.33	3.79e-13	Opioid sensitivity;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg20916646	chr4:852691	GAK	0.53	9.28	0.4	6.46e-19	Sjögren's syndrome;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs10014986	chr4:99000687	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4700695	0.841	rs153367	chr5:65419170	G/A	cg21114390	chr5:65439923	SFRS12	-0.55	-6.93	-0.31	1.45e-11	Facial morphology (factor 19);
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-9.3	-0.4	5.78e-19	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg24829409	chr8:58192753	C8orf71	-0.62	-8.86	-0.38	1.73e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.73	-0.3	5.07e-11	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2133450	0.712	rs13090234	chr3:7365244	T/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.22	-0.36	2.11e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs4740619	0.557	rs997410	chr9:16040430	A/G	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.28	0.36	1.37e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg27121462	chr16:89883253	FANCA	0.63	11.78	0.48	3.25e-28	Vitiligo;
LGG	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08564027	chr20:61660810	NA	1.02	24.88	0.76	2.13e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg18357526	chr6:26021779	HIST1H4A	0.59	10.3	0.43	1.52e-22	Height;
LGG	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg17330251	chr7:94953956	PON1	-0.42	-7.98	-0.35	1.14e-14	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4262150	0.883	rs12654450	chr5:152238850	T/C	cg12297329	chr5:152029980	NA	-0.65	-12.27	-0.5	3.53e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg23461800	chr14:103021989	NA	0.52	8.31	0.36	1.09e-15	Platelet count;
LGG	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg04064380	chr11:117688259	NA	-0.5	-7.24	-0.32	1.84e-12	Myopia;
LGG	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.62e-28	Lymphocyte counts;
LGG	cis	rs4728302	0.583	rs12707091	chr7:133185749	A/G	cg10665199	chr7:133106180	EXOC4	0.59	9.94	0.42	3.16e-21	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs6912958	0.967	rs6905947	chr6:88161949	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.69	-0.44	5.58e-24	Monocyte percentage of white cells;
LGG	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.17	-0.55	4.13e-38	Hair morphology;
LGG	cis	rs1707322	1.000	rs11211204	chr1:46317864	A/G	cg03146154	chr1:46216737	IPP	0.54	10.34	0.43	1.1e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg22437258	chr11:111473054	SIK2	0.53	9.38	0.4	2.87e-19	Primary sclerosing cholangitis;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg19469297	chr7:45151440	TBRG4	0.41	6.97	0.31	1.1e-11	Body mass index;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg09517075	chr8:22133004	PIWIL2	-0.45	-9.82	-0.42	8.38e-21	Hypertriglyceridemia;
LGG	cis	rs6688363	0.943	rs1016732	chr1:160086968	A/G	cg01023271	chr1:160068607	IGSF8	0.55	7.22	0.32	2.19e-12	Response to antipsychotic treatment;
LGG	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg20578329	chr17:80767326	TBCD	0.85	13.17	0.52	7.33e-34	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1018697	0.518	rs2250301	chr10:104548393	G/A	cg04362960	chr10:104952993	NT5C2	-0.63	-10.01	-0.42	1.78e-21	Colorectal adenoma (advanced);
LGG	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.61	-0.37	1.14e-16	Aortic root size;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg05863683	chr7:1912471	MAD1L1	0.46	8.98	0.39	6.82e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9487094	0.744	rs13220304	chr6:109652236	C/T	cg01125227	chr6:109776195	MICAL1	0.47	7.85	0.34	2.99e-14	Height;
LGG	cis	rs793278	0.607	rs77055095	chr11:19221518	G/A	cg14704941	chr11:19224659	CSRP3	-0.55	-8.91	-0.38	1.14e-17	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg00599393	chr8:22457479	C8orf58	0.45	8.04	0.35	7.35e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs367615	0.704	rs55956735	chr5:108845042	A/G	cg17395555	chr5:108820864	NA	0.87	15.87	0.59	1.28e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg19168338	chr16:4465731	CORO7	0.73	13.48	0.53	3.76e-35	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02146091	chr20:30135177	HM13;PSIMCT-1	-0.41	-7.61	-0.33	1.51e-13	Lung adenocarcinoma;
LGG	cis	rs36051895	0.659	rs61284219	chr9:5062816	C/A	cg02405213	chr9:5042618	JAK2	-0.82	-16.07	-0.6	1.64e-46	Pediatric autoimmune diseases;
LGG	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg17644776	chr2:200775616	C2orf69	-0.6	-7.57	-0.33	2.09e-13	Schizophrenia;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	3.2e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg04362960	chr10:104952993	NT5C2	0.57	10.57	0.44	1.58e-23	Arsenic metabolism;
LGG	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg07936489	chr17:37558343	FBXL20	-1.03	-15.33	-0.58	3.37e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12432903	chr7:1882776	MAD1L1	-0.49	-8.2	-0.36	2.44e-15	Bipolar disorder;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18876405	chr7:65276391	NA	0.55	9.88	0.42	5.09e-21	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05300158	chr4:140477727	SETD7	0.51	8.24	0.36	1.84e-15	Cognitive performance;
LGG	cis	rs864537	0.590	rs1214596	chr1:167427170	A/T	cg09179987	chr1:167433047	CD247	-0.44	-9.82	-0.42	8.37e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs9902453	0.904	rs12103671	chr17:28408217	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.57	-0.53	1.46e-35	Coffee consumption (cups per day);
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg07511668	chr11:68622177	NA	0.5	9.66	0.41	3.04e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs3808502	0.501	rs7012219	chr8:11145679	T/A	cg16141378	chr3:129829833	LOC729375	-0.32	-6.85	-0.3	2.39e-11	Neuroticism;
LGG	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs365132	1.000	rs2292256	chr5:176333126	C/T	cg16309518	chr5:176445507	NA	-0.55	-12.22	-0.49	5.86e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2640806	0.524	rs34690929	chr8:97363428	A/G	cg22138393	chr8:97340270	PTDSS1	0.28	7.2	0.32	2.53e-12	Obesity-related traits;
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg12395012	chr8:11607386	GATA4	0.37	6.96	0.31	1.15e-11	Neuroticism;
LGG	cis	rs2287838	0.668	rs12979274	chr19:10000925	A/G	cg07950397	chr19:10022659	OLFM2	-0.29	-6.77	-0.3	3.9e-11	Sleep duration;
LGG	cis	rs12143943	0.834	rs34812029	chr1:204546987	A/G	cg20240347	chr1:204465584	NA	-0.34	-7.45	-0.33	4.49e-13	Cognitive performance;
LGG	cis	rs921968	0.643	rs563268	chr2:219372912	T/G	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Vitiligo;
LGG	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg01043669	chr3:72786069	NA	-0.42	-6.97	-0.31	1.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	8.93	0.38	1.03e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4262150	0.883	rs55967446	chr5:152207140	G/T	cg12297329	chr5:152029980	NA	-0.67	-12.46	-0.5	6.02e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.71	-0.34	8.03e-14	Gut microbiome composition (summer);
LGG	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg16386425	chr10:429943	DIP2C	-0.36	-7.24	-0.32	1.84e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs4906332	1.000	rs28711288	chr14:103906126	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.8e-14	Coronary artery disease;
LGG	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg00784671	chr22:46762841	CELSR1	-0.59	-7.51	-0.33	3.07e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg11473876	chr11:109292803	C11orf87	0.45	9.13	0.39	2.13e-18	Schizophrenia;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07234876	chr8:600039	NA	1.17	11.6	0.47	1.78e-27	IgG glycosylation;
LGG	cis	rs10744422	0.800	rs7138436	chr12:123223920	G/T	cg25930673	chr12:123319894	HIP1R	-0.72	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.43e-18	Gut microbiome composition (summer);
LGG	cis	rs73086581	1.000	rs6052196	chr20:3945824	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg24998770	chr7:37888106	TXNDC3	-0.49	-7.97	-0.35	1.22e-14	Alzheimer's disease (late onset);
LGG	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.12	0.39	2.36e-18	Motion sickness;
LGG	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg15395560	chr15:45543142	SLC28A2	0.42	6.92	0.31	1.51e-11	Glomerular filtration rate;
LGG	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg23782820	chr8:58130467	NA	0.5	7.67	0.34	1e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.48	-0.4	1.34e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.77	0.34	5.05e-14	Glycated hemoglobin levels;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg16270222	chr17:41446396	NA	-0.3	-7.24	-0.32	1.88e-12	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05231509	chr11:108094111	ATM;NPAT	0.44	7.12	0.31	4.16e-12	Cognitive performance;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg06112835	chr11:68658793	MRPL21	0.64	10.29	0.43	1.73e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	trans	rs1459104	0.704	rs12806568	chr11:54892378	G/A	cg15704280	chr7:45808275	SEPT13	0.79	7.71	0.34	7.7e-14	Body mass index;
LGG	cis	rs953492	0.624	rs4469702	chr1:243365196	T/C	cg02356786	chr1:243265016	LOC731275	-0.38	-6.69	-0.3	6.43e-11	Diastolic blood pressure;
LGG	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.1e-100	Height;
LGG	cis	rs4936894	0.500	rs11602188	chr11:124167145	A/G	cg27160556	chr11:124181099	OR8D1	0.47	10.68	0.44	6.02e-24	Aging (time to death);
LGG	cis	rs4704187	0.687	rs13360638	chr5:74433258	G/A	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-7.21	-0.32	2.26e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1345301	1.000	rs1345301	chr2:102875587	A/G	cg05295703	chr2:102895712	NA	0.38	7.73	0.34	6.89e-14	Waist circumference;
LGG	trans	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg08344181	chr3:125677491	NA	-0.6	-6.7	-0.3	6.08e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg00599393	chr8:22457479	C8orf58	-0.47	-8.67	-0.37	7.38e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg24596788	chr1:163392923	NA	-0.65	-12.06	-0.49	2.63e-29	Motion sickness;
LGG	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg21605333	chr4:119757512	SEC24D	1.18	12.42	0.5	8.79e-31	Cannabis dependence symptom count;
LGG	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	24.64	0.75	2.77e-86	IgG glycosylation;
LGG	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-12.04	-0.49	3.12e-29	Hemoglobin concentration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14986359	chr19:59085030	MZF1;LOC100131691	0.45	7.27	0.32	1.5e-12	Cognitive performance;
LGG	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	cg07245641	chr1:182991651	LAMC1	0.4	9.06	0.39	3.64e-18	Colorectal cancer;
LGG	cis	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg19338460	chr6:170058176	WDR27	-0.87	-9.11	-0.39	2.49e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.49	-0.33	3.49e-13	Joint mobility (Beighton score);
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.48	0.4	1.28e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs45430	1.000	rs443099	chr21:42743327	G/T	cg06102954	chr21:42741788	MX2	0.39	7.32	0.32	1.08e-12	Melanoma;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.43	7.13	0.31	3.97e-12	Lymphocyte counts;
LGG	cis	rs6860806	0.531	rs274556	chr5:131722075	A/G	cg07395648	chr5:131743802	NA	0.49	9.97	0.42	2.5e-21	Breast cancer;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg04503457	chr17:41445688	NA	-0.39	-9.18	-0.39	1.47e-18	Menopause (age at onset);
LGG	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg23625390	chr15:77176239	SCAPER	-0.7	-13.83	-0.54	1.21e-36	Blood metabolite levels;
LGG	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg00677455	chr12:58241039	CTDSP2	0.44	8.14	0.35	3.77e-15	Multiple sclerosis;
LGG	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.16	-0.35	3.28e-15	HDL cholesterol;
LGG	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg21427119	chr20:30132790	HM13	0.43	7.31	0.32	1.2e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7011049	0.778	rs118059348	chr8:53865777	C/T	cg26025543	chr8:53854495	NA	0.64	8.93	0.38	1.01e-17	Systolic blood pressure;
LGG	trans	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.27	-0.32	1.49e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.13	-0.46	1.19e-25	Hemoglobin concentration;
LGG	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg08668359	chr10:1443807	ADARB2	0.65	12.25	0.49	4.6e-30	Radiation response;
LGG	cis	rs1124376	0.935	rs56117426	chr3:20094236	C/T	cg05072819	chr3:20081367	KAT2B	0.67	8.53	0.37	2.17e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg02297831	chr4:17616191	MED28	0.5	9.15	0.39	1.78e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg08200770	chr17:80723486	TBCD	-0.45	-8.01	-0.35	9.22e-15	Glycated hemoglobin levels;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg09033563	chr22:24373618	LOC391322	-0.53	-8.92	-0.38	1.07e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6714710	0.603	rs17489454	chr2:98407350	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs17208368	0.628	rs4784473	chr16:55093016	C/T	cg11181171	chr16:55090946	NA	0.46	7.59	0.33	1.77e-13	Hypospadias;
LGG	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-11.41	-0.47	9.39e-27	Morning vs. evening chronotype;
LGG	cis	rs34599045	0.614	rs36033488	chr1:152860594	T/C	cg07796016	chr1:152779584	LCE1C	-0.93	-9.22	-0.39	1.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs4330281	0.692	rs4312680	chr3:17788430	G/A	cg20981856	chr3:17787350	NA	-0.4	-7.24	-0.32	1.84e-12	Schizophrenia;
LGG	trans	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg26043149	chr18:55253948	FECH	0.92	15.81	0.59	2.35e-45	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg09263875	chr16:632152	PIGQ	0.64	12.63	0.51	1.21e-31	Height;
LGG	cis	rs4740619	0.682	rs3824502	chr9:16016557	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.7	-0.45	4.99e-24	Body mass index;
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg13009111	chr11:71350975	NA	-0.33	-7.18	-0.32	2.88e-12	Triglycerides;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00684032	chr4:1343700	KIAA1530	0.66	13.69	0.54	4.63e-36	Obesity-related traits;
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg23978390	chr7:1156363	C7orf50	0.44	7.21	0.32	2.3e-12	Longevity;Endometriosis;
LGG	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg05791153	chr7:19748676	TWISTNB	0.77	10.4	0.44	6.32e-23	Thyroid stimulating hormone;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05025164	chr4:1340916	KIAA1530	0.86	16.97	0.62	1.43e-50	Longevity;
LGG	trans	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg25214090	chr10:38739885	LOC399744	0.71	11.73	0.48	5.26e-28	Corneal astigmatism;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.95	0.31	1.25e-11	Lung cancer;
LGG	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-15.78	-0.59	3.43e-45	Gallbladder cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04910183	chr1:193090988	CDC73	-0.47	-6.84	-0.3	2.57e-11	Systemic lupus erythematosus;
LGG	cis	rs870825	0.549	rs28542773	chr4:185617935	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02119073	chr17:77984409	TBC1D16	0.37	6.73	0.3	4.92e-11	Menarche (age at onset);
LGG	cis	rs8017423	0.647	rs12882973	chr14:90820502	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.64	-0.33	1.27e-13	Triglycerides;
LGG	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg22676075	chr6:135203613	NA	-0.48	-8.41	-0.36	5.25e-16	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg05556477	chr5:131705319	SLC22A5	-0.78	-9.75	-0.41	1.48e-20	Rheumatoid arthritis;
LGG	cis	rs3862030	0.720	rs11593583	chr10:104228149	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.53	9.81	0.41	8.79e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg19847130	chr8:10466454	RP1L1	-0.31	-6.71	-0.3	5.7e-11	Mood instability;
LGG	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.3	0.32	1.3e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg06521331	chr12:34319734	NA	-0.44	-7.64	-0.33	1.24e-13	Heart rate;
LGG	cis	rs7937890	0.559	rs2575831	chr11:14486194	A/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg27624424	chr6:160112604	SOD2	0.65	9.27	0.4	6.84e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg04731861	chr2:219085781	ARPC2	0.29	6.91	0.31	1.59e-11	Ulcerative colitis;
LGG	cis	rs35740288	0.770	rs11631386	chr15:86191995	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.6	0.37	1.26e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.95	-0.31	1.26e-11	Longevity;Endometriosis;
LGG	cis	rs7119	0.717	rs12910594	chr15:77817103	G/A	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg18681998	chr4:17616180	MED28	0.82	18.14	0.64	5.8e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4776059	0.798	rs4774634	chr15:52872488	G/C	cg22715398	chr15:52968154	KIAA1370	-0.45	-6.96	-0.31	1.2e-11	Schizophrenia;
LGG	cis	rs3820068	0.705	rs4646096	chr1:15820758	A/G	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.01	-0.31	8.27e-12	Menopause (age at onset);
LGG	cis	rs4262150	0.658	rs2964223	chr5:151940822	C/T	cg12297329	chr5:152029980	NA	-0.66	-12.43	-0.5	7.95e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9807989	0.507	rs10204757	chr2:102998974	A/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg00666640	chr1:248458726	OR2T12	0.55	8.75	0.38	3.92e-17	Common traits (Other);
LGG	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg02002194	chr4:3960332	NA	0.49	9.16	0.39	1.66e-18	Neuroticism;
LGG	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg05484508	chr16:89589025	SPG7	0.47	7.78	0.34	4.88e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.17	0.32	2.97e-12	Height;
LGG	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06634786	chr22:41940651	POLR3H	0.73	12.19	0.49	8e-30	Vitiligo;
LGG	cis	rs4566357	0.615	rs10178260	chr2:227914458	G/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.09	-0.39	2.9e-18	Coronary artery disease;
LGG	cis	rs12200782	0.510	rs9467738	chr6:26382181	T/C	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs7326068	0.558	rs8002588	chr13:21339386	A/G	cg04906043	chr13:21280425	IL17D	-0.51	-8.13	-0.35	3.96e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg08499158	chr17:42289980	UBTF	-0.39	-7.17	-0.32	2.9e-12	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.52	-0.53	2.37e-35	Personality dimensions;
LGG	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg07936489	chr17:37558343	FBXL20	-0.99	-15.28	-0.58	5.95e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.17	0.87	4.28e-145	Chronic sinus infection;
LGG	cis	rs4742903	0.967	rs4742904	chr9:106856952	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.59	0.37	1.37e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg24231037	chr15:68117551	LBXCOR1	0.37	8.05	0.35	7.15e-15	Restless legs syndrome;
LGG	cis	rs7172677	0.691	rs12901092	chr15:75374145	C/A	cg14664628	chr15:75095509	CSK	0.43	8.13	0.35	3.86e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7481584	0.924	rs4758502	chr11:2998461	C/T	cg08508325	chr11:3079039	CARS	0.38	6.99	0.31	9.42e-12	Calcium levels;
LGG	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg13010199	chr12:38710504	ALG10B	-0.65	-13.73	-0.54	3.1e-36	Bladder cancer;
LGG	cis	rs4595586	0.525	rs35046524	chr12:39414535	A/G	cg26384229	chr12:38710491	ALG10B	0.69	12.69	0.51	7.25e-32	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg00717180	chr2:96193071	NA	-0.43	-7.71	-0.34	7.5e-14	Height;
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg03264133	chr6:25882463	NA	-0.43	-7.7	-0.34	8.26e-14	Height;
LGG	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.35	0.36	7.69e-16	Neuroticism;
LGG	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg21211680	chr2:198530	NA	-1.16	-19.42	-0.67	6.98e-62	Blood protein levels;
LGG	cis	rs7166081	1.000	rs8025621	chr15:67556726	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.98	-0.31	1.03e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs72925845	0.524	rs690790	chr17:76426179	T/C	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.79	-0.57	8.48e-41	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg04863758	chr4:1303710	MAEA	0.45	7.54	0.33	2.53e-13	Obesity-related traits;
LGG	cis	rs962528	0.701	rs34362681	chr2:6696178	A/C	cg20510474	chr2:6675896	NA	0.33	6.66	0.3	7.66e-11	Visceral fat;
LGG	cis	rs9359856	0.564	rs6914142	chr6:90398903	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.74	-0.41	1.57e-20	Bipolar disorder;
LGG	cis	rs9790314	0.704	rs4618258	chr3:160869129	G/C	cg04691961	chr3:161091175	C3orf57	-0.51	-11.05	-0.46	2.41e-25	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.72	-0.34	7.36e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19524238	chr7:2802976	GNA12	0.37	8.69	0.37	6.12e-17	Height;
LGG	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg13010199	chr12:38710504	ALG10B	0.47	9.17	0.39	1.53e-18	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.812	rs13084436	chr3:42017537	T/A	cg03022575	chr3:42003672	ULK4	-0.62	-7.64	-0.33	1.22e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg15763984	chr4:1342303	KIAA1530	0.38	6.79	0.3	3.55e-11	Obesity-related traits;
LGG	cis	rs526231	0.511	rs10515341	chr5:102317117	G/A	cg23492399	chr5:102201601	PAM	-0.62	-9.26	-0.4	7.74e-19	Primary biliary cholangitis;
LGG	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.45	0.44	4.26e-23	Dupuytren's disease;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.63	0.54	8.58e-36	Lung cancer;
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25517755	chr10:38738941	LOC399744	-0.35	-6.73	-0.3	5.17e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg26384229	chr12:38710491	ALG10B	0.75	15.15	0.58	2.15e-42	Heart rate;
LGG	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg17802220	chr15:77601643	NA	-0.54	-12.0	-0.49	4.45e-29	Type 2 diabetes;
LGG	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg15704280	chr7:45808275	SEPT13	0.5	8.02	0.35	8.78e-15	HDL cholesterol;
LGG	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg20991723	chr1:152506922	NA	-0.72	-14.87	-0.57	3.72e-41	Hair morphology;
LGG	cis	rs4713675	0.565	rs6904816	chr6:33676156	G/A	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.79e-11	Plateletcrit;
LGG	cis	rs28374715	0.532	rs7164211	chr15:41705041	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.32	-34.11	-0.85	1.99e-128	Ulcerative colitis;
LGG	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg18252515	chr7:66147081	NA	-1.39	-18.77	-0.66	7.15e-59	Diabetic kidney disease;
LGG	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.9	0.45	9e-25	Bone mineral density;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg13206674	chr6:150067644	NUP43	0.66	14.72	0.56	1.68e-40	Lung cancer;
LGG	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg04398451	chr17:18023971	MYO15A	-0.67	-14.08	-0.55	9.87e-38	Total body bone mineral density;
LGG	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg08109568	chr15:31115862	NA	-0.54	-9.36	-0.4	3.46e-19	Huntington's disease progression;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg05084668	chr3:125655381	ALG1L	-0.57	-7.72	-0.34	7.02e-14	Blood pressure (smoking interaction);
LGG	cis	rs7537765	0.696	rs55788159	chr1:11897926	T/C	cg02448276	chr1:11845238	NA	-0.56	-7.6	-0.33	1.64e-13	QRS complex (12-leadsum);
LGG	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg19847130	chr8:10466454	RP1L1	0.35	7.55	0.33	2.28e-13	Neuroticism;
LGG	cis	rs6430585	0.528	rs309172	chr2:136674028	A/G	cg07169764	chr2:136633963	MCM6	1.22	24.08	0.75	1.12e-83	Corneal structure;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07791516	chr6:150247246	NA	0.31	6.84	0.3	2.5e-11	Testicular germ cell tumor;
LGG	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg18876405	chr7:65276391	NA	0.67	12.82	0.51	2.16e-32	Calcium levels;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg14668632	chr7:2872130	GNA12	-0.37	-7.68	-0.34	9.4e-14	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15868421	chr11:46368810	DGKZ	0.5	7.66	0.34	1.11e-13	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg01966878	chr4:90757139	SNCA	-0.37	-7.55	-0.33	2.29e-13	Dementia with Lewy bodies;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg19318889	chr4:1322082	MAEA	0.47	8.11	0.35	4.56e-15	Longevity;
LGG	cis	rs73086581	0.945	rs6037715	chr20:3972166	A/T	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg16586182	chr3:47516702	SCAP	0.77	15.17	0.58	1.73e-42	Colorectal cancer;
LGG	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-7.15	-0.32	3.41e-12	Menarche (age at onset);
LGG	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.48	-0.37	3.16e-16	Response to antipsychotic treatment;
LGG	cis	rs308971	0.563	rs2600229	chr3:12038453	A/T	cg15873301	chr3:12045459	SYN2	0.52	6.79	0.3	3.39e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.23	0.39	9.89e-19	Life satisfaction;
LGG	cis	rs6429082	0.689	rs10802803	chr1:235709610	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.54	-8.33	-0.36	8.95e-16	Adiposity;
LGG	cis	rs7638995	0.617	rs9842761	chr3:69194345	C/A	cg26574240	chr3:69171822	LMOD3	0.61	9.93	0.42	3.39e-21	Alzheimer's disease (late onset);
LGG	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg02151108	chr14:50098012	C14orf104	-0.49	-10.45	-0.44	4.4e-23	Carotid intima media thickness;
LGG	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.88	-0.38	1.44e-17	Retinal vascular caliber;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.25	0.36	1.66e-15	Schizophrenia;
LGG	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg22437258	chr11:111473054	SIK2	0.56	9.8	0.41	9.73e-21	Primary sclerosing cholangitis;
LGG	trans	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg07211511	chr3:129823064	LOC729375	-1.19	-17.67	-0.63	8.42e-54	Blood pressure (smoking interaction);
LGG	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.63	-0.33	1.39e-13	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.49	-7.89	-0.34	2.12e-14	Longevity;
LGG	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.69	10.16	0.43	5.14e-22	Homoarginine levels;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg11050988	chr7:1952600	MAD1L1	-0.39	-9.26	-0.4	7.53e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg25039879	chr17:56429692	SUPT4H1	0.63	8.84	0.38	2.09e-17	Cognitive test performance;
LGG	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg21775007	chr8:11205619	TDH	0.75	13.05	0.52	2.39e-33	Retinal vascular caliber;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.76	-0.41	1.32e-20	Personality dimensions;
LGG	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.44	-0.33	4.83e-13	Hemoglobin concentration;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg24642439	chr20:33292090	TP53INP2	0.47	7.68	0.34	9.56e-14	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22493809	chr1:120838387	FAM72B	0.47	7.63	0.33	1.32e-13	Cognitive performance;
LGG	cis	rs254781	0.527	rs254778	chr5:88009593	A/G	cg22951263	chr5:87985283	NA	0.42	6.69	0.3	6.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg07460842	chr6:66804631	NA	-0.69	-12.75	-0.51	4.19e-32	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs2013441	0.901	rs2526474	chr17:20137134	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg04166393	chr7:2884313	GNA12	0.37	7.16	0.32	3.15e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg13385521	chr17:29058706	SUZ12P	0.82	9.99	0.42	2.06e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg02297831	chr4:17616191	MED28	-0.46	-8.56	-0.37	1.65e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.99	0.45	4.07e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs782590	0.643	rs13032503	chr2:55739093	C/T	cg18811423	chr2:55921094	PNPT1	-0.68	-12.1	-0.49	1.85e-29	Metabolic syndrome;
LGG	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg27087555	chr16:88793112	FAM38A	-1.42	-18.3	-0.65	1.04e-56	Plateletcrit;
LGG	cis	rs9911578	0.967	rs2429369	chr17:56501420	A/G	cg12560992	chr17:57184187	TRIM37	0.87	15.19	0.58	1.43e-42	Intelligence (multi-trait analysis);
LGG	cis	rs11225247	1.000	rs11605133	chr11:102321203	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.93	0.31	1.42e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs17253792	1.000	rs28616134	chr14:56178802	G/A	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.64e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1355223	0.867	rs1377495	chr11:34682962	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.74	0.3	4.66e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg23594656	chr7:65796392	TPST1	0.39	8.54	0.37	1.96e-16	Aortic root size;
LGG	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg19049858	chr12:53661747	ESPL1	-0.37	-6.74	-0.3	4.69e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-6.9	-0.31	1.73e-11	Height;
LGG	cis	rs208520	0.690	rs1351867	chr6:66760995	A/G	cg07460842	chr6:66804631	NA	0.96	18.02	0.64	2.24e-55	Exhaled nitric oxide output;
LGG	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg16230307	chr14:35515116	FAM177A1	0.58	9.17	0.39	1.51e-18	Psoriasis;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg22907277	chr7:1156413	C7orf50	0.82	11.31	0.47	2.42e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg20302533	chr7:39170763	POU6F2	0.32	7.74	0.34	6.48e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	1.000	rs7073432	chr10:75953350	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.15	0.46	9.44e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg08975724	chr8:8085496	FLJ10661	0.56	11.6	0.47	1.77e-27	Mood instability;
LGG	trans	rs6787172	0.702	rs2682405	chr3:157993838	G/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg02725872	chr8:58115012	NA	-0.95	-14.1	-0.55	7.75e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs11676348	0.755	rs1008562	chr2:219026972	G/C	cg00012203	chr2:219082015	ARPC2	0.55	10.01	0.42	1.72e-21	Ulcerative colitis;
LGG	cis	rs28588043	1.000	rs28581981	chr1:170976565	G/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.47	-0.33	3.97e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2070433	0.706	rs3788265	chr21:47833789	G/T	cg12379764	chr21:47803548	PCNT	0.66	9.09	0.39	2.98e-18	Lymphocyte counts;
LGG	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg11764359	chr7:65958608	NA	-0.73	-12.47	-0.5	5.66e-31	Aortic root size;
LGG	cis	rs3767633	0.800	rs6685369	chr1:161754834	T/C	cg09175582	chr1:161736000	ATF6	0.66	8.24	0.36	1.72e-15	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7851660	0.967	rs12348691	chr9:100608682	G/A	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.58e-40	Strep throat;
LGG	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.19e-18	Motion sickness;
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	17.2	0.62	1.31e-51	Personality dimensions;
LGG	cis	rs9467160	0.581	rs2760144	chr6:24479197	A/G	cg20631270	chr6:24437470	GPLD1	0.44	7.03	0.31	7.27e-12	Liver enzyme levels;
LGG	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg00857998	chr1:205179979	DSTYK	0.57	9.23	0.39	9.79e-19	Red blood cell count;
LGG	cis	rs4363385	0.510	rs10494282	chr1:152923762	G/C	cg13444842	chr1:152974279	SPRR3	-0.48	-9.55	-0.41	7.71e-20	Inflammatory skin disease;
LGG	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg26384229	chr12:38710491	ALG10B	0.75	14.97	0.57	1.39e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.6	-0.33	1.61e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7020830	0.789	rs17408112	chr9:37114065	A/G	cg14294708	chr9:37120828	ZCCHC7	1.17	34.61	0.85	1.66e-130	Schizophrenia;
LGG	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18018828	chr7:79081791	MAGI2	0.44	7.08	0.31	5.23e-12	Cognitive performance;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg05861140	chr6:150128134	PCMT1	-0.35	-6.72	-0.3	5.24e-11	Lung cancer;
LGG	cis	rs16912285	0.535	rs7109619	chr11:24251339	G/A	ch.11.24196551F	chr11:24239977	NA	0.93	14.11	0.55	7.4e-38	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs3106136	0.527	rs2632411	chr4:95149434	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.06	-0.46	2.14e-25	Capecitabine sensitivity;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	7.96	0.35	1.31e-14	Retinal vascular caliber;
LGG	cis	rs7226408	0.600	rs9304167	chr18:34557276	T/G	cg15022739	chr18:34823045	BRUNOL4	0.42	9.1	0.39	2.67e-18	Obesity-related traits;
LGG	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg03511173	chr18:77590860	NA	0.6	7.38	0.32	7.43e-13	Opioid sensitivity;
LGG	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg03511173	chr18:77590860	NA	0.43	7.22	0.32	2.2e-12	Schizophrenia;
LGG	cis	rs60180747	0.544	rs11635867	chr15:66571246	T/C	cg07575407	chr15:66541975	MEGF11	0.63	13.64	0.54	7.88e-36	Testicular germ cell tumor;
LGG	cis	rs2273669	0.915	rs6928200	chr6:109294164	A/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg17294928	chr15:75287854	SCAMP5	-0.91	-16.85	-0.62	4.89e-50	Blood trace element (Zn levels);
LGG	cis	rs944722	0.901	rs1060826	chr17:26089867	T/C	cg07704981	chr17:26127537	NOS2	-0.48	-8.4	-0.36	5.37e-16	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs7639513	0.767	rs6784168	chr3:12702847	T/G	cg23032965	chr3:12705835	RAF1	0.84	16.23	0.6	3.25e-47	Itch intensity from mosquito bite;
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.09	0.35	5.35e-15	Prostate cancer;
LGG	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.17	0.39	1.59e-18	Neuroticism;
LGG	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg14893161	chr1:205819251	PM20D1	-0.44	-7.54	-0.33	2.49e-13	Menarche (age at onset);
LGG	cis	rs9462027	0.628	rs2744961	chr6:34655000	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.25	-0.43	2.41e-22	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.42	-0.33	5.56e-13	Triglycerides;
LGG	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg15704280	chr7:45808275	SEPT13	-0.63	-11.11	-0.46	1.34e-25	HDL cholesterol;
LGG	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg10760299	chr15:45669010	GATM	0.4	7.96	0.35	1.36e-14	Homoarginine levels;
LGG	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03352830	chr11:487213	PTDSS2	0.87	11.02	0.46	3.17e-25	Body mass index;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16955499	chr12:46766294	SLC38A2	0.45	6.89	0.3	1.87e-11	Gut microbiome composition (summer);
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.2	-0.36	2.37e-15	IgG glycosylation;
LGG	cis	rs977987	0.800	rs12922951	chr16:75355096	C/G	cg03315344	chr16:75512273	CHST6	0.5	10.09	0.42	8.87e-22	Dupuytren's disease;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg11062466	chr8:58055876	NA	0.51	7.8	0.34	4.05e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.3e-14	Calcium levels;
LGG	cis	rs7582720	0.561	rs114407963	chr2:204154677	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.27	0.4	6.87e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.38	-0.36	6.24e-16	Lung cancer;
LGG	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.69e-11	Schizophrenia;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg12070911	chr6:150209640	RAET1E	0.28	6.95	0.31	1.25e-11	Lung cancer;
LGG	cis	rs7666738	0.830	rs921521	chr4:98838339	A/G	cg05340658	chr4:99064831	C4orf37	0.49	8.12	0.35	4.16e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs523522	0.962	rs12814055	chr12:120987391	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.89	0.51	1.02e-32	High light scatter reticulocyte count;
LGG	cis	rs7177699	0.557	rs62011002	chr15:79120578	C/T	cg00540400	chr15:79124168	NA	0.54	11.53	0.47	3.34e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.68	-0.44	5.88e-24	Lung cancer;
LGG	trans	rs8073060	0.544	rs225246	chr17:33944773	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.69	-0.64	6.87e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs12144044	0.912	rs3806442	chr1:113249504	C/T	cg19507217	chr1:113251308	RHOC	-0.58	-10.51	-0.44	2.58e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.15e-11	Iron status biomarkers;
LGG	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg11161011	chr14:65562177	MAX	-0.63	-12.37	-0.5	1.42e-30	Obesity-related traits;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg00166722	chr3:10149974	C3orf24	0.52	8.77	0.38	3.56e-17	Alzheimer's disease;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.53	-9.56	-0.41	7.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08045932	chr20:61659980	NA	0.6	13.19	0.52	5.74e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06634786	chr22:41940651	POLR3H	-0.79	-12.68	-0.51	8.11e-32	Vitiligo;
LGG	cis	rs896854	0.846	rs2340584	chr8:95916811	A/G	cg16049864	chr8:95962084	TP53INP1	-0.37	-8.12	-0.35	4.2e-15	Type 2 diabetes;
LGG	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg05147244	chr20:61493195	TCFL5	-0.75	-7.25	-0.32	1.76e-12	Obesity-related traits;
LGG	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.08	-0.35	5.54e-15	IgG glycosylation;
LGG	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg22232500	chr2:134024266	NCKAP5	-0.55	-8.29	-0.36	1.2e-15	Bipolar disorder;
LGG	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.61	-12.39	-0.5	1.19e-30	Height;
LGG	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.13	-0.31	4e-12	Blood metabolite levels;
LGG	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg27478167	chr7:817139	HEATR2	-0.44	-6.97	-0.31	1.11e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs79146658	0.736	rs1565287	chr2:179735946	C/T	cg17765952	chr2:179737173	CCDC141	0.6	9.08	0.39	3.2e-18	Diastolic blood pressure;
LGG	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg15485101	chr11:133734466	NA	0.46	7.89	0.34	2.15e-14	Childhood ear infection;
LGG	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Lung cancer;
LGG	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg11279151	chr3:101281821	RG9MTD1	0.41	7.35	0.32	9.28e-13	Colorectal cancer;
LGG	cis	rs10274279	0.660	rs2021743	chr7:157381899	T/C	cg09270525	chr7:157391030	PTPRN2	0.82	13.45	0.53	4.61e-35	Myopia (pathological);
LGG	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg01420254	chr6:26195488	NA	0.57	8.49	0.37	2.92e-16	Gout;Renal underexcretion gout;
LGG	cis	rs68170813	0.605	rs74632724	chr7:107136759	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-9.91	-0.42	3.9e-21	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg08888203	chr3:10149979	C3orf24	-0.54	-9.38	-0.4	2.97e-19	Alzheimer's disease;
LGG	cis	rs12956009	0.559	rs12607072	chr18:44839888	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.87	0.3	2.1e-11	Educational attainment (years of education);
LGG	cis	rs2270450	0.650	rs1592704	chr6:46715761	T/A	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.51e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg25986240	chr4:9926439	SLC2A9	-0.44	-9.22	-0.39	1.05e-18	Bone mineral density;
LGG	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-13.31	-0.53	1.91e-34	Menarche (age at onset);
LGG	cis	rs3106136	0.967	rs61004493	chr4:95163317	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.15	-0.35	3.32e-15	Capecitabine sensitivity;
LGG	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg22903471	chr2:27725779	GCKR	0.39	8.68	0.37	6.89e-17	Oral cavity cancer;
LGG	cis	rs7188861	0.768	rs9939877	chr16:11396779	G/A	cg01510278	chr16:11456238	NA	0.31	7.4	0.33	6.55e-13	HDL cholesterol;
LGG	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg22852734	chr6:133119734	C6orf192	1.17	15.08	0.57	4.36e-42	Type 2 diabetes nephropathy;
LGG	trans	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.72	-0.41	1.87e-20	Bladder cancer;
LGG	cis	rs317865	0.737	rs73234667	chr4:16240097	T/G	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.75	7.46	0.33	4.19e-13	Kidney disease (early stage) in type 1 diabetes;
LGG	cis	rs9715521	0.900	rs72634623	chr4:59827419	T/C	cg11281224	chr4:60001000	NA	-0.43	-7.11	-0.31	4.5e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg21775007	chr8:11205619	TDH	0.47	7.63	0.33	1.37e-13	Mood instability;
LGG	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg00531865	chr16:30841666	NA	-0.52	-10.34	-0.43	1.14e-22	Multiple myeloma;
LGG	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-8.37	-0.36	6.88e-16	Aortic root size;
LGG	cis	rs2213920	0.680	rs7863450	chr9:118242611	G/C	cg13918206	chr9:118159781	DEC1	0.58	7.7	0.34	8.5e-14	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg26384229	chr12:38710491	ALG10B	0.61	10.95	0.45	5.89e-25	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs1620921	0.967	rs11902	chr6:161174871	C/G	cg01280913	chr6:161186852	NA	-0.37	-7.59	-0.33	1.75e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg05835009	chr4:710272	PCGF3	0.47	8.04	0.35	7.48e-15	White blood cell count;
LGG	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	6.67e-18	Motion sickness;
LGG	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.2	-0.36	2.37e-15	Glycated hemoglobin levels;
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-8.29	-0.36	1.2e-15	Electroencephalogram traits;
LGG	cis	rs6725517	0.737	rs7576788	chr2:25083310	A/G	cg04586622	chr2:25135609	ADCY3	0.36	9.93	0.42	3.44e-21	Breast cancer;
LGG	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg18252515	chr7:66147081	NA	-1.43	-20.72	-0.69	5.87e-68	Diabetic kidney disease;
LGG	cis	rs2860975	0.580	rs11572120	chr10:96815303	A/C	cg09036531	chr10:96991505	NA	-0.48	-8.43	-0.36	4.47e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-7.4	-0.33	6.35e-13	Hip circumference adjusted for BMI;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg02002194	chr4:3960332	NA	0.44	8.02	0.35	8.52e-15	Neuroticism;
LGG	cis	rs2120243	0.539	rs6801110	chr3:157084731	C/G	cg24825693	chr3:157122686	VEPH1	-0.51	-11.1	-0.46	1.55e-25	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg12193833	chr17:30244370	NA	-0.29	-6.94	-0.31	1.31e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4731207	0.724	rs2057907	chr7:124443684	G/A	cg05630886	chr7:124431682	NA	0.34	7.93	0.35	1.63e-14	Cutaneous malignant melanoma;
LGG	cis	rs12230513	0.732	rs60643523	chr12:55842928	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-11.08	-0.46	1.8e-25	Contrast sensitivity;
LGG	cis	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg11266682	chr4:10021025	SLC2A9	0.4	7.73	0.34	6.76e-14	Bone mineral density;
LGG	cis	rs6815814	0.768	rs6835514	chr4:38894380	C/T	cg06935464	chr4:38784597	TLR10	-0.44	-7.09	-0.31	5.02e-12	Breast cancer;
LGG	cis	rs6961069	0.837	rs1722505	chr7:80240689	T/C	cg04458919	chr7:80252533	CD36	-0.28	-6.65	-0.3	8.21e-11	Platelet count;
LGG	cis	rs7953508	0.636	rs10859535	chr12:93979892	A/G	cg18151635	chr12:93972918	NA	-0.48	-8.58	-0.37	1.39e-16	Pubertal anthropometrics;
LGG	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg17691542	chr6:26056736	HIST1H1C	0.54	9.74	0.41	1.64e-20	Height;
LGG	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs11877825	0.865	rs8098008	chr18:10569443	C/T	cg25239095	chr18:10589360	NA	0.49	9.2	0.39	1.28e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg08885076	chr2:99613938	TSGA10	-0.32	-6.7	-0.3	5.99e-11	Fear of minor pain;
LGG	cis	rs36051895	0.659	rs7036476	chr9:5063664	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-16.08	-0.6	1.45e-46	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.78	-0.3	3.68e-11	Lung cancer;
LGG	cis	rs2016266	0.752	rs10783562	chr12:53657467	G/A	cg04065151	chr12:53682969	ESPL1	-0.58	-9.58	-0.41	5.79e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	11.87	0.48	1.42e-28	Lung cancer in ever smokers;
LGG	cis	rs12615966	0.651	rs72830471	chr2:105407062	A/C	cg16465502	chr2:105461796	NA	0.99	11.3	0.46	2.59e-26	Pancreatic cancer;
LGG	cis	rs4430311	0.600	rs4603115	chr1:243816636	T/C	cg25706552	chr1:244017396	NA	-0.6	-13.15	-0.52	8.63e-34	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs11239187	0.530	rs10900070	chr10:45064840	A/G	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	trans	rs11989744	1.000	rs17782264	chr8:23570489	C/T	cg03492747	chr16:86543808	FOXF1	0.52	7.85	0.34	3e-14	Waist-hip ratio;
LGG	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08677398	chr8:58056175	NA	0.51	8.06	0.35	6.56e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2074585	0.583	rs28406958	chr15:91069364	C/A	cg22089800	chr15:90895588	ZNF774	-0.5	-8.19	-0.36	2.57e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs9287719	0.934	rs6432115	chr2:10748343	G/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg02153584	chr22:29168773	CCDC117	0.62	9.7	0.41	2.29e-20	Lymphocyte counts;
LGG	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.66e-12	Hair morphology;
LGG	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	9.46	0.4	1.53e-19	Bone mineral density;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.33	0.36	9.35e-16	Lung cancer;
LGG	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2905347	0.560	rs2961291	chr7:22681504	C/T	cg18045685	chr7:22629474	NA	-0.74	-16.01	-0.6	3.22e-46	Major depression and alcohol dependence;
LGG	cis	rs7017914	0.967	rs2732087	chr8:71860439	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.66	-0.3	7.92e-11	Bone mineral density;
LGG	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg04681579	chr7:75027559	TRIM73;TRIM74	-0.46	-7.81	-0.34	3.74e-14	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14082959	chr9:11618283	NA	0.38	7.04	0.31	6.84e-12	Menarche (age at onset);
LGG	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.24	0.32	1.84e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg08733933	chr1:2954429	NA	-0.4	-8.72	-0.38	4.92e-17	Plateletcrit;
LGG	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.02	0.57	7.65e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1620921	0.563	rs13217026	chr6:161269951	A/G	cg01280913	chr6:161186852	NA	-0.35	-7.1	-0.31	4.62e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1044826	0.597	rs1017468	chr3:139145778	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.89	0.31	1.81e-11	Obesity-related traits;
LGG	cis	rs1506636	0.962	rs2456551	chr7:123394610	C/G	cg03229431	chr7:123269106	ASB15	0.73	18.17	0.65	4.5e-56	Plateletcrit;Platelet count;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13012494	chr21:47604986	C21orf56	0.49	8.18	0.36	2.78e-15	Testicular germ cell tumor;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg06968155	chr5:131705112	SLC22A5	0.75	8.62	0.37	1.1e-16	Rheumatoid arthritis;
LGG	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg24250549	chr1:154909240	PMVK	0.53	9.53	0.41	8.76e-20	Prostate cancer;
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	11.07	0.46	2.05e-25	Personality dimensions;
LGG	cis	rs12464559	0.649	rs6708645	chr2:152620387	A/T	cg01189475	chr2:152685088	ARL5A	0.74	6.73	0.3	4.97e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6681460	0.625	rs6680364	chr1:67104834	G/A	cg13052034	chr1:66999238	SGIP1	0.35	6.91	0.31	1.66e-11	Presence of antiphospholipid antibodies;
LGG	trans	rs9354308	0.764	rs9342511	chr6:66589672	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg19507638	chr5:93509721	C5orf36	0.4	6.72	0.3	5.36e-11	Diabetic retinopathy;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.71	-0.54	3.62e-36	Tonsillectomy;
LGG	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg11673840	chr17:47092156	IGF2BP1	-0.38	-6.85	-0.3	2.37e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs62380364	0.602	rs11743441	chr5:88065637	G/T	cg22951263	chr5:87985283	NA	-0.55	-10.05	-0.42	1.23e-21	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg22089800	chr15:90895588	ZNF774	-0.67	-12.27	-0.5	3.79e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg09021430	chr5:549028	NA	-0.69	-9.72	-0.41	1.91e-20	Obesity-related traits;
LGG	cis	rs3849046	0.790	rs13187637	chr5:137876651	T/C	cg10920316	chr5:137946599	NA	0.42	6.72	0.3	5.27e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.15	0.46	9.6e-26	Hemoglobin concentration;
LGG	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg15704280	chr7:45808275	SEPT13	0.84	8.83	0.38	2.18e-17	Myopia (pathological);
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg04287289	chr16:89883240	FANCA	0.86	8.22	0.36	2.04e-15	Skin colour saturation;
LGG	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg14593290	chr7:50529359	DDC	0.65	11.81	0.48	2.49e-28	Malaria;
LGG	cis	rs12410462	0.551	rs12085546	chr1:227886463	C/T	cg23173402	chr1:227635558	NA	0.36	6.75	0.3	4.4e-11	Major depressive disorder;
LGG	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13798302	chr4:100870323	LOC256880;H2AFZ	0.47	7.24	0.32	1.83e-12	Gut microbiome composition (summer);
LGG	cis	rs7100689	0.577	rs1417219	chr10:82041409	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.35	0.55	6.98e-39	Post bronchodilator FEV1;
LGG	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg17971929	chr21:40555470	PSMG1	-0.5	-8.18	-0.36	2.82e-15	Menarche (age at onset);
LGG	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg02269571	chr22:50332266	NA	-0.8	-9.78	-0.41	1.16e-20	Mean platelet volume;
LGG	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg02297831	chr4:17616191	MED28	0.46	8.22	0.36	2.1e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.12	-0.31	4.2e-12	Obesity-related traits;
LGG	cis	rs227808	0.680	rs9472323	chr6:44647119	C/T	cg18551225	chr6:44695536	NA	0.48	7.02	0.31	7.97e-12	Male-pattern baldness;
LGG	cis	rs6586163	0.872	rs7082720	chr10:90742049	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.41	-7.22	-0.32	2.09e-12	Chronic lymphocytic leukemia;
LGG	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg09873164	chr1:152488093	CRCT1	0.57	11.64	0.48	1.18e-27	Hair morphology;
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg21017887	chr14:105400489	NA	-0.39	-7.53	-0.33	2.69e-13	Rheumatoid arthritis;
LGG	cis	rs4774899	1.000	rs12900986	chr15:57258736	C/G	cg08128148	chr15:57256372	TCF12	0.34	8.04	0.35	7.68e-15	Urinary tract infection frequency;
LGG	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg20387954	chr3:183756860	HTR3D	0.45	8.58	0.37	1.39e-16	Anterior chamber depth;
LGG	cis	rs9443645	0.901	rs9352667	chr6:79572296	A/G	cg18132916	chr6:79620363	NA	0.32	8.71	0.38	5.32e-17	Intelligence (multi-trait analysis);
LGG	cis	rs77669868	0.810	rs686494	chr11:114070160	A/G	cg01914181	chr11:114070210	ZBTB16	-0.53	-7.09	-0.31	5.19e-12	Monocyte percentage of white cells;
LGG	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.85e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17453880	0.890	rs11167585	chr5:152029577	A/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg06271696	chr7:157225062	NA	-0.54	-11.39	-0.47	1.16e-26	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.77e-14	Iron status biomarkers;
LGG	cis	rs920590	0.704	rs7008703	chr8:19656648	C/T	cg03894339	chr8:19674705	INTS10	0.45	7.6	0.33	1.65e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-12.89	-0.51	1.08e-32	Blood metabolite levels;
LGG	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.16e-17	Cognitive test performance;
LGG	cis	rs9863	0.861	rs7131882	chr12:124426736	C/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.32	-0.32	1.08e-12	White blood cell count;
LGG	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg08916839	chr5:415575	AHRR	0.99	14.25	0.55	1.88e-38	Fat distribution (HIV);
LGG	cis	rs9815354	1.000	rs4973991	chr3:41927273	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18299363	chr10:103816089	C10orf76	0.46	7.7	0.34	8.28e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.07	0.42	1.06e-21	Joint mobility (Beighton score);
LGG	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg21385522	chr1:16154831	NA	0.45	7.41	0.33	6.02e-13	Dilated cardiomyopathy;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-10.03	-0.42	1.5e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7246760	1.000	rs12462027	chr19:9926860	G/A	cg16876255	chr19:9731953	ZNF561	0.77	7.11	0.31	4.47e-12	Pursuit maintenance gain;
LGG	cis	rs4356975	0.583	rs4351080	chr4:69972319	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs564799	0.966	rs545143	chr3:159731995	A/G	cg04855961	chr3:159719849	NA	0.28	7.68	0.34	9.5e-14	Systemic lupus erythematosus;
LGG	cis	rs2544527	0.635	rs2693008	chr2:15913019	C/G	cg26669897	chr2:15909070	NA	-0.35	-8.62	-0.37	1.04e-16	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs920590	0.502	rs2035891	chr8:19634395	G/C	cg03894339	chr8:19674705	INTS10	0.44	7.49	0.33	3.53e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7267979	0.932	rs446649	chr20:25467359	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.0	0.42	1.88e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs67311347	0.577	rs1880763	chr3:40283255	C/T	cg13683864	chr3:40499215	RPL14	0.76	14.54	0.56	1.03e-39	Renal cell carcinoma;
LGG	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.63	0.41	3.99e-20	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03073402	chr19:42927676	LIPE	0.38	6.86	0.3	2.26e-11	Gut microbiome composition (summer);
LGG	trans	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.9	0.31	1.77e-11	Recombination measurement;
LGG	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.51e-21	Colorectal cancer;
LGG	cis	rs2075423	1.000	rs2075423	chr1:214154719	A/C	cg00795024	chr1:214157026	NA	-0.35	-9.8	-0.41	9.88e-21	Type 2 diabetes;
LGG	cis	rs3847687	0.966	rs3847689	chr12:131525534	T/G	cg06093039	chr12:131527216	GPR133	0.29	7.47	0.33	4.02e-13	Longevity;
LGG	cis	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg21605333	chr4:119757512	SEC24D	0.73	8.31	0.36	1.1e-15	Cannabis dependence symptom count;
LGG	cis	rs883565	0.502	rs4496420	chr3:38942716	A/C	cg01426195	chr3:39028469	NA	0.57	11.84	0.48	1.9e-28	Handedness;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.56	0.41	6.93e-20	Bipolar disorder;
LGG	cis	rs7953508	0.750	rs7310512	chr12:93976703	C/T	cg18151635	chr12:93972918	NA	-0.46	-8.29	-0.36	1.2e-15	Pubertal anthropometrics;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.22	-0.32	2.18e-12	Lung cancer;
LGG	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.43	-6.88	-0.3	1.97e-11	Cognitive ability;
LGG	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg08885076	chr2:99613938	TSGA10	0.38	8.19	0.36	2.54e-15	Chronic sinus infection;
LGG	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg01620082	chr3:125678407	NA	-0.83	-9.66	-0.41	3.22e-20	Breast cancer;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg21948465	chr5:131705150	SLC22A5	0.64	7.22	0.32	2.13e-12	Rheumatoid arthritis;
LGG	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg20503657	chr10:835505	NA	0.54	7.08	0.31	5.29e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg27432699	chr2:27873401	GPN1	-0.49	-8.29	-0.36	1.2e-15	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg27165867	chr14:105738592	BRF1	-0.46	-7.83	-0.34	3.46e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6840360	0.642	rs11099815	chr4:152343888	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	6.93	0.31	1.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg20026190	chr17:76395443	PGS1	0.57	10.0	0.42	1.9e-21	HDL cholesterol levels;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg06916706	chr16:4465613	CORO7	-0.84	-14.19	-0.55	3.39e-38	Schizophrenia;
LGG	cis	rs34172651	0.837	rs12596793	chr16:24823667	C/G	cg02428538	chr16:24856791	SLC5A11	-0.42	-7.22	-0.32	2.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7928758	0.887	rs34702205	chr11:134270721	G/A	cg25213107	chr11:134282864	B3GAT1	1.12	13.63	0.54	8.62e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg03433033	chr1:76189801	ACADM	-0.64	-9.12	-0.39	2.31e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg00666640	chr1:248458726	OR2T12	0.59	9.38	0.4	2.86e-19	Common traits (Other);
LGG	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6867032	0.527	rs4975792	chr5:2010496	T/G	cg26168224	chr5:2018326	NA	0.92	17.26	0.63	7.01e-52	Gut microbiome composition (winter);
LGG	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg20608306	chr11:116969690	SIK3	0.35	10.46	0.44	4.01e-23	Blood protein levels;
LGG	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg10523679	chr1:76189770	ACADM	0.81	15.45	0.58	9.91e-44	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8072100	0.875	rs4794047	chr17:45763005	A/T	cg08085267	chr17:45401833	C17orf57	0.53	10.53	0.44	2.12e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7247513	0.856	rs2162863	chr19:12699777	G/T	cg01871581	chr19:12707946	ZNF490	-0.45	-9.19	-0.39	1.33e-18	Bipolar disorder;
LGG	cis	rs7149337	0.836	rs11622116	chr14:51670744	C/T	cg23942311	chr14:51606299	NA	0.33	7.16	0.32	3.18e-12	Cancer;
LGG	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg17294928	chr15:75287854	SCAMP5	0.66	12.24	0.49	4.66e-30	Breast cancer;
LGG	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-8.05	-0.35	7.14e-15	Body mass index;
LGG	cis	rs7172689	1.000	rs57131042	chr15:81538554	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.41	-0.44	6.19e-23	Inattentive symptoms;
LGG	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg23933602	chr10:16859644	RSU1	1.01	26.18	0.77	2.25e-93	Platelet distribution width;
LGG	cis	rs1784581	0.588	rs7451121	chr6:162412344	A/G	cg17173639	chr6:162384350	PARK2	0.64	13.44	0.53	5.15e-35	Itch intensity from mosquito bite;
LGG	cis	rs2075466	0.514	rs111431826	chr16:4907112	A/G	cg04440724	chr16:4920505	UBN1	-0.62	-9.06	-0.39	3.62e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg00405596	chr8:11794950	NA	-0.42	-7.22	-0.32	2.15e-12	Neuroticism;
LGG	trans	rs62103177	0.564	rs1864529	chr18:77748975	G/A	cg05926928	chr17:57297772	GDPD1	-1.03	-13.96	-0.54	3.29e-37	Opioid sensitivity;
LGG	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs988958	0.565	rs35033846	chr2:42237228	G/A	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.33	-0.32	1.04e-12	Iron status biomarkers;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg08742575	chr21:47604166	C21orf56	0.51	8.7	0.37	5.72e-17	Testicular germ cell tumor;
LGG	cis	rs1847505	0.663	rs8002365	chr13:61589772	A/G	cg25164009	chr13:61490935	NA	0.59	10.6	0.44	1.18e-23	Polychlorinated biphenyl levels;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg14092988	chr3:52407081	DNAH1	-0.28	-7.41	-0.33	5.88e-13	Bipolar disorder;
LGG	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-8.33	-0.36	9.34e-16	Subjective well-being;
LGG	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs4409675	0.576	rs6598912	chr1:28233289	C/T	cg23691781	chr1:28212827	C1orf38	0.41	10.55	0.44	1.84e-23	Corneal astigmatism;
LGG	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg18351406	chr4:77819688	ANKRD56	0.43	7.36	0.32	8.6e-13	Emphysema distribution in smoking;
LGG	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg15704280	chr7:45808275	SEPT13	-0.94	-19.51	-0.67	2.65e-62	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs7697315	chr4:98938764	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.88	0.34	2.42e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg08807101	chr21:30365312	RNF160	-0.81	-15.6	-0.59	2.12e-44	Dental caries;
LGG	cis	rs367943	0.712	rs1120091	chr5:112684229	C/A	cg12552261	chr5:112820674	MCC	0.54	9.78	0.41	1.17e-20	Type 2 diabetes;
LGG	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.42	6.74	0.3	4.59e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21659725	chr3:3221576	CRBN	0.93	20.77	0.69	3.33e-68	Intelligence (multi-trait analysis);
LGG	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg08270023	chr12:132619174	NA	-0.42	-6.97	-0.31	1.07e-11	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg27189623	chr16:705930	WDR90	0.4	7.63	0.33	1.39e-13	Height;
LGG	cis	rs4478858	0.684	rs10753245	chr1:31731208	A/G	cg19084893	chr1:31688959	NA	0.31	6.65	0.3	8.05e-11	Alcohol dependence;
LGG	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg23815491	chr16:72088622	HP	-0.42	-8.93	-0.38	1.04e-17	Prostate cancer;
LGG	cis	rs74781061	0.860	rs1456432	chr15:75003051	T/C	cg02384859	chr15:74862662	ARID3B	-0.32	-6.7	-0.3	5.94e-11	Endometriosis;
LGG	cis	rs17023223	0.537	rs10923767	chr1:119732347	C/T	cg05756136	chr1:119680316	WARS2	-0.42	-8.58	-0.37	1.46e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs4746059	0.610	rs10999479	chr10:72477232	A/C	cg18679544	chr10:72432482	ADAMTS14	-0.52	-9.03	-0.39	4.72e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2898857	0.524	rs11652146	chr17:47422363	G/A	cg08112188	chr17:47440006	ZNF652	-0.43	-7.0	-0.31	9.03e-12	Cancer;
LGG	cis	rs870825	0.616	rs7692104	chr4:185650895	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg04362960	chr10:104952993	NT5C2	-0.44	-6.86	-0.3	2.26e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg16590910	chr6:42928470	GNMT	-0.3	-6.93	-0.31	1.43e-11	Blood protein levels;
LGG	cis	rs8141529	0.529	rs16987024	chr22:29208975	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Lymphocyte counts;
LGG	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.54	0.53	2.01e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7216064	1.000	rs62084246	chr17:65867911	G/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.69	-0.37	6.51e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs514024	0.501	rs55648910	chr9:130409081	C/T	cg13643465	chr9:130375613	STXBP1	0.5	8.6	0.37	1.21e-16	Eating disorders (purging via substances);
LGG	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg09165964	chr15:75287851	SCAMP5	0.55	9.93	0.42	3.39e-21	Breast cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11368578	chr7:150754936	CDK5	0.38	6.7	0.3	6.1e-11	Obesity-related traits;
LGG	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg21427119	chr20:30132790	HM13	0.58	9.13	0.39	2.17e-18	Mean corpuscular hemoglobin;
LGG	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	26.57	0.78	3.73e-95	Cognitive ability;
LGG	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg11366901	chr6:160182831	ACAT2	1.05	16.24	0.6	3.03e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	cis	rs1519814	1.000	rs4588897	chr8:121139142	A/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs7301016	0.707	rs11174583	chr12:63051064	T/C	cg11441379	chr12:63026424	NA	0.58	8.14	0.35	3.73e-15	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs988958	0.600	rs34917148	chr2:42217721	G/T	cg27428208	chr2:42229179	NA	0.57	9.45	0.4	1.69e-19	Hypospadias;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01490772	chr12:7282593	CLSTN3;RBP5	0.42	7.48	0.33	3.88e-13	Bipolar disorder;
LGG	cis	rs6430585	0.697	rs6724569	chr2:136516970	G/A	cg07169764	chr2:136633963	MCM6	1.28	24.11	0.75	8.5e-84	Corneal structure;
LGG	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.68	-11.73	-0.48	5.19e-28	Social autistic-like traits;
LGG	cis	rs67460515	0.500	rs9860537	chr3:160660500	G/T	cg04691961	chr3:161091175	C3orf57	0.4	7.57	0.33	2.09e-13	Parkinson's disease;
LGG	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg01631408	chr1:248437212	OR2T33	-0.38	-7.03	-0.31	7.22e-12	Common traits (Other);
LGG	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.42	6.69	0.3	6.5e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg14926445	chr8:58193284	C8orf71	-0.45	-7.03	-0.31	7.67e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg19748678	chr4:122722346	EXOSC9	0.51	9.48	0.4	1.34e-19	Type 2 diabetes;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg23610053	chr20:44509853	ZSWIM1	-0.34	-6.76	-0.3	4.18e-11	Iris color (L* coordinate);
LGG	cis	rs701145	0.585	rs1620712	chr3:153790050	C/G	cg12800244	chr3:153838788	SGEF	0.85	9.89	0.42	4.81e-21	Coronary artery disease;
LGG	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-17.77	-0.64	3.15e-54	Vitiligo;
LGG	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg11764359	chr7:65958608	NA	0.63	9.77	0.41	1.23e-20	Aortic root size;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-33.76	-0.84	6.51e-127	Prudent dietary pattern;
LGG	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00294572	chr6:26285232	NA	0.4	6.89	0.3	1.85e-11	Educational attainment;
LGG	cis	rs2408955	0.521	rs10875749	chr12:48531917	T/A	cg24011408	chr12:48396354	COL2A1	-0.56	-9.36	-0.4	3.59e-19	Glycated hemoglobin levels;
LGG	cis	rs12220238	1.000	rs10824112	chr10:75969003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs12195424	0.730	rs2224749	chr6:56305457	G/C	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1.05e-11	Cerebrospinal fluid clusterin levels;
LGG	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg19847130	chr8:10466454	RP1L1	-0.32	-7.23	-0.32	1.98e-12	Mood instability;
LGG	cis	rs1461503	0.932	rs7107575	chr11:122845406	C/T	cg27398637	chr11:122830231	C11orf63	0.69	13.27	0.52	2.84e-34	Menarche (age at onset);
LGG	cis	rs4748857	0.947	rs4603206	chr10:23607192	C/T	cg18853376	chr10:23633759	C10orf67	0.36	6.91	0.31	1.63e-11	Systemic lupus erythematosus;
LGG	cis	rs2718058	0.606	rs2598077	chr7:37870427	G/C	cg15028436	chr7:37888078	TXNDC3	0.57	9.0	0.39	5.75e-18	Alzheimer's disease (late onset);
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.27	-0.32	1.49e-12	Total body bone mineral density;
LGG	cis	rs7017914	0.934	rs7006615	chr8:71639807	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15645079	chr20:3140569	FASTKD5;UBOX5	0.52	7.78	0.34	4.93e-14	Gut microbiome composition (summer);
LGG	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-7.31	-0.32	1.18e-12	Subjective well-being;
LGG	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg26666090	chr16:58549219	SETD6	1.15	10.19	0.43	3.94e-22	Schizophrenia;
LGG	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.74	-0.3	4.75e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.88	0.59	1.24e-45	Lung cancer;
LGG	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.76	-0.78	5.01e-96	Schizophrenia;
LGG	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs9815354	1.000	rs6791806	chr3:41889995	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.23	0.36	1.99e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12780845	0.505	rs11254419	chr10:17209192	A/C	cg01003015	chr10:17271136	VIM	-0.43	-7.35	-0.32	8.8e-13	Homocysteine levels;
LGG	cis	rs1878931	0.580	rs4785932	chr16:3410456	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.95	20.74	0.69	4.73e-68	Body mass index (adult);
LGG	cis	rs11209002	0.915	rs6588240	chr1:67577367	A/T	cg02640540	chr1:67518911	SLC35D1	0.46	6.89	0.3	1.86e-11	Crohn's disease;
LGG	cis	rs2180341	0.961	rs3798857	chr6:127659473	A/T	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg26384229	chr12:38710491	ALG10B	0.8	16.15	0.6	7.52e-47	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.72	0.54	3.33e-36	Lung cancer;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg08621203	chr6:150244597	RAET1G	0.41	6.9	0.31	1.68e-11	Lung cancer;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.08	-0.35	5.86e-15	IgG glycosylation;
LGG	cis	rs4478037	0.915	rs12635828	chr3:33142076	G/A	cg19404215	chr3:33155277	CRTAP	1.01	11.43	0.47	8.24e-27	Major depressive disorder;
LGG	cis	rs17321999	1.000	rs72787724	chr2:30491746	T/C	cg05247661	chr2:30472410	LBH	0.56	8.64	0.37	9.06e-17	Systemic lupus erythematosus;
LGG	trans	rs3857536	0.730	rs4710585	chr6:66967579	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.19e-12	Blood trace element (Cu levels);
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg18350739	chr11:68623251	NA	-0.87	-22.64	-0.72	6.19e-77	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.57	10.46	0.44	3.95e-23	Longevity;
LGG	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg07936489	chr17:37558343	FBXL20	-0.51	-8.64	-0.37	9.04e-17	Asthma;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.41	0.33	5.89e-13	Schizophrenia;
LGG	trans	rs2548003	1.000	rs1559248	chr5:28746315	A/G	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	11.33	0.47	2e-26	Lung cancer in ever smokers;
LGG	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11764359	chr7:65958608	NA	0.56	9.54	0.41	8.17e-20	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12649615	chr1:150602426	ENSA	0.4	6.74	0.3	4.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11890956	chr21:40555474	PSMG1	1.21	30.92	0.82	1.09e-114	Cognitive function;
LGG	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg07636037	chr3:49044803	WDR6	0.93	17.09	0.62	4.02e-51	Menarche (age at onset);
LGG	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg05835009	chr4:710272	PCGF3	0.48	8.15	0.35	3.47e-15	White blood cell count;
LGG	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.2800000000000005e-13	Hemoglobin concentration;
LGG	trans	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04565464	chr8:145669602	NFKBIL2	0.39	6.67	0.3	7.24e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	10.08	0.42	9.93e-22	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs5742933	0.817	rs1055091	chr2:190635143	C/T	cg04003228	chr2:190539410	ANKAR	-0.51	-7.41	-0.33	6.06e-13	Ferritin levels;
LGG	cis	rs151997	0.830	rs27282	chr5:50198970	G/A	cg06027927	chr5:50259733	NA	0.61	10.31	0.43	1.43e-22	Callous-unemotional behaviour;
LGG	cis	rs9463078	0.804	rs9395086	chr6:45225331	T/A	cg25276700	chr6:44698697	NA	-0.38	-8.0	-0.35	9.99e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.14	-0.31	3.73e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs56399783	0.708	rs55868372	chr7:2758563	G/C	cg19731401	chr7:2775893	GNA12	0.35	7.14	0.32	3.53e-12	Childhood ear infection;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.1	-0.31	4.6e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2239547	0.618	rs2071041	chr3:52864693	T/G	cg11645453	chr3:52864694	ITIH4	0.74	11.59	0.47	1.84e-27	Schizophrenia;
LGG	cis	rs7503807	0.515	rs12601001	chr17:78681084	T/C	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg08742575	chr21:47604166	C21orf56	0.49	8.48	0.37	3.15e-16	Testicular germ cell tumor;
LGG	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.63e-11	Bladder cancer;
LGG	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.06	-0.39	3.59e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs7814319	0.700	rs7838479	chr8:97268077	G/A	cg20787634	chr8:97240163	UQCRB	-0.69	-14.02	-0.55	1.82e-37	Lung function (FVC);
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs988958	0.675	rs1866669	chr2:42221789	C/T	cg27428208	chr2:42229179	NA	0.54	9.17	0.39	1.54e-18	Hypospadias;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26567249	chr8:97247842	UQCRB	0.43	6.83	0.3	2.73e-11	Cognitive performance;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg11766577	chr21:47581405	C21orf56	-0.5	-8.87	-0.38	1.56e-17	Testicular germ cell tumor;
LGG	cis	rs9596863	0.898	rs17088922	chr13:54375033	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.09	0.31	5.18e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs9929218	0.954	rs9929239	chr16:68821126	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-12.08	-0.49	2.07e-29	Colorectal cancer;
LGG	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg21435375	chr2:172878103	MAP1D	0.31	6.87	0.3	2.13e-11	Schizophrenia;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg09238746	chr17:78121135	EIF4A3	-0.61	-10.52	-0.44	2.3e-23	Yeast infection;
LGG	cis	rs2486288	0.656	rs1706770	chr15:45575062	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.84	-0.45	1.5e-24	Glomerular filtration rate;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.42	0.33	5.81e-13	Prudent dietary pattern;
LGG	trans	rs9914544	0.545	rs7212905	chr17:18774271	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.85	-0.34	2.86e-14	Educational attainment (years of education);
LGG	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg19628046	chr18:33552617	C18orf21	-0.49	-7.28	-0.32	1.47e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs3617	0.625	rs2245647	chr3:52862753	A/G	cg11645453	chr3:52864694	ITIH4	0.44	7.4	0.33	6.63e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg16077055	chr2:106428750	NCK2	0.29	7.58	0.33	1.91e-13	Addiction;
LGG	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-25.65	-0.77	6.19e-91	Renal cell carcinoma;
LGG	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg15309053	chr8:964076	NA	0.41	8.9	0.38	1.25e-17	Schizophrenia;
LGG	cis	rs888194	0.587	rs6606711	chr12:109849297	A/G	cg19025524	chr12:109796872	NA	-0.52	-10.6	-0.44	1.23e-23	Neuroticism;
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2154319	0.673	rs2011981	chr1:41540853	A/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.01	-0.39	5.45e-18	Height;
LGG	cis	rs9733	0.687	rs12410050	chr1:150857141	A/G	cg13175981	chr1:150552382	MCL1	0.54	8.67	0.37	7.55e-17	Tonsillectomy;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	trans	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07923666	chr12:49932857	KCNH3	-0.49	-7.48	-0.33	3.85e-13	Resting heart rate;
LGG	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg13444538	chr7:158905317	VIPR2	-0.53	-8.15	-0.35	3.41e-15	Facial morphology (factor 20);
LGG	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs300774	0.925	rs300717	chr2:136638	G/A	cg04617936	chr2:214353	NA	-0.5	-7.58	-0.33	1.96e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Colorectal cancer;
LGG	cis	rs9400467	0.506	rs12192617	chr6:111490275	A/G	cg15721981	chr6:111408429	SLC16A10	0.59	7.15	0.32	3.43e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7587476	0.906	rs17487827	chr2:215644335	C/G	cg04530015	chr2:215796436	ABCA12	-0.42	-6.75	-0.3	4.36e-11	Neuroblastoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13129888	chr1:28415099	EYA3	0.53	8.64	0.37	9.52e-17	Cognitive performance;
LGG	cis	rs7914558	0.966	rs10450373	chr10:104728616	T/C	cg04362960	chr10:104952993	NT5C2	0.54	10.3	0.43	1.57e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.21	0.32	2.25e-12	Obesity-related traits;
LGG	cis	rs7799006	0.929	rs7781856	chr7:2257199	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-7.74	-0.34	6.46e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg10207240	chr12:122356781	WDR66	0.26	7.82	0.34	3.52e-14	Mean corpuscular volume;
LGG	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.64	0.41	3.67e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3796619	1.000	rs4974601	chr4:1095410	G/A	cg27284194	chr4:1044797	NA	0.57	11.79	0.48	3.21e-28	Recombination rate (males);
LGG	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg16400903	chr5:693638	TPPP	0.47	7.03	0.31	7.29e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg11062466	chr8:58055876	NA	0.51	8.62	0.37	1.04e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3736485	0.578	rs1456300	chr15:51982016	T/C	cg13474965	chr15:52030001	LYSMD2	0.42	7.13	0.31	3.82e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg13679303	chr9:96623674	NA	-0.39	-6.89	-0.3	1.85e-11	DNA methylation (variation);
LGG	cis	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg24134504	chr18:76639479	NA	-0.47	-8.22	-0.36	2.03e-15	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs2482927	chr20:25327151	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.2	-0.43	3.59e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3816183	0.959	rs3772061	chr2:43016941	A/G	cg14631114	chr2:43023945	NA	0.51	9.5	0.4	1.17e-19	Hypospadias;
LGG	trans	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg25482853	chr8:67687455	SGK3	0.94	11.86	0.48	1.7e-28	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg11062466	chr8:58055876	NA	0.53	8.8	0.38	2.64e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13138137	chr18:35146478	BRUNOL4	-0.44	-6.98	-0.31	1.06e-11	Pancreatic cancer;
LGG	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg12654349	chr5:56205094	C5orf35	-0.69	-10.67	-0.44	6.49e-24	Initial pursuit acceleration;
LGG	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg21926883	chr2:100939477	LONRF2	-0.48	-9.25	-0.39	8.44e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.73	-0.34	6.8e-14	Response to antipsychotic treatment;
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg19635926	chr16:89946313	TCF25	0.81	9.19	0.39	1.35e-18	Skin colour saturation;
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.64	8.44	0.37	4.19e-16	Lung function (FEV1/FVC);
LGG	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.12	-0.31	4.26e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07167872	chr1:205819463	PM20D1	-0.47	-9.84	-0.42	7.24e-21	Monocyte percentage of white cells;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.84	-0.34	3.04e-14	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs1021993	0.545	rs6681466	chr1:209529258	G/T	cg24446417	chr1:209558027	NA	-0.68	-9.92	-0.42	3.64e-21	Gut microbiome composition (winter);
LGG	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.98	-0.31	1.04e-11	Childhood ear infection;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg10505658	chr17:80084571	CCDC57	-0.4	-8.17	-0.36	2.92e-15	Life satisfaction;
LGG	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg21775007	chr8:11205619	TDH	0.77	13.54	0.53	2.07e-35	Retinal vascular caliber;
LGG	cis	rs1580019	0.961	rs766657	chr7:32499510	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.8	14.94	0.57	1.89e-41	Cognitive ability;
LGG	cis	rs6066825	0.606	rs2869668	chr20:47321393	T/C	cg18078177	chr20:47281410	PREX1	0.49	8.18	0.36	2.83e-15	Colorectal cancer;
LGG	cis	rs67133203	0.861	rs35379220	chr12:51345784	C/T	cg14688905	chr12:51403056	SLC11A2	0.68	10.3	0.43	1.51e-22	Urinary tract infection frequency;
LGG	cis	rs1505368	0.505	rs2135156	chr2:213259226	C/T	cg20637307	chr2:213403960	ERBB4	0.49	9.26	0.4	7.87e-19	Symmetrical dimethylarginine levels;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg11644478	chr21:40555479	PSMG1	-0.57	-9.36	-0.4	3.48e-19	Menarche (age at onset);
LGG	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.1	0.35	5.07e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs2131877	0.913	rs9825498	chr3:194848021	G/C	cg07250128	chr3:194833983	C3orf21	0.39	7.21	0.32	2.33e-12	Non-small cell lung cancer;
LGG	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg05444541	chr17:17804740	TOM1L2	-0.61	-14.39	-0.56	4.39e-39	Total body bone mineral density;
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg27411982	chr8:10470053	RP1L1	0.42	7.36	0.32	8.41e-13	Mood instability;
LGG	cis	rs457717	0.730	rs2432188	chr5:75948848	G/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.81	0.3	2.99e-11	Hearing impairment;
LGG	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg27124370	chr19:33622961	WDR88	-0.51	-9.0	-0.39	5.95e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10504130	0.569	rs16916966	chr8:52843329	C/A	cg13492337	chr8:52722140	PXDNL	-0.52	-7.9	-0.34	2.12e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs4474465	0.688	rs4945302	chr11:78283454	T/C	cg27205649	chr11:78285834	NARS2	0.6	11.17	0.46	8.52e-26	Alzheimer's disease (survival time);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05014952	chr14:35873130	NFKBIA	0.5	8.2	0.36	2.35e-15	Cognitive performance;
LGG	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg21775007	chr8:11205619	TDH	0.82	15.31	0.58	4.2e-43	Retinal vascular caliber;
LGG	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg24848339	chr3:12840334	CAND2	0.38	8.44	0.36	4.23e-16	P wave duration;
LGG	cis	rs9359856	0.564	rs72913921	chr6:90328692	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.62	-0.41	4.24e-20	Bipolar disorder;
LGG	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg23649088	chr2:200775458	C2orf69	0.45	8.1	0.35	5.07e-15	Systolic blood pressure;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.3	0.4	5.61e-19	Electroencephalogram traits;
LGG	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00198680	chr16:28758506	NA	0.28	6.76	0.3	4.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg05368731	chr17:41323189	NBR1	0.93	17.8	0.64	2.32e-54	Menopause (age at onset);
LGG	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg17971929	chr21:40555470	PSMG1	0.84	16.18	0.6	5.3e-47	Cognitive function;
LGG	cis	rs11641365	0.678	rs877579	chr16:88770621	A/G	cg00034003	chr16:88779146	CTU2	-0.41	-6.78	-0.3	3.64e-11	Autism spectrum disorder-related traits;
LGG	cis	rs2270450	0.729	rs12195701	chr6:46687419	C/T	cg10156739	chr6:46714674	LOC100287718	-0.44	-9.07	-0.39	3.52e-18	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg20891283	chr12:69753455	YEATS4	0.6	11.21	0.46	5.57e-26	Blood protein levels;
LGG	trans	rs11875185	0.588	rs74379317	chr18:55641246	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg23057051	chr16:89984268	MC1R	-0.35	-6.89	-0.3	1.86e-11	Vitiligo;
LGG	cis	rs9790314	1.000	rs28515190	chr3:161028605	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-14.83	-0.57	5.58e-41	Morning vs. evening chronotype;
LGG	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg02002194	chr4:3960332	NA	0.38	6.91	0.31	1.6e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs644799	0.932	rs523934	chr11:95641775	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	12.34	0.5	1.85e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12188164	0.515	rs11742006	chr5:408529	C/T	cg26076054	chr5:421317	AHRR	-0.43	-6.83	-0.3	2.76e-11	Cystic fibrosis severity;
LGG	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg25019033	chr10:957182	NA	-0.55	-9.96	-0.42	2.75e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs55788414	0.932	rs8043592	chr16:81182537	A/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg15485101	chr11:133734466	NA	0.59	10.38	0.43	7.56e-23	Childhood ear infection;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25735425	chr17:40307262	RAB5C	-0.44	-7.15	-0.32	3.38e-12	Pancreatic cancer;
LGG	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.3	0.47	2.49e-26	Vitamin D levels;
LGG	cis	rs708547	0.957	rs781667	chr4:57798469	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	8.95	0.38	8.85e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.39	6.73	0.3	4.96e-11	Schizophrenia;
LGG	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs2294693	0.947	rs742492	chr6:40996381	G/A	cg14769373	chr6:40998127	UNC5CL	-0.44	-7.65	-0.33	1.2e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.38	0.32	7.32e-13	Longevity;
LGG	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg07636037	chr3:49044803	WDR6	0.82	14.47	0.56	1.99e-39	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg04568710	chr12:38710424	ALG10B	-0.34	-7.36	-0.32	8.28e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7617773	0.963	rs6771787	chr3:48194242	C/T	cg11946769	chr3:48343235	NME6	-0.54	-8.49	-0.37	2.76e-16	Coronary artery disease;
LGG	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg12458913	chr13:53173898	NA	0.8	17.66	0.63	9.86e-54	Lewy body disease;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg14675211	chr2:100938903	LONRF2	-0.47	-6.72	-0.3	5.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.597	rs10496327	chr2:99066827	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.52	0.37	2.28e-16	Bipolar disorder;
LGG	cis	rs9905704	0.647	rs9898048	chr17:57108543	C/T	cg12560992	chr17:57184187	TRIM37	0.51	8.23	0.36	1.9e-15	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.94	0.38	9.67e-18	Fuchs's corneal dystrophy;
LGG	trans	rs9951602	0.512	rs8097996	chr18:76648035	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	13.48	0.53	3.57e-35	Obesity-related traits;
LGG	cis	rs15676	0.783	rs2417128	chr9:131571756	G/A	cg04621255	chr9:131581398	ENDOG	-0.39	-6.92	-0.31	1.48e-11	Blood metabolite levels;
LGG	cis	rs9443189	0.570	rs9343316	chr6:76411800	G/A	cg01950844	chr6:76311363	SENP6	0.76	10.05	0.42	1.24e-21	Prostate cancer;
LGG	cis	rs3540	0.960	rs8040585	chr15:91026477	T/C	cg22089800	chr15:90895588	ZNF774	0.53	8.29	0.36	1.28e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs9682041	0.696	rs16855034	chr3:170097842	C/G	cg11886554	chr3:170076028	SKIL	0.66	8.51	0.37	2.48e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg02725872	chr8:58115012	NA	-1.03	-15.3	-0.58	4.53e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4604732	0.812	rs6663238	chr1:247624971	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.48	-7.8	-0.34	4.26e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504073	0.584	rs10957356	chr8:49980634	G/A	cg00325661	chr8:49890786	NA	0.76	14.85	0.57	4.63e-41	Blood metabolite ratios;
LGG	cis	rs9952991	0.941	rs2847280	chr18:12779342	A/G	cg23544223	chr18:12777786	NA	0.62	9.35	0.4	3.76e-19	Inflammatory skin disease;
LGG	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg03929089	chr4:120376271	NA	-1.02	-22.67	-0.73	4.25e-77	Height;
LGG	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg08824895	chr13:115047677	UPF3A	0.4	6.89	0.3	1.88e-11	Schizophrenia;
LGG	cis	rs3106136	0.546	rs7685121	chr4:95175682	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.35	-0.47	1.6e-26	Capecitabine sensitivity;
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.12	0.31	4.14e-12	Personality dimensions;
LGG	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.36	-0.32	8.71e-13	Blood metabolite levels;
LGG	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg24250549	chr1:154909240	PMVK	-0.51	-9.28	-0.4	6.37e-19	Prostate cancer;
LGG	cis	rs9341835	0.584	rs2622307	chr6:64152049	G/C	cg00787780	chr6:64151745	NA	0.44	8.12	0.35	4.32e-15	Schizophrenia;
LGG	cis	rs4731207	0.698	rs10248775	chr7:124444207	T/G	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs11203032	1.000	rs17117124	chr10:90963997	C/G	cg16672925	chr10:90967113	CH25H	0.84	11.85	0.48	1.79e-28	Heart failure;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg18350739	chr11:68623251	NA	-0.86	-21.88	-0.71	2.07e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13421350	0.579	rs12052253	chr2:173314713	A/T	cg15021238	chr2:173305865	ITGA6	-0.8	-9.36	-0.4	3.47e-19	Diabetic kidney disease;
LGG	cis	rs773506	0.551	rs7856089	chr9:94105457	G/A	cg14446406	chr9:93919335	NA	0.41	6.92	0.31	1.54e-11	Type 2 diabetes nephropathy;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg12070911	chr6:150209640	RAET1E	0.28	6.74	0.3	4.67e-11	Lung cancer;
LGG	cis	rs7666738	0.761	rs28758886	chr4:99059704	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg04733989	chr22:42467013	NAGA	0.58	10.34	0.43	1.14e-22	Schizophrenia;
LGG	cis	rs7100689	0.646	rs7092237	chr10:82165640	A/G	cg01528321	chr10:82214614	TSPAN14	0.89	16.3	0.6	1.62e-47	Post bronchodilator FEV1;
LGG	cis	rs8064024	0.680	rs1827983	chr16:4898517	G/C	cg08329684	chr16:4932620	PPL	0.52	11.74	0.48	4.67e-28	Cancer;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg04287289	chr16:89883240	FANCA	0.88	8.74	0.38	4.37e-17	Skin colour saturation;
LGG	cis	rs668210	0.947	rs559161	chr11:65761637	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.73	10.63	0.44	8.84e-24	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.99	-0.49	4.75e-29	Intelligence (multi-trait analysis);
LGG	cis	rs13102973	0.640	rs13151892	chr4:135831375	G/A	cg14419869	chr4:135874104	NA	0.51	9.43	0.4	2.04e-19	Subjective well-being;
LGG	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs477692	0.699	rs578932	chr10:131370724	C/A	cg05714579	chr10:131428358	MGMT	0.46	8.83	0.38	2.17e-17	Response to temozolomide;
LGG	cis	rs9549367	0.712	rs2316443	chr13:113864837	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.45	-0.37	3.78e-16	Platelet distribution width;
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.93	-0.35	1.64e-14	Breast cancer;
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg02002194	chr4:3960332	NA	0.42	7.49	0.33	3.41e-13	Triglycerides;
LGG	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg00757033	chr12:89920650	WDR51B	0.63	8.93	0.38	9.88e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9309473	1.000	rs6753344	chr2:73653138	C/T	cg20560298	chr2:73613845	ALMS1	0.48	7.91	0.35	1.9e-14	Metabolite levels;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.26	-0.5	3.89e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.63	-0.54	8.27e-36	Morning vs. evening chronotype;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg18225595	chr11:63971243	STIP1	0.59	8.56	0.37	1.65e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.9	-0.48	1.12e-28	Morning vs. evening chronotype;
LGG	trans	rs6787172	0.702	rs4679822	chr3:157889775	C/T	cg23275840	chr4:47708675	CORIN	-0.41	-8.8	-0.38	2.73e-17	Subjective well-being;
LGG	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg09904177	chr6:26538194	HMGN4	-0.38	-6.77	-0.3	3.92e-11	Schizophrenia;
LGG	cis	rs7945718	0.967	rs4415740	chr11:12783911	C/T	cg25843174	chr11:12811716	TEAD1	0.39	8.07	0.35	5.92e-15	Educational attainment (years of education);
LGG	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.933	rs6464940	chr7:148826309	G/T	cg23583168	chr7:148888333	NA	-0.87	-16.92	-0.62	2.38e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-20.56	-0.69	3.17e-67	Systemic lupus erythematosus;
LGG	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg20503657	chr10:835505	NA	0.96	12.85	0.51	1.6e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7937612	0.965	rs7118391	chr11:120270709	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.02	-0.52	3.18e-33	Intraocular pressure;
LGG	cis	rs9916302	0.706	rs903507	chr17:37726423	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.3	-0.58	4.61e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs12519773	0.526	rs4632783	chr5:92528309	A/G	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg08200770	chr17:80723486	TBCD	-0.47	-8.32	-0.36	9.85e-16	Glycated hemoglobin levels;
LGG	trans	rs7404843	0.925	rs12600043	chr16:15539952	A/G	cg02716450	chr16:28638775	NA	0.72	7.44	0.33	4.78e-13	Testicular germ cell tumor;
LGG	cis	rs3857536	0.730	rs2214126	chr6:66969162	G/A	cg07460842	chr6:66804631	NA	-0.43	-7.2	-0.32	2.49e-12	Blood trace element (Cu levels);
LGG	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg20503657	chr10:835505	NA	0.77	10.63	0.44	9.28e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4851266	1.000	rs11684761	chr2:100826871	C/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs10463554	0.963	rs67068617	chr5:102375681	C/G	cg23492399	chr5:102201601	PAM	-0.53	-7.83	-0.34	3.42e-14	Parkinson's disease;
LGG	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1153858	0.562	rs8025019	chr15:45735865	C/T	cg26924012	chr15:45694286	SPATA5L1	0.7	7.25	0.32	1.73e-12	Homoarginine levels;
LGG	cis	rs4764487	0.687	rs3181300	chr12:6345199	C/T	cg08284733	chr12:6341482	CD9	0.37	10.22	0.43	3e-22	Mean platelet volume;
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.12	-0.31	4.2e-12	Bipolar disorder;
LGG	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg12560992	chr17:57184187	TRIM37	0.92	16.58	0.61	8.32e-49	Intelligence (multi-trait analysis);
LGG	cis	rs5753037	0.564	rs131298	chr22:30180001	C/T	cg01021169	chr22:30184971	ASCC2	0.42	8.52	0.37	2.25e-16	Type 1 diabetes;
LGG	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg20493526	chr2:3714936	ALLC	0.38	7.87	0.34	2.56e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11644478	chr21:40555479	PSMG1	-0.6	-9.85	-0.42	6.35e-21	Menarche (age at onset);
LGG	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg11317459	chr13:21872234	NA	-1.17	-18.82	-0.66	4.33e-59	White matter hyperintensity burden;
LGG	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.01	-0.31	8.39e-12	Sudden cardiac arrest;
LGG	cis	rs7219021	0.705	rs11869991	chr17:47027763	C/T	cg09029085	chr17:47094198	IGF2BP1	0.27	6.91	0.31	1.61e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs6138458	1.000	rs2387362	chr20:24899906	C/T	cg26195577	chr20:24973756	C20orf3	-1.22	-25.52	-0.76	2.39e-90	Blood protein levels;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.86	-0.3	2.23e-11	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23814691	chr3:50649161	CISH	0.47	6.96	0.31	1.17e-11	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.862	rs11637444	chr15:86311188	G/A	cg04173714	chr15:86211321	AKAP13	0.41	7.22	0.32	2.08e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1355223	0.506	rs12294339	chr11:34860199	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.4	-0.36	5.51e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg09873164	chr1:152488093	CRCT1	0.61	14.71	0.56	1.83e-40	Hair morphology;
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg20246863	chr2:73402720	NA	-0.27	-6.81	-0.3	3.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	0.663	rs10946205	chr6:167451311	A/G	cg07741184	chr6:167504864	NA	0.4	8.72	0.38	4.86e-17	Crohn's disease;
LGG	cis	rs4700695	1.000	rs153389	chr5:65422729	C/T	cg21114390	chr5:65439923	SFRS12	-0.61	-7.77	-0.34	5.21e-14	Facial morphology (factor 19);
LGG	cis	rs35160687	0.814	rs1863063	chr2:86518249	A/C	cg10973622	chr2:86423274	IMMT	0.45	8.05	0.35	7.27e-15	Night sleep phenotypes;
LGG	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-6.95	-0.31	1.26e-11	LDL cholesterol;Cholesterol, total;
LGG	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg08975724	chr8:8085496	FLJ10661	0.36	6.91	0.31	1.64e-11	Neuroticism;
LGG	cis	rs6694672	1.000	rs7520503	chr1:197152989	A/G	cg13682187	chr1:196946512	CFHR5	0.48	6.86	0.3	2.23e-11	Asthma;
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.5	-0.47	4.45e-27	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg25767906	chr1:53392781	SCP2	-0.38	-7.66	-0.34	1.12e-13	Monocyte count;
LGG	cis	rs7572644	0.699	rs13416434	chr2:28162274	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs10893109	0.538	rs1453655	chr11:123796413	T/A	cg12387464	chr11:123775935	OR8D4	0.39	8.25	0.36	1.61e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21292152	chr19:37406949	ZNF829;ZNF568	0.49	7.88	0.34	2.39e-14	Cognitive performance;
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.54	-0.47	3.03e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg03990033	chr1:208084030	CD34	0.56	8.18	0.36	2.83e-15	Facial morphology (factor 18);
LGG	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg13683864	chr3:40499215	RPL14	-1.08	-23.46	-0.74	8.84e-81	Renal cell carcinoma;
LGG	cis	rs4478858	0.698	rs4949204	chr1:31800415	A/G	cg19084893	chr1:31688959	NA	0.32	6.84	0.3	2.5e-11	Alcohol dependence;
LGG	cis	rs4774830	0.744	rs62046381	chr15:56300281	T/G	cg24530489	chr15:56299380	NA	-0.87	-8.07	-0.35	6.02e-15	Delta-5 desaturase activity;
LGG	cis	rs28830936	1.000	rs28830936	chr15:41906408	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.67	-0.51	8.9e-32	Diastolic blood pressure;
LGG	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg12193833	chr17:30244370	NA	-0.27	-7.25	-0.32	1.75e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2073300	1.000	rs34449811	chr20:23443771	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11088226	0.681	rs2833895	chr21:33929802	G/A	cg09050820	chr6:167586206	TCP10L2	0.88	12.71	0.51	5.73e-32	Gastritis;
LGG	cis	rs36093844	0.752	rs17744675	chr11:85593906	C/T	cg16165120	chr11:85566439	CCDC83	0.41	6.64	0.3	8.55e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg27129171	chr3:47204927	SETD2	0.73	11.54	0.47	2.91e-27	Birth weight;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	trans	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs3784262	1.000	rs7495968	chr15:58244103	C/G	cg12031962	chr15:58353849	ALDH1A2	0.37	8.05	0.35	7.08e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg11211951	chr8:145729740	GPT	0.53	13.37	0.53	1.01e-34	Age at first birth;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.37	0.53	1.09e-34	Obesity-related traits;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg02725872	chr8:58115012	NA	-0.86	-16.34	-0.6	1.07e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg13256891	chr4:100009986	ADH5	0.57	9.72	0.41	1.87e-20	Alcohol dependence;
LGG	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg15522984	chr1:182991683	LAMC1	-0.49	-10.01	-0.42	1.77e-21	Colorectal cancer;
LGG	cis	rs1055129	0.560	rs2608880	chr17:73938957	C/T	cg08125733	chr17:73851984	WBP2	0.42	7.15	0.32	3.46e-12	White matter hyperintensity burden;
LGG	cis	rs875971	1.000	rs4718307	chr7:65610988	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.88e-21	Aortic root size;
LGG	cis	rs9487094	0.961	rs12190920	chr6:109800599	G/T	cg16315928	chr6:109776240	MICAL1	0.54	9.0	0.39	5.71e-18	Height;
LGG	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.74	-0.3	4.64e-11	Resting heart rate;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs4740619	0.870	rs10756715	chr9:15888024	A/C	cg14451791	chr9:16040625	NA	-0.39	-9.88	-0.42	5.16e-21	Body mass index;
LGG	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.29	0.58	5.25e-43	Colorectal cancer;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.65e-16	Body mass index;
LGG	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg05639522	chr1:247681581	NA	0.64	10.64	0.44	8.69e-24	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg06521331	chr12:34319734	NA	-0.47	-7.91	-0.35	1.97e-14	Bladder cancer;
LGG	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21659725	chr3:3221576	CRBN	0.63	11.71	0.48	6.17e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2249694	0.803	rs3020501	chr10:135381592	C/G	cg20169779	chr10:135381914	SYCE1	0.52	7.79	0.34	4.31e-14	Obesity-related traits;
LGG	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg15145296	chr3:125709740	NA	-0.6	-7.69	-0.34	9.17e-14	Blood pressure (smoking interaction);
LGG	cis	rs12971120	1.000	rs12971120	chr18:72174023	A/G	cg25817165	chr18:72167213	CNDP2	-0.66	-13.93	-0.54	4.35e-37	Refractive error;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg16507663	chr6:150244633	RAET1G	0.43	7.95	0.35	1.44e-14	Lung cancer;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg06925179	chr17:43578568	NA	0.32	8.27	0.36	1.41e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4742903	0.935	rs10991165	chr9:106973498	A/G	cg14250997	chr9:106856677	SMC2	-0.31	-6.76	-0.3	4.18e-11	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg27171569	chr16:83987465	OSGIN1	-0.66	-11.36	-0.47	1.44e-26	Pursuit maintenance gain;
LGG	cis	rs3736594	0.513	rs62138964	chr2:27814438	C/T	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg24607181	chr17:41446203	NA	-0.3	-7.03	-0.31	7.49e-12	Menopause (age at onset);
LGG	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	14.03	0.55	1.55e-37	IgG glycosylation;
LGG	cis	rs584438	0.780	rs632224	chr17:38592990	A/G	cg09358481	chr17:38600305	IGFBP4	-0.44	-8.34	-0.36	8.46e-16	Height;
LGG	cis	rs4417704	0.551	rs6754171	chr2:241896013	G/C	cg05025159	chr2:241905733	NA	0.52	10.59	0.44	1.28e-23	Joint mobility (Beighton score);
LGG	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg10253484	chr15:75165896	SCAMP2	-0.67	-10.26	-0.43	2.1e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs10924309	0.855	rs7413150	chr1:245858729	G/A	cg00036263	chr1:245852353	KIF26B	-0.46	-6.81	-0.3	3.13e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.49	-7.21	-0.32	2.3e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg10523679	chr1:76189770	ACADM	0.82	15.91	0.59	8.98e-46	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs593982	0.925	rs585272	chr11:65505289	A/G	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19717773	chr7:2847554	GNA12	-0.34	-7.11	-0.31	4.32e-12	Height;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg06916706	chr16:4465613	CORO7	-1.15	-23.98	-0.74	3.43e-83	Schizophrenia;
LGG	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg08603382	chr10:743973	NA	-0.65	-12.82	-0.51	2.11e-32	Psychosis in Alzheimer's disease;
LGG	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg12856521	chr11:46389249	DGKZ	0.39	6.71	0.3	5.71e-11	Leprosy;
LGG	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg20891283	chr12:69753455	YEATS4	1.09	29.07	0.8	1.81e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs514024	0.729	rs2256139	chr9:130486915	T/C	cg13643465	chr9:130375613	STXBP1	0.59	11.19	0.46	6.77e-26	Eating disorders (purging via substances);
LGG	cis	rs7216064	0.861	rs73352810	chr17:65875184	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.47e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9398803	0.687	rs853987	chr6:127024775	A/G	cg19875578	chr6:126661172	C6orf173	-0.52	-9.53	-0.41	8.61e-20	Male-pattern baldness;
LGG	trans	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg14791747	chr16:20752902	THUMPD1	0.49	7.42	0.33	5.49e-13	Cognitive test performance;
LGG	cis	rs9527	0.590	rs7073323	chr10:104797423	A/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.68	-0.3	7.01e-11	Arsenic metabolism;
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.7	-0.34	8.07e-14	Prostate cancer;
LGG	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.6	-0.51	1.6e-31	Vitiligo;
LGG	cis	rs7408868	1.000	rs10410514	chr19:15277610	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.08	-0.42	9.6e-22	Total body bone mineral density;
LGG	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg05791153	chr7:19748676	TWISTNB	0.77	10.08	0.42	1.01e-21	Thyroid stimulating hormone;
LGG	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs17739167	0.550	rs17739125	chr15:42234424	T/C	cg20935245	chr15:42234343	EHD4	-0.45	-8.4	-0.36	5.36e-16	Monocyte count;
LGG	cis	rs883115	0.791	rs7532595	chr1:224794237	T/C	cg01808320	chr1:224927238	CNIH3	-0.41	-7.54	-0.33	2.56e-13	Cancer;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.62	-0.41	4.24e-20	Personality dimensions;
LGG	cis	rs7851660	0.839	rs7027221	chr9:100662379	T/C	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg23815491	chr16:72088622	HP	0.49	11.12	0.46	1.23e-25	Fibrinogen levels;
LGG	trans	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg06521331	chr12:34319734	NA	0.44	8.04	0.35	7.62e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6772849	0.901	rs9849126	chr3:128312069	C/T	cg08795948	chr3:128337044	NA	-0.49	-8.17	-0.36	2.88e-15	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg22398616	chr13:53314203	LECT1	-0.39	-7.8	-0.34	4.02e-14	Lewy body disease;
LGG	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.95	0.38	8.92e-18	Lung cancer in ever smokers;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg04968132	chr16:27560915	GTF3C1;KIAA0556	-0.4	-6.7	-0.3	6.12e-11	Brain structure;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.51	-9.75	-0.41	1.55e-20	Obesity-related traits;
LGG	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg05335186	chr13:53173507	NA	0.68	16.68	0.61	3.02e-49	Lewy body disease;
LGG	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg08859206	chr1:53392774	SCP2	0.33	6.66	0.3	7.74e-11	Monocyte count;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06028808	chr11:68637592	NA	0.73	12.19	0.49	7.9e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.716	rs13136721	chr4:99085602	G/A	cg05340658	chr4:99064831	C4orf37	0.44	7.12	0.31	4.03e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04080417	chr5:1859792	NA	-0.52	-8.53	-0.37	2.12e-16	Cardiovascular disease risk factors;
LGG	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg11502198	chr6:26597334	ABT1	0.7	12.19	0.49	8.04e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.28	0.46	3.09e-26	Hip circumference adjusted for BMI;
LGG	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg24253500	chr15:84953950	NA	0.59	10.91	0.45	8.4e-25	Schizophrenia;
LGG	cis	rs1707322	1.000	rs10789479	chr1:46352500	T/C	cg03146154	chr1:46216737	IPP	0.55	10.41	0.44	6.31e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.62	-0.41	4.27e-20	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2041895	0.509	rs7970139	chr12:107312430	T/C	cg13944111	chr12:107296891	NA	0.27	7.05	0.31	6.5e-12	Glaucoma (low intraocular pressure);
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg16325326	chr1:53192061	ZYG11B	0.59	12.69	0.51	7.16e-32	Monocyte count;
LGG	cis	rs7216064	1.000	rs11079707	chr17:65835617	A/G	cg12091567	chr17:66097778	LOC651250	0.58	8.61	0.37	1.14e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22618164	chr12:122356400	WDR66	0.39	11.98	0.49	5.3e-29	Mean corpuscular volume;
LGG	cis	rs4660214	0.666	rs10888788	chr1:39937696	G/A	cg18385671	chr1:39797026	MACF1	-0.49	-9.94	-0.42	3.02e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2806561	1.000	rs2473851	chr1:23489869	A/G	cg19743168	chr1:23544995	NA	0.34	6.98	0.31	1.04e-11	Height;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.62	-0.48	1.5e-27	Obesity-related traits;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	14.03	0.55	1.65e-37	Obesity-related traits;
LGG	cis	rs12210905	1.000	rs72843641	chr6:27203335	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-7.34	-0.32	9.73e-13	Hip circumference adjusted for BMI;
LGG	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.3	0.5	2.85e-30	Rheumatoid arthritis;
LGG	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg16797656	chr11:68205561	LRP5	0.55	10.27	0.43	1.91e-22	Total body bone mineral density;
LGG	cis	rs17331151	0.573	rs2240916	chr3:52859212	T/A	cg04865290	chr3:52927548	TMEM110	-0.41	-6.97	-0.31	1.12e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs12999616	0.948	rs35958372	chr2:98330858	T/C	cg26665480	chr2:98280029	ACTR1B	0.68	9.66	0.41	3.14e-20	Colorectal cancer;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg06634786	chr22:41940651	POLR3H	0.66	11.23	0.46	4.62e-26	Vitiligo;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00684032	chr4:1343700	KIAA1530	-0.47	-9.12	-0.39	2.29e-18	Obesity-related traits;
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg17911788	chr17:44343683	NA	-0.6	-9.11	-0.39	2.5e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs330048	0.545	rs10503387	chr8:9150525	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.81	0.3	3.11e-11	Systemic lupus erythematosus;
LGG	cis	rs7945718	0.781	rs11022505	chr11:12822366	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-7.12	-0.31	4.19e-12	Educational attainment (years of education);
LGG	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs7264396	0.635	rs6058363	chr20:34505054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.11	-0.31	4.48e-12	Total cholesterol levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27478700	chr11:130298435	ADAMTS8	0.6	6.81	0.3	3.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	1.000	rs1528402	chr2:27857517	G/A	cg27432699	chr2:27873401	GPN1	0.69	13.9	0.54	5.93e-37	Oral cavity cancer;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07362569	chr17:61921086	SMARCD2	0.49	9.46	0.4	1.5e-19	Prudent dietary pattern;
LGG	cis	rs77633900	0.772	rs2957607	chr15:76686527	A/G	cg21673338	chr15:77095150	SCAPER	0.63	8.52	0.37	2.22e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg22963979	chr7:1858916	MAD1L1	0.44	8.82	0.38	2.39e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.7	-0.34	8.1e-14	IgG glycosylation;
LGG	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg22426938	chr7:1423890	NA	-0.64	-8.45	-0.37	3.87e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs2932538	0.961	rs4839257	chr1:113219388	A/T	cg22162597	chr1:113214053	CAPZA1	-0.51	-9.93	-0.42	3.37e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg21963583	chr11:68658836	MRPL21	0.57	9.91	0.42	4.05e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4409675	0.956	rs4072743	chr1:28270934	T/C	cg07233700	chr1:28261706	SMPDL3B	-0.3	-6.71	-0.3	5.59e-11	Corneal astigmatism;
LGG	cis	rs10489202	0.632	rs202273	chr1:167919963	A/G	cg24449463	chr1:168025552	DCAF6	-0.58	-10.23	-0.43	2.68e-22	Schizophrenia;
LGG	cis	rs751728	0.664	rs4711347	chr6:33735292	G/A	cg25922239	chr6:33757077	LEMD2	0.4	6.78	0.3	3.7e-11	Crohn's disease;
LGG	cis	rs6912958	0.712	rs2754260	chr6:88397666	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.43	-0.36	4.56e-16	Monocyte percentage of white cells;
LGG	cis	rs9513627	1.000	rs9517755	chr13:100168408	C/A	cg15490075	chr13:100150979	NA	0.63	6.74	0.3	4.69e-11	Obesity-related traits;
LGG	cis	rs9814567	1.000	rs13071551	chr3:134310867	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21178548	chr17:48207167	SAMD14	-0.4	-6.82	-0.3	2.93e-11	Brain structure;
LGG	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg14593290	chr7:50529359	DDC	-0.57	-10.31	-0.43	1.36e-22	Malaria;
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18252515	chr7:66147081	NA	0.44	7.42	0.33	5.5e-13	Aortic root size;
LGG	cis	rs7255436	0.931	rs7249520	chr19:8446056	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.69	-0.3	6.54e-11	HDL cholesterol;
LGG	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg04568710	chr12:38710424	ALG10B	0.4	8.53	0.37	2.17e-16	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23927769	chr6:41755626	TOMM6	0.49	7.85	0.34	2.87e-14	Cognitive performance;
LGG	cis	rs1577917	1.000	rs1577917	chr6:86691940	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-13.94	-0.54	4.07e-37	Response to antipsychotic treatment;
LGG	cis	rs9807989	0.507	rs2041739	chr2:102994333	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.44	-0.4	1.82e-19	Asthma;
LGG	cis	rs3806843	0.576	rs246064	chr5:140324309	C/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9467773	0.626	rs9379860	chr6:26370605	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-8.25	-0.36	1.65e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7202877	0.572	rs8051611	chr16:75388933	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.19	0.32	2.64e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs11690935	0.550	rs62183785	chr2:172866976	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	12.0	0.49	4.59e-29	Schizophrenia;
LGG	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg02269571	chr22:50332266	NA	-0.8	-9.78	-0.41	1.16e-20	Schizophrenia;
LGG	cis	rs4970988	0.556	rs6681426	chr1:150586971	G/A	cg13175981	chr1:150552382	MCL1	0.43	6.79	0.3	3.48e-11	Urate levels;
LGG	cis	rs6504108	0.624	rs1002330	chr17:46253515	T/C	cg02219949	chr17:45927392	SP6	0.43	8.07	0.35	6.18e-15	Body mass index;
LGG	cis	rs4684776	0.867	rs7640175	chr3:11353039	G/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs758324	0.947	rs1500115	chr5:131216427	G/T	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	3.01e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg00800038	chr16:89945340	TCF25	-0.7	-8.56	-0.37	1.71e-16	Skin colour saturation;
LGG	cis	rs11096990	0.892	rs4974924	chr4:39197711	T/A	cg24403649	chr4:39172243	NA	-0.47	-7.74	-0.34	6.23e-14	Cognitive function;
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.88e-11	Aortic root size;
LGG	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4845570	1.000	rs6683364	chr1:151746202	T/A	cg07092448	chr1:151763213	TDRKH	-1.1	-18.22	-0.65	2.57e-56	Coronary artery disease;
LGG	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg03959625	chr15:84868606	LOC388152	0.49	7.25	0.32	1.81e-12	Schizophrenia;
LGG	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg05084668	chr3:125655381	ALG1L	-0.57	-7.62	-0.33	1.48e-13	Blood pressure (smoking interaction);
LGG	cis	rs7267979	0.866	rs437635	chr20:25456888	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.1	0.42	8.35e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg04450456	chr4:17643702	FAM184B	0.32	6.87	0.3	2.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9303280	0.934	rs56380902	chr17:38066372	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-8.9	-0.38	1.25e-17	Self-reported allergy;
LGG	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg12560992	chr17:57184187	TRIM37	-0.93	-16.68	-0.61	2.96e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	8.92	0.38	1.12e-17	Systolic blood pressure;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg16141378	chr3:129829833	LOC729375	-0.39	-9.1	-0.39	2.79e-18	Neuroticism;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.81	-0.45	1.87e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4356975	0.527	rs57102579	chr4:69991194	T/C	cg27372994	chr4:70080453	UGT2B11	0.39	7.02	0.31	8.05e-12	Obesity-related traits;
LGG	cis	rs7615952	0.800	rs2062773	chr3:125639648	T/C	cg05084668	chr3:125655381	ALG1L	-0.88	-11.03	-0.46	2.84e-25	Blood pressure (smoking interaction);
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.53e-19	Alzheimer's disease;
LGG	cis	rs9486715	0.838	rs7770889	chr6:96858453	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-14.4	-0.56	4.06e-39	Headache;
LGG	cis	rs12643440	0.538	rs6852278	chr4:17138490	A/C	cg22650099	chr4:17144496	NA	0.5	8.66	0.37	7.82e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs78366141	0.649	rs73842241	chr4:89727597	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	1.07	8.91	0.38	1.18e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2735413	0.632	rs111694993	chr16:78094311	G/A	cg04733911	chr16:78082701	NA	0.67	11.06	0.46	2.08e-25	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg21782813	chr7:2030301	MAD1L1	-0.46	-11.19	-0.46	6.64e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs798766	1.000	rs798755	chr4:1720824	A/G	cg00006948	chr4:1768889	NA	-0.5	-6.98	-0.31	1.05e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs2070488	0.965	rs2051216	chr3:38562288	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.77	-0.64	3.05e-54	Electrocardiographic conduction measures;
LGG	cis	rs6065	0.618	rs4790719	chr17:4881434	A/G	cg03443944	chr17:4872326	CAMTA2;SPAG7	0.5	6.91	0.31	1.56e-11	Platelet count;
LGG	cis	rs2797160	1.000	rs1739347	chr6:126014157	C/T	cg05901451	chr6:126070800	HEY2	0.43	7.3	0.32	1.3e-12	Endometrial cancer;
LGG	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg16325326	chr1:53192061	ZYG11B	-0.75	-18.02	-0.64	2.25e-55	Monocyte count;
LGG	cis	rs4743820	0.651	rs10820838	chr9:93930913	G/A	cg14446406	chr9:93919335	NA	0.88	14.96	0.57	1.52e-41	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg15681537	chr21:22370733	NCAM2	0.38	6.73	0.3	5.02e-11	Response to antipsychotic treatment;
LGG	cis	rs6708331	0.941	rs13028968	chr2:70407123	A/G	cg01613454	chr2:70366299	NA	0.5	8.91	0.38	1.19e-17	Obesity-related traits;
LGG	trans	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg01620082	chr3:125678407	NA	-0.63	-6.68	-0.3	7e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.510	rs2200158	chr12:33648538	G/A	cg26384229	chr12:38710491	ALG10B	-0.47	-8.26	-0.36	1.55e-15	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg12310025	chr6:25882481	NA	0.72	14.38	0.56	4.94e-39	Blood metabolite levels;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg19168338	chr16:4465731	CORO7	-0.87	-16.2	-0.6	4.34e-47	Schizophrenia;
LGG	cis	rs7923609	0.934	rs10761763	chr10:65188318	T/C	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg17691542	chr6:26056736	HIST1H1C	-0.63	-10.54	-0.44	2.02e-23	Iron status biomarkers;
LGG	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.8e-12	Aortic root size;
LGG	cis	rs6032067	0.852	rs2233882	chr20:43835683	T/A	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg03452623	chr4:187889614	NA	1.04	29.55	0.81	1.24e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg03342759	chr3:160939853	NMD3	-0.43	-7.24	-0.32	1.93e-12	Morning vs. evening chronotype;
LGG	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.86	-0.3	2.27e-11	Educational attainment;
LGG	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs10905065	1.000	rs10905065	chr10:5769827	C/T	cg11519256	chr10:5708881	ASB13	0.4	6.92	0.31	1.49e-11	Menopause (age at onset);
LGG	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg18196295	chr10:418757	DIP2C	0.65	13.2	0.52	5.67e-34	Psychosis in Alzheimer's disease;
LGG	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg11965913	chr1:205819406	PM20D1	-0.43	-6.76	-0.3	4.15e-11	Parkinson's disease;
LGG	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.17	-0.43	4.75e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs1982963	0.639	rs2749875	chr14:52503396	G/A	cg05884192	chr14:52515736	NID2	-0.33	-8.12	-0.35	4.29e-15	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs79839061	0.562	rs10516158	chr4:942439	A/G	cg07828340	chr4:882639	GAK	-0.89	-9.48	-0.4	1.32e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.840	rs6428560	chr1:90102462	A/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.33	0.5	2.14e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg19131313	chr8:1704013	NA	-0.3	-6.69	-0.3	6.36e-11	Systolic blood pressure;
LGG	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.42	-6.75	-0.3	4.55e-11	Bipolar disorder;
LGG	trans	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg02800362	chr5:177631904	HNRNPAB	0.51	7.13	0.31	3.96e-12	Obesity-related traits;
LGG	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.74	0.71	9.56e-73	Bladder cancer;
LGG	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg05207973	chr5:176823642	SLC34A1	0.37	6.65	0.3	8.5e-11	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12431410	0.550	rs8007780	chr14:60198047	T/C	cg07950296	chr14:60194823	RTN1	-0.39	-7.47	-0.33	4.13e-13	Schizophrenia;
LGG	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg27129171	chr3:47204927	SETD2	0.78	15.1	0.57	3.61e-42	Colorectal cancer;
LGG	cis	rs270601	0.721	rs162891	chr5:131623268	T/C	cg07395648	chr5:131743802	NA	-0.37	-7.28	-0.32	1.46e-12	Acylcarnitine levels;
LGG	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg18854424	chr1:2615690	NA	-0.35	-7.35	-0.32	9.06e-13	Ulcerative colitis;
LGG	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.26	0.43	2.24e-22	Motion sickness;
LGG	cis	rs4774899	0.966	rs2593237	chr15:57481049	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.21	-0.32	2.24e-12	Urinary tract infection frequency;
LGG	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.95	-0.38	8.89e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19944463	chr1:160068529	IGSF8	0.46	6.99	0.31	9.51e-12	Gut microbiome composition (summer);
LGG	cis	rs3816183	0.958	rs4952939	chr2:43025207	T/C	cg14631114	chr2:43023945	NA	0.49	9.25	0.39	8.19e-19	Hypospadias;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs5769765	0.671	rs138841	chr22:50181960	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-8.51	-0.37	2.35e-16	Schizophrenia;
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg16885296	chr6:26284938	NA	-0.36	-7.66	-0.34	1.12e-13	Educational attainment;
LGG	trans	rs877282	0.898	rs11253340	chr10:764786	G/T	cg22713356	chr15:30763199	NA	0.52	7.68	0.34	9.24e-14	Uric acid levels;
LGG	trans	rs6787172	0.622	rs12629125	chr3:158133270	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.44	-0.33	4.91e-13	Subjective well-being;
LGG	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.8	0.3	3.33e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs7760949	0.889	rs9475816	chr6:13935425	T/C	cg27413430	chr6:13925136	RNF182	0.48	7.23	0.32	1.95e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs16976116	0.901	rs8027256	chr15:55492323	C/A	cg11288833	chr15:55489084	RSL24D1	0.55	7.17	0.32	2.95e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4684776	1.000	rs6789482	chr3:11440597	G/A	cg24705426	chr3:11550659	ATG7	-0.41	-7.52	-0.33	2.84e-13	Small vessel stroke;
LGG	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg06115741	chr20:33292138	TP53INP2	0.55	8.86	0.38	1.76e-17	Coronary artery disease;
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.07	0.35	6.01e-15	Systemic lupus erythematosus;
LGG	cis	rs6489785	0.525	rs558275	chr12:121196891	A/G	cg02419362	chr12:121203948	SPPL3	0.42	6.68	0.3	6.75e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6456042	0.829	rs3127419	chr6:166538527	A/G	cg11088901	chr6:166572345	T	-0.36	-7.41	-0.33	6.25e-13	Asthma;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg02002194	chr4:3960332	NA	0.42	7.66	0.34	1.08e-13	Triglycerides;
LGG	trans	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg05059571	chr16:84539110	KIAA1609	0.58	11.03	0.46	2.83e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg14993813	chr1:46806288	NSUN4	-0.55	-9.12	-0.39	2.39e-18	Menopause (age at onset);
LGG	cis	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.64	0.33	1.27e-13	Platelet distribution width;
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg18032289	chr17:61959525	GH2	-0.42	-7.1	-0.31	4.7e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16856342	chr1:67895909	SERBP1	-0.39	-7.37	-0.32	8.13e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7666738	0.830	rs11935078	chr4:99010476	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7808935	0.591	rs62451117	chr7:27942357	T/C	cg22168087	chr7:27702803	HIBADH	0.75	10.47	0.44	3.49e-23	Prostate cancer;
LGG	cis	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg07460842	chr6:66804631	NA	0.73	12.59	0.51	1.76e-31	Type 2 diabetes;
LGG	cis	rs564799	1.000	rs564799	chr3:159728987	C/T	cg04855961	chr3:159719849	NA	-0.29	-7.82	-0.34	3.65e-14	Systemic lupus erythematosus;
LGG	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg00170343	chr3:11313890	ATG7	0.52	6.69	0.3	6.66e-11	Circulating chemerin levels;
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00149659	chr3:10157352	C3orf10	0.88	11.35	0.47	1.69e-26	Alzheimer's disease;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg11494091	chr17:61959527	GH2	0.49	7.43	0.33	5.35e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs657075	0.595	rs35719560	chr5:131584395	T/C	cg14196790	chr5:131705035	SLC22A5	0.49	6.86	0.3	2.22e-11	Rheumatoid arthritis;
LGG	cis	rs714031	0.772	rs4821914	chr22:40091547	A/G	cg21377881	chr22:40064566	CACNA1I	-0.57	-13.16	-0.52	8.07e-34	Schizophrenia;
LGG	trans	rs9354308	0.868	rs6907911	chr6:66555683	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.96	-0.38	8.2e-18	Metabolite levels;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg06654118	chr4:1303317	MAEA	-0.4	-6.8	-0.3	3.25e-11	Obesity-related traits;
LGG	cis	rs13260300	0.657	rs10957733	chr8:75523288	A/T	cg22993706	chr8:75542856	NA	-0.42	-8.19	-0.36	2.54e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.78e-11	Coronary artery disease;
LGG	cis	rs2404602	0.735	rs11857327	chr15:76764263	G/C	cg23625390	chr15:77176239	SCAPER	-0.65	-12.89	-0.51	1.08e-32	Blood metabolite levels;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg21782813	chr7:2030301	MAD1L1	0.53	13.17	0.52	7.17e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs6426558	0.537	rs4500279	chr1:227484482	G/A	cg10327440	chr1:227177885	CDC42BPA	0.61	10.12	0.43	6.93e-22	Neutrophil percentage of white cells;
LGG	cis	rs1816854	1.000	rs1816854	chr12:44205018	A/G	cg00106942	chr12:44200524	TWF1	0.44	6.8	0.3	3.18e-11	Inflammatory bowel disease;
LGG	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg13441142	chr10:134499734	INPP5A	0.49	8.26	0.36	1.51e-15	Primary sclerosing cholangitis;
LGG	cis	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05901451	chr6:126070800	HEY2	-0.69	-12.92	-0.51	7.83e-33	Brugada syndrome;
LGG	cis	rs16854884	1.000	rs7649614	chr3:143789028	G/A	cg06585982	chr3:143692056	C3orf58	0.54	8.33	0.36	9.36e-16	Economic and political preferences (feminism/equality);
LGG	cis	rs4604732	0.631	rs1106719	chr1:247624713	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.59	-9.07	-0.39	3.53e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs11700980	0.551	rs2832030	chr21:30114620	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.02	-0.35	8.86e-15	Calcium levels;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.05	-0.42	1.25e-21	Platelet count;
LGG	cis	rs68170813	0.617	rs76923959	chr7:107182915	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.33	-0.36	9.27e-16	Coronary artery disease;
LGG	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-10.51	-0.44	2.56e-23	Morning vs. evening chronotype;
LGG	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.84e-16	Aortic root size;
LGG	cis	rs4302748	0.862	rs11772280	chr7:36186110	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	trans	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs9768139	0.903	rs28503558	chr7:158119568	C/T	cg15736062	chr7:158136485	PTPRN2	0.38	7.54	0.33	2.48e-13	Calcium levels;
LGG	cis	rs1620921	0.524	rs7450979	chr6:161186889	A/C	cg01280913	chr6:161186852	NA	0.53	11.12	0.46	1.23e-25	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9357271	1.000	rs9380740	chr6:38333474	T/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.55	-0.44	1.83e-23	Restless legs syndrome;
LGG	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.12	0.31	4.22e-12	Educational attainment;
LGG	trans	rs34421088	0.532	rs2736258	chr8:11170449	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs3820068	0.608	rs7519899	chr1:16045579	A/G	cg05660106	chr1:15850417	CASP9	0.75	13.79	0.54	1.7e-36	Systolic blood pressure;
LGG	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs7765175	0.698	rs9320440	chr6:113667184	A/C	cg26552650	chr6:113682475	NA	0.33	7.55	0.33	2.35e-13	Coronary artery calcification;
LGG	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg02811702	chr13:24901961	NA	0.4	7.55	0.33	2.27e-13	Obesity-related traits;
LGG	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.65	-0.33	1.21e-13	Morning vs. evening chronotype;
LGG	cis	rs7017914	0.902	rs7831792	chr8:71565356	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.91	-0.31	1.6e-11	Bone mineral density;
LGG	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg13877915	chr19:58951672	ZNF132	1.0	27.05	0.78	2.37e-97	Uric acid clearance;
LGG	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	1.99e-19	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4948102	0.924	rs13240915	chr7:56090752	G/C	cg17215666	chr7:56131930	SUMF2	0.43	6.91	0.31	1.61e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16405210	chr4:1374714	KIAA1530	-0.83	-15.36	-0.58	2.61e-43	Longevity;
LGG	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg01557791	chr16:72042693	DHODH	-0.51	-9.38	-0.4	2.93e-19	Fibrinogen levels;
LGG	cis	rs9815354	1.000	rs9842305	chr3:41998412	G/A	cg03022575	chr3:42003672	ULK4	-0.63	-8.13	-0.35	3.99e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg13385521	chr17:29058706	SUZ12P	0.77	8.69	0.37	6.26e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12153243	0.714	rs6894302	chr5:142913502	G/A	cg13907255	chr5:142895549	NA	-0.49	-8.51	-0.37	2.47e-16	Migraine;
LGG	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg03160526	chr17:80928410	B3GNTL1	0.5	7.88	0.34	2.39e-14	Glycated hemoglobin levels;
LGG	cis	rs7666738	0.830	rs11097606	chr4:99011486	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.2e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs838147	0.844	rs8102032	chr19:49249795	C/T	cg13540341	chr19:49222985	MAMSTR	0.44	10.54	0.44	2.03e-23	Dietary macronutrient intake;
LGG	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.43	-7.35	-0.32	8.93e-13	Blood metabolite levels;
LGG	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18876405	chr7:65276391	NA	-0.59	-11.13	-0.46	1.19e-25	Aortic root size;
LGG	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg25809561	chr17:30822961	MYO1D	0.4	9.79	0.41	1.03e-20	Schizophrenia;
LGG	cis	rs11696845	0.761	rs11698203	chr20:43357899	C/T	cg25301532	chr20:43378953	KCNK15	-0.44	-10.32	-0.43	1.25e-22	Obesity-related traits;
LGG	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.44	0.37	4.02e-16	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg06968155	chr5:131705112	SLC22A5	0.72	8.3	0.36	1.18e-15	Rheumatoid arthritis;
LGG	cis	rs12493885	0.818	rs61791543	chr3:153766797	C/G	cg12800244	chr3:153838788	SGEF	-0.82	-8.95	-0.38	8.88e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.12	-0.6	9.81e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2671245	1.000	rs2767515	chr1:56165742	C/G	cg11523071	chr1:56160889	NA	-0.29	-6.87	-0.3	2.1e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg24675658	chr1:53192096	ZYG11B	0.62	13.11	0.52	1.25e-33	Monocyte count;
LGG	cis	rs919433	0.783	rs55725278	chr2:198238223	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.37	0.32	8.15e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7247513	1.000	rs12459123	chr19:12689741	T/C	cg01871581	chr19:12707946	ZNF490	-0.43	-8.73	-0.38	4.52e-17	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg04287289	chr16:89883240	FANCA	0.8	16.86	0.62	4.57e-50	Vitiligo;
LGG	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.93	-16.7	-0.61	2.33e-49	Homoarginine levels;
LGG	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg03264133	chr6:25882463	NA	-0.45	-7.4	-0.33	6.2800000000000005e-13	Iron status biomarkers;
LGG	trans	rs9929218	0.608	rs35158985	chr16:68796746	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.6	-10.24	-0.43	2.62e-22	Colorectal cancer;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg01988459	chr11:68622903	NA	-0.64	-12.77	-0.51	3.37e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs919433	0.927	rs3843857	chr2:198195965	T/C	cg00792783	chr2:198669748	PLCL1	-0.46	-7.25	-0.32	1.79e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.27	-42.87	-0.89	2.59e-163	Myeloid white cell count;
LGG	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg08085267	chr17:45401833	C17orf57	0.57	11.31	0.47	2.28e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.19	0.36	2.58e-15	Retinal vascular caliber;
LGG	cis	rs7385804	0.727	rs551238	chr7:100321528	G/T	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.37e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg10818794	chr15:86012489	AKAP13	0.36	7.29	0.32	1.36e-12	Bulimia nervosa;
LGG	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg04398451	chr17:18023971	MYO15A	-0.86	-19.52	-0.67	2.3e-62	Total body bone mineral density;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg04863758	chr4:1303710	MAEA	0.46	7.7	0.34	8.51e-14	Obesity-related traits;
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14893161	chr1:205819251	PM20D1	0.48	7.72	0.34	7.04e-14	Parkinson's disease;
LGG	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg13385794	chr1:248469461	NA	0.44	7.65	0.34	1.14e-13	Common traits (Other);
LGG	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg05491587	chr18:77659695	KCNG2	-0.52	-6.8	-0.3	3.21e-11	Opioid sensitivity;
LGG	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg17211192	chr8:82754475	SNX16	0.78	12.04	0.49	3.1e-29	Diastolic blood pressure;
LGG	cis	rs9309473	1.000	rs2421555	chr2:73816955	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.24	-0.32	1.89e-12	Metabolite levels;
LGG	cis	rs9733	0.818	rs11204702	chr1:150663507	C/A	cg13175981	chr1:150552382	MCL1	0.54	9.18	0.39	1.42e-18	Tonsillectomy;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.71	-0.34	8.03e-14	Personality dimensions;
LGG	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.47	0.37	3.31e-16	Triglycerides;
LGG	cis	rs12286929	0.589	rs4938190	chr11:115087750	C/T	cg04055981	chr11:115044050	NA	0.36	6.76	0.3	4.11e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg08888203	chr3:10149979	C3orf24	-0.54	-7.77	-0.34	5.23e-14	Alzheimer's disease;
LGG	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg01244601	chr4:120671846	NA	-0.42	-7.91	-0.34	1.96e-14	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg23758822	chr17:41437982	NA	0.85	14.6	0.56	5.35e-40	Menopause (age at onset);
LGG	cis	rs7020830	0.867	rs55845273	chr9:37362219	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	31.9	0.83	5.71e-119	Schizophrenia;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-11.9	-0.48	1.16e-28	Longevity;Endometriosis;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	8.54	0.37	1.94e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.27	-0.32	1.57e-12	Lung cancer;
LGG	cis	rs9447004	0.584	rs12215671	chr6:74435607	T/C	cg03006477	chr6:74432658	CD109	0.28	7.22	0.32	2.14e-12	Blood protein levels;Calcium levels;
LGG	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.79e-14	Iron status biomarkers;
LGG	cis	rs9357271	1.000	rs7743023	chr6:38348437	C/G	cg07362130	chr6:38359646	BTBD9	-0.48	-10.99	-0.45	3.89e-25	Restless legs syndrome;
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.07e-18	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19853927	chr3:153839743	SGEF	0.39	6.65	0.3	8.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs870825	0.860	rs72703529	chr4:185607351	T/C	cg04058563	chr4:185651563	MLF1IP	1.04	19.68	0.67	4.31e-63	Blood protein levels;
LGG	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg13010199	chr12:38710504	ALG10B	0.56	11.12	0.46	1.24e-25	Heart rate;
LGG	cis	rs3771570	1.000	rs59536819	chr2:242272388	A/G	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs9487094	0.922	rs68042406	chr6:109803595	G/A	cg16315928	chr6:109776240	MICAL1	0.53	8.85	0.38	1.82e-17	Height;
LGG	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg16662043	chr16:48846231	NA	0.37	7.19	0.32	2.67e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9309711	0.736	rs9309717	chr2:3495078	C/T	cg10845886	chr2:3471009	TTC15	0.58	10.96	0.45	5.02e-25	Neurofibrillary tangles;
LGG	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg19507638	chr5:93509721	C5orf36	-0.73	-10.09	-0.42	9.28e-22	Diabetic retinopathy;
LGG	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.34	-0.4	4.22e-19	Coronary artery disease;
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-8.98	-0.39	6.95e-18	Dementia with Lewy bodies;
LGG	cis	rs10463316	0.604	rs28744577	chr5:150768983	A/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.09	-0.42	9.06e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18432924	chr14:50359459	ARF6	0.46	7.34	0.32	9.77e-13	Cognitive performance;
LGG	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.32	-0.4	4.65e-19	Height;
LGG	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.0	-0.31	8.93e-12	Schizophrenia;
LGG	cis	rs6087990	0.806	rs4911108	chr20:31375311	A/G	cg13636640	chr20:31349939	DNMT3B	0.95	20.21	0.68	1.35e-65	Ulcerative colitis;
LGG	cis	rs72781680	0.799	rs2551332	chr2:23988950	T/C	cg08917208	chr2:24149416	ATAD2B	0.64	8.41	0.36	5.18e-16	Lymphocyte counts;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.09	0.42	8.74e-22	Prudent dietary pattern;
LGG	cis	rs7928758	0.945	rs55986667	chr11:134280126	A/C	cg15243474	chr11:134282918	B3GAT1	1.06	13.7	0.54	4.38e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg13312174	chr5:178288687	ZNF354B	-0.35	-6.89	-0.31	1.78e-11	Sleep duration;
LGG	cis	rs9944715	0.954	rs13381523	chr18:43747750	A/C	cg26436583	chr18:43649176	PSTPIP2	0.39	7.41	0.33	5.96e-13	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2952156	1.000	rs1565923	chr17:37858678	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-13.5	-0.53	2.93e-35	Asthma;
LGG	cis	rs10463316	0.862	rs10071166	chr5:150768795	T/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.11	-0.43	7.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg00800038	chr16:89945340	TCF25	-0.69	-9.16	-0.39	1.71e-18	Skin colour saturation;
LGG	trans	rs656319	0.729	rs671370	chr8:9813317	T/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.75	-0.3	4.46e-11	Myopia (pathological);
LGG	cis	rs17221829	0.739	rs72971036	chr11:89370552	G/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.18	-0.39	1.46e-18	Anxiety in major depressive disorder;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4742903	0.935	rs10820618	chr9:106960503	T/A	cg14250997	chr9:106856677	SMC2	0.39	8.1	0.35	4.87e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1801251	1.000	rs13003675	chr2:233584109	C/T	cg08000102	chr2:233561755	GIGYF2	0.58	9.46	0.4	1.54e-19	Coronary artery disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16424920	chr8:9760855	LOC157627	0.59	6.72	0.3	5.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	26.63	0.78	1.86e-95	Height;
LGG	cis	rs9473924	0.542	rs2817378	chr6:50789197	G/A	cg14470998	chr6:50812995	TFAP2B	0.69	8.25	0.36	1.62e-15	Body mass index;
LGG	cis	rs7000551	0.715	rs2461477	chr8:22378314	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	12.35	0.5	1.72e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2131877	0.599	rs60329099	chr3:194875310	G/A	cg07250128	chr3:194833983	C3orf21	0.32	6.85	0.3	2.3e-11	Non-small cell lung cancer;
LGG	cis	rs2236918	1.000	rs2995544	chr1:242020495	C/T	cg17736920	chr1:242011382	EXO1	0.5	8.95	0.38	8.5e-18	Menopause (age at onset);
LGG	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg25427524	chr10:38739819	LOC399744	0.36	6.7	0.3	6.06e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg23601095	chr6:26197514	HIST1H3D	0.7	8.33	0.36	9.34e-16	Gout;Renal underexcretion gout;
LGG	cis	rs35740288	0.822	rs11629690	chr15:86287724	G/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.06	-0.31	5.95e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-9.0	-0.39	5.66e-18	Menarche (age at onset);
LGG	cis	rs3126085	0.935	rs6681457	chr1:152297117	C/T	cg26876637	chr1:152193138	HRNR	-0.5	-7.76	-0.34	5.55e-14	Atopic dermatitis;
LGG	cis	rs714515	0.934	rs9425592	chr1:172359116	A/G	cg01573306	chr1:172330400	DNM3	0.34	7.42	0.33	5.49e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs7717393	0.786	rs7722282	chr5:155797834	G/A	cg12904904	chr5:155754151	SGCD	0.68	7.8	0.34	4.06e-14	Egg allergy;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.13	-0.31	3.84e-12	Obesity-related traits;
LGG	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg16339924	chr4:17578868	LAP3	-0.47	-7.81	-0.34	3.91e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7909791	0.743	rs12776760	chr10:105627575	C/A	cg11005552	chr10:105648138	OBFC1	0.64	9.58	0.41	5.75e-20	White matter hyperintensity burden;
LGG	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.86	-0.59	1.49e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs9815354	0.761	rs73079307	chr3:41862273	A/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg03474202	chr17:45855739	NA	0.27	7.87	0.34	2.51e-14	IgG glycosylation;
LGG	cis	rs7315438	0.512	rs10850528	chr12:115948433	G/A	cg18639984	chr12:115943877	NA	-0.41	-8.92	-0.38	1.07e-17	Colorectal cancer;
LGG	cis	rs28595532	0.764	rs115877991	chr4:119728298	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.85	0.34	3e-14	Cannabis dependence symptom count;
LGG	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg24011408	chr12:48396354	COL2A1	0.5	8.07	0.35	6.21e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.05	-0.39	4.08e-18	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg04863758	chr4:1303710	MAEA	0.44	7.59	0.33	1.74e-13	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.5e-77	Homoarginine levels;
LGG	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg06138931	chr13:21896616	NA	-0.42	-6.88	-0.3	1.89e-11	White matter hyperintensity burden;
LGG	cis	rs7582180	0.838	rs6754867	chr2:100895081	A/G	cg26150922	chr2:100937072	LONRF2	0.44	7.59	0.33	1.72e-13	Intelligence (multi-trait analysis);
LGG	cis	rs13053817	1.000	rs78186489	chr22:29845703	C/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.75	-0.3	4.35e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs17227506	0.560	rs11779678	chr8:13483857	T/C	cg03566418	chr8:13424080	C8orf48	0.55	8.16	0.35	3.27e-15	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05786287	chr3:120460945	RABL3;GTF2E1	0.39	6.87	0.3	2.06e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg26384229	chr12:38710491	ALG10B	0.73	14.69	0.56	2.34e-40	Morning vs. evening chronotype;
LGG	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg06138931	chr13:21896616	NA	-0.44	-7.22	-0.32	2.17e-12	White matter hyperintensity burden;
LGG	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg19812747	chr11:111475976	SIK2	0.41	8.69	0.37	6.2e-17	Primary sclerosing cholangitis;
LGG	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg03098644	chr7:100410630	EPHB4	0.47	7.18	0.32	2.83e-12	Other erythrocyte phenotypes;
LGG	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg26384229	chr12:38710491	ALG10B	0.86	19.23	0.67	5.43e-61	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg13683864	chr3:40499215	RPL14	1.15	28.92	0.8	8.46e-106	Renal cell carcinoma;
LGG	cis	rs9633740	0.773	rs7080009	chr10:82269461	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	16.56	0.61	1.04e-48	Post bronchodilator FEV1;
LGG	cis	rs4538187	0.901	rs67765474	chr2:64168437	C/T	cg19915305	chr2:64069682	UGP2	-0.68	-15.27	-0.58	5.98e-43	Systolic blood pressure;
LGG	cis	rs9359856	0.510	rs2748298	chr6:90436877	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-13.18	-0.52	6.77e-34	Bipolar disorder;
LGG	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg23978390	chr7:1156363	C7orf50	0.51	8.79	0.38	3e-17	Longevity;Endometriosis;
LGG	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.69	0.3	6.39e-11	Bronchopulmonary dysplasia;
LGG	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	13.53	0.53	2.26e-35	Colorectal cancer;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg21972741	chr5:435613	AHRR	0.49	8.41	0.36	5.13e-16	Cystic fibrosis severity;
LGG	cis	rs2777491	1.000	rs316610	chr15:41752852	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.1	-0.68	4.42e-65	Ulcerative colitis;
LGG	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.72	-0.38	5.13e-17	Alcohol dependence;
LGG	cis	rs4417704	0.551	rs4675789	chr2:241875481	A/G	cg05025159	chr2:241905733	NA	-0.46	-9.48	-0.4	1.33e-19	Joint mobility (Beighton score);
LGG	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.77	0.54	2.18e-36	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04703844	chr8:74207197	RPL7;RDH10	0.44	6.8	0.3	3.24e-11	Gut microbiome composition (summer);
LGG	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.84	0.3	2.53e-11	Hemoglobin concentration;
LGG	cis	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.21e-25	Corneal astigmatism;
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg16339924	chr4:17578868	LAP3	0.63	10.92	0.45	7.52e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg15971980	chr6:150254442	NA	0.45	8.53	0.37	2.13e-16	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26705425	chr19:54024076	ZNF331	0.42	6.67	0.3	7.36e-11	Cognitive performance;
LGG	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg03689076	chr20:33865952	NA	-0.7	-9.34	-0.4	4.03e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs1256531	0.661	rs28583930	chr14:66223660	G/C	cg15999311	chr14:65749247	NA	0.83	7.0	0.31	9.31e-12	Conduct disorder (symptom count);
LGG	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg12856521	chr11:46389249	DGKZ	-0.39	-6.81	-0.3	2.98e-11	Leprosy;
LGG	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg19507638	chr5:93509721	C5orf36	0.41	6.88	0.3	1.97e-11	Diabetic retinopathy;
LGG	cis	rs599083	0.530	rs583545	chr11:68178635	T/C	cg16797656	chr11:68205561	LRP5	-0.46	-7.67	-0.34	1.05e-13	Bone mineral density (spine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11754343	chr17:5322575	RPAIN;NUP88	0.48	7.04	0.31	6.78e-12	Gut microbiome composition (summer);
LGG	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg24812749	chr6:127587940	RNF146	0.97	16.06	0.6	1.86e-46	Breast cancer;
LGG	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	7.45	0.33	4.66e-13	Educational attainment;
LGG	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg25019033	chr10:957182	NA	-0.6	-12.68	-0.51	8.1e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	21.2	0.7	3.26e-70	Platelet count;
LGG	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg24812749	chr6:127587940	RNF146	0.97	16.19	0.6	4.78e-47	Breast cancer;
LGG	cis	rs11770686	0.513	rs2705825	chr7:75301209	T/C	cg07211516	chr7:75296079	HIP1	-0.38	-7.78	-0.34	4.86e-14	Essential tremor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06694616	chr6:110012409	AKD1;FIG4	0.39	6.67	0.3	7.25e-11	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg15704280	chr7:45808275	SEPT13	0.42	6.67	0.3	7.43e-11	HDL cholesterol;
LGG	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg22283653	chr8:49824208	NA	-0.49	-8.93	-0.38	9.96e-18	Sudden cardiac arrest;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg18350739	chr11:68623251	NA	-0.89	-21.72	-0.71	1.17e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6815814	0.898	rs5743562	chr4:38806096	T/C	cg06935464	chr4:38784597	TLR10	0.6	8.24	0.36	1.76e-15	Breast cancer;
LGG	cis	rs1345301	1.000	rs1420093	chr2:102870458	T/C	cg05295703	chr2:102895712	NA	0.38	7.53	0.33	2.59e-13	Waist circumference;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg15665833	chr6:26285013	NA	0.37	7.11	0.31	4.49e-12	Educational attainment;
LGG	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg26076054	chr5:421317	AHRR	0.42	7.62	0.33	1.48e-13	Cystic fibrosis severity;
LGG	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.72	-0.41	1.84e-20	Retinal vascular caliber;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg18350739	chr11:68623251	NA	-0.85	-21.84	-0.71	3.45e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs425535	0.702	rs168450	chr4:74793605	C/A	cg01447579	chr4:74847100	PF4	0.54	6.68	0.3	6.82e-11	Blood protein levels;
LGG	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg20848291	chr7:100343083	ZAN	-0.66	-9.5	-0.4	1.14e-19	Other erythrocyte phenotypes;
LGG	cis	rs9944715	0.954	rs62096526	chr18:43745639	G/A	cg26436583	chr18:43649176	PSTPIP2	0.4	7.39	0.32	6.98e-13	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.43	-0.33	5.19e-13	Personality dimensions;
LGG	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg05775895	chr3:12838266	CAND2	0.65	11.75	0.48	4.26e-28	QRS complex (12-leadsum);
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.75	0.41	1.51e-20	Joint mobility (Beighton score);
LGG	cis	rs774359	0.789	rs17779457	chr9:27488092	G/T	cg21249376	chr9:27528432	MOBKL2B	-0.47	-9.04	-0.39	4.25e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs4891159	0.548	rs690423	chr18:74117984	G/A	cg24786174	chr18:74118243	ZNF516	0.69	17.28	0.63	5.54e-52	Longevity;
LGG	trans	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg02002194	chr4:3960332	NA	0.44	8.11	0.35	4.45e-15	Monocyte count;
LGG	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-10.72	-0.45	4.21e-24	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.01	-0.55	1.94e-37	Alzheimer's disease;
LGG	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.49	0.56	1.61e-39	Heart rate;
LGG	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.3	-7.38	-0.32	7.42e-13	Restless legs syndrome;
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.82	-0.34	3.5e-14	Initial pursuit acceleration;
LGG	cis	rs4975709	0.758	rs4975756	chr5:1882443	T/C	cg12288994	chr5:1860383	NA	0.69	11.0	0.46	3.65e-25	Cardiovascular disease risk factors;
LGG	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg11941060	chr3:133502564	NA	-0.48	-8.03	-0.35	8.18e-15	Iron status biomarkers;
LGG	cis	rs208520	0.690	rs207077	chr6:66769855	A/C	cg07460842	chr6:66804631	NA	-0.96	-17.75	-0.64	3.64e-54	Exhaled nitric oxide output;
LGG	cis	rs11122272	0.735	rs2808585	chr1:231514218	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7950696	1	rs7950696	chr11:47481533	T/C	cg20307385	chr11:47447363	PSMC3	0.6	11.8	0.48	2.9e-28	Platelet count;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg22798384	chr13:114889589	RASA3	0.4	6.96	0.31	1.18e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs9547996	0.879	rs7333205	chr13:38187458	A/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.65e-11	Diastolic blood pressure;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg14926445	chr8:58193284	C8orf71	-0.82	-10.6	-0.44	1.17e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg00024416	chr22:24240387	NA	-0.38	-6.99	-0.31	9.4e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12431410	0.550	rs11628085	chr14:60226370	T/C	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14240646	chr10:27532245	ACBD5	-0.56	-8.57	-0.37	1.58e-16	Breast cancer;
LGG	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	9.24	0.39	9.17e-19	Blood protein levels;
LGG	cis	rs6496044	0.568	rs11632326	chr15:86079834	A/C	cg13263323	chr15:86062960	AKAP13	-0.33	-6.84	-0.3	2.44e-11	Interstitial lung disease;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.29	-0.4	6.05e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01751605	chr7:137028546	PTN	0.44	7.0	0.31	9.29e-12	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-14.87	-0.57	3.57e-41	Prudent dietary pattern;
LGG	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg20587970	chr11:113659929	NA	0.9	14.02	0.55	1.8e-37	Hip circumference adjusted for BMI;
LGG	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg03342759	chr3:160939853	NMD3	-0.66	-11.77	-0.48	3.6e-28	Morning vs. evening chronotype;
LGG	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg11502198	chr6:26597334	ABT1	0.55	9.42	0.4	2.17e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1847505	0.574	rs112031726	chr13:61475108	C/T	cg25164009	chr13:61490935	NA	0.59	9.18	0.39	1.39e-18	Polychlorinated biphenyl levels;
LGG	cis	rs738322	0.804	rs4821742	chr22:38514839	T/C	cg03162506	chr22:38580953	NA	0.31	7.36	0.32	8.49e-13	Cutaneous nevi;
LGG	cis	rs611744	0.810	rs619227	chr8:109215100	C/A	cg21045802	chr8:109455806	TTC35	0.41	7.31	0.32	1.17e-12	Dupuytren's disease;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8028182	0.549	rs11072542	chr15:75634599	G/A	cg20655648	chr15:75932815	IMP3	-0.47	-7.65	-0.33	1.2e-13	Sudden cardiac arrest;
LGG	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-13.81	-0.54	1.43e-36	Gut microbiome composition (summer);
LGG	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg00864171	chr11:67383662	NA	-0.43	-7.08	-0.31	5.52e-12	Mean corpuscular volume;
LGG	cis	rs785830	0.717	rs600951	chr9:224742	A/G	cg14500300	chr9:211689	NA	0.3	7.57	0.33	1.99e-13	Platelet distribution width;
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg16590910	chr6:42928470	GNMT	0.46	13.4	0.53	7.46e-35	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg13385521	chr17:29058706	SUZ12P	0.68	8.08	0.35	5.63e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7226408	0.857	rs11661504	chr18:34518724	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6693567	0.545	rs2133129	chr1:150355537	T/C	cg15654264	chr1:150340011	RPRD2	0.33	6.79	0.3	3.4e-11	Migraine;
LGG	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg06766960	chr11:133703094	NA	-0.57	-11.39	-0.47	1.1e-26	Childhood ear infection;
LGG	cis	rs2041895	0.509	rs2024518	chr12:107296902	G/A	cg13944111	chr12:107296891	NA	0.27	7.29	0.32	1.35e-12	Glaucoma (low intraocular pressure);
LGG	cis	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg13647721	chr17:30228624	UTP6	0.67	6.89	0.3	1.83e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4696584	0.816	rs56223712	chr4:155403065	G/A	cg04517429	chr4:155413618	DCHS2	-0.32	-7.33	-0.32	1.06e-12	Folding of antihelix;
LGG	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg06609049	chr19:2785107	THOP1	0.96	16.62	0.61	5.4e-49	Total cholesterol levels;
LGG	cis	rs10870270	1.000	rs9971066	chr10:133788233	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.79	-0.51	2.71e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26887302	chr17:27181995	ERAL1	-0.49	-7.07	-0.31	5.9e-12	Systemic lupus erythematosus;
LGG	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.24	0.36	1.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg13385794	chr1:248469461	NA	0.49	8.27	0.36	1.47e-15	Common traits (Other);
LGG	cis	rs11809207	0.855	rs17257155	chr1:26526439	C/T	cg23602478	chr1:26503979	CNKSR1	-0.38	-7.26	-0.32	1.62e-12	Height;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.47e-27	Personality dimensions;
LGG	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg26597838	chr10:835615	NA	0.95	13.06	0.52	2.04e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg10189774	chr4:17578691	LAP3	-0.39	-7.08	-0.31	5.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.38	6.92	0.31	1.51e-11	Schizophrenia;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.8	-0.38	2.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11644478	chr21:40555479	PSMG1	0.92	17.88	0.64	9.15e-55	Cognitive function;
LGG	cis	rs4474465	0.688	rs10751296	chr11:78277277	C/T	cg27205649	chr11:78285834	NARS2	-0.6	-11.17	-0.46	8.52e-26	Alzheimer's disease (survival time);
LGG	cis	rs6964587	0.900	rs6465352	chr7:91775117	A/G	cg17063962	chr7:91808500	NA	0.53	9.81	0.42	8.76e-21	Breast cancer;
LGG	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-6.87	-0.3	2.14e-11	Huntington's disease progression;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	3.85e-20	Schizophrenia;
LGG	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg23594656	chr7:65796392	TPST1	0.36	8.04	0.35	7.79e-15	Aortic root size;
LGG	cis	rs12791968	0.765	rs12794846	chr11:44998943	C/T	cg11846598	chr11:44996168	LOC221122	0.59	9.98	0.42	2.29e-21	Inhibitory control;
LGG	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg05064044	chr6:292385	DUSP22	-0.67	-11.38	-0.47	1.22e-26	Menopause (age at onset);
LGG	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg15704280	chr7:45808275	SEPT13	0.77	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.86	-0.54	8.83e-37	Extrinsic epigenetic age acceleration;
LGG	trans	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg24247370	chr13:99142703	STK24	-0.37	-7.02	-0.31	8.14e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs7529073	0.683	rs340882	chr1:214145731	C/G	cg24083324	chr1:214162604	PROX1	0.43	7.58	0.33	1.92e-13	Schizophrenia;
LGG	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.69	0.3	6.58e-11	Homoarginine levels;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg26338869	chr17:61819248	STRADA	0.6	10.02	0.42	1.66e-21	Prudent dietary pattern;
LGG	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-31.6	-0.83	1.19e-117	Myeloid white cell count;
LGG	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg06606381	chr12:133084897	FBRSL1	0.9	9.02	0.39	5.14e-18	Depression;
LGG	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg20476274	chr7:133979776	SLC35B4	0.74	14.75	0.57	1.28e-40	Mean platelet volume;
LGG	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.33	0.36	9.31e-16	Type 2 diabetes;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg09426994	chr11:118478258	PHLDB1	-0.44	-8.15	-0.35	3.49e-15	Glioma;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.25	-0.32	1.73e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9354308	0.838	rs9354305	chr6:66542891	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.85	-0.34	2.86e-14	Metabolite levels;
LGG	cis	rs1506403	0.735	rs315281	chr7:142831639	C/T	cg11323483	chr7:142828068	PIP	-0.38	-6.97	-0.31	1.07e-11	Cancer;
LGG	cis	rs7666738	0.830	rs11097609	chr4:99011707	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.69e-16	Aortic root size;
LGG	cis	rs4906332	1.000	rs12892062	chr14:103883512	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.9	-0.34	2.08e-14	Coronary artery disease;
LGG	cis	rs2549003	0.811	rs10072700	chr5:131816903	A/C	cg21138405	chr5:131827807	IRF1	0.37	8.96	0.38	8.27e-18	Asthma (sex interaction);
LGG	cis	rs16854884	0.657	rs12107291	chr3:143739547	T/C	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs6728642	0.908	rs10207116	chr2:98018281	G/A	cg26665480	chr2:98280029	ACTR1B	-0.71	-8.4	-0.36	5.53e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg05623727	chr3:50126028	RBM5	-0.34	-7.54	-0.33	2.53e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.21	0.43	3.36e-22	Motion sickness;
LGG	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.79	-0.41	1.05e-20	Primary sclerosing cholangitis;
LGG	cis	rs7917772	0.636	rs7894154	chr10:104524647	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.98	-0.35	1.16e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg24687543	chr11:63912206	MACROD1	0.45	6.73	0.3	4.96e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg08930214	chr7:62859557	LOC100287834	0.45	7.63	0.33	1.35e-13	Obesity-related traits;
LGG	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg21045802	chr8:109455806	TTC35	0.53	9.84	0.42	6.9e-21	Dupuytren's disease;
LGG	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg13010199	chr12:38710504	ALG10B	0.72	14.05	0.55	1.39e-37	Morning vs. evening chronotype;
LGG	cis	rs1109114	0.738	rs9325136	chr5:148627252	G/A	cg06539116	chr5:148597365	ABLIM3	-0.52	-12.54	-0.5	3.02e-31	Body mass index;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg02158880	chr13:53174818	NA	0.47	9.67	0.41	2.85e-20	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17782706	chr4:184580436	C4orf41;RWDD4A	0.49	8.0	0.35	1.02e-14	Gut microbiome composition (summer);
LGG	cis	rs7192750	0.586	rs4788571	chr16:71920823	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.72	0.45	4.21e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7646881	1.000	rs7646987	chr3:158453442	A/G	cg19483011	chr3:158453295	NA	0.65	9.89	0.42	4.69e-21	Tetralogy of Fallot;
LGG	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg07549998	chr6:150325970	RAET1K	-0.37	-7.15	-0.32	3.43e-12	Alopecia areata;
LGG	cis	rs4363385	0.747	rs6587716	chr1:152966705	C/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.22	-0.39	1.08e-18	Inflammatory skin disease;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg13395646	chr4:1353034	KIAA1530	0.48	8.13	0.35	4e-15	Obesity-related traits;
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg14074117	chr16:1909714	C16orf73	0.54	8.1	0.35	5.07e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.47	-0.37	3.37e-16	Hemoglobin concentration;
LGG	cis	rs7107174	1.000	rs2512544	chr11:77986371	A/T	cg02023728	chr11:77925099	USP35	0.44	7.64	0.33	1.28e-13	Testicular germ cell tumor;
LGG	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.42	-0.36	4.93e-16	Type 2 diabetes;
LGG	cis	rs4959677	0.901	rs12210993	chr6:2480890	G/A	cg20147862	chr6:2634573	C6orf195	-0.41	-9.0	-0.39	5.85e-18	Orthostatic hypotension;
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg26554054	chr8:600488	NA	0.85	9.76	0.41	1.35e-20	IgG glycosylation;
LGG	cis	rs1506636	0.962	rs1472808	chr7:123354536	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs9549367	0.713	rs3024764	chr13:113824314	A/G	cg18105134	chr13:113819100	PROZ	-0.76	-16.58	-0.61	8.7e-49	Platelet distribution width;
LGG	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-7.22	-0.32	2.2e-12	Vitiligo;
LGG	cis	rs7582720	1.000	rs72934554	chr2:203987806	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.3	0.4	5.46e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg00531865	chr16:30841666	NA	0.6	12.85	0.51	1.58e-32	Dementia with Lewy bodies;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs789294	1	rs789294	chr3:154057741	C/G	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	cis	rs4851254	0.920	rs11686599	chr2:100753475	A/G	cg17356467	chr2:100759845	AFF3	0.4	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs4262150	0.774	rs4958564	chr5:152005941	T/C	cg12297329	chr5:152029980	NA	-0.79	-15.59	-0.59	2.27e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs3806843	0.966	rs2563261	chr5:140137713	G/T	cg19875535	chr5:140030758	IK	-0.54	-11.21	-0.46	5.53e-26	Depressive symptoms (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg12386194	chr3:101231763	SENP7	0.42	7.48	0.33	3.73e-13	Colorectal cancer;
LGG	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg23625390	chr15:77176239	SCAPER	0.49	9.56	0.41	6.92e-20	Blood metabolite levels;
LGG	cis	rs36051895	0.659	rs10974935	chr9:5050307	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.95	-0.6	5.75e-46	Pediatric autoimmune diseases;
LGG	cis	rs17106184	0.636	rs7543272	chr1:51069102	T/C	cg07174182	chr1:51127561	FAF1	0.38	6.67	0.3	7.35e-11	Type 2 diabetes;
LGG	cis	rs9649465	0.967	rs12537072	chr7:123377213	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg02002194	chr4:3960332	NA	0.39	6.99	0.31	9.75e-12	Neuroticism;
LGG	cis	rs1829883	0.835	rs2682139	chr5:98909924	G/A	cg08333243	chr5:99726346	NA	0.37	6.94	0.31	1.33e-11	Hemostatic factors and hematological phenotypes;
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.35	-0.4	3.69e-19	Systolic blood pressure;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg00855466	chr17:19652056	ALDH3A1	-0.58	-11.38	-0.47	1.29e-26	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg06521331	chr12:34319734	NA	-0.53	-8.78	-0.38	3.26e-17	Resting heart rate;
LGG	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg03342759	chr3:160939853	NMD3	-0.59	-10.11	-0.43	7.91e-22	Morning vs. evening chronotype;
LGG	cis	rs6964587	1.000	rs10236397	chr7:91691601	C/T	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26451873	chr13:26829095	CDK8	0.45	7.66	0.34	1.07e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs8002861	0.747	rs12866387	chr13:44391936	A/G	cg17145862	chr1:211918768	LPGAT1	0.83	18.31	0.65	1.03e-56	Leprosy;
LGG	cis	rs745821	0.879	rs3867257	chr18:48146048	T/G	cg18923635	chr18:48083994	NA	0.42	7.11	0.31	4.45e-12	Diastolic blood pressure;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg18681998	chr4:17616180	MED28	0.89	19.74	0.68	2.1e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs778371	0.697	rs4973564	chr2:233718440	A/G	cg08000102	chr2:233561755	GIGYF2	-0.73	-12.43	-0.5	8.41e-31	Schizophrenia;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.38	-0.53	9.53e-35	Alzheimer's disease;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.28	-0.4	6.79e-19	Platelet count;
LGG	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg17911788	chr17:44343683	NA	0.47	7.94	0.35	1.56e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg12373951	chr3:133503437	NA	0.43	7.76	0.34	5.48e-14	Iron status biomarkers;
LGG	cis	rs919433	0.617	rs700642	chr2:198600730	G/T	cg00792783	chr2:198669748	PLCL1	-0.65	-10.56	-0.44	1.75e-23	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7113874	0.524	rs10840092	chr11:8624915	A/G	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.68e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16405210	chr4:1374714	KIAA1530	0.67	12.29	0.5	3.15e-30	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.2e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.33e-26	Colorectal cancer;
LGG	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	7.0	0.31	9.24e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs2186369	0.681	rs9608185	chr22:24142977	G/C	cg10122452	chr22:24128767	SMARCB1	-0.4	-7.96	-0.35	1.35e-14	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11239187	0.530	rs10793544	chr10:45060304	C/T	cg03916630	chr10:45065415	NA	0.37	9.01	0.39	5.33e-18	Body mass index;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02475777	chr4:1388615	CRIPAK	0.6	10.76	0.45	3.06e-24	Longevity;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00657871	chr1:85156634	SSX2IP	0.39	6.75	0.3	4.47e-11	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg01221209	chr5:554886	NA	-0.47	-6.77	-0.3	3.99e-11	Obesity-related traits;
LGG	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	7.77	0.34	5.09e-14	Menarche (age at onset);
LGG	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.26	-0.32	1.67e-12	Hemoglobin concentration;
LGG	trans	rs9409565	0.826	rs9409556	chr9:97239268	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-7.99	-0.35	1.07e-14	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9814567	0.929	rs2241556	chr3:134183312	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.61	0.51	1.45e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.14	0.58	2.27e-42	Cognitive test performance;
LGG	trans	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg01134436	chr17:81009848	B3GNTL1	0.84	8.86	0.38	1.72e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.38	0.32	7.56e-13	Coronary artery disease;
LGG	cis	rs13314892	0.881	rs17006419	chr3:69816117	T/C	cg17445875	chr3:69859618	MITF	-0.35	-7.11	-0.31	4.52e-12	QRS complex (12-leadsum);
LGG	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg11584989	chr19:19387371	SF4	0.7	11.56	0.47	2.56e-27	Bipolar disorder;
LGG	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg15596359	chr8:11213517	TDH	0.41	8.43	0.36	4.55e-16	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01497487	chr22:38141814	TRIOBP	0.47	7.25	0.32	1.73e-12	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.5	-0.37	2.6e-16	Neuroticism;
LGG	cis	rs12949688	0.682	rs11657181	chr17:55838543	C/T	cg12582317	chr17:55822272	NA	0.53	12.44	0.5	7.55e-31	Schizophrenia;
LGG	cis	rs981844	0.767	rs6857738	chr4:154689140	A/C	cg14289246	chr4:154710475	SFRP2	-0.6	-10.6	-0.44	1.19e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs877282	0.842	rs35117541	chr10:764683	C/T	cg17470449	chr10:769945	NA	0.56	6.83	0.3	2.65e-11	Uric acid levels;
LGG	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-14.69	-0.56	2.28e-40	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs4038782	0.503	rs11862351	chr16:4903583	G/A	cg08329684	chr16:4932620	PPL	0.48	7.25	0.32	1.72e-12	Cancer;
LGG	cis	rs6684428	0.764	rs61777585	chr1:56394683	G/A	cg11651538	chr1:56320950	NA	-0.66	-11.9	-0.48	1.11e-28	Airflow obstruction;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg07959490	chr17:80112427	CCDC57	0.45	9.0	0.39	5.84e-18	Life satisfaction;
LGG	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg27432699	chr2:27873401	GPN1	-0.76	-15.89	-0.59	1.06e-45	Oral cavity cancer;
LGG	cis	rs6878727	0.815	rs988409	chr5:123730483	G/A	cg01806427	chr5:123737813	NA	0.32	6.83	0.3	2.63e-11	Breast cancer;
LGG	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.93	-0.31	1.38e-11	Blood metabolite levels;
LGG	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg26384229	chr12:38710491	ALG10B	0.88	19.75	0.68	2.06e-63	Bladder cancer;
LGG	cis	rs9354308	0.764	rs1938081	chr6:66611361	A/G	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg26597838	chr10:835615	NA	0.55	7.14	0.31	3.65e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg15704280	chr7:45808275	SEPT13	-1.09	-27.1	-0.78	1.39e-97	Height;
LGG	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg04058563	chr4:185651563	MLF1IP	-0.46	-9.76	-0.41	1.36e-20	Kawasaki disease;
LGG	cis	rs4704187	0.687	rs1477933	chr5:74437153	G/A	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.64	-0.56	3.74e-40	Schizophrenia;
LGG	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg26138144	chr22:38071188	LGALS1	0.68	15.51	0.58	5.21e-44	Fat distribution (HIV);
LGG	cis	rs1395	0.744	rs11126931	chr2:27474306	C/T	cg23587288	chr2:27483067	SLC30A3	-0.34	-7.75	-0.34	5.78e-14	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06214220	chr9:36400252	RNF38	0.42	7.01	0.31	8.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg05425664	chr17:57184151	TRIM37	0.62	9.89	0.42	4.74e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6684428	0.614	rs11206680	chr1:56364414	A/G	cg11651538	chr1:56320950	NA	-0.75	-12.82	-0.51	2.15e-32	Airflow obstruction;
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-8.43	-0.36	4.56e-16	Dementia with Lewy bodies;
LGG	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.8	-0.54	1.63e-36	Response to antipsychotic treatment;
LGG	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs13217239	0.608	rs6930508	chr6:27053142	T/C	cg12292205	chr6:26970375	C6orf41	-0.55	-10.82	-0.45	1.84e-24	Schizophrenia;
LGG	cis	rs1847505	0.609	rs78738196	chr13:61511592	C/T	cg25164009	chr13:61490935	NA	0.62	9.42	0.4	2.08e-19	Polychlorinated biphenyl levels;
LGG	cis	rs6860806	0.507	rs272880	chr5:131670178	C/T	cg07395648	chr5:131743802	NA	-0.49	-9.96	-0.42	2.6e-21	Breast cancer;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04455180	chr1:227506639	CDC42BPA	0.38	6.71	0.3	5.59e-11	Bilirubin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26853628	chr3:137834231	DZIP1L	0.47	7.47	0.33	3.95e-13	Gut microbiome composition (summer);
LGG	cis	rs6714710	0.603	rs11123974	chr2:98605982	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.02e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.34e-17	Bladder cancer;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg11062466	chr8:58055876	NA	0.48	8.27	0.36	1.41e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg08885076	chr2:99613938	TSGA10	0.5	10.53	0.44	2.15e-23	Chronic sinus infection;
LGG	cis	rs4954585	0.683	rs11678502	chr2:136994454	C/T	cg07169764	chr2:136633963	MCM6	-0.47	-7.58	-0.33	1.84e-13	Colorectal cancer;
LGG	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg06212747	chr3:49208901	KLHDC8B	0.61	10.3	0.43	1.52e-22	Parkinson's disease;
LGG	cis	rs2559856	1.000	rs2695298	chr12:102082589	G/A	cg12924262	chr12:102091054	CHPT1	0.64	12.8	0.51	2.44e-32	Blood protein levels;
LGG	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2273669	0.915	rs6907937	chr6:109293898	T/G	cg05315195	chr6:109294784	ARMC2	-0.51	-7.29	-0.32	1.35e-12	Prostate cancer;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04772025	chr11:68637568	NA	0.74	12.89	0.51	1.11e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	cis	rs36051895	0.559	rs6476949	chr9:5208048	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-11.61	-0.47	1.63e-27	Pediatric autoimmune diseases;
LGG	cis	rs9811920	0.609	rs9872871	chr3:99658702	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.05	-0.39	4.07e-18	Axial length;
LGG	cis	rs2071303	1.000	rs2071303	chr6:26091336	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.43	-6.89	-0.31	1.78e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.903	rs2474769	chr20:25248725	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.4	0.44	6.48e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	cis	rs4959677	0.725	rs9503212	chr6:2501535	A/G	cg20147862	chr6:2634573	C6orf195	-0.39	-8.58	-0.37	1.49e-16	Orthostatic hypotension;
LGG	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-12.75	-0.51	4.11e-32	Cognitive function;
LGG	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.27e-11	Bladder cancer;
LGG	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.9	0.57	2.72e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-8.91	-0.38	1.18e-17	Chronic sinus infection;
LGG	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg02002194	chr4:3960332	NA	-0.52	-9.65	-0.41	3.41e-20	Retinal vascular caliber;
LGG	cis	rs4959677	0.703	rs4959672	chr6:2473242	T/A	cg20147862	chr6:2634573	C6orf195	-0.35	-7.29	-0.32	1.33e-12	Orthostatic hypotension;
LGG	cis	rs2635047	0.542	rs2684853	chr18:44793532	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.5	0.33	3.27e-13	Educational attainment;
LGG	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.8	-0.34	4.17e-14	Depression;
LGG	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg06115741	chr20:33292138	TP53INP2	-0.55	-9.53	-0.4	9.04e-20	Coronary artery disease;
LGG	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg03213289	chr20:61660250	NA	0.65	14.36	0.56	5.95e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg04842962	chr6:43655489	MRPS18A	0.78	14.31	0.55	1.05e-38	IgG glycosylation;
LGG	trans	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.18	-0.32	2.87e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg27471124	chr11:109292789	C11orf87	0.5	9.79	0.41	1.1e-20	Schizophrenia;
LGG	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.78	0.38	3.27e-17	Eosinophil percentage of white cells;
LGG	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-12.32	-0.5	2.35e-30	Parkinson's disease;
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg01966878	chr4:90757139	SNCA	-0.37	-7.72	-0.34	7.32e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.53	-0.53	2.26e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7546668	1.000	rs12741552	chr1:15853276	T/C	cg21858823	chr1:15850916	CASP9	0.38	7.0	0.31	9.03e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg08847335	chr10:891726	LARP4B	-0.5	-8.44	-0.37	4e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs2952156	0.920	rs732083	chr17:37834367	G/A	cg00129232	chr17:37814104	STARD3	-0.76	-16.59	-0.61	7.94e-49	Asthma;
LGG	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg17376030	chr22:41985996	PMM1	0.53	8.79	0.38	2.91e-17	Vitiligo;
LGG	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg26838691	chr2:24397539	C2orf84	-0.47	-6.75	-0.3	4.34e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg26513180	chr16:89883248	FANCA	0.84	8.05	0.35	7.12e-15	Skin colour saturation;
LGG	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg05784532	chr1:230284198	GALNT2	0.56	9.07	0.39	3.3e-18	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	cis	rs765787	0.505	rs12593605	chr15:45497448	T/A	cg24006582	chr15:45444508	DUOX1	0.67	12.4	0.5	1.11e-30	Uric acid levels;
LGG	cis	rs7017914	0.967	rs6472539	chr8:71629810	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs9815354	1.000	rs9848754	chr3:41753647	C/T	cg03022575	chr3:42003672	ULK4	0.68	8.51	0.37	2.4e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg18854424	chr1:2615690	NA	0.36	7.64	0.33	1.27e-13	Ulcerative colitis;
LGG	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg12501888	chr15:85177176	SCAND2	0.56	9.12	0.39	2.39e-18	P wave terminal force;
LGG	cis	rs9902453	0.709	rs6505162	chr17:28444183	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	12.96	0.52	5.36e-33	Coffee consumption (cups per day);
LGG	cis	rs16944613	0.588	rs10852136	chr15:91139798	T/G	cg26821196	chr15:91095069	CRTC3	0.52	7.39	0.32	7.02e-13	Colorectal cancer;
LGG	cis	rs2455799	0.573	rs2455812	chr3:15734096	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.53	-0.33	2.62e-13	Mean platelet volume;
LGG	cis	rs11971779	0.680	rs11768023	chr7:139054395	T/A	cg07862535	chr7:139043722	LUC7L2	0.46	7.6	0.33	1.66e-13	Diisocyanate-induced asthma;
LGG	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-9.69	-0.41	2.51e-20	Menarche (age at onset);
LGG	cis	rs4926611	0.730	rs6662142	chr1:54059368	T/C	cg23596471	chr1:54105337	GLIS1	-0.42	-8.64	-0.37	9.52e-17	Hand grip strength;
LGG	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.16	-0.78	7.4e-98	Height;
LGG	cis	rs727505	0.866	rs56216989	chr7:124729068	T/A	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg14926445	chr8:58193284	C8orf71	-0.66	-8.28	-0.36	1.32e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09883264	chr5:141489170	NDFIP1	-0.47	-6.87	-0.3	2.1e-11	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs6684428	1.000	rs12123418	chr1:56383394	C/T	cg11651538	chr1:56320950	NA	0.72	13.0	0.52	3.7e-33	Airflow obstruction;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.53	-0.37	2.04e-16	Personality dimensions;
LGG	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg11380483	chr2:127933992	NA	-0.34	-6.65	-0.3	8.5e-11	Self-rated health;
LGG	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg14210321	chr2:106509881	NCK2	-0.57	-9.95	-0.42	2.95e-21	Addiction;
LGG	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg02153584	chr22:29168773	CCDC117	0.62	10.31	0.43	1.46e-22	Lymphocyte counts;
LGG	cis	rs9815354	1.000	rs7617397	chr3:41959037	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01087382	chr6:91297190	MAP3K7	0.45	7.42	0.33	5.68e-13	Cognitive performance;
LGG	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg18477163	chr1:228402036	OBSCN	-0.27	-7.25	-0.32	1.76e-12	Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07025343	chr14:77606922	ZDHHC22	0.41	6.75	0.3	4.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	8.48	0.37	3.03e-16	Longevity;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.77	-0.3	3.99e-11	Longevity;Endometriosis;
LGG	cis	rs7077256	0.564	rs72837051	chr10:65254058	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3106136	0.967	rs12646184	chr4:95183216	A/G	cg11021082	chr4:95130006	SMARCAD1	0.46	8.16	0.35	3.27e-15	Capecitabine sensitivity;
LGG	cis	rs758324	0.812	rs12653237	chr5:131241778	C/T	cg06307176	chr5:131281290	NA	0.53	8.69	0.37	6.15e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20620272	chr3:167968129	C3orf50	0.4	7.13	0.31	3.93e-12	Bipolar disorder;
LGG	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg04398451	chr17:18023971	MYO15A	0.64	13.04	0.52	2.46e-33	Total body bone mineral density;
LGG	cis	rs2370759	0.891	rs76164690	chr10:32590362	T/G	cg01819863	chr10:32635814	EPC1	1.09	13.19	0.52	5.91e-34	Sexual dysfunction (female);
LGG	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg04398451	chr17:18023971	MYO15A	0.84	19.46	0.67	4.7e-62	Total body bone mineral density;
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	6.75	0.3	4.52e-11	Myopia (pathological);
LGG	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg03517284	chr6:25882590	NA	-0.43	-6.94	-0.31	1.33e-11	Iron status biomarkers;
LGG	cis	rs17253792	0.822	rs74935793	chr14:56143277	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	cis	rs11690935	0.731	rs10930491	chr2:172569824	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	14.67	0.56	2.87e-40	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-9.41	-0.4	2.33e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9814567	0.806	rs9857995	chr3:134316706	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	11.14	0.46	1.07e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg02002194	chr4:3960332	NA	0.39	6.82	0.3	2.83e-11	Neuroticism;
LGG	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg00631329	chr6:26305371	NA	-0.46	-7.69	-0.34	9.14e-14	Educational attainment;
LGG	cis	rs763121	0.853	rs5750622	chr22:38956464	C/G	cg06022373	chr22:39101656	GTPBP1	0.86	16.95	0.62	1.83e-50	Menopause (age at onset);
LGG	cis	rs7828089	0.715	rs11136029	chr8:22253485	A/G	cg13512537	chr8:22265999	SLC39A14	0.37	6.7	0.3	6.16e-11	Verbal declarative memory;
LGG	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg13660082	chr14:53194042	PSMC6	-0.54	-7.64	-0.33	1.25e-13	Alzheimer's disease (late onset);
LGG	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg13010199	chr12:38710504	ALG10B	-0.49	-9.07	-0.39	3.49e-18	Morning vs. evening chronotype;
LGG	cis	rs13177180	0.749	rs13184723	chr5:114897524	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.39	-8.62	-0.37	1.04e-16	Conotruncal heart defects (inherited effects);
LGG	cis	rs2117029	0.555	rs2279596	chr12:49498751	G/A	cg24176009	chr12:49580217	TUBA1A	0.56	10.52	0.44	2.45e-23	Intelligence (multi-trait analysis);
LGG	cis	rs35883536	0.588	rs955337	chr1:101108834	A/T	cg06223162	chr1:101003688	GPR88	0.34	7.73	0.34	6.67e-14	Monocyte count;
LGG	cis	rs9547692	1.000	rs9547691	chr13:37468588	T/C	cg02985381	chr13:37494744	SMAD9	0.72	12.77	0.51	3.21e-32	Coronary artery disease;
LGG	cis	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg15596359	chr8:11213517	TDH	0.35	6.85	0.3	2.41e-11	Systolic blood pressure;
LGG	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.87	13.54	0.53	2.1e-35	HIV-1 control;
LGG	cis	rs2153535	0.580	rs1335633	chr6:8448800	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg21972741	chr5:435613	AHRR	0.49	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-11.88	-0.48	1.42e-28	Response to antipsychotic treatment;
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	4.17e-16	Neuroticism;
LGG	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg25358565	chr5:93447407	FAM172A	-0.71	-10.21	-0.43	3.19e-22	Diabetic retinopathy;
LGG	cis	rs3741151	0.773	rs17244616	chr11:73293112	C/T	cg17517138	chr11:73019481	ARHGEF17	0.84	8.02	0.35	8.93e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs4664304	0.658	rs2667008	chr2:160865095	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.93	-0.35	1.7e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1580019	0.961	rs4320456	chr7:32496003	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs4776059	1.000	rs10851521	chr15:52942111	G/A	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.74	-0.34	6.44e-14	Schizophrenia;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02018176	chr4:1364513	KIAA1530	0.52	12.74	0.51	4.26e-32	Longevity;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs882632	0.668	rs62132765	chr2:29296870	C/T	cg23429306	chr2:29287725	C2orf71	0.41	8.1	0.35	4.83e-15	Major depressive disorder;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg13206674	chr6:150067644	NUP43	0.42	8.87	0.38	1.56e-17	Testicular germ cell tumor;
LGG	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg01221209	chr5:554886	NA	-0.46	-7.0	-0.31	9.12e-12	Obesity-related traits;
LGG	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.86	0.42	5.99e-21	Hypertriglyceridemia;
LGG	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.47e-12	Hemoglobin concentration;
LGG	cis	rs9527	0.571	rs12765337	chr10:104635344	G/C	cg04362960	chr10:104952993	NT5C2	0.55	10.22	0.43	2.93e-22	Arsenic metabolism;
LGG	cis	rs1109114	0.816	rs3797315	chr5:148620224	A/C	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.66	-0.59	1.11e-44	Body mass index;
LGG	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.89	-0.38	1.41e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs17253792	0.822	rs28513551	chr14:56094993	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.24	0.36	1.74e-15	Type 2 diabetes;
LGG	cis	rs2760061	0.583	rs708124	chr1:228220771	A/T	cg01200585	chr1:228362443	C1orf69	0.47	8.15	0.35	3.48e-15	Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.24e-12	Lung cancer;
LGG	cis	rs7851660	0.809	rs7037324	chr9:100658318	A/G	cg13688889	chr9:100608707	NA	-0.6	-11.97	-0.49	6.04e-29	Strep throat;
LGG	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg16339924	chr4:17578868	LAP3	0.59	10.31	0.43	1.45e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12643440	0.538	rs1522081	chr4:17135357	T/C	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg27624424	chr6:160112604	SOD2	0.6	8.65	0.37	8.21e-17	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11245990	chr11:68621969	NA	0.44	9.12	0.39	2.37e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9863	0.828	rs7307277	chr12:124475156	A/G	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.99e-12	White blood cell count;
LGG	cis	rs2274273	1.000	rs1009977	chr14:55603002	T/G	cg04306507	chr14:55594613	LGALS3	0.61	17.06	0.62	5.65e-51	Protein biomarker;
LGG	cis	rs9660992	0.762	rs1172137	chr1:205246061	G/T	cg21545522	chr1:205238299	TMCC2	0.42	7.73	0.34	6.81e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Aortic root size;
LGG	cis	rs17208368	0.628	rs2397357	chr16:55099215	T/C	cg09947736	chr16:55091198	NA	0.67	12.87	0.51	1.32e-32	Hypospadias;
LGG	cis	rs6594499	0.903	rs1438672	chr5:110467753	G/A	cg04022379	chr5:110408740	TSLP	0.41	7.52	0.33	2.83e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg24375607	chr4:120327624	NA	0.6	9.99	0.42	2.01e-21	Corneal astigmatism;
LGG	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg06028605	chr16:24865363	SLC5A11	0.47	7.69	0.34	8.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14240646	chr10:27532245	ACBD5	-0.66	-9.65	-0.41	3.33e-20	Breast cancer;
LGG	cis	rs2131877	0.871	rs2279633	chr3:194869225	G/A	cg07250128	chr3:194833983	C3orf21	0.4	6.67	0.3	7.33e-11	Non-small cell lung cancer;
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg11871910	chr12:69753446	YEATS4	0.85	15.85	0.59	1.59e-45	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg16482183	chr6:26056742	HIST1H1C	0.42	7.3	0.32	1.3e-12	Height;
LGG	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg11789530	chr4:8429930	ACOX3	0.88	17.48	0.63	6.44e-53	Response to antineoplastic agents;
LGG	cis	rs10875746	0.669	rs4760701	chr12:48698518	A/G	cg24011408	chr12:48396354	COL2A1	-0.57	-7.46	-0.33	4.43e-13	Longevity (90 years and older);
LGG	cis	rs4363385	0.747	rs2339491	chr1:152985322	T/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.06	-0.39	3.78e-18	Inflammatory skin disease;
LGG	trans	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs7215564	0.908	rs1471788	chr17:78672153	A/G	cg16980736	chr17:78789706	RPTOR	-0.61	-8.06	-0.35	6.61e-15	Myopia (pathological);
LGG	cis	rs11690935	0.550	rs6730085	chr2:172864845	C/A	cg13550731	chr2:172543902	DYNC1I2	0.62	11.88	0.48	1.3e-28	Schizophrenia;
LGG	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg09754948	chr16:28834200	ATXN2L	0.47	7.54	0.33	2.49e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25392269	chr19:13049289	CALR	0.38	6.88	0.3	1.89e-11	Obesity-related traits;
LGG	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs7586879	0.681	rs6723803	chr2:25120713	G/C	cg04586622	chr2:25135609	ADCY3	0.47	12.86	0.51	1.4e-32	Body mass index;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01585322	chr12:70637221	CNOT2	0.43	6.93	0.31	1.41e-11	Hip circumference;
LGG	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.59e-13	Uric acid levels;
LGG	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg06637938	chr14:75390232	RPS6KL1	0.56	10.2	0.43	3.59e-22	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11442050	chr22:31886454	EIF4ENIF1	-0.46	-6.96	-0.31	1.21e-11	Pancreatic cancer;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg02733842	chr7:1102375	C7orf50	0.65	9.86	0.42	6.08e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1982963	0.587	rs2516593	chr14:52503369	T/C	cg05884192	chr14:52515736	NID2	-0.33	-8.12	-0.35	4.11e-15	Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg06521331	chr12:34319734	NA	0.41	7.46	0.33	4.43e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2415984	0.622	rs2415998	chr14:46930712	A/G	cg14871534	chr14:47121158	RPL10L	-0.59	-10.25	-0.43	2.34e-22	Number of children ever born;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08280861	chr8:58055591	NA	0.65	7.93	0.35	1.68e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7660883	0.964	rs17012368	chr4:87996119	T/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.4	-0.4	2.53e-19	HDL cholesterol levels;
LGG	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.39	0.32	6.91e-13	Neuroticism;
LGG	cis	rs67133203	0.851	rs6580784	chr12:51468311	G/A	cg14688905	chr12:51403056	SLC11A2	0.69	10.52	0.44	2.41e-23	Urinary tract infection frequency;
LGG	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg06634786	chr22:41940651	POLR3H	0.76	12.1	0.49	1.8e-29	Vitiligo;
LGG	cis	rs62238980	0.614	rs116941748	chr22:32404361	C/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg18551225	chr6:44695536	NA	-0.56	-8.25	-0.36	1.62e-15	Total body bone mineral density;
LGG	cis	rs78487399	0.710	rs6544665	chr2:43729212	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg01620082	chr3:125678407	NA	-0.69	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs612683	0.690	rs11166440	chr1:100808363	C/T	cg06223162	chr1:101003688	GPR88	-0.36	-8.43	-0.36	4.28e-16	Breast cancer;
LGG	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg18129748	chr3:49941408	MST1R	0.22	7.14	0.31	3.62e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg15704280	chr7:45808275	SEPT13	0.77	10.75	0.45	3.3e-24	Axial length;
LGG	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg14983838	chr19:29218262	NA	0.55	7.16	0.32	3.28e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.62	0.51	1.34e-31	Alzheimer's disease;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.42	-0.36	4.71e-16	Personality dimensions;
LGG	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	trans	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.66	0.37	8.11e-17	Mood instability;
LGG	cis	rs7219021	1.000	rs72831853	chr17:46842575	A/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.64	-0.3	8.59e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.27	-0.43	2.07e-22	Colorectal cancer;
LGG	cis	rs4538187	0.661	rs17562423	chr2:64200119	T/C	cg02541582	chr2:64069798	UGP2	-0.58	-10.74	-0.45	3.66e-24	Systolic blood pressure;
LGG	cis	rs4936894	0.500	rs10893197	chr11:124148690	A/G	cg27160556	chr11:124181099	OR8D1	-0.45	-10.45	-0.44	4.15e-23	Aging (time to death);
LGG	trans	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.81	-0.38	2.53e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2945232	1	rs2945232	chr8:8098038	T/C	cg21775007	chr8:11205619	TDH	0.5	8.24	0.36	1.81e-15	Schizophrenia;
LGG	cis	rs17030434	1.000	rs79094565	chr4:154718997	T/C	cg14289246	chr4:154710475	SFRP2	-0.72	-11.0	-0.46	3.77e-25	Electrocardiographic conduction measures;
LGG	cis	rs6087990	0.863	rs1569686	chr20:31367079	G/T	cg13636640	chr20:31349939	DNMT3B	0.98	21.47	0.71	1.75e-71	Ulcerative colitis;
LGG	cis	rs11096990	0.613	rs2060805	chr4:39234408	A/G	cg24403649	chr4:39172243	NA	0.39	6.92	0.31	1.48e-11	Cognitive function;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	trans	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg16141378	chr3:129829833	LOC729375	-0.42	-9.87	-0.42	5.69e-21	Mood instability;
LGG	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	3.87e-18	Motion sickness;
LGG	cis	rs7584262	0.573	rs11891679	chr2:42275726	C/G	cg27428208	chr2:42229179	NA	0.44	7.45	0.33	4.48e-13	Bone mineral density;
LGG	cis	rs10979	0.931	rs9484770	chr6:143896758	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.58	-0.5	2.1e-31	Hypospadias;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.18e-21	Prudent dietary pattern;
LGG	cis	rs28374715	0.662	rs691907	chr15:41474657	C/G	cg18705301	chr15:41695430	NDUFAF1	1.0	17.93	0.64	5.47e-55	Ulcerative colitis;
LGG	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg08508325	chr11:3079039	CARS	0.38	7.05	0.31	6.63e-12	Calcium levels;
LGG	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg21435375	chr2:172878103	MAP1D	-0.3	-6.69	-0.3	6.38e-11	Schizophrenia;
LGG	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.8	0.34	4e-14	Colorectal cancer;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.51	13.33	0.53	1.53e-34	Tonsillectomy;
LGG	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg26384229	chr12:38710491	ALG10B	0.76	15.4	0.58	1.66e-43	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg18131467	chr2:239335373	ASB1	-1.02	-23.49	-0.74	6.54e-81	Multiple system atrophy;
LGG	cis	rs9487094	0.626	rs12195904	chr6:109815963	A/T	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg23625390	chr15:77176239	SCAPER	-0.71	-13.92	-0.54	4.85e-37	Blood metabolite levels;
LGG	cis	rs7000551	0.751	rs1116084	chr8:22395309	C/T	cg12081754	chr8:22256438	SLC39A14	0.6	11.29	0.46	2.77e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs709400	0.663	rs62007684	chr14:103894223	T/C	cg26031613	chr14:104095156	KLC1	0.79	13.6	0.53	1.07e-35	Body mass index;
LGG	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-10.59	-0.44	1.32e-23	Morning vs. evening chronotype;
LGG	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg23815491	chr16:72088622	HP	0.55	11.74	0.48	5.05e-28	Fibrinogen levels;
LGG	cis	rs3816183	1.000	rs6717616	chr2:43013337	G/T	cg14631114	chr2:43023945	NA	0.51	9.67	0.41	2.87e-20	Hypospadias;
LGG	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg07701084	chr6:150067640	NUP43	0.64	12.19	0.49	7.64e-30	Lung cancer;
LGG	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg23625390	chr15:77176239	SCAPER	0.39	7.32	0.32	1.08e-12	Blood metabolite levels;
LGG	cis	rs2075466	0.514	rs111601308	chr16:4897103	C/G	cg04440724	chr16:4920505	UBN1	-0.61	-8.95	-0.38	8.42e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs870825	0.616	rs7678864	chr4:185635158	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs1056053	0.514	rs3127332	chr6:166573438	G/A	cg11088901	chr6:166572345	T	-0.51	-9.61	-0.41	4.61e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9952991	0.566	rs534911	chr18:12857335	G/A	cg23598886	chr18:12777645	NA	0.51	7.2	0.32	2.53e-12	Inflammatory skin disease;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.92	-0.38	1.1e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2274273	0.624	rs12050123	chr14:55840386	G/A	cg04306507	chr14:55594613	LGALS3	0.52	12.34	0.5	1.89e-30	Protein biomarker;
LGG	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.21	-0.32	2.34e-12	Joint mobility (Beighton score);
LGG	cis	rs11690935	1.000	rs312918	chr2:172569587	C/G	cg21435375	chr2:172878103	MAP1D	-0.3	-6.77	-0.3	3.87e-11	Schizophrenia;
LGG	cis	rs17221829	0.645	rs12288897	chr11:89388816	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.26	-0.4	7.46e-19	Anxiety in major depressive disorder;
LGG	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.18	-0.7	4.04e-70	Heart rate;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18106800	chr5:94890715	ARSK;TTC37	0.43	7.24	0.32	1.91e-12	Bipolar disorder;
LGG	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs10193935	0.901	rs59984817	chr2:42566909	C/G	cg27598129	chr2:42591480	NA	-0.65	-9.81	-0.41	8.92e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6960043	0.905	rs11514706	chr7:15059272	A/C	cg19272540	chr7:15055459	NA	-0.39	-8.54	-0.37	1.96e-16	Type 2 diabetes;
LGG	cis	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg07460842	chr6:66804631	NA	0.9	14.84	0.57	5.02e-41	Exhaled nitric oxide output;
LGG	cis	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.96	-0.42	2.63e-21	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg07777115	chr5:623756	CEP72	-0.62	-7.87	-0.34	2.48e-14	Obesity-related traits;
LGG	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9333075	0.507	rs2236579	chr10:15762114	A/G	cg14364212	chr10:15760690	ITGA8	0.48	9.08	0.39	3.11e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs78487399	0.808	rs6544669	chr2:43736171	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.61	-10.74	-0.45	3.71e-24	Obesity-related traits;
LGG	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg01990225	chr2:97406019	LMAN2L	-0.63	-7.15	-0.32	3.4e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg09021430	chr5:549028	NA	-0.72	-10.12	-0.43	7.18e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg19168338	chr16:4465731	CORO7	0.87	15.62	0.59	1.76e-44	Schizophrenia;
LGG	cis	rs17221829	0.521	rs4338531	chr11:89315132	C/A	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.27	-0.36	1.46e-15	Anxiety in major depressive disorder;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg21798802	chr22:38057573	PDXP	0.61	14.09	0.55	9.33e-38	Fat distribution (HIV);
LGG	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18876405	chr7:65276391	NA	-0.6	-11.4	-0.47	1.01e-26	Aortic root size;
LGG	cis	rs1014246	0.848	rs10787716	chr10:118459575	C/A	cg14919929	chr10:118506882	NA	0.61	11.63	0.48	1.29e-27	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06481639	chr22:41940642	POLR3H	0.52	7.16	0.32	3.11e-12	Vitiligo;
LGG	cis	rs1620921	0.594	rs2489960	chr6:161261315	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg23782820	chr8:58130467	NA	0.53	7.39	0.32	6.9e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg25482853	chr8:67687455	SGK3	0.84	11.01	0.46	3.32e-25	Obesity-related traits;
LGG	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg22980697	chr10:16874865	CUBN	0.59	9.41	0.4	2.33e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg04025307	chr7:1156635	C7orf50	0.79	15.93	0.6	6.96e-46	Longevity;Endometriosis;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.18	-0.39	1.49e-18	Menopause (age at onset);
LGG	cis	rs7193541	1.000	rs7193541	chr16:74664743	C/T	cg01733217	chr16:74700730	RFWD3	-0.89	-20.5	-0.69	6.4e-67	Multiple myeloma;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg15133208	chr4:90757351	SNCA	-0.4	-9.14	-0.39	1.98e-18	Dementia with Lewy bodies;
LGG	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg12463550	chr7:65579703	CRCP	0.79	8.53	0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	8.78	0.38	3.28e-17	Cognitive test performance;
LGG	cis	rs908922	0.676	rs7547628	chr1:152527738	T/C	cg03606772	chr1:152487856	CRCT1	0.28	6.65	0.3	8.48e-11	Hair morphology;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg03188948	chr7:1209495	NA	0.41	7.08	0.31	5.54e-12	Longevity;Endometriosis;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.51	-0.33	3.1e-13	Mood instability;
LGG	cis	rs13132184	0.507	rs13118113	chr4:38035396	A/G	cg24826020	chr4:38070998	TBC1D1	0.5	8.49	0.37	2.83e-16	Verbal declarative memory;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00684032	chr4:1343700	KIAA1530	0.51	10.12	0.43	7.04e-22	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.38e-13	HDL cholesterol;
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.05	-0.31	6.66e-12	Neuroticism;
LGG	cis	rs11971779	0.680	rs7779900	chr7:139082987	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs853679	0.517	rs3173443	chr6:28137027	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg02023728	chr11:77925099	USP35	0.43	7.7	0.34	8.45e-14	Testicular germ cell tumor;
LGG	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.32	0.4	4.59e-19	Lung cancer;
LGG	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg26384229	chr12:38710491	ALG10B	0.73	13.6	0.53	1.16e-35	Resting heart rate;
LGG	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg05368731	chr17:41323189	NBR1	0.89	14.2	0.55	3.08e-38	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg07005078	chr4:17578674	LAP3	0.36	6.72	0.3	5.45e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg07483650	chr1:248525007	OR2T4	0.38	7.09	0.31	5.02e-12	Common traits (Other);
LGG	cis	rs9916302	0.821	rs4795386	chr17:37746847	A/G	cg07936489	chr17:37558343	FBXL20	-0.69	-12.08	-0.49	2.2e-29	Glomerular filtration rate (creatinine);
LGG	cis	rs2798269	0.604	rs2185883	chr13:22157265	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.35	-0.32	8.94e-13	PR segment;
LGG	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.55	-0.33	2.41e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.15	-0.72	1.23e-74	Primary sclerosing cholangitis;
LGG	cis	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg06636001	chr8:8085503	FLJ10661	0.63	12.84	0.51	1.67e-32	Neuroticism;
LGG	cis	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg00383909	chr3:49044727	WDR6	0.99	12.41	0.5	9.76e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg18681998	chr4:17616180	MED28	0.86	19.73	0.68	2.51e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg17830980	chr10:43048298	ZNF37B	-0.35	-7.27	-0.32	1.59e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg01448562	chr3:133502909	NA	-0.46	-7.73	-0.34	6.84e-14	Iron status biomarkers (transferrin levels);
LGG	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg24189917	chr7:1970923	MAD1L1	0.51	7.87	0.34	2.62e-14	Bipolar disorder;
LGG	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.92	0.82	1.09e-114	Cognitive function;
LGG	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.8	0.51	2.53e-32	Motion sickness;
LGG	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg15596359	chr8:11213517	TDH	-0.41	-8.37	-0.36	6.74e-16	Retinal vascular caliber;
LGG	cis	rs9814567	1.000	rs9985356	chr3:134232920	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	12.63	0.51	1.23e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg23978390	chr7:1156363	C7orf50	0.45	6.77	0.3	3.93e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2274273	0.600	rs35112084	chr14:55781100	T/A	cg04306507	chr14:55594613	LGALS3	0.53	12.45	0.5	6.96e-31	Protein biomarker;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.16	0.39	1.65e-18	Alzheimer's disease;
LGG	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.35	0.4	3.86e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4731207	0.698	rs2107936	chr7:124449041	A/T	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.71	0.56	1.92e-40	Bladder cancer;
LGG	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg26666090	chr16:58549219	SETD6	1.15	10.19	0.43	3.94e-22	Schizophrenia;
LGG	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg22643751	chr7:855365	UNC84A	-0.55	-14.03	-0.55	1.67e-37	Perceived unattractiveness to mosquitoes;
LGG	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg03605463	chr16:89740564	NA	-0.42	-6.67	-0.3	7.32e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.51	6.95	0.31	1.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27030612	chr5:127537124	NA	0.47	6.78	0.3	3.57e-11	Gut microbiome composition (summer);
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	12.16	0.49	9.95e-30	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg15971980	chr6:150254442	NA	-0.43	-6.99	-0.31	9.49e-12	Lung cancer;
LGG	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg01324343	chr3:183735012	ABCC5	0.66	12.84	0.51	1.74e-32	Anterior chamber depth;
LGG	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.25	0.32	1.8e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.66	0.41	3.06e-20	Lung cancer in ever smokers;
LGG	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg19455335	chr8:22457658	C8orf58	-0.46	-9.36	-0.4	3.37e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs35771425	1.000	rs11119742	chr1:211624504	A/T	cg10512769	chr1:211675356	NA	-0.74	-11.98	-0.49	5.61e-29	Educational attainment (years of education);
LGG	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg09873164	chr1:152488093	CRCT1	0.64	15.62	0.59	1.68e-44	Hair morphology;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.26	0.32	1.69e-12	Longevity;
LGG	cis	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19171272	chr22:38449367	NA	0.41	7.04	0.31	7.01e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.91	-0.31	1.58e-11	Heart rate;
LGG	cis	rs2213920	0.679	rs10759780	chr9:118196088	A/C	cg13918206	chr9:118159781	DEC1	0.63	8.92	0.38	1.12e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00933542	chr6:150070202	PCMT1	0.38	6.91	0.31	1.63e-11	Lung cancer;
LGG	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg20608306	chr11:116969690	SIK3	0.31	6.83	0.3	2.68e-11	Blood protein levels;
LGG	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.69	-0.3	6.4e-11	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	3.91e-17	Lung cancer;
LGG	cis	rs67133203	0.904	rs12824840	chr12:51333744	G/A	cg14688905	chr12:51403056	SLC11A2	0.7	10.47	0.44	3.75e-23	Urinary tract infection frequency;
LGG	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24110177	chr3:50126178	RBM5	-0.56	-10.14	-0.43	5.85e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.2	0.6	4.5e-47	Lymphocyte counts;
LGG	cis	rs36071027	0.577	rs6862399	chr5:158441675	G/T	cg23468002	chr5:158532401	NA	0.42	6.91	0.31	1.6e-11	Carotid intima media thickness;
LGG	cis	rs4950322	0.744	rs2353987	chr1:146827556	G/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.74	-0.34	6.51e-14	Protein quantitative trait loci;
LGG	trans	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.88	-0.34	2.42e-14	Resting heart rate;
LGG	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg09173681	chr1:183549694	NCF2	0.37	8.48	0.37	3.03e-16	Systemic lupus erythematosus;
LGG	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.57	-0.41	6.56e-20	Common traits (Other);
LGG	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg02002194	chr4:3960332	NA	0.43	7.29	0.32	1.36e-12	Neuroticism;
LGG	cis	rs6580649	1.000	rs3825404	chr12:48399931	A/G	cg24011408	chr12:48396354	COL2A1	0.62	7.93	0.35	1.71e-14	Lung cancer;
LGG	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02788857	chr8:22132959	PIWIL2	0.5	11.69	0.48	7.86e-28	Hypertriglyceridemia;
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs9547996	0.879	rs4432141	chr13:38172236	A/G	cg13634560	chr13:38173852	POSTN	-0.35	-6.93	-0.31	1.39e-11	Diastolic blood pressure;
LGG	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg04842962	chr6:43655489	MRPS18A	0.84	11.98	0.49	5.26e-29	IgG glycosylation;
LGG	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-13.33	-0.53	1.5e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs4604732	0.631	rs74154676	chr1:247625894	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg16141378	chr3:129829833	LOC729375	0.32	7.26	0.32	1.65e-12	Mood instability;
LGG	cis	rs66887589	0.934	rs56843000	chr4:120516597	T/C	cg09307838	chr4:120376055	NA	-0.47	-8.18	-0.36	2.81e-15	Diastolic blood pressure;
LGG	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	15.97	0.6	4.55e-46	Hip circumference adjusted for BMI;
LGG	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg26116260	chr4:7069785	GRPEL1	-0.75	-6.88	-0.3	1.92e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17102423	0.651	rs2296316	chr14:65520246	A/G	cg26396452	chr14:65542826	MAX	0.48	10.05	0.42	1.21e-21	Obesity-related traits;
LGG	cis	rs965469	0.625	rs1043159	chr20:3232031	C/T	cg25506879	chr20:3388711	C20orf194	-0.44	-7.05	-0.31	6.73e-12	IFN-related cytopenia;
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.27	-0.43	1.96e-22	Retinal vascular caliber;
LGG	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs9649465	1.000	rs2052128	chr7:123380405	T/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg00012203	chr2:219082015	ARPC2	-0.66	-11.5	-0.47	4.24e-27	Colorectal cancer;
LGG	trans	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.84	-0.38	2.08e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg22907277	chr7:1156413	C7orf50	0.62	11.46	0.47	6.24e-27	Longevity;Endometriosis;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg02018176	chr4:1364513	KIAA1530	0.41	9.19	0.39	1.32e-18	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg05941027	chr17:61774174	LIMD2	0.37	9.49	0.4	1.22e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.63	-0.33	1.36e-13	Neuroticism;
LGG	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg00631329	chr6:26305371	NA	-0.46	-7.72	-0.34	7.35e-14	Educational attainment;
LGG	cis	rs1978968	0.731	rs9617648	chr22:18460059	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.73	-0.54	3.14e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-9.12	-0.39	2.35e-18	Obesity-related traits;
LGG	cis	rs7727544	0.564	rs3852206	chr5:131415436	G/A	cg07395648	chr5:131743802	NA	-0.46	-9.85	-0.42	6.6e-21	Blood metabolite levels;
LGG	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.66	0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg12219531	chr12:120966889	COQ5	0.66	11.02	0.46	3.02e-25	High light scatter reticulocyte count;
LGG	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.14	0.39	1.95e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs35146811	0.961	rs1880949	chr7:99722266	A/C	cg22906224	chr7:99728672	NA	-0.61	-9.98	-0.42	2.22e-21	Coronary artery disease;
LGG	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-11.75	-0.48	4.58e-28	Fibrinogen levels;
LGG	trans	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg21775007	chr8:11205619	TDH	0.42	6.77	0.3	3.96e-11	Neuroticism;
LGG	cis	rs55871839	0.643	rs10105665	chr8:59799367	A/G	cg07426533	chr8:59803705	TOX	-0.57	-12.83	-0.51	1.82e-32	Pneumonia;
LGG	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg11645453	chr3:52864694	ITIH4	0.42	6.77	0.3	3.79e-11	Bipolar disorder;
LGG	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg21058520	chr6:100914733	NA	0.4	6.89	0.31	1.8e-11	Neuroticism;
LGG	cis	rs6963495	0.745	rs2392749	chr7:105182605	A/G	cg21420622	chr7:105162941	PUS7	-0.46	-7.21	-0.32	2.23e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg09998033	chr7:158218633	PTPRN2	0.45	8.24	0.36	1.75e-15	Obesity-related traits;
LGG	cis	rs9362426	0.895	rs242292	chr6:88078074	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.51	9.83	0.42	7.94e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg11984989	chr7:158649758	WDR60	1.02	14.64	0.56	3.84e-40	Height;
LGG	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10847980	0.590	rs1979236	chr12:123325993	G/A	cg25930673	chr12:123319894	HIP1R	1.17	9.79	0.41	1.09e-20	Adiponectin levels;
LGG	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-7.56	-0.33	2.25e-13	Breast cancer;
LGG	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.2	-0.49	7.36e-30	Cognitive function;
LGG	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-14.75	-0.57	1.17e-40	Total body bone mineral density;
LGG	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Vitiligo;
LGG	cis	rs12410462	0.551	rs67216605	chr1:227901637	A/G	cg23173402	chr1:227635558	NA	0.38	7.08	0.31	5.4e-12	Major depressive disorder;
LGG	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg14191688	chr11:70257035	CTTN	0.56	8.21	0.36	2.19e-15	Coronary artery disease;
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03452623	chr4:187889614	NA	-1.04	-29.47	-0.81	3.02e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg16400903	chr5:693638	TPPP	0.44	6.78	0.3	3.72e-11	Obesity-related traits;
LGG	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg23173402	chr1:227635558	NA	0.49	8.39	0.36	5.92e-16	Major depressive disorder;
LGG	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.31	-0.6	1.34e-47	Total body bone mineral density;
LGG	cis	rs4732038	0.510	rs6948014	chr7:134274486	T/C	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg11752832	chr7:134001865	SLC35B4	0.64	11.52	0.47	3.67e-27	Mean platelet volume;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-13.42	-0.53	6.63e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs7572733	0.534	rs1464211	chr2:198798630	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.13	0.46	1.12e-25	Dermatomyositis;
LGG	cis	rs7551222	0.716	rs10494852	chr1:204457786	A/G	cg20240347	chr1:204465584	NA	0.52	10.2	0.43	3.58e-22	Schizophrenia;
LGG	cis	rs1659258	0.568	rs1258409	chr2:88619238	G/A	cg00685853	chr2:88648947	NA	-0.44	-6.77	-0.3	3.81e-11	Visceral fat;
LGG	trans	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg11441553	chr12:57614120	NXPH4	-0.58	-7.35	-0.32	9.29e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7149337	0.809	rs10134478	chr14:51693708	G/C	cg23942311	chr14:51606299	NA	0.33	7.16	0.32	3.11e-12	Cancer;
LGG	cis	rs7843479	0.965	rs11784535	chr8:21857787	G/A	cg17168535	chr8:21777572	XPO7	0.59	9.6	0.41	5.11e-20	Mean corpuscular volume;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg03575189	chr17:44344142	NA	0.49	7.19	0.32	2.59e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7917772	0.582	rs12782153	chr10:104368294	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.61	-11.69	-0.48	7.73e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg21466736	chr12:48725269	NA	-0.39	-7.79	-0.34	4.34e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs12780845	0.540	rs2273736	chr10:17195428	G/C	cg01003015	chr10:17271136	VIM	-0.46	-7.77	-0.34	5.25e-14	Homocysteine levels;
LGG	cis	rs6032067	0.538	rs6017489	chr20:43731932	C/T	cg10761708	chr20:43804764	PI3	0.68	10.0	0.42	1.88e-21	Blood protein levels;
LGG	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	9.2	0.39	1.2e-18	Cognitive test performance;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26279152	chr13:20356101	PSPC1	-0.51	-7.4	-0.33	6.43e-13	Systemic lupus erythematosus;
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg16434002	chr17:42200994	HDAC5	-0.52	-9.78	-0.41	1.19e-20	Total body bone mineral density;
LGG	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg13010199	chr12:38710504	ALG10B	0.51	9.85	0.42	6.43e-21	Morning vs. evening chronotype;
LGG	cis	rs11700980	0.551	rs62223676	chr21:30118000	C/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2777491	0.574	rs11858812	chr15:41731550	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.34	-34.5	-0.85	4.62e-130	Ulcerative colitis;
LGG	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg03453431	chr7:157225567	NA	-0.48	-8.49	-0.37	2.81e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg16751781	chr15:78858589	CHRNA5	0.45	8.96	0.38	8.07e-18	Sudden cardiac arrest;
LGG	cis	rs950169	0.887	rs62029593	chr15:84955180	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs9487094	0.670	rs12198938	chr6:109822632	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.65	0.33	1.19e-13	Height;
LGG	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg26446133	chr18:72167187	CNDP2	-0.69	-13.86	-0.54	8.65e-37	Refractive error;
LGG	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg21775007	chr8:11205619	TDH	-0.43	-6.77	-0.3	3.85e-11	Neuroticism;
LGG	cis	rs4253772	0.591	rs6007795	chr22:46686792	C/G	cg24881330	chr22:46731750	TRMU	0.78	9.49	0.4	1.18e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg05925327	chr15:68127851	NA	-0.36	-8.41	-0.36	5.16e-16	Restless legs syndrome;
LGG	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.32e-28	Gout;Renal underexcretion gout;
LGG	cis	rs7294478	0.597	rs7139078	chr12:7256628	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.51	-11.85	-0.48	1.85e-28	Neuritic plaque;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.53	-0.33	2.72e-13	Lung cancer;
LGG	cis	rs4243830	0.850	rs6679649	chr1:6606608	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.69	12.1	0.49	1.79e-29	Body mass index;
LGG	cis	rs11158198	0.560	rs10132166	chr14:58595164	C/T	cg15908186	chr14:58618357	C14orf37	0.57	9.97	0.42	2.47e-21	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs35160687	0.623	rs7569654	chr2:86478022	C/T	cg10973622	chr2:86423274	IMMT	-0.41	-7.24	-0.32	1.88e-12	Night sleep phenotypes;
LGG	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg18761221	chr20:60518478	NA	-0.42	-6.76	-0.3	4.25e-11	Body mass index;
LGG	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg03894339	chr8:19674705	INTS10	0.56	9.1	0.39	2.66e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg09339527	chr5:178322752	ZFP2	-0.41	-7.54	-0.33	2.49e-13	Sleep duration;
LGG	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg22643751	chr7:855365	UNC84A	-0.43	-7.56	-0.33	2.22e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08564027	chr20:61660810	NA	0.86	14.84	0.57	5.16e-41	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs524281	0.692	rs10896076	chr11:65840668	A/G	cg16950941	chr11:66035639	RAB1B	-0.51	-7.89	-0.34	2.21e-14	Electroencephalogram traits;
LGG	cis	rs36051895	0.664	rs10116560	chr9:5096433	A/G	cg02405213	chr9:5042618	JAK2	-0.81	-15.5	-0.58	6.23e-44	Pediatric autoimmune diseases;
LGG	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg19077165	chr18:44547161	KATNAL2	0.49	8.82	0.38	2.36e-17	Educational attainment;
LGG	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.78	-0.45	2.49e-24	Vitiligo;
LGG	cis	rs79149102	0.579	rs12591175	chr15:75356073	C/T	cg09165964	chr15:75287851	SCAMP5	-0.73	-7.9	-0.34	2e-14	Lung cancer;
LGG	cis	rs28595532	0.720	rs72670222	chr4:119300095	A/T	cg21605333	chr4:119757512	SEC24D	0.9	8.55	0.37	1.84e-16	Cannabis dependence symptom count;
LGG	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg16950941	chr11:66035639	RAB1B	0.55	10.37	0.43	8.24e-23	Gout;
LGG	cis	rs11235843	0.636	rs1464908	chr11:73402679	A/C	cg18195628	chr11:73498948	MRPL48	-0.51	-7.25	-0.32	1.81e-12	Hand grip strength;
LGG	cis	rs4319547	0.585	rs7953007	chr12:122816977	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.56	-0.41	6.71e-20	Body mass index;
LGG	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.79e-13	Coronary artery disease;
LGG	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.13e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72827839	0.644	rs72833479	chr17:45960449	G/A	cg02219949	chr17:45927392	SP6	0.45	7.3	0.32	1.26e-12	Ease of getting up in the morning;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12016809	chr21:47604291	C21orf56	0.58	10.56	0.44	1.68e-23	Testicular germ cell tumor;
LGG	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg03162506	chr22:38580953	NA	0.28	6.87	0.3	2.05e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs2273669	0.667	rs12195836	chr6:109357701	T/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.53	-0.37	2.06e-16	Prostate cancer;
LGG	trans	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg02002194	chr4:3960332	NA	0.42	7.5	0.33	3.24e-13	Systemic lupus erythematosus;
LGG	cis	rs1566085	0.674	rs57209039	chr8:142658642	A/G	cg26331504	chr8:142652174	NA	-0.29	-6.75	-0.3	4.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg15133208	chr4:90757351	SNCA	-0.4	-9.04	-0.39	4.15e-18	Dementia with Lewy bodies;
LGG	cis	rs13082711	0.911	rs13082777	chr3:27421942	A/G	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.73e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.55	-0.61	1.13e-48	Total body bone mineral density;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-7.79	-0.34	4.44e-14	Obesity-related traits;
LGG	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg27624424	chr6:160112604	SOD2	0.65	9.33	0.4	4.33e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg18551225	chr6:44695536	NA	-0.72	-12.67	-0.51	8.67e-32	Total body bone mineral density;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg05729581	chr11:3078854	CARS	0.41	6.66	0.3	7.8e-11	Calcium levels;
LGG	cis	rs2108225	0.934	rs2283045	chr7:107440714	G/A	cg18560240	chr7:107437656	SLC26A3	-0.56	-9.89	-0.42	4.87e-21	Ulcerative colitis;
LGG	cis	rs4302748	0.862	rs73335286	chr7:36184728	C/T	cg24442661	chr7:36192818	EEPD1	0.55	7.16	0.32	3.17e-12	Platelet count;
LGG	cis	rs870825	0.860	rs72689295	chr4:185600930	T/C	cg04058563	chr4:185651563	MLF1IP	1.08	20.51	0.69	5.61e-67	Blood protein levels;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg16920238	chr17:80076378	CCDC57	0.32	7.31	0.32	1.22e-12	Life satisfaction;
LGG	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg20821713	chr7:1055600	C7orf50	-0.47	-6.73	-0.3	5.14e-11	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg21724239	chr8:58056113	NA	0.7	15.65	0.59	1.28e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.95	0.38	8.46e-18	Aortic root size;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.62	0.59	1.74e-44	Obesity-related traits;
LGG	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs4474465	1.000	rs10899534	chr11:78210502	G/C	cg27205649	chr11:78285834	NARS2	0.48	8.1	0.35	5.03e-15	Alzheimer's disease (survival time);
LGG	trans	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg25482853	chr8:67687455	SGK3	0.86	11.22	0.46	5.18e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg17757837	chr7:157058334	UBE3C	-0.78	-15.76	-0.59	4.13e-45	Body mass index;
LGG	cis	rs6714710	0.580	rs35564270	chr2:98602165	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	9.54	0.41	8.3e-20	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs11203032	0.831	rs12219735	chr10:90922890	C/T	cg16672925	chr10:90967113	CH25H	0.77	11.0	0.46	3.81e-25	Heart failure;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.28	0.32	1.42e-12	Prudent dietary pattern;
LGG	cis	rs283228	0.617	rs493123	chr6:101742978	G/A	cg27451362	chr6:101846650	GRIK2	0.86	13.5	0.53	3.05e-35	Coenzyme Q10 levels;
LGG	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg23752985	chr2:85803571	VAMP8	0.39	7.61	0.33	1.54e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2916247	0.908	rs993790	chr8:93160730	G/A	cg10183463	chr8:93005414	RUNX1T1	0.38	7.69	0.34	8.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2273669	0.667	rs76267985	chr6:109326183	A/T	cg05315195	chr6:109294784	ARMC2	-0.62	-8.39	-0.36	6.03e-16	Prostate cancer;
LGG	cis	rs57927100	0.507	rs72896129	chr17:75327533	G/A	cg18271897	chr17:75316784	SEPT9	0.48	9.9	0.42	4.45e-21	Systolic blood pressure;
LGG	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.4	-0.36	5.47e-16	Coronary artery disease;
LGG	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.72	0.45	4.34e-24	Morning vs. evening chronotype;
LGG	cis	rs17767392	1.000	rs725673	chr14:71878468	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	trans	rs11875185	0.510	rs76587153	chr18:55616080	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.03	-0.39	4.66e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg03264133	chr6:25882463	NA	-0.4	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs727505	0.607	rs67454509	chr7:124792500	A/G	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg20336341	chr7:50628841	DDC	0.42	7.49	0.33	3.42e-13	Malaria;
LGG	cis	rs113835537	0.529	rs17495838	chr11:66196265	T/C	cg24851651	chr11:66362959	CCS	0.43	7.26	0.32	1.66e-12	Airway imaging phenotypes;
LGG	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg03078520	chr22:18463400	MICAL3	-0.67	-13.23	-0.52	4.1e-34	Presence of antiphospholipid antibodies;
LGG	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26734620	chr12:56694298	CS	-0.74	-6.84	-0.3	2.44e-11	Psoriasis vulgaris;
LGG	cis	rs3736594	0.765	rs12994085	chr2:27952406	C/T	cg27432699	chr2:27873401	GPN1	-0.59	-9.45	-0.4	1.68e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.23	-0.39	9.99e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1021993	0.545	rs17014375	chr1:209543560	T/G	cg24446417	chr1:209558027	NA	-0.71	-10.62	-0.44	9.81e-24	Gut microbiome composition (winter);
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.86	0.3	2.24e-11	Bipolar disorder;
LGG	cis	rs11608355	0.545	rs918107	chr12:109904198	C/T	cg05360138	chr12:110035743	NA	-0.84	-12.13	-0.49	1.41e-29	Neuroticism;
LGG	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.16	-0.43	5.21e-22	Schizophrenia;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg16141378	chr3:129829833	LOC729375	0.39	8.95	0.38	8.68e-18	Retinal vascular caliber;
LGG	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.82	0.59	2.27e-45	Intelligence (multi-trait analysis);
LGG	cis	rs8027181	0.617	rs4777541	chr15:73082240	C/T	cg02923145	chr15:73089643	NA	0.46	8.77	0.38	3.53e-17	Triglyceride levels;
LGG	cis	rs7727544	0.571	rs12521097	chr5:131575338	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.83	-0.3	2.62e-11	Blood metabolite levels;
LGG	cis	rs6942756	1.000	rs1473236	chr7:128880831	G/T	cg02491457	chr7:128862824	NA	-0.77	-14.02	-0.55	1.87e-37	White matter hyperintensity burden;
LGG	cis	rs7017914	0.967	rs7012404	chr8:71668698	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs8017423	0.935	rs7160304	chr14:90752908	G/T	cg04374321	chr14:90722782	PSMC1	0.84	17.67	0.63	9.06e-54	Mortality in heart failure;
LGG	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg00383909	chr3:49044727	WDR6	0.57	8.1	0.35	5e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg18357526	chr6:26021779	HIST1H4A	0.57	9.74	0.41	1.59e-20	Height;
LGG	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.83	0.38	2.18e-17	Colorectal cancer;
LGG	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg14979609	chr8:8086686	FLJ10661	0.3	7.3	0.32	1.25e-12	Mood instability;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.02	-0.49	3.86e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19717773	chr7:2847554	GNA12	-0.35	-7.81	-0.34	3.78e-14	Height;
LGG	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27286337	chr10:134555280	INPP5A	0.87	12.79	0.51	2.75e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7717393	0.786	rs6889255	chr5:155792114	G/T	cg04435420	chr5:155754009	SGCD	0.75	9.66	0.41	3.12e-20	Egg allergy;
LGG	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg04198125	chr7:157211777	NA	0.41	7.59	0.33	1.82e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg13114125	chr14:105738426	BRF1	-0.84	-16.05	-0.6	2.15e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1003719	0.788	rs2835575	chr21:38455936	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg03605463	chr16:89740564	NA	0.4	6.76	0.3	4.14e-11	Vitiligo;
LGG	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.88	-8.24	-0.36	1.84e-15	Facial emotion recognition (sad faces);
LGG	cis	rs2282802	0.685	rs12188849	chr5:139621570	G/A	cg26211634	chr5:139558579	C5orf32	0.34	7.58	0.33	1.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs1894633	0.574	rs61806089	chr1:172338301	A/G	cg01573306	chr1:172330400	DNM3	-0.42	-7.31	-0.32	1.16e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504130	0.666	rs7834181	chr8:52873130	A/G	cg24946253	chr8:52722146	PXDNL	-0.5	-7.59	-0.33	1.78e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg08621203	chr6:150244597	RAET1G	0.46	8.11	0.35	4.65e-15	Lung cancer;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg15971980	chr6:150254442	NA	-0.45	-7.15	-0.32	3.46e-12	Lung cancer;
LGG	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.97	-0.42	2.36e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.49	-0.33	3.46e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs5757676	1.000	rs5757676	chr22:39841700	T/C	cg04986931	chr22:39850128	NA	0.39	8.22	0.36	2.09e-15	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs365132	0.517	rs3762974	chr5:176328336	G/A	cg16309518	chr5:176445507	NA	0.5	9.98	0.42	2.23e-21	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs9814567	1.000	rs7374325	chr3:134275601	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	4.08e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7582720	1.000	rs4675310	chr2:203880834	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.76	-8.94	-0.38	9.23e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-6.68	-0.3	6.79e-11	Lung cancer;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.53	-0.33	2.7e-13	Skin colour saturation;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21963583	chr11:68658836	MRPL21	0.59	9.71	0.41	1.99e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg06115741	chr20:33292138	TP53INP2	0.54	8.34	0.36	8.61e-16	Coronary artery disease;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg26668828	chr6:292823	DUSP22	-0.7	-12.2	-0.49	6.9e-30	Menopause (age at onset);
LGG	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.8	-0.38	2.72e-17	Cutaneous nevi;
LGG	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.52	0.59	4.68e-44	Hair morphology;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg11328405	chr15:49170157	SHC4;EID1	-0.43	-6.86	-0.3	2.27e-11	Body fat percentage;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg11062466	chr8:58055876	NA	0.44	7.35	0.32	9.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18099408	chr3:52552593	STAB1	-0.37	-7.41	-0.33	5.88e-13	Electroencephalogram traits;
LGG	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg26441486	chr22:50317300	CRELD2	0.41	7.11	0.31	4.34e-12	Schizophrenia;
LGG	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.48	-0.33	3.8e-13	Lung cancer in ever smokers;
LGG	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.97	-0.35	1.23e-14	Alzheimer's disease (survival time);
LGG	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg13009111	chr11:71350975	NA	0.35	7.64	0.33	1.29e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-11.17	-0.46	8.52e-26	Morning vs. evening chronotype;
LGG	cis	rs4268898	1.000	rs1203	chr2:24443330	A/G	cg06627628	chr2:24431161	ITSN2	0.53	8.98	0.39	6.81e-18	Asthma;
LGG	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	16.89	0.62	3.27e-50	Smoking behavior;
LGG	cis	rs1420338	0.839	rs918036	chr7:34181859	A/G	cg01275685	chr7:34179230	BMPER	-0.52	-9.48	-0.4	1.36e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg05169160	chr2:178484487	TTC30A	0.34	6.64	0.3	8.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2404602	0.536	rs12915248	chr15:76765615	A/T	cg23625390	chr15:77176239	SCAPER	0.41	7.89	0.34	2.16e-14	Blood metabolite levels;
LGG	cis	rs16957091	0.909	rs1995939	chr15:43012517	A/G	cg07484255	chr15:43025164	CDAN1	-0.48	-6.9	-0.31	1.76e-11	MGMT methylation in smokers;
LGG	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg21665744	chr7:39171113	POU6F2	0.38	7.28	0.32	1.42e-12	IgG glycosylation;
LGG	cis	rs42648	0.869	rs10266179	chr7:89909982	C/T	cg25739043	chr7:89950458	NA	-0.4	-8.58	-0.37	1.41e-16	Homocysteine levels;
LGG	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.76e-44	Colorectal cancer;
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg02158880	chr13:53174818	NA	0.47	9.54	0.41	7.89e-20	Lewy body disease;
LGG	cis	rs72925845	0.519	rs690752	chr17:76426464	T/C	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-11.65	-0.48	1.13e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg25025879	chr12:53359317	NA	-0.49	-8.52	-0.37	2.28e-16	Cancer (pleiotropy);
LGG	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg13075951	chr6:39282393	KCNK17	0.26	6.82	0.3	2.94e-11	Type 2 diabetes;
LGG	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.75	-14.47	-0.56	1.94e-39	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.43	-0.36	4.56e-16	Neuroticism;
LGG	cis	rs11792861	0.781	rs11789252	chr9:111762010	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.08	0.42	9.87e-22	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg03806693	chr22:41940476	POLR3H	1.05	17.7	0.64	6.27e-54	Vitiligo;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.76e-16	Life satisfaction;
LGG	cis	rs7551222	0.752	rs4252685	chr1:204496856	C/A	cg20240347	chr1:204465584	NA	-0.57	-11.45	-0.47	6.66e-27	Schizophrenia;
LGG	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.15	0.35	3.54e-15	Headache;
LGG	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg11247378	chr22:39784982	NA	-0.32	-8.69	-0.37	6.48e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs1665650	0.914	rs1665649	chr10:118487161	T/C	cg14919929	chr10:118506882	NA	0.48	8.45	0.37	3.75e-16	Colorectal cancer;
LGG	cis	rs7667	1.000	rs10917434	chr1:19707302	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.38	-6.74	-0.3	4.66e-11	Crohn's disease and psoriasis;
LGG	cis	rs4727027	0.933	rs917122	chr7:148848257	T/C	cg23583168	chr7:148888333	NA	-0.88	-17.13	-0.62	2.73e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17453880	0.890	rs6869035	chr5:152028258	C/T	cg10931792	chr5:152022470	NA	0.41	8.92	0.38	1.05e-17	Subjective well-being;
LGG	cis	rs28374715	0.532	rs7168431	chr15:41672384	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.03e-133	Ulcerative colitis;
LGG	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg10596483	chr8:143751796	JRK	0.58	9.49	0.4	1.25e-19	Schizophrenia;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.96	0.49	6.58e-29	Lymphocyte counts;
LGG	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg25174290	chr11:3078921	CARS	0.75	16.38	0.61	6.51e-48	Longevity;
LGG	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg06026331	chr20:60912101	LAMA5	0.84	15.08	0.57	4.47e-42	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs4740619	0.905	rs12346205	chr9:15767898	A/T	cg14451791	chr9:16040625	NA	-0.41	-10.67	-0.44	6.73e-24	Body mass index;
LGG	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg04731861	chr2:219085781	ARPC2	-0.4	-9.51	-0.4	1.02e-19	Colorectal cancer;
LGG	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.55	12.14	0.49	1.27e-29	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg06573787	chr8:143070187	NA	0.49	8.49	0.37	2.76e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.6	-0.37	1.24e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.76	-0.57	1.13e-40	IgG glycosylation;
LGG	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg15627072	chr1:2432621	PLCH2	0.33	7.41	0.33	5.93e-13	Ulcerative colitis;
LGG	cis	rs6669919	0.967	rs6678844	chr1:211674774	G/T	cg10512769	chr1:211675356	NA	-0.66	-14.28	-0.55	1.37e-38	Intelligence (multi-trait analysis);
LGG	cis	rs3771570	0.792	rs4675970	chr2:242200406	G/A	cg21155796	chr2:242212141	HDLBP	0.64	8.86	0.38	1.66e-17	Prostate cancer;
LGG	cis	rs7580658	0.963	rs4233584	chr2:128060163	C/T	cg10021288	chr2:128175891	PROC	-0.64	-13.28	-0.53	2.51e-34	Protein C levels;
LGG	trans	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.54	0.41	8e-20	Diabetic kidney disease;
LGG	cis	rs7582720	1.000	rs72928605	chr2:203832120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.03	0.39	4.56e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs939658	0.805	rs11638625	chr15:79434787	T/G	cg17916960	chr15:79447300	NA	-0.66	-13.06	-0.52	2.11e-33	Refractive error;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.9	0.38	1.29e-17	Platelet count;
LGG	cis	rs4794202	0.579	rs9904503	chr17:45884372	T/C	cg02219949	chr17:45927392	SP6	0.53	7.4	0.33	6.5e-13	Alzheimer's disease (cognitive decline);
LGG	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs4740619	0.544	rs9407653	chr9:15828967	C/G	cg14451791	chr9:16040625	NA	0.32	7.81	0.34	4e-14	Body mass index;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg22963979	chr7:1858916	MAD1L1	-0.4	-7.89	-0.34	2.14e-14	Schizophrenia;
LGG	cis	rs11122272	0.705	rs2808599	chr1:231533482	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs2290402	0.536	rs73207790	chr4:865430	G/A	cg09237302	chr4:906077	GAK	-0.43	-7.39	-0.32	6.93e-13	Type 2 diabetes;
LGG	cis	rs6901004	0.803	rs354531	chr6:111548933	C/T	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.73	-0.34	6.82e-14	Blood metabolite levels;
LGG	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg21385522	chr1:16154831	NA	-1.02	-18.52	-0.65	9.97e-58	Dilated cardiomyopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01278209	chr2:139259574	SPOPL	0.49	7.32	0.32	1.13e-12	Gut microbiome composition (summer);
LGG	cis	rs4936894	0.500	rs7929241	chr11:124151614	G/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.45	-0.44	4.25e-23	Aging (time to death);
LGG	cis	rs807669	0.770	rs807458	chr22:19220648	G/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.41	0.36	5.07e-16	Metabolite levels;
LGG	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg03701759	chr13:99174930	STK24	-0.36	-7.0	-0.31	9.08e-12	Neuroticism;
LGG	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg06611532	chr13:114900021	NA	0.29	7.33	0.32	1e-12	Schizophrenia;
LGG	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg23609528	chr2:113191194	RGPD5;RGPD8	0.56	6.85	0.3	2.29e-11	Yeast infection;
LGG	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-7.71	-0.34	7.8e-14	Vitiligo;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg08885076	chr2:99613938	TSGA10	-0.44	-8.14	-0.35	3.59e-15	Chronic sinus infection;
LGG	cis	rs13191362	0.938	rs13192618	chr6:163132822	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.9	9.51	0.4	1.01e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	8.42	0.36	4.62e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10189230	0.935	rs3770146	chr2:222344196	G/A	cg14652038	chr2:222343519	EPHA4	0.61	12.36	0.5	1.55e-30	Urate levels in lean individuals;
LGG	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg11766577	chr21:47581405	C21orf56	-0.47	-8.23	-0.36	1.88e-15	Testicular germ cell tumor;
LGG	cis	rs4731207	0.596	rs115520589	chr7:124635877	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg03959625	chr15:84868606	LOC388152	0.48	7.12	0.31	4.01e-12	Schizophrenia;
LGG	cis	rs721917	0.525	rs2254017	chr10:81658391	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg11266682	chr4:10021025	SLC2A9	0.54	10.97	0.45	4.82e-25	Bone mineral density;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.67	0.51	8.65e-32	Obesity-related traits;
LGG	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg16850897	chr7:100343110	ZAN	-0.63	-9.14	-0.39	1.93e-18	Other erythrocyte phenotypes;
LGG	cis	rs6467136	0.560	rs62468948	chr7:127165052	C/T	cg25922125	chr7:127225783	GCC1	-0.45	-6.75	-0.3	4.35e-11	Type 2 diabetes;
LGG	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg25811766	chr13:21894605	NA	-0.56	-7.42	-0.33	5.62e-13	White matter hyperintensity burden;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.702	rs1110127	chr2:36768456	G/C	cg09467607	chr2:36825704	FEZ2	0.52	9.56	0.41	7.11e-20	Height;
LGG	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg12386194	chr3:101231763	SENP7	0.7	12.14	0.49	1.26e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10193935	0.901	rs13413617	chr2:42537546	A/G	cg27598129	chr2:42591480	NA	-0.59	-8.83	-0.38	2.11e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg14835575	chr10:16859367	RSU1	0.36	7.32	0.32	1.09e-12	Platelet distribution width;
LGG	cis	rs4664308	0.935	rs6731260	chr2:160977769	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.48	-0.63	6.36e-53	Idiopathic membranous nephropathy;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg17356718	chr2:240230587	HDAC4	-0.3	-6.7	-0.3	6.04e-11	Liver disease severity in Alagille syndrome;
LGG	trans	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg18252515	chr7:66147081	NA	-1.35	-18.78	-0.66	6.65e-59	Diabetic kidney disease;
LGG	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg15268244	chr15:77196840	NA	0.47	10.17	0.43	4.66e-22	Blood metabolite levels;
LGG	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg20026190	chr17:76395443	PGS1	-0.55	-9.7	-0.41	2.2e-20	HDL cholesterol levels;
LGG	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg13009111	chr11:71350975	NA	-0.3	-6.69	-0.3	6.42e-11	Systolic blood pressure;
LGG	cis	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg08112188	chr17:47440006	ZNF652	1.27	15.22	0.58	1.08e-42	Prostate cancer;
LGG	cis	rs6997458	0.785	rs6996345	chr8:86331075	T/A	cg02393479	chr8:86352350	CA3	-0.3	-6.74	-0.3	4.64e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2371030	1.000	rs12473296	chr2:211583281	A/C	cg18417063	chr2:211583084	NA	-0.64	-12.3	-0.5	2.79e-30	Non-small cell lung cancer;
LGG	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg11707556	chr5:10655725	ANKRD33B	0.48	7.03	0.31	7.67e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg02725872	chr8:58115012	NA	-1.03	-14.08	-0.55	9.84e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg05861140	chr6:150128134	PCMT1	-0.4	-9.16	-0.39	1.63e-18	Lung cancer;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg13010199	chr12:38710504	ALG10B	0.76	16.27	0.6	2.21e-47	Heart rate;
LGG	cis	rs9487094	0.813	rs35969918	chr6:109763040	G/C	cg16315928	chr6:109776240	MICAL1	0.55	9.07	0.39	3.29e-18	Height;
LGG	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg25457927	chr22:38595422	NA	-0.4	-9.54	-0.41	8.14e-20	Breast cancer;
LGG	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg04568710	chr12:38710424	ALG10B	0.34	6.82	0.3	2.83e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg17809284	chr5:56205270	C5orf35	0.55	10.24	0.43	2.64e-22	Initial pursuit acceleration;
LGG	cis	rs6688613	0.729	rs10918603	chr1:166936503	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.48	7.06	0.31	6.01e-12	Refractive astigmatism;
LGG	trans	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg17712092	chr4:129076599	LARP1B	0.72	13.87	0.54	7.97e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs36051895	0.589	rs6476946	chr9:5195275	C/G	cg02405213	chr9:5042618	JAK2	0.73	11.91	0.48	9.94e-29	Pediatric autoimmune diseases;
LGG	cis	rs4330281	0.692	rs4637311	chr3:17686445	C/T	cg20981856	chr3:17787350	NA	-0.38	-7.0	-0.31	9.09e-12	Schizophrenia;
LGG	cis	rs9487051	0.773	rs421790	chr6:109543428	T/A	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5.04e-12	Reticulocyte fraction of red cells;
LGG	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.71	0.54	3.94e-36	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg06766960	chr11:133703094	NA	-0.51	-10.07	-0.42	1.07e-21	Childhood ear infection;
LGG	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.49	-0.33	3.53e-13	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.16	-0.39	1.64e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7301016	0.948	rs11614822	chr12:62931690	T/G	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.38	-7.8	-0.34	4.07e-14	Neuroticism;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg10207240	chr12:122356781	WDR66	0.26	7.99	0.35	1.11e-14	Mean corpuscular volume;
LGG	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg25019033	chr10:957182	NA	-0.63	-12.06	-0.49	2.65e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs986417	1.000	rs1955686	chr14:61093560	C/T	cg27398547	chr14:60952738	C14orf39	0.75	7.03	0.31	7.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg10402321	chr1:26617780	UBXN11	-0.36	-6.87	-0.3	2.03e-11	Obesity-related traits;
LGG	cis	rs3736594	1.000	rs3736594	chr2:27995781	A/C	cg27432699	chr2:27873401	GPN1	-0.54	-8.9	-0.38	1.25e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg05338066	chr1:7812865	CAMTA1	0.46	7.28	0.32	1.44e-12	Inflammatory bowel disease;
LGG	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	trans	rs1422110	0.616	rs6452688	chr5:85445038	C/T	cg01787110	chr1:109008453	NBPF6	0.68	11.98	0.49	5.59e-29	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg24829409	chr8:58192753	C8orf71	-0.65	-9.1	-0.39	2.62e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21862992	chr11:68658383	NA	0.5	8.5	0.37	2.67e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg17425144	chr1:10567563	PEX14	-0.41	-9.32	-0.4	4.85e-19	Hepatocellular carcinoma;
LGG	cis	rs11637783	1	rs11637783	chr15:79139000	T/C	cg00540400	chr15:79124168	NA	-0.43	-8.68	-0.37	6.65e-17	Coronary artery disease;
LGG	cis	rs7523273	0.586	rs2796264	chr1:207919968	A/G	cg22525895	chr1:207977042	MIR29B2	0.6	11.92	0.48	9.44e-29	Schizophrenia;
LGG	cis	rs7929679	0.521	rs11032852	chr11:34788308	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs4363385	0.574	rs4041402	chr1:152947397	T/C	cg13444842	chr1:152974279	SPRR3	-0.51	-10.32	-0.43	1.25e-22	Inflammatory skin disease;
LGG	trans	rs78049276	0.688	rs75697049	chr4:148375242	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.32	-0.32	1.12e-12	Pulse pressure;
LGG	cis	rs8044868	0.586	rs7200854	chr16:72083318	G/A	cg23815491	chr16:72088622	HP	0.36	7.61	0.33	1.56e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs10506458	0.915	rs12426017	chr12:63396272	T/G	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2124969	0.548	rs7586751	chr2:160958145	T/C	cg03641300	chr2:160917029	PLA2R1	-0.65	-9.43	-0.4	2.03e-19	Waist circumference adjusted for body mass index;
LGG	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-16.02	-0.6	2.8e-46	Chronic sinus infection;
LGG	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg16434002	chr17:42200994	HDAC5	-0.46	-8.26	-0.36	1.52e-15	Total body bone mineral density;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg06654118	chr4:1303317	MAEA	0.42	7.2	0.32	2.46e-12	Obesity-related traits;
LGG	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg20368463	chr18:77673604	PQLC1	-0.48	-8.39	-0.36	5.74e-16	Schizophrenia;
LGG	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.78e-12	Blood metabolite levels;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg23102388	chr7:1867652	MAD1L1	0.35	6.95	0.31	1.22e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg02269571	chr22:50332266	NA	0.7	10.75	0.45	3.29e-24	Schizophrenia;
LGG	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.65	-11.02	-0.46	2.96e-25	Height;
LGG	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.01	0.42	1.74e-21	Neuroticism;
LGG	cis	rs1018836	0.828	rs4734250	chr8:91591239	C/G	cg16814680	chr8:91681699	NA	0.76	14.14	0.55	5.49e-38	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.28	-0.32	1.46e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs4604732	0.631	rs4436425	chr1:247632323	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.18	0.39	1.48e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs981844	0.696	rs7695605	chr4:154635436	C/G	cg14289246	chr4:154710475	SFRP2	0.64	10.52	0.44	2.39e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg24692254	chr21:30365293	RNF160	1.02	29.17	0.8	6.43e-107	Dental caries;
LGG	cis	rs2587949	0.615	rs2629266	chr3:4191792	A/T	cg16519197	chr3:4211558	NA	-0.33	-6.96	-0.31	1.2e-11	Periodontitis (DPAL);
LGG	cis	rs2692947	0.673	rs4907279	chr2:96399968	G/C	cg22654517	chr2:96458247	NA	0.39	7.68	0.34	9.82e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9517313	0.592	rs61969458	chr13:99177633	A/G	cg07423050	chr13:99094983	FARP1	-0.56	-10.91	-0.45	8.4e-25	Neuroticism;
LGG	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg06271696	chr7:157225062	NA	0.39	7.91	0.34	1.94e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08927489	chr1:151254500	ZNF687	0.45	6.69	0.3	6.38e-11	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs8064024	0.676	rs9938805	chr16:4877553	A/C	cg08329684	chr16:4932620	PPL	-0.38	-8.03	-0.35	8.1e-15	Cancer;
LGG	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg13455623	chr4:3480656	DOK7	-0.52	-8.58	-0.37	1.45e-16	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs6578185	0.782	rs6578184	chr8:142453003	A/G	cg07762003	chr8:142452454	FLJ43860	-0.64	-13.42	-0.53	6.5e-35	Endometriosis;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg13206674	chr6:150067644	NUP43	0.41	8.63	0.37	9.81e-17	Testicular germ cell tumor;
LGG	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg13009111	chr11:71350975	NA	0.33	7.11	0.31	4.47e-12	Monocyte count;
LGG	cis	rs4732038	0.903	rs7811759	chr7:134231615	A/G	cg06906464	chr7:134288099	NA	-0.41	-9.59	-0.41	5.4e-20	Longevity;
LGG	cis	rs10892173	0.765	rs7125694	chr11:117670657	C/T	cg21640587	chr11:117668038	DSCAML1	0.46	7.74	0.34	6.37e-14	Myopia;
LGG	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg12800244	chr3:153838788	SGEF	0.57	8.2	0.36	2.37e-15	Coronary artery disease;
LGG	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	3.92e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs807669	0.903	rs1018764	chr22:19172006	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	16.25	0.6	2.7e-47	Metabolite levels;
LGG	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.44	-0.37	4.06e-16	Type 2 diabetes;
LGG	cis	rs7666738	0.830	rs13328042	chr4:99055406	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.62e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.95	0.38	8.66e-18	Cognitive test performance;
LGG	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.38	-0.36	6.29e-16	Body mass index;
LGG	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg19812747	chr11:111475976	SIK2	0.47	9.6	0.41	5.09e-20	Primary sclerosing cholangitis;
LGG	cis	rs12425451	0.544	rs3741951	chr12:3147080	A/G	cg05389053	chr12:3131226	TEAD4	0.6	10.53	0.44	2.15e-23	Narcolepsy with cataplexy;
LGG	cis	rs472402	0.560	rs10037161	chr5:6624294	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.97	-0.31	1.11e-11	Response to amphetamines;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg26513180	chr16:89883248	FANCA	0.81	8.5	0.37	2.57e-16	Skin colour saturation;
LGG	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg27087555	chr16:88793112	FAM38A	-1.44	-18.72	-0.66	1.2e-58	Plateletcrit;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.56	-10.03	-0.42	1.48e-21	Longevity;
LGG	trans	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg09858108	chr8:58055024	NA	0.42	6.69	0.3	6.64e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8078723	0.738	rs4065321	chr17:38143548	C/T	cg17467752	chr17:38218738	THRA	-0.62	-11.29	-0.46	2.91e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs4604732	0.536	rs10925056	chr1:247650472	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	10.64	0.44	8.25e-24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs4148087	1.000	rs8126971	chr21:43636412	C/T	cg10192877	chr21:43641690	ABCG1	-0.39	-7.03	-0.31	7.4e-12	Eating disorder in bipolar disorder;
LGG	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs526231	0.547	rs72783895	chr5:102287496	C/A	cg23492399	chr5:102201601	PAM	-0.69	-10.54	-0.44	2.01e-23	Primary biliary cholangitis;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg07332563	chr6:291687	DUSP22	-0.57	-9.35	-0.4	3.64e-19	Menopause (age at onset);
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg06969265	chr17:73775802	H3F3B	0.87	9.51	0.4	1.07e-19	Psoriasis;
LGG	cis	rs1691799	0.899	rs4762091	chr12:66747863	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	cis	rs4493873	0.869	rs10095065	chr8:92089473	T/C	cg16814680	chr8:91681699	NA	0.45	6.95	0.31	1.21e-11	Migraine - clinic-based;
LGG	cis	rs5015933	1.000	rs11998746	chr9:128135362	G/A	cg14078157	chr9:128172775	NA	-0.36	-6.81	-0.3	3e-11	Body mass index;
LGG	cis	rs1784581	0.500	rs9355379	chr6:162421466	C/T	cg17173639	chr6:162384350	PARK2	0.69	13.12	0.52	1.2e-33	Itch intensity from mosquito bite;
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.9e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.82	-0.38	2.35e-17	Neuroticism;
LGG	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg01620082	chr3:125678407	NA	-0.87	-7.47	-0.33	4.04e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2766692	1.000	rs4905941	chr14:100725438	A/G	cg14866419	chr14:100704911	YY1	0.6	9.38	0.4	2.93e-19	Electroencephalographic traits in alcoholism;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.6	-11.19	-0.46	7e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06634786	chr22:41940651	POLR3H	0.79	12.62	0.51	1.43e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06112835	chr11:68658793	MRPL21	0.62	10.34	0.43	1.06e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12230513	0.732	rs4343668	chr12:55868936	G/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.98	-0.45	4.45e-25	Contrast sensitivity;
LGG	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-11.95	-0.49	6.93e-29	Height;
LGG	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15532942	chr18:77220712	NFATC1	0.47	7.67	0.34	1.03e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs344364	0.602	rs2745193	chr16:1853959	A/G	cg00490583	chr16:1843685	IGFALS	0.47	10.1	0.42	8.17e-22	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg13397898	chr9:133768931	QRFP	-0.33	-6.97	-0.31	1.07e-11	Response to amphetamines;
LGG	cis	rs1806153	0.611	rs1806156	chr11:31840416	A/T	cg11990419	chr11:31841155	NA	-0.36	-8.25	-0.36	1.61e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg05784532	chr1:230284198	GALNT2	0.56	9.13	0.39	2.15e-18	Coronary artery disease;
LGG	cis	rs12956009	0.518	rs983095	chr18:44899258	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.42	0.33	5.59e-13	Educational attainment (years of education);
LGG	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	7.64	0.33	1.27e-13	Osteoporosis;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.12	-0.31	4.25e-12	Life satisfaction;
LGG	cis	rs7580658	0.613	rs12463538	chr2:128196854	G/T	cg10021288	chr2:128175891	PROC	-0.67	-13.62	-0.53	9.02e-36	Protein C levels;
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.41	-0.33	6.19e-13	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs3784262	0.669	rs4646626	chr15:58256127	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.12e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12568669	chr8:11666485	FDFT1	-0.34	-6.74	-0.3	4.61e-11	Myopia (pathological);
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg22907277	chr7:1156413	C7orf50	0.84	15.06	0.57	5.15e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67311347	1.000	rs9817142	chr3:40425774	C/A	cg13683864	chr3:40499215	RPL14	-1.15	-25.96	-0.77	2.38e-92	Renal cell carcinoma;
LGG	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg03929089	chr4:120376271	NA	0.73	7.78	0.34	4.81e-14	Axial length;
LGG	cis	rs9811920	0.809	rs1384062	chr3:99597928	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	8.92	0.38	1.1e-17	Axial length;
LGG	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.54	-0.59	4.16e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1670533	1.000	rs7669622	chr4:1058659	A/G	cg27284194	chr4:1044797	NA	0.54	9.81	0.41	9.22e-21	Recombination rate (females);
LGG	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	Neuroticism;
LGG	cis	rs9611519	0.894	rs9623320	chr22:41478482	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-8.4	-0.36	5.64e-16	Neuroticism;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.6	-0.53	1.14e-35	Personality dimensions;
LGG	trans	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg07817883	chr1:32538562	TMEM39B	-0.66	-9.33	-0.4	4.32e-19	Monocyte percentage of white cells;
LGG	cis	rs738322	1.000	rs133009	chr22:38569653	G/C	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg02725872	chr8:58115012	NA	-0.76	-11.33	-0.47	1.96e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.7	-0.34	8.06e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7666738	0.962	rs13147921	chr4:99069296	C/G	cg05340658	chr4:99064831	C4orf37	0.43	6.89	0.3	1.83e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.57	0.37	1.58e-16	Bipolar disorder;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg00800038	chr16:89945340	TCF25	-0.66	-7.85	-0.34	3e-14	Skin colour saturation;
LGG	cis	rs10479542	0.533	rs10464056	chr5:178972705	G/T	cg14851468	chr5:179071604	C5orf60	0.47	7.41	0.33	5.85e-13	Lung cancer;
LGG	cis	rs988958	0.565	rs12712819	chr2:42236349	A/G	cg27252766	chr2:42229092	NA	0.52	7.47	0.33	4.16e-13	Hypospadias;
LGG	cis	rs7394190	0.748	rs11000775	chr10:75539010	T/C	cg07699608	chr10:75541558	CHCHD1	0.54	7.35	0.32	9.04e-13	Incident atrial fibrillation;
LGG	cis	rs3106136	0.546	rs183993	chr4:95130025	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.56	-10.48	-0.44	3.33e-23	Capecitabine sensitivity;
LGG	cis	rs2117029	0.521	rs1056875	chr12:49580180	T/C	cg24176009	chr12:49580217	TUBA1A	0.65	12.69	0.51	7.04e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7077256	0.564	rs34577847	chr10:65346509	C/G	cg02276361	chr10:65351566	REEP3	-0.35	-7.13	-0.31	3.83e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.789	rs2476559	chr1:178592919	A/G	cg12486710	chr1:178512616	C1orf220	-0.4	-7.98	-0.35	1.13e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6489785	0.775	rs2649994	chr12:121363836	T/C	cg02419362	chr12:121203948	SPPL3	0.44	6.91	0.31	1.61e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg18335740	chr13:41363409	SLC25A15	-0.52	-9.25	-0.39	8.57e-19	Lewy body disease;
LGG	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12654349	chr5:56205094	C5orf35	0.8	12.27	0.5	3.54e-30	Initial pursuit acceleration;
LGG	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.63	-0.33	1.39e-13	IgG glycosylation;
LGG	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg27124370	chr19:33622961	WDR88	-0.56	-11.01	-0.46	3.28e-25	Bone properties (heel);
LGG	cis	rs2239547	0.522	rs9844736	chr3:52931971	T/G	cg11645453	chr3:52864694	ITIH4	-0.72	-10.95	-0.45	5.76e-25	Schizophrenia;
LGG	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9296095	0.796	rs3846855	chr6:33555877	G/A	cg14003231	chr6:33640908	ITPR3	0.41	8.1	0.35	5.07e-15	Platelet count;
LGG	cis	rs921968	0.643	rs711186	chr2:219346102	A/G	cg02985541	chr2:219472218	PLCD4	-0.3	-6.9	-0.31	1.76e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3742264	0.683	rs1080108	chr13:46516826	A/G	cg15192986	chr13:46630673	CPB2	-0.35	-6.93	-0.31	1.44e-11	Blood protein levels;
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.93	-0.42	3.42e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2708240	0.967	rs2710140	chr7:147570584	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.74	-0.3	4.65e-11	QT interval (drug interaction);
LGG	cis	rs6460942	0.915	rs62448623	chr7:12464122	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-7.12	-0.31	4.21e-12	Coronary artery disease;
LGG	cis	rs2235573	0.805	rs4821738	chr22:38500480	G/T	cg19171272	chr22:38449367	NA	0.46	8.51	0.37	2.39e-16	Glioblastoma;Glioma;
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs524281	0.814	rs1055615	chr11:65846922	C/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.75	-0.3	4.3e-11	Electroencephalogram traits;
LGG	cis	rs7129556	0.690	rs695046	chr11:77594354	A/G	cg12586386	chr11:77299805	AQP11	0.43	6.83	0.3	2.72e-11	Weight loss (gastric bypass surgery);
LGG	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg03929089	chr4:120376271	NA	0.91	18.36	0.65	5.89e-57	Coronary artery disease;
LGG	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg13798912	chr7:905769	UNC84A	-0.57	-7.1	-0.31	4.61e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10979	1.000	rs12191231	chr6:143891114	A/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.4	-0.5	1.08e-30	Hypospadias;
LGG	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.84	-0.42	7.4e-21	Personality dimensions;
LGG	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Myopia (pathological);
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.28	-0.32	1.44e-12	Bipolar disorder;
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.83	-0.3	2.64e-11	Height;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg06521331	chr12:34319734	NA	0.48	9.07	0.39	3.29e-18	Heart rate;
LGG	cis	rs4622507	0.566	rs35449369	chr16:55071137	G/A	cg09947736	chr16:55091198	NA	0.77	11.66	0.48	1.05e-27	Social communication problems;
LGG	cis	rs774359	0.830	rs3849942	chr9:27543281	T/C	cg21249376	chr9:27528432	MOBKL2B	-0.44	-8.15	-0.35	3.48e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	10.11	0.43	7.44e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	15.24	0.58	8.5e-43	Tonsillectomy;
LGG	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg17859187	chr1:168147929	TIPRL	0.46	6.65	0.3	8.33e-11	Schizophrenia;
LGG	cis	rs68170813	0.559	rs4730223	chr7:106814234	A/T	cg02696742	chr7:106810147	HBP1	0.78	11.58	0.47	2.1e-27	Coronary artery disease;
LGG	cis	rs7617773	0.743	rs13081633	chr3:48357281	A/G	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.4	0.71	3.91e-71	Bladder cancer;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg13047869	chr3:10149882	C3orf24	0.56	9.38	0.4	3.04e-19	Alzheimer's disease;
LGG	cis	rs778371	0.723	rs6739794	chr2:233576165	G/A	cg08000102	chr2:233561755	GIGYF2	0.7	11.69	0.48	7.47e-28	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07850338	chr4:155471484	PLRG1	0.5	7.38	0.32	7.24e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-13.85	-0.54	1e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg22875332	chr1:76189707	ACADM	-0.64	-10.66	-0.44	7.09e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg05082376	chr22:42548792	NA	-0.39	-7.9	-0.34	2.01e-14	Schizophrenia;
LGG	cis	rs9640161	0.830	rs13307276	chr7:150061525	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-10.29	-0.43	1.7e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg02018176	chr4:1364513	KIAA1530	0.65	16.07	0.6	1.67e-46	Longevity;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.51	7.54	0.33	2.58e-13	Renal function-related traits (BUN);
LGG	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.81	-0.34	3.8e-14	Blood metabolite levels;
LGG	cis	rs877282	0.945	rs11253391	chr10:788752	G/A	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	trans	rs4714291	0.925	rs847747	chr6:40080069	G/T	cg02267698	chr19:7991119	CTXN1	0.6	9.44	0.4	1.83e-19	Strep throat;
LGG	cis	rs3106136	1.000	rs2632401	chr4:95147055	C/G	cg11021082	chr4:95130006	SMARCAD1	0.45	8.0	0.35	1.04e-14	Capecitabine sensitivity;
LGG	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg07636037	chr3:49044803	WDR6	1.09	27.66	0.79	3.86e-100	Parkinson's disease;
LGG	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs10220309	1.000	rs1388382	chr14:80584701	A/G	cg08183125	chr14:80678293	DIO2	-0.45	-6.85	-0.3	2.32e-11	Lung function (FEV1);
LGG	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.36	-0.47	1.55e-26	Schizophrenia;
LGG	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4764487	0.685	rs2268010	chr12:6339856	T/C	cg08284733	chr12:6341482	CD9	0.36	9.48	0.4	1.32e-19	Mean platelet volume;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	7.39	0.32	6.88e-13	Personality dimensions;
LGG	cis	rs6963495	0.745	rs56239334	chr7:105165351	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07546262	chr12:54753490	NA	0.54	8.3	0.36	1.15e-15	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs911555	0.713	rs10162425	chr14:103931621	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-7.26	-0.32	1.69e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17776563	0.887	rs28790085	chr15:89128287	T/C	cg05013243	chr15:89149849	MIR1179	-0.5	-10.43	-0.44	5.32e-23	Thyroid hormone levels;
LGG	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg12395012	chr8:11607386	GATA4	-0.38	-6.86	-0.3	2.16e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs17767392	0.813	rs61989379	chr14:71964406	G/C	cg02058870	chr14:72053146	SIPA1L1	0.39	8.02	0.35	8.71e-15	Mitral valve prolapse;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.7	-0.34	8.05e-14	Testicular germ cell tumor;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	7.97	0.35	1.27e-14	Lung function (FEV1/FVC);
LGG	cis	rs34467563	0.872	rs34957989	chr8:97349856	A/G	cg22138393	chr8:97340270	PTDSS1	0.3	6.65	0.3	8.11e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg15147215	chr3:52552868	STAB1	-0.4	-8.04	-0.35	7.51e-15	Bipolar disorder;
LGG	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg12193833	chr17:30244370	NA	-0.28	-6.74	-0.3	4.76e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2171564	0.791	rs9826586	chr3:112441312	C/T	cg06685282	chr3:112453648	NA	0.47	8.7	0.37	5.69e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1728785	1.000	rs1645979	chr16:68603660	G/T	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	12.19	0.49	7.9e-30	Mean platelet volume;
LGG	cis	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.27e-17	Neuroticism;
LGG	cis	rs7914558	0.966	rs10786719	chr10:104637992	C/T	cg04362960	chr10:104952993	NT5C2	-0.52	-9.97	-0.42	2.44e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg25208724	chr1:156163844	SLC25A44	1.09	23.5	0.74	5.63e-81	Testicular germ cell tumor;
LGG	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.78	-0.68	1.42e-63	Height;
LGG	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4849975	0.510	rs13431927	chr2:3713706	G/C	cg14882966	chr2:3699353	NA	0.64	7.46	0.33	4.27e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg24634471	chr8:143751801	JRK	0.53	8.54	0.37	2.01e-16	Schizophrenia;
LGG	cis	rs10463554	0.963	rs26817	chr5:102540366	C/T	cg23492399	chr5:102201601	PAM	0.49	7.36	0.32	8.69e-13	Parkinson's disease;
LGG	cis	rs7582720	1.000	rs72934732	chr2:203739856	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1386478	0.853	rs13070378	chr3:113793682	G/A	cg14431476	chr3:113822413	NA	-0.42	-6.65	-0.3	8.07e-11	Crohn's disease and psoriasis;
LGG	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.46	0.5	6.49e-31	Cognitive test performance;
LGG	cis	rs6496044	0.963	rs7165300	chr15:86070069	G/C	cg13263323	chr15:86062960	AKAP13	-0.34	-6.77	-0.3	3.98e-11	Interstitial lung disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20433014	chr15:75018583	CYP1A1	0.43	7.64	0.33	1.26e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10426930	0.547	rs2054519	chr19:5059360	T/C	cg18473234	chr19:5097819	KDM4B	-0.44	-7.66	-0.34	1.1e-13	Monocyte percentage of white cells;
LGG	cis	rs2718058	0.589	rs10258728	chr7:37792922	C/T	cg24998770	chr7:37888106	TXNDC3	-0.41	-6.97	-0.31	1.07e-11	Alzheimer's disease (late onset);
LGG	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.51	0.4	1.04e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg24503407	chr1:205819492	PM20D1	0.73	16.91	0.62	2.57e-50	Menarche (age at onset);
LGG	cis	rs225245	0.755	rs226432	chr17:34043825	G/A	cg05299278	chr17:33885742	SLFN14	-0.43	-8.23	-0.36	1.97e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs477692	0.935	rs554458	chr10:131427372	A/G	cg05714579	chr10:131428358	MGMT	0.66	14.09	0.55	9.1e-38	Response to temozolomide;
LGG	cis	rs2479724	0.870	rs6902650	chr6:41764080	G/A	cg17623882	chr6:41773611	USP49	0.52	9.2	0.39	1.24e-18	Menarche (age at onset);
LGG	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	5.17e-45	Intelligence (multi-trait analysis);
LGG	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.75	0.59	4.44e-45	Intelligence (multi-trait analysis);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg01353809	chr12:46123569	ARID2	-0.41	-6.97	-0.31	1.13e-11	Brain structure;
LGG	cis	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg14673194	chr17:80132900	CCDC57	-0.44	-7.71	-0.34	7.7e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg11502198	chr6:26597334	ABT1	0.57	9.96	0.42	2.72e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6807915	0.647	rs310756	chr3:12277612	C/T	cg22839075	chr3:12045461	SYN2	0.39	6.72	0.3	5.36e-11	Leprosy;
LGG	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.94	-0.38	9.46e-18	Morning vs. evening chronotype;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg04156016	chr5:1868137	NA	0.33	7.28	0.32	1.47e-12	Cardiovascular disease risk factors;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs74781061	0.860	rs3985310	chr15:74735167	T/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.71	-0.3	5.64e-11	Endometriosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12790134	chr8:67578787	VCPIP1	0.44	7.07	0.31	5.7e-12	Cognitive performance;
LGG	cis	rs10791097	0.519	rs74866549	chr11:130730380	A/G	cg12179176	chr11:130786555	SNX19	0.73	13.54	0.53	2.06e-35	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg18050959	chr15:68126178	NA	-0.37	-6.91	-0.31	1.59e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs36051895	0.632	rs61461940	chr9:5157277	T/C	cg02405213	chr9:5042618	JAK2	-0.79	-15.44	-0.58	1.14e-43	Pediatric autoimmune diseases;
LGG	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg24642439	chr20:33292090	TP53INP2	0.55	9.36	0.4	3.48e-19	Coronary artery disease;
LGG	trans	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg21659725	chr3:3221576	CRBN	0.74	11.98	0.49	5.63e-29	Resting heart rate;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg12070911	chr6:150209640	RAET1E	0.33	8.07	0.35	6.07e-15	Lung cancer;
LGG	cis	rs16976116	0.855	rs28522816	chr15:55495114	C/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs17125944	0.505	rs2295826	chr14:53174923	C/T	cg00686598	chr14:53173677	PSMC6	-1.29	-15.36	-0.58	2.56e-43	Alzheimer's disease (late onset);
LGG	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18252515	chr7:66147081	NA	0.41	7.03	0.31	7.52e-12	Aortic root size;
LGG	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs6496044	0.568	rs7176291	chr15:86067398	T/C	cg13263323	chr15:86062960	AKAP13	-0.38	-8.33	-0.36	9.21e-16	Interstitial lung disease;
LGG	cis	rs7312933	0.612	rs10785334	chr12:42620377	A/G	cg19980929	chr12:42632907	YAF2	-0.38	-8.03	-0.35	8.04e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.29	0.5	3.15e-30	Rheumatoid arthritis;
LGG	cis	rs12410462	0.591	rs903695	chr1:227733069	A/G	cg21459583	chr1:227974177	NA	0.35	6.75	0.3	4.54e-11	Major depressive disorder;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg22398616	chr13:53314203	LECT1	-0.46	-9.71	-0.41	2.12e-20	Lewy body disease;
LGG	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg18937875	chr11:14930189	NA	-0.48	-7.84	-0.34	3.13e-14	Vitamin D levels;
LGG	cis	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg24623649	chr8:11872141	NA	0.32	7.8	0.34	4.13e-14	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg04851639	chr8:1020857	NA	-0.43	-9.14	-0.39	1.98e-18	Schizophrenia;
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18252515	chr7:66147081	NA	-0.42	-7.01	-0.31	8.61e-12	Aortic root size;
LGG	cis	rs17030434	0.834	rs6535958	chr4:154760834	C/G	cg14289246	chr4:154710475	SFRP2	0.62	10.08	0.42	9.69e-22	Electrocardiographic conduction measures;
LGG	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg07615347	chr10:60278583	BICC1	0.64	18.37	0.65	5.03e-57	Refractive error;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg19143629	chr17:61920732	SMARCD2	-0.4	-6.68	-0.3	6.73e-11	Prudent dietary pattern;
LGG	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg18876405	chr7:65276391	NA	-0.58	-10.42	-0.44	5.39e-23	Aortic root size;
LGG	cis	rs35883536	0.588	rs12568329	chr1:101104588	A/G	cg06223162	chr1:101003688	GPR88	-0.35	-8.28	-0.36	1.36e-15	Monocyte count;
LGG	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.83	-0.38	2.13e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs68170813	0.559	rs6946036	chr7:106853659	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.63	-0.44	8.88e-24	Coronary artery disease;
LGG	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.62	-0.44	9.93e-24	Neuroticism;
LGG	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg23422044	chr7:1970798	MAD1L1	-0.61	-10.52	-0.44	2.34e-23	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg23758822	chr17:41437982	NA	0.87	15.31	0.58	4.15e-43	Menopause (age at onset);
LGG	cis	rs2028299	0.879	rs4932263	chr15:90439627	T/C	cg23731826	chr15:90371692	NA	0.35	7.76	0.34	5.3e-14	Type 2 diabetes;
LGG	cis	rs2040494	0.562	rs2079147	chr7:92332375	C/T	cg15732164	chr7:92237376	CDK6	-0.34	-7.13	-0.31	3.86e-12	Height;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg13206674	chr6:150067644	NUP43	0.66	15.4	0.58	1.66e-43	Lung cancer;
LGG	cis	rs834603	0.575	rs834592	chr7:47474328	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.77	0.34	5e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg03342759	chr3:160939853	NMD3	0.68	12.33	0.5	2.12e-30	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-12.58	-0.5	2.06e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg06916706	chr16:4465613	CORO7	-1.07	-20.53	-0.69	4.63e-67	Schizophrenia;
LGG	cis	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.79	-0.57	7.91e-41	IgG glycosylation;
LGG	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg06115741	chr20:33292138	TP53INP2	0.6	10.15	0.43	5.42e-22	Coronary artery disease;
LGG	cis	rs12348691	0.503	rs1867279	chr9:100616041	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs721399	1.000	rs11780610	chr8:18259876	C/T	cg18736775	chr8:18248649	NAT2	0.51	8.89	0.38	1.33e-17	Blood metabolite levels;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23587005	chr12:9600941	DDX12	0.4	6.94	0.31	1.36e-11	Bilirubin levels;
LGG	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.52	0.61	1.59e-48	Smoking behavior;
LGG	cis	rs12464559	0.649	rs9288006	chr2:152661831	G/A	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9810089	0.900	rs11915629	chr3:136139730	C/G	cg21827317	chr3:136751795	NA	0.44	7.65	0.33	1.18e-13	Gestational age at birth (child effect);
LGG	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15369054	chr17:80825471	TBCD	-0.4	-7.77	-0.34	5.01e-14	Breast cancer;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	14.35	0.55	6.91e-39	Alzheimer's disease;
LGG	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.65	-0.41	3.31e-20	Body mass index;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg07414643	chr4:187882934	NA	0.56	11.44	0.47	7.67e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg16141378	chr3:129829833	LOC729375	0.32	7.28	0.32	1.48e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2235649	1.000	rs2235649	chr16:1837406	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.66	-0.3	7.66e-11	Blood metabolite levels;
LGG	cis	rs17125944	0.686	rs11621275	chr14:53363316	C/G	cg00686598	chr14:53173677	PSMC6	-0.62	-6.74	-0.3	4.86e-11	Alzheimer's disease (late onset);
LGG	trans	rs6787172	0.622	rs3845981	chr3:158082506	G/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.41	-0.33	6.08e-13	Subjective well-being;
LGG	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.83	0.7	1.83e-68	Calcium levels;
LGG	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg02002194	chr4:3960332	NA	0.4	6.78	0.3	3.61e-11	Neuroticism;
LGG	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs9640161	0.789	rs66688634	chr7:150053806	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-11.17	-0.46	7.96e-26	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg09640425	chr7:158790006	NA	-0.36	-6.76	-0.3	4.26e-11	Facial morphology (factor 20);
LGG	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg09441152	chr18:77712293	PQLC1	0.39	6.66	0.3	7.69e-11	Schizophrenia;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg05868516	chr6:26286170	HIST1H4H	0.46	7.98	0.35	1.18e-14	Educational attainment;
LGG	cis	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg24623649	chr8:11872141	NA	-0.3	-6.93	-0.31	1.44e-11	Retinal vascular caliber;
LGG	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg19766460	chr21:43528205	UMODL1;C21orf128	0.5	9.48	0.4	1.36e-19	IgG glycosylation;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.47	-0.37	3.39e-16	Aortic root size;
LGG	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg05491587	chr18:77659695	KCNG2	-0.41	-7.34	-0.32	9.52e-13	Schizophrenia;
LGG	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg21775007	chr8:11205619	TDH	0.48	7.62	0.33	1.4e-13	Neuroticism;
LGG	cis	rs7133214	0.824	rs11049138	chr12:27927103	A/C	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.92	-0.31	1.48e-11	Gut microbiota (functional units);
LGG	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.1	-0.39	2.69e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4538187	0.707	rs67308158	chr2:64129453	G/A	cg02541582	chr2:64069798	UGP2	-0.61	-12.88	-0.51	1.13e-32	Systolic blood pressure;
LGG	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12365681	chr11:67980256	SUV420H1	0.4	6.84	0.3	2.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg12310025	chr6:25882481	NA	-0.43	-7.01	-0.31	8.24e-12	Iron status biomarkers;
LGG	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg22920501	chr2:26401640	FAM59B	0.46	9.35	0.4	3.75e-19	Gut microbiome composition (summer);
LGG	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.59	-0.33	1.8e-13	Testicular germ cell tumor;
LGG	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg00757033	chr12:89920650	WDR51B	0.64	9.24	0.39	8.71e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs66887589	0.967	rs56173225	chr4:120509972	G/A	cg09307838	chr4:120376055	NA	-0.47	-8.18	-0.36	2.81e-15	Diastolic blood pressure;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.25	-0.32	1.7e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs9914544	0.545	rs57035178	chr17:18797767	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs858239	0.601	rs4140959	chr7:23170776	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.19	0.32	2.68e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg08621203	chr6:150244597	RAET1G	-0.47	-7.15	-0.32	3.44e-12	Lung cancer;
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg21926883	chr2:100939477	LONRF2	-0.7	-16.57	-0.61	9.37e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg03254818	chr6:169586852	NA	0.52	8.01	0.35	9.25e-15	Pulse pressure;
LGG	cis	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	9.04e-26	Morning vs. evening chronotype;
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg04287289	chr16:89883240	FANCA	0.81	16.66	0.61	3.52e-49	Vitiligo;
LGG	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.35	-0.36	8.09e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg12438819	chr7:158236134	PTPRN2	-0.31	-8.35	-0.36	8.19e-16	Obesity-related traits;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg02951883	chr7:2050386	MAD1L1	-0.81	-18.22	-0.65	2.59e-56	Bipolar disorder and schizophrenia;
LGG	cis	rs9467773	0.620	rs2504592	chr6:26640951	C/G	cg09904177	chr6:26538194	HMGN4	0.67	14.01	0.55	1.99e-37	Intelligence (multi-trait analysis);
LGG	cis	rs9427116	0.702	rs884618	chr1:154601157	A/G	cg11650704	chr1:154556575	ADAR	-0.44	-8.53	-0.37	2.13e-16	Blood protein levels;
LGG	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg18854424	chr1:2615690	NA	-0.32	-6.89	-0.3	1.87e-11	Ulcerative colitis;
LGG	cis	rs2694528	1.000	rs1020371	chr5:60145010	A/C	cg11474532	chr5:59995715	DEPDC1B	0.72	7.63	0.33	1.33e-13	Parkinson's disease;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6466055	0.611	rs3213742	chr7:104643230	C/A	cg03782966	chr7:104585482	NA	0.31	6.72	0.3	5.26e-11	Schizophrenia;
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg16482183	chr6:26056742	HIST1H1C	0.41	7.07	0.31	5.66e-12	Height;
LGG	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg03929089	chr4:120376271	NA	-1.04	-24.43	-0.75	2.68e-85	Height;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg26174226	chr8:58114915	NA	-0.55	-7.32	-0.32	1.14e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.04	-0.31	6.85e-12	Neuroticism;
LGG	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg27624424	chr6:160112604	SOD2	0.65	9.3	0.4	5.37e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg04851639	chr8:1020857	NA	-0.38	-8.26	-0.36	1.57e-15	Schizophrenia;
LGG	cis	rs2016266	0.859	rs10876433	chr12:53734114	G/A	cg04065151	chr12:53682969	ESPL1	0.56	8.79	0.38	2.98e-17	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6558530	0.666	rs4242539	chr8:1694236	A/G	cg25947184	chr8:1697459	NA	0.44	7.65	0.34	1.14e-13	Systolic blood pressure;
LGG	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.5	-11.82	-0.48	2.43e-28	Oropharynx cancer;
LGG	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg18850127	chr7:39170497	POU6F2	0.55	13.51	0.53	2.76e-35	IgG glycosylation;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg10360139	chr7:1886902	MAD1L1	0.38	6.83	0.3	2.69e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs3812049	0.532	rs251216	chr5:127543280	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.65	0.37	8.62e-17	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-7.44	-0.33	4.8e-13	Depression;
LGG	trans	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs4698048	0.510	rs12509714	chr4:10107091	C/G	cg25986240	chr4:9926439	SLC2A9	-0.31	-6.64	-0.3	8.55e-11	Skin aging (microtopography measurement);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02482700	chr2:101033747	CHST10	0.47	7.59	0.33	1.82e-13	Cognitive performance;
LGG	cis	rs17655565	1.000	rs76413558	chr12:52694156	A/G	cg08257133	chr12:52711352	KRT83	0.52	7.08	0.31	5.5e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.57	-0.37	1.55e-16	Alzheimer's disease (survival time);
LGG	cis	rs9878978	0.685	rs11711409	chr3:2502197	C/T	cg21928760	chr3:2462534	CNTN4	0.38	7.58	0.33	1.85e-13	Blood pressure (smoking interaction);
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg11766577	chr21:47581405	C21orf56	-0.5	-8.67	-0.37	7.57e-17	Testicular germ cell tumor;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.68	-12.17	-0.49	9.6e-30	Obesity-related traits;
LGG	cis	rs17253792	0.822	rs13379340	chr14:56050346	C/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.62	-0.51	1.41e-31	Putamen volume;
LGG	trans	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg18187862	chr3:45730750	SACM1L	-0.57	-9.42	-0.4	2.11e-19	Primary sclerosing cholangitis;
LGG	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg25809561	chr17:30822961	MYO1D	0.39	9.2	0.39	1.21e-18	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26959380	chr12:130498820	NA	0.41	6.88	0.3	1.9e-11	Cognitive performance;
LGG	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.11e-13	Dupuytren's disease;
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg23985595	chr17:80112537	CCDC57	0.39	7.54	0.33	2.47e-13	Life satisfaction;
LGG	cis	rs924607	0.966	rs1621827	chr5:635074	A/G	cg07001201	chr5:642380	CEP72	-0.4	-6.74	-0.3	4.76e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	trans	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.93	-0.31	1.41e-11	Retinal vascular caliber;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg09699651	chr6:150184138	LRP11	0.5	8.77	0.38	3.48e-17	Lung cancer;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-6.85	-0.3	2.32e-11	Schizophrenia;
LGG	cis	rs1044826	0.642	rs9833307	chr3:139181370	G/A	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg07701084	chr6:150067640	NUP43	0.68	12.98	0.52	4.7e-33	Lung cancer;
LGG	cis	rs2013441	0.866	rs2703813	chr17:20115315	A/G	cg13482628	chr17:19912719	NA	-0.4	-6.9	-0.31	1.72e-11	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.81	-0.34	3.91e-14	Iron status biomarkers;
LGG	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs3087591	1.000	rs2952980	chr17:29473353	G/A	cg24425628	chr17:29625626	OMG;NF1	0.71	14.92	0.57	2.25e-41	Hip circumference;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.16	-0.32	3.24e-12	Bipolar disorder;
LGG	cis	rs651907	0.737	rs9844218	chr3:101584983	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.58	-9.5	-0.4	1.12e-19	Colorectal cancer;
LGG	cis	rs7607369	0.791	rs72965151	chr2:219344165	G/T	cg01130898	chr2:219473002	PLCD4	0.46	7.81	0.34	3.87e-14	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs9875589	0.957	rs13077668	chr3:13929756	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.17	0.39	1.54e-18	Ovarian reserve;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.72	-0.34	7.1e-14	Menopause (age at onset);
LGG	cis	rs1003719	0.762	rs3787787	chr21:38463452	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg03894339	chr8:19674705	INTS10	0.93	14.99	0.57	1.05e-41	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02788857	chr8:22132959	PIWIL2	0.51	11.83	0.48	2.14e-28	Hypertriglyceridemia;
LGG	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17830980	chr10:43048298	ZNF37B	-0.6	-13.57	-0.53	1.56e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs7584330	0.955	rs58643200	chr2:238389855	A/G	cg16989719	chr2:238392110	NA	-0.35	-7.64	-0.33	1.28e-13	Prostate cancer;
LGG	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg12310025	chr6:25882481	NA	0.41	6.76	0.3	4.09e-11	Iron status biomarkers;
LGG	cis	rs2071403	0.527	rs11694732	chr2:1408350	G/C	cg06500727	chr2:1417164	TPO	-0.6	-12.14	-0.49	1.23e-29	Thyroid peroxidase antibody positivity;
LGG	cis	rs3820068	0.705	rs57238793	chr1:15890029	A/G	cg05660106	chr1:15850417	CASP9	1.18	23.87	0.74	1.07e-82	Systolic blood pressure;
LGG	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg18252515	chr7:66147081	NA	-1.41	-19.45	-0.67	4.98e-62	Diabetic kidney disease;
LGG	cis	rs3849570	1.000	rs2290081	chr3:81810725	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-7.91	-0.34	1.93e-14	Waist circumference;Body mass index;
LGG	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg00031303	chr3:195681400	NA	0.51	8.06	0.35	6.64e-15	Pancreatic cancer;
LGG	cis	rs7572733	0.515	rs1356542	chr2:198835702	G/T	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs10089	0.904	rs2195921	chr5:127489754	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.61	0.47	1.53e-27	Ileal carcinoids;
LGG	cis	rs6696846	0.765	rs72757524	chr1:205086473	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.18	0.32	2.73e-12	Red blood cell count;
LGG	cis	rs919433	0.680	rs788021	chr2:198293691	T/C	cg00792783	chr2:198669748	PLCL1	0.51	8.04	0.35	7.4e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs16976116	0.851	rs28393427	chr15:55490981	A/G	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10927875	0.864	rs12744578	chr1:16173110	A/T	cg07117364	chr1:16154769	NA	-0.51	-8.14	-0.35	3.67e-15	Dilated cardiomyopathy;
LGG	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg03060546	chr3:49711283	APEH	-0.63	-10.4	-0.44	6.53e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg09021430	chr5:549028	NA	-0.74	-10.57	-0.44	1.58e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg06606381	chr12:133084897	FBRSL1	-1.27	-11.76	-0.48	4.24e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg02018176	chr4:1364513	KIAA1530	-0.43	-9.91	-0.42	4.12e-21	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20349687	chr2:88927127	EIF2AK3	0.52	8.59	0.37	1.37e-16	Cognitive performance;
LGG	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg16797656	chr11:68205561	LRP5	-0.51	-10.04	-0.42	1.38e-21	Total body bone mineral density;
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg06848047	chr4:90757629	SNCA	-0.4	-7.55	-0.33	2.41e-13	Dementia with Lewy bodies;
LGG	cis	rs10789491	1.000	rs11211342	chr1:47163098	T/C	cg15501359	chr1:47185051	KIAA0494	0.75	14.6	0.56	5.56e-40	Response to hepatitis C treatment;
LGG	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg27476859	chr7:2772710	GNA12	0.63	12.82	0.51	2.05e-32	Height;
LGG	cis	rs67133203	0.632	rs422637	chr12:51403870	G/A	cg14688905	chr12:51403056	SLC11A2	-0.58	-10.04	-0.42	1.41e-21	Urinary tract infection frequency;
LGG	trans	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg05926928	chr17:57297772	GDPD1	-0.51	-7.8	-0.34	4.28e-14	Schizophrenia;
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg15017067	chr4:17643749	FAM184B	0.3	6.94	0.31	1.32e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg23933602	chr10:16859644	RSU1	1.02	26.66	0.78	1.38e-95	Platelet distribution width;
LGG	cis	rs1018836	0.632	rs7017295	chr8:91482356	C/T	cg16814680	chr8:91681699	NA	0.65	11.2	0.46	6.45e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.44e-15	Lung cancer;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20295408	chr7:1910781	MAD1L1	-0.41	-7.12	-0.31	4.26e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.37	0.56	5.66e-39	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs57590327	0.503	rs13079104	chr3:81886039	A/T	cg07356753	chr3:81810745	GBE1	-0.44	-7.12	-0.31	4.24e-12	Extraversion;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg23743428	chr13:21893420	NA	-0.49	-10.92	-0.45	7.1e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.77	12.97	0.52	4.82e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg14541582	chr5:601475	NA	-0.68	-10.63	-0.44	8.81e-24	Obesity-related traits;
LGG	cis	rs2479106	0.791	rs2058432	chr9:126703738	T/C	cg16191174	chr9:126692580	DENND1A	0.49	6.88	0.3	1.98e-11	Polycystic ovary syndrome;
LGG	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg04398451	chr17:18023971	MYO15A	0.74	15.54	0.59	3.96e-44	Total body bone mineral density;
LGG	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.26	-0.43	2.24e-22	Colorectal cancer;
LGG	cis	rs758324	0.947	rs600661	chr5:131290894	T/C	cg06307176	chr5:131281290	NA	-0.59	-9.5	-0.4	1.16e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4604732	0.588	rs7552443	chr1:247628583	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.14	0.39	1.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02580604	chr1:63250136	ATG4C	0.41	6.82	0.3	2.84e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.06	0.31	6.08e-12	Prudent dietary pattern;
LGG	cis	rs1594829	0.500	rs2046223	chr8:26210178	C/T	cg11498726	chr8:26250323	BNIP3L	0.43	9.79	0.41	1.05e-20	Height;
LGG	cis	rs6912958	0.630	rs4707377	chr6:88280332	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs3087591	0.960	rs2066736	chr17:29559932	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-14.19	-0.55	3.39e-38	Hip circumference;
LGG	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs2652834	0.851	rs9888735	chr15:63410141	G/A	cg05507819	chr15:63340323	TPM1	0.5	7.03	0.31	7.23e-12	HDL cholesterol;
LGG	cis	rs889398	0.741	rs2362642	chr16:69931458	G/A	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.29	-0.32	1.39e-12	Body mass index;
LGG	cis	rs17253792	0.822	rs28409547	chr14:56047826	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.54	-0.5	2.91e-31	Putamen volume;
LGG	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg09264619	chr17:80180166	NA	-0.52	-10.13	-0.43	6.19e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.66	-9.32	-0.4	4.92e-19	Homoarginine levels;
LGG	cis	rs887829	0.508	rs1104892	chr2:234620272	G/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.45	-8.44	-0.36	4.24e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs12474201	0.889	rs2346878	chr2:46922870	C/T	cg06386533	chr2:46925753	SOCS5	0.79	14.93	0.57	2.06e-41	Height;
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg02524346	chr8:600233	NA	1.12	10.35	0.43	1.02e-22	IgG glycosylation;
LGG	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.57	-0.41	6.35e-20	Eosinophil percentage of white cells;
LGG	cis	rs74781061	0.929	rs12439505	chr15:74786362	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.76	13.79	0.54	1.75e-36	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.85	-0.3	2.38e-11	Aortic root size;
LGG	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.87	-0.42	5.53e-21	Sudden cardiac arrest;
LGG	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.65	-0.33	1.2e-13	Monocyte percentage of white cells;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg00490583	chr16:1843685	IGFALS	0.44	9.77	0.41	1.27e-20	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs600231	0.665	rs1784858	chr11:65222952	T/C	cg17120908	chr11:65337727	SSSCA1	-0.49	-8.85	-0.38	1.82e-17	Bone mineral density;
LGG	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.26	0.43	2.07e-22	Iron status biomarkers;
LGG	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg06494592	chr3:125709126	NA	-0.52	-6.65	-0.3	8.41e-11	Blood pressure (smoking interaction);
LGG	cis	rs12618769	0.652	rs3769698	chr2:99233894	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.79	0.34	4.58e-14	Bipolar disorder;
LGG	cis	rs7666738	0.830	rs1896154	chr4:99021161	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg25143771	chr10:104629124	AS3MT	0.42	6.79	0.3	3.52e-11	Arsenic metabolism;
LGG	cis	rs7582720	1.000	rs72932727	chr2:203649501	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.44	0.4	1.89e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg02725872	chr8:58115012	NA	-0.76	-10.85	-0.45	1.42e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	1.000	rs1554166	chr2:172541609	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.77	-0.78	4.27e-96	Schizophrenia;
LGG	cis	rs4604732	0.685	rs4925673	chr1:247636800	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.52	0.37	2.24e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	trans	rs61931739	0.649	rs815028	chr12:33718591	T/C	cg26384229	chr12:38710491	ALG10B	0.48	8.53	0.37	2.03e-16	Morning vs. evening chronotype;
LGG	cis	rs727505	0.721	rs67277928	chr7:124776704	G/T	cg23710748	chr7:124431027	NA	-0.43	-8.49	-0.37	2.86e-16	Lewy body disease;
LGG	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg05926928	chr17:57297772	GDPD1	1.36	21.78	0.71	6.66e-73	Opioid sensitivity;
LGG	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-7.82	-0.34	3.5e-14	Schizophrenia;
LGG	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg22022881	chr2:105853494	NA	0.34	6.91	0.31	1.65e-11	Type 2 diabetes;
LGG	trans	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.44	-0.37	4.12e-16	Systolic blood pressure;
LGG	cis	rs8048589	0.641	rs3851012	chr16:12193583	T/G	cg02910054	chr16:12241554	SNX29	0.44	7.53	0.33	2.7e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs1707322	0.963	rs11211238	chr1:46449415	G/A	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg24375607	chr4:120327624	NA	0.68	11.03	0.46	2.81e-25	Corneal astigmatism;
LGG	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg22232500	chr2:134024266	NCKAP5	-0.57	-8.11	-0.35	4.61e-15	Bipolar disorder;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20878095	chr19:49298744	BCAT2	0.38	6.92	0.31	1.48e-11	Obesity-related traits;
LGG	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	2.01e-11	HDL cholesterol;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.54	8.42	0.36	4.71e-16	Longevity;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	12.04	0.49	3.17e-29	Longevity;
LGG	cis	rs7017914	0.967	rs6987007	chr8:71600942	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.15e-11	Bone mineral density;
LGG	cis	rs7481584	0.624	rs413368	chr11:3047646	C/G	cg25174290	chr11:3078921	CARS	-0.51	-9.25	-0.39	8.45e-19	Calcium levels;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs7119	0.717	rs34981488	chr15:77723403	T/G	cg17802220	chr15:77601643	NA	-0.55	-12.35	-0.5	1.69e-30	Type 2 diabetes;
LGG	trans	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg26043149	chr18:55253948	FECH	0.4	6.68	0.3	7.06e-11	Bone mineral density;
LGG	cis	rs9560113	0.764	rs1177401	chr13:112173067	T/C	cg14952266	chr13:112191215	NA	0.44	7.96	0.35	1.33e-14	Menarche (age at onset);
LGG	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg22432760	chr17:80829718	TBCD	0.41	7.03	0.31	7.3e-12	Breast cancer;
LGG	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg10326726	chr10:51549505	MSMB	-0.69	-14.15	-0.55	5.08e-38	Prostate-specific antigen levels;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.25	-0.32	1.72e-12	Obesity;
LGG	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg26897989	chr16:1907736	C16orf73	-0.52	-9.56	-0.41	7.16e-20	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27119451	chr5:137514611	BRD8;KIF20A	0.49	7.11	0.31	4.29e-12	Gut microbiome composition (summer);
LGG	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg12927641	chr6:109611667	NA	0.37	7.11	0.31	4.47e-12	Reticulocyte fraction of red cells;
LGG	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg21466736	chr12:48725269	NA	-0.4	-8.03	-0.35	8.04e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg00631329	chr6:26305371	NA	-0.38	-6.7	-0.3	5.97e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs754466	0.606	rs7084705	chr10:79596675	A/G	cg17075019	chr10:79541650	NA	-0.92	-19.62	-0.67	7.72e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg05791153	chr7:19748676	TWISTNB	0.63	9.07	0.39	3.52e-18	Thyroid stimulating hormone;
LGG	cis	rs7220401	0.542	rs55644350	chr17:27913368	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.57	10.64	0.44	8.51e-24	Coronary artery disease;
LGG	cis	rs7924176	0.601	rs7099026	chr10:75888528	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.98	-0.31	1.06e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.96	0.31	1.2e-11	Systemic lupus erythematosus;
LGG	cis	rs4077515	0.967	rs4078099	chr9:139267533	G/A	cg21253087	chr9:139290292	SNAPC4	0.35	7.04	0.31	6.9e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.71	0.34	7.61e-14	Coronary artery disease;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg21775007	chr8:11205619	TDH	0.43	6.69	0.3	6.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg14186256	chr22:23484241	RTDR1	0.95	23.25	0.73	8.58e-80	Bone mineral density;
LGG	cis	rs4474465	0.688	rs7108439	chr11:78277708	A/T	cg27205649	chr11:78285834	NARS2	0.59	11.09	0.46	1.63e-25	Alzheimer's disease (survival time);
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg26554054	chr8:600488	NA	0.94	9.87	0.42	5.57e-21	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15747848	chr15:40074985	FSIP1	0.47	7.02	0.31	7.87e-12	Gut microbiome composition (summer);
LGG	cis	rs4731207	0.735	rs720616	chr7:124452961	A/G	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg09818912	chr17:20140352	CYTSB	0.3	7.06	0.31	6.23e-12	Schizophrenia;
LGG	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.51	-0.44	2.48e-23	Hepatocellular carcinoma;
LGG	cis	rs3784262	0.669	rs3784257	chr15:58262974	C/T	cg12031962	chr15:58353849	ALDH1A2	0.34	7.24	0.32	1.86e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9287719	0.967	rs6751398	chr2:10738972	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg12292205	chr6:26970375	C6orf41	-0.77	-15.68	-0.59	9.57e-45	Autism spectrum disorder or schizophrenia;
LGG	trans	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg16105309	chr15:79090380	ADAMTS7	0.44	7.77	0.34	5.15e-14	Schizophrenia;
LGG	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg27147174	chr7:100797783	AP1S1	-0.58	-10.28	-0.43	1.8e-22	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.98	0.35	1.13e-14	Height;
LGG	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg25358565	chr5:93447407	FAM172A	-1.31	-15.98	-0.6	4.4e-46	Diabetic retinopathy;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg23188684	chr11:67383651	NA	-0.42	-6.91	-0.31	1.59e-11	Mean corpuscular volume;
LGG	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg07541023	chr7:19748670	TWISTNB	0.63	8.92	0.38	1.08e-17	Thyroid stimulating hormone;
LGG	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg08645402	chr16:4508243	NA	0.43	7.11	0.31	4.33e-12	Schizophrenia;
LGG	cis	rs1009647	0.583	rs72715746	chr14:55741370	G/A	cg04306507	chr14:55594613	LGALS3	0.48	7.93	0.35	1.69e-14	Testicular germ cell tumor;
LGG	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg16885296	chr6:26284938	NA	0.35	7.2	0.32	2.43e-12	Educational attainment;
LGG	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg17145862	chr1:211918768	LPGAT1	0.97	25.2	0.76	7.41e-89	Leprosy;
LGG	cis	rs28655083	1.000	rs11863397	chr16:77060388	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.72	-0.34	7.33e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12765878	1.000	rs11191843	chr10:105648651	G/C	cg11005552	chr10:105648138	OBFC1	1.04	27.19	0.78	5.22e-98	Coronary artery disease;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg08677398	chr8:58056175	NA	0.43	7.01	0.31	8.5e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3736485	0.578	rs4775968	chr15:51980821	A/G	cg13474965	chr15:52030001	LYSMD2	-0.42	-7.13	-0.31	3.93e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs4714291	0.963	rs2395543	chr6:39965020	A/G	cg02267698	chr19:7991119	CTXN1	0.58	8.94	0.38	9.04e-18	Strep throat;
LGG	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg12310025	chr6:25882481	NA	-0.53	-10.15	-0.43	5.56e-22	Blood metabolite levels;
LGG	cis	rs11585357	1.000	rs11203346	chr1:17600822	A/G	cg08277548	chr1:17600880	PADI3	-0.75	-8.69	-0.37	6.3e-17	Hair shape;
LGG	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.74	0.69	4.75e-68	Calcium levels;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01341218	chr17:43662625	NA	0.93	15.59	0.59	2.46e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08645402	chr16:4508243	NA	0.46	8.67	0.37	7.09e-17	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg18032289	chr17:61959525	GH2	-0.39	-6.79	-0.3	3.36e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2235642	0.582	rs11643891	chr16:1565540	C/T	cg04525384	chr16:1557733	TELO2	0.48	8.38	0.36	6.36e-16	Coronary artery disease;
LGG	cis	rs2117029	0.586	rs1874908	chr12:49584030	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.77	0.51	3.2e-32	Intelligence (multi-trait analysis);
LGG	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg16141378	chr3:129829833	LOC729375	0.33	6.83	0.3	2.69e-11	Neuroticism;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16405210	chr4:1374714	KIAA1530	-0.59	-10.4	-0.44	6.78e-23	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12656632	chr6:42981813	MEA1;KLHDC3	0.46	6.98	0.31	1.01e-11	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs1003719	1.000	rs2835607	chr21:38491973	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.79	15.51	0.58	5.56e-44	Eye color traits;
LGG	trans	rs75804782	0.521	rs56340711	chr2:239440080	A/T	cg01134436	chr17:81009848	B3GNTL1	0.77	8.56	0.37	1.62e-16	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11857246	chr1:11741390	MAD2L2	-0.45	-7.0	-0.31	9.23e-12	Pancreatic cancer;
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg24328539	chr15:45671016	LOC145663;GATM	-0.34	-6.73	-0.3	5.01e-11	Homoarginine levels;
LGG	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg15704280	chr7:45808275	SEPT13	0.81	14.32	0.55	9.5e-39	Coronary artery disease;
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg13939156	chr17:80058883	NA	0.53	10.77	0.45	2.79e-24	Life satisfaction;
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg14017655	chr6:133562193	EYA4	0.41	7.31	0.32	1.17e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg23758822	chr17:41437982	NA	0.89	15.65	0.59	1.27e-44	Menopause (age at onset);
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.67	-0.41	2.83e-20	Platelet count;
LGG	cis	rs2346160	0.899	rs1736585	chr6:167688325	G/A	cg20683250	chr6:167653907	NA	-0.41	-6.76	-0.3	4.29e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg13010199	chr12:38710504	ALG10B	0.67	13.65	0.54	7.08e-36	Bladder cancer;
LGG	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg02461776	chr11:598696	PHRF1	0.54	8.68	0.37	6.86e-17	Systemic lupus erythematosus;
LGG	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg12463550	chr7:65579703	CRCP	0.46	7.62	0.33	1.42e-13	Aortic root size;
LGG	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg23324259	chr8:82754387	SNX16	-0.41	-7.06	-0.31	5.99e-12	Diastolic blood pressure;
LGG	cis	rs1775715	0.737	rs2808090	chr10:32143208	A/C	cg14930904	chr10:32216787	ARHGAP12	0.35	6.82	0.3	2.83e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg05926928	chr17:57297772	GDPD1	0.87	10.71	0.45	4.71e-24	Opioid sensitivity;
LGG	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg01236616	chr12:121019343	POP5	-1.17	-20.02	-0.68	1.04e-64	Type 1 diabetes nephropathy;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs2735413	0.958	rs1922611	chr16:78053121	C/T	cg04733911	chr16:78082701	NA	-0.71	-15.76	-0.59	4.33e-45	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg14074117	chr16:1909714	C16orf73	-0.51	-7.62	-0.33	1.42e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg26384229	chr12:38710491	ALG10B	0.83	17.35	0.63	2.67e-52	Heart rate;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg01059449	chr18:44338099	ST8SIA5	-0.4	-8.61	-0.37	1.18e-16	Personality dimensions;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs4965869	0.824	rs4965867	chr15:101976039	G/A	cg12371147	chr15:101978424	PCSK6	-0.42	-7.69	-0.34	9.03e-14	Platelet-derived growth factor BB levels;
LGG	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg02487422	chr3:49467188	NICN1	0.41	6.93	0.31	1.4e-11	Parkinson's disease;
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02711726	chr17:80685570	FN3KRP	-0.54	-9.54	-0.41	8.16e-20	Glycated hemoglobin levels;
LGG	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-8.41	-0.36	5.12e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.01	0.31	8.67e-12	Lung cancer;
LGG	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs75059851	0.756	rs7106806	chr11:133838837	G/C	cg20042908	chr11:133852938	NA	-0.77	-14.28	-0.55	1.33e-38	Schizophrenia;
LGG	cis	rs7666738	0.830	rs6833312	chr4:98951356	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg14416269	chr4:6271139	WFS1	0.52	9.74	0.41	1.62e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.98	-0.31	1.01e-11	Neuroticism;
LGG	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.64	-0.37	9.52e-17	Retinal vascular caliber;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg17202724	chr17:61916730	SMARCD2	0.49	10.79	0.45	2.21e-24	Prudent dietary pattern;
LGG	cis	rs10779751	0.734	rs1130683	chr1:11132217	G/A	cg08854313	chr1:11322531	MTOR	0.75	16.74	0.61	1.52e-49	Body mass index;
LGG	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.78	-0.57	8.88e-41	Calcium levels;
LGG	cis	rs6993813	0.653	rs7017881	chr8:120047857	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.29	-7.29	-0.32	1.35e-12	Bone mineral density (hip);
LGG	cis	rs4774899	0.966	rs12903115	chr15:57495151	T/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.32	-0.32	1.09e-12	Urinary tract infection frequency;
LGG	cis	rs62209	0.605	rs17149140	chr10:10977601	A/C	cg26901096	chr10:10994189	LOC254312	0.44	7.34	0.32	9.8e-13	Alzheimer's disease (late onset);
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg05896524	chr21:47604654	C21orf56	0.55	9.47	0.4	1.45e-19	Testicular germ cell tumor;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.92	-19.88	-0.68	4.79e-64	Prudent dietary pattern;
LGG	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg15432903	chr11:17409602	KCNJ11	0.86	17.66	0.63	1.01e-53	Type 2 diabetes;
LGG	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg10223061	chr2:219282414	VIL1	-0.31	-6.85	-0.3	2.43e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	7.85	0.34	2.91e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9581857	0.615	rs3759435	chr13:27996813	T/G	cg01674679	chr13:27998804	GTF3A	-0.7	-8.83	-0.38	2.21e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.75	-0.34	6.04e-14	Retinal vascular caliber;
LGG	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-9.76	-0.41	1.42e-20	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03274991	chr11:120207803	ARHGEF12	0.46	7.84	0.34	3.15e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs800082	0.501	rs9844730	chr3:144216886	T/G	cg24215973	chr2:240111563	HDAC4	0.42	7.4	0.33	6.46e-13	Smoking behavior;
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.09	-0.31	4.89e-12	Bipolar disorder;
LGG	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	9.45	0.4	1.64e-19	Height;
LGG	cis	rs77741769	0.571	rs11065300	chr12:121298512	G/C	cg02419362	chr12:121203948	SPPL3	0.53	9.07	0.39	3.29e-18	Mean corpuscular volume;
LGG	cis	rs6028335	0.610	rs12624839	chr20:37573816	G/A	cg16355469	chr20:37678765	NA	0.55	7.34	0.32	9.59e-13	Alcohol and nicotine co-dependence;
LGG	cis	rs7647973	1.000	rs2312462	chr3:49601255	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	6.87	0.3	2.04e-11	Menarche (age at onset);
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-7.69	-0.34	8.73e-14	Vitiligo;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.78	-0.34	4.89e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg13637042	chr22:42228724	SREBF2	-0.42	-7.29	-0.32	1.33e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs41005	1.000	rs41003	chr2:8111772	A/C	cg03155496	chr2:8117019	LOC339788	0.89	20.08	0.68	5.91e-65	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	trans	rs7944735	0.607	rs34895872	chr11:48021778	A/G	cg15704280	chr7:45808275	SEPT13	0.69	9.54	0.41	8.25e-20	Intraocular pressure;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg24253500	chr15:84953950	NA	-0.42	-7.75	-0.34	6.07e-14	P wave terminal force;
LGG	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg22681709	chr2:178499509	PDE11A	-0.51	-7.52	-0.33	2.84e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9611519	0.828	rs4822008	chr22:41539206	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.39	-0.36	5.78e-16	Neuroticism;
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg12310025	chr6:25882481	NA	-0.91	-17.95	-0.64	4.36e-55	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24497897	chr11:65658826	CCDC85B	-0.5	-7.51	-0.33	3.01e-13	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.85	0.51	1.62e-32	Hip circumference adjusted for BMI;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06532184	chr4:16227813	FLJ39653;TAPT1	0.67	7.77	0.34	5.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs861020	0.606	rs657844	chr1:210006873	T/G	cg05527609	chr1:210001259	C1orf107	0.6	9.62	0.41	4.35e-20	Orofacial clefts;
LGG	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23248424	chr5:179741104	GFPT2	-0.59	-10.87	-0.45	1.14e-24	Height;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg15268244	chr15:77196840	NA	0.47	10.11	0.43	7.61e-22	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05621273	chr16:81070150	ATMIN	0.49	7.27	0.32	1.55e-12	Gut microbiome composition (summer);
LGG	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg00531865	chr16:30841666	NA	0.56	12.01	0.49	4e-29	Dementia with Lewy bodies;
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14893161	chr1:205819251	PM20D1	0.57	9.25	0.39	8.61e-19	Parkinson's disease;
LGG	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg00376283	chr12:123451042	ABCB9	0.6	11.01	0.46	3.39e-25	Platelet count;
LGG	cis	rs2760061	0.717	rs708117	chr1:228199902	G/A	cg18477163	chr1:228402036	OBSCN	0.25	6.74	0.3	4.66e-11	Diastolic blood pressure;
LGG	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg09361094	chr10:834503	NA	-0.26	-6.76	-0.3	4.26e-11	Survival in rectal cancer;
LGG	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg13334819	chr7:99746414	C7orf59	0.49	7.55	0.33	2.36e-13	Coronary artery disease;
LGG	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-10.27	-0.43	2.03e-22	Personality dimensions;
LGG	cis	rs7444	0.941	rs181363	chr22:21932264	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.99	-0.35	1.06e-14	Systemic lupus erythematosus;
LGG	trans	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.13	0.46	1.12e-25	Corneal astigmatism;
LGG	cis	rs735539	0.718	rs7985552	chr13:21280738	A/T	cg04906043	chr13:21280425	IL17D	0.59	9.72	0.41	1.88e-20	Dental caries;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04041942	chr8:28747613	INTS9;HMBOX1	0.41	6.95	0.31	1.21e-11	Body mass index;
LGG	cis	rs7077256	0.564	rs12775231	chr10:65018253	C/T	cg02276361	chr10:65351566	REEP3	-0.33	-6.83	-0.3	2.66e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg14703610	chr5:56206110	C5orf35	0.43	7.53	0.33	2.65e-13	Coronary artery disease;
LGG	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg14092988	chr3:52407081	DNAH1	0.38	9.64	0.41	3.63e-20	Bipolar disorder;
LGG	cis	rs9460578	0.673	rs4712562	chr6:20897896	G/T	cg13405222	chr6:20811065	CDKAL1	0.67	11.19	0.46	6.95e-26	Breast cancer;
LGG	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg11812906	chr14:75593930	NEK9	0.54	10.1	0.42	8.45e-22	Height;
LGG	trans	rs11039798	1.000	rs6485848	chr11:48541517	G/T	cg03929089	chr4:120376271	NA	0.73	8.44	0.37	4.1e-16	Axial length;
LGG	cis	rs12618769	0.597	rs3769738	chr2:99078367	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg13453750	chr1:205783389	SLC41A1	-0.38	-7.36	-0.32	8.61e-13	Menarche (age at onset);
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.43	8.97	0.38	7.55e-18	Schizophrenia;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.72	-0.34	7.2e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg27476859	chr7:2772710	GNA12	0.53	10.33	0.43	1.18e-22	Height;
LGG	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg20891283	chr12:69753455	YEATS4	0.97	22.07	0.72	2.79e-74	Blood protein levels;
LGG	cis	rs3106136	0.527	rs2664872	chr4:95146952	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.97	-0.45	4.69e-25	Capecitabine sensitivity;
LGG	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg09307838	chr4:120376055	NA	0.79	12.93	0.51	7.54e-33	Corneal astigmatism;
LGG	cis	rs897984	0.806	rs11640534	chr16:30949515	G/A	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	cis	rs4950322	0.570	rs72692907	chr1:146773610	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs7166081	1.000	rs4776917	chr15:67600344	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.81	-0.3	3.06e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	cis	rs3857747	0.931	rs11767708	chr7:40364316	A/G	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18482256	chr19:38865041	PSMD8	-0.43	-7.15	-0.32	3.38e-12	Menarche (age at onset);
LGG	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg23920097	chr1:209922102	NA	0.48	8.1	0.35	4.8e-15	Red blood cell count;
LGG	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg06191203	chr2:152266755	RIF1	-0.37	-6.66	-0.3	8e-11	Lung cancer;
LGG	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs58785573	0.504	rs62294474	chr4:38628725	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.45	7.42	0.33	5.62e-13	Lymphocyte percentage of white cells;
LGG	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg27129171	chr3:47204927	SETD2	-0.67	-11.18	-0.46	7.73e-26	Birth weight;
LGG	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg08847533	chr14:75593920	NEK9	-0.55	-10.45	-0.44	4.43e-23	Height;
LGG	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs6750047	0.647	rs11124632	chr2:38276412	G/C	cg07380506	chr2:38303506	CYP1B1	0.45	7.47	0.33	3.98e-13	Cutaneous malignant melanoma;Melanoma;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18382590	chr9:131219195	ODF2	0.38	6.88	0.3	1.98e-11	Body mass index;
LGG	cis	rs4629180	0.593	rs6707517	chr2:102089878	C/T	cg16435561	chr2:102091048	RFX8	0.39	6.73	0.3	5.15e-11	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg03795903	chr2:30669940	LCLAT1	0.53	7.38	0.32	7.37e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs2797369	0.609	rs1093425	chr6:101417133	C/G	cg27451362	chr6:101846650	GRIK2	0.76	10.26	0.43	2.17e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.67	-8.1	-0.35	4.75e-15	Lung cancer in ever smokers;
LGG	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg17376030	chr22:41985996	PMM1	0.66	10.7	0.45	5.01e-24	Vitiligo;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs17102423	0.559	rs3783720	chr14:65475411	A/G	cg11161011	chr14:65562177	MAX	-0.76	-12.37	-0.5	1.41e-30	Obesity-related traits;
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg19077165	chr18:44547161	KATNAL2	0.55	9.99	0.42	2.1e-21	Personality dimensions;
LGG	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.36	-0.36	7.3e-16	Coronary artery disease;
LGG	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.4	-0.33	6.65e-13	Mean corpuscular volume;
LGG	cis	rs6723226	0.699	rs376914	chr2:32508393	G/C	cg02381751	chr2:32503542	YIPF4	0.74	12.61	0.51	1.49e-31	Intelligence (multi-trait analysis);
LGG	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg05491587	chr18:77659695	KCNG2	-0.4	-7.37	-0.32	8.13e-13	Schizophrenia;
LGG	cis	rs55665837	1.000	rs3923294	chr11:14441402	T/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.86	-0.38	1.78e-17	Vitamin D levels;
LGG	cis	rs4917300	0.571	rs4917287	chr8:143113997	A/G	cg06573787	chr8:143070187	NA	0.6	10.02	0.42	1.57e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs6504108	0.577	rs2109982	chr17:46244769	G/A	cg02219949	chr17:45927392	SP6	0.43	8.07	0.35	6.22e-15	Body mass index;
LGG	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg11764359	chr7:65958608	NA	-0.55	-9.45	-0.4	1.74e-19	Aortic root size;
LGG	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg18105134	chr13:113819100	PROZ	0.8	16.87	0.62	4.09e-50	Platelet distribution width;
LGG	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.24	-0.43	2.57e-22	Hip circumference adjusted for BMI;
LGG	cis	rs6960043	0.818	rs2191348	chr7:15064255	G/T	cg19272540	chr7:15055459	NA	-0.35	-7.76	-0.34	5.45e-14	Type 2 diabetes;
LGG	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg02428538	chr16:24856791	SLC5A11	-0.7	-10.76	-0.45	2.88e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4742903	0.904	rs10114234	chr9:107003646	C/T	cg14250997	chr9:106856677	SMC2	-0.36	-7.47	-0.33	4.16e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	14.47	0.56	2.05e-39	Menarche (age at onset);
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.96	-0.35	1.38e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7172689	0.908	rs11072995	chr15:81527032	A/T	cg11808699	chr15:81528661	IL16	0.4	9.15	0.39	1.88e-18	Inattentive symptoms;
LGG	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg15595755	chr5:1867978	NA	0.44	7.65	0.33	1.2e-13	Cardiovascular disease risk factors;
LGG	cis	rs1933488	0.522	rs611499	chr6:153450489	C/T	cg17707550	chr6:153380415	RGS17	0.35	7.39	0.32	7.06e-13	Prostate cancer;
LGG	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.83e-14	Neuroticism;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg08280861	chr8:58055591	NA	0.52	6.98	0.31	1.01e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6977660	0.619	rs10223937	chr7:19787697	C/T	cg07541023	chr7:19748670	TWISTNB	0.53	7.94	0.35	1.57e-14	Thyroid stimulating hormone;
LGG	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg21535247	chr6:8435926	SLC35B3	-0.5	-8.17	-0.35	3.03e-15	Motion sickness;
LGG	cis	rs7572733	0.935	rs1607373	chr2:198800532	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.24	0.36	1.84e-15	Dermatomyositis;
LGG	cis	rs7715806	0.500	rs17563589	chr5:74980019	A/G	cg19683494	chr5:74908142	NA	0.52	6.86	0.3	2.24e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs943466	0.793	rs59137082	chr6:33732365	C/T	cg07519485	chr6:33762594	MLN	0.51	10.57	0.44	1.6e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.48	-0.4	1.35e-19	Sudden cardiac arrest;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21796825	chr12:64173751	TMEM5	0.63	9.74	0.41	1.61e-20	Gut microbiome composition (summer);
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.85	-0.3	2.42e-11	Bipolar disorder;
LGG	cis	rs7945718	0.621	rs11022463	chr11:12685395	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs7241530	0.636	rs8096302	chr18:75909790	T/A	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	8.11e-17	Educational attainment (years of education);
LGG	cis	rs9912468	0.555	rs4366742	chr17:64212242	T/C	cg19474267	chr17:64306194	PRKCA	-0.73	-15.19	-0.58	1.35e-42	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12893428	chr3:195717962	SDHAP1	0.51	10.8	0.45	2.2e-24	Pancreatic cancer;
LGG	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg16497277	chr3:49208875	KLHDC8B	0.42	6.72	0.3	5.45e-11	Menarche (age at onset);
LGG	cis	rs8018967	1.000	rs8018967	chr14:73976934	A/G	cg10076968	chr14:74006090	HEATR4;ACOT1	0.33	7.74	0.34	6.48e-14	Blood metabolite ratios;
LGG	trans	rs4819388	0.915	rs6518352	chr21:45646698	A/G	cg17383793	chr5:52405638	MOCS2	0.45	7.01	0.31	8.55e-12	Celiac disease;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg02297831	chr4:17616191	MED28	-0.51	-9.63	-0.41	3.91e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	6.92	0.31	1.55e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.32	0.32	1.08e-12	Morning vs. evening chronotype;
LGG	cis	rs12210905	0.925	rs115507154	chr6:26970811	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2455799	0.613	rs7620787	chr3:15882826	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.81	-0.34	3.91e-14	Mean platelet volume;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg05091796	chr16:4465799	CORO7	-0.61	-9.93	-0.42	3.36e-21	Schizophrenia;
LGG	cis	rs7666738	0.830	rs34273190	chr4:99004568	C/T	cg05340658	chr4:99064831	C4orf37	0.49	8.27	0.36	1.42e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.81	0.34	3.78e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg06453172	chr10:134556979	INPP5A	-0.55	-8.18	-0.36	2.7e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09742170	chr7:25021208	OSBPL3	0.4	6.76	0.3	4.09e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2573652	0.722	rs12914189	chr15:100544429	A/T	cg14911520	chr15:100542628	ADAMTS17	0.28	6.87	0.3	2.04e-11	Height;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg23958373	chr8:599963	NA	-0.92	-8.52	-0.37	2.32e-16	IgG glycosylation;
LGG	cis	rs9900972	0.720	rs6501257	chr17:76877655	G/A	cg00961940	chr17:76876995	TIMP2	0.46	9.12	0.39	2.37e-18	Obesity-related traits;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.07e-15	Aortic root size;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-12.99	-0.52	4.13e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg01314568	chr7:57830625	NA	-0.48	-7.79	-0.34	4.52e-14	Obesity-related traits;
LGG	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.82	-0.34	3.6e-14	Pancreatic cancer;
LGG	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg13009111	chr11:71350975	NA	-0.34	-7.37	-0.32	7.89e-13	Monocyte count;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg04025307	chr7:1156635	C7orf50	0.62	11.31	0.47	2.45e-26	Longevity;Endometriosis;
LGG	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg03733263	chr8:22462867	KIAA1967	1.1	28.24	0.8	9.61e-103	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12379764	chr21:47803548	PCNT	-0.39	-6.65	-0.3	8.29e-11	Testicular germ cell tumor;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.59	0.47	1.91e-27	Electroencephalogram traits;
LGG	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.2	0.32	2.42e-12	Hemoglobin concentration;
LGG	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg00290607	chr11:67383545	NA	-0.48	-8.68	-0.37	6.72e-17	Mean corpuscular volume;
LGG	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg13647721	chr17:30228624	UTP6	0.65	8.73	0.38	4.78e-17	Hip circumference adjusted for BMI;
LGG	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg24011408	chr12:48396354	COL2A1	0.5	7.92	0.35	1.78e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6881634	0.903	rs10074125	chr5:77625504	G/A	cg11446398	chr5:77624930	NA	0.42	9.21	0.39	1.14e-18	Hippocampal atrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10536369	chr2:170335894	BBS5	0.4	6.94	0.31	1.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg05863683	chr7:1912471	MAD1L1	0.45	8.89	0.38	1.42e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg10204951	chr7:910479	UNC84A	-0.53	-7.06	-0.31	6.29e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs283228	0.550	rs675259	chr6:101830113	A/T	cg27451362	chr6:101846650	GRIK2	0.98	14.58	0.56	7.1e-40	Coenzyme Q10 levels;
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg14092988	chr3:52407081	DNAH1	-0.28	-7.54	-0.33	2.52e-13	Electroencephalogram traits;
LGG	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.36	-0.32	8.33e-13	HDL cholesterol;
LGG	cis	rs7937890	0.531	rs2575828	chr11:14484192	T/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08704250	chr15:31115839	NA	0.42	7.84	0.34	3.09e-14	Huntington's disease progression;
LGG	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg13147721	chr7:65941812	NA	-0.79	-9.54	-0.41	8.02e-20	Diabetic kidney disease;
LGG	cis	rs7084402	0.967	rs1427196	chr10:60278573	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs1003719	0.591	rs2040125	chr21:38549236	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.67	11.96	0.49	6.66e-29	Eye color traits;
LGG	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg04617936	chr2:214353	NA	-0.4	-7.34	-0.32	9.78e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1519814	0.696	rs6985424	chr8:121062976	C/T	cg22335954	chr8:121166405	COL14A1	-0.53	-10.19	-0.43	3.77e-22	Breast cancer;
LGG	cis	rs11150038	0.826	rs7203736	chr16:78089119	A/C	cg04733911	chr16:78082701	NA	0.64	8.98	0.39	7.04e-18	Colorectal or endometrial cancer;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg24829409	chr8:58192753	C8orf71	-0.48	-8.33	-0.36	9.34e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg10021288	chr2:128175891	PROC	-0.38	-6.94	-0.31	1.32e-11	Self-rated health;
LGG	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.86	0.3	2.18e-11	Neuroticism;
LGG	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11987759	chr7:65425863	GUSB	0.41	7.94	0.35	1.5e-14	Corneal structure;
LGG	cis	rs4684776	1.000	rs2454503	chr3:11498740	G/C	cg24705426	chr3:11550659	ATG7	-0.47	-8.5	-0.37	2.67e-16	Small vessel stroke;
LGG	trans	rs17685	0.672	rs1639623	chr7:75707951	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.74	0.77	2.32e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6445975	0.572	rs6768547	chr3:58434969	C/T	cg24175188	chr3:58374923	PXK	0.54	8.69	0.37	6.26e-17	Systemic lupus erythematosus;
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs2070488	0.804	rs13100195	chr3:38482539	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	14.93	0.57	1.97e-41	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00933542	chr6:150070202	PCMT1	0.4	7.34	0.32	9.6e-13	Lung cancer;
LGG	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.31	0.43	1.37e-22	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11712217	chr17:80455631	NA	0.43	7.06	0.31	6.25e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg17230874	chr3:125932073	NA	0.58	11.6	0.47	1.78e-27	Metabolite levels;
LGG	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg07791516	chr6:150247246	NA	0.37	6.82	0.3	2.92e-11	Lung cancer;
LGG	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.04	-0.35	7.37e-15	Myopia (pathological);
LGG	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg21058520	chr6:100914733	NA	0.39	6.84	0.3	2.57e-11	Neuroticism;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	1.000	rs4581755	chr17:28427898	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.13	0.52	1.1e-33	Coffee consumption (cups per day);
LGG	cis	rs6882076	0.884	rs7717984	chr5:156369171	A/G	cg12943317	chr5:156479607	HAVCR1	0.66	11.49	0.47	4.62e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs6694672	0.867	rs1759013	chr1:197023411	T/G	cg13682187	chr1:196946512	CFHR5	0.52	7.3	0.32	1.25e-12	Asthma;
LGG	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg07061783	chr6:25882402	NA	-0.42	-7.21	-0.32	2.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg26655873	chr3:72818019	SHQ1	0.37	7.52	0.33	2.88e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg07777115	chr5:623756	CEP72	-0.62	-8.02	-0.35	8.89e-15	Obesity-related traits;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg13397359	chr6:42928475	GNMT	0.57	16.03	0.6	2.53e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.66	-11.53	-0.47	3.2e-27	Longevity;Endometriosis;
LGG	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg24699146	chr1:24152579	HMGCL	-0.26	-7.73	-0.34	6.74e-14	Immature fraction of reticulocytes;
LGG	cis	rs6754311	0.551	rs6739713	chr2:136488978	A/G	cg07169764	chr2:136633963	MCM6	0.64	10.78	0.45	2.48e-24	Mosquito bite size;
LGG	cis	rs7681440	0.728	rs974711	chr4:90737327	G/A	cg26578617	chr4:90757533	SNCA	-0.35	-6.9	-0.31	1.69e-11	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg23782820	chr8:58130467	NA	0.52	7.3	0.32	1.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs975210	0.652	rs4777230	chr15:70365762	A/G	cg01666796	chr15:70364327	TLE3	-0.54	-6.96	-0.31	1.19e-11	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg00745463	chr17:30367425	LRRC37B	-0.68	-9.66	-0.41	3.22e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg19539972	chr4:7069911	GRPEL1	0.68	9.93	0.42	3.4e-21	Monocyte percentage of white cells;
LGG	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg27661571	chr11:113659931	NA	-0.69	-9.55	-0.41	7.49e-20	Hip circumference adjusted for BMI;
LGG	cis	rs36051895	0.695	rs10120763	chr9:5002911	C/G	cg02405213	chr9:5042618	JAK2	-0.78	-14.35	-0.55	6.55e-39	Pediatric autoimmune diseases;
LGG	cis	rs7586879	0.681	rs6545790	chr2:25109302	A/G	cg04586622	chr2:25135609	ADCY3	0.45	12.07	0.49	2.28e-29	Body mass index;
LGG	cis	rs11920090	0.932	rs61791060	chr3:170699552	G/A	cg09710316	chr3:170744871	SLC2A2	0.59	8.39	0.36	6.06e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08280861	chr8:58055591	NA	0.63	7.79	0.34	4.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg19913688	chr11:428466	ANO9	-0.66	-8.48	-0.37	3.14e-16	Body mass index;
LGG	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg11693508	chr17:37793320	STARD3	-0.67	-9.65	-0.41	3.5e-20	Bipolar disorder;
LGG	cis	rs6503525	0.628	rs4065985	chr17:38101932	G/C	cg17467752	chr17:38218738	THRA	0.49	8.16	0.35	3.25e-15	Asthma;
LGG	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg07936489	chr17:37558343	FBXL20	1.07	19.52	0.67	2.25e-62	Glomerular filtration rate (creatinine);
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg17178900	chr1:205818956	PM20D1	0.54	12.16	0.49	1.03e-29	Menarche (age at onset);
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.37	0.53	1.09e-34	Obesity-related traits;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.93e-31	Lymphocyte counts;
LGG	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg14154082	chr13:112174009	NA	-0.36	-7.93	-0.35	1.71e-14	Menarche (age at onset);
LGG	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg00405596	chr8:11794950	NA	0.65	11.52	0.47	3.45e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.22	-0.32	2.12e-12	Dementia with Lewy bodies;
LGG	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg17145862	chr1:211918768	LPGAT1	0.77	15.97	0.6	4.9e-46	Leprosy;
LGG	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg02187348	chr16:89574699	SPG7	0.57	9.52	0.4	9.74e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs17039065	0.920	rs1595197	chr4:109472301	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.94	0.31	1.3e-11	Gut microbiome composition (summer);
LGG	cis	rs793571	0.590	rs347115	chr15:59082959	C/T	cg05156742	chr15:59063176	FAM63B	0.59	10.03	0.42	1.49e-21	Schizophrenia;
LGG	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.6	-0.41	4.89e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-12.98	-0.52	4.47e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs3741151	0.773	rs73544720	chr11:73173496	A/G	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-20.35	-0.69	2.99e-66	Gut microbiome composition (summer);
LGG	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg04317338	chr11:64019027	PLCB3	0.65	7.84	0.34	3.2e-14	Mean platelet volume;
LGG	cis	rs9333075	0.507	rs2298031	chr10:15760670	C/G	cg14364212	chr10:15760690	ITGA8	0.48	8.77	0.38	3.53e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9815354	0.951	rs6794211	chr3:41751324	A/T	cg03022575	chr3:42003672	ULK4	0.58	7.23	0.32	1.99e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7843479	0.965	rs733544	chr8:21835628	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.08	0.42	9.71e-22	Mean corpuscular volume;
LGG	trans	rs1941687	0.526	rs9959347	chr18:31316169	C/T	cg04226714	chr8:49833948	SNAI2	-0.43	-7.45	-0.33	4.49e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6834538	0.964	rs2129407	chr4:113387928	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.49	8.15	0.35	3.43e-15	Free thyroxine concentration;
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.61	-8.82	-0.38	2.33e-17	Lung function (FEV1/FVC);
LGG	cis	rs4481887	1.000	rs4244178	chr1:248468441	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.95	0.42	2.89e-21	Common traits (Other);
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg05313129	chr8:58192883	C8orf71	-0.58	-7.73	-0.34	6.72e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.86	-0.42	6.04e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs35160687	0.644	rs9309635	chr2:86499402	G/T	cg10973622	chr2:86423274	IMMT	0.41	7.29	0.32	1.36e-12	Night sleep phenotypes;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09914581	chr2:11606494	E2F6	0.41	7.69	0.34	8.87e-14	Obesity-related traits;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg17971929	chr21:40555470	PSMG1	-0.52	-8.95	-0.38	8.79e-18	Menarche (age at onset);
LGG	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg23625390	chr15:77176239	SCAPER	-0.7	-12.71	-0.51	6.03e-32	Blood metabolite levels;
LGG	cis	rs57502260	0.651	rs3781586	chr11:68199393	C/A	cg01657329	chr11:68192670	LRP5	-0.61	-8.37	-0.36	6.9e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs7937612	1.000	rs6589811	chr11:120235703	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.69	-0.51	6.8e-32	Intraocular pressure;
LGG	cis	rs17767392	0.958	rs4902942	chr14:72140659	A/T	cg13720639	chr14:72061746	SIPA1L1	0.39	8.39	0.36	5.99e-16	Mitral valve prolapse;
LGG	cis	rs34044649	0.840	rs1616634	chr7:155653078	T/C	cg17395211	chr7:155654226	NA	-0.37	-7.05	-0.31	6.69e-12	Triptolide cytotoxicity;
LGG	cis	rs11239177	0.807	rs59737398	chr10:45098161	G/A	cg03916630	chr10:45065415	NA	0.36	8.4	0.36	5.69e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4948275	0.550	rs10994749	chr10:63156222	G/C	cg02023345	chr10:63212226	TMEM26	0.41	7.59	0.33	1.83e-13	Night sleep phenotypes;
LGG	cis	rs7566780	0.693	rs6531160	chr2:16671359	A/G	cg09580478	chr2:16689509	NA	0.47	6.84	0.3	2.48e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.13	-0.35	3.84e-15	Joint mobility (Beighton score);
LGG	cis	rs11966931	1.000	rs112538772	chr6:108112220	G/A	cg04749840	chr6:108095067	SCML4	0.44	7.59	0.33	1.72e-13	Neutrophil percentage of white cells;
LGG	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.56	-0.33	2.16e-13	Mean corpuscular volume;
LGG	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs2832191	0.935	rs11910316	chr21:30519729	G/A	cg08807101	chr21:30365312	RNF160	-0.76	-14.5	-0.56	1.57e-39	Dental caries;
LGG	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.7	0.34	8.26e-14	Total cholesterol levels;
LGG	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs6500395	1.000	rs3817029	chr16:48584942	C/T	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg26384229	chr12:38710491	ALG10B	1.0	25.1	0.76	2.2e-88	Heart rate;
LGG	cis	rs9925964	0.748	rs4889603	chr16:30982225	C/T	cg02466173	chr16:30829666	NA	-0.39	-7.26	-0.32	1.62e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.56e-18	Menopause (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10536120	chr10:101380212	SLC25A28	-0.41	-6.87	-0.3	2.1e-11	Pancreatic cancer;
LGG	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	11.41	0.47	9.8e-27	Neuroticism;
LGG	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg03929089	chr4:120376271	NA	0.74	10.39	0.43	7.13e-23	Axial length;
LGG	cis	rs870825	0.860	rs28696121	chr4:185598743	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	20.72	0.69	5.75e-68	Blood protein levels;
LGG	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06481639	chr22:41940642	POLR3H	-0.55	-7.77	-0.34	5.13e-14	Vitiligo;
LGG	cis	rs72781680	0.898	rs72786288	chr2:24075416	G/T	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.29	0.63	4.81e-52	Chronic sinus infection;
LGG	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	7.94	0.35	1.53e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg04287289	chr16:89883240	FANCA	0.81	16.57	0.61	9.19e-49	Vitiligo;
LGG	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg23335576	chr14:104009727	NA	0.48	8.33	0.36	9.17e-16	Reticulocyte count;
LGG	trans	rs7939886	0.764	rs7113688	chr11:55946865	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg18171855	chr10:2543474	NA	0.38	7.5	0.33	3.19e-13	Age-related hearing impairment;
LGG	cis	rs713587	0.520	rs483428	chr2:25305136	A/G	cg04586622	chr2:25135609	ADCY3	0.31	7.79	0.34	4.47e-14	Body mass index in non-asthmatics;
LGG	cis	rs2290159	0.747	rs6777175	chr3:12646255	A/T	cg23032965	chr3:12705835	RAF1	0.67	9.78	0.41	1.21e-20	Cholesterol, total;
LGG	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17255878	chr17:4699455	PSMB6	0.39	6.65	0.3	8.26e-11	Bipolar disorder;
LGG	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	cis	rs6450176	0.909	rs66872223	chr5:53292730	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.0	-0.46	3.53e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg14092988	chr3:52407081	DNAH1	0.31	8.12	0.35	4.36e-15	Bipolar disorder;
LGG	cis	rs6840360	0.571	rs7678080	chr4:152557350	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.67	-0.34	9.95e-14	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.39	-0.43	6.91e-23	Depression;
LGG	cis	rs1256061	0.624	rs1152586	chr14:64690784	T/C	cg23250157	chr14:64679961	SYNE2	0.39	7.07	0.31	5.69e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg04025307	chr7:1156635	C7orf50	0.59	11.06	0.46	2.14e-25	Longevity;Endometriosis;
LGG	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.54	0.33	2.55e-13	Red cell distribution width;
LGG	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12292205	chr6:26970375	C6orf41	-0.62	-8.25	-0.36	1.63e-15	Intelligence (multi-trait analysis);
LGG	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg22916017	chr11:64110731	CCDC88B	0.47	9.47	0.4	1.43e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2479724	0.935	rs62396748	chr6:41782007	A/G	cg17623882	chr6:41773611	USP49	0.46	7.74	0.34	6.48e-14	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg18379455	chr17:41446167	NA	-0.31	-7.07	-0.31	5.56e-12	Menopause (age at onset);
LGG	cis	rs11748327	0.567	rs28618140	chr5:4010817	T/G	cg01025095	chr5:4101132	NA	-0.43	-6.99	-0.31	9.65e-12	Myocardial infarction;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.3	0.5	2.77e-30	Prudent dietary pattern;
LGG	cis	rs8014204	1.000	rs10483863	chr14:75322327	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.74	-15.15	-0.58	2.11e-42	Caffeine consumption;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg15242686	chr22:24348715	GSTTP1	0.41	7.66	0.34	1.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12200782	0.577	rs12208220	chr6:26382635	C/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.56	-0.33	2.18e-13	Small cell lung carcinoma;
LGG	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg26597838	chr10:835615	NA	0.5	6.71	0.3	5.73e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.83	-17.31	-0.63	3.9e-52	Schizophrenia;
LGG	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg12386194	chr3:101231763	SENP7	0.47	8.33	0.36	9.55e-16	Colorectal cancer;
LGG	trans	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg25214090	chr10:38739885	LOC399744	-0.66	-11.52	-0.47	3.67e-27	Corneal astigmatism;
LGG	cis	rs1555322	0.858	rs2425035	chr20:33855819	T/C	cg17927777	chr20:33865990	NA	0.68	7.65	0.33	1.21e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs6565180	0.962	rs35480350	chr16:30366039	G/A	cg17640201	chr16:30407289	ZNF48	-0.85	-16.32	-0.6	1.27e-47	Tonsillectomy;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15128208	chr22:42549153	NA	-0.36	-7.24	-0.32	1.84e-12	Cognitive function;
LGG	cis	rs7226408	0.802	rs72892528	chr18:34673014	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.07	-0.31	5.89e-12	Obesity-related traits;
LGG	cis	rs2070488	0.804	rs1817364	chr3:38474513	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	14.93	0.57	1.97e-41	Electrocardiographic conduction measures;
LGG	cis	rs2933343	0.951	rs796862	chr3:128593040	G/A	cg25356066	chr3:128598488	ACAD9	0.46	6.84	0.3	2.45e-11	IgG glycosylation;
LGG	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg17294928	chr15:75287854	SCAMP5	-0.56	-10.46	-0.44	3.93e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg00343986	chr7:65444356	GUSB	0.39	6.72	0.3	5.27e-11	Aortic root size;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg12070911	chr6:150209640	RAET1E	0.26	6.68	0.3	7.01e-11	Lung cancer;
LGG	cis	rs748404	0.631	rs7163288	chr15:43671355	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.45	6.73	0.3	4.88e-11	Lung cancer;
LGG	cis	rs9878978	0.722	rs17194427	chr3:2495202	C/A	cg21928760	chr3:2462534	CNTN4	0.36	7.01	0.31	8.43e-12	Blood pressure (smoking interaction);
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.25	-0.36	1.68e-15	Total body bone mineral density;
LGG	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.43	-0.33	5.36e-13	Morning vs. evening chronotype;
LGG	cis	rs9503598	0.636	rs7766753	chr6:3467708	A/C	cg00476032	chr6:3446245	SLC22A23	0.52	10.43	0.44	5.08e-23	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.07	0.35	6.1e-15	Prudent dietary pattern;
LGG	cis	rs741702	0.819	rs62108438	chr19:13000247	T/C	cg23899408	chr19:12877188	HOOK2	-0.48	-7.84	-0.34	3.13e-14	Red blood cell traits;
LGG	cis	rs78456975	1.000	rs11898988	chr2:1560336	G/A	cg26248373	chr2:1572462	NA	-0.69	-8.88	-0.38	1.51e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg10847948	chr11:71163743	NADSYN1	0.65	11.63	0.48	1.38e-27	Vitamin D levels;
LGG	cis	rs718515	0.527	rs11877350	chr18:43867311	A/G	cg26436583	chr18:43649176	PSTPIP2	0.37	7.55	0.33	2.34e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13102973	0.965	rs11099302	chr4:135880751	G/T	cg14419869	chr4:135874104	NA	0.57	10.7	0.45	5.07e-24	Subjective well-being;
LGG	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg00405596	chr8:11794950	NA	0.66	11.64	0.48	1.18e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs5756813	0.903	rs13054052	chr22:38130385	A/C	cg19894588	chr14:64061835	NA	0.64	10.76	0.45	3.05e-24	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg02002194	chr4:3960332	NA	0.47	8.75	0.38	4.01e-17	Retinal vascular caliber;
LGG	cis	rs8112449	0.894	rs34681319	chr19:10517696	G/A	cg21868191	chr19:10515988	NA	-0.48	-8.27	-0.36	1.48e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg26384229	chr12:38710491	ALG10B	0.97	21.93	0.71	1.21e-73	Bladder cancer;
LGG	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.98	-0.42	2.25e-21	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25136961	chr6:71122946	FAM135A	0.44	7.45	0.33	4.74e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.17	-0.46	8.23e-26	Lung cancer;
LGG	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg26783146	chr16:4423632	VASN;CORO7	-0.39	-7.29	-0.32	1.34e-12	Schizophrenia;
LGG	cis	rs8017423	0.845	rs80167706	chr14:90727629	G/C	cg04374321	chr14:90722782	PSMC1	0.9	18.94	0.66	1.2e-59	Mortality in heart failure;
LGG	cis	rs7301016	0.707	rs11174587	chr12:63052559	A/T	cg11441379	chr12:63026424	NA	0.56	7.9	0.34	2.08e-14	IgG glycosylation;
LGG	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg12591125	chr7:1885375	MAD1L1	0.48	6.9	0.31	1.72e-11	Bipolar disorder;
LGG	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.89	-0.3	1.84e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs10504073	0.609	rs17644494	chr8:50019679	T/C	cg00325661	chr8:49890786	NA	0.68	13.27	0.53	2.65e-34	Blood metabolite ratios;
LGG	cis	rs7089973	0.836	rs1966384	chr10:116627910	G/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.45	0.33	4.65e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs12348691	0.503	rs1348386	chr9:100612807	A/G	cg13688889	chr9:100608707	NA	-0.82	-15.83	-0.59	1.92e-45	Alopecia areata;
LGG	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg19455335	chr8:22457658	C8orf58	-0.4	-8.11	-0.35	4.59e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs80282103	0.618	rs10794720	chr10:1156165	A/G	cg08668510	chr10:1095578	IDI1	-0.75	-7.68	-0.34	9.41e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg04287289	chr16:89883240	FANCA	0.89	8.34	0.36	8.62e-16	Skin colour saturation;
LGG	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.24	-0.43	2.58e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.53	0.47	3.36e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7255436	0.965	rs7249624	chr19:8446135	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.69	-0.3	6.54e-11	HDL cholesterol;
LGG	cis	rs9894429	0.646	rs7210026	chr17:79612382	T/C	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg00646381	chr17:77835854	NA	0.39	7.24	0.32	1.91e-12	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg15128208	chr22:42549153	NA	0.75	11.92	0.48	9.42e-29	Birth weight;
LGG	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4561483	0.743	rs28653099	chr16:12009150	C/A	cg08843971	chr16:11963173	GSPT1	0.59	14.73	0.56	1.54e-40	Testicular germ cell tumor;
LGG	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg22878388	chr2:105853796	NA	-0.45	-8.31	-0.36	1.07e-15	Type 2 diabetes;
LGG	cis	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg07460842	chr6:66804631	NA	0.93	16.87	0.62	3.94e-50	Exhaled nitric oxide levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07545714	chr3:122135128	WDR5B	0.5	7.23	0.32	1.98e-12	Gut microbiome composition (summer);
LGG	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg16576597	chr16:28551801	NUPR1	-0.36	-8.0	-0.35	1e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2115630	1.000	rs11854313	chr15:85304048	G/C	cg12501888	chr15:85177176	SCAND2	-0.41	-6.82	-0.3	2.81e-11	P wave terminal force;
LGG	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg26384229	chr12:38710491	ALG10B	0.61	11.92	0.48	9.13e-29	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13193676	chr8:80942319	MRPS28	-0.46	-6.66	-0.3	7.73e-11	Systemic lupus erythematosus;
LGG	cis	rs7010267	0.935	rs10955915	chr8:119963547	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.43	0.44	5.18e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg03528353	chr17:61819722	STRADA	0.47	8.04	0.35	7.35e-15	Prudent dietary pattern;
LGG	cis	rs9811920	0.638	rs793471	chr3:99546335	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.75	-0.38	4.09e-17	Axial length;
LGG	cis	rs283228	1.000	rs283211	chr6:101753661	T/C	cg27451362	chr6:101846650	GRIK2	0.53	8.93	0.38	9.97e-18	Coenzyme Q10 levels;
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.33	-0.36	9.06e-16	Life satisfaction;
LGG	cis	rs897080	0.515	rs1067325	chr2:44628997	C/T	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs7100689	0.646	rs10400045	chr10:82077032	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.69	0.56	2.33e-40	Post bronchodilator FEV1;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-9.69	-0.41	2.52e-20	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-8.85	-0.38	1.92e-17	Life satisfaction;
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg24101359	chr6:42928495	GNMT	0.58	16.96	0.62	1.55e-50	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg22283653	chr8:49824208	NA	0.51	9.49	0.4	1.24e-19	Sudden cardiac arrest;
LGG	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg24803719	chr17:45855879	NA	-0.3	-8.63	-0.37	1.01e-16	IgG glycosylation;
LGG	cis	rs3087591	0.922	rs11867284	chr17:29597464	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.59	0.56	6.31e-40	Hip circumference;
LGG	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg07150166	chr2:30669952	LCLAT1	1.04	10.62	0.44	1.04e-23	Midgestational circulating levels of PBDEs (fetal genetic effect);
LGG	cis	rs17122278	0.613	rs477106	chr11:118363424	A/C	cg20110707	chr11:118481992	PHLDB1	0.47	7.05	0.31	6.72e-12	Total cholesterol levels;
LGG	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.97	0.42	2.43e-21	Lung cancer in ever smokers;
LGG	cis	rs3857067	0.967	rs5019896	chr4:95035751	C/T	cg11021082	chr4:95130006	SMARCAD1	0.41	7.6	0.33	1.65e-13	QT interval;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.41	-0.4	2.27e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs755249	0.530	rs16826087	chr1:39812518	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.46	0.33	4.28e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs11693319	1.000	rs56791846	chr2:179745089	G/T	cg17765952	chr2:179737173	CCDC141	0.6	9.18	0.39	1.44e-18	Blood pressure measurement (cold pressor test);
LGG	cis	rs5742933	0.817	rs1233288	chr2:190690725	C/T	cg04003228	chr2:190539410	ANKAR	0.45	6.67	0.3	7.47e-11	Ferritin levels;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.15	-0.6	7.11e-47	Longevity;
LGG	trans	rs800082	1.000	rs9882503	chr3:144321296	A/T	cg24215973	chr2:240111563	HDAC4	-0.51	-9.0	-0.39	5.99e-18	Smoking behavior;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16517634	chr2:8977876	KIDINS220	0.61	6.86	0.3	2.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17453880	0.963	rs6868331	chr5:151950825	A/G	cg10931792	chr5:152022470	NA	0.37	7.96	0.35	1.31e-14	Subjective well-being;
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg07648498	chr16:89883185	FANCA	0.39	6.76	0.3	4.07e-11	Vitiligo;
LGG	cis	rs2033908	0.620	rs1440272	chr11:12852309	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-7.21	-0.32	2.24e-12	Sitting height ratio;
LGG	cis	rs807669	0.548	rs723414	chr22:19185736	G/A	cg02655711	chr22:19163373	SLC25A1	0.63	12.39	0.5	1.26e-30	Metabolite levels;
LGG	cis	rs757110	0.866	rs5213	chr11:17408404	C/T	cg04705435	chr11:17411270	KCNJ11	0.46	8.74	0.38	4.33e-17	Type 2 diabetes;
LGG	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg03806693	chr22:41940476	POLR3H	0.95	16.04	0.6	2.2e-46	Vitiligo;
LGG	cis	rs2594989	0.943	rs2606748	chr3:11373989	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.45	-0.33	4.53e-13	Circulating chemerin levels;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg11360546	chr7:1094263	C7orf50	-0.42	-7.57	-0.33	1.99e-13	Longevity;Endometriosis;
LGG	cis	rs4774899	1.000	rs12916958	chr15:57267365	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.19	-0.36	2.49e-15	Urinary tract infection frequency;
LGG	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg09307838	chr4:120376055	NA	0.73	12.16	0.49	1.02e-29	Corneal astigmatism;
LGG	cis	rs7928758	0.943	rs2360225	chr11:134265254	A/G	cg22777979	chr11:134283252	B3GAT1	0.96	12.1	0.49	1.79e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.98	-0.31	1.02e-11	Arsenic metabolism;
LGG	trans	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg25214090	chr10:38739885	LOC399744	0.67	11.79	0.48	2.98e-28	Corneal astigmatism;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg16284684	chr7:1164063	C7orf50	0.35	6.81	0.3	2.96e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.47	-0.37	3.27e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9290877	0.704	rs9864066	chr3:188413119	A/C	cg17392043	chr3:188495102	LPP	-0.4	-6.68	-0.3	6.92e-11	IgE levels;
LGG	trans	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.18e-19	Diabetic kidney disease;
LGG	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg08888203	chr3:10149979	C3orf24	0.57	9.39	0.4	2.72e-19	Alzheimer's disease;
LGG	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg09048205	chr5:1608656	LOC728613	0.4	7.12	0.31	4.24e-12	Breast cancer;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23289197	chr7:16685473	BZW2;ANKMY2	0.44	7.7	0.34	8.6e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.68	-0.37	7.02e-17	Obesity-related traits;
LGG	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg02640540	chr1:67518911	SLC35D1	0.38	7.4	0.33	6.26e-13	Lymphocyte percentage of white cells;
LGG	cis	rs9399135	0.967	rs2327580	chr6:135364417	A/C	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.08e-19	Red blood cell count;
LGG	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg14186256	chr22:23484241	RTDR1	0.95	23.29	0.73	5.39e-80	Bone mineral density;
LGG	cis	rs11608355	0.545	rs6606723	chr12:109905044	C/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs7166081	1.000	rs35524716	chr15:67578987	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.2	-0.32	2.45e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-6.96	-0.31	1.14e-11	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.58	-0.44	1.41e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.84e-12	Lung cancer;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg19635926	chr16:89946313	TCF25	0.71	7.41	0.33	5.91e-13	Skin colour saturation;
LGG	cis	rs7927771	0.524	rs6485786	chr11:47837408	G/C	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg18032289	chr17:61959525	GH2	-0.4	-6.94	-0.31	1.31e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6976053	0.846	rs3847068	chr7:100500745	C/T	cg03098644	chr7:100410630	EPHB4	-0.41	-7.43	-0.33	5.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22618164	chr12:122356400	WDR66	0.38	10.92	0.45	7.22e-25	Mean corpuscular volume;
LGG	cis	rs9815354	0.638	rs60525434	chr3:42044286	T/G	cg03022575	chr3:42003672	ULK4	0.66	8.0	0.35	9.94e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs773506	0.965	rs2494386	chr9:94090486	C/A	cg14446406	chr9:93919335	NA	-0.46	-8.4	-0.36	5.37e-16	Type 2 diabetes nephropathy;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.57	0.37	1.56e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg03929089	chr4:120376271	NA	0.8	11.04	0.46	2.62e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs68170813	0.559	rs12535081	chr7:106979291	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.39	-0.43	6.92e-23	Coronary artery disease;
LGG	cis	rs6665290	0.904	rs7541033	chr1:227188371	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg16325326	chr1:53192061	ZYG11B	-0.84	-22.46	-0.72	4.26e-76	Monocyte count;
LGG	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	cis	rs4732038	0.526	rs12672016	chr7:134273321	T/C	cg06906464	chr7:134288099	NA	-0.72	-20.87	-0.7	1.21e-68	Longevity;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.57	-0.44	1.48e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs4148883	0.675	rs116265877	chr4:100096896	G/A	cg12011299	chr4:100065546	ADH4	0.4	8.56	0.37	1.67e-16	Alcohol dependence;
LGG	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg22044901	chr15:68126292	NA	-0.41	-6.66	-0.3	7.62e-11	Restless legs syndrome;
LGG	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg11764359	chr7:65958608	NA	0.63	10.94	0.45	6.37e-25	Aortic root size;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.55	-0.33	2.35e-13	Neuroticism;
LGG	cis	rs1003719	0.641	rs13046844	chr21:38517603	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.56	-0.59	3.26e-44	Eye color traits;
LGG	cis	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg19171272	chr22:38449367	NA	-0.62	-12.24	-0.49	4.75e-30	Glioblastoma;Glioma;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7923837	1.000	rs10786053	chr10:94474097	G/A	cg25093409	chr10:94429542	NA	0.38	6.93	0.31	1.43e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg17971929	chr21:40555470	PSMG1	-0.53	-8.98	-0.39	6.79e-18	Menarche (age at onset);
LGG	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg22875332	chr1:76189707	ACADM	0.54	8.23	0.36	1.9e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs274567	0.550	rs272885	chr5:131667736	A/G	cg07395648	chr5:131743802	NA	-0.48	-9.87	-0.42	5.39e-21	Blood metabolite levels;
LGG	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg00543991	chr22:32367038	NA	0.78	8.52	0.37	2.3e-16	Childhood ear infection;
LGG	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg01028140	chr2:1542097	TPO	-0.47	-8.65	-0.37	8.81e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg04166393	chr7:2884313	GNA12	0.45	8.21	0.36	2.19e-15	Height;
LGG	cis	rs882300	0.967	rs1519528	chr2:136973781	A/G	cg07169764	chr2:136633963	MCM6	0.44	7.21	0.32	2.28e-12	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.99	-0.31	9.8e-12	Lung cancer;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.42	-0.4	2.17e-19	Lung cancer;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.44	8.19	0.36	2.53e-15	Obesity-related traits;
LGG	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg07936489	chr17:37558343	FBXL20	-0.52	-8.74	-0.38	4.3e-17	Asthma;
LGG	cis	rs5769765	0.954	rs910799	chr22:50278568	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-7.12	-0.31	4.11e-12	Schizophrenia;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg08677398	chr8:58056175	NA	0.47	7.52	0.33	2.92e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.720	rs6665527	chr1:152967009	C/A	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.11e-18	Inflammatory skin disease;
LGG	cis	rs6580649	0.941	rs12580764	chr12:48453882	G/A	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07157834	chr1:205819609	PM20D1	0.5	9.98	0.42	2.31e-21	Menarche (age at onset);
LGG	cis	rs9902453	1.000	rs62070312	chr17:28438877	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.18	0.52	6.57e-34	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	trans	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.93e-30	Corneal astigmatism;
LGG	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-7.63	-0.33	1.33e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg19645103	chr12:69753606	YEATS4	-0.51	-7.46	-0.33	4.41e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs7267979	0.528	rs2387976	chr20:25599560	C/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.52	-0.33	2.8e-13	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-8.16	-0.35	3.11e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg17712092	chr4:129076599	LARP1B	-0.59	-10.32	-0.43	1.32e-22	DNA methylation (variation);
LGG	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg07005078	chr4:17578674	LAP3	0.38	6.97	0.31	1.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg01346077	chr3:125931526	NA	-0.43	-11.22	-0.46	5.32e-26	Metabolite levels;
LGG	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg22676075	chr6:135203613	NA	0.53	8.52	0.37	2.29e-16	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2731664	0.756	rs4976695	chr5:176862963	T/A	cg23176889	chr5:176863531	GRK6	-0.62	-11.8	-0.48	2.73e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.15e-25	Homoarginine levels;
LGG	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.3	-0.4	5.47e-19	Ovarian reserve;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.41	0.36	5.18e-16	Skin colour saturation;
LGG	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.56	-0.74	3.15e-81	Primary sclerosing cholangitis;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg13647721	chr17:30228624	UTP6	0.6	7.72	0.34	7.01e-14	Hip circumference adjusted for BMI;
LGG	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.52e-11	Dupuytren's disease;
LGG	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	5.37e-87	Height;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg05665937	chr4:1216051	CTBP1	0.59	11.0	0.46	3.58e-25	Obesity-related traits;
LGG	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg18196295	chr10:418757	DIP2C	0.61	12.33	0.5	2.08e-30	Psychosis in Alzheimer's disease;
LGG	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg02158880	chr13:53174818	NA	0.67	15.36	0.58	2.51e-43	Lewy body disease;
LGG	cis	rs735539	0.521	rs9552280	chr13:21365361	T/A	cg04906043	chr13:21280425	IL17D	-0.5	-7.84	-0.34	3.13e-14	Dental caries;
LGG	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg25356066	chr3:128598488	ACAD9	0.45	6.79	0.3	3.55e-11	IgG glycosylation;
LGG	cis	rs2013441	0.866	rs12949485	chr17:20021661	A/G	cg13482628	chr17:19912719	NA	0.42	7.08	0.31	5.42e-12	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1658495	chr10:60280153	C/A	cg09696939	chr10:60272079	BICC1	0.36	7.05	0.31	6.63e-12	Refractive error;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06481639	chr22:41940642	POLR3H	0.59	8.65	0.37	8.46e-17	Vitiligo;
LGG	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg00012203	chr2:219082015	ARPC2	0.86	17.86	0.64	1.23e-54	Colorectal cancer;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg26150922	chr2:100937072	LONRF2	0.61	11.94	0.49	7.73e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.47	-7.45	-0.33	4.77e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs847577	0.722	rs7790736	chr7:97713039	G/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.65	-0.3	8.25e-11	Breast cancer;
LGG	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-7.81	-0.34	3.76e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4594175	0.926	rs10138345	chr14:51624651	A/G	cg23942311	chr14:51606299	NA	0.34	6.77	0.3	4.04e-11	Cancer;
LGG	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.21	-0.43	3.38e-22	Total body bone mineral density;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.82	-0.38	2.29e-17	Longevity;Endometriosis;
LGG	cis	rs4481887	0.741	rs6421453	chr1:248533285	A/G	cg01631408	chr1:248437212	OR2T33	-0.38	-6.91	-0.31	1.57e-11	Common traits (Other);
LGG	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.47	-0.37	3.28e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg12070911	chr6:150209640	RAET1E	0.32	7.85	0.34	3.01e-14	Lung cancer;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs4731207	0.698	rs6973812	chr7:124506750	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs4380275	0.782	rs4854276	chr2:764357	C/T	cg14072418	chr2:740025	NA	-0.35	-6.97	-0.31	1.13e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs41278232	1.000	rs41278232	chr20:62606617	G/A	cg03065311	chr20:62601662	ZNF512B	0.64	8.88	0.38	1.46e-17	Tonsillectomy;
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.55	-0.5	2.55e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg10503236	chr1:231470652	EXOC8	-0.36	-6.87	-0.3	2.12e-11	Hemoglobin concentration;
LGG	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg07511668	chr11:68622177	NA	0.51	9.94	0.42	3.25e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	9.02	0.39	5.15e-18	Schizophrenia;
LGG	cis	rs151234	0.612	rs11641853	chr16:28589719	A/G	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.94	-0.42	3.01e-21	Platelet distribution width;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03452623	chr4:187889614	NA	-1.04	-28.89	-0.8	1.08e-105	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07508260	chr11:111742291	ALG9	0.51	7.83	0.34	3.34e-14	Gut microbiome composition (summer);
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01516881	chr6:292596	DUSP22	-0.69	-11.61	-0.47	1.53e-27	Menopause (age at onset);
LGG	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg19628046	chr18:33552617	C18orf21	0.53	7.73	0.34	6.95e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4243971	0.516	rs6141700	chr20:30982566	C/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2120243	0.508	rs1965246	chr3:157111586	G/A	cg24825693	chr3:157122686	VEPH1	-0.58	-13.6	-0.53	1.11e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7572733	0.555	rs6745726	chr2:198934080	A/G	cg00792783	chr2:198669748	PLCL1	0.6	9.52	0.4	9.79e-20	Dermatomyositis;
LGG	cis	rs6594713	0.885	rs6594716	chr5:112745118	G/A	cg12552261	chr5:112820674	MCC	0.5	7.18	0.32	2.8e-12	Brain cytoarchitecture;
LGG	trans	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.18e-19	Diabetic kidney disease;
LGG	cis	rs1475718	0.526	rs10785876	chr9:137122767	C/G	cg21243944	chr9:137118148	NA	-0.3	-7.59	-0.33	1.76e-13	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg19077165	chr18:44547161	KATNAL2	0.51	9.0	0.39	5.84e-18	Personality dimensions;
LGG	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.12	-0.35	4.17e-15	Huntington's disease progression;
LGG	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04530015	chr2:215796436	ABCA12	-0.42	-6.72	-0.3	5.2e-11	Neuroblastoma;
LGG	cis	rs61931739	0.620	rs61927753	chr12:33699277	A/G	cg06521331	chr12:34319734	NA	0.4	6.78	0.3	3.78e-11	Morning vs. evening chronotype;
LGG	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg02023728	chr11:77925099	USP35	0.47	8.29	0.36	1.22e-15	Testicular germ cell tumor;
LGG	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg05527609	chr1:210001259	C1orf107	-0.49	-6.83	-0.3	2.76e-11	Red blood cell count;
LGG	cis	rs834603	1.000	rs834603	chr7:47447921	A/G	cg23694490	chr7:47445681	TNS3	-0.53	-16.24	-0.6	2.91e-47	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg22906224	chr7:99728672	NA	-0.58	-9.57	-0.41	6.41e-20	Coronary artery disease;
LGG	cis	rs968567	1.000	rs968567	chr11:61595564	C/T	cg19610905	chr11:61596333	FADS2	-0.68	-8.28	-0.36	1.38e-15	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs3733418	0.860	rs13110286	chr4:165956403	G/A	cg10852876	chr4:165953100	TRIM60	-0.5	-6.93	-0.31	1.4e-11	Obesity-related traits;
LGG	cis	rs17102423	0.615	rs7147987	chr14:65538131	A/G	cg11161011	chr14:65562177	MAX	-0.53	-9.51	-0.4	1.01e-19	Obesity-related traits;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.48	0.37	3.02e-16	Schizophrenia;
LGG	cis	rs7106204	0.514	rs7126508	chr11:24255147	G/A	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.68	-0.34	9.43e-14	Colorectal cancer;
LGG	cis	rs368123	1.000	rs316168	chr6:160755057	G/T	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.61	-0.33	1.54e-13	Waist circumference;
LGG	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg08470875	chr2:26401718	FAM59B	-0.37	-6.84	-0.3	2.59e-11	Gut microbiome composition (summer);
LGG	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg25173405	chr17:45401733	C17orf57	-0.55	-9.65	-0.41	3.39e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg05535760	chr7:792225	HEATR2	-0.45	-7.72	-0.34	7.22e-14	Perceived unattractiveness to mosquitoes;
LGG	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	11.99	0.49	4.84e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg11764359	chr7:65958608	NA	0.56	9.32	0.4	4.65e-19	Aortic root size;
LGG	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.8	-0.78	3.27e-96	Schizophrenia;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg04234412	chr22:24373322	LOC391322	-0.77	-16.54	-0.61	1.29e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6867032	0.527	rs13162781	chr5:2012235	C/T	cg26168224	chr5:2018326	NA	0.93	17.82	0.64	1.72e-54	Gut microbiome composition (winter);
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg04166393	chr7:2884313	GNA12	0.48	9.31	0.4	5.28e-19	Height;
LGG	cis	rs9399135	0.967	rs6929661	chr6:135328792	G/A	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.91e-20	Red blood cell count;
LGG	trans	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg21659725	chr3:3221576	CRBN	-0.59	-7.29	-0.32	1.39e-12	Menarche (age at onset);
LGG	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg07537917	chr2:241836409	C2orf54	-0.43	-8.53	-0.37	2.08e-16	Urinary metabolites;
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.4e-16	Aortic root size;
LGG	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.81	0.34	3.92e-14	Homoarginine levels;
LGG	trans	rs208520	0.789	rs9351549	chr6:66871851	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.18	-0.62	1.54e-51	Exhaled nitric oxide output;
LGG	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg26031613	chr14:104095156	KLC1	0.59	9.38	0.4	3.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7017914	0.967	rs62508819	chr8:71718106	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.68	-0.3	6.89e-11	Bone mineral density;
LGG	cis	rs1707322	0.865	rs785501	chr1:46579611	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.5	-0.4	1.12e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs283228	0.959	rs283225	chr6:101756221	A/C	cg27451362	chr6:101846650	GRIK2	0.51	8.57	0.37	1.6e-16	Coenzyme Q10 levels;
LGG	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Breast cancer;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.73	13.54	0.53	1.94e-35	Obesity-related traits;
LGG	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2013441	0.761	rs2526468	chr17:20163072	C/G	cg13482628	chr17:19912719	NA	-0.41	-6.98	-0.31	1.04e-11	Obesity-related traits;
LGG	cis	rs11971779	0.774	rs7785906	chr7:139122652	T/C	cg07862535	chr7:139043722	LUC7L2	0.58	9.13	0.39	2.2e-18	Diisocyanate-induced asthma;
LGG	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg19906672	chr4:6918868	TBC1D14	0.62	6.67	0.3	7.32e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.88	0.34	2.37e-14	Obesity-related traits;
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.04	-0.42	1.37e-21	Total body bone mineral density;
LGG	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11644478	chr21:40555479	PSMG1	-0.71	-12.68	-0.51	7.9e-32	Cognitive function;
LGG	cis	rs6546550	0.901	rs10496174	chr2:70153436	T/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.16	-0.35	3.09e-15	Prevalent atrial fibrillation;
LGG	cis	rs748404	0.578	rs510108	chr15:43605439	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	8.1	0.35	4.82e-15	Lung cancer;
LGG	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg10253484	chr15:75165896	SCAMP2	-0.67	-10.88	-0.45	1.04e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg25482853	chr8:67687455	SGK3	1.04	13.42	0.53	6.24e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs4417704	0.551	rs10204458	chr2:241899236	C/G	cg14055004	chr2:241860995	NA	0.28	7.26	0.32	1.64e-12	Joint mobility (Beighton score);
LGG	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	21.13	0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg22643751	chr7:855365	UNC84A	0.41	7.24	0.32	1.91e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs6688613	0.685	rs2142615	chr1:166922731	G/C	ch.1.3259774R	chr1:166827647	TADA1	0.47	6.95	0.31	1.25e-11	Refractive astigmatism;
LGG	trans	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg06521331	chr12:34319734	NA	0.44	7.76	0.34	5.59e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19894588	chr14:64061835	NA	0.51	8.56	0.37	1.63e-16	Glioblastoma;Glioma;
LGG	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg12165864	chr7:66369176	NA	-0.58	-9.26	-0.4	7.55e-19	Corneal structure;
LGG	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg07395648	chr5:131743802	NA	-0.52	-11.02	-0.46	3e-25	Breast cancer;Mosquito bite size;
LGG	cis	rs757081	0.671	rs214091	chr11:17296463	A/C	cg15432903	chr11:17409602	KCNJ11	-0.55	-8.36	-0.36	7.3e-16	Systolic blood pressure;
LGG	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	12.12	0.49	1.48e-29	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg14675211	chr2:100938903	LONRF2	0.65	11.28	0.46	3.03e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6462411	0.877	rs6958535	chr7:3918251	A/G	cg18022346	chr7:3920534	SDK1	-0.36	-7.15	-0.32	3.34e-12	Quantitative traits;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.36	-0.32	8.7e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-9.15	-0.39	1.79e-18	Systemic lupus erythematosus;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg12708336	chr17:41446283	NA	-0.34	-8.21	-0.36	2.27e-15	Menopause (age at onset);
LGG	cis	rs7017914	0.967	rs6472543	chr8:71664408	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.13	-0.43	6.31e-22	Type 2 diabetes;
LGG	cis	rs67133203	0.659	rs422982	chr12:51406354	T/A	cg14688905	chr12:51403056	SLC11A2	-0.58	-10.04	-0.42	1.41e-21	Urinary tract infection frequency;
LGG	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg12623918	chr2:306882	NA	0.53	9.93	0.42	3.36e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4330281	0.647	rs13097908	chr3:17719764	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.84	-14.0	-0.55	2.27e-37	Chronic sinus infection;
LGG	cis	rs2073300	1.000	rs6137962	chr20:23443966	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	3.91e-17	Resting heart rate;
LGG	cis	rs3008870	1.000	rs3008859	chr1:67390999	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.68	0.73	3.76e-77	Lymphocyte percentage of white cells;
LGG	cis	rs62432291	0.681	rs435521	chr6:159662638	C/T	cg14500486	chr6:159655392	FNDC1	0.6	6.69	0.3	6.62e-11	Joint mobility (Beighton score);
LGG	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg03929089	chr4:120376271	NA	-1.03	-24.71	-0.75	1.43e-86	Height;
LGG	cis	rs6500395	0.588	rs6500392	chr16:48564143	A/G	cg04672837	chr16:48644449	N4BP1	0.49	8.51	0.37	2.49e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.83	-0.45	1.66e-24	Coronary artery disease;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg27532560	chr4:187881888	NA	-0.6	-13.14	-0.52	9.26e-34	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg16141378	chr3:129829833	LOC729375	-0.43	-10.25	-0.43	2.34e-22	Mood instability;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg20607798	chr8:58055168	NA	0.68	7.67	0.34	1.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.705	rs4899393	chr14:71739924	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.36	-7.82	-0.34	3.68e-14	Mitral valve prolapse;
LGG	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg15309053	chr8:964076	NA	0.38	7.65	0.33	1.19e-13	Schizophrenia;
LGG	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-16.06	-0.6	1.95e-46	Headache;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02418899	chr7:31092589	ADCYAP1R1	0.43	6.75	0.3	4.55e-11	Gut microbiome composition (summer);
LGG	cis	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg19847130	chr8:10466454	RP1L1	0.31	6.77	0.3	3.91e-11	Neuroticism;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.67	0.63	9.03e-54	Alzheimer's disease;
LGG	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04530015	chr2:215796436	ABCA12	-0.46	-7.71	-0.34	7.87e-14	Neuroblastoma;
LGG	cis	rs7122257	0.507	rs11043112	chr11:11151583	C/T	cg16931664	chr11:11169707	NA	-0.26	-7.58	-0.33	1.87e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6840360	0.571	rs62327271	chr4:152535916	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg07005078	chr4:17578674	LAP3	0.39	7.08	0.31	5.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4959677	1.000	rs4959677	chr6:2500820	C/G	cg20147862	chr6:2634573	C6orf195	0.4	8.5	0.37	2.55e-16	Orthostatic hypotension;
LGG	cis	rs2439831	0.850	rs7179388	chr15:44123945	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.63	0.44	9.47e-24	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.82	0.38	2.36e-17	Obesity-related traits;
LGG	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.09	0.35	5.21e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8060686	0.641	rs73612222	chr16:68216072	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.63	-0.33	1.31e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.92	0.35	1.82e-14	Platelet count;
LGG	cis	rs7928758	1.000	rs56134226	chr11:134279882	T/C	cg15243474	chr11:134282918	B3GAT1	1.06	13.7	0.54	4.38e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg24687335	chr11:118901407	SLC37A4	-0.59	-10.44	-0.44	4.61e-23	Coronary artery disease;
LGG	cis	rs7129556	0.690	rs24356	chr11:77567528	C/T	cg12586386	chr11:77299805	AQP11	0.45	7.34	0.32	9.5e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.51	0.37	2.51e-16	Renal function-related traits (BUN);
LGG	cis	rs832540	0.898	rs252888	chr5:56227326	T/A	cg12654349	chr5:56205094	C5orf35	-0.4	-7.15	-0.32	3.47e-12	Coronary artery disease;
LGG	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.23e-36	Cognitive function;
LGG	cis	rs10463316	0.608	rs13360453	chr5:150769143	T/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-9.79	-0.41	1.05e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs537930	0.560	rs576845	chr5:134354738	C/G	cg24576358	chr5:134350122	NA	0.4	9.07	0.39	3.28e-18	Height;
LGG	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg04568710	chr12:38710424	ALG10B	0.35	7.25	0.32	1.75e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg18187862	chr3:45730750	SACM1L	0.57	9.25	0.39	8.54e-19	Primary sclerosing cholangitis;
LGG	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg27572855	chr1:25598939	RHD	-0.53	-11.99	-0.49	5.05e-29	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs7572644	0.699	rs10209126	chr2:28209283	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs73198271	0.562	rs17154743	chr8:8650787	A/G	cg01851573	chr8:8652454	MFHAS1	0.53	8.86	0.38	1.7e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg26769984	chr7:1090371	C7orf50	0.41	7.47	0.33	3.95e-13	Bronchopulmonary dysplasia;
LGG	cis	rs2070488	0.766	rs6808093	chr3:38498160	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.71	0.56	1.75e-40	Electrocardiographic conduction measures;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.36	0.32	8.49e-13	Life satisfaction;
LGG	cis	rs2486288	0.656	rs11637838	chr15:45550657	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-10.01	-0.42	1.68e-21	Glomerular filtration rate;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.03	0.31	7.61e-12	Schizophrenia;
LGG	trans	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.62	0.37	1.1e-16	Mood instability;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg09303159	chr6:26284866	NA	0.35	7.89	0.34	2.28e-14	Educational attainment;
LGG	cis	rs6732160	0.588	rs7578991	chr2:73376171	A/G	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg16606324	chr3:10149918	C3orf24	0.65	7.34	0.32	9.48e-13	Alzheimer's disease;
LGG	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg23625390	chr15:77176239	SCAPER	-0.7	-13.7	-0.54	4.19e-36	Blood metabolite levels;
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg02002194	chr4:3960332	NA	0.43	7.77	0.34	5.03e-14	Neuroticism;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6772849	1.000	rs2712379	chr3:128309060	C/T	cg08795948	chr3:128337044	NA	0.53	8.71	0.38	5.55e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1355223	0.902	rs11605785	chr11:34751387	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-6.9	-0.31	1.71e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7503807	1.000	rs4890056	chr17:78591211	C/T	cg06872548	chr17:78716983	RPTOR	-0.46	-11.21	-0.46	5.85e-26	Obesity;
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg22875332	chr1:76189707	ACADM	0.62	10.89	0.45	9.52e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs4262150	0.883	rs55829928	chr5:152189967	T/G	cg12297329	chr5:152029980	NA	-0.69	-12.89	-0.51	1.1e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.22	-0.46	5.24e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg20673091	chr1:2541236	MMEL1	-0.75	-18.21	-0.65	2.77e-56	Ulcerative colitis;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.2	0.32	2.39e-12	Prudent dietary pattern;
LGG	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg25418670	chr11:30344373	C11orf46	0.53	7.5	0.33	3.37e-13	Morning vs. evening chronotype;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg17178900	chr1:205818956	PM20D1	-0.51	-11.67	-0.48	9.55e-28	Monocyte percentage of white cells;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg05863683	chr7:1912471	MAD1L1	0.43	8.37	0.36	6.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2050392	0.590	rs17547917	chr10:30718303	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-12.2	-0.49	6.81e-30	Inflammatory bowel disease;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg04529724	chr6:150244392	RAET1G	0.33	6.65	0.3	8.12e-11	Testicular germ cell tumor;
LGG	cis	rs12476592	0.571	rs2176415	chr2:63636568	A/C	cg17519650	chr2:63277830	OTX1	-0.51	-7.68	-0.34	9.52e-14	Childhood ear infection;
LGG	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg08198773	chr8:1697536	NA	0.36	7.0	0.31	9.02e-12	Systolic blood pressure;
LGG	cis	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg06521331	chr12:34319734	NA	0.62	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs9486719	1.000	rs2472886	chr6:96864876	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg08344181	chr3:125677491	NA	-0.82	-8.03	-0.35	8.26e-15	Intelligence (multi-trait analysis);
LGG	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg17145862	chr1:211918768	LPGAT1	0.65	8.89	0.38	1.35e-17	Crohn's disease;
LGG	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.63	-0.69	1.54e-67	Gout;
LGG	trans	rs6601327	0.665	rs11249949	chr8:9655612	T/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.95	-0.31	1.22e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg06074448	chr4:187884817	NA	-0.58	-12.86	-0.51	1.44e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2470578	0.740	rs2733478	chr3:17321551	A/G	cg20981856	chr3:17787350	NA	0.35	6.73	0.3	4.95e-11	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00222601	chr5:179718685	MAPK9	0.61	6.7	0.3	5.97e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.54	-0.78	4.94e-95	Renal cell carcinoma;
LGG	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg24375607	chr4:120327624	NA	0.62	10.24	0.43	2.45e-22	Corneal astigmatism;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg01145232	chr6:150245071	RAET1G	0.46	8.45	0.37	3.89e-16	Lung cancer;
LGG	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.66e-22	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23818142	chr2:170550784	C2orf77;KLHL23;PHOSPHO2	0.49	7.97	0.35	1.25e-14	Cognitive performance;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg04025307	chr7:1156635	C7orf50	0.89	19.23	0.67	5.43e-61	Longevity;Endometriosis;
LGG	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.55	-0.37	1.85e-16	Total body bone mineral density;
LGG	cis	rs2976388	0.609	rs2376491	chr8:143790934	G/A	cg06565975	chr8:143823917	SLURP1	0.37	9.44	0.4	1.88e-19	Urinary tract infection frequency;
LGG	cis	rs7827545	1.000	rs7832857	chr8:135565477	A/G	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	trans	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg06521331	chr12:34319734	NA	0.42	7.44	0.33	4.88e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.13	-0.31	3.88e-12	Total cholesterol levels;
LGG	cis	rs4363385	0.719	rs4845501	chr1:152937401	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-7.54	-0.33	2.58e-13	Inflammatory skin disease;
LGG	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.750	rs28637614	chr17:19985108	G/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.81	-0.3	3e-11	Schizophrenia;
LGG	trans	rs637571	0.544	rs617791	chr11:65702523	C/G	cg17712092	chr4:129076599	LARP1B	0.82	16.46	0.61	2.98e-48	Eosinophil percentage of white cells;
LGG	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg02733842	chr7:1102375	C7orf50	-0.51	-7.81	-0.34	3.76e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg01494348	chr8:144660395	NAPRT1	0.93	7.4	0.33	6.38e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg11062466	chr8:58055876	NA	0.62	9.84	0.42	7.26e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.723	rs1000282	chr1:209894785	T/C	cg23920097	chr1:209922102	NA	-0.43	-7.23	-0.32	2.06e-12	Red blood cell count;
LGG	trans	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.65	-0.33	1.17e-13	Resting heart rate;
LGG	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.1	-0.31	4.64e-12	Pancreatic cancer;
LGG	cis	rs6693567	0.545	rs12049177	chr1:150474337	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.7	0.3	6.07e-11	Migraine;
LGG	cis	rs3008870	1.000	rs2065000	chr1:67468124	G/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.97	-22.7	-0.73	3.09e-77	Lymphocyte percentage of white cells;
LGG	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.12	0.7	8.14e-70	Morning vs. evening chronotype;
LGG	cis	rs4950322	0.947	rs58671552	chr1:146881266	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-6.95	-0.31	1.27e-11	Protein quantitative trait loci;
LGG	cis	rs4148883	0.545	rs17595102	chr4:99986316	C/G	cg12011299	chr4:100065546	ADH4	0.39	8.22	0.36	2.07e-15	Alcohol dependence;
LGG	cis	rs722599	0.715	rs12147629	chr14:75307588	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-8.85	-0.38	1.91e-17	IgG glycosylation;
LGG	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07440826	chr16:89882328	FANCA	-0.25	-6.69	-0.3	6.39e-11	Vitiligo;
LGG	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg03098644	chr7:100410630	EPHB4	-0.51	-7.74	-0.34	6.21e-14	Other erythrocyte phenotypes;
LGG	cis	rs9487051	0.799	rs830553	chr6:109550017	T/G	cg21918786	chr6:109611834	NA	-0.4	-7.13	-0.31	3.94e-12	Reticulocyte fraction of red cells;
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.71	-0.41	2.12e-20	Triglycerides;
LGG	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg02002194	chr4:3960332	NA	-0.41	-7.47	-0.33	4.12e-13	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.86e-66	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg05692746	chr2:100937584	LONRF2	-0.65	-11.95	-0.49	6.89e-29	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.21	-0.32	2.36e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg09029085	chr17:47094198	IGF2BP1	0.31	8.28	0.36	1.36e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27218536	chr17:35969412	SYNRG	0.44	6.83	0.3	2.63e-11	Gut microbiome composition (summer);
LGG	cis	rs9393777	0.588	rs6926677	chr6:26478825	G/C	cg12826209	chr6:26865740	GUSBL1	0.8	11.99	0.49	4.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg08645402	chr16:4508243	NA	-0.51	-9.01	-0.39	5.38e-18	Schizophrenia;
LGG	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg25110126	chr1:46999211	NA	0.51	8.44	0.37	4.18e-16	Monobrow;
LGG	cis	rs7586879	0.616	rs916485	chr2:25082273	T/C	cg04586622	chr2:25135609	ADCY3	0.42	11.34	0.47	1.8e-26	Body mass index;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg11247378	chr22:39784982	NA	-0.31	-8.54	-0.37	1.94e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg12463550	chr7:65579703	CRCP	0.47	7.87	0.34	2.53e-14	Aortic root size;
LGG	cis	rs11677416	0.961	rs3783557	chr2:113530712	C/T	cg27083787	chr2:113543245	IL1A	0.55	8.91	0.38	1.21e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs9291683	0.588	rs35866697	chr4:10018604	C/A	cg00071950	chr4:10020882	SLC2A9	0.44	9.21	0.39	1.14e-18	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11099291	chr17:1620044	C17orf91;WDR81	0.49	7.27	0.32	1.56e-12	Gut microbiome composition (summer);
LGG	cis	rs6912958	0.712	rs7746465	chr6:88348996	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.84	-0.38	2.06e-17	Monocyte percentage of white cells;
LGG	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg15596359	chr8:11213517	TDH	0.44	8.91	0.38	1.19e-17	Retinal vascular caliber;
LGG	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-29.54	-0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs6693567	0.565	rs698917	chr1:150319884	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.73	0.3	5.16e-11	Migraine;
LGG	cis	rs12949688	0.651	rs4793915	chr17:55838163	C/T	cg12229367	chr17:55822335	NA	0.37	6.66	0.3	7.64e-11	Schizophrenia;
LGG	cis	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg24375607	chr4:120327624	NA	0.68	11.13	0.46	1.12e-25	Corneal astigmatism;
LGG	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.28	-0.4	6.64e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8048589	0.604	rs62038898	chr16:12223637	A/G	cg02910054	chr16:12241554	SNX29	0.6	9.0	0.39	6.03e-18	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs4891159	0.548	rs689902	chr18:74119969	C/T	cg24786174	chr18:74118243	ZNF516	-0.69	-17.34	-0.63	2.83e-52	Longevity;
LGG	cis	rs12738007	0.967	rs12032470	chr1:29464954	C/A	cg01115565	chr1:29584222	PTPRU	-0.28	-7.48	-0.33	3.78e-13	Schizophrenia;
LGG	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg15556689	chr8:8085844	FLJ10661	0.51	9.55	0.41	7.34e-20	Mood instability;
LGG	cis	rs7843479	0.509	rs3758156	chr8:21770796	A/G	cg17168535	chr8:21777572	XPO7	0.72	13.65	0.54	6.61e-36	Mean corpuscular volume;
LGG	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg08807101	chr21:30365312	RNF160	0.76	13.58	0.53	1.39e-35	Selective IgA deficiency;
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg00830817	chr11:109293614	C11orf87	0.6	9.68	0.41	2.64e-20	Schizophrenia;
LGG	cis	rs35771425	0.750	rs34440485	chr1:211549553	C/T	cg10512769	chr1:211675356	NA	-0.68	-9.46	-0.4	1.53e-19	Educational attainment (years of education);
LGG	cis	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg06521331	chr12:34319734	NA	-0.52	-9.0	-0.39	5.94e-18	Morning vs. evening chronotype;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg18957973	chr2:97303987	KIAA1310	0.45	7.48	0.33	3.71e-13	Hip circumference;
LGG	cis	rs3796352	1.000	rs13072457	chr3:53102389	G/A	cg12962167	chr3:53033115	SFMBT1	0.77	8.03	0.35	7.94e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	cis	rs6800768	0.633	rs59374114	chr3:24112202	G/T	cg10674438	chr3:24145617	LOC152024	-0.48	-8.67	-0.37	7.37e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg05925327	chr15:68127851	NA	-0.4	-8.24	-0.36	1.73e-15	Restless legs syndrome;
LGG	cis	rs72720396	0.803	rs114328297	chr1:91190854	T/G	cg13456504	chr1:91191583	NA	0.65	9.26	0.4	7.52e-19	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1790761	0.505	rs7103713	chr11:67338242	G/A	cg00864171	chr11:67383662	NA	-0.42	-6.67	-0.3	7.43e-11	Mean corpuscular volume;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg13047869	chr3:10149882	C3orf24	0.53	8.76	0.38	3.65e-17	Alzheimer's disease;
LGG	cis	rs7712401	0.601	rs246269	chr5:122256741	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg02959939	chr21:47813025	PCNT	-0.33	-7.66	-0.34	1.09e-13	Testicular germ cell tumor;
LGG	cis	rs12643440	0.718	rs543525	chr4:17143562	C/T	cg22650099	chr4:17144496	NA	-0.4	-7.35	-0.32	9.27e-13	Metabolite levels (Pyroglutamine);
LGG	trans	rs17685	0.816	rs11763076	chr7:75765963	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7000551	0.663	rs11778831	chr8:22335088	C/T	cg12081754	chr8:22256438	SLC39A14	0.66	12.4	0.5	1.07e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg11764359	chr7:65958608	NA	0.63	9.41	0.4	2.29e-19	Aortic root size;
LGG	cis	rs6834538	0.597	rs1471881	chr4:113557539	T/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.37	0.36	6.73e-16	Free thyroxine concentration;
LGG	cis	rs6743226	0.603	rs3755324	chr2:242203220	T/C	cg10021735	chr2:242295487	FARP2	0.4	7.06	0.31	6.16e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs11239187	0.530	rs11239143	chr10:45063388	G/T	cg03916630	chr10:45065415	NA	0.37	8.98	0.39	6.66e-18	Body mass index;
LGG	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg26446133	chr18:72167187	CNDP2	-0.69	-13.54	-0.53	1.92e-35	Refractive error;
LGG	cis	rs672059	1.000	rs3118181	chr1:183166970	T/C	cg07928641	chr1:182991847	LAMC1	0.35	7.05	0.31	6.66e-12	Hypertriglyceridemia;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16700650	chr16:69344975	VPS4A	0.58	6.84	0.3	2.47e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg00717180	chr2:96193071	NA	-0.45	-8.16	-0.35	3.11e-15	HDL cholesterol;
LGG	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	18.89	0.66	2.11e-59	Chronic sinus infection;
LGG	cis	rs4660214	0.666	rs1775656	chr1:39911001	C/T	cg18385671	chr1:39797026	MACF1	0.48	9.86	0.42	6.21e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg23758822	chr17:41437982	NA	0.89	15.46	0.58	9e-44	Menopause (age at onset);
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.17	-0.6	5.71e-47	Longevity;
LGG	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.43	-7.85	-0.34	2.94e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg23782820	chr8:58130467	NA	0.57	8.37	0.36	6.67e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.47	-0.33	3.9e-13	Refractive error;
LGG	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg27211696	chr2:191398769	TMEM194B	0.39	9.12	0.39	2.39e-18	Pulse pressure;
LGG	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg08000102	chr2:233561755	GIGYF2	0.59	9.67	0.41	2.91e-20	Coronary artery disease;
LGG	cis	rs34978289	1	rs34978289	chr6:2504622	C/CT	cg20147862	chr6:2634573	C6orf195	-0.38	-8.28	-0.36	1.37e-15	Immature fraction of reticulocytes;
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg14196790	chr5:131705035	SLC22A5	0.6	7.62	0.33	1.46e-13	Rheumatoid arthritis;
LGG	cis	rs6963495	0.818	rs73190163	chr7:105157294	G/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg08847533	chr14:75593920	NEK9	0.62	12.04	0.49	3.25e-29	Height;
LGG	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.07	0.39	3.36e-18	Diabetic retinopathy;
LGG	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg20891283	chr12:69753455	YEATS4	0.8	13.08	0.52	1.68e-33	Response to diuretic therapy;
LGG	cis	rs1519814	1.000	rs7818027	chr8:121158662	G/C	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg18479299	chr3:125709523	NA	-0.61	-7.82	-0.34	3.68e-14	Blood pressure (smoking interaction);
LGG	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg11887960	chr12:57824829	NA	0.58	7.15	0.32	3.46e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10991814	1.000	rs59581968	chr9:93943140	C/T	cg14446406	chr9:93919335	NA	-0.82	-8.84	-0.38	2.01e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs208520	0.690	rs12194057	chr6:66745616	A/G	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	5.27e-55	Exhaled nitric oxide output;
LGG	cis	rs524281	0.861	rs10896080	chr11:65876796	G/A	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs17253792	0.822	rs17747083	chr14:56110594	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.78e-31	Putamen volume;
LGG	cis	rs2737618	0.889	rs2737617	chr1:200097130	A/G	cg21825944	chr1:200113062	NR5A2	-0.5	-8.31	-0.36	1.1e-15	Uric acid levels;
LGG	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.41	-0.33	6.16e-13	IgG glycosylation;
LGG	cis	rs7927771	0.832	rs10838697	chr11:47384484	T/A	cg20307385	chr11:47447363	PSMC3	-0.56	-10.14	-0.43	5.91e-22	Subjective well-being;
LGG	cis	rs6684428	0.536	rs12119831	chr1:56392010	A/G	cg11651538	chr1:56320950	NA	0.44	8.5	0.37	2.7e-16	Airflow obstruction;
LGG	cis	rs7095944	0.584	rs4962692	chr10:126424823	G/A	cg08799069	chr10:126477246	METTL10	-0.43	-9.45	-0.4	1.63e-19	Asthma;
LGG	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg09324608	chr17:30823087	MYO1D	0.3	7.3	0.32	1.24e-12	Schizophrenia;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.55	0.37	1.82e-16	Prudent dietary pattern;
LGG	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs240764	0.658	rs846803	chr6:101272801	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.6	-0.33	1.62e-13	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19015582	chr11:75946767	NA	0.44	6.97	0.31	1.13e-11	Cognitive performance;
LGG	cis	rs4308124	0.708	rs67816163	chr2:111963310	A/G	cg04571233	chr2:111982156	NA	-0.6	-9.9	-0.42	4.32e-21	Vitiligo;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg20975532	chr1:184939506	FAM129A	-0.39	-7.06	-0.31	6.2e-12	Apolipoprotein A-IV levels;
LGG	cis	rs4319547	1.000	rs7307735	chr12:123087442	A/G	cg23029597	chr12:123009494	RSRC2	-0.92	-18.35	-0.65	6.68e-57	Body mass index;
LGG	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg22535103	chr8:58192502	C8orf71	-0.61	-8.07	-0.35	6.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg00666640	chr1:248458726	OR2T12	0.54	9.03	0.39	4.72e-18	Common traits (Other);
LGG	cis	rs10929925	0.966	rs2693827	chr2:6160207	A/T	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7241530	0.585	rs12964467	chr18:75890849	T/C	cg14642773	chr18:75888474	NA	0.46	9.0	0.39	5.75e-18	Educational attainment (years of education);
LGG	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg26655873	chr3:72818019	SHQ1	0.35	6.94	0.31	1.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg02002194	chr4:3960332	NA	0.39	7.11	0.31	4.48e-12	Myopia (pathological);
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.4	-6.75	-0.3	4.4e-11	Schizophrenia;
LGG	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg04672837	chr16:48644449	N4BP1	0.56	9.31	0.4	5.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg15596359	chr8:11213517	TDH	0.41	8.38	0.36	6.5e-16	Retinal vascular caliber;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.57	10.51	0.44	2.49e-23	Longevity;
LGG	cis	rs41005	1.000	rs193929	chr2:8107620	G/T	cg03155496	chr2:8117019	LOC339788	0.88	19.94	0.68	2.47e-64	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.71e-21	Colorectal cancer;
LGG	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg13010199	chr12:38710504	ALG10B	-0.65	-13.7	-0.54	4.23e-36	Heart rate;
LGG	cis	rs4629710	0.545	rs2077490	chr6:131554184	C/T	cg12606694	chr6:131520996	AKAP7	0.48	8.0	0.35	9.95e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs9640161	0.783	rs35435439	chr7:150063534	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-10.1	-0.42	8.38e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9814567	1.000	rs7374158	chr3:134270156	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg02725872	chr8:58115012	NA	-0.93	-11.61	-0.47	1.52e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07791516	chr6:150247246	NA	0.33	6.78	0.3	3.69e-11	Lung cancer;
LGG	cis	rs7010267	0.570	rs7004539	chr8:120040499	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg14829360	chr17:73884958	NA	-0.78	-12.89	-0.51	1.02e-32	Psoriasis;
LGG	cis	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.27	-0.46	3.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.95	0.31	1.22e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg23188684	chr11:67383651	NA	0.49	8.26	0.36	1.57e-15	Mean corpuscular volume;
LGG	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg12633918	chr20:23549525	CST9L	-0.33	-6.67	-0.3	7.5e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs747782	0.528	rs7937670	chr11:48313216	C/T	cg03929089	chr4:120376271	NA	0.68	8.08	0.35	5.72e-15	Intraocular pressure;
LGG	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg19980929	chr12:42632907	YAF2	-0.35	-7.98	-0.35	1.19e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.12	-0.49	1.53e-29	Height;
LGG	cis	rs35160687	0.644	rs57270703	chr2:86516873	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-7.01	-0.31	8.36e-12	Night sleep phenotypes;
LGG	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg07148914	chr20:33460835	GGT7	-0.55	-9.22	-0.39	1.02e-18	Height;
LGG	cis	rs78366141	0.649	rs76401410	chr4:89694624	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.01	8.83	0.38	2.16e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20814179	chr4:940893	TMEM175	0.56	11.8	0.48	2.73e-28	Sjögren's syndrome;
LGG	trans	rs61931739	0.620	rs11829476	chr12:33699285	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.63	-0.37	9.68e-17	Morning vs. evening chronotype;
LGG	cis	rs926938	0.527	rs360667	chr1:115481451	C/G	cg12756093	chr1:115239321	AMPD1	-0.43	-7.87	-0.34	2.52e-14	Autism;
LGG	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	8.02e-12	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg12708336	chr17:41446283	NA	-0.3	-6.91	-0.31	1.6e-11	Menopause (age at onset);
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.92	0.35	1.82e-14	Height;
LGG	cis	rs10267417	0.603	rs10281428	chr7:19857374	G/A	cg05791153	chr7:19748676	TWISTNB	0.61	7.77	0.34	4.97e-14	Night sleep phenotypes;
LGG	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg25664220	chr3:72788482	NA	-0.27	-7.99	-0.35	1.08e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg23281280	chr6:28129359	ZNF389	0.39	6.68	0.3	6.82e-11	Parkinson's disease;
LGG	cis	rs4746818	1.000	rs4342912	chr10:70959282	T/C	cg11621586	chr10:70884670	VPS26A	1.11	19.07	0.66	3.01e-60	Left atrial antero-posterior diameter;
LGG	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg20608306	chr11:116969690	SIK3	0.33	8.74	0.38	4.29e-17	Blood protein levels;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg26174226	chr8:58114915	NA	-0.52	-7.24	-0.32	1.85e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.91	-0.38	1.16e-17	Schizophrenia;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg06028808	chr11:68637592	NA	0.69	11.86	0.48	1.56e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.96	0.45	5.2e-25	Parkinson's disease;
LGG	cis	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	cis	rs4742903	0.935	rs7875929	chr9:106931408	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg19455335	chr8:22457658	C8orf58	-0.39	-8.11	-0.35	4.6e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2708377	0.929	rs73053768	chr12:11155747	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.46	6.93	0.31	1.39e-11	Bitter taste perception;
LGG	cis	rs3820068	0.705	rs4646110	chr1:15817318	A/T	cg05660106	chr1:15850417	CASP9	1.08	24.21	0.75	3.01e-84	Systolic blood pressure;
LGG	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg16208657	chr15:68119293	LBXCOR1	0.35	6.8	0.3	3.14e-11	Obesity;
LGG	cis	rs883565	0.655	rs4676649	chr3:39064948	T/C	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg06848047	chr4:90757629	SNCA	0.39	7.32	0.32	1.09e-12	Dementia with Lewy bodies;
LGG	cis	rs12410462	0.688	rs35582095	chr1:227959206	A/G	cg21459583	chr1:227974177	NA	0.45	8.36	0.36	7.62e-16	Major depressive disorder;
LGG	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg16980736	chr17:78789706	RPTOR	-0.63	-8.32	-0.36	9.64e-16	Myopia (pathological);
LGG	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs6142618	0.562	rs6061186	chr20:30731740	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	7.96	0.35	1.33e-14	Inflammatory bowel disease;
LGG	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg16141378	chr3:129829833	LOC729375	0.33	7.67	0.34	1.02e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10193935	0.901	rs222478	chr2:42656919	G/T	cg27598129	chr2:42591480	NA	-0.64	-9.68	-0.41	2.59e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg06889755	chr6:150326021	RAET1K	-0.37	-7.44	-0.33	5.06e-13	Alopecia areata;
LGG	cis	rs1957429	0.614	rs73279823	chr14:65351315	A/G	cg23373153	chr14:65346875	NA	-1.08	-12.1	-0.49	1.76e-29	Pediatric areal bone mineral density (radius);
LGG	cis	rs4253772	0.678	rs1055659	chr22:46638298	C/T	cg24881330	chr22:46731750	TRMU	0.57	6.97	0.31	1.13e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9658691	0.607	rs12412701	chr10:90782323	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.75	-9.26	-0.4	7.64e-19	Mosquito bite size;
LGG	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.52	0.56	1.19e-39	Bladder cancer;
LGG	cis	rs12220238	0.822	rs10824160	chr10:76132267	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.75	0.38	4.02e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03576123	chr11:487126	PTDSS2	-1.29	-17.21	-0.62	1.15e-51	Body mass index;
LGG	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4700695	0.719	rs27587	chr5:65444163	C/T	cg21114390	chr5:65439923	SFRS12	-0.72	-10.45	-0.44	4.24e-23	Facial morphology (factor 19);
LGG	cis	rs6594713	0.642	rs6871934	chr5:112787828	T/C	cg12552261	chr5:112820674	MCC	0.64	8.06	0.35	6.67e-15	Brain cytoarchitecture;
LGG	cis	rs17067123	0.614	rs1036767	chr4:180068417	G/A	cg26610307	chr4:180072759	NA	-0.48	-6.95	-0.31	1.22e-11	Response to hepatitis C treatment;
LGG	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg19338460	chr6:170058176	WDR27	-0.63	-8.42	-0.36	4.69e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.32	-0.36	1.02e-15	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg06916706	chr16:4465613	CORO7	0.86	14.66	0.56	2.95e-40	Schizophrenia;
LGG	cis	rs2587949	0.593	rs7611166	chr3:4179312	C/G	cg16519197	chr3:4211558	NA	-0.36	-7.22	-0.32	2.18e-12	Periodontitis (DPAL);
LGG	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg08975724	chr8:8085496	FLJ10661	0.52	10.16	0.43	4.93e-22	Mood instability;
LGG	cis	rs5769707	0.632	rs1476037	chr22:49991377	G/A	cg06623630	chr22:50017776	C22orf34	-0.44	-8.92	-0.38	1.08e-17	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.41	-0.47	9.92e-27	Tonsillectomy;
LGG	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg05163923	chr11:71159392	DHCR7	-0.55	-8.09	-0.35	5.19e-15	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20011807	chr14:39736465	CTAGE5	0.52	7.76	0.34	5.45e-14	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg01620082	chr3:125678407	NA	-0.85	-7.42	-0.33	5.52e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs36051895	0.695	rs2225125	chr9:4998639	A/G	cg02405213	chr9:5042618	JAK2	-0.79	-14.4	-0.56	3.92e-39	Pediatric autoimmune diseases;
LGG	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg13736514	chr6:26305472	NA	-0.35	-7.22	-0.32	2.2e-12	Educational attainment;
LGG	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06634786	chr22:41940651	POLR3H	-0.61	-10.22	-0.43	2.99e-22	Vitiligo;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01570182	chr17:44337453	NA	-0.67	-11.11	-0.46	1.35e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg18379455	chr17:41446167	NA	-0.33	-6.65	-0.3	8.23e-11	Menopause (age at onset);
LGG	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg08400814	chr5:56204995	C5orf35	0.45	7.24	0.32	1.92e-12	Initial pursuit acceleration;
LGG	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg27661571	chr11:113659931	NA	-0.73	-9.81	-0.41	8.96e-21	Hip circumference adjusted for BMI;
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg25407064	chr15:40226267	EIF2AK4	-0.65	-9.36	-0.4	3.59e-19	Response to haloperidol in psychosis;
LGG	cis	rs2652834	1.000	rs2652832	chr15:63396928	T/C	cg05507819	chr15:63340323	TPM1	0.57	7.74	0.34	6.31e-14	HDL cholesterol;
LGG	cis	rs3771570	0.892	rs62186433	chr2:242257835	A/G	cg21155796	chr2:242212141	HDLBP	0.73	9.25	0.39	8.38e-19	Prostate cancer;
LGG	cis	rs5742933	0.817	rs13035966	chr2:190591233	T/G	cg04003228	chr2:190539410	ANKAR	-0.5	-7.35	-0.32	9.27e-13	Ferritin levels;
LGG	cis	rs10489202	0.608	rs6659593	chr1:168072152	A/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.21	-0.43	3.3e-22	Schizophrenia;
LGG	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg11247378	chr22:39784982	NA	-0.31	-8.74	-0.38	4.32e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.52	-0.4	9.78e-20	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.55e-18	Menopause (age at onset);
LGG	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs988958	0.637	rs67710195	chr2:42219378	G/C	cg27428208	chr2:42229179	NA	0.57	9.9	0.42	4.34e-21	Hypospadias;
LGG	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.51e-24	Lung cancer in ever smokers;
LGG	cis	rs72949976	0.646	rs13029384	chr2:214029164	G/A	cg08319019	chr2:214017104	IKZF2	0.64	11.94	0.49	7.74e-29	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs6450176	0.625	rs11747281	chr5:53289047	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-13.59	-0.53	1.2e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg24250549	chr1:154909240	PMVK	0.76	15.69	0.59	8.26e-45	Prostate cancer;
LGG	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg26384229	chr12:38710491	ALG10B	0.74	14.78	0.57	9.18e-41	Bladder cancer;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-6.65	-0.3	8.42e-11	Schizophrenia;
LGG	cis	rs3008870	1.000	rs2985811	chr1:67377722	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.05	22.83	0.73	7.75e-78	Lymphocyte percentage of white cells;
LGG	cis	rs10276381	0.786	rs73089302	chr7:28187134	G/A	cg23620719	chr7:28220237	JAZF1	0.81	10.42	0.44	5.57e-23	Crohn's disease;
LGG	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	7.01e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg01028140	chr2:1542097	TPO	-0.47	-8.97	-0.38	7.58e-18	IgG glycosylation;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg04165120	chr20:443331	TBC1D20	-0.38	-7.05	-0.31	6.36e-12	Iris color (L* coordinate);
LGG	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg18105134	chr13:113819100	PROZ	0.69	14.35	0.55	6.88e-39	Platelet distribution width;
LGG	trans	rs6598955	0.627	rs3924324	chr1:26616280	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.42	-0.5	8.89e-31	Obesity-related traits;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.43	-0.33	5.46e-13	Skin colour saturation;
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs988958	0.565	rs6753173	chr2:42235975	C/T	cg27252766	chr2:42229092	NA	0.52	7.48	0.33	3.73e-13	Hypospadias;
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg10207240	chr12:122356781	WDR66	-0.26	-8.0	-0.35	1.01e-14	Mean corpuscular volume;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg11062466	chr8:58055876	NA	0.42	7.75	0.34	5.69e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06634786	chr22:41940651	POLR3H	0.77	12.32	0.5	2.22e-30	Vitiligo;
LGG	cis	rs7737355	0.947	rs6895841	chr5:130773534	A/G	cg06307176	chr5:131281290	NA	0.54	9.07	0.39	3.28e-18	Life satisfaction;
LGG	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg23815491	chr16:72088622	HP	0.35	7.34	0.32	9.9e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg06606381	chr12:133084897	FBRSL1	-1.13	-11.38	-0.47	1.29e-26	Intelligence (multi-trait analysis);
LGG	cis	rs503734	0.689	rs2317699	chr3:101137107	T/C	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35771425	1.000	rs35513231	chr1:211619503	T/C	cg10512769	chr1:211675356	NA	-0.73	-11.82	-0.48	2.24e-28	Educational attainment (years of education);
LGG	cis	rs12643440	0.538	rs970428	chr4:17136795	C/A	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.49	7.91	0.35	1.9e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg21100191	chr22:23484243	RTDR1	1.0	22.93	0.73	2.65e-78	Bone mineral density;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.7	-0.45	5.03e-24	Prostate cancer;
LGG	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg11366901	chr6:160182831	ACAT2	1.07	16.42	0.61	4.38e-48	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.32	-0.43	1.25e-22	IgG glycosylation;
LGG	cis	rs9398803	0.865	rs9388496	chr6:126785062	A/G	cg19875578	chr6:126661172	C6orf173	0.58	10.37	0.43	8.77e-23	Male-pattern baldness;
LGG	cis	rs7017914	0.934	rs56043721	chr8:71630427	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs9547996	0.879	rs9532090	chr13:38203891	A/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.91	-0.31	1.65e-11	Diastolic blood pressure;
LGG	cis	rs9916302	0.851	rs11078906	chr17:37662767	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07570687	chr10:102243282	WNT8B	0.42	7.48	0.33	3.71e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2235642	0.928	rs9932984	chr16:1605051	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	10.09	0.42	8.94e-22	Coronary artery disease;
LGG	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.22	0.43	3.01e-22	Motion sickness;
LGG	cis	rs858239	0.539	rs28716381	chr7:23189015	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.46e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs656319	0.513	rs34748716	chr8:9973718	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.34	-0.32	9.95e-13	Myopia (pathological);
LGG	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.98	-0.52	4.49e-33	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg18357526	chr6:26021779	HIST1H4A	0.57	9.91	0.42	3.88e-21	Blood metabolite levels;
LGG	trans	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg06521331	chr12:34319734	NA	0.46	8.29	0.36	1.28e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.01e-34	Prudent dietary pattern;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.07e-18	Bipolar disorder;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg16757992	chr13:69559194	NA	-0.37	-6.74	-0.3	4.65e-11	Iris color (L* coordinate);
LGG	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.27	0.46	3.26e-26	Schizophrenia;
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg27471124	chr11:109292789	C11orf87	0.56	10.28	0.43	1.81e-22	Schizophrenia;
LGG	cis	rs959260	0.588	rs7219	chr17:73315368	A/G	cg14668889	chr17:73230827	NUP85	0.53	9.1	0.39	2.66e-18	Systemic lupus erythematosus;
LGG	trans	rs6787172	0.702	rs1193521	chr3:157989300	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs516946	0.666	rs6986080	chr8:41488038	G/C	cg12439423	chr8:41522721	ANK1	0.42	7.55	0.33	2.32e-13	Type 2 diabetes;
LGG	cis	rs35417517	1	rs35417517	chr7:91772730	CG/C	cg17063962	chr7:91808500	NA	0.53	9.81	0.42	8.76e-21	Breast cancer;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9783347	1.000	rs4150550	chr11:18350898	C/G	cg15585147	chr11:18324498	HPS5	0.42	8.95	0.38	8.8e-18	Pancreatic cancer;
LGG	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg03806693	chr22:41940476	POLR3H	-0.81	-13.81	-0.54	1.38e-36	Vitiligo;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18299363	chr10:103816089	C10orf76	0.44	7.0	0.31	8.93e-12	Cognitive performance;
LGG	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg20891283	chr12:69753455	YEATS4	0.5	7.84	0.34	3.09e-14	Response to diuretic therapy;
LGG	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs1497828	0.956	rs2492872	chr1:217556242	C/A	cg04411442	chr1:217543379	NA	0.47	7.91	0.34	1.95e-14	Dialysis-related mortality;
LGG	trans	rs12517041	0.935	rs1428628	chr5:23311925	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.75	-0.48	4.27e-28	Calcium levels;
LGG	cis	rs3750082	0.852	rs6462425	chr7:32898595	C/A	cg08946731	chr7:32981826	RP9P	0.4	6.75	0.3	4.53e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg25801113	chr15:45476975	SHF	-0.87	-18.63	-0.65	3.11e-58	Uric acid levels;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.95	-0.38	8.84e-18	Lung cancer;
LGG	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-17.91	-0.64	6.95e-55	Brugada syndrome;
LGG	cis	rs68170813	0.559	rs59782202	chr7:107032766	G/T	cg02696742	chr7:106810147	HBP1	-0.69	-9.72	-0.41	1.86e-20	Coronary artery disease;
LGG	cis	rs9915657	0.715	rs9906100	chr17:70095365	C/T	cg09344028	chr17:70110421	NA	0.58	13.37	0.53	1.01e-34	Thyroid hormone levels;
LGG	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.34	-0.6	1.01e-47	Intelligence (multi-trait analysis);
LGG	cis	rs11966931	1.000	rs17528993	chr6:108114633	C/G	cg04749840	chr6:108095067	SCML4	0.43	7.16	0.32	3.15e-12	Neutrophil percentage of white cells;
LGG	cis	rs61352607	1.000	rs61352607	chr12:57839173	G/T	cg21878918	chr12:57634762	NDUFA4L2	0.34	6.71	0.3	5.8e-11	Triglycerides;
LGG	trans	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg23484912	chr5:273055	PDCD6	0.41	7.88	0.34	2.34e-14	Pancreatic cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18951187	chr15:72524237	PKM2	-0.46	-6.81	-0.3	3.03e-11	Systemic lupus erythematosus;
LGG	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.69	0.37	6.07e-17	Hypertriglyceridemia;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-7.91	-0.34	1.98e-14	Personality dimensions;
LGG	cis	rs9513627	1.000	rs7334844	chr13:100121047	G/C	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs8056893	0.550	rs11644360	chr16:68327089	C/T	cg07273125	chr16:68295692	NA	0.44	9.66	0.41	3.2e-20	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg16141378	chr3:129829833	LOC729375	0.32	7.17	0.32	3.08e-12	Myopia (pathological);
LGG	cis	rs4732038	0.565	rs10234988	chr7:134285608	T/G	cg06906464	chr7:134288099	NA	-0.72	-20.26	-0.69	8.51e-66	Longevity;
LGG	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.82e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.08e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg12070911	chr6:150209640	RAET1E	0.3	6.99	0.31	9.86e-12	Lung cancer;
LGG	cis	rs12908161	1.000	rs12903134	chr15:85337699	T/A	cg03959625	chr15:84868606	LOC388152	0.48	7.03	0.31	7.62e-12	Schizophrenia;
LGG	trans	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.56	-0.33	2.18e-13	Menarche (age at onset);
LGG	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg18089426	chr14:101175970	NA	0.68	11.33	0.47	1.9e-26	Plateletcrit;
LGG	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg01657329	chr11:68192670	LRP5	0.62	10.24	0.43	2.47e-22	Bone mineral density (spine);
LGG	cis	rs4363385	0.693	rs2339487	chr1:152983528	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-8.97	-0.38	7.54e-18	Inflammatory skin disease;
LGG	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.3	-0.4	5.79e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.52	-0.44	2.31e-23	Hepatocellular carcinoma;
LGG	cis	rs13343954	0.518	rs7252086	chr19:33534929	T/C	cg17764715	chr19:33622953	WDR88	0.52	9.27	0.4	6.87e-19	Colorectal cancer;
LGG	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs8064299	0.560	rs11077763	chr17:72786029	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.33	0.72	1.73e-75	Monocyte count;
LGG	cis	rs9314323	0.729	rs7007256	chr8:26203081	G/A	cg11498726	chr8:26250323	BNIP3L	-0.52	-10.63	-0.44	9.49e-24	Red cell distribution width;
LGG	cis	rs7432375	0.901	rs7616204	chr3:136444589	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.48	-0.37	3.04e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-8.51	-0.37	2.44e-16	Response to antipsychotic treatment;
LGG	cis	rs9309473	0.950	rs1052162	chr2:73829372	A/G	cg20560298	chr2:73613845	ALMS1	0.46	7.78	0.34	4.77e-14	Metabolite levels;
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg22433210	chr17:43662623	NA	0.91	15.11	0.57	3.24e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs858239	0.508	rs10242104	chr7:23220450	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.75	0.3	4.57e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg11789530	chr4:8429930	ACOX3	0.86	16.19	0.6	4.67e-47	Response to antineoplastic agents;
LGG	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg09127314	chr1:152161683	NA	0.45	7.31	0.32	1.16e-12	Inflammatory skin disease;
LGG	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg02002194	chr4:3960332	NA	-0.42	-8.02	-0.35	8.63e-15	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg19635926	chr16:89946313	TCF25	0.76	7.33	0.32	1.01e-12	Skin colour saturation;
LGG	cis	rs2066819	1.000	rs2066818	chr12:56753822	C/A	cg26714650	chr12:56694279	CS	-1.58	-15.14	-0.58	2.42e-42	Psoriasis vulgaris;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.14e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7246760	1.000	rs10412903	chr19:9880927	C/A	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs1975974	0.511	rs8078505	chr17:21755889	A/G	cg18423549	chr17:21743878	NA	-0.53	-8.12	-0.35	4.27e-15	Psoriasis;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg19773385	chr1:10388646	KIF1B	0.45	9.72	0.41	1.93e-20	Hepatocellular carcinoma;
LGG	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg11812906	chr14:75593930	NEK9	0.52	9.65	0.41	3.42e-20	Height;
LGG	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg23625390	chr15:77176239	SCAPER	-0.68	-13.14	-0.52	9.75e-34	Blood metabolite levels;
LGG	cis	rs921968	0.541	rs733925	chr2:219302466	G/A	cg01130898	chr2:219473002	PLCD4	0.43	7.38	0.32	7.24e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7143963	0.636	rs6575933	chr14:103346616	A/G	cg23020514	chr14:103360112	TRAF3	0.4	8.4	0.36	5.32e-16	Body mass index;
LGG	cis	rs782590	0.967	rs1823893	chr2:55788921	T/C	cg18811423	chr2:55921094	PNPT1	0.88	20.14	0.68	3.14e-65	Metabolic syndrome;
LGG	trans	rs4714291	0.925	rs847750	chr6:40074250	G/A	cg02267698	chr19:7991119	CTXN1	0.6	9.36	0.4	3.35e-19	Strep throat;
LGG	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.64	-0.33	1.3e-13	Triglycerides;
LGG	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg17809284	chr5:56205270	C5orf35	0.55	10.2	0.43	3.64e-22	Initial pursuit acceleration;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg02725872	chr8:58115012	NA	-0.84	-11.73	-0.48	5.55e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs62064224	0.589	rs9903650	chr17:30689370	T/A	cg25809561	chr17:30822961	MYO1D	0.37	8.76	0.38	3.63e-17	Schizophrenia;
LGG	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.67	0.37	7.11e-17	Neuroticism;
LGG	cis	rs968451	0.865	rs5757609	chr22:39707845	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	11.92	0.48	9.42e-29	Primary biliary cholangitis;
LGG	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg18898632	chr2:242989856	NA	-0.79	-9.8	-0.41	1.03e-20	Obesity-related traits;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg04117972	chr1:227635322	NA	0.83	13.2	0.52	5.37e-34	Major depressive disorder;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg23758822	chr17:41437982	NA	0.87	15.48	0.58	7.57e-44	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3764563	1.000	rs4646530	chr19:15735238	A/T	cg20725493	chr19:15740067	CYP4F8	0.64	8.38	0.36	6.18e-16	Inflammatory biomarkers;
LGG	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3106136	0.967	rs35670996	chr4:95199479	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.15	-0.35	3.52e-15	Capecitabine sensitivity;
LGG	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg24642844	chr7:1081250	C7orf50	-0.68	-8.9	-0.38	1.22e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs504918	0.556	rs73188197	chr3:124029897	A/G	cg05766129	chr3:123988013	KALRN	-0.58	-10.16	-0.43	4.8e-22	Schizophrenia;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.49	0.37	2.92e-16	Prudent dietary pattern;
LGG	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg03162506	chr22:38580953	NA	0.37	9.66	0.41	3.09e-20	Cutaneous nevi;
LGG	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg06917634	chr15:78832804	PSMA4	0.48	7.87	0.34	2.52e-14	Sudden cardiac arrest;
LGG	cis	rs17767392	0.871	rs35468256	chr14:71839524	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.02	-0.39	5.11e-18	Mitral valve prolapse;
LGG	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.15	-0.39	1.77e-18	Bone mineral density;
LGG	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg09307838	chr4:120376055	NA	0.82	13.76	0.54	2.4e-36	Corneal astigmatism;
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg01059449	chr18:44338099	ST8SIA5	0.36	7.88	0.34	2.36e-14	Personality dimensions;
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.43	0.47	8.38e-27	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20573919	chr11:8710810	RPL27A	0.46	6.74	0.3	4.64e-11	Gut microbiome composition (summer);
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11645453	chr3:52864694	ITIH4	0.4	6.67	0.3	7.13e-11	Bipolar disorder;
LGG	cis	rs35740288	0.770	rs62022909	chr15:86207481	A/G	cg04173714	chr15:86211321	AKAP13	0.48	8.76	0.38	3.65e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-8.95	-0.38	8.31e-18	Schizophrenia;
LGG	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.51	-0.37	2.46e-16	Neurofibrillary tangles;
LGG	cis	rs2070488	0.965	rs1065800	chr3:38566480	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.53	-0.63	3.95e-53	Electrocardiographic conduction measures;
LGG	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg03213289	chr20:61660250	NA	0.65	14.15	0.55	4.95e-38	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4538187	1.000	rs6710763	chr2:64068788	G/T	cg02541582	chr2:64069798	UGP2	0.58	13.7	0.54	4.21e-36	Systolic blood pressure;
LGG	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.69	0.34	9.08e-14	Cystic fibrosis severity;
LGG	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-10.84	-0.45	1.46e-24	Parkinson's disease;
LGG	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.13	-0.31	3.77e-12	Hemoglobin concentration;
LGG	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg08875078	chr22:50639485	SELO	0.47	6.96	0.31	1.14e-11	Late-onset Alzheimer's disease;
LGG	cis	rs113835537	0.529	rs4930183	chr11:66255732	C/T	cg24851651	chr11:66362959	CCS	0.43	7.59	0.33	1.75e-13	Airway imaging phenotypes;
LGG	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	6.91e-32	Coronary artery disease;
LGG	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg11757124	chr7:157526947	PTPRN2	-0.5	-9.21	-0.39	1.13e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-12.46	-0.5	6.31e-31	Schizophrenia;
LGG	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg20673091	chr1:2541236	MMEL1	-0.75	-18.1	-0.64	8.94e-56	Multiple sclerosis;
LGG	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.81	-0.38	2.55e-17	Mean corpuscular volume;
LGG	cis	rs7319311	0.589	rs952358	chr13:111026738	T/A	cg06243866	chr13:111019493	COL4A2	0.45	6.71	0.3	5.74e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22496380	chr5:211416	CCDC127	-1.07	-10.3	-0.43	1.61e-22	Breast cancer;
LGG	trans	rs75804782	0.625	rs61178898	chr2:239461810	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.97	0.35	1.25e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2072732	0.861	rs12048975	chr1:2962225	T/C	cg08733933	chr1:2954429	NA	-0.46	-8.87	-0.38	1.63e-17	Plateletcrit;
LGG	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.47	-0.4	1.43e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg27205649	chr11:78285834	NARS2	-0.52	-8.59	-0.37	1.39e-16	Alzheimer's disease (survival time);
LGG	cis	rs12980942	0.872	rs3816052	chr19:41773797	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.47	6.85	0.3	2.38e-11	Coronary artery disease;
LGG	cis	rs3087591	0.922	rs12950506	chr17:29598392	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.57	0.56	7.62e-40	Hip circumference;
LGG	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg20744362	chr22:50050164	C22orf34	0.41	7.13	0.31	3.84e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg02959939	chr21:47813025	PCNT	-0.31	-6.93	-0.31	1.44e-11	Lymphocyte counts;
LGG	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg23887609	chr12:130822674	PIWIL1	-0.54	-9.75	-0.41	1.51e-20	Menopause (age at onset);
LGG	cis	rs710216	0.879	rs710218	chr1:43427218	A/T	cg03128534	chr1:43423976	SLC2A1	0.44	7.22	0.32	2.21e-12	Red cell distribution width;
LGG	cis	rs7226408	0.857	rs9675466	chr18:34502792	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	8.91e-16	Personality dimensions;
LGG	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg15733309	chr7:157513707	PTPRN2	0.61	14.23	0.55	2.27e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg22535103	chr8:58192502	C8orf71	-0.84	-11.87	-0.48	1.45e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14373873	chr11:113211441	TTC12	0.56	12.35	0.5	1.75e-30	Neuroticism;
LGG	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg00700412	chr12:58011837	NA	0.38	7.46	0.33	4.3e-13	Multiple sclerosis;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.72	-0.38	4.89e-17	Lung cancer;
LGG	cis	rs9649465	0.935	rs1605285	chr7:123374412	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.97	-0.38	7.47e-18	Migraine;
LGG	cis	rs7551222	0.714	rs4951401	chr1:204537648	G/A	cg20240347	chr1:204465584	NA	-0.46	-8.12	-0.35	4.36e-15	Schizophrenia;
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg03036210	chr16:89904091	SPIRE2	-0.69	-8.12	-0.35	4.25e-15	Skin colour saturation;
LGG	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg09307838	chr4:120376055	NA	0.8	13.13	0.52	1.11e-33	Corneal astigmatism;
LGG	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg17376030	chr22:41985996	PMM1	0.5	8.09	0.35	5.42e-15	Vitiligo;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg02733842	chr7:1102375	C7orf50	0.42	7.4	0.33	6.56e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg06699216	chr8:19333253	CSGALNACT1	0.49	11.56	0.47	2.39e-27	Oropharynx cancer;
LGG	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg03605463	chr16:89740564	NA	0.62	11.31	0.47	2.32e-26	Vitiligo;
LGG	cis	rs911119	1.000	rs67567111	chr20:23619075	G/T	cg16589663	chr20:23618590	CST3	0.48	6.75	0.3	4.41e-11	Chronic kidney disease;
LGG	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Vitiligo;
LGG	cis	rs2273669	0.585	rs6900472	chr6:109372120	G/A	cg05315195	chr6:109294784	ARMC2	-0.61	-8.33	-0.36	9.13e-16	Prostate cancer;
LGG	trans	rs7819412	0.522	rs10101329	chr8:10990672	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.61	-0.33	1.6e-13	Triglycerides;
LGG	cis	rs4604732	0.588	rs7552461	chr1:247628644	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.14	0.39	1.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg04025307	chr7:1156635	C7orf50	0.77	11.15	0.46	9.63e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7512552	0.839	rs6662108	chr1:150420541	G/T	cg15654264	chr1:150340011	RPRD2	0.45	9.12	0.39	2.27e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg24375607	chr4:120327624	NA	0.59	9.66	0.41	3.17e-20	Corneal astigmatism;
LGG	cis	rs35740288	0.770	rs34048547	chr15:86181067	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.59	0.37	1.39e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg24450063	chr1:156163899	SLC25A44	-1.26	-32.54	-0.83	1.07e-121	Testicular germ cell tumor;
LGG	trans	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.43	-0.4	1.98e-19	Diabetic kidney disease;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg08297393	chr2:100937505	LONRF2	-0.54	-10.13	-0.43	6.31e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9596863	0.898	rs9563178	chr13:54373714	C/A	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2077654	0.822	rs12279699	chr11:17443348	G/A	cg25308976	chr11:17434268	ABCC8	0.77	7.49	0.33	3.48e-13	Gout;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	15.43	0.58	1.27e-43	Platelet count;
LGG	cis	rs701145	0.585	rs12493885	chr3:153839866	G/C	cg12800244	chr3:153838788	SGEF	0.82	8.9	0.38	1.25e-17	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg21782813	chr7:2030301	MAD1L1	0.53	13.79	0.54	1.73e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-8.52	-0.37	2.21e-16	Parkinson's disease;
LGG	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg27411982	chr8:10470053	RP1L1	-0.47	-8.03	-0.35	7.89e-15	Retinal vascular caliber;
LGG	cis	rs834603	0.965	rs834601	chr7:47445812	T/C	cg09696706	chr7:47479511	TNS3	0.31	6.68	0.3	6.79e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.15	-0.7	5.52e-70	Leprosy;
LGG	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.62	0.33	1.47e-13	Total cholesterol levels;
LGG	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg01346077	chr3:125931526	NA	0.54	13.44	0.53	5.49e-35	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg14191688	chr11:70257035	CTTN	0.55	7.94	0.35	1.52e-14	Coronary artery disease;
LGG	cis	rs4664308	0.740	rs877635	chr2:160902847	A/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.72	-0.48	5.77e-28	Idiopathic membranous nephropathy;
LGG	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg12042659	chr19:58951599	ZNF132	0.34	6.78	0.3	3.79e-11	Uric acid clearance;
LGG	cis	rs6997458	0.785	rs713488	chr8:86342216	T/C	cg02393479	chr8:86352350	CA3	-0.32	-7.13	-0.31	3.93e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs1461503	0.512	rs4293126	chr11:122804133	A/G	cg27398637	chr11:122830231	C11orf63	0.6	11.99	0.49	4.84e-29	Menarche (age at onset);
LGG	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg27490568	chr2:178487706	NA	0.47	9.02	0.39	5.05e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg06808227	chr14:105710500	BRF1	-0.64	-10.79	-0.45	2.33e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3806843	0.676	rs778594	chr5:140027304	T/C	cg19875535	chr5:140030758	IK	-0.59	-12.27	-0.5	3.73e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1519814	0.740	rs7845541	chr8:121044393	G/C	cg22335954	chr8:121166405	COL14A1	-0.49	-9.61	-0.41	4.55e-20	Breast cancer;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.02	-0.52	3.09e-33	Vitamin D levels;
LGG	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg17376030	chr22:41985996	PMM1	-0.57	-9.05	-0.39	4.06e-18	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.09	18.1	0.64	9.36e-56	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04064611	chr7:72298987	SBDSP;TYW1B	0.44	7.55	0.33	2.39e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.47	-7.72	-0.34	7.14e-14	Osteoporosis;
LGG	cis	rs6594499	0.872	rs10038177	chr5:110436450	C/T	cg04022379	chr5:110408740	TSLP	0.41	7.67	0.34	1.05e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg15704280	chr7:45808275	SEPT13	0.72	9.86	0.42	6e-21	Axial length;
LGG	cis	rs10193935	1.000	rs13421289	chr2:42412808	T/C	cg27598129	chr2:42591480	NA	-0.64	-9.4	-0.4	2.42e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2692947	0.800	rs61409777	chr2:96581373	C/A	cg22654517	chr2:96458247	NA	0.38	8.2	0.36	2.34e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg01918114	chr16:954222	LMF1	-0.45	-8.86	-0.38	1.67e-17	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.55	-0.33	2.35e-13	Testicular germ cell tumor;
LGG	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg26384229	chr12:38710491	ALG10B	0.77	13.92	0.54	4.94e-37	Resting heart rate;
LGG	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg19761014	chr17:28927070	LRRC37B2	0.67	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2070488	0.965	rs35553573	chr3:38441439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.53	0.63	3.84e-53	Electrocardiographic conduction measures;
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg13736514	chr6:26305472	NA	0.35	7.08	0.31	5.41e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs950169	0.580	rs2271431	chr15:85189464	A/C	cg24253500	chr15:84953950	NA	0.42	7.03	0.31	7.54e-12	Schizophrenia;
LGG	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg14541582	chr5:601475	NA	-0.54	-8.75	-0.38	4.14e-17	Obesity-related traits;
LGG	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs4474465	1.000	rs7121283	chr11:78149340	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.63	-0.37	1.02e-16	Alzheimer's disease (survival time);
LGG	cis	rs10267417	0.604	rs7785317	chr7:19853482	G/T	cg07541023	chr7:19748670	TWISTNB	-0.44	-6.68	-0.3	7.07e-11	Night sleep phenotypes;
LGG	cis	rs4604732	0.631	rs34443739	chr1:247626913	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.84	0.38	1.99e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg21724239	chr8:58056113	NA	0.45	6.69	0.3	6.37e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10147008	1	rs10147008	chr14:59990474	G/A	cg04329105	chr14:59932321	GPR135	0.32	7.03	0.31	7.42e-12	Tonsillectomy;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg11494091	chr17:61959527	GH2	1.03	25.26	0.76	3.73e-89	Prudent dietary pattern;
LGG	cis	rs6424115	0.545	rs11576333	chr1:24065770	C/T	cg15997130	chr1:24165203	NA	-0.4	-8.98	-0.39	6.65e-18	Immature fraction of reticulocytes;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg21548813	chr6:291882	DUSP22	-0.48	-8.36	-0.36	7.28e-16	Menopause (age at onset);
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs1371867	0.846	rs1660330	chr8:101305015	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.96	-0.38	7.99e-18	Bone mineral density;
LGG	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.55e-19	Colorectal cancer;
LGG	cis	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg18196295	chr10:418757	DIP2C	0.66	13.54	0.53	2.02e-35	Psychosis in Alzheimer's disease;
LGG	trans	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	6.91e-19	Diabetic kidney disease;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.72	0.45	4.32e-24	Obesity-related traits;
LGG	cis	rs4926611	0.698	rs10888795	chr1:54061446	A/G	cg23596471	chr1:54105337	GLIS1	0.39	8.22	0.36	2.02e-15	Hand grip strength;
LGG	cis	rs6807915	0.603	rs7632481	chr3:12293966	A/G	cg22839075	chr3:12045461	SYN2	-0.4	-6.82	-0.3	2.83e-11	Leprosy;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg21782813	chr7:2030301	MAD1L1	-0.47	-11.35	-0.47	1.68e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10743315	0.557	rs77194694	chr12:19354075	A/G	cg02471346	chr12:19282374	PLEKHA5	0.87	8.28	0.36	1.29e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg13550731	chr2:172543902	DYNC1I2	1.04	26.05	0.77	9.19e-93	Schizophrenia;
LGG	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.74	0.34	6.47e-14	Glycated hemoglobin levels;
LGG	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg15103426	chr22:29168792	CCDC117	0.58	8.82	0.38	2.33e-17	Lymphocyte counts;
LGG	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.24	0.36	1.85e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg25919922	chr13:100150906	NA	-0.77	-10.52	-0.44	2.3e-23	Obesity-related traits;
LGG	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg13514129	chr1:39547527	MACF1	0.7	12.72	0.51	5.43e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs7737355	0.812	rs3756289	chr5:130982194	A/G	cg06307176	chr5:131281290	NA	0.52	8.63	0.37	9.7e-17	Life satisfaction;
LGG	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.84	-0.3	2.5e-11	Daytime sleep phenotypes;
LGG	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	9.07	0.39	3.32e-18	Colorectal cancer;
LGG	cis	rs9486719	1.000	rs12529248	chr6:96895377	T/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs5742933	0.725	rs1132360	chr2:190526224	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-7.6	-0.33	1.65e-13	Ferritin levels;
LGG	cis	rs4788570	0.584	rs11075898	chr16:71705215	T/C	cg06353428	chr16:71660113	MARVELD3	1.27	21.65	0.71	2.64e-72	Intelligence (multi-trait analysis);
LGG	cis	rs17776563	0.593	rs17197715	chr15:89152462	T/C	cg05013243	chr15:89149849	MIR1179	-0.34	-7.0	-0.31	9.04e-12	Thyroid hormone levels;
LGG	cis	rs6429082	0.967	rs704709	chr1:235620964	C/T	cg26050004	chr1:235667680	B3GALNT2	0.48	7.94	0.35	1.49e-14	Adiposity;
LGG	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg09264619	chr17:80180166	NA	0.5	9.07	0.39	3.47e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9399137	0.529	rs7739722	chr6:135282225	T/C	cg22676075	chr6:135203613	NA	0.46	8.04	0.35	7.34e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs12615966	1.000	rs61013045	chr2:105370775	G/A	cg16465502	chr2:105461796	NA	0.88	10.44	0.44	4.82e-23	Pancreatic cancer;
LGG	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg09307838	chr4:120376055	NA	0.73	12.2	0.49	7.27e-30	Corneal astigmatism;
LGG	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg06640241	chr16:89574553	SPG7	0.68	11.16	0.46	9.13e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg25173405	chr17:45401733	C17orf57	0.48	8.41	0.36	5.1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg11062466	chr8:58055876	NA	0.59	9.26	0.4	7.68e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg26043149	chr18:55253948	FECH	0.42	6.9	0.31	1.67e-11	Bone mineral density;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7814319	0.838	rs951194	chr8:97230489	T/A	cg20787634	chr8:97240163	UQCRB	-0.7	-15.41	-0.58	1.57e-43	Lung function (FVC);
LGG	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg20240347	chr1:204465584	NA	-0.53	-10.56	-0.44	1.68e-23	Schizophrenia;
LGG	cis	rs4148883	0.504	rs4585310	chr4:100120233	T/C	cg13256891	chr4:100009986	ADH5	-0.37	-6.84	-0.3	2.49e-11	Alcohol dependence;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg20308403	chr7:2120281	MAD1L1	0.33	6.91	0.31	1.58e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg23782820	chr8:58130467	NA	0.54	7.5	0.33	3.21e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2997447	0.655	rs11247852	chr1:26383125	C/G	cg19633962	chr1:26362018	EXTL1	0.57	7.64	0.33	1.29e-13	QRS complex (12-leadsum);
LGG	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg26384229	chr12:38710491	ALG10B	1.08	29.83	0.81	7.56e-110	Heart rate;
LGG	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg00012203	chr2:219082015	ARPC2	0.84	17.14	0.62	2.32e-51	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg11301795	chr4:187892539	NA	-0.95	-24.97	-0.76	8.12e-88	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3799977	0.531	rs62436031	chr6:44722203	A/G	cg25276700	chr6:44698697	NA	0.4	8.01	0.35	9.48e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06028808	chr11:68637592	NA	0.69	12.03	0.49	3.25e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.76	13.8	0.54	1.56e-36	Chronic sinus infection;
LGG	cis	rs17376456	0.542	rs17083380	chr5:93170476	C/G	cg25358565	chr5:93447407	FAM172A	-0.64	-9.24	-0.39	8.9e-19	Diabetic retinopathy;
LGG	cis	rs9399135	0.967	rs2327578	chr6:135329969	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.91e-20	Red blood cell count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19832312	chr10:74855378	P4HA1	0.39	6.73	0.3	5.06e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg15145296	chr3:125709740	NA	-0.6	-7.7	-0.34	8.29e-14	Blood pressure (smoking interaction);
LGG	trans	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg25482853	chr8:67687455	SGK3	0.95	11.77	0.48	3.6e-28	Obesity-related traits;
LGG	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-8.38	-0.36	6.24e-16	Breast cancer;
LGG	cis	rs2629540	0.765	rs7097254	chr10:126512248	A/C	cg08799069	chr10:126477246	METTL10	-0.54	-12.1	-0.49	1.81e-29	Cocaine dependence;
LGG	cis	rs7617773	0.710	rs36064160	chr3:48243101	C/G	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	cis	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg07460842	chr6:66804631	NA	-0.98	-18.54	-0.65	8.87e-58	Exhaled nitric oxide output;
LGG	cis	rs10484885	0.793	rs9359862	chr6:90474508	A/G	cg13799429	chr6:90582589	CASP8AP2	0.86	13.4	0.53	7.83e-35	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg00933542	chr6:150070202	PCMT1	0.39	7.02	0.31	7.75e-12	Lung cancer;
LGG	cis	rs2708240	0.666	rs1861010	chr7:147601401	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-7.86	-0.34	2.76e-14	QT interval (drug interaction);
LGG	cis	rs67478160	0.619	rs1187416	chr14:104311465	A/G	cg26031613	chr14:104095156	KLC1	-0.41	-6.75	-0.3	4.47e-11	Schizophrenia;
LGG	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg05044414	chr3:183734942	ABCC5	0.57	11.42	0.47	8.55e-27	Anterior chamber depth;
LGG	cis	rs62244186	0.659	rs56234157	chr3:44516221	G/A	cg02073558	chr3:44770973	ZNF501	0.64	11.57	0.47	2.31e-27	Depressive symptoms;
LGG	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg10523679	chr1:76189770	ACADM	0.81	14.87	0.57	3.58e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2735413	0.781	rs11649473	chr16:78077238	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.5	6.73	0.3	5.02e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg19635926	chr16:89946313	TCF25	0.67	8.0	0.35	1.02e-14	Interleukin-17 levels;
LGG	cis	rs13260300	0.657	rs7834864	chr8:75487889	A/G	cg22993706	chr8:75542856	NA	0.38	7.11	0.31	4.39e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg27532560	chr4:187881888	NA	-0.6	-13.25	-0.52	3.32e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-7.89	-0.34	2.21e-14	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12220238	0.915	rs11001020	chr10:76139217	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.68	8.61	0.37	1.15e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg13628971	chr7:2884303	GNA12	0.56	11.92	0.48	9.31e-29	Height;
LGG	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg05084668	chr3:125655381	ALG1L	-0.56	-7.52	-0.33	2.86e-13	Blood pressure (smoking interaction);
LGG	cis	rs4774899	0.752	rs7175436	chr15:57418814	T/C	cg08128148	chr15:57256372	TCF12	0.28	6.81	0.3	2.98e-11	Urinary tract infection frequency;
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.0	0.39	5.81e-18	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg15017067	chr4:17643749	FAM184B	0.32	7.42	0.33	5.54e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.63	-11.87	-0.48	1.52e-28	Total body bone mineral density;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.66	11.91	0.48	9.84e-29	Obesity-related traits;
LGG	cis	rs7949566	0.607	rs4553380	chr11:126293037	C/T	cg05055844	chr11:126275997	ST3GAL4	0.34	6.88	0.3	1.91e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg11764359	chr7:65958608	NA	0.77	14.38	0.56	4.98e-39	Aortic root size;
LGG	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.02	-0.35	8.99e-15	Obesity;
LGG	cis	rs6430585	0.591	rs77096272	chr2:136663605	C/A	cg07169764	chr2:136633963	MCM6	1.22	22.34	0.72	1.46e-75	Corneal structure;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg11473876	chr11:109292803	C11orf87	0.47	9.12	0.39	2.36e-18	Schizophrenia;
LGG	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg15133208	chr4:90757351	SNCA	-0.32	-7.22	-0.32	2.1e-12	Dementia with Lewy bodies;
LGG	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg13385521	chr17:29058706	SUZ12P	0.9	10.18	0.43	4.36e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.96	14.36	0.56	6.23e-39	Schizophrenia;
LGG	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg04132472	chr17:19861366	AKAP10	0.26	7.17	0.32	3e-12	Schizophrenia;
LGG	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg17749961	chr2:30669863	LCLAT1	0.73	10.29	0.43	1.65e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg20453264	chr5:131705742	SLC22A5	0.65	8.27	0.36	1.46e-15	Rheumatoid arthritis;
LGG	cis	rs703842	1.000	rs2069502	chr12:58144665	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-7.95	-0.35	1.43e-14	Multiple sclerosis;
LGG	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.88	-0.42	5.23e-21	Aortic root size;
LGG	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs1182436	1	rs1182436	chr7:157027753	T/C	cg17757837	chr7:157058334	UBE3C	-0.56	-7.54	-0.33	2.45e-13	Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs9393025	chr6:8490618	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg19847130	chr8:10466454	RP1L1	0.34	7.54	0.33	2.46e-13	Neuroticism;
LGG	trans	rs1945213	0.694	rs12422168	chr11:55866840	A/G	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4979906	1.000	rs11813624	chr10:79453162	T/C	cg07817648	chr10:79422355	NA	-0.46	-7.17	-0.32	2.95e-12	Mortality in heart failure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22704520	chr2:200820451	C2orf60;C2orf47	0.5	8.56	0.37	1.64e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.04	0.52	2.64e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.59	7.01	0.31	8.68e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4664308	0.618	rs62175487	chr2:160892521	C/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.6	-0.47	1.73e-27	Idiopathic membranous nephropathy;
LGG	cis	rs4262150	0.810	rs4246033	chr5:152009417	T/C	cg12297329	chr5:152029980	NA	-0.79	-15.59	-0.59	2.27e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs1669338	0.588	rs73009149	chr3:3220473	G/C	cg16797762	chr3:3221439	CRBN	-0.97	-12.55	-0.5	2.73e-31	White matter integrity;
LGG	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.27e-12	Diabetic retinopathy;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.62e-13	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg02297831	chr4:17616191	MED28	0.52	9.89	0.42	4.58e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4771450	0.925	rs7320377	chr13:103984839	C/T	cg02987523	chr13:103978230	NA	-0.33	-7.02	-0.31	7.93e-12	Uric acid levels;
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.24	0.43	2.57e-22	Neuroticism;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg22963979	chr7:1858916	MAD1L1	0.44	8.72	0.38	5.1e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs12780845	0.505	rs10904893	chr10:17204944	T/C	cg01003015	chr10:17271136	VIM	-0.42	-6.96	-0.31	1.18e-11	Homocysteine levels;
LGG	cis	rs3816183	0.585	rs10865183	chr2:42882210	A/G	cg14631114	chr2:43023945	NA	0.34	6.74	0.3	4.78e-11	Hypospadias;
LGG	cis	rs3784262	0.669	rs3784259	chr15:58257847	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.17	-0.32	3.05e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs8060686	0.545	rs12600062	chr16:68287544	C/A	cg27539214	chr16:67997921	SLC12A4	-0.52	-7.5	-0.33	3.32e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg24375607	chr4:120327624	NA	-0.54	-9.15	-0.39	1.81e-18	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg22676075	chr6:135203613	NA	-0.46	-8.07	-0.35	6.14e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg12458913	chr13:53173898	NA	0.63	12.18	0.49	8.21e-30	Lewy body disease;
LGG	cis	rs9403521	1.000	rs7776119	chr6:144003643	A/G	cg18240653	chr6:144019428	PHACTR2	-0.58	-9.25	-0.4	8.13e-19	Obesity-related traits;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg19147804	chr7:1989927	MAD1L1	-0.45	-8.85	-0.38	1.85e-17	Schizophrenia;
LGG	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.48	-0.33	3.75e-13	Schizophrenia;
LGG	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg13334819	chr7:99746414	C7orf59	0.51	7.83	0.34	3.45e-14	Coronary artery disease;
LGG	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg03098644	chr7:100410630	EPHB4	0.5	7.42	0.33	5.62e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs9902453	0.740	rs2628189	chr17:28088813	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.24	-0.55	1.97e-38	Coffee consumption (cups per day);
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg13397359	chr6:42928475	GNMT	0.57	15.84	0.59	1.9e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.73	-0.3	5.06e-11	Total body bone mineral density;
LGG	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	2.8e-18	Motion sickness;
LGG	trans	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg16141378	chr3:129829833	LOC729375	-0.41	-9.49	-0.4	1.25e-19	Neuroticism;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.49e-22	Tonsillectomy;
LGG	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Vitiligo;
LGG	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg10847948	chr11:71163743	NADSYN1	0.57	8.74	0.38	4.19e-17	Vitamin D levels;
LGG	cis	rs2737618	0.722	rs2821330	chr1:200082464	C/T	cg21825944	chr1:200113062	NR5A2	0.57	11.18	0.46	7.22e-26	Uric acid levels;
LGG	cis	rs67478160	0.643	rs6575999	chr14:104250609	C/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.49e-13	Schizophrenia;
LGG	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg15823100	chr22:32027580	PISD	-0.81	-9.03	-0.39	4.62e-18	Age-related hearing impairment;
LGG	cis	rs9640161	0.750	rs1983440	chr7:150023941	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.77	-16.07	-0.6	1.77e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7932354	0.710	rs6485702	chr11:46898771	T/C	cg03339077	chr11:47165057	C11orf49	-0.45	-8.16	-0.35	3.21e-15	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg00784671	chr22:46762841	CELSR1	-0.64	-7.91	-0.34	1.97e-14	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9972944	0.651	rs12601958	chr17:63820304	A/G	cg07283582	chr17:63770753	CCDC46	-0.38	-6.91	-0.31	1.57e-11	Total body bone mineral density;
LGG	cis	rs7666738	0.830	rs1967979	chr4:98966201	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.88	-0.3	1.92e-11	Type 2 diabetes;
LGG	cis	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg15148918	chr7:75625777	STYXL1	-0.7	-7.84	-0.34	3.14e-14	Mononucleosis;
LGG	cis	rs72772090	0.908	rs76539796	chr5:96038675	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.44	-7.1	-0.31	4.77e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs35771425	1.000	rs34418448	chr1:211570581	A/G	cg10512769	chr1:211675356	NA	-0.74	-11.83	-0.48	2.19e-28	Educational attainment (years of education);
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.85	0.42	6.43e-21	Prudent dietary pattern;
LGG	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg09307838	chr4:120376055	NA	0.81	13.64	0.54	7.2e-36	Corneal astigmatism;
LGG	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg24450063	chr1:156163899	SLC25A44	1.18	26.37	0.77	3.11e-94	Testicular germ cell tumor;
LGG	cis	rs977987	0.742	rs12928898	chr16:75462081	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.86	0.42	6.22e-21	Dupuytren's disease;
LGG	cis	rs7216064	0.953	rs4791300	chr17:65930772	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.07	-0.39	3.45e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg27661571	chr11:113659931	NA	-0.47	-6.72	-0.3	5.2e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg19168338	chr16:4465731	CORO7	-0.77	-14.41	-0.56	3.66e-39	Schizophrenia;
LGG	cis	rs7572263	0.833	rs6710217	chr2:209050352	C/T	cg00164906	chr2:209055251	C2orf80	0.53	9.05	0.39	4.09e-18	Glioma;Non-glioblastoma glioma;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg17218041	chr13:113365319	ATP11A	-0.41	-6.76	-0.3	4.24e-11	Glycated hemoglobin levels;
LGG	cis	rs9916302	0.808	rs12947281	chr17:37652210	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.16e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00166722	chr3:10149974	C3orf24	0.51	8.7	0.37	5.93e-17	Alzheimer's disease;
LGG	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.07	-0.35	6.06e-15	Neuroticism;
LGG	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.04	0.52	2.52e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7666738	0.830	rs13147768	chr4:98833675	A/T	cg05340658	chr4:99064831	C4orf37	0.47	7.72	0.34	7.28e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg16980736	chr17:78789706	RPTOR	-0.7	-9.25	-0.4	8.18e-19	Myopia (pathological);
LGG	cis	rs3741151	1.000	rs74795285	chr11:73033387	A/G	cg17517138	chr11:73019481	ARHGEF17	1.05	10.56	0.44	1.61e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg14210321	chr2:106509881	NCK2	-0.49	-8.39	-0.36	6e-16	Addiction;
LGG	cis	rs1497406	0.744	rs12562207	chr1:16508059	G/A	cg20430773	chr1:16534157	ARHGEF19	0.28	8.04	0.35	7.79e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.1	0.31	4.88e-12	Schizophrenia;
LGG	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg24060327	chr5:131705240	SLC22A5	0.49	8.52	0.37	2.22e-16	Blood metabolite levels;
LGG	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg10847948	chr11:71163743	NADSYN1	-0.66	-12.85	-0.51	1.55e-32	Vitamin D levels;
LGG	cis	rs11644362	1.000	rs976243	chr16:12991679	A/T	cg06890432	chr16:12997467	SHISA9	-0.31	-6.84	-0.3	2.56e-11	Positive affect;Subjective well-being;
LGG	cis	rs1978968	0.731	rs9605469	chr22:18461231	T/C	cg03078520	chr22:18463400	MICAL3	-0.68	-14.66	-0.56	3.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg19717773	chr7:2847554	GNA12	-0.44	-10.38	-0.43	8.09e-23	Height;
LGG	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs283228	0.917	rs979173	chr6:101829558	C/T	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs2282802	0.685	rs6580515	chr5:139698110	A/C	cg26211634	chr5:139558579	C5orf32	-0.34	-7.44	-0.33	5.01e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg23625390	chr15:77176239	SCAPER	0.41	7.69	0.34	8.66e-14	Blood metabolite levels;
LGG	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg00701064	chr4:6280414	WFS1	0.77	17.5	0.63	5.38e-53	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.65e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs477692	0.569	rs10764886	chr10:131310680	C/T	cg05714579	chr10:131428358	MGMT	0.51	10.11	0.43	7.6e-22	Response to temozolomide;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs8002861	0.664	rs1808097	chr13:44424766	A/G	cg17145862	chr1:211918768	LPGAT1	0.79	17.19	0.62	1.35e-51	Leprosy;
LGG	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg16230307	chr14:35515116	FAM177A1	0.91	13.22	0.52	4.41e-34	Psoriasis;
LGG	cis	rs7336332	0.517	rs9581842	chr13:27978953	G/C	cg01674679	chr13:27998804	GTF3A	-0.69	-8.81	-0.38	2.46e-17	Weight;
LGG	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-17.61	-0.63	1.71e-53	Sudden cardiac arrest;
LGG	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg23625390	chr15:77176239	SCAPER	-0.71	-14.06	-0.55	1.17e-37	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg05692746	chr2:100937584	LONRF2	-0.57	-9.39	-0.4	2.73e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg18252515	chr7:66147081	NA	1.32	18.83	0.66	3.84e-59	Diabetic kidney disease;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg08677398	chr8:58056175	NA	0.44	7.35	0.32	9.16e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs16973500	0.764	rs16973477	chr16:71887381	A/G	cg09427745	chr16:71932006	KIAA0174	-0.45	-6.81	-0.3	3.07e-11	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs17767392	1.000	rs61991204	chr14:71768073	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg20290983	chr6:43655470	MRPS18A	-0.86	-12.43	-0.5	8.51e-31	IgG glycosylation;
LGG	cis	rs2249625	0.545	rs10498880	chr6:72882183	G/T	cg27608224	chr6:72922399	RIMS1	-0.33	-7.39	-0.32	6.75e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg08742575	chr21:47604166	C21orf56	0.49	8.85	0.38	1.85e-17	Testicular germ cell tumor;
LGG	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg11812906	chr14:75593930	NEK9	-0.5	-9.46	-0.4	1.59e-19	Height;
LGG	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.75	-0.3	4.36e-11	Schizophrenia;
LGG	cis	rs2933343	0.621	rs728838	chr3:128589013	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.7	0.3	6.15e-11	IgG glycosylation;
LGG	cis	rs503734	0.935	rs9870114	chr3:100970240	A/G	cg27318481	chr3:100970896	IMPG2	-0.37	-7.93	-0.35	1.6e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14829155	chr15:31115871	NA	-0.59	-10.04	-0.42	1.41e-21	Huntington's disease progression;
LGG	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg03806693	chr22:41940476	POLR3H	-1.03	-17.39	-0.63	1.66e-52	Vitiligo;
LGG	cis	rs61931739	0.649	rs864173	chr12:33721422	A/C	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	trans	rs208520	0.661	rs207099	chr6:66796373	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.3	-0.65	1.07e-56	Exhaled nitric oxide output;
LGG	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg17376030	chr22:41985996	PMM1	-0.55	-8.9	-0.38	1.26e-17	Vitiligo;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg08302650	chr8:145750040	LRRC24;LRRC14	0.4	8.44	0.37	4.19e-16	Age at first birth;
LGG	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg21995068	chr20:25989032	LOC100134868	-0.41	-8.13	-0.35	3.84e-15	Colorectal or endometrial cancer;
LGG	cis	rs60180747	1.000	rs11637556	chr15:66728951	A/C	cg07575407	chr15:66541975	MEGF11	0.35	6.91	0.31	1.65e-11	Testicular germ cell tumor;
LGG	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg25706552	chr1:244017396	NA	0.52	8.34	0.36	8.78e-16	RR interval (heart rate);
LGG	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.24	-0.36	1.74e-15	Intelligence (multi-trait analysis);
LGG	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg24253500	chr15:84953950	NA	0.61	11.39	0.47	1.13e-26	Schizophrenia;
LGG	cis	rs308971	0.563	rs307560	chr3:12093405	A/G	cg15873301	chr3:12045459	SYN2	0.54	7.05	0.31	6.35e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg18258770	chr4:90757814	SNCA	0.37	6.77	0.3	4.02e-11	Dementia with Lewy bodies;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.56e-19	Diabetic retinopathy;
LGG	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg16473166	chr22:50639996	SELO	-0.59	-9.98	-0.42	2.26e-21	Obesity-related traits;
LGG	cis	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg05623727	chr3:50126028	RBM5	-0.4	-8.77	-0.38	3.51e-17	Body mass index;
LGG	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg02297831	chr4:17616191	MED28	0.42	7.78	0.34	4.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg08344181	chr3:125677491	NA	-0.7	-7.35	-0.32	8.82e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg13565492	chr6:43139072	SRF	-0.68	-8.54	-0.37	1.95e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg00732059	chr16:71740210	PHLPP2	-0.6	-9.81	-0.41	8.9e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg16586182	chr3:47516702	SCAP	-0.78	-14.52	-0.56	1.24e-39	Colorectal cancer;
LGG	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg15103426	chr22:29168792	CCDC117	0.72	11.58	0.47	2.09e-27	Lymphocyte counts;
LGG	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-6.75	-0.3	4.39e-11	Ulcerative colitis;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.8	-10.4	-0.44	6.58e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.65e-12	Prudent dietary pattern;
LGG	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg13010199	chr12:38710504	ALG10B	0.4	7.08	0.31	5.32e-12	Morning vs. evening chronotype;
LGG	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.55	-0.33	2.36e-13	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00166722	chr3:10149974	C3orf24	0.57	8.19	0.36	2.48e-15	Alzheimer's disease;
LGG	cis	rs7572733	0.935	rs771015	chr2:198668294	G/A	cg00792783	chr2:198669748	PLCL1	0.48	8.21	0.36	2.27e-15	Dermatomyositis;
LGG	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg11366901	chr6:160182831	ACAT2	1.07	17.28	0.63	5.56e-52	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.36e-17	Mean corpuscular volume;
LGG	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.06	-0.35	6.73e-15	Triglycerides;
LGG	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg06028605	chr16:24865363	SLC5A11	0.48	7.87	0.34	2.46e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22566565	chr10:131909018	NA	0.55	8.35	0.36	7.88e-16	Gut microbiome composition (summer);
LGG	cis	rs975739	1.000	rs1279397	chr13:78378687	A/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.75	0.3	4.51e-11	Hair color;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.13	0.52	1.09e-33	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19884546	chr22:38082237	NOL12	0.4	6.88	0.3	1.9e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.21	-0.32	2.29e-12	Neuroticism;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs6714710	0.603	rs11679828	chr2:98517626	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.95	0.42	2.82e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16680214	chr1:154839983	KCNN3	0.49	9.69	0.41	2.38e-20	Prostate cancer;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.94	-0.42	3.01e-21	Lung cancer;
LGG	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs7463659	0.512	rs6992045	chr8:135448749	T/C	cg09855544	chr8:135498122	ZFAT	-0.38	-6.67	-0.3	7.33e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg08270023	chr12:132619174	NA	-0.43	-7.14	-0.32	3.54e-12	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg14582100	chr15:45693742	SPATA5L1	0.42	7.15	0.32	3.49e-12	Homoarginine levels;
LGG	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg10818794	chr15:86012489	AKAP13	-0.37	-7.65	-0.33	1.21e-13	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.37	0.5	1.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2239547	0.563	rs4302374	chr3:52905802	T/C	cg11645453	chr3:52864694	ITIH4	0.71	11.0	0.46	3.82e-25	Schizophrenia;
LGG	cis	rs3767633	0.925	rs6427639	chr1:161866372	C/A	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs6942756	0.915	rs6946938	chr7:129004662	A/C	cg02491457	chr7:128862824	NA	-0.66	-12.01	-0.49	4.26e-29	White matter hyperintensity burden;
LGG	cis	rs72781680	0.848	rs56371415	chr2:23932603	C/G	cg08917208	chr2:24149416	ATAD2B	0.85	9.15	0.39	1.84e-18	Lymphocyte counts;
LGG	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.4	6.66	0.3	7.76e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.93	0.31	1.38e-11	Schizophrenia;
LGG	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg23845249	chr11:68861649	NA	0.45	8.2	0.36	2.42e-15	Blond vs. brown hair color;
LGG	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg22676075	chr6:135203613	NA	-0.59	-11.27	-0.46	3.35e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs963731	0.649	rs2123879	chr2:39292598	A/G	cg04010122	chr2:39346883	SOS1	-0.86	-6.81	-0.3	3.03e-11	Corticobasal degeneration;
LGG	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg12437481	chr16:420112	MRPL28	-0.54	-8.48	-0.37	2.99e-16	Body mass index;
LGG	trans	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs9814567	0.806	rs4519744	chr3:134321523	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8027181	0.617	rs11072389	chr15:73088483	C/T	cg02923145	chr15:73089643	NA	-0.45	-8.75	-0.38	4.09e-17	Triglyceride levels;
LGG	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg24375607	chr4:120327624	NA	0.64	10.48	0.44	3.32e-23	Corneal astigmatism;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.97	-0.31	1.12e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg00846425	chr4:957561	DGKQ	0.43	6.74	0.3	4.66e-11	Type 2 diabetes;
LGG	trans	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg06521331	chr12:34319734	NA	-0.42	-7.56	-0.33	2.17e-13	Heart rate;
LGG	cis	rs7555523	0.832	rs7524755	chr1:165694897	A/G	cg24409356	chr1:165738333	TMCO1	0.68	8.45	0.37	3.89e-16	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg24375607	chr4:120327624	NA	0.68	11.34	0.47	1.75e-26	Corneal astigmatism;
LGG	cis	rs9388451	0.626	rs1343115	chr6:126069817	C/G	cg05901451	chr6:126070800	HEY2	-0.68	-12.91	-0.51	9.16e-33	Brugada syndrome;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg18402987	chr7:1209562	NA	0.52	7.54	0.33	2.5e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9788721	0.775	rs8040868	chr15:78911181	C/T	cg16751781	chr15:78858589	CHRNA5	0.35	6.71	0.3	5.58e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	cis	rs6489882	0.836	rs12322160	chr12:113368505	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.6	-0.33	1.64e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs847851	0.958	rs847850	chr6:34904968	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-6.69	-0.3	6.53e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7512552	0.698	rs12028001	chr1:150407820	C/T	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	9.9e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8114671	0.586	rs734111	chr20:33533736	A/C	cg24642439	chr20:33292090	TP53INP2	0.46	7.2	0.32	2.51e-12	Height;
LGG	cis	rs11191205	0.686	rs10883671	chr10:103413862	G/T	cg15320455	chr10:103880129	LDB1	0.53	7.79	0.34	4.54e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9863	0.828	rs7311969	chr12:124470333	C/T	cg13487667	chr12:124434373	CCDC92	0.34	6.79	0.3	3.39e-11	White blood cell count;
LGG	cis	rs4926611	0.729	rs3013754	chr1:54061978	A/C	cg23596471	chr1:54105337	GLIS1	-0.39	-8.23	-0.36	1.9e-15	Hand grip strength;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg02725872	chr8:58115012	NA	-0.84	-12.02	-0.49	3.74e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg24006582	chr15:45444508	DUOX1	0.68	12.65	0.51	9.92e-32	Uric acid levels;
LGG	cis	rs367615	0.661	rs9326773	chr5:108833523	C/T	cg17395555	chr5:108820864	NA	0.88	15.99	0.6	3.69e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg07615347	chr10:60278583	BICC1	0.63	18.19	0.65	3.39e-56	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00261534	chr10:3826854	KLF6	0.51	8.29	0.36	1.19e-15	Gut microbiome composition (summer);
LGG	trans	rs9944715	1.000	rs4890634	chr18:43854259	C/T	cg01718231	chr17:29326311	RNF135	-0.42	-6.72	-0.3	5.3e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg15320075	chr8:145703422	NA	-0.72	-14.18	-0.55	3.75e-38	Age at first birth;
LGG	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg02002194	chr4:3960332	NA	-0.43	-8.12	-0.35	4.15e-15	Mood instability;
LGG	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg12310025	chr6:25882481	NA	-0.62	-11.5	-0.47	4.23e-27	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.543	rs58778964	chr2:99110599	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03797768	chr13:24040813	NA	0.44	7.14	0.31	3.71e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00149659	chr3:10157352	C3orf10	1.2	14.09	0.55	8.88e-38	Alzheimer's disease;
LGG	cis	rs10504073	0.647	rs1511359	chr8:50006448	T/A	cg00325661	chr8:49890786	NA	0.74	14.34	0.55	7.46e-39	Blood metabolite ratios;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg08125733	chr17:73851984	WBP2	0.96	15.69	0.59	8.84e-45	Psoriasis;
LGG	cis	rs9596863	1.000	rs9596860	chr13:54431215	G/A	ch.13.53330881F	chr13:54432880	NA	0.51	6.98	0.31	1.03e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs35771425	0.600	rs34256746	chr1:211445464	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.36	-0.36	7.43e-16	Educational attainment (years of education);
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg27400746	chr16:89904261	SPIRE2	-0.88	-15.06	-0.57	5.09e-42	Interleukin-17 levels;
LGG	cis	rs1707322	0.963	rs34907901	chr1:46405214	T/G	cg03146154	chr1:46216737	IPP	0.55	10.41	0.44	6.06e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-9.92	-0.42	3.62e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.58	-9.44	-0.4	1.83e-19	Blood metabolite levels;
LGG	cis	rs10186029	0.676	rs10497991	chr2:213968775	G/A	cg08319019	chr2:214017104	IKZF2	0.47	8.28	0.36	1.29e-15	Systemic sclerosis;
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.38	0.43	8.09e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg21153622	chr11:89784906	NA	-0.39	-6.68	-0.3	6.84e-11	HDL cholesterol;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg07511668	chr11:68622177	NA	0.51	9.46	0.4	1.56e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg02886208	chr11:14281011	SPON1	-0.36	-6.86	-0.3	2.15e-11	Sense of smell;
LGG	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-18.51	-0.65	1.19e-57	Coronary artery disease;
LGG	cis	rs12477438	0.501	rs7589365	chr2:99990324	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.72	-0.3	5.31e-11	Chronic sinus infection;
LGG	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg00343986	chr7:65444356	GUSB	-0.48	-8.31	-0.36	1.09e-15	Aortic root size;
LGG	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.27	0.32	1.57e-12	Birth weight;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00933542	chr6:150070202	PCMT1	0.4	7.14	0.32	3.58e-12	Lung cancer;
LGG	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg03213289	chr20:61660250	NA	0.67	14.61	0.56	4.99e-40	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7843479	1.000	rs2306641	chr8:21833965	A/G	cg17168535	chr8:21777572	XPO7	-0.61	-9.99	-0.42	2.07e-21	Mean corpuscular volume;
LGG	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg20240347	chr1:204465584	NA	-0.54	-10.86	-0.45	1.27e-24	Schizophrenia;
LGG	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.37	0.36	6.76e-16	Mood instability;
LGG	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.81	-0.59	2.5e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.02	0.52	3e-33	Tonsillectomy;
LGG	cis	rs990171	1.000	rs2058660	chr2:103054449	G/A	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg18279126	chr7:2041391	MAD1L1	-0.31	-6.66	-0.3	7.7e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg00701064	chr4:6280414	WFS1	0.77	17.8	0.64	2.13e-54	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4689388	0.609	rs4688988	chr4:6287456	C/T	cg14416269	chr4:6271139	WFS1	0.45	7.33	0.32	1.01e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21963583	chr11:68658836	MRPL21	0.59	10.19	0.43	3.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11608355	0.515	rs11611012	chr12:109945203	G/A	cg05360138	chr12:110035743	NA	0.83	11.15	0.46	1.01e-25	Neuroticism;
LGG	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg01620082	chr3:125678407	NA	-0.58	-7.33	-0.32	1.01e-12	Depression;
LGG	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg23188684	chr11:67383651	NA	-0.42	-6.83	-0.3	2.6e-11	Mean corpuscular volume;
LGG	trans	rs801193	0.613	rs2016325	chr7:66323500	T/C	cg18876405	chr7:65276391	NA	-0.48	-7.82	-0.34	3.7e-14	Aortic root size;
LGG	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Body mass index;
LGG	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.35	0.6	9.24e-48	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	10.42	0.44	5.35e-23	Obesity-related traits;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg22105103	chr4:187893119	NA	0.57	10.92	0.45	7.1e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs653465	0.739	rs1402975	chr3:27125652	A/G	cg02860705	chr3:27208620	NA	0.39	7.53	0.33	2.75e-13	Breast cancer (early onset);
LGG	cis	rs9636252	0.564	rs6722542	chr2:9274636	A/G	cg20341998	chr2:9276514	NA	0.39	7.14	0.32	3.55e-12	IgG glycosylation;
LGG	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.05	-0.49	2.87e-29	Hemoglobin concentration;
LGG	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg11766577	chr21:47581405	C21orf56	-0.56	-10.36	-0.43	9.29e-23	Testicular germ cell tumor;
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg16301924	chr13:53314226	LECT1	0.41	8.4	0.36	5.72e-16	Lewy body disease;
LGG	cis	rs10504073	0.584	rs11784268	chr8:49956339	T/G	cg00325661	chr8:49890786	NA	0.78	15.33	0.58	3.37e-43	Blood metabolite ratios;
LGG	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg25457927	chr22:38595422	NA	0.43	11.15	0.46	9.49e-26	Cutaneous nevi;
LGG	cis	rs2133450	0.712	rs9990013	chr3:7366352	A/C	cg19930620	chr3:7340148	GRM7	0.37	7.93	0.35	1.65e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs7149337	0.805	rs2999354	chr14:51607179	C/G	cg23942311	chr14:51606299	NA	0.32	7.09	0.31	5.16e-12	Cancer;
LGG	cis	rs1256061	0.603	rs3020445	chr14:64788644	A/G	cg23250157	chr14:64679961	SYNE2	0.37	6.68	0.3	7.01e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.5	0.37	2.58e-16	Aortic root size;
LGG	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg22916017	chr11:64110731	CCDC88B	0.47	9.56	0.41	7.22e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02704927	chr5:65440543	SFRS12	0.44	7.02	0.31	7.77e-12	Cognitive performance;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.41	0.44	6.27e-23	Prudent dietary pattern;
LGG	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg26597838	chr10:835615	NA	0.76	10.48	0.44	3.46e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs12220238	0.915	rs11000987	chr10:76073265	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.88	0.38	1.44e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg08645402	chr16:4508243	NA	0.44	7.94	0.35	1.51e-14	Schizophrenia;
LGG	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg19441908	chr8:41529140	ANK1	-0.42	-7.41	-0.33	5.92e-13	Type 2 diabetes;
LGG	cis	rs9828933	0.752	rs73117082	chr3:63947565	A/G	cg17941049	chr3:63904683	ATXN7	0.7	7.65	0.34	1.14e-13	Type 2 diabetes;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.96	0.7	4.16e-69	Platelet count;
LGG	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg07636037	chr3:49044803	WDR6	0.9	16.44	0.61	3.49e-48	Menarche (age at onset);
LGG	cis	rs2075371	0.932	rs2241333	chr7:133970750	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.3	0.58	4.62e-43	Mean platelet volume;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.08	0.55	9.76e-38	Tonsillectomy;
LGG	cis	rs4666002	0.957	rs1919128	chr2:27801759	A/G	cg27432699	chr2:27873401	GPN1	0.46	6.86	0.3	2.28e-11	Phospholipid levels (plasma);
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg16270222	chr17:41446396	NA	-0.3	-7.21	-0.32	2.26e-12	Menopause (age at onset);
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg02002194	chr4:3960332	NA	0.42	7.44	0.33	4.95e-13	Neuroticism;
LGG	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg25356066	chr3:128598488	ACAD9	0.44	6.74	0.3	4.69e-11	IgG glycosylation;
LGG	cis	rs10237118	0.915	rs6952208	chr7:140226038	C/G	cg09787580	chr7:140227335	DENND2A	0.67	8.3	0.36	1.15e-15	Optic nerve measurement (cup area);
LGG	cis	rs240764	0.817	rs240147	chr6:101078300	G/A	cg09795085	chr6:101329169	ASCC3	0.47	7.89	0.34	2.19e-14	Neuroticism;
LGG	trans	rs941408	0.515	rs1005556	chr19:2778543	G/T	cg19676328	chr12:49525230	TUBA1B	-0.59	-8.82	-0.38	2.27e-17	Total cholesterol levels;
LGG	cis	rs2033732	0.642	rs1370417	chr8:85056283	A/G	cg05716166	chr8:85095498	RALYL	0.42	6.67	0.3	7.3e-11	Body mass index;
LGG	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.1	0.35	4.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12493885	0.818	rs1521324	chr3:153758863	G/T	cg12800244	chr3:153838788	SGEF	-0.82	-8.95	-0.38	8.88e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs240764	0.725	rs11155477	chr6:100935505	T/A	cg21058520	chr6:100914733	NA	0.53	9.26	0.4	7.49e-19	Neuroticism;
LGG	cis	rs16866061	1.000	rs1568750	chr2:225342597	A/T	cg12698349	chr2:225449008	CUL3	0.92	19.16	0.67	1.09e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	trans	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19282742	chr16:31469983	ARMC5	0.46	7.49	0.33	3.43e-13	Cognitive performance;
LGG	trans	rs7615952	0.932	rs1976458	chr3:125647512	T/G	cg07211511	chr3:129823064	LOC729375	-1.37	-21.22	-0.7	2.68e-70	Blood pressure (smoking interaction);
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg16110940	chr22:21400158	LOC400891	0.41	6.71	0.3	5.71e-11	Lung cancer in ever smokers;
LGG	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg25427524	chr10:38739819	LOC399744	0.46	8.78	0.38	3.23e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg22705602	chr4:152727874	NA	-0.32	-7.86	-0.34	2.67e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.966	rs2261784	chr20:25262396	G/C	cg06421707	chr20:25228305	PYGB	0.47	10.05	0.42	1.26e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg26441486	chr22:50317300	CRELD2	0.4	7.35	0.32	9.11e-13	Schizophrenia;
LGG	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15557168	chr22:42548783	NA	-0.35	-7.84	-0.34	3.08e-14	Cognitive function;
LGG	cis	rs698833	0.962	rs698830	chr2:44730863	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	7.42	0.33	5.73e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg25706552	chr1:244017396	NA	0.53	8.58	0.37	1.47e-16	RR interval (heart rate);
LGG	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.32e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.48	0.56	1.81e-39	Lung cancer;
LGG	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.23	-0.32	2e-12	Blood metabolite levels;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg25811766	chr13:21894605	NA	0.81	16.37	0.61	7.69e-48	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.75	15.4	0.58	1.68e-43	Lymphocyte percentage of white cells;
LGG	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.35	0.36	7.81e-16	Educational attainment;
LGG	cis	rs9534288	0.659	rs2146883	chr13:46660576	C/A	cg15192986	chr13:46630673	CPB2	-0.7	-14.37	-0.56	5.71e-39	Blood protein levels;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-12.94	-0.52	6.86e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1719271	0.908	rs61009920	chr15:65181280	C/A	cg11671771	chr15:65133392	PLEKHO2	-0.53	-7.2	-0.32	2.49e-12	Platelet count;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.1	0.84	4.08e-124	Prudent dietary pattern;
LGG	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg06115741	chr20:33292138	TP53INP2	0.58	9.79	0.41	1.07e-20	Coronary artery disease;
LGG	trans	rs61332075	0.518	rs72993031	chr2:239380028	A/G	cg01134436	chr17:81009848	B3GNTL1	0.82	8.84	0.38	1.94e-17	Lung function (FEV1/FVC);
LGG	cis	rs611744	0.573	rs674580	chr8:109251690	C/G	cg21045802	chr8:109455806	TTC35	0.53	10.06	0.42	1.16e-21	Dupuytren's disease;
LGG	cis	rs12681287	0.547	rs66808088	chr8:87521212	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.1e-13	Caudate activity during reward;
LGG	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg25208724	chr1:156163844	SLC25A44	1.09	22.86	0.73	5.69e-78	Testicular germ cell tumor;
LGG	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg04673462	chr1:38461896	NA	-0.45	-7.73	-0.34	6.95e-14	Coronary artery disease;
LGG	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg07936489	chr17:37558343	FBXL20	1.0	15.52	0.59	4.73e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs11239187	0.927	rs7097377	chr10:45108658	G/A	cg03916630	chr10:45065415	NA	0.34	7.56	0.33	2.24e-13	Body mass index;
LGG	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg13385521	chr17:29058706	SUZ12P	0.93	10.83	0.45	1.6e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs4944092	0.855	rs608747	chr11:75916477	A/G	cg04588336	chr11:75916460	WNT11	-0.42	-9.72	-0.41	1.85e-20	PR interval;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg14926445	chr8:58193284	C8orf71	-0.84	-10.11	-0.43	7.57e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs1813642	chr4:98852225	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.27	0.36	1.43e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg05861140	chr6:150128134	PCMT1	-0.39	-8.84	-0.38	2.07e-17	Lung cancer;
LGG	cis	rs6993813	0.786	rs1872423	chr8:120048320	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.82	0.3	2.94e-11	Bone mineral density (hip);
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.78	0.3	3.59e-11	Schizophrenia;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg26354017	chr1:205819088	PM20D1	0.85	20.45	0.69	1.01e-66	Menarche (age at onset);
LGG	cis	rs755249	0.510	rs582883	chr1:39835540	T/C	cg18385671	chr1:39797026	MACF1	0.48	9.93	0.42	3.5e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg15046935	chr19:45595006	NA	0.41	7.06	0.31	6.05e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	cis	rs68170813	0.559	rs1548524	chr7:106944563	G/T	cg02696742	chr7:106810147	HBP1	0.74	10.7	0.45	5.21e-24	Coronary artery disease;
LGG	cis	rs2463822	1.000	rs2463821	chr11:62111662	T/C	cg06239285	chr11:62104954	ASRGL1	1.16	15.71	0.59	7.19e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs1997103	1.000	rs2177802	chr7:55410789	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs1957429	0.808	rs4902327	chr14:65344803	C/T	cg23373153	chr14:65346875	NA	0.95	11.9	0.48	1.14e-28	Pediatric areal bone mineral density (radius);
LGG	cis	rs3087591	1.000	rs12948444	chr17:29443614	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	14.15	0.55	4.88e-38	Hip circumference;
LGG	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg25457927	chr22:38595422	NA	-0.4	-10.14	-0.43	6.03e-22	Cutaneous nevi;
LGG	cis	rs9543976	0.858	rs9530447	chr13:76166802	G/A	cg01531495	chr13:76123901	UCHL3	0.62	7.57	0.33	2.07e-13	Diabetic retinopathy;
LGG	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg21475434	chr5:93447410	FAM172A	0.71	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg06968155	chr5:131705112	SLC22A5	0.72	8.29	0.36	1.21e-15	Rheumatoid arthritis;
LGG	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	6.76	0.3	4.21e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.09	0.55	9.43e-38	Bladder cancer;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg15971980	chr6:150254442	NA	0.43	8.14	0.35	3.61e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09441963	chr22:38198576	NA	0.48	7.24	0.32	1.87e-12	Gut microbiome composition (summer);
LGG	cis	rs11800820	0.555	rs12565947	chr1:246650225	T/C	cg16700716	chr1:246684329	NA	-0.41	-7.2	-0.32	2.45e-12	Obesity-related traits;
LGG	cis	rs17286411	0.750	rs8044004	chr16:71868168	A/C	cg06353428	chr16:71660113	MARVELD3	0.41	7.25	0.32	1.8e-12	Blood protein levels;
LGG	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg14664628	chr15:75095509	CSK	-0.55	-10.69	-0.44	5.46e-24	Breast cancer;
LGG	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg18551225	chr6:44695536	NA	-0.57	-10.27	-0.43	2.01e-22	Total body bone mineral density;
LGG	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21659725	chr3:3221576	CRBN	0.75	11.78	0.48	3.39e-28	Resting heart rate;
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg06558623	chr16:89946397	TCF25	1.24	13.52	0.53	2.52e-35	Skin colour saturation;
LGG	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg11502198	chr6:26597334	ABT1	-0.59	-10.1	-0.42	8.29e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7074356	0.569	rs17102596	chr10:82035173	T/C	cg27171509	chr10:82033454	MAT1A	-0.41	-8.26	-0.36	1.6e-15	Borderline personality disorder;
LGG	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg02297831	chr4:17616191	MED28	0.44	8.23	0.36	1.9e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4535700	0.501	rs10227764	chr7:56012422	A/C	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	3.81e-11	Macular telangiectasia type 2;
LGG	cis	rs4629710	0.592	rs13195700	chr6:131585299	C/T	cg12606694	chr6:131520996	AKAP7	0.51	8.35	0.36	8.19e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	20.17	0.68	2.1e-65	Platelet count;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg07701084	chr6:150067640	NUP43	0.65	12.34	0.5	1.94e-30	Lung cancer;
LGG	cis	rs4478137	1.000	rs4478137	chr4:164238385	G/A	cg06758707	chr4:164254230	NPY1R	0.71	12.71	0.51	6.15e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg27532318	chr7:32358331	NA	0.85	8.0	0.35	1.01e-14	Body mass index;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg08198773	chr8:1697536	NA	0.41	7.31	0.32	1.22e-12	Systolic blood pressure;
LGG	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.91	0.48	9.87e-29	Rheumatoid arthritis;
LGG	cis	rs6430585	0.527	rs12467569	chr2:136413847	T/C	cg07169764	chr2:136633963	MCM6	0.98	16.13	0.6	8.62e-47	Corneal structure;
LGG	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg12288994	chr5:1860383	NA	0.72	12.26	0.5	3.97e-30	Cardiovascular disease risk factors;
LGG	cis	rs17445240	1.000	rs78506209	chr2:3699715	G/A	cg17046650	chr2:3699563	NA	0.97	11.0	0.46	3.64e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.42	-0.36	4.6e-16	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs509477	0.718	rs273357	chr18:32597237	G/T	cg23791764	chr18:32556832	MAPRE2	0.45	7.53	0.33	2.71e-13	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.07	-0.31	5.75e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.02	0.39	4.95e-18	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs1355223	0.902	rs1539251	chr11:34742772	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs36051895	0.589	rs2224571	chr9:5196253	A/C	cg02405213	chr9:5042618	JAK2	-0.79	-14.03	-0.55	1.69e-37	Pediatric autoimmune diseases;
LGG	cis	rs2371030	0.833	rs13000743	chr2:211571015	G/A	cg18417063	chr2:211583084	NA	-0.57	-10.49	-0.44	3.07e-23	Non-small cell lung cancer;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22618164	chr12:122356400	WDR66	0.38	11.29	0.46	2.88e-26	Mean corpuscular volume;
LGG	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg06885757	chr1:42089581	HIVEP3	0.57	12.92	0.51	8.24e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17433780	0.808	rs12125301	chr1:89508501	G/A	cg09516651	chr1:89888402	LOC400759	0.77	18.59	0.65	5.03e-58	Carotid intima media thickness;
LGG	trans	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg21659725	chr3:3221576	CRBN	0.66	12.3	0.5	2.91e-30	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.506	rs1513118	chr3:101661789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	7.48	0.33	3.88e-13	Colorectal cancer;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.04e-23	Lymphocyte counts;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07677032	chr17:61819896	STRADA	-0.61	-11.04	-0.46	2.49e-25	Prudent dietary pattern;
LGG	cis	rs4950322	0.570	rs72692948	chr1:146792016	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg16141378	chr3:129829833	LOC729375	0.37	7.92	0.35	1.77e-14	Retinal vascular caliber;
LGG	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg04455712	chr21:45112962	RRP1B	-0.51	-9.62	-0.41	4.2e-20	Mean corpuscular volume;
LGG	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	7.64	0.33	1.26e-13	Total cholesterol levels;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22618164	chr12:122356400	WDR66	0.42	13.4	0.53	7.56e-35	Mean corpuscular volume;
LGG	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg09307838	chr4:120376055	NA	0.8	13.64	0.54	7.42e-36	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.79e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs4148883	0.603	rs6833176	chr4:100131163	G/C	cg12011299	chr4:100065546	ADH4	-0.34	-7.11	-0.31	4.32e-12	Alcohol dependence;
LGG	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg07395648	chr5:131743802	NA	-0.44	-9.68	-0.41	2.54e-20	Blood metabolite levels;
LGG	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-9.18	-0.39	1.39e-18	Vitiligo;
LGG	cis	rs2798269	1.000	rs10870842	chr13:22150209	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.08	-0.31	5.49e-12	PR segment;
LGG	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg24011408	chr12:48396354	COL2A1	0.5	7.94	0.35	1.54e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-7.09	-0.31	4.94e-12	Total body bone mineral density;
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs2120019	1.000	rs35736167	chr15:75332002	T/G	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.4	-0.65	3.66e-57	Blood trace element (Zn levels);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06688411	chr11:65153958	FRMD8	0.46	6.73	0.3	5.14e-11	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2587949	0.571	rs2587907	chr3:4235671	C/T	cg16519197	chr3:4211558	NA	0.34	6.77	0.3	3.87e-11	Periodontitis (DPAL);
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.66e-13	Rheumatoid arthritis;
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	20.08	0.68	5.67e-65	Platelet count;
LGG	cis	rs1707322	1.000	rs785507	chr1:46541558	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.76	-0.41	1.41e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7666738	0.830	rs6532721	chr4:99048015	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03264133	chr6:25882463	NA	-0.82	-15.36	-0.58	2.63e-43	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08677398	chr8:58056175	NA	0.51	8.05	0.35	6.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg11360546	chr7:1094263	C7orf50	-0.4	-6.98	-0.31	1.06e-11	Longevity;Endometriosis;
LGG	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg20503657	chr10:835505	NA	0.65	9.54	0.41	8.15e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.29	0.58	4.99e-43	Coronary artery disease;
LGG	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-10.96	-0.45	5.14e-25	Total body bone mineral density;
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.66	-0.34	1.09e-13	Dementia with Lewy bodies;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg07142201	chr11:109293216	C11orf87	0.47	8.09	0.35	5.34e-15	Schizophrenia;
LGG	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg08000102	chr2:233561755	GIGYF2	0.56	9.06	0.39	3.75e-18	Coronary artery disease;
LGG	cis	rs564799	0.966	rs587422	chr3:159729805	G/C	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.33	0.5	2.08e-30	Prudent dietary pattern;
LGG	cis	rs881375	0.967	rs2109896	chr9:123683106	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.32e-18	Rheumatoid arthritis;
LGG	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg24397884	chr7:158709396	WDR60	-1.05	-24.98	-0.76	7.89e-88	Height;
LGG	cis	rs3796352	1.000	rs11718538	chr3:52975987	C/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.64	0.37	9.17e-17	Prudent dietary pattern;
LGG	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg06360820	chr2:242988706	NA	-1.14	-14.15	-0.55	4.98e-38	Obesity-related traits;
LGG	cis	rs11608355	0.538	rs11611957	chr12:109801803	A/G	cg19025524	chr12:109796872	NA	-0.59	-12.73	-0.51	4.87e-32	Neuroticism;
LGG	cis	rs2535633	0.631	rs2710346	chr3:52974152	C/T	cg11645453	chr3:52864694	ITIH4	-0.47	-7.83	-0.34	3.31e-14	Body mass index;
LGG	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg05234568	chr11:5960015	NA	-0.67	-11.43	-0.47	7.73e-27	DNA methylation (variation);
LGG	cis	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.81	-0.3	3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4696584	0.877	rs12643014	chr4:155381726	G/A	cg04517429	chr4:155413618	DCHS2	-0.34	-7.38	-0.32	7.5e-13	Folding of antihelix;
LGG	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.4	6.66	0.3	7.87e-11	Carotid intima media thickness;
LGG	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.66	0.3	7.65e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2075064	0.500	rs34341106	chr9:126815471	T/C	cg14112217	chr9:126806003	NA	0.48	8.91	0.38	1.15e-17	Waist circumference;
LGG	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg15557168	chr22:42548783	NA	-0.48	-10.53	-0.44	2.21e-23	Schizophrenia;
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-12.87	-0.51	1.24e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs6424115	0.679	rs2267961	chr1:24071048	A/G	cg15997130	chr1:24165203	NA	-0.4	-8.85	-0.38	1.82e-17	Immature fraction of reticulocytes;
LGG	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.05	-0.52	2.27e-33	Vitamin D levels;
LGG	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg07636037	chr3:49044803	WDR6	1.12	27.35	0.79	9.95e-99	Parkinson's disease;
LGG	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.37	-0.36	7.07e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg22875332	chr1:76189707	ACADM	0.61	10.37	0.43	8.2000000000000006e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1707322	0.964	rs785508	chr1:46527159	G/A	cg03146154	chr1:46216737	IPP	-0.55	-10.14	-0.43	5.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9397585	0.502	rs6557273	chr6:153443159	A/G	cg17707550	chr6:153380415	RGS17	0.45	9.99	0.42	2.06e-21	Body mass index;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.33	-0.53	1.62e-34	Alzheimer's disease;
LGG	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg17971929	chr21:40555470	PSMG1	0.71	13.41	0.53	6.99e-35	Cognitive function;
LGG	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg27129171	chr3:47204927	SETD2	-0.85	-15.91	-0.59	8.67e-46	Colorectal cancer;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.82	0.38	2.36e-17	Obesity-related traits;
LGG	cis	rs2070488	0.804	rs2276541	chr3:38512779	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.76	0.57	1.16e-40	Electrocardiographic conduction measures;
LGG	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.0	0.71	5.77e-74	Bladder cancer;
LGG	cis	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.44e-42	Heart rate;
LGG	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs9902453	0.619	rs2244585	chr17:28072176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-14.12	-0.55	6.53e-38	Coffee consumption (cups per day);
LGG	cis	rs8064024	0.560	rs741769	chr16:4936205	G/T	cg04440724	chr16:4920505	UBN1	-0.46	-8.96	-0.38	8.14e-18	Cancer;
LGG	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs9470366	0.883	rs9462210	chr6:36628953	G/A	cg08179530	chr6:36648295	CDKN1A	0.62	9.02	0.39	5.1e-18	QRS duration;
LGG	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg03877680	chr5:178157825	ZNF354A	0.82	13.85	0.54	9.99e-37	Neutrophil percentage of white cells;
LGG	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg16141378	chr3:129829833	LOC729375	-0.45	-10.77	-0.45	2.78e-24	Mood instability;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25072359	chr17:41440525	NA	0.52	9.99	0.42	2.14e-21	Menopause (age at onset);
LGG	cis	rs883565	0.771	rs2056613	chr3:39125293	G/T	cg01426195	chr3:39028469	NA	-0.66	-13.5	-0.53	2.87e-35	Handedness;
LGG	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.33	0.87	9.71e-146	Chronic sinus infection;
LGG	cis	rs367943	0.634	rs6594701	chr5:112685743	C/T	cg12552261	chr5:112820674	MCC	0.54	9.78	0.41	1.17e-20	Type 2 diabetes;
LGG	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	9.03	0.39	4.73e-18	Mood instability;
LGG	cis	rs1707322	0.627	rs3014213	chr1:46045522	T/C	cg03146154	chr1:46216737	IPP	-0.55	-10.1	-0.42	8.44e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.92	0.31	1.54e-11	Schizophrenia;
LGG	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.73	8.17	0.35	3e-15	Initial pursuit acceleration;
LGG	cis	rs4144027	0.967	rs56126771	chr14:104361143	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-7.11	-0.31	4.32e-12	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.25	-0.32	1.75e-12	Menopause (age at onset);
LGG	cis	rs9849248	0.627	rs6551281	chr3:88208201	T/A	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.89	-0.34	2.15e-14	Schizophrenia;
LGG	cis	rs7781557	1.000	rs12113073	chr7:102482527	T/C	cg18108683	chr7:102477205	FBXL13	-0.55	-8.75	-0.38	4.04e-17	Colorectal adenoma (advanced);
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg26513180	chr16:89883248	FANCA	0.94	21.15	0.7	5.44e-70	Vitiligo;
LGG	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg14019146	chr3:50243930	SLC38A3	0.54	11.72	0.48	5.96e-28	Intelligence (multi-trait analysis);
LGG	cis	rs5756813	0.661	rs6000898	chr22:38202399	T/C	cg24232236	chr22:38142998	TRIOBP	0.35	6.74	0.3	4.66e-11	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg11693508	chr17:37793320	STARD3	0.62	9.34	0.4	3.92e-19	Bipolar disorder;
LGG	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg02461776	chr11:598696	PHRF1	0.53	8.5	0.37	2.58e-16	Systemic lupus erythematosus;
LGG	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	13.02	0.52	3.07e-33	Hip circumference adjusted for BMI;
LGG	cis	rs4901847	0.716	rs2273442	chr14:58563694	C/G	cg15908186	chr14:58618357	C14orf37	0.44	7.54	0.33	2.47e-13	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg17133734	chr15:86042851	AKAP13	-0.28	-6.78	-0.3	3.65e-11	Coronary artery disease;
LGG	cis	rs17767392	0.788	rs61989239	chr14:71705928	T/C	cg02058870	chr14:72053146	SIPA1L1	0.36	7.01	0.31	8.45e-12	Mitral valve prolapse;
LGG	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs4631830	0.720	rs2012677	chr10:51504797	T/A	cg10326726	chr10:51549505	MSMB	-0.61	-12.27	-0.5	3.56e-30	Prostate-specific antigen levels;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17253792	0.822	rs10142497	chr14:56047948	C/T	cg01858014	chr14:56050164	KTN1	0.9	12.54	0.5	2.91e-31	Putamen volume;
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.46	2.61e-26	Bipolar disorder;
LGG	trans	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26093954	chr3:50375239	RASSF1	0.48	6.71	0.3	5.59e-11	IgG glycosylation;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.82	-0.45	1.77e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs1982963	0.951	rs2516592	chr14:52503545	A/G	cg05884192	chr14:52515736	NID2	-0.31	-6.7	-0.3	6.19e-11	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg16049864	chr8:95962084	TP53INP1	-0.44	-9.59	-0.41	5.44e-20	Type 2 diabetes;
LGG	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg04568710	chr12:38710424	ALG10B	-0.38	-7.73	-0.34	6.97e-14	Morning vs. evening chronotype;
LGG	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg21782813	chr7:2030301	MAD1L1	0.36	8.56	0.37	1.72e-16	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg02023728	chr11:77925099	USP35	0.46	8.01	0.35	9.58e-15	Testicular germ cell tumor;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg13047869	chr3:10149882	C3orf24	0.53	8.91	0.38	1.21e-17	Alzheimer's disease;
LGG	cis	rs1408799	0.750	rs10809811	chr9:12650996	C/G	cg05274944	chr9:12693694	TYRP1	-0.34	-7.98	-0.35	1.15e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs6993813	0.758	rs7013731	chr8:120038365	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg10596483	chr8:143751796	JRK	0.52	8.19	0.36	2.64e-15	Schizophrenia;
LGG	cis	rs9302635	0.688	rs763665	chr16:72078043	C/T	cg08717414	chr16:71523259	ZNF19	-0.58	-7.18	-0.32	2.76e-12	Blood protein levels;
LGG	cis	rs7940866	0.738	rs10791114	chr11:130889850	G/A	cg12179176	chr11:130786555	SNX19	0.71	13.23	0.52	4.15e-34	Schizophrenia;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg12419862	chr22:24373484	LOC391322	-0.87	-17.82	-0.64	1.77e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg26384229	chr12:38710491	ALG10B	-0.92	-20.86	-0.7	1.33e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2455799	0.613	rs2455813	chr3:15735051	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.72	-0.34	7.29e-14	Mean platelet volume;
LGG	cis	rs6735179	0.565	rs6726887	chr2:1749257	A/G	cg20570797	chr2:1712800	PXDN	-0.47	-8.02	-0.35	8.65e-15	Response to antipsychotic treatment;
LGG	cis	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg19399532	chr1:178512495	C1orf220	0.54	10.89	0.45	9.86e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg19812747	chr11:111475976	SIK2	0.48	9.29	0.4	6.21e-19	Primary sclerosing cholangitis;
LGG	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg01448562	chr3:133502909	NA	-0.8	-15.5	-0.58	6.15e-44	Iron status biomarkers;
LGG	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg22643751	chr7:855365	UNC84A	-0.42	-7.23	-0.32	2.05e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08219700	chr8:58056026	NA	-0.46	-7.02	-0.31	8.16e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs57590327	0.716	rs4352391	chr3:81802318	T/C	cg07356753	chr3:81810745	GBE1	-0.51	-7.69	-0.34	9.22e-14	Extraversion;
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00290607	chr11:67383545	NA	0.66	12.84	0.51	1.7e-32	Mean corpuscular volume;
LGG	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-8.67	-0.37	7.42e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.63	-0.48	1.37e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg13147721	chr7:65941812	NA	-0.79	-9.56	-0.41	7.18e-20	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08280861	chr8:58055591	NA	0.54	6.87	0.3	2.08e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.541	rs1016914	chr3:99640121	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.01	0.39	5.36e-18	Axial length;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.14	-0.35	3.79e-15	Prudent dietary pattern;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg11360546	chr7:1094263	C7orf50	-0.41	-7.37	-0.32	8.07e-13	Longevity;Endometriosis;
LGG	cis	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.86	-0.45	1.29e-24	Resting heart rate;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg26338869	chr17:61819248	STRADA	-0.46	-7.49	-0.33	3.42e-13	Prudent dietary pattern;
LGG	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27297192	chr10:134578999	INPP5A	0.31	6.9	0.31	1.73e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.15	0.32	3.3e-12	Height;
LGG	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.63	0.48	1.28e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.43	7.01	0.31	8.23e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg16230307	chr14:35515116	FAM177A1	0.92	13.32	0.53	1.69e-34	Psoriasis;
LGG	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.85	0.42	6.73e-21	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07080220	chr10:102295463	HIF1AN	-0.68	-11.98	-0.49	5.52e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	9.33	0.4	4.48e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.7	-0.41	2.16e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2718058	0.564	rs10268172	chr7:37795634	G/A	cg15028436	chr7:37888078	TXNDC3	-0.45	-7.48	-0.33	3.82e-13	Alzheimer's disease (late onset);
LGG	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.38	0.47	1.26e-26	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14968603	chr10:102046143	BLOC1S2	0.45	7.44	0.33	5.03e-13	Cognitive performance;
LGG	cis	rs4900538	0.855	rs72698597	chr14:102868633	C/T	cg18135206	chr14:102964638	TECPR2	-0.69	-12.56	-0.5	2.38e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7565124	1.000	rs60676431	chr2:20263863	G/A	cg24657347	chr2:20261756	NA	-0.76	-15.04	-0.57	6.27e-42	Major depressive disorder;
LGG	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.21e-66	Intelligence (multi-trait analysis);
LGG	cis	rs965513	1.000	rs1443438	chr9:100550028	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.64	-0.41	3.68e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs11866815	0.602	rs66720247	chr16:374126	G/A	cg07915516	chr16:377344	AXIN1	-0.5	-11.27	-0.46	3.43e-26	Body mass index;
LGG	cis	rs6537837	0.838	rs12046010	chr1:110104189	A/C	cg05049280	chr1:110155535	GNAT2	0.33	7.03	0.31	7.37e-12	Major depressive disorder;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.88	-0.38	1.52e-17	Longevity;Endometriosis;
LGG	cis	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg07460842	chr6:66804631	NA	0.57	9.46	0.4	1.55e-19	Metabolite levels;
LGG	cis	rs1707322	1.000	rs12097799	chr1:46459886	C/A	cg03146154	chr1:46216737	IPP	0.54	10.02	0.42	1.59e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.36	-0.32	8.58e-13	Menarche (age at onset);
LGG	cis	rs6815814	0.904	rs73236628	chr4:38825443	C/T	cg06935464	chr4:38784597	TLR10	0.58	7.99	0.35	1.05e-14	Breast cancer;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07132326	chr6:150258058	NA	0.37	7.96	0.35	1.34e-14	Lung cancer;
LGG	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.11	0.57	3.13e-42	Cognitive test performance;
LGG	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg03315344	chr16:75512273	CHST6	0.54	10.81	0.45	2.01e-24	Dupuytren's disease;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.93	13.52	0.53	2.4e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13053817	1.000	rs13054354	chr22:29840180	T/C	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.66	-0.3	7.96e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs2455799	0.553	rs12495958	chr3:15941439	G/T	cg16303742	chr3:15540471	COLQ	-0.37	-7.27	-0.32	1.58e-12	Mean platelet volume;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.55	-9.67	-0.41	2.95e-20	Longevity;Endometriosis;
LGG	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg19507638	chr5:93509721	C5orf36	-0.77	-9.91	-0.42	4.17e-21	Diabetic retinopathy;
LGG	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg05182265	chr7:156933206	UBE3C	-0.33	-6.67	-0.3	7.15e-11	Body mass index;
LGG	cis	rs2117029	0.767	rs10875912	chr12:49416944	T/C	cg24176009	chr12:49580217	TUBA1A	0.45	8.05	0.35	6.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg17971929	chr21:40555470	PSMG1	0.82	14.81	0.57	6.43e-41	Cognitive function;
LGG	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	Neuroticism;
LGG	cis	rs4742903	0.935	rs7853727	chr9:106990048	T/G	cg14250997	chr9:106856677	SMC2	0.39	8.01	0.35	9.37e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2963155	0.518	rs865482	chr5:142640317	C/A	cg17617527	chr5:142782415	NR3C1	0.98	12.92	0.51	8.02e-33	Breast cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03129910	chr4:57333643	SRP72	0.4	6.88	0.3	1.95e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9287719	0.746	rs6742448	chr2:10759126	G/A	cg02196655	chr2:10830764	NOL10	-0.47	-8.16	-0.35	3.12e-15	Prostate cancer;
LGG	trans	rs7246760	0.618	rs73008113	chr19:9738196	C/T	cg02900749	chr2:68251473	NA	-0.98	-9.86	-0.42	6.13e-21	Pursuit maintenance gain;
LGG	cis	rs7084402	1.000	rs7073504	chr10:60271987	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.25	-0.65	1.88e-56	Refractive error;
LGG	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg10578777	chr12:7781093	NA	-0.78	-8.6	-0.37	1.25e-16	HDL cholesterol levels;
LGG	cis	rs870825	0.556	rs6552811	chr4:185653351	T/A	cg04058563	chr4:185651563	MLF1IP	-1.03	-21.45	-0.71	2.12e-71	Blood protein levels;
LGG	cis	rs73086581	1.000	rs17287486	chr20:3946267	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg00717180	chr2:96193071	NA	-0.39	-6.93	-0.31	1.45e-11	Height;
LGG	cis	rs7444	0.882	rs5749495	chr22:21940310	A/G	cg15846791	chr22:21984385	YDJC	-0.47	-7.09	-0.31	5.06e-12	Systemic lupus erythematosus;
LGG	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg27432699	chr2:27873401	GPN1	0.7	14.34	0.55	7.58e-39	Oral cavity cancer;
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	5.9e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg24250549	chr1:154909240	PMVK	0.7	13.81	0.54	1.37e-36	Prostate cancer;
LGG	cis	rs60180747	0.909	rs11638268	chr15:66770164	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.6	10.01	0.42	1.79e-21	Testicular germ cell tumor;
LGG	trans	rs11650494	0.908	rs73340392	chr17:47358308	G/A	cg11430096	chr6:110968061	CDK19	0.64	6.75	0.3	4.53e-11	Prostate cancer;
LGG	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	6.91e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg11494091	chr17:61959527	GH2	0.51	7.67	0.34	1.05e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.09	-0.31	5.14e-12	Retinal vascular caliber;
LGG	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs61989804	0.590	rs61989032	chr14:65792151	G/T	cg15999311	chr14:65749247	NA	0.79	7.93	0.35	1.67e-14	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs4906332	1.000	rs8012623	chr14:103937086	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-7.82	-0.34	3.56e-14	Coronary artery disease;
LGG	cis	rs7017914	0.870	rs34282253	chr8:71582366	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.89	-0.31	1.81e-11	Bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14369405	chr18:32556760	MAPRE2	-0.47	-7.2	-0.32	2.44e-12	Systemic lupus erythematosus;
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg01494348	chr8:144660395	NAPRT1	0.93	7.4	0.33	6.66e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg05308233	chr10:104796373	CNNM2	0.31	6.87	0.3	2.14e-11	Arsenic metabolism;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	ch.12.2922115F	chr12:133248407	POLE	-0.41	-7.33	-0.32	1.01e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg13010199	chr12:38710504	ALG10B	0.69	13.35	0.53	1.33e-34	Morning vs. evening chronotype;
LGG	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg25809561	chr17:30822961	MYO1D	0.38	9.1	0.39	2.74e-18	Schizophrenia;
LGG	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03517284	chr6:25882590	NA	-0.69	-13.41	-0.53	6.79e-35	Intelligence (multi-trait analysis);
LGG	cis	rs11877825	0.813	rs34276557	chr18:10571005	A/G	cg07277756	chr18:10589357	NA	0.58	10.4	0.44	6.74e-23	Gut microbiota (bacterial taxa);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27218536	chr17:35969412	SYNRG	0.5	7.56	0.33	2.21e-13	Hip circumference;
LGG	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.53	-7.72	-0.34	7.05e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	8.39	0.36	5.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	7.32	0.32	1.11e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg07511668	chr11:68622177	NA	0.5	9.66	0.41	3.04e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10461617	0.535	rs7709874	chr5:56047451	C/T	cg12654349	chr5:56205094	C5orf35	-0.43	-7.32	-0.32	1.14e-12	Type 2 diabetes;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.93	-0.48	8.42e-29	Parkinson's disease;
LGG	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg12560992	chr17:57184187	TRIM37	0.88	15.54	0.59	3.91e-44	Intelligence (multi-trait analysis);
LGG	cis	rs13095912	0.778	rs11914529	chr3:185296513	C/T	cg11274856	chr3:185301563	NA	0.5	8.09	0.35	5.4e-15	Systolic blood pressure;
LGG	cis	rs858239	0.539	rs57864591	chr7:23184424	T/A	cg23682824	chr7:23144976	KLHL7	0.41	6.79	0.3	3.38e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.67e-12	Lung cancer;
LGG	cis	rs6141769	0.569	rs6057621	chr20:31265297	A/G	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.07	-0.31	5.61e-12	Subjective well-being;
LGG	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg04398451	chr17:18023971	MYO15A	-0.73	-14.77	-0.57	1.02e-40	Total body bone mineral density;
LGG	cis	rs8078723	1.000	rs709592	chr17:38175553	C/T	cg17467752	chr17:38218738	THRA	0.74	13.85	0.54	9.36e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg22907277	chr7:1156413	C7orf50	0.7	8.8	0.38	2.76e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.501	rs7585019	chr2:100077327	C/G	cg23527387	chr2:100056660	REV1	-0.38	-8.53	-0.37	2.14e-16	Chronic sinus infection;
LGG	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg12661370	chr5:149340060	SLC26A2	-0.54	-8.08	-0.35	5.53e-15	HIV-1 control;
LGG	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs6032067	0.759	rs6104052	chr20:43808783	T/G	cg10761708	chr20:43804764	PI3	0.61	9.3	0.4	5.52e-19	Blood protein levels;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg07303275	chr16:75499416	TMEM170A	0.43	7.59	0.33	1.84e-13	Dupuytren's disease;
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.32	2.09e-12	Bipolar disorder;
LGG	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.61e-12	Blood metabolite levels;
LGG	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg12636538	chr11:118901039	SLC37A4	-0.6	-12.3	-0.5	2.88e-30	Coronary artery disease;
LGG	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg19500275	chr17:80737654	TBCD	0.52	6.88	0.3	1.9e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg16141378	chr3:129829833	LOC729375	-0.32	-6.77	-0.3	3.94e-11	Neuroticism;
LGG	cis	rs12282928	0.959	rs1354292	chr11:48264647	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.24	-0.32	1.94e-12	Migraine - clinic-based;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg06343212	chr7:84815881	NA	0.48	7.19	0.32	2.55e-12	Breast cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25472172	chr2:11685235	GREB1	0.37	6.79	0.3	3.45e-11	Menarche (age at onset);
LGG	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs7666738	0.830	rs28687737	chr4:99009226	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11645453	chr3:52864694	ITIH4	-0.42	-6.91	-0.31	1.64e-11	Bipolar disorder;
LGG	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-13.99	-0.55	2.44e-37	Morning vs. evening chronotype;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg18350739	chr11:68623251	NA	-0.89	-22.06	-0.72	2.94e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg01200585	chr1:228362443	C1orf69	-0.45	-7.98	-0.35	1.13e-14	Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17355835	chr15:40886331	CASC5	0.47	7.76	0.34	5.42e-14	Cognitive performance;
LGG	cis	rs9815354	1.000	rs1994157	chr3:41897482	G/A	cg03022575	chr3:42003672	ULK4	0.73	9.19	0.39	1.34e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6840360	0.593	rs867800	chr4:152691470	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	trans	rs9354308	0.764	rs2351721	chr6:66602789	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22100476	chr1:43638037	WDR65;EBNA1BP2	0.43	7.07	0.31	5.64e-12	Cognitive performance;
LGG	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	6.21e-34	Resting heart rate;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg15971980	chr6:150254442	NA	0.45	8.5	0.37	2.72e-16	Lung cancer;
LGG	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03517284	chr6:25882590	NA	0.66	12.62	0.51	1.42e-31	Blood metabolite levels;
LGG	trans	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.68e-11	Depression;
LGG	cis	rs4742903	0.935	rs1507515	chr9:106989653	A/G	cg14250997	chr9:106856677	SMC2	-0.39	-8.15	-0.35	3.41e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs870825	1.000	rs72689245	chr4:185579788	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	18.48	0.65	1.59e-57	Blood protein levels;
LGG	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	cis	rs6547631	0.622	rs1837115	chr2:85928411	C/A	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.68e-11	Blood protein levels;
LGG	trans	rs61931739	0.649	rs864614	chr12:33725409	C/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08645402	chr16:4508243	NA	0.54	9.79	0.41	1.07e-20	Schizophrenia;
LGG	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg10845886	chr2:3471009	TTC15	-0.53	-10.31	-0.43	1.41e-22	Neurofibrillary tangles;
LGG	cis	rs7301826	1.000	rs4759524	chr12:131315610	G/A	cg11011512	chr12:131303247	STX2	0.34	7.48	0.33	3.82e-13	Plasma plasminogen activator levels;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-9.64	-0.41	3.64e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.67	0.48	9.62e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg14703610	chr5:56206110	C5orf35	0.42	7.26	0.32	1.69e-12	Coronary artery disease;
LGG	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg19761014	chr17:28927070	LRRC37B2	0.66	7.53	0.33	2.66e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07701084	chr6:150067640	NUP43	0.43	7.97	0.35	1.24e-14	Testicular germ cell tumor;
LGG	cis	rs7084402	0.967	rs1658469	chr10:60292402	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.24	0.32	1.83e-12	Refractive error;
LGG	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.58	-0.47	2.14e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg09699651	chr6:150184138	LRP11	0.5	8.71	0.38	5.57e-17	Lung cancer;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg02018176	chr4:1364513	KIAA1530	0.45	9.9	0.42	4.43e-21	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg13206674	chr6:150067644	NUP43	0.43	9.09	0.39	2.88e-18	Testicular germ cell tumor;
LGG	cis	rs1920116	0.778	rs34237331	chr3:169551870	C/A	cg08193579	chr3:169529701	LRRC34	0.41	7.05	0.31	6.35e-12	Glioma (high-grade);
LGG	cis	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg20368463	chr18:77673604	PQLC1	0.53	6.89	0.3	1.87e-11	Opioid sensitivity;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.12	-0.31	4.23e-12	Obesity-related traits;
LGG	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg18131467	chr2:239335373	ASB1	1.03	23.43	0.74	1.25e-80	Multiple system atrophy;
LGG	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg12463550	chr7:65579703	CRCP	0.77	8.48	0.37	3.1e-16	Diabetic kidney disease;
LGG	cis	rs6912958	0.781	rs4707379	chr6:88310623	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.73	-0.38	4.74e-17	Monocyte percentage of white cells;
LGG	trans	rs17685	0.712	rs4552844	chr7:75718095	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27221266	chr10:96122679	NOC3L	0.49	7.72	0.34	7.08e-14	Gut microbiome composition (summer);
LGG	cis	rs174601	0.861	rs174580	chr11:61606642	A/G	cg19610905	chr11:61596333	FADS2	-0.75	-13.58	-0.53	1.39e-35	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg08045932	chr20:61659980	NA	0.59	12.82	0.51	1.99e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.95	-0.31	1.28e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg20913747	chr6:44695427	NA	-0.61	-10.26	-0.43	2.09e-22	Total body bone mineral density;
LGG	cis	rs2635047	0.713	rs9304344	chr18:44758665	A/C	cg19077165	chr18:44547161	KATNAL2	0.41	6.89	0.3	1.82e-11	Educational attainment;
LGG	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg04455712	chr21:45112962	RRP1B	0.46	7.97	0.35	1.27e-14	Mean corpuscular hemoglobin;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.1	0.57	3.57e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2243480	0.901	rs73142137	chr7:65343442	A/T	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-16.5	-0.61	1.88e-48	Tonsillectomy;
LGG	trans	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.21	0.39	1.09e-18	Aortic root size;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg04503457	chr17:41445688	NA	-0.39	-9.37	-0.4	3.26e-19	Menopause (age at onset);
LGG	cis	rs12195424	0.730	rs2209037	chr6:56305330	G/T	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg13770153	chr20:60521292	NA	-1.08	-19.64	-0.67	6.51e-63	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg01145232	chr6:150245071	RAET1G	0.34	6.71	0.3	5.74e-11	Lung cancer;
LGG	cis	rs698813	0.674	rs3738985	chr2:44502788	A/C	cg00619915	chr2:44497795	NA	-0.61	-8.73	-0.38	4.5e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg14227996	chr4:17616232	MED28	-0.52	-6.74	-0.3	4.75e-11	Opioid sensitivity;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02071572	chr4:1403502	NA	0.41	7.5	0.33	3.34e-13	Longevity;
LGG	cis	rs2018055	0.827	rs13202514	chr6:117791155	G/A	cg14611402	chr6:117803162	DCBLD1	0.32	9.07	0.39	3.39e-18	Diastolic blood pressure;
LGG	cis	rs3736594	0.513	rs6547735	chr2:27831607	T/C	cg27432699	chr2:27873401	GPN1	0.56	8.57	0.37	1.59e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg12395012	chr8:11607386	GATA4	0.52	7.53	0.33	2.73e-13	Alcohol dependence;Nicotine use;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	11.45	0.47	6.75e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs10644111	1	rs10644111	chr7:91652178	A/AAAC	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs9815354	0.951	rs9850310	chr3:41891098	T/C	cg03022575	chr3:42003672	ULK4	0.73	9.19	0.39	1.34e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7819412	0.502	rs10095003	chr8:11042449	G/A	cg21775007	chr8:11205619	TDH	-0.48	-6.97	-0.31	1.07e-11	Triglycerides;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.33	0.36	8.93e-16	Personality dimensions;
LGG	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.13	-0.35	4.05e-15	Schizophrenia;
LGG	cis	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg22496380	chr5:211416	CCDC127	-1.35	-18.73	-0.66	1.06e-58	Breast cancer;
LGG	cis	rs877426	0.681	rs56352545	chr13:114839620	A/G	cg27119904	chr13:114814333	RASA3	0.35	7.15	0.32	3.43e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.76	-0.51	3.74e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg11965913	chr1:205819406	PM20D1	0.55	10.3	0.43	1.59e-22	Menarche (age at onset);
LGG	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.45	-0.47	6.88e-27	Triglycerides;
LGG	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg13385794	chr1:248469461	NA	0.43	7.11	0.31	4.32e-12	Common traits (Other);
LGG	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.39	0.61	5.8e-48	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19717773	chr7:2847554	GNA12	0.32	6.67	0.3	7.45e-11	Height;
LGG	cis	rs113835537	0.529	rs2279864	chr11:66247844	G/A	cg24851651	chr11:66362959	CCS	0.43	7.54	0.33	2.48e-13	Airway imaging phenotypes;
LGG	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg15162869	chr22:32027605	PISD	-0.67	-7.14	-0.32	3.58e-12	Age-related hearing impairment;
LGG	cis	rs34929064	0.536	rs2961278	chr7:22634779	C/G	cg18045685	chr7:22629474	NA	-0.76	-15.56	-0.59	3.22e-44	Major depression and alcohol dependence;
LGG	cis	rs36051895	0.623	rs7035456	chr9:5261440	G/A	cg02405213	chr9:5042618	JAK2	-0.71	-12.51	-0.5	3.73e-31	Pediatric autoimmune diseases;
LGG	cis	rs2832191	0.692	rs2245734	chr21:30359965	C/T	cg08807101	chr21:30365312	RNF160	0.91	19.28	0.67	3.11e-61	Dental caries;
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.45	-9.06	-0.39	3.77e-18	Schizophrenia;
LGG	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg03162506	chr22:38580953	NA	0.4	9.78	0.41	1.14e-20	Breast cancer;
LGG	cis	rs1322639	0.657	rs12203887	chr6:169572252	C/T	cg04662567	chr6:169592167	NA	-0.86	-11.91	-0.48	1.03e-28	Pulse pressure;
LGG	cis	rs68170813	0.559	rs6964798	chr7:106933013	C/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.37	-0.43	8.39e-23	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07659893	chr17:61819838	STRADA	0.5	8.43	0.36	4.38e-16	Prudent dietary pattern;
LGG	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg13009111	chr11:71350975	NA	0.33	7.17	0.32	2.96e-12	Monocyte count;
LGG	trans	rs75804782	0.625	rs10929276	chr2:239468585	A/G	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11203032	0.710	rs10887923	chr10:90930404	C/T	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11199428	chr13:52027379	INTS6	0.58	6.79	0.3	3.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg09307838	chr4:120376055	NA	0.67	11.67	0.48	9.3e-28	Corneal astigmatism;
LGG	cis	rs2486288	0.656	rs1719232	chr15:45572072	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-11.07	-0.46	2.05e-25	Glomerular filtration rate;
LGG	cis	rs9807989	0.507	rs4851572	chr2:103019031	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06470251	chr20:60548479	NA	0.47	8.18	0.36	2.69e-15	Body mass index;
LGG	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg22601191	chr20:60968625	CABLES2	0.49	9.19	0.39	1.32e-18	Colorectal cancer;
LGG	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg23306229	chr2:178417860	TTC30B	0.62	7.74	0.34	6.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs6499188	0.522	rs8046299	chr16:68672346	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	9.86	0.42	6.07e-21	Ulcerative colitis;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.39	0.43	7.13e-23	Diabetic retinopathy;
LGG	cis	rs12908161	0.959	rs17534709	chr15:85314397	G/C	cg24253500	chr15:84953950	NA	0.43	7.01	0.31	8.69e-12	Schizophrenia;
LGG	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.75	-0.45	3.35e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9443645	0.901	rs9343843	chr6:79585625	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	0.920	rs7941889	chr11:78154401	T/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.17	-0.36	2.87e-15	Alzheimer's disease (survival time);
LGG	cis	rs6032067	1.000	rs34885285	chr20:43804789	C/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.54e-28	Blood protein levels;
LGG	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg16386425	chr10:429943	DIP2C	0.39	6.96	0.31	1.19e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2289583	0.573	rs12148555	chr15:75395475	C/T	cg10253484	chr15:75165896	SCAMP2	0.45	7.09	0.31	5.19e-12	Systemic lupus erythematosus;
LGG	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.77e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.15	-0.35	3.39e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	cis	rs2273669	0.915	rs4992383	chr6:109292816	C/A	cg05315195	chr6:109294784	ARMC2	-0.51	-7.35	-0.32	8.92e-13	Prostate cancer;
LGG	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg14541582	chr5:601475	NA	-0.72	-10.96	-0.45	5.3e-25	Obesity-related traits;
LGG	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg11941060	chr3:133502564	NA	0.49	8.35	0.36	7.99e-16	Iron status biomarkers;
LGG	cis	rs10865397	0.506	rs6546807	chr2:73386212	C/T	cg01422370	chr2:73384389	NA	0.54	9.98	0.42	2.19e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.68	0.41	2.73e-20	Blood metabolite levels;
LGG	cis	rs6694672	0.681	rs6670056	chr1:196982776	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.86	0.3	2.26e-11	Asthma;
LGG	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.81	-16.04	-0.6	2.19e-46	Lung cancer;
LGG	cis	rs12618769	0.652	rs76525766	chr2:99221088	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg24375607	chr4:120327624	NA	0.4	7.0	0.31	8.89e-12	Diastolic blood pressure;
LGG	cis	rs2649	0.542	rs8023506	chr15:63884462	A/G	cg22599514	chr15:63798201	USP3	0.43	7.18	0.32	2.73e-12	Aortic root size;
LGG	trans	rs1493916	0.721	rs4471760	chr18:31374233	G/A	cg04226714	chr8:49833948	SNAI2	-0.5	-8.99	-0.39	6.14e-18	Life satisfaction;
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.09	-0.35	5.15e-15	Total body bone mineral density;
LGG	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06108461	chr20:60628389	TAF4	-0.72	-12.88	-0.51	1.15e-32	Body mass index;
LGG	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg20503657	chr10:835505	NA	0.71	9.08	0.39	3.03e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg05001520	chr19:47760154	CCDC9	-0.36	-7.13	-0.31	3.78e-12	Iris color (L* coordinate);
LGG	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.79	9.13	0.39	2.06e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4740619	0.618	rs10738421	chr9:15975380	T/A	cg14451791	chr9:16040625	NA	-0.41	-10.78	-0.45	2.43e-24	Body mass index;
LGG	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg02297831	chr4:17616191	MED28	0.51	9.5	0.4	1.1e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg14092988	chr3:52407081	DNAH1	0.3	7.85	0.34	3.01e-14	Electroencephalogram traits;
LGG	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.47	7.81	0.34	3.82e-14	Osteoporosis;
LGG	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg05484508	chr16:89589025	SPG7	0.45	7.3	0.32	1.24e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.35	-0.53	1.28e-34	Colorectal cancer;
LGG	cis	rs35740288	0.929	rs11636821	chr15:86306005	T/G	cg07943548	chr15:86304357	KLHL25	-0.36	-7.27	-0.32	1.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg18379455	chr17:41446167	NA	-0.33	-7.73	-0.34	6.59e-14	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg01620082	chr3:125678407	NA	-0.62	-6.67	-0.3	7.53e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20013855	chr1:178062503	LOC100302401;RASAL2	-0.41	-6.91	-0.31	1.64e-11	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.44	8.15	0.35	3.51e-15	Longevity;
LGG	trans	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg07211511	chr3:129823064	LOC729375	-0.65	-9.02	-0.39	4.86e-18	Blood pressure (smoking interaction);
LGG	cis	rs1806153	0.611	rs1806183	chr11:31838763	A/G	cg11990419	chr11:31841155	NA	0.33	7.75	0.34	6.01e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg25706552	chr1:244017396	NA	0.51	8.46	0.37	3.53e-16	RR interval (heart rate);
LGG	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg06115741	chr20:33292138	TP53INP2	0.56	8.86	0.38	1.77e-17	Coronary artery disease;
LGG	cis	rs151997	0.924	rs32480	chr5:50208099	G/A	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs8077889	0.956	rs6503476	chr17:41850163	C/T	cg26893861	chr17:41843967	DUSP3	0.99	17.61	0.63	1.69e-53	Triglycerides;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs17639063	0.571	rs17696120	chr3:62551030	C/T	cg23802518	chr10:80827482	ZMIZ1;LOC283050	-0.6	-6.73	-0.3	4.97e-11	QT interval (sulfonylurea treatment interaction);
LGG	cis	rs7166081	1.000	rs35008245	chr15:67614967	G/A	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.81e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.4	0.65	3.62e-57	Refractive error;
LGG	cis	rs6032067	0.714	rs6104069	chr20:43852243	C/A	cg10761708	chr20:43804764	PI3	0.58	8.87	0.38	1.65e-17	Blood protein levels;
LGG	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg21724239	chr8:58056113	NA	0.61	9.03	0.39	4.56e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs56399783	0.901	rs56007918	chr7:2826205	A/G	cg19731401	chr7:2775893	GNA12	0.36	7.42	0.33	5.52e-13	Childhood ear infection;
LGG	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg00129232	chr17:37814104	STARD3	-0.75	-16.39	-0.61	6.24e-48	Asthma;
LGG	cis	rs6840360	0.615	rs9996320	chr4:152610587	T/G	cg22705602	chr4:152727874	NA	-0.39	-9.72	-0.41	1.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6489785	0.737	rs623857	chr12:121230762	C/T	cg02419362	chr12:121203948	SPPL3	0.43	6.74	0.3	4.82e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs861020	1.000	rs680923	chr1:209986672	T/C	cg05527609	chr1:210001259	C1orf107	0.73	10.13	0.43	6.29e-22	Orofacial clefts;
LGG	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg00578828	chr5:131826934	IRF1	0.41	7.48	0.33	3.64e-13	Asthma (sex interaction);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg09427429	chr2:128450658	NA	-0.39	-6.68	-0.3	6.66e-11	Apolipoprotein A-IV levels;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.7e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs300774	0.844	rs1810329	chr2:176395	A/T	cg04617936	chr2:214353	NA	0.49	7.19	0.32	2.65e-12	Suicide attempts in bipolar disorder;
LGG	trans	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.86	0.3	2.2e-11	Retinal vascular caliber;
LGG	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.71	-0.34	7.73e-14	Response to antipsychotic treatment;
LGG	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	14.39	0.56	4.32e-39	Mean platelet volume;
LGG	cis	rs10193935	0.901	rs13384885	chr2:42536646	G/C	cg27598129	chr2:42591480	NA	-0.64	-9.54	-0.41	8.49e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg02023728	chr11:77925099	USP35	0.45	7.83	0.34	3.44e-14	Testicular germ cell tumor;
LGG	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg09818912	chr17:20140352	CYTSB	-0.3	-7.04	-0.31	7.12e-12	Schizophrenia;
LGG	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-9.23	-0.39	9.9e-19	Schizophrenia;
LGG	trans	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.64	0.37	9e-17	Mood instability;
LGG	cis	rs929596	0.603	rs2602363	chr2:234520525	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.28	-0.4	6.64e-19	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg18876405	chr7:65276391	NA	-0.63	-11.79	-0.48	3.21e-28	Aortic root size;
LGG	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg05585630	chr7:157510462	PTPRN2	-0.64	-13.49	-0.53	3.16e-35	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08039585	chr1:1020002	C1orf159	0.43	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.08e-11	Blood metabolite levels;
LGG	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg10523679	chr1:76189770	ACADM	-0.43	-6.98	-0.31	1.04e-11	Daytime sleep phenotypes;
LGG	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	trans	rs7181230	1.000	rs28620926	chr15:40357171	A/G	cg22705835	chr10:65332833	REEP3	-0.61	-10.82	-0.45	1.83e-24	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs17428076	0.681	rs62182401	chr2:172733348	G/T	cg21435375	chr2:172878103	MAP1D	0.42	7.63	0.33	1.32e-13	Myopia;
LGG	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs77372450	0.636	rs77291311	chr5:157018650	T/C	cg25387487	chr5:157003181	ADAM19	-0.54	-6.68	-0.3	6.85e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg06454157	chr6:167490870	NA	0.31	6.76	0.3	4.15e-11	Rheumatoid arthritis;
LGG	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06481639	chr22:41940642	POLR3H	-0.48	-7.28	-0.32	1.48e-12	Vitiligo;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.49	0.69	6.6e-67	Platelet count;
LGG	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg17145862	chr1:211918768	LPGAT1	0.91	22.05	0.72	3.43e-74	Leprosy;
LGG	cis	rs7666738	0.830	rs34070283	chr4:98893027	A/T	cg05340658	chr4:99064831	C4orf37	0.47	7.79	0.34	4.4e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62025270	0.747	rs17639314	chr15:86309909	A/G	cg25843651	chr15:86329602	KLHL25	0.66	10.81	0.45	2.01e-24	Idiopathic pulmonary fibrosis;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs35362007	0.530	rs17835086	chr14:96012465	A/G	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.78	9.44	0.4	1.89e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.45	8.35	0.36	7.74e-16	Longevity;
LGG	cis	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.12	-0.35	4.41e-15	Triglycerides;
LGG	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.42e-12	Blood metabolite levels;
LGG	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.18e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2270450	0.614	rs1421379	chr6:46705994	G/A	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.68	-0.44	6.09e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs5742933	0.857	rs11685425	chr2:190612703	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-7.44	-0.33	4.79e-13	Ferritin levels;
LGG	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg27535305	chr1:53392650	SCP2	-0.31	-7.23	-0.32	2e-12	Monocyte count;
LGG	cis	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg13010199	chr12:38710504	ALG10B	0.77	16.36	0.61	8.19e-48	Heart rate;
LGG	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22496380	chr5:211416	CCDC127	-1.32	-18.7	-0.66	1.55e-58	Breast cancer;
LGG	cis	rs8133932	0.505	rs387320	chr21:47347750	A/G	cg11214348	chr21:47283868	PCBP3	-0.48	-9.43	-0.4	2.06e-19	Schizophrenia;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.86	-0.38	1.79e-17	Neuroticism;
LGG	cis	rs12765878	0.967	rs10883948	chr10:105667552	G/T	cg11005552	chr10:105648138	OBFC1	1.03	26.91	0.78	1.08e-96	Coronary artery disease;
LGG	cis	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg11502198	chr6:26597334	ABT1	-0.83	-6.81	-0.3	3.07e-11	Small cell lung carcinoma;
LGG	cis	rs8133932	0.654	rs2839050	chr21:47326666	G/A	cg11214348	chr21:47283868	PCBP3	0.45	8.02	0.35	8.45e-15	Schizophrenia;
LGG	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg21926883	chr2:100939477	LONRF2	-0.61	-13.25	-0.52	3.35e-34	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg03264133	chr6:25882463	NA	-0.43	-7.7	-0.34	8.26e-14	Height;
LGG	cis	rs2404602	0.647	rs12903331	chr15:77168268	C/G	cg15268244	chr15:77196840	NA	0.48	10.16	0.43	5.08e-22	Blood metabolite levels;
LGG	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg22105103	chr4:187893119	NA	0.53	10.2	0.43	3.57e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs922107	0.713	rs7532966	chr1:89955188	T/C	cg01128109	chr1:89989507	LRRC8B	0.31	6.92	0.31	1.52e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg25703541	chr22:24373054	LOC391322	1.06	23.6	0.74	1.97e-81	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg13206674	chr6:150067644	NUP43	0.6	13.32	0.53	1.77e-34	Lung cancer;
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	2.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg20637307	chr2:213403960	ERBB4	0.75	16.9	0.62	3.06e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3087591	0.920	rs4795592	chr17:29612620	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.5	-0.56	1.48e-39	Hip circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00121148	chr3:113603874	GRAMD1C	0.43	6.84	0.3	2.44e-11	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21898392	chr2:60983440	PAPOLG	0.42	6.86	0.3	2.23e-11	Cognitive performance;
LGG	trans	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg26043149	chr18:55253948	FECH	0.42	7.19	0.32	2.65e-12	Bone mineral density;
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.4	-0.44	6.42e-23	Platelet count;
LGG	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.66	-0.34	1.06e-13	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.16e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg17830980	chr10:43048298	ZNF37B	0.62	14.74	0.57	1.42e-40	Extrinsic epigenetic age acceleration;
LGG	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg16141378	chr3:129829833	LOC729375	0.39	8.43	0.36	4.34e-16	Triglycerides;
LGG	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg13512537	chr8:22265999	SLC39A14	-0.48	-8.23	-0.36	1.87e-15	Verbal declarative memory;
LGG	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.58	-0.33	1.89e-13	HDL cholesterol;
LGG	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg06885757	chr1:42089581	HIVEP3	0.57	12.92	0.51	7.97e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg22771759	chr13:24902376	NA	0.4	6.76	0.3	4.09e-11	Obesity-related traits;
LGG	cis	rs2587949	0.615	rs73120432	chr3:4221648	T/C	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-9.74	-0.41	1.6e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg14926445	chr8:58193284	C8orf71	-0.69	-8.56	-0.37	1.67e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00699941	chr2:86332848	POLR1A;PTCD3	-0.47	-6.76	-0.3	4.04e-11	Systemic lupus erythematosus;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg04025307	chr7:1156635	C7orf50	0.62	8.06	0.35	6.4e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg15595755	chr5:1867978	NA	0.51	10.2	0.43	3.59e-22	Cardiovascular disease risk factors;
LGG	cis	rs2637030	0.559	rs6881928	chr5:52988609	C/A	cg06476337	chr5:52856530	NDUFS4	0.44	6.88	0.3	1.99e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg21605333	chr4:119757512	SEC24D	1.37	12.81	0.51	2.19e-32	Cannabis dependence symptom count;
LGG	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg05791153	chr7:19748676	TWISTNB	0.56	8.2	0.36	2.38e-15	Thyroid stimulating hormone;
LGG	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg22437258	chr11:111473054	SIK2	0.56	9.73	0.41	1.71e-20	Primary sclerosing cholangitis;
LGG	cis	rs1707322	0.686	rs3014239	chr1:46089801	G/A	cg03146154	chr1:46216737	IPP	-0.57	-11.08	-0.46	1.77e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9534288	0.702	rs7331472	chr13:46644173	C/T	cg15192986	chr13:46630673	CPB2	-0.71	-14.97	-0.57	1.28e-41	Blood protein levels;
LGG	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg06611532	chr13:114900021	NA	0.28	6.95	0.31	1.21e-11	Schizophrenia;
LGG	cis	rs10189230	0.967	rs7573758	chr2:222357326	G/T	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	7.37e-32	Urate levels in lean individuals;
LGG	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07080220	chr10:102295463	HIF1AN	0.64	9.55	0.41	7.77e-20	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs2562456	0.833	rs7260065	chr19:21516977	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.38	-0.32	7.54e-13	Pain;
LGG	trans	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg07211511	chr3:129823064	LOC729375	0.66	9.13	0.39	2.12e-18	Blood pressure (smoking interaction);
LGG	cis	rs554111	0.963	rs710312	chr1:21042462	A/G	cg15613048	chr1:21044031	KIF17	-0.35	-6.97	-0.31	1.06e-11	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.9	-0.31	1.73e-11	Height;
LGG	cis	rs919433	0.679	rs10166328	chr2:198511917	A/G	cg00792783	chr2:198669748	PLCL1	0.57	9.22	0.39	1.02e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs870825	0.932	rs2696059	chr4:185575127	A/T	cg04058563	chr4:185651563	MLF1IP	-0.95	-17.45	-0.63	8.83e-53	Blood protein levels;
LGG	cis	rs9815354	0.723	rs61182696	chr3:42032511	C/T	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg12432903	chr7:1882776	MAD1L1	0.5	8.74	0.38	4.37e-17	Bipolar disorder;
LGG	cis	rs9486719	0.843	rs2103539	chr6:96844342	T/A	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.1	-0.42	8.45e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1341267	0.529	rs6492720	chr13:95256305	T/C	cg18412871	chr13:95254051	GPR180	-0.51	-8.36	-0.36	7.52e-16	Triglyceride levels;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg04632378	chr13:21900426	NA	0.41	8.44	0.37	3.96e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.44	-0.4	1.85e-19	Height;
LGG	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg12560992	chr17:57184187	TRIM37	0.88	15.64	0.59	1.49e-44	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg02227867	chr8:22457446	C8orf58	0.41	7.8	0.34	4.28e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg19676328	chr12:49525230	TUBA1B	-0.63	-9.99	-0.42	2.05e-21	Total cholesterol levels;
LGG	cis	rs7226408	0.857	rs72887036	chr18:34475737	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.08e-23	Prudent dietary pattern;
LGG	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.76	0.54	2.39e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	10.45	0.44	4.15e-23	Hypertriglyceridemia;
LGG	cis	rs16910800	0.689	rs7101737	chr11:23165031	C/T	cg20040320	chr11:23191996	NA	-0.61	-6.85	-0.3	2.3e-11	Cancer;
LGG	cis	rs357618	1.000	rs357622	chr5:150848405	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	8.74	0.38	4.27e-17	Breast cancer;
LGG	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg08461772	chr7:95026248	PON3	0.35	7.43	0.33	5.18e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4926611	0.736	rs12733756	chr1:54120307	A/G	cg23596471	chr1:54105337	GLIS1	-0.32	-6.7	-0.3	5.99e-11	Hand grip strength;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg26174226	chr8:58114915	NA	-0.46	-6.93	-0.31	1.38e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg11502198	chr6:26597334	ABT1	0.58	10.05	0.42	1.3e-21	Intelligence (multi-trait analysis);
LGG	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg00531865	chr16:30841666	NA	0.51	10.3	0.43	1.57e-22	Dementia with Lewy bodies;
LGG	cis	rs2540226	0.539	rs2540247	chr2:39909949	C/T	cg18968196	chr2:39892502	TMEM178	0.32	8.91	0.38	1.16e-17	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14361641	chr2:70056642	GMCL1	0.45	7.12	0.31	4.12e-12	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg02002194	chr4:3960332	NA	0.44	8.12	0.35	4.18e-15	Neuroticism;
LGG	cis	rs7923609	0.967	rs4454603	chr10:65012750	C/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.75	-0.3	4.51e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg05896524	chr21:47604654	C21orf56	0.55	9.75	0.41	1.44e-20	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24942186	chr3:55521373	WNT5A	0.43	7.01	0.31	8.26e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10267417	0.603	rs2390196	chr7:19864026	G/A	cg05791153	chr7:19748676	TWISTNB	0.56	7.26	0.32	1.61e-12	Night sleep phenotypes;
LGG	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs7914558	0.966	rs7096269	chr10:104736721	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.52	0.44	2.47e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7267979	0.549	rs6138536	chr20:25182648	A/G	cg06421707	chr20:25228305	PYGB	0.41	8.41	0.36	5.08e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg08603382	chr10:743973	NA	0.63	12.17	0.49	9.49e-30	Psychosis in Alzheimer's disease;
LGG	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11764359	chr7:65958608	NA	-0.64	-10.7	-0.45	5.02e-24	Aortic root size;
LGG	cis	rs7674212	0.537	rs2623060	chr4:104047504	G/A	cg16532752	chr4:104119610	CENPE	-0.42	-7.26	-0.32	1.69e-12	Type 2 diabetes;
LGG	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1007190	0.764	rs8064669	chr17:42874870	C/T	cg15406952	chr17:42872593	NA	-1.19	-12.05	-0.49	2.77e-29	DNA methylation (variation);
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg14541582	chr5:601475	NA	-0.68	-10.66	-0.44	7.01e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg12310025	chr6:25882481	NA	-0.43	-7.05	-0.31	6.56e-12	Iron status biomarkers;
LGG	cis	rs6466055	0.669	rs6948885	chr7:104664879	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.13	-0.31	4e-12	Schizophrenia;
LGG	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.22	0.65	2.7e-56	Smoking behavior;
LGG	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11890956	chr21:40555474	PSMG1	-0.68	-11.52	-0.47	3.51e-27	Menarche (age at onset);
LGG	cis	rs9487051	0.676	rs9372208	chr6:109596168	A/G	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.01e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9972944	0.756	rs6504352	chr17:63765287	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg22535103	chr8:58192502	C8orf71	-0.86	-11.12	-0.46	1.23e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7975161	0.521	rs4447242	chr12:104720708	T/G	cg25273343	chr12:104657179	TXNRD1	-0.77	-7.39	-0.32	6.88e-13	Toenail selenium levels;
LGG	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03576123	chr11:487126	PTDSS2	-1.32	-16.88	-0.62	3.64e-50	Body mass index;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.09	-0.42	9.36e-22	Lung cancer;
LGG	cis	rs883115	0.846	rs1566388	chr1:224795474	A/T	cg01808320	chr1:224927238	CNIH3	-0.43	-7.87	-0.34	2.45e-14	Cancer;
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.79	0.38	3e-17	Bipolar disorder;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg16606324	chr3:10149918	C3orf24	0.64	7.17	0.32	2.94e-12	Alzheimer's disease;
LGG	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg13013644	chr5:502571	SLC9A3	0.32	7.15	0.32	3.38e-12	Cystic fibrosis severity;
LGG	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.96e-20	Retinal vascular caliber;
LGG	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.05	-0.42	1.22e-21	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg06521331	chr12:34319734	NA	-0.49	-8.5	-0.37	2.68e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6087990	0.965	rs6058869	chr20:31348750	C/T	cg13636640	chr20:31349939	DNMT3B	1.02	22.2	0.72	6.83e-75	Ulcerative colitis;
LGG	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.44	0.58	1.07e-43	Hair morphology;
LGG	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.4e-16	Axial length;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03647317	chr4:187891568	NA	-0.39	-8.47	-0.37	3.33e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1594829	0.553	rs7003030	chr8:26172699	G/T	cg11498726	chr8:26250323	BNIP3L	-0.39	-8.68	-0.37	6.95e-17	Height;
LGG	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg17054900	chr3:154042577	DHX36	0.48	7.37	0.32	8.04e-13	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03945577	chr1:150602196	ENSA	0.45	7.07	0.31	5.66e-12	Gut microbiome composition (summer);
LGG	cis	rs9300255	0.543	rs1260294	chr12:123560289	T/C	cg00376283	chr12:123451042	ABCB9	-0.57	-8.29	-0.36	1.27e-15	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg13683864	chr3:40499215	RPL14	-1.11	-25.26	-0.76	4.03e-89	Renal cell carcinoma;
LGG	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg17145862	chr1:211918768	LPGAT1	0.85	19.37	0.67	1.19e-61	Leprosy;
LGG	cis	rs17655565	0.904	rs3809172	chr12:52695198	G/C	cg08257133	chr12:52711352	KRT83	0.52	7.08	0.31	5.5e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs7124681	0.584	rs11039448	chr11:47918416	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-11.15	-0.46	1e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	6.65	0.3	8.15e-11	Neuroticism;
LGG	cis	rs4919694	1.000	rs7100592	chr10:104769098	T/G	cg04362960	chr10:104952993	NT5C2	1.06	14.74	0.57	1.33e-40	Arsenic metabolism;
LGG	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg15145296	chr3:125709740	NA	-0.59	-7.72	-0.34	7.25e-14	Blood pressure (smoking interaction);
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg05091796	chr16:4465799	CORO7	-0.62	-10.19	-0.43	3.87e-22	Schizophrenia;
LGG	cis	rs79349575	0.783	rs4399576	chr17:47009835	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs12431410	0.550	rs1957995	chr14:60199568	T/C	cg07950296	chr14:60194823	RTN1	-0.38	-7.31	-0.32	1.2e-12	Schizophrenia;
LGG	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg23649088	chr2:200775458	C2orf69	0.58	9.18	0.39	1.47e-18	Schizophrenia;
LGG	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs8044868	0.586	rs8182213	chr16:72080005	C/T	cg23815491	chr16:72088622	HP	0.36	7.61	0.33	1.56e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg26655873	chr3:72818019	SHQ1	0.37	7.55	0.33	2.3e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-18.56	-0.65	6.57e-58	Lymphocyte percentage of white cells;
LGG	cis	rs9393777	0.513	rs9368447	chr6:26646674	A/C	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg14416269	chr4:6271139	WFS1	0.53	9.93	0.42	3.41e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07569756	chr17:48474564	LRRC59	0.45	6.99	0.31	9.75e-12	Gut microbiome composition (summer);
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs7267979	0.528	rs34485039	chr20:25583763	G/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.61	-0.33	1.5700000000000001e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.12	-0.43	6.83e-22	Obesity-related traits;
LGG	cis	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg07460842	chr6:66804631	NA	0.57	9.52	0.4	9.88e-20	Metabolite levels;
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg12648201	chr2:27665141	KRTCAP3	-0.26	-6.67	-0.3	7.24e-11	Total body bone mineral density;
LGG	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.31	-0.4	5.06e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17776563	0.614	rs16942055	chr15:89122550	A/C	cg05013243	chr15:89149849	MIR1179	-0.34	-6.99	-0.31	9.4e-12	Thyroid hormone levels;
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg09448879	chr15:79043637	NA	-0.49	-11.73	-0.48	5.32e-28	Coronary artery disease or large artery stroke;
LGG	cis	rs4363385	0.510	rs7541328	chr1:152894142	C/G	cg13444842	chr1:152974279	SPRR3	-0.46	-9.31	-0.4	5.29e-19	Inflammatory skin disease;
LGG	cis	rs1318772	1.000	rs11739509	chr5:112650751	T/C	cg12552261	chr5:112820674	MCC	0.69	7.99	0.35	1.09e-14	F-cell distribution;
LGG	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.27	0.32	1.51e-12	Bladder cancer;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg04234412	chr22:24373322	LOC391322	-0.73	-14.93	-0.57	1.97e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg14983838	chr19:29218262	NA	0.71	11.42	0.47	8.53e-27	Methadone dose in opioid dependence;
LGG	cis	rs2273669	0.667	rs12153822	chr6:109315115	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.41	-0.36	5.07e-16	Prostate cancer;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20145149	chr1:115124491	BCAS2	0.5	7.39	0.32	6.93e-13	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.966	rs11925823	chr3:47443065	C/G	cg27129171	chr3:47204927	SETD2	0.77	15.02	0.57	8.21e-42	Colorectal cancer;
LGG	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.28	0.84	7.14e-125	Chronic sinus infection;
LGG	cis	rs9290065	0.519	rs1447608	chr3:160682019	G/T	cg03342759	chr3:160939853	NMD3	-0.52	-8.68	-0.37	6.7e-17	Kawasaki disease;
LGG	cis	rs9513627	1.000	rs9582302	chr13:100125985	A/T	cg15490075	chr13:100150979	NA	-0.66	-6.97	-0.31	1.13e-11	Obesity-related traits;
LGG	cis	rs62244186	0.773	rs6809116	chr3:44712097	A/C	cg02073558	chr3:44770973	ZNF501	0.71	13.73	0.54	3.01e-36	Depressive symptoms;
LGG	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg03517284	chr6:25882590	NA	-0.41	-6.79	-0.3	3.55e-11	Iron status biomarkers;
LGG	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Vitiligo;
LGG	cis	rs9902453	0.904	rs9905638	chr17:28261022	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.22	0.55	2.4e-38	Coffee consumption (cups per day);
LGG	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.99	-0.31	9.64e-12	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.545	rs6580895	chr12:39372011	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-11.02	-0.46	2.96e-25	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg12708336	chr17:41446283	NA	-0.32	-7.43	-0.33	5.21e-13	Menopause (age at onset);
LGG	cis	rs9814567	1.000	rs9809619	chr3:134280948	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg16850897	chr7:100343110	ZAN	-0.69	-10.24	-0.43	2.55e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3617	0.539	rs4687689	chr3:52948674	A/C	cg11645453	chr3:52864694	ITIH4	-0.46	-7.83	-0.34	3.45e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg15352829	chr14:105391018	PLD4	-0.46	-11.08	-0.46	1.79e-25	Rheumatoid arthritis;
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.69	0.37	6.12e-17	Neuroticism;
LGG	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg04568710	chr12:38710424	ALG10B	-0.4	-8.35	-0.36	7.78e-16	Morning vs. evening chronotype;
LGG	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.59	-0.53	1.18e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04013166	chr16:89971882	TCF25	0.5	6.78	0.3	3.67e-11	Skin colour saturation;
LGG	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg09307838	chr4:120376055	NA	0.82	13.67	0.54	5.75e-36	Corneal astigmatism;
LGG	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7017914	0.967	rs13274381	chr8:71765094	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.98	-0.31	1.05e-11	Bone mineral density;
LGG	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg26695010	chr11:65641043	EFEMP2	0.46	7.19	0.32	2.68e-12	Breast cancer;
LGG	cis	rs2463822	0.669	rs72919475	chr11:62042361	T/A	cg06239285	chr11:62104954	ASRGL1	-1.02	-12.53	-0.5	3.27e-31	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6121246	0.909	rs6089058	chr20:30326338	T/G	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6933660	0.512	rs13198669	chr6:151799924	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.59	-7.67	-0.34	1.02e-13	Menarche (age at onset);
LGG	cis	rs11229555	0.598	rs12269888	chr11:58184336	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs75059851	0.756	rs11223648	chr11:133840412	C/T	cg20042908	chr11:133852938	NA	-0.77	-14.28	-0.55	1.4e-38	Schizophrenia;
LGG	trans	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs3008870	1.000	rs2182143	chr1:67378936	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	22.83	0.73	7.75e-78	Lymphocyte percentage of white cells;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26805306	chr1:43855055	MED8;C1orf84	0.51	7.62	0.33	1.42e-13	Apolipoprotein A-IV levels;
LGG	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs12135191	0.933	rs7528511	chr1:236471581	C/T	cg21399712	chr1:236511386	NA	-0.4	-7.72	-0.34	7.33e-14	Urate levels (BMI interaction);
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg17202724	chr17:61916730	SMARCD2	0.49	10.96	0.45	5.16e-25	Prudent dietary pattern;
LGG	trans	rs970548	0.738	rs1051713	chr10:45938746	C/T	cg14222797	chr10:16859974	RSU1	-0.65	-7.62	-0.33	1.48e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg05059571	chr16:84539110	KIAA1609	-0.61	-11.47	-0.47	5.46e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg09263875	chr16:632152	PIGQ	0.67	13.43	0.53	5.71e-35	Height;
LGG	trans	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17712092	chr4:129076599	LARP1B	0.75	14.46	0.56	2.23e-39	Eosinophil percentage of white cells;
LGG	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.14e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg19539972	chr4:7069911	GRPEL1	0.67	9.74	0.41	1.57e-20	Monocyte percentage of white cells;
LGG	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.7	-0.41	2.16e-20	Diabetic retinopathy;
LGG	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.98	0.57	1.14e-41	Cognitive test performance;
LGG	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg03929089	chr4:120376271	NA	-0.67	-8.33	-0.36	9.02e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	13.04	0.52	2.62e-33	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg05313129	chr8:58192883	C8orf71	-0.75	-9.99	-0.42	2.05e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs26528	0.584	rs153103	chr16:28528623	A/G	cg00198680	chr16:28758506	NA	-0.28	-6.68	-0.3	7e-11	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg03970086	chr16:88974840	CBFA2T3	0.41	8.23	0.36	1.85e-15	Social autistic-like traits;
LGG	cis	rs12286929	0.637	rs3802858	chr11:115078492	T/C	cg04055981	chr11:115044050	NA	-0.37	-6.84	-0.3	2.52e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7767084	0.572	rs7754014	chr6:160918295	A/T	cg04181478	chr6:161122748	PLG	0.46	6.96	0.31	1.16e-11	Coronary heart disease;
LGG	cis	rs17818399	0.547	rs62134736	chr2:46766446	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.55	8.4	0.36	5.64e-16	Height;
LGG	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-9.08	-0.39	3.12e-18	Diabetic retinopathy;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg11878867	chr6:150167359	LRP11	-0.47	-8.25	-0.36	1.63e-15	Lung cancer;
LGG	cis	rs941873	0.772	rs7086293	chr10:81103247	T/C	cg09469691	chr10:81107165	PPIF	0.58	10.28	0.43	1.75e-22	Height;
LGG	cis	rs7945718	0.805	rs6486059	chr11:12824581	A/G	cg25843174	chr11:12811716	TEAD1	-0.37	-7.47	-0.33	4.02e-13	Educational attainment (years of education);
LGG	cis	rs7660883	1.000	rs4693156	chr4:88007227	A/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.36	-0.4	3.38e-19	HDL cholesterol levels;
LGG	cis	rs6893300	0.524	rs10516146	chr5:179166974	A/G	cg14593053	chr5:179126677	CANX	0.4	6.92	0.31	1.55e-11	Resting heart rate;
LGG	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-26.94	-0.78	7.43e-97	Height;
LGG	cis	rs2860975	1.000	rs11492718	chr10:96787377	A/T	cg09036531	chr10:96991505	NA	-0.47	-8.56	-0.37	1.73e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7215564	0.908	rs2340773	chr17:78744395	T/C	cg06153925	chr17:78755379	RPTOR	-0.41	-7.13	-0.31	4.01e-12	Myopia (pathological);
LGG	cis	rs9473924	0.542	rs6901576	chr6:50926064	G/T	cg14470998	chr6:50812995	TFAP2B	-0.64	-7.63	-0.33	1.33e-13	Body mass index;
LGG	cis	rs7945718	0.967	rs11022496	chr11:12789561	G/A	cg25843174	chr11:12811716	TEAD1	0.4	8.3	0.36	1.13e-15	Educational attainment (years of education);
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.75	-0.41	1.5e-20	Lung cancer;
LGG	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg09307838	chr4:120376055	NA	0.81	13.52	0.53	2.53e-35	Corneal astigmatism;
LGG	cis	rs854037	0.759	rs6864832	chr5:57055941	G/A	cg08523694	chr5:57076192	NA	0.49	6.86	0.3	2.2e-11	Birth weight;
LGG	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg13607699	chr17:42295918	UBTF	-0.43	-6.81	-0.3	2.97e-11	Total body bone mineral density;
LGG	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg09222892	chr1:25734099	RHCE	-0.46	-9.58	-0.41	6.01e-20	Erythrocyte sedimentation rate;
LGG	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg12091567	chr17:66097778	LOC651250	0.78	12.85	0.51	1.56e-32	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1707322	0.929	rs785500	chr1:46593044	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.5	-0.4	1.12e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2574985	0.739	rs3011791	chr10:52310421	T/C	cg18558237	chr10:81444220	LOC650623	0.43	6.65	0.3	8.09e-11	Subjective well-being;
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.6e-23	Bipolar disorder;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01208855	chr16:54545949	NA	0.37	7.11	0.31	4.44e-12	Electrocardiographic conduction measures;
LGG	cis	rs6489882	0.703	rs10774673	chr12:113361158	C/T	cg25319449	chr12:113376135	OAS3	-0.37	-6.65	-0.3	8.22e-11	Chronic lymphocytic leukemia;
LGG	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	9.0	0.39	5.95e-18	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs782590	0.748	rs782634	chr2:55897700	T/C	cg18811423	chr2:55921094	PNPT1	0.9	19.66	0.67	5.12e-63	Metabolic syndrome;
LGG	cis	rs13108043	0.511	rs13149938	chr4:87768517	G/T	cg11209507	chr4:87813803	C4orf36	-0.64	-8.36	-0.36	7.63e-16	Red blood cell count;
LGG	cis	rs4664308	0.870	rs55959207	chr2:161016981	A/C	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.86	-0.59	1.45e-45	Idiopathic membranous nephropathy;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9399135	0.967	rs12527683	chr6:135324534	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg02487422	chr3:49467188	NICN1	0.57	10.68	0.44	6.15e-24	Resting heart rate;
LGG	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg09596252	chr17:78655493	RPTOR	0.45	8.18	0.36	2.81e-15	Obesity;
LGG	cis	rs1847202	0.826	rs1979884	chr3:72948515	T/C	cg25664220	chr3:72788482	NA	-0.25	-7.59	-0.33	1.82e-13	Motion sickness;
LGG	cis	rs9875589	0.509	rs4685058	chr3:14030384	T/C	cg19554555	chr3:13937349	NA	-0.53	-9.7	-0.41	2.3e-20	Ovarian reserve;
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.6	-0.41	5.16e-20	Aortic root size;
LGG	cis	rs17301259	0.548	rs2246562	chr7:88401837	C/T	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-7.3	-0.32	1.3e-12	Heschl's gyrus morphology;
LGG	cis	rs4132509	1.000	rs73124169	chr1:243804939	T/C	cg21452805	chr1:244014465	NA	0.64	7.82	0.34	3.49e-14	RR interval (heart rate);
LGG	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.05	-0.31	6.47e-12	Triglycerides;
LGG	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.58	-0.44	1.41e-23	Bladder cancer;
LGG	cis	rs10876993	0.728	rs1082503	chr12:58036717	G/A	cg18357645	chr12:58087776	OS9	0.67	12.1	0.49	1.76e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg25664220	chr3:72788482	NA	-0.3	-7.92	-0.35	1.75e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.82	-0.38	2.27e-17	Menopause (age at onset);
LGG	trans	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs7904368	0.806	rs6602161	chr10:16862280	A/G	cg23933602	chr10:16859644	RSU1	0.64	9.45	0.4	1.74e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs13421350	0.579	rs4405725	chr2:173305382	T/A	cg15021238	chr2:173305865	ITGA6	-0.81	-9.28	-0.4	6.42e-19	Diabetic kidney disease;
LGG	cis	rs7119	0.931	rs62009087	chr15:77833064	C/T	cg17802220	chr15:77601643	NA	-0.34	-7.18	-0.32	2.8e-12	Type 2 diabetes;
LGG	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11890956	chr21:40555474	PSMG1	-0.98	-21.05	-0.7	1.65e-69	Cognitive function;
LGG	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg25947184	chr8:1697459	NA	0.46	8.08	0.35	5.79e-15	Systolic blood pressure;
LGG	cis	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg00383909	chr3:49044727	WDR6	1.01	12.61	0.51	1.57e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2386661	0.712	rs11259544	chr10:5646708	T/C	cg17085576	chr10:5658249	NA	-0.41	-7.58	-0.33	1.95e-13	Breast cancer;
LGG	cis	rs6594713	0.643	rs10077431	chr5:112927686	A/C	cg12552261	chr5:112820674	MCC	-0.61	-8.58	-0.37	1.5e-16	Brain cytoarchitecture;
LGG	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.0	-0.31	8.88e-12	Uric acid levels;
LGG	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23598886	chr18:12777645	NA	-0.65	-8.62	-0.37	1.07e-16	Inflammatory skin disease;
LGG	trans	rs7939886	0.920	rs61887958	chr11:55938234	A/G	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.81	0.41	9.2e-21	Colorectal cancer;
LGG	cis	rs1869026	0.967	rs11122802	chr2:121335866	C/A	cg22272644	chr2:121334640	NA	0.3	7.24	0.32	1.93e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7666738	0.830	rs10470951	chr4:99037051	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs629535	0.814	rs78813708	chr8:70073977	A/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg00908189	chr16:619842	PIGQ	0.87	16.55	0.61	1.19e-48	Height;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.18e-21	Prudent dietary pattern;
LGG	cis	rs6076065	0.723	rs6083119	chr20:23390923	T/G	cg12633918	chr20:23549525	CST9L	-0.36	-6.71	-0.3	5.58e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg24134504	chr18:76639479	NA	-0.47	-8.23	-0.36	1.94e-15	Obesity-related traits;
LGG	cis	rs6964587	0.758	rs35963176	chr7:91617115	C/T	cg17063962	chr7:91808500	NA	0.47	7.01	0.31	8.49e-12	Breast cancer;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg05368731	chr17:41323189	NBR1	0.96	19.07	0.66	2.9e-60	Menopause (age at onset);
LGG	cis	rs7147624	1.000	rs7160390	chr14:66052460	G/A	cg03016385	chr14:66212404	NA	-0.78	-9.64	-0.41	3.58e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg06494592	chr3:125709126	NA	-0.55	-7.0	-0.31	9.02e-12	Blood pressure (smoking interaction);
LGG	cis	rs7107174	1.000	rs11601161	chr11:78073280	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg08999081	chr20:33150536	PIGU	-0.41	-10.31	-0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg26384229	chr12:38710491	ALG10B	-0.68	-13.51	-0.53	2.81e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.98	-0.31	1.02e-11	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10150615	chr22:24372951	LOC391322	0.45	7.78	0.34	4.76e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg11050988	chr7:1952600	MAD1L1	0.34	8.04	0.35	7.41e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg25482853	chr8:67687455	SGK3	1.03	13.14	0.52	9.64e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs2594989	0.943	rs2443713	chr3:11537540	T/G	cg01796438	chr3:11312864	ATG7	-0.56	-7.55	-0.33	2.36e-13	Circulating chemerin levels;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg05861140	chr6:150128134	PCMT1	0.45	10.53	0.44	2.09e-23	Lung cancer;
LGG	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs929596	0.531	rs2741019	chr2:234510688	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-8.3	-0.36	1.19e-15	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-11.75	-0.48	4.5e-28	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-9.8	-0.41	9.79e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg05234568	chr11:5960015	NA	-0.72	-11.74	-0.48	4.77e-28	DNA methylation (variation);
LGG	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs6546550	0.869	rs6720498	chr2:70124805	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.02	-0.35	8.62e-15	Prevalent atrial fibrillation;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.92e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15664640	chr17:80829946	TBCD	0.76	14.54	0.56	1.01e-39	Breast cancer;
LGG	trans	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg21659725	chr3:3221576	CRBN	0.54	8.11	0.35	4.55e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	8.44	0.37	4.05e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02249930	chr10:70166207	RUFY2	0.54	9.1	0.39	2.68e-18	Cognitive performance;
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.33	-0.36	9.17e-16	Life satisfaction;
LGG	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.08	-0.42	9.98e-22	Schizophrenia;
LGG	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-27.59	-0.79	8.3e-100	Height;
LGG	trans	rs7939886	0.920	rs12223785	chr11:56058820	T/A	cg15704280	chr7:45808275	SEPT13	0.82	7.62	0.33	1.47e-13	Myopia (pathological);
LGG	cis	rs9393813	0.967	rs764284	chr6:27312078	C/T	cg18711553	chr6:27366782	ZNF391	0.49	8.91	0.38	1.21e-17	Bipolar disorder;
LGG	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg16329650	chr2:213403929	ERBB4	0.43	7.69	0.34	9.02e-14	Symmetrical dimethylarginine levels;
LGG	cis	rs4774899	0.966	rs1814585	chr15:57509058	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.37	-0.32	8.17e-13	Urinary tract infection frequency;
LGG	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg16141378	chr3:129829833	LOC729375	0.41	9.33	0.4	4.32e-19	Retinal vascular caliber;
LGG	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg10935138	chr17:73851978	WBP2	-0.51	-8.08	-0.35	5.64e-15	Psoriasis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04139300	chr20:40247070	CHD6	0.39	7.17	0.32	3.02e-12	Bilirubin levels;
LGG	cis	rs975739	1.000	rs1668619	chr13:78385750	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.1e-11	Hair color;
LGG	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs4988958	0.584	rs7589142	chr2:103024660	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg12856521	chr11:46389249	DGKZ	0.44	7.64	0.33	1.29e-13	Leprosy;
LGG	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg10523679	chr1:76189770	ACADM	0.83	14.98	0.57	1.16e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg16486109	chr11:613632	IRF7	0.43	7.41	0.33	6.03e-13	Systemic lupus erythematosus;
LGG	cis	rs4363385	0.747	rs2339494	chr1:152975143	G/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.39	-0.4	2.63e-19	Inflammatory skin disease;
LGG	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg25664220	chr3:72788482	NA	-0.33	-9.38	-0.4	3.03e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs896854	0.738	rs1713669	chr8:95958637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.68	-0.37	6.71e-17	Type 2 diabetes;
LGG	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg04117972	chr1:227635322	NA	-0.82	-13.27	-0.52	2.69e-34	Major depressive disorder;
LGG	cis	rs9487094	0.644	rs9320286	chr6:109724937	G/A	cg01125227	chr6:109776195	MICAL1	0.4	6.99	0.31	9.41e-12	Height;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg20607798	chr8:58055168	NA	0.61	7.06	0.31	6.3e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6087990	0.835	rs4911106	chr20:31331330	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	18.81	0.66	4.93e-59	Ulcerative colitis;
LGG	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.53	-7.08	-0.31	5.36e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13082711	0.911	rs13081368	chr3:27521998	G/T	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.24e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg22681709	chr2:178499509	PDE11A	-0.51	-7.02	-0.31	7.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs432925	0.576	rs11866815	chr16:387867	C/T	cg00101154	chr16:420108	MRPL28	-0.48	-6.78	-0.3	3.57e-11	Morning vs. evening chronotype;
LGG	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg13334819	chr7:99746414	C7orf59	-0.46	-7.14	-0.31	3.75e-12	Coronary artery disease;
LGG	cis	rs897080	0.515	rs1067332	chr2:44626972	G/A	cg00619915	chr2:44497795	NA	-0.49	-6.93	-0.31	1.41e-11	Height;
LGG	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg03433033	chr1:76189801	ACADM	0.69	10.43	0.44	5.23e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg06636001	chr8:8085503	FLJ10661	0.64	12.81	0.51	2.37e-32	Mood instability;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg02462569	chr6:150064036	NUP43	-0.39	-8.34	-0.36	8.73e-16	Lung cancer;
LGG	trans	rs11875185	0.510	rs73451170	chr18:55617835	G/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.38e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs42648	0.869	rs6973816	chr7:89921072	C/T	cg25739043	chr7:89950458	NA	-0.44	-9.4	-0.4	2.53e-19	Homocysteine levels;
LGG	cis	rs1707322	0.721	rs11211165	chr1:46157906	C/T	cg03146154	chr1:46216737	IPP	0.56	10.91	0.45	7.93e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.24e-13	Bladder cancer;
LGG	trans	rs9354308	0.764	rs9885896	chr6:66595931	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs698813	0.555	rs7605771	chr2:44479778	G/A	cg00619915	chr2:44497795	NA	-0.6	-8.87	-0.38	1.62e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.15	-0.39	1.88e-18	Personality dimensions;
LGG	cis	rs4363385	0.588	rs7540609	chr1:153024589	C/A	cg13444842	chr1:152974279	SPRR3	-0.48	-9.81	-0.41	8.95e-21	Inflammatory skin disease;
LGG	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg27411982	chr8:10470053	RP1L1	-0.48	-8.17	-0.36	2.9e-15	Neuroticism;
LGG	cis	rs2304069	0.826	rs2244195	chr5:149403528	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	13.52	0.53	2.42e-35	HIV-1 control;
LGG	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.77	9.44	0.4	1.86e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs11239187	0.530	rs10900069	chr10:45062758	A/G	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.31e-18	Body mass index;
LGG	cis	rs138249	1.000	rs138249	chr22:50569790	C/T	cg07310406	chr22:50524374	MLC1	0.46	9.25	0.4	8.14e-19	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs6763768	0.606	rs1001222	chr3:53352099	G/A	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-12.21	-0.49	6.19e-30	Cognitive function;
LGG	trans	rs17685	0.725	rs1044483	chr7:75659815	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.05	-25.07	-0.76	2.95e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs12230513	0.793	rs6581066	chr12:55926695	G/A	cg19537932	chr12:55886519	OR6C68	-0.39	-6.88	-0.3	2e-11	Contrast sensitivity;
LGG	cis	rs1249910	0.660	rs9833456	chr3:112395286	A/G	cg02954903	chr3:112359935	CCDC80	0.41	7.25	0.32	1.75e-12	Diabetic kidney disease;
LGG	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg26384229	chr12:38710491	ALG10B	0.76	15.56	0.59	3.27e-44	Morning vs. evening chronotype;
LGG	cis	rs977987	0.762	rs1364079	chr16:75393131	C/A	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.16e-22	Dupuytren's disease;
LGG	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.27	-0.32	1.52e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg10339854	chr22:39548620	CBX7	-0.4	-6.88	-0.3	1.92e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs78049276	0.512	rs7659823	chr4:148398877	C/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.65	-10.42	-0.44	5.53e-23	Pulse pressure;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11169552	0.510	rs10783383	chr12:51102869	A/G	cg12884762	chr12:50931848	DIP2B	-0.42	-7.96	-0.35	1.3e-14	Colorectal cancer;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.53	-0.44	2.19e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs751728	0.585	rs9380381	chr6:33771070	C/T	cg25922239	chr6:33757077	LEMD2	0.67	10.43	0.44	4.95e-23	Crohn's disease;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg06654118	chr4:1303317	MAEA	0.47	8.39	0.36	6.05e-16	Obesity-related traits;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg09796094	chr14:105350432	KIAA0284	-0.37	-7.23	-0.32	2e-12	Migraine with aura;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg26513180	chr16:89883248	FANCA	1.02	9.6	0.41	5.2e-20	Skin colour saturation;
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.66	-0.3	7.55e-11	Retinal vascular caliber;
LGG	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.39	-7.18	-0.32	2.88e-12	Educational attainment;
LGG	cis	rs7582720	1.000	rs7582720	chr2:203753072	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg11473876	chr11:109292803	C11orf87	0.48	9.45	0.4	1.64e-19	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	0.45	7.28	0.32	1.42e-12	Cognitive performance;
LGG	cis	rs2011503	1.000	rs8110250	chr19:19559989	G/A	cg11584989	chr19:19387371	SF4	0.75	12.35	0.5	1.76e-30	Bipolar disorder;
LGG	trans	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg02030672	chr11:45687055	CHST1	0.56	10.17	0.43	4.77e-22	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg02725872	chr8:58115012	NA	-0.78	-10.74	-0.45	3.45e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.534	rs10844728	chr12:34020109	G/C	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg17330251	chr7:94953956	PON1	-0.43	-8.15	-0.35	3.38e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.36	0.5	1.59e-30	Obesity-related traits;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.25	0.36	1.71e-15	Neuroticism;
LGG	cis	rs2865126	0.818	rs2865118	chr18:10759961	G/A	cg21165219	chr18:10698044	FAM38B	-0.45	-7.3	-0.32	1.27e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg11812906	chr14:75593930	NEK9	-0.44	-7.92	-0.35	1.79e-14	Height;
LGG	cis	rs4919044	0.562	rs79873247	chr10:94622388	A/C	cg05127821	chr10:94822908	CYP26C1	-0.4	-6.98	-0.31	1.04e-11	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.05	-0.39	4.12e-18	Obesity-related traits;
LGG	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg19507638	chr5:93509721	C5orf36	0.62	8.96	0.38	7.88e-18	Diabetic retinopathy;
LGG	cis	rs10046574	0.561	rs13438700	chr7:135207626	C/A	cg27474649	chr7:135195673	CNOT4	0.73	9.2	0.39	1.21e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg25986240	chr4:9926439	SLC2A9	-0.35	-7.15	-0.32	3.47e-12	Bone mineral density;
LGG	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg21435375	chr2:172878103	MAP1D	-0.32	-7.18	-0.32	2.79e-12	Schizophrenia;
LGG	cis	rs7633857	0.512	rs13098529	chr3:160657053	A/G	cg04691961	chr3:161091175	C3orf57	-0.39	-7.89	-0.34	2.18e-14	Educational attainment (years of education);
LGG	cis	rs3762637	0.943	rs9289198	chr3:122277160	G/T	cg24169773	chr3:122142474	KPNA1	-0.61	-10.4	-0.44	6.4e-23	LDL cholesterol levels;
LGG	cis	rs4356932	1.000	rs4356932	chr4:76955194	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg03511173	chr18:77590860	NA	0.62	7.71	0.34	7.78e-14	Opioid sensitivity;
LGG	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg27661571	chr11:113659931	NA	-0.58	-8.48	-0.37	3.16e-16	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.9	-0.34	2.1e-14	Life satisfaction;
LGG	cis	rs4692589	0.606	rs12645495	chr4:170933909	T/C	cg19918862	chr4:170955249	NA	0.4	7.23	0.32	2.01e-12	Anxiety disorder;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	trans	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs7215564	0.908	rs8074870	chr17:78684132	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.08	-0.35	5.84e-15	Myopia (pathological);
LGG	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg11871910	chr12:69753446	YEATS4	0.92	22.2	0.72	6.71e-75	Blood protein levels;
LGG	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.87	-0.51	1.34e-32	Chronic sinus infection;
LGG	trans	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.15e-16	Blood pressure (smoking interaction);
LGG	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg04226714	chr8:49833948	SNAI2	-0.49	-8.77	-0.38	3.42e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs367943	0.608	rs6859352	chr5:113007384	A/C	cg12552261	chr5:112820674	MCC	0.52	8.49	0.37	2.79e-16	Type 2 diabetes;
LGG	cis	rs2201728	0.739	rs67077969	chr4:100154214	C/G	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	trans	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.75	0.64	3.64e-54	Exhaled nitric oxide output;
LGG	cis	rs1927790	0.643	rs9556570	chr13:96999093	G/T	cg02571835	chr13:96230311	CLDN10	0.34	7.07	0.31	5.87e-12	Body mass index;
LGG	cis	rs6598955	0.671	rs12139514	chr1:26575939	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.17	0.35	3.04e-15	Obesity-related traits;
LGG	cis	rs9815354	0.680	rs73073266	chr3:42021116	A/G	cg03022575	chr3:42003672	ULK4	0.74	8.17	0.35	3.04e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg11764359	chr7:65958608	NA	0.63	9.74	0.41	1.64e-20	Aortic root size;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.48	0.33	3.77e-13	Prudent dietary pattern;
LGG	cis	rs7523273	0.925	rs12749612	chr1:208006749	A/G	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.46	-0.47	6.28e-27	Schizophrenia;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg05925327	chr15:68127851	NA	0.37	8.56	0.37	1.65e-16	Restless legs syndrome;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22946670	chr1:154909930	PMVK	0.47	7.55	0.33	2.3e-13	Cognitive performance;
LGG	cis	rs7106204	0.686	rs12803800	chr11:24258319	A/G	ch.11.24196551F	chr11:24239977	NA	0.86	9.48	0.4	1.34e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9460578	0.508	rs9465906	chr6:20822510	G/A	cg13405222	chr6:20811065	CDKAL1	0.76	17.35	0.63	2.69e-52	Breast cancer;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg17202724	chr17:61916730	SMARCD2	-0.6	-14.46	-0.56	2.25e-39	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04071427	chr10:70091481	HNRNPH3;PBLD	0.46	7.49	0.33	3.41e-13	Cognitive performance;
LGG	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.32	3.56e-12	Neuroticism;
LGG	cis	rs494459	0.838	rs1784543	chr11:118631653	A/T	cg20110707	chr11:118481992	PHLDB1	0.31	6.68	0.3	6.86e-11	Height;
LGG	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg04989706	chr14:50066350	PPIL5	-0.55	-8.68	-0.37	6.77e-17	Carotid intima media thickness;
LGG	cis	rs11700980	0.551	rs2832028	chr21:30114431	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs28595532	0.623	rs34082100	chr4:119220563	C/T	cg21605333	chr4:119757512	SEC24D	0.88	9.54	0.41	8.08e-20	Cannabis dependence symptom count;
LGG	cis	rs3540	0.514	rs2601192	chr15:90936704	G/A	cg22089800	chr15:90895588	ZNF774	0.69	12.75	0.51	4.19e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4363385	0.818	rs653332	chr1:153010481	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs2120243	0.510	rs10936087	chr3:157106628	T/G	cg24825693	chr3:157122686	VEPH1	-0.58	-13.53	-0.53	2.17e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.44	8.2	0.36	2.31e-15	Schizophrenia;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs10207628	0.823	rs10166461	chr2:127859413	G/A	cg06223080	chr2:127868745	NA	-0.77	-14.92	-0.57	2.19e-41	Psychosis and Alzheimer's disease;
LGG	cis	rs41271473	0.950	rs72750042	chr1:228854138	T/C	cg10167378	chr1:228756711	NA	0.58	8.29	0.36	1.28e-15	Chronic lymphocytic leukemia;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs4921915	0.526	rs13277738	chr8:18241507	C/T	cg18736775	chr8:18248649	NAT2	-0.77	-11.39	-0.47	1.15e-26	Iron status biomarkers (transferrin levels);
LGG	cis	rs9427116	0.677	rs9426831	chr1:154609657	A/T	cg11650704	chr1:154556575	ADAR	0.43	8.28	0.36	1.37e-15	Blood protein levels;
LGG	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg05677249	chr15:77158041	SCAPER	-0.32	-6.85	-0.3	2.32e-11	Blood metabolite levels;
LGG	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	8.15e-18	Cognitive test performance;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.58	0.33	1.89e-13	Schizophrenia;
LGG	cis	rs4493873	1.000	rs10110267	chr8:92073814	G/A	cg16814680	chr8:91681699	NA	0.47	7.24	0.32	1.86e-12	Migraine - clinic-based;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6076065	0.723	rs2236022	chr20:23373534	G/A	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs7408868	0.572	rs2074616	chr19:15294991	C/T	cg14696996	chr19:15285081	NOTCH3	0.81	10.97	0.45	4.64e-25	Pulse pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22835709	chr15:41408719	INO80	0.46	6.72	0.3	5.23e-11	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.16	-0.39	1.73e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg23758822	chr17:41437982	NA	0.86	15.24	0.58	8.63e-43	Menopause (age at onset);
LGG	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg05890377	chr2:74357713	NA	0.49	9.79	0.41	1.04e-20	Gestational age at birth (maternal effect);
LGG	trans	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.39	0.47	1.12e-26	Mean corpuscular volume;
LGG	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.4	-7.6	-0.33	1.68e-13	Social autistic-like traits;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.14	-0.46	1.04e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22455342	chr2:225449267	CUL3	0.84	14.71	0.56	1.88e-40	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg03060546	chr3:49711283	APEH	0.62	8.65	0.37	8.29e-17	Menarche (age at onset);
LGG	cis	rs57221529	0.654	rs11740553	chr5:672593	C/T	cg07777115	chr5:623756	CEP72	-0.57	-6.84	-0.3	2.44e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07856758	chr19:37861652	ZNF527	0.47	8.33	0.36	8.92e-16	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06380007	chr15:41408085	INO80	0.47	6.77	0.3	3.86e-11	Gut microbiome composition (summer);
LGG	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.83	-0.34	3.35e-14	Testicular germ cell tumor;
LGG	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg16329650	chr2:213403929	ERBB4	-0.52	-9.62	-0.41	4.25e-20	Symmetrical dimethylarginine levels;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg19761014	chr17:28927070	LRRC37B2	0.59	7.42	0.33	5.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg26384229	chr12:38710491	ALG10B	0.74	15.24	0.58	8.15e-43	Morning vs. evening chronotype;
LGG	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-7.6	-0.33	1.69e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs12908161	0.853	rs11633788	chr15:85305142	T/A	cg03959625	chr15:84868606	LOC388152	0.45	6.94	0.31	1.33e-11	Schizophrenia;
LGG	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg24011408	chr12:48396354	COL2A1	0.5	8.0	0.35	1.02e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs35160687	0.644	rs11127024	chr2:86505453	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.87	0.3	2.02e-11	Night sleep phenotypes;
LGG	cis	rs13260300	0.549	rs4534109	chr8:75539052	C/T	cg22993706	chr8:75542856	NA	0.45	9.61	0.41	4.82e-20	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs4631830	0.863	rs4554834	chr10:51530146	A/C	cg16070123	chr10:51489643	NA	-0.4	-7.34	-0.32	9.44e-13	Prostate-specific antigen levels;
LGG	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-8.44	-0.36	4.23e-16	Height;
LGG	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg15704280	chr7:45808275	SEPT13	0.72	9.93	0.42	3.42e-21	Axial length;
LGG	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg16473166	chr22:50639996	SELO	0.59	9.81	0.41	9.42e-21	Obesity-related traits;
LGG	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg20290983	chr6:43655470	MRPS18A	-0.81	-10.95	-0.45	5.54e-25	IgG glycosylation;
LGG	cis	rs7737355	0.812	rs11750704	chr5:130911578	C/A	cg06307176	chr5:131281290	NA	0.53	8.75	0.38	3.9e-17	Life satisfaction;
LGG	cis	rs67478160	0.643	rs2295141	chr14:104212949	T/C	cg26031613	chr14:104095156	KLC1	-0.44	-7.27	-0.32	1.55e-12	Schizophrenia;
LGG	cis	rs986417	1.000	rs1254324	chr14:60908551	C/T	cg27398547	chr14:60952738	C14orf39	-0.66	-6.66	-0.3	7.72e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2404602	0.647	rs8025991	chr15:77155268	C/T	cg23625390	chr15:77176239	SCAPER	-0.73	-14.54	-0.56	1.01e-39	Blood metabolite levels;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg09690326	chr7:23720549	C7orf46	0.47	10.85	0.45	1.33e-24	Schizophrenia;
LGG	cis	rs17767392	1.000	rs17767392	chr14:71764777	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.08	-0.46	1.84e-25	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg11161011	chr14:65562177	MAX	-0.65	-12.52	-0.5	3.4e-31	Obesity-related traits;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg08742575	chr21:47604166	C21orf56	0.56	10.03	0.42	1.46e-21	Testicular germ cell tumor;
LGG	cis	rs6912958	0.605	rs2754247	chr6:88383571	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.32	-0.36	9.68e-16	Monocyte percentage of white cells;
LGG	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg08508325	chr11:3079039	CARS	0.43	8.14	0.35	3.75e-15	Calcium levels;
LGG	cis	rs6942756	1.000	rs68076553	chr7:128959632	A/G	cg02491457	chr7:128862824	NA	-0.74	-13.48	-0.53	3.47e-35	White matter hyperintensity burden;
LGG	cis	rs4660214	0.666	rs1537818	chr1:39647038	G/A	cg18385671	chr1:39797026	MACF1	-0.46	-9.23	-0.39	9.82e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg15890332	chr12:107067104	RFX4	0.31	8.24	0.36	1.84e-15	Total body bone mineral density;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.24	-0.32	1.86e-12	Triglycerides;
LGG	cis	rs3806843	0.705	rs35614340	chr5:140043618	C/G	cg19875535	chr5:140030758	IK	-0.57	-11.98	-0.49	5.64e-29	Depressive symptoms (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07734253	chr16:30194717	CORO1A	0.42	6.94	0.31	1.3e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.87	-0.3	2.06e-11	Lung cancer;
LGG	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.0	-0.31	9.27e-12	Joint mobility (Beighton score);
LGG	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.99	-0.31	9.52e-12	Aortic root size;
LGG	cis	rs300774	0.925	rs300739	chr2:161605	A/G	cg04617936	chr2:214353	NA	-0.48	-7.31	-0.32	1.14e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-9.04	-0.39	4.24e-18	Glomerular filtration rate (creatinine);
LGG	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	6.72e-22	Axial length;
LGG	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg05623727	chr3:50126028	RBM5	-0.39	-8.52	-0.37	2.34e-16	Body mass index;
LGG	trans	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	13.19	0.52	5.71e-34	Obesity-related traits;
LGG	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.75	0.34	5.76e-14	Birth weight;
LGG	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.95	0.42	2.78e-21	Mood instability;
LGG	cis	rs9640161	0.830	rs3735165	chr7:150068371	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.07	-0.42	1.04e-21	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg02631450	chr22:32366979	NA	1.0	9.65	0.41	3.41e-20	Childhood ear infection;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08280861	chr8:58055591	NA	0.6	7.77	0.34	4.99e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.96	-0.31	1.18e-11	Blood metabolite levels;
LGG	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg04455712	chr21:45112962	RRP1B	0.51	9.95	0.42	2.99e-21	Mean corpuscular volume;
LGG	cis	rs75920871	0.528	rs7108912	chr11:116925996	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	cis	rs787274	0.681	rs4978506	chr9:115600162	C/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs4731207	0.569	rs7799535	chr7:124592060	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.47e-11	Cutaneous malignant melanoma;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg04234412	chr22:24373322	LOC391322	-0.72	-14.52	-0.56	1.26e-39	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19472759	chr11:69456837	CCND1	0.59	6.73	0.3	4.97e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs4237845	0.773	rs6650218	chr12:58289078	T/A	cg02175503	chr12:58329896	NA	0.67	12.63	0.51	1.3e-31	Intelligence (multi-trait analysis);
LGG	trans	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg10840412	chr1:235813424	GNG4	-0.61	-8.25	-0.36	1.63e-15	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.56	-0.33	2.19e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4819852	0.706	rs2240717	chr22:19969106	A/G	cg07821417	chr22:19972146	ARVCF	0.49	10.58	0.44	1.44e-23	Pulse pressure;
LGG	cis	rs35740288	0.539	rs4843100	chr15:86339210	G/C	cg04173714	chr15:86211321	AKAP13	0.43	7.07	0.31	5.67e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09695647	chr3:48754612	IP6K2	0.48	7.05	0.31	6.5e-12	Hip circumference;
LGG	cis	rs10220309	0.501	rs56017760	chr14:80658261	T/C	cg08183125	chr14:80678293	DIO2	-0.46	-7.31	-0.32	1.21e-12	Lung function (FEV1);
LGG	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg00898013	chr13:113819073	PROZ	-0.45	-7.43	-0.33	5.16e-13	Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01269469	chr7:155090211	INSIG1	0.48	7.39	0.32	6.95e-13	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06634786	chr22:41940651	POLR3H	0.76	12.13	0.49	1.32e-29	Vitiligo;
LGG	cis	rs1707322	0.928	rs10732844	chr1:46372688	T/C	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg23625390	chr15:77176239	SCAPER	0.49	9.66	0.41	3.18e-20	Blood metabolite levels;
LGG	cis	rs2239547	0.603	rs34230854	chr3:53078590	C/A	cg11645453	chr3:52864694	ITIH4	0.65	9.65	0.41	3.42e-20	Schizophrenia;
LGG	cis	rs62481355	1.000	rs55791028	chr7:127204881	T/C	cg25922125	chr7:127225783	GCC1	-0.47	-6.97	-0.31	1.1e-11	Type 2 diabetes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24594819	chr4:105416480	NA	-0.52	-7.73	-0.34	6.72e-14	Systemic lupus erythematosus;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs7179456	0.547	rs653765	chr15:59042012	T/C	cg05156742	chr15:59063176	FAM63B	0.59	9.46	0.4	1.55e-19	Asperger disorder;
LGG	trans	rs4714291	1.000	rs4714291	chr6:40003632	G/A	cg02267698	chr19:7991119	CTXN1	0.53	8.03	0.35	7.85e-15	Strep throat;
LGG	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-13.97	-0.54	2.98e-37	Vitiligo;
LGG	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.21	-0.32	2.22e-12	Mood instability;
LGG	cis	rs2235649	0.956	rs3829540	chr16:1836393	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.78	-0.3	3.66e-11	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg03160526	chr17:80928410	B3GNTL1	0.51	8.15	0.35	3.39e-15	Glycated hemoglobin levels;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06028808	chr11:68637592	NA	0.72	12.24	0.49	4.94e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg18854424	chr1:2615690	NA	0.32	6.94	0.31	1.34e-11	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg11764359	chr7:65958608	NA	-0.62	-9.28	-0.4	6.79e-19	Aortic root size;
LGG	cis	rs7666738	0.830	rs62321587	chr4:98997958	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg16507663	chr6:150244633	RAET1G	0.43	7.18	0.32	2.76e-12	Lung cancer;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg08035479	chr8:58172643	NA	-0.53	-8.11	-0.35	4.69e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11897279	chr19:13044638	FARSA	0.5	7.35	0.32	8.82e-13	Gut microbiome composition (summer);
LGG	trans	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg02153584	chr22:29168773	CCDC117	0.6	7.6	0.33	1.61e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg08888203	chr3:10149979	C3orf24	0.54	9.16	0.39	1.65e-18	Alzheimer's disease;
LGG	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg18898632	chr2:242989856	NA	-0.8	-9.92	-0.42	3.55e-21	Obesity-related traits;
LGG	cis	rs7412746	0.658	rs3768016	chr1:150809919	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.12	0.31	4.14e-12	Melanoma;
LGG	cis	rs2708377	0.929	rs73066828	chr12:11270654	A/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.41	0.33	6.11e-13	Bitter taste perception;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.37e-35	Personality dimensions;
LGG	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs9951602	0.512	rs6506874	chr18:76653467	G/T	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.22	-0.43	3.06e-22	Menarche (age at onset);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07701084	chr6:150067640	NUP43	0.42	7.75	0.34	5.84e-14	Testicular germ cell tumor;
LGG	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg14191688	chr11:70257035	CTTN	0.6	9.1	0.39	2.8e-18	Coronary artery disease;
LGG	cis	rs1978968	0.871	rs5746498	chr22:18435794	C/T	cg03078520	chr22:18463400	MICAL3	0.44	8.45	0.37	3.85e-16	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs11122272	0.735	rs2355872	chr1:231478489	A/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.25e-12	Hemoglobin concentration;
LGG	cis	rs2544527	0.586	rs1477253	chr2:15910457	T/C	cg26669897	chr2:15909070	NA	0.37	9.2	0.39	1.23e-18	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-10.53	-0.44	2.25e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg09137382	chr11:130731461	NA	0.38	7.18	0.32	2.81e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg02187348	chr16:89574699	SPG7	0.63	10.54	0.44	2.0500000000000001e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs4690686	1.000	rs2278904	chr4:177248622	C/G	cg17059388	chr4:177262070	NA	-0.73	-15.65	-0.59	1.34e-44	Essential tremor;
LGG	cis	rs61931739	0.583	rs1873011	chr12:33752808	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.71	-0.3	5.7e-11	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg15485101	chr11:133734466	NA	0.53	9.37	0.4	3.29e-19	Childhood ear infection;
LGG	cis	rs9596863	0.898	rs9591534	chr13:54363861	C/G	ch.13.53330881F	chr13:54432880	NA	0.52	6.87	0.3	2.08e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg07414643	chr4:187882934	NA	0.55	11.24	0.46	4.24e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12282928	1.000	rs11039657	chr11:48320979	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg21399703	chr1:247681439	NA	0.64	11.92	0.48	9.17e-29	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg27129171	chr3:47204927	SETD2	-0.82	-15.86	-0.59	1.5e-45	Colorectal cancer;
LGG	cis	rs477692	0.673	rs10764889	chr10:131341521	G/A	cg05714579	chr10:131428358	MGMT	0.43	8.29	0.36	1.22e-15	Response to temozolomide;
LGG	cis	rs3540	1.000	rs6496678	chr15:91034456	A/G	cg22089800	chr15:90895588	ZNF774	0.5	7.89	0.34	2.15e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.18	0.68	1.94e-65	Bladder cancer;
LGG	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg03264133	chr6:25882463	NA	-0.4	-6.99	-0.31	9.6e-12	Height;
LGG	cis	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg13010199	chr12:38710504	ALG10B	0.59	11.69	0.48	7.91e-28	Morning vs. evening chronotype;
LGG	trans	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg06521331	chr12:34319734	NA	0.4	6.72	0.3	5.42e-11	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.8	0.38	2.77e-17	Obesity-related traits;
LGG	cis	rs12368653	0.641	rs12826708	chr12:58058373	G/A	cg12615879	chr12:58013172	SLC26A10	0.31	7.05	0.31	6.62e-12	Multiple sclerosis;
LGG	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg05890377	chr2:74357713	NA	0.49	9.83	0.42	8.01e-21	Gestational age at birth (maternal effect);
LGG	cis	rs12431410	0.786	rs61164679	chr14:60169895	C/T	cg07950296	chr14:60194823	RTN1	-0.36	-6.95	-0.31	1.21e-11	Schizophrenia;
LGG	cis	rs62400317	0.821	rs72857080	chr6:45198373	G/A	cg20913747	chr6:44695427	NA	-0.61	-10.03	-0.42	1.49e-21	Total body bone mineral density;
LGG	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-9.67	-0.41	2.8e-20	Chronic sinus infection;
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg01145232	chr6:150245071	RAET1G	-0.52	-9.58	-0.41	5.84e-20	Lung cancer;
LGG	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.48	-0.33	3.82e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.43	-0.36	4.34e-16	Bone mineral density;
LGG	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg25173405	chr17:45401733	C17orf57	-0.55	-9.29	-0.4	6.09e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2084898	0.891	rs504236	chr11:120000263	T/C	cg07435449	chr11:120005650	TRIM29	0.68	8.3	0.36	1.16e-15	Stroke (pediatric);
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11877825	0.826	rs4121956	chr18:10569930	C/T	cg25239095	chr18:10589360	NA	0.49	9.2	0.39	1.22e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs2286885	1.000	rs10760438	chr9:129245334	C/A	cg14319473	chr9:129242481	FAM125B	0.44	8.16	0.35	3.2e-15	Intraocular pressure;
LGG	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg00319359	chr11:70116639	PPFIA1	-0.71	-7.62	-0.33	1.41e-13	Coronary artery disease;
LGG	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg16583315	chr14:65563665	MAX	-0.35	-6.81	-0.3	3.05e-11	Obesity-related traits;
LGG	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg08847533	chr14:75593920	NEK9	-0.63	-12.07	-0.49	2.32e-29	Height;
LGG	cis	rs847851	1.000	rs57951780	chr6:34852891	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.37	-6.75	-0.3	4.53e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg15268244	chr15:77196840	NA	0.48	10.19	0.43	3.86e-22	Blood metabolite levels;
LGG	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.48	0.5	5.14e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg18165381	chr3:44552316	NA	-0.41	-6.82	-0.3	2.84e-11	Depressive symptoms;
LGG	trans	rs6956675	0.793	rs6946559	chr7:62660568	A/T	cg01314568	chr7:57830625	NA	-0.5	-7.95	-0.35	1.43e-14	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.13	-0.31	3.9e-12	Bipolar disorder;
LGG	cis	rs4732038	0.510	rs10251749	chr7:134268548	G/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg04450456	chr4:17643702	FAM184B	0.32	7.13	0.31	3.81e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1032833	0.732	rs17363183	chr2:179973673	A/T	cg23654767	chr2:101192981	PDCL3	-0.7	-8.23	-0.36	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs8056893	0.569	rs9937244	chr16:68307559	T/A	cg07273125	chr16:68295692	NA	0.47	10.38	0.43	7.9e-23	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs975739	0.657	rs1330893	chr13:78608042	C/T	cg07847733	chr13:78271382	SLAIN1	0.47	8.12	0.35	4.15e-15	Hair color;
LGG	cis	rs10540	1.000	rs71487296	chr11:500282	G/A	cg03352830	chr11:487213	PTDSS2	0.87	11.29	0.46	2.81e-26	Body mass index;
LGG	cis	rs9487094	0.813	rs3799835	chr6:109693287	A/G	cg16315928	chr6:109776240	MICAL1	0.51	8.6	0.37	1.23e-16	Height;
LGG	cis	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg18131467	chr2:239335373	ASB1	-0.68	-6.84	-0.3	2.49e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11690935	0.531	rs4280428	chr2:172813219	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.91	0.48	9.98e-29	Schizophrenia;
LGG	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg17376030	chr22:41985996	PMM1	0.54	8.69	0.37	6.45e-17	Vitiligo;
LGG	cis	rs11683229	0.777	rs11696083	chr2:63347964	T/G	cg19915305	chr2:64069682	UGP2	-0.44	-6.87	-0.3	2.14e-11	Protein quantitative trait loci;
LGG	cis	rs1978968	0.763	rs8140977	chr22:18463608	C/T	cg03078520	chr22:18463400	MICAL3	-0.68	-14.78	-0.57	8.7e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs1816752	1.000	rs9511272	chr13:25020633	A/G	cg22771759	chr13:24902376	NA	0.45	7.53	0.33	2.76e-13	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg21798802	chr22:38057573	PDXP	0.4	8.65	0.37	8.58e-17	Fat distribution (HIV);
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.35	-6.95	-0.31	1.28e-11	Personality dimensions;
LGG	cis	rs6693567	0.545	rs9436009	chr1:150459426	T/A	cg15654264	chr1:150340011	RPRD2	0.33	6.75	0.3	4.46e-11	Migraine;
LGG	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15369054	chr17:80825471	TBCD	-0.52	-9.11	-0.39	2.41e-18	Breast cancer;
LGG	cis	rs6918586	0.658	rs1572982	chr6:26094367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	9.57	0.41	6.33e-20	Schizophrenia;
LGG	cis	rs7177699	0.557	rs10083696	chr15:79124016	G/A	cg00540400	chr15:79124168	NA	-0.54	-11.43	-0.47	7.77e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg08677398	chr8:58056175	NA	0.44	7.09	0.31	5.03e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15369054	chr17:80825471	TBCD	0.48	7.03	0.31	7.24e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg04727924	chr7:799746	HEATR2	-0.5	-7.02	-0.31	7.92e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.49e-20	Bipolar disorder;
LGG	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg21130718	chr4:1044621	NA	0.4	7.78	0.34	4.78e-14	Recombination rate (males);
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.4	-8.46	-0.37	3.41e-16	Schizophrenia;
LGG	cis	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	trans	rs11134654	1.000	rs1895409	chr5:170241249	T/C	cg20034712	chr19:52675470	ZNF836	-0.46	-7.63	-0.33	1.31e-13	Smooth-surface caries;
LGG	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg27411982	chr8:10470053	RP1L1	-0.48	-7.77	-0.34	5.26e-14	Neuroticism;
LGG	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg27398817	chr8:82754497	SNX16	-0.71	-10.15	-0.43	5.53e-22	Diastolic blood pressure;
LGG	cis	rs4481887	0.508	rs4390207	chr1:248400174	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-7.34	-0.32	9.55e-13	Common traits (Other);
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg14926445	chr8:58193284	C8orf71	-0.86	-12.12	-0.49	1.53e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21659725	chr3:3221576	CRBN	0.66	12.4	0.5	1.06e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08396677	chr2:136288699	ZRANB3;R3HDM1	0.45	7.73	0.34	6.83e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.42	-0.44	5.51e-23	Intelligence (multi-trait analysis);
LGG	cis	rs5769707	0.521	rs5769720	chr22:50062133	G/C	cg20744362	chr22:50050164	C22orf34	0.42	7.39	0.32	6.76e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.71	0.41	2.04e-20	Coronary artery disease;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg05484376	chr2:27715224	FNDC4	0.46	9.85	0.42	6.85e-21	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.25e-16	Personality dimensions;
LGG	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.81e-22	Motion sickness;
LGG	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs2658782	1.000	rs2605585	chr11:93171862	C/T	cg15737290	chr11:93063684	CCDC67	0.54	7.89	0.34	2.17e-14	Pulmonary function decline;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05102288	chr16:30968551	SETD1A	0.6	6.78	0.3	3.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1867631	1.000	rs10889636	chr1:67089924	A/G	cg13052034	chr1:66999238	SGIP1	-0.47	-9.45	-0.4	1.63e-19	Menopause (age at onset);
LGG	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.14	0.58	2.27e-42	Cognitive test performance;
LGG	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg25986240	chr4:9926439	SLC2A9	-0.54	-9.88	-0.42	5.17e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg21926883	chr2:100939477	LONRF2	0.55	11.64	0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	9.44	0.4	1.79e-19	Height;
LGG	cis	rs12135191	0.771	rs61835531	chr1:236499757	A/C	cg21399712	chr1:236511386	NA	-0.41	-7.75	-0.34	5.77e-14	Urate levels (BMI interaction);
LGG	cis	rs6489785	0.509	rs4767937	chr12:121223244	G/C	cg02419362	chr12:121203948	SPPL3	0.55	9.58	0.41	5.93e-20	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg03517284	chr6:25882590	NA	0.67	12.68	0.51	7.62e-32	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.44	0.33	5.01e-13	Cystic fibrosis severity;
LGG	trans	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg17712092	chr4:129076599	LARP1B	-0.7	-13.24	-0.52	3.79e-34	Eosinophil percentage of white cells;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg18402987	chr7:1209562	NA	0.73	10.92	0.45	7.39e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg09307838	chr4:120376055	NA	0.78	12.64	0.51	1.15e-31	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	0.5	8.19	0.36	2.6e-15	Cognitive performance;
LGG	cis	rs10266483	1.000	rs10266483	chr7:63733331	A/G	cg24201672	chr7:64023550	ZNF680	-0.45	-7.05	-0.31	6.7e-12	Response to statin therapy;
LGG	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.61e-23	Aortic root size;
LGG	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs7188861	0.681	rs12922090	chr16:11415117	C/T	cg01510278	chr16:11456238	NA	0.29	6.65	0.3	8.19e-11	HDL cholesterol;
LGG	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg08859206	chr1:53392774	SCP2	0.47	9.17	0.39	1.59e-18	Monocyte count;
LGG	cis	rs9976767	0.608	rs2277797	chr21:43823910	A/G	cg23042151	chr21:43824109	UBASH3A	-0.64	-13.35	-0.53	1.25e-34	Type 1 diabetes;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11866815	0.649	rs56355849	chr16:380641	T/C	cg07915516	chr16:377344	AXIN1	-0.5	-11.4	-0.47	1.01e-26	Body mass index;
LGG	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.84	-0.51	1.67e-32	Bladder cancer;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	0.33	8.74	0.38	4.29e-17	IgG glycosylation;
LGG	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg02002194	chr4:3960332	NA	0.41	7.11	0.31	4.46e-12	Neuroticism;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg09033563	chr22:24373618	LOC391322	-0.5	-8.32	-0.36	9.99e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg00129232	chr17:37814104	STARD3	0.58	8.7	0.37	5.96e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg01631408	chr1:248437212	OR2T33	0.51	9.4	0.4	2.49e-19	Common traits (Other);
LGG	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.44	0.37	3.96e-16	Neuroticism;
LGG	trans	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg08280861	chr8:58055591	NA	0.54	6.91	0.31	1.63e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-7.05	-0.31	6.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2377585	0.653	rs7976729	chr12:8848685	A/G	cg03761649	chr12:8850719	RIMKLB	0.47	7.89	0.34	2.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-7.13	-0.31	3.91e-12	Obesity (extreme);
LGG	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.81	-0.3	3.1e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11875185	0.510	rs76571697	chr18:55632303	A/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.05	0.39	3.85e-18	Motion sickness;
LGG	cis	rs12681287	0.640	rs12541793	chr8:87462558	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg02002194	chr4:3960332	NA	-0.51	-9.95	-0.42	2.91e-21	Mood instability;
LGG	cis	rs3806843	0.576	rs251376	chr5:140253689	A/G	cg19875535	chr5:140030758	IK	-0.38	-7.47	-0.33	3.96e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11229555	0.609	rs11229434	chr11:58185501	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	7.4	0.33	6.27e-13	Obesity-related traits;
LGG	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg15485101	chr11:133734466	NA	0.61	10.62	0.44	9.8599999999999993e-24	Childhood ear infection;
LGG	cis	rs7143963	0.636	rs7147531	chr14:103299716	T/C	cg23020514	chr14:103360112	TRAF3	0.41	8.59	0.37	1.37e-16	Body mass index;
LGG	trans	rs877282	0.797	rs35927768	chr10:753095	T/C	cg22713356	chr15:30763199	NA	0.47	6.96	0.31	1.18e-11	Uric acid levels;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg11645453	chr3:52864694	ITIH4	0.44	7.36	0.32	8.38e-13	Bipolar disorder;
LGG	cis	rs10267417	0.603	rs10279352	chr7:19903294	T/G	cg05791153	chr7:19748676	TWISTNB	0.56	7.35	0.32	9.17e-13	Night sleep phenotypes;
LGG	cis	rs2455799	0.573	rs2455793	chr3:15743844	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.72	-0.34	7.12e-14	Mean platelet volume;
LGG	cis	rs12545109	0.800	rs1837614	chr8:57414497	T/A	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg09462578	chr12:12878428	APOLD1	0.63	11.09	0.46	1.72e-25	Birth weight;
LGG	cis	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.82	-0.3	2.88e-11	Neuroticism;
LGG	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.61	0.41	4.64e-20	Joint mobility (Beighton score);
LGG	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.75	-8.13	-0.35	4e-15	Smoking behavior;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.55	0.65	7.6e-58	Personality dimensions;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg00364696	chr7:1142433	C7orf50	-0.38	-7.48	-0.33	3.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.25	0.36	1.67e-15	Initial pursuit acceleration;
LGG	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.5	-0.33	3.21e-13	Depression;
LGG	cis	rs80282103	0.717	rs74117685	chr10:1100410	A/G	cg08668510	chr10:1095578	IDI1	0.88	8.51	0.37	2.46e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1267303	0.637	rs1745371	chr1:46985192	C/T	cg16387850	chr1:46982889	NA	-0.35	-8.72	-0.38	5.1e-17	Monobrow;
LGG	cis	rs9309473	0.718	rs10175529	chr2:73606093	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-8.95	-0.38	8.73e-18	Metabolite levels;
LGG	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.21	0.58	1.18e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2041895	0.509	rs1035236	chr12:107310797	C/T	cg13944111	chr12:107296891	NA	0.27	7.0	0.31	8.82e-12	Glaucoma (low intraocular pressure);
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg21226059	chr5:178986404	RUFY1	-0.52	-9.32	-0.4	4.77e-19	Lung cancer;
LGG	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.32	-0.5	2.4e-30	Cognitive function;
LGG	trans	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07923666	chr12:49932857	KCNH3	-0.48	-7.14	-0.31	3.74e-12	Resting heart rate;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg14926445	chr8:58193284	C8orf71	-0.94	-13.0	-0.52	3.6e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg23262073	chr20:60523788	NA	-0.63	-10.02	-0.42	1.6e-21	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	0.699	rs17091772	chr2:1519679	A/C	cg01028140	chr2:1542097	TPO	-0.51	-7.99	-0.35	1.08e-14	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1620921	0.653	rs62435278	chr6:161265459	C/G	cg01280913	chr6:161186852	NA	-0.37	-7.44	-0.33	5.01e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg06521331	chr12:34319734	NA	0.41	6.85	0.3	2.42e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07909359	chr16:67208405	NOL3	0.47	6.69	0.3	6.44e-11	Hip circumference;
LGG	cis	rs2933343	0.729	rs813945	chr3:128660937	A/G	cg25356066	chr3:128598488	ACAD9	0.46	6.85	0.3	2.43e-11	IgG glycosylation;
LGG	cis	rs7551222	0.646	rs10900590	chr1:204451086	C/T	cg20240347	chr1:204465584	NA	-0.49	-9.08	-0.39	3.24e-18	Schizophrenia;
LGG	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.23	-0.32	2.02e-12	Refractive error;
LGG	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	12.61	0.51	1.48e-31	Mean corpuscular hemoglobin;
LGG	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Bone mineral density;
LGG	cis	rs9815354	0.909	rs1716975	chr3:41960006	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.18	-0.36	2.86e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6429082	0.755	rs291371	chr1:235693105	C/G	cg26050004	chr1:235667680	B3GALNT2	0.68	11.93	0.49	8.21e-29	Adiposity;
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg13047869	chr3:10149882	C3orf24	-0.57	-8.26	-0.36	1.5e-15	Alzheimer's disease;
LGG	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg18105134	chr13:113819100	PROZ	0.79	16.79	0.62	9.64e-50	Platelet distribution width;
LGG	cis	rs274567	0.602	rs272853	chr5:131688561	A/G	cg07395648	chr5:131743802	NA	-0.48	-9.81	-0.41	9.22e-21	Blood metabolite levels;
LGG	cis	rs9807989	0.507	rs3755266	chr2:103042712	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.51	0.4	1.02e-19	Asthma;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg07870213	chr5:140052090	DND1	-0.81	-14.65	-0.56	3.26e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.14	-0.35	3.77e-15	Total body bone mineral density;
LGG	cis	rs1729951	0.575	rs16844325	chr3:136678161	C/G	cg12473912	chr3:136751656	NA	0.43	7.62	0.33	1.42e-13	Neuroticism;
LGG	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23598886	chr18:12777645	NA	0.75	10.48	0.44	3.41e-23	Inflammatory skin disease;
LGG	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.09e-22	Iron status biomarkers;
LGG	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg23625390	chr15:77176239	SCAPER	0.48	9.32	0.4	4.81e-19	Blood metabolite levels;
LGG	cis	rs7432375	0.933	rs55970317	chr3:136353193	T/G	cg12473912	chr3:136751656	NA	0.41	6.95	0.31	1.28e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11644478	chr21:40555479	PSMG1	-0.75	-13.76	-0.54	2.26e-36	Cognitive function;
LGG	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.72	-0.48	5.64e-28	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04219515	chr8:70746368	SLCO5A1	0.48	7.12	0.31	4.15e-12	Gut microbiome composition (summer);
LGG	cis	rs10231759	0.617	rs11982701	chr7:150512156	G/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.42	0.36	4.68e-16	Height;
LGG	cis	rs7586879	0.796	rs10187348	chr2:25078415	G/C	cg04586622	chr2:25135609	ADCY3	0.36	8.56	0.37	1.71e-16	Body mass index;
LGG	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg25008857	chr14:105974488	NA	0.55	9.39	0.4	2.84e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6831352	0.877	rs2602890	chr4:100043179	C/T	cg12011299	chr4:100065546	ADH4	0.42	8.51	0.37	2.4e-16	Alcohol dependence;
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.88	0.45	1.07e-24	Personality dimensions;
LGG	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02788857	chr8:22132959	PIWIL2	0.5	11.37	0.47	1.33e-26	Hypertriglyceridemia;
LGG	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg21775007	chr8:11205619	TDH	0.46	7.38	0.32	7.38e-13	Neuroticism;
LGG	cis	rs2797369	0.824	rs2518329	chr6:101690690	A/C	cg27451362	chr6:101846650	GRIK2	0.79	10.57	0.44	1.6e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.42	-10.47	-0.44	3.77e-23	IgG glycosylation;
LGG	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.73	-0.41	1.82e-20	Alcohol dependence;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06656553	chr16:89960601	TCF25	-0.7	-6.92	-0.31	1.54e-11	Skin colour saturation;
LGG	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	trans	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg07393940	chr7:158741817	NA	-0.58	-10.7	-0.45	4.87e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg26174226	chr8:58114915	NA	-0.52	-7.7	-0.34	8.2e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.967	rs6970743	chr7:91744311	C/G	cg17063962	chr7:91808500	NA	0.51	9.27	0.4	7.33e-19	Breast cancer;
LGG	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02788857	chr8:22132959	PIWIL2	0.5	11.78	0.48	3.36e-28	Hypertriglyceridemia;
LGG	cis	rs701145	0.585	rs2060622	chr3:153833862	A/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg02640540	chr1:67518911	SLC35D1	-0.39	-7.73	-0.34	6.91e-14	Lymphocyte percentage of white cells;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.34	-0.32	9.42e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4148087	0.790	rs4148099	chr21:43639591	A/C	cg08841829	chr21:43638893	ABCG1	-0.67	-9.73	-0.41	1.73e-20	Eating disorder in bipolar disorder;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg07701084	chr6:150067640	NUP43	0.44	6.83	0.3	2.74e-11	Lung cancer;
LGG	cis	rs12731740	1.000	rs35232605	chr1:208011241	G/A	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.41	-0.33	6.1e-13	Biomedical quantitative traits;
LGG	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg02403541	chr12:121454288	C12orf43	0.64	10.24	0.43	2.48e-22	N-glycan levels;
LGG	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.19	0.32	2.57e-12	Systemic lupus erythematosus;
LGG	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg01028140	chr2:1542097	TPO	-0.47	-8.84	-0.38	1.97e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.71	0.41	2.15e-20	Mood instability;
LGG	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg00579200	chr11:133705235	NA	-0.6	-11.41	-0.47	9.27e-27	Childhood ear infection;
LGG	cis	rs2013441	0.931	rs4925089	chr17:20064784	A/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.5e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs60180747	1.000	rs14303	chr15:66783261	C/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	10.99	0.45	3.89e-25	Testicular germ cell tumor;
LGG	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.6e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18252515	chr7:66147081	NA	0.4	6.76	0.3	4.23e-11	Aortic root size;
LGG	cis	rs4262150	0.960	rs4262151	chr5:152288508	T/C	cg12297329	chr5:152029980	NA	0.58	11.11	0.46	1.34e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg25664220	chr3:72788482	NA	-0.33	-9.0	-0.39	5.91e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg26818010	chr10:134567672	INPP5A	-0.72	-10.95	-0.45	5.67e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11886014	chr5:41904500	C5orf51	0.39	6.68	0.3	6.86e-11	Bipolar disorder;
LGG	cis	rs9487094	0.670	rs1406899	chr6:109816305	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg10840412	chr1:235813424	GNG4	0.65	8.71	0.38	5.38e-17	Bipolar disorder;
LGG	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg03605463	chr16:89740564	NA	-0.58	-10.12	-0.43	6.83e-22	Vitiligo;
LGG	cis	rs9649465	0.561	rs2429618	chr7:123421662	G/A	cg03229431	chr7:123269106	ASB15	0.61	13.98	0.54	2.62e-37	Migraine;
LGG	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg02023728	chr11:77925099	USP35	0.41	7.13	0.31	3.89e-12	Alzheimer's disease (survival time);
LGG	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg14416269	chr4:6271139	WFS1	-0.46	-8.16	-0.35	3.15e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10865541	0.806	rs10187625	chr2:3421168	A/G	cg11642891	chr2:3452563	TTC15	-0.42	-8.08	-0.35	5.75e-15	Obesity-related traits;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.95	-0.38	8.95e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7949566	0.652	rs7927916	chr11:126292262	C/T	cg05055844	chr11:126275997	ST3GAL4	0.35	7.01	0.31	8.53e-12	Platelet distribution width;Mean platelet volume;
LGG	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg01043669	chr3:72786069	NA	0.38	6.77	0.3	3.96e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.33	-0.36	9.07e-16	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg21459583	chr1:227974177	NA	0.46	6.72	0.3	5.37e-11	Major depressive disorder;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg11494091	chr17:61959527	GH2	0.5	8.15	0.35	3.34e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.51	-8.01	-0.35	9.53e-15	Menarche (age at onset);
LGG	cis	rs701145	0.585	rs1727957	chr3:153870407	G/A	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	trans	rs5744897	1.000	rs36118826	chr12:133223685	A/C	cg04991071	chr3:71615924	FOXP1	0.63	6.98	0.31	1.02e-11	Urate levels in overweight individuals;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.89	0.68	4.29e-64	Platelet count;
LGG	cis	rs7666738	0.830	rs11932887	chr4:99072965	C/G	cg05340658	chr4:99064831	C4orf37	0.51	8.57	0.37	1.59e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg10556349	chr10:835070	NA	-0.3	-7.66	-0.34	1.13e-13	Survival in rectal cancer;
LGG	cis	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg09307838	chr4:120376055	NA	0.49	8.46	0.37	3.61e-16	Diastolic blood pressure;
LGG	cis	rs9309473	1.000	rs13432605	chr2:73810981	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.31	-0.32	1.21e-12	Metabolite levels;
LGG	cis	rs8017423	0.967	rs28424204	chr14:90705669	G/C	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.73e-57	Mortality in heart failure;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg13264159	chr8:625131	ERICH1	0.91	8.41	0.36	5.04e-16	IgG glycosylation;
LGG	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg05418105	chr22:50981406	NA	-0.48	-8.66	-0.37	7.99e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg14829360	chr17:73884958	NA	-0.44	-8.07	-0.35	6.17e-15	White matter hyperintensity burden;
LGG	cis	rs6558530	0.640	rs4875889	chr8:1695291	C/G	cg25947184	chr8:1697459	NA	0.45	7.91	0.35	1.88e-14	Systolic blood pressure;
LGG	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.62	-0.33	1.43e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1620921	0.625	rs57127570	chr6:161272996	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	Cognitive function;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.56	-0.44	1.69e-23	IgG glycosylation;
LGG	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.52	-0.33	2.84e-13	Aortic root size;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg04267008	chr7:1944627	MAD1L1	0.57	9.51	0.4	1.08e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.830	rs13121558	chr4:99002848	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.56e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg15208524	chr1:10270712	KIF1B	-0.41	-6.94	-0.31	1.29e-11	Hepatocellular carcinoma;
LGG	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg24006582	chr15:45444508	DUOX1	-0.71	-13.62	-0.53	9.03e-36	Uric acid levels;
LGG	cis	rs2276314	0.857	rs28540805	chr18:33641975	T/G	cg05985134	chr18:33552581	C18orf21	0.62	9.24	0.39	9.12e-19	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4900538	0.821	rs7012	chr14:102814945	C/T	cg18135206	chr14:102964638	TECPR2	-0.7	-12.63	-0.51	1.25e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2531992	0.925	rs2531993	chr16:4014245	A/G	cg05927578	chr16:4029543	ADCY9	0.68	9.41	0.4	2.39e-19	Waist circumference;
LGG	cis	rs721917	0.506	rs7073842	chr10:81656400	T/C	cg25562619	chr10:81652821	NA	-0.34	-7.89	-0.34	2.18e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg26150922	chr2:100937072	LONRF2	-0.61	-11.97	-0.49	5.87e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg21775007	chr8:11205619	TDH	0.74	12.79	0.51	2.65e-32	Retinal vascular caliber;
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.11	-15.28	-0.58	5.49e-43	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs908922	1.000	rs908922	chr1:152454591	C/T	cg09873164	chr1:152488093	CRCT1	0.51	10.21	0.43	3.38e-22	Hair morphology;
LGG	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg00129232	chr17:37814104	STARD3	-0.57	-8.44	-0.37	4.2e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9677476	0.863	rs16827863	chr2:232077670	C/T	cg14237567	chr2:232057245	NA	0.32	6.65	0.3	8.15e-11	Food antigen IgG levels;
LGG	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.45	-0.4	1.76e-19	Height;
LGG	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.4	-0.33	6.53e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg02466173	chr16:30829666	NA	0.46	8.3	0.36	1.11e-15	Dementia with Lewy bodies;
LGG	cis	rs611744	0.967	rs475865	chr8:109235858	G/C	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.04e-11	Dupuytren's disease;
LGG	cis	rs3813359	0.545	rs1932112	chr6:130555264	T/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg07157834	chr1:205819609	PM20D1	-0.42	-7.1	-0.31	4.61e-12	Parkinson's disease;
LGG	cis	rs6546537	0.824	rs55864699	chr2:69803650	C/T	cg10773587	chr2:69614142	GFPT1	-0.48	-7.97	-0.35	1.29e-14	Serum thyroid-stimulating hormone levels;
LGG	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg26384229	chr12:38710491	ALG10B	-0.73	-14.18	-0.55	3.75e-38	Morning vs. evening chronotype;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg10852096	chr15:79043040	NA	-0.29	-8.23	-0.36	1.92e-15	Coronary artery disease or large artery stroke;
LGG	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg27523141	chr10:43048294	ZNF37B	0.36	7.59	0.33	1.79e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg01620082	chr3:125678407	NA	-0.67	-8.12	-0.35	4.2e-15	Depression;
LGG	cis	rs12220238	1.000	rs11000901	chr10:75919971	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.85	0.45	1.4e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs8180040	0.726	rs34344887	chr3:47042161	A/G	cg27129171	chr3:47204927	SETD2	0.83	15.87	0.59	1.31e-45	Colorectal cancer;
LGG	cis	rs12765878	1.000	rs10883942	chr10:105651386	A/G	cg11005552	chr10:105648138	OBFC1	1.03	27.58	0.79	9.29e-100	Coronary artery disease;
LGG	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg10621924	chr7:39171070	POU6F2	0.46	9.73	0.41	1.78e-20	IgG glycosylation;
LGG	cis	rs57590327	0.555	rs6795133	chr3:81756267	A/G	cg07356753	chr3:81810745	GBE1	-0.51	-8.3	-0.36	1.17e-15	Extraversion;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg22535103	chr8:58192502	C8orf71	-0.45	-7.22	-0.32	2.14e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs6083804	chr20:25317060	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	trans	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg07211511	chr3:129823064	LOC729375	-0.54	-8.09	-0.35	5.34e-15	Blood pressure (smoking interaction);
LGG	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08045932	chr20:61659980	NA	-0.59	-12.95	-0.52	5.77e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs584438	0.780	rs11078945	chr17:38594756	T/G	cg09358481	chr17:38600305	IGFBP4	-0.44	-8.32	-0.36	9.92e-16	Height;
LGG	cis	rs11157436	0.560	rs11623957	chr14:22692632	A/G	cg00994629	chr14:22694547	NA	0.35	7.78	0.34	4.63e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.34	-0.65	7.48e-57	Lung cancer;
LGG	cis	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg06360820	chr2:242988706	NA	-0.54	-7.48	-0.33	3.66e-13	Obesity-related traits;
LGG	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg08250081	chr4:10125330	NA	0.41	8.0	0.35	1.03e-14	Bone mineral density;
LGG	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg12310025	chr6:25882481	NA	-0.68	-13.01	-0.52	3.49e-33	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-7.14	-0.31	3.67e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs240764	0.612	rs7751185	chr6:100949565	A/G	cg21058520	chr6:100914733	NA	0.47	8.35	0.36	7.75e-16	Neuroticism;
LGG	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg06421707	chr20:25228305	PYGB	0.48	10.63	0.44	8.95e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-9.16	-0.39	1.74e-18	HDL cholesterol;
LGG	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg20387954	chr3:183756860	HTR3D	-0.71	-10.58	-0.44	1.43e-23	Body mass index;
LGG	cis	rs758324	0.947	rs683749	chr5:131283376	C/T	cg06307176	chr5:131281290	NA	-0.59	-9.55	-0.41	7.55e-20	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.64e-39	Hair morphology;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24335600	chr1:241682994	FH	-0.39	-6.89	-0.3	1.85e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2721811	0.738	rs2521758	chr7:24762292	G/T	cg06301139	chr7:24798175	DFNA5	-0.41	-7.53	-0.33	2.69e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg02002194	chr4:3960332	NA	0.44	8.2	0.36	2.36e-15	Monocyte count;
LGG	cis	rs2880765	0.546	rs35316253	chr15:86065560	T/C	cg10818794	chr15:86012489	AKAP13	-0.4	-8.12	-0.35	4.25e-15	Coronary artery disease;
LGG	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg07796016	chr1:152779584	LCE1C	-0.41	-6.65	-0.3	8.24e-11	Inflammatory skin disease;
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg20453264	chr5:131705742	SLC22A5	0.61	7.76	0.34	5.39e-14	Rheumatoid arthritis;
LGG	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg03433033	chr1:76189801	ACADM	0.79	12.91	0.51	8.58e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	2.04e-26	Bipolar disorder;
LGG	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.33	-0.32	1.03e-12	Testicular germ cell tumor;
LGG	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg19847130	chr8:10466454	RP1L1	0.33	7.14	0.31	3.63e-12	Neuroticism;
LGG	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.07e-33	Response to antipsychotic treatment;
LGG	cis	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg26384229	chr12:38710491	ALG10B	0.97	21.99	0.71	6.89e-74	Bladder cancer;
LGG	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg18511798	chr11:2018149	H19;MIR675	0.42	7.71	0.34	7.84e-14	DNA methylation (variation);
LGG	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.87	-0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg13047869	chr3:10149882	C3orf24	0.54	8.98	0.39	6.63e-18	Alzheimer's disease;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.49	-0.4	1.25e-19	Lung cancer;
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.73	-0.3	4.88e-11	Personality dimensions;
LGG	cis	rs139371	0.516	rs139286	chr22:39495800	T/C	cg17972162	chr22:39496387	APOBEC3H	-0.28	-7.07	-0.31	5.73e-12	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg26031613	chr14:104095156	KLC1	-0.59	-9.26	-0.4	7.7e-19	Reticulocyte count;
LGG	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.74	-0.38	4.31e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08704250	chr15:31115839	NA	-0.49	-8.56	-0.37	1.68e-16	Huntington's disease progression;
LGG	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg08916839	chr5:415575	AHRR	-0.66	-10.82	-0.45	1.83e-24	Fat distribution (HIV);
LGG	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19748678	chr4:122722346	EXOSC9	-0.57	-10.32	-0.43	1.3e-22	Type 2 diabetes;
LGG	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg17376030	chr22:41985996	PMM1	0.67	10.79	0.45	2.21e-24	Vitiligo;
LGG	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg27316798	chr5:14870666	ANKH	-0.51	-10.36	-0.43	9.52e-23	Blood metabolite levels;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.47	0.37	3.19e-16	Schizophrenia;
LGG	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg07636037	chr3:49044803	WDR6	0.77	13.79	0.54	1.8e-36	Menarche (age at onset);
LGG	cis	rs17767392	0.914	rs10139519	chr14:72109270	C/A	cg13720639	chr14:72061746	SIPA1L1	0.39	8.25	0.36	1.64e-15	Mitral valve prolapse;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-9.53	-0.4	8.9e-20	Prostate cancer;
LGG	cis	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.99	-0.31	9.48e-12	Joint mobility (Beighton score);
LGG	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg06521331	chr12:34319734	NA	-0.6	-11.11	-0.46	1.4e-25	Morning vs. evening chronotype;
LGG	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg23029597	chr12:123009494	RSRC2	-0.93	-17.27	-0.63	5.92e-52	Body mass index;
LGG	trans	rs7939886	0.920	rs4489763	chr11:55944474	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.93	-0.38	1.03e-17	Chronic sinus infection;
LGG	cis	rs6696846	0.765	rs61822568	chr1:205081166	C/G	cg21545522	chr1:205238299	TMCC2	0.37	7.04	0.31	6.87e-12	Red blood cell count;
LGG	trans	rs9914544	0.564	rs8072860	chr17:18807884	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.81	-0.34	3.78e-14	Educational attainment (years of education);
LGG	cis	rs6696846	0.791	rs7520752	chr1:205054114	C/T	cg00857998	chr1:205179979	DSTYK	-0.61	-10.01	-0.42	1.7e-21	Red blood cell count;
LGG	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.51	6.99	0.31	9.41e-12	Crohn's disease;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00495681	chr13:53174319	NA	0.57	10.47	0.44	3.5e-23	Lewy body disease;
LGG	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.75	9.36	0.4	3.43e-19	Crohn's disease;
LGG	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg08048268	chr3:133502702	NA	-0.61	-11.44	-0.47	7.6e-27	Iron status biomarkers;
LGG	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg15704280	chr7:45808275	SEPT13	-0.95	-19.74	-0.68	2.18e-63	Coronary artery disease;
LGG	cis	rs17433780	0.808	rs7541867	chr1:89513537	G/A	cg09516651	chr1:89888402	LOC400759	0.77	18.48	0.65	1.61e-57	Carotid intima media thickness;
LGG	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg26655873	chr3:72818019	SHQ1	0.37	7.43	0.33	5.19e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.37	6.78	0.3	3.66e-11	Schizophrenia;
LGG	trans	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.26e-19	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.42e-16	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg23758822	chr17:41437982	NA	0.9	15.9	0.59	9.66e-46	Menopause (age at onset);
LGG	cis	rs73001065	0.636	rs11668104	chr19:19426181	G/A	cg03709012	chr19:19516395	GATAD2A	0.87	9.9	0.42	4.49e-21	LDL cholesterol;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.21e-38	Tonsillectomy;
LGG	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg26384229	chr12:38710491	ALG10B	-0.59	-10.79	-0.45	2.28e-24	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs7216064	1.000	rs7216064	chr17:65898809	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-9.0	-0.39	6e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4919044	0.866	rs835265	chr10:94786259	A/G	cg05127821	chr10:94822908	CYP26C1	-0.44	-8.0	-0.35	1.02e-14	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg03342759	chr3:160939853	NMD3	-0.66	-11.78	-0.48	3.38e-28	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg26585981	chr11:48327164	OR4S1	0.41	7.13	0.31	3.91e-12	Migraine - clinic-based;
LGG	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.01	0.52	3.44e-33	Lung cancer in ever smokers;
LGG	cis	rs975739	0.872	rs1279663	chr13:78369102	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	4e-11	Hair color;
LGG	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg12473912	chr3:136751656	NA	0.43	7.57	0.33	2.09e-13	Neuroticism;
LGG	cis	rs2307022	0.586	rs11645944	chr16:68409057	A/G	cg07273125	chr16:68295692	NA	0.44	9.7	0.41	2.17e-20	Body mass index;
LGG	cis	rs9487094	0.961	rs11153177	chr6:109737428	A/G	cg01125227	chr6:109776195	MICAL1	0.53	9.07	0.39	3.28e-18	Height;
LGG	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg00129232	chr17:37814104	STARD3	0.58	8.47	0.37	3.27e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-8.58	-0.37	1.49e-16	Alzheimer's disease (survival time);
LGG	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg18357526	chr6:26021779	HIST1H4A	0.93	17.46	0.63	8.44e-53	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg18551225	chr6:44695536	NA	-0.69	-11.41	-0.47	9.5e-27	Total body bone mineral density;
LGG	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-13.69	-0.54	4.77e-36	Heart rate;
LGG	cis	rs1580019	0.961	rs4357201	chr7:32496333	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	trans	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15656113	chr5:172482832	C5orf41	0.53	7.92	0.35	1.74e-14	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg27129171	chr3:47204927	SETD2	-0.79	-15.32	-0.58	3.93e-43	Colorectal cancer;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16405210	chr4:1374714	KIAA1530	-0.66	-12.17	-0.49	9.04e-30	Longevity;
LGG	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg12395012	chr8:11607386	GATA4	0.39	6.93	0.31	1.38e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4938330	0.608	rs2277287	chr11:117096652	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-7.54	-0.33	2.54e-13	Blood protein levels;
LGG	cis	rs11644362	0.932	rs3848239	chr16:12996642	A/G	cg08528231	chr16:12997261	SHISA9	-0.36	-7.32	-0.32	1.11e-12	Positive affect;Subjective well-being;
LGG	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg27147174	chr7:100797783	AP1S1	-0.64	-11.87	-0.48	1.53e-28	Life satisfaction;
LGG	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.44	-0.44	4.5e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg09238746	chr17:78121135	EIF4A3	-0.61	-10.44	-0.44	4.75e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg13903179	chr13:21900392	NA	0.45	8.48	0.37	3.05e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg13010199	chr12:38710504	ALG10B	-0.68	-13.04	-0.52	2.6e-33	Morning vs. evening chronotype;
LGG	trans	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg26384229	chr12:38710491	ALG10B	0.78	14.28	0.55	1.33e-38	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07991241	chr10:33269695	NA	0.47	8.15	0.35	3.51e-15	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg24829409	chr8:58192753	C8orf71	-0.48	-8.3	-0.36	1.18e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg04450456	chr4:17643702	FAM184B	0.33	6.95	0.31	1.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.4	-0.36	5.57e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-7.89	-0.34	2.16e-14	Total body bone mineral density;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg02475777	chr4:1388615	CRIPAK	0.46	8.67	0.37	7.12e-17	Longevity;
LGG	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg13207630	chr7:32358064	NA	0.68	7.27	0.32	1.52e-12	Body mass index;
LGG	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.66	-11.4	-0.47	1.05e-26	Mean platelet volume;
LGG	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg03929089	chr4:120376271	NA	0.44	7.07	0.31	5.81e-12	HDL cholesterol;
LGG	cis	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-14.89	-0.57	2.88e-41	Morning vs. evening chronotype;
LGG	trans	rs7939886	0.920	rs78769647	chr11:55965527	C/T	cg03929089	chr4:120376271	NA	0.73	6.79	0.3	3.52e-11	Myopia (pathological);
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg14926445	chr8:58193284	C8orf71	-0.9	-13.09	-0.52	1.58e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.15	-0.49	1.15e-29	Depression;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg12692727	chr7:1102344	C7orf50	0.48	6.76	0.3	4.1e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg03474202	chr17:45855739	NA	-0.27	-7.96	-0.35	1.32e-14	IgG glycosylation;
LGG	cis	rs55871839	0.684	rs13271523	chr8:59806664	T/C	cg07426533	chr8:59803705	TOX	-0.57	-12.9	-0.51	9.39e-33	Pneumonia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25480799	chr2:184472883	NA	0.36	7.15	0.32	3.5e-12	Menarche (age at onset);
LGG	cis	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg09307838	chr4:120376055	NA	0.49	8.38	0.36	6.34e-16	Diastolic blood pressure;
LGG	cis	rs7666738	0.830	rs7663661	chr4:99014761	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2249694	0.960	rs4335490	chr10:135402350	T/C	cg20169779	chr10:135381914	SYCE1	-0.49	-7.63	-0.33	1.39e-13	Obesity-related traits;
LGG	cis	rs4262150	0.810	rs4473761	chr5:151973508	C/G	cg12297329	chr5:152029980	NA	-0.8	-15.33	-0.58	3.3400000000000002e-43	Bipolar disorder and schizophrenia;
LGG	trans	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.04	-0.39	4.35e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg05941027	chr17:61774174	LIMD2	0.34	8.76	0.38	3.74e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg19635926	chr16:89946313	TCF25	0.71	7.73	0.34	6.6e-14	Skin colour saturation;
LGG	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg11166453	chr1:247681781	NA	0.66	10.39	0.43	7.19e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6743226	0.603	rs11896191	chr2:242226751	T/C	cg10021735	chr2:242295487	FARP2	0.4	7.08	0.31	5.49e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15045943	chr5:171614719	STK10	0.49	7.46	0.33	4.38e-13	Gut microbiome composition (summer);
LGG	cis	rs477692	0.685	rs534430	chr10:131398734	A/C	cg05714579	chr10:131428358	MGMT	0.58	11.99	0.49	4.71e-29	Response to temozolomide;
LGG	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg11822372	chr1:151115635	SEMA6C	0.49	8.76	0.38	3.82e-17	Childhood ear infection;
LGG	cis	rs2173063	0.881	rs75088107	chr15:93127959	A/G	cg07052004	chr15:93132129	NA	0.68	7.14	0.31	3.75e-12	Subcutaneous adipose tissue;
LGG	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22766014	chr2:69241106	ANTXR1	0.48	6.98	0.31	1.06e-11	Gut microbiome composition (summer);
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	0.31	8.06	0.35	6.56e-15	IgG glycosylation;
LGG	cis	rs10979	0.597	rs9496691	chr6:143910970	T/C	cg25407410	chr6:143891975	LOC285740	-0.55	-8.18	-0.36	2.71e-15	Hypospadias;
LGG	cis	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg13010199	chr12:38710504	ALG10B	0.76	16.24	0.6	2.86e-47	Heart rate;
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg19635926	chr16:89946313	TCF25	0.71	6.93	0.31	1.4e-11	Skin colour saturation;
LGG	cis	rs7712401	0.601	rs246328	chr5:122287628	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs368123	1.000	rs435294	chr6:160717708	T/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.15	-0.32	3.3e-12	Waist circumference;
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.34	0.32	9.46e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01484320	chr1:109757057	SARS	0.48	7.46	0.33	4.34e-13	Gut microbiome composition (summer);
LGG	cis	rs13102973	0.829	rs13126756	chr4:135900185	G/A	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	trans	rs225245	0.782	rs321599	chr17:33905745	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-7.08	-0.31	5.47e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.78	0.38	3.13e-17	Bipolar disorder;
LGG	trans	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.88	0.48	1.35e-28	Mean corpuscular volume;
LGG	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.05	-0.31	6.42e-12	Neuroticism;
LGG	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg20308403	chr7:2120281	MAD1L1	-0.35	-7.9	-0.34	2.07e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.79	0.3	3.55e-11	Bladder cancer;
LGG	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg08344181	chr3:125677491	NA	-0.91	-9.3	-0.4	5.71e-19	Depression;
LGG	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg13010199	chr12:38710504	ALG10B	0.77	16.48	0.61	2.31e-48	Heart rate;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg09033563	chr22:24373618	LOC391322	-0.5	-8.32	-0.36	9.99e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg15440763	chr7:158190612	PTPRN2	0.38	7.89	0.34	2.13e-14	Obesity-related traits;
LGG	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.27	-0.32	1.59e-12	Alzheimer's disease (late onset);
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.84	13.22	0.52	4.3e-34	Alzheimer's disease;
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg07685180	chr8:600429	NA	1.22	11.92	0.48	9.18e-29	IgG glycosylation;
LGG	cis	rs17539620	0.506	rs77962262	chr6:154845814	T/A	cg17771515	chr6:154831774	CNKSR3	0.61	7.09	0.31	5.2e-12	Lipoprotein (a) levels;
LGG	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.97e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.5	-0.4	1.16e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-10.36	-0.43	9.59e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.41	-0.36	5e-16	Total body bone mineral density;
LGG	trans	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg24247370	chr13:99142703	STK24	-0.39	-6.88	-0.3	1.92e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.33	-0.32	1.02e-12	Skin colour saturation;
LGG	cis	rs2997447	0.846	rs3008417	chr1:26403470	G/A	cg23602478	chr1:26503979	CNKSR1	0.34	7.06	0.31	5.99e-12	QRS complex (12-leadsum);
LGG	cis	rs13102973	0.797	rs4453983	chr4:135905424	A/C	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs7011049	1.000	rs72643588	chr8:53849335	C/T	cg26025543	chr8:53854495	NA	0.75	9.92	0.42	3.73e-21	Systolic blood pressure;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg04234412	chr22:24373322	LOC391322	0.73	14.71	0.56	1.92e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.4	-0.36	5.36e-16	Myopia (pathological);
LGG	cis	rs61990749	0.597	rs176971	chr14:78191599	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.56	6.98	0.31	1.03e-11	Fibroblast growth factor basic levels;
LGG	cis	rs947474	0.838	rs4558075	chr10:6401625	C/T	cg19837174	chr10:6389707	NA	0.61	8.67	0.37	7.32e-17	Type 1 diabetes;Rheumatoid arthritis;
LGG	trans	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg06529181	chr19:52193933	NA	0.51	7.83	0.34	3.34e-14	IgG glycosylation;
LGG	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg14036092	chr11:66035641	RAB1B	0.45	7.79	0.34	4.55e-14	Gout;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09807466	chr5:175875199	FAF2	-0.41	-6.69	-0.3	6.56e-11	Pancreatic cancer;
LGG	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.91	-0.31	1.62e-11	Neuroticism;
LGG	cis	rs3761218	0.668	rs6052079	chr20:3774209	G/T	cg25011176	chr20:3776985	CDC25B	-0.43	-6.74	-0.3	4.6e-11	Bipolar disorder;
LGG	cis	rs2153535	0.540	rs9378557	chr6:8517381	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.63	11.23	0.46	4.64e-26	Response to antipsychotic treatment;
LGG	cis	rs36051895	0.558	rs7038687	chr9:5134065	C/T	cg02405213	chr9:5042618	JAK2	0.79	15.69	0.59	8.63e-45	Pediatric autoimmune diseases;
LGG	cis	rs2224391	0.822	rs2773321	chr6:5262220	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.95	-0.35	1.47e-14	Height;
LGG	trans	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-11.12	-0.46	1.22e-25	Mean corpuscular volume;
LGG	cis	rs9473924	0.580	rs68118663	chr6:50815367	C/T	cg14470998	chr6:50812995	TFAP2B	0.65	7.75	0.34	5.74e-14	Body mass index;
LGG	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg13770153	chr20:60521292	NA	-0.56	-8.76	-0.38	3.79e-17	Body mass index;
LGG	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.94	-0.74	4.96e-83	Lymphocyte percentage of white cells;
LGG	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg23335576	chr14:104009727	NA	0.49	8.52	0.37	2.22e-16	Reticulocyte count;
LGG	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg25817165	chr18:72167213	CNDP2	-0.68	-15.17	-0.58	1.74e-42	Refractive error;
LGG	cis	rs72772090	0.539	rs72773981	chr5:96156059	A/C	cg00188032	chr5:96141721	ERAP1	0.53	6.92	0.31	1.56e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.51e-12	Refractive error;
LGG	cis	rs9296092	0.517	rs62405949	chr6:33522800	G/A	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10929925	0.966	rs2693826	chr2:6160943	C/T	cg00493617	chr2:6141445	NA	0.33	7.45	0.33	4.69e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs9287719	0.967	rs6432122	chr2:10753844	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.4	6.69	0.3	6.5500000000000006e-11	Ulcerative colitis;
LGG	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs4356975	0.527	rs60423649	chr4:69993670	T/G	cg27372994	chr4:70080453	UGT2B11	0.38	6.92	0.31	1.47e-11	Obesity-related traits;
LGG	cis	rs4356932	1.000	rs10003240	chr4:76955330	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.37e-11	Body mass index;
LGG	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	6.76	0.3	4.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg14505434	chr11:89522851	NA	0.65	8.36	0.36	7.34e-16	Trans fatty acid levels;
LGG	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg00666640	chr1:248458726	OR2T12	0.61	9.94	0.42	3.17e-21	Common traits (Other);
LGG	cis	rs7737355	0.704	rs11749484	chr5:131061607	T/C	cg06307176	chr5:131281290	NA	0.52	8.55	0.37	1.8e-16	Life satisfaction;
LGG	cis	rs17767392	0.958	rs35231795	chr14:71987374	T/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.17	0.39	1.58e-18	Mitral valve prolapse;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg20887711	chr4:1340912	KIAA1530	-0.52	-9.62	-0.41	4.32e-20	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.54	0.44	2.04e-23	Personality dimensions;
LGG	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg25482853	chr8:67687455	SGK3	0.93	11.88	0.48	1.4e-28	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20122548	chr15:45694411	SPATA5L1	0.43	7.01	0.31	8.66e-12	Cognitive performance;
LGG	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.16	0.35	3.17e-15	Iron status biomarkers;
LGG	cis	rs250677	0.652	rs168751	chr5:148438264	C/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-6.92	-0.31	1.5e-11	Breast cancer;
LGG	cis	rs4731207	0.596	rs1871772	chr7:124678872	G/T	cg05630886	chr7:124431682	NA	-0.32	-7.39	-0.32	6.71e-13	Cutaneous malignant melanoma;
LGG	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-7.72	-0.34	7.09e-14	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.5	-11.7	-0.48	7.03e-28	Oropharynx cancer;
LGG	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg00405596	chr8:11794950	NA	0.49	8.41	0.36	5.31e-16	Neuroticism;
LGG	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg05082376	chr22:42548792	NA	-0.42	-8.87	-0.38	1.64e-17	Schizophrenia;
LGG	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg23982607	chr1:1823379	GNB1	0.41	7.07	0.31	5.78e-12	Body mass index;
LGG	trans	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.85	0.38	1.9e-17	Retinal vascular caliber;
LGG	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11644478	chr21:40555479	PSMG1	0.85	15.26	0.58	7.05e-43	Cognitive function;
LGG	cis	rs698813	0.604	rs7565928	chr2:44489956	T/C	cg00619915	chr2:44497795	NA	-0.61	-8.92	-0.38	1.08e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs12980942	0.630	rs11881940	chr19:41808432	A/T	cg25627403	chr19:41769009	HNRNPUL1	0.59	7.28	0.32	1.43e-12	Coronary artery disease;
LGG	cis	rs12042938	1.000	rs4366301	chr1:231806286	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-10.35	-0.43	1.04e-22	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	9.13	0.39	2.13e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs3806843	1.000	rs1476768	chr5:140173597	G/A	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11641365	1.000	rs11641365	chr16:88773893	A/G	cg02389323	chr16:88786976	FAM38A	-0.49	-7.66	-0.34	1.06e-13	Autism spectrum disorder-related traits;
LGG	cis	rs975722	0.736	rs2106155	chr7:117241031	C/A	cg10524701	chr7:117356490	CTTNBP2	0.45	8.95	0.38	8.86e-18	Coronary artery disease;
LGG	cis	rs3849046	0.817	rs7711958	chr5:137901501	C/T	cg10920316	chr5:137946599	NA	0.43	6.91	0.31	1.66e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.43	-0.44	5.3e-23	Neuroticism;
LGG	cis	rs9796	0.662	rs8033435	chr15:41436479	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.74	-0.41	1.63e-20	Menopause (age at onset);
LGG	cis	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.31	0.32	1.15e-12	Neuroticism;
LGG	cis	rs6708331	1.000	rs7578027	chr2:70401108	A/G	cg01613454	chr2:70366299	NA	0.54	9.38	0.4	2.99e-19	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg02002194	chr4:3960332	NA	0.53	9.98	0.42	2.34e-21	Retinal vascular caliber;
LGG	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.86	-0.38	1.75e-17	Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg00376283	chr12:123451042	ABCB9	0.62	11.46	0.47	5.91e-27	Neutrophil percentage of white cells;
LGG	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2404602	0.552	rs11634428	chr15:77084582	T/C	cg23625390	chr15:77176239	SCAPER	-0.74	-13.26	-0.52	2.94e-34	Blood metabolite levels;
LGG	cis	rs368123	0.961	rs439039	chr6:160725359	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.78e-12	Waist circumference;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg05793240	chr7:2802953	GNA12	0.35	8.04	0.35	7.5e-15	Height;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18110333	chr6:292329	DUSP22	-0.7	-12.02	-0.49	3.73e-29	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs11726604	chr4:99000969	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7582720	1.000	rs72932789	chr2:203699379	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg13010199	chr12:38710504	ALG10B	0.62	12.08	0.49	2.22e-29	Heart rate;
LGG	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg17376030	chr22:41985996	PMM1	0.49	7.91	0.35	1.89e-14	Vitiligo;
LGG	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9308731	0.966	rs36018702	chr2:111928373	G/T	cg26001287	chr2:111877753	BCL2L11	0.38	7.63	0.33	1.36e-13	Chronic lymphocytic leukemia;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	8.45	0.37	3.75e-16	Lung function (FEV1/FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26512142	chr11:2554198	KCNQ1	0.59	9.23	0.39	1e-18	Gut microbiome composition (summer);
LGG	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.11	-0.31	4.53e-12	Retinal vascular caliber;
LGG	cis	rs6912958	0.712	rs2754262	chr6:88405585	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.28	-0.36	1.38e-15	Monocyte percentage of white cells;
LGG	cis	rs3816183	0.585	rs12712855	chr2:42861598	G/A	cg14631114	chr2:43023945	NA	0.35	6.89	0.3	1.88e-11	Hypospadias;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	8.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7975161	0.630	rs4129598	chr12:104620638	T/C	cg25273343	chr12:104657179	TXNRD1	-0.73	-8.19	-0.36	2.59e-15	Toenail selenium levels;
LGG	cis	rs9916302	0.904	rs4239222	chr17:37696235	A/C	cg07936489	chr17:37558343	FBXL20	0.83	15.3	0.58	4.62e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.71	-0.3	5.56e-11	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.85	-0.38	1.91e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.77	-13.82	-0.54	1.26e-36	Gut microbiome composition (summer);
LGG	cis	rs2708240	0.666	rs2710118	chr7:147603362	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-7.98	-0.35	1.18e-14	QT interval (drug interaction);
LGG	cis	rs3815700	1.000	rs8104726	chr19:33094675	G/A	cg02997394	chr19:33096574	ANKRD27	0.88	12.95	0.52	6.14e-33	Eosinophilic esophagitis;
LGG	cis	rs2832191	0.791	rs2832199	chr21:30498501	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-24.05	-0.75	1.51e-83	Dental caries;
LGG	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.74	0.3	4.85e-11	Parkinson's disease;
LGG	cis	rs877282	1.000	rs2004479	chr10:770854	G/A	cg17470449	chr10:769945	NA	0.65	8.27	0.36	1.43e-15	Uric acid levels;
LGG	cis	rs1659258	0.568	rs1258443	chr2:88597243	A/C	cg00685853	chr2:88648947	NA	-0.45	-6.73	-0.3	4.91e-11	Visceral fat;
LGG	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.53e-15	Neuroticism;
LGG	cis	rs2708977	0.609	rs611943	chr2:97067074	T/C	cg01950434	chr2:97203154	ARID5A	-0.46	-7.08	-0.31	5.36e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg22535103	chr8:58192502	C8orf71	-0.97	-13.35	-0.53	1.21e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.16	-0.35	3.3e-15	Educational attainment;
LGG	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg12463550	chr7:65579703	CRCP	0.51	8.61	0.37	1.16e-16	Aortic root size;
LGG	cis	rs10751667	0.666	rs7396677	chr11:958878	C/T	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.61e-15	Alzheimer's disease (late onset);
LGG	cis	rs12618769	0.597	rs4069739	chr2:99049528	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.64	0.37	9.24e-17	Bipolar disorder;
LGG	cis	rs6964587	0.869	rs10276682	chr7:91486070	G/A	cg17063962	chr7:91808500	NA	-0.4	-6.94	-0.31	1.35e-11	Breast cancer;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg03188948	chr7:1209495	NA	0.41	7.14	0.31	3.68e-12	Longevity;Endometriosis;
LGG	trans	rs57046232	0.552	rs6133306	chr20:6333294	T/G	cg21095983	chr6:86352623	SYNCRIP	0.42	6.99	0.31	9.85e-12	Colorectal cancer;
LGG	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg07005078	chr4:17578674	LAP3	0.38	6.77	0.3	4.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg19920283	chr7:105172520	RINT1	0.6	7.97	0.35	1.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.01	0.31	8.63e-12	Prudent dietary pattern;
LGG	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.33	0.36	8.9e-16	Rheumatoid arthritis;
LGG	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg13512537	chr8:22265999	SLC39A14	-0.44	-7.13	-0.31	3.99e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6460942	0.749	rs74834695	chr7:12464779	G/A	cg06484146	chr7:12443880	VWDE	-0.39	-6.92	-0.31	1.5e-11	Coronary artery disease;
LGG	cis	rs9796	0.689	rs561301	chr15:41444723	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.58	-0.41	5.71e-20	Menopause (age at onset);
LGG	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg25019033	chr10:957182	NA	-0.55	-10.08	-0.42	9.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg03342759	chr3:160939853	NMD3	-0.62	-10.88	-0.45	1.03e-24	Morning vs. evening chronotype;
LGG	trans	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg06875740	chr19:51307921	C19orf48	-0.73	-6.87	-0.3	2.03e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg18105134	chr13:113819100	PROZ	-0.8	-16.87	-0.62	3.8300000000000002e-50	Platelet distribution width;
LGG	cis	rs6669919	0.967	rs11119752	chr1:211675765	A/G	cg10512769	chr1:211675356	NA	-0.71	-15.81	-0.59	2.36e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg10483660	chr13:112241077	NA	0.36	6.97	0.31	1.12e-11	Menarche (age at onset);
LGG	trans	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg13565492	chr6:43139072	SRF	-0.88	-14.88	-0.57	3.43e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12286929	0.577	rs7101437	chr11:115063641	A/G	cg04055981	chr11:115044050	NA	-0.37	-6.94	-0.31	1.31e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg07267674	chr5:1049712	NA	-0.75	-14.63	-0.56	4.19e-40	QT interval;
LGG	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg16797656	chr11:68205561	LRP5	0.51	9.92	0.42	3.73e-21	Total body bone mineral density;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.83	-15.66	-0.59	1.14e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg20608306	chr11:116969690	SIK3	-0.41	-10.61	-0.44	1.07e-23	Subjective well-being;
LGG	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg19442545	chr10:75533431	FUT11	-0.45	-7.49	-0.33	3.57e-13	Inflammatory bowel disease;
LGG	cis	rs42648	0.508	rs39201	chr7:89734104	A/G	cg04070188	chr7:89809444	NA	0.27	6.65	0.3	8.5e-11	Homocysteine levels;
LGG	cis	rs12472274	0.618	rs12477307	chr2:239110514	G/T	cg17459225	chr2:239074497	NA	0.64	10.96	0.45	5.34e-25	Phospholipid levels (plasma);
LGG	cis	rs4731207	0.596	rs1481333	chr7:124643059	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-10.19	-0.43	3.98e-22	Chronic sinus infection;
LGG	trans	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg02800362	chr5:177631904	HNRNPAB	0.99	12.43	0.5	8.44e-31	Obesity-related traits;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25427524	chr10:38739819	LOC399744	-0.64	-11.92	-0.48	9.05e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs11122272	0.701	rs11122273	chr1:231476789	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.91	-0.45	7.85e-25	Hemoglobin concentration;
LGG	cis	rs4919694	1.000	rs75691516	chr10:104652045	C/T	cg04362960	chr10:104952993	NT5C2	1.09	14.99	0.57	1.08e-41	Arsenic metabolism;
LGG	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-10.42	-0.44	5.4e-23	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.28	-0.32	1.45e-12	Hemoglobin concentration;
LGG	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg16482183	chr6:26056742	HIST1H1C	0.63	9.82	0.42	8.25e-21	Iron status biomarkers;
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg02002194	chr4:3960332	NA	0.48	9.2	0.39	1.2e-18	Neuroticism;
LGG	cis	rs2286885	1.000	rs741022	chr9:129252113	C/G	cg14319473	chr9:129242481	FAM125B	0.45	8.52	0.37	2.29e-16	Intraocular pressure;
LGG	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.35	-0.32	9.25e-13	Body mass index;
LGG	trans	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg00953403	chr17:74099816	EXOC7	-0.49	-8.33	-0.36	9.3e-16	Psychosis in Alzheimer's disease;
LGG	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	cis	rs7619833	0.693	rs7622813	chr3:27309145	C/T	cg02860705	chr3:27208620	NA	0.39	7.58	0.33	1.84e-13	Breast cancer;
LGG	cis	rs10781543	0.845	rs10735662	chr9:139327869	A/T	cg14019695	chr9:139328340	INPP5E	0.42	7.51	0.33	3.06e-13	Monocyte percentage of white cells;
LGG	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg24450063	chr1:156163899	SLC25A44	1.08	22.6	0.72	9.43e-77	Testicular germ cell tumor;
LGG	cis	rs1909881	0.543	rs3133731	chr8:96506122	G/T	cg04203453	chr8:96504381	NA	-0.49	-8.94	-0.38	9.64e-18	Obesity-related traits;
LGG	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg08344181	chr3:125677491	NA	-0.91	-9.21	-0.39	1.11e-18	Depression;
LGG	cis	rs6032067	0.641	rs74174932	chr20:43756133	G/A	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs12220238	1.000	rs10824125	chr10:75997498	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.73	0.48	5.15e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.92	0.54	4.78e-37	Lung cancer in ever smokers;
LGG	cis	rs7586879	0.593	rs11689543	chr2:25130440	A/T	cg04586622	chr2:25135609	ADCY3	0.47	12.99	0.52	3.92e-33	Body mass index;
LGG	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg12386194	chr3:101231763	SENP7	0.75	13.0	0.52	3.61e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2502399	0.898	rs984500	chr6:113507536	A/G	cg20413948	chr6:113544930	NA	0.3	6.94	0.31	1.35e-11	Plasma clusterin levels;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-6.86	-0.3	2.19e-11	Prudent dietary pattern;
LGG	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.55	-0.37	1.75e-16	Retinal vascular caliber;
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.32	-0.5	2.26e-30	Alzheimer's disease;
LGG	cis	rs11662586	1.000	rs7243921	chr18:77695237	G/A	cg20368463	chr18:77673604	PQLC1	0.49	7.83	0.34	3.36e-14	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg05552183	chr6:42928497	GNMT	0.48	14.83	0.57	5.52e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3796352	1.000	rs34979715	chr3:53048960	G/A	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2070997	0.816	rs1800609	chr9:133731184	A/G	cg13397898	chr9:133768931	QRFP	0.39	7.95	0.35	1.44e-14	Response to amphetamines;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05165339	chr4:1420672	NA	-0.35	-8.93	-0.38	1.01e-17	Longevity;
LGG	cis	rs2692947	0.832	rs2438978	chr2:96679740	G/C	cg22654517	chr2:96458247	NA	0.38	7.62	0.33	1.45e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg04617936	chr2:214353	NA	-0.4	-7.44	-0.33	4.97e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.59	0.37	1.31e-16	Schizophrenia;
LGG	cis	rs11690935	0.879	rs13017585	chr2:172721808	C/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.83	-0.3	2.73e-11	Schizophrenia;
LGG	cis	rs4851254	0.660	rs35869550	chr2:100684578	T/A	cg17356467	chr2:100759845	AFF3	0.46	7.34	0.32	9.71e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg22437258	chr11:111473054	SIK2	0.57	9.83	0.42	7.57e-21	Primary sclerosing cholangitis;
LGG	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg13514129	chr1:39547527	MACF1	0.68	12.71	0.51	5.66e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.26	0.46	3.56e-26	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg02002194	chr4:3960332	NA	0.42	7.67	0.34	1.05e-13	Triglycerides;
LGG	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.02e-24	Schizophrenia;
LGG	cis	rs1044826	0.642	rs9826544	chr3:139162831	A/G	cg15131784	chr3:139108705	COPB2	0.43	7.05	0.31	6.58e-12	Obesity-related traits;
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg16434002	chr17:42200994	HDAC5	-0.52	-9.78	-0.41	1.19e-20	Total body bone mineral density;
LGG	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.27	-0.46	3.33e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.53	7.98	0.35	1.12e-14	Huntington's disease progression;
LGG	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg12011299	chr4:100065546	ADH4	0.45	9.35	0.4	3.68e-19	Alcohol dependence;
LGG	cis	rs7215564	0.908	rs7503757	chr17:78685599	A/G	cg16980736	chr17:78789706	RPTOR	-0.71	-9.14	-0.39	1.95e-18	Myopia (pathological);
LGG	cis	rs1570884	0.516	rs7334387	chr13:50172133	T/A	cg08779649	chr13:50194554	NA	0.36	9.13	0.39	2.21e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg15642758	chr15:83876612	HDGFRP3	0.41	6.96	0.31	1.19e-11	Body mass index;
LGG	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.89	-0.38	1.33e-17	Kawasaki disease;
LGG	trans	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	7.03e-19	Diabetic kidney disease;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.9	-0.48	1.18e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.25	-0.32	1.77e-12	Skin colour saturation;
LGG	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.0	-0.31	9.08e-12	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg19318889	chr4:1322082	MAEA	0.48	8.17	0.35	3.04e-15	Longevity;
LGG	cis	rs4363385	0.647	rs1995308	chr1:153014082	A/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.47	-0.4	1.45e-19	Inflammatory skin disease;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs7523273	0.606	rs2488253	chr1:207938709	C/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.92	0.48	9.08e-29	Schizophrenia;
LGG	cis	rs4690686	0.500	rs17062801	chr4:177262381	G/A	cg17059388	chr4:177262070	NA	1.03	24.3	0.75	1.05e-84	Essential tremor;
LGG	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg27624424	chr6:160112604	SOD2	0.64	9.15	0.39	1.84e-18	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg23231163	chr10:75533350	FUT11	-0.41	-6.92	-0.31	1.54e-11	Inflammatory bowel disease;
LGG	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs7124681	0.584	rs1471712	chr11:47912150	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-11.15	-0.46	9.68e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.39	-0.43	7.4e-23	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07355551	chr20:2489285	ZNF343	0.55	8.77	0.38	3.36e-17	Gut microbiome composition (summer);
LGG	cis	rs919433	0.617	rs700646	chr2:198608511	C/T	cg00792783	chr2:198669748	PLCL1	0.66	10.7	0.45	4.84e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs9409565	0.559	rs9409774	chr9:97241983	G/A	cg05679027	chr9:99775184	HIATL2	-0.46	-6.86	-0.3	2.29e-11	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs7737355	0.947	rs42264	chr5:130810028	T/G	cg06307176	chr5:131281290	NA	0.55	9.26	0.4	7.9e-19	Life satisfaction;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.77	-0.34	5.11e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs804280	0.525	rs1004712	chr8:11622293	C/T	cg12395012	chr8:11607386	GATA4	-0.57	-10.8	-0.45	2.19e-24	Myopia (pathological);
LGG	cis	rs11190604	1.000	rs74210981	chr10:102287520	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.33	0.32	1.05e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg04117972	chr1:227635322	NA	0.83	13.05	0.52	2.35e-33	Major depressive disorder;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg08677398	chr8:58056175	NA	0.43	7.11	0.31	4.38e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.59	-10.5	-0.44	2.83e-23	Lymphocyte counts;
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg16606324	chr3:10149918	C3orf24	0.64	7.29	0.32	1.36e-12	Alzheimer's disease;
LGG	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg23594656	chr7:65796392	TPST1	-0.36	-8.02	-0.35	8.6e-15	Aortic root size;
LGG	cis	rs283228	0.798	rs649828	chr6:101748341	T/C	cg27451362	chr6:101846650	GRIK2	0.65	10.61	0.44	1.12e-23	Coenzyme Q10 levels;
LGG	cis	rs11785693	0.862	rs62491171	chr8:4987177	G/A	cg26367366	chr8:4980734	NA	0.95	15.37	0.58	2.38e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs4950322	0.543	rs114302864	chr1:146789849	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs28830936	0.966	rs2277535	chr15:42119711	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.95	-0.52	6.23e-33	Diastolic blood pressure;
LGG	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.64	0.33	1.29e-13	Longevity;
LGG	trans	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg21775007	chr8:11205619	TDH	0.43	6.87	0.3	2.14e-11	Systolic blood pressure;
LGG	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg27129171	chr3:47204927	SETD2	0.78	15.09	0.57	3.89e-42	Colorectal cancer;
LGG	cis	rs1620921	0.756	rs783163	chr6:161182401	A/T	cg01280913	chr6:161186852	NA	-0.51	-10.46	-0.44	4.09e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg05084668	chr3:125655381	ALG1L	-0.91	-11.11	-0.46	1.39e-25	Blood pressure (smoking interaction);
LGG	cis	rs9976767	0.792	rs883868	chr21:43845092	C/T	cg23042151	chr21:43824109	UBASH3A	0.46	9.47	0.4	1.48e-19	Type 1 diabetes;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg21948465	chr5:131705150	SLC22A5	0.67	7.53	0.33	2.6e-13	Rheumatoid arthritis;
LGG	cis	rs4665809	1.000	rs1550382	chr2:26266877	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.91	-0.51	8.59e-33	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.57	-0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2802728	0.881	rs55696172	chr1:243582771	A/G	cg05593162	chr1:243577377	SDCCAG8	0.51	6.91	0.31	1.61e-11	Toenail selenium levels;
LGG	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg21045802	chr8:109455806	TTC35	0.49	8.99	0.39	6.37e-18	Dupuytren's disease;
LGG	cis	rs926392	0.666	rs56877916	chr20:37696192	A/T	cg16355469	chr20:37678765	NA	0.55	8.75	0.38	3.98e-17	Dialysis-related mortality;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09217309	chr6:150244204	RAET1G	0.4	7.23	0.32	2.02e-12	Testicular germ cell tumor;
LGG	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg04568710	chr12:38710424	ALG10B	0.38	8.36	0.36	7.55e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg20568497	chr10:133558893	NA	0.33	6.87	0.3	2.13e-11	Survival in rectal cancer;
LGG	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg01403660	chr11:68851641	TPCN2	0.52	7.34	0.32	9.72e-13	Blond vs. brown hair color;
LGG	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg22517653	chr1:2918612	NA	-0.45	-6.96	-0.31	1.18e-11	Plateletcrit;
LGG	cis	rs1728785	1.000	rs1728765	chr16:68589433	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-11.72	-0.48	5.78e-28	Longevity;Endometriosis;
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00290607	chr11:67383545	NA	0.66	12.79	0.51	2.63e-32	Mean corpuscular volume;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.11	18.46	0.65	1.97e-57	Platelet count;
LGG	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg02811702	chr13:24901961	NA	0.39	7.19	0.32	2.59e-12	Obesity-related traits;
LGG	cis	rs477692	0.637	rs7098619	chr10:131315856	C/T	cg05714579	chr10:131428358	MGMT	0.45	8.47	0.37	3.19e-16	Response to temozolomide;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13972706	chr6:144671686	UTRN	0.31	6.71	0.3	5.68e-11	Gut microbiome composition (summer);
LGG	trans	rs7939886	0.920	rs2460212	chr11:55886155	C/T	cg15704280	chr7:45808275	SEPT13	-0.77	-7.9	-0.34	2.1e-14	Myopia (pathological);
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21862992	chr11:68658383	NA	0.51	8.4	0.36	5.39e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg21775007	chr8:11205619	TDH	-0.78	-13.71	-0.54	3.92e-36	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg15971980	chr6:150254442	NA	0.44	8.46	0.37	3.5e-16	Lung cancer;
LGG	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.31e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.46	-6.82	-0.3	2.81e-11	Childhood ear infection;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13012494	chr21:47604986	C21orf56	0.49	8.22	0.36	2.11e-15	Testicular germ cell tumor;
LGG	cis	rs1105228	0.679	rs4709933	chr6:165702705	C/T	cg12582777	chr6:165658423	NA	0.25	6.67	0.3	7.39e-11	Number of pregnancies;Number of children;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg15921436	chr17:44337874	NA	0.58	12.35	0.5	1.81e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg11502198	chr6:26597334	ABT1	-0.56	-9.56	-0.41	7.01e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12348691	0.503	rs7046645	chr9:100617375	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs72781680	0.898	rs17462670	chr2:24026579	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs2963155	0.518	rs853179	chr5:142634773	G/T	cg17617527	chr5:142782415	NR3C1	0.98	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg13939156	chr17:80058883	NA	0.41	7.34	0.32	9.49e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs75804782	0.625	rs72984508	chr2:239462765	C/G	cg01134436	chr17:81009848	B3GNTL1	0.75	7.97	0.35	1.25e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs71403859	0.614	rs12149533	chr16:71801946	C/T	cg08717414	chr16:71523259	ZNF19	-1.06	-13.04	-0.52	2.52e-33	Post bronchodilator FEV1;
LGG	cis	rs10991814	0.920	rs75136602	chr9:93969277	G/A	cg14446406	chr9:93919335	NA	-0.8	-7.42	-0.33	5.76e-13	Neutrophil percentage of granulocytes;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg12419862	chr22:24373484	LOC391322	-0.91	-19.0	-0.66	6.04e-60	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.16	-0.43	4.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg00290607	chr11:67383545	NA	-0.52	-9.22	-0.39	1.07e-18	Mean corpuscular volume;
LGG	cis	rs1719271	0.908	rs1631677	chr15:65198591	A/G	cg11671771	chr15:65133392	PLEKHO2	-0.5	-7.0	-0.31	8.82e-12	Platelet count;
LGG	cis	rs9815354	0.909	rs11717540	chr3:41932938	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg14668632	chr7:2872130	GNA12	-0.33	-7.02	-0.31	8.07e-12	Height;
LGG	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg17646820	chr3:66848679	NA	0.53	8.2	0.36	2.37e-15	Type 2 diabetes;
LGG	cis	rs4268898	0.932	rs7577964	chr2:24598279	A/G	cg06627628	chr2:24431161	ITSN2	0.49	8.23	0.36	1.92e-15	Asthma;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.62	-0.37	1.04e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.41	0.56	3.67e-39	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg06634786	chr22:41940651	POLR3H	0.67	10.69	0.44	5.47e-24	Vitiligo;
LGG	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.77	0.75	6.98e-87	Chronic sinus infection;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg24575275	chr7:1094737	C7orf50	-0.39	-7.43	-0.33	5.45e-13	Longevity;Endometriosis;
LGG	cis	rs7247513	0.658	rs4804728	chr19:12752928	G/A	cg01871581	chr19:12707946	ZNF490	-0.37	-7.36	-0.32	8.34e-13	Bipolar disorder;
LGG	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg00376283	chr12:123451042	ABCB9	0.62	11.45	0.47	7e-27	Platelet count;
LGG	cis	rs1620921	0.625	rs28715036	chr6:161266045	G/A	cg01280913	chr6:161186852	NA	-0.37	-7.44	-0.33	5.01e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.45	-8.23	-0.36	1.88e-15	Rheumatoid arthritis;
LGG	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27511599	chr7:32358540	NA	0.63	6.67	0.3	7.21e-11	Body mass index;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg10950524	chr7:2139216	MAD1L1	0.33	7.34	0.32	9.86e-13	Schizophrenia;
LGG	trans	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg05059571	chr16:84539110	KIAA1609	0.56	10.99	0.45	4.08e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs611744	0.870	rs685358	chr8:109161413	T/C	cg21045802	chr8:109455806	TTC35	0.39	7.01	0.31	8.66e-12	Dupuytren's disease;
LGG	cis	rs3126085	1.000	rs55957623	chr1:152223196	T/A	cg26876637	chr1:152193138	HRNR	-0.5	-7.23	-0.32	1.98e-12	Atopic dermatitis;
LGG	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg03162506	chr22:38580953	NA	0.28	6.98	0.31	1.04e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.55	0.37	1.74e-16	Schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00586367	chr8:74790437	UBE2W	0.39	6.8	0.3	3.3e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg14789911	chr21:47582049	C21orf56	-0.44	-7.42	-0.33	5.74e-13	Testicular germ cell tumor;
LGG	trans	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg10756647	chr7:56101905	PSPH	0.74	8.62	0.37	1.05e-16	Diabetic kidney disease;
LGG	cis	rs17253792	0.822	rs9323289	chr14:56106784	G/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.78e-31	Putamen volume;
LGG	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg16070123	chr10:51489643	NA	-0.39	-7.19	-0.32	2.67e-12	Prostate-specific antigen levels;
LGG	cis	rs858239	0.539	rs28624974	chr7:23188936	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.46e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg04111992	chr7:158790115	NA	-0.36	-7.33	-0.32	1e-12	Facial morphology (factor 20);
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg05484376	chr2:27715224	FNDC4	0.45	9.68	0.41	2.7e-20	Total body bone mineral density;
LGG	cis	rs240764	0.507	rs9390695	chr6:101266770	A/G	cg09795085	chr6:101329169	ASCC3	0.43	7.0	0.31	9.14e-12	Neuroticism;
LGG	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg03264133	chr6:25882463	NA	-0.49	-7.93	-0.35	1.68e-14	Iron status biomarkers;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs910187	0.678	rs3818012	chr20:45816594	G/A	cg27589058	chr20:45804311	EYA2	-0.34	-9.0	-0.39	5.9e-18	Migraine;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg09033563	chr22:24373618	LOC391322	-0.53	-8.99	-0.39	6.39e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4253772	0.591	rs6008545	chr22:46686375	C/T	cg24881330	chr22:46731750	TRMU	0.77	9.29	0.4	6.19e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg02297831	chr4:17616191	MED28	-0.41	-7.47	-0.33	4.05e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.67	-0.41	2.95e-20	Response to antipsychotic treatment;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.84	0.34	3.17e-14	Personality dimensions;
LGG	cis	rs7546668	1.000	rs4646090	chr1:15822073	A/G	cg21858823	chr1:15850916	CASP9	0.37	7.05	0.31	6.75e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7020830	0.894	rs12337316	chr9:37148105	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	30.99	0.82	5.44e-115	Schizophrenia;
LGG	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg03733263	chr8:22462867	KIAA1967	-0.89	-18.79	-0.66	5.73e-59	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg20040747	chr15:74715105	SEMA7A	0.76	22.95	0.73	2.09e-78	Airflow obstruction;
LGG	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22857025	chr5:266934	NA	-1.37	-24.39	-0.75	4.19e-85	Breast cancer;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.12	0.31	4.1e-12	Prudent dietary pattern;
LGG	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.25	-0.32	1.72e-12	Obesity;
LGG	cis	rs6920372	0.799	rs9480947	chr6:109718565	C/G	cg01125227	chr6:109776195	MICAL1	0.39	6.91	0.31	1.56e-11	Height;
LGG	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg03929089	chr4:120376271	NA	0.44	7.02	0.31	7.93e-12	HDL cholesterol;
LGG	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg21926883	chr2:100939477	LONRF2	-0.49	-9.45	-0.4	1.63e-19	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg20991723	chr1:152506922	NA	-0.73	-15.04	-0.57	6.6e-42	Hair morphology;
LGG	cis	rs8044868	0.530	rs4788464	chr16:72223899	T/C	cg23815491	chr16:72088622	HP	0.36	7.65	0.34	1.15e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00689492	chr4:1303491	MAEA	0.49	8.48	0.37	2.97e-16	Obesity-related traits;
LGG	cis	rs2742417	1.000	rs938363	chr3:45746364	T/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7927592	0.913	rs7106010	chr11:68365212	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.42	-0.36	4.73e-16	Total body bone mineral density;
LGG	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg26138144	chr22:38071188	LGALS1	0.68	15.4	0.58	1.6e-43	Fat distribution (HIV);
LGG	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg00142150	chr22:38071001	LGALS1	0.68	13.1	0.52	1.49e-33	Fat distribution (HIV);
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13126279	chr21:47581558	C21orf56	-0.56	-9.83	-0.42	7.64e-21	Testicular germ cell tumor;
LGG	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.84	-0.3	2.57e-11	Total cholesterol levels;
LGG	cis	rs11700980	0.636	rs115245768	chr21:30256118	T/G	cg08807101	chr21:30365312	RNF160	-0.65	-7.35	-0.32	8.84e-13	QRS complex (12-leadsum);
LGG	cis	rs77633900	0.772	rs284897	chr15:76750722	T/C	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.79	-0.41	1.04e-20	Triglycerides;
LGG	cis	rs7226408	0.857	rs72892509	chr18:34661797	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.14	-0.31	3.71e-12	Obesity-related traits;
LGG	cis	rs6840360	0.642	rs6851814	chr4:152346437	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.06	0.31	6.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg13232821	chr7:50628718	DDC	-0.37	-7.27	-0.32	1.53e-12	Malaria;
LGG	cis	rs4750440	0.706	rs11258767	chr10:14016565	C/T	cg00551146	chr10:14014579	FRMD4A	0.29	7.15	0.32	3.43e-12	Adiponectin levels;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg24623649	chr8:11872141	NA	0.32	7.69	0.34	9.1e-14	Monocyte count;
LGG	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg08250081	chr4:10125330	NA	-0.35	-6.71	-0.3	5.8e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs4742903	0.935	rs12351370	chr9:106928940	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.2	0.36	2.37e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg18357526	chr6:26021779	HIST1H4A	0.58	9.93	0.42	3.52e-21	Height;
LGG	cis	rs4356932	1.000	rs6846814	chr4:76952288	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.75	-0.3	4.5e-11	Blood protein levels;
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.64	-0.41	3.7799999999999997e-20	Triglycerides;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.84	-0.3	2.5e-11	Menopause (age at onset);
LGG	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg27446573	chr6:127587934	RNF146	0.93	17.78	0.64	2.61e-54	Breast cancer;
LGG	cis	rs7580658	0.963	rs12622436	chr2:128081682	C/A	cg10021288	chr2:128175891	PROC	-0.64	-13.28	-0.53	2.44e-34	Protein C levels;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg27189623	chr16:705930	WDR90	0.4	7.73	0.34	6.55e-14	Height;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg00431236	chr2:264988	ACP1;SH3YL1	0.42	7.44	0.33	4.9e-13	Body mass index;
LGG	cis	rs36051895	0.623	rs57707737	chr9:5062844	A/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.87	-0.57	3.77e-41	Pediatric autoimmune diseases;
LGG	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.61	0.33	1.52e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs56346965	1.000	rs2192008	chr2:191545147	C/T	cg06753949	chr19:15334309	NA	-0.44	-6.91	-0.31	1.61e-11	Bone mineral density (Ward's triangle area);
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg24690094	chr11:67383802	NA	-0.43	-7.95	-0.35	1.47e-14	Mean corpuscular volume;
LGG	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg15704280	chr7:45808275	SEPT13	0.88	9.21	0.39	1.1e-18	Myopia (pathological);
LGG	cis	rs7927592	0.630	rs510772	chr11:68218731	T/C	cg16797656	chr11:68205561	LRP5	0.52	9.93	0.42	3.42e-21	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.85	-0.34	2.82e-14	IgG glycosylation;
LGG	cis	rs7113850	0.541	rs75893426	chr11:24210429	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	9.78	0.41	1.13e-20	Bone fracture in osteoporosis;
LGG	cis	rs6815814	0.851	rs73236644	chr4:38863193	A/G	cg06935464	chr4:38784597	TLR10	0.56	7.55	0.33	2.37e-13	Breast cancer;
LGG	cis	rs13323323	0.728	rs1004631	chr3:44592979	T/G	cg02073558	chr3:44770973	ZNF501	0.52	7.41	0.33	6.2e-13	IgG glycosylation;
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg13699009	chr12:122356056	WDR66	0.57	14.82	0.57	6.21e-41	Mean corpuscular volume;
LGG	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.34	-0.58	2.95e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg08250081	chr4:10125330	NA	0.44	8.67	0.37	7.46e-17	Bone mineral density;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg14926445	chr8:58193284	C8orf71	-0.91	-13.43	-0.53	5.79e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.4e-12	Total cholesterol levels;
LGG	cis	rs5997397	0.934	rs6005863	chr22:29156448	A/G	cg02153584	chr22:29168773	CCDC117	0.39	6.69	0.3	6.34e-11	Red cell distribution width;
LGG	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg26318627	chr11:63887540	MACROD1	0.38	7.87	0.34	2.55e-14	Platelet count;
LGG	cis	rs10888329	0.744	rs6587431	chr1:248354978	T/C	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Autism spectrum disorder;
LGG	cis	rs9399135	0.507	rs2072825	chr6:135253451	A/G	cg24558204	chr6:135376177	HBS1L	-0.57	-9.66	-0.41	3.18e-20	Red blood cell count;
LGG	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg20026190	chr17:76395443	PGS1	0.57	10.11	0.43	7.86e-22	HDL cholesterol levels;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg00106254	chr7:1943704	MAD1L1	0.48	8.88	0.38	1.47e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg18681998	chr4:17616180	MED28	-0.74	-14.95	-0.57	1.62e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs36051895	0.555	rs6476953	chr9:5248742	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-13.53	-0.53	2.14e-35	Pediatric autoimmune diseases;
LGG	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.71	0.3	5.72e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg15309053	chr8:964076	NA	0.42	9.01	0.39	5.25e-18	Schizophrenia;
LGG	cis	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg21775007	chr8:11205619	TDH	0.47	7.76	0.34	5.49e-14	Mood instability;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14893161	chr1:205819251	PM20D1	0.88	20.47	0.69	8.87e-67	Menarche (age at onset);
LGG	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg02153584	chr22:29168773	CCDC117	0.6	9.26	0.4	7.67e-19	Lymphocyte counts;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg06719900	chr11:109292894	C11orf87	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.8	0.62	8.01e-50	Obesity-related traits;
LGG	cis	rs7226408	0.857	rs72887072	chr18:34499453	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg00761968	chr13:53314142	LECT1	-0.36	-7.03	-0.31	7.54e-12	Lewy body disease;
LGG	cis	rs8028182	0.636	rs8028277	chr15:75684085	A/G	cg20655648	chr15:75932815	IMP3	0.45	7.55	0.33	2.29e-13	Sudden cardiac arrest;
LGG	cis	rs16854884	0.739	rs1898265	chr3:143776096	A/G	cg06585982	chr3:143692056	C3orf58	-0.59	-10.02	-0.42	1.62e-21	Economic and political preferences (feminism/equality);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21243939	chr14:55033137	SAMD4A	0.44	7.13	0.31	4.01e-12	Cognitive performance;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	10.05	0.42	1.31e-21	Tonsillectomy;
LGG	cis	rs17767392	0.958	rs34454371	chr14:71881502	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	1e-17	Mitral valve prolapse;
LGG	cis	rs4684776	0.867	rs11706903	chr3:11343551	C/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.2	-0.36	2.44e-15	Total body bone mineral density;
LGG	cis	rs9527	0.590	rs11191578	chr10:104902337	A/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.75	-0.3	4.37e-11	Arsenic metabolism;
LGG	trans	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.27	0.43	1.99e-22	Mean corpuscular volume;
LGG	cis	rs2274273	1.000	rs7142704	chr14:55630603	C/A	cg04306507	chr14:55594613	LGALS3	0.61	16.82	0.62	6.52e-50	Protein biomarker;
LGG	cis	rs6541297	0.941	rs6693579	chr1:230282707	T/C	cg05784532	chr1:230284198	GALNT2	0.54	8.01	0.35	9.36e-15	Coronary artery disease;
LGG	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-12.12	-0.49	1.54e-29	Vitiligo;
LGG	trans	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.53	0.47	3.28e-27	Corneal astigmatism;
LGG	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg07636037	chr3:49044803	WDR6	0.56	7.49	0.33	3.43e-13	Menarche (age at onset);
LGG	cis	rs9534288	0.730	rs7985754	chr13:46581287	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg06115741	chr20:33292138	TP53INP2	0.6	9.84	0.42	7.16e-21	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg01145232	chr6:150245071	RAET1G	0.32	6.89	0.31	1.81e-11	Testicular germ cell tumor;
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs7795605	chr7:124578447	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg26150922	chr2:100937072	LONRF2	-0.59	-11.39	-0.47	1.18e-26	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.818	rs4576617	chr1:152985729	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.11e-16	Inflammatory skin disease;
LGG	cis	rs853679	0.517	rs9368556	chr6:28131153	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	trans	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.06	-0.35	6.64e-15	Heart rate;
LGG	cis	rs9815354	1.000	rs6789260	chr3:41776350	G/C	cg03022575	chr3:42003672	ULK4	0.66	8.29	0.36	1.23e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07080220	chr10:102295463	HIF1AN	0.65	11.24	0.46	4.32e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1371867	0.846	rs1692006	chr8:101252462	C/T	cg06636551	chr8:101224915	SPAG1	0.48	8.82	0.38	2.4e-17	Atrioventricular conduction;
LGG	cis	rs6764363	0.527	rs13064013	chr3:283284	G/T	cg02057681	chr3:285234	CHL1	-0.42	-7.34	-0.32	9.88e-13	Sudden cardiac arrest;
LGG	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.52	-8.27	-0.36	1.43e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg24692254	chr21:30365293	RNF160	-1.04	-29.16	-0.8	7.21e-107	Dental caries;
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.21	0.43	3.31e-22	Tonsillectomy;
LGG	cis	rs1127311	0.846	rs61811388	chr1:154581231	G/C	cg11650704	chr1:154556575	ADAR	-0.5	-9.91	-0.42	4.04e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg04608330	chr12:45269318	NELL2	-0.64	-11.54	-0.47	2.85e-27	Gut microbiome composition (summer);
LGG	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg13010199	chr12:38710504	ALG10B	-0.58	-11.31	-0.47	2.39e-26	Morning vs. evening chronotype;
LGG	cis	rs3806843	0.838	rs2337514	chr5:140132732	T/C	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg08297393	chr2:100937505	LONRF2	0.5	9.3	0.4	5.62e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4950322	0.570	rs80070044	chr1:146801969	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.31	0.43	1.46e-22	Aortic root size;
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.64e-24	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs10046574	0.519	rs7810403	chr7:135216172	G/A	cg27474649	chr7:135195673	CNOT4	0.71	9.01	0.39	5.5e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg08344181	chr3:125677491	NA	-0.68	-7.19	-0.32	2.66e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.32	-0.5	2.21e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.47	7.49	0.33	3.46e-13	Colorectal cancer;
LGG	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg21475434	chr5:93447410	FAM172A	0.67	6.76	0.3	4.14e-11	Diabetic retinopathy;
LGG	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.98	-0.39	6.62e-18	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-9.0	-0.39	6.01e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs3106136	0.934	rs34145031	chr4:95167123	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.01	-0.35	9.11e-15	Capecitabine sensitivity;
LGG	trans	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg16141378	chr3:129829833	LOC729375	-0.44	-10.53	-0.44	2.12e-23	Systolic blood pressure;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	trans	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.44e-15	Bladder cancer;
LGG	cis	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg22496380	chr5:211416	CCDC127	0.8	10.44	0.44	4.77e-23	Breast cancer;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.69	0.37	6.32e-17	Platelet count;
LGG	cis	rs504918	0.783	rs11717452	chr3:124120599	T/C	cg05766129	chr3:123988013	KALRN	-0.44	-7.99	-0.35	1.06e-14	Schizophrenia;
LGG	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg11965913	chr1:205819406	PM20D1	0.43	6.86	0.3	2.23e-11	Parkinson's disease;
LGG	cis	rs6430585	0.583	rs12373779	chr2:136586840	A/C	cg07169764	chr2:136633963	MCM6	1.29	25.53	0.76	2.09e-90	Corneal structure;
LGG	trans	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg23484912	chr5:273055	PDCD6	0.5	9.88	0.42	5.11e-21	Pancreatic cancer;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.81	0.41	9.28e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs10849893	0.576	rs7296507	chr12:121847135	A/G	cg01154721	chr12:121881891	KDM2B	-0.41	-7.15	-0.32	3.37e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.47	-0.37	3.3e-16	Neuroticism;
LGG	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg22630939	chr7:1135958	C7orf50	0.33	6.74	0.3	4.83e-11	Bronchopulmonary dysplasia;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02018176	chr4:1364513	KIAA1530	0.64	15.5	0.58	6.1e-44	Longevity;
LGG	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg17376030	chr22:41985996	PMM1	0.67	10.77	0.45	2.81e-24	Vitiligo;
LGG	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.14e-54	Cognitive function;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.88	-10.1	-0.42	8.58e-22	Smoking behavior;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs7147624	1.000	rs4902408	chr14:66111901	A/T	cg03016385	chr14:66212404	NA	-0.82	-10.03	-0.42	1.48e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs367615	0.704	rs7705399	chr5:108850351	G/C	cg17395555	chr5:108820864	NA	0.87	15.92	0.59	7.63e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1620921	0.711	rs2802356	chr6:161238215	G/A	cg01280913	chr6:161186852	NA	-0.34	-7.0	-0.31	9.11e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6445975	0.715	rs6769100	chr3:58259999	C/T	cg24175188	chr3:58374923	PXK	-0.4	-7.49	-0.33	3.42e-13	Systemic lupus erythematosus;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.54	-14.55	-0.56	8.76e-40	Tonsillectomy;
LGG	cis	rs6714710	0.603	rs2278700	chr2:98427382	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs3818285	0.504	rs4917547	chr10:111652285	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.54	-9.75	-0.41	1.45e-20	Superior crus of antihelix expression;
LGG	trans	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08382705	chr11:45687319	CHST1	0.5	7.02	0.31	7.78e-12	Height;
LGG	cis	rs9880211	0.948	rs6806123	chr3:136305476	C/G	cg21827317	chr3:136751795	NA	-0.49	-7.18	-0.32	2.71e-12	Body mass index;Height;
LGG	trans	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg02002194	chr4:3960332	NA	-0.46	-8.81	-0.38	2.49e-17	Mood instability;
LGG	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs17445240	1.000	rs78506209	chr2:3699715	G/A	cg20720597	chr2:3699334	NA	0.89	9.33	0.4	4.53e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1847202	1.000	rs1847202	chr3:72934371	T/C	cg25664220	chr3:72788482	NA	-0.24	-7.42	-0.33	5.79e-13	Motion sickness;
LGG	cis	rs11748327	0.959	rs11134030	chr5:4065252	C/T	cg01025095	chr5:4101132	NA	0.57	9.29	0.4	5.96e-19	Myocardial infarction;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.41	-0.33	6e-13	Restless legs syndrome;
LGG	cis	rs4702718	0.549	rs267945	chr5:10747689	C/T	cg14521931	chr5:10832172	NA	-0.46	-8.89	-0.38	1.4e-17	Obesity-related traits;
LGG	cis	rs758324	0.617	rs12719447	chr5:131118100	C/A	cg06307176	chr5:131281290	NA	0.57	9.41	0.4	2.3e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg03188948	chr7:1209495	NA	0.71	10.31	0.43	1.43e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12282928	1.000	rs10838840	chr11:48258010	C/A	cg26585981	chr11:48327164	OR4S1	0.44	7.11	0.31	4.4e-12	Migraine - clinic-based;
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-8.03	-0.35	8.12e-15	Skin colour saturation;
LGG	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg20578329	chr17:80767326	TBCD	-0.46	-7.93	-0.35	1.69e-14	Breast cancer;
LGG	cis	rs1519814	0.616	rs28885745	chr8:121012458	T/C	cg22335954	chr8:121166405	COL14A1	-0.47	-8.37	-0.36	7.12e-16	Breast cancer;
LGG	cis	rs892961	0.932	rs11655686	chr17:75419535	G/A	cg05865280	chr17:75406074	SEPT9	0.42	9.63	0.41	3.93e-20	Airflow obstruction;
LGG	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg06618935	chr21:46677482	NA	0.5	9.79	0.41	1.04e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs600231	0.542	rs12360896	chr11:65238306	G/T	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.71	-0.38	5.56e-17	Bone mineral density;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.37	0.32	8.07e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-7.51	-0.33	2.99e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg06360820	chr2:242988706	NA	-0.91	-12.24	-0.49	4.7e-30	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.603	rs10224041	chr7:19903837	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	7.86	0.34	2.72e-14	Night sleep phenotypes;
LGG	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg20040747	chr15:74715105	SEMA7A	0.38	7.28	0.32	1.44e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg14820908	chr5:178986412	RUFY1	-0.39	-6.68	-0.3	6.99e-11	Lung cancer;
LGG	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg00431813	chr7:1051703	C7orf50	-0.35	-7.54	-0.33	2.43e-13	Longevity;Endometriosis;
LGG	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg08975724	chr8:8085496	FLJ10661	-0.57	-11.83	-0.48	2.15e-28	Neuroticism;
LGG	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg11584989	chr19:19387371	SF4	0.78	13.01	0.52	3.22e-33	Bipolar disorder;
LGG	cis	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.32	-0.43	1.35e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg12081754	chr8:22256438	SLC39A14	1.15	25.59	0.77	1.21e-90	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2224391	0.590	rs2773312	chr6:5251798	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.45	-0.33	4.46e-13	Height;
LGG	cis	rs12493885	0.585	rs61790899	chr3:153642124	C/T	cg17054900	chr3:154042577	DHX36	-0.57	-7.11	-0.31	4.4e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9660992	0.624	rs72745217	chr1:205261482	C/G	cg21545522	chr1:205238299	TMCC2	0.47	8.44	0.37	4.2e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs10883723	0.962	rs1056740	chr10:104236552	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.85	0.51	1.56e-32	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg13206674	chr6:150067644	NUP43	0.43	7.52	0.33	2.79e-13	Lung cancer;
LGG	cis	rs9811920	0.609	rs809415	chr3:99582242	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-8.96	-0.38	7.83e-18	Axial length;
LGG	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.99	-0.31	9.47e-12	Uric acid levels;
LGG	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg12419862	chr22:24373484	LOC391322	0.87	13.13	0.52	1.09e-33	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24394865	chr11:66206319	MRPL11	0.45	6.79	0.3	3.49e-11	Gut microbiome composition (summer);
LGG	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg09537434	chr19:41945824	ATP5SL	0.89	23.53	0.74	4.04e-81	Height;
LGG	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg05484376	chr2:27715224	FNDC4	0.45	9.62	0.41	4.22e-20	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.81	-0.3	2.97e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.03	-0.39	4.67e-18	Bladder cancer;
LGG	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.25	-0.4	8.09e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11750568	0.967	rs4701034	chr5:178513921	T/C	cg10208897	chr5:178548229	ADAMTS2	0.42	6.84	0.3	2.48e-11	Height;
LGG	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1962073	0.528	rs12544112	chr8:10318815	C/A	cg06636001	chr8:8085503	FLJ10661	0.45	7.7	0.34	8.07e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg26850624	chr5:429559	AHRR	-0.33	-7.59	-0.33	1.8e-13	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05045001	chr17:40729964	PSMC3IP	0.46	6.88	0.3	1.94e-11	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.15	0.43	5.24e-22	Retinal vascular caliber;
LGG	cis	rs911555	0.755	rs12435516	chr14:103954404	T/C	cg24130564	chr14:104152367	KLC1	0.39	7.23	0.32	2.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	0.515	rs2757039	chr6:167370353	G/T	cg18261144	chr6:167370276	RNASET2	-0.38	-7.71	-0.34	7.78e-14	Crohn's disease;
LGG	cis	rs11650494	0.808	rs61286260	chr17:47433222	T/C	cg08112188	chr17:47440006	ZNF652	1.16	13.95	0.54	3.47e-37	Prostate cancer;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs7011049	0.778	rs113964834	chr8:53866524	T/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs629535	0.821	rs497398	chr8:70037434	A/T	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.545	rs885275	chr2:127951095	T/C	cg10021288	chr2:128175891	PROC	-0.46	-8.77	-0.38	3.44e-17	Protein C levels;
LGG	cis	rs6694672	1.000	rs928439	chr1:196950482	G/A	cg13682187	chr1:196946512	CFHR5	-0.49	-6.7	-0.3	6.21e-11	Asthma;
LGG	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.54e-22	Motion sickness;
LGG	cis	rs9633740	1.000	rs10749609	chr10:82249752	G/A	cg01528321	chr10:82214614	TSPAN14	1.02	16.26	0.6	2.44e-47	Post bronchodilator FEV1;
LGG	cis	rs939658	0.805	rs12902831	chr15:79433171	G/A	cg17916960	chr15:79447300	NA	-0.68	-13.17	-0.52	7.08e-34	Refractive error;
LGG	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.82	-0.3	2.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2735413	0.599	rs73562710	chr16:78124606	T/C	cg04733911	chr16:78082701	NA	0.57	7.99	0.35	1.1e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6871536	1.000	rs2040703	chr5:131972258	C/G	cg04303330	chr5:131992430	IL13	0.27	6.68	0.3	6.98e-11	Asthma (childhood onset);
LGG	cis	rs3126085	0.935	rs12760382	chr1:152260287	G/T	cg26876637	chr1:152193138	HRNR	-0.54	-8.52	-0.37	2.24e-16	Atopic dermatitis;
LGG	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg12654349	chr5:56205094	C5orf35	-0.4	-7.06	-0.31	6.28e-12	Coronary artery disease;
LGG	trans	rs8073060	0.586	rs225294	chr17:33925762	G/A	cg19694781	chr19:47549865	TMEM160	-1.13	-17.25	-0.63	7.77e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	6.95	0.31	1.25e-11	Resting heart rate;
LGG	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.65	-0.56	3.48e-40	Prudent dietary pattern;
LGG	cis	rs877282	1.000	rs71491304	chr10:772982	C/T	cg17470449	chr10:769945	NA	0.65	8.35	0.36	8.26e-16	Uric acid levels;
LGG	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg11764359	chr7:65958608	NA	-0.62	-10.67	-0.44	6.52e-24	Aortic root size;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-8.16	-0.35	3.28e-15	Schizophrenia;
LGG	trans	rs9650657	0.596	rs2409674	chr8:10595878	C/A	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.27	-0.32	1.54e-12	Neuroticism;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg21724239	chr8:58056113	NA	0.61	9.12	0.39	2.24e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg04863758	chr4:1303710	MAEA	0.4	6.97	0.31	1.11e-11	Obesity-related traits;
LGG	cis	rs1691799	0.899	rs1168300	chr12:66736467	C/A	cg16791601	chr12:66731901	HELB	-0.66	-15.53	-0.59	4.4e-44	White blood cell count (basophil);
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.54	0.33	2.5e-13	Schizophrenia;
LGG	cis	rs10274279	1.000	rs10274279	chr7:157387441	C/T	cg09270525	chr7:157391030	PTPRN2	-0.69	-9.07	-0.39	3.51e-18	Myopia (pathological);
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.8	-0.38	2.72e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs13256369	0.762	rs13278972	chr8:8597180	T/C	cg02002194	chr4:3960332	NA	-0.41	-6.94	-0.31	1.35e-11	Obesity-related traits;
LGG	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg03929089	chr4:120376271	NA	0.82	8.52	0.37	2.26e-16	Myopia (pathological);
LGG	cis	rs3820928	0.874	rs13403281	chr2:227880769	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.6	-0.33	1.63e-13	Pulmonary function;
LGG	trans	rs330071	0.515	rs12545193	chr8:9251880	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	7.49	0.33	3.52e-13	Acne (severe);
LGG	cis	rs2346177	0.811	rs4953373	chr2:46652145	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-10.0	-0.42	1.9e-21	HDL cholesterol;
LGG	cis	rs2832270	0.562	rs8133819	chr21:30458754	T/C	cg24692254	chr21:30365293	RNF160	-0.61	-7.22	-0.32	2.12e-12	Response to mTOR inhibitor (everolimus);
LGG	cis	rs4774899	0.902	rs11633061	chr15:57488193	A/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.19	-0.32	2.7e-12	Urinary tract infection frequency;
LGG	trans	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-9.31	-0.4	5.19e-19	Vitiligo;
LGG	cis	rs7444	0.882	rs5749495	chr22:21940310	A/G	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.53e-14	Systemic lupus erythematosus;
LGG	cis	rs60180747	0.909	rs11639266	chr15:66600417	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.53	8.71	0.38	5.27e-17	Testicular germ cell tumor;
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.45e-16	Testicular germ cell tumor;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.34	0.36	8.87e-16	Life satisfaction;
LGG	cis	rs1847505	0.609	rs717049	chr13:61497129	C/T	cg25164009	chr13:61490935	NA	0.6	9.35	0.4	3.83e-19	Polychlorinated biphenyl levels;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-20.23	-0.68	1.14e-65	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-9.18	-0.39	1.39e-18	Vitiligo;
LGG	cis	rs4417704	0.526	rs6733049	chr2:241902718	C/G	cg26818257	chr2:241905806	NA	0.49	10.58	0.44	1.45e-23	Joint mobility (Beighton score);
LGG	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.18	0.36	2.67e-15	Iron status biomarkers;
LGG	cis	rs4919694	0.901	rs74376228	chr10:104677662	G/C	cg04362960	chr10:104952993	NT5C2	1.05	13.27	0.52	2.88e-34	Arsenic metabolism;
LGG	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.78	-0.3	3.6e-11	Neuroticism;
LGG	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15596359	chr8:11213517	TDH	0.42	8.75	0.38	4.05e-17	Retinal vascular caliber;
LGG	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg03433033	chr1:76189801	ACADM	-0.45	-7.01	-0.31	8.59e-12	Daytime sleep phenotypes;
LGG	cis	rs4363385	0.510	rs6689510	chr1:153048039	G/A	cg13444842	chr1:152974279	SPRR3	-0.47	-9.33	-0.4	4.43e-19	Inflammatory skin disease;
LGG	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.14	0.39	1.94e-18	Colorectal cancer;
LGG	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.7	-12.94	-0.52	6.65e-33	Colorectal cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15408407	chr19:1438438	RPS15	-0.41	-6.86	-0.3	2.26e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4919087	0.561	rs793522	chr10:99022614	T/G	cg25902810	chr10:99078978	FRAT1	-0.43	-6.98	-0.31	1.06e-11	Monocyte count;
LGG	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg26384229	chr12:38710491	ALG10B	0.8	16.28	0.6	2e-47	Morning vs. evening chronotype;
LGG	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg13334819	chr7:99746414	C7orf59	0.48	7.53	0.33	2.62e-13	Coronary artery disease;
LGG	cis	rs848	0.540	rs2706370	chr5:131933016	A/C	cg04303330	chr5:131992430	IL13	0.28	6.86	0.3	2.16e-11	Alopecia areata;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9398803	0.673	rs1262557	chr6:127054588	C/T	cg19875578	chr6:126661172	C6orf173	-0.5	-9.1	-0.39	2.77e-18	Male-pattern baldness;
LGG	cis	rs62238980	0.614	rs77696994	chr22:32390280	C/T	cg00543991	chr22:32367038	NA	0.74	7.43	0.33	5.15e-13	Childhood ear infection;
LGG	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.73	0.34	6.88e-14	Homoarginine levels;
LGG	cis	rs9487094	0.961	rs3778475	chr6:109696206	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.95e-18	Height;
LGG	cis	rs939658	1.000	rs939658	chr15:79451869	A/G	cg17916960	chr15:79447300	NA	0.62	11.91	0.48	1.03e-28	Refractive error;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.87	0.34	2.5e-14	Colorectal cancer;
LGG	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg23649088	chr2:200775458	C2orf69	0.65	9.04	0.39	4.44e-18	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs17253792	0.822	rs7145064	chr14:56088860	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.05	-0.49	2.75e-29	Putamen volume;
LGG	cis	rs4148883	0.645	rs2851264	chr4:100029715	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.68	0.37	6.98e-17	Alcohol dependence;
LGG	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg02297831	chr4:17616191	MED28	-0.47	-8.6	-0.37	1.24e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs16937	0.711	rs6682229	chr1:205152932	T/C	cg00889227	chr1:205173544	DSTYK	-0.31	-7.63	-0.33	1.34e-13	Schizophrenia;
LGG	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.52	-0.47	3.56e-27	Response to antipsychotic treatment;
LGG	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-15.13	-0.58	2.73e-42	Response to antipsychotic treatment;
LGG	cis	rs6793245	0.960	rs7373779	chr3:38593943	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-8.19	-0.36	2.51e-15	QT interval;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg12708336	chr17:41446283	NA	-0.33	-7.94	-0.35	1.51e-14	Menopause (age at onset);
LGG	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.78	12.76	0.51	3.71e-32	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17169635	0.765	rs1014832	chr7:134572672	C/T	cg13549461	chr7:134575145	CALD1	0.34	6.77	0.3	3.97e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.2	0.39	1.27e-18	Mood instability;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20447079	chr7:50658381	GRB10	0.34	7.0	0.31	9.2e-12	Body fat percentage;
LGG	cis	rs2587949	0.615	rs1087729	chr3:4202492	T/C	cg16519197	chr3:4211558	NA	-0.34	-7.0	-0.31	8.84e-12	Periodontitis (DPAL);
LGG	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg10295955	chr4:187884368	NA	-1.13	-28.46	-0.8	9.97e-104	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1620921	0.594	rs9347450	chr6:161269890	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.02e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.03	-0.39	4.74e-18	Obesity-related traits;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23332955	chr17:77904095	NA	0.45	7.24	0.32	1.87e-12	Cognitive performance;
LGG	cis	rs981844	0.775	rs1037656	chr4:154750786	A/G	cg14289246	chr4:154710475	SFRP2	-0.62	-10.41	-0.44	6.15e-23	Response to statins (LDL cholesterol change);
LGG	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg09021430	chr5:549028	NA	-0.71	-9.79	-0.41	1.08e-20	Lung disease severity in cystic fibrosis;
LGG	cis	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.4	-0.56	4.31e-39	IgG glycosylation;
LGG	cis	rs7715811	1.000	rs1502052	chr5:13774908	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.96	-0.42	2.61e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg11062466	chr8:58055876	NA	0.48	8.23	0.36	1.89e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs10793304	chr11:78064907	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs10895140	0.590	rs10791508	chr11:101500220	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.85	-0.3	2.37e-11	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs42648	0.748	rs10227385	chr7:89890368	C/A	cg25739043	chr7:89950458	NA	-0.35	-7.35	-0.32	9.17e-13	Homocysteine levels;
LGG	cis	rs193541	0.545	rs112390044	chr5:122312002	A/C	cg19412675	chr5:122181750	SNX24	-0.44	-7.09	-0.31	4.97e-12	Glucose homeostasis traits;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-9.22	-0.39	1.02e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.567	rs13005448	chr2:42267903	A/C	cg27252766	chr2:42229092	NA	0.5	7.83	0.34	3.25e-14	Hypospadias;
LGG	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.34	0.43	1.07e-22	Diabetic retinopathy;
LGG	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg16339924	chr4:17578868	LAP3	-0.65	-10.41	-0.44	5.82e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05491587	chr18:77659695	KCNG2	-0.41	-7.62	-0.33	1.5e-13	Schizophrenia;
LGG	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg22961513	chr11:14280813	SPON1	0.38	9.58	0.41	6.15e-20	Mitochondrial DNA levels;
LGG	cis	rs3740540	0.761	rs61870251	chr10:126284415	A/C	cg04949429	chr10:126290192	LHPP	-0.43	-6.77	-0.3	3.86e-11	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3099143	1.000	rs10431768	chr15:77162158	A/G	cg21673338	chr15:77095150	SCAPER	0.65	10.34	0.43	1.09e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs561341	0.556	rs118032208	chr17:30395634	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.6	-0.37	1.23e-16	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.01	-0.42	1.78e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg15664640	chr17:80829946	TBCD	-0.63	-8.62	-0.37	1.08e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7953249	0.807	rs7970695	chr12:121423376	G/A	cg14101638	chr12:121416612	HNF1A	-0.36	-8.17	-0.35	3.06e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs13401104	0.716	rs1377443	chr2:237129648	G/T	cg15742758	chr2:237126235	ASB18	0.47	7.8	0.34	4.13e-14	Educational attainment;
LGG	cis	rs1568889	1.000	rs66702115	chr11:28181703	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.78	0.57	8.74e-41	Bipolar disorder;
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg21926883	chr2:100939477	LONRF2	-0.68	-16.24	-0.6	2.92e-47	Intelligence (multi-trait analysis);
LGG	cis	rs1125355	0.690	rs62183019	chr2:159628366	G/A	cg02251393	chr2:159651559	DAPL1	0.41	7.99	0.35	1.11e-14	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg22903471	chr2:27725779	GCKR	0.38	8.62	0.37	1.06e-16	Oral cavity cancer;
LGG	cis	rs12049351	0.612	rs10753459	chr1:229575764	G/A	cg13547644	chr1:229569608	ACTA1	0.32	6.99	0.31	9.45e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.33	-7.42	-0.33	5.51e-13	Obesity;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.34	6.97	0.31	1.09e-11	Schizophrenia;
LGG	cis	rs2117029	1.000	rs10783299	chr12:49390677	T/C	cg24176009	chr12:49580217	TUBA1A	0.43	7.78	0.34	4.66e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	6.85	0.3	2.36e-11	Cognitive test performance;
LGG	cis	rs4743820	0.651	rs73494917	chr9:93923120	T/G	cg14446406	chr9:93919335	NA	-0.9	-15.33	-0.58	3.27e-43	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs870825	0.616	rs28582728	chr4:185646920	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg22771759	chr13:24902376	NA	0.42	7.13	0.31	3.86e-12	Obesity-related traits;
LGG	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs6500395	0.588	rs1011666	chr16:48704293	T/C	cg04672837	chr16:48644449	N4BP1	-0.49	-8.4	-0.36	5.54e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg22906224	chr7:99728672	NA	0.56	9.26	0.4	7.89e-19	Coronary artery disease;
LGG	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg02153584	chr22:29168773	CCDC117	0.61	9.27	0.4	6.98e-19	Lymphocyte counts;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	8.07	0.35	6.18e-15	Longevity;
LGG	cis	rs35110281	0.720	rs162380	chr21:44925283	T/C	cg01579765	chr21:45077557	HSF2BP	0.39	8.48	0.37	3.08e-16	Mean corpuscular volume;
LGG	cis	rs12410462	0.591	rs6688145	chr1:227800160	C/T	cg04117972	chr1:227635322	NA	0.45	8.3	0.36	1.13e-15	Major depressive disorder;
LGG	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg07636037	chr3:49044803	WDR6	0.78	14.0	0.55	2.16e-37	Menarche (age at onset);
LGG	trans	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.22e-14	Resting heart rate;
LGG	cis	rs9341835	0.518	rs2622294	chr6:64218316	T/A	cg00787780	chr6:64151745	NA	-0.39	-6.97	-0.31	1.11e-11	Schizophrenia;
LGG	cis	rs9790314	0.605	rs2593812	chr3:160703069	T/G	cg03342759	chr3:160939853	NMD3	0.44	7.45	0.33	4.49e-13	Morning vs. evening chronotype;
LGG	cis	rs9972944	0.627	rs746627	chr17:63850776	C/T	cg07283582	chr17:63770753	CCDC46	-0.38	-6.68	-0.3	6.73e-11	Total body bone mineral density;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.34	-8.93	-0.38	1.02e-17	IgG glycosylation;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06028808	chr11:68637592	NA	0.72	12.37	0.5	1.43e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg15704280	chr7:45808275	SEPT13	0.84	8.83	0.38	2.18e-17	Myopia (pathological);
LGG	cis	rs950169	0.881	rs72750843	chr15:85135783	C/T	cg03959625	chr15:84868606	LOC388152	0.59	9.34	0.4	4.07e-19	Schizophrenia;
LGG	trans	rs2736340	0.539	rs9644687	chr8:11323025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.68	-0.34	9.28e-14	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
LGG	cis	rs10421328	0.848	rs10415278	chr19:19769157	C/A	cg11584989	chr19:19387371	SF4	0.5	7.46	0.33	4.17e-13	Parental longevity (combined parental age at death);
LGG	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg19338460	chr6:170058176	WDR27	-0.54	-7.72	-0.34	7.29e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7129556	0.645	rs684813	chr11:77494754	G/A	cg12586386	chr11:77299805	AQP11	0.47	7.13	0.31	3.97e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs11157436	0.602	rs11157439	chr14:22638958	T/C	cg00994629	chr14:22694547	NA	0.33	7.14	0.31	3.68e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg20978937	chr14:105399321	PLD4	0.49	11.19	0.46	6.96e-26	Rheumatoid arthritis;
LGG	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg05082376	chr22:42548792	NA	-0.36	-7.5	-0.33	3.37e-13	Schizophrenia;
LGG	cis	rs870825	0.616	rs10022834	chr4:185649431	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs10743315	0.557	rs17505123	chr12:19301353	G/A	cg02471346	chr12:19282374	PLEKHA5	0.88	8.53	0.37	2.13e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2455799	0.519	rs2062821	chr3:15697644	A/T	cg16303742	chr3:15540471	COLQ	-0.45	-8.99	-0.39	6.15e-18	Mean platelet volume;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	trans	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.53	-0.33	2.68e-13	Joint mobility (Beighton score);
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.42	-0.4	2.08e-19	Neuroticism;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg12708336	chr17:41446283	NA	-0.32	-7.65	-0.33	1.21e-13	Menopause (age at onset);
LGG	cis	rs1372520	0.684	rs184810	chr4:90697979	T/C	cg15133208	chr4:90757351	SNCA	0.39	7.59	0.33	1.77e-13	Neuroticism;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.15e-12	Menopause (age at onset);
LGG	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg12751644	chr20:60527061	NA	-0.31	-7.41	-0.33	5.99e-13	Body mass index;
LGG	cis	rs787274	1.000	rs4979153	chr9:115554984	G/A	cg13803584	chr9:115635662	SNX30	-0.57	-7.86	-0.34	2.71e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6977940	0.818	rs73033466	chr7:2902617	G/C	cg19731401	chr7:2775893	GNA12	0.36	6.68	0.3	6.71e-11	White matter integrity;
LGG	cis	rs2117029	0.767	rs3741622	chr12:49425978	T/C	cg24176009	chr12:49580217	TUBA1A	0.47	8.45	0.37	3.77e-16	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.26	-0.36	1.57e-15	Breast cancer;
LGG	cis	rs972578	0.765	rs4820492	chr22:43276030	A/C	cg01576275	chr22:43409880	NA	-0.23	-6.87	-0.3	2.08e-11	Mean platelet volume;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.83	-0.51	1.9e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg17376030	chr22:41985996	PMM1	0.51	8.21	0.36	2.25e-15	Vitiligo;
LGG	cis	rs7191700	0.644	rs918738	chr16:11439679	C/G	cg00044050	chr16:11439710	C16orf75	-0.71	-12.39	-0.5	1.25e-30	Multiple sclerosis;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.37	0.4	3.08e-19	Height;
LGG	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg25208724	chr1:156163844	SLC25A44	1.17	24.69	0.75	1.63e-86	Testicular germ cell tumor;
LGG	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17376030	chr22:41985996	PMM1	0.49	7.88	0.34	2.37e-14	Vitiligo;
LGG	trans	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg18187862	chr3:45730750	SACM1L	0.57	9.43	0.4	1.95e-19	Primary sclerosing cholangitis;
LGG	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg11266682	chr4:10021025	SLC2A9	0.51	10.14	0.43	5.92e-22	Bone mineral density;
LGG	cis	rs7017914	0.967	rs1348535	chr8:71662741	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.39	-7.09	-0.31	4.89e-12	Bone mineral density;
LGG	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.83	0.38	2.1e-17	Educational attainment;
LGG	cis	rs9473924	0.542	rs4294001	chr6:50850065	G/A	cg14470998	chr6:50812995	TFAP2B	0.63	7.64	0.33	1.24e-13	Body mass index;
LGG	cis	rs6430585	0.583	rs61253125	chr2:136618178	T/C	cg07169764	chr2:136633963	MCM6	1.3	26.9	0.78	1.11e-96	Corneal structure;
LGG	cis	rs4430311	0.723	rs12125920	chr1:243911397	A/C	cg25706552	chr1:244017396	NA	-0.65	-15.73	-0.59	5.4e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs2816062	0.775	rs2816048	chr1:18893763	T/C	cg10574377	chr1:18908098	NA	0.34	6.83	0.3	2.7e-11	Urate levels in lean individuals;
LGG	cis	rs757081	0.648	rs7108316	chr11:17275035	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.86	-0.34	2.76e-14	Systolic blood pressure;
LGG	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg09021430	chr5:549028	NA	0.69	9.55	0.41	7.65e-20	Obesity-related traits;
LGG	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg08344181	chr3:125677491	NA	-0.87	-8.58	-0.37	1.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4906332	0.933	rs34606394	chr14:103915636	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-8.0	-0.35	1.04e-14	Coronary artery disease;
LGG	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg08400814	chr5:56204995	C5orf35	0.4	7.14	0.31	3.68e-12	Initial pursuit acceleration;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.46	0.37	3.53e-16	Bipolar disorder;
LGG	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg09795085	chr6:101329169	ASCC3	0.42	7.1	0.31	4.79e-12	Neuroticism;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18402987	chr7:1209562	NA	0.45	8.69	0.37	6.51e-17	Longevity;Endometriosis;
LGG	cis	rs17445240	1.000	rs17445240	chr2:3703041	C/T	cg17046650	chr2:3699563	NA	-0.97	-11.36	-0.47	1.48e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs11976180	1.000	rs4726669	chr7:143758191	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.83	-0.3	2.72e-11	Obesity-related traits;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00933542	chr6:150070202	PCMT1	0.42	7.42	0.33	5.7e-13	Lung cancer;
LGG	cis	rs7660883	0.897	rs342438	chr4:88040406	A/G	cg21988461	chr4:88008667	AFF1	0.32	9.04	0.39	4.18e-18	HDL cholesterol levels;
LGG	cis	rs67311347	1.000	rs4973989	chr3:40451543	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-25.64	-0.77	6.5e-91	Renal cell carcinoma;
LGG	cis	rs908922	0.676	rs4845441	chr1:152485421	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.84	0.3	2.59e-11	Hair morphology;
LGG	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg04672837	chr16:48644449	N4BP1	0.55	8.91	0.38	1.15e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs77972916	0.609	rs72790907	chr2:43575195	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.99	-0.31	9.66e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs3816183	0.958	rs4953664	chr2:43024676	A/C	cg14631114	chr2:43023945	NA	-0.49	-9.21	-0.39	1.17e-18	Hypospadias;
LGG	cis	rs4330281	0.605	rs6442681	chr3:17454766	A/T	cg20981856	chr3:17787350	NA	0.35	6.65	0.3	8.04e-11	Schizophrenia;
LGG	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11644478	chr21:40555479	PSMG1	-0.6	-10.21	-0.43	3.36e-22	Menarche (age at onset);
LGG	cis	rs4819852	0.752	rs917479	chr22:19973205	T/G	cg07821417	chr22:19972146	ARVCF	0.49	10.58	0.44	1.44e-23	Pulse pressure;
LGG	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.79	-14.65	-0.56	3.45e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13191362	0.507	rs2155506	chr6:163035342	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-8.49	-0.37	2.75e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1691799	0.777	rs11176145	chr12:66719795	A/G	cg16791601	chr12:66731901	HELB	0.52	11.27	0.46	3.28e-26	White blood cell count (basophil);
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.29	-0.32	1.31e-12	Menopause (age at onset);
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg13129888	chr1:28415099	EYA3	-0.41	-6.75	-0.3	4.39e-11	Leprosy;
LGG	trans	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg24247370	chr13:99142703	STK24	-0.42	-7.59	-0.33	1.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2797369	0.600	rs705598	chr6:101303669	T/C	cg27451362	chr6:101846650	GRIK2	0.67	9.19	0.39	1.31e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs3820928	0.839	rs4675123	chr2:227800205	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	2.93e-14	Pulmonary function;
LGG	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg08999081	chr20:33150536	PIGU	0.31	7.43	0.33	5.4e-13	Coronary artery disease;
LGG	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg25457927	chr22:38595422	NA	-0.37	-8.88	-0.38	1.5e-17	Cutaneous nevi;
LGG	cis	rs28588043	0.938	rs28810106	chr1:170972104	G/A	cg03458344	chr1:170964477	C1orf129	-0.5	-7.3	-0.32	1.3e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs6976053	0.810	rs2405975	chr7:100508212	T/C	cg03098644	chr7:100410630	EPHB4	-0.41	-7.3	-0.32	1.28e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9916302	0.706	rs667193	chr17:37448835	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7927771	0.524	rs7943213	chr11:47715524	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.19	0.46	7.09e-26	Subjective well-being;
LGG	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg27489772	chr12:121021490	NA	-0.55	-7.33	-0.32	1e-12	Type 1 diabetes nephropathy;
LGG	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg25427524	chr10:38739819	LOC399744	-0.62	-12.56	-0.5	2.32e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs6065	0.618	rs16942618	chr17:4877358	G/A	cg01912298	chr17:4872499	CAMTA2;SPAG7	-0.6	-8.08	-0.35	5.62e-15	Platelet count;
LGG	cis	rs4704187	0.687	rs922390	chr5:74401269	A/G	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06475006	chr16:89985975	MC1R	-0.58	-6.72	-0.3	5.25e-11	Skin colour saturation;
LGG	cis	rs2084898	1.000	rs2084899	chr11:120026810	A/C	cg13907859	chr11:120009124	TRIM29	0.87	12.05	0.49	2.79e-29	Stroke (pediatric);
LGG	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg23894439	chr1:183413866	NA	0.5	9.29	0.4	6.15e-19	Systemic lupus erythematosus;
LGG	cis	rs9457247	0.730	rs9459841	chr6:167431949	G/A	cg07741184	chr6:167504864	NA	0.42	9.48	0.4	1.37e-19	Crohn's disease;
LGG	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.93	-0.42	3.31e-21	Body mass index;
LGG	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.02e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.15	-0.32	3.41e-12	Schizophrenia;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.16	0.58	2.02e-42	Platelet count;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.16e-21	Prudent dietary pattern;
LGG	cis	rs2236293	0.965	rs13284995	chr9:35842854	C/T	cg12876594	chr9:35791798	NPR2	0.38	7.14	0.31	3.73e-12	Blood protein levels;
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg09448879	chr15:79043637	NA	-0.49	-11.7	-0.48	6.8e-28	Coronary artery disease or large artery stroke;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.83	-16.86	-0.62	4.55e-50	Personality dimensions;
LGG	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg20913747	chr6:44695427	NA	-0.67	-11.95	-0.49	6.95e-29	Total body bone mineral density;
LGG	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg00343986	chr7:65444356	GUSB	-0.4	-6.82	-0.3	2.93e-11	Aortic root size;
LGG	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.5	-0.33	3.26e-13	Neuroticism;
LGG	cis	rs9457247	0.588	rs35171809	chr6:167432766	A/G	cg07741184	chr6:167504864	NA	0.38	8.51	0.37	2.37e-16	Crohn's disease;
LGG	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.51	-0.47	4.09e-27	Type 2 diabetes;
LGG	cis	rs787274	1.000	rs4246892	chr9:115588649	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1691799	0.899	rs1168357	chr12:66749879	T/C	cg16791601	chr12:66731901	HELB	-0.66	-15.58	-0.59	2.5e-44	White blood cell count (basophil);
LGG	trans	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg21659725	chr3:3221576	CRBN	0.55	7.14	0.31	3.61e-12	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg21775007	chr8:11205619	TDH	-0.48	-7.9	-0.34	2e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs67311347	1.000	rs4246666	chr3:40407670	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.31	-0.69	4.56e-66	Renal cell carcinoma;
LGG	cis	rs7766436	0.610	rs13195654	chr6:22601416	C/G	cg13666174	chr6:22585274	NA	-0.41	-9.55	-0.41	7.6e-20	Coronary artery disease;
LGG	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs17208368	0.628	rs12446032	chr16:55097648	A/C	cg09947736	chr16:55091198	NA	0.66	12.55	0.5	2.64e-31	Hypospadias;
LGG	cis	rs7617773	0.780	rs35297395	chr3:48342882	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg15674680	chr20:60982522	CABLES2	-0.47	-7.47	-0.33	4.08e-13	Colorectal cancer;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00149659	chr3:10157352	C3orf10	0.77	10.67	0.44	6.58e-24	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg21724239	chr8:58056113	NA	0.44	6.7	0.3	6.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg22852734	chr6:133119734	C6orf192	1.16	15.75	0.59	4.47e-45	Type 2 diabetes nephropathy;
LGG	cis	rs35160687	0.722	rs6728029	chr2:86555381	C/T	cg10973622	chr2:86423274	IMMT	-0.43	-7.98	-0.35	1.13e-14	Night sleep phenotypes;
LGG	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22857025	chr5:266934	NA	-1.31	-13.55	-0.53	1.83e-35	Breast cancer;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg18105134	chr13:113819100	PROZ	0.66	13.15	0.52	9.16e-34	Platelet distribution width;
LGG	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg14917874	chr2:235941519	SH3BP4	-0.52	-9.46	-0.4	1.6e-19	Dialysis-related mortality;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	cis	rs11750568	0.935	rs10070609	chr5:178524969	T/C	cg10208897	chr5:178548229	ADAMTS2	0.43	6.93	0.31	1.43e-11	Height;
LGG	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg02002194	chr4:3960332	NA	0.44	8.09	0.35	5.34e-15	Monocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00349776	chr1:165414189	RXRG	0.41	7.27	0.32	1.54e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg02002194	chr4:3960332	NA	0.4	6.82	0.3	2.93e-11	Schizophrenia;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg16507663	chr6:150244633	RAET1G	0.44	8.13	0.35	4.02e-15	Lung cancer;
LGG	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.53	9.69	0.41	2.4e-20	HDL cholesterol;
LGG	trans	rs12517041	1.000	rs6887969	chr5:23304261	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.26	-0.4	7.37e-19	Life satisfaction;
LGG	cis	rs1961637	0.524	rs895771	chr2:223894051	C/T	cg02552189	chr2:223891284	NA	-0.39	-7.76	-0.34	5.43e-14	Oropharynx cancer;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12016809	chr21:47604291	C21orf56	0.59	9.82	0.42	8.38e-21	Testicular germ cell tumor;
LGG	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.97	0.35	1.28e-14	Retinal vascular caliber;
LGG	cis	rs2067615	0.524	rs10778498	chr12:107063340	C/A	cg15890332	chr12:107067104	RFX4	0.41	12.15	0.49	1.13e-29	Heart rate;
LGG	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg08392591	chr16:89556376	ANKRD11	0.44	6.78	0.3	3.74e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.07	-0.35	6.31e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.48	-0.71	1.65e-71	Leprosy;
LGG	cis	rs8038465	0.622	rs17185525	chr15:73885539	T/C	cg15420318	chr15:73925796	NPTN	0.49	8.35	0.36	7.76e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.62	-0.41	4.33e-20	Response to antipsychotic treatment;
LGG	cis	rs7301826	1.000	rs4759793	chr12:131297238	A/G	cg11011512	chr12:131303247	STX2	0.35	7.57	0.33	2.04e-13	Plasma plasminogen activator levels;
LGG	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg04546413	chr19:29218101	NA	0.78	13.35	0.53	1.29e-34	Methadone dose in opioid dependence;
LGG	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg17971929	chr21:40555470	PSMG1	0.67	9.56	0.41	6.96e-20	Cognitive function;
LGG	trans	rs1459104	1.000	rs12576361	chr11:55192401	G/A	cg15704280	chr7:45808275	SEPT13	0.72	6.68	0.3	6.69e-11	Body mass index;
LGG	cis	rs708547	0.647	rs1718839	chr4:57827206	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.54	9.0	0.39	5.65e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg21427119	chr20:30132790	HM13	-0.42	-7.17	-0.32	2.99e-12	Mean corpuscular hemoglobin;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.35	-0.4	3.73e-19	Triglycerides;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg11520665	chr12:56223332	DNAJC14	-0.42	-7.14	-0.31	3.67e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.54	0.67	1.86e-62	Platelet count;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs10421328	0.784	rs11667828	chr19:19768474	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.35	-7.76	-0.34	5.48e-14	Parental longevity (combined parental age at death);
LGG	cis	rs8044868	0.530	rs12918956	chr16:72224335	A/G	cg23815491	chr16:72088622	HP	-0.36	-7.8	-0.34	4.03e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg04398451	chr17:18023971	MYO15A	-0.86	-19.45	-0.67	5.24e-62	Total body bone mineral density;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03761979	chr4:57843892	C4orf14;POLR2B	0.42	7.52	0.33	2.8e-13	Obesity-related traits;
LGG	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg25554036	chr4:6271136	WFS1	0.56	10.47	0.44	3.74e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3820928	0.874	rs10933165	chr2:227883648	C/G	cg11843606	chr2:227700838	RHBDD1	0.41	7.0	0.31	9.17e-12	Pulmonary function;
LGG	cis	rs727505	1.000	rs9655845	chr7:124513355	G/C	cg23710748	chr7:124431027	NA	-0.51	-9.68	-0.41	2.6e-20	Lewy body disease;
LGG	cis	rs62238980	0.614	rs115866486	chr22:32510228	A/T	cg00543991	chr22:32367038	NA	0.78	8.45	0.37	3.73e-16	Childhood ear infection;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg03395511	chr6:291903	DUSP22	0.67	11.49	0.47	4.74e-27	Menopause (age at onset);
LGG	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19524238	chr7:2802976	GNA12	0.34	8.12	0.35	4.11e-15	Height;
LGG	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg15017067	chr4:17643749	FAM184B	0.32	7.43	0.33	5.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg20302533	chr7:39170763	POU6F2	0.35	8.23	0.36	1.91e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg00106254	chr7:1943704	MAD1L1	-0.45	-7.82	-0.34	3.54e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.3	-0.36	1.13e-15	Total body bone mineral density;
LGG	cis	rs11718455	0.921	rs35872933	chr3:44028515	T/G	cg21419209	chr3:44054225	NA	-0.43	-7.02	-0.31	7.94e-12	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg04503457	chr17:41445688	NA	0.38	9.03	0.39	4.51e-18	Menopause (age at onset);
LGG	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14240646	chr10:27532245	ACBD5	-0.55	-8.19	-0.36	2.66e-15	Breast cancer;
LGG	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.34	0.32	9.57e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.79	0.45	2.33e-24	Corneal astigmatism;
LGG	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg04362960	chr10:104952993	NT5C2	0.57	10.56	0.44	1.74e-23	Arsenic metabolism;
LGG	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg20587970	chr11:113659929	NA	-1.32	-23.52	-0.74	4.46e-81	Hip circumference adjusted for BMI;
LGG	cis	rs55883249	1.000	rs56372340	chr2:9741536	A/G	cg23886495	chr2:9695866	ADAM17	0.61	8.56	0.37	1.62e-16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg14689365	chr7:158441557	NCAPG2	0.57	6.95	0.31	1.23e-11	Height;
LGG	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg24803719	chr17:45855879	NA	-0.28	-7.88	-0.34	2.43e-14	IgG glycosylation;
LGG	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-24.05	-0.75	1.64e-83	Primary sclerosing cholangitis;
LGG	cis	rs7928758	0.767	rs7932600	chr11:134276142	A/G	cg15243474	chr11:134282918	B3GAT1	0.79	12.03	0.49	3.54e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs3820928	0.934	rs16822890	chr2:227761477	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.36	-0.32	8.54e-13	Pulmonary function;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27224392	chr10:104474430	SFXN2;ARL3	0.47	7.36	0.32	8.52e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs8028182	0.636	rs7163451	chr15:75861076	G/T	cg20655648	chr15:75932815	IMP3	0.44	7.24	0.32	1.9e-12	Sudden cardiac arrest;
LGG	trans	rs877282	0.853	rs11596346	chr10:756673	A/T	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.08e-25	Morning vs. evening chronotype;
LGG	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg04731861	chr2:219085781	ARPC2	-0.5	-12.84	-0.51	1.66e-32	Colorectal cancer;
LGG	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.8	-0.34	4e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19524238	chr7:2802976	GNA12	0.4	9.63	0.41	3.93e-20	Height;
LGG	trans	rs7944735	0.938	rs59185955	chr11:47961566	G/C	cg03929089	chr4:120376271	NA	0.67	8.13	0.35	4.09e-15	Intraocular pressure;
LGG	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg14835575	chr10:16859367	RSU1	0.53	10.68	0.44	5.88e-24	Platelet distribution width;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg20821713	chr7:1055600	C7orf50	-0.45	-6.86	-0.3	2.16e-11	Bronchopulmonary dysplasia;
LGG	cis	rs258892	0.895	rs34653	chr5:72146480	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.16e-11	Small cell lung carcinoma;
LGG	cis	rs12477438	0.520	rs4143760	chr2:100101762	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs738321	0.757	rs4820314	chr22:38518538	G/A	cg25457927	chr22:38595422	NA	-0.41	-9.42	-0.4	2.1e-19	Breast cancer;
LGG	cis	rs4731207	0.596	rs1871773	chr7:124674939	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.53	-0.33	2.64e-13	Cutaneous malignant melanoma;
LGG	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-8.2	-0.36	2.35e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7402982	0.625	rs4966009	chr15:99203496	C/T	cg03437748	chr15:99193247	IGF1R	0.77	13.35	0.53	1.29e-34	Birth weight;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg11356029	chr5:72112729	TNPO1	-0.42	-6.89	-0.3	1.86e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2172802	0.638	rs12642037	chr4:62503837	C/T	cg04118610	chr4:62707027	LPHN3	0.4	6.66	0.3	7.88e-11	Partial epilepsies;
LGG	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg05791153	chr7:19748676	TWISTNB	0.76	10.33	0.43	1.18e-22	Thyroid stimulating hormone;
LGG	trans	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg06521331	chr12:34319734	NA	0.46	8.63	0.37	1.01e-16	Heart rate;
LGG	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg24375607	chr4:120327624	NA	0.4	6.66	0.3	7.69e-11	Diastolic blood pressure;
LGG	cis	rs10743315	0.732	rs16915316	chr12:19431725	A/C	cg02471346	chr12:19282374	PLEKHA5	-0.63	-7.37	-0.32	7.65e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs881375	0.501	rs10156413	chr9:123867782	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	8.59	0.37	1.33e-16	Rheumatoid arthritis;
LGG	cis	rs6882046	0.513	rs681446	chr5:88054292	C/T	cg22951263	chr5:87985283	NA	0.56	10.36	0.43	9.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs9467160	1.000	rs9467162	chr6:24442047	T/C	cg20631270	chr6:24437470	GPLD1	0.53	7.69	0.34	8.89e-14	Liver enzyme levels;
LGG	cis	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.15	0.39	1.79e-18	Cognitive test performance;
LGG	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg05182265	chr7:156933206	UBE3C	0.37	7.48	0.33	3.74e-13	Body mass index;
LGG	cis	rs10927875	0.894	rs10927878	chr1:16319957	C/T	cg21385522	chr1:16154831	NA	-0.73	-13.25	-0.52	3.31e-34	Dilated cardiomyopathy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02353148	chr19:11670241	ELOF1	0.42	6.76	0.3	4.07e-11	Cognitive performance;
LGG	cis	rs6844506	0.898	rs12506922	chr4:185234505	A/C	cg12654155	chr4:185238627	NA	0.38	6.71	0.3	5.86e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg25358565	chr5:93447407	FAM172A	1.41	17.32	0.63	3.65e-52	Diabetic retinopathy;
LGG	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg25706552	chr1:244017396	NA	0.5	8.17	0.36	2.93e-15	RR interval (heart rate);
LGG	cis	rs523522	0.926	rs10849766	chr12:121025894	G/A	cg27279351	chr12:120934652	DYNLL1	0.81	12.92	0.51	7.6e-33	High light scatter reticulocyte count;
LGG	cis	rs4650994	0.816	rs2761470	chr1:178596033	G/C	cg19399532	chr1:178512495	C1orf220	-0.37	-6.99	-0.31	9.51e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12348691	0.503	rs7849497	chr9:100615660	G/C	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg27400746	chr16:89904261	SPIRE2	-1.09	-16.53	-0.61	1.41e-48	Skin colour saturation;
LGG	cis	rs2694528	0.623	rs1563517	chr5:60063511	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.57	-6.78	-0.3	3.79e-11	Parkinson's disease;
LGG	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.8	-9.36	-0.4	3.61e-19	Response to haloperidol in psychosis;
LGG	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg27129171	chr3:47204927	SETD2	0.82	15.2	0.58	1.22e-42	Colorectal cancer;
LGG	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18099408	chr3:52552593	STAB1	-0.35	-6.71	-0.3	5.73e-11	Electroencephalogram traits;
LGG	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg11166453	chr1:247681781	NA	0.64	10.04	0.42	1.34e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg11494091	chr17:61959527	GH2	-0.6	-10.07	-0.42	1.07e-21	Height;
LGG	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg16141378	chr3:129829833	LOC729375	0.37	8.34	0.36	8.9e-16	Triglycerides;
LGG	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg24331049	chr13:111365604	ING1	-0.87	-16.29	-0.6	1.64e-47	Coronary artery disease;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.47	0.33	4.07e-13	Lung cancer;
LGG	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg20608306	chr11:116969690	SIK3	0.41	13.14	0.52	9.6e-34	Blood protein levels;
LGG	cis	rs8180040	0.654	rs6791062	chr3:47174343	T/A	cg16586182	chr3:47516702	SCAP	-0.73	-13.05	-0.52	2.36e-33	Colorectal cancer;
LGG	cis	rs2731664	0.792	rs335466	chr5:176889530	C/A	cg23176889	chr5:176863531	GRK6	-0.66	-13.01	-0.52	3.42e-33	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.512	rs771324	chr3:101610365	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.5	8.01	0.35	9.36e-15	Colorectal cancer;
LGG	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.3	-0.43	1.6e-22	Alzheimer's disease;
LGG	cis	rs4538187	0.901	rs68117986	chr2:64239566	G/A	cg14150252	chr2:64069583	UGP2	-0.49	-9.75	-0.41	1.45e-20	Systolic blood pressure;
LGG	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	12.48	0.5	5.26e-31	Response to antipsychotic treatment;
LGG	trans	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg15971980	chr6:150254442	NA	0.45	8.48	0.37	3.11e-16	Lung cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14969806	chr1:5919854	NA	0.34	6.88	0.3	1.93e-11	Electrocardiographic conduction measures;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.61	0.33	1.5e-13	Rheumatoid arthritis;
LGG	cis	rs1408224	0.657	rs4942558	chr13:47206582	T/C	cg24453118	chr13:47229927	LRCH1	-0.29	-6.82	-0.3	2.79e-11	QRS complex (12-leadsum);
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	trans	rs4427176	0.507	rs4305907	chr8:9586468	G/C	cg16141378	chr3:129829833	LOC729375	0.34	6.68	0.3	6.82e-11	Mosquito bite size;
LGG	cis	rs7770628	0.653	rs1009124	chr6:161117913	G/A	cg04181478	chr6:161122748	PLG	-0.42	-8.36	-0.36	7.35e-16	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg18850127	chr7:39170497	POU6F2	0.46	10.3	0.43	1.56e-22	IgG glycosylation;
LGG	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg02002194	chr4:3960332	NA	-0.43	-8.07	-0.35	6.1e-15	Retinal vascular caliber;
LGG	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.24	0.43	2.48e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg11878867	chr6:150167359	LRP11	-0.53	-10.87	-0.45	1.17e-24	Lung cancer;
LGG	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.16e-17	Cognitive test performance;
LGG	cis	rs9640161	0.636	rs3735171	chr7:150033882	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.77	-15.84	-0.59	1.76e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg18681998	chr4:17616180	MED28	0.81	17.86	0.64	1.12e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-8.66	-0.37	7.63e-17	Facial emotion recognition (sad faces);
LGG	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.07	0.31	5.62e-12	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07659893	chr17:61819838	STRADA	0.49	8.25	0.36	1.69e-15	Prudent dietary pattern;
LGG	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg20767356	chr1:150693100	HORMAD1	0.38	6.86	0.3	2.17e-11	Pancreatic cancer;
LGG	cis	rs896854	0.654	rs13248607	chr8:95986637	T/G	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.52	-0.37	2.25e-16	Type 2 diabetes;
LGG	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg13072238	chr3:49761600	GMPPB	0.52	6.73	0.3	5.07e-11	Menarche (age at onset);
LGG	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.34	0.32	9.4e-13	Lung disease severity in cystic fibrosis;
LGG	trans	rs9929218	0.551	rs2296405	chr16:68721470	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.15	-33.31	-0.84	5.4e-125	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg00761968	chr13:53314142	LECT1	-0.35	-7.44	-0.33	4.89e-13	Lewy body disease;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	3.13e-16	Personality dimensions;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03646474	chr1:174992368	MRPS14	0.49	8.23	0.36	1.98e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg25019033	chr10:957182	NA	-0.55	-10.0	-0.42	1.86e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs1957429	0.808	rs7144718	chr14:65333831	G/A	cg23373153	chr14:65346875	NA	1.05	13.12	0.52	1.16e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs7666738	0.830	rs7686456	chr4:99019695	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg21659725	chr3:3221576	CRBN	-0.66	-6.95	-0.31	1.21e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05930166	chr1:222884917	AIDA;C1orf58	0.42	7.12	0.31	4.22e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.51	-7.0	-0.31	9.03e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4727027	0.868	rs10952799	chr7:148840772	C/T	cg23583168	chr7:148888333	NA	-0.88	-17.16	-0.62	1.83e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg26396452	chr14:65542826	MAX	0.46	9.29	0.4	6.15e-19	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs3106136	0.934	rs17376404	chr4:95224046	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.18	-0.36	2.74e-15	Capecitabine sensitivity;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg00035636	chr13:21900591	NA	0.38	8.25	0.36	1.62e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg26396452	chr14:65542826	MAX	0.45	8.8	0.38	2.75e-17	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs12458462	0.851	rs3859317	chr18:77443093	A/C	cg11879182	chr18:77439856	CTDP1	0.8	15.18	0.58	1.49e-42	Monocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12032620	chr15:43802735	TP53BP1	0.4	6.87	0.3	2.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11190604	1.000	rs2295770	chr10:102239829	G/A	cg07570687	chr10:102243282	WNT8B	0.44	7.75	0.34	5.96e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	18.45	0.65	2.32e-57	Lymphocyte percentage of white cells;
LGG	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg01130898	chr2:219473002	PLCD4	-0.39	-6.69	-0.3	6.41e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg03806693	chr22:41940476	POLR3H	1.07	19.48	0.67	3.75e-62	Vitiligo;
LGG	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg06027949	chr8:82754900	SNX16	-0.55	-8.59	-0.37	1.38e-16	Diastolic blood pressure;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.65	-0.3	8.11e-11	Obesity-related traits;
LGG	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg05692746	chr2:100937584	LONRF2	-0.57	-9.52	-0.4	9.41e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg26384229	chr12:38710491	ALG10B	0.67	13.03	0.52	2.74e-33	Morning vs. evening chronotype;
LGG	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg18105134	chr13:113819100	PROZ	0.68	13.91	0.54	5.39e-37	Platelet distribution width;
LGG	cis	rs2239547	0.522	rs2581797	chr3:52972468	C/T	cg11645453	chr3:52864694	ITIH4	-0.65	-10.11	-0.43	7.4e-22	Schizophrenia;
LGG	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg01420254	chr6:26195488	NA	0.85	11.06	0.46	2.14e-25	Gout;Renal underexcretion gout;
LGG	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg03877680	chr5:178157825	ZNF354A	0.78	12.61	0.51	1.5e-31	Neutrophil percentage of white cells;
LGG	cis	rs7195287	0.826	rs9925824	chr16:2827973	C/T	cg05687563	chr16:2837658	PRSS33	-0.43	-8.62	-0.37	1.1e-16	Eosinophil counts;
LGG	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.91	0.38	1.22e-17	Aortic root size;
LGG	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg11441379	chr12:63026424	NA	0.7	9.71	0.41	2.14e-20	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.7	-0.41	2.16e-20	Lung cancer;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03452623	chr4:187889614	NA	-1.04	-29.39	-0.81	6.88e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9863	0.827	rs7134121	chr12:124447346	T/C	cg13487667	chr12:124434373	CCDC92	-0.37	-7.47	-0.33	4.08e-13	White blood cell count;
LGG	trans	rs17685	0.753	rs6951808	chr7:75772413	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg04568710	chr12:38710424	ALG10B	-0.38	-8.18	-0.36	2.7e-15	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.43	-0.36	4.32e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6554196	0.508	rs981959	chr4:55526962	G/T	cg18836493	chr4:55524333	KIT	-0.44	-8.11	-0.35	4.69e-15	Monocyte count;
LGG	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg26384229	chr12:38710491	ALG10B	0.83	16.68	0.61	2.84e-49	Morning vs. evening chronotype;
LGG	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg04705435	chr11:17411270	KCNJ11	0.44	8.8	0.38	2.78e-17	Type 2 diabetes;
LGG	cis	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg25558440	chr8:11882962	NA	0.37	6.68	0.3	6.74e-11	Monocyte count;
LGG	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg02254774	chr11:50257496	LOC441601	0.57	6.76	0.3	4.15e-11	Myopia (pathological);
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg16590910	chr6:42928470	GNMT	0.42	11.95	0.49	7.09e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-9.03	-0.39	4.77e-18	Testicular germ cell tumor;
LGG	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg21775007	chr8:11205619	TDH	0.8	14.11	0.55	7.51e-38	Retinal vascular caliber;
LGG	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg19847130	chr8:10466454	RP1L1	-0.34	-7.22	-0.32	2.18e-12	Neuroticism;
LGG	cis	rs72781680	0.699	rs72796125	chr2:23919169	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	8.86	0.38	1.71e-17	Lymphocyte counts;
LGG	cis	rs7766436	1.000	rs13217022	chr6:22612757	T/C	cg13666174	chr6:22585274	NA	-0.45	-10.31	-0.43	1.38e-22	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg25358565	chr5:93447407	FAM172A	-1.34	-16.46	-0.61	3.07e-48	Diabetic retinopathy;
LGG	cis	rs12220238	0.908	rs10824133	chr10:76020585	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.53	0.44	2.12e-23	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26696260	chr8:144588465	ZC3H3	0.36	6.66	0.3	7.9e-11	Electrocardiographic conduction measures;
LGG	cis	rs8079658	1.000	rs8079658	chr17:63791483	C/T	cg18091269	chr17:63822838	CCDC46	-0.45	-7.43	-0.33	5.29e-13	Post bronchodilator FEV1;
LGG	cis	rs504918	1.000	rs1879804	chr3:124077663	A/G	cg05766129	chr3:123988013	KALRN	0.38	7.01	0.31	8.24e-12	Schizophrenia;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17554472	chr22:41940697	POLR3H	-0.49	-7.02	-0.31	7.89e-12	Vitiligo;
LGG	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-10.78	-0.45	2.43e-24	Chronic sinus infection;
LGG	cis	rs9902453	0.967	rs12450956	chr17:28529025	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.63	12.29	0.5	3.12e-30	Coffee consumption (cups per day);
LGG	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.73	-0.34	6.56e-14	Colorectal cancer;
LGG	cis	rs7267979	0.586	rs6050431	chr20:25183908	C/T	cg06421707	chr20:25228305	PYGB	0.39	7.99	0.35	1.12e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2439831	0.850	rs28413881	chr15:44174099	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.45	0.37	3.78e-16	Lung cancer in ever smokers;
LGG	cis	rs3096299	0.506	rs3114863	chr16:89438667	G/C	cg06640241	chr16:89574553	SPG7	0.63	10.01	0.42	1.75e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.57	0.53	1.55e-35	Psoriasis;
LGG	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.31	0.32	1.19e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg04450456	chr4:17643702	FAM184B	0.34	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg05793240	chr7:2802953	GNA12	0.31	7.42	0.33	5.6e-13	Height;
LGG	cis	rs61906588	0.628	rs61906586	chr11:116360636	T/C	cg12564567	chr11:116371188	NA	-0.39	-7.14	-0.31	3.71e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs10739695	0.510	rs10819309	chr9:130581723	A/G	cg13492245	chr9:130566157	FPGS	0.4	6.96	0.31	1.14e-11	Monocyte percentage of white cells;
LGG	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.6	0.47	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.84	-0.38	2.08e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg15557168	chr22:42548783	NA	0.4	8.64	0.37	9.08e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.69	-14.81	-0.57	6.51e-41	Colorectal cancer;
LGG	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.71	17.43	0.63	1.13e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3824867	0.920	rs7126210	chr11:47460306	A/G	cg20307385	chr11:47447363	PSMC3	0.47	7.55	0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs7119	0.717	rs12915548	chr15:77818042	A/G	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.87	0.3	2.06e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg00149659	chr3:10157352	C3orf10	0.58	8.31	0.36	1.09e-15	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.65e-13	Prudent dietary pattern;
LGG	cis	rs763121	0.853	rs1065201	chr22:39069510	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.23	0.65	2.27e-56	Menopause (age at onset);
LGG	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg11693508	chr17:37793320	STARD3	0.53	7.47	0.33	4.03e-13	Bipolar disorder;
LGG	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.73	-0.48	5.3e-28	Hemoglobin concentration;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.66	-0.37	7.98e-17	Blood metabolite levels;
LGG	cis	rs2066819	1.000	rs58852079	chr12:56706922	A/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg21545522	chr1:205238299	TMCC2	-0.38	-7.21	-0.32	2.35e-12	Red blood cell count;
LGG	cis	rs11122272	0.735	rs2739518	chr1:231537633	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.18e-16	Alzheimer's disease;
LGG	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg19441908	chr8:41529140	ANK1	0.42	7.47	0.33	4.1e-13	Type 2 diabetes;
LGG	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg03433033	chr1:76189801	ACADM	0.65	9.35	0.4	3.63e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.24	0.84	1.06e-124	Prudent dietary pattern;
LGG	trans	rs9657904	0.774	rs7432372	chr3:105525502	C/T	cg14088669	chr1:158435396	OR10K1	0.42	7.92	0.35	1.75e-14	Multiple sclerosis;
LGG	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg03709012	chr19:19516395	GATAD2A	0.98	15.12	0.57	2.86e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.68	-0.3	6.81e-11	Alzheimer's disease (survival time);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg05025164	chr4:1340916	KIAA1530	0.57	10.75	0.45	3.38e-24	Longevity;
LGG	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg16339924	chr4:17578868	LAP3	0.61	10.7	0.45	5.1e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.43	7.51	0.33	3.01e-13	Alzheimer's disease (late onset);
LGG	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.5	8.32	0.36	1.02e-15	Response to antipsychotic treatment;
LGG	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.76	8.33	0.36	9.28e-16	Initial pursuit acceleration;
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg05925327	chr15:68127851	NA	-0.34	-6.88	-0.3	1.95e-11	Obesity;
LGG	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg03060546	chr3:49711283	APEH	-0.65	-10.64	-0.44	8.73e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13102973	1.000	rs4611981	chr4:135902585	C/T	cg14419869	chr4:135874104	NA	0.55	10.16	0.43	5.21e-22	Subjective well-being;
LGG	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg16096631	chr1:42092165	HIVEP3	-0.42	-8.81	-0.38	2.61e-17	Airway imaging phenotypes;
LGG	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg24623649	chr8:11872141	NA	0.3	7.23	0.32	1.97e-12	Retinal vascular caliber;
LGG	cis	rs11225247	1.000	rs7104841	chr11:102270051	T/C	cg06323957	chr11:102217781	BIRC2	0.77	6.88	0.3	1.89e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs7106204	1.000	rs6484025	chr11:24214514	C/G	ch.11.24196551F	chr11:24239977	NA	0.96	12.28	0.5	3.29e-30	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18106800	chr5:94890715	ARSK;TTC37	-0.41	-6.73	-0.3	5.16e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13102973	0.710	rs4428340	chr4:135886451	C/T	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs9868809	0.656	rs13324119	chr3:48710606	G/C	cg00383909	chr3:49044727	WDR6	0.83	10.0	0.42	1.97e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs701145	0.585	rs1358405	chr3:153810992	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.86	0.38	1.79e-17	Coronary artery disease;
LGG	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg06219351	chr7:158114137	PTPRN2	0.76	14.92	0.57	2.3e-41	Calcium levels;
LGG	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg13010199	chr12:38710504	ALG10B	0.48	8.52	0.37	2.28e-16	Morning vs. evening chronotype;
LGG	cis	rs11645898	0.872	rs72791121	chr16:72225294	C/T	cg14768367	chr16:72042858	DHODH	-0.75	-10.27	-0.43	1.92e-22	Blood protein levels;
LGG	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg01493522	chr13:37497338	NA	-0.5	-8.37	-0.36	6.66e-16	Coronary artery disease;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.15	-0.32	3.3e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs36051895	0.659	rs3780366	chr9:5068596	T/C	cg02405213	chr9:5042618	JAK2	-0.84	-15.77	-0.59	3.83e-45	Pediatric autoimmune diseases;
LGG	cis	rs3857067	1.000	rs7694820	chr4:95017026	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.49	-0.33	3.53e-13	QT interval;
LGG	cis	rs17767392	1.000	rs34057981	chr14:71823981	T/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.59e-18	Mitral valve prolapse;
LGG	cis	rs7216064	0.817	rs12603589	chr17:65825248	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.52	-0.37	2.19e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg17211192	chr8:82754475	SNX16	-0.74	-12.48	-0.5	5.3e-31	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00460911	chr2:180872053	CWC22	-0.48	-7.08	-0.31	5.36e-12	Systemic lupus erythematosus;
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs72960926	1.000	rs72958951	chr6:75118214	G/A	cg03266952	chr6:74778945	NA	-0.68	-6.8	-0.3	3.25e-11	Metabolite levels (MHPG);
LGG	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg05673287	chr15:77411982	SGK269	-0.43	-9.35	-0.4	3.61e-19	Type 2 diabetes;
LGG	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg05692746	chr2:100937584	LONRF2	-0.64	-11.65	-0.48	1.13e-27	Intelligence (multi-trait analysis);
LGG	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg16512390	chr1:228756714	NA	0.48	6.72	0.3	5.35e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs7129556	0.520	rs7943742	chr11:77268856	C/T	cg12586386	chr11:77299805	AQP11	0.39	6.87	0.3	2.1e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	9.01	0.39	5.33e-18	Eosinophil percentage of white cells;
LGG	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.42	-0.33	5.62e-13	Neuroticism;
LGG	cis	rs2304069	0.507	rs13167061	chr5:149388624	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.19	0.36	2.51e-15	HIV-1 control;
LGG	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.73	0.48	5.14e-28	Morning vs. evening chronotype;
LGG	cis	rs4774899	0.966	rs4353440	chr15:57559318	C/T	cg08128148	chr15:57256372	TCF12	-0.32	-7.28	-0.32	1.47e-12	Urinary tract infection frequency;
LGG	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg11752832	chr7:134001865	SLC35B4	0.63	11.56	0.47	2.54e-27	Mean platelet volume;
LGG	cis	rs2413583	0.591	rs79605405	chr22:39696638	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	7.82	0.34	3.52e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg18129748	chr3:49941408	MST1R	0.22	7.12	0.31	4.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs10034619	chr4:98970067	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9790314	0.934	rs461638	chr3:161103166	A/G	cg04691961	chr3:161091175	C3orf57	-0.59	-13.36	-0.53	1.12e-34	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg15704280	chr7:45808275	SEPT13	-1.06	-23.95	-0.74	4.64e-83	Height;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg06885757	chr1:42089581	HIVEP3	0.62	14.43	0.56	3.17e-39	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05320259	chr20:25370897	ABHD12	0.61	9.51	0.4	1.08e-19	Gut microbiome composition (summer);
LGG	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg11845111	chr2:191398756	TMEM194B	0.36	8.12	0.35	4.35e-15	Pulse pressure;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg02733842	chr7:1102375	C7orf50	0.68	10.12	0.43	6.9e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12282928	1.000	rs6485821	chr11:48292594	C/G	cg26585981	chr11:48327164	OR4S1	0.44	7.11	0.31	4.29e-12	Migraine - clinic-based;
LGG	cis	rs9902453	0.904	rs9894893	chr17:28270350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.26	0.55	1.66e-38	Coffee consumption (cups per day);
LGG	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg25554036	chr4:6271136	WFS1	0.63	11.78	0.48	3.33e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg04287289	chr16:89883240	FANCA	0.54	9.67	0.41	2.79e-20	Hemoglobin concentration;
LGG	cis	rs9658691	0.607	rs9658757	chr10:90769455	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.74	-9.0	-0.39	5.72e-18	Mosquito bite size;
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg26449787	chr6:133562087	EYA4	0.34	6.87	0.3	2.01e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs6141769	0.542	rs6058845	chr20:31323919	G/T	cg13636640	chr20:31349939	DNMT3B	0.45	6.82	0.3	2.9e-11	Subjective well-being;
LGG	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg26396452	chr14:65542826	MAX	0.43	8.49	0.37	2.93e-16	Obesity-related traits;
LGG	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg27426351	chr10:43362370	NA	-0.55	-7.79	-0.34	4.49e-14	Blood protein levels;
LGG	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.89	0.34	2.19e-14	Platelet count;
LGG	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00631329	chr6:26305371	NA	-0.52	-9.66	-0.41	3.06e-20	Educational attainment;
LGG	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.4e-22	Motion sickness;
LGG	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17428076	0.756	rs62182432	chr2:172774731	C/T	cg21435375	chr2:172878103	MAP1D	0.42	7.52	0.33	2.87e-13	Myopia;
LGG	cis	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg19338460	chr6:170058176	WDR27	-0.85	-10.08	-0.42	9.81e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25161386	chr17:27621177	NUFIP2	0.47	7.73	0.34	6.62e-14	Cognitive performance;
LGG	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg27532318	chr7:32358331	NA	0.74	7.34	0.32	9.77e-13	Body mass index;
LGG	cis	rs9768139	0.512	rs1121014	chr7:158081769	T/C	cg02855558	chr7:158107723	PTPRN2	0.45	8.02	0.35	8.69e-15	Calcium levels;
LGG	cis	rs7568458	0.660	rs2289972	chr2:85766545	C/T	cg17127132	chr2:85788382	GGCX	0.52	8.16	0.35	3.17e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg19147804	chr7:1989927	MAD1L1	-0.51	-10.11	-0.43	7.48e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs11875185	0.510	rs111625645	chr18:55631579	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg18032289	chr17:61959525	GH2	-0.41	-6.97	-0.31	1.08e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23333501	chr19:1885628	FAM108A1	0.46	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.82e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg00579200	chr11:133705235	NA	-0.58	-11.12	-0.46	1.23e-25	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11151820	chr5:10250162	CCT5;FAM173B	0.43	7.15	0.32	3.48e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7444	0.941	rs5749493	chr22:21939687	C/A	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs994014	0.640	rs11733845	chr4:82211636	C/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.33	-0.32	1.04e-12	Height;
LGG	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg02153584	chr22:29168773	CCDC117	0.7	11.73	0.48	5.37e-28	Lymphocyte counts;
LGG	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg03806693	chr22:41940476	POLR3H	-0.96	-16.44	-0.61	3.7e-48	Vitiligo;
LGG	cis	rs2991971	0.934	rs7903	chr1:45976472	G/C	cg24296786	chr1:45957014	TESK2	0.42	7.5	0.33	3.22e-13	High light scatter reticulocyte count;
LGG	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs79146658	0.736	rs4894057	chr2:179735372	A/G	cg17765952	chr2:179737173	CCDC141	0.6	9.06	0.39	3.72e-18	Diastolic blood pressure;
LGG	trans	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg20290983	chr6:43655470	MRPS18A	-0.76	-14.35	-0.55	6.94e-39	IgG glycosylation;
LGG	cis	rs11225247	1.000	rs76479943	chr11:102305200	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06634786	chr22:41940651	POLR3H	0.76	12.11	0.49	1.57e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs727505	0.551	rs2293346	chr7:124783849	C/T	cg23710748	chr7:124431027	NA	-0.42	-8.17	-0.36	2.89e-15	Lewy body disease;
LGG	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg16141378	chr3:129829833	LOC729375	0.4	8.63	0.37	1e-16	Retinal vascular caliber;
LGG	cis	rs2274273	0.901	rs7147136	chr14:55826688	G/C	cg04306507	chr14:55594613	LGALS3	0.6	16.52	0.61	1.49e-48	Protein biomarker;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg26338869	chr17:61819248	STRADA	0.6	10.0	0.42	1.97e-21	Prudent dietary pattern;
LGG	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg05863683	chr7:1912471	MAD1L1	0.39	7.74	0.34	6.41e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4732038	0.565	rs55935438	chr7:134278238	C/T	cg06906464	chr7:134288099	NA	-0.72	-20.9	-0.7	8.39e-69	Longevity;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg11878867	chr6:150167359	LRP11	-0.54	-11.26	-0.46	3.52e-26	Lung cancer;
LGG	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg06618935	chr21:46677482	NA	-0.43	-8.51	-0.37	2.51e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.68	-12.46	-0.5	6.16e-31	Lymphocyte counts;
LGG	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg20848291	chr7:100343083	ZAN	-0.69	-10.19	-0.43	3.91e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3736594	0.513	rs62138966	chr2:27819172	G/A	cg27432699	chr2:27873401	GPN1	0.56	8.49	0.37	2.88e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg09640425	chr7:158790006	NA	-0.36	-6.8	-0.3	3.19e-11	Facial morphology (factor 20);
LGG	cis	rs6504108	0.541	rs12603115	chr17:46248994	A/G	cg02219949	chr17:45927392	SP6	-0.4	-7.47	-0.33	4.08e-13	Body mass index;
LGG	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg23730037	chr7:158596552	ESYT2	-0.78	-8.4	-0.36	5.65e-16	Hippocampal volume;
LGG	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg27165867	chr14:105738592	BRF1	-0.48	-8.33	-0.36	8.96e-16	Mean platelet volume;Platelet distribution width;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs35160687	0.644	rs4832272	chr2:86516211	A/G	cg10973622	chr2:86423274	IMMT	-0.4	-7.01	-0.31	8.36e-12	Night sleep phenotypes;
LGG	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	8.2	0.36	2.36e-15	Cognitive test performance;
LGG	cis	rs350251	0.899	rs350274	chr16:12233259	G/C	cg02910054	chr16:12241554	SNX29	0.48	8.96	0.38	7.73e-18	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.29	-0.36	1.27e-15	Neuroticism;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.77e-14	Personality dimensions;
LGG	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg03114573	chr12:45410052	DBX2	-0.69	-12.55	-0.5	2.73e-31	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg05368731	chr17:41323189	NBR1	0.96	18.93	0.66	1.25e-59	Menopause (age at onset);
LGG	cis	rs3790455	1.000	rs11264486	chr1:156455173	G/A	cg14087168	chr1:156450669	MEF2D	0.47	7.73	0.34	6.61e-14	Migraine;
LGG	cis	rs300774	1.000	rs300773	chr2:115035	C/T	cg04617936	chr2:214353	NA	-0.45	-6.79	-0.3	3.37e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg01403660	chr11:68851641	TPCN2	0.51	7.19	0.32	2.58e-12	Blond vs. brown hair color;
LGG	cis	rs4363385	0.719	rs12748969	chr1:152932654	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-7.56	-0.33	2.14e-13	Inflammatory skin disease;
LGG	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg10840412	chr1:235813424	GNG4	0.51	6.89	0.3	1.84e-11	Neuroticism;
LGG	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg02389323	chr16:88786976	FAM38A	1.07	13.04	0.52	2.64e-33	Plateletcrit;
LGG	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	-0.43	-7.64	-0.33	1.23e-13	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7777677	0.963	rs7796324	chr7:142371540	A/G	cg18540325	chr9:33795118	PRSS3	-0.42	-7.21	-0.32	2.32e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg12654349	chr5:56205094	C5orf35	-0.37	-6.68	-0.3	6.99e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs79057730	0.527	rs34519158	chr7:811114	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.53	0.33	2.73e-13	Initial pursuit acceleration;
LGG	cis	rs17767392	0.846	rs4899394	chr14:71773497	C/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.28	0.36	1.31e-15	Mitral valve prolapse;
LGG	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.81	-0.34	3.97e-14	Response to antipsychotic treatment;
LGG	cis	rs7945718	0.650	rs10831889	chr11:12665834	A/T	cg25843174	chr11:12811716	TEAD1	0.33	6.94	0.31	1.35e-11	Educational attainment (years of education);
LGG	cis	rs12681287	0.605	rs13262672	chr8:87355812	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.66	-0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs4689642	0.666	rs4689658	chr4:7228171	A/G	cg21353189	chr4:7228343	SORCS2	-0.39	-9.38	-0.4	2.85e-19	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	7.33	0.32	1.04e-12	Schizophrenia;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg23131131	chr22:24373011	LOC391322	-0.49	-8.0	-0.35	1.01e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs490234	0.783	rs937481	chr9:128194443	C/G	cg14078157	chr9:128172775	NA	-0.41	-7.64	-0.33	1.22e-13	Mean arterial pressure;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg09448879	chr15:79043637	NA	-0.56	-14.63	-0.56	4.03e-40	Coronary artery disease or large artery stroke;
LGG	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.73	8.29	0.36	1.25e-15	Initial pursuit acceleration;
LGG	cis	rs12282928	1.000	rs10838872	chr11:48336147	C/G	cg26585981	chr11:48327164	OR4S1	0.45	7.21	0.32	2.24e-12	Migraine - clinic-based;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13634736	chr11:3181575	OSBPL5	0.41	7.68	0.34	9.52e-14	Obesity-related traits;
LGG	cis	rs472402	0.580	rs3822430	chr5:6651970	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.82	-0.3	2.81e-11	Response to amphetamines;
LGG	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	7.35	0.32	8.98e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.15	-19.31	-0.67	2.29e-61	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.78	0.34	4.88e-14	Lung cancer;
LGG	trans	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.04	-0.39	4.41e-18	Bladder cancer;
LGG	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.69	-0.41	2.37e-20	Diabetic kidney disease;
LGG	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg00543991	chr22:32367038	NA	0.83	8.78	0.38	3.16e-17	Childhood ear infection;
LGG	cis	rs1707322	0.717	rs3014245	chr1:46086913	C/T	cg03146154	chr1:46216737	IPP	-0.56	-10.69	-0.44	5.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg04662567	chr6:169592167	NA	-0.76	-13.73	-0.54	3.05e-36	Pulse pressure;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.71	-0.45	4.72e-24	Lung cancer;
LGG	cis	rs4144743	1.000	rs34492688	chr17:45321622	C/A	cg18085866	chr17:45331354	ITGB3	-0.78	-9.89	-0.42	4.65e-21	Body mass index;
LGG	cis	rs789852	0.867	rs1675938	chr3:194327370	T/A	cg18000598	chr3:194342907	TMEM44	-0.86	-8.01	-0.35	9.32e-15	QT interval;
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg10505658	chr17:80084571	CCDC57	0.43	8.75	0.38	4.06e-17	Life satisfaction;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.64	0.33	1.26e-13	Obesity-related traits;
LGG	trans	rs7980799	0.935	rs10732554	chr12:33533374	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.53	-0.37	2.13e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg23188684	chr11:67383651	NA	0.52	8.7	0.37	5.83e-17	Mean corpuscular volume;
LGG	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg03929089	chr4:120376271	NA	-0.56	-9.89	-0.42	4.7e-21	HDL cholesterol;
LGG	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.24	-0.36	1.73e-15	Bone mineral density;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6976053	0.868	rs7783457	chr7:100471595	A/G	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	8e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg00732059	chr16:71740210	PHLPP2	-0.61	-9.99	-0.42	2e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg24692254	chr21:30365293	RNF160	0.58	10.57	0.44	1.51e-23	Pancreatic cancer;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg00800038	chr16:89945340	TCF25	-0.59	-7.88	-0.34	2.39e-14	Skin colour saturation;
LGG	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.43	6.92	0.31	1.5e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg27165867	chr14:105738592	BRF1	-0.43	-7.01	-0.31	8.56e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg07747251	chr5:1868357	NA	0.45	9.03	0.39	4.51e-18	Cardiovascular disease risk factors;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg05941027	chr17:61774174	LIMD2	0.37	9.42	0.4	2.19e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00933542	chr6:150070202	PCMT1	0.39	6.99	0.31	9.54e-12	Lung cancer;
LGG	cis	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2073300	1.000	rs6137980	chr20:23466726	G/T	cg12062639	chr20:23401060	NAPB	0.89	7.18	0.32	2.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4696584	1.000	rs4696584	chr4:155397517	A/G	cg04517429	chr4:155413618	DCHS2	0.31	7.22	0.32	2.12e-12	Folding of antihelix;
LGG	cis	rs25645	0.502	rs7209742	chr17:38108708	A/G	cg17467752	chr17:38218738	THRA	0.45	6.94	0.31	1.36e-11	Myeloid white cell count;
LGG	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg17376030	chr22:41985996	PMM1	-0.68	-10.96	-0.45	5.44e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs807669	0.548	rs885978	chr22:19198226	A/G	cg02655711	chr22:19163373	SLC25A1	0.64	12.34	0.5	1.97e-30	Metabolite levels;
LGG	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg07465881	chr4:1713556	SLBP	-0.45	-7.08	-0.31	5.24e-12	Hip circumference adjusted for BMI;Height;
LGG	trans	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.5e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504073	0.584	rs55838473	chr8:49948281	C/A	cg00325661	chr8:49890786	NA	0.79	15.42	0.58	1.41e-43	Blood metabolite ratios;
LGG	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg16586182	chr3:47516702	SCAP	-0.74	-13.38	-0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg04990556	chr1:26633338	UBXN11	0.57	7.74	0.34	6.14e-14	Obesity-related traits;
LGG	cis	rs2201728	0.967	rs3749551	chr4:100221551	C/T	cg07219303	chr4:100140905	ADH6	-0.4	-8.22	-0.36	1.99e-15	Cardiac Troponin-T levels;
LGG	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27297192	chr10:134578999	INPP5A	0.31	7.43	0.33	5.43e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9287719	0.967	rs7600728	chr2:10739999	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs2377585	0.653	rs34187657	chr12:8844413	G/C	cg03761649	chr12:8850719	RIMKLB	0.49	8.17	0.35	2.98e-15	Reticulocyte fraction of red cells;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg00149659	chr3:10157352	C3orf10	0.79	9.4	0.4	2.53e-19	Alzheimer's disease;
LGG	cis	rs7512552	0.839	rs698916	chr1:150388385	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg02466173	chr16:30829666	NA	-0.44	-7.75	-0.34	5.96e-14	Dementia with Lewy bodies;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg04450456	chr4:17643702	FAM184B	0.32	7.15	0.32	3.45e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4566357	0.615	rs1800517	chr2:227915832	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.97e-18	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg02269571	chr22:50332266	NA	-0.68	-10.55	-0.44	1.82e-23	Schizophrenia;
LGG	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg04568710	chr12:38710424	ALG10B	-0.37	-8.08	-0.35	5.85e-15	Bladder cancer;
LGG	cis	rs7928758	0.778	rs1866767	chr11:134274763	A/G	cg15243474	chr11:134282918	B3GAT1	-1.13	-14.99	-0.57	1.05e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-9.58	-0.41	5.83e-20	Erythrocyte sedimentation rate;
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00495681	chr13:53174319	NA	-0.51	-9.3	-0.4	5.58e-19	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25328417	chr13:50655384	DLEU1;DLEU2	0.45	7.65	0.33	1.17e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs714515	0.868	rs9425568	chr1:172316593	G/A	cg01573306	chr1:172330400	DNM3	-0.34	-7.66	-0.34	1.11e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg02158880	chr13:53174818	NA	0.49	10.05	0.42	1.23e-21	Lewy body disease;
LGG	cis	rs41271473	0.948	rs11803118	chr1:228826831	A/G	cg10167378	chr1:228756711	NA	0.56	7.41	0.33	5.92e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg18709589	chr6:96969512	KIAA0776	-0.53	-8.36	-0.36	7.26e-16	Migraine;Coronary artery disease;
LGG	cis	rs714515	0.868	rs9425300	chr1:172361977	T/G	cg01573306	chr1:172330400	DNM3	0.33	7.33	0.32	1.01e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg00071950	chr4:10020882	SLC2A9	0.39	7.86	0.34	2.68e-14	Bone mineral density;
LGG	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg26655873	chr3:72818019	SHQ1	0.33	7.02	0.31	7.71e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg09307838	chr4:120376055	NA	0.82	13.68	0.54	4.88e-36	Corneal astigmatism;
LGG	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.65	0.54	7.03e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg18379455	chr17:41446167	NA	-0.31	-6.94	-0.31	1.31e-11	Menopause (age at onset);
LGG	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.32	2.01e-12	Blood metabolite levels;
LGG	cis	rs368123	1.000	rs685289	chr6:160747902	T/C	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	cis	rs477692	0.544	rs7923750	chr10:131446895	G/C	cg05714579	chr10:131428358	MGMT	-0.86	-20.15	-0.68	2.58e-65	Response to temozolomide;
LGG	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	trans	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg00383909	chr3:49044727	WDR6	0.43	6.86	0.3	2.23e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.84	0.3	2.44e-11	Glycated hemoglobin levels;
LGG	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg00579200	chr11:133705235	NA	-0.6	-11.42	-0.47	8.55e-27	Childhood ear infection;
LGG	cis	rs9914988	0.943	rs2046759	chr17:27138817	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs3806843	0.966	rs2563262	chr5:140137712	C/G	cg19875535	chr5:140030758	IK	-0.52	-10.79	-0.45	2.34e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	11.62	0.48	1.49e-27	Hemoglobin concentration;
LGG	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.3	0.43	1.58e-22	Neuroticism;
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00149659	chr3:10157352	C3orf10	0.83	10.68	0.44	5.84e-24	Alzheimer's disease;
LGG	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.4	-0.33	6.44e-13	Interstitial lung disease;
LGG	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg24565620	chr2:194026	NA	0.67	8.25	0.36	1.64e-15	Blood protein levels;
LGG	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.73	-0.38	4.79e-17	Chronic sinus infection;
LGG	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg10253484	chr15:75165896	SCAMP2	-0.4	-6.68	-0.3	7.02e-11	Breast cancer;
LGG	cis	rs9807989	0.507	rs6755905	chr2:103048207	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.52	0.4	9.77e-20	Asthma;
LGG	cis	rs3820068	0.581	rs72645861	chr1:15920314	A/G	cg05660106	chr1:15850417	CASP9	0.87	17.71	0.64	6e-54	Systolic blood pressure;
LGG	cis	rs7444	0.941	rs738128	chr22:21971010	G/A	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs9486719	1.000	rs12191653	chr6:96903898	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.77	0.38	3.5e-17	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00739661	chr19:12721658	ZNF490;ZNF791	0.47	7.1	0.31	4.61e-12	Gut microbiome composition (summer);
LGG	cis	rs17321999	1.000	rs9558	chr2:30481917	A/G	cg05247661	chr2:30472410	LBH	-0.52	-8.16	-0.35	3.17e-15	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.74	-0.38	4.34e-17	Personality dimensions;
LGG	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.92	0.38	1.09e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2594989	0.780	rs2443706	chr3:11550505	C/G	cg01796438	chr3:11312864	ATG7	-0.54	-7.43	-0.33	5.21e-13	Circulating chemerin levels;
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg11584989	chr19:19387371	SF4	-0.4	-7.12	-0.31	4.28e-12	Tonsillectomy;
LGG	cis	rs9557207	0.652	rs9300532	chr13:99803553	A/G	cg24509225	chr13:100037070	UBAC2	0.59	11.03	0.46	2.73e-25	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg04503457	chr17:41445688	NA	0.4	9.72	0.41	1.9e-20	Menopause (age at onset);
LGG	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg00825309	chr19:58991885	ZNF446	-0.45	-9.12	-0.39	2.33e-18	Uric acid clearance;
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.66	0.41	3.11e-20	Bipolar disorder;
LGG	cis	rs1408799	0.772	rs7023927	chr9:12749596	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.55	0.37	1.82e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg05444541	chr17:17804740	TOM1L2	-0.59	-13.22	-0.52	4.28e-34	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.2.1276589F	chr2:54854755	SPTBN1	0.38	6.86	0.3	2.17e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs57590327	0.528	rs13086292	chr3:81705368	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.61	-0.33	1.55e-13	Extraversion;
LGG	cis	rs2274273	0.840	rs2009291	chr14:55838230	A/C	cg04306507	chr14:55594613	LGALS3	-0.63	-17.9	-0.64	8.08e-55	Protein biomarker;
LGG	cis	rs2273669	0.667	rs12205053	chr6:109338110	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs7444	0.825	rs5994638	chr22:21953276	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-7.13	-0.31	3.83e-12	Systemic lupus erythematosus;
LGG	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg07493874	chr5:1342172	CLPTM1L	0.81	15.9	0.59	9.87e-46	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05821866	chr1:167905319	DCAF6;BRP44	0.5	8.32	0.36	9.6e-16	Gut microbiome composition (summer);
LGG	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg11812906	chr14:75593930	NEK9	0.53	9.75	0.41	1.47e-20	Height;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.32	-8.37	-0.36	6.91e-16	IgG glycosylation;
LGG	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17554472	chr22:41940697	POLR3H	0.47	6.95	0.31	1.21e-11	Vitiligo;
LGG	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	cg07245641	chr1:182991651	LAMC1	-0.34	-7.63	-0.33	1.39e-13	Colorectal cancer;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg18402987	chr7:1209562	NA	0.5	7.43	0.33	5.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2108225	0.900	rs2051956	chr7:107441358	G/C	cg18560240	chr7:107437656	SLC26A3	-0.59	-10.44	-0.44	4.85e-23	Ulcerative colitis;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07308232	chr7:1071921	C7orf50	-0.52	-9.65	-0.41	3.41e-20	Longevity;Endometriosis;
LGG	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg19500275	chr17:80737654	TBCD	-0.51	-6.82	-0.3	2.92e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg12615879	chr12:58013172	SLC26A10	0.34	7.67	0.34	1.06e-13	Multiple sclerosis;
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.43	-0.33	5.16e-13	Height;
LGG	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg17644776	chr2:200775616	C2orf69	0.61	8.48	0.37	3.1e-16	Schizophrenia;
LGG	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.13e-12	Height;
LGG	cis	rs9952991	0.566	rs487273	chr18:12853458	T/G	cg23598886	chr18:12777645	NA	0.53	7.43	0.33	5.12e-13	Inflammatory skin disease;
LGG	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg07636037	chr3:49044803	WDR6	1.02	22.3	0.72	2.25e-75	Parkinson's disease;
LGG	cis	rs57244997	0.872	rs11759694	chr6:162405705	C/G	cg17173639	chr6:162384350	PARK2	0.63	7.83	0.34	3.26e-14	Mosquito bite size;
LGG	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg06219351	chr7:158114137	PTPRN2	0.69	13.71	0.54	3.62e-36	Calcium levels;
LGG	cis	rs9616064	0.506	rs11705341	chr22:47066294	T/C	cg05621596	chr22:47072043	GRAMD4	-0.36	-7.18	-0.32	2.71e-12	Urate levels in obese individuals;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg18446336	chr7:2847575	GNA12	0.3	7.24	0.32	1.84e-12	Height;
LGG	trans	rs1945213	0.694	rs9888298	chr11:55865704	T/C	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01538066	chr19:57946466	ZNF749	-0.39	-6.84	-0.3	2.54e-11	Body fat percentage;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg20102877	chr2:27665638	KRTCAP3	-0.29	-6.65	-0.3	8.47e-11	Total body bone mineral density;
LGG	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.19	0.36	2.5e-15	Aortic root size;
LGG	cis	rs4262150	0.690	rs6871699	chr5:152014666	T/C	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	12.81	0.51	2.34e-32	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16873684	chr2:201828587	ORC2L	-0.41	-6.93	-0.31	1.46e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg00857998	chr1:205179979	DSTYK	0.47	6.87	0.3	2.06e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg21211680	chr2:198530	NA	-1.3	-22.08	-0.72	2.53e-74	Blood protein levels;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02475777	chr4:1388615	CRIPAK	0.41	7.6	0.33	1.64e-13	Longevity;
LGG	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg10587741	chr22:38071170	LGALS1	0.6	13.78	0.54	1.92e-36	Fat distribution (HIV);
LGG	cis	rs7587476	0.906	rs2734674	chr2:215658895	A/G	cg04530015	chr2:215796436	ABCA12	0.44	7.23	0.32	2.07e-12	Neuroblastoma;
LGG	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg26384229	chr12:38710491	ALG10B	0.88	19.98	0.68	1.71e-64	Bladder cancer;
LGG	cis	rs7712401	0.601	rs30029	chr5:122283170	A/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.83	-0.3	2.64e-11	Mean platelet volume;
LGG	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-11.87	-0.48	1.54e-28	Height;
LGG	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.8	-0.45	2.16e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.75	0.34	6.03e-14	Eosinophil percentage of white cells;
LGG	cis	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.47	4.6e-27	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg15212455	chr7:39170539	POU6F2	0.38	8.4	0.36	5.54e-16	IgG glycosylation;
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg07701084	chr6:150067640	NUP43	-0.45	-6.7	-0.3	6.04e-11	Lung cancer;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.75	0.54	2.5e-36	Obesity-related traits;
LGG	cis	rs3820928	1.000	rs10193316	chr2:227777650	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.29	-0.32	1.36e-12	Pulmonary function;
LGG	cis	rs10421328	0.717	rs2288865	chr19:19763635	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.32	6.84	0.3	2.58e-11	Parental longevity (combined parental age at death);
LGG	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg17971929	chr21:40555470	PSMG1	0.87	17.13	0.62	2.69e-51	Cognitive function;
LGG	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg11247378	chr22:39784982	NA	-0.32	-8.53	-0.37	2.09e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg06046430	chr4:77819534	ANKRD56	0.55	11.32	0.47	2.11e-26	Emphysema distribution in smoking;
LGG	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg01244601	chr4:120671846	NA	-0.4	-7.56	-0.33	2.13e-13	Corneal astigmatism;
LGG	trans	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg25214090	chr10:38739885	LOC399744	0.57	10.39	0.43	7.47e-23	Corneal astigmatism;
LGG	cis	rs763121	0.752	rs6001190	chr22:39073811	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	4.04e-56	Menopause (age at onset);
LGG	cis	rs7651039	0.846	rs2174267	chr3:15645835	T/C	cg16303742	chr3:15540471	COLQ	0.39	7.65	0.33	1.21e-13	Coronary heart disease;
LGG	cis	rs2735413	0.802	rs6564504	chr16:78095419	G/T	cg04733911	chr16:78082701	NA	0.75	17.47	0.63	7.5e-53	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.48	-7.77	-0.34	4.95e-14	Mean platelet volume;
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg05313129	chr8:58192883	C8orf71	-0.58	-7.85	-0.34	2.96e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.86	-0.3	2.23e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.39	-0.61	6.17e-48	Morning vs. evening chronotype;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01516881	chr6:292596	DUSP22	-0.53	-9.12	-0.39	2.27e-18	Menopause (age at onset);
LGG	cis	rs3784262	1.000	rs4369598	chr15:58318603	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.2	-0.36	2.45e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.41	0.4	2.39e-19	Lung cancer in ever smokers;
LGG	trans	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg11887960	chr12:57824829	NA	0.57	6.93	0.31	1.45e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg15440763	chr7:158190612	PTPRN2	0.44	9.44	0.4	1.78e-19	Obesity-related traits;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02653800	chr10:60095305	UBE2D1	0.43	7.25	0.32	1.8e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.47	-0.37	3.19e-16	Skin colour saturation;
LGG	cis	rs4650994	0.623	rs12121188	chr1:178622499	G/A	cg12486710	chr1:178512616	C1orf220	-0.38	-7.39	-0.32	6.94e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg23845249	chr11:68861649	NA	0.45	8.03	0.35	8.14e-15	Blond vs. brown hair color;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs711245	0.796	rs848606	chr2:36770736	G/T	cg09467607	chr2:36825704	FEZ2	0.46	8.98	0.38	7.09e-18	Height;
LGG	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg20848291	chr7:100343083	ZAN	-0.6	-8.25	-0.36	1.69e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg25319279	chr11:5960081	NA	-0.53	-8.52	-0.37	2.22e-16	DNA methylation (variation);
LGG	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg00142150	chr22:38071001	LGALS1	0.39	6.76	0.3	4.26e-11	Glioblastoma;Glioma;
LGG	cis	rs4474465	1.000	rs4945277	chr11:78166967	C/T	cg02023728	chr11:77925099	USP35	0.4	6.97	0.31	1.1e-11	Alzheimer's disease (survival time);
LGG	trans	rs3960554	0.808	rs867973	chr7:75686007	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.22	0.49	5.75e-30	Eotaxin levels;
LGG	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.56	0.33	2.17e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg07701084	chr6:150067640	NUP43	0.68	12.76	0.51	3.72e-32	Lung cancer;
LGG	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg20573242	chr4:122745356	CCNA2	0.42	7.53	0.33	2.7e-13	Type 2 diabetes;
LGG	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg11038491	chr20:34638489	LOC647979	-0.55	-7.22	-0.32	2.09e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7786808	0.760	rs10259321	chr7:158221038	G/A	cg15440763	chr7:158190612	PTPRN2	-0.39	-8.03	-0.35	7.9e-15	Obesity-related traits;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg05896524	chr21:47604654	C21orf56	-0.65	-11.93	-0.49	8.17e-29	Testicular germ cell tumor;
LGG	cis	rs4750440	0.706	rs4237437	chr10:14018711	G/A	cg00551146	chr10:14014579	FRMD4A	0.29	6.99	0.31	9.72e-12	Adiponectin levels;
LGG	cis	rs4262150	0.960	rs10056647	chr5:152286477	T/G	cg12297329	chr5:152029980	NA	0.6	11.44	0.47	7.51e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07701084	chr6:150067640	NUP43	0.44	7.9	0.34	2.08e-14	Testicular germ cell tumor;
LGG	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg25418670	chr11:30344373	C11orf46	0.57	7.86	0.34	2.7e-14	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	7.05e-48	Intelligence (multi-trait analysis);
LGG	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg11871910	chr12:69753446	YEATS4	0.69	13.37	0.53	1.04e-34	Blood protein levels;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06028808	chr11:68637592	NA	0.74	12.65	0.51	1.01e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3743102	0.591	rs78104714	chr15:83381199	C/G	cg00614314	chr15:82944287	LOC80154	-0.74	-7.7	-0.34	8.47e-14	Colorectal adenoma (advanced);
LGG	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.18	-0.39	1.43e-18	Coronary artery disease;
LGG	cis	rs7843479	0.965	rs11135741	chr8:21801091	C/T	cg17168535	chr8:21777572	XPO7	0.61	10.01	0.42	1.75e-21	Mean corpuscular volume;
LGG	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg24687543	chr11:63912206	MACROD1	0.6	8.34	0.36	8.42e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs939658	0.805	rs939661	chr15:79431063	A/G	cg17916960	chr15:79447300	NA	-0.67	-13.25	-0.52	3.26e-34	Refractive error;
LGG	cis	rs59104589	1.000	rs59104589	chr2:242237902	C/T	cg10021735	chr2:242295487	FARP2	0.45	7.61	0.33	1.55e-13	Fibrinogen levels;
LGG	cis	rs9783347	1.000	rs4150641	chr11:18370739	C/A	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.26	-0.32	1.62e-12	Pancreatic cancer;
LGG	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg27129171	chr3:47204927	SETD2	-0.82	-14.99	-0.57	1.13e-41	Colorectal cancer;
LGG	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.41	-0.44	6.21e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg16590910	chr6:42928470	GNMT	0.49	14.61	0.56	5.17e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg03647317	chr4:187891568	NA	-0.42	-9.3	-0.4	5.77e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	7.99	0.35	1.05e-14	Tonsillectomy;
LGG	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04004882	chr2:215674386	BARD1	0.53	7.07	0.31	5.61e-12	Neuroblastoma;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.59	0.33	1.76e-13	Prudent dietary pattern;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.31	0.4	5.21e-19	Height;
LGG	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.67	-0.51	8.82e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs4595586	0.545	rs6580893	chr12:39371885	G/T	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg23131131	chr22:24373011	LOC391322	-0.55	-9.51	-0.4	1.08e-19	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.78	-0.48	3.31e-28	Type 2 diabetes;
LGG	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg08400814	chr5:56204995	C5orf35	-0.41	-7.32	-0.32	1.11e-12	Initial pursuit acceleration;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg25019033	chr10:957182	NA	-0.54	-8.95	-0.38	8.62e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.55	-0.44	1.89e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7216064	1.000	rs8071463	chr17:65938655	C/T	cg12091567	chr17:66097778	LOC651250	0.6	8.62	0.37	1.1e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg03929089	chr4:120376271	NA	0.84	13.21	0.52	4.73e-34	Coronary artery disease;
LGG	trans	rs6011368	0.765	rs6062683	chr20:62891887	G/A	cg13869341	chr1:15865	WASH5P	0.53	9.54	0.41	7.88e-20	Clozapine-induced cytotoxicity;
LGG	cis	rs35160687	0.901	rs67903513	chr2:86512099	A/C	cg10973622	chr2:86423274	IMMT	0.39	6.67	0.3	7.29e-11	Night sleep phenotypes;
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg04911050	chr16:677664	RAB40C	0.35	6.94	0.31	1.33e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03177231	chr17:45772386	TBKBP1	0.42	6.82	0.3	2.9e-11	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.09	-0.42	8.74e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg15733309	chr7:157513707	PTPRN2	0.6	13.92	0.54	4.62e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.13	0.39	2.13e-18	Gout;Renal underexcretion gout;
LGG	cis	rs6763768	0.606	rs60287116	chr3:53388457	C/T	cg16894138	chr3:53270350	TKT	0.42	8.08	0.35	5.75e-15	Bacterial meningitis;
LGG	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04530015	chr2:215796436	ABCA12	0.5	10.11	0.43	7.5e-22	Neuroblastoma (high-risk);
LGG	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs208520	0.560	rs2351880	chr6:66863707	G/A	cg07460842	chr6:66804631	NA	-0.97	-18.03	-0.64	1.97e-55	Exhaled nitric oxide output;
LGG	cis	rs2870946	1.000	rs2870945	chr12:68596790	A/T	cg01673780	chr12:68619593	IL26	-0.82	-7.79	-0.34	4.4e-14	Ulcerative colitis;
LGG	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg12081754	chr8:22256438	SLC39A14	1.18	26.42	0.78	1.75e-94	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.87	-0.38	1.59e-17	Triglycerides;
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg19774624	chr17:42201019	HDAC5	0.91	19.18	0.67	9.28e-61	Total body bone mineral density;
LGG	cis	rs6426558	0.537	rs1320494	chr1:227241300	A/T	cg10327440	chr1:227177885	CDC42BPA	0.61	10.26	0.43	2.12e-22	Neutrophil percentage of white cells;
LGG	cis	rs1577917	0.771	rs2475791	chr6:86368164	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-11.97	-0.49	5.83e-29	Response to antipsychotic treatment;
LGG	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs62400317	0.859	rs12191566	chr6:45160002	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.51	0.61	1.77e-48	Obesity-related traits;
LGG	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.42	-0.36	4.6e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg06916706	chr16:4465613	CORO7	-0.85	-15.59	-0.59	2.3e-44	Schizophrenia;
LGG	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg02297831	chr4:17616191	MED28	-0.43	-7.85	-0.34	3e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8017423	0.967	rs8022531	chr14:90729931	T/C	cg04374321	chr14:90722782	PSMC1	0.9	19.49	0.67	3.31e-62	Mortality in heart failure;
LGG	cis	rs9947295	0.649	rs1477484	chr18:11781076	G/T	cg14735704	chr18:11749182	GNAL	-0.49	-7.35	-0.32	9.27e-13	QT interval (drug interaction);
LGG	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	7.97	0.35	1.26e-14	Menarche (age at onset);
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.26	-0.5	3.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	0.551	rs68046179	chr1:227897635	G/A	cg04117972	chr1:227635322	NA	0.44	7.91	0.34	1.96e-14	Major depressive disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04529582	chr20:30697510	TM9SF4	0.45	7.18	0.32	2.71e-12	Cognitive performance;
LGG	trans	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg01134436	chr17:81009848	B3GNTL1	0.83	8.68	0.37	6.89e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg26138144	chr22:38071188	LGALS1	0.91	24.49	0.75	1.35e-85	Fat distribution (HIV);
LGG	cis	rs368123	1.000	rs440429	chr6:160726192	A/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.78e-12	Waist circumference;
LGG	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg22771759	chr13:24902376	NA	0.42	7.19	0.32	2.66e-12	Obesity-related traits;
LGG	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.1	-0.43	8.04e-22	Morning vs. evening chronotype;
LGG	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.79	0.34	4.57e-14	Eosinophil percentage of white cells;
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg00713939	chr8:144660590	NAPRT1	0.87	7.17	0.32	2.91e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.7	14.64	0.56	3.58e-40	Obesity-related traits;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg04008888	chr11:68622739	NA	-0.49	-10.48	-0.44	3.32e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg08677398	chr8:58056175	NA	0.57	12.57	0.5	2.31e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg02536541	chr18:77568900	NA	-0.58	-9.45	-0.4	1.71e-19	Schizophrenia;
LGG	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.72e-13	Aortic root size;
LGG	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg24253500	chr15:84953950	NA	0.58	10.5	0.44	2.9e-23	Schizophrenia;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.56	9.79	0.41	1.08e-20	Lymphocyte counts;
LGG	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-10.8	-0.45	2.08e-24	Morning vs. evening chronotype;
LGG	cis	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg24110177	chr3:50126178	RBM5	0.61	11.22	0.46	5.22e-26	Body mass index;
LGG	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg15268244	chr15:77196840	NA	0.31	6.72	0.3	5.26e-11	Blood metabolite levels;
LGG	trans	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg18187862	chr3:45730750	SACM1L	0.63	10.33	0.43	1.17e-22	Primary sclerosing cholangitis;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18402987	chr7:1209562	NA	0.4	7.09	0.31	4.95e-12	Longevity;Endometriosis;
LGG	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg01620082	chr3:125678407	NA	-0.81	-9.28	-0.4	6.73e-19	Depression;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	9.85	0.42	6.39e-21	Tonsillectomy;
LGG	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg08847335	chr10:891726	LARP4B	-0.53	-9.0	-0.39	6.07e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg02753203	chr1:228287806	NA	-0.65	-12.22	-0.49	5.84e-30	Diastolic blood pressure;
LGG	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg11764359	chr7:65958608	NA	0.64	10.03	0.42	1.52e-21	Aortic root size;
LGG	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Gut microbiome composition (summer);
LGG	cis	rs7785730	0.652	rs4470907	chr7:28095304	C/T	cg17702455	chr7:28058989	JAZF1	-0.42	-7.61	-0.33	1.5e-13	Free thyroxine concentration;
LGG	trans	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.93	0.45	6.64e-25	Corneal astigmatism;
LGG	cis	rs4006360	0.604	rs1976318	chr17:39250906	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg27411982	chr8:10470053	RP1L1	0.45	7.79	0.34	4.39e-14	Joint mobility (Beighton score);
LGG	cis	rs4750440	0.585	rs7072791	chr10:14028195	A/C	cg27542038	chr10:14027202	FRMD4A	-0.77	-14.55	-0.56	9.54e-40	Adiponectin levels;
LGG	trans	rs2055729	1.000	rs35649764	chr8:9793000	T/C	cg12395012	chr8:11607386	GATA4	0.41	7.03	0.31	7.28e-12	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15906409	chr17:17685582	RAI1	0.4	6.66	0.3	7.76e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs9929218	0.551	rs4783663	chr16:68720271	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.15	33.17	0.84	1.95e-124	Colorectal cancer;
LGG	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg12310025	chr6:25882481	NA	-0.58	-11.31	-0.47	2.32e-26	Blood metabolite levels;
LGG	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg12395012	chr8:11607386	GATA4	-0.42	-7.49	-0.33	3.42e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11608355	0.960	rs3742021	chr12:109883117	T/C	cg19025524	chr12:109796872	NA	-0.49	-9.15	-0.39	1.83e-18	Neuroticism;
LGG	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg02297831	chr4:17616191	MED28	0.5	9.39	0.4	2.76e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs67460515	0.563	rs13071892	chr3:160817877	A/C	cg04691961	chr3:161091175	C3orf57	-0.43	-8.21	-0.36	2.25e-15	Parkinson's disease;
LGG	cis	rs4704187	0.687	rs6860441	chr5:74389799	G/A	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-6.81	-0.3	2.99e-11	Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06689961	chr12:12870959	CDKN1B	0.44	7.36	0.32	8.74e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7119	0.717	rs12904212	chr15:77815833	C/A	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs7296418	0.663	rs11057284	chr12:123830692	G/C	cg05973401	chr12:123451056	ABCB9	0.44	7.51	0.33	3.01e-13	Platelet count;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs557514	1.000	rs557514	chr1:182404684	A/G	cg14851700	chr1:182362230	GLUL	-0.41	-7.13	-0.31	3.98e-12	Common carotid intima-media thickness;
LGG	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.95	-0.35	1.48e-14	Neuroticism;
LGG	cis	rs8067545	0.720	rs6587206	chr17:19881587	T/C	cg13482628	chr17:19912719	NA	0.55	10.05	0.42	1.22e-21	Schizophrenia;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.12	-0.35	4.14e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg01532694	chr8:8243576	NA	0.4	6.69	0.3	6.53e-11	Prudent dietary pattern;
LGG	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-21.14	-0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs4740619	0.846	rs950234	chr9:15755645	T/A	cg14451791	chr9:16040625	NA	-0.4	-10.7	-0.45	5.0600000000000004e-24	Body mass index;
LGG	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg03342759	chr3:160939853	NMD3	0.44	7.5	0.33	3.35e-13	Morning vs. evening chronotype;
LGG	cis	rs7106204	0.920	rs7946615	chr11:24221036	T/C	ch.11.24196551F	chr11:24239977	NA	0.94	12.17	0.49	9.54e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs701145	0.585	rs1727882	chr3:153837246	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs4731207	0.596	rs2170353	chr7:124595169	T/G	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.16e-23	Prudent dietary pattern;
LGG	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg07882059	chr11:68924751	NA	0.41	7.33	0.32	1.02e-12	Blond vs. brown hair color;
LGG	cis	rs3768617	0.740	rs28533496	chr1:183019885	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.77	0.3	3.93e-11	Fuchs's corneal dystrophy;
LGG	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06481639	chr22:41940642	POLR3H	-0.54	-8.03	-0.35	7.89e-15	Vitiligo;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8067287	0.597	rs4985724	chr17:16863362	A/G	cg26910001	chr17:16838321	NA	0.38	7.5	0.33	3.21e-13	Diabetic kidney disease;
LGG	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg22044901	chr15:68126292	NA	-0.42	-6.93	-0.31	1.46e-11	Restless legs syndrome;
LGG	cis	rs3126085	0.877	rs4457589	chr1:152247860	T/C	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07701084	chr6:150067640	NUP43	0.44	7.89	0.34	2.22e-14	Testicular germ cell tumor;
LGG	trans	rs6828577	0.732	rs2200517	chr4:119462685	T/C	cg26518628	chr1:97050305	NA	-0.54	-8.56	-0.37	1.65e-16	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg24699146	chr1:24152579	HMGCL	-0.27	-7.9	-0.34	2e-14	Immature fraction of reticulocytes;
LGG	trans	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07923666	chr12:49932857	KCNH3	-0.51	-7.61	-0.33	1.5700000000000001e-13	Resting heart rate;
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.93	-0.54	4.37e-37	Alzheimer's disease;
LGG	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs4740619	0.819	rs276435	chr9:15619125	T/C	cg14451791	chr9:16040625	NA	-0.31	-7.62	-0.33	1.47e-13	Body mass index;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24110177	chr3:50126178	RBM5	0.57	10.54	0.44	1.96e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg20607798	chr8:58055168	NA	0.68	7.67	0.34	1.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs926392	0.640	rs4616534	chr20:37693564	G/A	cg16355469	chr20:37678765	NA	0.59	9.24	0.39	8.72e-19	Dialysis-related mortality;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.38	0.5	1.36e-30	Lymphocyte counts;
LGG	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.58	-0.33	1.87e-13	Morning vs. evening chronotype;
LGG	cis	rs9443645	0.901	rs10455356	chr6:79664748	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg16606324	chr3:10149918	C3orf24	0.64	7.17	0.32	2.94e-12	Alzheimer's disease;
LGG	cis	rs36093844	0.752	rs56036199	chr11:85548763	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07677032	chr17:61819896	STRADA	0.68	12.67	0.51	8.84e-32	Prudent dietary pattern;
LGG	cis	rs4948275	0.773	rs2606079	chr10:63289635	T/C	cg03237606	chr10:63212265	TMEM26	-0.39	-7.04	-0.31	6.83e-12	Night sleep phenotypes;
LGG	cis	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg15596359	chr8:11213517	TDH	-0.4	-8.03	-0.35	7.99e-15	Retinal vascular caliber;
LGG	cis	rs4474465	0.646	rs4945301	chr11:78283362	A/G	cg27205649	chr11:78285834	NARS2	0.6	11.17	0.46	8.52e-26	Alzheimer's disease (survival time);
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-12.5	-0.5	4.15e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4906332	1.000	rs12896919	chr14:103956713	T/C	cg26031613	chr14:104095156	KLC1	-0.5	-7.61	-0.33	1.6e-13	Coronary artery disease;
LGG	cis	rs62238980	0.521	rs78249378	chr22:32409893	C/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs2242663	0.654	rs2282640	chr11:66245851	G/T	cg01599099	chr11:66649832	PC	0.39	7.99	0.35	1.09e-14	Bipolar disorder;
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.9	-0.31	1.67e-11	Triglycerides;
LGG	cis	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg06521331	chr12:34319734	NA	-0.63	-11.83	-0.48	2.21e-28	Morning vs. evening chronotype;
LGG	cis	rs1927790	0.759	rs35092596	chr13:96977392	T/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.9	-0.31	1.74e-11	Body mass index;
LGG	cis	rs897080	0.515	rs1067331	chr2:44627626	T/C	cg00619915	chr2:44497795	NA	-0.49	-6.93	-0.31	1.41e-11	Height;
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg04156016	chr5:1868137	NA	0.32	7.0	0.31	9.06e-12	Cardiovascular disease risk factors;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08638395	chr1:180601032	XPR1	0.46	7.11	0.31	4.36e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.18	-0.52	6.81e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg24503407	chr1:205819492	PM20D1	0.58	11.43	0.47	8.03e-27	Menarche (age at onset);
LGG	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg07636037	chr3:49044803	WDR6	0.76	13.56	0.53	1.62e-35	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.76	-0.38	3.57e-17	Menopause (age at onset);
LGG	cis	rs2274273	1.000	rs61508494	chr14:55587297	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.03	0.62	7.38e-51	Protein biomarker;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg17951613	chr5:131705445	SLC22A5	0.67	7.52	0.33	2.84e-13	Rheumatoid arthritis;
LGG	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg02753203	chr1:228287806	NA	0.76	14.7	0.56	2.01e-40	Diastolic blood pressure;
LGG	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.91	0.35	1.9e-14	Coronary artery disease;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.27	-0.36	1.38e-15	Total body bone mineral density;
LGG	cis	rs11064837	0.504	rs34500179	chr12:120068852	G/A	cg25937854	chr12:120150414	CIT	-0.6	-10.58	-0.44	1.44e-23	Schizophrenia;
LGG	cis	rs763121	0.853	rs3747170	chr22:39067331	G/A	cg06022373	chr22:39101656	GTPBP1	0.88	18.0	0.64	2.53e-55	Menopause (age at onset);
LGG	cis	rs2274273	0.592	rs2878174	chr14:55470624	T/C	cg04306507	chr14:55594613	LGALS3	0.35	8.46	0.37	3.63e-16	Protein biomarker;
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.75	0.34	5.99e-14	Bipolar disorder;
LGG	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs1030877	0.515	rs1020064	chr2:105897740	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.64	10.21	0.43	3.23e-22	Obesity-related traits;
LGG	cis	rs754466	0.580	rs10762763	chr10:79560803	C/G	cg17075019	chr10:79541650	NA	-0.93	-20.87	-0.7	1.21e-68	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.7	13.31	0.53	1.84e-34	Total body bone mineral density;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-11.89	-0.48	1.19e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg20387954	chr3:183756860	HTR3D	0.66	13.33	0.53	1.48e-34	Anterior chamber depth;
LGG	trans	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg26043149	chr18:55253948	FECH	-0.41	-6.72	-0.3	5.25e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg02725872	chr8:58115012	NA	-0.78	-10.5	-0.44	2.9e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	Neuroticism;
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg08888203	chr3:10149979	C3orf24	0.54	9.05	0.39	3.85e-18	Alzheimer's disease;
LGG	cis	rs1577917	0.771	rs7762321	chr6:86412146	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.25	0.36	1.69e-15	Response to antipsychotic treatment;
LGG	cis	rs7561149	0.500	rs35770984	chr2:179626080	T/A	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.44	6.87	0.3	2.07e-11	QT interval;
LGG	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	trans	rs1941687	0.797	rs8098255	chr18:31401850	A/G	cg27147174	chr7:100797783	AP1S1	0.51	8.53	0.37	2.14e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9633740	1.000	rs9633740	chr10:82265271	A/G	cg01528321	chr10:82214614	TSPAN14	1.07	16.61	0.61	5.81e-49	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2012796	0.743	rs61986598	chr14:81856865	G/A	cg02996355	chr14:81879375	NA	0.56	9.28	0.4	6.37e-19	Night sleep phenotypes;
LGG	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg02640540	chr1:67518911	SLC35D1	0.39	7.3	0.32	1.29e-12	Lymphocyte percentage of white cells;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs7666738	0.715	rs61114099	chr4:98931270	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs963731	0.649	rs297129	chr2:39299271	C/T	cg04010122	chr2:39346883	SOS1	0.81	7.42	0.33	5.59e-13	Corticobasal degeneration;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg13939156	chr17:80058883	NA	-0.46	-9.02	-0.39	5.15e-18	Life satisfaction;
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg08835221	chr22:38071607	LGALS1	0.28	7.74	0.34	6.44e-14	Fat distribution (HIV);
LGG	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg05925327	chr15:68127851	NA	-0.44	-8.88	-0.38	1.48e-17	Restless legs syndrome;
LGG	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg16316162	chr8:144660157	NAPRT1	0.75	6.81	0.3	3.06e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs7113874	0.569	rs11041994	chr11:8597866	C/A	cg23764900	chr11:8616102	STK33	-0.38	-6.68	-0.3	6.93e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.24	-0.32	1.92e-12	Schizophrenia;
LGG	cis	rs2587949	0.615	rs2600131	chr3:4216523	G/A	cg16519197	chr3:4211558	NA	0.32	6.7	0.3	5.91e-11	Periodontitis (DPAL);
LGG	cis	rs7582720	1.000	rs72934753	chr2:203750272	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9976767	1.000	rs11702374	chr21:43829758	G/A	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.84	-0.3	2.56e-11	Type 1 diabetes;
LGG	cis	rs7091068	0.706	rs620043	chr10:95405257	T/C	cg20715218	chr10:95462985	C10orf4	-0.58	-7.93	-0.35	1.67e-14	Urinary tract infection frequency;
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.96e-21	Tonsillectomy;
LGG	cis	rs17253792	0.545	rs12893061	chr14:56016097	A/T	cg01858014	chr14:56050164	KTN1	-0.75	-9.29	-0.4	6.07e-19	Putamen volume;
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.13	-0.31	3.87e-12	Bipolar disorder;
LGG	cis	rs8064024	0.679	rs2072595	chr16:4897153	A/G	cg08329684	chr16:4932620	PPL	0.52	11.74	0.48	4.67e-28	Cancer;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs988958	0.526	rs12712830	chr2:42252955	T/G	cg27252766	chr2:42229092	NA	0.49	7.14	0.31	3.75e-12	Hypospadias;
LGG	cis	rs780094	0.500	rs12464616	chr2:27827092	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.3	2.38e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg19773385	chr1:10388646	KIF1B	-0.51	-10.87	-0.45	1.1e-24	Hepatocellular carcinoma;
LGG	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.13	0.43	6.31e-22	Motion sickness;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7463659	0.512	rs62524716	chr8:135450378	A/G	cg09855544	chr8:135498122	ZFAT	-0.39	-6.82	-0.3	2.8e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7927771	0.524	rs10458915	chr11:47864392	T/A	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	trans	rs75804782	0.521	rs72993034	chr2:239385895	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	8.76	0.38	3.7e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs5742933	0.817	rs6942	chr2:190636411	C/G	cg10453823	chr2:190539512	ANKAR	-0.47	-6.81	-0.3	3.05e-11	Ferritin levels;
LGG	cis	rs8016982	0.633	rs8019108	chr14:81716781	A/T	cg01989461	chr14:81687754	GTF2A1	0.78	18.56	0.65	6.89e-58	Schizophrenia;
LGG	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.08e-11	Blood metabolite levels;
LGG	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs2239547	0.522	rs2581779	chr3:53056199	T/C	cg11645453	chr3:52864694	ITIH4	-0.68	-10.55	-0.44	1.79e-23	Schizophrenia;
LGG	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.58	-11.53	-0.47	3.21e-27	IgG glycosylation;
LGG	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg20891283	chr12:69753455	YEATS4	1.1	29.0	0.8	3.51e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg03060546	chr3:49711283	APEH	-0.66	-11.16	-0.46	8.91e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11166927	0.524	rs2035087	chr8:140831320	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.63	-12.7	-0.51	6.64e-32	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-10.98	-0.45	4.44e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12195424	0.730	rs73465822	chr6:56298684	T/C	cg07152817	chr6:56299822	NA	-0.58	-7.38	-0.32	7.32e-13	Cerebrospinal fluid clusterin levels;
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.82	-0.42	8.6e-21	Triglycerides;
LGG	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg22961513	chr11:14280813	SPON1	0.38	9.6	0.41	5.16e-20	Mitochondrial DNA levels;
LGG	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg11812906	chr14:75593930	NEK9	0.47	8.67	0.37	7.38e-17	Height;
LGG	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg02493740	chr2:85810744	VAMP5	-0.39	-7.13	-0.31	3.84e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg12813108	chr7:99719912	CNPY4	0.64	10.27	0.43	1.99e-22	Lung function (FEV1/FVC);
LGG	cis	rs1620921	1.000	rs1620921	chr6:161197087	C/T	cg01280913	chr6:161186852	NA	0.33	6.96	0.31	1.18e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg04025307	chr7:1156635	C7orf50	0.88	18.85	0.66	3.16e-59	Longevity;Endometriosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14395634	chr11:65626208	CFL1	0.45	7.25	0.32	1.77e-12	Cognitive performance;
LGG	cis	rs6430585	0.583	rs58509842	chr2:136586027	G/A	cg07169764	chr2:136633963	MCM6	1.29	25.54	0.76	1.88e-90	Corneal structure;
LGG	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg04132472	chr17:19861366	AKAP10	0.26	7.15	0.32	3.36e-12	Schizophrenia;
LGG	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg15017067	chr4:17643749	FAM184B	0.3	6.96	0.31	1.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg14191688	chr11:70257035	CTTN	0.59	8.36	0.36	7.37e-16	Coronary artery disease;
LGG	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg01206211	chr2:36825736	FEZ2	0.36	6.91	0.31	1.61e-11	Height;
LGG	cis	rs564799	0.966	rs483714	chr3:159729877	T/C	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs4363385	0.934	rs1415964	chr1:152955085	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-7.86	-0.34	2.67e-14	Inflammatory skin disease;
LGG	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.52	0.61	1.54e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22625903	chr11:62313283	AHNAK	0.46	6.81	0.3	2.95e-11	Gut microbiome composition (summer);
LGG	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg08648136	chr8:956695	NA	0.35	7.37	0.32	7.91e-13	Schizophrenia;
LGG	trans	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg01426195	chr3:39028469	NA	-0.48	-9.19	-0.39	1.38e-18	Verbal declarative memory;
LGG	cis	rs6138458	1.000	rs11906373	chr20:24938832	A/G	cg26195577	chr20:24973756	C20orf3	1.24	26.23	0.77	1.29e-93	Blood protein levels;
LGG	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-12.49	-0.5	4.64e-31	Menarche (age at onset);
LGG	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.33	0.4	4.53e-19	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10289190	chr9:37422575	GRHPR	0.4	6.65	0.3	8.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4926611	0.966	rs10888800	chr1:54108494	G/A	cg23596471	chr1:54105337	GLIS1	0.4	8.35	0.36	8.08e-16	Hand grip strength;
LGG	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg00631329	chr6:26305371	NA	-0.46	-7.36	-0.32	8.37e-13	Educational attainment;
LGG	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg13010199	chr12:38710504	ALG10B	0.46	8.67	0.37	7.59e-17	Morning vs. evening chronotype;
LGG	cis	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg13443165	chr9:33130375	B4GALT1	-0.76	-14.86	-0.57	4.23e-41	IgG glycosylation;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.57	0.37	1.51e-16	Prudent dietary pattern;
LGG	trans	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg02002194	chr4:3960332	NA	0.42	7.44	0.33	4.83e-13	Neuroticism;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.99e-12	Prudent dietary pattern;
LGG	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg11161011	chr14:65562177	MAX	-0.61	-11.74	-0.48	4.94e-28	Obesity-related traits;
LGG	trans	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.2	-0.32	2.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg11494091	chr17:61959527	GH2	0.99	23.63	0.74	1.45e-81	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.73	-0.38	4.51e-17	Menopause (age at onset);
LGG	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg00409905	chr10:38381863	ZNF37A	0.5	7.51	0.33	3.11e-13	Obesity (extreme);
LGG	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg04398451	chr17:18023971	MYO15A	-0.81	-17.46	-0.63	8.34e-53	Total body bone mineral density;
LGG	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg13482628	chr17:19912719	NA	0.53	9.99	0.42	2.13e-21	Schizophrenia;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg25457927	chr22:38595422	NA	-0.44	-10.86	-0.45	1.27e-24	Cutaneous nevi;
LGG	cis	rs6558530	0.932	rs9022	chr8:1710977	A/C	cg08198773	chr8:1697536	NA	0.36	6.76	0.3	4.09e-11	Systolic blood pressure;
LGG	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.54	0.33	2.54e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14154082	chr13:112174009	NA	0.42	9.28	0.4	6.41e-19	Menarche (age at onset);
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg05868516	chr6:26286170	HIST1H4H	-0.45	-7.82	-0.34	3.71e-14	Educational attainment;
LGG	trans	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg00938859	chr5:1591904	SDHAP3	0.93	13.69	0.54	4.51e-36	Breast cancer;
LGG	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg02700894	chr3:12045449	SYN2	-0.4	-6.7	-0.3	6.08e-11	Platelet count;
LGG	cis	rs2832191	1.000	rs2832189	chr21:30487414	C/T	cg24692254	chr21:30365293	RNF160	-0.87	-20.0	-0.68	1.32e-64	Dental caries;
LGG	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg18898632	chr2:242989856	NA	-0.76	-9.53	-0.41	8.62e-20	Obesity-related traits;
LGG	cis	rs5756391	0.568	rs2280976	chr22:37318426	C/T	cg21209356	chr22:37319042	CSF2RB	0.42	9.41	0.4	2.32e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg03162506	chr22:38580953	NA	0.31	7.34	0.32	9.61e-13	Triglycerides;
LGG	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.9	0.59	1e-45	Headache;
LGG	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg23166289	chr1:210001082	C1orf107	-0.39	-7.43	-0.33	5.42e-13	Orofacial clefts;
LGG	cis	rs2976388	0.609	rs2585152	chr8:143786214	A/T	cg06565975	chr8:143823917	SLURP1	0.35	9.09	0.39	2.97e-18	Urinary tract infection frequency;
LGG	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg05623727	chr3:50126028	RBM5	-0.39	-8.52	-0.37	2.34e-16	Body mass index;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg09858108	chr8:58055024	NA	0.45	7.09	0.31	5.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs936229	0.656	rs12898397	chr15:75130093	T/C	cg14664628	chr15:75095509	CSK	-0.62	-12.24	-0.49	4.77e-30	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg07636037	chr3:49044803	WDR6	1.1	27.79	0.79	9.88e-101	Parkinson's disease;
LGG	cis	rs2239547	0.522	rs6792578	chr3:53004604	G/A	cg11645453	chr3:52864694	ITIH4	0.68	10.74	0.45	3.45e-24	Schizophrenia;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9796	0.689	rs692153	chr15:41452681	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.56	-9.24	-0.39	8.94e-19	Menopause (age at onset);
LGG	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg21775007	chr8:11205619	TDH	0.8	14.19	0.55	3.2e-38	Retinal vascular caliber;
LGG	cis	rs12410462	0.892	rs75757169	chr1:227629855	A/G	cg04117972	chr1:227635322	NA	0.75	12.11	0.49	1.7e-29	Major depressive disorder;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg15991262	chr7:23720454	C7orf46	0.46	10.63	0.44	8.91e-24	Schizophrenia;
LGG	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06634786	chr22:41940651	POLR3H	-0.8	-12.47	-0.5	5.91e-31	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.46	-0.5	5.94e-31	Height;
LGG	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.61	-0.41	4.74e-20	Response to antipsychotic treatment;
LGG	trans	rs561341	0.714	rs474455	chr17:30312465	A/T	cg27661571	chr11:113659931	NA	-0.65	-9.27	-0.4	7.07e-19	Hip circumference adjusted for BMI;
LGG	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03517284	chr6:25882590	NA	0.51	9.32	0.4	4.66e-19	Blood metabolite levels;
LGG	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg21466736	chr12:48725269	NA	0.37	7.77	0.34	5.19e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.14	0.6	8.41e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg18551225	chr6:44695536	NA	-0.71	-12.37	-0.5	1.51e-30	Total body bone mineral density;
LGG	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.02	-0.42	1.64e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg16060761	chr17:80687452	NA	-0.55	-9.96	-0.42	2.63e-21	Glycated hemoglobin levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg14092529	chr5:21459600	LOC728411	0.41	6.75	0.3	4.5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg10223061	chr2:219282414	VIL1	0.31	6.85	0.3	2.32e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg20887711	chr4:1340912	KIAA1530	0.69	14.25	0.55	1.92e-38	Longevity;
LGG	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg03453431	chr7:157225567	NA	-0.47	-8.19	-0.36	2.65e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4950322	0.543	rs2883323	chr1:146788708	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg13397359	chr6:42928475	GNMT	0.57	15.63	0.59	1.62e-44	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.96	0.45	5.36e-25	Ulcerative colitis;
LGG	cis	rs457717	0.730	rs458581	chr5:75949635	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.19e-11	Hearing impairment;
LGG	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs3784262	0.669	rs6493981	chr15:58352923	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.93	-0.31	1.46e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg27489772	chr12:121021490	NA	0.59	7.83	0.34	3.37e-14	Type 1 diabetes nephropathy;
LGG	cis	rs6840360	0.615	rs12647465	chr4:152607318	C/A	cg22705602	chr4:152727874	NA	-0.38	-9.15	-0.39	1.8e-18	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.12e-25	Homoarginine levels;
LGG	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21659725	chr3:3221576	CRBN	0.73	11.68	0.48	8.47e-28	Resting heart rate;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg18032289	chr17:61959525	GH2	-0.41	-6.81	-0.3	2.97e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2795502	0.882	rs2744091	chr10:43339441	A/G	cg27426351	chr10:43362370	NA	-0.55	-7.83	-0.34	3.34e-14	Blood protein levels;
LGG	cis	rs11074306	0.561	rs17747098	chr15:28071173	T/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.27e-23	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17490921	chr11:116658887	ZNF259	0.42	7.07	0.31	5.79e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg01493522	chr13:37497338	NA	-0.51	-8.58	-0.37	1.42e-16	Coronary artery disease;
LGG	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg25319279	chr11:5960081	NA	-0.54	-8.63	-0.37	9.62e-17	DNA methylation (variation);
LGG	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg18478394	chr8:109455254	TTC35	0.41	8.22	0.36	2.14e-15	Dupuytren's disease;
LGG	trans	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg06521331	chr12:34319734	NA	0.46	8.11	0.35	4.59e-15	Bladder cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13251490	chr17:1531887	SLC43A2	-0.43	-6.87	-0.3	2.1e-11	Pancreatic cancer;
LGG	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.85	0.3	2.38e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg09307838	chr4:120376055	NA	0.8	12.85	0.51	1.62e-32	Corneal astigmatism;
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	5.9e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg13482628	chr17:19912719	NA	0.53	9.74	0.41	1.58e-20	Schizophrenia;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg16507663	chr6:150244633	RAET1G	0.5	9.25	0.39	8.23e-19	Lung cancer;
LGG	cis	rs11229555	0.609	rs12273635	chr11:58186327	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-8.36	-0.36	7.18e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	10.69	0.44	5.67e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4851254	0.961	rs11692215	chr2:100746573	C/T	cg17356467	chr2:100759845	AFF3	0.4	7.07	0.31	5.89e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg26039829	chr8:22132926	PIWIL2	0.54	12.34	0.5	1.99e-30	Hypertriglyceridemia;
LGG	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg15128208	chr22:42549153	NA	0.75	11.78	0.48	3.41e-28	Birth weight;
LGG	trans	rs3758785	0.512	rs75719210	chr11:94101765	T/G	cg14656441	chr1:39500070	NDUFS5	-0.3	-6.81	-0.3	3.08e-11	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LGG	trans	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	9.53	0.4	8.9e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs896543	0.702	rs6711222	chr2:237494444	C/T	cg25295825	chr2:237489920	CXCR7	0.91	13.91	0.54	5.33e-37	Alcohol dependence (age at onset);
LGG	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg15103426	chr22:29168792	CCDC117	0.61	9.36	0.4	3.49e-19	Lymphocyte counts;
LGG	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.23	-0.49	5.46e-30	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg13443165	chr9:33130375	B4GALT1	-0.73	-14.13	-0.55	6.15e-38	IgG glycosylation;
LGG	cis	rs4906332	0.966	rs12588705	chr14:103865477	T/A	cg26031613	chr14:104095156	KLC1	-0.53	-8.18	-0.36	2.84e-15	Coronary artery disease;
LGG	cis	rs735539	0.521	rs12430409	chr13:21349667	A/G	cg04906043	chr13:21280425	IL17D	-0.46	-7.44	-0.33	4.78e-13	Dental caries;
LGG	trans	rs800082	1.000	rs1405596	chr3:144314033	C/G	cg24215973	chr2:240111563	HDAC4	-0.51	-9.0	-0.39	5.99e-18	Smoking behavior;
LGG	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg26769984	chr7:1090371	C7orf50	-0.44	-8.06	-0.35	6.79e-15	Bronchopulmonary dysplasia;
LGG	cis	rs77216612	0.874	rs11055034	chr12:12890626	C/A	cg24098013	chr12:12878779	APOLD1	0.5	8.11	0.35	4.71e-15	Lymphocyte counts;
LGG	cis	rs7814319	0.933	rs13261690	chr8:97238661	C/A	cg20787634	chr8:97240163	UQCRB	-0.78	-18.53	-0.65	9.28e-58	Lung function (FVC);
LGG	cis	rs643506	0.874	rs673679	chr11:111686800	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.89	0.31	1.81e-11	Breast cancer;
LGG	cis	rs4689642	0.507	rs7699292	chr4:7218750	G/A	cg21353189	chr4:7228343	SORCS2	0.31	6.77	0.3	3.97e-11	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11212172	chr10:53459438	PRKG1;CSTF2T	0.52	8.28	0.36	1.36e-15	Gut microbiome composition (summer);
LGG	cis	rs9362426	0.708	rs9342112	chr6:88092491	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.42	8.2	0.36	2.4e-15	Depressive episodes in bipolar disorder;
LGG	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.18e-12	HDL cholesterol;
LGG	cis	rs7301826	0.651	rs10848209	chr12:131311272	A/G	cg11011512	chr12:131303247	STX2	0.41	8.88	0.38	1.49e-17	Plasma plasminogen activator levels;
LGG	cis	rs2153535	0.580	rs2183112	chr6:8528212	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg00784671	chr22:46762841	CELSR1	-0.6	-7.6	-0.33	1.66e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10089	1.000	rs4835941	chr5:127430905	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.97	0.49	5.87e-29	Ileal carcinoids;
LGG	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg24699146	chr1:24152579	HMGCL	-0.27	-7.92	-0.35	1.83e-14	Immature fraction of reticulocytes;
LGG	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg18854424	chr1:2615690	NA	0.35	7.08	0.31	5.51e-12	Ulcerative colitis;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.7	-0.41	2.32e-20	Educational attainment;
LGG	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg19442545	chr10:75533431	FUT11	-0.43	-7.04	-0.31	6.87e-12	Inflammatory bowel disease;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg03213289	chr20:61660250	NA	0.65	14.18	0.55	3.63e-38	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1595825	0.891	rs78835808	chr2:198669110	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.3	6.85e-11	Ulcerative colitis;
LGG	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg26441486	chr22:50317300	CRELD2	0.43	8.04	0.35	7.33e-15	Schizophrenia;
LGG	cis	rs2013441	1.000	rs34712254	chr17:20049308	C/T	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	trans	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg25214090	chr10:38739885	LOC399744	0.56	10.26	0.43	2.1e-22	Corneal astigmatism;
LGG	cis	rs7192380	0.639	rs2917666	chr16:69763960	C/G	cg00738113	chr16:70207722	CLEC18C	0.33	8.79	0.38	3.02e-17	Sjögren's syndrome;
LGG	cis	rs9487094	0.645	rs12529505	chr6:109946561	A/G	cg16315928	chr6:109776240	MICAL1	-0.48	-7.5	-0.33	3.34e-13	Height;
LGG	cis	rs4731207	0.596	rs10239507	chr7:124596785	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg25338242	chr13:114786047	RASA3	0.4	7.36	0.32	8.21e-13	Schizophrenia;
LGG	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.34	0.4	3.93e-19	Blood metabolite levels;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.92e-43	Prudent dietary pattern;
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg15145296	chr3:125709740	NA	-0.62	-8.14	-0.35	3.66e-15	Blood pressure (smoking interaction);
LGG	cis	rs7301826	0.651	rs34749116	chr12:131280752	G/A	cg11011512	chr12:131303247	STX2	-0.39	-8.12	-0.35	4.16e-15	Plasma plasminogen activator levels;
LGG	cis	rs2302729	0.625	rs10848693	chr12:2833013	A/T	cg19945202	chr12:2788847	CACNA1C	0.7	9.17	0.39	1.58e-18	Sleep quality;
LGG	cis	rs4722166	0.573	rs35436671	chr7:22775508	G/A	cg05265849	chr7:22767390	IL6	0.43	8.24	0.36	1.75e-15	Lung cancer;
LGG	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg18225595	chr11:63971243	STIP1	0.47	6.79	0.3	3.38e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.67e-14	Life satisfaction;
LGG	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.49	-0.47	4.8e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7133214	0.771	rs11049128	chr12:27922925	A/G	cg04279139	chr12:27925367	LOC100133893	-0.33	-7.03	-0.31	7.42e-12	Gut microbiota (functional units);
LGG	cis	rs13401104	0.716	rs11685999	chr2:237143226	G/A	cg15742758	chr2:237126235	ASB18	0.49	7.89	0.34	2.27e-14	Educational attainment;
LGG	cis	rs11690935	0.632	rs62184165	chr2:172558328	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	14.62	0.56	4.43e-40	Schizophrenia;
LGG	trans	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg06521331	chr12:34319734	NA	-0.42	-7.35	-0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs6815814	0.808	rs7673348	chr4:38845198	G/A	cg06935464	chr4:38784597	TLR10	0.43	6.88	0.3	1.96e-11	Breast cancer;
LGG	cis	rs3789045	0.774	rs12039365	chr1:204488687	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.67	-0.37	7.09e-17	Educational attainment (college completion);
LGG	cis	rs67311347	1.000	rs2887995	chr3:40409029	C/G	cg13683864	chr3:40499215	RPL14	-0.98	-20.35	-0.69	3.1e-66	Renal cell carcinoma;
LGG	trans	rs61931739	0.534	rs10506120	chr12:34235603	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.38e-45	Morning vs. evening chronotype;
LGG	cis	rs7226408	0.847	rs115623155	chr18:34684712	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.05	-0.31	6.35e-12	Obesity-related traits;
LGG	cis	rs897984	0.770	rs3813020	chr16:30934075	G/A	cg00531865	chr16:30841666	NA	0.56	12.01	0.49	4e-29	Dementia with Lewy bodies;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg18379455	chr17:41446167	NA	-0.32	-7.35	-0.32	9.21e-13	Menopause (age at onset);
LGG	trans	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg25214090	chr10:38739885	LOC399744	0.68	11.92	0.48	9.7e-29	Corneal astigmatism;
LGG	cis	rs2011503	1.000	rs1036215	chr19:19657198	C/T	cg11584989	chr19:19387371	SF4	0.75	11.92	0.48	9.06e-29	Bipolar disorder;
LGG	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg12373951	chr3:133503437	NA	0.4	6.99	0.31	9.47e-12	Iron status biomarkers;
LGG	cis	rs4363385	0.655	rs11205163	chr1:152983677	C/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.2	-0.39	1.21e-18	Inflammatory skin disease;
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg02524346	chr8:600233	NA	0.96	10.16	0.43	5.13e-22	IgG glycosylation;
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg10295955	chr4:187884368	NA	-1.15	-30.41	-0.82	1.9e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg11301795	chr4:187892539	NA	0.94	25.62	0.77	8.78e-91	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7296418	0.675	rs1879379	chr12:123727443	G/A	cg00376283	chr12:123451042	ABCB9	0.62	11.37	0.47	1.37e-26	Platelet count;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.97e-22	Menopause (age at onset);
LGG	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.4	-0.36	5.62e-16	Body mass index;
LGG	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg06191203	chr2:152266755	RIF1	0.43	7.57	0.33	2.03e-13	Lung cancer;
LGG	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg07930552	chr6:133119739	C6orf192	1.15	10.6	0.44	1.22e-23	Type 2 diabetes nephropathy;
LGG	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg25208724	chr1:156163844	SLC25A44	1.15	24.51	0.75	1.1400000000000001e-85	Testicular germ cell tumor;
LGG	cis	rs2470578	0.792	rs2733499	chr3:17276334	A/G	cg20981856	chr3:17787350	NA	-0.36	-6.79	-0.3	3.39e-11	Schizophrenia;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.11	-0.35	4.6e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg26384229	chr12:38710491	ALG10B	1.04	26.76	0.78	4.71e-96	Heart rate;
LGG	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.15e-11	Iron status biomarkers;
LGG	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	9.54	0.41	8.06e-20	Aortic root size;
LGG	trans	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27338897	chr3:125802820	SLC41A3	0.64	7.18	0.32	2.76e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9393777	0.777	rs35984974	chr6:27410422	G/A	cg06606381	chr12:133084897	FBRSL1	-0.89	-8.88	-0.38	1.46e-17	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15910013	chr10:21822787	MLLT10	-0.5	-7.46	-0.33	4.28e-13	Systemic lupus erythematosus;
LGG	cis	rs7590368	0.640	rs12472302	chr2:10941301	G/A	cg15705551	chr2:10952987	PDIA6	0.57	7.38	0.32	7.38e-13	Educational attainment (years of education);
LGG	cis	rs977987	0.669	rs1001861	chr16:75306455	G/A	cg07303275	chr16:75499416	TMEM170A	0.38	6.67	0.3	7.32e-11	Dupuytren's disease;
LGG	cis	rs9419702	0.568	rs7075233	chr10:133545170	A/G	cg20568497	chr10:133558893	NA	-0.33	-7.3	-0.32	1.25e-12	Survival in rectal cancer;
LGG	cis	rs7527798	0.592	rs6684643	chr1:207846242	A/T	cg09232269	chr1:207846808	CR1L	-0.37	-6.91	-0.31	1.57e-11	Erythrocyte sedimentation rate;
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg16434002	chr17:42200994	HDAC5	-0.49	-8.38	-0.36	6.57e-16	Total body bone mineral density;
LGG	cis	rs12134245	0.874	rs17501937	chr1:92021705	C/T	cg25838465	chr1:92012736	NA	0.4	7.16	0.32	3.24e-12	Breast cancer;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00761968	chr13:53314142	LECT1	-0.38	-8.16	-0.35	3.15e-15	Lewy body disease;
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg11859384	chr17:80120422	CCDC57	0.44	7.8	0.34	4.16e-14	Life satisfaction;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6784615	1.000	rs61734640	chr3:52390789	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.68	7.41	0.33	6.01e-13	Waist-hip ratio;
LGG	cis	rs6964587	0.967	rs6465340	chr7:91588664	G/A	cg17063962	chr7:91808500	NA	0.47	8.27	0.36	1.48e-15	Breast cancer;
LGG	cis	rs11264213	0.792	rs12562583	chr1:36178868	G/T	cg27506609	chr1:36549197	TEKT2	0.7	7.88	0.34	2.3e-14	Schizophrenia;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg21782813	chr7:2030301	MAD1L1	-0.43	-10.02	-0.42	1.66e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs698813	0.674	rs6725676	chr2:44497828	T/A	cg00619915	chr2:44497795	NA	-0.6	-8.6	-0.37	1.21e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg09818912	chr17:20140352	CYTSB	-0.31	-7.32	-0.32	1.12e-12	Obesity-related traits;
LGG	cis	rs4363385	0.747	rs1611753	chr1:152956381	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.12	-0.39	2.35e-18	Inflammatory skin disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07190450	chr5:154320539	MRPL22	0.45	7.36	0.32	8.73e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6784615	0.744	rs11721286	chr3:52509029	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.62	-7.24	-0.32	1.9e-12	Waist-hip ratio;
LGG	cis	rs7928758	0.945	rs28378882	chr11:134280503	G/T	cg15243474	chr11:134282918	B3GAT1	1.05	13.44	0.53	5.28e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.54	-7.21	-0.32	2.3e-12	Schizophrenia;
LGG	cis	rs17253792	0.822	rs74653073	chr14:56079528	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.11	-0.49	1.56e-29	Putamen volume;
LGG	cis	rs7572733	0.967	rs11889326	chr2:198899275	A/C	cg00792783	chr2:198669748	PLCL1	0.44	7.41	0.33	6.07e-13	Dermatomyositis;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg04863758	chr4:1303710	MAEA	0.41	6.97	0.31	1.1e-11	Obesity-related traits;
LGG	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.88	-0.74	9.84e-83	Lymphocyte percentage of white cells;
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.53	0.4	9.12e-20	Bipolar disorder;
LGG	cis	rs597583	0.715	rs2276340	chr11:117391966	G/A	cg27161313	chr11:117392002	DSCAML1	-0.63	-9.97	-0.42	2.42e-21	Putamen volume;
LGG	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.38e-12	Menopause (age at onset);
LGG	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg12011299	chr4:100065546	ADH4	0.45	9.3	0.4	5.46e-19	Alcohol dependence;
LGG	cis	rs6882076	0.883	rs1553318	chr5:156479323	G/C	cg12943317	chr5:156479607	HAVCR1	-0.73	-13.04	-0.52	2.54e-33	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg05444541	chr17:17804740	TOM1L2	0.56	12.35	0.5	1.76e-30	Total body bone mineral density;
LGG	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg18681998	chr4:17616180	MED28	0.8	15.99	0.6	4.02e-46	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9796	0.835	rs28455998	chr15:41430969	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.76	-0.38	3.72e-17	Menopause (age at onset);
LGG	cis	rs988958	0.637	rs67710195	chr2:42219378	G/C	cg27252766	chr2:42229092	NA	0.58	8.98	0.39	6.86e-18	Hypospadias;
LGG	trans	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg06521331	chr12:34319734	NA	-0.54	-9.33	-0.4	4.45e-19	Bladder cancer;
LGG	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg07599136	chr5:415885	AHRR	0.61	9.4	0.4	2.59e-19	Fat distribution (HIV);
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.78	0.34	4.73e-14	Lung cancer;
LGG	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg13009111	chr11:71350975	NA	0.35	7.7	0.34	8.43e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg13482628	chr17:19912719	NA	-0.53	-9.99	-0.42	2.09e-21	Schizophrenia;
LGG	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg23306229	chr2:178417860	TTC30B	0.75	8.63	0.37	1e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02908587	chr9:77112187	RORB	0.44	6.9	0.31	1.76e-11	Gut microbiome composition (summer);
LGG	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg12292205	chr6:26970375	C6orf41	0.73	14.16	0.55	4.65e-38	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	7.85e-13	Testicular germ cell tumor;
LGG	cis	rs11585357	1.000	rs11585357	chr1:17601165	C/T	cg08277548	chr1:17600880	PADI3	-0.76	-8.73	-0.38	4.79e-17	Hair shape;
LGG	cis	rs981844	1.000	rs62325092	chr4:154668674	T/C	cg14289246	chr4:154710475	SFRP2	0.71	11.75	0.48	4.61e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg13010199	chr12:38710504	ALG10B	0.76	16.2	0.6	4.58e-47	Heart rate;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18000306	chr6:288505	NA	0.61	10.94	0.45	6.29e-25	Menopause (age at onset);
LGG	cis	rs11785400	0.793	rs11543967	chr8:143739435	A/G	cg10596483	chr8:143751796	JRK	-0.52	-8.1	-0.35	4.8e-15	Schizophrenia;
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg03517284	chr6:25882590	NA	-0.4	-7.17	-0.32	2.92e-12	Height;
LGG	cis	rs4538187	1.000	rs4233930	chr2:64077305	C/G	cg14150252	chr2:64069583	UGP2	0.47	9.45	0.4	1.73e-19	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21442773	chr1:236029828	LYST	0.43	6.98	0.31	1.06e-11	Cognitive performance;
LGG	cis	rs2444240	1.000	rs2444240	chr11:120040442	T/G	cg16005559	chr11:120040616	NA	-0.34	-7.56	-0.33	2.24e-13	Corneal curvature;
LGG	cis	rs74781061	0.799	rs4372642	chr15:74752436	T/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.34	-0.32	9.94e-13	Endometriosis;
LGG	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-6.97	-0.31	1.13e-11	Diastolic blood pressure;
LGG	cis	rs9902453	0.817	rs7217961	chr17:28403112	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-13.81	-0.54	1.44e-36	Coffee consumption (cups per day);
LGG	cis	rs1881396	0.947	rs8731	chr2:27873326	C/G	cg27432699	chr2:27873401	GPN1	0.59	9.08	0.39	3.23e-18	Nonalcoholic fatty liver disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01252659	chr19:7198410	INSR	0.42	6.83	0.3	2.65e-11	Cognitive performance;
LGG	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.22	-0.36	2e-15	Myopia (pathological);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00543632	chr16:19098067	NA	0.45	6.72	0.3	5.46e-11	Gut microbiome composition (summer);
LGG	cis	rs258892	0.843	rs11954478	chr5:72019275	A/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.66	-0.3	7.95e-11	Small cell lung carcinoma;
LGG	cis	rs367943	0.712	rs6867397	chr5:112725759	C/T	cg12552261	chr5:112820674	MCC	-0.57	-10.31	-0.43	1.4e-22	Type 2 diabetes;
LGG	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg27532318	chr7:32358331	NA	0.75	7.55	0.33	2.35e-13	Body mass index;
LGG	cis	rs2304069	0.913	rs7734382	chr5:149383241	A/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	7.67	0.34	1.04e-13	HIV-1 control;
LGG	cis	rs2046867	0.908	rs11927166	chr3:72795149	C/G	cg26655873	chr3:72818019	SHQ1	0.34	6.81	0.3	3.04e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4605213	0.686	rs8076111	chr17:49302782	C/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.42	-7.02	-0.31	7.72e-12	Height;
LGG	cis	rs6960043	0.818	rs2358158	chr7:15054063	T/C	cg19272540	chr7:15055459	NA	0.37	8.37	0.36	6.63e-16	Type 2 diabetes;
LGG	cis	rs1707322	1.000	rs10890376	chr1:46406582	C/T	cg03146154	chr1:46216737	IPP	0.55	10.21	0.43	3.36e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg08534653	chr2:1747700	PXDN	0.44	6.8	0.3	3.27e-11	Response to antipsychotic treatment;
LGG	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.38e-12	Vitiligo;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg05863683	chr7:1912471	MAD1L1	0.41	8.12	0.35	4.16e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9916302	0.706	rs8075737	chr17:37727316	C/T	cg00129232	chr17:37814104	STARD3	0.63	10.26	0.43	2.13e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg15268244	chr15:77196840	NA	-0.35	-7.65	-0.33	1.2e-13	Blood metabolite levels;
LGG	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	27.76	0.79	1.36e-100	Height;
LGG	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg17971929	chr21:40555470	PSMG1	-0.54	-9.33	-0.4	4.49e-19	Menarche (age at onset);
LGG	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg22467129	chr15:76604101	ETFA	0.42	7.1	0.31	4.66e-12	Blood metabolite levels;
LGG	cis	rs6032067	0.925	rs62208424	chr20:43813341	G/A	cg10761708	chr20:43804764	PI3	0.76	11.93	0.49	8.26e-29	Blood protein levels;
LGG	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg11764359	chr7:65958608	NA	0.62	10.62	0.44	1.02e-23	Aortic root size;
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg11494091	chr17:61959527	GH2	-0.54	-8.8	-0.38	2.78e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg12395012	chr8:11607386	GATA4	-0.38	-6.67	-0.3	7.51e-11	Retinal vascular caliber;
LGG	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.11e-17	Aortic root size;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg15971980	chr6:150254442	NA	0.46	8.64	0.37	9.27e-17	Lung cancer;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-7.76	-0.34	5.38e-14	Self-reported allergy;
LGG	cis	rs7179456	0.544	rs2555357	chr15:59087115	A/G	cg05156742	chr15:59063176	FAM63B	0.66	12.33	0.5	2.12e-30	Asperger disorder;
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg05692746	chr2:100937584	LONRF2	0.63	11.7	0.48	6.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1869026	0.967	rs11122802	chr2:121335866	C/A	cg03661458	chr2:121334411	NA	0.32	7.45	0.33	4.53e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17208368	0.628	rs12598595	chr16:55093224	A/C	cg09947736	chr16:55091198	NA	0.68	12.92	0.51	8.16e-33	Hypospadias;
LGG	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.58	-0.47	2.07e-27	Morning vs. evening chronotype;
LGG	cis	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg24110177	chr3:50126178	RBM5	-0.51	-7.71	-0.34	7.98e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg08949735	chr16:89699720	DPEP1	-0.48	-9.98	-0.42	2.33e-21	Vitiligo;
LGG	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.16	-28.1	-0.79	4.23e-102	Height;
LGG	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg11707556	chr5:10655725	ANKRD33B	0.44	7.91	0.35	1.96e-14	Coronary artery disease;
LGG	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg03433033	chr1:76189801	ACADM	0.53	7.46	0.33	4.29e-13	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.62	-11.2	-0.46	6.35e-26	Personality dimensions;
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-10.98	-0.45	4.45e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg02002194	chr4:3960332	NA	0.44	7.92	0.35	1.77e-14	Triglycerides;
LGG	cis	rs61931739	0.583	rs1873010	chr12:33756375	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.83	-0.3	2.63e-11	Morning vs. evening chronotype;
LGG	cis	rs1062177	0.756	rs2964588	chr5:151118386	C/T	cg00977110	chr5:151150581	G3BP1	-0.47	-7.52	-0.33	2.86e-13	Preschool internalizing problems;
LGG	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	18.28	0.65	1.34e-56	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-10.64	-0.44	8.52e-24	Prostate cancer;
LGG	cis	rs883565	0.740	rs6599003	chr3:39093326	A/G	cg01426195	chr3:39028469	NA	0.7	16.04	0.6	2.4e-46	Handedness;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-9.9	-0.42	4.29e-21	Bronchopulmonary dysplasia;
LGG	cis	rs17428076	0.749	rs62182404	chr2:172748162	A/G	cg21435375	chr2:172878103	MAP1D	0.41	7.36	0.32	8.26e-13	Myopia;
LGG	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg18898632	chr2:242989856	NA	-0.78	-9.65	-0.41	3.47e-20	Obesity-related traits;
LGG	cis	rs1707322	0.963	rs12022335	chr1:46402732	C/A	cg03146154	chr1:46216737	IPP	0.54	10.15	0.43	5.47e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg12855166	chr17:30846586	MYO1D	0.39	6.9	0.31	1.74e-11	Schizophrenia;
LGG	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg05468064	chr22:46423449	NA	0.4	7.57	0.33	2.09e-13	Dupuytren's disease;
LGG	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	trans	rs2055729	0.807	rs36102779	chr8:9749609	G/A	cg12395012	chr8:11607386	GATA4	0.42	6.88	0.3	2e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-10.99	-0.45	4.17e-25	Mean platelet volume;Platelet distribution width;
LGG	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg27147174	chr7:100797783	AP1S1	-0.6	-10.48	-0.44	3.44e-23	Life satisfaction;
LGG	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg25811766	chr13:21894605	NA	-0.55	-7.43	-0.33	5.38e-13	White matter hyperintensity burden;
LGG	cis	rs10465746	0.780	rs1324486	chr1:84384825	A/G	cg10977910	chr1:84465055	TTLL7	-0.66	-10.68	-0.44	5.78e-24	Obesity-related traits;
LGG	cis	rs9318086	0.648	rs35449605	chr13:24472582	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.31	0.4	5.14e-19	Myopia (pathological);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25437947	chr8:17941982	ASAH1	0.48	7.06	0.31	6.08e-12	Hip circumference;
LGG	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg15556689	chr8:8085844	FLJ10661	0.44	7.76	0.34	5.61e-14	Mood instability;
LGG	cis	rs7914558	1.000	rs10883824	chr10:104812897	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.72	0.45	4.37e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg24134504	chr18:76639479	NA	-0.47	-8.22	-0.36	2.03e-15	Obesity-related traits;
LGG	cis	rs12476592	0.571	rs262520	chr2:63892432	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.34	-0.36	8.68e-16	Life satisfaction;
LGG	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg20673091	chr1:2541236	MMEL1	-0.77	-17.99	-0.64	2.9e-55	Ulcerative colitis;
LGG	cis	rs11585357	0.895	rs72633806	chr1:17617943	A/G	cg08277548	chr1:17600880	PADI3	-0.74	-8.23	-0.36	1.98e-15	Hair shape;
LGG	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15501526	chr10:2543763	NA	0.69	14.52	0.56	1.28e-39	Age-related hearing impairment;
LGG	cis	rs10779751	0.734	rs1194820	chr1:11129259	A/C	cg08854313	chr1:11322531	MTOR	0.81	16.53	0.61	1.39e-48	Body mass index;
LGG	trans	rs7210837	0.656	rs11649762	chr17:16793254	C/G	cg11294312	chr17:28900046	NA	-0.73	-9.09	-0.39	2.84e-18	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs11718455	1.000	rs3856744	chr3:44045812	T/C	cg21419209	chr3:44054225	NA	-0.44	-7.03	-0.31	7.68e-12	Coronary artery disease;
LGG	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg17646820	chr3:66848679	NA	0.5	7.8	0.34	4.06e-14	Type 2 diabetes;
LGG	cis	rs7208859	0.623	rs170051	chr17:28914153	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.17e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg06606381	chr12:133084897	FBRSL1	-0.54	-6.82	-0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-9.01	-0.39	5.48e-18	Kawasaki disease;
LGG	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg03806693	chr22:41940476	POLR3H	-0.8	-13.16	-0.52	7.8e-34	Vitiligo;
LGG	cis	rs1566085	0.704	rs4382507	chr8:142653848	C/T	cg26331504	chr8:142652174	NA	-0.3	-6.93	-0.31	1.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg20608306	chr11:116969690	SIK3	0.33	8.25	0.36	1.6e-15	Blood protein levels;
LGG	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg14092571	chr14:90743983	NA	-0.74	-15.16	-0.58	1.94e-42	Gut microbiota (bacterial taxa);
LGG	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.83e-11	Red blood cell count;
LGG	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-11.1	-0.46	1.46e-25	Coronary artery disease;
LGG	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.94e-11	Aortic root size;
LGG	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg02002494	chr3:119013045	CDGAP	0.44	6.77	0.3	3.83e-11	Mitral valve prolapse;
LGG	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg07343612	chr16:622815	PIGQ	-0.51	-8.26	-0.36	1.57e-15	Height;
LGG	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg24231037	chr15:68117551	LBXCOR1	0.39	8.59	0.37	1.3e-16	Restless legs syndrome;
LGG	cis	rs977987	0.835	rs1010630	chr16:75328591	G/T	cg03315344	chr16:75512273	CHST6	0.49	9.89	0.42	4.66e-21	Dupuytren's disease;
LGG	cis	rs4750440	0.706	rs10906555	chr10:14016879	G/A	cg00551146	chr10:14014579	FRMD4A	0.28	6.94	0.31	1.35e-11	Adiponectin levels;
LGG	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg16141378	chr3:129829833	LOC729375	0.42	9.52	0.4	9.59e-20	Retinal vascular caliber;
LGG	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg10845886	chr2:3471009	TTC15	-0.48	-9.74	-0.41	1.63e-20	Neurofibrillary tangles;
LGG	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg04842962	chr6:43655489	MRPS18A	1.11	24.06	0.75	1.37e-83	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.11	0.31	4.29e-12	Lung cancer;
LGG	cis	rs698833	0.926	rs698827	chr2:44730496	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-6.9	-0.31	1.73e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs2734839	0.964	rs12800853	chr11:113302514	C/T	cg14159747	chr11:113255604	NA	0.27	6.97	0.31	1.07e-11	Information processing speed;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg23088430	chr8:144679052	EEF1D;TIGD5	0.47	6.8	0.3	3.16e-11	Breast cancer;
LGG	cis	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg12486710	chr1:178512616	C1orf220	0.4	8.13	0.35	3.92e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25072359	chr17:41440525	NA	-0.51	-10.11	-0.43	7.57e-22	Menopause (age at onset);
LGG	cis	rs9640161	0.789	rs2098053	chr7:150043205	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-14.94	-0.57	1.76e-41	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs11645898	0.935	rs4788614	chr16:72188828	C/T	cg14768367	chr16:72042858	DHODH	0.73	10.19	0.43	3.95e-22	Blood protein levels;
LGG	cis	rs7633770	0.643	rs59048074	chr3:46689155	C/T	cg11219411	chr3:46661640	NA	-0.49	-10.68	-0.44	6.08e-24	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs12971120	0.891	rs12608037	chr18:72169395	A/G	cg25817165	chr18:72167213	CNDP2	-0.67	-13.87	-0.54	7.87e-37	Refractive error;
LGG	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg15268244	chr15:77196840	NA	-0.45	-9.87	-0.42	5.7e-21	Blood metabolite levels;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.38	-0.58	2.02e-43	Longevity;
LGG	trans	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg24247370	chr13:99142703	STK24	-0.38	-6.97	-0.31	1.11e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg14829360	chr17:73884958	NA	-0.76	-12.5	-0.5	4.2e-31	Psoriasis;
LGG	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23604584	chr13:50367114	KPNA3	0.39	6.78	0.3	3.78e-11	Bilirubin levels;
LGG	cis	rs6694672	0.681	rs865071	chr1:197017976	G/A	cg13682187	chr1:196946512	CFHR5	0.51	7.06	0.31	6.02e-12	Asthma;
LGG	cis	rs7412746	0.658	rs4970986	chr1:150907955	A/G	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg11812906	chr14:75593930	NEK9	0.54	9.94	0.42	3.15e-21	Height;
LGG	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.58	6.92	0.31	1.54e-11	Endometriosis;
LGG	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg05791153	chr7:19748676	TWISTNB	0.75	9.1	0.39	2.78e-18	Thyroid stimulating hormone;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.31	0.4	5.23e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg11301795	chr4:187892539	NA	-0.93	-23.83	-0.74	1.74e-82	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg03929089	chr4:120376271	NA	0.74	7.83	0.34	3.38e-14	Axial length;
LGG	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg02466173	chr16:30829666	NA	-0.41	-7.09	-0.31	5.03e-12	Dementia with Lewy bodies;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	17.18	0.62	1.55e-51	Platelet count;
LGG	cis	rs4740619	0.810	rs6474952	chr9:15711234	A/C	cg14451791	chr9:16040625	NA	-0.33	-8.39	-0.36	5.96e-16	Body mass index;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.65	0.41	3.42e-20	Longevity;
LGG	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.85	-0.34	2.83e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7937890	0.559	rs2597217	chr11:14532883	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs6088590	1.000	rs6119516	chr20:33328024	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.93	0.42	3.34e-21	Coronary artery disease;
LGG	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg05535760	chr7:792225	HEATR2	-0.79	-10.41	-0.44	6.14e-23	Cerebrospinal P-tau181p levels;
LGG	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg18850127	chr7:39170497	POU6F2	0.54	13.32	0.53	1.64e-34	IgG glycosylation;
LGG	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg16141378	chr3:129829833	LOC729375	0.35	7.76	0.34	5.48e-14	Retinal vascular caliber;
LGG	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg09818912	chr17:20140352	CYTSB	0.3	7.05	0.31	6.53e-12	Schizophrenia;
LGG	trans	rs7944735	0.817	rs6485774	chr11:47773226	C/T	cg03929089	chr4:120376271	NA	0.56	6.91	0.31	1.57e-11	Intraocular pressure;
LGG	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.41	2.16e-20	Morning vs. evening chronotype;
LGG	trans	rs17685	0.753	rs1637037	chr7:75692927	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs1371867	0.817	rs1788179	chr8:101333345	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg26384229	chr12:38710491	ALG10B	0.87	20.51	0.69	5.84e-67	Heart rate;
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg09060608	chr5:178986726	RUFY1	-0.51	-8.59	-0.37	1.33e-16	Lung cancer;
LGG	cis	rs870825	0.929	rs72689255	chr4:185590141	T/C	cg04058563	chr4:185651563	MLF1IP	1.07	19.62	0.67	8.25e-63	Blood protein levels;
LGG	cis	rs2652822	0.935	rs12148069	chr15:63443792	A/T	cg02713581	chr15:63449717	RPS27L	0.49	8.37	0.36	6.67e-16	Metabolic traits;
LGG	cis	rs10883723	0.810	rs10883728	chr10:104269301	A/G	cg05096777	chr10:104283225	SUFU	-0.33	-7.17	-0.32	3e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6921919	0.832	rs17312661	chr6:28300336	A/G	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.41	-0.33	5.97e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.71	-11.83	-0.48	2.14e-28	Mean platelet volume;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg11168104	chr5:1857477	NA	-0.41	-6.82	-0.3	2.94e-11	Cardiovascular disease risk factors;
LGG	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.86	13.68	0.54	5.07e-36	Cognitive test performance;
LGG	trans	rs9354308	0.764	rs1938098	chr6:66599700	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.24	0.46	4.23e-26	Bone mineral density;
LGG	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24110177	chr3:50126178	RBM5	0.58	10.75	0.45	3.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.45	0.37	3.7e-16	Mood instability;
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg18245976	chr7:158708271	WDR60	-0.57	-10.09	-0.42	8.69e-22	Height;
LGG	cis	rs526231	0.578	rs10463553	chr5:102249207	T/C	cg23492399	chr5:102201601	PAM	-0.61	-9.33	-0.4	4.51e-19	Primary biliary cholangitis;
LGG	cis	rs1620921	0.505	rs11756434	chr6:161201356	T/C	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg00376283	chr12:123451042	ABCB9	0.65	11.41	0.47	9.8e-27	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs4474465	0.920	rs7125628	chr11:78223028	C/G	cg27205649	chr11:78285834	NARS2	0.48	8.35	0.36	7.69e-16	Alzheimer's disease (survival time);
LGG	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs972578	0.765	rs5758982	chr22:43244723	A/T	cg01576275	chr22:43409880	NA	-0.23	-6.86	-0.3	2.29e-11	Mean platelet volume;
LGG	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.83	-0.42	8.06e-21	Mood instability;
LGG	cis	rs10779751	1.000	rs11121711	chr1:11317661	A/T	cg08854313	chr1:11322531	MTOR	0.75	16.5	0.61	1.94e-48	Body mass index;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.39	-0.36	5.87e-16	Personality dimensions;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.79e-11	Personality dimensions;
LGG	cis	rs1707322	0.686	rs2230659	chr1:46078884	C/T	cg03146154	chr1:46216737	IPP	-0.57	-10.96	-0.45	5.4e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.85	-0.42	6.55e-21	Personality dimensions;
LGG	trans	rs9354308	0.738	rs9294666	chr6:66598420	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg07636037	chr3:49044803	WDR6	0.99	21.94	0.71	1.11e-73	Menarche (age at onset);
LGG	cis	rs3806843	0.576	rs251370	chr5:140246287	C/T	cg19875535	chr5:140030758	IK	-0.38	-7.6	-0.33	1.62e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs36715	0.951	rs36698	chr5:127549749	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	7.44	0.33	4.84e-13	Breast cancer;
LGG	cis	rs2742417	1.000	rs2742432	chr3:45737467	G/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.43e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs12545109	0.800	rs2576592	chr8:57419357	A/C	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg15704280	chr7:45808275	SEPT13	-0.97	-19.39	-0.67	9.28e-62	Height;
LGG	trans	rs2562456	0.754	rs58338799	chr19:21521811	G/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg00339695	chr16:24857497	SLC5A11	0.4	6.97	0.31	1.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs62238980	0.614	rs74924328	chr22:32416228	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg04617936	chr2:214353	NA	-0.37	-6.68	-0.3	7.02e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg03188948	chr7:1209495	NA	0.4	6.79	0.3	3.54e-11	Longevity;Endometriosis;
LGG	trans	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg06521331	chr12:34319734	NA	0.42	7.63	0.33	1.36e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs757081	0.648	rs12276859	chr11:17276965	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.77	-0.34	5.19e-14	Systolic blood pressure;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg07460842	chr6:66804631	NA	0.57	9.51	0.4	1e-19	Metabolite levels;
LGG	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.23	-0.36	1.86e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.33	-0.36	9.01e-16	Educational attainment;
LGG	cis	rs4845570	0.834	rs7007	chr1:151735576	T/C	cg07092448	chr1:151763213	TDRKH	-1.07	-15.81	-0.59	2.5e-45	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15929201	chr5:31531945	RNASEN;C5orf22	0.44	6.84	0.3	2.58e-11	Gut microbiome composition (summer);
LGG	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs7264396	0.635	rs6060692	chr20:34517925	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	7.25	0.32	1.8e-12	Total cholesterol levels;
LGG	cis	rs9357271	0.956	rs4714151	chr6:38341991	G/A	cg07362130	chr6:38359646	BTBD9	-0.42	-8.93	-0.38	1.02e-17	Restless legs syndrome;
LGG	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg08250081	chr4:10125330	NA	0.43	8.49	0.37	2.77e-16	Bone mineral density;
LGG	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-7.23	-0.32	1.97e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs490234	0.702	rs5016056	chr9:128310807	C/T	cg14078157	chr9:128172775	NA	-0.55	-10.35	-0.43	9.74e-23	Mean arterial pressure;
LGG	cis	rs8133932	0.701	rs9653780	chr21:47303774	A/G	cg11214348	chr21:47283868	PCBP3	0.44	8.02	0.35	8.74e-15	Schizophrenia;
LGG	cis	rs4740619	0.544	rs9298738	chr9:15833445	T/C	cg14451791	chr9:16040625	NA	0.31	7.45	0.33	4.62e-13	Body mass index;
LGG	cis	rs9356171	0.572	rs11756250	chr6:164325686	A/G	cg25752492	chr6:164341247	NA	-0.46	-9.26	-0.4	7.65e-19	Diisocyanate-induced asthma;
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg10207240	chr12:122356781	WDR66	0.26	7.92	0.35	1.74e-14	Mean platelet volume;
LGG	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg00376283	chr12:123451042	ABCB9	0.67	12.47	0.5	5.68e-31	Platelet count;
LGG	cis	rs2976388	0.609	rs2263092	chr8:143789966	A/G	cg06565975	chr8:143823917	SLURP1	0.35	9.09	0.39	2.97e-18	Urinary tract infection frequency;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.84e-16	Lung cancer;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01171360	chr6:293285	DUSP22	-0.58	-9.6	-0.41	5.16e-20	Menopause (age at onset);
LGG	cis	rs10791097	0.935	rs4601795	chr11:130729430	T/C	cg12179176	chr11:130786555	SNX19	0.75	14.23	0.55	2.33e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2070488	0.930	rs2370840	chr3:38529825	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.89	19.47	0.67	4.01e-62	Electrocardiographic conduction measures;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg11608241	chr8:8085544	FLJ10661	-0.34	-7.72	-0.34	7e-14	Triglycerides;
LGG	trans	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg22358067	chr17:16797159	NA	-0.5	-7.13	-0.31	3.85e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg09795085	chr6:101329169	ASCC3	0.45	7.63	0.33	1.33e-13	Neuroticism;
LGG	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg24764310	chr7:157512201	PTPRN2	-0.46	-8.72	-0.38	4.87e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg20503657	chr10:835505	NA	0.65	9.57	0.41	6.51e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	trans	rs61931739	0.511	rs116844963	chr12:33648783	A/T	cg26384229	chr12:38710491	ALG10B	-0.46	-8.0	-0.35	9.99e-15	Morning vs. evening chronotype;
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07167872	chr1:205819463	PM20D1	0.5	10.02	0.42	1.63e-21	Menarche (age at onset);
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs12780845	0.540	rs2295809	chr10:17199871	A/T	cg01003015	chr10:17271136	VIM	-0.45	-7.6	-0.33	1.65e-13	Homocysteine levels;
LGG	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22601191	chr20:60968625	CABLES2	0.46	7.23	0.32	2.06e-12	Colorectal cancer;
LGG	cis	rs4417704	0.551	rs4334491	chr2:241892478	G/A	cg05025159	chr2:241905733	NA	0.51	10.55	0.44	1.78e-23	Joint mobility (Beighton score);
LGG	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg27535305	chr1:53392650	SCP2	-0.34	-7.91	-0.35	1.87e-14	Monocyte count;
LGG	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg10402321	chr1:26617780	UBXN11	-0.36	-7.07	-0.31	5.67e-12	Obesity-related traits;
LGG	cis	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	8.17	0.35	2.95e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.85	-0.48	1.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg21545522	chr1:205238299	TMCC2	0.37	7.02	0.31	7.81e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.93e-22	Asthma (sex interaction);
LGG	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.87	-0.34	2.57e-14	HDL cholesterol;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg19147804	chr7:1989927	MAD1L1	-0.6	-12.08	-0.49	2.24e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg07022442	chr13:21864356	NA	-0.4	-7.04	-0.31	7.07e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.14	-0.52	9.5e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg05526886	chr2:227700861	RHBDD1	-0.43	-7.64	-0.33	1.3e-13	Pulmonary function;
LGG	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg08250081	chr4:10125330	NA	0.36	7.06	0.31	6.28e-12	Bone mineral density;
LGG	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg21827317	chr3:136751795	NA	0.53	9.95	0.42	2.77e-21	Neuroticism;
LGG	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs75804782	0.581	rs55931535	chr2:239372632	A/G	cg01134436	chr17:81009848	B3GNTL1	0.82	8.66	0.37	8.16e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.99	-0.31	9.45e-12	Menopause (age at onset);
LGG	cis	rs193541	0.593	rs154499	chr5:122219666	A/C	cg19412675	chr5:122181750	SNX24	0.54	8.66	0.37	7.8e-17	Glucose homeostasis traits;
LGG	cis	rs638893	0.947	rs515707	chr11:118685481	T/C	cg22253036	chr11:118662786	DDX6	0.44	7.56	0.33	2.14e-13	Vitiligo;
LGG	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg07549998	chr6:150325970	RAET1K	-0.37	-6.96	-0.31	1.14e-11	Alopecia areata;
LGG	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg20476274	chr7:133979776	SLC35B4	0.51	9.04	0.39	4.32e-18	Mean platelet volume;
LGG	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg15103426	chr22:29168792	CCDC117	0.66	9.7	0.41	2.23e-20	Lymphocyte counts;
LGG	cis	rs7651039	0.619	rs924814	chr3:15649550	G/A	cg16303742	chr3:15540471	COLQ	0.6	12.1	0.49	1.81e-29	Coronary heart disease;
LGG	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg16414030	chr3:133502952	NA	-0.59	-10.14	-0.43	5.78e-22	Iron status biomarkers;
LGG	cis	rs6594713	0.648	rs36023163	chr5:112891009	A/G	cg12552261	chr5:112820674	MCC	0.64	7.87	0.34	2.54e-14	Brain cytoarchitecture;
LGG	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.06	0.42	1.14e-21	Diabetic retinopathy;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.63e-13	Prudent dietary pattern;
LGG	cis	rs11748327	0.543	rs2398655	chr5:4085030	A/G	cg01025095	chr5:4101132	NA	-0.63	-10.29	-0.43	1.74e-22	Myocardial infarction;
LGG	cis	rs877282	0.945	rs10904554	chr10:786768	T/C	cg17470449	chr10:769945	NA	0.62	7.66	0.34	1.06e-13	Uric acid levels;
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg11473876	chr11:109292803	C11orf87	0.46	9.37	0.4	3.11e-19	Schizophrenia;
LGG	cis	rs870825	0.616	rs7682557	chr4:185640773	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs16854884	0.526	rs7643341	chr3:143726980	C/T	cg06585982	chr3:143692056	C3orf58	0.6	10.33	0.43	1.15e-22	Economic and political preferences (feminism/equality);
LGG	cis	rs2718058	0.606	rs2722247	chr7:37869308	C/T	cg24998770	chr7:37888106	TXNDC3	-0.45	-7.38	-0.32	7.51e-13	Alzheimer's disease (late onset);
LGG	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg09998033	chr7:158218633	PTPRN2	-0.56	-10.32	-0.43	1.35e-22	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23806411	chr16:49890167	NA	-0.43	-6.8	-0.3	3.24e-11	Pancreatic cancer;
LGG	cis	rs7172689	0.908	rs11633024	chr15:81561359	C/T	cg11808699	chr15:81528661	IL16	0.42	8.97	0.38	7.4e-18	Inattentive symptoms;
LGG	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg02227867	chr8:22457446	C8orf58	-0.41	-7.94	-0.35	1.54e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18404041	chr3:52824283	ITIH1	0.55	10.54	0.44	1.94e-23	Bipolar disorder;
LGG	cis	rs6547631	0.622	rs1437743	chr2:85924989	A/G	cg24620635	chr2:85921963	GNLY	-0.49	-9.65	-0.41	3.32e-20	Blood protein levels;
LGG	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg11766577	chr21:47581405	C21orf56	-0.41	-6.79	-0.3	3.37e-11	Testicular germ cell tumor;
LGG	cis	rs9487051	1.000	rs9487052	chr6:109617086	C/T	cg21918786	chr6:109611834	NA	-0.44	-8.2	-0.36	2.43e-15	Reticulocyte fraction of red cells;
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg19539972	chr4:7069911	GRPEL1	-0.66	-9.65	-0.41	3.36e-20	Monocyte percentage of white cells;
LGG	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg06092702	chr1:163392909	NA	-0.47	-8.26	-0.36	1.49e-15	Motion sickness;
LGG	trans	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.76	-0.41	1.34e-20	Diabetic kidney disease;
LGG	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg25358565	chr5:93447407	FAM172A	1.19	14.69	0.56	2.19e-40	Diabetic retinopathy;
LGG	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg06611532	chr13:114900021	NA	0.28	6.93	0.31	1.4e-11	Schizophrenia;
LGG	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.83	0.34	3.46e-14	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.76	-0.3	4.09e-11	Lung cancer;
LGG	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg24611264	chr11:120008944	TRIM29	0.38	9.85	0.42	6.74e-21	Stroke (pediatric);
LGG	cis	rs34734847	1.000	rs55730005	chr12:121157536	C/A	cg21892295	chr12:121157589	UNC119B	-0.47	-8.96	-0.38	8.23e-18	Mean corpuscular volume;
LGG	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-10.17	-0.43	4.46e-22	Common traits (Other);
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.54	0.44	1.92e-23	Obesity-related traits;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg24101359	chr6:42928495	GNMT	0.52	14.95	0.57	1.6e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.7	-0.45	4.88e-24	Lung cancer;
LGG	cis	rs910316	1.000	rs175425	chr14:75626131	T/C	cg08847533	chr14:75593920	NEK9	-0.59	-11.11	-0.46	1.37e-25	Height;
LGG	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg12386194	chr3:101231763	SENP7	0.42	7.52	0.33	2.8e-13	Colorectal cancer;
LGG	cis	rs11748327	0.543	rs2174979	chr5:4086086	T/C	cg01025095	chr5:4101132	NA	-0.63	-10.24	-0.43	2.55e-22	Myocardial infarction;
LGG	cis	rs6500395	1.000	rs12599028	chr16:48713082	C/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs1018836	0.828	rs1858673	chr8:91551526	C/A	cg16814680	chr8:91681699	NA	-0.72	-12.99	-0.52	4.06e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg05863683	chr7:1912471	MAD1L1	-0.43	-8.56	-0.37	1.65e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22981628	chr17:27332559	SEZ6	0.5	7.55	0.33	2.26e-13	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg09307838	chr4:120376055	NA	0.73	12.11	0.49	1.57e-29	Corneal astigmatism;
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19524238	chr7:2802976	GNA12	0.34	8.24	0.36	1.76e-15	Height;
LGG	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.97	-0.52	4.98e-33	Gut microbiome composition (summer);
LGG	cis	rs1775715	0.737	rs2808072	chr10:32205504	A/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.7	0.3	5.92e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs2013441	1.000	rs9915059	chr17:20177104	G/T	cg13482628	chr17:19912719	NA	-0.52	-9.04	-0.39	4.26e-18	Obesity-related traits;
LGG	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg16141378	chr3:129829833	LOC729375	0.32	7.28	0.32	1.48e-12	Monocyte count;
LGG	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.38	-0.32	7.54e-13	Refractive error;
LGG	cis	rs1018836	0.632	rs6988302	chr8:91477660	C/T	cg16814680	chr8:91681699	NA	-0.67	-11.42	-0.47	8.54e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.67	0.61	3.3e-49	Smoking behavior;
LGG	cis	rs6467136	0.623	rs12671806	chr7:127147628	A/G	cg25922125	chr7:127225783	GCC1	-0.43	-6.78	-0.3	3.64e-11	Type 2 diabetes;
LGG	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg05791153	chr7:19748676	TWISTNB	1.16	16.19	0.6	4.7e-47	Thyroid stimulating hormone;
LGG	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg18252515	chr7:66147081	NA	-1.36	-14.4	-0.56	4.16e-39	Diabetic kidney disease;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.85e-12	Menopause (age at onset);
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2373794	0.845	rs6755509	chr2:40372924	C/T	cg17740179	chr2:40377776	SLC8A1	-0.9	-19.13	-0.66	1.5e-60	Asthma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10179964	chr12:2113874	DCP1B	0.4	6.66	0.3	7.87e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.88	-0.3	1.95e-11	Resting heart rate;
LGG	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.5	0.81	2.16e-108	Dental caries;
LGG	cis	rs490234	0.841	rs10123054	chr9:128452054	C/T	cg14078157	chr9:128172775	NA	-0.42	-7.64	-0.33	1.22e-13	Mean arterial pressure;
LGG	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg13010199	chr12:38710504	ALG10B	0.6	12.05	0.49	2.81e-29	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.619	rs12530799	chr7:19782793	G/A	cg07541023	chr7:19748670	TWISTNB	0.53	7.89	0.34	2.25e-14	Thyroid stimulating hormone;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg05863683	chr7:1912471	MAD1L1	0.43	8.39	0.36	5.98e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7202877	0.656	rs4888374	chr16:75322228	T/C	cg03315344	chr16:75512273	CHST6	0.51	6.96	0.31	1.18e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs793571	0.590	rs673813	chr15:59077171	A/T	cg05156742	chr15:59063176	FAM63B	0.6	10.18	0.43	4.2e-22	Schizophrenia;
LGG	cis	rs11677416	1.000	rs1800587	chr2:113542960	C/T	cg27083787	chr2:113543245	IL1A	0.52	8.62	0.37	1.07e-16	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs4740619	0.905	rs10756704	chr9:15783816	C/T	cg14451791	chr9:16040625	NA	-0.38	-9.76	-0.41	1.39e-20	Body mass index;
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg05941027	chr17:61774174	LIMD2	0.36	9.1	0.39	2.78e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg22535103	chr8:58192502	C8orf71	-0.47	-7.44	-0.33	5.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg22907277	chr7:1156413	C7orf50	0.67	8.47	0.37	3.23e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4076764	0.801	rs4571944	chr1:163367975	T/C	cg06092702	chr1:163392909	NA	-0.41	-7.2	-0.32	2.4e-12	Motion sickness;
LGG	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg09029085	chr17:47094198	IGF2BP1	0.32	8.83	0.38	2.2e-17	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs66573146	0.831	rs73088564	chr4:6984553	G/C	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9976767	0.792	rs883869	chr21:43844840	T/C	cg23042151	chr21:43824109	UBASH3A	-0.46	-9.46	-0.4	1.6e-19	Type 1 diabetes;
LGG	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03352830	chr11:487213	PTDSS2	0.86	11.34	0.47	1.76e-26	Body mass index;
LGG	cis	rs4432842	1.000	rs4254858	chr5:57172368	C/T	cg08523694	chr5:57076192	NA	0.48	9.29	0.4	6e-19	Birth weight;
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg10505658	chr17:80084571	CCDC57	0.33	6.76	0.3	4.19e-11	Life satisfaction;
LGG	cis	rs4731207	0.596	rs7795199	chr7:124578345	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.84	-0.3	2.53e-11	Cutaneous malignant melanoma;
LGG	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg05696931	chr1:227175867	NA	-0.38	-7.22	-0.32	2.13e-12	Myeloid white cell count;
LGG	cis	rs7927771	0.507	rs11039432	chr11:47873327	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	1.92e-25	Subjective well-being;
LGG	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg16794390	chr17:18148240	FLII	0.35	8.57	0.37	1.61e-16	Parental longevity (combined parental age at death);
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.62	-0.44	9.73e-24	Lung cancer;
LGG	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg11812906	chr14:75593930	NEK9	-0.51	-9.44	-0.4	1.76e-19	Height;
LGG	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg17054900	chr3:154042577	DHX36	0.49	7.42	0.33	5.68e-13	Coronary artery disease;
LGG	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs25645	0.830	rs3935281	chr17:38188419	C/T	cg17467752	chr17:38218738	THRA	-0.63	-10.77	-0.45	2.67e-24	Myeloid white cell count;
LGG	cis	rs6429082	0.702	rs10802797	chr1:235705673	A/G	cg26050004	chr1:235667680	B3GALNT2	0.5	7.76	0.34	5.38e-14	Adiposity;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.65	0.3	8.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.36	0.36	7.35e-16	Retinal vascular caliber;
LGG	cis	rs6834538	0.692	rs116138196	chr4:113399192	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	7.64	0.33	1.27e-13	Free thyroxine concentration;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.72e-13	Platelet count;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg11168104	chr5:1857477	NA	-0.4	-7.07	-0.31	5.75e-12	Cardiovascular disease risk factors;
LGG	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg00579200	chr11:133705235	NA	0.58	11.21	0.46	5.64e-26	Childhood ear infection;
LGG	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg07803811	chr1:43423981	SLC2A1	0.48	9.37	0.4	3.19e-19	Red cell distribution width;
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg03517284	chr6:25882590	NA	-0.39	-6.99	-0.31	9.73e-12	Height;
LGG	cis	rs7617773	0.963	rs12495221	chr3:48179178	C/T	cg11946769	chr3:48343235	NME6	-0.5	-8.13	-0.35	3.87e-15	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18455759	chr8:126443767	TRIB1	0.4	6.73	0.3	4.88e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg03528353	chr17:61819722	STRADA	-0.41	-6.72	-0.3	5.44e-11	Prudent dietary pattern;
LGG	cis	rs9783347	0.754	rs4757637	chr11:18307575	G/T	cg15585147	chr11:18324498	HPS5	0.4	8.71	0.38	5.34e-17	Pancreatic cancer;
LGG	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.11	0.52	1.3e-33	Bladder cancer;
LGG	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs1015291	0.700	rs2220683	chr12:19995503	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg18446336	chr7:2847575	GNA12	-0.31	-8.14	-0.35	3.78e-15	Height;
LGG	cis	rs7408868	0.908	rs10416777	chr19:15276923	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg10621924	chr7:39171070	POU6F2	0.44	9.09	0.39	2.92e-18	IgG glycosylation;
LGG	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.07	0.31	5.76e-12	Bladder cancer;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.33	-0.36	8.91e-16	Longevity;Endometriosis;
LGG	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg01631408	chr1:248437212	OR2T33	-0.56	-10.11	-0.43	7.73e-22	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26059219	chr3:4508837	SUMF1	0.51	7.9	0.34	2.09e-14	Gut microbiome composition (summer);
LGG	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg21453758	chr17:80185943	SLC16A3	0.35	7.14	0.32	3.55e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs804280	0.662	rs11250164	chr8:11610686	C/T	cg12395012	chr8:11607386	GATA4	0.61	10.12	0.43	7.1e-22	Myopia (pathological);
LGG	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg08468577	chr11:2973342	NAP1L4	0.37	7.81	0.34	3.88e-14	Calcium levels;
LGG	cis	rs7188861	0.861	rs1968268	chr16:11446223	G/A	cg01510278	chr16:11456238	NA	-0.34	-7.9	-0.34	2.12e-14	HDL cholesterol;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg05368731	chr17:41323189	NBR1	0.95	18.86	0.66	2.81e-59	Menopause (age at onset);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg22963979	chr7:1858916	MAD1L1	-0.4	-7.9	-0.34	2.07e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs12541491	0.506	rs11250007	chr8:10285086	C/G	cg12940923	chr8:10282607	MSRA	-0.3	-6.92	-0.31	1.48e-11	Schizophrenia;
LGG	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg19507638	chr5:93509721	C5orf36	0.41	7.25	0.32	1.73e-12	Diabetic retinopathy;
LGG	cis	rs3087591	0.708	rs4794887	chr17:29649696	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg16662043	chr16:48846231	NA	0.34	6.68	0.3	6.7e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.52	-0.67	2.34e-62	Blood trace element (Zn levels);
LGG	cis	rs2346177	0.554	rs13002880	chr2:46708129	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.15	0.39	1.82e-18	HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01222684	chr5:159435961	TTC1	0.41	6.71	0.3	5.77e-11	Cognitive performance;
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.88	-0.34	2.36e-14	Neuroticism;
LGG	cis	rs2236918	1.000	rs2526701	chr1:242018427	T/C	cg17736920	chr1:242011382	EXO1	0.52	9.39	0.4	2.68e-19	Menopause (age at onset);
LGG	cis	rs2133450	0.712	rs35202421	chr3:7365899	C/T	cg19930620	chr3:7340148	GRM7	-0.38	-8.21	-0.36	2.29e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs35740288	0.721	rs11636347	chr15:86241233	A/G	cg04173714	chr15:86211321	AKAP13	0.46	7.85	0.34	2.89e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg18876405	chr7:65276391	NA	-0.44	-7.66	-0.34	1.11e-13	Calcium levels;
LGG	cis	rs36051895	0.632	rs62541899	chr9:5143291	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-14.34	-0.55	7.27e-39	Pediatric autoimmune diseases;
LGG	cis	rs56283067	0.578	rs1321078	chr6:45368214	G/T	cg18551225	chr6:44695536	NA	-0.58	-8.51	-0.37	2.37e-16	Total body bone mineral density;
LGG	cis	rs4642101	0.737	rs9877165	chr3:12828497	C/T	cg05775895	chr3:12838266	CAND2	0.64	11.45	0.47	6.62e-27	QRS complex (12-leadsum);
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.37	0.4	3.27e-19	Systolic blood pressure;
LGG	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.53	-0.37	2.11e-16	Monocyte count;
LGG	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	-0.41	-6.92	-0.31	1.49e-11	Resistin levels;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs10463554	0.927	rs34821	chr5:102437617	T/A	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs7523050	0.643	rs34920128	chr1:109400889	C/T	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08280861	chr8:58055591	NA	0.53	6.8	0.3	3.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg21775007	chr8:11205619	TDH	0.83	15.24	0.58	8.38e-43	Retinal vascular caliber;
LGG	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg03476357	chr21:30257390	N6AMT1	-0.51	-7.46	-0.33	4.29e-13	Cognitive test performance;
LGG	trans	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.81	0.34	3.8e-14	Retinal vascular caliber;
LGG	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg19761014	chr17:28927070	LRRC37B2	0.6	7.22	0.32	2.09e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7659604	0.935	rs73844280	chr4:122664687	G/A	cg20573242	chr4:122745356	CCNA2	0.42	7.79	0.34	4.34e-14	Type 2 diabetes;
LGG	cis	rs782590	0.967	rs782586	chr2:55836165	A/C	cg18811423	chr2:55921094	PNPT1	0.89	20.68	0.69	9.14e-68	Metabolic syndrome;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.21	-0.32	2.25e-12	Bipolar disorder;
LGG	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg13010199	chr12:38710504	ALG10B	0.6	11.88	0.48	1.39e-28	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg09699651	chr6:150184138	LRP11	0.47	8.36	0.36	7.26e-16	Lung cancer;
LGG	cis	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg26116260	chr4:7069785	GRPEL1	-0.99	-8.69	-0.37	6.07e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg19414122	chr8:18896631	NA	0.48	8.78	0.38	3.08e-17	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg07636037	chr3:49044803	WDR6	0.94	20.25	0.69	8.87e-66	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg12070911	chr6:150209640	RAET1E	0.31	7.64	0.33	1.24e-13	Lung cancer;
LGG	cis	rs12519773	0.717	rs6557063	chr5:92493318	T/C	cg18783429	chr5:92414398	NA	0.27	6.82	0.3	2.9e-11	Migraine;
LGG	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.63	0.48	1.36e-27	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg05791153	chr7:19748676	TWISTNB	0.74	9.93	0.42	3.51e-21	Thyroid stimulating hormone;
LGG	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg16141378	chr3:129829833	LOC729375	0.37	8.4	0.36	5.41e-16	Morning vs. evening chronotype;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.66e-12	Cognitive ability;
LGG	trans	rs10838798	0.584	rs4752899	chr11:48141855	T/G	cg15704280	chr7:45808275	SEPT13	-0.43	-6.79	-0.3	3.47e-11	Height;
LGG	cis	rs939658	0.967	rs7172074	chr15:79452726	T/C	cg17916960	chr15:79447300	NA	0.63	12.14	0.49	1.18e-29	Refractive error;
LGG	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11644478	chr21:40555479	PSMG1	0.9	17.28	0.63	5.24e-52	Cognitive function;
LGG	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg24253500	chr15:84953950	NA	0.5	8.76	0.38	3.72e-17	Schizophrenia;
LGG	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs12493885	0.769	rs61791540	chr3:153757041	G/A	cg17054900	chr3:154042577	DHX36	-0.7	-8.79	-0.38	2.85e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.6	-0.37	1.23e-16	Retinal vascular caliber;
LGG	cis	rs12282928	0.657	rs10838826	chr11:48219812	G/T	cg26585981	chr11:48327164	OR4S1	-0.39	-6.76	-0.3	4.17e-11	Migraine - clinic-based;
LGG	cis	rs7937612	1.000	rs7937612	chr11:120278688	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.0	-0.52	3.78e-33	Intraocular pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13464496	chr1:28100114	STX12	0.43	6.78	0.3	3.62e-11	Gut microbiome composition (summer);
LGG	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg18198730	chr1:247681584	NA	0.73	12.28	0.5	3.21e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs283228	0.798	rs283216	chr6:101762076	T/G	cg27451362	chr6:101846650	GRIK2	0.63	10.41	0.44	5.99e-23	Coenzyme Q10 levels;
LGG	cis	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.75	-0.34	5.77e-14	Morning vs. evening chronotype;
LGG	cis	rs35740288	0.822	rs17636864	chr15:86234589	A/C	cg04173714	chr15:86211321	AKAP13	0.47	8.18	0.36	2.78e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.18	0.67	9.21e-61	Platelet count;
LGG	cis	rs13040088	1.000	rs6090155	chr20:61527378	G/A	cg23096297	chr20:61557774	DIDO1	0.9	12.73	0.51	5.09e-32	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg02725872	chr8:58115012	NA	-1.06	-14.8	-0.57	7.59e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg16797656	chr11:68205561	LRP5	0.4	7.1	0.31	4.64e-12	Total body bone mineral density;
LGG	cis	rs11969893	0.850	rs9386260	chr6:101329428	G/A	cg12253828	chr6:101329408	ASCC3	1.21	10.17	0.43	4.76e-22	Economic and political preferences (immigration/crime);
LGG	cis	rs2224391	0.704	rs17139985	chr6:5261603	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.11	-0.35	4.58e-15	Height;
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg13047869	chr3:10149882	C3orf24	0.54	8.98	0.39	6.63e-18	Alzheimer's disease;
LGG	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.68	-0.37	6.64e-17	Coronary artery disease;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs911555	0.511	rs8007489	chr14:104054572	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-8.32	-0.36	9.78e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2455799	0.533	rs924754	chr3:15756215	A/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.49	-0.33	3.63e-13	Mean platelet volume;
LGG	cis	rs2735413	0.881	rs12918547	chr16:78082746	G/A	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6450176	1.000	rs3776705	chr5:53304955	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.23	-0.7	2.33e-70	Heart rate;
LGG	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg17376030	chr22:41985996	PMM1	-0.55	-8.89	-0.38	1.41e-17	Vitiligo;
LGG	cis	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg14228332	chr4:119757509	SEC24D	0.68	7.41	0.33	5.96e-13	Cannabis dependence symptom count;
LGG	cis	rs13082711	0.554	rs10514679	chr3:27412591	A/G	cg02860705	chr3:27208620	NA	0.89	15.6	0.59	2.11e-44	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg06873352	chr17:61820015	STRADA	-0.74	-13.42	-0.53	6.43e-35	Prudent dietary pattern;
LGG	cis	rs4493873	1.000	rs10095630	chr8:92071264	C/A	cg16814680	chr8:91681699	NA	0.48	7.24	0.32	1.86e-12	Migraine - clinic-based;
LGG	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22857025	chr5:266934	NA	-1.48	-25.89	-0.77	4.65e-92	Breast cancer;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg08888203	chr3:10149979	C3orf24	0.56	9.15	0.39	1.78e-18	Alzheimer's disease;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.57	0.33	2.07e-13	Lung cancer;
LGG	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg20891283	chr12:69753455	YEATS4	0.84	15.08	0.57	4.18e-42	Response to diuretic therapy;
LGG	cis	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.05	-0.46	2.38e-25	Resting heart rate;
LGG	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg03264133	chr6:25882463	NA	0.45	8.37	0.36	6.99e-16	Blood metabolite levels;
LGG	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg26441486	chr22:50317300	CRELD2	-0.39	-7.02	-0.31	7.9e-12	Schizophrenia;
LGG	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg14983838	chr19:29218262	NA	0.55	7.09	0.31	5.03e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg22232500	chr2:134024266	NCKAP5	0.56	7.84	0.34	3.24e-14	Bipolar disorder;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.9	-19.43	-0.67	6.05e-62	Personality dimensions;
LGG	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.9	10.32	0.43	1.26e-22	Diabetic retinopathy;
LGG	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.3	-0.58	4.57e-43	Chronic sinus infection;
LGG	cis	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.17	-0.46	8.19e-26	Resting heart rate;
LGG	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-13.71	-0.54	3.77e-36	Blood metabolite levels;
LGG	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg00012203	chr2:219082015	ARPC2	-0.77	-14.71	-0.56	1.8e-40	Colorectal cancer;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg11905131	chr22:24372483	LOC391322	-0.39	-6.78	-0.3	3.59e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11931598	0.702	rs10937780	chr4:7048842	A/G	cg26116260	chr4:7069785	GRPEL1	-0.53	-9.29	-0.4	6.18e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg23740940	chr11:68924746	NA	0.44	7.09	0.31	5.15e-12	Blond vs. brown hair color;
LGG	cis	rs774359	0.744	rs895021	chr9:27484911	G/A	cg14173147	chr9:27528300	MOBKL2B	0.47	8.63	0.37	9.97e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg11757124	chr7:157526947	PTPRN2	-0.79	-15.6	-0.59	2.24e-44	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg07701084	chr6:150067640	NUP43	0.7	13.08	0.52	1.71e-33	Lung cancer;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg02153584	chr22:29168773	CCDC117	0.69	11.88	0.48	1.38e-28	Lymphocyte counts;
LGG	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg04826882	chr13:114838756	RASA3	-0.61	-9.55	-0.41	7.65e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.3	-0.5	2.66e-30	Resting heart rate;
LGG	cis	rs7215564	0.908	rs35071767	chr17:78652575	A/G	cg16980736	chr17:78789706	RPTOR	-0.63	-8.42	-0.36	4.75e-16	Myopia (pathological);
LGG	cis	rs7129556	0.737	rs7951033	chr11:77534444	G/A	cg12586386	chr11:77299805	AQP11	-0.45	-7.4	-0.33	6.52e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.81	0.41	9.2e-21	Colorectal cancer;
LGG	trans	rs4942242	0.640	rs17538959	chr13:44229911	T/G	cg19169023	chr15:41853346	TYRO3	-0.45	-8.94	-0.38	9.23e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9868809	0.772	rs12107252	chr3:48691316	T/C	cg00383909	chr3:49044727	WDR6	0.78	9.6	0.41	5.22e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg07460842	chr6:66804631	NA	0.96	17.81	0.64	2.08e-54	Exhaled nitric oxide output;
LGG	cis	rs477692	1.000	rs480643	chr10:131400308	A/G	cg05714579	chr10:131428358	MGMT	0.56	11.42	0.47	8.73e-27	Response to temozolomide;
LGG	cis	rs6976053	0.564	rs314347	chr7:100399149	G/A	cg03098644	chr7:100410630	EPHB4	-0.57	-11.04	-0.46	2.57e-25	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	11.75	0.48	4.45e-28	Personality dimensions;
LGG	cis	rs12410462	0.591	rs6688145	chr1:227800160	C/T	cg23173402	chr1:227635558	NA	0.38	7.23	0.32	1.99e-12	Major depressive disorder;
LGG	cis	rs9916302	0.752	rs6503513	chr17:37561613	A/G	cg00129232	chr17:37814104	STARD3	0.58	9.49	0.4	1.19e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.37	0.56	5.39e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.6	12.33	0.5	2.03e-30	Prudent dietary pattern;
LGG	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.35	-6.66	-0.3	7.98e-11	Alzheimer's disease (late onset);
LGG	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.57	-0.71	6.26e-72	Height;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.26	-0.32	1.65e-12	IgG glycosylation;
LGG	trans	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg06521331	chr12:34319734	NA	-0.53	-8.94	-0.38	9.47e-18	Morning vs. evening chronotype;
LGG	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg11553311	chr5:66541588	NA	0.44	9.84	0.42	6.95e-21	Breast cancer;
LGG	trans	rs9354308	0.738	rs4379273	chr6:66582222	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.05e-12	Metabolite levels;
LGG	cis	rs4740619	0.933	rs7847144	chr9:15714658	C/T	cg14451791	chr9:16040625	NA	-0.37	-9.41	-0.4	2.28e-19	Body mass index;
LGG	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.51e-11	Asthma;
LGG	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg24331049	chr13:111365604	ING1	0.9	15.47	0.58	8.11e-44	Coronary artery disease;
LGG	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg27411982	chr8:10470053	RP1L1	-0.47	-8.13	-0.35	3.92e-15	Triglycerides;
LGG	cis	rs2712184	0.756	rs2541395	chr2:217647675	C/T	cg05032264	chr2:217675019	NA	-0.42	-9.18	-0.39	1.47e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs3806843	0.966	rs3806842	chr5:140212676	C/T	cg19875535	chr5:140030758	IK	0.49	10.13	0.43	6.6e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg25019033	chr10:957182	NA	-0.63	-12.06	-0.49	2.65e-29	Eosinophil percentage of granulocytes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18154422	chr10:31609200	ZEB1;LOC220930	0.47	7.67	0.34	1.01e-13	Cognitive performance;
LGG	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg27446573	chr6:127587934	RNF146	1.12	22.53	0.72	2e-76	Breast cancer;
LGG	cis	rs6835098	0.509	rs2332655	chr4:174093002	A/G	cg08422745	chr4:174089978	GALNT7	0.58	10.39	0.43	7.02e-23	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs10155981	0.510	rs4722159	chr7:22584279	C/G	cg05062323	chr7:22590069	NA	-0.75	-10.2	-0.43	3.47e-22	Bilirubin levels;
LGG	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.8	0.48	2.81e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs847649	1.000	rs13233521	chr7:102593794	C/T	cg18108683	chr7:102477205	FBXL13	0.62	13.62	0.53	9.37e-36	Morning vs. evening chronotype;
LGG	cis	rs4319547	0.661	rs7398014	chr12:122943980	T/C	cg23029597	chr12:123009494	RSRC2	-0.95	-17.85	-0.64	1.27e-54	Body mass index;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.1	0.42	8.32e-22	Schizophrenia;
LGG	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-13.28	-0.53	2.55e-34	Chronic sinus infection;
LGG	cis	rs9359856	0.564	rs72915904	chr6:90421412	C/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.8	-0.41	9.97e-21	Bipolar disorder;
LGG	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.63	-0.37	9.83e-17	Blood metabolite levels;
LGG	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs31872	0.678	rs702390	chr5:140442209	G/A	cg19650706	chr5:140594406	PCDHB13	-0.65	-11.58	-0.47	2.09e-27	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs12681287	0.547	rs13249177	chr8:87513034	A/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg03733263	chr8:22462867	KIAA1967	1.13	33.17	0.84	2.07e-124	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4356975	0.563	rs34814736	chr4:69980478	C/G	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs757278	0.513	rs2188150	chr7:117274256	G/A	cg10524701	chr7:117356490	CTTNBP2	0.46	7.87	0.34	2.55e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.22e-29	Aortic root size;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg04034577	chr2:241836375	C2orf54	-0.53	-11.31	-0.47	2.38e-26	Urinary metabolites;
LGG	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg08085267	chr17:45401833	C17orf57	0.58	11.41	0.47	9.6e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg19338460	chr6:170058176	WDR27	-0.59	-8.05	-0.35	7.28e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4740619	0.935	rs10810436	chr9:15723547	T/C	cg14451791	chr9:16040625	NA	-0.4	-10.21	-0.43	3.24e-22	Body mass index;
LGG	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg13798912	chr7:905769	UNC84A	-0.57	-7.15	-0.32	3.51e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9381107	0.932	rs2223603	chr6:9487956	C/T	cg14735645	chr6:9486422	NA	0.48	7.97	0.35	1.28e-14	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	1.1	30.87	0.82	1.88e-114	Birth weight;
LGG	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg00850481	chr1:228891306	NA	-0.64	-14.79	-0.57	8.01e-41	Chronic lymphocytic leukemia;
LGG	cis	rs5769765	0.646	rs9616205	chr22:50309915	A/T	cg02269571	chr22:50332266	NA	-0.71	-11.18	-0.46	7.35e-26	Schizophrenia;
LGG	cis	rs2274273	0.837	rs6573010	chr14:55721592	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.34	0.63	2.74e-52	Protein biomarker;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.94	-0.31	1.37e-11	Triglycerides;
LGG	cis	rs8067545	0.611	rs2703795	chr17:20077141	C/A	cg13482628	chr17:19912719	NA	-0.53	-10.07	-0.42	1.07e-21	Schizophrenia;
LGG	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg01324343	chr3:183735012	ABCC5	0.86	18.39	0.65	4.13e-57	Anterior chamber depth;
LGG	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg05623727	chr3:50126028	RBM5	-0.32	-6.98	-0.31	1.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg26769984	chr7:1090371	C7orf50	-0.56	-10.18	-0.43	4.16e-22	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19171272	chr22:38449367	NA	0.4	6.82	0.3	2.77e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs629922	0.533	rs643123	chr11:114065457	C/T	cg01914181	chr11:114070210	ZBTB16	-0.53	-6.74	-0.3	4.82e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs4771450	0.925	rs876669	chr13:103979399	A/G	cg02987523	chr13:103978230	NA	-0.33	-7.02	-0.31	8.19e-12	Uric acid levels;
LGG	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.31	-0.4	5.22e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11750568	0.967	rs10464079	chr5:178525779	G/A	cg10208897	chr5:178548229	ADAMTS2	0.43	6.93	0.31	1.43e-11	Height;
LGG	cis	rs1519814	1.000	rs7826920	chr8:121121010	T/C	cg22335954	chr8:121166405	COL14A1	-0.53	-10.9	-0.45	8.5e-25	Breast cancer;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-9.52	-0.4	9.58e-20	Skin colour saturation;
LGG	cis	rs2172802	0.599	rs2088462	chr4:62512727	G/C	cg04118610	chr4:62707027	LPHN3	-0.41	-6.67	-0.3	7.43e-11	Partial epilepsies;
LGG	cis	rs34311866	0.808	rs62294491	chr4:969111	C/T	cg07828340	chr4:882639	GAK	0.83	8.96	0.38	7.88e-18	Parkinson's disease;
LGG	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg26656751	chr17:43910226	CRHR1	0.35	7.05	0.31	6.63e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10489202	0.632	rs12401555	chr1:168069473	G/C	cg24449463	chr1:168025552	DCAF6	-0.58	-10.28	-0.43	1.77e-22	Schizophrenia;
LGG	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg13073564	chr4:8508604	NA	0.59	11.71	0.48	6.66e-28	Response to antineoplastic agents;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.19	0.32	2.62e-12	Alzheimer's disease;
LGG	cis	rs4538187	0.950	rs35336851	chr2:64244541	T/C	cg02541582	chr2:64069798	UGP2	-0.61	-14.22	-0.55	2.45e-38	Systolic blood pressure;
LGG	cis	rs867371	1.000	rs13380319	chr15:82506867	G/T	cg00614314	chr15:82944287	LOC80154	0.59	9.83	0.42	7.95e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg26384229	chr12:38710491	ALG10B	0.95	20.7	0.69	7.41e-68	Morning vs. evening chronotype;
LGG	cis	rs12618769	0.597	rs4851142	chr2:99133611	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.68	0.37	6.81e-17	Bipolar disorder;
LGG	cis	rs8078723	0.866	rs3935280	chr17:38189055	A/G	cg17467752	chr17:38218738	THRA	-0.8	-15.76	-0.59	4.01e-45	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13732083	chr21:47605072	C21orf56	0.46	7.67	0.34	1.04e-13	Testicular germ cell tumor;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs75804782	0.572	rs11900963	chr2:239308049	A/T	cg01134436	chr17:81009848	B3GNTL1	0.77	6.71	0.3	5.76e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.36	0.32	8.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg02151108	chr14:50098012	C14orf104	-0.43	-9.29	-0.4	6.11e-19	Carotid intima media thickness;
LGG	cis	rs2439831	0.702	rs3784275	chr15:44091386	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.02	0.35	8.59e-15	Lung cancer in ever smokers;
LGG	cis	rs62400317	0.821	rs62400268	chr6:45183011	C/T	cg20913747	chr6:44695427	NA	-0.63	-10.25	-0.43	2.31e-22	Total body bone mineral density;
LGG	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-8.03	-0.35	7.89e-15	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg07701084	chr6:150067640	NUP43	0.71	13.89	0.54	6.72e-37	Lung cancer;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.780	rs7210991	chr17:28190961	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg01966878	chr4:90757139	SNCA	-0.33	-6.78	-0.3	3.6e-11	Dementia with Lewy bodies;
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg14338887	chr6:42928500	GNMT	0.27	8.69	0.37	6.48e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs35146811	0.555	rs2527896	chr7:99537653	A/G	cg22906224	chr7:99728672	NA	0.44	6.92	0.31	1.51e-11	Coronary artery disease;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04008888	chr11:68622739	NA	-0.53	-11.35	-0.47	1.61e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2708977	0.637	rs676007	chr2:97075052	G/A	cg01950434	chr2:97203154	ARID5A	-0.46	-7.02	-0.31	8.03e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg15383120	chr6:291909	DUSP22	-0.56	-9.18	-0.39	1.43e-18	Menopause (age at onset);
LGG	cis	rs11700980	0.636	rs77555990	chr21:30229776	C/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.28	-0.32	1.4e-12	QRS complex (12-leadsum);
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg07959490	chr17:80112427	CCDC57	0.39	7.56	0.33	2.15e-13	Life satisfaction;
LGG	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.13	-0.78	1.01e-97	Primary sclerosing cholangitis;
LGG	cis	rs17030434	0.906	rs4145339	chr4:154710481	C/T	cg14289246	chr4:154710475	SFRP2	-0.75	-11.7	-0.48	6.89e-28	Electrocardiographic conduction measures;
LGG	cis	rs847851	0.612	rs7768189	chr6:34742450	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.4	-0.47	1.05e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.15e-11	Iron status biomarkers;
LGG	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg23788917	chr6:8435910	SLC35B3	-0.45	-7.39	-0.32	6.71e-13	Motion sickness;
LGG	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg16586182	chr3:47516702	SCAP	0.77	14.97	0.57	1.3e-41	Colorectal cancer;
LGG	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.59	-0.47	1.83e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10754283	0.901	rs10047070	chr1:90098715	G/C	cg21401794	chr1:90099060	LRRC8C	0.56	11.94	0.49	7.7e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7923452	0.507	rs612802	chr10:30756441	G/A	cg25182066	chr10:30743637	MAP3K8	-0.65	-13.93	-0.54	4.3e-37	Itch intensity from mosquito bite;
LGG	cis	rs6976053	0.905	rs13232524	chr7:100512824	A/G	cg03098644	chr7:100410630	EPHB4	0.44	7.88	0.34	2.43e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs8028182	0.501	rs7166281	chr15:75928192	G/T	cg20655648	chr15:75932815	IMP3	-0.46	-7.6	-0.33	1.64e-13	Sudden cardiac arrest;
LGG	cis	rs17767392	0.813	rs8013161	chr14:72021499	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.42	-8.88	-0.38	1.47e-17	Mitral valve prolapse;
LGG	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg16325326	chr1:53192061	ZYG11B	-0.7	-16.78	-0.62	1.01e-49	Monocyte count;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.11	0.31	4.34e-12	Lung cancer;
LGG	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg09307838	chr4:120376055	NA	0.72	12.18	0.49	8.52e-30	Corneal astigmatism;
LGG	cis	rs765787	0.530	rs1706830	chr15:45516229	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg09845145	chr15:78292470	TBC1D2B	0.66	12.83	0.51	1.88e-32	Coronary artery disease or large artery stroke;
LGG	cis	rs7224668	0.647	rs8070549	chr17:79247099	A/G	cg03823431	chr17:79229385	SLC38A10	0.35	7.44	0.33	4.94e-13	IgG glycosylation;
LGG	cis	rs2916247	1.000	rs2920471	chr8:92981874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.24	-0.36	1.77e-15	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs56322132	chr4:119742496	T/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg05973401	chr12:123451056	ABCB9	0.5	7.67	0.34	1.06e-13	Neutrophil percentage of white cells;
LGG	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg26655873	chr3:72818019	SHQ1	0.34	6.75	0.3	4.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg17182837	chr8:41585554	ANK1	0.65	9.27	0.4	6.94e-19	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg08975724	chr8:8085496	FLJ10661	0.49	9.28	0.4	6.38e-19	Triglycerides;
LGG	trans	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg05926928	chr17:57297772	GDPD1	-0.55	-9.1	-0.39	2.76e-18	Schizophrenia;
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.55	-0.37	1.79e-16	Neuroticism;
LGG	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg00405596	chr8:11794950	NA	0.65	11.35	0.47	1.58e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs283228	0.916	rs1338168	chr6:101794298	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.9	0.38	1.27e-17	Coenzyme Q10 levels;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.03	-0.39	4.65e-18	Life satisfaction;
LGG	cis	rs7727544	0.735	rs4705933	chr5:131678412	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.85	-0.38	1.91e-17	Blood metabolite levels;
LGG	cis	rs11628318	0.515	rs4906239	chr14:103078073	A/G	cg12046867	chr14:103022105	NA	-0.4	-7.52	-0.33	2.93e-13	Platelet count;
LGG	cis	rs3087591	0.960	rs12942397	chr17:29462498	C/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.35	0.55	6.54e-39	Hip circumference;
LGG	cis	rs6594713	0.732	rs34951736	chr5:112727149	T/C	cg12552261	chr5:112820674	MCC	0.54	7.58	0.33	1.93e-13	Brain cytoarchitecture;
LGG	cis	rs6684428	1.000	rs61774843	chr1:56367384	C/T	cg11651538	chr1:56320950	NA	-0.75	-12.83	-0.51	1.97e-32	Airflow obstruction;
LGG	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.79	0.34	4.46e-14	Intelligence (multi-trait analysis);
LGG	trans	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs5758511	0.573	rs139558	chr22:42189551	A/G	cg15128208	chr22:42549153	NA	-0.42	-7.25	-0.32	1.76e-12	Birth weight;
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.26	-0.32	1.63e-12	Neuroticism;
LGG	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11644478	chr21:40555479	PSMG1	0.6	10.14	0.43	6.07e-22	Menarche (age at onset);
LGG	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.33	-0.32	1.05e-12	HDL cholesterol;
LGG	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg18681998	chr4:17616180	MED28	0.87	18.31	0.65	1e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg26076054	chr5:421317	AHRR	-0.52	-7.63	-0.33	1.36e-13	Cystic fibrosis severity;
LGG	cis	rs7173389	1.000	rs7174098	chr15:73664041	G/A	cg01796676	chr15:73680284	NA	0.51	8.5	0.37	2.7e-16	Resting heart rate;
LGG	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03517284	chr6:25882590	NA	-0.53	-10.02	-0.42	1.62e-21	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06083525	chr1:27216957	GPN2	0.43	7.13	0.31	3.98e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs780096	0.814	rs780093	chr2:27742603	T/C	cg22903471	chr2:27725779	GCKR	-0.35	-7.01	-0.31	8.52e-12	Total body bone mineral density;
LGG	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.61	0.44	1.11e-23	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs4713675	0.565	rs6928010	chr6:33676590	T/C	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.79e-11	Plateletcrit;
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs7166081	1.000	rs12595736	chr15:67582602	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg12070911	chr6:150209640	RAET1E	0.32	7.67	0.34	1.02e-13	Lung cancer;
LGG	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.75	-0.34	5.86e-14	Pancreatic cancer;
LGG	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg19729930	chr2:74357872	NA	0.56	11.52	0.47	3.47e-27	Gestational age at birth (maternal effect);
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg06221963	chr1:154839813	KCNN3	-0.51	-10.67	-0.44	6.79e-24	Prostate cancer;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg26338869	chr17:61819248	STRADA	0.6	10.0	0.42	1.97e-21	Prudent dietary pattern;
LGG	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.56	0.37	1.63e-16	Aortic root size;
LGG	trans	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg26043149	chr18:55253948	FECH	-0.4	-6.74	-0.3	4.73e-11	Bone mineral density;
LGG	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg16141378	chr3:129829833	LOC729375	0.32	6.9	0.31	1.73e-11	Myopia (pathological);
LGG	cis	rs7551222	0.681	rs2926533	chr1:204480742	T/A	cg20240347	chr1:204465584	NA	0.45	7.98	0.35	1.2e-14	Schizophrenia;
LGG	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.52	0.5	3.58e-31	Alzheimer's disease;
LGG	cis	rs2470578	0.740	rs2596656	chr3:17235490	G/A	cg20981856	chr3:17787350	NA	0.36	6.74	0.3	4.69e-11	Schizophrenia;
LGG	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg13256891	chr4:100009986	ADH5	0.55	9.83	0.42	7.6e-21	Alcohol dependence;
LGG	cis	rs9815354	1.000	rs9867627	chr3:41795841	G/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.14	-0.35	3.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4713118	0.513	rs156739	chr6:28013410	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.95	-0.31	1.28e-11	Parkinson's disease;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg04011671	chr2:43202474	NA	-0.37	-6.98	-0.31	1.04e-11	Blood metabolite levels;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs3889237	0.796	rs4254365	chr17:64793333	G/T	cg09655520	chr17:64786064	PRKCA	0.35	7.16	0.32	3.11e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22769031	chr20:35580195	SAMHD1	0.44	6.82	0.3	2.85e-11	Gut microbiome composition (summer);
LGG	trans	rs2018683	0.711	rs2158788	chr7:28971958	G/A	cg19402173	chr7:128379420	CALU	-0.56	-9.49	-0.4	1.26e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg27284194	chr4:1044797	NA	0.56	11.19	0.46	6.62e-26	Recombination rate (males);
LGG	cis	rs975722	0.671	rs885993	chr7:117129404	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.91	0.42	3.92e-21	Coronary artery disease;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg08742575	chr21:47604166	C21orf56	-0.54	-9.83	-0.42	7.56e-21	Testicular germ cell tumor;
LGG	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.45	0.65	2.21e-57	Menopause (age at onset);
LGG	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.29	-0.32	1.39e-12	Retinal vascular caliber;
LGG	cis	rs1109114	0.844	rs2304611	chr5:148627723	T/C	cg06539116	chr5:148597365	ABLIM3	-0.48	-11.42	-0.47	8.81e-27	Body mass index;
LGG	cis	rs722599	0.715	rs2080086	chr14:75338408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.19	-0.39	1.33e-18	IgG glycosylation;
LGG	cis	rs12410462	0.551	rs1923819	chr1:227874314	C/T	cg04117972	chr1:227635322	NA	-0.44	-8.09	-0.35	5.13e-15	Major depressive disorder;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs778371	0.697	rs2344613	chr2:233603065	C/G	cg08000102	chr2:233561755	GIGYF2	0.67	10.91	0.45	7.96e-25	Schizophrenia;
LGG	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg14416269	chr4:6271139	WFS1	0.51	9.31	0.4	4.99e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	12.98	0.52	4.33e-33	Lung cancer in ever smokers;
LGG	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg01221209	chr5:554886	NA	-0.45	-6.73	-0.3	5.19e-11	Obesity-related traits;
LGG	cis	rs7250872	0.619	rs2396359	chr19:1819125	T/C	cg18850929	chr19:1828978	REXO1	0.48	7.8	0.34	4.18e-14	Bipolar disorder;
LGG	cis	rs4639966	0.836	rs11217018	chr11:118635364	T/C	cg19182353	chr11:118479428	PHLDB1	-0.53	-8.65	-0.37	8.62e-17	Systemic lupus erythematosus;
LGG	cis	rs80282103	0.618	rs12250141	chr10:1160106	A/T	cg08668510	chr10:1095578	IDI1	0.85	7.76	0.34	5.48e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.79	-0.38	2.85e-17	Lung cancer;
LGG	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	cis	rs7587476	0.906	rs3768713	chr2:215637505	G/A	cg04530015	chr2:215796436	ABCA12	-0.42	-6.78	-0.3	3.65e-11	Neuroblastoma;
LGG	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg05861140	chr6:150128134	PCMT1	0.41	9.12	0.39	2.38e-18	Lung cancer;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs1044826	0.642	rs2118981	chr3:139178853	A/G	cg15131784	chr3:139108705	COPB2	0.41	6.65	0.3	8.4e-11	Obesity-related traits;
LGG	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-6.99	-0.31	9.87e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg16511985	chr3:153974050	SGEF	0.49	8.37	0.36	6.86e-16	Coronary artery disease;
LGG	cis	rs7647973	0.626	rs9824435	chr3:49674343	A/G	cg13072238	chr3:49761600	GMPPB	0.55	7.22	0.32	2.08e-12	Menarche (age at onset);
LGG	cis	rs7246760	0.618	rs73008113	chr19:9738196	C/T	cg16876255	chr19:9731953	ZNF561	0.9	8.17	0.36	2.92e-15	Pursuit maintenance gain;
LGG	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg16339924	chr4:17578868	LAP3	0.66	11.05	0.46	2.38e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.89	0.59	1.13e-45	Lung cancer;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.5	-0.44	2.71e-23	IgG glycosylation;
LGG	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg25986240	chr4:9926439	SLC2A9	0.33	6.73	0.3	5.04e-11	Bone mineral density;
LGG	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg07005078	chr4:17578674	LAP3	-0.37	-6.94	-0.31	1.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.61	-0.33	1.53e-13	Total cholesterol levels;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.27	-0.32	1.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg13385521	chr17:29058706	SUZ12P	0.82	9.76	0.41	1.41e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.65	-11.49	-0.47	4.51e-27	Longevity;Endometriosis;
LGG	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg25554036	chr4:6271136	WFS1	0.63	12.18	0.49	8.32e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs9354308	0.764	rs3939863	chr6:66601673	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg01879757	chr17:41196368	BRCA1	-0.39	-8.05	-0.35	6.85e-15	Menopause (age at onset);
LGG	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg02002194	chr4:3960332	NA	-0.48	-9.08	-0.39	3.22e-18	Retinal vascular caliber;
LGG	cis	rs8180040	1.000	rs553989	chr3:47400328	A/G	cg27129171	chr3:47204927	SETD2	-0.8	-15.59	-0.59	2.27e-44	Colorectal cancer;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg20607798	chr8:58055168	NA	0.65	7.17	0.32	3.04e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.57	-0.41	6.58e-20	Height;
LGG	cis	rs8114671	0.869	rs2038503	chr20:33675900	G/A	cg24642439	chr20:33292090	TP53INP2	-0.49	-8.11	-0.35	4.69e-15	Height;
LGG	cis	rs3820928	0.839	rs58580037	chr2:227876274	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.8	-0.34	4.01e-14	Pulmonary function;
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg23939001	chr4:940644	TMEM175	0.72	18.15	0.64	5.2e-56	Sjögren's syndrome;
LGG	cis	rs4664308	1.000	rs1511218	chr2:160906390	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.99	-0.64	3.06e-55	Idiopathic membranous nephropathy;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7551222	0.614	rs4951386	chr1:204454547	A/G	cg20240347	chr1:204465584	NA	-0.49	-9.14	-0.39	1.96e-18	Schizophrenia;
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg16141378	chr3:129829833	LOC729375	0.44	9.92	0.42	3.69e-21	Neuroticism;
LGG	cis	rs12681287	0.546	rs12546802	chr8:87499335	T/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.72	-0.34	7.24e-14	Caudate activity during reward;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg04863758	chr4:1303710	MAEA	0.44	7.7	0.34	8.26e-14	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.73	-11.08	-0.46	1.82e-25	Homoarginine levels;
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg14926445	chr8:58193284	C8orf71	0.68	9.1	0.39	2.63e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs912057	0.526	rs201061	chr6:6730512	C/T	cg06612196	chr6:6737390	NA	-0.5	-11.26	-0.46	3.68e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.65	-0.51	1.03e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs774359	0.789	rs2492818	chr9:27505639	A/G	cg21249376	chr9:27528432	MOBKL2B	0.45	8.58	0.37	1.5e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00059053	chr12:3602162	PRMT8	0.44	6.92	0.31	1.54e-11	Gut microbiome composition (summer);
LGG	cis	rs2239547	0.522	rs2581815	chr3:52982159	C/G	cg11645453	chr3:52864694	ITIH4	0.65	10.14	0.43	6.1e-22	Schizophrenia;
LGG	trans	rs9929218	1.000	rs2113201	chr16:68815000	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.57	-0.5	2.15e-31	Colorectal cancer;
LGG	cis	rs7017914	0.934	rs7814274	chr8:71570411	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.38	6.99	0.31	9.69e-12	Bone mineral density;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg07414643	chr4:187882934	NA	0.52	10.93	0.45	6.83e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3820068	0.608	rs10927840	chr1:16045250	A/G	cg05660106	chr1:15850417	CASP9	0.75	13.79	0.54	1.7e-36	Systolic blood pressure;
LGG	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg00129232	chr17:37814104	STARD3	0.57	8.47	0.37	3.32e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg21775007	chr8:11205619	TDH	0.44	7.15	0.32	3.32e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20299236	chr22:32870557	FBXO7	0.49	7.86	0.34	2.72e-14	Gut microbiome composition (summer);
LGG	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg20476274	chr7:133979776	SLC35B4	0.7	13.17	0.52	7.15e-34	Mean platelet volume;
LGG	cis	rs9534288	0.742	rs7337140	chr13:46641481	C/T	cg15192986	chr13:46630673	CPB2	0.65	13.51	0.53	2.73e-35	Blood protein levels;
LGG	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg05555928	chr11:63887634	MACROD1	-0.59	-9.99	-0.42	2.12e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.14	-0.35	3.7e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg00012203	chr2:219082015	ARPC2	-0.75	-14.11	-0.55	7.5e-38	Colorectal cancer;
LGG	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg22491629	chr6:157744540	C6orf35	0.91	13.28	0.53	2.52e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs3762318	1.000	rs3762318	chr1:67597119	A/G	cg17031739	chr1:67600172	NA	-0.45	-6.72	-0.3	5.43e-11	Leprosy;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.18	-0.36	2.73e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg00908189	chr16:619842	PIGQ	0.87	16.73	0.61	1.77e-49	Height;
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg02002194	chr4:3960332	NA	0.42	7.71	0.34	7.87e-14	Neuroticism;
LGG	cis	rs7940866	0.838	rs7122268	chr11:130892029	A/T	cg12179176	chr11:130786555	SNX19	0.71	13.13	0.52	1.08e-33	Schizophrenia;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg14980563	chr5:95670504	NA	-0.41	-6.74	-0.3	4.59e-11	Apolipoprotein A-IV levels;
LGG	cis	rs6784615	0.744	rs13096571	chr3:52407725	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.71	7.65	0.33	1.21e-13	Waist-hip ratio;
LGG	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg01244601	chr4:120671846	NA	0.37	6.9	0.31	1.72e-11	Corneal astigmatism;
LGG	cis	rs8067287	0.597	rs7223652	chr17:16864559	C/T	cg26910001	chr17:16838321	NA	0.39	7.65	0.33	1.18e-13	Diabetic kidney disease;
LGG	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs6456156	0.846	rs9364891	chr6:167516319	C/T	cg07741184	chr6:167504864	NA	-0.34	-7.59	-0.33	1.8e-13	Primary biliary cholangitis;
LGG	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg00383909	chr3:49044727	WDR6	0.43	7.0	0.31	9.24e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg05556477	chr5:131705319	SLC22A5	0.82	9.79	0.41	1.03e-20	Rheumatoid arthritis;
LGG	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.83	-16.81	-0.62	7.59e-50	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg02753203	chr1:228287806	NA	-0.64	-11.95	-0.49	6.97e-29	Diastolic blood pressure;
LGG	cis	rs7166081	0.951	rs16950805	chr15:67560677	T/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.89e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.36	-0.5	1.57e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.64	0.33	1.27e-13	Longevity;
LGG	cis	rs1318772	1.000	rs67767339	chr5:112679491	C/T	cg12552261	chr5:112820674	MCC	0.72	8.36	0.36	7.18e-16	F-cell distribution;
LGG	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg13010199	chr12:38710504	ALG10B	-0.58	-11.15	-0.46	9.75e-26	Morning vs. evening chronotype;
LGG	cis	rs10779751	0.734	rs2791647	chr1:11132801	G/A	cg08854313	chr1:11322531	MTOR	0.76	16.88	0.62	3.52e-50	Body mass index;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.54	0.53	2.04e-35	Obesity-related traits;
LGG	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg25482853	chr8:67687455	SGK3	-0.94	-11.98	-0.49	5.31e-29	Obesity-related traits;
LGG	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg07928641	chr1:182991847	LAMC1	0.49	10.04	0.42	1.36e-21	Colorectal cancer;
LGG	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg25008857	chr14:105974488	NA	0.56	9.83	0.42	7.82e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg05044414	chr3:183734942	ABCC5	0.77	16.88	0.62	3.71e-50	Anterior chamber depth;
LGG	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.1	-0.52	1.47e-33	Response to antipsychotic treatment;
LGG	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg18252515	chr7:66147081	NA	0.72	11.47	0.47	5.52e-27	Corneal structure;
LGG	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg19468946	chr17:37922297	IKZF3	-0.45	-7.95	-0.35	1.41e-14	Self-reported allergy;
LGG	cis	rs7911264	0.739	rs10882091	chr10:94374377	C/T	cg25093409	chr10:94429542	NA	0.49	9.56	0.41	7.18e-20	Inflammatory bowel disease;
LGG	cis	rs1555895	0.599	rs12243303	chr10:861390	C/T	cg10556349	chr10:835070	NA	-0.28	-7.1	-0.31	4.59e-12	Survival in rectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07987587	chr22:42486991	NDUFA6	0.41	6.85	0.3	2.42e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6868223	0.617	rs4504387	chr5:33649807	A/C	cg10594543	chr5:33649717	ADAMTS12	-0.65	-15.04	-0.57	6.51e-42	Mortality in heart failure;
LGG	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.03e-40	Retinal vascular caliber;
LGG	cis	rs67133203	0.606	rs1038525	chr12:51434701	C/T	cg14688905	chr12:51403056	SLC11A2	-0.51	-8.6	-0.37	1.24e-16	Urinary tract infection frequency;
LGG	cis	rs988958	0.565	rs34465637	chr2:42229346	G/A	cg27428208	chr2:42229179	NA	0.47	7.26	0.32	1.66e-12	Hypospadias;
LGG	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg18451016	chr1:38461880	NA	0.51	10.24	0.43	2.52e-22	Coronary artery disease;
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg17734273	chr15:78292508	TBC1D2B	-0.33	-7.89	-0.34	2.15e-14	Coronary artery disease or large artery stroke;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg24270191	chr3:33840469	PDCD6IP	-0.39	-6.95	-0.31	1.21e-11	Brain structure;
LGG	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.71	-0.38	5.48e-17	Post bronchodilator FEV1;
LGG	cis	rs4006360	0.543	rs7502165	chr17:39268037	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.47	-9.45	-0.4	1.65e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.44	-0.61	3.47e-48	Asthma;
LGG	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg23625390	chr15:77176239	SCAPER	0.63	11.93	0.48	8.86e-29	Blood metabolite levels;
LGG	cis	rs4430311	1.000	rs2953328	chr1:244023680	C/T	cg25706552	chr1:244017396	NA	-0.68	-17.61	-0.63	1.71e-53	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg04198125	chr7:157211777	NA	0.4	7.39	0.32	7.13e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.21	-0.39	1.12e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8017423	0.874	rs4900029	chr14:90686257	T/A	cg04374321	chr14:90722782	PSMC1	0.87	18.39	0.65	4.21e-57	Mortality in heart failure;
LGG	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.86	-0.34	2.67e-14	Schizophrenia;
LGG	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08045932	chr20:61659980	NA	0.59	12.82	0.51	1.99e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	cis	rs12190007	0.547	rs3006184	chr6:169805128	C/T	cg15038512	chr6:170123185	PHF10	-0.44	-8.54	-0.37	2.01e-16	Obesity-related traits;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg11965913	chr1:205819406	PM20D1	0.84	18.36	0.65	6.03e-57	Menarche (age at onset);
LGG	cis	rs9534288	0.699	rs9534320	chr13:46665572	A/G	cg15192986	chr13:46630673	CPB2	-0.66	-13.82	-0.54	1.23e-36	Blood protein levels;
LGG	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg00898013	chr13:113819073	PROZ	-0.48	-9.62	-0.41	4.43e-20	Platelet distribution width;
LGG	cis	rs8017423	1.000	rs10129210	chr14:90668379	G/T	cg04374321	chr14:90722782	PSMC1	0.85	18.09	0.64	1.07e-55	Mortality in heart failure;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg02951883	chr7:2050386	MAD1L1	0.6	11.99	0.49	4.98e-29	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg13334819	chr7:99746414	C7orf59	0.52	7.85	0.34	2.91e-14	Coronary artery disease;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg20608306	chr11:116969690	SIK3	0.38	10.19	0.43	3.86e-22	Subjective well-being;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.93	-0.31	1.42e-11	Triglycerides;
LGG	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.5	-9.17	-0.39	1.51e-18	Rheumatoid arthritis;
LGG	cis	rs17604090	0.938	rs850027	chr7:29675792	G/T	cg19413766	chr7:29689036	LOC646762	-0.58	-7.51	-0.33	2.98e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs9487094	0.961	rs11153171	chr6:109653825	C/T	cg01125227	chr6:109776195	MICAL1	0.43	7.4	0.33	6.53e-13	Height;
LGG	cis	rs1953600	0.668	rs11201879	chr10:81908573	A/C	cg04850286	chr10:81895943	PLAC9	0.35	7.62	0.33	1.41e-13	Sarcoidosis;
LGG	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.41	-0.33	5.88e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4974559	0.739	rs28573879	chr4:1285910	C/T	cg02980000	chr4:1222292	CTBP1	0.82	9.32	0.4	4.63e-19	Systolic blood pressure;
LGG	cis	rs2486288	0.656	rs11629807	chr15:45547037	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.9	-0.42	4.31e-21	Glomerular filtration rate;
LGG	cis	rs6665290	0.904	rs11587443	chr1:227187896	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs7945705	0.935	rs2653567	chr11:8889630	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.96	-0.35	1.3e-14	Hemoglobin concentration;
LGG	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.18	0.36	2.72e-15	Retinal vascular caliber;
LGG	cis	rs7512552	0.839	rs3820544	chr1:150457876	A/T	cg15654264	chr1:150340011	RPRD2	0.45	9.25	0.39	8.33e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2797160	0.967	rs2747715	chr6:126007719	A/T	cg05901451	chr6:126070800	HEY2	0.45	7.61	0.33	1.52e-13	Endometrial cancer;
LGG	cis	rs774359	0.789	rs2492818	chr9:27505639	A/G	cg14173147	chr9:27528300	MOBKL2B	0.45	8.7	0.37	5.99e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs7937612	1.000	rs4938808	chr11:120336902	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.54	-12.99	-0.52	4.12e-33	Intraocular pressure;
LGG	cis	rs6692729	0.966	rs6697431	chr1:227015198	C/T	cg08708961	chr1:227070630	PSEN2	-0.28	-7.26	-0.32	1.64e-12	Electrodermal activity;
LGG	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg23649088	chr2:200775458	C2orf69	0.58	8.61	0.37	1.12e-16	Schizophrenia;
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-13.03	-0.52	2.65e-33	Obesity-related traits;
LGG	cis	rs497273	0.534	rs13746	chr12:121201167	C/T	cg02419362	chr12:121203948	SPPL3	0.52	8.86	0.38	1.72e-17	Systemic lupus erythematosus;
LGG	cis	rs9287719	0.934	rs12692416	chr2:10745627	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg18187862	chr3:45730750	SACM1L	0.56	9.22	0.39	1.02e-18	Primary sclerosing cholangitis;
LGG	cis	rs367943	0.666	rs7725589	chr5:112693366	G/A	cg12552261	chr5:112820674	MCC	0.57	10.12	0.43	7.28e-22	Type 2 diabetes;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg06916706	chr16:4465613	CORO7	0.7	12.0	0.49	4.39e-29	Schizophrenia;
LGG	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg05234568	chr11:5960015	NA	-0.77	-12.37	-0.5	1.44e-30	DNA methylation (variation);
LGG	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg21972741	chr5:435613	AHRR	0.49	8.86	0.38	1.68e-17	Cystic fibrosis severity;
LGG	trans	rs877282	0.755	rs2486579	chr10:785647	G/A	cg22713356	chr15:30763199	NA	0.5	7.85	0.34	2.91e-14	Uric acid levels;
LGG	cis	rs9290877	0.667	rs9866839	chr3:188452557	A/G	cg17392043	chr3:188495102	LPP	-0.43	-7.39	-0.32	6.9e-13	IgE levels;
LGG	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.85e-21	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg04166393	chr7:2884313	GNA12	0.47	9.37	0.4	3.17e-19	Height;
LGG	cis	rs9543976	1.000	rs3818355	chr13:76196867	C/T	cg01531495	chr13:76123901	UCHL3	0.63	7.36	0.32	8.37e-13	Diabetic retinopathy;
LGG	cis	rs9457247	1.000	rs4710147	chr6:167374239	G/A	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.22e-15	Bipolar disorder;
LGG	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg01620082	chr3:125678407	NA	-0.91	-9.0	-0.39	5.67e-18	Lung cancer;Intelligence (multi-trait analysis);
LGG	cis	rs12458462	0.812	rs34583578	chr18:77491070	C/T	cg11879182	chr18:77439856	CTDP1	0.79	14.51	0.56	1.41e-39	Monocyte count;
LGG	cis	rs6558174	0.965	rs4072394	chr8:22490800	C/T	cg03733263	chr8:22462867	KIAA1967	0.64	10.52	0.44	2.37e-23	Breast cancer;
LGG	cis	rs2117029	0.586	rs11168904	chr12:49571017	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.79	0.51	2.83e-32	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.642	rs1443090	chr4:152451819	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.11	0.31	4.56e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg17644776	chr2:200775616	C2orf69	-0.54	-7.28	-0.32	1.48e-12	Schizophrenia;
LGG	cis	rs6686643	0.630	rs7554034	chr1:165610464	G/A	cg19407955	chr1:165599744	MGST3	-0.68	-9.12	-0.39	2.33e-18	Total ventricular volume;
LGG	cis	rs75059851	0.756	rs73036087	chr11:133842361	G/A	cg17703048	chr11:133852993	NA	-0.87	-15.95	-0.6	6.02e-46	Schizophrenia;
LGG	cis	rs1451375	0.756	rs11761683	chr7:50542879	C/T	cg14593290	chr7:50529359	DDC	-0.42	-7.74	-0.34	6.12e-14	Malaria;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05665937	chr4:1216051	CTBP1	0.49	9.09	0.39	2.81e-18	Obesity-related traits;
LGG	cis	rs4330281	0.647	rs9812199	chr3:17555377	C/T	cg20981856	chr3:17787350	NA	0.38	7.16	0.32	3.12e-12	Schizophrenia;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.23	-0.32	2.06e-12	Bipolar disorder;
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.19	-0.32	2.56e-12	Bipolar disorder;
LGG	cis	rs6963495	0.538	rs55967123	chr7:105163678	C/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs13314892	0.764	rs74945202	chr3:69872697	C/T	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg08048268	chr3:133502702	NA	-0.6	-11.17	-0.46	8e-26	Iron status biomarkers;
LGG	trans	rs3960554	0.741	rs28446604	chr7:75662518	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.29	0.5	3.19e-30	Eotaxin levels;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.11	-0.57	3.04e-42	Prudent dietary pattern;
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11645453	chr3:52864694	ITIH4	0.41	6.76	0.3	4.27e-11	Bipolar disorder;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg01805784	chr5:176873808	PRR7	-0.37	-6.83	-0.3	2.66e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg13207630	chr7:32358064	NA	0.81	8.28	0.36	1.34e-15	Body mass index;
LGG	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.19	-0.32	2.66e-12	Bipolar disorder;
LGG	cis	rs9911578	1.000	rs9897326	chr17:56902297	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.680	rs6965212	chr7:139026465	G/T	cg07862535	chr7:139043722	LUC7L2	0.43	7.0	0.31	8.95e-12	Diisocyanate-induced asthma;
LGG	cis	rs7760949	0.852	rs9464423	chr6:13931851	A/G	cg27413430	chr6:13925136	RNF182	0.49	7.32	0.32	1.07e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7737355	0.755	rs12519233	chr5:130960093	C/A	cg06307176	chr5:131281290	NA	0.59	9.62	0.41	4.47e-20	Life satisfaction;
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg08499158	chr17:42289980	UBTF	0.55	10.43	0.44	5.11e-23	Total body bone mineral density;
LGG	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg18129748	chr3:49941408	MST1R	-0.22	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg16141378	chr3:129829833	LOC729375	0.4	9.52	0.4	9.48e-20	Neuroticism;
LGG	cis	rs7590368	0.961	rs13431852	chr2:10960410	T/C	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18418962	chr18:2571633	METTL4;NDC80	0.44	7.08	0.31	5.34e-12	Cognitive performance;
LGG	cis	rs12775980	0.737	rs58636472	chr10:29846093	C/T	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	trans	rs747782	0.528	rs10838881	chr11:48387275	T/C	cg03929089	chr4:120376271	NA	0.72	8.37	0.36	7e-16	Intraocular pressure;
LGG	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12826209	chr6:26865740	GUSBL1	0.57	6.96	0.31	1.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.929	rs72689260	chr4:185590656	G/T	cg04058563	chr4:185651563	MLF1IP	1.02	18.66	0.66	2.32e-58	Blood protein levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09658576	chr7:139477957	TBXAS1;HIPK2	0.57	6.8	0.3	3.16e-11	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg25457927	chr22:38595422	NA	-0.34	-8.17	-0.35	3.03e-15	Melanoma;
LGG	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg04568710	chr12:38710424	ALG10B	-0.36	-7.57	-0.33	2.08e-13	Morning vs. evening chronotype;
LGG	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg15704280	chr7:45808275	SEPT13	0.74	7.88	0.34	2.39e-14	Axial length;
LGG	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg22601191	chr20:60968625	CABLES2	0.44	8.02	0.35	8.98e-15	Colorectal cancer;
LGG	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.21	-0.36	2.2e-15	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25777818	chr7:157345520	PTPRN2	0.34	6.68	0.3	7e-11	Menarche (age at onset);
LGG	cis	rs12762955	0.561	rs2620942	chr10:1048398	C/T	cg25019033	chr10:957182	NA	-0.32	-6.79	-0.3	3.35e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg04362960	chr10:104952993	NT5C2	0.56	10.53	0.44	2.14e-23	Arsenic metabolism;
LGG	trans	rs2389217	0.614	rs7309229	chr12:33592681	C/G	cg26384229	chr12:38710491	ALG10B	-0.46	-7.96	-0.35	1.35e-14	Morning vs. evening chronotype;
LGG	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg12708336	chr17:41446283	NA	-0.31	-6.95	-0.31	1.21e-11	Menopause (age at onset);
LGG	cis	rs1719271	0.831	rs1522744	chr15:65187874	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.92	-0.31	1.47e-11	Platelet count;
LGG	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.15	-0.55	4.79e-38	Type 2 diabetes;
LGG	cis	rs6867032	0.958	rs4246754	chr5:2014776	A/C	cg26168224	chr5:2018326	NA	1.25	25.53	0.76	2.27e-90	Gut microbiome composition (winter);
LGG	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.4	0.5	1.14e-30	Rheumatoid arthritis;
LGG	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg22437258	chr11:111473054	SIK2	0.57	10.08	0.42	9.78e-22	Primary sclerosing cholangitis;
LGG	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg16583315	chr14:65563665	MAX	-0.43	-8.54	-0.37	1.98e-16	Obesity-related traits;
LGG	cis	rs1568889	0.838	rs7933991	chr11:28059761	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.63e-61	Bipolar disorder;
LGG	cis	rs9460578	0.673	rs4077404	chr6:20876613	A/G	cg13405222	chr6:20811065	CDKAL1	-0.67	-11.82	-0.48	2.35e-28	Breast cancer;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	5.01e-18	Lung cancer;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg05861140	chr6:150128134	PCMT1	-0.39	-8.71	-0.38	5.6e-17	Lung cancer;
LGG	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.02	0.42	1.68e-21	Iron status biomarkers;
LGG	cis	rs9815354	0.812	rs809930	chr3:42065005	A/G	cg03022575	chr3:42003672	ULK4	0.55	7.13	0.31	3.94e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg26138144	chr22:38071188	LGALS1	0.9	23.89	0.74	8.6e-83	Fat distribution (HIV);
LGG	cis	rs79349575	0.655	rs62078384	chr17:47044463	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.18	0.36	2.66e-15	Type 2 diabetes;
LGG	cis	rs58649573	0.509	rs917784	chr9:126790201	T/C	cg14112217	chr9:126806003	NA	0.4	7.87	0.34	2.61e-14	Post-traumatic stress disorder;
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg19223190	chr17:80058835	NA	-0.49	-9.77	-0.41	1.23e-20	Life satisfaction;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23405575	chr3:11034281	SLC6A1	-0.46	-7.25	-0.32	1.79e-12	Pancreatic cancer;
LGG	cis	rs1620921	0.967	rs1740443	chr6:161197042	T/C	cg01280913	chr6:161186852	NA	-0.32	-6.76	-0.3	4.1e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg13334819	chr7:99746414	C7orf59	-0.46	-6.71	-0.3	5.7e-11	Coronary artery disease;
LGG	cis	rs4740619	0.544	rs9407651	chr9:15827796	T/A	cg14451791	chr9:16040625	NA	0.32	7.88	0.34	2.36e-14	Body mass index;
LGG	cis	rs3849046	1.000	rs13155345	chr5:137854924	T/C	cg10920316	chr5:137946599	NA	-0.4	-6.73	-0.3	4.95e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg07460842	chr6:66804631	NA	0.57	9.47	0.4	1.41e-19	Metabolite levels;
LGG	cis	rs9649465	1.000	rs608447	chr7:123395983	A/G	cg03229431	chr7:123269106	ASB15	0.4	8.86	0.38	1.76e-17	Migraine;
LGG	cis	rs745821	0.701	rs11873631	chr18:48100404	C/T	cg18923635	chr18:48083994	NA	0.42	7.41	0.33	5.93e-13	Diastolic blood pressure;
LGG	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07950158	chr19:45874032	ERCC2	0.46	7.27	0.32	1.54e-12	Gut microbiome composition (summer);
LGG	cis	rs975739	1.000	rs1759973	chr13:78383914	A/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.75	0.3	4.5e-11	Hair color;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	trans	rs225245	0.791	rs720774	chr17:34017453	T/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs71403859	0.502	rs12927006	chr16:71549911	A/G	cg08717414	chr16:71523259	ZNF19	-1.32	-17.76	-0.64	3.35e-54	Post bronchodilator FEV1;
LGG	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-8.44	-0.37	4.11e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.6	-0.37	1.26e-16	Alcohol dependence;
LGG	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg14983838	chr19:29218262	NA	0.57	7.3	0.32	1.28e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg20026190	chr17:76395443	PGS1	0.57	10.1	0.42	8.26e-22	HDL cholesterol levels;
LGG	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg25823085	chr7:87105416	ABCB4	0.29	7.14	0.31	3.73e-12	Gallbladder cancer;
LGG	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg17691542	chr6:26056736	HIST1H1C	0.68	11.16	0.46	9.24e-26	Iron status biomarkers;
LGG	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.07	-0.55	1.06e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg26924012	chr15:45694286	SPATA5L1	1.06	22.05	0.72	3.6e-74	Homoarginine levels;
LGG	cis	rs5742933	0.762	rs2033746	chr2:190599452	G/A	cg10453823	chr2:190539512	ANKAR	-0.46	-6.88	-0.3	1.9e-11	Ferritin levels;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.5	-0.37	2.63e-16	Personality dimensions;
LGG	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.79	0.34	4.36e-14	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08280861	chr8:58055591	NA	0.65	7.93	0.35	1.68e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.14	-0.32	3.57e-12	Bipolar disorder;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.44	-0.47	7.54e-27	Obesity-related traits;
LGG	cis	rs61990749	0.597	rs8016447	chr14:78222068	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.56	7.08	0.31	5.41e-12	Fibroblast growth factor basic levels;
LGG	trans	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg27523141	chr10:43048294	ZNF37B	0.36	7.39	0.32	6.73e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6693295	0.536	rs59080925	chr1:246221360	C/G	cg11798871	chr1:246315928	SMYD3	-0.62	-8.37	-0.36	7.05e-16	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs12049351	0.613	rs7552561	chr1:229580986	C/T	cg13547644	chr1:229569608	ACTA1	0.32	7.12	0.31	4.14e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs6141769	0.542	rs28536730	chr20:31301954	A/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.81	-0.3	3.05e-11	Subjective well-being;
LGG	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg24110177	chr3:50126178	RBM5	-0.59	-10.76	-0.45	2.93e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1371867	0.846	rs1660345	chr8:101322762	C/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	trans	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-6.79	-0.3	3.46e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs3820068	0.608	rs11544523	chr1:15904318	C/T	cg05660106	chr1:15850417	CASP9	1.17	24.26	0.75	1.73e-84	Systolic blood pressure;
LGG	cis	rs5769765	0.542	rs1033666	chr22:50252783	T/C	cg02269571	chr22:50332266	NA	0.65	8.68	0.37	6.58e-17	Schizophrenia;
LGG	trans	rs72991	0.793	rs10790440	chr11:121226406	T/G	cg27192990	chr6:129479024	LAMA2	-0.43	-7.19	-0.32	2.66e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06469307	chr17:42264507	TMUB2;C17orf65	0.44	7.17	0.32	2.89e-12	Menarche (age at onset);
LGG	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg15369054	chr17:80825471	TBCD	-0.59	-10.72	-0.45	4.27e-24	Breast cancer;
LGG	cis	rs36071027	0.615	rs10515785	chr5:158443352	G/T	cg00594129	chr5:158524270	EBF1	0.45	7.98	0.35	1.2e-14	Carotid intima media thickness;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg11878867	chr6:150167359	LRP11	-0.53	-11.02	-0.46	3.06e-25	Lung cancer;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg09699651	chr6:150184138	LRP11	0.57	10.91	0.45	8.2e-25	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10960666	chr17:33446614	RAD51L3	0.47	7.06	0.31	6.16e-12	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-14.85	-0.57	4.62e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg04267008	chr7:1944627	MAD1L1	-0.47	-7.98	-0.35	1.2e-14	Schizophrenia;
LGG	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg21545522	chr1:205238299	TMCC2	0.38	7.11	0.31	4.32e-12	Red blood cell count;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08219700	chr8:58056026	NA	0.48	7.06	0.31	5.95e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7241530	0.662	rs56261404	chr18:75905961	G/A	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	2.86e-31	Motion sickness;
LGG	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg12560992	chr17:57184187	TRIM37	0.91	16.27	0.6	2.22e-47	Intelligence (multi-trait analysis);
LGG	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg05623727	chr3:50126028	RBM5	-0.4	-8.66	-0.37	8.03e-17	Body mass index;
LGG	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.35e-13	Bladder cancer;
LGG	cis	rs9902453	0.904	rs8078638	chr17:28290358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.61	0.53	1.02e-35	Coffee consumption (cups per day);
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.43	-0.36	4.41e-16	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4948102	0.691	rs10435504	chr7:56059591	G/C	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs4942242	0.967	rs58325557	chr13:44217771	A/G	cg19169023	chr15:41853346	TYRO3	0.33	6.91	0.31	1.59e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs73198271	0.740	rs10092720	chr8:8649117	A/C	cg01851573	chr8:8652454	MFHAS1	0.37	6.65	0.3	8.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7572733	0.534	rs4850813	chr2:198775982	C/T	cg00792783	chr2:198669748	PLCL1	-0.69	-11.11	-0.46	1.36e-25	Dermatomyositis;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs2408955	0.522	rs7139330	chr12:48483484	A/C	cg24011408	chr12:48396354	COL2A1	-0.58	-9.67	-0.41	2.88e-20	Glycated hemoglobin levels;
LGG	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg11871910	chr12:69753446	YEATS4	0.67	13.14	0.52	1.01e-33	Blood protein levels;
LGG	cis	rs2976388	0.507	rs13259549	chr8:143838519	T/C	cg07661805	chr8:143867942	LY6D	0.27	7.24	0.32	1.84e-12	Urinary tract infection frequency;
LGG	cis	rs2535633	0.631	rs6799185	chr3:53101580	C/T	cg11645453	chr3:52864694	ITIH4	0.5	8.17	0.35	3.04e-15	Body mass index;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg05659262	chr3:195539315	MUC4	0.52	7.88	0.34	2.31e-14	Lung disease severity in cystic fibrosis;
LGG	cis	rs7917772	0.582	rs10786680	chr10:104317192	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.47e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.86	-0.34	2.67e-14	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.71	-0.34	7.86e-14	Lung cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16890600	chr5:98265530	NA	-0.41	-7.09	-0.31	4.89e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.46e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg10327440	chr1:227177885	CDC42BPA	1.28	43.31	0.9	6.27e-165	Myeloid white cell count;
LGG	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.17	-0.32	2.94e-12	Hip circumference adjusted for BMI;
LGG	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg25809561	chr17:30822961	MYO1D	0.46	11.07	0.46	1.94e-25	Schizophrenia;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg05659262	chr3:195539315	MUC4	0.56	8.09	0.35	5.24e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs1707322	0.721	rs10157795	chr1:46228192	G/A	cg03146154	chr1:46216737	IPP	0.59	11.02	0.46	3.07e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg24189917	chr7:1970923	MAD1L1	-0.4	-6.8	-0.3	3.21e-11	Neuroticism;
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs8179	0.645	rs11771637	chr7:92260161	G/A	cg15732164	chr7:92237376	CDK6	-0.52	-9.8	-0.41	9.98e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs10504073	0.669	rs818558	chr8:50030855	A/G	cg00325661	chr8:49890786	NA	0.68	13.22	0.52	4.56e-34	Blood metabolite ratios;
LGG	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-11.28	-0.46	3.04e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg06917634	chr15:78832804	PSMA4	-0.83	-17.54	-0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.35	-0.32	9.04e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.7	0.3	5.96e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs13160562	0.527	rs27525	chr5:96101959	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.17	0.32	2.94e-12	Alcohol dependence;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.14	0.31	3.62e-12	Personality dimensions;
LGG	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.18	-0.52	6.26e-34	Alzheimer's disease;
LGG	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg03733263	chr8:22462867	KIAA1967	-1.04	-25.43	-0.76	6.07e-90	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg13798912	chr7:905769	UNC84A	0.57	7.07	0.31	5.9e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg23601095	chr6:26197514	HIST1H3D	0.51	7.39	0.32	6.92e-13	Gout;Renal underexcretion gout;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.57	0.44	1.5e-23	Obesity-related traits;
LGG	cis	rs975739	0.669	rs7317154	chr13:78533260	C/T	cg07847733	chr13:78271382	SLAIN1	0.43	7.4	0.33	6.33e-13	Hair color;
LGG	cis	rs73787773	0.629	rs27981	chr5:111465851	G/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.58	-7.53	-0.33	2.68e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.13	0.46	1.21e-25	Vitamin D levels;
LGG	cis	rs9807841	0.592	rs10407349	chr19:10758453	G/A	cg17710535	chr19:10819994	QTRT1	0.49	7.84	0.34	3.12e-14	Inflammatory skin disease;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg13607699	chr17:42295918	UBTF	0.55	9.06	0.39	3.82e-18	Total body bone mineral density;
LGG	cis	rs1165472	1.000	rs1392140	chr1:56101822	C/T	cg11523071	chr1:56160889	NA	0.5	10.02	0.42	1.64e-21	Paclitaxel-induced neuropathy;
LGG	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg07636037	chr3:49044803	WDR6	1.07	24.95	0.76	1.03e-87	Parkinson's disease;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4845570	1.000	rs6681093	chr1:151755284	C/G	cg07092448	chr1:151763213	TDRKH	-1.01	-15.0	-0.57	9.7e-42	Coronary artery disease;
LGG	trans	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg26384229	chr12:38710491	ALG10B	0.62	11.34	0.47	1.84e-26	Resting heart rate;
LGG	cis	rs1595825	1.000	rs79508374	chr2:198864568	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-7.08	-0.31	5.22e-12	Ulcerative colitis;
LGG	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg10661904	chr17:79619235	PDE6G	0.4	8.15	0.35	3.48e-15	Eye color traits;
LGG	cis	rs4664304	0.903	rs72957576	chr2:160754132	A/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.33	-0.32	1.06e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.41	-0.47	9.87e-27	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg09361094	chr10:834503	NA	-0.31	-8.25	-0.36	1.6e-15	Survival in rectal cancer;
LGG	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg00717180	chr2:96193071	NA	0.43	7.56	0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.43	-0.33	5.33e-13	Fear of minor pain;
LGG	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs607541	0.850	rs675890	chr15:45936864	A/G	cg26924012	chr15:45694286	SPATA5L1	0.51	7.12	0.31	4.11e-12	Obesity-related traits;
LGG	cis	rs523522	0.923	rs2235217	chr12:120884328	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	12.55	0.5	2.71e-31	High light scatter reticulocyte count;
LGG	cis	rs1005277	0.522	rs289645	chr10:37943642	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-12.94	-0.52	6.54e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg03315344	chr16:75512273	CHST6	0.5	10.15	0.43	5.34e-22	Dupuytren's disease;
LGG	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs2204008	0.713	rs12366709	chr12:38210179	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.91	-0.38	1.15e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.86	-0.62	4.39e-50	Height;
LGG	cis	rs4901847	0.901	rs8019367	chr14:58553750	A/G	cg15908186	chr14:58618357	C14orf37	0.54	9.63	0.41	3.99e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg16662043	chr16:48846231	NA	0.37	7.2	0.32	2.53e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs36051895	0.632	rs10217652	chr9:5119939	A/G	cg02405213	chr9:5042618	JAK2	-0.81	-15.72	-0.59	6.07e-45	Pediatric autoimmune diseases;
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg19901468	chr14:105411992	AHNAK2	-0.89	-18.7	-0.66	1.61e-58	Rheumatoid arthritis;
LGG	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg23752985	chr2:85803571	VAMP8	0.4	7.81	0.34	3.84e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7523273	0.548	rs3109808	chr1:207948477	C/A	cg22525895	chr1:207977042	MIR29B2	0.62	12.12	0.49	1.5e-29	Schizophrenia;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg11494091	chr17:61959527	GH2	1.04	27.24	0.78	3.04e-98	Prudent dietary pattern;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg21724239	chr8:58056113	NA	0.47	7.07	0.31	5.88e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7336332	0.598	rs7669	chr13:28009851	C/T	cg01674679	chr13:27998804	GTF3A	-0.64	-7.96	-0.35	1.39e-14	Weight;
LGG	cis	rs7737355	0.741	rs6875363	chr5:130581195	A/G	cg06307176	chr5:131281290	NA	-0.46	-6.96	-0.31	1.16e-11	Life satisfaction;
LGG	cis	rs2071426	0.580	rs6583966	chr10:96759902	C/T	cg09036531	chr10:96991505	NA	-0.42	-6.74	-0.3	4.77e-11	Blood metabolite levels;
LGG	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg02503808	chr4:7069936	GRPEL1	-0.98	-13.65	-0.54	6.79e-36	Monocyte percentage of white cells;
LGG	cis	rs11018904	0.861	rs61903723	chr11:89968246	C/T	cg27158573	chr11:89632121	NA	-0.44	-7.54	-0.33	2.58e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.892	rs72783890	chr5:102274540	A/C	cg23492399	chr5:102201601	PAM	-0.55	-8.48	-0.37	3.05e-16	Parkinson's disease;
LGG	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg24699146	chr1:24152579	HMGCL	-0.27	-7.88	-0.34	2.34e-14	Immature fraction of reticulocytes;
LGG	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.59	0.33	1.82e-13	Colorectal cancer;
LGG	cis	rs244731	0.959	rs7721671	chr5:176630984	A/G	cg17509989	chr5:176798049	RGS14	-0.59	-8.47	-0.37	3.34e-16	Urate levels in lean individuals;
LGG	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg13010199	chr12:38710504	ALG10B	0.65	13.38	0.53	9.09e-35	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.9	-0.42	4.24e-21	Lung cancer;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg18918831	chr3:195489782	MUC4	-0.64	-8.95	-0.38	8.84e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg08112188	chr17:47440006	ZNF652	1.28	15.09	0.57	3.9e-42	Prostate cancer;
LGG	cis	rs4742903	0.967	rs10820599	chr9:106856691	T/G	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2274273	0.805	rs11628437	chr14:55775468	G/A	cg04306507	chr14:55594613	LGALS3	0.62	17.21	0.62	1.18e-51	Protein biomarker;
LGG	cis	rs858239	0.539	rs6955969	chr7:23186699	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.71	0.3	5.58e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg02002194	chr4:3960332	NA	-0.42	-8.0	-0.35	9.81e-15	Joint mobility (Beighton score);
LGG	cis	rs7312933	1.000	rs7957213	chr12:42475438	T/G	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.73	-0.3	5.08e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6784615	0.744	rs6445483	chr3:52503701	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg14186256	chr22:23484241	RTDR1	0.99	25.25	0.76	4.39e-89	Bone mineral density;
LGG	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.81	-0.45	1.9e-24	Cannabis dependence symptom count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17466768	chr2:25194156	DNAJC27	0.42	6.74	0.3	4.62e-11	Cognitive performance;
LGG	cis	rs6594713	0.756	rs6872490	chr5:112784592	T/C	cg12552261	chr5:112820674	MCC	0.63	9.04	0.39	4.46e-18	Brain cytoarchitecture;
LGG	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg20503657	chr10:835505	NA	0.95	13.14	0.52	9.88e-34	Eosinophil percentage of granulocytes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01438737	chr20:42086396	SFRS6	0.4	6.78	0.3	3.72e-11	Body mass index;
LGG	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg03929089	chr4:120376271	NA	-0.53	-8.98	-0.39	6.86e-18	HDL cholesterol;
LGG	cis	rs8141529	0.529	rs5762767	chr22:29141241	C/T	cg15103426	chr22:29168792	CCDC117	0.63	6.68	0.3	7.02e-11	Lymphocyte counts;
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg26354017	chr1:205819088	PM20D1	-0.55	-10.75	-0.45	3.14e-24	Menarche (age at onset);
LGG	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg03477792	chr4:77819574	ANKRD56	0.51	8.95	0.38	8.44e-18	Emphysema distribution in smoking;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.07	-0.46	2.05e-25	Prostate cancer;
LGG	trans	rs783540	0.542	rs62009945	chr15:83299956	T/A	cg16105309	chr15:79090380	ADAMTS7	0.49	7.91	0.35	1.86e-14	Schizophrenia;
LGG	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2241941	0.879	rs7109418	chr11:20623007	C/T	cg09136245	chr11:20631761	SLC6A5	-0.41	-7.4	-0.33	6.31e-13	Obesity-related traits;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.45e-16	Testicular germ cell tumor;
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg03351412	chr1:154909251	PMVK	0.63	11.92	0.48	8.99e-29	Prostate cancer;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg14159672	chr1:205819179	PM20D1	0.77	16.47	0.61	2.76e-48	Menarche (age at onset);
LGG	cis	rs11574514	1.000	rs73591936	chr16:67761825	G/A	cg09738193	chr16:67926317	PSKH1	-0.74	-6.85	-0.3	2.33e-11	Crohn's disease;
LGG	cis	rs7851660	0.844	rs12343182	chr9:100624259	G/C	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg13271783	chr10:134563150	INPP5A	-0.63	-9.67	-0.41	2.83e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg07148914	chr20:33460835	GGT7	-0.42	-6.77	-0.3	3.98e-11	Height;
LGG	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg02733842	chr7:1102375	C7orf50	-0.44	-7.19	-0.32	2.65e-12	Bronchopulmonary dysplasia;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.82	-0.42	8.43e-21	Tonsillectomy;
LGG	cis	rs16937	0.640	rs6664706	chr1:205182563	T/C	cg00889227	chr1:205173544	DSTYK	-0.28	-7.05	-0.31	6.52e-12	Schizophrenia;
LGG	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-8.02	-0.35	8.61e-15	Diabetic retinopathy;
LGG	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.93	-0.35	1.61e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.78e-18	Primary sclerosing cholangitis;
LGG	cis	rs3617	0.559	rs11915546	chr3:52866845	A/C	cg11645453	chr3:52864694	ITIH4	-0.43	-7.28	-0.32	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7940866	0.834	rs7939417	chr11:130853832	T/A	cg12179176	chr11:130786555	SNX19	0.71	13.24	0.52	3.65e-34	Schizophrenia;
LGG	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg15208524	chr1:10270712	KIF1B	0.44	7.42	0.33	5.53e-13	Hepatocellular carcinoma;
LGG	cis	rs5758659	0.652	rs133358	chr22:42442539	A/T	cg15128208	chr22:42549153	NA	-0.43	-8.6	-0.37	1.28e-16	Cognitive function;
LGG	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.76	-0.34	5.33e-14	HDL cholesterol;
LGG	cis	rs11809207	0.903	rs17257148	chr1:26526348	G/C	cg23602478	chr1:26503979	CNKSR1	0.38	7.31	0.32	1.2e-12	Height;
LGG	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.53	0.4	9.09e-20	Mean corpuscular volume;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg05692746	chr2:100937584	LONRF2	-0.58	-9.34	-0.4	4.08e-19	Intelligence (multi-trait analysis);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg25258812	chr8:42195612	POLB	0.45	7.28	0.32	1.43e-12	Apolipoprotein A-IV levels;
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.4e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9354308	0.764	rs9351531	chr6:66589985	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs13314892	0.881	rs115233187	chr3:69807225	T/G	cg17445875	chr3:69859618	MITF	-0.33	-6.88	-0.3	1.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-11.92	-0.48	9.33e-29	Menarche (age at onset);
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg24503407	chr1:205819492	PM20D1	0.89	23.18	0.73	1.74e-79	Menarche (age at onset);
LGG	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg02023728	chr11:77925099	USP35	0.45	7.73	0.34	6.8e-14	Testicular germ cell tumor;
LGG	cis	rs6748734	0.548	rs4441463	chr2:241872597	A/G	cg14055004	chr2:241860995	NA	0.27	6.99	0.31	9.92e-12	Urinary metabolites;
LGG	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg06951627	chr6:26196580	NA	0.53	8.09	0.35	5.41e-15	Gout;Renal underexcretion gout;
LGG	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg25338242	chr13:114786047	RASA3	0.39	7.01	0.31	8.74e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.65	-0.34	1.14e-13	Life satisfaction;
LGG	cis	rs6931421	1.000	rs6931421	chr6:80880138	A/C	cg08355045	chr6:80787529	NA	0.41	7.5	0.33	3.32e-13	Sitting height ratio;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.79	15.92	0.59	7.85e-46	Obesity-related traits;
LGG	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs240764	0.612	rs9386154	chr6:100923704	G/C	cg21058520	chr6:100914733	NA	0.48	8.4	0.36	5.36e-16	Neuroticism;
LGG	cis	rs1707322	0.752	rs6658700	chr1:46160260	C/T	cg03146154	chr1:46216737	IPP	0.56	10.61	0.44	1.13e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7666738	0.830	rs7678911	chr4:99057430	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.72	-0.34	7.16e-14	Triglycerides;
LGG	cis	rs4660214	0.666	rs2275186	chr1:39766055	C/T	cg18385671	chr1:39797026	MACF1	-0.46	-9.6	-0.41	5e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg15704280	chr7:45808275	SEPT13	0.8	12.84	0.51	1.66e-32	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.08e-17	Alzheimer's disease;
LGG	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg02002194	chr4:3960332	NA	-0.5	-9.9	-0.42	4.34e-21	Mood instability;
LGG	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	9.98e-14	Neutrophil percentage of white cells;
LGG	cis	rs259282	0.605	rs3760939	chr19:33106911	A/C	cg02997394	chr19:33096574	ANKRD27	-0.35	-6.69	-0.3	6.57e-11	Schizophrenia;
LGG	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg18357526	chr6:26021779	HIST1H4A	0.48	7.93	0.35	1.61e-14	Iron status biomarkers;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-8.2	-0.36	2.37e-15	Aortic root size;
LGG	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg02428538	chr16:24856791	SLC5A11	0.71	10.91	0.45	8.3e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.6	0.33	1.63e-13	Eosinophil percentage of white cells;
LGG	cis	rs12472274	0.529	rs11677996	chr2:239118007	A/G	cg17459225	chr2:239074497	NA	0.76	10.99	0.45	4.13e-25	Phospholipid levels (plasma);
LGG	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg01557791	chr16:72042693	DHODH	-0.52	-9.53	-0.41	8.69e-20	Fibrinogen levels;
LGG	cis	rs4664304	0.966	rs3792198	chr2:160760338	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.22	-0.32	2.1e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg26578617	chr4:90757533	SNCA	0.41	8.16	0.35	3.21e-15	Dementia with Lewy bodies;
LGG	cis	rs367943	0.608	rs7705084	chr5:112990748	G/A	cg12552261	chr5:112820674	MCC	0.5	8.9	0.38	1.3e-17	Type 2 diabetes;
LGG	cis	rs1044826	0.597	rs6772199	chr3:139178133	C/T	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03390183	chr3:36779043	DCLK3	-0.36	-6.73	-0.3	4.93e-11	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02473395	chr12:7053926	C12orf57	0.43	6.68	0.3	6.95e-11	Gut microbiome composition (summer);
LGG	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	3.97e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13732083	chr21:47605072	C21orf56	0.49	8.53	0.37	2.13e-16	Testicular germ cell tumor;
LGG	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg13939156	chr17:80058883	NA	-0.39	-7.03	-0.31	7.24e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9640161	0.711	rs60268791	chr7:150023800	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.83	-0.59	2.04e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7091068	0.536	rs6583901	chr10:95409998	C/T	cg20715218	chr10:95462985	C10orf4	-0.61	-9.45	-0.4	1.73e-19	Urinary tract infection frequency;
LGG	trans	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs752010	0.905	rs4525030	chr1:42091307	G/C	cg06885757	chr1:42089581	HIVEP3	0.49	10.6	0.44	1.2e-23	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg17971929	chr21:40555470	PSMG1	0.59	10.1	0.43	7.96e-22	Cognitive function;
LGG	cis	rs7660883	0.897	rs236985	chr4:88008782	C/T	cg21988461	chr4:88008667	AFF1	-0.36	-10.21	-0.43	3.33e-22	HDL cholesterol levels;
LGG	trans	rs17685	0.672	rs6465011	chr7:75811297	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	23.97	0.74	3.79e-83	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7166081	1.000	rs8042237	chr15:67556625	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.79	-0.3	3.47e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6032067	0.609	rs1011536	chr20:43793370	A/G	cg10761708	chr20:43804764	PI3	0.59	9.06	0.39	3.81e-18	Blood protein levels;
LGG	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-9.55	-0.41	7.27e-20	Kawasaki disease;
LGG	cis	rs1109114	0.780	rs2918274	chr5:148601748	T/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.64	-0.59	1.39e-44	Body mass index;
LGG	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs7267979	0.789	rs1983974	chr20:25530619	A/C	cg06421707	chr20:25228305	PYGB	-0.44	-9.27	-0.4	7.08e-19	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.74e-12	Tonsillectomy;
LGG	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs362272	0.505	rs13104157	chr4:3366950	T/C	cg06533319	chr4:3265114	C4orf44	-0.33	-6.65	-0.3	8.3e-11	Serum sulfate level;
LGG	cis	rs1497828	0.871	rs2047401	chr1:217544107	T/A	cg04411442	chr1:217543379	NA	0.48	8.07	0.35	6.1e-15	Dialysis-related mortality;
LGG	cis	rs780094	0.500	rs12467476	chr2:27825715	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.3	2.38e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs972578	1.000	rs4822248	chr22:43403379	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.89	-0.31	1.8e-11	Mean platelet volume;
LGG	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.23	-0.49	5.23e-30	Height;
LGG	cis	rs6546550	1.000	rs6546550	chr2:70038232	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-7.14	-0.32	3.59e-12	Prevalent atrial fibrillation;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.5	-0.4	1.12e-19	Height;
LGG	cis	rs6834538	0.637	rs923237	chr4:113429731	C/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	7.01	0.31	8.47e-12	Free thyroxine concentration;
LGG	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg05623727	chr3:50126028	RBM5	0.33	7.2	0.32	2.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7584330	0.955	rs6729659	chr2:238385126	T/C	cg16989719	chr2:238392110	NA	-0.36	-7.78	-0.34	4.72e-14	Prostate cancer;
LGG	cis	rs7512552	0.839	rs1260367	chr1:150344514	C/T	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg21659725	chr3:3221576	CRBN	0.58	7.66	0.34	1.07e-13	Menarche (age at onset);
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg06558623	chr16:89946397	TCF25	0.92	11.9	0.48	1.15e-28	Skin colour saturation;
LGG	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.12	0.52	1.15e-33	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.61	-0.41	4.62e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.56	0.37	1.67e-16	Alzheimer's disease;
LGG	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg02254774	chr11:50257496	LOC441601	0.58	6.78	0.3	3.68e-11	Myopia (pathological);
LGG	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-12.79	-0.51	2.63e-32	Schizophrenia;
LGG	cis	rs4936894	0.500	rs12577620	chr11:124101649	T/C	cg27160556	chr11:124181099	OR8D1	-0.46	-10.7	-0.45	5.15e-24	Aging (time to death);
LGG	cis	rs847577	0.748	rs55784506	chr7:97718201	G/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.88	-0.3	2.01e-11	Breast cancer;
LGG	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg01967586	chr1:228894546	NA	-0.37	-7.72	-0.34	7.34e-14	Chronic lymphocytic leukemia;
LGG	trans	rs6561151	0.957	rs3764147	chr13:44457925	C/T	cg17145862	chr1:211918768	LPGAT1	-0.7	-12.74	-0.51	4.34e-32	Crohn's disease;
LGG	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg26769984	chr7:1090371	C7orf50	0.44	7.64	0.33	1.26e-13	Bronchopulmonary dysplasia;
LGG	cis	rs11239187	0.530	rs11239148	chr10:45064931	C/T	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg01988459	chr11:68622903	NA	-0.62	-12.46	-0.5	6.35e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14893161	chr1:205819251	PM20D1	0.87	20.23	0.69	1.1000000000000001e-65	Menarche (age at onset);
LGG	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	2.02e-13	Colorectal cancer;
LGG	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg18551225	chr6:44695536	NA	-0.62	-10.13	-0.43	6.62e-22	Total body bone mineral density;
LGG	cis	rs1577917	1.000	rs12664335	chr6:86597774	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	13.7	0.54	4.34e-36	Response to antipsychotic treatment;
LGG	cis	rs4713675	0.565	rs9366828	chr6:33672798	G/A	cg14003231	chr6:33640908	ITPR3	0.29	6.73	0.3	5.12e-11	Plateletcrit;
LGG	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg06238570	chr21:40685208	BRWD1	0.44	6.7	0.3	6.04e-11	Cognitive function;
LGG	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg04166393	chr7:2884313	GNA12	0.54	10.02	0.42	1.61e-21	Height;
LGG	cis	rs546131	0.928	rs552868	chr11:34830694	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.4	0.33	6.64e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg19399532	chr1:178512495	C1orf220	0.57	11.25	0.46	3.92e-26	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Metabolite levels (small molecules and protein measures);
LGG	trans	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg16141378	chr3:129829833	LOC729375	-0.47	-11.3	-0.46	2.6e-26	Mood instability;
LGG	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.51	-0.53	2.59e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	trans	rs56114371	0.568	rs200468	chr6:27757855	C/G	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.77	-0.3	3.86e-11	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07206840	chr1:110949893	HBXIP	0.42	6.99	0.31	9.48e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03115081	chr17:74722049	C17orf95;JMJD6	0.49	7.57	0.33	2.08e-13	Gut microbiome composition (summer);
LGG	cis	rs2544527	0.586	rs6728750	chr2:15904734	C/T	cg26669897	chr2:15909070	NA	0.37	9.26	0.4	7.5e-19	Pulmonary function (smoking interaction);Pulmonary function;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.25	-0.32	1.74e-12	Systolic blood pressure;
LGG	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.7	-0.34	8.11e-14	Iron status biomarkers;
LGG	cis	rs254781	0.550	rs410216	chr5:88004101	G/A	cg22951263	chr5:87985283	NA	-0.41	-6.7	-0.3	5.89e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2718058	0.589	rs7779539	chr7:37795566	G/A	cg15028436	chr7:37888078	TXNDC3	-0.45	-7.48	-0.33	3.82e-13	Alzheimer's disease (late onset);
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.03	-0.55	1.56e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg17294928	chr15:75287854	SCAMP5	-0.96	-18.03	-0.64	1.94e-55	Blood trace element (Zn levels);
LGG	trans	rs11088226	0.846	rs2154501	chr21:33926451	G/A	cg09050820	chr6:167586206	TCP10L2	0.69	10.79	0.45	2.27e-24	Gastritis;
LGG	trans	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg10756647	chr7:56101905	PSPH	0.46	7.0	0.31	9.03e-12	Corneal structure;
LGG	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs2235642	0.750	rs2755185	chr16:1645827	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.25	0.39	8.27e-19	Coronary artery disease;
LGG	cis	rs17286411	0.750	rs4788579	chr16:71951845	A/C	cg03805757	chr16:71968109	PKD1L3	0.33	6.82	0.3	2.86e-11	Blood protein levels;
LGG	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg27398817	chr8:82754497	SNX16	0.69	10.6	0.44	1.23e-23	Diastolic blood pressure;
LGG	cis	rs11574514	1.000	rs9929423	chr16:67733113	T/C	cg09738193	chr16:67926317	PSKH1	-0.71	-6.98	-0.31	1.05e-11	Crohn's disease;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.62	11.43	0.47	8.31e-27	Total body bone mineral density;
LGG	cis	rs12136530	0.509	rs2268809	chr1:19667552	A/G	cg17081867	chr1:19768096	CAPZB	0.34	7.89	0.34	2.14e-14	Lead levels in blood;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.06e-43	Menopause (age at onset);
LGG	cis	rs6466055	0.669	rs2299304	chr7:104771857	T/C	cg04380332	chr7:105027541	SRPK2	-0.36	-6.9	-0.31	1.69e-11	Schizophrenia;
LGG	cis	rs1348850	0.958	rs12471741	chr2:178448196	A/G	cg22681709	chr2:178499509	PDE11A	-0.42	-7.74	-0.34	6.21e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9815354	0.812	rs17217746	chr3:41926021	A/G	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs9300255	0.602	rs1790131	chr12:123701010	G/T	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg19338460	chr6:170058176	WDR27	-0.63	-8.63	-0.37	9.98e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg24375607	chr4:120327624	NA	0.62	10.39	0.43	7.1e-23	Corneal astigmatism;
LGG	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg21045802	chr8:109455806	TTC35	0.5	9.32	0.4	4.95e-19	Dupuytren's disease;
LGG	cis	rs4409675	0.619	rs12070173	chr1:28231955	G/C	cg23691781	chr1:28212827	C1orf38	0.39	10.57	0.44	1.51e-23	Corneal astigmatism;
LGG	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.06	-0.35	6.37e-15	Menarche (age at onset);
LGG	cis	rs11123406	0.723	rs4849463	chr2:111958854	C/G	cg26001287	chr2:111877753	BCL2L11	0.36	6.77	0.3	3.84e-11	Type 2 diabetes;
LGG	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg17230874	chr3:125932073	NA	0.77	16.2	0.6	4.19e-47	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg02487422	chr3:49467188	NICN1	0.57	10.63	0.44	9.42e-24	Resting heart rate;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg03395511	chr6:291903	DUSP22	-0.67	-11.39	-0.47	1.14e-26	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg03213289	chr20:61660250	NA	0.66	14.57	0.56	7.81e-40	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg00012203	chr2:219082015	ARPC2	0.76	14.17	0.55	3.86e-38	Colorectal cancer;
LGG	cis	rs10463554	0.759	rs461609	chr5:102447305	G/A	cg23492399	chr5:102201601	PAM	-0.57	-8.38	-0.36	6.2e-16	Parkinson's disease;
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg13009111	chr11:71350975	NA	0.39	8.9	0.38	1.28e-17	Neuroticism;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg16070123	chr10:51489643	NA	-0.39	-7.16	-0.32	3.11e-12	Prostate-specific antigen levels;
LGG	cis	rs3219090	0.962	rs2695236	chr1:226603003	T/C	cg17127702	chr1:226594323	PARP1	0.39	12.42	0.5	8.68e-31	Melanoma;
LGG	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs9309473	0.607	rs2421489	chr2:73593448	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-9.03	-0.39	4.79e-18	Metabolite levels;
LGG	cis	rs36051895	0.623	rs12349113	chr9:5254224	T/A	cg02405213	chr9:5042618	JAK2	-0.7	-12.31	-0.5	2.45e-30	Pediatric autoimmune diseases;
LGG	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.81	-0.48	2.51e-28	Response to antipsychotic treatment;
LGG	cis	rs10979	0.597	rs9390118	chr6:143907610	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-8.07	-0.35	6.26e-15	Hypospadias;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	7.32	0.32	1.13e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg24596788	chr1:163392923	NA	0.67	12.64	0.51	1.11e-31	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26743569	chr2:25194997	DNAJC27	0.48	7.22	0.32	2.2e-12	Gut microbiome composition (summer);
LGG	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05491587	chr18:77659695	KCNG2	-0.41	-7.4	-0.33	6.66e-13	Schizophrenia;
LGG	cis	rs12681287	0.547	rs6471360	chr8:87513469	C/T	cg27223183	chr8:87520930	FAM82B	0.5	7.62	0.33	1.42e-13	Caudate activity during reward;
LGG	cis	rs919433	0.679	rs1598469	chr2:198515658	T/C	cg00792783	chr2:198669748	PLCL1	0.57	9.18	0.39	1.44e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6942756	0.713	rs691807	chr7:129076203	G/C	cg02491457	chr7:128862824	NA	-0.67	-11.34	-0.47	1.88e-26	White matter hyperintensity burden;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg11859384	chr17:80120422	CCDC57	0.45	7.98	0.35	1.13e-14	Life satisfaction;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg06221963	chr1:154839813	KCNN3	0.52	10.79	0.45	2.35e-24	Prostate cancer;
LGG	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2544523	0.511	rs2544536	chr2:15906854	T/C	cg26669897	chr2:15909070	NA	0.45	12.61	0.51	1.49e-31	Asthma or chronic obstructive pulmonary disease;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs2467099	1.000	rs2467099	chr17:73949045	C/T	cg23806715	chr17:73775811	H3F3B	0.49	7.25	0.32	1.73e-12	Systolic blood pressure;
LGG	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg10818794	chr15:86012489	AKAP13	-0.55	-12.43	-0.5	8.42e-31	Coronary artery disease;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg08461457	chr11:2027003	NA	0.4	7.74	0.34	6.23e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.79e-16	Body mass index;
LGG	cis	rs1670533	0.872	rs13108222	chr4:1054256	C/A	cg27284194	chr4:1044797	NA	0.55	9.76	0.41	1.37e-20	Recombination rate (females);
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg21782813	chr7:2030301	MAD1L1	-0.4	-9.51	-0.4	1.06e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg09237302	chr4:906077	GAK	-0.42	-8.66	-0.37	8.08e-17	Parkinson's disease;
LGG	cis	rs4731207	0.844	rs33935352	chr7:124395310	A/G	cg05630886	chr7:124431682	NA	0.31	6.84	0.3	2.48e-11	Cutaneous malignant melanoma;
LGG	trans	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	9.4	0.4	2.6e-19	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs12450239	0.884	rs1877681	chr17:77448020	T/C	cg07832143	chr17:77435199	HRNBP3	0.35	6.89	0.3	1.86e-11	Body mass index;
LGG	cis	rs7107174	0.892	rs10899490	chr11:78105879	C/T	cg02023728	chr11:77925099	USP35	0.46	8.05	0.35	7.27e-15	Testicular germ cell tumor;
LGG	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	7.42	0.33	5.75e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.64	-0.44	8.8e-24	Height;
LGG	cis	rs11997175	1.000	rs6468200	chr8:33745191	A/T	ch.8.33884649F	chr8:33765107	NA	0.37	6.79	0.3	3.43e-11	Body mass index;
LGG	cis	rs10769945	0.605	rs656757	chr11:1966106	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.44	-7.94	-0.35	1.54e-14	DNA methylation (variation);
LGG	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.16	-0.32	3.14e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg14789911	chr21:47582049	C21orf56	-0.43	-7.32	-0.32	1.13e-12	Testicular germ cell tumor;
LGG	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg11161011	chr14:65562177	MAX	-0.72	-13.49	-0.53	3.41e-35	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	6.04e-17	IgG glycosylation;
LGG	cis	rs2070433	0.706	rs3788265	chr21:47833789	G/T	cg02959939	chr21:47813025	PCNT	-0.37	-6.88	-0.3	1.99e-11	Lymphocyte counts;
LGG	cis	rs1344694	0.566	rs4672790	chr2:216892446	C/T	cg12620499	chr2:216877984	MREG	0.61	11.82	0.48	2.28e-28	Alcohol dependence;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg02002194	chr4:3960332	NA	-0.52	-10.16	-0.43	4.94e-22	Neuroticism;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg06238570	chr21:40685208	BRWD1	0.44	6.72	0.3	5.36e-11	Cognitive function;
LGG	cis	rs763121	0.962	rs6001193	chr22:39074737	A/G	cg06022373	chr22:39101656	GTPBP1	0.83	16.94	0.62	1.88e-50	Menopause (age at onset);
LGG	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.62e-12	Cognitive ability;
LGG	cis	rs283228	1.000	rs2579927	chr6:101830650	C/T	cg27451362	chr6:101846650	GRIK2	0.54	8.92	0.38	1.07e-17	Coenzyme Q10 levels;
LGG	cis	rs2273669	0.667	rs10457185	chr6:109322477	G/C	cg05315195	chr6:109294784	ARMC2	-0.66	-8.68	-0.37	6.93e-17	Prostate cancer;
LGG	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.29	-0.36	1.25e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9463078	0.625	rs6926370	chr6:44947280	G/C	cg25276700	chr6:44698697	NA	-0.33	-6.83	-0.3	2.61e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9381040	0.610	rs742495	chr6:41018233	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.75	-0.3	4.49e-11	Alzheimer's disease (late onset);
LGG	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg26384229	chr12:38710491	ALG10B	-0.82	-18.17	-0.65	4.32e-56	Bladder cancer;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-7.9	-0.34	2.12e-14	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15660466	chr17:49230788	NME1;NME1-NME2	0.47	7.66	0.34	1.06e-13	Cognitive performance;
LGG	cis	rs6426558	0.537	rs4653813	chr1:227461510	G/C	cg10327440	chr1:227177885	CDC42BPA	0.62	10.27	0.43	1.99e-22	Neutrophil percentage of white cells;
LGG	cis	rs4950322	0.570	rs72692973	chr1:146805013	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg25358565	chr5:93447407	FAM172A	1.32	16.39	0.61	6.21e-48	Diabetic retinopathy;
LGG	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg03264133	chr6:25882463	NA	-0.38	-6.73	-0.3	4.98e-11	Height;
LGG	cis	rs972578	0.668	rs11705627	chr22:43381650	C/T	cg01576275	chr22:43409880	NA	-0.25	-7.63	-0.33	1.34e-13	Mean platelet volume;
LGG	cis	rs78487399	0.808	rs13409687	chr2:43701151	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.72	-0.3	5.46e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg21827317	chr3:136751795	NA	0.53	9.91	0.42	4.1e-21	Neuroticism;
LGG	trans	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg10756647	chr7:56101905	PSPH	0.77	8.78	0.38	3.15e-17	Diabetic kidney disease;
LGG	cis	rs2797369	0.713	rs2749136	chr6:101494021	T/A	cg27451362	chr6:101846650	GRIK2	0.85	11.39	0.47	1.19e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg11859384	chr17:80120422	CCDC57	0.39	6.79	0.3	3.56e-11	Life satisfaction;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9287719	0.781	rs6714795	chr2:10759134	C/T	cg02196655	chr2:10830764	NOL10	-0.47	-8.16	-0.35	3.12e-15	Prostate cancer;
LGG	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs11785693	0.862	rs17435612	chr8:4987896	C/T	cg26367366	chr8:4980734	NA	-0.93	-14.87	-0.57	3.78e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg06766960	chr11:133703094	NA	-0.58	-11.49	-0.47	4.79e-27	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08158076	chr1:90287038	LRRC8D	0.47	7.11	0.31	4.57e-12	Gut microbiome composition (summer);
LGG	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg13256891	chr4:100009986	ADH5	0.55	9.53	0.4	8.96e-20	Alcohol dependence;
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2270927	0.510	rs2937738	chr5:75633515	C/A	cg13563193	chr19:33072644	PDCD5	0.79	8.17	0.35	3.07e-15	Mean corpuscular volume;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg19147804	chr7:1989927	MAD1L1	0.51	10.0	0.42	1.94e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs74781061	0.929	rs6495118	chr15:74912012	T/G	cg02384859	chr15:74862662	ARID3B	-0.34	-6.96	-0.31	1.14e-11	Endometriosis;
LGG	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg26031613	chr14:104095156	KLC1	0.49	7.7	0.34	8.22e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7566780	0.575	rs4832645	chr2:16694736	C/G	cg09580478	chr2:16689509	NA	0.47	7.42	0.33	5.54e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg02466173	chr16:30829666	NA	0.4	7.19	0.32	2.69e-12	Dementia with Lewy bodies;
LGG	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.24	0.6	2.86e-47	Smoking behavior;
LGG	cis	rs2735413	0.599	rs112375862	chr16:78079237	T/C	cg04733911	chr16:78082701	NA	0.53	7.17	0.32	3.06e-12	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg14829155	chr15:31115871	NA	-0.58	-9.54	-0.41	8.48e-20	Huntington's disease progression;
LGG	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg24687543	chr11:63912206	MACROD1	0.62	8.74	0.38	4.45e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg22105103	chr4:187893119	NA	0.57	10.82	0.45	1.72e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24868098	chr19:47249198	STRN4;FKRP	0.53	6.78	0.3	3.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg19554555	chr3:13937349	NA	-0.53	-9.55	-0.41	7.58e-20	Ovarian reserve;
LGG	cis	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07243736	chr16:783730	NARFL	0.41	7.09	0.31	5.2e-12	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16730369	chr11:120823575	GRIK4	0.43	7.13	0.31	3.87e-12	Cognitive performance;
LGG	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg17085576	chr10:5658249	NA	-0.42	-7.85	-0.34	2.96e-14	Breast cancer;
LGG	cis	rs240764	0.531	rs1070990	chr6:101264412	T/A	cg09795085	chr6:101329169	ASCC3	0.46	7.7	0.34	8.33e-14	Neuroticism;
LGG	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg08250081	chr4:10125330	NA	0.36	7.05	0.31	6.39e-12	Bone mineral density;
LGG	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg23840854	chr1:161414152	NA	-0.69	-8.46	-0.37	3.59e-16	Rheumatoid arthritis;
LGG	trans	rs3932549	1	rs3932549	chr9:97073588	A/C	cg05679027	chr9:99775184	HIATL2	0.49	8.22	0.36	2.03e-15	Body mass index;
LGG	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.02	-0.46	3.13e-25	Hemoglobin concentration;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs6867032	0.876	rs1552435	chr5:2018378	A/G	cg26168224	chr5:2018326	NA	1.3	32.02	0.83	1.78e-119	Gut microbiome composition (winter);
LGG	cis	rs1408799	0.711	rs1886586	chr9:12626009	A/C	cg05274944	chr9:12693694	TYRP1	0.32	7.43	0.33	5.22e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg19168338	chr16:4465731	CORO7	-1.16	-25.75	-0.77	2.15e-91	Schizophrenia;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.12e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg01673284	chr16:4527211	HMOX2	0.33	6.82	0.3	2.9e-11	Schizophrenia;
LGG	cis	rs9952991	0.528	rs612058	chr18:12850211	T/C	cg23598886	chr18:12777645	NA	0.53	7.43	0.33	5.12e-13	Inflammatory skin disease;
LGG	cis	rs4409675	0.576	rs6660899	chr1:28214281	G/C	cg23691781	chr1:28212827	C1orf38	0.39	10.54	0.44	1.98e-23	Corneal astigmatism;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg00933542	chr6:150070202	PCMT1	0.38	6.93	0.31	1.43e-11	Lung cancer;
LGG	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.42	-0.4	2.1e-19	Neuroticism;
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg23730037	chr7:158596552	ESYT2	-0.4	-6.79	-0.3	3.5e-11	Height;
LGG	trans	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.22e-18	Bladder cancer;
LGG	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.78	-0.34	4.68e-14	Mood instability;
LGG	trans	rs12545912	0.739	rs12541617	chr8:9539099	A/G	cg16141378	chr3:129829833	LOC729375	0.33	6.98	0.31	1.04e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs2652834	0.851	rs2652792	chr15:63411492	G/C	cg05507819	chr15:63340323	TPM1	0.5	7.04	0.31	7.08e-12	HDL cholesterol;
LGG	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg21775007	chr8:11205619	TDH	0.8	14.65	0.56	3.5e-40	Retinal vascular caliber;
LGG	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg18357526	chr6:26021779	HIST1H4A	0.5	8.33	0.36	9.15e-16	Height;
LGG	cis	rs4731207	0.591	rs9691875	chr7:124675705	A/T	cg05630886	chr7:124431682	NA	-0.31	-7.11	-0.31	4.45e-12	Cutaneous malignant melanoma;
LGG	cis	rs7236492	0.748	rs79548165	chr18:77183529	C/T	cg15644404	chr18:77186268	NFATC1	-0.8	-9.55	-0.41	7.53e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg02297831	chr4:17616191	MED28	0.5	9.41	0.4	2.4e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg02725872	chr8:58115012	NA	-0.94	-12.31	-0.5	2.54e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3806843	0.808	rs6893708	chr5:140125922	T/C	cg19875535	chr5:140030758	IK	-0.54	-11.24	-0.46	4.51e-26	Depressive symptoms (multi-trait analysis);
LGG	trans	rs2572431	0.543	rs2256016	chr8:11162602	C/A	cg02002194	chr4:3960332	NA	-0.42	-7.66	-0.34	1.07e-13	Neuroticism;
LGG	cis	rs6831352	0.851	rs1230164	chr4:99986023	C/G	cg13256891	chr4:100009986	ADH5	0.48	8.17	0.35	3.04e-15	Alcohol dependence;
LGG	cis	rs67133203	0.904	rs12369639	chr12:51328269	T/C	cg14688905	chr12:51403056	SLC11A2	0.73	10.77	0.45	2.64e-24	Urinary tract infection frequency;
LGG	cis	rs4330281	0.647	rs12494513	chr3:17427622	A/G	cg20981856	chr3:17787350	NA	0.36	6.77	0.3	3.81e-11	Schizophrenia;
LGG	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.92	0.45	7.15e-25	Parkinson's disease;
LGG	cis	rs11191205	0.686	rs12358045	chr10:103399708	C/T	cg15320455	chr10:103880129	LDB1	0.48	6.93	0.31	1.4e-11	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.22	0.49	6.09e-30	Colorectal cancer;
LGG	cis	rs7100689	0.646	rs7894762	chr10:82086779	C/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.65	0.56	3.21e-40	Post bronchodilator FEV1;
LGG	cis	rs919433	0.750	rs788012	chr2:198229856	A/T	cg00792783	chr2:198669748	PLCL1	0.47	7.39	0.32	6.96e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21139845	chr12:7053993	C12orf57	-0.46	-6.8	-0.3	3.19e-11	Systemic lupus erythematosus;
LGG	cis	rs2976388	0.590	rs10087426	chr8:143814554	G/A	cg06565975	chr8:143823917	SLURP1	-0.52	-13.14	-0.52	9.75e-34	Urinary tract infection frequency;
LGG	cis	rs3857747	0.931	rs4588741	chr7:40365508	G/T	cg00420559	chr7:40367873	C7orf10	-0.4	-8.05	-0.35	6.92e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg21427119	chr20:30132790	HM13	-0.55	-8.7	-0.37	5.99e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.71	-6.81	-0.3	3.07e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg25811766	chr13:21894605	NA	0.7	9.26	0.4	7.81e-19	White matter hyperintensity burden;
LGG	cis	rs7267979	0.844	rs35735333	chr20:25337205	T/G	cg06421707	chr20:25228305	PYGB	-0.43	-9.11	-0.39	2.41e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs75920871	0.920	rs7924318	chr11:116816630	C/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.66e-12	Subjective well-being;
LGG	cis	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg19847130	chr8:10466454	RP1L1	0.34	7.0	0.31	9.15e-12	Neuroticism;
LGG	cis	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg07460842	chr6:66804631	NA	0.96	17.92	0.64	5.89e-55	Exhaled nitric oxide output;
LGG	cis	rs17776563	0.887	rs11638658	chr15:89124610	C/G	cg05013243	chr15:89149849	MIR1179	0.5	10.31	0.43	1.47e-22	Thyroid hormone levels;
LGG	cis	rs2273669	0.667	rs78383792	chr6:109312498	A/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.39	-0.36	5.81e-16	Prostate cancer;
LGG	cis	rs9394438	0.628	rs10947680	chr6:37543668	T/C	cg00985040	chr6:37553208	NA	-0.36	-7.83	-0.34	3.37e-14	IgG glycosylation;
LGG	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	13.84	0.54	1.02e-36	Type 2 diabetes;
LGG	cis	rs397969	0.596	rs12450857	chr17:19895248	C/T	cg13482628	chr17:19912719	NA	0.51	8.31	0.36	1.07e-15	Platelet count;
LGG	cis	rs7517126	0.858	rs16840422	chr1:196652834	C/T	cg07209298	chr1:196795943	CFHR1	-0.5	-6.75	-0.3	4.39e-11	Blood protein levels;
LGG	cis	rs721917	0.629	rs1304463	chr10:81729272	G/A	cg25562619	chr10:81652821	NA	-0.3	-6.78	-0.3	3.75e-11	Chronic obstructive pulmonary disease;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.85	-0.38	1.9e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1847202	1.000	rs6807627	chr3:72939767	C/T	cg25664220	chr3:72788482	NA	-0.23	-7.22	-0.32	2.13e-12	Motion sickness;
LGG	cis	rs12367572	0.620	rs1857925	chr12:45344385	T/C	cg04608330	chr12:45269318	NELL2	-0.41	-6.68	-0.3	7.05e-11	Gut microbiome composition (summer);
LGG	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg24634471	chr8:143751801	JRK	0.5	7.64	0.33	1.29e-13	Schizophrenia;
LGG	cis	rs524281	0.692	rs2302884	chr11:65824084	C/T	cg16950941	chr11:66035639	RAB1B	-0.52	-8.32	-0.36	1.02e-15	Electroencephalogram traits;
LGG	cis	rs977987	0.835	rs8046109	chr16:75360096	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.69	0.41	2.47e-20	Dupuytren's disease;
LGG	cis	rs3781913	0.874	rs12362256	chr11:72368654	C/T	cg02728101	chr11:72386540	PDE2A	0.31	6.81	0.3	2.98e-11	Rheumatoid arthritis;
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg26116260	chr4:7069785	GRPEL1	-1.13	-21.78	-0.71	6.24e-73	Monocyte percentage of white cells;
LGG	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs6977660	0.714	rs10950753	chr7:19817302	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg04568710	chr12:38710424	ALG10B	-0.38	-8.05	-0.35	6.85e-15	Bladder cancer;
LGG	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg27297192	chr10:134578999	INPP5A	0.31	6.85	0.3	2.43e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	31.89	0.83	6.37e-119	Chronic sinus infection;
LGG	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg12751644	chr20:60527061	NA	-0.3	-6.68	-0.3	6.87e-11	Body mass index;
LGG	cis	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs6547741	0.935	rs2384626	chr2:27773648	A/G	cg22903471	chr2:27725779	GCKR	0.36	8.19	0.36	2.59e-15	Oral cavity cancer;
LGG	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.56	-0.56	8.22e-40	Blood metabolite levels;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.64	0.54	7.69e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.55	-0.37	1.86e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2304069	0.550	rs216144	chr5:149445480	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.6	9.09	0.39	2.92e-18	HIV-1 control;
LGG	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-8.67	-0.37	7.59e-17	Monocyte count;
LGG	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg15440763	chr7:158190612	PTPRN2	-0.43	-9.33	-0.4	4.47e-19	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1620404	chr10:60327830	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg07541023	chr7:19748670	TWISTNB	0.49	6.72	0.3	5.21e-11	Night sleep phenotypes;
LGG	cis	rs568617	0.903	rs601863	chr11:65646557	C/A	cg26695010	chr11:65641043	EFEMP2	0.47	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs2213920	0.749	rs10121366	chr9:118244022	T/C	cg13918206	chr9:118159781	DEC1	0.53	7.44	0.33	4.92e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs514024	0.700	rs538927	chr9:130488494	C/T	cg13643465	chr9:130375613	STXBP1	0.58	10.95	0.45	5.52e-25	Eating disorders (purging via substances);
LGG	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs738321	0.790	rs4820317	chr22:38543287	T/C	cg03162506	chr22:38580953	NA	0.39	9.55	0.41	7.43e-20	Breast cancer;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.51	0.56	1.34e-39	Obesity-related traits;
LGG	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg24585782	chr17:78113791	EIF4A3	-0.51	-8.42	-0.36	4.85e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-10.3	-0.43	1.51e-22	Hepatocellular carcinoma;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg06925179	chr17:43578568	NA	0.32	7.73	0.34	6.96e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg23750338	chr8:142222470	SLC45A4	0.59	12.31	0.5	2.6e-30	Immature fraction of reticulocytes;
LGG	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg13010199	chr12:38710504	ALG10B	0.4	7.43	0.33	5.35e-13	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg02002194	chr4:3960332	NA	0.41	7.65	0.33	1.14e-13	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.06	-0.35	6.55e-15	Skin colour saturation;
LGG	cis	rs1595825	1.000	rs1595825	chr2:198875464	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-7.18	-0.32	2.72e-12	Ulcerative colitis;
LGG	cis	rs7524258	0.868	rs1304712	chr1:7270538	C/T	cg07173049	chr1:7289937	CAMTA1	0.68	15.9	0.59	9.51e-46	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs11966931	0.711	rs9320236	chr6:108089688	G/T	cg04749840	chr6:108095067	SCML4	-0.46	-9.35	-0.4	3.89e-19	Neutrophil percentage of white cells;
LGG	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.97	0.38	7.19e-18	Rheumatoid arthritis;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg04861929	chr11:109293070	C11orf87	0.56	10.03	0.42	1.5e-21	Schizophrenia;
LGG	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg25358565	chr5:93447407	FAM172A	1.28	16.09	0.6	1.44e-46	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6430585	0.941	rs6708957	chr2:136520043	C/T	cg07169764	chr2:136633963	MCM6	1.0	19.16	0.67	1.07e-60	Corneal structure;
LGG	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg12623918	chr2:306882	NA	0.38	7.11	0.31	4.39e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-11.54	-0.47	2.88e-27	Vitiligo;
LGG	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg19812747	chr11:111475976	SIK2	-0.48	-9.67	-0.41	2.81e-20	Primary sclerosing cholangitis;
LGG	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg14541582	chr5:601475	NA	-0.71	-11.21	-0.46	5.75e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg06637938	chr14:75390232	RPS6KL1	0.52	9.41	0.4	2.33e-19	Height;
LGG	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg07148914	chr20:33460835	GGT7	0.52	8.78	0.38	3.24e-17	Height;
LGG	cis	rs2074193	0.627	rs11183921	chr12:47774206	G/T	cg02516419	chr12:47771422	NA	-0.7	-10.59	-0.44	1.28e-23	Migraine with aura;
LGG	cis	rs3849046	0.817	rs11959184	chr5:137931878	A/G	cg10920316	chr5:137946599	NA	0.42	6.65	0.3	8.31e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7432375	0.523	rs12486911	chr3:136558953	C/G	cg21827317	chr3:136751795	NA	0.53	9.24	0.39	9.2e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg18551225	chr6:44695536	NA	-0.61	-9.85	-0.42	6.5e-21	Total body bone mineral density;
LGG	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg04691961	chr3:161091175	C3orf57	-0.42	-8.7	-0.37	5.68e-17	Kawasaki disease;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.6	0.33	1.69e-13	Longevity;
LGG	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg21138405	chr5:131827807	IRF1	-0.31	-7.05	-0.31	6.51e-12	Breast cancer;Mosquito bite size;
LGG	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-7.29	-0.32	1.36e-12	Alzheimer's disease (late onset);
LGG	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	cg15522984	chr1:182991683	LAMC1	0.45	8.97	0.38	7.34e-18	Colorectal cancer;
LGG	cis	rs6909430	0.901	rs1487449	chr6:98576999	G/A	cg12860156	chr6:98744658	NA	-0.44	-7.46	-0.33	4.27e-13	Quantitative traits;
LGG	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg25801113	chr15:45476975	SHF	-0.86	-18.67	-0.66	2.19e-58	Uric acid levels;
LGG	cis	rs4478137	0.501	rs7657483	chr4:164232102	T/C	cg06758707	chr4:164254230	NPY1R	-0.55	-8.09	-0.35	5.29e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg06611532	chr13:114900021	NA	0.27	6.74	0.3	4.71e-11	Schizophrenia;
LGG	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.52	-0.33	2.85e-13	Total cholesterol levels;
LGG	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.98	-0.31	1.02e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg06808227	chr14:105710500	BRF1	0.64	11.65	0.48	1.08e-27	Mean platelet volume;Platelet distribution width;
LGG	trans	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.47	-0.5	5.64e-31	Obesity-related traits;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg11301795	chr4:187892539	NA	-0.94	-24.71	-0.75	1.34e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9326248	0.817	rs6589598	chr11:117002403	A/G	cg20608306	chr11:116969690	SIK3	0.34	8.29	0.36	1.28e-15	Blood protein levels;
LGG	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg18252515	chr7:66147081	NA	-1.41	-20.61	-0.69	1.84e-67	Diabetic kidney disease;
LGG	cis	rs11585357	0.501	rs17458002	chr1:17591524	A/G	cg08277548	chr1:17600880	PADI3	-0.62	-6.73	-0.3	5.18e-11	Hair shape;
LGG	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg03651054	chr13:50194643	NA	0.3	6.75	0.3	4.31e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6743226	0.603	rs62186421	chr2:242248772	T/C	cg10021735	chr2:242295487	FARP2	0.41	7.21	0.32	2.37e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.11	-0.35	4.44e-15	Height;
LGG	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.68	0.34	9.25e-14	Systolic blood pressure;
LGG	cis	rs1707322	0.964	rs7546237	chr1:46285610	A/C	cg03146154	chr1:46216737	IPP	0.54	10.35	0.43	9.77e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7113850	0.541	rs77054343	chr11:24215636	A/G	ch.11.24196551F	chr11:24239977	NA	0.91	9.23	0.39	9.97e-19	Bone fracture in osteoporosis;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.36	-0.32	8.22e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg01262667	chr19:19385393	TM6SF2	0.36	7.26	0.32	1.6e-12	Bipolar disorder;
LGG	cis	rs11920090	0.656	rs11719104	chr3:170628895	T/C	cg09710316	chr3:170744871	SLC2A2	0.65	7.67	0.34	1.03e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg03929089	chr4:120376271	NA	0.85	13.3	0.53	2.05e-34	Coronary artery disease;
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs4788570	0.615	rs7206470	chr16:71668800	G/A	cg06353428	chr16:71660113	MARVELD3	1.27	21.48	0.71	1.62e-71	Intelligence (multi-trait analysis);
LGG	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg14784868	chr12:69753453	YEATS4	0.76	15.11	0.57	3.12e-42	Blood protein levels;
LGG	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg27489772	chr12:121021490	NA	0.57	7.52	0.33	2.96e-13	Type 1 diabetes nephropathy;
LGG	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg13073564	chr4:8508604	NA	-0.53	-10.91	-0.45	8.43e-25	Response to antineoplastic agents;
LGG	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg18681998	chr4:17616180	MED28	0.72	14.74	0.57	1.42e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs747782	0.527	rs76142260	chr11:48331068	T/C	cg15704280	chr7:45808275	SEPT13	0.7	7.71	0.34	7.82e-14	Intraocular pressure;
LGG	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg12855166	chr17:30846586	MYO1D	0.4	7.11	0.31	4.49e-12	Schizophrenia;
LGG	cis	rs9400467	0.506	rs77549436	chr6:111690730	T/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs975722	0.531	rs10249988	chr7:117382261	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	8.35	0.36	8.2e-16	Coronary artery disease;
LGG	cis	rs9368481	0.524	rs9393768	chr6:26885619	A/G	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11039798	0.841	rs12221667	chr11:48548549	G/T	cg15704280	chr7:45808275	SEPT13	0.74	7.88	0.34	2.39e-14	Axial length;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	15.04	0.57	6.35e-42	Personality dimensions;
LGG	trans	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg16141378	chr3:129829833	LOC729375	0.47	11.11	0.46	1.45e-25	Mood instability;
LGG	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-19.28	-0.67	3.08e-61	Gut microbiome composition (summer);
LGG	cis	rs2859741	0.546	rs2102087	chr1:37482849	G/A	cg09363841	chr1:37513479	NA	-0.57	-11.63	-0.48	1.28e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.67	12.33	0.5	2.02e-30	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.688	rs17638180	chr15:86278395	A/C	cg25843651	chr15:86329602	KLHL25	0.58	8.99	0.39	6.53e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs11025559	0.796	rs10833317	chr11:20412277	A/T	cg19653624	chr11:20408972	PRMT3	-0.49	-8.05	-0.35	7.26e-15	Pursuit maintenance gain;
LGG	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	7.13	0.31	3.89e-12	Mood instability;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg05665937	chr4:1216051	CTBP1	0.48	8.37	0.36	6.91e-16	Obesity-related traits;
LGG	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.46	-0.33	4.44e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.69	0.41	2.45e-20	Mean corpuscular volume;
LGG	cis	rs7100689	0.646	rs1340376	chr10:82128963	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.56	-0.75	6.83e-86	Height;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg03188948	chr7:1209495	NA	0.62	8.15	0.35	3.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7923609	0.869	rs10733792	chr10:65232539	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.7	-0.3	6.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11875185	1.000	rs11875185	chr18:55627840	A/G	cg15513957	chr14:69354734	ACTN1	-0.7	-7.91	-0.35	1.97e-14	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9878978	0.685	rs34556922	chr3:2504892	A/T	cg21928760	chr3:2462534	CNTN4	0.37	7.32	0.32	1.11e-12	Blood pressure (smoking interaction);
LGG	cis	rs9503598	1.000	rs9503598	chr6:3446263	A/G	cg00476032	chr6:3446245	SLC22A23	-0.69	-15.25	-0.58	7.73e-43	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg06827562	chr3:125932279	NA	0.46	9.81	0.41	9.36e-21	Metabolite levels;
LGG	cis	rs2239547	0.521	rs9682464	chr3:52888485	C/T	cg11645453	chr3:52864694	ITIH4	0.71	11.24	0.46	4.28e-26	Schizophrenia;
LGG	cis	rs1345301	0.552	rs1558626	chr2:102862070	T/A	cg05295703	chr2:102895712	NA	0.48	9.54	0.41	8.22e-20	Waist circumference;
LGG	cis	rs9815354	0.680	rs7649989	chr3:41865843	A/C	cg03022575	chr3:42003672	ULK4	0.65	8.33	0.36	9.23e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg08603382	chr10:743973	NA	0.38	6.83	0.3	2.72e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs10927875	0.619	rs12121764	chr1:16138059	A/T	cg21385522	chr1:16154831	NA	-0.73	-15.11	-0.57	3.35e-42	Dilated cardiomyopathy;
LGG	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg19812747	chr11:111475976	SIK2	-0.46	-9.32	-0.4	4.6e-19	Primary sclerosing cholangitis;
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.18	-0.32	2.77e-12	Retinal vascular caliber;
LGG	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg27661571	chr11:113659931	NA	-0.67	-9.35	-0.4	3.85e-19	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.3	6.9	0.31	1.7e-11	Schizophrenia;
LGG	trans	rs5756813	0.668	rs5756805	chr22:38144618	A/G	cg19894588	chr14:64061835	NA	-0.46	-7.62	-0.33	1.42e-13	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03573702	chr19:44669354	ZNF226	0.42	6.84	0.3	2.54e-11	Gut microbiome composition (summer);
LGG	cis	rs2282300	0.696	rs1222214	chr11:30347695	C/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.9	-0.34	2.03e-14	Morning vs. evening chronotype;
LGG	cis	rs6784615	1.000	rs71297391	chr3:52376773	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.68	7.41	0.33	6.01e-13	Waist-hip ratio;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-11.71	-0.48	6.29e-28	Personality dimensions;
LGG	cis	rs6964587	0.967	rs28399886	chr7:91638451	A/G	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg05535760	chr7:792225	HEATR2	0.79	12.71	0.51	6.11e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg06889755	chr6:150326021	RAET1K	-0.34	-6.86	-0.3	2.25e-11	Alopecia areata;
LGG	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.55	-8.0	-0.35	1e-14	Yeast infection;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg05313129	chr8:58192883	C8orf71	-0.82	-12.2	-0.49	7.22e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg09873164	chr1:152488093	CRCT1	-0.63	-15.42	-0.58	1.32e-43	Hair morphology;
LGG	cis	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg07460842	chr6:66804631	NA	-0.88	-14.65	-0.56	3.49e-40	Exhaled nitric oxide output;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg19168338	chr16:4465731	CORO7	-0.89	-17.99	-0.64	3.01e-55	Schizophrenia;
LGG	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.39	-0.32	6.81e-13	Mood instability;
LGG	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	trans	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.53e-30	Corneal astigmatism;
LGG	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.65e-12	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg21427119	chr20:30132790	HM13	-0.41	-7.13	-0.31	3.93e-12	Mean corpuscular hemoglobin;
LGG	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg18225595	chr11:63971243	STIP1	0.65	12.8	0.51	2.45e-32	Platelet count;
LGG	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg09596252	chr17:78655493	RPTOR	0.43	7.75	0.34	5.76e-14	Obesity;
LGG	cis	rs9473924	0.505	rs9473921	chr6:50828072	C/T	cg14470998	chr6:50812995	TFAP2B	0.68	8.14	0.35	3.6e-15	Body mass index;
LGG	cis	rs4689642	0.507	rs4689650	chr4:7223032	C/T	cg21353189	chr4:7228343	SORCS2	0.34	7.22	0.32	2.1e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg12454169	chr2:30669597	LCLAT1	0.59	7.96	0.35	1.3e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.67	-0.41	2.95e-20	Response to antipsychotic treatment;
LGG	cis	rs6723226	1.000	rs6723226	chr2:32849207	C/T	cg02381751	chr2:32503542	YIPF4	0.62	10.45	0.44	4.25e-23	Intelligence (multi-trait analysis);
LGG	cis	rs11969893	0.850	rs9404055	chr6:101302260	C/T	cg12253828	chr6:101329408	ASCC3	1.13	9.77	0.41	1.29e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs870825	0.860	rs72703527	chr4:185605997	C/A	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	trans	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.89e-30	Corneal astigmatism;
LGG	cis	rs17039065	1.000	rs17039068	chr4:109385975	C/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.84	0.3	2.53e-11	Gut microbiome composition (summer);
LGG	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg06808227	chr14:105710500	BRF1	-0.64	-10.98	-0.45	4.19e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6988985	0.647	rs28558934	chr8:143986555	T/C	cg10324643	chr8:143916377	GML	0.45	9.32	0.4	4.87e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg20637307	chr2:213403960	ERBB4	0.59	10.49	0.44	2.98e-23	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.94e-12	Bipolar disorder;
LGG	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg03929089	chr4:120376271	NA	-0.66	-9.46	-0.4	1.62e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	trans	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg06521331	chr12:34319734	NA	0.51	9.46	0.4	1.55e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg09264619	chr17:80180166	NA	0.36	7.27	0.32	1.55e-12	Life satisfaction;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	6.12e-20	Life satisfaction;
LGG	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	7.97	0.35	1.28e-14	Educational attainment;
LGG	cis	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg08112188	chr17:47440006	ZNF652	1.2	13.13	0.52	1.08e-33	Prostate cancer;
LGG	cis	rs6466055	0.720	rs3801999	chr7:105027646	G/A	cg04380332	chr7:105027541	SRPK2	0.4	7.53	0.33	2.66e-13	Schizophrenia;
LGG	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg18854424	chr1:2615690	NA	0.34	7.43	0.33	5.28e-13	Ulcerative colitis;
LGG	cis	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg06521331	chr12:34319734	NA	-0.44	-7.63	-0.33	1.34e-13	Morning vs. evening chronotype;
LGG	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg15704280	chr7:45808275	SEPT13	0.76	7.94	0.35	1.6e-14	Axial length;
LGG	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24308560	chr3:49941425	MST1R	0.22	6.83	0.3	2.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.15	0.64	5.24e-56	Refractive error;
LGG	cis	rs11690935	0.885	rs10202823	chr2:172780132	T/C	cg21435375	chr2:172878103	MAP1D	-0.34	-7.62	-0.33	1.42e-13	Schizophrenia;
LGG	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.21	-0.72	6.16e-75	Total body bone mineral density;
LGG	cis	rs34172651	0.917	rs200533	chr16:24754771	C/T	cg02428538	chr16:24856791	SLC5A11	0.41	7.04	0.31	7.15e-12	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg13647721	chr17:30228624	UTP6	0.63	8.09	0.35	5.11e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12477438	0.520	rs62155809	chr2:100084008	T/C	cg23527387	chr2:100056660	REV1	0.42	9.39	0.4	2.72e-19	Chronic sinus infection;
LGG	cis	rs7932354	0.528	rs4319472	chr11:47109514	G/C	cg03339077	chr11:47165057	C11orf49	0.53	9.97	0.42	2.42e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.7	-0.34	8.47e-14	Height;
LGG	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg03653399	chr8:142233436	SLC45A4	0.43	8.35	0.36	7.69e-16	Immature fraction of reticulocytes;
LGG	cis	rs367943	0.965	rs463249	chr5:112797430	A/C	cg27587195	chr5:112824172	MCC	-0.46	-7.39	-0.32	7.08e-13	Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs56283736	chr4:119747268	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-17.2	-0.62	1.31e-51	Personality dimensions;
LGG	cis	rs600231	0.623	rs3015966	chr11:65217589	T/C	cg17120908	chr11:65337727	SSSCA1	-0.48	-8.58	-0.37	1.39e-16	Bone mineral density;
LGG	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg04733989	chr22:42467013	NAGA	0.53	9.24	0.39	8.79e-19	Schizophrenia;
LGG	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg20913747	chr6:44695427	NA	-0.6	-10.33	-0.43	1.23e-22	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14036868	chr2:38604442	ATL2	0.42	7.03	0.31	7.48e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7326068	0.543	rs2785740	chr13:21423525	C/G	cg04906043	chr13:21280425	IL17D	-0.5	-7.85	-0.34	3e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs9549260	0.785	rs2253001	chr13:41145330	A/T	cg21288729	chr13:41239152	FOXO1	0.33	6.64	0.3	8.55e-11	Red blood cell count;
LGG	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg05163923	chr11:71159392	DHCR7	-0.54	-7.97	-0.35	1.27e-14	Vitamin D levels;
LGG	cis	rs12731740	0.908	rs2294911	chr1:207988603	G/C	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.35	-0.32	9.21e-13	Biomedical quantitative traits;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.03	0.39	4.52e-18	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	8.07e-12	Lung cancer;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg10295955	chr4:187884368	NA	-1.13	-29.79	-0.81	1.04e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.09	0.46	1.59e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg25208724	chr1:156163844	SLC25A44	1.19	26.02	0.77	1.17e-92	Testicular germ cell tumor;
LGG	trans	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17712092	chr4:129076599	LARP1B	0.75	14.47	0.56	2.02e-39	Eosinophil percentage of white cells;
LGG	cis	rs490234	0.812	rs4329365	chr9:128445758	A/C	cg14078157	chr9:128172775	NA	-0.48	-8.37	-0.36	7.05e-16	Mean arterial pressure;
LGG	cis	rs2273669	0.667	rs6651000	chr6:109281411	G/T	cg05315195	chr6:109294784	ARMC2	-0.63	-8.16	-0.35	3.26e-15	Prostate cancer;
LGG	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg07936489	chr17:37558343	FBXL20	0.86	16.07	0.6	1.64e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs4959677	0.901	rs13200224	chr6:2485653	C/T	cg23817096	chr6:1620687	NA	-0.32	-7.59	-0.33	1.82e-13	Orthostatic hypotension;
LGG	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg06238570	chr21:40685208	BRWD1	0.44	6.76	0.3	4.07e-11	Cognitive function;
LGG	cis	rs4767841	1.000	rs7961569	chr12:120157345	A/C	cg25937854	chr12:120150414	CIT	-0.39	-6.77	-0.3	3.8e-11	Urgency urinary incontinence;
LGG	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg27490568	chr2:178487706	NA	0.45	9.08	0.39	3.07e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4704187	0.687	rs13359143	chr5:74433360	T/C	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs3916	0.911	rs3999408	chr12:121167387	C/T	cg21892295	chr12:121157589	UNC119B	-0.42	-7.27	-0.32	1.56e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs36051895	0.659	rs4495487	chr9:5072798	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-14.98	-0.57	1.14e-41	Pediatric autoimmune diseases;
LGG	cis	rs240764	0.645	rs240152	chr6:101067489	G/C	cg09795085	chr6:101329169	ASCC3	0.45	7.56	0.33	2.26e-13	Neuroticism;
LGG	cis	rs9462027	0.628	rs9469892	chr6:34769101	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs7241530	0.610	rs58651431	chr18:75891656	T/C	cg14642773	chr18:75888474	NA	0.47	9.09	0.39	2.99e-18	Educational attainment (years of education);
LGG	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs9467773	0.967	rs9295694	chr6:26512994	A/T	cg11502198	chr6:26597334	ABT1	0.54	9.44	0.4	1.81e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20916646	chr4:852691	GAK	0.67	11.05	0.46	2.4e-25	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg12486710	chr1:178512616	C1orf220	0.41	8.38	0.36	6.29e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4629180	0.586	rs1509497	chr2:102138184	C/T	cg16435561	chr2:102091048	RFX8	0.46	8.6	0.37	1.23e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs3741151	1.000	rs74749711	chr11:73052839	A/T	cg17517138	chr11:73019481	ARHGEF17	0.92	9.61	0.41	4.56e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs17253792	0.908	rs9972177	chr14:56073206	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.37	-0.32	7.68e-13	Triglycerides;
LGG	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-15.99	-0.6	3.81e-46	Morning vs. evening chronotype;
LGG	cis	rs5015933	1.000	rs7357647	chr9:128136833	T/A	cg14078157	chr9:128172775	NA	-0.36	-6.77	-0.3	4.02e-11	Body mass index;
LGG	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-10.19	-0.43	3.74e-22	Personality dimensions;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-9.24	-0.39	8.69e-19	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21740146	chr1:247171252	ZNF695	0.37	6.99	0.31	9.44e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg02002194	chr4:3960332	NA	0.48	9.3	0.4	5.61e-19	Neuroticism;
LGG	cis	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg08930214	chr7:62859557	LOC100287834	0.46	7.5	0.33	3.25e-13	Obesity-related traits;
LGG	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg04733989	chr22:42467013	NAGA	0.56	10.0	0.42	1.9e-21	Schizophrenia;
LGG	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg02461776	chr11:598696	PHRF1	0.42	6.87	0.3	2.13e-11	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	8.53	0.37	2.17e-16	Retinal vascular caliber;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20887711	chr4:1340912	KIAA1530	-0.6	-11.24	-0.46	4.27e-26	Obesity-related traits;
LGG	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg12070911	chr6:150209640	RAET1E	0.28	6.75	0.3	4.37e-11	Lung cancer;
LGG	cis	rs34172651	0.517	rs11862923	chr16:24767303	G/T	cg00339695	chr16:24857497	SLC5A11	0.39	6.75	0.3	4.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg04287289	chr16:89883240	FANCA	0.72	8.15	0.35	3.39e-15	Skin colour saturation;
LGG	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg13010199	chr12:38710504	ALG10B	0.63	12.63	0.51	1.28e-31	Morning vs. evening chronotype;
LGG	cis	rs72843166	0.545	rs72839486	chr17:61014661	T/C	cg27279583	chr17:61514753	CYB561	0.39	6.65	0.3	8.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg13114125	chr14:105738426	BRF1	-0.84	-15.99	-0.6	3.87e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg11764359	chr7:65958608	NA	0.64	9.76	0.41	1.34e-20	Aortic root size;
LGG	cis	rs240764	0.583	rs11155638	chr6:101203801	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-7.89	-0.34	2.14e-14	Neuroticism;
LGG	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.21	-0.49	6.3e-30	Response to antipsychotic treatment;
LGG	trans	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs2274273	0.905	rs28429419	chr14:55574793	T/C	cg04306507	chr14:55594613	LGALS3	0.65	18.41	0.65	3.24e-57	Protein biomarker;
LGG	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.41	-0.36	4.94e-16	Breast cancer;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg00290607	chr11:67383545	NA	-0.55	-10.51	-0.44	2.5e-23	Mean corpuscular volume;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.42	0.65	3.02e-57	Platelet count;
LGG	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.83	-17.68	-0.63	7.84e-54	Caffeine consumption;
LGG	cis	rs4936894	0.500	rs12280723	chr11:124075804	A/G	cg27160556	chr11:124181099	OR8D1	-0.44	-10.02	-0.42	1.66e-21	Aging (time to death);
LGG	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg23625390	chr15:77176239	SCAPER	0.46	8.93	0.38	1e-17	Blood metabolite levels;
LGG	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	8.72	0.38	4.92e-17	Neuroticism;
LGG	cis	rs17504614	0.634	rs17569799	chr2:51068308	T/G	cg23851515	chr2:51057218	NRXN1	0.46	7.55	0.33	2.38e-13	Educational attainment (years of education);
LGG	cis	rs11239177	0.772	rs11239138	chr10:45062334	C/T	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.24e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.73	8.84	0.38	2.01e-17	Yeast infection;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.96e-15	HDL cholesterol;
LGG	cis	rs3750082	0.817	rs2060731	chr7:32968346	G/A	cg08946731	chr7:32981826	RP9P	-0.41	-6.93	-0.31	1.45e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs3816183	0.585	rs10195899	chr2:42881534	C/T	cg14631114	chr2:43023945	NA	0.35	6.75	0.3	4.52e-11	Hypospadias;
LGG	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg16724585	chr3:197361211	NA	-0.49	-8.53	-0.37	2.05e-16	Pancreatic cancer;
LGG	cis	rs2273669	0.667	rs7759014	chr6:109351125	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-10.77	-0.45	2.73e-24	Prostate cancer;
LGG	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.92	0.38	1.06e-17	Eosinophil percentage of white cells;
LGG	cis	rs8016982	0.589	rs12586249	chr14:81701004	T/C	cg01989461	chr14:81687754	GTF2A1	-0.6	-9.13	-0.39	2.06e-18	Schizophrenia;
LGG	cis	rs68170813	0.559	rs11773514	chr7:106958469	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.6	-0.44	1.15e-23	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.79	0.34	4.36e-14	Prudent dietary pattern;
LGG	cis	rs2587949	0.615	rs1994272	chr3:4232201	C/T	cg16519197	chr3:4211558	NA	0.34	7.1	0.31	4.86e-12	Periodontitis (DPAL);
LGG	cis	rs737693	0.834	rs1940938	chr11:102774844	G/A	cg14995062	chr11:102826570	MMP13	0.55	7.13	0.31	3.9e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2274273	0.554	rs3742564	chr14:55530120	C/T	cg04306507	chr14:55594613	LGALS3	-0.38	-8.88	-0.38	1.44e-17	Protein biomarker;
LGG	cis	rs17125944	0.506	rs7151491	chr14:53313711	C/G	cg00686598	chr14:53173677	PSMC6	-0.75	-7.78	-0.34	4.77e-14	Alzheimer's disease (late onset);
LGG	cis	rs9308433	0.529	rs1391553	chr1:214474119	T/C	cg06198575	chr1:214491504	SMYD2	0.52	7.9	0.34	2.11e-14	IgG glycosylation;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg05091796	chr16:4465799	CORO7	-0.61	-10.16	-0.43	4.96e-22	Schizophrenia;
LGG	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg11693508	chr17:37793320	STARD3	0.53	7.59	0.33	1.78e-13	Bipolar disorder;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg14004847	chr7:1930337	MAD1L1	0.49	8.53	0.37	2.16e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.95	-0.45	5.95e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7085104	0.700	rs6163	chr10:104596924	C/A	cg04362960	chr10:104952993	NT5C2	0.49	9.2	0.39	1.26e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg23484912	chr5:273055	PDCD6	0.48	9.59	0.41	5.41e-20	Pancreatic cancer;
LGG	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.28	-0.75	1.41e-84	Height;
LGG	cis	rs10936602	0.527	rs9878316	chr3:169533717	T/A	cg00832555	chr3:169529716	LRRC34	0.35	7.23	0.32	2.03e-12	Renal cell carcinoma;
LGG	cis	rs17102423	0.661	rs4468529	chr14:65611968	C/T	cg16583315	chr14:65563665	MAX	-0.37	-6.83	-0.3	2.7e-11	Obesity-related traits;
LGG	cis	rs8017423	0.967	rs2151748	chr14:90694897	G/C	cg04374321	chr14:90722782	PSMC1	0.88	18.31	0.65	9.96e-57	Mortality in heart failure;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg07519485	chr6:33762594	MLN	-0.3	-6.86	-0.3	2.27e-11	Crohn's disease;
LGG	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.72	-0.41	1.88e-20	Body mass index;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg15971980	chr6:150254442	NA	0.43	8.08	0.35	5.77e-15	Lung cancer;
LGG	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.3	-0.43	1.6e-22	Alzheimer's disease;
LGG	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.54	7.61e-36	Cognitive test performance;
LGG	cis	rs4363385	1.000	rs310124	chr1:153020275	C/T	cg13444842	chr1:152974279	SPRR3	-0.36	-7.26	-0.32	1.67e-12	Inflammatory skin disease;
LGG	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg12310025	chr6:25882481	NA	-0.66	-12.57	-0.5	2.21e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9460578	0.537	rs9465900	chr6:20811620	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.67	0.63	9.26e-54	Breast cancer;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg23131131	chr22:24373011	LOC391322	-0.49	-8.03	-0.35	8.12e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17227506	0.583	rs11776158	chr8:13484121	C/T	cg03566418	chr8:13424080	C8orf48	0.55	8.21	0.36	2.29e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg11168104	chr5:1857477	NA	-0.4	-6.94	-0.31	1.32e-11	Cardiovascular disease risk factors;
LGG	cis	rs709400	0.633	rs8013101	chr14:103951772	G/C	cg26031613	chr14:104095156	KLC1	0.78	13.95	0.54	3.44e-37	Body mass index;
LGG	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg04568710	chr12:38710424	ALG10B	0.35	6.91	0.31	1.61e-11	Bladder cancer;
LGG	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg23933602	chr10:16859644	RSU1	0.64	9.3	0.4	5.56e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2694528	0.858	rs113445535	chr5:60420775	C/T	cg11474532	chr5:59995715	DEPDC1B	0.67	7.11	0.31	4.51e-12	Parkinson's disease;
LGG	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg21775007	chr8:11205619	TDH	0.64	11.08	0.46	1.87e-25	Retinal vascular caliber;
LGG	cis	rs6141769	0.542	rs6057632	chr20:31319841	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.75	-0.3	4.49e-11	Subjective well-being;
LGG	cis	rs12493885	0.585	rs701264	chr3:153628080	A/G	cg12800244	chr3:153838788	SGEF	-0.66	-7.72	-0.34	7.1e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.31	0.63	4e-52	Refractive error;
LGG	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.01e-33	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.88	-0.38	1.43e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg02002194	chr4:3960332	NA	0.43	8.03	0.35	8.2e-15	Triglycerides;
LGG	cis	rs718857	0.553	rs10117877	chr9:106716787	C/T	cg14250997	chr9:106856677	SMC2	0.35	6.73	0.3	5.18e-11	Breast cancer;
LGG	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Vitiligo;
LGG	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg05692746	chr2:100937584	LONRF2	-0.5	-8.44	-0.36	4.23e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1843834	0.688	rs2396149	chr2:225601985	G/A	cg22455342	chr2:225449267	CUL3	0.46	7.91	0.34	1.95e-14	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg02002194	chr4:3960332	NA	0.43	7.86	0.34	2.68e-14	Monocyte count;
LGG	cis	rs79349575	0.715	rs11657238	chr17:46985634	A/G	cg16584676	chr17:46985605	UBE2Z	0.53	9.49	0.4	1.25e-19	Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg11846333	chr4:119757529	SEC24D	0.85	7.36	0.32	8.48e-13	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.64	0.37	9.07e-17	Rheumatoid arthritis;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg00689492	chr4:1303491	MAEA	0.49	8.47	0.37	3.32e-16	Obesity-related traits;
LGG	trans	rs2562456	0.755	rs11670868	chr19:21556415	T/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.77	-0.34	5.04e-14	Pain;
LGG	cis	rs12780845	0.505	rs11254394	chr10:17183072	G/A	cg01003015	chr10:17271136	VIM	-0.42	-6.89	-0.3	1.88e-11	Homocysteine levels;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.63	-0.33	1.32e-13	Bipolar disorder;
LGG	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg15268244	chr15:77196840	NA	0.43	9.43	0.4	1.96e-19	Blood metabolite levels;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg05165339	chr4:1420672	NA	-0.35	-9.06	-0.39	3.82e-18	Longevity;
LGG	cis	rs11105298	0.891	rs4842653	chr12:89834113	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs62025270	0.688	rs55851385	chr15:86268631	C/G	cg25843651	chr15:86329602	KLHL25	0.58	8.9	0.38	1.25e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11920090	0.720	rs60354090	chr3:170740217	C/T	cg09710316	chr3:170744871	SLC2A2	0.68	8.81	0.38	2.47e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg11247378	chr22:39784982	NA	-0.31	-8.64	-0.37	8.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg17691542	chr6:26056736	HIST1H1C	0.58	10.38	0.43	8.02e-23	Height;
LGG	trans	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg26043149	chr18:55253948	FECH	0.43	7.22	0.32	2.12e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg18200150	chr17:30822561	MYO1D	0.51	9.86	0.42	6.21e-21	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25428423	chr7:27780234	TAX1BP1	-0.41	-7.03	-0.31	7.67e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg27490568	chr2:178487706	NA	0.82	14.25	0.55	1.9e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3771570	0.901	rs4675964	chr2:242324760	A/C	cg21155796	chr2:242212141	HDLBP	0.64	9.08	0.39	3.09e-18	Prostate cancer;
LGG	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.29	0.72	2.61e-75	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.6	-0.33	1.66e-13	Personality dimensions;
LGG	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg05527609	chr1:210001259	C1orf107	0.58	7.51	0.33	3.1e-13	Red blood cell count;
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg22903471	chr2:27725779	GCKR	0.59	13.83	0.54	1.16e-36	Total body bone mineral density;
LGG	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.39e-16	Restless legs syndrome;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg16507663	chr6:150244633	RAET1G	0.44	7.1	0.31	4.75e-12	Lung cancer;
LGG	cis	rs4561483	0.583	rs11075030	chr16:11976414	C/A	cg08843971	chr16:11963173	GSPT1	0.58	14.4	0.56	4.05e-39	Testicular germ cell tumor;
LGG	cis	rs67311347	1.000	rs66841330	chr3:40531123	G/A	cg24209194	chr3:40518798	ZNF619	0.46	7.17	0.32	2.89e-12	Renal cell carcinoma;
LGG	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg07086112	chr8:22853394	RHOBTB2	-0.47	-7.13	-0.31	3.95e-12	Anxiety disorder;
LGG	cis	rs9296092	0.517	rs3912041	chr6:33521271	T/C	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs629535	0.814	rs558511	chr8:70069908	C/A	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg23188684	chr11:67383651	NA	-0.45	-7.75	-0.34	5.73e-14	Mean corpuscular volume;
LGG	cis	rs9902453	0.817	rs880749	chr17:28059970	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.96	-0.54	3.15e-37	Coffee consumption (cups per day);
LGG	cis	rs6977660	1.000	rs6974669	chr7:19793296	T/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.67	0.37	7.6e-17	Thyroid stimulating hormone;
LGG	cis	rs2455601	0.608	rs59025804	chr11:8870301	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-9.66	-0.41	2.99e-20	Schizophrenia;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.85e-15	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.79	0.3	3.51e-11	Parkinson's disease;
LGG	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22539505	chr3:50330110	IFRD2	0.41	6.95	0.31	1.27e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.859	rs12212745	chr6:45166258	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.18	-0.43	4.07e-22	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08675654	chr10:112403955	RBM20	0.5	8.16	0.35	3.22e-15	Gut microbiome composition (summer);
LGG	cis	rs73787773	0.867	rs73787775	chr5:111472611	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.63	-7.86	-0.34	2.71e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs62238980	0.614	rs4289286	chr22:32458612	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs7582720	1.000	rs72934738	chr2:203740861	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg12402800	chr5:56204917	C5orf35	0.42	6.65	0.3	8.49e-11	Initial pursuit acceleration;
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg01145232	chr6:150245071	RAET1G	-0.52	-9.67	-0.41	2.79e-20	Lung cancer;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.68	0.37	6.84e-17	Personality dimensions;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17606287	chr9:99776144	HIATL2	-0.47	-6.97	-0.31	1.11e-11	Systemic lupus erythematosus;
LGG	cis	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg24375607	chr4:120327624	NA	0.62	10.37	0.43	8.55e-23	Corneal astigmatism;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	8.12	0.35	4.3e-15	Personality dimensions;
LGG	trans	rs1997103	1.000	rs4948011	chr7:55403859	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.26	0.36	1.52e-15	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg01420254	chr6:26195488	NA	0.92	12.41	0.5	1.03e-30	Gout;Renal underexcretion gout;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.7	-0.37	5.67e-17	Menopause (age at onset);
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg16584290	chr5:462447	EXOC3	0.44	8.98	0.38	7.11e-18	Cystic fibrosis severity;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.27	-0.5	3.75e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs4704187	0.687	rs1903839	chr5:74421397	A/G	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs754466	0.580	rs2289308	chr10:79579251	G/A	cg17075019	chr10:79541650	NA	-0.98	-21.53	-0.71	9.18e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2731664	0.792	rs163199	chr5:176890067	A/G	cg23176889	chr5:176863531	GRK6	-0.63	-12.64	-0.51	1.14e-31	Intelligence (multi-trait analysis);
LGG	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg08344181	chr3:125677491	NA	0.53	7.27	0.32	1.53e-12	Depression;
LGG	cis	rs8072100	0.640	rs3851808	chr17:45425144	C/T	cg25173405	chr17:45401733	C17orf57	-0.56	-9.42	-0.4	2.16e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg03433033	chr1:76189801	ACADM	0.76	12.18	0.49	8.24e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg10847948	chr11:71163743	NADSYN1	0.66	11.72	0.48	5.62e-28	Vitamin D levels;
LGG	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg02466173	chr16:30829666	NA	0.46	8.3	0.36	1.11e-15	Dementia with Lewy bodies;
LGG	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12229367	chr17:55822335	NA	0.45	8.63	0.37	1.03e-16	Schizophrenia;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06475006	chr16:89985975	MC1R	-0.59	-6.95	-0.31	1.23e-11	Skin colour saturation;
LGG	cis	rs9397585	0.824	rs7761831	chr6:153371503	C/T	cg17707550	chr6:153380415	RGS17	0.61	14.13	0.55	5.75e-38	Body mass index;
LGG	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg26850624	chr5:429559	AHRR	-0.39	-8.61	-0.37	1.15e-16	Cystic fibrosis severity;
LGG	cis	rs9547692	0.878	rs9547688	chr13:37449413	G/A	cg01493522	chr13:37497338	NA	-0.51	-8.5	-0.37	2.59e-16	Coronary artery disease;
LGG	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg05692746	chr2:100937584	LONRF2	-0.57	-9.48	-0.4	1.35e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10267417	0.603	rs10258555	chr7:19868344	T/G	cg07541023	chr7:19748670	TWISTNB	0.5	6.69	0.3	6.36e-11	Night sleep phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06611727	chr15:48009656	SEMA6D	0.44	6.67	0.3	7.49e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg04863758	chr4:1303710	MAEA	0.46	7.86	0.34	2.63e-14	Obesity-related traits;
LGG	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg01181863	chr3:195395398	SDHAP2	0.49	7.46	0.33	4.23e-13	Mean corpuscular volume;
LGG	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.1	0.55	8.14e-38	Bladder cancer;
LGG	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg25114630	chr15:101792522	CHSY1	0.56	9.68	0.41	2.7e-20	Corneal structure;
LGG	cis	rs13088645	0.683	rs9790169	chr3:134151959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.43	-7.86	-0.34	2.69e-14	Coronary artery disease;
LGG	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs4740619	0.544	rs9407650	chr9:15827685	A/C	cg14451791	chr9:16040625	NA	0.32	7.81	0.34	4e-14	Body mass index;
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	16.69	0.61	2.71e-49	Platelet count;
LGG	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.84	-0.34	3.15e-14	Diabetic retinopathy;
LGG	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.676	rs1538704	chr1:248523554	C/T	cg00666640	chr1:248458726	OR2T12	0.52	8.99	0.39	6.29e-18	Common traits (Other);
LGG	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.48	0.37	2.94e-16	Mood instability;
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg11317459	chr13:21872234	NA	1.4	26.33	0.77	4.63e-94	White matter hyperintensity burden;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.71	13.9	0.54	5.94e-37	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.95	0.45	5.76e-25	Personality dimensions;
LGG	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.9	0.48	1.15e-28	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-12.95	-0.52	6.07e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs12210905	0.925	rs6920115	chr6:26988417	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs588177	1.000	rs588177	chr11:64024056	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.46	7.08	0.31	5.45e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg22601191	chr20:60968625	CABLES2	0.39	7.43	0.33	5.46e-13	Colorectal cancer;
LGG	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg02959939	chr21:47813025	PCNT	-0.36	-6.68	-0.3	6.83e-11	Lymphocyte counts;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.21	0.32	2.22e-12	Renal function-related traits (BUN);
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16318349	chr1:154917307	PBXIP1	0.28	7.48	0.33	3.84e-13	Prostate cancer;
LGG	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.27e-23	Resting heart rate;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.81	0.41	9.02e-21	Prudent dietary pattern;
LGG	trans	rs75804782	0.515	rs75251934	chr2:239288387	A/C	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg18032289	chr17:61959525	GH2	-0.38	-6.67	-0.3	7.51e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7216064	1.000	rs62084210	chr17:65828710	A/G	cg12091567	chr17:66097778	LOC651250	-0.59	-8.5	-0.37	2.63e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg09754948	chr16:28834200	ATXN2L	0.5	7.93	0.35	1.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.98	-0.42	2.19e-21	Joint mobility (Beighton score);
LGG	cis	rs2717559	0.568	rs35093407	chr8:143885501	G/A	cg06565975	chr8:143823917	SLURP1	-0.34	-8.62	-0.37	1.09e-16	Urinary tract infection frequency;
LGG	cis	rs3771570	0.901	rs3815262	chr2:242352582	A/T	cg21155796	chr2:242212141	HDLBP	0.64	8.96	0.38	8.07e-18	Prostate cancer;
LGG	cis	rs7945705	0.902	rs7930026	chr11:9013639	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.23	0.46	4.87e-26	Hemoglobin concentration;
LGG	trans	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg10756647	chr7:56101905	PSPH	0.45	6.76	0.3	4.13e-11	Corneal structure;
LGG	cis	rs6540556	0.723	rs1000283	chr1:209894661	A/G	cg23920097	chr1:209922102	NA	0.47	7.67	0.34	1.01e-13	Red blood cell count;
LGG	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg24375607	chr4:120327624	NA	0.62	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.32	-0.47	2.13e-26	Tonsillectomy;
LGG	cis	rs59197085	0.515	rs2402938	chr7:128444295	T/C	cg00734629	chr7:128471146	FLNC	0.31	6.66	0.3	7.86e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs12517041	0.935	rs4701359	chr5:23284257	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.9	-0.45	8.86e-25	Calcium levels;
LGG	cis	rs151997	0.569	rs10035173	chr5:50276059	C/G	cg06027927	chr5:50259733	NA	0.62	10.14	0.43	6.14e-22	Callous-unemotional behaviour;
LGG	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg15325629	chr6:28072465	NA	1.01	7.69	0.34	9.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	32.44	0.83	2.63e-121	Prudent dietary pattern;
LGG	cis	rs9868809	0.505	rs9811027	chr3:48725014	G/C	cg00383909	chr3:49044727	WDR6	0.92	11.44	0.47	7.14e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg19147804	chr7:1989927	MAD1L1	-0.5	-9.2	-0.39	1.23e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg15088822	chr5:140998632	DIAPH1	-0.4	-6.9	-0.31	1.73e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg23601095	chr6:26197514	HIST1H3D	0.72	9.11	0.39	2.42e-18	Gout;Renal underexcretion gout;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25446086	chr1:155829549	SYT11	0.43	6.78	0.3	3.7e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.71	-0.54	3.99e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs57244997	0.860	rs9458425	chr6:162376946	C/T	cg17173639	chr6:162384350	PARK2	-0.58	-7.43	-0.33	5.13e-13	Mosquito bite size;
LGG	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg12454169	chr2:30669597	LCLAT1	0.55	7.81	0.34	3.82e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1941687	0.800	rs1845387	chr18:31358940	T/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.86	-0.38	1.76e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs77633900	0.614	rs2439991	chr15:76877227	A/G	cg21673338	chr15:77095150	SCAPER	-0.67	-10.4	-0.44	6.59e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg15208524	chr1:10270712	KIF1B	0.45	8.07	0.35	6.17e-15	Hepatocellular carcinoma;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.94	-0.38	9.33e-18	Longevity;
LGG	trans	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg06521331	chr12:34319734	NA	-0.44	-7.61	-0.33	1.51e-13	Heart rate;
LGG	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg27446573	chr6:127587934	RNF146	1.11	22.01	0.72	5.07e-74	Breast cancer;
LGG	cis	rs228437	0.913	rs1535117	chr6:134911816	G/A	cg24504307	chr6:134963096	NA	0.37	7.13	0.31	3.77e-12	Melanoma;
LGG	cis	rs283228	0.550	rs2518326	chr6:101813283	G/A	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg03709012	chr19:19516395	GATAD2A	0.46	7.05	0.31	6.45e-12	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg23782820	chr8:58130467	NA	0.53	7.39	0.32	6.9e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg17951613	chr5:131705445	SLC22A5	0.67	7.57	0.33	2.09e-13	Rheumatoid arthritis;
LGG	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg03929089	chr4:120376271	NA	0.69	7.38	0.32	7.46e-13	Intraocular pressure;
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.23	-0.43	2.71e-22	Platelet count;
LGG	cis	rs4771450	0.962	rs3916929	chr13:103969608	C/T	cg02987523	chr13:103978230	NA	-0.32	-6.88	-0.3	1.95e-11	Uric acid levels;
LGG	trans	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2597513	0.860	rs2731345	chr3:13564303	C/T	cg24006715	chr3:13568212	NA	0.6	9.7	0.41	2.25e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2386661	0.603	rs11259704	chr10:5646999	C/T	cg12223502	chr10:5658492	NA	-0.36	-7.08	-0.31	5.42e-12	Breast cancer;
LGG	cis	rs7113850	0.541	rs56732861	chr11:24234333	C/G	ch.11.24196551F	chr11:24239977	NA	0.91	10.45	0.44	4.3e-23	Bone fracture in osteoporosis;
LGG	cis	rs6840360	0.692	rs1838043	chr4:152411462	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	6.89	0.31	1.78e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6792151	0.652	rs3850188	chr3:171559827	C/A	cg26441893	chr3:171559851	TMEM212	-0.44	-7.89	-0.34	2.25e-14	Red cell distribution width;
LGG	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg14768367	chr16:72042858	DHODH	0.78	8.43	0.36	4.56e-16	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs944722	0.934	rs4796040	chr17:26097480	C/G	cg07704981	chr17:26127537	NOS2	-0.52	-9.06	-0.39	3.7e-18	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11220663	chr2:70994863	ADD2	0.41	6.81	0.3	3e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs4363385	0.818	rs1415969	chr1:153006448	G/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.09e-16	Inflammatory skin disease;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4538187	0.660	rs67615384	chr2:64133432	T/C	cg19915305	chr2:64069682	UGP2	-0.66	-13.47	-0.53	4e-35	Systolic blood pressure;
LGG	cis	rs9443645	0.527	rs9361479	chr6:79723755	T/A	cg18132916	chr6:79620363	NA	-0.27	-7.0	-0.31	8.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg06808227	chr14:105710500	BRF1	-0.65	-11.84	-0.48	1.95e-28	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1927790	0.727	rs1925122	chr13:96938173	T/C	cg02571835	chr13:96230311	CLDN10	-0.35	-7.17	-0.32	3.03e-12	Body mass index;
LGG	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg00599393	chr8:22457479	C8orf58	-0.41	-7.53	-0.33	2.64e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1941687	0.831	rs55671114	chr18:31386284	C/A	cg27147174	chr7:100797783	AP1S1	-0.54	-9.03	-0.39	4.62e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9902453	0.791	rs9904051	chr17:28244122	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.33	0.55	8.31e-39	Coffee consumption (cups per day);
LGG	cis	rs7289126	1.000	rs7289126	chr22:38628306	A/C	cg25457927	chr22:38595422	NA	0.33	7.99	0.35	1.07e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.11	-0.31	4.56e-12	Arsenic metabolism;
LGG	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.42	7.18	0.32	2.85e-12	Response to antipsychotic treatment;
LGG	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.89	8.77	0.38	3.44e-17	Diabetic retinopathy;
LGG	cis	rs8017423	0.872	rs7492857	chr14:90684867	T/G	cg04374321	chr14:90722782	PSMC1	-0.89	-18.57	-0.65	6.39e-58	Mortality in heart failure;
LGG	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg15208524	chr1:10270712	KIF1B	0.46	8.25	0.36	1.64e-15	Hepatocellular carcinoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01245787	chr4:71859630	DCK	-0.44	-7.38	-0.32	7.21e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	9.11e-26	Corneal astigmatism;
LGG	cis	rs2798269	0.604	rs1200034	chr13:22165262	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.43	-7.56	-0.33	2.21e-13	PR segment;
LGG	cis	rs13382275	0.632	rs6548283	chr2:941534	A/C	cg10902693	chr2:875509	NA	0.41	7.56	0.33	2.11e-13	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4700695	0.764	rs152993	chr5:65262968	A/T	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs7173743	0.756	rs8030937	chr15:79129587	G/T	cg00540400	chr15:79124168	NA	0.44	9.1	0.39	2.78e-18	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg22027946	chr17:80790580	TBCD;ZNF750	-0.4	-7.05	-0.31	6.71e-12	Glycated hemoglobin levels;
LGG	cis	rs9329289	0.510	rs12356215	chr10:2545390	C/G	cg15501526	chr10:2543763	NA	0.48	9.18	0.39	1.45e-18	Age-related hearing impairment;
LGG	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg09165964	chr15:75287851	SCAMP5	0.6	11.16	0.46	8.55e-26	Breast cancer;
LGG	cis	rs6456156	0.586	rs2001115	chr6:167486218	A/C	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	cis	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg16386425	chr10:429943	DIP2C	-0.47	-9.53	-0.41	8.71e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg24397884	chr7:158709396	WDR60	1.08	16.33	0.6	1.19e-47	Height;
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.73	-0.3	5.11e-11	Personality dimensions;
LGG	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg18252515	chr7:66147081	NA	-1.37	-16.06	-0.6	1.83e-46	Gout;
LGG	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12112058	chr1:224622605	WDR26	0.45	7.29	0.32	1.33e-12	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.642	rs2724567	chr4:152351160	C/T	cg17217059	chr4:152329364	FAM160A1	-0.2	-7.22	-0.32	2.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg14541582	chr5:601475	NA	-0.71	-10.94	-0.45	6.46e-25	Obesity-related traits;
LGG	trans	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg07211511	chr3:129823064	LOC729375	-0.65	-9.0	-0.39	5.87e-18	Blood pressure (smoking interaction);
LGG	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.58	-0.44	1.47e-23	Pancreatic cancer;
LGG	cis	rs988958	0.565	rs4952399	chr2:42289107	A/G	cg27252766	chr2:42229092	NA	-0.38	-6.8	-0.3	3.24e-11	Hypospadias;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02976543	chr2:239197607	PER2	0.45	7.35	0.32	9.09e-13	Cognitive performance;
LGG	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2708240	0.936	rs2710099	chr7:147574666	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs7572733	0.935	rs700659	chr2:198659923	T/C	cg00792783	chr2:198669748	PLCL1	0.48	8.13	0.35	3.96e-15	Dermatomyositis;
LGG	cis	rs17221829	0.549	rs1844196	chr11:89389256	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs2933343	0.951	rs7648327	chr3:128570708	A/G	cg25356066	chr3:128598488	ACAD9	0.46	6.71	0.3	5.74e-11	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg13206674	chr6:150067644	NUP43	0.66	15.12	0.57	2.82e-42	Lung cancer;
LGG	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg12856521	chr11:46389249	DGKZ	-0.41	-7.03	-0.31	7.24e-12	Leprosy;
LGG	trans	rs9354308	0.764	rs9345711	chr6:66591447	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.42	7.15	0.32	3.4e-12	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27185128	chr17:45000622	GOSR2	0.45	6.79	0.3	3.48e-11	Gut microbiome composition (summer);
LGG	cis	rs947474	0.838	rs10752291	chr10:6402679	C/G	cg19837174	chr10:6389707	NA	0.61	8.67	0.37	7.32e-17	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg13206674	chr6:150067644	NUP43	-0.65	-15.01	-0.57	8.64e-42	Lung cancer;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	7.36	0.32	8.68e-13	Height;
LGG	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	11.0	0.46	3.61e-25	Mean platelet volume;
LGG	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg01620082	chr3:125678407	NA	-0.66	-7.3	-0.32	1.26e-12	Depression;
LGG	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg13334819	chr7:99746414	C7orf59	0.51	7.85	0.34	2.98e-14	Coronary artery disease;
LGG	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08564027	chr20:61660810	NA	1.02	24.88	0.76	2.13e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg10621924	chr7:39171070	POU6F2	0.43	8.51	0.37	2.5e-16	IgG glycosylation;
LGG	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs778371	0.723	rs283470	chr2:233656918	G/A	cg08000102	chr2:233561755	GIGYF2	0.76	12.84	0.51	1.72e-32	Schizophrenia;
LGG	cis	rs6547631	0.622	rs11127	chr2:85924729	C/T	cg24620635	chr2:85921963	GNLY	0.5	10.05	0.42	1.23e-21	Blood protein levels;
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs7917772	0.503	rs7893155	chr10:104294228	C/A	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2455601	1.000	rs72632952	chr11:8917976	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.57	-0.47	2.18e-27	Schizophrenia;
LGG	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg13010199	chr12:38710504	ALG10B	-0.62	-13.19	-0.52	5.95e-34	Heart rate;
LGG	cis	rs12220238	0.915	rs7922519	chr10:75976573	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4268898	0.662	rs56006260	chr2:24409903	A/G	cg06627628	chr2:24431161	ITSN2	-0.78	-12.51	-0.5	4.02e-31	Asthma;
LGG	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg19680485	chr15:31195859	MTMR15	0.53	9.31	0.4	4.96e-19	Huntington's disease progression;
LGG	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg14581129	chr12:53358946	NA	-0.33	-7.3	-0.32	1.3e-12	Cancer (pleiotropy);
LGG	cis	rs2354432	0.556	rs2275249	chr1:146759320	C/G	cg25205988	chr1:146714368	CHD1L	1.33	14.34	0.55	7.84e-39	Mitochondrial DNA levels;
LGG	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.34	-0.32	9.99e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1707322	1.000	rs6429580	chr1:46275648	A/G	cg03146154	chr1:46216737	IPP	0.55	10.33	0.43	1.19e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22914934	chr11:76156056	C11orf30	0.46	6.88	0.3	1.95e-11	Gut microbiome composition (summer);
LGG	cis	rs9354308	0.764	rs4476812	chr6:66594554	A/C	cg07460842	chr6:66804631	NA	0.4	6.82	0.3	2.85e-11	Metabolite levels;
LGG	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg02574844	chr11:5959923	NA	-0.6	-10.45	-0.44	4.18e-23	DNA methylation (variation);
LGG	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg11245990	chr11:68621969	NA	0.44	9.19	0.39	1.37e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.68	-0.37	6.91e-17	Personality dimensions;
LGG	cis	rs13082711	0.871	rs35572617	chr3:27499247	A/T	cg02860705	chr3:27208620	NA	0.74	13.2	0.52	5.57e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07140808	chr4:78978772	FRAS1	0.5	7.7	0.34	8.58e-14	Gut microbiome composition (summer);
LGG	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg26597838	chr10:835615	NA	0.95	13.12	0.52	1.16e-33	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22833807	chr22:36925177	EIF3D	0.45	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	cis	rs2629540	0.543	rs2559515	chr10:126513925	A/G	cg08799069	chr10:126477246	METTL10	0.63	11.31	0.47	2.27e-26	Cocaine dependence;
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg06197492	chr11:2016605	H19	0.5	10.14	0.43	6.03e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs12586317	0.597	rs28452109	chr14:35653056	T/C	cg05294307	chr14:35346193	BAZ1A	-0.37	-6.95	-0.31	1.21e-11	Psoriasis;
LGG	cis	rs9815354	0.812	rs111967505	chr3:41873157	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	10.22	0.43	3.11e-22	Obesity-related traits;
LGG	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7945705	0.818	rs4929916	chr11:8824996	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.38	7.77	0.34	5.28e-14	Hemoglobin concentration;
LGG	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.13e-95	Breast cancer;
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs806321	0.534	rs1149865	chr13:50902103	C/T	cg10393508	chr13:50950265	NA	-0.34	-8.59	-0.37	1.36e-16	Multiple sclerosis;
LGG	cis	rs10940138	0.887	rs58669650	chr5:67194598	C/A	ch.5.1281357F	chr5:67228439	NA	0.73	12.05	0.49	2.83e-29	Menarche (age at onset);
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg07157834	chr1:205819609	PM20D1	0.43	7.19	0.32	2.65e-12	Parkinson's disease;
LGG	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg01236616	chr12:121019343	POP5	-1.16	-19.43	-0.67	5.85e-62	Type 1 diabetes nephropathy;
LGG	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg09998033	chr7:158218633	PTPRN2	0.56	10.56	0.44	1.68e-23	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg25358565	chr5:93447407	FAM172A	1.39	17.11	0.62	3.18e-51	Diabetic retinopathy;
LGG	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg23752985	chr2:85803571	VAMP8	-0.42	-8.31	-0.36	1.04e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-11.88	-0.48	1.4e-28	Migraine;Coronary artery disease;
LGG	cis	rs7558370	0.737	rs17017879	chr2:3713658	C/G	cg20720597	chr2:3699334	NA	0.76	7.07	0.31	5.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg25208724	chr1:156163844	SLC25A44	0.8	7.25	0.32	1.76e-12	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	12.75	0.51	4.07e-32	Menarche (age at onset);
LGG	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg13173536	chr2:3403300	TTC15	-0.34	-7.12	-0.31	4.21e-12	Obesity-related traits;
LGG	trans	rs1032833	0.732	rs78758361	chr2:180108616	C/A	cg23654767	chr2:101192981	PDCL3	0.72	8.3	0.36	1.18e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.09	-0.42	9.33e-22	Type 2 diabetes;
LGG	cis	rs7615952	0.546	rs2922197	chr3:125322032	G/A	cg21696256	chr3:125484277	NA	-0.44	-6.69	-0.3	6.27e-11	Blood pressure (smoking interaction);
LGG	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	10.3	0.43	1.53e-22	Coronary artery disease;
LGG	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.1	-0.49	1.75e-29	Morning vs. evening chronotype;
LGG	cis	rs1003719	0.788	rs2835592	chr21:38464387	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs72781680	0.652	rs12618900	chr2:23910775	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	8.55	0.37	1.76e-16	Lymphocyte counts;
LGG	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg00490583	chr16:1843685	IGFALS	0.44	10.2	0.43	3.61e-22	Insulin-like growth factors;
LGG	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg15704280	chr7:45808275	SEPT13	0.94	19.68	0.67	4.35e-63	Coronary artery disease;
LGG	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs564799	0.933	rs589545	chr3:159733600	G/A	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs4716602	0.622	rs36071136	chr7:156166303	G/C	cg16983916	chr7:156159713	NA	-0.48	-9.32	-0.4	4.96e-19	Anti-saccade response;
LGG	cis	rs972578	0.791	rs8135794	chr22:43316145	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.32	-0.5	2.36e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg00376283	chr12:123451042	ABCB9	0.62	11.51	0.47	3.84e-27	Platelet count;
LGG	trans	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg16070123	chr10:51489643	NA	-0.42	-7.75	-0.34	5.88e-14	Prostate-specific antigen levels;
LGG	cis	rs3771570	1.000	rs56052835	chr2:242243251	T/G	cg21155796	chr2:242212141	HDLBP	0.76	9.87	0.42	5.65e-21	Prostate cancer;
LGG	cis	rs1904096	0.506	rs10024642	chr4:95179295	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.6	-11.36	-0.47	1.46e-26	Type 2 diabetes;
LGG	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg13010199	chr12:38710504	ALG10B	0.54	10.1	0.42	8.22e-22	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.65e-54	Menopause (age at onset);
LGG	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg27286337	chr10:134555280	INPP5A	0.85	13.87	0.54	7.77e-37	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs240764	0.604	rs1336242	chr6:101199634	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.62	0.33	1.41e-13	Neuroticism;
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10802521	chr3:52805072	NEK4	-0.39	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg01236616	chr12:121019343	POP5	-1.25	-21.8	-0.71	5.13e-73	Type 1 diabetes nephropathy;
LGG	cis	rs11229555	0.645	rs1986404	chr11:58194614	T/C	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.57	-0.53	1.53e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg12658694	chr1:38397304	INPP5B	-0.5	-11.38	-0.47	1.23e-26	Coronary artery disease;
LGG	cis	rs4774899	0.752	rs2920265	chr15:57337480	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.84	-0.3	2.58e-11	Urinary tract infection frequency;
LGG	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg06636001	chr8:8085503	FLJ10661	0.57	10.04	0.42	1.38e-21	Triglycerides;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg27532560	chr4:187881888	NA	-0.61	-14.09	-0.55	9.23e-38	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2180341	1.000	rs6937287	chr6:127645719	T/A	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs76419734	0.558	rs10019217	chr4:106588509	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.63	9.39	0.4	2.79e-19	Post bronchodilator FEV1;
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg09021430	chr5:549028	NA	-0.69	-9.85	-0.42	6.69e-21	Obesity-related traits;
LGG	trans	rs6787172	0.652	rs699927	chr3:157932227	T/G	cg23275840	chr4:47708675	CORIN	0.41	8.67	0.37	7.53e-17	Subjective well-being;
LGG	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg15432903	chr11:17409602	KCNJ11	0.87	17.45	0.63	9.02e-53	Type 2 diabetes;
LGG	trans	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.5	0.47	4.25e-27	Mean corpuscular volume;
LGG	cis	rs16837677	0.649	rs16837622	chr1:156695504	C/T	cg14991358	chr1:156767203	PRCC	-0.65	-7.24	-0.32	1.82e-12	Sjögren's syndrome;
LGG	cis	rs7551222	0.752	rs10900597	chr1:204522489	C/T	cg18851795	chr1:204543875	NA	-0.35	-6.7	-0.3	6.23e-11	Schizophrenia;
LGG	cis	rs6784615	0.744	rs929528	chr3:52505445	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg13647721	chr17:30228624	UTP6	0.62	7.75	0.34	5.68e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg26174226	chr8:58114915	NA	0.5	7.15	0.32	3.34e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Myopia (pathological);
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg20607798	chr8:58055168	NA	0.62	7.27	0.32	1.56e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg22618164	chr12:122356400	WDR66	0.4	12.3	0.5	2.82e-30	Mean corpuscular volume;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00631329	chr6:26305371	NA	-0.52	-9.49	-0.4	1.24e-19	Educational attainment;
LGG	cis	rs9902453	0.967	rs7212741	chr17:28322941	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.35	0.53	1.28e-34	Coffee consumption (cups per day);
LGG	trans	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg24247370	chr13:99142703	STK24	-0.37	-6.9	-0.31	1.71e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.25	-0.32	1.78e-12	Testicular germ cell tumor;
LGG	cis	rs1873147	0.569	rs11636033	chr15:63311091	G/T	cg12160578	chr15:63334699	TPM1	-0.48	-7.17	-0.32	2.97e-12	Orofacial clefts;
LGG	cis	rs7558370	0.737	rs77681530	chr2:3712062	C/G	cg17046650	chr2:3699563	NA	0.91	9.19	0.39	1.36e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg25358565	chr5:93447407	FAM172A	1.38	17.11	0.62	3.41e-51	Diabetic retinopathy;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg00933542	chr6:150070202	PCMT1	0.4	7.11	0.31	4.34e-12	Lung cancer;
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.14e-22	Colorectal cancer;
LGG	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.24	0.36	1.85e-15	Response to antipsychotic treatment;
LGG	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.1	-0.39	2.72e-18	Neuroticism;
LGG	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg01028140	chr2:1542097	TPO	-0.47	-8.73	-0.38	4.52e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.54	-0.44	1.96e-23	Bladder cancer;
LGG	cis	rs1691799	0.867	rs1168347	chr12:66757303	T/C	cg16791601	chr12:66731901	HELB	-0.63	-14.78	-0.57	8.71e-41	White blood cell count (basophil);
LGG	cis	rs877426	0.681	rs58312371	chr13:114837577	C/T	cg00571178	chr13:114841904	RASA3	-0.54	-9.49	-0.4	1.25e-19	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs77372450	0.636	rs10057597	chr5:157012870	A/G	cg25387487	chr5:157003181	ADAM19	-0.57	-7.16	-0.32	3.24e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs4604732	0.642	rs4266925	chr1:247639165	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.51	0.37	2.36e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2562152	0.613	rs216599	chr16:109671	A/G	cg02949481	chr16:131562	MPG	0.64	8.89	0.38	1.41e-17	Glioblastoma;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21184075	chr14:58766462	ARID4A	0.33	6.8	0.3	3.15e-11	Pancreatic cancer;
LGG	cis	rs909685	1.000	rs2069235	chr22:39747780	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.59	9.89	0.42	4.89e-21	Rheumatoid arthritis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07006042	chr3:141595655	ATP1B3	0.45	7.39	0.32	6.89e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4330281	0.586	rs7630433	chr3:17371582	G/C	cg20981856	chr3:17787350	NA	0.36	6.89	0.31	1.81e-11	Schizophrenia;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.69	-0.37	6.37e-17	Schizophrenia;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.31e-11	Lung cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg18397137	chr19:59055873	TRIM28	-0.37	-7.22	-0.32	2.16e-12	Iris color (L* coordinate);
LGG	cis	rs17021463	0.902	rs10516950	chr4:95254730	C/T	cg11021082	chr4:95130006	SMARCAD1	0.51	9.43	0.4	1.91e-19	Testicular germ cell tumor;
LGG	cis	rs972578	0.677	rs2056946	chr22:43350377	C/G	cg01576275	chr22:43409880	NA	-0.25	-7.43	-0.33	5.24e-13	Mean platelet volume;
LGG	cis	rs79387448	0.701	rs11465586	chr2:102982709	C/G	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.88	-0.3	1.92e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1018836	0.886	rs4734246	chr8:91569028	A/C	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	5.12e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs6772849	0.930	rs9813197	chr3:128369104	G/A	cg08795948	chr3:128337044	NA	0.67	11.38	0.47	1.31e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs10155981	0.510	rs28439106	chr7:22592349	T/C	cg05062323	chr7:22590069	NA	-0.86	-10.86	-0.45	1.27e-24	Bilirubin levels;
LGG	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg23029597	chr12:123009494	RSRC2	-0.82	-15.27	-0.58	6.18e-43	Body mass index;
LGG	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8114671	0.935	rs35193912	chr20:33785050	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.4	-0.33	6.5e-13	Height;
LGG	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg24231037	chr15:68117551	LBXCOR1	0.37	8.17	0.36	2.9e-15	Restless legs syndrome;
LGG	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg05425664	chr17:57184151	TRIM37	0.71	11.67	0.48	8.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg27532318	chr7:32358331	NA	0.85	8.34	0.36	8.51e-16	Body mass index;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg02002194	chr4:3960332	NA	0.46	8.82	0.38	2.41e-17	Systolic blood pressure;
LGG	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.45	-0.37	3.92e-16	Tonsillectomy;
LGG	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg15269541	chr15:43626905	ADAL	0.43	7.2	0.32	2.46e-12	Lung cancer in ever smokers;
LGG	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg26597838	chr10:835615	NA	0.64	9.37	0.4	3.19e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg01988459	chr11:68622903	NA	-0.62	-12.61	-0.51	1.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7980799	0.591	rs10844614	chr12:33605702	A/C	cg26384229	chr12:38710491	ALG10B	-0.65	-11.64	-0.48	1.26e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg13047869	chr3:10149882	C3orf24	0.54	8.44	0.37	4.22e-16	Alzheimer's disease;
LGG	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg18105134	chr13:113819100	PROZ	0.72	15.34	0.58	2.99e-43	Platelet distribution width;
LGG	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg03806693	chr22:41940476	POLR3H	1.05	17.74	0.64	4.31e-54	Vitiligo;
LGG	cis	rs919433	0.679	rs10203581	chr2:198515900	G/A	cg00792783	chr2:198669748	PLCL1	0.57	9.18	0.39	1.44e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2073300	1.000	rs12625999	chr20:23442085	A/G	cg12062639	chr20:23401060	NAPB	-0.86	-6.95	-0.31	1.24e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs6840360	0.571	rs11099823	chr4:152510565	T/G	cg25486957	chr4:152246857	NA	-0.48	-7.94	-0.35	1.55e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.83	-17.67	-0.63	8.86e-54	Schizophrenia;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg14782152	chr13:114913410	NA	-0.33	-6.66	-0.3	8.01e-11	Schizophrenia;
LGG	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg03709012	chr19:19516395	GATAD2A	0.98	15.63	0.59	1.62e-44	Nonalcoholic fatty liver disease;
LGG	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg04691961	chr3:161091175	C3orf57	-0.46	-9.64	-0.41	3.53e-20	Morning vs. evening chronotype;
LGG	cis	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg05084668	chr3:125655381	ALG1L	-0.91	-10.81	-0.45	1.92e-24	Blood pressure (smoking interaction);
LGG	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg02891314	chr5:179741120	GFPT2	-0.63	-11.66	-0.48	9.72e-28	Height;
LGG	trans	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.43	-0.44	4.97e-23	Total cholesterol levels;
LGG	cis	rs3087591	0.708	rs8067440	chr17:29708155	A/T	cg24425628	chr17:29625626	OMG;NF1	0.6	12.39	0.5	1.2e-30	Hip circumference;
LGG	cis	rs7635838	0.819	rs2454481	chr3:11535178	C/T	cg00170343	chr3:11313890	ATG7	0.41	6.77	0.3	3.95e-11	HDL cholesterol;
LGG	cis	rs798766	0.909	rs11724531	chr4:1753424	A/G	cg00006948	chr4:1768889	NA	-0.5	-6.85	-0.3	2.33e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs7191700	0.583	rs243314	chr16:11385104	G/C	cg00044050	chr16:11439710	C16orf75	0.7	12.12	0.49	1.46e-29	Multiple sclerosis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25025968	chr11:4116056	RRM1	0.4	6.98	0.31	1.04e-11	Bilirubin levels;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg23782820	chr8:58130467	NA	0.54	7.46	0.33	4.32e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	7.65	0.33	1.19e-13	Mononucleosis;
LGG	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg19761014	chr17:28927070	LRRC37B2	-0.68	-8.56	-0.37	1.66e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg25173405	chr17:45401733	C17orf57	-0.51	-8.67	-0.37	7.52e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3789045	0.729	rs16853822	chr1:204450341	C/G	cg17419461	chr1:204415978	PIK3C2B	-0.42	-8.23	-0.36	1.94e-15	Educational attainment (college completion);
LGG	cis	rs9943753	0.605	rs3825393	chr12:109883374	C/T	cg19025524	chr12:109796872	NA	0.38	6.91	0.31	1.64e-11	HDL cholesterol;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.74	-0.34	6.12e-14	Personality dimensions;
LGG	cis	rs12908161	1.000	rs62021219	chr15:85256159	C/T	cg03959625	chr15:84868606	LOC388152	0.49	7.28	0.32	1.44e-12	Schizophrenia;
LGG	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.3	0.5	2.69e-30	Rheumatoid arthritis;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08280861	chr8:58055591	NA	0.64	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.52	-0.61	1.55e-48	Asthma;
LGG	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg21775007	chr8:11205619	TDH	-0.78	-13.6	-0.53	1.07e-35	Retinal vascular caliber;
LGG	cis	rs9814567	1.000	rs4423809	chr3:134300107	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	12.84	0.51	1.73e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg11995313	chr8:8860691	ERI1	-0.43	-7.15	-0.32	3.35e-12	Joint mobility (Beighton score);
LGG	cis	rs17445240	0.901	rs13418767	chr2:3704830	G/T	cg20720597	chr2:3699334	NA	0.72	8.0	0.35	1e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16939364	chr8:56015750	XKR4	0.41	6.83	0.3	2.75e-11	Cognitive performance;
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.29	0.4	6.22e-19	Monocyte count;
LGG	cis	rs9287719	0.745	rs4997810	chr2:10755540	T/A	cg02196655	chr2:10830764	NOL10	-0.41	-6.91	-0.31	1.59e-11	Prostate cancer;
LGG	cis	rs7712401	0.601	rs30047	chr5:122270524	G/A	cg19412675	chr5:122181750	SNX24	0.43	7.24	0.32	1.86e-12	Mean platelet volume;
LGG	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg02836325	chr17:76403955	PGS1	0.77	16.23	0.6	3.05e-47	HDL cholesterol levels;
LGG	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.07	0.55	1.06e-37	IgG glycosylation;
LGG	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.72	-10.38	-0.43	7.58e-23	Alzheimer's disease;
LGG	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.26e-11	Self-reported allergy;
LGG	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg23583168	chr7:148888333	NA	-0.84	-16.03	-0.6	2.52e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13537196	chr9:15553060	C9orf93	0.48	8.18	0.36	2.8e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs885389	0.924	rs7957882	chr12:131617417	G/T	cg07124762	chr12:131619285	GPR133	-0.44	-8.61	-0.37	1.16e-16	RR interval (heart rate);
LGG	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg07395648	chr5:131743802	NA	-0.51	-10.75	-0.45	3.21e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg03264133	chr6:25882463	NA	-0.69	-12.88	-0.51	1.12e-32	Intelligence (multi-trait analysis);
LGG	cis	rs367943	0.712	rs7731465	chr5:112687385	A/G	cg12552261	chr5:112820674	MCC	-0.54	-9.41	-0.4	2.28e-19	Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.53	-0.33	2.59e-13	Retinal vascular caliber;
LGG	cis	rs782590	0.643	rs5012561	chr2:55742032	G/C	cg18811423	chr2:55921094	PNPT1	-0.68	-12.03	-0.49	3.29e-29	Metabolic syndrome;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg16141378	chr3:129829833	LOC729375	0.39	8.94	0.38	9.37e-18	Neuroticism;
LGG	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.35	-0.32	8.84e-13	Breast cancer;
LGG	cis	rs7129556	0.954	rs10793255	chr11:77267611	A/G	cg12586386	chr11:77299805	AQP11	0.51	8.58	0.37	1.43e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.52	-7.72	-0.34	7.42e-14	Huntington's disease progression;
LGG	cis	rs4774899	0.752	rs2703580	chr15:57353034	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-7.15	-0.32	3.36e-12	Urinary tract infection frequency;
LGG	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-22.83	-0.73	7.77e-78	Blood trace element (Zn levels);
LGG	cis	rs6424115	1.000	rs4649115	chr1:24155731	A/G	cg15997130	chr1:24165203	NA	-0.5	-13.48	-0.53	3.46e-35	Immature fraction of reticulocytes;
LGG	cis	rs7937612	1.000	rs723937	chr11:120312746	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.66	-0.51	9.13e-32	Intraocular pressure;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg21948465	chr5:131705150	SLC22A5	0.68	7.58	0.33	1.88e-13	Rheumatoid arthritis;
LGG	cis	rs2307022	0.586	rs10852441	chr16:68385439	T/A	cg07273125	chr16:68295692	NA	0.44	9.88	0.42	5.02e-21	Body mass index;
LGG	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg15704280	chr7:45808275	SEPT13	0.49	8.09	0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg00757033	chr12:89920650	WDR51B	0.63	9.06	0.39	3.65e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg10596483	chr8:143751796	JRK	0.52	8.06	0.35	6.61e-15	Schizophrenia;
LGG	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.18	-0.43	4.3e-22	Response to antipsychotic treatment;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg09303159	chr6:26284866	NA	0.35	7.89	0.34	2.25e-14	Educational attainment;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg19077165	chr18:44547161	KATNAL2	0.7	13.39	0.53	8.27e-35	Personality dimensions;
LGG	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg16511985	chr3:153974050	SGEF	-0.49	-8.48	-0.37	3.08e-16	Coronary artery disease;
LGG	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.48	-7.89	-0.34	2.15e-14	Bipolar disorder;
LGG	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-6.8	-0.3	3.26e-11	Neuroticism;
LGG	cis	rs6942756	0.806	rs68184415	chr7:128988862	C/T	cg02491457	chr7:128862824	NA	-0.62	-11.46	-0.47	6.38e-27	White matter hyperintensity burden;
LGG	cis	rs9457247	0.663	rs2282860	chr6:167440244	T/C	cg07741184	chr6:167504864	NA	0.4	8.77	0.38	3.42e-17	Crohn's disease;
LGG	cis	rs11264213	0.892	rs11264194	chr1:36195372	C/T	cg27506609	chr1:36549197	TEKT2	0.66	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg12310025	chr6:25882481	NA	0.49	9.11	0.39	2.55e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6908034	0.660	rs111509549	chr6:19798370	A/G	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs709400	0.663	rs11628213	chr14:103952453	A/C	cg26031613	chr14:104095156	KLC1	0.8	13.84	0.54	1.03e-36	Body mass index;
LGG	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.48	-0.63	6.77e-53	Morning vs. evening chronotype;
LGG	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg02811702	chr13:24901961	NA	0.38	7.21	0.32	2.22e-12	Obesity-related traits;
LGG	cis	rs6444746	1.000	rs6444746	chr3:193495155	A/G	cg22553634	chr3:193489233	NA	-0.71	-8.61	-0.37	1.12e-16	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg16885296	chr6:26284938	NA	0.44	9.52	0.4	9.31e-20	Educational attainment;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21963583	chr11:68658836	MRPL21	0.6	10.04	0.42	1.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.38	-0.43	8.04e-23	Bipolar disorder;
LGG	cis	rs12155623	0.834	rs6472110	chr8:49784810	T/C	cg22283653	chr8:49824208	NA	-0.49	-8.86	-0.38	1.7e-17	Sudden cardiac arrest;
LGG	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.04e-11	Bone mineral density;
LGG	trans	rs9354308	0.764	rs1846565	chr6:66571909	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.66	-0.3	7.55e-11	Metabolite levels;
LGG	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.86	-0.54	8.45e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg19847130	chr8:10466454	RP1L1	0.31	6.78	0.3	3.59e-11	Neuroticism;
LGG	trans	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.1	0.55	8.12e-38	Morning vs. evening chronotype;
LGG	cis	rs6424115	1.000	rs7521961	chr1:24157634	C/T	cg15997130	chr1:24165203	NA	-0.5	-13.48	-0.53	3.77e-35	Immature fraction of reticulocytes;
LGG	cis	rs12580194	1.000	rs7974051	chr12:55713210	A/C	cg19537932	chr12:55886519	OR6C68	-0.39	-6.96	-0.31	1.19e-11	Cancer;
LGG	trans	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg21659725	chr3:3221576	CRBN	-0.67	-12.51	-0.5	3.97e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg02733842	chr7:1102375	C7orf50	-0.4	-6.94	-0.31	1.34e-11	Bronchopulmonary dysplasia;
LGG	cis	rs4481887	0.508	rs4916115	chr1:248383316	T/G	cg01631408	chr1:248437212	OR2T33	-0.42	-7.1	-0.31	4.76e-12	Common traits (Other);
LGG	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg26897989	chr16:1907736	C16orf73	0.52	9.87	0.42	5.48e-21	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.33	-0.32	1.03e-12	Neuroticism;
LGG	cis	rs17655565	1.000	rs17655565	chr12:52691958	T/C	cg08257133	chr12:52711352	KRT83	0.54	7.6	0.33	1.64e-13	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg07382826	chr16:28625726	SULT1A1	0.4	8.11	0.35	4.54e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg08305652	chr11:111469057	NA	-0.46	-9.31	-0.4	5.3e-19	Primary sclerosing cholangitis;
LGG	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg12654349	chr5:56205094	C5orf35	0.58	9.95	0.42	2.89e-21	Initial pursuit acceleration;
LGG	cis	rs1371867	0.846	rs1788205	chr8:101306546	G/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	6.87	0.3	2.05e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9359856	0.564	rs17584290	chr6:90467114	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.87	-0.42	5.71e-21	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.97	0.54	3.05e-37	Lung cancer;
LGG	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg07382826	chr16:28625726	SULT1A1	-0.4	-8.1	-0.35	4.8e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17125944	0.686	rs7158645	chr14:53332152	C/T	cg00686598	chr14:53173677	PSMC6	-0.67	-7.06	-0.31	6.05e-12	Alzheimer's disease (late onset);
LGG	cis	rs266717	0.844	rs266728	chr3:186523301	T/G	cg00373256	chr3:186519153	RFC4	-0.42	-8.59	-0.37	1.37e-16	Adiponectin levels;
LGG	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs7179456	0.515	rs602602	chr15:59057023	T/A	cg05156742	chr15:59063176	FAM63B	0.57	9.09	0.39	2.95e-18	Asperger disorder;
LGG	cis	rs10743315	0.557	rs77299796	chr12:19365100	T/C	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04530015	chr2:215796436	ABCA12	-0.46	-7.65	-0.33	1.19e-13	Neuroblastoma;
LGG	cis	rs7192750	0.562	rs8063403	chr16:71931032	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.79	0.45	2.26e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg21775007	chr8:11205619	TDH	0.43	6.83	0.3	2.7e-11	Myopia (pathological);
LGG	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2074585	0.806	rs8033813	chr15:90999715	A/T	cg22089800	chr15:90895588	ZNF774	0.7	12.93	0.52	7.25e-33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs883565	0.543	rs35628459	chr3:39174437	T/A	cg01426195	chr3:39028469	NA	0.64	13.57	0.53	1.47e-35	Handedness;
LGG	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.53e-21	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.72	-0.45	4.23e-24	Lung cancer;
LGG	cis	rs7011049	1.000	rs72643574	chr8:53844501	G/C	cg26025543	chr8:53854495	NA	0.75	9.96	0.42	2.64e-21	Systolic blood pressure;
LGG	cis	rs6598955	0.617	rs11247895	chr1:26599542	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	9.73	0.41	1.72e-20	Schizophrenia;
LGG	cis	rs10462794	0.686	rs2060701	chr5:4503514	C/A	cg18482690	chr5:4511582	NA	-0.37	-6.73	-0.3	5.13e-11	DNA methylation (variation);
LGG	cis	rs4262150	0.842	rs4246036	chr5:152205430	C/T	cg12297329	chr5:152029980	NA	0.65	12.1	0.49	1.85e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7503807	0.664	rs11150736	chr17:78613507	C/T	cg06872548	chr17:78716983	RPTOR	0.39	8.58	0.37	1.45e-16	Obesity;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg06558623	chr16:89946397	TCF25	1.24	14.34	0.55	7.11e-39	Skin colour saturation;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17243582	chr15:59969081	BNIP2	0.39	6.86	0.3	2.15e-11	Menarche (age at onset);
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.76	-0.34	5.62e-14	Personality dimensions;
LGG	cis	rs4566357	0.790	rs4389330	chr2:227957483	C/G	cg11843606	chr2:227700838	RHBDD1	0.42	7.48	0.33	3.83e-13	Coronary artery disease;
LGG	cis	rs17767392	0.813	rs36052007	chr14:71984705	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.66	-0.37	7.83e-17	Mitral valve prolapse;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.37	6.8	0.3	3.26e-11	Schizophrenia;
LGG	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg25554036	chr4:6271136	WFS1	0.61	11.61	0.47	1.57e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6735179	0.549	rs56066419	chr2:1755649	G/A	cg10160682	chr2:1713001	PXDN	-0.53	-9.5	-0.4	1.15e-19	Response to antipsychotic treatment;
LGG	cis	rs9487051	0.714	rs7744284	chr6:109616218	C/T	cg21918786	chr6:109611834	NA	-0.5	-9.3	-0.4	5.53e-19	Reticulocyte fraction of red cells;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.73	0.48	5.18e-28	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03390183	chr3:36779043	DCLK3	-0.35	-6.85	-0.3	2.41e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg16141378	chr3:129829833	LOC729375	-0.35	-8.09	-0.35	5.13e-15	Schizophrenia;
LGG	cis	rs4731207	0.662	rs7782031	chr7:124505784	C/A	cg05630886	chr7:124431682	NA	-0.33	-7.74	-0.34	6.44e-14	Cutaneous malignant melanoma;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.54	-9.4	-0.4	2.57e-19	Longevity;Endometriosis;
LGG	cis	rs977987	0.654	rs8054194	chr16:75497160	G/T	cg03315344	chr16:75512273	CHST6	0.57	11.22	0.46	5.14e-26	Dupuytren's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19880899	chr2:64067976	UGP2	0.45	7.23	0.32	1.99e-12	Gut microbiome composition (summer);
LGG	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-23.13	-0.73	3.02e-79	Blood trace element (Zn levels);
LGG	cis	rs736408	0.632	rs2240919	chr3:52831701	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	6.69	0.3	6.52e-11	Bipolar disorder;
LGG	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs7552167	0.925	rs11249021	chr1:24512881	G/T	cg01960748	chr1:24522592	NA	-0.47	-7.6	-0.33	1.69e-13	Psoriasis vulgaris;
LGG	cis	rs74781061	0.789	rs1078011	chr15:74734862	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-6.98	-0.31	1.04e-11	Endometriosis;
LGG	cis	rs782590	0.967	rs11125579	chr2:55739804	T/C	cg18811423	chr2:55921094	PNPT1	0.84	17.77	0.64	2.96e-54	Metabolic syndrome;
LGG	cis	rs4474465	1.000	rs7950813	chr11:78215082	A/T	cg27205649	chr11:78285834	NARS2	0.46	7.95	0.35	1.44e-14	Alzheimer's disease (survival time);
LGG	cis	rs9534288	0.797	rs9534277	chr13:46578349	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs9467160	0.871	rs9461015	chr6:24449020	C/G	cg20631270	chr6:24437470	GPLD1	-0.48	-7.3	-0.32	1.3e-12	Liver enzyme levels;
LGG	cis	rs7119	0.717	rs12899390	chr15:77815238	A/C	cg10437265	chr15:77819839	NA	0.25	7.05	0.31	6.39e-12	Type 2 diabetes;
LGG	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg08079166	chr15:68083412	MAP2K5	-0.35	-8.05	-0.35	6.87e-15	Restless legs syndrome;
LGG	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg16586182	chr3:47516702	SCAP	0.77	15.09	0.57	3.83e-42	Colorectal cancer;
LGG	cis	rs854037	0.595	rs13175128	chr5:57141390	G/A	cg08523694	chr5:57076192	NA	0.52	6.86	0.3	2.28e-11	Birth weight;
LGG	cis	rs4727027	0.933	rs757738	chr7:148872351	T/G	cg23583168	chr7:148888333	NA	-0.87	-16.9	-0.62	2.99e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg03351412	chr1:154909251	PMVK	0.64	12.33	0.5	2.06e-30	Prostate cancer;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.26	0.63	6.52e-52	Obesity-related traits;
LGG	cis	rs10884984	0.874	rs55669803	chr10:112285685	A/G	cg18756771	chr10:112261994	DUSP5	0.69	11.74	0.48	4.69e-28	Facial morphology (factor 22);
LGG	cis	rs793571	0.522	rs11071398	chr15:59120077	A/G	cg05156742	chr15:59063176	FAM63B	0.65	12.09	0.49	2.02e-29	Schizophrenia;
LGG	cis	rs7717393	0.786	rs10059872	chr5:155779927	G/T	cg04435420	chr5:155754009	SGCD	0.72	9.18	0.39	1.48e-18	Egg allergy;
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg04166393	chr7:2884313	GNA12	0.47	9.27	0.4	6.93e-19	Height;
LGG	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg22681709	chr2:178499509	PDE11A	0.48	8.82	0.38	2.37e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs783540	0.500	rs7178459	chr15:83398384	T/C	cg16105309	chr15:79090380	ADAMTS7	-0.46	-7.37	-0.32	8.17e-13	Schizophrenia;
LGG	trans	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.94e-30	Corneal astigmatism;
LGG	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.43	7.25	0.32	1.74e-12	Height;
LGG	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg20336341	chr7:50628841	DDC	-0.43	-7.45	-0.33	4.57e-13	Malaria;
LGG	cis	rs17818399	0.597	rs12104572	chr2:46862466	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.43	-7.65	-0.33	1.21e-13	Height;
LGG	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.45	-0.33	4.76e-13	Neuroticism;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.33	-0.32	1.05e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.84	-0.42	6.97e-21	Mean corpuscular volume;
LGG	cis	rs965513	1.000	rs1561962	chr9:100546219	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.77	-0.41	1.26e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs12145833	0.538	rs12026408	chr1:243366805	G/A	cg02356786	chr1:243265016	LOC731275	0.61	6.65	0.3	8.43e-11	Obesity (early onset extreme);
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.23e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.613	rs61927732	chr12:33678166	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-8.87	-0.38	1.55e-17	Morning vs. evening chronotype;
LGG	cis	rs7106204	0.609	rs11824883	chr11:24284952	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	9.73	0.41	1.76e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.58	0.63	2.18e-53	Vitiligo;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.7	0.3	5.96e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9303401	0.555	rs8073699	chr17:57236317	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	8.21	0.36	2.18e-15	Cognitive test performance;
LGG	cis	rs2251260	0.685	rs2246700	chr14:62008147	T/A	cg23386212	chr14:62041363	NA	0.58	8.06	0.35	6.45e-15	Yeast infection;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg13880726	chr7:1868755	MAD1L1	0.44	7.54	0.33	2.48e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.87	-0.42	5.65e-21	Neuroticism;
LGG	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg07541023	chr7:19748670	TWISTNB	-0.47	-7.05	-0.31	6.58e-12	Thyroid stimulating hormone;
LGG	cis	rs61931739	0.500	rs1601628	chr12:34047375	A/C	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06634786	chr22:41940651	POLR3H	0.78	12.86	0.51	1.4e-32	Vitiligo;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.82	-0.45	1.78e-24	Lung cancer;
LGG	trans	rs459571	0.629	rs441233	chr9:136876021	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.73	12.91	0.51	8.6e-33	Platelet distribution width;
LGG	cis	rs2694528	0.620	rs79524768	chr5:59930164	C/A	cg11474532	chr5:59995715	DEPDC1B	0.9	7.35	0.32	9.19e-13	Parkinson's disease;
LGG	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.2	31.11	0.82	1.61e-115	Chronic sinus infection;
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.6	0.33	1.66e-13	Tonsillectomy;
LGG	cis	rs12476592	0.516	rs4671503	chr2:63637091	A/T	cg17519650	chr2:63277830	OTX1	-0.49	-7.5	-0.33	3.19e-13	Childhood ear infection;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.26	0.32	1.59e-12	Lung cancer;
LGG	trans	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg06875740	chr19:51307921	C19orf48	-0.62	-6.81	-0.3	3.1e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg23649088	chr2:200775458	C2orf69	0.52	7.29	0.32	1.35e-12	Schizophrenia;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.34	-0.53	1.34e-34	Personality dimensions;
LGG	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.85	-0.34	2.84e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg07243736	chr16:783730	NARFL	0.6	10.06	0.42	1.19e-21	Height;
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs2797369	0.713	rs7758949	chr6:101570400	T/C	cg27451362	chr6:101846650	GRIK2	-0.84	-11.2	-0.46	6.29e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg05926928	chr17:57297772	GDPD1	0.96	15.41	0.58	1.47e-43	Opioid sensitivity;
LGG	cis	rs3845702	0.668	rs3856415	chr2:180807367	G/A	cg01881094	chr2:180872142	CWC22	-1.24	-16.6	-0.61	7.11e-49	Schizophrenia;
LGG	cis	rs16854884	0.632	rs34038325	chr3:143685097	G/A	cg06585982	chr3:143692056	C3orf58	0.62	10.63	0.44	9.45e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.57	0.37	1.58e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9323205	1.000	rs9323205	chr14:51586467	A/G	cg23942311	chr14:51606299	NA	-0.38	-6.82	-0.3	2.83e-11	Cancer;
LGG	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg07882059	chr11:68924751	NA	0.41	7.36	0.32	8.7e-13	Blond vs. brown hair color;
LGG	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg02002194	chr4:3960332	NA	0.44	8.03	0.35	8.11e-15	Retinal vascular caliber;
LGG	cis	rs7241530	0.662	rs12458336	chr18:75909080	T/A	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	8.11e-17	Educational attainment (years of education);
LGG	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg24060327	chr5:131705240	SLC22A5	0.48	8.25	0.36	1.68e-15	Blood metabolite levels;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg00933542	chr6:150070202	PCMT1	0.37	6.75	0.3	4.31e-11	Lung cancer;
LGG	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	trans	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg17712092	chr4:129076599	LARP1B	0.72	14.03	0.55	1.59e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg09238746	chr17:78121135	EIF4A3	-0.84	-14.48	-0.56	1.84e-39	Yeast infection;
LGG	cis	rs986417	0.818	rs8005621	chr14:61106699	G/A	cg27398547	chr14:60952738	C14orf39	0.65	6.73	0.3	4.92e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9487051	0.803	rs410449	chr6:109539853	C/T	cg21918786	chr6:109611834	NA	-0.4	-7.14	-0.31	3.7e-12	Reticulocyte fraction of red cells;
LGG	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg12288994	chr5:1860383	NA	0.71	11.36	0.47	1.51e-26	Cardiovascular disease risk factors;
LGG	trans	rs5756813	0.754	rs4821708	chr22:38164106	C/T	cg19894588	chr14:64061835	NA	-0.6	-9.69	-0.41	2.37e-20	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.75	-0.3	4.37e-11	Mood instability;
LGG	cis	rs7666738	0.962	rs11932892	chr4:99072967	C/T	cg05340658	chr4:99064831	C4orf37	0.44	7.01	0.31	8.71e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg13232821	chr7:50628718	DDC	0.37	7.27	0.32	1.58e-12	Malaria;
LGG	cis	rs240764	0.578	rs9498252	chr6:101194481	A/G	cg09795085	chr6:101329169	ASCC3	0.48	8.29	0.36	1.21e-15	Neuroticism;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21862992	chr11:68658383	NA	-0.46	-7.78	-0.34	4.74e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	9.75	0.41	1.49e-20	Lung cancer in ever smokers;
LGG	cis	rs9902453	0.808	rs56088359	chr17:28173659	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.83	0.54	1.13e-36	Coffee consumption (cups per day);
LGG	cis	rs11626933	0.959	rs8005973	chr14:90774951	C/T	cg14092571	chr14:90743983	NA	-0.79	-16.35	-0.61	9.1e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg17809284	chr5:56205270	C5orf35	-0.38	-7.28	-0.32	1.46e-12	Coronary artery disease;
LGG	cis	rs4704846	1.000	rs4704850	chr5:156532952	A/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	trans	rs7395662	0.591	rs7483212	chr11:48607182	T/A	cg00717180	chr2:96193071	NA	-0.46	-8.39	-0.36	5.96e-16	HDL cholesterol;
LGG	cis	rs3857067	1.000	rs7685048	chr4:95027784	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.82	-0.34	3.72e-14	QT interval;
LGG	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.01	-0.35	9.69e-15	HDL cholesterol;
LGG	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	21.17	0.7	4.33e-70	Homoarginine levels;
LGG	cis	rs2274273	0.870	rs7153645	chr14:55771518	C/G	cg04306507	chr14:55594613	LGALS3	0.62	16.93	0.62	2.04e-50	Protein biomarker;
LGG	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg01028140	chr2:1542097	TPO	-0.48	-7.6	-0.33	1.71e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.9	-0.42	4.32e-21	Body mass index;
LGG	cis	rs34467563	0.576	rs7001397	chr8:97342582	C/T	cg22138393	chr8:97340270	PTDSS1	0.33	8.58	0.37	1.45e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg19913688	chr11:428466	ANO9	-0.71	-8.93	-0.38	1.04e-17	Body mass index;
LGG	cis	rs35160687	0.901	rs17738096	chr2:86513893	C/G	cg10973622	chr2:86423274	IMMT	0.39	6.68	0.3	6.71e-11	Night sleep phenotypes;
LGG	cis	rs735539	0.521	rs7997062	chr13:21368822	A/G	cg04906043	chr13:21280425	IL17D	-0.5	-7.84	-0.34	3.13e-14	Dental caries;
LGG	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg15704280	chr7:45808275	SEPT13	0.72	8.59	0.37	1.38e-16	Axial length;
LGG	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg09137382	chr11:130731461	NA	0.36	6.84	0.3	2.51e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.44	-0.37	3.95e-16	Tonsillectomy;
LGG	cis	rs72634258	0.945	rs7522911	chr1:8097145	C/T	cg00042356	chr1:8021962	PARK7	0.84	10.84	0.45	1.46e-24	Inflammatory bowel disease;
LGG	cis	rs67311347	1.000	rs4973994	chr3:40453024	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-26.11	-0.77	4.54e-93	Renal cell carcinoma;
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.75	-0.34	5.85e-14	Systolic blood pressure;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	11.69	0.48	7.47e-28	Lymphocyte counts;
LGG	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.61	-0.33	1.55e-13	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.48	-0.53	3.42e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10922622	chr9:108210153	FSD1L	0.49	7.39	0.32	6.99e-13	Gut microbiome composition (summer);
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg12310025	chr6:25882481	NA	-0.89	-17.19	-0.62	1.4e-51	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	0.587	rs10946812	chr6:26344975	G/C	cg09904177	chr6:26538194	HMGN4	-0.45	-8.27	-0.36	1.41e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11753937	0.735	rs572004	chr6:133580411	G/T	cg26449787	chr6:133562087	EYA4	0.33	6.85	0.3	2.39e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs17767392	0.834	rs61989252	chr14:71727914	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.7	-0.37	5.74e-17	Mitral valve prolapse;
LGG	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg13683864	chr3:40499215	RPL14	-1.13	-26.46	-0.78	1.23e-94	Renal cell carcinoma;
LGG	cis	rs2708377	0.656	rs116607079	chr12:11262044	C/T	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.41	0.33	6.11e-13	Bitter taste perception;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg14926445	chr8:58193284	C8orf71	-0.88	-13.32	-0.53	1.72e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.93	-0.35	1.63e-14	Mean corpuscular hemoglobin;
LGG	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg11764359	chr7:65958608	NA	-0.77	-14.41	-0.56	3.62e-39	Aortic root size;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.84	-0.3	2.59e-11	Morning vs. evening chronotype;
LGG	cis	rs7226408	0.625	rs2586793	chr18:34784138	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-9.05	-0.39	3.89e-18	Obesity-related traits;
LGG	cis	rs10791097	0.690	rs12284540	chr11:130729772	T/C	cg12179176	chr11:130786555	SNX19	0.75	14.56	0.56	8.47e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.37	0.5	1.47e-30	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.84	-13.63	-0.54	8.64e-36	Chronic sinus infection;
LGG	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg24642439	chr20:33292090	TP53INP2	-0.58	-9.71	-0.41	2.13e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.52	-8.86	-0.38	1.78e-17	Prudent dietary pattern;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg07701084	chr6:150067640	NUP43	0.49	7.52	0.33	2.96e-13	Lung cancer;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg12458913	chr13:53173898	NA	-0.54	-10.12	-0.43	7.03e-22	Lewy body disease;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	9.42	0.4	2.1e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07414239	chr6:126278153	HINT3	0.44	6.8	0.3	3.15e-11	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs6735179	0.565	rs736869	chr2:1748463	G/A	cg10160682	chr2:1713001	PXDN	-0.54	-9.36	-0.4	3.42e-19	Response to antipsychotic treatment;
LGG	cis	rs679087	0.606	rs167318	chr12:29943124	T/C	cg14258853	chr12:29935411	TMTC1	-0.4	-6.79	-0.3	3.42e-11	Schizophrenia;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.07	-0.35	6.1e-15	IgG glycosylation;
LGG	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg00254258	chr1:3105189	PRDM16	-0.69	-13.15	-0.52	8.92e-34	Migraine;
LGG	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg03929089	chr4:120376271	NA	-0.55	-9.61	-0.41	4.5e-20	HDL cholesterol;
LGG	cis	rs1983891	1.000	rs9296365	chr6:41535379	A/G	cg20194872	chr6:41519635	FOXP4	0.59	10.18	0.43	4.09e-22	Prostate cancer;
LGG	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.47	0.37	3.37e-16	Mean corpuscular volume;
LGG	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg24687543	chr11:63912206	MACROD1	0.61	8.46	0.37	3.41e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.0	0.62	9.87e-51	Alzheimer's disease;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg17470184	chr11:118478236	PHLDB1	0.43	7.74	0.34	6.17e-14	Cholesterol, total;
LGG	cis	rs7512552	0.839	rs11205357	chr1:150267798	T/C	cg15654264	chr1:150340011	RPRD2	-0.44	-8.91	-0.38	1.15e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.94	14.58	0.56	6.73e-40	Chronic sinus infection;
LGG	cis	rs10186029	0.680	rs4673726	chr2:213981115	T/C	cg08319019	chr2:214017104	IKZF2	0.46	8.04	0.35	7.32e-15	Systemic sclerosis;
LGG	cis	rs72717009	0.825	rs7552317	chr1:161479438	C/T	cg12643083	chr1:161476548	FCGR2A	-0.65	-9.85	-0.42	6.79e-21	Rheumatoid arthritis;
LGG	cis	rs9296092	0.517	rs55963187	chr6:33523778	G/C	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2236267	0.726	rs2755075	chr14:88579279	A/G	cg18078958	chr14:88630771	NA	-0.3	-7.0	-0.31	8.91e-12	Food antigen IgG levels;
LGG	cis	rs7241530	0.662	rs924888	chr18:75900840	G/A	cg14642773	chr18:75888474	NA	0.47	9.2	0.39	1.25e-18	Educational attainment (years of education);
LGG	cis	rs4750440	0.702	rs7911259	chr10:14031051	T/C	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.54	-0.53	2.03e-35	Adiponectin levels;
LGG	cis	rs62007496	0.520	rs59138495	chr14:103612137	C/G	cg09274347	chr14:103599552	TNFAIP2	0.56	6.67	0.3	7.13e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg12473912	chr3:136751656	NA	0.4	6.85	0.3	2.29e-11	Gestational age at birth (child effect);
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21862992	chr11:68658383	NA	0.5	8.55	0.37	1.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs6942756	0.513	rs10954224	chr7:128893513	T/A	cg02491457	chr7:128862824	NA	0.51	9.64	0.41	3.59e-20	White matter hyperintensity burden;
LGG	cis	rs6594713	0.921	rs13181534	chr5:112724641	A/G	cg12552261	chr5:112820674	MCC	0.51	7.23	0.32	1.97e-12	Brain cytoarchitecture;
LGG	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg03929089	chr4:120376271	NA	0.44	7.23	0.32	1.96e-12	HDL cholesterol;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.84	-0.42	7.4e-21	Personality dimensions;
LGG	cis	rs4356932	1.000	rs4593163	chr4:76976056	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	6.68e-11	Blood protein levels;
LGG	cis	rs6918586	0.658	rs198822	chr6:26123539	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.6	-0.41	4.87e-20	Schizophrenia;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.97	-0.52	4.78e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs10173297	0.686	rs13392120	chr2:3708685	C/T	cg16123090	chr2:3699210	NA	0.58	7.84	0.34	3.22e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7927592	0.913	rs10896338	chr11:68299360	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg20026190	chr17:76395443	PGS1	0.57	10.08	0.42	9.85e-22	HDL cholesterol levels;
LGG	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.75	0.38	3.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	8.12	0.35	4.25e-15	Height;
LGG	cis	rs11239187	0.530	rs35616948	chr10:45062178	A/T	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.24e-18	Body mass index;
LGG	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.68	12.99	0.52	4.06e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7010267	0.692	rs3134063	chr8:119959657	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.96	0.35	1.38e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs10463554	0.746	rs6876072	chr5:102587573	C/T	cg23492399	chr5:102201601	PAM	-0.46	-7.04	-0.31	7.09e-12	Parkinson's disease;
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs4722585	0.533	rs6964215	chr7:26196819	G/A	cg07876897	chr7:26191696	NFE2L3	0.35	6.98	0.31	1.04e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs240764	0.619	rs9403962	chr6:101129997	T/A	cg09795085	chr6:101329169	ASCC3	0.41	6.79	0.3	3.41e-11	Neuroticism;
LGG	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.49	-0.33	3.41e-13	Testicular germ cell tumor;
LGG	cis	rs10048158	0.510	rs8082415	chr17:64205481	T/C	cg19474267	chr17:64306194	PRKCA	0.62	12.41	0.5	9.51e-31	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs12765878	1.000	rs7100920	chr10:105640978	A/G	cg11005552	chr10:105648138	OBFC1	-0.99	-24.54	-0.75	8.6e-86	Coronary artery disease;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg02002194	chr4:3960332	NA	0.43	7.97	0.35	1.23e-14	Morning vs. evening chronotype;
LGG	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg12179176	chr11:130786555	SNX19	-0.84	-17.61	-0.63	1.66e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23077509	chr3:142166793	XRN1	0.49	8.23	0.36	1.98e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs71403859	0.502	rs35981926	chr16:71500755	A/T	cg08717414	chr16:71523259	ZNF19	-1.34	-16.2	-0.6	4.55e-47	Post bronchodilator FEV1;
LGG	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.49	0.53	3.3e-35	Prudent dietary pattern;
LGG	cis	rs8141529	0.764	rs5762854	chr22:29246278	T/C	cg02153584	chr22:29168773	CCDC117	0.68	11.56	0.47	2.4e-27	Lymphocyte counts;
LGG	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs7143963	0.943	rs34503276	chr14:103266077	C/T	cg23020514	chr14:103360112	TRAF3	0.54	9.95	0.42	2.89e-21	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03900353	chr1:212732456	NA	0.49	8.08	0.35	5.58e-15	Gut microbiome composition (summer);
LGG	cis	rs9611519	0.929	rs4820425	chr22:41431342	C/A	cg03806693	chr22:41940476	POLR3H	-0.53	-7.99	-0.35	1.1e-14	Neuroticism;
LGG	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6429082	0.846	rs2270538	chr1:235602404	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.64	-10.86	-0.45	1.22e-24	Adiposity;
LGG	cis	rs4950322	0.634	rs7542951	chr1:146812058	C/T	cg22381352	chr1:146742008	CHD1L	-0.51	-8.24	-0.36	1.73e-15	Protein quantitative trait loci;
LGG	cis	rs6882046	0.513	rs601942	chr5:88031820	T/C	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg00800038	chr16:89945340	TCF25	-0.58	-8.25	-0.36	1.71e-15	Skin colour saturation;
LGG	cis	rs7923609	1.000	rs4595427	chr10:65012944	A/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.75	-0.3	4.51e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg13844804	chr7:814759	HEATR2	-0.52	-6.88	-0.3	1.92e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg11995313	chr8:8860691	ERI1	0.43	7.13	0.31	3.86e-12	Joint mobility (Beighton score);
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.82	0.48	2.31e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg19904058	chr10:135279010	LOC619207	-0.28	-6.82	-0.3	2.77e-11	Systemic lupus erythematosus;
LGG	cis	rs6942756	0.876	rs1559486	chr7:129015894	C/T	cg02491457	chr7:128862824	NA	-0.65	-12.02	-0.49	3.65e-29	White matter hyperintensity burden;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs11122272	0.701	rs743120	chr1:231531232	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg16339924	chr4:17578868	LAP3	-0.65	-11.11	-0.46	1.45e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10463316	0.894	rs10476980	chr5:150764157	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.52	-0.5	3.66e-31	Obesity-related traits;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg07538946	chr5:131705188	SLC22A5	0.67	7.8	0.34	4.22e-14	Rheumatoid arthritis;
LGG	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11644478	chr21:40555479	PSMG1	0.91	17.6	0.63	1.87e-53	Cognitive function;
LGG	cis	rs60180747	1.000	rs80326387	chr15:66705043	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	11.12	0.46	1.31e-25	Testicular germ cell tumor;
LGG	cis	rs2859741	0.546	rs10489413	chr1:37513906	C/T	cg09363841	chr1:37513479	NA	-0.57	-12.53	-0.5	3.34e-31	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.28	0.32	1.48e-12	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs9487094	0.885	rs3818934	chr6:109668480	C/T	cg01125227	chr6:109776195	MICAL1	0.54	9.39	0.4	2.72e-19	Height;
LGG	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-11.1	-0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg06848047	chr4:90757629	SNCA	-0.4	-7.72	-0.34	7.31e-14	Dementia with Lewy bodies;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-9.27	-0.4	6.91e-19	Skin colour saturation;
LGG	cis	rs9942416	0.660	rs4704234	chr5:75001432	A/G	cg19683494	chr5:74908142	NA	0.43	6.68	0.3	6.78e-11	Age-related disease endophenotypes;
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs3204270	0.714	rs7189	chr17:79668897	C/T	cg18367735	chr17:79674897	NA	0.62	7.83	0.34	3.3e-14	Dental caries;
LGG	cis	rs8016982	0.632	rs7142641	chr14:81677454	A/G	cg01989461	chr14:81687754	GTF2A1	0.57	9.02	0.39	5.09e-18	Schizophrenia;
LGG	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg16662043	chr16:48846231	NA	-0.35	-6.96	-0.31	1.16e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg19812747	chr11:111475976	SIK2	-0.45	-9.03	-0.39	4.74e-18	Primary sclerosing cholangitis;
LGG	cis	rs12618769	0.597	rs4850874	chr2:99069799	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.52	0.37	2.34e-16	Bipolar disorder;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg00684032	chr4:1343700	KIAA1530	0.43	8.34	0.36	8.3e-16	Longevity;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23212579	chr2:219256018	SLC11A1	0.37	6.75	0.3	4.31e-11	Pancreatic cancer;
LGG	cis	rs4740619	0.525	rs2153726	chr9:15828904	G/C	cg14451791	chr9:16040625	NA	0.32	7.81	0.34	4e-14	Body mass index;
LGG	cis	rs75920871	0.528	rs7935834	chr11:116944437	C/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.46	-0.44	3.9699999999999997e-23	Subjective well-being;
LGG	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg12633918	chr20:23549525	CST9L	-0.36	-7.19	-0.32	2.68e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs12410462	0.591	rs2819496	chr1:227733902	G/A	cg04117972	chr1:227635322	NA	0.46	8.62	0.37	1.04e-16	Major depressive disorder;
LGG	cis	rs12282928	0.959	rs1483122	chr11:48327186	T/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.3	-0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.61	0.44	1.09e-23	Prudent dietary pattern;
LGG	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg16797656	chr11:68205561	LRP5	0.51	9.92	0.42	3.69e-21	Total body bone mineral density;
LGG	trans	rs9354308	0.868	rs8180586	chr6:66548669	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-8.35	-0.36	8.01e-16	Metabolite levels;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08645402	chr16:4508243	NA	0.5	9.48	0.4	1.31e-19	Schizophrenia;
LGG	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.33	0.32	1.04e-12	Neuroticism;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7011049	0.778	rs72648433	chr8:53879562	C/T	cg26025543	chr8:53854495	NA	0.61	8.61	0.37	1.16e-16	Systolic blood pressure;
LGG	cis	rs13260300	0.571	rs2059533	chr8:75547136	T/G	cg22993706	chr8:75542856	NA	0.51	10.84	0.45	1.55e-24	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.93	0.48	8.44e-29	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10559432	chr20:50179543	NFATC2	0.49	7.75	0.34	6e-14	Gut microbiome composition (summer);
LGG	cis	rs2963155	0.590	rs258757	chr5:142620736	A/G	cg17617527	chr5:142782415	NR3C1	-0.8	-10.53	-0.44	2.14e-23	Breast cancer;
LGG	cis	rs7843479	0.601	rs3824338	chr8:21864540	A/C	cg17168535	chr8:21777572	XPO7	0.81	15.9	0.59	9.47e-46	Mean corpuscular volume;
LGG	cis	rs208520	0.661	rs7766144	chr6:66827795	C/T	cg07460842	chr6:66804631	NA	-0.97	-18.12	-0.64	7.59e-56	Exhaled nitric oxide output;
LGG	cis	rs7192380	0.965	rs4633710	chr16:69632961	A/G	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.59	-0.33	1.79e-13	Sjögren's syndrome;
LGG	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg15921436	chr17:44337874	NA	0.45	10.58	0.44	1.37e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs2562456	0.793	rs2219839	chr19:21516322	A/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs11074306	0.508	rs12911001	chr15:28044435	T/C	cg26402630	chr15:28053930	OCA2	0.34	6.79	0.3	3.56e-11	Uveal melanoma;
LGG	cis	rs4363385	0.720	rs1415968	chr1:152970219	C/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.26	-0.4	7.71e-19	Inflammatory skin disease;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg06112835	chr11:68658793	MRPL21	0.64	10.4	0.44	6.59e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs41005	1.000	rs34505904	chr2:8115159	T/C	cg03155496	chr2:8117019	LOC339788	-0.9	-19.97	-0.68	1.86e-64	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg09021430	chr5:549028	NA	-0.69	-9.68	-0.41	2.6e-20	Obesity-related traits;
LGG	cis	rs9513627	1.000	rs7322368	chr13:100213990	T/C	cg15490075	chr13:100150979	NA	0.64	6.79	0.3	3.41e-11	Obesity-related traits;
LGG	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	8.65	0.37	8.35e-17	Coronary artery disease;
LGG	cis	rs17824933	0.848	rs11230559	chr11:60769534	T/C	cg16817237	chr11:60793675	NA	0.35	6.71	0.3	5.8200000000000003e-11	Multiple sclerosis;
LGG	cis	rs12738007	0.967	rs12032470	chr1:29464954	C/A	cg11747820	chr1:29584023	PTPRU	-0.35	-8.04	-0.35	7.73e-15	Schizophrenia;
LGG	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg24623649	chr8:11872141	NA	0.35	8.35	0.36	7.96e-16	Neuroticism;
LGG	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.48	-7.69	-0.34	9.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs151041685	1	rs151041685	chr2:179725237	G/T	cg17765952	chr2:179737173	CCDC141	0.65	7.44	0.33	4.93e-13	Resting heart rate;
LGG	cis	rs1816752	0.583	rs6490918	chr13:25002115	G/A	cg22771759	chr13:24902376	NA	-0.4	-6.69	-0.3	6.63e-11	Obesity-related traits;
LGG	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg12756686	chr19:29218302	NA	0.62	8.14	0.35	3.78e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg25237894	chr2:233734115	C2orf82	0.65	12.56	0.5	2.52e-31	Coronary artery disease;
LGG	cis	rs1670533	0.685	rs56019586	chr4:1059842	C/G	cg27284194	chr4:1044797	NA	0.56	10.02	0.42	1.57e-21	Recombination rate (females);
LGG	cis	rs727505	0.520	rs1454125	chr7:124862733	C/T	cg23710748	chr7:124431027	NA	-0.44	-8.32	-0.36	1.01e-15	Lewy body disease;
LGG	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg09324608	chr17:30823087	MYO1D	0.31	7.52	0.33	2.81e-13	Schizophrenia;
LGG	cis	rs36071027	0.615	rs57523915	chr5:158434036	G/T	cg00594129	chr5:158524270	EBF1	0.45	8.11	0.35	4.69e-15	Carotid intima media thickness;
LGG	cis	rs9948	0.655	rs7568206	chr2:97393108	A/C	cg01990225	chr2:97406019	LMAN2L	-0.77	-8.2	-0.36	2.46e-15	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.72	0.51	5.44e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05845236	chr13:67804635	PCDH9	-0.36	-6.9	-0.31	1.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg18721089	chr20:30220636	NA	-0.53	-7.77	-0.34	5.27e-14	Mean corpuscular hemoglobin;
LGG	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg24642439	chr20:33292090	TP53INP2	-0.6	-10.53	-0.44	2.21e-23	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.3	-0.63	4.56e-52	Refractive error;
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg07061783	chr6:25882402	NA	-0.39	-7.0	-0.31	9.3e-12	Blood metabolite levels;
LGG	cis	rs9879311	0.932	rs7427473	chr3:10413197	C/T	cg21387009	chr3:10280255	IRAK2	-0.37	-6.83	-0.3	2.74e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1878931	0.535	rs10852706	chr16:3412582	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	11.11	0.46	1.35e-25	Body mass index (adult);
LGG	cis	rs1451375	0.572	rs4948205	chr7:50557774	G/A	cg14593290	chr7:50529359	DDC	-0.67	-11.91	-0.48	1.02e-28	Malaria;
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg15948088	chr11:109293068	C11orf87	0.8	15.21	0.58	1.16e-42	Schizophrenia;
LGG	cis	rs2213920	0.619	rs7042718	chr9:118202187	C/T	cg13918206	chr9:118159781	DEC1	0.62	8.81	0.38	2.57e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs28588043	0.938	rs9427214	chr1:170966813	C/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.41	-0.33	6.06e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs4731207	0.698	rs10260227	chr7:124446486	T/C	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.95	0.31	1.27e-11	Bone mineral density;
LGG	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg00405596	chr8:11794950	NA	-0.46	-7.84	-0.34	3.22e-14	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg02297831	chr4:17616191	MED28	0.45	8.29	0.36	1.27e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg11584989	chr19:19387371	SF4	0.69	11.44	0.47	7.35e-27	Bipolar disorder;
LGG	cis	rs17221829	0.673	rs10765226	chr11:89385013	A/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	1.9e-18	Anxiety in major depressive disorder;
LGG	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.42e-31	Motion sickness;
LGG	cis	rs7432375	0.519	rs34799319	chr3:136586618	G/A	cg12473912	chr3:136751656	NA	0.42	7.01	0.31	8.72e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg26585981	chr11:48327164	OR4S1	-0.4	-7.02	-0.31	7.71e-12	Migraine - clinic-based;
LGG	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg06611532	chr13:114900021	NA	0.28	7.09	0.31	4.98e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4845570	0.831	rs11588634	chr1:151780686	T/A	cg07092448	chr1:151763213	TDRKH	-1.07	-15.42	-0.58	1.37e-43	Coronary artery disease;
LGG	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg06963709	chr7:155150793	NA	0.37	7.22	0.32	2.2e-12	Stem cell growth factor beta levels;
LGG	cis	rs11190604	0.767	rs7076606	chr10:102192267	T/C	cg07570687	chr10:102243282	WNT8B	0.41	7.49	0.33	3.59e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	8.4	0.36	5.35e-16	Obesity-related traits;
LGG	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-9.94	-0.42	3.12e-21	Parkinson's disease;
LGG	cis	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg06521331	chr12:34319734	NA	-0.52	-8.8	-0.38	2.72e-17	Resting heart rate;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg23782820	chr8:58130467	NA	0.52	7.2	0.32	2.5e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg10253484	chr15:75165896	SCAMP2	-0.63	-9.51	-0.4	1.07e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg04705435	chr11:17411270	KCNJ11	0.51	10.29	0.43	1.73e-22	Type 2 diabetes;
LGG	cis	rs11585357	0.895	rs72633828	chr1:17632251	G/A	cg08277548	chr1:17600880	PADI3	-0.74	-8.35	-0.36	8.22e-16	Hair shape;
LGG	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg14675211	chr2:100938903	LONRF2	0.63	11.23	0.46	5.01e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2307022	0.586	rs3760001	chr16:68407454	G/A	cg07273125	chr16:68295692	NA	0.44	9.89	0.42	4.85e-21	Body mass index;
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg25077389	chr14:35451556	SRP54	-0.43	-7.14	-0.31	3.69e-12	Breast cancer;
LGG	cis	rs7191700	0.511	rs243330	chr16:11350991	C/T	cg00044050	chr16:11439710	C16orf75	0.54	9.15	0.39	1.82e-18	Multiple sclerosis;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03452623	chr4:187889614	NA	-1.04	-29.57	-0.81	1.01e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg01346077	chr3:125931526	NA	0.43	11.16	0.46	9.23e-26	Metabolite levels;
LGG	cis	rs3740909	1.000	rs7930220	chr11:125886414	A/G	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs10220309	0.959	rs1073391	chr14:80588744	G/A	cg08183125	chr14:80678293	DIO2	0.47	6.77	0.3	3.85e-11	Lung function (FEV1);
LGG	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg15704280	chr7:45808275	SEPT13	-0.98	-21.13	-0.7	7.04e-70	Height;
LGG	cis	rs62025270	0.688	rs11073516	chr15:86285227	G/C	cg25843651	chr15:86329602	KLHL25	0.59	9.2	0.39	1.23e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg05793240	chr7:2802953	GNA12	0.33	7.63	0.33	1.31e-13	Height;
LGG	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg12561776	chr17:30844705	MYO1D	-0.28	-7.06	-0.31	5.97e-12	Schizophrenia;
LGG	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg20587970	chr11:113659929	NA	-1.06	-18.2	-0.65	3.21e-56	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.44	-0.33	5.05e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7301826	0.651	rs4759521	chr12:131297313	C/T	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.25	0.32	1.74e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Vitiligo;
LGG	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg05625103	chr10:2543513	NA	0.4	7.68	0.34	9.34e-14	Age-related hearing impairment;
LGG	cis	rs912057	0.601	rs1294413	chr6:6739924	C/A	cg06612196	chr6:6737390	NA	0.52	11.85	0.48	1.82e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg12183467	chr14:104352244	NA	0.41	7.16	0.32	3.21e-12	Bipolar disorder;
LGG	trans	rs2562456	0.839	rs2562411	chr19:21601983	T/G	cg00806126	chr19:22604979	ZNF98	-0.54	-7.28	-0.32	1.48e-12	Pain;
LGG	cis	rs9398803	0.966	rs9388487	chr6:126678268	G/T	cg19875578	chr6:126661172	C6orf173	0.57	10.3	0.43	1.52e-22	Male-pattern baldness;
LGG	trans	rs783540	0.935	rs2278355	chr15:83331155	C/T	cg16105309	chr15:79090380	ADAMTS7	-0.39	-6.91	-0.31	1.6e-11	Schizophrenia;
LGG	trans	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg25214090	chr10:38739885	LOC399744	-0.52	-9.42	-0.4	2.13e-19	Corneal astigmatism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17323045	chr14:58764804	FLJ31306;ARID4A	0.43	7.89	0.34	2.22e-14	Obesity-related traits;
LGG	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg04287289	chr16:89883240	FANCA	-0.45	-8.02	-0.35	8.86e-15	Vitiligo;
LGG	trans	rs1493916	0.870	rs1389531	chr18:31386616	C/T	cg27147174	chr7:100797783	AP1S1	-0.68	-13.01	-0.52	3.37e-33	Life satisfaction;
LGG	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.49	0.33	3.46e-13	Colorectal cancer;
LGG	cis	rs4888262	0.545	rs8052923	chr16:74680105	C/T	cg01733217	chr16:74700730	RFWD3	0.93	19.47	0.67	4.21e-62	Testicular germ cell tumor;
LGG	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.81	0.41	9.13e-21	Joint mobility (Beighton score);
LGG	cis	rs9807841	0.544	rs10407692	chr19:10770783	A/G	cg17710535	chr19:10819994	QTRT1	0.5	8.09	0.35	5.14e-15	Inflammatory skin disease;
LGG	cis	rs35771425	1.000	rs72743233	chr1:211556996	C/T	cg10512769	chr1:211675356	NA	-0.75	-11.75	-0.48	4.43e-28	Educational attainment (years of education);
LGG	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg03970086	chr16:88974840	CBFA2T3	0.45	8.7	0.37	5.97e-17	Social autistic-like traits;
LGG	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Body mass index;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09742170	chr7:25021208	OSBPL3	0.43	7.49	0.33	3.47e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-8.4	-0.36	5.61e-16	Personality dimensions;
LGG	cis	rs4950322	0.570	rs72692971	chr1:146804820	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs10463554	0.892	rs34816	chr5:102434645	T/G	cg23492399	chr5:102201601	PAM	-0.52	-7.68	-0.34	9.44e-14	Parkinson's disease;
LGG	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Alcohol dependence;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08575399	chr20:60719638	PSMA7;SS18L1	0.58	9.15	0.39	1.89e-18	Gut microbiome composition (summer);
LGG	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg07636037	chr3:49044803	WDR6	1.01	22.75	0.73	1.89e-77	Parkinson's disease;
LGG	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.94	0.35	1.56e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg08222618	chr4:941054	TMEM175	0.8	19.66	0.67	5.4e-63	Sjögren's syndrome;
LGG	cis	rs2797160	0.967	rs2797162	chr6:126011381	G/T	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.47e-13	Endometrial cancer;
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.29	-8.4	-0.36	5.48e-16	IgG glycosylation;
LGG	trans	rs7944735	0.517	rs7952205	chr11:48199227	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.05	0.35	7.1e-15	Intraocular pressure;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg12395012	chr8:11607386	GATA4	0.38	6.66	0.3	7.57e-11	Neuroticism;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.53	0.37	2.14e-16	Obesity-related traits;
LGG	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.52	0.47	3.48e-27	Mean platelet volume;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.46	-0.33	4.45e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg11766577	chr21:47581405	C21orf56	-0.47	-8.07	-0.35	6.07e-15	Testicular germ cell tumor;
LGG	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg02297831	chr4:17616191	MED28	0.45	8.21	0.36	2.27e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7177699	0.557	rs7178051	chr15:79118296	A/G	cg00540400	chr15:79124168	NA	0.54	11.45	0.47	6.52e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg19338460	chr6:170058176	WDR27	-0.64	-8.73	-0.38	4.61e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg16634245	chr2:149831082	KIF5C	-0.4	-6.98	-0.31	1.01e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg08975724	chr8:8085496	FLJ10661	0.36	6.74	0.3	4.72e-11	Mood instability;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.99	0.45	4.07e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg11952622	chr19:58962976	ZNF324B	-0.45	-6.84	-0.3	2.51e-11	Mean platelet volume;
LGG	cis	rs367943	0.576	rs10074024	chr5:112980820	G/A	cg12552261	chr5:112820674	MCC	0.51	8.9	0.38	1.3e-17	Type 2 diabetes;
LGG	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg03806693	chr22:41940476	POLR3H	0.96	16.8	0.62	8.31e-50	Vitiligo;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.6	0.37	1.23e-16	Longevity;
LGG	cis	rs4918072	0.606	rs78381949	chr10:105612418	G/A	cg11005552	chr10:105648138	OBFC1	0.67	9.62	0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg17927777	chr20:33865990	NA	0.74	10.49	0.44	2.98e-23	Attention deficit hyperactivity disorder;
LGG	cis	rs17767392	0.881	rs9672060	chr14:72010126	G/T	cg02058870	chr14:72053146	SIPA1L1	0.43	8.88	0.38	1.52e-17	Mitral valve prolapse;
LGG	trans	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg16141378	chr3:129829833	LOC729375	0.31	6.86	0.3	2.27e-11	Recombination measurement;
LGG	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-20.5	-0.69	6.25e-67	Systemic lupus erythematosus;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.82	0.34	3.53e-14	Height;
LGG	cis	rs2652834	0.808	rs2652789	chr15:63415223	A/C	cg05507819	chr15:63340323	TPM1	0.48	6.67	0.3	7.13e-11	HDL cholesterol;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg00684032	chr4:1343700	KIAA1530	0.4	7.85	0.34	2.9e-14	Longevity;
LGG	cis	rs9814567	1.000	rs6763093	chr3:134254995	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.03	0.52	2.84e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.73	-0.3	5.05e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg06026331	chr20:60912101	LAMA5	0.36	6.74	0.3	4.79e-11	Colorectal cancer;
LGG	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg18131467	chr2:239335373	ASB1	1.03	23.63	0.74	1.42e-81	Multiple system atrophy;
LGG	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg19847130	chr8:10466454	RP1L1	0.31	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.77	-0.41	1.29e-20	Lung cancer;
LGG	cis	rs1185460	0.565	rs2276060	chr11:118919132	G/A	cg24687335	chr11:118901407	SLC37A4	-0.61	-10.82	-0.45	1.76e-24	Coronary artery disease;
LGG	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.19	-0.49	7.79e-30	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg11494091	chr17:61959527	GH2	0.55	9.0	0.39	6.09e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.99	0.52	3.94e-33	Alzheimer's disease;
LGG	cis	rs10504073	0.647	rs10808744	chr8:49988984	A/G	cg00325661	chr8:49890786	NA	0.74	14.52	0.56	1.2e-39	Blood metabolite ratios;
LGG	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg04672837	chr16:48644449	N4BP1	0.55	9.07	0.39	3.5e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10871290	0.881	rs4099290	chr16:74468889	A/G	cg01733217	chr16:74700730	RFWD3	-0.74	-14.23	-0.55	2.26e-38	Breast cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00085830	chr1:182808254	DHX9	0.4	7.23	0.32	2.03e-12	Obesity-related traits;
LGG	cis	rs847649	0.618	rs6465880	chr7:102515237	T/C	cg18108683	chr7:102477205	FBXL13	-0.63	-13.78	-0.54	1.82e-36	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg15133208	chr4:90757351	SNCA	-0.34	-7.55	-0.33	2.4e-13	Dementia with Lewy bodies;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg15948088	chr11:109293068	C11orf87	0.53	8.92	0.38	1.12e-17	Schizophrenia;
LGG	cis	rs4961252	0.505	rs4961327	chr8:142102053	C/T	cg17960426	chr8:142067321	NA	-0.38	-7.28	-0.32	1.41e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg06889755	chr6:150326021	RAET1K	-0.4	-8.27	-0.36	1.48e-15	Alopecia areata;
LGG	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.28	0.36	1.31e-15	Mood instability;
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg18357526	chr6:26021779	HIST1H4A	0.76	12.52	0.5	3.4e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.593	rs7552110	chr1:178542154	A/T	cg19399532	chr1:178512495	C1orf220	-0.4	-7.5	-0.33	3.22e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.54	-0.33	2.46e-13	Vitamin D levels;
LGG	cis	rs735539	0.645	rs1329518	chr13:21203611	C/G	cg04906043	chr13:21280425	IL17D	-0.5	-8.15	-0.35	3.52e-15	Dental caries;
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.64e-15	Bipolar disorder;
LGG	cis	rs6694672	0.867	rs10737687	chr1:197108693	C/T	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.69e-12	Asthma;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.32	-0.32	1.08e-12	Lung cancer;
LGG	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4750440	0.706	rs1031753	chr10:14020110	T/C	cg00551146	chr10:14014579	FRMD4A	0.29	6.96	0.31	1.13e-11	Adiponectin levels;
LGG	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	8.04	0.35	7.56e-15	Menarche (age at onset);
LGG	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06634786	chr22:41940651	POLR3H	-0.79	-12.69	-0.51	6.98e-32	Vitiligo;
LGG	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg25174290	chr11:3078921	CARS	0.72	14.45	0.56	2.59e-39	Longevity;
LGG	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	7.5	0.33	3.32e-13	Bone mineral density;
LGG	trans	rs9784649	1.000	rs7702197	chr5:24975778	A/G	cg11038491	chr20:34638489	LOC647979	0.55	7.21	0.32	2.33e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg00531865	chr16:30841666	NA	-0.55	-10.29	-0.43	1.68e-22	Multiple myeloma;
LGG	cis	rs12711979	0.765	rs10208316	chr2:3827630	T/C	cg17052675	chr2:3827356	NA	-0.34	-6.64	-0.3	8.58e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.4e-21	Lymphocyte counts;
LGG	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg24006582	chr15:45444508	DUOX1	0.66	12.26	0.49	4.17e-30	Uric acid levels;
LGG	cis	rs73198271	0.740	rs10092600	chr8:8649023	A/G	cg01851573	chr8:8652454	MFHAS1	0.37	6.65	0.3	8.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg16141378	chr3:129829833	LOC729375	-0.41	-9.32	-0.4	4.61e-19	Mood instability;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg14092988	chr3:52407081	DNAH1	0.32	8.38	0.36	6.33e-16	Bipolar disorder;
LGG	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.36	0.36	7.5e-16	Dupuytren's disease;
LGG	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg00631329	chr6:26305371	NA	-0.54	-9.53	-0.4	8.9e-20	Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17829318	chr4:37688612	RELL1	0.42	6.66	0.3	7.78e-11	Gut microbiome composition (summer);
LGG	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.78	-0.3	3.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg18851795	chr1:204543875	NA	0.37	6.95	0.31	1.27e-11	Schizophrenia;
LGG	cis	rs12928939	0.862	rs7197104	chr16:71794061	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-10.49	-0.44	2.99e-23	Post bronchodilator FEV1;
LGG	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg09197432	chr4:183729176	NA	0.61	8.94	0.38	9.51e-18	Pediatric autoimmune diseases;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.36	6.72	0.3	5.36e-11	Longevity;
LGG	trans	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs2742417	1.000	rs2742431	chr3:45737121	C/G	cg04837898	chr3:45731254	SACM1L	0.37	7.32	0.32	1.09e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-10.92	-0.45	7.14e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12753569	0.934	rs10430051	chr1:76491628	T/G	cg00791851	chr1:76518896	NA	-0.42	-9.8	-0.41	9.65e-21	Personality dimensions;
LGG	cis	rs7072216	0.727	rs7913541	chr10:100172479	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.17	-0.32	3.07e-12	Metabolite levels;
LGG	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	9.61	0.41	4.75e-20	Ovarian reserve;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg04525384	chr16:1557733	TELO2	0.48	8.51	0.37	2.44e-16	Coronary artery disease;
LGG	cis	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.72	-13.12	-0.52	1.15e-33	Primary sclerosing cholangitis;
LGG	cis	rs1909881	0.935	rs2202057	chr8:96516266	T/C	cg04203453	chr8:96504381	NA	-1.08	-18.36	-0.65	5.69e-57	Obesity-related traits;
LGG	cis	rs703842	1.000	rs11172344	chr12:58193448	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg07460842	chr6:66804631	NA	-0.97	-18.17	-0.65	4.14e-56	Exhaled nitric oxide output;
LGG	cis	rs490234	0.902	rs10739663	chr9:128278739	A/G	cg14078157	chr9:128172775	NA	-0.4	-7.56	-0.33	2.22e-13	Mean arterial pressure;
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg11757124	chr7:157526947	PTPRN2	-0.51	-9.3	-0.4	5.77e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6694672	0.571	rs4915338	chr1:197093832	T/C	cg13682187	chr1:196946512	CFHR5	0.5	7.12	0.31	4.16e-12	Asthma;
LGG	cis	rs4870684	1.000	rs4870684	chr7:57699151	C/T	cg01314568	chr7:57830625	NA	-0.58	-9.79	-0.41	1.08e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs4722166	0.541	rs1800795	chr7:22766645	C/G	cg05265849	chr7:22767390	IL6	0.44	8.29	0.36	1.24e-15	Lung cancer;
LGG	cis	rs867371	0.519	rs1566560	chr15:82524457	C/T	cg00614314	chr15:82944287	LOC80154	0.47	7.81	0.34	3.96e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs10870270	1.000	rs10781564	chr10:133757922	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.62	-0.51	1.42e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1185460	1.000	rs1614264	chr11:118942638	A/C	cg23280166	chr11:118938394	VPS11	0.6	10.98	0.45	4.44e-25	Coronary artery disease;
LGG	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11890956	chr21:40555474	PSMG1	1.18	29.49	0.81	2.44e-108	Cognitive function;
LGG	cis	rs2976388	0.590	rs3736011	chr8:143817789	G/A	cg06565975	chr8:143823917	SLURP1	-0.53	-13.62	-0.53	8.92e-36	Urinary tract infection frequency;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00090767	chr14:65569376	MAX	-0.42	-7.02	-0.31	8.09e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs372883	0.564	rs766928	chr21:30753606	A/G	cg24692254	chr21:30365293	RNF160	0.61	10.62	0.44	1.04e-23	Pancreatic cancer;
LGG	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	11.85	0.48	1.75e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs988958	0.958	rs34482969	chr2:42280300	G/A	cg19376973	chr2:42229025	NA	0.48	8.05	0.35	6.96e-15	Hypospadias;
LGG	cis	rs17453880	0.890	rs4958319	chr5:151961998	T/A	cg12297329	chr5:152029980	NA	-0.86	-21.98	-0.71	7.27e-74	Subjective well-being;
LGG	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg27490568	chr2:178487706	NA	-0.68	-12.1	-0.49	1.75e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2074977	0.500	rs10153493	chr19:3447745	C/T	cg08380311	chr19:3435252	NFIC	-0.6	-10.83	-0.45	1.66e-24	Height;
LGG	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-16.44	-0.61	3.47e-48	Asthma;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg15971980	chr6:150254442	NA	0.43	8.02	0.35	8.5e-15	Lung cancer;
LGG	cis	rs9633740	0.947	rs1878036	chr10:82280137	T/G	cg01528321	chr10:82214614	TSPAN14	1.05	15.94	0.6	6.46e-46	Post bronchodilator FEV1;
LGG	cis	rs72792276	1.000	rs72794361	chr5:127435188	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.75	0.3	4.57e-11	Red cell distribution width;
LGG	cis	rs8017423	1.000	rs2183189	chr14:90670057	A/G	cg04374321	chr14:90722782	PSMC1	0.86	18.29	0.65	1.26e-56	Mortality in heart failure;
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.89	0.31	1.81e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs708547	0.914	rs58228066	chr4:57735787	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-8.21	-0.36	2.25e-15	Response to bleomycin (chromatid breaks);
LGG	cis	rs2797369	0.574	rs2764275	chr6:101671211	G/C	cg27451362	chr6:101846650	GRIK2	-0.47	-7.18	-0.32	2.71e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg11062466	chr8:58055876	NA	0.48	7.9	0.34	2.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs600550	0.588	rs2304935	chr11:60102384	C/T	cg05040360	chr11:60102449	MS4A6E	0.36	7.76	0.34	5.5e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	trans	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19894588	chr14:64061835	NA	0.64	10.63	0.44	9.57e-24	Glioblastoma;Glioma;
LGG	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-8.63	-0.37	9.93e-17	Height;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg13699009	chr12:122356056	WDR66	0.56	15.05	0.57	5.72e-42	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.85	0.38	1.81e-17	Lung cancer;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg19455335	chr8:22457658	C8orf58	0.44	8.82	0.38	2.31e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg16584676	chr17:46985605	UBE2Z	0.47	8.12	0.35	4.24e-15	Type 2 diabetes;
LGG	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.66	10.19	0.43	4.02e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.35	0.36	7.7e-16	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19379625	chr4:71859087	DCK	0.46	7.03	0.31	7.3e-12	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.79e-21	Aortic root size;
LGG	cis	rs3741151	0.656	rs12290785	chr11:73259012	G/T	cg17517138	chr11:73019481	ARHGEF17	0.81	7.79	0.34	4.54e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2820315	1.000	rs2459761	chr1:201808469	C/G	cg10061532	chr1:201886748	LMOD1	0.33	6.82	0.3	2.79e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-9.01	-0.39	5.35e-18	Menopause (age at onset);
LGG	cis	rs2455799	0.573	rs2654650	chr3:15779214	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs889398	0.802	rs8050414	chr16:69886813	T/A	cg00738113	chr16:70207722	CLEC18C	-0.25	-6.92	-0.31	1.49e-11	Body mass index;
LGG	cis	rs7267979	1.000	rs6050632	chr20:25432601	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg25947184	chr8:1697459	NA	0.47	8.28	0.36	1.3e-15	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08677398	chr8:58056175	NA	0.51	7.89	0.34	2.17e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs754466	0.580	rs10824573	chr10:79540969	T/C	cg17075019	chr10:79541650	NA	-0.98	-21.71	-0.71	1.37e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg10760299	chr15:45669010	GATM	0.41	8.07	0.35	6.23e-15	Homoarginine levels;
LGG	cis	rs926938	0.584	rs360606	chr1:115391769	C/T	cg12756093	chr1:115239321	AMPD1	0.47	9.14	0.39	1.93e-18	Autism;
LGG	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg00170343	chr3:11313890	ATG7	0.53	6.65	0.3	8.11e-11	Circulating chemerin levels;
LGG	cis	rs1863824	0.625	rs10887598	chr10:88166160	T/A	cg07322936	chr10:88137208	NA	-0.52	-8.61	-0.37	1.19e-16	Schizophrenia;
LGG	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs2236918	1.000	rs851782	chr1:242033783	A/G	cg17736920	chr1:242011382	EXO1	0.48	8.46	0.37	3.56e-16	Menopause (age at onset);
LGG	cis	rs9303280	0.901	rs12103884	chr17:38045725	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-9.17	-0.39	1.5e-18	Self-reported allergy;
LGG	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.89	-9.18	-0.39	1.39e-18	Diabetic retinopathy;
LGG	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg03733263	chr8:22462867	KIAA1967	1.05	27.45	0.79	3.45e-99	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14829155	chr15:31115871	NA	-0.57	-9.28	-0.4	6.79e-19	Huntington's disease progression;
LGG	trans	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.25	-0.39	8.61e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg18851795	chr1:204543875	NA	-0.35	-6.69	-0.3	6.27e-11	Schizophrenia;
LGG	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-8.88	-0.38	1.48e-17	Electroencephalogram traits;
LGG	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg13009111	chr11:71350975	NA	0.36	7.87	0.34	2.45e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs722599	0.683	rs7145246	chr14:75242394	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.54	-8.8	-0.38	2.82e-17	IgG glycosylation;
LGG	cis	rs9427116	0.502	rs9427104	chr1:154589232	C/T	cg11650704	chr1:154556575	ADAR	-0.48	-9.44	-0.4	1.77e-19	Blood protein levels;
LGG	cis	rs6993813	0.590	rs10955919	chr8:120020918	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.74	0.34	6.39e-14	Bone mineral density (hip);
LGG	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg22875332	chr1:76189707	ACADM	0.6	9.42	0.4	2.09e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg15971980	chr6:150254442	NA	0.42	8.06	0.35	6.34e-15	Lung cancer;
LGG	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.72	-0.45	4.17e-24	Bipolar disorder;
LGG	cis	rs4812048	1.000	rs55905547	chr20:57589995	A/G	cg23907860	chr20:57583709	CTSZ	0.46	6.82	0.3	2.84e-11	Mean platelet volume;
LGG	cis	rs17208368	0.628	rs2129367	chr16:55098707	A/C	cg09947736	chr16:55091198	NA	0.67	12.85	0.51	1.55e-32	Hypospadias;
LGG	trans	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19894588	chr14:64061835	NA	-0.57	-8.96	-0.38	7.72e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg15268244	chr15:77196840	NA	-0.48	-10.06	-0.42	1.12e-21	Blood metabolite levels;
LGG	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg16885296	chr6:26284938	NA	0.35	7.2	0.32	2.43e-12	Educational attainment;
LGG	cis	rs17253792	0.732	rs8017891	chr14:56172967	A/G	cg01858014	chr14:56050164	KTN1	0.86	12.34	0.5	1.87e-30	Putamen volume;
LGG	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.25	0.4	7.98e-19	Blood metabolite levels;
LGG	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg07245641	chr1:182991651	LAMC1	-0.39	-8.79	-0.38	2.85e-17	Colorectal cancer;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.37	-0.53	1.05e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.77	-0.69	3.44e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1519814	0.696	rs7822000	chr8:121034112	C/G	cg22335954	chr8:121166405	COL14A1	-0.5	-8.99	-0.39	6.17e-18	Breast cancer;
LGG	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.48	-0.44	3.46e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8014204	0.804	rs7154845	chr14:75247746	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.96	-0.31	1.15e-11	Caffeine consumption;
LGG	cis	rs3820068	0.677	rs72643691	chr1:15856251	T/C	cg05660106	chr1:15850417	CASP9	1.11	27.19	0.78	5.18e-98	Systolic blood pressure;
LGG	cis	rs8064024	0.625	rs960006	chr16:4911195	T/C	cg08329684	chr16:4932620	PPL	0.53	11.99	0.49	5.14e-29	Cancer;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg22329336	chr7:1950478	MAD1L1	0.38	6.67	0.3	7.28e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg23131131	chr22:24373011	LOC391322	-0.48	-7.74	-0.34	6.23e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11997175	0.819	rs6415400	chr8:33783714	C/T	ch.8.33884649F	chr8:33765107	NA	0.42	8.12	0.35	4.22e-15	Body mass index;
LGG	trans	rs637571	0.676	rs634534	chr11:65665256	A/G	cg17712092	chr4:129076599	LARP1B	-0.85	-17.69	-0.64	6.92e-54	Eosinophil percentage of white cells;
LGG	cis	rs6594713	0.643	rs59195845	chr5:112738011	C/T	cg12552261	chr5:112820674	MCC	0.49	6.97	0.31	1.12e-11	Brain cytoarchitecture;
LGG	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.68	0.34	9.34e-14	Homoarginine levels;
LGG	cis	rs4906332	1.000	rs17617832	chr14:103943140	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.87	-0.34	2.46e-14	Coronary artery disease;
LGG	cis	rs16854884	0.837	rs4380409	chr3:143800896	A/G	cg06585982	chr3:143692056	C3orf58	0.55	9.04	0.39	4.25e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs7193541	0.646	rs7188880	chr16:74664810	A/T	cg01733217	chr16:74700730	RFWD3	1.09	34.02	0.85	4.96e-128	Multiple myeloma;
LGG	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg23173402	chr1:227635558	NA	0.47	8.1	0.35	5.06e-15	Major depressive disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13616963	chr3:57583610	ARF4	-0.51	-7.39	-0.32	6.97e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.43e-30	Lung cancer;
LGG	cis	rs11608355	0.521	rs7972346	chr12:109808771	C/G	cg19025524	chr12:109796872	NA	0.56	12.09	0.49	2.02e-29	Neuroticism;
LGG	cis	rs9814567	0.752	rs4955544	chr3:134332776	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.65	-0.44	7.47e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01495174	chr2:8825373	NA	0.47	6.98	0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg16482183	chr6:26056742	HIST1H1C	0.43	7.34	0.32	9.48e-13	Height;
LGG	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg12473912	chr3:136751656	NA	0.44	7.67	0.34	1.01e-13	Neuroticism;
LGG	cis	rs6062302	0.522	rs6090475	chr20:62245397	C/A	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	cis	rs12912251	0.895	rs35795311	chr15:38998669	C/G	cg01338139	chr15:38987640	C15orf53	-0.58	-8.72	-0.38	5.17e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs7572644	0.640	rs13027427	chr2:28021043	G/T	cg27432699	chr2:27873401	GPN1	0.47	6.86	0.3	2.21e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs13257813	0.727	rs691605	chr8:19028649	A/G	cg15587955	chr8:19026658	NA	0.44	6.66	0.3	7.82e-11	Mean platelet volume;
LGG	cis	rs11225247	0.881	rs11605573	chr11:102259959	G/T	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg05896524	chr21:47604654	C21orf56	0.64	11.73	0.48	5.14e-28	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4664304	0.770	rs55860731	chr2:160875437	C/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.57	-0.37	1.57e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11583043	1.000	rs17123612	chr1:101476814	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	7.88	0.34	2.34e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11874712	0.563	rs2850646	chr18:43674646	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.21	-0.39	1.13e-18	Migraine - clinic-based;
LGG	cis	rs654950	0.806	rs10749832	chr1:42041806	C/T	cg16096631	chr1:42092165	HIVEP3	0.42	9.27	0.4	6.9e-19	Airway imaging phenotypes;
LGG	trans	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Bladder cancer;
LGG	cis	rs1010254	0.510	rs17543421	chr5:151701350	T/C	cg12297329	chr5:152029980	NA	-0.47	-6.81	-0.3	3.11e-11	Optic nerve measurement (cup area);
LGG	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.08e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2013441	1.000	rs2263175	chr17:20128029	C/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.24e-19	Obesity-related traits;
LGG	cis	rs240764	0.604	rs9377234	chr6:101263035	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.73	0.34	6.59e-14	Neuroticism;
LGG	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg24596788	chr1:163392923	NA	-0.62	-11.71	-0.48	6.26e-28	Motion sickness;
LGG	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg03030879	chr14:75389066	RPS6KL1	0.37	6.66	0.3	7.64e-11	Caffeine consumption;
LGG	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs77106637	0.929	rs74333814	chr11:72457487	C/T	cg03713592	chr11:72463424	ARAP1	0.44	7.56	0.33	2.17e-13	Type 2 diabetes;
LGG	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg18876405	chr7:65276391	NA	0.6	10.99	0.45	4.02e-25	Aortic root size;
LGG	trans	rs2562456	0.833	rs516519	chr19:21481532	C/G	cg00806126	chr19:22604979	ZNF98	0.55	7.75	0.34	6.03e-14	Pain;
LGG	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.52	-0.47	3.42e-27	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.5	-0.4	1.16e-19	Triglycerides;
LGG	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-7.35	-0.32	8.88e-13	Electroencephalogram traits;
LGG	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg27121462	chr16:89883253	FANCA	0.61	11.22	0.46	5.27e-26	Vitiligo;
LGG	cis	rs9487051	0.676	rs1608044	chr6:109594076	T/C	cg21918786	chr6:109611834	NA	-0.44	-8.1	-0.35	4.86e-15	Reticulocyte fraction of red cells;
LGG	cis	rs9549260	0.755	rs9532577	chr13:41231542	A/G	cg21288729	chr13:41239152	FOXO1	0.33	6.65	0.3	8.04e-11	Red blood cell count;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05665937	chr4:1216051	CTBP1	0.39	6.77	0.3	4.01e-11	Obesity-related traits;
LGG	cis	rs60871478	0.735	rs62432241	chr7:795360	G/A	cg13798912	chr7:905769	UNC84A	0.61	6.82	0.3	2.78e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1620921	0.774	rs783153	chr6:161229578	G/T	cg01280913	chr6:161186852	NA	0.33	6.91	0.31	1.56e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4639966	0.836	rs11217016	chr11:118627149	A/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.94	-0.31	1.32e-11	Systemic lupus erythematosus;
LGG	cis	rs4595586	0.679	rs1156706	chr12:39372641	G/A	cg26384229	chr12:38710491	ALG10B	0.47	8.48	0.37	3.02e-16	Morning vs. evening chronotype;
LGG	cis	rs6838801	0.823	rs28583649	chr4:77591712	T/A	cg17476223	chr4:77663285	SHROOM3	0.37	6.7	0.3	6.09e-11	Cleft lip with or without cleft palate;
LGG	cis	rs11585357	0.843	rs113593167	chr1:17613355	G/A	cg08277548	chr1:17600880	PADI3	-0.76	-8.54	-0.37	1.99e-16	Hair shape;
LGG	cis	rs41271951	0.512	rs116666233	chr1:151056058	C/T	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.02	-0.31	7.83e-12	Blood protein levels;
LGG	cis	rs7188861	0.768	rs12925649	chr16:11390445	T/C	cg01510278	chr16:11456238	NA	0.31	7.4	0.33	6.31e-13	HDL cholesterol;
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg12458913	chr13:53173898	NA	0.45	7.6	0.33	1.71e-13	Lewy body disease;
LGG	cis	rs2742417	1.000	rs9829631	chr3:45740558	T/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4243830	0.737	rs11581831	chr1:6609958	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-12.26	-0.5	4.05e-30	Body mass index;
LGG	cis	rs6500637	0.570	rs1049205	chr16:4942099	C/T	cg08329684	chr16:4932620	PPL	-0.57	-12.89	-0.51	1.03e-32	Cancer;
LGG	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.36	0.81	9.16e-108	Chronic sinus infection;
LGG	cis	rs4919044	0.599	rs11187206	chr10:94659515	C/G	cg05127821	chr10:94822908	CYP26C1	-0.4	-7.12	-0.31	4.26e-12	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs12431410	0.892	rs7149112	chr14:60155307	C/A	cg07950296	chr14:60194823	RTN1	0.38	7.11	0.31	4.28e-12	Schizophrenia;
LGG	cis	rs67385638	0.962	rs2187608	chr11:5269931	G/C	cg12559170	chr11:5275217	HBG2	0.57	13.25	0.52	3.22e-34	Hemoglobin levels;
LGG	cis	rs75920871	0.748	rs61905689	chr11:116869217	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-7.97	-0.35	1.22e-14	Subjective well-being;
LGG	cis	rs7851660	0.844	rs907581	chr9:100622189	A/G	cg13688889	chr9:100608707	NA	-0.63	-12.56	-0.5	2.39e-31	Strep throat;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20620272	chr3:167968129	C3orf50	0.47	8.27	0.36	1.48e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.28	-0.43	1.76e-22	Diabetic kidney disease;
LGG	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg06115741	chr20:33292138	TP53INP2	0.59	9.77	0.41	1.29e-20	Coronary artery disease;
LGG	trans	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg06606381	chr12:133084897	FBRSL1	-0.54	-7.02	-0.31	7.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg16576597	chr16:28551801	NUPR1	0.36	8.42	0.36	4.7e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22409223	chr3:130465572	PIK3R4	0.49	7.42	0.33	5.53e-13	Gut microbiome composition (summer);
LGG	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg16141378	chr3:129829833	LOC729375	0.37	7.93	0.35	1.7e-14	Neuroticism;
LGG	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.1e-16	Resting heart rate;
LGG	cis	rs72781680	1.000	rs72798411	chr2:24184343	A/G	cg08917208	chr2:24149416	ATAD2B	0.92	10.12	0.43	6.8e-22	Lymphocyte counts;
LGG	cis	rs4740619	0.755	rs9298741	chr9:15837531	A/G	cg14451791	chr9:16040625	NA	0.33	8.13	0.35	3.83e-15	Body mass index;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs73416724	1.000	rs70953686	chr6:43269516	G/A	cg26312998	chr6:43337775	ZNF318	0.59	7.99	0.35	1.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	11.69	0.48	7.49e-28	Breast cancer;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	trans	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.56	-0.37	1.69e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg05925327	chr15:68127851	NA	-0.4	-8.22	-0.36	2.1e-15	Restless legs syndrome;
LGG	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.67	-0.41	2.95e-20	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg07541023	chr7:19748670	TWISTNB	0.61	8.34	0.36	8.38e-16	Thyroid stimulating hormone;
LGG	cis	rs1580019	0.844	rs1901202	chr7:32503724	A/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.77	0.59	3.88e-45	Cognitive ability;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18621852	chr3:10150065	C3orf24	0.42	6.66	0.3	7.99e-11	Alzheimer's disease;
LGG	cis	rs9790314	0.663	rs55888276	chr3:160651406	A/G	cg04691961	chr3:161091175	C3orf57	0.43	9.2	0.39	1.27e-18	Morning vs. evening chronotype;
LGG	cis	rs9486719	0.895	rs4486019	chr6:96883814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg08344181	chr3:125677491	NA	-0.91	-9.01	-0.39	5.44e-18	Urinary tract infection frequency;
LGG	cis	rs9811920	0.514	rs1287283	chr3:99515750	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-7.56	-0.33	2.2e-13	Axial length;
LGG	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	10.72	0.45	4.25e-24	Blood metabolite levels;
LGG	cis	rs4356975	0.563	rs4337789	chr4:69973044	A/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-15.03	-0.57	6.88e-42	Morning vs. evening chronotype;
LGG	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg15704280	chr7:45808275	SEPT13	-0.66	-9.24	-0.39	8.63e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06634786	chr22:41940651	POLR3H	0.71	11.76	0.48	4.09e-28	Vitiligo;
LGG	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg04935436	chr20:30431758	NA	-0.41	-7.21	-0.32	2.24e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg11901034	chr3:128598214	ACAD9	-0.45	-6.83	-0.3	2.64e-11	IgG glycosylation;
LGG	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg06718696	chr17:78121285	EIF4A3	0.89	14.4	0.56	4.24e-39	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	cis	rs9972944	0.702	rs987930	chr17:63765862	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs36093844	0.706	rs7931771	chr11:85549888	C/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	9.2	0.39	1.21e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7927771	0.524	rs7129797	chr11:47667167	G/C	cg20307385	chr11:47447363	PSMC3	0.57	11.0	0.46	3.6e-25	Subjective well-being;
LGG	cis	rs1707322	1.000	rs6682683	chr1:46342337	A/G	cg03146154	chr1:46216737	IPP	0.54	10.44	0.44	4.85e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3099143	0.901	rs76036665	chr15:77232720	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-9.39	-0.4	2.67e-19	Recalcitrant atopic dermatitis;
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.86	-0.3	2.28e-11	Height;
LGG	cis	rs7091068	0.671	rs620890	chr10:95405424	G/A	cg20715218	chr10:95462985	C10orf4	-0.6	-9.49	-0.4	1.24e-19	Urinary tract infection frequency;
LGG	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg15128208	chr22:42549153	NA	-0.37	-7.23	-0.32	2e-12	Cognitive function;
LGG	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.7	-0.45	5.23e-24	Alzheimer's disease;
LGG	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg10621924	chr7:39171070	POU6F2	0.45	9.12	0.39	2.29e-18	IgG glycosylation;
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs796364	0.806	rs78037592	chr2:201105734	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-8.59	-0.37	1.37e-16	Schizophrenia;
LGG	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.92	-0.31	1.52e-11	Neuroticism;
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	8.27	0.36	1.45e-15	Personality dimensions;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.71	0.45	4.49e-24	Morning vs. evening chronotype;
LGG	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg26597838	chr10:835615	NA	0.94	12.7	0.51	6.2e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg00277334	chr10:82204260	NA	-0.54	-13.47	-0.53	3.83e-35	Post bronchodilator FEV1;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg18402987	chr7:1209562	NA	0.4	6.76	0.3	4.09e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15596359	chr8:11213517	TDH	0.43	8.88	0.38	1.47e-17	Retinal vascular caliber;
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.77	0.34	5.1e-14	Monocyte count;
LGG	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.65	-0.3	8.38e-11	Blood metabolite levels;
LGG	cis	rs7660883	0.866	rs342468	chr4:88051908	G/A	cg21988461	chr4:88008667	AFF1	0.35	10.0	0.42	1.89e-21	HDL cholesterol levels;
LGG	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg20637307	chr2:213403960	ERBB4	-0.47	-9.2	-0.39	1.2e-18	Symmetrical dimethylarginine levels;
LGG	cis	rs6772849	0.930	rs4467479	chr3:128369055	C/G	cg08795948	chr3:128337044	NA	0.67	11.4	0.47	1.03e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg04986931	chr22:39850128	NA	0.4	8.7	0.37	5.75e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg02158880	chr13:53174818	NA	0.4	7.95	0.35	1.44e-14	Lewy body disease;
LGG	cis	rs58785573	0.504	rs13151185	chr4:38609196	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.44	7.09	0.31	5.21e-12	Lymphocyte percentage of white cells;
LGG	cis	rs9810089	0.814	rs834305	chr3:136119354	C/T	cg21827317	chr3:136751795	NA	0.46	8.04	0.35	7.65e-15	Gestational age at birth (child effect);
LGG	cis	rs4732038	0.691	rs28729518	chr7:134246511	A/G	cg06906464	chr7:134288099	NA	-0.51	-12.73	-0.51	4.65e-32	Longevity;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.94	-0.54	4.09e-37	Alzheimer's disease;
LGG	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg24881330	chr22:46731750	TRMU	0.71	6.73	0.3	5.15e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg16586182	chr3:47516702	SCAP	-0.44	-7.12	-0.31	4.06e-12	Birth weight;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06850241	chr22:41845214	NA	0.46	7.17	0.32	2.93e-12	Vitiligo;
LGG	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.25	-0.39	8.62e-19	Body mass index;
LGG	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg00042356	chr1:8021962	PARK7	0.61	7.12	0.31	4.11e-12	Inflammatory bowel disease;
LGG	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg09904177	chr6:26538194	HMGN4	0.67	13.8	0.54	1.56e-36	Intelligence (multi-trait analysis);
LGG	cis	rs36071027	0.615	rs17643640	chr5:158407296	C/G	cg23468002	chr5:158532401	NA	0.42	7.16	0.32	3.12e-12	Carotid intima media thickness;
LGG	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.32	0.43	1.3e-22	Arsenic metabolism;
LGG	cis	rs6066825	0.644	rs6095248	chr20:47320932	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.07	0.35	5.98e-15	Colorectal cancer;
LGG	cis	rs77633900	0.772	rs4886492	chr15:76672817	T/A	cg21673338	chr15:77095150	SCAPER	0.59	7.98	0.35	1.15e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg00686598	chr14:53173677	PSMC6	-1.29	-13.9	-0.54	5.71e-37	Alzheimer's disease (late onset);
LGG	cis	rs6743376	0.556	rs3180235	chr2:113820672	C/T	cg05949173	chr2:113825882	IL1F10	-0.5	-9.59	-0.41	5.4e-20	Inflammatory biomarkers;
LGG	cis	rs10489202	0.608	rs16828093	chr1:168078384	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.15	-0.43	5.32e-22	Schizophrenia;
LGG	cis	rs737693	0.915	rs28381684	chr11:102737192	A/T	cg14995062	chr11:102826570	MMP13	0.5	6.79	0.3	3.46e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg26309111	chr7:23720005	C7orf46	0.39	8.12	0.35	4.16e-15	Schizophrenia;
LGG	cis	rs2905347	0.757	rs2905318	chr7:22696653	A/C	cg18045685	chr7:22629474	NA	0.66	13.69	0.54	4.52e-36	Major depression and alcohol dependence;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01814186	chr16:69600788	NFAT5;MIR1538	0.47	7.06	0.31	6.23e-12	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.5	0.37	2.68e-16	Retinal vascular caliber;
LGG	cis	rs6835098	0.924	rs13125240	chr4:174151619	T/C	cg08422745	chr4:174089978	GALNT7	0.81	13.58	0.53	1.31e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs4804815	0.780	rs2081100	chr19:7840273	T/C	cg00970558	chr19:7854469	CLEC4GP1	0.64	9.69	0.41	2.53e-20	Neutrophil count;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg16507663	chr6:150244633	RAET1G	0.48	8.37	0.36	7.03e-16	Lung cancer;
LGG	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs6504108	0.624	rs4794517	chr17:46291853	C/G	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.62e-15	Body mass index;
LGG	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.88	0.38	1.51e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs35740288	0.929	rs11073537	chr15:86312681	G/A	cg04173714	chr15:86211321	AKAP13	0.42	7.24	0.32	1.89e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4430311	0.723	rs2085555	chr1:243744321	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.53	-0.59	4.44e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg27624424	chr6:160112604	SOD2	0.7	10.31	0.43	1.45e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs941873	0.803	rs2105461	chr10:81101679	A/G	cg09469691	chr10:81107165	PPIF	-0.58	-10.26	-0.43	2.14e-22	Height;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg23302884	chr18:44338147	ST8SIA5	0.45	9.03	0.39	4.82e-18	Personality dimensions;
LGG	cis	rs12049351	0.719	rs10799537	chr1:229664544	C/G	cg13547644	chr1:229569608	ACTA1	0.28	6.65	0.3	8.39e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs17767392	0.881	rs757850	chr14:72016006	C/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.5	0.37	2.67e-16	Mitral valve prolapse;
LGG	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg10503236	chr1:231470652	EXOC8	-0.36	-7.05	-0.31	6.46e-12	Hemoglobin concentration;
LGG	cis	rs2235649	0.798	rs9922462	chr16:1848011	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-7.13	-0.31	3.86e-12	Blood metabolite levels;
LGG	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.64	0.33	1.28e-13	Homoarginine levels;
LGG	cis	rs3806843	0.548	rs246052	chr5:140326413	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg01528321	chr10:82214614	TSPAN14	0.68	11.98	0.49	5.37e-29	Post bronchodilator FEV1;
LGG	cis	rs4774899	1.000	rs11631228	chr15:57256390	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-7.98	-0.35	1.12e-14	Urinary tract infection frequency;
LGG	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg03188948	chr7:1209495	NA	0.4	6.98	0.31	1e-11	Longevity;Endometriosis;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg12395012	chr8:11607386	GATA4	-0.36	-6.74	-0.3	4.65e-11	Mood instability;
LGG	cis	rs11166927	0.870	rs11166930	chr8:140824621	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.5	-10.54	-0.44	2.06e-23	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs9354308	0.764	rs12661106	chr6:66594110	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.8	-0.3	3.24e-11	Metabolite levels;
LGG	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-9.35	-0.4	3.66e-19	Erythrocyte sedimentation rate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02542118	chr2:61245510	PEX13;PUS10	0.45	7.53	0.33	2.6e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg00092383	chr7:157075207	NA	-0.38	-6.72	-0.3	5.45e-11	Body mass index;
LGG	cis	rs258892	0.947	rs4443401	chr5:72213483	G/A	cg21869765	chr5:72125136	TNPO1	0.43	6.73	0.3	5.18e-11	Small cell lung carcinoma;
LGG	cis	rs6694672	0.867	rs568757	chr1:197218051	G/A	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15084286	chr11:17036142	PLEKHA7	0.63	11.89	0.48	1.23e-28	Coronary artery disease;
LGG	cis	rs9398803	0.661	rs1262543	chr6:127032499	G/A	cg19875578	chr6:126661172	C6orf173	-0.52	-9.64	-0.41	3.57e-20	Male-pattern baldness;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg02127607	chr17:61920694	SMARCD2	0.46	8.23	0.36	1.92e-15	Prudent dietary pattern;
LGG	cis	rs7166081	0.950	rs12476	chr15:67493726	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.81	-0.3	3.11e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9816226	0.793	rs869400	chr3:185826740	T/G	cg00760338	chr3:185826511	ETV5	0.87	12.39	0.5	1.19e-30	Obesity;Body mass index;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.17	0.52	6.92e-34	Lung cancer;
LGG	cis	rs7215564	0.908	rs34333328	chr17:78683420	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg05926928	chr17:57297772	GDPD1	0.95	15.06	0.57	5.31e-42	Opioid sensitivity;
LGG	cis	rs4891159	0.548	rs654754	chr18:74143695	T/C	cg24786174	chr18:74118243	ZNF516	0.67	16.55	0.61	1.1e-48	Longevity;
LGG	cis	rs9914988	0.832	rs9903248	chr17:27127439	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	6.83e-37	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00166722	chr3:10149974	C3orf24	0.53	9.01	0.39	5.58e-18	Alzheimer's disease;
LGG	cis	rs4629180	0.538	rs6746761	chr2:102122390	G/T	cg16435561	chr2:102091048	RFX8	0.48	8.77	0.38	3.33e-17	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12081917	chr17:39804985	NA	0.5	7.41	0.33	5.91e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg14092988	chr3:52407081	DNAH1	0.3	7.98	0.35	1.15e-14	Bipolar disorder;
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg26354017	chr1:205819088	PM20D1	0.49	7.97	0.35	1.22e-14	Parkinson's disease;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.91	0.34	1.92e-14	Renal function-related traits (BUN);
LGG	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg20476274	chr7:133979776	SLC35B4	-0.7	-13.3	-0.53	2e-34	Mean platelet volume;
LGG	cis	rs8060686	0.641	rs7204192	chr16:68039309	A/G	cg27539214	chr16:67997921	SLC12A4	-0.42	-6.93	-0.31	1.41e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03456512	chr7:107531689	DLD	0.43	6.8	0.3	3.31e-11	Cognitive performance;
LGG	cis	rs6867032	1.000	rs4398675	chr5:2015816	G/A	cg26168224	chr5:2018326	NA	1.29	31.3	0.82	2.45e-116	Gut microbiome composition (winter);
LGG	cis	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.12	-0.31	4.16e-12	Neuroticism;
LGG	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.46	0.5	6.11e-31	Motion sickness;
LGG	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-8.03	-0.35	7.89e-15	Vitiligo;
LGG	cis	rs12230513	0.793	rs7138601	chr12:55895730	A/T	cg19537932	chr12:55886519	OR6C68	0.39	6.96	0.31	1.18e-11	Contrast sensitivity;
LGG	cis	rs490234	0.841	rs513568	chr9:128411854	G/A	cg14078157	chr9:128172775	NA	-0.42	-7.81	-0.34	3.96e-14	Mean arterial pressure;
LGG	cis	rs7172677	1.000	rs7177528	chr15:75409594	T/C	cg14664628	chr15:75095509	CSK	-0.48	-7.22	-0.32	2.09e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg27478167	chr7:817139	HEATR2	-0.46	-7.24	-0.32	1.86e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg03114573	chr12:45410052	DBX2	-0.54	-9.53	-0.4	9.19e-20	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg04267008	chr7:1944627	MAD1L1	-0.71	-12.42	-0.5	9.17e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg21782813	chr7:2030301	MAD1L1	0.37	8.73	0.38	4.67e-17	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg19723775	chr5:179050963	HNRNPH1	0.62	10.05	0.42	1.21e-21	Lung cancer;
LGG	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg18876405	chr7:65276391	NA	-0.63	-11.79	-0.48	3.21e-28	Aortic root size;
LGG	cis	rs1971762	0.527	rs6580952	chr12:53937452	C/T	cg06632207	chr12:54070931	ATP5G2	0.21	6.71	0.3	5.7e-11	Height;
LGG	trans	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.32	0.5	2.28e-30	Corneal astigmatism;
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.03	-0.35	7.94e-15	Neuroticism;
LGG	trans	rs931812	0.825	rs6993937	chr8:101898707	A/G	cg20993868	chr7:22813445	NA	0.7	13.23	0.52	4.17e-34	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs806215	0.526	rs114283033	chr7:127530017	G/A	cg25922125	chr7:127225783	GCC1	-0.48	-6.98	-0.31	1.04e-11	Type 2 diabetes;
LGG	cis	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11292385	chr22:29138453	CHEK2;HSCB	0.41	6.65	0.3	8.31e-11	Cognitive performance;
LGG	cis	rs4262150	0.883	rs4394168	chr5:152264172	T/C	cg12297329	chr5:152029980	NA	-0.65	-12.31	-0.5	2.56e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02207944	chr16:89603606	SPG7	-0.29	-7.63	-0.33	1.37e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs75059851	0.756	rs56241440	chr11:133840830	A/C	cg20042908	chr11:133852938	NA	-0.77	-14.33	-0.55	8.49e-39	Schizophrenia;
LGG	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07080220	chr10:102295463	HIF1AN	0.73	12.13	0.49	1.35e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs523522	0.962	rs603574	chr12:120998443	A/G	cg27279351	chr12:120934652	DYNLL1	0.81	13.09	0.52	1.62e-33	High light scatter reticulocyte count;
LGG	cis	rs7010267	0.773	rs13277230	chr8:119922993	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.8	-0.41	1.01e-20	Total body bone mineral density (age 45-60);
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg02002194	chr4:3960332	NA	-0.43	-7.88	-0.34	2.32e-14	Neuroticism;
LGG	cis	rs4851266	0.966	rs2309838	chr2:100838455	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.67	0.69	1.01e-67	Platelet count;
LGG	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg08508325	chr11:3079039	CARS	-0.61	-13.19	-0.52	5.69e-34	Longevity;
LGG	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12591125	chr7:1885375	MAD1L1	-0.48	-7.52	-0.33	2.83e-13	Bipolar disorder;
LGG	cis	rs17401966	0.931	rs1555849	chr1:10400602	G/T	cg19773385	chr1:10388646	KIF1B	0.52	11.35	0.47	1.67e-26	Hepatocellular carcinoma;
LGG	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.26	-0.55	1.72e-38	HDL cholesterol levels;
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg02524346	chr8:600233	NA	1.35	12.66	0.51	9.44e-32	IgG glycosylation;
LGG	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg05775895	chr3:12838266	CAND2	0.64	11.06	0.46	2.18e-25	QRS complex (12-leadsum);
LGG	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.42	-0.36	4.6e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg15704280	chr7:45808275	SEPT13	-0.58	-9.85	-0.42	6.36e-21	HDL cholesterol;
LGG	cis	rs7149337	0.805	rs7146561	chr14:51608889	C/G	cg23942311	chr14:51606299	NA	0.32	7.09	0.31	5.16e-12	Cancer;
LGG	cis	rs9487094	0.744	rs13192476	chr6:109725154	G/A	cg16315928	chr6:109776240	MICAL1	0.54	8.99	0.39	6.1e-18	Height;
LGG	cis	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs721917	0.607	rs4319455	chr10:81739145	G/A	cg25562619	chr10:81652821	NA	-0.31	-6.87	-0.3	2.14e-11	Chronic obstructive pulmonary disease;
LGG	cis	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg16876255	chr19:9731953	ZNF561	0.81	7.57	0.33	2.08e-13	Pursuit maintenance gain;
LGG	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.28	-0.58	5.42e-43	Chronic sinus infection;
LGG	cis	rs4851266	1.000	rs4851264	chr2:100810188	T/C	cg21926883	chr2:100939477	LONRF2	-0.43	-7.76	-0.34	5.3e-14	Educational attainment;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg02127607	chr17:61920694	SMARCD2	-0.51	-9.01	-0.39	5.46e-18	Prudent dietary pattern;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg08621203	chr6:150244597	RAET1G	-0.48	-7.12	-0.31	4.1e-12	Lung cancer;
LGG	cis	rs3087591	1.000	rs7216033	chr17:29574642	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.67	-0.56	2.78e-40	Hip circumference;
LGG	cis	rs1034435	0.755	rs713923	chr22:48891519	C/T	cg05992904	chr22:48892994	FAM19A5	0.79	15.88	0.59	1.25e-45	Late-onset Alzheimer's disease;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg23594656	chr7:65796392	TPST1	0.4	8.77	0.38	3.44e-17	Aortic root size;
LGG	cis	rs17776563	0.853	rs72763822	chr15:89143949	C/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.28	-0.43	1.88e-22	Thyroid hormone levels;
LGG	cis	rs1707322	1.000	rs1707322	chr1:46505147	C/T	cg03146154	chr1:46216737	IPP	0.54	10.49	0.44	2.97e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg25986240	chr4:9926439	SLC2A9	0.37	7.62	0.33	1.49e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9487094	0.961	rs3807005	chr6:109791110	T/C	cg01125227	chr6:109776195	MICAL1	0.55	9.3	0.4	5.71e-19	Height;
LGG	cis	rs3816183	0.756	rs10196084	chr2:43048241	T/G	cg14631114	chr2:43023945	NA	0.46	8.36	0.36	7.55e-16	Hypospadias;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.44	-0.37	4e-16	Menopause (age at onset);
LGG	cis	rs6120849	0.518	rs11696652	chr20:33637060	T/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.67	0.3	7.23e-11	Protein C levels;
LGG	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg20503657	chr10:835505	NA	0.76	10.48	0.44	3.22e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs537626	1.000	rs537626	chr11:69307695	C/G	cg08353955	chr11:69289746	NA	0.95	14.03	0.55	1.64e-37	Breast cancer (early onset);
LGG	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12826209	chr6:26865740	GUSBL1	0.97	14.76	0.57	1.07e-40	Intelligence (multi-trait analysis);
LGG	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.39	-0.36	5.77e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg04166393	chr7:2884313	GNA12	0.44	8.34	0.36	8.3e-16	Height;
LGG	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.99	-0.62	1.18e-50	Intelligence (multi-trait analysis);
LGG	cis	rs2273669	0.667	rs7759680	chr6:109310649	C/T	cg05315195	chr6:109294784	ARMC2	-0.5	-7.15	-0.32	3.35e-12	Prostate cancer;
LGG	cis	rs62238980	0.614	rs117963082	chr22:32367505	T/G	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg11040518	chr10:102331378	NA	-0.36	-6.73	-0.3	5.12e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7216064	0.813	rs12601919	chr17:65825374	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.52	-0.37	2.19e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2072732	0.861	rs67289919	chr1:2954208	G/A	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.54	12.1	0.49	1.82e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.63	-0.37	9.95e-17	Life satisfaction;
LGG	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.12	-0.64	7.26e-56	Refractive error;
LGG	cis	rs4430311	0.723	rs12144546	chr1:243883877	T/G	cg25706552	chr1:244017396	NA	-0.64	-15.8	-0.59	2.86e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs36071027	0.615	rs57523915	chr5:158434036	G/T	cg04248271	chr5:158524404	EBF1	0.42	7.32	0.32	1.11e-12	Carotid intima media thickness;
LGG	cis	rs7727544	0.647	rs6898270	chr5:131421190	C/T	cg07395648	chr5:131743802	NA	-0.42	-9.05	-0.39	3.94e-18	Blood metabolite levels;
LGG	cis	rs2274273	0.564	rs3783649	chr14:55834410	G/A	cg04306507	chr14:55594613	LGALS3	0.51	12.11	0.49	1.67e-29	Protein biomarker;
LGG	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	8.63	0.37	1.01e-16	Retinal vascular caliber;
LGG	cis	rs1801251	1.000	rs7606090	chr2:233606740	T/C	cg08000102	chr2:233561755	GIGYF2	0.56	9.17	0.39	1.53e-18	Coronary artery disease;
LGG	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg23920097	chr1:209922102	NA	0.45	7.32	0.32	1.09e-12	Red blood cell count;
LGG	cis	rs17331151	0.573	rs4687556	chr3:52890475	T/C	cg04865290	chr3:52927548	TMEM110	0.39	7.08	0.31	5.47e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg27286337	chr10:134555280	INPP5A	0.8	12.12	0.49	1.44e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1465370	0.644	rs1558919	chr7:130029508	A/T	cg25718383	chr7:130020096	CPA1	0.34	8.68	0.37	6.76e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9487094	0.689	rs1046943	chr6:109783941	A/G	cg01125227	chr6:109776195	MICAL1	0.4	6.86	0.3	2.24e-11	Height;
LGG	cis	rs2415984	0.562	rs34386313	chr14:46908479	C/T	cg14871534	chr14:47121158	RPL10L	0.44	7.24	0.32	1.91e-12	Number of children ever born;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.92e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg12458913	chr13:53173898	NA	-0.54	-9.88	-0.42	5.03e-21	Lewy body disease;
LGG	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.14e-35	Corneal astigmatism;
LGG	cis	rs12220238	0.908	rs11000937	chr10:75998785	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.85	12.01	0.49	3.96e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg13607699	chr17:42295918	UBTF	0.89	18.62	0.65	3.7e-58	Total body bone mineral density;
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg05793240	chr7:2802953	GNA12	0.34	7.85	0.34	2.94e-14	Height;
LGG	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg04455712	chr21:45112962	RRP1B	0.49	9.08	0.39	3.15e-18	Mean corpuscular volume;
LGG	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg26924012	chr15:45694286	SPATA5L1	0.42	6.84	0.3	2.49e-11	Uric acid levels;
LGG	cis	rs4819388	0.709	rs1048710	chr21:45643008	A/G	cg01992765	chr21:45622493	NA	0.46	8.95	0.38	8.33e-18	Celiac disease;
LGG	cis	rs10504130	0.569	rs13274159	chr8:52674010	G/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg10224037	chr5:178157518	ZNF354A	0.73	11.29	0.46	2.73e-26	Neutrophil percentage of white cells;
LGG	trans	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg26384229	chr12:38710491	ALG10B	0.79	15.7	0.59	7.53e-45	Morning vs. evening chronotype;
LGG	cis	rs2172802	0.659	rs28713421	chr4:62497085	C/T	cg04118610	chr4:62707027	LPHN3	0.61	10.92	0.45	7.23e-25	Partial epilepsies;
LGG	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.6	-0.37	1.22e-16	Platelet distribution width;
LGG	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg03060546	chr3:49711283	APEH	-0.6	-8.45	-0.37	3.75e-16	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg05665937	chr4:1216051	CTBP1	0.5	9.24	0.39	9.06e-19	Obesity-related traits;
LGG	trans	rs3206736	0.548	rs328937	chr7:35049131	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.0	0.31	8.84e-12	Diastolic blood pressure;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14466961	chr4:493368	ZNF721;PIGG	-0.4	-6.73	-0.3	5.11e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13314892	0.764	rs62251031	chr3:69865083	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg13939156	chr17:80058883	NA	-0.47	-9.09	-0.39	2.89e-18	Life satisfaction;
LGG	cis	rs763121	0.889	rs9607557	chr22:39040279	G/A	cg06022373	chr22:39101656	GTPBP1	0.85	17.1	0.62	3.74e-51	Menopause (age at onset);
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg13939156	chr17:80058883	NA	0.49	9.67	0.41	2.96e-20	Life satisfaction;
LGG	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg18252515	chr7:66147081	NA	0.41	6.83	0.3	2.62e-11	Aortic root size;
LGG	cis	rs10463316	0.894	rs7723016	chr5:150764828	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs9783347	1.000	rs7947378	chr11:18381327	T/C	cg15585147	chr11:18324498	HPS5	0.44	9.33	0.4	4.45e-19	Pancreatic cancer;
LGG	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-16.76	-0.61	1.28e-49	Vitiligo;
LGG	cis	rs10991814	1.000	rs73650963	chr9:93943033	T/C	cg14446406	chr9:93919335	NA	-0.82	-8.84	-0.38	2.01e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs11112613	0.713	rs60865625	chr12:105940256	A/C	cg03607813	chr12:105948248	NA	0.61	10.54	0.44	2.02e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs2535633	0.820	rs7626551	chr3:52938092	C/G	cg11645453	chr3:52864694	ITIH4	-0.44	-7.37	-0.32	8e-13	Body mass index;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg00106254	chr7:1943704	MAD1L1	-0.45	-7.82	-0.34	3.54e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.24	-0.7	2.2e-70	Heart rate;
LGG	cis	rs7614601	1	rs7614601	chr3:112443737	G/A	cg06685282	chr3:112453648	NA	-0.4	-7.23	-0.32	1.99e-12	Itch intensity from mosquito bite;
LGG	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.64	0.33	1.28e-13	Mood instability;
LGG	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg13385794	chr1:248469461	NA	0.45	7.93	0.35	1.68e-14	Common traits (Other);
LGG	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07685180	chr8:600429	NA	1.04	10.56	0.44	1.67e-23	IgG glycosylation;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06028048	chr5:175815674	HIGD2A;NOP16	0.39	6.65	0.3	8.24e-11	Menarche (age at onset);
LGG	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs968567	0.705	rs174575	chr11:61602003	C/G	cg19610905	chr11:61596333	FADS2	-0.7	-11.47	-0.47	5.68e-27	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs7980799	0.840	rs7315695	chr12:33551841	G/C	cg26384229	chr12:38710491	ALG10B	-0.52	-9.03	-0.39	4.51e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9287719	0.781	rs6714413	chr2:10758859	C/T	cg02196655	chr2:10830764	NOL10	-0.47	-8.16	-0.35	3.12e-15	Prostate cancer;
LGG	cis	rs9472414	0.771	rs1935549	chr6:44763188	C/T	cg20913747	chr6:44695427	NA	0.46	6.99	0.31	9.54e-12	Height;
LGG	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.62e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg11494091	chr17:61959527	GH2	0.99	24.07	0.75	1.23e-83	Prudent dietary pattern;
LGG	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg07148914	chr20:33460835	GGT7	0.57	9.48	0.4	1.29e-19	Height;
LGG	cis	rs367615	0.879	rs4351197	chr5:108866667	A/G	cg17395555	chr5:108820864	NA	0.66	9.28	0.4	6.71e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10743315	0.778	rs7397459	chr12:19377578	C/G	cg02471346	chr12:19282374	PLEKHA5	0.51	7.17	0.32	2.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12681287	0.517	rs13249753	chr8:87513216	A/G	cg27223183	chr8:87520930	FAM82B	-0.49	-7.49	-0.33	3.42e-13	Caudate activity during reward;
LGG	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg19847130	chr8:10466454	RP1L1	0.34	7.27	0.32	1.55e-12	Neuroticism;
LGG	cis	rs2708240	1.000	rs2710102	chr7:147574390	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs12360000	0.800	rs34963788	chr10:1926436	A/C	cg26364871	chr10:1889757	NA	-0.69	-12.91	-0.51	8.8e-33	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-12.1	-0.49	1.76e-29	Vitiligo;
LGG	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-9.07	-0.39	3.5e-18	Hemoglobin concentration;
LGG	cis	rs753778	0.667	rs6578153	chr8:142209543	C/T	cg18755752	chr8:142205143	DENND3	-0.48	-9.77	-0.41	1.31e-20	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs12780845	0.540	rs11254406	chr10:17191692	C/T	cg01003015	chr10:17271136	VIM	-0.44	-7.4	-0.33	6.5e-13	Homocysteine levels;
LGG	cis	rs9715521	0.935	rs6818912	chr4:59834738	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.48	-0.33	3.7e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35160687	0.644	rs1863058	chr2:86509267	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.78	0.3	3.66e-11	Night sleep phenotypes;
LGG	cis	rs3813359	0.545	rs6928022	chr6:130551142	G/A	cg23281432	chr6:130554730	NA	0.52	7.41	0.33	6.04e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7666738	0.861	rs28829607	chr4:98964325	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg20476274	chr7:133979776	SLC35B4	0.72	13.87	0.54	8.13e-37	Mean platelet volume;
LGG	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6546324	0.625	rs6752799	chr2:67858503	G/A	cg18237512	chr2:67827392	NA	-0.38	-6.65	-0.3	8.12e-11	Endometriosis;
LGG	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	18.61	0.65	4.17e-58	Platelet count;
LGG	cis	rs990171	0.913	rs4851007	chr2:103024813	A/C	cg05295703	chr2:102895712	NA	-0.43	-7.22	-0.32	2.15e-12	Lymphocyte counts;
LGG	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs3820928	0.845	rs10165767	chr2:227781863	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.16e-14	Pulmonary function;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.5e-16	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs10849893	0.554	rs10849888	chr12:121892786	A/G	cg01154721	chr12:121881891	KDM2B	-0.44	-7.65	-0.33	1.22e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg18402987	chr7:1209562	NA	0.38	6.79	0.3	3.55e-11	Longevity;Endometriosis;
LGG	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg27490568	chr2:178487706	NA	0.49	9.65	0.41	3.27e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.83	-0.38	2.21e-17	Retinal vascular caliber;
LGG	cis	rs703842	1.000	rs10431505	chr12:58178589	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.83e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg13009111	chr11:71350975	NA	-0.31	-7.03	-0.31	7.48e-12	Systolic blood pressure;
LGG	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-8.47	-0.37	3.27e-16	Height;
LGG	cis	rs42648	0.935	rs42651	chr7:89978590	A/G	cg25739043	chr7:89950458	NA	-0.37	-7.62	-0.33	1.47e-13	Homocysteine levels;
LGG	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-16.53	-0.61	1.46e-48	Intelligence (multi-trait analysis);
LGG	cis	rs4674676	1	rs4674676	chr2:223529112	A/G	cg25565276	chr2:223520875	FARSB	1.21	20.48	0.69	7.44e-67	Chin dimples;
LGG	trans	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.74	-0.34	6.51e-14	Menarche (age at onset);
LGG	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.37	0.43	8.65e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7666738	0.830	rs28522896	chr4:99008243	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.62	-0.33	1.45e-13	Mean corpuscular volume;
LGG	cis	rs11158198	0.599	rs34969541	chr14:58607006	G/A	cg15908186	chr14:58618357	C14orf37	0.58	10.1	0.42	8.51e-22	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-13.72	-0.54	3.54e-36	Gut microbiome composition (summer);
LGG	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg02493740	chr2:85810744	VAMP5	-0.41	-7.39	-0.32	6.74e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13177180	0.523	rs256986	chr5:114906653	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.29	-0.32	1.33e-12	Conotruncal heart defects (inherited effects);
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg05793240	chr7:2802953	GNA12	0.36	8.17	0.35	3e-15	Height;
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.66e-25	Intelligence (multi-trait analysis);
LGG	cis	rs365132	0.905	rs10068703	chr5:176377069	T/A	cg16309518	chr5:176445507	NA	-0.55	-12.28	-0.5	3.43e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.19e-13	White matter hyperintensity burden;
LGG	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.24	-0.39	9.21e-19	Neuroticism;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg19147804	chr7:1989927	MAD1L1	-0.61	-11.91	-0.48	1.07e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06634786	chr22:41940651	POLR3H	0.79	12.59	0.51	1.82e-31	Vitiligo;
LGG	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.09	-0.46	1.61e-25	Hemoglobin concentration;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4356203	0.905	rs7927240	chr11:17078228	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg13312174	chr5:178288687	ZNF354B	-0.35	-6.95	-0.31	1.28e-11	Sleep duration;
LGG	cis	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg04455712	chr21:45112962	RRP1B	0.55	10.83	0.45	1.66e-24	Mean corpuscular volume;
LGG	cis	rs2131877	0.913	rs12634646	chr3:194842911	A/G	cg07250128	chr3:194833983	C3orf21	0.41	7.53	0.33	2.66e-13	Non-small cell lung cancer;
LGG	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg05444541	chr17:17804740	TOM1L2	0.67	14.89	0.57	2.86e-41	Total body bone mineral density;
LGG	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.28	0.36	1.37e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs4780401	0.967	rs11075011	chr16:11828282	T/A	cg01061890	chr16:11836724	TXNDC11	-0.45	-7.66	-0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07570687	chr10:102243282	WNT8B	0.41	7.02	0.31	8.08e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4911259	0.552	rs6057663	chr20:31463071	G/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.91	-0.48	1.01e-28	Inflammatory bowel disease;
LGG	cis	rs36051895	0.587	rs7036761	chr9:5198781	A/C	cg02405213	chr9:5042618	JAK2	0.72	12.5	0.5	4.43e-31	Pediatric autoimmune diseases;
LGG	cis	rs17001868	0.568	rs9611318	chr22:40739414	C/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	trans	rs9467711	1.000	rs9467701	chr6:26312170	G/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.01	-0.31	8.3e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.62	0.44	1.01e-23	Morning vs. evening chronotype;
LGG	cis	rs7539542	0.556	rs10753926	chr1:202876085	C/T	cg19681188	chr1:202830198	LOC148709	0.52	8.68	0.37	6.84e-17	Mean platelet volume;
LGG	cis	rs3126085	0.935	rs11584427	chr1:152299788	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-7.11	-0.31	4.52e-12	Atopic dermatitis;
LGG	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4356203	0.905	rs550667	chr11:17218975	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.23	-0.32	2.02e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg16359550	chr11:109292809	C11orf87	0.69	14.33	0.55	8.16e-39	Schizophrenia;
LGG	cis	rs727505	0.607	rs17387591	chr7:124799471	A/G	cg23710748	chr7:124431027	NA	-0.41	-7.95	-0.35	1.44e-14	Lewy body disease;
LGG	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.4	0.63	1.46e-52	Sudden cardiac arrest;
LGG	cis	rs677665	0.537	rs72641831	chr1:9335173	G/T	cg25755851	chr1:9335794	NA	0.3	8.58	0.37	1.42e-16	Eosinophil percentage of white cells;
LGG	cis	rs67478160	0.679	rs7156834	chr14:104211180	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-7.25	-0.32	1.72e-12	Schizophrenia;
LGG	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.02	-0.35	8.6e-15	Height;
LGG	cis	rs7523273	0.606	rs2796266	chr1:207922945	C/T	cg22525895	chr1:207977042	MIR29B2	-0.6	-11.92	-0.48	9.57e-29	Schizophrenia;
LGG	cis	rs10876993	0.821	rs1678522	chr12:58049923	G/A	cg18357645	chr12:58087776	OS9	0.69	12.35	0.5	1.79e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.18e-27	Height;
LGG	trans	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.96	0.35	1.39e-14	Obesity-related traits;
LGG	cis	rs2587949	0.593	rs2600135	chr3:4209896	C/T	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.76e-11	Periodontitis (DPAL);
LGG	trans	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg18187862	chr3:45730750	SACM1L	0.66	11.0	0.46	3.68e-25	Primary sclerosing cholangitis;
LGG	cis	rs267939	0.501	rs267959	chr5:10737802	A/G	cg14521931	chr5:10832172	NA	-0.38	-6.88	-0.3	1.98e-11	Gut microbiota (functional units);Ulcerative colitis;
LGG	trans	rs72991	0.793	rs10790443	chr11:121234131	G/T	cg27192990	chr6:129479024	LAMA2	-0.42	-7.2	-0.32	2.52e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1044826	0.642	rs6787649	chr3:139193321	C/T	cg15131784	chr3:139108705	COPB2	0.41	6.79	0.3	3.43e-11	Obesity-related traits;
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg17376030	chr22:41985996	PMM1	0.59	9.3	0.4	5.81e-19	Vitiligo;
LGG	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-8.77	-0.38	3.31e-17	Vitiligo;
LGG	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.52	-0.37	2.31e-16	Eosinophil percentage of white cells;
LGG	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg19336497	chr11:14380999	RRAS2	-0.41	-8.04	-0.35	7.82e-15	Mitochondrial DNA levels;
LGG	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg13010199	chr12:38710504	ALG10B	0.53	10.26	0.43	2.19e-22	Morning vs. evening chronotype;
LGG	cis	rs6540556	0.954	rs2076150	chr1:209933540	A/G	cg23920097	chr1:209922102	NA	-0.45	-8.02	-0.35	8.93e-15	Red blood cell count;
LGG	cis	rs7219021	1.000	rs11868085	chr17:46847575	C/T	cg16584676	chr17:46985605	UBE2Z	-0.44	-6.99	-0.31	9.72e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.21	0.39	1.12e-18	Height;
LGG	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg02023728	chr11:77925099	USP35	0.4	6.97	0.31	1.07e-11	Alzheimer's disease (survival time);
LGG	cis	rs7527798	0.571	rs12045913	chr1:207844625	A/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.79	-0.3	3.41e-11	Erythrocyte sedimentation rate;
LGG	cis	rs3008870	0.755	rs1925410	chr1:67365230	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.7	-13.77	-0.54	2.21e-36	Lymphocyte percentage of white cells;
LGG	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.14	0.35	3.73e-15	Mood instability;
LGG	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg00343986	chr7:65444356	GUSB	-0.49	-8.61	-0.37	1.14e-16	Calcium levels;
LGG	cis	rs9486719	0.857	rs11759769	chr6:97065212	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-8.28	-0.36	1.3e-15	Migraine;Coronary artery disease;
LGG	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg00204512	chr16:28754710	NA	0.24	6.66	0.3	7.62e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs910187	0.631	rs62201431	chr20:45810994	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-9.54	-0.41	8.04e-20	Migraine;
LGG	cis	rs4774899	0.752	rs28414972	chr15:57399694	T/C	cg08128148	chr15:57256372	TCF12	0.28	6.85	0.3	2.39e-11	Urinary tract infection frequency;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.05	15.79	0.59	2.95e-45	Platelet count;
LGG	cis	rs2074193	0.671	rs215352	chr12:47736198	C/T	cg02516419	chr12:47771422	NA	-0.64	-8.96	-0.38	8.08e-18	Migraine with aura;
LGG	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-11.91	-0.48	1.02e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg20387954	chr3:183756860	HTR3D	0.64	13.02	0.52	3.19e-33	Anterior chamber depth;
LGG	cis	rs11239187	0.530	rs11239139	chr10:45062495	G/A	cg03916630	chr10:45065415	NA	0.36	8.79	0.38	2.84e-17	Body mass index;
LGG	cis	rs9649213	0.533	rs62478235	chr7:98030349	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.5	-8.38	-0.36	6.5e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6540556	0.723	rs9430012	chr1:209900615	G/C	cg23920097	chr1:209922102	NA	-0.44	-7.31	-0.32	1.21e-12	Red blood cell count;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.02	0.31	7.85e-12	Prudent dietary pattern;
LGG	cis	rs7267979	1.000	rs6083856	chr20:25407585	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.12	-0.43	6.83e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs6743376	0.556	rs957201	chr2:113821200	T/C	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04772025	chr11:68637568	NA	0.75	13.47	0.53	3.88e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9811920	0.555	rs68092024	chr3:99691522	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.45	-7.69	-0.34	8.9e-14	Axial length;
LGG	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg04622731	chr7:157956161	PTPRN2	-0.93	-20.13	-0.68	3.48e-65	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10922622	chr9:108210153	FSD1L	0.46	7.92	0.35	1.77e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg20573242	chr4:122745356	CCNA2	0.41	7.53	0.33	2.75e-13	Type 2 diabetes;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg11905131	chr22:24372483	LOC391322	-0.39	-6.85	-0.3	2.35e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg06637938	chr14:75390232	RPS6KL1	0.56	10.29	0.43	1.72e-22	Height;
LGG	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.6	-0.33	1.71e-13	Triglycerides;
LGG	cis	rs7191700	0.511	rs12923756	chr16:11359675	C/T	cg00044050	chr16:11439710	C16orf75	-0.56	-9.4	-0.4	2.6e-19	Multiple sclerosis;
LGG	cis	rs4356932	1.000	rs4241578	chr4:76944491	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs453301	0.506	rs686189	chr8:8623637	A/G	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.88	-0.3	1.97e-11	Joint mobility (Beighton score);
LGG	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg14228332	chr4:119757509	SEC24D	0.88	9.28	0.4	6.42e-19	Cannabis dependence symptom count;
LGG	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg25922239	chr6:33757077	LEMD2	-0.42	-7.39	-0.33	6.7e-13	Crohn's disease;
LGG	cis	rs6684428	0.536	rs4573554	chr1:56398037	C/T	cg11651538	chr1:56320950	NA	-0.42	-8.15	-0.35	3.45e-15	Airflow obstruction;
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg16434002	chr17:42200994	HDAC5	-0.52	-9.78	-0.41	1.19e-20	Total body bone mineral density;
LGG	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg15268244	chr15:77196840	NA	0.42	8.29	0.36	1.21e-15	Blood metabolite levels;
LGG	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg16576597	chr16:28551801	NUPR1	0.33	7.25	0.32	1.78e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2470578	0.792	rs283921	chr3:17325889	G/A	cg20981856	chr3:17787350	NA	0.35	6.65	0.3	8.28e-11	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04921619	chr12:7000534	NA	0.4	7.33	0.32	1.03e-12	Obesity-related traits;
LGG	cis	rs4262150	0.667	rs4130910	chr5:152251643	T/C	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs4774899	1.000	rs12911518	chr15:57501494	T/G	cg08128148	chr15:57256372	TCF12	-0.3	-6.94	-0.31	1.33e-11	Urinary tract infection frequency;
LGG	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg26031613	chr14:104095156	KLC1	-0.62	-9.8	-0.41	9.56e-21	Reticulocyte count;
LGG	cis	rs8017423	0.935	rs59444150	chr14:90767175	T/C	cg04374321	chr14:90722782	PSMC1	0.83	17.24	0.63	8.14e-52	Mortality in heart failure;
LGG	trans	rs9929218	1.000	rs4783681	chr16:68806508	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.82	-0.51	2e-32	Colorectal cancer;
LGG	cis	rs2282032	0.825	rs17799220	chr14:90739446	C/A	cg04374321	chr14:90722782	PSMC1	0.5	6.77	0.3	3.97e-11	Longevity;
LGG	cis	rs2380220	0.935	rs7744491	chr6:95994980	T/G	cg04719120	chr6:96025338	MANEA	0.49	6.66	0.3	7.89e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs1595825	0.945	rs73058818	chr2:198862600	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-7.01	-0.31	8.61e-12	Ulcerative colitis;
LGG	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg06618935	chr21:46677482	NA	-0.43	-8.46	-0.37	3.57e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9929218	1.000	rs12596061	chr16:68807828	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.18	-0.52	6.35e-34	Colorectal cancer;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.93	-0.48	8.81e-29	Alzheimer's disease;
LGG	cis	rs1506636	1.000	rs689341	chr7:123403974	C/A	cg03229431	chr7:123269106	ASB15	0.73	18.0	0.64	2.6e-55	Plateletcrit;Platelet count;
LGG	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg27476859	chr7:2772710	GNA12	-0.59	-11.39	-0.47	1.19e-26	Height;
LGG	cis	rs2802728	0.881	rs7531548	chr1:243549522	A/C	cg05593162	chr1:243577377	SDCCAG8	0.47	6.82	0.3	2.89e-11	Toenail selenium levels;
LGG	cis	rs9625935	0.536	rs9608819	chr22:30260809	A/C	cg01021169	chr22:30184971	ASCC2	0.37	7.21	0.32	2.36e-12	Tonsillectomy;
LGG	cis	rs4430311	0.723	rs971285	chr1:243919773	C/T	cg25706552	chr1:244017396	NA	-0.64	-15.54	-0.59	3.95e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs340849	0.703	rs17762192	chr1:214125127	C/G	cg05052969	chr1:214156842	NA	0.37	6.67	0.3	7.42e-11	Alzheimer's disease;
LGG	cis	rs858239	0.600	rs28646184	chr7:23139595	T/C	cg23682824	chr7:23144976	KLHL7	0.44	7.69	0.34	8.84e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg26384229	chr12:38710491	ALG10B	-0.71	-13.65	-0.54	6.78e-36	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.13	-0.31	3.79e-12	Bipolar disorder;
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.75	0.38	4.11e-17	Bipolar disorder;
LGG	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.48	-0.56	1.78e-39	Response to antipsychotic treatment;
LGG	cis	rs17092148	0.887	rs6120684	chr20:33179788	A/G	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.42	-7.39	-0.32	6.78e-13	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs5769707	0.967	rs9616333	chr22:50050847	G/A	cg06623630	chr22:50017776	C22orf34	-0.36	-7.61	-0.33	1.51e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.6	7.86	0.34	2.65e-14	HIV-1 control;
LGG	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.66	-0.61	3.53e-49	Total body bone mineral density;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg22907277	chr7:1156413	C7orf50	0.59	9.13	0.39	2.08e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1580019	0.520	rs13228793	chr7:32711465	C/T	cg07520158	chr7:32535189	LSM5;AVL9	0.48	7.24	0.32	1.85e-12	Cognitive ability;
LGG	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-10.01	-0.42	1.73e-21	Coronary artery disease;
LGG	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19524238	chr7:2802976	GNA12	-0.39	-9.26	-0.4	7.76e-19	Height;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg21782813	chr7:2030301	MAD1L1	-0.38	-9.06	-0.39	3.65e-18	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg22105103	chr4:187893119	NA	0.58	11.23	0.46	4.65e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg05313129	chr8:58192883	C8orf71	-0.68	-8.74	-0.38	4.32e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.27	-0.4	6.83e-19	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg05791153	chr7:19748676	TWISTNB	0.63	8.09	0.35	5.17e-15	Thyroid stimulating hormone;
LGG	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg15704280	chr7:45808275	SEPT13	0.85	8.87	0.38	1.62e-17	Myopia (pathological);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20887711	chr4:1340912	KIAA1530	-0.91	-20.03	-0.68	1.03e-64	Longevity;
LGG	cis	rs4650994	0.550	rs12047530	chr1:178543407	A/G	cg19399532	chr1:178512495	C1orf220	-0.4	-7.5	-0.33	3.22e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1620921	0.625	rs2997097	chr6:161263200	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs870825	0.616	rs2090590	chr4:185647850	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg26354017	chr1:205819088	PM20D1	0.98	26.54	0.78	4.84e-95	Menarche (age at onset);
LGG	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-10.0	-0.42	1.88e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4748857	0.853	rs7095016	chr10:23610272	C/G	cg18853376	chr10:23633759	C10orf67	-0.36	-6.71	-0.3	5.63e-11	Systemic lupus erythematosus;
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.75	0.3	4.37e-11	Vitiligo;
LGG	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg13009111	chr11:71350975	NA	-0.34	-7.38	-0.32	7.59e-13	Monocyte count;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.58	-0.53	1.34e-35	Alzheimer's disease;
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg27411982	chr8:10470053	RP1L1	0.4	6.76	0.3	4.29e-11	Neuroticism;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	8.6	0.37	1.21e-16	Lung function (FEV1/FVC);
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg15948088	chr11:109293068	C11orf87	-0.56	-9.65	-0.41	3.43e-20	Schizophrenia;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg00204512	chr16:28754710	NA	-0.26	-6.75	-0.3	4.49e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.62	0.33	1.41e-13	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14728276	chr1:26798723	HMGN2	0.47	7.13	0.31	3.85e-12	Gut microbiome composition (summer);
LGG	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg10523679	chr1:76189770	ACADM	0.77	14.2	0.55	2.99e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7635838	0.819	rs2447607	chr3:11552027	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.69	0.3	6.63e-11	HDL cholesterol;
LGG	cis	rs36051895	0.623	rs62541541	chr9:5040817	G/C	cg02405213	chr9:5042618	JAK2	-0.83	-15.44	-0.58	1.06e-43	Pediatric autoimmune diseases;
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.29	-6.79	-0.3	3.47e-11	Total body bone mineral density;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg06925179	chr17:43578568	NA	0.42	9.81	0.41	9.09e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs5742933	0.857	rs1233282	chr2:190688244	G/A	cg04003228	chr2:190539410	ANKAR	0.46	6.74	0.3	4.69e-11	Ferritin levels;
LGG	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.5	-0.4	1.12e-19	Mean corpuscular volume;
LGG	cis	rs6882046	0.513	rs454214	chr5:88003403	A/G	cg22951263	chr5:87985283	NA	0.55	10.33	0.43	1.2e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg18105134	chr13:113819100	PROZ	-0.71	-14.16	-0.55	4.27e-38	Platelet distribution width;
LGG	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.02e-12	HDL cholesterol;
LGG	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg13482628	chr17:19912719	NA	0.54	10.18	0.43	4.38e-22	Schizophrenia;
LGG	cis	rs9911578	0.757	rs4793954	chr17:56629527	G/T	cg12560992	chr17:57184187	TRIM37	-0.77	-12.06	-0.49	2.62e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.647	rs7613953	chr3:17743150	G/T	cg20981856	chr3:17787350	NA	-0.38	-6.96	-0.31	1.16e-11	Schizophrenia;
LGG	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg10189774	chr4:17578691	LAP3	-0.42	-7.38	-0.32	7.6e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7512552	0.839	rs2873669	chr1:150426224	C/T	cg15654264	chr1:150340011	RPRD2	-0.46	-9.4	-0.4	2.44e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg06238570	chr21:40685208	BRWD1	0.42	6.66	0.3	7.61e-11	Cognitive function;
LGG	cis	rs896854	0.812	rs12546365	chr8:95911477	T/C	cg16049864	chr8:95962084	TP53INP1	-0.37	-8.11	-0.35	4.58e-15	Type 2 diabetes;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg24149806	chr17:7308003	C17orf61	-0.5	-6.8	-0.3	3.2e-11	Educational attainment (years of education);
LGG	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.53	-0.47	3.38e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4595586	0.545	rs11615700	chr12:39365104	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10493773	0.649	rs17398321	chr1:86084493	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.46	-7.15	-0.32	3.3e-12	Urate levels in overweight individuals;
LGG	cis	rs2832191	0.511	rs7278227	chr21:30482707	C/T	cg08807101	chr21:30365312	RNF160	-0.65	-11.49	-0.47	4.5e-27	Dental caries;
LGG	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg27398817	chr8:82754497	SNX16	0.71	10.96	0.45	5.4e-25	Diastolic blood pressure;
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg07157834	chr1:205819609	PM20D1	0.45	7.55	0.33	2.4e-13	Parkinson's disease;
LGG	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.51	-7.92	-0.35	1.83e-14	Menarche (age at onset);
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.78	-0.3	3.74e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11645898	1.000	rs72791117	chr16:72217385	T/C	cg14768367	chr16:72042858	DHODH	-0.75	-10.21	-0.43	3.32e-22	Blood protein levels;
LGG	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg14042143	chr7:2646782	IQCE	0.81	12.57	0.5	2.24e-31	Urate levels in lean individuals;
LGG	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	7.65	0.33	1.2e-13	Initial pursuit acceleration;
LGG	trans	rs7944735	0.508	rs2305982	chr11:47857168	A/G	cg15704280	chr7:45808275	SEPT13	0.62	6.87	0.3	2.15e-11	Intraocular pressure;
LGG	cis	rs1775715	0.737	rs2799018	chr10:32202069	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.8	0.3	3.26e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03428813	chr2:62115351	CCT4	0.48	7.12	0.31	4.21e-12	Gut microbiome composition (summer);
LGG	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15532942	chr18:77220712	NFATC1	0.46	7.46	0.33	4.32e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-14.02	-0.55	1.84e-37	Platelet distribution width;
LGG	cis	rs12476592	0.602	rs2121351	chr2:63828361	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.48e-11	Childhood ear infection;
LGG	cis	rs7681440	0.647	rs1442136	chr4:90819026	C/T	cg20003494	chr4:90757398	SNCA	0.34	6.67	0.3	7.47e-11	Dementia with Lewy bodies;
LGG	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.57e-23	Aortic root size;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg24829409	chr8:58192753	C8orf71	-0.83	-13.33	-0.53	1.6e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg15212455	chr7:39170539	POU6F2	-0.4	-8.66	-0.37	8.1e-17	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16308174	chr11:70049109	FADD	0.51	7.96	0.35	1.36e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.2	0.32	2.45e-12	Lung cancer;
LGG	trans	rs1600249	0.562	rs11250144	chr8:11386276	G/C	cg06636001	chr8:8085503	FLJ10661	0.44	6.78	0.3	3.75e-11	Rheumatoid arthritis;
LGG	cis	rs7236492	0.572	rs76694706	chr18:77236006	T/C	cg15644404	chr18:77186268	NFATC1	-0.76	-8.95	-0.38	8.35e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg05692746	chr2:100937584	LONRF2	-0.57	-9.32	-0.4	4.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs977987	0.843	rs59465235	chr16:75483810	C/G	cg03315344	chr16:75512273	CHST6	0.53	10.5	0.44	2.8e-23	Dupuytren's disease;
LGG	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg00578828	chr5:131826934	IRF1	0.41	7.36	0.32	8.21e-13	Asthma (sex interaction);
LGG	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11890956	chr21:40555474	PSMG1	-0.97	-20.83	-0.7	1.68e-68	Cognitive function;
LGG	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg24308560	chr3:49941425	MST1R	0.22	6.75	0.3	4.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg19784903	chr17:45786737	TBKBP1	-0.33	-7.11	-0.31	4.3e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13065560	0.594	rs4234134	chr3:38887970	A/T	cg01426195	chr3:39028469	NA	0.41	8.99	0.39	6.57e-18	Interleukin-18 levels;
LGG	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg04691961	chr3:161091175	C3orf57	-0.7	-17.26	-0.63	6.71e-52	Morning vs. evening chronotype;
LGG	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.89	0.45	1e-24	Parkinson's disease;
LGG	cis	rs3820928	0.874	rs7562776	chr2:227806550	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs11920090	0.858	rs12633935	chr3:170674865	A/C	cg09710316	chr3:170744871	SLC2A2	0.65	8.62	0.37	1.08e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Vitiligo;
LGG	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg01601518	chr4:2404284	ZFYVE28	-0.48	-8.34	-0.36	8.84e-16	Cognitive function;
LGG	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg15440763	chr7:158190612	PTPRN2	0.39	7.69	0.34	8.69e-14	Obesity-related traits;
LGG	cis	rs988958	0.675	rs12712815	chr2:42224021	A/G	cg27428208	chr2:42229179	NA	0.53	9.19	0.39	1.34e-18	Hypospadias;
LGG	cis	rs342442	0.754	rs17703785	chr4:88079535	G/A	cg21988461	chr4:88008667	AFF1	0.26	6.9	0.31	1.68e-11	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
LGG	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.17e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.01	18.09	0.64	9.96e-56	Lymphocyte percentage of white cells;
LGG	cis	rs858239	0.601	rs6980224	chr7:23149137	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.21e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7659604	0.540	rs4240264	chr4:122683818	A/G	cg19671926	chr4:122722719	EXOSC9	0.49	7.64	0.33	1.22e-13	Type 2 diabetes;
LGG	cis	rs2439831	0.850	rs3736180	chr15:44106624	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.29	0.4	6.2800000000000005e-19	Lung cancer in ever smokers;
LGG	trans	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.18	-0.32	2.84e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs34421088	0.624	rs13278982	chr8:11589033	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	6.86	0.3	2.26e-11	Neuroticism;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg26682337	chr5:145429192	SH3RF2	-0.46	-7.53	-0.33	2.7e-13	Body fat percentage;
LGG	cis	rs9815354	1.000	rs56207540	chr3:41976627	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	6.73	0.3	5.04e-11	Aortic root size;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs17209837	0.915	rs17149660	chr7:87089524	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.45	6.68	0.3	6.83e-11	HIV-1 control;
LGG	trans	rs629535	0.783	rs658407	chr8:70035247	T/C	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs2273669	0.667	rs12206834	chr6:109303967	T/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.23e-18	Motion sickness;
LGG	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.9	-0.42	4.32e-21	Body mass index;
LGG	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.52	10.88	0.45	1.09e-24	Hemoglobin concentration;
LGG	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg16329197	chr12:53359506	NA	-0.64	-11.52	-0.47	3.51e-27	Cancer (pleiotropy);
LGG	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg02002194	chr4:3960332	NA	0.48	9.12	0.39	2.27e-18	Mood instability;
LGG	cis	rs1577917	1.000	rs2166663	chr6:86593896	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-8.5	-0.37	2.65e-16	Response to antipsychotic treatment;
LGG	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg19773385	chr1:10388646	KIF1B	-0.51	-10.87	-0.45	1.1e-24	Hepatocellular carcinoma;
LGG	cis	rs2153535	0.580	rs7742794	chr6:8459723	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.19e-13	HDL cholesterol;
LGG	cis	rs4722585	0.533	rs757371	chr7:26199207	A/G	cg07876897	chr7:26191696	NFE2L3	0.35	7.09	0.31	5.15e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg18681998	chr4:17616180	MED28	0.82	16.81	0.62	7.9e-50	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg05182265	chr7:156933206	UBE3C	0.36	7.42	0.33	5.55e-13	Body mass index;
LGG	cis	rs1055129	0.537	rs10852766	chr17:73951864	T/C	cg14829360	chr17:73884958	NA	0.53	9.9	0.42	4.32e-21	White matter hyperintensity burden;
LGG	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.26e-36	Cognitive function;
LGG	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-8.56	-0.37	1.67e-16	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs2033732	0.613	rs10101678	chr8:85060063	G/T	cg05716166	chr8:85095498	RALYL	0.43	6.94	0.31	1.37e-11	Body mass index;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg03188948	chr7:1209495	NA	0.49	7.82	0.34	3.67e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg07142201	chr11:109293216	C11orf87	-0.51	-9.26	-0.4	7.59e-19	Schizophrenia;
LGG	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	10.3	0.43	1.55e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.59	0.41	5.61e-20	Prudent dietary pattern;
LGG	cis	rs526231	0.511	rs3776861	chr5:102349662	A/C	cg23492399	chr5:102201601	PAM	-0.55	-8.17	-0.35	3.05e-15	Primary biliary cholangitis;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg17911788	chr17:44343683	NA	0.61	9.33	0.4	4.4e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4665809	0.627	rs7562192	chr2:26469457	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.07	21.13	0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs7216064	0.953	rs62086043	chr17:65968003	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.21	-0.39	1.16e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg03135127	chr19:13227421	TRMT1	-0.41	-7.2	-0.32	2.44e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.26	-0.36	1.52e-15	Neuroticism;
LGG	cis	rs16854884	0.657	rs6440210	chr3:143705763	A/G	cg06585982	chr3:143692056	C3orf58	0.64	11.11	0.46	1.45e-25	Economic and political preferences (feminism/equality);
LGG	trans	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg24247370	chr13:99142703	STK24	-0.37	-6.73	-0.3	5.03e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.38	0.65	4.91e-57	Personality dimensions;
LGG	cis	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg21775007	chr8:11205619	TDH	-0.42	-6.93	-0.31	1.39e-11	Triglycerides;
LGG	cis	rs877282	0.786	rs11253392	chr10:788768	G/A	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg03929089	chr4:120376271	NA	0.84	13.14	0.52	9.51e-34	Coronary artery disease;
LGG	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	13.13	0.52	1.04e-33	Menarche (age at onset);
LGG	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg22535103	chr8:58192502	C8orf71	-0.84	-11.87	-0.48	1.45e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg07414643	chr4:187882934	NA	0.57	11.78	0.48	3.35e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4665809	0.531	rs12987980	chr2:26462093	A/T	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs9309473	1.000	rs6740223	chr2:73653332	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.46	-0.33	4.22e-13	Metabolite levels;
LGG	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.69	12.14	0.49	1.26e-29	Colorectal cancer;
LGG	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg18128536	chr17:47092178	IGF2BP1	-0.49	-9.3	-0.4	5.42e-19	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs7715811	1.000	rs1502041	chr5:13758529	A/G	cg07548982	chr5:13769939	DNAH5	-0.47	-9.81	-0.41	8.92e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg04058563	chr4:185651563	MLF1IP	0.48	10.34	0.43	1.06e-22	Kawasaki disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg27654529	chr19:35418345	ZNF30	0.37	7.14	0.31	3.66e-12	Body mass index;
LGG	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg25019033	chr10:957182	NA	-0.54	-9.99	-0.42	2.09e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.33e-18	Obesity-related traits;
LGG	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg23625390	chr15:77176239	SCAPER	0.48	9.49	0.4	1.19e-19	Blood metabolite levels;
LGG	trans	rs11098499	0.913	rs68128210	chr4:120137819	T/G	cg25214090	chr10:38739885	LOC399744	0.62	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs11264213	0.901	rs116757422	chr1:36349560	G/A	cg27506609	chr1:36549197	TEKT2	0.72	7.3	0.32	1.22e-12	Schizophrenia;
LGG	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg16141378	chr3:129829833	LOC729375	0.39	8.82	0.38	2.32e-17	Neuroticism;
LGG	trans	rs3960554	0.569	rs1894761	chr7:75876754	C/T	cg19862616	chr7:65841803	NCRNA00174	-0.6	-9.67	-0.41	2.96e-20	Eotaxin levels;
LGG	trans	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.01	-0.31	8.46e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17276794	chr5:1474048	LPCAT1	-0.37	-6.8	-0.3	3.28e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg07005078	chr4:17578674	LAP3	-0.36	-6.89	-0.31	1.78e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.42	-0.36	4.68e-16	Schizophrenia;
LGG	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg03909863	chr11:638404	DRD4	-0.41	-6.65	-0.3	8.28e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs2227631	1.000	rs2227631	chr7:100769538	A/G	cg01975495	chr7:100779017	SERPINE1	0.34	9.01	0.39	5.27e-18	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg08125733	chr17:73851984	WBP2	0.7	10.78	0.45	2.5300000000000002e-24	Psoriasis;
LGG	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg01448562	chr3:133502909	NA	0.74	13.75	0.54	2.65e-36	Iron status biomarkers;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-10.04	-0.42	1.32e-21	Prudent dietary pattern;
LGG	cis	rs79839061	0.610	rs11732965	chr4:869359	C/A	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg03161606	chr19:29218774	NA	0.69	10.56	0.44	1.73e-23	Methadone dose in opioid dependence;
LGG	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.63e-34	Corneal astigmatism;
LGG	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.01	-0.74	2.49e-83	Height;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg23131131	chr22:24373011	LOC391322	-0.46	-7.66	-0.34	1.07e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	8.13	0.35	4.03e-15	Platelet count;
LGG	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg01206211	chr2:36825736	FEZ2	-0.42	-8.13	-0.35	4.01e-15	Height;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg13047869	chr3:10149882	C3orf24	0.55	9.41	0.4	2.3e-19	Alzheimer's disease;
LGG	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-10.54	-0.44	2e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9341808	0.690	rs3805926	chr6:80879280	C/G	cg08355045	chr6:80787529	NA	0.41	7.9	0.34	1.99e-14	Sitting height ratio;
LGG	cis	rs4771450	0.925	rs7321957	chr13:103984977	T/A	cg02987523	chr13:103978230	NA	-0.32	-6.99	-0.31	9.4e-12	Uric acid levels;
LGG	cis	rs6504108	0.624	rs11079814	chr17:46268439	T/C	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.45e-15	Body mass index;
LGG	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg04034577	chr2:241836375	C2orf54	-0.51	-10.66	-0.44	7.03e-24	Urinary metabolites;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg05091796	chr16:4465799	CORO7	-0.82	-13.72	-0.54	3.52e-36	Schizophrenia;
LGG	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-8.97	-0.38	7.58e-18	Retinal vascular caliber;
LGG	cis	rs1497828	0.956	rs1497834	chr1:217535731	G/T	cg04411442	chr1:217543379	NA	-0.47	-7.97	-0.35	1.25e-14	Dialysis-related mortality;
LGG	cis	rs4262150	0.810	rs72797241	chr5:151999410	G/A	cg12297329	chr5:152029980	NA	-0.8	-15.64	-0.59	1.36e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg24607181	chr17:41446203	NA	-0.3	-7.0	-0.31	9.07e-12	Menopause (age at onset);
LGG	trans	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	8.1	0.35	4.87e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg25039879	chr17:56429692	SUPT4H1	0.57	8.04	0.35	7.45e-15	Cognitive test performance;
LGG	cis	rs10267417	0.603	rs114520435	chr7:19944551	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg25486957	chr4:152246857	NA	-0.41	-6.7	-0.3	5.89e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.836	rs10900800	chr5:130914946	G/A	cg06307176	chr5:131281290	NA	0.52	8.63	0.37	9.57e-17	Life satisfaction;
LGG	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.73	0.54	3.12e-36	Prudent dietary pattern;
LGG	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg04617936	chr2:214353	NA	-0.39	-7.16	-0.32	3.2e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg03213289	chr20:61660250	NA	0.65	14.42	0.56	3.53e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.58	-0.41	5.71e-20	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7523273	0.606	rs2724398	chr1:207993699	A/G	cg22525895	chr1:207977042	MIR29B2	-0.6	-11.62	-0.48	1.47e-27	Schizophrenia;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.27e-16	Obesity-related traits;
LGG	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.03	-0.35	8.24e-15	HDL cholesterol;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg06885757	chr1:42089581	HIVEP3	0.82	21.16	0.7	5.23e-70	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs4714291	0.832	rs6936016	chr6:40097013	A/G	cg02267698	chr19:7991119	CTXN1	-0.61	-10.22	-0.43	3.02e-22	Strep throat;
LGG	cis	rs2797160	1.000	rs1739367	chr6:126004720	G/T	cg05901451	chr6:126070800	HEY2	-0.44	-7.31	-0.32	1.18e-12	Endometrial cancer;
LGG	cis	rs8064299	0.584	rs2384957	chr17:72784630	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.6	0.72	8.98e-77	Monocyte count;
LGG	cis	rs727505	0.789	rs66756015	chr7:124740641	C/A	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg02023728	chr11:77925099	USP35	0.47	8.36	0.36	7.28e-16	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00933542	chr6:150070202	PCMT1	0.4	7.2	0.32	2.5e-12	Lung cancer;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg04287289	chr16:89883240	FANCA	0.74	7.9	0.34	2.07e-14	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02307161	chr20:16710695	SNRPB2	0.42	6.9	0.31	1.76e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg02733842	chr7:1102375	C7orf50	0.69	8.03	0.35	8.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs6901004	0.803	rs11153272	chr6:111479539	C/T	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.58	-0.33	1.89e-13	Blood metabolite levels;
LGG	cis	rs4478858	0.684	rs4949202	chr1:31736800	T/C	cg19084893	chr1:31688959	NA	0.31	6.83	0.3	2.64e-11	Alcohol dependence;
LGG	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg06618935	chr21:46677482	NA	-0.44	-8.71	-0.38	5.31e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg05491587	chr18:77659695	KCNG2	-0.4	-7.21	-0.32	2.34e-12	Schizophrenia;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.9	-0.45	9.06e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg14926445	chr8:58193284	C8orf71	-0.87	-13.12	-0.52	1.19e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01880437	chr4:26321873	RBPJ	0.44	6.97	0.31	1.07e-11	Cognitive performance;
LGG	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19171272	chr22:38449367	NA	0.41	6.95	0.31	1.25e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg01262667	chr19:19385393	TM6SF2	-0.35	-7.92	-0.35	1.75e-14	Tonsillectomy;
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.84e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg15596359	chr8:11213517	TDH	-0.42	-8.82	-0.38	2.31e-17	Retinal vascular caliber;
LGG	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.93	0.48	8.44e-29	Response to antipsychotic treatment;
LGG	cis	rs1111571	0.576	rs1110571	chr16:68396516	T/A	cg07273125	chr16:68295692	NA	0.38	8.21	0.36	2.17e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs227808	0.812	rs4711796	chr6:44640911	G/A	cg18551225	chr6:44695536	NA	0.49	7.04	0.31	7.15e-12	Male-pattern baldness;
LGG	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg03929089	chr4:120376271	NA	0.44	7.17	0.32	3.05e-12	HDL cholesterol;
LGG	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.86	-0.34	2.75e-14	Menopause (age at onset);
LGG	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg01194073	chr14:101175302	NA	-0.46	-7.05	-0.31	6.35e-12	Plateletcrit;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	8.27	0.36	1.42e-15	Obesity-related traits;
LGG	cis	rs17253792	0.822	rs28549152	chr14:56091239	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg08067677	chr16:67260902	LRRC29;TMEM208	-0.39	-6.73	-0.3	5.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1927790	0.727	rs9556559	chr13:96974352	C/T	cg02571835	chr13:96230311	CLDN10	-0.35	-7.17	-0.32	3.03e-12	Body mass index;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg08610935	chr16:1836813	NUBP2	-0.45	-6.98	-0.31	1.01e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2463822	1.000	rs2513076	chr11:62103711	A/G	cg06239285	chr11:62104954	ASRGL1	1.16	16.32	0.6	1.28e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs4918072	0.667	rs10430666	chr10:105702425	T/C	cg11005552	chr10:105648138	OBFC1	0.47	8.26	0.36	1.49e-15	Coronary artery disease;
LGG	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg11584989	chr19:19387371	SF4	0.65	10.77	0.45	2.66e-24	Bipolar disorder;
LGG	cis	rs4363385	0.818	rs2787629	chr1:153011966	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.89	-0.3	1.78e-11	Retinal vascular caliber;
LGG	cis	rs71403859	0.502	rs34380814	chr16:71488175	C/T	cg08717414	chr16:71523259	ZNF19	-1.23	-16.83	-0.62	6.17e-50	Post bronchodilator FEV1;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg13628971	chr7:2884303	GNA12	0.55	11.68	0.48	8.24e-28	Height;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg27476859	chr7:2772710	GNA12	0.39	6.72	0.3	5.47e-11	Height;
LGG	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.29	0.36	1.24e-15	Diabetic kidney disease;
LGG	cis	rs9534288	0.830	rs2897027	chr13:46636235	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-16.75	-0.61	1.41e-49	Blood protein levels;
LGG	cis	rs9296092	0.517	rs9461877	chr6:33516667	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.7	-0.69	7.11e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg11473876	chr11:109292803	C11orf87	-0.45	-8.35	-0.36	7.99e-16	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20321375	chr12:8185526	FOXJ2	0.52	7.66	0.34	1.08e-13	Gut microbiome composition (summer);
LGG	cis	rs4731207	0.596	rs2127971	chr7:124595309	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9381040	0.610	rs717883	chr6:41045270	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.66	-0.3	7.75e-11	Alzheimer's disease (late onset);
LGG	cis	rs896854	0.654	rs13278601	chr8:95972974	G/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.85	-0.38	1.8e-17	Type 2 diabetes;
LGG	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg25703541	chr22:24373054	LOC391322	0.93	14.25	0.55	1.9e-38	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg09361094	chr10:834503	NA	-0.3	-8.02	-0.35	8.99e-15	Survival in rectal cancer;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg27476859	chr7:2772710	GNA12	0.41	7.21	0.32	2.34e-12	Height;
LGG	cis	rs2050392	0.737	rs7898978	chr10:30699800	T/C	cg25182066	chr10:30743637	MAP3K8	0.61	12.44	0.5	7.74e-31	Inflammatory bowel disease;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.93	-0.31	1.39e-11	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	8.01	0.35	9.22e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2559856	0.935	rs7957666	chr12:102081551	T/C	cg15068132	chr12:102092402	CHPT1	-0.36	-6.68	-0.3	6.7e-11	Blood protein levels;
LGG	cis	rs7503807	0.515	rs12939413	chr17:78679449	C/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs7020830	0.898	rs13290794	chr9:37183628	C/T	cg14294708	chr9:37120828	ZCCHC7	1.18	33.53	0.84	5.87e-126	Schizophrenia;
LGG	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg05639522	chr1:247681581	NA	0.61	10.62	0.44	9.96e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg09264619	chr17:80180166	NA	0.35	7.05	0.31	6.49e-12	Life satisfaction;
LGG	cis	rs7113850	0.541	rs80031332	chr11:24211553	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	9.8	0.41	9.8e-21	Bone fracture in osteoporosis;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.18	-0.32	2.78e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07362569	chr17:61921086	SMARCD2	0.49	9.34	0.4	4.18e-19	Prudent dietary pattern;
LGG	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg16301924	chr13:53314226	LECT1	-0.44	-8.49	-0.37	2.85e-16	Lewy body disease;
LGG	cis	rs6694672	0.850	rs1576880	chr1:196992511	C/T	cg13682187	chr1:196946512	CFHR5	0.5	6.84	0.3	2.53e-11	Asthma;
LGG	cis	rs9972944	0.729	rs7502798	chr17:63781615	C/T	cg07283582	chr17:63770753	CCDC46	0.4	7.58	0.33	1.88e-13	Total body bone mineral density;
LGG	trans	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	11.27	0.46	3.24e-26	Mean corpuscular volume;
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs240764	0.619	rs9390626	chr6:101163109	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.9	0.31	1.68e-11	Neuroticism;
LGG	cis	rs9463078	0.753	rs1329716	chr6:44953758	C/T	cg25276700	chr6:44698697	NA	-0.38	-8.11	-0.35	4.66e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs35123781	0.696	rs10067965	chr5:139071353	T/C	cg21230503	chr5:139085173	NA	0.36	8.45	0.37	3.86e-16	Schizophrenia;
LGG	cis	rs9911578	1.000	rs2531729	chr17:56539890	C/T	cg05425664	chr17:57184151	TRIM37	-0.61	-9.7	-0.41	2.21e-20	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg05556477	chr5:131705319	SLC22A5	0.82	9.79	0.41	1.03e-20	Rheumatoid arthritis;
LGG	cis	rs2286885	1.000	rs2277159	chr9:129243383	C/T	cg14319473	chr9:129242481	FAM125B	0.44	8.23	0.36	1.99e-15	Intraocular pressure;
LGG	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.97	0.49	6.06e-29	Lung disease severity in cystic fibrosis;
LGG	trans	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg20978937	chr14:105399321	PLD4	0.44	9.81	0.41	9.27e-21	Rheumatoid arthritis;
LGG	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg03433033	chr1:76189801	ACADM	0.73	12.66	0.51	9e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2708240	1.000	rs2708240	chr7:147577537	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.26	-6.65	-0.3	8.24e-11	QT interval (drug interaction);
LGG	cis	rs28680850	0.541	rs28501642	chr8:1379528	G/A	cg06035437	chr8:1398411	NA	-0.65	-8.94	-0.38	9.04e-18	Triglycerides;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.84	0.51	1.77e-32	Obesity-related traits;
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs7107174	1.000	rs2512532	chr11:77968641	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.35	-0.32	8.99e-13	Testicular germ cell tumor;
LGG	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg23461800	chr14:103021989	NA	0.44	6.69	0.3	6.37e-11	Platelet count;
LGG	trans	rs73191547	1.000	rs11787370	chr8:10030902	G/T	cg16141378	chr3:129829833	LOC729375	-0.31	-6.73	-0.3	4.99e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24511898	chr2:242576823	ATG4B;THAP4	0.49	7.77	0.34	5.26e-14	Gut microbiome composition (summer);
LGG	cis	rs1595825	0.891	rs111340803	chr2:198612877	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg09165964	chr15:75287851	SCAMP5	-0.79	-8.93	-0.38	1.04e-17	Lung cancer;
LGG	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.82	-0.34	3.56e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.69	0.64	6.75e-54	Alzheimer's disease;
LGG	cis	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs4774830	0.744	rs62045229	chr15:56280869	G/C	cg24530489	chr15:56299380	NA	-0.84	-7.45	-0.33	4.75e-13	Delta-5 desaturase activity;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg14926445	chr8:58193284	C8orf71	0.9	11.84	0.48	2.04e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg01028140	chr2:1542097	TPO	-0.5	-7.65	-0.34	1.15e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg25809561	chr17:30822961	MYO1D	0.37	8.77	0.38	3.56e-17	Schizophrenia;
LGG	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg18876405	chr7:65276391	NA	-0.46	-8.09	-0.35	5.25e-15	Calcium levels;
LGG	cis	rs7582720	1.000	rs72936830	chr2:203769803	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs921968	0.584	rs2305833	chr2:219305404	G/C	cg01130898	chr2:219473002	PLCD4	-0.39	-6.76	-0.3	4.29e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7928758	0.887	rs78760579	chr11:134281332	T/G	cg25213107	chr11:134282864	B3GAT1	1.23	14.14	0.55	5.54e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2718058	0.630	rs2718051	chr7:37824790	G/A	cg24998770	chr7:37888106	TXNDC3	0.44	7.17	0.32	3.02e-12	Alzheimer's disease (late onset);
LGG	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg08250081	chr4:10125330	NA	0.41	8.06	0.35	6.74e-15	Bone mineral density;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg11062466	chr8:58055876	NA	0.48	7.87	0.34	2.53e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.834	rs1563106	chr2:99701381	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-10.61	-0.44	1.06e-23	Chronic sinus infection;
LGG	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg17691542	chr6:26056736	HIST1H1C	0.87	13.86	0.54	8.54e-37	Iron status biomarkers;
LGG	cis	rs62064224	0.614	rs11656445	chr17:30694164	T/C	cg25809561	chr17:30822961	MYO1D	0.37	8.85	0.38	1.85e-17	Schizophrenia;
LGG	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg02297831	chr4:17616191	MED28	0.49	8.89	0.38	1.34e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs27434	0.607	rs26654	chr5:96140367	C/T	cg16492584	chr5:96139282	ERAP1	-0.35	-6.98	-0.31	1.05e-11	Ankylosing spondylitis;
LGG	cis	rs6429082	0.783	rs291385	chr1:235646613	T/C	cg26050004	chr1:235667680	B3GALNT2	0.61	10.16	0.43	5.13e-22	Adiposity;
LGG	cis	rs9880211	0.800	rs35100027	chr3:136467561	T/A	cg21827317	chr3:136751795	NA	-0.47	-6.78	-0.3	3.61e-11	Body mass index;Height;
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.37e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6784615	0.744	rs13093555	chr3:52298171	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.67	7.4	0.33	6.56e-13	Waist-hip ratio;
LGG	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.06	0.49	2.56e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg07549998	chr6:150325970	RAET1K	-0.39	-7.35	-0.32	9.33e-13	Alopecia areata;
LGG	cis	rs3540	0.512	rs7176518	chr15:91079637	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-12.37	-0.5	1.41e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg13072238	chr3:49761600	GMPPB	0.55	7.08	0.31	5.39e-12	Menarche (age at onset);
LGG	cis	rs7940866	0.738	rs10894308	chr11:130891895	G/A	cg12179176	chr11:130786555	SNX19	0.72	13.31	0.53	1.84e-34	Schizophrenia;
LGG	cis	rs11190604	1.000	rs3750629	chr10:102275727	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.53	0.33	2.7e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9463078	0.727	rs2396371	chr6:44946550	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.61	-0.37	1.19e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.27	0.36	1.41e-15	Initial pursuit acceleration;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.47e-12	Lung cancer;
LGG	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.84	-0.3	2.56e-11	Triglycerides;
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10802521	chr3:52805072	NEK4	-0.46	-7.78	-0.34	4.67e-14	Bipolar disorder;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg11878867	chr6:150167359	LRP11	0.48	8.16	0.35	3.15e-15	Lung cancer;
LGG	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17767392	0.670	rs11620632	chr14:71729438	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.35	-7.55	-0.33	2.32e-13	Mitral valve prolapse;
LGG	cis	rs4356975	0.563	rs62296936	chr4:69948621	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.67	0.3	7.23e-11	Obesity-related traits;
LGG	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg11871910	chr12:69753446	YEATS4	0.42	6.67	0.3	7.27e-11	Response to diuretic therapy;
LGG	cis	rs67133203	0.904	rs12817386	chr12:51373227	G/C	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.57e-30	Urinary tract infection frequency;
LGG	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.17	0.32	2.95e-12	Neuroticism;
LGG	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.74	0.3	4.69e-11	IgG glycosylation;
LGG	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg05973401	chr12:123451056	ABCB9	0.51	8.18	0.36	2.76e-15	Schizophrenia;
LGG	cis	rs11264213	0.901	rs716926	chr1:36424476	A/G	cg27506609	chr1:36549197	TEKT2	0.64	8.02	0.35	8.71e-15	Schizophrenia;
LGG	cis	rs9354308	0.714	rs9354315	chr6:66573653	A/T	cg07460842	chr6:66804631	NA	-0.4	-6.91	-0.31	1.6e-11	Metabolite levels;
LGG	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg09696939	chr10:60272079	BICC1	-0.39	-7.53	-0.33	2.76e-13	Refractive error;
LGG	trans	rs3858145	0.588	rs4142049	chr10:70044452	C/A	cg04882175	chr6:131122610	NA	-0.57	-8.11	-0.35	4.55e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.28	-0.43	1.84e-22	Neuroticism;
LGG	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg22517653	chr1:2918612	NA	-0.45	-6.97	-0.31	1.09e-11	Plateletcrit;
LGG	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.36	2.92e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg05335186	chr13:53173507	NA	0.43	8.57	0.37	1.53e-16	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00431236	chr2:264988	ACP1;SH3YL1	0.43	7.32	0.32	1.13e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	cg07245641	chr1:182991651	LAMC1	0.4	9.28	0.4	6.56e-19	Colorectal cancer;
LGG	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg26384229	chr12:38710491	ALG10B	1.0	24.91	0.76	1.57e-87	Heart rate;
LGG	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg27121462	chr16:89883253	FANCA	0.63	11.35	0.47	1.66e-26	Vitiligo;
LGG	trans	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.7	-0.34	8.1e-14	Resting heart rate;
LGG	cis	rs66887589	0.870	rs10518336	chr4:120522934	G/A	cg09307838	chr4:120376055	NA	0.49	8.34	0.36	8.89e-16	Diastolic blood pressure;
LGG	cis	rs11866815	0.557	rs12599449	chr16:397269	A/T	cg07915516	chr16:377344	AXIN1	-0.5	-10.62	-0.44	9.7e-24	Body mass index;
LGG	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	33.1	0.84	4.15e-124	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3008870	0.755	rs2755271	chr1:67474977	C/T	cg02640540	chr1:67518911	SLC35D1	0.37	7.36	0.32	8.28e-13	Lymphocyte percentage of white cells;
LGG	cis	rs477692	1.000	rs485576	chr10:131425496	G/C	cg05714579	chr10:131428358	MGMT	0.59	12.26	0.5	4.02e-30	Response to temozolomide;
LGG	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs834603	0.575	rs1620852	chr7:47481786	A/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.91	-0.48	1.07e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.28	-0.32	1.46e-12	Refractive error;
LGG	cis	rs11158026	0.757	rs7146285	chr14:55412869	T/C	cg04306507	chr14:55594613	LGALS3	0.3	6.82	0.3	2.77e-11	Parkinson's disease;
LGG	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg10523679	chr1:76189770	ACADM	-0.7	-11.32	-0.47	2.17e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg10596483	chr8:143751796	JRK	0.58	9.43	0.4	2.03e-19	Schizophrenia;
LGG	cis	rs3540	0.960	rs10083661	chr15:91022339	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.05	0.35	6.93e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7106204	0.609	rs10500976	chr11:24335921	A/G	ch.11.24196551F	chr11:24239977	NA	-0.87	-10.25	-0.43	2.39e-22	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg17734273	chr15:78292508	TBC1D2B	-0.35	-8.5	-0.37	2.64e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg06112835	chr11:68658793	MRPL21	0.6	9.82	0.42	8.18e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.5	-0.44	2.86e-23	Bipolar disorder;
LGG	cis	rs1355223	0.902	rs286861	chr11:34718424	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.67	-0.3	7.22e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11203032	0.831	rs7074977	chr10:90948409	C/T	cg16672925	chr10:90967113	CH25H	0.51	7.85	0.34	2.86e-14	Heart failure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17025674	chr5:127537216	NA	0.44	7.15	0.32	3.47e-12	Gut microbiome composition (summer);
LGG	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.8	0.3	3.28e-11	Systemic lupus erythematosus;
LGG	cis	rs12540874	0.931	rs9791817	chr7:50661187	C/G	cg04490037	chr7:50633773	DDC	0.33	7.4	0.33	6.59e-13	Systemic sclerosis;
LGG	cis	rs4849845	0.637	rs11688038	chr2:121026582	A/G	cg15425061	chr2:121036351	RALB	0.37	6.74	0.3	4.84e-11	Mean platelet volume;
LGG	cis	rs6815814	0.808	rs7653908	chr4:38782221	G/C	cg06935464	chr4:38784597	TLR10	0.52	7.66	0.34	1.11e-13	Breast cancer;
LGG	cis	rs78487399	0.808	rs7561287	chr2:43689071	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.69e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.87	0.42	5.56e-21	Morning vs. evening chronotype;
LGG	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.62	11.39	0.47	1.12e-26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.54	-6.94	-0.31	1.37e-11	Smoking behavior;
LGG	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg02403541	chr12:121454288	C12orf43	0.53	8.66	0.37	7.71e-17	N-glycan levels;
LGG	cis	rs9788682	0.642	rs2568483	chr15:78752343	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-8.08	-0.35	5.87e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg02127607	chr17:61920694	SMARCD2	0.38	6.72	0.3	5.4e-11	Prudent dietary pattern;
LGG	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg23939001	chr4:940644	TMEM175	-0.4	-7.8	-0.34	4.15e-14	Parkinson's disease;
LGG	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.63	-9.06	-0.39	3.55e-18	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg17376030	chr22:41985996	PMM1	-0.49	-7.88	-0.34	2.3e-14	Cannabis dependence symptom count;
LGG	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg11764359	chr7:65958608	NA	-0.64	-10.95	-0.45	5.55e-25	Cotinine glucuronidation;
LGG	cis	rs9902453	0.904	rs7208579	chr17:28263067	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.12	0.55	6.51e-38	Coffee consumption (cups per day);
LGG	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg17509989	chr5:176798049	RGS14	0.86	13.43	0.53	5.96e-35	Urinary electrolytes (magnesium/calcium ratio);
LGG	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg21775007	chr8:11205619	TDH	0.44	7.22	0.32	2.18e-12	Mood instability;
LGG	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9354308	0.738	rs9360168	chr6:66601632	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	cis	rs35849525	0.633	rs62263602	chr3:50152491	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-7.99	-0.35	1.07e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.66e-18	Alzheimer's disease;
LGG	cis	rs1371867	0.810	rs1692004	chr8:101247320	T/C	cg06636551	chr8:101224915	SPAG1	0.49	8.99	0.39	6.38e-18	Atrioventricular conduction;
LGG	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg07061783	chr6:25882402	NA	-0.39	-7.12	-0.31	4.22e-12	Blood metabolite levels;
LGG	cis	rs757081	0.648	rs7108315	chr11:17267164	C/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.64	-0.33	1.27e-13	Systolic blood pressure;
LGG	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg03477792	chr4:77819574	ANKRD56	0.52	9.07	0.39	3.48e-18	Emphysema distribution in smoking;
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.93	-0.57	1.96e-41	Platelet count;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.33	0.32	1.07e-12	Height;
LGG	cis	rs17767392	0.958	rs2214836	chr14:72025078	G/T	cg02058870	chr14:72053146	SIPA1L1	-0.48	-9.87	-0.42	5.44e-21	Mitral valve prolapse;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg13880726	chr7:1868755	MAD1L1	0.45	7.87	0.34	2.56e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg24110177	chr3:50126178	RBM5	0.61	11.22	0.46	5.22e-26	Body mass index;
LGG	trans	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.11	-0.39	2.58e-18	Bladder cancer;
LGG	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg03894339	chr8:19674705	INTS10	0.53	8.58	0.37	1.43e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg09904177	chr6:26538194	HMGN4	-0.37	-6.66	-0.3	7.81e-11	Schizophrenia;
LGG	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.78	-0.34	4.65e-14	Neuroticism;
LGG	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	25.2	0.76	7.03e-89	IgG glycosylation;
LGG	cis	rs1620921	0.625	rs9355842	chr6:161267442	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg19761014	chr17:28927070	LRRC37B2	0.67	7.77	0.34	5.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2629540	0.806	rs10901812	chr10:126419384	A/G	cg08799069	chr10:126477246	METTL10	-0.65	-13.58	-0.53	1.34e-35	Cocaine dependence;
LGG	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.89	0.34	2.25e-14	Electroencephalogram traits;
LGG	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.91	-0.31	1.65e-11	Joint mobility (Beighton score);
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.34	0.5	1.93e-30	Colorectal cancer;
LGG	cis	rs503734	0.666	rs3846091	chr3:101217617	A/C	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07187585	chr17:10600923	C17orf48;SCO1	0.41	6.69	0.3	6.43e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4891159	0.548	rs690082	chr18:74116668	C/T	cg24786174	chr18:74118243	ZNF516	0.68	17.24	0.63	8.53e-52	Longevity;
LGG	trans	rs7246760	0.748	rs73006398	chr19:9723447	A/G	cg02900749	chr2:68251473	NA	-0.95	-9.5	-0.4	1.14e-19	Pursuit maintenance gain;
LGG	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs11203032	0.831	rs10430718	chr10:90937951	A/T	cg16672925	chr10:90967113	CH25H	0.77	11.02	0.46	3.11e-25	Heart failure;
LGG	trans	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	cis	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg12395012	chr8:11607386	GATA4	0.41	7.38	0.32	7.42e-13	Monocyte count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17984783	chr8:59465534	SDCBP	0.67	7.69	0.34	9.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.36	0.32	8.57e-13	Prudent dietary pattern;
LGG	cis	rs9783347	0.714	rs11024622	chr11:18352685	C/G	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.38	-0.5	1.34e-30	Pancreatic cancer;
LGG	cis	rs2274273	0.588	rs7158791	chr14:55828607	A/G	cg04306507	chr14:55594613	LGALS3	0.52	12.24	0.49	4.79e-30	Protein biomarker;
LGG	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.84	-0.45	1.51e-24	Bladder cancer;
LGG	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg02269571	chr22:50332266	NA	-0.72	-10.94	-0.45	6.31e-25	Schizophrenia;
LGG	cis	rs782590	0.774	rs782632	chr2:55898290	C/G	cg18811423	chr2:55921094	PNPT1	0.92	22.13	0.72	1.53e-74	Metabolic syndrome;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.92	0.35	1.73e-14	Bipolar disorder;
LGG	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg19025524	chr12:109796872	NA	-0.39	-7.86	-0.34	2.63e-14	Neuroticism;
LGG	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg17108064	chr15:78857060	CHRNA5	0.47	10.08	0.42	1.01e-21	Sudden cardiac arrest;
LGG	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg27432699	chr2:27873401	GPN1	0.69	14.29	0.55	1.21e-38	Oral cavity cancer;
LGG	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs7267979	0.668	rs2387977	chr20:25599776	C/T	cg06421707	chr20:25228305	PYGB	-0.39	-8.21	-0.36	2.26e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg11859384	chr17:80120422	CCDC57	0.4	6.92	0.31	1.53e-11	Life satisfaction;
LGG	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6694672	1.000	rs1412633	chr1:197027220	C/G	cg13682187	chr1:196946512	CFHR5	0.5	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg13256891	chr4:100009986	ADH5	-0.57	-9.89	-0.42	4.86e-21	Alcohol dependence;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	16.68	0.61	3.09e-49	Platelet count;
LGG	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg20818283	chr2:191399100	TMEM194B	-0.3	-7.15	-0.32	3.39e-12	Pulse pressure;
LGG	cis	rs36093844	0.747	rs17817314	chr11:85594972	T/C	cg16165120	chr11:85566439	CCDC83	-0.44	-7.1	-0.31	4.73e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg04691961	chr3:161091175	C3orf57	0.44	9.39	0.4	2.63e-19	Morning vs. evening chronotype;
LGG	cis	rs9397585	0.626	rs13215045	chr6:153447516	C/T	cg17707550	chr6:153380415	RGS17	0.46	10.21	0.43	3.24e-22	Body mass index;
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.26	-0.46	3.79e-26	Personality dimensions;
LGG	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg24675658	chr1:53192096	ZYG11B	-0.59	-12.28	-0.5	3.41e-30	Monocyte count;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.94e-21	Educational attainment;
LGG	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.19	0.39	1.31e-18	Motion sickness;
LGG	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.56	0.37	1.62e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.93	-0.31	1.41e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.67	-0.34	1.02e-13	Menarche (age at onset);
LGG	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg19628046	chr18:33552617	C18orf21	0.53	7.7	0.34	8.26e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07659893	chr17:61819838	STRADA	0.47	7.89	0.34	2.21e-14	Prudent dietary pattern;
LGG	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.77	-12.07	-0.49	2.29e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs185694	1.000	rs202098	chr13:30896774	G/T	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.68	-0.3	6.96e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg23202291	chr11:1979235	NA	0.37	7.18	0.32	2.73e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg02153584	chr22:29168773	CCDC117	0.69	11.68	0.48	8.64e-28	Lymphocyte counts;
LGG	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.16	0.68	2.33e-65	Bladder cancer;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg05333889	chr7:157238977	NA	-0.5	-9.59	-0.41	5.38e-20	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4665809	1.000	rs10182857	chr2:26344411	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14315863	chr3:160283655	KPNA4	-0.46	-6.81	-0.3	2.98e-11	Systemic lupus erythematosus;
LGG	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg26031613	chr14:104095156	KLC1	-0.6	-9.44	-0.4	1.8e-19	Reticulocyte count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26759552	chr7:139877471	LOC100134229;JHDM1D	-0.47	-6.91	-0.31	1.63e-11	Systemic lupus erythematosus;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14673162	chr5:176074305	TSPAN17	0.65	7.39	0.32	6.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7267979	1.000	rs397119	chr20:25440187	C/A	cg06421707	chr20:25228305	PYGB	0.47	10.08	0.42	9.73e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg18258770	chr4:90757814	SNCA	-0.43	-7.86	-0.34	2.79e-14	Dementia with Lewy bodies;
LGG	cis	rs56161922	1.000	rs55883147	chr1:207840002	C/T	cg09557387	chr1:207818395	CR1L	0.99	9.72	0.41	1.98e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	trans	rs1997103	1.000	rs9649857	chr7:55411777	C/T	cg20935933	chr6:143382018	AIG1	0.55	8.54	0.37	1.9e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.6	-9.24	-0.39	8.75e-19	Body mass index;
LGG	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg19455335	chr8:22457658	C8orf58	0.38	7.75	0.34	5.75e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	cis	rs11225247	1.000	rs1058606	chr11:102267098	A/T	cg06323957	chr11:102217781	BIRC2	0.8	7.03	0.31	7.51e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs12681287	0.640	rs6471309	chr8:87387760	C/T	cg27223183	chr8:87520930	FAM82B	-0.51	-7.71	-0.34	7.66e-14	Caudate activity during reward;
LGG	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg17108064	chr15:78857060	CHRNA5	0.46	9.96	0.42	2.57e-21	Sudden cardiac arrest;
LGG	cis	rs9912468	0.803	rs4423457	chr17:64284000	G/A	cg19474267	chr17:64306194	PRKCA	0.92	23.62	0.74	1.66e-81	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg23894439	chr1:183413866	NA	0.49	9.2	0.39	1.27e-18	Systemic lupus erythematosus;
LGG	cis	rs3742264	0.656	rs9534261	chr13:46534058	G/A	cg15192986	chr13:46630673	CPB2	-0.36	-6.89	-0.3	1.88e-11	Blood protein levels;
LGG	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs17776563	0.639	rs11635416	chr15:89112062	C/A	cg05013243	chr15:89149849	MIR1179	-0.33	-6.86	-0.3	2.15e-11	Thyroid hormone levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18108022	chr8:103666233	KLF10	-0.48	-7.02	-0.31	8.17e-12	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05591758	chr2:74685531	WBP1	0.43	7.17	0.32	2.92e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs701145	0.640	rs357495	chr3:153939099	A/G	cg12800244	chr3:153838788	SGEF	0.8	8.17	0.36	2.92e-15	Coronary artery disease;
LGG	cis	rs9596863	1.000	rs9536564	chr13:54460395	G/A	ch.13.53330881F	chr13:54432880	NA	-0.52	-7.34	-0.32	9.94e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs8028182	0.636	rs4486847	chr15:75728531	C/G	cg20655648	chr15:75932815	IMP3	0.46	7.81	0.34	3.91e-14	Sudden cardiac arrest;
LGG	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg24253500	chr15:84953950	NA	0.58	10.3	0.43	1.59e-22	Schizophrenia;
LGG	trans	rs8073060	0.533	rs178736	chr17:33928158	G/T	cg19694781	chr19:47549865	TMEM160	-1.15	-17.24	-0.63	7.93e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.47	-0.47	5.61e-27	Personality dimensions;
LGG	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-10.11	-0.43	7.45e-22	Parkinson's disease;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02475777	chr4:1388615	CRIPAK	-0.58	-10.3	-0.43	1.56e-22	Longevity;
LGG	cis	rs75920871	0.588	rs4938321	chr11:116852507	C/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.92	-0.45	7.2e-25	Subjective well-being;
LGG	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg03060546	chr3:49711283	APEH	-0.6	-8.44	-0.37	4.14e-16	Menarche (age at onset);
LGG	cis	rs17767392	0.670	rs17767386	chr14:71748353	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.65	-0.37	8.46e-17	Mitral valve prolapse;
LGG	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03576123	chr11:487126	PTDSS2	0.97	14.19	0.55	3.49e-38	Body mass index;
LGG	cis	rs79839061	0.520	rs2279187	chr4:875529	C/T	cg07828340	chr4:882639	GAK	0.86	9.07	0.39	3.5e-18	Intelligence (multi-trait analysis);
LGG	trans	rs877282	0.838	rs34912955	chr10:772222	T/C	cg22713356	chr15:30763199	NA	0.57	8.55	0.37	1.82e-16	Uric acid levels;
LGG	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg06026331	chr20:60912101	LAMA5	0.46	8.18	0.36	2.77e-15	Colorectal cancer;
LGG	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	1.9e-54	Refractive error;
LGG	cis	rs1707322	1.000	rs4073847	chr1:46463012	A/C	cg03146154	chr1:46216737	IPP	-0.52	-9.83	-0.42	7.72e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg06219351	chr7:158114137	PTPRN2	-0.76	-14.48	-0.56	1.91e-39	Calcium levels;
LGG	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg00701064	chr4:6280414	WFS1	0.64	13.0	0.52	3.79e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4919044	0.808	rs9420608	chr10:94800903	C/G	cg05127821	chr10:94822908	CYP26C1	0.45	8.22	0.36	2.11e-15	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg24848339	chr3:12840334	CAND2	0.37	8.33	0.36	9.55e-16	QRS complex (12-leadsum);
LGG	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg09764611	chr12:132620959	NA	-0.57	-8.41	-0.36	4.99e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.49	0.4	1.24e-19	Testicular germ cell tumor;
LGG	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.94	0.57	1.71e-41	Cognitive test performance;
LGG	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg16576597	chr16:28551801	NUPR1	0.31	7.02	0.31	7.72e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.89	-0.34	2.2e-14	Initial pursuit acceleration;
LGG	trans	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg17712092	chr4:129076599	LARP1B	-0.66	-12.23	-0.49	5.48e-30	Eosinophil percentage of white cells;
LGG	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.42	0.36	4.77e-16	Neuroticism;
LGG	cis	rs4141404	0.851	rs5749222	chr22:31556759	C/G	cg22777020	chr22:31556080	RNF185	-0.44	-6.77	-0.3	3.95e-11	Paclitaxel-induced neuropathy;
LGG	cis	rs6912958	1.000	rs6454630	chr6:88171357	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	10.26	0.43	2.09e-22	Monocyte percentage of white cells;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	10.24	0.43	2.6e-22	Longevity;
LGG	cis	rs12476592	0.571	rs4671512	chr2:63753095	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.68	-0.3	7.06e-11	Childhood ear infection;
LGG	cis	rs1869026	1.000	rs9308615	chr2:121338985	T/C	cg22272644	chr2:121334640	NA	-0.3	-7.17	-0.32	2.92e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg11301795	chr4:187892539	NA	0.95	25.63	0.77	7.63e-91	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12464559	0.522	rs10200512	chr2:152626147	T/C	cg01189475	chr2:152685088	ARL5A	0.68	7.06	0.31	5.95e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg08508337	chr8:144660607	NAPRT1	0.9	6.96	0.31	1.13e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs11190604	1.000	rs7085439	chr10:102210100	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.41	0.56	3.67e-39	Colorectal cancer;
LGG	cis	rs2522056	0.932	rs1012793	chr5:131781345	G/C	cg07395648	chr5:131743802	NA	0.39	6.85	0.3	2.31e-11	Lymphocyte counts;Fibrinogen;
LGG	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg15596359	chr8:11213517	TDH	0.4	8.22	0.36	2.14e-15	Retinal vascular caliber;
LGG	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg14949292	chr17:78079608	GAA	-0.27	-7.22	-0.32	2.2e-12	Yeast infection;
LGG	cis	rs3735485	0.738	rs2289370	chr7:45114089	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.57	-0.41	6.37e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6088590	0.561	rs6059934	chr20:33178324	G/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.62	0.37	1.06e-16	Coronary artery disease;
LGG	trans	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg18187862	chr3:45730750	SACM1L	-0.68	-10.92	-0.45	7.28e-25	Primary sclerosing cholangitis;
LGG	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg20290983	chr6:43655470	MRPS18A	-1.01	-17.54	-0.63	3.63e-53	IgG glycosylation;
LGG	cis	rs1408799	0.579	rs970944	chr9:12738401	C/T	cg05274944	chr9:12693694	TYRP1	-0.31	-6.82	-0.3	2.86e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs4262150	0.774	rs17565839	chr5:152082740	C/T	cg12297329	chr5:152029980	NA	-0.75	-14.02	-0.55	1.74e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg12552261	chr5:112820674	MCC	0.75	14.27	0.55	1.49e-38	Type 2 diabetes;
LGG	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg14675211	chr2:100938903	LONRF2	-0.49	-7.51	-0.33	3.1400000000000003e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg09307838	chr4:120376055	NA	0.64	10.31	0.43	1.45e-22	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05477933	chr12:54426537	HOXC4;HOXC5	0.45	7.08	0.31	5.21e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-9.27	-0.4	6.98e-19	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2070677	0.877	rs8192777	chr10:135350871	G/T	cg20169779	chr10:135381914	SYCE1	0.96	12.74	0.51	4.48e-32	Gout;
LGG	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs9682041	1.000	rs15709	chr3:170110529	T/A	cg11886554	chr3:170076028	SKIL	0.97	11.7	0.48	6.76e-28	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg13256891	chr4:100009986	ADH5	0.38	6.75	0.3	4.55e-11	Alcohol dependence;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg26174226	chr8:58114915	NA	-0.52	-7.26	-0.32	1.66e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.12	0.68	3.87e-65	Smoking behavior;
LGG	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	10.84	0.45	1.44e-24	Height;
LGG	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg23782820	chr8:58130467	NA	0.5	6.93	0.31	1.42e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.55	-0.33	2.34e-13	Initial pursuit acceleration;
LGG	cis	rs6840360	0.615	rs66852535	chr4:152472227	C/A	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg00745463	chr17:30367425	LRRC37B	-0.77	-10.96	-0.45	5.17e-25	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.64	11.51	0.47	3.81e-27	Obesity-related traits;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-12.65	-0.51	1.09e-31	Longevity;Endometriosis;
LGG	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.87e-16	Asthma;
LGG	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg00129232	chr17:37814104	STARD3	0.59	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7582720	1.000	rs115396314	chr2:203721314	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg08400814	chr5:56204995	C5orf35	-0.54	-8.29	-0.36	1.27e-15	Initial pursuit acceleration;
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.21	-0.36	2.26e-15	Total body bone mineral density;
LGG	trans	rs3857536	0.776	rs9363560	chr6:66949686	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs1420338	0.933	rs10228731	chr7:34150782	G/T	cg01275685	chr7:34179230	BMPER	-0.47	-8.34	-0.36	8.51e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs4363385	0.747	rs9919227	chr1:152970867	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.87e-18	Inflammatory skin disease;
LGG	cis	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17253792	0.822	rs77990307	chr14:56070049	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg15485101	chr11:133734466	NA	0.55	9.63	0.41	3.83e-20	Childhood ear infection;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg06916706	chr16:4465613	CORO7	-0.76	-13.31	-0.53	1.88e-34	Schizophrenia;
LGG	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	trans	rs7937682	0.593	rs1944117	chr11:111351184	T/C	cg18187862	chr3:45730750	SACM1L	-0.41	-6.69	-0.3	6.62e-11	Primary sclerosing cholangitis;
LGG	cis	rs7077256	0.564	rs12761593	chr10:65213577	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08247611	chr16:71928811	KIAA0174	0.56	8.79	0.38	2.84e-17	Gut microbiome composition (summer);
LGG	cis	rs9517320	0.534	rs3858776	chr13:99161457	C/T	cg03701759	chr13:99174930	STK24	-0.35	-6.76	-0.3	4.13e-11	Longevity;
LGG	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.96	-13.46	-0.53	4.46e-35	Schizophrenia;
LGG	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.7	-0.56	2.09e-40	Leprosy;
LGG	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg15268244	chr15:77196840	NA	0.48	10.31	0.43	1.38e-22	Blood metabolite levels;
LGG	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg07022442	chr13:21864356	NA	-0.39	-6.89	-0.3	1.83e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2916247	0.909	rs2083844	chr8:93014149	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7945718	0.967	rs12417886	chr11:12811731	A/C	cg25843174	chr11:12811716	TEAD1	-0.43	-8.9	-0.38	1.3e-17	Educational attainment (years of education);
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg06654118	chr4:1303317	MAEA	0.49	8.59	0.37	1.33e-16	Obesity-related traits;
LGG	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.9	0.54	6.1e-37	IgG glycosylation;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.57e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg18357526	chr6:26021779	HIST1H4A	0.95	18.71	0.66	1.32e-58	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.72	-0.38	5.15e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg09461388	chr22:46763229	CELSR1	-0.71	-6.99	-0.31	9.39e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg16662043	chr16:48846231	NA	0.35	6.88	0.3	1.99e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg27219399	chr15:67835830	MAP2K5	0.32	6.86	0.3	2.22e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2070488	0.662	rs7652475	chr3:38481341	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	11.74	0.48	4.99e-28	Electrocardiographic conduction measures;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03647317	chr4:187891568	NA	-0.42	-8.91	-0.38	1.13e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.52	8.81	0.38	2.46e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs3806843	0.576	rs246027	chr5:140333601	A/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg19700328	chr14:106028568	NA	0.59	9.97	0.42	2.54e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg00647317	chr7:50633725	DDC	-0.35	-7.72	-0.34	7.07e-14	Malaria;
LGG	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg04450456	chr4:17643702	FAM184B	0.34	7.58	0.33	1.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7945718	0.967	rs4757945	chr11:12808718	A/G	cg25843174	chr11:12811716	TEAD1	-0.41	-8.67	-0.37	7.29e-17	Educational attainment (years of education);
LGG	cis	rs9487094	0.670	rs2277114	chr6:109827716	C/T	cg01125227	chr6:109776195	MICAL1	0.42	7.32	0.32	1.08e-12	Height;
LGG	cis	rs7911264	0.739	rs7096101	chr10:94362928	G/A	cg25093409	chr10:94429542	NA	0.49	9.6	0.41	5.13e-20	Inflammatory bowel disease;
LGG	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.79	-0.54	1.74e-36	Response to antipsychotic treatment;
LGG	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg13393036	chr8:95962371	TP53INP1	-0.26	-6.89	-0.3	1.82e-11	Type 2 diabetes;
LGG	cis	rs4639966	0.836	rs7124498	chr11:118616253	G/A	cg20110707	chr11:118481992	PHLDB1	-0.42	-6.75	-0.3	4.51e-11	Systemic lupus erythematosus;
LGG	cis	rs2905347	0.737	rs756879	chr7:22634005	A/G	cg18045685	chr7:22629474	NA	-0.89	-21.79	-0.71	5.88e-73	Major depression and alcohol dependence;
LGG	cis	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg21775007	chr8:11205619	TDH	-0.49	-8.02	-0.35	9.01e-15	Neuroticism;
LGG	cis	rs7555523	0.830	rs4656460	chr1:165672367	A/C	cg24409356	chr1:165738333	TMCO1	0.61	6.98	0.31	1e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg07636037	chr3:49044803	WDR6	0.44	6.74	0.3	4.8e-11	Resting heart rate;
LGG	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	14.03	0.55	1.55e-37	Total body bone mineral density;
LGG	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg26617929	chr16:1858877	NA	0.55	7.59	0.33	1.77e-13	Insulin-like growth factors;
LGG	cis	rs4262150	0.545	rs72806715	chr5:152345579	G/T	cg12297329	chr5:152029980	NA	-0.58	-7.77	-0.34	5.04e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.33	-0.4	4.25e-19	Neuroticism;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg02524346	chr8:600233	NA	-1.33	-11.22	-0.46	5.24e-26	IgG glycosylation;
LGG	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg06713675	chr4:122721982	EXOSC9	-0.65	-11.0	-0.46	3.82e-25	Type 2 diabetes;
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg18335740	chr13:41363409	SLC25A15	-0.57	-11.08	-0.46	1.87e-25	Lewy body disease;
LGG	cis	rs2117029	1.000	rs2293445	chr12:49398862	G/A	cg24176009	chr12:49580217	TUBA1A	0.43	7.86	0.34	2.77e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2066819	1.000	rs41423244	chr12:56693520	A/C	cg26714650	chr12:56694279	CS	1.58	16.18	0.6	5.66e-47	Psoriasis vulgaris;
LGG	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.52	-0.37	2.3e-16	Triglycerides;
LGG	cis	rs7617773	0.963	rs6766754	chr3:48182589	T/C	cg11946769	chr3:48343235	NME6	-0.5	-8.23	-0.36	1.98e-15	Coronary artery disease;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	9.22	0.39	1.06e-18	Schizophrenia;
LGG	cis	rs12580194	0.593	rs61957899	chr12:55731971	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-9.38	-0.4	2.94e-19	Cancer;
LGG	cis	rs774359	0.789	rs9969832	chr9:27493063	C/T	cg14173147	chr9:27528300	MOBKL2B	0.49	8.98	0.38	7.07e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.94	-12.46	-0.5	6.45e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	trans	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg25214090	chr10:38739885	LOC399744	0.56	9.75	0.41	1.54e-20	Corneal astigmatism;
LGG	cis	rs17221829	0.699	rs7118152	chr11:89383654	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.1e-18	Anxiety in major depressive disorder;
LGG	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg19748678	chr4:122722346	EXOSC9	0.6	12.02	0.49	3.66e-29	Type 2 diabetes;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.57e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03264133	chr6:25882463	NA	-0.67	-12.2	-0.49	7.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7975161	0.572	rs7132418	chr12:104603591	C/A	cg25273343	chr12:104657179	TXNRD1	-0.75	-8.25	-0.36	1.71e-15	Toenail selenium levels;
LGG	cis	rs9788682	0.694	rs10851906	chr15:78774676	A/G	cg06917634	chr15:78832804	PSMA4	-0.52	-7.9	-0.34	2.06e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs686320	0.748	rs580933	chr11:65196884	C/G	cg17392047	chr11:65247138	NA	-0.53	-6.8	-0.3	3.22e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg12560992	chr17:57184187	TRIM37	0.54	8.71	0.38	5.38e-17	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.24	0.39	9.05e-19	Diabetic retinopathy;
LGG	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg26597838	chr10:835615	NA	0.61	7.8	0.34	4.03e-14	Eosinophil percentage of granulocytes;
LGG	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg26150922	chr2:100937072	LONRF2	-0.54	-9.45	-0.4	1.68e-19	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg08773314	chr2:239334832	ASB1	0.41	7.9	0.34	2.08e-14	Multiple system atrophy;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.46	0.4	1.54e-19	Longevity;
LGG	cis	rs10493773	0.748	rs12758511	chr1:86165987	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.64	-12.96	-0.52	5.69e-33	Urate levels in overweight individuals;
LGG	cis	rs3096299	0.617	rs2353030	chr16:89405827	C/T	cg06640241	chr16:89574553	SPG7	-0.58	-9.76	-0.41	1.39e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg07308232	chr7:1071921	C7orf50	-0.63	-12.46	-0.5	5.97e-31	Longevity;Endometriosis;
LGG	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg08847533	chr14:75593920	NEK9	0.56	10.31	0.43	1.47e-22	Height;
LGG	cis	rs877282	0.733	rs11253342	chr10:765072	A/G	cg17470449	chr10:769945	NA	0.56	6.83	0.3	2.65e-11	Uric acid levels;
LGG	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg12923728	chr3:195709715	SDHAP1	0.56	9.47	0.4	1.46e-19	Mean corpuscular volume;
LGG	cis	rs3126085	1.000	rs114304428	chr1:152254010	T/C	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.62e-16	Aortic root size;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.75	-0.38	3.9e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21605986	chr5:175788725	KIAA1191	0.47	7.57	0.33	2.06e-13	Cognitive performance;
LGG	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.58e-45	Morning vs. evening chronotype;
LGG	cis	rs7267979	0.932	rs2260997	chr20:25256266	A/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.16	-0.43	4.93e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg15309053	chr8:964076	NA	0.38	7.57	0.33	2.05e-13	Schizophrenia;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg13628971	chr7:2884303	GNA12	-0.47	-9.22	-0.39	1.06e-18	Height;
LGG	cis	rs477692	0.905	rs693402	chr10:131422882	G/A	cg05714579	chr10:131428358	MGMT	0.65	13.7	0.54	4.33e-36	Response to temozolomide;
LGG	cis	rs8016947	0.583	rs12891895	chr14:35827557	A/C	cg03549618	chr14:35838977	NA	0.38	7.81	0.34	3.96e-14	Psoriasis;
LGG	trans	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg26043149	chr18:55253948	FECH	0.95	16.39	0.61	5.89e-48	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10463316	0.817	rs6877498	chr5:150802876	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.2	-0.43	3.54e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs9354308	0.691	rs9445610	chr6:66598938	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.76	-0.3	4.22e-11	Metabolite levels;
LGG	cis	rs7551222	0.752	rs6681905	chr1:204535789	T/G	cg20240347	chr1:204465584	NA	-0.56	-11.19	-0.46	6.59e-26	Schizophrenia;
LGG	cis	rs8180040	0.967	rs4858856	chr3:47565424	G/A	cg27129171	chr3:47204927	SETD2	0.78	14.58	0.56	6.53e-40	Colorectal cancer;
LGG	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.89	0.42	4.67e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg26384229	chr12:38710491	ALG10B	-0.68	-13.46	-0.53	4.53e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12230513	0.938	rs4336160	chr12:55891377	C/T	cg19537932	chr12:55886519	OR6C68	-0.46	-7.42	-0.33	5.47e-13	Contrast sensitivity;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	0.38	6.87	0.3	2.08e-11	Obesity-related traits;
LGG	cis	rs7226408	0.857	rs56331183	chr18:34621913	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	trans	rs34421088	0.532	rs1369368	chr8:11150213	C/A	cg02002194	chr4:3960332	NA	-0.41	-7.27	-0.32	1.53e-12	Neuroticism;
LGG	cis	rs2303319	1.000	rs62197073	chr2:162161388	C/T	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg26446133	chr18:72167187	CNDP2	-0.67	-13.28	-0.53	2.44e-34	Refractive error;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.13	0.39	2.21e-18	Life satisfaction;
LGG	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.38	-0.32	7.19e-13	Neuroticism;
LGG	cis	rs12931792	0.846	rs9924308	chr16:30154740	C/T	cg17640201	chr16:30407289	ZNF48	-0.47	-8.0	-0.35	1.04e-14	Tonsillectomy;
LGG	trans	rs17685	0.712	rs2158867	chr7:75815141	C/A	cg19862616	chr7:65841803	NCRNA00174	1.05	23.69	0.74	7.3e-82	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg05234568	chr11:5960015	NA	-0.68	-11.26	-0.46	3.55e-26	DNA methylation (variation);
LGG	cis	rs12282928	0.759	rs7395503	chr11:48344386	C/T	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.49	-0.37	2.86e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2354432	0.607	rs1530335	chr1:146685288	T/C	cg25205988	chr1:146714368	CHD1L	1.09	9.39	0.4	2.82e-19	Mitochondrial DNA levels;
LGG	cis	rs17039065	0.920	rs1595198	chr4:109472351	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.15	0.32	3.32e-12	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.810	rs7917525	chr10:104246755	C/G	cg05096777	chr10:104283225	SUFU	0.32	7.14	0.31	3.63e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	9.1	0.39	2.78e-18	Schizophrenia;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.54	10.46	0.44	3.98e-23	Prudent dietary pattern;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.37	0.32	8.04e-13	Bipolar disorder;
LGG	cis	rs1059312	0.932	rs4760589	chr12:129284382	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.08	-0.62	4.35e-51	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg16141378	chr3:129829833	LOC729375	0.31	6.95	0.31	1.28e-11	Triglycerides;
LGG	cis	rs7107174	0.901	rs2450136	chr11:77925273	T/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.44	-0.33	5.09e-13	Testicular germ cell tumor;
LGG	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg01448562	chr3:133502909	NA	0.4	6.78	0.3	3.76e-11	Iron status biomarkers;
LGG	cis	rs1355223	1.000	rs2221720	chr11:34754921	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.78	0.3	3.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4774899	1.000	rs11630195	chr15:57294085	T/C	cg08128148	chr15:57256372	TCF12	-0.34	-8.12	-0.35	4.3e-15	Urinary tract infection frequency;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg18402987	chr7:1209562	NA	0.67	9.29	0.4	5.95e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.69	-9.31	-0.4	5.17e-19	Diabetic retinopathy;
LGG	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	5.14e-20	Hypertriglyceridemia;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs4356932	1.000	rs4859415	chr4:76956528	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs1707322	0.964	rs7512395	chr1:46361177	G/A	cg03146154	chr1:46216737	IPP	0.55	10.41	0.44	6.02e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10937275	0.793	rs35376159	chr3:186648929	T/A	cg16751732	chr3:186648392	ST6GAL1	0.72	7.31	0.32	1.16e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8060686	0.641	rs7201742	chr16:68099821	T/G	cg27539214	chr16:67997921	SLC12A4	-0.43	-6.77	-0.3	3.96e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.18e-31	Prudent dietary pattern;
LGG	cis	rs4538187	0.813	rs2302808	chr2:64139834	A/T	cg14150252	chr2:64069583	UGP2	-0.44	-8.91	-0.38	1.18e-17	Systolic blood pressure;
LGG	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg22654517	chr2:96458247	NA	0.34	6.66	0.3	7.77e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11890956	chr21:40555474	PSMG1	-0.96	-19.63	-0.67	7.05e-63	Cognitive function;
LGG	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg20608306	chr11:116969690	SIK3	0.42	13.29	0.53	2.2e-34	Blood protein levels;
LGG	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06481639	chr22:41940642	POLR3H	0.52	7.75	0.34	5.98e-14	Vitiligo;
LGG	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg05623727	chr3:50126028	RBM5	0.36	7.63	0.33	1.32e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg16339924	chr4:17578868	LAP3	0.61	10.45	0.44	4.45e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg10760299	chr15:45669010	GATM	0.4	7.8	0.34	4.07e-14	Homoarginine levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.11.1222938R	chr11:62653851	SLC3A2	-0.46	-6.71	-0.3	5.81e-11	Systemic lupus erythematosus;
LGG	cis	rs8114671	0.869	rs2145559	chr20:33651725	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.4	-0.36	5.49e-16	Height;
LGG	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg14768367	chr16:72042858	DHODH	0.85	8.71	0.38	5.31e-17	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs68170813	0.559	rs12536485	chr7:106978005	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.3	-0.43	1.59e-22	Coronary artery disease;
LGG	cis	rs6456156	0.586	rs2001114	chr6:167486578	A/G	cg07741184	chr6:167504864	NA	0.42	9.51	0.4	1.03e-19	Primary biliary cholangitis;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.21	0.32	2.35e-12	Prudent dietary pattern;
LGG	cis	rs7226408	0.857	rs11081970	chr18:34484766	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1790761	0.967	rs10274	chr11:67202826	G/A	cg00290607	chr11:67383545	NA	-0.47	-8.38	-0.36	6.17e-16	Mean corpuscular volume;
LGG	cis	rs9443189	0.813	rs2748948	chr6:76437994	T/A	cg01950844	chr6:76311363	SENP6	-0.54	-7.08	-0.31	5.22e-12	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26446449	chr12:46661718	SLC38A1	0.45	6.71	0.3	5.76e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs7227917	0.536	rs76932461	chr18:45512167	G/C	cg22195133	chr18:45534586	NA	0.76	7.0	0.31	8.87e-12	Lung cancer in ever smokers;
LGG	cis	rs2307022	0.586	rs4783557	chr16:68403945	T/C	cg07273125	chr16:68295692	NA	0.43	9.51	0.4	1.07e-19	Body mass index;
LGG	cis	rs4771450	0.925	rs9284200	chr13:103986641	A/C	cg02987523	chr13:103978230	NA	-0.33	-7.2	-0.32	2.52e-12	Uric acid levels;
LGG	cis	rs9788682	0.747	rs2568485	chr15:78752114	C/T	cg06917634	chr15:78832804	PSMA4	0.53	8.08	0.35	5.57e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg13010199	chr12:38710504	ALG10B	0.76	16.2	0.6	4.58e-47	Heart rate;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg16359550	chr11:109292809	C11orf87	0.43	8.29	0.36	1.21e-15	Schizophrenia;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-9.54	-0.41	8.35e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.17	-0.32	2.99e-12	Testicular germ cell tumor;
LGG	trans	rs941408	1.000	rs941408	chr19:2814181	C/T	cg19676328	chr12:49525230	TUBA1B	-0.64	-9.97	-0.42	2.46e-21	Total cholesterol levels;
LGG	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	6.67	0.3	7.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg15665833	chr6:26285013	NA	0.36	6.74	0.3	4.7e-11	Educational attainment;
LGG	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg24060327	chr5:131705240	SLC22A5	0.41	6.87	0.3	2.02e-11	Blood metabolite levels;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.39	-7.36	-0.32	8.74e-13	Schizophrenia;
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg24829409	chr8:58192753	C8orf71	-0.63	-8.14	-0.35	3.78e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs3741151	0.686	rs73546735	chr11:73256797	C/T	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs858239	0.508	rs2390754	chr7:23190494	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.69	0.3	6.57e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7166081	1.000	rs12916403	chr15:67591665	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07080220	chr10:102295463	HIF1AN	0.59	10.24	0.43	2.53e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg21535247	chr6:8435926	SLC35B3	-0.86	-12.78	-0.51	3.07e-32	Motion sickness;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg04234412	chr22:24373322	LOC391322	-0.73	-14.89	-0.57	2.89e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg13628971	chr7:2884303	GNA12	0.51	10.08	0.42	9.66e-22	Height;
LGG	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg03342759	chr3:160939853	NMD3	-0.65	-10.75	-0.45	3.2e-24	Parkinson's disease;
LGG	cis	rs16866061	1.000	rs34345163	chr2:225459080	A/G	cg12698349	chr2:225449008	CUL3	0.93	19.03	0.66	4.55e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg25919922	chr13:100150906	NA	0.76	11.24	0.46	4.37e-26	Obesity-related traits;
LGG	cis	rs36051895	0.589	rs10283734	chr9:5217139	A/T	cg02405213	chr9:5042618	JAK2	-0.79	-14.4	-0.56	4.12e-39	Pediatric autoimmune diseases;
LGG	cis	rs3806843	1.000	rs6885319	chr5:140200611	A/C	cg19875535	chr5:140030758	IK	0.5	10.32	0.43	1.27e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg07959490	chr17:80112427	CCDC57	-0.46	-9.15	-0.39	1.82e-18	Life satisfaction;
LGG	trans	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg18187862	chr3:45730750	SACM1L	0.64	10.5	0.44	2.74e-23	Primary sclerosing cholangitis;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg06074448	chr4:187884817	NA	-0.58	-12.83	-0.51	1.93e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-9.55	-0.41	7.27e-20	Menarche (age at onset);
LGG	cis	rs9467160	0.520	rs793671	chr6:24438662	C/T	cg20631270	chr6:24437470	GPLD1	-0.4	-6.77	-0.3	3.86e-11	Liver enzyme levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06023702	chr2:71454313	PAIP2B	0.41	6.77	0.3	3.8e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs4919694	1.000	rs35159404	chr10:104805610	C/A	cg04362960	chr10:104952993	NT5C2	1.07	14.92	0.57	2.17e-41	Arsenic metabolism;
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.46	-0.4	1.53e-19	Neuroticism;
LGG	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4639966	0.836	rs1893029	chr11:118610826	G/T	cg20309703	chr11:118481025	PHLDB1	-0.46	-6.8	-0.3	3.19e-11	Systemic lupus erythematosus;
LGG	cis	rs4356932	1.000	rs6844097	chr4:76950757	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.62e-11	Blood protein levels;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-11.92	-0.48	9.55e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs9309473	1.000	rs13383871	chr2:73631779	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-7.97	-0.35	1.26e-14	Metabolite levels;
LGG	cis	rs71636778	0.543	rs34409791	chr1:27245363	A/G	cg12203394	chr1:27248618	NUDC	0.5	6.65	0.3	8.25e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LGG	cis	rs10421328	0.821	rs2288867	chr19:19765568	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	7.28	0.32	1.46e-12	Parental longevity (combined parental age at death);
LGG	cis	rs9771228	0.585	rs73306623	chr7:32280815	G/A	cg27532318	chr7:32358331	NA	0.53	7.67	0.34	1.02e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs2415984	0.622	rs12434073	chr14:46921265	G/A	cg14871534	chr14:47121158	RPL10L	-0.58	-10.16	-0.43	5.17e-22	Number of children ever born;
LGG	cis	rs3742264	0.656	rs9526128	chr13:46578354	C/T	cg15192986	chr13:46630673	CPB2	-0.36	-6.97	-0.31	1.07e-11	Blood protein levels;
LGG	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.16	0.58	2.02e-42	Platelet count;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07362569	chr17:61921086	SMARCD2	0.52	9.98	0.42	2.32e-21	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg27279351	chr12:120934652	DYNLL1	0.8	13.01	0.52	3.29e-33	High light scatter reticulocyte count;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22618164	chr12:122356400	WDR66	0.37	10.83	0.45	1.66e-24	Mean corpuscular volume;
LGG	trans	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.65	10.11	0.43	7.87e-22	Ulcerative colitis;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg08297393	chr2:100937505	LONRF2	0.46	7.12	0.31	4.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4664308	1.000	rs6759924	chr2:160912747	G/A	cg03641300	chr2:160917029	PLA2R1	-0.85	-17.6	-0.63	1.94e-53	Idiopathic membranous nephropathy;
LGG	cis	rs368123	1.000	rs667538	chr6:160738920	G/T	cg07349212	chr6:160770346	SLC22A3	0.37	7.91	0.35	1.91e-14	Waist circumference;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg04025307	chr7:1156635	C7orf50	0.65	8.42	0.36	4.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.39	0.56	4.32e-39	Tonsillectomy;
LGG	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg03806693	chr22:41940476	POLR3H	-1.01	-17.3	-0.63	4.26e-52	Vitiligo;
LGG	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg26384229	chr12:38710491	ALG10B	-0.76	-15.05	-0.57	5.69e-42	Morning vs. evening chronotype;
LGG	cis	rs11168618	0.967	rs11168619	chr12:48933605	G/C	cg24011408	chr12:48396354	COL2A1	0.46	7.5	0.33	3.31e-13	Adiponectin levels;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.35	-6.83	-0.3	2.63e-11	Bipolar disorder;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg15477097	chr7:44161483	POLD2	-0.32	-6.69	-0.3	6.32e-11	Corneal astigmatism;
LGG	cis	rs877282	0.898	rs12357016	chr10:765675	C/T	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.05e-11	Uric acid levels;
LGG	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg09873164	chr1:152488093	CRCT1	0.6	14.74	0.57	1.3e-40	Hair morphology;
LGG	trans	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs7765175	0.698	rs4945494	chr6:113672212	G/A	cg26552650	chr6:113682475	NA	0.34	7.64	0.33	1.24e-13	Coronary artery calcification;
LGG	cis	rs17453880	0.890	rs12515178	chr5:152039638	G/A	cg10931792	chr5:152022470	NA	0.41	8.88	0.38	1.53e-17	Subjective well-being;
LGG	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg07777115	chr5:623756	CEP72	-0.62	-7.91	-0.35	1.92e-14	Obesity-related traits;
LGG	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	trans	rs10506458	0.688	rs60936040	chr12:63416461	G/A	cg22491629	chr6:157744540	C6orf35	-0.77	-11.8	-0.48	2.88e-28	Hemostatic factors and hematological phenotypes;
LGG	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.2	-0.36	2.3e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9467160	1.000	rs9467166	chr6:24444435	G/A	cg20631270	chr6:24437470	GPLD1	0.53	7.66	0.34	1.12e-13	Liver enzyme levels;
LGG	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg12386194	chr3:101231763	SENP7	0.44	7.66	0.34	1.08e-13	Colorectal cancer;
LGG	cis	rs7587476	0.765	rs2121284	chr2:215656260	T/C	cg04004882	chr2:215674386	BARD1	-0.57	-8.83	-0.38	2.17e-17	Neuroblastoma;
LGG	cis	rs10819861	0.645	rs4078421	chr9:98863169	G/A	cg14508093	chr9:98862825	NA	0.29	6.78	0.3	3.78e-11	Electrocardiographic traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23400208	chr10:60936031	PHYHIPL	0.49	8.11	0.35	4.55e-15	Cognitive performance;
LGG	cis	rs6065	0.529	rs1056626	chr17:4931553	G/T	cg03443944	chr17:4872326	CAMTA2;SPAG7	-0.48	-7.06	-0.31	6.21e-12	Platelet count;
LGG	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg18252515	chr7:66147081	NA	0.44	7.23	0.32	2.07e-12	Aortic root size;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg04166393	chr7:2884313	GNA12	0.46	8.55	0.37	1.79e-16	Height;
LGG	cis	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg17462356	chr17:80056334	FASN	0.45	6.79	0.3	3.38e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs5758511	0.731	rs12158579	chr22:42351289	C/T	cg15128208	chr22:42549153	NA	0.57	9.08	0.39	3.08e-18	Birth weight;
LGG	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.81	0.38	2.53e-17	Colorectal cancer;
LGG	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.78	-15.56	-0.59	3.07e-44	Caffeine consumption;
LGG	cis	rs9362426	0.943	rs242291	chr6:88077083	A/T	cg06087457	chr6:88040249	C6orf162;GJB7	-0.53	-10.27	-0.43	1.97e-22	Depressive episodes in bipolar disorder;
LGG	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs9300255	0.739	rs12824957	chr12:123750228	T/C	cg05973401	chr12:123451056	ABCB9	-0.48	-6.81	-0.3	3.08e-11	Neutrophil percentage of white cells;
LGG	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-8.98	-0.39	6.59e-18	Schizophrenia;
LGG	cis	rs9341835	0.642	rs1723535	chr6:64136886	A/G	cg00787780	chr6:64151745	NA	0.45	8.18	0.36	2.85e-15	Schizophrenia;
LGG	cis	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg09307838	chr4:120376055	NA	-0.48	-8.03	-0.35	8.01e-15	Diastolic blood pressure;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.43	-0.44	5.08e-23	Initial pursuit acceleration;
LGG	cis	rs11190604	1.000	rs2495759	chr10:102320363	C/T	cg07080220	chr10:102295463	HIF1AN	0.72	11.77	0.48	3.75e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg12310025	chr6:25882481	NA	-0.52	-9.86	-0.42	6.23e-21	Height;
LGG	cis	rs9902453	1.000	rs6505152	chr17:28331466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg07460842	chr6:66804631	NA	0.9	14.77	0.57	9.71e-41	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.07	0.55	1.04e-37	Prudent dietary pattern;
LGG	cis	rs7712401	0.645	rs246316	chr5:122266197	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	3.01e-12	Mean platelet volume;
LGG	trans	rs8073060	0.586	rs7217533	chr17:34015876	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg18551225	chr6:44695536	NA	-0.66	-10.87	-0.45	1.1e-24	Total body bone mineral density;
LGG	cis	rs60180747	1.000	rs79350921	chr15:66801937	G/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.63	11.34	0.47	1.83e-26	Testicular germ cell tumor;
LGG	cis	rs7539542	0.556	rs2000331	chr1:202857578	G/T	cg19681188	chr1:202830198	LOC148709	0.53	8.84	0.38	2.03e-17	Mean platelet volume;
LGG	trans	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg26384229	chr12:38710491	ALG10B	0.7	14.2	0.55	2.87e-38	Morning vs. evening chronotype;
LGG	cis	rs2297797	0.660	rs3820667	chr1:109968410	A/C	cg08367326	chr1:110052010	AMIGO1	0.39	8.52	0.37	2.31e-16	Cognitive function;
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.81	-0.3	3.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg24375607	chr4:120327624	NA	0.59	9.64	0.41	3.75e-20	Corneal astigmatism;
LGG	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg17330251	chr7:94953956	PON1	-0.44	-8.47	-0.37	3.35e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs11997175	0.574	rs9642707	chr8:33645789	C/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.15	0.32	3.31e-12	Body mass index;
LGG	cis	rs793571	0.543	rs11854073	chr15:58972995	G/A	cg05156742	chr15:59063176	FAM63B	0.6	9.96	0.42	2.66e-21	Schizophrenia;
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg26150922	chr2:100937072	LONRF2	-0.57	-11.04	-0.46	2.59e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	11.18	0.46	7.6e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6504108	0.624	rs3792694	chr17:46260442	A/G	cg02219949	chr17:45927392	SP6	-0.44	-8.37	-0.36	7.06e-16	Body mass index;
LGG	cis	rs9739070	1	rs9739070	chr12:123771032	A/G	cg00376283	chr12:123451042	ABCB9	0.57	8.76	0.38	3.65e-17	Allergy;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.41	-8.46	-0.37	3.49e-16	Schizophrenia;
LGG	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg25039879	chr17:56429692	SUPT4H1	0.66	9.34	0.4	4.2e-19	Cognitive test performance;
LGG	trans	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs758324	0.797	rs417585	chr5:131327898	A/G	cg06307176	chr5:131281290	NA	-0.49	-7.34	-0.32	9.87e-13	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs3780378	1.000	rs10117591	chr9:5094539	G/A	cg02405213	chr9:5042618	JAK2	-0.48	-8.44	-0.36	4.25e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02976543	chr2:239197607	PER2	-0.48	-6.76	-0.3	4.23e-11	Lung cancer in ever smokers;
LGG	cis	rs3087591	1.000	rs7226006	chr17:29650656	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-14.1	-0.55	8.34e-38	Hip circumference;
LGG	cis	rs10267417	0.603	rs7794070	chr7:19899716	C/T	cg05791153	chr7:19748676	TWISTNB	0.55	7.28	0.32	1.49e-12	Night sleep phenotypes;
LGG	cis	rs757081	0.578	rs7109536	chr11:17255512	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.8	-0.34	4.09e-14	Systolic blood pressure;
LGG	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg03162506	chr22:38580953	NA	0.41	10.18	0.43	4.24e-22	Cutaneous nevi;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.71	-0.34	7.92e-14	Personality dimensions;
LGG	cis	rs9828933	0.766	rs704361	chr3:63883671	T/G	cg17941049	chr3:63904683	ATXN7	-0.72	-7.49	-0.33	3.42e-13	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19872317	chr14:65346686	NA	0.43	6.7	0.3	6.02e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20232748	chr6:109415386	C6orf182;SESN1	0.44	6.86	0.3	2.22e-11	Gut microbiome composition (summer);
LGG	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg01631408	chr1:248437212	OR2T33	-0.55	-10.06	-0.42	1.11e-21	Common traits (Other);
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs990171	1.000	rs6755786	chr2:103048103	C/T	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.05	0.49	2.82e-29	Lung cancer in ever smokers;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs1691799	0.899	rs1168293	chr12:66733904	G/A	cg16791601	chr12:66731901	HELB	-0.64	-15.02	-0.57	8.24e-42	White blood cell count (basophil);
LGG	cis	rs963731	0.522	rs1454225	chr2:39228632	T/G	cg04010122	chr2:39346883	SOS1	-0.78	-6.91	-0.31	1.62e-11	Corticobasal degeneration;
LGG	cis	rs7845219	0.510	rs10113282	chr8:96038252	C/G	cg16049864	chr8:95962084	TP53INP1	-0.32	-6.82	-0.3	2.94e-11	Type 2 diabetes;
LGG	trans	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.39	8.23	0.36	1.92e-15	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs34170300	chr17:56789905	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg16339924	chr4:17578868	LAP3	0.49	8.25	0.36	1.69e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg22432760	chr17:80829718	TBCD	0.41	7.16	0.32	3.25e-12	Breast cancer;
LGG	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg04117972	chr1:227635322	NA	0.72	11.79	0.48	2.96e-28	Major depressive disorder;
LGG	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg06618935	chr21:46677482	NA	-0.46	-8.96	-0.38	8.28e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg06521331	chr12:34319734	NA	0.41	6.67	0.3	7.41e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg06885757	chr1:42089581	HIVEP3	0.61	14.35	0.55	6.81e-39	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.58	0.33	1.94e-13	Schizophrenia;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.98	0.6	4.13e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg19812747	chr11:111475976	SIK2	-0.41	-8.67	-0.37	7.18e-17	Primary sclerosing cholangitis;
LGG	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg06026331	chr20:60912101	LAMA5	0.72	12.02	0.49	3.88e-29	Colorectal cancer;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.28	0.6	1.99e-47	Lymphocyte counts;
LGG	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg03517284	chr6:25882590	NA	-0.61	-11.23	-0.46	4.65e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.66e-12	Bipolar disorder;
LGG	cis	rs10193935	0.901	rs12619348	chr2:42625586	C/T	cg27598129	chr2:42591480	NA	-0.66	-9.92	-0.42	3.55e-21	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12579753	0.956	rs11115039	chr12:82217338	A/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.22e-14	Resting heart rate;
LGG	cis	rs7799006	0.722	rs33981648	chr7:2288669	T/C	cg02951883	chr7:2050386	MAD1L1	-0.41	-7.23	-0.32	1.98e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9814567	0.712	rs4955545	chr3:134332926	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.63	-0.44	9.15e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg09537434	chr19:41945824	ATP5SL	0.93	23.19	0.73	1.65e-79	Height;
LGG	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg26408565	chr15:76604113	ETFA	-0.39	-6.76	-0.3	4.08e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.86e-13	Life satisfaction;
LGG	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs6554196	0.525	rs2192159	chr4:55505529	C/G	cg18836493	chr4:55524333	KIT	-0.43	-8.19	-0.36	2.65e-15	Monocyte count;
LGG	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.87	-0.38	1.64e-17	Retinal vascular caliber;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09217309	chr6:150244204	RAET1G	0.4	7.17	0.32	2.93e-12	Testicular germ cell tumor;
LGG	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg21427119	chr20:30132790	HM13	-0.42	-7.17	-0.32	2.99e-12	Mean corpuscular hemoglobin;
LGG	cis	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.02	-0.49	3.75e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs3796352	0.527	rs11716506	chr3:52944328	C/T	cg04865290	chr3:52927548	TMEM110	-0.46	-7.45	-0.33	4.61e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg11814155	chr7:99998594	ZCWPW1	0.58	8.68	0.37	6.57e-17	Platelet count;
LGG	cis	rs4785763	0.570	rs4785759	chr16:90050880	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.65	-11.72	-0.48	5.72e-28	Melanoma;
LGG	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg07930552	chr6:133119739	C6orf192	0.71	7.72	0.34	7.24e-14	Type 2 diabetes nephropathy;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg26513180	chr16:89883248	FANCA	0.85	9.13	0.39	2.18e-18	Skin colour saturation;
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg00101154	chr16:420108	MRPL28	-0.67	-10.73	-0.45	3.73e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs2587949	0.638	rs2686701	chr3:4192861	T/C	cg16519197	chr3:4211558	NA	-0.35	-7.19	-0.32	2.7e-12	Periodontitis (DPAL);
LGG	cis	rs12472274	0.646	rs34465035	chr2:239114093	C/A	cg17459225	chr2:239074497	NA	0.75	10.93	0.45	6.49e-25	Phospholipid levels (plasma);
LGG	trans	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26979473	chr7:137028389	PTN	0.41	6.66	0.3	7.82e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs853679	0.546	rs34871267	chr6:28364232	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22946670	chr1:154909930	PMVK	0.42	6.98	0.31	1.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3859192	0.561	rs12451547	chr17:38181168	T/C	cg17467752	chr17:38218738	THRA	-0.57	-9.69	-0.41	2.47e-20	White blood cell count;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14893161	chr1:205819251	PM20D1	0.81	18.05	0.64	1.55e-55	Menarche (age at onset);
LGG	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.21	0.39	1.1e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2072732	0.861	rs12409277	chr1:2957600	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.95	-0.38	8.32e-18	Plateletcrit;
LGG	trans	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.46	-0.47	5.98e-27	Platelet distribution width;
LGG	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.56	0.44	1.7e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg20587970	chr11:113659929	NA	-1.07	-16.46	-0.61	3.01e-48	Hip circumference adjusted for BMI;
LGG	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg25811766	chr13:21894605	NA	-0.56	-7.4	-0.33	6.2800000000000005e-13	White matter hyperintensity burden;
LGG	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.71	-9.1	-0.39	2.75e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10751667	0.643	rs6597969	chr11:928843	C/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs3053386	1	rs3053386	chr6:2488337	C/CAA	cg23817096	chr6:1620687	NA	-0.34	-8.25	-0.36	1.68e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4819052	0.840	rs914217	chr21:46698299	A/G	cg06618935	chr21:46677482	NA	-0.53	-9.28	-0.4	6.53e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.97	-0.35	1.21e-14	Menopause (age at onset);
LGG	cis	rs61990749	0.597	rs12887282	chr14:78200585	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg16751781	chr15:78858589	CHRNA5	-0.42	-8.46	-0.37	3.54e-16	Sudden cardiac arrest;
LGG	trans	rs1032833	0.732	rs113603559	chr2:180022064	C/T	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6708331	0.941	rs7595262	chr2:70358997	C/T	cg01613454	chr2:70366299	NA	0.53	9.4	0.4	2.57e-19	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg08885076	chr2:99613938	TSGA10	-0.5	-10.54	-0.44	2.03e-23	Chronic sinus infection;
LGG	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg11764359	chr7:65958608	NA	0.63	10.89	0.45	9.29e-25	Aortic root size;
LGG	cis	rs7106204	1.000	rs7110656	chr11:24216034	G/T	ch.11.24196551F	chr11:24239977	NA	0.95	12.04	0.49	3.04e-29	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs870825	0.616	rs6552801	chr4:185620623	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg15369054	chr17:80825471	TBCD	-0.55	-9.92	-0.42	3.74e-21	Breast cancer;
LGG	cis	rs721917	0.506	rs4320898	chr10:81651078	C/G	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09172817	chr18:9915098	VAPA	0.43	7.16	0.32	3.17e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg26578617	chr4:90757533	SNCA	-0.44	-8.71	-0.38	5.4e-17	Dementia with Lewy bodies;
LGG	cis	rs8062405	0.723	rs35175818	chr16:28608746	A/C	cg07382826	chr16:28625726	SULT1A1	0.4	8.18	0.36	2.72e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.08	-0.42	1.01e-21	Response to antipsychotic treatment;
LGG	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.66e-11	Schizophrenia;
LGG	cis	rs75920871	0.623	rs59097294	chr11:116964437	T/C	cg20608306	chr11:116969690	SIK3	-0.34	-8.02	-0.35	8.83e-15	Subjective well-being;
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4742903	0.967	rs10820600	chr9:106856692	T/C	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg00666640	chr1:248458726	OR2T12	0.62	9.94	0.42	3.25e-21	Common traits (Other);
LGG	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg00376283	chr12:123451042	ABCB9	-0.64	-11.03	-0.46	2.77e-25	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg24829409	chr8:58192753	C8orf71	0.66	9.21	0.39	1.13e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.528	rs6570969	chr6:101233016	T/A	cg09795085	chr6:101329169	ASCC3	0.44	7.06	0.31	6.03e-12	Neuroticism;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.06	0.39	3.56e-18	Alzheimer's disease;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.18e-17	Aortic root size;
LGG	cis	rs2916247	1.000	rs9297902	chr8:93036884	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.35	-0.36	7.73e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6787172	0.702	rs1104288	chr3:157967519	A/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg05182265	chr7:156933206	UBE3C	0.35	7.17	0.32	3.04e-12	Body mass index;
LGG	cis	rs929596	0.639	rs2070959	chr2:234602191	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.57	-0.41	6.46e-20	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg08851530	chr6:28072375	NA	0.84	6.68	0.3	6.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.15e-15	Coronary artery disease;
LGG	cis	rs1620921	0.563	rs10945700	chr6:161266764	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs4330281	0.669	rs6779834	chr3:17668766	G/A	cg20981856	chr3:17787350	NA	0.39	7.45	0.33	4.65e-13	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs9487094	0.626	rs1980591	chr6:109939823	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.74	0.34	6.48e-14	Height;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.46e-13	Lung cancer;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.95	-0.42	2.99e-21	Bipolar disorder;
LGG	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg26384229	chr12:38710491	ALG10B	0.95	21.24	0.7	2.11e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.89	0.38	1.33e-17	Lung cancer in ever smokers;
LGG	cis	rs4731207	0.698	rs12154816	chr7:124478299	G/A	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.57e-14	Cutaneous malignant melanoma;
LGG	cis	rs2290159	0.800	rs59821954	chr3:12687613	T/C	cg23032965	chr3:12705835	RAF1	0.67	9.78	0.41	1.12e-20	Cholesterol, total;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg22968622	chr17:43663579	NA	0.8	15.54	0.59	4.03e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7312933	0.510	rs10880223	chr12:42413443	G/A	cg01943504	chr12:42538901	GXYLT1	-0.54	-9.89	-0.42	4.61e-21	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	0.511	rs16921553	chr8:57979314	T/C	cg02725872	chr8:58115012	NA	-0.72	-9.66	-0.41	2.99e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22654495	chr11:116658782	ZNF259	0.49	7.29	0.32	1.37e-12	Gut microbiome composition (summer);
LGG	trans	rs3206736	0.548	rs73110554	chr7:35066531	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.31	0.32	1.19e-12	Diastolic blood pressure;
LGG	cis	rs2201728	0.677	rs34928642	chr4:100189238	C/T	cg07219303	chr4:100140905	ADH6	-0.37	-6.95	-0.31	1.27e-11	Cardiac Troponin-T levels;
LGG	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg24623649	chr8:11872141	NA	0.29	6.74	0.3	4.7e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.33e-26	Colorectal cancer;
LGG	trans	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg07461501	chr17:79650226	HGS;ARL16	0.36	7.49	0.33	3.47e-13	Obesity-related traits;
LGG	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg08344181	chr3:125677491	NA	-0.88	-8.6	-0.37	1.25e-16	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.91e-101	Cognitive ability;
LGG	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.51	0.63	4.81e-53	Cognitive function;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04368716	chr14:104028314	BAG5;C14orf153	0.4	6.69	0.3	6.47e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg06640241	chr16:89574553	SPG7	0.7	12.22	0.49	6.07e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg16583315	chr14:65563665	MAX	-0.36	-6.82	-0.3	2.82e-11	Obesity-related traits;
LGG	cis	rs368123	1.000	rs667538	chr6:160738920	G/T	cg08303612	chr6:160770090	SLC22A3	0.34	6.76	0.3	4.07e-11	Waist circumference;
LGG	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.3	-6.65	-0.3	8.26e-11	Social autistic-like traits;
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.31	0.4	5.26e-19	Alzheimer's disease;
LGG	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg11366901	chr6:160182831	ACAT2	1.05	16.39	0.61	6.08e-48	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg07332563	chr6:291687	DUSP22	-0.6	-9.9	-0.42	4.46e-21	Menopause (age at onset);
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg02446647	chr6:133562101	EYA4	0.32	7.76	0.34	5.54e-14	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg18681998	chr4:17616180	MED28	0.88	19.98	0.68	1.7600000000000002e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg02153584	chr22:29168773	CCDC117	0.61	9.94	0.42	3.14e-21	Lymphocyte counts;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg13395646	chr4:1353034	KIAA1530	-0.42	-7.24	-0.32	1.9e-12	Obesity-related traits;
LGG	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-18.86	-0.66	2.84e-59	Body mass index;
LGG	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg14675211	chr2:100938903	LONRF2	0.63	11.13	0.46	1.18e-25	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.733	rs1962259	chr11:89380637	G/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.12	-0.39	2.35e-18	Anxiety in major depressive disorder;
LGG	cis	rs11690935	0.959	rs7586207	chr2:172671094	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.32	-0.32	1.08e-12	Schizophrenia;
LGG	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.18	-0.32	2.77e-12	HDL cholesterol;
LGG	trans	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs11630290	0.736	rs6494440	chr15:64145709	C/T	cg12036633	chr15:63758958	NA	0.56	6.88	0.3	1.98e-11	Iris characteristics;
LGG	cis	rs67311347	1.000	rs977652	chr3:40479169	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-21.0	-0.7	2.77e-69	Renal cell carcinoma;
LGG	cis	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg06521331	chr12:34319734	NA	0.55	9.46	0.4	1.61e-19	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs77630998	chr22:32452744	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.47	0.33	4.05e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9596863	0.898	rs4573825	chr13:54324876	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.19	0.32	2.55e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg13482628	chr17:19912719	NA	0.62	12.17	0.49	9.63e-30	Schizophrenia;
LGG	cis	rs7552404	0.824	rs1251077	chr1:76189745	C/G	cg22875332	chr1:76189707	ACADM	-0.58	-10.73	-0.45	3.78e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-10.52	-0.44	2.29e-23	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.85	0.42	6.43e-21	Diabetic retinopathy;
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.08e-15	Aortic root size;
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.14	-0.31	3.64e-12	Life satisfaction;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.86	-0.54	8.44e-37	Tonsillectomy;
LGG	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-11.67	-0.48	8.8e-28	Longevity;Endometriosis;
LGG	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg10760299	chr15:45669010	GATM	0.4	7.64	0.33	1.26e-13	Homoarginine levels;
LGG	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg06026331	chr20:60912101	LAMA5	0.45	8.11	0.35	4.44e-15	Colorectal cancer;
LGG	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.27	0.43	1.98e-22	Retinal vascular caliber;
LGG	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg05535760	chr7:792225	HEATR2	0.81	12.58	0.5	1.95e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs2299587	0.562	rs6586682	chr8:17909323	G/A	cg18067069	chr8:17937731	ASAH1	-0.33	-7.98	-0.35	1.15e-14	Economic and political preferences;
LGG	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg02891314	chr5:179741120	GFPT2	-0.63	-11.66	-0.48	9.72e-28	Height;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.46e-16	Life satisfaction;
LGG	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.12	0.35	4.13e-15	Menarche (age at onset);
LGG	cis	rs3099143	0.803	rs28618274	chr15:77220243	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-9.3	-0.4	5.45e-19	Recalcitrant atopic dermatitis;
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.1	-0.35	5.04e-15	IgG glycosylation;
LGG	cis	rs16976116	0.901	rs28630909	chr15:55500102	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.87	-0.34	2.52e-14	Morning vs. evening chronotype;
LGG	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg25358565	chr5:93447407	FAM172A	1.34	16.26	0.6	2.26e-47	Diabetic retinopathy;
LGG	cis	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs151997	1.000	rs42736	chr5:50244838	G/C	cg06027927	chr5:50259733	NA	0.65	10.71	0.45	4.65e-24	Callous-unemotional behaviour;
LGG	cis	rs7503807	0.515	rs12453880	chr17:78637655	A/G	cg22878693	chr17:78755604	RPTOR	-0.55	-8.91	-0.38	1.22e-17	Obesity;
LGG	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg14664628	chr15:75095509	CSK	-0.51	-8.86	-0.38	1.76e-17	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg06521331	chr12:34319734	NA	0.55	9.79	0.41	1.08e-20	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs738128	chr22:21971010	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs4330281	0.669	rs12634893	chr3:17729692	T/C	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs9783347	0.621	rs2305564	chr11:18317458	T/A	cg03595886	chr11:18357587	GTF2H1	-0.48	-11.7	-0.48	6.88e-28	Pancreatic cancer;
LGG	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg03162506	chr22:38580953	NA	-0.39	-9.87	-0.42	5.59e-21	Cutaneous nevi;
LGG	trans	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.67	-0.34	9.89e-14	Triglycerides;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.51	0.5	3.79e-31	Total body bone mineral density;
LGG	cis	rs10193935	0.901	rs62142596	chr2:42529339	C/T	cg27598129	chr2:42591480	NA	-0.54	-8.17	-0.35	3.03e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg10189774	chr4:17578691	LAP3	0.42	7.41	0.33	5.97e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg08885076	chr2:99613938	TSGA10	-0.54	-9.54	-0.41	8.39e-20	Chronic sinus infection;
LGG	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg05985134	chr18:33552581	C18orf21	0.64	9.96	0.42	2.65e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	32.37	0.83	5.8e-121	Prudent dietary pattern;
LGG	cis	rs6834538	0.637	rs11937201	chr4:113427458	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.43	7.07	0.31	5.63e-12	Free thyroxine concentration;
LGG	cis	rs79146658	1.000	rs79146658	chr2:179786068	T/C	cg17765952	chr2:179737173	CCDC141	0.65	7.31	0.32	1.16e-12	Diastolic blood pressure;
LGG	cis	rs79387448	0.655	rs79091585	chr2:102917243	C/T	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.92	-0.31	1.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	trans	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg16141378	chr3:129829833	LOC729375	0.44	10.37	0.43	8.28e-23	Mood instability;
LGG	cis	rs7582720	0.943	rs72936866	chr2:203787120	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19859486	chr3:45730655	SACM1L	0.42	6.81	0.3	3.13e-11	Cognitive performance;
LGG	cis	rs2274273	0.623	rs1187877	chr14:55495161	T/C	cg04306507	chr14:55594613	LGALS3	-0.43	-10.38	-0.43	7.79e-23	Protein biomarker;
LGG	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18252515	chr7:66147081	NA	-0.4	-6.8	-0.3	3.17e-11	Aortic root size;
LGG	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg09911534	chr15:67153556	NA	0.51	7.0	0.31	9.11e-12	Lung cancer (smoking interaction);
LGG	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg00254258	chr1:3105189	PRDM16	0.73	14.32	0.55	8.96e-39	Migraine;
LGG	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg10840412	chr1:235813424	GNG4	0.53	7.13	0.31	3.77e-12	Bipolar disorder;
LGG	cis	rs9878978	0.722	rs34160306	chr3:2498127	C/A	cg21928760	chr3:2462534	CNTN4	0.35	7.0	0.31	9.06e-12	Blood pressure (smoking interaction);
LGG	cis	rs9309711	0.922	rs13431788	chr2:3482912	G/A	cg10845886	chr2:3471009	TTC15	-0.73	-14.27	-0.55	1.43e-38	Neurofibrillary tangles;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.37	-0.4	3.32e-19	Retinal vascular caliber;
LGG	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg27205649	chr11:78285834	NARS2	0.51	8.82	0.38	2.27e-17	Alzheimer's disease (survival time);
LGG	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg01620082	chr3:125678407	NA	-0.67	-7.4	-0.33	6.2800000000000005e-13	Depression;
LGG	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg18198730	chr1:247681584	NA	0.71	12.32	0.5	2.25e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg05791153	chr7:19748676	TWISTNB	0.74	9.85	0.42	6.51e-21	Thyroid stimulating hormone;
LGG	cis	rs9902453	0.872	rs34698290	chr17:28500465	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.26	0.52	2.99e-34	Coffee consumption (cups per day);
LGG	cis	rs2688419	0.509	rs115374	chr3:23048377	A/G	cg00327796	chr3:23032191	NA	-0.37	-7.04	-0.31	6.9e-12	Type 2 diabetes;
LGG	cis	rs8048589	0.549	rs4781176	chr16:12181080	A/G	cg02910054	chr16:12241554	SNX29	0.42	7.35	0.32	9.32e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.89	-0.34	2.2e-14	Schizophrenia;
LGG	cis	rs10193935	1.000	rs12612527	chr2:42392099	T/C	cg27598129	chr2:42591480	NA	-0.61	-8.71	-0.38	5.22e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12618769	0.625	rs12618524	chr2:99064029	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.56e-17	Bipolar disorder;
LGG	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg14673194	chr17:80132900	CCDC57	-0.46	-8.39	-0.36	5.82e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06873684	chr19:4472059	HDGF2	0.41	6.94	0.31	1.32e-11	Bipolar disorder;
LGG	trans	rs116095464	0.558	rs6962	chr5:256509	G/A	cg09048205	chr5:1608656	LOC728613	-0.51	-8.23	-0.36	1.92e-15	Breast cancer;
LGG	cis	rs477692	1.000	rs553371	chr10:131413676	T/C	cg05714579	chr10:131428358	MGMT	0.57	11.77	0.48	3.64e-28	Response to temozolomide;
LGG	cis	rs4466137	0.830	rs6886695	chr5:82994293	T/A	cg16102102	chr5:83017553	HAPLN1	-0.62	-11.31	-0.47	2.28e-26	Prostate cancer;
LGG	cis	rs9902453	1.000	rs8065059	chr17:28417376	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.07	-0.52	1.83e-33	Coffee consumption (cups per day);
LGG	trans	rs11875185	0.510	rs5007040	chr18:55618641	A/T	cg15513957	chr14:69354734	ACTN1	-0.79	-8.28	-0.36	1.33e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7794364	0.658	rs6965740	chr7:117514840	A/C	cg21880328	chr7:117514017	CTTNBP2	-0.32	-6.75	-0.3	4.43e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg21782813	chr7:2030301	MAD1L1	-0.48	-11.62	-0.48	1.51e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg05697832	chr7:4257050	SDK1	-0.37	-6.69	-0.3	6.62e-11	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LGG	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.39	-0.36	5.99e-16	Alzheimer's disease (survival time);
LGG	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg26874229	chr2:105853672	NA	-0.34	-7.41	-0.33	5.89e-13	Type 2 diabetes;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg05335186	chr13:53173507	NA	0.5	10.39	0.43	7.34e-23	Lewy body disease;
LGG	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg23594656	chr7:65796392	TPST1	-0.38	-8.42	-0.36	4.92e-16	Aortic root size;
LGG	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg01338084	chr22:32026380	PISD	1.45	11.76	0.48	3.94e-28	Age-related hearing impairment;
LGG	cis	rs1977876	1.000	rs1977876	chr1:211702179	C/T	cg01575408	chr1:211752895	SLC30A1	0.52	7.22	0.32	2.15e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs17453880	0.890	rs28842566	chr5:152048590	A/G	cg12297329	chr5:152029980	NA	-0.9	-23.18	-0.73	1.8e-79	Subjective well-being;
LGG	cis	rs3736594	0.513	rs1881396	chr2:27844601	G/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.56	-0.37	1.69e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.83	0.51	1.96e-32	Obesity-related traits;
LGG	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg02002194	chr4:3960332	NA	-0.45	-8.05	-0.35	6.93e-15	Retinal vascular caliber;
LGG	cis	rs6594713	0.921	rs6887482	chr5:112741433	G/T	cg12552261	chr5:112820674	MCC	-0.5	-7.29	-0.32	1.31e-12	Brain cytoarchitecture;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg13736514	chr6:26305472	NA	-0.47	-9.65	-0.41	3.4e-20	Educational attainment;
LGG	cis	rs13260300	0.657	rs1425765	chr8:75485927	G/A	cg22993706	chr8:75542856	NA	0.37	7.05	0.31	6.72e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs13082711	0.513	rs7612102	chr3:27372826	A/G	cg02860705	chr3:27208620	NA	-0.76	-13.92	-0.54	4.87e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	13.53	0.53	2.31e-35	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg19399532	chr1:178512495	C1orf220	0.55	11.54	0.47	2.88e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7192750	0.538	rs8054403	chr16:71990573	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.82	0.45	1.81e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs8114671	0.836	rs2425006	chr20:33571228	T/G	cg07148914	chr20:33460835	GGT7	-0.49	-8.16	-0.35	3.23e-15	Height;
LGG	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg09696939	chr10:60272079	BICC1	-0.39	-7.56	-0.33	2.15e-13	Refractive error;
LGG	cis	rs9359856	0.529	rs72915915	chr6:90430593	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.79	-0.41	1.11e-20	Bipolar disorder;
LGG	cis	rs3106136	0.933	rs34383543	chr4:95163792	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	4.02e-15	Capecitabine sensitivity;
LGG	cis	rs3740540	0.507	rs2362500	chr10:126290431	T/C	cg04949429	chr10:126290192	LHPP	0.62	11.91	0.48	9.97e-29	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs965513	0.524	rs6478413	chr9:100582024	A/G	cg13688889	chr9:100608707	NA	-0.57	-11.08	-0.46	1.88e-25	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs7129220	0.660	rs61878632	chr11:10136032	A/C	cg01453529	chr11:10209919	SBF2	-0.41	-6.66	-0.3	7.75e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs72925845	0.577	rs618842	chr17:76429696	G/A	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg12310025	chr6:25882481	NA	0.72	14.36	0.56	6.26e-39	Blood metabolite levels;
LGG	cis	rs4727027	0.870	rs13237714	chr7:148884083	A/G	cg23583168	chr7:148888333	NA	-0.88	-17.26	-0.63	6.4e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs208520	0.690	rs10944872	chr6:66708239	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.58	0.63	2.18e-53	Exhaled nitric oxide output;
LGG	cis	rs9467160	1.000	rs9295624	chr6:24439600	A/G	cg20631270	chr6:24437470	GPLD1	-0.54	-7.77	-0.34	4.95e-14	Liver enzyme levels;
LGG	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg06360820	chr2:242988706	NA	-0.96	-11.88	-0.48	1.3e-28	Obesity-related traits;
LGG	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.73e-13	Testicular germ cell tumor;
LGG	cis	rs138249	0.902	rs138240	chr22:50564181	A/C	cg07310406	chr22:50524374	MLC1	-0.41	-8.05	-0.35	6.93e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	trans	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg26384229	chr12:38710491	ALG10B	0.64	12.17	0.49	9.22e-30	Morning vs. evening chronotype;
LGG	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.96	0.31	1.14e-11	Myopia (pathological);
LGG	trans	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.91	0.31	1.57e-11	Mean corpuscular volume;
LGG	cis	rs4740619	0.766	rs56401042	chr9:15806573	T/C	cg14451791	chr9:16040625	NA	0.32	8.04	0.35	7.49e-15	Body mass index;
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.76	-0.3	4.1e-11	Bipolar disorder;
LGG	cis	rs7633787	0.571	rs11129106	chr3:23144691	C/T	cg00327796	chr3:23032191	NA	-0.39	-7.31	-0.32	1.17e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.72	0.34	7.29e-14	Schizophrenia;
LGG	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg02820901	chr13:113351484	ATP11A	0.58	6.91	0.31	1.64e-11	Glycated hemoglobin levels;
LGG	cis	rs4742903	0.584	rs56681737	chr9:107006662	T/C	cg14250997	chr9:106856677	SMC2	0.35	7.05	0.31	6.63e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4979906	1.000	rs4979907	chr10:79451969	C/A	cg07817648	chr10:79422355	NA	-0.5	-7.96	-0.35	1.33e-14	Mortality in heart failure;
LGG	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.65	0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.69	-0.66	1.66e-58	Monocyte count;
LGG	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.55	0.56	8.87e-40	Cognitive test performance;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	12.57	0.5	2.17e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9796	0.870	rs7162992	chr15:41290861	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.08	-0.35	5.63e-15	Menopause (age at onset);
LGG	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.07	0.35	6.11e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg04986931	chr22:39850128	NA	0.33	7.54	0.33	2.52e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	15.84	0.59	1.77e-45	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7853377	0.723	rs7047907	chr9:86368660	G/A	cg12437157	chr9:86433764	GKAP1	-0.39	-6.78	-0.3	3.64e-11	Height;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg02127607	chr17:61920694	SMARCD2	-0.4	-6.95	-0.31	1.25e-11	Prudent dietary pattern;
LGG	trans	rs783540	0.967	rs1864699	chr15:83323318	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.41	-7.22	-0.32	2.13e-12	Schizophrenia;
LGG	cis	rs7089973	0.966	rs12772800	chr10:116630962	A/G	cg08188268	chr10:116634841	FAM160B1	0.32	6.65	0.3	8.08e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.28	0.46	3.03e-26	Tonsillectomy;
LGG	cis	rs4954585	0.683	rs4072434	chr2:137014023	C/G	cg05194412	chr2:137003533	NA	0.37	8.07	0.35	6.29e-15	Colorectal cancer;
LGG	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	11.9	0.48	1.13e-28	IgG glycosylation;
LGG	cis	rs17767392	0.595	rs8005925	chr14:71661292	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.06	-0.31	6.22e-12	Mitral valve prolapse;
LGG	cis	rs67311347	0.635	rs73071706	chr3:40288190	C/A	cg13683864	chr3:40499215	RPL14	-0.85	-16.2	-0.6	4.38e-47	Renal cell carcinoma;
LGG	cis	rs9816226	0.618	rs1516728	chr3:185829891	A/T	cg00760338	chr3:185826511	ETV5	0.97	18.73	0.66	1.09e-58	Obesity;Body mass index;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.58	-0.33	1.97e-13	Testicular germ cell tumor;
LGG	cis	rs7586879	1.000	rs11683212	chr2:25120196	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs9486719	1.000	rs12213426	chr6:96896035	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs6142618	0.583	rs6119771	chr20:30770375	G/C	cg00028034	chr20:30779307	TSPYL3	0.34	7.39	0.32	7.09e-13	Inflammatory bowel disease;
LGG	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg25173405	chr17:45401733	C17orf57	0.49	8.48	0.37	2.94e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg02297831	chr4:17616191	MED28	0.5	9.4	0.4	2.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg08621203	chr6:150244597	RAET1G	-0.48	-7.05	-0.31	6.72e-12	Lung cancer;
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg15556689	chr8:8085844	FLJ10661	-0.55	-9.92	-0.42	3.8e-21	Triglycerides;
LGG	cis	rs7236492	0.748	rs79548165	chr18:77183529	C/T	cg15532942	chr18:77220712	NFATC1	0.46	7.18	0.32	2.87e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	9.34	0.4	4.05e-19	Gout;Renal underexcretion gout;
LGG	cis	rs4788570	0.510	rs9931074	chr16:71667680	C/T	cg06353428	chr16:71660113	MARVELD3	1.27	20.82	0.7	1.87e-68	Intelligence (multi-trait analysis);
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.93	-0.42	3.41e-21	Bipolar disorder;
LGG	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg07777115	chr5:623756	CEP72	-0.53	-6.83	-0.3	2.76e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs11105298	0.786	rs10777186	chr12:89921277	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg16482183	chr6:26056742	HIST1H1C	0.75	11.42	0.47	8.86e-27	Iron status biomarkers;
LGG	cis	rs9815354	0.857	rs7652369	chr3:42020973	T/G	cg03022575	chr3:42003672	ULK4	0.65	7.96	0.35	1.31e-14	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.92	0.38	1.1e-17	Neuroticism;
LGG	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg25767906	chr1:53392781	SCP2	0.37	6.9	0.31	1.77e-11	Monocyte count;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.47	0.47	5.73e-27	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.45	-0.33	4.76e-13	Lung cancer;
LGG	cis	rs3816183	1.000	rs893730	chr2:43015366	T/A	cg27299406	chr2:43020013	HAAO	-0.28	-6.83	-0.3	2.69e-11	Hypospadias;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg23758822	chr17:41437982	NA	0.86	15.12	0.58	2.76e-42	Menopause (age at onset);
LGG	cis	rs73416724	1.000	rs111882537	chr6:43366075	C/A	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.98e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg05425664	chr17:57184151	TRIM37	-0.64	-10.11	-0.43	7.9e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg18279126	chr7:2041391	MAD1L1	0.32	6.69	0.3	6.39e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs72781680	0.821	rs116583405	chr2:24208221	T/C	cg08917208	chr2:24149416	ATAD2B	0.66	8.75	0.38	3.9e-17	Lymphocyte counts;
LGG	cis	rs67133203	0.851	rs4768967	chr12:51506328	C/T	cg14688905	chr12:51403056	SLC11A2	0.53	7.61	0.33	1.6e-13	Urinary tract infection frequency;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	9.04	0.39	4.33e-18	Renal function-related traits (BUN);
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.59	0.5	1.9e-31	Obesity-related traits;
LGG	cis	rs13314892	0.881	rs60551165	chr3:69827409	T/C	cg17445875	chr3:69859618	MITF	-0.36	-7.21	-0.32	2.24e-12	QRS complex (12-leadsum);
LGG	cis	rs2905347	0.895	rs2961282	chr7:22640389	C/G	cg18045685	chr7:22629474	NA	-0.73	-15.77	-0.59	3.92e-45	Major depression and alcohol dependence;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg04287289	chr16:89883240	FANCA	0.54	9.91	0.42	3.86e-21	Vitiligo;
LGG	cis	rs10791323	0.569	rs2156680	chr11:133742292	T/G	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg12486710	chr1:178512616	C1orf220	-0.51	-10.65	-0.44	7.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1728785	1.000	rs698717	chr16:68560199	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.96	0.45	5.36e-25	Ulcerative colitis;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg05313129	chr8:58192883	C8orf71	-0.78	-12.44	-0.5	7.84e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13537196	chr9:15553060	C9orf93	0.41	7.12	0.31	4.11e-12	Bipolar disorder;
LGG	trans	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg26043149	chr18:55253948	FECH	0.95	16.14	0.6	8.55e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg09033563	chr22:24373618	LOC391322	-0.51	-8.59	-0.37	1.35e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.55	0.33	2.33e-13	Joint mobility (Beighton score);
LGG	cis	rs12282928	1.000	rs2134554	chr11:48262351	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-7.13	-0.31	3.82e-12	Migraine - clinic-based;
LGG	cis	rs372883	0.624	rs1153286	chr21:30684383	A/G	cg24692254	chr21:30365293	RNF160	-0.62	-11.55	-0.47	2.85e-27	Pancreatic cancer;
LGG	cis	rs2073300	0.609	rs6137951	chr20:23429459	T/C	cg12062639	chr20:23401060	NAPB	0.88	8.14	0.35	3.71e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg18898632	chr2:242989856	NA	-0.87	-10.48	-0.44	3.4e-23	Obesity-related traits;
LGG	cis	rs10487112	0.536	rs7779628	chr7:90007258	T/A	cg03098837	chr7:89748686	DPY19L2P4	-0.49	-7.2	-0.32	2.47e-12	Perceived unattractiveness to mosquitoes;
LGG	trans	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.36	-0.36	7.47e-16	Bladder cancer;
LGG	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg18196295	chr10:418757	DIP2C	0.64	13.12	0.52	1.17e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs11096990	0.855	rs1597722	chr4:39174875	C/T	cg24403649	chr4:39172243	NA	0.45	7.36	0.32	8.29e-13	Cognitive function;
LGG	cis	rs8064299	0.565	rs12453550	chr17:72786086	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	21.81	0.71	4.74e-73	Monocyte count;
LGG	cis	rs34783982	0.510	rs59753611	chr15:89528467	G/A	cg09489435	chr15:89561491	NA	-0.38	-7.16	-0.32	3.13e-12	Squamous cell lung carcinoma;
LGG	trans	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg02002194	chr4:3960332	NA	-0.44	-7.93	-0.35	1.67e-14	Red cell distribution width;
LGG	cis	rs2832191	0.791	rs9983651	chr21:30491227	T/A	cg24692254	chr21:30365293	RNF160	-0.95	-24.11	-0.75	8.15e-84	Dental caries;
LGG	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg21772509	chr8:41503840	NKX6-3	0.54	8.35	0.36	8.13e-16	Type 2 diabetes;
LGG	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg03098644	chr7:100410630	EPHB4	0.46	6.85	0.3	2.44e-11	Other erythrocyte phenotypes;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.56e-18	Alzheimer's disease;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.67	-11.96	-0.49	6.58e-29	Lymphocyte counts;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg13206674	chr6:150067644	NUP43	0.44	7.73	0.34	6.96e-14	Lung cancer;
LGG	cis	rs7572733	0.534	rs700662	chr2:198668751	T/C	cg00792783	chr2:198669748	PLCL1	0.7	11.36	0.47	1.5e-26	Dermatomyositis;
LGG	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg08923054	chr8:41654455	ANK1	-0.77	-12.84	-0.51	1.7e-32	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs3780378	1.000	rs3780378	chr9:5112288	C/T	cg02405213	chr9:5042618	JAK2	-0.47	-8.13	-0.35	3.91e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12995162	chr2:129079641	NA	-0.47	-6.95	-0.31	1.28e-11	Systemic lupus erythematosus;
LGG	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg22920501	chr2:26401640	FAM59B	-0.41	-8.11	-0.35	4.65e-15	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23610841	chr8:30891077	WRN;PURG	0.45	7.51	0.33	3.13e-13	Cognitive performance;
LGG	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg07636037	chr3:49044803	WDR6	1.1	27.79	0.79	9.88e-101	Parkinson's disease;
LGG	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg16141378	chr3:129829833	LOC729375	-0.45	-11.04	-0.46	2.62e-25	Mood instability;
LGG	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg15268244	chr15:77196840	NA	-0.4	-8.25	-0.36	1.64e-15	Blood metabolite levels;
LGG	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.87	-0.42	5.64e-21	Primary sclerosing cholangitis;
LGG	cis	rs7737355	0.812	rs116825489	chr5:131061504	C/T	cg06307176	chr5:131281290	NA	0.51	8.42	0.36	4.88e-16	Life satisfaction;
LGG	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg24397884	chr7:158709396	WDR60	-1.1	-15.46	-0.58	9.12e-44	Height;
LGG	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-6.93	-0.31	1.45e-11	Coronary artery disease;
LGG	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg01262667	chr19:19385393	TM6SF2	0.35	6.78	0.3	3.61e-11	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg15971980	chr6:150254442	NA	-0.46	-8.54	-0.37	2e-16	Lung cancer;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg20887711	chr4:1340912	KIAA1530	0.7	14.47	0.56	1.95e-39	Longevity;
LGG	trans	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg10756647	chr7:56101905	PSPH	0.84	9.88	0.42	5.27e-21	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26220528	chr12:57623348	SHMT2	0.41	6.74	0.3	4.8e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs422249	0.512	rs174546	chr11:61569830	C/T	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	Trans fatty acid levels;
LGG	trans	rs9354308	0.933	rs2802062	chr6:66561973	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.05	0.42	1.27e-21	Metabolite levels;
LGG	cis	rs1519814	1.000	rs7000609	chr8:121106264	C/T	cg22335954	chr8:121166405	COL14A1	0.56	11.75	0.48	4.32e-28	Breast cancer;
LGG	cis	rs17428076	0.872	rs55863868	chr2:172888509	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.82	0.42	8.27e-21	Myopia;
LGG	trans	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg26043149	chr18:55253948	FECH	-0.41	-6.92	-0.31	1.54e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3820068	0.608	rs7514858	chr1:16035246	G/A	cg05660106	chr1:15850417	CASP9	0.76	13.98	0.54	2.79e-37	Systolic blood pressure;
LGG	cis	rs6565189	0.865	rs4500746	chr16:30504344	T/C	cg17640201	chr16:30407289	ZNF48	0.44	6.86	0.3	2.27e-11	Tonsillectomy;
LGG	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11758351	0.500	rs17533076	chr6:26183816	G/A	cg03181300	chr6:26195995	NA	0.88	6.68	0.3	6.88e-11	Gout;Renal underexcretion gout;
LGG	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg17757837	chr7:157058334	UBE3C	0.77	15.63	0.59	1.5e-44	Body mass index;
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.66	-0.34	1.09e-13	Schizophrenia;
LGG	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs3741151	0.773	rs73542976	chr11:73127471	A/G	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22022881	chr2:105853494	NA	-0.37	-7.61	-0.33	1.59e-13	Type 2 diabetes;
LGG	cis	rs975739	0.872	rs1146926	chr13:78365938	A/G	cg07847733	chr13:78271382	SLAIN1	0.38	6.9	0.31	1.72e-11	Hair color;
LGG	cis	rs1620921	0.505	rs2115869	chr6:161207892	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.43	-0.44	4.95e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg09307838	chr4:120376055	NA	0.79	12.98	0.52	4.29e-33	Corneal astigmatism;
LGG	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg01943504	chr12:42538901	GXYLT1	-0.4	-6.73	-0.3	4.97e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg14582100	chr15:45693742	SPATA5L1	-0.4	-6.71	-0.3	5.79e-11	Homoarginine levels;
LGG	trans	rs2270927	0.790	rs4613682	chr5:75576455	G/C	cg13563193	chr19:33072644	PDCD5	0.67	9.72	0.41	1.98e-20	Mean corpuscular volume;
LGG	cis	rs9399135	0.967	rs6910530	chr6:135332770	C/T	cg24558204	chr6:135376177	HBS1L	0.54	9.88	0.42	5.25e-21	Red blood cell count;
LGG	cis	rs72634258	1.000	rs72634258	chr1:8150638	T/C	cg00042356	chr1:8021962	PARK7	0.82	9.8	0.41	9.86e-21	Inflammatory bowel disease;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg21605333	chr4:119757512	SEC24D	1.38	14.22	0.55	2.48e-38	Cannabis dependence symptom count;
LGG	cis	rs1790761	0.803	rs2302264	chr11:67207426	G/A	cg00864171	chr11:67383662	NA	-0.41	-6.77	-0.3	3.95e-11	Mean corpuscular volume;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg24846343	chr22:24311635	DDTL	0.6	12.05	0.49	2.78e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg10756647	chr7:56101905	PSPH	0.47	7.17	0.32	2.95e-12	Corneal structure;
LGG	trans	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.41	0.36	5.05e-16	Mood instability;
LGG	trans	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg25214090	chr10:38739885	LOC399744	0.62	11.17	0.46	8.17e-26	Corneal astigmatism;
LGG	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9513627	1.000	rs9517755	chr13:100168408	C/A	cg25919922	chr13:100150906	NA	0.74	7.81	0.34	3.83e-14	Obesity-related traits;
LGG	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg04539111	chr16:67997858	SLC12A4	-0.4	-6.65	-0.3	8.24e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2276314	0.857	rs28435069	chr18:33628475	A/G	cg05985134	chr18:33552581	C18orf21	0.64	10.18	0.43	4.15e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs11239187	0.530	rs10159760	chr10:45059741	G/T	cg03916630	chr10:45065415	NA	0.33	8.12	0.35	4.34e-15	Body mass index;
LGG	cis	rs6960043	0.905	rs10264723	chr7:15054370	T/C	cg19272540	chr7:15055459	NA	0.34	7.84	0.34	3.17e-14	Type 2 diabetes;
LGG	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg11494091	chr17:61959527	GH2	0.45	6.88	0.3	1.97e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15106226	chr19:11878036	ZNF441	-0.47	-7.34	-0.32	9.38e-13	Pancreatic cancer;
LGG	cis	rs7911264	0.739	rs10786050	chr10:94367230	A/G	cg25093409	chr10:94429542	NA	0.49	9.59	0.41	5.44e-20	Inflammatory bowel disease;
LGG	cis	rs2073300	0.609	rs8183135	chr20:23384284	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6840360	0.967	rs1511170	chr4:152701110	A/G	cg22705602	chr4:152727874	NA	-0.27	-6.73	-0.3	4.89e-11	Intelligence (multi-trait analysis);
LGG	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg02002194	chr4:3960332	NA	-0.48	-8.94	-0.38	9.67e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs4787491	0.729	rs8043883	chr16:30044581	G/A	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	2.94e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg23335576	chr14:104009727	NA	0.42	7.21	0.32	2.31e-12	Reticulocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24334809	chr2:178483498	TTC30A	0.43	7.06	0.31	5.94e-12	Cognitive performance;
LGG	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg27170947	chr2:26402098	FAM59B	0.3	6.83	0.3	2.75e-11	Gut microbiome composition (summer);
LGG	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.37	0.5	1.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg15028436	chr7:37888078	TXNDC3	0.58	9.49	0.4	1.18e-19	Alzheimer's disease (late onset);
LGG	cis	rs714515	0.934	rs7539464	chr1:172359576	T/A	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6988985	0.589	rs6995989	chr8:143985583	C/T	cg10324643	chr8:143916377	GML	0.45	9.3	0.4	5.62e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.39	-0.32	6.74e-13	Blood metabolite levels;
LGG	cis	rs1620921	0.621	rs12194479	chr6:161263485	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08409301	chr19:36359556	APLP1	0.41	6.76	0.3	4.16e-11	Gut microbiome composition (summer);
LGG	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg22875332	chr1:76189707	ACADM	0.58	8.37	0.36	6.73e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02825527	chr7:2087843	MAD1L1	-0.37	-7.35	-0.32	9.24e-13	Neuroticism;
LGG	cis	rs1691799	0.867	rs2172881	chr12:66766039	C/G	cg16791601	chr12:66731901	HELB	-0.67	-15.91	-0.59	8.46e-46	White blood cell count (basophil);
LGG	cis	rs1983891	0.673	rs9381083	chr6:41570250	T/A	cg20194872	chr6:41519635	FOXP4	0.48	8.32	0.36	9.89e-16	Prostate cancer;
LGG	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.87	-0.42	5.77e-21	Morning vs. evening chronotype;
LGG	cis	rs1843834	0.858	rs4674933	chr2:225514923	C/T	cg22455342	chr2:225449267	CUL3	0.62	10.42	0.44	5.41e-23	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg21238619	chr17:78079768	GAA	-0.32	-6.86	-0.3	2.18e-11	Yeast infection;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs972578	1.000	rs2010366	chr22:43381288	T/G	cg01576275	chr22:43409880	NA	-0.24	-6.92	-0.31	1.53e-11	Mean platelet volume;
LGG	cis	rs11711311	0.736	rs2278941	chr3:113350508	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.29	0.5	2.94e-30	IgG glycosylation;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16008616	chr19:20163138	NA	0.4	6.65	0.3	8.03e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg01620082	chr3:125678407	NA	0.62	6.87	0.3	2.12e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.67	-0.3	7.28e-11	Aortic root size;
LGG	cis	rs9611519	1.000	rs9611519	chr22:41613188	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-8.47	-0.37	3.24e-16	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26872475	chr11:119039430	NLRX1	0.47	7.01	0.31	8.48e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12379940	chr13:44947923	SERP2	0.44	6.67	0.3	7.28e-11	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.14	0.35	3.71e-15	Obesity-related traits;
LGG	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg25358565	chr5:93447407	FAM172A	-1.17	-14.05	-0.55	1.31e-37	Diabetic retinopathy;
LGG	cis	rs2415984	0.622	rs17672908	chr14:46934527	T/C	cg14871534	chr14:47121158	RPL10L	-0.59	-10.3	-0.43	1.52e-22	Number of children ever born;
LGG	cis	rs7312933	0.558	rs4768411	chr12:42855390	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.52	-8.32	-0.36	1.01e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.18	-0.36	2.74e-15	Small cell lung carcinoma;
LGG	cis	rs2976388	0.669	rs2976391	chr8:143762724	C/A	cg06565975	chr8:143823917	SLURP1	0.34	8.67	0.37	7.44e-17	Urinary tract infection frequency;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.9	-0.38	1.27e-17	Lung cancer;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg19147804	chr7:1989927	MAD1L1	0.51	9.99	0.42	2.06e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.909	rs2127821	chr4:120394535	T/C	cg09307838	chr4:120376055	NA	0.81	13.56	0.53	1.73e-35	Corneal astigmatism;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg18681998	chr4:17616180	MED28	0.88	19.36	0.67	1.36e-61	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs61935443	0.832	rs11107768	chr12:95274182	A/T	cg21533806	chr12:95267307	NA	-0.5	-6.97	-0.31	1.12e-11	Schizophrenia;
LGG	cis	rs1957429	0.634	rs59000318	chr14:65419473	C/A	cg23373153	chr14:65346875	NA	-0.94	-12.26	-0.5	4.09e-30	Pediatric areal bone mineral density (radius);
LGG	cis	rs13082711	0.834	rs2840088	chr3:27428371	G/A	cg02860705	chr3:27208620	NA	0.75	13.67	0.54	5.53e-36	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg11812906	chr14:75593930	NEK9	0.45	8.28	0.36	1.29e-15	Height;
LGG	cis	rs13260300	1.000	rs746460	chr8:75474529	C/T	cg22993706	chr8:75542856	NA	0.41	8.63	0.37	1.02e-16	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg13010199	chr12:38710504	ALG10B	0.64	12.83	0.51	1.82e-32	Morning vs. evening chronotype;
LGG	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg16701003	chr16:89028210	CBFA2T3	0.52	8.13	0.35	4.1e-15	Social autistic-like traits;
LGG	trans	rs11875185	0.510	rs79062633	chr18:55628875	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg23758822	chr17:41437982	NA	-0.84	-15.29	-0.58	5.26e-43	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs2692947	0.562	rs11693248	chr2:96884553	G/A	cg22654517	chr2:96458247	NA	0.37	7.34	0.32	9.54e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg06121193	chr1:90282411	NA	-0.37	-7.25	-0.32	1.71e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs59336	1.000	rs545076	chr12:115119903	C/T	cg06000530	chr20:30135108	HM13;PSIMCT-1	0.38	6.68	0.3	6.98e-11	Colorectal cancer;
LGG	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg19847130	chr8:10466454	RP1L1	0.35	7.31	0.32	1.16e-12	Neuroticism;
LGG	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg05639522	chr1:247681581	NA	-0.62	-10.53	-0.44	2.23e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.74	0.48	4.93e-28	Rheumatoid arthritis;
LGG	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs4262150	0.727	rs6876403	chr5:151929221	A/G	cg12297329	chr5:152029980	NA	-0.72	-13.82	-0.54	1.28e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs10771431	0.810	rs10771418	chr12:9358995	A/G	cg00504896	chr12:9437009	LOC642846	-0.51	-10.07	-0.42	1.1e-21	Breast size;
LGG	cis	rs1018836	0.828	rs12547016	chr8:91563847	T/C	cg16814680	chr8:91681699	NA	-0.73	-13.25	-0.52	3.29e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg27426351	chr10:43362370	NA	0.59	8.34	0.36	8.64e-16	Blood protein levels;
LGG	cis	rs12493885	0.697	rs55955923	chr3:153660054	G/A	cg12800244	chr3:153838788	SGEF	-0.74	-8.21	-0.36	2.3e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.08	-0.31	5.55e-12	Lung cancer;
LGG	cis	rs8133932	0.736	rs2839030	chr21:47292007	A/C	cg11214348	chr21:47283868	PCBP3	0.45	8.02	0.35	8.98e-15	Schizophrenia;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.94	0.35	1.58e-14	Prostate cancer;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg19168338	chr16:4465731	CORO7	-0.79	-15.03	-0.57	7.41e-42	Schizophrenia;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.71	14.84	0.57	5.12e-41	Obesity-related traits;
LGG	cis	rs12949688	0.538	rs3883321	chr17:55804006	C/G	cg12582317	chr17:55822272	NA	0.4	9.46	0.4	1.53e-19	Schizophrenia;
LGG	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.27	0.43	1.93e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7572644	0.699	rs12465000	chr2:28199424	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.66	-0.3	7.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg00599393	chr8:22457479	C8orf58	-0.44	-8.01	-0.35	9.64e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg10852096	chr15:79043040	NA	-0.29	-8.41	-0.36	5.02e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg17158414	chr2:27665306	KRTCAP3	0.3	7.71	0.34	8e-14	Total body bone mineral density;
LGG	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg03474202	chr17:45855739	NA	-0.26	-7.78	-0.34	4.9e-14	IgG glycosylation;
LGG	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-15.8	-0.59	2.62e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.87	0.57	3.76e-41	Post bronchodilator FEV1;
LGG	cis	rs6546550	0.935	rs3214007	chr2:70098808	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.18	-0.36	2.81e-15	Prevalent atrial fibrillation;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.9	-0.38	1.27e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.9	-0.34	2.05e-14	IgG glycosylation;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg06074448	chr4:187884817	NA	0.59	12.94	0.52	6.47e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2834081	0.536	rs11702285	chr21:34474294	G/A	cg00274965	chr21:34405681	NA	0.26	7.23	0.32	2e-12	Sum eosinophil basophil counts;
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg02549819	chr16:58548995	SETD6	1.46	14.02	0.55	1.76e-37	Schizophrenia;
LGG	trans	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg06521331	chr12:34319734	NA	0.44	7.85	0.34	2.89e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1659258	0.568	rs1713941	chr2:88629360	C/T	cg00685853	chr2:88648947	NA	-0.44	-6.83	-0.3	2.74e-11	Visceral fat;
LGG	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg15704280	chr7:45808275	SEPT13	0.73	10.19	0.43	3.94e-22	Axial length;
LGG	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.3	0.55	1.06e-38	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg13147721	chr7:65941812	NA	0.84	10.18	0.43	4.21e-22	Diabetic kidney disease;
LGG	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.86	-0.59	1.49e-45	Glomerular filtration rate (creatinine);
LGG	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg26384229	chr12:38710491	ALG10B	0.8	15.92	0.59	7.65e-46	Morning vs. evening chronotype;
LGG	cis	rs6120849	0.754	rs13433216	chr20:33616301	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs1256531	0.661	rs61989977	chr14:65864452	A/G	cg15999311	chr14:65749247	NA	0.85	6.91	0.31	1.56e-11	Conduct disorder (symptom count);
LGG	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	9.83	0.42	7.63e-21	Height;
LGG	trans	rs2562456	0.833	rs74711277	chr19:21505443	C/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7927592	0.731	rs643609	chr11:68241833	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-10.47	-0.44	3.53e-23	Total body bone mineral density;
LGG	cis	rs2018055	0.871	rs13192130	chr6:117808200	C/T	cg14611402	chr6:117803162	DCBLD1	0.3	8.42	0.36	4.89e-16	Diastolic blood pressure;
LGG	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-12.6	-0.51	1.65e-31	Diastolic blood pressure;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg11245990	chr11:68621969	NA	0.39	8.35	0.36	8.23e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16199879	chr14:58667190	ACTR10	0.45	7.35	0.32	9.18e-13	Cognitive performance;
LGG	cis	rs4700695	0.668	rs36837	chr5:65480007	C/A	cg21114390	chr5:65439923	SFRS12	-0.68	-9.91	-0.42	3.93e-21	Facial morphology (factor 19);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.6	-9.84	-0.42	6.89e-21	Longevity;
LGG	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg00325661	chr8:49890786	NA	0.42	7.22	0.32	2.22e-12	Sudden cardiac arrest;
LGG	cis	rs7727544	0.716	rs2089855	chr5:131573529	A/G	cg07395648	chr5:131743802	NA	-0.42	-9.02	-0.39	5.08e-18	Blood metabolite levels;
LGG	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.62	-0.67	7.91e-63	Height;
LGG	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg23625390	chr15:77176239	SCAPER	-0.4	-7.56	-0.33	2.22e-13	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02686769	chr12:106695932	TCP11L2	0.49	7.48	0.33	3.83e-13	Gut microbiome composition (summer);
LGG	trans	rs36715	0.953	rs36700	chr5:127551273	A/G	cg16011800	chr17:1958478	HIC1	-0.46	-6.8	-0.3	3.15e-11	Breast cancer;
LGG	cis	rs13382275	0.915	rs28393260	chr2:972978	A/G	cg10902693	chr2:875509	NA	0.42	6.95	0.31	1.28e-11	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9902453	0.845	rs12601963	chr17:28246358	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.63	0.54	8.52e-36	Coffee consumption (cups per day);
LGG	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg24699146	chr1:24152579	HMGCL	0.25	7.3	0.32	1.24e-12	Immature fraction of reticulocytes;
LGG	cis	rs2236293	0.965	rs10814281	chr9:35837515	G/A	cg12876594	chr9:35791798	NPR2	0.39	7.34	0.32	9.51e-13	Blood protein levels;
LGG	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg04450456	chr4:17643702	FAM184B	0.34	7.51	0.33	3.07e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4774899	1.000	rs2414494	chr15:57441738	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.36	-0.32	8.22e-13	Urinary tract infection frequency;
LGG	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg22906224	chr7:99728672	NA	-0.58	-9.5	-0.4	1.15e-19	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.2	-0.32	2.45e-12	Lung cancer;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.16	-0.35	3.1e-15	Personality dimensions;
LGG	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg12081754	chr8:22256438	SLC39A14	0.72	13.78	0.54	1.86e-36	Verbal declarative memory;
LGG	cis	rs7602441	0.521	rs78567942	chr2:14767845	C/A	cg06545361	chr2:14773388	FAM84A	0.82	7.56	0.33	2.21e-13	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.47	-0.33	4.16e-13	Restless legs syndrome;
LGG	cis	rs853679	0.517	rs9368555	chr6:28108967	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.59	-0.33	1.78e-13	Depression;
LGG	cis	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.0	-0.35	1.01e-14	Ulcerative colitis;
LGG	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg25706552	chr1:244017396	NA	0.5	7.08	0.31	5.36e-12	RR interval (heart rate);
LGG	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg00543991	chr22:32367038	NA	0.78	8.58	0.37	1.46e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg12856521	chr11:46389249	DGKZ	0.87	14.49	0.56	1.75e-39	Crohn's disease;
LGG	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg16486109	chr11:613632	IRF7	0.42	7.16	0.32	3.15e-12	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03258011	chr17:54857409	NA	0.48	7.78	0.34	4.88e-14	Gut microbiome composition (summer);
LGG	cis	rs17125944	1.000	rs17125944	chr14:53400629	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-7.73	-0.34	6.94e-14	Alzheimer's disease (late onset);
LGG	cis	rs72781680	0.821	rs72796325	chr2:24134537	G/A	cg08917208	chr2:24149416	ATAD2B	0.66	8.67	0.37	7.33e-17	Lymphocyte counts;
LGG	cis	rs7928758	0.562	rs1561613	chr11:134294571	A/T	cg15243474	chr11:134282918	B3GAT1	-0.91	-10.96	-0.45	5.33e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg18681998	chr4:17616180	MED28	0.73	15.04	0.57	6.28e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-8.83	-0.38	2.1e-17	Height;
LGG	cis	rs9815354	0.812	rs73081383	chr3:41920614	A/G	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.41	0.33	6.17e-13	Homoarginine levels;
LGG	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg11247378	chr22:39784982	NA	-0.31	-9.03	-0.39	4.76e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.5e-25	Corneal astigmatism;
LGG	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.41	-0.33	5.87e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg19773385	chr1:10388646	KIF1B	0.48	10.19	0.43	3.79e-22	Hepatocellular carcinoma;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13129888	chr1:28415099	EYA3	-0.47	-6.84	-0.3	2.59e-11	Systemic lupus erythematosus;
LGG	cis	rs2463822	0.925	rs1881535	chr11:62121623	C/T	cg06239285	chr11:62104954	ASRGL1	1.15	15.87	0.59	1.39e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6547741	1.000	rs1972669	chr2:27767107	T/G	cg27432699	chr2:27873401	GPN1	0.69	14.03	0.55	1.66e-37	Oral cavity cancer;
LGG	cis	rs7241530	0.595	rs4799016	chr18:75913929	T/C	cg14642773	chr18:75888474	NA	0.43	8.18	0.36	2.76e-15	Educational attainment (years of education);
LGG	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.42	-0.33	5.7e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs7927771	0.524	rs1563821	chr11:47756568	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.09	0.46	1.73e-25	Subjective well-being;
LGG	cis	rs9378357	0.702	rs4521639	chr6:3280600	C/G	cg08754725	chr6:3293098	SLC22A23	0.56	6.84	0.3	2.46e-11	Obesity-related traits;
LGG	cis	rs12210905	1.000	rs72843641	chr6:27203335	C/G	cg15325629	chr6:28072465	NA	0.77	6.67	0.3	7.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg00142150	chr22:38071001	LGALS1	0.65	10.29	0.43	1.63e-22	Fat distribution (HIV);
LGG	cis	rs10266483	1.000	rs1960321	chr7:63731284	T/C	cg24201672	chr7:64023550	ZNF680	-0.45	-7.12	-0.31	4.13e-12	Response to statin therapy;
LGG	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs78905543	0.967	rs4242388	chr8:22932711	T/C	cg16861508	chr8:22926909	TNFRSF10B	0.37	7.13	0.31	3.89e-12	Mean corpuscular volume;
LGG	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.96	-0.35	1.37e-14	HDL cholesterol;
LGG	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg00579200	chr11:133705235	NA	-0.59	-11.18	-0.46	7.37e-26	Childhood ear infection;
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.79	-0.41	1.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.16e-19	Bone mineral density;
LGG	cis	rs2243480	1.000	rs313813	chr7:65503500	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19171272	chr22:38449367	NA	-0.55	-10.77	-0.45	2.69e-24	Glioblastoma;Glioma;
LGG	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg08344181	chr3:125677491	NA	-0.64	-7.59	-0.33	1.81e-13	Depression;
LGG	cis	rs4566357	1.000	rs4566357	chr2:227922015	C/T	cg11843606	chr2:227700838	RHBDD1	0.41	7.24	0.32	1.92e-12	Coronary artery disease;
LGG	trans	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.42	-0.36	4.82e-16	Lung cancer in ever smokers;
LGG	cis	rs867371	1.000	rs6495643	chr15:82479254	C/G	cg00614314	chr15:82944287	LOC80154	0.59	9.58	0.41	5.98e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9425766	0.640	rs2295366	chr1:173825692	A/C	cg06124660	chr1:173389066	NA	-0.42	-7.51	-0.33	3.15e-13	Life satisfaction;
LGG	cis	rs9948	0.655	rs75763821	chr2:97392694	G/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.62e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg14074117	chr16:1909714	C16orf73	-0.54	-8.02	-0.35	8.53e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9815354	1.000	rs9864217	chr3:41762206	G/A	cg03022575	chr3:42003672	ULK4	0.67	8.47	0.37	3.21e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6062302	0.522	rs3810492	chr20:62219740	G/A	cg16989086	chr20:62203971	PRIC285	0.49	7.1	0.31	4.78e-12	Glioblastoma;
LGG	cis	rs17453880	0.963	rs57358310	chr5:151948242	A/T	cg12297329	chr5:152029980	NA	-0.83	-19.39	-0.67	9.44e-62	Subjective well-being;
LGG	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	14.04	0.55	1.44e-37	Cognitive test performance;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08753297	chr6:56716612	DST	0.42	7.15	0.32	3.31e-12	Bipolar disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.48	-7.15	-0.32	3.4e-12	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	10.82	0.45	1.73e-24	Obesity-related traits;
LGG	cis	rs3820928	0.967	rs4675114	chr2:227768362	C/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.16	-0.32	3.23e-12	Pulmonary function;
LGG	cis	rs10895140	0.756	rs2513181	chr11:101492958	A/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs4665809	1.000	rs2053367	chr2:26293413	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.26e-14	Gut microbiome composition (summer);
LGG	cis	rs1109114	0.934	rs34564665	chr5:148604890	G/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.42	-0.58	1.35e-43	Body mass index;
LGG	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs12493885	0.628	rs61790906	chr3:153653953	T/G	cg17054900	chr3:154042577	DHX36	-0.55	-6.98	-0.31	1.02e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg17050807	chr22:42548356	NA	-0.33	-6.69	-0.3	6.61e-11	Cognitive function;
LGG	cis	rs2247341	0.965	rs2854917	chr4:1720550	T/C	cg07465881	chr4:1713556	SLBP	-0.46	-7.38	-0.32	7.27e-13	Hip circumference adjusted for BMI;Height;
LGG	cis	rs35771425	0.529	rs1890326	chr1:211376211	C/A	cg10512769	chr1:211675356	NA	-0.62	-7.62	-0.33	1.46e-13	Educational attainment (years of education);
LGG	cis	rs61990749	0.686	rs11159288	chr14:78216972	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.3	0.32	1.28e-12	Fibroblast growth factor basic levels;
LGG	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg08994789	chr17:28903642	LRRC37B2	0.72	9.23	0.39	9.77e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg27624424	chr6:160112604	SOD2	0.66	9.82	0.42	8.74e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs2933343	0.729	rs813732	chr3:128619357	C/T	cg25356066	chr3:128598488	ACAD9	0.46	6.75	0.3	4.34e-11	IgG glycosylation;
LGG	cis	rs2133450	0.935	rs12637466	chr3:7321909	C/T	cg19930620	chr3:7340148	GRM7	-0.38	-8.44	-0.37	4.11e-16	Early response to risperidone in schizophrenia;
LGG	trans	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg06521331	chr12:34319734	NA	0.51	9.35	0.4	3.85e-19	Bladder cancer;
LGG	cis	rs1941023	0.584	rs2233253	chr11:60157166	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-8.94	-0.38	9.33e-18	Congenital heart disease (maternal effect);
LGG	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	16.98	0.62	1.27e-50	Smoking behavior;
LGG	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg27165867	chr14:105738592	BRF1	-0.49	-8.22	-0.36	2.02e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2549003	1.000	rs7734334	chr5:131815004	C/A	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.93e-22	Asthma (sex interaction);
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.33	-0.32	1e-12	Prostate cancer;
LGG	cis	rs9309473	1.000	rs2056486	chr2:73717567	G/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.65	-0.33	1.19e-13	Metabolite levels;
LGG	cis	rs11718455	0.883	rs4682926	chr3:44006170	C/T	cg21419209	chr3:44054225	NA	-0.4	-6.72	-0.3	5.35e-11	Coronary artery disease;
LGG	cis	rs6540556	0.723	rs12034758	chr1:209920545	G/A	cg05527609	chr1:210001259	C1orf107	-0.52	-6.82	-0.3	2.88e-11	Red blood cell count;
LGG	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg07120314	chr15:79043507	NA	0.37	6.65	0.3	8.36e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18099408	chr3:52552593	STAB1	-0.37	-7.13	-0.31	4.01e-12	Bipolar disorder;
LGG	cis	rs6963495	0.818	rs6957192	chr7:105150255	A/C	cg19920283	chr7:105172520	RINT1	-0.55	-7.21	-0.32	2.25e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs910187	0.605	rs3787239	chr20:45802729	T/C	cg27589058	chr20:45804311	EYA2	-0.37	-9.55	-0.41	7.5599999999999994e-20	Migraine;
LGG	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.6e-29	Total body bone mineral density;
LGG	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Body mass index;
LGG	cis	rs11690935	0.549	rs796839	chr2:172916214	A/C	cg13550731	chr2:172543902	DYNC1I2	0.68	13.28	0.53	2.43e-34	Schizophrenia;
LGG	cis	rs7598759	0.617	rs6437017	chr2:232327584	C/A	cg19187155	chr2:232395269	NMUR1	0.42	7.57	0.33	2.09e-13	Noise-induced hearing loss;
LGG	cis	rs7953508	0.506	rs3782415	chr12:93967755	T/C	cg18151635	chr12:93972918	NA	-0.56	-10.53	-0.44	2.1e-23	Pubertal anthropometrics;
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg05335186	chr13:53173507	NA	0.4	8.04	0.35	7.3e-15	Lewy body disease;
LGG	trans	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.73	0.3	4.97e-11	Neuroticism;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13732083	chr21:47605072	C21orf56	0.47	7.98	0.35	1.16e-14	Testicular germ cell tumor;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.17e-14	Menopause (age at onset);
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10743315	0.778	rs7399032	chr12:19371546	T/C	cg02471346	chr12:19282374	PLEKHA5	-0.55	-7.89	-0.34	2.18e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg27661571	chr11:113659931	NA	-0.69	-9.52	-0.4	9.92e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1620921	0.625	rs11753537	chr6:161267022	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4891159	0.548	rs948646	chr18:74118168	G/A	cg24786174	chr18:74118243	ZNF516	0.69	17.47	0.63	7.38e-53	Longevity;
LGG	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.75	0.61	1.36e-49	Anterior chamber depth;
LGG	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg24375607	chr4:120327624	NA	0.58	9.26	0.4	7.66e-19	Corneal astigmatism;
LGG	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.88	-0.3	1.97e-11	Blood metabolite levels;
LGG	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2117029	0.965	rs2293446	chr12:49412709	G/A	cg24176009	chr12:49580217	TUBA1A	0.44	7.93	0.35	1.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.47	-8.16	-0.35	3.15e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg22732515	chr19:44031385	ETHE1	0.54	9.4	0.4	2.51e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg05896524	chr21:47604654	C21orf56	-0.59	-10.6	-0.44	1.15e-23	Testicular germ cell tumor;
LGG	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg17971929	chr21:40555470	PSMG1	-0.67	-12.32	-0.5	2.3e-30	Cognitive function;
LGG	cis	rs6500637	0.686	rs8048701	chr16:4913537	T/A	cg04440724	chr16:4920505	UBN1	-0.68	-13.29	-0.53	2.35e-34	Cancer;
LGG	cis	rs727505	0.954	rs1009450	chr7:124628723	C/G	cg23710748	chr7:124431027	NA	-0.49	-9.19	-0.39	1.31e-18	Lewy body disease;
LGG	cis	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs12210905	1.000	rs72843640	chr6:27202093	T/A	cg15325629	chr6:28072465	NA	0.77	6.67	0.3	7.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4808199	0.895	rs10421505	chr19:19459554	C/T	cg03709012	chr19:19516395	GATAD2A	0.93	14.9	0.57	2.7e-41	Nonalcoholic fatty liver disease;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7312774	0.618	rs11612483	chr12:107346884	A/G	cg16260113	chr12:107380972	MTERFD3	0.95	8.77	0.38	3.53e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs7998202	0.667	rs282575	chr13:113359524	G/C	cg17218041	chr13:113365319	ATP11A	-0.42	-6.95	-0.31	1.28e-11	Glycated hemoglobin levels;
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg14668632	chr7:2872130	GNA12	-0.36	-7.36	-0.32	8.33e-13	Height;
LGG	cis	rs4774899	0.934	rs12912392	chr15:57489503	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.78	-0.3	3.59e-11	Urinary tract infection frequency;
LGG	cis	rs9815354	1.000	rs6599170	chr3:41772718	C/G	cg03022575	chr3:42003672	ULK4	0.6	7.77	0.34	5.02e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2535633	0.631	rs2710314	chr3:52969128	T/C	cg11645453	chr3:52864694	ITIH4	-0.49	-8.05	-0.35	7.16e-15	Body mass index;
LGG	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	21.94	0.71	1.08e-73	Platelet count;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg05234568	chr11:5960015	NA	-0.68	-12.24	-0.49	4.72e-30	DNA methylation (variation);
LGG	cis	rs72781680	0.821	rs72790329	chr2:24129277	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.62	0.37	1.05e-16	Lymphocyte counts;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.49	-0.37	2.93e-16	Menopause (age at onset);
LGG	trans	rs7777677	0.925	rs4726542	chr7:142367013	G/T	cg18540325	chr9:33795118	PRSS3	-0.42	-7.18	-0.32	2.86e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs283228	0.959	rs2518341	chr6:101770755	G/A	cg27451362	chr6:101846650	GRIK2	0.53	8.89	0.38	1.32e-17	Coenzyme Q10 levels;
LGG	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg05793240	chr7:2802953	GNA12	0.31	7.36	0.32	8.36e-13	Height;
LGG	cis	rs7793919	0.691	rs4077986	chr7:4766676	A/G	cg09789173	chr7:4769017	FOXK1	0.72	14.49	0.56	1.68e-39	Mosquito bite size;
LGG	cis	rs2373794	0.884	rs4952490	chr2:40372704	C/T	cg17740179	chr2:40377776	SLC8A1	0.88	18.59	0.65	5.22e-58	Asthma;
LGG	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg24253500	chr15:84953950	NA	0.58	10.43	0.44	4.94e-23	Schizophrenia;
LGG	cis	rs1451375	0.657	rs7802148	chr7:50648284	T/C	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs1620921	0.594	rs9365215	chr6:161268788	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.86e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg16270222	chr17:41446396	NA	-0.3	-7.14	-0.31	3.67e-12	Menopause (age at onset);
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg22907277	chr7:1156413	C7orf50	0.41	7.08	0.31	5.26e-12	Longevity;Endometriosis;
LGG	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs526231	0.511	rs3910557	chr5:102350471	T/A	cg23492399	chr5:102201601	PAM	-0.56	-8.38	-0.36	6.52e-16	Primary biliary cholangitis;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.73	-0.48	5.31e-28	Personality dimensions;
LGG	cis	rs13102973	0.640	rs13113331	chr4:135838729	C/T	cg14419869	chr4:135874104	NA	0.51	9.51	0.4	1.01e-19	Subjective well-being;
LGG	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg07382826	chr16:28625726	SULT1A1	0.41	8.92	0.38	1.09e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2275620	0.903	rs1341163	chr10:96810552	T/C	cg09036531	chr10:96991505	NA	-0.4	-7.19	-0.32	2.6e-12	Gout;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.0	-0.31	8.77e-12	Vitiligo;
LGG	cis	rs13191362	1.000	rs4260737	chr6:163137746	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.45	0.5	6.62e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06481639	chr22:41940642	POLR3H	0.58	8.05	0.35	6.85e-15	Vitiligo;
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg02297831	chr4:17616191	MED28	0.51	9.3	0.4	5.6e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2074193	0.627	rs215394	chr12:47765869	A/T	cg02516419	chr12:47771422	NA	-0.72	-10.6	-0.44	1.16e-23	Migraine with aura;
LGG	cis	rs1372520	0.684	rs2619347	chr4:90745770	G/A	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.47	0.47	5.48e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg25214090	chr10:38739885	LOC399744	0.56	10.31	0.43	1.38e-22	Corneal astigmatism;
LGG	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg18196295	chr10:418757	DIP2C	-0.43	-7.96	-0.35	1.34e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg21518248	chr2:162101506	NA	0.24	7.35	0.32	8.79e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs262150	0.851	rs2730249	chr7:158767628	A/G	cg19418458	chr7:158789849	NA	0.46	9.47	0.4	1.39e-19	Facial morphology (factor 20);
LGG	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg17211192	chr8:82754475	SNX16	-0.74	-11.47	-0.47	5.52e-27	Diastolic blood pressure;
LGG	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.09	0.57	3.9e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs7312774	0.748	rs12320535	chr12:107295813	T/C	cg16260113	chr12:107380972	MTERFD3	0.63	6.71	0.3	5.75e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg26850624	chr5:429559	AHRR	-0.38	-8.41	-0.36	5.04e-16	Cystic fibrosis severity;
LGG	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg07460842	chr6:66804631	NA	0.57	9.51	0.4	1.05e-19	Metabolite levels;
LGG	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	3.94e-11	Parkinson's disease;
LGG	cis	rs7766436	0.767	rs7757005	chr6:22613847	G/A	cg13666174	chr6:22585274	NA	-0.37	-8.4	-0.36	5.47e-16	Coronary artery disease;
LGG	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs28374715	0.662	rs10851403	chr15:41466087	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.0	-17.51	-0.63	4.92e-53	Ulcerative colitis;
LGG	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03517284	chr6:25882590	NA	-0.67	-12.7	-0.51	6.38e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2241941	0.840	rs72927519	chr11:20628407	C/G	cg05572763	chr11:20631898	SLC6A5	-0.48	-8.87	-0.38	1.64e-17	Obesity-related traits;
LGG	cis	rs8017423	0.935	rs59179255	chr14:90691773	A/C	cg04374321	chr14:90722782	PSMC1	0.87	18.59	0.65	4.76e-58	Mortality in heart failure;
LGG	cis	rs9308433	0.529	rs10465697	chr1:214499948	T/C	cg06198575	chr1:214491504	SMYD2	0.51	7.79	0.34	4.59e-14	IgG glycosylation;
LGG	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg10494973	chr17:80897199	TBCD	-0.42	-7.42	-0.33	5.66e-13	Breast cancer;
LGG	trans	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg27661571	chr11:113659931	NA	-0.73	-9.78	-0.41	1.16e-20	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg08847335	chr10:891726	LARP4B	-0.5	-8.94	-0.38	9.6e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs4604732	0.504	rs4634945	chr1:247636015	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.43	-7.02	-0.31	7.85e-12	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg01028140	chr2:1542097	TPO	-0.57	-8.33	-0.36	9.49e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg25237894	chr2:233734115	C2orf82	-0.66	-12.43	-0.5	7.94e-31	Coronary artery disease;
LGG	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs7267979	0.966	rs2261795	chr20:25263136	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	3.15e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1793639	0.967	rs1790172	chr11:131935863	T/G	cg13908476	chr11:131942942	NTM	0.44	9.32	0.4	4.72e-19	Myopia;
LGG	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs6732160	0.845	rs6752507	chr2:73385158	C/G	cg01422370	chr2:73384389	NA	0.53	10.4	0.44	6.76e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.94	0.45	6.05e-25	Personality dimensions;
LGG	trans	rs208520	0.690	rs864314	chr6:66814830	G/T	cg08225398	chr13:45563328	KIAA1704;NUFIP1	0.93	10.38	0.43	8e-23	Exhaled nitric oxide output;
LGG	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.39	-6.79	-0.3	3.42e-11	Glycated hemoglobin levels;
LGG	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs6032067	0.516	rs6017530	chr20:43899731	G/A	cg10761708	chr20:43804764	PI3	0.46	7.35	0.32	8.92e-13	Blood protein levels;
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg00976097	chr5:421733	AHRR	-0.46	-7.58	-0.33	1.88e-13	Cystic fibrosis severity;
LGG	cis	rs4330281	0.647	rs9881850	chr3:17554181	C/T	cg20981856	chr3:17787350	NA	0.39	7.49	0.33	3.54e-13	Schizophrenia;
LGG	cis	rs4330281	0.626	rs9852861	chr3:17513896	C/T	cg20981856	chr3:17787350	NA	0.36	6.81	0.3	3.13e-11	Schizophrenia;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.46	0.47	6.14e-27	Bipolar disorder;
LGG	cis	rs7166081	1.000	rs9806590	chr15:67516341	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.91	-0.31	1.64e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg24692254	chr21:30365293	RNF160	-0.66	-12.08	-0.49	2.24e-29	Pancreatic cancer;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.9	-0.31	1.75e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg08085267	chr17:45401833	C17orf57	0.57	11.13	0.46	1.19e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs240764	0.764	rs11155472	chr6:100921549	A/T	cg21058520	chr6:100914733	NA	0.5	8.69	0.37	6.08e-17	Neuroticism;
LGG	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg03453431	chr7:157225567	NA	-0.48	-8.24	-0.36	1.79e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg08250081	chr4:10125330	NA	0.66	12.22	0.49	5.75e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.48	0.33	3.82e-13	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16579354	chr2:216974337	XRCC5	0.51	7.64	0.33	1.27e-13	Gut microbiome composition (summer);
LGG	cis	rs733592	0.560	rs2158515	chr12:48507668	T/C	cg24011408	chr12:48396354	COL2A1	-0.67	-11.79	-0.48	2.98e-28	Plateletcrit;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00143700	chr13:49107116	RCBTB2	0.45	7.54	0.33	2.57e-13	Cognitive performance;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18918831	chr3:195489782	MUC4	0.61	8.6	0.37	1.28e-16	Lung disease severity in cystic fibrosis;
LGG	cis	rs2371030	0.796	rs2287416	chr2:211580219	A/G	cg18417063	chr2:211583084	NA	-0.56	-10.44	-0.44	4.56e-23	Non-small cell lung cancer;
LGG	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg11846333	chr4:119757529	SEC24D	0.85	7.87	0.34	2.55e-14	Cannabis dependence symptom count;
LGG	cis	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	7.39	0.33	6.69e-13	Joint mobility (Beighton score);
LGG	cis	rs9815354	0.812	rs17283929	chr3:41941898	C/G	cg03022575	chr3:42003672	ULK4	-0.81	-9.48	-0.4	1.31e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10463554	0.963	rs28301	chr5:102441482	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.56	-0.33	2.12e-13	Parkinson's disease;
LGG	cis	rs4075765	0.764	rs72872737	chr11:26247314	A/G	cg19182008	chr11:26298241	NA	0.87	8.27	0.36	1.43e-15	Cannabis dependence symptom count;
LGG	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.48	-7.48	-0.33	3.65e-13	Menarche (age at onset);
LGG	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg00012203	chr2:219082015	ARPC2	-0.76	-14.59	-0.56	6.23e-40	Colorectal cancer;
LGG	cis	rs73086581	0.735	rs6037730	chr20:4026818	A/G	cg02187196	chr20:3869020	PANK2	0.66	9.52	0.4	9.96e-20	Response to antidepressants in depression;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.53	-9.23	-0.39	9.38e-19	Longevity;Endometriosis;
LGG	cis	rs77633900	0.614	rs113557153	chr15:76994445	A/G	cg21673338	chr15:77095150	SCAPER	-0.68	-9.64	-0.41	3.59e-20	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1595825	0.891	rs73056840	chr2:198783466	C/A	cg00982548	chr2:198649783	BOLL	-0.52	-7.11	-0.31	4.53e-12	Ulcerative colitis;
LGG	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg03806693	chr22:41940476	POLR3H	0.98	17.55	0.63	3.05e-53	Vitiligo;
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.59	-0.33	1.76e-13	Personality dimensions;
LGG	cis	rs7143963	0.609	rs3783386	chr14:103367708	C/T	cg23020514	chr14:103360112	TRAF3	0.36	7.24	0.32	1.84e-12	Body mass index;
LGG	cis	rs6121246	0.567	rs6060261	chr20:30192948	C/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2832191	0.597	rs8127842	chr21:30516461	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-14.32	-0.55	9.23e-39	Dental caries;
LGG	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg11764359	chr7:65958608	NA	-0.8	-14.86	-0.57	4.04e-41	Aortic root size;
LGG	cis	rs911263	0.603	rs1108590	chr14:68772610	A/G	cg18825221	chr14:68749962	RAD51L1	0.37	7.95	0.35	1.4e-14	Primary biliary cholangitis;
LGG	cis	rs9470366	0.883	rs12199346	chr6:36641546	C/A	cg08179530	chr6:36648295	CDKN1A	0.65	9.45	0.4	1.7e-19	QRS duration;
LGG	cis	rs807029	0.533	rs3740485	chr10:102750621	C/T	cg04662943	chr10:102668895	NA	0.47	6.92	0.31	1.52e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs9409565	1.000	rs9409567	chr9:97252505	A/G	cg05679027	chr9:99775184	HIATL2	0.48	8.12	0.35	4.18e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg26513180	chr16:89883248	FANCA	0.65	11.92	0.48	9.43e-29	Vitiligo;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.63	-0.44	9.16e-24	IgG glycosylation;
LGG	cis	rs1465370	0.711	rs11767377	chr7:130004758	A/G	cg04743876	chr7:130013617	NA	0.33	7.16	0.32	3.17e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg00149659	chr3:10157352	C3orf10	0.57	8.35	0.36	8.06e-16	Alzheimer's disease;
LGG	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg16141378	chr3:129829833	LOC729375	0.31	6.91	0.31	1.64e-11	Neuroticism;
LGG	cis	rs1577917	0.771	rs9362233	chr6:86358247	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.14	-0.62	2.27e-51	Response to antipsychotic treatment;
LGG	cis	rs548181	0.577	rs569766	chr11:125532369	G/A	cg03464685	chr11:125439445	EI24	1.31	19.77	0.68	1.58e-63	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg13010199	chr12:38710504	ALG10B	0.74	15.2	0.58	1.35e-42	Heart rate;
LGG	cis	rs7814319	0.933	rs13260865	chr8:97238472	A/T	cg20787634	chr8:97240163	UQCRB	-0.78	-18.53	-0.65	9.28e-58	Lung function (FVC);
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11890956	chr21:40555474	PSMG1	-0.95	-18.99	-0.66	6.63e-60	Cognitive function;
LGG	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26306683	chr17:18585705	ZNF286B	0.37	7.1	0.31	4.86e-12	Educational attainment (years of education);
LGG	cis	rs975722	0.516	rs4727849	chr7:117014072	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.39	-8.35	-0.36	8.21e-16	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg05368731	chr17:41323189	NBR1	0.96	18.92	0.66	1.43e-59	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg04863758	chr4:1303710	MAEA	0.42	7.2	0.32	2.41e-12	Obesity-related traits;
LGG	cis	rs988958	0.567	rs13409420	chr2:42233150	C/T	cg19376973	chr2:42229025	NA	-0.6	-9.85	-0.42	6.49e-21	Hypospadias;
LGG	trans	rs800082	1.000	rs1961653	chr3:144286098	C/T	cg24215973	chr2:240111563	HDAC4	-0.5	-8.81	-0.38	2.53e-17	Smoking behavior;
LGG	cis	rs2415984	0.562	rs1389604	chr14:46972218	C/A	cg14871534	chr14:47121158	RPL10L	0.46	7.34	0.32	9.57e-13	Number of children ever born;
LGG	trans	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg16141378	chr3:129829833	LOC729375	0.35	8.03	0.35	8.29e-15	Joint mobility (Beighton score);
LGG	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg08498830	chr11:832797	CD151	-0.44	-7.23	-0.32	1.98e-12	Mean platelet volume;
LGG	cis	rs11690935	0.595	rs788166	chr2:172915489	G/C	cg13550731	chr2:172543902	DYNC1I2	0.72	14.6	0.56	5.32e-40	Schizophrenia;
LGG	trans	rs5756813	0.754	rs4820308	chr22:38176216	G/A	cg19894588	chr14:64061835	NA	-0.6	-9.26	-0.4	7.65e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs921968	0.643	rs2556386	chr2:219534530	C/T	cg01130898	chr2:219473002	PLCD4	0.41	7.1	0.31	4.63e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10893109	0.517	rs2123709	chr11:123773838	T/A	cg12387464	chr11:123775935	OR8D4	0.39	8.49	0.37	2.77e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs537930	0.925	rs177252	chr5:134343799	A/G	cg24576358	chr5:134350122	NA	0.49	10.33	0.43	1.24e-22	Height;
LGG	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.95	0.54	3.56e-37	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07659893	chr17:61819838	STRADA	-0.43	-7.04	-0.31	6.95e-12	Prudent dietary pattern;
LGG	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg21475434	chr5:93447410	FAM172A	0.69	7.12	0.31	4.26e-12	Diabetic retinopathy;
LGG	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg26150922	chr2:100937072	LONRF2	-0.58	-11.23	-0.46	5.02e-26	Intelligence (multi-trait analysis);
LGG	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.5	0.33	3.24e-13	Joint mobility (Beighton score);
LGG	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg10596483	chr8:143751796	JRK	0.58	9.38	0.4	2.98e-19	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs2692947	0.696	rs1724121	chr2:96808549	T/C	cg22654517	chr2:96458247	NA	0.39	8.49	0.37	2.92e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs9309473	0.948	rs10199224	chr2:73761446	C/G	cg20560298	chr2:73613845	ALMS1	-0.49	-8.0	-0.35	9.74e-15	Metabolite levels;
LGG	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.66	0.3	7.6e-11	Cognitive function;
LGG	cis	rs4950322	1.000	rs59498179	chr1:146872147	T/C	cg22381352	chr1:146742008	CHD1L	-0.44	-6.95	-0.31	1.27e-11	Protein quantitative trait loci;
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs425535	0.757	rs164616	chr4:74798566	A/G	cg01447579	chr4:74847100	PF4	0.53	6.66	0.3	7.73e-11	Blood protein levels;
LGG	cis	rs8067545	0.750	rs4925069	chr17:19953531	C/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs11191205	0.686	rs12255825	chr10:103422107	A/C	cg15320455	chr10:103880129	LDB1	0.53	7.77	0.34	5.18e-14	Intelligence (multi-trait analysis);
LGG	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	17.86	0.64	1.19e-54	Smoking behavior;
LGG	cis	rs4953318	0.619	rs13406901	chr2:46363066	T/G	cg12428440	chr2:46370979	PRKCE	0.5	9.29	0.4	6.06e-19	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-7.35	-0.32	8.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg18252515	chr7:66147081	NA	-1.32	-18.77	-0.66	7.29e-59	Diabetic kidney disease;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg19147804	chr7:1989927	MAD1L1	-0.5	-9.82	-0.42	8.61e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs2070488	0.689	rs6809352	chr3:38544349	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.42	-0.56	3.38e-39	Electrocardiographic conduction measures;
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.26	-0.5	3.89e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs977987	0.778	rs12445726	chr16:75465575	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg13385794	chr1:248469461	NA	0.49	8.35	0.36	8.06e-16	Common traits (Other);
LGG	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg00551146	chr10:14014579	FRMD4A	0.33	7.69	0.34	8.75e-14	Adiponectin levels;
LGG	cis	rs12615966	0.651	rs58796108	chr2:105408088	T/A	cg16465502	chr2:105461796	NA	0.99	11.27	0.46	3.25e-26	Pancreatic cancer;
LGG	cis	rs7937612	1.000	rs7107211	chr11:120262922	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.27	-0.5	3.65e-30	Intraocular pressure;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg19318889	chr4:1322082	MAEA	0.48	8.21	0.36	2.19e-15	Longevity;
LGG	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg25823085	chr7:87105416	ABCB4	0.3	7.38	0.32	7.51e-13	Gallbladder cancer;
LGG	cis	rs894734	0.535	rs2366144	chr12:54324069	G/T	cg12374095	chr12:54320830	NA	-0.38	-6.89	-0.3	1.82e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.08	-0.31	5.47e-12	Response to amphetamines;
LGG	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg21479132	chr6:26055353	NA	0.83	8.06	0.35	6.36e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg11890956	chr21:40555474	PSMG1	-0.71	-12.3	-0.5	2.82e-30	Menarche (age at onset);
LGG	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg13256891	chr4:100009986	ADH5	0.38	6.95	0.31	1.26e-11	Alcohol dependence;
LGG	cis	rs2227564	0.620	rs3911887	chr10:75548026	A/G	cg00564723	chr10:75632066	CAMK2G	-0.47	-10.02	-0.42	1.56e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4330281	0.647	rs4566567	chr3:17749177	C/T	cg20981856	chr3:17787350	NA	-0.39	-7.26	-0.32	1.68e-12	Schizophrenia;
LGG	cis	rs6430585	0.583	rs3769008	chr2:136586183	C/T	cg07169764	chr2:136633963	MCM6	1.29	25.54	0.76	1.88e-90	Corneal structure;
LGG	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.13	0.39	2.19e-18	Diabetic retinopathy;
LGG	cis	rs6120849	1.000	rs6120849	chr20:33730387	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	6.87	0.3	2.06e-11	Protein C levels;
LGG	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg08975724	chr8:8085496	FLJ10661	0.37	6.8	0.3	3.23e-11	Neuroticism;
LGG	cis	rs988958	0.567	rs10193034	chr2:42249064	G/A	cg27428208	chr2:42229179	NA	0.55	9.05	0.39	3.87e-18	Hypospadias;
LGG	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs425535	0.757	rs352024	chr4:74797139	G/T	cg01447579	chr4:74847100	PF4	-0.53	-6.74	-0.3	4.66e-11	Blood protein levels;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg00495681	chr13:53174319	NA	-0.83	-16.73	-0.61	1.82e-49	Lewy body disease;
LGG	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg04691961	chr3:161091175	C3orf57	-0.38	-7.38	-0.32	7.33e-13	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.56	-0.41	6.74e-20	Lung cancer;
LGG	cis	rs4740619	0.905	rs10962151	chr9:15774379	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.81	-0.45	1.87e-24	Body mass index;
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-8.24	-0.36	1.8e-15	Dementia with Lewy bodies;
LGG	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg17971929	chr21:40555470	PSMG1	-0.72	-13.73	-0.54	3.16e-36	Cognitive function;
LGG	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg03733263	chr8:22462867	KIAA1967	-1.01	-25.16	-0.76	1.13e-88	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs283228	0.550	rs570556	chr6:101741702	A/G	cg02011392	chr6:101847541	GRIK2	0.53	7.32	0.32	1.07e-12	Coenzyme Q10 levels;
LGG	cis	rs9354308	0.738	rs1392149	chr6:66613218	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs4740619	0.836	rs13292699	chr9:15910044	A/C	cg14451791	chr9:16040625	NA	-0.39	-10.03	-0.42	1.44e-21	Body mass index;
LGG	cis	rs11693319	1.000	rs10171447	chr2:179747390	G/C	cg17765952	chr2:179737173	CCDC141	0.46	7.81	0.34	3.93e-14	Blood pressure measurement (cold pressor test);
LGG	cis	rs709400	0.663	rs7145113	chr14:103945414	A/G	cg26031613	chr14:104095156	KLC1	0.78	13.68	0.54	5.05e-36	Body mass index;
LGG	cis	rs653465	0.708	rs17349692	chr3:27124001	G/A	cg02860705	chr3:27208620	NA	-0.4	-7.71	-0.34	7.63e-14	Breast cancer (early onset);
LGG	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg02640540	chr1:67518911	SLC35D1	0.36	6.98	0.31	1.01e-11	Lymphocyte percentage of white cells;
LGG	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg09873164	chr1:152488093	CRCT1	0.62	15.35	0.58	2.79e-43	Plantar warts;
LGG	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.9e-22	Diabetic retinopathy;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg09033563	chr22:24373618	LOC391322	-0.43	-6.66	-0.3	7.88e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9815354	1.000	rs1716664	chr3:41948378	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3784262	0.669	rs4646603	chr15:58290024	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.99	-0.31	9.82e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg04455712	chr21:45112962	RRP1B	-0.52	-10.01	-0.42	1.73e-21	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18832029	chr20:40321656	NA	0.46	6.71	0.3	5.76e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.43	-0.36	4.5e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg16096631	chr1:42092165	HIVEP3	0.54	12.73	0.51	4.74e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10489202	0.632	rs202259	chr1:167962072	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-10.69	-0.44	5.43e-24	Schizophrenia;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.64	-0.33	1.26e-13	Dementia with Lewy bodies;
LGG	cis	rs7011049	0.841	rs12375409	chr8:53868886	G/T	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs877282	0.945	rs12782447	chr10:771870	C/T	cg22713356	chr15:30763199	NA	0.52	7.91	0.35	1.92e-14	Uric acid levels;
LGG	cis	rs6840360	0.642	rs2709834	chr4:152375424	T/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	3.08e-12	Intelligence (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23858532	chr4:154073915	TRIM2	0.36	6.71	0.3	5.62e-11	Obesity-related traits;
LGG	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg16662043	chr16:48846231	NA	0.39	7.58	0.33	1.94e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11088226	0.645	rs78172258	chr21:33936539	T/G	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.46	-0.37	3.45e-16	Schizophrenia;
LGG	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg23422044	chr7:1970798	MAD1L1	-0.6	-9.05	-0.39	4.11e-18	Neuroticism;
LGG	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	8.93	0.38	9.84e-18	Headache;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.98	0.57	1.14e-41	Cognitive test performance;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.33	-0.43	1.15e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg25566285	chr7:158114605	PTPRN2	0.7	11.74	0.48	4.91e-28	Response to amphetamines;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs12493885	0.585	rs10513453	chr3:153640591	G/A	cg12800244	chr3:153838788	SGEF	-0.59	-7.04	-0.31	6.88e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1519814	0.581	rs1879150	chr8:121011233	A/T	cg22335954	chr8:121166405	COL14A1	-0.45	-8.06	-0.35	6.62e-15	Breast cancer;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.48	-0.33	3.66e-13	Lung cancer;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs9460578	0.537	rs4330530	chr6:20811091	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.67	0.63	9.26e-54	Breast cancer;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.46	0.33	4.43e-13	Tonsillectomy;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03103374	chr12:70133049	RAB3IP	0.44	6.71	0.3	5.55e-11	Hip circumference;
LGG	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.59	-0.47	1.97e-27	Hemoglobin concentration;
LGG	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg15432903	chr11:17409602	KCNJ11	0.81	16.62	0.61	5.29e-49	Type 2 diabetes;
LGG	cis	rs283228	0.798	rs2518336	chr6:101765624	G/A	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs76917914	0.820	rs7041811	chr9:100821028	C/T	cg03040243	chr9:100819229	NANS	0.48	6.73	0.3	5.18e-11	Immature fraction of reticulocytes;
LGG	cis	rs3087591	1.000	rs2854322	chr17:29699416	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.36	0.55	6.37e-39	Hip circumference;
LGG	trans	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	7.84e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23221052	chr5:179740743	GFPT2	-0.64	-11.55	-0.47	2.79e-27	Height;
LGG	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg23933602	chr10:16859644	RSU1	0.93	23.01	0.73	1.12e-78	Platelet distribution width;
LGG	cis	rs4662750	0.650	rs1083297	chr2:128356997	C/T	cg10021288	chr2:128175891	PROC	0.37	6.81	0.3	2.98e-11	Renal cell carcinoma;
LGG	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.64	0.51	1.13e-31	Motion sickness;
LGG	cis	rs2070488	0.775	rs1073505	chr3:38566722	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.16	-0.55	4.33e-38	Electrocardiographic conduction measures;
LGG	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg05082376	chr22:42548792	NA	-0.37	-7.71	-0.34	7.67e-14	Schizophrenia;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.06	0.46	2.16e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	trans	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg11430096	chr6:110968061	CDK19	0.65	6.65	0.3	8.04e-11	Prostate cancer;
LGG	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-11.82	-0.48	2.41e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02018176	chr4:1364513	KIAA1530	-0.48	-11.14	-0.46	1.05e-25	Obesity-related traits;
LGG	cis	rs72781680	0.784	rs72798406	chr2:24180144	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	8.61	0.37	1.14e-16	Lymphocyte counts;
LGG	cis	rs523522	0.962	rs4766969	chr12:120988238	A/G	cg12219531	chr12:120966889	COQ5	0.67	11.18	0.46	7.65e-26	High light scatter reticulocyte count;
LGG	cis	rs8067545	0.611	rs7212500	chr17:20045658	A/G	cg13482628	chr17:19912719	NA	0.53	10.1	0.42	8.58e-22	Schizophrenia;
LGG	cis	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg04990556	chr1:26633338	UBXN11	-0.48	-8.03	-0.35	8.4e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs847649	0.731	rs12666317	chr7:102704135	C/T	cg18108683	chr7:102477205	FBXL13	0.56	11.36	0.47	1.46e-26	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06028808	chr11:68637592	NA	0.73	12.53	0.5	3.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.18e-95	Breast cancer;
LGG	cis	rs6076065	0.748	rs999068	chr20:23376483	G/A	cg11657817	chr20:23433608	CST11	0.4	8.2	0.36	2.39e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2013441	1.000	rs2526467	chr17:20165054	T/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs7267979	0.966	rs4815425	chr20:25398876	G/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.5	-0.44	2.81e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6601327	0.632	rs4841220	chr8:9656059	T/G	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.78e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg03511173	chr18:77590860	NA	0.62	7.77	0.34	5.16e-14	Opioid sensitivity;
LGG	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.64	-0.41	3.61e-20	Cutaneous nevi;
LGG	cis	rs4782309	0.544	rs6500488	chr16:88753865	A/G	cg02389323	chr16:88786976	FAM38A	0.82	8.1	0.35	4.79e-15	Hair color;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg19913688	chr11:428466	ANO9	-0.68	-8.26	-0.36	1.54e-15	Body mass index;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23634678	chr11:102963104	DCUN1D5	-0.43	-7.32	-0.32	1.1e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02638755	chr17:78902369	RPTOR	-0.31	-7.11	-0.31	4.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs556990	0.570	rs5960	chr13:113801737	C/T	cg18105134	chr13:113819100	PROZ	0.59	9.68	0.41	2.64e-20	Blood protein levels;
LGG	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-8.3	-0.36	1.11e-15	Height;
LGG	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg02733842	chr7:1102375	C7orf50	0.64	7.85	0.34	3e-14	Longevity;Endometriosis;
LGG	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg04691961	chr3:161091175	C3orf57	0.4	8.26	0.36	1.53e-15	Kawasaki disease;
LGG	cis	rs11158198	0.628	rs11628557	chr14:58611314	A/G	cg15908186	chr14:58618357	C14orf37	0.56	9.81	0.41	8.82e-21	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg23335576	chr14:104009727	NA	0.39	6.67	0.3	7.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	0.929	rs13088413	chr3:134309977	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	12.84	0.51	1.73e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7444	0.941	rs5754344	chr22:21963786	A/G	cg15846791	chr22:21984385	YDJC	-0.47	-7.05	-0.31	6.57e-12	Systemic lupus erythematosus;
LGG	cis	rs1595825	1.000	rs1440090	chr2:198879297	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-7.16	-0.32	3.24e-12	Ulcerative colitis;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg15971980	chr6:150254442	NA	0.45	8.58	0.37	1.5e-16	Lung cancer;
LGG	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg02476566	chr12:106696527	TCP11L2	-0.51	-6.81	-0.3	3.06e-11	Tourette syndrome;
LGG	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg08648136	chr8:956695	NA	0.46	10.04	0.42	1.4e-21	Schizophrenia;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg21548813	chr6:291882	DUSP22	-0.72	-12.48	-0.5	5.11e-31	Menopause (age at onset);
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg13397359	chr6:42928475	GNMT	0.58	16.18	0.6	5.15e-47	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg27490568	chr2:178487706	NA	0.85	15.27	0.58	6.38e-43	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16803707	chr20:1099736	PSMF1	0.48	7.46	0.33	4.17e-13	Gut microbiome composition (summer);
LGG	cis	rs806215	0.526	rs62481416	chr7:127478125	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	6.87e-12	Type 2 diabetes;
LGG	cis	rs295140	1.000	rs55677233	chr2:201168695	T/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg04008888	chr11:68622739	NA	-0.56	-11.99	-0.49	4.94e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6598955	0.671	rs11247901	chr1:26612693	T/A	cg04990556	chr1:26633338	UBXN11	0.58	8.05	0.35	6.8e-15	Obesity-related traits;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs9815354	0.812	rs17214945	chr3:41808660	A/C	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.12e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg16268157	chr7:99778414	STAG3	-0.47	-7.67	-0.34	1.02e-13	Lung function (FEV1/FVC);
LGG	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.29	0.4	6.27e-19	Blood metabolite levels;
LGG	cis	rs208520	0.690	rs207119	chr6:66786408	C/T	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.21e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4356203	0.870	rs10832748	chr11:17251731	A/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6580649	0.941	rs7957764	chr12:48429701	C/T	cg24011408	chr12:48396354	COL2A1	-0.57	-7.05	-0.31	6.44e-12	Lung cancer;
LGG	cis	rs67478160	0.609	rs6576003	chr14:104291330	C/A	cg26031613	chr14:104095156	KLC1	-0.45	-7.23	-0.32	2.04e-12	Schizophrenia;
LGG	cis	rs2952156	0.920	rs2247862	chr17:37829129	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-14.04	-0.55	1.5e-37	Asthma;
LGG	cis	rs4650994	0.816	rs2811304	chr1:178596794	A/T	cg19399532	chr1:178512495	C1orf220	-0.37	-7.0	-0.31	9.25e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4950322	0.570	rs113498894	chr1:146790598	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs41271473	0.687	rs10916364	chr1:228884405	A/G	cg00850481	chr1:228891306	NA	0.55	11.26	0.46	3.66e-26	Chronic lymphocytic leukemia;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-9.87	-0.42	5.6e-21	Menarche (age at onset);
LGG	cis	rs4689642	0.709	rs4689657	chr4:7225818	G/C	cg21353189	chr4:7228343	SORCS2	0.38	8.95	0.38	8.36e-18	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19704074	chr1:63062212	DOCK7;ANGPTL3	-0.41	-6.75	-0.3	4.42e-11	Menarche (age at onset);
LGG	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg00080972	chr5:178986291	RUFY1	0.4	6.89	0.3	1.84e-11	Lung cancer;
LGG	cis	rs4776059	0.959	rs12898644	chr15:52905233	A/G	cg22715398	chr15:52968154	KIAA1370	-0.51	-8.67	-0.37	7.16e-17	Schizophrenia;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg10560079	chr2:191398806	TMEM194B	0.36	7.91	0.35	1.87e-14	Pulse pressure;
LGG	cis	rs7241530	0.585	rs12970672	chr18:75890525	G/C	cg14642773	chr18:75888474	NA	0.46	8.98	0.39	6.84e-18	Educational attainment (years of education);
LGG	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg04568710	chr12:38710424	ALG10B	0.34	6.9	0.31	1.74e-11	Morning vs. evening chronotype;
LGG	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg27129171	chr3:47204927	SETD2	0.86	16.58	0.61	8.13e-49	Colorectal cancer;
LGG	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg12310025	chr6:25882481	NA	-0.56	-10.56	-0.44	1.7e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.65	0.44	8.06e-24	Total body bone mineral density;
LGG	cis	rs1018836	0.828	rs9297870	chr8:91570691	C/G	cg16814680	chr8:91681699	NA	-0.74	-13.27	-0.52	2.82e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg26384229	chr12:38710491	ALG10B	-0.77	-15.9	-0.59	9.3e-46	Morning vs. evening chronotype;
LGG	trans	rs8073060	0.586	rs117573546	chr17:33909588	G/A	cg19694781	chr19:47549865	TMEM160	1.13	16.82	0.62	7.08e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs36051895	0.575	rs7035251	chr9:5133665	T/A	cg02405213	chr9:5042618	JAK2	-0.78	-15.13	-0.58	2.73e-42	Pediatric autoimmune diseases;
LGG	cis	rs11971779	0.715	rs6943973	chr7:139029893	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.37e-11	Diisocyanate-induced asthma;
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.87	-0.3	2.11e-11	Neuroticism;
LGG	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.3	-0.53	2.15e-34	Bladder cancer;
LGG	trans	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.7	11.59	0.47	1.85e-27	Obesity-related traits;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08169394	chr17:11143830	SHISA6	-0.45	-6.75	-0.3	4.48e-11	Systemic lupus erythematosus;
LGG	cis	rs1163251	0.837	rs592762	chr1:120247355	A/G	cg19096424	chr1:120255104	PHGDH	0.67	12.11	0.49	1.62e-29	Blood metabolite levels;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg05552183	chr6:42928497	GNMT	-0.44	-13.13	-0.52	1.07e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12478296	0.581	rs4973645	chr2:242993577	T/C	cg18898632	chr2:242989856	NA	-0.89	-10.09	-0.42	9.08e-22	Obesity-related traits;
LGG	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg14227996	chr4:17616232	MED28	-0.62	-7.45	-0.33	4.66e-13	Opioid sensitivity;
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.16e-12	Bipolar disorder;
LGG	cis	rs1014246	0.848	rs58568639	chr10:118456886	C/G	cg14919929	chr10:118506882	NA	0.61	11.58	0.47	2.02e-27	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs3820068	0.581	rs16851851	chr1:15929628	C/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg10204951	chr7:910479	UNC84A	-0.51	-6.83	-0.3	2.63e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg20488157	chr14:104394430	TDRD9	0.56	9.12	0.39	2.29e-18	Bipolar disorder;
LGG	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.57	-0.41	6.56e-20	Common traits (Other);
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg05941027	chr17:61774174	LIMD2	0.36	9.35	0.4	3.63e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg08280861	chr8:58055591	NA	0.58	9.89	0.42	4.91e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg24812749	chr6:127587940	RNF146	0.96	15.92	0.59	8.29e-46	Breast cancer;
LGG	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.52e-12	HDL cholesterol;
LGG	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg18131467	chr2:239335373	ASB1	-0.77	-11.33	-0.47	1.9e-26	Multiple system atrophy;
LGG	cis	rs6076065	0.723	rs2424531	chr20:23372754	C/T	cg12633918	chr20:23549525	CST9L	0.36	6.73	0.3	4.95e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.3e-17	Schizophrenia;
LGG	cis	rs9916302	0.904	rs8079303	chr17:37530755	G/C	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2976388	0.507	rs13279795	chr8:143838669	G/A	cg07661805	chr8:143867942	LY6D	0.27	7.19	0.32	2.64e-12	Urinary tract infection frequency;
LGG	cis	rs2933343	0.729	rs1683816	chr3:128651195	G/T	cg25356066	chr3:128598488	ACAD9	-0.43	-6.69	-0.3	6.42e-11	IgG glycosylation;
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg13047869	chr3:10149882	C3orf24	0.6	8.6	0.37	1.24e-16	Alzheimer's disease;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.57	-0.33	2e-13	Tonsillectomy;
LGG	cis	rs77633900	0.772	rs494268	chr15:76815713	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-7.99	-0.35	1.11e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00149659	chr3:10157352	C3orf10	0.87	11.24	0.46	4.3e-26	Alzheimer's disease;
LGG	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg23533926	chr12:111358616	MYL2	0.41	7.28	0.32	1.46e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-9.01	-0.39	5.38e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17208368	0.628	rs58863998	chr16:55100720	G/A	cg11181171	chr16:55090946	NA	0.48	7.94	0.35	1.55e-14	Hypospadias;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.71e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10193935	0.901	rs222469	chr2:42640235	T/C	cg27598129	chr2:42591480	NA	-0.64	-9.71	-0.41	2.11e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs735539	0.521	rs1810717	chr13:21412235	A/G	cg04906043	chr13:21280425	IL17D	-0.47	-7.35	-0.32	8.8e-13	Dental caries;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.67e-17	Lung cancer;
LGG	cis	rs2124969	0.506	rs62175396	chr2:161043603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.19	-0.39	1.29e-18	Waist circumference adjusted for body mass index;
LGG	cis	rs1018836	0.632	rs2879361	chr8:91481909	C/T	cg16814680	chr8:91681699	NA	0.63	10.69	0.44	5.46e-24	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	17.44	0.63	1.02e-52	Hip circumference adjusted for BMI;
LGG	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg23691781	chr1:28212827	C1orf38	-0.31	-7.16	-0.32	3.15e-12	Corneal astigmatism;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg21724239	chr8:58056113	NA	0.46	7.08	0.31	5.43e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg01864069	chr14:103024347	NA	0.67	9.64	0.41	3.67e-20	Platelet count;
LGG	cis	rs2865126	0.818	rs35033671	chr18:10759840	C/A	cg21165219	chr18:10698044	FAM38B	0.46	7.4	0.33	6.4e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs2067615	0.579	rs7486905	chr12:107160169	G/A	cg15890332	chr12:107067104	RFX4	0.4	11.88	0.48	1.36e-28	Heart rate;
LGG	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-20.87	-0.7	1.15e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.78	-0.41	1.21e-20	Common traits (Other);
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.94	-0.35	1.53e-14	Life satisfaction;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg06112835	chr11:68658793	MRPL21	-0.39	-6.79	-0.3	3.54e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00294572	chr6:26285232	NA	0.42	7.65	0.33	1.2e-13	Educational attainment;
LGG	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.73	-0.45	3.88e-24	Primary sclerosing cholangitis;
LGG	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.24	0.36	1.84e-15	HIV-1 control;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs504918	0.967	rs7647524	chr3:124088816	C/T	cg05766129	chr3:123988013	KALRN	0.37	6.74	0.3	4.71e-11	Schizophrenia;
LGG	cis	rs9849248	0.531	rs4858940	chr3:88254820	A/G	cg14530983	chr3:88190749	ZNF654	-0.56	-7.73	-0.34	6.92e-14	Menarche (age at onset);
LGG	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg02886208	chr11:14281011	SPON1	-0.36	-6.88	-0.3	1.99e-11	Sense of smell;
LGG	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg26811252	chr16:29126840	RRN3P2	0.68	10.89	0.45	9.96e-25	Menopause (age at onset);
LGG	cis	rs2235573	0.673	rs5756894	chr22:38450136	C/A	cg19171272	chr22:38449367	NA	-0.64	-13.38	-0.53	9.86e-35	Glioblastoma;Glioma;
LGG	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg16751781	chr15:78858589	CHRNA5	0.38	7.08	0.31	5.52e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.77	14.78	0.57	9.13e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg03517284	chr6:25882590	NA	-0.51	-9.43	-0.4	2.03e-19	Height;
LGG	cis	rs17286411	0.750	rs8044335	chr16:71869520	A/C	cg06353428	chr16:71660113	MARVELD3	0.41	7.22	0.32	2.21e-12	Blood protein levels;
LGG	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs8014204	0.773	rs2241275	chr14:75251440	C/T	cg03030879	chr14:75389066	RPS6KL1	0.37	6.73	0.3	5.13e-11	Caffeine consumption;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.63	-0.48	1.27e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.5	-0.37	2.71e-16	Obesity-related traits;
LGG	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg16386425	chr10:429943	DIP2C	-0.37	-7.46	-0.33	4.33e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-15.29	-0.58	4.91e-43	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.8e-21	Prudent dietary pattern;
LGG	trans	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg16006296	chr10:38738647	LOC399744	0.34	6.69	0.3	6.53e-11	Diastolic blood pressure;
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg13114125	chr14:105738426	BRF1	-0.84	-15.92	-0.59	7.99e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	trans	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.38	-0.36	6.51e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9457247	0.534	rs1130033	chr6:167385623	C/T	cg18261144	chr6:167370276	RNASET2	0.39	7.82	0.34	3.6e-14	Crohn's disease;
LGG	cis	rs4774899	0.932	rs12912868	chr15:57537199	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.17	-0.32	3.04e-12	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08677398	chr8:58056175	NA	-0.5	-7.78	-0.34	4.76e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4771450	0.962	rs1888320	chr13:103971475	A/G	cg02987523	chr13:103978230	NA	-0.32	-6.79	-0.3	3.45e-11	Uric acid levels;
LGG	cis	rs17321999	1.000	rs17009304	chr2:30479283	A/T	cg05247661	chr2:30472410	LBH	0.55	8.92	0.38	1.06e-17	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03647317	chr4:187891568	NA	-0.41	-8.83	-0.38	2.09e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.12	0.57	3.02e-42	Alzheimer's disease;
LGG	cis	rs7572644	0.621	rs4462754	chr2:28063994	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs9487094	0.961	rs1546980	chr6:109773946	T/C	cg01125227	chr6:109776195	MICAL1	0.56	9.49	0.4	1.21e-19	Height;
LGG	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg21427119	chr20:30132790	HM13	-0.5	-8.27	-0.36	1.48e-15	Mean corpuscular hemoglobin;
LGG	cis	rs3771570	1.000	rs73018141	chr2:242221570	G/A	cg21155796	chr2:242212141	HDLBP	0.75	9.8	0.41	9.52e-21	Prostate cancer;
LGG	cis	rs9815354	0.812	rs59476821	chr3:41946481	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3857067	1.000	rs28876091	chr4:95000394	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.53	-0.33	2.67e-13	QT interval;
LGG	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg01221209	chr5:554886	NA	-0.46	-6.81	-0.3	3e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs17539620	0.624	rs58469593	chr6:154850105	G/A	cg17771515	chr6:154831774	CNKSR3	0.62	7.3	0.32	1.25e-12	Lipoprotein (a) levels;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg20607798	chr8:58055168	NA	-0.64	-7.52	-0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2832191	0.692	rs2245517	chr21:30357968	C/T	cg08807101	chr21:30365312	RNF160	0.92	19.42	0.67	6.55e-62	Dental caries;
LGG	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.65	-11.15	-0.46	9.71e-26	Mean platelet volume;
LGG	cis	rs4423214	0.524	rs4944046	chr11:71123794	C/G	cg05163923	chr11:71159392	DHCR7	0.39	6.89	0.3	1.84e-11	Vitamin D levels;
LGG	cis	rs6768930	0.509	rs9819294	chr3:57720901	G/C	cg01571842	chr3:57934672	NA	0.3	6.7	0.3	5.89e-11	Obesity-related traits;
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg18446336	chr7:2847575	GNA12	-0.28	-7.23	-0.32	1.96e-12	Height;
LGG	trans	rs800082	0.934	rs1007566	chr3:144311752	G/A	cg24215973	chr2:240111563	HDAC4	-0.49	-8.6	-0.37	1.25e-16	Smoking behavior;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg15971980	chr6:150254442	NA	0.44	8.39	0.36	5.78e-16	Lung cancer;
LGG	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg10168709	chr10:75599394	CAMK2G	-0.35	-6.97	-0.31	1.1e-11	Inflammatory bowel disease;
LGG	cis	rs11608355	0.508	rs2075434	chr12:109797051	G/A	cg19025524	chr12:109796872	NA	-0.47	-8.34	-0.36	8.49e-16	Neuroticism;
LGG	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg23029597	chr12:123009494	RSRC2	-0.97	-17.36	-0.63	2.27e-52	Body mass index;
LGG	cis	rs4517514	0.509	rs10830396	chr11:89831383	G/A	cg14505434	chr11:89522851	NA	0.63	7.88	0.34	2.44e-14	Trans fatty acid levels;
LGG	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg12591125	chr7:1885375	MAD1L1	-0.45	-6.69	-0.3	6.37e-11	Bipolar disorder;
LGG	cis	rs12478296	1.000	rs59036157	chr2:243040228	C/A	cg18898632	chr2:242989856	NA	-0.87	-10.48	-0.44	3.2e-23	Obesity-related traits;
LGG	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-8.13	-0.35	3.97e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg12654349	chr5:56205094	C5orf35	-0.68	-10.47	-0.44	3.49e-23	Initial pursuit acceleration;
LGG	cis	rs8077889	0.750	rs76557360	chr17:41936842	G/A	cg26893861	chr17:41843967	DUSP3	0.92	12.53	0.5	3.08e-31	Triglycerides;
LGG	cis	rs28655083	1.000	rs1843457	chr16:77072400	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.66	-0.34	1.06e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2976388	1.000	rs2920296	chr8:143763109	A/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs2070488	0.965	rs1046048	chr3:38524742	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.22	0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg04455712	chr21:45112962	RRP1B	0.52	9.84	0.42	7.01e-21	Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.82	0.34	3.61e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs77106637	0.932	rs17244499	chr11:72629946	C/T	cg03878208	chr11:72483293	STARD10	-0.49	-7.14	-0.31	3.72e-12	Type 2 diabetes;
LGG	cis	rs908922	0.535	rs11205006	chr1:152440176	A/T	cg09873164	chr1:152488093	CRCT1	0.39	7.18	0.32	2.71e-12	Hair morphology;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00149659	chr3:10157352	C3orf10	0.7	9.89	0.42	4.92e-21	Alzheimer's disease;
LGG	cis	rs8067545	0.667	rs7222403	chr17:19879164	T/C	cg13482628	chr17:19912719	NA	0.55	10.05	0.42	1.22e-21	Schizophrenia;
LGG	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs240764	0.658	rs7753317	chr6:101220433	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs10463554	0.927	rs257312	chr5:102419627	T/A	cg23492399	chr5:102201601	PAM	-0.5	-7.47	-0.33	3.9e-13	Parkinson's disease;
LGG	cis	rs975722	0.646	rs213935	chr7:117178208	A/G	cg10524701	chr7:117356490	CTTNBP2	0.45	9.79	0.41	1.03e-20	Coronary artery disease;
LGG	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.34	-0.4	4.02e-19	Response to antipsychotic treatment;
LGG	cis	rs2991971	0.933	rs2356553	chr1:46009313	G/C	cg24296786	chr1:45957014	TESK2	0.39	6.73	0.3	5.12e-11	High light scatter reticulocyte count;
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg00495681	chr13:53174319	NA	0.89	19.67	0.67	4.49e-63	Lewy body disease;
LGG	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	8.11	0.35	4.69e-15	Mood instability;
LGG	cis	rs829402	0.836	rs829373	chr1:21988563	C/T	cg20288655	chr1:21985693	RAP1GAP	0.76	12.44	0.5	7.35e-31	High light scatter reticulocyte count;
LGG	cis	rs7226408	0.600	rs9961412	chr18:34644340	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.16	-0.39	1.69e-18	Obesity-related traits;
LGG	cis	rs6840360	0.681	rs9968292	chr4:152297368	T/C	cg25486957	chr4:152246857	NA	-0.41	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.84	13.28	0.53	2.54e-34	HIV-1 control;
LGG	cis	rs11225247	0.881	rs12271457	chr11:102247928	C/T	cg06323957	chr11:102217781	BIRC2	0.82	7.18	0.32	2.8e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg27411982	chr8:10470053	RP1L1	0.44	7.79	0.34	4.35e-14	Neuroticism;
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7215564	0.908	rs35361366	chr17:78684751	T/C	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs13314892	0.689	rs79563518	chr3:69888242	C/A	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs10267417	0.603	rs36077006	chr7:19933853	A/G	cg05791153	chr7:19748676	TWISTNB	0.55	7.27	0.32	1.52e-12	Night sleep phenotypes;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25665590	chr6:149068439	UST	0.47	6.96	0.31	1.13e-11	Hip circumference;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.44	0.33	5.06e-13	Tonsillectomy;
LGG	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.74	-9.52	-0.4	9.84e-20	Schizophrenia;
LGG	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg03254818	chr6:169586852	NA	-0.54	-8.21	-0.36	2.25e-15	Pulse pressure;
LGG	cis	rs6681460	0.625	rs12127199	chr1:67103742	T/C	cg20812318	chr1:67072952	SGIP1	-0.31	-7.23	-0.32	2.03e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg05556477	chr5:131705319	SLC22A5	0.81	9.81	0.41	9.35e-21	Rheumatoid arthritis;
LGG	cis	rs4430311	0.691	rs61833200	chr1:243779250	C/G	cg25706552	chr1:244017396	NA	-0.64	-15.64	-0.59	1.46e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26850624	chr5:429559	AHRR	-0.37	-8.08	-0.35	5.52e-15	Cystic fibrosis severity;
LGG	cis	rs9783347	0.714	rs4150606	chr11:18363569	C/A	cg15585147	chr11:18324498	HPS5	0.33	7.56	0.33	2.26e-13	Pancreatic cancer;
LGG	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.33	-0.63	3.07e-52	Chronic sinus infection;
LGG	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19717773	chr7:2847554	GNA12	-0.36	-8.41	-0.36	4.94e-16	Height;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	1.000	rs9854838	chr3:41805670	C/A	cg03022575	chr3:42003672	ULK4	0.6	7.71	0.34	7.71e-14	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs3858145	0.588	rs55888445	chr10:70036456	C/T	cg04882175	chr6:131122610	NA	-0.56	-8.0	-0.35	1.04e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg06521331	chr12:34319734	NA	-0.63	-11.98	-0.49	5.16e-29	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26378065	chr17:18585709	ZNF286B	0.56	10.88	0.45	1.09e-24	Educational attainment (years of education);
LGG	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.26	-0.36	1.58e-15	Eosinophil percentage of granulocytes;
LGG	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg03511173	chr18:77590860	NA	0.61	7.43	0.33	5.38e-13	Opioid sensitivity;
LGG	cis	rs36051895	0.659	rs7045342	chr9:5183892	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-14.63	-0.56	4.02e-40	Pediatric autoimmune diseases;
LGG	cis	rs4851266	1.000	rs4851266	chr2:100818479	C/T	cg21926883	chr2:100939477	LONRF2	-0.43	-7.65	-0.33	1.2e-13	Educational attainment;
LGG	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg14893161	chr1:205819251	PM20D1	0.48	7.76	0.34	5.59e-14	Parkinson's disease;
LGG	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg26769984	chr7:1090371	C7orf50	0.57	10.27	0.43	2.02e-22	Bronchopulmonary dysplasia;
LGG	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03517284	chr6:25882590	NA	-0.64	-12.09	-0.49	1.87e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-16.84	-0.62	5.41e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10883723	0.810	rs2296589	chr10:104248106	T/A	cg05096777	chr10:104283225	SUFU	0.32	7.1	0.31	4.67e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2236293	0.754	rs10814276	chr9:35794913	T/A	cg12876594	chr9:35791798	NPR2	0.44	8.32	0.36	1.01e-15	Blood protein levels;
LGG	cis	rs8114671	0.562	rs1060615	chr20:33478381	C/T	cg07148914	chr20:33460835	GGT7	-0.54	-9.12	-0.39	2.33e-18	Height;
LGG	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg06885757	chr1:42089581	HIVEP3	0.59	13.99	0.55	2.44e-37	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg16141378	chr3:129829833	LOC729375	-0.59	-16.16	-0.6	6.65e-47	Mood instability;
LGG	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg18721089	chr20:30220636	NA	-0.51	-7.74	-0.34	6.27e-14	Mean corpuscular hemoglobin;
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg27532560	chr4:187881888	NA	-0.55	-11.97	-0.49	6e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg24011408	chr12:48396354	COL2A1	0.5	7.99	0.35	1.09e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs12042938	1.000	rs12042938	chr1:231816842	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.55	9.54	0.41	8.5e-20	Neuranatomic and neurocognitive phenotypes;
LGG	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs1620921	0.711	rs9346839	chr6:161255046	C/T	cg01280913	chr6:161186852	NA	-0.35	-7.17	-0.32	3.06e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg02959939	chr21:47813025	PCNT	-0.37	-6.79	-0.3	3.52e-11	Lymphocyte counts;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg20308403	chr7:2120281	MAD1L1	0.34	7.36	0.32	8.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.35	-0.4	3.87e-19	Sudden cardiac arrest;
LGG	cis	rs12519773	0.597	rs4308464	chr5:92468867	G/C	cg18783429	chr5:92414398	NA	0.33	8.19	0.36	2.48e-15	Migraine;
LGG	cis	rs6867032	1.000	rs4975796	chr5:2015520	A/T	cg26168224	chr5:2018326	NA	-1.24	-28.0	-0.79	1.17e-101	Gut microbiome composition (winter);
LGG	cis	rs889312	0.500	rs832570	chr5:56156408	G/A	cg14703610	chr5:56206110	C5orf35	0.38	6.65	0.3	8.43e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18252515	chr7:66147081	NA	-0.41	-6.87	-0.3	2.12e-11	Aortic root size;
LGG	cis	rs10214930	0.697	rs2041714	chr7:27598847	G/A	cg22168087	chr7:27702803	HIBADH	0.46	6.67	0.3	7.23e-11	Hypospadias;
LGG	cis	rs6964587	1.000	rs3753107	chr7:91629151	C/T	cg17063962	chr7:91808500	NA	-0.49	-8.72	-0.38	5.09e-17	Breast cancer;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.43	-9.18	-0.39	1.43e-18	Schizophrenia;
LGG	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg02403541	chr12:121454288	C12orf43	0.54	8.56	0.37	1.68e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs11096990	0.964	rs6842390	chr4:39263482	C/G	cg24403649	chr4:39172243	NA	-0.42	-6.84	-0.3	2.56e-11	Cognitive function;
LGG	trans	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.41	-0.4	2.34e-19	Bladder cancer;
LGG	cis	rs12618769	0.597	rs72819986	chr2:99045867	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.7	0.37	6.04e-17	Bipolar disorder;
LGG	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs9640161	0.659	rs59572505	chr7:150014986	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.71	-14.31	-0.55	9.86e-39	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg05863683	chr7:1912471	MAD1L1	0.41	7.48	0.33	3.74e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6547741	1.000	rs4666009	chr2:27857992	T/A	cg22903471	chr2:27725779	GCKR	0.38	8.56	0.37	1.68e-16	Oral cavity cancer;
LGG	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.08	-0.39	3.04e-18	Mood instability;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20620272	chr3:167968129	C3orf50	0.44	7.33	0.32	1.01e-12	Cognitive performance;
LGG	cis	rs926392	0.640	rs62202616	chr20:37692775	G/C	cg16355469	chr20:37678765	NA	0.59	9.24	0.39	8.72e-19	Dialysis-related mortality;
LGG	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg08188268	chr10:116634841	FAM160B1	0.31	7.01	0.31	8.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs73787773	0.644	rs79705195	chr5:111478829	G/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.16	-0.32	3.19e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg22676075	chr6:135203613	NA	0.47	8.1	0.35	4.87e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	5.04e-24	Aortic root size;
LGG	trans	rs225245	0.755	rs226441	chr17:34033072	C/T	cg19694781	chr19:47549865	TMEM160	-0.4	-6.84	-0.3	2.48e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.84	-0.3	2.46e-11	Fear of minor pain;
LGG	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	trans	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg00711542	chr16:29343894	RUNDC2C	0.41	6.85	0.3	2.35e-11	Menopause (age at onset);
LGG	cis	rs59104589	0.916	rs62193162	chr2:242268436	T/A	cg10021735	chr2:242295487	FARP2	0.43	7.68	0.34	9.56e-14	Fibrinogen levels;
LGG	cis	rs77633900	0.772	rs4886491	chr15:76661925	C/T	cg21673338	chr15:77095150	SCAPER	-0.55	-7.86	-0.34	2.74e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg17376030	chr22:41985996	PMM1	-0.57	-9.13	-0.39	2.07e-18	Vitiligo;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	10.88	0.45	1.01e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs911555	0.755	rs8016676	chr14:103904842	C/A	cg24130564	chr14:104152367	KLC1	0.37	7.04	0.31	7.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg15268244	chr15:77196840	NA	0.43	9.39	0.4	2.8e-19	Blood metabolite levels;
LGG	cis	rs7267979	1.000	rs401166	chr20:25446308	C/G	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00142150	chr22:38071001	LGALS1	0.67	12.8	0.51	2.44e-32	Fat distribution (HIV);
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.15	0.35	3.37e-15	Systolic blood pressure;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.88	-0.3	1.95e-11	Neuroticism;
LGG	cis	rs28830936	1.000	rs9672298	chr15:41912368	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.68	-0.51	7.91e-32	Diastolic blood pressure;
LGG	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg05182265	chr7:156933206	UBE3C	0.37	7.49	0.33	3.48e-13	Body mass index;
LGG	cis	rs17767392	0.813	rs66645707	chr14:71985931	T/C	cg02058870	chr14:72053146	SIPA1L1	0.41	8.53	0.37	2.05e-16	Mitral valve prolapse;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.9	0.48	1.15e-28	Hip circumference adjusted for BMI;
LGG	cis	rs6598955	0.671	rs11247908	chr1:26638222	G/A	cg04990556	chr1:26633338	UBXN11	0.62	8.05	0.35	6.93e-15	Obesity-related traits;
LGG	cis	rs1707322	0.691	rs11211175	chr1:46220884	C/G	cg03146154	chr1:46216737	IPP	0.57	11.17	0.46	7.84e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.75	-9.17	-0.39	1.5e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.28e-17	Retinal vascular caliber;
LGG	cis	rs240764	0.658	rs12213201	chr6:101176285	C/A	cg09795085	chr6:101329169	ASCC3	-0.49	-8.34	-0.36	8.67e-16	Neuroticism;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-13.34	-0.53	1.44e-34	Bipolar disorder and schizophrenia;
LGG	trans	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08862035	chr2:2617432	NA	0.42	6.86	0.3	2.17e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs283228	0.570	rs532796	chr6:101727112	A/G	cg27451362	chr6:101846650	GRIK2	0.91	13.27	0.52	2.7e-34	Coenzyme Q10 levels;
LGG	cis	rs722599	0.683	rs8022046	chr14:75278302	G/A	cg06637938	chr14:75390232	RPS6KL1	0.55	8.94	0.38	9.47e-18	IgG glycosylation;
LGG	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg07936489	chr17:37558343	FBXL20	-0.7	-12.21	-0.49	6.66e-30	Mean corpuscular volume;
LGG	cis	rs4936891	0.577	rs12224791	chr11:123919128	A/G	cg22125253	chr11:123886957	OR10G4	-0.51	-8.78	-0.38	3.11e-17	Male fertility;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs2976388	0.935	rs2978980	chr8:143757708	T/G	cg06565975	chr8:143823917	SLURP1	-0.42	-10.57	-0.44	1.52e-23	Urinary tract infection frequency;
LGG	cis	rs755249	0.508	rs624971	chr1:39858947	C/T	cg18385671	chr1:39797026	MACF1	0.47	9.73	0.41	1.71e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6032067	0.777	rs13037651	chr20:43782230	C/G	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg02975922	chr3:195473998	MUC4	-0.55	-8.93	-0.38	1e-17	Pancreatic cancer;
LGG	cis	rs804292	0.600	rs3729851	chr8:11612842	G/A	cg26752888	chr8:11627280	NEIL2	0.92	9.95	0.42	2.92e-21	Alcohol dependence;Nicotine use;
LGG	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg16077055	chr2:106428750	NCK2	0.31	8.23	0.36	1.91e-15	Addiction;
LGG	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.65	0.59	1.27e-44	Platelet count;
LGG	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.59	-0.53	1.18e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1042058	0.565	rs2480297	chr10:30754512	A/G	cg25182066	chr10:30743637	MAP3K8	-0.66	-14.09	-0.55	8.66e-38	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7444	0.941	rs12158299	chr22:21979584	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.78	-0.3	3.77e-11	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25750404	chr12:6579648	VAMP1	0.47	7.26	0.32	1.6e-12	Gut microbiome composition (summer);
LGG	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18876405	chr7:65276391	NA	0.6	11.02	0.46	3.13e-25	Aortic root size;
LGG	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg13263323	chr15:86062960	AKAP13	0.34	6.87	0.3	2.13e-11	Coronary artery disease;
LGG	cis	rs9880211	1.000	rs6768743	chr3:136205007	C/T	cg21827317	chr3:136751795	NA	0.48	7.16	0.32	3.09e-12	Body mass index;Height;
LGG	cis	rs17767392	0.958	rs3784064	chr14:72059551	G/A	cg13720639	chr14:72061746	SIPA1L1	0.39	8.25	0.36	1.64e-15	Mitral valve prolapse;
LGG	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg00531865	chr16:30841666	NA	-0.56	-11.29	-0.46	2.78e-26	Multiple myeloma;
LGG	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg04132472	chr17:19861366	AKAP10	0.26	7.17	0.32	3e-12	Schizophrenia;
LGG	cis	rs9534288	0.762	rs1571053	chr13:46554854	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.22	-0.52	4.68e-34	Blood protein levels;
LGG	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg23894439	chr1:183413866	NA	0.49	9.12	0.39	2.38e-18	Systemic lupus erythematosus;
LGG	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg25174290	chr11:3078921	CARS	0.73	15.64	0.59	1.47e-44	Longevity;
LGG	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11821927	chr15:45694435	SPATA5L1	0.42	6.7	0.3	6.05e-11	Cognitive performance;
LGG	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg21130718	chr4:1044621	NA	0.39	7.58	0.33	1.88e-13	Recombination rate (males);
LGG	cis	rs2239547	0.607	rs9836178	chr3:52925403	T/C	cg11645453	chr3:52864694	ITIH4	-0.71	-10.49	-0.44	3.04e-23	Schizophrenia;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg15971980	chr6:150254442	NA	0.44	8.07	0.35	5.93e-15	Lung cancer;
LGG	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.3e-41	Cannabis dependence symptom count;
LGG	cis	rs3857067	1.000	rs1397025	chr4:95018987	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg02725872	chr8:58115012	NA	-0.7	-10.52	-0.44	2.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.54e-24	Aortic root size;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg08508337	chr8:144660607	NAPRT1	0.9	7.25	0.32	1.74e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs7000551	0.751	rs2461481	chr8:22382780	A/G	cg12081754	chr8:22256438	SLC39A14	-0.64	-11.55	-0.47	2.66e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg16482183	chr6:26056742	HIST1H1C	-0.53	-9.45	-0.4	1.65e-19	Height;
LGG	cis	rs6993813	0.843	rs4401893	chr8:120044383	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs8017423	0.845	rs114583024	chr14:90727628	T/C	cg04374321	chr14:90722782	PSMC1	0.9	18.94	0.66	1.2e-59	Mortality in heart failure;
LGG	cis	rs2227564	0.620	rs12783161	chr10:75572201	G/C	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.76	-0.41	1.41e-20	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs774359	0.789	rs2453552	chr9:27527512	A/C	cg21249376	chr9:27528432	MOBKL2B	0.42	8.08	0.35	5.74e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.83	0.54	1.18e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs7717393	1.000	rs13358340	chr5:155757872	C/T	cg04435420	chr5:155754009	SGCD	1.13	13.01	0.52	3.5e-33	Egg allergy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15358743	chr18:56807035	SEC11C	0.47	7.71	0.34	7.51e-14	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.19	-0.49	7.43e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs1419980	0.673	rs7296837	chr12:7757832	A/G	cg10578777	chr12:7781093	NA	0.63	8.58	0.37	1.42e-16	HDL cholesterol levels;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.39	-0.43	7.4e-23	Tonsillectomy;
LGG	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22496380	chr5:211416	CCDC127	-1.25	-17.6	-0.63	1.83e-53	Breast cancer;
LGG	cis	rs72925845	0.525	rs72907478	chr17:76431015	C/T	cg03830375	chr17:76426088	DNAH17	0.51	7.24	0.32	1.83e-12	Triglycerides;
LGG	trans	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.35	0.43	9.95e-23	Ulcerative colitis;
LGG	cis	rs6500395	0.554	rs2355302	chr16:48738428	C/T	cg16662043	chr16:48846231	NA	0.44	7.87	0.34	2.52e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg10295955	chr4:187884368	NA	-1.13	-31.31	-0.82	2.11e-116	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4819852	0.736	rs7292055	chr22:19974654	G/A	cg07821417	chr22:19972146	ARVCF	0.51	10.96	0.45	5.13e-25	Pulse pressure;
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.37	-6.64	-0.3	8.57e-11	Schizophrenia;
LGG	cis	rs13126513	0.708	rs7665289	chr4:100448167	G/T	cg05468953	chr4:100565104	NA	0.41	8.28	0.36	1.36e-15	Metabolite levels (MHPG);
LGG	cis	rs10979	1.000	rs12738	chr6:143890049	A/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.44	-0.5	7.29e-31	Hypospadias;
LGG	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg05025159	chr2:241905733	NA	0.47	9.64	0.41	3.65e-20	Joint mobility (Beighton score);
LGG	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg07148914	chr20:33460835	GGT7	0.51	8.37	0.36	7.03e-16	Height;
LGG	cis	rs7166081	1.000	rs12148121	chr15:67494922	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.74	-0.3	4.72e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg00933542	chr6:150070202	PCMT1	0.4	7.14	0.32	3.57e-12	Lung cancer;
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg16141378	chr3:129829833	LOC729375	0.39	8.91	0.38	1.21e-17	Triglycerides;
LGG	cis	rs7582720	1.000	rs72932588	chr2:203883193	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.34	0.4	3.94e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg05623727	chr3:50126028	RBM5	0.39	8.51	0.37	2.35e-16	Body mass index;
LGG	trans	rs2562456	0.833	rs1781867	chr19:21487170	T/C	cg00806126	chr19:22604979	ZNF98	-0.56	-7.54	-0.33	2.56e-13	Pain;
LGG	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-10.11	-0.43	7.73e-22	Common traits (Other);
LGG	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.38	-0.36	6.28e-16	Monocyte count;
LGG	cis	rs17067123	0.614	rs11727059	chr4:180065225	G/A	cg26610307	chr4:180072759	NA	-0.47	-6.68	-0.3	6.79e-11	Response to hepatitis C treatment;
LGG	cis	rs6489882	0.867	rs4766665	chr12:113363109	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.18e-13	Chronic lymphocytic leukemia;
LGG	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg02487422	chr3:49467188	NICN1	0.58	10.75	0.45	3.16e-24	Resting heart rate;
LGG	cis	rs988958	0.565	rs13030802	chr2:42237344	T/C	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs4748857	0.947	rs4748851	chr10:23565338	T/C	cg18853376	chr10:23633759	C10orf67	0.36	6.84	0.3	2.52e-11	Systemic lupus erythematosus;
LGG	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg21053147	chr12:120880522	NA	0.53	8.04	0.35	7.64e-15	Type 1 diabetes nephropathy;
LGG	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg07930552	chr6:133119739	C6orf192	0.88	11.39	0.47	1.18e-26	Type 2 diabetes nephropathy;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.84	0.42	7.38e-21	Longevity;
LGG	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg05169160	chr2:178484487	TTC30A	0.35	7.11	0.31	4.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg07677032	chr17:61819896	STRADA	-0.56	-9.74	-0.41	1.66e-20	Prudent dietary pattern;
LGG	cis	rs11098499	1.000	rs11098500	chr4:120219239	T/A	cg09307838	chr4:120376055	NA	0.72	11.88	0.48	1.36e-28	Corneal astigmatism;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg26338869	chr17:61819248	STRADA	-0.53	-8.86	-0.38	1.68e-17	Prudent dietary pattern;
LGG	cis	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg21775007	chr8:11205619	TDH	0.81	14.17	0.55	3.91e-38	Retinal vascular caliber;
LGG	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06108461	chr20:60628389	TAF4	-0.71	-12.84	-0.51	1.76e-32	Body mass index;
LGG	cis	rs62380364	0.602	rs650702	chr5:88055313	G/A	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.49e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6663390	0.510	rs2267895	chr1:208081063	C/T	cg03990033	chr1:208084030	CD34	0.56	7.45	0.33	4.69e-13	Facial morphology (factor 18);
LGG	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg11247378	chr22:39784982	NA	-0.31	-8.54	-0.37	1.96e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs3008870	1.000	rs58680688	chr1:67443751	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-24.01	-0.74	2.46e-83	Lymphocyte percentage of white cells;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg24101359	chr6:42928495	GNMT	0.53	15.19	0.58	1.37e-42	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4740619	0.905	rs1355171	chr9:15681694	C/A	cg14451791	chr9:16040625	NA	-0.35	-8.99	-0.39	6.13e-18	Body mass index;
LGG	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg27523141	chr10:43048294	ZNF37B	-0.4	-8.04	-0.35	7.44e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs6495367	1.000	rs745030	chr15:79381705	G/A	cg17916960	chr15:79447300	NA	0.53	9.22	0.39	1.01e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.65	-12.35	-0.5	1.78e-30	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg18032289	chr17:61959525	GH2	-0.4	-6.88	-0.3	1.95e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg20309703	chr11:118481025	PHLDB1	0.57	11.09	0.46	1.6e-25	Cholesterol, total;
LGG	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg01181863	chr3:195395398	SDHAP2	-0.63	-10.05	-0.42	1.25e-21	Pancreatic cancer;
LGG	cis	rs889398	0.594	rs7202233	chr16:69894432	A/G	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.59	-0.33	1.81e-13	Body mass index;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.7	-0.37	5.86e-17	Joint mobility (Beighton score);
LGG	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg15440763	chr7:158190612	PTPRN2	-0.44	-9.33	-0.4	4.27e-19	Obesity-related traits;
LGG	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	cis	rs7666738	0.791	rs2865953	chr4:99040319	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.34	0.36	8.54e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3857067	0.806	rs34396894	chr4:95097600	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.98	-0.35	1.17e-14	QT interval;
LGG	cis	rs113835537	0.597	rs3737525	chr11:66306355	A/G	cg24851651	chr11:66362959	CCS	0.45	7.72	0.34	7.1e-14	Airway imaging phenotypes;
LGG	cis	rs1107366	0.722	rs9851577	chr3:125908310	C/T	cg17230874	chr3:125932073	NA	0.59	11.79	0.48	2.98e-28	Metabolite levels;
LGG	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.24	-0.36	1.74e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10934753	0.609	rs2077523	chr3:125905389	A/C	cg17230874	chr3:125932073	NA	0.55	11.37	0.47	1.43e-26	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg27189623	chr16:705930	WDR90	0.41	7.79	0.34	4.57e-14	Height;
LGG	cis	rs8067545	0.750	rs4925072	chr17:19956899	C/T	cg13482628	chr17:19912719	NA	-0.61	-12.08	-0.49	2.09e-29	Schizophrenia;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg01673284	chr16:4527211	HMOX2	-0.37	-7.27	-0.32	1.58e-12	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19738182	chr2:223726189	ACSL3	0.46	6.89	0.3	1.89e-11	Gut microbiome composition (summer);
LGG	cis	rs7717393	1.000	rs7725121	chr5:155753983	A/T	cg19569526	chr5:155754265	SGCD	0.83	7.86	0.34	2.7e-14	Egg allergy;
LGG	cis	rs3845702	0.935	rs6433822	chr2:180840422	G/C	cg01881094	chr2:180872142	CWC22	-0.9	-13.89	-0.54	6.48e-37	Schizophrenia;
LGG	cis	rs975739	1.000	rs1759975	chr13:78385158	G/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.7	0.3	6.02e-11	Hair color;
LGG	cis	rs3219090	0.861	rs9426568	chr1:226603897	T/G	cg17127702	chr1:226594323	PARP1	-0.38	-12.32	-0.5	2.32e-30	Melanoma;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18632527	chr7:6120830	NA	0.49	7.36	0.32	8.7e-13	Gut microbiome composition (summer);
LGG	cis	rs28830936	0.510	rs7174099	chr15:42099059	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.78	-26.4	-0.78	2.23e-94	Diastolic blood pressure;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.59	-10.09	-0.42	9.06e-22	Obesity-related traits;
LGG	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10802521	chr3:52805072	NEK4	0.44	7.5	0.33	3.19e-13	Bipolar disorder;
LGG	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg15208524	chr1:10270712	KIF1B	0.47	7.93	0.35	1.66e-14	Hepatocellular carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19034708	chr8:17780168	PCM1	0.49	8.27	0.36	1.4e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-6.7	-0.3	6.07e-11	Neuroticism;
LGG	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9462027	0.606	rs9462024	chr6:34772793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.943	rs76703022	chr6:25703529	A/C	cg16482183	chr6:26056742	HIST1H1C	0.68	9.22	0.39	1.02e-18	Iron status biomarkers;
LGG	cis	rs11229555	0.645	rs34530191	chr11:58200854	A/G	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg27211696	chr2:191398769	TMEM194B	0.4	9.31	0.4	5.13e-19	Pulse pressure;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.63	11.45	0.47	6.89e-27	Lymphocyte counts;
LGG	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.24	-0.43	2.63e-22	Hepatocellular carcinoma;
LGG	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg04617936	chr2:214353	NA	-0.39	-7.34	-0.32	9.61e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs666930	0.967	rs637868	chr1:120257110	A/G	cg19096424	chr1:120255104	PHGDH	0.44	7.72	0.34	7.08e-14	Breast cancer;
LGG	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg16141378	chr3:129829833	LOC729375	0.33	7.27	0.32	1.55e-12	Neuroticism;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	8.26	0.36	1.55e-15	Schizophrenia;
LGG	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg07120314	chr15:79043507	NA	-0.48	-8.86	-0.38	1.67e-17	Post bronchodilator FEV1;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.82	0.51	2.04e-32	Obesity-related traits;
LGG	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.02	-0.42	1.67e-21	Retinal vascular caliber;
LGG	cis	rs2688608	0.752	rs1916341	chr10:75671162	G/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.29	-0.32	1.35e-12	Inflammatory bowel disease;
LGG	cis	rs4950322	0.570	rs4950409	chr1:146807614	G/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-9.67	-0.41	2.96e-20	Glycated hemoglobin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21735648	chr20:46130382	NCOA3	0.41	7.05	0.31	6.36e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.02	-0.31	8.05e-12	Bipolar disorder;
LGG	cis	rs16976116	0.901	rs28864456	chr15:55503092	T/C	cg11288833	chr15:55489084	RSL24D1	0.56	7.51	0.33	3.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.15e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35160687	0.623	rs13005014	chr2:86487216	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.9	0.31	1.74e-11	Night sleep phenotypes;
LGG	cis	rs60695258	0.572	rs375795	chr4:87972465	C/T	cg01323104	chr4:87958903	AFF1	0.24	6.78	0.3	3.57e-11	Hematocrit;
LGG	trans	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs6728642	1.000	rs6728642	chr2:97607071	A/G	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.59	-0.33	1.73e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9463078	0.547	rs764396	chr6:44710691	C/G	cg25276700	chr6:44698697	NA	0.4	8.01	0.35	9.21e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg03929089	chr4:120376271	NA	-1.03	-23.58	-0.74	2.44e-81	Height;
LGG	cis	rs7660883	0.897	rs342469	chr4:88050554	G/A	cg21988461	chr4:88008667	AFF1	0.35	9.98	0.42	2.24e-21	HDL cholesterol levels;
LGG	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg10523679	chr1:76189770	ACADM	0.75	12.31	0.5	2.46e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1062177	1.000	rs2915877	chr5:151150601	C/G	cg00977110	chr5:151150581	G3BP1	0.5	8.0	0.35	1.04e-14	Preschool internalizing problems;
LGG	cis	rs1322639	0.618	rs9505942	chr6:169591793	T/C	cg04662567	chr6:169592167	NA	-0.86	-11.87	-0.48	1.55e-28	Pulse pressure;
LGG	cis	rs1620921	0.505	rs13203571	chr6:161208765	A/G	cg01280913	chr6:161186852	NA	-0.51	-10.75	-0.45	3.35e-24	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.01	-0.35	9.49e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20232060	chr3:141457873	RNF7	0.48	7.14	0.31	3.7e-12	Gut microbiome composition (summer);
LGG	cis	rs5756391	0.555	rs5756390	chr22:37296129	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	8.65	0.37	8.65e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs853679	0.517	rs9357066	chr6:28129831	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg06221963	chr1:154839813	KCNN3	-0.49	-9.89	-0.42	4.71e-21	Prostate cancer;
LGG	cis	rs9583531	0.509	rs12184676	chr13:111396484	A/G	cg24331049	chr13:111365604	ING1	-0.86	-11.71	-0.48	6.57e-28	Coronary artery disease;
LGG	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-7.99	-0.35	1.12e-14	Retinal vascular caliber;
LGG	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg12856521	chr11:46389249	DGKZ	-0.4	-6.85	-0.3	2.4e-11	Leprosy;
LGG	cis	rs6439153	0.524	rs1531807	chr3:128748148	A/C	cg24176926	chr3:128744824	CCDC48	0.36	7.83	0.34	3.32e-14	Pneumococcal bacteremia;
LGG	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg17971929	chr21:40555470	PSMG1	0.88	17.2	0.62	1.27e-51	Cognitive function;
LGG	cis	rs17122278	0.613	rs573971	chr11:118393396	A/G	cg20110707	chr11:118481992	PHLDB1	0.47	7.2	0.32	2.43e-12	Total cholesterol levels;
LGG	cis	rs11608355	0.545	rs35018715	chr12:109893134	T/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg06212747	chr3:49208901	KLHDC8B	0.72	12.95	0.52	6.23e-33	Menarche (age at onset);
LGG	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg05941027	chr17:61774174	LIMD2	0.32	7.68	0.34	9.73e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg21775007	chr8:11205619	TDH	-0.49	-7.71	-0.34	7.68e-14	Neuroticism;
LGG	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg20573242	chr4:122745356	CCNA2	-0.46	-7.89	-0.34	2.17e-14	Type 2 diabetes;
LGG	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg08344181	chr3:125677491	NA	-0.54	-7.26	-0.32	1.68e-12	Depression;
LGG	cis	rs7444	0.882	rs5749495	chr22:21940310	A/G	cg22858872	chr22:21984481	YDJC	-0.37	-6.81	-0.3	3.08e-11	Systemic lupus erythematosus;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg06968155	chr5:131705112	SLC22A5	-0.72	-8.69	-0.37	6.33e-17	Rheumatoid arthritis;
LGG	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg04851639	chr8:1020857	NA	-0.45	-9.37	-0.4	3.11e-19	Schizophrenia;
LGG	cis	rs11168187	0.891	rs2003471	chr12:48124893	G/A	cg12761788	chr12:48120090	P11	0.45	7.46	0.33	4.31e-13	Vertical cup-disc ratio;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.49e-22	Tonsillectomy;
LGG	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg02951883	chr7:2050386	MAD1L1	0.46	7.81	0.34	3.77e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02018176	chr4:1364513	KIAA1530	-0.49	-11.51	-0.47	4.06e-27	Obesity-related traits;
LGG	cis	rs34734847	0.703	rs3794215	chr12:121168083	T/C	cg21892295	chr12:121157589	UNC119B	-0.38	-7.1	-0.31	4.71e-12	Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.37e-17	Self-reported allergy;
LGG	cis	rs926392	0.640	rs1007913	chr20:37693592	G/A	cg16355469	chr20:37678765	NA	0.59	9.23	0.39	9.68e-19	Dialysis-related mortality;
LGG	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg26248373	chr2:1572462	NA	-0.72	-8.98	-0.39	6.9e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.52	-8.44	-0.37	4.17e-16	Renal function-related traits (BUN);
LGG	cis	rs367943	0.666	rs6594705	chr5:112692851	T/G	cg12552261	chr5:112820674	MCC	0.56	10.09	0.42	8.95e-22	Type 2 diabetes;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.71	-0.38	5.27e-17	Personality dimensions;
LGG	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7923609	0.967	rs2393977	chr10:65247609	A/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.7	-0.3	6.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg02269571	chr22:50332266	NA	0.65	8.68	0.37	6.58e-17	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg11494091	chr17:61959527	GH2	0.56	9.1	0.39	2.67e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs490234	0.776	rs10115455	chr9:128458850	T/C	cg14078157	chr9:128172775	NA	-0.48	-8.39	-0.36	6.05e-16	Mean arterial pressure;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg18446336	chr7:2847575	GNA12	-0.29	-6.75	-0.3	4.41e-11	Height;
LGG	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.59	-0.37	1.32e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7929679	0.577	rs10836306	chr11:34797962	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.78	0.3	3.78e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05165339	chr4:1420672	NA	-0.28	-7.49	-0.33	3.56e-13	Longevity;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.51e-20	Prudent dietary pattern;
LGG	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg13402656	chr8:1511478	DLGAP2	-0.73	-13.51	-0.53	2.76e-35	Lung cancer;
LGG	cis	rs672059	1.000	rs566625	chr1:183161441	A/G	cg07928641	chr1:182991847	LAMC1	0.34	6.85	0.3	2.34e-11	Hypertriglyceridemia;
LGG	cis	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.619	rs7012218	chr8:11145676	T/A	cg16141378	chr3:129829833	LOC729375	-0.32	-6.85	-0.3	2.39e-11	Retinal vascular caliber;
LGG	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg26384229	chr12:38710491	ALG10B	0.62	11.21	0.46	5.79e-26	Morning vs. evening chronotype;
LGG	cis	rs12282928	1.000	rs10838851	chr11:48286231	T/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.28	-0.32	1.43e-12	Migraine - clinic-based;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	9.92	0.42	3.67e-21	Longevity;
LGG	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg00376283	chr12:123451042	ABCB9	-0.6	-11.29	-0.46	2.91e-26	Platelet count;
LGG	cis	rs735539	0.521	rs2818992	chr13:21398087	G/A	cg04906043	chr13:21280425	IL17D	-0.46	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.29	0.43	1.74e-22	Lung cancer in ever smokers;
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg02158880	chr13:53174818	NA	0.35	6.71	0.3	5.58e-11	Lewy body disease;
LGG	cis	rs4751006	0.543	rs9794336	chr10:128777873	C/T	cg05702161	chr10:128779687	DOCK1	0.68	8.35	0.36	7.7e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1032833	0.732	rs2305170	chr2:179974761	A/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg00647317	chr7:50633725	DDC	0.36	8.61	0.37	1.15e-16	Body mass index;
LGG	cis	rs7017914	0.934	rs13255886	chr8:71565954	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.91	-0.31	1.6e-11	Bone mineral density;
LGG	cis	rs3087591	0.960	rs2905803	chr17:29520056	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.5	0.56	1.49e-39	Hip circumference;
LGG	cis	rs11971779	0.715	rs7779390	chr7:139112953	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.35	0.36	7.72e-16	Platelet count;
LGG	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg12011299	chr4:100065546	ADH4	0.41	8.87	0.38	1.63e-17	Alcohol dependence;
LGG	cis	rs1203833	0.573	rs2685131	chr16:209764	G/C	cg25425005	chr16:202905	HBZ	-0.63	-10.09	-0.42	9.07e-22	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs12791968	0.765	rs11038250	chr11:45009114	A/G	cg11846598	chr11:44996168	LOC221122	-0.54	-8.98	-0.39	7.04e-18	Inhibitory control;
LGG	cis	rs7107174	0.901	rs2450139	chr11:77924544	G/A	cg02023728	chr11:77925099	USP35	0.43	7.75	0.34	5.71e-14	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.31	-0.63	4.08e-52	Skin colour saturation;
LGG	cis	rs11771526	0.901	rs11767695	chr7:32315960	G/A	cg27532318	chr7:32358331	NA	0.73	7.43	0.33	5.29e-13	Body mass index;
LGG	cis	rs7928758	0.767	rs746431	chr11:134267093	A/G	cg22777979	chr11:134283252	B3GAT1	0.58	8.39	0.36	5.96e-16	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.21	-0.49	6.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.4	-7.16	-0.32	3.15e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg21435375	chr2:172878103	MAP1D	-0.3	-6.74	-0.3	4.68e-11	Schizophrenia;
LGG	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.09	-0.31	5.19e-12	Blood metabolite levels;
LGG	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-8.34	-0.36	8.38e-16	Aortic root size;
LGG	cis	rs9660992	0.700	rs7547565	chr1:205259402	G/A	cg21545522	chr1:205238299	TMCC2	-0.43	-7.88	-0.34	2.31e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg02487422	chr3:49467188	NICN1	0.59	10.96	0.45	5.31e-25	Resting heart rate;
LGG	cis	rs774359	0.789	rs2492823	chr9:27502005	A/G	cg21249376	chr9:27528432	MOBKL2B	0.47	8.97	0.38	7.2e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.63	0.48	1.28e-27	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.76	-0.34	5.62e-14	Resting heart rate;
LGG	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg08400814	chr5:56204995	C5orf35	-0.45	-7.34	-0.32	9.68e-13	Initial pursuit acceleration;
LGG	cis	rs3761847	0.500	rs7037673	chr9:123740484	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.46	8.31	0.36	1.11e-15	Rheumatoid arthritis;
LGG	cis	rs1003719	0.628	rs2835635	chr21:38528866	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-12.81	-0.51	2.2e-32	Eye color traits;
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg05091796	chr16:4465799	CORO7	-1.0	-17.88	-0.64	9e-55	Schizophrenia;
LGG	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg24692254	chr21:30365293	RNF160	0.72	13.43	0.53	5.8e-35	Selective IgA deficiency;
LGG	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg16586182	chr3:47516702	SCAP	-0.8	-15.49	-0.58	6.37e-44	Colorectal cancer;
LGG	cis	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg07460842	chr6:66804631	NA	0.96	17.9	0.64	7.68e-55	Exhaled nitric oxide output;
LGG	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg20476274	chr7:133979776	SLC35B4	0.53	9.47	0.4	1.45e-19	Mean platelet volume;
LGG	cis	rs7216064	0.861	rs62084252	chr17:65879578	G/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.85	-0.38	1.89e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1408799	0.732	rs12115198	chr9:12763450	C/G	cg05274944	chr9:12693694	TYRP1	-0.38	-8.97	-0.38	7.61e-18	Eye color;Blue vs. green eyes;
LGG	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg22875332	chr1:76189707	ACADM	-0.61	-9.75	-0.41	1.48e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10861342	1.000	rs11112368	chr12:105494218	T/C	cg23923672	chr12:105501055	KIAA1033	0.72	6.65	0.3	8.32e-11	IgG glycosylation;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.69	-0.34	8.98e-14	Lung cancer;
LGG	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs7851660	0.809	rs1561957	chr9:100670272	T/C	cg13688889	chr9:100608707	NA	-0.64	-12.84	-0.51	1.75e-32	Strep throat;
LGG	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.18	0.52	6.78e-34	Psoriasis;
LGG	cis	rs5753037	0.809	rs2074706	chr22:30200893	G/C	cg27665648	chr22:30112403	NA	0.29	6.82	0.3	2.85e-11	Type 1 diabetes;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.33	-0.32	1.02e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.85	0.42	6.8e-21	Height;
LGG	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs1806153	0.673	rs628224	chr11:31819174	A/G	cg11990419	chr11:31841155	NA	-0.36	-7.62	-0.33	1.41e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs12431410	0.782	rs4901955	chr14:60170383	G/A	cg07950296	chr14:60194823	RTN1	-0.35	-6.77	-0.3	3.82e-11	Schizophrenia;
LGG	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg15704280	chr7:45808275	SEPT13	0.49	7.97	0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg03733263	chr8:22462867	KIAA1967	1.13	33.05	0.84	6.78e-124	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9534288	0.619	rs6561292	chr13:46683560	G/T	cg15192986	chr13:46630673	CPB2	0.68	14.39	0.56	4.54e-39	Blood protein levels;
LGG	cis	rs7666738	0.783	rs10028584	chr4:98962404	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.14e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.15	-0.39	1.85e-18	Educational attainment;
LGG	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11644478	chr21:40555479	PSMG1	-0.59	-9.64	-0.41	3.55e-20	Menarche (age at onset);
LGG	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.14e-11	Retinal vascular caliber;
LGG	cis	rs368123	1.000	rs433992	chr6:160738830	T/C	cg07349212	chr6:160770346	SLC22A3	-0.36	-7.8	-0.34	4.04e-14	Waist circumference;
LGG	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg03453431	chr7:157225567	NA	-0.47	-8.08	-0.35	5.48e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1568889	1.000	rs11826837	chr11:28322566	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.73	-13.79	-0.54	1.8e-36	Bipolar disorder;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02506923	chr20:30410603	MYLK2	-0.44	-7.27	-0.32	1.59e-12	Pancreatic cancer;
LGG	cis	rs78545713	0.536	rs2179516	chr6:26229411	C/T	cg01420254	chr6:26195488	NA	0.76	7.36	0.32	8.65e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs2239547	0.603	rs4687698	chr3:53097108	C/T	cg11645453	chr3:52864694	ITIH4	0.66	10.5	0.44	2.8e-23	Schizophrenia;
LGG	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg06481639	chr22:41940642	POLR3H	-0.52	-7.67	-0.34	1.04e-13	Vitiligo;
LGG	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg21605333	chr4:119757512	SEC24D	1.39	12.69	0.51	6.95e-32	Cannabis dependence symptom count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08209724	chr17:30677138	MIR632;ZNF207	-0.5	-7.27	-0.32	1.55e-12	Systemic lupus erythematosus;
LGG	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg14593290	chr7:50529359	DDC	-0.67	-12.05	-0.49	2.71e-29	Malaria;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg07870213	chr5:140052090	DND1	0.92	16.99	0.62	1.14e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.81	0.3	3.04e-11	Schizophrenia;
LGG	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.08	-0.31	5.55e-12	Neuroticism;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20887711	chr4:1340912	KIAA1530	0.6	11.6	0.47	1.75e-27	Obesity-related traits;
LGG	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg13770153	chr20:60521292	NA	-0.51	-8.37	-0.36	7.08e-16	Body mass index;
LGG	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	9.28	0.4	6.36e-19	Neuroticism;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.85	0.59	1.69e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9513627	1.000	rs73556165	chr13:100120317	C/T	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	trans	rs3206736	0.548	rs328942	chr7:35051815	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.0	0.31	8.84e-12	Diastolic blood pressure;
LGG	cis	rs7147624	1.000	rs2411349	chr14:66214426	T/C	cg03016385	chr14:66212404	NA	-0.76	-9.25	-0.39	8.22e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs9682041	0.561	rs6444928	chr3:170147875	A/G	cg11886554	chr3:170076028	SKIL	0.63	7.59	0.33	1.72e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.87	0.38	1.57e-17	Aortic root size;
LGG	cis	rs73086581	1.000	rs73086588	chr20:3982224	A/T	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.43e-26	Response to antidepressants in depression;
LGG	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg10523679	chr1:76189770	ACADM	0.83	14.3	0.55	1.09e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.67	0.37	7.6e-17	Mean platelet volume;
LGG	cis	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg09904177	chr6:26538194	HMGN4	-0.52	-7.26	-0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.51	-9.76	-0.41	1.42e-20	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg18350739	chr11:68623251	NA	-0.85	-21.64	-0.71	2.95e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17554472	chr22:41940697	POLR3H	0.44	6.73	0.3	5.12e-11	Vitiligo;
LGG	cis	rs2467099	0.786	rs1046446	chr17:73896299	C/T	cg23806715	chr17:73775811	H3F3B	0.51	7.47	0.33	3.95e-13	Systolic blood pressure;
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	trans	rs526821	0.553	rs519637	chr11:55295935	A/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	7.98	0.35	1.15e-14	Menarche (age at onset);
LGG	cis	rs9397585	0.857	rs9371663	chr6:153377320	T/G	cg17707550	chr6:153380415	RGS17	0.62	14.41	0.56	3.57e-39	Body mass index;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg09448879	chr15:79043637	NA	-0.53	-13.39	-0.53	8.84e-35	Coronary artery disease or large artery stroke;
LGG	cis	rs1801251	0.778	rs2592116	chr2:233735709	G/A	cg25237894	chr2:233734115	C2orf82	-0.73	-15.72	-0.59	6.54e-45	Coronary artery disease;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	14.87	0.57	3.64e-41	Obesity-related traits;
LGG	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-7.09	-0.31	5.05e-12	Aortic root size;
LGG	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg00605270	chr1:28261552	SMPDL3B	-0.35	-7.55	-0.33	2.4e-13	Corneal astigmatism;
LGG	trans	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.61	0.47	1.52e-27	Corneal astigmatism;
LGG	cis	rs12135191	0.834	rs10925066	chr1:236475696	G/A	cg21399712	chr1:236511386	NA	-0.41	-7.88	-0.34	2.3e-14	Urate levels (BMI interaction);
LGG	cis	rs8064029	0.881	rs72633271	chr16:4903321	C/G	cg04440724	chr16:4920505	UBN1	-0.62	-7.54	-0.33	2.58e-13	Cancer;
LGG	cis	rs4774899	0.966	rs4447362	chr15:57563354	G/C	cg08128148	chr15:57256372	TCF12	-0.32	-7.29	-0.32	1.38e-12	Urinary tract infection frequency;
LGG	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18252515	chr7:66147081	NA	0.46	7.42	0.33	5.58e-13	Aortic root size;
LGG	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg09307838	chr4:120376055	NA	0.66	11.32	0.47	2.19e-26	Corneal astigmatism;
LGG	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg00531865	chr16:30841666	NA	-0.55	-11.33	-0.47	2.04e-26	Multiple myeloma;
LGG	cis	rs11676348	0.755	rs13410318	chr2:219022910	T/G	cg00012203	chr2:219082015	ARPC2	0.55	9.75	0.41	1.5e-20	Ulcerative colitis;
LGG	trans	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.56	-0.33	2.15e-13	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27054308	chr14:20922865	APEX1;OSGEP	0.47	7.48	0.33	3.75e-13	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg04863758	chr4:1303710	MAEA	0.44	7.39	0.33	6.69e-13	Obesity-related traits;
LGG	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.41	-8.82	-0.38	2.33e-17	Restless legs syndrome;
LGG	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg18196295	chr10:418757	DIP2C	0.55	10.78	0.45	2.5300000000000002e-24	Psychosis in Alzheimer's disease;
LGG	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	7.61	0.33	1.54e-13	Systolic blood pressure;
LGG	cis	rs477692	0.905	rs508360	chr10:131424969	A/G	cg05714579	chr10:131428358	MGMT	0.66	14.07	0.55	1.14e-37	Response to temozolomide;
LGG	cis	rs6792151	0.598	rs3850191	chr3:171561701	C/G	cg26441893	chr3:171559851	TMEM212	-0.44	-7.71	-0.34	7.72e-14	Red cell distribution width;
LGG	cis	rs6466055	0.748	rs41563	chr7:104852654	G/A	cg04380332	chr7:105027541	SRPK2	-0.36	-6.89	-0.3	1.86e-11	Schizophrenia;
LGG	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3771570	1.000	rs62193202	chr2:242303717	G/A	cg21155796	chr2:242212141	HDLBP	0.72	9.2	0.39	1.27e-18	Prostate cancer;
LGG	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.17e-12	HDL cholesterol;
LGG	trans	rs2471042	0.574	rs1493354	chr5:86174147	C/T	cg16752029	chr16:27214750	JMJD5	-0.42	-6.74	-0.3	4.64e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25072359	chr17:41440525	NA	0.53	10.18	0.43	4.36e-22	Menopause (age at onset);
LGG	cis	rs2274273	0.837	rs7148171	chr14:55770744	G/C	cg04306507	chr14:55594613	LGALS3	0.64	18.06	0.64	1.37e-55	Protein biomarker;
LGG	trans	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg13565492	chr6:43139072	SRF	-0.9	-15.7	-0.59	7.84e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12431410	0.584	rs10145080	chr14:60234102	G/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.29	-0.32	1.39e-12	Schizophrenia;
LGG	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg04568710	chr12:38710424	ALG10B	-0.34	-7.37	-0.32	7.87e-13	Bladder cancer;
LGG	cis	rs3796619	1.000	rs1466214	chr4:1073760	C/T	cg21130718	chr4:1044621	NA	0.38	7.38	0.32	7.18e-13	Recombination rate (males);
LGG	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg00405596	chr8:11794950	NA	0.63	10.91	0.45	7.92e-25	Myopia (pathological);
LGG	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.22	0.39	1.06e-18	HDL cholesterol;
LGG	cis	rs7737355	0.738	rs3776011	chr5:130868840	C/T	cg06307176	chr5:131281290	NA	0.51	8.59	0.37	1.33e-16	Life satisfaction;
LGG	cis	rs727505	0.909	rs1031958	chr7:124627309	C/T	cg23710748	chr7:124431027	NA	-0.51	-9.39	-0.4	2.69e-19	Lewy body disease;
LGG	cis	rs4363385	0.747	rs4845506	chr1:152968407	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.02	-0.39	4.84e-18	Inflammatory skin disease;
LGG	cis	rs7267979	0.934	rs2482913	chr20:25405086	T/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.29e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14016089	chr9:115818857	ZFP37	0.49	7.05	0.31	6.51e-12	Hip circumference;
LGG	cis	rs2249625	0.564	rs2463734	chr6:72882558	C/T	cg27608224	chr6:72922399	RIMS1	0.32	7.23	0.32	2.05e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs7623687	0.786	rs34759087	chr3:49162284	C/T	cg19401529	chr3:49056140	DALRD3	0.73	7.57	0.33	2.1e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs7911264	0.628	rs6583833	chr10:94409800	C/T	cg25093409	chr10:94429542	NA	0.43	8.78	0.38	3.21e-17	Inflammatory bowel disease;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg19168338	chr16:4465731	CORO7	-0.73	-13.33	-0.53	1.6e-34	Schizophrenia;
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.09e-21	Electroencephalogram traits;
LGG	cis	rs7666738	0.716	rs7656233	chr4:99079237	G/A	cg05340658	chr4:99064831	C4orf37	0.44	7.12	0.31	4.22e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg02269571	chr22:50332266	NA	0.63	10.02	0.42	1.62e-21	Schizophrenia;
LGG	cis	rs773506	0.628	rs10733739	chr9:93929515	C/T	cg14446406	chr9:93919335	NA	0.64	11.24	0.46	4.55e-26	Type 2 diabetes nephropathy;
LGG	cis	rs477692	1.000	rs531572	chr10:131427569	A/G	cg05714579	chr10:131428358	MGMT	-0.57	-11.8	-0.48	2.81e-28	Response to temozolomide;
LGG	cis	rs1466045	0.698	rs1867911	chr11:3158300	T/A	cg01418188	chr11:3145609	OSBPL5	0.29	7.37	0.32	8.05e-13	Cisplatin-induced ototoxicity;
LGG	cis	rs4851266	1.000	rs12990462	chr2:100827216	G/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg01420254	chr6:26195488	NA	0.92	12.54	0.5	2.86e-31	Gout;Renal underexcretion gout;
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg18681998	chr4:17616180	MED28	0.86	18.7	0.66	1.47e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.89e-22	Arsenic metabolism;
LGG	cis	rs34929064	0.536	rs2961279	chr7:22638154	T/C	cg18045685	chr7:22629474	NA	-0.86	-19.56	-0.67	1.57e-62	Major depression and alcohol dependence;
LGG	cis	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg01579765	chr21:45077557	HSF2BP	0.4	8.4	0.36	5.62e-16	Mean corpuscular hemoglobin;
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg09359103	chr1:154839909	KCNN3	-0.52	-10.75	-0.45	3.24e-24	Prostate cancer;
LGG	cis	rs9972944	0.756	rs2873818	chr17:63762867	A/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.3	-0.36	1.13e-15	Total body bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11841349	chr3:9791615	OGG1	-0.41	-6.68	-0.3	6.7e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg08355456	chr11:67383691	NA	-0.5	-8.72	-0.38	4.99e-17	Mean corpuscular volume;
LGG	trans	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg17712092	chr4:129076599	LARP1B	-0.57	-10.07	-0.42	1.08e-21	DNA methylation (variation);
LGG	cis	rs1014246	0.848	rs10787718	chr10:118467648	A/G	cg14919929	chr10:118506882	NA	-0.58	-10.38	-0.43	7.59e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.48	-0.33	3.7e-13	HDL cholesterol;
LGG	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg06917634	chr15:78832804	PSMA4	-0.66	-12.66	-0.51	9.57e-32	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg08000102	chr2:233561755	GIGYF2	0.6	9.75	0.41	1.52e-20	Coronary artery disease;
LGG	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg16724585	chr3:197361211	NA	-0.49	-8.53	-0.37	2.05e-16	Pancreatic cancer;
LGG	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg08344181	chr3:125677491	NA	-0.7	-7.35	-0.32	9.15e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6032067	0.641	rs17332243	chr20:43756071	T/C	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg06212747	chr3:49208901	KLHDC8B	0.44	7.13	0.31	3.97e-12	Resting heart rate;
LGG	cis	rs11785400	0.793	rs4403386	chr8:143736770	C/G	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg23758822	chr17:41437982	NA	0.9	15.48	0.58	7.18e-44	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15919258	chr14:90849921	NA	0.45	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	cis	rs9358372	0.502	rs59212709	chr6:20793993	G/T	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.42	-0.4	2.07e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg08048268	chr3:133502702	NA	-0.61	-10.57	-0.44	1.58e-23	Iron status biomarkers;
LGG	cis	rs701145	0.585	rs357465	chr3:153903095	T/A	cg12800244	chr3:153838788	SGEF	0.82	8.55	0.37	1.8e-16	Coronary artery disease;
LGG	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg09307838	chr4:120376055	NA	0.82	13.68	0.54	4.88e-36	Corneal astigmatism;
LGG	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.39	-0.4	2.8e-19	Height;
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03517284	chr6:25882590	NA	-0.88	-16.95	-0.62	1.83e-50	Intelligence (multi-trait analysis);
LGG	cis	rs7122539	0.506	rs7944999	chr11:66687863	A/G	cg24851651	chr11:66362959	CCS	0.36	7.02	0.31	7.85e-12	HIV-1 susceptibility;
LGG	cis	rs1371867	0.846	rs1660312	chr8:101330634	C/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.76	-0.38	3.84e-17	Atrioventricular conduction;
LGG	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg00784671	chr22:46762841	CELSR1	0.51	6.89	0.3	1.85e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.37e-15	Obesity-related traits;
LGG	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg10523679	chr1:76189770	ACADM	0.77	12.46	0.5	6.47e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.97	-0.31	1.1e-11	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg12070911	chr6:150209640	RAET1E	-0.31	-7.52	-0.33	2.94e-13	Lung cancer;
LGG	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.17	0.39	1.61e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg14593290	chr7:50529359	DDC	0.64	11.7	0.48	7.3e-28	Malaria;
LGG	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11890956	chr21:40555474	PSMG1	1.0	21.46	0.71	1.95e-71	Cognitive function;
LGG	cis	rs2742417	1.000	rs2742392	chr3:45757282	T/C	cg04837898	chr3:45731254	SACM1L	-0.36	-7.07	-0.31	5.61e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4974559	0.739	rs4333131	chr4:1323789	A/G	cg02980000	chr4:1222292	CTBP1	0.75	10.8	0.45	2.08e-24	Systolic blood pressure;
LGG	cis	rs77633900	0.772	rs284902	chr15:76745687	G/C	cg21673338	chr15:77095150	SCAPER	-0.64	-8.39	-0.36	5.81e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg08733933	chr1:2954429	NA	-0.42	-8.33	-0.36	9.22e-16	Plateletcrit;
LGG	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.04e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg03188948	chr7:1209495	NA	0.68	9.5	0.4	1.1e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17683430	0.702	rs76915002	chr22:32421694	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.54e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.64	0.67	6.31e-63	Platelet count;
LGG	cis	rs7747724	0.715	rs9358366	chr6:20773560	G/A	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Bladder cancer;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg13047869	chr3:10149882	C3orf24	0.58	8.43	0.36	4.31e-16	Alzheimer's disease;
LGG	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	7.72e-13	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs972578	0.715	rs4820491	chr22:43261065	C/G	cg01576275	chr22:43409880	NA	-0.22	-6.68	-0.3	6.88e-11	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.93	0.38	1.04e-17	Alzheimer's disease;
LGG	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg11890956	chr21:40555474	PSMG1	1.19	26.28	0.77	8.13e-94	Cognitive function;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg22963979	chr7:1858916	MAD1L1	-0.37	-7.27	-0.32	1.5e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-12.03	-0.49	3.48e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.88	0.34	2.33e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.91	-10.47	-0.44	3.57e-23	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg02018176	chr4:1364513	KIAA1530	0.43	9.87	0.42	5.74e-21	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09564133	chr5:176738847	MXD3	0.51	8.24	0.36	1.79e-15	Gut microbiome composition (summer);
LGG	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.4	7.15	0.32	3.39e-12	Total cholesterol levels;
LGG	cis	rs6430585	0.941	rs12469551	chr2:136510012	T/G	cg07169764	chr2:136633963	MCM6	-0.99	-18.73	-0.66	1.11e-58	Corneal structure;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg20607798	chr8:58055168	NA	0.57	6.86	0.3	2.26e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6735179	0.588	rs6726313	chr2:1756908	C/T	cg20570797	chr2:1712800	PXDN	-0.45	-8.2	-0.36	2.32e-15	Response to antipsychotic treatment;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg20991723	chr1:152506922	NA	-0.72	-14.9	-0.57	2.65e-41	Hair morphology;
LGG	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg19847130	chr8:10466454	RP1L1	0.32	6.83	0.3	2.75e-11	Neuroticism;
LGG	cis	rs3736594	0.879	rs4666011	chr2:27980912	G/C	cg27432699	chr2:27873401	GPN1	0.56	8.93	0.38	1.01e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18876405	chr7:65276391	NA	0.6	11.01	0.46	3.25e-25	Aortic root size;
LGG	trans	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg23762105	chr12:34175262	ALG10	0.35	7.16	0.32	3.24e-12	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg02002194	chr4:3960332	NA	0.47	8.78	0.38	3.24e-17	Joint mobility (Beighton score);
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.46	-0.33	4.42e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14442939	chr10:27389572	ANKRD26	0.7	9.01	0.39	5.38e-18	Breast cancer;
LGG	cis	rs7666738	0.830	rs991168	chr4:98928293	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.34	0.5	1.83e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg02002194	chr4:3960332	NA	0.42	7.74	0.34	6.33e-14	Triglycerides;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg21724239	chr8:58056113	NA	0.55	8.11	0.35	4.59e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.04e-23	Lymphocyte counts;
LGG	cis	rs2201728	0.967	rs4147531	chr4:100212197	G/A	cg07219303	chr4:100140905	ADH6	-0.4	-7.94	-0.35	1.49e-14	Cardiac Troponin-T levels;
LGG	cis	rs61990749	0.544	rs176962	chr14:78185510	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.13	0.31	3.94e-12	Fibroblast growth factor basic levels;
LGG	cis	rs972578	0.765	rs738536	chr22:43260427	C/T	cg01576275	chr22:43409880	NA	-0.23	-7.1	-0.31	4.64e-12	Mean platelet volume;
LGG	cis	rs6912958	0.781	rs6454631	chr6:88225863	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.51	-0.33	3.06e-13	Monocyte percentage of white cells;
LGG	cis	rs818427	0.865	rs1093611	chr5:112218476	A/T	cg07820702	chr5:112228657	REEP5	0.35	6.67	0.3	7.46e-11	Total body bone mineral density;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg18350739	chr11:68623251	NA	-0.87	-22.59	-0.72	1.07e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg07460842	chr6:66804631	NA	0.96	17.93	0.64	5.63e-55	Exhaled nitric oxide output;
LGG	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg20891283	chr12:69753455	YEATS4	0.73	13.61	0.53	1.02e-35	Blood protein levels;
LGG	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.81	0.41	9.35e-21	Dupuytren's disease;
LGG	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs34891900	0.507	rs12167823	chr22:18124362	G/A	cg19898043	chr22:18121309	BCL2L13	0.57	9.26	0.4	7.42e-19	Sum neutrophil eosinophil counts;
LGG	cis	rs61931739	0.620	rs4323992	chr12:33693639	G/A	cg06521331	chr12:34319734	NA	0.4	6.88	0.3	2e-11	Morning vs. evening chronotype;
LGG	cis	rs10751667	0.666	rs11246358	chr11:967349	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.04	0.35	7.74e-15	Alzheimer's disease (late onset);
LGG	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.84	-0.3	2.58e-11	Menopause (age at onset);
LGG	cis	rs67311347	1.000	rs9874499	chr3:40441908	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.57	-0.69	2.81e-67	Renal cell carcinoma;
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg06494592	chr3:125709126	NA	-0.57	-7.26	-0.32	1.59e-12	Blood pressure (smoking interaction);
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	9.13	0.39	2.12e-18	Bipolar disorder;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg00364696	chr7:1142433	C7orf50	-0.39	-7.5	-0.33	3.18e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2377058	0.924	rs7203947	chr16:89722511	T/C	cg07835443	chr16:89734986	C16orf55	-0.46	-7.84	-0.34	3.23e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg18681998	chr4:17616180	MED28	0.85	18.8	0.66	5.39e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg17545662	chr6:170176663	C6orf70	0.64	6.7	0.3	6.22e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7927592	0.546	rs599083	chr11:68192346	T/G	cg01657329	chr11:68192670	LRP5	-0.6	-10.73	-0.45	3.95e-24	Total body bone mineral density;
LGG	cis	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg12826209	chr6:26865740	GUSBL1	0.78	8.18	0.36	2.78e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17152411	0.625	rs4962713	chr10:126654536	A/T	cg06432487	chr10:126623651	NA	0.39	6.76	0.3	4.14e-11	Height;
LGG	cis	rs7649275	1.000	rs2612032	chr3:53768915	A/G	cg21503701	chr3:53781065	CACNA1D	-0.47	-6.92	-0.31	1.49e-11	Trans fatty acid levels;
LGG	cis	rs77633900	0.614	rs2469242	chr15:76876710	A/G	cg21673338	chr15:77095150	SCAPER	-0.67	-10.4	-0.44	6.59e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs12612619	0.765	rs12615303	chr2:27140573	C/T	cg12045002	chr2:27069975	DPYSL5	-0.34	-7.19	-0.32	2.55e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg07080220	chr10:102295463	HIF1AN	0.73	12.03	0.49	3.3e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10870270	0.956	rs4880405	chr10:133787021	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.61	-0.51	1.48e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs4417704	0.526	rs6733049	chr2:241902718	C/G	cg14055004	chr2:241860995	NA	0.27	6.9	0.31	1.71e-11	Joint mobility (Beighton score);
LGG	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg26816564	chr1:7831052	VAMP3	-0.53	-8.54	-0.37	1.88e-16	Inflammatory bowel disease;
LGG	cis	rs2188561	0.697	rs66560125	chr7:107370034	G/A	cg16793755	chr7:107334138	SLC26A4	0.42	7.4	0.33	6.57e-13	Alcohol consumption;
LGG	cis	rs240764	0.658	rs7746961	chr6:101215244	A/G	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs6142618	0.562	rs2281360	chr20:30726829	A/G	cg00028034	chr20:30779307	TSPYL3	0.37	8.03	0.35	8.41e-15	Inflammatory bowel disease;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.25	-0.32	1.7e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs877282	0.947	rs4133015	chr10:774131	T/C	cg22713356	chr15:30763199	NA	0.56	8.7	0.37	5.85e-17	Uric acid levels;
LGG	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg08949735	chr16:89699720	DPEP1	-0.48	-10.12	-0.43	6.73e-22	Vitiligo;
LGG	cis	rs262150	0.788	rs2657408	chr7:158782275	A/G	cg19418458	chr7:158789849	NA	-0.49	-9.76	-0.41	1.34e-20	Facial morphology (factor 20);
LGG	cis	rs17739167	0.550	rs11070354	chr15:42233211	C/T	cg20935245	chr15:42234343	EHD4	0.44	8.41	0.36	5.24e-16	Monocyte count;
LGG	cis	rs7122539	0.647	rs2167457	chr11:66642396	C/T	cg01599099	chr11:66649832	PC	0.47	9.42	0.4	2.22e-19	HIV-1 susceptibility;
LGG	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg14541582	chr5:601475	NA	-0.71	-11.21	-0.46	5.75e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.36e-18	Motion sickness;
LGG	cis	rs72781680	0.898	rs72788218	chr2:24090435	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	9.25	0.39	8.2e-19	Lymphocyte counts;
LGG	trans	rs800082	1.000	rs62275526	chr3:144291707	G/A	cg24215973	chr2:240111563	HDAC4	-0.48	-8.46	-0.37	3.43e-16	Smoking behavior;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs7408868	0.831	rs1548555	chr19:15278057	A/G	cg14696996	chr19:15285081	NOTCH3	1.1	13.17	0.52	7.11e-34	Pulse pressure;
LGG	cis	rs1003719	0.788	rs2835574	chr21:38455324	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs1408224	0.657	rs1467604	chr13:47211879	G/A	cg24453118	chr13:47229927	LRCH1	-0.29	-6.82	-0.3	2.83e-11	QRS complex (12-leadsum);
LGG	trans	rs9314614	0.934	rs2980955	chr8:6694434	A/G	cg11829072	chr8:125463024	TRMT12	-0.41	-6.81	-0.3	3.07e-11	IgA nephropathy;White blood cell count (basophil);
LGG	cis	rs972578	0.791	rs5751392	chr22:43261694	T/G	cg01576275	chr22:43409880	NA	-0.23	-6.95	-0.31	1.28e-11	Mean platelet volume;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg11584989	chr19:19387371	SF4	0.41	7.29	0.32	1.37e-12	Tonsillectomy;
LGG	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg14228332	chr4:119757509	SEC24D	0.84	7.97	0.35	1.23e-14	Cannabis dependence symptom count;
LGG	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.16	-0.32	3.12e-12	Coronary artery disease;
LGG	cis	rs2797160	0.967	rs1739358	chr6:126019736	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.41e-13	Endometrial cancer;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg01059449	chr18:44338099	ST8SIA5	0.32	7.06	0.31	6.19e-12	Personality dimensions;
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg15665833	chr6:26285013	NA	0.41	7.75	0.34	5.7e-14	Educational attainment;
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.95	-0.38	8.68e-18	Triglycerides;
LGG	cis	rs7077164	1.000	rs1227775	chr10:71580862	C/G	cg20696214	chr10:71583771	COL13A1	-0.4	-7.76	-0.34	5.42e-14	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs314370	0.818	rs13245899	chr7:100497131	A/G	cg10426581	chr7:100472382	SRRT	0.49	6.91	0.31	1.61e-11	Resting heart rate;
LGG	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg26116260	chr4:7069785	GRPEL1	-0.82	-7.4	-0.33	6.52e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2288073	0.801	rs6757275	chr2:24375230	A/G	cg06627628	chr2:24431161	ITSN2	-0.51	-8.28	-0.36	1.36e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4926611	0.795	rs4927014	chr1:54072249	G/A	cg23596471	chr1:54105337	GLIS1	0.39	7.85	0.34	2.86e-14	Hand grip strength;
LGG	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.6	0.51	1.66e-31	Coronary artery disease;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.67	11.82	0.48	2.42e-28	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11096990	0.964	rs11096987	chr4:39259190	A/G	cg24403649	chr4:39172243	NA	-0.41	-6.73	-0.3	4.93e-11	Cognitive function;
LGG	cis	rs2996428	0.601	rs10909804	chr1:3770929	A/G	cg10555106	chr1:3691387	LOC388588	-0.38	-8.69	-0.37	6.31e-17	Red cell distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08561821	chr17:2241027	SGSM2;TSR1	0.56	8.39	0.36	5.84e-16	Gut microbiome composition (summer);
LGG	cis	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2013441	0.965	rs1544421	chr17:20114217	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg06634786	chr22:41940651	POLR3H	-0.42	-7.41	-0.33	6.13e-13	Alzheimer's disease biomarkers;
LGG	cis	rs9420907	0.579	rs2488000	chr10:105671109	A/C	cg11005552	chr10:105648138	OBFC1	0.67	7.25	0.32	1.73e-12	Telomere length;
LGG	cis	rs6032067	0.714	rs2206888	chr20:43882006	A/G	cg10761708	chr20:43804764	PI3	0.57	8.69	0.37	6.2e-17	Blood protein levels;
LGG	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.82	-0.34	3.7e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.86	-0.3	2.16e-11	Vitiligo;
LGG	cis	rs2652834	0.904	rs2729827	chr15:63360564	C/T	cg05507819	chr15:63340323	TPM1	0.61	8.36	0.36	7.18e-16	HDL cholesterol;
LGG	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg08392591	chr16:89556376	ANKRD11	0.59	9.57	0.41	6.38e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs1355223	0.583	rs2915178	chr11:34878051	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.87	0.57	3.48e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.36	2.9e-15	Iron status biomarkers;
LGG	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg26384229	chr12:38710491	ALG10B	0.72	14.45	0.56	2.62e-39	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.87	-0.34	2.62e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs73001065	0.551	rs79954596	chr19:19548643	T/G	cg03709012	chr19:19516395	GATAD2A	0.97	11.3	0.47	2.52e-26	LDL cholesterol;
LGG	cis	rs6988985	0.678	rs28571827	chr8:144003207	G/A	cg10324643	chr8:143916377	GML	0.48	10.23	0.43	2.68e-22	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.3	-0.43	1.56e-22	Blood metabolite levels;
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg25866889	chr13:114914595	NA	0.36	7.42	0.33	5.69e-13	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg25358565	chr5:93447407	FAM172A	1.29	16.12	0.6	9.97e-47	Diabetic retinopathy;
LGG	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.57e-15	Bone mineral density;
LGG	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg08773314	chr2:239334832	ASB1	0.4	7.56	0.33	2.21e-13	Multiple system atrophy;
LGG	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg14541582	chr5:601475	NA	-0.69	-10.64	-0.44	8.45e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg16797656	chr11:68205561	LRP5	0.42	7.49	0.33	3.51e-13	Total body bone mineral density;
LGG	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg26031613	chr14:104095156	KLC1	1.15	27.87	0.79	4.31e-101	Body mass index;
LGG	cis	rs6434928	1	rs6434928	chr2:198304577	G/A	cg00792783	chr2:198669748	PLCL1	0.5	7.95	0.35	1.44e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg24631222	chr15:78858424	CHRNA5	0.43	6.85	0.3	2.4e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg04703951	chr17:43578652	NA	-0.36	-7.14	-0.31	3.66e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg05868516	chr6:26286170	HIST1H4H	0.46	7.98	0.35	1.18e-14	Educational attainment;
LGG	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg16141378	chr3:129829833	LOC729375	0.36	8.11	0.35	4.59e-15	Triglycerides;
LGG	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg13385794	chr1:248469461	NA	-0.47	-7.57	-0.33	2.11e-13	Common traits (Other);
LGG	cis	rs368123	1.000	rs622624	chr6:160716932	G/T	cg04181478	chr6:161122748	PLG	-0.37	-6.65	-0.3	8.11e-11	Waist circumference;
LGG	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	Neuroticism;
LGG	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg10204951	chr7:910479	UNC84A	-0.56	-7.09	-0.31	5.19e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.7	-12.86	-0.51	1.39e-32	Menarche (age at onset);
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-12.92	-0.51	8.19e-33	Total body bone mineral density;
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg27400746	chr16:89904261	SPIRE2	-1.08	-15.82	-0.59	2.13e-45	Skin colour saturation;
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg06153925	chr17:78755379	RPTOR	0.41	6.84	0.3	2.57e-11	Myopia (pathological);
LGG	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-10.03	-0.42	1.52e-21	Coronary artery disease;
LGG	cis	rs12887734	0.546	rs4906376	chr14:104272165	A/C	cg26031613	chr14:104095156	KLC1	-0.55	-8.59	-0.37	1.37e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs240764	0.658	rs11155635	chr6:101199367	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg03528353	chr17:61819722	STRADA	-0.41	-6.75	-0.3	4.32e-11	Prudent dietary pattern;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.88	-0.3	1.95e-11	Obesity-related traits;
LGG	cis	rs11229555	0.645	rs4506677	chr11:58213852	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.72	-0.34	7.42e-14	Lung cancer;
LGG	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg15704280	chr7:45808275	SEPT13	-0.82	-13.72	-0.54	3.32e-36	Coronary artery disease;
LGG	cis	rs36051895	0.632	rs7040922	chr9:5174829	A/G	cg02405213	chr9:5042618	JAK2	0.77	15.19	0.58	1.47e-42	Pediatric autoimmune diseases;
LGG	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.7	-0.56	2e-40	Schizophrenia;
LGG	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.09	0.35	5.12e-15	Neuroticism;
LGG	cis	rs6684428	0.536	rs4927276	chr1:56396569	G/A	cg11651538	chr1:56320950	NA	0.39	7.5	0.33	3.29e-13	Airflow obstruction;
LGG	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	trans	rs11039798	0.588	rs11039781	chr11:48523085	T/G	cg15704280	chr7:45808275	SEPT13	0.73	9.98	0.42	2.24e-21	Axial length;
LGG	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.92e-26	Corneal astigmatism;
LGG	cis	rs6964587	1.000	rs2301559	chr7:91746727	T/C	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.48e-18	Breast cancer;
LGG	cis	rs1847505	0.520	rs78824663	chr13:61486175	C/G	cg25164009	chr13:61490935	NA	0.54	8.93	0.38	1.02e-17	Polychlorinated biphenyl levels;
LGG	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg25554036	chr4:6271136	WFS1	0.6	11.26	0.46	3.65e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs12517041	0.938	rs34072953	chr5:23269936	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.91	-0.38	1.15e-17	Calcium levels;
LGG	cis	rs7336332	0.598	rs75439483	chr13:28010512	A/G	cg01674679	chr13:27998804	GTF3A	-0.63	-8.13	-0.35	3.93e-15	Weight;
LGG	cis	rs6912958	0.781	rs1051148	chr6:88221892	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.46	-8.24	-0.36	1.78e-15	Monocyte percentage of white cells;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-6.74	-0.3	4.82e-11	Vitiligo;
LGG	cis	rs16912285	0.636	rs7114960	chr11:24310828	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	13.28	0.53	2.52e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg00713939	chr8:144660590	NAPRT1	0.86	6.76	0.3	4.07e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg04989706	chr14:50066350	PPIL5	0.53	8.45	0.37	3.8e-16	Carotid intima media thickness;
LGG	cis	rs6450176	1.000	rs4334835	chr5:53300612	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.48	-0.47	5.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05025164	chr4:1340916	KIAA1530	0.89	16.79	0.62	9.69e-50	Longevity;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg21735344	chr14:102553260	HSP90AA1	-0.43	-7.32	-0.32	1.13e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10532262	chr3:172428426	NCEH1	0.47	7.86	0.34	2.68e-14	Cognitive performance;
LGG	trans	rs11875185	0.510	rs79492915	chr18:55612129	T/A	cg15513957	chr14:69354734	ACTN1	-0.95	-9.2	-0.39	1.2e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9815354	0.680	rs73075204	chr3:42030392	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8064299	0.655	rs16978176	chr17:72761242	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	9.0	0.39	5.95e-18	Monocyte count;
LGG	cis	rs9487094	0.670	rs749517	chr6:109852916	A/G	cg01125227	chr6:109776195	MICAL1	-0.45	-7.86	-0.34	2.79e-14	Height;
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.67e-16	Rheumatoid arthritis;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.6	-0.33	1.71e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.83	15.11	0.57	3.15e-42	Subjective well-being;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.01	-0.6	3.29e-46	Longevity;
LGG	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-11.11	-0.46	1.38e-25	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg13072238	chr3:49761600	GMPPB	-0.53	-7.15	-0.32	3.5e-12	Menarche (age at onset);
LGG	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg10167378	chr1:228756711	NA	0.48	7.95	0.35	1.46e-14	Chronic lymphocytic leukemia;
LGG	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.77	-0.3	3.84e-11	Triglycerides;
LGG	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	trans	rs11875185	0.510	rs79946375	chr18:55596642	C/G	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9902453	1.000	rs8065261	chr17:28418041	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.07	-0.52	1.84e-33	Coffee consumption (cups per day);
LGG	cis	rs7666738	0.830	rs13113899	chr4:99050422	T/C	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs131777	0.576	rs131758	chr22:51017082	T/A	cg05418105	chr22:50981406	NA	-0.5	-8.83	-0.38	2.19e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs13314892	0.764	rs61148813	chr3:69870033	C/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg08888203	chr3:10149979	C3orf24	0.56	9.51	0.4	1.05e-19	Alzheimer's disease;
LGG	trans	rs7944735	0.817	rs6485788	chr11:47873883	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-8.06	-0.35	6.65e-15	Intraocular pressure;
LGG	cis	rs12545109	0.765	rs1960726	chr8:57411733	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.75	15.1	0.57	3.64e-42	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	1.03e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg00405596	chr8:11794950	NA	0.4	6.66	0.3	7.93e-11	Neuroticism;
LGG	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.69	-0.34	9.15e-14	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14047339	chr6:45345544	RUNX2;SUPT3H	-0.51	-7.58	-0.33	1.88e-13	Gut microbiome composition (summer);
LGG	cis	rs3862030	0.720	rs3740414	chr10:104232809	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.48	-0.4	1.36e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.99	-0.35	1.06e-14	Height;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg15394860	chr11:2017084	H19	0.63	13.88	0.54	6.87e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg15665833	chr6:26285013	NA	0.39	7.54	0.33	2.45e-13	Educational attainment;
LGG	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg00277334	chr10:82204260	NA	-0.51	-12.17	-0.49	9.71e-30	Post bronchodilator FEV1;
LGG	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg08885076	chr2:99613938	TSGA10	0.42	8.96	0.38	7.73e-18	Chronic sinus infection;
LGG	cis	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg08499158	chr17:42289980	UBTF	-0.58	-11.06	-0.46	2.21e-25	Total body bone mineral density;
LGG	cis	rs765787	0.556	rs10851422	chr15:45513738	T/C	cg24006582	chr15:45444508	DUOX1	0.66	11.98	0.49	5.65e-29	Uric acid levels;
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.15	-0.35	3.35e-15	Total body bone mineral density;
LGG	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.07	0.66	3.03e-60	Smoking behavior;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg21911579	chr5:131705225	SLC22A5	0.66	7.39	0.32	7.13e-13	Rheumatoid arthritis;
LGG	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg13009111	chr11:71350975	NA	0.3	6.65	0.3	8.1e-11	Retinal vascular caliber;
LGG	cis	rs17453880	0.929	rs12517065	chr5:152054583	A/T	cg12297329	chr5:152029980	NA	0.9	23.31	0.73	4.39e-80	Subjective well-being;
LGG	cis	rs2404602	0.631	rs9646213	chr15:76807672	G/C	cg23625390	chr15:77176239	SCAPER	0.48	9.54	0.41	8.21e-20	Blood metabolite levels;
LGG	cis	rs16912285	0.892	rs80332091	chr11:24255248	T/A	ch.11.24196551F	chr11:24239977	NA	0.84	9.46	0.4	1.58e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.53	-0.37	2.07e-16	Joint mobility (Beighton score);
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.68e-123	Prudent dietary pattern;
LGG	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg13334819	chr7:99746414	C7orf59	-0.48	-7.39	-0.32	6.99e-13	Coronary artery disease;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg05091796	chr16:4465799	CORO7	-0.75	-12.94	-0.52	6.48e-33	Schizophrenia;
LGG	cis	rs944722	1.000	rs28662210	chr17:26093864	A/G	cg07704981	chr17:26127537	NOS2	-0.49	-8.56	-0.37	1.63e-16	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg15456646	chr14:60716665	PPM1A	-0.38	-7.01	-0.31	8.42e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7408868	1.000	rs10415431	chr19:15277027	G/A	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	trans	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.29	0.36	1.22e-15	Joint mobility (Beighton score);
LGG	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg16325326	chr1:53192061	ZYG11B	-0.89	-23.44	-0.74	1.06e-80	Monocyte count;
LGG	trans	rs9409565	0.826	rs2139189	chr9:97238538	A/G	cg05679027	chr9:99775184	HIATL2	-0.49	-8.14	-0.35	3.65e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs7928758	0.945	rs7108756	chr11:134280860	C/A	cg25213107	chr11:134282864	B3GAT1	0.98	12.36	0.5	1.54e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg15596359	chr8:11213517	TDH	-0.34	-6.79	-0.3	3.36e-11	Retinal vascular caliber;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09929564	chr1:153643582	ILF2	0.37	6.88	0.3	1.97e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg18000306	chr6:288505	NA	0.6	10.79	0.45	2.22e-24	Menopause (age at onset);
LGG	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.54	0.56	1.05e-39	Morning vs. evening chronotype;
LGG	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14159747	chr11:113255604	NA	-0.27	-7.34	-0.32	9.98e-13	Neuroticism;
LGG	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg04450456	chr4:17643702	FAM184B	0.32	7.13	0.31	3.89e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg13385794	chr1:248469461	NA	-0.41	-7.0	-0.31	9.27e-12	Common traits (Other);
LGG	cis	rs7666738	0.830	rs10022389	chr4:99022229	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs151349	0.714	rs7474	chr20:57609590	A/G	cg23907860	chr20:57583709	CTSZ	-0.36	-6.83	-0.3	2.74e-11	Platelet distribution width;
LGG	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15557168	chr22:42548783	NA	0.34	7.69	0.34	9.02e-14	Cognitive function;
LGG	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg04568710	chr12:38710424	ALG10B	-0.33	-7.12	-0.31	4.12e-12	Bladder cancer;
LGG	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.84	-9.0	-0.39	5.99e-18	Lung cancer in ever smokers;
LGG	cis	rs2067615	0.579	rs6539283	chr12:107222989	C/T	cg15890332	chr12:107067104	RFX4	0.41	11.98	0.49	5.35e-29	Heart rate;
LGG	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg22467129	chr15:76604101	ETFA	-0.4	-6.66	-0.3	7.81e-11	Blood metabolite levels;
LGG	cis	rs9849248	0.531	rs2735556	chr3:88105360	T/C	cg14530983	chr3:88190749	ZNF654	0.54	7.98	0.35	1.16e-14	Menarche (age at onset);
LGG	cis	rs2116941	0.523	rs17000211	chr19:10369086	C/T	cg01850179	chr19:10340795	S1PR2	0.51	8.15	0.35	3.47e-15	Pulse pressure;
LGG	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.48	0.4	1.37e-19	Hypertriglyceridemia;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.6	10.33	0.43	1.22e-22	Obesity-related traits;
LGG	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg12395012	chr8:11607386	GATA4	-0.53	-9.85	-0.42	6.47e-21	Myopia (pathological);
LGG	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.16	0.32	3.27e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7937612	1.000	rs6589813	chr11:120293490	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.69	-0.51	6.95e-32	Intraocular pressure;
LGG	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg04851639	chr8:1020857	NA	-0.42	-9.27	-0.4	7.18e-19	Schizophrenia;
LGG	cis	rs34172651	0.517	rs2547040	chr16:24736408	G/C	cg02428538	chr16:24856791	SLC5A11	0.71	10.94	0.45	6.14e-25	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs11700980	0.551	rs11700705	chr21:30117502	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.14e-20	Bipolar disorder;
LGG	cis	rs11157436	0.560	rs988997	chr14:22693832	C/G	cg00994629	chr14:22694547	NA	0.35	7.8	0.34	4.05e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs10861342	1.000	rs10861360	chr12:105570041	A/G	cg23923672	chr12:105501055	KIAA1033	-0.77	-7.45	-0.33	4.75e-13	IgG glycosylation;
LGG	cis	rs2816316	0.806	rs4658054	chr1:192524985	G/T	cg02586212	chr1:192544902	RGS1	0.42	8.56	0.37	1.7e-16	Celiac disease;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9354308	0.764	rs1938118	chr6:66568876	G/T	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.92e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs911555	0.755	rs8014800	chr14:103946302	T/C	cg24130564	chr14:104152367	KLC1	0.39	7.21	0.32	2.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7851660	0.967	rs1443435	chr9:100617583	T/C	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs4689642	0.507	rs11724245	chr4:7223787	C/A	cg21353189	chr4:7228343	SORCS2	0.35	7.39	0.32	6.99e-13	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs4077515	0.649	rs3087886	chr9:139301583	T/C	cg21253087	chr9:139290292	SNAPC4	0.34	6.83	0.3	2.69e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Neuroticism;
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg23958373	chr8:599963	NA	1.18	11.77	0.48	3.81e-28	IgG glycosylation;
LGG	cis	rs9640161	0.659	rs11975886	chr7:150010362	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.71	-14.74	-0.57	1.31e-40	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07791516	chr6:150247246	NA	0.33	6.87	0.3	2.12e-11	Lung cancer;
LGG	cis	rs4683142	0.518	rs6802312	chr3:46025941	T/C	cg16320329	chr3:45981161	FYCO1	-0.36	-6.67	-0.3	7.15e-11	Methadone dose in opioid dependence;
LGG	cis	rs7937682	0.593	rs1113851	chr11:111354161	G/A	cg09085632	chr11:111637200	PPP2R1B	0.64	10.96	0.45	5.23e-25	Primary sclerosing cholangitis;
LGG	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg07835443	chr16:89734986	C16orf55	-0.46	-7.84	-0.34	3.06e-14	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-9.99	-0.42	2.04e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg26174226	chr8:58114915	NA	-0.54	-7.32	-0.32	1.08e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg23173402	chr1:227635558	NA	0.6	9.04	0.39	4.29e-18	Major depressive disorder;
LGG	cis	rs988958	0.530	rs6724482	chr2:42236010	A/C	cg19376973	chr2:42229025	NA	0.63	9.27	0.4	7.36e-19	Hypospadias;
LGG	trans	rs1941687	0.702	rs8090097	chr18:31413448	A/C	cg27147174	chr7:100797783	AP1S1	-0.51	-8.59	-0.37	1.29e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9462027	0.675	rs13206387	chr6:34696792	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.79	-0.45	2.38e-24	Systemic lupus erythematosus;
LGG	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.9	-0.38	1.23e-17	Joint mobility (Beighton score);
LGG	cis	rs9399135	0.967	rs4376365	chr6:135307740	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.6e-19	Red blood cell count;
LGG	cis	rs6546537	0.824	rs3771543	chr2:69784255	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-8.91	-0.38	1.13e-17	Serum thyroid-stimulating hormone levels;
LGG	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.52	-0.37	2.24e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg07395648	chr5:131743802	NA	-0.55	-12.86	-0.51	1.38e-32	Blood metabolite levels;
LGG	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg24375607	chr4:120327624	NA	0.66	10.64	0.44	8.78e-24	Corneal astigmatism;
LGG	cis	rs11997175	0.756	rs4739435	chr8:33818818	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	7.87	0.34	2.46e-14	Body mass index;
LGG	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.2	-0.39	1.24e-18	Post bronchodilator FEV1;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.58	-0.37	1.48e-16	Personality dimensions;
LGG	cis	rs561341	0.700	rs8079471	chr17:30218317	A/G	cg13647721	chr17:30228624	UTP6	0.76	12.03	0.49	3.43e-29	Hip circumference adjusted for BMI;
LGG	cis	rs56399783	0.901	rs6967664	chr7:2816384	A/G	cg19731401	chr7:2775893	GNA12	0.36	7.44	0.33	4.94e-13	Childhood ear infection;
LGG	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg14593290	chr7:50529359	DDC	0.65	11.84	0.48	1.94e-28	Malaria;
LGG	cis	rs1595825	0.891	rs16826873	chr2:198898222	A/C	cg00982548	chr2:198649783	BOLL	0.5	6.72	0.3	5.25e-11	Ulcerative colitis;
LGG	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg13010199	chr12:38710504	ALG10B	-0.6	-10.51	-0.44	2.52e-23	Heart rate;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	8.02	0.35	8.87e-15	Tonsillectomy;
LGG	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg27102117	chr16:15229624	NA	0.49	9.65	0.41	3.5e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2018055	1.000	rs13193572	chr6:117817122	T/C	cg14611402	chr6:117803162	DCBLD1	0.29	7.99	0.35	1.06e-14	Diastolic blood pressure;
LGG	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg06637938	chr14:75390232	RPS6KL1	0.59	10.87	0.45	1.14e-24	Height;
LGG	cis	rs6908034	0.660	rs12525506	chr6:19794234	G/T	cg02682789	chr6:19804855	NA	0.9	8.24	0.36	1.82e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg26875233	chr11:93583750	C11orf90	-0.44	-8.44	-0.37	4e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22455090	chr5:89825803	LYSMD3	0.55	8.13	0.35	4.05e-15	Gut microbiome composition (summer);
LGG	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg03929089	chr4:120376271	NA	0.66	6.8	0.3	3.17e-11	Intraocular pressure;
LGG	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg18825076	chr15:78729989	IREB2	-0.59	-9.27	-0.4	7.29e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs74781061	0.858	rs4278699	chr15:74792398	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg08645402	chr16:4508243	NA	0.51	9.67	0.41	2.86e-20	Schizophrenia;
LGG	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg05555928	chr11:63887634	MACROD1	-0.39	-7.19	-0.32	2.6e-12	Platelet count;
LGG	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.84	-0.3	2.55e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11169552	0.510	rs11169479	chr12:50922336	A/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.54	-0.33	2.46e-13	Colorectal cancer;
LGG	cis	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg03511173	chr18:77590860	NA	0.6	7.42	0.33	5.75e-13	Opioid sensitivity;
LGG	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg00908189	chr16:619842	PIGQ	0.5	7.48	0.33	3.83e-13	Height;
LGG	cis	rs523522	0.962	rs3759394	chr12:120933173	C/A	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg08085267	chr17:45401833	C17orf57	-0.62	-12.14	-0.49	1.24e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00049323	chr5:472564	LOC25845	0.4	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs12042938	0.507	rs1655299	chr1:231732161	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-14.76	-0.57	1.05e-40	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4818225	0.895	rs2183588	chr21:42626882	A/G	cg21268422	chr21:42620091	BACE2	0.46	8.41	0.36	5.28e-16	Educational attainment;
LGG	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.84	8.62	0.37	1.11e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.52	-8.52	-0.37	2.31e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg27490568	chr2:178487706	NA	0.53	10.2	0.43	3.57e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	10.45	0.44	4.32e-23	Lung cancer in ever smokers;
LGG	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg24375607	chr4:120327624	NA	0.51	8.68	0.37	7.02e-17	Corneal astigmatism;
LGG	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg25358565	chr5:93447407	FAM172A	-0.69	-9.94	-0.42	3.06e-21	Diabetic retinopathy;
LGG	cis	rs6988985	0.765	rs4379428	chr8:143988048	T/A	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.68e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg09624528	chr10:1369823	ADARB2	0.62	11.5	0.47	4.38e-27	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9314323	0.693	rs13264882	chr8:26224240	G/T	cg11498726	chr8:26250323	BNIP3L	-0.54	-11.24	-0.46	4.57e-26	Red cell distribution width;
LGG	cis	rs9457247	0.566	rs10946207	chr6:167456036	C/T	cg07741184	chr6:167504864	NA	0.44	9.99	0.42	2.02e-21	Crohn's disease;
LGG	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg05313129	chr8:58192883	C8orf71	-0.64	-8.63	-0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28588043	1.000	rs16863949	chr1:170992602	A/C	cg03458344	chr1:170964477	C1orf129	-0.53	-7.21	-0.32	2.28e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.99	-0.31	9.51e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs25645	0.771	rs10445310	chr17:38205396	C/A	cg17467752	chr17:38218738	THRA	-0.71	-12.35	-0.5	1.81e-30	Myeloid white cell count;
LGG	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.88	-0.51	1.19e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs9771228	0.585	rs11764155	chr7:32272112	C/G	cg27532318	chr7:32358331	NA	0.53	7.66	0.34	1.09e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs9522267	1.000	rs9522265	chr13:112195182	A/G	cg10483660	chr13:112241077	NA	-0.36	-7.36	-0.32	8.69e-13	Hepatitis;
LGG	cis	rs9303280	0.868	rs11650661	chr17:38026286	A/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.51e-11	Self-reported allergy;
LGG	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.91	10.47	0.44	3.7e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg21100191	chr22:23484243	RTDR1	0.98	22.56	0.72	1.46e-76	Bone mineral density;
LGG	trans	rs6011368	0.630	rs1570520	chr20:62910954	A/G	cg13869341	chr1:15865	WASH5P	0.58	10.58	0.44	1.39e-23	Clozapine-induced cytotoxicity;
LGG	cis	rs8053891	0.507	rs12919469	chr16:72028612	A/G	cg01557791	chr16:72042693	DHODH	-0.41	-6.85	-0.3	2.34e-11	Coronary artery disease;
LGG	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg19875535	chr5:140030758	IK	-0.56	-11.68	-0.48	8.34e-28	Depressive symptoms (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22832407	chr4:169931373	CBR4	0.46	7.25	0.32	1.81e-12	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg19077165	chr18:44547161	KATNAL2	0.53	9.23	0.39	1e-18	Personality dimensions;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05025164	chr4:1340916	KIAA1530	0.55	10.0	0.42	1.89e-21	Longevity;
LGG	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.82	-0.51	2.11e-32	Chronic sinus infection;
LGG	cis	rs9783347	0.621	rs2305564	chr11:18317458	T/A	cg15585147	chr11:18324498	HPS5	0.32	7.21	0.32	2.26e-12	Pancreatic cancer;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg18402987	chr7:1209562	NA	0.65	9.03	0.39	4.61e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.8	-0.34	4.11e-14	Triglycerides;
LGG	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.4	6.69	0.3	6.28e-11	Carotid intima media thickness;
LGG	cis	rs4538187	0.906	rs11695421	chr2:63954237	T/C	cg19915305	chr2:64069682	UGP2	-0.62	-13.77	-0.54	2.12e-36	Systolic blood pressure;
LGG	trans	rs1032833	0.732	rs115452203	chr2:180108663	A/G	cg23654767	chr2:101192981	PDCL3	0.64	7.58	0.33	1.87e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs12681287	0.608	rs1135451	chr8:87483608	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs1003719	0.715	rs6579	chr21:38568308	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.3	-0.58	4.74e-43	Eye color traits;
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.69	0.64	6.75e-54	Alzheimer's disease;
LGG	cis	rs12474201	0.925	rs1058157	chr2:46988275	G/A	cg06386533	chr2:46925753	SOCS5	0.78	14.2	0.55	3.13e-38	Height;
LGG	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.82e-44	Colorectal cancer;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.61e-12	Bipolar disorder;
LGG	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.52	0.56	1.19e-39	Colorectal cancer;
LGG	cis	rs2354432	0.607	rs11239980	chr1:146782698	G/A	cg25205988	chr1:146714368	CHD1L	-1.43	-14.66	-0.56	3.1e-40	Mitochondrial DNA levels;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08219700	chr8:58056026	NA	-0.44	-6.97	-0.31	1.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg01765077	chr12:122356316	WDR66	0.3	8.24	0.36	1.77e-15	Mean corpuscular volume;
LGG	cis	rs17641971	0.684	rs1876717	chr8:49994968	T/G	cg00325661	chr8:49890786	NA	0.57	10.77	0.45	2.84e-24	Blood metabolite levels;
LGG	cis	rs12410462	0.591	rs903693	chr1:227732787	A/G	cg23173402	chr1:227635558	NA	0.36	6.89	0.3	1.86e-11	Major depressive disorder;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg14773178	chr5:1868261	NA	0.35	7.7	0.34	8.1e-14	Cardiovascular disease risk factors;
LGG	cis	rs6817170	0.623	rs71620317	chr4:154387597	G/C	cg24020152	chr4:154419554	KIAA0922	0.34	7.49	0.33	3.58e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.69	-0.37	6.13e-17	Aortic root size;
LGG	cis	rs10884984	0.770	rs3750811	chr10:112271288	A/G	cg18756771	chr10:112261994	DUSP5	0.67	12.14	0.49	1.19e-29	Facial morphology (factor 22);
LGG	cis	rs727563	0.635	rs713988	chr22:42159072	A/G	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs7712401	0.601	rs39819	chr5:122301676	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.41e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6740322	0.696	rs11685054	chr2:43474295	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-11.21	-0.46	5.79e-26	Coronary artery disease;
LGG	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg12855166	chr17:30846586	MYO1D	0.38	6.7	0.3	6.01e-11	Schizophrenia;
LGG	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg27446573	chr6:127587934	RNF146	1.06	18.67	0.66	2.17e-58	Breast cancer;
LGG	cis	rs79146658	0.736	rs11884950	chr2:179746213	C/T	cg17765952	chr2:179737173	CCDC141	0.57	8.61	0.37	1.16e-16	Diastolic blood pressure;
LGG	cis	rs6456156	0.586	rs7761977	chr6:167485678	A/G	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.37	-0.36	7e-16	Axial length;
LGG	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.63	-0.51	1.29e-31	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg15948088	chr11:109293068	C11orf87	-0.46	-8.17	-0.35	2.96e-15	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03087334	chr18:33077969	INO80C	0.54	8.24	0.36	1.78e-15	Gut microbiome composition (summer);
LGG	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg04287289	chr16:89883240	FANCA	0.53	9.82	0.42	8.25e-21	Vitiligo;
LGG	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.62e-22	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.63	-0.33	1.32e-13	Lung cancer;
LGG	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg03511173	chr18:77590860	NA	0.6	7.23	0.32	1.99e-12	Opioid sensitivity;
LGG	cis	rs2798269	0.966	rs4770174	chr13:22138691	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs953387	1.000	rs4954569	chr2:136913375	C/T	cg07169764	chr2:136633963	MCM6	0.53	8.85	0.38	1.83e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg13385521	chr17:29058706	SUZ12P	0.7	8.28	0.36	1.32e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.64	-0.44	8.76e-24	Depression;
LGG	cis	rs4774899	0.869	rs2585087	chr15:57326455	G/A	cg08128148	chr15:57256372	TCF12	0.31	7.41	0.33	6.1e-13	Urinary tract infection frequency;
LGG	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.45	-0.71	2.28e-71	Height;
LGG	cis	rs11074306	0.561	rs10162623	chr15:28078436	A/G	cg26402630	chr15:28053930	OCA2	0.35	7.1	0.31	4.64e-12	Uveal melanoma;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.55	-0.33	2.34e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.71	0.41	2e-20	Height;
LGG	cis	rs77633900	0.772	rs182253	chr15:76800755	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-8.39	-0.36	5.81e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.35	-0.36	7.75e-16	Tonsillectomy;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.21	0.43	3.22e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.838	rs9646437	chr17:28209065	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.0	0.52	3.65e-33	Coffee consumption (cups per day);
LGG	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.44	0.37	4.11e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2710642	0.821	rs2710639	chr2:63138963	C/T	cg17519650	chr2:63277830	OTX1	0.42	6.78	0.3	3.75e-11	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs7666738	0.830	rs890470	chr4:98923435	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.99	0.31	9.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13082711	0.554	rs1494422	chr3:27375190	T/C	cg02860705	chr3:27208620	NA	-0.78	-14.17	-0.55	4.2e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.35	0.4	3.9e-19	Alzheimer's disease;
LGG	cis	rs537626	0.567	rs662169	chr11:69311250	G/A	cg08353955	chr11:69289746	NA	-0.64	-7.61	-0.33	1.58e-13	Breast cancer (early onset);
LGG	cis	rs1107366	0.722	rs1992855	chr3:125909669	C/T	cg01346077	chr3:125931526	NA	-0.42	-10.07	-0.42	1.1e-21	Metabolite levels;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg22920501	chr2:26401640	FAM59B	-0.43	-8.95	-0.38	8.35e-18	Gut microbiome composition (summer);
LGG	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs13095912	0.785	rs34619288	chr3:185331678	G/C	cg11274856	chr3:185301563	NA	0.49	8.02	0.35	8.75e-15	Systolic blood pressure;
LGG	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.28	0.32	1.43e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.68	0.34	9.46e-14	Lung cancer;
LGG	cis	rs6754311	0.597	rs6760329	chr2:136544752	A/G	cg07169764	chr2:136633963	MCM6	-0.86	-15.52	-0.59	4.73e-44	Mosquito bite size;
LGG	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg04398451	chr17:18023971	MYO15A	-0.69	-13.77	-0.54	2.1e-36	Total body bone mineral density;
LGG	cis	rs2901656	0.640	rs4916258	chr1:172413526	T/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	7.07	0.31	5.7e-12	Red cell distribution width;Platelet distribution width;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.03	0.46	2.78e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.3	-0.5	2.67e-30	Intelligence (multi-trait analysis);
LGG	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg00934597	chr7:893267	UNC84A	-0.52	-8.67	-0.37	7.29e-17	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-9.65	-0.41	3.32e-20	Lung cancer;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg10295955	chr4:187884368	NA	-1.16	-31.28	-0.82	3.06e-116	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.01	-0.46	3.38e-25	Coronary artery disease;
LGG	cis	rs2268241	0.938	rs9974603	chr21:34776300	C/A	cg14850771	chr21:34775459	IFNGR2	0.78	9.55	0.41	7.28e-20	Obesity-related traits;
LGG	cis	rs3806843	0.612	rs246075	chr5:140300557	T/C	cg19875535	chr5:140030758	IK	0.38	7.48	0.33	3.72e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg15971980	chr6:150254442	NA	0.46	8.69	0.37	6.39e-17	Lung cancer;
LGG	trans	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg27411982	chr8:10470053	RP1L1	0.43	7.33	0.32	1.04e-12	Joint mobility (Beighton score);
LGG	trans	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.83e-31	Corneal astigmatism;
LGG	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	9.9	0.42	4.43e-21	Obesity-related traits;
LGG	cis	rs9399137	0.507	rs6904897	chr6:135382980	T/G	cg22676075	chr6:135203613	NA	0.4	6.85	0.3	2.35e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs12282928	0.959	rs873043	chr11:48278965	T/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.15	-0.32	3.38e-12	Migraine - clinic-based;
LGG	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg16141378	chr3:129829833	LOC729375	0.31	6.69	0.3	6.34e-11	Myopia (pathological);
LGG	cis	rs4430311	0.723	rs2290753	chr1:243806438	G/A	cg25706552	chr1:244017396	NA	-0.64	-15.78	-0.59	3.25e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.85	-0.42	6.73e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.76	-0.41	1.4e-20	Retinal vascular caliber;
LGG	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg11621586	chr10:70884670	VPS26A	1.13	20.1	0.68	4.84e-65	Left atrial antero-posterior diameter;
LGG	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg25358565	chr5:93447407	FAM172A	1.17	14.39	0.56	4.5e-39	Diabetic retinopathy;
LGG	cis	rs13421350	0.579	rs75689576	chr2:173300939	G/A	cg15021238	chr2:173305865	ITGA6	-0.83	-9.31	-0.4	5.27e-19	Diabetic kidney disease;
LGG	trans	rs9657904	0.738	rs13085563	chr3:105509918	A/C	cg14088669	chr1:158435396	OR10K1	0.41	7.63	0.33	1.37e-13	Multiple sclerosis;
LGG	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.61	-8.46	-0.37	3.65e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2798269	1.000	rs17622810	chr13:22098213	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.02	-0.31	7.74e-12	PR segment;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg26174226	chr8:58114915	NA	-0.44	-6.89	-0.3	1.88e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7010267	0.508	rs1385500	chr8:119976186	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.72	0.3	5.48e-11	Total body bone mineral density (age 45-60);
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-9.19	-0.39	1.34e-18	Schizophrenia;
LGG	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.45	-7.78	-0.34	4.69e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs972578	0.645	rs5751388	chr22:43250614	G/A	cg01576275	chr22:43409880	NA	-0.23	-7.01	-0.31	8.35e-12	Mean platelet volume;
LGG	cis	rs4262150	0.689	rs72795371	chr5:151924995	G/A	cg12297329	chr5:152029980	NA	-0.73	-13.69	-0.54	4.46e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.56	0.33	2.2e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6580649	0.941	rs6580651	chr12:48429933	A/T	cg24011408	chr12:48396354	COL2A1	-0.55	-6.79	-0.3	3.45e-11	Lung cancer;
LGG	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.48	-0.37	3.13e-16	Primary sclerosing cholangitis;
LGG	cis	rs4692589	0.802	rs2877501	chr4:170955277	G/T	cg19918862	chr4:170955249	NA	0.44	8.68	0.37	6.83e-17	Anxiety disorder;
LGG	trans	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	cis	rs7010267	0.596	rs4307369	chr8:120036953	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.78	0.38	3.3e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs12210905	1.000	rs10946906	chr6:27252780	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg26656751	chr17:43910226	CRHR1	0.49	9.03	0.39	4.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3816183	1.000	rs6717616	chr2:43013337	G/T	cg27299406	chr2:43020013	HAAO	-0.27	-6.74	-0.3	4.64e-11	Hypospadias;
LGG	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.38	-0.32	7.19e-13	Retinal vascular caliber;
LGG	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg07274523	chr3:49395745	GPX1	0.58	9.68	0.41	2.6e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9487094	0.626	rs4947016	chr6:110062098	A/T	cg16315928	chr6:109776240	MICAL1	0.43	7.52	0.33	2.92e-13	Height;
LGG	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg15627072	chr1:2432621	PLCH2	-0.35	-7.86	-0.34	2.79e-14	Ulcerative colitis;
LGG	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.53	0.53	2.15e-35	Colorectal cancer;
LGG	cis	rs10463554	0.963	rs257318	chr5:102445470	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.5e-13	Parkinson's disease;
LGG	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.71	-0.41	2.12e-20	Common traits (Other);
LGG	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg04455712	chr21:45112962	RRP1B	0.53	10.08	0.42	9.69e-22	Mean corpuscular volume;
LGG	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg01579765	chr21:45077557	HSF2BP	0.39	9.0	0.39	6.03e-18	Mean corpuscular volume;
LGG	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg00012203	chr2:219082015	ARPC2	-0.71	-12.92	-0.51	7.94e-33	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg09699651	chr6:150184138	LRP11	0.45	6.71	0.3	5.56e-11	Lung cancer;
LGG	cis	rs367943	0.712	rs6594707	chr5:112700503	C/T	cg12552261	chr5:112820674	MCC	0.58	10.55	0.44	1.84e-23	Type 2 diabetes;
LGG	cis	rs8077889	0.956	rs58242860	chr17:41847300	T/C	cg26893861	chr17:41843967	DUSP3	0.96	17.03	0.62	7.16e-51	Triglycerides;
LGG	cis	rs2797160	0.875	rs12527010	chr6:125991507	A/G	cg05901451	chr6:126070800	HEY2	0.47	8.0	0.35	1.01e-14	Endometrial cancer;
LGG	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-9.01	-0.39	5.47e-18	Aortic root size;
LGG	cis	rs7267979	0.565	rs6107059	chr20:25592431	C/A	cg06421707	chr20:25228305	PYGB	-0.35	-7.24	-0.32	1.85e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg15921436	chr17:44337874	NA	0.56	11.72	0.48	5.6e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.51	9.74	0.41	1.67e-20	Longevity;
LGG	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg03060546	chr3:49711283	APEH	-0.7	-11.73	-0.48	5.11e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs883565	0.682	rs7623850	chr3:39053311	C/T	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	cis	rs897080	0.552	rs1067377	chr2:44648239	T/G	cg00619915	chr2:44497795	NA	-0.5	-6.99	-0.31	9.57e-12	Height;
LGG	cis	rs11074306	0.561	rs74344562	chr15:28071907	G/T	cg26402630	chr15:28053930	OCA2	0.36	7.23	0.32	2.04e-12	Uveal melanoma;
LGG	cis	rs154659	0.961	rs164739	chr16:89667699	C/G	cg01710450	chr16:89662404	CPNE7	-0.65	-11.7	-0.48	7.11e-28	Tanning;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg11965913	chr1:205819406	PM20D1	-0.56	-10.37	-0.43	8.55e-23	Menarche (age at onset);
LGG	cis	rs10463316	0.744	rs6579869	chr5:150763621	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg19847130	chr8:10466454	RP1L1	-0.32	-6.98	-0.31	1.06e-11	Mood instability;
LGG	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.36	0.32	8.25e-13	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23349402	chr2:27603760	ZNF513	0.46	6.93	0.31	1.42e-11	Gut microbiome composition (summer);
LGG	cis	rs988958	0.526	rs10177811	chr2:42263580	G/A	cg27428208	chr2:42229179	NA	0.5	7.57	0.33	2.04e-13	Hypospadias;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg05368731	chr17:41323189	NBR1	0.87	17.03	0.62	7.84e-51	Menopause (age at onset);
LGG	cis	rs6840360	0.642	rs7680013	chr4:152409477	A/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg07659893	chr17:61819838	STRADA	-0.41	-6.68	-0.3	6.86e-11	Prudent dietary pattern;
LGG	cis	rs17767392	0.958	rs7145755	chr14:71848110	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.94	-0.38	9e-18	Mitral valve prolapse;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-12.05	-0.49	2.74e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs75804782	0.625	rs72984530	chr2:239469431	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.92	0.35	1.73e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg01966878	chr4:90757139	SNCA	-0.34	-6.94	-0.31	1.29e-11	Dementia with Lewy bodies;
LGG	cis	rs10819861	0.598	rs7041954	chr9:98856401	T/C	cg14508093	chr9:98862825	NA	0.3	7.21	0.32	2.32e-12	Electrocardiographic traits;
LGG	cis	rs6429082	0.715	rs2153204	chr1:235580382	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	trans	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg24247370	chr13:99142703	STK24	-0.42	-7.46	-0.33	4.4e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.811	rs12066082	chr1:183054863	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.71	0.3	5.8200000000000003e-11	Fuchs's corneal dystrophy;
LGG	cis	rs11785400	1.000	rs13266249	chr8:143732433	A/C	cg10596483	chr8:143751796	JRK	0.57	9.44	0.4	1.85e-19	Schizophrenia;
LGG	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg23815491	chr16:72088622	HP	0.46	7.4	0.33	6.2800000000000005e-13	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.46	8.47	0.37	3.25e-16	Obesity-related traits;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg16507663	chr6:150244633	RAET1G	0.43	7.94	0.35	1.52e-14	Lung cancer;
LGG	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg04733989	chr22:42467013	NAGA	0.6	10.62	0.44	9.96e-24	Schizophrenia;
LGG	cis	rs9682041	0.561	rs1477211	chr3:170140792	A/G	cg11886554	chr3:170076028	SKIL	0.63	7.62	0.33	1.41e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2285947	0.967	rs2285948	chr7:21584229	T/C	cg04471919	chr7:21584483	DNAH11	0.5	13.88	0.54	6.95e-37	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11651000	0.625	rs4794063	chr17:45804494	C/T	cg06532163	chr17:45867833	NA	0.5	7.8	0.34	4.07e-14	IgG glycosylation;
LGG	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg03959625	chr15:84868606	LOC388152	0.48	7.12	0.31	4.11e-12	Schizophrenia;
LGG	cis	rs9916302	0.821	rs1966915	chr17:37425262	A/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg20821713	chr7:1055600	C7orf50	0.4	7.79	0.34	4.46e-14	Longevity;Endometriosis;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg02158880	chr13:53174818	NA	0.5	10.23	0.43	2.7e-22	Lewy body disease;
LGG	cis	rs9354308	0.764	rs9283822	chr6:66596203	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.78	-0.3	3.71e-11	Metabolite levels;
LGG	cis	rs7851660	0.809	rs9299258	chr9:100666543	T/G	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.06	-0.35	6.52e-15	IgG glycosylation;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13732083	chr21:47605072	C21orf56	-0.53	-9.11	-0.39	2.4e-18	Testicular germ cell tumor;
LGG	cis	rs9640161	0.750	rs59211922	chr7:150023790	T/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.83	-0.59	2.04e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10107145	0.509	rs73209953	chr8:10760112	G/C	cg21775007	chr8:11205619	TDH	-0.46	-6.8	-0.3	3.29e-11	Systolic blood pressure;
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26076054	chr5:421317	AHRR	-0.54	-8.94	-0.38	9.68e-18	Cystic fibrosis severity;
LGG	cis	rs5995756	1.000	rs5995756	chr22:40000313	A/G	cg21377881	chr22:40064566	CACNA1I	0.35	7.21	0.32	2.28e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg02018176	chr4:1364513	KIAA1530	0.43	9.87	0.42	5.72e-21	Obesity-related traits;
LGG	cis	rs36051895	0.659	rs10121491	chr9:5046935	T/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.89	-0.59	1.1e-45	Pediatric autoimmune diseases;
LGG	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg09021430	chr5:549028	NA	-0.69	-9.65	-0.41	3.44e-20	Lung disease severity in cystic fibrosis;
LGG	cis	rs1355223	0.902	rs6484726	chr11:34697558	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.38	-0.32	7.31e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs3087591	0.922	rs2905806	chr17:29502507	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.5	-0.37	2.68e-16	Retinal vascular caliber;
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg11984989	chr7:158649758	WDR60	1.05	23.05	0.73	7.05e-79	Height;
LGG	cis	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs933688	0.532	rs868557	chr5:90550379	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.58	-7.66	-0.34	1.08e-13	Smoking behavior;
LGG	cis	rs9815354	0.812	rs11129935	chr3:41985203	A/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17021463	0.807	rs6847989	chr4:95277099	A/C	cg11021082	chr4:95130006	SMARCAD1	0.41	7.49	0.33	3.5e-13	Testicular germ cell tumor;
LGG	cis	rs12701220	0.655	rs34344742	chr7:1149288	C/G	cg02733842	chr7:1102375	C7orf50	-0.44	-7.29	-0.32	1.38e-12	Bronchopulmonary dysplasia;
LGG	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06470251	chr20:60548479	NA	0.52	8.57	0.37	1.57e-16	Body mass index;
LGG	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg26384229	chr12:38710491	ALG10B	0.69	12.71	0.51	5.93e-32	Morning vs. evening chronotype;
LGG	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg00405596	chr8:11794950	NA	0.45	7.06	0.31	6.24e-12	Systemic lupus erythematosus;
LGG	cis	rs9937943	1.000	rs9937943	chr16:74499046	C/G	cg01733217	chr16:74700730	RFWD3	0.5	7.11	0.31	4.48e-12	Neutrophil percentage of white cells;
LGG	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg05163923	chr11:71159392	DHCR7	0.71	13.69	0.54	4.46e-36	Vitamin D levels;
LGG	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg26597838	chr10:835615	NA	0.95	13.07	0.52	1.94e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg16583315	chr14:65563665	MAX	-0.43	-8.72	-0.38	4.86e-17	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg23758822	chr17:41437982	NA	0.87	16.2	0.6	4.22e-47	Menopause (age at onset);
LGG	trans	rs7395662	0.674	rs7124275	chr11:48162305	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.27	-0.32	1.59e-12	HDL cholesterol;
LGG	cis	rs12731740	0.908	rs6671947	chr1:207936491	C/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.34	-0.32	9.5e-13	Biomedical quantitative traits;
LGG	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.18	0.36	2.76e-15	Mood instability;
LGG	cis	rs9890032	0.581	rs62070592	chr17:29022549	T/C	cg19761014	chr17:28927070	LRRC37B2	0.43	6.91	0.31	1.58e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2018055	0.917	rs4357172	chr6:117810114	G/A	cg14611402	chr6:117803162	DCBLD1	0.3	8.46	0.37	3.58e-16	Diastolic blood pressure;
LGG	cis	rs6750047	0.605	rs1374191	chr2:38265420	T/G	cg07380506	chr2:38303506	CYP1B1	-0.43	-7.12	-0.31	4.23e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.3	-0.32	1.28e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.75	0.34	5.91e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg22980697	chr10:16874865	CUBN	0.57	9.34	0.4	4.15e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs13082711	0.522	rs533175	chr3:27361432	A/G	cg02860705	chr3:27208620	NA	-0.57	-10.92	-0.45	7.16e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7267979	1.000	rs6083809	chr20:25329309	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.49	-0.44	3.04e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.34	0.72	1.53e-75	Breast cancer;
LGG	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg12463550	chr7:65579703	CRCP	0.77	8.31	0.36	1.08e-15	Diabetic kidney disease;
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	16.97	0.62	1.41e-50	Tonsillectomy;
LGG	cis	rs12230513	0.732	rs7304753	chr12:55886489	T/A	cg19537932	chr12:55886519	OR6C68	-0.61	-10.66	-0.44	7.27e-24	Contrast sensitivity;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg23633679	chr1:173793655	CENPL;DARS2	0.41	7.25	0.32	1.75e-12	Body mass index;
LGG	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg03929089	chr4:120376271	NA	-0.67	-8.41	-0.36	5.12e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg01620082	chr3:125678407	NA	-0.87	-8.64	-0.37	9.04e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg05555928	chr11:63887634	MACROD1	-0.39	-7.11	-0.31	4.37e-12	Platelet count;
LGG	cis	rs2271404	0.506	rs12329287	chr2:111995287	A/T	cg23466623	chr2:111982296	NA	-0.35	-6.71	-0.3	5.6e-11	Atopic dermatitis;
LGG	cis	rs1472147	0.503	rs58691638	chr7:128433690	A/T	cg00734629	chr7:128471146	FLNC	0.32	6.81	0.3	2.96e-11	Calcium levels;
LGG	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.46	-0.5	6.06e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.45	0.4	1.68e-19	Life satisfaction;
LGG	cis	rs4731207	0.724	rs35535003	chr7:124442464	A/T	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs76070545	0.636	rs6989822	chr8:104198669	T/C	cg03923813	chr8:104230441	BAALC	-1.12	-10.31	-0.43	1.45e-22	Alzheimer disease and age of onset;
LGG	cis	rs240764	0.645	rs454747	chr6:101055566	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.42	0.33	5.67e-13	Neuroticism;
LGG	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg14979609	chr8:8086686	FLJ10661	-0.33	-8.15	-0.35	3.49e-15	Neuroticism;
LGG	cis	rs9460578	0.537	rs10806926	chr6:20824997	G/A	cg13405222	chr6:20811065	CDKAL1	0.76	17.27	0.63	6.07e-52	Breast cancer;
LGG	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg26769984	chr7:1090371	C7orf50	0.5	8.51	0.37	2.36e-16	Bronchopulmonary dysplasia;
LGG	cis	rs972578	0.967	rs5759091	chr22:43407464	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.09	-0.31	4.98e-12	Mean platelet volume;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.12	-0.57	2.86e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17689437	0.647	rs821166	chr16:68578481	A/G	cg02972257	chr16:68554789	NA	-0.44	-7.49	-0.33	3.4e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs7166081	1.000	rs35151633	chr15:67568265	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.75	-0.3	4.5e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9287719	0.934	rs4371336	chr2:10755723	C/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs41271473	0.649	rs72751952	chr1:228901715	G/T	cg00850481	chr1:228891306	NA	-0.46	-7.84	-0.34	3.1e-14	Chronic lymphocytic leukemia;
LGG	cis	rs9660992	0.700	rs1172125	chr1:205258442	A/T	cg21545522	chr1:205238299	TMCC2	0.43	7.83	0.34	3.28e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg08677398	chr8:58056175	NA	0.4	6.88	0.3	1.93e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.788	rs7155259	chr14:71698090	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.99	-0.31	9.5e-12	Mitral valve prolapse;
LGG	cis	rs7193541	0.965	rs28616016	chr16:74676964	T/C	cg01733217	chr16:74700730	RFWD3	0.91	21.53	0.71	9.71e-72	Multiple myeloma;
LGG	cis	rs9912468	0.934	rs8071250	chr17:64321567	C/T	cg19474267	chr17:64306194	PRKCA	-0.97	-28.4	-0.8	1.77e-103	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4660306	0.614	rs11211116	chr1:45930038	A/G	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.47	7.25	0.32	1.71e-12	Homocysteine levels;
LGG	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg14074117	chr16:1909714	C16orf73	0.54	7.98	0.35	1.14e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7444	0.941	rs1034329	chr22:21943938	T/C	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.57e-11	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.7e-20	Intelligence (multi-trait analysis);
LGG	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg06521331	chr12:34319734	NA	-0.41	-7.19	-0.32	2.64e-12	Morning vs. evening chronotype;
LGG	cis	rs13421350	0.579	rs6743174	chr2:173405330	G/T	cg15021238	chr2:173305865	ITGA6	-0.72	-8.05	-0.35	7.09e-15	Diabetic kidney disease;
LGG	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.15	0.35	3.31e-15	Colorectal cancer;
LGG	cis	rs763121	0.853	rs1062687	chr22:39134715	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	17.97	0.64	3.66e-55	Menopause (age at onset);
LGG	cis	rs2251260	0.945	rs2247196	chr14:62024317	T/A	cg23386212	chr14:62041363	NA	0.61	8.79	0.38	2.94e-17	Yeast infection;
LGG	cis	rs7647973	0.961	rs4955443	chr3:49286618	T/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.31	0.36	1.1e-15	Menarche (age at onset);
LGG	cis	rs6743376	0.556	rs4849146	chr2:113824840	A/T	cg05949173	chr2:113825882	IL1F10	0.51	9.78	0.41	1.18e-20	Inflammatory biomarkers;
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg09264619	chr17:80180166	NA	0.38	7.47	0.33	4.01e-13	Life satisfaction;
LGG	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg04608330	chr12:45269318	NELL2	0.63	11.11	0.46	1.34e-25	Gut microbiome composition (summer);
LGG	cis	rs1355223	0.902	rs1773910	chr11:34741253	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9796	0.621	rs58109657	chr15:41471750	A/G	cg18705301	chr15:41695430	NDUFAF1	0.58	9.89	0.42	4.91e-21	Menopause (age at onset);
LGG	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-9.96	-0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	trans	rs2562456	0.833	rs4359573	chr19:21542296	A/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	trans	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg00938859	chr5:1591904	SDHAP3	0.91	12.29	0.5	3.14e-30	Breast cancer;
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg02297831	chr4:17616191	MED28	0.47	8.78	0.38	3.07e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.65	-0.3	8.27e-11	Neuroticism;
LGG	cis	rs4330281	0.669	rs7652156	chr3:17780490	C/G	cg20981856	chr3:17787350	NA	-0.41	-7.67	-0.34	1e-13	Schizophrenia;
LGG	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.31	-0.63	4.09e-52	Response to antipsychotic treatment;
LGG	cis	rs4974559	0.501	rs1732115	chr4:1244416	C/T	cg02980000	chr4:1222292	CTBP1	0.97	11.79	0.48	2.99e-28	Systolic blood pressure;
LGG	cis	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.71	-0.3	5.61e-11	Joint mobility (Beighton score);
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg23978390	chr7:1156363	C7orf50	0.52	8.94	0.38	9.56e-18	Longevity;Endometriosis;
LGG	cis	rs6764363	0.683	rs393254	chr3:300949	G/A	cg02057681	chr3:285234	CHL1	0.38	6.75	0.3	4.33e-11	Sudden cardiac arrest;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.92	-0.38	1.08e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9640161	0.742	rs11767726	chr7:150018096	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	0.73	15.35	0.58	2.6900000000000002e-43	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs75804782	0.521	rs56087929	chr2:239455564	G/A	cg01134436	chr17:81009848	B3GNTL1	0.77	8.58	0.37	1.48e-16	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg06521331	chr12:34319734	NA	-0.5	-8.81	-0.38	2.57e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5742933	0.744	rs13002216	chr2:190611084	T/C	cg10453823	chr2:190539512	ANKAR	-0.45	-6.72	-0.3	5.28e-11	Ferritin levels;
LGG	cis	rs2777491	0.957	rs6493002	chr15:41709195	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.06	-0.68	6.94e-65	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26087598	chr5:176739400	MXD3	0.47	6.8	0.3	3.27e-11	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg16141378	chr3:129829833	LOC729375	-0.51	-12.96	-0.52	5.24e-33	Mood instability;
LGG	trans	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg26043149	chr18:55253948	FECH	-0.48	-7.84	-0.34	3.14e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9354308	0.764	rs1938112	chr6:66567508	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs4911259	0.507	rs8118663	chr20:31398876	A/G	cg13636640	chr20:31349939	DNMT3B	0.7	10.82	0.45	1.75e-24	Inflammatory bowel disease;
LGG	trans	rs783540	0.500	rs1313494	chr15:83274279	C/T	cg16105309	chr15:79090380	ADAMTS7	0.43	7.07	0.31	5.88e-12	Schizophrenia;
LGG	cis	rs4731207	0.698	rs4379394	chr7:124519627	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg00666640	chr1:248458726	OR2T12	0.58	9.36	0.4	3.61e-19	Common traits (Other);
LGG	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.6	0.33	1.71e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	5.93e-38	Bladder cancer;
LGG	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-6.77	-0.3	3.8e-11	Subjective well-being;
LGG	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg02461776	chr11:598696	PHRF1	0.52	8.17	0.36	2.87e-15	Systemic lupus erythematosus;
LGG	cis	rs2117029	0.782	rs11168850	chr12:49472965	G/A	cg24176009	chr12:49580217	TUBA1A	0.41	7.32	0.32	1.14e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7572644	0.662	rs12465103	chr2:28199736	G/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs17221829	0.589	rs7930747	chr11:89377160	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg19507638	chr5:93509721	C5orf36	-0.69	-9.6	-0.41	5.05e-20	Diabetic retinopathy;
LGG	cis	rs35160687	0.712	rs1863057	chr2:86502101	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.76	0.3	4.18e-11	Night sleep phenotypes;
LGG	cis	rs9326248	0.559	rs10892064	chr11:116896553	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.85	0.45	1.39e-24	Blood protein levels;
LGG	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg00701064	chr4:6280414	WFS1	0.74	16.4	0.61	5.55e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs2066819	1.000	rs116849218	chr12:56683975	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.72	0.41	1.95e-20	Menarche (age at onset);
LGG	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg13385794	chr1:248469461	NA	0.5	8.52	0.37	2.29e-16	Common traits (Other);
LGG	cis	rs62025270	0.593	rs7166540	chr15:86244085	A/G	cg25843651	chr15:86329602	KLHL25	0.58	8.75	0.38	3.91e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs11096990	0.634	rs745642	chr4:39281262	G/T	cg24403649	chr4:39172243	NA	-0.4	-7.14	-0.31	3.68e-12	Cognitive function;
LGG	cis	rs1015291	0.836	rs951062	chr12:19988377	C/T	cg25401612	chr12:20009446	NA	-0.34	-7.43	-0.33	5.19e-13	Diastolic blood pressure;
LGG	cis	rs6456156	0.565	rs6921588	chr6:167494397	G/T	cg07741184	chr6:167504864	NA	0.43	9.49	0.4	1.23e-19	Primary biliary cholangitis;
LGG	cis	rs3008870	1.000	rs3008855	chr1:67386204	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.98	-18.99	-0.66	6.77e-60	Lymphocyte percentage of white cells;
LGG	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.32	-0.5	2.24e-30	Morning vs. evening chronotype;
LGG	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.15	0.52	8.86e-34	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg08677398	chr8:58056175	NA	0.51	8.03	0.35	8.03e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2649	0.518	rs4556742	chr15:63864433	C/T	cg22599514	chr15:63798201	USP3	0.44	7.37	0.32	7.87e-13	Aortic root size;
LGG	cis	rs7770628	0.682	rs2144723	chr6:161121390	A/G	cg04181478	chr6:161122748	PLG	0.41	8.17	0.36	2.92e-15	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.57	-0.59	2.85e-44	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11728900	chr10:13203459	MCM10	0.44	7.09	0.31	5.2e-12	Cognitive performance;
LGG	cis	rs2235642	0.893	rs2076439	chr16:1587277	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.42	10.28	0.43	1.87e-22	Coronary artery disease;
LGG	cis	rs539514	0.690	rs34545980	chr13:76309637	C/A	cg04757411	chr13:76259545	LMO7	-0.27	-7.11	-0.31	4.28e-12	Type 1 diabetes;
LGG	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg14893161	chr1:205819251	PM20D1	0.44	7.44	0.33	5.05e-13	Menarche (age at onset);
LGG	cis	rs9419702	0.526	rs9419637	chr10:133548059	T/C	cg20568497	chr10:133558893	NA	0.35	7.63	0.33	1.39e-13	Survival in rectal cancer;
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg11764359	chr7:65958608	NA	0.7	12.68	0.51	7.6e-32	Aortic root size;
LGG	cis	rs910316	1.000	rs2098297	chr14:75619118	G/T	cg11812906	chr14:75593930	NEK9	-0.53	-10.04	-0.42	1.34e-21	Height;
LGG	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg15557168	chr22:42548783	NA	-0.39	-8.5	-0.37	2.69e-16	Schizophrenia;
LGG	cis	rs847649	0.692	rs10271184	chr7:102477176	A/G	cg18108683	chr7:102477205	FBXL13	-0.71	-15.89	-0.59	1.06e-45	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.08	-0.39	3.24e-18	Primary sclerosing cholangitis;
LGG	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.38	-0.32	7.28e-13	Mean corpuscular volume;
LGG	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.41	-0.33	5.87e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs3735485	0.800	rs4720489	chr7:45041813	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg02772935	chr3:125709198	NA	-0.53	-6.73	-0.3	4.9e-11	Blood pressure (smoking interaction);
LGG	cis	rs7077256	0.542	rs36089084	chr10:65238652	A/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3857747	0.861	rs4723962	chr7:40453414	A/T	cg00420559	chr7:40367873	C7orf10	-0.36	-7.28	-0.32	1.45e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	trans	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg25214090	chr10:38739885	LOC399744	0.72	12.84	0.51	1.76e-32	Corneal astigmatism;
LGG	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg08344181	chr3:125677491	NA	-0.71	-7.67	-0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg23958373	chr8:599963	NA	1.37	13.0	0.52	3.75e-33	IgG glycosylation;
LGG	trans	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.9	0.34	2.01e-14	Retinal vascular caliber;
LGG	cis	rs9527	0.590	rs6584537	chr10:104778267	C/G	cg05308233	chr10:104796373	CNNM2	-0.32	-6.97	-0.31	1.13e-11	Arsenic metabolism;
LGG	cis	rs11885103	0.791	rs4402801	chr2:585333	G/A	cg21195176	chr2:593345	NA	0.39	7.42	0.33	5.64e-13	Heschl's gyrus morphology;
LGG	cis	rs9443645	0.901	rs2050660	chr6:79734726	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.62	-0.37	1.06e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4732038	0.510	rs56816317	chr7:134278493	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.31	-0.63	3.81e-52	Longevity;
LGG	cis	rs741702	0.928	rs116374652	chr19:13014235	T/C	cg04657146	chr19:12876947	HOOK2	-0.43	-7.09	-0.31	4.98e-12	Red blood cell traits;
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg22307297	chr20:60903441	LAMA5	0.44	8.47	0.37	3.22e-16	Colorectal cancer;
LGG	cis	rs9325144	0.881	rs56344858	chr12:39180935	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-11.85	-0.48	1.81e-28	Morning vs. evening chronotype;
LGG	cis	rs4356932	0.935	rs4406046	chr4:76969955	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.05e-11	Blood protein levels;
LGG	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14373873	chr11:113211441	TTC12	0.41	8.35	0.36	7.69e-16	Information processing speed;
LGG	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.67	-0.41	2.95e-20	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27415899	chr3:196438768	PIGX;C3orf34	0.42	7.08	0.31	5.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs919433	0.857	rs36071109	chr2:198183191	C/A	cg00792783	chr2:198669748	PLCL1	-0.46	-7.05	-0.31	6.34e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs75059851	1.000	rs75059851	chr11:133822569	A/G	cg20042908	chr11:133852938	NA	-0.67	-11.58	-0.47	2.05e-27	Schizophrenia;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg01114163	chr5:1856713	NA	-0.41	-7.15	-0.32	3.35e-12	Cardiovascular disease risk factors;
LGG	cis	rs7408868	1.000	rs757472	chr19:15273221	T/C	cg14696996	chr19:15285081	NOTCH3	1.01	12.58	0.5	1.92e-31	Pulse pressure;
LGG	cis	rs7216064	0.953	rs10445361	chr17:65962238	G/T	cg12091567	chr17:66097778	LOC651250	0.64	9.55	0.41	7.58e-20	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs17689437	0.671	rs7195656	chr16:68586791	C/T	cg02972257	chr16:68554789	NA	-0.45	-7.51	-0.33	2.97e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.3	0.36	1.16e-15	Life satisfaction;
LGG	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg17050807	chr22:42548356	NA	-0.39	-7.49	-0.33	3.59e-13	Schizophrenia;
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.66	-0.3	7.87e-11	Total body bone mineral density;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.8	-0.34	4.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg10483660	chr13:112241077	NA	0.42	8.64	0.37	9.3e-17	Menarche (age at onset);
LGG	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg08717414	chr16:71523259	ZNF19	-0.49	-7.42	-0.33	5.67e-13	Post bronchodilator FEV1;
LGG	cis	rs7166081	1.000	rs10438355	chr15:67487549	C/G	cg05925327	chr15:68127851	NA	-0.32	-6.79	-0.3	3.55e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg26384229	chr12:38710491	ALG10B	0.76	14.12	0.55	6.89e-38	Resting heart rate;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg04911050	chr16:677664	RAB40C	0.34	6.86	0.3	2.22e-11	Height;
LGG	cis	rs11625487	0.515	rs12434419	chr14:77855617	G/A	cg20045696	chr14:77926864	AHSA1	-0.74	-11.57	-0.47	2.29e-27	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg11494091	chr17:61959527	GH2	0.51	8.25	0.36	1.63e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg04025307	chr7:1156635	C7orf50	0.71	12.37	0.5	1.49e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	7.86	0.34	2.72e-14	Renal function-related traits (BUN);
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.47	0.37	3.33e-16	Alzheimer's disease;
LGG	cis	rs283228	0.550	rs658318	chr6:101733396	A/G	cg27451362	chr6:101846650	GRIK2	-0.95	-13.63	-0.54	8.25e-36	Coenzyme Q10 levels;
LGG	cis	rs8135665	0.625	rs34385006	chr22:38450291	C/T	cg19171272	chr22:38449367	NA	-0.47	-8.52	-0.37	2.29e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs10751667	0.666	rs10902242	chr11:949700	G/A	cg22143635	chr11:980567	AP2A2	0.43	7.91	0.35	1.89e-14	Alzheimer's disease (late onset);
LGG	cis	rs7113874	0.569	rs11041980	chr11:8579081	T/A	cg23764900	chr11:8616102	STK33	-0.39	-7.01	-0.31	8.3e-12	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg06916706	chr16:4465613	CORO7	-0.7	-12.11	-0.49	1.69e-29	Schizophrenia;
LGG	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.18e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7226408	0.857	rs2166294	chr18:34488534	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs963731	0.649	rs6544185	chr2:39190964	C/T	cg04010122	chr2:39346883	SOS1	-0.76	-6.96	-0.31	1.15e-11	Corticobasal degeneration;
LGG	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg16662043	chr16:48846231	NA	0.33	6.64	0.3	8.54e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7717393	0.786	rs7714142	chr5:155771022	C/T	cg12904904	chr5:155754151	SGCD	0.69	7.6	0.33	1.68e-13	Egg allergy;
LGG	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg20892847	chr12:58011875	NA	0.33	6.98	0.31	1e-11	Multiple sclerosis;
LGG	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.43e-12	Self-reported allergy;
LGG	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg00531865	chr16:30841666	NA	-0.52	-10.72	-0.45	4.29e-24	Dementia with Lewy bodies;
LGG	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg21605333	chr4:119757512	SEC24D	1.44	15.06	0.57	5.24e-42	Cannabis dependence symptom count;
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg27476859	chr7:2772710	GNA12	0.53	10.36	0.43	9.61e-23	Height;
LGG	cis	rs6964587	0.773	rs12536421	chr7:92008220	A/G	cg17063962	chr7:91808500	NA	0.48	8.33	0.36	8.97e-16	Breast cancer;
LGG	cis	rs4771450	0.962	rs9582684	chr13:103974736	G/A	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.08e-17	Menopause (age at onset);
LGG	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg15764593	chr10:829463	NA	-0.66	-9.78	-0.41	1.21e-20	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20176194	chr2:220173205	PTPRN	0.51	8.07	0.35	6.27e-15	Gut microbiome composition (summer);
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs6489882	0.966	rs4767044	chr12:113402899	C/A	cg25319449	chr12:113376135	OAS3	-0.38	-6.66	-0.3	8e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.48	-0.4	1.29e-19	Common traits (Other);
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg18761221	chr20:60518478	NA	-0.52	-8.24	-0.36	1.78e-15	Obesity-related traits;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg04160749	chr8:58172571	NA	-0.51	-7.99	-0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs55633855	0.516	rs72970458	chr11:88146659	T/C	cg08522340	chr11:88068493	CTSC	-0.39	-6.86	-0.3	2.23e-11	Body mass index;
LGG	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg16329650	chr2:213403929	ERBB4	0.78	16.57	0.61	9.65e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs350251	0.833	rs9922788	chr16:12243932	A/G	cg02910054	chr16:12241554	SNX29	0.49	9.28	0.4	6.49e-19	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs57590327	0.555	rs13072957	chr3:81776242	A/G	cg07356753	chr3:81810745	GBE1	0.51	8.28	0.36	1.31e-15	Extraversion;
LGG	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.66e-11	Schizophrenia;
LGG	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg04455712	chr21:45112962	RRP1B	0.54	10.27	0.43	2.04e-22	Mean corpuscular volume;
LGG	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	7.96	0.35	1.38e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg07541023	chr7:19748670	TWISTNB	0.57	7.79	0.34	4.59e-14	Thyroid stimulating hormone;
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Electroencephalogram traits;
LGG	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg23422044	chr7:1970798	MAD1L1	-0.8	-13.8	-0.54	1.59e-36	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20415828	chr12:123011764	RSRC2;KNTC1	0.44	7.22	0.32	2.1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9398803	0.865	rs4895808	chr6:126781434	C/T	cg19875578	chr6:126661172	C6orf173	0.58	10.51	0.44	2.48e-23	Male-pattern baldness;
LGG	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg26138144	chr22:38071188	LGALS1	0.69	12.8	0.51	2.59e-32	Fat distribution (HIV);
LGG	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.3	0.32	1.28e-12	Total cholesterol levels;
LGG	cis	rs7584330	0.695	rs77922291	chr2:238366317	T/G	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	trans	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs6565180	0.888	rs12447833	chr16:30390314	T/C	cg17640201	chr16:30407289	ZNF48	0.87	16.73	0.61	1.73e-49	Tonsillectomy;
LGG	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.06	-0.31	6.1e-12	Hemoglobin concentration;
LGG	cis	rs9815354	0.761	rs57638657	chr3:41809238	G/C	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg11764359	chr7:65958608	NA	0.59	10.34	0.43	1.11e-22	Aortic root size;
LGG	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22496380	chr5:211416	CCDC127	-1.35	-18.68	-0.66	1.84e-58	Breast cancer;
LGG	trans	rs17685	0.672	rs10952841	chr7:75778626	A/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1971762	0.545	rs4759280	chr12:54064958	C/A	cg06632207	chr12:54070931	ATP5G2	0.24	7.33	0.32	1.01e-12	Height;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.49	0.33	3.49e-13	Cystic fibrosis severity;
LGG	cis	rs7084783	0.593	rs2902634	chr10:105404504	T/A	cg00126946	chr10:105363258	SH3PXD2A	0.41	7.67	0.34	1.04e-13	Fear of pain;
LGG	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg10167378	chr1:228756711	NA	0.56	8.0	0.35	1.03e-14	Chronic lymphocytic leukemia;
LGG	cis	rs72781680	0.898	rs56413706	chr2:24086961	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.57	0.41	6.46e-20	Lymphocyte counts;
LGG	cis	rs2730245	0.527	rs924910	chr7:158672272	C/T	cg11984989	chr7:158649758	WDR60	1.01	14.27	0.55	1.47e-38	Height;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7923609	0.561	rs1991571	chr10:65310154	C/A	cg02276361	chr10:65351566	REEP3	-0.31	-6.8	-0.3	3.22e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg18850127	chr7:39170497	POU6F2	0.64	16.39	0.61	6e-48	IgG glycosylation;
LGG	cis	rs2188554	0.785	rs7789741	chr7:117206941	T/G	cg10524701	chr7:117356490	CTTNBP2	0.39	6.74	0.3	4.73e-11	Esophageal adenocarcinoma;
LGG	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg09165964	chr15:75287851	SCAMP5	0.64	12.05	0.49	2.9e-29	Breast cancer;
LGG	cis	rs1107366	0.722	rs2364368	chr3:125905080	A/T	cg06827562	chr3:125932279	NA	0.58	13.63	0.54	8.36e-36	Metabolite levels;
LGG	cis	rs7843479	0.965	rs11135742	chr8:21802910	A/T	cg17168535	chr8:21777572	XPO7	0.61	9.97	0.42	2.36e-21	Mean corpuscular volume;
LGG	cis	rs9487094	0.813	rs13203252	chr6:109672736	A/G	cg01125227	chr6:109776195	MICAL1	0.5	8.4	0.36	5.34e-16	Height;
LGG	cis	rs4732038	0.739	rs17775934	chr7:134252718	C/T	cg06906464	chr7:134288099	NA	-0.48	-11.49	-0.47	4.52e-27	Longevity;
LGG	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.48	7.3	0.32	1.22e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.54e-11	Aortic root size;
LGG	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.66	0.51	9.48e-32	Mean corpuscular hemoglobin;
LGG	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs6142618	0.562	rs6142608	chr20:30690943	G/T	cg00028034	chr20:30779307	TSPYL3	0.36	7.92	0.35	1.75e-14	Inflammatory bowel disease;
LGG	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg02023728	chr11:77925099	USP35	0.46	8.09	0.35	5.14e-15	Testicular germ cell tumor;
LGG	trans	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.93	-0.6	7e-46	Colorectal cancer;
LGG	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg01262667	chr19:19385393	TM6SF2	0.37	7.41	0.33	5.86e-13	Bipolar disorder;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.02e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg14675211	chr2:100938903	LONRF2	-0.63	-11.2	-0.46	6.44e-26	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	1.000	rs4646586	chr15:58305344	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.13	-0.35	3.86e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg07150166	chr2:30669952	LCLAT1	0.6	8.44	0.37	4.18e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg02825527	chr7:2087843	MAD1L1	-0.35	-7.15	-0.32	3.3e-12	Neuroticism;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25072359	chr17:41440525	NA	0.52	10.14	0.43	5.8e-22	Menopause (age at onset);
LGG	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.94	-11.48	-0.47	5.19e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs9783347	0.621	rs2037867	chr11:18382021	A/G	cg15585147	chr11:18324498	HPS5	0.31	7.02	0.31	7.76e-12	Pancreatic cancer;
LGG	trans	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.46	-0.33	4.34e-13	Neuroticism;
LGG	trans	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg07211511	chr3:129823064	LOC729375	-0.69	-9.74	-0.41	1.57e-20	Blood pressure (smoking interaction);
LGG	trans	rs877282	0.898	rs2004478	chr10:770709	C/A	cg22713356	chr15:30763199	NA	0.56	8.5	0.37	2.55e-16	Uric acid levels;
LGG	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs1318772	0.932	rs11744737	chr5:112932389	T/G	cg12552261	chr5:112820674	MCC	0.68	7.73	0.34	6.87e-14	F-cell distribution;
LGG	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg26384229	chr12:38710491	ALG10B	-0.68	-13.73	-0.54	3.14e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.75	9.98	0.42	2.16e-21	Lung function (FEV1/FVC);
LGG	cis	rs9398803	0.678	rs9388500	chr6:126876580	C/G	cg19875578	chr6:126661172	C6orf173	0.5	9.13	0.39	2.06e-18	Male-pattern baldness;
LGG	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.06	-0.31	5.95e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7572733	0.515	rs6726506	chr2:198846486	G/T	cg00792783	chr2:198669748	PLCL1	0.68	11.13	0.46	1.13e-25	Dermatomyositis;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg22963979	chr7:1858916	MAD1L1	0.51	10.11	0.43	7.75e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg01673284	chr16:4527211	HMOX2	0.33	6.87	0.3	2.14e-11	Schizophrenia;
LGG	cis	rs79349575	0.783	rs12453394	chr17:46994970	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.43	0.36	4.32e-16	Lung cancer;
LGG	cis	rs10781543	0.817	rs1128874	chr9:139323424	T/C	cg14169450	chr9:139327907	INPP5E	0.4	7.42	0.33	5.82e-13	Monocyte percentage of white cells;
LGG	cis	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.1	0.42	8.36e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs2235642	0.928	rs1057610	chr16:1605537	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	10.09	0.42	8.94e-22	Coronary artery disease;
LGG	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg13802316	chr11:70253460	CTTN	-0.57	-7.39	-0.32	6.77e-13	Coronary artery disease;
LGG	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg15704280	chr7:45808275	SEPT13	-0.64	-8.19	-0.36	2.52e-15	D-dimer levels;
LGG	cis	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-7.3	-0.32	1.27e-12	Neuroticism;
LGG	cis	rs4891159	0.724	rs690401	chr18:74108576	C/T	cg24786174	chr18:74118243	ZNF516	0.57	13.27	0.52	2.78e-34	Longevity;
LGG	cis	rs209489	0.892	rs57336333	chr6:53115190	T/C	cg15607103	chr6:53167650	ELOVL5	0.62	7.57	0.33	2.07e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs17221829	0.703	rs12365715	chr11:89374075	G/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.05	-0.39	4.08e-18	Anxiety in major depressive disorder;
LGG	cis	rs6750047	0.546	rs2082255	chr2:38273758	C/A	cg07380506	chr2:38303506	CYP1B1	0.44	7.38	0.32	7.29e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs714515	1.000	rs714515	chr1:172352990	G/A	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs11997175	0.550	rs6468206	chr8:33780878	A/C	ch.8.33884649F	chr8:33765107	NA	0.4	7.6	0.33	1.69e-13	Body mass index;
LGG	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg04691961	chr3:161091175	C3orf57	-0.61	-14.3	-0.55	1.13e-38	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.51	0.37	2.5e-16	Retinal vascular caliber;
LGG	cis	rs701145	0.537	rs357471	chr3:153896403	C/T	cg17054900	chr3:154042577	DHX36	0.88	10.22	0.43	3.13e-22	Coronary artery disease;
LGG	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.33	0.55	8.22e-39	Morning vs. evening chronotype;
LGG	cis	rs9358372	0.574	rs9368239	chr6:20813013	T/A	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.57	-0.41	6.57e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8008758	0.500	rs1763212	chr14:101693911	G/A	cg26224664	chr14:101693935	NA	-0.86	-20.15	-0.68	2.83e-65	Body mass index (alcohol intake interaction);
LGG	cis	rs8179	0.620	rs73232029	chr7:92287283	G/C	cg15732164	chr7:92237376	CDK6	-0.54	-10.01	-0.42	1.78e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.39	0.4	2.78e-19	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05719877	chr11:114271629	C11orf71;RBM7	0.45	7.53	0.33	2.71e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.32	-0.4	4.63e-19	Life satisfaction;
LGG	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.62	0.41	4.13e-20	Mean corpuscular hemoglobin;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg05863683	chr7:1912471	MAD1L1	0.43	8.38	0.36	6.48e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg24558204	chr6:135376177	HBS1L	0.62	10.85	0.45	1.33e-24	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs13191362	0.507	rs2849518	chr6:163134248	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-8.56	-0.37	1.74e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg21238619	chr17:78079768	GAA	-0.45	-8.38	-0.36	6.2e-16	Yeast infection;
LGG	cis	rs7742824	1.000	rs7752653	chr6:44093808	T/G	cg04074908	chr6:44101190	TMEM63B	0.68	13.34	0.53	1.35e-34	Major depressive disorder;
LGG	cis	rs8062405	0.688	rs3924376	chr16:28925978	T/C	cg16576597	chr16:28551801	NUPR1	-0.35	-7.5	-0.33	3.29e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8060686	0.565	rs55857142	chr16:68236741	A/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.38	-0.32	7.5e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg05775895	chr3:12838266	CAND2	0.59	10.01	0.42	1.81e-21	QRS complex (12-leadsum);
LGG	cis	rs7326068	0.610	rs3924006	chr13:21331779	T/A	cg04906043	chr13:21280425	IL17D	-0.5	-7.96	-0.35	1.29e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg24006582	chr15:45444508	DUOX1	-0.66	-12.63	-0.51	1.25e-31	Uric acid levels;
LGG	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-10.91	-0.45	8.02e-25	Morning vs. evening chronotype;
LGG	cis	rs990171	0.955	rs10165460	chr2:103085631	C/T	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs7226408	0.600	rs2017596	chr18:34687457	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.12	-0.39	2.37e-18	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg02725872	chr8:58115012	NA	-0.85	-11.93	-0.48	8.57e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7336332	0.598	rs9581850	chr13:28012265	A/G	cg01674679	chr13:27998804	GTF3A	-0.65	-8.4	-0.36	5.33e-16	Weight;
LGG	cis	rs4742903	0.935	rs7024069	chr9:107008176	A/G	cg14250997	chr9:106856677	SMC2	0.36	7.29	0.32	1.35e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	13.08	0.52	1.75e-33	Mean platelet volume;
LGG	cis	rs3806843	0.762	rs3756337	chr5:140186438	G/C	cg19875535	chr5:140030758	IK	0.45	9.0	0.39	5.68e-18	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg00800038	chr16:89945340	TCF25	-0.67	-8.49	-0.37	2.9e-16	Skin colour saturation;
LGG	cis	rs2708240	1.000	rs2247137	chr7:147581002	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.84	-0.3	2.48e-11	QT interval (drug interaction);
LGG	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg05044414	chr3:183734942	ABCC5	0.77	16.96	0.62	1.53e-50	Anterior chamber depth;
LGG	cis	rs28374715	0.787	rs11856169	chr15:41547938	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.07	-19.87	-0.68	5.51e-64	Ulcerative colitis;
LGG	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg07382826	chr16:28625726	SULT1A1	0.42	8.88	0.38	1.51e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9880211	0.948	rs34282798	chr3:136143357	G/C	cg21827317	chr3:136751795	NA	-0.48	-7.09	-0.31	4.9e-12	Body mass index;Height;
LGG	cis	rs6448317	0.911	rs10939013	chr4:24903015	G/A	cg21108841	chr4:24914750	CCDC149	0.52	7.22	0.32	2.09e-12	Heschl's gyrus morphology;
LGG	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg27279351	chr12:120934652	DYNLL1	0.81	13.11	0.52	1.26e-33	Reticulocyte fraction of red cells;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.8	-0.54	1.62e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg15997130	chr1:24165203	NA	0.5	13.73	0.54	3.2e-36	Immature fraction of reticulocytes;
LGG	cis	rs34891900	0.507	rs2535679	chr22:18202850	A/G	cg19898043	chr22:18121309	BCL2L13	0.56	9.17	0.39	1.5e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg13047869	chr3:10149882	C3orf24	0.56	9.28	0.4	6.29e-19	Alzheimer's disease;
LGG	trans	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.74	-0.34	6.32e-14	Heart rate;
LGG	cis	rs8179	0.593	rs6948097	chr7:92281953	C/T	cg15732164	chr7:92237376	CDK6	-0.52	-9.85	-0.42	6.84e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs2229238	0.911	rs112394421	chr1:154512008	T/C	cg10237817	chr1:154519846	TDRD10	0.35	7.0	0.31	9.06e-12	Coronary heart disease;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.03	-0.31	7.45e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10927875	0.632	rs6677321	chr1:16149301	A/C	cg21385522	chr1:16154831	NA	-1.04	-25.96	-0.77	2.23e-92	Dilated cardiomyopathy;
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg23302884	chr18:44338147	ST8SIA5	0.35	6.8	0.3	3.22e-11	Personality dimensions;
LGG	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg09462578	chr12:12878428	APOLD1	-0.5	-7.04	-0.31	6.84e-12	Systemic lupus erythematosus;
LGG	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg03342759	chr3:160939853	NMD3	0.61	10.55	0.44	1.84e-23	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.91e-31	Motion sickness;
LGG	cis	rs10875746	0.537	rs4760625	chr12:48673743	A/T	cg24011408	chr12:48396354	COL2A1	-0.59	-7.51	-0.33	2.98e-13	Longevity (90 years and older);
LGG	trans	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg22358067	chr17:16797159	NA	-0.52	-7.32	-0.32	1.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11168618	0.875	rs7972785	chr12:48877056	T/C	cg24011408	chr12:48396354	COL2A1	0.49	8.04	0.35	7.49e-15	Adiponectin levels;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg07870213	chr5:140052090	DND1	0.91	16.85	0.62	4.87e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs986417	0.818	rs761557	chr14:61077484	C/T	cg27398547	chr14:60952738	C14orf39	-0.68	-6.79	-0.3	3.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9814567	0.806	rs4074522	chr3:134325626	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	10.87	0.45	1.19e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.63	-0.48	1.36e-27	Hemoglobin concentration;
LGG	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg26384229	chr12:38710491	ALG10B	0.83	17.35	0.63	2.67e-52	Heart rate;
LGG	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg17788362	chr6:86352627	SYNCRIP	0.54	9.17	0.39	1.58e-18	Smooth-surface caries;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg16507663	chr6:150244633	RAET1G	0.5	10.38	0.43	7.62e-23	Lung cancer;
LGG	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg09021430	chr5:549028	NA	-0.68	-9.62	-0.41	4.42e-20	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03930948	chr17:5322888	RPAIN;NUP88	0.44	6.77	0.3	3.97e-11	Gut microbiome composition (summer);
LGG	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg17108064	chr15:78857060	CHRNA5	0.46	9.42	0.4	2.22e-19	Sudden cardiac arrest;
LGG	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg18196295	chr10:418757	DIP2C	0.42	7.91	0.34	1.95e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.4	0.36	5.45e-16	Diabetic kidney disease;
LGG	trans	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg06521331	chr12:34319734	NA	0.44	7.77	0.34	5e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg21775007	chr8:11205619	TDH	-0.48	-7.69	-0.34	8.8e-14	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg02725872	chr8:58115012	NA	0.53	8.61	0.37	1.15e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1620921	0.594	rs9766412	chr6:161268255	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2692947	0.537	rs11679899	chr2:96378162	A/G	cg06850509	chr2:96314847	NA	-0.37	-6.93	-0.31	1.41e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg19628046	chr18:33552617	C18orf21	0.54	7.87	0.34	2.51e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.02e-11	Aortic root size;
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26076054	chr5:421317	AHRR	0.44	8.05	0.35	7.18e-15	Cystic fibrosis severity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01356703	chr12:7262021	C1RL;LOC283314	0.42	6.81	0.3	3.09e-11	Cognitive performance;
LGG	cis	rs7851660	0.809	rs7034648	chr9:100654093	C/A	cg13688889	chr9:100608707	NA	-0.64	-12.76	-0.51	3.55e-32	Strep throat;
LGG	cis	rs2905347	0.737	rs2905349	chr7:22629285	A/G	cg23521230	chr7:22704884	NA	-0.42	-7.49	-0.33	3.63e-13	Major depression and alcohol dependence;
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg20978937	chr14:105399321	PLD4	0.49	11.19	0.46	6.96e-26	Rheumatoid arthritis;
LGG	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg06636001	chr8:8085503	FLJ10661	0.71	14.97	0.57	1.39e-41	Mood instability;
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.84	0.48	1.96e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12209877	1.000	rs12209877	chr6:21027761	G/T	cg13405222	chr6:20811065	CDKAL1	0.37	6.74	0.3	4.61e-11	Cognitive function;
LGG	trans	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg02002194	chr4:3960332	NA	-0.38	-6.75	-0.3	4.55e-11	Retinal vascular caliber;
LGG	cis	rs2067615	0.507	rs10746063	chr12:107086240	G/T	cg15890332	chr12:107067104	RFX4	0.44	12.87	0.51	1.28e-32	Heart rate;
LGG	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg25019033	chr10:957182	NA	-0.55	-9.97	-0.42	2.44e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	20.74	0.69	4.82e-68	Homoarginine levels;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4919694	1.000	rs12254254	chr10:104765605	C/T	cg04362960	chr10:104952993	NT5C2	1.06	14.74	0.57	1.33e-40	Arsenic metabolism;
LGG	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg12463550	chr7:65579703	CRCP	0.78	8.46	0.37	3.5e-16	Diabetic kidney disease;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.29	0.4	6.07e-19	Platelet count;
LGG	cis	rs1843834	0.539	rs12694643	chr2:225446603	A/G	cg22509189	chr2:225307070	NA	-0.59	-9.59	-0.41	5.34e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1816752	0.679	rs7999480	chr13:24972003	A/T	cg02811702	chr13:24901961	NA	-0.39	-7.08	-0.31	5.27e-12	Obesity-related traits;
LGG	cis	rs4988958	0.584	rs7559845	chr2:103046214	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.58	0.41	5.74e-20	Asthma (childhood onset);
LGG	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.41	-0.33	5.89e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg04731861	chr2:219085781	ARPC2	0.49	12.63	0.51	1.21e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.5	-0.44	2.92e-23	Prostate cancer;
LGG	cis	rs1003719	0.762	rs1155786	chr21:38448025	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.82	16.86	0.62	4.32e-50	Eye color traits;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg19774624	chr17:42201019	HDAC5	-0.73	-14.2	-0.55	3.11e-38	Total body bone mineral density;
LGG	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	trans	rs75804782	0.691	rs55886641	chr2:239319185	T/C	cg01134436	chr17:81009848	B3GNTL1	0.85	8.97	0.38	7.27e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs3790455	0.965	rs2274320	chr1:156453247	T/A	cg14087168	chr1:156450669	MEF2D	0.47	7.73	0.34	6.61e-14	Migraine;
LGG	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg15596359	chr8:11213517	TDH	-0.39	-7.95	-0.35	1.39e-14	Retinal vascular caliber;
LGG	cis	rs4432842	0.500	rs6887541	chr5:57009426	T/G	cg08523694	chr5:57076192	NA	0.53	9.22	0.39	1.08e-18	Birth weight;
LGG	cis	rs9397585	0.857	rs9383643	chr6:153374482	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.4	0.56	3.99e-39	Body mass index;
LGG	cis	rs6121246	0.559	rs6060857	chr20:30300222	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.18	0.67	8.84e-61	Mean corpuscular hemoglobin;
LGG	cis	rs7113850	0.541	rs4367945	chr11:24215605	A/C	ch.11.24196551F	chr11:24239977	NA	0.91	10.04	0.42	1.34e-21	Bone fracture in osteoporosis;
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg03036210	chr16:89904091	SPIRE2	-0.47	-6.69	-0.3	6.5500000000000006e-11	Skin colour saturation;
LGG	cis	rs10493773	0.618	rs34746573	chr1:86075360	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.46	-6.98	-0.31	1.04e-11	Urate levels in overweight individuals;
LGG	cis	rs59197085	0.818	rs4472439	chr7:128466635	G/A	cg00734629	chr7:128471146	FLNC	0.34	6.96	0.31	1.19e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs478607	0.831	rs59739006	chr11:64415903	C/T	cg19395706	chr11:64412079	NRXN2	0.43	7.15	0.32	3.48e-12	Urate levels;
LGG	cis	rs11758351	0.500	rs75551401	chr6:26185387	T/C	cg03181300	chr6:26195995	NA	0.87	6.68	0.3	6.97e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9381107	0.932	rs13219694	chr6:9422441	T/G	cg14735645	chr6:9486422	NA	-0.41	-6.8	-0.3	3.24e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs11864453	0.647	rs9932062	chr16:72136055	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-8.4	-0.36	5.51e-16	Fibrinogen levels;
LGG	cis	rs7923609	0.756	rs7910951	chr10:65338304	A/G	cg02276361	chr10:65351566	REEP3	-0.31	-6.86	-0.3	2.26e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg16414030	chr3:133502952	NA	-0.52	-8.28	-0.36	1.33e-15	Iron status biomarkers;
LGG	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.37e-19	Height;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.79	0.34	4.49e-14	Schizophrenia;
LGG	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg24060327	chr5:131705240	SLC22A5	-0.45	-7.57	-0.33	2.02e-13	Blood metabolite levels;
LGG	cis	rs2133450	0.724	rs1858061	chr3:7361210	C/A	cg19930620	chr3:7340148	GRM7	-0.37	-7.88	-0.34	2.4e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs61884328	0.789	rs61897788	chr11:47181051	A/T	cg03339077	chr11:47165057	C11orf49	0.63	6.89	0.31	1.77e-11	Total body bone mineral density (age over 60);
LGG	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.64	0.33	1.25e-13	Obesity-related traits;
LGG	cis	rs283228	0.617	rs566507	chr6:101790255	A/G	cg27451362	chr6:101846650	GRIK2	0.86	13.51	0.53	2.67e-35	Coenzyme Q10 levels;
LGG	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	2.97e-33	Aortic root size;
LGG	cis	rs79349575	0.783	rs318090	chr17:46991752	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg13147721	chr7:65941812	NA	-0.47	-7.39	-0.32	7.1e-13	Corneal structure;
LGG	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.88	-0.3	2.01e-11	Type 2 diabetes;
LGG	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.15	-0.32	3.51e-12	Testicular germ cell tumor;
LGG	cis	rs7582720	1.000	rs72934714	chr2:203711581	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg20913747	chr6:44695427	NA	-0.6	-10.22	-0.43	3.01e-22	Total body bone mineral density;
LGG	cis	rs11157436	0.602	rs1894369	chr14:22634493	A/G	cg00994629	chr14:22694547	NA	-0.33	-7.23	-0.32	2.03e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	trans	rs6787172	0.702	rs1095628	chr3:157976574	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg19980929	chr12:42632907	YAF2	0.35	7.95	0.35	1.46e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg01673284	chr16:4527211	HMOX2	0.32	6.77	0.3	3.91e-11	Schizophrenia;
LGG	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg10935138	chr17:73851978	WBP2	0.54	7.98	0.35	1.17e-14	Psoriasis;
LGG	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg11764359	chr7:65958608	NA	-0.79	-14.76	-0.57	1.1e-40	Aortic root size;
LGG	cis	rs7394190	0.748	rs2306325	chr10:75506674	T/C	cg07699608	chr10:75541558	CHCHD1	0.54	7.14	0.31	3.62e-12	Incident atrial fibrillation;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg20821713	chr7:1055600	C7orf50	-0.36	-7.03	-0.31	7.33e-12	Longevity;Endometriosis;
LGG	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.52	0.37	2.31e-16	Personality dimensions;
LGG	cis	rs1949733	0.635	rs4358384	chr4:8536913	C/T	cg13073564	chr4:8508604	NA	0.44	7.69	0.34	8.72e-14	Response to antineoplastic agents;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.89	-0.3	1.88e-11	Renal cell carcinoma;
LGG	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg18350739	chr11:68623251	NA	-0.89	-22.13	-0.72	1.52e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg11630169	chr10:3283847	NA	0.44	10.56	0.44	1.68e-23	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs9796	0.621	rs690733	chr15:41476465	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.95	-0.42	2.96e-21	Menopause (age at onset);
LGG	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg10189774	chr4:17578691	LAP3	-0.39	-6.9	-0.31	1.67e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2415984	0.600	rs61993295	chr14:46932614	T/C	cg14871534	chr14:47121158	RPL10L	-0.58	-10.09	-0.42	8.71e-22	Number of children ever born;
LGG	cis	rs9914988	0.559	rs1109024	chr17:27189971	C/T	cg20469991	chr17:27169893	C17orf63	0.55	6.93	0.31	1.46e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.06	-0.35	6.74e-15	Height;
LGG	cis	rs7918232	0.941	rs7096505	chr10:27326999	T/C	cg14442939	chr10:27389572	ANKRD26	0.67	10.57	0.44	1.56e-23	Breast cancer;
LGG	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg07621104	chr11:117668040	DSCAML1	0.65	9.21	0.39	1.13e-18	Myopia;
LGG	cis	rs701145	0.585	rs6789213	chr3:153792795	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.38	0.4	3.03e-19	Coronary artery disease;
LGG	cis	rs1318772	0.932	rs2860483	chr5:112846185	G/A	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs477692	0.507	rs7080570	chr10:131455328	C/T	cg05714579	chr10:131428358	MGMT	-0.47	-8.99	-0.39	6.29e-18	Response to temozolomide;
LGG	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg10167378	chr1:228756711	NA	0.56	8.02	0.35	8.82e-15	Chronic lymphocytic leukemia;
LGG	cis	rs7122539	0.610	rs10791892	chr11:66549740	C/G	cg01599099	chr11:66649832	PC	0.48	9.73	0.41	1.69e-20	HIV-1 susceptibility;
LGG	trans	rs1728785	1.000	rs7192341	chr16:68569224	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	11.04	0.46	2.53e-25	Ulcerative colitis;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6831352	0.918	rs13133633	chr4:100058697	C/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg23205692	chr1:25664452	TMEM50A	-0.45	-9.34	-0.4	4.07e-19	Erythrocyte sedimentation rate;
LGG	cis	rs6732160	0.932	rs6546803	chr2:73381315	C/G	cg01422370	chr2:73384389	NA	0.53	10.16	0.43	5.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg04568710	chr12:38710424	ALG10B	0.41	8.78	0.38	3.13e-17	Morning vs. evening chronotype;
LGG	cis	rs2011503	1.000	rs2011503	chr19:19443986	C/T	cg11584989	chr19:19387371	SF4	0.76	12.69	0.51	7.09e-32	Bipolar disorder;
LGG	cis	rs6942756	0.806	rs6967464	chr7:128909727	T/C	cg02491457	chr7:128862824	NA	0.65	12.2	0.49	7.29e-30	White matter hyperintensity burden;
LGG	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs4936891	0.599	rs10893128	chr11:123890745	C/T	cg22125253	chr11:123886957	OR10G4	-0.52	-9.1	-0.39	2.73e-18	Male fertility;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03452623	chr4:187889614	NA	-1.04	-29.44	-0.81	3.74e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-21.71	-0.71	1.3e-72	Vitiligo;
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg10505658	chr17:80084571	CCDC57	0.34	6.68	0.3	6.84e-11	Life satisfaction;
LGG	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg05082376	chr22:42548792	NA	-0.36	-7.62	-0.33	1.46e-13	Schizophrenia;
LGG	cis	rs7432375	0.966	rs7618871	chr3:136400420	G/T	cg12473912	chr3:136751656	NA	-0.4	-6.85	-0.3	2.36e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg13880726	chr7:1868755	MAD1L1	-0.39	-6.88	-0.3	1.96e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1497828	0.956	rs2810780	chr1:217543521	T/C	cg04411442	chr1:217543379	NA	0.48	8.05	0.35	7.2e-15	Dialysis-related mortality;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.82	-0.48	2.43e-28	Obesity-related traits;
LGG	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg13736514	chr6:26305472	NA	-0.48	-9.19	-0.39	1.28e-18	Educational attainment;
LGG	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.16	-31.68	-0.83	5.17e-118	Myeloid white cell count;
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.86	-0.34	2.66e-14	Bipolar disorder;
LGG	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg19338460	chr6:170058176	WDR27	-0.61	-8.27	-0.36	1.4e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13314892	0.764	rs62251009	chr3:69849835	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.72	-0.34	7.48e-14	QRS complex (12-leadsum);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03440066	chr20:44420729	WFDC3;DNTTIP1	0.45	6.67	0.3	7.22e-11	Hip circumference;
LGG	cis	rs4906332	1.000	rs7155980	chr14:103922419	C/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.99	-0.35	1.1e-14	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07791516	chr6:150247246	NA	0.32	6.74	0.3	4.87e-11	Lung cancer;
LGG	cis	rs12618769	0.597	rs11884553	chr2:99131206	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20105082	chr7:75921097	NA	0.48	7.45	0.33	4.77e-13	Gut microbiome composition (summer);
LGG	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	cis	rs7973719	0.865	rs12820829	chr12:7347534	G/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.67	-0.34	9.92e-14	IgG glycosylation;
LGG	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg13256891	chr4:100009986	ADH5	0.54	9.62	0.41	4.15e-20	Alcohol dependence;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg19524238	chr7:2802976	GNA12	-0.39	-9.02	-0.39	4.86e-18	Height;
LGG	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.32	-0.32	1.09e-12	Interstitial lung disease;
LGG	cis	rs11074306	0.561	rs7163017	chr15:28072157	T/C	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg08888203	chr3:10149979	C3orf24	0.57	8.08	0.35	5.61e-15	Alzheimer's disease;
LGG	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg00666640	chr1:248458726	OR2T12	0.55	8.86	0.38	1.77e-17	Common traits (Other);
LGG	cis	rs1847202	0.859	rs13090900	chr3:72946560	C/A	cg25664220	chr3:72788482	NA	-0.26	-7.59	-0.33	1.73e-13	Motion sickness;
LGG	cis	rs7267979	0.933	rs2424708	chr20:25281398	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.11	0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13732083	chr21:47605072	C21orf56	-0.48	-7.74	-0.34	6.42e-14	Testicular germ cell tumor;
LGG	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg06618935	chr21:46677482	NA	-0.45	-8.68	-0.37	6.71e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.55	9.63	0.41	4.02e-20	Longevity;
LGG	cis	rs62025270	0.688	rs62022940	chr15:86252520	T/C	cg25843651	chr15:86329602	KLHL25	0.58	8.9	0.38	1.24e-17	Idiopathic pulmonary fibrosis;
LGG	trans	rs11039798	0.614	rs2174703	chr11:48788242	G/A	cg15704280	chr7:45808275	SEPT13	0.75	8.5	0.37	2.62e-16	Axial length;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.01	0.46	3.27e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg21862992	chr11:68658383	NA	0.5	8.55	0.37	1.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23221052	chr5:179740743	GFPT2	-0.62	-11.33	-0.47	1.95e-26	Height;
LGG	cis	rs12912251	1.000	rs12903120	chr15:38988097	G/T	cg01338139	chr15:38987640	C15orf53	-0.55	-8.69	-0.37	6.31e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.43	0.44	5.04e-23	Thyroid stimulating hormone;
LGG	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg24189917	chr7:1970923	MAD1L1	-0.52	-7.57	-0.33	1.97e-13	Bipolar disorder;
LGG	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.69	0.3	6.4e-11	Dupuytren's disease;
LGG	cis	rs7241530	0.560	rs35810817	chr18:75891249	G/A	cg14642773	chr18:75888474	NA	0.47	9.02	0.39	5.03e-18	Educational attainment (years of education);
LGG	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg26597838	chr10:835615	NA	0.54	6.92	0.31	1.56e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.96	0.45	5.4e-25	Diabetic retinopathy;
LGG	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.7	-11.79	-0.48	3.01e-28	Mean platelet volume;
LGG	cis	rs12681287	0.547	rs11992656	chr8:87534869	T/A	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg06917634	chr15:78832804	PSMA4	0.69	12.82	0.51	2.05e-32	Sudden cardiac arrest;
LGG	cis	rs7106204	0.764	rs58215218	chr11:24234720	G/T	ch.11.24196551F	chr11:24239977	NA	0.9	10.3	0.43	1.49e-22	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg05775895	chr3:12838266	CAND2	0.79	15.92	0.59	7.96e-46	QRS complex (12-leadsum);
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs920590	0.796	rs11778257	chr8:19634598	A/T	cg03894339	chr8:19674705	INTS10	0.55	8.95	0.38	8.32e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg04568710	chr12:38710424	ALG10B	-0.36	-7.88	-0.34	2.43e-14	Morning vs. evening chronotype;
LGG	cis	rs67311347	0.506	rs55962832	chr3:40244451	T/C	cg13683864	chr3:40499215	RPL14	-0.79	-14.99	-0.57	1.06e-41	Renal cell carcinoma;
LGG	cis	rs1577917	0.958	rs11755642	chr6:86450066	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.51	-0.44	2.56e-23	Response to antipsychotic treatment;
LGG	cis	rs6696846	0.936	rs1042831	chr1:205043250	G/C	cg00857998	chr1:205179979	DSTYK	0.54	8.75	0.38	4.13e-17	Red blood cell count;
LGG	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg07636037	chr3:49044803	WDR6	1.11	28.55	0.8	3.72e-104	Parkinson's disease;
LGG	trans	rs561341	1.000	rs561341	chr17:30316385	T/G	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7924176	0.601	rs12414280	chr10:75934400	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.93	-0.31	1.41e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs1568889	0.838	rs11030206	chr11:28099747	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	19.44	0.67	5.77e-62	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.48	-0.44	3.27e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.69	-0.41	2.35e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22496380	chr5:211416	CCDC127	-1.12	-10.5	-0.44	2.75e-23	Breast cancer;
LGG	cis	rs9467160	0.817	rs12194966	chr6:24437611	G/A	cg20631270	chr6:24437470	GPLD1	0.52	7.23	0.32	1.96e-12	Liver enzyme levels;
LGG	cis	rs2522056	0.935	rs1981524	chr5:131756506	C/T	cg07395648	chr5:131743802	NA	0.41	6.99	0.31	9.36e-12	Lymphocyte counts;Fibrinogen;
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.43e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.02	-0.35	8.87e-15	Bipolar disorder;
LGG	cis	rs10504130	0.569	rs12679983	chr8:52678156	T/A	cg22653915	chr8:52722023	PXDNL	-0.43	-6.83	-0.3	2.73e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg17467752	chr17:38218738	THRA	-0.43	-7.03	-0.31	7.29e-12	Self-reported allergy;
LGG	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg01169559	chr10:831247	NA	0.54	9.32	0.4	4.83e-19	Uric acid levels;
LGG	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.5	-0.44	2.93e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00149659	chr3:10157352	C3orf10	0.87	11.12	0.46	1.29e-25	Alzheimer's disease;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.19	0.52	5.7e-34	Lung cancer;
LGG	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg11812906	chr14:75593930	NEK9	-0.47	-8.65	-0.37	8.61e-17	Height;
LGG	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg08999081	chr20:33150536	PIGU	0.31	7.35	0.32	9.13e-13	Coronary artery disease;
LGG	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-12.17	-0.49	9.6e-30	Cognitive function;
LGG	cis	rs58616815	0.857	rs72824614	chr10:92157034	A/T	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg06917634	chr15:78832804	PSMA4	-0.66	-9.92	-0.42	3.68e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7965445	0.614	rs4907419	chr12:131972442	C/A	cg16675054	chr5:171616574	STK10	0.35	6.69	0.3	6.41e-11	Mortality in heart failure;
LGG	cis	rs1784581	0.651	rs1784590	chr6:162389462	C/A	cg17173639	chr6:162384350	PARK2	-0.76	-17.1	-0.62	3.64e-51	Itch intensity from mosquito bite;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.16e-21	Prudent dietary pattern;
LGG	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.49	-0.4	1.2e-19	Retinal vascular caliber;
LGG	trans	rs1997103	0.954	rs6593236	chr7:55410992	C/T	cg20935933	chr6:143382018	AIG1	0.54	8.42	0.36	4.62e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2916247	0.862	rs7012347	chr8:93116149	T/C	cg10183463	chr8:93005414	RUNX1T1	0.4	8.23	0.36	1.87e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg22168489	chr12:122356033	WDR66	0.43	10.12	0.43	7.28e-22	Mean corpuscular volume;
LGG	cis	rs9911578	0.835	rs723991	chr17:56482039	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-13.67	-0.54	5.9e-36	Intelligence (multi-trait analysis);
LGG	cis	rs7222240	1.000	rs73984321	chr17:43163019	T/C	cg24806326	chr17:43207588	PLCD3	0.46	7.82	0.34	3.49e-14	Craniofacial microsomia;
LGG	cis	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg24232236	chr22:38142998	TRIOBP	-0.39	-7.4	-0.33	6.37e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg07636037	chr3:49044803	WDR6	1.06	25.31	0.76	2.39e-89	Parkinson's disease;
LGG	cis	rs67311347	1.000	rs1466237	chr3:40462026	C/G	cg13683864	chr3:40499215	RPL14	-0.97	-20.05	-0.68	8.16e-65	Renal cell carcinoma;
LGG	trans	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.92	-0.35	1.81e-14	Resting heart rate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07318088	chr6:90539243	CASP8AP2	0.48	8.09	0.35	5.4e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4740619	0.933	rs10756695	chr9:15712674	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.66	-0.41	3e-20	Body mass index;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.35	-0.36	8.03e-16	Skin colour saturation;
LGG	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg25809561	chr17:30822961	MYO1D	0.38	8.96	0.38	8.02e-18	Schizophrenia;
LGG	cis	rs3126085	0.935	rs6676012	chr1:152213203	G/A	cg26876637	chr1:152193138	HRNR	0.55	8.36	0.36	7.27e-16	Atopic dermatitis;
LGG	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg08885076	chr2:99613938	TSGA10	0.39	8.37	0.36	6.9e-16	Chronic sinus infection;
LGG	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg15556689	chr8:8085844	FLJ10661	0.41	7.17	0.32	2.95e-12	Mood instability;
LGG	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg16141378	chr3:129829833	LOC729375	0.44	10.5	0.44	2.86e-23	Mood instability;
LGG	cis	rs4891159	0.548	rs609487	chr18:74134382	C/G	cg24786174	chr18:74118243	ZNF516	-0.68	-17.23	-0.63	8.72e-52	Longevity;
LGG	cis	rs9487094	0.744	rs2275652	chr6:109703683	G/C	cg01125227	chr6:109776195	MICAL1	0.54	9.06	0.39	3.68e-18	Height;
LGG	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg26446133	chr18:72167187	CNDP2	-0.66	-12.93	-0.51	7.53e-33	Refractive error;
LGG	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg02023728	chr11:77925099	USP35	0.44	7.73	0.34	6.86e-14	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.16	-0.58	2.02e-42	Prudent dietary pattern;
LGG	cis	rs7586879	0.551	rs7565460	chr2:25130073	C/T	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs977987	0.843	rs12928036	chr16:75483132	G/A	cg03315344	chr16:75512273	CHST6	0.53	10.5	0.44	2.8e-23	Dupuytren's disease;
LGG	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg13802316	chr11:70253460	CTTN	-0.6	-7.55	-0.33	2.36e-13	Coronary artery disease;
LGG	cis	rs4262150	0.883	rs72802856	chr5:152218952	G/A	cg12297329	chr5:152029980	NA	-0.68	-12.61	-0.51	1.56e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs564799	0.966	rs6808498	chr3:159730679	T/A	cg04855961	chr3:159719849	NA	-0.28	-7.62	-0.33	1.44e-13	Systemic lupus erythematosus;
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg04166393	chr7:2884313	GNA12	0.45	8.51	0.37	2.38e-16	Height;
LGG	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg04287289	chr16:89883240	FANCA	-0.53	-9.72	-0.41	1.93e-20	Vitiligo;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.52e-16	Obesity-related traits;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06558623	chr16:89946397	TCF25	0.94	12.3	0.5	2.87e-30	Skin colour saturation;
LGG	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg15557168	chr22:42548783	NA	0.39	8.5	0.37	2.69e-16	Schizophrenia;
LGG	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg04287289	chr16:89883240	FANCA	-0.49	-8.73	-0.38	4.73e-17	Vitiligo;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg23978390	chr7:1156363	C7orf50	0.56	9.77	0.41	1.26e-20	Longevity;Endometriosis;
LGG	cis	rs2916247	0.909	rs720444	chr8:93098924	G/T	cg10183463	chr8:93005414	RUNX1T1	0.38	7.77	0.34	4.94e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7166081	1.000	rs12900758	chr15:67523043	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.98	-0.31	1.04e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg16606324	chr3:10149918	C3orf24	-0.56	-7.26	-0.32	1.65e-12	Alzheimer's disease;
LGG	cis	rs7695597	0.684	rs4862344	chr4:185178220	C/T	cg12654155	chr4:185238627	NA	-0.42	-7.5	-0.33	3.27e-13	Night sleep phenotypes;
LGG	cis	rs9341835	0.740	rs9294198	chr6:64136993	T/C	cg00787780	chr6:64151745	NA	0.4	7.35	0.32	9.28e-13	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18012350	chr15:74753669	UBL7	0.42	6.79	0.3	3.35e-11	Cognitive performance;
LGG	cis	rs711245	0.899	rs848605	chr2:36773260	G/A	cg01206211	chr2:36825736	FEZ2	0.41	7.76	0.34	5.48e-14	Height;
LGG	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg02023728	chr11:77925099	USP35	0.47	8.29	0.36	1.22e-15	Testicular germ cell tumor;
LGG	cis	rs870825	0.616	rs28463742	chr4:185611005	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	22.24	0.72	4.4e-75	Blood protein levels;
LGG	cis	rs763121	0.853	rs5750672	chr22:39104168	C/T	cg06022373	chr22:39101656	GTPBP1	-0.9	-17.84	-0.64	1.52e-54	Menopause (age at onset);
LGG	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg19761014	chr17:28927070	LRRC37B2	0.67	7.77	0.34	5.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2075371	0.830	rs1421478	chr7:133922793	T/A	cg11752832	chr7:134001865	SLC35B4	0.56	9.99	0.42	2e-21	Mean platelet volume;
LGG	cis	rs2274273	1.000	rs7493394	chr14:55617755	A/T	cg04306507	chr14:55594613	LGALS3	0.61	17.21	0.62	1.11e-51	Protein biomarker;
LGG	cis	rs2880765	0.835	rs4843063	chr15:86048748	G/T	cg17133734	chr15:86042851	AKAP13	-0.3	-7.1	-0.31	4.77e-12	Coronary artery disease;
LGG	cis	rs41005	0.805	rs10469618	chr2:8117622	C/T	cg03155496	chr2:8117019	LOC339788	-0.92	-21.74	-0.71	9.54e-73	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs12410462	0.551	rs2814084	chr1:227714296	C/A	cg23173402	chr1:227635558	NA	0.38	7.23	0.32	2.01e-12	Major depressive disorder;
LGG	trans	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg26043149	chr18:55253948	FECH	0.42	7.02	0.31	7.9e-12	Bone mineral density;
LGG	cis	rs2742417	0.967	rs2742426	chr3:45735901	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.41e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21666675	chr3:14165843	TMEM43;CHCHD4	0.42	7.14	0.31	3.63e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11711311	1.000	rs2305545	chr3:113499733	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.84	-0.34	3.1e-14	IgG glycosylation;
LGG	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg02002194	chr4:3960332	NA	0.44	8.05	0.35	7.17e-15	Monocyte count;
LGG	cis	rs11096990	0.634	rs1057807	chr4:39289473	A/G	cg24403649	chr4:39172243	NA	-0.37	-6.72	-0.3	5.25e-11	Cognitive function;
LGG	cis	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg07424592	chr7:64974309	NA	0.73	7.2	0.32	2.43e-12	Diabetic kidney disease;
LGG	cis	rs7267979	0.932	rs2387891	chr20:25470328	C/G	cg06421707	chr20:25228305	PYGB	0.46	9.79	0.41	1.07e-20	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2120243	1.000	rs2873258	chr3:157144986	C/A	cg24825693	chr3:157122686	VEPH1	-0.42	-8.63	-0.37	1.02e-16	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg21153622	chr11:89784906	NA	-0.68	-8.54	-0.37	2e-16	White blood cell types;
LGG	cis	rs988958	0.526	rs36109745	chr2:42252990	C/A	cg27428208	chr2:42229179	NA	0.48	7.63	0.33	1.34e-13	Hypospadias;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg22903657	chr4:1355424	KIAA1530	-0.35	-7.45	-0.33	4.53e-13	Obesity-related traits;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.99	-0.39	6.23e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2710247	1	rs2710247	chr2:219467508	A/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.07	-0.31	5.81e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs362296	0.661	rs3095078	chr4:3265479	C/T	cg06533319	chr4:3265114	C4orf44	0.53	11.03	0.46	2.91e-25	Parental longevity (mother's age at death);
LGG	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.84e-13	Testicular germ cell tumor;
LGG	cis	rs7619833	0.728	rs1352941	chr3:27368425	C/T	cg02860705	chr3:27208620	NA	-0.41	-8.03	-0.35	8.29e-15	Breast cancer;
LGG	cis	rs6993813	0.843	rs1586273	chr8:120022886	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.95e-11	Bone mineral density (hip);
LGG	cis	rs11264213	0.901	rs72661640	chr1:36447232	T/G	cg27506609	chr1:36549197	TEKT2	0.83	8.38	0.36	6.37e-16	Schizophrenia;
LGG	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	8.94	0.38	9.36e-18	Gout;Renal underexcretion gout;
LGG	cis	rs5753037	0.809	rs2057882	chr22:30217827	A/T	cg27665648	chr22:30112403	NA	0.28	6.65	0.3	8.31e-11	Type 1 diabetes;
LGG	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg00071950	chr4:10020882	SLC2A9	0.4	8.08	0.35	5.79e-15	Bone mineral density;
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	7.47	0.33	4.11e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs807669	0.835	rs1780639	chr22:19174603	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	16.0	0.6	3.57e-46	Metabolite levels;
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.06	-0.31	6.16e-12	Bipolar disorder;
LGG	cis	rs870825	0.616	rs7659101	chr4:185632158	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.77	0.73	1.52e-77	Blood protein levels;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26111184	chr2:27255694	TMEM214	-0.5	-7.26	-0.32	1.7e-12	Gut microbiome composition (summer);
LGG	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs3849046	0.846	rs462783	chr5:137872116	C/T	cg10920316	chr5:137946599	NA	-0.46	-7.41	-0.33	6.05e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg11812906	chr14:75593930	NEK9	-0.51	-9.14	-0.39	1.98e-18	Height;
LGG	cis	rs67311347	0.544	rs2278930	chr3:40351092	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-15.57	-0.59	2.96e-44	Renal cell carcinoma;
LGG	trans	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg05926928	chr17:57297772	GDPD1	0.87	10.84	0.45	1.46e-24	Opioid sensitivity;
LGG	cis	rs975739	0.872	rs1279662	chr13:78369349	T/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.68	0.3	6.92e-11	Hair color;
LGG	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg00599393	chr8:22457479	C8orf58	0.45	8.18	0.36	2.72e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg26384229	chr12:38710491	ALG10B	0.81	17.09	0.62	4e-51	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14036868	chr2:38604442	ATL2	-0.49	-7.19	-0.32	2.64e-12	Systemic lupus erythematosus;
LGG	cis	rs4843185	0.576	rs381624	chr16:85728679	G/A	cg08861369	chr16:85671714	KIAA0182	0.44	6.68	0.3	6.97e-11	Platelet distribution width;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs7192750	0.586	rs8062946	chr16:71930807	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4148087	1.000	rs4148091	chr21:43635126	C/T	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2.04e-13	HDL cholesterol;
LGG	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg04607235	chr12:12878440	APOLD1	0.63	8.94	0.38	9.47e-18	Systemic lupus erythematosus;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg21775007	chr8:11205619	TDH	0.42	6.68	0.3	6.91e-11	Myopia (pathological);
LGG	cis	rs4356932	0.967	rs4859586	chr4:76943235	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs2153535	0.541	rs945304	chr6:8442892	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.1	0.42	8.14e-22	Motion sickness;
LGG	cis	rs16854884	0.584	rs34372603	chr3:143738249	T/C	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs7103648	0.864	rs10769264	chr11:47423340	C/T	cg20307385	chr11:47447363	PSMC3	0.97	23.92	0.74	6.66e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs11088226	0.645	rs2833904	chr21:33941089	T/C	cg09050820	chr6:167586206	TCP10L2	0.91	12.96	0.52	5.56e-33	Gastritis;
LGG	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg00198680	chr16:28758506	NA	0.28	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg19628046	chr18:33552617	C18orf21	-0.54	-7.86	-0.34	2.73e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08219700	chr8:58056026	NA	0.45	7.09	0.31	5.19e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4819852	0.958	rs9606204	chr22:19976510	C/A	cg07821417	chr22:19972146	ARVCF	0.62	13.05	0.52	2.3e-33	Pulse pressure;
LGG	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg00495681	chr13:53174319	NA	0.81	17.02	0.62	8.59e-51	Lewy body disease;
LGG	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg04000281	chr11:63949212	NA	-0.42	-8.07	-0.35	6e-15	Platelet count;
LGG	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11890956	chr21:40555474	PSMG1	1.18	28.61	0.8	1.98e-104	Cognitive function;
LGG	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg25358565	chr5:93447407	FAM172A	-0.84	-11.73	-0.48	5.18e-28	Diabetic retinopathy;
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.46e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6076065	0.683	rs1419010	chr20:23365254	G/C	cg12633918	chr20:23549525	CST9L	-0.35	-6.65	-0.3	8.19e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs858239	0.570	rs6968242	chr7:23167411	T/G	cg23682824	chr7:23144976	KLHL7	0.42	7.08	0.31	5.24e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11748327	0.554	rs10038800	chr5:4011171	A/G	cg01025095	chr5:4101132	NA	-0.43	-7.02	-0.31	7.91e-12	Myocardial infarction;
LGG	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg02711726	chr17:80685570	FN3KRP	-0.65	-13.25	-0.52	3.47e-34	Glycated hemoglobin levels;
LGG	trans	rs9467711	1.000	rs6939799	chr6:26328366	G/A	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.18	-0.32	2.78e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs834603	0.547	rs834598	chr7:47463937	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.81	0.34	3.79e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19717773	chr7:2847554	GNA12	-0.31	-6.84	-0.3	2.58e-11	Height;
LGG	cis	rs7084402	0.967	rs3001714	chr10:60285494	A/G	cg09696939	chr10:60272079	BICC1	-0.36	-6.84	-0.3	2.52e-11	Refractive error;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-8.18	-0.36	2.8e-15	Lung cancer;
LGG	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7241530	0.636	rs8085845	chr18:75896982	C/T	cg14642773	chr18:75888474	NA	0.47	9.05	0.39	4.06e-18	Educational attainment (years of education);
LGG	cis	rs7937890	0.559	rs2575837	chr11:14498001	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.68	0.3	6.89e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9640161	0.659	rs7781827	chr7:150008858	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.73	-15.0	-0.57	1.02e-41	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.7	0.51	6.55e-32	Prudent dietary pattern;
LGG	cis	rs4356932	1.000	rs6820370	chr4:76952278	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.74	-0.3	4.68e-11	Blood protein levels;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.36	-0.32	8.28e-13	Bipolar disorder;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.25	-0.36	1.72e-15	Triglycerides;
LGG	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg25019033	chr10:957182	NA	-0.57	-8.83	-0.38	2.24e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg09904177	chr6:26538194	HMGN4	-0.64	-12.78	-0.51	2.92e-32	Intelligence (multi-trait analysis);
LGG	trans	rs877282	0.945	rs17293517	chr10:778770	C/T	cg22713356	chr15:30763199	NA	0.57	8.6	0.37	1.23e-16	Uric acid levels;
LGG	cis	rs11239187	0.927	rs12241419	chr10:45111529	A/G	cg03916630	chr10:45065415	NA	0.34	7.58	0.33	1.95e-13	Body mass index;
LGG	trans	rs4714291	0.963	rs1743969	chr6:40096918	A/G	cg02267698	chr19:7991119	CTXN1	0.6	9.51	0.4	1.05e-19	Strep throat;
LGG	cis	rs6547631	0.622	rs1437744	chr2:85925084	G/A	cg19805943	chr2:85933069	NA	0.32	6.73	0.3	5.17e-11	Blood protein levels;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	5.07e-34	Prudent dietary pattern;
LGG	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06850241	chr22:41845214	NA	0.45	7.22	0.32	2.15e-12	Vitiligo;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10802521	chr3:52805072	NEK4	0.41	6.98	0.31	1e-11	Bipolar disorder;
LGG	cis	rs10979	1.000	rs9376760	chr6:143886969	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.52	-0.5	3.49e-31	Hypospadias;
LGG	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg03342759	chr3:160939853	NMD3	-0.54	-9.14	-0.39	1.94e-18	Kawasaki disease;
LGG	cis	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.27	0.72	3.2700000000000002e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg23978390	chr7:1156363	C7orf50	0.44	7.21	0.32	2.36e-12	Longevity;Endometriosis;
LGG	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.85	-0.48	1.74e-28	Alzheimer's disease;
LGG	cis	rs2404602	0.598	rs11855999	chr15:76627333	A/C	cg15268244	chr15:77196840	NA	0.45	9.0	0.39	6.07e-18	Blood metabolite levels;
LGG	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.36e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg15145296	chr3:125709740	NA	-0.62	-8.07	-0.35	6.03e-15	Blood pressure (smoking interaction);
LGG	cis	rs4417704	0.551	rs7594525	chr2:241893722	G/C	cg26818257	chr2:241905806	NA	0.5	10.98	0.45	4.52e-25	Joint mobility (Beighton score);
LGG	cis	rs9790314	0.605	rs13089559	chr3:160641688	T/A	cg03342759	chr3:160939853	NMD3	0.44	7.33	0.32	1.06e-12	Morning vs. evening chronotype;
LGG	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg11342453	chr6:26196699	NA	0.49	6.84	0.3	2.58e-11	Gout;Renal underexcretion gout;
LGG	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11987759	chr7:65425863	GUSB	0.4	7.82	0.34	3.68e-14	Aortic root size;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs13102973	0.931	rs13103718	chr4:135843990	C/T	cg14419869	chr4:135874104	NA	0.57	10.71	0.45	4.47e-24	Subjective well-being;
LGG	cis	rs9487051	1.000	rs1341271	chr6:109617542	A/T	cg21918786	chr6:109611834	NA	-0.42	-7.74	-0.34	6.35e-14	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.08	0.42	1.02e-21	Height;
LGG	cis	rs67311347	0.605	rs1880762	chr3:40283215	A/G	cg13683864	chr3:40499215	RPL14	-0.73	-13.62	-0.53	8.85e-36	Renal cell carcinoma;
LGG	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.61	-0.44	1.08e-23	Hemoglobin concentration;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs42648	0.869	rs42609	chr7:89949855	A/T	cg25739043	chr7:89950458	NA	-0.44	-9.4	-0.4	2.45e-19	Homocysteine levels;
LGG	cis	rs11203032	0.901	rs4074851	chr10:90958618	A/G	cg16672925	chr10:90967113	CH25H	-0.82	-11.81	-0.48	2.52e-28	Heart failure;
LGG	cis	rs17023223	0.537	rs12087987	chr1:119734821	C/A	cg05756136	chr1:119680316	WARS2	-0.41	-8.38	-0.36	6.55e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs55871839	0.684	rs7002967	chr8:59816806	T/A	cg07426533	chr8:59803705	TOX	-0.57	-12.9	-0.51	9.53e-33	Pneumonia;
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg26752003	chr8:145688521	CYHR1	-0.51	-11.25	-0.46	3.9e-26	Age at first birth;
LGG	cis	rs365132	1.000	rs402511	chr5:176434440	G/A	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13968953	chr3:97483466	ARL6	-0.39	-6.67	-0.3	7.46e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg15145174	chr5:6755386	POLS	-0.39	-7.4	-0.33	6.65e-13	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs4740619	0.846	rs7031365	chr9:15643077	T/G	cg14451791	chr9:16040625	NA	0.35	8.96	0.38	8.24e-18	Body mass index;
LGG	trans	rs9467711	1.000	rs9467707	chr6:26327905	G/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.18	-0.32	2.78e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7246760	0.541	rs67646978	chr19:9976530	A/T	cg02900749	chr2:68251473	NA	-0.73	-8.16	-0.35	3.17e-15	Pursuit maintenance gain;
LGG	cis	rs2235649	0.828	rs9936486	chr16:1849888	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.16e-11	Blood metabolite levels;
LGG	trans	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg13010199	chr12:38710504	ALG10B	0.67	12.9	0.51	9.33e-33	Morning vs. evening chronotype;
LGG	cis	rs8048589	0.604	rs12929519	chr16:12207439	A/G	cg02910054	chr16:12241554	SNX29	-0.52	-7.96	-0.35	1.35e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs2274273	0.935	rs3818451	chr14:55621116	C/G	cg04306507	chr14:55594613	LGALS3	0.6	16.44	0.61	3.68e-48	Protein biomarker;
LGG	cis	rs2354432	0.607	rs894471	chr1:146687913	A/G	cg25205988	chr1:146714368	CHD1L	-0.98	-8.32	-0.36	1e-15	Mitochondrial DNA levels;
LGG	cis	rs757978	1.000	rs7601738	chr2:242375813	A/T	cg03294028	chr2:242255774	SEPT2;HDLBP	0.78	8.61	0.37	1.15e-16	Chronic lymphocytic leukemia;
LGG	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg04719120	chr6:96025338	MANEA	0.53	7.93	0.35	1.67e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg13207630	chr7:32358064	NA	0.8	7.93	0.35	1.71e-14	Body mass index;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.8	-0.3	3.25e-11	Longevity;Endometriosis;
LGG	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.15	0.32	3.44e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.06	0.31	6.08e-12	Prudent dietary pattern;
LGG	cis	rs11971779	0.680	rs11980313	chr7:139034643	C/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg01262667	chr19:19385393	TM6SF2	0.35	6.9	0.31	1.71e-11	Bipolar disorder;
LGG	cis	rs3126085	1.000	rs3120662	chr1:152302865	G/T	cg26876637	chr1:152193138	HRNR	-0.52	-7.97	-0.35	1.21e-14	Atopic dermatitis;
LGG	cis	rs17641971	0.662	rs2385229	chr8:50003869	T/C	cg00325661	chr8:49890786	NA	0.55	10.48	0.44	3.22e-23	Blood metabolite levels;
LGG	cis	rs807669	0.525	rs9605955	chr22:19181557	C/T	cg02655711	chr22:19163373	SLC25A1	0.52	9.33	0.4	4.28e-19	Metabolite levels;
LGG	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.85	-0.48	1.77e-28	Height;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00689492	chr4:1303491	MAEA	0.51	8.64	0.37	9.5e-17	Obesity-related traits;
LGG	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg03806693	chr22:41940476	POLR3H	-0.84	-14.42	-0.56	3.26e-39	Vitiligo;
LGG	trans	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg11887960	chr12:57824829	NA	0.57	6.7	0.3	6.17e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs17685	0.753	rs2868203	chr7:75680026	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.87	-0.77	6.17e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.52	-0.33	2.91e-13	Testicular germ cell tumor;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	9.0	0.39	5.92e-18	Cognitive test performance;
LGG	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-8.86	-0.38	1.78e-17	Menarche (age at onset);
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs10274279	1.000	rs73163815	chr7:157388047	A/G	cg09270525	chr7:157391030	PTPRN2	0.74	9.53	0.4	9.22e-20	Myopia (pathological);
LGG	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	cg07928641	chr1:182991847	LAMC1	-0.47	-9.37	-0.4	3.2e-19	Hypertriglyceridemia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg11122301	chr12:122255844	SETD1B	0.39	6.69	0.3	6.56e-11	Menarche (age at onset);
LGG	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-16.78	-0.62	9.88e-50	Vitiligo;
LGG	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.79e-13	Coronary artery disease;
LGG	trans	rs1459104	0.925	rs35473011	chr11:54881353	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.74	0.34	6.5e-14	Body mass index;
LGG	cis	rs7226408	0.857	rs3967207	chr18:34474742	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg12826209	chr6:26865740	GUSBL1	0.82	6.93	0.31	1.42e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg15309053	chr8:964076	NA	0.41	8.9	0.38	1.25e-17	Schizophrenia;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.04	-0.35	7.36e-15	Menopause (age at onset);
LGG	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.91	0.42	4.05e-21	Colorectal cancer;
LGG	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.05	-0.35	6.94e-15	IgG glycosylation;
LGG	cis	rs981844	1.000	rs2251994	chr4:154654097	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.56	0.47	2.58e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg04455712	chr21:45112962	RRP1B	0.54	9.95	0.42	2.84e-21	Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.85	0.38	1.92e-17	Platelet count;
LGG	cis	rs11098499	0.913	rs10010696	chr4:120164303	T/C	cg09307838	chr4:120376055	NA	0.71	11.84	0.48	1.97e-28	Corneal astigmatism;
LGG	cis	rs1927790	0.648	rs2389631	chr13:96932868	A/C	cg02571835	chr13:96230311	CLDN10	-0.36	-7.43	-0.33	5.13e-13	Body mass index;
LGG	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.53	0.33	2.61e-13	Obesity-related traits;
LGG	cis	rs1015291	0.708	rs10743340	chr12:19994777	G/A	cg25401612	chr12:20009446	NA	0.35	7.59	0.33	1.78e-13	Diastolic blood pressure;
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00142150	chr22:38071001	LGALS1	0.92	19.65	0.67	6.04e-63	Fat distribution (HIV);
LGG	cis	rs7202877	0.656	rs4888394	chr16:75413709	T/C	cg03315344	chr16:75512273	CHST6	0.53	7.2	0.32	2.5e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.7e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.6	-0.47	1.75e-27	Schizophrenia;
LGG	cis	rs6604026	0.922	rs11164825	chr1:93311707	C/T	cg22128645	chr1:93425802	FAM69A	-0.4	-7.44	-0.33	5.07e-13	Multiple sclerosis;
LGG	trans	rs2562456	0.958	rs2562508	chr19:21726281	G/A	cg25042112	chr7:64838748	ZNF92	0.46	6.67	0.3	7.35e-11	Pain;
LGG	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg11845111	chr2:191398756	TMEM194B	0.35	7.93	0.35	1.71e-14	Pulse pressure;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.68e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.28	0.36	1.38e-15	Retinal vascular caliber;
LGG	cis	rs5756391	0.568	rs4821570	chr22:37317177	C/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.53	0.4	8.85e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg01943577	chr7:158741284	NA	-0.47	-8.41	-0.36	5.13e-16	Height;
LGG	cis	rs4711336	0.809	rs749338	chr6:33653448	A/G	cg14003231	chr6:33640908	ITPR3	-0.29	-6.87	-0.3	2.09e-11	Height;
LGG	cis	rs12431410	0.550	rs9323355	chr14:60186360	T/C	cg07950296	chr14:60194823	RTN1	-0.39	-7.45	-0.33	4.64e-13	Schizophrenia;
LGG	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg20587970	chr11:113659929	NA	1.06	15.99	0.6	3.68e-46	Hip circumference adjusted for BMI;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs7077256	0.564	rs17740989	chr10:65188403	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs727505	0.954	rs2054586	chr7:124708414	C/T	cg23710748	chr7:124431027	NA	-0.49	-8.86	-0.38	1.72e-17	Lewy body disease;
LGG	cis	rs9398803	0.865	rs2184968	chr6:126760994	A/G	cg19875578	chr6:126661172	C6orf173	0.54	9.77	0.41	1.29e-20	Male-pattern baldness;
LGG	cis	rs7666738	0.761	rs1456210	chr4:98645932	T/G	cg05340658	chr4:99064831	C4orf37	0.46	7.49	0.33	3.63e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg22907277	chr7:1156413	C7orf50	0.7	8.78	0.38	3.12e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs26868	0.712	rs26832	chr16:2238337	A/G	cg25665528	chr16:2260870	C16orf79	-0.37	-8.07	-0.35	5.89e-15	Height;
LGG	cis	rs9902453	0.902	rs4075014	chr17:28305674	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.4	0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg22349387	chr12:9600060	DDX12	-0.28	-6.93	-0.31	1.41e-11	Breast size;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg07690219	chr3:49449608	TCTA;RHOA	-0.46	-6.72	-0.3	5.42e-11	Beard thickness;
LGG	cis	rs3736594	0.546	rs7571558	chr2:27839832	C/G	cg27432699	chr2:27873401	GPN1	0.57	8.71	0.38	5.62e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.64	-0.41	3.66e-20	Extrinsic epigenetic age acceleration;
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-10.06	-0.42	1.19e-21	Retinal vascular caliber;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.11	-0.43	7.67e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg25785477	chr4:130014987	SCLT1;C4orf33	0.47	7.08	0.31	5.24e-12	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg06598544	chr20:61472147	COL9A3	-0.9	-10.22	-0.43	3.04e-22	Obesity-related traits;
LGG	cis	rs7010267	0.568	rs2220189	chr8:120007708	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.36	9.21	0.39	1.14e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg05335186	chr13:53173507	NA	-0.41	-8.38	-0.36	6.31e-16	Lewy body disease;
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.0	0.57	1.02e-41	Alzheimer's disease;
LGG	cis	rs59197085	0.636	rs2307037	chr7:128449405	G/A	cg00734629	chr7:128471146	FLNC	0.35	7.11	0.31	4.56e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg06212747	chr3:49208901	KLHDC8B	0.45	6.8	0.3	3.17e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.25	-0.32	1.7e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10463554	0.963	rs257115	chr5:102531808	C/T	cg23492399	chr5:102201601	PAM	-0.5	-7.55	-0.33	2.31e-13	Parkinson's disease;
LGG	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.46	-0.37	3.45e-16	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02750587	chr1:85156370	SSX2IP	0.44	7.08	0.31	5.21e-12	Cognitive performance;
LGG	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg09264619	chr17:80180166	NA	-0.51	-10.04	-0.42	1.37e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9393777	0.623	rs9358944	chr6:26469875	A/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.73	-0.3	5.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg08621203	chr6:150244597	RAET1G	0.46	8.1	0.35	4.8e-15	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15698851	chr8:29940391	TMEM66	0.44	6.99	0.31	9.43e-12	Cognitive performance;
LGG	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg27432699	chr2:27873401	GPN1	-0.5	-8.69	-0.37	6.33e-17	Total body bone mineral density;
LGG	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg27490568	chr2:178487706	NA	0.52	10.2	0.43	3.45e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	10.24	0.43	2.46e-22	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04018622	chr12:3602291	PRMT8	0.43	7.14	0.31	3.62e-12	Cognitive performance;
LGG	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.03	-0.31	7.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg26338869	chr17:61819248	STRADA	-0.59	-9.95	-0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs9358372	0.574	rs9366360	chr6:20817988	A/G	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.59	-0.41	5.52e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs896854	0.516	rs12679044	chr8:95891356	C/A	cg16049864	chr8:95962084	TP53INP1	-0.31	-6.74	-0.3	4.61e-11	Type 2 diabetes;
LGG	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg26116260	chr4:7069785	GRPEL1	-0.85	-8.69	-0.37	6.41e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7914558	0.966	rs10786721	chr10:104654383	C/A	cg04362960	chr10:104952993	NT5C2	0.52	9.87	0.42	5.71e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9644630	0.930	rs7005075	chr8:19367452	G/C	cg01280390	chr8:19363452	CSGALNACT1	-0.62	-17.98	-0.64	3.33e-55	Oropharynx cancer;
LGG	cis	rs3820068	0.705	rs4646103	chr1:15819827	T/A	cg05660106	chr1:15850417	CASP9	1.09	24.99	0.76	7.02e-88	Systolic blood pressure;
LGG	trans	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.22	0.46	5.26e-26	Corneal astigmatism;
LGG	cis	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.69	-0.41	2.43e-20	Fuchs's corneal dystrophy;
LGG	cis	rs9325144	0.600	rs1817648	chr12:38733424	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-14.64	-0.56	3.77e-40	Morning vs. evening chronotype;
LGG	cis	rs72781680	0.898	rs6712175	chr2:24023431	T/G	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.71	-0.3	5.56e-11	Blood metabolite levels;
LGG	cis	rs61612642	0.537	rs6915565	chr6:42192582	G/A	cg01092361	chr6:42185687	MRPS10	0.87	11.63	0.48	1.31e-27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg11494091	chr17:61959527	GH2	0.6	9.95	0.42	2.98e-21	Height;
LGG	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	Neuroticism;
LGG	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg22705602	chr4:152727874	NA	-0.33	-7.52	-0.33	2.78e-13	Intelligence (multi-trait analysis);
LGG	cis	rs41271951	0.512	rs79122717	chr1:151093526	G/A	cg11822372	chr1:151115635	SEMA6C	-0.68	-7.09	-0.31	5.19e-12	Blood protein levels;
LGG	cis	rs6540556	0.608	rs4844891	chr1:209914409	A/C	cg23920097	chr1:209922102	NA	-0.43	-7.89	-0.34	2.22e-14	Red blood cell count;
LGG	cis	rs9487094	0.961	rs1358998	chr6:109701218	C/T	cg01125227	chr6:109776195	MICAL1	-0.52	-8.87	-0.38	1.57e-17	Height;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09659208	chr10:323366	DIP2C	0.38	6.78	0.3	3.73e-11	Electrocardiographic conduction measures;
LGG	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg00206168	chr11:65308501	LTBP3	0.58	6.86	0.3	2.2e-11	Height;
LGG	cis	rs17023223	0.537	rs4590715	chr1:119750201	C/T	cg05756136	chr1:119680316	WARS2	-0.43	-8.52	-0.37	2.29e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs4417704	0.551	rs10173220	chr2:241896909	G/A	cg05025159	chr2:241905733	NA	0.49	9.97	0.42	2.35e-21	Joint mobility (Beighton score);
LGG	cis	rs7794364	0.658	rs35895632	chr7:117506470	C/G	cg21880328	chr7:117514017	CTTNBP2	-0.35	-7.31	-0.32	1.18e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs62005083	0.500	rs10135300	chr14:74574561	G/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.49	6.91	0.31	1.58e-11	Mean corpuscular volume;
LGG	cis	rs11229555	1.000	rs3168135	chr11:58386177	G/A	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs61931739	0.534	rs1586410	chr12:33999142	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.94e-46	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.52	-0.37	2.2e-16	Lung cancer;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg00830817	chr11:109293614	C11orf87	0.42	6.86	0.3	2.18e-11	Schizophrenia;
LGG	cis	rs1003719	0.788	rs4411798	chr21:38453183	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.81	16.48	0.61	2.43e-48	Eye color traits;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.48e-23	Prudent dietary pattern;
LGG	cis	rs9879311	0.966	rs775018	chr3:10400145	A/G	cg21387009	chr3:10280255	IRAK2	-0.37	-6.99	-0.31	9.79e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg11062466	chr8:58055876	NA	-0.48	-7.84	-0.34	3.06e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17453880	0.929	rs4473762	chr5:152065361	T/C	cg12297329	chr5:152029980	NA	-0.86	-21.44	-0.71	2.5e-71	Subjective well-being;
LGG	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg09359103	chr1:154839909	KCNN3	-0.38	-7.36	-0.32	8.18e-13	Prostate cancer;
LGG	cis	rs876084	0.505	rs7815878	chr8:121103137	C/T	cg06265175	chr8:121136014	COL14A1	0.47	9.63	0.41	4.01e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs74781061	0.789	rs2289188	chr15:74742468	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs2041895	0.509	rs2024518	chr12:107296902	G/A	cg15890332	chr12:107067104	RFX4	0.29	6.65	0.3	8.06e-11	Glaucoma (low intraocular pressure);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg12960782	chr5:59996455	DEPDC1B	0.4	6.99	0.31	9.86e-12	Body mass index;
LGG	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs6840360	0.533	rs13147021	chr4:152722688	A/C	cg22705602	chr4:152727874	NA	0.37	9.12	0.39	2.39e-18	Intelligence (multi-trait analysis);
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-9.18	-0.39	1.46e-18	Bipolar disorder;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.94	-0.38	9.4e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03431137	chr16:50059103	TMEM188	0.43	6.76	0.3	4.17e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7741085	1.000	rs7741085	chr6:44636919	C/T	cg18551225	chr6:44695536	NA	0.44	7.43	0.33	5.13e-13	Total body bone mineral density;
LGG	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.25e-12	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.72e-43	Prudent dietary pattern;
LGG	cis	rs10895140	0.574	rs4475890	chr11:101519273	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.87	-0.3	2.06e-11	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs12832312	chr12:34031199	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.92	0.59	7.65e-46	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg12463550	chr7:65579703	CRCP	0.74	8.06	0.35	6.67e-15	Diabetic kidney disease;
LGG	cis	rs6558174	0.965	rs7831119	chr8:22489678	C/T	cg03733263	chr8:22462867	KIAA1967	-0.64	-10.84	-0.45	1.54e-24	Breast cancer;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg14926445	chr8:58193284	C8orf71	-0.9	-13.35	-0.53	1.24e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2463822	1.000	rs2463825	chr11:62094493	G/A	cg06239285	chr11:62104954	ASRGL1	1.16	16.32	0.6	1.28e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs972578	1.000	rs5759067	chr22:43372799	T/C	cg01576275	chr22:43409880	NA	-0.22	-6.66	-0.3	7.94e-11	Mean platelet volume;
LGG	cis	rs10048158	0.617	rs1558359	chr17:64208396	G/A	cg19474267	chr17:64306194	PRKCA	-0.59	-11.27	-0.46	3.48e-26	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.07	0.39	3.44e-18	Alzheimer's disease;
LGG	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.8	-12.95	-0.52	5.92e-33	Chronic sinus infection;
LGG	cis	rs9303401	0.704	rs740605	chr17:56604811	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	7.19	0.32	2.57e-12	Cognitive test performance;
LGG	cis	rs17767392	1.000	rs61991248	chr14:71860529	C/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.07	0.39	3.33e-18	Mitral valve prolapse;
LGG	trans	rs6011368	0.840	rs2427638	chr20:62900717	C/T	cg13869341	chr1:15865	WASH5P	0.59	10.53	0.44	2.2e-23	Clozapine-induced cytotoxicity;
LGG	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.96	-0.31	1.19e-11	Myopia;Myopia (pathological);
LGG	cis	rs6743226	0.515	rs56061376	chr2:242243435	T/C	cg10021735	chr2:242295487	FARP2	0.4	7.01	0.31	8.61e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs1983891	0.742	rs9369295	chr6:41564026	G/C	cg20194872	chr6:41519635	FOXP4	0.49	8.58	0.37	1.45e-16	Prostate cancer;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg12070911	chr6:150209640	RAET1E	0.32	7.64	0.33	1.25e-13	Lung cancer;
LGG	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.08	-0.46	1.89e-25	Mean platelet volume;
LGG	cis	rs74781061	0.932	rs61168092	chr15:74809960	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.25	-0.32	1.79e-12	Endometriosis;
LGG	trans	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg13565492	chr6:43139072	SRF	-0.77	-9.09	-0.39	2.88e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs36093844	0.698	rs55951560	chr11:85548342	T/C	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.75	0.38	4.13e-17	Schizophrenia;
LGG	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg09165964	chr15:75287851	SCAMP5	0.77	9.04	0.39	4.37e-18	Lung cancer;
LGG	cis	rs12928939	0.727	rs8053623	chr16:71647529	A/G	cg03805757	chr16:71968109	PKD1L3	-0.46	-8.67	-0.37	7.38e-17	Post bronchodilator FEV1;
LGG	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg20283391	chr11:68216788	NA	0.49	8.13	0.35	4.01e-15	Total body bone mineral density;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.45	8.24	0.36	1.84e-15	Longevity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27417846	chr2:88927289	EIF2AK3	0.49	8.05	0.35	6.85e-15	Cognitive performance;
LGG	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-6.8	-0.3	3.18e-11	Type 2 diabetes;
LGG	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs9912468	0.621	rs7342920	chr17:64244645	T/G	cg19474267	chr17:64306194	PRKCA	-0.78	-16.93	-0.62	2.17e-50	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg06212747	chr3:49208901	KLHDC8B	0.72	12.82	0.51	2.04e-32	Menarche (age at onset);
LGG	cis	rs6878727	0.850	rs1363308	chr5:123707222	A/G	cg01806427	chr5:123737813	NA	0.32	6.95	0.31	1.28e-11	Breast cancer;
LGG	cis	rs590121	0.876	rs652054	chr11:75275532	C/A	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.61	-0.37	1.15e-16	Coronary artery disease;
LGG	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	cis	rs6942756	0.806	rs1880854	chr7:128949748	G/T	cg02491457	chr7:128862824	NA	0.62	11.67	0.48	9.05e-28	White matter hyperintensity burden;
LGG	cis	rs7226408	0.901	rs1013833	chr18:34462214	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4742903	0.935	rs1507513	chr9:106973857	A/G	cg14250997	chr9:106856677	SMC2	0.39	7.97	0.35	1.23e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg14541582	chr5:601475	NA	-0.7	-10.84	-0.45	1.53e-24	Obesity-related traits;
LGG	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-14.8	-0.57	7.63e-41	Pancreatic cancer;
LGG	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg10792982	chr14:105748885	BRF1	0.55	10.82	0.45	1.78e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg23601095	chr6:26197514	HIST1H3D	0.72	9.21	0.39	1.11e-18	Gout;Renal underexcretion gout;
LGG	cis	rs3849046	0.817	rs154069	chr5:137876920	G/A	cg10920316	chr5:137946599	NA	0.45	7.38	0.32	7.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4731207	0.596	rs10269342	chr7:124693845	C/G	cg05630886	chr7:124431682	NA	0.32	7.44	0.33	5e-13	Cutaneous malignant melanoma;
LGG	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg18478394	chr8:109455254	TTC35	0.44	8.81	0.38	2.54e-17	Dupuytren's disease;
LGG	trans	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg18335740	chr13:41363409	SLC25A15	-0.57	-10.93	-0.45	6.63e-25	Lewy body disease;
LGG	cis	rs228437	0.874	rs7743660	chr6:134943460	A/G	cg24504307	chr6:134963096	NA	0.38	7.37	0.32	7.95e-13	Melanoma;
LGG	cis	rs12200560	0.505	rs211171	chr6:97070579	T/G	cg06623918	chr6:96969491	KIAA0776	0.46	7.78	0.34	4.8e-14	Coronary heart disease;
LGG	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg04568710	chr12:38710424	ALG10B	0.34	6.81	0.3	2.96e-11	Heart rate;
LGG	cis	rs7011049	1.000	rs72640868	chr8:53843812	C/A	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg19773385	chr1:10388646	KIF1B	-0.48	-10.27	-0.43	1.92e-22	Hepatocellular carcinoma;
LGG	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.64	-0.41	3.55e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13088645	0.532	rs9835166	chr3:134166224	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.48	8.04	0.35	7.75e-15	Coronary artery disease;
LGG	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg01620082	chr3:125678407	NA	-1.04	-9.8	-0.41	9.71e-21	Depression;
LGG	cis	rs77372450	0.636	rs6879084	chr5:157029188	C/T	cg25387487	chr5:157003181	ADAM19	-0.55	-7.02	-0.31	8.01e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.89	0.31	1.79e-11	Total cholesterol levels;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg22535103	chr8:58192502	C8orf71	-0.95	-15.42	-0.58	1.36e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs35740288	0.770	rs11632750	chr15:86215614	A/C	cg07943548	chr15:86304357	KLHL25	-0.33	-6.66	-0.3	7.62e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.73	-0.34	6.54e-14	Diabetic retinopathy;
LGG	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg06885757	chr1:42089581	HIVEP3	0.59	13.99	0.54	2.53e-37	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6800768	0.556	rs73134512	chr3:24089762	G/C	cg10674438	chr3:24145617	LOC152024	-0.47	-8.34	-0.36	8.58e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg25214090	chr10:38739885	LOC399744	0.57	10.42	0.44	5.63e-23	Corneal astigmatism;
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.46	0.4	1.6e-19	Height;
LGG	cis	rs8013055	0.898	rs8014913	chr14:105977313	T/C	cg19700328	chr14:106028568	NA	-0.6	-10.14	-0.43	5.71e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg14004847	chr7:1930337	MAD1L1	-0.57	-9.81	-0.41	8.83e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.69	-0.3	6.64e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs4690686	0.509	rs13147303	chr4:177256126	G/A	cg17059388	chr4:177262070	NA	0.93	18.48	0.65	1.53e-57	Essential tremor;
LGG	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.13	-0.35	3.94e-15	Neuroticism;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25172604	chr17:41446521	NA	-0.3	-6.76	-0.3	4.05e-11	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg14784868	chr12:69753453	YEATS4	0.44	6.8	0.3	3.29e-11	Response to diuretic therapy;
LGG	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg21775007	chr8:11205619	TDH	0.42	6.99	0.31	9.71e-12	Mood instability;
LGG	cis	rs11771526	0.901	rs17161084	chr7:32293192	G/C	cg27532318	chr7:32358331	NA	0.72	7.42	0.33	5.82e-13	Body mass index;
LGG	cis	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg06609049	chr19:2785107	THOP1	0.65	10.0	0.42	1.89e-21	Total cholesterol levels;
LGG	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.14e-20	Diabetic retinopathy;
LGG	cis	rs9443645	0.527	rs10943595	chr6:79575291	C/G	cg18132916	chr6:79620363	NA	-0.27	-7.14	-0.31	3.63e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14159747	chr11:113255604	NA	0.31	8.48	0.37	2.96e-16	Neuroticism;
LGG	cis	rs2613964	0.504	rs17317945	chr3:112850781	A/G	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	5.83e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs73086581	0.786	rs6037705	chr20:3952830	G/C	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	trans	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-9.48	-0.4	1.32e-19	Neuroticism;
LGG	cis	rs13102973	0.965	rs28799927	chr4:135867094	A/G	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg22839075	chr3:12045461	SYN2	0.4	7.14	0.32	3.54e-12	Leprosy;
LGG	cis	rs12791968	0.527	rs4755924	chr11:45013328	A/G	cg11846598	chr11:44996168	LOC221122	-0.5	-6.97	-0.31	1.1e-11	Inhibitory control;
LGG	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.44	8.7	0.37	5.91e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs9463078	0.809	rs6933553	chr6:45027770	T/C	cg25276700	chr6:44698697	NA	-0.39	-8.17	-0.35	3.07e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg12373951	chr3:133503437	NA	0.4	7.07	0.31	5.91e-12	Iron status biomarkers;
LGG	cis	rs9389248	0.500	rs116273677	chr6:135339135	A/C	cg24558204	chr6:135376177	HBS1L	0.53	9.67	0.41	2.79e-20	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-12.43	-0.5	8.35e-31	Vitiligo;
LGG	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg15212455	chr7:39170539	POU6F2	0.3	6.74	0.3	4.63e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6764363	0.527	rs4684328	chr3:275101	T/C	cg02057681	chr3:285234	CHL1	-0.44	-7.72	-0.34	7.04e-14	Sudden cardiac arrest;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13003239	chr3:49044627	WDR6	-0.49	-7.59	-0.33	1.75e-13	Gut microbiome composition (summer);
LGG	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg16395133	chr6:150326394	RAET1K	0.27	6.67	0.3	7.48e-11	Alopecia areata;
LGG	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg24375607	chr4:120327624	NA	0.41	6.93	0.31	1.42e-11	Diastolic blood pressure;
LGG	cis	rs8141529	0.551	rs34578331	chr22:29347215	G/T	cg15103426	chr22:29168792	CCDC117	0.58	6.71	0.3	5.83e-11	Lymphocyte counts;
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg14092988	chr3:52407081	DNAH1	0.32	8.43	0.36	4.52e-16	Bipolar disorder;
LGG	trans	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.95	-0.31	1.27e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	trans	rs330048	0.545	rs7002693	chr8:9148830	G/C	cg16141378	chr3:129829833	LOC729375	-0.32	-6.73	-0.3	5e-11	Systemic lupus erythematosus;
LGG	cis	rs7927771	0.524	rs6485773	chr11:47763509	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.09	0.46	1.73e-25	Subjective well-being;
LGG	cis	rs4808199	0.948	rs2301668	chr19:19452249	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.63	0.59	1.62e-44	Nonalcoholic fatty liver disease;
LGG	cis	rs10950821	0.843	rs73684578	chr7:20665782	T/A	cg21202529	chr7:20656503	ABCB5	-0.37	-6.74	-0.3	4.87e-11	Response to statin therapy;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05617973	chr19:49468917	FTL	-0.39	-6.69	-0.3	6.52e-11	Pancreatic cancer;
LGG	cis	rs834603	0.575	rs1704968	chr7:47468231	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2285947	1.000	rs2285949	chr7:21584243	G/A	cg23045935	chr7:21583304	DNAH11	0.43	9.33	0.4	4.36e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg05868516	chr6:26286170	HIST1H4H	0.47	8.04	0.35	7.83e-15	Educational attainment;
LGG	cis	rs17125944	0.542	rs75723366	chr14:53256882	T/C	cg00686598	chr14:53173677	PSMC6	1.38	14.89	0.57	3.12e-41	Alzheimer's disease (late onset);
LGG	trans	rs6787172	0.702	rs827114	chr3:157979174	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg05091796	chr16:4465799	CORO7	-0.73	-11.76	-0.48	4.19e-28	Schizophrenia;
LGG	cis	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg05084668	chr3:125655381	ALG1L	0.56	7.25	0.32	1.75e-12	Blood pressure (smoking interaction);
LGG	cis	rs67311347	0.866	rs11712426	chr3:40330322	G/A	cg13683864	chr3:40499215	RPL14	-0.88	-17.56	-0.63	2.82e-53	Renal cell carcinoma;
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg02002194	chr4:3960332	NA	0.48	9.09	0.39	2.82e-18	Neuroticism;
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.68	-0.34	9.44e-14	Skin colour saturation;
LGG	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg11764359	chr7:65958608	NA	0.74	13.06	0.52	2.18e-33	Aortic root size;
LGG	cis	rs151997	0.671	rs27281	chr5:50200764	C/T	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs300774	0.858	rs300712	chr2:138903	A/T	cg04617936	chr2:214353	NA	-0.5	-7.71	-0.34	8e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs9596863	0.851	rs9568894	chr13:54309601	C/T	ch.13.53330881F	chr13:54432880	NA	0.52	6.95	0.31	1.26e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg20744362	chr22:50050164	C22orf34	0.42	7.39	0.32	6.76e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg08888203	chr3:10149979	C3orf24	0.54	8.97	0.38	7.64e-18	Alzheimer's disease;
LGG	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	trans	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.03	0.42	1.43e-21	Metabolite levels;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg03188948	chr7:1209495	NA	0.62	8.28	0.36	1.34e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg12386194	chr3:101231763	SENP7	0.69	11.98	0.49	5.17e-29	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg13010199	chr12:38710504	ALG10B	0.59	11.74	0.48	4.76e-28	Morning vs. evening chronotype;
LGG	cis	rs782590	0.721	rs782641	chr2:55929294	C/T	cg18811423	chr2:55921094	PNPT1	0.94	22.25	0.72	3.83e-75	Metabolic syndrome;
LGG	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.76	0.3	4.17e-11	Triglycerides;
LGG	cis	rs1371867	0.846	rs1660329	chr8:101304048	G/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs9815354	0.638	rs73069277	chr3:41967521	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.43	0.4	2e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9473924	0.542	rs2245173	chr6:50810540	T/C	cg14470998	chr6:50812995	TFAP2B	0.69	8.18	0.36	2.7e-15	Body mass index;
LGG	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs6993813	0.872	rs9650075	chr8:120017079	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.87	0.3	2.14e-11	Bone mineral density (hip);
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.64	10.98	0.45	4.19e-25	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.25	0.32	1.78e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9796	0.866	rs544744	chr15:41366290	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.06	-0.39	3.68e-18	Menopause (age at onset);
LGG	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.505	rs7103713	chr11:67338242	G/A	cg00290607	chr11:67383545	NA	-0.51	-8.86	-0.38	1.77e-17	Mean corpuscular volume;
LGG	cis	rs9814567	1.000	rs7371896	chr3:134249769	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.51	-0.53	2.75e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg01620082	chr3:125678407	NA	-0.66	-7.41	-0.33	5.97e-13	Depression;
LGG	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.65	-11.07	-0.46	2.05e-25	Chronic sinus infection;
LGG	cis	rs6066825	0.644	rs6019386	chr20:47326440	T/G	cg18078177	chr20:47281410	PREX1	0.47	8.0	0.35	9.77e-15	Colorectal cancer;
LGG	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.21e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs4919087	0.683	rs1687371	chr10:98978183	T/A	cg25902810	chr10:99078978	FRAT1	-0.45	-7.8	-0.34	4.17e-14	Monocyte count;
LGG	cis	rs988958	0.675	rs12712816	chr2:42224048	G/C	cg27428208	chr2:42229179	NA	0.54	9.32	0.4	4.71e-19	Hypospadias;
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg12395012	chr8:11607386	GATA4	0.37	6.96	0.31	1.15e-11	Neuroticism;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg07414643	chr4:187882934	NA	0.55	11.25	0.46	3.87e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg02811702	chr13:24901961	NA	0.41	7.84	0.34	3.12e-14	Obesity-related traits;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg10605767	chr8:28621703	NA	-0.42	-6.88	-0.3	1.91e-11	Apolipoprotein A-IV levels;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-12.58	-0.5	2.04e-31	Prudent dietary pattern;
LGG	trans	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg18335740	chr13:41363409	SLC25A15	0.56	10.4	0.44	6.56e-23	Lewy body disease;
LGG	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.47	-0.44	3.57e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs4740619	0.870	rs7020760	chr9:15544049	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.07	-0.42	1.09e-21	Body mass index;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19524238	chr7:2802976	GNA12	0.34	8.28	0.36	1.3e-15	Height;
LGG	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs4740619	0.846	rs10122339	chr9:15691712	G/T	cg14451791	chr9:16040625	NA	0.34	8.61	0.37	1.18e-16	Body mass index;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00166722	chr3:10149974	C3orf24	0.51	8.67	0.37	7.25e-17	Alzheimer's disease;
LGG	cis	rs75804782	0.641	rs11904390	chr2:239344663	T/A	cg18131467	chr2:239335373	ASB1	-0.66	-6.69	-0.3	6.43e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.46	-0.33	4.44e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg27144592	chr16:783916	NARFL	-0.76	-13.51	-0.53	2.76e-35	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24095088	chr6:160210874	MRPL18;TCP1	0.48	7.74	0.34	6.35e-14	Cognitive performance;
LGG	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg01221209	chr5:554886	NA	-0.48	-7.64	-0.33	1.24e-13	Obesity-related traits;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00864171	chr11:67383662	NA	-0.52	-8.32	-0.36	9.95e-16	Mean corpuscular volume;
LGG	cis	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg13293535	chr8:11597251	GATA4	0.33	8.01	0.35	9.36e-15	Neuroticism;
LGG	cis	rs1927790	0.759	rs7320735	chr13:96976507	G/C	cg02571835	chr13:96230311	CLDN10	-0.34	-6.95	-0.31	1.27e-11	Body mass index;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs225245	0.782	rs321617	chr17:33915246	A/G	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21851142	chr6:132129008	ENPP1	0.42	7.15	0.32	3.5e-12	Gut microbiome composition (summer);
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg27432699	chr2:27873401	GPN1	-0.52	-8.92	-0.38	1.06e-17	Total body bone mineral density;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg21017887	chr14:105400489	NA	0.44	8.87	0.38	1.61e-17	Rheumatoid arthritis;
LGG	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg09408571	chr1:101003634	GPR88	0.28	7.01	0.31	8.56e-12	Breast cancer;
LGG	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg06637938	chr14:75390232	RPS6KL1	0.57	10.57	0.44	1.6e-23	Height;
LGG	cis	rs2964802	0.505	rs7728436	chr5:10814464	T/A	cg14521931	chr5:10832172	NA	-0.74	-16.2	-0.6	4.6e-47	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs12681287	0.640	rs7830480	chr8:87403137	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs6732160	0.631	rs7557285	chr2:73442812	G/A	cg01422370	chr2:73384389	NA	0.47	8.97	0.38	7.19e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg20283391	chr11:68216788	NA	-0.49	-8.13	-0.35	4.01e-15	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.3	-0.32	1.29e-12	Lung cancer;
LGG	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs4704846	1.000	rs4704854	chr5:156543114	T/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.72	-0.34	7.31e-14	Blood protein levels;
LGG	cis	rs757278	0.591	rs17140297	chr7:117300259	C/G	cg10524701	chr7:117356490	CTTNBP2	0.4	7.16	0.32	3.19e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg14092988	chr3:52407081	DNAH1	0.27	7.12	0.31	4.17e-12	Bipolar disorder;
LGG	cis	rs7590368	0.673	rs17456162	chr2:10948090	C/T	cg15705551	chr2:10952987	PDIA6	-0.58	-7.5	-0.33	3.35e-13	Educational attainment (years of education);
LGG	cis	rs10421328	0.821	rs10423311	chr19:19757262	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.33	7.09	0.31	4.97e-12	Parental longevity (combined parental age at death);
LGG	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg11584989	chr19:19387371	SF4	0.8	12.62	0.51	1.34e-31	Bipolar disorder;
LGG	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs5769707	0.521	rs74351010	chr22:50036820	G/A	cg06623630	chr22:50017776	C22orf34	0.42	6.85	0.3	2.41e-11	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6912958	1.000	rs2207144	chr6:88150816	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.68	-0.44	5.93e-24	Monocyte percentage of white cells;
LGG	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	-0.4	-6.94	-0.31	1.31e-11	Multiple sclerosis;
LGG	cis	rs72829446	0.530	rs9646411	chr17:7398909	A/G	cg17364949	chr17:7383474	AMAC1L3;ZBTB4	0.43	6.69	0.3	6.28e-11	Androgen levels;
LGG	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.24	0.43	2.65e-22	Diabetic retinopathy;
LGG	cis	rs1707322	0.686	rs3014236	chr1:46091305	T/C	cg03146154	chr1:46216737	IPP	-0.57	-11.1	-0.46	1.47e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg26384229	chr12:38710491	ALG10B	-0.86	-19.7	-0.68	3.49e-63	Bladder cancer;
LGG	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg17467752	chr17:38218738	THRA	-0.43	-6.96	-0.31	1.18e-11	Self-reported allergy;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.04e-13	Tonsillectomy;
LGG	cis	rs7020830	0.867	rs7852593	chr9:37332380	A/T	cg14294708	chr9:37120828	ZCCHC7	1.15	32.68	0.84	2.45e-122	Schizophrenia;
LGG	cis	rs9768139	0.634	rs11762383	chr7:158113889	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.3	-0.32	1.28e-12	Calcium levels;
LGG	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg05280133	chr15:45670068	GATM;LOC145663	-0.41	-7.13	-0.31	3.98e-12	Homoarginine levels;
LGG	trans	rs656319	0.652	rs7816333	chr8:9808809	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.56	-0.33	2.21e-13	Myopia (pathological);
LGG	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.84	-0.34	3.14e-14	Eosinophil percentage of white cells;
LGG	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs57590327	0.555	rs13084107	chr3:81833577	T/C	cg07356753	chr3:81810745	GBE1	-0.5	-8.02	-0.35	8.45e-15	Extraversion;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.63	-12.83	-0.51	1.92e-32	Prudent dietary pattern;
LGG	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg18240062	chr17:79603768	NPLOC4	-0.83	-15.73	-0.59	5.67e-45	Eye color traits;
LGG	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg00701064	chr4:6280414	WFS1	0.73	16.01	0.6	3.09e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs911263	0.603	rs12880842	chr14:68764254	A/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.23	0.36	1.91e-15	Primary biliary cholangitis;
LGG	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg02772935	chr3:125709198	NA	-0.54	-6.88	-0.3	1.95e-11	Blood pressure (smoking interaction);
LGG	cis	rs959260	0.623	rs7207618	chr17:73321687	T/C	cg14668889	chr17:73230827	NUP85	-0.52	-8.75	-0.38	3.99e-17	Systemic lupus erythematosus;
LGG	cis	rs8017423	0.967	rs8016385	chr14:90721946	G/A	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs7737355	0.947	rs9885286	chr5:130883270	C/T	cg06307176	chr5:131281290	NA	0.56	9.28	0.4	6.42e-19	Life satisfaction;
LGG	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg19761014	chr17:28927070	LRRC37B2	0.55	6.95	0.31	1.23e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg07120314	chr15:79043507	NA	-0.77	-19.23	-0.67	5.09e-61	Coronary artery disease or large artery stroke;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg04293180	chr8:144700367	TSTA3	0.88	6.75	0.3	4.52e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg06026331	chr20:60912101	LAMA5	-0.48	-9.14	-0.39	1.91e-18	Colorectal cancer;
LGG	cis	rs6439153	0.524	rs7642885	chr3:128747369	G/C	cg24176926	chr3:128744824	CCDC48	0.36	7.85	0.34	2.82e-14	Pneumococcal bacteremia;
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg01943577	chr7:158741284	NA	-0.45	-7.91	-0.34	1.94e-14	Height;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs4417704	0.501	rs13015336	chr2:241900706	T/C	cg14055004	chr2:241860995	NA	0.28	7.23	0.32	1.98e-12	Joint mobility (Beighton score);
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.07	0.31	5.83e-12	Tonsillectomy;
LGG	cis	rs9397585	0.588	rs6932473	chr6:153438573	A/T	cg12989544	chr6:153429875	RGS17	0.31	7.06	0.31	6.06e-12	Body mass index;
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.57	-0.53	1.49e-35	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg26656751	chr17:43910226	CRHR1	0.48	8.74	0.38	4.26e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.14	0.49	1.21e-29	Skin colour saturation;
LGG	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.93	-0.38	1e-17	Schizophrenia;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.65	-0.37	8.34e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg17712092	chr4:129076599	LARP1B	0.55	9.11	0.39	2.46e-18	Breast cancer;
LGG	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg19507638	chr5:93509721	C5orf36	0.72	9.96	0.42	2.64e-21	Diabetic retinopathy;
LGG	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg01236616	chr12:121019343	POP5	1.29	23.47	0.74	7.75e-81	Type 1 diabetes nephropathy;
LGG	cis	rs7095944	0.614	rs7099316	chr10:126469005	G/A	cg08799069	chr10:126477246	METTL10	-0.5	-11.56	-0.47	2.59e-27	Asthma;
LGG	cis	rs6735179	0.550	rs13396286	chr2:1759021	A/G	cg10160682	chr2:1713001	PXDN	-0.54	-9.6	-0.41	5.23e-20	Response to antipsychotic treatment;
LGG	cis	rs7927771	1.000	rs11039412	chr11:47841581	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.69	-0.37	6.51e-17	Subjective well-being;
LGG	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg24565620	chr2:194026	NA	0.67	10.55	0.44	1.86e-23	Blood protein levels;
LGG	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg22878388	chr2:105853796	NA	-0.45	-8.34	-0.36	8.57e-16	Type 2 diabetes;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg03767565	chr16:69144869	HAS3	-0.39	-6.71	-0.3	5.68e-11	Apolipoprotein A-IV levels;
LGG	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.18	-0.7	3.95e-70	Gut microbiome composition (summer);
LGG	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6840360	0.593	rs10033405	chr4:152474489	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs308971	0.563	rs454615	chr3:12077010	A/G	cg22839075	chr3:12045461	SYN2	0.51	6.67	0.3	7.24e-11	Fasting blood insulin (BMI interaction);
LGG	trans	rs6601327	0.635	rs10112972	chr8:9655218	T/A	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.51e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9814567	1.000	rs6804770	chr3:134230234	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.35e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg00599393	chr8:22457479	C8orf58	-0.43	-7.97	-0.35	1.23e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg12310025	chr6:25882481	NA	-0.4	-7.33	-0.32	1.02e-12	Height;
LGG	cis	rs4664308	1.000	rs2175416	chr2:160904021	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.99	-0.64	3.06e-55	Idiopathic membranous nephropathy;
LGG	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.43	0.44	5.13e-23	Cognitive test performance;
LGG	cis	rs6426558	0.514	rs3754418	chr1:227348473	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.64	-10.59	-0.44	1.25e-23	Neutrophil percentage of white cells;
LGG	cis	rs28719689	0.655	rs58892423	chr8:1276014	A/C	cg22761795	chr8:1265118	NA	0.76	8.29	0.36	1.24e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4704187	0.595	rs7717337	chr5:74377001	T/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.62	-0.37	1.06e-16	Triglycerides;
LGG	cis	rs77633900	0.614	rs2629021	chr15:76974083	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-10.22	-0.43	2.95e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2797160	1.000	rs6904069	chr6:125995134	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-7.21	-0.32	2.22e-12	Endometrial cancer;
LGG	cis	rs34638952	0.577	rs7217365	chr17:27434490	G/A	cg27392559	chr17:27410759	MYO18A	-0.38	-7.22	-0.32	2.16e-12	Sitting height ratio;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg13206674	chr6:150067644	NUP43	0.66	14.98	0.57	1.21e-41	Lung cancer;
LGG	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg11987759	chr7:65425863	GUSB	0.38	7.0	0.31	9.1e-12	Aortic root size;
LGG	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19524238	chr7:2802976	GNA12	0.29	7.01	0.31	8.41e-12	Height;
LGG	cis	rs1348850	0.567	rs3770009	chr2:178536544	C/T	cg27490568	chr2:178487706	NA	0.52	10.25	0.43	2.41e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2408955	0.542	rs7975632	chr12:48443048	C/T	cg24011408	chr12:48396354	COL2A1	0.58	9.32	0.4	4.84e-19	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs4660214	0.590	rs11205885	chr1:39772305	C/T	cg18385671	chr1:39797026	MACF1	-0.47	-9.65	-0.41	3.29e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-21.72	-0.71	1.24e-72	Vitiligo;
LGG	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg23815491	chr16:72088622	HP	0.5	8.9	0.38	1.27e-17	Blood protein levels;
LGG	cis	rs7927592	0.913	rs11228276	chr11:68307525	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.94	-0.31	1.37e-11	Triglycerides;
LGG	cis	rs6754311	0.638	rs1011361	chr2:136553639	G/A	cg07169764	chr2:136633963	MCM6	-0.79	-13.85	-0.54	9.6e-37	Mosquito bite size;
LGG	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg15627072	chr1:2432621	PLCH2	-0.38	-8.32	-0.36	1.02e-15	Ulcerative colitis;
LGG	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4517514	0.509	rs12224461	chr11:89871111	C/T	cg14505434	chr11:89522851	NA	0.64	7.82	0.34	3.69e-14	Trans fatty acid levels;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.13	-0.31	3.92e-12	Prostate cancer;
LGG	cis	rs9612	0.664	rs164069	chr19:44260199	T/C	cg08581076	chr19:44259116	C19orf61	0.45	7.73	0.34	6.6e-14	Exhaled nitric oxide output;
LGG	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-13.58	-0.53	1.36e-35	Coronary artery disease;
LGG	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.54	-7.84	-0.34	3.05e-14	Subjective well-being;
LGG	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg25817165	chr18:72167213	CNDP2	-0.67	-15.05	-0.57	6.13e-42	Refractive error;
LGG	cis	rs7301016	0.515	rs10877904	chr12:63047678	C/T	cg11441379	chr12:63026424	NA	0.48	7.11	0.31	4.29e-12	IgG glycosylation;
LGG	cis	rs7503807	0.651	rs901065	chr17:78599655	G/T	cg06872548	chr17:78716983	RPTOR	0.38	8.34	0.36	8.41e-16	Obesity;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg16606324	chr3:10149918	C3orf24	0.59	7.3	0.32	1.25e-12	Alzheimer's disease;
LGG	cis	rs11690935	0.550	rs62183769	chr2:172838074	A/C	cg13550731	chr2:172543902	DYNC1I2	0.63	12.18	0.49	8.16e-30	Schizophrenia;
LGG	cis	rs6163	0.508	rs12776506	chr10:104532828	A/G	cg04362960	chr10:104952993	NT5C2	0.39	6.67	0.3	7.45e-11	Waist circumference;Hip circumference;
LGG	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg25358565	chr5:93447407	FAM172A	1.32	16.43	0.61	4.17e-48	Diabetic retinopathy;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.21	0.39	1.11e-18	Obesity-related traits;
LGG	cis	rs2268241	0.938	rs7283827	chr21:34769904	A/G	cg14850771	chr21:34775459	IFNGR2	0.82	10.08	0.42	9.89e-22	Obesity-related traits;
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg00405596	chr8:11794950	NA	-0.41	-6.7	-0.3	6.18e-11	Neuroticism;
LGG	cis	rs7412746	0.587	rs3849279	chr1:150944707	T/C	cg15448220	chr1:150897856	SETDB1	0.37	6.91	0.31	1.61e-11	Melanoma;
LGG	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg27087555	chr16:88793112	FAM38A	-1.51	-19.25	-0.67	4.42e-61	Plateletcrit;
LGG	cis	rs11627756	0.957	rs7144340	chr14:103128777	G/T	cg12046867	chr14:103022105	NA	0.43	8.05	0.35	6.83e-15	Mean platelet volume;
LGG	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg04398451	chr17:18023971	MYO15A	0.66	13.87	0.54	8.26e-37	Total body bone mineral density;
LGG	cis	rs12220238	1.000	rs10824096	chr10:75937554	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.5e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs3816183	0.721	rs6544600	chr2:43033345	T/C	cg14631114	chr2:43023945	NA	0.47	8.71	0.38	5.33e-17	Hypospadias;
LGG	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2562456	0.833	rs11666447	chr19:21599072	G/A	cg00806126	chr19:22604979	ZNF98	-0.58	-7.68	-0.34	9.62e-14	Pain;
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg21911579	chr5:131705225	SLC22A5	0.7	7.71	0.34	7.67e-14	Rheumatoid arthritis;
LGG	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg21665744	chr7:39171113	POU6F2	0.34	6.7	0.3	6.23e-11	IgG glycosylation;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.38	-0.32	7.39e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2832191	0.791	rs57721945	chr21:30498744	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	2.04e-82	Dental caries;
LGG	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg24253500	chr15:84953950	NA	0.57	10.3	0.43	1.53e-22	Schizophrenia;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-12.62	-0.51	1.38e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs526231	0.543	rs60633061	chr5:102330049	C/T	cg23492399	chr5:102201601	PAM	-0.59	-9.13	-0.39	2.09e-18	Primary biliary cholangitis;
LGG	cis	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg00806126	chr19:22604979	ZNF98	0.65	9.64	0.41	3.61e-20	Pain;
LGG	cis	rs3770081	1.000	rs74607112	chr2:86305534	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-1.0	-8.69	-0.37	6.31e-17	Facial emotion recognition (sad faces);
LGG	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.31	0.4	5.1e-19	Sudden cardiac arrest;
LGG	cis	rs9473924	0.505	rs6908879	chr6:50869856	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.9	-0.38	1.27e-17	Lung cancer;
LGG	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg19901956	chr11:77921274	USP35	-0.41	-6.74	-0.3	4.73e-11	Testicular germ cell tumor;
LGG	cis	rs7301016	0.793	rs11174557	chr12:62979216	C/T	cg11441379	chr12:63026424	NA	0.62	8.81	0.38	2.6e-17	IgG glycosylation;
LGG	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg05484508	chr16:89589025	SPG7	0.42	6.87	0.3	2.07e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg13271783	chr10:134563150	INPP5A	-0.58	-8.53	-0.37	2.18e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg21926883	chr2:100939477	LONRF2	0.59	12.42	0.5	9.45e-31	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg27490568	chr2:178487706	NA	0.72	13.11	0.52	1.3e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs35110281	0.666	rs2838348	chr21:45107285	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.89	-0.42	4.62e-21	Mean corpuscular volume;
LGG	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25373794	chr1:162760220	HSD17B7	-0.41	-6.96	-0.31	1.18e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-16.05	-0.6	2.15e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs733592	0.599	rs12819124	chr12:48409054	G/T	cg24011408	chr12:48396354	COL2A1	0.47	7.95	0.35	1.42e-14	Plateletcrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02472543	chr2:217277071	SMARCAL1	0.48	7.1	0.31	4.75e-12	Gut microbiome composition (summer);
LGG	cis	rs11405769	1	rs11405769	chr2:63658293	A/AT	cg17519650	chr2:63277830	OTX1	-0.49	-7.42	-0.33	5.51e-13	Childhood ear infection;
LGG	cis	rs6977660	0.619	rs10263780	chr7:19778086	A/G	cg07541023	chr7:19748670	TWISTNB	-0.53	-8.32	-0.36	1e-15	Thyroid stimulating hormone;
LGG	trans	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19894588	chr14:64061835	NA	-0.53	-8.91	-0.38	1.15e-17	Glioblastoma;Glioma;
LGG	trans	rs12517041	1.000	rs6891825	chr5:23299740	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs847649	0.732	rs56269620	chr7:102489456	A/G	cg18108683	chr7:102477205	FBXL13	-0.67	-14.96	-0.57	1.45e-41	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.01	-0.31	8.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg14664628	chr15:75095509	CSK	0.59	9.5	0.4	1.16e-19	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs524281	0.861	rs7943911	chr11:65943054	G/A	cg16950941	chr11:66035639	RAB1B	-0.45	-6.65	-0.3	8.3e-11	Electroencephalogram traits;
LGG	trans	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19894588	chr14:64061835	NA	0.63	10.47	0.44	3.75e-23	Glioblastoma;Glioma;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02357877	chr7:56032049	GBAS	0.39	6.83	0.3	2.75e-11	Bilirubin levels;
LGG	cis	rs271738	0.674	rs271766	chr1:234674802	A/C	cg05133706	chr1:234667230	NA	-0.3	-6.73	-0.3	5.05e-11	Bipolar disorder;
LGG	cis	rs11169552	0.510	rs4768858	chr12:51039818	C/T	cg12884762	chr12:50931848	DIP2B	-0.39	-7.41	-0.33	6.04e-13	Colorectal cancer;
LGG	cis	rs10875746	0.551	rs3751273	chr12:48739438	T/C	cg24011408	chr12:48396354	COL2A1	-0.55	-7.1	-0.31	4.77e-12	Longevity (90 years and older);
LGG	cis	rs4148087	0.858	rs28435557	chr21:43634623	A/G	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-9.92	-0.42	3.7e-21	Obesity-related traits;
LGG	cis	rs2455601	0.882	rs11042118	chr11:8928791	T/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.49	-0.47	4.7e-27	Schizophrenia;
LGG	cis	rs4888262	0.507	rs9888976	chr16:74580924	C/T	cg01733217	chr16:74700730	RFWD3	0.82	16.34	0.6	1.07e-47	Testicular germ cell tumor;
LGG	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.77	0.75	6.98e-87	Chronic sinus infection;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01364968	chr1:50834303	NA	-0.47	-7.94	-0.35	1.51e-14	Pancreatic cancer;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7000551	0.606	rs11780055	chr8:22268929	T/A	cg12081754	chr8:22256438	SLC39A14	1.16	24.48	0.75	1.65e-85	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg03469862	chr11:68924853	NA	0.45	6.98	0.31	1.01e-11	Blond vs. brown hair color;
LGG	cis	rs727505	1.000	rs988699	chr7:124409814	C/T	cg23710748	chr7:124431027	NA	-0.52	-9.65	-0.41	3.29e-20	Lewy body disease;
LGG	cis	rs220324	1.000	rs220324	chr21:43586699	C/T	cg15319517	chr21:43638949	ABCG1	0.42	6.94	0.31	1.35e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg08916839	chr5:415575	AHRR	0.99	14.15	0.55	4.9e-38	Fat distribution (HIV);
LGG	cis	rs2549003	1.000	rs2070727	chr5:131820275	C/A	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg19980929	chr12:42632907	YAF2	0.38	8.58	0.37	1.42e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1847505	0.609	rs1606636	chr13:61416080	T/A	cg25164009	chr13:61490935	NA	0.58	9.7	0.41	2.19e-20	Polychlorinated biphenyl levels;
LGG	cis	rs600550	0.552	rs11605466	chr11:60097461	A/T	cg05040360	chr11:60102449	MS4A6E	-0.34	-7.51	-0.33	3.05e-13	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.79e-21	Diabetic retinopathy;
LGG	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25517755	chr10:38738941	LOC399744	-0.35	-6.68	-0.3	6.73e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg09021430	chr5:549028	NA	-0.69	-9.63	-0.41	4.05e-20	Obesity-related traits;
LGG	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg14664628	chr15:75095509	CSK	-0.55	-10.4	-0.44	6.64e-23	Breast cancer;
LGG	cis	rs250677	0.687	rs2915809	chr5:148452111	A/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.41	-0.33	5.84e-13	Breast cancer;
LGG	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg08470875	chr2:26401718	FAM59B	0.43	8.24	0.36	1.73e-15	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg04691961	chr3:161091175	C3orf57	0.41	8.64	0.37	9.23e-17	Morning vs. evening chronotype;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg08200770	chr17:80723486	TBCD	-0.41	-8.04	-0.35	7.79e-15	Glycated hemoglobin levels;
LGG	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.32e-28	Gout;Renal underexcretion gout;
LGG	cis	rs1790761	0.967	rs1638588	chr11:67199706	C/A	cg14500267	chr11:67383377	NA	-0.39	-7.22	-0.32	2.22e-12	Mean corpuscular volume;
LGG	cis	rs12476592	0.602	rs4671509	chr2:63686004	C/T	cg17519650	chr2:63277830	OTX1	-0.46	-7.1	-0.31	4.85e-12	Childhood ear infection;
LGG	cis	rs11785400	0.793	rs2280879	chr8:143722228	T/C	cg24634471	chr8:143751801	JRK	0.49	7.46	0.33	4.34e-13	Schizophrenia;
LGG	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	9.03	0.39	4.65e-18	Joint mobility (Beighton score);
LGG	cis	rs2976388	0.578	rs13263987	chr8:143827387	A/C	cg06565975	chr8:143823917	SLURP1	-0.57	-14.03	-0.55	1.67e-37	Urinary tract infection frequency;
LGG	cis	rs2285947	1.000	rs6970985	chr7:21583597	G/T	cg23045935	chr7:21583304	DNAH11	0.43	9.43	0.4	1.96e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3916	0.794	rs10431384	chr12:121127347	C/T	cg21892295	chr12:121157589	UNC119B	0.37	6.76	0.3	4.07e-11	Urinary metabolites (H-NMR features);
LGG	cis	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg24110177	chr3:50126178	RBM5	0.39	6.82	0.3	2.88e-11	Intelligence (multi-trait analysis);
LGG	trans	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg19894588	chr14:64061835	NA	-0.6	-9.33	-0.4	4.49e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	6.99	0.31	9.9e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21054441	chr15:68871409	CORO2B	0.48	7.22	0.32	2.18e-12	Gut microbiome composition (summer);
LGG	cis	rs4888262	0.526	rs8057279	chr16:74627303	C/T	cg01733217	chr16:74700730	RFWD3	0.89	18.09	0.64	1.03e-55	Testicular germ cell tumor;
LGG	cis	rs300774	0.925	rs300734	chr2:167167	T/G	cg04617936	chr2:214353	NA	-0.45	-6.85	-0.3	2.36e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs988958	0.958	rs13419617	chr2:42280854	C/T	cg27252766	chr2:42229092	NA	0.46	7.62	0.33	1.42e-13	Hypospadias;
LGG	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.29	-0.4	6.07e-19	Systemic lupus erythematosus;
LGG	trans	rs12579753	0.797	rs1922561	chr12:82152640	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-8.09	-0.35	5.3e-15	Resting heart rate;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-7.04	-0.31	6.82e-12	Longevity;Endometriosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07532072	chr22:42016555	PPPDE2;XRCC6	0.44	7.03	0.31	7.68e-12	Cognitive performance;
LGG	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2249694	0.503	rs9418982	chr10:135320622	C/T	cg20169779	chr10:135381914	SYCE1	0.61	8.51	0.37	2.37e-16	Obesity-related traits;
LGG	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.91	0.38	1.2e-17	Rheumatoid arthritis;
LGG	cis	rs7737355	0.773	rs9327616	chr5:130902196	C/T	cg06307176	chr5:131281290	NA	0.52	8.66	0.37	8.2e-17	Life satisfaction;
LGG	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg03237606	chr10:63212265	TMEM26	0.45	8.23	0.36	1.94e-15	Night sleep phenotypes;
LGG	cis	rs7577696	0.568	rs410469	chr2:32476992	G/T	cg02381751	chr2:32503542	YIPF4	-0.45	-6.67	-0.3	7.38e-11	Inflammatory biomarkers;
LGG	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg24450063	chr1:156163899	SLC25A44	1.08	22.16	0.72	1.08e-74	Intracerebral hemorrhage;White matter hyperintensity burden;
LGG	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-8.57	-0.37	1.53e-16	Height;
LGG	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg00086871	chr4:6988644	TBC1D14	1.12	10.35	0.43	1.01e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg23173402	chr1:227635558	NA	0.54	8.9	0.38	1.23e-17	Major depressive disorder;
LGG	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg24110177	chr3:50126178	RBM5	-0.59	-10.61	-0.44	1.1e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	8.9	0.38	1.29e-17	Bone mineral density;
LGG	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg20503657	chr10:835505	NA	0.75	10.41	0.44	5.88e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs7737355	0.812	rs13179482	chr5:130626073	G/A	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs13108043	0.605	rs10516787	chr4:87920334	T/C	cg11209507	chr4:87813803	C4orf36	0.54	7.1	0.31	4.77e-12	Red blood cell count;
LGG	cis	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg09085632	chr11:111637200	PPP2R1B	0.74	13.79	0.54	1.74e-36	Primary sclerosing cholangitis;
LGG	cis	rs7617773	0.780	rs6793223	chr3:48364101	C/T	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg02389323	chr16:88786976	FAM38A	1.09	13.21	0.52	5.03e-34	Plateletcrit;
LGG	cis	rs6489882	0.902	rs1981556	chr12:113372961	C/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg13009111	chr11:71350975	NA	-0.33	-7.34	-0.32	9.51e-13	Monocyte count;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.51e-14	Lung cancer;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg23034840	chr1:205782522	SLC41A1	0.57	9.21	0.39	1.13e-18	Menarche (age at onset);
LGG	cis	rs1577917	1.000	rs6936048	chr6:86702608	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.61	-0.41	4.49e-20	Response to antipsychotic treatment;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg04691961	chr3:161091175	C3orf57	0.41	8.62	0.37	1.09e-16	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.67	-0.34	1.03e-13	Skin colour saturation;
LGG	cis	rs2735413	0.564	rs11863954	chr16:78127149	C/G	cg04733911	chr16:78082701	NA	-0.55	-7.23	-0.32	1.97e-12	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2273669	0.667	rs1424479	chr6:109355790	G/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg11301795	chr4:187892539	NA	-0.94	-24.92	-0.76	1.46e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12618769	0.597	rs3754888	chr2:99090674	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.39	8.5e-19	Diabetic retinopathy;
LGG	cis	rs2115630	0.967	rs10438428	chr15:85330745	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.89	-0.31	1.79e-11	P wave terminal force;
LGG	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.83e-18	Cognitive test performance;
LGG	trans	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg27661571	chr11:113659931	NA	-0.57	-7.89	-0.34	2.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg06808227	chr14:105710500	BRF1	-0.62	-11.39	-0.47	1.19e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs35771425	0.529	rs12731366	chr1:211378802	C/T	cg10512769	chr1:211675356	NA	-0.61	-7.94	-0.35	1.52e-14	Educational attainment (years of education);
LGG	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs2172802	0.693	rs11131337	chr4:62491495	T/C	cg04118610	chr4:62707027	LPHN3	-0.51	-7.93	-0.35	1.6e-14	Partial epilepsies;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.27e-17	Prudent dietary pattern;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.43	-0.33	5.13e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg12813108	chr7:99719912	CNPY4	-0.56	-8.3	-0.36	1.17e-15	Lung function (FEV1/FVC);
LGG	cis	rs8064024	0.676	rs2075467	chr16:4873242	A/G	cg08329684	chr16:4932620	PPL	-0.4	-8.59	-0.37	1.31e-16	Cancer;
LGG	cis	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg16876255	chr19:9731953	ZNF561	0.79	7.35	0.32	8.89e-13	Pursuit maintenance gain;
LGG	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg24110177	chr3:50126178	RBM5	0.54	8.77	0.38	3.38e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6835098	1.000	rs6826412	chr4:174109622	C/T	cg08422745	chr4:174089978	GALNT7	-0.85	-15.05	-0.57	5.98e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs755249	0.567	rs16826093	chr1:39815143	T/A	cg18385671	chr1:39797026	MACF1	0.44	7.46	0.33	4.28e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg03806693	chr22:41940476	POLR3H	-0.54	-8.28	-0.36	1.31e-15	Neuroticism;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03647317	chr4:187891568	NA	-0.41	-8.87	-0.38	1.63e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs952623	0.649	rs7801660	chr7:39072473	C/T	cg18850127	chr7:39170497	POU6F2	0.35	8.14	0.35	3.59e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.533	rs11099829	chr4:152727299	A/G	cg22705602	chr4:152727874	NA	0.37	9.24	0.39	9.15e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.898	rs4706025	chr5:130913788	T/A	cg06307176	chr5:131281290	NA	0.54	8.96	0.38	7.96e-18	Life satisfaction;
LGG	cis	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.76	-0.57	1.13e-40	IgG glycosylation;
LGG	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg22437258	chr11:111473054	SIK2	0.4	6.69	0.3	6.28e-11	Primary sclerosing cholangitis;
LGG	cis	rs8048589	0.527	rs9939383	chr16:12176120	C/T	cg02910054	chr16:12241554	SNX29	0.41	6.77	0.3	4e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg09696939	chr10:60272079	BICC1	-0.39	-7.53	-0.33	2.76e-13	Refractive error;
LGG	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg18478394	chr8:109455254	TTC35	0.43	8.71	0.38	5.35e-17	Dupuytren's disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg05760417	chr1:247094694	AHCTF1	-0.39	-7.17	-0.32	3.04e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs9303280	0.628	rs12939565	chr17:38038389	A/T	cg00129232	chr17:37814104	STARD3	-0.49	-9.4	-0.4	2.62e-19	Self-reported allergy;
LGG	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg02461776	chr11:598696	PHRF1	0.46	7.57	0.33	2.09e-13	Systemic lupus erythematosus;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg09690326	chr7:23720549	C7orf46	-0.47	-10.94	-0.45	6.12e-25	Schizophrenia;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.77	0.38	3.33e-17	Mood instability;
LGG	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs34599045	0.522	rs71517761	chr1:152901128	T/A	cg07796016	chr1:152779584	LCE1C	-0.81	-7.49	-0.33	3.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg12654349	chr5:56205094	C5orf35	-0.39	-6.9	-0.31	1.72e-11	Coronary artery disease;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06873352	chr17:61820015	STRADA	0.49	7.55	0.33	2.34e-13	Height;
LGG	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	7.57	0.33	2.01e-13	HIV-1 control;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.25e-11	Electroencephalogram traits;
LGG	cis	rs4740619	0.933	rs10810432	chr9:15707317	G/T	cg14451791	chr9:16040625	NA	-0.4	-10.08	-0.42	9.44e-22	Body mass index;
LGG	trans	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.73	-13.24	-0.52	3.67e-34	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg17376030	chr22:41985996	PMM1	0.54	8.68	0.37	7.01e-17	Vitiligo;
LGG	cis	rs1927790	0.727	rs12871045	chr13:96971721	G/T	cg02571835	chr13:96230311	CLDN10	-0.35	-7.21	-0.32	2.36e-12	Body mass index;
LGG	cis	rs3617	0.625	rs3774364	chr3:52863605	G/A	cg11645453	chr3:52864694	ITIH4	0.4	6.87	0.3	2.11e-11	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg11040518	chr10:102331378	NA	-0.4	-7.2	-0.32	2.5e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9487094	0.670	rs12212476	chr6:109822605	C/T	cg16315928	chr6:109776240	MICAL1	0.46	8.03	0.35	8.17e-15	Height;
LGG	cis	rs919433	0.680	rs788018	chr2:198265526	A/G	cg00792783	chr2:198669748	PLCL1	0.51	8.0	0.35	1.02e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg27446573	chr6:127587934	RNF146	0.93	17.35	0.63	2.51e-52	Breast cancer;
LGG	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.12	-0.31	4.16e-12	Joint mobility (Beighton score);
LGG	cis	rs9473924	0.542	rs9473952	chr6:50921779	T/C	cg14470998	chr6:50812995	TFAP2B	0.65	7.8	0.34	4.03e-14	Body mass index;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	trans	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg24247370	chr13:99142703	STK24	-0.36	-6.8	-0.3	3.31e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg06565975	chr8:143823917	SLURP1	-0.28	-6.84	-0.3	2.52e-11	Urinary tract infection frequency;
LGG	cis	rs3815700	0.841	rs10410895	chr19:33093655	T/G	cg02997394	chr19:33096574	ANKRD27	0.87	13.02	0.52	3.04e-33	Eosinophilic esophagitis;
LGG	cis	rs858239	0.537	rs2286272	chr7:23224367	T/C	cg23682824	chr7:23144976	KLHL7	0.41	6.8	0.3	3.24e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg16586182	chr3:47516702	SCAP	-0.72	-12.81	-0.51	2.18e-32	QT interval;
LGG	cis	rs3219090	0.861	rs2136875	chr1:226606536	G/A	cg17127702	chr1:226594323	PARP1	0.39	12.44	0.5	7.76e-31	Melanoma;
LGG	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg04450456	chr4:17643702	FAM184B	0.3	6.7	0.3	5.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2637030	0.515	rs256103	chr5:53012475	A/G	cg06476337	chr5:52856530	NDUFS4	0.43	6.81	0.3	3.11e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg20587970	chr11:113659929	NA	-0.95	-14.38	-0.56	4.98e-39	Hip circumference adjusted for BMI;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg16680214	chr1:154839983	KCNN3	0.46	8.92	0.38	1.12e-17	Prostate cancer;
LGG	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.85	-0.48	1.73e-28	Mean platelet volume;
LGG	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.35	-6.69	-0.3	6.65e-11	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13268671	chr2:166810585	TTC21B	0.42	6.84	0.3	2.44e-11	Cognitive performance;
LGG	cis	rs2735413	0.837	rs12920830	chr16:78083149	A/C	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg07936489	chr17:37558343	FBXL20	-0.49	-8.38	-0.36	6.21e-16	Asthma;
LGG	cis	rs12791968	0.527	rs12285862	chr11:45014326	T/G	cg11846598	chr11:44996168	LOC221122	-0.49	-6.85	-0.3	2.43e-11	Inhibitory control;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13859216	chr5:137910711	HSPA9	0.45	6.71	0.3	5.84e-11	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.545	rs11701805	chr21:40618683	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-12.46	-0.5	6.36e-31	Menarche (age at onset);
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.22	-0.36	2.08e-15	Bipolar disorder;
LGG	cis	rs9487094	0.670	rs1476388	chr6:109839986	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.81	0.34	3.83e-14	Height;
LGG	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg10845886	chr2:3471009	TTC15	-0.49	-9.85	-0.42	6.47e-21	Neurofibrillary tangles;
LGG	cis	rs12042938	0.600	rs1865225	chr1:231763004	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-10.99	-0.45	3.92e-25	Neuranatomic and neurocognitive phenotypes;
LGG	trans	rs35110281	0.567	rs4819219	chr21:44984864	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.73	13.84	0.54	1.11e-36	Mean corpuscular volume;
LGG	cis	rs3816183	0.547	rs2374432	chr2:42741914	G/T	cg14631114	chr2:43023945	NA	-0.4	-7.37	-0.32	7.93e-13	Hypospadias;
LGG	cis	rs4262150	0.767	rs4958317	chr5:151942880	G/A	cg12297329	chr5:152029980	NA	-0.73	-13.9	-0.54	6.16e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg03517284	chr6:25882590	NA	0.43	7.05	0.31	6.73e-12	Iron status biomarkers;
LGG	cis	rs1707322	0.682	rs12037459	chr1:46094959	T/G	cg03146154	chr1:46216737	IPP	0.56	10.44	0.44	4.5e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg14154082	chr13:112174009	NA	0.35	7.58	0.33	1.87e-13	Menarche (age at onset);
LGG	cis	rs9596863	0.799	rs11148279	chr13:54309775	C/T	ch.13.53330881F	chr13:54432880	NA	0.52	6.95	0.31	1.26e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg09426994	chr11:118478258	PHLDB1	-0.44	-7.71	-0.34	7.86e-14	Cholesterol, total;
LGG	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.6	-0.37	1.27e-16	Lung cancer in ever smokers;
LGG	cis	rs1355223	1.000	rs1396879	chr11:34766653	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.33	-0.32	1.07e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg04234412	chr22:24373322	LOC391322	-0.72	-14.14	-0.55	5.26e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg24998770	chr7:37888106	TXNDC3	0.61	10.62	0.44	1.01e-23	Alzheimer's disease (late onset);
LGG	cis	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.93	-0.42	3.31e-21	Mean corpuscular volume;
LGG	cis	rs6598955	0.671	rs11247910	chr1:26645666	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.14	0.35	3.71e-15	Obesity-related traits;
LGG	cis	rs8028182	0.636	rs4564532	chr15:75706296	C/G	cg20655648	chr15:75932815	IMP3	0.46	7.8	0.34	4.07e-14	Sudden cardiac arrest;
LGG	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-12.35	-0.5	1.74e-30	Colorectal cancer;
LGG	cis	rs7617773	0.925	rs6442105	chr3:48182326	A/G	cg11946769	chr3:48343235	NME6	-0.54	-8.73	-0.38	4.57e-17	Coronary artery disease;
LGG	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.25	-0.32	1.79e-12	Neuroticism;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg19168338	chr16:4465731	CORO7	-0.73	-13.56	-0.53	1.58e-35	Schizophrenia;
LGG	cis	rs4604732	0.603	rs10802512	chr1:247633730	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.36	0.36	7.22e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs8180040	0.726	rs2305638	chr3:47046842	G/C	cg27129171	chr3:47204927	SETD2	0.82	15.2	0.58	1.35e-42	Colorectal cancer;
LGG	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg18252515	chr7:66147081	NA	1.44	20.55	0.69	3.59e-67	Diabetic kidney disease;
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg02002194	chr4:3960332	NA	-0.48	-9.36	-0.4	3.34e-19	Systolic blood pressure;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25072359	chr17:41440525	NA	0.53	9.88	0.42	5.25e-21	Menopause (age at onset);
LGG	trans	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg12575136	chr18:32820987	ZNF397	0.48	8.86	0.38	1.67e-17	White blood cell count;
LGG	cis	rs4936894	0.500	rs11219498	chr11:124076699	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.12	-0.43	7.02e-22	Aging (time to death);
LGG	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg17971929	chr21:40555470	PSMG1	0.79	14.25	0.55	1.9e-38	Cognitive function;
LGG	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs1035144	0.510	rs12432357	chr14:81299468	A/G	cg06600135	chr14:81408086	NA	-0.58	-11.3	-0.46	2.6e-26	Male sexual orientation;
LGG	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	11.55	0.47	2.61e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9814567	1.000	rs13096604	chr3:134250099	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.03	0.52	2.84e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7975161	0.630	rs4964260	chr12:104634270	A/G	cg25273343	chr12:104657179	TXNRD1	-0.74	-7.46	-0.33	4.2e-13	Toenail selenium levels;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg06074448	chr4:187884817	NA	0.58	12.46	0.5	6.17e-31	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg18357526	chr6:26021779	HIST1H4A	0.59	10.38	0.43	7.62e-23	Height;
LGG	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.85	-0.38	1.81e-17	Initial pursuit acceleration;
LGG	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg21427119	chr20:30132790	HM13	-0.41	-7.13	-0.31	3.93e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg16006841	chr5:176797999	RGS14	-0.53	-8.4	-0.36	5.41e-16	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs853679	0.517	rs9348794	chr6:28117757	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs7932354	0.528	rs747650	chr11:47176005	C/T	cg03339077	chr11:47165057	C11orf49	0.57	10.83	0.45	1.6e-24	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.05	0.52	2.4e-33	Rheumatoid arthritis;
LGG	cis	rs888194	0.568	rs10850137	chr12:109874794	C/G	cg19025524	chr12:109796872	NA	-0.38	-7.18	-0.32	2.72e-12	Neuroticism;
LGG	trans	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.71	0.3	5.74e-11	Triglycerides;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg10664184	chr19:17420304	DDA1	0.55	8.65	0.37	8.22e-17	Systemic lupus erythematosus;
LGG	cis	rs17767392	0.813	rs12880291	chr14:71884567	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.84	-0.38	2.03e-17	Mitral valve prolapse;
LGG	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg12591125	chr7:1885375	MAD1L1	0.47	6.72	0.3	5.25e-11	Bipolar disorder;
LGG	cis	rs2074193	0.543	rs11183924	chr12:47776503	T/G	cg02516419	chr12:47771422	NA	0.7	10.34	0.43	1.06e-22	Migraine with aura;
LGG	cis	rs3087591	0.659	rs757376	chr17:29717909	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.22	0.49	5.7e-30	Hip circumference;
LGG	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg25208724	chr1:156163844	SLC25A44	0.82	7.37	0.32	8.13e-13	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.93	10.41	0.44	6.27e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs988958	0.635	rs9309078	chr2:42249890	C/G	cg27252766	chr2:42229092	NA	0.52	7.99	0.35	1.09e-14	Hypospadias;
LGG	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	8.97	0.38	7.67e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04643103	chr1:150039325	VPS45	0.45	7.55	0.33	2.3e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg04691961	chr3:161091175	C3orf57	-0.45	-8.72	-0.38	4.9e-17	Parkinson's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15875120	chr10:15902605	FAM188A	0.42	7.16	0.32	3.12e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	7.26	0.32	1.6e-12	Bipolar disorder;
LGG	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg16400903	chr5:693638	TPPP	0.46	6.92	0.31	1.47e-11	Obesity-related traits;
LGG	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg12432903	chr7:1882776	MAD1L1	0.55	8.27	0.36	1.47e-15	Bipolar disorder;
LGG	cis	rs2041895	0.509	rs12368448	chr12:107316796	A/C	cg13944111	chr12:107296891	NA	-0.26	-7.08	-0.31	5.47e-12	Glaucoma (low intraocular pressure);
LGG	cis	rs9863	0.896	rs7311233	chr12:124475940	C/T	cg13487667	chr12:124434373	CCDC92	0.36	7.22	0.32	2.11e-12	White blood cell count;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs8028182	0.549	rs7402293	chr15:75636137	A/G	cg20655648	chr15:75932815	IMP3	-0.46	-7.6	-0.33	1.7e-13	Sudden cardiac arrest;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00689492	chr4:1303491	MAEA	-0.47	-8.09	-0.35	5.42e-15	Obesity-related traits;
LGG	cis	rs6723108	0.603	rs3769023	chr2:135713703	G/A	cg07169764	chr2:136633963	MCM6	0.43	6.7	0.3	5.93e-11	Type 2 diabetes;
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.61	-0.44	1.07e-23	Triglycerides;
LGG	trans	rs4234798	0.546	rs4689667	chr4:7249188	A/T	cg18432924	chr14:50359459	ARF6	-0.43	-6.67	-0.3	7.45e-11	Insulin-like growth factors;
LGG	cis	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg19399532	chr1:178512495	C1orf220	0.42	8.23	0.36	1.86e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg25632114	chr8:95732714	DPY19L4	0.42	7.27	0.32	1.52e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.18	-0.39	1.48e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs7584330	0.744	rs72620822	chr2:238379582	C/T	cg16989719	chr2:238392110	NA	-0.37	-7.29	-0.32	1.39e-12	Prostate cancer;
LGG	cis	rs62400317	0.821	rs12206568	chr6:45152747	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.15	-0.43	5.3e-22	Total body bone mineral density;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-12.67	-0.51	8.69e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg11905131	chr22:24372483	LOC391322	-0.46	-7.96	-0.35	1.33e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7572733	0.534	rs1436131	chr2:198731230	A/C	cg00792783	chr2:198669748	PLCL1	0.68	11.07	0.46	2.06e-25	Dermatomyositis;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg02462569	chr6:150064036	NUP43	0.37	7.88	0.34	2.37e-14	Lung cancer;
LGG	cis	rs11158198	0.689	rs10873108	chr14:58575102	A/G	cg15908186	chr14:58618357	C14orf37	0.53	9.17	0.39	1.5e-18	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-12.22	-0.49	5.79e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-21.81	-0.71	4.52e-73	Total body bone mineral density;
LGG	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg05926928	chr17:57297772	GDPD1	1.38	21.41	0.71	3.6e-71	Opioid sensitivity;
LGG	cis	rs2108225	1.000	rs6466190	chr7:107451045	G/T	cg18560240	chr7:107437656	SLC26A3	0.51	9.23	0.39	9.62e-19	Ulcerative colitis;
LGG	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.73	-0.3	5.07e-11	Mean corpuscular volume;
LGG	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg14784868	chr12:69753453	YEATS4	1.0	24.04	0.75	1.77e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1065852	0.510	rs5751247	chr22:42633054	T/C	cg15128208	chr22:42549153	NA	0.5	8.37	0.36	6.65e-16	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.9	-0.34	2.08e-14	HDL cholesterol;
LGG	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.38e-15	Myopia (pathological);
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.56	-0.37	1.65e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs977987	0.806	rs4888418	chr16:75460306	C/G	cg03315344	chr16:75512273	CHST6	0.52	10.33	0.43	1.18e-22	Dupuytren's disease;
LGG	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12654349	chr5:56205094	C5orf35	-0.81	-12.29	-0.5	2.97e-30	Initial pursuit acceleration;
LGG	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg25358565	chr5:93447407	FAM172A	1.36	16.52	0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-10.08	-0.42	9.74e-22	Prostate cancer;
LGG	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.33	-0.32	1.06e-12	HDL cholesterol;
LGG	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg12310025	chr6:25882481	NA	-0.53	-10.21	-0.43	3.27e-22	Blood metabolite levels;
LGG	cis	rs9815354	1.000	rs7632387	chr3:41853161	C/T	cg03022575	chr3:42003672	ULK4	0.69	8.73	0.38	4.73e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg25986240	chr4:9926439	SLC2A9	0.37	7.6	0.33	1.65e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02750587	chr1:85156370	SSX2IP	0.42	7.09	0.31	4.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-9.1	-0.39	2.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.29	-0.32	1.39e-12	Refractive error;
LGG	cis	rs9443645	0.868	rs9443643	chr6:79798838	A/G	cg18132916	chr6:79620363	NA	-0.3	-7.96	-0.35	1.35e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg02753203	chr1:228287806	NA	0.78	15.12	0.57	3.04e-42	Diastolic blood pressure;
LGG	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg24209194	chr3:40518798	ZNF619	-0.44	-7.06	-0.31	6.18e-12	Renal cell carcinoma;
LGG	cis	rs9783347	1.000	rs4150650	chr11:18374279	G/A	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.56	-0.33	2.17e-13	Pancreatic cancer;
LGG	cis	rs9359856	0.564	rs56396054	chr6:90360406	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.58	-0.41	5.94e-20	Bipolar disorder;
LGG	cis	rs2075064	0.900	rs7035028	chr9:126789000	C/T	cg14112217	chr9:126806003	NA	0.4	7.81	0.34	3.82e-14	Waist circumference;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-7.91	-0.35	1.85e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs75059851	0.756	rs7106715	chr11:133838905	A/G	cg20042908	chr11:133852938	NA	0.76	14.34	0.55	7.55e-39	Schizophrenia;
LGG	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg19468946	chr17:37922297	IKZF3	0.45	8.28	0.36	1.36e-15	Self-reported allergy;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.68	12.86	0.51	1.42e-32	Lymphocyte counts;
LGG	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg15556689	chr8:8085844	FLJ10661	0.53	9.87	0.42	5.52e-21	Neuroticism;
LGG	cis	rs7582720	1.000	rs72934545	chr2:203975958	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.3	0.4	5.46e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6867032	0.527	rs4975777	chr5:1973324	G/T	cg26168224	chr5:2018326	NA	-0.97	-14.53	-0.56	1.08e-39	Gut microbiome composition (winter);
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7147624	1.000	rs2411821	chr14:65896914	G/T	cg03016385	chr14:66212404	NA	-0.77	-10.06	-0.42	1.14e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.2	0.36	2.34e-15	Obesity-related traits;
LGG	cis	rs9733	0.526	rs6587542	chr1:150907701	G/T	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Tonsillectomy;
LGG	cis	rs60180747	1.000	rs59718328	chr15:66662620	A/T	cg07575407	chr15:66541975	MEGF11	0.37	7.49	0.33	3.55e-13	Testicular germ cell tumor;
LGG	cis	rs4555082	0.874	rs10151638	chr14:105761592	T/C	cg10792982	chr14:105748885	BRF1	0.53	10.34	0.43	1.12e-22	Mean platelet volume;Platelet distribution width;
LGG	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg24747557	chr10:131355152	MGMT	-0.33	-7.31	-0.32	1.16e-12	Response to temozolomide;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs17854409	1.000	rs6011427	chr20:61496680	C/T	cg06598544	chr20:61472147	COL9A3	-0.86	-9.86	-0.42	6.23e-21	Obesity-related traits;
LGG	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg01657329	chr11:68192670	LRP5	0.57	10.79	0.45	2.27e-24	Total body bone mineral density;
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	-0.55	-10.1	-0.42	8.27e-22	Total body bone mineral density;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg11050988	chr7:1952600	MAD1L1	-0.3	-6.94	-0.31	1.29e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4363385	0.818	rs1591736	chr1:152987497	A/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.94	-0.38	9.64e-18	Inflammatory skin disease;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg26384229	chr12:38710491	ALG10B	-0.97	-21.58	-0.71	5.57e-72	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.6	-0.37	1.21e-16	Retinal vascular caliber;
LGG	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg25237894	chr2:233734115	C2orf82	0.72	15.47	0.58	7.76e-44	Coronary artery disease;
LGG	cis	rs858239	0.539	rs4504540	chr7:23186198	C/G	cg23682824	chr7:23144976	KLHL7	0.41	6.77	0.3	3.92e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg08885076	chr2:99613938	TSGA10	-0.43	-8.19	-0.36	2.52e-15	Chronic sinus infection;
LGG	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs12928939	0.859	rs11670	chr16:71679027	G/T	cg08717414	chr16:71523259	ZNF19	-0.51	-7.48	-0.33	3.82e-13	Post bronchodilator FEV1;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg07167872	chr1:205819463	PM20D1	0.58	11.57	0.47	2.32e-27	Menarche (age at onset);
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.41e-14	Lung cancer;
LGG	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.99	0.42	2.14e-21	Ovarian reserve;
LGG	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.42	0.56	3.23e-39	Cognitive test performance;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.43	-0.36	4.3e-16	Schizophrenia;
LGG	cis	rs36051895	0.623	rs10118434	chr9:5238460	A/G	cg02405213	chr9:5042618	JAK2	-0.74	-12.96	-0.52	5.2e-33	Pediatric autoimmune diseases;
LGG	cis	rs16854884	0.632	rs1466941	chr3:143670131	A/G	cg06585982	chr3:143692056	C3orf58	0.67	11.96	0.49	6.41e-29	Economic and political preferences (feminism/equality);
LGG	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg04166393	chr7:2884313	GNA12	0.47	8.65	0.37	8.84e-17	Height;
LGG	trans	rs9379850	1.000	rs9379850	chr6:26343057	C/G	cg06606381	chr12:133084897	FBRSL1	-0.61	-6.76	-0.3	4.26e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg08250081	chr4:10125330	NA	-0.37	-7.08	-0.31	5.31e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg14926445	chr8:58193284	C8orf71	-0.9	-13.35	-0.53	1.24e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.01e-17	Menopause (age at onset);
LGG	cis	rs6121246	0.909	rs8126355	chr20:30332660	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg10150615	chr22:24372951	LOC391322	-0.41	-6.99	-0.31	9.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7737355	0.812	rs4705890	chr5:130855000	A/G	cg06307176	chr5:131281290	NA	0.52	8.65	0.37	8.65e-17	Life satisfaction;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg11245990	chr11:68621969	NA	0.44	9.18	0.39	1.43e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7106204	0.534	rs76397001	chr11:24254188	A/C	ch.11.24196551F	chr11:24239977	NA	0.84	9.46	0.4	1.58e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg03806693	chr22:41940476	POLR3H	-1.04	-17.61	-0.63	1.6e-53	Vitiligo;
LGG	cis	rs12079745	0.826	rs3766045	chr1:169098275	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.71	-6.66	-0.3	8e-11	QT interval;
LGG	cis	rs711245	0.863	rs848607	chr2:36770192	G/A	cg09467607	chr2:36825704	FEZ2	0.47	9.11	0.39	2.55e-18	Height;
LGG	cis	rs4689642	0.709	rs13133665	chr4:7226157	G/A	cg21353189	chr4:7228343	SORCS2	0.38	9.01	0.39	5.46e-18	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7241530	0.610	rs7239715	chr18:75893061	T/C	cg14642773	chr18:75888474	NA	0.48	8.99	0.39	6.49e-18	Educational attainment (years of education);
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg04450456	chr4:17643702	FAM184B	0.32	6.92	0.31	1.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.81	0.41	8.93e-21	Longevity;
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg11764359	chr7:65958608	NA	0.7	12.68	0.51	7.6e-32	Aortic root size;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg24607181	chr17:41446203	NA	-0.3	-7.11	-0.31	4.31e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg05025164	chr4:1340916	KIAA1530	0.68	13.24	0.52	3.51e-34	Longevity;
LGG	cis	rs7412746	0.503	rs72704639	chr1:150798335	A/C	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.29e-11	Melanoma;
LGG	cis	rs988958	0.567	rs7594766	chr2:42228804	C/T	cg19376973	chr2:42229025	NA	0.61	9.64	0.41	3.69e-20	Hypospadias;
LGG	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26076054	chr5:421317	AHRR	-0.45	-7.57	-0.33	2.07e-13	Cystic fibrosis severity;
LGG	cis	rs17453880	0.895	rs4610448	chr5:152019865	A/T	cg12297329	chr5:152029980	NA	-0.9	-23.8	-0.74	2.38e-82	Subjective well-being;
LGG	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06310300	chr7:100076089	TSC22D4	0.44	6.93	0.31	1.38e-11	Gut microbiome composition (summer);
LGG	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg19773385	chr1:10388646	KIF1B	0.45	9.26	0.4	7.42e-19	Hepatocellular carcinoma;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg13206674	chr6:150067644	NUP43	0.66	14.98	0.57	1.17e-41	Lung cancer;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs8005677	0.798	rs4982713	chr14:23404102	C/T	cg25600027	chr14:23388339	RBM23	-0.43	-7.2	-0.32	2.38e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg23324259	chr8:82754387	SNX16	-0.43	-6.86	-0.3	2.27e-11	Diastolic blood pressure;
LGG	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg05623727	chr3:50126028	RBM5	0.34	7.4	0.33	6.54e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.47e-48	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.84	-0.3	2.5e-11	Schizophrenia;
LGG	cis	rs3820928	1.000	rs4675120	chr2:227774888	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.3	-0.32	1.27e-12	Pulmonary function;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.59	0.47	1.91e-27	Electroencephalogram traits;
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg07959490	chr17:80112427	CCDC57	0.39	7.52	0.33	2.92e-13	Life satisfaction;
LGG	cis	rs11718455	0.960	rs35869565	chr3:44002394	G/C	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.56e-11	Coronary artery disease;
LGG	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs6087990	0.735	rs2424921	chr20:31385814	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	16.78	0.61	1.07e-49	Ulcerative colitis;
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg08888203	chr3:10149979	C3orf24	0.5	8.6	0.37	1.23e-16	Alzheimer's disease;
LGG	cis	rs8030485	0.728	rs13379886	chr15:79394894	A/G	cg17916960	chr15:79447300	NA	-0.52	-8.76	-0.38	3.64e-17	Left ventricle wall thickness;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg20453264	chr5:131705742	SLC22A5	-0.61	-8.12	-0.35	4.11e-15	Rheumatoid arthritis;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.67	12.59	0.51	1.77e-31	Obesity-related traits;
LGG	cis	rs2070488	0.775	rs4407366	chr3:38521425	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.57	0.56	7.23e-40	Electrocardiographic conduction measures;
LGG	cis	rs193541	0.632	rs1363200	chr5:122163802	G/T	cg19412675	chr5:122181750	SNX24	0.53	8.51	0.37	2.36e-16	Glucose homeostasis traits;
LGG	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.73	-0.38	4.67e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19541837	chr11:71823834	C11orf51	0.42	6.72	0.3	5.19e-11	Cognitive performance;
LGG	cis	rs6714710	0.580	rs6711101	chr2:98379813	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	9.4	0.4	2.48e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7267979	1.000	rs11087520	chr20:25436827	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.08	0.42	9.73e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.06	-0.46	2.12e-25	Prostate cancer;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.29	0.36	1.26e-15	Personality dimensions;
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.98	-0.31	1.02e-11	Aortic root size;
LGG	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg19168338	chr16:4465731	CORO7	0.73	13.29	0.53	2.18e-34	Schizophrenia;
LGG	cis	rs17824933	1.000	rs929230	chr11:60760971	C/T	cg16817237	chr11:60793675	NA	0.35	6.82	0.3	2.84e-11	Multiple sclerosis;
LGG	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg03254818	chr6:169586852	NA	0.57	8.24	0.36	1.81e-15	Pulse pressure;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.24	-0.46	4.55e-26	Triglycerides;
LGG	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg11752832	chr7:134001865	SLC35B4	-0.54	-9.51	-0.4	1.06e-19	Mean platelet volume;
LGG	cis	rs7166081	0.950	rs72625778	chr15:67590103	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11252926	0.523	rs816596	chr10:548004	C/T	cg08603382	chr10:743973	NA	0.42	7.7	0.34	8.29e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.51e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-12.49	-0.5	4.67e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs889312	0.500	rs11960484	chr5:56109154	C/T	cg14703610	chr5:56206110	C5orf35	-0.39	-6.82	-0.3	2.79e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.3	-0.32	1.26e-12	Bipolar disorder;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.49	0.33	3.51e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs478607	0.748	rs61884413	chr11:64459406	C/T	cg19395706	chr11:64412079	NRXN2	0.44	7.36	0.32	8.73e-13	Urate levels;
LGG	cis	rs6674970	0.627	rs2864700	chr1:151028929	C/T	cg11822372	chr1:151115635	SEMA6C	0.38	6.9	0.31	1.71e-11	Childhood ear infection;
LGG	cis	rs12949688	0.682	rs1476730	chr17:55838676	G/T	cg12582317	chr17:55822272	NA	-0.43	-9.38	-0.4	2.94e-19	Schizophrenia;
LGG	cis	rs7226408	0.857	rs72888926	chr18:34530957	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1658458	chr10:60301382	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.05e-56	Refractive error;
LGG	cis	rs4075765	0.536	rs55788608	chr11:26264820	C/G	cg19182008	chr11:26298241	NA	0.99	8.79	0.38	3e-17	Cannabis dependence symptom count;
LGG	cis	rs1003719	0.646	rs2835671	chr21:38581125	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.78	-0.57	8.96e-41	Eye color traits;
LGG	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg08773314	chr2:239334832	ASB1	0.43	8.19	0.36	2.56e-15	Multiple system atrophy;
LGG	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.69	-0.3	6.5e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs17030434	0.769	rs11727144	chr4:154645181	G/C	cg14289246	chr4:154710475	SFRP2	-0.63	-9.62	-0.41	4.28e-20	Electrocardiographic conduction measures;
LGG	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs4979906	1.000	rs11002249	chr10:79447228	C/T	cg07817648	chr10:79422355	NA	-0.44	-7.3	-0.32	1.27e-12	Mortality in heart failure;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg05313129	chr8:58192883	C8orf71	-0.84	-12.54	-0.5	2.89e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.51	-0.33	3.03e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg25208724	chr1:156163844	SLC25A44	1.21	28.05	0.79	6.78e-102	Testicular germ cell tumor;
LGG	cis	rs7215564	0.818	rs4890054	chr17:78587195	C/T	cg16980736	chr17:78789706	RPTOR	-0.66	-8.53	-0.37	2.15e-16	Myopia (pathological);
LGG	cis	rs67311347	1.000	rs4973898	chr3:40459532	A/G	cg13683864	chr3:40499215	RPL14	1.03	22.83	0.73	8.11e-78	Renal cell carcinoma;
LGG	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg04568710	chr12:38710424	ALG10B	0.33	7.17	0.32	2.94e-12	Bladder cancer;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.93	0.38	9.91e-18	Platelet count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01773306	chr2:85555458	TGOLN2	0.46	7.46	0.33	4.37e-13	Cognitive performance;
LGG	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.55	2.46e-37	Bladder cancer;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg19635926	chr16:89946313	TCF25	0.75	7.35	0.32	8.78e-13	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs17125944	0.686	rs6572868	chr14:53325090	C/T	cg00686598	chr14:53173677	PSMC6	-0.7	-7.49	-0.33	3.57e-13	Alzheimer's disease (late onset);
LGG	cis	rs12681287	0.640	rs10095498	chr8:87425651	C/T	cg27223183	chr8:87520930	FAM82B	0.5	7.7	0.34	8.59e-14	Caudate activity during reward;
LGG	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg24692254	chr21:30365293	RNF160	-0.87	-20.05	-0.68	8.13e-65	Dental caries;
LGG	cis	rs11105298	0.891	rs11105325	chr12:89938590	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.13	-0.39	2.11e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21782712	chr6:33257137	WDR46;PFDN6	0.42	7.08	0.31	5.46e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7799006	0.929	rs6951493	chr7:2257612	G/A	cg02951883	chr7:2050386	MAD1L1	-0.43	-7.74	-0.34	6.46e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg11693508	chr17:37793320	STARD3	0.54	7.85	0.34	2.85e-14	Bipolar disorder;
LGG	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.83e-22	Axial length;
LGG	cis	rs7412746	0.658	rs10305711	chr1:150802996	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.06	0.31	6.07e-12	Melanoma;
LGG	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg12046867	chr14:103022105	NA	-0.69	-14.12	-0.55	6.8e-38	Platelet count;
LGG	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg14154082	chr13:112174009	NA	-0.36	-7.98	-0.35	1.15e-14	Menarche (age at onset);
LGG	cis	rs7071206	0.891	rs10824559	chr10:79409222	A/G	cg07817648	chr10:79422355	NA	-0.8	-14.9	-0.57	2.7e-41	Bone mineral density;
LGG	cis	rs757978	1.000	rs2074771	chr2:242350944	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.77	-8.33	-0.36	9.34e-16	Chronic lymphocytic leukemia;
LGG	cis	rs4330281	0.647	rs9810675	chr3:17449619	C/T	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.79e-11	Schizophrenia;
LGG	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs77633900	0.614	rs280008	chr15:77011815	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.43	-0.44	5.02e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg26174226	chr8:58114915	NA	-0.5	-6.96	-0.31	1.15e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	0.835	rs1446310	chr2:233683245	G/C	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.29	-0.36	1.2e-15	Coronary artery disease;
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg06925179	chr17:43578568	NA	-0.41	-9.58	-0.41	6.09e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00495681	chr13:53174319	NA	0.43	7.11	0.31	4.38e-12	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11947960	chr2:112655492	MERTK	0.5	7.69	0.34	8.9e-14	Gut microbiome composition (summer);
LGG	cis	rs7166081	1.000	rs4491456	chr15:67653639	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.34	-0.32	9.99e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg10818794	chr15:86012489	AKAP13	-0.37	-8.0	-0.35	1.03e-14	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.85	0.54	9.89e-37	Lung cancer;
LGG	cis	rs988958	0.635	rs9309078	chr2:42249890	C/G	cg27428208	chr2:42229179	NA	0.51	8.78	0.38	3.16e-17	Hypospadias;
LGG	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg05169160	chr2:178484487	TTC30A	0.36	7.13	0.31	3.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06656553	chr16:89960601	TCF25	-0.72	-7.17	-0.32	3.08e-12	Skin colour saturation;
LGG	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg15145296	chr3:125709740	NA	-0.6	-7.72	-0.34	7.05e-14	Blood pressure (smoking interaction);
LGG	trans	rs9929218	1.000	rs13339591	chr16:68809273	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.85	-0.51	1.59e-32	Colorectal cancer;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg07243736	chr16:783730	NARFL	0.41	7.15	0.32	3.31e-12	Height;
LGG	cis	rs763121	0.853	rs5757200	chr22:39043491	T/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.85	13.28	0.53	2.51e-34	HIV-1 control;
LGG	cis	rs7149337	0.805	rs71422017	chr14:51612417	A/T	cg23942311	chr14:51606299	NA	0.32	7.08	0.31	5.32e-12	Cancer;
LGG	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg00745463	chr17:30367425	LRRC37B	0.54	7.5	0.33	3.24e-13	Hip circumference adjusted for BMI;
LGG	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg17691542	chr6:26056736	HIST1H1C	-0.61	-9.95	-0.42	2.79e-21	Iron status biomarkers;
LGG	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg20026190	chr17:76395443	PGS1	0.57	10.0	0.42	1.95e-21	HDL cholesterol levels;
LGG	trans	rs3779273	1.000	rs1829990	chr7:77829312	A/G	cg05596911	chr5:118502651	DMXL1	-0.42	-8.91	-0.38	1.15e-17	Body mass index;
LGG	cis	rs1497406	0.744	rs924203	chr1:16511539	G/T	cg20430773	chr1:16534157	ARHGEF19	0.28	8.02	0.35	8.81e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.41	0.47	9.29e-27	Intelligence (multi-trait analysis);
LGG	cis	rs13082711	0.863	rs34611823	chr3:27500344	A/G	cg02860705	chr3:27208620	NA	0.69	12.55	0.5	2.63e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07132326	chr6:150258058	NA	0.37	7.86	0.34	2.78e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1419980	0.673	rs10772553	chr12:7768089	G/A	cg10578777	chr12:7781093	NA	-0.59	-7.97	-0.35	1.25e-14	HDL cholesterol levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21160472	chr1:212782112	ATF3	-0.5	-7.27	-0.32	1.55e-12	Systemic lupus erythematosus;
LGG	cis	rs16837677	1.000	rs80036288	chr1:156720907	C/T	cg14991358	chr1:156767203	PRCC	0.78	8.11	0.35	4.56e-15	Sjögren's syndrome;
LGG	cis	rs12949688	0.601	rs11079326	chr17:55837207	G/A	cg12582317	chr17:55822272	NA	0.47	10.78	0.45	2.48e-24	Schizophrenia;
LGG	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs870825	0.616	rs2130393	chr4:185642335	T/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.16	0.72	1.03e-74	Blood protein levels;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06873352	chr17:61820015	STRADA	0.72	13.41	0.53	7.4e-35	Prudent dietary pattern;
LGG	cis	rs910873	0.505	rs6059969	chr20:33245284	T/C	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.3	-0.32	1.22e-12	Melanoma;
LGG	cis	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.82	0.42	8.35e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg20991723	chr1:152506922	NA	-0.71	-14.46	-0.56	2.37e-39	Hair morphology;
LGG	cis	rs6840360	0.615	rs4696096	chr4:152475387	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg10756647	chr7:56101905	PSPH	0.83	9.79	0.41	1.05e-20	Diabetic kidney disease;
LGG	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	7.32e-32	Coronary artery disease;
LGG	cis	rs2270875	0.696	rs10464871	chr8:132931374	C/T	cg24184792	chr8:132919238	EFR3A	-0.44	-7.61	-0.33	1.52e-13	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg07382826	chr16:28625726	SULT1A1	0.39	8.44	0.37	3.99e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg24253500	chr15:84953950	NA	0.42	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg07615347	chr10:60278583	BICC1	0.63	17.85	0.64	1.3e-54	Refractive error;
LGG	cis	rs1034435	0.755	rs5768679	chr22:48892847	T/G	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.74	-0.61	1.49e-49	Late-onset Alzheimer's disease;
LGG	cis	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg21775007	chr8:11205619	TDH	0.47	7.37	0.32	7.75e-13	Neuroticism;
LGG	cis	rs611744	0.550	rs57045491	chr8:109279120	A/C	cg21045802	chr8:109455806	TTC35	0.53	9.94	0.42	3.21e-21	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg20607798	chr8:58055168	NA	0.68	7.79	0.34	4.38e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.51	0.33	2.98e-13	Neuroticism;
LGG	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	9.34	0.4	4.22e-19	Cognitive ability;
LGG	cis	rs7267979	0.966	rs2261747	chr20:25261784	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.02	0.42	1.62e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.29	-0.32	1.36e-12	Life satisfaction;
LGG	trans	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.3	0.32	1.25e-12	Retinal vascular caliber;
LGG	cis	rs2289328	0.943	rs12905240	chr15:40672145	C/T	cg13931752	chr15:40660718	DISP2	0.37	7.43	0.33	5.27e-13	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg17328964	chr8:145687451	CYHR1	-0.67	-12.64	-0.51	1.1e-31	Age at first birth;
LGG	cis	rs9325144	0.560	rs10506125	chr12:39120287	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.58	0.56	6.55e-40	Morning vs. evening chronotype;
LGG	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg08109568	chr15:31115862	NA	-0.55	-9.4	-0.4	2.43e-19	Huntington's disease progression;
LGG	cis	rs4474465	0.915	rs4944204	chr11:78222013	G/T	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs7095944	0.613	rs11245366	chr10:126482849	C/T	cg08799069	chr10:126477246	METTL10	-0.47	-10.76	-0.45	3.02e-24	Asthma;
LGG	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg15736062	chr7:158136485	PTPRN2	-0.41	-7.9	-0.34	2.07e-14	Calcium levels;
LGG	cis	rs2073300	0.609	rs3736755	chr20:23377642	C/T	cg12062639	chr20:23401060	NAPB	0.84	8.41	0.36	5.07e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg18335740	chr13:41363409	SLC25A15	-0.58	-11.14	-0.46	1.08e-25	Lewy body disease;
LGG	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.37	-0.53	1.01e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08677398	chr8:58056175	NA	0.54	8.19	0.36	2.57e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.19	0.39	1.31e-18	Motion sickness;
LGG	cis	rs7241530	0.662	rs6506751	chr18:75904506	T/C	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	trans	rs629535	0.773	rs686683	chr8:70070364	G/A	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	trans	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.96	-0.31	1.15e-11	Joint mobility (Beighton score);
LGG	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg02951883	chr7:2050386	MAD1L1	0.46	7.91	0.35	1.9e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs994014	0.629	rs2034631	chr4:82225529	T/C	cg07938847	chr4:82126349	PRKG2	-0.3	-7.33	-0.32	1.05e-12	Height;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg17202724	chr17:61916730	SMARCD2	-0.41	-8.27	-0.36	1.46e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3857536	0.740	rs7769722	chr6:66891363	C/T	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg08498830	chr11:832797	CD151	-0.45	-7.35	-0.32	9.21e-13	Mean platelet volume;
LGG	cis	rs61989804	0.623	rs2151756	chr14:65735437	T/A	cg15999311	chr14:65749247	NA	0.77	7.74	0.34	6.24e-14	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs7727544	0.684	rs274546	chr5:131699867	A/G	cg07395648	chr5:131743802	NA	-0.55	-12.91	-0.51	8.58e-33	Blood metabolite levels;
LGG	cis	rs7975161	0.630	rs4246264	chr12:104637743	C/G	cg25273343	chr12:104657179	TXNRD1	-0.73	-7.14	-0.31	3.72e-12	Toenail selenium levels;
LGG	cis	rs12476592	0.602	rs4671068	chr2:63798333	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.9	-0.31	1.72e-11	Childhood ear infection;
LGG	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14169450	chr9:139327907	INPP5E	0.4	7.38	0.32	7.5e-13	Monocyte percentage of white cells;
LGG	cis	rs17001868	0.527	rs9611324	chr22:40781162	T/C	cg07138101	chr22:40742427	ADSL	0.62	8.16	0.35	3.23e-15	Mammographic density (dense area);
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs10851478	0.590	rs12591300	chr15:49704741	A/G	cg08060515	chr15:49448048	GALK2;COPS2	-0.44	-7.79	-0.34	4.54e-14	Oral cavity cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20913106	chr8:38324522	FGFR1	0.49	8.02	0.35	8.79e-15	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.86	-0.38	1.75e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3750082	0.748	rs10248427	chr7:32898969	C/G	cg08946731	chr7:32981826	RP9P	0.4	6.73	0.3	5.16e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs528418	0.527	rs1856265	chr6:145718052	T/C	cg03642472	chr6:145670687	NA	0.55	7.13	0.31	3.8e-12	Methadone dose in opioid dependence;
LGG	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg06565975	chr8:143823917	SLURP1	0.28	6.73	0.3	4.99e-11	Urinary tract infection frequency;
LGG	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg05169099	chr5:481640	SLC9A3	0.46	6.75	0.3	4.57e-11	Fat distribution (HIV);
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg12419862	chr22:24373484	LOC391322	-0.93	-19.26	-0.67	3.97e-61	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7560272	0.723	rs4852927	chr2:73641557	C/T	cg20560298	chr2:73613845	ALMS1	0.36	6.66	0.3	7.91e-11	Schizophrenia;
LGG	cis	rs2066819	1.000	rs17118409	chr12:56630764	G/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.64	-0.41	3.64e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06634786	chr22:41940651	POLR3H	0.76	11.88	0.48	1.32e-28	Cannabis dependence symptom count;
LGG	cis	rs9487094	0.670	rs12197950	chr6:109963389	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.09	0.35	5.41e-15	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20801500	chr2:220462218	STK11IP	-0.39	-6.86	-0.3	2.2e-11	Pancreatic cancer;
LGG	trans	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg11887960	chr12:57824829	NA	-0.54	-6.67	-0.3	7.13e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05775809	chr10:103880419	LDB1	0.45	6.96	0.31	1.2e-11	Gut microbiome composition (summer);
LGG	cis	rs7107174	0.901	rs1055250	chr11:77925708	C/G	cg02023728	chr11:77925099	USP35	0.45	7.47	0.33	4.04e-13	Testicular germ cell tumor;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00761968	chr13:53314142	LECT1	-0.44	-9.76	-0.41	1.37e-20	Lewy body disease;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg24623649	chr8:11872141	NA	-0.31	-7.52	-0.33	2.9e-13	Neuroticism;
LGG	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg26384229	chr12:38710491	ALG10B	0.8	15.87	0.59	1.36e-45	Morning vs. evening chronotype;
LGG	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg06076350	chr7:157294107	NA	0.37	7.07	0.31	5.79e-12	Inattentive symptoms;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-7.37	-0.32	7.97e-13	Lung cancer;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg15971980	chr6:150254442	NA	0.45	8.59	0.37	1.29e-16	Lung cancer;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.7	0.37	5.88e-17	Prudent dietary pattern;
LGG	cis	rs78366141	0.649	rs78179026	chr4:89657456	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.55	0.37	1.87e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.03	-0.39	4.57e-18	Erythrocyte sedimentation rate;
LGG	cis	rs7512552	0.839	rs11590787	chr1:150398531	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs701145	0.585	rs365119	chr3:153916502	A/T	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-9.58	-0.41	6.01e-20	Erythrocyte sedimentation rate;
LGG	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.26	0.36	1.58e-15	Neuroticism;
LGG	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg03078520	chr22:18463400	MICAL3	-0.61	-11.33	-0.47	1.9e-26	Presence of antiphospholipid antibodies;
LGG	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	12.09	0.49	2.04e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Electroencephalogram traits;
LGG	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6087990	1.000	rs2424901	chr20:31344512	A/G	cg13636640	chr20:31349939	DNMT3B	1.01	21.89	0.71	1.96e-73	Ulcerative colitis;
LGG	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg24110177	chr3:50126178	RBM5	0.56	10.14	0.43	5.79e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg20255370	chr15:40268687	EIF2AK4	-0.85	-9.01	-0.39	5.42e-18	Corneal curvature;
LGG	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.66	-0.37	7.92e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10876993	0.890	rs1678539	chr12:58060359	A/G	cg18357645	chr12:58087776	OS9	0.69	12.43	0.5	8.61e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.61	11.05	0.46	2.34e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg27400746	chr16:89904261	SPIRE2	-1.04	-15.58	-0.59	2.72e-44	Skin colour saturation;
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg11764359	chr7:65958608	NA	0.74	13.39	0.53	8.69e-35	Aortic root size;
LGG	cis	rs7129220	0.512	rs11042666	chr11:10227393	A/T	cg01453529	chr11:10209919	SBF2	-0.48	-7.96	-0.35	1.38e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.66	0.41	3.08e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3806843	0.657	rs2563283	chr5:140105978	C/A	cg19875535	chr5:140030758	IK	-0.59	-12.16	-0.49	9.78e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.79	-0.34	4.5e-14	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.36	-0.4	3.37e-19	Life satisfaction;
LGG	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24308560	chr3:49941425	MST1R	0.22	6.82	0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2088885	0.868	rs7615457	chr3:170966507	A/C	cg18052528	chr3:170975382	TNIK	-0.31	-7.61	-0.33	1.54e-13	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-6.77	-0.3	3.99e-11	Educational attainment;
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.26e-25	Intelligence (multi-trait analysis);
LGG	cis	rs113835537	0.529	rs11227512	chr11:66281291	T/C	cg24851651	chr11:66362959	CCS	0.44	7.65	0.33	1.21e-13	Airway imaging phenotypes;
LGG	cis	rs876084	0.505	rs9969405	chr8:121107146	A/G	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.03	-0.35	8.14e-15	Neuroticism;
LGG	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	trans	rs7181230	1.000	rs28587891	chr15:40365106	T/A	cg22705835	chr10:65332833	REEP3	-0.6	-10.69	-0.44	5.57e-24	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.22	0.32	2.09e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs6500395	1.000	rs9937610	chr16:48671274	C/G	cg04672837	chr16:48644449	N4BP1	0.53	8.77	0.38	3.4e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2865126	0.818	rs4432309	chr18:10758974	C/T	cg21165219	chr18:10698044	FAM38B	-0.45	-7.27	-0.32	1.51e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22496380	chr5:211416	CCDC127	-1.21	-17.24	-0.63	8.46e-52	Breast cancer;
LGG	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.07	-0.35	5.91e-15	Neuroticism;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg04503457	chr17:41445688	NA	-0.39	-9.22	-0.39	1.07e-18	Menopause (age at onset);
LGG	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.29	0.36	1.27e-15	Menopause (age at onset);
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg04278597	chr1:63154320	DOCK7	0.46	6.75	0.3	4.47e-11	Breast cancer;
LGG	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg20283391	chr11:68216788	NA	-0.5	-8.18	-0.36	2.83e-15	Total body bone mineral density;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.7	-0.34	8.35e-14	Lung cancer;
LGG	cis	rs2229238	0.911	rs60368585	chr1:154509340	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.88	0.3	1.99e-11	Coronary heart disease;
LGG	cis	rs12422267	0.536	rs12303484	chr12:132609558	G/A	cg09764611	chr12:132620959	NA	-0.57	-8.48	-0.37	2.94e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Myopia (pathological);
LGG	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg04691961	chr3:161091175	C3orf57	-0.48	-9.93	-0.42	3.38e-21	Parkinson's disease;
LGG	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.66	0.41	3e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7587476	1.000	rs1542173	chr2:215657560	C/T	cg04530015	chr2:215796436	ABCA12	0.43	7.2	0.32	2.48e-12	Neuroblastoma;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg21724239	chr8:58056113	NA	0.71	9.06	0.39	3.6e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg21918786	chr6:109611834	NA	-0.48	-9.02	-0.39	5.03e-18	Reticulocyte fraction of red cells;
LGG	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.4	-0.33	6.58e-13	Triglycerides;
LGG	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.35	0.32	9.19e-13	Hair morphology;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17453880	0.929	rs4958571	chr5:152030714	A/C	cg12297329	chr5:152029980	NA	0.9	23.5	0.74	5.84e-81	Subjective well-being;
LGG	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg03114573	chr12:45410052	DBX2	-0.69	-12.55	-0.5	2.62e-31	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.82	0.3	2.81e-11	Retinal vascular caliber;
LGG	cis	rs13082711	0.596	rs479404	chr3:27363064	T/C	cg02860705	chr3:27208620	NA	0.64	12.09	0.49	2e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg02158880	chr13:53174818	NA	0.36	6.84	0.3	2.54e-11	Lewy body disease;
LGG	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14159747	chr11:113255604	NA	0.3	8.26	0.36	1.57e-15	Neuroticism;
LGG	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg08000102	chr2:233561755	GIGYF2	-0.42	-6.87	-0.3	2.12e-11	Coronary artery disease;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-7.51	-0.33	3.1e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg12432903	chr7:1882776	MAD1L1	-0.48	-7.57	-0.33	2.03e-13	Bipolar disorder;
LGG	cis	rs12347191	0.500	rs907580	chr9:100622597	T/C	cg13688889	chr9:100608707	NA	-0.82	-16.1	-0.6	1.18e-46	Orofacial clefts;
LGG	cis	rs7172689	1.000	rs66718746	chr15:81543973	G/A	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.03	0.39	4.51e-18	Blood metabolite levels;
LGG	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg15764593	chr10:829463	NA	-0.69	-10.37	-0.43	8.27e-23	Uric acid levels;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.58	-9.9	-0.42	4.26e-21	Renal function-related traits (BUN);
LGG	trans	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg06521331	chr12:34319734	NA	0.5	9.34	0.4	4.21e-19	Bladder cancer;
LGG	trans	rs453301	0.686	rs6748	chr8:8890802	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.67	-0.34	1.03e-13	Joint mobility (Beighton score);
LGG	cis	rs968567	0.539	rs174549	chr11:61571382	A/G	cg19610905	chr11:61596333	FADS2	0.77	13.11	0.52	1.29e-33	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	trans	rs1997103	1.000	rs1997103	chr7:55395390	C/G	cg20935933	chr6:143382018	AIG1	0.6	9.25	0.39	8.52e-19	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.45	-0.4	1.63e-19	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.37	0.32	7.94e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.42	0.4	2.21e-19	Diabetic retinopathy;
LGG	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg02187348	chr16:89574699	SPG7	-0.62	-10.36	-0.43	9.13e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs79349575	0.783	rs4793992	chr17:47008207	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.83	0.3	2.62e-11	Type 2 diabetes;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.08e-12	Electroencephalogram traits;
LGG	cis	rs490234	0.841	rs476819	chr9:128362737	C/T	cg14078157	chr9:128172775	NA	-0.43	-7.91	-0.35	1.91e-14	Mean arterial pressure;
LGG	cis	rs701145	0.585	rs1727880	chr3:153835972	G/A	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg12454169	chr2:30669597	LCLAT1	0.59	8.04	0.35	7.65e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.34	0.43	1.13e-22	Blood protein levels;
LGG	cis	rs780094	0.500	rs13022873	chr2:27815510	A/C	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.3	5.48e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs7267979	1.000	rs2258135	chr20:25272323	C/A	cg06421707	chr20:25228305	PYGB	0.48	10.4	0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg09699651	chr6:150184138	LRP11	0.51	9.06	0.39	3.55e-18	Lung cancer;
LGG	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.68	0.61	3.07e-49	Personality dimensions;
LGG	cis	rs77372450	0.636	rs6556105	chr5:157022864	C/T	cg25387487	chr5:157003181	ADAM19	-0.57	-7.24	-0.32	1.83e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg03175030	chr11:2018143	H19;MIR675	0.42	8.1	0.35	4.96e-15	DNA methylation (variation);
LGG	cis	rs9324022	0.929	rs72698721	chr14:101181189	G/A	cg18089426	chr14:101175970	NA	0.65	10.38	0.43	7.56e-23	Plateletcrit;
LGG	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	trans	rs1032833	0.558	rs1838873	chr2:179939457	C/T	cg23654767	chr2:101192981	PDCL3	0.89	10.4	0.44	6.45e-23	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg27211696	chr2:191398769	TMEM194B	-0.39	-8.99	-0.39	6.2e-18	Pulse pressure;
LGG	cis	rs1010254	0.510	rs2112538	chr5:151711392	G/T	cg12297329	chr5:152029980	NA	-0.47	-6.89	-0.3	1.82e-11	Optic nerve measurement (cup area);
LGG	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.55	-9.04	-0.39	4.29e-18	Glomerular filtration rate;
LGG	cis	rs7241530	0.585	rs35772443	chr18:75891302	T/C	cg14642773	chr18:75888474	NA	0.46	9.01	0.39	5.6e-18	Educational attainment (years of education);
LGG	cis	rs7512552	0.839	rs12040949	chr1:150447462	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.37	0.4	3.08e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2153904	0.609	rs4951254	chr1:205642390	T/C	cg23034840	chr1:205782522	SLC41A1	0.56	7.04	0.31	6.84e-12	Prostate-specific antigen levels;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19510075	chr4:184580508	C4orf41;RWDD4A	0.48	7.37	0.32	7.83e-13	Gut microbiome composition (summer);
LGG	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg00204512	chr16:28754710	NA	0.26	7.16	0.32	3.13e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.3	-0.36	1.17e-15	Retinal vascular caliber;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	9.14	0.39	2e-18	Lung function (FEV1/FVC);
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.43	7.17	0.32	3.02e-12	Personality dimensions;
LGG	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg27661571	chr11:113659931	NA	-0.58	-8.36	-0.36	7.62e-16	Hip circumference adjusted for BMI;
LGG	cis	rs12681287	0.547	rs13261956	chr8:87478765	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg01191920	chr7:158217561	PTPRN2	0.92	24.53	0.75	8.99e-86	Obesity-related traits;
LGG	cis	rs3806843	0.868	rs2531345	chr5:140126781	T/G	cg19875535	chr5:140030758	IK	-0.54	-11.1	-0.46	1.5e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06634786	chr22:41940651	POLR3H	0.74	12.31	0.5	2.54e-30	Vitiligo;
LGG	cis	rs4918072	0.834	rs7084332	chr10:105713413	A/T	cg11005552	chr10:105648138	OBFC1	0.42	7.31	0.32	1.17e-12	Coronary artery disease;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.53	-9.21	-0.39	1.13e-18	Longevity;Endometriosis;
LGG	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg21775007	chr8:11205619	TDH	0.81	14.18	0.55	3.82e-38	Retinal vascular caliber;
LGG	cis	rs7192750	0.586	rs1834035	chr16:71972271	C/G	cg06353428	chr16:71660113	MARVELD3	0.66	10.25	0.43	2.42e-22	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg12463550	chr7:65579703	CRCP	0.5	8.41	0.36	5.04e-16	Aortic root size;
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.49e-20	Bipolar disorder;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg04008888	chr11:68622739	NA	-0.56	-11.45	-0.47	6.81e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg26384229	chr12:38710491	ALG10B	0.76	15.7	0.59	7.73e-45	Morning vs. evening chronotype;
LGG	cis	rs4789693	0.544	rs4789770	chr17:80376655	C/T	cg04308225	chr17:80449738	NA	0.49	7.63	0.33	1.36e-13	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs62244186	0.714	rs2293600	chr3:44599103	G/T	cg18165381	chr3:44552316	NA	0.41	6.84	0.3	2.47e-11	Depressive symptoms;
LGG	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-9.08	-0.39	3.08e-18	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17139983	chr19:58987604	ZNF446	0.47	7.07	0.31	5.71e-12	Gut microbiome composition (summer);
LGG	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg19645103	chr12:69753606	YEATS4	-0.51	-7.5	-0.33	3.23e-13	Response to diuretic therapy;
LGG	cis	rs6840360	0.642	rs4696089	chr4:152395733	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg04546413	chr19:29218101	NA	0.65	8.87	0.38	1.63e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.25e-13	Educational attainment;
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg13009111	chr11:71350975	NA	-0.32	-6.69	-0.3	6.38e-11	Triglycerides;
LGG	cis	rs3806843	0.966	rs3806844	chr5:140206263	A/T	cg19875535	chr5:140030758	IK	0.48	9.61	0.41	4.6e-20	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4780401	0.967	rs11075012	chr16:11831030	T/C	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.2	-0.32	2.52e-12	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-8.25	-0.36	1.68e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.96	-0.31	1.17e-11	Blood metabolite levels;
LGG	cis	rs6466055	0.611	rs3213742	chr7:104643230	C/A	cg04380332	chr7:105027541	SRPK2	-0.38	-7.05	-0.31	6.51e-12	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14350545	chr9:135820463	TSC1	0.4	6.81	0.3	3.1e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7508	0.535	rs4124899	chr8:17785258	A/C	cg18067069	chr8:17937731	ASAH1	-0.29	-6.71	-0.3	5.54e-11	Atrial fibrillation;
LGG	cis	rs7808935	0.633	rs12668668	chr7:27936709	T/G	cg22168087	chr7:27702803	HIBADH	0.72	9.76	0.41	1.34e-20	Prostate cancer;
LGG	cis	rs7166081	1.000	rs10163040	chr15:67490486	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.79	-0.3	3.36e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20887711	chr4:1340912	KIAA1530	-0.53	-9.86	-0.42	5.85e-21	Obesity-related traits;
LGG	cis	rs6831352	0.879	rs2602888	chr4:100041706	C/T	cg13256891	chr4:100009986	ADH5	0.55	9.32	0.4	4.68e-19	Alcohol dependence;
LGG	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg20503657	chr10:835505	NA	-0.74	-10.28	-0.43	1.76e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs3126085	0.935	rs877776	chr1:152178018	C/G	cg26876637	chr1:152193138	HRNR	0.52	8.6	0.37	1.27e-16	Atopic dermatitis;
LGG	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg11812906	chr14:75593930	NEK9	-0.53	-9.75	-0.41	1.44e-20	Height;
LGG	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg13647721	chr17:30228624	UTP6	0.64	7.88	0.34	2.35e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg04731861	chr2:219085781	ARPC2	0.48	12.15	0.49	1.13e-29	Colorectal cancer;
LGG	cis	rs826838	0.510	rs10876149	chr12:39228083	C/G	cg26384229	chr12:38710491	ALG10B	-0.86	-16.04	-0.6	2.29e-46	Heart rate;
LGG	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg22852734	chr6:133119734	C6orf192	1.39	11.69	0.48	7.39e-28	Type 2 diabetes nephropathy;
LGG	cis	rs12540874	0.542	rs4947582	chr7:50566090	C/T	cg00647317	chr7:50633725	DDC	0.35	8.5	0.37	2.72e-16	Systemic sclerosis;
LGG	cis	rs6598955	0.543	rs61608823	chr1:26555090	G/A	cg04990556	chr1:26633338	UBXN11	0.71	10.47	0.44	3.75e-23	Obesity-related traits;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.67	0.3	7.16e-11	Schizophrenia;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs1843834	0.898	rs4674936	chr2:225553731	C/T	cg22455342	chr2:225449267	CUL3	0.57	9.62	0.41	4.32e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1566085	0.641	rs59636564	chr8:142651387	T/C	cg26331504	chr8:142652174	NA	-0.31	-7.47	-0.33	3.92e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11191205	0.644	rs75972556	chr10:103377022	G/A	cg15320455	chr10:103880129	LDB1	0.49	6.9	0.31	1.73e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.91	-0.31	1.58e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	trans	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.82	0.34	3.49e-14	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs7119	0.717	rs62007350	chr15:77804590	G/A	cg10437265	chr15:77819839	NA	0.25	6.82	0.3	2.8e-11	Type 2 diabetes;
LGG	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.84	-0.48	1.87e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg21906852	chr1:75198582	TYW3;CRYZ	0.39	6.77	0.3	3.92e-11	Resistin levels;
LGG	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.15	0.35	3.4e-15	Diabetic kidney disease;
LGG	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.53	-0.44	2.11e-23	Aortic root size;
LGG	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.04	-0.39	4.35e-18	Coronary artery disease;
LGG	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg27398817	chr8:82754497	SNX16	0.71	11.03	0.46	2.77e-25	Diastolic blood pressure;
LGG	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg09165964	chr15:75287851	SCAMP5	-0.64	-7.34	-0.32	9.5e-13	Lung cancer;
LGG	cis	rs7226408	0.600	rs1147765	chr18:34411602	A/G	cg15022739	chr18:34823045	BRUNOL4	0.39	8.02	0.35	8.76e-15	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg26597838	chr10:835615	NA	0.74	10.01	0.42	1.81e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs6956675	1.000	rs1967430	chr7:62599308	C/T	cg08930214	chr7:62859557	LOC100287834	0.46	7.5	0.33	3.25e-13	Obesity-related traits;
LGG	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.27	0.4	7.17e-19	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg11502198	chr6:26597334	ABT1	0.56	9.72	0.41	1.88e-20	Intelligence (multi-trait analysis);
LGG	trans	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs644799	0.710	rs11021309	chr11:95501898	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.22	0.58	1.08e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	14.04	0.55	1.47e-37	Cognitive test performance;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg26554054	chr8:600488	NA	0.95	9.98	0.42	2.27e-21	IgG glycosylation;
LGG	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.34	-0.32	9.58e-13	Prostate-specific antigen levels;
LGG	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg24623649	chr8:11872141	NA	-0.29	-6.65	-0.3	8.08e-11	Monocyte count;
LGG	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.72	0.48	5.94e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06634786	chr22:41940651	POLR3H	-0.68	-11.4	-0.47	1.09e-26	Vitiligo;
LGG	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg26039829	chr8:22132926	PIWIL2	0.53	12.07	0.49	2.33e-29	Hypertriglyceridemia;
LGG	cis	rs2594989	1.000	rs2595002	chr3:11373700	G/A	cg01796438	chr3:11312864	ATG7	-0.56	-7.92	-0.35	1.77e-14	Circulating chemerin levels;
LGG	cis	rs10905065	0.965	rs10737019	chr10:5783733	G/A	cg11519256	chr10:5708881	ASB13	0.42	7.41	0.33	6.19e-13	Menopause (age at onset);
LGG	cis	rs12449964	0.515	rs9899364	chr17:17567112	G/A	cg01246520	chr17:17644344	RAI1	0.32	7.13	0.31	3.98e-12	Coronary artery disease or ischemic stroke;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22968622	chr17:43663579	NA	1.08	20.76	0.69	3.89e-68	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg24812749	chr6:127587940	RNF146	0.71	11.39	0.47	1.14e-26	Breast cancer;
LGG	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-14.01	-0.55	2.03e-37	Morning vs. evening chronotype;
LGG	cis	rs8180040	1.000	rs807810	chr3:47403892	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-15.06	-0.57	5.12e-42	Colorectal cancer;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg16805816	chr17:41150871	RPL27	0.45	7.04	0.31	7.11e-12	Hepatitis;
LGG	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg25338242	chr13:114786047	RASA3	0.41	7.47	0.33	4.03e-13	Schizophrenia;
LGG	cis	rs62380364	0.602	rs640177	chr5:88002084	T/A	cg22951263	chr5:87985283	NA	-0.55	-10.3	-0.43	1.53e-22	Intelligence (multi-trait analysis);
LGG	cis	rs3857067	0.772	rs4438731	chr4:95091384	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.34	1.95e-14	QT interval;
LGG	cis	rs4692589	0.743	rs3806825	chr4:170948619	T/C	cg19918862	chr4:170955249	NA	0.45	8.84	0.38	2.04e-17	Anxiety disorder;
LGG	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.74	0.3	4.67e-11	Bladder cancer;
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs17286411	0.715	rs9932707	chr16:71862133	A/C	cg06353428	chr16:71660113	MARVELD3	0.43	7.56	0.33	2.19e-13	Blood protein levels;
LGG	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-16.71	-0.61	2.15e-49	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13758310	chr4:1834493	LETM1	0.41	7.54	0.33	2.43e-13	Gut microbiome composition (summer);
LGG	cis	rs17428076	0.958	rs72890842	chr2:172843278	T/G	cg21435375	chr2:172878103	MAP1D	0.45	9.69	0.41	2.47e-20	Myopia;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17376030	chr22:41985996	PMM1	0.6	9.48	0.4	1.31e-19	Vitiligo;
LGG	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.37	0.32	8.14e-13	Morning vs. evening chronotype;
LGG	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-9.06	-0.39	3.75e-18	Electroencephalogram traits;
LGG	cis	rs9783347	0.714	rs4757638	chr11:18312953	G/A	cg15585147	chr11:18324498	HPS5	0.34	7.67	0.34	1.02e-13	Pancreatic cancer;
LGG	cis	rs62025270	0.632	rs3169119	chr15:86291269	C/T	cg25843651	chr15:86329602	KLHL25	0.62	9.28	0.4	6.32e-19	Idiopathic pulmonary fibrosis;
LGG	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	7.85	0.34	3e-14	Coronary artery disease;
LGG	cis	rs9400467	0.537	rs73530951	chr6:111484814	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	7.16	0.32	3.27e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg19601865	chr12:132687172	GALNT9	0.52	11.91	0.48	1.07e-28	Anti-saccade response;
LGG	cis	rs2692947	0.732	rs56847058	chr2:96406893	C/T	cg22654517	chr2:96458247	NA	0.38	7.49	0.33	3.55e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.84e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.42e-50	Skin colour saturation;
LGG	cis	rs10193935	1.000	rs13419669	chr2:42387254	T/C	cg27598129	chr2:42591480	NA	-0.62	-9.31	-0.4	5.13e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2895526	0.580	rs11257930	chr10:12696120	A/G	cg00115178	chr10:12648176	CAMK1D	0.23	6.7	0.3	6.13e-11	Headache;
LGG	trans	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg06521331	chr12:34319734	NA	0.44	8.04	0.35	7.62e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12282928	0.959	rs960640	chr11:48290320	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.31	-0.32	1.21e-12	Migraine - clinic-based;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	9.47	0.4	1.41e-19	Bone mineral density;
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg26116260	chr4:7069785	GRPEL1	1.13	19.29	0.67	2.78e-61	Monocyte percentage of white cells;
LGG	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg02002194	chr4:3960332	NA	-0.5	-9.44	-0.4	1.77e-19	Myopia (pathological);
LGG	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg13072238	chr3:49761600	GMPPB	0.52	6.85	0.3	2.31e-11	Menarche (age at onset);
LGG	cis	rs7129220	0.588	rs7124925	chr11:10143700	G/A	cg01453529	chr11:10209919	SBF2	-0.42	-6.65	-0.3	8.39e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	9.31	0.4	5.03e-19	Obesity-related traits;
LGG	trans	rs75804782	0.572	rs55764347	chr2:239253529	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg06027949	chr8:82754900	SNX16	-0.48	-6.84	-0.3	2.59e-11	Diastolic blood pressure;
LGG	cis	rs240764	0.817	rs239201	chr6:101123993	T/A	cg09795085	chr6:101329169	ASCC3	0.45	7.5	0.33	3.35e-13	Neuroticism;
LGG	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26617929	chr16:1858877	NA	-0.62	-8.73	-0.38	4.56e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17453880	0.929	rs10041396	chr5:152041300	T/C	cg10931792	chr5:152022470	NA	0.41	8.88	0.38	1.53e-17	Subjective well-being;
LGG	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.51e-13	Body mass index;
LGG	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg15145296	chr3:125709740	NA	-0.6	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.61	10.32	0.43	1.26e-22	Cognitive ability;
LGG	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.59	-0.33	1.75e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg00173435	chr12:106696525	TCP11L2	0.61	8.31	0.36	1.05e-15	Tourette syndrome;
LGG	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg25809561	chr17:30822961	MYO1D	0.34	7.88	0.34	2.28e-14	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23805780	chr6:130342187	L3MBTL3	-0.46	-6.81	-0.3	2.95e-11	Systemic lupus erythematosus;
LGG	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg06153925	chr17:78755379	RPTOR	0.38	6.67	0.3	7.39e-11	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6909430	0.901	rs9375223	chr6:98585767	C/G	cg12860156	chr6:98744658	NA	-0.45	-7.59	-0.33	1.82e-13	Quantitative traits;
LGG	cis	rs75920871	0.528	rs3886960	chr11:116924990	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	trans	rs7944735	0.567	rs7111404	chr11:48011283	C/G	cg03929089	chr4:120376271	NA	0.66	6.99	0.31	9.45e-12	Intraocular pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22856972	chr6:134275178	TBPL1	0.54	8.01	0.35	9.67e-15	Gut microbiome composition (summer);
LGG	cis	rs4901847	0.643	rs7153396	chr14:58596356	C/T	cg15908186	chr14:58618357	C14orf37	-0.7	-13.07	-0.52	1.83e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-10.07	-0.42	1.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7226408	0.857	rs72885291	chr18:34449344	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07685180	chr8:600429	NA	1.22	11.92	0.48	9.61e-29	IgG glycosylation;
LGG	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg06353428	chr16:71660113	MARVELD3	-0.43	-7.17	-0.32	2.97e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg22563815	chr15:78856949	CHRNA5	0.29	7.27	0.32	1.56e-12	Sudden cardiac arrest;
LGG	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg12463550	chr7:65579703	CRCP	0.76	8.28	0.36	1.36e-15	Diabetic kidney disease;
LGG	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-11.59	-0.47	1.88e-27	Hemoglobin concentration;
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg00908189	chr16:619842	PIGQ	0.85	15.73	0.59	5.69e-45	Height;
LGG	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.68	0.37	6.75e-17	Fuchs's corneal dystrophy;
LGG	cis	rs300703	0.719	rs385272	chr2:206704	A/G	cg24565620	chr2:194026	NA	0.66	10.25	0.43	2.39e-22	Blood protein levels;
LGG	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7742824	0.843	rs55772024	chr6:44078830	G/A	cg04074908	chr6:44101190	TMEM63B	0.6	12.24	0.49	4.69e-30	Major depressive disorder;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg10295955	chr4:187884368	NA	-1.13	-29.49	-0.81	2.35e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15128208	chr22:42549153	NA	-0.5	-10.14	-0.43	6.1e-22	Cognitive function;
LGG	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08857478	chr17:74722826	JMJD6;C17orf95	0.48	7.23	0.32	2.04e-12	Gut microbiome composition (summer);
LGG	cis	rs283228	0.535	rs2852503	chr6:101842189	A/T	cg27451362	chr6:101846650	GRIK2	-0.99	-15.83	-0.59	1.97e-45	Coenzyme Q10 levels;
LGG	cis	rs2963155	0.518	rs2918419	chr5:142722353	T/C	cg17617527	chr5:142782415	NR3C1	1.0	13.42	0.53	6.67e-35	Breast cancer;
LGG	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.51	0.53	2.67e-35	Bladder cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg17327630	chr7:148937187	ZNF212	0.4	6.78	0.3	3.64e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs787274	1.000	rs787297	chr9:115542133	G/T	cg13803584	chr9:115635662	SNX30	-0.55	-7.72	-0.34	7.01e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs607541	1.000	rs607594	chr15:45934840	G/A	cg26924012	chr15:45694286	SPATA5L1	0.54	7.6	0.33	1.68e-13	Obesity-related traits;
LGG	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg10204951	chr7:910479	UNC84A	-0.53	-7.06	-0.31	6.29e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10816533	1.000	rs10118617	chr9:99550469	A/G	cg13983307	chr9:99539795	ZNF510	0.75	7.1	0.31	4.75e-12	Height;
LGG	cis	rs1982963	0.613	rs2749885	chr14:52516567	T/G	cg05884192	chr14:52515736	NID2	-0.45	-13.33	-0.53	1.48e-34	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6908034	0.607	rs111533721	chr6:19803745	C/G	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg11663600	chr3:49941416	MST1R	0.23	6.67	0.3	7.29e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg17376030	chr22:41985996	PMM1	0.58	9.17	0.39	1.56e-18	Vitiligo;
LGG	cis	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19171272	chr22:38449367	NA	-0.49	-8.85	-0.38	1.89e-17	Glioblastoma;Glioma;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg06916706	chr16:4465613	CORO7	-0.71	-12.42	-0.5	9.03e-31	Schizophrenia;
LGG	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.26	-0.36	1.51e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg06121193	chr1:90282411	NA	-0.41	-7.88	-0.34	2.28e-14	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.15	-31.25	-0.82	3.89e-116	Myeloid white cell count;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg01114163	chr5:1856713	NA	-0.41	-7.13	-0.31	3.84e-12	Cardiovascular disease risk factors;
LGG	cis	rs3845702	0.736	rs1904850	chr2:180852767	A/G	cg01881094	chr2:180872142	CWC22	-1.28	-17.0	-0.62	1.07e-50	Schizophrenia;
LGG	cis	rs4804815	0.784	rs2098701	chr19:7840140	G/A	cg00970558	chr19:7854469	CLEC4GP1	0.64	9.69	0.41	2.53e-20	Neutrophil count;
LGG	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.24e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	trans	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.47e-12	Prostate cancer;
LGG	cis	rs6754311	0.731	rs892715	chr2:136576577	T/C	cg07169764	chr2:136633963	MCM6	-0.75	-12.8	-0.51	2.44e-32	Mosquito bite size;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	8.5	0.37	2.54e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7246760	0.867	rs7259075	chr19:9778776	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg04990556	chr1:26633338	UBXN11	0.58	8.05	0.35	6.8e-15	Obesity-related traits;
LGG	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.59	0.53	1.22e-35	Psoriasis;
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22168489	chr12:122356033	WDR66	0.35	8.08	0.35	5.62e-15	Mean corpuscular volume;
LGG	cis	rs6430585	0.528	rs10496738	chr2:136751488	C/T	cg07169764	chr2:136633963	MCM6	1.23	22.6	0.72	9.25e-77	Corneal structure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16854524	chr4:83931902	LIN54	0.43	7.53	0.33	2.59e-13	Bipolar disorder;
LGG	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg05234568	chr11:5960015	NA	-0.67	-11.33	-0.47	2.03e-26	DNA methylation (variation);
LGG	cis	rs7172677	0.731	rs1108059	chr15:75338890	A/C	cg10253484	chr15:75165896	SCAMP2	0.55	8.08	0.35	5.54e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26888861	chr11:62521812	ZBTB3	0.46	7.45	0.33	4.53e-13	Cognitive performance;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg16507663	chr6:150244633	RAET1G	0.47	8.86	0.38	1.69e-17	Lung cancer;
LGG	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg00129232	chr17:37814104	STARD3	-0.63	-11.34	-0.47	1.79e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs3735485	0.843	rs62458106	chr7:45084707	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11041264	chr20:33872554	EIF6	0.49	7.94	0.35	1.57e-14	Cognitive performance;
LGG	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg01244601	chr4:120671846	NA	-0.35	-6.75	-0.3	4.37e-11	Corneal astigmatism;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13537196	chr9:15553060	C9orf93	-0.44	-7.43	-0.33	5.41e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	3.03e-16	Personality dimensions;
LGG	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.85	-0.34	2.91e-14	Systolic blood pressure;
LGG	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg05793240	chr7:2802953	GNA12	0.3	7.65	0.34	1.16e-13	Height;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg16301924	chr13:53314226	LECT1	-0.46	-9.17	-0.39	1.6e-18	Lewy body disease;
LGG	cis	rs17221829	0.733	rs12421374	chr11:89381067	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs4650994	0.593	rs12040058	chr1:178503557	C/G	cg19399532	chr1:178512495	C1orf220	-0.4	-7.78	-0.34	4.81e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.74	-0.45	3.49e-24	Response to antipsychotic treatment;
LGG	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg27398817	chr8:82754497	SNX16	0.77	11.02	0.46	3.17e-25	Diastolic blood pressure;
LGG	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg00405596	chr8:11794950	NA	0.61	10.57	0.44	1.53e-23	Monocyte count;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.45	0.58	9.69e-44	Lung cancer;
LGG	cis	rs1957429	0.520	rs230715	chr14:65320549	G/C	cg23373153	chr14:65346875	NA	-1.03	-10.91	-0.45	8.42e-25	Pediatric areal bone mineral density (radius);
LGG	cis	rs7695597	0.607	rs1217947	chr4:185170503	T/C	cg12654155	chr4:185238627	NA	0.43	7.81	0.34	3.85e-14	Night sleep phenotypes;
LGG	cis	rs11191205	0.686	rs11191070	chr10:103396862	C/T	cg15320455	chr10:103880129	LDB1	0.48	6.96	0.31	1.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg13147721	chr7:65941812	NA	-0.44	-6.75	-0.3	4.38e-11	Corneal structure;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25072359	chr17:41440525	NA	0.51	9.98	0.42	2.24e-21	Menopause (age at onset);
LGG	cis	rs7474896	0.583	rs1735621	chr10:38167723	G/T	cg00409905	chr10:38381863	ZNF37A	0.54	7.97	0.35	1.28e-14	Obesity (extreme);
LGG	cis	rs9942416	0.660	rs193344	chr5:74977854	T/C	cg19683494	chr5:74908142	NA	-0.44	-7.02	-0.31	7.86e-12	Age-related disease endophenotypes;
LGG	cis	rs4919694	1.000	rs12252500	chr10:104794984	G/C	cg04362960	chr10:104952993	NT5C2	1.08	15.13	0.58	2.62e-42	Arsenic metabolism;
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg16339924	chr4:17578868	LAP3	0.65	11.18	0.46	7.5e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.74	0.54	2.77e-36	Lung cancer;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	0.833	rs286885	chr11:34687346	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.83	0.3	2.65e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.37	2.51e-16	Prostate cancer;
LGG	cis	rs3087591	0.639	rs2342052	chr17:29721011	T/C	cg24425628	chr17:29625626	OMG;NF1	0.59	12.21	0.49	6.7e-30	Hip circumference;
LGG	cis	rs17253792	0.822	rs78323463	chr14:56045451	T/G	cg01858014	chr14:56050164	KTN1	-0.89	-11.99	-0.49	5.08e-29	Putamen volume;
LGG	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.64	0.41	3.64e-20	Mean corpuscular volume;
LGG	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.06	0.39	3.55e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg17971929	chr21:40555470	PSMG1	0.88	17.74	0.64	4.11e-54	Cognitive function;
LGG	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.74	-0.34	6.46e-14	Myopia (pathological);
LGG	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg05697835	chr1:2722811	NA	0.3	7.14	0.31	3.73e-12	Ulcerative colitis;
LGG	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg17757837	chr7:157058334	UBE3C	-0.92	-20.91	-0.7	7.82e-69	Body mass index;
LGG	cis	rs35425515	0.706	rs1490688	chr10:98860474	A/G	cg09122387	chr10:98855762	SLIT1	-0.66	-8.89	-0.38	1.37e-17	Bipolar disorder;
LGG	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Body mass index;
LGG	cis	rs926938	0.563	rs360586	chr1:115467489	A/G	cg12756093	chr1:115239321	AMPD1	0.45	8.46	0.37	3.47e-16	Autism;
LGG	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs2084898	0.943	rs477337	chr11:120000885	T/C	cg13907859	chr11:120009124	TRIM29	-0.88	-12.57	-0.5	2.23e-31	Stroke (pediatric);
LGG	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06470251	chr20:60548479	NA	0.43	7.7	0.34	8.4e-14	Body mass index;
LGG	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg23788917	chr6:8435910	SLC35B3	-0.51	-8.64	-0.37	9.32e-17	Motion sickness;
LGG	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24308560	chr3:49941425	MST1R	-0.23	-7.06	-0.31	6.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg07423050	chr13:99094983	FARP1	-0.55	-10.78	-0.45	2.48e-24	Longevity;
LGG	trans	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.17	-0.32	2.98e-12	Mood instability;
LGG	cis	rs3784262	0.631	rs3742961	chr15:58247977	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.22	-0.32	2.16e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs921968	0.608	rs495855	chr2:219357858	A/G	cg01130898	chr2:219473002	PLCD4	-0.39	-6.77	-0.3	3.82e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.15	-0.32	3.4e-12	Inflammatory bowel disease;
LGG	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg26150922	chr2:100937072	LONRF2	0.59	11.38	0.47	1.21e-26	Intelligence (multi-trait analysis);
LGG	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg02487422	chr3:49467188	NICN1	0.46	7.42	0.33	5.63e-13	Resting heart rate;
LGG	trans	rs877282	0.898	rs11253350	chr10:765968	G/A	cg22713356	chr15:30763199	NA	0.51	7.51	0.33	3.17e-13	Uric acid levels;
LGG	cis	rs17604090	0.877	rs68169519	chr7:29685158	A/G	cg19413766	chr7:29689036	LOC646762	-0.62	-7.71	-0.34	7.76e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg18187862	chr3:45730750	SACM1L	0.55	9.09	0.39	2.99e-18	Primary sclerosing cholangitis;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.75	-0.3	4.54e-11	Total body bone mineral density;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04772025	chr11:68637568	NA	0.73	12.92	0.51	7.94e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg00198680	chr16:28758506	NA	0.29	7.19	0.32	2.64e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs111326718	1	rs111326718	chr10:104771211	A/AAAAAT	cg04362960	chr10:104952993	NT5C2	0.53	10.18	0.43	4.2e-22	Reticulocyte count;
LGG	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-13.19	-0.52	6.14e-34	Bladder cancer;
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs8073060	0.559	rs17550632	chr17:33890883	G/C	cg19694781	chr19:47549865	TMEM160	1.11	16.69	0.61	2.72e-49	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.4	-0.4	2.52e-19	Neuroticism;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg08888203	chr3:10149979	C3orf24	0.56	9.42	0.4	2.08e-19	Alzheimer's disease;
LGG	cis	rs9308731	0.623	rs2241844	chr2:111879364	C/T	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.78	-0.3	3.72e-11	Chronic lymphocytic leukemia;
LGG	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg26897989	chr16:1907736	C16orf73	0.52	9.89	0.42	4.71e-21	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-20.89	-0.7	9.06e-69	Leprosy;
LGG	cis	rs2213920	0.749	rs7467654	chr9:118253677	C/T	cg13918206	chr9:118159781	DEC1	0.55	7.37	0.32	7.74e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.96	0.35	1.29e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg22875332	chr1:76189707	ACADM	0.58	11.09	0.46	1.71e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9912468	0.933	rs35135345	chr17:64325539	G/A	cg19474267	chr17:64306194	PRKCA	0.95	25.22	0.76	5.67e-89	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	12.78	0.51	2.99e-32	Chronic sinus infection;
LGG	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	Myopia (pathological);
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.14	-0.35	3.75e-15	Life satisfaction;
LGG	cis	rs13065560	0.534	rs9857724	chr3:38897005	C/T	cg01426195	chr3:39028469	NA	-0.43	-8.86	-0.38	1.77e-17	Interleukin-18 levels;
LGG	cis	rs6693567	0.565	rs7513182	chr1:150442612	A/G	cg15654264	chr1:150340011	RPRD2	-0.32	-6.66	-0.3	7.69e-11	Migraine;
LGG	cis	rs6684428	0.536	rs6695436	chr1:56390156	G/T	cg11651538	chr1:56320950	NA	-0.44	-8.47	-0.37	3.39e-16	Airflow obstruction;
LGG	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.27	0.46	3.46e-26	Hemoglobin concentration;
LGG	cis	rs9916302	0.904	rs2168785	chr17:37407135	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.68	-0.48	8.46e-28	Glomerular filtration rate (creatinine);
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg21775007	chr8:11205619	TDH	-0.47	-7.52	-0.33	2.79e-13	Neuroticism;
LGG	cis	rs12780845	0.540	rs10904894	chr10:17219656	T/C	cg01003015	chr10:17271136	VIM	-0.45	-7.52	-0.33	2.93e-13	Homocysteine levels;
LGG	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg05973401	chr12:123451056	ABCB9	0.48	7.0	0.31	8.89e-12	Neutrophil percentage of white cells;
LGG	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs12615966	0.858	rs17030286	chr2:105381220	T/G	cg16465502	chr2:105461796	NA	0.89	10.59	0.44	1.28e-23	Pancreatic cancer;
LGG	cis	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-8.01	-0.35	9.67e-15	Mononucleosis;
LGG	cis	rs10871290	0.507	rs3851731	chr16:74485788	C/T	cg01733217	chr16:74700730	RFWD3	0.6	10.74	0.45	3.41e-24	Breast cancer;
LGG	cis	rs7444	0.825	rs131664	chr22:21920403	G/A	cg22858872	chr22:21984481	YDJC	-0.36	-6.72	-0.3	5.51e-11	Systemic lupus erythematosus;
LGG	cis	rs7412746	0.658	rs2272214	chr1:150931462	C/T	cg15448220	chr1:150897856	SETDB1	0.4	7.27	0.32	1.5e-12	Melanoma;
LGG	cis	rs897984	0.609	rs732172	chr16:31050033	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.26	-0.32	1.66e-12	Dementia with Lewy bodies;
LGG	cis	rs6752107	1.000	rs12994971	chr2:234178453	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.76	0.34	5.43e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg26396452	chr14:65542826	MAX	-0.53	-11.09	-0.46	1.69e-25	Obesity-related traits;
LGG	cis	rs4906332	1.000	rs55731474	chr14:103878481	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-8.08	-0.35	5.69e-15	Coronary artery disease;
LGG	cis	rs4389656	0.629	rs274669	chr5:6711947	T/A	cg25011763	chr5:6727354	POLS	0.38	6.86	0.3	2.17e-11	Coronary artery disease;
LGG	cis	rs7412746	0.588	rs10305664	chr1:150839686	A/C	cg15448220	chr1:150897856	SETDB1	0.39	7.15	0.32	3.38e-12	Melanoma;
LGG	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg20026190	chr17:76395443	PGS1	0.57	10.08	0.42	9.6e-22	HDL cholesterol levels;
LGG	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21582582	chr3:182698605	DCUN1D1	0.39	6.8	0.3	3.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg11366901	chr6:160182831	ACAT2	1.05	16.33	0.6	1.19e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.22	0.32	2.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg07959490	chr17:80112427	CCDC57	0.38	7.41	0.33	5.86e-13	Life satisfaction;
LGG	cis	rs68170813	0.559	rs7809508	chr7:107004119	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-9.75	-0.41	1.47e-20	Coronary artery disease;
LGG	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg14074117	chr16:1909714	C16orf73	-0.54	-7.85	-0.34	2.92e-14	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.25	-0.36	1.63e-15	Breast cancer;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.87e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs7937890	0.561	rs2575849	chr11:14539639	T/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg07636037	chr3:49044803	WDR6	0.91	17.15	0.62	2.15e-51	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.25e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	trans	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg06521331	chr12:34319734	NA	-0.49	-8.33	-0.36	9.14e-16	Bladder cancer;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.79	-0.48	2.98e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Vitiligo;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08501054	chr8:9413133	TNKS	0.41	6.72	0.3	5.5e-11	Cognitive performance;
LGG	cis	rs698833	0.962	rs1085447	chr2:44670996	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-7.23	-0.32	1.96e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9397585	0.667	rs9397581	chr6:153383590	G/A	cg17707550	chr6:153380415	RGS17	0.56	11.79	0.48	3.02e-28	Body mass index;
LGG	cis	rs12286929	0.644	rs3793957	chr11:115095654	C/T	cg04055981	chr11:115044050	NA	0.37	6.88	0.3	1.99e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4740619	0.870	rs10962064	chr9:15545737	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.82	-0.42	8.18e-21	Body mass index;
LGG	cis	rs72772090	0.539	rs11748795	chr5:96168056	G/T	cg00188032	chr5:96141721	ERAP1	0.55	7.2	0.32	2.45e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9596863	0.898	rs9568911	chr13:54338082	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.22	0.32	2.16e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9649465	0.935	rs1506641	chr7:123390143	G/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.8	-0.38	2.83e-17	Migraine;
LGG	cis	rs8067545	0.641	rs203466	chr17:19809953	C/G	cg13482628	chr17:19912719	NA	-0.53	-9.6	-0.41	5e-20	Schizophrenia;
LGG	cis	rs12493885	0.585	rs6781145	chr3:153633999	C/A	cg12800244	chr3:153838788	SGEF	-0.58	-6.93	-0.31	1.46e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4742903	1.000	rs2274724	chr9:106860568	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.25	0.36	1.66e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg11890956	chr21:40555474	PSMG1	-0.73	-12.48	-0.5	5.01e-31	Menarche (age at onset);
LGG	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.4	-0.33	6.44e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs77505915	0.512	rs12921808	chr16:75383984	T/C	cg07303275	chr16:75499416	TMEM170A	-0.42	-6.84	-0.3	2.54e-11	Migraine;
LGG	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg03929089	chr4:120376271	NA	0.74	8.51	0.37	2.35e-16	Axial length;
LGG	cis	rs6912958	0.781	rs2207146	chr6:88180641	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.65	-0.37	8.61e-17	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7551222	0.613	rs10900592	chr1:204460681	T/C	cg20240347	chr1:204465584	NA	-0.48	-8.99	-0.39	6.17e-18	Schizophrenia;
LGG	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs11229555	0.645	rs61903159	chr11:58184475	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9649465	1.000	rs2109723	chr7:123325339	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00294572	chr6:26285232	NA	0.41	7.25	0.32	1.72e-12	Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23003290	chr6:158653760	NA	0.46	6.84	0.3	2.46e-11	Gut microbiome composition (summer);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02083259	chr16:57220135	RSPRY1;FAM192A	0.4	7.18	0.32	2.88e-12	Obesity-related traits;
LGG	cis	rs701145	0.585	rs1727893	chr3:153849866	A/C	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.61	-0.47	1.59e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg03563238	chr19:33554763	RHPN2	0.46	10.49	0.44	3.17e-23	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4363385	0.818	rs454993	chr1:153008992	C/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg12923728	chr3:195709715	SDHAP1	0.53	8.14	0.35	3.72e-15	Red cell distribution width;
LGG	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg17145862	chr1:211918768	LPGAT1	0.79	17.09	0.62	4.2e-51	Leprosy;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg21724239	chr8:58056113	NA	0.5	7.58	0.33	1.87e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.625	rs2390203	chr7:19970430	C/T	cg05791153	chr7:19748676	TWISTNB	-0.47	-6.82	-0.3	2.92e-11	Night sleep phenotypes;
LGG	cis	rs17433780	1.000	rs17433780	chr1:89474818	C/T	cg09516651	chr1:89888402	LOC400759	-0.71	-16.07	-0.6	1.63e-46	Carotid intima media thickness;
LGG	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg06634786	chr22:41940651	POLR3H	-0.57	-9.44	-0.4	1.79e-19	Vitiligo;
LGG	cis	rs72781680	0.715	rs72796332	chr2:24142060	G/A	cg08917208	chr2:24149416	ATAD2B	0.66	8.67	0.37	7.33e-17	Lymphocyte counts;
LGG	cis	rs73086581	0.947	rs56123574	chr20:3878081	C/G	cg02187196	chr20:3869020	PANK2	0.9	12.68	0.51	7.87e-32	Response to antidepressants in depression;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.66	0.34	1.1e-13	Lung cancer;
LGG	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.66	-0.37	7.87e-17	Retinal vascular caliber;
LGG	cis	rs11608355	0.515	rs2241204	chr12:109972037	G/A	cg05360138	chr12:110035743	NA	0.84	12.05	0.49	2.81e-29	Neuroticism;
LGG	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.58e-15	Retinal vascular caliber;
LGG	cis	rs4262150	0.883	rs72799172	chr5:152148371	A/G	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16514818	chr2:242766284	NA	0.41	7.32	0.32	1.11e-12	Body fat percentage;
LGG	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg08250081	chr4:10125330	NA	-0.43	-8.64	-0.37	9e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg14154082	chr13:112174009	NA	0.39	8.36	0.36	7.36e-16	Menarche (age at onset);
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg05861140	chr6:150128134	PCMT1	-0.31	-7.01	-0.31	8.52e-12	Testicular germ cell tumor;
LGG	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4363385	0.600	rs10888532	chr1:153063407	C/A	cg07796016	chr1:152779584	LCE1C	-0.41	-6.65	-0.3	8.24e-11	Inflammatory skin disease;
LGG	cis	rs4888378	0.600	rs729109	chr16:75316074	A/G	cg07303275	chr16:75499416	TMEM170A	-0.44	-7.12	-0.31	4.02e-12	Coronary artery disease;
LGG	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18876405	chr7:65276391	NA	0.49	8.8	0.38	2.83e-17	Aortic root size;
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.3e-19	Menopause (age at onset);
LGG	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg03709012	chr19:19516395	GATAD2A	0.8	14.97	0.57	1.37e-41	Tonsillectomy;
LGG	cis	rs8072100	0.840	rs12453233	chr17:45454570	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-10.57	-0.44	1.55e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg21100191	chr22:23484243	RTDR1	1.0	22.87	0.73	5.0899999999999995e-78	Bone mineral density;
LGG	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg02023728	chr11:77925099	USP35	0.39	6.81	0.3	3.14e-11	Alzheimer's disease (survival time);
LGG	cis	rs9596863	0.898	rs9568915	chr13:54341214	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.18	0.32	2.84e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg13010199	chr12:38710504	ALG10B	0.59	10.74	0.45	3.6e-24	Morning vs. evening chronotype;
LGG	cis	rs1555322	1.000	rs2425037	chr20:33856429	A/T	cg17927777	chr20:33865990	NA	-0.61	-6.77	-0.3	4.03e-11	Attention deficit hyperactivity disorder;
LGG	trans	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-29.57	-0.81	9.88e-109	Exhaled nitric oxide output;
LGG	trans	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg26384229	chr12:38710491	ALG10B	0.59	11.11	0.46	1.42e-25	Morning vs. evening chronotype;
LGG	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.46	-8.52	-0.37	2.32e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-7.58	-0.33	1.89e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7100689	0.784	rs4934139	chr10:82177023	C/A	cg01528321	chr10:82214614	TSPAN14	1.04	19.93	0.68	2.83e-64	Post bronchodilator FEV1;
LGG	cis	rs9397585	0.637	rs6901945	chr6:153399655	T/C	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg18252515	chr7:66147081	NA	1.27	16.86	0.62	4.53e-50	Diabetic kidney disease;
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26617929	chr16:1858877	NA	-0.62	-8.69	-0.37	6.34e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs5753037	0.543	rs140126	chr22:30147038	A/G	cg01021169	chr22:30184971	ASCC2	-0.37	-7.13	-0.31	3.9e-12	Type 1 diabetes;
LGG	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg26031613	chr14:104095156	KLC1	-0.61	-9.6	-0.41	5.13e-20	Reticulocyte count;
LGG	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg02549819	chr16:58548995	SETD6	1.45	13.95	0.54	3.49e-37	Schizophrenia;
LGG	cis	rs7202877	0.706	rs247434	chr16:75445304	G/A	cg03315344	chr16:75512273	CHST6	-0.52	-6.98	-0.31	1.04e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.61	0.33	1.51e-13	Systolic blood pressure;
LGG	cis	rs9972944	0.756	rs6504344	chr17:63756668	C/T	cg07283582	chr17:63770753	CCDC46	-0.4	-7.82	-0.34	3.7e-14	Total body bone mineral density;
LGG	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	9.29e-26	Colorectal cancer;
LGG	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.31	-0.43	1.46e-22	Schizophrenia;
LGG	cis	rs892961	0.806	rs312910	chr17:75413961	A/C	cg05865280	chr17:75406074	SEPT9	0.42	9.83	0.42	7.76e-21	Airflow obstruction;
LGG	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg00071950	chr4:10020882	SLC2A9	0.44	9.29	0.4	5.85e-19	Bone mineral density;
LGG	cis	rs7639513	0.591	rs9849171	chr3:12622623	G/C	cg23032965	chr3:12705835	RAF1	0.77	14.69	0.56	2.18e-40	Itch intensity from mosquito bite;
LGG	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.01	0.52	3.3e-33	Colorectal cancer;
LGG	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.4	0.33	6.55e-13	Total cholesterol levels;
LGG	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.14	-0.31	3.65e-12	Neuroticism;
LGG	cis	rs7264396	0.635	rs6060688	chr20:34516731	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.5	-7.41	-0.33	5.86e-13	Total cholesterol levels;
LGG	cis	rs11971779	0.650	rs10085842	chr7:139064582	A/G	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.35e-12	Diisocyanate-induced asthma;
LGG	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg25457927	chr22:38595422	NA	-0.38	-8.78	-0.38	3.06e-17	Breast cancer;
LGG	cis	rs357618	1.000	rs165352	chr5:150856107	T/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.77	-0.3	3.81e-11	Basophil percentage of white cells;
LGG	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs11966931	1.000	rs17589215	chr6:108147664	C/T	cg04749840	chr6:108095067	SCML4	0.4	6.96	0.31	1.16e-11	Neutrophil percentage of white cells;
LGG	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg09818912	chr17:20140352	CYTSB	-0.34	-8.07	-0.35	6.2e-15	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.01	0.42	1.8e-21	Height;
LGG	cis	rs2797369	0.545	rs705594	chr6:101295168	A/G	cg27451362	chr6:101846650	GRIK2	0.67	9.16	0.39	1.72e-18	Renal function-related traits (eGRFcrea);
LGG	trans	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg06521331	chr12:34319734	NA	0.43	7.64	0.33	1.23e-13	Heart rate;
LGG	cis	rs7789940	0.809	rs12533836	chr7:75935622	G/T	cg10167463	chr7:75959203	YWHAG	-0.43	-7.13	-0.31	3.96e-12	Multiple sclerosis;
LGG	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg07777115	chr5:623756	CEP72	-0.63	-8.16	-0.35	3.28e-15	Obesity-related traits;
LGG	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg02269571	chr22:50332266	NA	0.65	10.14	0.43	5.92e-22	Schizophrenia;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg05368731	chr17:41323189	NBR1	0.93	18.01	0.64	2.46e-55	Menopause (age at onset);
LGG	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg21545522	chr1:205238299	TMCC2	0.37	7.07	0.31	5.59e-12	Red blood cell count;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.76	-0.38	3.74e-17	Menopause (age at onset);
LGG	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg27165867	chr14:105738592	BRF1	-0.47	-7.55	-0.33	2.32e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.29	0.36	1.21e-15	Aortic root size;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg19168338	chr16:4465731	CORO7	-0.9	-16.91	-0.62	2.74e-50	Schizophrenia;
LGG	cis	rs12615966	0.932	rs4013898	chr2:105369671	C/T	cg16465502	chr2:105461796	NA	0.91	10.44	0.44	4.87e-23	Pancreatic cancer;
LGG	cis	rs9290877	0.667	rs6801161	chr3:188458169	T/A	cg17392043	chr3:188495102	LPP	-0.42	-7.26	-0.32	1.7e-12	IgE levels;
LGG	cis	rs858239	0.600	rs7787110	chr7:23138474	C/T	cg23682824	chr7:23144976	KLHL7	0.44	7.7	0.34	8.06e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg18357526	chr6:26021779	HIST1H4A	0.61	10.6	0.44	1.24e-23	Blood metabolite levels;
LGG	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg00409905	chr10:38381863	ZNF37A	-0.67	-13.57	-0.53	1.56e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs67460515	0.500	rs9812507	chr3:160723393	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.03	-0.35	8.17e-15	Parkinson's disease;
LGG	cis	rs4789294	0.806	rs7207108	chr17:74413885	C/T	cg27112972	chr17:74378252	NA	0.26	6.73	0.3	4.89e-11	Lymphocyte percentage of white cells;
LGG	cis	rs2172802	0.961	rs7690595	chr4:62464414	A/G	cg04118610	chr4:62707027	LPHN3	-0.53	-8.74	-0.38	4.28e-17	Partial epilepsies;
LGG	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.61	-0.41	4.69e-20	Body mass index;
LGG	trans	rs11165623	0.602	rs4127309	chr1:97006892	T/C	cg10631902	chr5:14652156	NA	-0.47	-10.05	-0.42	1.3e-21	Hip circumference;Waist circumference;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.17	-0.43	4.59e-22	Tonsillectomy;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg05863683	chr7:1912471	MAD1L1	0.46	8.9	0.38	1.23e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-12.44	-0.5	7.63e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7568458	0.837	rs3731827	chr2:85806068	T/C	cg17127132	chr2:85788382	GGCX	0.46	8.13	0.35	3.82e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg05194412	chr2:137003533	NA	0.38	8.28	0.36	1.35e-15	Colorectal cancer;
LGG	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg14993813	chr1:46806288	NSUN4	-0.55	-9.16	-0.39	1.69e-18	Menopause (age at onset);
LGG	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-10.3	-0.43	1.55e-22	Migraine;Coronary artery disease;
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg06558623	chr16:89946397	TCF25	1.11	12.33	0.5	2.02e-30	Skin colour saturation;
LGG	cis	rs7267979	0.932	rs417130	chr20:25458320	T/C	cg06421707	chr20:25228305	PYGB	0.47	9.9	0.42	4.27e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs782590	0.935	rs782649	chr2:55860308	T/C	cg18811423	chr2:55921094	PNPT1	0.89	20.8	0.7	2.47e-68	Metabolic syndrome;
LGG	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-27.16	-0.78	7.18e-98	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.21	0.46	5.5e-26	Homoarginine levels;
LGG	trans	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg11441553	chr12:57614120	NXPH4	-0.66	-7.86	-0.34	2.7e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg22903471	chr2:27725779	GCKR	0.37	8.4	0.36	5.35e-16	Oral cavity cancer;
LGG	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg17971929	chr21:40555470	PSMG1	-0.56	-9.66	-0.41	3.19e-20	Menarche (age at onset);
LGG	cis	rs1953600	0.668	rs7091565	chr10:81913561	A/G	cg04850286	chr10:81895943	PLAC9	-0.34	-7.41	-0.33	6.23e-13	Sarcoidosis;
LGG	cis	rs877282	0.945	rs11253397	chr10:789774	A/G	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16602504	chr2:48132902	FBXO11	0.6	6.76	0.3	4.23e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg00717180	chr2:96193071	NA	0.41	7.29	0.32	1.36e-12	HDL cholesterol;
LGG	cis	rs1595825	1.000	rs73058829	chr2:198871145	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-7.07	-0.31	5.56e-12	Ulcerative colitis;
LGG	cis	rs9290877	0.667	rs9845169	chr3:188457255	G/T	cg17392043	chr3:188495102	LPP	-0.42	-7.26	-0.32	1.7e-12	IgE levels;
LGG	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg09904177	chr6:26538194	HMGN4	-0.45	-6.9	-0.31	1.67e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg07930552	chr6:133119739	C6orf192	1.12	10.14	0.43	5.99e-22	Type 2 diabetes nephropathy;
LGG	cis	rs898097	0.812	rs7406011	chr17:80829980	C/T	cg15369054	chr17:80825471	TBCD	0.59	10.74	0.45	3.55e-24	Breast cancer;
LGG	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg07599136	chr5:415885	AHRR	0.81	11.28	0.46	3.17e-26	Fat distribution (HIV);
LGG	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs7444	0.882	rs5754387	chr22:21974703	C/G	cg11654148	chr22:21984483	YDJC	0.38	7.31	0.32	1.14e-12	Systemic lupus erythematosus;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18830952	chr12:132606769	EP400NL	0.32	6.71	0.3	5.55e-11	Electrocardiographic conduction measures;
LGG	cis	rs752010	0.631	rs4660549	chr1:42088102	A/G	cg06885757	chr1:42089581	HIVEP3	0.86	21.24	0.7	2.03e-70	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg01864069	chr14:103024347	NA	0.67	9.35	0.4	3.63e-19	Platelet count;
LGG	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26952205	chr17:42404036	NA	0.44	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg02549819	chr16:58548995	SETD6	1.45	13.81	0.54	1.37e-36	Schizophrenia;
LGG	cis	rs858239	0.539	rs3950345	chr7:23191114	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.85	0.3	2.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs189798	0.807	rs330909	chr8:8995387	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	6.9	0.31	1.73e-11	Myopia (pathological);
LGG	cis	rs1555322	0.505	rs591590	chr20:33866028	A/G	cg17927777	chr20:33865990	NA	-0.76	-10.6	-0.44	1.15e-23	Attention deficit hyperactivity disorder;
LGG	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg25801113	chr15:45476975	SHF	0.88	20.26	0.69	8.23e-66	Uric acid levels;
LGG	trans	rs11782517	0.883	rs12544801	chr8:10107382	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-6.87	-0.3	2.14e-11	Nose size;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg06719900	chr11:109292894	C11orf87	0.45	7.89	0.34	2.18e-14	Schizophrenia;
LGG	trans	rs73198271	0.632	rs57687880	chr8:8602910	C/T	cg16141378	chr3:129829833	LOC729375	0.36	7.02	0.31	7.89e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg10840412	chr1:235813424	GNG4	0.7	9.42	0.4	2.21e-19	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18262051	chr7:100026182	MEPCE;ZCWPW1	0.47	6.87	0.3	2.06e-11	Gut microbiome composition (summer);
LGG	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg05973401	chr12:123451056	ABCB9	-0.51	-7.67	-0.34	9.98e-14	Neutrophil percentage of white cells;
LGG	cis	rs7666738	0.830	rs7669407	chr4:98750251	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs972578	0.791	rs4822220	chr22:43290583	T/C	cg01576275	chr22:43409880	NA	-0.23	-7.16	-0.32	3.23e-12	Mean platelet volume;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08677398	chr8:58056175	NA	0.47	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3784262	1.000	rs4646622	chr15:58257199	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.45	-0.37	3.92e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06634786	chr22:41940651	POLR3H	0.78	12.83	0.51	1.89e-32	Vitiligo;
LGG	cis	rs7617773	0.780	rs4541431	chr3:48365218	G/C	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg16270222	chr17:41446396	NA	-0.29	-6.97	-0.31	1.08e-11	Menopause (age at onset);
LGG	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	8.44	0.37	4.17e-16	Thyroid stimulating hormone;
LGG	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg24375607	chr4:120327624	NA	0.68	11.23	0.46	4.79e-26	Corneal astigmatism;
LGG	cis	rs2708377	0.858	rs73051630	chr12:11147188	G/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.63	-6.9	-0.31	1.77e-11	Bitter taste perception;
LGG	cis	rs4846580	0.660	rs4846578	chr1:219897709	A/T	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.39e-12	Total body bone mineral density;
LGG	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg07274523	chr3:49395745	GPX1	0.56	9.17	0.39	1.51e-18	Educational attainment;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.31	-0.5	2.52e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7660883	1.000	rs28677145	chr4:87986381	G/A	cg21988461	chr4:88008667	AFF1	-0.31	-8.46	-0.37	3.48e-16	HDL cholesterol levels;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg19168338	chr16:4465731	CORO7	-0.87	-16.17	-0.6	6.17e-47	Schizophrenia;
LGG	cis	rs6763768	0.606	rs931253	chr3:53298604	A/C	cg16894138	chr3:53270350	TKT	0.43	8.05	0.35	7.08e-15	Bacterial meningitis;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04008888	chr11:68622739	NA	-0.56	-12.22	-0.49	5.72e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	trans	rs853679	0.607	rs200489	chr6:27798257	T/C	cg08344181	chr3:125677491	NA	-0.68	-7.92	-0.35	1.73e-14	Depression;
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25427524	chr10:38739819	LOC399744	-0.68	-12.9	-0.51	9.2e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs71403859	0.614	rs12447033	chr16:71583655	G/T	cg08717414	chr16:71523259	ZNF19	-1.12	-15.4	-0.58	1.65e-43	Post bronchodilator FEV1;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg26578617	chr4:90757533	SNCA	-0.46	-9.24	-0.39	8.86e-19	Dementia with Lewy bodies;
LGG	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg04287289	chr16:89883240	FANCA	-0.55	-9.81	-0.41	9.17e-21	Vitiligo;
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.42	-0.44	5.35e-23	Triglycerides;
LGG	cis	rs9733	0.715	rs7534124	chr1:150739073	C/T	cg13175981	chr1:150552382	MCL1	0.54	8.8	0.38	2.81e-17	Tonsillectomy;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12379764	chr21:47803548	PCNT	0.43	7.37	0.32	7.87e-13	Testicular germ cell tumor;
LGG	cis	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg24110177	chr3:50126178	RBM5	0.41	7.01	0.31	8.42e-12	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg17951613	chr5:131705445	SLC22A5	0.63	7.14	0.31	3.68e-12	Rheumatoid arthritis;
LGG	cis	rs7172689	0.866	rs67882884	chr15:81575544	C/T	cg11808699	chr15:81528661	IL16	-0.49	-9.96	-0.42	2.58e-21	Inattentive symptoms;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg04234412	chr22:24373322	LOC391322	0.72	14.58	0.56	6.45e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs937213	0.573	rs3816900	chr15:40302243	C/T	cg22705835	chr10:65332833	REEP3	0.41	7.29	0.32	1.36e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.76	0.3	4.1e-11	Bone mineral density;
LGG	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg21772509	chr8:41503840	NKX6-3	-0.55	-8.47	-0.37	3.31e-16	Type 2 diabetes;
LGG	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg19554555	chr3:13937349	NA	-0.54	-9.8	-0.41	9.73e-21	Ovarian reserve;
LGG	cis	rs2273669	0.667	rs11153139	chr6:109279381	C/T	cg05315195	chr6:109294784	ARMC2	-0.59	-7.79	-0.34	4.59e-14	Prostate cancer;
LGG	cis	rs7107174	1.000	rs10899453	chr11:77997482	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg24623649	chr8:11872141	NA	-0.3	-6.92	-0.31	1.5e-11	Retinal vascular caliber;
LGG	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg06212747	chr3:49208901	KLHDC8B	0.67	11.42	0.47	8.76e-27	Parkinson's disease;
LGG	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg23173402	chr1:227635558	NA	0.6	9.93	0.42	3.28e-21	Major depressive disorder;
LGG	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg04842962	chr6:43655489	MRPS18A	0.81	15.57	0.59	2.83e-44	IgG glycosylation;
LGG	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg11342453	chr6:26196699	NA	-0.51	-6.73	-0.3	4.98e-11	Gout;Renal underexcretion gout;
LGG	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg25358565	chr5:93447407	FAM172A	1.37	16.87	0.62	4.1e-50	Diabetic retinopathy;
LGG	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg18252515	chr7:66147081	NA	-1.42	-19.61	-0.67	8.73e-63	Diabetic kidney disease;
LGG	cis	rs9640161	0.783	rs1132261	chr7:150059987	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.58	-10.67	-0.44	6.62e-24	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9400467	0.537	rs449308	chr6:111480395	A/C	cg15721981	chr6:111408429	SLC16A10	-0.54	-6.66	-0.3	7.85e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg14159672	chr1:205819179	PM20D1	-0.47	-8.77	-0.38	3.37e-17	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.78	-0.69	2.96e-68	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg06636001	chr8:8085503	FLJ10661	0.57	10.27	0.43	2e-22	Retinal vascular caliber;
LGG	cis	rs10991814	0.920	rs10512211	chr9:94104260	C/G	cg14446406	chr9:93919335	NA	-0.68	-7.66	-0.34	1.09e-13	Neutrophil percentage of granulocytes;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.86	0.38	1.78e-17	Alzheimer's disease;
LGG	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg15556689	chr8:8085844	FLJ10661	0.51	8.83	0.38	2.19e-17	Retinal vascular caliber;
LGG	cis	rs365132	0.870	rs2454949	chr5:176466011	G/A	cg16309518	chr5:176445507	NA	-0.55	-12.27	-0.5	3.81e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs7789940	1.000	rs76024966	chr7:75995021	C/T	cg10167463	chr7:75959203	YWHAG	-0.45	-7.58	-0.33	1.96e-13	Multiple sclerosis;
LGG	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg07382826	chr16:28625726	SULT1A1	0.35	7.33	0.32	1.02e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg05096777	chr10:104283225	SUFU	0.32	6.81	0.3	2.97e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20560182	chr5:140700478	TAF7	0.45	7.54	0.33	2.59e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg08120226	chr3:195531633	MUC4	0.5	7.94	0.35	1.55e-14	Lung disease severity in cystic fibrosis;
LGG	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg05696931	chr1:227175867	NA	-0.36	-6.96	-0.31	1.14e-11	Myeloid white cell count;
LGG	cis	rs11676855	0.924	rs11680626	chr2:235927511	A/T	cg14917874	chr2:235941519	SH3BP4	-0.61	-11.63	-0.48	1.33e-27	Dialysis-related mortality;
LGG	trans	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg18187862	chr3:45730750	SACM1L	-0.58	-9.51	-0.4	1.06e-19	Primary sclerosing cholangitis;
LGG	cis	rs17221829	0.562	rs10830306	chr11:89366979	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs28374715	0.783	rs11635269	chr15:41570710	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.28	-27.9	-0.79	3.27e-101	Ulcerative colitis;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs763121	1.000	rs86796	chr22:38881454	A/C	cg06022373	chr22:39101656	GTPBP1	-0.81	-16.09	-0.6	1.36e-46	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.19	0.32	2.58e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4474465	0.790	rs6592784	chr11:78234790	C/T	cg27205649	chr11:78285834	NARS2	0.5	8.48	0.37	3.15e-16	Alzheimer's disease (survival time);
LGG	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg08999081	chr20:33150536	PIGU	0.4	10.05	0.42	1.22e-21	Coronary artery disease;
LGG	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg06618935	chr21:46677482	NA	-0.5	-9.75	-0.41	1.55e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7312933	0.558	rs4768402	chr12:42755576	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.26	-0.36	1.51e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00149659	chr3:10157352	C3orf10	0.81	10.48	0.44	3.44e-23	Alzheimer's disease;
LGG	cis	rs1519814	0.702	rs4871032	chr8:121042074	C/T	cg22335954	chr8:121166405	COL14A1	0.5	9.88	0.42	4.99e-21	Breast cancer;
LGG	cis	rs1065656	0.553	rs344359	chr16:1838640	T/C	cg14074117	chr16:1909714	C16orf73	0.47	6.84	0.3	2.46e-11	Insulin-like growth factors;
LGG	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.31	0.5	2.44e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg12798833	chr22:18958832	DGCR5	0.51	8.74	0.38	4.33e-17	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6732160	0.588	rs1430344	chr2:73373344	G/A	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs35160687	0.901	rs12622200	chr2:86498595	A/G	cg10973622	chr2:86423274	IMMT	-0.39	-6.75	-0.3	4.56e-11	Night sleep phenotypes;
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02018176	chr4:1364513	KIAA1530	0.64	15.83	0.59	1.94e-45	Longevity;
LGG	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg23188684	chr11:67383651	NA	-0.41	-6.75	-0.3	4.45e-11	Mean corpuscular volume;
LGG	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-10.71	-0.45	4.73e-24	Bipolar disorder;
LGG	cis	rs9807989	0.507	rs2160201	chr2:103033961	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs4731207	0.594	rs6968500	chr7:124431722	G/C	cg05630886	chr7:124431682	NA	-0.36	-8.57	-0.37	1.54e-16	Cutaneous malignant melanoma;
LGG	trans	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg25214090	chr10:38739885	LOC399744	0.71	12.56	0.5	2.38e-31	Corneal astigmatism;
LGG	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg20848291	chr7:100343083	ZAN	-0.61	-8.5	-0.37	2.57e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6598955	0.543	rs6699798	chr1:26556442	G/T	cg04990556	chr1:26633338	UBXN11	0.71	10.46	0.44	3.83e-23	Obesity-related traits;
LGG	cis	rs7712401	0.601	rs30035	chr5:122278545	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Gut microbiome composition (summer);
LGG	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg03078520	chr22:18463400	MICAL3	-0.67	-14.34	-0.55	7.47e-39	Presence of antiphospholipid antibodies;
LGG	cis	rs4731207	0.596	rs13234368	chr7:124676054	A/C	cg05630886	chr7:124431682	NA	-0.31	-7.11	-0.31	4.45e-12	Cutaneous malignant melanoma;
LGG	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg26150922	chr2:100937072	LONRF2	-0.58	-10.93	-0.45	6.82e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9399135	1.000	rs35123050	chr6:135302740	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.38e-19	Red blood cell count;
LGG	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.4e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg20887711	chr4:1340912	KIAA1530	0.9	19.87	0.68	5.59e-64	Longevity;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs28647808	0.881	rs28494844	chr9:136266188	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs7186831	1	rs7186831	chr16:75473155	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.0	0.42	1.89e-21	Chronic obstructive pulmonary disease;
LGG	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.52	-0.37	2.25e-16	Retinal vascular caliber;
LGG	cis	rs4788570	0.584	rs9934301	chr16:71756845	C/G	cg06353428	chr16:71660113	MARVELD3	1.28	20.54	0.69	4.07e-67	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	1.000	rs1716683	chr3:41923074	A/G	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.05e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-11.44	-0.47	7.65e-27	Chronic sinus infection;
LGG	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg10621924	chr7:39171070	POU6F2	-0.42	-8.29	-0.36	1.22e-15	IgG glycosylation;
LGG	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg05484508	chr16:89589025	SPG7	0.47	7.62	0.33	1.45e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg16950941	chr11:66035639	RAB1B	-0.47	-7.35	-0.32	9.27e-13	Electroencephalogram traits;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg12070911	chr6:150209640	RAET1E	0.3	7.12	0.31	4.21e-12	Lung cancer;
LGG	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg14228332	chr4:119757509	SEC24D	0.99	10.17	0.43	4.45e-22	Cannabis dependence symptom count;
LGG	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.8	-0.3	3.22e-11	Lymphocyte percentage of white cells;
LGG	cis	rs3767633	0.925	rs1806594	chr1:161858860	T/C	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.52	-0.33	2.93e-13	Total cholesterol levels;
LGG	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-9.89	-0.42	4.63e-21	Common traits (Other);
LGG	cis	rs988958	0.565	rs6737944	chr2:42226621	G/A	cg27252766	chr2:42229092	NA	0.59	7.94	0.35	1.57e-14	Hypospadias;
LGG	cis	rs17818399	0.612	rs4952834	chr2:46777462	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-11.07	-0.46	2.01e-25	Height;
LGG	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg08885076	chr2:99613938	TSGA10	-0.56	-11.44	-0.47	7.65e-27	Chronic sinus infection;
LGG	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-13.04	-0.52	2.45e-33	Morning vs. evening chronotype;
LGG	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg08601574	chr20:25228251	PYGB	-0.36	-7.29	-0.32	1.36e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg13453750	chr1:205783389	SLC41A1	-0.4	-7.76	-0.34	5.48e-14	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg03060546	chr3:49711283	APEH	0.59	8.35	0.36	7.71e-16	Menarche (age at onset);
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.79	-0.38	2.97e-17	Personality dimensions;
LGG	cis	rs225245	0.817	rs2301730	chr17:33998683	A/G	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs12042938	1.000	rs823158	chr1:231782650	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	10.68	0.44	6.11e-24	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03517284	chr6:25882590	NA	-0.56	-10.62	-0.44	1.01e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg25356066	chr3:128598488	ACAD9	0.44	6.69	0.3	6.45e-11	IgG glycosylation;
LGG	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.1	-0.46	1.51e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs5742933	0.817	rs2033870	chr2:190603830	A/G	cg04003228	chr2:190539410	ANKAR	0.48	7.05	0.31	6.5e-12	Ferritin levels;
LGG	cis	rs10046574	0.561	rs9656458	chr7:135202300	G/A	cg27474649	chr7:135195673	CNOT4	0.74	8.97	0.38	7.15e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs67311347	1.000	rs13324109	chr3:40460767	T/C	cg13683864	chr3:40499215	RPL14	-0.98	-20.23	-0.68	1.17e-65	Renal cell carcinoma;
LGG	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs10865541	0.935	rs12999423	chr2:3392513	T/C	cg11642891	chr2:3452563	TTC15	-0.39	-7.34	-0.32	9.98e-13	Obesity-related traits;
LGG	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg08079166	chr15:68083412	MAP2K5	-0.35	-7.84	-0.34	3.09e-14	Restless legs syndrome;
LGG	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg03709012	chr19:19516395	GATAD2A	0.93	13.6	0.53	1.08e-35	Nonalcoholic fatty liver disease;
LGG	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg15704280	chr7:45808275	SEPT13	-0.91	-18.98	-0.66	7.5e-60	Coronary artery disease;
LGG	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg10295955	chr4:187884368	NA	-1.16	-31.63	-0.83	8.47e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg00647317	chr7:50633725	DDC	0.47	11.46	0.47	5.96e-27	Systemic sclerosis;
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19723775	chr5:179050963	HNRNPH1	-0.47	-7.44	-0.33	5.06e-13	Lung cancer;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.31	0.43	1.38e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg02725872	chr8:58115012	NA	-0.86	-11.81	-0.48	2.6e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.679	rs10899537	chr11:78222424	C/G	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs986417	0.901	rs8020867	chr14:61093246	A/T	cg27398547	chr14:60952738	C14orf39	0.75	7.49	0.33	3.47e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg14927855	chr7:155151427	NA	0.6	10.8	0.45	2.07e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8067287	0.708	rs56408153	chr17:16841034	G/C	cg26910001	chr17:16838321	NA	-0.5	-9.5	-0.4	1.12e-19	Diabetic kidney disease;
LGG	cis	rs2777491	0.574	rs316611	chr15:41751678	A/G	cg18705301	chr15:41695430	NDUFAF1	1.33	32.54	0.83	1.07e-121	Ulcerative colitis;
LGG	cis	rs2120243	0.539	rs7629293	chr3:157114462	C/T	cg24825693	chr3:157122686	VEPH1	-0.58	-13.56	-0.53	1.62e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg03929089	chr4:120376271	NA	-0.69	-10.83	-0.45	1.6e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg06917634	chr15:78832804	PSMA4	0.65	11.56	0.47	2.41e-27	Sudden cardiac arrest;
LGG	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.07	0.66	3.03e-60	Smoking behavior;
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs897080	0.515	rs1067334	chr2:44626633	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.8	-0.3	3.25e-11	Height;
LGG	cis	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg08112188	chr17:47440006	ZNF652	1.33	15.72	0.59	6.2e-45	Prostate cancer;
LGG	cis	rs1062746	0.771	rs9308348	chr16:87371941	G/A	cg02258303	chr16:87377426	FBXO31	-0.6	-11.8	-0.48	2.79e-28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg06766960	chr11:133703094	NA	-0.55	-11.13	-0.46	1.19e-25	Childhood ear infection;
LGG	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg00666640	chr1:248458726	OR2T12	0.59	9.67	0.41	2.88e-20	Common traits (Other);
LGG	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.14	0.31	3.74e-12	Refractive error;
LGG	cis	rs1577917	0.559	rs2223788	chr6:86811920	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	9.6e-16	Response to antipsychotic treatment;
LGG	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg10840412	chr1:235813424	GNG4	-0.54	-7.45	-0.33	4.69e-13	Bipolar disorder;
LGG	cis	rs7712401	0.601	rs431878	chr5:122261791	G/T	cg19412675	chr5:122181750	SNX24	-0.42	-6.98	-0.31	1.04e-11	Mean platelet volume;
LGG	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.86	-0.3	2.24e-11	Alzheimer's disease (survival time);
LGG	cis	rs504918	0.584	rs4420813	chr3:123990232	A/G	cg05766129	chr3:123988013	KALRN	-0.63	-11.45	-0.47	6.54e-27	Schizophrenia;
LGG	cis	rs62238980	0.614	rs1475996	chr22:32464980	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs10046574	0.517	rs7782727	chr7:135200299	A/G	cg27474649	chr7:135195673	CNOT4	0.75	9.02	0.39	5.07e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6087990	0.806	rs2424918	chr20:31382770	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	19.66	0.67	5.24e-63	Ulcerative colitis;
LGG	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg13852791	chr20:30311386	BCL2L1	0.7	10.27	0.43	1.96e-22	Mean corpuscular hemoglobin;
LGG	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg05793240	chr7:2802953	GNA12	-0.29	-7.23	-0.32	1.98e-12	Height;
LGG	cis	rs17776563	1.000	rs11638818	chr15:89119711	C/T	cg05013243	chr15:89149849	MIR1179	-0.52	-10.51	-0.44	2.5e-23	Thyroid hormone levels;
LGG	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg20387954	chr3:183756860	HTR3D	0.69	14.03	0.55	1.66e-37	Anterior chamber depth;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg10207240	chr12:122356781	WDR66	0.27	8.06	0.35	6.43e-15	Mean corpuscular volume;
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg22072935	chr14:105399595	NA	0.53	10.18	0.43	4.38e-22	Rheumatoid arthritis;
LGG	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.65	10.39	0.43	7.17e-23	Chronic sinus infection;
LGG	cis	rs140244541	1	rs140244541	chr2:203808532	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.69	8.86	0.38	1.68e-17	LDL cholesterol;
LGG	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.84	0.42	6.94e-21	Coronary artery disease;
LGG	cis	rs6066825	0.569	rs2281288	chr20:47343460	T/G	cg18078177	chr20:47281410	PREX1	0.46	7.59	0.33	1.83e-13	Colorectal cancer;
LGG	cis	rs2334880	0.641	rs12325234	chr16:71459628	A/T	cg06353428	chr16:71660113	MARVELD3	-0.8	-11.16	-0.46	9.3e-26	Malaria;
LGG	trans	rs2975734	0.680	rs10503406	chr8:10108972	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.67	-0.34	1e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.72	-0.34	7.48e-14	Systemic lupus erythematosus;
LGG	trans	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.77	-0.34	5.22e-14	Resting heart rate;
LGG	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg02811702	chr13:24901961	NA	0.42	7.86	0.34	2.77e-14	Obesity-related traits;
LGG	cis	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg07460842	chr6:66804631	NA	0.73	12.59	0.51	1.78e-31	Type 2 diabetes;
LGG	cis	rs7209395	0.500	rs874618	chr17:64130204	C/T	cg19474267	chr17:64306194	PRKCA	0.57	11.32	0.47	2.16e-26	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs2237234	1.000	rs2237234	chr6:26391394	G/A	cg12826209	chr6:26865740	GUSBL1	0.45	6.72	0.3	5.25e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs26868	0.746	rs27381	chr16:2239402	C/T	cg25665528	chr16:2260870	C16orf79	-0.36	-7.77	-0.34	5.25e-14	Height;
LGG	cis	rs11792861	0.816	rs7027263	chr9:111699569	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.33	0.43	1.23e-22	Menarche (age at onset);
LGG	cis	rs4466137	0.830	rs10039752	chr5:82974532	G/A	cg16102102	chr5:83017553	HAPLN1	-0.59	-11.22	-0.46	5.39e-26	Prostate cancer;
LGG	cis	rs10937275	0.590	rs116050195	chr3:186672937	G/A	cg24050613	chr3:186648279	ST6GAL1	0.82	8.71	0.38	5.57e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.65	11.77	0.48	3.67e-28	Longevity;
LGG	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg25706281	chr1:46860511	FAAH	-0.3	-7.2	-0.32	2.39e-12	Menopause (age at onset);
LGG	trans	rs12543645	0.525	rs4349986	chr8:10278851	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.64	0.33	1.3e-13	Schizophrenia;
LGG	cis	rs9815354	0.868	rs1716653	chr3:41975598	C/A	cg03022575	chr3:42003672	ULK4	-0.68	-8.74	-0.38	4.19e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	14.69	0.56	2.19e-40	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.57	0.37	1.57e-16	Schizophrenia;
LGG	cis	rs6542838	0.580	rs1607256	chr2:99543444	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.04	-0.31	6.93e-12	Fear of minor pain;
LGG	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.4e-12	Colorectal cancer;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.24	0.39	8.77e-19	Height;
LGG	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg19404813	chr2:208988932	CRYGD	0.31	7.01	0.31	8.69e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.42	-0.47	8.71e-27	Lung cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26014017	chr1:38019849	SNIP1	0.39	7.07	0.31	5.61e-12	Obesity-related traits;
LGG	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.62e-13	Platelet count;
LGG	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg25664220	chr3:72788482	NA	-0.29	-7.93	-0.35	1.68e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg18446336	chr7:2847575	GNA12	-0.4	-10.75	-0.45	3.24e-24	Height;
LGG	cis	rs6920372	0.748	rs2025147	chr6:110070767	A/G	cg16315928	chr6:109776240	MICAL1	0.43	7.46	0.33	4.41e-13	Height;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06028808	chr11:68637592	NA	0.73	12.34	0.5	2e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg15595755	chr5:1867978	NA	0.52	10.26	0.43	2.17e-22	Cardiovascular disease risk factors;
LGG	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg05182265	chr7:156933206	UBE3C	-0.37	-7.48	-0.33	3.74e-13	Body mass index;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg21963583	chr11:68658836	MRPL21	0.59	9.74	0.41	1.63e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.56	11.18	0.46	7.7e-26	Obesity-related traits;
LGG	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.64	0.3	8.61e-11	Vitiligo;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.72	-0.3	5.5e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1018836	0.631	rs9987164	chr8:91470910	T/G	cg16814680	chr8:91681699	NA	-0.61	-10.18	-0.43	4.26e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs1577917	0.523	rs1413724	chr6:86814549	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.65	-0.3	8.23e-11	Response to antipsychotic treatment;
LGG	cis	rs9612	0.718	rs173202	chr19:44253588	C/T	cg08581076	chr19:44259116	C19orf61	0.47	8.29	0.36	1.23e-15	Exhaled nitric oxide output;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg05896524	chr21:47604654	C21orf56	-0.53	-8.77	-0.38	3.52e-17	Testicular germ cell tumor;
LGG	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs9354308	0.764	rs9354319	chr6:66583656	A/G	cg07460842	chr6:66804631	NA	-0.41	-7.03	-0.31	7.46e-12	Metabolite levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24904084	chr5:14653382	NA	-0.55	-6.84	-0.3	2.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs67996804	chr6:96884387	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.69	0.56	2.3e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs2463822	0.669	rs72919480	chr11:62043133	G/A	cg06239285	chr11:62104954	ASRGL1	-1.13	-13.72	-0.54	3.34e-36	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2267681	0.544	rs2361644	chr7:139516316	G/A	cg14116596	chr7:139528673	TBXAS1	0.32	7.05	0.31	6.43e-12	Cervical cancer;
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg20120463	chr17:44301886	NA	-0.45	-6.81	-0.3	3.13e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	9.26	0.4	7.52e-19	Systolic blood pressure;
LGG	cis	rs2865126	0.743	rs8084621	chr18:10749429	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-7.48	-0.33	3.64e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	trans	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.96	0.31	1.18e-11	Retinal vascular caliber;
LGG	cis	rs9972944	0.902	rs10512504	chr17:63772091	C/T	cg07283582	chr17:63770753	CCDC46	0.43	8.34	0.36	8.32e-16	Total body bone mineral density;
LGG	cis	rs3789045	0.837	rs57450685	chr1:204580832	A/T	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.66	-0.37	7.73e-17	Educational attainment (college completion);
LGG	cis	rs8049040	0.967	rs7203200	chr16:71465613	T/G	cg08717414	chr16:71523259	ZNF19	-0.41	-6.8	-0.3	3.22e-11	Blood protein levels;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.67e-17	Testicular germ cell tumor;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.52	0.33	2.93e-13	Lung cancer;
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg22907277	chr7:1156413	C7orf50	-0.47	-8.13	-0.35	3.88e-15	Longevity;Endometriosis;
LGG	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg13147721	chr7:65941812	NA	-0.71	-9.45	-0.4	1.63e-19	Diabetic kidney disease;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.43	-9.09	-0.39	3e-18	Schizophrenia;
LGG	cis	rs7558370	1.000	rs72769383	chr2:3720836	C/A	cg17046650	chr2:3699563	NA	0.71	7.22	0.32	2.13e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg22398616	chr13:53314203	LECT1	-0.35	-6.9	-0.31	1.71e-11	Lewy body disease;
LGG	cis	rs75059851	0.756	rs11223647	chr11:133839588	G/A	cg17703048	chr11:133852993	NA	-0.87	-16.06	-0.6	1.94e-46	Schizophrenia;
LGG	cis	rs12368653	0.651	rs2277326	chr12:58202419	A/C	cg02175503	chr12:58329896	NA	0.44	7.05	0.31	6.56e-12	Multiple sclerosis;
LGG	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.37	0.47	1.35e-26	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.03e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs67311347	1.000	rs9332450	chr3:40458041	C/T	cg13683864	chr3:40499215	RPL14	0.97	19.97	0.68	1.84e-64	Renal cell carcinoma;
LGG	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10493773	0.618	rs17394091	chr1:86075098	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.16	-0.32	3.22e-12	Urate levels in overweight individuals;
LGG	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg19445457	chr11:5799446	OR52N5	-0.41	-6.85	-0.3	2.32e-11	DNA methylation (variation);
LGG	trans	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg06521331	chr12:34319734	NA	-0.51	-9.42	-0.4	2.22e-19	Bladder cancer;
LGG	cis	rs4566357	0.964	rs6436648	chr2:227923004	C/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	cis	rs2028299	1.000	rs4932148	chr15:90394356	C/T	cg23731826	chr15:90371692	NA	0.37	8.82	0.38	2.42e-17	Type 2 diabetes;
LGG	cis	rs2251666	0.514	rs2271135	chr16:4929392	A/G	cg08329684	chr16:4932620	PPL	0.46	6.69	0.3	6.54e-11	Cancer;
LGG	cis	rs4629710	0.592	rs9492865	chr6:131534403	T/A	cg12606694	chr6:131520996	AKAP7	0.52	8.46	0.37	3.43e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs2455601	0.744	rs11042133	chr11:8966511	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.72	-12.26	-0.49	4.22e-30	Schizophrenia;
LGG	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22857025	chr5:266934	NA	-1.47	-25.35	-0.76	1.55e-89	Breast cancer;
LGG	cis	rs17826219	0.789	rs4794873	chr17:28748352	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.64	-7.98	-0.35	1.15e-14	Body mass index;
LGG	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.04	-0.31	7e-12	Neuroticism;
LGG	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.79	-0.3	3.54e-11	Coronary artery disease;
LGG	cis	rs4740619	0.782	rs62573118	chr9:15702540	C/A	cg14451791	chr9:16040625	NA	0.33	8.46	0.37	3.44e-16	Body mass index;
LGG	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.2	-0.46	6.3e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg24812749	chr6:127587940	RNF146	0.53	8.75	0.38	4.04e-17	Breast cancer;
LGG	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs7267979	1.000	rs2257809	chr20:25266476	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.28	0.43	1.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg11494091	chr17:61959527	GH2	0.56	9.07	0.39	3.47e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg16885296	chr6:26284938	NA	0.39	8.48	0.37	3.04e-16	Educational attainment;
LGG	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00294572	chr6:26285232	NA	0.4	6.91	0.31	1.65e-11	Educational attainment;
LGG	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.1	-0.49	1.72e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7918232	0.800	rs7907981	chr10:27444329	T/C	cg14442939	chr10:27389572	ANKRD26	0.79	13.92	0.54	4.97e-37	Breast cancer;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.16	0.35	3.2e-15	Prostate cancer;
LGG	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24110177	chr3:50126178	RBM5	0.55	10.08	0.42	9.9700000000000009e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.13	-0.31	3.95e-12	Monocyte percentage of white cells;
LGG	cis	rs11700980	0.636	rs17797032	chr21:30265585	G/A	cg08807101	chr21:30365312	RNF160	-0.67	-7.5	-0.33	3.32e-13	QRS complex (12-leadsum);
LGG	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg21948465	chr5:131705150	SLC22A5	-0.64	-7.08	-0.31	5.34e-12	Rheumatoid arthritis;
LGG	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.62	-0.44	9.89e-24	Aortic root size;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-7.44	-0.33	4.89e-13	Longevity;
LGG	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs4262150	0.641	rs4958586	chr5:152248567	G/A	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	10.19	0.43	3.79e-22	Triglycerides;
LGG	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-8.68	-0.37	6.59e-17	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg00666640	chr1:248458726	OR2T12	0.62	10.0	0.42	1.85e-21	Common traits (Other);
LGG	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg15212455	chr7:39170539	POU6F2	0.51	11.99	0.49	4.93e-29	IgG glycosylation;
LGG	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg07308232	chr7:1071921	C7orf50	-0.45	-8.27	-0.36	1.42e-15	Longevity;Endometriosis;
LGG	cis	rs763121	0.853	rs4821809	chr22:39065743	G/C	cg06022373	chr22:39101656	GTPBP1	0.88	17.67	0.63	8.35e-54	Menopause (age at onset);
LGG	cis	rs2802728	1.000	rs2802728	chr1:243518151	C/T	cg05593162	chr1:243577377	SDCCAG8	-0.48	-6.87	-0.3	2.13e-11	Toenail selenium levels;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg07747251	chr5:1868357	NA	0.44	8.96	0.38	8.02e-18	Cardiovascular disease risk factors;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12290896	chr5:96038388	CAST	0.5	7.93	0.35	1.67e-14	Gut microbiome composition (summer);
LGG	cis	rs981844	1.000	rs17298985	chr4:154664261	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.81	0.48	2.58e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg24623649	chr8:11872141	NA	0.3	6.73	0.3	5.13e-11	Myopia (pathological);
LGG	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21659725	chr3:3221576	CRBN	0.74	11.73	0.48	5.23e-28	Resting heart rate;
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	trans	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.78	-0.34	4.81e-14	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03392679	chr3:71773917	EIF4E3	-0.4	-6.81	-0.3	3.01e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10186029	0.582	rs1992395	chr2:214003871	G/T	cg08319019	chr2:214017104	IKZF2	-0.4	-7.11	-0.31	4.44e-12	Systemic sclerosis;
LGG	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs13102973	0.645	rs7692242	chr4:135886041	A/G	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs870825	0.616	rs28608669	chr4:185632890	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.95	0.73	2.07e-78	Blood protein levels;
LGG	cis	rs7932354	0.798	rs2282686	chr11:46750638	T/C	cg03339077	chr11:47165057	C11orf49	0.41	6.99	0.31	9.38e-12	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	24.21	0.75	2.92e-84	IgG glycosylation;
LGG	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg08305652	chr11:111469057	NA	-0.46	-9.31	-0.4	5.3e-19	Primary sclerosing cholangitis;
LGG	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg03929089	chr4:120376271	NA	-1.03	-24.71	-0.75	1.43e-86	Height;
LGG	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.83	0.38	2.15e-17	Motion sickness;
LGG	cis	rs7444	0.941	rs2298429	chr22:21983260	A/G	cg05046821	chr22:21984468	YDJC	-0.38	-6.9	-0.31	1.77e-11	Systemic lupus erythematosus;
LGG	cis	rs17221829	0.673	rs10830334	chr11:89403921	A/G	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.69	-0.37	6.17e-17	Anxiety in major depressive disorder;
LGG	cis	rs11166927	1.000	rs11778622	chr8:140805582	A/G	cg16909799	chr8:140841666	TRAPPC9	0.59	12.3	0.5	2.9e-30	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg06074448	chr4:187884817	NA	-0.59	-13.16	-0.52	8.26e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06028808	chr11:68637592	NA	0.69	11.86	0.48	1.56e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6868223	0.617	rs10042292	chr5:33648317	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.51	0.58	5.52e-44	Mortality in heart failure;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg05335186	chr13:53173507	NA	0.75	18.86	0.66	2.75e-59	Lewy body disease;
LGG	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.54	7.75	0.34	6.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs77972916	0.561	rs13411629	chr2:43566990	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-6.91	-0.31	1.66e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs283228	0.550	rs1385762	chr6:101811976	T/C	cg27451362	chr6:101846650	GRIK2	0.96	14.64	0.56	3.53e-40	Coenzyme Q10 levels;
LGG	cis	rs2303319	1.000	rs16845734	chr2:162124590	G/C	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg14159672	chr1:205819179	PM20D1	0.76	16.25	0.6	2.55e-47	Menarche (age at onset);
LGG	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg09855544	chr8:135498122	ZFAT	-0.51	-7.64	-0.33	1.26e-13	Educational attainment;
LGG	cis	rs6840360	0.667	rs2709832	chr4:152379394	C/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg04166393	chr7:2884313	GNA12	0.46	8.57	0.37	1.51e-16	Height;
LGG	cis	rs17453880	0.963	rs6863717	chr5:152027165	G/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg24375607	chr4:120327624	NA	0.52	8.77	0.38	3.47e-17	Corneal astigmatism;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg14338887	chr6:42928500	GNMT	0.27	8.67	0.37	7.53e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg18551225	chr6:44695536	NA	-0.68	-11.29	-0.46	2.92e-26	Total body bone mineral density;
LGG	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg26248373	chr2:1572462	NA	-0.83	-12.98	-0.52	4.7e-33	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17253792	0.822	rs10145687	chr14:56124384	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.51	-0.5	3.89e-31	Putamen volume;
LGG	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg20573242	chr4:122745356	CCNA2	0.42	7.53	0.33	2.7e-13	Type 2 diabetes;
LGG	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs10504073	0.647	rs341807	chr8:50032676	C/T	cg00325661	chr8:49890786	NA	0.69	13.53	0.53	2.31e-35	Blood metabolite ratios;
LGG	cis	rs1003719	0.788	rs2835602	chr21:38469069	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.65	-0.44	7.96e-24	Lung cancer;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs55665837	1.000	rs10832264	chr11:14459982	T/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.7	-0.37	5.87e-17	Vitamin D levels;
LGG	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg21045802	chr8:109455806	TTC35	0.52	9.81	0.41	8.85e-21	Dupuytren's disease;
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg18761221	chr20:60518478	NA	0.6	9.69	0.41	2.5e-20	Obesity-related traits;
LGG	cis	rs11255291	1.000	rs2182652	chr10:7735876	C/T	cg13340899	chr10:7670827	ITIH5	-0.4	-6.92	-0.31	1.48e-11	Ovarian reserve;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.51e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7215564	0.908	rs2315923	chr17:78693678	A/G	cg16980736	chr17:78789706	RPTOR	-0.61	-7.98	-0.35	1.16e-14	Myopia (pathological);
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.75e-14	Lung cancer;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-15.04	-0.57	6.48e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg20120463	chr17:44301886	NA	-0.47	-7.34	-0.32	9.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.89	-0.45	9.96e-25	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.81	-0.59	2.42e-45	Tonsillectomy;
LGG	cis	rs1519814	0.956	rs4369033	chr8:121138921	C/A	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg05163923	chr11:71159392	DHCR7	0.71	13.92	0.54	4.8e-37	Vitamin D levels;
LGG	cis	rs10089	1.000	rs72794396	chr5:127501386	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.15	0.46	9.76e-26	Ileal carcinoids;
LGG	trans	rs12478296	0.534	rs67092377	chr2:243002171	T/G	cg01596870	chr19:55963115	NA	-0.49	-7.38	-0.32	7.44e-13	Obesity-related traits;
LGG	cis	rs2315504	0.509	rs2051806	chr17:39031451	C/T	cg05063374	chr17:38953512	KRT28	-0.39	-7.25	-0.32	1.75e-12	Height;
LGG	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg14227996	chr4:17616232	MED28	0.73	9.02	0.39	4.99e-18	Opioid sensitivity;
LGG	cis	rs240764	0.631	rs12195369	chr6:101204106	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.72	-0.34	7.24e-14	Neuroticism;
LGG	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg26396452	chr14:65542826	MAX	0.39	7.62	0.33	1.49e-13	Obesity-related traits;
LGG	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg22437258	chr11:111473054	SIK2	0.55	9.43	0.4	1.98e-19	Primary sclerosing cholangitis;
LGG	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg09818912	chr17:20140352	CYTSB	-0.32	-7.64	-0.33	1.26e-13	Schizophrenia;
LGG	cis	rs2658782	0.789	rs3020057	chr11:93118515	C/T	cg15737290	chr11:93063684	CCDC67	0.51	7.78	0.34	4.79e-14	Pulmonary function decline;
LGG	cis	rs35160687	0.862	rs13024964	chr2:86511868	G/A	cg10973622	chr2:86423274	IMMT	0.45	7.68	0.34	9.26e-14	Night sleep phenotypes;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg05941027	chr17:61774174	LIMD2	0.34	8.62	0.37	1.06e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02475777	chr4:1388615	CRIPAK	0.38	6.98	0.31	1.03e-11	Longevity;
LGG	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Parkinson's disease;
LGG	cis	rs975722	0.540	rs254536	chr7:116970582	T/C	cg10524701	chr7:117356490	CTTNBP2	0.37	7.74	0.34	6.25e-14	Coronary artery disease;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg20790798	chr5:1857306	NA	-0.43	-7.1	-0.31	4.79e-12	Cardiovascular disease risk factors;
LGG	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg16339924	chr4:17578868	LAP3	-0.64	-10.11	-0.43	7.33e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg06521331	chr12:34319734	NA	0.46	8.63	0.37	1.01e-16	Heart rate;
LGG	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.84	-0.34	3.23e-14	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.97e-26	Bipolar disorder;
LGG	cis	rs977987	0.800	rs3784935	chr16:75336430	T/G	cg03315344	chr16:75512273	CHST6	0.48	9.7	0.41	2.31e-20	Dupuytren's disease;
LGG	cis	rs4936894	0.500	rs11219541	chr11:124130982	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.18	-0.43	4.38e-22	Aging (time to death);
LGG	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg13647721	chr17:30228624	UTP6	0.75	10.87	0.45	1.18e-24	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.57	-0.37	1.56e-16	Menopause (age at onset);
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg18357526	chr6:26021779	HIST1H4A	0.78	12.34	0.5	1.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg24503407	chr1:205819492	PM20D1	-0.4	-7.2	-0.32	2.45e-12	Menarche (age at onset);
LGG	cis	rs4696584	0.818	rs6844895	chr4:155397991	T/C	cg04517429	chr4:155413618	DCHS2	0.31	7.22	0.32	2.21e-12	Folding of antihelix;
LGG	cis	rs17023223	0.537	rs1325940	chr1:119586687	G/A	cg05756136	chr1:119680316	WARS2	-0.41	-8.55	-0.37	1.87e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs7927771	1.000	rs34910028	chr11:47758449	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg07541023	chr7:19748670	TWISTNB	0.6	8.67	0.37	7.43e-17	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.36	-0.58	2.39e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18771653	chr1:2126479	C1orf86;LOC100128003	-0.44	-7.47	-0.33	4.13e-13	Pancreatic cancer;
LGG	trans	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg25214090	chr10:38739885	LOC399744	0.6	10.83	0.45	1.64e-24	Corneal astigmatism;
LGG	cis	rs11239187	0.586	rs10900078	chr10:45105046	C/T	cg03916630	chr10:45065415	NA	0.36	8.57	0.37	1.53e-16	Body mass index;
LGG	cis	rs4731207	0.596	rs723444	chr7:124659224	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.61e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs11168618	0.567	rs56354789	chr12:48803943	C/A	cg24011408	chr12:48396354	COL2A1	0.48	7.71	0.34	7.95e-14	Adiponectin levels;
LGG	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg02503808	chr4:7069936	GRPEL1	-0.95	-8.73	-0.38	4.6e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.11	-0.43	7.58e-22	Total body bone mineral density;
LGG	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.95	-0.35	1.46e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.91	0.31	1.58e-11	Schizophrenia;
LGG	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.66	0.59	1.2e-44	Diabetic retinopathy;
LGG	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg13770153	chr20:60521292	NA	-0.53	-8.38	-0.36	6.32e-16	Body mass index;
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.2	0.6	4.31e-47	Lymphocyte counts;
LGG	cis	rs3796352	1.000	rs11706035	chr3:53011868	A/T	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.38	-0.43	8.11e-23	Bipolar disorder;
LGG	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.37	-0.32	7.9e-13	IgG glycosylation;
LGG	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg13010199	chr12:38710504	ALG10B	0.45	8.45	0.37	3.67e-16	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-9.89	-0.42	4.81e-21	Prudent dietary pattern;
LGG	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg25486957	chr4:152246857	NA	-0.51	-8.04	-0.35	7.65e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.93	-0.42	3.41e-21	Bipolar disorder;
LGG	cis	rs9640161	0.789	rs3735174	chr7:150020489	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.73	-15.3	-0.58	4.77e-43	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.6	-0.47	1.78e-27	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg06521331	chr12:34319734	NA	0.43	7.72	0.34	7.17e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs889398	0.617	rs11075742	chr16:69898934	A/G	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.66	-0.34	1.13e-13	Body mass index;
LGG	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.7	0.34	8.26e-14	Schizophrenia;
LGG	cis	rs4664308	1.000	rs6759836	chr2:160912802	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.99	-0.64	3.06e-55	Idiopathic membranous nephropathy;
LGG	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	12.98	0.52	4.68e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	13.82	0.54	1.32e-36	Mean platelet volume;
LGG	trans	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg07817883	chr1:32538562	TMEM39B	1.15	12.07	0.49	2.45e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4423214	0.840	rs1792233	chr11:71182179	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	8.45e-26	Vitamin D levels;
LGG	cis	rs9660992	0.539	rs113699533	chr1:205122895	G/A	cg00857998	chr1:205179979	DSTYK	0.56	8.98	0.38	7.09e-18	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg02002194	chr4:3960332	NA	-0.45	-7.67	-0.34	9.93e-14	Neuroticism;
LGG	cis	rs11203032	0.831	rs4617498	chr10:90943713	G/A	cg16672925	chr10:90967113	CH25H	0.75	11.23	0.46	4.91e-26	Heart failure;
LGG	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg25664220	chr3:72788482	NA	-0.28	-8.16	-0.35	3.21e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3008870	1.000	rs35365746	chr1:67438900	G/A	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.84	-0.3	2.51e-11	Lymphocyte percentage of white cells;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg05863683	chr7:1912471	MAD1L1	0.45	8.74	0.38	4.31e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.46	-0.37	3.49e-16	Systolic blood pressure;
LGG	cis	rs208520	0.690	rs207118	chr6:66788948	T/A	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs67311347	0.544	rs12054197	chr3:40337562	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.84e-45	Renal cell carcinoma;
LGG	cis	rs7617773	0.817	rs6800492	chr3:48323890	G/A	cg11946769	chr3:48343235	NME6	0.63	10.56	0.44	1.65e-23	Coronary artery disease;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21963583	chr11:68658836	MRPL21	0.6	10.47	0.44	3.67e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10905065	0.895	rs3736462	chr10:5804455	A/G	cg11519256	chr10:5708881	ASB13	0.43	7.44	0.33	4.9e-13	Menopause (age at onset);
LGG	cis	rs17253792	0.822	rs75399477	chr14:56174413	T/C	cg01858014	chr14:56050164	KTN1	-0.87	-10.63	-0.44	9.49e-24	Putamen volume;
LGG	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.62	-0.51	1.33e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.97	-0.31	1.08e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs12579753	0.642	rs11115072	chr12:82284991	T/A	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.23	-0.32	1.98e-12	Resting heart rate;
LGG	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.0500000000000001e-23	Lymphocyte counts;
LGG	cis	rs4664308	0.840	rs17218566	chr2:161054748	C/T	cg03641300	chr2:160917029	PLA2R1	-0.78	-15.85	-0.59	1.67e-45	Idiopathic membranous nephropathy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00180470	chr16:11343465	NA	-0.39	-6.76	-0.3	4.22e-11	Cognitive performance;
LGG	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg16339924	chr4:17578868	LAP3	0.51	8.51	0.37	2.36e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg26384229	chr12:38710491	ALG10B	1.0	23.84	0.74	1.56e-82	Heart rate;
LGG	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7586879	0.789	rs13035239	chr2:25134000	T/A	cg04586622	chr2:25135609	ADCY3	0.39	9.39	0.4	2.7e-19	Body mass index;
LGG	cis	rs4516970	0.826	rs59246098	chr6:160149462	C/CA	cg25736982	chr6:160182554	ACAT2	0.55	7.28	0.32	1.43e-12	Iron status biomarkers;
LGG	trans	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.11	-0.46	1.43e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7107174	0.901	rs1046780	chr11:77926769	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.15	-0.32	3.36e-12	Testicular germ cell tumor;
LGG	cis	rs139371	0.742	rs139322	chr22:39501285	T/A	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.93	-0.31	1.43e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs9815354	0.830	rs1624519	chr3:41984800	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-10.9	-0.45	8.88e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.69	7.18	0.32	2.72e-12	Facial emotion recognition (sad faces);
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg02725872	chr8:58115012	NA	-0.89	-12.11	-0.49	1.56e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06470251	chr20:60548479	NA	0.42	7.28	0.32	1.43e-12	Body mass index;
LGG	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg15269541	chr15:43626905	ADAL	-0.44	-6.97	-0.31	1.08e-11	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.17	-0.46	8.12e-26	Obesity-related traits;
LGG	cis	rs3735485	0.738	rs10280402	chr7:45089018	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.62	-0.41	4.35e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs11971779	0.715	rs10085527	chr7:139064360	G/A	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.35e-12	Diisocyanate-induced asthma;
LGG	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.31	0.6	1.35e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	24.59	0.75	5.12e-86	IgG glycosylation;
LGG	cis	rs2073499	0.935	rs2624840	chr3:50199015	T/C	cg03645007	chr3:50255295	SLC38A3	-0.65	-7.19	-0.32	2.68e-12	Schizophrenia;
LGG	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.09	-0.46	1.71e-25	Lung cancer;
LGG	cis	rs6871536	1.000	rs2074369	chr5:131973663	T/C	cg04303330	chr5:131992430	IL13	0.27	6.65	0.3	8.35e-11	Asthma (childhood onset);
LGG	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.38	-0.61	7e-48	Headache;
LGG	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg02254774	chr11:50257496	LOC441601	0.57	6.97	0.31	1.1e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg21017887	chr14:105400489	NA	0.4	7.62	0.33	1.43e-13	Rheumatoid arthritis;
LGG	cis	rs9487094	0.645	rs1322818	chr6:109691101	A/G	cg16315928	chr6:109776240	MICAL1	0.47	7.23	0.32	1.97e-12	Height;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs1014246	0.848	rs11197799	chr10:118457650	C/T	cg14919929	chr10:118506882	NA	0.62	11.72	0.48	5.79e-28	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.07e-38	Tonsillectomy;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs16837677	1.000	rs75954255	chr1:156722658	T/C	cg14991358	chr1:156767203	PRCC	0.77	7.94	0.35	1.55e-14	Sjögren's syndrome;
LGG	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg10160682	chr2:1713001	PXDN	-0.53	-9.54	-0.41	8.18e-20	Response to antipsychotic treatment;
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg21171335	chr12:122356390	WDR66	0.28	7.93	0.35	1.65e-14	Mean corpuscular volume;
LGG	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.6	0.33	1.61e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	cis	rs1878931	0.624	rs27241	chr16:3447282	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-12.22	-0.49	5.6e-30	Body mass index (adult);
LGG	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg24692254	chr21:30365293	RNF160	0.59	10.34	0.43	1.1e-22	Pancreatic cancer;
LGG	cis	rs6732160	0.691	rs1960233	chr2:73421378	A/G	cg01422370	chr2:73384389	NA	0.47	9.05	0.39	4.04e-18	Intelligence (multi-trait analysis);
LGG	trans	rs800082	0.690	rs6440260	chr3:144289214	C/A	cg24215973	chr2:240111563	HDAC4	-0.64	-12.57	-0.5	2.23e-31	Smoking behavior;
LGG	cis	rs4356932	0.967	rs10856873	chr4:76972924	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs704	0.584	rs6505081	chr17:26737888	A/G	cg10342447	chr17:26645325	TMEM97	0.4	7.32	0.32	1.11e-12	Osteoprotegerin levels;
LGG	cis	rs7106204	0.764	rs7949823	chr11:24213668	C/G	ch.11.24196551F	chr11:24239977	NA	0.94	11.22	0.46	5.19e-26	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg19014664	chr5:877076	BRD9	-0.37	-7.22	-0.32	2.1e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg20608306	chr11:116969690	SIK3	-0.41	-10.82	-0.45	1.7e-24	Subjective well-being;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg14092988	chr3:52407081	DNAH1	-0.28	-7.57	-0.33	2.04e-13	Bipolar disorder;
LGG	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Aortic root size;
LGG	cis	rs12621278	0.655	rs114161133	chr2:173318244	G/T	cg15021238	chr2:173305865	ITGA6	-0.84	-9.68	-0.41	2.56e-20	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg02023728	chr11:77925099	USP35	0.39	6.82	0.3	2.84e-11	Alzheimer's disease (survival time);
LGG	cis	rs12540874	0.965	rs9791887	chr7:50661170	A/C	cg04490037	chr7:50633773	DDC	0.37	8.06	0.35	6.72e-15	Systemic sclerosis;
LGG	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg26769984	chr7:1090371	C7orf50	0.45	7.15	0.32	3.46e-12	Bronchopulmonary dysplasia;
LGG	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg03929089	chr4:120376271	NA	-0.53	-9.0	-0.39	5.78e-18	HDL cholesterol;
LGG	cis	rs6694672	1.000	rs6428383	chr1:197044770	C/T	cg13682187	chr1:196946512	CFHR5	0.54	7.46	0.33	4.36e-13	Asthma;
LGG	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg24375607	chr4:120327624	NA	0.67	10.93	0.45	6.79e-25	Corneal astigmatism;
LGG	cis	rs295140	1.000	rs7559005	chr2:201161371	C/T	cg25099087	chr2:201172481	SPATS2L	0.27	6.71	0.3	5.88e-11	QT interval;
LGG	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg17211192	chr8:82754475	SNX16	0.78	12.07	0.49	2.27e-29	Diastolic blood pressure;
LGG	cis	rs4256922	0.680	rs10761501	chr10:52524173	G/A	cg12289553	chr10:52500425	ASAH2B	-0.45	-8.46	-0.37	3.51e-16	Urate levels in lean individuals;
LGG	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg19774624	chr17:42201019	HDAC5	0.67	11.9	0.48	1.1e-28	Total body bone mineral density;
LGG	cis	rs61931739	0.576	rs7297346	chr12:33700544	T/C	cg06521331	chr12:34319734	NA	0.4	6.95	0.31	1.25e-11	Morning vs. evening chronotype;
LGG	cis	rs9457247	1.000	rs430477	chr6:167389851	T/C	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs72827839	0.846	rs72825504	chr17:46139479	C/T	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	trans	rs11760633	0.672	rs7811019	chr7:1843541	C/G	cg22232500	chr2:134024266	NCKAP5	0.52	7.22	0.32	2.08e-12	Coronary artery disease;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.47	-0.47	5.62e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs35740288	0.822	rs17637142	chr15:86240503	T/C	cg07943548	chr15:86304357	KLHL25	-0.36	-6.96	-0.31	1.14e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.681	rs540388	chr15:43606494	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.97	0.54	2.99e-37	Lung cancer in ever smokers;
LGG	cis	rs7226408	0.600	rs719847	chr18:34422350	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.21	-0.36	2.24e-15	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg26384229	chr12:38710491	ALG10B	0.61	10.95	0.45	5.89e-25	Morning vs. evening chronotype;
LGG	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg10840412	chr1:235813424	GNG4	0.52	7.06	0.31	6.2e-12	Bipolar disorder;
LGG	cis	rs6964587	1.000	rs6976122	chr7:91610962	T/C	cg17063962	chr7:91808500	NA	0.48	8.52	0.37	2.29e-16	Breast cancer;
LGG	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-27.16	-0.78	7.4e-98	Height;
LGG	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.82	-0.38	2.28e-17	Response to antipsychotic treatment;
LGG	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.55	-0.37	1.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7572733	0.534	rs700687	chr2:198721560	A/T	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.15	30.78	0.82	4.57e-114	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs4700695	0.764	rs251327	chr5:65269464	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.26	0.32	1.66e-12	Facial morphology (factor 19);
LGG	trans	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17712092	chr4:129076599	LARP1B	0.75	14.3	0.55	1.1e-38	Eosinophil percentage of white cells;
LGG	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs10484885	0.757	rs12215741	chr6:90154845	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.03	-0.31	7.65e-12	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2073300	0.609	rs6132610	chr20:23403987	C/T	cg12062639	chr20:23401060	NAPB	0.92	8.72	0.38	4.86e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg25208724	chr1:156163844	SLC25A44	1.22	27.35	0.79	9.97e-99	Testicular germ cell tumor;
LGG	cis	rs1775715	0.737	rs2799015	chr10:32107712	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.77	0.3	3.8e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg02466173	chr16:30829666	NA	0.58	11.4	0.47	1.08e-26	Dementia with Lewy bodies;
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs6032067	0.929	rs17425504	chr20:43880089	T/C	cg10761708	chr20:43804764	PI3	0.76	11.48	0.47	5.05e-27	Blood protein levels;
LGG	cis	rs2694528	0.858	rs7718028	chr5:60472308	C/G	cg11474532	chr5:59995715	DEPDC1B	-0.67	-7.41	-0.33	6e-13	Parkinson's disease;
LGG	cis	rs12956009	0.583	rs919979	chr18:44902739	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.07	0.31	5.62e-12	Educational attainment (years of education);
LGG	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg23324259	chr8:82754387	SNX16	-0.46	-7.46	-0.33	4.26e-13	Diastolic blood pressure;
LGG	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg18479299	chr3:125709523	NA	-0.58	-7.37	-0.32	7.86e-13	Blood pressure (smoking interaction);
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22618164	chr12:122356400	WDR66	0.38	11.18	0.46	7.17e-26	Mean corpuscular volume;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.52	-0.4	9.36e-20	Lung cancer;
LGG	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs9341808	0.935	rs1535825	chr6:80938586	C/T	cg08355045	chr6:80787529	NA	-0.37	-7.47	-0.33	4.13e-13	Sitting height ratio;
LGG	cis	rs2073300	1.000	rs6137961	chr20:23443102	G/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6732160	0.691	rs13432787	chr2:73430234	T/C	cg01422370	chr2:73384389	NA	0.48	9.22	0.39	1.05e-18	Intelligence (multi-trait analysis);
LGG	trans	rs2270927	0.510	rs13188781	chr5:75580409	C/A	cg13563193	chr19:33072644	PDCD5	0.85	10.15	0.43	5.58e-22	Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-11.11	-0.46	1.35e-25	Coronary artery disease;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg09448879	chr15:79043637	NA	0.47	10.5	0.44	2.92e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1408799	0.679	rs7025914	chr9:12760884	C/T	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	4.99e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs4704846	0.898	rs9790947	chr5:156542182	T/C	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.47	-0.33	4.15e-13	Blood protein levels;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.51	-9.79	-0.41	1.04e-20	Obesity-related traits;
LGG	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg01620082	chr3:125678407	NA	-1.08	-10.72	-0.45	4.18e-24	Depression;
LGG	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	9.14	0.39	1.97e-18	Mean corpuscular volume;
LGG	cis	rs12200560	0.505	rs9400167	chr6:97077192	G/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs2274273	0.905	rs8007614	chr14:55586575	A/G	cg04306507	chr14:55594613	LGALS3	0.63	17.76	0.64	3.4e-54	Protein biomarker;
LGG	cis	rs6809651	0.524	rs4686728	chr3:185795333	C/T	cg00760338	chr3:185826511	ETV5	0.9	15.09	0.57	3.95e-42	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.4e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs514406	0.861	rs7526275	chr1:53245849	C/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.6	-0.65	4.35e-58	Monocyte count;
LGG	cis	rs3540	0.533	rs2256110	chr15:90971036	T/C	cg22089800	chr15:90895588	ZNF774	0.69	12.66	0.51	9.62e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs614226	0.938	rs7963543	chr12:120923948	C/A	cg27489772	chr12:121021490	NA	0.57	7.76	0.34	5.62e-14	Type 1 diabetes nephropathy;
LGG	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg17050807	chr22:42548356	NA	-0.39	-7.47	-0.33	4.08e-13	Schizophrenia;
LGG	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg26897989	chr16:1907736	C16orf73	-0.53	-9.92	-0.42	3.63e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs9467160	0.651	rs7755403	chr6:24453447	C/G	cg20631270	chr6:24437470	GPLD1	0.46	7.74	0.34	6.43e-14	Liver enzyme levels;
LGG	cis	rs4862307	0.964	rs76550057	chr4:184998476	C/G	cg06737308	chr4:185021514	ENPP6	0.48	7.97	0.35	1.24e-14	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs9378357	0.702	rs4383859	chr6:3280241	C/G	cg08754725	chr6:3293098	SLC22A23	0.78	8.11	0.35	4.67e-15	Obesity-related traits;
LGG	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	25.12	0.76	1.71e-88	IgG glycosylation;
LGG	cis	rs9472414	0.771	rs3799966	chr6:44798665	T/C	cg20913747	chr6:44695427	NA	0.45	6.72	0.3	5.3e-11	Height;
LGG	trans	rs1994135	0.715	rs10506110	chr12:33708552	A/C	cg13010199	chr12:38710504	ALG10B	0.53	9.21	0.39	1.18e-18	Resting heart rate;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs3750965	0.881	rs61057353	chr11:68817050	C/G	cg23121140	chr11:68816938	TPCN2	0.39	7.52	0.33	2.85e-13	Hair color;
LGG	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.92	-0.35	1.74e-14	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20561454	chr22:38578013	PLA2G6	0.46	6.87	0.3	2.06e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.806	rs11777002	chr8:11096153	G/C	cg02002194	chr4:3960332	NA	0.41	7.38	0.32	7.31e-13	Retinal vascular caliber;
LGG	cis	rs111294930	1	rs111294930	chr5:152177121	A/G	cg12297329	chr5:152029980	NA	-0.68	-12.07	-0.49	2.43e-29	Schizophrenia;
LGG	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg08344181	chr3:125677491	NA	-0.7	-7.35	-0.32	8.82e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35160687	0.623	rs11127019	chr2:86467618	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	7.27	0.32	1.59e-12	Night sleep phenotypes;
LGG	cis	rs7267979	1.000	rs6050609	chr20:25411751	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.38	-0.43	8.06e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.72	-0.51	5.32e-32	Diastolic blood pressure;
LGG	cis	rs7143963	0.580	rs6575931	chr14:103301574	A/G	cg23020514	chr14:103360112	TRAF3	0.41	8.57	0.37	1.53e-16	Body mass index;
LGG	cis	rs932287	0.545	rs1960181	chr11:9046767	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.42	7.81	0.34	3.78e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg06212747	chr3:49208901	KLHDC8B	0.62	10.3	0.43	1.59e-22	Parkinson's disease;
LGG	cis	rs10895140	0.670	rs7936141	chr11:101521711	G/C	cg23650423	chr11:101454676	TRPC6	-0.4	-6.71	-0.3	5.55e-11	Menarche (age at onset);
LGG	cis	rs12142240	0.698	rs17357683	chr1:46815378	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-8.99	-0.39	6.49e-18	Menopause (age at onset);
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.17	0.32	2.96e-12	Tonsillectomy;
LGG	cis	rs11105298	0.891	rs11105313	chr12:89923376	A/T	cg00757033	chr12:89920650	WDR51B	-0.64	-9.37	-0.4	3.12e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs11039798	0.511	rs7948129	chr11:48167828	G/A	cg03929089	chr4:120376271	NA	-0.62	-7.94	-0.35	1.6e-14	Axial length;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg23034840	chr1:205782522	SLC41A1	0.53	8.65	0.37	8.69e-17	Menarche (age at onset);
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19626725	chr5:178986131	RUFY1	0.45	7.43	0.33	5.46e-13	Lung cancer;
LGG	cis	rs10875746	0.768	rs4760609	chr12:48415757	A/C	cg24011408	chr12:48396354	COL2A1	0.53	7.33	0.32	1.04e-12	Longevity (90 years and older);
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg19318889	chr4:1322082	MAEA	0.47	8.11	0.35	4.56e-15	Longevity;
LGG	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg17809284	chr5:56205270	C5orf35	-0.49	-8.89	-0.38	1.37e-17	Coronary artery disease;
LGG	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	9.5	0.4	1.1e-19	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg15971980	chr6:150254442	NA	0.45	8.56	0.37	1.7e-16	Lung cancer;
LGG	trans	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.25	-0.36	1.64e-15	Blood trace element (Cu levels);
LGG	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg25919922	chr13:100150906	NA	-0.71	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	8.52	0.37	2.27e-16	Lung cancer in ever smokers;
LGG	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg04492858	chr10:133558786	NA	0.43	8.59	0.37	1.36e-16	Survival in rectal cancer;
LGG	cis	rs4356203	0.905	rs11821773	chr11:17117354	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.33	-0.32	1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs16854884	0.657	rs62268458	chr3:143736219	T/C	cg06585982	chr3:143692056	C3orf58	0.56	9.6	0.41	5.16e-20	Economic and political preferences (feminism/equality);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12124516	chr2:136634144	MCM6	0.44	7.13	0.31	3.78e-12	Cognitive performance;
LGG	cis	rs6580649	0.941	rs72644845	chr12:48503881	G/A	cg24011408	chr12:48396354	COL2A1	-0.53	-6.66	-0.3	7.65e-11	Lung cancer;
LGG	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.19	0.36	2.48e-15	Birth weight;
LGG	cis	rs2455799	0.552	rs2470516	chr3:15759050	T/G	cg16303742	chr3:15540471	COLQ	-0.41	-8.15	-0.35	3.43e-15	Mean platelet volume;
LGG	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg02297831	chr4:17616191	MED28	-0.49	-8.99	-0.39	6.19e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg04617936	chr2:214353	NA	-0.39	-7.15	-0.32	3.36e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg19147804	chr7:1989927	MAD1L1	-0.37	-7.09	-0.31	5.07e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg24642844	chr7:1081250	C7orf50	-0.84	-14.03	-0.55	1.64e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg00012203	chr2:219082015	ARPC2	0.6	10.51	0.44	2.59e-23	Colorectal cancer;
LGG	cis	rs11105298	0.891	rs11105314	chr12:89924559	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.57	-0.41	6.43e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg05082376	chr22:42548792	NA	-0.36	-7.63	-0.33	1.35e-13	Schizophrenia;
LGG	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg16339924	chr4:17578868	LAP3	-0.62	-10.99	-0.45	3.96e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg01678292	chr8:41522873	ANK1	0.35	8.21	0.36	2.19e-15	Type 2 diabetes;
LGG	cis	rs910187	0.571	rs6124958	chr20:45801117	T/C	cg27589058	chr20:45804311	EYA2	-0.37	-9.51	-0.4	1.01e-19	Migraine;
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg00800038	chr16:89945340	TCF25	0.72	8.53	0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs9381107	0.932	rs10484246	chr6:9451197	T/A	cg14735645	chr6:9486422	NA	-0.43	-7.29	-0.32	1.35e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.42	0.36	4.86e-16	Schizophrenia;
LGG	cis	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg24375607	chr4:120327624	NA	-0.65	-10.74	-0.45	3.56e-24	Corneal astigmatism;
LGG	cis	rs12410462	0.591	rs2814059	chr1:227721233	A/G	cg04117972	chr1:227635322	NA	0.45	8.3	0.36	1.14e-15	Major depressive disorder;
LGG	cis	rs6444746	0.689	rs6788594	chr3:193489212	C/T	cg22553634	chr3:193489233	NA	0.89	10.75	0.45	3.2e-24	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs9534288	0.912	rs2404732	chr13:46618611	C/A	cg15192986	chr13:46630673	CPB2	-0.72	-15.88	-0.59	1.23e-45	Blood protein levels;
LGG	trans	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04565464	chr8:145669602	NFKBIL2	0.4	6.87	0.3	2.03e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.24e-13	Type 2 diabetes;
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs6504108	0.624	rs10853098	chr17:46236581	G/A	cg02219949	chr17:45927392	SP6	0.44	8.2	0.36	2.41e-15	Body mass index;
LGG	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs12545109	0.800	rs1440762	chr8:57410708	C/T	cg19413350	chr8:57351067	NA	-0.43	-6.92	-0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.09	-0.35	5.38e-15	IgG glycosylation;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg01673284	chr16:4527211	HMOX2	0.33	6.65	0.3	8.21e-11	Schizophrenia;
LGG	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.79	0.41	1.05e-20	Colorectal cancer;
LGG	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg05294307	chr14:35346193	BAZ1A	-0.38	-7.1	-0.31	4.7e-12	Psoriasis;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg13395646	chr4:1353034	KIAA1530	0.49	8.17	0.35	2.99e-15	Obesity-related traits;
LGG	cis	rs68170813	0.641	rs4730228	chr7:106904077	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.45	-0.44	4.33e-23	Coronary artery disease;
LGG	cis	rs12220238	1.000	rs9665468	chr10:75938838	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.16	0.46	9.09e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.68	-0.34	9.44e-14	Skin colour saturation;
LGG	cis	rs7100689	0.622	rs7082093	chr10:82134954	T/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.05	0.57	5.6e-42	Post bronchodilator FEV1;
LGG	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.34	-0.43	1.11e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.88	0.48	1.37e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg19992207	chr2:111874495	ACOXL	-0.36	-6.7	-0.3	6.1e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.34	-0.4	4.03e-19	Bladder cancer;
LGG	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.22	-0.36	2.05e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs283228	0.798	rs597750	chr6:101791131	G/A	cg27451362	chr6:101846650	GRIK2	0.65	10.58	0.44	1.45e-23	Coenzyme Q10 levels;
LGG	cis	rs7264396	0.528	rs6058370	chr20:34518592	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	6.72	0.3	5.43e-11	Total cholesterol levels;
LGG	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg11845111	chr2:191398756	TMEM194B	0.36	7.98	0.35	1.16e-14	Pulse pressure;
LGG	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg02640540	chr1:67518911	SLC35D1	0.39	6.7	0.3	6e-11	Lymphocyte percentage of white cells;
LGG	cis	rs17221829	0.644	rs12420632	chr11:89366231	G/C	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.51	-0.37	2.38e-16	Anxiety in major depressive disorder;
LGG	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.12	0.35	4.26e-15	Schizophrenia;
LGG	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11890956	chr21:40555474	PSMG1	1.0	21.47	0.71	1.77e-71	Cognitive function;
LGG	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg08807101	chr21:30365312	RNF160	0.92	19.3	0.67	2.53e-61	Dental caries;
LGG	cis	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg12486710	chr1:178512616	C1orf220	-0.52	-10.69	-0.44	5.49e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.64	-0.41	3.67e-20	Aortic root size;
LGG	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg09696939	chr10:60272079	BICC1	0.39	7.51	0.33	3.02e-13	Refractive error;
LGG	cis	rs698833	0.758	rs7586188	chr2:44544955	G/A	cg00619915	chr2:44497795	NA	-0.44	-6.75	-0.3	4.45e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs3857536	0.730	rs6927862	chr6:66971450	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-6.98	-0.31	9.96e-12	Blood trace element (Cu levels);
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.85	0.3	2.37e-11	Schizophrenia;
LGG	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg17133734	chr15:86042851	AKAP13	-0.29	-6.89	-0.3	1.84e-11	Coronary artery disease;
LGG	cis	rs4363385	0.668	rs1933386	chr1:152959265	T/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.86	-0.38	1.71e-17	Inflammatory skin disease;
LGG	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.26	-0.32	1.6e-12	Neuroticism;
LGG	cis	rs897080	0.518	rs1067330	chr2:44627822	A/G	cg00619915	chr2:44497795	NA	-0.5	-7.01	-0.31	8.23e-12	Height;
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18252515	chr7:66147081	NA	0.43	7.18	0.32	2.77e-12	Aortic root size;
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg01765077	chr12:122356316	WDR66	0.28	7.34	0.32	9.97e-13	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.03	-0.35	8.31e-15	Skin colour saturation;
LGG	cis	rs11719291	0.831	rs11715177	chr3:48763894	G/A	cg00383909	chr3:49044727	WDR6	0.93	11.59	0.47	1.83e-27	Cognitive function;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg10360139	chr7:1886902	MAD1L1	0.38	6.83	0.3	2.69e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg08930214	chr7:62859557	LOC100287834	0.44	7.22	0.32	2.15e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.89	-0.31	1.78e-11	Lung cancer;
LGG	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg15704280	chr7:45808275	SEPT13	0.94	19.6	0.67	1e-62	Coronary artery disease;
LGG	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs2599510	0.783	rs2710626	chr2:32758754	G/C	cg02381751	chr2:32503542	YIPF4	0.46	7.42	0.33	5.8e-13	Interleukin-18 levels;
LGG	cis	rs757978	0.929	rs111943976	chr2:242378905	T/C	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.8	-8.62	-0.37	1.09e-16	Chronic lymphocytic leukemia;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.18	-0.32	2.74e-12	Schizophrenia;
LGG	cis	rs10751667	0.714	rs7396700	chr11:963863	A/C	cg22143635	chr11:980567	AP2A2	0.45	8.45	0.37	3.74e-16	Alzheimer's disease (late onset);
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg18681998	chr4:17616180	MED28	0.85	18.8	0.66	5.39e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg14186256	chr22:23484241	RTDR1	0.96	23.82	0.74	1.83e-82	Bone mineral density;
LGG	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg26248373	chr2:1572462	NA	-0.9	-15.78	-0.59	3.53e-45	IgG glycosylation;
LGG	cis	rs1461503	0.966	rs11218908	chr11:122841687	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs7107174	0.892	rs4945265	chr11:78027458	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg02951883	chr7:2050386	MAD1L1	-0.78	-17.31	-0.63	4.01e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg18225595	chr11:63971243	STIP1	0.48	9.28	0.4	6.57e-19	Platelet count;
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.09	0.39	2.84e-18	Aortic root size;
LGG	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg27366882	chr3:133540807	NA	-0.47	-9.77	-0.41	1.26e-20	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.3	0.32	1.29e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg04990556	chr1:26633338	UBXN11	-0.69	-14.32	-0.55	8.8e-39	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-8.24	-0.36	1.82e-15	Skin colour saturation;
LGG	cis	rs4363385	0.747	rs2075739	chr1:152975495	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg05169160	chr2:178484487	TTC30A	0.34	6.67	0.3	7.52e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7084402	0.934	rs1658426	chr10:60331542	A/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.3	-0.32	1.25e-12	Refractive error;
LGG	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.62	0.33	1.49e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17767392	0.633	rs7160587	chr14:71704684	A/G	cg02058870	chr14:72053146	SIPA1L1	0.35	7.02	0.31	7.96e-12	Mitral valve prolapse;
LGG	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg25554036	chr4:6271136	WFS1	0.57	10.41	0.44	6.05e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg04691961	chr3:161091175	C3orf57	-0.41	-8.33	-0.36	9.3e-16	Kawasaki disease;
LGG	cis	rs2797160	1.000	rs1739363	chr6:126020980	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.69	0.34	9.12e-14	Endometrial cancer;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs2652834	0.851	rs1566660	chr15:63429258	C/G	cg05507819	chr15:63340323	TPM1	0.48	6.82	0.3	2.84e-11	HDL cholesterol;
LGG	cis	rs7017914	0.967	rs7013657	chr8:71637559	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.59e-11	Type 2 diabetes;
LGG	cis	rs1318772	0.932	rs7736165	chr5:112866157	G/A	cg12552261	chr5:112820674	MCC	-0.68	-7.64	-0.33	1.22e-13	F-cell distribution;
LGG	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg04317338	chr11:64019027	PLCB3	0.64	8.04	0.35	7.83e-15	Mean platelet volume;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs62238980	0.614	rs17683011	chr22:32445946	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg11247378	chr22:39784982	NA	0.31	8.74	0.38	4.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	1.000	rs1126671	chr4:100048414	T/C	cg12011299	chr4:100065546	ADH4	0.45	9.3	0.4	5.46e-19	Alcohol dependence;
LGG	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.08	-0.39	3.07e-18	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	8.2	0.36	2.43e-15	Iron status biomarkers;
LGG	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg16141378	chr3:129829833	LOC729375	0.35	8.08	0.35	5.82e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7119038	0.509	rs11216961	chr11:118580338	C/G	cg20309703	chr11:118481025	PHLDB1	0.4	6.86	0.3	2.23e-11	Sjögren's syndrome;
LGG	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg22920501	chr2:26401640	FAM59B	-0.41	-8.12	-0.35	4.2e-15	Gut microbiome composition (summer);
LGG	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg14598338	chr9:96623480	NA	-0.53	-9.55	-0.41	7.8e-20	DNA methylation (variation);
LGG	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg15038512	chr6:170123185	PHF10	0.52	6.75	0.3	4.38e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1775715	0.677	rs2808074	chr10:32179184	A/C	cg14930904	chr10:32216787	ARHGAP12	0.35	6.72	0.3	5.48e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg00938859	chr5:1591904	SDHAP3	0.89	13.14	0.52	9.22e-34	Breast cancer;
LGG	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg21452805	chr1:244014465	NA	0.7	8.42	0.36	4.93e-16	RR interval (heart rate);
LGG	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg12463550	chr7:65579703	CRCP	0.77	8.31	0.36	1.08e-15	Diabetic kidney disease;
LGG	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.21e-25	Corneal astigmatism;
LGG	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7508	0.535	rs11779988	chr8:17784414	T/C	cg18067069	chr8:17937731	ASAH1	-0.29	-6.8	-0.3	3.16e-11	Atrial fibrillation;
LGG	cis	rs4629710	0.545	rs11755717	chr6:131547028	A/T	cg12606694	chr6:131520996	AKAP7	-0.47	-7.83	-0.34	3.32e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs735539	0.521	rs2818991	chr13:21397196	A/G	cg04906043	chr13:21280425	IL17D	-0.5	-8.0	-0.35	9.77e-15	Dental caries;
LGG	cis	rs57994353	0.826	rs34619169	chr9:139327277	G/A	cg14169450	chr9:139327907	INPP5E	0.39	6.83	0.3	2.7e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LGG	cis	rs11225247	0.881	rs79796684	chr11:102257170	T/C	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.79e-39	Exhaled nitric oxide output;
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.54e-12	Bipolar disorder;
LGG	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg27476859	chr7:2772710	GNA12	0.48	8.9	0.38	1.29e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg15309053	chr8:964076	NA	0.36	7.32	0.32	1.11e-12	Schizophrenia;
LGG	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	12.39	0.5	1.2e-30	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg25838465	chr1:92012736	NA	0.55	9.49	0.4	1.19e-19	Breast cancer;
LGG	cis	rs2298450	0.541	rs2835332	chr21:37656940	A/G	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.88	-0.38	1.43e-17	Schizophrenia;
LGG	cis	rs6693567	0.565	rs12731296	chr1:150411787	A/G	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.19	0.43	3.74e-22	Menopause (age at onset);
LGG	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg00376283	chr12:123451042	ABCB9	0.67	12.32	0.5	2.4e-30	Platelet count;
LGG	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.39e-12	HDL cholesterol;
LGG	cis	rs7572733	0.840	rs700640	chr2:198590886	C/T	cg00792783	chr2:198669748	PLCL1	0.46	7.81	0.34	3.96e-14	Dermatomyositis;
LGG	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.75	-0.38	4.04e-17	Aortic root size;
LGG	cis	rs7216064	0.773	rs74541577	chr17:65853651	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9467160	1.000	rs12198188	chr6:24442482	A/G	cg20631270	chr6:24437470	GPLD1	0.53	7.7	0.34	8.17e-14	Liver enzyme levels;
LGG	cis	rs7166081	1.000	rs12592400	chr15:67558010	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.91	-0.31	1.61e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9899728	0.539	rs113775187	chr17:73047290	A/G	cg27626185	chr17:73056755	KCTD2	-1.03	-12.17	-0.49	9.65e-30	Alzheimer's disease or small vessel stroke;
LGG	cis	rs524281	0.861	rs7935336	chr11:65865325	C/T	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg21427119	chr20:30132790	HM13	-0.41	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;
LGG	trans	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg25482853	chr8:67687455	SGK3	0.95	11.74	0.48	4.99e-28	Obesity-related traits;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg19168338	chr16:4465731	CORO7	-1.16	-26.04	-0.77	9.52e-93	Schizophrenia;
LGG	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg12165864	chr7:66369176	NA	0.56	9.02	0.39	5.22e-18	Corneal structure;
LGG	cis	rs883565	0.569	rs7614000	chr3:39152575	C/G	cg01426195	chr3:39028469	NA	-0.65	-14.06	-0.55	1.22e-37	Handedness;
LGG	cis	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg02972257	chr16:68554789	NA	-0.55	-8.36	-0.36	7.17e-16	Ulcerative colitis;
LGG	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg25427524	chr10:38739819	LOC399744	-0.46	-7.1	-0.31	4.77e-12	Obesity (extreme);
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.29	0.6	1.79e-47	Lymphocyte counts;
LGG	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg08048268	chr3:133502702	NA	-0.6	-10.6	-0.44	1.15e-23	Iron status biomarkers;
LGG	cis	rs36093844	0.752	rs78589744	chr11:85555999	T/C	cg16165120	chr11:85566439	CCDC83	-0.46	-7.34	-0.32	9.75e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg19812747	chr11:111475976	SIK2	-0.46	-9.31	-0.4	5.35e-19	Primary sclerosing cholangitis;
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg19635926	chr16:89946313	TCF25	0.76	7.33	0.32	1.01e-12	Skin colour saturation;
LGG	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg01448562	chr3:133502909	NA	-0.43	-7.32	-0.32	1.12e-12	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg11050988	chr7:1952600	MAD1L1	-0.36	-8.51	-0.37	2.38e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs912057	0.671	rs1294417	chr6:6741932	T/C	cg06612196	chr6:6737390	NA	0.51	11.06	0.46	2.08e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7638909	0.512	rs6799868	chr3:38601556	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-8.11	-0.35	4.67e-15	Electrocardiographic conduction measures;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.94	0.31	1.31e-11	Schizophrenia;
LGG	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.53	-0.44	2.18e-23	Chronic sinus infection;
LGG	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	cg07245641	chr1:182991651	LAMC1	0.4	9.11	0.39	2.46e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.44	0.5	7.33e-31	Prudent dietary pattern;
LGG	cis	rs9814567	0.896	rs6799110	chr3:134206749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.26	-0.52	3.18e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg25885449	chr18:77638415	KCNG2	-0.38	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs11628318	0.614	rs942022	chr14:103108842	C/T	cg23461800	chr14:103021989	NA	-0.52	-8.36	-0.36	7.26e-16	Platelet count;
LGG	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg20891283	chr12:69753455	YEATS4	-1.06	-28.31	-0.8	4.77e-103	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	8.1	0.35	4.92e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4233802	0.708	rs7598384	chr2:151118644	A/C	cg25300694	chr2:151184358	NA	0.48	7.88	0.34	2.32e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7940866	0.903	rs1347283	chr11:130868583	T/G	cg12179176	chr11:130786555	SNX19	0.72	13.18	0.52	6.88e-34	Schizophrenia;
LGG	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.56	-0.37	1.62e-16	Triglycerides;
LGG	cis	rs9487094	0.567	rs13196280	chr6:110085366	G/T	cg01125227	chr6:109776195	MICAL1	0.51	8.33	0.36	9.29e-16	Height;
LGG	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg16414030	chr3:133502952	NA	-0.42	-6.91	-0.31	1.62e-11	Iron status biomarkers (transferrin levels);
LGG	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.78	0.54	1.87e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg12395012	chr8:11607386	GATA4	0.39	7.25	0.32	1.75e-12	Neuroticism;
LGG	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg07061783	chr6:25882402	NA	-0.48	-8.08	-0.35	5.78e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1475911	1.000	rs1475911	chr21:43513480	A/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.48	-8.64	-0.37	9.06e-17	IgG glycosylation;
LGG	cis	rs6580649	0.941	rs17122613	chr12:48460016	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.57	-0.47	2.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg02269571	chr22:50332266	NA	0.64	10.17	0.43	4.62e-22	Schizophrenia;
LGG	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	cis	rs9462027	0.517	rs2744973	chr6:34580221	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.47	-9.13	-0.39	2.19e-18	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.55e-15	Bipolar disorder;
LGG	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg13385521	chr17:29058706	SUZ12P	0.88	10.39	0.43	7.01e-23	Body mass index;
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg03351412	chr1:154909251	PMVK	-0.64	-11.96	-0.49	6.47e-29	Prostate cancer;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.86	-0.3	2.22e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.23	0.43	2.87e-22	Neuroticism;
LGG	cis	rs9393777	0.623	rs9358945	chr6:26472114	C/T	cg12826209	chr6:26865740	GUSBL1	-0.79	-11.28	-0.46	2.96e-26	Intelligence (multi-trait analysis);
LGG	cis	rs77741769	0.571	rs869781	chr12:121340246	T/C	cg02419362	chr12:121203948	SPPL3	0.54	9.3	0.4	5.66e-19	Mean corpuscular volume;
LGG	cis	rs2377585	0.653	rs73053867	chr12:8847598	A/G	cg03761649	chr12:8850719	RIMKLB	0.49	7.97	0.35	1.24e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9878978	1.000	rs13074392	chr3:2485795	A/G	cg21928760	chr3:2462534	CNTN4	0.4	8.8	0.38	2.74e-17	Blood pressure (smoking interaction);
LGG	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg16850897	chr7:100343110	ZAN	-0.66	-9.8	-0.41	9.6e-21	Other erythrocyte phenotypes;
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00166722	chr3:10149974	C3orf24	0.53	9.0	0.39	5.65e-18	Alzheimer's disease;
LGG	cis	rs11676348	0.714	rs4674254	chr2:218986077	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-9.77	-0.41	1.31e-20	Ulcerative colitis;
LGG	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg15704280	chr7:45808275	SEPT13	0.49	8.0	0.35	1e-14	HDL cholesterol;
LGG	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.63	-0.48	1.28e-27	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08821673	chr11:57103388	SSRP1	0.48	7.15	0.32	3.45e-12	Gut microbiome composition (summer);
LGG	cis	rs8051149	0.688	rs16943320	chr16:87870379	A/G	cg01412419	chr16:87856264	NA	0.61	10.45	0.44	4.16e-23	Blood metabolite levels;
LGG	cis	rs62238980	0.614	rs78680556	chr22:32395329	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2033908	0.620	rs10765996	chr11:12853043	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-7.16	-0.32	3.14e-12	Sitting height ratio;
LGG	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.89	-16.49	-0.61	2.16e-48	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14013300	chr22:29196047	XBP1	-0.45	-6.76	-0.3	4.08e-11	Systemic lupus erythematosus;
LGG	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg13072238	chr3:49761600	GMPPB	0.55	7.19	0.32	2.56e-12	Menarche (age at onset);
LGG	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg03517284	chr6:25882590	NA	0.41	6.83	0.3	2.67e-11	Iron status biomarkers;
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg03806693	chr22:41940476	POLR3H	-1.17	-21.76	-0.71	7.89e-73	Vitiligo;
LGG	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs3219090	0.861	rs1858548	chr1:226607774	A/G	cg17127702	chr1:226594323	PARP1	0.39	12.19	0.49	7.6e-30	Melanoma;
LGG	cis	rs4481887	0.893	rs4512685	chr1:248446246	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-10.04	-0.42	1.32e-21	Common traits (Other);
LGG	cis	rs7091068	0.566	rs1326220	chr10:95486155	G/A	cg20715218	chr10:95462985	C10orf4	0.65	9.68	0.41	2.75e-20	Urinary tract infection frequency;
LGG	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs12478296	0.892	rs11897561	chr2:243014976	C/A	cg06360820	chr2:242988706	NA	-0.86	-11.26	-0.46	3.61e-26	Obesity-related traits;
LGG	cis	rs72777070	0.857	rs72777064	chr2:9795369	T/C	cg14973360	chr2:9800511	NA	-0.5	-6.74	-0.3	4.76e-11	Platelet-derived growth factor BB levels;
LGG	cis	rs6546537	1.000	rs6712370	chr2:69855094	C/G	cg10773587	chr2:69614142	GFPT1	0.47	7.79	0.34	4.39e-14	Serum thyroid-stimulating hormone levels;
LGG	cis	rs56146971	0.763	rs12587463	chr14:91859967	C/T	cg14409461	chr14:91925021	SMEK1	-0.43	-7.0	-0.31	9.31e-12	Alzheimer disease and age of onset;
LGG	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.9	-0.31	1.7e-11	Bipolar disorder;
LGG	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.29	-0.32	1.38e-12	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.72	-0.34	7.15e-14	Lung cancer;
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg16434002	chr17:42200994	HDAC5	0.52	9.81	0.41	9.22e-21	Total body bone mineral density;
LGG	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg10483660	chr13:112241077	NA	-0.46	-9.55	-0.41	7.77e-20	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg11878867	chr6:150167359	LRP11	-0.57	-11.78	-0.48	3.45e-28	Lung cancer;
LGG	cis	rs7927771	1.000	rs4752873	chr11:47857520	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.66	-0.37	7.78e-17	Subjective well-being;
LGG	cis	rs2067615	0.579	rs1073261	chr12:107135942	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.19	0.49	7.94e-30	Heart rate;
LGG	cis	rs4075765	0.764	rs17243217	chr11:26276738	G/A	cg19182008	chr11:26298241	NA	1.0	8.96	0.38	7.81e-18	Cannabis dependence symptom count;
LGG	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg08648136	chr8:956695	NA	0.37	7.77	0.34	5.01e-14	Schizophrenia;
LGG	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.25	-0.36	1.64e-15	Blood pressure (smoking interaction);
LGG	cis	rs2201728	0.967	rs4147532	chr4:100211786	T/C	cg07219303	chr4:100140905	ADH6	-0.39	-7.81	-0.34	3.96e-14	Cardiac Troponin-T levels;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-9.72	-0.41	1.93e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11168351	0.833	rs6580652	chr12:48447105	C/A	cg24011408	chr12:48396354	COL2A1	-0.58	-9.67	-0.41	2.88e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs16957091	1.000	rs8027427	chr15:43025174	T/A	cg07484255	chr15:43025164	CDAN1	-0.49	-7.03	-0.31	7.33e-12	MGMT methylation in smokers;
LGG	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg07005078	chr4:17578674	LAP3	0.36	6.74	0.3	4.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs853679	0.567	rs9969098	chr6:28398748	G/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.66	-0.3	7.89e-11	Depression;
LGG	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.94	0.42	3.01e-21	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07526883	chr14:39572542	SEC23A	0.46	7.49	0.33	3.44e-13	Cognitive performance;
LGG	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg13647721	chr17:30228624	UTP6	0.79	12.44	0.5	7.82e-31	Hip circumference adjusted for BMI;
LGG	cis	rs12493885	0.628	rs61790906	chr3:153653953	T/G	cg12800244	chr3:153838788	SGEF	-0.65	-7.57	-0.33	2.07e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.57	-0.44	1.48e-23	Platelet count;
LGG	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.41	0.44	6.18e-23	Diabetic retinopathy;
LGG	trans	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg16751781	chr15:78858589	CHRNA5	-0.39	-6.96	-0.31	1.14e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs283228	0.798	rs2399727	chr6:101788334	C/A	cg27451362	chr6:101846650	GRIK2	0.63	10.36	0.43	9.28e-23	Coenzyme Q10 levels;
LGG	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg16141378	chr3:129829833	LOC729375	0.37	8.71	0.38	5.54e-17	Joint mobility (Beighton score);
LGG	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg10596483	chr8:143751796	JRK	0.58	9.62	0.41	4.15e-20	Schizophrenia;
LGG	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-12.86	-0.51	1.42e-32	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs8180040	1.000	rs4858888	chr3:47405305	C/T	cg16586182	chr3:47516702	SCAP	0.77	14.97	0.57	1.29e-41	Colorectal cancer;
LGG	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg11941060	chr3:133502564	NA	-0.53	-9.24	-0.39	8.85e-19	Iron status biomarkers;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.21e-38	Tonsillectomy;
LGG	cis	rs17767392	0.846	rs56180634	chr14:71989933	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.91	-0.38	1.16e-17	Mitral valve prolapse;
LGG	cis	rs7928758	0.943	rs77478906	chr11:134264596	T/C	cg15243474	chr11:134282918	B3GAT1	1.19	15.37	0.58	2.23e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg03609598	chr5:56110824	MAP3K1	0.53	7.81	0.34	3.78e-14	Initial pursuit acceleration;
LGG	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg10661904	chr17:79619235	PDE6G	0.5	10.14	0.43	6.13e-22	Eye color traits;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs8133932	0.906	rs112980369	chr21:47063054	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-7.25	-0.32	1.74e-12	Schizophrenia;
LGG	cis	rs972578	0.691	rs4822200	chr22:43201210	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.72	-0.3	5.46e-11	Mean platelet volume;
LGG	cis	rs9948	0.521	rs61750875	chr2:97359364	A/G	cg01990225	chr2:97406019	LMAN2L	-0.73	-7.75	-0.34	6e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs3806843	0.766	rs702397	chr5:140050265	A/G	cg19875535	chr5:140030758	IK	-0.54	-10.99	-0.45	4.02e-25	Depressive symptoms (multi-trait analysis);
LGG	trans	rs9650657	0.769	rs6601527	chr8:10665444	C/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.07	-0.31	5.57e-12	Neuroticism;
LGG	cis	rs7173389	0.560	rs7174643	chr15:73680301	A/C	cg01796676	chr15:73680284	NA	0.51	9.66	0.41	3.05e-20	Resting heart rate;
LGG	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.9	-0.34	2.05e-14	Joint mobility (Beighton score);
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.58	9.81	0.41	8.9e-21	Obesity-related traits;
LGG	cis	rs9807841	0.592	rs2742313	chr19:10799750	T/C	cg17710535	chr19:10819994	QTRT1	0.52	8.31	0.36	1.08e-15	Inflammatory skin disease;
LGG	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg22920501	chr2:26401640	FAM59B	0.45	8.94	0.38	8.99e-18	Gut microbiome composition (summer);
LGG	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg11812906	chr14:75593930	NEK9	-0.51	-9.37	-0.4	3.23e-19	Height;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg20887711	chr4:1340912	KIAA1530	0.45	7.94	0.35	1.56e-14	Obesity-related traits;
LGG	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg01221209	chr5:554886	NA	-0.46	-6.81	-0.3	3e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.29	-8.36	-0.36	7.55e-16	IgG glycosylation;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21578322	chr20:30458044	TTLL9;DUSP15	0.59	6.79	0.3	3.47e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35176054	0.730	rs71476605	chr10:105508502	C/T	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.91	-0.31	1.59e-11	Atrial fibrillation;
LGG	cis	rs3740909	1.000	rs79748132	chr11:125883950	T/C	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs3849570	0.961	rs10154945	chr3:81833766	A/C	cg07356753	chr3:81810745	GBE1	-0.48	-7.84	-0.34	3.05e-14	Waist circumference;Body mass index;
LGG	cis	rs4423214	0.592	rs10898234	chr11:71236684	A/G	cg10847948	chr11:71163743	NADSYN1	0.57	8.7	0.37	6.03e-17	Vitamin D levels;
LGG	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	trans	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.27e-14	Heart rate;
LGG	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg05677249	chr15:77158041	SCAPER	-0.31	-6.74	-0.3	4.74e-11	Blood metabolite levels;
LGG	cis	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.8	-0.38	2.72e-17	Resting heart rate;
LGG	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg02073558	chr3:44770973	ZNF501	0.86	18.93	0.66	1.34e-59	Depressive symptoms;
LGG	cis	rs4679904	0.920	rs12638633	chr3:160227892	T/C	cg20378687	chr3:160281681	KPNA4	-0.35	-6.69	-0.3	6.48e-11	Primary biliary cholangitis;
LGG	trans	rs2018683	0.711	rs917214	chr7:28968293	T/C	cg19402173	chr7:128379420	CALU	-0.55	-9.38	-0.4	2.89e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg23057051	chr16:89984268	MC1R	-0.37	-6.95	-0.31	1.25e-11	Vitiligo;
LGG	cis	rs17539620	0.624	rs12665520	chr6:154835273	C/T	cg17771515	chr6:154831774	CNKSR3	0.63	7.76	0.34	5.35e-14	Lipoprotein (a) levels;
LGG	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Vitiligo;
LGG	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-19.48	-0.67	3.68e-62	Cognitive function;
LGG	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22857025	chr5:266934	NA	-1.51	-26.42	-0.78	1.83e-94	Breast cancer;
LGG	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg14689365	chr7:158441557	NCAPG2	0.6	10.13	0.43	6.51e-22	Height;
LGG	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-8.21	-0.36	2.3e-15	Menarche (age at onset);
LGG	cis	rs6540556	0.635	rs17389184	chr1:209916789	C/T	cg23920097	chr1:209922102	NA	-0.45	-7.26	-0.32	1.6e-12	Red blood cell count;
LGG	cis	rs757978	0.810	rs35319025	chr2:242402463	C/G	cg10173475	chr2:242152697	ANO7	-0.54	-6.97	-0.31	1.11e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg26384229	chr12:38710491	ALG10B	0.75	14.97	0.57	1.39e-41	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs4821018	chr22:32403318	A/G	cg02631450	chr22:32366979	NA	-0.84	-8.81	-0.38	2.59e-17	Childhood ear infection;
LGG	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg25358565	chr5:93447407	FAM172A	1.36	16.72	0.61	1.94e-49	Diabetic retinopathy;
LGG	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg10760299	chr15:45669010	GATM	0.4	7.9	0.34	2.09e-14	Homoarginine levels;
LGG	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.05	-0.35	6.94e-15	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg27400746	chr16:89904261	SPIRE2	-1.09	-16.53	-0.61	1.41e-48	Skin colour saturation;
LGG	cis	rs9309473	0.687	rs6747145	chr2:73609177	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-9.07	-0.39	3.35e-18	Metabolite levels;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg02461776	chr11:598696	PHRF1	0.47	7.77	0.34	5.08e-14	Systemic lupus erythematosus;
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg18258770	chr4:90757814	SNCA	0.39	7.17	0.32	3.06e-12	Dementia with Lewy bodies;
LGG	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.31	0.32	1.18e-12	Myopia (pathological);
LGG	cis	rs6028335	0.674	rs59096774	chr20:37603529	A/G	cg16355469	chr20:37678765	NA	0.6	7.97	0.35	1.21e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg14912033	chr15:79043428	NA	-0.33	-6.74	-0.3	4.83e-11	Coronary artery disease or large artery stroke;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23000464	chr19:633785	POLRMT	0.43	7.41	0.33	6.01e-13	Bipolar disorder;
LGG	cis	rs2712184	0.935	rs2541387	chr2:217666174	A/C	cg05032264	chr2:217675019	NA	-0.54	-12.64	-0.51	1.14e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.78	-0.34	4.84e-14	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04575325	chr6:160210070	MRPL18;TCP1	0.48	7.25	0.32	1.77e-12	Gut microbiome composition (summer);
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg05650719	chr12:132293520	NA	-0.38	-8.49	-0.37	2.91e-16	Migraine;
LGG	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs2013441	0.813	rs4925088	chr17:20049344	A/G	cg13482628	chr17:19912719	NA	0.43	8.03	0.35	8e-15	Obesity-related traits;
LGG	cis	rs3008870	0.583	rs17497947	chr1:67457199	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-18.56	-0.65	6.57e-58	Lymphocyte percentage of white cells;
LGG	trans	rs1459104	1.000	rs66654577	chr11:55168539	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.8	0.3	3.23e-11	Body mass index;
LGG	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg07936489	chr17:37558343	FBXL20	1.0	15.52	0.59	4.73e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.71	0.34	7.67e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg03605463	chr16:89740564	NA	0.56	10.28	0.43	1.77e-22	Vitiligo;
LGG	cis	rs9287719	0.967	rs10929682	chr2:10732189	C/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9814567	0.896	rs13089566	chr3:134349710	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.68	0.51	8.03e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2470578	0.792	rs2167118	chr3:17283278	G/A	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg26513180	chr16:89883248	FANCA	-0.53	-9.29	-0.4	5.9e-19	Vitiligo;
LGG	cis	rs10197940	0.578	rs2432957	chr2:152287897	A/C	cg19508488	chr2:152266495	RIF1	0.48	8.63	0.37	9.63e-17	Lung cancer;
LGG	cis	rs9358372	0.752	rs9356754	chr6:20808742	A/C	cg13405222	chr6:20811065	CDKAL1	0.51	10.74	0.45	3.55e-24	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	19.71	0.68	3.11e-63	Platelet count;
LGG	cis	rs9399137	0.507	rs7754722	chr6:135260303	T/C	cg24558204	chr6:135376177	HBS1L	-0.6	-10.28	-0.43	1.75e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg14789911	chr21:47582049	C21orf56	0.52	9.33	0.4	4.43e-19	Testicular germ cell tumor;
LGG	cis	rs1124376	1.000	rs9857135	chr3:20147790	G/A	cg05072819	chr3:20081367	KAT2B	0.63	8.42	0.36	4.65e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.62	0.33	1.49e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.79	0.3	3.41e-11	Schizophrenia;
LGG	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg14926445	chr8:58193284	C8orf71	-0.69	-9.16	-0.39	1.67e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7635838	0.684	rs2594966	chr3:11325276	A/G	cg00170343	chr3:11313890	ATG7	-0.5	-8.68	-0.37	6.59e-17	HDL cholesterol;
LGG	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.6	-0.65	4.35e-58	Monocyte count;
LGG	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg16482183	chr6:26056742	HIST1H1C	0.52	9.21	0.39	1.17e-18	Height;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Electroencephalogram traits;
LGG	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg06916706	chr16:4465613	CORO7	0.74	12.23	0.49	5.46e-30	Schizophrenia;
LGG	cis	rs5742933	0.803	rs1233302	chr2:190668880	C/A	cg04003228	chr2:190539410	ANKAR	0.46	6.71	0.3	5.77e-11	Ferritin levels;
LGG	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.56	-7.13	-0.31	3.76e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.15e-14	HDL cholesterol;
LGG	cis	rs6694672	0.867	rs1115247	chr1:197037667	A/G	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.31e-11	Asthma;
LGG	cis	rs4363385	0.747	rs4240867	chr1:152954921	A/G	cg13444842	chr1:152974279	SPRR3	0.44	8.86	0.38	1.77e-17	Inflammatory skin disease;
LGG	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	19.41	0.67	7.43e-62	Smoking behavior;
LGG	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06481639	chr22:41940642	POLR3H	0.54	7.69	0.34	8.99e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9300255	0.602	rs2851438	chr12:123643689	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18876405	chr7:65276391	NA	0.54	9.73	0.41	1.8e-20	Aortic root size;
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.61	7.41	0.33	5.84e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs8050755	0.649	rs2516737	chr16:2101749	A/G	cg04515572	chr16:2107413	TSC2	0.85	11.52	0.47	3.54e-27	Major depressive disorder;
LGG	cis	rs9534288	0.783	rs7987385	chr13:46634131	A/G	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs10979	1.000	rs9390110	chr6:143893413	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.54	-0.5	2.83e-31	Hypospadias;
LGG	cis	rs9902453	0.578	rs8073217	chr17:28164263	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.72	0.54	3.37e-36	Coffee consumption (cups per day);
LGG	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg14784868	chr12:69753453	YEATS4	0.71	11.12	0.46	1.23e-25	Response to diuretic therapy;
LGG	cis	rs2274273	0.840	rs72715769	chr14:55762429	C/G	cg04306507	chr14:55594613	LGALS3	0.62	16.93	0.62	2.04e-50	Protein biomarker;
LGG	cis	rs1003719	0.680	rs2835620	chr21:38505581	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs5742933	0.857	rs893784	chr2:190536283	C/T	cg04003228	chr2:190539410	ANKAR	0.51	7.37	0.32	8.14e-13	Ferritin levels;
LGG	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11764359	chr7:65958608	NA	0.57	9.58	0.41	5.89e-20	Aortic root size;
LGG	cis	rs7639513	0.767	rs3806661	chr3:12705855	A/G	cg23032965	chr3:12705835	RAF1	0.85	16.8	0.62	8.47e-50	Itch intensity from mosquito bite;
LGG	cis	rs526231	0.543	rs40092	chr5:102424213	A/G	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.1	-0.31	4.63e-12	Personality dimensions;
LGG	cis	rs6960043	1.000	rs12666046	chr7:15050381	A/G	cg19272540	chr7:15055459	NA	-0.36	-8.09	-0.35	5.36e-15	Type 2 diabetes;
LGG	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg11494091	chr17:61959527	GH2	-0.68	-11.86	-0.48	1.65e-28	Height;
LGG	cis	rs6456156	0.565	rs7750209	chr6:167482895	T/G	cg07741184	chr6:167504864	NA	0.41	9.33	0.4	4.49e-19	Primary biliary cholangitis;
LGG	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg15440763	chr7:158190612	PTPRN2	0.5	10.43	0.44	4.97e-23	Obesity-related traits;
LGG	cis	rs4538187	0.662	rs66980330	chr2:64125978	C/G	cg19915305	chr2:64069682	UGP2	-0.61	-12.82	-0.51	2.09e-32	Systolic blood pressure;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg21782813	chr7:2030301	MAD1L1	0.47	10.78	0.45	2.51e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.86	0.3	2.27e-11	Vitiligo;
LGG	cis	rs953387	0.910	rs4954397	chr2:136946433	A/G	cg07169764	chr2:136633963	MCM6	0.53	8.74	0.38	4.33e-17	Arthritis (juvenile idiopathic);
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.57	-0.37	1.51e-16	Neuroticism;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg16270222	chr17:41446396	NA	-0.3	-7.27	-0.32	1.52e-12	Menopause (age at onset);
LGG	cis	rs9486719	0.843	rs1009597	chr6:96843540	A/T	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg06640241	chr16:89574553	SPG7	0.9	17.01	0.62	8.96e-51	Multiple myeloma (IgH translocation);
LGG	cis	rs8078723	0.690	rs3785549	chr17:38149724	T/C	cg17467752	chr17:38218738	THRA	-0.62	-11.2	-0.46	6e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.6e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.77	0.48	3.69e-28	Mean corpuscular volume;
LGG	cis	rs1109114	0.816	rs2963492	chr5:148595285	C/T	cg06539116	chr5:148597365	ABLIM3	0.62	16.45	0.61	3.27e-48	Body mass index;
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18404041	chr3:52824283	ITIH1	0.5	9.86	0.42	6.22e-21	Electroencephalogram traits;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg11301795	chr4:187892539	NA	-0.93	-25.54	-0.76	2.02e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6735179	0.565	rs6726887	chr2:1749257	A/G	cg08534653	chr2:1747700	PXDN	0.5	7.42	0.33	5.67e-13	Response to antipsychotic treatment;
LGG	cis	rs8072100	0.840	rs4968319	chr17:45464967	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-10.58	-0.44	1.39e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg06654118	chr4:1303317	MAEA	0.49	8.56	0.37	1.7e-16	Obesity-related traits;
LGG	cis	rs10992471	0.756	rs2761681	chr9:95186937	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.35	-0.32	8.77e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.94	0.57	1.71e-41	Cognitive test performance;
LGG	cis	rs8060686	0.545	rs9931987	chr16:68256639	G/A	cg27539214	chr16:67997921	SLC12A4	-0.44	-6.91	-0.31	1.6e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs36071027	0.577	rs11747844	chr5:158441176	A/T	cg04248271	chr5:158524404	EBF1	-0.41	-7.3	-0.32	1.3e-12	Carotid intima media thickness;
LGG	cis	rs6107516	0.645	rs6116471	chr20:4669534	C/T	cg02413285	chr20:4668134	PRNP	-0.56	-8.92	-0.38	1.1e-17	Creutzfeldt-Jakob disease (variant);Creutzfeldt-Jakob disease (sporadic);
LGG	cis	rs10465746	0.746	rs6699501	chr1:84389993	A/G	cg10977910	chr1:84465055	TTLL7	0.58	10.71	0.45	4.8e-24	Obesity-related traits;
LGG	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg14979609	chr8:8086686	FLJ10661	-0.28	-7.2	-0.32	2.4e-12	Mood instability;
LGG	cis	rs2274273	0.870	rs3783652	chr14:55854208	A/G	cg04306507	chr14:55594613	LGALS3	0.62	17.0	0.62	1.03e-50	Protein biomarker;
LGG	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23544223	chr18:12777786	NA	0.59	8.91	0.38	1.19e-17	Inflammatory skin disease;
LGG	cis	rs2688608	0.592	rs11000760	chr10:75493734	G/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.11	-0.31	4.37e-12	Inflammatory bowel disease;
LGG	cis	rs7010267	0.743	rs3134049	chr8:119942643	T/G	cg17171407	chr8:119960777	TNFRSF11B	-0.37	-9.35	-0.4	3.64e-19	Total body bone mineral density (age 45-60);
LGG	trans	rs2018683	0.707	rs917215	chr7:28971367	C/T	cg19402173	chr7:128379420	CALU	-0.53	-9.26	-0.4	7.54e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs13095912	0.719	rs7625483	chr3:185297113	T/C	cg11274856	chr3:185301563	NA	0.49	8.0	0.35	1.01e-14	Systolic blood pressure;
LGG	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.5	-0.33	3.33e-13	Testicular germ cell tumor;
LGG	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg04111992	chr7:158790115	NA	-0.38	-7.68	-0.34	9.41e-14	Facial morphology (factor 20);
LGG	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg17809284	chr5:56205270	C5orf35	-0.5	-8.97	-0.38	7.24e-18	Coronary artery disease;
LGG	cis	rs4478037	1.000	rs56733391	chr3:33161434	G/A	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs2044029	0.504	rs1372214	chr15:71655424	G/A	cg19634315	chr15:71679485	THSD4	0.46	8.71	0.38	5.36e-17	Airflow obstruction;
LGG	cis	rs12477438	0.520	rs4143760	chr2:100101762	C/A	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	16.98	0.62	1.33e-50	Smoking behavior;
LGG	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg02187348	chr16:89574699	SPG7	0.46	7.53	0.33	2.69e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg26384229	chr12:38710491	ALG10B	0.67	12.17	0.49	9.29e-30	Morning vs. evening chronotype;
LGG	cis	rs4953318	0.619	rs12105417	chr2:46361255	A/C	cg12428440	chr2:46370979	PRKCE	0.5	9.24	0.39	9.05e-19	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs16854884	0.657	rs16854819	chr3:143736126	C/T	cg06585982	chr3:143692056	C3orf58	-0.58	-10.05	-0.42	1.31e-21	Economic and political preferences (feminism/equality);
LGG	cis	rs2074585	0.806	rs2657949	chr15:90950790	G/A	cg22089800	chr15:90895588	ZNF774	0.68	12.4	0.5	1.06e-30	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs1010254	0.559	rs991635	chr5:151748921	A/G	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.86e-11	Optic nerve measurement (cup area);
LGG	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg13293535	chr8:11597251	GATA4	0.35	8.62	0.37	1.08e-16	Neuroticism;
LGG	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg00599393	chr8:22457479	C8orf58	-0.44	-8.08	-0.35	5.83e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00989323	chr10:49864621	NA	0.44	7.31	0.32	1.22e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.95	-0.38	8.84e-18	Lung cancer;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg04098458	chr2:149402448	EPC2	0.38	7.02	0.31	7.73e-12	Corneal astigmatism;
LGG	cis	rs2229238	0.911	rs111600849	chr1:154487489	G/A	cg10237817	chr1:154519846	TDRD10	0.33	6.74	0.3	4.59e-11	Coronary heart disease;
LGG	cis	rs6450176	0.909	rs7732139	chr5:53292017	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.0	-0.46	3.53e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs28374715	0.662	rs13329579	chr15:41467435	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-17.51	-0.63	4.92e-53	Ulcerative colitis;
LGG	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.52	-0.63	4.12e-53	Refractive error;
LGG	cis	rs72925845	0.577	rs72907460	chr17:76428659	T/C	cg03830375	chr17:76426088	DNAH17	0.5	7.13	0.31	3.9e-12	Triglycerides;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg08082602	chr14:67914417	NA	0.34	7.49	0.33	3.49e-13	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs61931739	0.534	rs814669	chr12:34102459	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.69	0.56	2.34e-40	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg10756647	chr7:56101905	PSPH	0.8	9.39	0.4	2.64e-19	Diabetic kidney disease;
LGG	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.58	0.33	1.92e-13	Eosinophil percentage of white cells;
LGG	cis	rs11674184	0.632	rs17529680	chr2:11727087	A/C	cg07314298	chr2:11723111	GREB1	0.74	15.83	0.59	2.08e-45	Endometriosis;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08677398	chr8:58056175	NA	0.57	9.16	0.39	1.66e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg24130564	chr14:104152367	KLC1	0.37	6.7	0.3	5.98e-11	Reticulocyte count;
LGG	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06470251	chr20:60548479	NA	0.51	8.51	0.37	2.35e-16	Body mass index;
LGG	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.46	-0.33	4.32e-13	Testicular germ cell tumor;
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg19774624	chr17:42201019	HDAC5	-0.97	-20.94	-0.7	5.66e-69	Total body bone mineral density;
LGG	cis	rs7586879	0.796	rs36071142	chr2:25080570	C/T	cg04586622	chr2:25135609	ADCY3	0.36	8.68	0.37	6.58e-17	Body mass index;
LGG	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg00599393	chr8:22457479	C8orf58	-0.42	-7.8	-0.34	4.02e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7444	0.941	rs4821130	chr22:21980894	C/T	cg11654148	chr22:21984483	YDJC	-0.38	-7.29	-0.32	1.31e-12	Systemic lupus erythematosus;
LGG	cis	rs7737355	0.945	rs245801	chr5:130666955	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.62	-0.37	1.04e-16	Life satisfaction;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-8.06	-0.35	6.55e-15	Blood metabolite levels;
LGG	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.65	-0.75	2.61e-86	Height;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg02725872	chr8:58115012	NA	-0.92	-11.94	-0.49	7.77e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.03e-21	HDL cholesterol levels;
LGG	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs17504614	0.634	rs67090318	chr2:51046482	T/A	cg23851515	chr2:51057218	NRXN1	0.47	7.65	0.34	1.14e-13	Educational attainment (years of education);
LGG	cis	rs72752223	0.541	rs12438772	chr15:93753488	T/C	cg01959025	chr15:93749169	NA	0.47	6.99	0.31	9.63e-12	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
LGG	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg11764359	chr7:65958608	NA	0.55	9.33	0.4	4.5e-19	Aortic root size;
LGG	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg05096777	chr10:104283225	SUFU	0.32	7.0	0.31	9.13e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2952156	0.959	rs1495101	chr17:37832103	C/A	cg00129232	chr17:37814104	STARD3	-0.7	-14.16	-0.55	4.28e-38	Asthma;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19306474	chr10:6243561	PFKFB3	0.65	7.64	0.33	1.22e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17331151	0.541	rs1139106	chr3:52871101	G/A	cg04865290	chr3:52927548	TMEM110	-0.4	-6.98	-0.31	1.05e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4901847	0.967	rs7143935	chr14:58558112	C/G	cg15908186	chr14:58618357	C14orf37	0.54	9.64	0.41	3.76e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs8073060	0.586	rs6505487	chr17:33996850	A/G	cg19694781	chr19:47549865	TMEM160	-1.15	-17.15	-0.62	2.03e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs308971	0.563	rs2618403	chr3:12039463	C/T	cg22839075	chr3:12045461	SYN2	0.5	6.66	0.3	7.65e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg11764359	chr7:65958608	NA	-0.8	-14.86	-0.57	3.92e-41	Aortic root size;
LGG	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg05425664	chr17:57184151	TRIM37	-0.71	-11.65	-0.48	1.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4417704	0.551	rs4610050	chr2:241891914	A/G	cg05025159	chr2:241905733	NA	0.49	10.26	0.43	2.12e-22	Joint mobility (Beighton score);
LGG	cis	rs10197940	0.624	rs3771901	chr2:152432481	G/A	cg19508488	chr2:152266495	RIF1	0.6	10.55	0.44	1.82e-23	Lung cancer;
LGG	cis	rs2133450	0.662	rs67047759	chr3:7273100	T/C	cg19930620	chr3:7340148	GRM7	-0.34	-7.34	-0.32	9.84e-13	Early response to risperidone in schizophrenia;
LGG	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg27170947	chr2:26402098	FAM59B	-0.29	-6.75	-0.3	4.41e-11	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20887711	chr4:1340912	KIAA1530	0.89	19.77	0.68	1.52e-63	Longevity;
LGG	cis	rs7011049	1.000	rs10958336	chr8:53841318	G/A	cg26025543	chr8:53854495	NA	0.75	9.96	0.42	2.66e-21	Systolic blood pressure;
LGG	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg26597838	chr10:835615	NA	0.74	10.06	0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.91e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7097780	0.801	rs7913599	chr10:6022562	A/G	cg10686550	chr10:6020330	IL15RA	-0.4	-7.63	-0.33	1.32e-13	Blood protein levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18493069	chr6:108582623	SNX3	-0.54	-7.99	-0.35	1.1e-14	Systemic lupus erythematosus;
LGG	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.46	-0.47	6.2e-27	Urinary tract infection frequency;
LGG	cis	rs10191773	0.589	rs72831638	chr2:112949212	C/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.55	-8.12	-0.35	4.33e-15	Yeast infection;
LGG	trans	rs7945404	0.548	rs4936618	chr11:121223996	G/T	cg27192990	chr6:129479024	LAMA2	0.57	8.3	0.36	1.19e-15	QT interval;
LGG	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg08344181	chr3:125677491	NA	-0.85	-8.49	-0.37	2.89e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg19812747	chr11:111475976	SIK2	0.43	8.68	0.37	7.01e-17	Primary sclerosing cholangitis;
LGG	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg23250157	chr14:64679961	SYNE2	0.4	7.19	0.32	2.64e-12	Atrial fibrillation;
LGG	cis	rs10267417	0.603	rs4721829	chr7:19873199	A/G	cg05791153	chr7:19748676	TWISTNB	0.64	8.28	0.36	1.35e-15	Night sleep phenotypes;
LGG	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.77	-0.51	3.28e-32	Morning vs. evening chronotype;
LGG	cis	rs9596837	0.514	rs9596840	chr13:54267629	C/T	ch.13.53330881F	chr13:54432880	NA	0.42	6.69	0.3	6.49e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg25008857	chr14:105974488	NA	0.57	10.15	0.43	5.52e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg20302533	chr7:39170763	POU6F2	0.59	14.99	0.57	1.09e-41	IgG glycosylation;
LGG	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-13.34	-0.53	1.44e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2976388	0.609	rs2572907	chr8:143801938	G/A	cg06565975	chr8:143823917	SLURP1	0.37	9.43	0.4	2.01e-19	Urinary tract infection frequency;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.76e-17	Bipolar disorder;
LGG	cis	rs9915657	0.870	rs12941066	chr17:70141226	C/T	cg09344028	chr17:70110421	NA	0.46	10.15	0.43	5.55e-22	Thyroid hormone levels;
LGG	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.01	-0.39	5.39e-18	Primary sclerosing cholangitis;
LGG	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03576123	chr11:487126	PTDSS2	-1.25	-16.7	-0.61	2.29e-49	Body mass index;
LGG	cis	rs10934753	0.609	rs2077523	chr3:125905389	A/C	cg01346077	chr3:125931526	NA	0.41	10.36	0.43	9.23e-23	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg13385521	chr17:29058706	SUZ12P	0.93	10.68	0.44	6.02e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.15	0.43	5.49e-22	Iron status biomarkers;
LGG	cis	rs2235649	0.833	rs9929185	chr16:1852070	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.96	-0.31	1.2e-11	Blood metabolite levels;
LGG	cis	rs10850519	0.502	rs1874900	chr12:115950911	A/G	cg18639984	chr12:115943877	NA	0.35	6.74	0.3	4.78e-11	Diastolic blood pressure;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs9911578	1.000	rs1472288	chr17:56910720	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4262150	0.672	rs72806793	chr5:152356172	G/A	cg12297329	chr5:152029980	NA	-0.56	-8.73	-0.38	4.71e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-8.17	-0.36	2.92e-15	Lung cancer;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.52	10.32	0.43	1.28e-22	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13662262	chr21:30364895	RNF160	0.41	7.17	0.32	2.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg05234568	chr11:5960015	NA	-0.64	-10.35	-0.43	9.66e-23	DNA methylation (variation);
LGG	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.17	0.52	7.06e-34	Menopause (age at onset);
LGG	cis	rs7085104	0.700	rs743572	chr10:104597152	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.19	0.39	1.35e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11644478	chr21:40555479	PSMG1	0.92	17.75	0.64	3.67e-54	Cognitive function;
LGG	cis	rs300774	0.925	rs405258	chr2:145646	T/A	cg04617936	chr2:214353	NA	-0.5	-7.49	-0.33	3.48e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.86	0.42	6.29e-21	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25072359	chr17:41440525	NA	0.54	10.2	0.43	3.46e-22	Menopause (age at onset);
LGG	cis	rs651907	0.588	rs1378838	chr3:101634543	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.85	0.34	2.96e-14	Colorectal cancer;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-10.29	-0.43	1.61e-22	Prudent dietary pattern;
LGG	cis	rs4804815	0.784	rs2098701	chr19:7840140	G/A	cg00371453	chr19:7854482	CLEC4GP1	0.7	10.57	0.44	1.61e-23	Neutrophil count;
LGG	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg19455335	chr8:22457658	C8orf58	-0.44	-8.92	-0.38	1.09e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9921222	0.500	rs8046256	chr16:393948	C/T	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.46	-6.94	-0.31	1.36e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg23815491	chr16:72088622	HP	0.52	11.74	0.48	4.84e-28	Fibrinogen levels;
LGG	cis	rs7945718	0.875	rs9888178	chr11:12782643	C/T	cg25843174	chr11:12811716	TEAD1	0.39	8.13	0.35	4.06e-15	Educational attainment (years of education);
LGG	cis	rs2688608	0.672	rs2688621	chr10:75687849	C/T	cg10168709	chr10:75599394	CAMK2G	-0.35	-6.94	-0.31	1.3e-11	Inflammatory bowel disease;
LGG	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg19812747	chr11:111475976	SIK2	-0.51	-10.66	-0.44	6.97e-24	Primary sclerosing cholangitis;
LGG	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.51	-0.44	2.54e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg24450063	chr1:156163899	SLC25A44	1.25	32.46	0.83	2.22e-121	Testicular germ cell tumor;
LGG	cis	rs16912285	0.688	rs12801367	chr11:24321827	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	13.15	0.52	8.61e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.42	-0.4	2.18e-19	Triglycerides;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg21518151	chr13:112631009	NA	-0.39	-6.72	-0.3	5.39e-11	Alzheimer's disease (survival time);
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs988958	0.565	rs6756395	chr2:42236128	G/C	cg27428208	chr2:42229179	NA	0.49	7.73	0.34	6.78e-14	Hypospadias;
LGG	trans	rs1728785	0.748	rs889560	chr16:68605784	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs1957429	0.520	rs7144515	chr14:65333725	G/A	cg23373153	chr14:65346875	NA	-1.02	-10.84	-0.45	1.48e-24	Pediatric areal bone mineral density (radius);
LGG	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg00290607	chr11:67383545	NA	-0.52	-9.24	-0.39	9.33e-19	Mean corpuscular volume;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.34	-0.5	1.88e-30	Lymphocyte counts;
LGG	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg25358565	chr5:93447407	FAM172A	0.67	9.31	0.4	5.03e-19	Diabetic retinopathy;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.47	-0.33	3.94e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17453880	0.890	rs6860811	chr5:152049653	G/T	cg10931792	chr5:152022470	NA	0.42	9.01	0.39	5.63e-18	Subjective well-being;
LGG	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg02002194	chr4:3960332	NA	0.51	9.53	0.4	9.07e-20	Retinal vascular caliber;
LGG	cis	rs5769707	0.967	rs4524218	chr22:50018639	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.68	0.34	9.7e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs17818399	0.708	rs1531133	chr2:46843631	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-8.62	-0.37	1.09e-16	Height;
LGG	cis	rs12928939	0.518	rs12445564	chr16:71943309	C/T	cg03805757	chr16:71968109	PKD1L3	-0.64	-13.04	-0.52	2.53e-33	Post bronchodilator FEV1;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg01988459	chr11:68622903	NA	-0.63	-12.81	-0.51	2.34e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2268241	0.938	rs28653198	chr21:34782395	A/C	cg14850771	chr21:34775459	IFNGR2	0.78	9.41	0.4	2.41e-19	Obesity-related traits;
LGG	cis	rs2640806	0.506	rs13254991	chr8:97371686	T/C	cg22138393	chr8:97340270	PTDSS1	0.27	6.91	0.31	1.57e-11	Obesity-related traits;
LGG	cis	rs1014246	0.813	rs11197805	chr10:118479677	G/A	cg14919929	chr10:118506882	NA	0.65	12.56	0.5	2.38e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg04398451	chr17:18023971	MYO15A	-0.66	-12.97	-0.52	4.93e-33	Total body bone mineral density;
LGG	cis	rs6763768	0.606	rs11130365	chr3:53291478	C/T	cg16894138	chr3:53270350	TKT	0.39	7.36	0.32	8.19e-13	Bacterial meningitis;
LGG	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.52	-0.44	2.41e-23	Bladder cancer;
LGG	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	7.12	0.31	4.03e-12	Multiple sclerosis;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg26513180	chr16:89883248	FANCA	0.8	8.89	0.38	1.41e-17	Skin colour saturation;
LGG	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.41	0.56	3.73e-39	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4689642	0.507	rs12647557	chr4:7221041	T/G	cg21353189	chr4:7228343	SORCS2	0.32	6.84	0.3	2.5e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6964587	0.585	rs10266481	chr7:91554338	T/C	cg17063962	chr7:91808500	NA	-0.47	-8.75	-0.38	4.11e-17	Breast cancer;
LGG	cis	rs35978510	1	rs35978510	chr1:243776117	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.64	-0.59	1.46e-44	Schizophrenia;
LGG	cis	rs6960043	0.875	rs6976381	chr7:15048814	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.77	-0.34	5.19e-14	Type 2 diabetes;
LGG	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.69	0.41	2.41e-20	Height;
LGG	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg09264619	chr17:80180166	NA	-0.52	-9.98	-0.42	2.33e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg17376030	chr22:41985996	PMM1	-0.61	-9.89	-0.42	4.72e-21	Vitiligo;
LGG	trans	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.91	-0.38	1.14e-17	Bladder cancer;
LGG	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27286337	chr10:134555280	INPP5A	0.84	12.09	0.49	1.93e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg05313129	chr8:58192883	C8orf71	-0.84	-12.47	-0.5	5.87e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg13647721	chr17:30228624	UTP6	0.63	7.88	0.34	2.41e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1318772	0.932	rs11744710	chr5:112932318	A/C	cg12552261	chr5:112820674	MCC	0.72	7.94	0.35	1.59e-14	F-cell distribution;
LGG	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.38	6.81	0.3	3.05e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg04317338	chr11:64019027	PLCB3	0.59	6.66	0.3	7.8e-11	Mean platelet volume;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03699307	chr16:75600014	GABARAPL2	0.43	7.21	0.32	2.29e-12	Bipolar disorder;
LGG	cis	rs911263	0.961	rs1885013	chr14:68754695	G/A	cg18825221	chr14:68749962	RAD51L1	0.53	11.37	0.47	1.33e-26	Primary biliary cholangitis;
LGG	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg17376030	chr22:41985996	PMM1	0.64	9.68	0.41	2.68e-20	Vitiligo;
LGG	cis	rs8049040	0.586	rs16972663	chr16:71460564	C/T	cg06353428	chr16:71660113	MARVELD3	-0.56	-8.77	-0.38	3.54e-17	Blood protein levels;
LGG	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg03929089	chr4:120376271	NA	0.41	6.69	0.3	6.65e-11	HDL cholesterol;
LGG	cis	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02753865	chr7:56119046	CCT6A;PSPH	0.4	6.71	0.3	5.6e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg27129171	chr3:47204927	SETD2	-0.72	-12.53	-0.5	3.27e-31	Birth weight;
LGG	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg00666640	chr1:248458726	OR2T12	0.57	9.05	0.39	3.89e-18	Common traits (Other);
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg11878867	chr6:150167359	LRP11	-0.59	-12.61	-0.51	1.45e-31	Lung cancer;
LGG	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg26384229	chr12:38710491	ALG10B	0.97	21.99	0.71	6.89e-74	Bladder cancer;
LGG	cis	rs9596863	0.851	rs9591532	chr13:54308351	A/G	ch.13.53330881F	chr13:54432880	NA	0.5	6.71	0.3	5.62e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs564799	0.966	rs2647931	chr3:159737076	G/A	cg04855961	chr3:159719849	NA	-0.28	-7.48	-0.33	3.69e-13	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00689492	chr4:1303491	MAEA	0.46	8.15	0.35	3.33e-15	Obesity-related traits;
LGG	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.44	-6.93	-0.31	1.38e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.06	0.39	3.59e-18	Alzheimer's disease;
LGG	cis	rs911263	0.603	rs3784108	chr14:68789683	T/C	cg18825221	chr14:68749962	RAD51L1	0.35	7.73	0.34	6.98e-14	Primary biliary cholangitis;
LGG	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg25482853	chr8:67687455	SGK3	1.04	13.42	0.53	6.24e-35	Lung disease severity in cystic fibrosis;
LGG	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6748734	0.519	rs9973362	chr2:241898198	T/C	cg26818257	chr2:241905806	NA	0.49	10.36	0.43	9.11e-23	Urinary metabolites;
LGG	cis	rs2562456	0.833	rs2681388	chr19:21732253	G/C	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	cis	rs1185460	0.967	rs1786690	chr11:118942067	A/G	cg23280166	chr11:118938394	VPS11	0.58	10.67	0.44	6.27e-24	Coronary artery disease;
LGG	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.14e-36	Corneal astigmatism;
LGG	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg05484508	chr16:89589025	SPG7	0.46	7.5	0.33	3.21e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg02002194	chr4:3960332	NA	-0.47	-8.8	-0.38	2.65e-17	Monocyte count;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs12468557	0.527	rs12694205	chr2:211499367	A/G	cg07063745	chr2:211341572	LANCL1;CPS1	-0.5	-8.73	-0.38	4.55e-17	Body mass index in asthmatics;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg00830817	chr11:109293614	C11orf87	0.41	7.0	0.31	9.08e-12	Schizophrenia;
LGG	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg17218041	chr13:113365319	ATP11A	0.42	7.06	0.31	6.2e-12	Glycated hemoglobin levels;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08035479	chr8:58172643	NA	-0.5	-7.52	-0.33	2.91e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.69	-0.3	6.62e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14298792	chr15:30685198	CHRFAM7A	0.5	7.35	0.32	8.94e-13	Huntington's disease progression;
LGG	cis	rs2694528	0.925	rs1038144	chr5:60199201	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.58	-0.33	1.96e-13	Parkinson's disease;
LGG	cis	rs16866061	1.000	rs72974269	chr2:225454907	C/T	cg12698349	chr2:225449008	CUL3	0.93	18.96	0.66	9.42e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg24098013	chr12:12878779	APOLD1	0.52	8.65	0.37	8.74e-17	Lymphocyte counts;
LGG	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg23649088	chr2:200775458	C2orf69	0.52	8.86	0.38	1.74e-17	Osteoporosis;
LGG	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.59	-0.79	8.3e-100	Height;
LGG	trans	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs10991814	0.841	rs79219699	chr9:94028898	C/T	cg14446406	chr9:93919335	NA	-0.73	-8.14	-0.35	3.56e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs80282103	0.618	rs11816485	chr10:1147974	T/C	cg08668510	chr10:1095578	IDI1	0.77	7.63	0.33	1.37e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg13385794	chr1:248469461	NA	0.49	8.17	0.35	2.97e-15	Common traits (Other);
LGG	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-10.01	-0.42	1.78e-21	Menarche (age at onset);
LGG	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg13385521	chr17:29058706	SUZ12P	0.89	10.01	0.42	1.82e-21	Body mass index;
LGG	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.59	-0.33	1.72e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	9.65	0.41	3.24e-20	Schizophrenia;
LGG	cis	rs8064024	0.681	rs1395602	chr16:4911239	A/C	cg04440724	chr16:4920505	UBN1	-0.57	-12.67	-0.51	8.78e-32	Cancer;
LGG	cis	rs16854884	0.683	rs2053211	chr3:143774592	C/T	cg06585982	chr3:143692056	C3orf58	-0.56	-9.46	-0.4	1.54e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs2370759	1.000	rs79806114	chr10:32618022	T/C	cg01819863	chr10:32635814	EPC1	1.11	15.46	0.58	9.12e-44	Sexual dysfunction (female);
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.37	-0.47	1.39e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25072359	chr17:41440525	NA	0.52	10.14	0.43	5.8e-22	Menopause (age at onset);
LGG	cis	rs9397585	0.599	rs582367	chr6:153408708	A/G	cg17707550	chr6:153380415	RGS17	-0.44	-9.9	-0.42	4.39e-21	Body mass index;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.85	-0.54	9.69e-37	Tonsillectomy;
LGG	cis	rs7394190	0.748	rs11000780	chr10:75559077	G/A	cg07699608	chr10:75541558	CHCHD1	0.57	7.62	0.33	1.41e-13	Incident atrial fibrillation;
LGG	cis	rs870825	0.518	rs12512933	chr4:185665055	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	16.04	0.6	2.34e-46	Blood protein levels;
LGG	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg20573242	chr4:122745356	CCNA2	0.44	8.24	0.36	1.78e-15	Type 2 diabetes;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg07414643	chr4:187882934	NA	0.55	11.24	0.46	4.24e-26	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08976451	chr10:92631876	RPP30	0.46	6.99	0.31	9.69e-12	Gut microbiome composition (summer);
LGG	cis	rs3857747	0.827	rs1532722	chr7:40438667	T/A	cg00420559	chr7:40367873	C7orf10	-0.38	-7.64	-0.33	1.23e-13	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg10840412	chr1:235813424	GNG4	0.53	7.11	0.31	4.28e-12	Bipolar disorder;
LGG	cis	rs2334880	0.638	rs17343777	chr16:71439172	T/A	cg06353428	chr16:71660113	MARVELD3	-0.74	-10.02	-0.42	1.67e-21	Malaria;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	cis	rs986417	0.711	rs2224409	chr14:60957216	C/T	cg27398547	chr14:60952738	C14orf39	0.72	6.97	0.31	1.12e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7666738	0.830	rs11938686	chr4:98964470	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.85	0.34	2.88e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4006360	0.646	rs7501601	chr17:39293957	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.07	-0.46	1.91e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9296092	0.538	rs62407567	chr6:33537213	A/G	cg13560919	chr6:33536144	NA	-1.0	-19.55	-0.67	1.76e-62	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg05677249	chr15:77158041	SCAPER	-0.32	-6.76	-0.3	4.18e-11	Blood metabolite levels;
LGG	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg11494091	chr17:61959527	GH2	0.51	7.81	0.34	3.79e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.876	rs4618490	chr6:86518403	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.2	-0.49	7.3e-30	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs8017423	0.967	rs7160032	chr14:90708472	A/G	cg04374321	chr14:90722782	PSMC1	0.89	18.87	0.66	2.57e-59	Mortality in heart failure;
LGG	cis	rs10504073	0.647	rs62507246	chr8:50013449	G/A	cg00325661	chr8:49890786	NA	0.74	14.19	0.55	3.39e-38	Blood metabolite ratios;
LGG	trans	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs9534288	0.619	rs9526143	chr13:46675991	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-14.18	-0.55	3.5e-38	Blood protein levels;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg08280861	chr8:58055591	NA	0.58	9.88	0.42	5.34e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.35	-0.4	3.63e-19	Triglycerides;
LGG	cis	rs1003719	0.713	rs7277150	chr21:38490006	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.33	0.63	3.07e-52	Eye color traits;
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg02297831	chr4:17616191	MED28	0.51	9.27	0.4	7.12e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.8	-0.34	4.1e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	7.37	0.32	7.77e-13	Bipolar disorder;
LGG	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg00071950	chr4:10020882	SLC2A9	0.38	7.75	0.34	5.69e-14	Bone mineral density;
LGG	cis	rs7717393	0.786	rs10043401	chr5:155790030	A/C	cg04435420	chr5:155754009	SGCD	0.71	9.15	0.39	1.83e-18	Egg allergy;
LGG	cis	rs7929679	0.551	rs10836303	chr11:34792702	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.0	0.64	2.58e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs643506	0.934	rs4936690	chr11:111646915	T/A	cg09085632	chr11:111637200	PPP2R1B	0.52	8.22	0.36	2.06e-15	Breast cancer;
LGG	cis	rs4356203	0.905	rs589319	chr11:17202597	G/A	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.16	-0.32	3.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.73e-21	Diabetic kidney disease;
LGG	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg03060546	chr3:49711283	APEH	-0.68	-10.9	-0.45	8.52e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13314892	0.881	rs79150208	chr3:69807059	T/A	cg17445875	chr3:69859618	MITF	-0.33	-6.88	-0.3	1.91e-11	QRS complex (12-leadsum);
LGG	trans	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.92	0.35	1.75e-14	Retinal vascular caliber;
LGG	cis	rs11874712	0.545	rs35935345	chr18:43651549	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.11	-0.39	2.41e-18	Migraine - clinic-based;
LGG	cis	rs2562456	0.617	rs34203148	chr19:21773545	T/A	cg00806126	chr19:22604979	ZNF98	-0.62	-8.65	-0.37	8.49e-17	Pain;
LGG	cis	rs3820928	0.874	rs11685983	chr2:227799853	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	2.93e-14	Pulmonary function;
LGG	cis	rs7635838	0.718	rs2594991	chr3:11362704	G/A	cg00170343	chr3:11313890	ATG7	0.49	8.51	0.37	2.38e-16	HDL cholesterol;
LGG	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.47	-0.33	3.97e-13	Obesity;
LGG	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11645453	chr3:52864694	ITIH4	0.39	6.65	0.3	8.06e-11	Electroencephalogram traits;
LGG	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg00012203	chr2:219082015	ARPC2	-0.67	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg23000734	chr10:126850823	CTBP2	0.31	9.5	0.4	1.18e-19	Menarche (age at onset);
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg26554054	chr8:600488	NA	0.8	9.34	0.4	3.96e-19	IgG glycosylation;
LGG	cis	rs6564851	0.508	rs7199144	chr16:81251846	A/T	cg00163702	chr16:81254719	PKD1L2	0.36	8.37	0.36	6.89e-16	Carotenoid and tocopherol levels;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg25072359	chr17:41440525	NA	0.51	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg26384229	chr12:38710491	ALG10B	0.89	19.71	0.68	3.14e-63	Bladder cancer;
LGG	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg02002194	chr4:3960332	NA	0.47	9.19	0.39	1.35e-18	Joint mobility (Beighton score);
LGG	cis	rs4409675	0.576	rs11247706	chr1:28213983	G/C	cg23691781	chr1:28212827	C1orf38	0.42	11.3	0.46	2.54e-26	Corneal astigmatism;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs754466	0.580	rs1058198	chr10:79566632	G/A	cg17075019	chr10:79541650	NA	-0.93	-19.77	-0.68	1.65e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg23924007	chr4:140099401	NA	0.39	6.65	0.3	8.14e-11	Body mass index;
LGG	cis	rs13314892	0.764	rs6800508	chr3:69870871	C/T	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs4918072	0.728	rs7099351	chr10:105710933	A/G	cg11005552	chr10:105648138	OBFC1	0.43	7.47	0.33	4.12e-13	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22496380	chr5:211416	CCDC127	-1.22	-17.01	-0.62	8.82e-51	Breast cancer;
LGG	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23280290	chr7:35734964	HERPUD2	0.42	7.04	0.31	6.94e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg26384229	chr12:38710491	ALG10B	0.63	12.44	0.5	7.4e-31	Morning vs. evening chronotype;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23752198	chr20:30311963	BCL2L1	0.39	7.03	0.31	7.22e-12	Obesity-related traits;
LGG	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg21775007	chr8:11205619	TDH	0.44	6.88	0.3	2.01e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg23188684	chr11:67383651	NA	-0.41	-6.75	-0.3	4.3e-11	Mean corpuscular volume;
LGG	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg12395012	chr8:11607386	GATA4	0.38	6.69	0.3	6.31e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2070488	0.775	rs4679066	chr3:38568527	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.16	-0.55	4.33e-38	Electrocardiographic conduction measures;
LGG	trans	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg16141378	chr3:129829833	LOC729375	0.31	7.17	0.32	2.95e-12	Neuroticism;
LGG	cis	rs10170846	0.789	rs972650	chr2:223520287	C/T	cg25565276	chr2:223520875	FARSB	0.64	11.26	0.46	3.69e-26	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg05623727	chr3:50126028	RBM5	-0.44	-9.56	-0.41	7.19e-20	Body mass index;
LGG	cis	rs9463078	0.739	rs1041333	chr6:44945206	A/T	cg25276700	chr6:44698697	NA	-0.4	-8.54	-0.37	2.01e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	7.11e-16	Tonsillectomy;
LGG	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg11764359	chr7:65958608	NA	-0.58	-9.89	-0.42	4.87e-21	Aortic root size;
LGG	cis	rs2013441	0.508	rs17685923	chr17:19974604	A/G	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.84	-17.57	-0.63	2.42e-53	Personality dimensions;
LGG	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg04111992	chr7:158790115	NA	-0.36	-7.19	-0.32	2.57e-12	Facial morphology (factor 20);
LGG	cis	rs9783347	0.925	rs3825025	chr11:18343822	C/G	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs883565	0.569	rs1274970	chr3:39163252	A/G	cg01426195	chr3:39028469	NA	0.64	13.9	0.54	5.78e-37	Handedness;
LGG	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg11764359	chr7:65958608	NA	0.63	10.86	0.45	1.24e-24	Aortic root size;
LGG	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	8.33	0.36	9.44e-16	Thyroid stimulating hormone;
LGG	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg03462622	chr3:195777018	TFRC	0.32	6.86	0.3	2.26e-11	Mean corpuscular volume;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg15971980	chr6:150254442	NA	0.42	7.19	0.32	2.66e-12	Testicular germ cell tumor;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg13395646	chr4:1353034	KIAA1530	-0.54	-8.91	-0.38	1.15e-17	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1620921	0.711	rs2465846	chr6:161258027	C/G	cg01280913	chr6:161186852	NA	-0.35	-7.16	-0.32	3.19e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9399135	0.967	rs2297338	chr6:135375762	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.57e-19	Red blood cell count;
LGG	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.68	-0.48	8.46e-28	Response to antipsychotic treatment;
LGG	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg10523679	chr1:76189770	ACADM	0.83	14.99	0.57	1.03e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg06153925	chr17:78755379	RPTOR	0.41	7.16	0.32	3.26e-12	Myopia (pathological);
LGG	trans	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg09048205	chr5:1608656	LOC728613	-0.51	-8.29	-0.36	1.22e-15	Breast cancer;
LGG	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg24375607	chr4:120327624	NA	0.64	10.61	0.44	1.07e-23	Corneal astigmatism;
LGG	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg13206674	chr6:150067644	NUP43	0.41	7.15	0.32	3.35e-12	Lung cancer;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.85	-0.38	1.8e-17	Schizophrenia;
LGG	cis	rs6882046	0.513	rs625970	chr5:88042296	A/G	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg13009111	chr11:71350975	NA	0.35	7.49	0.33	3.54e-13	Monocyte count;
LGG	cis	rs1008375	0.932	rs1008894	chr4:17704667	C/T	cg02297831	chr4:17616191	MED28	-0.44	-7.95	-0.35	1.45e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg02733842	chr7:1102375	C7orf50	0.73	10.93	0.45	6.67e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg14664628	chr15:75095509	CSK	0.47	8.9	0.38	1.26e-17	Caffeine consumption;
LGG	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4959677	0.725	rs1680829	chr6:2503120	A/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.43	-0.36	4.31e-16	Orthostatic hypotension;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg24503407	chr1:205819492	PM20D1	0.7	16.53	0.61	1.34e-48	Monocyte percentage of white cells;
LGG	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg10911889	chr6:126070802	HEY2	0.44	7.58	0.33	1.86e-13	Brugada syndrome;
LGG	cis	rs12364620	1	rs12364620	chr11:68252123	T/G	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.19e-16	Total body bone mineral density (age 0-15);
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Electroencephalogram traits;
LGG	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs17221829	0.965	rs10830359	chr11:89455444	A/G	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.58	-0.33	1.93e-13	Anxiety in major depressive disorder;
LGG	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15546353	chr2:234160822	ATG16L1	0.48	7.12	0.31	4.23e-12	Gut microbiome composition (summer);
LGG	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.62	-8.09	-0.35	5.35e-15	Hip circumference adjusted for BMI;
LGG	cis	rs12618769	0.597	rs3769737	chr2:99088873	C/G	cg18455616	chr2:99124870	INPP4A	-0.3	-8.71	-0.38	5.59e-17	Bipolar disorder;
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.14	-0.31	3.71e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg00409905	chr10:38381863	ZNF37A	0.44	7.43	0.33	5.2e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg00129232	chr17:37814104	STARD3	-0.74	-16.16	-0.6	6.61e-47	Asthma;
LGG	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.05	-0.35	7.07e-15	Joint mobility (Beighton score);
LGG	cis	rs7572733	0.967	rs1318867	chr2:198880481	A/C	cg00792783	chr2:198669748	PLCL1	-0.46	-7.74	-0.34	6.39e-14	Dermatomyositis;
LGG	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg27286337	chr10:134555280	INPP5A	0.89	13.06	0.52	2.09e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg14683738	chr19:37701593	ZNF585B	0.44	6.88	0.3	2.01e-11	Coronary artery calcification;
LGG	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg15268244	chr15:77196840	NA	-0.31	-6.73	-0.3	4.94e-11	Blood metabolite levels;
LGG	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg15997130	chr1:24165203	NA	-0.5	-13.58	-0.53	1.34e-35	Immature fraction of reticulocytes;
LGG	cis	rs963731	0.522	rs297136	chr2:39305489	G/T	cg04010122	chr2:39346883	SOS1	-0.68	-7.0	-0.31	9.33e-12	Corticobasal degeneration;
LGG	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg04471919	chr7:21584483	DNAH11	0.49	13.62	0.53	9.25e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9358372	1.000	rs9368240	chr6:20826033	G/A	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.46	-0.58	9.33e-44	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg26384229	chr12:38710491	ALG10B	-0.82	-17.44	-0.63	9.66e-53	Morning vs. evening chronotype;
LGG	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	10.47	0.44	3.7e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg01238044	chr22:24384105	GSTT1	0.4	6.87	0.3	2.07e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6462411	0.877	rs6958385	chr7:3918183	T/C	cg18022346	chr7:3920534	SDK1	-0.36	-7.01	-0.31	8.67e-12	Quantitative traits;
LGG	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.49e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.62	-0.37	1.08e-16	Educational attainment (years of education);
LGG	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.86	-0.34	2.81e-14	IgG glycosylation;
LGG	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.67	-0.34	1e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10861342	1.000	rs10861342	chr12:105458797	C/T	cg23923672	chr12:105501055	KIAA1033	-0.82	-7.32	-0.32	1.14e-12	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.87	-0.64	1.1e-54	Refractive error;
LGG	cis	rs9517320	0.515	rs4771307	chr13:99221879	A/G	cg03701759	chr13:99174930	STK24	-0.38	-7.32	-0.32	1.14e-12	Longevity;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg05868516	chr6:26286170	HIST1H4H	0.4	6.68	0.3	6.99e-11	Educational attainment;
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg14675211	chr2:100938903	LONRF2	0.66	11.53	0.47	3.36e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9944715	0.954	rs7234695	chr18:43762182	T/A	cg26436583	chr18:43649176	PSTPIP2	0.36	6.69	0.3	6.5500000000000006e-11	Red cell distribution width;Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10338412	chr8:74086760	NA	0.45	7.21	0.32	2.26e-12	Cognitive performance;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg21466736	chr12:48725269	NA	-0.39	-7.79	-0.34	4.52e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2693698	0.550	rs2693695	chr14:99686614	A/G	cg07440398	chr14:99712966	BCL11B	0.51	10.76	0.45	2.99e-24	Schizophrenia;
LGG	cis	rs7927771	0.864	rs2053979	chr11:47439444	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-10.72	-0.45	4.19e-24	Subjective well-being;
LGG	trans	rs459571	0.959	rs408307	chr9:136892523	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.66	11.3	0.46	2.57e-26	Platelet distribution width;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20670292	chr2:131099506	IMP4;CCDC115	0.45	7.13	0.31	3.76e-12	Cognitive performance;
LGG	cis	rs1909881	0.605	rs3133723	chr8:96479988	T/C	cg04203453	chr8:96504381	NA	-0.62	-11.4	-0.47	1.09e-26	Obesity-related traits;
LGG	cis	rs9462027	0.540	rs9366863	chr6:34688946	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs834603	0.575	rs834608	chr7:47451918	A/T	cg09696706	chr7:47479511	TNS3	-0.35	-7.87	-0.34	2.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09747578	chr1:46769076	LRRC41;UQCRH	-0.51	-7.56	-0.33	2.2e-13	Systemic lupus erythematosus;
LGG	cis	rs9287719	0.901	rs13034017	chr2:10739592	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs9948	0.655	rs6751132	chr2:97405866	T/C	cg01990225	chr2:97406019	LMAN2L	-0.74	-7.96	-0.35	1.33e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.25	-0.49	4.36e-30	Cognitive function;
LGG	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	trans	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.61e-22	Diabetic kidney disease;
LGG	cis	rs2070488	0.932	rs1841776	chr3:38480727	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.03	0.64	1.83e-55	Electrocardiographic conduction measures;
LGG	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-6.93	-0.31	1.45e-11	Lung cancer in ever smokers;
LGG	cis	rs3820928	0.874	rs67513858	chr2:227804819	A/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs774359	0.789	rs2492821	chr9:27503506	T/A	cg21249376	chr9:27528432	MOBKL2B	0.48	9.04	0.39	4.25e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg24503407	chr1:205819492	PM20D1	0.47	8.07	0.35	5.97e-15	Parkinson's disease;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.14	0.31	3.62e-12	Personality dimensions;
LGG	cis	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg19847130	chr8:10466454	RP1L1	-0.31	-6.82	-0.3	2.88e-11	Neuroticism;
LGG	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21659725	chr3:3221576	CRBN	0.61	10.86	0.45	1.23e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	0.800	rs13172774	chr5:112925439	G/A	cg12552261	chr5:112820674	MCC	0.69	7.31	0.32	1.18e-12	F-cell distribution;
LGG	cis	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg06521331	chr12:34319734	NA	-0.58	-10.04	-0.42	1.42e-21	Morning vs. evening chronotype;
LGG	cis	rs9393813	0.516	rs4713099	chr6:27405202	T/G	cg18711553	chr6:27366782	ZNF391	-0.47	-8.99	-0.39	6.52e-18	Bipolar disorder;
LGG	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs740698	0.529	rs9895414	chr17:60793399	A/C	cg13195520	chr17:60813227	MARCH10	-0.59	-13.69	-0.54	4.49e-36	Pulse pressure;
LGG	cis	rs9354308	0.764	rs9351529	chr6:66589556	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.57e-15	Bone mineral density;
LGG	cis	rs910316	0.737	rs398896	chr14:75482827	C/A	cg08847533	chr14:75593920	NEK9	-0.53	-9.81	-0.41	9.34e-21	Height;
LGG	cis	rs4664308	1.000	rs62175517	chr2:160911575	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11987759	chr7:65425863	GUSB	-0.41	-8.02	-0.35	8.45e-15	Calcium levels;
LGG	trans	rs2562456	0.833	rs11666540	chr19:21539352	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.6e-13	Pain;
LGG	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg04025307	chr7:1156635	C7orf50	0.84	15.16	0.58	1.88e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.74	0.73	2.04e-77	Homoarginine levels;
LGG	cis	rs36051895	0.632	rs7030853	chr9:5179002	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-15.12	-0.57	2.94e-42	Pediatric autoimmune diseases;
LGG	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg00490583	chr16:1843685	IGFALS	-0.42	-7.07	-0.31	5.65e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6964587	1.000	rs10280927	chr7:91582205	G/A	cg17063962	chr7:91808500	NA	-0.48	-8.62	-0.37	1.09e-16	Breast cancer;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.66	-0.37	8.21e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6e-39	Colorectal cancer;
LGG	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.66	-0.34	1.07e-13	HDL cholesterol;
LGG	cis	rs16866061	1.000	rs72974263	chr2:225447371	C/T	cg12698349	chr2:225449008	CUL3	0.93	18.87	0.66	2.41e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs6834538	0.862	rs7659503	chr4:113425304	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.52	-8.54	-0.37	1.91e-16	Free thyroxine concentration;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg00684032	chr4:1343700	KIAA1530	0.42	8.27	0.36	1.39e-15	Obesity-related traits;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.8	0.54	1.58e-36	IgG glycosylation;
LGG	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg22681709	chr2:178499509	PDE11A	-0.44	-6.99	-0.31	9.51e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg03098644	chr7:100410630	EPHB4	0.48	7.27	0.32	1.58e-12	Other erythrocyte phenotypes;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg00504896	chr12:9437009	LOC642846	-0.52	-10.27	-0.43	1.97e-22	Breast size;
LGG	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.23e-15	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14099990	chr13:35517154	NBEA	0.55	8.37	0.36	7.08e-16	Gut microbiome composition (summer);
LGG	cis	rs12493885	0.818	rs10935972	chr3:153774029	G/A	cg17054900	chr3:154042577	DHX36	-0.74	-8.8	-0.38	2.66e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.45	-0.4	1.71e-19	Blood metabolite levels;
LGG	cis	rs9487094	0.744	rs13212535	chr6:110034391	G/A	cg01125227	chr6:109776195	MICAL1	0.5	8.12	0.35	4.12e-15	Height;
LGG	cis	rs870825	0.932	rs28702958	chr4:185575562	C/T	cg04058563	chr4:185651563	MLF1IP	1.0	17.99	0.64	2.89e-55	Blood protein levels;
LGG	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg04398451	chr17:18023971	MYO15A	0.75	15.8	0.59	2.87e-45	Total body bone mineral density;
LGG	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.62	0.53	9.51e-36	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs36051895	0.632	rs11788164	chr9:5129395	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.49	-0.56	1.6e-39	Pediatric autoimmune diseases;
LGG	cis	rs7103648	0.966	rs896817	chr11:47394305	A/G	cg20307385	chr11:47447363	PSMC3	-0.94	-22.15	-0.72	1.17e-74	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20488697	chr17:79885644	LOC92659;MAFG	0.46	6.75	0.3	4.49e-11	Gut microbiome composition (summer);
LGG	cis	rs57927100	0.554	rs11868657	chr17:75335939	G/A	cg18271897	chr17:75316784	SEPT9	0.42	8.94	0.38	9.65e-18	Systolic blood pressure;
LGG	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.2	-0.39	1.2e-18	Sudden cardiac arrest;
LGG	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.88	0.3	2e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg10818794	chr15:86012489	AKAP13	-0.55	-12.33	-0.5	2.12e-30	Coronary artery disease;
LGG	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12756686	chr19:29218302	NA	0.71	11.88	0.48	1.34e-28	Methadone dose in opioid dependence;
LGG	cis	rs7246760	0.618	rs73008109	chr19:9734056	C/T	cg16876255	chr19:9731953	ZNF561	0.9	8.17	0.36	2.92e-15	Pursuit maintenance gain;
LGG	cis	rs61884328	0.852	rs61896126	chr11:47099167	T/G	cg03339077	chr11:47165057	C11orf49	0.64	6.76	0.3	4.12e-11	Total body bone mineral density (age over 60);
LGG	cis	rs1318772	1.000	rs36611	chr5:112755990	A/C	cg12552261	chr5:112820674	MCC	0.7	7.89	0.34	2.21e-14	F-cell distribution;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.87	0.45	1.18e-24	Obesity-related traits;
LGG	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg23649088	chr2:200775458	C2orf69	-0.6	-7.78	-0.34	4.73e-14	Schizophrenia;
LGG	cis	rs362296	0.671	rs1006798	chr4:3258373	A/G	cg06533319	chr4:3265114	C4orf44	0.51	9.96	0.42	2.61e-21	Parental longevity (mother's age at death);
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.86	-0.34	2.76e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg23758822	chr17:41437982	NA	0.9	15.84	0.59	1.83e-45	Menopause (age at onset);
LGG	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg03352830	chr11:487213	PTDSS2	0.85	10.69	0.44	5.59e-24	Body mass index;
LGG	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.39	-6.78	-0.3	3.72e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg23758822	chr17:41437982	NA	0.86	15.73	0.59	5.8e-45	Menopause (age at onset);
LGG	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg00012203	chr2:219082015	ARPC2	0.66	12.03	0.49	3.3e-29	Colorectal cancer;
LGG	cis	rs17767392	0.958	rs4902942	chr14:72140659	A/T	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.44	-0.4	1.79e-19	Mitral valve prolapse;
LGG	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg02187348	chr16:89574699	SPG7	0.57	9.68	0.41	2.66e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs9807989	0.507	rs6734762	chr2:103062926	C/T	cg03938978	chr2:103052716	IL18RAP	0.42	9.79	0.41	1.09e-20	Asthma;
LGG	cis	rs11785693	0.731	rs11136822	chr8:4946470	A/G	cg26367366	chr8:4980734	NA	0.62	8.44	0.37	4e-16	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7312933	0.558	rs11181466	chr12:42765181	A/T	cg19980929	chr12:42632907	YAF2	0.35	7.95	0.35	1.46e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg14820908	chr5:178986412	RUFY1	0.4	6.84	0.3	2.5e-11	Lung cancer;
LGG	cis	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg19399532	chr1:178512495	C1orf220	0.42	8.23	0.36	1.86e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg25767906	chr1:53392781	SCP2	-0.38	-7.61	-0.33	1.54e-13	Monocyte count;
LGG	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg04568710	chr12:38710424	ALG10B	0.36	7.53	0.33	2.62e-13	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.05e-12	Bipolar disorder;
LGG	cis	rs9557207	0.703	rs7997823	chr13:100018856	C/T	cg24509225	chr13:100037070	UBAC2	0.63	11.61	0.47	1.65e-27	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg00149659	chr3:10157352	C3orf10	0.58	8.29	0.36	1.24e-15	Alzheimer's disease;
LGG	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.05	-0.31	6.71e-12	Crohn's disease;
LGG	cis	rs806215	0.950	rs3735644	chr7:127222157	G/A	cg25922125	chr7:127225783	GCC1	-0.79	-10.58	-0.44	1.36e-23	Type 2 diabetes;
LGG	cis	rs4253772	0.614	rs11090859	chr22:46687460	T/G	cg24881330	chr22:46731750	TRMU	0.77	9.25	0.39	8.34e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs870825	0.929	rs871253	chr4:185589234	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	18.69	0.66	1.68e-58	Blood protein levels;
LGG	trans	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.26	0.43	2.19e-22	Mean corpuscular volume;
LGG	cis	rs17683430	0.702	rs117079807	chr22:32407021	A/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg07701084	chr6:150067640	NUP43	0.68	13.11	0.52	1.3e-33	Lung cancer;
LGG	trans	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.72	-0.34	7.43e-14	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.29	0.36	1.21e-15	Platelet count;
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg04166393	chr7:2884313	GNA12	0.47	8.91	0.38	1.16e-17	Height;
LGG	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg02002194	chr4:3960332	NA	0.39	7.16	0.32	3.21e-12	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04074766	chr7:100861094	ZNHIT1;PLOD3	0.45	7.25	0.32	1.73e-12	Cognitive performance;
LGG	cis	rs4737010	0.959	rs4737009	chr8:41630405	A/G	cg08923054	chr8:41654455	ANK1	0.44	7.48	0.33	3.75e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	cis	rs7617773	0.780	rs7653152	chr3:48362097	G/C	cg11946769	chr3:48343235	NME6	0.71	11.94	0.49	7.58e-29	Coronary artery disease;
LGG	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg11644478	chr21:40555479	PSMG1	-0.73	-13.02	-0.52	3.02e-33	Cognitive function;
LGG	cis	rs4262150	0.508	rs72795352	chr5:151911070	G/A	cg12297329	chr5:152029980	NA	-0.65	-11.75	-0.48	4.6e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg13698153	chr12:118541722	VSIG10	-0.41	-6.86	-0.3	2.17e-11	Vitiligo;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26894438	chr17:15902633	ZSWIM7;TTC19	-0.45	-7.29	-0.32	1.39e-12	Pancreatic cancer;
LGG	cis	rs12586317	0.547	rs28577270	chr14:35498443	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.57	0.53	1.55e-35	Psoriasis;
LGG	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.25	0.36	1.64e-15	Mood instability;
LGG	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg04672837	chr16:48644449	N4BP1	0.56	9.28	0.4	6.58e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.32	-0.43	1.34e-22	Glycated hemoglobin levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14438609	chr14:30396153	PRKD1	-0.43	-6.92	-0.31	1.54e-11	Pancreatic cancer;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg00495681	chr13:53174319	NA	1.0	23.18	0.73	1.78e-79	Lewy body disease;
LGG	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs7107174	1.000	rs10899451	chr11:77991222	A/C	cg02023728	chr11:77925099	USP35	0.44	7.46	0.33	4.42e-13	Testicular germ cell tumor;
LGG	cis	rs1055129	0.655	rs8067076	chr17:73837142	G/T	cg14829360	chr17:73884958	NA	0.44	8.08	0.35	5.87e-15	White matter hyperintensity burden;
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg13628971	chr7:2884303	GNA12	0.55	11.91	0.48	1.07e-28	Height;
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs7737355	0.947	rs7724769	chr5:130954943	C/T	cg06307176	chr5:131281290	NA	0.58	9.42	0.4	2.2e-19	Life satisfaction;
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg19717773	chr7:2847554	GNA12	-0.35	-7.89	-0.34	2.22e-14	Height;
LGG	cis	rs1878931	0.597	rs37814	chr16:3455247	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-11.81	-0.48	2.6e-28	Body mass index (adult);
LGG	cis	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17554472	chr22:41940697	POLR3H	0.48	6.79	0.3	3.46e-11	Vitiligo;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.14	0.39	1.97e-18	Bipolar disorder;
LGG	cis	rs9308731	1.000	rs6750599	chr2:111893869	A/T	cg26001287	chr2:111877753	BCL2L11	0.36	7.37	0.32	7.68e-13	Chronic lymphocytic leukemia;
LGG	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.13	-0.46	1.19e-25	Hemoglobin concentration;
LGG	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07570687	chr10:102243282	WNT8B	0.41	6.91	0.31	1.64e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg02153584	chr22:29168773	CCDC117	0.7	11.8	0.48	2.8e-28	Lymphocyte counts;
LGG	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg25475839	chr6:20697104	CDKAL1	0.31	6.69	0.3	6.37e-11	Hematocrit;Hemoglobin concentration;Red blood cell count;
LGG	cis	rs4676380	0.855	rs1583261	chr2:241644740	T/C	cg06356454	chr2:241631498	AQP12A	0.44	8.35	0.36	8.14e-16	Response to metformin (IC50);
LGG	cis	rs4006360	0.575	rs6503607	chr17:39315344	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.65	-14.7	-0.56	2.06e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.77	0.38	3.5e-17	Vitiligo;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg07870213	chr5:140052090	DND1	0.93	17.29	0.63	4.62e-52	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs283228	0.535	rs2852513	chr6:101846616	C/G	cg02011392	chr6:101847541	GRIK2	0.57	7.87	0.34	2.56e-14	Coenzyme Q10 levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23181591	chr8:123793873	ZHX2	0.49	7.52	0.33	2.84e-13	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg27400746	chr16:89904261	SPIRE2	-1.06	-15.78	-0.59	3.38e-45	Skin colour saturation;
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.53	0.37	2.02e-16	Skin colour saturation;
LGG	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg25208724	chr1:156163844	SLC25A44	1.21	28.2	0.79	1.49e-102	Testicular germ cell tumor;
LGG	cis	rs10050311	0.746	rs17420607	chr4:87670201	A/C	cg11209507	chr4:87813803	C4orf36	0.53	6.83	0.3	2.66e-11	Insulin-related traits;
LGG	cis	rs793571	0.503	rs1427281	chr15:58959273	T/C	cg05156742	chr15:59063176	FAM63B	0.46	6.88	0.3	2e-11	Schizophrenia;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg23782820	chr8:58130467	NA	0.58	8.39	0.36	6.07e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	0.902	rs1588353	chr11:34730814	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.93	-0.31	1.46e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg00405596	chr8:11794950	NA	0.44	7.36	0.32	8.74e-13	Mood instability;
LGG	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06915872	chr16:87998081	BANP	-0.45	-6.79	-0.3	3.43e-11	Menopause (age at onset);
LGG	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg13786083	chr1:19110734	NA	-0.41	-6.75	-0.3	4.44e-11	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg16751781	chr15:78858589	CHRNA5	0.36	6.7	0.3	6.16e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2288073	0.965	rs6545340	chr2:24422269	C/G	cg06627628	chr2:24431161	ITSN2	-0.66	-10.66	-0.44	7.13e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4951018	0.887	rs3761916	chr1:205630893	A/G	cg26354017	chr1:205819088	PM20D1	-0.38	-7.25	-0.32	1.81e-12	Prostate-specific antigen levels;
LGG	trans	rs12517041	1.000	rs16892325	chr5:23283742	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.45e-25	Calcium levels;
LGG	cis	rs11718455	0.960	rs11921995	chr3:44017301	C/A	cg21419209	chr3:44054225	NA	-0.43	-6.97	-0.31	1.07e-11	Coronary artery disease;
LGG	trans	rs3206736	0.548	rs7779894	chr7:35061509	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.31	0.32	1.15e-12	Diastolic blood pressure;
LGG	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.02	0.42	1.64e-21	Mood instability;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg06223162	chr1:101003688	GPR88	-0.47	-11.79	-0.48	3.17e-28	Breast cancer;
LGG	cis	rs2976388	1.000	rs2976398	chr8:143764879	G/C	cg06565975	chr8:143823917	SLURP1	-0.41	-10.36	-0.43	9.31e-23	Urinary tract infection frequency;
LGG	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg09165964	chr15:75287851	SCAMP5	0.66	11.99	0.49	4.82e-29	Caffeine consumption;
LGG	cis	rs13053817	1.000	rs7290855	chr22:29852474	G/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.45	-6.83	-0.3	2.69e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Vitiligo;
LGG	cis	rs1707322	1.000	rs11211190	chr1:46266255	C/T	cg03146154	chr1:46216737	IPP	0.55	10.33	0.43	1.19e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7666738	0.791	rs7684521	chr4:99071219	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.48	0.37	2.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10789491	1.000	rs12794	chr1:47141718	T/C	cg15501359	chr1:47185051	KIAA0494	0.73	14.31	0.55	1.04e-38	Response to hepatitis C treatment;
LGG	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27286337	chr10:134555280	INPP5A	0.84	12.09	0.49	1.93e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08872617	chr16:4783947	ANKS3;C16orf71	0.5	7.68	0.34	9.44e-14	Gut microbiome composition (summer);
LGG	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	trans	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.17	0.46	8.39e-26	Corneal astigmatism;
LGG	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg14088196	chr11:70211408	PPFIA1	0.94	13.2	0.52	5.29e-34	Coronary artery disease;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-6.82	-0.3	2.87e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12410462	0.551	rs16848029	chr1:227845283	C/A	cg04117972	chr1:227635322	NA	0.44	8.11	0.35	4.54e-15	Major depressive disorder;
LGG	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.81e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg01864069	chr14:103024347	NA	-0.74	-12.09	-0.49	1.94e-29	Platelet count;
LGG	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.76	-0.38	3.84e-17	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.27	-0.36	1.39e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs41298997	1	rs41298997	chr1:206655331	C/T	cg11166312	chr1:206654246	IKBKE	0.55	10.86	0.45	1.2e-24	Psoriasis;
LGG	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg26138144	chr22:38071188	LGALS1	0.34	6.73	0.3	5.09e-11	Glioblastoma;Glioma;
LGG	cis	rs2133450	0.526	rs62237060	chr3:7346588	T/C	cg19930620	chr3:7340148	GRM7	-0.42	-9.34	-0.4	4.04e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-8.98	-0.39	6.92e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs754423	0.515	rs34973015	chr14:52552690	T/C	cg12071775	chr14:52591786	NA	-0.42	-6.95	-0.31	1.24e-11	Craniofacial microsomia;
LGG	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg03806693	chr22:41940476	POLR3H	0.91	15.07	0.57	4.61e-42	Vitiligo;
LGG	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03576123	chr11:487126	PTDSS2	-1.21	-15.58	-0.59	2.5e-44	Body mass index;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.76	-0.41	1.35e-20	Lung cancer;
LGG	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs9300255	0.639	rs1716171	chr12:123716376	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1e-13	Neutrophil percentage of white cells;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg08645402	chr16:4508243	NA	0.5	8.65	0.37	8.4e-17	Schizophrenia;
LGG	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg21459583	chr1:227974177	NA	0.46	6.81	0.3	3.09e-11	Major depressive disorder;
LGG	cis	rs7937612	1.000	rs10892578	chr11:120308290	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.66	-0.51	9.13e-32	Intraocular pressure;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19524238	chr7:2802976	GNA12	0.38	8.66	0.37	8.16e-17	Height;
LGG	cis	rs3735485	0.760	rs1294960	chr7:45065649	T/C	cg03440944	chr7:45023329	C7orf40	0.56	9.5	0.4	1.16e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg07606381	chr6:8435919	SLC35B3	-0.68	-12.26	-0.5	4.04e-30	Motion sickness;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg05861140	chr6:150128134	PCMT1	-0.32	-7.23	-0.32	2.03e-12	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.24	0.32	1.88e-12	Lung cancer;
LGG	cis	rs4417704	0.501	rs13015336	chr2:241900706	T/C	cg05025159	chr2:241905733	NA	0.52	10.73	0.45	3.99e-24	Joint mobility (Beighton score);
LGG	cis	rs36093844	0.752	rs80193798	chr11:85577529	C/T	cg16165120	chr11:85566439	CCDC83	-0.43	-6.88	-0.3	1.96e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg19507638	chr5:93509721	C5orf36	-0.73	-10.09	-0.42	9.28e-22	Diabetic retinopathy;
LGG	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg01448562	chr3:133502909	NA	-0.51	-8.58	-0.37	1.43e-16	Iron status biomarkers;
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg13607699	chr17:42295918	UBTF	0.64	10.95	0.45	5.69e-25	Total body bone mineral density;
LGG	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.35	-0.32	8.87e-13	Recombination measurement;
LGG	cis	rs7236492	0.532	rs8090536	chr18:77195553	C/T	cg15644404	chr18:77186268	NFATC1	-0.54	-8.25	-0.36	1.64e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.25	-0.46	4.03e-26	Morning vs. evening chronotype;
LGG	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.41	-0.33	5.97e-13	Depression;
LGG	cis	rs12543645	0.598	rs35338507	chr8:10277982	G/A	cg12940923	chr8:10282607	MSRA	0.31	7.4	0.33	6.66e-13	Schizophrenia;
LGG	cis	rs66887589	0.720	rs2036858	chr4:120249237	A/C	cg09307838	chr4:120376055	NA	0.5	8.47	0.37	3.3e-16	Diastolic blood pressure;
LGG	cis	rs3771570	1.000	rs62186411	chr2:242236667	A/C	cg21155796	chr2:242212141	HDLBP	0.76	9.91	0.42	4.02e-21	Prostate cancer;
LGG	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg10596483	chr8:143751796	JRK	-0.47	-6.68	-0.3	6.77e-11	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11225247	1.000	rs75055689	chr11:102269738	G/T	cg06323957	chr11:102217781	BIRC2	0.79	6.81	0.3	3.09e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9815354	0.812	rs10510733	chr3:42009192	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.28	0.4	6.36e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.85	-0.3	2.41e-11	Blood metabolite levels;
LGG	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg13147721	chr7:65941812	NA	0.8	9.74	0.41	1.65e-20	Diabetic kidney disease;
LGG	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs7914558	0.966	rs10748835	chr10:104660256	C/T	cg04362960	chr10:104952993	NT5C2	0.53	10.06	0.42	1.17e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg09359103	chr1:154839909	KCNN3	-0.52	-9.75	-0.41	1.44e-20	Prostate cancer;
LGG	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.73	-0.34	6.93e-14	HDL cholesterol;
LGG	cis	rs9447004	0.583	rs28360541	chr6:74432427	T/G	cg03006477	chr6:74432658	CD109	0.28	7.18	0.32	2.84e-12	Blood protein levels;Calcium levels;
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs988958	0.755	rs7560852	chr2:42291949	A/G	cg19376973	chr2:42229025	NA	0.46	6.85	0.3	2.38e-11	Hypospadias;
LGG	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	6.89	0.3	1.84e-11	Retinal vascular caliber;
LGG	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.61	0.41	4.58e-20	Menarche (age at onset);
LGG	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg27400746	chr16:89904261	SPIRE2	-0.79	-13.17	-0.52	7.12e-34	Skin colour saturation;
LGG	cis	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.11	-0.46	1.39e-25	Resting heart rate;
LGG	cis	rs4891159	0.790	rs17059325	chr18:74119567	A/C	cg24786174	chr18:74118243	ZNF516	-0.56	-12.89	-0.51	1.03e-32	Longevity;
LGG	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg01262667	chr19:19385393	TM6SF2	-0.35	-7.9	-0.34	1.99e-14	Tonsillectomy;
LGG	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.48	0.4	1.31e-19	Height;
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs6500395	1.000	rs6500398	chr16:48650332	C/T	cg16662043	chr16:48846231	NA	0.38	7.41	0.33	5.96e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18252515	chr7:66147081	NA	0.42	7.09	0.31	5.02e-12	Aortic root size;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg13147721	chr7:65941812	NA	0.77	9.53	0.4	8.89e-20	Diabetic kidney disease;
LGG	cis	rs4851266	1.000	rs1122231	chr2:100834546	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs6964587	1.000	rs4727267	chr7:91570290	G/C	cg17063962	chr7:91808500	NA	-0.48	-8.59	-0.37	1.34e-16	Breast cancer;
LGG	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg03517284	chr6:25882590	NA	-0.41	-6.67	-0.3	7.13e-11	Iron status biomarkers;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-9.47	-0.4	1.45e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs12681288	0.676	rs2600514	chr8:994175	G/A	cg15309053	chr8:964076	NA	0.37	7.54	0.33	2.52e-13	Schizophrenia;
LGG	cis	rs6087990	0.735	rs6058892	chr20:31388461	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	16.69	0.61	2.6e-49	Ulcerative colitis;
LGG	cis	rs11608355	0.515	rs2287192	chr12:109931594	C/T	cg05360138	chr12:110035743	NA	0.83	11.82	0.48	2.38e-28	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23451291	chr7:25891427	NA	0.45	7.19	0.32	2.56e-12	Cognitive performance;
LGG	cis	rs7619833	0.607	rs7634878	chr3:27241219	C/T	cg02860705	chr3:27208620	NA	0.45	9.57	0.41	6.35e-20	Breast cancer;
LGG	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.3	-0.32	1.28e-12	Neuroticism;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.73	8.49	0.37	2.83e-16	Mean platelet volume;
LGG	cis	rs6546537	1.000	rs6546535	chr2:69833382	G/T	cg10773587	chr2:69614142	GFPT1	-0.43	-7.16	-0.32	3.19e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs1519814	0.654	rs11986190	chr8:121013325	G/A	cg22335954	chr8:121166405	COL14A1	-0.45	-8.06	-0.35	6.45e-15	Breast cancer;
LGG	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.06	0.42	1.13e-21	Motion sickness;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17428076	0.914	rs72889094	chr2:172794769	A/G	cg21435375	chr2:172878103	MAP1D	0.46	9.86	0.42	5.86e-21	Myopia;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg13939156	chr17:80058883	NA	-0.47	-9.2	-0.39	1.19e-18	Life satisfaction;
LGG	cis	rs4950322	0.857	rs72693002	chr1:146829304	T/A	cg22381352	chr1:146742008	CHD1L	-0.48	-7.98	-0.35	1.14e-14	Protein quantitative trait loci;
LGG	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg16662043	chr16:48846231	NA	0.35	6.86	0.3	2.25e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-10.31	-0.43	1.46e-22	Aortic root size;
LGG	cis	rs806215	1.000	rs712701	chr7:127251188	T/G	cg25922125	chr7:127225783	GCC1	0.75	10.29	0.43	1.61e-22	Type 2 diabetes;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.45	-0.33	4.57e-13	Bipolar disorder;
LGG	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg03517284	chr6:25882590	NA	0.51	9.68	0.41	2.63e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6704644	0.651	rs11694406	chr2:234331810	G/A	cg27060346	chr2:234359958	DGKD	-0.61	-7.32	-0.32	1.07e-12	Bilirubin levels;
LGG	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg00666640	chr1:248458726	OR2T12	0.59	9.52	0.4	9.85e-20	Common traits (Other);
LGG	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.63e-19	Diabetic retinopathy;
LGG	trans	rs72991	0.639	rs297529	chr11:121243347	T/C	cg27192990	chr6:129479024	LAMA2	-0.55	-8.39	-0.36	5.73e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg16606324	chr3:10149918	C3orf24	0.6	6.86	0.3	2.28e-11	Alzheimer's disease;
LGG	cis	rs11792861	0.591	rs2282206	chr9:111746267	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	11.3	0.47	2.53e-26	Menarche (age at onset);
LGG	cis	rs13323323	0.696	rs66922431	chr3:44474551	C/T	cg02073558	chr3:44770973	ZNF501	0.52	7.22	0.32	2.21e-12	IgG glycosylation;
LGG	cis	rs11971779	0.680	rs10229249	chr7:139052510	A/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg10523679	chr1:76189770	ACADM	0.75	13.92	0.54	4.85e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7192750	0.586	rs11075908	chr16:71928850	C/T	cg06353428	chr16:71660113	MARVELD3	-0.68	-10.82	-0.45	1.77e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg11812906	chr14:75593930	NEK9	-0.54	-10.12	-0.43	7.09e-22	Height;
LGG	cis	rs7666738	0.830	rs13111977	chr4:98953813	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg15103426	chr22:29168792	CCDC117	0.66	7.63	0.33	1.34e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.56	0.37	1.63e-16	Aortic root size;
LGG	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg18854424	chr1:2615690	NA	-0.33	-7.0	-0.31	8.83e-12	Ulcerative colitis;
LGG	cis	rs2404618	0.561	rs9918765	chr8:1484467	C/T	cg13402656	chr8:1511478	DLGAP2	-0.73	-13.41	-0.53	7.08e-35	Lung cancer;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	9.6	0.41	4.89e-20	Height;
LGG	cis	rs4629710	0.592	rs9492877	chr6:131562577	C/G	cg12606694	chr6:131520996	AKAP7	0.51	8.28	0.36	1.35e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs1707322	1.000	rs7539800	chr1:46262129	C/G	cg03146154	chr1:46216737	IPP	-0.57	-10.4	-0.44	6.79e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg22105103	chr4:187893119	NA	0.53	10.22	0.43	2.99e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.38	0.47	1.21e-26	Electroencephalogram traits;
LGG	cis	rs10883723	0.703	rs7898410	chr10:104245858	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.89	0.57	2.97e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2016266	0.929	rs7399003	chr12:53659536	C/T	cg04065151	chr12:53682969	ESPL1	-0.59	-10.12	-0.43	6.8e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05901451	chr6:126070800	HEY2	-0.82	-17.54	-0.63	3.3e-53	Brugada syndrome;
LGG	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs11608355	0.597	rs2304548	chr12:109795166	T/G	cg19025524	chr12:109796872	NA	-0.6	-13.09	-0.52	1.55e-33	Neuroticism;
LGG	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-12.16	-0.49	1.04e-29	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.69	0.51	6.98e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6964587	0.935	rs28412174	chr7:91577245	T/G	cg17063962	chr7:91808500	NA	-0.49	-8.59	-0.37	1.39e-16	Breast cancer;
LGG	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.48	0.44	3.37e-23	Lung cancer in ever smokers;
LGG	trans	rs1032833	0.732	rs111644090	chr2:179947366	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.52	0.37	2.22e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs4731207	0.564	rs10279816	chr7:124581580	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg03970086	chr16:88974840	CBFA2T3	0.44	8.94	0.38	9.38e-18	Social autistic-like traits;
LGG	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.81	0.48	2.61e-28	Hip circumference adjusted for BMI;
LGG	cis	rs7635838	0.718	rs2594981	chr3:11380638	C/G	cg00170343	chr3:11313890	ATG7	0.49	8.58	0.37	1.45e-16	HDL cholesterol;
LGG	cis	rs2455799	0.573	rs2455836	chr3:15754538	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-8.14	-0.35	3.76e-15	Mean platelet volume;
LGG	cis	rs9828933	0.832	rs2292662	chr3:63897215	C/T	cg17941049	chr3:63904683	ATXN7	0.74	9.52	0.4	9.52e-20	Type 2 diabetes;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.66	-0.44	7.19e-24	Longevity;Endometriosis;
LGG	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg16586182	chr3:47516702	SCAP	-0.55	-9.41	-0.4	2.36e-19	Birth weight;
LGG	cis	rs12200782	0.649	rs7756881	chr6:26389926	C/T	cg27193005	chr6:26382695	BTN2A2	-0.51	-7.27	-0.32	1.59e-12	Small cell lung carcinoma;
LGG	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.54	0.33	2.47e-13	Schizophrenia;
LGG	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.33	-0.36	9.33e-16	Aortic root size;
LGG	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg15733309	chr7:157513707	PTPRN2	0.62	14.73	0.56	1.44e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.8	0.3	3.26e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg16141378	chr3:129829833	LOC729375	0.41	9.57	0.41	6.35e-20	Systolic blood pressure;
LGG	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg02487422	chr3:49467188	NICN1	0.58	10.75	0.45	3.16e-24	Resting heart rate;
LGG	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.52	-6.97	-0.31	1.07e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22857025	chr5:266934	NA	-1.52	-26.7	-0.78	9.59e-96	Breast cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13042092	chr7:23637017	CCDC126	-0.46	-7.06	-0.31	6.01e-12	Pancreatic cancer;
LGG	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg03476357	chr21:30257390	N6AMT1	0.43	7.31	0.32	1.14e-12	Cognitive test performance;
LGG	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg13009111	chr11:71350975	NA	0.35	7.81	0.34	3.78e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7444	0.941	rs4821108	chr22:21959038	G/C	cg15846791	chr22:21984385	YDJC	-0.44	-6.73	-0.3	5.15e-11	Systemic lupus erythematosus;
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg07685180	chr8:600429	NA	1.06	10.77	0.45	2.72e-24	IgG glycosylation;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg27189623	chr16:705930	WDR90	0.4	7.63	0.33	1.39e-13	Height;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21963583	chr11:68658836	MRPL21	0.61	10.54	0.44	2e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg23306229	chr2:178417860	TTC30B	0.56	7.26	0.32	1.68e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6540556	0.654	rs6540549	chr1:209922668	G/T	cg23920097	chr1:209922102	NA	0.43	8.17	0.36	2.87e-15	Red blood cell count;
LGG	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg18105134	chr13:113819100	PROZ	0.72	15.51	0.58	5.42e-44	Platelet distribution width;
LGG	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs2171564	1.000	rs2171564	chr3:112440004	C/G	cg06685282	chr3:112453648	NA	0.38	6.91	0.31	1.62e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00294572	chr6:26285232	NA	0.42	7.84	0.34	3.13e-14	Educational attainment;
LGG	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg15268244	chr15:77196840	NA	0.48	10.17	0.43	4.44e-22	Blood metabolite levels;
LGG	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	8.16e-17	Lung cancer;
LGG	cis	rs73198271	0.960	rs73198288	chr8:8613940	G/A	cg01851573	chr8:8652454	MFHAS1	0.4	6.66	0.3	7.92e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs11875185	0.510	rs79853616	chr18:55618244	C/T	cg15513957	chr14:69354734	ACTN1	-0.93	-9.2	-0.39	1.2e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs116095464	0.718	rs62331563	chr5:355286	T/C	cg22857025	chr5:266934	NA	-1.2	-10.59	-0.44	1.3e-23	Breast cancer;
LGG	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg15485101	chr11:133734466	NA	0.61	10.68	0.44	6e-24	Childhood ear infection;
LGG	cis	rs10189230	0.967	rs12993766	chr2:222350321	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs209489	0.892	rs78271907	chr6:53144016	T/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.16	0.39	1.65e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg09699651	chr6:150184138	LRP11	0.53	9.45	0.4	1.74e-19	Lung cancer;
LGG	cis	rs7572644	0.699	rs2337373	chr2:28092922	T/C	cg27432699	chr2:27873401	GPN1	-0.45	-6.94	-0.31	1.33e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.7	-0.38	5.63e-17	Personality dimensions;
LGG	cis	rs68170813	0.652	rs76924513	chr7:107205887	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.35	-0.36	7.85e-16	Coronary artery disease;
LGG	cis	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.97	-0.49	6.09e-29	Morning vs. evening chronotype;
LGG	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-7.11	-0.31	4.3e-12	Migraine;Coronary artery disease;
LGG	cis	rs9326248	0.581	rs10790167	chr11:116800943	T/C	cg20608306	chr11:116969690	SIK3	0.42	13.37	0.53	1.1e-34	Blood protein levels;
LGG	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	trans	rs1032833	0.732	rs77593278	chr2:180029855	A/G	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	trans	rs2471042	0.574	rs1493354	chr5:86174147	C/T	cg12531328	chr13:31192104	USPL1	-0.41	-6.7	-0.3	6.2e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LGG	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	15.62	0.59	1.79e-44	IgG glycosylation;
LGG	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.79	-0.34	4.44e-14	Blood metabolite levels;
LGG	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.73	0.56	1.45e-40	Cognitive test performance;
LGG	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs12618769	0.652	rs7595120	chr2:99231805	C/G	cg18455616	chr2:99124870	INPP4A	0.26	7.39	0.32	7e-13	Bipolar disorder;
LGG	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-25.88	-0.77	5.55e-92	Schizophrenia;
LGG	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.66	0.34	1.08e-13	Electroencephalogram traits;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg09264619	chr17:80180166	NA	-0.36	-7.22	-0.32	2.2e-12	Life satisfaction;
LGG	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg26384229	chr12:38710491	ALG10B	0.8	16.87	0.62	3.9e-50	Morning vs. evening chronotype;
LGG	cis	rs35883536	0.588	rs72977389	chr1:101107053	A/C	cg06223162	chr1:101003688	GPR88	0.34	7.86	0.34	2.76e-14	Monocyte count;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02475777	chr4:1388615	CRIPAK	0.58	10.57	0.44	1.49e-23	Longevity;
LGG	cis	rs16944613	0.541	rs6496690	chr15:91097401	T/C	cg26821196	chr15:91095069	CRTC3	0.57	8.55	0.37	1.75e-16	Colorectal cancer;
LGG	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg19847130	chr8:10466454	RP1L1	0.3	6.69	0.3	6.35e-11	Joint mobility (Beighton score);
LGG	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-16.49	-0.61	2.21e-48	Glomerular filtration rate (creatinine);
LGG	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02251663	chr11:14281053	SPON1	-0.3	-7.17	-0.32	2.98e-12	Mitochondrial DNA levels;
LGG	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.71e-19	Menarche (age at onset);
LGG	trans	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	trans	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-9.2	-0.39	1.24e-18	Brugada syndrome;
LGG	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg09307838	chr4:120376055	NA	0.73	12.31	0.5	2.48e-30	Corneal astigmatism;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg07061783	chr6:25882402	NA	-0.69	-12.29	-0.5	3e-30	Urate levels;
LGG	cis	rs1185460	1.000	rs7938944	chr11:118954066	T/C	cg23280166	chr11:118938394	VPS11	0.52	9.11	0.39	2.44e-18	Coronary artery disease;
LGG	cis	rs988958	0.755	rs11900314	chr2:42291658	C/G	cg19376973	chr2:42229025	NA	0.45	6.8	0.3	3.26e-11	Hypospadias;
LGG	cis	rs2289328	0.941	rs11636147	chr15:40721128	C/G	cg13931752	chr15:40660718	DISP2	0.39	7.74	0.34	6.34e-14	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7572733	0.534	rs700682	chr2:198712310	C/A	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg18446336	chr7:2847575	GNA12	-0.32	-8.18	-0.36	2.75e-15	Height;
LGG	cis	rs28830936	0.528	rs11630242	chr15:42124643	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.77	-24.58	-0.75	5.69e-86	Diastolic blood pressure;
LGG	cis	rs9462027	0.628	rs1125340	chr6:34786408	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg08677398	chr8:58056175	NA	0.56	12.25	0.49	4.59e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.881	rs12880611	chr14:71923349	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs4732038	1.000	rs7787818	chr7:134251597	C/G	cg06906464	chr7:134288099	NA	-0.5	-12.68	-0.51	7.52e-32	Longevity;
LGG	cis	rs2153535	0.580	rs763376	chr6:8492776	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs7226408	0.857	rs56308574	chr18:34586293	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg21605333	chr4:119757512	SEC24D	1.33	12.7	0.51	6.18e-32	Cannabis dependence symptom count;
LGG	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-9.63	-0.41	3.89e-20	Schizophrenia;
LGG	cis	rs1185460	0.547	rs34150933	chr11:118911039	C/T	cg24687335	chr11:118901407	SLC37A4	-0.59	-10.69	-0.45	5.31e-24	Coronary artery disease;
LGG	cis	rs72634258	0.553	rs112697022	chr1:7949253	G/A	cg00042356	chr1:8021962	PARK7	0.7	8.04	0.35	7.69e-15	Inflammatory bowel disease;
LGG	cis	rs7143963	0.945	rs56101042	chr14:103256961	A/G	cg23020514	chr14:103360112	TRAF3	0.51	9.62	0.41	4.2e-20	Body mass index;
LGG	cis	rs903263	1.000	rs2134646	chr1:84678260	A/T	cg10977910	chr1:84465055	TTLL7	-0.4	-6.64	-0.3	8.55e-11	Breast cancer (male);
LGG	cis	rs55665837	1.000	rs10466412	chr11:14505189	A/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.81	-0.38	2.53e-17	Vitamin D levels;
LGG	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.8	-0.34	4.23e-14	Psoriasis;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05165339	chr4:1420672	NA	0.31	8.02	0.35	8.89e-15	Obesity-related traits;
LGG	cis	rs853679	0.517	rs9380052	chr6:28064623	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.55	-6.98	-0.31	1.02e-11	Depression;
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg00405596	chr8:11794950	NA	0.4	6.74	0.3	4.71e-11	Mood instability;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02532999	chr21:38639929	DSCR3	-0.44	-6.9	-0.31	1.74e-11	Pancreatic cancer;
LGG	cis	rs2117029	0.521	rs10875925	chr12:49536358	G/A	cg24176009	chr12:49580217	TUBA1A	0.63	12.27	0.5	3.52e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.512	rs3862433	chr15:91076028	G/A	cg22089800	chr15:90895588	ZNF774	-0.67	-12.31	-0.5	2.54e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.13	-0.31	3.84e-12	Life satisfaction;
LGG	cis	rs9457247	0.663	rs9457257	chr6:167440736	G/A	cg07741184	chr6:167504864	NA	0.39	8.68	0.37	7.05e-17	Crohn's disease;
LGG	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.13	-0.35	4e-15	Bone mineral density;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg03474202	chr17:45855739	NA	-0.27	-7.9	-0.34	2.03e-14	IgG glycosylation;
LGG	cis	rs8032158	1.000	rs8024944	chr15:56125135	C/A	cg02198044	chr15:56286336	NEDD4	-0.69	-11.82	-0.48	2.44e-28	Keloid;
LGG	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg02886208	chr11:14281011	SPON1	-0.54	-11.96	-0.49	6.78e-29	Mitochondrial DNA levels;
LGG	cis	rs2173063	0.881	rs115966816	chr15:93126568	C/T	cg07052004	chr15:93132129	NA	0.66	7.39	0.32	6.87e-13	Subcutaneous adipose tissue;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09487611	chr12:5019311	KCNA1	0.4	6.72	0.3	5.25e-11	Cognitive performance;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs1009647	0.645	rs72715709	chr14:55711692	C/T	cg04306507	chr14:55594613	LGALS3	0.45	7.75	0.34	6.04e-14	Testicular germ cell tumor;
LGG	cis	rs9287719	0.967	rs4519489	chr2:10739087	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.96e-13	Prostate cancer;
LGG	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg02002194	chr4:3960332	NA	0.41	7.19	0.32	2.54e-12	Neuroticism;
LGG	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg00717180	chr2:96193071	NA	0.4	7.01	0.31	8.47e-12	HDL cholesterol;
LGG	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg00599393	chr8:22457479	C8orf58	-0.44	-8.01	-0.35	9.1e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg19442545	chr10:75533431	FUT11	-0.43	-7.0	-0.31	9.21e-12	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs10936602	0.527	rs1920119	chr3:169540397	T/C	cg08193579	chr3:169529701	LRRC34	0.37	7.56	0.33	2.19e-13	Renal cell carcinoma;
LGG	cis	rs6456042	1.000	rs6940243	chr6:166534658	C/G	cg11088901	chr6:166572345	T	0.37	7.66	0.34	1.07e-13	Asthma;
LGG	cis	rs9527	0.567	rs11191573	chr10:104896816	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.07	-0.46	1.9e-25	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.79e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg20712883	chr12:51590929	POU6F1	0.49	8.31	0.36	1.08e-15	Cisplatin-induced ototoxicity;
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20814179	chr4:940893	TMEM175	0.48	9.01	0.39	5.44e-18	Sjögren's syndrome;
LGG	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg04058563	chr4:185651563	MLF1IP	0.47	10.11	0.43	7.33e-22	Kawasaki disease;
LGG	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg14541582	chr5:601475	NA	-0.71	-10.08	-0.42	1.01e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.03	0.31	7.62e-12	Obesity-related traits;
LGG	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg17133734	chr15:86042851	AKAP13	-0.29	-6.99	-0.31	9.62e-12	Interstitial lung disease;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.87	-0.42	5.8e-21	Lung cancer;
LGG	cis	rs11264213	0.686	rs645383	chr1:36373823	C/G	cg27506609	chr1:36549197	TEKT2	-0.72	-8.69	-0.37	6.48e-17	Schizophrenia;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg04529724	chr6:150244392	RAET1G	0.34	6.95	0.31	1.25e-11	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg07928641	chr1:182991847	LAMC1	-0.45	-9.1	-0.39	2.74e-18	Fuchs's corneal dystrophy;
LGG	cis	rs250677	0.687	rs36043	chr5:148440983	G/A	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.12	-0.31	4.2e-12	Breast cancer;
LGG	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg25338242	chr13:114786047	RASA3	0.4	7.16	0.32	3.24e-12	Schizophrenia;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg27532560	chr4:187881888	NA	-0.6	-13.14	-0.52	9.26e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7647973	0.626	rs7637711	chr3:49829653	A/G	cg03060546	chr3:49711283	APEH	-0.59	-8.35	-0.36	7.82e-16	Menarche (age at onset);
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.47	0.33	3.93e-13	Lung cancer;
LGG	cis	rs2120243	0.874	rs9868133	chr3:157151461	G/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	7.08	0.31	5.39e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg22044901	chr15:68126292	NA	-0.41	-6.91	-0.31	1.6e-11	Restless legs syndrome;
LGG	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg17644776	chr2:200775616	C2orf69	-0.6	-7.01	-0.31	8.46e-12	Schizophrenia;
LGG	cis	rs965513	1.000	rs7032019	chr9:100548144	G/A	cg13688889	chr9:100608707	NA	-0.53	-9.71	-0.41	2.04e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg08677398	chr8:58056175	NA	0.44	7.55	0.33	2.38e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6141769	0.542	rs6058813	chr20:31270861	C/T	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.08	-0.31	5.21e-12	Subjective well-being;
LGG	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.71	-12.07	-0.49	2.31e-29	Height;
LGG	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg19992207	chr2:111874495	ACOXL	-0.37	-6.77	-0.3	3.79e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg12432903	chr7:1882776	MAD1L1	-0.53	-8.53	-0.37	2.12e-16	Bipolar disorder;
LGG	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.92	0.38	1.06e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs6754311	0.731	rs2236783	chr2:136594158	G/A	cg07169764	chr2:136633963	MCM6	-0.77	-13.07	-0.52	1.91e-33	Mosquito bite size;
LGG	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg01657329	chr11:68192670	LRP5	0.62	10.28	0.43	1.86e-22	Bone mineral density (spine);
LGG	cis	rs9470366	0.816	rs7774130	chr6:36623756	C/T	cg08179530	chr6:36648295	CDKN1A	0.64	9.46	0.4	1.62e-19	QRS duration;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg21775007	chr8:11205619	TDH	0.81	14.18	0.55	3.82e-38	Retinal vascular caliber;
LGG	trans	rs2548003	1.000	rs1345787	chr5:28754303	C/T	cg12623145	chr2:97778927	ANKRD36	0.45	6.88	0.3	1.98e-11	Hip geometry;
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	7.52	0.33	2.88e-13	Renal function-related traits (BUN);
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg12419862	chr22:24373484	LOC391322	-1.04	-23.98	-0.74	3.45e-83	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1109114	0.934	rs11168096	chr5:148618424	C/T	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.27	-0.58	6.01e-43	Body mass index;
LGG	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg22535103	chr8:58192502	C8orf71	-0.58	-8.48	-0.37	3.05e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs887829	0.570	rs7563561	chr2:234598991	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.08	-0.35	5.51e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs17685	0.712	rs1859794	chr7:75821544	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	23.69	0.74	7.3e-82	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg22232500	chr2:134024266	NCKAP5	-0.67	-9.37	-0.4	3.12e-19	Bipolar disorder;
LGG	cis	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg00405596	chr8:11794950	NA	-0.62	-10.82	-0.45	1.76e-24	Monocyte count;
LGG	cis	rs3816183	0.602	rs9917172	chr2:43110476	C/G	cg14631114	chr2:43023945	NA	0.41	7.46	0.33	4.24e-13	Hypospadias;
LGG	cis	rs787274	0.867	rs1361719	chr9:115535576	A/G	cg13803584	chr9:115635662	SNX30	-0.55	-7.73	-0.34	6.75e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs73086581	1.000	rs6116130	chr20:3947026	A/T	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg26031613	chr14:104095156	KLC1	0.59	9.26	0.4	7.87e-19	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg10756647	chr7:56101905	PSPH	-0.82	-9.55	-0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26850624	chr5:429559	AHRR	-0.38	-8.27	-0.36	1.47e-15	Cystic fibrosis severity;
LGG	cis	rs7570971	0.500	rs13413101	chr2:135859371	A/T	cg07169764	chr2:136633963	MCM6	0.69	11.66	0.48	9.93e-28	Blood metabolite levels;Body mass index;Cholesterol, total;
LGG	cis	rs12997796	0.556	rs34933869	chr2:86922397	T/C	cg25203885	chr2:87302643	LOC285074	-0.64	-7.54	-0.33	2.58e-13	Schizophrenia;
LGG	cis	rs1555322	1.000	rs1555322	chr20:33849179	C/T	cg17927777	chr20:33865990	NA	0.66	7.51	0.33	3.01e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs17767392	0.874	rs34767050	chr14:71780957	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.12	0.39	2.39e-18	Mitral valve prolapse;
LGG	cis	rs6920372	0.748	rs12528392	chr6:110068614	G/A	cg01125227	chr6:109776195	MICAL1	0.43	7.53	0.33	2.69e-13	Height;
LGG	trans	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg06521331	chr12:34319734	NA	-0.53	-9.07	-0.39	3.28e-18	Bladder cancer;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-15.9	-0.59	9.41e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.17	-0.35	2.99e-15	Retinal vascular caliber;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00495681	chr13:53174319	NA	-0.6	-11.13	-0.46	1.12e-25	Lewy body disease;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs1003719	0.715	rs8129942	chr21:38552070	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.15	-0.58	2.09e-42	Eye color traits;
LGG	trans	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg06521331	chr12:34319734	NA	0.51	9.4	0.4	2.53e-19	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg02297831	chr4:17616191	MED28	-0.48	-9.03	-0.39	4.68e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg26354017	chr1:205819088	PM20D1	0.5	8.13	0.35	4.06e-15	Parkinson's disease;
LGG	cis	rs1843834	0.539	rs6739735	chr2:225405253	A/G	cg22509189	chr2:225307070	NA	0.6	9.82	0.42	8.5e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs975722	0.646	rs43032	chr7:117107284	A/C	cg10524701	chr7:117356490	CTTNBP2	0.42	9.46	0.4	1.61e-19	Coronary artery disease;
LGG	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg13902645	chr11:5959945	NA	-0.64	-9.92	-0.42	3.79e-21	DNA methylation (variation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26221243	chr8:128747973	MYC	0.46	6.85	0.3	2.4e-11	Gut microbiome composition (summer);
LGG	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs2463822	0.592	rs72919486	chr11:62043501	G/C	cg06239285	chr11:62104954	ASRGL1	-1.13	-13.73	-0.54	3.01e-36	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs1032833	0.732	rs60072979	chr2:180030486	C/T	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg19507638	chr5:93509721	C5orf36	-0.66	-9.34	-0.4	4.07e-19	Diabetic retinopathy;
LGG	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg02269571	chr22:50332266	NA	-0.59	-9.17	-0.39	1.54e-18	Schizophrenia;
LGG	cis	rs12618769	0.597	rs961242	chr2:99138979	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs2933343	0.649	rs2638845	chr3:128587369	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-6.83	-0.3	2.73e-11	IgG glycosylation;
LGG	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg03806693	chr22:41940476	POLR3H	0.95	17.01	0.62	8.86e-51	Vitiligo;
LGG	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg27476859	chr7:2772710	GNA12	-0.51	-10.03	-0.42	1.46e-21	Height;
LGG	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg25019033	chr10:957182	NA	-0.52	-8.85	-0.38	1.93e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg09137382	chr11:130731461	NA	0.42	8.01	0.35	9.65e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg25214090	chr10:38739885	LOC399744	-0.6	-10.97	-0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-6.93	-0.31	1.4e-11	Height;
LGG	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg02536541	chr18:77568900	NA	-0.55	-8.7	-0.37	5.83e-17	Schizophrenia;
LGG	cis	rs10744422	1.000	rs921808	chr12:123323135	A/G	cg25930673	chr12:123319894	HIP1R	0.71	9.28	0.4	6.3e-19	Schizophrenia;
LGG	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg10587741	chr22:38071170	LGALS1	0.59	13.67	0.54	5.52e-36	Fat distribution (HIV);
LGG	cis	rs68170813	0.563	rs6979198	chr7:107197694	T/G	cg02696742	chr7:106810147	HBP1	-0.72	-9.72	-0.41	1.93e-20	Coronary artery disease;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.8	-0.48	2.82e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg04731861	chr2:219085781	ARPC2	0.46	11.21	0.46	5.85e-26	Colorectal cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06689961	chr12:12870959	CDKN1B	0.4	6.74	0.3	4.73e-11	Bipolar disorder;
LGG	cis	rs999943	0.810	rs57088429	chr6:33644189	G/A	cg14003231	chr6:33640908	ITPR3	0.67	14.78	0.57	9.17e-41	Obesity (extreme);
LGG	cis	rs826838	0.967	rs826858	chr12:39116731	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.23	-0.7	2.33e-70	Heart rate;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17384381	1.000	rs12128907	chr1:85891385	A/G	cg16011679	chr1:85725395	C1orf52	0.58	9.85	0.42	6.46e-21	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs36051895	0.659	rs2149555	chr9:5053743	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.42	-0.58	1.39e-43	Pediatric autoimmune diseases;
LGG	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08564027	chr20:61660810	NA	1.02	25.72	0.77	3.06e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg07777115	chr5:623756	CEP72	-0.56	-7.12	-0.31	4.26e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg03806693	chr22:41940476	POLR3H	1.02	18.05	0.64	1.58e-55	Vitiligo;
LGG	cis	rs1018836	0.786	rs10086401	chr8:91572818	C/T	cg16814680	chr8:91681699	NA	-0.73	-13.2	-0.52	5.35e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg13206674	chr6:150067644	NUP43	0.68	15.95	0.6	5.91e-46	Lung cancer;
LGG	cis	rs4330281	0.570	rs35642812	chr3:17741409	C/G	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs7619833	0.632	rs481519	chr3:27327214	C/T	cg02860705	chr3:27208620	NA	0.39	7.5	0.33	3.25e-13	Breast cancer;
LGG	cis	rs2373794	0.884	rs448517	chr2:40374912	G/A	cg17740179	chr2:40377776	SLC8A1	-0.89	-19.01	-0.66	5.5e-60	Asthma;
LGG	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.22	-0.52	4.4e-34	Longevity;
LGG	cis	rs7747724	0.757	rs10946405	chr6:20753441	C/T	cg13405222	chr6:20811065	CDKAL1	0.39	7.27	0.32	1.55e-12	Bladder cancer;
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-7.36	-0.32	8.69e-13	Height;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.7e-21	Electroencephalogram traits;
LGG	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg05973401	chr12:123451056	ABCB9	-0.49	-6.97	-0.31	1.09e-11	Neutrophil percentage of white cells;
LGG	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03517284	chr6:25882590	NA	-0.52	-9.96	-0.42	2.61e-21	Blood metabolite levels;
LGG	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg04166393	chr7:2884313	GNA12	0.38	7.37	0.32	7.92e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs13082711	0.911	rs67104968	chr3:27510304	A/G	cg02860705	chr3:27208620	NA	0.7	12.37	0.5	1.4e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	trans	rs8073060	0.963	rs4795082	chr17:33873501	C/T	cg19694781	chr19:47549865	TMEM160	0.65	10.4	0.44	6.56e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs12200782	1.000	rs12211201	chr6:26461461	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.36	-0.32	8.61e-13	Small cell lung carcinoma;
LGG	cis	rs8067545	0.532	rs12946508	chr17:19952059	A/T	cg13482628	chr17:19912719	NA	0.53	8.87	0.38	1.66e-17	Schizophrenia;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.45	-0.33	4.51e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-10.98	-0.45	4.47e-25	Hemoglobin concentration;
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg04025307	chr7:1156635	C7orf50	0.56	9.5	0.4	1.09e-19	Bronchopulmonary dysplasia;
LGG	cis	rs17655565	0.636	rs73311144	chr12:52717544	G/A	cg08257133	chr12:52711352	KRT83	0.56	8.4	0.36	5.5e-16	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs138249	0.523	rs138229	chr22:50557407	A/G	cg18875453	chr22:50517795	MLC1	0.27	6.99	0.31	9.36e-12	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg13010199	chr12:38710504	ALG10B	0.57	11.27	0.46	3.42e-26	Morning vs. evening chronotype;
LGG	cis	rs283228	0.920	rs1352039	chr6:101837957	G/C	cg27451362	chr6:101846650	GRIK2	0.57	9.73	0.41	1.74e-20	Coenzyme Q10 levels;
LGG	cis	rs4716602	0.596	rs12386632	chr7:156158221	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.5	-0.4	1.14e-19	Anti-saccade response;
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg07005078	chr4:17578674	LAP3	0.38	6.69	0.3	6.59e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg21782813	chr7:2030301	MAD1L1	0.34	8.26	0.36	1.49e-15	Schizophrenia;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-9.74	-0.41	1.63e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs77106637	0.860	rs75896506	chr11:72429579	G/A	cg03713592	chr11:72463424	ARAP1	0.46	7.94	0.35	1.51e-14	Type 2 diabetes;
LGG	cis	rs727505	0.954	rs1014163	chr7:124443604	G/A	cg23710748	chr7:124431027	NA	-0.55	-10.5	-0.44	2.84e-23	Lewy body disease;
LGG	cis	rs9815354	0.680	rs73073291	chr3:42028004	G/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16307484	chr11:34073025	CAPRIN1	-0.42	-6.8	-0.3	3.32e-11	Pancreatic cancer;
LGG	cis	rs4262150	0.767	rs116745399	chr5:152136262	C/A	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg02269571	chr22:50332266	NA	-0.65	-9.71	-0.41	2.12e-20	Schizophrenia;
LGG	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg02187348	chr16:89574699	SPG7	0.66	11.23	0.46	4.76e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg10326726	chr10:51549505	MSMB	0.62	12.55	0.5	2.64e-31	Prostate-specific antigen levels;
LGG	cis	rs7267979	0.586	rs1007708	chr20:25190959	C/T	cg06421707	chr20:25228305	PYGB	0.39	8.04	0.35	7.6e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4144027	0.935	rs881056	chr14:104354225	G/A	cg26031613	chr14:104095156	KLC1	0.46	7.49	0.33	3.64e-13	Blood metabolite levels;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.32	0.32	1.11e-12	Schizophrenia;
LGG	cis	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg08930214	chr7:62859557	LOC100287834	0.45	7.58	0.33	1.93e-13	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg16606324	chr3:10149918	C3orf24	0.56	7.3	0.32	1.27e-12	Alzheimer's disease;
LGG	cis	rs2455799	0.613	rs11713820	chr3:15866590	A/G	cg16303742	chr3:15540471	COLQ	0.4	8.09	0.35	5.11e-15	Mean platelet volume;
LGG	cis	rs4409675	0.597	rs1000431	chr1:28225114	C/T	cg23691781	chr1:28212827	C1orf38	0.39	10.47	0.44	3.51e-23	Corneal astigmatism;
LGG	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	9.26	0.4	7.88e-19	Neuroticism;
LGG	cis	rs7766436	0.885	rs1954272	chr6:22586499	A/G	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.87	-0.3	2.11e-11	Menopause (age at onset);
LGG	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.04	0.57	6.39e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs2282802	0.685	rs10051345	chr5:139670932	C/G	cg26211634	chr5:139558579	C5orf32	-0.34	-7.36	-0.32	8.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.71	0.45	4.67e-24	Aortic root size;
LGG	cis	rs11690935	0.550	rs6746701	chr2:172869255	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.96	0.49	6.61e-29	Schizophrenia;
LGG	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.62	-0.33	1.49e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1497828	1.000	rs2646810	chr1:217523112	A/G	cg04411442	chr1:217543379	NA	-0.48	-8.19	-0.36	2.57e-15	Dialysis-related mortality;
LGG	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.56	-0.37	1.71e-16	Alzheimer's disease (survival time);
LGG	cis	rs10463316	0.894	rs7708499	chr5:150765906	A/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.2800000000000002e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs12474201	1.000	rs12474201	chr2:46921285	C/T	cg06386533	chr2:46925753	SOCS5	0.76	14.12	0.55	6.76e-38	Height;
LGG	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg18196295	chr10:418757	DIP2C	0.44	8.03	0.35	8.18e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs1829883	1.000	rs2461971	chr5:98777650	A/G	cg08333243	chr5:99726346	NA	-0.39	-7.67	-0.34	1.01e-13	Hemostatic factors and hematological phenotypes;
LGG	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg15704280	chr7:45808275	SEPT13	0.66	9.32	0.4	4.77e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs116979167	0.630	rs56230603	chr7:105165268	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg08250081	chr4:10125330	NA	0.43	8.38	0.36	6.22e-16	Bone mineral density;
LGG	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.19	-0.32	2.64e-12	Menopause (age at onset);
LGG	cis	rs255758	0.501	rs696199	chr5:53311918	G/A	ch.5.1024479R	chr5:53302184	ARL15	0.39	7.22	0.32	2.15e-12	Rheumatoid arthritis;
LGG	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.6	-0.33	1.7e-13	Triglycerides;
LGG	cis	rs9486719	0.947	rs72932805	chr6:96902933	T/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs7088827	chr10:102303865	C/G	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg12654349	chr5:56205094	C5orf35	-0.65	-9.99	-0.42	2.08e-21	Initial pursuit acceleration;
LGG	cis	rs7940866	0.903	rs11222411	chr11:130838682	A/G	cg12179176	chr11:130786555	SNX19	0.74	13.75	0.54	2.62e-36	Schizophrenia;
LGG	cis	rs6540556	0.723	rs11119331	chr1:209889712	G/A	cg23920097	chr1:209922102	NA	-0.43	-6.92	-0.31	1.52e-11	Red blood cell count;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg20790798	chr5:1857306	NA	-0.43	-7.06	-0.31	6.11e-12	Cardiovascular disease risk factors;
LGG	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09833538	chr9:123605306	PSMD5;LOC253039	0.42	6.67	0.3	7.46e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10861342	1.000	rs10861346	chr12:105473245	G/T	cg23923672	chr12:105501055	KIAA1033	0.76	6.84	0.3	2.49e-11	IgG glycosylation;
LGG	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg22563815	chr15:78856949	CHRNA5	-0.28	-6.79	-0.3	3.5e-11	Sudden cardiac arrest;
LGG	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg21058520	chr6:100914733	NA	-0.39	-6.75	-0.3	4.32e-11	Neuroticism;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.44	-0.53	5.09e-35	Personality dimensions;
LGG	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg04719120	chr6:96025338	MANEA	0.52	7.82	0.34	3.53e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.71	-0.3	5.72e-11	Educational attainment;
LGG	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg20476274	chr7:133979776	SLC35B4	0.72	13.7	0.54	4.18e-36	Mean platelet volume;
LGG	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg10224037	chr5:178157518	ZNF354A	0.75	11.64	0.48	1.17e-27	Neutrophil percentage of white cells;
LGG	cis	rs17021463	0.902	rs36099342	chr4:95239783	T/C	cg11021082	chr4:95130006	SMARCAD1	0.52	9.72	0.41	1.8899999999999998e-20	Testicular germ cell tumor;
LGG	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-7.17	-0.32	2.9e-12	Height;
LGG	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.31	0.36	1.1e-15	Educational attainment;
LGG	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg02463440	chr8:22132932	PIWIL2	0.49	10.72	0.45	4.12e-24	Hypertriglyceridemia;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg24642844	chr7:1081250	C7orf50	-0.77	-13.73	-0.54	3.11e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.96	-0.38	7.71e-18	Neuroticism;
LGG	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11731892	chr2:98207378	ANKRD36B	-0.49	-7.33	-0.32	1.01e-12	Systemic lupus erythematosus;
LGG	cis	rs9863	0.828	rs7135314	chr12:124478566	A/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.07	-0.31	5.67e-12	White blood cell count;
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22168489	chr12:122356033	WDR66	0.42	9.8	0.41	9.95e-21	Mean corpuscular volume;
LGG	cis	rs66716358	0.744	rs1869480	chr11:44319657	C/G	cg16977035	chr11:44330474	ALX4	-0.38	-10.03	-0.42	1.52e-21	Monobrow;
LGG	cis	rs6445975	0.667	rs2037123	chr3:58239193	G/T	cg24175188	chr3:58374923	PXK	0.39	7.22	0.32	2.1e-12	Systemic lupus erythematosus;
LGG	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg19784903	chr17:45786737	TBKBP1	-0.31	-6.9	-0.31	1.69e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs6787172	0.702	rs1724700	chr3:158017153	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg25703541	chr22:24373054	LOC391322	-0.91	-18.3	-0.65	1.13e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.78	0.45	2.42e-24	Total body bone mineral density;
LGG	cis	rs9912468	0.933	rs35105653	chr17:64321521	G/A	cg19474267	chr17:64306194	PRKCA	0.94	24.53	0.75	9.37e-86	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs11225247	1.000	rs17349689	chr11:102269050	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.81	0.3	3.09e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs10186029	0.524	rs10932471	chr2:214009667	G/A	cg08319019	chr2:214017104	IKZF2	0.42	7.37	0.32	7.77e-13	Systemic sclerosis;
LGG	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg26874164	chr19:58962979	ZNF324B	0.37	7.29	0.32	1.39e-12	Uric acid clearance;
LGG	cis	rs9948	0.655	rs76653480	chr2:97375549	C/T	cg01990225	chr2:97406019	LMAN2L	-0.76	-7.31	-0.32	1.2e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg05368731	chr17:41323189	NBR1	0.87	17.03	0.62	7.84e-51	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg18032289	chr17:61959525	GH2	-0.42	-6.93	-0.31	1.38e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.5	-0.33	3.38e-13	Systemic lupus erythematosus;
LGG	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg13455623	chr4:3480656	DOK7	-0.71	-14.85	-0.57	4.61e-41	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg24397884	chr7:158709396	WDR60	0.87	17.26	0.63	7.01e-52	Height;
LGG	cis	rs2470578	0.792	rs2596658	chr3:17245725	C/T	cg20981856	chr3:17787350	NA	0.36	6.88	0.3	2e-11	Schizophrenia;
LGG	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.95	-0.35	1.46e-14	Triglycerides;
LGG	cis	rs9557207	1.000	rs12877371	chr13:100002941	A/C	cg24509225	chr13:100037070	UBAC2	0.72	13.15	0.52	8.47e-34	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.25	-0.32	1.77e-12	Menopause (age at onset);
LGG	cis	rs7584262	0.822	rs1550428	chr2:42240763	C/G	cg27428208	chr2:42229179	NA	0.48	7.59	0.33	1.77e-13	Bone mineral density;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.37	7.12	0.31	4.02e-12	Schizophrenia;
LGG	trans	rs9650657	0.540	rs10094732	chr8:10603015	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.3	-0.32	1.25e-12	Neuroticism;
LGG	trans	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.4	0.56	4.01e-39	Lung cancer;
LGG	cis	rs240764	0.717	rs6904959	chr6:101157916	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.43	-0.33	5.19e-13	Neuroticism;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg05665937	chr4:1216051	CTBP1	0.66	12.71	0.51	5.94e-32	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg07701084	chr6:150067640	NUP43	0.71	13.82	0.54	1.35e-36	Lung cancer;
LGG	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs738322	0.805	rs11570734	chr22:38518622	A/G	cg03162506	chr22:38580953	NA	0.32	7.67	0.34	9.9e-14	Cutaneous nevi;
LGG	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.23	-0.43	2.85e-22	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18482256	chr19:38865041	PSMD8	-0.59	-9.12	-0.39	2.37e-18	Gut microbiome composition (summer);
LGG	cis	rs9487051	1.000	rs9374080	chr6:109616420	C/T	cg21918786	chr6:109611834	NA	0.43	8.12	0.35	4.17e-15	Reticulocyte fraction of red cells;
LGG	cis	rs4262150	0.544	rs55802718	chr5:151916541	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.51	-0.47	3.83e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs8067287	0.688	rs11078356	chr17:16846208	A/G	cg26910001	chr17:16838321	NA	0.4	7.99	0.35	1.09e-14	Diabetic kidney disease;
LGG	cis	rs1010254	0.559	rs72808324	chr5:151742995	T/C	cg12297329	chr5:152029980	NA	-0.47	-6.85	-0.3	2.33e-11	Optic nerve measurement (cup area);
LGG	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	11.14	0.46	1.07e-25	Lung cancer in ever smokers;
LGG	trans	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg06521331	chr12:34319734	NA	0.43	7.71	0.34	7.88e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9479482	0.648	rs912557	chr6:150385977	C/T	cg03788504	chr6:150331562	NA	-0.46	-9.81	-0.41	9.13e-21	Alopecia areata;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03627896	chr16:30934334	NCRNA00095	-0.41	-6.76	-0.3	4.12e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.29	0.46	2.84e-26	Mean platelet volume;
LGG	cis	rs75920871	0.920	rs4316540	chr11:116819241	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.66e-12	Subjective well-being;
LGG	cis	rs4740619	0.905	rs2105317	chr9:15799343	C/T	cg14451791	chr9:16040625	NA	-0.38	-9.88	-0.42	5.19e-21	Body mass index;
LGG	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg17376030	chr22:41985996	PMM1	-0.42	-7.11	-0.31	4.39e-12	Vitiligo;
LGG	cis	rs6998277	1.000	rs35155104	chr8:103646559	G/T	cg10187029	chr8:103597600	NA	0.79	11.51	0.47	3.96e-27	Migraine;
LGG	trans	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg01620082	chr3:125678407	NA	-0.62	-6.91	-0.31	1.56e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15369054	chr17:80825471	TBCD	-0.4	-7.84	-0.34	3.04e-14	Breast cancer;
LGG	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg20673091	chr1:2541236	MMEL1	-0.77	-18.34	-0.65	7.12e-57	Ulcerative colitis;
LGG	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg24596788	chr1:163392923	NA	-0.65	-12.14	-0.49	1.24e-29	Motion sickness;
LGG	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg21452805	chr1:244014465	NA	0.93	9.27	0.4	6.92e-19	RR interval (heart rate);
LGG	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg09904177	chr6:26538194	HMGN4	0.77	17.45	0.63	9.21e-53	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg27147174	chr7:100797783	AP1S1	-0.64	-11.53	-0.47	3.32e-27	Life satisfaction;
LGG	cis	rs2797369	0.824	rs1149271	chr6:101608851	A/G	cg27451362	chr6:101846650	GRIK2	-0.77	-10.33	-0.43	1.15e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs9513627	1.000	rs73556172	chr13:100121684	A/G	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg14673194	chr17:80132900	CCDC57	0.44	7.7	0.34	8.05e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11792861	0.926	rs72607173	chr9:111879398	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.76	0.41	1.4e-20	Menarche (age at onset);
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.77	0.34	5.01e-14	Bipolar disorder;
LGG	cis	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19171272	chr22:38449367	NA	-0.48	-8.67	-0.37	7.47e-17	Glioblastoma;Glioma;
LGG	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.59	0.37	1.3e-16	Alzheimer's disease;
LGG	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg03060546	chr3:49711283	APEH	0.55	8.57	0.37	1.59e-16	Resting heart rate;
LGG	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg24250549	chr1:154909240	PMVK	0.74	14.97	0.57	1.35e-41	Prostate cancer;
LGG	cis	rs6083	0.571	rs41294813	chr15:58847807	T/C	cg05156742	chr15:59063176	FAM63B	-0.45	-8.22	-0.36	2.06e-15	Schizophrenia;
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.01	-0.31	8.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg16339924	chr4:17578868	LAP3	0.51	8.51	0.37	2.5e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.508	rs4347239	chr1:248401116	A/G	cg00666640	chr1:248458726	OR2T12	0.46	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs1707322	0.752	rs6703748	chr1:46095976	G/A	cg03146154	chr1:46216737	IPP	0.57	10.83	0.45	1.62e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs34864796	0.547	rs200476	chr6:27768348	A/T	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.86	-0.3	2.26e-11	Lung function (FEV1);Lung function (FEV1/FVC);Lung function (FVC);
LGG	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.26	0.6	2.26e-47	Diabetic retinopathy;
LGG	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg00784671	chr22:46762841	CELSR1	-0.65	-7.23	-0.32	1.97e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.09	-0.35	5.4e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.65	0.41	3.31e-20	Menopause (age at onset);
LGG	cis	rs9388451	0.531	rs9321057	chr6:126156943	G/A	cg05901451	chr6:126070800	HEY2	-0.59	-10.55	-0.44	1.8e-23	Brugada syndrome;
LGG	cis	rs758324	0.812	rs7709934	chr5:131145210	C/T	cg06307176	chr5:131281290	NA	0.53	8.83	0.38	2.23e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12318506	0.826	rs35933860	chr12:75731821	A/G	cg04728562	chr12:75699417	CAPS2	-1.37	-12.5	-0.5	4.24e-31	Coronary artery calcification;
LGG	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg23752985	chr2:85803571	VAMP8	0.39	7.63	0.33	1.38e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs926938	0.527	rs360594	chr1:115472401	G/A	cg12756093	chr1:115239321	AMPD1	0.43	8.01	0.35	9.25e-15	Autism;
LGG	trans	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.52	-0.37	2.26e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs79149102	0.579	rs3910748	chr15:75318652	A/G	cg17294928	chr15:75287854	SCAMP5	-0.8	-8.85	-0.38	1.9e-17	Lung cancer;
LGG	trans	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.0	-0.31	9.19e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.1e-16	Menopause (age at onset);
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	6.91	0.31	1.66e-11	Renal function-related traits (BUN);
LGG	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.35	-0.43	1.03e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg27411982	chr8:10470053	RP1L1	0.41	7.27	0.32	1.57e-12	Joint mobility (Beighton score);
LGG	cis	rs7617773	0.676	rs13060020	chr3:48372646	C/T	cg11946769	chr3:48343235	NME6	0.71	11.83	0.48	2.23e-28	Coronary artery disease;
LGG	cis	rs3741151	1.000	rs7129663	chr11:73045129	C/T	cg17517138	chr11:73019481	ARHGEF17	1.07	10.8	0.45	2.19e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs953387	1.000	rs10803550	chr2:136907790	C/T	cg07169764	chr2:136633963	MCM6	0.53	8.9	0.38	1.24e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg04287289	chr16:89883240	FANCA	0.89	8.6	0.37	1.23e-16	Skin colour saturation;
LGG	cis	rs9359856	0.673	rs2039053	chr6:90303760	G/A	cg13799429	chr6:90582589	CASP8AP2	0.61	8.15	0.35	3.31e-15	Bipolar disorder;
LGG	cis	rs12282928	0.670	rs4752810	chr11:48224060	A/T	cg20307385	chr11:47447363	PSMC3	-0.43	-7.0	-0.31	8.93e-12	Migraine - clinic-based;
LGG	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.36	0.32	8.67e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg00666640	chr1:248458726	OR2T12	0.58	9.16	0.39	1.66e-18	Common traits (Other);
LGG	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg26248373	chr2:1572462	NA	-0.7	-8.42	-0.36	4.67e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2708240	1.000	rs2710096	chr7:147579836	T/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.8	-0.3	3.2e-11	QT interval (drug interaction);
LGG	cis	rs12586317	0.576	rs10143690	chr14:35651945	T/A	cg05294307	chr14:35346193	BAZ1A	-0.37	-6.95	-0.31	1.21e-11	Psoriasis;
LGG	cis	rs1669338	0.588	rs4684375	chr3:3170966	T/C	cg16797762	chr3:3221439	CRBN	-0.97	-12.76	-0.51	3.53e-32	White matter integrity;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg19182353	chr11:118479428	PHLDB1	-0.49	-10.11	-0.43	7.76e-22	Glioma;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg07580895	chr4:1043494	NA	-0.31	-7.08	-0.31	5.45e-12	Recombination rate (males);
LGG	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.46	0.53	4.28e-35	Colorectal cancer;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	14.91	0.57	2.46e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6942756	0.876	rs57263220	chr7:129010858	C/A	cg02491457	chr7:128862824	NA	-0.68	-12.33	-0.5	2.09e-30	White matter hyperintensity burden;
LGG	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.83	9.17	0.39	1.6e-18	Diabetic retinopathy;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07791516	chr6:150247246	NA	0.34	7.47	0.33	3.97e-13	Testicular germ cell tumor;
LGG	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg07570687	chr10:102243282	WNT8B	-0.44	-7.57	-0.33	1.99e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg04287289	chr16:89883240	FANCA	0.81	16.66	0.61	3.52e-49	Vitiligo;
LGG	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.46e-11	Blood metabolite levels;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg15242686	chr22:24348715	GSTTP1	0.42	8.16	0.35	3.28e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg24623649	chr8:11872141	NA	-0.29	-7.12	-0.31	4.07e-12	Neuroticism;
LGG	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg04731861	chr2:219085781	ARPC2	0.48	11.76	0.48	4.24e-28	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs12618769	0.543	rs2278211	chr2:99149946	G/A	cg18455616	chr2:99124870	INPP4A	0.28	7.97	0.35	1.21e-14	Bipolar disorder;
LGG	cis	rs11920090	0.932	rs1905506	chr3:170695385	C/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.39	0.36	6.06e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.99	-0.39	6.31e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg04863758	chr4:1303710	MAEA	0.42	7.26	0.32	1.69e-12	Obesity-related traits;
LGG	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg18867708	chr6:26865862	GUSBL1	0.44	7.18	0.32	2.71e-12	Schizophrenia;
LGG	cis	rs3740909	0.826	rs7946424	chr11:125883177	G/C	cg24940576	chr11:125904314	CDON	-0.47	-7.27	-0.32	1.51e-12	Blood protein levels;
LGG	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.28	0.36	1.33e-15	Type 2 diabetes;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.83	-0.42	7.79e-21	IgG glycosylation;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.68	-0.34	9.27e-14	Personality dimensions;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs10884984	0.802	rs17127481	chr10:112268801	C/T	cg18756771	chr10:112261994	DUSP5	0.66	12.03	0.49	3.43e-29	Facial morphology (factor 22);
LGG	cis	rs2916247	0.954	rs7007307	chr8:93063802	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.870	rs7320102	chr13:25011573	T/C	cg02811702	chr13:24901961	NA	0.41	7.69	0.34	8.87e-14	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25427524	chr10:38739819	LOC399744	-0.64	-12.06	-0.49	2.51e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs7527798	0.592	rs10746386	chr1:207855095	C/T	cg09232269	chr1:207846808	CR1L	-0.38	-7.27	-0.32	1.58e-12	Erythrocyte sedimentation rate;
LGG	cis	rs73086581	0.592	rs2300217	chr20:3938575	A/G	cg02187196	chr20:3869020	PANK2	0.46	7.27	0.32	1.59e-12	Response to antidepressants in depression;
LGG	trans	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg05926928	chr17:57297772	GDPD1	-0.49	-7.75	-0.34	5.76e-14	Schizophrenia;
LGG	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg10523679	chr1:76189770	ACADM	0.8	14.64	0.56	3.56e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs701145	0.585	rs454837	chr3:153915417	T/C	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg02297831	chr4:17616191	MED28	-0.46	-8.32	-0.36	9.7e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2797369	0.600	rs846784	chr6:101283047	A/C	cg27451362	chr6:101846650	GRIK2	0.67	9.31	0.4	5.26e-19	Renal function-related traits (eGRFcrea);
LGG	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg04317338	chr11:64019027	PLCB3	0.57	6.97	0.31	1.12e-11	Mean platelet volume;
LGG	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.8	0.41	9.89e-21	Tonsillectomy;
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg13628971	chr7:2884303	GNA12	0.34	7.03	0.31	7.44e-12	Height;
LGG	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.67	-0.41	2.97e-20	Retinal vascular caliber;
LGG	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg17971929	chr21:40555470	PSMG1	0.87	17.13	0.62	2.69e-51	Cognitive function;
LGG	cis	rs926938	0.563	rs360645	chr1:115427218	A/G	cg12756093	chr1:115239321	AMPD1	0.46	8.69	0.37	6.1e-17	Autism;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05665937	chr4:1216051	CTBP1	0.57	10.53	0.44	2.09e-23	Obesity-related traits;
LGG	trans	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg05059571	chr16:84539110	KIAA1609	0.54	10.13	0.43	6.35e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11677416	1.000	rs34015482	chr2:113525745	A/G	cg27083787	chr2:113543245	IL1A	0.54	8.97	0.38	7.27e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg14416269	chr4:6271139	WFS1	0.47	8.21	0.36	2.29e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12130219	1.000	rs34428306	chr1:152184316	G/C	cg25272121	chr1:152190972	HRNR	0.39	6.77	0.3	3.88e-11	Inflammatory skin disease;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.49	0.4	1.22e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg16507663	chr6:150244633	RAET1G	0.45	8.47	0.37	3.19e-16	Lung cancer;
LGG	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg18105134	chr13:113819100	PROZ	-0.8	-16.77	-0.61	1.14e-49	Platelet distribution width;
LGG	cis	rs977987	0.815	rs11646677	chr16:75408981	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.36	0.43	9.54e-23	Dupuytren's disease;
LGG	cis	rs225245	0.610	rs321607	chr17:33880584	A/G	cg05299278	chr17:33885742	SLFN14	0.38	7.23	0.32	1.98e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg21775007	chr8:11205619	TDH	0.83	14.71	0.56	1.75e-40	Retinal vascular caliber;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg07511668	chr11:68622177	NA	0.5	9.14	0.39	2.01e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs68170813	0.559	rs12537785	chr7:107050221	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.15	-0.43	5.48e-22	Coronary artery disease;
LGG	cis	rs10876993	0.928	rs2928053	chr12:58063475	T/C	cg18357645	chr12:58087776	OS9	0.71	13.09	0.52	1.6e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs2274273	0.870	rs59629906	chr14:55781189	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.03	0.62	7.18e-51	Protein biomarker;
LGG	cis	rs9581857	0.579	rs76578450	chr13:27982656	C/A	cg01674679	chr13:27998804	GTF3A	-0.74	-8.56	-0.37	1.65e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs9796	0.558	rs11855102	chr15:41513257	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-10.16	-0.43	4.86e-22	Menopause (age at onset);
LGG	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.58	-0.44	1.47e-23	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs9715521	0.775	rs56957240	chr4:59847774	C/A	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg26338869	chr17:61819248	STRADA	0.58	9.67	0.41	2.85e-20	Prudent dietary pattern;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg15485101	chr11:133734466	NA	0.6	10.54	0.44	2.07e-23	Childhood ear infection;
LGG	cis	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-10.0	-0.42	1.84e-21	Hip circumference adjusted for BMI;
LGG	cis	rs209489	0.786	rs79129577	chr6:53167449	G/A	cg15607103	chr6:53167650	ELOVL5	0.72	9.01	0.39	5.41e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs7945718	0.591	rs7926971	chr11:12698040	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.09	0.31	5.07e-12	Educational attainment (years of education);
LGG	trans	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.04	0.42	1.37e-21	Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg01145232	chr6:150245071	RAET1G	0.33	7.07	0.31	5.82e-12	Testicular germ cell tumor;
LGG	cis	rs10193935	0.901	rs222468	chr2:42642531	C/T	cg27598129	chr2:42591480	NA	-0.64	-9.52	-0.4	9.48e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2177596	0.525	rs2229814	chr2:227954599	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-8.73	-0.38	4.6e-17	Body mass index;
LGG	cis	rs2463822	0.925	rs12292586	chr11:62156312	C/T	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.68	-0.59	9.08e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6120849	0.754	rs6119560	chr20:33606977	G/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs11877825	0.826	rs9675768	chr18:10571709	T/C	cg25239095	chr18:10589360	NA	0.49	9.02	0.39	4.94e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg27446573	chr6:127587934	RNF146	0.78	14.89	0.57	2.85e-41	Breast cancer;
LGG	cis	rs3796352	1.000	rs2564926	chr3:53094730	G/A	cg12962167	chr3:53033115	SFMBT1	-0.75	-7.89	-0.34	2.27e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs8005745	0.614	rs71423444	chr14:62196197	C/A	cg01748970	chr14:62088363	NA	-0.82	-9.79	-0.41	1.12e-20	Select biomarker traits;
LGG	cis	rs17221829	0.600	rs3881248	chr11:89362196	T/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.02	-0.39	4.97e-18	Anxiety in major depressive disorder;
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.72	-0.3	5.27e-11	Triglycerides;
LGG	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	13.34	0.53	1.46e-34	Birth weight;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.58	-0.33	1.91e-13	Personality dimensions;
LGG	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg25356066	chr3:128598488	ACAD9	0.48	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg03263685	chr2:68480160	PPP3R1	-0.38	-6.68	-0.3	7.07e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg06640241	chr16:89574553	SPG7	0.74	13.11	0.52	1.29e-33	Multiple myeloma (IgH translocation);
LGG	cis	rs9517313	0.551	rs2274051	chr13:99091634	A/G	cg07423050	chr13:99094983	FARP1	0.61	11.82	0.48	2.3e-28	Neuroticism;
LGG	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg24110177	chr3:50126178	RBM5	0.61	11.23	0.46	4.77e-26	Body mass index;
LGG	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg22906224	chr7:99728672	NA	0.59	9.29	0.4	6.15e-19	Coronary artery disease;
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg18681998	chr4:17616180	MED28	0.89	19.82	0.68	9.4e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9504361	0.808	rs3765437	chr6:563013	C/T	cg13471009	chr6:564609	EXOC2	-0.37	-7.85	-0.34	2.99e-14	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LGG	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg01262667	chr19:19385393	TM6SF2	0.45	11.41	0.47	9.92e-27	Tonsillectomy;
LGG	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg26384229	chr12:38710491	ALG10B	0.7	13.02	0.52	3.09e-33	Resting heart rate;
LGG	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg25986240	chr4:9926439	SLC2A9	0.34	7.02	0.31	7.85e-12	Bone mineral density;
LGG	cis	rs9788682	0.747	rs8043009	chr15:78908154	G/C	cg06917634	chr15:78832804	PSMA4	-0.51	-8.05	-0.35	7.15e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7072216	0.763	rs942803	chr10:100168631	G/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs1978968	0.717	rs35645198	chr22:18408322	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.51	-9.78	-0.41	1.22e-20	Presence of antiphospholipid antibodies;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06588087	chr4:36245610	ARAP2	0.43	7.73	0.34	6.74e-14	Bilirubin levels;
LGG	cis	rs870825	0.860	rs72703525	chr4:185605154	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg27205649	chr11:78285834	NARS2	0.48	8.02	0.35	8.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg01879757	chr17:41196368	BRCA1	-0.42	-8.44	-0.37	4.16e-16	Menopause (age at onset);
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.32	0.4	4.93e-19	Bipolar disorder;
LGG	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.3	-0.36	1.19e-15	Myopia (pathological);
LGG	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.71	14.17	0.55	4.2e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg21171335	chr12:122356390	WDR66	0.27	7.94	0.35	1.49e-14	Mean corpuscular volume;
LGG	cis	rs9362426	0.503	rs6454609	chr6:88106028	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.36	7.16	0.32	3.13e-12	Depressive episodes in bipolar disorder;
LGG	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.68	-14.34	-0.55	7.28e-39	Colorectal cancer;
LGG	cis	rs1670533	0.932	rs13140571	chr4:1054358	T/C	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	cis	rs10499694	0.933	rs998850	chr7:50607388	G/C	cg04490037	chr7:50633773	DDC	0.32	7.04	0.31	6.84e-12	Body mass index;
LGG	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg16414030	chr3:133502952	NA	-0.66	-11.51	-0.47	4.05e-27	Iron status biomarkers;
LGG	cis	rs2070677	0.736	rs4498943	chr10:135422505	A/T	cg20169779	chr10:135381914	SYCE1	1.05	11.22	0.46	5.36e-26	Gout;
LGG	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg09021430	chr5:549028	NA	-0.69	-9.64	-0.41	3.77e-20	Lung disease severity in cystic fibrosis;
LGG	cis	rs700651	0.789	rs1371663	chr2:198900305	C/T	cg00792783	chr2:198669748	PLCL1	-0.63	-9.81	-0.41	8.87e-21	Intracranial aneurysm;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.74	-14.4	-0.56	4.29e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs4732038	0.510	rs10255114	chr7:134269158	C/A	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.17	-0.49	9.43e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11866815	0.602	rs12923240	chr16:376836	C/T	cg07915516	chr16:377344	AXIN1	-0.52	-11.52	-0.47	3.67e-27	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13996731	chr4:149363522	NR3C2	0.48	7.17	0.32	2.97e-12	Gut microbiome composition (summer);
LGG	cis	rs4959677	0.935	rs9503208	chr6:2499191	C/T	cg20147862	chr6:2634573	C6orf195	-0.4	-8.72	-0.38	5.14e-17	Orthostatic hypotension;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg13206674	chr6:150067644	NUP43	0.66	14.76	0.57	1.08e-40	Lung cancer;
LGG	cis	rs9560113	0.764	rs1177401	chr13:112173067	T/C	cg14154082	chr13:112174009	NA	-0.4	-8.73	-0.38	4.76e-17	Menarche (age at onset);
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg04234412	chr22:24373322	LOC391322	-0.91	-20.6	-0.69	2.12e-67	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs539514	0.664	rs634729	chr13:76307981	C/T	cg04757411	chr13:76259545	LMO7	-0.26	-6.85	-0.3	2.43e-11	Type 1 diabetes;
LGG	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-9.87	-0.42	5.51e-21	Schizophrenia;
LGG	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg11693508	chr17:37793320	STARD3	-0.52	-7.7	-0.34	8.56e-14	Bipolar disorder;
LGG	cis	rs1577917	1.000	rs12205336	chr6:86722367	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.15	-0.43	5.42e-22	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.14	0.31	3.69e-12	Lung cancer;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00689492	chr4:1303491	MAEA	0.51	8.57	0.37	1.56e-16	Obesity-related traits;
LGG	trans	rs12310956	0.515	rs1872745	chr12:33985987	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.88	0.57	3.22e-41	Morning vs. evening chronotype;
LGG	cis	rs564799	0.966	rs485789	chr3:159730148	G/T	cg04855961	chr3:159719849	NA	-0.28	-7.55	-0.33	2.38e-13	Systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19717773	chr7:2847554	GNA12	-0.36	-8.4	-0.36	5.54e-16	Height;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.05	0.35	6.95e-15	Obesity-related traits;
LGG	cis	rs17604090	0.793	rs73687726	chr7:29688773	T/C	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg14791747	chr16:20752902	THUMPD1	0.49	7.44	0.33	4.98e-13	Cognitive test performance;
LGG	cis	rs9309473	0.607	rs6716776	chr2:73587713	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-9.08	-0.39	3.21e-18	Metabolite levels;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	6.91	0.31	1.58e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg18446336	chr7:2847575	GNA12	-0.29	-7.05	-0.31	6.38e-12	Height;
LGG	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg03606772	chr1:152487856	CRCT1	0.31	7.37	0.32	8.07e-13	Hair morphology;
LGG	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg04691961	chr3:161091175	C3orf57	-0.47	-9.51	-0.4	1.04e-19	Parkinson's disease;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg04863758	chr4:1303710	MAEA	0.42	7.24	0.32	1.9e-12	Obesity-related traits;
LGG	trans	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.87	-0.38	1.66e-17	Triglycerides;
LGG	cis	rs6694672	1.000	rs7516700	chr1:197110331	T/G	cg13682187	chr1:196946512	CFHR5	0.5	6.9	0.31	1.73e-11	Asthma;
LGG	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg21775007	chr8:11205619	TDH	0.54	9.02	0.39	5.03e-18	Neuroticism;
LGG	cis	rs9341835	0.510	rs2622284	chr6:64193572	T/C	cg00787780	chr6:64151745	NA	-0.39	-6.96	-0.31	1.14e-11	Schizophrenia;
LGG	trans	rs6787172	0.702	rs7643792	chr3:157992814	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.55	-0.33	2.34e-13	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs892961	0.932	rs7224116	chr17:75413177	A/G	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg24397884	chr7:158709396	WDR60	0.86	17.43	0.63	1.07e-52	Height;
LGG	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.7e-21	Corneal astigmatism;
LGG	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.47	-0.33	4.13e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1185460	0.967	rs2509121	chr11:118928253	C/T	cg23280166	chr11:118938394	VPS11	0.6	10.91	0.45	7.88e-25	Coronary artery disease;
LGG	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.75	-0.41	1.52e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4788570	0.547	rs6499538	chr16:71762285	A/C	cg06353428	chr16:71660113	MARVELD3	1.28	20.2	0.68	1.53e-65	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00149659	chr3:10157352	C3orf10	0.83	10.72	0.45	4.28e-24	Alzheimer's disease;
LGG	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg04833646	chr19:10679720	CDKN2D	1.01	16.29	0.6	1.69e-47	Red cell distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13374225	chr1:10093824	UBE4B	0.44	6.89	0.3	1.85e-11	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16041611	chr6:43139680	SRF	0.53	8.75	0.38	4.13e-17	Cognitive performance;
LGG	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg12310025	chr6:25882481	NA	-0.44	-6.83	-0.3	2.61e-11	Height;
LGG	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16386425	chr10:429943	DIP2C	-0.47	-9.7	-0.41	2.34e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs6993813	0.678	rs2062376	chr8:120010009	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.84	0.34	3.04e-14	Bone mineral density (hip);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg16672685	chr2:219081914	ARPC2	-0.4	-6.95	-0.31	1.28e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs17767392	0.748	rs58952176	chr14:71704043	C/G	cg02058870	chr14:72053146	SIPA1L1	0.35	7.02	0.31	7.96e-12	Mitral valve prolapse;
LGG	trans	rs7395662	1.000	rs9645642	chr11:48705455	G/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs7565124	0.955	rs67500069	chr2:20269864	A/C	cg24657347	chr2:20261756	NA	-0.75	-14.62	-0.56	4.31e-40	Major depressive disorder;
LGG	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.32e-35	Corneal astigmatism;
LGG	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.35	0.43	1.03e-22	Aortic root size;
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg16141378	chr3:129829833	LOC729375	0.39	8.98	0.39	6.59e-18	Neuroticism;
LGG	cis	rs10267417	0.603	rs28770193	chr7:19860804	A/T	cg05791153	chr7:19748676	TWISTNB	0.6	7.75	0.34	5.7e-14	Night sleep phenotypes;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg05793240	chr7:2802953	GNA12	0.29	7.14	0.31	3.67e-12	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14968603	chr10:102046143	BLOC1S2	0.45	7.71	0.34	8.01e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs75920871	0.764	rs1473327	chr11:116823996	A/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.07	-0.31	5.83e-12	Subjective well-being;
LGG	cis	rs3768617	1.000	rs2027077	chr1:183073453	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.76	0.3	4.2e-11	Fuchs's corneal dystrophy;
LGG	cis	rs9473924	0.580	rs66462826	chr6:50814877	C/A	cg14470998	chr6:50812995	TFAP2B	0.65	7.75	0.34	5.74e-14	Body mass index;
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.82	-0.38	2.42e-17	Life satisfaction;
LGG	cis	rs9359856	0.517	rs11962350	chr6:90592406	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.87	-11.01	-0.46	3.23e-25	Bipolar disorder;
LGG	cis	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs5995756	0.627	rs3788568	chr22:40011273	G/T	cg21377881	chr22:40064566	CACNA1I	-0.34	-7.09	-0.31	5.13e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg03907864	chr22:41865051	ACO2;PHF5A	0.41	7.38	0.32	7.6e-13	Eye color traits;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.75e-14	Lung cancer;
LGG	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-12.1	-0.49	1.85e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg07777115	chr5:623756	CEP72	-0.56	-7.12	-0.31	4.26e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.37	0.43	8.59e-23	Prudent dietary pattern;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg19231082	chr3:119217133	C3orf1	-0.45	-6.75	-0.3	4.37e-11	Educational attainment (years of education);
LGG	trans	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg16141378	chr3:129829833	LOC729375	0.44	10.39	0.43	7.1e-23	Mood instability;
LGG	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.08	26.54	0.78	5.29e-95	Cognitive ability;
LGG	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.34	0.32	9.36e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs75804782	0.625	rs72984533	chr2:239470005	T/C	cg01134436	chr17:81009848	B3GNTL1	0.75	7.92	0.35	1.74e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3825932	0.961	rs28655102	chr15:79232700	C/T	cg25744700	chr15:79237217	CTSH	0.35	6.7	0.3	6.13e-11	Type 1 diabetes;
LGG	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg15704280	chr7:45808275	SEPT13	-0.74	-8.79	-0.38	2.88e-17	Intraocular pressure;
LGG	cis	rs3617	0.503	rs9866243	chr3:52915219	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-7.59	-0.33	1.82e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.03	-0.31	7.35e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	4e-21	Bipolar disorder;
LGG	cis	rs12618769	0.652	rs3203856	chr2:99226021	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.7	0.34	8.26e-14	Bipolar disorder;
LGG	cis	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg09307838	chr4:120376055	NA	0.48	7.87	0.34	2.58e-14	Diastolic blood pressure;
LGG	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg14912033	chr15:79043428	NA	-0.4	-9.89	-0.42	4.68e-21	Coronary artery disease or large artery stroke;
LGG	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg02023728	chr11:77925099	USP35	0.4	7.16	0.32	3.25e-12	Alzheimer's disease (survival time);
LGG	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg17218041	chr13:113365319	ATP11A	-0.47	-7.83	-0.34	3.41e-14	Glycated hemoglobin levels;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs2463822	1.000	rs12279819	chr11:62137245	G/A	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.68	-0.59	9.08e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg21535247	chr6:8435926	SLC35B3	0.61	10.3	0.43	1.57e-22	Motion sickness;
LGG	cis	rs7107174	0.901	rs990706	chr11:78135704	C/T	cg02023728	chr11:77925099	USP35	0.43	7.45	0.33	4.64e-13	Testicular germ cell tumor;
LGG	cis	rs1949733	1.000	rs3103071	chr4:8508579	C/G	cg11789530	chr4:8429930	ACOX3	-0.87	-17.06	-0.62	5.43e-51	Response to antineoplastic agents;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.65	11.63	0.48	1.31e-27	Prudent dietary pattern;
LGG	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg20818283	chr2:191399100	TMEM194B	0.3	7.1	0.31	4.79e-12	Pulse pressure;
LGG	cis	rs2073499	0.872	rs2239801	chr3:50402309	C/G	cg03645007	chr3:50255295	SLC38A3	0.61	6.79	0.3	3.43e-11	Schizophrenia;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg00908189	chr16:619842	PIGQ	0.88	16.61	0.61	6.32e-49	Height;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg00024416	chr22:24240387	NA	-0.37	-6.86	-0.3	2.22e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10484885	0.824	rs112817281	chr6:90555658	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.82	-10.35	-0.43	1.01e-22	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg14088196	chr11:70211408	PPFIA1	0.93	13.07	0.52	1.9e-33	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.52e-22	Diabetic kidney disease;
LGG	cis	rs6993813	0.843	rs1485312	chr8:120043935	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs3736594	0.840	rs57238885	chr2:27974260	C/G	cg27432699	chr2:27873401	GPN1	0.56	9.13	0.39	2.18e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs35123781	1.000	rs601728	chr5:139057076	T/C	cg21230503	chr5:139085173	NA	0.31	7.41	0.33	5.92e-13	Schizophrenia;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.4	0.61	5.42e-48	Obesity-related traits;
LGG	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg24253500	chr15:84953950	NA	-0.4	-7.39	-0.32	6.87e-13	P wave terminal force;
LGG	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08862035	chr2:2617432	NA	-0.41	-6.65	-0.3	8.21e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7939886	0.920	rs7112815	chr11:55960104	T/C	cg03929089	chr4:120376271	NA	0.73	6.79	0.3	3.52e-11	Myopia (pathological);
LGG	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.58	-0.44	1.41e-23	Bladder cancer;
LGG	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs2304069	0.909	rs8073	chr5:149362400	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.9	-13.77	-0.54	2.09e-36	HIV-1 control;
LGG	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.48	-0.33	3.67e-13	Vitamin D levels;
LGG	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg00531865	chr16:30841666	NA	-0.47	-9.92	-0.42	3.54e-21	Dementia with Lewy bodies;
LGG	trans	rs225245	0.541	rs321612	chr17:33881631	T/C	cg19694781	chr19:47549865	TMEM160	-0.53	-9.44	-0.4	1.79e-19	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg20607798	chr8:58055168	NA	0.57	8.77	0.38	3.33e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.14e-54	Cognitive function;
LGG	cis	rs10895140	0.665	rs3018707	chr11:101490306	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7914558	1.000	rs7914558	chr10:104775908	G/A	cg04362960	chr10:104952993	NT5C2	0.53	10.18	0.43	4.2e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-12.3	-0.5	2.89e-30	Monocyte count;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg05368731	chr17:41323189	NBR1	0.86	16.26	0.6	2.46e-47	Menopause (age at onset);
LGG	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg11941060	chr3:133502564	NA	0.47	7.95	0.35	1.39e-14	Iron status biomarkers;
LGG	cis	rs225245	0.610	rs321608	chr17:33880636	A/G	cg05299278	chr17:33885742	SLFN14	0.38	7.23	0.32	1.98e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.55	8.57	0.37	1.51e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg03351412	chr1:154909251	PMVK	0.67	12.86	0.51	1.39e-32	Prostate cancer;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.12	-0.35	4.13e-15	IgG glycosylation;
LGG	trans	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	15.43	0.58	1.21e-43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.47	0.4	1.5e-19	Renal function-related traits (BUN);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19971804	chr2:39102883	MORN2;DHX57	0.41	6.79	0.3	3.55e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	17.58	0.63	2.25e-53	Obesity-related traits;
LGG	trans	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.49	-0.4	1.23e-19	Mood instability;
LGG	cis	rs7973719	0.966	rs1450962	chr12:7320545	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-7.98	-0.35	1.13e-14	IgG glycosylation;
LGG	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.22	0.32	2.18e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.87	-0.42	5.54e-21	Lung cancer;
LGG	cis	rs7133214	0.771	rs12370269	chr12:27924658	A/G	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.98	-0.31	1.03e-11	Gut microbiota (functional units);
LGG	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg12856521	chr11:46389249	DGKZ	0.52	9.42	0.4	2.14e-19	Leprosy;
LGG	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg06271696	chr7:157225062	NA	-0.55	-11.68	-0.48	8.37e-28	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg02187348	chr16:89574699	SPG7	0.6	9.75	0.41	1.51e-20	Multiple myeloma (IgH translocation);
LGG	trans	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.41	-0.4	2.34e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2333194	0.772	rs12589739	chr14:73903056	A/G	cg10076968	chr14:74006090	HEATR4;ACOT1	0.27	6.77	0.3	3.84e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.78	-0.64	2.79e-54	Breast cancer;
LGG	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg16262614	chr3:133464971	TF	0.48	8.75	0.38	3.89e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs988958	0.958	rs35771566	chr2:42280358	C/T	cg27428208	chr2:42229179	NA	0.41	7.49	0.33	3.56e-13	Hypospadias;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	16.83	0.62	5.98e-50	Alzheimer's disease;
LGG	cis	rs12912251	0.947	rs7171233	chr15:38988760	T/A	cg01338139	chr15:38987640	C15orf53	-0.55	-8.74	-0.38	4.17e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs9303280	0.901	rs921650	chr17:38069076	G/A	cg00129232	chr17:37814104	STARD3	0.45	8.36	0.36	7.46e-16	Self-reported allergy;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg05863683	chr7:1912471	MAD1L1	0.44	8.77	0.38	3.45e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg18357526	chr6:26021779	HIST1H4A	0.49	8.13	0.35	3.99e-15	Height;
LGG	cis	rs9398803	0.713	rs9401888	chr6:126877523	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.54	0.41	8.53e-20	Male-pattern baldness;
LGG	cis	rs9972944	0.702	rs6416947	chr17:63763970	C/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.44	-0.37	4.1e-16	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg18032289	chr17:61959525	GH2	-0.4	-6.82	-0.3	2.82e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg11266682	chr4:10021025	SLC2A9	0.5	9.71	0.41	2.13e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg13010199	chr12:38710504	ALG10B	0.51	9.79	0.41	1.09e-20	Morning vs. evening chronotype;
LGG	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.67	0.44	6.78e-24	Height;
LGG	cis	rs13108043	0.605	rs62306509	chr4:87957073	T/G	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs9796	0.775	rs57393155	chr15:41426251	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.87	-0.38	1.55e-17	Menopause (age at onset);
LGG	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg11764359	chr7:65958608	NA	0.64	9.61	0.41	4.81e-20	Aortic root size;
LGG	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg02811702	chr13:24901961	NA	0.39	7.1	0.31	4.79e-12	Obesity-related traits;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.06	27.82	0.79	7.54e-101	Prudent dietary pattern;
LGG	cis	rs7267979	0.789	rs6083841	chr20:25384564	C/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.82	-0.34	3.51e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7786808	0.760	rs10259321	chr7:158221038	G/A	cg09998033	chr7:158218633	PTPRN2	0.54	10.13	0.43	6.6e-22	Obesity-related traits;
LGG	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	12.7	0.51	6.6e-32	High light scatter reticulocyte count;
LGG	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg05890377	chr2:74357713	NA	0.47	9.08	0.39	3.18e-18	Gestational age at birth (maternal effect);
LGG	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg23202291	chr11:1979235	NA	-0.37	-7.68	-0.34	9.41e-14	DNA methylation (variation);
LGG	cis	rs7192750	0.586	rs9937936	chr16:71934419	A/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4969178	0.965	rs3744217	chr17:76400258	G/A	cg05887092	chr17:76393375	PGS1	0.72	16.0	0.6	3.37e-46	HDL cholesterol levels;
LGG	cis	rs1010254	0.527	rs72804360	chr5:151657057	A/G	cg12297329	chr5:152029980	NA	-0.5	-6.76	-0.3	4.13e-11	Optic nerve measurement (cup area);
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	9.84	0.42	7.1e-21	Longevity;
LGG	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.81	0.3	3.08e-11	Parkinson's disease;
LGG	cis	rs7106204	0.514	rs12282611	chr11:24271352	A/C	ch.11.24196551F	chr11:24239977	NA	0.91	12.32	0.5	2.28e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs758324	0.947	rs6861174	chr5:131156129	A/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.68e-123	Prudent dietary pattern;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg24503407	chr1:205819492	PM20D1	-0.7	-16.44	-0.61	3.47e-48	Monocyte percentage of white cells;
LGG	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg00579200	chr11:133705235	NA	-0.57	-11.1	-0.46	1.47e-25	Childhood ear infection;
LGG	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg03264133	chr6:25882463	NA	-0.38	-6.71	-0.3	5.68e-11	Height;
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.33	-0.43	1.21e-22	Bipolar disorder;
LGG	cis	rs4538187	0.950	rs35336851	chr2:64244541	T/C	cg14150252	chr2:64069583	UGP2	-0.49	-9.56	-0.41	6.78e-20	Systolic blood pressure;
LGG	cis	rs7000551	0.581	rs4872487	chr8:22256414	C/T	cg13512537	chr8:22265999	SLC39A14	-0.41	-6.9	-0.31	1.74e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26444995	chr2:198670187	PLCL1	0.44	7.09	0.31	4.95e-12	Cognitive performance;
LGG	cis	rs9462027	0.628	rs7771778	chr6:34660324	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.86	0.45	1.25e-24	Systemic lupus erythematosus;
LGG	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	8.74	0.38	4.19e-17	Neuroticism;
LGG	cis	rs3087591	1.000	rs2905791	chr17:29472888	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg19318889	chr4:1322082	MAEA	-0.4	-7.13	-0.31	3.84e-12	Obesity-related traits;
LGG	cis	rs2067615	0.579	rs12312782	chr12:107135647	G/A	cg15890332	chr12:107067104	RFX4	0.41	12.19	0.49	7.94e-30	Heart rate;
LGG	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.63	-0.44	9.3e-24	Hip circumference adjusted for BMI;
LGG	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26076054	chr5:421317	AHRR	-0.44	-6.96	-0.31	1.17e-11	Cystic fibrosis severity;
LGG	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg17757837	chr7:157058334	UBE3C	-0.94	-21.36	-0.7	5.56e-71	Body mass index;
LGG	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg23231163	chr10:75533350	FUT11	-0.43	-7.49	-0.33	3.44e-13	Inflammatory bowel disease;
LGG	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.8	-0.45	2.12e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9972944	0.902	rs12939558	chr17:63772152	A/G	cg07283582	chr17:63770753	CCDC46	0.42	8.14	0.35	3.58e-15	Total body bone mineral density;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg02002194	chr4:3960332	NA	0.56	10.76	0.45	3.09e-24	Triglycerides;
LGG	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg02461776	chr11:598696	PHRF1	0.54	8.52	0.37	2.18e-16	Systemic lupus erythematosus;
LGG	cis	rs12019136	1	rs12019136	chr19:5835677	G/A	cg25387410	chr19:5844109	FUT3	-1.09	-10.71	-0.45	4.44e-24	Advanced age-related macular degeneration;IgG N-glycosylation phenotypes (multivariate analysis);
LGG	cis	rs7084783	0.519	rs1047425	chr10:105345201	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.49	8.7	0.37	5.75e-17	Fear of pain;
LGG	cis	rs59197085	0.534	rs2307038	chr7:128449356	A/C	cg00734629	chr7:128471146	FLNC	0.35	7.11	0.31	4.56e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07274776	chr2:203241322	BMPR2	0.44	7.15	0.32	3.5e-12	Cognitive performance;
LGG	trans	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg22153745	chr1:153894579	GATAD2B	-0.58	-8.61	-0.37	1.16e-16	Total cholesterol levels;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg25072359	chr17:41440525	NA	0.52	9.95	0.42	2.8e-21	Menopause (age at onset);
LGG	cis	rs9486719	1.000	rs34236778	chr6:96884556	C/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs17767392	0.958	rs17767553	chr14:71910587	A/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.33	0.4	4.44e-19	Mitral valve prolapse;
LGG	cis	rs7215564	0.822	rs2340771	chr17:78752947	A/C	cg16980736	chr17:78789706	RPTOR	0.6	7.71	0.34	7.92e-14	Myopia (pathological);
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg07870213	chr5:140052090	DND1	-0.86	-15.7	-0.59	7.32e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg27532560	chr4:187881888	NA	-0.59	-12.92	-0.51	8.02e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7940866	0.838	rs10736592	chr11:130800572	C/T	cg12179176	chr11:130786555	SNX19	0.78	14.91	0.57	2.52e-41	Schizophrenia;
LGG	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg13647721	chr17:30228624	UTP6	0.64	8.0	0.35	9.91e-15	Hip circumference adjusted for BMI;
LGG	cis	rs1152591	0.543	rs1152592	chr14:64676098	A/G	cg21174375	chr14:64681225	SYNE2	0.42	7.94	0.35	1.54e-14	Atrial fibrillation;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2028299	0.839	rs2279849	chr15:90444639	A/G	cg23731826	chr15:90371692	NA	0.35	7.89	0.34	2.18e-14	Type 2 diabetes;
LGG	cis	rs2732480	0.577	rs2634680	chr12:48734564	T/C	cg21466736	chr12:48725269	NA	-0.4	-8.03	-0.35	8.04e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs1020064	0.609	rs2576748	chr2:105911258	A/C	cg02079111	chr2:105885981	TGFBRAP1	-0.42	-7.05	-0.31	6.59e-12	AIDS;
LGG	cis	rs12928939	0.774	rs7205340	chr16:71645670	A/T	cg08717414	chr16:71523259	ZNF19	0.46	7.18	0.32	2.73e-12	Post bronchodilator FEV1;
LGG	cis	rs9834373	0.593	rs11127621	chr3:78500847	G/C	cg06138941	chr3:78371609	NA	-0.46	-8.58	-0.37	1.46e-16	Protein quantitative trait loci;
LGG	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg02461776	chr11:598696	PHRF1	0.52	8.1	0.35	4.95e-15	Systemic lupus erythematosus;
LGG	cis	rs2011503	1.000	rs76095338	chr19:19633908	G/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg15268244	chr15:77196840	NA	-0.31	-6.78	-0.3	3.65e-11	Blood metabolite levels;
LGG	cis	rs6901004	0.771	rs6900781	chr6:111422856	T/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.79	-0.34	4.47e-14	Blood metabolite levels;
LGG	cis	rs5769765	0.542	rs5770720	chr22:50253101	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.22	0.32	2.2e-12	Schizophrenia;
LGG	cis	rs67311347	1.000	rs4571217	chr3:40521973	A/G	cg24209194	chr3:40518798	ZNF619	0.44	6.71	0.3	5.69e-11	Renal cell carcinoma;
LGG	cis	rs2777491	0.915	rs9302109	chr15:41612180	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.71	-14.41	-0.56	3.78e-39	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs12431410	0.550	rs7154315	chr14:60234996	G/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.21	-0.32	2.35e-12	Schizophrenia;
LGG	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.1	-0.31	4.68e-12	Neuroticism;
LGG	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03264133	chr6:25882463	NA	-0.6	-11.09	-0.46	1.62e-25	Intelligence (multi-trait analysis);
LGG	cis	rs877282	1.000	rs12779159	chr10:772143	T/C	cg17470449	chr10:769945	NA	0.63	7.8	0.34	4.28e-14	Uric acid levels;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	-0.35	-7.58	-0.33	1.89e-13	Schizophrenia;
LGG	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.31	0.47	2.27e-26	Tonsillectomy;
LGG	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg07537917	chr2:241836409	C2orf54	-0.39	-7.78	-0.34	4.71e-14	Urinary metabolites;
LGG	cis	rs35160687	0.644	rs10204589	chr2:86493223	A/G	cg10973622	chr2:86423274	IMMT	0.4	7.16	0.32	3.28e-12	Night sleep phenotypes;
LGG	cis	rs7674212	0.570	rs1031804	chr4:104066049	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-7.34	-0.32	9.42e-13	Type 2 diabetes;
LGG	cis	rs870825	0.616	rs7692367	chr4:185651056	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9715521	0.900	rs6551646	chr4:59824827	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.38	-0.32	7.15e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7326068	0.595	rs2785741	chr13:21421240	C/T	cg04906043	chr13:21280425	IL17D	-0.5	-7.67	-0.34	1.03e-13	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs11252926	0.574	rs7068976	chr10:453112	A/G	cg00953403	chr17:74099816	EXOC7	0.41	6.7	0.3	6.05e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg22907277	chr7:1156413	C7orf50	0.84	15.04	0.57	6.22e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs774359	0.744	rs12115670	chr9:27486172	C/G	cg14173147	chr9:27528300	MOBKL2B	0.47	8.65	0.37	8.3e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg00647317	chr7:50633725	DDC	-0.34	-7.64	-0.33	1.27e-13	Malaria;
LGG	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.23	-0.43	2.66e-22	Total body bone mineral density;
LGG	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	17.16	0.62	1.89e-51	Response to antipsychotic treatment;
LGG	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.57	0.33	2.1e-13	Birth weight;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.53	-10.08	-0.42	1.01e-21	Prudent dietary pattern;
LGG	cis	rs73001065	0.818	rs73004975	chr19:19727152	A/G	cg03709012	chr19:19516395	GATAD2A	0.73	6.75	0.3	4.5e-11	LDL cholesterol;
LGG	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg02002194	chr4:3960332	NA	-0.44	-8.16	-0.35	3.09e-15	Retinal vascular caliber;
LGG	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.13	0.35	3.95e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3857536	0.813	rs6904511	chr6:66939102	A/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg03477792	chr4:77819574	ANKRD56	0.53	9.3	0.4	5.6e-19	Emphysema distribution in smoking;
LGG	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	5.9e-15	Neuroticism;
LGG	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg21775007	chr8:11205619	TDH	0.82	14.64	0.56	3.7e-40	Retinal vascular caliber;
LGG	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.45	-0.44	4.49e-23	Total body bone mineral density;
LGG	cis	rs17209837	1.000	rs58083477	chr7:87117706	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.0	-0.49	4.53e-29	Gallbladder cancer;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg09699651	chr6:150184138	LRP11	0.55	10.58	0.44	1.39e-23	Testicular germ cell tumor;
LGG	cis	rs524281	0.814	rs10896093	chr11:65958411	C/G	cg16950941	chr11:66035639	RAB1B	-0.46	-6.73	-0.3	4.91e-11	Electroencephalogram traits;
LGG	cis	rs9443189	0.737	rs2842553	chr6:76456632	A/T	cg01950844	chr6:76311363	SENP6	-0.56	-7.31	-0.32	1.14e-12	Prostate cancer;
LGG	cis	rs377457	0.857	rs11644122	chr16:85740750	C/T	cg08768472	chr16:85689701	KIAA0182	0.45	8.2	0.36	2.32e-15	Type 2 diabetes;
LGG	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg26769984	chr7:1090371	C7orf50	0.46	8.26	0.36	1.53e-15	Bronchopulmonary dysplasia;
LGG	cis	rs78487399	0.808	rs13419380	chr2:43739184	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-13.81	-0.54	1.49e-36	Morning vs. evening chronotype;
LGG	trans	rs6787172	0.702	rs827092	chr3:157985182	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.75	0.38	3.92e-17	Subjective well-being;
LGG	cis	rs4740619	0.803	rs2382554	chr9:15897372	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.97	-0.42	2.51e-21	Body mass index;
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs2718058	0.501	rs2717938	chr7:37702545	C/T	cg15028436	chr7:37888078	TXNDC3	-0.44	-7.55	-0.33	2.29e-13	Alzheimer's disease (late onset);
LGG	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14159747	chr11:113255604	NA	0.32	8.59	0.37	1.35e-16	Neuroticism;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.72	10.0	0.42	1.84e-21	Lung function (FEV1/FVC);
LGG	cis	rs9964724	0.559	rs17570353	chr18:35154734	C/T	cg27332583	chr18:35150602	NA	0.59	11.28	0.46	3.04e-26	Educational attainment (years of education);
LGG	cis	rs7582720	1.000	rs72932574	chr2:203866336	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs701145	0.550	rs450115	chr3:153923418	A/C	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	cg15522984	chr1:182991683	LAMC1	0.46	9.14	0.39	1.98e-18	Hypertriglyceridemia;
LGG	cis	rs854037	0.759	rs10487616	chr5:57105894	A/G	cg08523694	chr5:57076192	NA	0.6	7.28	0.32	1.45e-12	Birth weight;
LGG	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg09264619	chr17:80180166	NA	-0.52	-10.2	-0.43	3.73e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.23	-0.43	2.85e-22	Morning vs. evening chronotype;
LGG	cis	rs4804815	0.780	rs62125168	chr19:7840521	T/G	cg00970558	chr19:7854469	CLEC4GP1	0.65	9.81	0.41	9.18e-21	Neutrophil count;
LGG	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg15522984	chr1:182991683	LAMC1	0.45	8.83	0.38	2.25e-17	Fuchs's corneal dystrophy;
LGG	cis	rs209489	0.892	rs2294858	chr6:53159399	T/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2371030	1.000	rs2371030	chr2:211569722	A/G	cg18417063	chr2:211583084	NA	0.64	12.09	0.49	1.94e-29	Non-small cell lung cancer;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.03	0.46	2.92e-25	Personality dimensions;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg02002194	chr4:3960332	NA	0.43	7.92	0.35	1.8e-14	Neuroticism;
LGG	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg00339695	chr16:24857497	SLC5A11	0.34	6.68	0.3	6.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04772025	chr11:68637568	NA	0.73	12.72	0.51	5.24e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg04503457	chr17:41445688	NA	-0.39	-8.83	-0.38	2.12e-17	Menopause (age at onset);
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg13009111	chr11:71350975	NA	-0.31	-6.82	-0.3	2.9100000000000002e-11	Neuroticism;
LGG	cis	rs11700980	0.551	rs2832012	chr21:30110932	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.67	-0.3	7.13e-11	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	7.69e-17	Lung cancer;
LGG	cis	rs7617773	0.780	rs13082859	chr3:48344675	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg03254818	chr6:169586852	NA	0.53	8.23	0.36	1.93e-15	Pulse pressure;
LGG	cis	rs12497850	0.897	rs6446252	chr3:48911125	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.84	0.45	1.55e-24	Parkinson's disease;
LGG	cis	rs9462027	0.628	rs10947531	chr6:34765118	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.54	11.27	0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.85	0.48	1.81e-28	Lewy body disease;
LGG	cis	rs9790314	0.613	rs55956394	chr3:160590693	C/T	cg04691961	chr3:161091175	C3orf57	0.43	9.02	0.39	5.2e-18	Morning vs. evening chronotype;
LGG	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg21466736	chr12:48725269	NA	-0.36	-7.33	-0.32	1.06e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg00745463	chr17:30367425	LRRC37B	0.58	7.23	0.32	2.04e-12	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.06	0.42	1.15e-21	Tonsillectomy;
LGG	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg18200150	chr17:30822561	MYO1D	0.76	16.87	0.62	4.03e-50	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08377800	chr16:31885014	ZNF267	0.38	6.8	0.3	3.28e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.24	0.36	1.78e-15	Rheumatoid arthritis;
LGG	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg26656751	chr17:43910226	CRHR1	-0.33	-6.77	-0.3	3.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8028182	0.636	rs28737338	chr15:75768679	C/T	cg20655648	chr15:75932815	IMP3	0.47	7.83	0.34	3.36e-14	Sudden cardiac arrest;
LGG	cis	rs907612	0.638	rs907613	chr11:1874292	G/A	cg05305434	chr11:1874049	LSP1	0.4	10.39	0.43	7.31e-23	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LGG	trans	rs2048656	0.524	rs12543959	chr8:9539000	G/A	cg16141378	chr3:129829833	LOC729375	0.33	6.98	0.31	1.04e-11	Schizophrenia;
LGG	cis	rs7394190	0.748	rs11541237	chr10:75530962	C/T	cg07699608	chr10:75541558	CHCHD1	0.55	7.33	0.32	1.03e-12	Incident atrial fibrillation;
LGG	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg15736062	chr7:158136485	PTPRN2	-0.41	-7.93	-0.35	1.68e-14	Calcium levels;
LGG	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.63	-10.37	-0.43	8.24e-23	Iron status biomarkers;
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg19635926	chr16:89946313	TCF25	0.72	7.14	0.31	3.63e-12	Skin colour saturation;
LGG	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg08807101	chr21:30365312	RNF160	-0.84	-17.05	-0.62	5.85e-51	Dental caries;
LGG	cis	rs11718455	0.961	rs3846068	chr3:44029835	G/A	cg21419209	chr3:44054225	NA	-0.43	-7.12	-0.31	4.17e-12	Coronary artery disease;
LGG	cis	rs7940866	0.745	rs1368853	chr11:130866084	A/G	cg12179176	chr11:130786555	SNX19	0.74	13.64	0.54	7.64e-36	Schizophrenia;
LGG	cis	rs11650494	1.000	rs11650494	chr17:47345186	G/A	cg08112188	chr17:47440006	ZNF652	1.14	13.88	0.54	6.85e-37	Prostate cancer;
LGG	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg06766960	chr11:133703094	NA	-0.58	-11.58	-0.47	2.04e-27	Childhood ear infection;
LGG	cis	rs1035144	0.505	rs6574617	chr14:81457615	G/A	cg06600135	chr14:81408086	NA	-0.48	-9.36	-0.4	3.48e-19	Male sexual orientation;
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.56	-0.33	2.13e-13	Height;
LGG	cis	rs10931896	0.531	rs295117	chr2:201146828	C/T	cg23649088	chr2:200775458	C2orf69	0.45	7.99	0.35	1.06e-14	Systolic blood pressure;
LGG	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17219203	chr10:38645113	HSD17B7P2	0.44	7.14	0.32	3.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg17054900	chr3:154042577	DHX36	0.51	7.72	0.34	7.2e-14	Coronary artery disease;
LGG	cis	rs17818399	0.962	rs2122715	chr2:46845849	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-9.58	-0.41	5.94e-20	Height;
LGG	cis	rs2067615	0.896	rs2589266	chr12:107255986	T/G	cg15890332	chr12:107067104	RFX4	0.28	7.59	0.33	1.78e-13	Heart rate;
LGG	cis	rs672059	0.812	rs61418038	chr1:183155717	C/A	cg07928641	chr1:182991847	LAMC1	0.35	7.05	0.31	6.38e-12	Hypertriglyceridemia;
LGG	cis	rs10979	0.965	rs9376758	chr6:143886878	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.29	-0.5	3.09e-30	Hypospadias;
LGG	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-9.12	-0.39	2.31e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs1580019	0.922	rs766658	chr7:32499391	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.8	14.94	0.57	1.89e-41	Cognitive ability;
LGG	trans	rs11134654	1.000	rs6871931	chr5:170255591	A/C	cg20034712	chr19:52675470	ZNF836	-0.47	-7.74	-0.34	6.39e-14	Smooth-surface caries;
LGG	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg16096631	chr1:42092165	HIVEP3	-0.42	-8.83	-0.38	2.22e-17	Airway imaging phenotypes;
LGG	cis	rs2249694	0.520	rs7077457	chr10:135324370	G/T	cg20169779	chr10:135381914	SYCE1	-0.55	-7.65	-0.33	1.19e-13	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg25214090	chr10:38739885	LOC399744	0.56	10.38	0.43	7.62e-23	Corneal astigmatism;
LGG	trans	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg07211511	chr3:129823064	LOC729375	-1.36	-21.15	-0.7	5.7e-70	Blood pressure (smoking interaction);
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.05	-0.31	6.64e-12	Height;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg09038676	chr11:67351608	GSTP1	-0.36	-7.24	-0.32	1.93e-12	Mean corpuscular volume;
LGG	cis	rs638893	0.578	rs5006102	chr11:118662340	A/T	cg13782932	chr11:118662891	DDX6	0.38	6.93	0.31	1.41e-11	Vitiligo;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.59	-0.33	1.78e-13	Menopause (age at onset);
LGG	cis	rs864537	0.618	rs1214595	chr1:167427557	G/A	cg09179987	chr1:167433047	CD247	0.44	9.82	0.42	8.37e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg20503657	chr10:835505	NA	0.65	9.57	0.41	6.51e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg21827317	chr3:136751795	NA	0.53	9.82	0.42	8.37e-21	Neuroticism;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg01879757	chr17:41196368	BRCA1	0.39	7.95	0.35	1.45e-14	Menopause (age at onset);
LGG	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg00495681	chr13:53174319	NA	-0.42	-7.03	-0.31	7.25e-12	Lewy body disease;
LGG	cis	rs2439831	0.717	rs690170	chr15:43810422	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	8.66	0.37	8.12e-17	Lung cancer in ever smokers;
LGG	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.25e-13	Refractive error;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.46	-0.4	1.5e-19	Life satisfaction;
LGG	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg00919237	chr7:87102261	ABCB4	-0.79	-16.12	-0.6	9.77e-47	Gallbladder cancer;
LGG	cis	rs9527	0.637	rs12219247	chr10:104613361	A/G	cg04362960	chr10:104952993	NT5C2	0.52	9.39	0.4	2.68e-19	Arsenic metabolism;
LGG	cis	rs898097	0.805	rs60233158	chr17:80896612	A/G	cg20578329	chr17:80767326	TBCD	0.44	7.61	0.33	1.56e-13	Breast cancer;
LGG	cis	rs1059312	0.778	rs4760594	chr12:129296865	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-20.58	-0.69	2.6e-67	Systemic lupus erythematosus;
LGG	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg14673194	chr17:80132900	CCDC57	0.47	8.52	0.37	2.29e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9682041	0.561	rs6790483	chr3:170154406	G/A	cg11886554	chr3:170076028	SKIL	0.99	10.68	0.44	6.07e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.6	-0.33	1.61e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs28588043	1.000	rs28588043	chr1:170966012	C/T	cg03458344	chr1:170964477	C1orf129	0.5	7.27	0.32	1.57e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg11586189	chr1:201857591	SHISA4	-0.36	-8.0	-0.35	9.81e-15	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs9359856	0.564	rs1036853	chr6:90499502	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.08	-0.42	9.84e-22	Bipolar disorder;
LGG	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.61	0.53	9.84e-36	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.5	2.13e-30	Lymphocyte counts;
LGG	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg13010199	chr12:38710504	ALG10B	0.7	14.46	0.56	2.33e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs9916302	0.851	rs11078907	chr17:37662954	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.67	-0.3	7.26e-11	Resting heart rate;
LGG	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg06618935	chr21:46677482	NA	-0.43	-8.33	-0.36	9.48e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg06637938	chr14:75390232	RPS6KL1	0.53	9.87	0.42	5.38e-21	Coronary artery disease;
LGG	cis	rs11105298	0.891	rs11105318	chr12:89926658	C/T	cg00757033	chr12:89920650	WDR51B	0.59	8.45	0.37	3.84e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.79	0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.71	-13.04	-0.52	2.48e-33	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg05313129	chr8:58192883	C8orf71	-0.61	-8.55	-0.37	1.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.01	-0.31	8.26e-12	Renal cell carcinoma;
LGG	cis	rs1665650	0.830	rs7922859	chr10:118485415	T/C	cg14919929	chr10:118506882	NA	-0.49	-8.35	-0.36	8.09e-16	Colorectal cancer;
LGG	cis	rs7107174	0.711	rs66583694	chr11:78037773	C/T	cg02023728	chr11:77925099	USP35	0.47	8.37	0.36	7.07e-16	Testicular germ cell tumor;
LGG	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg22643751	chr7:855365	UNC84A	0.37	6.97	0.31	1.08e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg00204512	chr16:28754710	NA	0.25	7.02	0.31	7.85e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg19524238	chr7:2802976	GNA12	0.41	9.26	0.4	7.73e-19	Height;
LGG	cis	rs17767392	0.834	rs61991190	chr14:71737278	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.6	-0.37	1.28e-16	Mitral valve prolapse;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.9	0.38	1.24e-17	Lung cancer;
LGG	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.73	0.56	1.46e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.4	0.33	6.35e-13	Lung cancer;
LGG	cis	rs2798269	0.604	rs2798277	chr13:22155781	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.39	-0.32	6.74e-13	PR segment;
LGG	cis	rs9807841	0.643	rs4435370	chr19:10774623	G/A	cg17710535	chr19:10819994	QTRT1	0.44	6.84	0.3	2.57e-11	Inflammatory skin disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg24929613	chr19:37064166	ZNF529	-0.33	-7.15	-0.32	3.45e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.6	-0.41	4.96e-20	Lewy body disease;
LGG	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.31	-0.32	1.18e-12	Blood metabolite levels;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg08621203	chr6:150244597	RAET1G	0.49	8.91	0.38	1.2e-17	Testicular germ cell tumor;
LGG	cis	rs67311347	1.000	rs7636719	chr3:40432084	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.53	-0.69	4.45e-67	Renal cell carcinoma;
LGG	cis	rs3789045	1.000	rs3789045	chr1:204586812	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.62	-0.37	1.03e-16	Educational attainment (college completion);
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg19006130	chr11:118478252	PHLDB1	0.41	7.2	0.32	2.38e-12	Systemic lupus erythematosus;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg20574550	chr3:125876169	ALDH1L1	0.38	7.06	0.31	6.15e-12	Menarche (age at onset);
LGG	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg25482853	chr8:67687455	SGK3	0.94	12.14	0.49	1.24e-29	Obesity-related traits;
LGG	cis	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg21775007	chr8:11205619	TDH	0.54	8.82	0.38	2.27e-17	Retinal vascular caliber;
LGG	cis	rs6901004	0.712	rs367734	chr6:111512378	C/G	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.74	-0.34	6.1e-14	Blood metabolite levels;
LGG	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg04234412	chr22:24373322	LOC391322	-0.65	-11.78	-0.48	3.31e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7113874	0.524	rs4244804	chr11:8617550	C/T	cg23764900	chr11:8616102	STK33	0.39	6.75	0.3	4.3e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-7.35	-0.32	8.86e-13	Lung cancer in ever smokers;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg00800038	chr16:89945340	TCF25	-0.68	-7.71	-0.34	7.73e-14	Skin colour saturation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23752198	chr20:30311963	BCL2L1	0.41	6.8	0.3	3.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.64	0.33	1.28e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg03351412	chr1:154909251	PMVK	0.65	12.63	0.51	1.31e-31	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07341129	chr10:126685689	CTBP2	0.4	7.0	0.31	9.32e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2587949	0.638	rs2587912	chr3:4195565	C/T	cg16519197	chr3:4211558	NA	-0.34	-7.09	-0.31	4.95e-12	Periodontitis (DPAL);
LGG	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg11161011	chr14:65562177	MAX	-0.55	-10.39	-0.43	7.17e-23	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg26384229	chr12:38710491	ALG10B	-0.59	-10.28	-0.43	1.88e-22	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7928758	0.767	rs1866769	chr11:134274676	C/T	cg22777979	chr11:134283252	B3GAT1	-0.54	-8.3	-0.36	1.18e-15	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.91	-0.45	7.83e-25	Body mass index;
LGG	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg14101638	chr12:121416612	HNF1A	-0.39	-7.92	-0.35	1.73e-14	N-glycan levels;
LGG	cis	rs597583	0.806	rs2276339	chr11:117395481	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.36	-0.36	7.64e-16	Putamen volume;
LGG	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.55	14.53	0.56	1.1e-39	Oropharynx cancer;
LGG	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-9.48	-0.4	1.38e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.32	-0.58	3.84e-43	Chronic sinus infection;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04911050	chr16:677664	RAB40C	0.34	6.75	0.3	4.46e-11	Height;
LGG	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg02487422	chr3:49467188	NICN1	0.41	6.77	0.3	3.85e-11	Resting heart rate;
LGG	cis	rs10463316	0.817	rs13359941	chr5:150802118	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.2	-0.43	3.54e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.18	-0.32	2.77e-12	Iron status biomarkers;
LGG	cis	rs773506	0.628	rs4743820	chr9:93928416	C/T	cg14446406	chr9:93919335	NA	0.64	11.29	0.46	2.74e-26	Type 2 diabetes nephropathy;
LGG	trans	rs28595532	0.720	rs72670222	chr4:119300095	A/T	cg26518628	chr1:97050305	NA	-0.81	-7.07	-0.31	5.64e-12	Cannabis dependence symptom count;
LGG	cis	rs875971	0.545	rs67775320	chr7:65658779	T/C	cg11764359	chr7:65958608	NA	0.64	9.8	0.41	9.68e-21	Aortic root size;
LGG	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg23649088	chr2:200775458	C2orf69	0.4	7.0	0.31	9.2e-12	QT interval;
LGG	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.47	-0.5	5.52e-31	Morning vs. evening chronotype;
LGG	cis	rs6545977	0.531	rs2539981	chr2:63104904	T/C	cg17519650	chr2:63277830	OTX1	0.64	12.29	0.5	3.18e-30	Prostate cancer;
LGG	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg14456004	chr13:21872349	NA	-1.22	-19.62	-0.67	8.44e-63	White matter hyperintensity burden;
LGG	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg11161011	chr14:65562177	MAX	-0.71	-13.3	-0.53	2.02e-34	Obesity-related traits;
LGG	cis	rs6546324	0.625	rs4533457	chr2:67787348	T/G	cg18237512	chr2:67827392	NA	-0.38	-6.7	-0.3	6.25e-11	Endometriosis;
LGG	cis	rs883565	0.528	rs4504116	chr3:38953768	A/G	cg01426195	chr3:39028469	NA	0.59	12.61	0.51	1.57e-31	Handedness;
LGG	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg25338242	chr13:114786047	RASA3	0.48	8.11	0.35	4.7e-15	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs887829	0.569	rs4663967	chr2:234653184	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.65	-0.37	8.43e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg24375607	chr4:120327624	NA	0.68	11.14	0.46	1.07e-25	Corneal astigmatism;
LGG	cis	rs8038465	0.622	rs2509	chr15:73859488	A/T	cg15420318	chr15:73925796	NPTN	-0.49	-8.31	-0.36	1.1e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs258892	0.895	rs9293450	chr5:72068476	G/A	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg24687543	chr11:63912206	MACROD1	0.59	8.36	0.36	7.61e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7939886	0.920	rs59300271	chr11:55961792	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.78	0.34	4.68e-14	Myopia (pathological);
LGG	cis	rs1015291	0.635	rs2694978	chr12:20009962	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.29	-0.32	1.33e-12	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15806518	chr9:127177817	PSMB7	-0.46	-6.67	-0.3	7.53e-11	Systemic lupus erythematosus;
LGG	cis	rs727505	0.754	rs56056794	chr7:124783027	C/T	cg23710748	chr7:124431027	NA	-0.44	-8.59	-0.37	1.31e-16	Lewy body disease;
LGG	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs4725982	0.506	rs36090824	chr7:150572048	G/A	cg08530064	chr7:150598393	NA	0.29	6.9	0.31	1.76e-11	Electrocardiographic traits;QT interval;
LGG	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg26597838	chr10:835615	NA	0.64	9.54	0.41	8.19e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg00938859	chr5:1591904	SDHAP3	0.91	13.45	0.53	4.67e-35	Breast cancer;
LGG	cis	rs6460942	0.915	rs7802454	chr7:12454508	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-7.04	-0.31	6.98e-12	Coronary artery disease;
LGG	cis	rs7226408	0.857	rs72887034	chr18:34474187	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs943466	1.000	rs6933568	chr6:33751261	G/A	cg07519485	chr6:33762594	MLN	0.57	11.61	0.47	1.53e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.46	0.53	4.41e-35	Morning vs. evening chronotype;
LGG	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs4237845	0.844	rs4630335	chr12:58302258	A/G	cg02175503	chr12:58329896	NA	0.64	11.38	0.47	1.22e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6496667	0.533	rs2601206	chr15:90962699	C/T	cg22089800	chr15:90895588	ZNF774	0.51	8.2	0.36	2.43e-15	Rheumatoid arthritis;
LGG	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Schizophrenia;
LGG	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg00334542	chr7:100209784	MOSPD3	-0.54	-7.36	-0.32	8.33e-13	Other erythrocyte phenotypes;
LGG	cis	rs9358372	0.574	rs9356755	chr6:20829772	C/A	cg13405222	chr6:20811065	CDKAL1	-0.45	-9.14	-0.39	2.03e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25072359	chr17:41440525	NA	0.52	9.91	0.42	4.17e-21	Menopause (age at onset);
LGG	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg25817165	chr18:72167213	CNDP2	-0.45	-10.06	-0.42	1.12e-21	Refractive error;
LGG	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.75	0.64	3.83e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.57	0.53	1.48e-35	Anterior chamber depth;
LGG	cis	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg08112188	chr17:47440006	ZNF652	1.33	15.68	0.59	9.63e-45	Prostate cancer;
LGG	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg16576597	chr16:28551801	NUPR1	0.32	7.12	0.31	4.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.52	0.4	9.34e-20	Life satisfaction;
LGG	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs35160687	0.644	rs36079379	chr2:86545960	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.83	0.3	2.64e-11	Night sleep phenotypes;
LGG	trans	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg06521331	chr12:34319734	NA	0.44	7.75	0.34	5.8e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7737355	0.947	rs40400	chr5:130831365	C/T	cg06307176	chr5:131281290	NA	-0.54	-8.97	-0.38	7.43e-18	Life satisfaction;
LGG	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg05696931	chr1:227175867	NA	-0.4	-7.79	-0.34	4.44e-14	Myeloid white cell count;
LGG	cis	rs4845570	0.850	rs4504897	chr1:151766851	T/A	cg07092448	chr1:151763213	TDRKH	1.16	24.64	0.75	3.01e-86	Coronary artery disease;
LGG	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg24110177	chr3:50126178	RBM5	-0.59	-10.76	-0.45	3.07e-24	Intelligence (multi-trait analysis);
LGG	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	5.83e-34	Resting heart rate;
LGG	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.61	0.33	1.59e-13	Renal function-related traits (BUN);
LGG	cis	rs2066819	1.000	rs80317430	chr12:56727705	G/A	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	trans	rs1997103	1.000	rs4947500	chr7:55407270	C/A	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg21775007	chr8:11205619	TDH	-0.57	-9.39	-0.4	2.82e-19	Retinal vascular caliber;
LGG	trans	rs5770872	0.511	rs56168974	chr22:50831338	A/G	cg09860653	chr1:19970708	NBL1	-0.45	-7.31	-0.32	1.19e-12	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg05368731	chr17:41323189	NBR1	0.93	18.38	0.65	4.86e-57	Menopause (age at onset);
LGG	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg04833646	chr19:10679720	CDKN2D	1.1	17.8	0.64	2.32e-54	Red cell distribution width;
LGG	cis	rs10463316	0.963	rs10463315	chr5:150745615	T/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.17	-0.43	4.69e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg14541582	chr5:601475	NA	-0.68	-10.87	-0.45	1.16e-24	Obesity-related traits;
LGG	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg17376030	chr22:41985996	PMM1	0.55	8.93	0.38	1.04e-17	Vitiligo;
LGG	cis	rs10267417	0.603	rs9654951	chr7:19945169	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.86	-0.42	5.99e-21	Aortic root size;
LGG	cis	rs6546324	0.592	rs2861648	chr2:67803908	C/T	cg18237512	chr2:67827392	NA	-0.41	-7.39	-0.32	6.72e-13	Endometriosis;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.42	0.4	2.12e-19	Schizophrenia;
LGG	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg23815491	chr16:72088622	HP	0.49	11.12	0.46	1.23e-25	Fibrinogen levels;
LGG	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs472402	0.623	rs8192131	chr5:6636465	C/T	cg08700190	chr5:6636046	SRD5A1	-0.35	-7.58	-0.33	1.93e-13	Response to amphetamines;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs77972916	0.536	rs7562101	chr2:43592756	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.54	-8.0	-0.35	9.74e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs7166081	1.000	rs12443472	chr15:67555958	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.65	-0.3	8.45e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs778371	0.671	rs13008436	chr2:233719948	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-10.8	-0.45	2.04e-24	Schizophrenia;
LGG	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg00666640	chr1:248458726	OR2T12	0.62	10.0	0.42	1.85e-21	Common traits (Other);
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg14893161	chr1:205819251	PM20D1	1.01	27.34	0.79	1.11e-98	Menarche (age at onset);
LGG	cis	rs6909430	0.901	rs9401631	chr6:98575301	G/A	cg12860156	chr6:98744658	NA	-0.44	-7.45	-0.33	4.74e-13	Quantitative traits;
LGG	cis	rs6032067	0.586	rs13044116	chr20:43754444	T/C	cg10761708	chr20:43804764	PI3	0.69	10.15	0.43	5.44e-22	Blood protein levels;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg27532560	chr4:187881888	NA	-0.6	-13.18	-0.52	6.52e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.92	-0.31	1.48e-11	Lung cancer;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.16	0.43	5.12e-22	Motion sickness;
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.72	0.56	1.68e-40	Platelet count;
LGG	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg18225595	chr11:63971243	STIP1	0.47	6.79	0.3	3.38e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg12654349	chr5:56205094	C5orf35	-0.4	-7.19	-0.32	2.53e-12	Coronary artery disease;
LGG	cis	rs9419702	0.538	rs9419625	chr10:133534954	T/G	cg04492858	chr10:133558786	NA	0.4	7.86	0.34	2.77e-14	Survival in rectal cancer;
LGG	cis	rs9308433	0.529	rs11800749	chr1:214499754	A/G	cg06198575	chr1:214491504	SMYD2	-0.5	-7.49	-0.33	3.45e-13	IgG glycosylation;
LGG	cis	rs2816316	1.000	rs1323298	chr1:192519865	T/C	cg02586212	chr1:192544902	RGS1	0.42	8.29	0.36	1.2e-15	Celiac disease;
LGG	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg02466173	chr16:30829666	NA	-0.61	-11.88	-0.48	1.37e-28	Dementia with Lewy bodies;
LGG	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg04000281	chr11:63949212	NA	-0.43	-8.28	-0.36	1.3e-15	Platelet count;
LGG	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg06453172	chr10:134556979	INPP5A	-0.49	-7.5	-0.33	3.27e-13	Migraine;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg10523679	chr1:76189770	ACADM	0.75	11.86	0.48	1.66e-28	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6964587	1.000	rs10225892	chr7:91671020	A/G	cg17063962	chr7:91808500	NA	0.49	8.65	0.37	8.85e-17	Breast cancer;
LGG	trans	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.9e-13	Menarche (age at onset);
LGG	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.9	0.31	1.69e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg16389209	chr10:63809121	ARID5B	0.42	8.21	0.36	2.28e-15	Systemic lupus erythematosus;
LGG	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg05887092	chr17:76393375	PGS1	0.79	18.28	0.65	1.33e-56	HDL cholesterol;
LGG	cis	rs10050311	0.698	rs17454154	chr4:87636160	A/G	cg11209507	chr4:87813803	C4orf36	0.51	6.72	0.3	5.41e-11	Insulin-related traits;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.71e-15	Life satisfaction;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.53	-0.53	2.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4788570	0.511	rs4788830	chr16:71732267	A/G	cg06353428	chr16:71660113	MARVELD3	1.28	20.38	0.69	2.25e-66	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	0.932	rs17333442	chr5:112947050	A/C	cg12552261	chr5:112820674	MCC	0.66	7.54	0.33	2.57e-13	F-cell distribution;
LGG	cis	rs72827839	0.649	rs80347400	chr17:46012502	A/G	cg02219949	chr17:45927392	SP6	0.53	7.08	0.31	5.47e-12	Ease of getting up in the morning;
LGG	cis	rs1018836	0.608	rs6986165	chr8:91477062	C/G	cg16814680	chr8:91681699	NA	-0.59	-9.86	-0.42	6.27e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs528418	0.592	rs6900171	chr6:145714888	G/C	cg03642472	chr6:145670687	NA	0.56	7.29	0.32	1.36e-12	Methadone dose in opioid dependence;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg15971980	chr6:150254442	NA	0.45	8.4	0.36	5.34e-16	Lung cancer;
LGG	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg17376030	chr22:41985996	PMM1	-0.65	-10.58	-0.44	1.39e-23	Vitiligo;
LGG	cis	rs35146811	0.961	rs35991721	chr7:99728790	G/T	cg22906224	chr7:99728672	NA	0.62	10.08	0.42	9.85e-22	Coronary artery disease;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10791097	0.739	rs735094	chr11:130725109	G/C	cg12179176	chr11:130786555	SNX19	0.76	14.24	0.55	1.94e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1506403	0.945	rs371089	chr7:142821657	G/A	cg11323483	chr7:142828068	PIP	-0.39	-7.19	-0.32	2.7e-12	Cancer;
LGG	cis	rs7666738	0.830	rs28416660	chr4:98899525	C/G	cg05340658	chr4:99064831	C4orf37	0.47	7.76	0.34	5.32e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg09264619	chr17:80180166	NA	0.37	7.45	0.33	4.66e-13	Life satisfaction;
LGG	cis	rs7619833	0.620	rs9842044	chr3:27263248	G/C	cg02860705	chr3:27208620	NA	0.42	8.21	0.36	2.19e-15	Breast cancer;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.55	-0.37	1.83e-16	Obesity-related traits;
LGG	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg02820901	chr13:113351484	ATP11A	0.62	7.41	0.33	5.97e-13	Glycated hemoglobin levels;
LGG	cis	rs7572263	0.724	rs34082227	chr2:209055449	G/T	cg00164906	chr2:209055251	C2orf80	0.75	9.72	0.41	1.84e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.3	-0.4	5.71e-19	Monocyte percentage of white cells;
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg18252515	chr7:66147081	NA	-1.31	-18.92	-0.66	1.47e-59	Diabetic kidney disease;
LGG	cis	rs2797160	0.967	rs926854	chr6:126021780	A/G	cg05901451	chr6:126070800	HEY2	0.46	7.8	0.34	4.2e-14	Endometrial cancer;
LGG	cis	rs8053891	0.906	rs12149877	chr16:71996067	T/C	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.77	-0.3	3.98e-11	Coronary artery disease;
LGG	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg00666640	chr1:248458726	OR2T12	0.53	8.95	0.38	8.65e-18	Common traits (Other);
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg11494091	chr17:61959527	GH2	0.5	8.03	0.35	7.96e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg02023728	chr11:77925099	USP35	0.39	6.77	0.3	4.02e-11	Alzheimer's disease (survival time);
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.9	0.31	1.74e-11	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23542284	chr19:19314328	NR2C2AP	0.42	6.96	0.31	1.2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs4888262	0.526	rs4887776	chr16:74635632	A/G	cg01733217	chr16:74700730	RFWD3	0.89	18.21	0.65	2.89e-56	Testicular germ cell tumor;
LGG	cis	rs8180040	1.000	rs295458	chr3:47385585	C/A	cg27129171	chr3:47204927	SETD2	0.78	15.09	0.57	4.03e-42	Colorectal cancer;
LGG	cis	rs2652834	1.000	rs2652840	chr15:63393220	T/C	cg05507819	chr15:63340323	TPM1	0.56	7.28	0.32	1.47e-12	HDL cholesterol;
LGG	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg01579765	chr21:45077557	HSF2BP	0.34	7.65	0.33	1.18e-13	Mean corpuscular volume;
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg15556689	chr8:8085844	FLJ10661	0.41	7.25	0.32	1.73e-12	Neuroticism;
LGG	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14373873	chr11:113211441	TTC12	-0.45	-9.48	-0.4	1.33e-19	Neuroticism;
LGG	cis	rs6735179	0.565	rs73182754	chr2:1747733	A/C	cg20570797	chr2:1712800	PXDN	-0.46	-7.99	-0.35	1.1e-14	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg06606381	chr12:133084897	FBRSL1	1.2	11.26	0.46	3.72e-26	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12291225	0.535	rs11023203	chr11:14409815	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.03	-0.42	1.5e-21	Sense of smell;
LGG	trans	rs7615952	0.741	rs13314845	chr3:125644782	C/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04900565	chr14:33408948	NPAS3	0.61	6.93	0.31	1.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg27121462	chr16:89883253	FANCA	-0.6	-10.91	-0.45	8.06e-25	Vitiligo;
LGG	cis	rs11971779	0.680	rs10229358	chr7:139052545	C/T	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.01	-0.31	8.51e-12	Diisocyanate-induced asthma;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg10523679	chr1:76189770	ACADM	0.82	15.11	0.57	3.3e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.51	-0.4	1.07e-19	Mean corpuscular volume;
LGG	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.17	0.32	3.01e-12	Obesity-related traits;
LGG	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg21775007	chr8:11205619	TDH	0.81	14.17	0.55	3.89e-38	Retinal vascular caliber;
LGG	cis	rs1420338	0.933	rs12540602	chr7:34174056	G/A	cg01275685	chr7:34179230	BMPER	-0.53	-9.82	-0.42	8.35e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.9	-0.38	1.26e-17	Menopause (age at onset);
LGG	cis	rs4711350	0.723	rs623813	chr6:33703089	C/T	cg06471254	chr6:33690276	IP6K3	0.49	7.04	0.31	6.86e-12	Schizophrenia;
LGG	cis	rs4474465	0.831	rs7121299	chr11:78189133	G/T	cg27205649	chr11:78285834	NARS2	-0.49	-8.49	-0.37	2.79e-16	Alzheimer's disease (survival time);
LGG	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.58	-9.25	-0.39	8.35e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg18473234	chr19:5097819	KDM4B	-0.42	-7.37	-0.32	7.68e-13	Monocyte percentage of white cells;
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.09	-0.31	4.88e-12	Life satisfaction;
LGG	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg15556689	chr8:8085844	FLJ10661	0.44	8.07	0.35	6.27e-15	Neuroticism;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25495613	chr7:134895782	WDR91	-0.4	-6.89	-0.3	1.88e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.91	0.38	1.15e-17	Height;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg16920238	chr17:80076378	CCDC57	0.33	7.45	0.33	4.59e-13	Life satisfaction;
LGG	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7084402	0.967	rs1658446	chr10:60314183	A/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs785830	0.749	rs2479325	chr9:253282	C/G	cg14500300	chr9:211689	NA	-0.3	-7.68	-0.34	9.47e-14	Platelet distribution width;
LGG	cis	rs367615	0.704	rs4320313	chr5:108828687	A/G	cg17395555	chr5:108820864	NA	0.86	15.43	0.58	1.29e-43	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.65	-12.59	-0.5	1.9e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17039065	1.000	rs12502981	chr4:109392960	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg16512390	chr1:228756714	NA	0.61	8.37	0.36	6.71e-16	Chronic lymphocytic leukemia;
LGG	cis	rs367943	0.698	rs4538600	chr5:112963488	T/C	cg12552261	chr5:112820674	MCC	0.53	9.6	0.41	5.04e-20	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg13206674	chr6:150067644	NUP43	0.67	15.7	0.59	7.89e-45	Lung cancer;
LGG	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg17971929	chr21:40555470	PSMG1	0.82	14.73	0.56	1.5e-40	Cognitive function;
LGG	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg03929089	chr4:120376271	NA	-0.69	-9.53	-0.4	8.8e-20	Axial length;
LGG	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg02975922	chr3:195473998	MUC4	0.45	7.18	0.32	2.72e-12	Mean corpuscular volume;
LGG	cis	rs2832191	0.740	rs2853830	chr21:30416824	A/G	cg24692254	chr21:30365293	RNF160	1.04	28.85	0.8	1.64e-105	Dental caries;
LGG	cis	rs2865126	0.818	rs2178100	chr18:10765352	A/G	cg21165219	chr18:10698044	FAM38B	-0.46	-7.42	-0.33	5.62e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	28.06	0.79	6.13e-102	Height;
LGG	cis	rs9290877	0.667	rs9877870	chr3:188456755	A/C	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs9992101	0.645	rs2870229	chr4:77281077	G/A	cg17010112	chr4:77227123	STBD1	-0.47	-9.65	-0.41	3.4e-20	Creatinine levels;
LGG	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg03929089	chr4:120376271	NA	0.66	9.5	0.4	1.09e-19	Intraocular pressure;
LGG	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg24812749	chr6:127587940	RNF146	0.69	11.61	0.47	1.64e-27	Breast cancer;
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg18379455	chr17:41446167	NA	-0.33	-7.85	-0.34	2.86e-14	Menopause (age at onset);
LGG	cis	rs2274273	1.000	rs57970196	chr14:55600405	C/T	cg04306507	chr14:55594613	LGALS3	0.61	16.99	0.62	1.11e-50	Protein biomarker;
LGG	cis	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-11.01	-0.46	3.42e-25	Resting heart rate;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg20295408	chr7:1910781	MAD1L1	-0.4	-6.78	-0.3	3.62e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs755249	0.532	rs2296173	chr1:39913351	A/G	cg18385671	chr1:39797026	MACF1	0.45	7.64	0.33	1.24e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7246760	0.881	rs68018725	chr19:9855919	C/T	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.39e-11	Pursuit maintenance gain;
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg18446336	chr7:2847575	GNA12	-0.29	-7.38	-0.32	7.63e-13	Height;
LGG	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg07915516	chr16:377344	AXIN1	-0.35	-10.72	-0.45	4.13e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs975739	0.657	rs7324307	chr13:78603301	C/A	cg07847733	chr13:78271382	SLAIN1	0.46	8.08	0.35	5.61e-15	Hair color;
LGG	cis	rs7000551	0.725	rs1075534	chr8:22374074	A/G	cg12081754	chr8:22256438	SLC39A14	0.63	11.68	0.48	8.44e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg00599393	chr8:22457479	C8orf58	0.42	7.52	0.33	2.93e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3764563	1.000	rs3764563	chr19:15724203	A/G	cg20725493	chr19:15740067	CYP4F8	-0.62	-7.56	-0.33	2.24e-13	Inflammatory biomarkers;
LGG	cis	rs793571	0.568	rs6494029	chr15:58923206	T/C	cg05156742	chr15:59063176	FAM63B	0.6	10.6	0.44	1.15e-23	Schizophrenia;
LGG	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg11812906	chr14:75593930	NEK9	-0.41	-7.46	-0.33	4.27e-13	Coronary artery disease;
LGG	cis	rs972578	0.791	rs9607980	chr22:43317568	A/C	cg01576275	chr22:43409880	NA	-0.22	-6.72	-0.3	5.38e-11	Mean platelet volume;
LGG	cis	rs138665726	1	rs138665726	chr22:21917859	A/C	cg11654148	chr22:21984483	YDJC	-0.41	-7.83	-0.34	3.37e-14	Mean corpuscular volume;Red cell distribution width;
LGG	cis	rs854765	0.547	rs4925135	chr17:17952868	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs17373728	0.507	rs13248105	chr8:76166869	G/A	cg07016329	chr8:76221503	NA	0.47	8.63	0.37	1.01e-16	Diabetic kidney disease;
LGG	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg26384229	chr12:38710491	ALG10B	0.7	13.02	0.52	3.2e-33	Resting heart rate;
LGG	cis	rs8095374	0.935	rs11082513	chr18:43747153	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.42	-9.01	-0.39	5.4e-18	Clinical laboratory measurements;
LGG	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	9.57	0.41	6.65e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.58	9.09	0.39	2.9e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.63e-15	Common traits (Other);
LGG	cis	rs10849893	0.576	rs889970	chr12:121856217	G/A	cg01154721	chr12:121881891	KDM2B	-0.41	-7.12	-0.31	4.1e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg03264133	chr6:25882463	NA	-0.41	-7.14	-0.31	3.68e-12	Height;
LGG	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg00976097	chr5:421733	AHRR	-0.4	-6.66	-0.3	7.83e-11	Cystic fibrosis severity;
LGG	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.42	-0.58	1.3e-43	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.32	-0.53	1.62e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg26338869	chr17:61819248	STRADA	0.54	8.84	0.38	1.95e-17	Prudent dietary pattern;
LGG	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg18131467	chr2:239335373	ASB1	1.03	23.58	0.74	2.45e-81	Multiple system atrophy;
LGG	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg19812747	chr11:111475976	SIK2	0.48	9.43	0.4	1.91e-19	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg02725872	chr8:58115012	NA	-0.53	-8.55	-0.37	1.79e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.71	-0.41	2.1e-20	Coronary artery disease;
LGG	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg10253484	chr15:75165896	SCAMP2	-0.71	-11.12	-0.46	1.25e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25107608	chr1:154155675	TPM3	-0.43	-6.65	-0.3	8.15e-11	Pancreatic cancer;
LGG	cis	rs7523050	0.643	rs7551313	chr1:109399881	G/A	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg06558623	chr16:89946397	TCF25	0.92	12.02	0.49	3.76e-29	Skin colour saturation;
LGG	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg26677194	chr12:130822605	PIWIL1	-0.57	-10.19	-0.43	3.74e-22	Menopause (age at onset);
LGG	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.79	0.3	3.43e-11	Renal cell carcinoma;
LGG	cis	rs80282103	0.867	rs7075830	chr10:1091650	G/C	cg08668510	chr10:1095578	IDI1	0.79	8.15	0.35	3.38e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.67	-0.59	1.05e-44	Rheumatoid arthritis;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg18402987	chr7:1209562	NA	0.71	10.5	0.44	2.71e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1577917	0.771	rs9450319	chr6:86427325	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	14.55	0.56	9.57e-40	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-11.95	-0.49	6.86e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs4732038	0.510	rs2059329	chr7:134269080	G/C	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22618164	chr12:122356400	WDR66	0.38	10.91	0.45	7.92e-25	Mean corpuscular volume;
LGG	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg03605463	chr16:89740564	NA	-0.4	-6.82	-0.3	2.85e-11	Vitiligo;
LGG	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	7.99	0.35	1.1e-14	Bone mineral density;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.86	0.34	2.77e-14	Lung cancer;
LGG	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs7747724	0.702	rs4585542	chr6:20766103	C/T	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.98e-19	Bladder cancer;
LGG	cis	rs9399135	0.933	rs9389262	chr6:135376409	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.57e-19	Red blood cell count;
LGG	cis	rs7662987	0.517	rs2602880	chr4:100040653	C/T	cg13256891	chr4:100009986	ADH5	0.56	9.58	0.41	5.88e-20	Smoking initiation;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.06	0.35	6.72e-15	Retinal vascular caliber;
LGG	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.68	-0.37	6.6e-17	Restless legs syndrome;
LGG	cis	rs4363385	0.818	rs6661791	chr1:152994113	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.52e-17	Inflammatory skin disease;
LGG	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg10523679	chr1:76189770	ACADM	-0.73	-11.22	-0.46	5.44e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg10402321	chr1:26617780	UBXN11	-0.45	-7.47	-0.33	3.92e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg01420254	chr6:26195488	NA	0.87	10.72	0.45	4.4e-24	Gout;Renal underexcretion gout;
LGG	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg12373951	chr3:133503437	NA	0.39	6.89	0.31	1.81e-11	Iron status biomarkers;
LGG	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg13607699	chr17:42295918	UBTF	-0.9	-18.57	-0.65	5.89e-58	Total body bone mineral density;
LGG	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg14703610	chr5:56206110	C5orf35	0.46	7.97	0.35	1.27e-14	Coronary artery disease;
LGG	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.86e-12	Morning vs. evening chronotype;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04371818	chr17:77987371	TBC1D16	0.37	6.65	0.3	8.16e-11	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02334926	chr5:63802741	RGS7BP	0.52	8.39	0.36	5.9e-16	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2227564	0.729	rs2633304	chr10:75650650	T/C	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.86	-0.38	1.7e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.92	-0.45	7.5e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg08344181	chr3:125677491	NA	-0.58	-7.18	-0.32	2.77e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg15145296	chr3:125709740	NA	-0.6	-7.71	-0.34	7.82e-14	Blood pressure (smoking interaction);
LGG	cis	rs6669919	0.967	rs7513031	chr1:211671900	C/T	cg10512769	chr1:211675356	NA	0.7	15.52	0.58	4.99e-44	Intelligence (multi-trait analysis);
LGG	cis	rs7582720	1.000	rs72932553	chr2:203842661	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.94	0.57	1.71e-41	Cognitive test performance;
LGG	cis	rs7010267	0.870	rs7014574	chr8:119977077	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.39	10.12	0.43	6.71e-22	Total body bone mineral density (age 45-60);
LGG	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06470251	chr20:60548479	NA	0.39	6.78	0.3	3.75e-11	Body mass index;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.48	-0.4	1.29e-19	Myopia (pathological);
LGG	trans	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg18335740	chr13:41363409	SLC25A15	0.59	11.36	0.47	1.56e-26	Lewy body disease;
LGG	cis	rs7572733	0.534	rs696817	chr2:198722225	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg21782813	chr7:2030301	MAD1L1	0.44	10.51	0.44	2.65e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs250677	0.687	rs185155	chr5:148455893	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.38	-0.32	7.47e-13	Breast cancer;
LGG	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	trans	rs330048	0.545	rs7002693	chr8:9148830	G/C	cg15556689	chr8:8085844	FLJ10661	0.42	6.99	0.31	9.94e-12	Systemic lupus erythematosus;
LGG	cis	rs6539288	0.630	rs10778519	chr12:107357329	A/G	cg15890332	chr12:107067104	RFX4	0.29	7.56	0.33	2.23e-13	Total body bone mineral density;
LGG	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg14019146	chr3:50243930	SLC38A3	-0.52	-11.04	-0.46	2.67e-25	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.14	-0.31	3.54e-12	HDL cholesterol;
LGG	cis	rs6964587	1.000	rs9785013	chr7:91674302	G/A	cg17063962	chr7:91808500	NA	0.49	8.62	0.37	1.04e-16	Breast cancer;
LGG	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg04568710	chr12:38710424	ALG10B	0.38	8.03	0.35	7.99e-15	Bladder cancer;
LGG	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg17971929	chr21:40555470	PSMG1	-0.68	-12.68	-0.51	7.62e-32	Cognitive function;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg16270222	chr17:41446396	NA	-0.3	-7.19	-0.32	2.54e-12	Menopause (age at onset);
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg00599393	chr8:22457479	C8orf58	-0.47	-8.28	-0.36	1.33e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19748678	chr4:122722346	EXOSC9	-0.42	-7.34	-0.32	9.97e-13	Type 2 diabetes;
LGG	cis	rs9309473	1.000	rs62151652	chr2:73700131	A/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.78	-0.34	4.69e-14	Metabolite levels;
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg09307838	chr4:120376055	NA	0.66	11.2	0.46	6.11e-26	Corneal astigmatism;
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.21	-0.32	2.32e-12	Retinal vascular caliber;
LGG	cis	rs28655083	0.509	rs285020	chr16:77099517	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.88	0.3	2e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs740698	0.522	rs1024653	chr17:60791818	A/C	cg13195520	chr17:60813227	MARCH10	-0.56	-12.66	-0.51	9.19e-32	Pulse pressure;
LGG	cis	rs62238980	0.614	rs2413063	chr22:32458252	A/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2115630	0.967	rs12595786	chr15:85336670	T/C	cg12501888	chr15:85177176	SCAND2	-0.41	-6.71	-0.3	5.72e-11	P wave terminal force;
LGG	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg18850127	chr7:39170497	POU6F2	0.6	14.79	0.57	8.47e-41	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs17221829	0.965	rs7927936	chr11:89460495	C/G	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.51	-0.33	3.08e-13	Anxiety in major depressive disorder;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.98	0.35	1.15e-14	Bipolar disorder;
LGG	cis	rs713587	0.571	rs546217	chr2:25311537	A/C	cg04586622	chr2:25135609	ADCY3	-0.27	-6.94	-0.31	1.36e-11	Body mass index in non-asthmatics;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03517284	chr6:25882590	NA	-0.71	-13.51	-0.53	2.71e-35	Intelligence (multi-trait analysis);
LGG	cis	rs4788570	0.647	rs904764	chr16:71772795	G/A	cg06353428	chr16:71660113	MARVELD3	1.25	20.71	0.69	6.76e-68	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg02002194	chr4:3960332	NA	-0.52	-10.08	-0.42	9.5e-22	Triglycerides;
LGG	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.23	-0.36	1.96e-15	Neuroticism;
LGG	cis	rs295140	1.000	rs13005573	chr2:201164696	G/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg09904177	chr6:26538194	HMGN4	0.68	14.16	0.55	4.64e-38	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.19	0.36	2.61e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.12	-0.31	4.06e-12	Mean corpuscular hemoglobin;
LGG	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.09	-0.42	8.93e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs360798	0.532	rs11125942	chr2:62966758	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-7.14	-0.32	3.55e-12	Coronary artery disease;
LGG	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg03433033	chr1:76189801	ACADM	0.62	9.43	0.4	2.05e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8133932	0.667	rs3788218	chr21:47287332	A/G	cg13695288	chr21:47294981	PCBP3	-0.37	-7.43	-0.33	5.21e-13	Schizophrenia;
LGG	cis	rs7751419	0.651	rs10947780	chr6:39093663	T/C	cg08089693	chr6:39098871	NA	-0.44	-7.91	-0.35	1.85e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18252515	chr7:66147081	NA	0.44	7.47	0.33	3.97e-13	Aortic root size;
LGG	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg21475434	chr5:93447410	FAM172A	-0.71	-7.25	-0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg14675211	chr2:100938903	LONRF2	0.67	11.82	0.48	2.32e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg15971980	chr6:150254442	NA	0.46	8.61	0.37	1.11e-16	Lung cancer;
LGG	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg00666640	chr1:248458726	OR2T12	0.58	9.27	0.4	7e-19	Common traits (Other);
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg05692746	chr2:100937584	LONRF2	-0.65	-11.84	-0.48	1.89e-28	Intelligence (multi-trait analysis);
LGG	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.13	-0.35	3.89e-15	Neuroticism;
LGG	cis	rs2455799	0.613	rs3924773	chr3:15796853	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20266104	chr17:21116851	TMEM11	-0.43	-7.16	-0.32	3.23e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13108043	0.605	rs62306510	chr4:87962634	T/A	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs763121	0.853	rs4821812	chr22:39075235	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.7e-56	Menopause (age at onset);
LGG	cis	rs6500395	0.775	rs7185541	chr16:48664681	A/G	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs34891900	0.507	rs2008085	chr22:18204316	T/G	cg19898043	chr22:18121309	BCL2L13	0.56	9.17	0.39	1.5e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08677398	chr8:58056175	NA	0.59	9.21	0.39	1.1e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs7474896	0.515	rs594594	chr10:38307723	A/G	cg25427524	chr10:38739819	LOC399744	0.52	7.73	0.34	6.85e-14	Obesity (extreme);
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.46	7.1	0.31	4.75e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs73001065	0.636	rs28720066	chr19:19572220	G/T	cg03709012	chr19:19516395	GATAD2A	0.96	10.96	0.45	5.13e-25	LDL cholesterol;
LGG	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs283228	0.798	rs2518339	chr6:101767872	G/A	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.83e-41	Hair morphology;
LGG	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.08	0.35	5.67e-15	Retinal vascular caliber;
LGG	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg07382826	chr16:28625726	SULT1A1	0.39	8.4	0.36	5.52e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.54	-0.33	2.45e-13	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.84e-12	Prudent dietary pattern;
LGG	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.99	-0.49	4.85e-29	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16316507	chr7:144533041	TPK1	0.47	7.23	0.32	2.02e-12	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.83	-0.42	7.45e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.95	-0.31	1.26e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs11758351	0.500	rs74660303	chr6:26183710	C/T	cg03181300	chr6:26195995	NA	0.88	6.68	0.3	6.88e-11	Gout;Renal underexcretion gout;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.77	-0.34	5.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs651907	0.935	rs2926538	chr3:101587585	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.43	7.49	0.33	3.46e-13	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08280861	chr8:58055591	NA	-0.54	-6.88	-0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	0.868	rs8139952	chr22:38606989	C/A	cg03162506	chr22:38580953	NA	-0.36	-9.39	-0.4	2.81e-19	Cutaneous nevi;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg05941027	chr17:61774174	LIMD2	0.37	9.3	0.4	5.49e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg23484912	chr5:273055	PDCD6	0.45	9.06	0.39	3.68e-18	Pancreatic cancer;
LGG	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg03929089	chr4:120376271	NA	0.43	6.96	0.31	1.13e-11	HDL cholesterol;
LGG	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg13385794	chr1:248469461	NA	0.48	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.11	0.52	1.33e-33	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs765787	0.530	rs1706831	chr15:45516230	T/C	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs34330	0.562	rs17212236	chr12:12855483	G/C	cg09462578	chr12:12878428	APOLD1	-0.56	-7.67	-0.34	1.01e-13	Systemic lupus erythematosus;
LGG	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.91	0.35	1.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9397585	0.637	rs9479503	chr6:153403812	A/C	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs35740288	0.770	rs11635711	chr15:86126486	C/G	cg04173714	chr15:86211321	AKAP13	0.49	8.48	0.37	2.96e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.19	-0.39	1.31e-18	Coronary artery disease;
LGG	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg05163923	chr11:71159392	DHCR7	-0.63	-11.06	-0.46	2.16e-25	Vitamin D levels;
LGG	trans	rs61931739	0.649	rs12426686	chr12:33714473	A/G	cg26384229	chr12:38710491	ALG10B	-0.48	-8.61	-0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs738322	0.574	rs738323	chr22:38569527	C/T	cg03162506	chr22:38580953	NA	0.41	10.09	0.42	9.37e-22	Cutaneous nevi;
LGG	cis	rs4731207	0.671	rs12706626	chr7:124531370	G/A	cg05630886	chr7:124431682	NA	0.33	7.37	0.32	8.03e-13	Cutaneous malignant melanoma;
LGG	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg27426351	chr10:43362370	NA	0.59	8.34	0.36	8.64e-16	Blood protein levels;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg11062466	chr8:58055876	NA	-0.47	-7.72	-0.34	7.15e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs314370	0.951	rs12667888	chr7:100474289	T/C	cg10426581	chr7:100472382	SRRT	0.51	7.09	0.31	5.02e-12	Resting heart rate;
LGG	cis	rs4740619	0.530	rs10810524	chr9:16036646	C/T	cg14451791	chr9:16040625	NA	-0.44	-11.72	-0.48	5.73e-28	Body mass index;
LGG	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg01420254	chr6:26195488	NA	0.86	11.24	0.46	4.4e-26	Gout;Renal underexcretion gout;
LGG	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg22120825	chr2:201024476	NA	0.51	6.76	0.3	4.17e-11	Schizophrenia;
LGG	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-14.43	-0.56	3.07e-39	Morning vs. evening chronotype;
LGG	cis	rs7226408	0.842	rs1609425	chr18:34345684	A/G	cg15022739	chr18:34823045	BRUNOL4	0.46	6.87	0.3	2.05e-11	Obesity-related traits;
LGG	cis	rs35771425	0.529	rs12567304	chr1:211388281	C/G	cg10512769	chr1:211675356	NA	-0.68	-8.66	-0.37	8.14e-17	Educational attainment (years of education);
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.02	0.31	7.72e-12	Schizophrenia;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07157834	chr1:205819609	PM20D1	0.74	16.71	0.61	2.21e-49	Menarche (age at onset);
LGG	cis	rs9467773	1.000	rs9986382	chr6:26550619	T/C	cg09904177	chr6:26538194	HMGN4	0.76	17.04	0.62	7.05e-51	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg26513180	chr16:89883248	FANCA	1.02	9.6	0.41	4.88e-20	Skin colour saturation;
LGG	trans	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.59	0.33	1.73e-13	Retinal vascular caliber;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26188571	chr5:179050811	HNRNPH1	0.44	7.41	0.33	6.13e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	6.03e-16	Life satisfaction;
LGG	cis	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	7.34	0.32	9.54e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg16060761	chr17:80687452	NA	0.43	7.47	0.33	3.94e-13	Glycated hemoglobin levels;
LGG	cis	rs7020830	0.858	rs1492714	chr9:37141259	T/C	cg14294708	chr9:37120828	ZCCHC7	1.2	36.51	0.86	2.15e-138	Schizophrenia;
LGG	cis	rs8180040	0.726	rs4682844	chr3:46982737	T/C	cg16586182	chr3:47516702	SCAP	0.73	13.13	0.52	1.09e-33	Colorectal cancer;
LGG	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg25986240	chr4:9926439	SLC2A9	-0.35	-6.89	-0.3	1.87e-11	Bone mineral density;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg26354017	chr1:205819088	PM20D1	-0.41	-8.17	-0.35	2.97e-15	Prostate-specific antigen levels;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg04632378	chr13:21900426	NA	0.41	8.45	0.37	3.86e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs56283067	0.847	rs10948156	chr6:44689459	G/A	cg18551225	chr6:44695536	NA	-0.7	-12.3	-0.5	2.72e-30	Total body bone mineral density;
LGG	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.62	17.78	0.64	2.7e-54	Oropharynx cancer;
LGG	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg24503407	chr1:205819492	PM20D1	0.47	7.94	0.35	1.52e-14	Parkinson's disease;
LGG	cis	rs11920090	0.720	rs58284370	chr3:170738849	G/A	cg09710316	chr3:170744871	SLC2A2	0.65	8.24	0.36	1.81e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg03342759	chr3:160939853	NMD3	0.64	11.39	0.47	1.2e-26	Morning vs. evening chronotype;
LGG	cis	rs7216064	1.000	rs56393562	chr17:65933918	C/T	cg12091567	chr17:66097778	LOC651250	-0.61	-9.03	-0.39	4.63e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg26043149	chr18:55253948	FECH	0.43	7.25	0.32	1.82e-12	Bone mineral density;
LGG	cis	rs9900972	0.959	rs4789941	chr17:76877500	G/C	cg00961940	chr17:76876995	TIMP2	0.46	9.1	0.39	2.64e-18	Obesity-related traits;
LGG	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg11189052	chr15:85197271	WDR73	0.46	6.76	0.3	4.08e-11	Schizophrenia;
LGG	cis	rs737693	0.920	rs17368814	chr11:102748695	C/T	cg14995062	chr11:102826570	MMP13	-0.47	-6.81	-0.3	3.05e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg13512537	chr8:22265999	SLC39A14	-0.37	-6.68	-0.3	6.99e-11	Verbal declarative memory;
LGG	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.74	0.45	3.65e-24	Lung cancer in ever smokers;
LGG	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg01620082	chr3:125678407	NA	-0.65	-7.2	-0.32	2.39e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs774359	0.830	rs2453555	chr9:27563868	G/A	cg21249376	chr9:27528432	MOBKL2B	0.42	7.61	0.33	1.6e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs490234	0.756	rs10986849	chr9:128469683	A/G	cg14078157	chr9:128172775	NA	-0.45	-8.24	-0.36	1.82e-15	Mean arterial pressure;
LGG	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.54	0.67	1.99e-62	Smoking behavior;
LGG	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg14191688	chr11:70257035	CTTN	0.6	8.51	0.37	2.41e-16	Coronary artery disease;
LGG	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg03806693	chr22:41940476	POLR3H	0.94	16.81	0.62	7.58e-50	Vitiligo;
LGG	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg13010199	chr12:38710504	ALG10B	0.43	7.76	0.34	5.37e-14	Resting heart rate;
LGG	cis	rs926938	0.520	rs4140445	chr1:115291978	T/C	cg12756093	chr1:115239321	AMPD1	-0.55	-9.34	-0.4	3.98e-19	Autism;
LGG	cis	rs11758351	0.660	rs6918339	chr6:26211780	G/C	cg01420254	chr6:26195488	NA	0.55	8.14	0.35	3.68e-15	Gout;Renal underexcretion gout;
LGG	cis	rs10489202	0.657	rs3767479	chr1:168069840	C/A	cg24449463	chr1:168025552	DCAF6	-0.58	-10.27	-0.43	1.97e-22	Schizophrenia;
LGG	cis	rs11229555	0.645	rs11560908	chr11:58434545	A/C	cg15696309	chr11:58395628	NA	0.88	11.84	0.48	2.03e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.9e-12	Electroencephalogram traits;
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.15	0.35	3.53e-15	Bipolar disorder;
LGG	cis	rs6908034	0.607	rs112659166	chr6:19807409	C/T	cg02682789	chr6:19804855	NA	0.92	8.67	0.37	7.45e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6540556	0.768	rs4990735	chr1:209943592	C/T	cg05527609	chr1:210001259	C1orf107	-0.61	-7.4	-0.33	6.5e-13	Red blood cell count;
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22455342	chr2:225449267	CUL3	0.91	15.48	0.58	7.04e-44	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.44	0.36	4.25e-16	Prostate cancer;
LGG	cis	rs4732038	0.510	rs6967100	chr7:134262085	A/G	cg06906464	chr7:134288099	NA	-0.64	-17.77	-0.64	3.17e-54	Longevity;
LGG	cis	rs9309473	0.687	rs12465867	chr2:73612102	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-9.07	-0.39	3.35e-18	Metabolite levels;
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.56	-10.49	-0.44	2.99e-23	Total body bone mineral density;
LGG	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg04691961	chr3:161091175	C3orf57	0.42	8.87	0.38	1.54e-17	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.721	rs12049027	chr1:46118184	A/T	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs78545713	0.649	rs79308455	chr6:26224377	A/G	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs8077889	0.956	rs4792910	chr17:41840229	T/C	cg26893861	chr17:41843967	DUSP3	1.0	17.0	0.62	1.03e-50	Triglycerides;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg02352203	chr17:78518437	RPTOR	-0.39	-6.88	-0.3	1.99e-11	Alzheimer's disease (survival time);
LGG	cis	rs12476592	0.602	rs10469944	chr2:63816672	C/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg13293535	chr8:11597251	GATA4	-0.28	-6.78	-0.3	3.6e-11	Neuroticism;
LGG	cis	rs308971	0.656	rs2648347	chr3:12057200	T/G	cg02700894	chr3:12045449	SYN2	0.49	7.06	0.31	6.23e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs921968	0.643	rs833083	chr2:219336959	A/T	cg01130898	chr2:219473002	PLCD4	0.4	6.89	0.3	1.83e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9581857	0.685	rs9319371	chr13:28042564	A/G	cg01674679	chr13:27998804	GTF3A	-0.68	-7.92	-0.35	1.73e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.27	-0.46	3.45e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg21775007	chr8:11205619	TDH	0.83	14.62	0.56	4.6e-40	Retinal vascular caliber;
LGG	cis	rs1729951	0.575	rs747843	chr3:136703130	G/C	cg12473912	chr3:136751656	NA	0.44	7.67	0.34	1.01e-13	Neuroticism;
LGG	cis	rs477692	0.905	rs524545	chr10:131411840	A/C	cg05714579	chr10:131428358	MGMT	-0.65	-13.83	-0.54	1.14e-36	Response to temozolomide;
LGG	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg01620082	chr3:125678407	NA	-0.67	-7.33	-0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4689642	0.666	rs4689659	chr4:7228214	C/T	cg21353189	chr4:7228343	SORCS2	0.39	8.98	0.39	6.72e-18	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2952156	1.000	rs2088126	chr17:37879030	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-13.47	-0.53	4.15e-35	Asthma;
LGG	cis	rs9303401	0.703	rs9910629	chr17:57210301	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	8.81	0.38	2.51e-17	Cognitive test performance;
LGG	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.45	-0.33	4.71e-13	Schizophrenia;
LGG	trans	rs3206736	0.548	rs328908	chr7:35026008	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.23	0.32	1.99e-12	Diastolic blood pressure;
LGG	cis	rs6882076	1.000	rs7724832	chr5:156381370	C/T	cg12943317	chr5:156479607	HAVCR1	-0.7	-12.06	-0.49	2.49e-29	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg06026331	chr20:60912101	LAMA5	-0.47	-9.08	-0.39	3.18e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs12479254	0.537	rs6733504	chr2:242495953	A/G	cg24828208	chr2:242500484	BOK	-0.36	-9.24	-0.39	8.75e-19	Brain structure;
LGG	cis	rs992157	0.775	rs1877714	chr2:219134928	A/G	cg04731861	chr2:219085781	ARPC2	0.44	10.94	0.45	6.01e-25	Colorectal cancer;
LGG	cis	rs56283067	0.887	rs12215971	chr6:44784566	A/G	cg20913747	chr6:44695427	NA	-0.66	-10.9	-0.45	9.2e-25	Total body bone mineral density;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg09904177	chr6:26538194	HMGN4	-0.38	-6.76	-0.3	4.13e-11	Schizophrenia;
LGG	trans	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-7.7	-0.34	8.11e-14	Body mass index;
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.73	0.34	6.56e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03517284	chr6:25882590	NA	0.51	9.41	0.4	2.24e-19	Blood metabolite levels;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg06916706	chr16:4465613	CORO7	-0.95	-17.51	-0.63	5.03e-53	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07808509	chr6:52926847	ICK	0.48	7.04	0.31	6.91e-12	Gut microbiome composition (summer);
LGG	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg05585630	chr7:157510462	PTPRN2	-0.65	-13.7	-0.54	4.34e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg27490568	chr2:178487706	NA	0.87	15.32	0.58	3.92e-43	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.08	-0.42	9.9700000000000009e-22	Lung cancer;
LGG	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.87	-0.38	1.61e-17	Response to antipsychotic treatment;
LGG	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-7.67	-0.34	1.03e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.96	-0.31	1.2e-11	Triglycerides;
LGG	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.73	0.3	5.18e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.44	0.44	4.71e-23	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25172604	chr17:41446521	NA	-0.29	-6.66	-0.3	7.63e-11	Menopause (age at onset);
LGG	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg04058563	chr4:185651563	MLF1IP	0.52	11.09	0.46	1.71e-25	Kawasaki disease;
LGG	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg15208524	chr1:10270712	KIF1B	0.45	7.64	0.33	1.25e-13	Hepatocellular carcinoma;
LGG	cis	rs4812048	1.000	rs4812048	chr20:57587771	C/T	cg23907860	chr20:57583709	CTSZ	0.48	6.99	0.31	9.38e-12	Mean platelet volume;
LGG	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	12.27	0.5	3.73e-30	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg10160682	chr2:1713001	PXDN	-0.54	-9.75	-0.41	1.47e-20	Response to antipsychotic treatment;
LGG	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs8133932	0.701	rs9653791	chr21:47303328	G/A	cg11214348	chr21:47283868	PCBP3	0.45	8.07	0.35	6.16e-15	Schizophrenia;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.22e-18	Alzheimer's disease;
LGG	cis	rs12410462	0.551	rs2819513	chr1:227630987	G/A	cg04117972	chr1:227635322	NA	-0.38	-6.92	-0.31	1.53e-11	Major depressive disorder;
LGG	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.45	0.4	1.68e-19	Red blood cell count;
LGG	cis	rs8077059	0.513	rs9892194	chr17:55825825	C/T	cg12229367	chr17:55822335	NA	-0.37	-6.79	-0.3	3.43e-11	Sex hormone-binding globulin levels;
LGG	cis	rs727505	0.789	rs4731233	chr7:124736291	C/T	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.78	-0.66	6.36e-59	Monocyte count;
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.45	0.37	3.86e-16	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs17221829	0.965	rs10830365	chr11:89459065	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.77	-0.34	4.95e-14	Anxiety in major depressive disorder;
LGG	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.14e-14	HDL cholesterol;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13732083	chr21:47605072	C21orf56	0.52	8.68	0.37	6.63e-17	Testicular germ cell tumor;
LGG	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.02	-0.35	8.86e-15	Retinal vascular caliber;
LGG	cis	rs9640161	0.742	rs2159235	chr7:150017228	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.57	-0.59	2.83e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.76	0.54	2.39e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2239547	0.562	rs2581810	chr3:52960859	C/T	cg11645453	chr3:52864694	ITIH4	-0.65	-10.1	-0.42	8.54e-22	Schizophrenia;
LGG	cis	rs6743226	0.603	rs72484048	chr2:242227359	G/C	cg10021735	chr2:242295487	FARP2	0.4	7.01	0.31	8.47e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-7.97	-0.35	1.23e-14	Retinal vascular caliber;
LGG	cis	rs7937890	0.559	rs2575853	chr11:14533963	T/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.96	-0.35	1.36e-14	Mitochondrial DNA levels;
LGG	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg25019033	chr10:957182	NA	-0.53	-9.07	-0.39	3.44e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs11229555	0.574	rs11603800	chr11:58202085	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.04	-0.39	4.43e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.8	0.45	2.17e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg13385794	chr1:248469461	NA	0.49	8.24	0.36	1.77e-15	Common traits (Other);
LGG	cis	rs981844	0.796	rs17030437	chr4:154704225	A/C	cg14289246	chr4:154710475	SFRP2	-0.67	-11.55	-0.47	2.67e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.63	-0.41	3.91e-20	Lung cancer;
LGG	cis	rs1580019	0.961	rs1580022	chr7:32497712	C/A	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs1904096	0.513	rs2632405	chr4:95152215	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.95	-0.45	5.52e-25	Type 2 diabetes;
LGG	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg02297831	chr4:17616191	MED28	0.43	8.09	0.35	5.24e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg06766960	chr11:133703094	NA	-0.55	-10.81	-0.45	1.93e-24	Childhood ear infection;
LGG	cis	rs4740619	0.967	rs10962105	chr9:15642225	T/C	cg14451791	chr9:16040625	NA	-0.42	-10.8	-0.45	2.14e-24	Body mass index;
LGG	cis	rs7975161	0.638	rs7137288	chr12:104591886	C/A	cg25273343	chr12:104657179	TXNRD1	-0.6	-9.85	-0.42	6.78e-21	Toenail selenium levels;
LGG	cis	rs3748022	1.000	rs3748022	chr1:206669465	C/T	cg11166312	chr1:206654246	IKBKE	0.41	6.84	0.3	2.45e-11	Lymphocyte counts;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs526231	0.543	rs32849	chr5:102470043	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs2635047	0.638	rs2668760	chr18:44682891	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.86	0.34	2.67e-14	Educational attainment;
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00149659	chr3:10157352	C3orf10	0.76	9.69	0.41	2.51e-20	Alzheimer's disease;
LGG	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg12395012	chr8:11607386	GATA4	0.38	7.04	0.31	6.89e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2777491	0.957	rs3743038	chr15:41694743	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.69	-0.68	3.72e-63	Ulcerative colitis;
LGG	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg25885449	chr18:77638415	KCNG2	0.43	9.15	0.39	1.81e-18	Schizophrenia;
LGG	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg27476859	chr7:2772710	GNA12	0.65	13.34	0.53	1.35e-34	Plateletcrit;
LGG	cis	rs2247341	0.928	rs2854916	chr4:1721348	G/A	cg08446824	chr4:1720184	TMEM129	-0.68	-13.08	-0.52	1.68e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg08250081	chr4:10125330	NA	-0.39	-7.7	-0.34	8.41e-14	Bone mineral density;
LGG	cis	rs240764	0.612	rs1894561	chr6:100933962	G/C	cg21058520	chr6:100914733	NA	0.48	8.38	0.36	6.19e-16	Neuroticism;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg07414643	chr4:187882934	NA	0.57	11.95	0.49	7.35e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.6	-8.65	-0.37	8.68e-17	Schizophrenia;
LGG	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg24397884	chr7:158709396	WDR60	1.08	16.34	0.6	9.73e-48	Height;
LGG	cis	rs9914988	0.943	rs7211502	chr17:27163295	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2227631	0.505	rs12530730	chr7:100758591	T/A	cg18465962	chr7:100767262	NA	0.57	10.28	0.43	1.82e-22	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs2976388	0.647	rs2585138	chr8:143808951	C/T	cg06565975	chr8:143823917	SLURP1	0.38	9.66	0.41	3.21e-20	Urinary tract infection frequency;
LGG	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg03929089	chr4:120376271	NA	0.74	8.51	0.37	2.35e-16	Axial length;
LGG	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.17	0.52	7.52e-34	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg18681998	chr4:17616180	MED28	0.88	20.44	0.69	1.22e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs17685	0.753	rs11972240	chr7:75694079	A/C	cg19862616	chr7:65841803	NCRNA00174	1.08	26.29	0.77	7.29e-94	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg02725872	chr8:58115012	NA	-0.78	-11.01	-0.46	3.37e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10857712	0.754	rs2297032	chr10:135234580	C/T	cg00491522	chr10:135256596	NA	0.52	8.23	0.36	1.85e-15	Systemic lupus erythematosus;
LGG	cis	rs3820928	0.874	rs2177593	chr2:227833869	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-7.91	-0.35	1.88e-14	Pulmonary function;
LGG	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg13455623	chr4:3480656	DOK7	-0.53	-8.38	-0.36	6.26e-16	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs4788570	0.624	rs9929985	chr16:71838458	A/G	cg06353428	chr16:71660113	MARVELD3	1.26	20.11	0.68	3.95e-65	Intelligence (multi-trait analysis);
LGG	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.93e-18	Colorectal cancer;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.04	0.46	2.63e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9368481	0.594	rs7768814	chr6:26892036	C/A	cg12292205	chr6:26970375	C6orf41	0.69	13.16	0.52	7.98e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.69	0.45	5.3e-24	Rheumatoid arthritis;
LGG	cis	rs4604732	0.588	rs6677477	chr1:247629411	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	9.04	0.39	4.42e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg04226714	chr8:49833948	SNAI2	-0.44	-7.69	-0.34	8.93e-14	Life satisfaction;
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07685180	chr8:600429	NA	-0.98	-10.41	-0.44	5.82e-23	IgG glycosylation;
LGG	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg26513180	chr16:89883248	FANCA	-0.6	-11.09	-0.46	1.69e-25	Vitiligo;
LGG	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg01346077	chr3:125931526	NA	0.4	9.25	0.4	8.12e-19	Metabolite levels;
LGG	trans	rs8002861	0.664	rs1466005	chr13:44424210	T/C	cg12856521	chr11:46389249	DGKZ	0.52	9.3	0.4	5.71e-19	Leprosy;
LGG	cis	rs8014204	0.819	rs2003490	chr14:75377555	C/A	cg06637938	chr14:75390232	RPS6KL1	0.87	18.18	0.65	3.87e-56	Caffeine consumption;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.54	-0.33	2.48e-13	Retinal vascular caliber;
LGG	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.36	-7.63	-0.33	1.4e-13	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.82	-0.54	1.35e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs9467773	1.000	rs4713006	chr6:26519872	A/G	cg09904177	chr6:26538194	HMGN4	0.79	18.25	0.65	1.8e-56	Intelligence (multi-trait analysis);
LGG	cis	rs758324	0.812	rs13174462	chr5:131217988	A/G	cg06307176	chr5:131281290	NA	0.53	8.74	0.38	4.34e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7444	0.941	rs878825	chr22:21982249	A/G	cg11654148	chr22:21984483	YDJC	-0.38	-7.78	-0.34	4.85e-14	Systemic lupus erythematosus;
LGG	cis	rs4950322	0.580	rs2083720	chr1:146593878	A/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.67	-0.34	1.03e-13	Protein quantitative trait loci;
LGG	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.89	-0.3	1.84e-11	Morning vs. evening chronotype;
LGG	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg25823085	chr7:87105416	ABCB4	0.29	7.3	0.32	1.22e-12	Gallbladder cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21641552	chr12:88535903	TMTC3;CEP290	0.42	7.1	0.31	4.73e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.44	-0.33	4.86e-13	Menopause (age at onset);
LGG	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.26e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06470251	chr20:60548479	NA	0.53	8.48	0.37	3.1e-16	Body mass index;
LGG	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-10.42	-0.44	5.4e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10131894	0.611	rs175002	chr14:75436466	C/G	cg08847533	chr14:75593920	NEK9	0.45	8.37	0.36	6.84e-16	Coronary artery disease;
LGG	cis	rs9612	1.000	rs346545	chr19:44256386	T/C	cg08581076	chr19:44259116	C19orf61	0.51	8.56	0.37	1.63e-16	Exhaled nitric oxide output;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.85	-0.42	6.79e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg16141378	chr3:129829833	LOC729375	0.44	10.07	0.42	1.06e-21	Neuroticism;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg24642844	chr7:1081250	C7orf50	-0.46	-8.61	-0.37	1.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg24232236	chr22:38142998	TRIOBP	0.35	6.73	0.3	4.96e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs225245	0.817	rs1634684	chr17:33941051	A/G	cg05299278	chr17:33885742	SLFN14	0.42	8.1	0.35	5.07e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg13939156	chr17:80058883	NA	-0.41	-7.32	-0.32	1.1e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg04034577	chr2:241836375	C2orf54	-0.51	-10.68	-0.44	6.21e-24	Urinary metabolites;
LGG	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg00339695	chr16:24857497	SLC5A11	0.41	7.01	0.31	8.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg12473912	chr3:136751656	NA	0.43	7.63	0.33	1.34e-13	Neuroticism;
LGG	cis	rs60180747	0.909	rs78921612	chr15:66826037	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.24	0.43	2.45e-22	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg17218041	chr13:113365319	ATP11A	-0.48	-7.93	-0.35	1.64e-14	Glycated hemoglobin levels;
LGG	cis	rs757081	0.702	rs522619	chr11:17204448	A/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.0	-0.39	5.95e-18	Systolic blood pressure;
LGG	cis	rs4356203	0.905	rs214936	chr11:17191019	A/G	cg15432903	chr11:17409602	KCNJ11	0.39	7.31	0.32	1.17e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6489785	0.775	rs1151861	chr12:121332873	A/G	cg02419362	chr12:121203948	SPPL3	-0.43	-6.76	-0.3	4.28e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg20848291	chr7:100343083	ZAN	-0.7	-10.36	-0.43	9.16e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7465272	1.000	rs7835613	chr8:143682428	C/T	cg10104451	chr8:143696006	ARC	-0.72	-10.64	-0.44	8.53e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Bone mineral density;
LGG	cis	rs9397585	0.857	rs1933258	chr6:153377807	G/C	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs72781680	0.846	rs55770503	chr2:24030126	A/T	cg08917208	chr2:24149416	ATAD2B	0.78	8.88	0.38	1.46e-17	Lymphocyte counts;
LGG	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.27	-0.79	2.28e-98	Height;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18252515	chr7:66147081	NA	0.44	7.47	0.33	3.97e-13	Aortic root size;
LGG	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs139371	0.713	rs139317	chr22:39499902	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.81	-0.3	3.09e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs42648	0.693	rs194533	chr7:89870777	A/G	cg25739043	chr7:89950458	NA	-0.33	-6.87	-0.3	2.07e-11	Homocysteine levels;
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg04861929	chr11:109293070	C11orf87	0.54	9.62	0.41	4.42e-20	Schizophrenia;
LGG	cis	rs7586879	0.616	rs11900505	chr2:25131986	A/C	cg04586622	chr2:25135609	ADCY3	0.48	13.12	0.52	1.18e-33	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15068522	chr6:57086371	RAB23	0.39	6.77	0.3	3.99e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg27121462	chr16:89883253	FANCA	0.6	10.56	0.44	1.62e-23	Vitiligo;
LGG	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs240764	0.584	rs11155653	chr6:101217123	G/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.64	-0.33	1.22e-13	Neuroticism;
LGG	cis	rs10864302	0.525	rs7528931	chr1:7429606	T/G	cg08923594	chr1:7462176	CAMTA1	0.66	8.11	0.35	4.72e-15	Photic sneeze reflex;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg13395646	chr4:1353034	KIAA1530	-0.6	-10.47	-0.44	3.72e-23	Obesity-related traits;
LGG	cis	rs2458413	0.521	rs2458427	chr8:105339594	G/T	cg23108931	chr8:105342351	NA	-0.28	-7.4	-0.33	6.55e-13	Paget's disease;
LGG	cis	rs2072732	0.904	rs2993480	chr1:2973322	A/G	cg08733933	chr1:2954429	NA	0.33	7.5	0.33	3.25e-13	Plateletcrit;
LGG	trans	rs7605827	0.930	rs1015836	chr2:15665719	A/G	cg23167307	chr17:36981148	CCDC49	0.33	6.8	0.3	3.2e-11	Educational attainment (years of education);
LGG	cis	rs2171564	0.934	rs10934183	chr3:112442385	A/G	cg06685282	chr3:112453648	NA	-0.4	-7.2	-0.32	2.42e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.88	-0.38	1.45e-17	Bladder cancer;
LGG	cis	rs875971	0.545	rs73146609	chr7:65767464	A/G	cg11764359	chr7:65958608	NA	0.62	9.24	0.39	9.2e-19	Aortic root size;
LGG	trans	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.76	0.48	3.89e-28	Corneal astigmatism;
LGG	cis	rs921968	0.643	rs659185	chr2:219335935	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7188861	0.768	rs430966	chr16:11389482	C/T	cg01510278	chr16:11456238	NA	0.31	7.44	0.33	4.95e-13	HDL cholesterol;
LGG	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg02403541	chr12:121454288	C12orf43	-0.55	-9.1	-0.39	2.77e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	trans	rs2048656	0.524	rs13270518	chr8:9536713	C/G	cg16141378	chr3:129829833	LOC729375	0.33	7.08	0.31	5.37e-12	Schizophrenia;
LGG	trans	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg25214090	chr10:38739885	LOC399744	0.57	10.36	0.43	9.14e-23	Corneal astigmatism;
LGG	cis	rs17818399	0.574	rs6544907	chr2:46868319	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-7.97	-0.35	1.23e-14	Height;
LGG	cis	rs7582720	0.945	rs72936860	chr2:203783484	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs17689437	0.625	rs1728791	chr16:68596509	T/C	cg02972257	chr16:68554789	NA	-0.45	-7.51	-0.33	2.97e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.8	0.41	1.01e-20	Monocyte count;
LGG	cis	rs9915657	0.933	rs8075603	chr17:70136833	G/T	cg09344028	chr17:70110421	NA	0.49	10.98	0.45	4.44e-25	Thyroid hormone levels;
LGG	cis	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg13789015	chr9:136890014	NCRNA00094	0.58	11.06	0.46	2.26e-25	Platelet distribution width;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-14.93	-0.57	1.97e-41	Prudent dietary pattern;
LGG	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-9.97	-0.42	2.4e-21	Bladder cancer;
LGG	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg04731861	chr2:219085781	ARPC2	0.46	11.17	0.46	8.07e-26	Colorectal cancer;
LGG	cis	rs4880487	0.853	rs1876898	chr10:1249986	C/T	cg03183215	chr10:1252341	ADARB2	-0.7	-14.82	-0.57	6.06e-41	Migraine;
LGG	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg19784903	chr17:45786737	TBKBP1	-0.32	-7.07	-0.31	5.86e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg06916706	chr16:4465613	CORO7	-0.71	-12.28	-0.5	3.5e-30	Schizophrenia;
LGG	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg03605463	chr16:89740564	NA	0.6	10.49	0.44	3.12e-23	Vitiligo;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs75059851	0.756	rs11223649	chr11:133840471	T/C	cg17703048	chr11:133852993	NA	-0.87	-16.03	-0.6	2.6e-46	Schizophrenia;
LGG	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.1	-0.78	1.36e-97	Schizophrenia;
LGG	cis	rs504918	0.588	rs73188200	chr3:124031989	G/C	cg05766129	chr3:123988013	KALRN	-0.57	-10.04	-0.42	1.42e-21	Schizophrenia;
LGG	trans	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.42	-0.33	5.71e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4417704	0.551	rs6753109	chr2:241877597	C/T	cg26818257	chr2:241905806	NA	-0.47	-10.44	-0.44	4.87e-23	Joint mobility (Beighton score);
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs3816183	0.547	rs4952940	chr2:43048620	T/C	cg14631114	chr2:43023945	NA	0.46	8.44	0.37	4.08e-16	Hypospadias;
LGG	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.72	0.51	5.32e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9796	0.621	rs691702	chr15:41474399	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.95	-0.42	2.92e-21	Menopause (age at onset);
LGG	cis	rs5753618	0.583	rs738657	chr22:31841749	T/A	cg02404636	chr22:31891804	SFI1	0.38	6.97	0.31	1.12e-11	Colorectal cancer;
LGG	cis	rs3768617	0.706	rs8179460	chr1:183056222	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.36	7.06	0.31	6.21e-12	Fuchs's corneal dystrophy;
LGG	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19719120	chr19:12780479	MORG1;C19orf56	0.44	7.16	0.32	3.11e-12	Cognitive performance;
LGG	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.09	-0.35	5.33e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08692130	chr10:18948698	ARL5B	0.56	6.78	0.3	3.78e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2470578	0.766	rs2596647	chr3:17300133	A/C	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.38e-11	Schizophrenia;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05025164	chr4:1340916	KIAA1530	0.56	10.0	0.42	1.89e-21	Obesity-related traits;
LGG	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg06046430	chr4:77819534	ANKRD56	0.56	11.42	0.47	8.53e-27	Emphysema distribution in smoking;
LGG	cis	rs11064837	0.523	rs7972600	chr12:120095319	G/T	cg25937854	chr12:120150414	CIT	-0.66	-10.78	-0.45	2.57e-24	Schizophrenia;
LGG	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg13512537	chr8:22265999	SLC39A14	-0.49	-8.72	-0.38	4.97e-17	Verbal declarative memory;
LGG	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	trans	rs3857536	0.813	rs6455084	chr6:66935658	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs2797369	0.713	rs4615398	chr6:101539082	C/T	cg27451362	chr6:101846650	GRIK2	-0.85	-11.51	-0.47	4.04e-27	Renal function-related traits (eGRFcrea);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19529645	chr17:79196743	AZI1	0.52	7.75	0.34	5.91e-14	Gut microbiome composition (summer);
LGG	cis	rs4595586	1.000	rs4384412	chr12:39218113	T/C	cg26384229	chr12:38710491	ALG10B	-0.4	-7.06	-0.31	6.01e-12	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.883	rs10515678	chr5:152323236	A/G	cg12297329	chr5:152029980	NA	0.51	9.81	0.41	9.43e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs71636778	0.543	rs36109400	chr1:27247822	G/A	cg12203394	chr1:27248618	NUDC	0.5	6.65	0.3	8.25e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg16006296	chr10:38738647	LOC399744	0.35	6.78	0.3	3.59e-11	Diastolic blood pressure;
LGG	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg11502198	chr6:26597334	ABT1	0.71	12.85	0.51	1.53e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs10000573	chr4:99048785	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg26597838	chr10:835615	NA	0.75	10.44	0.44	4.69e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.5	-0.33	3.22e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs17253792	0.822	rs10149408	chr14:56046075	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.27	-0.5	3.59e-30	Putamen volume;
LGG	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg17330251	chr7:94953956	PON1	-0.42	-7.84	-0.34	3.08e-14	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9357271	0.955	rs6903060	chr6:38374397	T/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.81	-0.45	1.97e-24	Restless legs syndrome;
LGG	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg22044901	chr15:68126292	NA	-0.4	-7.08	-0.31	5.36e-12	Obesity;
LGG	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg26656751	chr17:43910226	CRHR1	0.35	7.13	0.31	4e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.62	-10.86	-0.45	1.26e-24	Lymphocyte counts;
LGG	cis	rs2239547	0.618	rs4687663	chr3:52870618	T/A	cg11645453	chr3:52864694	ITIH4	0.72	11.29	0.46	2.89e-26	Schizophrenia;
LGG	cis	rs8032158	0.896	rs8028559	chr15:56130909	A/G	cg02198044	chr15:56286336	NEDD4	-0.63	-10.96	-0.45	5.03e-25	Keloid;
LGG	trans	rs1459104	1.000	rs12577585	chr11:55302603	G/A	cg15704280	chr7:45808275	SEPT13	0.68	6.72	0.3	5.48e-11	Body mass index;
LGG	cis	rs1408224	0.657	rs9526208	chr13:47208767	A/G	cg24453118	chr13:47229927	LRCH1	-0.3	-6.98	-0.31	1.03e-11	QRS complex (12-leadsum);
LGG	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg18357526	chr6:26021779	HIST1H4A	0.58	10.22	0.43	3.14e-22	Blood metabolite levels;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.46e-14	Obesity-related traits;
LGG	cis	rs11711311	0.868	rs13091621	chr3:113481977	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.51	0.53	2.62e-35	IgG glycosylation;
LGG	cis	rs9547996	0.837	rs1924298	chr13:38183502	A/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.65e-11	Diastolic blood pressure;
LGG	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.14	0.31	3.66e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg16006296	chr10:38738647	LOC399744	0.34	6.69	0.3	6.53e-11	Diastolic blood pressure;
LGG	cis	rs6964587	1.000	rs10234071	chr7:91645152	C/G	cg17063962	chr7:91808500	NA	-0.47	-8.45	-0.37	3.87e-16	Breast cancer;
LGG	cis	rs5742933	0.779	rs114408326	chr2:190581396	C/T	cg04003228	chr2:190539410	ANKAR	-0.5	-7.38	-0.32	7.19e-13	Ferritin levels;
LGG	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg26818010	chr10:134567672	INPP5A	-0.73	-11.03	-0.46	2.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs34929064	0.881	rs2961313	chr7:22735220	C/T	cg18045685	chr7:22629474	NA	0.51	9.12	0.39	2.34e-18	Major depression and alcohol dependence;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12485212	chr8:61565947	NA	0.43	7.32	0.32	1.11e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.66	0.3	7.6e-11	Schizophrenia;
LGG	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Neuroticism;
LGG	cis	rs2721811	0.738	rs2529037	chr7:24722178	G/C	cg06301139	chr7:24798175	DFNA5	-0.38	-6.98	-0.31	1.02e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg25554036	chr4:6271136	WFS1	-0.57	-10.75	-0.45	3.22e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.12	-0.43	7.08e-22	Bladder cancer;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg05409276	chr17:73400549	GRB2	-0.49	-6.84	-0.3	2.46e-11	Lung cancer in ever smokers;
LGG	cis	rs4722166	0.630	rs6969258	chr7:22782528	C/T	cg05265849	chr7:22767390	IL6	0.43	8.19	0.36	2.63e-15	Lung cancer;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs4865875	0.892	rs7728418	chr5:54101579	T/A	cg22421804	chr5:54100067	NA	0.52	7.74	0.34	6.4e-14	Sense of smell;
LGG	cis	rs7412746	0.566	rs11204743	chr1:150890406	A/T	cg15448220	chr1:150897856	SETDB1	0.39	6.97	0.31	1.12e-11	Melanoma;
LGG	cis	rs12765878	0.967	rs10883940	chr10:105650598	G/A	cg11005552	chr10:105648138	OBFC1	1.03	27.18	0.78	6.22e-98	Coronary artery disease;
LGG	cis	rs2862064	1.000	rs9313405	chr5:156447750	T/C	cg12943317	chr5:156479607	HAVCR1	-0.77	-10.32	-0.43	1.31e-22	Platelet count;
LGG	cis	rs4974559	0.790	rs2293631	chr4:1315917	C/A	cg02980000	chr4:1222292	CTBP1	0.68	9.57	0.41	6.54e-20	Systolic blood pressure;
LGG	cis	rs62400317	0.859	rs10948220	chr6:45236654	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	cis	rs8141529	0.515	rs16986861	chr22:29343188	G/C	cg15103426	chr22:29168792	CCDC117	0.6	6.97	0.31	1.08e-11	Lymphocyte counts;
LGG	cis	rs10949834	0.529	rs7785826	chr7:73548785	C/A	cg07137043	chr7:73588983	EIF4H	-0.61	-9.02	-0.39	4.98e-18	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs240764	0.612	rs2397974	chr6:100925828	C/T	cg21058520	chr6:100914733	NA	0.47	8.36	0.36	7.16e-16	Neuroticism;
LGG	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8067287	0.645	rs55770108	chr17:16841424	A/G	cg26910001	chr17:16838321	NA	-0.5	-9.44	-0.4	1.88e-19	Diabetic kidney disease;
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	cis	rs7312774	0.618	rs9651926	chr12:107356820	G/A	cg16260113	chr12:107380972	MTERFD3	1.1	10.11	0.43	7.62e-22	Severe influenza A (H1N1) infection;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.38e-17	Prudent dietary pattern;
LGG	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg08498830	chr11:832797	CD151	-0.45	-7.32	-0.32	1.11e-12	Mean platelet volume;
LGG	cis	rs7246865	0.954	rs10427132	chr19:17207156	T/G	cg19418318	chr19:17219073	MYO9B	0.35	9.62	0.41	4.18e-20	Reticulocyte fraction of red cells;
LGG	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg05457941	chr1:149858211	HIST2H2BE;HIST2H2AC	-0.43	-6.71	-0.3	5.8200000000000003e-11	Sitting height ratio;
LGG	cis	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg24803719	chr17:45855879	NA	-0.28	-7.43	-0.33	5.29e-13	IgG glycosylation;
LGG	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg07777115	chr5:623756	CEP72	-0.56	-7.21	-0.32	2.29e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg17644776	chr2:200775616	C2orf69	0.7	12.5	0.5	4.32e-31	Osteoporosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06291595	chr14:74960292	NPC2;ISCA2	0.46	6.7	0.3	5.94e-11	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	12.11	0.49	1.65e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9527	0.615	rs10883811	chr10:104727279	A/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.85	-0.3	2.31e-11	Arsenic metabolism;
LGG	cis	rs6952809	0.590	rs1468337	chr7:2432211	C/T	cg23289794	chr7:2394357	EIF3B	-0.77	-9.71	-0.41	2.01e-20	Multiple sclerosis;
LGG	cis	rs7945705	0.902	rs10743093	chr11:8869129	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.37	7.5	0.33	3.23e-13	Hemoglobin concentration;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg05896524	chr21:47604654	C21orf56	0.63	11.38	0.47	1.27e-26	Testicular germ cell tumor;
LGG	trans	rs208520	1.000	rs208529	chr6:66957549	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.19	-0.55	3.28e-38	Exhaled nitric oxide output;
LGG	cis	rs8127571	0.529	rs9306142	chr21:47225575	A/G	cg11214348	chr21:47283868	PCBP3	-0.48	-8.11	-0.35	4.54e-15	Immune reponse to smallpox (secreted IFN-alpha);
LGG	cis	rs4919694	1.000	rs11191445	chr10:104651055	C/T	cg04362960	chr10:104952993	NT5C2	1.1	15.11	0.57	3.29e-42	Arsenic metabolism;
LGG	cis	rs2354432	0.607	rs11579626	chr1:146741960	A/C	cg25205988	chr1:146714368	CHD1L	-1.48	-15.04	-0.57	6.37e-42	Mitochondrial DNA levels;
LGG	cis	rs2386661	0.826	rs11255996	chr10:5670832	G/A	cg26603656	chr10:5671107	NA	0.39	7.76	0.34	5.59e-14	Breast cancer;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11141652	chr22:24348549	GSTTP1	0.41	6.94	0.31	1.32e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg04287289	chr16:89883240	FANCA	0.74	7.21	0.32	2.36e-12	Skin colour saturation;
LGG	cis	rs9611565	0.625	rs9611606	chr22:41931074	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.74	0.38	4.4e-17	Vitiligo;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-9.96	-0.42	2.6e-21	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.5e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4363385	1.000	rs310124	chr1:153020275	C/T	cg07796016	chr1:152779584	LCE1C	-0.42	-7.17	-0.32	2.91e-12	Inflammatory skin disease;
LGG	cis	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	6.74	0.3	4.61e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6908034	0.607	rs79406203	chr6:19816221	T/G	cg02682789	chr6:19804855	NA	0.9	8.43	0.36	4.45e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9381107	0.932	rs9380847	chr6:9442372	T/C	cg14735645	chr6:9486422	NA	-0.42	-7.21	-0.32	2.32e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg00677455	chr12:58241039	CTDSP2	0.45	8.25	0.36	1.64e-15	Multiple sclerosis;
LGG	cis	rs847649	1.000	rs9718453	chr7:102594976	T/G	cg18108683	chr7:102477205	FBXL13	0.64	14.27	0.55	1.52e-38	Morning vs. evening chronotype;
LGG	cis	rs6542838	0.553	rs6739503	chr2:99537295	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.1	-0.31	4.74e-12	Fear of minor pain;
LGG	cis	rs7712401	0.580	rs10076327	chr5:122367347	A/G	cg19412675	chr5:122181750	SNX24	0.49	7.83	0.34	3.32e-14	Mean platelet volume;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06873684	chr19:4472059	HDGF2	0.41	6.8	0.3	3.27e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12495069	chr2:1652362	PXDN	0.39	7.04	0.31	6.88e-12	Electrocardiographic conduction measures;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	10.93	0.45	6.79e-25	Personality dimensions;
LGG	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg27121462	chr16:89883253	FANCA	0.62	11.57	0.47	2.22e-27	Vitiligo;
LGG	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg07915516	chr16:377344	AXIN1	-0.28	-7.07	-0.31	5.71e-12	Body mass index;
LGG	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg26441486	chr22:50317300	CRELD2	0.43	7.45	0.33	4.51e-13	Schizophrenia;
LGG	cis	rs7143963	0.666	rs7151954	chr14:103323448	A/G	cg23020514	chr14:103360112	TRAF3	0.41	8.48	0.37	2.99e-16	Body mass index;
LGG	cis	rs882300	0.934	rs13431630	chr2:136930587	T/C	cg07169764	chr2:136633963	MCM6	0.46	7.52	0.33	2.82e-13	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg13802316	chr11:70253460	CTTN	-0.66	-8.9	-0.38	1.22e-17	Coronary artery disease;
LGG	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg27119904	chr13:114814333	RASA3	0.36	7.47	0.33	4.03e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.57	-0.37	1.6e-16	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05029193	chr1:78148830	ZZZ3	0.4	6.67	0.3	7.4e-11	Gut microbiome composition (summer);
LGG	cis	rs12220238	1.000	rs11000905	chr10:75925532	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.5e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg04450456	chr4:17643702	FAM184B	0.3	6.67	0.3	7.26e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg11584989	chr19:19387371	SF4	0.39	7.17	0.32	2.95e-12	Tonsillectomy;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	10.11	0.43	7.39e-22	Obesity-related traits;
LGG	cis	rs9358372	0.574	rs9350296	chr6:20875582	T/C	cg13405222	chr6:20811065	CDKAL1	-0.45	-9.03	-0.39	4.47e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.9	-0.45	9.04e-25	IgG glycosylation;
LGG	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg13607699	chr17:42295918	UBTF	0.88	18.15	0.64	5.19e-56	Red cell distribution width;Reticulocyte count;
LGG	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.92	0.35	1.82e-14	Retinal vascular caliber;
LGG	trans	rs9929218	0.954	rs72785165	chr16:68755635	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-14.16	-0.55	4.69e-38	Colorectal cancer;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.37e-16	Lung cancer;
LGG	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.83	0.38	2.11e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs546131	0.928	rs552171	chr11:34830709	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	10.37	0.43	8.59e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs3126085	0.935	rs6681433	chr1:152277396	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.02	-0.35	8.43e-15	Atopic dermatitis;
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.23	0.58	9.18e-43	Platelet count;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg20309703	chr11:118481025	PHLDB1	-0.56	-10.46	-0.44	3.79e-23	Cholesterol, total;
LGG	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.65	-0.33	1.21e-13	Triglycerides;
LGG	cis	rs137603	0.623	rs470075	chr22:39686806	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.73	-14.14	-0.55	5.36e-38	Primary biliary cholangitis;
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg14092988	chr3:52407081	DNAH1	0.3	8.07	0.35	5.99e-15	Bipolar disorder;
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.57e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03092551	chr2:58273420	VRK2	0.35	7.5	0.33	3.35e-13	Gut microbiome composition (summer);
LGG	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.65	-12.46	-0.5	6.25e-31	Total body bone mineral density;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.86	-0.59	1.52e-45	Height;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23039505	chr14:81685593	GTF2A1	0.38	6.78	0.3	3.7e-11	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.71	-0.3	5.55e-11	Lung cancer;
LGG	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.58	0.63	2.26e-53	Vitiligo;
LGG	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg14004847	chr7:1930337	MAD1L1	-0.47	-8.39	-0.36	5.85e-16	Schizophrenia;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg08677398	chr8:58056175	NA	0.44	7.37	0.32	7.97e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg00531865	chr16:30841666	NA	-0.48	-10.14	-0.43	5.93e-22	Dementia with Lewy bodies;
LGG	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg21435375	chr2:172878103	MAP1D	-0.31	-7.06	-0.31	6.3e-12	Schizophrenia;
LGG	cis	rs4950322	0.570	rs72691012	chr1:146711400	G/C	cg22381352	chr1:146742008	CHD1L	-0.47	-7.7	-0.34	8.22e-14	Protein quantitative trait loci;
LGG	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg01631408	chr1:248437212	OR2T33	0.54	9.57	0.41	6.44e-20	Common traits (Other);
LGG	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.54	-0.41	7.96e-20	Aortic root size;
LGG	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.47	-0.33	4.05e-13	Blood protein levels;
LGG	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg23029597	chr12:123009494	RSRC2	-0.88	-16.74	-0.61	1.65e-49	Body mass index;
LGG	cis	rs75229567	0.541	rs775443	chr12:70122623	C/T	cg10114359	chr12:70132523	RAB3IP	-0.99	-9.12	-0.39	2.37e-18	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03833794	chr17:78190983	SGSH	0.39	6.71	0.3	5.8200000000000003e-11	Electrocardiographic conduction measures;
LGG	cis	rs6496667	0.510	rs7495784	chr15:91068882	T/C	cg22089800	chr15:90895588	ZNF774	-0.5	-8.21	-0.36	2.23e-15	Rheumatoid arthritis;
LGG	trans	rs1994135	0.692	rs7297538	chr12:33693438	T/C	cg13010199	chr12:38710504	ALG10B	0.56	9.77	0.41	1.23e-20	Resting heart rate;
LGG	cis	rs6496667	0.509	rs2253419	chr15:90945875	A/G	cg22089800	chr15:90895588	ZNF774	0.52	8.52	0.37	2.28e-16	Rheumatoid arthritis;
LGG	trans	rs8002861	0.840	rs7989353	chr13:44438957	T/C	cg17145862	chr1:211918768	LPGAT1	0.98	24.94	0.76	1.2e-87	Leprosy;
LGG	trans	rs13128441	0.593	rs4370072	chr4:5149543	C/T	cg26099876	chr8:141644609	EIF2C2	-0.53	-7.79	-0.34	4.48e-14	Celiac disease;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.19	0.52	6.04e-34	Obesity-related traits;
LGG	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg07541023	chr7:19748670	TWISTNB	0.49	7.56	0.33	2.14e-13	Thyroid stimulating hormone;
LGG	cis	rs231513	1.000	rs231513	chr17:41965200	C/G	cg26893861	chr17:41843967	DUSP3	-0.58	-6.87	-0.3	2.14e-11	Cognitive function;
LGG	cis	rs77140172	0.655	rs79387006	chr4:89672775	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.83	7.9	0.34	2.02e-14	Post bronchodilator FEV1;
LGG	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg05535760	chr7:792225	HEATR2	0.78	12.43	0.5	8.15e-31	Cerebrospinal P-tau181p levels;
LGG	trans	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.65	-0.33	1.16e-13	Heart rate;
LGG	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg08975724	chr8:8085496	FLJ10661	0.47	9.02	0.39	5.21e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.46	-0.33	4.41e-13	Lung cancer;
LGG	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg20302533	chr7:39170763	POU6F2	0.55	13.58	0.53	1.34e-35	IgG glycosylation;
LGG	trans	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	1.99e-13	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14645526	chr11:91959086	NA	0.46	7.72	0.34	7.3e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg26513180	chr16:89883248	FANCA	0.63	11.35	0.47	1.61e-26	Vitiligo;
LGG	trans	rs9467711	0.651	rs67491322	chr6:25961352	C/T	cg01620082	chr3:125678407	NA	-0.75	-6.92	-0.31	1.48e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg00086871	chr4:6988644	TBC1D14	0.85	8.41	0.36	5.12e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg12463550	chr7:65579703	CRCP	0.46	7.62	0.33	1.42e-13	Aortic root size;
LGG	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg22232500	chr2:134024266	NCKAP5	0.63	8.93	0.38	1.03e-17	Bipolar disorder;
LGG	cis	rs74781061	0.858	rs35752918	chr15:74786581	T/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03909863	chr11:638404	DRD4	-0.41	-6.65	-0.3	8.28e-11	Systemic lupus erythematosus;
LGG	cis	rs9462027	0.628	rs66506671	chr6:34777149	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.3	-0.46	2.64e-26	Systemic lupus erythematosus;
LGG	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg26924012	chr15:45694286	SPATA5L1	1.04	21.84	0.71	3.16e-73	Homoarginine levels;
LGG	cis	rs1883415	0.534	rs2253794	chr6:24479642	C/A	cg20631270	chr6:24437470	GPLD1	0.49	8.52	0.37	2.19e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.62	0.37	1.09e-16	Personality dimensions;
LGG	cis	rs829402	1.000	rs829396	chr1:22003793	A/G	cg20487231	chr1:21986101	RAP1GAP	0.48	9.37	0.4	3.28e-19	High light scatter reticulocyte count;
LGG	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.44	0.4	1.85e-19	Bone mineral density;
LGG	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg15309053	chr8:964076	NA	0.42	8.24	0.36	1.84e-15	Schizophrenia;
LGG	cis	rs9875589	0.509	rs1386932	chr3:14061369	G/A	cg19554555	chr3:13937349	NA	-0.54	-9.83	-0.42	8.04e-21	Ovarian reserve;
LGG	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg14101638	chr12:121416612	HNF1A	-0.35	-7.3	-0.32	1.26e-12	N-glycan levels;
LGG	cis	rs10779751	0.960	rs4845857	chr1:11285680	T/C	cg08854313	chr1:11322531	MTOR	0.75	16.44	0.61	3.48e-48	Body mass index;
LGG	cis	rs6554196	0.508	rs11727273	chr4:55509748	C/T	cg18836493	chr4:55524333	KIT	-0.43	-8.13	-0.35	3.92e-15	Monocyte count;
LGG	cis	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.22	-0.43	2.91e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.57	-10.91	-0.45	8.26e-25	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9359856	0.529	rs56352205	chr6:90439272	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.69	-0.41	2.41e-20	Bipolar disorder;
LGG	cis	rs34638952	0.601	rs7219105	chr17:27434446	A/T	cg13672501	chr17:27410685	MYO18A	-0.41	-7.34	-0.32	9.6e-13	Sitting height ratio;
LGG	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg10189774	chr4:17578691	LAP3	0.4	7.27	0.32	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04911050	chr16:677664	RAB40C	0.33	6.68	0.3	6.8e-11	Height;
LGG	cis	rs7619833	0.512	rs12715119	chr3:27221769	T/C	cg02860705	chr3:27208620	NA	0.42	8.13	0.35	4.03e-15	Breast cancer;
LGG	cis	rs600231	0.708	rs682845	chr11:65254201	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.11	-0.39	2.43e-18	Bone mineral density;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs9600832	0.553	rs9544448	chr13:36069426	G/A	cg20704442	chr13:36052768	MIR548F5;NBEA	-0.41	-12.16	-0.49	1.06e-29	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs26232	0.526	rs61654927	chr5:102382725	C/A	cg23492399	chr5:102201601	PAM	-0.51	-7.51	-0.33	3.12e-13	Rheumatoid arthritis;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg14773178	chr5:1868261	NA	0.36	7.95	0.35	1.48e-14	Cardiovascular disease risk factors;
LGG	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg25237894	chr2:233734115	C2orf82	-0.73	-15.25	-0.58	8.08e-43	Coronary artery disease;
LGG	cis	rs11096990	0.634	rs7654501	chr4:39283984	G/C	cg24403649	chr4:39172243	NA	-0.4	-7.16	-0.32	3.18e-12	Cognitive function;
LGG	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg18188782	chr20:61659543	NA	0.42	6.89	0.3	1.83e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg03514404	chr7:143579665	FAM115A	-0.37	-7.15	-0.32	3.43e-12	Brain structure;
LGG	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg09085632	chr11:111637200	PPP2R1B	1.02	20.04	0.68	9.2e-65	Primary sclerosing cholangitis;
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.13	-0.43	6.4e-22	Tonsillectomy;
LGG	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg11984989	chr7:158649758	WDR60	-0.98	-20.48	-0.69	7.4e-67	Height;
LGG	cis	rs4740619	0.870	rs2039980	chr9:15537508	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.72	-0.41	1.9e-20	Body mass index;
LGG	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg15485101	chr11:133734466	NA	0.59	10.41	0.44	5.94e-23	Childhood ear infection;
LGG	cis	rs2268241	0.938	rs9978166	chr21:34770516	A/G	cg14850771	chr21:34775459	IFNGR2	0.81	9.89	0.42	4.64e-21	Obesity-related traits;
LGG	cis	rs3008870	1.000	rs3008858	chr1:67390416	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.57	0.72	1.3e-76	Lymphocyte percentage of white cells;
LGG	cis	rs701145	0.585	rs357465	chr3:153903095	T/A	cg17054900	chr3:154042577	DHX36	0.88	10.22	0.43	3.13e-22	Coronary artery disease;
LGG	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg10253484	chr15:75165896	SCAMP2	-0.55	-8.89	-0.38	1.32e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg02158880	chr13:53174818	NA	0.42	8.22	0.36	2e-15	Lewy body disease;
LGG	cis	rs4478037	0.818	rs17522946	chr3:33138777	A/G	cg19404215	chr3:33155277	CRTAP	0.78	9.3	0.4	5.57e-19	Major depressive disorder;
LGG	cis	rs4417704	0.502	rs6714289	chr2:241880461	G/A	cg05025159	chr2:241905733	NA	0.45	9.34	0.4	4.19e-19	Joint mobility (Beighton score);
LGG	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg13844804	chr7:814759	HEATR2	0.52	6.68	0.3	6.82e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06475006	chr16:89985975	MC1R	-0.58	-6.8	-0.3	3.16e-11	Skin colour saturation;
LGG	cis	rs1355223	0.573	rs7125773	chr11:34723573	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.23	-0.32	2.04e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7572733	0.534	rs11899188	chr2:198740121	C/T	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs2629540	0.765	rs11245387	chr10:126537825	C/T	cg08799069	chr10:126477246	METTL10	-0.58	-12.37	-0.5	1.44e-30	Cocaine dependence;
LGG	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg09624528	chr10:1369823	ADARB2	-0.41	-6.93	-0.31	1.45e-11	Radiation response;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-10.03	-0.42	1.5e-21	Height;
LGG	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs7444	0.941	rs73166619	chr22:21930093	C/T	cg22858872	chr22:21984481	YDJC	-0.37	-6.82	-0.3	2.95e-11	Systemic lupus erythematosus;
LGG	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg26655873	chr3:72818019	SHQ1	-0.36	-6.99	-0.31	9.72e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg04662567	chr6:169592167	NA	-0.79	-11.7	-0.48	7.05e-28	Pulse pressure;
LGG	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7582720	0.943	rs72932583	chr2:203869847	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9905704	0.647	rs10221208	chr17:57047885	T/C	cg12560992	chr17:57184187	TRIM37	0.53	8.5	0.37	2.65e-16	Testicular germ cell tumor;
LGG	trans	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	9.88	0.42	5.31e-21	Ulcerative colitis;
LGG	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg25809561	chr17:30822961	MYO1D	-0.37	-8.92	-0.38	1.13e-17	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs755249	0.532	rs61779278	chr1:39834617	A/G	cg18385671	chr1:39797026	MACF1	0.43	7.41	0.33	6.19e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg12826209	chr6:26865740	GUSBL1	0.59	7.3	0.32	1.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg19507638	chr5:93509721	C5orf36	0.4	7.1	0.31	4.62e-12	Diabetic retinopathy;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	14.6	0.56	5.44e-40	Platelet count;
LGG	trans	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.64	-0.33	1.26e-13	Heart rate;
LGG	cis	rs2224391	0.628	rs6913120	chr6:5260505	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-6.76	-0.3	4.23e-11	Height;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs7147624	1.000	rs2898816	chr14:66008160	T/C	cg03016385	chr14:66212404	NA	-0.77	-9.64	-0.41	3.75e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.61	0.44	1.07e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg10950524	chr7:2139216	MAD1L1	0.33	7.0	0.31	9.04e-12	Schizophrenia;
LGG	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.89	-0.38	1.36e-17	Fuchs's corneal dystrophy;
LGG	cis	rs877282	0.755	rs2790388	chr10:786084	T/C	cg17470449	chr10:769945	NA	0.53	6.91	0.31	1.6e-11	Uric acid levels;
LGG	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg06827562	chr3:125932279	NA	0.61	13.1	0.52	1.46e-33	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7301826	0.610	rs4759791	chr12:131296495	A/G	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs16854884	0.609	rs2885197	chr3:143636616	A/T	cg06585982	chr3:143692056	C3orf58	-0.55	-9.33	-0.4	4.28e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs9815354	0.812	rs55788971	chr3:41843965	T/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7727544	0.547	rs10076758	chr5:131524299	A/G	cg07395648	chr5:131743802	NA	-0.39	-8.51	-0.37	2.38e-16	Blood metabolite levels;
LGG	cis	rs9863	0.931	rs11057401	chr12:124427306	A/T	cg13487667	chr12:124434373	CCDC92	-0.37	-7.35	-0.32	9.16e-13	White blood cell count;
LGG	trans	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.75	0.38	4.01e-17	Schizophrenia;
LGG	trans	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg26043149	chr18:55253948	FECH	-0.42	-7.07	-0.31	5.89e-12	Bone mineral density;
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.81	0.34	3.83e-14	Glycated hemoglobin levels;
LGG	cis	rs35146811	0.735	rs6948729	chr7:99787372	A/G	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.74	0.41	1.67e-20	Longevity;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.59	-0.33	1.73e-13	Menopause (age at onset);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg14932684	chr12:42632001	YAF2	0.39	6.72	0.3	5.45e-11	Body mass index;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05165339	chr4:1420672	NA	0.37	9.41	0.4	2.33e-19	Longevity;
LGG	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-8.05	-0.35	6.84e-15	Menarche (age at onset);
LGG	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03517284	chr6:25882590	NA	0.66	12.84	0.51	1.77e-32	Blood metabolite levels;
LGG	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs728616	0.614	rs56147535	chr10:82027625	G/T	cg27171509	chr10:82033454	MAT1A	-0.44	-6.84	-0.3	2.57e-11	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.23e-15	Rheumatoid arthritis;
LGG	cis	rs11711311	0.747	rs2895415	chr3:113345565	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-7.0	-0.31	9.03e-12	IgG glycosylation;
LGG	cis	rs6141769	0.866	rs12481717	chr20:31215664	G/A	cg13636640	chr20:31349939	DNMT3B	0.54	6.83	0.3	2.76e-11	Subjective well-being;
LGG	cis	rs11096990	0.613	rs12505690	chr4:39169045	G/A	cg24403649	chr4:39172243	NA	0.41	7.32	0.32	1.08e-12	Cognitive function;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03773681	chr2:63815918	MDH1;C2orf86	0.45	7.35	0.32	9.11e-13	Cognitive performance;
LGG	cis	rs4690686	0.509	rs11730559	chr4:177259257	A/T	cg17059388	chr4:177262070	NA	0.96	21.29	0.7	1.25e-70	Essential tremor;
LGG	cis	rs2415984	0.579	rs10151988	chr14:46955203	C/T	cg14871534	chr14:47121158	RPL10L	-0.55	-9.74	-0.41	1.61e-20	Number of children ever born;
LGG	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg04455712	chr21:45112962	RRP1B	-0.54	-10.15	-0.43	5.27e-22	Mean corpuscular volume;
LGG	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg16096631	chr1:42092165	HIVEP3	-0.62	-13.68	-0.54	5.03e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	11.27	0.46	3.23e-26	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	17.94	0.64	5.28e-55	Obesity-related traits;
LGG	cis	rs11630290	0.566	rs4777395	chr15:64161693	T/G	cg12036633	chr15:63758958	NA	0.5	7.15	0.32	3.45e-12	Iris characteristics;
LGG	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg20720597	chr2:3699334	NA	0.86	9.14	0.39	1.94e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg06916706	chr16:4465613	CORO7	-0.88	-15.38	-0.58	2.14e-43	Schizophrenia;
LGG	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg05835009	chr4:710272	PCGF3	0.48	8.18	0.36	2.71e-15	White blood cell count;
LGG	cis	rs883565	0.569	rs1298712	chr3:39169693	A/G	cg01426195	chr3:39028469	NA	0.64	13.67	0.54	5.42e-36	Handedness;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg15284433	chr12:132323321	MMP17	-0.37	-7.14	-0.31	3.72e-12	Migraine;
LGG	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg00204512	chr16:28754710	NA	0.25	7.02	0.31	8.13e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg05313129	chr8:58192883	C8orf71	-0.64	-8.3	-0.36	1.18e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17453880	1.000	rs17453880	chr5:151977841	G/A	cg10931792	chr5:152022470	NA	0.38	8.15	0.35	3.52e-15	Subjective well-being;
LGG	cis	rs3087591	0.600	rs2905808	chr17:29493993	A/T	cg24425628	chr17:29625626	OMG;NF1	0.66	9.51	0.4	1.06e-19	Hip circumference;
LGG	cis	rs7646881	0.812	rs73017539	chr3:158460743	A/G	cg19483011	chr3:158453295	NA	-0.62	-8.33	-0.36	9.16e-16	Tetralogy of Fallot;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg12813108	chr7:99719912	CNPY4	-0.64	-10.14	-0.43	6.02e-22	Lung function (FEV1/FVC);
LGG	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg16141378	chr3:129829833	LOC729375	0.39	8.67	0.37	7.37e-17	Neuroticism;
LGG	trans	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg05925327	chr15:68127851	NA	-0.43	-8.65	-0.37	8.78e-17	Restless legs syndrome;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27189623	chr16:705930	WDR90	0.42	8.14	0.35	3.64e-15	Height;
LGG	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg25008857	chr14:105974488	NA	0.56	9.58	0.41	5.98e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs7166081	1.000	rs4352000	chr15:67643705	T/C	cg05925327	chr15:68127851	NA	-0.34	-7.14	-0.31	3.67e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17445240	0.515	rs9308790	chr2:3705712	C/T	cg16123090	chr2:3699210	NA	0.54	7.78	0.34	4.66e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg26384229	chr12:38710491	ALG10B	0.63	12.22	0.49	5.67e-30	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg20607798	chr8:58055168	NA	0.57	8.77	0.38	3.33e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9443645	0.901	rs2050662	chr6:79753073	G/C	cg18132916	chr6:79620363	NA	-0.3	-8.19	-0.36	2.57e-15	Intelligence (multi-trait analysis);
LGG	cis	rs787274	0.850	rs10739378	chr9:115639631	C/T	cg13803584	chr9:115635662	SNX30	-0.65	-9.0	-0.39	5.76e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.74	-0.41	1.68e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.18	-0.32	2.75e-12	Educational attainment (years of education);
LGG	cis	rs6908034	0.607	rs73376681	chr6:19808175	A/G	cg02682789	chr6:19804855	NA	0.92	8.74	0.38	4.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.71	13.05	0.52	2.36e-33	Obesity-related traits;
LGG	cis	rs7551222	0.716	rs4245738	chr1:204506107	C/T	cg20240347	chr1:204465584	NA	-0.57	-11.37	-0.47	1.39e-26	Schizophrenia;
LGG	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-8.32	-0.36	1.02e-15	Schizophrenia;
LGG	trans	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg22232500	chr2:134024266	NCKAP5	0.6	8.19	0.36	2.62e-15	Bipolar disorder;
LGG	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg04731861	chr2:219085781	ARPC2	0.29	6.98	0.31	1.06e-11	Ulcerative colitis;
LGG	cis	rs3784262	0.607	rs4646576	chr15:58338998	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.39	-7.89	-0.34	2.24e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg14668632	chr7:2872130	GNA12	-0.36	-7.34	-0.32	9.49e-13	Height;
LGG	cis	rs12101261	0.560	rs1035144	chr14:81445121	C/T	cg06600135	chr14:81408086	NA	0.38	7.22	0.32	2.2e-12	Graves' disease;
LGG	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.09	-0.42	8.7e-22	Sudden cardiac arrest;
LGG	cis	rs3820928	0.904	rs2396431	chr2:227765488	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.44	-0.33	4.8e-13	Pulmonary function;
LGG	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs62025270	0.632	rs80036674	chr15:86114448	A/G	cg25843651	chr15:86329602	KLHL25	0.54	8.05	0.35	7.11e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.09	-0.31	4.91e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg21479132	chr6:26055353	NA	0.79	7.61	0.33	1.51e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06112835	chr11:68658793	MRPL21	0.6	10.17	0.43	4.58e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg06637938	chr14:75390232	RPS6KL1	0.76	15.17	0.58	1.71e-42	Caffeine consumption;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6594713	0.605	rs72792189	chr5:112814965	A/G	cg12552261	chr5:112820674	MCC	0.64	7.98	0.35	1.17e-14	Brain cytoarchitecture;
LGG	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg11707556	chr5:10655725	ANKRD33B	0.5	9.69	0.41	2.41e-20	Coronary artery disease;
LGG	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg00012203	chr2:219082015	ARPC2	-0.68	-12.23	-0.49	5.26e-30	Colorectal cancer;
LGG	trans	rs6598955	0.617	rs11247883	chr1:26576247	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg23758822	chr17:41437982	NA	0.9	15.84	0.59	1.74e-45	Menopause (age at onset);
LGG	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg08508325	chr11:3079039	CARS	-0.62	-13.41	-0.53	7.04e-35	Longevity;
LGG	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg16586182	chr3:47516702	SCAP	0.77	14.83	0.57	5.33e-41	Colorectal cancer;
LGG	cis	rs10484885	0.878	rs1328018	chr6:90297847	A/G	cg13799429	chr6:90582589	CASP8AP2	0.69	8.88	0.38	1.5e-17	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17712092	chr4:129076599	LARP1B	0.74	14.34	0.55	7.19e-39	Eosinophil percentage of white cells;
LGG	cis	rs3206736	0.548	rs73110554	chr7:35066531	A/G	cg13400248	chr7:35225412	NA	0.55	9.59	0.41	5.65e-20	Diastolic blood pressure;
LGG	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg16329197	chr12:53359506	NA	-0.55	-10.46	-0.44	3.99e-23	Prostate cancer;
LGG	cis	rs3784262	0.904	rs4646616	chr15:58261349	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.25	-0.36	1.61e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg05793240	chr7:2802953	GNA12	0.28	6.7	0.3	6.19e-11	Height;
LGG	cis	rs12681366	0.734	rs10112606	chr8:95396066	T/C	cg13257157	chr8:95487014	RAD54B	0.38	6.77	0.3	3.82e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11141652	chr22:24348549	GSTTP1	0.46	8.02	0.35	8.74e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1978968	0.956	rs35598889	chr22:18450794	T/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.3	-0.5	2.71e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs11785400	1.000	rs4736342	chr8:143735190	A/G	cg10596483	chr8:143751796	JRK	0.58	9.48	0.4	1.35e-19	Schizophrenia;
LGG	cis	rs71403859	0.502	rs36122765	chr16:71504183	G/C	cg08717414	chr16:71523259	ZNF19	-1.35	-18.56	-0.65	6.89e-58	Post bronchodilator FEV1;
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg27471124	chr11:109292789	C11orf87	0.48	9.59	0.41	5.27e-20	Schizophrenia;
LGG	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.77	0.38	3.42e-17	Motion sickness;
LGG	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg18681998	chr4:17616180	MED28	0.85	18.11	0.64	8.26e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.12	-0.39	2.33e-18	Lung cancer;
LGG	cis	rs988958	0.526	rs58351981	chr2:42245125	T/G	cg27428208	chr2:42229179	NA	0.47	7.5	0.33	3.39e-13	Hypospadias;
LGG	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg23029597	chr12:123009494	RSRC2	-0.97	-18.66	-0.66	2.42e-58	Body mass index;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.68e-28	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.85	-0.34	2.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg24764310	chr7:157512201	PTPRN2	-0.46	-8.86	-0.38	1.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs34172651	0.917	rs7202252	chr16:24741686	T/C	cg02428538	chr16:24856791	SLC5A11	0.48	8.14	0.35	3.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg08648136	chr8:956695	NA	0.35	7.07	0.31	5.75e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs4880487	1.000	rs4880487	chr10:1246883	C/T	cg03183215	chr10:1252341	ADARB2	-0.75	-16.61	-0.61	5.87e-49	Migraine;
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.57	-0.33	2.05e-13	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23833208	chr12:49962100	MCRS1	0.44	6.8	0.3	3.27e-11	Gut microbiome composition (summer);
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg26897989	chr16:1907736	C16orf73	-0.85	-14.04	-0.55	1.54e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7010267	0.596	rs6996754	chr8:120034870	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg02297831	chr4:17616191	MED28	0.49	9.32	0.4	4.76e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs838705	1.000	rs838705	chr2:234273242	G/A	cg17212304	chr2:234394541	USP40	0.38	7.38	0.32	7.47e-13	Calcium levels;
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg05335186	chr13:53173507	NA	0.44	8.61	0.37	1.18e-16	Lewy body disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02512878	chr4:79698168	BMP2K	0.4	6.93	0.31	1.42e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs4740619	0.819	rs9407624	chr9:15568070	T/A	cg14451791	chr9:16040625	NA	-0.33	-8.43	-0.36	4.39e-16	Body mass index;
LGG	cis	rs13314892	0.689	rs62252230	chr3:69888682	C/T	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08219700	chr8:58056026	NA	0.47	7.11	0.31	4.55e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12649615	chr1:150602426	ENSA	0.39	6.75	0.3	4.32e-11	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg13385521	chr17:29058706	SUZ12P	0.91	10.31	0.43	1.43e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6466055	0.777	rs3801281	chr7:104889573	T/C	cg04380332	chr7:105027541	SRPK2	0.38	7.06	0.31	6.31e-12	Schizophrenia;
LGG	cis	rs7172689	1.000	rs11636298	chr15:81537612	A/G	cg11808699	chr15:81528661	IL16	-0.51	-10.44	-0.44	4.49e-23	Inattentive symptoms;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg13880726	chr7:1868755	MAD1L1	0.47	8.11	0.35	4.64e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg26655873	chr3:72818019	SHQ1	0.33	7.13	0.31	3.92e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9964724	0.865	rs12967741	chr18:35168263	A/G	cg27332583	chr18:35150602	NA	-0.42	-9.13	-0.39	2.12e-18	Educational attainment (years of education);
LGG	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg00732059	chr16:71740210	PHLPP2	-0.61	-9.89	-0.42	4.6e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg27661571	chr11:113659931	NA	-0.65	-9.31	-0.4	5.27e-19	Hip circumference adjusted for BMI;
LGG	cis	rs7193541	0.682	rs28681530	chr16:74682496	C/T	cg01733217	chr16:74700730	RFWD3	1.1	34.98	0.85	4.78e-132	Multiple myeloma;
LGG	cis	rs929354	0.739	rs12533082	chr7:157014172	T/A	cg00092383	chr7:157075207	NA	-0.39	-6.78	-0.3	3.58e-11	Body mass index;
LGG	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg08807101	chr21:30365312	RNF160	0.68	11.47	0.47	5.51e-27	Cognitive test performance;
LGG	trans	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg20587970	chr11:113659929	NA	-1.36	-18.03	-0.64	1.94e-55	Hip circumference adjusted for BMI;
LGG	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg04490037	chr7:50633773	DDC	0.31	6.86	0.3	2.22e-11	Body mass index;
LGG	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg01338084	chr22:32026380	PISD	-1.4	-11.79	-0.48	3.13e-28	Age-related hearing impairment;
LGG	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00198680	chr16:28758506	NA	0.28	6.76	0.3	4.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4746818	1.000	rs10733850	chr10:70959617	C/T	cg11621586	chr10:70884670	VPS26A	1.11	16.04	0.6	2.37e-46	Left atrial antero-posterior diameter;
LGG	cis	rs6032067	0.929	rs6017503	chr20:43815103	G/A	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.5e-28	Blood protein levels;
LGG	cis	rs16933812	0.510	rs7850976	chr9:36988851	C/T	cg13738729	chr9:36989127	PAX5	-0.39	-8.71	-0.38	5.61e-17	Obesity-related traits;
LGG	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.48	-7.48	-0.33	3.82e-13	Red cell distribution width;
LGG	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg11789530	chr4:8429930	ACOX3	-0.73	-14.53	-0.56	1.16e-39	Response to antineoplastic agents;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.49	0.65	1.42e-57	Personality dimensions;
LGG	cis	rs36051895	0.632	rs62541945	chr9:5161571	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-13.72	-0.54	3.4e-36	Pediatric autoimmune diseases;
LGG	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg00376283	chr12:123451042	ABCB9	0.62	10.09	0.42	8.85e-22	Neutrophil percentage of white cells;
LGG	trans	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg18187862	chr3:45730750	SACM1L	0.66	10.96	0.45	5.15e-25	Primary sclerosing cholangitis;
LGG	cis	rs2070433	0.800	rs2073380	chr21:47863757	A/C	cg12379764	chr21:47803548	PCNT	0.64	9.07	0.39	3.33e-18	Lymphocyte counts;
LGG	trans	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg06521331	chr12:34319734	NA	0.42	7.02	0.31	7.96e-12	Morning vs. evening chronotype;
LGG	cis	rs35771425	0.642	rs11586974	chr1:211464115	A/G	cg10512769	chr1:211675356	NA	0.44	7.86	0.34	2.74e-14	Educational attainment (years of education);
LGG	cis	rs8179	0.514	rs6954290	chr7:92283098	G/T	cg15732164	chr7:92237376	CDK6	-0.52	-10.77	-0.45	2.69e-24	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg19717773	chr7:2847554	GNA12	-0.33	-7.31	-0.32	1.22e-12	Height;
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-8.96	-0.38	7.91e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg26818010	chr10:134567672	INPP5A	-0.51	-8.52	-0.37	2.21e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7923609	0.967	rs3740331	chr10:65192288	G/A	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18876405	chr7:65276391	NA	-0.54	-9.6	-0.41	5.16e-20	Aortic root size;
LGG	cis	rs4417704	0.551	rs7594525	chr2:241893722	G/C	cg14055004	chr2:241860995	NA	0.28	7.35	0.32	9.34e-13	Joint mobility (Beighton score);
LGG	trans	rs2562456	0.833	rs11666828	chr19:21525020	T/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.61	-0.33	1.6e-13	Pain;
LGG	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.36	0.56	6.09e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.57	-0.33	2.07e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg15979348	chr13:112237479	NA	-0.46	-7.93	-0.35	1.61e-14	Menarche (age at onset);
LGG	cis	rs2976388	0.647	rs2585154	chr8:143783485	C/T	cg06565975	chr8:143823917	SLURP1	0.38	9.63	0.41	4.07e-20	Urinary tract infection frequency;
LGG	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg04317338	chr11:64019027	PLCB3	0.65	8.03	0.35	8.25e-15	Mean platelet volume;
LGG	cis	rs3857067	0.740	rs10024198	chr4:95060602	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.52	-0.33	2.86e-13	QT interval;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.68	-0.34	9.84e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg02725872	chr8:58115012	NA	-0.78	-10.69	-0.44	5.41e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.99	-0.31	9.85e-12	Neuroticism;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-12.93	-0.51	7.57e-33	Menopause (age at onset);
LGG	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.42	-0.33	5.7e-13	Bone mineral density;
LGG	cis	rs17604090	0.646	rs75322793	chr7:29683176	G/A	cg19413766	chr7:29689036	LOC646762	-0.59	-7.14	-0.32	3.6e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7177699	0.557	rs4380028	chr15:79111093	C/T	cg00540400	chr15:79124168	NA	-0.54	-11.46	-0.47	6.32e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg01420254	chr6:26195488	NA	0.91	11.75	0.48	4.56e-28	Gout;Renal underexcretion gout;
LGG	cis	rs12887734	0.524	rs12588797	chr14:104300020	C/T	cg26031613	chr14:104095156	KLC1	0.55	8.76	0.38	3.8e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg20891283	chr12:69753455	YEATS4	0.75	14.44	0.56	2.81e-39	Blood protein levels;
LGG	cis	rs9914988	0.832	rs4795462	chr17:27130991	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6988985	0.589	rs13252628	chr8:143994944	T/G	cg10324643	chr8:143916377	GML	-0.42	-8.6	-0.37	1.22e-16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4919087	1.000	rs10786333	chr10:99090390	A/G	cg25902810	chr10:99078978	FRAT1	-0.5	-9.17	-0.39	1.51e-18	Monocyte count;
LGG	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg13902645	chr11:5959945	NA	-0.64	-10.06	-0.42	1.18e-21	DNA methylation (variation);
LGG	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg05697835	chr1:2722811	NA	0.3	7.16	0.32	3.19e-12	Ulcerative colitis;
LGG	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg05169099	chr5:481640	SLC9A3	0.47	6.93	0.31	1.42e-11	Fat distribution (HIV);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14944514	chr11:115375192	CADM1	0.46	6.83	0.3	2.6e-11	Gut microbiome composition (summer);
LGG	trans	rs1463132	0.553	rs1868289	chr16:10215813	G/T	cg08466385	chr6:18368294	NA	0.32	6.85	0.3	2.35e-11	HIV-1 control;
LGG	cis	rs6840360	0.904	rs73862064	chr4:152503100	T/A	cg25486957	chr4:152246857	NA	-0.39	-6.86	-0.3	2.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12282928	0.837	rs7125962	chr11:48245266	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-6.88	-0.3	1.96e-11	Migraine - clinic-based;
LGG	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg17644776	chr2:200775616	C2orf69	0.72	13.04	0.52	2.5e-33	Osteoporosis;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs72781680	1.000	rs6751655	chr2:24155478	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	10.2	0.43	3.61e-22	Lymphocyte counts;
LGG	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.48	-0.44	3.21e-23	Total body bone mineral density;
LGG	trans	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg12045294	chr17:78518616	RPTOR	0.47	7.34	0.32	9.76e-13	Glycated hemoglobin levels;
LGG	trans	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg26248373	chr2:1572462	NA	-0.71	-9.4	-0.4	2.47e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.14	0.46	1.08e-25	Hemoglobin concentration;
LGG	cis	rs11920090	0.722	rs67125861	chr3:170670753	C/T	cg09710316	chr3:170744871	SLC2A2	0.65	7.55	0.33	2.37e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6977660	0.714	rs6970798	chr7:19816741	G/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.49	0.37	2.85e-16	Thyroid stimulating hormone;
LGG	cis	rs7586673	0.930	rs7591506	chr2:161960925	T/G	cg22496339	chr2:162101262	NA	-0.34	-6.75	-0.3	4.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	trans	rs1459104	1.000	rs35851721	chr11:55199098	T/G	cg15704280	chr7:45808275	SEPT13	0.66	6.67	0.3	7.25e-11	Body mass index;
LGG	trans	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg01134436	chr17:81009848	B3GNTL1	0.83	8.68	0.37	6.89e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs240764	0.717	rs239215	chr6:101147426	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.92	0.35	1.75e-14	Neuroticism;
LGG	cis	rs36051895	0.586	rs12342421	chr9:5065750	G/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.32	-0.58	3.74e-43	Pediatric autoimmune diseases;
LGG	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06919568	chr16:89940311	TCF25	0.44	6.81	0.3	3.07e-11	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.03	-0.35	8e-15	Triglycerides;
LGG	cis	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg05084668	chr3:125655381	ALG1L	0.93	11.95	0.49	7.17e-29	Blood pressure (smoking interaction);
LGG	cis	rs11785400	0.731	rs9720504	chr8:143725502	T/C	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg04287289	chr16:89883240	FANCA	0.84	7.98	0.35	1.17e-14	Skin colour saturation;
LGG	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg12654349	chr5:56205094	C5orf35	0.58	9.91	0.42	4.11e-21	Initial pursuit acceleration;
LGG	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg20503657	chr10:835505	NA	0.49	6.78	0.3	3.69e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs4740619	0.875	rs6474966	chr9:15757537	G/A	cg14451791	chr9:16040625	NA	-0.38	-10.02	-0.42	1.57e-21	Body mass index;
LGG	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg17757837	chr7:157058334	UBE3C	-0.78	-15.89	-0.59	1.12e-45	Body mass index;
LGG	cis	rs9297145	0.761	rs12534399	chr7:98746401	A/G	cg05967295	chr7:98741636	SMURF1	0.91	15.07	0.57	4.99e-42	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg00012203	chr2:219082015	ARPC2	0.64	11.36	0.47	1.53e-26	Colorectal cancer;
LGG	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.57	-11.19	-0.46	7.06e-26	IgG glycosylation;
LGG	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-11.58	-0.47	2.1e-27	Height;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6815814	0.678	rs9715841	chr4:38774503	T/C	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.95	-0.31	1.21e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg15068132	chr12:102092402	CHPT1	-0.37	-6.78	-0.3	3.57e-11	Blood protein levels;
LGG	cis	rs11191270	0.554	rs11191265	chr10:104102118	G/A	cg15320455	chr10:103880129	LDB1	0.65	8.45	0.37	3.86e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16405210	chr4:1374714	KIAA1530	0.43	7.11	0.31	4.32e-12	Obesity-related traits;
LGG	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg08807101	chr21:30365312	RNF160	0.77	14.86	0.57	3.96e-41	Dental caries;
LGG	cis	rs6840360	0.533	rs13119490	chr4:152713412	A/G	cg22705602	chr4:152727874	NA	0.37	9.38	0.4	2.89e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.95	0.31	1.22e-11	Longevity;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg13009111	chr11:71350975	NA	0.39	8.88	0.38	1.5e-17	Monocyte count;
LGG	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg07606381	chr6:8435919	SLC35B3	-0.58	-10.18	-0.43	4.12e-22	Motion sickness;
LGG	cis	rs28437878	1	rs28437878	chr15:78807872	C/T	cg24631222	chr15:78858424	CHRNA5	0.49	7.43	0.33	5.14e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7551222	0.752	rs4245736	chr1:204486205	G/C	cg20240347	chr1:204465584	NA	-0.57	-11.37	-0.47	1.32e-26	Schizophrenia;
LGG	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	cg07245641	chr1:182991651	LAMC1	-0.39	-8.92	-0.38	1.11e-17	Colorectal cancer;
LGG	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg08250081	chr4:10125330	NA	-0.36	-7.0	-0.31	8.88e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-13.11	-0.52	1.32e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg00919237	chr7:87102261	ABCB4	-0.78	-15.84	-0.59	1.91e-45	Gallbladder cancer;
LGG	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs1322639	0.806	rs1322640	chr6:169586887	T/C	cg03254818	chr6:169586852	NA	-0.61	-10.9	-0.45	9.08e-25	Pulse pressure;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.63	0.59	1.5e-44	Body mass index;
LGG	cis	rs4731207	0.698	rs11975788	chr7:124497811	T/A	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-10.2	-0.43	3.56e-22	Prudent dietary pattern;
LGG	cis	rs17221829	0.574	rs7930964	chr11:89377313	A/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.19	-0.39	1.3e-18	Anxiety in major depressive disorder;
LGG	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.37	0.32	7.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs4740619	0.935	rs10481557	chr9:15604746	G/T	cg14451791	chr9:16040625	NA	0.39	9.8	0.41	9.69e-21	Body mass index;
LGG	cis	rs7558370	0.737	rs77681530	chr2:3712062	C/G	cg16123090	chr2:3699210	NA	0.79	7.63	0.33	1.34e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg26513180	chr16:89883248	FANCA	0.67	7.4	0.33	6.65e-13	Skin colour saturation;
LGG	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg25457927	chr22:38595422	NA	0.49	13.17	0.52	7.08e-34	Cutaneous nevi;
LGG	cis	rs10173297	0.686	rs13389263	chr2:3711989	A/G	cg17046650	chr2:3699563	NA	0.66	9.12	0.39	2.28e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9911578	1.000	rs4482353	chr17:56896834	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.55e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	1.000	rs12259315	chr10:60266152	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-17.64	-0.63	1.26e-53	Refractive error;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.04	-0.31	7.14e-12	Lung cancer;
LGG	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03909863	chr11:638404	DRD4	-0.46	-7.11	-0.31	4.54e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg06618935	chr21:46677482	NA	0.5	9.76	0.41	1.42e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg03264133	chr6:25882463	NA	-0.43	-7.61	-0.33	1.6e-13	Height;
LGG	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	8.26	0.36	1.55e-15	Neuroticism;
LGG	cis	rs9733	0.681	rs7412746	chr1:150860471	C/T	cg13175981	chr1:150552382	MCL1	0.52	8.31	0.36	1.06e-15	Tonsillectomy;
LGG	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.71	0.34	7.88e-14	Schizophrenia;
LGG	cis	rs727505	0.954	rs2239532	chr7:124405676	A/C	cg23710748	chr7:124431027	NA	-0.53	-9.9	-0.42	4.39e-21	Lewy body disease;
LGG	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	23.3	0.73	4.96e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.43	-0.4	1.95e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg19980929	chr12:42632907	YAF2	0.35	7.67	0.34	9.99e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2916247	1.000	rs6991006	chr8:93064270	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.590	rs6944104	chr7:139051120	T/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.52	8.17	0.36	2.91e-15	Longevity;
LGG	cis	rs17021463	0.673	rs12507134	chr4:95283980	C/A	cg11021082	chr4:95130006	SMARCAD1	0.39	6.79	0.3	3.39e-11	Testicular germ cell tumor;
LGG	cis	rs8018808	0.935	rs4899654	chr14:77867314	A/C	cg20045696	chr14:77926864	AHSA1	0.4	6.66	0.3	7.56e-11	Myeloid white cell count;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg03528353	chr17:61819722	STRADA	-0.4	-6.75	-0.3	4.54e-11	Prudent dietary pattern;
LGG	trans	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg26384229	chr12:38710491	ALG10B	0.63	12.22	0.49	5.91e-30	Morning vs. evening chronotype;
LGG	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg24596788	chr1:163392923	NA	-0.68	-12.77	-0.51	3.19e-32	Motion sickness;
LGG	cis	rs7122539	0.763	rs4008953	chr11:66660949	A/G	cg01599099	chr11:66649832	PC	0.46	9.27	0.4	6.98e-19	HIV-1 susceptibility;
LGG	cis	rs2692947	0.759	rs2692937	chr2:96751871	G/A	cg22654517	chr2:96458247	NA	0.37	7.29	0.32	1.39e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2274273	0.840	rs7153110	chr14:55820628	A/G	cg04306507	chr14:55594613	LGALS3	0.63	17.89	0.64	8.65e-55	Protein biomarker;
LGG	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.26	-0.36	1.57e-15	Mood instability;
LGG	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg06808227	chr14:105710500	BRF1	-0.62	-10.04	-0.42	1.33e-21	Mean platelet volume;Platelet distribution width;
LGG	cis	rs526231	0.511	rs55896090	chr5:102362004	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.23e-16	Primary biliary cholangitis;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.74	0.59	5.02e-45	Lung cancer;
LGG	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg20387954	chr3:183756860	HTR3D	0.65	13.24	0.52	3.58e-34	Anterior chamber depth;
LGG	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.99	-0.78	4.46e-97	Height;
LGG	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24308560	chr3:49941425	MST1R	0.22	6.74	0.3	4.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7715811	1.000	rs10039621	chr5:13772457	C/T	cg07548982	chr5:13769939	DNAH5	-0.48	-10.12	-0.43	7.28e-22	Subclinical atherosclerosis traits (other);
LGG	cis	rs4262150	0.774	rs56014830	chr5:152028204	T/A	cg12297329	chr5:152029980	NA	-0.82	-16.02	-0.6	2.73e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs11105298	0.891	rs10858872	chr12:89872932	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg02466173	chr16:30829666	NA	-0.56	-10.11	-0.43	7.9e-22	Multiple myeloma;
LGG	cis	rs7503807	0.688	rs11150745	chr17:78757626	A/G	cg06872548	chr17:78716983	RPTOR	0.45	9.46	0.4	1.56e-19	Obesity;
LGG	cis	rs713587	0.571	rs2918630	chr2:25314186	A/G	cg04586622	chr2:25135609	ADCY3	-0.27	-6.93	-0.31	1.41e-11	Body mass index in non-asthmatics;
LGG	cis	rs4423214	0.569	rs4944044	chr11:71120213	G/A	cg05163923	chr11:71159392	DHCR7	0.5	9.13	0.39	2.11e-18	Vitamin D levels;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.02	-0.31	7.85e-12	Lung cancer;
LGG	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg11752832	chr7:134001865	SLC35B4	0.61	10.86	0.45	1.21e-24	Mean platelet volume;
LGG	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg27661571	chr11:113659931	NA	-0.69	-9.57	-0.41	6.32e-20	Hip circumference adjusted for BMI;
LGG	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg05791153	chr7:19748676	TWISTNB	0.57	8.47	0.37	3.37e-16	Thyroid stimulating hormone;
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg16141378	chr3:129829833	LOC729375	0.43	10.08	0.42	1.02e-21	Triglycerides;
LGG	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs11229555	0.645	rs12289985	chr11:58185436	C/G	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.77	-0.34	5.03e-14	Initial pursuit acceleration;
LGG	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07570687	chr10:102243282	WNT8B	0.42	7.55	0.33	2.27e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg02733842	chr7:1102375	C7orf50	-0.52	-7.88	-0.34	2.31e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2304069	0.909	rs8073	chr5:149362400	T/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.59	-7.82	-0.34	3.54e-14	HIV-1 control;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-16.22	-0.6	3.47e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg06640241	chr16:89574553	SPG7	0.73	12.43	0.5	8.58e-31	Multiple myeloma (IgH translocation);
LGG	trans	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg25482853	chr8:67687455	SGK3	0.67	9.44	0.4	1.88e-19	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg24503407	chr1:205819492	PM20D1	-0.52	-10.34	-0.43	1.1e-22	Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25762744	chr1:155278691	FDPS	-0.41	-6.82	-0.3	2.94e-11	Menarche (age at onset);
LGG	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg00339695	chr16:24857497	SLC5A11	0.35	6.91	0.31	1.66e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.94e-30	Corneal astigmatism;
LGG	cis	rs9287719	0.967	rs12692417	chr2:10745718	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg10661904	chr17:79619235	PDE6G	-0.45	-9.17	-0.39	1.56e-18	Eye color traits;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg08888203	chr3:10149979	C3orf24	0.58	9.78	0.41	1.15e-20	Alzheimer's disease;
LGG	trans	rs2270927	0.510	rs10942765	chr5:75591324	G/A	cg13563193	chr19:33072644	PDCD5	0.86	10.17	0.43	4.63e-22	Mean corpuscular volume;
LGG	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs6076960	0.684	rs6054041	chr20:6247288	C/T	cg24759859	chr6:86352639	SYNCRIP	0.42	6.98	0.31	1.03e-11	Smooth-surface caries;
LGG	cis	rs34888975	1	rs34888975	chr16:1695896	T/TA	cg09065629	chr16:1709722	CRAMP1L	1.11	11.43	0.47	8.14e-27	Snoring;
LGG	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.28e-13	HDL cholesterol;
LGG	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21659725	chr3:3221576	CRBN	0.56	9.72	0.41	1.94e-20	Body mass index;
LGG	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.33	0.53	1.55e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11874712	0.688	rs12954742	chr18:43703223	C/G	cg26436583	chr18:43649176	PSTPIP2	-0.41	-8.21	-0.36	2.3e-15	Migraine - clinic-based;
LGG	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg13699009	chr12:122356056	WDR66	0.45	11.98	0.49	5.56e-29	Mean corpuscular volume;
LGG	cis	rs10791097	0.592	rs4936122	chr11:130734264	A/C	cg12179176	chr11:130786555	SNX19	0.88	18.03	0.64	1.96e-55	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6430585	0.528	rs309161	chr2:136688749	A/G	cg07169764	chr2:136633963	MCM6	-1.13	-19.96	-0.68	2.01e-64	Corneal structure;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg06916706	chr16:4465613	CORO7	-0.75	-13.0	-0.52	3.56e-33	Schizophrenia;
LGG	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6963495	0.818	rs73190167	chr7:105160418	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.52	9.13	0.39	2.18e-18	Menarche (age at onset);
LGG	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg23625390	chr15:77176239	SCAPER	0.49	9.82	0.42	8.53e-21	Blood metabolite levels;
LGG	trans	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg24247370	chr13:99142703	STK24	-0.42	-7.49	-0.33	3.47e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10197940	0.789	rs2444256	chr2:152280365	C/T	cg19508488	chr2:152266495	RIF1	0.61	11.32	0.47	2.08e-26	Lung cancer;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.5	8.7	0.37	5.87e-17	Longevity;
LGG	trans	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.15e-16	Blood pressure (smoking interaction);
LGG	cis	rs3008870	0.755	rs2815362	chr1:67496803	C/T	cg02640540	chr1:67518911	SLC35D1	0.37	7.21	0.32	2.33e-12	Lymphocyte percentage of white cells;
LGG	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.96e-13	Uric acid levels;
LGG	cis	rs1034435	0.505	rs5768690	chr22:48902117	G/A	cg05992904	chr22:48892994	FAM19A5	-0.69	-11.99	-0.49	5.08e-29	Late-onset Alzheimer's disease;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21963583	chr11:68658836	MRPL21	0.61	10.54	0.44	1.91e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg21545522	chr1:205238299	TMCC2	0.36	6.92	0.31	1.56e-11	Red blood cell count;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg01194073	chr14:101175302	NA	0.44	7.09	0.31	4.99e-12	Plateletcrit;
LGG	cis	rs7666738	0.830	rs3846445	chr4:99032939	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg00325661	chr8:49890786	NA	0.45	7.76	0.34	5.31e-14	Sudden cardiac arrest;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg15145296	chr3:125709740	NA	-0.62	-8.12	-0.35	4.37e-15	Blood pressure (smoking interaction);
LGG	cis	rs3820068	0.603	rs41270279	chr1:15988878	A/G	cg05660106	chr1:15850417	CASP9	0.81	16.18	0.6	5.16e-47	Systolic blood pressure;
LGG	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg22771759	chr13:24902376	NA	0.4	6.76	0.3	4.16e-11	Obesity-related traits;
LGG	cis	rs7619833	0.621	rs6779140	chr3:27285151	C/T	cg02860705	chr3:27208620	NA	0.4	7.65	0.33	1.19e-13	Breast cancer;
LGG	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.54	-12.84	-0.51	1.69e-32	Oropharynx cancer;
LGG	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg23205692	chr1:25664452	TMEM50A	0.48	10.08	0.42	9.89e-22	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-13.42	-0.53	6.31e-35	Morning vs. evening chronotype;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.6	0.33	1.66e-13	Tonsillectomy;
LGG	cis	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg03709012	chr19:19516395	GATAD2A	-0.6	-10.04	-0.42	1.37e-21	Tonsillectomy;
LGG	cis	rs2976388	1.000	rs2572910	chr8:143770135	C/G	cg06565975	chr8:143823917	SLURP1	-0.42	-10.78	-0.45	2.57e-24	Urinary tract infection frequency;
LGG	cis	rs10979	0.597	rs9496687	chr6:143908815	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-7.77	-0.34	5.19e-14	Hypospadias;
LGG	cis	rs9443645	0.527	rs9352691	chr6:79785607	C/T	cg18132916	chr6:79620363	NA	-0.26	-6.76	-0.3	4.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.76	0.3	4.09e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg12751644	chr20:60527061	NA	-0.32	-7.12	-0.31	4.16e-12	Body mass index;
LGG	cis	rs1832871	0.599	rs7752547	chr6:158751163	C/T	cg07215822	chr6:158701037	NA	0.45	8.89	0.38	1.39e-17	Height;
LGG	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.46	0.33	4.27e-13	Myopia (pathological);
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg21911579	chr5:131705225	SLC22A5	0.61	6.76	0.3	4.11e-11	Rheumatoid arthritis;
LGG	cis	rs6840360	0.530	rs11946622	chr4:152486018	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.69	-0.34	8.63e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg17211192	chr8:82754475	SNX16	-0.66	-11.31	-0.47	2.34e-26	Diastolic blood pressure;
LGG	cis	rs7568458	0.709	rs56819945	chr2:85755139	C/T	cg17127132	chr2:85788382	GGCX	0.51	7.9	0.34	1.99e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.49	-0.4	1.26e-19	Common traits (Other);
LGG	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	10.78	0.45	2.59e-24	Iron status biomarkers;
LGG	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.41	0.4	2.38e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg19223190	chr17:80058835	NA	-0.45	-8.67	-0.37	7.18e-17	Life satisfaction;
LGG	cis	rs7660520	0.524	rs114404677	chr4:183733832	G/A	cg25287198	chr4:183728479	NA	0.48	7.61	0.33	1.55e-13	Pediatric autoimmune diseases;
LGG	trans	rs4650994	1.000	rs12138561	chr1:178518784	G/T	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1355223	0.583	rs1396880	chr11:34870552	C/T	cg24088639	chr11:34937564	PDHX;APIP	0.4	7.34	0.32	9.65e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20397086	chr17:79876123	SIRT7	0.42	6.72	0.3	5.52e-11	Gut microbiome composition (summer);
LGG	cis	rs4731207	0.596	rs3903521	chr7:124668184	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.09	-0.31	5.01e-12	Cutaneous malignant melanoma;
LGG	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg02187348	chr16:89574699	SPG7	0.45	7.16	0.32	3.24e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.48	-0.5	5.03e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.37	-0.47	1.36e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs13202913	0.837	rs9397052	chr6:151779228	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	7.26	0.32	1.7e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg12310025	chr6:25882481	NA	-0.42	-7.5	-0.33	3.3e-13	Height;
LGG	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg19338460	chr6:170058176	WDR27	-0.61	-8.27	-0.36	1.4e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg17178900	chr1:205818956	PM20D1	-0.36	-7.32	-0.32	1.11e-12	Menarche (age at onset);
LGG	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg06238570	chr21:40685208	BRWD1	-0.51	-8.4	-0.36	5.53e-16	Cognitive function;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	18.75	0.66	9.25e-59	Personality dimensions;
LGG	cis	rs35160687	0.644	rs4832274	chr2:86529084	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.71	0.3	5.86e-11	Night sleep phenotypes;
LGG	cis	rs10864302	0.525	rs3752542	chr1:7430266	C/T	cg08923594	chr1:7462176	CAMTA1	0.68	8.73	0.38	4.76e-17	Photic sneeze reflex;
LGG	cis	rs10078	0.528	rs2434697	chr5:466811	T/C	cg07599136	chr5:415885	AHRR	0.84	11.48	0.47	5.24e-27	Fat distribution (HIV);
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.66	0.51	9.86e-32	Prudent dietary pattern;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg02462569	chr6:150064036	NUP43	-0.38	-7.98	-0.35	1.16e-14	Lung cancer;
LGG	cis	rs10504073	0.506	rs7007271	chr8:49941897	T/C	cg00325661	chr8:49890786	NA	0.77	15.13	0.58	2.62e-42	Blood metabolite ratios;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13903460	chr12:16035090	STRAP	0.46	6.88	0.3	1.92e-11	Gut microbiome composition (summer);
LGG	cis	rs365132	0.967	rs11740768	chr5:176339499	G/A	cg16309518	chr5:176445507	NA	-0.55	-12.22	-0.49	5.86e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs1707322	0.826	rs10890349	chr1:46249955	T/C	cg03146154	chr1:46216737	IPP	0.58	10.69	0.44	5.7e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9547996	0.879	rs9547958	chr13:38140879	A/T	cg13634560	chr13:38173852	POSTN	0.39	7.82	0.34	3.53e-14	Diastolic blood pressure;
LGG	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg26384229	chr12:38710491	ALG10B	0.94	21.95	0.71	1.02e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs526231	0.543	rs158395	chr5:102411389	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs668210	0.793	rs677350	chr11:65761967	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	9.41	0.4	2.35e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg05368731	chr17:41323189	NBR1	0.9	14.23	0.55	2.31e-38	Menopause (age at onset);
LGG	cis	rs738322	0.934	rs84473	chr22:38557326	T/C	cg03162506	chr22:38580953	NA	0.36	9.1	0.39	2.74e-18	Cutaneous nevi;
LGG	cis	rs4663969	0.873	rs759174	chr2:234668245	A/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.75	-0.34	6.02e-14	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs9650657	0.740	rs7002282	chr8:10666993	A/G	cg06636001	chr8:8085503	FLJ10661	-0.37	-6.67	-0.3	7.32e-11	Neuroticism;
LGG	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.37	0.32	8.16e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.54	-0.37	1.88e-16	Retinal vascular caliber;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg17187048	chr2:122407283	CLASP1	0.44	6.76	0.3	4.23e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs17685	0.753	rs4728586	chr7:75802869	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	24.98	0.76	8.03e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1577917	0.816	rs12664099	chr6:86648572	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.63	-0.33	1.34e-13	Response to antipsychotic treatment;
LGG	cis	rs1783925	0.600	rs672945	chr11:125295506	T/C	cg03464685	chr11:125439445	EI24	-0.57	-9.19	-0.39	1.29e-18	Formal thought disorder in schizophrenia;
LGG	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg26924012	chr15:45694286	SPATA5L1	0.43	7.19	0.32	2.64e-12	Uric acid levels;
LGG	cis	rs1801251	1.000	rs1867778	chr2:233679644	C/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.32	-0.4	4.7e-19	Coronary artery disease;
LGG	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg26384229	chr12:38710491	ALG10B	-0.64	-12.1	-0.49	1.75e-29	Morning vs. evening chronotype;
LGG	cis	rs7566780	0.516	rs4550668	chr2:16663494	A/T	cg09580478	chr2:16689509	NA	-0.44	-6.78	-0.3	3.72e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg22431228	chr1:16359049	CLCNKA	-0.39	-7.29	-0.32	1.37e-12	Systolic blood pressure;
LGG	cis	rs1816752	0.819	rs1981276	chr13:24983499	C/A	cg02811702	chr13:24901961	NA	0.39	7.22	0.32	2.16e-12	Obesity-related traits;
LGG	cis	rs548181	0.668	rs579661	chr11:125474766	A/G	cg03464685	chr11:125439445	EI24	1.34	19.96	0.68	2.13e-64	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs4919044	0.599	rs10882131	chr10:94711319	C/T	cg05127821	chr10:94822908	CYP26C1	-0.4	-7.05	-0.31	6.57e-12	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg00666640	chr1:248458726	OR2T12	0.61	9.95	0.42	2.89e-21	Common traits (Other);
LGG	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs8112449	0.894	rs12611227	chr19:10501740	A/G	cg21868191	chr19:10515988	NA	-0.47	-7.87	-0.34	2.56e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.66	-0.34	1.08e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.07e-22	Colorectal cancer;
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg24189917	chr7:1970923	MAD1L1	-0.47	-6.98	-0.31	1.06e-11	Bipolar disorder;
LGG	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg21427119	chr20:30132790	HM13	-0.41	-7.07	-0.31	5.72e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.06	0.31	6.3e-12	Educational attainment;
LGG	cis	rs2562152	0.744	rs1045001	chr16:107275	G/T	cg02949481	chr16:131562	MPG	-0.53	-7.93	-0.35	1.7e-14	Glioblastoma;
LGG	cis	rs4538187	0.802	rs35480874	chr2:64221458	T/C	cg14150252	chr2:64069583	UGP2	-0.49	-9.66	-0.41	3.11e-20	Systolic blood pressure;
LGG	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.91	-0.31	1.57e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9393692	0.557	rs989133	chr6:26336300	T/C	cg00631329	chr6:26305371	NA	-0.46	-7.37	-0.32	8e-13	Educational attainment;
LGG	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.56	11.66	0.48	1.05e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26389255	chr6:170374555	NA	0.34	6.94	0.31	1.35e-11	Electrocardiographic conduction measures;
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg18404041	chr3:52824283	ITIH1	-0.6	-11.8	-0.48	2.8e-28	Bipolar disorder;
LGG	cis	rs503734	0.934	rs487623	chr3:100963761	T/C	cg27318481	chr3:100970896	IMPG2	-0.37	-7.95	-0.35	1.46e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg03078520	chr22:18463400	MICAL3	-0.63	-12.67	-0.51	8.35e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs7647973	0.925	rs11130183	chr3:49228946	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	8.46	0.37	3.56e-16	Menarche (age at onset);
LGG	cis	rs7250872	0.647	rs12976128	chr19:1817113	A/C	cg18850929	chr19:1828978	REXO1	0.47	7.58	0.33	1.85e-13	Bipolar disorder;
LGG	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg12473912	chr3:136751656	NA	0.43	7.57	0.33	2.09e-13	Neuroticism;
LGG	cis	rs7703051	0.707	rs7730344	chr5:74587940	C/A	cg19683494	chr5:74908142	NA	0.47	8.11	0.35	4.56e-15	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg00830817	chr11:109293614	C11orf87	0.42	6.93	0.31	1.45e-11	Schizophrenia;
LGG	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg19980929	chr12:42632907	YAF2	0.34	7.42	0.33	5.71e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg21659725	chr3:3221576	CRBN	0.56	7.04	0.31	6.89e-12	Menarche (age at onset);
LGG	cis	rs9443645	0.901	rs56057971	chr6:79607182	G/A	cg18132916	chr6:79620363	NA	-0.32	-8.92	-0.38	1.13e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4689642	0.507	rs12647848	chr4:7222362	A/C	cg21353189	chr4:7228343	SORCS2	0.33	6.95	0.31	1.25e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg26384229	chr12:38710491	ALG10B	0.65	12.51	0.5	3.71e-31	Morning vs. evening chronotype;
LGG	cis	rs858239	0.601	rs10263110	chr7:23160551	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.15e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	cis	rs7766436	0.885	rs13202434	chr6:22583694	G/C	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27076777	chr19:12844868	C19orf43	-0.41	-6.77	-0.3	3.9e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs3806843	0.576	rs246062	chr5:140324580	T/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs13118945	chr4:98968586	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	9.73e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg14668632	chr7:2872130	GNA12	-0.33	-6.92	-0.31	1.51e-11	Height;
LGG	cis	rs9790314	0.613	rs11716265	chr3:160602111	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-7.57	-0.33	1.97e-13	Morning vs. evening chronotype;
LGG	cis	rs4901847	0.643	rs1998101	chr14:58598706	T/C	cg15908186	chr14:58618357	C14orf37	0.69	12.77	0.51	3.34e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs67311347	1.000	rs9875245	chr3:40442280	G/T	cg13683864	chr3:40499215	RPL14	-1.14	-25.84	-0.77	8.4e-92	Renal cell carcinoma;
LGG	cis	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg10483660	chr13:112241077	NA	-0.43	-8.84	-0.38	2.05e-17	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.49	0.53	3.13e-35	Colorectal cancer;
LGG	trans	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.76	-0.38	3.65e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg22437258	chr11:111473054	SIK2	0.54	9.49	0.4	1.23e-19	Primary sclerosing cholangitis;
LGG	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	cis	rs7106204	0.609	rs34237482	chr11:24295932	G/A	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs11039798	0.623	rs584851	chr11:48416321	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-8.94	-0.38	9.52e-18	Axial length;
LGG	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg08250081	chr4:10125330	NA	-0.48	-9.39	-0.4	2.7e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72634258	0.945	rs67717282	chr1:8041290	C/T	cg00042356	chr1:8021962	PARK7	0.85	11.27	0.46	3.3e-26	Inflammatory bowel disease;
LGG	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg24764310	chr7:157512201	PTPRN2	-0.47	-10.18	-0.43	4.21e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg05973401	chr12:123451056	ABCB9	0.45	6.68	0.3	6.95e-11	Neutrophil percentage of white cells;
LGG	cis	rs9816226	0.938	rs73052046	chr3:185832414	C/T	cg00760338	chr3:185826511	ETV5	-0.88	-12.32	-0.5	2.31e-30	Obesity;Body mass index;
LGG	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg14664628	chr15:75095509	CSK	0.56	9.71	0.41	2.04e-20	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg00166722	chr3:10149974	C3orf24	0.51	8.58	0.37	1.4e-16	Alzheimer's disease;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg08219700	chr8:58056026	NA	0.52	11.3	0.46	2.59e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs78049276	0.568	rs10305839	chr4:148400413	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.54	-0.33	2.56e-13	Pulse pressure;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.47	-0.33	3.95e-13	Triglycerides;
LGG	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg15704280	chr7:45808275	SEPT13	-0.67	-8.37	-0.36	6.96e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14312018	chr17:8151491	C17orf68;PFAS	-0.46	-7.97	-0.35	1.22e-14	Pancreatic cancer;
LGG	cis	rs77741769	0.571	rs989987	chr12:121274062	C/T	cg02419362	chr12:121203948	SPPL3	0.54	9.36	0.4	3.6e-19	Mean corpuscular volume;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg05896524	chr21:47604654	C21orf56	0.57	9.71	0.41	2.14e-20	Testicular germ cell tumor;
LGG	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.27	-0.46	3.33e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7582720	1.000	rs72926796	chr2:203827480	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07077115	chr13:28024429	MTIF3	0.38	6.8	0.3	3.2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg10189774	chr4:17578691	LAP3	0.39	6.88	0.3	1.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7633770	0.841	rs11709020	chr3:46680063	A/G	cg11219411	chr3:46661640	NA	-0.56	-12.78	-0.51	3.13e-32	Coronary artery disease;
LGG	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg24450063	chr1:156163899	SLC25A44	1.24	31.42	0.83	6.93e-117	Testicular germ cell tumor;
LGG	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg19748678	chr4:122722346	EXOSC9	0.5	9.38	0.4	3e-19	Type 2 diabetes;
LGG	trans	rs7916697	0.520	rs12246624	chr10:70036562	C/T	cg04882175	chr6:131122610	NA	-0.46	-6.91	-0.31	1.62e-11	Optic disc area;
LGG	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.51	-0.33	3.07e-13	Blood metabolite levels;
LGG	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg02487422	chr3:49467188	NICN1	0.58	10.75	0.45	3.16e-24	Resting heart rate;
LGG	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.72	0.3	5.33e-11	Parkinson's disease;
LGG	cis	rs13190036	1.000	rs28580074	chr5:176721198	T/C	cg06733329	chr5:176740039	MXD3	-0.48	-6.77	-0.3	3.94e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg20368463	chr18:77673604	PQLC1	-0.51	-9.62	-0.41	4.44e-20	Schizophrenia;
LGG	trans	rs1814175	0.645	rs847639	chr11:49919603	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs11018904	0.817	rs11601793	chr11:89946354	T/G	cg16176437	chr11:89678848	NA	0.4	6.81	0.3	3.06e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg11707556	chr5:10655725	ANKRD33B	0.66	11.79	0.48	3.11e-28	Height;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.02	-0.35	8.99e-15	Skin colour saturation;
LGG	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.38	0.32	7.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9308731	1.000	rs6746608	chr2:111892984	C/T	cg19992207	chr2:111874495	ACOXL	0.4	7.4	0.33	6.68e-13	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08677398	chr8:58056175	NA	0.46	7.69	0.34	9.11e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.0	18.23	0.65	2.18e-56	Lymphocyte percentage of white cells;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07791516	chr6:150247246	NA	0.32	7.11	0.31	4.42e-12	Testicular germ cell tumor;
LGG	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.89	0.45	9.85e-25	Mean platelet volume;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20887711	chr4:1340912	KIAA1530	-0.75	-15.48	-0.58	7.68e-44	Obesity-related traits;
LGG	cis	rs16854884	0.739	rs56196484	chr3:143786160	G/T	cg06585982	chr3:143692056	C3orf58	0.63	10.79	0.45	2.35e-24	Economic and political preferences (feminism/equality);
LGG	trans	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg16141378	chr3:129829833	LOC729375	0.4	9.63	0.41	3.82e-20	Mood instability;
LGG	cis	rs28588043	0.938	rs28641869	chr1:170972588	G/A	cg03458344	chr1:170964477	C1orf129	-0.5	-7.3	-0.32	1.3e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.58e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg08923054	chr8:41654455	ANK1	0.82	13.91	0.54	5.2e-37	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs10949834	1.000	rs34346732	chr7:73485813	G/A	cg07137043	chr7:73588983	EIF4H	-0.67	-7.55	-0.33	2.34e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg05425664	chr17:57184151	TRIM37	0.58	9.25	0.39	8.31e-19	Intelligence (multi-trait analysis);
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg14668632	chr7:2872130	GNA12	-0.35	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs6087990	0.842	rs4911253	chr20:31352585	A/G	cg13636640	chr20:31349939	DNMT3B	0.87	17.62	0.63	1.48e-53	Ulcerative colitis;
LGG	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.22	0.32	2.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2354432	0.714	rs7531962	chr1:146746023	G/A	cg25205988	chr1:146714368	CHD1L	-1.44	-19.18	-0.67	8.61e-61	Mitochondrial DNA levels;
LGG	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg23625390	chr15:77176239	SCAPER	-0.67	-13.73	-0.54	3.2e-36	Blood metabolite levels;
LGG	trans	rs61931739	0.620	rs61927753	chr12:33699277	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-8.63	-0.37	9.68e-17	Morning vs. evening chronotype;
LGG	cis	rs4356932	1.000	rs10856875	chr4:76987167	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.13e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.28	0.36	1.36e-15	Neuroticism;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg17911788	chr17:44343683	NA	0.61	9.23	0.39	9.88e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.33	0.5	2.07e-30	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg05368731	chr17:41323189	NBR1	0.96	19.18	0.67	8.86e-61	Menopause (age at onset);
LGG	cis	rs7843479	0.544	rs7839925	chr8:21792983	G/C	cg17168535	chr8:21777572	XPO7	0.8	15.49	0.58	6.76e-44	Mean corpuscular volume;
LGG	cis	rs1395	0.744	rs62130714	chr2:27532870	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.12	-0.31	4.27e-12	Blood metabolite levels;
LGG	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.41e-35	Bladder cancer;
LGG	cis	rs3741151	0.773	rs7934218	chr11:73206729	C/T	cg17517138	chr11:73019481	ARHGEF17	0.7	7.31	0.32	1.16e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs8072100	0.967	rs3760370	chr17:45695832	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg24998770	chr7:37888106	TXNDC3	0.53	8.59	0.37	1.34e-16	Alzheimer's disease (late onset);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12496657	chr2:105488809	NA	0.41	7.16	0.32	3.21e-12	Bipolar disorder;
LGG	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	10.91	0.45	8.29e-25	Post bronchodilator FEV1;
LGG	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg23250157	chr14:64679961	SYNE2	0.39	7.05	0.31	6.39e-12	Atrial fibrillation;
LGG	cis	rs9400467	0.506	rs12192147	chr6:111648057	G/C	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.74	0.3	4.6e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	8.77	0.38	3.41e-17	Platelet count;
LGG	cis	rs9677476	0.863	rs13423632	chr2:232079116	T/C	cg14237567	chr2:232057245	NA	-0.33	-6.65	-0.3	8.4e-11	Food antigen IgG levels;
LGG	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.67	-0.34	9.91e-14	Neuroticism;
LGG	cis	rs77633900	0.614	rs2439993	chr15:76861532	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-10.4	-0.44	6.59e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs3087591	0.639	rs1048317	chr17:29704002	T/C	cg24425628	chr17:29625626	OMG;NF1	0.6	12.01	0.49	4.11e-29	Hip circumference;
LGG	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg06108461	chr20:60628389	TAF4	-0.87	-16.57	-0.61	9.41e-49	Body mass index;
LGG	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg06046430	chr4:77819534	ANKRD56	0.54	11.05	0.46	2.37e-25	Emphysema distribution in smoking;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.44e-16	Life satisfaction;
LGG	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-11.0	-0.46	3.53e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2573652	0.722	rs12903458	chr15:100542673	T/G	cg14911520	chr15:100542628	ADAMTS17	-0.31	-7.47	-0.33	4.04e-13	Height;
LGG	cis	rs4789294	0.806	rs66597649	chr17:74399884	T/C	cg27112972	chr17:74378252	NA	-0.26	-6.67	-0.3	7.42e-11	Lymphocyte percentage of white cells;
LGG	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg10122326	chr6:28072925	NA	0.94	7.23	0.32	1.96e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18713687	chr3:195489789	MUC4	0.66	8.93	0.38	1.03e-17	Lung disease severity in cystic fibrosis;
LGG	cis	rs7119	0.931	rs11630540	chr15:77833625	G/A	cg17802220	chr15:77601643	NA	-0.34	-7.21	-0.32	2.34e-12	Type 2 diabetes;
LGG	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg07061783	chr6:25882402	NA	0.45	7.96	0.35	1.29e-14	Blood metabolite levels;
LGG	cis	rs4716602	0.542	rs10249935	chr7:156159781	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.57	-0.41	6.41e-20	Anti-saccade response;
LGG	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg04691961	chr3:161091175	C3orf57	-0.62	-14.62	-0.56	4.6e-40	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04533881	chr14:50583218	C14orf138	0.48	8.12	0.35	4.14e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.23	-0.39	9.84e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs58688157	0.705	rs7941547	chr11:611503	G/A	cg16486109	chr11:613632	IRF7	0.42	7.54	0.33	2.53e-13	Systemic lupus erythematosus;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg20578329	chr17:80767326	TBCD	0.4	7.4	0.33	6.5e-13	Glycated hemoglobin levels;
LGG	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg08250081	chr4:10125330	NA	-0.5	-9.42	-0.4	2.22e-19	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2964802	0.505	rs6876703	chr5:10831629	G/A	cg14521931	chr5:10832172	NA	-0.75	-16.37	-0.61	7.73e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	7.33	0.32	1.05e-12	Prudent dietary pattern;
LGG	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.46	-0.37	3.64e-16	Retinal vascular caliber;
LGG	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.2	0.36	2.3e-15	Headache;
LGG	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg13010199	chr12:38710504	ALG10B	-0.42	-7.41	-0.33	6.23e-13	Morning vs. evening chronotype;
LGG	cis	rs2033732	0.596	rs1550212	chr8:85057433	C/T	cg05716166	chr8:85095498	RALYL	0.42	6.67	0.3	7.3e-11	Body mass index;
LGG	cis	rs10744422	1.000	rs2292135	chr12:123334075	G/A	cg25930673	chr12:123319894	HIP1R	-0.73	-8.97	-0.38	7.28e-18	Schizophrenia;
LGG	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg26655873	chr3:72818019	SHQ1	0.31	6.69	0.3	6.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03100196	chr7:143077761	ZYX	0.43	7.44	0.33	4.89e-13	Bilirubin levels;
LGG	cis	rs722599	0.683	rs2302834	chr14:75279395	T/A	cg06637938	chr14:75390232	RPS6KL1	0.55	8.91	0.38	1.14e-17	IgG glycosylation;
LGG	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.36	-0.4	3.45e-19	Response to antipsychotic treatment;
LGG	cis	rs12464559	0.522	rs4316939	chr2:152525120	C/T	cg01189475	chr2:152685088	ARL5A	-0.64	-7.35	-0.32	9.27e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs7110818	0.510	rs6592652	chr11:76285579	G/A	cg17647271	chr11:76299819	NA	-0.38	-6.67	-0.3	7.29e-11	Gut microbiota (functional units);
LGG	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg07936489	chr17:37558343	FBXL20	1.0	15.63	0.59	1.55e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.65	0.3	8.22e-11	Morning vs. evening chronotype;
LGG	cis	rs7168592	1.000	rs7164068	chr15:101719380	G/C	cg24254196	chr15:101719523	CHSY1	-0.61	-6.91	-0.31	1.65e-11	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.79	0.34	4.49e-14	Homoarginine levels;
LGG	cis	rs6795744	0.908	rs13318092	chr3:13918034	A/G	cg19554555	chr3:13937349	NA	0.59	7.35	0.32	9e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs721399	0.539	rs57180587	chr8:18269581	A/T	cg18736775	chr8:18248649	NAT2	-0.76	-11.53	-0.47	3.27e-27	Blood metabolite levels;
LGG	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-7.75	-0.34	5.81e-14	Mood instability;
LGG	cis	rs4302748	0.862	rs4723481	chr7:36180023	A/G	cg24442661	chr7:36192818	EEPD1	0.55	7.32	0.32	1.11e-12	Platelet count;
LGG	cis	rs8056893	0.885	rs6499165	chr16:68326200	A/C	cg07273125	chr16:68295692	NA	0.36	6.76	0.3	4.15e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.61e-17	Fuchs's corneal dystrophy;
LGG	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.25	0.49	4.39e-30	Rheumatoid arthritis;
LGG	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.57	0.37	1.57e-16	Retinal vascular caliber;
LGG	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg02772935	chr3:125709198	NA	-0.53	-6.73	-0.3	4.99e-11	Blood pressure (smoking interaction);
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg00830817	chr11:109293614	C11orf87	0.4	6.77	0.3	4.02e-11	Schizophrenia;
LGG	cis	rs9796	0.870	rs7169375	chr15:41311046	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.5	-8.64	-0.37	9.03e-17	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02257712	chr5:150080478	RBM22	0.56	8.58	0.37	1.45e-16	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.19	-0.49	7.9e-30	Height;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04080417	chr5:1859792	NA	-0.54	-8.99	-0.39	6.41e-18	Cardiovascular disease risk factors;
LGG	cis	rs600550	0.588	rs10792268	chr11:60102631	A/G	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.8	-0.34	4.09e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs1568889	0.877	rs34351528	chr11:28304293	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	14.05	0.55	1.31e-37	Bipolar disorder;
LGG	cis	rs883115	0.846	rs6697510	chr1:224810687	T/C	cg01808320	chr1:224927238	CNIH3	-0.42	-7.51	-0.33	3.11e-13	Cancer;
LGG	trans	rs9650657	0.683	rs7830431	chr8:10700317	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.41	-0.33	5.93e-13	Neuroticism;
LGG	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg05484376	chr2:27715224	FNDC4	0.45	9.65	0.41	3.44e-20	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6547631	0.622	rs10180445	chr2:85926218	C/G	cg19805943	chr2:85933069	NA	-0.31	-6.68	-0.3	6.75e-11	Blood protein levels;
LGG	cis	rs7737355	0.738	rs13174592	chr5:130963700	C/T	cg06307176	chr5:131281290	NA	0.54	8.89	0.38	1.34e-17	Life satisfaction;
LGG	cis	rs4732038	0.739	rs2113451	chr7:134239978	C/A	cg06906464	chr7:134288099	NA	-0.48	-11.25	-0.46	4.18e-26	Longevity;
LGG	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg07930552	chr6:133119739	C6orf192	0.7	8.8	0.38	2.73e-17	Type 2 diabetes nephropathy;
LGG	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.26	-0.32	1.65e-12	Morning vs. evening chronotype;
LGG	trans	rs1459104	0.789	rs28896554	chr11:54812637	C/T	cg03929089	chr4:120376271	NA	0.7	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg12486710	chr1:178512616	C1orf220	-0.43	-8.74	-0.38	4.29e-17	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9815354	1.000	rs9828398	chr3:41895893	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-6.81	-0.3	2.98e-11	Inflammatory bowel disease;
LGG	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs2108225	0.967	rs6979054	chr7:107447488	A/C	cg18560240	chr7:107437656	SLC26A3	-0.53	-9.39	-0.4	2.72e-19	Ulcerative colitis;
LGG	cis	rs7666738	0.830	rs957742	chr4:99029409	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.23e-18	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07971474	chr2:39005158	GEMIN6	0.4	6.71	0.3	5.65e-11	Cognitive performance;
LGG	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg21926883	chr2:100939477	LONRF2	-0.49	-9.36	-0.4	3.47e-19	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg21475434	chr5:93447410	FAM172A	0.71	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg13560919	chr6:33536144	NA	-0.41	-7.3	-0.32	1.27e-12	Crohn's disease;
LGG	cis	rs7216064	1.000	rs9912770	chr17:65868233	C/T	cg12091567	chr17:66097778	LOC651250	-0.61	-8.9	-0.38	1.23e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs193541	0.593	rs1035372	chr5:122169448	C/A	cg19412675	chr5:122181750	SNX24	0.53	8.44	0.37	4.01e-16	Glucose homeostasis traits;
LGG	cis	rs1408224	0.646	rs2181786	chr13:47199611	T/C	cg24453118	chr13:47229927	LRCH1	-0.29	-6.86	-0.3	2.18e-11	QRS complex (12-leadsum);
LGG	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23213688	chr1:231473791	C1orf124;EXOC8	0.38	6.76	0.3	4.18e-11	Obesity-related traits;
LGG	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg08400814	chr5:56204995	C5orf35	-0.41	-7.37	-0.32	8.01e-13	Initial pursuit acceleration;
LGG	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.27	-0.52	2.82e-34	Diastolic blood pressure;
LGG	cis	rs1018836	0.923	rs7837230	chr8:91574281	C/T	cg16814680	chr8:91681699	NA	-0.8	-14.76	-0.57	1.1e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9398803	0.713	rs1490384	chr6:126851160	C/T	cg19875578	chr6:126661172	C6orf173	0.53	9.59	0.41	5.44e-20	Male-pattern baldness;
LGG	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.92	-0.31	1.53e-11	Retinal vascular caliber;
LGG	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.27	-0.32	1.58e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6429082	0.967	rs1305557	chr1:235627837	C/T	cg26050004	chr1:235667680	B3GALNT2	0.5	8.48	0.37	2.96e-16	Adiposity;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.25e-11	Electroencephalogram traits;
LGG	cis	rs4846580	0.660	rs1591737	chr1:219893214	C/A	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.34e-12	Total body bone mineral density;
LGG	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg22643751	chr7:855365	UNC84A	-0.44	-7.0	-0.31	9.11e-12	Cerebrospinal P-tau181p levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04412648	chr12:8179016	NA	-0.46	-6.71	-0.3	5.6e-11	Systemic lupus erythematosus;
LGG	trans	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg02030672	chr11:45687055	CHST1	-0.47	-8.71	-0.38	5.41e-17	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg15971980	chr6:150254442	NA	0.44	8.27	0.36	1.39e-15	Lung cancer;
LGG	trans	rs2562456	0.833	rs76646508	chr19:21518049	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg02403541	chr12:121454288	C12orf43	-0.53	-8.67	-0.37	7.46e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05875844	chr14:52119522	FRMD6	0.47	6.92	0.31	1.51e-11	Gut microbiome composition (summer);
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.8	0.3	3.31e-11	Bipolar disorder;
LGG	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg07148914	chr20:33460835	GGT7	0.44	7.09	0.31	5.04e-12	Height;
LGG	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs80130819	0.515	rs1793917	chr12:48384944	A/T	cg24011408	chr12:48396354	COL2A1	0.61	7.23	0.32	1.96e-12	Prostate cancer;
LGG	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-6.92	-0.31	1.52e-11	Migraine - clinic-based;
LGG	cis	rs7551222	0.714	rs2926534	chr1:204464181	C/T	cg20240347	chr1:204465584	NA	0.45	7.85	0.34	2.96e-14	Schizophrenia;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs921968	0.541	rs599973	chr2:219387273	C/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.74	-0.45	3.54e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11718455	1.000	rs17076273	chr3:44020113	A/G	cg21419209	chr3:44054225	NA	-0.44	-7.11	-0.31	4.34e-12	Coronary artery disease;
LGG	cis	rs1572438	0.868	rs4959474	chr6:878185	A/T	cg21062780	chr6:887772	NA	-0.4	-7.09	-0.31	5.17e-12	Aging;
LGG	cis	rs1784581	0.721	rs9365356	chr6:162414789	A/G	cg17173639	chr6:162384350	PARK2	0.76	17.85	0.64	1.35e-54	Itch intensity from mosquito bite;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07234876	chr8:600039	NA	-1.3	-10.84	-0.45	1.54e-24	IgG glycosylation;
LGG	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	cg07245641	chr1:182991651	LAMC1	0.43	9.64	0.41	3.65e-20	Fuchs's corneal dystrophy;
LGG	cis	rs12711979	0.509	rs10200764	chr2:3827772	C/G	cg17052675	chr2:3827356	NA	-0.51	-9.93	-0.42	3.36e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg19992207	chr2:111874495	ACOXL	-0.37	-6.82	-0.3	2.85e-11	Chronic lymphocytic leukemia;
LGG	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg01620082	chr3:125678407	NA	-0.68	-6.68	-0.3	6.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4478858	0.735	rs4531329	chr1:31817810	A/T	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs9487094	0.961	rs7773095	chr6:109727077	G/T	cg01125227	chr6:109776195	MICAL1	-0.53	-9.1	-0.39	2.62e-18	Height;
LGG	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg02002194	chr4:3960332	NA	-0.44	-8.21	-0.36	2.29e-15	Neuroticism;
LGG	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.86e-11	Total cholesterol levels;
LGG	cis	rs225245	0.817	rs225255	chr17:33955243	A/G	cg05299278	chr17:33885742	SLFN14	-0.41	-8.02	-0.35	8.46e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04772025	chr11:68637568	NA	0.71	12.24	0.49	4.64e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14893161	chr1:205819251	PM20D1	0.84	19.07	0.66	3.06e-60	Menarche (age at onset);
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.83	0.59	2.06e-45	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg20891283	chr12:69753455	YEATS4	0.86	15.41	0.58	1.56e-43	Response to diuretic therapy;
LGG	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.73	-0.54	3.14e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs12912251	0.591	rs3102118	chr15:39003475	A/C	cg10631289	chr15:39006617	NA	-0.42	-7.14	-0.31	3.75e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.15	0.39	1.84e-18	Bipolar disorder;
LGG	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.93	0.38	1.03e-17	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg05335186	chr13:53173507	NA	0.53	11.29	0.46	2.77e-26	Lewy body disease;
LGG	cis	rs208520	0.955	rs208538	chr6:66964492	C/G	cg07460842	chr6:66804631	NA	-0.89	-14.62	-0.56	4.71e-40	Exhaled nitric oxide output;
LGG	cis	rs17433780	0.860	rs61798916	chr1:89493957	G/A	cg09516651	chr1:89888402	LOC400759	0.76	17.4	0.63	1.52e-52	Carotid intima media thickness;
LGG	cis	rs12135191	0.866	rs12132017	chr1:236485213	G/A	cg21399712	chr1:236511386	NA	-0.4	-7.82	-0.34	3.57e-14	Urate levels (BMI interaction);
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.61	10.36	0.43	9.26e-23	Longevity;
LGG	cis	rs3099143	1.000	rs3106375	chr15:77142243	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.7	-0.45	5.13e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs7927771	0.507	rs1483988	chr11:47899030	C/T	cg20307385	chr11:47447363	PSMC3	0.57	10.99	0.45	3.9e-25	Subjective well-being;
LGG	cis	rs4262150	0.767	rs10041133	chr5:152328596	A/G	cg12297329	chr5:152029980	NA	0.62	10.97	0.45	4.95e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs17604090	0.701	rs60930239	chr7:29688544	A/G	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2304069	1.000	rs216126	chr5:149428424	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.54	7.29	0.32	1.33e-12	HIV-1 control;
LGG	cis	rs3820928	0.845	rs2177596	chr2:227890283	A/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.56	-0.33	2.18e-13	Pulmonary function;
LGG	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-13.6	-0.53	1.11e-35	Bladder cancer;
LGG	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg03929089	chr4:120376271	NA	-0.95	-20.13	-0.68	3.51e-65	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07866137	chr8:67579786	VCPIP1	0.46	7.7	0.34	8.18e-14	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.11	-0.7	8.96e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.25	0.49	4.6e-30	Rheumatoid arthritis;
LGG	cis	rs2760061	0.626	rs596675	chr1:228117892	G/A	cg18477163	chr1:228402036	OBSCN	-0.26	-7.23	-0.32	2.05e-12	Diastolic blood pressure;
LGG	cis	rs62209	0.800	rs11256938	chr10:11009060	A/G	cg26901096	chr10:10994189	LOC254312	0.61	9.1	0.39	2.8e-18	Alzheimer's disease (late onset);
LGG	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg04490037	chr7:50633773	DDC	-0.34	-7.39	-0.32	7.12e-13	Systemic sclerosis;
LGG	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg02725872	chr8:58115012	NA	-0.7	-10.52	-0.44	2.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12928939	0.517	rs12149307	chr16:71968091	A/C	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.37	-0.53	1.07e-34	Post bronchodilator FEV1;
LGG	cis	rs11586313	1.000	rs11586313	chr1:152890470	C/T	cg07796016	chr1:152779584	LCE1C	-0.61	-10.48	-0.44	3.19e-23	Vitamin D levels;
LGG	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg22732515	chr19:44031385	ETHE1	0.53	9.36	0.4	3.47e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg04727924	chr7:799746	HEATR2	-0.47	-7.54	-0.33	2.45e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg06521331	chr12:34319734	NA	-0.4	-7.01	-0.31	8.66e-12	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.6	-0.44	1.15e-23	Prostate cancer;
LGG	cis	rs867371	0.896	rs8033831	chr15:82513294	C/A	cg00614314	chr15:82944287	LOC80154	0.56	9.28	0.4	6.74e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg10122326	chr6:28072925	NA	0.93	7.21	0.32	2.29e-12	Hip circumference adjusted for BMI;
LGG	cis	rs59918340	0.509	rs11784862	chr8:142203452	T/C	cg23750338	chr8:142222470	SLC45A4	0.53	10.16	0.43	4.97e-22	Immature fraction of reticulocytes;
LGG	trans	rs6601327	0.767	rs10109026	chr8:9411986	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-7.19	-0.32	2.66e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg14416269	chr4:6271139	WFS1	0.45	7.55	0.33	2.41e-13	Cisplatin-induced ototoxicity;
LGG	cis	rs6547741	1.000	rs4666007	chr2:27856495	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.48	0.37	2.97e-16	Oral cavity cancer;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.09	-0.35	5.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.4	6.8	0.3	3.14e-11	Depressive symptoms;
LGG	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg23752985	chr2:85803571	VAMP8	0.4	7.67	0.34	1.02e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg03644281	chr6:41068752	NFYA;LOC221442	-0.43	-6.89	-0.31	1.81e-11	Alzheimer's disease (late onset);
LGG	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.88	-0.51	1.19e-32	Intelligence (multi-trait analysis);
LGG	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg16486109	chr11:613632	IRF7	0.41	7.31	0.32	1.14e-12	Systemic lupus erythematosus;
LGG	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs11168187	0.783	rs3764018	chr12:48120835	G/T	cg12761788	chr12:48120090	P11	0.51	8.86	0.38	1.73e-17	Vertical cup-disc ratio;
LGG	trans	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg06521331	chr12:34319734	NA	0.46	8.13	0.35	3.94e-15	Bladder cancer;
LGG	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg00012203	chr2:219082015	ARPC2	0.79	15.9	0.59	9.55e-46	Colorectal cancer;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.44	-0.4	1.83e-19	Neuroticism;
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg15971980	chr6:150254442	NA	0.43	7.43	0.33	5.45e-13	Lung cancer;
LGG	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	cg07928641	chr1:182991847	LAMC1	0.47	9.33	0.4	4.52e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg13206674	chr6:150067644	NUP43	0.58	12.87	0.51	1.29e-32	Lung cancer;
LGG	cis	rs10979	0.597	rs9403514	chr6:143907790	T/C	cg25407410	chr6:143891975	LOC285740	-0.54	-8.07	-0.35	6.26e-15	Hypospadias;
LGG	cis	rs1065852	0.526	rs2413663	chr22:42402399	T/A	cg15128208	chr22:42549153	NA	0.41	7.15	0.32	3.34e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs2587949	0.615	rs971042	chr3:4189685	G/T	cg16519197	chr3:4211558	NA	0.33	6.84	0.3	2.58e-11	Periodontitis (DPAL);
LGG	cis	rs7264396	0.790	rs6121026	chr20:34266883	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.73	-0.34	6.95e-14	Total cholesterol levels;
LGG	trans	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg06521331	chr12:34319734	NA	-0.53	-9.26	-0.4	7.96e-19	Bladder cancer;
LGG	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.98	-0.39	6.62e-18	Mean corpuscular hemoglobin;
LGG	trans	rs2562456	0.754	rs62109228	chr19:21536931	G/C	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg01420254	chr6:26195488	NA	0.85	10.96	0.45	5.09e-25	Gout;Renal underexcretion gout;
LGG	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	10.97	0.45	4.96e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg13009111	chr11:71350975	NA	-0.32	-6.96	-0.31	1.14e-11	Triglycerides;
LGG	cis	rs7106204	0.748	rs12293729	chr11:24224679	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	16.86	0.62	4.51e-50	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3008870	1.000	rs2815361	chr1:67494591	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	22.44	0.72	4.96e-76	Lymphocyte percentage of white cells;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg02725872	chr8:58115012	NA	-0.76	-11.26	-0.46	3.79e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg25664220	chr3:72788482	NA	-0.33	-8.99	-0.39	6.57e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17253792	0.822	rs78615025	chr14:56168012	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-11.93	-0.48	8.86e-29	Putamen volume;
LGG	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg06238570	chr21:40685208	BRWD1	-0.52	-8.67	-0.37	7.4e-17	Cognitive function;
LGG	cis	rs7781557	1.000	rs17474893	chr7:102480757	C/T	cg18108683	chr7:102477205	FBXL13	-0.53	-8.42	-0.36	4.88e-16	Colorectal adenoma (advanced);
LGG	cis	rs9397585	1.000	rs9397585	chr6:153396875	C/T	cg17707550	chr6:153380415	RGS17	-0.5	-11.2	-0.46	6.4e-26	Body mass index;
LGG	trans	rs9354308	0.764	rs9342509	chr6:66586197	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs34172651	0.917	rs172066	chr16:24756449	C/T	cg02428538	chr16:24856791	SLC5A11	-0.41	-7.04	-0.31	6.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11554610	chr20:30410856	MYLK2	0.42	6.68	0.3	6.86e-11	Cognitive performance;
LGG	cis	rs6728642	0.908	rs13400545	chr2:97871626	A/G	cg26665480	chr2:98280029	ACTR1B	-0.7	-8.07	-0.35	6.19e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs12949688	0.570	rs12600654	chr17:55834916	G/A	cg12582317	chr17:55822272	NA	0.48	10.97	0.45	4.97e-25	Schizophrenia;
LGG	cis	rs704	0.605	rs2227736	chr17:26693231	G/C	cg10342447	chr17:26645325	TMEM97	-0.52	-9.86	-0.42	5.81e-21	Osteoprotegerin levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02996684	chr17:73257924	GGA3;MRPS7	-0.42	-6.94	-0.31	1.36e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg01240734	chr10:71892593	AIFM2	-0.31	-6.84	-0.3	2.54e-11	Blood protein levels;
LGG	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg02002194	chr4:3960332	NA	0.44	8.16	0.35	3.17e-15	Triglycerides;
LGG	trans	rs9693857	0.520	rs7830572	chr8:9356802	T/G	cg21775007	chr8:11205619	TDH	0.46	6.7	0.3	5.89e-11	Systolic blood pressure;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg01262667	chr19:19385393	TM6SF2	0.41	10.11	0.43	7.31e-22	Tonsillectomy;
LGG	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg01448562	chr3:133502909	NA	0.8	15.91	0.59	8.75e-46	Iron status biomarkers;
LGG	cis	rs4330281	0.528	rs6763681	chr3:17409517	G/A	cg20981856	chr3:17787350	NA	0.38	7.15	0.32	3.3e-12	Schizophrenia;
LGG	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.7	0.64	6.6e-54	Vitiligo;
LGG	cis	rs7666738	0.830	rs1534318	chr4:98965058	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.85	0.34	2.88e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg15627072	chr1:2432621	PLCH2	-0.38	-8.41	-0.36	4.95e-16	Ulcerative colitis;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-8.17	-0.35	2.98e-15	Small cell lung carcinoma;
LGG	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-9.73	-0.41	1.82e-20	Menarche (age at onset);
LGG	cis	rs6594499	0.872	rs10059658	chr5:110452815	T/C	cg04022379	chr5:110408740	TSLP	0.4	7.31	0.32	1.17e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs42648	0.935	rs2188232	chr7:89958314	A/C	cg25739043	chr7:89950458	NA	-0.42	-8.91	-0.38	1.22e-17	Homocysteine levels;
LGG	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg21453758	chr17:80185943	SLC16A3	0.35	7.48	0.33	3.69e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg00666640	chr1:248458726	OR2T12	0.62	9.99	0.42	2.08e-21	Common traits (Other);
LGG	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs7084783	0.519	rs4918025	chr10:105342866	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.49	8.37	0.36	6.73e-16	Fear of pain;
LGG	cis	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg21775007	chr8:11205619	TDH	0.81	15.09	0.57	3.97e-42	Retinal vascular caliber;
LGG	cis	rs4950928	0.823	rs2486065	chr1:203167871	A/G	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.87	-0.34	2.49e-14	YKL-40 levels;
LGG	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg10224037	chr5:178157518	ZNF354A	0.77	12.68	0.51	7.54e-32	Neutrophil percentage of white cells;
LGG	cis	rs476633	0.691	rs28735224	chr15:41537539	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.47	-0.44	3.72e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg27205649	chr11:78285834	NARS2	-0.42	-6.93	-0.31	1.38e-11	Testicular germ cell tumor;
LGG	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.4	6.78	0.3	3.75e-11	Depressive symptoms;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08645402	chr16:4508243	NA	0.53	9.68	0.41	2.63e-20	Schizophrenia;
LGG	cis	rs1568889	0.938	rs7128045	chr11:28190180	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.78	0.57	8.74e-41	Bipolar disorder;
LGG	cis	rs3126085	0.935	rs11204951	chr1:152224404	A/G	cg26876637	chr1:152193138	HRNR	0.55	9.12	0.39	2.22e-18	Atopic dermatitis;
LGG	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg26924012	chr15:45694286	SPATA5L1	1.0	19.29	0.67	2.91e-61	Homoarginine levels;
LGG	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg27661571	chr11:113659931	NA	-0.67	-9.64	-0.41	3.77e-20	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg05863683	chr7:1912471	MAD1L1	0.46	8.95	0.38	8.64e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7582720	1.000	rs72926771	chr2:203801226	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2067615	0.579	rs7975576	chr12:107132501	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.37	0.5	1.4e-30	Heart rate;
LGG	cis	rs2071403	0.901	rs938325	chr2:1401447	A/G	cg06500727	chr2:1417164	TPO	-0.52	-10.16	-0.43	5.07e-22	Thyroid peroxidase antibody positivity;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs17453880	0.963	rs6869968	chr5:151945837	A/G	cg12297329	chr5:152029980	NA	-0.82	-19.05	-0.66	3.72e-60	Subjective well-being;
LGG	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg23306229	chr2:178417860	TTC30B	0.67	8.69	0.37	6.27e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07570687	chr10:102243282	WNT8B	0.44	7.31	0.32	1.16e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	9.95	0.42	2.91e-21	Cognitive ability;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.96	0.45	5.08e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.65	0.41	3.26e-20	Bone mineral density;
LGG	cis	rs7587476	0.906	rs2734674	chr2:215658895	A/G	cg04004882	chr2:215674386	BARD1	-0.53	-7.56	-0.33	2.16e-13	Neuroblastoma;
LGG	cis	rs8031584	0.678	rs798086	chr15:31129211	C/G	cg14829155	chr15:31115871	NA	0.68	11.47	0.47	5.65e-27	Huntington's disease progression;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.63	0.33	1.37e-13	Longevity;
LGG	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg16797656	chr11:68205561	LRP5	-0.5	-9.61	-0.41	4.58e-20	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs13065560	0.534	rs4481097	chr3:38909570	C/T	cg01426195	chr3:39028469	NA	0.43	8.79	0.38	2.95e-17	Interleukin-18 levels;
LGG	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg15103426	chr22:29168792	CCDC117	0.66	7.65	0.34	1.17e-13	Pancreatic cancer;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg02574844	chr11:5959923	NA	-0.54	-8.73	-0.38	4.61e-17	DNA methylation (variation);
LGG	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.68	-0.37	6.94e-17	Self-reported allergy;
LGG	cis	rs4851254	0.695	rs12712069	chr2:100766354	C/G	cg17356467	chr2:100759845	AFF3	0.41	7.12	0.31	4.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9972944	0.656	rs10083855	chr17:63773139	T/C	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg13852791	chr20:30311386	BCL2L1	0.66	8.86	0.38	1.73e-17	Mean corpuscular hemoglobin;
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.37	0.4	3.25e-19	Lung cancer;
LGG	cis	rs7928758	0.832	rs56007027	chr11:134270955	G/A	cg22777979	chr11:134283252	B3GAT1	0.91	12.49	0.5	4.84e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.55	-0.44	1.78e-23	Prostate cancer;
LGG	cis	rs8135665	0.600	rs6519097	chr22:38451465	C/T	cg19171272	chr22:38449367	NA	-0.46	-8.4	-0.36	5.6e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.19	-0.43	3.73e-22	Retinal vascular caliber;
LGG	cis	rs526231	0.543	rs7714539	chr5:102328878	G/A	cg23492399	chr5:102201601	PAM	-0.59	-9.13	-0.39	2.09e-18	Primary biliary cholangitis;
LGG	cis	rs7646881	1.000	rs59313096	chr3:158452242	G/C	cg19483011	chr3:158453295	NA	-0.66	-9.89	-0.42	4.83e-21	Tetralogy of Fallot;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg01059449	chr18:44338099	ST8SIA5	0.36	7.9	0.34	2.02e-14	Personality dimensions;
LGG	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg25237894	chr2:233734115	C2orf82	0.65	12.23	0.49	5.48e-30	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.93	0.6	7.2e-46	Lung cancer;
LGG	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs55728055	0.661	rs9619217	chr22:32043611	A/G	cg01338084	chr22:32026380	PISD	1.49	12.96	0.52	5.2e-33	Age-related hearing impairment;
LGG	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg12310025	chr6:25882481	NA	-0.65	-11.93	-0.48	8.91e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10186029	0.676	rs10804213	chr2:213964399	G/A	cg08319019	chr2:214017104	IKZF2	0.47	8.28	0.36	1.29e-15	Systemic sclerosis;
LGG	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18252515	chr7:66147081	NA	-0.4	-6.82	-0.3	2.94e-11	Aortic root size;
LGG	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg04362960	chr10:104952993	NT5C2	0.48	7.88	0.34	2.42e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.7e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs4079681	chr15:76695230	G/A	cg15268244	chr15:77196840	NA	-0.32	-7.2	-0.32	2.49e-12	Blood metabolite levels;
LGG	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg02297831	chr4:17616191	MED28	0.42	7.57	0.33	2.01e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4787491	0.765	rs8054507	chr16:30046042	G/A	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4727027	0.899	rs4727025	chr7:148862863	A/G	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs208520	0.690	rs176289	chr6:66766522	C/T	cg07460842	chr6:66804631	NA	-0.96	-18.08	-0.64	1.18e-55	Exhaled nitric oxide output;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-6.86	-0.3	2.2e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504130	0.569	rs7820177	chr8:52836933	A/T	cg24946253	chr8:52722146	PXDNL	-0.5	-8.18	-0.36	2.71e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg08250081	chr4:10125330	NA	0.65	12.39	0.5	1.22e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7267979	1.000	rs6115159	chr20:25350944	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs4293296	0.525	rs761509	chr14:54820582	G/T	cg11186706	chr14:54815745	NA	-0.59	-8.12	-0.35	4.4e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs62400317	0.859	rs62400267	chr6:45180440	C/T	cg20913747	chr6:44695427	NA	-0.63	-10.26	-0.43	2.25e-22	Total body bone mineral density;
LGG	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg22484793	chr3:52261325	TLR9	0.3	7.01	0.31	8.7e-12	Bipolar disorder;
LGG	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg23750729	chr17:78120972	EIF4A3	0.43	7.13	0.31	4.01e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs751728	0.965	rs2296743	chr6:33740025	C/T	cg25922239	chr6:33757077	LEMD2	0.7	12.3	0.5	2.74e-30	Crohn's disease;
LGG	cis	rs4776059	1.000	rs62023352	chr15:52889448	T/C	cg22715398	chr15:52968154	KIAA1370	-0.49	-8.06	-0.35	6.41e-15	Schizophrenia;
LGG	cis	rs593531	0.571	rs35170680	chr11:74085420	T/G	cg18195628	chr11:73498948	MRPL48	-0.41	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs7178909	0.902	rs8038480	chr15:90441597	T/C	cg19708238	chr15:90437601	AP3S2	0.42	7.0	0.31	9.13e-12	Common traits (Other);
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg02462569	chr6:150064036	NUP43	-0.37	-7.85	-0.34	2.97e-14	Lung cancer;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16405210	chr4:1374714	KIAA1530	0.52	8.8	0.38	2.63e-17	Obesity-related traits;
LGG	cis	rs7246760	0.748	rs61604825	chr19:9726998	C/A	cg16876255	chr19:9731953	ZNF561	0.87	7.76	0.34	5.52e-14	Pursuit maintenance gain;
LGG	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg20673091	chr1:2541236	MMEL1	0.57	12.63	0.51	1.28e-31	Ulcerative colitis;
LGG	cis	rs67311347	1.000	rs6801859	chr3:40493218	G/T	cg13683864	chr3:40499215	RPL14	1.05	24.34	0.75	7.19e-85	Renal cell carcinoma;
LGG	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg25358565	chr5:93447407	FAM172A	0.81	11.11	0.46	1.36e-25	Diabetic retinopathy;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg02951883	chr7:2050386	MAD1L1	-0.59	-11.52	-0.47	3.68e-27	Schizophrenia;
LGG	cis	rs2282032	1.000	rs17799244	chr14:90760040	C/T	cg04374321	chr14:90722782	PSMC1	0.52	7.61	0.33	1.6e-13	Longevity;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02475777	chr4:1388615	CRIPAK	0.58	10.5	0.44	2.7e-23	Longevity;
LGG	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.57	-7.91	-0.35	1.92e-14	Diabetic retinopathy;
LGG	cis	rs6960043	0.818	rs10244051	chr7:15063833	T/G	cg19272540	chr7:15055459	NA	-0.36	-7.94	-0.35	1.51e-14	Type 2 diabetes;
LGG	cis	rs9831754	0.704	rs7647185	chr3:78468807	T/C	cg06138941	chr3:78371609	NA	-0.8	-15.67	-0.59	1.09e-44	Calcium levels;
LGG	cis	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg21775007	chr8:11205619	TDH	0.44	6.92	0.31	1.48e-11	Myopia (pathological);
LGG	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg02811702	chr13:24901961	NA	0.41	7.64	0.33	1.25e-13	Obesity-related traits;
LGG	cis	rs950169	0.800	rs34302901	chr15:85110943	C/G	cg24253500	chr15:84953950	NA	0.61	11.45	0.47	6.58e-27	Schizophrenia;
LGG	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.36	-0.36	7.3e-16	Total body bone mineral density;
LGG	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg08508337	chr8:144660607	NAPRT1	0.91	7.07	0.31	5.74e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs9355610	0.609	rs62436424	chr6:167374258	A/G	cg18261144	chr6:167370276	RNASET2	-0.37	-6.71	-0.3	5.59e-11	Graves' disease;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg23758822	chr17:41437982	NA	0.85	15.43	0.58	1.22e-43	Menopause (age at onset);
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.82	-0.34	3.64e-14	Menarche (age at onset);
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.31	-0.36	1.1e-15	Personality dimensions;
LGG	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg14664628	chr15:75095509	CSK	0.68	11.16	0.46	9.05e-26	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7143963	1.000	rs7153002	chr14:103323915	C/T	cg23020514	chr14:103360112	TRAF3	0.51	9.95	0.42	2.98e-21	Body mass index;
LGG	trans	rs12517041	1.000	rs10805749	chr5:23300740	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.04e-25	Calcium levels;
LGG	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.64	0.44	8.64e-24	Calcium levels;
LGG	cis	rs8135665	0.600	rs3026682	chr22:38452482	G/A	cg13116946	chr22:38479732	SLC16A8	0.53	8.43	0.36	4.46e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg24692254	chr21:30365293	RNF160	0.84	16.84	0.62	5.65e-50	Selective IgA deficiency;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg13206674	chr6:150067644	NUP43	0.66	15.21	0.58	1.1e-42	Lung cancer;
LGG	cis	rs9388451	0.536	rs34725880	chr6:126155237	A/G	cg05901451	chr6:126070800	HEY2	-0.58	-10.37	-0.43	8.17e-23	Brugada syndrome;
LGG	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg17757837	chr7:157058334	UBE3C	0.77	15.23	0.58	9.14e-43	Body mass index;
LGG	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg25817165	chr18:72167213	CNDP2	-0.64	-12.8	-0.51	2.53e-32	Refractive error;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg05368731	chr17:41323189	NBR1	0.88	16.87	0.62	3.93e-50	Menopause (age at onset);
LGG	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.02	-0.35	8.73e-15	Retinal vascular caliber;
LGG	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	12.93	0.51	7.57e-33	Coronary artery disease;
LGG	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-9.75	-0.41	1.53e-20	Intelligence (multi-trait analysis);
LGG	trans	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg20587970	chr11:113659929	NA	-1.06	-16.1	-0.6	1.25e-46	Hip circumference adjusted for BMI;
LGG	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg07395648	chr5:131743802	NA	0.43	9.33	0.4	4.46e-19	Blood metabolite levels;
LGG	cis	rs8141529	0.529	rs5762812	chr22:29200117	T/C	cg15103426	chr22:29168792	CCDC117	0.66	6.91	0.31	1.59e-11	Lymphocyte counts;
LGG	trans	rs225245	0.755	rs6505493	chr17:34028901	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.2	-0.32	2.5e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2131877	0.645	rs11721261	chr3:194876993	C/T	cg07250128	chr3:194833983	C3orf21	0.32	6.95	0.31	1.26e-11	Non-small cell lung cancer;
LGG	cis	rs498079	0.544	rs509685	chr6:133517005	A/G	cg02446647	chr6:133562101	EYA4	0.31	7.59	0.33	1.83e-13	Total body bone mineral density;
LGG	cis	rs62025270	0.632	rs62022920	chr15:86223390	T/G	cg25843651	chr15:86329602	KLHL25	0.56	8.48	0.37	3.04e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.88	0.38	1.52e-17	Alzheimer's disease;
LGG	cis	rs8135665	0.600	rs6519097	chr22:38451465	C/T	cg13116946	chr22:38479732	SLC16A8	0.54	8.78	0.38	3.25e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03264133	chr6:25882463	NA	-0.55	-10.33	-0.43	1.18e-22	Blood metabolite levels;
LGG	cis	rs910187	0.641	rs3186647	chr20:45817067	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-9.17	-0.39	1.53e-18	Migraine;
LGG	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg03060546	chr3:49711283	APEH	-0.53	-7.11	-0.31	4.31e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs72634258	0.945	rs225132	chr1:8095500	A/C	cg00042356	chr1:8021962	PARK7	0.54	7.72	0.34	7.13e-14	Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.35e-16	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06346696	chr3:50365798	TUSC2	0.47	7.7	0.34	8.45e-14	Cognitive performance;
LGG	cis	rs9814567	1.000	rs934093	chr3:134195885	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.79	-0.51	2.84e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1062177	0.756	rs2964589	chr5:151118189	G/T	cg00977110	chr5:151150581	G3BP1	-0.47	-7.41	-0.33	5.86e-13	Preschool internalizing problems;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg13009111	chr11:71350975	NA	-0.33	-6.89	-0.3	1.78e-11	Neuroticism;
LGG	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg04989706	chr14:50066350	PPIL5	-0.61	-9.5	-0.4	1.13e-19	Carotid intima media thickness;
LGG	trans	rs56804039	1.000	rs56804039	chr8:8381029	C/G	cg02002194	chr4:3960332	NA	0.43	6.9	0.31	1.73e-11	Cervical cancer;
LGG	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.61	-0.33	1.58e-13	Mood instability;
LGG	cis	rs8017423	0.536	rs11625794	chr14:90811229	C/T	cg04374321	chr14:90722782	PSMC1	0.58	10.32	0.43	1.32e-22	Mortality in heart failure;
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg26513180	chr16:89883248	FANCA	0.66	7.42	0.33	5.78e-13	Skin colour saturation;
LGG	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.67e-12	Neuroticism;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07242783	chr1:28052377	FAM76A	-0.41	-6.89	-0.3	1.8e-11	Menarche (age at onset);
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.39	0.36	5.89e-16	Schizophrenia;
LGG	cis	rs36051895	0.632	rs62543560	chr9:5175938	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-13.31	-0.53	1.94e-34	Pediatric autoimmune diseases;
LGG	cis	rs73001065	0.551	rs56397647	chr19:19642795	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	9.73	0.41	1.82e-20	LDL cholesterol;
LGG	cis	rs16944613	0.588	rs6416553	chr15:91135411	A/G	cg26821196	chr15:91095069	CRTC3	-0.54	-7.93	-0.35	1.61e-14	Colorectal cancer;
LGG	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	-0.43	-6.73	-0.3	5.04e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg05313129	chr8:58192883	C8orf71	-0.79	-11.9	-0.48	1.15e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.819	rs7938885	chr11:71170043	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.06	-0.52	2.09e-33	Vitamin D levels;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg19168338	chr16:4465731	CORO7	-0.89	-16.82	-0.62	7.16e-50	Schizophrenia;
LGG	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg14061069	chr19:46274453	DMPK	-0.29	-8.18	-0.36	2.81e-15	Coronary artery disease;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg14773178	chr5:1868261	NA	0.36	7.85	0.34	2.95e-14	Cardiovascular disease risk factors;
LGG	trans	rs62458065	0.513	rs10268803	chr7:32547835	A/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.42	-0.33	5.82e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.33e-14	Huntington's disease progression;
LGG	cis	rs2120243	0.539	rs6441128	chr3:157121258	A/C	cg24825693	chr3:157122686	VEPH1	-0.57	-12.93	-0.52	7.18e-33	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg02487422	chr3:49467188	NICN1	0.45	8.08	0.35	5.54e-15	Parkinson's disease;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg04503457	chr17:41445688	NA	-0.38	-8.94	-0.38	9.32e-18	Menopause (age at onset);
LGG	cis	rs2120243	0.539	rs1869859	chr3:157107762	G/T	cg24825693	chr3:157122686	VEPH1	-0.58	-13.63	-0.54	8.25e-36	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg18258770	chr4:90757814	SNCA	-0.42	-7.75	-0.34	5.8e-14	Dementia with Lewy bodies;
LGG	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg05527609	chr1:210001259	C1orf107	-0.49	-6.83	-0.3	2.61e-11	Red blood cell count;
LGG	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	9.18	0.39	1.48e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05025164	chr4:1340916	KIAA1530	0.87	16.54	0.61	1.24e-48	Longevity;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.27	-0.32	1.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16318349	chr1:154917307	PBXIP1	-0.29	-7.74	-0.34	6.14e-14	Prostate cancer;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg02725872	chr8:58115012	NA	-0.98	-13.53	-0.53	2.26e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06826039	chr1:204379650	PPP1R15B	0.47	7.89	0.34	2.2e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg05368731	chr17:41323189	NBR1	0.97	19.12	0.66	1.65e-60	Menopause (age at onset);
LGG	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14893161	chr1:205819251	PM20D1	0.88	20.47	0.69	8.87e-67	Menarche (age at onset);
LGG	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.39e-16	Restless legs syndrome;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg12708336	chr17:41446283	NA	-0.3	-6.95	-0.31	1.25e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg05555928	chr11:63887634	MACROD1	-0.74	-10.76	-0.45	2.95e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07460838	chr14:21738077	HNRNPC	0.41	6.85	0.3	2.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1971762	0.527	rs1247956	chr12:53963814	G/T	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.86	-0.3	2.2e-11	Height;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06028808	chr11:68637592	NA	0.73	12.34	0.5	1.95e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.47e-12	Prostate cancer;
LGG	cis	rs7666738	0.791	rs6833691	chr4:98951508	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg17202724	chr17:61916730	SMARCD2	0.53	11.95	0.49	6.91e-29	Prudent dietary pattern;
LGG	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg21665744	chr7:39171113	POU6F2	0.42	8.72	0.38	5.21e-17	IgG glycosylation;
LGG	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg08508325	chr11:3079039	CARS	0.38	6.94	0.31	1.3e-11	Calcium levels;
LGG	cis	rs72949976	1.000	rs62186569	chr2:214034151	C/T	cg08319019	chr2:214017104	IKZF2	-0.6	-10.03	-0.42	1.52e-21	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.01	-0.35	9.7e-15	Neuroticism;
LGG	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg03806693	chr22:41940476	POLR3H	-1.0	-18.28	-0.65	1.42e-56	Vitiligo;
LGG	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg06191203	chr2:152266755	RIF1	-0.42	-6.79	-0.3	3.41e-11	Lung cancer;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.04	-0.35	7.37e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg06221963	chr1:154839813	KCNN3	-0.52	-10.71	-0.45	4.72e-24	Prostate cancer;
LGG	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg08949735	chr16:89699720	DPEP1	-0.47	-9.71	-0.41	2.13e-20	Vitiligo;
LGG	cis	rs9384488	0.524	rs9480379	chr6:157020791	A/G	cg05282260	chr6:156983263	NA	-0.49	-7.66	-0.34	1.11e-13	Alzheimer's disease biomarkers;
LGG	trans	rs7980799	0.660	rs10844589	chr12:33568844	A/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.83	-0.3	2.75e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg24247370	chr13:99142703	STK24	-0.38	-6.95	-0.31	1.27e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg23202291	chr11:1979235	NA	-0.44	-8.91	-0.38	1.16e-17	DNA methylation (variation);
LGG	cis	rs8180040	0.593	rs12715421	chr3:47084859	A/G	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.32e-42	Colorectal cancer;
LGG	cis	rs7914558	1.000	rs10883826	chr10:104830819	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.47	0.44	3.62e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg06197492	chr11:2016605	H19	0.5	10.25	0.43	2.4e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg06718696	chr17:78121285	EIF4A3	0.45	7.13	0.31	3.98e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs944722	0.967	rs2297512	chr17:26092555	G/A	cg07704981	chr17:26127537	NOS2	-0.49	-8.5	-0.37	2.7e-16	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs977987	0.843	rs11860231	chr16:75385159	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.11	0.43	7.6e-22	Dupuytren's disease;
LGG	cis	rs10752881	0.602	rs9425569	chr1:182942202	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.37	6.87	0.3	2.11e-11	Colorectal cancer;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs7572263	0.724	rs6704765	chr2:209054267	C/G	cg00164906	chr2:209055251	C2orf80	0.73	9.85	0.42	6.81e-21	Glioma;Non-glioblastoma glioma;
LGG	cis	rs7432375	0.933	rs55970317	chr3:136353193	T/G	cg21827317	chr3:136751795	NA	0.48	8.68	0.37	6.94e-17	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg16482183	chr6:26056742	HIST1H1C	0.76	11.36	0.47	1.45e-26	Iron status biomarkers;
LGG	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg03078520	chr22:18463400	MICAL3	-0.63	-12.34	-0.5	1.84e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	11.24	0.46	4.47e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.9	0.42	4.33e-21	Prudent dietary pattern;
LGG	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg17644776	chr2:200775616	C2orf69	0.6	6.89	0.3	1.89e-11	Schizophrenia;
LGG	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg04568710	chr12:38710424	ALG10B	-0.35	-7.38	-0.32	7.32e-13	Morning vs. evening chronotype;
LGG	cis	rs7766436	0.885	rs6908600	chr6:22582002	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26959380	chr12:130498820	NA	-0.46	-7.09	-0.31	4.99e-12	Systemic lupus erythematosus;
LGG	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	7.34	0.32	9.63e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	7.41	0.33	5.86e-13	Schizophrenia;
LGG	cis	rs113835537	0.529	rs75685325	chr11:66235242	A/G	cg24851651	chr11:66362959	CCS	0.43	7.25	0.32	1.77e-12	Airway imaging phenotypes;
LGG	cis	rs4430311	0.723	rs2291409	chr1:243732197	A/G	cg25706552	chr1:244017396	NA	0.63	15.08	0.57	4.24e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1580019	0.883	rs6945294	chr7:32472099	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.68	0.59	9.54e-45	Cognitive ability;
LGG	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Body mass index;
LGG	cis	rs11753937	0.735	rs572004	chr6:133580411	G/T	cg02446647	chr6:133562101	EYA4	0.27	6.69	0.3	6.63e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs1505368	0.534	rs10185241	chr2:213244124	C/T	cg20637307	chr2:213403960	ERBB4	0.46	9.02	0.39	4.96e-18	Symmetrical dimethylarginine levels;
LGG	cis	rs1595825	0.891	rs7587716	chr2:198630667	G/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.65	-0.3	8.53e-11	Ulcerative colitis;
LGG	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.4	-0.4	2.55e-19	Retinal vascular caliber;
LGG	cis	rs8077889	0.672	rs4793028	chr17:41857212	T/C	cg26893861	chr17:41843967	DUSP3	1.07	25.24	0.76	4.67e-89	Triglycerides;
LGG	cis	rs7089973	0.836	rs1046492	chr10:116624067	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.62	0.33	1.4e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	16.12	0.6	1.05e-46	Smoking behavior;
LGG	cis	rs757978	1.000	rs3732276	chr2:242343404	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.52	-0.37	2.34e-16	Chronic lymphocytic leukemia;
LGG	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	9.93	0.42	3.37e-21	Breast cancer;
LGG	cis	rs7241530	0.610	rs4799268	chr18:75896184	G/A	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs2067615	0.524	rs1922433	chr12:107077172	A/G	cg15890332	chr12:107067104	RFX4	0.44	12.86	0.51	1.45e-32	Heart rate;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg25173405	chr17:45401733	C17orf57	0.53	9.04	0.39	4.31e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs360798	0.532	rs360797	chr2:62942840	C/T	cg17519650	chr2:63277830	OTX1	-0.42	-6.69	-0.3	6.61e-11	Coronary artery disease;
LGG	cis	rs4262150	0.804	rs4958316	chr5:151942251	C/A	cg12297329	chr5:152029980	NA	-0.72	-13.56	-0.53	1.65e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs17227506	0.679	rs34945202	chr8:13433510	A/G	cg03566418	chr8:13424080	C8orf48	0.63	9.84	0.42	7.16e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg14228332	chr4:119757509	SEC24D	0.94	9.73	0.41	1.74e-20	Cannabis dependence symptom count;
LGG	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07570687	chr10:102243282	WNT8B	0.45	7.81	0.34	3.84e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6032067	0.777	rs17423897	chr20:43780307	T/C	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg18446336	chr7:2847575	GNA12	-0.31	-8.16	-0.35	3.15e-15	Height;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.16	-0.32	3.28e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg03433033	chr1:76189801	ACADM	0.81	13.85	0.54	1e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7224668	0.647	rs2292184	chr17:79244802	T/C	cg03823431	chr17:79229385	SLC38A10	0.35	7.45	0.33	4.53e-13	IgG glycosylation;
LGG	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.02	0.31	8.04e-12	Educational attainment;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19524238	chr7:2802976	GNA12	0.34	8.35	0.36	7.84e-16	Height;
LGG	cis	rs12681366	0.663	rs3099398	chr8:95479879	A/G	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg18451016	chr1:38461880	NA	-0.49	-8.77	-0.38	3.37e-17	Coronary artery disease;
LGG	cis	rs7917772	0.536	rs4919667	chr10:104426011	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.68	-12.47	-0.5	5.59e-31	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs6787172	0.702	rs827176	chr3:157964669	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs11018874	0.808	rs71471032	chr11:89888921	A/T	cg14505434	chr11:89522851	NA	0.61	7.72	0.34	7.1e-14	White blood cell types;
LGG	cis	rs2230307	0.536	rs834164	chr1:100603948	A/C	cg24955406	chr1:100503596	HIAT1	-0.58	-7.97	-0.35	1.22e-14	Carotid intima media thickness;
LGG	cis	rs3099143	1.000	rs4583202	chr15:77161676	G/A	cg21673338	chr15:77095150	SCAPER	0.65	10.34	0.43	1.09e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs6733011	0.508	rs4851173	chr2:99520608	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.93	-0.31	1.43e-11	Bipolar disorder;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg11965913	chr1:205819406	PM20D1	0.59	11.13	0.46	1.21e-25	Menarche (age at onset);
LGG	cis	rs68170813	0.652	rs8180747	chr7:107106308	T/C	cg02696742	chr7:106810147	HBP1	-0.68	-8.64	-0.37	8.86e-17	Coronary artery disease;
LGG	trans	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg06521331	chr12:34319734	NA	-0.44	-7.79	-0.34	4.59e-14	Morning vs. evening chronotype;
LGG	trans	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg05926928	chr17:57297772	GDPD1	-0.55	-9.02	-0.39	5.22e-18	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20074007	chr10:99161109	RRP12	0.42	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs7944584	0.837	rs11039149	chr11:47276675	A/G	cg20307385	chr11:47447363	PSMC3	0.67	12.41	0.5	1e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.32	-0.32	1.14e-12	HDL cholesterol;
LGG	cis	rs2470578	0.792	rs2596679	chr3:17320788	A/G	cg20981856	chr3:17787350	NA	0.36	6.89	0.3	1.86e-11	Schizophrenia;
LGG	cis	rs4601821	0.635	rs11214579	chr11:113208186	A/C	cg14373873	chr11:113211441	TTC12	-0.4	-8.01	-0.35	9.57e-15	Alcoholic chronic pancreatitis;
LGG	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.79e-16	Body mass index;
LGG	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22496380	chr5:211416	CCDC127	-1.32	-18.4	-0.65	3.94e-57	Breast cancer;
LGG	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg14979609	chr8:8086686	FLJ10661	0.28	7.09	0.31	5.07e-12	Mood instability;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs7909791	0.743	rs11191821	chr10:105597446	G/A	cg11005552	chr10:105648138	OBFC1	0.63	9.08	0.39	3.11e-18	White matter hyperintensity burden;
LGG	cis	rs6763768	0.606	rs34774173	chr3:53294445	G/C	cg16894138	chr3:53270350	TKT	0.41	7.83	0.34	3.31e-14	Bacterial meningitis;
LGG	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.53	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9473924	0.505	rs28360639	chr6:50783501	G/A	cg14470998	chr6:50812995	TFAP2B	0.69	8.16	0.35	3.14e-15	Body mass index;
LGG	cis	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs11096990	0.964	rs6831700	chr4:39256964	G/T	cg24403649	chr4:39172243	NA	0.41	6.68	0.3	7.02e-11	Cognitive function;
LGG	trans	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg10756647	chr7:56101905	PSPH	0.46	6.93	0.31	1.44e-11	Corneal structure;
LGG	cis	rs36051895	0.623	rs7859361	chr9:5237479	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-12.86	-0.51	1.46e-32	Pediatric autoimmune diseases;
LGG	cis	rs11203032	0.831	rs10887921	chr10:90925667	T/G	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	Neuroticism;
LGG	cis	rs10924309	0.737	rs1122734	chr1:245853336	A/T	cg00036263	chr1:245852353	KIF26B	-0.44	-6.9	-0.31	1.68e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs75059851	1.000	rs3758927	chr11:133829644	C/G	cg17703048	chr11:133852993	NA	0.76	13.52	0.53	2.33e-35	Schizophrenia;
LGG	trans	rs2048656	0.507	rs7813718	chr8:9676094	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.73	-0.34	6.81e-14	Schizophrenia;
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg11814155	chr7:99998594	ZCWPW1	0.63	9.72	0.41	1.9e-20	Platelet count;
LGG	cis	rs763121	0.853	rs2064088	chr22:39053382	A/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg11812906	chr14:75593930	NEK9	-0.44	-8.03	-0.35	7.86e-15	Height;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg24846343	chr22:24311635	DDTL	0.55	10.67	0.44	6.58e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.49	8.67	0.37	7.38e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.44	-0.4	1.84e-19	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs4535700	0.501	rs11765577	chr7:55997938	G/T	cg17215666	chr7:56131930	SUMF2	-0.44	-6.75	-0.3	4.5e-11	Macular telangiectasia type 2;
LGG	cis	rs4819052	0.851	rs4819042	chr21:46660072	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8133932	0.654	rs425232	chr21:47346525	G/T	cg11214348	chr21:47283868	PCBP3	-0.45	-7.88	-0.34	2.34e-14	Schizophrenia;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7481584	0.564	rs432585	chr11:3084903	G/A	cg25174290	chr11:3078921	CARS	-0.53	-9.48	-0.4	1.35e-19	Calcium levels;
LGG	cis	rs7143963	0.945	rs10144464	chr14:103331590	A/T	cg23020514	chr14:103360112	TRAF3	-0.47	-9.01	-0.39	5.27e-18	Body mass index;
LGG	trans	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.81	0.41	9.12e-21	Morning vs. evening chronotype;
LGG	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-7.76	-0.34	5.46e-14	Mood instability;
LGG	cis	rs9925964	0.687	rs12917722	chr16:30948397	A/G	cg02466173	chr16:30829666	NA	0.39	7.24	0.32	1.84e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11191205	0.686	rs10786643	chr10:103394041	A/G	cg15320455	chr10:103880129	LDB1	0.48	6.86	0.3	2.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg01966878	chr4:90757139	SNCA	-0.37	-7.6	-0.33	1.69e-13	Dementia with Lewy bodies;
LGG	cis	rs9549367	0.713	rs556990	chr13:113845059	T/C	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs9878978	0.691	rs34831690	chr3:2437643	G/A	cg21928760	chr3:2462534	CNTN4	0.39	7.77	0.34	5.23e-14	Blood pressure (smoking interaction);
LGG	cis	rs4901847	0.967	rs8015039	chr14:58547391	A/C	cg15908186	chr14:58618357	C14orf37	-0.53	-9.4	-0.4	2.6e-19	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg04568710	chr12:38710424	ALG10B	-0.43	-9.18	-0.39	1.46e-18	Morning vs. evening chronotype;
LGG	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.98	-0.31	1.03e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01570182	chr17:44337453	NA	-0.5	-9.08	-0.39	3.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.83e-12	Morning vs. evening chronotype;
LGG	cis	rs10876993	0.855	rs1689601	chr12:58049557	G/A	cg18357645	chr12:58087776	OS9	0.68	12.33	0.5	2.05e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs3784262	0.669	rs12909423	chr15:58292433	C/G	cg12031962	chr15:58353849	ALDH1A2	0.31	6.77	0.3	3.85e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs3741151	0.686	rs61516411	chr11:73302768	T/C	cg17517138	chr11:73019481	ARHGEF17	0.71	7.5	0.33	3.28e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg19399532	chr1:178512495	C1orf220	-0.42	-8.16	-0.35	3.08e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7444	0.941	rs140489	chr22:21921294	G/A	cg05046821	chr22:21984468	YDJC	-0.38	-7.11	-0.31	4.33e-12	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg13385521	chr17:29058706	SUZ12P	0.88	10.41	0.44	6.28e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs35822567	chr4:98654138	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.79	0.34	4.39e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg04731861	chr2:219085781	ARPC2	0.29	6.98	0.31	1.02e-11	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.85	0.48	1.74e-28	Prudent dietary pattern;
LGG	cis	rs2071403	0.901	rs12471910	chr2:1412802	A/G	cg06500727	chr2:1417164	TPO	-0.51	-9.65	-0.41	3.44e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs7635838	0.557	rs347615	chr3:11277284	T/A	cg00170343	chr3:11313890	ATG7	0.52	9.13	0.39	2.14e-18	HDL cholesterol;
LGG	cis	rs7129220	0.588	rs77092969	chr11:10116298	G/A	cg01453529	chr11:10209919	SBF2	-0.43	-7.09	-0.31	5.03e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg05896524	chr21:47604654	C21orf56	0.59	10.6	0.44	1.15e-23	Testicular germ cell tumor;
LGG	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.99	-0.31	9.64e-12	Mood instability;
LGG	cis	rs11229555	0.645	rs10466679	chr11:58188257	T/C	cg15696309	chr11:58395628	NA	-0.93	-14.8	-0.57	7.74e-41	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9462027	0.585	rs1201873	chr6:34550657	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.53	-0.44	2.1e-23	Systemic lupus erythematosus;
LGG	cis	rs9815354	0.951	rs6599167	chr3:41750260	A/G	cg03022575	chr3:42003672	ULK4	0.57	7.16	0.32	3.11e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg00376283	chr12:123451042	ABCB9	0.62	11.5	0.47	4.25e-27	Platelet count;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg15921436	chr17:44337874	NA	0.59	12.67	0.51	8.68e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4237845	0.837	rs7954957	chr12:58299250	C/T	cg02175503	chr12:58329896	NA	0.69	12.8	0.51	2.39e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9948	0.655	rs62152771	chr2:97447121	C/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.55e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2071426	0.755	rs11572177	chr10:96797270	T/C	cg09036531	chr10:96991505	NA	-0.42	-7.06	-0.31	6.27e-12	Blood metabolite levels;
LGG	cis	rs637571	0.726	rs669371	chr11:65674153	G/T	cg26695010	chr11:65641043	EFEMP2	0.61	10.83	0.45	1.67e-24	Eosinophil percentage of white cells;
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg18357526	chr6:26021779	HIST1H4A	0.68	12.06	0.49	2.52e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs3820928	1.000	rs11686072	chr2:227777493	A/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.37	-0.32	8.05e-13	Pulmonary function;
LGG	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg23205692	chr1:25664452	TMEM50A	0.49	10.41	0.44	6.24e-23	Erythrocyte sedimentation rate;
LGG	trans	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-11.21	-0.46	5.56e-26	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21605986	chr5:175788725	KIAA1191	0.48	8.2	0.36	2.44e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04772025	chr11:68637568	NA	0.72	12.55	0.5	2.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.753	rs11097607	chr4:99011640	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg10840412	chr1:235813424	GNG4	0.53	7.39	0.32	6.96e-13	Bipolar disorder;
LGG	trans	rs11088226	0.846	rs13047501	chr21:33924660	G/A	cg09050820	chr6:167586206	TCP10L2	0.69	10.76	0.45	3.05e-24	Gastritis;
LGG	cis	rs7294478	0.664	rs10843440	chr12:7263438	G/T	cg01074767	chr12:7262137	C1RL;LOC283314	-0.38	-10.46	-0.44	4.02e-23	Neuritic plaque;
LGG	trans	rs7980799	0.935	rs2892701	chr12:33547395	C/T	cg26384229	chr12:38710491	ALG10B	0.5	8.73	0.38	4.8e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg02753203	chr1:228287806	NA	-0.64	-11.91	-0.48	1.01e-28	Diastolic blood pressure;
LGG	cis	rs1816752	0.783	rs7317439	chr13:24985077	A/T	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07167308	chr7:39773291	LOC349114	0.42	7.29	0.32	1.35e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17618194	chr7:100861352	ZNHIT1;PLOD3	0.44	7.16	0.32	3.1e-12	Cognitive performance;
LGG	cis	rs8179	0.514	rs11773884	chr7:92285123	A/G	cg15732164	chr7:92237376	CDK6	-0.48	-9.43	-0.4	1.96e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg03511173	chr18:77590860	NA	0.64	7.87	0.34	2.45e-14	Opioid sensitivity;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.56	0.47	2.53e-27	Bipolar disorder;
LGG	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs1719271	0.831	rs1684039	chr15:65173462	G/C	cg11671771	chr15:65133392	PLEKHO2	-0.53	-7.46	-0.33	4.28e-13	Platelet count;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs1847505	0.593	rs1355904	chr13:61412681	C/T	cg25164009	chr13:61490935	NA	0.57	9.33	0.4	4.53e-19	Polychlorinated biphenyl levels;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg05896524	chr21:47604654	C21orf56	0.56	9.67	0.41	2.84e-20	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12423398	chr17:655593	ELP2P;GEMIN4	0.51	7.44	0.33	4.81e-13	Gut microbiome composition (summer);
LGG	cis	rs7296418	0.922	rs1790134	chr12:123697898	T/C	cg05973401	chr12:123451056	ABCB9	0.47	7.88	0.34	2.29e-14	Platelet count;
LGG	cis	rs9790314	0.934	rs9290074	chr3:160997823	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg12310025	chr6:25882481	NA	-0.4	-7.16	-0.32	3.28e-12	Height;
LGG	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs3762637	0.943	rs9289199	chr3:122277172	G/A	cg24169773	chr3:122142474	KPNA1	-0.61	-10.4	-0.44	6.4e-23	LDL cholesterol levels;
LGG	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg10661904	chr17:79619235	PDE6G	-0.49	-10.09	-0.42	9.02e-22	Eye color traits;
LGG	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Aortic root size;
LGG	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg15394860	chr11:2017084	H19	0.5	10.86	0.45	1.24e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg21775007	chr8:11205619	TDH	0.62	10.14	0.43	5.79e-22	Retinal vascular caliber;
LGG	cis	rs7666738	0.830	rs7672720	chr4:98938760	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.48e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs826838	0.967	rs826856	chr12:39115434	G/A	cg06521331	chr12:34319734	NA	0.42	7.56	0.33	2.14e-13	Heart rate;
LGG	cis	rs9604529	0.628	rs61967980	chr13:114743579	T/C	cg03343631	chr13:114764489	RASA3	-0.58	-8.12	-0.35	4.35e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs787274	0.718	rs10739379	chr9:115640976	C/G	cg13803584	chr9:115635662	SNX30	-0.65	-8.94	-0.38	9.49e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg26597838	chr10:835615	NA	0.91	10.9	0.45	9.09e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg01943577	chr7:158741284	NA	-0.44	-7.89	-0.34	2.18e-14	Height;
LGG	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg02886208	chr11:14281011	SPON1	0.47	9.39	0.4	2.74e-19	Mitochondrial DNA levels;
LGG	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.51	0.33	3.16e-13	Retinal vascular caliber;
LGG	cis	rs9457247	1.000	rs376574	chr6:167389956	A/T	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.57	16.33	0.6	1.18e-47	Oropharynx cancer;
LGG	cis	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg07460842	chr6:66804631	NA	-0.48	-8.06	-0.35	6.33e-15	Metabolite levels;
LGG	cis	rs4780401	0.609	rs7205994	chr16:11815964	C/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.87	-0.51	1.27e-32	Rheumatoid arthritis;
LGG	cis	rs11700980	0.636	rs116306600	chr21:30232542	T/C	cg08807101	chr21:30365312	RNF160	-0.63	-7.0	-0.31	9.03e-12	QRS complex (12-leadsum);
LGG	cis	rs7312933	0.501	rs3810793	chr12:42729407	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.48	7.58	0.33	1.89e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.19	0.43	3.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.58	-0.47	2.07e-27	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.55	-0.5	2.55e-31	Chronic sinus infection;
LGG	trans	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.48	-0.33	3.88e-13	Triglycerides;
LGG	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	11.94	0.49	7.6e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs74781061	0.929	rs59946128	chr15:74785347	A/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.04	-0.31	7.08e-12	Endometriosis;
LGG	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.91	-0.31	1.63e-11	Monocyte count;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg14926445	chr8:58193284	C8orf71	-0.9	-13.31	-0.53	1.82e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2735413	0.918	rs4888733	chr16:78080523	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg11584989	chr19:19387371	SF4	-0.38	-6.68	-0.3	6.81e-11	Tonsillectomy;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.91	-0.48	1.01e-28	Alzheimer's disease;
LGG	cis	rs9972944	0.756	rs1421032	chr17:63766368	A/C	cg07283582	chr17:63770753	CCDC46	-0.42	-8.27	-0.36	1.42e-15	Total body bone mineral density;
LGG	cis	rs3820068	0.581	rs16851855	chr1:15930869	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs9463078	0.764	rs3846896	chr6:44834094	G/A	cg25276700	chr6:44698697	NA	-0.41	-8.65	-0.37	8.6e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg13009111	chr11:71350975	NA	-0.32	-7.2	-0.32	2.39e-12	Systolic blood pressure;
LGG	cis	rs17428076	0.514	rs3821095	chr2:172684006	A/G	cg21435375	chr2:172878103	MAP1D	-0.38	-9.73	-0.41	1.77e-20	Myopia;
LGG	cis	rs8067287	0.688	rs11654431	chr17:16844863	C/A	cg26910001	chr17:16838321	NA	-0.4	-7.92	-0.35	1.74e-14	Diabetic kidney disease;
LGG	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg06636001	chr8:8085503	FLJ10661	-0.59	-10.99	-0.45	4.17e-25	Triglycerides;
LGG	cis	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs9486719	1.000	rs2263192	chr6:96873037	C/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs539514	0.690	rs1924214	chr13:76317632	A/G	cg04757411	chr13:76259545	LMO7	-0.27	-7.05	-0.31	6.56e-12	Type 1 diabetes;
LGG	trans	rs12517041	0.935	rs36035239	chr5:23294107	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.77	0.3	3.89e-11	Type 2 diabetes;
LGG	cis	rs7216064	0.953	rs80135947	chr17:65836001	A/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.81	-0.38	2.63e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs13323323	1.000	rs13323323	chr3:44333324	G/T	cg02073558	chr3:44770973	ZNF501	0.52	7.17	0.32	3.01e-12	IgG glycosylation;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg00031303	chr3:195681400	NA	0.53	8.43	0.36	4.48e-16	Pancreatic cancer;
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.97	-0.31	1.12e-11	Bipolar disorder;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg15971980	chr6:150254442	NA	0.45	8.24	0.36	1.81e-15	Lung cancer;
LGG	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.48	-0.37	2.94e-16	Bone mineral density;
LGG	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg02002194	chr4:3960332	NA	0.44	8.08	0.35	5.51e-15	Monocyte count;
LGG	cis	rs936229	0.813	rs2168519	chr15:75080872	T/C	cg14664628	chr15:75095509	CSK	-1.13	-25.69	-0.77	3.99e-91	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7289126	1.000	rs4820328	chr22:38635679	C/T	cg25457927	chr22:38595422	NA	-0.33	-8.09	-0.35	5.18e-15	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.44	0.4	1.76e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3008870	1.000	rs975451	chr1:67480060	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.99	23.16	0.73	2.23e-79	Lymphocyte percentage of white cells;
LGG	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	8.23	0.36	1.95e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.25	0.52	3.2e-34	Breast cancer;
LGG	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.63	-0.37	1.01e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.99	-0.42	2.05e-21	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.837	rs11168334	chr12:37961768	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.03	-0.39	4.81e-18	Bladder cancer;
LGG	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg21972741	chr5:435613	AHRR	0.5	8.95	0.38	8.72e-18	Cystic fibrosis severity;
LGG	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.6	-0.33	1.63e-13	Iron status biomarkers;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg05091796	chr16:4465799	CORO7	-0.61	-9.95	-0.42	2.96e-21	Schizophrenia;
LGG	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg10847948	chr11:71163743	NADSYN1	-0.66	-12.99	-0.52	3.9e-33	Vitamin D levels;
LGG	trans	rs11875185	0.510	rs76808753	chr18:55593489	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4919694	0.901	rs12264456	chr10:104830634	C/T	cg04362960	chr10:104952993	NT5C2	1.06	15.51	0.58	5.26e-44	Arsenic metabolism;
LGG	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg18681998	chr4:17616180	MED28	-0.81	-15.11	-0.57	3.2e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg22681709	chr2:178499509	PDE11A	-0.44	-7.87	-0.34	2.61e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9486719	0.843	rs3860229	chr6:97036559	T/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.64	-0.33	1.25e-13	Migraine;Coronary artery disease;
LGG	cis	rs4132509	0.948	rs12032342	chr1:243834360	G/A	cg25706552	chr1:244017396	NA	0.51	7.57	0.33	2.02e-13	RR interval (heart rate);
LGG	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg16980736	chr17:78789706	RPTOR	-0.65	-8.57	-0.37	1.6e-16	Myopia (pathological);
LGG	cis	rs12410462	0.591	rs2819507	chr1:227707534	A/G	cg23173402	chr1:227635558	NA	0.39	7.29	0.32	1.37e-12	Major depressive disorder;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.37e-35	Personality dimensions;
LGG	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg09060608	chr5:178986726	RUFY1	0.47	8.45	0.37	3.72e-16	Lung cancer;
LGG	cis	rs13102973	0.640	rs6857995	chr4:135834193	G/A	cg14419869	chr4:135874104	NA	0.51	9.46	0.4	1.54e-19	Subjective well-being;
LGG	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg13482628	chr17:19912719	NA	0.63	12.4	0.5	1.13e-30	Schizophrenia;
LGG	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	11.01	0.46	3.23e-25	Emphysema distribution in smoking;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg00800038	chr16:89945340	TCF25	-0.61	-8.52	-0.37	2.25e-16	Skin colour saturation;
LGG	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.47	0.47	5.44e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg13444842	chr1:152974279	SPRR3	-0.41	-7.77	-0.34	5.09e-14	Inflammatory skin disease;
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.87	0.42	5.77e-21	Skin colour saturation;
LGG	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg03060546	chr3:49711283	APEH	-0.64	-10.59	-0.44	1.32e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg26384229	chr12:38710491	ALG10B	-0.89	-21.06	-0.7	1.43e-69	Heart rate;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg13206674	chr6:150067644	NUP43	0.67	15.46	0.58	9.2e-44	Lung cancer;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.38	0.4	2.94e-19	Neuroticism;
LGG	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25214090	chr10:38739885	LOC399744	0.64	11.32	0.47	2.1e-26	Corneal astigmatism;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-9.02	-0.39	4.92e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	7.41	0.33	5.97e-13	HDL cholesterol;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg04287289	chr16:89883240	FANCA	0.84	8.02	0.35	8.81e-15	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.4	-0.44	6.75e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg15971980	chr6:150254442	NA	0.45	8.97	0.38	7.15e-18	Testicular germ cell tumor;
LGG	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-7.08	-0.31	5.35e-12	Response to amphetamines;
LGG	cis	rs944722	0.967	rs2274894	chr17:26099171	T/G	cg07704981	chr17:26127537	NOS2	-0.51	-8.91	-0.38	1.19e-17	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1816752	0.633	rs8002387	chr13:24990444	A/G	cg02811702	chr13:24901961	NA	0.39	7.35	0.32	9.08e-13	Obesity-related traits;
LGG	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg22307297	chr20:60903441	LAMA5	0.43	8.32	0.36	9.81e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg08885076	chr2:99613938	TSGA10	-0.42	-7.91	-0.35	1.89e-14	Chronic sinus infection;
LGG	cis	rs1185460	0.934	rs10892328	chr11:118942654	T/A	cg23280166	chr11:118938394	VPS11	0.57	10.14	0.43	5.85e-22	Coronary artery disease;
LGG	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.36	0.32	8.54e-13	Systemic lupus erythematosus;
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.03	-0.31	7.64e-12	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.76	-0.38	3.74e-17	Menopause (age at onset);
LGG	cis	rs6456156	0.524	rs6934043	chr6:167466449	C/T	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs9815354	1.000	rs73079316	chr3:41863859	G/A	cg03022575	chr3:42003672	ULK4	0.73	9.19	0.39	1.3e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6977660	0.714	rs12672257	chr7:19813466	C/T	cg07541023	chr7:19748670	TWISTNB	0.6	8.18	0.36	2.85e-15	Thyroid stimulating hormone;
LGG	cis	rs1975974	0.511	rs66766425	chr17:21755307	G/T	cg18423549	chr17:21743878	NA	-0.53	-8.12	-0.35	4.27e-15	Psoriasis;
LGG	trans	rs970548	0.688	rs2082109	chr10:45931102	T/C	cg14222797	chr10:16859974	RSU1	-0.63	-7.61	-0.33	1.58e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.23	-0.43	2.73e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg05863683	chr7:1912471	MAD1L1	0.48	9.32	0.4	4.73e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg27446573	chr6:127587934	RNF146	1.14	22.6	0.72	9.29e-77	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08753297	chr6:56716612	DST	0.45	7.56	0.33	2.13e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg26174226	chr8:58114915	NA	-0.46	-6.85	-0.3	2.32e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs457717	0.867	rs442721	chr5:75921981	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.33	6.73	0.3	5.19e-11	Hearing impairment;
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.96	-0.54	3.38e-37	Alzheimer's disease;
LGG	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg12395012	chr8:11607386	GATA4	-0.39	-7.1	-0.31	4.78e-12	Monocyte count;
LGG	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg24675658	chr1:53192096	ZYG11B	0.62	13.32	0.53	1.78e-34	Monocyte count;
LGG	cis	rs7712401	0.540	rs416763	chr5:122317241	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs2117029	0.521	rs7953169	chr12:49578172	G/A	cg24176009	chr12:49580217	TUBA1A	0.63	12.28	0.5	3.45e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9771228	0.895	rs378642	chr7:32359278	G/A	cg27532318	chr7:32358331	NA	-0.43	-6.75	-0.3	4.36e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg09699651	chr6:150184138	LRP11	0.51	8.98	0.38	7.08e-18	Lung cancer;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-10.32	-0.43	1.34e-22	Prudent dietary pattern;
LGG	cis	rs67366981	1.000	rs8006117	chr14:77713279	G/A	cg22824376	chr14:77648248	TMEM63C	0.69	7.36	0.32	8.35e-13	Obsessive-compulsive symptoms;
LGG	cis	rs4664304	0.658	rs2667016	chr2:160868855	C/T	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.91	-0.34	1.92e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.18	0.32	2.77e-12	Schizophrenia;
LGG	cis	rs6558174	0.965	rs2009212	chr8:22491496	G/A	cg03733263	chr8:22462867	KIAA1967	0.64	10.81	0.45	1.9e-24	Breast cancer;
LGG	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.57e-13	Refractive error;
LGG	cis	rs10463554	0.853	rs246903	chr5:102589454	A/G	cg23492399	chr5:102201601	PAM	-0.45	-6.81	-0.3	2.98e-11	Parkinson's disease;
LGG	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg00717180	chr2:96193071	NA	-0.42	-7.53	-0.33	2.76e-13	HDL cholesterol;
LGG	cis	rs9814567	1.000	rs7433663	chr3:134235790	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.25	-0.52	3.28e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.57	0.63	2.49e-53	Cognitive function;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs7681423	1.000	rs2066854	chr4:155535181	T/A	cg20735720	chr4:155535218	FGG	-0.59	-10.86	-0.45	1.24e-24	Fibrinogen;
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.63	0.41	3.85e-20	Bipolar disorder;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.21	-0.43	3.25e-22	Lymphocyte counts;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	8.69	0.37	6.37e-17	Obesity-related traits;
LGG	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg06212747	chr3:49208901	KLHDC8B	0.61	9.38	0.4	3.07e-19	Menarche (age at onset);
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg08355456	chr11:67383691	NA	0.5	8.58	0.37	1.47e-16	Mean corpuscular volume;
LGG	cis	rs244293	0.760	rs8069447	chr17:53008873	A/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-6.81	-0.3	2.98e-11	Menarche (age at onset);
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg09327250	chr3:195381832	NA	-0.4	-6.93	-0.31	1.38e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs2652834	1.000	rs2652816	chr15:63403368	C/T	cg05507819	chr15:63340323	TPM1	0.61	8.43	0.36	4.51e-16	HDL cholesterol;
LGG	cis	rs7483296	0.705	rs2513638	chr11:115412993	T/C	cg02820646	chr11:115398838	NA	0.42	7.28	0.32	1.42e-12	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs5758511	0.680	rs1033460	chr22:42619308	A/G	cg15128208	chr22:42549153	NA	0.74	11.33	0.47	1.93e-26	Birth weight;
LGG	cis	rs35160687	0.798	rs2367233	chr2:86541666	A/C	cg10973622	chr2:86423274	IMMT	-0.41	-7.31	-0.32	1.21e-12	Night sleep phenotypes;
LGG	cis	rs9487094	0.626	rs12201444	chr6:110059954	G/A	cg16315928	chr6:109776240	MICAL1	0.43	7.51	0.33	3.04e-13	Height;
LGG	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-6.89	-0.31	1.81e-11	Schizophrenia;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	trans	rs9650657	0.737	rs4841436	chr8:10594474	A/C	cg06636001	chr8:8085503	FLJ10661	0.45	8.03	0.35	8.39e-15	Neuroticism;
LGG	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg19508488	chr2:152266495	RIF1	0.57	10.42	0.44	5.43e-23	Lung cancer;
LGG	cis	rs9596837	0.514	rs2785820	chr13:54272778	A/C	ch.13.53330881F	chr13:54432880	NA	-0.41	-6.68	-0.3	6.95e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.38e-12	Vitiligo;
LGG	cis	rs7444	0.941	rs181362	chr22:21932068	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26260369	chr14:68141723	VTI1B	0.46	7.66	0.34	1.09e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2273669	0.585	rs11153159	chr6:109376647	C/G	cg05315195	chr6:109294784	ARMC2	-0.56	-6.86	-0.3	2.24e-11	Prostate cancer;
LGG	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg06241208	chr11:30344200	C11orf46	0.5	6.69	0.3	6.53e-11	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03452623	chr4:187889614	NA	-1.04	-30.39	-0.82	2.39e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15128208	chr22:42549153	NA	-0.39	-7.19	-0.32	2.6e-12	Cognitive function;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.06	-0.35	6.37e-15	Total body bone mineral density;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg26155939	chr18:44337853	ST8SIA5	-0.41	-7.5	-0.33	3.26e-13	Personality dimensions;
LGG	cis	rs7580658	0.613	rs12478656	chr2:128196520	G/T	cg10021288	chr2:128175891	PROC	-0.67	-13.64	-0.54	7.67e-36	Protein C levels;
LGG	cis	rs714031	0.934	rs5750870	chr22:40067640	G/A	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.59	-0.56	5.98e-40	Schizophrenia;
LGG	cis	rs12200560	0.505	rs1334318	chr6:97079610	A/G	cg06623918	chr6:96969491	KIAA0776	-0.44	-7.39	-0.33	6.69e-13	Coronary heart disease;
LGG	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg16077055	chr2:106428750	NCK2	0.29	7.5	0.33	3.31e-13	Addiction;
LGG	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9849248	0.627	rs7432826	chr3:88190768	C/A	cg14530983	chr3:88190749	ZNF654	-0.58	-7.91	-0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	32.71	0.84	1.86e-122	Prudent dietary pattern;
LGG	cis	rs6088590	1.000	rs6119524	chr20:33373813	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.38	0.32	7.56e-13	Coronary artery disease;
LGG	cis	rs6604026	0.922	rs35183060	chr1:93346928	A/T	cg22128645	chr1:93425802	FAM69A	0.39	7.05	0.31	6.53e-12	Multiple sclerosis;
LGG	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	10.64	0.44	8.16e-24	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg13206674	chr6:150067644	NUP43	0.61	13.82	0.54	1.31e-36	Lung cancer;
LGG	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg06889755	chr6:150326021	RAET1K	-0.34	-6.89	-0.3	1.83e-11	Alopecia areata;
LGG	trans	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg19980929	chr12:42632907	YAF2	0.36	8.1	0.35	5e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs727563	0.565	rs132774	chr22:42031953	C/G	cg03806693	chr22:41940476	POLR3H	-0.88	-14.45	-0.56	2.59e-39	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg22842854	chr12:123319900	HIP1R	0.53	6.72	0.3	5.42e-11	Schizophrenia;
LGG	cis	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.21	-0.36	2.23e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.8	0.41	9.91e-21	Ovarian reserve;
LGG	trans	rs9388451	0.626	rs1268074	chr6:126107791	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.59	-10.9	-0.45	8.5e-25	Brugada syndrome;
LGG	cis	rs6840360	0.642	rs2724580	chr4:152372505	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	3.08e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9652490	0.536	rs8028808	chr15:77967416	G/A	cg07015412	chr15:78025260	NA	-0.48	-7.36	-0.32	8.59e-13	Essential tremor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14212634	chr20:3189677	ITPA	0.43	7.22	0.32	2.1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	4.91e-17	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg12463550	chr7:65579703	CRCP	0.79	8.64	0.37	9.54e-17	Diabetic kidney disease;
LGG	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.62	0.41	4.33e-20	Rheumatoid arthritis;
LGG	cis	rs75059851	0.756	rs11223659	chr11:133844708	G/A	cg20042908	chr11:133852938	NA	-0.76	-13.86	-0.54	8.99e-37	Schizophrenia;
LGG	cis	rs7916697	0.578	rs1900002	chr10:70004552	G/C	cg18338521	chr10:69995036	NA	-0.33	-7.17	-0.32	3.05e-12	Optic disc area;
LGG	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.21	-0.32	2.27e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.77	-0.3	3.84e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9902453	0.868	rs9902340	chr17:28476458	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.08	-0.52	1.72e-33	Coffee consumption (cups per day);
LGG	cis	rs11750568	1.000	rs1445846	chr5:178507069	A/G	cg10208897	chr5:178548229	ADAMTS2	0.42	6.67	0.3	7.49e-11	Height;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs17776563	0.959	rs28687418	chr15:89115862	G/A	cg05013243	chr15:89149849	MIR1179	-0.53	-10.65	-0.44	7.5e-24	Thyroid hormone levels;
LGG	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg12473912	chr3:136751656	NA	0.44	7.67	0.34	9.91e-14	Neuroticism;
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg05868516	chr6:26286170	HIST1H4H	0.46	7.81	0.34	3.84e-14	Educational attainment;
LGG	cis	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19171272	chr22:38449367	NA	-0.56	-11.01	-0.46	3.36e-25	Glioblastoma;Glioma;
LGG	trans	rs7507204	0.680	rs12975645	chr19:3419132	A/G	cg08382705	chr11:45687319	CHST1	-0.52	-7.09	-0.31	5.05e-12	Height;
LGG	cis	rs66887589	0.776	rs10518337	chr4:120574874	A/C	cg09307838	chr4:120376055	NA	-0.46	-7.82	-0.34	3.61e-14	Diastolic blood pressure;
LGG	trans	rs6825911	0.597	rs6533516	chr4:111340345	T/C	cg10580549	chr19:53101634	ZNF137	0.57	7.21	0.32	2.31e-12	Blood pressure;
LGG	trans	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg22232500	chr2:134024266	NCKAP5	0.58	8.17	0.35	3.02e-15	Bipolar disorder;
LGG	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.79	-0.34	4.34e-14	HDL cholesterol;
LGG	cis	rs7666738	0.830	rs13112131	chr4:98976784	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg15394860	chr11:2017084	H19	0.44	9.44	0.4	1.86e-19	DNA methylation (variation);
LGG	cis	rs2235649	0.667	rs2575372	chr16:1815757	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.48	-7.68	-0.34	9.7e-14	Blood metabolite levels;
LGG	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg04851639	chr8:1020857	NA	-0.45	-9.42	-0.4	2.19e-19	Schizophrenia;
LGG	cis	rs6743376	0.556	rs2515398	chr2:113819334	A/C	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.16e-18	Inflammatory biomarkers;
LGG	cis	rs7546668	1.000	rs2295626	chr1:15874961	T/A	cg21858823	chr1:15850916	CASP9	0.37	6.84	0.3	2.54e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg01620082	chr3:125678407	NA	-0.78	-7.96	-0.35	1.37e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-10.46	-0.44	3.81e-23	Morning vs. evening chronotype;
LGG	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg11984989	chr7:158649758	WDR60	1.01	14.31	0.55	1e-38	Height;
LGG	cis	rs9916302	0.904	rs8065963	chr17:37681332	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.69	-0.59	8.14e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg08621203	chr6:150244597	RAET1G	0.52	9.68	0.41	2.71e-20	Testicular germ cell tumor;
LGG	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg10792982	chr14:105748885	BRF1	0.65	12.85	0.51	1.51e-32	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg25358565	chr5:93447407	FAM172A	1.36	16.72	0.61	1.94e-49	Diabetic retinopathy;
LGG	cis	rs10461617	0.617	rs6874733	chr5:56069600	A/G	cg12654349	chr5:56205094	C5orf35	-0.41	-6.87	-0.3	2.06e-11	Type 2 diabetes;
LGG	cis	rs4478858	0.684	rs7549343	chr1:31752260	A/G	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.54e-11	Alcohol dependence;
LGG	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg11812906	chr14:75593930	NEK9	0.55	10.23	0.43	2.74e-22	Height;
LGG	cis	rs9814567	0.896	rs7653880	chr3:134345788	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.3	-0.5	2.7e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.43	-0.36	4.57e-16	Lung cancer;
LGG	cis	rs6460942	0.915	rs75158182	chr7:12456059	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg22875332	chr1:76189707	ACADM	0.56	9.24	0.39	9.19e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16632433	chr5:180649677	TRIM41	0.47	7.78	0.34	4.68e-14	Cognitive performance;
LGG	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.89	0.42	4.67e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg25801113	chr15:45476975	SHF	0.87	19.46	0.67	4.63e-62	Uric acid levels;
LGG	cis	rs58649573	0.530	rs7049026	chr9:126786918	A/C	cg14112217	chr9:126806003	NA	0.39	7.73	0.34	6.56e-14	Post-traumatic stress disorder;
LGG	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg23205692	chr1:25664452	TMEM50A	0.48	10.33	0.43	1.22e-22	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.92e-43	Prudent dietary pattern;
LGG	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg09222892	chr1:25734099	RHCE	0.46	9.57	0.41	6.27e-20	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.82	17.9	0.64	7.78e-55	Multiple sclerosis;
LGG	cis	rs9810089	0.934	rs66691851	chr3:136154828	C/T	cg21827317	chr3:136751795	NA	0.47	8.53	0.37	2.04e-16	Gestational age at birth (child effect);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01532694	chr8:8243576	NA	0.47	7.79	0.34	4.33e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg10207240	chr12:122356781	WDR66	0.26	7.86	0.34	2.78e-14	Mean corpuscular volume;
LGG	cis	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12926788	0.546	rs200537	chr16:24747787	G/C	cg06028605	chr16:24865363	SLC5A11	-0.48	-7.84	-0.34	3.06e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg18357526	chr6:26021779	HIST1H4A	0.89	17.35	0.63	2.71e-52	Intelligence (multi-trait analysis);
LGG	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.72	10.71	0.45	4.76e-24	Post bronchodilator FEV1;
LGG	cis	rs2735413	0.846	rs12923290	chr16:78079956	A/G	cg04733911	chr16:78082701	NA	-0.78	-18.8	-0.66	5.42e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs13256369	0.774	rs11777719	chr8:8581038	A/G	cg02002194	chr4:3960332	NA	-0.4	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.31	-0.32	1.19e-12	Bipolar disorder;
LGG	cis	rs151349	0.555	rs151343	chr20:57583298	C/G	cg23907860	chr20:57583709	CTSZ	0.54	11.27	0.46	3.42e-26	Platelet distribution width;
LGG	cis	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg09085632	chr11:111637200	PPP2R1B	-0.78	-14.61	-0.56	5.2e-40	Primary sclerosing cholangitis;
LGG	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	8.91e-16	Personality dimensions;
LGG	cis	rs9831754	0.526	rs11927217	chr3:78341723	A/G	cg06138941	chr3:78371609	NA	-0.6	-12.16	-0.49	1.07e-29	Calcium levels;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11890956	chr21:40555474	PSMG1	1.21	30.94	0.82	8.7e-115	Cognitive function;
LGG	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg06697600	chr4:7070879	GRPEL1	-0.51	-8.95	-0.38	8.76e-18	Monocyte percentage of white cells;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.92	-0.48	9.57e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6500395	0.775	rs8050844	chr16:48665696	A/G	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13401104	0.796	rs1466204	chr2:237121154	C/A	cg15742758	chr2:237126235	ASB18	0.41	6.67	0.3	7.28e-11	Educational attainment;
LGG	cis	rs7949566	0.630	rs4312076	chr11:126292961	C/T	cg05055844	chr11:126275997	ST3GAL4	0.34	6.9	0.31	1.67e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg09845145	chr15:78292470	TBC1D2B	-0.61	-10.65	-0.44	7.78e-24	Coronary artery disease or large artery stroke;
LGG	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg19773385	chr1:10388646	KIF1B	0.3	6.67	0.3	7.35e-11	Hepatocellular carcinoma;
LGG	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.24	-0.36	1.84e-15	Body mass index;
LGG	cis	rs4845570	0.920	rs3811414	chr1:151763246	A/G	cg07092448	chr1:151763213	TDRKH	-1.16	-24.12	-0.75	7.16e-84	Coronary artery disease;
LGG	cis	rs7267979	1.000	rs6050626	chr20:25428261	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg16486109	chr11:613632	IRF7	0.41	6.8	0.3	3.23e-11	Systemic lupus erythematosus;
LGG	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg01200585	chr1:228362443	C1orf69	-0.42	-7.52	-0.33	2.91e-13	Diastolic blood pressure;
LGG	cis	rs4924935	1.000	rs1737947	chr17:18831432	A/G	cg26378065	chr17:18585709	ZNF286B	-0.46	-7.68	-0.34	9.84e-14	Pancreatic cancer;
LGG	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.02	0.35	8.48e-15	Bipolar disorder;
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.88	-0.34	2.33e-14	Neuroticism;
LGG	cis	rs8032158	0.574	rs56093337	chr15:56133199	A/T	cg05129572	chr15:56138634	NEDD4	-0.53	-9.33	-0.4	4.32e-19	Keloid;
LGG	cis	rs3767633	0.925	rs10737502	chr1:161792321	G/A	cg09175582	chr1:161736000	ATF6	0.68	8.38	0.36	6.47e-16	IgG glycosylation;
LGG	cis	rs6565189	0.865	rs4350585	chr16:30505513	A/G	cg17640201	chr16:30407289	ZNF48	0.43	6.78	0.3	3.63e-11	Tonsillectomy;
LGG	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	17.17	0.62	1.66e-51	Smoking behavior;
LGG	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg13010199	chr12:38710504	ALG10B	-0.71	-14.1	-0.55	7.97e-38	Bladder cancer;
LGG	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.44	7.45	0.33	4.68e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg12708336	chr17:41446283	NA	0.28	6.76	0.3	4.05e-11	Menopause (age at onset);
LGG	cis	rs8077889	0.917	rs72836559	chr17:41913529	C/T	cg26893861	chr17:41843967	DUSP3	0.94	15.79	0.59	3.06e-45	Triglycerides;
LGG	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg17230874	chr3:125932073	NA	0.53	10.93	0.45	6.58e-25	Metabolite levels;
LGG	cis	rs3540	0.960	rs11853271	chr15:91025830	C/T	cg22089800	chr15:90895588	ZNF774	0.52	8.03	0.35	8e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	18.01	0.64	2.3e-55	Chronic sinus infection;
LGG	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.46	0.72	4.17e-76	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	6.91e-19	Diabetic kidney disease;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	7.82	0.34	3.67e-14	Bipolar disorder;
LGG	cis	rs7617773	0.743	rs4632568	chr3:48367819	C/T	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg02398342	chr17:80708632	TBCD;FN3K	0.5	9.0	0.39	5.84e-18	Glycated hemoglobin levels;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg16359550	chr11:109292809	C11orf87	0.41	7.82	0.34	3.67e-14	Schizophrenia;
LGG	cis	rs4731207	0.536	rs10254199	chr7:124655116	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.73	-0.3	5.01e-11	Cutaneous malignant melanoma;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.86	0.45	1.27e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.81	-0.38	2.52e-17	Personality dimensions;
LGG	cis	rs10231759	0.617	rs7809861	chr7:150513061	A/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.55	0.37	1.86e-16	Height;
LGG	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.78	-0.68	1.42e-63	Height;
LGG	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg21775007	chr8:11205619	TDH	-0.5	-8.23	-0.36	1.86e-15	Joint mobility (Beighton score);
LGG	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.07	0.6	1.68e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg15268244	chr15:77196840	NA	0.4	8.76	0.38	3.78e-17	Blood metabolite levels;
LGG	cis	rs1595825	0.945	rs73056883	chr2:198824638	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.78	-0.3	3.65e-11	Ulcerative colitis;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg18681998	chr4:17616180	MED28	0.89	20.54	0.69	4.16e-67	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg17809284	chr5:56205270	C5orf35	0.54	10.16	0.43	4.86e-22	Initial pursuit acceleration;
LGG	cis	rs7134594	0.677	rs2075432	chr12:109874230	A/G	cg19025524	chr12:109796872	NA	-0.44	-8.96	-0.38	8.3e-18	HDL cholesterol;
LGG	cis	rs4919087	0.962	rs3814164	chr10:98982749	G/A	cg25902810	chr10:99078978	FRAT1	0.53	9.88	0.42	5.13e-21	Monocyte count;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg13880726	chr7:1868755	MAD1L1	0.44	7.54	0.33	2.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg11266682	chr4:10021025	SLC2A9	0.44	8.5	0.37	2.61e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17102423	0.755	rs8009396	chr14:65573438	C/G	cg26396452	chr14:65542826	MAX	0.43	8.34	0.36	8.57e-16	Obesity-related traits;
LGG	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg22643751	chr7:855365	UNC84A	-0.55	-14.09	-0.55	8.63e-38	Perceived unattractiveness to mosquitoes;
LGG	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg02886208	chr11:14281011	SPON1	-0.48	-10.1	-0.42	8.55e-22	Mitochondrial DNA levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16841133	chr18:77496360	CTDP1	0.36	6.67	0.3	7.46e-11	Pancreatic cancer;
LGG	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg06347083	chr6:39282316	KCNK17	0.44	12.58	0.5	1.93e-31	Type 2 diabetes;
LGG	cis	rs4888262	0.526	rs7191754	chr16:74610850	G/T	cg01733217	chr16:74700730	RFWD3	0.84	16.8	0.62	8.23e-50	Testicular germ cell tumor;
LGG	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg08885076	chr2:99613938	TSGA10	0.43	9.08	0.39	3.17e-18	Chronic sinus infection;
LGG	cis	rs3771570	1.000	rs60604866	chr2:242352257	A/G	cg21155796	chr2:242212141	HDLBP	0.75	9.71	0.41	2.03e-20	Prostate cancer;
LGG	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.84	-0.38	1.99e-17	Bone mineral density;
LGG	cis	rs2247341	0.965	rs798761	chr4:1731126	G/A	cg05026014	chr4:1749153	NA	-0.34	-9.55	-0.41	7.32e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg01631408	chr1:248437212	OR2T33	-0.42	-7.09	-0.31	5.19e-12	Common traits (Other);
LGG	cis	rs881375	0.678	rs10760130	chr9:123701990	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	10.03	0.42	1.53e-21	Rheumatoid arthritis;
LGG	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg20302533	chr7:39170763	POU6F2	0.35	8.16	0.35	3.08e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2270450	0.513	rs1421378	chr6:46703513	C/T	cg10156739	chr6:46714674	LOC100287718	0.3	7.11	0.31	4.31e-12	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	9.17	0.39	1.6e-18	Lymphocyte counts;
LGG	cis	rs3816183	0.626	rs7563640	chr2:42811663	G/A	cg14631114	chr2:43023945	NA	0.34	6.76	0.3	4.21e-11	Hypospadias;
LGG	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg08999081	chr20:33150536	PIGU	0.44	11.09	0.46	1.6e-25	Coronary artery disease;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7432375	0.901	rs900818	chr3:136471815	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.43	-0.36	4.58e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7902587	0.677	rs2488001	chr10:105671132	A/G	cg11005552	chr10:105648138	OBFC1	0.66	7.09	0.31	4.97e-12	Lung cancer;Serous borderline ovarian cancer;Thyroid cancer;Low-grade serous and serous borderline ovarian cancer;
LGG	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg15704280	chr7:45808275	SEPT13	-0.9	-14.45	-0.56	2.55e-39	Height;
LGG	cis	rs9831754	0.906	rs2089934	chr3:78382448	T/C	cg06138941	chr3:78371609	NA	-0.9	-18.39	-0.65	4e-57	Calcium levels;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05665937	chr4:1216051	CTBP1	-0.5	-8.97	-0.38	7.66e-18	Obesity-related traits;
LGG	cis	rs4363385	0.791	rs512198	chr1:153006245	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.54	-0.37	1.99e-16	Inflammatory skin disease;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18404041	chr3:52824283	ITIH1	-0.44	-8.52	-0.37	2.19e-16	Bipolar disorder;
LGG	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg15485101	chr11:133734466	NA	0.6	10.62	0.44	9.85e-24	Childhood ear infection;
LGG	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.54	-6.89	-0.31	1.8e-11	Smoking behavior;
LGG	cis	rs2244613	0.882	rs7204940	chr16:55794983	C/G	cg02649063	chr16:55794731	CES4	0.48	7.7	0.34	8.41e-14	Response to dabigatran etexilate treatment;
LGG	cis	rs67133203	0.851	rs970099	chr12:51479268	T/C	cg14688905	chr12:51403056	SLC11A2	0.7	10.64	0.44	8.45e-24	Urinary tract infection frequency;
LGG	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg09537434	chr19:41945824	ATP5SL	-0.87	-22.74	-0.73	1.93e-77	Height;
LGG	cis	rs9972944	0.902	rs9972947	chr17:63771088	G/A	cg07283582	chr17:63770753	CCDC46	0.44	8.75	0.38	4.04e-17	Total body bone mineral density;
LGG	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.42	-0.44	5.75e-23	Subjective well-being;
LGG	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg18854424	chr1:2615690	NA	-0.33	-7.16	-0.32	3.22e-12	Ulcerative colitis;
LGG	cis	rs1920116	0.778	rs2421829	chr3:169554264	T/C	cg08193579	chr3:169529701	LRRC34	0.42	7.4	0.33	6.55e-13	Glioma (high-grade);
LGG	cis	rs368123	1.000	rs172722	chr6:160754202	T/C	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	cis	rs2274273	0.840	rs6573014	chr14:55735892	C/T	cg04306507	chr14:55594613	LGALS3	-0.63	-17.17	-0.62	1.69e-51	Protein biomarker;
LGG	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg12379764	chr21:47803548	PCNT	0.7	12.65	0.51	1.05e-31	Testicular germ cell tumor;
LGG	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs4900538	0.855	rs12590993	chr14:102844064	A/G	cg18135206	chr14:102964638	TECPR2	-0.7	-12.72	-0.51	5.23e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9324022	0.722	rs4905995	chr14:101163325	A/G	cg18089426	chr14:101175970	NA	0.62	7.53	0.33	2.59e-13	Plateletcrit;
LGG	cis	rs4950322	0.580	rs7514970	chr1:146592098	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-7.46	-0.33	4.41e-13	Protein quantitative trait loci;
LGG	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	9.73	0.41	1.72e-20	Schizophrenia;
LGG	cis	rs4065321	0.522	rs3744245	chr17:38146542	C/G	cg17467752	chr17:38218738	THRA	-0.59	-9.8	-0.41	9.62e-21	White blood cell count (basophil);White blood cell count;
LGG	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	cg07245641	chr1:182991651	LAMC1	0.41	9.6	0.41	5.07e-20	Colorectal cancer;
LGG	cis	rs7940866	0.774	rs12420126	chr11:130834811	C/T	cg12179176	chr11:130786555	SNX19	0.73	13.6	0.53	1.09e-35	Schizophrenia;
LGG	cis	rs12049351	0.665	rs10916479	chr1:229583547	C/T	cg13547644	chr1:229569608	ACTA1	0.32	7.12	0.31	4.14e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9868809	0.772	rs9836462	chr3:48712791	C/T	cg00383909	chr3:49044727	WDR6	-0.75	-8.52	-0.37	2.27e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.78	-0.34	4.81e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg00919237	chr7:87102261	ABCB4	-0.78	-15.69	-0.59	8.71e-45	Gallbladder cancer;
LGG	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.76	-0.3	4.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07343612	chr16:622815	PIGQ	-0.76	-15.37	-0.58	2.32e-43	Height;
LGG	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg11693508	chr17:37793320	STARD3	0.6	8.71	0.38	5.51e-17	Bipolar disorder;
LGG	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg11752832	chr7:134001865	SLC35B4	0.58	10.21	0.43	3.19e-22	Mean platelet volume;
LGG	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg00187635	chr16:83986795	OSGIN1	-0.45	-6.67	-0.3	7.19e-11	Pursuit maintenance gain;
LGG	cis	rs7617773	0.780	rs36075665	chr3:48343087	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs7927771	0.524	rs7939420	chr11:47723938	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-11.1	-0.46	1.49e-25	Subjective well-being;
LGG	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-9.12	-0.39	2.24e-18	Menopause (age at onset);
LGG	cis	rs7312933	0.645	rs12049942	chr12:42587052	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.2	0.32	2.49e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs5742933	0.817	rs11679767	chr2:190546300	A/G	cg04003228	chr2:190539410	ANKAR	-0.51	-7.4	-0.33	6.36e-13	Ferritin levels;
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-13.01	-0.52	3.24e-33	Vitiligo;
LGG	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9911578	0.967	rs72628392	chr17:56506160	A/G	cg05425664	chr17:57184151	TRIM37	0.6	9.43	0.4	2.02e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg08648136	chr8:956695	NA	0.45	9.75	0.41	1.44e-20	Schizophrenia;
LGG	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg08601574	chr20:25228251	PYGB	0.34	6.98	0.31	9.99e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs62400317	0.826	rs62400335	chr6:45347782	G/A	cg20913747	chr6:44695427	NA	-0.61	-10.23	-0.43	2.69e-22	Total body bone mineral density;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.69	-0.3	6.32e-11	Lung cancer;
LGG	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg23625390	chr15:77176239	SCAPER	-0.66	-13.38	-0.53	9.21e-35	Blood metabolite levels;
LGG	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07157834	chr1:205819609	PM20D1	0.72	16.64	0.61	4.31e-49	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24720442	chr19:56154855	ZNF581	0.42	6.74	0.3	4.69e-11	Cognitive performance;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.06	0.46	2.21e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17270561	1.000	rs17270561	chr6:25820439	A/C	cg16482183	chr6:26056742	HIST1H1C	-0.75	-10.69	-0.44	5.48e-24	Iron status biomarkers;
LGG	cis	rs1555322	0.932	rs6060321	chr20:33833781	C/A	cg17927777	chr20:33865990	NA	0.58	6.72	0.3	5.49e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6424115	0.557	rs35904775	chr1:24180623	T/C	cg24699146	chr1:24152579	HMGCL	-0.27	-8.02	-0.35	8.87e-15	Immature fraction of reticulocytes;
LGG	cis	rs999943	0.846	rs9357162	chr6:33613344	G/A	cg14003231	chr6:33640908	ITPR3	0.62	14.52	0.56	1.23e-39	Obesity (extreme);
LGG	cis	rs28830936	1.000	rs2004162	chr15:41965542	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.54	-12.76	-0.51	3.66e-32	Diastolic blood pressure;
LGG	cis	rs2760061	0.624	rs10442629	chr1:228191070	T/A	cg02753203	chr1:228287806	NA	0.89	17.59	0.63	2.02e-53	Diastolic blood pressure;
LGG	cis	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg19847130	chr8:10466454	RP1L1	0.35	7.31	0.32	1.15e-12	Neuroticism;
LGG	cis	rs8038465	0.615	rs11072430	chr15:73981701	A/G	cg15420318	chr15:73925796	NPTN	-0.39	-6.8	-0.3	3.27e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.72	0.34	7.23e-14	Retinal vascular caliber;
LGG	cis	rs10493773	0.502	rs12061951	chr1:86081453	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.51	-8.54	-0.37	1.98e-16	Urate levels in overweight individuals;
LGG	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.75	-0.38	3.85e-17	Neuroticism;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.41e-18	Fuchs's corneal dystrophy;
LGG	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg16096631	chr1:42092165	HIVEP3	0.53	12.51	0.5	3.76e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.46	-0.47	6.26e-27	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.45	0.4	1.63e-19	Neuroticism;
LGG	cis	rs17122278	0.613	rs477106	chr11:118363424	A/C	cg19182353	chr11:118479428	PHLDB1	0.47	6.98	0.31	1.05e-11	Total cholesterol levels;
LGG	cis	rs12580194	0.593	rs55637917	chr12:55747565	T/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	1.99e-82	Dental caries;
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.99	15.74	0.59	5.12e-45	Platelet count;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.63	0.33	1.31e-13	Menopause (age at onset);
LGG	cis	rs7412746	0.658	rs2089082	chr1:150800090	T/G	cg15448220	chr1:150897856	SETDB1	0.38	7.12	0.31	4.14e-12	Melanoma;
LGG	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg05372495	chr19:1063624	ABCA7	-0.55	-8.94	-0.38	9.67e-18	Alzheimer's disease (late onset);
LGG	cis	rs8060686	0.641	rs79719939	chr16:68240216	A/G	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.67	-0.34	1.01e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.15	-0.32	3.43e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.11	-0.39	2.41e-18	Morning vs. evening chronotype;
LGG	trans	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.81	0.48	2.49e-28	Mean corpuscular volume;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg21926883	chr2:100939477	LONRF2	-0.7	-16.85	-0.62	4.94e-50	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.680	rs1862879	chr7:139019951	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.97	0.31	1.1e-11	Diisocyanate-induced asthma;
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg17202724	chr17:61916730	SMARCD2	-0.47	-9.1	-0.39	2.7e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4919087	1.000	rs12221430	chr10:99061386	C/G	cg25902810	chr10:99078978	FRAT1	0.53	9.92	0.42	3.75e-21	Monocyte count;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.96	0.35	1.3e-14	Longevity;
LGG	cis	rs12136530	0.774	rs10442635	chr1:19775492	C/T	cg17081867	chr1:19768096	CAPZB	0.36	8.45	0.37	3.8e-16	Lead levels in blood;
LGG	cis	rs9916302	0.904	rs12452880	chr17:37591149	G/C	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs4417704	0.551	rs4430951	chr2:241894333	G/A	cg05025159	chr2:241905733	NA	0.52	10.58	0.44	1.38e-23	Joint mobility (Beighton score);
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.38	-0.32	7.4e-13	Neuroticism;
LGG	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg02151108	chr14:50098012	C14orf104	-0.48	-10.28	-0.43	1.82e-22	Carotid intima media thickness;
LGG	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg20637307	chr2:213403960	ERBB4	0.46	8.01	0.35	9.15e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2976388	0.609	rs2585153	chr8:143785345	G/A	cg06565975	chr8:143823917	SLURP1	0.35	9.14	0.39	1.94e-18	Urinary tract infection frequency;
LGG	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7765175	0.674	rs4945940	chr6:113670386	A/T	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.41e-13	Coronary artery calcification;
LGG	trans	rs66887589	0.774	rs9307477	chr4:120421809	G/A	cg25214090	chr10:38739885	LOC399744	0.37	6.93	0.31	1.38e-11	Diastolic blood pressure;
LGG	cis	rs4689388	0.926	rs10010131	chr4:6292915	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.7	0.48	7.08e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg12310025	chr6:25882481	NA	-0.42	-7.48	-0.33	3.68e-13	Height;
LGG	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg04986931	chr22:39850128	NA	0.39	8.69	0.37	6.44e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg12432903	chr7:1882776	MAD1L1	0.52	7.72	0.34	7.26e-14	Bipolar disorder;
LGG	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg08847533	chr14:75593920	NEK9	-0.54	-10.22	-0.43	2.97e-22	Height;
LGG	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.92	-0.45	7.43e-25	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19225308	chr19:3607139	TBXA2R	0.41	6.77	0.3	3.98e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.65	-0.3	8.2e-11	Menopause (age at onset);
LGG	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg25457927	chr22:38595422	NA	-0.36	-8.34	-0.36	8.87e-16	Breast cancer;
LGG	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg02503808	chr4:7069936	GRPEL1	0.88	13.74	0.54	2.96e-36	Monocyte percentage of white cells;
LGG	cis	rs7546668	1.000	rs4646068	chr1:15828704	T/C	cg21858823	chr1:15850916	CASP9	0.37	7.05	0.31	6.75e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg02002194	chr4:3960332	NA	0.41	7.26	0.32	1.6e-12	Neuroticism;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.37	-0.47	1.36e-26	Neuroticism;
LGG	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4474465	0.736	rs11237541	chr11:78261703	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.82	-0.3	2.9100000000000002e-11	Alzheimer's disease (survival time);
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.53e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs4731207	0.662	rs2219954	chr7:124555855	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.71	-0.34	7.67e-14	Cutaneous malignant melanoma;
LGG	cis	rs9399137	0.507	rs13196486	chr6:135283874	C/G	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg24623649	chr8:11872141	NA	-0.34	-7.93	-0.35	1.69e-14	Triglycerides;
LGG	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg03929089	chr4:120376271	NA	0.44	7.05	0.31	6.48e-12	HDL cholesterol;
LGG	cis	rs4363385	0.747	rs2339495	chr1:152975116	A/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.37e-18	Inflammatory skin disease;
LGG	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg26655873	chr3:72818019	SHQ1	0.34	6.9	0.31	1.76e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs56399783	0.614	rs11765492	chr7:2771642	G/A	cg19731401	chr7:2775893	GNA12	0.37	7.45	0.33	4.57e-13	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg08999081	chr20:33150536	PIGU	-0.4	-10.21	-0.43	3.2800000000000002e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs13314892	0.764	rs79151317	chr3:69872713	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg08975724	chr8:8085496	FLJ10661	0.36	7.08	0.31	5.42e-12	Mood instability;
LGG	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.77	0.45	2.82e-24	Mean platelet volume;
LGG	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg09201001	chr11:18656081	SPTY2D1	-0.98	-20.73	-0.69	4.94e-68	Breast cancer;
LGG	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18876405	chr7:65276391	NA	0.49	8.84	0.38	2.01e-17	Aortic root size;
LGG	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg22852734	chr6:133119734	C6orf192	1.16	15.78	0.59	3.31e-45	Type 2 diabetes nephropathy;
LGG	cis	rs4423214	0.559	rs11234042	chr11:71239086	C/A	cg10847948	chr11:71163743	NADSYN1	0.58	8.71	0.38	5.57e-17	Vitamin D levels;
LGG	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	13.93	0.54	4.21e-37	Total body bone mineral density;
LGG	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.81	-0.3	3.13e-11	Neuroticism;
LGG	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs12901789	1	rs12901789	chr15:67562214	A/C	cg05925327	chr15:68127851	NA	-0.32	-6.82	-0.3	2.81e-11	Total body bone mineral density;
LGG	cis	rs4742903	0.870	rs10991171	chr9:106976150	G/T	cg14250997	chr9:106856677	SMC2	0.4	8.34	0.36	8.29e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.49	0.33	3.45e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.68	-0.41	2.64e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs8005677	1.000	rs4982712	chr14:23403728	A/G	cg25600027	chr14:23388339	RBM23	-0.43	-6.98	-0.31	1.03e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs216026	0.689	rs61907987	chr12:2768017	G/A	cg19945202	chr12:2788847	CACNA1C	-0.63	-9.24	-0.39	8.78e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs8030485	0.536	rs4778918	chr15:79434040	T/C	cg17916960	chr15:79447300	NA	0.55	10.4	0.44	6.48e-23	Left ventricle wall thickness;
LGG	cis	rs7508	0.612	rs10503609	chr8:17918768	C/T	cg18067069	chr8:17937731	ASAH1	0.37	8.4	0.36	5.6e-16	Atrial fibrillation;
LGG	cis	rs13202913	0.608	rs17054363	chr6:151746586	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	6.93	0.31	1.42e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4742903	0.967	rs2417485	chr9:106867106	A/C	cg14250997	chr9:106856677	SMC2	0.4	8.51	0.37	2.51e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4262150	0.846	rs72799163	chr5:152132117	T/C	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.91	-0.31	1.58e-11	Morning vs. evening chronotype;
LGG	cis	rs17767392	0.881	rs7157241	chr14:72001296	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.77	-0.38	3.45e-17	Mitral valve prolapse;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs300774	1.000	rs300772	chr2:117230	C/T	cg04617936	chr2:214353	NA	-0.5	-7.48	-0.33	3.83e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.41e-11	Depression;
LGG	cis	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg00666640	chr1:248458726	OR2T12	0.59	9.52	0.4	9.4e-20	Common traits (Other);
LGG	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.89	0.45	9.23e-25	Parkinson's disease;
LGG	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.96	-0.38	7.84e-18	Bipolar disorder;
LGG	cis	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg00745463	chr17:30367425	LRRC37B	-0.48	-7.01	-0.31	8.64e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg14768367	chr16:72042858	DHODH	0.35	6.69	0.3	6.27e-11	Fibrinogen levels;
LGG	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.58	-0.61	8.36e-49	Height;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg23782820	chr8:58130467	NA	0.56	8.34	0.36	8.42e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9462027	0.651	rs7769820	chr6:34760228	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs1788820	0.917	rs1652349	chr18:21142734	A/T	cg14672496	chr18:21087552	C18orf8	0.38	6.96	0.31	1.14e-11	Body mass index;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	32.6	0.83	5.52e-122	Prudent dietary pattern;
LGG	cis	rs1375194	0.509	rs62150473	chr2:33822320	G/A	cg04131969	chr2:33951647	MYADML	-0.59	-10.39	-0.43	7.15e-23	Response to antidepressants in depression;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13012494	chr21:47604986	C21orf56	-0.55	-9.64	-0.41	3.55e-20	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.32	0.36	1e-15	Lung cancer;
LGG	cis	rs9462027	0.628	rs9296129	chr6:34774414	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.54	11.23	0.46	4.78e-26	Systemic lupus erythematosus;
LGG	trans	rs7939886	0.920	rs59168428	chr11:55956018	G/A	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.87	0.3	2.05e-11	Parkinson's disease;
LGG	cis	rs7666738	0.830	rs35276471	chr4:99068691	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.22	0.39	1.06e-18	Blood metabolite levels;
LGG	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg06917634	chr15:78832804	PSMA4	-0.68	-12.58	-0.5	2.06e-31	Sudden cardiac arrest;
LGG	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg12463550	chr7:65579703	CRCP	0.5	8.32	0.36	1.03e-15	Aortic root size;
LGG	cis	rs651907	0.541	rs2925325	chr3:101630668	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.83	0.34	3.32e-14	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8133932	0.636	rs2014421	chr21:47278308	A/G	cg11214348	chr21:47283868	PCBP3	0.43	7.61	0.33	1.5700000000000001e-13	Schizophrenia;
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg08528231	chr16:12997261	SHISA9	-0.34	-6.84	-0.3	2.56e-11	Positive affect;Subjective well-being;
LGG	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg15017067	chr4:17643749	FAM184B	0.29	6.65	0.3	8.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6930083	0.527	rs9368950	chr6:36627872	T/C	cg08179530	chr6:36648295	CDKN1A	-0.57	-9.65	-0.41	3.31e-20	Coronary artery disease;
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg26516362	chr5:178986906	RUFY1	0.43	7.94	0.35	1.5e-14	Lung cancer;
LGG	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.97	-0.35	1.28e-14	Testicular germ cell tumor;
LGG	cis	rs2797369	0.882	rs4240593	chr6:101615213	C/T	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg20368463	chr18:77673604	PQLC1	-0.47	-8.34	-0.36	8.55e-16	Schizophrenia;
LGG	cis	rs9486719	1.000	rs11153058	chr6:97012746	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.85	-0.3	2.37e-11	Migraine;Coronary artery disease;
LGG	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg08824895	chr13:115047677	UPF3A	0.43	7.41	0.33	6.2e-13	Schizophrenia;
LGG	cis	rs7666738	0.830	rs1813251	chr4:98921170	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.27e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg05294307	chr14:35346193	BAZ1A	-0.39	-7.27	-0.32	1.5e-12	Psoriasis;
LGG	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg26031613	chr14:104095156	KLC1	-0.67	-10.8	-0.45	2.14e-24	Reticulocyte count;
LGG	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6684428	0.536	rs6684599	chr1:56392558	G/T	cg11651538	chr1:56320950	NA	-0.43	-8.28	-0.36	1.32e-15	Airflow obstruction;
LGG	cis	rs10489202	0.632	rs203779	chr1:167877647	T/G	cg24449463	chr1:168025552	DCAF6	-0.58	-9.96	-0.42	2.65e-21	Schizophrenia;
LGG	cis	rs2153535	0.563	rs4428546	chr6:8490376	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.89	-0.31	1.8e-11	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-8.03	-0.35	8.13e-15	Skin colour saturation;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	trans	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg07817883	chr1:32538562	TMEM39B	0.68	9.71	0.41	2.05e-20	Monocyte percentage of white cells;
LGG	cis	rs3820928	0.874	rs6728239	chr2:227856552	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.53	-0.33	2.74e-13	Pulmonary function;
LGG	cis	rs977987	0.806	rs8050769	chr16:75388434	C/T	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs17818399	0.541	rs12712976	chr2:46786491	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-9.99	-0.42	2.03e-21	Height;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	9.39	0.4	2.63e-19	Obesity-related traits;
LGG	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Myopia (pathological);
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.52e-21	Lymphocyte counts;
LGG	trans	rs3857536	0.740	rs7745163	chr6:66889936	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg26396452	chr14:65542826	MAX	0.47	9.96	0.42	2.73e-21	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	5.9e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs870825	0.550	rs57301026	chr4:185646505	C/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs7980687	0.596	rs1727319	chr12:123701353	T/C	cg05973401	chr12:123451056	ABCB9	0.5	8.06	0.35	6.69e-15	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.27	-0.32	1.58e-12	Tonsillectomy;
LGG	cis	rs9534288	0.797	rs4294711	chr13:46575557	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs185694	1.000	rs185694	chr13:30885223	C/T	cg07600127	chr13:30881527	KATNAL1	0.55	7.32	0.32	1.1e-12	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.68e-54	Menopause (age at onset);
LGG	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg27446573	chr6:127587934	RNF146	1.12	22.04	0.72	4.01e-74	Breast cancer;
LGG	cis	rs9611519	0.929	rs2064560	chr22:41530040	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.39	-0.36	6.01e-16	Neuroticism;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25072359	chr17:41440525	NA	0.52	9.87	0.42	5.38e-21	Menopause (age at onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21783428	chr6:3118692	BPHL	0.6	6.73	0.3	5.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9547996	0.879	rs4432141	chr13:38172236	A/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.89	-0.3	1.87e-11	Diastolic blood pressure;
LGG	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9462027	0.628	rs34141614	chr6:34777031	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg02002194	chr4:3960332	NA	-0.44	-8.04	-0.35	7.6e-15	Retinal vascular caliber;
LGG	cis	rs11625487	0.957	rs28820314	chr14:77963272	A/C	cg20045696	chr14:77926864	AHSA1	-0.64	-8.27	-0.36	1.46e-15	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	trans	rs36715	0.953	rs2617613	chr5:127552589	G/A	cg16011800	chr17:1958478	HIC1	-0.48	-7.3	-0.32	1.24e-12	Breast cancer;
LGG	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg08400814	chr5:56204995	C5orf35	-0.52	-7.71	-0.34	7.93e-14	Initial pursuit acceleration;
LGG	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg13010199	chr12:38710504	ALG10B	-0.49	-9.21	-0.39	1.16e-18	Morning vs. evening chronotype;
LGG	cis	rs806321	0.534	rs1149870	chr13:50899752	A/G	cg10393508	chr13:50950265	NA	-0.34	-8.6	-0.37	1.27e-16	Multiple sclerosis;
LGG	cis	rs990171	0.955	rs4241210	chr2:103078740	G/A	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs977987	0.806	rs4993969	chr16:75411521	A/T	cg03315344	chr16:75512273	CHST6	0.49	9.96	0.42	2.58e-21	Dupuytren's disease;
LGG	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg15948088	chr11:109293068	C11orf87	0.46	8.32	0.36	9.59e-16	Schizophrenia;
LGG	cis	rs2640806	0.645	rs28441183	chr8:97327294	G/T	cg22138393	chr8:97340270	PTDSS1	0.31	7.85	0.34	2.94e-14	Obesity-related traits;
LGG	cis	rs11168351	0.517	rs10875754	chr12:48557922	G/C	cg24011408	chr12:48396354	COL2A1	0.65	11.19	0.46	6.6900000000000006e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22022881	chr2:105853494	NA	-0.38	-7.86	-0.34	2.74e-14	Type 2 diabetes;
LGG	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg18850127	chr7:39170497	POU6F2	0.5	11.44	0.47	7.29e-27	IgG glycosylation;
LGG	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg03517284	chr6:25882590	NA	0.44	7.18	0.32	2.72e-12	Iron status biomarkers;
LGG	cis	rs2013441	0.508	rs4471741	chr17:19971553	T/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs7851660	0.844	rs10984103	chr9:100639275	G/T	cg13688889	chr9:100608707	NA	0.59	11.66	0.48	9.91e-28	Strep throat;
LGG	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.76	-0.3	4.09e-11	Aortic root size;
LGG	trans	rs9929218	0.911	rs4783685	chr16:68834107	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.32	-0.5	2.22e-30	Colorectal cancer;
LGG	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg11905131	chr22:24372483	LOC391322	-0.46	-8.25	-0.36	1.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2456568	0.803	rs10831141	chr11:93640728	C/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.74	-0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg13482628	chr17:19912719	NA	0.63	12.4	0.5	1.13e-30	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10038085	chr1:165797905	UCK2	0.46	7.28	0.32	1.42e-12	Cognitive performance;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg02018176	chr4:1364513	KIAA1530	0.34	7.42	0.33	5.8e-13	Obesity-related traits;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg16036305	chr1:115053835	TRIM33	-0.4	-6.76	-0.3	4.24e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs72945132	0.507	rs34612166	chr11:70244400	C/T	cg14191688	chr11:70257035	CTTN	0.6	8.82	0.38	2.27e-17	Coronary artery disease;
LGG	cis	rs7100689	0.622	rs1890890	chr10:82090643	A/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.51	0.56	1.32e-39	Post bronchodilator FEV1;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg23484912	chr5:273055	PDCD6	0.47	9.46	0.4	1.6e-19	Pancreatic cancer;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.06	-0.31	5.99e-12	Lung cancer;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06634786	chr22:41940651	POLR3H	-0.71	-11.63	-0.48	1.34e-27	Vitiligo;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.13	0.31	3.79e-12	Lung cancer;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00294572	chr6:26285232	NA	0.42	7.84	0.34	3.13e-14	Educational attainment;
LGG	cis	rs7911264	1.000	rs10786052	chr10:94446635	T/C	cg25093409	chr10:94429542	NA	0.59	12.29	0.5	2.92e-30	Inflammatory bowel disease;
LGG	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg04064380	chr11:117688259	NA	-0.51	-7.31	-0.32	1.16e-12	Myopia;
LGG	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg00701064	chr4:6280414	WFS1	0.73	16.35	0.6	9.54e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs7166081	1.000	rs12594229	chr15:67596084	A/C	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14240646	chr10:27532245	ACBD5	0.74	10.2	0.43	3.69e-22	Breast cancer;
LGG	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg25319279	chr11:5960081	NA	-0.57	-8.81	-0.38	2.57e-17	DNA methylation (variation);
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.3	0.55	1.07e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs16937	0.711	rs11240388	chr1:205177617	G/A	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg08733933	chr1:2954429	NA	-0.4	-8.72	-0.38	4.92e-17	Plateletcrit;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg16359550	chr11:109292809	C11orf87	-0.41	-8.15	-0.35	3.42e-15	Schizophrenia;
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.55	-0.37	1.74e-16	Systolic blood pressure;
LGG	cis	rs6066825	0.644	rs2143563	chr20:47320211	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.07	0.35	5.98e-15	Colorectal cancer;
LGG	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg25566285	chr7:158114605	PTPRN2	0.89	20.21	0.68	1.36e-65	Calcium levels;
LGG	cis	rs853679	0.517	rs9295758	chr6:28120663	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	2e-14	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05665937	chr4:1216051	CTBP1	0.44	7.97	0.35	1.23e-14	Obesity-related traits;
LGG	cis	rs13314892	0.692	rs62252228	chr3:69886816	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.87	-0.34	2.49e-14	QRS complex (12-leadsum);
LGG	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg16070123	chr10:51489643	NA	-0.39	-7.05	-0.31	6.49e-12	Prostate-specific antigen levels;
LGG	cis	rs4936894	0.500	rs4936918	chr11:124179835	C/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.4	-0.44	6.4e-23	Aging (time to death);
LGG	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2120243	0.533	rs1392798	chr3:157056287	A/G	cg24825693	chr3:157122686	VEPH1	0.37	8.2	0.36	2.4e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs62481355	1.000	rs62481355	chr7:127201664	C/T	cg25922125	chr7:127225783	GCC1	-0.47	-6.92	-0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.56	-0.63	2.86e-53	Exhaled nitric oxide output;
LGG	cis	rs6121246	0.559	rs6087782	chr20:30391580	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	19.15	0.66	1.23e-60	Mean corpuscular hemoglobin;
LGG	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	8.09	0.35	5.17e-15	Night sleep phenotypes;
LGG	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg02269571	chr22:50332266	NA	-0.47	-7.22	-0.32	2.19e-12	Schizophrenia;
LGG	cis	rs262150	1.000	rs262154	chr7:158773936	G/A	cg19418458	chr7:158789849	NA	-0.48	-9.56	-0.41	7.03e-20	Facial morphology (factor 20);
LGG	cis	rs988958	0.958	rs2425	chr2:42285642	G/A	cg27428208	chr2:42229179	NA	0.4	7.12	0.31	4.21e-12	Hypospadias;
LGG	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.75	0.51	4.02e-32	Alzheimer's disease;
LGG	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22496380	chr5:211416	CCDC127	-1.25	-16.61	-0.61	6.21e-49	Breast cancer;
LGG	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg06353428	chr16:71660113	MARVELD3	0.57	9.11	0.39	2.44e-18	Blood protein levels;
LGG	cis	rs75229567	0.618	rs10219700	chr12:70201730	A/G	cg10114359	chr12:70132523	RAB3IP	-1.09	-9.89	-0.42	4.71e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs9625935	0.518	rs9625870	chr22:30261219	C/T	cg01021169	chr22:30184971	ASCC2	-0.36	-7.01	-0.31	8.39e-12	Tonsillectomy;
LGG	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg26150922	chr2:100937072	LONRF2	-0.5	-9.12	-0.39	2.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg16507663	chr6:150244633	RAET1G	-0.46	-7.3	-0.32	1.26e-12	Lung cancer;
LGG	cis	rs490234	0.841	rs626667	chr9:128428404	A/G	cg14078157	chr9:128172775	NA	0.41	7.49	0.33	3.54e-13	Mean arterial pressure;
LGG	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg08859206	chr1:53392774	SCP2	0.34	6.93	0.31	1.4e-11	Monocyte count;
LGG	cis	rs734999	0.588	rs4648653	chr1:2535895	C/T	cg18854424	chr1:2615690	NA	0.35	7.12	0.31	4.26e-12	Ulcerative colitis;
LGG	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg17108064	chr15:78857060	CHRNA5	0.45	9.62	0.41	4.45e-20	Sudden cardiac arrest;
LGG	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.0	0.35	9.91e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.49	-0.37	2.92e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2974760	0.606	rs2858918	chr16:201183	T/C	cg08400316	chr16:204221	HBZ	0.92	15.41	0.58	1.54e-43	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg12458913	chr13:53173898	NA	0.61	11.65	0.48	1.15e-27	Lewy body disease;
LGG	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs11203032	0.831	rs12250945	chr10:90935206	A/G	cg16672925	chr10:90967113	CH25H	0.52	8.11	0.35	4.6e-15	Heart failure;
LGG	cis	rs28374715	0.578	rs17730589	chr15:41600878	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.32	-31.17	-0.82	9.44e-116	Ulcerative colitis;
LGG	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg08305652	chr11:111469057	NA	-0.46	-9.31	-0.4	5e-19	Primary sclerosing cholangitis;
LGG	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg00129232	chr17:37814104	STARD3	-0.49	-9.03	-0.39	4.66e-18	Self-reported allergy;
LGG	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.67	-0.37	7.58e-17	Alcohol dependence;
LGG	cis	rs4794202	0.534	rs10428	chr17:45915086	G/A	cg02219949	chr17:45927392	SP6	0.53	7.06	0.31	5.99e-12	Alzheimer's disease (cognitive decline);
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.87	-0.3	2.11e-11	Menopause (age at onset);
LGG	trans	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg04991071	chr3:71615924	FOXP1	0.61	7.26	0.32	1.69e-12	Urate levels in overweight individuals;
LGG	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg23461800	chr14:103021989	NA	-0.59	-10.4	-0.44	6.56e-23	Platelet count;
LGG	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg23129478	chr18:44337922	ST8SIA5	0.35	6.85	0.3	2.31e-11	Personality dimensions;
LGG	cis	rs3806843	0.712	rs2530244	chr5:140109155	A/G	cg19875535	chr5:140030758	IK	-0.55	-11.23	-0.46	4.87e-26	Depressive symptoms (multi-trait analysis);
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg21775007	chr8:11205619	TDH	-0.41	-6.74	-0.3	4.73e-11	Joint mobility (Beighton score);
LGG	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.26	-0.43	2.2e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg10760299	chr15:45669010	GATM	0.41	8.13	0.35	4.04e-15	Homoarginine levels;
LGG	cis	rs17221829	0.673	rs10765225	chr11:89384988	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs7572733	0.840	rs700655	chr2:198643631	G/A	cg00792783	chr2:198669748	PLCL1	0.46	7.76	0.34	5.49e-14	Dermatomyositis;
LGG	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg17467752	chr17:38218738	THRA	-0.44	-7.07	-0.31	5.83e-12	Self-reported allergy;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	10.53	0.44	2.24e-23	Obesity-related traits;
LGG	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg17971929	chr21:40555470	PSMG1	0.89	17.63	0.63	1.41e-53	Cognitive function;
LGG	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.64e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg13443165	chr9:33130375	B4GALT1	-0.76	-14.95	-0.57	1.69e-41	IgG glycosylation;
LGG	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.11	-0.46	1.38e-25	Morning vs. evening chronotype;
LGG	cis	rs4969178	1.000	rs7212201	chr17:76393896	C/A	cg05887092	chr17:76393375	PGS1	0.72	15.83	0.59	1.98e-45	HDL cholesterol levels;
LGG	cis	rs832540	0.629	rs10461616	chr5:56080347	T/C	cg12654349	chr5:56205094	C5orf35	-0.38	-6.81	-0.3	3e-11	Coronary artery disease;
LGG	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg23009067	chr7:2775923	GNA12	0.26	7.36	0.32	8.44e-13	Height;
LGG	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.82	-0.38	2.38e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07157834	chr1:205819609	PM20D1	0.73	16.66	0.61	3.66e-49	Menarche (age at onset);
LGG	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg06636001	chr8:8085503	FLJ10661	0.41	6.89	0.3	1.83e-11	Rheumatoid arthritis;
LGG	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.55e-17	Aortic root size;
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	trans	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg16141378	chr3:129829833	LOC729375	0.37	8.46	0.37	3.48e-16	Mood instability;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.36	-0.32	8.71e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg00405596	chr8:11794950	NA	-0.41	-6.81	-0.3	3.09e-11	Neuroticism;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01516881	chr6:292596	DUSP22	-0.7	-11.85	-0.48	1.72e-28	Menopause (age at onset);
LGG	cis	rs7927771	0.864	rs4752838	chr11:47466006	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-10.37	-0.43	8.61e-23	Subjective well-being;
LGG	cis	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg24110177	chr3:50126178	RBM5	0.4	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg27129171	chr3:47204927	SETD2	-0.84	-16.08	-0.6	1.58e-46	Colorectal cancer;
LGG	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg13628971	chr7:2884303	GNA12	0.37	7.52	0.33	2.94e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.54	-0.37	1.88e-16	Personality dimensions;
LGG	cis	rs231513	0.911	rs231511	chr17:41966335	T/C	cg26893861	chr17:41843967	DUSP3	-0.58	-6.89	-0.3	1.88e-11	Cognitive function;
LGG	cis	rs6547631	0.595	rs34702373	chr2:85927404	C/T	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.68e-11	Blood protein levels;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.03	0.39	4.53e-18	Alzheimer's disease;
LGG	cis	rs7106204	0.609	rs16912359	chr11:24290818	C/T	ch.11.24196551F	chr11:24239977	NA	0.87	9.59	0.41	5.43e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.7	-0.41	2.26e-20	Height;
LGG	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.1	-0.31	4.71e-12	Total cholesterol levels;
LGG	trans	rs853679	0.607	rs35030260	chr6:28305508	G/A	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.55	-0.5	2.63e-31	Depression;
LGG	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.37	0.65	5.28e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg02949469	chr2:219135266	PNKD;AAMP	-0.39	-6.79	-0.3	3.54e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg20887711	chr4:1340912	KIAA1530	0.42	7.18	0.32	2.8e-12	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.75	-0.64	3.78e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.48	-0.33	3.81e-13	Morning vs. evening chronotype;
LGG	cis	rs1555895	0.611	rs2892159	chr10:855061	G/A	cg09361094	chr10:834503	NA	-0.29	-7.75	-0.34	5.89e-14	Survival in rectal cancer;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg20887711	chr4:1340912	KIAA1530	0.59	11.6	0.47	1.81e-27	Longevity;
LGG	cis	rs13064447	0.753	rs9811396	chr3:12747915	A/G	cg23032965	chr3:12705835	RAF1	0.5	7.73	0.34	6.6e-14	Major depression and alcohol dependence;
LGG	cis	rs1030877	0.515	rs920217	chr2:105904662	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.66	-10.28	-0.43	1.8e-22	Obesity-related traits;
LGG	cis	rs1620921	0.505	rs12526591	chr6:161204311	T/A	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	26.45	0.78	1.25e-94	Cognitive ability;
LGG	cis	rs9815354	0.812	rs76966288	chr3:41825055	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg26597838	chr10:835615	NA	0.52	6.82	0.3	2.81e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg05665937	chr4:1216051	CTBP1	0.48	8.37	0.36	6.91e-16	Obesity-related traits;
LGG	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg23815491	chr16:72088622	HP	0.53	11.7	0.48	7.32e-28	Fibrinogen levels;
LGG	cis	rs847577	0.609	rs17435847	chr7:97792820	G/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.79	-0.3	3.5e-11	Breast cancer;
LGG	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06481639	chr22:41940642	POLR3H	0.54	7.49	0.33	3.41e-13	Vitiligo;
LGG	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg24110177	chr3:50126178	RBM5	0.6	10.97	0.45	4.68e-25	Intelligence (multi-trait analysis);
LGG	cis	rs75059851	0.778	rs73034263	chr11:133808038	C/G	cg17703048	chr11:133852993	NA	-0.72	-11.79	-0.48	3.08e-28	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22431590	chr1:6639959	ZBTB48	-0.44	-7.09	-0.31	5.21e-12	Pancreatic cancer;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18876405	chr7:65276391	NA	-0.61	-11.59	-0.47	1.94e-27	Calcium levels;
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.58	-0.33	1.89e-13	Height;
LGG	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.37	-0.4	3.28e-19	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11671005	0.504	rs3794964	chr19:59070916	T/C	cg22037779	chr5:139682734	PFDN1	-0.43	-6.74	-0.3	4.87e-11	Mean platelet volume;
LGG	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg18681998	chr4:17616180	MED28	-0.74	-14.61	-0.56	4.84e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg08484992	chr16:88977278	CBFA2T3	0.38	8.75	0.38	4.02e-17	Social autistic-like traits;
LGG	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg18681998	chr4:17616180	MED28	0.86	19.69	0.68	3.72e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs68170813	0.652	rs17481621	chr7:107113852	G/C	cg02696742	chr7:106810147	HBP1	-0.67	-8.55	-0.37	1.83e-16	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04238871	chr10:126431886	FAM53B	0.44	6.86	0.3	2.21e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.38	-0.32	7.59e-13	IgG glycosylation;
LGG	cis	rs4679904	0.920	rs7644186	chr3:160304072	C/A	cg20378687	chr3:160281681	KPNA4	-0.36	-6.71	-0.3	5.86e-11	Primary biliary cholangitis;
LGG	cis	rs8067287	0.749	rs62065421	chr17:16827887	T/C	cg26910001	chr17:16838321	NA	-0.48	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13303229	chr5:154136254	LARP1	0.46	7.64	0.33	1.28e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg24829409	chr8:58192753	C8orf71	-0.68	-9.4	-0.4	2.48e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06481639	chr22:41940642	POLR3H	0.54	7.61	0.33	1.55e-13	Vitiligo;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.27	0.46	3.43e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg18876405	chr7:65276391	NA	0.56	10.04	0.42	1.42e-21	Aortic root size;
LGG	cis	rs2070488	0.662	rs7373930	chr3:38454931	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	12.06	0.49	2.52e-29	Electrocardiographic conduction measures;
LGG	cis	rs9397585	0.637	rs11155894	chr6:153404250	A/G	cg17707550	chr6:153380415	RGS17	-0.47	-10.36	-0.43	9.25e-23	Body mass index;
LGG	cis	rs972578	1.000	rs4822249	chr22:43403506	C/G	cg01576275	chr22:43409880	NA	-0.23	-6.9	-0.31	1.77e-11	Mean platelet volume;
LGG	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg22681709	chr2:178499509	PDE11A	0.49	7.98	0.35	1.18e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg08222618	chr4:941054	TMEM175	0.8	19.57	0.67	1.33e-62	Sjögren's syndrome;
LGG	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg01966878	chr4:90757139	SNCA	-0.33	-6.7	-0.3	6.11e-11	Dementia with Lewy bodies;
LGG	cis	rs17767392	0.788	rs57723945	chr14:71699182	G/A	cg02058870	chr14:72053146	SIPA1L1	0.35	6.93	0.31	1.42e-11	Mitral valve prolapse;
LGG	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.39e-15	Menopause (age at onset);
LGG	cis	rs7172677	0.732	rs2289583	chr15:75311036	C/A	cg10253484	chr15:75165896	SCAMP2	0.6	8.64	0.37	8.86e-17	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg24687543	chr11:63912206	MACROD1	-0.6	-8.1	-0.35	4.91e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13031449	chr14:95623952	FLJ45244;DICER1	0.41	6.69	0.3	6.32e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4356932	1.000	rs4859416	chr4:76986499	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.18e-14	Restless legs syndrome;
LGG	cis	rs7503807	0.515	rs869190	chr17:78668593	G/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.27	-0.4	7.02e-19	Obesity;
LGG	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.94	-0.38	9.24e-18	Triglycerides;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.6	0.33	1.7e-13	Lung cancer;
LGG	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	7.85e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg16606324	chr3:10149918	C3orf24	0.52	6.99	0.31	9.49e-12	Alzheimer's disease;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.92	-0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs7617773	0.539	rs13082217	chr3:48383264	T/C	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs4926611	0.897	rs12140002	chr1:54084091	C/A	cg23596471	chr1:54105337	GLIS1	0.41	8.11	0.35	4.5e-15	Hand grip strength;
LGG	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg11062466	chr8:58055876	NA	0.49	7.89	0.34	2.19e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4566357	1.000	rs2251223	chr2:227914975	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.7	-0.3	5.89e-11	Coronary artery disease;
LGG	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.74	-0.38	4.38e-17	Bone mineral density;
LGG	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg21385522	chr1:16154831	NA	-0.73	-13.21	-0.52	4.87e-34	Dilated cardiomyopathy;
LGG	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.83	-0.34	3.25e-14	Mean platelet volume;
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg06074448	chr4:187884817	NA	-0.59	-13.09	-0.52	1.54e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	15.04	0.57	6.55e-42	Hip circumference adjusted for BMI;
LGG	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.59	-0.41	5.31e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11190604	0.697	rs12355942	chr10:102201320	T/C	cg07570687	chr10:102243282	WNT8B	-0.46	-8.0	-0.35	9.76e-15	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	4.07e-44	Lung cancer;
LGG	cis	rs2694528	0.844	rs976080	chr5:60217651	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.58	-0.33	1.96e-13	Parkinson's disease;
LGG	trans	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg02002194	chr4:3960332	NA	-0.44	-8.21	-0.36	2.29e-15	Parkinson's disease;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg05973401	chr12:123451056	ABCB9	0.49	7.19	0.32	2.63e-12	Neutrophil percentage of white cells;
LGG	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4262150	0.767	rs72795389	chr5:151944518	C/T	cg12297329	chr5:152029980	NA	-0.78	-14.77	-0.57	1.03e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs2548003	0.933	rs1862560	chr5:28733909	G/A	cg12623145	chr2:97778927	ANKRD36	0.45	6.86	0.3	2.2e-11	Hip geometry;
LGG	trans	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.56	-0.41	7.12e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7590720	1.000	rs7592663	chr2:216894978	T/C	cg12620499	chr2:216877984	MREG	0.77	14.27	0.55	1.51e-38	Alcohol dependence;
LGG	cis	rs9914988	0.943	rs9893782	chr17:27108132	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg10840412	chr1:235813424	GNG4	0.58	7.88	0.34	2.29e-14	Bipolar disorder;
LGG	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16660274	chr2:127976928	NA	0.47	7.08	0.31	5.52e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg09307838	chr4:120376055	NA	0.73	12.32	0.5	2.31e-30	Corneal astigmatism;
LGG	cis	rs9462027	1.000	rs6457796	chr6:34828553	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-8.35	-0.36	7.96e-16	Systemic lupus erythematosus;
LGG	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg26354017	chr1:205819088	PM20D1	0.47	7.78	0.34	4.76e-14	Parkinson's disease;
LGG	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg20387954	chr3:183756860	HTR3D	0.85	17.35	0.63	2.65e-52	Anterior chamber depth;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.09	0.31	5.13e-12	Lung cancer;
LGG	cis	rs9487094	0.670	rs2024850	chr6:109818456	C/T	cg01125227	chr6:109776195	MICAL1	-0.46	-7.9	-0.34	2e-14	Height;
LGG	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	6.76	0.3	4.28e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05422897	chr2:113403145	SLC20A1	0.5	7.49	0.33	3.53e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg13798912	chr7:905769	UNC84A	-0.57	-7.13	-0.31	3.84e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9443189	0.762	rs2748944	chr6:76436106	A/G	cg01950844	chr6:76311363	SENP6	0.58	7.93	0.35	1.71e-14	Prostate cancer;
LGG	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.7	-0.3	6.02e-11	HDL cholesterol;
LGG	trans	rs8073060	0.586	rs6505486	chr17:33996776	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.4	-0.63	1.55e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6032067	0.714	rs6032075	chr20:43884340	T/C	cg10761708	chr20:43804764	PI3	0.56	8.59	0.37	1.33e-16	Blood protein levels;
LGG	cis	rs72730918	0.528	rs3751585	chr15:51741056	C/T	cg19558802	chr15:51695713	GLDN	-0.49	-6.78	-0.3	3.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4262150	0.544	rs10045463	chr5:151920194	C/T	cg12297329	chr5:152029980	NA	-0.68	-12.03	-0.49	3.53e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.853	rs10838885	chr11:48398806	A/G	cg15704280	chr7:45808275	SEPT13	-0.46	-7.52	-0.33	2.81e-13	HDL cholesterol;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg20308403	chr7:2120281	MAD1L1	0.34	7.34	0.32	9.84e-13	Schizophrenia;
LGG	cis	rs17445240	1.000	rs80212323	chr2:3703959	C/T	cg16123090	chr2:3699210	NA	0.82	8.78	0.38	3.13e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2953145	0.617	rs7557192	chr2:241541274	T/C	cg07929629	chr2:241523174	NA	0.59	10.03	0.42	1.44e-21	Bipolar disorder;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.49	9.18	0.39	1.4e-18	Longevity;
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg11984989	chr7:158649758	WDR60	0.96	21.1	0.7	9.72e-70	Height;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs4700695	0.841	rs152994	chr5:65262989	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs12545109	0.800	rs970838	chr8:57414806	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs3820928	0.874	rs6740108	chr2:227889559	G/T	cg11843606	chr2:227700838	RHBDD1	0.44	7.61	0.33	1.58e-13	Pulmonary function;
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.36	0.36	7.61e-16	Aortic root size;
LGG	cis	rs9517320	0.967	rs6491430	chr13:99178276	G/A	cg07423050	chr13:99094983	FARP1	0.41	8.4	0.36	5.58e-16	Longevity;
LGG	cis	rs10463554	0.892	rs1438687	chr5:102304496	G/A	cg23492399	chr5:102201601	PAM	-0.56	-8.29	-0.36	1.27e-15	Parkinson's disease;
LGG	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.66	-0.34	1.11e-13	Colorectal cancer;
LGG	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs6450176	0.909	rs67721004	chr5:53290571	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-10.79	-0.45	2.22e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg24851651	chr11:66362959	CCS	-0.4	-7.19	-0.32	2.57e-12	Bipolar disorder;
LGG	cis	rs861020	0.563	rs61820640	chr1:210041297	G/T	cg05527609	chr1:210001259	C1orf107	-0.55	-8.06	-0.35	6.71e-15	Orofacial clefts;
LGG	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.94	0.31	1.32e-11	Neuroticism;
LGG	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.31	-0.4	5.34e-19	Neuroticism;
LGG	cis	rs258892	0.739	rs34667	chr5:72160050	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	14.47	0.56	2.13e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.29	0.55	1.29e-38	Platelet count;
LGG	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg09264619	chr17:80180166	NA	0.5	9.62	0.41	4.31e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg08109568	chr15:31115862	NA	-0.51	-8.49	-0.37	2.81e-16	Huntington's disease progression;
LGG	cis	rs2229238	0.780	rs61698846	chr1:154504854	C/T	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.11e-11	Coronary heart disease;
LGG	cis	rs877282	0.735	rs111609055	chr10:826539	A/G	cg15764593	chr10:829463	NA	-0.7	-10.61	-0.44	1.13e-23	Uric acid levels;
LGG	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg12432903	chr7:1882776	MAD1L1	0.56	8.56	0.37	1.64e-16	Bipolar disorder;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01301138	chr16:82660630	CDH13	0.39	6.69	0.3	6.39e-11	Bipolar disorder;
LGG	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg18551225	chr6:44695536	NA	0.63	10.3	0.43	1.53e-22	Total body bone mineral density;
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17376030	chr22:41985996	PMM1	0.58	9.16	0.39	1.72e-18	Vitiligo;
LGG	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg24846343	chr22:24311635	DDTL	0.53	9.92	0.42	3.69e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg25418670	chr11:30344373	C11orf46	-0.58	-8.02	-0.35	8.83e-15	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	1.000	rs1079576	chr22:18446318	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.43	-0.5	8.12e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg06606381	chr12:133084897	FBRSL1	-0.57	-7.22	-0.32	2.12e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.15	-0.35	3.52e-15	Triglycerides;
LGG	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.41	-0.36	5.19e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.39	-0.43	7.4e-23	Subjective well-being;
LGG	cis	rs73086581	0.787	rs67202952	chr20:3869099	A/C	cg02187196	chr20:3869020	PANK2	0.93	13.04	0.52	2.61e-33	Response to antidepressants in depression;
LGG	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Vitiligo;
LGG	cis	rs7444	1.000	rs7444	chr22:21976934	T/C	cg11654148	chr22:21984483	YDJC	-0.38	-7.48	-0.33	3.89e-13	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg25986240	chr4:9926439	SLC2A9	0.37	7.57	0.33	2.07e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.97	0.57	1.32e-41	Cognitive test performance;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.15	-0.35	3.32e-15	Neuroticism;
LGG	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg08885076	chr2:99613938	TSGA10	-0.56	-11.46	-0.47	6.21e-27	Chronic sinus infection;
LGG	cis	rs741702	0.928	rs2009222	chr19:13034543	T/C	cg11738485	chr19:12877000	HOOK2	0.43	6.86	0.3	2.27e-11	Red blood cell traits;
LGG	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg00631329	chr6:26305371	NA	-0.47	-7.95	-0.35	1.4e-14	Educational attainment;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06916706	chr16:4465613	CORO7	-0.88	-15.28	-0.58	5.82e-43	Schizophrenia;
LGG	cis	rs12291225	0.585	rs11023197	chr11:14380998	G/A	cg19336497	chr11:14380999	RRAS2	-0.63	-13.4	-0.53	7.7e-35	Sense of smell;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.28	-7.59	-0.33	1.77e-13	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09378111	chr2:211036309	C2orf67	0.41	6.91	0.31	1.62e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs9457247	1.000	rs407515	chr6:167407544	G/C	cg07741184	chr6:167504864	NA	0.33	7.35	0.32	9.33e-13	Crohn's disease;
LGG	cis	rs9796	0.866	rs2176998	chr15:41420807	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.74	-0.38	4.4e-17	Menopause (age at onset);
LGG	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg17644776	chr2:200775616	C2orf69	-0.61	-7.08	-0.31	5.31e-12	Schizophrenia;
LGG	cis	rs10489202	1.000	rs12727036	chr1:167972147	A/G	cg24449463	chr1:168025552	DCAF6	-0.61	-10.03	-0.42	1.47e-21	Schizophrenia;
LGG	cis	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-9.25	-0.4	8.05e-19	Schizophrenia;
LGG	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs4846580	0.550	rs1766402	chr1:219921528	G/T	cg08034750	chr1:219919793	NA	0.41	7.3	0.32	1.24e-12	Total body bone mineral density;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.62	0.37	1.04e-16	Schizophrenia;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.31	-0.36	1.03e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg08508325	chr11:3079039	CARS	-0.58	-12.65	-0.51	1e-31	Longevity;
LGG	trans	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs2455799	0.613	rs1532767	chr3:15733600	A/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.75	-0.34	6.06e-14	Mean platelet volume;
LGG	cis	rs721917	0.525	rs2758545	chr10:81700090	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.54	-0.33	2.49e-13	Chronic obstructive pulmonary disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg03773681	chr2:63815918	MDH1;C2orf86	0.43	7.19	0.32	2.65e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-8.57	-0.37	1.59e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.54	-0.33	2.51e-13	Schizophrenia;
LGG	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg25208724	chr1:156163844	SLC25A44	1.15	24.12	0.75	7.46e-84	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.81	-0.38	2.57e-17	Lung cancer;
LGG	cis	rs6665290	0.904	rs6664955	chr1:227183434	T/C	cg05696931	chr1:227175867	NA	-0.4	-7.94	-0.35	1.51e-14	Myeloid white cell count;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg24250549	chr1:154909240	PMVK	0.73	14.88	0.57	3.39e-41	Prostate cancer;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg20607798	chr8:58055168	NA	0.76	8.41	0.36	5.19e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7760949	0.963	rs9475771	chr6:13914869	A/G	cg27413430	chr6:13925136	RNF182	-0.45	-7.1	-0.31	4.82e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg12623918	chr2:306882	NA	0.52	9.75	0.41	1.46e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg03352830	chr11:487213	PTDSS2	-0.87	-11.26	-0.46	3.53e-26	Body mass index;
LGG	cis	rs7246865	0.871	rs10421727	chr19:17225128	G/A	cg19418318	chr19:17219073	MYO9B	0.34	9.12	0.39	2.24e-18	Reticulocyte fraction of red cells;
LGG	cis	rs534126	0.524	rs365964	chr7:142823484	G/A	cg11323483	chr7:142828068	PIP	-0.39	-7.19	-0.32	2.7e-12	Cancer;
LGG	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg02574844	chr11:5959923	NA	-0.6	-9.55	-0.41	7.29e-20	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19478983	chr7:120590592	ING3	0.41	6.91	0.31	1.63e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4950928	0.823	rs10920579	chr1:203158972	A/G	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.94	-0.35	1.58e-14	YKL-40 levels;
LGG	cis	rs209489	0.892	rs78889501	chr6:53110486	C/T	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg03517284	chr6:25882590	NA	-0.41	-7.38	-0.32	7.55e-13	Height;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg19223190	chr17:80058835	NA	-0.49	-9.81	-0.41	9.19e-21	Life satisfaction;
LGG	cis	rs7011049	1.000	rs72643577	chr8:53846358	A/T	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.08	-0.46	1.82e-25	Intelligence (multi-trait analysis);
LGG	cis	rs4356932	0.703	rs71629034	chr4:76964953	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.66e-11	Blood protein levels;
LGG	cis	rs10170846	0.861	rs6740452	chr2:223518452	C/T	cg25565276	chr2:223520875	FARSB	0.64	11.26	0.46	3.69e-26	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-11.66	-0.48	1.03e-27	Bipolar disorder;
LGG	cis	rs7927771	1.000	rs10838757	chr11:47763016	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs6964587	0.626	rs9008	chr7:91502407	C/G	cg17063962	chr7:91808500	NA	-0.43	-7.81	-0.34	3.84e-14	Breast cancer;
LGG	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg21153622	chr11:89784906	NA	-0.39	-6.7	-0.3	6.02e-11	HDL cholesterol;
LGG	cis	rs8114671	0.935	rs633198	chr20:33778434	T/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.35	-0.32	8.87e-13	Height;
LGG	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.04	0.31	6.89e-12	Neuroticism;
LGG	cis	rs12791968	0.527	rs12279115	chr11:45014587	G/C	cg11846598	chr11:44996168	LOC221122	-0.5	-6.69	-0.3	6.4e-11	Inhibitory control;
LGG	trans	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs283228	0.570	rs2852511	chr6:101845912	G/A	cg27451362	chr6:101846650	GRIK2	0.98	15.35	0.58	2.71e-43	Coenzyme Q10 levels;
LGG	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg26924012	chr15:45694286	SPATA5L1	0.59	10.29	0.43	1.72e-22	Response to fenofibrate (adiponectin levels);
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg05084668	chr3:125655381	ALG1L	-0.57	-7.69	-0.34	8.81e-14	Blood pressure (smoking interaction);
LGG	trans	rs800082	0.507	rs2222701	chr3:144258813	C/T	cg24215973	chr2:240111563	HDAC4	0.37	6.82	0.3	2.78e-11	Smoking behavior;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs888194	0.763	rs10744826	chr12:109965512	C/G	cg19025524	chr12:109796872	NA	-0.36	-7.15	-0.32	3.31e-12	Neuroticism;
LGG	cis	rs4363385	0.791	rs372490	chr1:153008971	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs2270450	0.765	rs12192544	chr6:46620252	C/G	cg10156739	chr6:46714674	LOC100287718	0.41	8.74	0.38	4.45e-17	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs10799590	0.928	rs7521396	chr1:224828559	C/T	cg01808320	chr1:224927238	CNIH3	-0.37	-6.65	-0.3	8.17e-11	Opioid dependence;
LGG	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg01620082	chr3:125678407	NA	-1.08	-10.57	-0.44	1.6e-23	Depression;
LGG	cis	rs10489202	1.000	rs7520232	chr1:168011995	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-10.15	-0.43	5.39e-22	Schizophrenia;
LGG	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.5	-0.44	2.77e-23	Response to antipsychotic treatment;
LGG	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg02811702	chr13:24901961	NA	0.4	7.45	0.33	4.54e-13	Obesity-related traits;
LGG	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg00204512	chr16:28754710	NA	0.27	7.62	0.33	1.47e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs36093844	0.800	rs112468922	chr11:85576694	A/G	cg16165120	chr11:85566439	CCDC83	-0.45	-7.33	-0.32	1.04e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg12395012	chr8:11607386	GATA4	0.41	7.37	0.32	7.81e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg13482628	chr17:19912719	NA	-0.53	-10.08	-0.42	9.98e-22	Schizophrenia;
LGG	cis	rs9487094	0.666	rs6920372	chr6:109723939	G/A	cg01125227	chr6:109776195	MICAL1	0.4	6.99	0.31	9.41e-12	Height;
LGG	cis	rs7173743	0.756	rs8032842	chr15:79125849	G/A	cg00540400	chr15:79124168	NA	0.43	9.07	0.39	3.3e-18	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs116888565	chr22:32419164	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs8030485	0.756	rs1521624	chr15:79412399	C/A	cg17916960	chr15:79447300	NA	0.49	9.05	0.39	3.85e-18	Left ventricle wall thickness;
LGG	cis	rs727505	0.819	rs4142718	chr7:124731688	T/A	cg23710748	chr7:124431027	NA	-0.49	-9.23	-0.39	1.01e-18	Lewy body disease;
LGG	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg07661805	chr8:143867942	LY6D	-0.3	-8.01	-0.35	9.6e-15	Urinary tract infection frequency;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg12310025	chr6:25882481	NA	-0.41	-7.3	-0.32	1.26e-12	Height;
LGG	cis	rs12477438	0.501	rs60257640	chr2:100074487	C/T	cg23527387	chr2:100056660	REV1	0.43	9.54	0.41	8.5e-20	Chronic sinus infection;
LGG	trans	rs8073060	0.544	rs2626626	chr17:34026717	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg09165964	chr15:75287851	SCAMP5	0.61	11.32	0.47	2.12e-26	Breast cancer;
LGG	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08704250	chr15:31115839	NA	-0.41	-7.68	-0.34	9.49e-14	Huntington's disease progression;
LGG	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg03929089	chr4:120376271	NA	0.79	8.19	0.36	2.51e-15	Myopia (pathological);
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.36	0.36	7.59e-16	Schizophrenia;
LGG	cis	rs11295209	1	rs11295209	chr4:120480233	TA/T	cg09307838	chr4:120376055	NA	-0.47	-8.26	-0.36	1.59e-15	Plateletcrit;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg05091796	chr16:4465799	CORO7	-0.6	-9.75	-0.41	1.45e-20	Schizophrenia;
LGG	cis	rs4950928	0.774	rs4950931	chr1:203164075	G/A	cg17014757	chr1:203156097	CHI3L1	-0.38	-8.03	-0.35	8.37e-15	YKL-40 levels;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00933542	chr6:150070202	PCMT1	0.39	7.17	0.32	2.9e-12	Lung cancer;
LGG	cis	rs2114646	0.731	rs7565350	chr2:170646069	T/C	cg17598339	chr2:170624727	NA	0.35	6.71	0.3	5.68e-11	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02071572	chr4:1403502	NA	-0.39	-6.67	-0.3	7.27e-11	Longevity;
LGG	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg27284194	chr4:1044797	NA	0.57	11.74	0.48	5.05e-28	Recombination rate (males);
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg15971980	chr6:150254442	NA	0.45	8.97	0.38	7.34e-18	Testicular germ cell tumor;
LGG	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg21665744	chr7:39171113	POU6F2	0.38	7.31	0.32	1.16e-12	IgG glycosylation;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg04772025	chr11:68637568	NA	0.75	12.86	0.51	1.46e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg12615879	chr12:58013172	SLC26A10	0.31	6.89	0.31	1.8e-11	Multiple sclerosis;
LGG	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-8.14	-0.35	3.62e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9814567	0.574	rs1391695	chr3:134171376	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.5	-8.68	-0.37	6.91e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11644478	chr21:40555479	PSMG1	-0.73	-13.31	-0.53	1.83e-34	Cognitive function;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18675616	chr4:1962842	WHSC1	0.37	7.36	0.32	8.65e-13	Electrocardiographic conduction measures;
LGG	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg00666640	chr1:248458726	OR2T12	0.6	9.65	0.41	3.28e-20	Common traits (Other);
LGG	cis	rs4771450	0.925	rs7327226	chr13:103985853	G/A	cg02987523	chr13:103978230	NA	-0.33	-7.08	-0.31	5.53e-12	Uric acid levels;
LGG	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg25319279	chr11:5960081	NA	-0.54	-8.48	-0.37	3.13e-16	DNA methylation (variation);
LGG	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	trans	rs2018683	0.649	rs221193	chr7:29015784	G/T	cg19402173	chr7:128379420	CALU	-0.59	-9.48	-0.4	1.37e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.83	-0.38	2.24e-17	Neuroticism;
LGG	cis	rs9547996	0.959	rs56312513	chr13:38249726	C/A	cg17979426	chr13:38220150	TRPC4	-0.4	-7.79	-0.34	4.42e-14	Diastolic blood pressure;
LGG	cis	rs71403859	0.502	rs12919417	chr16:71579711	A/G	cg08717414	chr16:71523259	ZNF19	1.19	15.74	0.59	5.14e-45	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg02725872	chr8:58115012	NA	-0.94	-13.04	-0.52	2.49e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	0.752	rs2464430	chr15:57348225	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.93	-0.31	1.43e-11	Urinary tract infection frequency;
LGG	cis	rs8067545	0.641	rs175922	chr17:19825579	T/C	cg04132472	chr17:19861366	AKAP10	0.25	7.02	0.31	7.86e-12	Schizophrenia;
LGG	cis	rs74417235	0.684	rs12655636	chr5:154057618	T/C	cg08754654	chr5:154026448	NA	0.53	10.86	0.45	1.22e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg11887960	chr12:57824829	NA	0.56	6.91	0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs7100689	0.784	rs7089058	chr10:82071263	T/C	cg01528321	chr10:82214614	TSPAN14	0.89	16.17	0.6	6.02e-47	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02707280	chr19:44617674	ZNF225	-0.45	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.33	-0.55	8.53e-39	Headache;
LGG	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg02002194	chr4:3960332	NA	0.45	8.3	0.36	1.14e-15	Retinal vascular caliber;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg19635926	chr16:89946313	TCF25	0.72	8.07	0.35	6.23e-15	Skin colour saturation;
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg05556477	chr5:131705319	SLC22A5	0.85	10.14	0.43	5.88e-22	Rheumatoid arthritis;
LGG	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg21775007	chr8:11205619	TDH	0.74	12.79	0.51	2.67e-32	Retinal vascular caliber;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.34	0.43	1.12e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs13314892	0.692	rs62252240	chr3:69894042	C/T	cg17445875	chr3:69859618	MITF	-0.41	-7.9	-0.34	2.07e-14	QRS complex (12-leadsum);
LGG	cis	rs4740619	0.689	rs2225182	chr9:15953575	C/A	cg14451791	chr9:16040625	NA	-0.4	-9.96	-0.42	2.69e-21	Body mass index;
LGG	cis	rs611744	0.647	rs631775	chr8:109252746	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.37	0.4	3.29e-19	Dupuytren's disease;
LGG	trans	rs2727020	0.587	rs1164658	chr11:49298551	C/A	cg11707556	chr5:10655725	ANKRD33B	0.51	9.74	0.41	1.59e-20	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg15213114	chr10:74927623	ECD;FAM149B1	0.36	6.67	0.3	7.2e-11	Obesity-related traits;
LGG	cis	rs10186029	0.648	rs13022006	chr2:213940309	A/C	cg08319019	chr2:214017104	IKZF2	0.49	8.58	0.37	1.49e-16	Systemic sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00615915	chr18:61637299	SERPINB8	0.46	7.31	0.32	1.17e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.43	-0.36	4.36e-16	Skin colour saturation;
LGG	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs929596	0.755	rs887829	chr2:234668570	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.72	12.85	0.51	1.49e-32	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.71e-21	Hypertriglyceridemia;
LGG	cis	rs1577917	0.559	rs7763210	chr6:86808618	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-8.17	-0.35	2.96e-15	Response to antipsychotic treatment;
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.22e-15	Bipolar disorder;
LGG	cis	rs12357919	0.542	rs3740471	chr10:105363289	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.8	13.09	0.52	1.59e-33	White matter hyperintensity burden;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.5	0.44	2.77e-23	Prudent dietary pattern;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.67	-11.92	-0.48	9.03e-29	Longevity;Endometriosis;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.4e-16	Aortic root size;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg00166722	chr3:10149974	C3orf24	0.54	8.86	0.38	1.71e-17	Alzheimer's disease;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.44	0.33	4.96e-13	Schizophrenia;
LGG	trans	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.43	-0.44	5.01e-23	Total cholesterol levels;
LGG	cis	rs1372520	0.748	rs1471484	chr4:90754313	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-8.05	-0.35	6.81e-15	Neuroticism;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.3	5.18e-11	Aortic root size;
LGG	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.45	0.56	2.39e-39	Colorectal cancer;
LGG	cis	rs4731207	0.698	rs1904975	chr7:124552802	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg20821713	chr7:1055600	C7orf50	-0.51	-8.02	-0.35	8.72e-15	Bronchopulmonary dysplasia;
LGG	cis	rs6032067	1.000	rs6017509	chr20:43830362	A/G	cg10761708	chr20:43804764	PI3	0.76	11.61	0.47	1.62e-27	Blood protein levels;
LGG	cis	rs17270561	0.666	rs4712976	chr6:25842203	C/T	cg03264133	chr6:25882463	NA	-0.44	-6.75	-0.3	4.32e-11	Iron status biomarkers;
LGG	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg06636001	chr8:8085503	FLJ10661	0.46	8.48	0.37	2.95e-16	Parkinson's disease;
LGG	cis	rs7267979	0.866	rs2424699	chr20:25257462	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.73	0.41	1.8e-20	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg16270222	chr17:41446396	NA	0.29	6.82	0.3	2.9e-11	Menopause (age at onset);
LGG	cis	rs10207628	0.943	rs10207708	chr2:127852056	G/A	cg06223080	chr2:127868745	NA	-0.76	-14.71	-0.56	1.81e-40	Psychosis and Alzheimer's disease;
LGG	cis	rs1009647	0.645	rs68153899	chr14:55702908	C/T	cg04306507	chr14:55594613	LGALS3	0.47	7.79	0.34	4.44e-14	Testicular germ cell tumor;
LGG	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg15704280	chr7:45808275	SEPT13	0.77	8.92	0.38	1.08e-17	Axial length;
LGG	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg08250081	chr4:10125330	NA	0.4	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs2415984	0.600	rs72672853	chr14:46932920	T/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.09	-0.42	8.71e-22	Number of children ever born;
LGG	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg06637938	chr14:75390232	RPS6KL1	0.51	9.0	0.39	5.82e-18	Height;
LGG	cis	rs7660883	1.000	rs9998251	chr4:87999055	G/A	cg21988461	chr4:88008667	AFF1	-0.33	-9.08	-0.39	3.06e-18	HDL cholesterol levels;
LGG	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg13607699	chr17:42295918	UBTF	-0.94	-19.08	-0.66	2.73e-60	Total body bone mineral density;
LGG	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg11752832	chr7:134001865	SLC35B4	0.6	11.1	0.46	1.52e-25	Mean platelet volume;
LGG	cis	rs2735413	0.564	rs7192226	chr16:78120260	T/A	cg04733911	chr16:78082701	NA	0.57	8.06	0.35	6.57e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg05552183	chr6:42928497	GNMT	0.48	14.73	0.56	1.54e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg16386425	chr10:429943	DIP2C	0.45	9.16	0.39	1.71e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.13e-33	Calcium levels;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg12016809	chr21:47604291	C21orf56	0.51	8.65	0.37	8.37e-17	Testicular germ cell tumor;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg21017887	chr14:105400489	NA	0.43	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg05753993	chr18:77199432	NFATC1	0.37	6.81	0.3	3.04e-11	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg02002194	chr4:3960332	NA	0.45	8.67	0.37	7.54e-17	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs548181	0.609	rs511822	chr11:125534115	C/T	cg03464685	chr11:125439445	EI24	1.35	19.97	0.68	1.79e-64	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg19455335	chr8:22457658	C8orf58	-0.45	-9.24	-0.39	8.91e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Body mass index;
LGG	cis	rs713587	0.691	rs754537	chr2:25176277	A/T	cg04586622	chr2:25135609	ADCY3	-0.37	-9.45	-0.4	1.66e-19	Body mass index in non-asthmatics;
LGG	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg18105134	chr13:113819100	PROZ	0.72	15.34	0.58	2.99e-43	Platelet distribution width;
LGG	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg26597838	chr10:835615	NA	0.74	10.15	0.43	5.55e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00166722	chr3:10149974	C3orf24	0.53	8.97	0.38	7.48e-18	Alzheimer's disease;
LGG	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg11984989	chr7:158649758	WDR60	-1.02	-13.44	-0.53	5.22e-35	Height;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.43e-15	Bipolar disorder;
LGG	cis	rs4959677	0.689	rs1772980	chr6:2499839	C/T	cg20147862	chr6:2634573	C6orf195	-0.39	-8.61	-0.37	1.18e-16	Orthostatic hypotension;
LGG	cis	rs7192750	0.586	rs13329779	chr16:71943940	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs2273669	0.667	rs2273668	chr6:109323519	G/T	cg05315195	chr6:109294784	ARMC2	-0.66	-8.68	-0.37	6.93e-17	Prostate cancer;
LGG	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg05535760	chr7:792225	HEATR2	-0.81	-11.42	-0.47	8.48e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg13642754	chr19:37803085	NA	-0.45	-7.3	-0.32	1.28e-12	Coronary artery calcification;
LGG	cis	rs7072216	0.763	rs10883091	chr10:100167239	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.26	-0.32	1.63e-12	Metabolite levels;
LGG	cis	rs416603	0.967	rs7191538	chr16:11363389	C/G	cg00044050	chr16:11439710	C16orf75	-0.55	-9.27	-0.4	6.94e-19	Type 1 diabetes;
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05525867	chr15:75661090	MAN2C1	0.38	6.72	0.3	5.46e-11	Obesity-related traits;
LGG	cis	rs2862064	1.000	rs6555787	chr5:156433699	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.8	-0.45	2.05e-24	Platelet count;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg10056627	chr6:42928773	GNMT	0.26	7.14	0.31	3.7e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg27124370	chr19:33622961	WDR88	-0.6	-11.28	-0.46	3.09e-26	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs758324	0.853	rs1604082	chr5:131176917	A/G	cg06307176	chr5:131281290	NA	0.54	8.9	0.38	1.26e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07659893	chr17:61819838	STRADA	-0.44	-7.33	-0.32	1.02e-12	Prudent dietary pattern;
LGG	trans	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg07817883	chr1:32538562	TMEM39B	-0.69	-9.73	-0.41	1.82e-20	Monocyte percentage of white cells;
LGG	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg20673091	chr1:2541236	MMEL1	-0.78	-20.11	-0.68	4.01e-65	Ulcerative colitis;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-11.79	-0.48	3.21e-28	Longevity;Endometriosis;
LGG	cis	rs9880211	1.000	rs17364492	chr3:136204437	G/T	cg21827317	chr3:136751795	NA	0.47	7.09	0.31	4.9e-12	Body mass index;Height;
LGG	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg20628663	chr10:43360327	NA	-0.42	-8.57	-0.37	1.6e-16	Blood protein levels;
LGG	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	12.93	0.51	7.56e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg25482853	chr8:67687455	SGK3	1.05	13.26	0.52	2.91e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19717773	chr7:2847554	GNA12	-0.31	-6.79	-0.3	3.43e-11	Height;
LGG	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.25	0.32	1.82e-12	Bipolar disorder;
LGG	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg17971929	chr21:40555470	PSMG1	0.88	17.79	0.64	2.47e-54	Cognitive function;
LGG	cis	rs933688	1.000	rs12656350	chr5:90751343	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.74	0.66	9.5e-59	Smoking behavior;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7202877	0.610	rs7202284	chr16:75374346	A/T	cg03315344	chr16:75512273	CHST6	0.51	6.94	0.31	1.37e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg10792982	chr14:105748885	BRF1	0.54	10.71	0.45	4.66e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg20913747	chr6:44695427	NA	-0.65	-11.16	-0.46	8.78e-26	Total body bone mineral density;
LGG	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg09021430	chr5:549028	NA	-0.81	-12.73	-0.51	4.69e-32	Obesity-related traits;
LGG	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg08392591	chr16:89556376	ANKRD11	0.61	9.83	0.42	7.53e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg13939156	chr17:80058883	NA	-0.52	-9.86	-0.42	6.06e-21	Life satisfaction;
LGG	cis	rs4732038	0.902	rs10228520	chr7:134238258	T/C	cg06906464	chr7:134288099	NA	-0.51	-12.58	-0.5	2e-31	Longevity;
LGG	cis	rs3540	0.618	rs11609	chr15:91043765	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-12.31	-0.5	2.6e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14442939	chr10:27389572	ANKRD26	-0.76	-11.3	-0.46	2.57e-26	Breast cancer;
LGG	cis	rs714515	0.934	rs9425297	chr1:172358816	A/G	cg01573306	chr1:172330400	DNM3	0.34	7.42	0.33	5.49e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg03653399	chr8:142233436	SLC45A4	0.42	8.32	0.36	1.01e-15	Immature fraction of reticulocytes;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.25	0.36	1.69e-15	Schizophrenia;
LGG	cis	rs2236918	1.000	rs1776133	chr1:242025098	C/T	cg17736920	chr1:242011382	EXO1	0.53	9.54	0.41	7.9e-20	Menopause (age at onset);
LGG	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	trans	rs7980799	0.621	rs7138393	chr12:33590787	G/C	cg26384229	chr12:38710491	ALG10B	-0.44	-7.64	-0.33	1.25e-13	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9357271	0.736	rs62397049	chr6:38402197	T/G	cg07362130	chr6:38359646	BTBD9	-0.4	-8.23	-0.36	1.87e-15	Restless legs syndrome;
LGG	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11644478	chr21:40555479	PSMG1	0.65	10.83	0.45	1.64e-24	Cognitive function;
LGG	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	trans	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg05926928	chr17:57297772	GDPD1	0.58	9.46	0.4	1.5700000000000001e-19	Schizophrenia;
LGG	cis	rs1941023	0.606	rs3825020	chr11:60184191	G/A	cg08716584	chr11:60157161	MS4A7	-0.39	-7.57	-0.33	2e-13	Congenital heart disease (maternal effect);
LGG	trans	rs1493916	0.721	rs4799723	chr18:31367050	T/G	cg04226714	chr8:49833948	SNAI2	-0.51	-9.07	-0.39	3.45e-18	Life satisfaction;
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg19847130	chr8:10466454	RP1L1	0.31	6.89	0.3	1.88e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08219700	chr8:58056026	NA	0.47	7.05	0.31	6.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.76e-11	Educational attainment;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg24829409	chr8:58192753	C8orf71	-0.7	-9.21	-0.39	1.14e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	1.000	rs780095	chr2:27741105	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-7.76	-0.34	5.39e-14	Total body bone mineral density;
LGG	cis	rs1577917	0.876	rs12190735	chr6:86686467	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.93	-0.38	1.05e-17	Response to antipsychotic treatment;
LGG	cis	rs12493885	0.769	rs61791509	chr3:153753178	T/C	cg17054900	chr3:154042577	DHX36	-0.72	-8.91	-0.38	1.21e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs490234	0.702	rs1891035	chr9:128258684	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.31	-0.43	1.46e-22	Mean arterial pressure;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	8.05e-29	Prudent dietary pattern;
LGG	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.46	-0.37	3.5e-16	Aortic root size;
LGG	cis	rs4948102	0.690	rs35844144	chr7:56050525	C/T	cg17215666	chr7:56131930	SUMF2	0.45	7.11	0.31	4.29e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.79	0.54	1.69e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.22	0.39	1.07e-18	Aortic root size;
LGG	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg27490568	chr2:178487706	NA	0.49	9.81	0.41	8.81e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.51	0.37	2.52e-16	Schizophrenia;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.49	0.61	2.21e-48	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-10.57	-0.44	1.49e-23	Hepatocellular carcinoma;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.66	-0.63	9.99e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg06719900	chr11:109292894	C11orf87	0.57	10.4	0.44	6.58e-23	Schizophrenia;
LGG	cis	rs66716358	0.744	rs10838253	chr11:44317477	C/T	cg16977035	chr11:44330474	ALX4	0.36	9.35	0.4	3.82e-19	Monobrow;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg10691809	chr22:31892045	SFI1	-0.34	-6.65	-0.3	8.07e-11	Brain structure;
LGG	cis	rs72781680	1.000	rs72788280	chr2:24095907	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.59	0.41	5.59e-20	Lymphocyte counts;
LGG	cis	rs3849046	0.680	rs11746692	chr5:137946355	G/T	cg10920316	chr5:137946599	NA	-0.45	-7.24	-0.32	1.85e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.11	-0.43	7.71e-22	Response to antipsychotic treatment;
LGG	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.57	0.47	2.34e-27	Mean platelet volume;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18252515	chr7:66147081	NA	0.42	7.15	0.32	3.43e-12	Aortic root size;
LGG	cis	rs4819852	0.752	rs917478	chr22:19972824	T/C	cg07821417	chr22:19972146	ARVCF	0.49	10.58	0.44	1.44e-23	Pulse pressure;
LGG	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg12046867	chr14:103022105	NA	-0.72	-12.42	-0.5	9.03e-31	Platelet count;
LGG	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg16141378	chr3:129829833	LOC729375	-0.43	-10.61	-0.44	1.05e-23	Mood instability;
LGG	cis	rs4788570	0.625	rs4788810	chr16:71621637	C/T	cg06353428	chr16:71660113	MARVELD3	-1.26	-18.83	-0.66	3.77e-59	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.57	-0.37	1.57e-16	Alcohol dependence;
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs2088885	1.000	rs7627954	chr3:170979975	T/C	cg18052528	chr3:170975382	TNIK	-0.27	-6.75	-0.3	4.45e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07570687	chr10:102243282	WNT8B	0.4	7.07	0.31	5.84e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs2571521	0.887	rs9298879	chr9:26097224	A/C	cg26642667	chr7:127292389	SND1	-0.63	-6.78	-0.3	3.73e-11	Pursuit maintenance gain in psychotic disorders;
LGG	cis	rs950173	1.000	rs13000153	chr2:172586067	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.92	-10.31	-0.43	1.4e-22	Hippocampal volume;
LGG	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg03264133	chr6:25882463	NA	0.48	8.63	0.37	9.64e-17	Blood metabolite levels;
LGG	cis	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg12826209	chr6:26865740	GUSBL1	-0.75	-8.08	-0.35	5.65e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg25214090	chr10:38739885	LOC399744	0.59	10.19	0.43	4e-22	Corneal astigmatism;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg24101359	chr6:42928495	GNMT	0.54	15.18	0.58	1.5e-42	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Calcium levels;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.16	0.35	3.28e-15	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.81	0.34	3.75e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs910187	0.605	rs6063079	chr20:45804275	C/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.61	-0.41	4.58e-20	Migraine;
LGG	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02463440	chr8:22132932	PIWIL2	0.5	11.17	0.46	8.1e-26	Hypertriglyceridemia;
LGG	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg00599393	chr8:22457479	C8orf58	-0.45	-8.13	-0.35	4.08e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-9.8	-0.41	1.02e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.73	-0.3	4.98e-11	Total body bone mineral density;
LGG	cis	rs765787	0.530	rs12904331	chr15:45518293	C/T	cg24006582	chr15:45444508	DUOX1	0.66	12.02	0.49	3.77e-29	Uric acid levels;
LGG	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.53e-11	Parkinson's disease;
LGG	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg20818283	chr2:191399100	TMEM194B	0.31	7.44	0.33	4.79e-13	Pulse pressure;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg20887711	chr4:1340912	KIAA1530	-0.6	-11.29	-0.46	2.77e-26	Obesity-related traits;
LGG	cis	rs6694672	1.000	rs7542397	chr1:197096720	G/A	cg13682187	chr1:196946512	CFHR5	0.49	6.89	0.3	1.88e-11	Asthma;
LGG	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg03929089	chr4:120376271	NA	0.81	11.17	0.46	7.87e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.0	-0.31	9.12e-12	Myopia (pathological);
LGG	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.0	-0.35	9.77e-15	Retinal vascular caliber;
LGG	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06850241	chr22:41845214	NA	-0.43	-6.82	-0.3	2.81e-11	Vitiligo;
LGG	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg19847130	chr8:10466454	RP1L1	0.32	6.94	0.31	1.34e-11	Neuroticism;
LGG	cis	rs12775980	0.737	rs74129723	chr10:29850135	G/A	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg04287289	chr16:89883240	FANCA	0.81	17.35	0.63	2.71e-52	Vitiligo;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.66	-0.3	7.88e-11	Obesity-related traits;
LGG	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg24558204	chr6:135376177	HBS1L	0.62	10.74	0.45	3.51e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7580658	0.545	rs67996371	chr2:127953417	G/A	cg10021288	chr2:128175891	PROC	-0.5	-9.51	-0.4	1.07e-19	Protein C levels;
LGG	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg07615347	chr10:60278583	BICC1	0.62	17.62	0.63	1.53e-53	Refractive error;
LGG	cis	rs10267417	0.603	rs6969717	chr7:19908081	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	7.68	0.34	9.54e-14	Night sleep phenotypes;
LGG	cis	rs9329289	0.590	rs11251295	chr10:2563183	C/T	cg15501526	chr10:2543763	NA	0.52	8.95	0.38	8.33e-18	Age-related hearing impairment;
LGG	cis	rs806215	0.951	rs327516	chr7:127255795	C/G	cg25922125	chr7:127225783	GCC1	0.7	9.94	0.42	3.07e-21	Type 2 diabetes;
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg26554054	chr8:600488	NA	-1.01	-9.3	-0.4	5.59e-19	IgG glycosylation;
LGG	cis	rs11864453	0.647	rs3764314	chr16:72127078	T/C	cg01557791	chr16:72042693	DHODH	-0.45	-8.24	-0.36	1.79e-15	Fibrinogen levels;
LGG	cis	rs368123	1.000	rs415897	chr6:160739505	A/G	cg07349212	chr6:160770346	SLC22A3	0.35	7.59	0.33	1.76e-13	Waist circumference;
LGG	cis	rs12476592	0.602	rs262503	chr2:63860437	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.76	-0.3	4.05e-11	Childhood ear infection;
LGG	cis	rs6696846	0.936	rs6662930	chr1:205041465	T/C	cg00857998	chr1:205179979	DSTYK	0.53	8.52	0.37	2.2e-16	Red blood cell count;
LGG	cis	rs7617773	0.817	rs9834095	chr3:48327751	G/A	cg11946769	chr3:48343235	NME6	0.63	10.57	0.44	1.48e-23	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-8.54	-0.37	1.89e-16	Brugada syndrome;
LGG	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg18424134	chr6:126068038	NA	0.21	6.66	0.3	7.95e-11	Brugada syndrome;
LGG	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg03060546	chr3:49711283	APEH	-0.63	-10.46	-0.44	3.82e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4700695	0.841	rs36301	chr5:65348940	A/G	cg21114390	chr5:65439923	SFRS12	0.58	7.04	0.31	7.18e-12	Facial morphology (factor 19);
LGG	cis	rs12137294	0.866	rs1172153	chr1:205220661	T/C	cg00889227	chr1:205173544	DSTYK	-0.27	-6.75	-0.3	4.49e-11	Red cell distribution width;
LGG	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.98	-0.35	1.13e-14	Bladder cancer;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg18350739	chr11:68623251	NA	-0.85	-21.64	-0.71	2.95e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-10.57	-0.44	1.54e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg11859384	chr17:80120422	CCDC57	0.44	7.7	0.34	8.1e-14	Life satisfaction;
LGG	trans	rs7777677	0.925	rs9655661	chr7:142370125	A/G	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19524238	chr7:2802976	GNA12	0.41	9.59	0.41	5.32e-20	Height;
LGG	trans	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	13.39	0.53	8.66e-35	Obesity-related traits;
LGG	cis	rs17221829	0.733	rs11600011	chr11:89407980	T/C	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.58	-0.37	1.4e-16	Anxiety in major depressive disorder;
LGG	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg11707556	chr5:10655725	ANKRD33B	0.5	9.74	0.41	1.56e-20	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg17691542	chr6:26056736	HIST1H1C	0.65	10.79	0.45	2.26e-24	Iron status biomarkers;
LGG	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.63	-0.33	1.35e-13	Testicular germ cell tumor;
LGG	cis	rs9815354	1.000	rs6599179	chr3:41855284	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00605358	chr12:89747739	DUSP6	0.5	7.89	0.34	2.17e-14	Gut microbiome composition (summer);
LGG	cis	rs943466	0.573	rs11751591	chr6:33794215	G/A	cg07519485	chr6:33762594	MLN	0.45	7.22	0.32	2.09e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg20503657	chr10:835505	NA	0.75	10.44	0.44	4.69e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg17202724	chr17:61916730	SMARCD2	0.47	10.47	0.44	3.53e-23	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg19223190	chr17:80058835	NA	-0.45	-8.67	-0.37	7.18e-17	Life satisfaction;
LGG	cis	rs1018836	0.851	rs12548741	chr8:91628878	G/A	cg16814680	chr8:91681699	NA	-0.85	-15.95	-0.6	5.71e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6537837	0.838	rs12023950	chr1:110099858	T/C	cg05049280	chr1:110155535	GNAT2	0.32	6.99	0.31	9.62e-12	Major depressive disorder;
LGG	cis	rs1865760	0.713	rs2013063	chr6:25994098	C/T	cg03264133	chr6:25882463	NA	-0.41	-7.19	-0.32	2.67e-12	Height;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg18402987	chr7:1209562	NA	0.5	8.36	0.36	7.23e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3925075	1.000	rs11859274	chr16:31361059	C/T	cg02846316	chr16:31340340	ITGAM	0.41	7.98	0.35	1.17e-14	IgA nephropathy;
LGG	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg03315344	chr16:75512273	CHST6	-0.5	-10.14	-0.43	6.03e-22	Dupuytren's disease;
LGG	trans	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.15e-16	Blood pressure (smoking interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23894005	chr6:37467649	C6orf129	-0.43	-7.1	-0.31	4.83e-12	Pancreatic cancer;
LGG	trans	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.69	-0.37	6.4e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs745080	1.000	rs729931	chr14:52988585	G/C	cg23333723	chr14:53022898	GPR137C	-0.33	-7.06	-0.31	6.26e-12	Orofacial clefts;
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg11859384	chr17:80120422	CCDC57	-0.47	-7.88	-0.34	2.29e-14	Life satisfaction;
LGG	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4944092	0.793	rs94111	chr11:75915139	A/G	cg04588336	chr11:75916460	WNT11	-0.43	-10.22	-0.43	3e-22	PR interval;
LGG	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg06026331	chr20:60912101	LAMA5	0.71	12.74	0.51	4.28e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg08807101	chr21:30365312	RNF160	0.93	19.77	0.68	1.68e-63	Dental caries;
LGG	cis	rs9318086	0.648	rs9507184	chr13:24473642	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.26	0.4	7.82e-19	Myopia (pathological);
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12379764	chr21:47803548	PCNT	-0.44	-7.44	-0.33	4.8e-13	Testicular germ cell tumor;
LGG	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg03060546	chr3:49711283	APEH	0.59	9.11	0.39	2.54e-18	Resting heart rate;
LGG	cis	rs1270639	0.778	rs2906928	chr7:157444976	T/G	cg13357408	chr7:157437802	PTPRN2	0.66	10.58	0.44	1.4e-23	Colorectal cancer;
LGG	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-7.23	-0.32	2.07e-12	Dementia with Lewy bodies;
LGG	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.4	0.47	1.08e-26	Ovarian reserve;
LGG	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg25319279	chr11:5960081	NA	-0.43	-7.05	-0.31	6.59e-12	DNA methylation (variation);
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg19147804	chr7:1989927	MAD1L1	-0.56	-10.93	-0.45	6.94e-25	Schizophrenia;
LGG	cis	rs7586879	0.638	rs10203482	chr2:25136916	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.92	0.51	7.98e-33	Body mass index;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.71	-0.3	5.74e-11	Obesity-related traits;
LGG	cis	rs9640161	0.789	rs28432021	chr7:150046235	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.01	-0.57	8.43e-42	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs11225247	0.772	rs11601671	chr11:102250065	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg19847130	chr8:10466454	RP1L1	0.35	7.7	0.34	8.4e-14	Neuroticism;
LGG	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.44e-33	Gut microbiome composition (summer);
LGG	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.18	-0.32	2.88e-12	Inflammatory bowel disease;
LGG	cis	rs597583	0.715	rs11216436	chr11:117391374	G/A	cg27161313	chr11:117392002	DSCAML1	-0.64	-10.08	-0.42	9.78e-22	Putamen volume;
LGG	cis	rs9863	0.931	rs3186071	chr12:124429279	G/A	cg13487667	chr12:124434373	CCDC92	-0.38	-7.44	-0.33	4.89e-13	White blood cell count;
LGG	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.0	0.35	9.79e-15	Electroencephalogram traits;
LGG	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.35	-0.32	9.27e-13	Prostate-specific antigen levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07025343	chr14:77606922	ZDHHC22	0.46	7.29	0.32	1.39e-12	Cognitive performance;
LGG	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.9	-0.45	8.71e-25	Aortic root size;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs2273669	0.667	rs11153156	chr6:109365911	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs9947295	0.649	rs1424913	chr18:11781962	G/C	cg14735704	chr18:11749182	GNAL	0.49	7.45	0.33	4.59e-13	QT interval (drug interaction);
LGG	cis	rs266717	0.788	rs266750	chr3:186512835	T/C	cg00373256	chr3:186519153	RFC4	-0.42	-8.65	-0.37	8.24e-17	Adiponectin levels;
LGG	cis	rs7932354	0.528	rs1872896	chr11:47160623	C/T	cg03339077	chr11:47165057	C11orf49	-0.55	-10.53	-0.44	2.18e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs17445240	0.515	rs6760466	chr2:3707136	T/C	cg17046650	chr2:3699563	NA	0.7	10.46	0.44	3.88e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg08200770	chr17:80723486	TBCD	-0.5	-9.47	-0.4	1.42e-19	Glycated hemoglobin levels;
LGG	cis	rs2658782	0.789	rs2605580	chr11:93147054	C/T	cg15737290	chr11:93063684	CCDC67	0.5	7.86	0.34	2.71e-14	Pulmonary function decline;
LGG	cis	rs2120243	0.572	rs3816528	chr3:157127290	C/T	cg24825693	chr3:157122686	VEPH1	0.58	13.29	0.53	2.27e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs3816183	0.959	rs3772063	chr2:43017095	A/G	cg14631114	chr2:43023945	NA	0.5	9.34	0.4	3.92e-19	Hypospadias;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.94	0.35	1.6e-14	Lung cancer;
LGG	cis	rs240764	0.635	rs4840134	chr6:100951699	T/C	cg21058520	chr6:100914733	NA	0.47	8.08	0.35	5.78e-15	Neuroticism;
LGG	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg02151108	chr14:50098012	C14orf104	-0.43	-9.14	-0.39	2.03e-18	Carotid intima media thickness;
LGG	cis	rs4481887	0.508	rs6695316	chr1:248394322	G/C	cg00666640	chr1:248458726	OR2T12	0.48	7.21	0.32	2.26e-12	Common traits (Other);
LGG	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg16208657	chr15:68119293	LBXCOR1	-0.38	-7.31	-0.32	1.22e-12	Obesity;
LGG	cis	rs7267979	0.903	rs2500423	chr20:25374882	G/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4787491	0.729	rs12446378	chr16:30043110	T/G	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4423214	1.000	rs1044482	chr11:71155171	C/T	cg05163923	chr11:71159392	DHCR7	0.71	14.16	0.55	4.46e-38	Vitamin D levels;
LGG	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg25358565	chr5:93447407	FAM172A	-0.84	-11.6	-0.47	1.71e-27	Diabetic retinopathy;
LGG	cis	rs4561483	0.801	rs4511557	chr16:11949458	T/C	cg08843971	chr16:11963173	GSPT1	0.66	17.29	0.63	5.05e-52	Testicular germ cell tumor;
LGG	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg21045802	chr8:109455806	TTC35	0.52	9.84	0.42	7.26e-21	Dupuytren's disease;
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg03517284	chr6:25882590	NA	-0.88	-18.3	-0.65	1.06e-56	Urate levels;
LGG	trans	rs9467711	0.659	rs72845428	chr6:26550144	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.36	-0.43	8.94e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg02153584	chr22:29168773	CCDC117	0.7	11.8	0.48	2.8e-28	Lymphocyte counts;
LGG	cis	rs7091068	0.671	rs1764322	chr10:95406276	T/G	cg20715218	chr10:95462985	C10orf4	-0.6	-9.78	-0.41	1.12e-20	Urinary tract infection frequency;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.66e-21	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.14	-0.35	3.67e-15	Obesity-related traits;
LGG	cis	rs7566780	0.568	rs4832448	chr2:16629754	C/T	cg09580478	chr2:16689509	NA	0.46	6.74	0.3	4.67e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg02158880	chr13:53174818	NA	0.4	7.91	0.35	1.89e-14	Lewy body disease;
LGG	cis	rs2694528	0.841	rs74985265	chr5:60417457	G/T	cg11474532	chr5:59995715	DEPDC1B	0.73	7.08	0.31	5.4e-12	Parkinson's disease;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg21226059	chr5:178986404	RUFY1	0.51	9.31	0.4	5.08e-19	Lung cancer;
LGG	cis	rs9314323	0.767	rs6557915	chr8:26209062	C/A	cg11498726	chr8:26250323	BNIP3L	-0.53	-11.22	-0.46	5.32e-26	Red cell distribution width;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs2632516	1.000	rs2526378	chr17:56404349	A/G	cg12560992	chr17:57184187	TRIM37	0.42	6.67	0.3	7.14e-11	Alzheimer's disease;Alzheimer's disease in APOE e4- carriers;Monocyte count;
LGG	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg21475434	chr5:93447410	FAM172A	0.66	6.72	0.3	5.42e-11	Diabetic retinopathy;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00166836	chr6:149721425	MAP3K7IP2;SUMO4	-0.58	-6.99	-0.31	9.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg06026331	chr20:60912101	LAMA5	-0.52	-9.88	-0.42	4.93e-21	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg23205692	chr1:25664452	TMEM50A	0.45	9.34	0.4	4.07e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg06532163	chr17:45867833	NA	0.55	9.31	0.4	5.18e-19	IgG glycosylation;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00933542	chr6:150070202	PCMT1	-0.4	-7.36	-0.32	8.25e-13	Lung cancer;
LGG	cis	rs9326248	0.727	rs4938347	chr11:117021759	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.74	0.34	6.32e-14	Blood protein levels;
LGG	cis	rs209489	0.892	rs9474465	chr6:53111504	T/C	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg19676328	chr12:49525230	TUBA1B	-0.65	-10.24	-0.43	2.58e-22	Total cholesterol levels;
LGG	cis	rs919433	0.713	rs10172961	chr2:198446859	T/C	cg00792783	chr2:198669748	PLCL1	0.5	7.98	0.35	1.17e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg07936489	chr17:37558343	FBXL20	-0.42	-6.76	-0.3	4.06e-11	Asthma;
LGG	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg13114125	chr14:105738426	BRF1	-0.87	-16.17	-0.6	5.75e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2016266	0.859	rs2886129	chr12:53731984	G/A	cg04065151	chr12:53682969	ESPL1	-0.51	-7.87	-0.34	2.61e-14	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg05793240	chr7:2802953	GNA12	0.36	8.25	0.36	1.63e-15	Height;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.22	0.39	1.06e-18	Life satisfaction;
LGG	cis	rs2304206	0.614	rs12104272	chr19:50148052	A/G	cg09250473	chr19:50168907	IRF3;BCL2L12	-0.65	-12.23	-0.49	5.49e-30	Vitiligo;
LGG	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs968567	0.539	rs174556	chr11:61580635	C/T	cg19610905	chr11:61596333	FADS2	-0.77	-13.11	-0.52	1.29e-33	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg14132834	chr19:41945861	ATP5SL	-0.49	-9.67	-0.41	2.94e-20	Height;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06697488	chr5:173314932	CPEB4	0.46	7.37	0.32	7.93e-13	Cognitive performance;
LGG	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs3845702	0.736	rs12465592	chr2:180862654	C/G	cg01881094	chr2:180872142	CWC22	1.28	16.5	0.61	1.84e-48	Schizophrenia;
LGG	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs12210905	1.000	rs6931711	chr6:27145586	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.0	-0.35	9.97e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6708331	0.564	rs4632370	chr2:70376825	A/T	cg01613454	chr2:70366299	NA	0.53	10.9	0.45	8.98e-25	Obesity-related traits;
LGG	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	17.97	0.64	3.79e-55	Platelet count;
LGG	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	8.04	0.35	7.42e-15	Response to antipsychotic treatment;
LGG	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg11584989	chr19:19387371	SF4	0.74	12.0	0.49	4.52e-29	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.26	-0.32	1.65e-12	Menopause (age at onset);
LGG	cis	rs4132509	0.739	rs10803150	chr1:243822600	C/T	cg21452805	chr1:244014465	NA	0.87	9.24	0.39	9.11e-19	RR interval (heart rate);
LGG	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.91	0.38	1.16e-17	Common traits (Other);
LGG	cis	rs131777	0.508	rs140518	chr22:50999182	C/T	cg05418105	chr22:50981406	NA	-0.69	-12.29	-0.5	2.94e-30	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.35e-16	Life satisfaction;
LGG	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg08344181	chr3:125677491	NA	-0.85	-8.49	-0.37	2.89e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17739167	0.532	rs8035074	chr15:42239779	C/T	cg20935245	chr15:42234343	EHD4	0.38	7.45	0.33	4.61e-13	Monocyte count;
LGG	cis	rs28588043	1.000	rs2421635	chr1:170983809	A/G	cg03458344	chr1:170964477	C1orf129	-0.46	-6.87	-0.3	2.1e-11	Number of children (6+ vs. 0 or 1);
LGG	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs75059851	0.756	rs11223647	chr11:133839588	G/A	cg20042908	chr11:133852938	NA	-0.77	-14.4	-0.56	4.18e-39	Schizophrenia;
LGG	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.85	-0.3	2.4e-11	Sudden cardiac arrest;
LGG	cis	rs741702	0.928	rs1010222	chr19:13048608	A/G	cg04657146	chr19:12876947	HOOK2	0.45	7.39	0.32	6.88e-13	Red blood cell traits;
LGG	trans	rs225245	0.782	rs161183	chr17:33919475	G/C	cg19694781	chr19:47549865	TMEM160	-0.41	-7.08	-0.31	5.47e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1790761	0.967	rs869736	chr11:67205462	C/A	cg24690094	chr11:67383802	NA	-0.38	-6.65	-0.3	8.2e-11	Mean corpuscular volume;
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-8.82	-0.38	2.3e-17	Skin colour saturation;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg21724239	chr8:58056113	NA	0.61	9.36	0.4	3.54e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg14123879	chr5:61602127	KIF2A	0.42	6.94	0.31	1.34e-11	Coronary artery disease;
LGG	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-8.08	-0.35	5.87e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.35	-0.32	8.91e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg22778903	chr21:42741698	MX2	0.46	9.19	0.39	1.37e-18	Melanoma;
LGG	trans	rs10506458	1.000	rs73127086	chr12:63415626	G/A	cg22491629	chr6:157744540	C6orf35	-0.94	-13.5	-0.53	2.95e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12654349	chr5:56205094	C5orf35	0.81	11.79	0.48	3.05e-28	Initial pursuit acceleration;
LGG	cis	rs4561483	0.801	rs33649	chr16:11979608	G/C	cg08843971	chr16:11963173	GSPT1	-0.67	-18.2	-0.65	3.02e-56	Testicular germ cell tumor;
LGG	cis	rs17767392	0.718	rs35609708	chr14:71843844	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	8.99	0.39	6.11e-18	Mitral valve prolapse;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg20887711	chr4:1340912	KIAA1530	0.5	9.34	0.4	4.17e-19	Obesity-related traits;
LGG	cis	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.89	-0.57	3.07e-41	IgG glycosylation;
LGG	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.95	-0.35	1.45e-14	HDL cholesterol;
LGG	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg26441486	chr22:50317300	CRELD2	0.39	7.0	0.31	9.12e-12	Schizophrenia;
LGG	cis	rs7914558	0.966	rs10748836	chr10:104693917	G/A	cg04362960	chr10:104952993	NT5C2	0.54	10.24	0.43	2.55e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1728785	0.818	rs1170430	chr16:68604954	T/C	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.33e-16	Ulcerative colitis;
LGG	cis	rs6694672	1.000	rs1332669	chr1:197005883	C/T	cg13682187	chr1:196946512	CFHR5	0.51	7.11	0.31	4.3e-12	Asthma;
LGG	cis	rs11676348	0.811	rs13027120	chr2:219020914	C/T	cg00012203	chr2:219082015	ARPC2	0.55	9.82	0.42	8.11e-21	Ulcerative colitis;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	0.953	rs1717010	chr3:41946903	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4474465	1.000	rs11237520	chr11:78201201	G/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.26	-0.36	1.53e-15	Alzheimer's disease (survival time);
LGG	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.97e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs4919087	0.892	rs10786319	chr10:99008951	T/C	cg25902810	chr10:99078978	FRAT1	0.48	8.99	0.39	6.18e-18	Monocyte count;
LGG	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg21772509	chr8:41503840	NKX6-3	0.8	16.74	0.61	1.5e-49	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2455601	0.744	rs11042107	chr11:8905871	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.59	-9.44	-0.4	1.8e-19	Schizophrenia;
LGG	cis	rs9393692	0.572	rs4145878	chr6:26198046	A/T	cg00631329	chr6:26305371	NA	-0.38	-6.95	-0.31	1.27e-11	Educational attainment;
LGG	trans	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg16105309	chr15:79090380	ADAMTS7	0.35	6.71	0.3	5.85e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.73	0.48	5.14e-28	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.934	rs4240865	chr1:152954839	G/T	cg13444842	chr1:152974279	SPRR3	0.38	7.46	0.33	4.25e-13	Inflammatory skin disease;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27567206	chr4:7787983	AFAP1	0.4	7.18	0.32	2.72e-12	Electrocardiographic conduction measures;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	20.64	0.69	1.36e-67	Alzheimer's disease;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	trans	rs2018683	0.707	rs10279870	chr7:28968935	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.16	-0.39	1.72e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs13095912	0.512	rs115865582	chr3:185308598	A/C	cg11274856	chr3:185301563	NA	0.5	8.08	0.35	5.53e-15	Systolic blood pressure;
LGG	cis	rs9534288	0.797	rs2404728	chr13:46581862	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs7166081	1.000	rs4776905	chr15:67500330	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs1461503	0.966	rs7110154	chr11:122843300	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.98	-0.35	1.13e-14	Joint mobility (Beighton score);
LGG	trans	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg06606381	chr12:133084897	FBRSL1	-1.36	-10.71	-0.45	4.64e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10911363	0.592	rs2782411	chr1:183476929	G/A	cg23894439	chr1:183413866	NA	0.47	8.81	0.38	2.59e-17	Systemic lupus erythematosus;
LGG	cis	rs9914988	0.943	rs11651867	chr17:27147248	T/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06108461	chr20:60628389	TAF4	-1.03	-20.58	-0.69	2.66e-67	Body mass index;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg11494091	chr17:61959527	GH2	0.51	8.11	0.35	4.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.63	-0.33	1.37e-13	Heart rate;
LGG	cis	rs4561483	0.801	rs33637	chr16:11989875	A/T	cg08843971	chr16:11963173	GSPT1	-0.68	-18.41	-0.65	3.5e-57	Testicular germ cell tumor;
LGG	cis	rs2074193	1.000	rs2074193	chr12:47771429	T/G	cg02516419	chr12:47771422	NA	0.85	18.31	0.65	9.75e-57	Migraine with aura;
LGG	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.95	0.38	8.51e-18	Axial length;
LGG	cis	rs2587949	0.615	rs1087727	chr3:4204974	A/G	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.76e-11	Periodontitis (DPAL);
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg15049968	chr18:44337910	ST8SIA5	-0.36	-6.7	-0.3	6.14e-11	Personality dimensions;
LGG	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg26818010	chr10:134567672	INPP5A	-0.73	-11.03	-0.46	2.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg06092702	chr1:163392909	NA	-0.47	-8.43	-0.36	4.38e-16	Motion sickness;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.99	0.49	5.15e-29	Tonsillectomy;
LGG	cis	rs17767392	0.958	rs36072220	chr14:71980744	A/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	2.89e-18	Mitral valve prolapse;
LGG	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.93	-0.42	3.49e-21	Depression;
LGG	cis	rs9880211	0.800	rs35198484	chr3:136492637	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	10.16	0.43	4.81e-22	Bone mineral density;
LGG	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg11764359	chr7:65958608	NA	-0.8	-14.94	-0.57	1.73e-41	Aortic root size;
LGG	cis	rs4917300	0.686	rs7824432	chr8:143104367	T/G	cg26003909	chr8:143102224	NA	-0.34	-6.83	-0.3	2.72e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg03528353	chr17:61819722	STRADA	0.43	7.36	0.32	8.46e-13	Prudent dietary pattern;
LGG	cis	rs31872	0.520	rs246053	chr5:140326290	T/A	cg19875535	chr5:140030758	IK	0.39	7.7	0.34	8.52e-14	Visceral adipose tissue adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14875093	chr19:38398164	WDR87;SIPA1L3	0.48	7.66	0.34	1.09e-13	Gut microbiome composition (summer);
LGG	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg05527609	chr1:210001259	C1orf107	-0.73	-10.73	-0.45	3.92e-24	Orofacial clefts;
LGG	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.38	-0.47	1.31e-26	Total body bone mineral density;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs62400317	0.859	rs62400289	chr6:45203783	T/C	cg18551225	chr6:44695536	NA	-0.64	-10.12	-0.43	6.91e-22	Total body bone mineral density;
LGG	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	7.83	0.34	3.41e-14	Renal function-related traits (BUN);
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.44	-0.47	7.4e-27	Tonsillectomy;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07677032	chr17:61819896	STRADA	-0.67	-12.42	-0.5	8.84e-31	Prudent dietary pattern;
LGG	cis	rs793571	0.523	rs7161889	chr15:58983425	C/G	cg05156742	chr15:59063176	FAM63B	0.57	9.67	0.41	2.84e-20	Schizophrenia;
LGG	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg11789530	chr4:8429930	ACOX3	-0.54	-8.88	-0.38	1.5e-17	Response to antineoplastic agents;
LGG	cis	rs113084984	0.718	rs1865574	chr2:11681438	A/G	cg07314298	chr2:11723111	GREB1	0.36	6.86	0.3	2.2e-11	Breast cancer;
LGG	cis	rs7929679	0.602	rs11032866	chr11:34803432	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.84	0.3	2.53e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg01620082	chr3:125678407	NA	-0.93	-9.41	-0.4	2.37e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.66	0.34	1.13e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs2153535	0.580	rs2143357	chr6:8497196	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.14e-31	Motion sickness;
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg04824913	chr4:887549	GAK	0.56	9.79	0.41	1.08e-20	Sjögren's syndrome;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg24829409	chr8:58192753	C8orf71	-0.63	-8.14	-0.35	3.78e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.74	-0.34	6.25e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.45	-0.33	4.51e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg25706281	chr1:46860511	FAAH	-0.28	-6.8	-0.3	3.3e-11	Menopause (age at onset);
LGG	cis	rs1552244	0.515	rs6768768	chr3:10177653	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.86	12.84	0.51	1.67e-32	Alzheimer's disease;
LGG	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg20744362	chr22:50050164	C22orf34	0.39	7.73	0.34	6.77e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14893161	chr1:205819251	PM20D1	-0.53	-8.74	-0.38	4.42e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs9399135	0.967	rs4896123	chr6:135295410	T/G	cg24558204	chr6:135376177	HBS1L	0.53	9.41	0.4	2.29e-19	Red blood cell count;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg21782813	chr7:2030301	MAD1L1	0.52	12.89	0.51	1.06e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs11920090	0.932	rs55679742	chr3:170714435	G/A	cg09710316	chr3:170744871	SLC2A2	0.59	8.38	0.36	6.26e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs11671005	0.735	rs34873624	chr19:58943402	G/A	cg13877915	chr19:58951672	ZNF132	0.6	8.36	0.36	7.47e-16	Mean platelet volume;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg01620082	chr3:125678407	NA	-0.85	-7.56	-0.33	2.12e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs5758511	0.773	rs9680671	chr22:42351477	T/C	cg15128208	chr22:42549153	NA	0.57	8.99	0.39	6.51e-18	Birth weight;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.4	8.47	0.37	3.3e-16	Hemoglobin concentration;
LGG	cis	rs6728642	0.803	rs11891457	chr2:97632449	G/T	cg26665480	chr2:98280029	ACTR1B	-0.76	-9.18	-0.39	1.46e-18	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg06453172	chr10:134556979	INPP5A	-0.56	-8.3	-0.36	1.12e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6684428	0.706	rs10493183	chr1:56333648	T/C	cg11651538	chr1:56320950	NA	-0.72	-13.0	-0.52	3.64e-33	Airflow obstruction;
LGG	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.91	0.42	4.13e-21	Height;
LGG	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg12386194	chr3:101231763	SENP7	0.7	12.11	0.49	1.63e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6032067	0.929	rs17333381	chr20:43804919	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.54e-28	Blood protein levels;
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.79	0.38	3e-17	Bipolar disorder;
LGG	cis	rs4732038	0.739	rs56097712	chr7:134253269	C/T	cg06906464	chr7:134288099	NA	-0.48	-11.37	-0.47	1.36e-26	Longevity;
LGG	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg13010199	chr12:38710504	ALG10B	-0.53	-10.08	-0.42	9.58e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9290065	0.519	rs6763532	chr3:160701816	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-9.03	-0.39	4.48e-18	Kawasaki disease;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs12545912	0.866	rs4626604	chr8:9588112	T/G	cg16141378	chr3:129829833	LOC729375	0.34	6.68	0.3	6.86e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.28	-0.43	1.86e-22	Lung cancer;
LGG	cis	rs4731207	0.735	rs17147494	chr7:124449835	G/A	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-12.18	-0.49	8.36e-30	Monocyte count;
LGG	cis	rs11239187	0.543	rs11239157	chr10:45078170	A/G	cg03916630	chr10:45065415	NA	-0.36	-8.83	-0.38	2.19e-17	Body mass index;
LGG	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg09911534	chr15:67153556	NA	0.53	7.26	0.32	1.69e-12	Lung cancer (smoking interaction);
LGG	cis	rs9902453	0.753	rs3097118	chr17:27978466	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.89	0.54	6.17e-37	Coffee consumption (cups per day);
LGG	cis	rs8064024	0.764	rs3827528	chr16:4853092	T/C	cg04440724	chr16:4920505	UBN1	-0.43	-8.97	-0.38	7.14e-18	Cancer;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.658	rs60658003	chr6:101201191	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.68	-0.37	6.8e-17	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg16339924	chr4:17578868	LAP3	0.58	9.5	0.4	1.13e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs853679	0.517	rs67878650	chr6:28142587	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	8.61e-14	Depression;
LGG	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg11812906	chr14:75593930	NEK9	0.54	10.11	0.43	7.54e-22	Height;
LGG	cis	rs12681287	0.640	rs4587306	chr8:87385511	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	trans	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.96e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs931812	0.757	rs34988706	chr8:101907062	C/T	cg20993868	chr7:22813445	NA	0.61	11.98	0.49	5.39e-29	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs79057730	0.639	rs6463933	chr7:793954	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	7.23	0.32	1.95e-12	Initial pursuit acceleration;
LGG	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg09085632	chr11:111637200	PPP2R1B	1.05	22.07	0.72	2.71e-74	Primary sclerosing cholangitis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11310527	chr4:187078771	FAM149A	0.39	6.81	0.3	3.1e-11	Electrocardiographic conduction measures;
LGG	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.63	0.56	4.17e-40	Colorectal cancer;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.48	0.37	3.01e-16	Lung cancer;
LGG	cis	rs11785400	0.793	rs13255558	chr8:143748080	C/T	cg24634471	chr8:143751801	JRK	0.51	7.7	0.34	8.56e-14	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs35771425	0.600	rs12754607	chr1:211470727	C/G	cg10512769	chr1:211675356	NA	-0.61	-8.3	-0.36	1.18e-15	Educational attainment (years of education);
LGG	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs6809651	0.524	rs7622914	chr3:185790895	T/C	cg00760338	chr3:185826511	ETV5	-0.88	-13.84	-0.54	1.03e-36	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg21459583	chr1:227974177	NA	0.47	7.01	0.31	8.49e-12	Major depressive disorder;
LGG	cis	rs12444795	0.855	rs12445265	chr16:4924160	A/G	cg04440724	chr16:4920505	UBN1	-0.61	-8.33	-0.36	9.12e-16	Cancer;
LGG	cis	rs17092148	0.887	rs6059931	chr20:33175338	A/G	cg12302830	chr20:33297742	TP53INP2	-0.44	-7.08	-0.31	5.5e-12	Neuroticism;
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.66e-13	Rheumatoid arthritis;
LGG	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-14.4	-0.56	4.01e-39	Headache;
LGG	cis	rs35160687	0.644	rs36079379	chr2:86545960	A/G	cg10973622	chr2:86423274	IMMT	-0.39	-6.92	-0.31	1.5e-11	Night sleep phenotypes;
LGG	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg16400903	chr5:693638	TPPP	0.44	6.78	0.3	3.72e-11	Obesity-related traits;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg24250549	chr1:154909240	PMVK	0.67	12.21	0.49	6.28e-30	Prostate cancer;
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-7.34	-0.32	9.82e-13	Breast cancer;
LGG	cis	rs6586163	1.000	rs7072828	chr10:90754953	T/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.9	-0.31	1.72e-11	Chronic lymphocytic leukemia;
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg00908189	chr16:619842	PIGQ	0.88	16.73	0.61	1.73e-49	Height;
LGG	cis	rs7805747	1.000	rs10480300	chr7:151406005	C/T	cg17611936	chr7:151411526	PRKAG2	0.54	8.01	0.35	9.39e-15	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs1345301	1.000	rs12470560	chr2:102868840	T/C	cg05295703	chr2:102895712	NA	0.38	7.51	0.33	3.1e-13	Waist circumference;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg04025307	chr7:1156635	C7orf50	0.67	12.86	0.51	1.48e-32	Longevity;Endometriosis;
LGG	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.51	-0.33	3.01e-13	IgG glycosylation;
LGG	cis	rs763121	0.853	rs5757181	chr22:39013522	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	17.38	0.63	1.84e-52	Menopause (age at onset);
LGG	cis	rs10744422	1.000	rs4759355	chr12:123316566	A/G	cg25930673	chr12:123319894	HIP1R	-0.71	-9.08	-0.39	3.14e-18	Schizophrenia;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	9.18	0.39	1.44e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg05163923	chr11:71159392	DHCR7	0.47	8.53	0.37	2.11e-16	Vitamin D levels;
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17030434	0.906	rs12641631	chr4:154665279	A/G	cg14289246	chr4:154710475	SFRP2	-0.7	-10.92	-0.45	7.68e-25	Electrocardiographic conduction measures;
LGG	cis	rs1707322	0.789	rs7540578	chr1:46252144	C/T	cg03146154	chr1:46216737	IPP	0.5	9.56	0.41	6.83e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg16511985	chr3:153974050	SGEF	0.45	7.31	0.32	1.18e-12	Coronary artery disease;
LGG	cis	rs7737355	0.773	rs6890410	chr5:130594747	C/T	cg06307176	chr5:131281290	NA	0.47	7.7	0.34	8.11e-14	Life satisfaction;
LGG	cis	rs7071206	0.853	rs57420220	chr10:79428886	C/T	cg07817648	chr10:79422355	NA	-0.79	-14.73	-0.57	1.43e-40	Bone mineral density;
LGG	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg08498830	chr11:832797	CD151	-0.45	-7.13	-0.31	3.76e-12	Mean platelet volume;
LGG	cis	rs9831754	0.906	rs7621811	chr3:78388816	G/A	cg06138941	chr3:78371609	NA	-0.9	-18.57	-0.65	5.83e-58	Calcium levels;
LGG	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg26695010	chr11:65641043	EFEMP2	0.55	9.39	0.4	2.76e-19	Eosinophil percentage of white cells;
LGG	cis	rs8077889	0.703	rs72836567	chr17:41945776	G/A	cg26893861	chr17:41843967	DUSP3	0.87	12.11	0.49	1.7e-29	Triglycerides;
LGG	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg07303275	chr16:75499416	TMEM170A	0.41	7.33	0.32	1.05e-12	Dupuytren's disease;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg07701084	chr6:150067640	NUP43	0.71	13.71	0.54	3.74e-36	Lung cancer;
LGG	trans	rs2562456	0.793	rs78467454	chr19:21504732	T/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg27147174	chr7:100797783	AP1S1	-0.69	-12.87	-0.51	1.28e-32	Life satisfaction;
LGG	cis	rs972578	0.765	rs4822216	chr22:43277147	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.88	-0.3	1.95e-11	Mean platelet volume;
LGG	cis	rs4262150	0.810	rs4958323	chr5:152021767	A/G	cg12297329	chr5:152029980	NA	-0.82	-16.05	-0.6	2.13e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg26513180	chr16:89883248	FANCA	0.98	9.39	0.4	2.83e-19	Skin colour saturation;
LGG	cis	rs4363385	0.669	rs4845519	chr1:153003916	G/T	cg13444842	chr1:152974279	SPRR3	0.38	7.78	0.34	4.85e-14	Inflammatory skin disease;
LGG	cis	rs11150038	1.000	rs2293779	chr16:78065506	C/T	cg04733911	chr16:78082701	NA	-0.67	-9.03	-0.39	4.69e-18	Colorectal or endometrial cancer;
LGG	cis	rs4740619	0.619	rs7040690	chr9:16038049	G/C	cg14451791	chr9:16040625	NA	-0.43	-11.42	-0.47	8.47e-27	Body mass index;
LGG	cis	rs1620921	0.564	rs28594774	chr6:161271666	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.62	-0.33	1.49e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg27205649	chr11:78285834	NARS2	0.48	8.14	0.35	3.68e-15	Alzheimer's disease (survival time);
LGG	cis	rs11630290	0.592	rs11071769	chr15:64156842	G/C	cg12036633	chr15:63758958	NA	0.48	6.89	0.3	1.88e-11	Iris characteristics;
LGG	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.7	10.67	0.44	6.29e-24	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03499777	chr13:98085463	RAP2A	0.41	6.7	0.3	5.91e-11	Cognitive performance;
LGG	cis	rs300703	0.719	rs378738	chr2:194039	A/G	cg21211680	chr2:198530	NA	1.3	20.01	0.68	1.16e-64	Blood protein levels;
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.01	0.31	8.23e-12	Personality dimensions;
LGG	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg15047889	chr8:124780837	FAM91A1	0.56	7.75	0.34	5.72e-14	Pancreatic cancer;
LGG	cis	rs12360000	0.770	rs11250852	chr10:1909726	A/G	cg26364871	chr10:1889757	NA	-0.7	-13.46	-0.53	4.25e-35	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.49	-0.44	3.19e-23	Bone mineral density;
LGG	cis	rs367943	1.000	rs348954	chr5:112821716	A/G	cg27587195	chr5:112824172	MCC	-0.46	-7.4	-0.33	6.39e-13	Type 2 diabetes;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.71	-13.24	-0.52	3.73e-34	Obesity-related traits;
LGG	cis	rs13108043	0.605	rs13136465	chr4:87958822	G/T	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05165339	chr4:1420672	NA	0.33	8.69	0.37	6.37e-17	Obesity-related traits;
LGG	cis	rs727505	1.000	rs7795943	chr7:124483796	C/A	cg23710748	chr7:124431027	NA	-0.53	-10.03	-0.42	1.43e-21	Lewy body disease;
LGG	trans	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg27275811	chr11:74457193	NA	-0.59	-6.88	-0.3	1.98e-11	Type 2 diabetes nephropathy;
LGG	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg21230503	chr5:139085173	NA	0.36	8.51	0.37	2.51e-16	Schizophrenia;
LGG	trans	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.35	-0.36	8.04e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4262150	0.726	rs4406125	chr5:152016594	G/A	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs787274	0.557	rs7026450	chr9:115666976	T/C	cg13803584	chr9:115635662	SNX30	-0.68	-7.47	-0.33	4.14e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg15537850	chr8:144661051	NAPRT1	0.96	7.51	0.33	3.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg26384229	chr12:38710491	ALG10B	0.98	22.35	0.72	1.34e-75	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.34	-0.32	9.44e-13	Mood instability;
LGG	cis	rs1568889	0.838	rs7121937	chr11:28359858	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.06	0.66	3.43e-60	Bipolar disorder;
LGG	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg09165964	chr15:75287851	SCAMP5	0.77	9.14	0.39	1.9e-18	Lung cancer;
LGG	cis	rs9534288	0.797	rs2182482	chr13:46582654	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs490234	0.841	rs7863341	chr9:128449085	A/G	cg14078157	chr9:128172775	NA	0.42	7.55	0.33	2.3e-13	Mean arterial pressure;
LGG	cis	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg19399532	chr1:178512495	C1orf220	-0.43	-8.34	-0.36	8.59e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6694672	1.000	rs9427942	chr1:196946448	G/A	cg13682187	chr1:196946512	CFHR5	-0.49	-6.73	-0.3	5.17e-11	Asthma;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg13282195	chr8:144660772	NAPRT1	0.91	7.33	0.32	1e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08953461	chr5:157158882	THG1L	0.47	7.28	0.32	1.43e-12	Gut microbiome composition (summer);
LGG	cis	rs4006360	0.657	rs12939793	chr17:39233537	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.18	-0.46	7.44e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg23034840	chr1:205782522	SLC41A1	-0.53	-8.72	-0.38	4.91e-17	Menarche (age at onset);
LGG	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.81	-15.22	-0.58	1.07e-42	Platelet count;
LGG	cis	rs7940866	0.803	rs10894307	chr11:130876350	G/A	cg12179176	chr11:130786555	SNX19	0.7	12.99	0.52	4.25e-33	Schizophrenia;
LGG	cis	rs807669	0.903	rs762527	chr22:19183470	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	16.03	0.6	2.62e-46	Metabolite levels;
LGG	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg05623727	chr3:50126028	RBM5	-0.33	-7.23	-0.32	2e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg12573674	chr2:1569213	NA	-0.62	-9.15	-0.39	1.76e-18	IgG glycosylation;
LGG	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg11266682	chr4:10021025	SLC2A9	0.57	11.66	0.48	9.85e-28	Bone mineral density;
LGG	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.43	-0.33	5.2e-13	Total cholesterol levels;
LGG	cis	rs9399135	0.967	rs4895434	chr6:135293365	G/A	cg24558204	chr6:135376177	HBS1L	0.53	9.41	0.4	2.3e-19	Red blood cell count;
LGG	cis	rs4566357	1.000	rs7588113	chr2:227942951	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.89	-0.3	1.85e-11	Coronary artery disease;
LGG	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-9.6	-0.41	4.96e-20	Morning vs. evening chronotype;
LGG	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg08027265	chr7:2291960	NA	0.38	6.7	0.3	6.21e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg03160526	chr17:80928410	B3GNTL1	0.5	7.93	0.35	1.64e-14	Glycated hemoglobin levels;
LGG	cis	rs11064837	0.504	rs746297	chr12:120042801	A/C	cg25937854	chr12:120150414	CIT	-0.59	-10.38	-0.43	7.88e-23	Schizophrenia;
LGG	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg20891283	chr12:69753455	YEATS4	1.08	28.83	0.8	2.01e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	2.97e-33	Aortic root size;
LGG	cis	rs9443645	0.810	rs10943613	chr6:79745107	C/T	cg18132916	chr6:79620363	NA	-0.26	-6.91	-0.31	1.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	0.902	rs11819839	chr11:34715778	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.88	-0.3	2e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.64	-0.48	1.16e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs11170468	0.697	rs9652005	chr12:39434060	T/C	cg26384229	chr12:38710491	ALG10B	-0.43	-6.84	-0.3	2.44e-11	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10460130	chr2:242625978	DTYMK	0.46	7.59	0.33	1.81e-13	Cognitive performance;
LGG	cis	rs17067123	0.614	rs7698554	chr4:180053504	T/C	cg26610307	chr4:180072759	NA	-0.51	-7.12	-0.31	4.09e-12	Response to hepatitis C treatment;
LGG	cis	rs3008870	1.000	rs1925411	chr1:67370292	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.4	0.72	8.28e-76	Lymphocyte percentage of white cells;
LGG	cis	rs600231	0.706	rs1111934	chr11:65329392	A/G	cg17120908	chr11:65337727	SSSCA1	-0.63	-11.22	-0.46	5.3e-26	Bone mineral density;
LGG	cis	rs7503807	0.515	rs12946206	chr17:78687270	G/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08811588	chr7:100473311	SRRT	0.46	7.33	0.32	1.06e-12	Cognitive performance;
LGG	cis	rs2587949	0.615	rs973177	chr3:4191172	A/C	cg16519197	chr3:4211558	NA	-0.35	-7.3	-0.32	1.26e-12	Periodontitis (DPAL);
LGG	cis	rs68170813	0.523	rs12532447	chr7:106940476	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1e-23	Coronary artery disease;
LGG	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-7.47	-0.33	3.93e-13	Mood instability;
LGG	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg00599393	chr8:22457479	C8orf58	-0.43	-7.92	-0.35	1.75e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.37	0.53	1.02e-34	Bladder cancer;
LGG	trans	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg02030672	chr11:45687055	CHST1	0.48	8.58	0.37	1.4e-16	Obesity-related traits;
LGG	cis	rs981844	0.775	rs17299211	chr4:154738284	G/A	cg14289246	chr4:154710475	SFRP2	0.67	11.03	0.46	2.89e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg03188948	chr7:1209495	NA	0.43	7.57	0.33	1.98e-13	Longevity;Endometriosis;
LGG	cis	rs68170813	0.559	rs61406169	chr7:106903421	A/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.52	-0.44	2.29e-23	Coronary artery disease;
LGG	cis	rs1869026	1.000	rs1880542	chr2:121338584	C/T	cg13274077	chr2:121334614	NA	0.32	7.48	0.33	3.82e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs883565	0.569	rs7638329	chr3:39020408	T/C	cg01426195	chr3:39028469	NA	-0.65	-13.56	-0.53	1.69e-35	Handedness;
LGG	cis	rs7909791	0.743	rs11596104	chr10:105623461	C/A	cg11005552	chr10:105648138	OBFC1	0.64	9.59	0.41	5.55e-20	White matter hyperintensity burden;
LGG	cis	rs858239	0.633	rs858300	chr7:23244631	A/G	cg23682824	chr7:23144976	KLHL7	0.4	6.87	0.3	2.09e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs858239	0.600	rs13438179	chr7:23143851	T/C	cg23682824	chr7:23144976	KLHL7	0.45	7.75	0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs938554	0.513	rs10939650	chr4:9998440	C/T	cg25986240	chr4:9926439	SLC2A9	-0.37	-6.83	-0.3	2.69e-11	Blood metabolite levels;
LGG	cis	rs4262150	0.726	rs4958569	chr5:152016105	A/G	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs2985684	0.894	rs4900932	chr14:50022928	A/G	cg04989706	chr14:50066350	PPIL5	-0.62	-10.19	-0.43	4.03e-22	Carotid intima media thickness;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.98e-12	Bipolar disorder;
LGG	cis	rs733592	0.507	rs10875739	chr12:48480919	C/T	cg24011408	chr12:48396354	COL2A1	0.63	9.87	0.42	5.57e-21	Plateletcrit;
LGG	cis	rs977987	0.843	rs6564260	chr16:75447426	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg16797656	chr11:68205561	LRP5	0.39	6.86	0.3	2.18e-11	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6988985	0.791	rs11775009	chr8:144008181	T/C	cg10324643	chr8:143916377	GML	-0.38	-7.34	-0.32	9.73e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg24692254	chr21:30365293	RNF160	-0.96	-24.63	-0.75	3.23e-86	Dental caries;
LGG	cis	rs6088590	1.000	rs55753039	chr20:33394940	C/T	cg08999081	chr20:33150536	PIGU	0.3	6.99	0.31	9.36e-12	Coronary artery disease;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	10.51	0.44	2.58e-23	Longevity;
LGG	cis	rs1003719	0.788	rs9975168	chr21:38450557	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.84	-17.33	-0.63	3.18e-52	Eye color traits;
LGG	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg15704280	chr7:45808275	SEPT13	0.93	19.29	0.67	2.63e-61	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg10760299	chr15:45669010	GATM	0.4	7.97	0.35	1.26e-14	Homoarginine levels;
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg10505658	chr17:80084571	CCDC57	0.42	8.67	0.37	7.43e-17	Life satisfaction;
LGG	cis	rs1555322	0.530	rs2275275	chr20:33872311	G/C	cg17927777	chr20:33865990	NA	0.75	10.92	0.45	7.67e-25	Attention deficit hyperactivity disorder;
LGG	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg07061783	chr6:25882402	NA	-0.38	-6.9	-0.31	1.7e-11	Blood metabolite levels;
LGG	trans	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.9	-0.34	1.99e-14	HDL cholesterol;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg21479132	chr6:26055353	NA	0.84	7.43	0.33	5.32e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09894929	chr7:8473578	NXPH1	0.42	6.77	0.3	3.91e-11	Cognitive performance;
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg09845145	chr15:78292470	TBC1D2B	0.57	10.47	0.44	3.74e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs7143963	0.943	rs8022770	chr14:103263489	C/G	cg23020514	chr14:103360112	TRAF3	0.52	9.3	0.4	5.68e-19	Body mass index;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.34	0.43	1.11e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg06634786	chr22:41940651	POLR3H	-0.55	-9.18	-0.39	1.48e-18	Vitiligo;
LGG	cis	rs9487094	0.670	rs12194061	chr6:109867642	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs919433	0.662	rs2043018	chr2:198236958	G/A	cg00792783	chr2:198669748	PLCL1	0.46	7.34	0.32	9.4e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11190604	1.000	rs10786598	chr10:102291579	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6088590	1.000	rs6120750	chr20:33465289	A/C	cg24642439	chr20:33292090	TP53INP2	0.81	14.36	0.56	5.88e-39	Coronary artery disease;
LGG	cis	rs4788815	0.718	rs6499545	chr16:71889173	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.47	0.44	3.63e-23	Metabolite levels;
LGG	cis	rs6714710	0.627	rs11680883	chr2:98472610	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	10.32	0.43	1.32e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	trans	rs4714291	0.832	rs1404002	chr6:40064600	C/T	cg02267698	chr19:7991119	CTXN1	-0.62	-10.1	-0.42	8.08e-22	Strep throat;
LGG	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg08975724	chr8:8085496	FLJ10661	-0.48	-8.85	-0.38	1.87e-17	Retinal vascular caliber;
LGG	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg27490568	chr2:178487706	NA	0.51	9.82	0.42	8.27e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06108461	chr20:60628389	TAF4	-1.06	-21.29	-0.7	1.28e-70	Body mass index;
LGG	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs977987	0.800	rs12935787	chr16:75332335	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.73	0.41	1.81e-20	Dupuytren's disease;
LGG	cis	rs2832191	0.755	rs55671430	chr21:30492421	G/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.91	-0.62	2.67e-50	Dental caries;
LGG	trans	rs2840044	1.000	rs11656138	chr17:33910218	T/C	cg19694781	chr19:47549865	TMEM160	0.55	9.06	0.39	3.55e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg10596483	chr8:143751796	JRK	0.58	9.61	0.41	4.51e-20	Schizophrenia;
LGG	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.48	0.37	3.1e-16	Alzheimer's disease (survival time);
LGG	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg12856521	chr11:46389249	DGKZ	-0.42	-7.23	-0.32	2.03e-12	Leprosy;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4478858	0.735	rs2271072	chr1:31840426	C/G	cg19084893	chr1:31688959	NA	0.32	6.77	0.3	3.98e-11	Alcohol dependence;
LGG	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg18446336	chr7:2847575	GNA12	-0.39	-10.47	-0.44	3.49e-23	Height;
LGG	cis	rs72772090	0.634	rs12186366	chr5:96088850	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.88	-0.38	1.52e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg01673284	chr16:4527211	HMOX2	0.35	6.96	0.31	1.15e-11	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02401220	chr17:39845253	EIF1	-0.42	-7.27	-0.32	1.53e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs653465	0.739	rs1402972	chr3:27131168	A/G	cg02860705	chr3:27208620	NA	-0.38	-7.43	-0.33	5.11e-13	Breast cancer (early onset);
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg07414643	chr4:187882934	NA	0.55	11.34	0.47	1.79e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg20110707	chr11:118481992	PHLDB1	0.51	9.96	0.42	2.75e-21	Cholesterol, total;
LGG	cis	rs2236267	0.601	rs2767532	chr14:88580709	A/G	cg02175263	chr14:88627849	NA	0.31	6.8	0.3	3.34e-11	Food antigen IgG levels;
LGG	cis	rs4740619	0.967	rs4741527	chr9:15643065	T/A	cg14451791	chr9:16040625	NA	-0.41	-10.71	-0.45	4.72e-24	Body mass index;
LGG	cis	rs9341808	0.690	rs2322634	chr6:80874014	A/C	cg08355045	chr6:80787529	NA	0.41	7.99	0.35	1.05e-14	Sitting height ratio;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg11473876	chr11:109292803	C11orf87	0.54	10.26	0.43	2.14e-22	Schizophrenia;
LGG	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.61	-0.33	1.53e-13	Joint mobility (Beighton score);
LGG	cis	rs4936894	0.500	rs10893193	chr11:124140263	C/T	cg27160556	chr11:124181099	OR8D1	-0.48	-11.12	-0.46	1.26e-25	Aging (time to death);
LGG	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs10779751	0.734	rs2748878	chr1:11129434	T/C	cg08854313	chr1:11322531	MTOR	0.75	16.61	0.61	6.26e-49	Body mass index;
LGG	cis	rs11018904	0.861	rs12786959	chr11:89943676	A/T	cg16176437	chr11:89678848	NA	0.39	6.68	0.3	7.03e-11	Intelligence (multi-trait analysis);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg07939768	chr17:27621433	NUFIP2	-0.46	-7.16	-0.32	3.17e-12	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs600231	0.508	rs35292734	chr11:65227700	C/T	cg17120908	chr11:65337727	SSSCA1	-0.6	-8.64	-0.37	8.97e-17	Bone mineral density;
LGG	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg13683864	chr3:40499215	RPL14	1.16	29.23	0.81	3.37e-107	Renal cell carcinoma;
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs11096990	0.855	rs2566183	chr4:39163908	T/G	cg24403649	chr4:39172243	NA	-0.48	-7.79	-0.34	4.42e-14	Cognitive function;
LGG	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg21055462	chr7:100276975	NA	0.44	9.19	0.39	1.3e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9616064	0.557	rs9615397	chr22:47049086	C/T	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.83	-0.3	2.74e-11	Urate levels in obese individuals;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg03115019	chr17:80708279	FN3K	0.35	6.65	0.3	8.54e-11	Glycated hemoglobin levels;
LGG	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg16586182	chr3:47516702	SCAP	0.78	15.2	0.58	1.28e-42	Colorectal cancer;
LGG	cis	rs9473924	0.580	rs58105163	chr6:50832730	C/T	cg14470998	chr6:50812995	TFAP2B	0.64	7.65	0.34	1.16e-13	Body mass index;
LGG	cis	rs9534288	0.716	rs2573304	chr13:46514642	C/T	cg15192986	chr13:46630673	CPB2	0.59	12.58	0.5	2.01e-31	Blood protein levels;
LGG	cis	rs314370	0.951	rs12705092	chr7:100473550	G/A	cg10426581	chr7:100472382	SRRT	0.51	7.09	0.31	5.02e-12	Resting heart rate;
LGG	cis	rs75059851	0.756	rs7127156	chr11:133839857	T/C	cg17703048	chr11:133852993	NA	-0.87	-16.03	-0.6	2.6e-46	Schizophrenia;
LGG	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.43e-15	Myopia (pathological);
LGG	cis	rs41005	1.000	rs193931	chr2:8107435	A/G	cg03155496	chr2:8117019	LOC339788	-0.88	-19.87	-0.68	5.34e-64	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs2188554	0.533	rs213981	chr7:117254527	G/T	cg10524701	chr7:117356490	CTTNBP2	-0.42	-7.26	-0.32	1.64e-12	Esophageal adenocarcinoma;
LGG	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg05234568	chr11:5960015	NA	-0.74	-12.1	-0.49	1.75e-29	DNA methylation (variation);
LGG	cis	rs67311347	0.955	rs4973999	chr3:40460383	G/A	cg13683864	chr3:40499215	RPL14	-1.01	-21.46	-0.71	1.89e-71	Renal cell carcinoma;
LGG	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10819861	0.645	rs7862829	chr9:98856744	C/T	cg14508093	chr9:98862825	NA	0.3	7.17	0.32	3.06e-12	Electrocardiographic traits;
LGG	cis	rs7551222	0.752	rs11240758	chr1:204528651	C/T	cg20240347	chr1:204465584	NA	-0.55	-10.88	-0.45	1.08e-24	Schizophrenia;
LGG	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.97	0.31	1.1e-11	Neuroticism;
LGG	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg20493526	chr2:3714936	ALLC	0.49	10.76	0.45	3.11e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2708240	0.967	rs2247042	chr7:147580224	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.46e-11	QT interval (drug interaction);
LGG	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg08305652	chr11:111469057	NA	-0.44	-8.98	-0.39	7e-18	Primary sclerosing cholangitis;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	8.43	0.36	4.5e-16	Bipolar disorder;
LGG	cis	rs9398803	0.830	rs1361109	chr6:126771143	C/T	cg19875578	chr6:126661172	C6orf173	0.55	10.09	0.42	9.17e-22	Male-pattern baldness;
LGG	cis	rs1801251	0.896	rs7573208	chr2:233696701	C/A	cg25237894	chr2:233734115	C2orf82	-0.57	-11.07	-0.46	1.94e-25	Coronary artery disease;
LGG	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg11941060	chr3:133502564	NA	-0.48	-8.2	-0.36	2.42e-15	Iron status biomarkers;
LGG	cis	rs988958	0.565	rs34465637	chr2:42229346	G/A	cg27252766	chr2:42229092	NA	0.54	7.57	0.33	1.97e-13	Hypospadias;
LGG	cis	rs3806843	0.900	rs2262576	chr5:140135536	T/C	cg19875535	chr5:140030758	IK	-0.54	-11.03	-0.46	2.79e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9543976	0.623	rs7982517	chr13:76162039	A/G	cg12827798	chr13:76122768	UCHL3	-0.44	-6.76	-0.3	4.2e-11	Diabetic retinopathy;
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.69	0.64	6.75e-54	Alzheimer's disease;
LGG	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22857025	chr5:266934	NA	-1.14	-11.98	-0.49	5.41e-29	Breast cancer;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01585723	chr16:33734837	NA	0.46	7.91	0.35	1.88e-14	Menopause (age at onset);
LGG	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg19784903	chr17:45786737	TBKBP1	0.31	6.89	0.31	1.81e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg04025307	chr7:1156635	C7orf50	0.82	14.74	0.57	1.38e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs883565	0.655	rs6599000	chr3:39061512	A/G	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	cis	rs4481887	1.000	rs10888360	chr1:248479282	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.89	-0.42	4.92e-21	Common traits (Other);
LGG	cis	rs6032067	0.538	rs62206431	chr20:43737073	G/A	cg10761708	chr20:43804764	PI3	0.68	10.0	0.42	1.97e-21	Blood protein levels;
LGG	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg14541582	chr5:601475	NA	-0.57	-9.14	-0.39	2.03e-18	Obesity-related traits;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.65	-0.48	1.06e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4918072	0.917	rs61861158	chr10:105661686	A/G	cg11005552	chr10:105648138	OBFC1	0.73	12.33	0.5	2.15e-30	Coronary artery disease;
LGG	cis	rs1015291	0.806	rs2638431	chr12:19986746	A/G	cg25401612	chr12:20009446	NA	0.34	7.48	0.33	3.7e-13	Diastolic blood pressure;
LGG	cis	rs4727027	0.933	rs12704062	chr7:148827865	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.14	-0.62	2.44e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg19824325	chr16:58548873	SETD6	1.22	11.06	0.46	2.08e-25	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.33	-0.32	1e-12	Hemoglobin concentration;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-11.02	-0.46	3.03e-25	Triglycerides;
LGG	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.18	-0.7	3.95e-70	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.62	-0.48	1.44e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg04455712	chr21:45112962	RRP1B	0.49	9.1	0.39	2.79e-18	Mean corpuscular volume;
LGG	cis	rs7072216	0.763	rs2274244	chr10:100175218	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.6e-12	Metabolite levels;
LGG	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg19507638	chr5:93509721	C5orf36	-0.69	-9.56	-0.41	6.95e-20	Diabetic retinopathy;
LGG	cis	rs748404	0.604	rs2278857	chr15:43632549	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.48	7.15	0.32	3.44e-12	Lung cancer;
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.27	0.46	3.43e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs778371	0.723	rs13001052	chr2:233683984	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-10.99	-0.46	3.85e-25	Schizophrenia;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.6	-10.55	-0.44	1.82e-23	Obesity-related traits;
LGG	cis	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg02972257	chr16:68554789	NA	-0.55	-8.4	-0.36	5.71e-16	Ulcerative colitis;
LGG	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.34	0.43	1.13e-22	Blood protein levels;
LGG	cis	rs3815700	1.000	rs8101356	chr19:33093402	C/T	cg02997394	chr19:33096574	ANKRD27	0.87	13.02	0.52	3.04e-33	Eosinophilic esophagitis;
LGG	cis	rs4262150	0.693	rs3924314	chr5:152302912	C/A	cg12297329	chr5:152029980	NA	0.58	11.24	0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg14829155	chr15:31115871	NA	-0.56	-9.78	-0.41	1.15e-20	Huntington's disease progression;
LGG	cis	rs10155981	0.510	rs75613086	chr7:22584526	A/C	cg05062323	chr7:22590069	NA	-0.77	-8.87	-0.38	1.59e-17	Bilirubin levels;
LGG	cis	rs7666738	0.830	rs2019163	chr4:99022747	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg27286069	chr11:118481882	PHLDB1	0.49	8.77	0.38	3.56e-17	Cholesterol, total;
LGG	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg22307297	chr20:60903441	LAMA5	0.39	7.82	0.34	3.73e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3796352	0.892	rs58515094	chr3:52995575	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg19812747	chr11:111475976	SIK2	-0.47	-9.63	-0.41	3.85e-20	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs7166081	1.000	rs35722009	chr15:67625533	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.1	-0.31	4.77e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3892630	0.588	rs2287881	chr19:33333155	A/G	cg22980127	chr19:33182716	NUDT19	-0.8	-14.58	-0.56	6.71e-40	Red blood cell traits;
LGG	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg02023728	chr11:77925099	USP35	-0.39	-6.86	-0.3	2.24e-11	Alzheimer's disease (survival time);
LGG	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg07636037	chr3:49044803	WDR6	-0.88	-14.53	-0.56	1.1e-39	Menarche (age at onset);
LGG	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg11890956	chr21:40555474	PSMG1	1.17	29.02	0.8	2.93e-106	Cognitive function;
LGG	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.27	0.5	3.82e-30	Colorectal cancer;
LGG	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg27476859	chr7:2772710	GNA12	-0.48	-9.83	-0.42	7.48e-21	Plateletcrit;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.87	-0.38	1.61e-17	Lung cancer;
LGG	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.83	9.42	0.4	2.08e-19	Diabetic retinopathy;
LGG	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg22852734	chr6:133119734	C6orf192	1.39	11.7	0.48	7.25e-28	Type 2 diabetes nephropathy;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.4	-0.33	6.56e-13	IgG glycosylation;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00691266	chr17:74015089	EVPL	-0.41	-6.74	-0.3	4.62e-11	Hepatitis;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.67	0.69	1.01e-67	Platelet count;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg04503457	chr17:41445688	NA	-0.37	-8.8	-0.38	2.76e-17	Menopause (age at onset);
LGG	cis	rs1595825	0.891	rs73054825	chr2:198636355	G/C	cg00982548	chr2:198649783	BOLL	-0.52	-7.06	-0.31	6.01e-12	Ulcerative colitis;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg08742575	chr21:47604166	C21orf56	0.48	8.27	0.36	1.42e-15	Testicular germ cell tumor;
LGG	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-11.61	-0.47	1.63e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	8.94	0.38	9.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg05044414	chr3:183734942	ABCC5	0.72	14.77	0.57	1.02e-40	Anterior chamber depth;
LGG	trans	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg12045294	chr17:78518616	RPTOR	-0.47	-7.26	-0.32	1.65e-12	Glycated hemoglobin levels;
LGG	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg17757837	chr7:157058334	UBE3C	0.78	15.75	0.59	4.4e-45	Body mass index;
LGG	cis	rs1961637	0.514	rs2395945	chr2:223890360	C/T	cg02552189	chr2:223891284	NA	0.46	8.71	0.38	5.24e-17	Oropharynx cancer;
LGG	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg26150922	chr2:100937072	LONRF2	-0.56	-9.72	-0.41	1.8899999999999998e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2051211	1.000	rs17037804	chr3:38559215	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.59	-9.35	-0.4	3.77e-19	QRS duration;
LGG	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg21605333	chr4:119757512	SEC24D	1.48	14.85	0.57	4.54e-41	Cannabis dependence symptom count;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00864171	chr11:67383662	NA	0.55	9.55	0.41	7.75e-20	Mean corpuscular volume;
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg19168338	chr16:4465731	CORO7	-0.99	-18.31	-0.65	9.81e-57	Schizophrenia;
LGG	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.67e-11	Menopause (age at onset);
LGG	cis	rs2073300	1.000	rs12626013	chr20:23442215	G/A	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7236492	0.935	rs7239086	chr18:77217030	A/C	cg15644404	chr18:77186268	NFATC1	-0.81	-9.94	-0.42	3.24e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12476592	0.602	rs10469945	chr2:63816776	T/C	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg11584989	chr19:19387371	SF4	0.79	13.08	0.52	1.64e-33	Bipolar disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01293313	chr2:122406171	CLASP1	-0.5	-7.38	-0.32	7.56e-13	Systemic lupus erythematosus;
LGG	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.45	-7.0	-0.31	9.32e-12	Tuberculosis;
LGG	cis	rs12348691	0.503	rs7023267	chr9:100603935	G/A	cg13688889	chr9:100608707	NA	-0.82	-16.12	-0.6	1.01e-46	Alopecia areata;
LGG	cis	rs4774830	0.744	rs62045236	chr15:56291171	A/G	cg24530489	chr15:56299380	NA	-0.85	-7.42	-0.33	5.51e-13	Delta-5 desaturase activity;
LGG	cis	rs1843834	0.624	rs2396110	chr2:225560219	A/G	cg22455342	chr2:225449267	CUL3	0.44	7.25	0.32	1.72e-12	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1371867	0.846	rs1788197	chr8:101290928	T/C	cg06636551	chr8:101224915	SPAG1	-0.44	-8.17	-0.35	2.98e-15	Atrioventricular conduction;
LGG	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg00343986	chr7:65444356	GUSB	0.42	7.13	0.31	3.88e-12	Aortic root size;
LGG	cis	rs8048589	0.948	rs11648468	chr16:12181510	A/G	cg02910054	chr16:12241554	SNX29	-0.43	-6.9	-0.31	1.69e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg27286337	chr10:134555280	INPP5A	0.81	13.34	0.53	1.37e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9715521	0.900	rs72634620	chr4:59822396	C/T	cg11281224	chr4:60001000	NA	-0.44	-7.27	-0.32	1.55e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19975543	chr11:125462536	STT3A	0.44	6.66	0.3	8.02e-11	Gut microbiome composition (summer);
LGG	cis	rs754466	0.651	rs10824583	chr10:79619402	C/T	cg17075019	chr10:79541650	NA	0.96	20.22	0.68	1.28e-65	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.65	-0.41	3.5e-20	Life satisfaction;
LGG	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	9.47e-26	Homoarginine levels;
LGG	cis	rs1419980	0.673	rs1978284	chr12:7771151	G/A	cg10578777	chr12:7781093	NA	0.63	8.58	0.37	1.42e-16	HDL cholesterol levels;
LGG	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-13.73	-0.54	3.02e-36	Cognitive function;
LGG	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs17767392	0.846	rs61991200	chr14:71762569	A/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.53	0.37	2.11e-16	Mitral valve prolapse;
LGG	cis	rs607541	1.000	rs644493	chr15:45935816	C/T	cg26924012	chr15:45694286	SPATA5L1	0.53	7.39	0.32	7e-13	Obesity-related traits;
LGG	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs9926296	0.744	rs164749	chr16:89708224	A/C	cg08949735	chr16:89699720	DPEP1	-0.46	-9.72	-0.41	1.93e-20	Vitiligo;
LGG	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg07615347	chr10:60278583	BICC1	0.62	17.31	0.63	4e-52	Refractive error;
LGG	cis	rs4731207	0.596	rs12538171	chr7:124645570	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg18876405	chr7:65276391	NA	0.59	10.87	0.45	1.19e-24	Aortic root size;
LGG	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.54e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3762637	0.943	rs78429050	chr3:122252428	T/C	cg24169773	chr3:122142474	KPNA1	-0.61	-10.26	-0.43	2.2e-22	LDL cholesterol levels;
LGG	cis	rs2816316	1.000	rs2984920	chr1:192544795	A/G	cg10861751	chr1:192544716	RGS1	0.34	6.68	0.3	6.92e-11	Celiac disease;
LGG	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg02002194	chr4:3960332	NA	-0.41	-7.59	-0.33	1.8e-13	Neuroticism;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg16606324	chr3:10149918	C3orf24	0.58	7.56	0.33	2.25e-13	Alzheimer's disease;
LGG	cis	rs12993904	0.501	rs2609196	chr2:6152899	G/A	cg00493617	chr2:6141445	NA	0.32	7.38	0.32	7.3e-13	Clozapine-induced agranulocytosis;
LGG	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.31	-0.32	1.16e-12	Iron status biomarkers;
LGG	cis	rs774359	0.789	rs10967972	chr9:27523082	C/G	cg21249376	chr9:27528432	MOBKL2B	0.45	8.31	0.36	1.09e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs300774	1.000	rs300793	chr2:108411	A/T	cg04617936	chr2:214353	NA	-0.51	-7.57	-0.33	2.08e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs2071403	1.000	rs2071403	chr2:1417244	C/T	cg06500727	chr2:1417164	TPO	0.52	9.96	0.42	2.63e-21	Thyroid peroxidase antibody positivity;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg06654118	chr4:1303317	MAEA	0.42	7.14	0.31	3.62e-12	Obesity-related traits;
LGG	cis	rs12042938	0.579	rs980394	chr1:231779507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-10.23	-0.43	2.83e-22	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs6964587	1.000	rs415	chr7:91580490	A/G	cg17063962	chr7:91808500	NA	-0.48	-8.62	-0.37	1.09e-16	Breast cancer;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg14926445	chr8:58193284	C8orf71	-0.72	-8.53	-0.37	2.17e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg25214090	chr10:38739885	LOC399744	0.56	10.31	0.43	1.47e-22	Corneal astigmatism;
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.75	-0.38	4.08e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg02227867	chr8:22457446	C8orf58	-0.42	-8.15	-0.35	3.5e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg14829360	chr17:73884958	NA	-0.76	-12.5	-0.5	4.2e-31	Psoriasis;
LGG	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg13802316	chr11:70253460	CTTN	-0.59	-7.49	-0.33	3.49e-13	Coronary artery disease;
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg13282195	chr8:144660772	NAPRT1	0.93	7.42	0.33	5.69e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.4	-0.4	2.47e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05926928	chr17:57297772	GDPD1	-0.52	-8.61	-0.37	1.13e-16	Schizophrenia;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.78	0.59	3.44e-45	Longevity;
LGG	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg00405596	chr8:11794950	NA	0.4	6.79	0.3	3.42e-11	Systolic blood pressure;
LGG	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.56	-0.37	1.68e-16	Mood instability;
LGG	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg24690094	chr11:67383802	NA	-0.4	-7.01	-0.31	8.38e-12	Mean corpuscular volume;
LGG	cis	rs7633770	0.786	rs950190	chr3:46683377	C/T	cg11219411	chr3:46661640	NA	0.59	14.09	0.55	9.38e-38	Coronary artery disease;
LGG	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg06606381	chr12:133084897	FBRSL1	-1.2	-11.4	-0.47	1.03e-26	Depression;
LGG	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.79	-0.41	1.05e-20	Common traits (Other);
LGG	trans	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg06521331	chr12:34319734	NA	-0.49	-8.71	-0.38	5.54e-17	Bladder cancer;
LGG	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19671926	chr4:122722719	EXOSC9	0.47	7.28	0.32	1.42e-12	Type 2 diabetes;
LGG	cis	rs7998202	0.567	rs914019	chr13:113352911	A/G	cg17218041	chr13:113365319	ATP11A	-0.43	-7.37	-0.32	7.91e-13	Glycated hemoglobin levels;
LGG	cis	rs9549367	0.577	rs776904	chr13:113810542	C/T	cg00898013	chr13:113819073	PROZ	-0.46	-7.73	-0.34	6.88e-14	Platelet distribution width;
LGG	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg12667521	chr19:29218732	NA	0.63	9.54	0.41	8.26e-20	Methadone dose in opioid dependence;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg12708336	chr17:41446283	NA	-0.33	-8.05	-0.35	7.17e-15	Menopause (age at onset);
LGG	cis	rs7224668	0.647	rs7219316	chr17:79248320	A/C	cg03823431	chr17:79229385	SLC38A10	0.35	7.58	0.33	1.86e-13	IgG glycosylation;
LGG	cis	rs4740619	0.745	rs961117	chr9:15938548	A/C	cg14451791	chr9:16040625	NA	-0.39	-9.84	-0.42	7.27e-21	Body mass index;
LGG	cis	rs9879311	0.643	rs1473183	chr3:10411827	C/T	cg21387009	chr3:10280255	IRAK2	-0.4	-7.01	-0.31	8.57e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.66	-0.3	7.86e-11	HDL cholesterol;
LGG	cis	rs139371	0.742	rs139323	chr22:39501478	A/G	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.93	-0.31	1.43e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs3849570	1.000	rs3772882	chr3:81808602	C/A	cg07356753	chr3:81810745	GBE1	-0.43	-7.41	-0.33	6.23e-13	Waist circumference;Body mass index;
LGG	cis	rs6784615	0.744	rs6445484	chr3:52503800	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs9397585	0.857	rs4318889	chr6:153377853	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg23391107	chr17:45924227	SP6	0.59	9.62	0.41	4.28e-20	Ease of getting up in the morning;
LGG	cis	rs2421770	0.532	rs6484781	chr11:35349242	A/G	cg10331829	chr11:35343789	SLC1A2	-0.35	-7.77	-0.34	4.96e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs9515201	0.859	rs9521732	chr13:111033821	G/T	cg06243866	chr13:111019493	COL4A2	-0.58	-11.35	-0.47	1.7e-26	White matter hyperintensity burden;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg09699830	chr16:72516874	NA	-0.38	-7.08	-0.31	5.54e-12	QT interval;
LGG	cis	rs1620921	0.625	rs12209829	chr6:161263938	C/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg22089800	chr15:90895588	ZNF774	-0.67	-12.27	-0.5	3.79e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg16400903	chr5:693638	TPPP	0.47	7.03	0.31	7.59e-12	Obesity-related traits;
LGG	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg15432903	chr11:17409602	KCNJ11	0.81	17.11	0.62	3.14e-51	Type 2 diabetes;
LGG	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg06890432	chr16:12997467	SHISA9	-0.32	-7.03	-0.31	7.48e-12	Positive affect;Subjective well-being;
LGG	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg20476274	chr7:133979776	SLC35B4	-0.5	-8.97	-0.38	7.49e-18	Mean platelet volume;
LGG	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg23625390	chr15:77176239	SCAPER	0.72	14.3	0.55	1.13e-38	Blood metabolite levels;
LGG	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00262122	chr8:11665843	FDFT1	0.41	6.66	0.3	7.76e-11	Myopia (pathological);
LGG	trans	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.77	0.3	4.02e-11	Neuroticism;
LGG	cis	rs172166	0.694	rs536704	chr6:28092603	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.9	-0.31	1.73e-11	Cardiac Troponin-T levels;
LGG	cis	rs1318772	0.867	rs6594727	chr5:112849294	A/G	cg12552261	chr5:112820674	MCC	-0.69	-7.45	-0.33	4.53e-13	F-cell distribution;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg22535103	chr8:58192502	C8orf71	-0.74	-9.61	-0.41	4.63e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.623	rs2093169	chr6:26495099	C/T	cg06606381	chr12:133084897	FBRSL1	-0.55	-6.87	-0.3	2.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg14893161	chr1:205819251	PM20D1	0.49	7.82	0.34	3.62e-14	Parkinson's disease;
LGG	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg13482628	chr17:19912719	NA	0.62	12.35	0.5	1.72e-30	Schizophrenia;
LGG	cis	rs12493885	0.818	rs7641039	chr3:153768638	A/C	cg12800244	chr3:153838788	SGEF	0.76	9.25	0.39	8.47e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.64e-24	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	12.68	0.51	8.18e-32	Obesity-related traits;
LGG	cis	rs36071027	0.577	rs6862399	chr5:158441675	G/T	cg04248271	chr5:158524404	EBF1	0.42	7.31	0.32	1.15e-12	Carotid intima media thickness;
LGG	cis	rs10463316	0.832	rs152087	chr5:150734419	C/T	cg03212797	chr5:150827313	SLC36A1	-0.49	-7.95	-0.35	1.39e-14	Metabolite levels (Pyroglutamine);
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.02	-0.31	7.71e-12	Bipolar disorder;
LGG	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg09165964	chr15:75287851	SCAMP5	0.65	12.44	0.5	7.4e-31	Breast cancer;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.54	-0.37	1.91e-16	Obesity-related traits;
LGG	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.26e-22	Dupuytren's disease;
LGG	trans	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs787274	1.000	rs10759584	chr9:115554736	T/G	cg13803584	chr9:115635662	SNX30	-0.57	-7.86	-0.34	2.71e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15586420	chr15:90294517	MESP1	0.43	7.46	0.33	4.2e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg18187862	chr3:45730750	SACM1L	-0.44	-7.43	-0.33	5.37e-13	Primary sclerosing cholangitis;
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg12310025	chr6:25882481	NA	-0.76	-14.94	-0.57	1.85e-41	Blood metabolite levels;
LGG	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.09	-0.31	5.16e-12	Restless legs syndrome;
LGG	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.62	-0.48	1.45e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg19729930	chr2:74357872	NA	0.54	11.52	0.47	3.66e-27	Gestational age at birth (maternal effect);
LGG	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg16586182	chr3:47516702	SCAP	0.74	13.46	0.53	4.28e-35	Colorectal cancer;
LGG	cis	rs11792861	0.926	rs7856626	chr9:111775502	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.52	0.4	9.83e-20	Menarche (age at onset);
LGG	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9393692	0.557	rs62394764	chr6:26305503	T/C	cg00631329	chr6:26305371	NA	-0.46	-7.76	-0.34	5.36e-14	Educational attainment;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.42	-8.17	-0.35	2.96e-15	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14843216	chr17:56064736	VEZF1	0.46	6.73	0.3	5.17e-11	Gut microbiome composition (summer);
LGG	cis	rs17169635	0.579	rs4732066	chr7:134569177	A/G	cg02516134	chr7:134575187	CALD1	-0.35	-7.72	-0.34	7.27e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	trans	rs1499972	0.517	rs1456193	chr3:117637697	T/C	cg23290159	chr5:150474234	NA	-0.29	-6.88	-0.3	1.98e-11	Schizophrenia;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg26174226	chr8:58114915	NA	-0.52	-7.7	-0.34	8.49e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg05863683	chr7:1912471	MAD1L1	0.39	7.55	0.33	2.31e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg01324343	chr3:183735012	ABCC5	0.85	18.13	0.64	6.85e-56	Anterior chamber depth;
LGG	cis	rs12410462	0.681	rs4614224	chr1:227574966	C/T	cg23173402	chr1:227635558	NA	0.57	8.98	0.39	7.02e-18	Major depressive disorder;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.86	-0.45	1.22e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7914558	0.933	rs10786729	chr10:104719378	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.24	0.43	2.55e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11967485	0.534	rs62435787	chr6:157141182	T/C	cg23222435	chr6:157204239	ARID1B	-0.8	-7.15	-0.32	3.5e-12	Calcium levels;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg22398616	chr13:53314203	LECT1	-0.48	-9.49	-0.4	1.27e-19	Lewy body disease;
LGG	cis	rs10929925	0.966	rs75496373	chr2:6160159	T/G	cg00493617	chr2:6141445	NA	0.32	7.13	0.31	3.91e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg02023728	chr11:77925099	USP35	0.4	6.9	0.31	1.75e-11	Alzheimer's disease (survival time);
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg00290607	chr11:67383545	NA	0.61	11.74	0.48	4.99e-28	Mean corpuscular volume;
LGG	cis	rs7084402	0.565	rs10826200	chr10:60333847	T/C	cg07615347	chr10:60278583	BICC1	0.49	12.0	0.49	4.54e-29	Refractive error;
LGG	cis	rs17453880	0.929	rs4618416	chr5:152028995	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg22437258	chr11:111473054	SIK2	-0.52	-8.87	-0.38	1.62e-17	Primary sclerosing cholangitis;
LGG	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	13.49	0.53	3.15e-35	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	6.12e-20	Life satisfaction;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.01	0.57	8.66e-42	Alzheimer's disease;
LGG	cis	rs4148883	0.651	rs2851301	chr4:100010127	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.39	0.36	5.8e-16	Alcohol dependence;
LGG	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg16586182	chr3:47516702	SCAP	-0.74	-13.38	-0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.05e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs73086581	0.947	rs55794220	chr20:3956402	C/T	cg02187196	chr20:3869020	PANK2	0.84	11.71	0.48	6.16e-28	Response to antidepressants in depression;
LGG	cis	rs7928758	0.887	rs11822913	chr11:134271645	T/A	cg25213107	chr11:134282864	B3GAT1	1.12	13.82	0.54	1.25e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7666738	0.800	rs2865987	chr4:99067852	A/C	cg05340658	chr4:99064831	C4orf37	0.51	8.34	0.36	8.28e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg16434002	chr17:42200994	HDAC5	-0.52	-9.58	-0.41	6.18e-20	Total body bone mineral density;
LGG	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.07	-27.94	-0.79	2.04e-101	Schizophrenia;
LGG	cis	rs9487094	0.744	rs13211604	chr6:110033728	G/C	cg16315928	chr6:109776240	MICAL1	0.52	8.34	0.36	8.46e-16	Height;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23394480	chr14:105487615	CDCA4	0.7	8.03	0.35	8.38e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.716	rs6720801	chr2:43079844	G/C	cg14631114	chr2:43023945	NA	0.45	8.07	0.35	6.19e-15	Hypospadias;
LGG	cis	rs847577	0.677	rs10242903	chr7:97741795	C/T	cg13397024	chr7:97797637	LMTK2	0.42	7.47	0.33	3.94e-13	Breast cancer;
LGG	cis	rs4740619	0.565	rs10756736	chr9:16032225	T/C	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.83e-26	Body mass index;
LGG	cis	rs13102973	0.899	rs13127659	chr4:135900604	G/A	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg25319279	chr11:5960081	NA	-0.55	-8.62	-0.37	1.1e-16	DNA methylation (variation);
LGG	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg22875332	chr1:76189707	ACADM	0.54	7.43	0.33	5.28e-13	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg03469862	chr11:68924853	NA	0.46	7.07	0.31	5.85e-12	Blond vs. brown hair color;
LGG	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-13.73	-0.54	3.14e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg18898632	chr2:242989856	NA	-0.84	-10.32	-0.43	1.29e-22	Obesity-related traits;
LGG	cis	rs7408868	0.563	rs10423702	chr19:15300069	T/C	cg14696996	chr19:15285081	NOTCH3	0.89	11.37	0.47	1.33e-26	Pulse pressure;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg26354017	chr1:205819088	PM20D1	0.82	18.93	0.66	1.25e-59	Menarche (age at onset);
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg03188948	chr7:1209495	NA	0.42	7.62	0.33	1.46e-13	Longevity;Endometriosis;
LGG	cis	rs2115536	0.935	rs11854390	chr15:80224817	C/T	cg11839771	chr15:80205821	ST20	-0.35	-7.22	-0.32	2.19e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.25	0.52	3.45e-34	Tonsillectomy;
LGG	cis	rs7945705	0.935	rs10769971	chr11:8925276	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.14	0.46	1.08e-25	Hemoglobin concentration;
LGG	cis	rs17641971	0.684	rs4873094	chr8:49989578	G/T	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.54	9.94	0.42	3.1e-21	Multiple sclerosis;
LGG	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg27572855	chr1:25598939	RHD	0.49	11.09	0.46	1.64e-25	Erythrocyte sedimentation rate;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.81	0.3	2.98e-11	Schizophrenia;
LGG	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg05335186	chr13:53173507	NA	0.49	10.26	0.43	2.16e-22	Lewy body disease;
LGG	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg01221209	chr5:554886	NA	-0.45	-6.67	-0.3	7.2e-11	Obesity-related traits;
LGG	cis	rs10929925	0.966	rs2609189	chr2:6159494	T/C	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs12731740	0.711	rs35970730	chr1:207914161	C/T	cg22525895	chr1:207977042	MIR29B2	-0.61	-7.26	-0.32	1.65e-12	Biomedical quantitative traits;
LGG	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs921968	0.541	rs4674308	chr2:219310483	A/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.25	-0.32	1.72e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	1.000	rs7947730	chr11:47786184	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs3813359	0.545	rs17058574	chr6:130555734	T/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs9473924	0.542	rs67538952	chr6:50894400	T/C	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs778371	0.676	rs11688166	chr2:233566210	A/G	cg08000102	chr2:233561755	GIGYF2	0.67	10.66	0.44	6.98e-24	Schizophrenia;
LGG	cis	rs13082711	0.554	rs73055724	chr3:27380397	T/G	cg02860705	chr3:27208620	NA	0.87	15.24	0.58	8.85e-43	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7077256	0.542	rs36036508	chr10:65027608	A/G	cg02276361	chr10:65351566	REEP3	-0.33	-6.75	-0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg00857998	chr1:205179979	DSTYK	0.57	9.23	0.39	9.36e-19	Red blood cell count;
LGG	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.12	-0.64	7.26e-56	Refractive error;
LGG	cis	rs17092148	0.836	rs4911157	chr20:33167075	T/C	cg12302830	chr20:33297742	TP53INP2	-0.44	-6.96	-0.31	1.21e-11	Neuroticism;
LGG	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg21535247	chr6:8435926	SLC35B3	0.61	10.36	0.43	9.17e-23	Motion sickness;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg16270222	chr17:41446396	NA	-0.29	-6.97	-0.31	1.11e-11	Menopause (age at onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27609508	chr16:30905407	BCL7C	0.59	6.73	0.3	5.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10908907	0.955	rs1360199	chr9:92258088	A/T	cg01515543	chr9:92254510	LOC100129066	0.44	7.9	0.34	2.07e-14	Alcoholism (heaviness of drinking);
LGG	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.95	-0.31	1.22e-11	Triglycerides;
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.66	0.3	7.88e-11	Vitiligo;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs7586879	0.789	rs67221599	chr2:25131948	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.49	11.53	0.47	3.17e-27	Oropharynx cancer;
LGG	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.5e-11	Alzheimer's disease (survival time);
LGG	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg19507638	chr5:93509721	C5orf36	0.41	7.22	0.32	2.11e-12	Diabetic retinopathy;
LGG	cis	rs4315565	0.688	rs4618092	chr2:69272987	T/C	cg13358873	chr2:69271042	ANTXR1	0.5	7.03	0.31	7.4e-12	Height;
LGG	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg13939156	chr17:80058883	NA	-0.4	-7.23	-0.32	2.01e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.44	0.44	4.76e-23	Morning vs. evening chronotype;
LGG	cis	rs7166081	1.000	rs4776350	chr15:67542179	C/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.84	-0.3	2.56e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg11301795	chr4:187892539	NA	-0.94	-24.92	-0.76	1.52e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.72	0.45	4.37e-24	Obesity-related traits;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg11766577	chr21:47581405	C21orf56	-0.51	-9.23	-0.39	9.56e-19	Testicular germ cell tumor;
LGG	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg20503657	chr10:835505	NA	0.54	6.96	0.31	1.16e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.83	-17.56	-0.63	2.7e-53	Caffeine consumption;
LGG	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg23649088	chr2:200775458	C2orf69	0.53	8.98	0.38	7.06e-18	Osteoporosis;
LGG	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg15479754	chr10:1447082	ADARB2	-0.35	-7.31	-0.32	1.21e-12	Radiation response;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs17685	0.712	rs10275521	chr7:75770972	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg15128208	chr22:42549153	NA	0.75	11.78	0.48	3.41e-28	Birth weight;
LGG	cis	rs16867321	0.694	rs11889207	chr2:181424527	A/C	cg23363182	chr2:181467187	NA	-0.44	-8.45	-0.37	3.82e-16	Obesity;
LGG	cis	rs6121246	0.542	rs2376990	chr20:30238744	G/A	cg21427119	chr20:30132790	HM13	-0.49	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;
LGG	cis	rs6138458	0.585	rs1007881	chr20:25014385	A/G	cg26195577	chr20:24973756	C20orf3	0.9	16.64	0.61	4.3e-49	Blood protein levels;
LGG	cis	rs7737355	0.947	rs6890784	chr5:130939540	T/C	cg06307176	chr5:131281290	NA	0.57	9.32	0.4	4.85e-19	Life satisfaction;
LGG	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg11871910	chr12:69753446	YEATS4	0.72	14.13	0.55	5.95e-38	Blood protein levels;
LGG	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.64	-0.33	1.22e-13	Mood instability;
LGG	trans	rs6787172	0.702	rs827177	chr3:157965276	T/A	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs2732480	0.577	rs2732466	chr12:48732459	A/G	cg21466736	chr12:48725269	NA	-0.4	-8.03	-0.35	8.04e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg03929089	chr4:120376271	NA	-0.88	-17.87	-0.64	1.09e-54	Coronary artery disease;
LGG	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9400467	0.537	rs12214550	chr6:111505499	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.11	0.31	4.29e-12	Blood metabolite levels;Amino acid levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14940636	chr12:56498092	PA2G4	0.39	6.94	0.31	1.32e-11	Obesity-related traits;
LGG	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.73	-11.05	-0.46	2.37e-25	Post bronchodilator FEV1;
LGG	cis	rs10751667	0.666	rs7943140	chr11:973824	T/C	cg22143635	chr11:980567	AP2A2	0.44	8.15	0.35	3.32e-15	Alzheimer's disease (late onset);
LGG	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg00701064	chr4:6280414	WFS1	0.76	17.75	0.64	3.86e-54	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7666738	0.830	rs13138920	chr4:99020786	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4664308	0.967	rs62175559	chr2:160955833	G/A	cg03641300	chr2:160917029	PLA2R1	-0.87	-17.95	-0.64	4.3e-55	Idiopathic membranous nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14862950	chr11:66112661	BRMS1	0.45	6.77	0.3	3.99e-11	Gut microbiome composition (summer);
LGG	trans	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg25214090	chr10:38739885	LOC399744	0.71	12.61	0.51	1.5e-31	Corneal astigmatism;
LGG	trans	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg22153745	chr1:153894579	GATAD2B	-0.63	-10.34	-0.43	1.05e-22	Total cholesterol levels;
LGG	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg25482853	chr8:67687455	SGK3	1.0	12.85	0.51	1.52e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.15	0.35	3.49e-15	Obesity-related traits;
LGG	cis	rs910187	0.605	rs3787235	chr20:45803522	C/T	cg27589058	chr20:45804311	EYA2	-0.38	-10.06	-0.42	1.14e-21	Migraine;
LGG	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.36	7.02	0.31	7.73e-12	Fuchs's corneal dystrophy;
LGG	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg27572855	chr1:25598939	RHD	0.49	11.1	0.46	1.56e-25	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03264133	chr6:25882463	NA	-0.75	-14.32	-0.55	9.37e-39	Blood metabolite levels;
LGG	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg23978390	chr7:1156363	C7orf50	0.54	7.35	0.32	9.21e-13	Bronchopulmonary dysplasia;
LGG	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg00745463	chr17:30367425	LRRC37B	0.54	7.33	0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg26384229	chr12:38710491	ALG10B	0.67	12.17	0.49	9.29e-30	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs12447804	1.000	rs1050779	chr16:58080215	G/C	cg03859792	chr16:58121049	NA	0.47	7.1	0.31	4.58e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.62	-0.37	1.04e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504130	0.666	rs7819892	chr8:52845476	A/C	cg24946253	chr8:52722146	PXDNL	0.49	7.74	0.34	6.27e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16706631	chr6:26204823	HIST1H4E	0.44	7.36	0.32	8.66e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.46	-8.9	-0.38	1.26e-17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg12826209	chr6:26865740	GUSBL1	-0.77	-6.97	-0.31	1.11e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg02297831	chr4:17616191	MED28	0.47	8.37	0.36	6.97e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg14092988	chr3:52407081	DNAH1	0.3	7.94	0.35	1.6e-14	Bipolar disorder;
LGG	cis	rs9303401	0.659	rs12935851	chr17:56600244	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs17767392	0.595	rs6574006	chr14:71652617	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.04	-0.31	7.16e-12	Mitral valve prolapse;
LGG	cis	rs568617	0.626	rs10896050	chr11:65577516	G/T	cg04055107	chr11:65626734	MUS81;CFL1	0.57	7.63	0.33	1.3e-13	Crohn's disease;
LGG	cis	rs45544231	0.544	rs9931232	chr16:52572832	A/G	cg09051775	chr16:52580266	TOX3	0.41	7.08	0.31	5.36e-12	Restless legs syndrome;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg18379455	chr17:41446167	NA	0.32	7.72	0.34	7.18e-14	Menopause (age at onset);
LGG	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs2050392	0.792	rs684395	chr10:30719112	C/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.86	-0.45	1.21e-24	Inflammatory bowel disease;
LGG	cis	rs4808199	0.793	rs12459676	chr19:19425141	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.7	0.3	5.94e-11	Nonalcoholic fatty liver disease;
LGG	cis	rs2279817	0.743	rs12023874	chr1:18025612	A/G	cg21791023	chr1:18019539	ARHGEF10L	0.64	11.6	0.47	1.73e-27	Neuroticism;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg00106254	chr7:1943704	MAD1L1	0.43	7.63	0.33	1.37e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	16.43	0.61	4.08e-48	Platelet count;
LGG	trans	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg14791747	chr16:20752902	THUMPD1	0.49	7.54	0.33	2.54e-13	Cognitive test performance;
LGG	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg06138931	chr13:21896616	NA	-0.44	-7.29	-0.32	1.35e-12	White matter hyperintensity burden;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.18	-0.32	2.78e-12	Life satisfaction;
LGG	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg26695010	chr11:65641043	EFEMP2	0.66	12.12	0.49	1.53e-29	Eosinophil percentage of white cells;
LGG	cis	rs599083	0.829	rs23691	chr11:68178668	G/A	cg16797656	chr11:68205561	LRP5	-0.52	-9.52	-0.4	9.66e-20	Bone mineral density (spine);
LGG	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.26	0.43	2.11e-22	Motion sickness;
LGG	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.37	-7.08	-0.31	5.46e-12	Total cholesterol levels;
LGG	cis	rs68170813	0.527	rs75382408	chr7:107010406	C/T	cg02696742	chr7:106810147	HBP1	-0.65	-9.29	-0.4	6.2e-19	Coronary artery disease;
LGG	cis	rs4481887	0.573	rs4412629	chr1:248411399	G/T	cg01631408	chr1:248437212	OR2T33	-0.44	-7.46	-0.33	4.29e-13	Common traits (Other);
LGG	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg05791153	chr7:19748676	TWISTNB	0.76	10.1	0.43	7.94e-22	Thyroid stimulating hormone;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg04025307	chr7:1156635	C7orf50	0.51	8.53	0.37	2.16e-16	Bronchopulmonary dysplasia;
LGG	cis	rs11945232	1.000	rs28372775	chr4:88343704	G/A	cg23841344	chr4:88312519	HSD17B11	-0.51	-9.07	-0.39	3.39e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	0.806	rs4074521	chr3:134325536	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.7	0.45	5.18e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg13101948	chr6:4056654	PRPF4B	0.34	6.84	0.3	2.5e-11	Lung cancer;
LGG	cis	rs68170813	0.559	rs1018946	chr7:106851754	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.65	-0.44	7.82e-24	Coronary artery disease;
LGG	cis	rs7586879	0.616	rs6545809	chr2:25126715	C/T	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs10751667	0.666	rs7396473	chr11:966181	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.26	0.36	1.59e-15	Alzheimer's disease (late onset);
LGG	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg16662043	chr16:48846231	NA	0.35	6.84	0.3	2.59e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.14	-0.35	3.72e-15	Joint mobility (Beighton score);
LGG	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	8.47	0.37	3.36e-16	Thyroid stimulating hormone;
LGG	cis	rs17767392	0.836	rs35415083	chr14:72009196	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.8	-0.38	2.82e-17	Mitral valve prolapse;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg11494091	chr17:61959527	GH2	1.01	25.11	0.76	1.91e-88	Prudent dietary pattern;
LGG	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs7246760	0.867	rs58461110	chr19:9833390	G/A	cg16876255	chr19:9731953	ZNF561	0.81	7.57	0.33	2.08e-13	Pursuit maintenance gain;
LGG	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.45	0.44	4.16e-23	Aortic root size;
LGG	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.85e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17321999	1.000	rs3817143	chr2:30482285	G/A	cg05247661	chr2:30472410	LBH	0.56	8.73	0.38	4.68e-17	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.72	0.38	4.9e-17	Vitiligo;
LGG	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg08198773	chr8:1697536	NA	0.44	7.82	0.34	3.62e-14	Systolic blood pressure;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg26513180	chr16:89883248	FANCA	0.83	8.83	0.38	2.21e-17	Skin colour saturation;
LGG	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg26354017	chr1:205819088	PM20D1	-0.42	-7.41	-0.33	5.84e-13	Menarche (age at onset);
LGG	cis	rs8067545	0.586	rs57837691	chr17:20203073	T/C	cg13482628	chr17:19912719	NA	-0.55	-10.32	-0.43	1.25e-22	Schizophrenia;
LGG	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg10792982	chr14:105748885	BRF1	0.66	12.89	0.51	1.06e-32	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.12	-0.31	4.23e-12	Lung cancer;
LGG	cis	rs4595586	0.655	rs11831502	chr12:39310127	A/T	cg26384229	chr12:38710491	ALG10B	0.48	8.84	0.38	2.02e-17	Morning vs. evening chronotype;
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.68	0.41	2.68e-20	Systolic blood pressure;
LGG	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-11.93	-0.48	8.48e-29	Bladder cancer;
LGG	cis	rs4731207	0.698	rs6960504	chr7:124530314	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.46	-0.33	4.25e-13	Cutaneous malignant melanoma;
LGG	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg11764359	chr7:65958608	NA	0.7	12.6	0.51	1.64e-31	Aortic root size;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg00684032	chr4:1343700	KIAA1530	0.39	7.33	0.32	1.03e-12	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs7106204	0.513	rs7131112	chr11:24249402	A/G	ch.11.24196551F	chr11:24239977	NA	0.97	15.24	0.58	8.8e-43	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg07395648	chr5:131743802	NA	0.56	13.17	0.52	7.52e-34	Blood metabolite levels;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg04287289	chr16:89883240	FANCA	0.6	6.89	0.3	1.85e-11	Skin colour saturation;
LGG	trans	rs61931739	0.635	rs7138254	chr12:33914422	G/T	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	9.15	0.39	1.76e-18	Diabetic retinopathy;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg06074448	chr4:187884817	NA	-0.58	-12.86	-0.51	1.44e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4642101	0.597	rs9839769	chr3:12821405	C/T	cg24848339	chr3:12840334	CAND2	0.45	10.84	0.45	1.47e-24	QRS complex (12-leadsum);
LGG	cis	rs6539267	0.847	rs12831519	chr12:106682917	A/G	cg02476566	chr12:106696527	TCP11L2	0.52	6.85	0.3	2.35e-11	Tourette syndrome;
LGG	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.39	-0.32	7.13e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.23	0.32	2.04e-12	Lung cancer;
LGG	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg20487152	chr13:99095054	FARP1	-0.36	-6.7	-0.3	5.95e-11	Neuroticism;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.39	-0.56	4.57e-39	Platelet count;
LGG	cis	rs6580649	0.882	rs59766465	chr12:48470169	G/A	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg02023728	chr11:77925099	USP35	0.44	7.88	0.34	2.42e-14	Testicular germ cell tumor;
LGG	cis	rs4561483	0.801	rs8061189	chr16:11951749	C/G	cg08843971	chr16:11963173	GSPT1	0.67	17.48	0.63	6.91e-53	Testicular germ cell tumor;
LGG	trans	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg02002194	chr4:3960332	NA	0.41	7.39	0.32	6.81e-13	Mood instability;
LGG	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg08807101	chr21:30365312	RNF160	0.49	8.19	0.36	2.64e-15	Pancreatic cancer;
LGG	cis	rs7940866	0.838	rs1118137	chr11:130890970	G/A	cg12179176	chr11:130786555	SNX19	0.71	12.93	0.52	7.14e-33	Schizophrenia;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.31	-0.32	1.16e-12	Bipolar disorder;
LGG	cis	rs208520	0.690	rs207102	chr6:66795671	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.26	-0.32	1.69e-12	Bipolar disorder;
LGG	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg16586182	chr3:47516702	SCAP	-0.77	-15.37	-0.58	2.33e-43	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07481194	chr14:23398747	PRMT5	0.45	6.7	0.3	5.98e-11	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg02475777	chr4:1388615	CRIPAK	0.61	10.7	0.45	5.04e-24	Longevity;
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.14	-0.31	3.65e-12	Bipolar disorder;
LGG	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg08885076	chr2:99613938	TSGA10	-0.57	-11.54	-0.47	2.98e-27	Chronic sinus infection;
LGG	cis	rs4732038	1.000	rs706201	chr7:134251041	A/G	cg06906464	chr7:134288099	NA	0.5	12.47	0.5	5.54e-31	Longevity;
LGG	cis	rs6142618	0.583	rs2235904	chr20:30721712	T/C	cg00028034	chr20:30779307	TSPYL3	0.34	7.48	0.33	3.7e-13	Inflammatory bowel disease;
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg17218041	chr13:113365319	ATP11A	-0.47	-7.74	-0.34	6.49e-14	Glycated hemoglobin levels;
LGG	cis	rs365132	0.875	rs3923879	chr5:176355312	C/T	cg16309518	chr5:176445507	NA	-0.51	-11.2	-0.46	6.3e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg05552183	chr6:42928497	GNMT	0.48	14.75	0.57	1.23e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg08999081	chr20:33150536	PIGU	0.33	7.99	0.35	1.11e-14	Coronary artery disease;
LGG	trans	rs9393777	0.720	rs35769282	chr6:26999908	G/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.25	-0.39	8.61e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg16141378	chr3:129829833	LOC729375	-0.51	-12.94	-0.52	6.29e-33	Mood instability;
LGG	cis	rs11096990	0.855	rs2566181	chr4:39159607	C/T	cg24403649	chr4:39172243	NA	-0.49	-7.88	-0.34	2.38e-14	Cognitive function;
LGG	cis	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg21775007	chr8:11205619	TDH	-0.44	-6.77	-0.3	3.85e-11	Neuroticism;
LGG	cis	rs7666738	0.753	rs10033138	chr4:98981922	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg04025307	chr7:1156635	C7orf50	0.63	8.22	0.36	2.02e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.754	rs878376	chr4:120237702	G/A	cg09307838	chr4:120376055	NA	0.71	12.01	0.49	4.15e-29	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg08621203	chr6:150244597	RAET1G	0.43	7.24	0.32	1.92e-12	Lung cancer;
LGG	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg05096777	chr10:104283225	SUFU	0.32	7.14	0.31	3.63e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg03733263	chr8:22462867	KIAA1967	1.11	28.77	0.8	3.93e-105	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs66573146	0.572	rs55740475	chr4:6954092	C/G	cg00086871	chr4:6988644	TBC1D14	0.84	8.33	0.36	9.23e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.58	-11.03	-0.46	2.78e-25	Total body bone mineral density;
LGG	cis	rs1044826	0.642	rs9859864	chr3:139091219	G/T	cg15131784	chr3:139108705	COPB2	-0.42	-7.04	-0.31	7.14e-12	Obesity-related traits;
LGG	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg03433033	chr1:76189801	ACADM	-0.65	-9.55	-0.41	7.76e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.47	-0.33	4.02e-13	Testicular germ cell tumor;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00684032	chr4:1343700	KIAA1530	0.66	13.69	0.54	4.48e-36	Obesity-related traits;
LGG	trans	rs3960554	0.808	rs78811105	chr7:75702795	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.46	0.5	6.43e-31	Eotaxin levels;
LGG	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg21435375	chr2:172878103	MAP1D	-0.33	-7.58	-0.33	1.91e-13	Schizophrenia;
LGG	cis	rs9814567	0.806	rs4245904	chr3:134321808	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg21775007	chr8:11205619	TDH	-0.43	-6.8	-0.3	3.19e-11	Morning vs. evening chronotype;
LGG	cis	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.42	-0.36	4.72e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7166081	1.000	rs34310656	chr15:67599975	C/T	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4924935	0.851	rs17743944	chr17:18809268	A/G	cg26378065	chr17:18585709	ZNF286B	-0.45	-7.12	-0.31	4.24e-12	Pancreatic cancer;
LGG	cis	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.53e-21	Corneal astigmatism;
LGG	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg26384229	chr12:38710491	ALG10B	0.61	11.83	0.48	2.06e-28	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg14500267	chr11:67383377	NA	-0.41	-7.48	-0.33	3.82e-13	Mean corpuscular volume;
LGG	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.13	-0.35	4.05e-15	Neuroticism;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	5.19e-31	Lung cancer;
LGG	trans	rs877282	0.853	rs12779017	chr10:763619	T/C	cg22713356	chr15:30763199	NA	0.52	7.66	0.34	1.12e-13	Uric acid levels;
LGG	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.41	-0.33	6.22e-13	Cognitive ability;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg17470184	chr11:118478236	PHLDB1	-0.41	-6.96	-0.31	1.15e-11	Cholesterol, total;
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg01145232	chr6:150245071	RAET1G	-0.53	-9.54	-0.41	8.15e-20	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06546717	chr12:113659579	TPCN1;IQCD	0.42	6.71	0.3	5.53e-11	Cognitive performance;
LGG	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg09021430	chr5:549028	NA	-0.68	-9.66	-0.41	3.15e-20	Obesity-related traits;
LGG	cis	rs7097780	0.869	rs8177655	chr10:6015119	G/A	cg10686550	chr10:6020330	IL15RA	0.38	6.82	0.3	2.82e-11	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00914033	chr10:81664698	NA	0.44	7.23	0.32	2.05e-12	Cognitive performance;
LGG	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg15268244	chr15:77196840	NA	-0.34	-7.59	-0.33	1.78e-13	Blood metabolite levels;
LGG	cis	rs225245	0.791	rs6505492	chr17:34026597	C/T	cg05299278	chr17:33885742	SLFN14	0.42	8.11	0.35	4.52e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18451256	chr2:128284158	IWS1	0.48	7.75	0.34	5.79e-14	Cognitive performance;
LGG	cis	rs4243971	0.516	rs4575791	chr20:30976304	A/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24308560	chr3:49941425	MST1R	0.22	6.83	0.3	2.65e-11	Intelligence (multi-trait analysis);
LGG	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg11887960	chr12:57824829	NA	0.6	7.34	0.32	9.36e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs13102973	0.720	rs67429820	chr4:135888003	G/A	cg14419869	chr4:135874104	NA	0.46	7.88	0.34	2.3e-14	Subjective well-being;
LGG	cis	rs6719977	0.935	rs1992286	chr2:42990336	T/G	cg14631114	chr2:43023945	NA	0.46	9.77	0.41	1.28e-20	Hyperactive-impulsive symptoms;
LGG	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg07148914	chr20:33460835	GGT7	0.5	8.15	0.35	3.39e-15	Height;
LGG	trans	rs11039798	0.623	rs594615	chr11:48402804	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.94	-0.42	3.09e-21	Axial length;
LGG	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.01	-0.39	5.39e-18	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg10756647	chr7:56101905	PSPH	0.8	9.39	0.4	2.64e-19	Diabetic kidney disease;
LGG	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.16	-0.32	3.26e-12	Joint mobility (Beighton score);
LGG	cis	rs10463316	0.894	rs6891272	chr5:150762842	G/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg21475434	chr5:93447410	FAM172A	0.71	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	trans	rs877282	0.898	rs34490091	chr10:765800	A/C	cg22713356	chr15:30763199	NA	0.51	7.34	0.32	9.7e-13	Uric acid levels;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg00343986	chr7:65444356	GUSB	-0.42	-7.34	-0.32	9.36e-13	Calcium levels;
LGG	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg26384229	chr12:38710491	ALG10B	0.64	11.95	0.49	7.23e-29	Morning vs. evening chronotype;
LGG	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg12927641	chr6:109611667	NA	0.39	7.28	0.32	1.47e-12	Reticulocyte fraction of red cells;
LGG	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.56	0.59	3.29e-44	Total body bone mineral density;
LGG	cis	rs10744422	0.858	rs10773627	chr12:123311853	A/G	cg25930673	chr12:123319894	HIP1R	-0.7	-9.02	-0.39	5.09e-18	Schizophrenia;
LGG	trans	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs6977660	1.000	rs10260527	chr7:19801930	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.59	0.37	1.34e-16	Thyroid stimulating hormone;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg27471124	chr11:109292789	C11orf87	0.63	12.15	0.49	1.09e-29	Schizophrenia;
LGG	trans	rs11039798	0.920	rs11040013	chr11:48782862	G/A	cg15704280	chr7:45808275	SEPT13	0.78	8.96	0.38	7.84e-18	Axial length;
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.69e-17	Bipolar disorder;
LGG	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2708977	0.842	rs10209780	chr2:97140142	T/G	cg01950434	chr2:97203154	ARID5A	-0.58	-9.32	-0.4	4.8e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-12.72	-0.51	5.25e-32	Parkinson's disease;
LGG	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg20991723	chr1:152506922	NA	-0.7	-14.13	-0.55	6.11e-38	Hair morphology;
LGG	cis	rs365132	1.000	rs7718874	chr5:176358065	A/G	cg16309518	chr5:176445507	NA	-0.55	-12.22	-0.49	6.12e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.57	0.41	6.4e-20	Fuchs's corneal dystrophy;
LGG	cis	rs4689388	0.889	rs13101355	chr4:6293446	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.34	0.4	4.12e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg08621203	chr6:150244597	RAET1G	0.46	7.86	0.34	2.75e-14	Lung cancer;
LGG	cis	rs10504073	0.647	rs4348510	chr8:50016027	C/A	cg00325661	chr8:49890786	NA	0.69	13.36	0.53	1.16e-34	Blood metabolite ratios;
LGG	cis	rs755249	0.567	rs61779285	chr1:39867055	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.5	0.33	3.32e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6840360	0.550	rs7683134	chr4:152503362	A/C	cg25486957	chr4:152246857	NA	-0.51	-8.4	-0.36	5.7e-16	Intelligence (multi-trait analysis);
LGG	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.2	-0.43	3.44e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg06685724	chr7:23720386	C7orf46	0.44	10.42	0.44	5.64e-23	Schizophrenia;
LGG	cis	rs2816316	0.887	rs2760522	chr1:192529414	C/G	cg02586212	chr1:192544902	RGS1	0.43	8.56	0.37	1.74e-16	Celiac disease;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.28	-0.4	6.43e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg21427119	chr20:30132790	HM13	-0.42	-7.16	-0.32	3.25e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1163251	0.837	rs839612	chr1:120247176	T/C	cg19096424	chr1:120255104	PHGDH	0.67	12.0	0.49	4.41e-29	Blood metabolite levels;
LGG	cis	rs548181	0.604	rs11608103	chr11:125627917	G/A	cg03464685	chr11:125439445	EI24	-1.13	-16.2	-0.6	4.35e-47	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg10852096	chr15:79043040	NA	0.29	7.24	0.32	1.85e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs745821	0.788	rs745823	chr18:48142784	A/G	cg18923635	chr18:48083994	NA	0.43	7.4	0.33	6.54e-13	Diastolic blood pressure;
LGG	cis	rs910316	0.967	rs1071989	chr14:75564659	G/T	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.62e-22	Height;
LGG	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg26384229	chr12:38710491	ALG10B	0.75	14.9	0.57	2.7e-41	Morning vs. evening chronotype;
LGG	cis	rs9359856	0.636	rs9344946	chr6:90298371	T/G	cg13799429	chr6:90582589	CASP8AP2	0.61	8.08	0.35	5.72e-15	Bipolar disorder;
LGG	cis	rs6912958	0.703	rs9359748	chr6:88095500	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	11.23	0.46	4.91e-26	Monocyte percentage of white cells;
LGG	cis	rs7177699	0.557	rs12898712	chr15:79112622	G/T	cg00540400	chr15:79124168	NA	0.54	11.48	0.47	5.23e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg10950524	chr7:2139216	MAD1L1	-0.32	-6.78	-0.3	3.7e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4639966	0.723	rs11217022	chr11:118641606	A/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.58	-0.37	1.41e-16	Systemic lupus erythematosus;
LGG	cis	rs9948	0.655	rs62156212	chr2:97399096	C/T	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs7666738	0.830	rs2865949	chr4:99039967	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg05692746	chr2:100937584	LONRF2	-0.64	-11.99	-0.49	4.74e-29	Intelligence (multi-trait analysis);
LGG	cis	rs920590	0.502	rs7816670	chr8:19634556	C/G	cg03894339	chr8:19674705	INTS10	0.44	7.43	0.33	5.18e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg09263875	chr16:632152	PIGQ	0.67	13.59	0.53	1.27e-35	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03734322	chr17:1532856	SLC43A2	0.47	7.26	0.32	1.63e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg23422044	chr7:1970798	MAD1L1	-0.46	-8.29	-0.36	1.23e-15	Neuroticism;
LGG	cis	rs12681366	0.663	rs2930970	chr8:95464337	A/G	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg24634471	chr8:143751801	JRK	0.48	7.32	0.32	1.12e-12	Schizophrenia;
LGG	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg01864069	chr14:103024347	NA	0.67	9.64	0.41	3.67e-20	Platelet count;
LGG	cis	rs10463316	0.894	rs4246024	chr5:150740987	C/T	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.37	-0.43	8.15e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg27490568	chr2:178487706	NA	0.53	10.24	0.43	2.58e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.49	0.5	4.68e-31	Prudent dietary pattern;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg18350739	chr11:68623251	NA	-0.81	-20.25	-0.69	9.44e-66	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg14773178	chr5:1868261	NA	0.37	8.07	0.35	6.22e-15	Cardiovascular disease risk factors;
LGG	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-15.84	-0.59	1.85e-45	Gallbladder cancer;
LGG	cis	rs80130819	0.688	rs2732476	chr12:48700691	T/C	cg24011408	chr12:48396354	COL2A1	0.57	6.66	0.3	7.63e-11	Prostate cancer;
LGG	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02825527	chr7:2087843	MAD1L1	0.43	7.77	0.34	5.15e-14	Bipolar disorder;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11905131	chr22:24372483	LOC391322	0.46	7.85	0.34	2.96e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11018874	0.735	rs4307680	chr11:89900630	A/C	cg14505434	chr11:89522851	NA	0.61	7.87	0.34	2.56e-14	White blood cell types;
LGG	cis	rs7773004	0.905	rs1053860	chr6:26325228	C/T	cg13736514	chr6:26305472	NA	-0.41	-8.36	-0.36	7.45e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4302748	0.862	rs73337008	chr7:36187715	G/T	cg24442661	chr7:36192818	EEPD1	0.56	7.34	0.32	9.65e-13	Platelet count;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg11859384	chr17:80120422	CCDC57	0.44	7.74	0.34	6.13e-14	Life satisfaction;
LGG	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-9.24	-0.39	9.33e-19	Erythrocyte sedimentation rate;
LGG	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.7	-13.37	-0.53	1.08e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg05091796	chr16:4465799	CORO7	-0.76	-13.11	-0.52	1.35e-33	Schizophrenia;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.34	0.4	4.06e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.04	0.52	2.52e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg24881330	chr22:46731750	TRMU	0.67	6.79	0.3	3.55e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9467773	0.838	rs3734540	chr6:26463321	A/C	cg11502198	chr6:26597334	ABT1	0.56	9.63	0.41	3.92e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12738007	1.000	rs34921636	chr1:29558281	A/G	cg01115565	chr1:29584222	PTPRU	-0.27	-7.41	-0.33	5.97e-13	Schizophrenia;
LGG	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg10556349	chr10:835070	NA	-0.3	-7.5	-0.33	3.34e-13	Survival in rectal cancer;
LGG	cis	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.98	0.31	1.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9964724	0.865	rs7505519	chr18:35172316	G/A	cg27332583	chr18:35150602	NA	-0.42	-9.03	-0.39	4.6e-18	Educational attainment (years of education);
LGG	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg07061783	chr6:25882402	NA	0.45	7.96	0.35	1.29e-14	Blood metabolite levels;
LGG	cis	rs35306767	0.623	rs72760943	chr10:1143104	G/A	cg25019033	chr10:957182	NA	-0.49	-8.61	-0.37	1.13e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs7133214	0.771	rs12367102	chr12:27920001	C/T	cg04279139	chr12:27925367	LOC100133893	-0.33	-7.08	-0.31	5.45e-12	Gut microbiota (functional units);
LGG	cis	rs701145	0.585	rs1534386	chr3:153819035	C/G	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.88	0.3	1.91e-11	Height;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg11766577	chr21:47581405	C21orf56	0.56	10.22	0.43	3.13e-22	Testicular germ cell tumor;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg23782820	chr8:58130467	NA	0.46	7.37	0.32	7.98e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.4	-21.97	-0.71	7.87e-74	Hemostatic factors and hematological phenotypes;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg22368624	chr6:169901913	WDR27	-0.66	-6.84	-0.3	2.6e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs7166081	0.951	rs12594065	chr15:67518001	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg05368731	chr17:41323189	NBR1	0.95	18.97	0.66	8.72e-60	Menopause (age at onset);
LGG	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg16414030	chr3:133502952	NA	-0.55	-8.67	-0.37	7.6e-17	Iron status biomarkers;
LGG	trans	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.01	-0.31	8.62e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg19507638	chr5:93509721	C5orf36	0.66	9.16	0.39	1.71e-18	Diabetic retinopathy;
LGG	cis	rs17221829	0.965	rs10830370	chr11:89461535	G/T	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.5	-0.33	3.18e-13	Anxiety in major depressive disorder;
LGG	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg19507638	chr5:93509721	C5orf36	-0.71	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg25809561	chr17:30822961	MYO1D	0.45	11.19	0.46	6.94e-26	Schizophrenia;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg06719900	chr11:109292894	C11orf87	-0.75	-15.29	-0.58	4.9e-43	Schizophrenia;
LGG	cis	rs943466	1.000	rs12524835	chr6:33730843	G/C	cg07519485	chr6:33762594	MLN	0.56	11.25	0.46	4.2e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs11608355	0.545	rs9943764	chr12:109905720	G/A	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs11758351	0.500	rs79697629	chr6:26196512	A/G	cg02612650	chr6:26195910	NA	0.88	6.85	0.3	2.4e-11	Gout;Renal underexcretion gout;
LGG	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg09307838	chr4:120376055	NA	0.69	11.16	0.46	8.85e-26	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg01879757	chr17:41196368	BRCA1	-0.46	-9.3	-0.4	5.78e-19	Menopause (age at onset);
LGG	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.34	0.53	1.45e-34	Bladder cancer;
LGG	trans	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg27121462	chr16:89883253	FANCA	0.62	11.4	0.47	1.1e-26	Vitiligo;
LGG	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg06766960	chr11:133703094	NA	-0.58	-11.43	-0.47	7.76e-27	Childhood ear infection;
LGG	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.24e-20	Mean corpuscular volume;
LGG	cis	rs7523273	0.586	rs2796276	chr1:207951513	G/A	cg22525895	chr1:207977042	MIR29B2	0.62	12.1	0.49	1.8e-29	Schizophrenia;
LGG	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.87e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg07511668	chr11:68622177	NA	0.47	8.98	0.38	7.09e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	cis	rs2120243	0.501	rs1456107	chr3:157119520	A/C	cg24825693	chr3:157122686	VEPH1	-0.58	-13.51	-0.53	2.59e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs4714291	0.722	rs9296320	chr6:40118298	C/G	cg02267698	chr19:7991119	CTXN1	0.52	8.68	0.37	6.79e-17	Strep throat;
LGG	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg22681709	chr2:178499509	PDE11A	0.46	8.51	0.37	2.49e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs7666738	0.830	rs10031190	chr4:98908683	C/A	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7927592	0.731	rs2156463	chr11:68386311	T/C	cg01657329	chr11:68192670	LRP5	-0.57	-10.79	-0.45	2.38e-24	Total body bone mineral density;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06942064	chr1:208417143	PLXNA2	0.41	6.77	0.3	3.84e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7215564	0.908	rs59254087	chr17:78665278	A/C	cg16980736	chr17:78789706	RPTOR	-0.61	-8.13	-0.35	4e-15	Myopia (pathological);
LGG	cis	rs8028182	0.636	rs11637068	chr15:75743002	G/A	cg20655648	chr15:75932815	IMP3	0.47	7.97	0.35	1.23e-14	Sudden cardiac arrest;
LGG	cis	rs740474	0.831	rs3828677	chr5:140993623	C/T	cg00076195	chr5:140892677	NA	-0.44	-8.02	-0.35	8.53e-15	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs703842	1.000	rs4646536	chr12:58157988	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.48	7.64	0.33	1.28e-13	Multiple sclerosis;
LGG	cis	rs227833	0.586	rs1283932	chr6:44643570	T/G	cg18551225	chr6:44695536	NA	0.42	6.94	0.31	1.35e-11	Monobrow;
LGG	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4919694	1.000	rs77969925	chr10:104649357	C/T	cg04362960	chr10:104952993	NT5C2	1.09	14.99	0.57	1.04e-41	Arsenic metabolism;
LGG	cis	rs1568889	1.000	rs1464897	chr11:28034844	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	15.51	0.58	5.29e-44	Bipolar disorder;
LGG	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	8.1	0.35	4.89e-15	Birth weight;
LGG	cis	rs4262150	0.883	rs72802877	chr5:152241855	A/G	cg12297329	chr5:152029980	NA	-0.65	-12.27	-0.5	3.53e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg14926445	chr8:58193284	C8orf71	-0.69	-8.28	-0.36	1.34e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.525	rs4441057	chr12:39420620	T/A	cg26384229	chr12:38710491	ALG10B	0.69	12.69	0.51	6.83e-32	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg15704280	chr7:45808275	SEPT13	-0.98	-21.74	-0.71	9.35e-73	Height;
LGG	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg14191688	chr11:70257035	CTTN	0.58	8.66	0.37	8.04e-17	Coronary artery disease;
LGG	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg25706552	chr1:244017396	NA	0.53	8.63	0.37	9.59e-17	RR interval (heart rate);
LGG	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg24209194	chr3:40518798	ZNF619	0.43	6.79	0.3	3.39e-11	Renal cell carcinoma;
LGG	cis	rs894734	0.535	rs7301643	chr12:54325796	G/T	cg12374095	chr12:54320830	NA	-0.4	-7.28	-0.32	1.45e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	trans	rs9467711	1.000	rs1883215	chr6:26314233	G/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-7.19	-0.32	2.65e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.12	-0.35	4.23e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg22852734	chr6:133119734	C6orf192	1.16	15.75	0.59	4.47e-45	Type 2 diabetes nephropathy;
LGG	cis	rs7402982	0.934	rs8027457	chr15:99204101	A/G	cg03437748	chr15:99193247	IGF1R	0.92	20.55	0.69	3.43e-67	Birth weight;
LGG	cis	rs9596863	0.634	rs2806739	chr13:54301779	T/C	ch.13.53330881F	chr13:54432880	NA	-0.46	-7.22	-0.32	2.12e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.04e-12	Electroencephalogram traits;
LGG	cis	rs9378357	0.850	rs6910086	chr6:3287118	T/C	cg08754725	chr6:3293098	SLC22A23	0.75	7.8	0.34	4.04e-14	Obesity-related traits;
LGG	cis	rs1978968	0.956	rs5992925	chr22:18447697	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg23758822	chr17:41437982	NA	0.83	14.83	0.57	5.55e-41	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg03036210	chr16:89904091	SPIRE2	-0.62	-7.69	-0.34	8.82e-14	Skin colour saturation;
LGG	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.08	-0.35	5.5e-15	Neuroticism;
LGG	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs45544231	0.569	rs9302556	chr16:52543645	C/A	cg09051775	chr16:52580266	TOX3	-0.4	-6.79	-0.3	3.44e-11	Restless legs syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10705236	chr19:57901745	ZNF548	0.42	6.78	0.3	3.64e-11	Gut microbiome composition (summer);
LGG	cis	rs6988985	0.703	rs4548164	chr8:143950501	G/A	cg10324643	chr8:143916377	GML	0.39	7.69	0.34	8.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg07701084	chr6:150067640	NUP43	0.61	11.32	0.47	2.17e-26	Lung cancer;
LGG	cis	rs6725041	0.819	rs10172672	chr2:213089291	C/A	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08882882	chr6:84937375	KIAA1009	0.5	8.18	0.36	2.75e-15	Gut microbiome composition (summer);
LGG	cis	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg24110177	chr3:50126178	RBM5	-0.52	-8.29	-0.36	1.21e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9788721	0.836	rs17405217	chr15:78731149	C/T	cg18825076	chr15:78729989	IREB2	-0.59	-9.41	-0.4	2.38e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg17202724	chr17:61916730	SMARCD2	0.49	10.82	0.45	1.74e-24	Prudent dietary pattern;
LGG	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.29	-0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7590720	1.000	rs4674048	chr2:216900023	G/A	cg12620499	chr2:216877984	MREG	0.76	14.1	0.55	8.3e-38	Alcohol dependence;
LGG	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg19812747	chr11:111475976	SIK2	0.45	9.33	0.4	4.28e-19	Primary sclerosing cholangitis;
LGG	cis	rs36051895	0.623	rs28872016	chr9:5253558	T/G	cg02405213	chr9:5042618	JAK2	-0.73	-12.25	-0.49	4.32e-30	Pediatric autoimmune diseases;
LGG	cis	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg06360820	chr2:242988706	NA	-0.84	-10.26	-0.43	2.1e-22	Obesity-related traits;
LGG	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg12458913	chr13:53173898	NA	0.81	18.16	0.64	4.95e-56	Lewy body disease;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-11.93	-0.48	8.74e-29	Prudent dietary pattern;
LGG	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.65	-0.37	8.27e-17	Alzheimer's disease (survival time);
LGG	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.38	-0.36	6.53e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg03476357	chr21:30257390	N6AMT1	-0.55	-8.2	-0.36	2.37e-15	Cognitive test performance;
LGG	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg08499158	chr17:42289980	UBTF	-0.39	-7.24	-0.32	1.88e-12	Total body bone mineral density;
LGG	cis	rs6831352	0.879	rs1984364	chr4:100070783	A/C	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg08302650	chr8:145750040	LRRC24;LRRC14	0.36	7.64	0.33	1.24e-13	Age at first birth;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04856096	chr8:68255097	ARFGEF1	0.37	6.81	0.3	3.04e-11	Obesity-related traits;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	8.19	0.36	2.64e-15	Obesity-related traits;
LGG	cis	rs9462027	0.628	rs9469889	chr6:34763900	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg22920501	chr2:26401640	FAM59B	0.46	9.48	0.4	1.38e-19	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg00405596	chr8:11794950	NA	0.42	6.69	0.3	6.33e-11	Neuroticism;
LGG	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg12395012	chr8:11607386	GATA4	0.39	6.91	0.31	1.61e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.59	-0.33	1.83e-13	Personality dimensions;
LGG	cis	rs981844	0.857	rs62325140	chr4:154714161	C/A	cg14289246	chr4:154710475	SFRP2	0.73	12.1	0.49	1.77e-29	Response to statins (LDL cholesterol change);
LGG	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.42e-16	Retinal vascular caliber;
LGG	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg22044901	chr15:68126292	NA	-0.4	-6.85	-0.3	2.32e-11	Restless legs syndrome;
LGG	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg10523679	chr1:76189770	ACADM	0.8	14.64	0.56	3.56e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2270450	0.650	rs9381478	chr6:46709021	C/T	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.67	-0.44	6.69e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg10523679	chr1:76189770	ACADM	0.66	11.76	0.48	3.93e-28	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg12310025	chr6:25882481	NA	-0.59	-11.64	-0.48	1.24e-27	Blood metabolite levels;
LGG	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs13421350	0.579	rs12613307	chr2:173325244	T/G	cg15021238	chr2:173305865	ITGA6	-0.8	-9.18	-0.39	1.42e-18	Diabetic kidney disease;
LGG	cis	rs72781680	1.000	rs6710426	chr2:24159288	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg23533926	chr12:111358616	MYL2	-0.44	-7.27	-0.32	1.56e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.43	0.4	2.06e-19	Bone mineral density;
LGG	trans	rs7246760	0.737	rs73501268	chr19:9803081	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.62	-0.44	9.76e-24	Pursuit maintenance gain;
LGG	cis	rs7408868	1.000	rs7247906	chr19:15271135	T/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.02	0.52	3.16e-33	Pulse pressure;
LGG	trans	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.96	0.45	5.36e-25	Ulcerative colitis;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg01988459	chr11:68622903	NA	-0.61	-12.37	-0.5	1.44e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	9.97	0.42	2.46e-21	Obesity-related traits;
LGG	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg13010199	chr12:38710504	ALG10B	0.77	16.35	0.6	9.35e-48	Heart rate;
LGG	cis	rs9875589	0.509	rs2731332	chr3:14110083	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.36	0.47	1.55e-26	Ovarian reserve;
LGG	cis	rs6912958	0.559	rs107689	chr6:88069333	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.05	0.52	2.21e-33	Monocyte percentage of white cells;
LGG	cis	rs7646881	0.812	rs74618709	chr3:158455281	G/C	cg19483011	chr3:158453295	NA	-0.57	-7.61	-0.33	1.5700000000000001e-13	Tetralogy of Fallot;
LGG	cis	rs58688157	0.705	rs12421646	chr11:578844	C/G	cg03576123	chr11:487126	PTDSS2	-0.49	-6.73	-0.3	4.91e-11	Systemic lupus erythematosus;
LGG	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.39	0.43	7.47e-23	Aortic root size;
LGG	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.33	0.4	4.38e-19	Diabetic retinopathy;
LGG	cis	rs73081554	0.611	rs4681851	chr3:58395891	C/G	cg24175188	chr3:58374923	PXK	0.56	7.52	0.33	2.81e-13	Rheumatoid arthritis;
LGG	cis	rs4716602	0.542	rs13224561	chr7:156161063	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.43	-0.4	1.92e-19	Anti-saccade response;
LGG	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15556689	chr8:8085844	FLJ10661	0.51	9.1	0.39	2.59e-18	Retinal vascular caliber;
LGG	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg08250081	chr4:10125330	NA	0.41	8.14	0.35	3.81e-15	Bone mineral density;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.42	7.12	0.31	4.19e-12	Longevity;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13173722	chr20:60553138	TAF4	0.4	6.84	0.3	2.58e-11	Menarche (age at onset);
LGG	cis	rs9457247	1.000	rs400063	chr6:167386592	C/T	cg07741184	chr6:167504864	NA	0.32	7.09	0.31	5.13e-12	Crohn's disease;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg13647721	chr17:30228624	UTP6	0.61	7.84	0.34	3.04e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg08499158	chr17:42289980	UBTF	-0.58	-10.49	-0.44	2.96e-23	Total body bone mineral density;
LGG	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg02462569	chr6:150064036	NUP43	-0.35	-7.5	-0.33	3.39e-13	Lung cancer;
LGG	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg26384229	chr12:38710491	ALG10B	0.95	20.94	0.7	5.52e-69	Morning vs. evening chronotype;
LGG	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg25418670	chr11:30344373	C11orf46	0.57	8.06	0.35	6.5e-15	Morning vs. evening chronotype;
LGG	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg11693508	chr17:37793320	STARD3	0.51	7.39	0.32	6.73e-13	Bipolar disorder;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25427524	chr10:38739819	LOC399744	0.72	15.21	0.58	1.13e-42	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.85	-0.34	3e-14	Total body bone mineral density;
LGG	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-19.16	-0.66	1.16e-60	Cognitive function;
LGG	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs9902453	0.765	rs2617883	chr17:28120488	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg12463550	chr7:65579703	CRCP	-0.73	-7.99	-0.35	1.11e-14	Diabetic kidney disease;
LGG	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg00789671	chr3:195488493	MUC4	-0.63	-8.9	-0.38	1.26e-17	Lung disease severity in cystic fibrosis;
LGG	trans	rs9393777	0.720	rs36022097	chr6:26995168	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.25	-0.39	8.61e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.560	rs4856701	chr3:161044106	G/T	cg03342759	chr3:160939853	NMD3	-0.59	-10.34	-0.43	1.09e-22	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg21775007	chr8:11205619	TDH	0.61	10.02	0.42	1.64e-21	Retinal vascular caliber;
LGG	cis	rs7191700	0.836	rs28502009	chr16:11426541	G/A	cg00044050	chr16:11439710	C16orf75	0.48	7.44	0.33	4.97e-13	Multiple sclerosis;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg05313129	chr8:58192883	C8orf71	-0.65	-9.31	-0.4	5.36e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg00012203	chr2:219082015	ARPC2	0.66	11.91	0.48	9.92e-29	Colorectal cancer;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.67	13.53	0.53	2.31e-35	Obesity-related traits;
LGG	trans	rs9929218	0.551	rs9888942	chr16:68727572	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	27.67	0.79	3.56e-100	Colorectal cancer;
LGG	cis	rs11676855	1.000	rs6710499	chr2:235898590	A/G	cg14917874	chr2:235941519	SH3BP4	0.52	9.23	0.39	1.01e-18	Dialysis-related mortality;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg01244601	chr4:120671846	NA	-0.35	-6.71	-0.3	5.67e-11	Corneal astigmatism;
LGG	cis	rs9914988	0.943	rs66588554	chr17:27141110	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs17767392	0.846	rs34281934	chr14:71979756	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.7	-0.37	6e-17	Mitral valve prolapse;
LGG	cis	rs9534288	0.797	rs2806922	chr13:46518059	A/G	cg15192986	chr13:46630673	CPB2	-0.57	-12.49	-0.5	4.69e-31	Blood protein levels;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.77	0.38	3.5e-17	Lung cancer;
LGG	cis	rs8017423	0.934	rs2401874	chr14:90682467	C/T	cg04374321	chr14:90722782	PSMC1	0.85	18.18	0.65	3.98e-56	Mortality in heart failure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08684830	chr9:80851119	CEP78	0.46	7.49	0.33	3.49e-13	Cognitive performance;
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg02772935	chr3:125709198	NA	-0.53	-6.78	-0.3	3.71e-11	Blood pressure (smoking interaction);
LGG	cis	rs11887277	0.902	rs12991828	chr2:27082559	C/T	cg12045002	chr2:27069975	DPYSL5	0.32	6.96	0.31	1.15e-11	Obesity-related traits;
LGG	trans	rs11875185	0.510	rs17693063	chr18:55649915	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-9.11	-0.39	2.4e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg00042356	chr1:8021962	PARK7	0.62	7.84	0.34	3.12e-14	Inflammatory bowel disease;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.22	0.49	5.91e-30	Prudent dietary pattern;
LGG	cis	rs6838801	0.892	rs28568554	chr4:77576016	T/G	cg17476223	chr4:77663285	SHROOM3	0.37	6.77	0.3	3.82e-11	Cleft lip with or without cleft palate;
LGG	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.96	-0.42	2.62e-21	Myopia (pathological);
LGG	cis	rs7572733	0.534	rs1983359	chr2:198805098	C/T	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs2708240	1.000	rs759178	chr7:147575112	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs975722	0.614	rs43033	chr7:117107707	C/A	cg10524701	chr7:117356490	CTTNBP2	0.45	9.94	0.42	3.15e-21	Coronary artery disease;
LGG	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-7.73	-0.34	6.72e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs9657904	0.826	rs7637327	chr3:105599169	A/G	cg14088669	chr1:158435396	OR10K1	0.43	7.99	0.35	1.1e-14	Multiple sclerosis;
LGG	cis	rs7084402	0.935	rs10763553	chr10:60274049	C/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.51	-0.63	4.55e-53	Refractive error;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg14926445	chr8:58193284	C8orf71	-0.72	-9.24	-0.39	8.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg12698349	chr2:225449008	CUL3	0.69	11.55	0.47	2.84e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs710865	1.000	rs710865	chr1:19568972	A/G	cg13387374	chr1:19411106	UBR4	0.45	8.72	0.38	5.04e-17	Brain structure;
LGG	cis	rs4363385	0.747	rs6671524	chr1:152974247	C/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.23	-0.39	9.52e-19	Inflammatory skin disease;
LGG	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg18698699	chr10:403730	DIP2C	-0.32	-7.05	-0.31	6.54e-12	Lung adenocarcinoma;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.44	7.98	0.35	1.12e-14	Schizophrenia;
LGG	cis	rs981844	0.890	rs55850399	chr4:154684906	C/T	cg14289246	chr4:154710475	SFRP2	0.74	12.13	0.49	1.31e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.52e-11	Dupuytren's disease;
LGG	cis	rs6800768	0.636	rs11928242	chr3:24092290	T/C	cg10674438	chr3:24145617	LOC152024	-0.32	-6.67	-0.3	7.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg23788917	chr6:8435910	SLC35B3	-0.53	-9.18	-0.39	1.4e-18	Motion sickness;
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.61	17.39	0.63	1.66e-52	Oropharynx cancer;
LGG	cis	rs989128	0.600	rs73338243	chr17:48631324	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	6.9	0.31	1.75e-11	Type 2 diabetes;
LGG	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg11941060	chr3:133502564	NA	-0.48	-8.17	-0.36	2.88e-15	Iron status biomarkers;
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg25660036	chr4:7070649	GRPEL1	-0.47	-7.07	-0.31	5.63e-12	Monocyte percentage of white cells;
LGG	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.76	0.54	2.3e-36	Bladder cancer;
LGG	cis	rs11792861	0.926	rs3750451	chr9:111822866	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.55	0.41	7.29e-20	Menarche (age at onset);
LGG	cis	rs11748327	1.000	rs11748327	chr5:4029789	C/T	cg01025095	chr5:4101132	NA	-0.55	-8.8	-0.38	2.67e-17	Myocardial infarction;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg03036210	chr16:89904091	SPIRE2	-0.58	-8.28	-0.36	1.32e-15	Skin colour saturation;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.07	-0.31	5.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg24812749	chr6:127587940	RNF146	0.89	13.9	0.54	5.66e-37	Breast cancer;
LGG	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg13009111	chr11:71350975	NA	-0.36	-7.87	-0.34	2.55e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.23	0.39	9.96e-19	Alzheimer's disease;
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg12458913	chr13:53173898	NA	0.51	8.67	0.37	7.08e-17	Lewy body disease;
LGG	cis	rs2797369	0.656	rs705612	chr6:101353230	G/C	cg27451362	chr6:101846650	GRIK2	0.77	10.7	0.45	5.05e-24	Renal function-related traits (eGRFcrea);
LGG	trans	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.47e-27	Corneal astigmatism;
LGG	cis	rs1620921	0.624	rs7381442	chr6:161276215	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.4	-6.95	-0.31	1.24e-11	Total body bone mineral density;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08525001	chr12:52417353	NA	-0.43	-6.81	-0.3	3.09e-11	Pancreatic cancer;
LGG	cis	rs1670533	0.929	rs6599280	chr4:1063818	A/G	cg27284194	chr4:1044797	NA	0.54	9.63	0.41	4.06e-20	Recombination rate (females);
LGG	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg11161011	chr14:65562177	MAX	-0.65	-12.52	-0.5	3.4e-31	Obesity-related traits;
LGG	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg08773314	chr2:239334832	ASB1	0.4	7.14	0.31	3.71e-12	Multiple system atrophy;
LGG	cis	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.87	-0.45	1.12e-24	Resting heart rate;
LGG	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg20336341	chr7:50628841	DDC	0.52	9.48	0.4	1.33e-19	Malaria;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg07562458	chr1:224622430	WDR26	0.39	6.94	0.31	1.31e-11	Corneal astigmatism;
LGG	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.23e-40	Retinal vascular caliber;
LGG	cis	rs6772849	0.796	rs9841521	chr3:128392274	A/G	cg08795948	chr3:128337044	NA	0.64	10.8	0.45	2.12e-24	Monocyte percentage of white cells;Monocyte count;
LGG	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.39	-0.47	1.16e-26	Height;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg13047869	chr3:10149882	C3orf24	0.52	8.83	0.38	2.13e-17	Alzheimer's disease;
LGG	trans	rs2161208	0.585	rs2974100	chr5:85336640	C/T	cg01787110	chr1:109008453	NBPF6	0.45	6.68	0.3	6.68e-11	Daytime sleep phenotypes;
LGG	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg26116260	chr4:7069785	GRPEL1	1.15	22.38	0.72	9.51e-76	Monocyte percentage of white cells;
LGG	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg10057126	chr4:77819792	ANKRD56	0.36	6.95	0.31	1.26e-11	Emphysema distribution in smoking;
LGG	cis	rs9425766	0.546	rs6691001	chr1:173819076	T/G	cg06124660	chr1:173389066	NA	-0.4	-7.13	-0.31	3.96e-12	Life satisfaction;
LGG	cis	rs7766641	1	rs7766641	chr6:26184102	G/A	cg13736514	chr6:26305472	NA	-0.4	-7.46	-0.33	4.17e-13	Height;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.03	-0.49	3.38e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs882300	0.900	rs12691875	chr2:136915698	C/A	cg07169764	chr2:136633963	MCM6	-0.49	-7.76	-0.34	5.37e-14	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs7647973	0.588	rs9883000	chr3:49667691	A/G	cg03060546	chr3:49711283	APEH	0.58	8.01	0.35	9.43e-15	Menarche (age at onset);
LGG	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.55	-0.37	1.75e-16	Aortic root size;
LGG	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.49	-0.37	2.92e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7100689	0.646	rs1340382	chr10:82096997	G/C	cg01528321	chr10:82214614	TSPAN14	0.82	14.71	0.56	1.89e-40	Post bronchodilator FEV1;
LGG	cis	rs2011503	1.000	rs2965201	chr19:19478051	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.65	-0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs11239187	0.606	rs899890	chr10:45073176	G/A	cg03916630	chr10:45065415	NA	0.35	8.63	0.37	1e-16	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22512377	chr22:42475683	C22orf32	0.44	7.36	0.32	8.4e-13	Cognitive performance;
LGG	trans	rs11039798	0.764	rs76882342	chr11:48939091	A/T	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.41e-18	Lung cancer;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs11168187	0.843	rs6580636	chr12:48116633	G/C	cg12761788	chr12:48120090	P11	0.5	8.72	0.38	4.91e-17	Vertical cup-disc ratio;
LGG	cis	rs3736594	0.918	rs9677663	chr2:27972445	G/A	cg27432699	chr2:27873401	GPN1	-0.57	-9.28	-0.4	6.75e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.48	-0.44	3.36e-23	Chronic sinus infection;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg21862992	chr11:68658383	NA	0.51	8.67	0.37	7.34e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27286337	chr10:134555280	INPP5A	0.88	14.05	0.55	1.28e-37	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg12045294	chr17:78518616	RPTOR	-0.47	-7.0	-0.31	8.89e-12	Glycated hemoglobin levels;
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg13397359	chr6:42928475	GNMT	0.5	12.82	0.51	2.02e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9948	0.786	rs56797569	chr2:97413555	G/T	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	5.09e-12	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-9.13	-0.39	2.17e-18	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15392845	chr14:73360933	DPF3	0.48	7.56	0.33	2.24e-13	Gut microbiome composition (summer);
LGG	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg19554555	chr3:13937349	NA	0.69	13.16	0.52	8.29e-34	Ovarian reserve;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg21605333	chr4:119757512	SEC24D	1.49	14.88	0.57	3.23e-41	Cannabis dependence symptom count;
LGG	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg19338460	chr6:170058176	WDR27	-0.59	-8.09	-0.35	5.43e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4538187	0.712	rs11684093	chr2:63901261	T/C	cg02541582	chr2:64069798	UGP2	-0.46	-8.81	-0.38	2.62e-17	Systolic blood pressure;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.31	0.36	1.04e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9944715	0.911	rs12969147	chr18:43806524	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.36	-6.65	-0.3	8.16e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs4973397	0.686	rs10933370	chr2:232289960	C/A	cg13347044	chr2:232276743	NA	0.35	6.72	0.3	5.4e-11	Anti-saccade response;
LGG	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs340849	0.703	rs1367951	chr1:214125513	C/T	cg05052969	chr1:214156842	NA	-0.38	-6.98	-0.31	1.04e-11	Alzheimer's disease;
LGG	cis	rs17001868	0.568	rs74424549	chr22:40736938	A/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.42e-13	Life satisfaction;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.3	-0.5	2.78e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24308560	chr3:49941425	MST1R	-0.22	-6.87	-0.3	2.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	2.02e-13	Colorectal cancer;
LGG	cis	rs12540874	0.529	rs732215	chr7:50544063	A/C	cg00647317	chr7:50633725	DDC	0.37	8.85	0.38	1.87e-17	Systemic sclerosis;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg08645402	chr16:4508243	NA	0.46	7.87	0.34	2.59e-14	Schizophrenia;
LGG	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.99	-0.42	2.07e-21	Rheumatoid arthritis;
LGG	cis	rs939658	0.728	rs11637459	chr15:79413554	A/G	cg17916960	chr15:79447300	NA	-0.63	-11.91	-0.48	1.05e-28	Refractive error;
LGG	cis	rs4472734	0.646	rs6667098	chr1:214629640	T/C	cg00063699	chr1:214624242	PTPN14	-0.41	-8.81	-0.38	2.6e-17	Height;
LGG	trans	rs629535	0.748	rs58675625	chr8:70034924	T/C	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs977987	0.966	rs6564261	chr16:75492242	C/T	cg03315344	chr16:75512273	CHST6	0.6	11.95	0.49	6.93e-29	Dupuytren's disease;
LGG	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs4704187	0.687	rs4361493	chr5:74405097	A/G	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg15557168	chr22:42548783	NA	-0.4	-8.51	-0.37	2.36e-16	Schizophrenia;
LGG	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg03511173	chr18:77590860	NA	0.62	7.82	0.34	3.58e-14	Opioid sensitivity;
LGG	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.71	-0.34	7.5e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg16506815	chr2:162101123	NA	0.26	6.71	0.3	5.88e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.95	-0.35	1.45e-14	Myopia (pathological);
LGG	cis	rs9463078	0.656	rs227843	chr6:44691703	A/G	cg25276700	chr6:44698697	NA	0.43	8.93	0.38	9.74e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs950027	0.620	rs2453533	chr15:45641225	C/A	cg26924012	chr15:45694286	SPATA5L1	0.68	12.39	0.5	1.25e-30	Response to fenofibrate (adiponectin levels);
LGG	trans	rs1962073	0.528	rs4582610	chr8:10318343	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.39	-0.36	6.04e-16	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs6546537	0.824	rs13011186	chr2:69778558	C/T	cg10773587	chr2:69614142	GFPT1	-0.55	-9.22	-0.39	1.01e-18	Serum thyroid-stimulating hormone levels;
LGG	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg03606772	chr1:152487856	CRCT1	0.3	7.27	0.32	1.59e-12	Hair morphology;
LGG	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.47	6.93	0.31	1.41e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs9393777	0.513	rs13210025	chr6:26654817	A/C	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	trans	rs11165623	0.715	rs1980769	chr1:96888201	A/T	cg10631902	chr5:14652156	NA	-0.59	-13.61	-0.53	1.06e-35	Hip circumference;Waist circumference;
LGG	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg00083206	chr6:110721305	DDO	-0.25	-6.64	-0.3	8.59e-11	Platelet distribution width;
LGG	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg11764359	chr7:65958608	NA	-0.73	-12.2	-0.49	7.11e-30	Aortic root size;
LGG	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg26384229	chr12:38710491	ALG10B	0.6	11.01	0.46	3.5e-25	Morning vs. evening chronotype;
LGG	trans	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg01620082	chr3:125678407	NA	-0.6	-6.88	-0.3	1.89e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.0	0.35	1.03e-14	Neuroticism;
LGG	cis	rs2991971	0.967	rs12743512	chr1:45954033	A/G	cg24296786	chr1:45957014	TESK2	-0.41	-7.41	-0.33	5.94e-13	High light scatter reticulocyte count;
LGG	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg04025307	chr7:1156635	C7orf50	0.66	8.49	0.37	2.85e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12210905	1.000	rs12209456	chr6:27085225	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.24	-0.36	1.78e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg25427524	chr10:38739819	LOC399744	-0.51	-7.43	-0.33	5.4e-13	Obesity (extreme);
LGG	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg03101763	chr11:65319844	LTBP3	-0.66	-6.77	-0.3	3.86e-11	Height;
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg03847636	chr4:7070632	GRPEL1	-0.49	-6.93	-0.31	1.39e-11	Monocyte percentage of white cells;
LGG	cis	rs4319547	0.637	rs61244464	chr12:123090565	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.43	-6.75	-0.3	4.51e-11	Body mass index;
LGG	cis	rs3806843	0.576	rs246049	chr5:140327590	T/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg16230307	chr14:35515116	FAM177A1	0.93	13.51	0.53	2.62e-35	Psoriasis;
LGG	cis	rs259282	0.652	rs2161458	chr19:33129038	C/T	cg02997394	chr19:33096574	ANKRD27	-0.37	-7.14	-0.32	3.56e-12	Schizophrenia;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg05335186	chr13:53173507	NA	0.41	7.42	0.33	5.61e-13	Lewy body disease;
LGG	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg00531865	chr16:30841666	NA	-0.53	-10.31	-0.43	1.41e-22	Dementia with Lewy bodies;
LGG	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg08297393	chr2:100937505	LONRF2	-0.52	-9.54	-0.41	8.13e-20	Intelligence (multi-trait analysis);
LGG	cis	rs67366981	1.000	rs2287379	chr14:77705411	A/C	cg22824376	chr14:77648248	TMEM63C	0.7	7.43	0.33	5.44e-13	Obsessive-compulsive symptoms;
LGG	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg00850481	chr1:228891306	NA	-0.63	-14.37	-0.56	5.4e-39	Chronic lymphocytic leukemia;
LGG	cis	rs4253772	0.515	rs74766656	chr22:46662497	A/G	cg00784671	chr22:46762841	CELSR1	-0.56	-6.77	-0.3	3.93e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.51	0.33	3.17e-13	Neuroticism;
LGG	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg10847948	chr11:71163743	NADSYN1	0.58	8.68	0.37	6.84e-17	Vitamin D levels;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg05335186	chr13:53173507	NA	0.48	10.03	0.42	1.46e-21	Lewy body disease;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01516881	chr6:292596	DUSP22	0.69	11.78	0.48	3.26e-28	Menopause (age at onset);
LGG	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08109568	chr15:31115862	NA	-0.53	-9.47	-0.4	1.46e-19	Huntington's disease progression;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg05313129	chr8:58192883	C8orf71	-0.6	-8.45	-0.37	3.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6547631	0.622	rs4240202	chr2:85925680	T/G	cg19805943	chr2:85933069	NA	0.32	6.8	0.3	3.3e-11	Blood protein levels;
LGG	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg22431228	chr1:16359049	CLCNKA	-0.39	-7.21	-0.32	2.24e-12	Systolic blood pressure;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg13129662	chr17:48227708	PPP1R9B	0.42	6.84	0.3	2.45e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg26384229	chr12:38710491	ALG10B	0.64	12.64	0.51	1.15e-31	Morning vs. evening chronotype;
LGG	cis	rs1018836	0.545	rs7840203	chr8:91701223	A/G	cg16814680	chr8:91681699	NA	-1.12	-28.54	-0.8	4.03e-104	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs79057730	0.528	rs4719313	chr7:822501	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.54	0.33	2.46e-13	Initial pursuit acceleration;
LGG	cis	rs16866061	1.000	rs72974219	chr2:225423784	G/C	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.48	-0.37	2.94e-16	Diabetic kidney disease;
LGG	cis	rs988958	0.567	rs7594766	chr2:42228804	C/T	cg27428208	chr2:42229179	NA	0.53	9.16	0.39	1.67e-18	Hypospadias;
LGG	cis	rs13082711	0.911	rs3816881	chr3:27432888	T/C	cg02860705	chr3:27208620	NA	0.72	13.38	0.53	9.7e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2070488	0.775	rs4371464	chr3:38548021	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.27	-0.55	1.57e-38	Electrocardiographic conduction measures;
LGG	cis	rs4330281	0.647	rs9857910	chr3:17697786	A/T	cg20981856	chr3:17787350	NA	-0.4	-7.56	-0.33	2.2e-13	Schizophrenia;
LGG	cis	rs796364	0.589	rs55700082	chr2:201135669	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-7.86	-0.34	2.81e-14	Schizophrenia;
LGG	trans	rs3960554	1.000	rs2097947	chr7:75836382	A/T	cg19862616	chr7:65841803	NCRNA00174	0.82	12.14	0.49	1.2e-29	Eotaxin levels;
LGG	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg04672837	chr16:48644449	N4BP1	0.55	9.07	0.39	3.5e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs643506	0.874	rs4936786	chr11:111727227	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.88	0.3	1.93e-11	Breast cancer;
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-11.91	-0.48	1.03e-28	Personality dimensions;
LGG	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg25986240	chr4:9926439	SLC2A9	0.46	9.76	0.41	1.36e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3735485	0.698	rs10248390	chr7:45110951	C/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.53	-0.41	8.77e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg24846343	chr22:24311635	DDTL	0.6	11.99	0.49	5.07e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg11247378	chr22:39784982	NA	-0.31	-8.64	-0.37	8.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4906332	1.000	rs3783400	chr14:103967045	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-7.75	-0.34	5.96e-14	Coronary artery disease;
LGG	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg19980929	chr12:42632907	YAF2	0.38	8.51	0.37	2.45e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg05182265	chr7:156933206	UBE3C	-0.37	-7.49	-0.33	3.41e-13	Body mass index;
LGG	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs9472414	0.510	rs227853	chr6:44699746	T/C	cg20913747	chr6:44695427	NA	0.47	7.88	0.34	2.31e-14	Height;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00424166	chr6:150045504	NUP43	0.34	7.03	0.31	7.44e-12	Lung cancer;
LGG	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg21153622	chr11:89784906	NA	-0.7	-9.15	-0.39	1.88e-18	White blood cell types;
LGG	cis	rs12681366	0.708	rs12680029	chr8:95404646	T/C	cg13257157	chr8:95487014	RAD54B	0.38	6.77	0.3	3.82e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs28588043	0.877	rs72710575	chr1:170988418	G/A	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00689492	chr4:1303491	MAEA	0.46	7.88	0.34	2.37e-14	Obesity-related traits;
LGG	cis	rs2072732	0.861	rs16823392	chr1:2953833	C/G	cg08733933	chr1:2954429	NA	-0.4	-8.54	-0.37	1.88e-16	Plateletcrit;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.52	9.63	0.41	3.88e-20	Obesity-related traits;
LGG	cis	rs9916302	0.904	rs3744348	chr17:37417575	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.99	-0.6	3.93e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg15268244	chr15:77196840	NA	-0.41	-8.25	-0.36	1.66e-15	Blood metabolite levels;
LGG	cis	rs7635838	0.653	rs2606749	chr3:11373635	A/G	cg00170343	chr3:11313890	ATG7	0.49	8.48	0.37	2.97e-16	HDL cholesterol;
LGG	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs2204008	0.744	rs11168870	chr12:37973333	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.11	0.72	1.75e-74	Bladder cancer;
LGG	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.65	0.33	1.18e-13	Neuroticism;
LGG	cis	rs13064447	0.817	rs11128611	chr3:12772365	C/G	cg23032965	chr3:12705835	RAF1	-0.44	-6.82	-0.3	2.93e-11	Major depression and alcohol dependence;
LGG	cis	rs2963155	0.518	rs853177	chr5:142635460	A/G	cg17617527	chr5:142782415	NR3C1	0.94	12.84	0.51	1.75e-32	Breast cancer;
LGG	cis	rs4748857	0.891	rs4747458	chr10:23586914	T/G	cg18853376	chr10:23633759	C10orf67	0.37	6.96	0.31	1.16e-11	Systemic lupus erythematosus;
LGG	cis	rs35771425	0.711	rs3738200	chr1:211548387	T/G	cg10512769	chr1:211675356	NA	-0.67	-9.3	-0.4	5.45e-19	Educational attainment (years of education);
LGG	cis	rs12519773	0.526	rs4285204	chr5:92528272	C/T	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	cis	rs834603	0.547	rs834598	chr7:47463937	C/T	cg23694490	chr7:47445681	TNS3	-0.43	-12.28	-0.5	3.35e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.0	-0.42	1.87e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs250677	1.000	rs36080	chr5:148430451	A/G	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.74	-0.34	6.32e-14	Breast cancer;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg02725872	chr8:58115012	NA	-1.03	-15.21	-0.58	1.11e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs2033908	0.620	rs7113256	chr11:12845849	T/C	cg25843174	chr11:12811716	TEAD1	-0.36	-7.46	-0.33	4.37e-13	Sitting height ratio;
LGG	cis	rs1793639	0.630	rs7941631	chr11:131930432	G/C	cg13908476	chr11:131942942	NTM	0.69	13.84	0.54	1.08e-36	Myopia;
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg08499158	chr17:42289980	UBTF	-0.59	-11.16	-0.46	8.69e-26	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg16507663	chr6:150244633	RAET1G	0.41	7.69	0.34	9.1e-14	Lung cancer;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg05973401	chr12:123451056	ABCB9	-0.5	-7.29	-0.32	1.34e-12	Neutrophil percentage of white cells;
LGG	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg15268244	chr15:77196840	NA	0.48	10.3	0.43	1.53e-22	Blood metabolite levels;
LGG	cis	rs963731	0.649	rs212322	chr2:39305928	C/T	cg04010122	chr2:39346883	SOS1	-0.74	-7.39	-0.32	6.96e-13	Corticobasal degeneration;
LGG	cis	rs2247341	1.000	rs2247341	chr4:1701317	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.87	-0.45	1.13e-24	Hip circumference adjusted for BMI;Height;
LGG	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.59	-0.41	5.65e-20	Retinal vascular caliber;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg04863758	chr4:1303710	MAEA	0.46	7.7	0.34	8.51e-14	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg13263323	chr15:86062960	AKAP13	-0.36	-7.34	-0.32	9.74e-13	Coronary artery disease;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg11814155	chr7:99998594	ZCWPW1	0.57	8.61	0.37	1.13e-16	Platelet count;
LGG	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.06	-0.42	1.15e-21	Retinal vascular caliber;
LGG	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-6.78	-0.3	3.71e-11	IgG glycosylation;
LGG	cis	rs10499694	0.933	rs11575356	chr7:50594821	T/C	cg04490037	chr7:50633773	DDC	0.32	6.96	0.31	1.18e-11	Body mass index;
LGG	cis	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg09307838	chr4:120376055	NA	0.81	13.47	0.53	3.79e-35	Corneal astigmatism;
LGG	cis	rs9815354	0.670	rs73073238	chr3:42014325	G/C	cg03022575	chr3:42003672	ULK4	0.8	9.2	0.39	1.18e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs963731	0.649	rs79361942	chr2:39336315	G/A	cg04010122	chr2:39346883	SOS1	0.93	8.24	0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg12623918	chr2:306882	NA	0.38	7.1	0.31	4.67e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs490234	0.756	rs1398142	chr9:128226712	C/A	cg14078157	chr9:128172775	NA	-0.46	-8.6	-0.37	1.25e-16	Mean arterial pressure;
LGG	trans	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.55	-0.37	1.83e-16	Heart rate;
LGG	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg00405596	chr8:11794950	NA	-0.43	-6.82	-0.3	2.88e-11	Systolic blood pressure;
LGG	cis	rs1355223	0.902	rs7129089	chr11:34699699	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.32	-0.32	1.11e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs17453880	0.929	rs4958572	chr5:152031109	C/T	cg10931792	chr5:152022470	NA	0.41	8.95	0.38	8.35e-18	Subjective well-being;
LGG	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg13385521	chr17:29058706	SUZ12P	-0.79	-9.4	-0.4	2.6e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2282802	0.685	rs13359519	chr5:139654664	G/A	cg26211634	chr5:139558579	C5orf32	0.35	7.67	0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg18252515	chr7:66147081	NA	-0.44	-7.48	-0.33	3.69e-13	Aortic root size;
LGG	cis	rs17221829	0.699	rs78403327	chr11:89384225	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	1.9e-18	Anxiety in major depressive disorder;
LGG	cis	rs6578185	0.684	rs9987318	chr8:142437352	A/G	cg07762003	chr8:142452454	FLJ43860	0.56	11.2	0.46	6.4e-26	Endometriosis;
LGG	cis	rs11630290	0.702	rs73444597	chr15:64126503	C/T	cg12036633	chr15:63758958	NA	-0.56	-7.68	-0.34	9.53e-14	Iris characteristics;
LGG	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07308232	chr7:1071921	C7orf50	-0.57	-10.51	-0.44	2.54e-23	Longevity;Endometriosis;
LGG	cis	rs3768617	0.782	rs10752893	chr1:183046261	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.83	0.3	2.76e-11	Fuchs's corneal dystrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08098457	chr2:63815963	MDH1;C2orf86	0.47	7.62	0.33	1.48e-13	Cognitive performance;
LGG	cis	rs11096990	0.892	rs3733288	chr4:39218569	G/T	cg24403649	chr4:39172243	NA	-0.46	-7.59	-0.33	1.75e-13	Cognitive function;
LGG	cis	rs2587949	0.593	rs2675207	chr3:4180254	C/G	cg16519197	chr3:4211558	NA	-0.36	-7.22	-0.32	2.18e-12	Periodontitis (DPAL);
LGG	trans	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.37e-14	Blood trace element (Cu levels);
LGG	trans	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg18252515	chr7:66147081	NA	1.43	20.57	0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs9303401	0.646	rs9303403	chr17:57219300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.48	-7.99	-0.35	1.09e-14	Cognitive test performance;
LGG	cis	rs77741769	0.571	rs1542859	chr12:121336766	A/G	cg02419362	chr12:121203948	SPPL3	0.54	9.41	0.4	2.34e-19	Mean corpuscular volume;
LGG	cis	rs10979	0.631	rs12530338	chr6:143872563	C/T	cg25407410	chr6:143891975	LOC285740	-0.5	-8.18	-0.36	2.84e-15	Hypospadias;
LGG	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg24253500	chr15:84953950	NA	0.58	10.46	0.44	4.08e-23	Schizophrenia;
LGG	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg05082376	chr22:42548792	NA	-0.35	-7.11	-0.31	4.47e-12	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09507928	chr5:140027484	IK;NDUFA2	0.51	8.41	0.36	5.17e-16	Cognitive performance;
LGG	cis	rs2000999	0.514	rs35930480	chr16:72217681	G/A	cg04254540	chr16:71951199	KIAA0174	-0.57	-6.8	-0.3	3.21e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg20003494	chr4:90757398	SNCA	-0.41	-8.04	-0.35	7.7e-15	Dementia with Lewy bodies;
LGG	cis	rs9487094	0.813	rs61233650	chr6:109686612	C/T	cg01125227	chr6:109776195	MICAL1	0.49	8.22	0.36	2.05e-15	Height;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.81e-18	Skin colour saturation;
LGG	cis	rs3008870	1.000	rs2755246	chr1:67488984	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.94	21.0	0.7	2.72e-69	Lymphocyte percentage of white cells;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg04234412	chr22:24373322	LOC391322	-0.8	-16.7	-0.61	2.38e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg18335740	chr13:41363409	SLC25A15	-0.59	-11.35	-0.47	1.7e-26	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13193676	chr8:80942319	MRPS28	0.45	7.35	0.32	8.81e-13	Cognitive performance;
LGG	trans	rs6825911	0.556	rs2017302	chr4:111364318	T/C	cg10580549	chr19:53101634	ZNF137	0.55	6.97	0.31	1.1e-11	Blood pressure;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.59	0.33	1.74e-13	Colorectal cancer;
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg24690094	chr11:67383802	NA	0.56	9.65	0.41	3.49e-20	Mean corpuscular volume;
LGG	cis	rs3764563	1.000	rs11673070	chr19:15746095	A/G	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.31	-0.36	1.04e-15	Inflammatory biomarkers;
LGG	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg10840412	chr1:235813424	GNG4	0.52	7.03	0.31	7.26e-12	Bipolar disorder;
LGG	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg10911889	chr6:126070802	HEY2	-0.45	-7.78	-0.34	4.61e-14	Brugada syndrome;
LGG	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06634786	chr22:41940651	POLR3H	-0.72	-11.54	-0.47	2.88e-27	Vitiligo;
LGG	cis	rs921968	0.643	rs2303561	chr2:219527005	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.14	0.31	3.68e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7666738	0.830	rs6532723	chr4:99052147	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs847649	0.692	rs6969054	chr7:102446569	T/C	cg18108683	chr7:102477205	FBXL13	-0.7	-15.64	-0.59	1.4e-44	Morning vs. evening chronotype;
LGG	cis	rs8067545	0.553	rs4577147	chr17:19944023	T/C	cg13482628	chr17:19912719	NA	0.5	8.17	0.36	2.91e-15	Schizophrenia;
LGG	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.8	9.51	0.4	1.07e-19	Schizophrenia;
LGG	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg06618935	chr21:46677482	NA	-0.52	-9.36	-0.4	3.58e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg15921436	chr17:44337874	NA	0.58	12.29	0.5	3.08e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg24397884	chr7:158709396	WDR60	1.11	16.67	0.61	3.31e-49	Height;
LGG	cis	rs597583	0.806	rs685425	chr11:117429728	C/T	cg27161313	chr11:117392002	DSCAML1	-0.52	-8.37	-0.36	6.94e-16	Putamen volume;
LGG	cis	rs193541	0.632	rs62377425	chr5:122332625	C/G	cg19412675	chr5:122181750	SNX24	-0.52	-8.36	-0.36	7.61e-16	Glucose homeostasis traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05639842	chr21:43639440	ABCG1	0.44	7.17	0.32	3.06e-12	Cognitive performance;
LGG	cis	rs7267979	1.000	rs6115140	chr20:25285507	C/A	cg06421707	chr20:25228305	PYGB	0.47	10.17	0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9916302	0.706	rs2879259	chr17:37410892	C/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.31	-0.58	4.15e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg04691961	chr3:161091175	C3orf57	0.42	8.8	0.38	2.77e-17	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.6	0.44	1.22e-23	Prudent dietary pattern;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.95	-0.38	8.49e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	0.780	rs2500413	chr20:25241155	T/C	cg06421707	chr20:25228305	PYGB	0.5	10.72	0.45	4.12e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11203032	0.706	rs1977501	chr10:90918714	G/T	cg16672925	chr10:90967113	CH25H	0.74	10.44	0.44	4.53e-23	Heart failure;
LGG	trans	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg16141378	chr3:129829833	LOC729375	0.44	10.54	0.44	2.01e-23	Mood instability;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg26752003	chr8:145688521	CYHR1	0.57	12.27	0.5	3.84e-30	Age at first birth;
LGG	cis	rs1620921	0.505	rs13216458	chr6:161204262	T/C	cg01280913	chr6:161186852	NA	-0.5	-10.37	-0.43	8.2000000000000006e-23	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg20587970	chr11:113659929	NA	-1.34	-23.13	-0.73	3.14e-79	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.958	rs11689550	chr2:178456298	A/G	cg22681709	chr2:178499509	PDE11A	-0.41	-7.31	-0.32	1.15e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg02153584	chr22:29168773	CCDC117	0.62	10.08	0.42	9.78e-22	Lymphocyte counts;
LGG	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15541040	chr2:3486749	NA	-0.44	-7.98	-0.35	1.13e-14	Neurofibrillary tangles;
LGG	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01341218	chr17:43662625	NA	0.95	16.47	0.61	2.61e-48	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.44	-0.56	2.66e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg17842157	chr17:42200988	HDAC5	-0.36	-6.84	-0.3	2.54e-11	Iris color (L* coordinate);
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs11971779	0.715	rs11772771	chr7:139058803	T/C	cg07862535	chr7:139043722	LUC7L2	0.48	7.87	0.34	2.51e-14	Diisocyanate-induced asthma;
LGG	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg26384229	chr12:38710491	ALG10B	0.74	14.61	0.56	5.14e-40	Morning vs. evening chronotype;
LGG	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg21385522	chr1:16154831	NA	0.54	9.7	0.41	2.18e-20	Systolic blood pressure;
LGG	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg18252515	chr7:66147081	NA	-1.34	-19.08	-0.66	2.52e-60	Diabetic kidney disease;
LGG	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg07245641	chr1:182991651	LAMC1	0.41	9.52	0.4	9.7e-20	Hypertriglyceridemia;
LGG	cis	rs2016266	0.784	rs6421176	chr12:53654052	A/G	cg04065151	chr12:53682969	ESPL1	-0.6	-9.93	-0.42	3.28e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg04861929	chr11:109293070	C11orf87	0.52	9.73	0.41	1.74e-20	Schizophrenia;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.08	0.31	5.3e-12	Schizophrenia;
LGG	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg15128208	chr22:42549153	NA	0.76	11.43	0.47	8.23e-27	Birth weight;
LGG	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg01472538	chr16:58549086	SETD6	0.98	8.78	0.38	3.23e-17	Schizophrenia;
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg05335186	chr13:53173507	NA	0.8	20.55	0.69	3.75e-67	Lewy body disease;
LGG	trans	rs6825911	0.537	rs939214	chr4:111371101	G/T	cg10580549	chr19:53101634	ZNF137	0.55	6.99	0.31	9.67e-12	Blood pressure;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg19147804	chr7:1989927	MAD1L1	-0.6	-12.07	-0.49	2.25e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg03175030	chr11:2018143	H19;MIR675	-0.6	-11.48	-0.47	5.31e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-13.16	-0.52	8.15e-34	Total body bone mineral density;
LGG	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.47e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2013441	0.965	rs6587063	chr17:20193940	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6e-11	Obesity-related traits;
LGG	cis	rs7222240	1.000	rs4280297	chr17:43140600	C/G	cg24806326	chr17:43207588	PLCD3	0.45	7.65	0.33	1.21e-13	Craniofacial microsomia;
LGG	cis	rs2742417	0.935	rs2248991	chr3:45754749	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7662987	0.517	rs2851268	chr4:100027878	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.81	0.34	3.74e-14	Smoking initiation;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg16301924	chr13:53314226	LECT1	-0.46	-9.0	-0.39	5.67e-18	Lewy body disease;
LGG	cis	rs2304069	0.954	rs2340462	chr5:149415219	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.53	7.19	0.32	2.55e-12	HIV-1 control;
LGG	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg12501888	chr15:85177176	SCAND2	-0.56	-9.26	-0.4	7.66e-19	P wave terminal force;
LGG	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg23306229	chr2:178417860	TTC30B	0.53	6.85	0.3	2.3e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg27400746	chr16:89904261	SPIRE2	-0.92	-14.6	-0.56	5.27e-40	Skin colour saturation;
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg21972741	chr5:435613	AHRR	0.49	8.4	0.36	5.36e-16	Cystic fibrosis severity;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg17178900	chr1:205818956	PM20D1	0.36	7.25	0.32	1.73e-12	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23639257	chr17:73663270	RECQL5;SAP30BP	0.43	6.86	0.3	2.22e-11	Cognitive performance;
LGG	cis	rs4330281	0.647	rs13093375	chr3:17435598	A/G	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.5e-11	Schizophrenia;
LGG	cis	rs3781663	0.500	rs10160730	chr11:70021687	T/C	cg06393558	chr11:69982916	ANO1	-0.39	-7.67	-0.34	1e-13	Survival in rectal cancer;
LGG	cis	rs2860975	0.620	rs6583968	chr10:96816357	A/T	cg09036531	chr10:96991505	NA	0.45	7.94	0.35	1.54e-14	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17158059	chr2:55746762	CCDC104	0.39	6.77	0.3	3.79e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg01448562	chr3:133502909	NA	-0.74	-13.76	-0.54	2.44e-36	Iron status biomarkers;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07677032	chr17:61819896	STRADA	-0.63	-11.34	-0.47	1.77e-26	Prudent dietary pattern;
LGG	cis	rs2439831	1.000	rs2467743	chr15:43750346	T/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.48	0.44	3.37e-23	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.01	-0.6	2.98e-46	Height;
LGG	cis	rs68170813	0.559	rs78079372	chr7:106934548	T/G	cg02696742	chr7:106810147	HBP1	-0.72	-10.36	-0.43	9.36e-23	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg15017067	chr4:17643749	FAM184B	-0.31	-7.17	-0.32	2.9e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg25237894	chr2:233734115	C2orf82	0.65	12.23	0.49	5.48e-30	Coronary artery disease;
LGG	cis	rs74781061	0.929	rs8043082	chr15:74857237	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.53e-12	Endometriosis;
LGG	cis	rs11514810	1.000	rs57444112	chr7:1430892	T/C	cg22426938	chr7:1423890	NA	-0.61	-7.78	-0.34	4.64e-14	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs1941023	0.584	rs2233252	chr11:60157107	T/G	cg08716584	chr11:60157161	MS4A7	-0.44	-8.94	-0.38	9.33e-18	Congenital heart disease (maternal effect);
LGG	cis	rs4959677	0.725	rs1680831	chr6:2503945	C/G	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.6e-15	Orthostatic hypotension;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg22535103	chr8:58192502	C8orf71	-0.89	-12.4	-0.5	1.09e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg13147721	chr7:65941812	NA	0.85	10.4	0.44	6.35e-23	Diabetic kidney disease;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-8.39	-0.36	5.96e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11209002	0.956	rs10749772	chr1:67586231	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	6.7	0.3	5.92e-11	Crohn's disease;
LGG	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.57	0.53	1.47e-35	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.43	-0.47	8e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg16339924	chr4:17578868	LAP3	0.6	10.41	0.44	6.3e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg03929089	chr4:120376271	NA	0.43	7.0	0.31	8.78e-12	HDL cholesterol;
LGG	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	7.67	0.34	1e-13	Acne (severe);
LGG	cis	rs889312	0.500	rs832566	chr5:56151744	C/T	cg14703610	chr5:56206110	C5orf35	0.42	7.34	0.32	9.49e-13	Breast cancer;Breast cancer (early onset);
LGG	cis	rs4740619	0.967	rs7854714	chr9:15688401	A/T	cg14451791	chr9:16040625	NA	-0.39	-10.09	-0.42	9.09e-22	Body mass index;
LGG	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg03929089	chr4:120376271	NA	-0.7	-9.45	-0.4	1.75e-19	Axial length;
LGG	cis	rs9992101	0.612	rs56049812	chr4:77227676	A/C	cg17010112	chr4:77227123	STBD1	-0.48	-9.9	-0.42	4.23e-21	Creatinine levels;
LGG	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg04607235	chr12:12878440	APOLD1	-0.98	-20.11	-0.68	4.15e-65	Lymphocyte counts;
LGG	cis	rs17767392	0.918	rs8007068	chr14:71770710	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	trans	rs7395662	0.929	rs10838959	chr11:48584732	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg11494091	chr17:61959527	GH2	0.56	9.16	0.39	1.68e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.66e-13	Refractive error;
LGG	trans	rs11088226	0.681	rs2833926	chr21:33975279	A/G	cg09050820	chr6:167586206	TCP10L2	0.86	12.53	0.5	3.16e-31	Gastritis;
LGG	cis	rs3796352	1.000	rs60942590	chr3:53016421	G/A	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2066819	0.892	rs75274818	chr12:56627619	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.42	-0.61	4.38e-48	Psoriasis vulgaris;
LGG	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg08305652	chr11:111469057	NA	-0.43	-8.13	-0.35	3.88e-15	Primary sclerosing cholangitis;
LGG	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	cg07928641	chr1:182991847	LAMC1	0.44	8.79	0.38	2.95e-17	Fuchs's corneal dystrophy;
LGG	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.23e-21	Aortic root size;
LGG	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg11789530	chr4:8429930	ACOX3	-0.89	-17.81	-0.64	1.99e-54	Response to antineoplastic agents;
LGG	trans	rs2562456	0.833	rs11669790	chr19:21511782	C/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg25811766	chr13:21894605	NA	-0.56	-7.41	-0.33	6.08e-13	White matter hyperintensity burden;
LGG	cis	rs7712401	0.601	rs35339188	chr5:122317685	A/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg00933542	chr6:150070202	PCMT1	0.38	6.85	0.3	2.31e-11	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01802975	chr1:67519155	SLC35D1	-0.54	-8.5	-0.37	2.54e-16	Pancreatic cancer;
LGG	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05491587	chr18:77659695	KCNG2	-0.53	-7.08	-0.31	5.26e-12	Opioid sensitivity;
LGG	cis	rs2880765	0.546	rs11637726	chr15:86059271	C/T	cg10818794	chr15:86012489	AKAP13	0.39	7.89	0.34	2.14e-14	Coronary artery disease;
LGG	cis	rs367615	0.704	rs72802966	chr5:108846754	T/G	cg17395555	chr5:108820864	NA	0.85	15.33	0.58	3.31e-43	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg27129171	chr3:47204927	SETD2	0.82	15.19	0.58	1.38e-42	Colorectal cancer;
LGG	cis	rs6456156	0.766	rs150112	chr6:167509878	C/T	cg07741184	chr6:167504864	NA	-0.38	-8.43	-0.36	4.28e-16	Primary biliary cholangitis;
LGG	cis	rs4538187	0.599	rs2919222	chr2:64293274	C/T	cg19915305	chr2:64069682	UGP2	-0.5	-12.57	-0.5	2.14e-31	Systolic blood pressure;
LGG	cis	rs7927771	0.864	rs7937331	chr11:47430458	T/C	cg20307385	chr11:47447363	PSMC3	0.57	10.59	0.44	1.28e-23	Subjective well-being;
LGG	cis	rs7202877	0.706	rs37599	chr16:75502132	C/T	cg03315344	chr16:75512273	CHST6	-0.51	-7.05	-0.31	6.7e-12	Type 2 diabetes;Type 1 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11150308	chr17:74068434	SRP68	0.47	7.6	0.33	1.67e-13	Cognitive performance;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.11	-0.43	7.32e-22	Lung cancer;
LGG	cis	rs11792861	0.926	rs11788904	chr9:111865052	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs6430585	0.583	rs59213715	chr2:136646582	A/C	cg07169764	chr2:136633963	MCM6	1.26	23.27	0.73	7.11e-80	Corneal structure;
LGG	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	18.54	0.65	8.61e-58	Platelet count;
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.41e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg27129171	chr3:47204927	SETD2	0.63	10.9	0.45	8.58e-25	Birth weight;
LGG	cis	rs240764	0.507	rs7759463	chr6:101183819	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.42	0.33	5.62e-13	Neuroticism;
LGG	cis	rs6964587	0.647	rs38801	chr7:92046327	G/T	cg17063962	chr7:91808500	NA	-0.41	-7.21	-0.32	2.3e-12	Breast cancer;
LGG	cis	rs9549260	0.755	rs2721044	chr13:41162225	C/T	cg21288729	chr13:41239152	FOXO1	0.33	6.71	0.3	5.64e-11	Red blood cell count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06942064	chr1:208417143	PLXNA2	0.51	8.79	0.38	3.02e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs4631830	0.863	rs6481329	chr10:51529746	G/A	cg10326726	chr10:51549505	MSMB	-0.69	-14.26	-0.55	1.67e-38	Prostate-specific antigen levels;
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg16141378	chr3:129829833	LOC729375	0.42	9.79	0.41	1.12e-20	Retinal vascular caliber;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs713587	0.520	rs839652	chr2:25334340	C/T	cg04586622	chr2:25135609	ADCY3	-0.32	-7.83	-0.34	3.36e-14	Body mass index in non-asthmatics;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	trans	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.84	-0.34	3.03e-14	HDL cholesterol;
LGG	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.24e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.15	-0.32	3.34e-12	Refractive error;
LGG	cis	rs7106204	0.748	rs4636667	chr11:24238615	T/C	ch.11.24196551F	chr11:24239977	NA	1.02	16.48	0.61	2.28e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg04025307	chr7:1156635	C7orf50	0.46	6.76	0.3	4.25e-11	Bronchopulmonary dysplasia;
LGG	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.98e-20	Depression;
LGG	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg02574844	chr11:5959923	NA	-0.6	-10.43	-0.44	5e-23	DNA methylation (variation);
LGG	cis	rs1355223	0.545	rs7123029	chr11:34874815	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.34	-0.36	8.35e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9976767	0.965	rs28755461	chr21:43821176	C/G	cg23042151	chr21:43824109	UBASH3A	-0.35	-6.88	-0.3	2e-11	Type 1 diabetes;
LGG	cis	rs763121	0.853	rs9607566	chr22:39075434	C/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.7e-56	Menopause (age at onset);
LGG	cis	rs34599045	0.522	rs71626746	chr1:152988568	G/A	cg07796016	chr1:152779584	LCE1C	-0.86	-7.79	-0.34	4.59e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg20587970	chr11:113659929	NA	-1.08	-16.33	-0.6	1.19e-47	Hip circumference adjusted for BMI;
LGG	cis	rs745821	0.659	rs8098724	chr18:48125899	G/A	cg18923635	chr18:48083994	NA	0.57	9.49	0.4	1.21e-19	Diastolic blood pressure;
LGG	cis	rs11168618	0.846	rs7974213	chr12:48881492	C/T	cg24011408	chr12:48396354	COL2A1	-0.48	-7.74	-0.34	6.25e-14	Adiponectin levels;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.53	0.37	2.08e-16	Tonsillectomy;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	16.81	0.62	7.72e-50	Platelet count;
LGG	cis	rs2455799	0.634	rs1345160	chr3:15862026	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.94	-0.35	1.58e-14	Mean platelet volume;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg26783146	chr16:4423632	VASN;CORO7	-0.39	-7.05	-0.31	6.44e-12	Schizophrenia;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.82	-0.42	8.18e-21	Prostate cancer;
LGG	cis	rs509477	0.962	rs723035	chr18:32562845	T/A	cg23791764	chr18:32556832	MAPRE2	0.5	8.47	0.37	3.27e-16	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.47	7.56	0.33	2.22e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg05863683	chr7:1912471	MAD1L1	-0.43	-8.38	-0.36	6.45e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	cg07245641	chr1:182991651	LAMC1	0.4	8.81	0.38	2.61e-17	Fuchs's corneal dystrophy;
LGG	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.64	0.3	8.57e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg17294928	chr15:75287854	SCAMP5	0.5	8.87	0.38	1.63e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.44	-0.61	3.49e-48	Skin colour saturation;
LGG	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21659725	chr3:3221576	CRBN	0.92	20.43	0.69	1.38e-66	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	trans	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg06521331	chr12:34319734	NA	0.45	8.15	0.35	3.46e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27144592	chr16:783916	NARFL	0.41	6.85	0.3	2.4e-11	Height;
LGG	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg24006582	chr15:45444508	DUOX1	-0.66	-12.64	-0.51	1.18e-31	Uric acid levels;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.46	-8.22	-0.36	2.1e-15	Obesity-related traits;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.96e-15	Life satisfaction;
LGG	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg15212455	chr7:39170539	POU6F2	0.37	8.13	0.35	3.98e-15	IgG glycosylation;
LGG	cis	rs7674212	0.539	rs6821617	chr4:104128410	G/A	cg16532752	chr4:104119610	CENPE	-0.4	-7.09	-0.31	5.15e-12	Type 2 diabetes;
LGG	trans	rs57046232	0.552	rs1998971	chr20:6334912	G/A	cg21095983	chr6:86352623	SYNCRIP	0.42	7.02	0.31	7.76e-12	Colorectal cancer;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.21	-0.32	2.28e-12	Personality dimensions;
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	trans	rs629535	0.767	rs62513418	chr8:70114376	G/T	cg21567404	chr3:27674614	NA	-0.4	-6.69	-0.3	6.48e-11	Dupuytren's disease;
LGG	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-9.67	-0.41	2.92e-20	Diabetic retinopathy;
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24906202	chr15:73345212	NEO1	0.46	7.79	0.34	4.4e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg20587970	chr11:113659929	NA	-0.75	-11.88	-0.48	1.31e-28	Hip circumference adjusted for BMI;
LGG	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg21055462	chr7:100276975	NA	0.45	9.46	0.4	1.53e-19	Other erythrocyte phenotypes;
LGG	trans	rs12517041	1.000	rs4701363	chr5:23301008	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.04e-25	Calcium levels;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg15383120	chr6:291909	DUSP22	-0.53	-8.69	-0.37	6.48e-17	Menopause (age at onset);
LGG	cis	rs9818758	0.556	rs73077200	chr3:49826987	C/T	cg00383909	chr3:49044727	WDR6	1.11	11.53	0.47	3.26e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs76419734	0.510	rs2553456	chr4:106751028	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.86	-0.34	2.72e-14	Post bronchodilator FEV1;
LGG	trans	rs225245	0.782	rs225272	chr17:33969911	T/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.1	-0.31	4.65e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.89	-0.3	1.86e-11	Bone mineral density;
LGG	trans	rs9354308	0.764	rs4644030	chr6:66582238	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.05e-12	Metabolite levels;
LGG	cis	rs9463078	0.764	rs976699	chr6:44952852	G/T	cg25276700	chr6:44698697	NA	-0.4	-8.44	-0.37	3.99e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	9.0	0.39	5.87e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg06618935	chr21:46677482	NA	-0.51	-8.94	-0.38	9.28e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg18032289	chr17:61959525	GH2	-0.38	-6.65	-0.3	8.05e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1163251	0.902	rs511059	chr1:120217081	G/T	cg19096424	chr1:120255104	PHGDH	0.64	11.09	0.46	1.67e-25	Blood metabolite levels;
LGG	cis	rs9467773	0.595	rs4320356	chr6:26423560	C/T	cg09904177	chr6:26538194	HMGN4	-0.43	-7.72	-0.34	7.24e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14326747	chr21:30397409	USP16	0.48	7.29	0.32	1.32e-12	Gut microbiome composition (summer);
LGG	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg18105134	chr13:113819100	PROZ	0.72	15.33	0.58	3.47e-43	Platelet distribution width;
LGG	cis	rs16910800	0.689	rs7128636	chr11:23164689	C/T	cg20040320	chr11:23191996	NA	-0.62	-6.91	-0.31	1.58e-11	Cancer;
LGG	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg00564723	chr10:75632066	CAMK2G	-0.3	-6.85	-0.3	2.4e-11	Inflammatory bowel disease;
LGG	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg15147215	chr3:52552868	STAB1	-0.45	-8.91	-0.38	1.16e-17	Electroencephalogram traits;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	13.94	0.54	4.13e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg20503657	chr10:835505	NA	0.57	7.21	0.32	2.25e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.33	-0.32	1.05e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06916706	chr16:4465613	CORO7	-0.9	-15.91	-0.59	8.61e-46	Schizophrenia;
LGG	cis	rs6462411	0.938	rs6963058	chr7:3918805	T/A	cg18022346	chr7:3920534	SDK1	-0.36	-7.09	-0.31	4.95e-12	Quantitative traits;
LGG	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.1	0.39	2.78e-18	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.53	-0.4	9.13e-20	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.49e-22	Motion sickness;
LGG	cis	rs2762353	0.526	rs3936052	chr6:25715534	A/G	cg17691542	chr6:26056736	HIST1H1C	0.4	6.86	0.3	2.19e-11	Blood metabolite levels;
LGG	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg01420254	chr6:26195488	NA	0.84	10.97	0.45	4.78e-25	Gout;Renal underexcretion gout;
LGG	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg07424592	chr7:64974309	NA	0.76	7.42	0.33	5.81e-13	Gout;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs4820539	0.611	rs28451783	chr22:23488569	G/T	cg14186256	chr22:23484241	RTDR1	0.92	20.56	0.69	3.13e-67	Bone mineral density;
LGG	cis	rs4731207	0.565	rs10227119	chr7:124593780	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.98	-0.31	1.05e-11	Cutaneous malignant melanoma;
LGG	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.49	0.72	2.93e-76	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08413565	chr3:129035733	H1FX;C3orf47	0.43	6.77	0.3	4.03e-11	Gut microbiome composition (summer);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13129662	chr17:48227708	PPP1R9B	-0.44	-7.29	-0.32	1.35e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	3.9e-11	Cognitive function;
LGG	cis	rs10489202	0.633	rs4657734	chr1:168086743	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.26	-0.43	2.07e-22	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg26513180	chr16:89883248	FANCA	1.02	9.77	0.41	1.29e-20	Skin colour saturation;
LGG	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg20283391	chr11:68216788	NA	-0.5	-8.18	-0.36	2.83e-15	Total body bone mineral density;
LGG	cis	rs16944613	0.588	rs8024734	chr15:91107067	T/C	cg26821196	chr15:91095069	CRTC3	0.59	9.06	0.39	3.79e-18	Colorectal cancer;
LGG	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg10636054	chr15:40330586	SRP14	1.15	13.36	0.53	1.11e-34	Corneal curvature;
LGG	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg00717180	chr2:96193071	NA	0.42	7.41	0.33	5.88e-13	HDL cholesterol;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg04852413	chr12:2986358	FOXM1;C12orf32	-0.37	-6.66	-0.3	7.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs972578	0.740	rs9611968	chr22:43324762	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.74	-0.3	4.6e-11	Mean platelet volume;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.85	0.42	6.8e-21	Height;
LGG	cis	rs2708240	1.000	rs2708238	chr7:147575818	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs1568889	1.000	rs7937778	chr11:28104605	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs457717	0.767	rs10045033	chr5:75923945	A/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.4	-7.54	-0.33	2.49e-13	Hearing impairment;
LGG	cis	rs10459221	1	rs10459221	chr12:49466994	C/G	cg24176009	chr12:49580217	TUBA1A	0.43	7.75	0.34	5.84e-14	Bipolar disorder;
LGG	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg03929089	chr4:120376271	NA	0.72	8.29	0.36	1.26e-15	Axial length;
LGG	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-11.0	-0.46	3.71e-25	Hip circumference adjusted for BMI;
LGG	cis	rs9815354	1.000	rs1612124	chr3:41967893	C/A	cg03022575	chr3:42003672	ULK4	-0.66	-8.49	-0.37	2.8e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7267979	1.000	rs6050598	chr20:25397257	C/G	cg06421707	chr20:25228305	PYGB	0.48	10.42	0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs79349575	0.783	rs1994970	chr17:47014127	C/T	cg24070195	chr17:46969581	ATP5G1	0.4	6.87	0.3	2.02e-11	Type 2 diabetes;
LGG	cis	rs477692	0.604	rs1008982	chr10:131445731	T/C	cg05714579	chr10:131428358	MGMT	-0.77	-17.59	-0.63	2.07e-53	Response to temozolomide;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16956456	chr5:172483378	C5orf41	0.49	7.63	0.33	1.36e-13	Gut microbiome composition (summer);
LGG	cis	rs477692	0.685	rs551491	chr10:131397821	G/A	cg05714579	chr10:131428358	MGMT	0.56	11.44	0.47	7.32e-27	Response to temozolomide;
LGG	cis	rs1595825	0.891	rs16826791	chr2:198895133	C/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.83	-0.3	2.73e-11	Ulcerative colitis;
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg03709012	chr19:19516395	GATAD2A	0.82	15.99	0.6	3.81e-46	Tonsillectomy;
LGG	cis	rs11229555	0.874	rs10896787	chr11:58285494	G/T	cg15696309	chr11:58395628	NA	-1.0	-17.15	-0.62	2.03e-51	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2370759	1.000	rs76998371	chr10:32631785	A/G	cg01819863	chr10:32635814	EPC1	1.09	15.51	0.58	5.66e-44	Sexual dysfunction (female);
LGG	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	4.87e-18	Lung cancer;
LGG	cis	rs3845702	0.736	rs72960660	chr2:180832482	A/G	cg01881094	chr2:180872142	CWC22	1.29	16.8	0.62	8.69e-50	Schizophrenia;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg07511668	chr11:68622177	NA	0.51	9.86	0.42	6.01e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.57	-0.78	3.71e-95	Schizophrenia;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg20905902	chr20:3748417	C20orf27	0.47	6.66	0.3	7.94e-11	Hip circumference;
LGG	cis	rs7766436	0.885	rs3734215	chr6:22571323	T/C	cg13666174	chr6:22585274	NA	-0.51	-11.94	-0.49	7.48e-29	Coronary artery disease;
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg00166722	chr3:10149974	C3orf24	0.5	7.93	0.35	1.65e-14	Alzheimer's disease;
LGG	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg21211680	chr2:198530	NA	1.22	21.4	0.71	3.94e-71	Blood protein levels;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg16578609	chr1:2399051	NA	-0.42	-8.83	-0.38	2.2e-17	Non-obstructive azoospermia;
LGG	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs6594713	0.717	rs10065790	chr5:112911165	C/T	cg12552261	chr5:112820674	MCC	0.62	8.42	0.36	4.9e-16	Brain cytoarchitecture;
LGG	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07080220	chr10:102295463	HIF1AN	0.58	10.09	0.42	8.88e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg15665833	chr6:26285013	NA	0.39	7.66	0.34	1.07e-13	Educational attainment;
LGG	cis	rs17453880	0.895	rs7730088	chr5:152028536	T/G	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs7737355	0.947	rs12659474	chr5:130801304	T/C	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.9e-19	Life satisfaction;
LGG	cis	rs2282802	0.685	rs2053055	chr5:139646776	C/T	cg26211634	chr5:139558579	C5orf32	0.34	7.57	0.33	1.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg14668632	chr7:2872130	GNA12	-0.31	-6.82	-0.3	2.83e-11	Height;
LGG	cis	rs7301016	1.000	rs7962519	chr12:62868885	T/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	trans	rs1032833	0.643	rs115110396	chr2:180107140	C/T	cg23654767	chr2:101192981	PDCL3	0.65	7.72	0.34	7.45e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-9.85	-0.42	6.67e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.76	-0.3	4.13e-11	Systolic blood pressure;
LGG	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.81	0.3	3.1e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-8.86	-0.38	1.69e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.33	-0.32	1.05e-12	HDL cholesterol;
LGG	cis	rs2050392	0.517	rs160017	chr10:30772894	A/G	cg25182066	chr10:30743637	MAP3K8	-0.62	-12.42	-0.5	8.98e-31	Inflammatory bowel disease;
LGG	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-7.91	-0.35	1.9e-14	Mean corpuscular volume;
LGG	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg01620082	chr3:125678407	NA	-0.64	-7.03	-0.31	7.22e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.36	-0.32	8.22e-13	Testicular germ cell tumor;
LGG	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.13e-16	Resting heart rate;
LGG	cis	rs72772090	0.539	rs11739020	chr5:96113838	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.58	8.92	0.38	1.1e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg17294928	chr15:75287854	SCAMP5	0.58	10.33	0.43	1.24e-22	Breast cancer;
LGG	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg09307838	chr4:120376055	NA	0.8	13.41	0.53	7.26e-35	Corneal astigmatism;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg11764359	chr7:65958608	NA	0.74	13.37	0.53	1.05e-34	Aortic root size;
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.64e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg07005078	chr4:17578674	LAP3	0.37	6.84	0.3	2.49e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2693698	0.562	rs11160503	chr14:99683189	C/T	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.71e-28	Schizophrenia;
LGG	cis	rs807669	0.742	rs1206544	chr22:19215039	C/T	cg02655711	chr22:19163373	SLC25A1	0.64	12.79	0.51	2.7e-32	Metabolite levels;
LGG	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg03342759	chr3:160939853	NMD3	0.44	7.45	0.33	4.71e-13	Kawasaki disease;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.49	0.53	3.15e-35	IgG glycosylation;
LGG	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg23625390	chr15:77176239	SCAPER	0.51	9.98	0.42	2.3e-21	Blood metabolite levels;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22968622	chr17:43663579	NA	0.79	15.5	0.58	6.16e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10489202	0.608	rs7533646	chr1:168077593	A/C	cg24449463	chr1:168025552	DCAF6	-0.56	-9.99	-0.42	2.03e-21	Schizophrenia;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg23958373	chr8:599963	NA	1.18	11.85	0.48	1.85e-28	IgG glycosylation;
LGG	cis	rs986417	1.000	rs12895784	chr14:60980116	G/T	cg27398547	chr14:60952738	C14orf39	0.73	7.13	0.31	3.81e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17030434	0.627	rs17371643	chr4:154769372	C/T	cg14289246	chr4:154710475	SFRP2	-0.44	-7.42	-0.33	5.71e-13	Electrocardiographic conduction measures;
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg27121462	chr16:89883253	FANCA	0.62	11.29	0.46	2.83e-26	Vitiligo;
LGG	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.84	-0.3	2.55e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg24607181	chr17:41446203	NA	-0.29	-6.85	-0.3	2.39e-11	Menopause (age at onset);
LGG	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg21775007	chr8:11205619	TDH	-0.46	-7.53	-0.33	2.63e-13	Neuroticism;
LGG	cis	rs9287719	0.967	rs7600587	chr2:10739851	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg16576597	chr16:28551801	NUPR1	0.43	10.29	0.43	1.61e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg26677194	chr12:130822605	PIWIL1	-0.57	-10.02	-0.42	1.6e-21	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.75	-0.45	3.17e-24	Body mass index;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg07511668	chr11:68622177	NA	0.5	9.69	0.41	2.52e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs36071027	0.615	rs13159303	chr5:158421063	A/G	cg07810726	chr5:158524649	EBF1	0.37	6.66	0.3	7.65e-11	Carotid intima media thickness;
LGG	cis	rs157093	1.000	rs157095	chr20:56254984	C/T	cg04055238	chr20:56251166	PMEPA1	0.45	7.73	0.34	6.55e-14	Verbal declarative memory;
LGG	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs597583	0.664	rs4938395	chr11:117384673	C/T	cg27161313	chr11:117392002	DSCAML1	0.56	8.87	0.38	1.54e-17	Putamen volume;
LGG	cis	rs4794202	0.629	rs16948424	chr17:45889712	G/T	cg02219949	chr17:45927392	SP6	0.55	6.7	0.3	6.16e-11	Alzheimer's disease (cognitive decline);
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg26338869	chr17:61819248	STRADA	-0.48	-7.71	-0.34	8.02e-14	Prudent dietary pattern;
LGG	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg02151108	chr14:50098012	C14orf104	-0.45	-9.69	-0.41	2.39e-20	Carotid intima media thickness;
LGG	cis	rs2737618	0.674	rs2821334	chr1:200093887	G/T	cg21825944	chr1:200113062	NR5A2	-0.59	-11.38	-0.47	1.29e-26	Uric acid levels;
LGG	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg06481639	chr22:41940642	POLR3H	-0.5	-7.35	-0.32	9.34e-13	Vitiligo;
LGG	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.59	7.78	0.34	4.7e-14	HIV-1 control;
LGG	cis	rs314370	0.904	rs314373	chr7:100456595	G/A	cg10426581	chr7:100472382	SRRT	0.53	7.36	0.32	8.37e-13	Resting heart rate;
LGG	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg17201900	chr20:34330562	RBM39	0.49	6.66	0.3	7.69e-11	Total cholesterol levels;
LGG	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg02836325	chr17:76403955	PGS1	-0.72	-14.51	-0.56	1.3e-39	HDL cholesterol levels;
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg26752003	chr8:145688521	CYHR1	0.48	10.31	0.43	1.41e-22	Age at first birth;
LGG	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg22906224	chr7:99728672	NA	-0.58	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	cis	rs3736594	1.000	rs13013484	chr2:27988821	G/A	cg27432699	chr2:27873401	GPN1	-0.54	-8.75	-0.38	4.1e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00292662	chr22:38071168	LGALS1	0.64	14.98	0.57	1.15e-41	Fat distribution (HIV);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06873684	chr19:4472059	HDGF2	0.47	7.51	0.33	3.02e-13	Cognitive performance;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs10927875	0.894	rs34957618	chr1:16320499	G/C	cg22431228	chr1:16359049	CLCNKA	0.39	6.65	0.3	8.07e-11	Dilated cardiomyopathy;
LGG	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg22916017	chr11:64110731	CCDC88B	0.46	9.37	0.4	3.19e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.28	0.32	1.45e-12	Menopause (age at onset);
LGG	cis	rs17641971	0.599	rs818555	chr8:49999211	A/G	cg00325661	chr8:49890786	NA	-0.57	-10.32	-0.43	1.27e-22	Blood metabolite levels;
LGG	cis	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs2013441	1.000	rs2703821	chr17:20121526	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.67	-0.3	7.26e-11	Aortic root size;
LGG	cis	rs7717393	0.881	rs7725923	chr5:155770753	A/C	cg04435420	chr5:155754009	SGCD	0.68	8.79	0.38	2.97e-17	Egg allergy;
LGG	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.12	-0.43	6.84e-22	Schizophrenia;
LGG	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.74	-0.3	4.73e-11	Diastolic blood pressure;
LGG	cis	rs7580658	0.724	rs7568261	chr2:128117324	C/T	cg10021288	chr2:128175891	PROC	-0.59	-12.04	-0.49	3.04e-29	Protein C levels;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.43	-0.47	7.85e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs3806843	1.000	rs12717860	chr5:140171442	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.77	0.34	5.14e-14	Bipolar disorder;
LGG	cis	rs1144	0.537	rs2470938	chr7:104581402	C/A	cg03782966	chr7:104585482	NA	0.34	7.9	0.34	2.01e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs7666738	0.927	rs6832373	chr4:99051967	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.46	0.37	3.63e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7408868	0.831	rs11672004	chr19:15277282	T/A	cg14696996	chr19:15285081	NOTCH3	0.89	11.62	0.48	1.43e-27	Pulse pressure;
LGG	cis	rs3008870	0.959	rs2815353	chr1:67483372	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.99	23.11	0.73	3.79e-79	Lymphocyte percentage of white cells;
LGG	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.39e-13	HDL cholesterol;
LGG	cis	rs7582720	1.000	rs114899426	chr2:203771652	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.63	0.51	1.31e-31	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg08344181	chr3:125677491	NA	0.64	7.66	0.34	1.09e-13	Depression;
LGG	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg04398451	chr17:18023971	MYO15A	-0.64	-10.95	-0.45	5.47e-25	Total body bone mineral density;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg05025164	chr4:1340916	KIAA1530	0.87	17.25	0.63	7.07e-52	Longevity;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.28	0.32	1.49e-12	Lung cancer;
LGG	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21659725	chr3:3221576	CRBN	-0.66	-12.41	-0.5	1.01e-30	Intelligence (multi-trait analysis);
LGG	trans	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg06636001	chr8:8085503	FLJ10661	0.45	7.67	0.34	1.06e-13	Neuroticism;
LGG	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg08847335	chr10:891726	LARP4B	-0.53	-8.67	-0.37	7.33e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg17951613	chr5:131705445	SLC22A5	0.68	7.69	0.34	9.06e-14	Rheumatoid arthritis;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.5	9.3	0.4	5.59e-19	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.09	0.57	4e-42	Cognitive test performance;
LGG	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05926928	chr17:57297772	GDPD1	1.36	21.68	0.71	1.93e-72	Opioid sensitivity;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.64	-0.37	9.3e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs1784135	chr11:95531748	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.86	0.34	2.73e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg11301795	chr4:187892539	NA	-0.95	-24.86	-0.76	2.69e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4824093	0.610	rs73441787	chr22:50269646	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.93	-0.31	1.43e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-6.87	-0.3	2.02e-11	Large artery stroke;
LGG	cis	rs7408868	1.000	rs10406754	chr19:15274201	T/A	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg24634471	chr8:143751801	JRK	0.49	7.43	0.33	5.12e-13	Schizophrenia;
LGG	trans	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg25214090	chr10:38739885	LOC399744	0.52	9.59	0.41	5.28e-20	Corneal astigmatism;
LGG	cis	rs4740619	0.689	rs9969685	chr9:15956278	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.37	-0.43	8.5e-23	Body mass index;
LGG	cis	rs2046867	0.818	rs60228315	chr3:72805034	C/A	cg25664220	chr3:72788482	NA	-0.32	-8.81	-0.38	2.51e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.67e-12	Height;
LGG	cis	rs9815354	1.000	rs6802340	chr3:41894034	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs75804782	0.641	rs55844289	chr2:239323207	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.92	0.38	1.11e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg12751644	chr20:60527061	NA	-0.29	-6.92	-0.31	1.54e-11	Body mass index;
LGG	cis	rs12618769	0.625	rs17034241	chr2:99224998	C/G	cg18455616	chr2:99124870	INPP4A	0.27	7.79	0.34	4.57e-14	Bipolar disorder;
LGG	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg10483660	chr13:112241077	NA	0.37	7.64	0.33	1.22e-13	Hepatitis;
LGG	cis	rs1538970	0.962	rs2153609	chr1:45814058	A/G	cg05343316	chr1:45956843	TESK2	0.69	11.25	0.46	3.92e-26	Platelet count;
LGG	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06481639	chr22:41940642	POLR3H	0.55	8.11	0.35	4.63e-15	Vitiligo;
LGG	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg00405596	chr8:11794950	NA	-0.42	-6.8	-0.3	3.31e-11	Retinal vascular caliber;
LGG	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.0	-0.35	9.77e-15	Mean corpuscular volume;
LGG	cis	rs4740619	0.688	rs4582646	chr9:15935502	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.1	-0.42	8.14e-22	Body mass index;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs6087990	0.966	rs1883730	chr20:31337487	T/A	cg13636640	chr20:31349939	DNMT3B	1.0	21.6	0.71	4.38e-72	Ulcerative colitis;
LGG	cis	rs7616330	0.945	rs1288987	chr3:71112417	A/C	cg23830205	chr3:71127516	FOXP1	-0.5	-8.19	-0.36	2.57e-15	QT interval;
LGG	cis	rs4253772	0.637	rs8135997	chr22:46651366	G/A	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.6e-32	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs4888262	0.545	rs4588013	chr16:74703388	C/T	cg01733217	chr16:74700730	RFWD3	0.94	19.63	0.67	7.21e-63	Testicular germ cell tumor;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.62	11.23	0.46	4.67e-26	Lymphocyte counts;
LGG	cis	rs7737355	0.812	rs7731773	chr5:130973943	A/G	cg06307176	chr5:131281290	NA	0.52	8.57	0.37	1.54e-16	Life satisfaction;
LGG	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg00531865	chr16:30841666	NA	-0.48	-10.02	-0.42	1.67e-21	Dementia with Lewy bodies;
LGG	cis	rs42648	0.837	rs13239439	chr7:89924400	C/A	cg25739043	chr7:89950458	NA	-0.44	-9.26	-0.4	7.69e-19	Homocysteine levels;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	trans	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg18379455	chr17:41446167	NA	0.33	7.9	0.34	2e-14	Menopause (age at onset);
LGG	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg27532318	chr7:32358331	NA	-0.63	-6.87	-0.3	2.08e-11	Body mass index;
LGG	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.04e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.31	-0.32	1.16e-12	Iron status biomarkers;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg13939156	chr17:80058883	NA	0.44	8.43	0.36	4.57e-16	Life satisfaction;
LGG	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.18e-19	Chronic lymphocytic leukemia;
LGG	cis	rs6964587	0.934	rs1544377	chr7:91687351	A/G	cg17063962	chr7:91808500	NA	0.48	8.5	0.37	2.61e-16	Breast cancer;
LGG	cis	rs11150038	0.826	rs12448742	chr16:78066684	T/C	cg04733911	chr16:78082701	NA	-0.68	-9.09	-0.39	2.9e-18	Colorectal or endometrial cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23054379	chr1:176176226	RFWD2	0.44	7.08	0.31	5.25e-12	Cognitive performance;
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg20814179	chr4:940893	TMEM175	0.55	11.39	0.47	1.18e-26	Sjögren's syndrome;
LGG	cis	rs12493885	0.818	rs1713817	chr3:153872345	A/G	cg12800244	chr3:153838788	SGEF	0.76	8.89	0.38	1.37e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg07615347	chr10:60278583	BICC1	0.64	18.19	0.65	3.44e-56	Refractive error;
LGG	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.37	-0.58	2.25e-43	Chronic sinus infection;
LGG	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg24977338	chr2:113188963	RGPD8;RGPD5	0.54	8.01	0.35	9.08e-15	Yeast infection;
LGG	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs3126085	0.800	rs55650366	chr1:152279920	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.16	-0.35	3.24e-15	Atopic dermatitis;
LGG	cis	rs2486288	0.656	rs12911186	chr15:45551423	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs5756813	0.727	rs4820303	chr22:38134166	G/A	cg19171272	chr22:38449367	NA	0.4	6.93	0.31	1.43e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg09307838	chr4:120376055	NA	-0.81	-13.54	-0.53	1.96e-35	Corneal astigmatism;
LGG	cis	rs9486719	0.552	rs9399923	chr6:96850379	G/A	cg06623918	chr6:96969491	KIAA0776	0.66	10.12	0.43	6.92e-22	Migraine;Coronary artery disease;
LGG	cis	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg06609049	chr19:2785107	THOP1	0.6	9.59	0.41	5.28e-20	Total cholesterol levels;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.53	0.63	4e-53	Obesity-related traits;
LGG	cis	rs701145	0.537	rs449361	chr3:153922410	T/C	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs9916302	0.904	rs6503506	chr17:37524653	C/A	cg00129232	chr17:37814104	STARD3	0.61	11.43	0.47	7.83e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg18850127	chr7:39170497	POU6F2	0.6	14.73	0.56	1.51e-40	IgG glycosylation;
LGG	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg16141378	chr3:129829833	LOC729375	0.4	9.22	0.39	1.04e-18	Triglycerides;
LGG	trans	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg06521331	chr12:34319734	NA	0.45	8.12	0.35	4.15e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9290065	0.538	rs898682	chr3:160773133	G/C	cg04691961	chr3:161091175	C3orf57	-0.46	-9.48	-0.4	1.31e-19	Kawasaki disease;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.45	-0.53	4.73e-35	Longevity;Endometriosis;
LGG	cis	rs1408224	0.657	rs9526207	chr13:47201226	C/T	cg24453118	chr13:47229927	LRCH1	-0.29	-6.86	-0.3	2.18e-11	QRS complex (12-leadsum);
LGG	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg19680485	chr15:31195859	MTMR15	-0.44	-7.27	-0.32	1.55e-12	Huntington's disease progression;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg04861929	chr11:109293070	C11orf87	-0.55	-9.93	-0.42	3.3e-21	Schizophrenia;
LGG	cis	rs4950322	1.000	rs72694715	chr1:146840183	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.19	-0.32	2.66e-12	Protein quantitative trait loci;
LGG	trans	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.41	-0.36	4.94e-16	Breast cancer;
LGG	cis	rs4330281	0.669	rs13071934	chr3:17757928	G/C	cg20981856	chr3:17787350	NA	-0.39	-7.3	-0.32	1.3e-12	Schizophrenia;
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11645453	chr3:52864694	ITIH4	-0.42	-7.01	-0.31	8.3e-12	Bipolar disorder;
LGG	cis	rs2777491	0.707	rs8024774	chr15:41792560	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.84	-15.63	-0.59	1.64e-44	Ulcerative colitis;
LGG	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg05132306	chr1:1846340	CALML6	-0.29	-7.09	-0.31	5.19e-12	Body mass index;
LGG	cis	rs10791097	0.765	rs7943757	chr11:130716157	C/T	cg12179176	chr11:130786555	SNX19	0.7	12.61	0.51	1.51e-31	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7432375	0.579	rs10935199	chr3:136563535	G/C	cg12473912	chr3:136751656	NA	0.41	6.78	0.3	3.7e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7219021	0.739	rs1800632	chr17:46970509	G/A	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.75	-0.3	4.36e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg04455712	chr21:45112962	RRP1B	0.5	9.37	0.4	3.08e-19	Mean corpuscular volume;
LGG	cis	rs889122	0.531	rs918539	chr19:10013840	C/G	cg00846166	chr19:10022875	OLFM2	-0.33	-7.33	-0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg02836325	chr17:76403955	PGS1	-0.72	-14.62	-0.56	4.73e-40	HDL cholesterol levels;
LGG	cis	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.66	12.67	0.51	8.28e-32	Eye color traits;
LGG	cis	rs17776563	0.887	rs12148467	chr15:89128870	G/A	cg05013243	chr15:89149849	MIR1179	-0.5	-10.43	-0.44	5.32e-23	Thyroid hormone levels;
LGG	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg13147721	chr7:65941812	NA	-0.81	-9.64	-0.41	3.68e-20	Diabetic kidney disease;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.56	0.63	2.82e-53	Longevity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17834180	chr10:124768240	IKZF5;ACADSB	0.46	7.54	0.33	2.57e-13	Cognitive performance;
LGG	trans	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.96e-27	Corneal astigmatism;
LGG	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg07520158	chr7:32535189	LSM5;AVL9	0.62	10.39	0.43	7.17e-23	Cognitive ability;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg22535103	chr8:58192502	C8orf71	-0.87	-11.21	-0.46	5.52e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg24112000	chr20:60950667	NA	-0.39	-7.88	-0.34	2.29e-14	Colorectal cancer;
LGG	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg09038676	chr11:67351608	GSTP1	0.36	6.99	0.31	9.58e-12	Mean corpuscular volume;
LGG	cis	rs12431410	0.853	rs1957990	chr14:60162312	A/G	cg07950296	chr14:60194823	RTN1	0.37	7.11	0.31	4.35e-12	Schizophrenia;
LGG	cis	rs4900538	0.855	rs60215817	chr14:102873886	A/G	cg18135206	chr14:102964638	TECPR2	-0.69	-12.5	-0.5	4.31e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9902453	1.000	rs9891871	chr17:28370191	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	cis	rs9487051	0.652	rs6568559	chr6:109592751	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06873352	chr17:61820015	STRADA	-0.43	-6.82	-0.3	2.88e-11	Height;
LGG	cis	rs4774830	0.744	rs17819312	chr15:56297427	G/A	cg05129572	chr15:56138634	NEDD4	0.75	7.18	0.32	2.83e-12	Delta-5 desaturase activity;
LGG	cis	rs3008870	0.755	rs2815380	chr1:67510857	A/G	cg02640540	chr1:67518911	SLC35D1	-0.59	-11.96	-0.49	6.52e-29	Lymphocyte percentage of white cells;
LGG	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg21699342	chr2:239360505	ASB1	0.39	7.51	0.33	3.17e-13	Multiple system atrophy;
LGG	cis	rs1728785	0.818	rs11648503	chr16:68598938	G/A	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06028808	chr11:68637592	NA	0.73	12.75	0.51	4.16e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg23730037	chr7:158596552	ESYT2	0.39	6.77	0.3	3.92e-11	Height;
LGG	cis	rs9388490	0.522	rs853980	chr6:127044769	T/A	cg19875578	chr6:126661172	C6orf173	-0.5	-9.02	-0.39	4.93e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.01	0.31	8.28e-12	Educational attainment;
LGG	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg24812749	chr6:127587940	RNF146	0.83	13.86	0.54	8.37e-37	Breast cancer;
LGG	cis	rs10893109	0.517	rs7120581	chr11:123778173	T/G	cg12387464	chr11:123775935	OR8D4	0.39	8.44	0.37	4.06e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs123509	0.645	rs112042968	chr3:42860158	A/G	cg12982090	chr3:42733453	KBTBD5	-0.93	-13.81	-0.54	1.41e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg06558623	chr16:89946397	TCF25	1.18	12.92	0.51	8.09e-33	Skin colour saturation;
LGG	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg02002194	chr4:3960332	NA	0.46	8.91	0.38	1.19e-17	Neuroticism;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg06026548	chr3:184529869	VPS8	-0.35	-6.85	-0.3	2.29e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg00579200	chr11:133705235	NA	-0.51	-9.74	-0.41	1.55e-20	Childhood ear infection;
LGG	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.15e-84	Height;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18110333	chr6:292329	DUSP22	-0.69	-11.78	-0.48	3.43e-28	Menopause (age at onset);
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg00800038	chr16:89945340	TCF25	-0.63	-8.82	-0.38	2.3e-17	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg13147721	chr7:65941812	NA	-0.84	-10.16	-0.43	4.94e-22	Diabetic kidney disease;
LGG	cis	rs367943	1.000	rs348962	chr5:112819086	C/T	cg12552261	chr5:112820674	MCC	0.75	14.32	0.55	8.83e-39	Type 2 diabetes;
LGG	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg18252515	chr7:66147081	NA	-1.38	-18.81	-0.66	4.92e-59	Diabetic kidney disease;
LGG	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.34	-0.36	8.42e-16	Morning vs. evening chronotype;
LGG	trans	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.71	-0.64	5.47e-54	Exhaled nitric oxide output;
LGG	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg13232821	chr7:50628718	DDC	-0.37	-7.47	-0.33	4.05e-13	Malaria;
LGG	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03517284	chr6:25882590	NA	-0.67	-12.46	-0.5	6.22e-31	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.68e-19	Diabetic retinopathy;
LGG	cis	rs10849893	0.557	rs6489812	chr12:121913559	T/A	cg01154721	chr12:121881891	KDM2B	0.43	7.38	0.32	7.37e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs13082711	0.554	rs66854845	chr3:27387008	C/T	cg02860705	chr3:27208620	NA	0.92	16.78	0.62	9.93e-50	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs524281	0.861	rs2293121	chr11:65961347	T/G	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg24450063	chr1:156163899	SLC25A44	1.22	30.6	0.82	2.82e-113	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs9443645	0.901	rs7749916	chr6:79814192	A/G	cg18132916	chr6:79620363	NA	-0.3	-8.08	-0.35	5.65e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3106136	0.967	rs11097411	chr4:95222626	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.48	-8.47	-0.37	3.36e-16	Capecitabine sensitivity;
LGG	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	11.14	0.46	1.05e-25	Emphysema distribution in smoking;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	10.64	0.44	8.68e-24	Longevity;
LGG	cis	rs2640806	0.506	rs2678329	chr8:97374653	A/G	cg22138393	chr8:97340270	PTDSS1	0.27	6.8	0.3	3.23e-11	Obesity-related traits;
LGG	cis	rs3820068	0.580	rs36100011	chr1:16046920	C/T	cg05660106	chr1:15850417	CASP9	0.75	13.79	0.54	1.7e-36	Systolic blood pressure;
LGG	cis	rs8058578	0.832	rs7500719	chr16:30840877	C/T	cg02466173	chr16:30829666	NA	-0.54	-9.89	-0.42	4.83e-21	Multiple myeloma;
LGG	cis	rs7681440	0.641	rs6841352	chr4:90781655	A/C	cg14346243	chr4:90757452	SNCA	0.35	6.9	0.31	1.76e-11	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg22535103	chr8:58192502	C8orf71	-0.95	-13.17	-0.52	7.32e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08795170	chr5:108746307	PJA2	-0.51	-7.45	-0.33	4.77e-13	Systemic lupus erythematosus;
LGG	cis	rs2270875	1.000	rs10464872	chr8:132932749	A/G	cg24184792	chr8:132919238	EFR3A	-0.44	-6.83	-0.3	2.75e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs7927592	0.763	rs3740628	chr11:68381415	A/G	cg16797656	chr11:68205561	LRP5	0.51	10.0	0.42	1.84e-21	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.32	0.32	1.09e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.18	-0.36	2.82e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.02	0.31	8.06e-12	Educational attainment;
LGG	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.27	0.4	6.92e-19	Diabetic retinopathy;
LGG	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg21926883	chr2:100939477	LONRF2	-0.49	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.676	rs778593	chr5:140027216	T/C	cg19875535	chr5:140030758	IK	-0.59	-12.27	-0.5	3.73e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3820068	0.532	rs1547034	chr1:15919049	T/A	cg05660106	chr1:15850417	CASP9	0.86	18.27	0.65	1.48e-56	Systolic blood pressure;
LGG	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg19913688	chr11:428466	ANO9	-0.66	-8.43	-0.36	4.31e-16	Body mass index;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.81e-21	Platelet count;
LGG	cis	rs910187	0.641	rs6018327	chr20:45813126	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-9.16	-0.39	1.69e-18	Migraine;
LGG	cis	rs9296092	0.538	rs75082458	chr6:33524792	C/T	cg13560919	chr6:33536144	NA	-1.03	-21.04	-0.7	1.9e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg06609049	chr19:2785107	THOP1	0.61	9.63	0.41	3.97e-20	Total cholesterol levels;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg11062466	chr8:58055876	NA	0.47	8.04	0.35	7.67e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.24	-0.39	8.74e-19	Blood metabolite levels;
LGG	cis	rs9457247	1.000	rs2149085	chr6:167371110	T/C	cg07741184	chr6:167504864	NA	-0.32	-7.07	-0.31	5.76e-12	Crohn's disease;
LGG	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.38	-0.43	7.53e-23	Chronic sinus infection;
LGG	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.02	0.39	5.21e-18	Platelet count;
LGG	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.73	0.51	4.85e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9815354	0.812	rs73079360	chr3:41888372	T/A	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.84	0.38	2.09e-17	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.48	0.71	1.58e-71	Morning vs. evening chronotype;
LGG	cis	rs4700695	1.000	rs153319	chr5:65419423	C/T	cg21114390	chr5:65439923	SFRS12	-0.55	-6.96	-0.31	1.16e-11	Facial morphology (factor 19);
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg04156016	chr5:1868137	NA	0.32	7.11	0.31	4.32e-12	Cardiovascular disease risk factors;
LGG	cis	rs7546668	1.000	rs4233533	chr1:15829187	G/A	cg21858823	chr1:15850916	CASP9	0.38	7.15	0.32	3.46e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.01	0.62	8.96e-51	Alzheimer's disease;
LGG	cis	rs2898857	0.524	rs2906100	chr17:47372764	C/T	cg08112188	chr17:47440006	ZNF652	0.46	7.52	0.33	2.9e-13	Cancer;
LGG	cis	rs9557207	1.000	rs9557192	chr13:99944165	C/T	cg24509225	chr13:100037070	UBAC2	-0.55	-9.7	-0.41	2.23e-20	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs11771526	1.000	rs11770367	chr7:32354319	C/T	cg27511599	chr7:32358540	NA	0.63	6.74	0.3	4.61e-11	Body mass index;
LGG	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg00409905	chr10:38381863	ZNF37A	0.48	7.29	0.32	1.38e-12	Obesity (extreme);
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.45e-15	Lymphocyte counts;
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg14689365	chr7:158441557	NCAPG2	0.6	10.03	0.42	1.44e-21	Height;
LGG	cis	rs10893109	0.517	rs10790608	chr11:123775313	T/C	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs6735179	0.958	rs1424921	chr2:1771874	A/G	cg10160682	chr2:1713001	PXDN	-0.48	-7.78	-0.34	4.85e-14	Response to antipsychotic treatment;
LGG	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg00376283	chr12:123451042	ABCB9	0.64	10.25	0.43	2.29e-22	Neutrophil percentage of white cells;
LGG	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.76	-0.3	4.13e-11	Blood metabolite levels;
LGG	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg27087555	chr16:88793112	FAM38A	-1.25	-12.31	-0.5	2.44e-30	Plateletcrit;
LGG	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg25664220	chr3:72788482	NA	-0.33	-8.93	-0.38	9.82e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs701145	0.585	rs12497267	chr3:153839960	T/C	cg12800244	chr3:153838788	SGEF	0.8	8.55	0.37	1.76e-16	Coronary artery disease;
LGG	cis	rs9810089	0.934	rs1153877	chr3:136004925	C/T	cg21827317	chr3:136751795	NA	0.44	7.64	0.33	1.3e-13	Gestational age at birth (child effect);
LGG	cis	rs7927771	0.524	rs7933184	chr11:47682402	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.0	0.46	3.55e-25	Subjective well-being;
LGG	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg01324343	chr3:183735012	ABCC5	0.87	18.07	0.64	1.2e-55	Anterior chamber depth;
LGG	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg00319359	chr11:70116639	PPFIA1	0.68	6.93	0.31	1.43e-11	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg11494091	chr17:61959527	GH2	0.53	8.59	0.37	1.32e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2075371	0.501	rs1613152	chr7:134019837	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	8.62	0.37	1.03e-16	Mean platelet volume;
LGG	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg19729930	chr2:74357872	NA	0.54	11.62	0.48	1.5e-27	Gestational age at birth (maternal effect);
LGG	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg05692746	chr2:100937584	LONRF2	-0.57	-9.52	-0.4	9.41e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.69	0.61	2.64e-49	Obesity-related traits;
LGG	cis	rs10462794	0.851	rs12517452	chr5:4492572	C/T	cg18482690	chr5:4511582	NA	-0.41	-6.9	-0.31	1.76e-11	DNA methylation (variation);
LGG	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg16386425	chr10:429943	DIP2C	0.35	6.67	0.3	7.1e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2535633	0.588	rs2564930	chr3:53017307	T/C	cg11645453	chr3:52864694	ITIH4	-0.49	-8.07	-0.35	5.98e-15	Body mass index;
LGG	trans	rs12517041	0.748	rs16892375	chr5:23304111	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg25358565	chr5:93447407	FAM172A	-1.27	-15.59	-0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs60695258	0.550	rs6531948	chr4:87972968	T/C	cg11209507	chr4:87813803	C4orf36	0.46	7.89	0.34	2.27e-14	Hematocrit;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs10851411	0.697	rs72711767	chr15:42843970	T/G	cg21293051	chr15:42870591	STARD9	0.5	7.09	0.31	5.14e-12	Glucose homeostasis traits;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20887711	chr4:1340912	KIAA1530	0.6	11.54	0.47	2.89e-27	Obesity-related traits;
LGG	cis	rs1003719	0.667	rs8127148	chr21:38481292	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.77	14.64	0.56	3.56e-40	Eye color traits;
LGG	cis	rs975722	0.736	rs214161	chr7:117319033	C/G	cg10524701	chr7:117356490	CTTNBP2	0.42	8.73	0.38	4.5e-17	Coronary artery disease;
LGG	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg21399703	chr1:247681439	NA	0.63	11.53	0.47	3.32e-27	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs4148087	1.000	rs28494082	chr21:43634547	A/G	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	cis	rs1385374	0.502	rs923077	chr12:129276708	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.61	-6.86	-0.3	2.2e-11	Systemic lupus erythematosus;
LGG	cis	rs490234	0.702	rs2416964	chr9:128360413	C/T	cg14078157	chr9:128172775	NA	-0.54	-10.09	-0.42	9.26e-22	Mean arterial pressure;
LGG	trans	rs17685	0.884	rs6978677	chr7:75636240	C/T	cg19862616	chr7:65841803	NCRNA00174	0.96	20.03	0.68	1.02e-64	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.4	0.33	6.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2816062	0.813	rs2745321	chr1:18889198	G/C	cg18795169	chr1:18902165	NA	-1.06	-32.79	-0.84	8.41e-123	Urate levels in lean individuals;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg19901468	chr14:105411992	AHNAK2	-0.52	-7.37	-0.32	8.01e-13	IgG glycosylation;
LGG	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08704250	chr15:31115839	NA	-0.48	-8.64	-0.37	8.95e-17	Huntington's disease progression;
LGG	cis	rs751728	0.687	rs943471	chr6:33738314	C/T	cg13560919	chr6:33536144	NA	-0.42	-7.72	-0.34	7.4e-14	Crohn's disease;
LGG	cis	rs10193935	0.901	rs6544533	chr2:42516372	G/C	cg27598129	chr2:42591480	NA	-0.59	-8.85	-0.38	1.88e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2562456	0.793	rs2562420	chr19:21631305	T/A	cg00806126	chr19:22604979	ZNF98	0.57	8.03	0.35	8.21e-15	Pain;
LGG	cis	rs7301826	0.627	rs34103763	chr12:131290149	G/A	cg11011512	chr12:131303247	STX2	-0.39	-8.38	-0.36	6.3e-16	Plasma plasminogen activator levels;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.61	0.33	1.58e-13	Lung cancer;
LGG	cis	rs9303401	0.614	rs28687626	chr17:57191904	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.41	0.53	6.8000000000000005e-35	Cognitive test performance;
LGG	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg02527881	chr3:46936655	PTH1R	-0.33	-7.83	-0.34	3.46e-14	Birth weight;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.6	-0.51	1.73e-31	Alzheimer's disease;
LGG	cis	rs3820928	0.934	rs66959645	chr2:227761582	C/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.46	-0.33	4.34e-13	Pulmonary function;
LGG	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg21827317	chr3:136751795	NA	-0.62	-11.45	-0.47	6.63e-27	Neuroticism;
LGG	cis	rs1878931	0.501	rs9635563	chr16:3416940	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	13.93	0.54	4.19e-37	Body mass index (adult);
LGG	cis	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg13647721	chr17:30228624	UTP6	0.79	11.27	0.46	3.25e-26	Hip circumference adjusted for BMI;
LGG	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.15	-0.32	3.4e-12	HDL cholesterol;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07939768	chr17:27621433	NUFIP2	0.41	6.66	0.3	7.84e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.37	-0.36	6.91e-16	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14804635	chr15:75747750	SIN3A	0.43	6.89	0.3	1.8e-11	Cognitive performance;
LGG	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg19338460	chr6:170058176	WDR27	-0.58	-8.07	-0.35	6.27e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg22044901	chr15:68126292	NA	-0.42	-7.68	-0.34	9.61e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2802728	0.881	rs4658568	chr1:243577313	A/G	cg05593162	chr1:243577377	SDCCAG8	0.48	6.85	0.3	2.31e-11	Toenail selenium levels;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg15971980	chr6:150254442	NA	0.43	8.09	0.35	5.33e-15	Lung cancer;
LGG	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg21174375	chr14:64681225	SYNE2	0.43	7.98	0.35	1.14e-14	Atrial fibrillation;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.17	0.55	4.1e-38	Obesity-related traits;
LGG	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg24642439	chr20:33292090	TP53INP2	-0.49	-8.17	-0.36	2.86e-15	Height;
LGG	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg20283391	chr11:68216788	NA	-0.5	-8.3	-0.36	1.18e-15	Total body bone mineral density;
LGG	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg25427524	chr10:38739819	LOC399744	0.53	8.56	0.37	1.65e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs314370	0.570	rs314324	chr7:100433794	C/T	cg03098644	chr7:100410630	EPHB4	-0.43	-6.9	-0.31	1.67e-11	Resting heart rate;
LGG	cis	rs17665859	0.925	rs62484458	chr8:482717	T/C	cg17960703	chr8:356704	FBXO25	0.87	8.07	0.35	6.18e-15	Bilirubin levels;
LGG	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg07169764	chr2:136633963	MCM6	-0.53	-8.91	-0.38	1.16e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.37e-11	Menopause (age at onset);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23927769	chr6:41755626	TOMM6	0.42	7.15	0.32	3.47e-12	Bipolar disorder;
LGG	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	trans	rs75804782	0.521	rs72993074	chr2:239413582	T/G	cg01134436	chr17:81009848	B3GNTL1	0.8	8.73	0.38	4.54e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6540556	0.723	rs12060420	chr1:209906819	T/G	cg23920097	chr1:209922102	NA	-0.44	-7.3	-0.32	1.23e-12	Red blood cell count;
LGG	trans	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg11430096	chr6:110968061	CDK19	0.65	6.84	0.3	2.49e-11	Prostate cancer;
LGG	cis	rs2463822	0.920	rs11828383	chr11:62067818	C/T	cg06239285	chr11:62104954	ASRGL1	-1.13	-15.07	-0.57	4.99e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.94	-0.35	1.52e-14	Mood instability;
LGG	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.86	-0.34	2.81e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.37	-0.43	8.54e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.24	-0.78	3.36e-98	Height;
LGG	cis	rs4731207	0.596	rs1871776	chr7:124674648	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.53	-0.33	2.64e-13	Cutaneous malignant melanoma;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg16103275	chr6:290800	DUSP22	0.49	7.99	0.35	1.1e-14	Menopause (age at onset);
LGG	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-15.06	-0.57	5.06e-42	Colorectal cancer;
LGG	cis	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg07460842	chr6:66804631	NA	-0.97	-18.18	-0.65	3.95e-56	Exhaled nitric oxide output;
LGG	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg13385521	chr17:29058706	SUZ12P	0.8	9.63	0.41	4.06e-20	Body mass index;
LGG	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg00083206	chr6:110721305	DDO	-0.26	-6.72	-0.3	5.19e-11	Platelet distribution width;
LGG	cis	rs2976388	0.590	rs11785290	chr8:143814849	A/G	cg06565975	chr8:143823917	SLURP1	-0.52	-13.14	-0.52	9.75e-34	Urinary tract infection frequency;
LGG	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg03162506	chr22:38580953	NA	-0.42	-10.57	-0.44	1.6e-23	Cutaneous nevi;
LGG	cis	rs4819852	0.752	rs2238781	chr22:19970547	G/T	cg06346307	chr22:19949965	COMT	0.29	6.99	0.31	9.95e-12	Pulse pressure;
LGG	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg10523679	chr1:76189770	ACADM	-0.71	-11.07	-0.46	2.03e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg27471124	chr11:109292789	C11orf87	0.47	9.35	0.4	3.75e-19	Schizophrenia;
LGG	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.92e-20	Red blood cell count;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	9.08	0.39	3.03e-18	Personality dimensions;
LGG	cis	rs7586879	0.964	rs11688665	chr2:25121168	G/T	cg04586622	chr2:25135609	ADCY3	0.39	9.91	0.42	4.08e-21	Body mass index;
LGG	cis	rs7124681	0.585	rs10838773	chr11:47834346	G/A	cg20307385	chr11:47447363	PSMC3	0.56	10.88	0.45	1.07e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2977993	1	rs2977993	chr9:131608786	G/A	cg04621255	chr9:131581398	ENDOG	-0.42	-7.36	-0.32	8.4e-13	Schizophrenia;
LGG	cis	rs4561483	0.603	rs62038777	chr16:11934176	A/C	cg08843971	chr16:11963173	GSPT1	0.55	13.04	0.52	2.57e-33	Testicular germ cell tumor;
LGG	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg14456004	chr13:21872349	NA	-1.22	-19.6	-0.67	9.99e-63	White matter hyperintensity burden;
LGG	cis	rs6694672	1.000	rs6677082	chr1:197112533	G/A	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.69e-12	Asthma;
LGG	cis	rs7166081	1.000	rs12899051	chr15:67573741	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9783347	0.714	rs4150628	chr11:18365868	G/A	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.24	-0.49	4.82e-30	Pancreatic cancer;
LGG	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg05887092	chr17:76393375	PGS1	0.78	18.49	0.65	1.42e-57	HDL cholesterol levels;
LGG	cis	rs932287	0.540	rs4910442	chr11:9044337	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	10.84	0.45	1.46e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-9.92	-0.42	3.71e-21	Lung cancer;
LGG	cis	rs6539288	0.691	rs10746071	chr12:107353595	C/T	cg15890332	chr12:107067104	RFX4	-0.3	-8.07	-0.35	6.28e-15	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg18681998	chr4:17616180	MED28	0.86	19.88	0.68	4.8e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6735179	0.550	rs13396286	chr2:1759021	A/G	cg20570797	chr2:1712800	PXDN	-0.46	-8.21	-0.36	2.3e-15	Response to antipsychotic treatment;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg11598736	chr3:195384522	SDHAP2	0.71	9.87	0.42	5.77e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs2548003	0.901	rs2433287	chr5:28730737	T/A	cg12623145	chr2:97778927	ANKRD36	0.46	6.94	0.31	1.32e-11	Hip geometry;
LGG	cis	rs4727027	0.933	rs6955564	chr7:148866173	A/G	cg23583168	chr7:148888333	NA	-0.84	-16.38	-0.61	6.4e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1371867	0.817	rs1660314	chr8:101332953	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.7e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12780845	0.540	rs2273735	chr10:17216419	T/C	cg01003015	chr10:17271136	VIM	0.41	6.89	0.3	1.82e-11	Homocysteine levels;
LGG	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg00198680	chr16:28758506	NA	0.29	7.14	0.31	3.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.19	-0.32	2.7e-12	Colorectal cancer;
LGG	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg27129171	chr3:47204927	SETD2	0.79	15.33	0.58	3.32e-43	Colorectal cancer;
LGG	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg10513866	chr5:139070639	NA	0.33	6.67	0.3	7.37e-11	Schizophrenia;
LGG	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.64	-0.41	3.58e-20	Triglycerides;
LGG	cis	rs6456156	0.528	rs6936261	chr6:167469676	A/C	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.54e-18	Primary biliary cholangitis;
LGG	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.79	15.1	0.57	3.64e-42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg11360546	chr7:1094263	C7orf50	-0.38	-6.81	-0.3	3.02e-11	Longevity;Endometriosis;
LGG	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg04733989	chr22:42467013	NAGA	-0.59	-10.64	-0.44	8.35e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.5	8.65	0.37	8.56e-17	Longevity;
LGG	cis	rs6723226	0.803	rs176415	chr2:32649778	G/A	cg02381751	chr2:32503542	YIPF4	-0.74	-12.6	-0.51	1.68e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10214930	0.697	rs11973492	chr7:27680389	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.83	0.3	2.67e-11	Hypospadias;
LGG	cis	rs2839186	0.508	rs12626873	chr21:47714848	G/T	cg12516959	chr21:47718080	NA	-0.26	-6.78	-0.3	3.73e-11	Testicular germ cell tumor;
LGG	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg03929089	chr4:120376271	NA	-0.61	-11.0	-0.46	3.74e-25	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs10504073	0.647	rs10957357	chr8:49988587	C/A	cg00325661	chr8:49890786	NA	0.73	14.08	0.55	1.03e-37	Blood metabolite ratios;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg11062466	chr8:58055876	NA	0.5	8.65	0.37	8.45e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs368123	1.000	rs402387	chr6:160723397	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.25e-12	Waist circumference;
LGG	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06634786	chr22:41940651	POLR3H	-0.65	-10.9	-0.45	8.88e-25	Vitiligo;
LGG	cis	rs2486288	0.656	rs2461705	chr15:45570241	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.87	-0.45	1.12e-24	Glomerular filtration rate;
LGG	cis	rs300774	0.925	rs6732024	chr2:148410	A/G	cg04617936	chr2:214353	NA	-0.5	-7.49	-0.33	3.48e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs6445975	0.956	rs7612923	chr3:58374433	A/G	cg24175188	chr3:58374923	PXK	-0.52	-9.57	-0.41	6.31e-20	Systemic lupus erythematosus;
LGG	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg00405596	chr8:11794950	NA	-0.42	-6.94	-0.31	1.37e-11	Mood instability;
LGG	cis	rs988958	0.565	rs6752667	chr2:42235445	G/A	cg19376973	chr2:42229025	NA	0.63	9.22	0.39	1.05e-18	Hypospadias;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.58	0.33	1.84e-13	Lung cancer;
LGG	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg05729581	chr11:3078854	CARS	-0.54	-9.39	-0.4	2.83e-19	Longevity;
LGG	trans	rs6598955	0.572	rs12089219	chr1:26638751	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.19	-0.49	7.83e-30	Obesity-related traits;
LGG	cis	rs2298450	0.654	rs9984891	chr21:37626379	A/G	cg02919814	chr21:37666008	DOPEY2	-0.44	-7.97	-0.35	1.23e-14	Schizophrenia;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg00933542	chr6:150070202	PCMT1	0.4	7.16	0.32	3.25e-12	Lung cancer;
LGG	cis	rs6840360	0.582	rs4696259	chr4:152310788	A/G	cg25486957	chr4:152246857	NA	-0.37	-6.7	-0.3	6.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg16096631	chr1:42092165	HIVEP3	0.47	10.92	0.45	7.16e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg05874882	chr4:1763078	NA	-0.47	-6.74	-0.3	4.82e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-7.97	-0.35	1.22e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.59	0.33	1.83e-13	Cystic fibrosis severity;
LGG	cis	rs2865126	0.818	rs1881088	chr18:10765792	C/G	cg21165219	chr18:10698044	FAM38B	-0.46	-7.44	-0.33	4.95e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs12586317	0.513	rs74564132	chr14:35472882	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg05993512	chr16:66600025	CMTM1;CKLF	0.37	6.72	0.3	5.51e-11	Menarche (age at onset);
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg01059449	chr18:44338099	ST8SIA5	0.36	7.87	0.34	2.49e-14	Personality dimensions;
LGG	cis	rs35425515	0.706	rs4919069	chr10:98861084	A/G	cg09122387	chr10:98855762	SLIT1	-0.71	-9.42	-0.4	2.19e-19	Bipolar disorder;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg11050988	chr7:1952600	MAD1L1	-0.36	-8.44	-0.37	4.06e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.21	0.43	3.36e-22	Motion sickness;
LGG	cis	rs4728302	0.559	rs12707093	chr7:133200817	C/T	cg10665199	chr7:133106180	EXOC4	0.57	9.44	0.4	1.88e-19	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	9.36	0.4	3.61e-19	Obesity-related traits;
LGG	cis	rs1018836	0.828	rs4140679	chr8:91584269	A/C	cg16814680	chr8:91681699	NA	-0.76	-13.79	-0.54	1.8e-36	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg18404041	chr3:52824283	ITIH1	0.59	11.31	0.47	2.33e-26	Bipolar disorder;
LGG	cis	rs3126085	0.877	rs868304	chr1:152178568	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.41	-0.36	5.16e-16	Skin colour saturation;
LGG	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.55	-9.86	-0.42	6.11e-21	Height;
LGG	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg01448562	chr3:133502909	NA	-0.46	-7.93	-0.35	1.6e-14	Iron status biomarkers;
LGG	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-8.19	-0.36	2.53e-15	Ovarian reserve;
LGG	cis	rs3820068	0.705	rs6656907	chr1:15896984	A/G	cg05660106	chr1:15850417	CASP9	1.12	24.45	0.75	2.14e-85	Systolic blood pressure;
LGG	trans	rs1997103	1.000	rs4948012	chr7:55412578	A/C	cg20935933	chr6:143382018	AIG1	0.54	8.48	0.37	3.13e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3740909	1.000	rs56706815	chr11:125886162	A/G	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs7572733	0.935	rs1914690	chr2:198809368	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.2	0.36	2.44e-15	Dermatomyositis;
LGG	cis	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg18252515	chr7:66147081	NA	-1.35	-18.83	-0.66	3.93e-59	Diabetic kidney disease;
LGG	cis	rs4509693	0.941	rs7914169	chr10:102495725	A/G	cg24179445	chr10:102496915	NA	0.38	7.06	0.31	6.14e-12	Alzheimer's disease;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	16.37	0.61	7.29e-48	Platelet count;
LGG	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg04450456	chr4:17643702	FAM184B	0.32	6.85	0.3	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs935334	1.000	rs6574278	chr14:76663838	T/C	cg14073839	chr14:76668648	C14orf118	-0.42	-7.01	-0.31	8.63e-12	Blood pressure;
LGG	cis	rs1003719	0.628	rs2252402	chr21:38520720	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.66	11.82	0.48	2.29e-28	Eye color traits;
LGG	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg06212747	chr3:49208901	KLHDC8B	0.65	11.14	0.46	1.03e-25	Parkinson's disease;
LGG	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Vitiligo;
LGG	cis	rs9308433	0.529	rs11120298	chr1:214500620	A/G	cg06198575	chr1:214491504	SMYD2	0.51	7.73	0.34	6.55e-14	IgG glycosylation;
LGG	cis	rs829661	0.947	rs829665	chr2:30724701	T/A	cg17749961	chr2:30669863	LCLAT1	1.21	12.68	0.51	7.79e-32	Midgestational circulating levels of PBDEs (fetal genetic effect);
LGG	cis	rs2282300	0.739	rs3858428	chr11:30296550	T/C	cg25418670	chr11:30344373	C11orf46	0.55	7.75	0.34	5.91e-14	Morning vs. evening chronotype;
LGG	cis	rs7590720	1.000	rs7559031	chr2:216902583	A/G	cg12620499	chr2:216877984	MREG	0.77	14.16	0.55	4.32e-38	Alcohol dependence;
LGG	cis	rs1909881	1.000	rs9297960	chr8:96517498	T/C	cg04203453	chr8:96504381	NA	-1.09	-18.61	-0.65	3.96e-58	Obesity-related traits;
LGG	cis	rs250677	0.958	rs10056942	chr5:148416114	C/A	cg18129178	chr5:148520854	ABLIM3	-0.41	-6.92	-0.31	1.47e-11	Breast cancer;
LGG	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg08807101	chr21:30365312	RNF160	-0.91	-19.31	-0.67	2.35e-61	Dental caries;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg18402987	chr7:1209562	NA	0.67	9.32	0.4	4.69e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg26384229	chr12:38710491	ALG10B	0.95	20.31	0.69	4.62e-66	Bladder cancer;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs4566357	0.787	rs6748048	chr2:227822440	T/C	cg11843606	chr2:227700838	RHBDD1	-0.47	-8.09	-0.35	5.18e-15	Coronary artery disease;
LGG	cis	rs1816752	0.837	rs7324645	chr13:25000855	A/G	cg22771759	chr13:24902376	NA	0.41	7.03	0.31	7.41e-12	Obesity-related traits;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.67e-14	Life satisfaction;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg02018176	chr4:1364513	KIAA1530	0.34	7.5	0.33	3.38e-13	Obesity-related traits;
LGG	cis	rs35740288	0.770	rs62022909	chr15:86207481	A/G	cg07943548	chr15:86304357	KLHL25	-0.34	-6.83	-0.3	2.73e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg23173402	chr1:227635558	NA	0.61	10.15	0.43	5.51e-22	Major depressive disorder;
LGG	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg06153925	chr17:78755379	RPTOR	0.39	6.71	0.3	5.67e-11	Myopia (pathological);
LGG	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.75	-0.34	5.89e-14	Cognitive test performance;
LGG	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.4	-0.33	6.52e-13	Fear of minor pain;
LGG	cis	rs868036	0.681	rs4548812	chr15:68060552	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.37	-0.36	6.73e-16	Restless legs syndrome;
LGG	trans	rs6787172	0.702	rs827098	chr3:157996727	T/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs1801251	1.000	rs283476	chr2:233650168	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.6	0.47	1.75e-27	Coronary artery disease;
LGG	cis	rs7747724	0.785	rs4710944	chr6:20744727	C/T	cg13405222	chr6:20811065	CDKAL1	0.42	7.84	0.34	3.18e-14	Bladder cancer;
LGG	cis	rs2386661	0.826	rs7073741	chr10:5671213	G/A	cg26603656	chr10:5671107	NA	0.37	7.6	0.33	1.62e-13	Breast cancer;
LGG	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.36	-0.4	3.46e-19	Aortic root size;
LGG	cis	rs2117029	0.521	rs11168910	chr12:49586490	C/T	cg24176009	chr12:49580217	TUBA1A	0.61	11.72	0.48	5.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs4919044	0.808	rs55856996	chr10:94808618	T/G	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg23782820	chr8:58130467	NA	0.54	7.49	0.33	3.49e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg14088196	chr11:70211408	PPFIA1	0.96	12.94	0.52	6.62e-33	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.55e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.13e-16	Eye color traits;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.61	0.33	1.58e-13	Educational attainment;
LGG	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.74	0.54	2.88e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg08305652	chr11:111469057	NA	0.42	8.33	0.36	8.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs708547	0.874	rs781551	chr4:57718406	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.27	-0.32	1.57e-12	Response to bleomycin (chromatid breaks);
LGG	cis	rs9911578	0.817	rs304264	chr17:56749628	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-9.96	-0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg11502198	chr6:26597334	ABT1	0.7	12.68	0.51	7.88e-32	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs2154319	0.887	rs4660500	chr1:41524669	G/A	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.84	-0.38	1.98e-17	Height;
LGG	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.09	0.39	2.88e-18	Rheumatoid arthritis;
LGG	cis	rs10992471	0.756	rs2516568	chr9:95187380	A/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.46	-7.35	-0.32	8.77e-13	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs7143963	0.609	rs57521303	chr14:103361937	T/C	cg23020514	chr14:103360112	TRAF3	0.38	7.76	0.34	5.64e-14	Body mass index;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05025164	chr4:1340916	KIAA1530	-0.7	-13.32	-0.53	1.63e-34	Obesity-related traits;
LGG	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg25486957	chr4:152246857	NA	-0.49	-8.09	-0.35	5.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs7194570	chr16:48672986	A/G	cg04672837	chr16:48644449	N4BP1	-0.5	-7.73	-0.34	6.66e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	6.15e-38	Bladder cancer;
LGG	cis	rs4774830	0.744	rs12900655	chr15:56151306	T/A	cg05129572	chr15:56138634	NEDD4	-0.86	-8.01	-0.35	9.29e-15	Delta-5 desaturase activity;
LGG	cis	rs9397585	0.824	rs7750557	chr6:153390496	A/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21637282	chr17:45000248	GOSR2	0.44	6.7	0.3	6e-11	Gut microbiome composition (summer);
LGG	cis	rs11229555	0.645	rs11229427	chr11:58180275	A/C	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	9.99	0.42	2.06e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.73	-0.34	6.56e-14	Restless legs syndrome;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg01879757	chr17:41196368	BRCA1	-0.39	-8.05	-0.35	7.25e-15	Menopause (age at onset);
LGG	cis	rs4650994	1.000	rs4076205	chr1:178534157	G/A	cg12486710	chr1:178512616	C1orf220	0.4	8.13	0.35	3.93e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs877282	0.583	rs12356155	chr10:823940	C/T	cg01169559	chr10:831247	NA	0.52	9.17	0.39	1.55e-18	Uric acid levels;
LGG	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg02002194	chr4:3960332	NA	0.42	7.69	0.34	9.07e-14	Neuroticism;
LGG	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-7.91	-0.35	1.91e-14	Inflammatory skin disease;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg07511668	chr11:68622177	NA	0.48	9.15	0.39	1.75e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4262150	0.544	rs56028813	chr5:151915830	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.46	-0.47	5.9e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs12410462	0.551	rs16848029	chr1:227845283	C/A	cg23173402	chr1:227635558	NA	0.35	6.65	0.3	8.38e-11	Major depressive disorder;
LGG	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Colorectal cancer;
LGG	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.99	0.35	1.05e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg22906224	chr7:99728672	NA	0.55	8.97	0.38	7.56e-18	Coronary artery disease;
LGG	cis	rs4538187	0.851	rs35960986	chr2:64221195	G/A	cg02541582	chr2:64069798	UGP2	-0.61	-14.37	-0.56	5.48e-39	Systolic blood pressure;
LGG	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-9.82	-0.42	8.75e-21	Diabetic retinopathy;
LGG	cis	rs1691799	0.867	rs1168338	chr12:66759369	T/C	cg16791601	chr12:66731901	HELB	-0.66	-15.54	-0.59	4.04e-44	White blood cell count (basophil);
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg12708336	chr17:41446283	NA	-0.3	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.22	0.7	2.57e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg05059571	chr16:84539110	KIAA1609	0.41	7.52	0.33	2.86e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7100689	0.598	rs2342815	chr10:82086532	T/C	cg01528321	chr10:82214614	TSPAN14	0.82	14.65	0.56	3.21e-40	Post bronchodilator FEV1;
LGG	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-9.9	-0.42	4.4e-21	Colorectal cancer;
LGG	cis	rs4363385	0.747	rs885096	chr1:152971313	T/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.87e-18	Inflammatory skin disease;
LGG	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg09904177	chr6:26538194	HMGN4	0.38	6.81	0.3	3.05e-11	Schizophrenia;
LGG	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	5.9e-15	Retinal vascular caliber;
LGG	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg24565620	chr2:194026	NA	0.65	10.26	0.43	2.2e-22	Blood protein levels;
LGG	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.64	-0.44	8.52e-24	Intelligence (multi-trait analysis);
LGG	cis	rs752010	1.000	rs4999015	chr1:42093547	G/A	cg16096631	chr1:42092165	HIVEP3	0.7	18.48	0.65	1.56e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.81	-0.48	2.64e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs9705909	chr12:34576419	G/C	cg26384229	chr12:38710491	ALG10B	0.96	20.85	0.7	1.49e-68	Morning vs. evening chronotype;
LGG	cis	rs6500395	1.000	rs8052640	chr16:48604096	G/T	cg04672837	chr16:48644449	N4BP1	0.54	9.02	0.39	4.92e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.69	0.45	5.28e-24	Neuroticism;
LGG	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	cis	rs10170846	0.893	rs11692810	chr2:223544096	A/C	cg25565276	chr2:223520875	FARSB	-0.63	-10.83	-0.45	1.67e-24	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-7.88	-0.34	2.39e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	trans	rs73198271	0.729	rs11786474	chr8:8605492	T/C	cg16141378	chr3:129829833	LOC729375	0.37	6.73	0.3	5.14e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg04824913	chr4:887549	GAK	0.43	7.42	0.33	5.76e-13	Sjögren's syndrome;
LGG	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg00012203	chr2:219082015	ARPC2	-0.75	-14.39	-0.56	4.47e-39	Colorectal cancer;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.93	-0.35	1.64e-14	Personality dimensions;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09476347	chr16:613343	C16orf11	-0.38	-6.87	-0.3	2.03e-11	Height;
LGG	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg16141378	chr3:129829833	LOC729375	0.32	7.28	0.32	1.48e-12	Monocyte count;
LGG	trans	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg18187862	chr3:45730750	SACM1L	-0.43	-7.04	-0.31	6.85e-12	Primary sclerosing cholangitis;
LGG	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.24	-0.32	1.84e-12	Caffeine consumption;
LGG	cis	rs73787773	0.867	rs75705984	chr5:111487993	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.21	-0.36	2.24e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs77633900	0.614	rs2439982	chr15:76925071	T/G	cg21673338	chr15:77095150	SCAPER	-0.65	-10.1	-0.43	7.96e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg01678292	chr8:41522873	ANK1	0.35	8.21	0.36	2.19e-15	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs9372253	1.000	rs7740028	chr6:110719180	A/G	cg01119278	chr6:110721349	DDO	-0.3	-7.16	-0.32	3.23e-12	Platelet distribution width;
LGG	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.69	0.41	2.41e-20	Bipolar disorder;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg19300475	chr17:27230118	DHRS13	-0.4	-7.0	-0.31	8.89e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.46	-0.37	3.64e-16	Mood instability;
LGG	cis	rs1754541	1.000	rs1754542	chr1:101625861	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.37	-6.72	-0.3	5.51e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	0.41	7.0	0.31	9.1e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2274273	0.805	rs60972460	chr14:55571773	A/T	cg04306507	chr14:55594613	LGALS3	0.64	17.47	0.63	7.21e-53	Protein biomarker;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.11	-0.31	4.42e-12	Monocyte percentage of white cells;
LGG	cis	rs887829	0.570	rs11680450	chr2:234597483	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.36	0.32	8.38e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10782582	0.593	rs115291524	chr1:76141811	A/G	cg10523679	chr1:76189770	ACADM	-0.43	-6.88	-0.3	1.98e-11	Daytime sleep phenotypes;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg16339924	chr4:17578868	LAP3	0.64	10.95	0.45	5.61e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11245990	chr11:68621969	NA	0.41	8.58	0.37	1.42e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2320614	0.806	rs17471740	chr4:164100276	C/T	cg15586945	chr4:164088095	NAF1	-0.47	-8.05	-0.35	6.89e-15	Lung adenocarcinoma;
LGG	trans	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.92	-0.35	1.81e-14	Resting heart rate;
LGG	trans	rs2562456	0.833	rs55899865	chr19:21481735	G/A	cg00806126	chr19:22604979	ZNF98	-0.56	-7.33	-0.32	1.04e-12	Pain;
LGG	cis	rs876084	0.505	rs11985173	chr8:121107511	G/A	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11150038	0.623	rs62044976	chr16:78018712	G/A	cg04733911	chr16:78082701	NA	0.58	7.44	0.33	5.08e-13	Colorectal or endometrial cancer;
LGG	cis	rs787274	1.000	rs787291	chr9:115507904	A/T	cg13803584	chr9:115635662	SNX30	0.57	7.11	0.31	4.35e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg02275930	chr1:2372054	NA	-0.64	-14.33	-0.55	7.96e-39	Schizophrenia;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg13047869	chr3:10149882	C3orf24	0.6	8.46	0.37	3.42e-16	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.12	-0.31	4.13e-12	Lung cancer;
LGG	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg03433033	chr1:76189801	ACADM	0.79	12.79	0.51	2.72e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg11301795	chr4:187892539	NA	0.92	22.39	0.72	9.26e-76	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6764363	0.527	rs4684332	chr3:278420	A/G	cg02057681	chr3:285234	CHL1	-0.42	-7.57	-0.33	2.1e-13	Sudden cardiac arrest;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.48	-0.5	5.23e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs721399	0.706	rs6997340	chr8:18286997	C/T	cg18736775	chr8:18248649	NAT2	-0.41	-7.25	-0.32	1.75e-12	Blood metabolite levels;
LGG	cis	rs9815354	1.000	rs56776628	chr3:41866856	A/G	cg03022575	chr3:42003672	ULK4	0.68	8.67	0.37	7.32e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg20637307	chr2:213403960	ERBB4	0.75	16.9	0.62	3.06e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9487094	0.885	rs59906308	chr6:109759552	G/A	cg01125227	chr6:109776195	MICAL1	0.55	9.2	0.39	1.24e-18	Height;
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	6.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08645402	chr16:4508243	NA	0.54	9.87	0.42	5.45e-21	Schizophrenia;
LGG	trans	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.92	0.35	1.73e-14	Obesity-related traits;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg13009111	chr11:71350975	NA	-0.32	-6.99	-0.31	9.62e-12	Neuroticism;
LGG	cis	rs11096990	1.000	rs11096990	chr4:39286949	A/G	cg24403649	chr4:39172243	NA	0.42	6.86	0.3	2.15e-11	Cognitive function;
LGG	cis	rs11098499	0.909	rs71614422	chr4:120359340	G/A	cg09307838	chr4:120376055	NA	0.82	13.72	0.54	3.33e-36	Corneal astigmatism;
LGG	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg00666640	chr1:248458726	OR2T12	0.58	9.39	0.4	2.76e-19	Common traits (Other);
LGG	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.49e-12	Hip circumference adjusted for BMI;
LGG	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs2050392	0.760	rs10826797	chr10:30690376	A/C	cg25182066	chr10:30743637	MAP3K8	-0.58	-12.34	-0.5	1.95e-30	Inflammatory bowel disease;
LGG	cis	rs2247341	0.965	rs13138643	chr4:1740675	G/A	cg05026014	chr4:1749153	NA	-0.34	-9.36	-0.4	3.45e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs75059851	0.756	rs11223659	chr11:133844708	G/A	cg17703048	chr11:133852993	NA	-0.88	-15.98	-0.6	4.32e-46	Schizophrenia;
LGG	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg09307838	chr4:120376055	NA	0.73	12.4	0.5	1.09e-30	Corneal astigmatism;
LGG	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg26597838	chr10:835615	NA	0.53	6.87	0.3	2.05e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs10214930	0.671	rs6945993	chr7:27681010	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.83	0.3	2.67e-11	Hypospadias;
LGG	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg06623918	chr6:96969491	KIAA0776	-0.73	-11.19	-0.46	7.14e-26	Migraine;Coronary artery disease;
LGG	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg26655873	chr3:72818019	SHQ1	0.36	7.28	0.32	1.48e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs758324	0.898	rs10037928	chr5:131142046	T/C	cg06307176	chr5:131281290	NA	0.53	8.73	0.38	4.57e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7568458	0.709	rs2043675	chr2:85769975	C/T	cg17127132	chr2:85788382	GGCX	-0.52	-8.13	-0.35	3.87e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg13009111	chr11:71350975	NA	0.35	7.48	0.33	3.82e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg23979923	chr15:90777592	C15orf58;CIB1	0.55	7.16	0.32	3.29e-12	Skin pigmentation;
LGG	cis	rs151997	0.962	rs27475	chr5:50180439	A/C	cg06027927	chr5:50259733	NA	0.68	11.16	0.46	8.97e-26	Callous-unemotional behaviour;
LGG	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg03060546	chr3:49711283	APEH	-0.62	-10.08	-0.42	9.67e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg10556349	chr10:835070	NA	-0.31	-7.89	-0.34	2.14e-14	Survival in rectal cancer;
LGG	trans	rs8073060	0.544	rs8071584	chr17:33999435	G/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs782590	0.517	rs13013133	chr2:55889466	G/A	cg18811423	chr2:55921094	PNPT1	-0.66	-10.78	-0.45	2.57e-24	Metabolic syndrome;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.69e-21	Menopause (age at onset);
LGG	trans	rs6828577	0.687	rs56203850	chr4:119454437	C/T	cg26518628	chr1:97050305	NA	-0.54	-8.64	-0.37	9.26e-17	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.24	0.49	4.97e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.96	-17.37	-0.63	2.03e-52	Gut microbiome composition (summer);
LGG	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg15208524	chr1:10270712	KIF1B	0.44	7.71	0.34	7.84e-14	Hepatocellular carcinoma;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.97	0.31	1.1e-11	Schizophrenia;
LGG	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.0	0.39	6.02e-18	Cognitive test performance;
LGG	cis	rs11634851	0.966	rs34887414	chr15:81024204	T/C	cg03950166	chr15:80988613	FAM108C1	-0.36	-6.72	-0.3	5.32e-11	Systolic blood pressure;
LGG	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg26384229	chr12:38710491	ALG10B	-0.64	-12.0	-0.49	4.57e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12617721	0.718	rs1857746	chr2:99017358	A/G	cg18455616	chr2:99124870	INPP4A	0.3	7.74	0.34	6.11e-14	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg10661904	chr17:79619235	PDE6G	-0.4	-8.15	-0.35	3.48e-15	Eye color traits;
LGG	cis	rs9902453	0.808	rs56216220	chr17:28209182	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.0	0.52	3.65e-33	Coffee consumption (cups per day);
LGG	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.38	-7.07	-0.31	5.6e-12	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg07511668	chr11:68622177	NA	0.5	9.66	0.41	3.22e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg11764359	chr7:65958608	NA	0.63	10.96	0.45	5.41e-25	Aortic root size;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	1.02e-16	Lung cancer;
LGG	cis	rs10744422	1.000	rs2292134	chr12:123334033	C/G	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	4.96e-19	Schizophrenia;
LGG	cis	rs2120019	0.508	rs8030528	chr15:75171825	C/T	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.04	-0.46	2.53e-25	Blood trace element (Zn levels);
LGG	cis	rs698833	0.538	rs1067396	chr2:44637738	A/G	cg00619915	chr2:44497795	NA	-0.48	-6.83	-0.3	2.62e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.34	-0.32	9.76e-13	Lung cancer;
LGG	cis	rs10937275	1.000	rs35102841	chr3:186649683	A/G	cg13419791	chr3:186648285	ST6GAL1	0.79	8.09	0.35	5.42e-15	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.9	-0.31	1.67e-11	Schizophrenia;
LGG	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg03098644	chr7:100410630	EPHB4	0.47	7.2	0.32	2.5e-12	Other erythrocyte phenotypes;
LGG	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg11871910	chr12:69753446	YEATS4	-0.73	-14.51	-0.56	1.33e-39	Blood protein levels;
LGG	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.09	0.35	5.39e-15	Iron status biomarkers;
LGG	cis	rs7241530	0.662	rs34015835	chr18:75905509	A/C	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21921996	chr20:55685638	NA	0.39	6.74	0.3	4.76e-11	Pancreatic cancer;
LGG	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.56	0.33	2.18e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.44	-0.33	4.85e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.82	-0.59	2.34e-45	Tonsillectomy;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	6.73	0.3	5.07e-11	Neuroticism;
LGG	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs738322	0.753	rs5756968	chr22:38595240	C/T	cg03162506	chr22:38580953	NA	-0.41	-10.75	-0.45	3.29e-24	Cutaneous nevi;
LGG	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg06212747	chr3:49208901	KLHDC8B	0.65	11.19	0.46	6.93e-26	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.8	0.3	3.3e-11	Lung cancer;
LGG	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg24881330	chr22:46731750	TRMU	0.68	6.69	0.3	6.6e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12410462	0.551	rs753541	chr1:227866483	A/G	cg04117972	chr1:227635322	NA	0.44	8.11	0.35	4.54e-15	Major depressive disorder;
LGG	cis	rs12474201	0.862	rs13025595	chr2:46977893	A/G	cg06386533	chr2:46925753	SOCS5	0.78	14.35	0.55	6.81e-39	Height;
LGG	cis	rs9399135	1.000	rs11754265	chr6:135356216	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.64	0.41	3.76e-20	Red blood cell count;
LGG	cis	rs240764	0.697	rs9485411	chr6:101261352	A/C	cg09795085	chr6:101329169	ASCC3	0.44	7.03	0.31	7.49e-12	Neuroticism;
LGG	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg25566285	chr7:158114605	PTPRN2	0.9	20.12	0.68	3.67e-65	Calcium levels;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.58	-8.67	-0.37	7.52e-17	Platelet count;
LGG	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.94	0.31	1.29e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12282928	0.959	rs871248	chr11:48284258	C/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.09	-0.31	4.96e-12	Migraine - clinic-based;
LGG	cis	rs2587949	0.593	rs795304	chr3:4165062	C/A	cg16519197	chr3:4211558	NA	-0.35	-7.17	-0.32	2.94e-12	Periodontitis (DPAL);
LGG	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg02153584	chr22:29168773	CCDC117	-0.57	-9.2	-0.39	1.21e-18	Lymphocyte counts;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg13009111	chr11:71350975	NA	0.32	7.07	0.31	5.91e-12	Neuroticism;
LGG	cis	rs300774	0.748	rs409657	chr2:129009	C/T	cg04617936	chr2:214353	NA	-0.49	-7.54	-0.33	2.47e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg14019146	chr3:50243930	SLC38A3	-0.31	-6.73	-0.3	5e-11	Body mass index;
LGG	trans	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.63	0.48	1.28e-27	Mean corpuscular volume;
LGG	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.58	-0.41	6.07e-20	Response to amphetamines;
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs9467773	1.000	rs3736782	chr6:26505403	C/A	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.81e-52	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16219178	chr22:29784644	AP1B1	0.46	6.7	0.3	5.91e-11	Gut microbiome composition (summer);
LGG	cis	rs11167764	1.000	rs3761757	chr5:141488219	A/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.89	-0.31	1.8e-11	Crohn's disease;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18402987	chr7:1209562	NA	0.4	7.22	0.32	2.14e-12	Longevity;Endometriosis;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg04267008	chr7:1944627	MAD1L1	-0.48	-8.01	-0.35	9.38e-15	Schizophrenia;
LGG	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15664640	chr17:80829946	TBCD	-0.78	-14.42	-0.56	3.42e-39	Breast cancer;
LGG	cis	rs11225247	0.881	rs75561520	chr11:102263309	A/G	cg06323957	chr11:102217781	BIRC2	0.8	6.81	0.3	3.11e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	9.93	0.42	3.53e-21	Colorectal cancer;
LGG	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg07027305	chr7:2059796	MAD1L1	-0.31	-7.62	-0.33	1.43e-13	Neuroticism;
LGG	cis	rs10504073	0.669	rs341799	chr8:50036574	A/G	cg00325661	chr8:49890786	NA	0.68	13.22	0.52	4.56e-34	Blood metabolite ratios;
LGG	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	13.28	0.53	2.52e-34	Alzheimer's disease;
LGG	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.09	-0.39	3.03e-18	Morning vs. evening chronotype;
LGG	cis	rs7072216	0.727	rs6584199	chr10:100169983	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.83e-12	Metabolite levels;
LGG	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	cg15522984	chr1:182991683	LAMC1	0.45	8.97	0.38	7.34e-18	Colorectal cancer;
LGG	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg01017244	chr2:74357527	NA	0.4	7.08	0.31	5.38e-12	Gestational age at birth (maternal effect);
LGG	cis	rs4948523	0.530	rs67362351	chr10:60306548	C/A	cg07615347	chr10:60278583	BICC1	-0.52	-12.67	-0.51	8.5e-32	Myopia;
LGG	cis	rs754466	0.580	rs1344966	chr10:79534527	T/C	cg17075019	chr10:79541650	NA	-0.98	-21.51	-0.71	1.2e-71	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg03477792	chr4:77819574	ANKRD56	0.52	9.13	0.39	2.13e-18	Emphysema distribution in smoking;
LGG	cis	rs34172651	0.917	rs12599643	chr16:24832693	C/T	cg02428538	chr16:24856791	SLC5A11	-0.43	-7.29	-0.32	1.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.14	0.52	9.77e-34	Prudent dietary pattern;
LGG	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-14.22	-0.55	2.58e-38	Headache;
LGG	cis	rs60180747	1.000	rs74581464	chr15:66760980	T/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	11.08	0.46	1.77e-25	Testicular germ cell tumor;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	0.869	rs2585102	chr15:57331821	G/A	cg08128148	chr15:57256372	TCF12	0.31	7.52	0.33	2.77e-13	Urinary tract infection frequency;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09264088	chr15:63569686	APH1B	-0.42	-7.0	-0.31	9.2e-12	Brain structure;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.63	-10.79	-0.45	2.39e-24	Obesity-related traits;
LGG	cis	rs1505368	0.505	rs12694279	chr2:213253406	C/A	cg20637307	chr2:213403960	ERBB4	0.49	9.38	0.4	2.85e-19	Symmetrical dimethylarginine levels;
LGG	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.17	0.32	2.92e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9815354	1.000	rs2272006	chr3:41997059	C/T	cg03022575	chr3:42003672	ULK4	-0.63	-8.13	-0.35	3.99e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7928758	0.945	rs28625034	chr11:134280504	C/T	cg25213107	chr11:134282864	B3GAT1	0.98	11.51	0.47	4.02e-27	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg16301924	chr13:53314226	LECT1	0.43	8.38	0.36	6.36e-16	Lewy body disease;
LGG	cis	rs703842	1.000	rs11172349	chr12:58212528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.18	0.36	2.8e-15	Multiple sclerosis;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg11473876	chr11:109292803	C11orf87	0.56	10.85	0.45	1.32e-24	Schizophrenia;
LGG	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg26924012	chr15:45694286	SPATA5L1	1.03	21.03	0.7	2.02e-69	Homoarginine levels;
LGG	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.75	-0.64	3.72e-54	Breast cancer;
LGG	cis	rs9341808	0.718	rs9448893	chr6:80837239	A/G	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.84e-14	Sitting height ratio;
LGG	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg11247378	chr22:39784982	NA	-0.31	-9.02	-0.39	5.08e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg12432903	chr7:1882776	MAD1L1	0.45	6.97	0.31	1.11e-11	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00933542	chr6:150070202	PCMT1	0.38	6.91	0.31	1.59e-11	Lung cancer;
LGG	cis	rs7010267	0.712	rs4567065	chr8:120008274	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.38	9.75	0.41	1.51e-20	Total body bone mineral density (age 45-60);
LGG	cis	rs524281	0.814	rs2270448	chr11:65835931	G/T	cg16950941	chr11:66035639	RAB1B	-0.48	-7.18	-0.32	2.88e-12	Electroencephalogram traits;
LGG	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg02297831	chr4:17616191	MED28	-0.49	-8.95	-0.38	8.55e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.74	0.34	6.35e-14	Retinal vascular caliber;
LGG	cis	rs17221829	0.644	rs72971008	chr11:89358706	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg13010199	chr12:38710504	ALG10B	-0.62	-12.52	-0.5	3.63e-31	Morning vs. evening chronotype;
LGG	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.42e-14	Huntington's disease progression;
LGG	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg05973401	chr12:123451056	ABCB9	0.47	7.85	0.34	2.98e-14	Platelet count;
LGG	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg02820901	chr13:113351484	ATP11A	0.6	7.32	0.32	1.08e-12	Glycated hemoglobin levels;
LGG	cis	rs4132509	0.948	rs320322	chr1:243750755	G/A	cg21452805	chr1:244014465	NA	-0.63	-7.48	-0.33	3.66e-13	RR interval (heart rate);
LGG	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.57	-0.33	2e-13	Mean corpuscular hemoglobin;
LGG	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.21	-0.32	2.36e-12	Restless legs syndrome;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.65	-0.44	7.82e-24	Platelet count;
LGG	cis	rs514406	0.861	rs562182	chr1:53270010	C/T	cg24675658	chr1:53192096	ZYG11B	-0.47	-9.3	-0.4	5.52e-19	Monocyte count;
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg06697600	chr4:7070879	GRPEL1	-0.55	-9.69	-0.41	2.37e-20	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.23	-0.36	1.95e-15	Prudent dietary pattern;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04008888	chr11:68622739	NA	-0.56	-11.72	-0.48	5.68e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2548003	1.000	rs2554900	chr5:28739577	A/C	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs78487399	0.710	rs6731998	chr2:43677273	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg05896524	chr21:47604654	C21orf56	0.55	9.62	0.41	4.38e-20	Testicular germ cell tumor;
LGG	cis	rs2795502	0.873	rs3123753	chr10:43404899	C/T	cg20628663	chr10:43360327	NA	0.37	7.36	0.32	8.62e-13	Blood protein levels;
LGG	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg07936489	chr17:37558343	FBXL20	0.85	15.98	0.6	4.2e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg20892847	chr12:58011875	NA	0.34	7.01	0.31	8.32e-12	Multiple sclerosis;
LGG	cis	rs151349	1.000	rs151345	chr20:57586849	G/C	cg23907860	chr20:57583709	CTSZ	-0.47	-9.66	-0.41	3.01e-20	Platelet distribution width;
LGG	cis	rs7539542	0.556	rs2275734	chr1:202887295	C/T	cg19681188	chr1:202830198	LOC148709	0.53	8.9	0.38	1.24e-17	Mean platelet volume;
LGG	cis	rs2249694	1.000	rs1952467	chr10:135353499	T/G	cg20169779	chr10:135381914	SYCE1	0.5	7.63	0.33	1.38e-13	Obesity-related traits;
LGG	cis	rs7582720	1.000	rs78128841	chr2:203663975	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg02018176	chr4:1364513	KIAA1530	0.41	9.19	0.39	1.32e-18	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs1025203	chr4:99023073	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.75	0.34	5.74e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08515713	chr11:64037528	BAD	-0.41	-6.76	-0.3	4.13e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03376183	chr17:61699771	MAP3K3	0.42	6.65	0.3	8.12e-11	Gut microbiome composition (summer);
LGG	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg11161011	chr14:65562177	MAX	-0.65	-12.72	-0.51	5.38e-32	Obesity-related traits;
LGG	cis	rs10484885	0.878	rs72921937	chr6:90579863	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.64	-0.44	8.27e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg06558623	chr16:89946397	TCF25	1.11	12.14	0.49	1.21e-29	Skin colour saturation;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg26174226	chr8:58114915	NA	-0.56	-7.74	-0.34	6.34e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.33	0.32	1.02e-12	Neuroticism;
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.26	-0.32	1.63e-12	Neuroticism;
LGG	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg03929089	chr4:120376271	NA	-1.04	-24.47	-0.75	1.77e-85	Height;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.66	0.41	3.1e-20	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.632	rs10974982	chr9:5149382	G/C	cg02405213	chr9:5042618	JAK2	-0.76	-14.31	-0.55	9.77e-39	Pediatric autoimmune diseases;
LGG	cis	rs897984	0.572	rs112906665	chr16:31040139	T/C	cg02466173	chr16:30829666	NA	-0.44	-7.84	-0.34	3.2e-14	Dementia with Lewy bodies;
LGG	cis	rs7551222	0.752	rs4245737	chr1:204486242	A/G	cg20240347	chr1:204465584	NA	-0.56	-11.5	-0.47	4.3e-27	Schizophrenia;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg14926445	chr8:58193284	C8orf71	-0.83	-10.36	-0.43	9.1e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs836589	0.508	rs12329241	chr2:173568451	A/G	cg06468108	chr2:173539091	NA	-0.48	-8.14	-0.35	3.74e-15	Erectile dysfunction in type 1 diabetes;
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.27	-0.43	2e-22	Neuroticism;
LGG	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg05234568	chr11:5960015	NA	-0.63	-10.92	-0.45	7.38e-25	DNA methylation (variation);
LGG	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.51	-0.37	2.42e-16	Neuroticism;
LGG	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.71	-0.45	4.43e-24	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs367943	0.712	rs255861	chr5:112745327	G/A	cg12552261	chr5:112820674	MCC	0.58	10.45	0.44	4.17e-23	Type 2 diabetes;
LGG	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg18129748	chr3:49941408	MST1R	-0.22	-6.96	-0.31	1.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg06623918	chr6:96969491	KIAA0776	0.72	11.41	0.47	9.35e-27	Migraine;Coronary artery disease;
LGG	cis	rs910187	0.678	rs1046664	chr20:45817223	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-9.21	-0.39	1.11e-18	Migraine;
LGG	cis	rs11627756	0.958	rs2146429	chr14:103071816	A/T	cg12046867	chr14:103022105	NA	-0.41	-7.92	-0.35	1.75e-14	Mean platelet volume;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg17243582	chr15:59969081	BNIP2	-0.39	-6.88	-0.3	2.01e-11	Iris color (L* coordinate);
LGG	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg18252515	chr7:66147081	NA	-0.44	-7.74	-0.34	6.36e-14	Aortic root size;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19723775	chr5:179050963	HNRNPH1	0.45	7.48	0.33	3.86e-13	Lung cancer;
LGG	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.78	0.66	6.45e-59	Smoking behavior;
LGG	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.64	-0.33	1.28e-13	Blood metabolite levels;
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.04	-0.42	1.37e-21	Total body bone mineral density;
LGG	cis	rs6071166	0.774	rs6027213	chr20:37305421	G/T	cg10737118	chr20:37354790	SLC32A1	-0.39	-6.65	-0.3	8.04e-11	circulating leptin levels adjusted for BMI;circulating leptin levels;
LGG	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg11477892	chr4:106580295	NA	-0.42	-6.89	-0.3	1.87e-11	Post bronchodilator FEV1;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg02353165	chr6:42928485	GNMT	0.51	15.74	0.59	5.09e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	8.1	0.35	4.94e-15	Iron status biomarkers;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs7215564	0.543	rs57677341	chr17:78514637	A/G	cg16980736	chr17:78789706	RPTOR	-0.54	-7.39	-0.32	6.92e-13	Myopia (pathological);
LGG	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.18	0.39	1.38e-18	Diabetic retinopathy;
LGG	cis	rs774359	0.797	rs774353	chr9:27516436	C/G	cg14173147	chr9:27528300	MOBKL2B	0.43	9.01	0.39	5.58e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs10267417	0.535	rs12530927	chr7:19949960	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	6.81	0.3	3.01e-11	Night sleep phenotypes;
LGG	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg17376030	chr22:41985996	PMM1	-0.56	-9.03	-0.39	4.47e-18	Vitiligo;
LGG	cis	rs4253772	0.626	rs9615960	chr22:46752307	G/A	cg09461388	chr22:46763229	CELSR1	-0.73	-7.13	-0.31	3.96e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.13	0.39	2.16e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.45	-0.37	3.86e-16	Personality dimensions;
LGG	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6988985	0.560	rs4736343	chr8:143933200	G/A	cg10324643	chr8:143916377	GML	0.4	7.96	0.35	1.36e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7666738	0.830	rs2865951	chr4:99040191	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.96	0.35	1.35e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg17971929	chr21:40555470	PSMG1	0.88	17.46	0.63	7.98e-53	Cognitive function;
LGG	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs7107174	1.000	rs10899479	chr11:78052539	A/G	cg02023728	chr11:77925099	USP35	0.46	7.93	0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg04362960	chr10:104952993	NT5C2	0.56	10.22	0.43	3.08e-22	Arsenic metabolism;
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.68e-18	Alzheimer's disease;
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.29	-0.36	1.26e-15	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07405021	chr5:115152019	CDO1	0.41	6.9	0.31	1.74e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12282928	0.959	rs4980427	chr11:48296486	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.13	-0.31	3.96e-12	Migraine - clinic-based;
LGG	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.23	-0.36	1.99e-15	Calcium levels;
LGG	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg01221209	chr5:554886	NA	-0.48	-7.7	-0.34	8.35e-14	Obesity-related traits;
LGG	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg04733989	chr22:42467013	NAGA	0.6	10.24	0.43	2.56e-22	Schizophrenia;
LGG	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.15	-0.35	3.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg12661370	chr5:149340060	SLC26A2	0.51	8.48	0.37	3.05e-16	HIV-1 control;
LGG	cis	rs9547996	1.000	rs9548000	chr13:38224053	A/G	cg17979426	chr13:38220150	TRPC4	-0.48	-9.0	-0.39	5.99e-18	Diastolic blood pressure;
LGG	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.13e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1395	0.778	rs11693660	chr2:27468856	T/C	cg23587288	chr2:27483067	SLC30A3	-0.3	-6.76	-0.3	4.12e-11	Blood metabolite levels;
LGG	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28829049	0.597	rs2313509	chr1:19437860	C/T	cg13387374	chr1:19411106	UBR4	0.38	6.82	0.3	2.94e-11	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.62	-0.37	1.1e-16	Alzheimer's disease (survival time);
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07167872	chr1:205819463	PM20D1	-0.56	-11.46	-0.47	5.91e-27	Menarche (age at onset);
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg25726756	chr21:47582351	C21orf56	-0.32	-6.91	-0.31	1.59e-11	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13872356	chr11:62341519	EEF1G	0.43	6.86	0.3	2.22e-11	Cognitive performance;
LGG	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg13939156	chr17:80058883	NA	0.55	11.26	0.46	3.82e-26	Life satisfaction;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.69e-12	Lung cancer;
LGG	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg26384229	chr12:38710491	ALG10B	-0.95	-21.01	-0.7	2.55e-69	Morning vs. evening chronotype;
LGG	cis	rs9677476	0.779	rs7569597	chr2:232102754	G/A	cg23338755	chr2:231921595	PSMD1	0.48	6.64	0.3	8.6e-11	Food antigen IgG levels;
LGG	cis	rs7927771	0.524	rs12421563	chr11:47780222	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-10.93	-0.45	6.72e-25	Subjective well-being;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.89	-0.31	1.78e-11	Total body bone mineral density;
LGG	cis	rs11601602	0.576	rs4075635	chr11:28511643	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	9.97	0.42	2.41e-21	Obesity-related traits;
LGG	cis	rs1670533	0.872	rs10017931	chr4:1060747	G/A	cg27284194	chr4:1044797	NA	0.56	10.2	0.43	3.48e-22	Recombination rate (females);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.66	13.5	0.53	3.03e-35	Obesity-related traits;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg06112835	chr11:68658793	MRPL21	0.41	7.29	0.32	1.39e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9393777	0.844	rs28360634	chr6:27332891	T/C	cg01620082	chr3:125678407	NA	-0.99	-9.37	-0.4	3.2e-19	Intelligence (multi-trait analysis);
LGG	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-11.99	-0.49	4.71e-29	Parkinson's disease;
LGG	cis	rs4951018	0.887	rs3761916	chr1:205630893	A/G	cg14893161	chr1:205819251	PM20D1	-0.38	-7.02	-0.31	8.06e-12	Prostate-specific antigen levels;
LGG	cis	rs7216064	0.817	rs12601921	chr17:65825354	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.52	-0.37	2.19e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg10483660	chr13:112241077	NA	0.34	6.76	0.3	4.27e-11	Menarche (age at onset);
LGG	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg19680485	chr15:31195859	MTMR15	-0.45	-7.23	-0.32	1.96e-12	Huntington's disease progression;
LGG	trans	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg26384229	chr12:38710491	ALG10B	0.76	14.12	0.55	6.89e-38	Resting heart rate;
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg03162506	chr22:38580953	NA	-0.42	-11.02	-0.46	3.12e-25	Cutaneous nevi;
LGG	cis	rs3099143	1.000	rs3106378	chr15:77110524	A/C	cg21673338	chr15:77095150	SCAPER	-0.64	-10.36	-0.43	9.38e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs7647973	0.560	rs77473999	chr3:49777660	T/C	cg03060546	chr3:49711283	APEH	-0.62	-8.25	-0.36	1.7e-15	Menarche (age at onset);
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg12458913	chr13:53173898	NA	1.03	25.51	0.76	2.86e-90	Lewy body disease;
LGG	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg01280390	chr8:19363452	CSGALNACT1	0.47	11.99	0.49	5.05e-29	Oropharynx cancer;
LGG	trans	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg27661571	chr11:113659931	NA	0.58	7.87	0.34	2.57e-14	Hip circumference adjusted for BMI;
LGG	cis	rs8114671	0.836	rs4911461	chr20:33629993	A/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg12432903	chr7:1882776	MAD1L1	0.45	6.98	0.31	1.02e-11	Neuroticism;
LGG	cis	rs4740619	0.507	rs7470881	chr9:15814756	G/A	cg14451791	chr9:16040625	NA	0.32	7.84	0.34	3.23e-14	Body mass index;
LGG	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg00149659	chr3:10157352	C3orf10	0.55	8.11	0.35	4.48e-15	Alzheimer's disease;
LGG	cis	rs2235649	0.833	rs9922139	chr16:1848329	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg08461457	chr11:2027003	NA	0.43	8.2	0.36	2.35e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7091068	0.706	rs1147645	chr10:95401241	C/G	cg20715218	chr10:95462985	C10orf4	-0.57	-7.64	-0.33	1.23e-13	Urinary tract infection frequency;
LGG	cis	rs4622507	0.618	rs2388876	chr16:55059283	C/T	cg09947736	chr16:55091198	NA	0.77	11.15	0.46	9.6e-26	Social communication problems;
LGG	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.33e-18	Blood metabolite levels;
LGG	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg01200585	chr1:228362443	C1orf69	0.46	7.97	0.35	1.21e-14	Diastolic blood pressure;
LGG	cis	rs12282928	1.000	rs7107408	chr11:48291558	T/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.22	-0.32	2.14e-12	Migraine - clinic-based;
LGG	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs62400317	0.859	rs56283067	chr6:45100330	T/C	cg18551225	chr6:44695536	NA	-0.62	-9.69	-0.41	2.44e-20	Total body bone mineral density;
LGG	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg05163923	chr11:71159392	DHCR7	-0.55	-7.98	-0.35	1.13e-14	Vitamin D levels;
LGG	cis	rs4924544	1	rs4924544	chr15:41693455	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.83	-0.38	2.2e-17	Eosinophil percentage of white cells;
LGG	cis	rs7129220	0.588	rs72860548	chr11:10128679	C/G	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg11494091	chr17:61959527	GH2	0.6	10.08	0.42	1.02e-21	Height;
LGG	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg21665744	chr7:39171113	POU6F2	0.35	6.89	0.31	1.81e-11	IgG glycosylation;
LGG	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.27	0.32	1.52e-12	Height;
LGG	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.63	-0.33	1.3e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg22681709	chr2:178499509	PDE11A	-0.43	-7.92	-0.35	1.78e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7666738	0.830	rs17027058	chr4:98864671	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.27	0.36	1.43e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg07005078	chr4:17578674	LAP3	-0.37	-6.84	-0.3	2.48e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg18942110	chr15:91072797	CRTC3	-0.3	-6.92	-0.31	1.54e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg06453172	chr10:134556979	INPP5A	-0.57	-8.41	-0.36	5.07e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2836974	0.931	rs12151994	chr21:40690397	A/C	cg17971929	chr21:40555470	PSMG1	0.84	15.91	0.59	8.94e-46	Cognitive function;
LGG	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.51	0.5	3.8e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6964587	0.869	rs6946764	chr7:91539003	A/G	cg17063962	chr7:91808500	NA	-0.42	-7.41	-0.33	5.99e-13	Breast cancer;
LGG	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.85	-9.37	-0.4	3.19e-19	Diabetic retinopathy;
LGG	cis	rs6977660	1.000	rs10240227	chr7:19823188	T/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.83e-13	Thyroid stimulating hormone;
LGG	cis	rs10463554	0.963	rs34380	chr5:102396949	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg04240660	chr16:89714849	CHMP1A	0.4	7.06	0.31	6.16e-12	Hemoglobin concentration;
LGG	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.69	0.3	6.38e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg21724239	chr8:58056113	NA	0.49	7.29	0.32	1.35e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg04156418	chr7:157293606	NA	-0.57	-13.16	-0.52	7.66e-34	Inattentive symptoms;
LGG	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22857025	chr5:266934	NA	-1.29	-13.45	-0.53	4.96e-35	Breast cancer;
LGG	cis	rs4764124	0.616	rs2052325	chr12:14948434	C/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.53	9.77	0.41	1.3e-20	Pubertal anthropometrics;
LGG	trans	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg16011800	chr17:1958478	HIC1	0.62	9.49	0.4	1.22e-19	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg10144569	chr3:42726640	KBTBD5	0.49	7.0	0.31	8.92e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg00564723	chr10:75632066	CAMK2G	0.32	7.2	0.32	2.48e-12	Inflammatory bowel disease;
LGG	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg03929089	chr4:120376271	NA	-0.86	-17.36	-0.63	2.35e-52	Coronary artery disease;
LGG	cis	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	8.77e-26	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg05313129	chr8:58192883	C8orf71	-0.61	-8.33	-0.36	9.49e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs1580019	0.844	rs1376290	chr7:32486922	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	16.03	0.6	2.42e-46	Cognitive ability;
LGG	cis	rs1056053	0.514	rs3127329	chr6:166572362	G/A	cg11088901	chr6:166572345	T	-0.52	-9.95	-0.42	2.88e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9309473	0.632	rs11885217	chr2:73553208	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-8.46	-0.37	3.48e-16	Metabolite levels;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.8	-0.45	2.17e-24	Longevity;Endometriosis;
LGG	cis	rs4474465	1.000	rs10899509	chr11:78170811	C/T	cg02023728	chr11:77925099	USP35	0.41	7.38	0.32	7.43e-13	Alzheimer's disease (survival time);
LGG	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.91	-18.57	-0.65	5.97e-58	Lung cancer;
LGG	cis	rs35123781	0.955	rs34530707	chr5:139059016	G/A	cg21230503	chr5:139085173	NA	0.3	7.33	0.32	1.04e-12	Schizophrenia;
LGG	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.22	-0.39	1.03e-18	Aortic root size;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg15971980	chr6:150254442	NA	0.44	8.11	0.35	4.64e-15	Lung cancer;
LGG	trans	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg11887960	chr12:57824829	NA	0.59	7.03	0.31	7.55e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg24011408	chr12:48396354	COL2A1	0.5	8.03	0.35	7.9e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12463199	chr20:49126897	PTPN1	0.52	8.1	0.35	4.9e-15	Gut microbiome composition (summer);
LGG	cis	rs7267979	1.000	rs6138572	chr20:25435934	G/C	cg06421707	chr20:25228305	PYGB	0.47	10.18	0.43	4.27e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg16230307	chr14:35515116	FAM177A1	0.94	13.31	0.53	1.87e-34	Psoriasis;
LGG	trans	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.4	-0.36	5.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.31	-0.43	1.46e-22	Tonsillectomy;
LGG	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg23939001	chr4:940644	TMEM175	0.61	12.16	0.49	1.02e-29	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs62400317	0.826	rs11963924	chr6:45306562	C/T	cg18551225	chr6:44695536	NA	-0.6	-9.89	-0.42	4.8e-21	Total body bone mineral density;
LGG	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg08344181	chr3:125677491	NA	-0.76	-6.91	-0.31	1.64e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg26677194	chr12:130822605	PIWIL1	0.56	9.99	0.42	1.98e-21	Menopause (age at onset);
LGG	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	cis	rs11122272	0.735	rs2749709	chr1:231530476	G/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.42	-0.33	5.61e-13	Hemoglobin concentration;
LGG	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.36	-0.4	3.46e-19	Aortic root size;
LGG	cis	rs9814567	0.964	rs4539979	chr3:134287597	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.4	-0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7932354	0.528	rs7937950	chr11:47098445	A/C	cg03339077	chr11:47165057	C11orf49	-0.54	-9.99	-0.42	2.14e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.45	-0.4	1.75e-19	Height;
LGG	cis	rs4865875	1.000	rs10042394	chr5:54120706	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.09e-14	Sense of smell;
LGG	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg11584989	chr19:19387371	SF4	-0.39	-6.7	-0.3	6.11e-11	Tonsillectomy;
LGG	cis	rs4774899	1.000	rs12914425	chr15:57476285	C/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.44	-0.33	5.05e-13	Urinary tract infection frequency;
LGG	cis	rs7215564	0.908	rs80183474	chr17:78655070	T/A	cg06153925	chr17:78755379	RPTOR	0.4	6.91	0.31	1.6e-11	Myopia (pathological);
LGG	cis	rs638893	0.578	rs4508234	chr11:118662203	G/C	cg13782932	chr11:118662891	DDX6	0.38	6.93	0.31	1.41e-11	Vitiligo;
LGG	cis	rs36051895	0.623	rs7847811	chr9:5237081	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-12.86	-0.51	1.46e-32	Pediatric autoimmune diseases;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04364194	chr1:202114085	ARL8A	0.41	6.78	0.3	3.75e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg05182265	chr7:156933206	UBE3C	0.37	7.49	0.33	3.48e-13	Body mass index;
LGG	cis	rs1595825	1.000	rs7582715	chr2:198874310	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-7.07	-0.31	5.56e-12	Ulcerative colitis;
LGG	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg16400903	chr5:693638	TPPP	0.44	6.71	0.3	5.62e-11	Obesity-related traits;
LGG	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg18105134	chr13:113819100	PROZ	-0.79	-13.78	-0.54	1.84e-36	Platelet distribution width;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.14	-0.58	2.35e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.21e-22	Blood metabolite levels;
LGG	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	7.98	0.35	1.18e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs350251	0.934	rs350207	chr16:12212914	T/G	cg02910054	chr16:12241554	SNX29	0.44	8.13	0.35	4.1e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.56	-8.26	-0.36	1.58e-15	Lung cancer in ever smokers;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs9815354	0.812	rs17218264	chr3:41975847	C/T	cg03022575	chr3:42003672	ULK4	-0.81	-9.49	-0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs714031	0.785	rs11704439	chr22:40069493	T/G	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.53	-0.56	1.11e-39	Schizophrenia;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs9604529	1.000	rs9604529	chr13:114622597	A/G	cg04826882	chr13:114838756	RASA3	-0.42	-6.74	-0.3	4.8e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2073499	0.872	rs7642692	chr3:50222693	T/C	cg03645007	chr3:50255295	SLC38A3	0.57	6.74	0.3	4.77e-11	Schizophrenia;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.05	0.35	6.99e-15	Obesity-related traits;
LGG	cis	rs7084402	0.902	rs1649017	chr10:60288531	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.01	0.64	2.4e-55	Refractive error;
LGG	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.23	0.43	2.85e-22	Motion sickness;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg06925179	chr17:43578568	NA	-0.31	-8.17	-0.35	2.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.92	0.68	3.36e-64	Platelet count;
LGG	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg15704280	chr7:45808275	SEPT13	0.81	14.35	0.55	6.49e-39	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06984945	chr6:26660160	ZNF322A	0.53	8.48	0.37	3.16e-16	Gut microbiome composition (summer);
LGG	cis	rs17739167	0.550	rs4924589	chr15:42229632	C/T	cg20935245	chr15:42234343	EHD4	0.44	8.58	0.37	1.44e-16	Monocyte count;
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg11584989	chr19:19387371	SF4	0.43	7.79	0.34	4.51e-14	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg25214090	chr10:38739885	LOC399744	0.6	10.84	0.45	1.48e-24	Corneal astigmatism;
LGG	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-9.97	-0.42	2.36e-21	Menarche (age at onset);
LGG	cis	rs9287719	0.967	rs2287062	chr2:10743191	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg12661370	chr5:149340060	SLC26A2	0.49	8.3	0.36	1.13e-15	HIV-1 control;
LGG	cis	rs4819852	1.000	rs1034566	chr22:19984277	C/T	cg07821417	chr22:19972146	ARVCF	0.63	13.32	0.53	1.72e-34	Pulse pressure;
LGG	cis	rs8133932	0.608	rs403192	chr21:47360641	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-7.7	-0.34	8.23e-14	Schizophrenia;
LGG	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg05791153	chr7:19748676	TWISTNB	0.77	10.34	0.43	1.09e-22	Thyroid stimulating hormone;
LGG	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs3206736	0.548	rs17793929	chr7:35068980	T/C	cg13400248	chr7:35225412	NA	0.55	9.52	0.4	9.85e-20	Diastolic blood pressure;
LGG	cis	rs6868223	0.617	rs4866353	chr5:33649220	A/G	cg10594543	chr5:33649717	ADAMTS12	0.66	15.5	0.58	6.2e-44	Mortality in heart failure;
LGG	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17830980	chr10:43048298	ZNF37B	-0.6	-13.5	-0.53	2.88e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs4538187	0.901	rs68117986	chr2:64239566	G/A	cg19915305	chr2:64069682	UGP2	-0.69	-15.57	-0.59	2.85e-44	Systolic blood pressure;
LGG	cis	rs733592	1.000	rs1859440	chr12:48427329	T/C	cg24011408	chr12:48396354	COL2A1	-0.68	-11.66	-0.48	1.04e-27	Plateletcrit;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg18402987	chr7:1209562	NA	0.5	8.37	0.36	6.73e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg05444541	chr17:17804740	TOM1L2	-0.61	-13.65	-0.54	7.14e-36	Total body bone mineral density;
LGG	cis	rs17539620	0.534	rs7768635	chr6:154827861	C/T	cg17771515	chr6:154831774	CNKSR3	0.57	8.15	0.35	3.37e-15	Lipoprotein (a) levels;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.92	0.38	1.05e-17	Alzheimer's disease;
LGG	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg26248373	chr2:1572462	NA	-0.9	-15.7	-0.59	7.32e-45	IgG glycosylation;
LGG	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.42	-0.33	5.63e-13	Bladder cancer;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.57	0.41	6.42e-20	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16275967	chr1:161172255	NDUFS2	0.52	8.08	0.35	5.74e-15	Gut microbiome composition (summer);
LGG	cis	rs9513627	0.831	rs9582301	chr13:100125814	C/T	cg25919922	chr13:100150906	NA	-0.72	-7.32	-0.32	1.08e-12	Obesity-related traits;
LGG	cis	rs986417	0.901	rs1955698	chr14:61029936	C/T	cg27398547	chr14:60952738	C14orf39	0.65	6.86	0.3	2.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	24.4	0.75	3.9e-85	Height;
LGG	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.56	0.44	1.73e-23	Blood protein levels;
LGG	cis	rs6708331	0.540	rs6546576	chr2:70401488	G/A	cg01613454	chr2:70366299	NA	0.53	10.88	0.45	1.05e-24	Obesity-related traits;
LGG	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg03517284	chr6:25882590	NA	-0.43	-6.76	-0.3	4.26e-11	Iron status biomarkers;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03169527	chr3:11888582	C3orf31	-0.49	-7.38	-0.32	7.24e-13	Systemic lupus erythematosus;
LGG	cis	rs2120243	0.539	rs1585080	chr3:157106982	A/G	cg24825693	chr3:157122686	VEPH1	-0.58	-13.54	-0.53	2.09e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6942756	1.000	rs6942756	chr7:128886821	T/G	cg02491457	chr7:128862824	NA	-0.77	-14.08	-0.55	1.02e-37	White matter hyperintensity burden;
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs4713118	0.513	rs149959	chr6:28013854	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.82	-0.3	2.83e-11	Parkinson's disease;
LGG	cis	rs16986825	0.546	rs9625612	chr22:29258140	T/A	cg15103426	chr22:29168792	CCDC117	0.68	7.68	0.34	9.83e-14	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15585372	chr7:97910571	BRI3	0.53	8.08	0.35	5.55e-15	Gut microbiome composition (summer);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg20013855	chr1:178062503	LOC100302401;RASAL2	-0.4	-7.41	-0.33	6.24e-13	Menarche (age at onset);
LGG	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg20713898	chr8:124780851	FAM91A1	-0.48	-7.39	-0.32	6.88e-13	Pancreatic cancer;
LGG	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg25809561	chr17:30822961	MYO1D	-0.41	-9.49	-0.4	1.18e-19	Schizophrenia;
LGG	cis	rs17776563	0.881	rs2165248	chr15:89118154	A/T	cg05013243	chr15:89149849	MIR1179	-0.49	-9.99	-0.42	2.06e-21	Thyroid hormone levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15259947	chr6:151187339	MTHFD1L	0.45	6.7	0.3	6.22e-11	Hip circumference;
LGG	cis	rs12476592	0.602	rs2421952	chr2:63749833	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.77	-0.3	3.94e-11	Childhood ear infection;
LGG	cis	rs4006360	0.579	rs1510075	chr17:39236452	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.57	-0.47	2.37e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs62064224	0.714	rs16967266	chr17:30632274	G/A	cg18200150	chr17:30822561	MYO1D	0.5	9.63	0.41	3.81e-20	Schizophrenia;
LGG	trans	rs9329221	0.502	rs11777364	chr8:10288546	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.12	0.31	4.21e-12	Neuroticism;
LGG	cis	rs6840360	0.642	rs2709820	chr4:152384039	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	3.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	11.3	0.46	2.61e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	4.93e-20	Colorectal cancer;
LGG	cis	rs2241941	0.840	rs72927519	chr11:20628407	C/G	cg18855426	chr11:20631935	SLC6A5	-0.45	-7.58	-0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.27	0.5	3.62e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg26513180	chr16:89883248	FANCA	-0.52	-9.24	-0.39	9.02e-19	Vitiligo;
LGG	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg16141378	chr3:129829833	LOC729375	0.4	8.99	0.39	6.51e-18	Retinal vascular caliber;
LGG	cis	rs4917300	0.571	rs4917287	chr8:143113997	A/G	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.32e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs12762955	0.561	rs11253567	chr10:1054444	A/G	cg25019033	chr10:957182	NA	-0.33	-6.9	-0.31	1.69e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9354308	0.738	rs1499704	chr6:66593133	C/A	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs9309473	0.948	rs13392691	chr2:73748980	G/A	cg20560298	chr2:73613845	ALMS1	-0.5	-8.3	-0.36	1.13e-15	Metabolite levels;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg06916706	chr16:4465613	CORO7	-0.86	-15.77	-0.59	3.79e-45	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	11.13	0.46	1.21e-25	Hemoglobin concentration;
LGG	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg17644776	chr2:200775616	C2orf69	0.59	6.76	0.3	4.2e-11	Schizophrenia;
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.28	-0.32	1.45e-12	Neuroticism;
LGG	cis	rs7717393	0.786	rs10062636	chr5:155804588	G/C	cg04435420	chr5:155754009	SGCD	0.76	9.03	0.39	4.68e-18	Egg allergy;
LGG	cis	rs2013441	0.508	rs35493088	chr17:19974063	G/A	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg13802316	chr11:70253460	CTTN	-0.6	-7.5	-0.33	3.32e-13	Coronary artery disease;
LGG	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.88	0.64	9.75e-55	Smoking behavior;
LGG	cis	rs11690935	0.550	rs7584187	chr2:172866105	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.63	-12.03	-0.49	3.29e-29	Schizophrenia;
LGG	cis	rs340874	0.703	rs340835	chr1:214163675	C/T	cg24083324	chr1:214162604	PROX1	0.51	9.0	0.39	5.81e-18	Type 2 diabetes;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08280861	chr8:58055591	NA	0.56	7.02	0.31	7.94e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.15	0.32	3.5e-12	Lung cancer;
LGG	cis	rs7763441	0.567	rs13196905	chr6:2429573	T/C	cg20586750	chr6:2413556	NA	-0.38	-7.19	-0.32	2.67e-12	Monobrow;
LGG	cis	rs2239547	0.522	rs9831409	chr3:52985711	A/T	cg11645453	chr3:52864694	ITIH4	-0.65	-10.21	-0.43	3.22e-22	Schizophrenia;
LGG	trans	rs12579753	1.000	rs10862368	chr12:82244514	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.9e-14	Resting heart rate;
LGG	cis	rs745821	0.783	rs4599004	chr18:48140238	A/G	cg18923635	chr18:48083994	NA	-0.45	-7.75	-0.34	6.03e-14	Diastolic blood pressure;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.69	-0.56	2.14e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs10751667	0.666	rs7395402	chr11:950293	A/G	cg22143635	chr11:980567	AP2A2	-0.42	-7.58	-0.33	1.96e-13	Alzheimer's disease (late onset);
LGG	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg26695010	chr11:65641043	EFEMP2	0.46	7.16	0.32	3.12e-12	Breast cancer;
LGG	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21659725	chr3:3221576	CRBN	-0.56	-9.77	-0.41	1.25e-20	Body mass index;
LGG	cis	rs11645898	0.872	rs4788459	chr16:72153125	C/G	cg14768367	chr16:72042858	DHODH	-0.81	-11.07	-0.46	1.91e-25	Blood protein levels;
LGG	cis	rs6723226	0.739	rs2069213	chr2:32743084	C/T	cg02381751	chr2:32503542	YIPF4	0.64	10.73	0.45	3.81e-24	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	1.000	rs6940188	chr6:26562029	G/C	cg09904177	chr6:26538194	HMGN4	0.77	17.23	0.63	9.09e-52	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.74	-0.3	4.65e-11	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16162927	chr6:136610857	BCLAF1	0.46	7.79	0.34	4.57e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.16	0.6	6.91e-47	Obesity-related traits;
LGG	cis	rs57994353	0.508	rs7874956	chr9:139336813	T/G	cg14169450	chr9:139327907	INPP5E	0.38	6.83	0.3	2.74e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LGG	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.65	-0.37	8.59e-17	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	0.557	rs7936076	chr11:34724672	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-7.19	-0.32	2.58e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg08250081	chr4:10125330	NA	0.43	8.27	0.36	1.45e-15	Bone mineral density;
LGG	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg18937875	chr11:14930189	NA	-0.48	-7.84	-0.34	3.21e-14	Vitamin D levels;
LGG	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00473462	chr5:472545	LOC25845	0.35	6.69	0.3	6.5500000000000006e-11	Cystic fibrosis severity;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs12220238	1.000	rs7907801	chr10:75976638	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-9.4	-0.4	2.62e-19	Diabetic retinopathy;
LGG	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.33	0.32	1.01e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs881375	0.715	rs11794516	chr9:123640230	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	9.92	0.42	3.59e-21	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9457247	0.967	rs385460	chr6:167403888	A/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs7222240	0.812	rs34886378	chr17:43133849	T/A	cg24806326	chr17:43207588	PLCD3	0.45	7.32	0.32	1.07e-12	Craniofacial microsomia;
LGG	cis	rs7649275	1.000	rs2633727	chr3:53746089	A/G	cg21503701	chr3:53781065	CACNA1D	-0.48	-6.96	-0.31	1.19e-11	Trans fatty acid levels;
LGG	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg20573242	chr4:122745356	CCNA2	-0.4	-7.13	-0.31	3.84e-12	Type 2 diabetes;
LGG	cis	rs6580649	0.941	rs7312326	chr12:48480643	G/A	cg24011408	chr12:48396354	COL2A1	-0.54	-6.65	-0.3	8.47e-11	Lung cancer;
LGG	cis	rs7715811	0.913	rs73749952	chr5:13762518	T/C	cg07548982	chr5:13769939	DNAH5	-0.45	-9.17	-0.39	1.61e-18	Subclinical atherosclerosis traits (other);
LGG	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg24692254	chr21:30365293	RNF160	0.82	16.85	0.62	4.85e-50	Selective IgA deficiency;
LGG	cis	rs9815354	1.000	rs7622259	chr3:41881351	A/T	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9463078	0.774	rs7740083	chr6:45274742	G/A	cg25276700	chr6:44698697	NA	-0.4	-8.54	-0.37	1.93e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg16141378	chr3:129829833	LOC729375	-0.42	-9.76	-0.41	1.42e-20	Neuroticism;
LGG	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg27523141	chr10:43048294	ZNF37B	0.33	6.79	0.3	3.48e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs12517041	1.000	rs6888168	chr5:23304401	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs209489	0.901	rs209530	chr6:53221076	C/T	cg15607103	chr6:53167650	ELOVL5	-0.52	-6.76	-0.3	4.17e-11	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.16	-0.32	3.25e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg02251663	chr11:14281053	SPON1	-0.31	-7.35	-0.32	9.2e-13	Mitochondrial DNA levels;
LGG	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12826209	chr6:26865740	GUSBL1	0.61	9.45	0.4	1.69e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg15522984	chr1:182991683	LAMC1	0.47	9.29	0.4	5.92e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.88	0.38	1.46e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg09307838	chr4:120376055	NA	0.82	13.74	0.54	2.95e-36	Corneal astigmatism;
LGG	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	trans	rs2362965	0.519	rs7651696	chr3:157895379	A/G	cg23275840	chr4:47708675	CORIN	0.36	6.74	0.3	4.85e-11	Height;
LGG	cis	rs6815814	0.851	rs11466617	chr4:38780471	T/C	cg06935464	chr4:38784597	TLR10	0.55	7.69	0.34	8.93e-14	Breast cancer;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08677398	chr8:58056175	NA	0.51	8.06	0.35	6.56e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg12253571	chr8:8283032	NA	-0.31	-6.74	-0.3	4.74e-11	Parkinson's disease;
LGG	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg09307838	chr4:120376055	NA	0.8	13.22	0.52	4.35e-34	Corneal astigmatism;
LGG	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	7.6	0.33	1.64e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7648466	0.915	rs3181077	chr3:46250652	C/T	cg13144783	chr3:46249795	CCR1	-0.7	-13.35	-0.53	1.31e-34	Eotaxin levels;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-9.74	-0.41	1.69e-20	Schizophrenia;
LGG	trans	rs2281558	0.517	rs16987966	chr20:25643414	T/C	cg25917747	chr17:21561886	NA	0.52	7.24	0.32	1.82e-12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LGG	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg11502198	chr6:26597334	ABT1	0.7	12.85	0.51	1.53e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.93	0.35	1.61e-14	Height;
LGG	cis	rs1062177	1.000	rs973529	chr5:151188158	T/C	cg00977110	chr5:151150581	G3BP1	0.5	8.04	0.35	7.32e-15	Preschool internalizing problems;
LGG	cis	rs12618769	0.597	rs3729568	chr2:99100196	T/G	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.41e-16	Bipolar disorder;
LGG	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.55	-10.2	-0.43	3.52e-22	Total body bone mineral density;
LGG	trans	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.41	-0.36	5.26e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg00684032	chr4:1343700	KIAA1530	0.4	7.81	0.34	3.79e-14	Longevity;
LGG	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs4764487	0.687	rs10744702	chr12:6349127	G/A	cg08284733	chr12:6341482	CD9	0.38	10.0	0.42	1.86e-21	Mean platelet volume;
LGG	cis	rs7336332	0.598	rs77055070	chr13:28010516	C/G	cg01674679	chr13:27998804	GTF3A	-0.63	-8.13	-0.35	3.93e-15	Weight;
LGG	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg12386194	chr3:101231763	SENP7	0.75	13.0	0.52	3.61e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg26384229	chr12:38710491	ALG10B	0.93	21.66	0.71	2.22e-72	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg18335740	chr13:41363409	SLC25A15	0.63	12.44	0.5	7.69e-31	Lewy body disease;
LGG	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07570687	chr10:102243282	WNT8B	0.44	7.42	0.33	5.83e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.47	0.4	1.45e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-10.06	-0.42	1.12e-21	Morning vs. evening chronotype;
LGG	cis	rs10267417	0.603	rs4721829	chr7:19873199	A/G	cg07541023	chr7:19748670	TWISTNB	0.5	6.76	0.3	4.19e-11	Night sleep phenotypes;
LGG	cis	rs68170813	0.522	rs12154818	chr7:107074515	G/C	cg02696742	chr7:106810147	HBP1	-0.51	-7.27	-0.32	1.5e-12	Coronary artery disease;
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4262150	0.842	rs56208248	chr5:152138598	A/G	cg12297329	chr5:152029980	NA	-0.7	-12.78	-0.51	3.08e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs2415984	0.622	rs61993303	chr14:46949716	G/C	cg14871534	chr14:47121158	RPL10L	-0.57	-10.09	-0.42	8.65e-22	Number of children ever born;
LGG	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg26850624	chr5:429559	AHRR	-0.38	-8.43	-0.36	4.44e-16	Cystic fibrosis severity;
LGG	trans	rs8073060	0.821	rs11080355	chr17:33872694	T/A	cg19694781	chr19:47549865	TMEM160	0.63	10.01	0.42	1.71e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.11	-0.43	7.67e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4356975	0.583	rs11936822	chr4:69979947	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg04267008	chr7:1944627	MAD1L1	0.56	9.45	0.4	1.72e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg08621203	chr6:150244597	RAET1G	-0.5	-9.32	-0.4	4.86e-19	Testicular germ cell tumor;
LGG	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.06	0.35	6.61e-15	Morning vs. evening chronotype;
LGG	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg07148914	chr20:33460835	GGT7	0.53	8.92	0.38	1.05e-17	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08121514	chr7:113726103	NA	0.45	7.49	0.33	3.49e-13	Cognitive performance;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-17.24	-0.63	8.67e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12143943	0.866	rs12030639	chr1:204530924	C/T	cg20240347	chr1:204465584	NA	-0.34	-7.54	-0.33	2.56e-13	Cognitive performance;
LGG	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg14191688	chr11:70257035	CTTN	0.58	8.63	0.37	9.92e-17	Coronary artery disease;
LGG	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg20673091	chr1:2541236	MMEL1	-0.78	-18.09	-0.64	9.98e-56	Ulcerative colitis;
LGG	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.91	0.34	1.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg09324608	chr17:30823087	MYO1D	0.31	7.47	0.33	4.16e-13	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.56	-0.37	1.67e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg27446573	chr6:127587934	RNF146	1.13	21.89	0.71	2e-73	Breast cancer;
LGG	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg03929089	chr4:120376271	NA	-0.56	-9.93	-0.42	3.45e-21	HDL cholesterol;
LGG	cis	rs11096990	0.892	rs1901404	chr4:39212610	A/C	cg24403649	chr4:39172243	NA	-0.48	-7.93	-0.35	1.66e-14	Cognitive function;
LGG	trans	rs12517041	1.000	rs28600340	chr5:23301774	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.19e-35	Anterior chamber depth;
LGG	cis	rs4731207	0.698	rs6466955	chr7:124518766	T/C	cg05630886	chr7:124431682	NA	-0.34	-7.95	-0.35	1.46e-14	Cutaneous malignant melanoma;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07157834	chr1:205819609	PM20D1	0.82	20.13	0.68	3.45e-65	Menarche (age at onset);
LGG	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs2901331	0.533	rs2174251	chr2:125418357	C/T	cg07771321	chr2:125368595	CNTNAP5	-0.46	-8.04	-0.35	7.54e-15	Response to statin therapy;
LGG	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15532942	chr18:77220712	NFATC1	-0.53	-8.2	-0.36	2.41e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs77741769	0.571	rs11611087	chr12:121267126	C/T	cg02419362	chr12:121203948	SPPL3	0.53	9.27	0.4	7.09e-19	Mean corpuscular volume;
LGG	cis	rs12711979	0.509	rs13000873	chr2:3823705	T/C	cg17052675	chr2:3827356	NA	-0.49	-9.64	-0.41	3.74e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.51	0.33	3.03e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9527	0.590	rs1541213	chr10:104885330	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs2334880	0.678	rs12919092	chr16:71446490	T/C	cg06353428	chr16:71660113	MARVELD3	-0.79	-10.67	-0.44	6.61e-24	Malaria;
LGG	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg21545522	chr1:205238299	TMCC2	0.48	8.55	0.37	1.79e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs703842	1.000	rs1875124	chr12:58196802	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.34	0.36	8.48e-16	Multiple sclerosis;
LGG	cis	rs2373794	0.884	rs444999	chr2:40373872	A/G	cg17740179	chr2:40377776	SLC8A1	-0.9	-19.11	-0.66	1.99e-60	Asthma;
LGG	cis	rs6964587	0.633	rs13231620	chr7:91507859	G/A	cg17063962	chr7:91808500	NA	-0.41	-6.87	-0.3	2.09e-11	Breast cancer;
LGG	cis	rs12282928	0.959	rs7928042	chr11:48257996	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-7.13	-0.31	3.89e-12	Migraine - clinic-based;
LGG	cis	rs7635838	0.654	rs4684766	chr3:11285474	G/A	cg00170343	chr3:11313890	ATG7	0.59	9.87	0.42	5.44e-21	HDL cholesterol;
LGG	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg01236616	chr12:121019343	POP5	-1.22	-22.35	-0.72	1.34e-75	Type 1 diabetes nephropathy;
LGG	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg23306229	chr2:178417860	TTC30B	0.63	6.88	0.3	1.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7558370	0.867	rs9941597	chr2:3717673	C/T	cg17046650	chr2:3699563	NA	0.71	7.23	0.32	1.96e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.54	0.37	1.89e-16	Skin colour saturation;
LGG	cis	rs11716531	0.510	rs513546	chr3:27348920	A/G	cg02860705	chr3:27208620	NA	0.57	10.56	0.44	1.73e-23	Diastolic blood pressure;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg19168338	chr16:4465731	CORO7	-0.9	-17.07	-0.62	4.84e-51	Schizophrenia;
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg15537850	chr8:144661051	NAPRT1	0.95	7.25	0.32	1.77e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs1904096	0.506	rs13435702	chr4:95167751	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.98	-0.45	4.39e-25	Type 2 diabetes;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.77	0.64	3.12e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs926392	0.965	rs6129168	chr20:37689360	T/C	cg16355469	chr20:37678765	NA	0.45	7.36	0.32	8.23e-13	Dialysis-related mortality;
LGG	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg14210321	chr2:106509881	NCK2	-0.51	-8.81	-0.38	2.47e-17	Addiction;
LGG	cis	rs2455601	1.000	rs12223690	chr11:8901824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-9.92	-0.42	3.78e-21	Schizophrenia;
LGG	cis	rs3774854	1.000	rs3774854	chr4:5711368	C/T	cg09558315	chr4:5711301	EVC2	0.32	7.2	0.32	2.46e-12	Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease;
LGG	cis	rs9400467	0.506	rs77097930	chr6:111615479	G/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.68	0.3	6.8e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6754311	0.593	rs55825471	chr2:136526981	T/A	cg07169764	chr2:136633963	MCM6	-0.78	-13.69	-0.54	4.82e-36	Mosquito bite size;
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs10892173	0.678	rs4537790	chr11:117661356	A/G	cg21640587	chr11:117668038	DSCAML1	0.51	8.53	0.37	2.03e-16	Myopia;
LGG	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-14.33	-0.55	8.06e-39	Dental caries;
LGG	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-11.8	-0.48	2.84e-28	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12806663	1	rs12806663	chr11:62001414	C/A	cg01969543	chr11:61895209	INCENP	0.63	9.92	0.42	3.7e-21	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.27	0.32	1.56e-12	Refractive error;
LGG	cis	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-10.23	-0.43	2.8e-22	Personality dimensions;
LGG	trans	rs9929218	0.551	rs8051095	chr16:68722049	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.14	32.35	0.83	6.53e-121	Colorectal cancer;
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.01	-0.31	8.6e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg17211192	chr8:82754475	SNX16	-0.72	-12.02	-0.49	3.77e-29	Diastolic blood pressure;
LGG	cis	rs526231	0.543	rs257303	chr5:102416727	A/G	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-7.76	-0.34	5.62e-14	Mood instability;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.39e-19	Life satisfaction;
LGG	cis	rs17253792	0.545	rs12886406	chr14:56027605	G/A	cg01858014	chr14:56050164	KTN1	-0.8	-9.91	-0.42	4.04e-21	Putamen volume;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13012494	chr21:47604986	C21orf56	0.54	9.06	0.39	3.78e-18	Testicular germ cell tumor;
LGG	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg21665744	chr7:39171113	POU6F2	0.41	8.52	0.37	2.23e-16	IgG glycosylation;
LGG	cis	rs8010715	0.848	rs2277483	chr14:24591892	A/G	cg06429887	chr14:24600500	FITM1	0.36	7.47	0.33	3.94e-13	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18876457	chr1:160071037	NA	0.57	8.95	0.38	8.87e-18	Gut microbiome composition (summer);
LGG	cis	rs1562975	0.609	rs60290218	chr4:109409501	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	8.14	0.35	3.82e-15	Height;
LGG	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg23422044	chr7:1970798	MAD1L1	0.6	10.06	0.42	1.19e-21	Bipolar disorder;
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.07	-0.35	6.03e-15	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg12708336	chr17:41446283	NA	-0.31	-7.22	-0.32	2.16e-12	Menopause (age at onset);
LGG	cis	rs11229555	0.645	rs12786744	chr11:58177549	T/C	cg15696309	chr11:58395628	NA	-0.96	-15.42	-0.58	1.37e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6546550	0.935	rs6747542	chr2:70106832	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.08	-0.35	5.57e-15	Prevalent atrial fibrillation;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg13445358	chr12:53661749	ESPL1	-0.38	-7.03	-0.31	7.48e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg00666640	chr1:248458726	OR2T12	0.62	9.98	0.42	2.29e-21	Common traits (Other);
LGG	cis	rs8032158	0.702	rs35040841	chr15:56124149	A/G	cg05129572	chr15:56138634	NEDD4	-0.4	-6.87	-0.3	2.14e-11	Keloid;
LGG	cis	rs10276381	0.786	rs10272155	chr7:28246989	A/G	cg23620719	chr7:28220237	JAZF1	0.79	9.86	0.42	6.06e-21	Crohn's disease;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.48	0.47	5.09e-27	Obesity-related traits;
LGG	cis	rs773506	0.628	rs10733740	chr9:93933158	G/T	cg14446406	chr9:93919335	NA	-0.55	-9.6	-0.41	4.94e-20	Type 2 diabetes nephropathy;
LGG	cis	rs10851411	0.618	rs72707484	chr15:42752254	A/G	cg21293051	chr15:42870591	STARD9	0.5	7.34	0.32	9.41e-13	Glucose homeostasis traits;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.88	-0.3	1.98e-11	Longevity;
LGG	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	12.84	0.51	1.66e-32	Response to antipsychotic treatment;
LGG	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg08250081	chr4:10125330	NA	0.39	7.61	0.33	1.5700000000000001e-13	Bone mineral density;
LGG	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.09	-0.42	8.77e-22	Diabetic kidney disease;
LGG	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.6	-0.44	1.14e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg16486109	chr11:613632	IRF7	0.4	6.98	0.31	9.96e-12	Systemic lupus erythematosus;
LGG	cis	rs72781680	1.000	rs72796359	chr2:24160545	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	10.18	0.43	4.41e-22	Lymphocyte counts;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09730820	chr16:15736852	NDE1;MIR484;KIAA0430	-0.37	-6.87	-0.3	2.09e-11	Brain structure;
LGG	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg10122326	chr6:28072925	NA	0.8	6.65	0.3	8.42e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6834538	0.597	rs2029211	chr4:113488134	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.86	0.38	1.78e-17	Free thyroxine concentration;
LGG	cis	rs9287719	0.967	rs7608498	chr2:10738428	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs424971	1.000	rs1519976	chr16:85945675	T/G	cg10334323	chr16:85945517	IRF8	-0.34	-7.13	-0.31	4e-12	Monocyte count;
LGG	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.36	-0.32	8.29e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg11693508	chr17:37793320	STARD3	0.7	9.94	0.42	3.06e-21	Bipolar disorder;
LGG	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg12560992	chr17:57184187	TRIM37	0.53	8.51	0.37	2.37e-16	Cognitive test performance;
LGG	cis	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg09044154	chr16:88155775	NA	-0.48	-7.44	-0.33	5.02e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg21724239	chr8:58056113	NA	0.59	8.58	0.37	1.47e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25064146	chr11:111957872	TIMM8B;SDHD	0.43	7.17	0.32	2.94e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs2953145	0.568	rs1133354	chr2:241522450	A/G	cg07929629	chr2:241523174	NA	0.61	10.73	0.45	3.88e-24	Bipolar disorder;
LGG	cis	rs6694672	1.000	rs1170881	chr1:196949271	G/A	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.87e-11	Asthma;
LGG	cis	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg24375607	chr4:120327624	NA	0.67	10.96	0.45	5.18e-25	Corneal astigmatism;
LGG	cis	rs7267979	0.966	rs2500417	chr20:25383287	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg12654349	chr5:56205094	C5orf35	0.58	9.91	0.42	4.11e-21	Initial pursuit acceleration;
LGG	cis	rs7444	0.941	rs131665	chr22:21920903	A/G	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.55e-14	Systemic lupus erythematosus;
LGG	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.59e-15	Obesity-related traits;
LGG	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg00376283	chr12:123451042	ABCB9	-0.61	-9.31	-0.4	5.02e-19	Neutrophil percentage of white cells;
LGG	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	20.91	0.7	7.81e-69	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg01152986	chr16:58549298	SETD6	0.84	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-7.47	-0.33	4.14e-13	Lung cancer;
LGG	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.56e-11	Coronary artery disease;
LGG	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg15128208	chr22:42549153	NA	0.47	9.6	0.41	5.2e-20	Cognitive function;
LGG	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg16511985	chr3:153974050	SGEF	0.47	7.68	0.34	9.38e-14	Coronary artery disease;
LGG	cis	rs6977660	0.941	rs5017197	chr7:19819967	T/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.75	0.38	3.9e-17	Thyroid stimulating hormone;
LGG	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.74	-0.3	4.86e-11	Blood metabolite levels;
LGG	trans	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.56	0.41	7.2e-20	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg11846333	chr4:119757529	SEC24D	0.85	7.86	0.34	2.73e-14	Cannabis dependence symptom count;
LGG	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg05484508	chr16:89589025	SPG7	0.44	7.06	0.31	5.97e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg03709012	chr19:19516395	GATAD2A	0.98	15.63	0.59	1.62e-44	Nonalcoholic fatty liver disease;
LGG	cis	rs10832963	1.000	rs10128711	chr11:18632984	A/G	cg20219074	chr11:18656078	SPTY2D1	0.83	15.9	0.59	9.86e-46	Breast cancer;
LGG	cis	rs2131877	0.610	rs750470	chr3:194878063	A/G	cg07250128	chr3:194833983	C3orf21	0.34	6.68	0.3	6.89e-11	Non-small cell lung cancer;
LGG	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-8.43	-0.36	4.42e-16	Thyroid stimulating hormone;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg06074448	chr4:187884817	NA	0.59	12.92	0.51	7.86e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.79	-0.3	3.51e-11	Electroencephalogram traits;
LGG	cis	rs4959677	0.901	rs9328100	chr6:2480664	G/T	cg23817096	chr6:1620687	NA	-0.32	-7.57	-0.33	2.03e-13	Orthostatic hypotension;
LGG	cis	rs9309711	0.770	rs13409323	chr2:3488184	C/T	cg10845886	chr2:3471009	TTC15	-0.66	-12.84	-0.51	1.69e-32	Neurofibrillary tangles;
LGG	cis	rs17504614	0.815	rs10490174	chr2:51083678	G/A	cg23851515	chr2:51057218	NRXN1	0.42	7.12	0.31	4.02e-12	Educational attainment (years of education);
LGG	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg18252515	chr7:66147081	NA	1.26	19.69	0.68	3.9e-63	Diabetic kidney disease;
LGG	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs77741769	0.571	rs12580949	chr12:121298164	A/G	cg02419362	chr12:121203948	SPPL3	0.53	9.18	0.39	1.44e-18	Mean corpuscular volume;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.13	-0.35	3.84e-15	IgG glycosylation;
LGG	cis	rs2072499	0.966	rs2842864	chr1:156159217	G/A	cg24450063	chr1:156163899	SLC25A44	1.25	32.46	0.83	2.22e-121	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs7458708	1	rs7458708	chr7:83111837	C/T	cg14519356	chr7:83097669	SEMA3E	0.27	7.54	0.33	2.44e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg00376283	chr12:123451042	ABCB9	0.62	10.12	0.43	7.08e-22	Neutrophil percentage of white cells;
LGG	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	7.26	0.32	1.64e-12	Educational attainment;
LGG	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg07606381	chr6:8435919	SLC35B3	-0.66	-12.18	-0.49	8.89e-30	Motion sickness;
LGG	trans	rs7395662	0.963	rs10838967	chr11:48595007	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.3	-0.32	1.29e-12	HDL cholesterol;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg07414643	chr4:187882934	NA	0.53	11.09	0.46	1.69e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg27129171	chr3:47204927	SETD2	0.77	15.02	0.57	8.21e-42	Colorectal cancer;
LGG	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg02462569	chr6:150064036	NUP43	-0.39	-8.28	-0.36	1.32e-15	Lung cancer;
LGG	trans	rs12517041	1.000	rs6870220	chr5:23304587	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.67	10.04	0.42	1.33e-21	Calcium levels;
LGG	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg20026190	chr17:76395443	PGS1	0.57	9.93	0.42	3.52e-21	HDL cholesterol levels;
LGG	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-16.98	-0.62	1.26e-50	Response to antipsychotic treatment;
LGG	cis	rs870825	0.655	rs28604350	chr4:185638723	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.58	0.72	1.14e-76	Blood protein levels;
LGG	cis	rs2237234	0.542	rs7755997	chr6:26483048	G/A	cg09904177	chr6:26538194	HMGN4	0.55	10.32	0.43	1.3e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs713587	0.935	rs4430895	chr2:25161386	C/T	cg04586622	chr2:25135609	ADCY3	0.42	10.71	0.45	4.57e-24	Body mass index in non-asthmatics;
LGG	cis	rs7917772	0.582	rs7087984	chr10:104380686	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	11.05	0.46	2.38e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg20573242	chr4:122745356	CCNA2	0.42	7.53	0.33	2.7e-13	Type 2 diabetes;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg08645402	chr16:4508243	NA	-0.51	-9.55	-0.41	7.77e-20	Schizophrenia;
LGG	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.55	0.47	2.8e-27	Response to antipsychotic treatment;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.85	0.34	2.9e-14	Schizophrenia;
LGG	trans	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg21659725	chr3:3221576	CRBN	-0.57	-7.55	-0.33	2.37e-13	Menarche (age at onset);
LGG	cis	rs2273669	0.667	rs12195372	chr6:109284223	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.28	-0.36	1.31e-15	Prostate cancer;
LGG	cis	rs4969178	0.965	rs8077859	chr17:76386335	C/T	cg05887092	chr17:76393375	PGS1	0.71	15.42	0.58	1.41e-43	HDL cholesterol levels;
LGG	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.02	0.62	8.32e-51	Intelligence (multi-trait analysis);
LGG	cis	rs11785693	0.862	rs11778306	chr8:4988269	A/C	cg26367366	chr8:4980734	NA	0.93	14.96	0.57	1.4e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-17.03	-0.62	7.46e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg05552183	chr6:42928497	GNMT	0.46	14.31	0.55	1.02e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg22348356	chr13:114891224	RASA3	0.38	7.21	0.32	2.23e-12	Schizophrenia;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg09264619	chr17:80180166	NA	-0.38	-7.54	-0.33	2.51e-13	Life satisfaction;
LGG	cis	rs912057	0.833	rs1294418	chr6:6742185	A/G	cg06612196	chr6:6737390	NA	0.46	9.32	0.4	4.76e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1883415	0.534	rs2817208	chr6:24481373	T/A	cg20631270	chr6:24437470	GPLD1	0.49	8.45	0.37	3.71e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2455601	0.608	rs16906256	chr11:8887097	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.48	-9.69	-0.41	2.41e-20	Schizophrenia;
LGG	cis	rs7923609	1.000	rs7910927	chr10:65138910	T/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.98e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg00405596	chr8:11794950	NA	0.63	11.2	0.46	6.37e-26	Myopia (pathological);
LGG	cis	rs2070488	0.965	rs4679053	chr3:38523495	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.22	0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.39	-0.65	3.99e-57	Lung cancer;
LGG	trans	rs800082	0.501	rs10935507	chr3:144214631	A/T	cg24215973	chr2:240111563	HDAC4	0.42	7.38	0.32	7.23e-13	Smoking behavior;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	7.33	0.32	1.05e-12	Longevity;
LGG	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-8.47	-0.37	3.4e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1048238	0.506	rs12023422	chr1:16187625	G/A	cg22431228	chr1:16359049	CLCNKA	-0.41	-7.41	-0.33	5.86e-13	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08434594	chr19:14640333	TECR;MIR639	0.45	6.83	0.3	2.73e-11	Gut microbiome composition (summer);
LGG	cis	rs7937612	1.000	rs11600703	chr11:120249287	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.66	-0.51	9.65e-32	Intraocular pressure;
LGG	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg15212455	chr7:39170539	POU6F2	0.51	11.99	0.49	4.93e-29	IgG glycosylation;
LGG	cis	rs6860806	0.531	rs2631359	chr5:131707892	C/T	cg07395648	chr5:131743802	NA	0.49	10.02	0.42	1.55e-21	Breast cancer;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.32	-6.86	-0.3	2.19e-11	Schizophrenia;
LGG	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg10326726	chr10:51549505	MSMB	-0.66	-13.73	-0.54	3.08e-36	Prostate-specific antigen levels;
LGG	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg24396566	chr4:52904500	SGCB	0.43	7.25	0.32	1.78e-12	Testicular germ cell tumor;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg05896524	chr21:47604654	C21orf56	-0.65	-10.97	-0.45	4.58e-25	Testicular germ cell tumor;
LGG	cis	rs228769	0.653	rs2523162	chr17:42179281	A/G	cg19774624	chr17:42201019	HDAC5	0.57	8.49	0.37	2.84e-16	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg06360820	chr2:242988706	NA	-0.88	-11.35	-0.47	1.6e-26	Obesity-related traits;
LGG	cis	rs6743226	0.603	rs58226367	chr2:242227547	C/T	cg10021735	chr2:242295487	FARP2	0.4	7.08	0.31	5.49e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg16141378	chr3:129829833	LOC729375	0.42	9.79	0.41	1.1e-20	Triglycerides;
LGG	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.39	-0.32	6.99e-13	HDL cholesterol;
LGG	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg06618935	chr21:46677482	NA	-0.53	-9.17	-0.39	1.52e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg04013166	chr16:89971882	TCF25	0.51	6.9	0.31	1.69e-11	Skin colour saturation;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.5	0.65	1.25e-57	Platelet count;
LGG	cis	rs7766436	0.885	rs13210010	chr6:22585075	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs12545109	0.879	rs2576588	chr8:57381627	G/A	cg19413350	chr8:57351067	NA	-0.42	-6.84	-0.3	2.48e-11	Obesity-related traits;
LGG	cis	rs11971779	0.618	rs10085814	chr7:139064089	A/G	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.35e-12	Diisocyanate-induced asthma;
LGG	cis	rs1707322	0.717	rs2991989	chr1:46082965	C/T	cg03146154	chr1:46216737	IPP	-0.55	-10.64	-0.44	8.57e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg23943801	chr12:72149029	RAB21	0.47	7.16	0.32	3.18e-12	Emphysema imaging phenotypes;
LGG	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11890956	chr21:40555474	PSMG1	0.76	13.02	0.52	2.92e-33	Cognitive function;
LGG	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg02531859	chr7:37888154	TXNDC3	-0.45	-7.01	-0.31	8.63e-12	Alzheimer's disease (late onset);
LGG	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.9	-0.57	2.61e-41	Aortic root size;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00166722	chr3:10149974	C3orf24	0.54	9.03	0.39	4.53e-18	Alzheimer's disease;
LGG	cis	rs6669919	0.653	rs12058879	chr1:211684876	G/A	cg10512769	chr1:211675356	NA	-0.69	-14.45	-0.56	2.56e-39	Intelligence (multi-trait analysis);
LGG	cis	rs4308124	0.708	rs56693625	chr2:111965155	G/A	cg04571233	chr2:111982156	NA	-0.6	-9.8	-0.41	9.82e-21	Vitiligo;
LGG	cis	rs3784262	0.869	rs4646628	chr15:58255282	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.3	-0.36	1.18e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7017914	1.000	rs13252719	chr8:71734569	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.68	-0.3	6.9e-11	Bone mineral density;
LGG	cis	rs708547	0.874	rs1401190	chr4:57885174	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg19913688	chr11:428466	ANO9	-0.66	-8.45	-0.37	3.71e-16	Body mass index;
LGG	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10493773	0.577	rs17398175	chr1:86074710	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.47	-7.07	-0.31	5.92e-12	Urate levels in overweight individuals;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9715521	0.746	rs57464801	chr4:59851169	C/G	cg11281224	chr4:60001000	NA	-0.51	-8.49	-0.37	2.78e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg00666640	chr1:248458726	OR2T12	-0.52	-8.64	-0.37	8.91e-17	Common traits (Other);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21302120	chr4:24585281	DHX15	0.43	6.98	0.31	1.06e-11	Menarche (age at onset);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg00603498	chr17:5322775	RPAIN;NUP88	0.39	6.71	0.3	5.61e-11	Body mass index;
LGG	cis	rs1018697	1.000	rs7896903	chr10:104566417	A/G	cg04362960	chr10:104952993	NT5C2	0.5	9.13	0.39	2.18e-18	Colorectal adenoma (advanced);
LGG	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.88	0.34	2.39e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs526231	0.578	rs59323174	chr5:102267869	T/C	cg23492399	chr5:102201601	PAM	-0.6	-9.21	-0.39	1.18e-18	Primary biliary cholangitis;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.61	-0.33	1.5700000000000001e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12545109	0.800	rs2670026	chr8:57424338	G/T	cg19413350	chr8:57351067	NA	-0.42	-6.82	-0.3	2.85e-11	Obesity-related traits;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg10950524	chr7:2139216	MAD1L1	0.34	7.32	0.32	1.13e-12	Schizophrenia;
LGG	cis	rs1461503	0.900	rs7107502	chr11:122830214	G/A	cg27398637	chr11:122830231	C11orf63	-0.74	-15.35	-0.58	2.74e-43	Menarche (age at onset);
LGG	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg06481639	chr22:41940642	POLR3H	0.46	6.67	0.3	7.49e-11	Vitiligo;
LGG	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.83	0.68	8.26e-64	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	trans	rs3858145	0.500	rs4633337	chr10:70045727	G/T	cg04882175	chr6:131122610	NA	0.53	7.37	0.32	7.73e-13	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs7177699	0.557	rs7403593	chr15:79111962	A/G	cg00540400	chr15:79124168	NA	-0.54	-11.46	-0.47	6.32e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs7077164	0.960	rs1227777	chr10:71581131	A/G	cg20696214	chr10:71583771	COL13A1	0.37	7.24	0.32	1.88e-12	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs365132	0.818	rs251843	chr5:176476106	A/G	cg16309518	chr5:176445507	NA	-0.51	-11.18	-0.46	7.53e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.64	-0.41	3.69e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs2227564	0.729	rs2633303	chr10:75645882	G/T	cg00564723	chr10:75632066	CAMK2G	-0.45	-9.06	-0.39	3.69e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs12738007	0.967	rs10915233	chr1:29475975	G/A	cg01115565	chr1:29584222	PTPRU	-0.26	-7.17	-0.32	2.91e-12	Schizophrenia;
LGG	cis	rs12190007	0.547	rs3006217	chr6:169862878	A/G	cg15038512	chr6:170123185	PHF10	-0.45	-8.62	-0.37	1.07e-16	Obesity-related traits;
LGG	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg13939156	chr17:80058883	NA	-0.52	-10.57	-0.44	1.58e-23	Life satisfaction;
LGG	cis	rs56283067	0.847	rs10807302	chr6:44710152	G/C	cg20913747	chr6:44695427	NA	-0.67	-11.96	-0.49	6.33e-29	Total body bone mineral density;
LGG	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.7	-0.51	6.21e-32	Diastolic blood pressure;
LGG	cis	rs3741151	0.773	rs113465107	chr11:73210416	T/G	cg17517138	chr11:73019481	ARHGEF17	0.85	8.14	0.35	3.75e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4690686	0.500	rs12498564	chr4:177264827	T/C	cg17059388	chr4:177262070	NA	1.03	24.15	0.75	5.55e-84	Essential tremor;
LGG	cis	rs9815354	0.904	rs9848992	chr3:41875297	C/T	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg04703951	chr17:43578652	NA	-0.29	-6.67	-0.3	7.21e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg05335186	chr13:53173507	NA	0.44	8.65	0.37	8.74e-17	Lewy body disease;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg23758822	chr17:41437982	NA	0.9	15.87	0.59	1.28e-45	Menopause (age at onset);
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.74	0.34	6.23e-14	Lung cancer;
LGG	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg25809561	chr17:30822961	MYO1D	0.4	9.52	0.4	9.49e-20	Schizophrenia;
LGG	cis	rs834603	0.687	rs10280277	chr7:47467178	G/A	cg23694490	chr7:47445681	TNS3	0.45	12.36	0.5	1.6e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.59e-11	Type 2 diabetes;
LGG	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg06808227	chr14:105710500	BRF1	-0.59	-10.77	-0.45	2.71e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2276314	0.857	rs72883058	chr18:33612917	G/A	cg05985134	chr18:33552581	C18orf21	0.63	9.97	0.42	2.47e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7568458	0.846	rs6547621	chr2:85774676	G/A	cg17127132	chr2:85788382	GGCX	0.48	8.49	0.37	2.74e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.23	-0.36	1.96e-15	Mood instability;
LGG	trans	rs9354308	0.764	rs9360166	chr6:66590974	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.9	-0.31	1.76e-11	Metabolite levels;
LGG	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.1	-0.31	4.68e-12	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20357023	chr2:178417605	TTC30B	0.55	8.45	0.37	3.79e-16	Gut microbiome composition (summer);
LGG	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg27121462	chr16:89883253	FANCA	0.62	11.45	0.47	6.66e-27	Vitiligo;
LGG	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg06634786	chr22:41940651	POLR3H	-0.56	-9.27	-0.4	7.32e-19	Vitiligo;
LGG	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg19336497	chr11:14380999	RRAS2	-0.58	-11.7	-0.48	7.1e-28	Sense of smell;
LGG	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	9.05	0.39	3.99e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4727027	0.933	rs12154382	chr7:148862284	C/T	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.35	0.32	9.34e-13	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg26384229	chr12:38710491	ALG10B	0.71	14.16	0.55	4.27e-38	Heart rate;
LGG	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.36	-0.32	8.24e-13	Height;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg19168338	chr16:4465731	CORO7	-0.84	-15.07	-0.57	4.71e-42	Schizophrenia;
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.72	0.41	1.88e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg01448562	chr3:133502909	NA	-0.74	-13.76	-0.54	2.43e-36	Iron status biomarkers;
LGG	cis	rs10870270	1.000	rs7077744	chr10:133770201	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.67	-0.51	8.82e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg13073564	chr4:8508604	NA	-0.6	-11.96	-0.49	6.74e-29	Response to antineoplastic agents;
LGG	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12016809	chr21:47604291	C21orf56	0.49	8.21	0.36	2.16e-15	Testicular germ cell tumor;
LGG	trans	rs9929218	0.859	rs9936682	chr16:68748223	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.57	-0.59	2.91e-44	Colorectal cancer;
LGG	cis	rs74781061	0.929	rs8041807	chr15:74826931	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg08997352	chr12:9597637	DDX12	-0.77	-15.36	-0.58	2.54e-43	Breast size;
LGG	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg04568710	chr12:38710424	ALG10B	0.36	7.44	0.33	4.79e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-9.86	-0.42	5.95e-21	Prostate cancer;
LGG	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg25883020	chr8:41504993	NKX6-3	0.33	7.27	0.32	1.58e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26306683	chr17:18585705	ZNF286B	-0.41	-6.86	-0.3	2.18e-11	Pancreatic cancer;
LGG	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-8.23	-0.36	1.87e-15	Height;
LGG	cis	rs2224391	0.540	rs1570085	chr6:5253063	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.41	-0.33	6.23e-13	Height;
LGG	cis	rs6964587	0.626	rs10234074	chr7:91520119	C/T	cg17063962	chr7:91808500	NA	-0.44	-7.98	-0.35	1.14e-14	Breast cancer;
LGG	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg25319279	chr11:5960081	NA	-0.59	-9.05	-0.39	4.05e-18	DNA methylation (variation);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23927983	chr2:179315956	PRKRA;MIR548N;DFNB59	0.65	7.45	0.33	4.6e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.559	rs78440378	chr7:106962782	C/A	cg02696742	chr7:106810147	HBP1	-0.73	-10.37	-0.43	8.86e-23	Coronary artery disease;
LGG	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg26039829	chr8:22132926	PIWIL2	0.52	11.56	0.47	2.59e-27	Hypertriglyceridemia;
LGG	cis	rs9486719	0.895	rs34051754	chr6:97007754	A/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.85	-0.3	2.37e-11	Migraine;Coronary artery disease;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg02725872	chr8:58115012	NA	-0.94	-13.15	-0.52	8.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs4936891	0.520	rs11219399	chr11:123868425	C/T	cg22125253	chr11:123886957	OR10G4	-0.46	-7.78	-0.34	4.9e-14	Male fertility;
LGG	cis	rs6032067	0.929	rs45461302	chr20:43805274	G/A	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06155802	chr1:228270483	ARF1	0.45	6.77	0.3	3.99e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-16.96	-0.62	1.57e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg06521331	chr12:34319734	NA	0.4	7.02	0.31	8.2e-12	Morning vs. evening chronotype;
LGG	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05901451	chr6:126070800	HEY2	0.51	8.57	0.37	1.55e-16	Endometrial cancer;
LGG	cis	rs6546550	0.867	rs1048266	chr2:70132676	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00761968	chr13:53314142	LECT1	0.33	6.92	0.31	1.52e-11	Lewy body disease;
LGG	trans	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07923666	chr12:49932857	KCNH3	-0.43	-6.65	-0.3	8.31e-11	Resting heart rate;
LGG	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg23601416	chr22:19950040	COMT	0.36	8.98	0.39	7.04e-18	Blood metabolite levels;
LGG	cis	rs8014204	0.935	rs8010840	chr14:75355203	T/C	cg03030879	chr14:75389066	RPS6KL1	0.39	7.11	0.31	4.37e-12	Caffeine consumption;
LGG	cis	rs7149337	1.000	rs4901103	chr14:51746873	C/T	cg23942311	chr14:51606299	NA	0.32	7.08	0.31	5.26e-12	Cancer;
LGG	trans	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	cis	rs701145	0.585	rs1713807	chr3:153883344	C/T	cg12800244	chr3:153838788	SGEF	0.79	8.33	0.36	9.17e-16	Coronary artery disease;
LGG	trans	rs13256369	0.826	rs7846050	chr8:8575669	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.83	-0.3	2.66e-11	Obesity-related traits;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg11878867	chr6:150167359	LRP11	0.48	8.16	0.35	3.15e-15	Lung cancer;
LGG	cis	rs7572733	0.935	rs2217837	chr2:198746259	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.49	0.37	2.91e-16	Dermatomyositis;
LGG	cis	rs16854884	0.770	rs7653331	chr3:143810909	G/A	cg06585982	chr3:143692056	C3orf58	0.57	9.23	0.39	9.93e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg18225595	chr11:63971243	STIP1	-0.53	-10.58	-0.44	1.46e-23	Platelet count;
LGG	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg26769984	chr7:1090371	C7orf50	0.43	6.71	0.3	5.8200000000000003e-11	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	trans	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.13	0.49	1.37e-29	Mean corpuscular volume;
LGG	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.89	0.38	1.35e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.99	-0.35	1.06e-14	IgG glycosylation;
LGG	cis	rs10937275	0.624	rs10513810	chr3:186667885	A/G	cg26193484	chr3:186648175	ST6GAL1	0.79	8.5	0.37	2.59e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg11062466	chr8:58055876	NA	0.54	8.87	0.38	1.56e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs17533156	0.525	rs77932036	chr17:75207586	T/G	cg11416367	chr17:75137675	SEC14L1	0.78	11.26	0.46	3.53e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12681288	0.523	rs112307130	chr8:962483	G/A	cg08648136	chr8:956695	NA	0.42	8.84	0.38	2.09e-17	Schizophrenia;
LGG	cis	rs7527798	0.592	rs6657161	chr1:207847128	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.01	-0.31	8.35e-12	Erythrocyte sedimentation rate;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08677398	chr8:58056175	NA	0.48	7.9	0.34	2.11e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg16885296	chr6:26284938	NA	0.37	8.17	0.35	3.03e-15	Educational attainment;
LGG	cis	rs7647973	0.731	rs9831648	chr3:49214303	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.5	-7.22	-0.32	2.17e-12	Menarche (age at onset);
LGG	cis	rs3806843	0.676	rs2245643	chr5:140029780	C/T	cg19875535	chr5:140030758	IK	-0.59	-12.33	-0.5	2.2e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7586879	0.828	rs10184813	chr2:25090236	T/C	cg04586622	chr2:25135609	ADCY3	0.35	8.48	0.37	3.07e-16	Body mass index;
LGG	cis	rs7246865	0.724	rs10424674	chr19:17183185	G/A	cg19418318	chr19:17219073	MYO9B	0.31	8.22	0.36	2.11e-15	Reticulocyte fraction of red cells;
LGG	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg13385794	chr1:248469461	NA	-0.48	-8.09	-0.35	5.26e-15	Common traits (Other);
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04008888	chr11:68622739	NA	-0.54	-11.6	-0.47	1.7e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.85	-0.54	9.74e-37	Response to antipsychotic treatment;
LGG	trans	rs8073060	0.586	rs7212488	chr17:33993476	A/T	cg19694781	chr19:47549865	TMEM160	-1.16	-18.21	-0.65	2.86e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6796502	0.541	rs28440083	chr3:46881986	A/G	cg22309949	chr3:46792192	NA	-0.59	-7.81	-0.34	3.82e-14	Breast cancer;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.95	-0.45	5.46e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg21782813	chr7:2030301	MAD1L1	0.54	13.14	0.52	9.43e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26076054	chr5:421317	AHRR	-0.46	-7.59	-0.33	1.8e-13	Cystic fibrosis severity;
LGG	cis	rs9880211	0.948	rs9844666	chr3:135974216	G/A	cg21827317	chr3:136751795	NA	-0.48	-6.89	-0.3	1.86e-11	Body mass index;Height;
LGG	cis	rs11722228	0.521	rs62288520	chr4:10099674	G/A	cg08250081	chr4:10125330	NA	0.67	12.34	0.5	1.9e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg10760299	chr15:45669010	GATM	0.4	8.02	0.35	8.96e-15	Homoarginine levels;
LGG	cis	rs283228	0.798	rs283226	chr6:101756042	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.38e-23	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg01338084	chr22:32026380	PISD	1.44	11.73	0.48	5.29e-28	Age-related hearing impairment;
LGG	cis	rs12612619	0.579	rs4552148	chr2:27080513	A/T	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.94	-0.31	1.3e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs62400317	0.859	rs12196217	chr6:45204921	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.09	-0.42	8.95e-22	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13789711	chr9:139743225	PHPT1	0.45	7.17	0.32	3.03e-12	Gut microbiome composition (summer);
LGG	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg27489772	chr12:121021490	NA	0.58	7.71	0.34	7.91e-14	Type 1 diabetes nephropathy;
LGG	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.61	7.28	0.32	1.44e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg23815491	chr16:72088622	HP	0.55	11.85	0.48	1.8e-28	Fibrinogen levels;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg27129171	chr3:47204927	SETD2	0.79	15.23	0.58	9.76e-43	Colorectal cancer;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg23758822	chr17:41437982	NA	0.87	15.39	0.58	1.84e-43	Menopause (age at onset);
LGG	cis	rs28595532	0.720	rs72670230	chr4:119312490	T/C	cg21605333	chr4:119757512	SEC24D	0.89	8.37	0.36	6.95e-16	Cannabis dependence symptom count;
LGG	cis	rs72772090	0.539	rs72773917	chr5:96111302	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-9.24	-0.39	8.68e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg25356066	chr3:128598488	ACAD9	0.45	6.86	0.3	2.27e-11	IgG glycosylation;
LGG	cis	rs600550	0.588	rs11230240	chr11:60072975	A/G	cg05040360	chr11:60102449	MS4A6E	0.38	8.23	0.36	1.99e-15	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	trans	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg16339924	chr4:17578868	LAP3	-0.5	-8.42	-0.36	4.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9992101	0.588	rs62300830	chr4:77221028	A/T	cg17010112	chr4:77227123	STBD1	-0.45	-9.39	-0.4	2.72e-19	Creatinine levels;
LGG	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7843479	0.601	rs4422769	chr8:21844265	A/G	cg17168535	chr8:21777572	XPO7	0.82	16.09	0.6	1.39e-46	Mean corpuscular volume;
LGG	cis	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg13010199	chr12:38710504	ALG10B	0.71	14.25	0.55	1.9e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13082711	1.000	rs6791212	chr3:27507179	C/A	cg02860705	chr3:27208620	NA	0.73	12.93	0.52	7.11e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.52	-0.4	1e-19	Alcohol dependence;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.14	-0.31	3.69e-12	Triglycerides;
LGG	cis	rs4538187	0.853	rs6546032	chr2:64075076	A/C	cg19915305	chr2:64069682	UGP2	0.69	14.46	0.56	2.18e-39	Systolic blood pressure;
LGG	cis	rs11574514	0.661	rs9925393	chr16:67780829	C/T	cg09738193	chr16:67926317	PSKH1	-0.74	-6.85	-0.3	2.33e-11	Crohn's disease;
LGG	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.85	-0.51	1.48e-32	Response to antipsychotic treatment;
LGG	cis	rs113835537	0.529	rs57724777	chr11:66236431	G/A	cg24851651	chr11:66362959	CCS	0.43	7.25	0.32	1.77e-12	Airway imaging phenotypes;
LGG	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26714650	chr12:56694279	CS	1.48	17.66	0.63	9.82e-54	Psoriasis vulgaris;
LGG	trans	rs1973993	0.967	rs1555543	chr1:96944797	A/C	cg10631902	chr5:14652156	NA	0.53	11.7	0.48	6.96e-28	Weight;
LGG	cis	rs701145	0.537	rs1713855	chr3:153847833	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.66	-0.37	8.07e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4595586	0.525	rs1400279	chr12:39343825	T/A	cg13010199	chr12:38710504	ALG10B	0.48	8.61	0.37	1.14e-16	Morning vs. evening chronotype;
LGG	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg27147174	chr7:100797783	AP1S1	-0.65	-12.34	-0.5	1.97e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs858239	0.600	rs28499396	chr7:23124098	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.54	0.33	2.52e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs367943	0.712	rs7734061	chr5:112700175	A/G	cg12552261	chr5:112820674	MCC	0.58	10.58	0.44	1.41e-23	Type 2 diabetes;
LGG	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg07537917	chr2:241836409	C2orf54	-0.42	-8.13	-0.35	4.03e-15	Urinary metabolites;
LGG	cis	rs597583	0.709	rs7940527	chr11:117398202	C/G	cg27161313	chr11:117392002	DSCAML1	0.44	7.32	0.32	1.11e-12	Putamen volume;
LGG	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg20476274	chr7:133979776	SLC35B4	0.71	13.93	0.54	4.22e-37	Mean platelet volume;
LGG	cis	rs10262624	1.000	rs10950974	chr7:23917280	C/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.78e-11	Schizophrenia;
LGG	cis	rs56146971	0.763	rs28624795	chr14:91859055	C/T	cg14409461	chr14:91925021	SMEK1	-0.44	-6.96	-0.31	1.15e-11	Alzheimer disease and age of onset;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.47	-8.86	-0.38	1.71e-17	Obesity-related traits;
LGG	cis	rs9503598	0.714	rs11242859	chr6:3454032	G/A	cg00476032	chr6:3446245	SLC22A23	0.61	13.03	0.52	2.86e-33	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26306683	chr17:18585705	ZNF286B	0.49	9.42	0.4	2.09e-19	Educational attainment (years of education);
LGG	cis	rs7793919	0.726	rs4720401	chr7:4780943	G/A	cg09789173	chr7:4769017	FOXK1	0.78	17.22	0.62	1.07e-51	Mosquito bite size;
LGG	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg09461388	chr22:46763229	CELSR1	-0.6	-6.77	-0.3	3.94e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg25237894	chr2:233734115	C2orf82	-0.43	-6.85	-0.3	2.34e-11	Schizophrenia;
LGG	cis	rs4268898	0.722	rs35520052	chr2:24415277	C/T	cg06627628	chr2:24431161	ITSN2	0.48	7.88	0.34	2.43e-14	Asthma;
LGG	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs12200782	0.649	rs9467733	chr6:26379675	T/C	cg27193005	chr6:26382695	BTN2A2	-0.49	-7.0	-0.31	9.31e-12	Small cell lung carcinoma;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.28e-13	Menopause (age at onset);
LGG	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.92	-10.23	-0.43	2.8e-22	Diabetic retinopathy;
LGG	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg21775007	chr8:11205619	TDH	-0.6	-9.97	-0.42	2.38e-21	Retinal vascular caliber;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.5	-8.15	-0.35	3.41e-15	Longevity;
LGG	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.95	-0.35	1.48e-14	Mean platelet volume;
LGG	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg02269571	chr22:50332266	NA	-0.62	-9.76	-0.41	1.42e-20	Schizophrenia;
LGG	cis	rs11920090	0.789	rs11711206	chr3:170732945	A/G	cg09710316	chr3:170744871	SLC2A2	0.7	9.32	0.4	4.69e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs922107	0.967	rs2045583	chr1:90018974	G/T	cg01128109	chr1:89989507	LRRC8B	0.32	7.28	0.32	1.41e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-11.0	-0.46	3.83e-25	Personality dimensions;
LGG	cis	rs714515	0.934	rs9425589	chr1:172355276	G/A	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg06970220	chr1:156163860	SLC25A44	0.45	6.68	0.3	6.96e-11	Testicular germ cell tumor;
LGG	cis	rs10875595	0.732	rs62378370	chr5:140679460	T/C	cg24830062	chr5:140700576	TAF7	-0.57	-7.21	-0.32	2.23e-12	Pulmonary function decline;
LGG	cis	rs1451375	0.617	rs17733244	chr7:50575495	T/C	cg20336341	chr7:50628841	DDC	0.44	7.54	0.33	2.43e-13	Malaria;
LGG	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12432903	chr7:1882776	MAD1L1	0.54	8.74	0.38	4.18e-17	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs58908911	chr17:29244558	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.27	-0.32	1.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg23806715	chr17:73775811	H3F3B	0.5	6.86	0.3	2.26e-11	Psoriasis;
LGG	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.11	0.35	4.54e-15	Homoarginine levels;
LGG	trans	rs2270927	1.000	rs13174383	chr5:75580416	T/G	cg13563193	chr19:33072644	PDCD5	0.86	11.48	0.47	5.34e-27	Mean corpuscular volume;
LGG	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.57e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4919694	1.000	rs4917988	chr10:104752830	T/G	cg04362960	chr10:104952993	NT5C2	1.07	15.17	0.58	1.68e-42	Arsenic metabolism;
LGG	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.61	-0.44	1.12e-23	Response to antipsychotic treatment;
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.2	-0.32	2.52e-12	Bipolar disorder;
LGG	cis	rs1419980	0.630	rs2377089	chr12:7737325	T/C	cg10578777	chr12:7781093	NA	0.62	8.39	0.36	5.97e-16	HDL cholesterol levels;
LGG	cis	rs72949976	0.707	rs10932473	chr2:214039057	C/T	cg08319019	chr2:214017104	IKZF2	-0.5	-7.9	-0.34	2.12e-14	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.51	8.15	0.35	3.39e-15	Longevity;
LGG	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg22563815	chr15:78856949	CHRNA5	-0.28	-6.98	-0.31	1.04e-11	Sudden cardiac arrest;
LGG	cis	rs12545109	0.800	rs973548	chr8:57416402	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06850241	chr22:41845214	NA	0.45	7.22	0.32	2.15e-12	Vitiligo;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.78	-0.51	2.97e-32	Blood trace element (Zn levels);
LGG	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg12623918	chr2:306882	NA	0.53	9.85	0.42	6.75e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg02462569	chr6:150064036	NUP43	0.4	8.45	0.37	3.75e-16	Lung cancer;
LGG	trans	rs2727020	0.894	rs11040333	chr11:49346332	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-13.52	-0.53	2.5e-35	Coronary artery disease;
LGG	cis	rs8078723	0.510	rs3087852	chr17:38137364	G/A	cg17467752	chr17:38218738	THRA	-0.54	-9.36	-0.4	3.51e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs2916247	0.954	rs990132	chr8:93106039	A/G	cg10183463	chr8:93005414	RUNX1T1	0.38	7.76	0.34	5.59e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg03342759	chr3:160939853	NMD3	-0.53	-8.95	-0.38	8.32e-18	Educational attainment (years of education);
LGG	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg03433033	chr1:76189801	ACADM	0.75	12.09	0.49	1.93e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.39	0.36	5.82e-16	Gout;
LGG	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg12756686	chr19:29218302	NA	0.59	7.89	0.34	2.19e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	trans	rs7939886	0.920	rs80232778	chr11:55970655	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	trans	rs2574985	0.739	rs3011783	chr10:52290355	C/T	cg18558237	chr10:81444220	LOC650623	0.44	6.82	0.3	2.89e-11	Subjective well-being;
LGG	cis	rs12731740	1.000	rs35187553	chr1:208026279	G/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.43	-0.33	5.21e-13	Biomedical quantitative traits;
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22168489	chr12:122356033	WDR66	0.41	9.71	0.41	2.03e-20	Mean corpuscular volume;
LGG	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg13009111	chr11:71350975	NA	-0.33	-7.27	-0.32	1.52e-12	Monocyte count;
LGG	trans	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs10001701	chr4:98918871	G/C	cg05340658	chr4:99064831	C4orf37	0.47	7.61	0.33	1.53e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1372520	0.684	rs2583978	chr4:90750326	A/C	cg15133208	chr4:90757351	SNCA	-0.41	-8.27	-0.36	1.48e-15	Neuroticism;
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg03517284	chr6:25882590	NA	-0.4	-7.26	-0.32	1.66e-12	Height;
LGG	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.32	-0.63	3.64e-52	Bladder cancer;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs3008870	1.000	rs2755240	chr1:67477339	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	23.49	0.74	6.16e-81	Lymphocyte percentage of white cells;
LGG	cis	rs7246657	0.722	rs2972437	chr19:38210511	G/T	cg23950597	chr19:37808831	NA	-0.59	-8.29	-0.36	1.24e-15	Coronary artery calcification;
LGG	cis	rs930421	0.544	rs4953645	chr2:42985036	A/T	cg14631114	chr2:43023945	NA	0.44	9.35	0.4	3.81e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs35661897	0.920	rs12469727	chr2:227301483	A/G	cg03426602	chr2:227312417	NA	0.45	6.96	0.31	1.18e-11	Urinary tract infection frequency;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15385623	chr3:24536309	THRB	0.46	7.48	0.33	3.81e-13	Cognitive performance;
LGG	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg26076054	chr5:421317	AHRR	-0.47	-7.75	-0.34	5.82e-14	Cystic fibrosis severity;
LGG	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	Neuroticism;
LGG	trans	rs1032833	0.660	rs77975658	chr2:179973354	G/A	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	trans	rs4427176	0.507	rs10464998	chr8:9584450	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Mosquito bite size;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg19168338	chr16:4465731	CORO7	-0.75	-13.96	-0.54	3.34e-37	Schizophrenia;
LGG	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg21775007	chr8:11205619	TDH	0.46	7.33	0.32	1.01e-12	Mood instability;
LGG	cis	rs7241530	0.636	rs34970639	chr18:75912255	A/G	cg14642773	chr18:75888474	NA	0.44	8.29	0.36	1.2e-15	Educational attainment (years of education);
LGG	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg10160682	chr2:1713001	PXDN	0.53	9.56	0.41	7.05e-20	Response to antipsychotic treatment;
LGG	cis	rs3849570	0.961	rs7620240	chr3:81762787	G/T	cg07356753	chr3:81810745	GBE1	-0.49	-8.04	-0.35	7.73e-15	Waist circumference;Body mass index;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.62	11.35	0.47	1.64e-26	Obesity-related traits;
LGG	cis	rs4789452	0.967	rs7217986	chr17:75369578	T/C	cg06761530	chr17:75373219	SEPT9	-0.38	-7.44	-0.33	4.83e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs7660883	0.836	rs342453	chr4:88018489	C/G	cg21988461	chr4:88008667	AFF1	0.34	9.83	0.42	7.6e-21	HDL cholesterol levels;
LGG	cis	rs708547	0.624	rs1277284	chr4:57855361	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	10.33	0.43	1.17e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg22509189	chr2:225307070	NA	-0.6	-9.71	-0.41	2.06e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs3771570	0.901	rs28433352	chr2:242339656	A/G	cg21155796	chr2:242212141	HDLBP	0.65	9.08	0.39	3.05e-18	Prostate cancer;
LGG	trans	rs12517041	1.000	rs1428618	chr5:23282263	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.03	-0.46	2.71e-25	Calcium levels;
LGG	cis	rs877282	0.520	rs12360072	chr10:813082	C/T	cg15764593	chr10:829463	NA	-0.43	-7.51	-0.33	2.99e-13	Uric acid levels;
LGG	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.79	0.3	3.53e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg18681998	chr4:17616180	MED28	-0.72	-14.84	-0.57	4.75e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg06437703	chr8:37914619	EIF4EBP1	0.75	11.01	0.46	3.47e-25	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.82	-0.3	2.89e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.74e-12	Lung cancer;
LGG	cis	rs4702718	0.592	rs364491	chr5:10732008	G/C	cg14521931	chr5:10832172	NA	-0.43	-8.1	-0.35	4.98e-15	Obesity-related traits;
LGG	cis	rs6032067	0.538	rs17331776	chr20:43744754	G/C	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.28e-22	Blood protein levels;
LGG	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.52	-0.33	2.93e-13	Morning vs. evening chronotype;
LGG	trans	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg16141378	chr3:129829833	LOC729375	-0.46	-11.22	-0.46	5.09e-26	Parkinson's disease;
LGG	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs6890695	1	rs6890695	chr5:130888424	C/G	cg06307176	chr5:131281290	NA	0.54	9.01	0.39	5.33e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg21459583	chr1:227974177	NA	0.59	8.35	0.36	8.2e-16	Major depressive disorder;
LGG	cis	rs889312	0.500	rs252906	chr5:56119190	G/T	cg14703610	chr5:56206110	C5orf35	0.47	8.66	0.37	8.16e-17	Breast cancer;Breast cancer (early onset);
LGG	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.1e-11	Retinal vascular caliber;
LGG	cis	rs7209395	1.000	rs8077672	chr17:64175187	G/A	cg19474267	chr17:64306194	PRKCA	0.52	8.07	0.35	6.11e-15	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs4330281	0.669	rs12631291	chr3:17758297	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.1e-13	Schizophrenia;
LGG	cis	rs3820068	0.608	rs7552400	chr1:16035892	A/G	cg05660106	chr1:15850417	CASP9	0.76	14.24	0.55	1.98e-38	Systolic blood pressure;
LGG	cis	rs963731	0.649	rs2924714	chr2:39333288	A/G	cg04010122	chr2:39346883	SOS1	-0.93	-8.24	-0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg23920097	chr1:209922102	NA	-0.49	-8.18	-0.36	2.85e-15	Red blood cell count;
LGG	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-10.65	-0.44	7.99e-24	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.03	-0.31	7.5e-12	Iron status biomarkers;
LGG	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg08470875	chr2:26401718	FAM59B	-0.43	-8.38	-0.36	6.27e-16	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.851	rs4818768	chr21:46659818	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs68170813	0.641	rs77487103	chr7:107078793	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-9.98	-0.42	2.32e-21	Coronary artery disease;
LGG	cis	rs701145	0.585	rs398512	chr3:153909988	T/C	cg17054900	chr3:154042577	DHX36	0.91	10.28	0.43	1.78e-22	Coronary artery disease;
LGG	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.32	0.36	9.64e-16	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg22676075	chr6:135203613	NA	0.43	7.4	0.33	6.44e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg16797656	chr11:68205561	LRP5	-0.46	-7.59	-0.33	1.74e-13	Bone mineral density (spine);
LGG	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg17691542	chr6:26056736	HIST1H1C	0.54	9.83	0.42	7.86e-21	Height;
LGG	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg02269571	chr22:50332266	NA	-0.59	-9.32	-0.4	4.95e-19	Schizophrenia;
LGG	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg24848339	chr3:12840334	CAND2	0.37	7.9	0.34	2.03e-14	QRS complex (12-leadsum);
LGG	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg18681998	chr4:17616180	MED28	0.86	19.74	0.68	2.27e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg12042659	chr19:58951599	ZNF132	0.35	7.11	0.31	4.56e-12	Uric acid clearance;
LGG	cis	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg26384229	chr12:38710491	ALG10B	0.94	22.0	0.71	6.06e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4566357	0.595	rs6707159	chr2:227909339	T/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.21	-0.39	1.12e-18	Coronary artery disease;
LGG	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	8.73	0.38	4.68e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7193541	0.585	rs3851729	chr16:74485529	A/G	cg01733217	chr16:74700730	RFWD3	-0.84	-18.8	-0.66	5.11e-59	Multiple myeloma;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20308403	chr7:2120281	MAD1L1	0.34	7.13	0.31	3.99e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10819861	0.645	rs10760765	chr9:98861229	C/T	cg14508093	chr9:98862825	NA	0.29	6.71	0.3	5.67e-11	Electrocardiographic traits;
LGG	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg15627072	chr1:2432621	PLCH2	0.38	8.18	0.36	2.83e-15	Ulcerative colitis;
LGG	cis	rs981844	0.796	rs11099904	chr4:154681861	A/G	cg14289246	chr4:154710475	SFRP2	0.63	10.87	0.45	1.11e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg06636001	chr8:8085503	FLJ10661	0.41	7.05	0.31	6.75e-12	Retinal vascular caliber;
LGG	cis	rs2239547	0.562	rs35380116	chr3:52979178	A/G	cg11645453	chr3:52864694	ITIH4	-0.65	-10.1	-0.43	8.02e-22	Schizophrenia;
LGG	cis	rs10789491	1.000	rs601060	chr1:47139580	C/G	cg15501359	chr1:47185051	KIAA0494	-0.75	-14.28	-0.55	1.42e-38	Response to hepatitis C treatment;
LGG	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg16797656	chr11:68205561	LRP5	0.38	6.72	0.3	5.45e-11	Total body bone mineral density;
LGG	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-11.86	-0.48	1.58e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2559856	0.903	rs10128996	chr12:102081498	G/A	cg15068132	chr12:102092402	CHPT1	-0.37	-6.73	-0.3	5.08e-11	Blood protein levels;
LGG	trans	rs1997103	1.000	rs2177803	chr7:55410773	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg17376030	chr22:41985996	PMM1	0.55	8.77	0.38	3.5e-17	Vitiligo;
LGG	cis	rs17092148	1.000	rs6088594	chr20:33343157	A/G	cg12302830	chr20:33297742	TP53INP2	0.47	7.84	0.34	3.2e-14	Neuroticism;
LGG	cis	rs2204008	0.805	rs11179579	chr12:38213957	A/C	cg26384229	chr12:38710491	ALG10B	0.94	21.35	0.7	6.59e-71	Bladder cancer;
LGG	cis	rs12220238	1.000	rs12256105	chr10:75909634	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.75	0.48	4.56e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6908034	0.607	rs74559916	chr6:19818717	G/T	cg02682789	chr6:19804855	NA	0.9	8.42	0.36	4.83e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs8067545	0.578	rs62066870	chr17:20063758	A/C	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.63e-22	Schizophrenia;
LGG	cis	rs9834373	0.553	rs9818134	chr3:78495979	A/C	cg06138941	chr3:78371609	NA	0.47	8.71	0.38	5.48e-17	Protein quantitative trait loci;
LGG	cis	rs9849248	0.627	rs6551287	chr3:88221933	G/A	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	trans	rs9354308	0.738	rs9360168	chr6:66601632	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.37	-0.32	7.83e-13	Obesity;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08645402	chr16:4508243	NA	0.56	10.11	0.43	7.88e-22	Schizophrenia;
LGG	trans	rs208520	0.690	rs207108	chr6:66794096	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.93	-0.31	1.46e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	6.92	0.31	1.52e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9341808	0.718	rs9448908	chr6:80898069	C/T	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg02158880	chr13:53174818	NA	0.47	9.76	0.41	1.38e-20	Lewy body disease;
LGG	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.47	-0.33	3.94e-13	Systolic blood pressure;
LGG	cis	rs5769707	0.837	rs1573726	chr22:50032872	G/A	cg06623630	chr22:50017776	C22orf34	-0.38	-8.05	-0.35	6.93e-15	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.44	6.86	0.3	2.26e-11	Bipolar disorder;
LGG	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg07636037	chr3:49044803	WDR6	-0.59	-10.37	-0.43	8.29e-23	Resting heart rate;
LGG	cis	rs8062405	0.757	rs2411453	chr16:28632021	A/C	cg16576597	chr16:28551801	NUPR1	-0.31	-7.02	-0.31	8.11e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.26	0.49	4.18e-30	Obesity-related traits;
LGG	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.58	-0.37	1.46e-16	Joint mobility (Beighton score);
LGG	trans	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg21775007	chr8:11205619	TDH	0.41	6.7	0.3	6.22e-11	Mood instability;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08645402	chr16:4508243	NA	-0.45	-8.49	-0.37	2.81e-16	Schizophrenia;
LGG	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg13736514	chr6:26305472	NA	0.35	7.02	0.31	7.78e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	0.29	7.97	0.35	1.29e-14	IgG glycosylation;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.46	0.61	2.86e-48	Platelet count;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg19143629	chr17:61920732	SMARCD2	0.39	6.71	0.3	5.66e-11	Prudent dietary pattern;
LGG	cis	rs10751667	0.666	rs10902247	chr11:953686	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.13	0.35	3.95e-15	Alzheimer's disease (late onset);
LGG	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.91	-0.31	1.61e-11	Neuroticism;
LGG	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg26384229	chr12:38710491	ALG10B	1.07	29.44	0.81	3.85e-108	Heart rate;
LGG	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg18188782	chr20:61659543	NA	0.39	6.72	0.3	5.33e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.61	-0.33	1.5e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg12654349	chr5:56205094	C5orf35	0.58	10.01	0.42	1.81e-21	Initial pursuit acceleration;
LGG	cis	rs7172677	0.696	rs56262544	chr15:75379471	A/G	cg10253484	chr15:75165896	SCAMP2	0.49	7.06	0.31	6.14e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.75	-0.3	4.54e-11	Systemic lupus erythematosus;
LGG	cis	rs963731	0.579	rs4670902	chr2:39220904	A/T	cg04010122	chr2:39346883	SOS1	-0.67	-6.94	-0.31	1.31e-11	Corticobasal degeneration;
LGG	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.7	-0.34	8.06e-14	Bladder cancer;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07677032	chr17:61819896	STRADA	-0.56	-9.84	-0.42	7.03e-21	Prudent dietary pattern;
LGG	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg10523679	chr1:76189770	ACADM	0.7	10.44	0.44	4.59e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg13385794	chr1:248469461	NA	0.49	8.2	0.36	2.4e-15	Common traits (Other);
LGG	cis	rs12618769	0.597	rs72821924	chr2:99114924	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.75	-0.3	4.37e-11	Arsenic metabolism;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.53	0.37	2.02e-16	Skin colour saturation;
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-8.56	-0.37	1.66e-16	Lung cancer;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg20453264	chr5:131705742	SLC22A5	0.66	8.42	0.36	4.7e-16	Rheumatoid arthritis;
LGG	cis	rs12220238	0.915	rs7073139	chr10:76071189	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.85	0.38	1.82e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs8180040	0.903	rs2276854	chr3:47276968	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.44	-0.58	1.09e-43	Colorectal cancer;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.43	0.33	5.32e-13	Lung cancer;
LGG	cis	rs16973500	0.808	rs57807129	chr16:71948043	T/C	cg09427745	chr16:71932006	KIAA0174	-0.52	-7.58	-0.33	1.86e-13	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1345301	1.000	rs11686567	chr2:102876609	A/G	cg05295703	chr2:102895712	NA	0.38	7.73	0.34	6.89e-14	Waist circumference;
LGG	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg08916839	chr5:415575	AHRR	0.67	10.91	0.45	8.32e-25	Fat distribution (HIV);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.73	-0.3	5.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg22437258	chr11:111473054	SIK2	-0.5	-8.83	-0.38	2.16e-17	Primary sclerosing cholangitis;
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg07936489	chr17:37558343	FBXL20	0.85	15.85	0.59	1.72e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.49	7.95	0.35	1.45e-14	Longevity;
LGG	trans	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg05926928	chr17:57297772	GDPD1	0.53	8.98	0.39	6.86e-18	Schizophrenia;
LGG	cis	rs2016266	0.964	rs1110720	chr12:53682326	G/A	cg13445358	chr12:53661749	ESPL1	-0.36	-6.79	-0.3	3.42e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs701145	0.585	rs17766586	chr3:153778918	C/T	cg12800244	chr3:153838788	SGEF	-0.79	-9.45	-0.4	1.64e-19	Coronary artery disease;
LGG	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg08601574	chr20:25228251	PYGB	0.38	7.92	0.35	1.73e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2905347	0.560	rs2961293	chr7:22684084	G/A	cg18045685	chr7:22629474	NA	-0.73	-15.99	-0.6	3.83e-46	Major depression and alcohol dependence;
LGG	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.57	0.41	6.4e-20	Fuchs's corneal dystrophy;
LGG	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg26384229	chr12:38710491	ALG10B	0.85	19.18	0.67	8.77e-61	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg02018176	chr4:1364513	KIAA1530	-0.49	-11.7	-0.48	6.77e-28	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.32	0.43	1.35e-22	Motion sickness;
LGG	cis	rs4474465	1.000	rs10899522	chr11:78190763	C/G	cg02023728	chr11:77925099	USP35	-0.4	-7.03	-0.31	7.34e-12	Alzheimer's disease (survival time);
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.52e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg00953403	chr17:74099816	EXOC7	-0.45	-6.82	-0.3	2.89e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg09580153	chr6:41068724	NFYA;LOC221442	-0.45	-7.64	-0.33	1.26e-13	Alzheimer's disease (late onset);
LGG	cis	rs6489882	0.902	rs3759376	chr12:113373563	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.68e-21	Prudent dietary pattern;
LGG	cis	rs4722166	0.630	rs7808457	chr7:22798265	A/T	cg05265849	chr7:22767390	IL6	-0.38	-7.03	-0.31	7.23e-12	Lung cancer;
LGG	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg15704280	chr7:45808275	SEPT13	-1.01	-23.08	-0.73	5.17e-79	Coronary artery disease;
LGG	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg09165964	chr15:75287851	SCAMP5	0.58	10.85	0.45	1.42e-24	Breast cancer;
LGG	cis	rs1832871	0.619	rs262821	chr6:158665197	C/T	cg07215822	chr6:158701037	NA	-0.48	-9.51	-0.4	1.07e-19	Height;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs3204270	0.810	rs8077959	chr17:79670122	G/A	cg18367735	chr17:79674897	NA	0.64	8.35	0.36	7.81e-16	Dental caries;
LGG	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg17376030	chr22:41985996	PMM1	-0.51	-8.08	-0.35	5.54e-15	Vitiligo;
LGG	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg27535305	chr1:53392650	SCP2	-0.3	-6.86	-0.3	2.25e-11	Monocyte count;
LGG	cis	rs9814567	1.000	rs1534026	chr3:134284767	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17376456	0.825	rs10058331	chr5:93279115	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-9.75	-0.41	1.49e-20	Acne (severe);
LGG	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg20673091	chr1:2541236	MMEL1	0.77	18.09	0.64	1.02e-55	Ulcerative colitis;
LGG	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.45	6.68	0.3	6.7e-11	Bipolar disorder;
LGG	cis	rs7209395	0.959	rs7216429	chr17:64160335	G/A	cg19474267	chr17:64306194	PRKCA	0.52	8.1	0.35	4.92e-15	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07677032	chr17:61819896	STRADA	0.66	12.25	0.49	4.46e-30	Prudent dietary pattern;
LGG	cis	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg06521331	chr12:34319734	NA	-0.43	-7.59	-0.33	1.76e-13	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs13125930	chr4:98654695	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.79	0.34	4.39e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.0	-0.6	3.61e-46	Calcium levels;
LGG	cis	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg06521331	chr12:34319734	NA	-0.41	-7.15	-0.32	3.37e-12	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.86	-0.54	8.83e-37	Extrinsic epigenetic age acceleration;
LGG	cis	rs7614311	0.681	rs73117036	chr3:63892725	G/C	cg22134162	chr3:63841271	THOC7	-0.46	-8.12	-0.35	4.14e-15	Lung function (FVC);Lung function (FEV1);
LGG	trans	rs2161208	0.527	rs12187298	chr5:85321958	T/G	cg01787110	chr1:109008453	NBPF6	0.44	6.65	0.3	8.36e-11	Daytime sleep phenotypes;
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg23758822	chr17:41437982	NA	0.85	14.87	0.57	3.75e-41	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg11846333	chr4:119757529	SEC24D	0.82	7.48	0.33	3.73e-13	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg26783146	chr16:4423632	VASN;CORO7	-0.42	-8.0	-0.35	1.01e-14	Schizophrenia;
LGG	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg16208657	chr15:68119293	LBXCOR1	-0.34	-6.78	-0.3	3.77e-11	Obesity;
LGG	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg08885076	chr2:99613938	TSGA10	0.6	11.61	0.47	1.59e-27	Chronic sinus infection;
LGG	cis	rs6719977	0.513	rs7591304	chr2:42977799	A/C	cg14631114	chr2:43023945	NA	0.48	10.14	0.43	6.11e-22	Hyperactive-impulsive symptoms;
LGG	cis	rs2066819	0.892	rs17118431	chr12:56667100	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.24	-0.6	2.78e-47	Psoriasis vulgaris;
LGG	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06634786	chr22:41940651	POLR3H	0.77	12.03	0.49	3.37e-29	Vitiligo;
LGG	cis	rs9357271	0.955	rs9380747	chr6:38375969	A/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.8	-0.45	2.02e-24	Restless legs syndrome;
LGG	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-8.81	-0.38	2.45e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg13010199	chr12:38710504	ALG10B	0.7	13.73	0.54	3.07e-36	Bladder cancer;
LGG	cis	rs6714710	0.603	rs35255677	chr2:98567820	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.83	0.42	7.56e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs4642101	0.765	rs4321514	chr3:12825901	C/T	cg24848339	chr3:12840334	CAND2	0.42	9.64	0.41	3.74e-20	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg21724239	chr8:58056113	NA	0.5	7.49	0.33	3.44e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	1.000	rs35243555	chr17:65876477	G/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg00166722	chr3:10149974	C3orf24	0.52	8.5	0.37	2.54e-16	Alzheimer's disease;
LGG	cis	rs11644362	1.000	rs12918494	chr16:12988455	C/T	cg06890432	chr16:12997467	SHISA9	-0.32	-7.0	-0.31	9.3e-12	Positive affect;Subjective well-being;
LGG	cis	rs11122272	0.735	rs2790881	chr1:231534181	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05835456	chr15:43785425	TP53BP1	0.44	7.23	0.32	1.95e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26271086	chr14:39901518	FBXO33	0.64	7.12	0.31	4.18e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs17776563	0.959	rs1348004	chr15:89113450	C/G	cg05013243	chr15:89149849	MIR1179	-0.49	-10.0	-0.42	1.89e-21	Thyroid hormone levels;
LGG	cis	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05901451	chr6:126070800	HEY2	-0.48	-7.95	-0.35	1.48e-14	Endometrial cancer;
LGG	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.52	-8.33	-0.36	8.91e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg15704280	chr7:45808275	SEPT13	0.89	12.6	0.51	1.73e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.13	0.39	2.21e-18	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.67e-23	Lung cancer;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.73	0.3	5.11e-11	Schizophrenia;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg25478109	chr3:179322476	NDUFB5;MRPL47	0.48	6.87	0.3	2.07e-11	Breast cancer;
LGG	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.48e-24	Aortic root size;
LGG	cis	rs57590327	0.528	rs3821552	chr3:81702139	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.58	-0.33	1.86e-13	Extraversion;
LGG	cis	rs963731	0.649	rs6419600	chr2:39342534	A/G	cg04010122	chr2:39346883	SOS1	0.75	7.68	0.34	9.65e-14	Corticobasal degeneration;
LGG	cis	rs209489	1.000	rs667537	chr6:53204545	C/G	cg15607103	chr6:53167650	ELOVL5	0.54	7.63	0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs3960554	0.709	rs56163935	chr7:75788744	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	12.38	0.5	1.34e-30	Eotaxin levels;
LGG	cis	rs61931739	0.649	rs815049	chr12:33726757	G/C	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs8014204	0.762	rs2359237	chr14:75245002	G/A	cg06637938	chr14:75390232	RPS6KL1	0.62	11.27	0.46	3.42e-26	Caffeine consumption;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.42	-0.36	4.6e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12972275	chr4:122722461	EXOSC9	0.48	7.67	0.34	1.04e-13	Cognitive performance;
LGG	trans	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg12045294	chr17:78518616	RPTOR	-0.46	-7.18	-0.32	2.82e-12	Glycated hemoglobin levels;
LGG	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.34	0.32	9.6e-13	Bladder cancer;
LGG	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg24690094	chr11:67383802	NA	-0.39	-6.86	-0.3	2.2e-11	Mean corpuscular volume;
LGG	cis	rs6558174	0.930	rs12676084	chr8:22493350	C/T	cg03733263	chr8:22462867	KIAA1967	0.65	11.0	0.46	3.72e-25	Breast cancer;
LGG	cis	rs9527	0.525	rs12770034	chr10:104635595	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.22	0.43	2.93e-22	Arsenic metabolism;
LGG	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg03733263	chr8:22462867	KIAA1967	1.12	32.65	0.83	3.53e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4888262	0.545	rs7195499	chr16:74693973	C/G	cg01733217	chr16:74700730	RFWD3	0.93	19.44	0.67	5.37e-62	Testicular germ cell tumor;
LGG	cis	rs12618769	0.656	rs56091613	chr2:99103761	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg17294928	chr15:75287854	SCAMP5	-0.81	-9.18	-0.39	1.42e-18	Lung cancer;
LGG	trans	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg13565492	chr6:43139072	SRF	-0.9	-15.64	-0.59	1.36e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4891159	0.513	rs35534021	chr18:74130523	G/A	cg24786174	chr18:74118243	ZNF516	0.69	17.47	0.63	7.02e-53	Longevity;
LGG	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18252515	chr7:66147081	NA	-0.42	-7.23	-0.32	2.01e-12	Aortic root size;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.63	10.87	0.45	1.14e-24	Obesity-related traits;
LGG	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2816316	0.848	rs3011685	chr1:192524993	C/T	cg02586212	chr1:192544902	RGS1	0.43	8.55	0.37	1.87e-16	Celiac disease;
LGG	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg16512390	chr1:228756714	NA	0.46	7.84	0.34	3.04e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2540226	0.575	rs2716683	chr2:39908418	T/C	cg18968196	chr2:39892502	TMEM178	0.31	8.44	0.37	4.16e-16	Personality dimensions;
LGG	cis	rs72960926	1.000	rs16884731	chr6:75064418	A/G	cg03266952	chr6:74778945	NA	-0.67	-6.84	-0.3	2.48e-11	Metabolite levels (MHPG);
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.56	0.33	2.12e-13	Rheumatoid arthritis;
LGG	cis	rs17209837	0.667	rs45605032	chr7:87090301	C/T	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs708547	0.830	rs1713983	chr4:57883084	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	11.89	0.48	1.24e-28	Response to bleomycin (chromatid breaks);
LGG	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg12046867	chr14:103022105	NA	-0.72	-12.05	-0.49	2.79e-29	Platelet count;
LGG	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg13114125	chr14:105738426	BRF1	-0.84	-16.42	-0.61	4.26e-48	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg11301795	chr4:187892539	NA	-0.95	-26.34	-0.77	4.08e-94	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.53	7.47	0.33	4.01e-13	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs6542838	0.611	rs1976766	chr2:99522754	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.93	-0.31	1.43e-11	Fear of minor pain;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19026306	chr9:35116525	KIAA1539	0.38	6.84	0.3	2.44e-11	Obesity-related traits;
LGG	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs10465746	0.752	rs10874426	chr1:84451820	A/G	cg10977910	chr1:84465055	TTLL7	0.56	10.26	0.43	2.2e-22	Obesity-related traits;
LGG	cis	rs9359856	0.564	rs17506403	chr6:90499059	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.73	-9.23	-0.39	9.8e-19	Bipolar disorder;
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg06916706	chr16:4465613	CORO7	-0.98	-16.84	-0.62	5.75e-50	Schizophrenia;
LGG	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg02002194	chr4:3960332	NA	0.39	7.05	0.31	6.57e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg21545522	chr1:205238299	TMCC2	0.37	7.07	0.31	5.62e-12	Red blood cell count;
LGG	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.5	-0.44	2.77e-23	Response to antipsychotic treatment;
LGG	cis	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.58	-0.5	1.92e-31	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04900785	chr2:44589279	PREPL;C2orf34	0.47	7.17	0.32	3.01e-12	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg16141378	chr3:129829833	LOC729375	0.31	6.74	0.3	4.77e-11	Triglycerides;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg10150615	chr22:24372951	LOC391322	-0.41	-7.08	-0.31	5.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17665859	1.000	rs17665859	chr8:445601	T/C	cg17960703	chr8:356704	FBXO25	0.89	8.07	0.35	5.94e-15	Bilirubin levels;
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg00976097	chr5:421733	AHRR	-0.47	-7.68	-0.34	9.69e-14	Cystic fibrosis severity;
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg23730037	chr7:158596552	ESYT2	-0.47	-8.47	-0.37	3.34e-16	Height;
LGG	cis	rs796364	0.806	rs11689664	chr2:201099961	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.6	-0.37	1.26e-16	Schizophrenia;
LGG	cis	rs9462027	0.628	rs2764197	chr6:34705055	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.68e-24	Systemic lupus erythematosus;
LGG	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg05775895	chr3:12838266	CAND2	0.81	15.61	0.59	1.84e-44	QRS complex (12-leadsum);
LGG	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	cis	rs79839061	0.536	rs3775128	chr4:885828	T/C	cg07828340	chr4:882639	GAK	0.61	7.6	0.33	1.64e-13	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.853	rs6519124	chr22:39045099	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.44	0.65	2.56e-57	Menopause (age at onset);
LGG	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.18	-0.43	4.12e-22	Chronic sinus infection;
LGG	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg14664628	chr15:75095509	CSK	0.46	8.69	0.37	6.53e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	8.02	0.35	8.9e-15	Menarche (age at onset);
LGG	trans	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg16724585	chr3:197361211	NA	-0.48	-8.36	-0.36	7.52e-16	Pancreatic cancer;
LGG	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg19168338	chr16:4465731	CORO7	-0.92	-16.84	-0.62	5.78e-50	Schizophrenia;
LGG	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg07117364	chr1:16154769	NA	-0.48	-8.99	-0.39	6.3e-18	Dilated cardiomyopathy;
LGG	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.5	-0.47	4.27e-27	Morning vs. evening chronotype;
LGG	cis	rs638893	0.530	rs1961138	chr11:118619423	C/T	cg13782932	chr11:118662891	DDX6	0.37	6.72	0.3	5.44e-11	Vitiligo;
LGG	cis	rs6694672	0.867	rs518149	chr1:197188664	A/G	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg15268244	chr15:77196840	NA	0.48	10.31	0.43	1.37e-22	Blood metabolite levels;
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg00405596	chr8:11794950	NA	-0.42	-6.96	-0.31	1.2e-11	Neuroticism;
LGG	cis	rs17227506	0.538	rs71522360	chr8:13463811	A/G	cg03566418	chr8:13424080	C8orf48	0.58	8.76	0.38	3.74e-17	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7011049	1.000	rs11993171	chr8:53832898	C/A	cg26025543	chr8:53854495	NA	0.73	9.66	0.41	3.02e-20	Systolic blood pressure;
LGG	cis	rs72781680	1.000	rs12616250	chr2:24211550	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.61e-20	Lymphocyte counts;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg17885191	chr8:135476712	NA	0.44	6.92	0.31	1.51e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs2131877	0.830	rs62285225	chr3:194880382	T/C	cg07250128	chr3:194833983	C3orf21	0.45	7.53	0.33	2.67e-13	Non-small cell lung cancer;
LGG	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg10168709	chr10:75599394	CAMK2G	-0.34	-6.65	-0.3	8.51e-11	Inflammatory bowel disease;
LGG	trans	rs1941687	0.831	rs11877286	chr18:31386764	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-8.99	-0.39	6.38e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10463316	0.894	rs12153347	chr5:150765471	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.11	-0.43	7.5e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs71403859	0.667	rs12924650	chr16:71705908	C/T	cg08717414	chr16:71523259	ZNF19	-1.01	-12.57	-0.5	2.21e-31	Post bronchodilator FEV1;
LGG	cis	rs72781680	0.898	rs72786277	chr2:24062818	T/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs2637030	0.559	rs256095	chr5:52972669	C/T	cg06476337	chr5:52856530	NDUFS4	-0.43	-6.68	-0.3	6.67e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.77	-0.45	2.77e-24	Primary sclerosing cholangitis;
LGG	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg06606381	chr12:133084897	FBRSL1	-1.02	-9.95	-0.42	2.97e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg15454534	chr1:248569605	OR2T1	0.37	6.74	0.3	4.68e-11	Common traits (Other);
LGG	trans	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg21659725	chr3:3221576	CRBN	0.68	9.73	0.41	1.78e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg01943577	chr7:158741284	NA	-0.45	-7.92	-0.35	1.77e-14	Height;
LGG	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg08112188	chr17:47440006	ZNF652	0.46	7.44	0.33	5.06e-13	Cancer;
LGG	cis	rs2224391	1.000	rs13191012	chr6:5261292	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.17	-0.35	3.06e-15	Height;
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg23594656	chr7:65796392	TPST1	0.38	8.35	0.36	7.87e-16	Aortic root size;
LGG	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-11.09	-0.46	1.66e-25	Morning vs. evening chronotype;
LGG	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-11.24	-0.46	4.47e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs10870270	0.956	rs11146325	chr10:133767529	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.56	-0.5	2.39e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg02297831	chr4:17616191	MED28	0.46	8.33	0.36	9.29e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9657904	0.813	rs2099892	chr3:105557340	T/C	cg14088669	chr1:158435396	OR10K1	0.42	7.96	0.35	1.31e-14	Multiple sclerosis;
LGG	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.02	-0.35	8.49e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-15.98	-0.6	4.23e-46	Platelet count;
LGG	cis	rs4919087	0.683	rs7091162	chr10:99071242	G/T	cg25902810	chr10:99078978	FRAT1	-0.41	-6.96	-0.31	1.14e-11	Monocyte count;
LGG	trans	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg16011800	chr17:1958478	HIC1	-0.46	-6.69	-0.3	6.65e-11	Lymphocyte counts;Red cell distribution width;
LGG	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.89	0.3	1.8e-11	Morning vs. evening chronotype;
LGG	trans	rs2921036	0.503	rs7817832	chr8:8380821	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-7.17	-0.32	2.93e-12	Neuroticism;
LGG	cis	rs4684776	0.935	rs4684067	chr3:11408873	G/C	cg24705426	chr3:11550659	ATG7	-0.43	-7.78	-0.34	4.7e-14	Small vessel stroke;
LGG	cis	rs6465657	0.903	rs11767962	chr7:97778576	C/T	cg13397024	chr7:97797637	LMTK2	-0.36	-6.76	-0.3	4.14e-11	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08582827	chr6:90529665	MDN1	0.51	7.75	0.34	5.71e-14	Gut microbiome composition (summer);
LGG	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg05444541	chr17:17804740	TOM1L2	0.69	16.4	0.61	5.24e-48	Total body bone mineral density;
LGG	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg13902645	chr11:5959945	NA	-0.66	-10.67	-0.44	6.8e-24	DNA methylation (variation);
LGG	cis	rs4330281	0.653	rs4908966	chr3:17773919	A/G	cg20981856	chr3:17787350	NA	-0.41	-7.67	-0.34	1e-13	Schizophrenia;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.27	0.32	1.58e-12	Schizophrenia;
LGG	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-16.12	-0.6	9.85e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg23743428	chr13:21893420	NA	-0.49	-10.8	-0.45	2.13e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg21926883	chr2:100939477	LONRF2	-0.62	-13.58	-0.53	1.29e-35	Intelligence (multi-trait analysis);
LGG	cis	rs2195525	0.598	rs10892352	chr11:119218553	T/C	cg01451205	chr11:119252210	USP2	0.41	6.87	0.3	2.08e-11	Urate levels;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	7.18	0.32	2.77e-12	Schizophrenia;
LGG	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg12636538	chr11:118901039	SLC37A4	-0.62	-12.35	-0.5	1.67e-30	Coronary artery disease;
LGG	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg21138405	chr5:131827807	IRF1	0.38	10.0	0.42	1.83e-21	Asthma (sex interaction);
LGG	cis	rs5753037	0.585	rs249401	chr22:30216168	C/T	cg01021169	chr22:30184971	ASCC2	-0.4	-8.09	-0.35	5.15e-15	Type 1 diabetes;
LGG	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.72	13.71	0.54	3.85e-36	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg13010199	chr12:38710504	ALG10B	0.66	13.11	0.52	1.32e-33	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9362426	1.000	rs6930076	chr6:88088654	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	10.05	0.42	1.25e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs240764	0.817	rs12199888	chr6:101154419	T/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.63	-0.33	1.36e-13	Neuroticism;
LGG	cis	rs924043	0.636	rs78932628	chr6:170393596	T/C	cg00389036	chr6:170409598	NA	0.54	6.91	0.31	1.6e-11	Type 1 diabetes;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg25703541	chr22:24373054	LOC391322	-0.87	-17.2	-0.62	1.27e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-8.69	-0.37	6.25e-17	Subjective well-being;
LGG	cis	rs7916697	0.947	rs4745950	chr10:69996455	A/G	cg18338521	chr10:69995036	NA	0.33	7.19	0.32	2.69e-12	Optic disc area;
LGG	cis	rs2013441	0.508	rs35191778	chr17:19967762	G/A	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	14.67	0.56	2.74e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6424115	0.679	rs2076345	chr1:24083494	C/T	cg15997130	chr1:24165203	NA	-0.39	-8.79	-0.38	2.86e-17	Immature fraction of reticulocytes;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg05793240	chr7:2802953	GNA12	0.33	7.76	0.34	5.41e-14	Height;
LGG	cis	rs9938149	0.736	rs7501109	chr16:88320862	C/G	cg05435882	chr16:88311214	NA	0.39	6.73	0.3	4.94e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg08621203	chr6:150244597	RAET1G	0.42	7.08	0.31	5.42e-12	Lung cancer;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg06654118	chr4:1303317	MAEA	0.48	8.07	0.35	6.16e-15	Obesity-related traits;
LGG	trans	rs7939886	0.920	rs10896157	chr11:56037621	T/G	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.23	-0.32	2.04e-12	Arsenic metabolism;
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.64	-0.33	1.26e-13	Dementia with Lewy bodies;
LGG	cis	rs10463554	0.963	rs26254	chr5:102556859	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.51	-0.33	3.03e-13	Parkinson's disease;
LGG	cis	rs2274273	0.745	rs8005399	chr14:55542845	A/G	cg04306507	chr14:55594613	LGALS3	0.45	11.07	0.46	2.04e-25	Protein biomarker;
LGG	trans	rs9929218	0.551	rs7201437	chr16:68727130	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	25.37	0.76	1.22e-89	Colorectal cancer;
LGG	trans	rs7944735	0.817	rs7942031	chr11:47868474	T/C	cg03929089	chr4:120376271	NA	0.56	6.9	0.31	1.68e-11	Intraocular pressure;
LGG	cis	rs17067123	0.614	rs6857116	chr4:180062542	G/A	cg26610307	chr4:180072759	NA	-0.51	-7.13	-0.31	3.77e-12	Response to hepatitis C treatment;
LGG	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg11789530	chr4:8429930	ACOX3	-0.87	-17.05	-0.62	6.3e-51	Response to antineoplastic agents;
LGG	cis	rs9443189	0.570	rs569731	chr6:76357593	G/A	cg01950844	chr6:76311363	SENP6	0.76	10.07	0.42	1.07e-21	Prostate cancer;
LGG	cis	rs7264396	0.635	rs2425166	chr20:34439391	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.42	0.33	5.59e-13	Total cholesterol levels;
LGG	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.02	0.62	8.32e-51	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	8.4	0.36	5.54e-16	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	1.000	rs114778020	chr4:119662584	C/A	cg14228332	chr4:119757509	SEC24D	0.98	9.38	0.4	3.07e-19	Cannabis dependence symptom count;
LGG	trans	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	cg07245641	chr1:182991651	LAMC1	0.4	9.1	0.39	2.69e-18	Fuchs's corneal dystrophy;
LGG	trans	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-11.09	-0.46	1.66e-25	Brugada syndrome;
LGG	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg05985134	chr18:33552581	C18orf21	0.64	10.12	0.43	7.07e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg08109568	chr15:31115862	NA	0.47	8.4	0.36	5.51e-16	Huntington's disease progression;
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.83	-0.34	3.33e-14	Personality dimensions;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00684032	chr4:1343700	KIAA1530	-0.52	-10.52	-0.44	2.28e-23	Obesity-related traits;
LGG	cis	rs17301259	0.548	rs7785139	chr7:88401172	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.83	-0.3	2.75e-11	Heschl's gyrus morphology;
LGG	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.2	-0.36	2.32e-15	Small cell lung carcinoma;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.17	-0.32	2.99e-12	Lung cancer;
LGG	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg12395012	chr8:11607386	GATA4	0.39	7.01	0.31	8.57e-12	Monocyte count;
LGG	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg07148914	chr20:33460835	GGT7	0.43	6.88	0.3	1.94e-11	Height;
LGG	cis	rs4919694	1.000	rs74749600	chr10:104732996	T/C	cg04362960	chr10:104952993	NT5C2	1.04	13.33	0.53	1.52e-34	Arsenic metabolism;
LGG	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.67	-0.48	8.97e-28	Type 2 diabetes;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg05941027	chr17:61774174	LIMD2	0.38	9.76	0.41	1.37e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17539620	0.628	rs62432728	chr6:154829511	G/C	cg17771515	chr6:154831774	CNKSR3	0.65	8.49	0.37	2.8e-16	Lipoprotein (a) levels;
LGG	cis	rs9309473	1.000	rs6745368	chr2:73809974	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.36	-0.32	8.68e-13	Metabolite levels;
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06634786	chr22:41940651	POLR3H	0.73	12.17	0.49	9.16e-30	Vitiligo;
LGG	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.33	0.32	1.02e-12	Hemoglobin concentration;
LGG	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg19168338	chr16:4465731	CORO7	0.73	13.51	0.53	2.62e-35	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16718678	chr11:64490633	NRXN2	0.46	6.94	0.31	1.35e-11	Gut microbiome composition (summer);
LGG	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.16e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs988958	0.526	rs58351981	chr2:42245125	T/G	cg27252766	chr2:42229092	NA	0.48	6.82	0.3	2.79e-11	Hypospadias;
LGG	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.95	0.42	2.98e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.48	-0.37	3.1e-16	Lung cancer;
LGG	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-10.95	-0.45	5.58e-25	Pulmonary function;
LGG	cis	rs11209002	0.614	rs7552205	chr1:67551741	C/A	cg02640540	chr1:67518911	SLC35D1	0.4	6.91	0.31	1.61e-11	Crohn's disease;
LGG	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs283228	0.793	rs406541	chr6:101714615	A/C	cg27451362	chr6:101846650	GRIK2	0.56	8.62	0.37	1.05e-16	Coenzyme Q10 levels;
LGG	cis	rs58616815	0.895	rs10881791	chr10:92156428	G/A	cg17905462	chr10:92153495	NA	-0.25	-6.77	-0.3	3.83e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs933688	0.532	rs28693622	chr5:90538722	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.58	-7.72	-0.34	7.26e-14	Smoking behavior;
LGG	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg13263323	chr15:86062960	AKAP13	0.34	6.89	0.3	1.87e-11	Coronary artery disease;
LGG	cis	rs9863	0.861	rs12317176	chr12:124404718	T/C	cg13487667	chr12:124434373	CCDC92	-0.35	-7.03	-0.31	7.39e-12	White blood cell count;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.26	-0.32	1.7e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs4714291	0.963	rs940352	chr6:40113614	C/T	cg02267698	chr19:7991119	CTXN1	-0.59	-9.45	-0.4	1.68e-19	Strep throat;
LGG	cis	rs7793239	0.550	rs10246191	chr7:130029811	G/A	cg04743876	chr7:130013617	NA	0.37	8.33	0.36	9.36e-16	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.6	-0.53	1.17e-35	Alzheimer's disease;
LGG	cis	rs7666738	0.710	rs7674407	chr4:98838522	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.71	0.34	7.8e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9657904	0.865	rs12636287	chr3:105598424	C/T	cg14088669	chr1:158435396	OR10K1	0.42	7.96	0.35	1.33e-14	Multiple sclerosis;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg20607798	chr8:58055168	NA	0.63	7.32	0.32	1.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.603	rs13241328	chr7:19939232	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	6.86	0.3	2.19e-11	Night sleep phenotypes;
LGG	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg07148914	chr20:33460835	GGT7	0.57	9.48	0.4	1.29e-19	Height;
LGG	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-19.48	-0.67	3.56e-62	Renal cell carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12026095	chr19:49468461	FTL	-0.48	-7.96	-0.35	1.35e-14	Gut microbiome composition (summer);
LGG	cis	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	cis	rs10463554	0.927	rs34795	chr5:102424420	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg14675211	chr2:100938903	LONRF2	0.64	11.37	0.47	1.38e-26	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.792	rs61991249	chr14:71869546	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.65	-0.37	8.72e-17	Mitral valve prolapse;
LGG	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg22906224	chr7:99728672	NA	-0.57	-9.32	-0.4	4.91e-19	Coronary artery disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13487284	chr17:26794878	NA	-0.35	-6.92	-0.31	1.47e-11	Intelligence (multi-trait analysis);
LGG	cis	rs5758511	0.773	rs8140869	chr22:42344297	A/G	cg15128208	chr22:42549153	NA	-0.53	-8.56	-0.37	1.65e-16	Birth weight;
LGG	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg24631222	chr15:78858424	CHRNA5	0.49	7.48	0.33	3.83e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg13628971	chr7:2884303	GNA12	0.55	11.91	0.48	1.07e-28	Height;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.97	-0.31	1.09e-11	Lung cancer;
LGG	cis	rs17253792	0.822	rs112308750	chr14:56080073	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs10744422	0.858	rs2292136	chr12:123339344	A/G	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	5.17e-19	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08567916	chr12:53473383	SPRYD3	0.44	6.67	0.3	7.46e-11	Gut microbiome composition (summer);
LGG	cis	rs8114671	0.647	rs1124511	chr20:33736697	A/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.67	0.37	7.07e-17	Height;
LGG	cis	rs17253792	0.822	rs74609892	chr14:56053002	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7010267	0.570	rs10090576	chr8:120037816	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg02574844	chr11:5959923	NA	-0.54	-8.71	-0.38	5.3e-17	DNA methylation (variation);
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs16937	0.711	rs10900465	chr1:205158183	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.5e-13	Schizophrenia;
LGG	cis	rs7727544	0.582	rs2301579	chr5:131553340	C/A	cg07395648	chr5:131743802	NA	-0.4	-8.67	-0.37	7.37e-17	Blood metabolite levels;
LGG	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg15627072	chr1:2432621	PLCH2	0.4	9.87	0.42	5.4e-21	Ulcerative colitis;
LGG	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg25885449	chr18:77638415	KCNG2	0.42	8.95	0.38	8.49e-18	Schizophrenia;
LGG	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	17.12	0.62	2.92e-51	Smoking behavior;
LGG	cis	rs6800768	0.633	rs6769284	chr3:24148448	T/G	cg10674438	chr3:24145617	LOC152024	-0.53	-9.5	-0.4	1.11e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg25039879	chr17:56429692	SUPT4H1	0.56	7.89	0.34	2.23e-14	Cognitive test performance;
LGG	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg00666640	chr1:248458726	OR2T12	0.61	9.76	0.41	1.37e-20	Common traits (Other);
LGG	cis	rs3735485	0.738	rs62458147	chr7:45093198	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-14.63	-0.56	4.13e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg06634786	chr22:41940651	POLR3H	-0.55	-9.02	-0.39	5.2e-18	Vitiligo;
LGG	cis	rs2084898	0.891	rs504976	chr11:120000233	C/A	cg13907859	chr11:120009124	TRIM29	-0.87	-12.13	-0.49	1.29e-29	Stroke (pediatric);
LGG	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg01017244	chr2:74357527	NA	0.46	8.6	0.37	1.2e-16	Gestational age at birth (maternal effect);
LGG	cis	rs4604732	0.631	rs12031694	chr1:247623653	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.33	0.4	4.26e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs701145	0.643	rs453699	chr3:153924784	A/G	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg05585630	chr7:157510462	PTPRN2	-0.65	-13.68	-0.54	5.18e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs941408	0.515	rs878893	chr19:2781325	A/G	cg06609049	chr19:2785107	THOP1	0.95	15.98	0.6	4.36e-46	Total cholesterol levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18036763	chr22:45404910	PHF21B	0.45	7.59	0.33	1.77e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs4919087	0.962	rs10882883	chr10:99013312	A/G	cg25902810	chr10:99078978	FRAT1	0.51	9.46	0.4	1.5700000000000001e-19	Monocyte count;
LGG	cis	rs4417704	0.525	rs12694990	chr2:241883621	C/G	cg26818257	chr2:241905806	NA	0.48	10.75	0.45	3.22e-24	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.26	0.4	7.61e-19	Diabetic retinopathy;
LGG	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg22903471	chr2:27725779	GCKR	0.39	8.67	0.37	7.52e-17	Oral cavity cancer;
LGG	trans	rs9354308	0.764	rs9294665	chr6:66598299	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs11628318	0.515	rs7142819	chr14:103133385	A/G	cg12046867	chr14:103022105	NA	0.39	7.21	0.32	2.28e-12	Platelet count;
LGG	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.77	-0.34	5.09e-14	Triglycerides;
LGG	cis	rs1965732	0.588	rs11682334	chr2:3716780	G/T	cg20493526	chr2:3714936	ALLC	0.45	9.95	0.42	2.89e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg18187862	chr3:45730750	SACM1L	-0.68	-11.07	-0.46	1.92e-25	Primary sclerosing cholangitis;
LGG	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.68	0.44	6.17e-24	Mood instability;
LGG	cis	rs6732160	0.588	rs28626211	chr2:73378522	G/A	cg01422370	chr2:73384389	NA	0.57	9.98	0.42	2.17e-21	Intelligence (multi-trait analysis);
LGG	cis	rs975722	0.646	rs43030	chr7:117106882	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.97	0.42	2.42e-21	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs1649063	chr10:60309215	G/A	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs7250872	0.647	rs2304613	chr19:1817943	G/C	cg18850929	chr19:1828978	REXO1	0.46	7.66	0.34	1.09e-13	Bipolar disorder;
LGG	cis	rs9796	0.870	rs3101436	chr15:41287689	A/G	cg18705301	chr15:41695430	NDUFAF1	0.48	8.2	0.36	2.46e-15	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs12111660	chr7:124584795	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.74	-0.41	1.65e-20	Alcohol dependence;
LGG	cis	rs4919044	0.808	rs10748590	chr10:94812426	A/T	cg05127821	chr10:94822908	CYP26C1	0.47	7.89	0.34	2.25e-14	Coronary artery disease;
LGG	trans	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg14791747	chr16:20752902	THUMPD1	0.5	7.61	0.33	1.6e-13	Cognitive test performance;
LGG	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.29e-11	Cognitive ability;
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg21775007	chr8:11205619	TDH	0.51	8.51	0.37	2.45e-16	Systolic blood pressure;
LGG	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg21475434	chr5:93447410	FAM172A	0.72	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs1878931	0.582	rs27239	chr16:3442140	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-11.53	-0.47	3.24e-27	Body mass index (adult);
LGG	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg01262667	chr19:19385393	TM6SF2	0.36	7.26	0.32	1.6e-12	Bipolar disorder;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg04293180	chr8:144700367	TSTA3	0.9	6.97	0.31	1.12e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.79e-14	Iron status biomarkers;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg08621203	chr6:150244597	RAET1G	0.48	8.14	0.35	3.6e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03383382	chr6:108487506	NR2E1	0.5	7.98	0.35	1.14e-14	Gut microbiome composition (summer);
LGG	cis	rs897984	0.568	rs8050107	chr16:30893451	C/T	cg00531865	chr16:30841666	NA	0.54	10.27	0.43	1.95e-22	Dementia with Lewy bodies;
LGG	cis	rs722599	0.748	rs11623342	chr14:75347937	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-9.63	-0.41	3.82e-20	IgG glycosylation;
LGG	cis	rs9359856	0.564	rs1179902	chr6:90321545	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.7	-9.12	-0.39	2.27e-18	Bipolar disorder;
LGG	cis	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg13010199	chr12:38710504	ALG10B	0.78	16.94	0.62	2.03e-50	Heart rate;
LGG	cis	rs4845570	0.834	rs1196467	chr1:151710038	T/C	cg07092448	chr1:151763213	TDRKH	1.05	15.18	0.58	1.65e-42	Coronary artery disease;
LGG	trans	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg10840412	chr1:235813424	GNG4	0.56	7.38	0.32	7.39e-13	Bipolar disorder;
LGG	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.59	-0.37	1.37e-16	Lung cancer;
LGG	cis	rs4965869	0.866	rs2412012	chr15:101974653	C/T	cg12371147	chr15:101978424	PCSK6	-0.39	-7.19	-0.32	2.66e-12	Platelet-derived growth factor BB levels;
LGG	cis	rs11112613	0.762	rs73184078	chr12:105950017	A/G	cg03607813	chr12:105948248	NA	0.64	11.25	0.46	4.14e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg06521331	chr12:34319734	NA	-0.64	-12.57	-0.5	2.3e-31	Morning vs. evening chronotype;
LGG	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg14092571	chr14:90743983	NA	-0.42	-8.27	-0.36	1.44e-15	Mortality in heart failure;
LGG	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2013441	0.965	rs8071665	chr17:20209943	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	trans	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.69	-0.3	6.53e-11	Triglycerides;
LGG	cis	rs7444	0.941	rs5754295	chr22:21951740	C/A	cg15846791	chr22:21984385	YDJC	-0.44	-6.8	-0.3	3.2e-11	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05665937	chr4:1216051	CTBP1	0.5	9.17	0.39	1.57e-18	Obesity-related traits;
LGG	cis	rs701145	0.585	rs1470663	chr3:153870883	A/G	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs10979	0.931	rs12191837	chr6:143898200	T/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg23009067	chr7:2775923	GNA12	0.35	6.65	0.3	8.23e-11	Childhood ear infection;
LGG	cis	rs34734847	0.648	rs575437	chr12:121173431	T/C	cg21892295	chr12:121157589	UNC119B	-0.38	-7.29	-0.32	1.33e-12	Mean corpuscular volume;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg27532560	chr4:187881888	NA	-0.62	-14.38	-0.56	4.94e-39	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00166722	chr3:10149974	C3orf24	0.57	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	cis	rs7914558	0.966	rs2297786	chr10:104679978	C/T	cg04362960	chr10:104952993	NT5C2	0.53	10.02	0.42	1.58e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg18335740	chr13:41363409	SLC25A15	0.65	13.02	0.52	3.17e-33	Lewy body disease;
LGG	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.62	-8.35	-0.36	8.01e-16	Diabetic retinopathy;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16207528	chr7:48964051	CDC14C	0.43	8.17	0.35	2.88e-15	Menarche (age at onset);
LGG	cis	rs7590368	1.000	rs17456225	chr2:10963238	C/G	cg15705551	chr2:10952987	PDIA6	0.61	9.08	0.39	3.09e-18	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08066755	chr14:58765184	FLJ31306;ARID4A	0.46	6.77	0.3	3.82e-11	Gut microbiome composition (summer);
LGG	cis	rs6714710	0.603	rs953320	chr2:98606770	T/C	cg26665480	chr2:98280029	ACTR1B	0.64	10.33	0.43	1.19e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7000551	0.725	rs2248987	chr8:22399002	C/G	cg12081754	chr8:22256438	SLC39A14	0.62	11.66	0.48	1.03e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg19680485	chr15:31195859	MTMR15	-0.45	-7.33	-0.32	1.01e-12	Huntington's disease progression;
LGG	cis	rs55665837	1.000	rs10832271	chr11:14466919	C/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.74	-0.38	4.24e-17	Vitamin D levels;
LGG	cis	rs9309473	0.861	rs6546856	chr2:73837751	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.64	-0.33	1.27e-13	Metabolite levels;
LGG	cis	rs6578185	0.782	rs10109519	chr8:142453669	T/C	cg07762003	chr8:142452454	FLJ43860	-0.62	-12.64	-0.51	1.15e-31	Endometriosis;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs4330281	0.586	rs283931	chr3:17361581	T/C	cg20981856	chr3:17787350	NA	0.36	6.91	0.31	1.59e-11	Schizophrenia;
LGG	cis	rs939658	0.805	rs34478496	chr15:79440997	C/A	cg17916960	chr15:79447300	NA	-0.66	-12.8	-0.51	2.6e-32	Refractive error;
LGG	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.55	-0.33	2.33e-13	Triglycerides;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs6952809	0.532	rs2023969	chr7:2449980	T/C	cg23289794	chr7:2394357	EIF3B	-0.8	-10.08	-0.42	9.44e-22	Multiple sclerosis;
LGG	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-15.22	-0.58	9.96e-43	Chronic sinus infection;
LGG	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg03929089	chr4:120376271	NA	0.45	7.38	0.32	7.31e-13	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs17767392	0.918	rs34533948	chr14:71772727	C/A	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.46	-0.5	6.29e-31	Resting heart rate;
LGG	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	cg07245641	chr1:182991651	LAMC1	0.4	9.16	0.39	1.71e-18	Hypertriglyceridemia;
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg02725872	chr8:58115012	NA	-0.78	-10.69	-0.44	5.41e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg15997130	chr1:24165203	NA	0.47	13.02	0.52	2.93e-33	Immature fraction of reticulocytes;
LGG	cis	rs7580658	0.891	rs55998967	chr2:128048674	A/C	cg10021288	chr2:128175891	PROC	-0.64	-13.22	-0.52	4.36e-34	Protein C levels;
LGG	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg14952266	chr13:112191215	NA	0.4	7.78	0.34	4.7e-14	Hepatitis;
LGG	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs1062177	1.000	rs1062177	chr5:151184701	C/T	cg00977110	chr5:151150581	G3BP1	0.5	7.97	0.35	1.25e-14	Preschool internalizing problems;
LGG	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg03162506	chr22:38580953	NA	0.33	8.36	0.36	7.18e-16	Cutaneous nevi;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.87e-12	Prudent dietary pattern;
LGG	cis	rs2694528	0.858	rs16878547	chr5:60367377	G/T	cg11474532	chr5:59995715	DEPDC1B	-0.66	-7.17	-0.32	3.08e-12	Parkinson's disease;
LGG	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg00049323	chr5:472564	LOC25845	0.38	8.5	0.37	2.57e-16	Cystic fibrosis severity;
LGG	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12016809	chr21:47604291	C21orf56	0.42	6.82	0.3	2.9e-11	Testicular germ cell tumor;
LGG	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg21775007	chr8:11205619	TDH	-0.54	-9.05	-0.39	3.93e-18	Neuroticism;
LGG	trans	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.77	0.64	2.95e-54	Exhaled nitric oxide output;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs2402762	chr7:124599846	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.93	-0.31	1.46e-11	Cutaneous malignant melanoma;
LGG	cis	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg13443165	chr9:33130375	B4GALT1	-0.73	-14.28	-0.55	1.42e-38	IgG glycosylation;
LGG	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg03651054	chr13:50194643	NA	0.29	6.68	0.3	7.08e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9682041	0.627	rs6786374	chr3:170105233	A/G	cg11886554	chr3:170076028	SKIL	-0.53	-7.01	-0.31	8.27e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs5753037	0.809	rs5763512	chr22:30212366	C/T	cg27665648	chr22:30112403	NA	0.28	6.66	0.3	7.61e-11	Type 1 diabetes;
LGG	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	8.92	0.38	1.06e-17	Myopia (pathological);
LGG	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg18129748	chr3:49941408	MST1R	0.21	6.68	0.3	6.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.550	rs496596	chr6:101752756	A/T	cg02011392	chr6:101847541	GRIK2	0.53	7.32	0.32	1.07e-12	Coenzyme Q10 levels;
LGG	cis	rs11214589	0.806	rs4551806	chr11:113250540	T/A	cg14373873	chr11:113211441	TTC12	0.4	8.06	0.35	6.38e-15	Neuroticism;
LGG	trans	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg02002194	chr4:3960332	NA	-0.39	-7.16	-0.32	3.2e-12	Neuroticism;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg06028808	chr11:68637592	NA	0.68	11.56	0.47	2.4e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	cis	rs1978968	0.956	rs1110661	chr22:18444734	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.19	-0.49	8.06e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg16751781	chr15:78858589	CHRNA5	0.47	9.18	0.39	1.46e-18	Sudden cardiac arrest;
LGG	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg08847533	chr14:75593920	NEK9	-0.61	-11.5	-0.47	4.16e-27	Height;
LGG	cis	rs10832963	0.961	rs10832954	chr11:18643559	G/A	cg20219074	chr11:18656078	SPTY2D1	0.84	15.93	0.6	7.1e-46	Breast cancer;
LGG	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	12.38	0.5	1.28e-30	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.12	-15.38	-0.58	2.13e-43	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-16.1	-0.6	1.23e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.94e-51	Morning vs. evening chronotype;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg23788167	chr9:74979561	ZFAND5	-0.39	-7.66	-0.34	1.12e-13	Iris color (L* coordinate);
LGG	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg22906224	chr7:99728672	NA	-0.58	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.97	0.35	1.26e-14	Personality dimensions;
LGG	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.28e-13	Menopause (age at onset);
LGG	trans	rs7923837	0.687	rs11187139	chr10:94466427	T/C	cg27639046	chr2:171608303	NA	-0.35	-6.79	-0.3	3.39e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13126279	chr21:47581558	C21orf56	0.54	9.89	0.42	4.69e-21	Testicular germ cell tumor;
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.81	-0.57	6.4e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg14926445	chr8:58193284	C8orf71	-0.72	-9.83	-0.42	7.79e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1580019	0.961	rs1868776	chr7:32494435	G/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.79	-14.89	-0.57	2.85e-41	Cognitive ability;
LGG	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.52	0.47	3.44e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6831352	0.879	rs17218003	chr4:100054723	G/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs4851266	1.000	rs11686372	chr2:100827907	C/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.2	0.43	3.57e-22	Retinal vascular caliber;
LGG	cis	rs7666738	0.830	rs4699580	chr4:98930673	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.83	0.54	1.21e-36	Prudent dietary pattern;
LGG	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg20290983	chr6:43655470	MRPS18A	1.13	25.29	0.76	2.82e-89	IgG glycosylation;
LGG	cis	rs787274	0.764	rs787281	chr9:115538568	C/T	cg13803584	chr9:115635662	SNX30	-0.58	-7.45	-0.33	4.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs990171	1.000	rs2041756	chr2:103049910	C/T	cg05295703	chr2:102895712	NA	0.53	9.21	0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg06636001	chr8:8085503	FLJ10661	0.48	8.99	0.39	6.3e-18	Systolic blood pressure;
LGG	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg15704280	chr7:45808275	SEPT13	-0.95	-19.72	-0.68	2.6e-63	Coronary artery disease;
LGG	cis	rs972578	0.668	rs8569	chr22:43266774	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.99e-11	Mean platelet volume;
LGG	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs6087990	0.966	rs2377667	chr20:31346925	A/G	cg13636640	chr20:31349939	DNMT3B	1.01	22.11	0.72	1.88e-74	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg24675658	chr1:53192096	ZYG11B	-0.48	-9.35	-0.4	3.63e-19	Monocyte count;
LGG	cis	rs9457247	0.715	rs6923582	chr6:167437162	T/A	cg07741184	chr6:167504864	NA	0.41	9.1	0.39	2.74e-18	Crohn's disease;
LGG	cis	rs1801251	0.656	rs10211596	chr2:233699415	C/T	cg08000102	chr2:233561755	GIGYF2	-0.55	-9.6	-0.41	5.2e-20	Coronary artery disease;
LGG	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg02454025	chr1:11042201	C1orf127	0.94	20.75	0.69	4.31e-68	Ewing sarcoma;
LGG	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg01262667	chr19:19385393	TM6SF2	0.35	7.1	0.31	4.85e-12	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15813570	chr14:64854563	MTHFD1	0.46	7.18	0.32	2.8e-12	Gut microbiome composition (summer);
LGG	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg05665937	chr4:1216051	CTBP1	0.48	8.77	0.38	3.37e-17	Obesity-related traits;
LGG	trans	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.05	-0.31	6.71e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9816226	0.591	rs74607912	chr3:185818559	G/A	cg00760338	chr3:185826511	ETV5	-0.84	-10.48	-0.44	3.44e-23	Obesity;Body mass index;
LGG	cis	rs9583531	0.509	rs9521923	chr13:111405462	C/T	cg24331049	chr13:111365604	ING1	-0.85	-11.59	-0.47	1.85e-27	Coronary artery disease;
LGG	cis	rs853679	0.517	rs9380050	chr6:28048538	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.34e-31	Motion sickness;
LGG	cis	rs2153535	0.542	rs1120393	chr6:8486890	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg03877680	chr5:178157825	ZNF354A	0.83	14.43	0.56	3.08e-39	Neutrophil percentage of white cells;
LGG	cis	rs10484885	0.588	rs9344947	chr6:90304789	A/G	cg13799429	chr6:90582589	CASP8AP2	0.6	8.02	0.35	9.04e-15	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7586879	0.616	rs10206196	chr2:25137323	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.71	0.51	6.14e-32	Body mass index;
LGG	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.35	-0.47	1.59e-26	Total body bone mineral density;
LGG	trans	rs12517041	1.000	rs115818285	chr5:23291449	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.03e-25	Calcium levels;
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.04	-0.31	7.03e-12	Aortic root size;
LGG	cis	rs17767392	0.958	rs9323561	chr14:72031563	A/C	cg13720639	chr14:72061746	SIPA1L1	0.38	8.31	0.36	1.06e-15	Mitral valve prolapse;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.06	-0.46	2.17e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg02002194	chr4:3960332	NA	0.42	7.77	0.34	5.15e-14	Triglycerides;
LGG	cis	rs4302748	1.000	rs4302748	chr7:36191699	C/T	cg24442661	chr7:36192818	EEPD1	0.58	7.63	0.33	1.39e-13	Platelet count;
LGG	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg02297831	chr4:17616191	MED28	0.49	9.35	0.4	3.83e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23104823	chr14:45553408	PRPF39	0.48	7.57	0.33	2.1e-13	Gut microbiome composition (summer);
LGG	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03713592	chr11:72463424	ARAP1	0.4	7.59	0.33	1.81e-13	Type 2 diabetes;
LGG	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg16414030	chr3:133502952	NA	-0.6	-10.52	-0.44	2.3e-23	Iron status biomarkers;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg24397884	chr7:158709396	WDR60	0.91	20.09	0.68	5.15e-65	Height;
LGG	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.3	0.43	1.59e-22	Neuroticism;
LGG	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg10818794	chr15:86012489	AKAP13	-0.55	-12.3	-0.5	2.78e-30	Coronary artery disease;
LGG	cis	rs4731207	0.596	rs1994023	chr7:124580670	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs8060686	0.641	rs78537727	chr16:68120606	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.43	-7.66	-0.34	1.13e-13	Myeloid white cell count;
LGG	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg08875078	chr22:50639485	SELO	0.46	7.47	0.33	4.15e-13	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.1	0.42	8.36e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs1816854	1.000	rs10880569	chr12:44201636	C/G	cg20956634	chr12:44200518	TWF1	0.52	7.61	0.33	1.54e-13	Inflammatory bowel disease;
LGG	cis	rs77633900	0.614	rs12442966	chr15:76918290	G/T	cg21673338	chr15:77095150	SCAPER	0.63	10.08	0.42	9.55e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25072359	chr17:41440525	NA	0.53	9.99	0.42	2.02e-21	Menopause (age at onset);
LGG	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.33	0.65	7.89e-57	Refractive error;
LGG	cis	rs9534288	0.797	rs2404729	chr13:46617368	C/T	cg15192986	chr13:46630673	CPB2	-0.5	-10.46	-0.44	3.81e-23	Blood protein levels;
LGG	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg00376283	chr12:123451042	ABCB9	0.62	11.41	0.47	9.19e-27	Platelet count;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg11473876	chr11:109292803	C11orf87	0.46	9.37	0.4	3.11e-19	Schizophrenia;
LGG	cis	rs6032067	0.526	rs2743347	chr20:43920493	T/C	cg10761708	chr20:43804764	PI3	0.56	8.54	0.37	1.96e-16	Blood protein levels;
LGG	trans	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg18187862	chr3:45730750	SACM1L	-0.41	-6.65	-0.3	8.09e-11	Primary sclerosing cholangitis;
LGG	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg17764715	chr19:33622953	WDR88	0.54	7.63	0.33	1.4e-13	Bone properties (heel);
LGG	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg04672837	chr16:48644449	N4BP1	-0.52	-8.58	-0.37	1.39e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg19635926	chr16:89946313	TCF25	0.66	7.96	0.35	1.38e-14	Skin colour saturation;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4959677	0.611	rs56543437	chr6:2474933	G/A	cg20147862	chr6:2634573	C6orf195	-0.34	-7.33	-0.32	1.06e-12	Orthostatic hypotension;
LGG	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg03315344	chr16:75512273	CHST6	0.5	10.08	0.42	9.91e-22	Dupuytren's disease;
LGG	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.43	6.76	0.3	4.22e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9457247	0.646	rs4710160	chr6:167409241	T/A	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs2797369	0.571	rs7454096	chr6:101541483	A/C	cg27451362	chr6:101846650	GRIK2	-0.7	-10.46	-0.44	3.87e-23	Renal function-related traits (eGRFcrea);
LGG	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	6.96	0.31	1.16e-11	Myopia (pathological);
LGG	cis	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg05084668	chr3:125655381	ALG1L	-0.85	-10.49	-0.44	3.17e-23	Blood pressure (smoking interaction);
LGG	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.97	0.52	4.8e-33	Alzheimer's disease;
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg26174226	chr8:58114915	NA	-0.51	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.77	-0.3	3.8e-11	Neuroticism;
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.99	-0.45	3.89e-25	Personality dimensions;
LGG	cis	rs6688613	0.721	rs2312675	chr1:166922533	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.48	7.16	0.32	3.29e-12	Refractive astigmatism;
LGG	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.25e-13	Hemoglobin concentration;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	10.93	0.45	6.53e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg16594139	chr19:49340574	PLEKHA4;HSD17B14	0.56	7.47	0.33	3.95e-13	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11096990	0.927	rs6845858	chr4:39238719	T/C	cg24403649	chr4:39172243	NA	-0.42	-6.92	-0.31	1.56e-11	Cognitive function;
LGG	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg25986240	chr4:9926439	SLC2A9	-0.4	-8.37	-0.36	7.01e-16	Bone mineral density;
LGG	cis	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg07460842	chr6:66804631	NA	0.96	17.92	0.64	5.89e-55	Exhaled nitric oxide output;
LGG	cis	rs6918586	0.636	rs198816	chr6:26127184	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.79	-0.41	1.05e-20	Schizophrenia;
LGG	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg26597838	chr10:835615	NA	0.51	6.64	0.3	8.58e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.77	0.3	3.84e-11	Resting heart rate;
LGG	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs9287719	0.967	rs10195802	chr2:10754532	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs6693567	0.545	rs2012751	chr1:150438266	T/C	cg15654264	chr1:150340011	RPRD2	0.32	6.66	0.3	7.69e-11	Migraine;
LGG	cis	rs8060686	0.545	rs78229587	chr16:68165243	T/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.47	-0.33	3.91e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg19445457	chr11:5799446	OR52N5	-0.4	-6.67	-0.3	7.43e-11	DNA methylation (variation);
LGG	cis	rs4268898	0.795	rs12470303	chr2:24619883	C/T	cg06627628	chr2:24431161	ITSN2	-0.42	-6.95	-0.31	1.28e-11	Asthma;
LGG	trans	rs961253	0.556	rs2025837	chr20:6364637	A/G	cg21095983	chr6:86352623	SYNCRIP	0.39	6.68	0.3	6.96e-11	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg11301795	chr4:187892539	NA	-0.94	-25.38	-0.76	1.07e-89	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg10857441	chr5:6722123	POLS	-0.28	-6.91	-0.31	1.65e-11	Menopause (age at onset);
LGG	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg27102117	chr16:15229624	NA	0.63	12.05	0.49	2.75e-29	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg11965913	chr1:205819406	PM20D1	0.54	8.38	0.36	6.48e-16	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2013441	0.613	rs4925082	chr17:19994673	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.55	-0.41	7.42e-20	Obesity-related traits;
LGG	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg00204512	chr16:28754710	NA	0.27	7.7	0.34	8.44e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg26043149	chr18:55253948	FECH	0.4	6.68	0.3	7.06e-11	Bone mineral density;
LGG	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.46	-7.32	-0.32	1.11e-12	Height;
LGG	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg01221209	chr5:554886	NA	-0.47	-6.84	-0.3	2.51e-11	Obesity-related traits;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg02446647	chr6:133562101	EYA4	0.31	7.46	0.33	4.29e-13	Total body bone mineral density;
LGG	cis	rs7666738	0.830	rs2903152	chr4:99067992	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4774899	0.932	rs12904933	chr15:57535465	C/T	cg08128148	chr15:57256372	TCF12	-0.32	-7.34	-0.32	9.44e-13	Urinary tract infection frequency;
LGG	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg22120825	chr2:201024476	NA	0.5	6.68	0.3	6.86e-11	Schizophrenia;
LGG	cis	rs2074193	0.569	rs215350	chr12:47734911	T/A	cg02516419	chr12:47771422	NA	-0.52	-7.53	-0.33	2.72e-13	Migraine with aura;
LGG	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg04935436	chr20:30431758	NA	0.41	7.24	0.32	1.83e-12	Mean corpuscular hemoglobin;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	trans	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg11441553	chr12:57614120	NXPH4	-0.62	-7.21	-0.32	2.29e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9657904	0.813	rs7651784	chr3:105554580	A/C	cg14088669	chr1:158435396	OR10K1	0.41	7.71	0.34	7.76e-14	Multiple sclerosis;
LGG	cis	rs8061903	0.653	rs12935363	chr16:9415765	C/T	cg03762483	chr16:10274847	GRIN2A	0.39	6.94	0.31	1.34e-11	HIV-1 viral setpoint;
LGG	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.07	0.42	1.04e-21	Lung cancer in ever smokers;
LGG	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg06618935	chr21:46677482	NA	-0.52	-9.05	-0.39	3.96e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg22455342	chr2:225449267	CUL3	0.86	15.02	0.57	7.99e-42	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7926971	0.756	rs6485968	chr11:12660201	G/A	cg25843174	chr11:12811716	TEAD1	0.32	6.94	0.31	1.34e-11	Height;
LGG	cis	rs6594713	0.851	rs7717630	chr5:112704266	A/G	cg12552261	chr5:112820674	MCC	0.47	6.78	0.3	3.59e-11	Brain cytoarchitecture;
LGG	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg18245976	chr7:158708271	WDR60	-0.45	-7.61	-0.33	1.5e-13	Height;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.94	-0.38	9.41e-18	Aortic root size;
LGG	cis	rs75229567	0.618	rs11177819	chr12:70134836	T/G	cg10114359	chr12:70132523	RAB3IP	1.19	10.28	0.43	1.85e-22	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.19	0.67	8.32e-61	Smoking behavior;
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg01765077	chr12:122356316	WDR66	0.28	7.32	0.32	1.1e-12	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg11062466	chr8:58055876	NA	0.48	8.22	0.36	2.09e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg17591343	chr1:93646016	TMED5;CCDC18	-0.43	-6.8	-0.3	3.32e-11	Coronary artery disease;
LGG	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg05973401	chr12:123451056	ABCB9	0.47	7.91	0.34	1.95e-14	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg18854424	chr1:2615690	NA	-0.35	-7.11	-0.31	4.41e-12	Ulcerative colitis;
LGG	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.18	0.39	1.44e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg25237894	chr2:233734115	C2orf82	-0.72	-15.59	-0.59	2.29e-44	Coronary artery disease;
LGG	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg09998033	chr7:158218633	PTPRN2	0.47	8.61	0.37	1.15e-16	Obesity-related traits;
LGG	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg26384229	chr12:38710491	ALG10B	0.95	21.24	0.7	2.11e-70	Bladder cancer;
LGG	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg03254818	chr6:169586852	NA	-0.52	-8.04	-0.35	7.72e-15	Pulse pressure;
LGG	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.75	-0.41	1.52e-20	Common traits (Other);
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg07538946	chr5:131705188	SLC22A5	0.61	7.13	0.31	3.78e-12	Rheumatoid arthritis;
LGG	trans	rs12517041	1.000	rs28421903	chr5:23281290	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.95	-0.45	5.5e-25	Calcium levels;
LGG	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	7.6	0.33	1.62e-13	Thyroid stimulating hormone;
LGG	cis	rs6489882	0.867	rs4766663	chr12:113362974	C/T	cg25319449	chr12:113376135	OAS3	0.4	7.39	0.33	6.69e-13	Chronic lymphocytic leukemia;
LGG	cis	rs1729951	0.575	rs10935213	chr3:136693459	A/G	cg12473912	chr3:136751656	NA	0.43	7.65	0.33	1.19e-13	Neuroticism;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg07061783	chr6:25882402	NA	0.4	7.05	0.31	6.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.23e-15	Rheumatoid arthritis;
LGG	cis	rs10744422	1.000	rs897386	chr12:123341289	A/C	cg25930673	chr12:123319894	HIP1R	-0.72	-9.14	-0.39	1.96e-18	Schizophrenia;
LGG	cis	rs2073300	0.609	rs2295238	chr20:23387946	C/G	cg12062639	chr20:23401060	NAPB	0.92	8.95	0.38	8.6e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.18	0.39	1.43e-18	Aortic root size;
LGG	cis	rs3784262	0.631	rs12903724	chr15:58310387	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.11	-0.31	4.31e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg01528321	chr10:82214614	TSPAN14	0.67	12.02	0.49	3.73e-29	Post bronchodilator FEV1;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09976724	chr15:41186526	VPS18	0.37	6.66	0.3	7.56e-11	Obesity-related traits;
LGG	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-16.63	-0.61	4.72e-49	Response to antipsychotic treatment;
LGG	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg01191920	chr7:158217561	PTPRN2	-0.93	-24.65	-0.75	2.64e-86	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.09	-0.42	9.36e-22	Lung cancer;
LGG	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.31	0.43	1.43e-22	Height;
LGG	trans	rs7937682	0.593	rs1944123	chr11:111356407	T/C	cg18187862	chr3:45730750	SACM1L	-0.41	-6.85	-0.3	2.32e-11	Primary sclerosing cholangitis;
LGG	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs367615	0.506	rs2963021	chr5:108800365	C/T	cg17395555	chr5:108820864	NA	0.8	14.31	0.55	1.04e-38	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg02428538	chr16:24856791	SLC5A11	-0.48	-8.13	-0.35	3.89e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.766	rs6848	chr5:140086062	A/T	cg19875535	chr5:140030758	IK	-0.53	-10.9	-0.45	8.73e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7811528	0.520	rs2286690	chr7:2695617	A/G	cg11411865	chr7:2701802	TTYH3	-0.52	-7.49	-0.33	3.4e-13	Schizophrenia;
LGG	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.92	0.45	7.52e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.66	-0.51	9.42e-32	Alzheimer's disease;
LGG	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg06481639	chr22:41940642	POLR3H	-0.63	-9.26	-0.4	7.86e-19	Vitiligo;
LGG	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-21.97	-0.71	8.01e-74	Height;
LGG	cis	rs1595825	0.786	rs74484541	chr2:198894223	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs7100689	0.646	rs10749581	chr10:82141651	A/G	cg01528321	chr10:82214614	TSPAN14	-0.88	-15.49	-0.58	6.47e-44	Post bronchodilator FEV1;
LGG	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg25173405	chr17:45401733	C17orf57	-0.53	-8.98	-0.39	6.94e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg08305652	chr11:111469057	NA	0.44	8.48	0.37	3.03e-16	Primary sclerosing cholangitis;
LGG	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg19442545	chr10:75533431	FUT11	-0.44	-7.26	-0.32	1.64e-12	Inflammatory bowel disease;
LGG	cis	rs17689437	0.647	rs1728786	chr16:68569706	C/A	cg02972257	chr16:68554789	NA	-0.45	-7.64	-0.33	1.28e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg22980697	chr10:16874865	CUBN	0.36	6.9	0.31	1.68e-11	Platelet distribution width;
LGG	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.4	8.06e-19	Diabetic retinopathy;
LGG	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg03929089	chr4:120376271	NA	0.83	13.05	0.52	2.24e-33	Coronary artery disease;
LGG	cis	rs7000551	0.725	rs2469776	chr8:22403451	A/G	cg12081754	chr8:22256438	SLC39A14	0.62	11.44	0.47	7.05e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1707322	0.686	rs1250	chr1:46094027	A/G	cg03146154	chr1:46216737	IPP	0.58	11.14	0.46	1.04e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1459104	1.000	rs34965777	chr11:55238748	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.67	0.3	7.28e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03705947	chr1:68152081	GADD45A	0.56	9.13	0.39	2.2e-18	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg00599393	chr8:22457479	C8orf58	0.46	8.38	0.36	6.59e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.79	0.34	4.55e-14	Mood instability;
LGG	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg00647317	chr7:50633725	DDC	-0.35	-8.08	-0.35	5.61e-15	Malaria;
LGG	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.31	-0.4	5.35e-19	Retinal vascular caliber;
LGG	cis	rs4959677	0.901	rs10458144	chr6:2479189	C/T	cg23817096	chr6:1620687	NA	0.32	7.45	0.33	4.57e-13	Orthostatic hypotension;
LGG	cis	rs4321325	0.733	rs13389505	chr2:127934888	T/C	cg11380483	chr2:127933992	NA	0.65	8.95	0.38	8.84e-18	Protein C levels;
LGG	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg02733842	chr7:1102375	C7orf50	-0.43	-7.13	-0.31	3.91e-12	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg05665937	chr4:1216051	CTBP1	0.61	11.43	0.47	8.3e-27	Obesity-related traits;
LGG	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	14.22	0.55	2.5e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg07615347	chr10:60278583	BICC1	0.61	17.28	0.63	5.15e-52	Refractive error;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10141801	chr11:76432938	GUCY2E	0.36	6.76	0.3	4.21e-11	Cognitive performance;
LGG	cis	rs4906332	0.966	rs35799018	chr14:103893475	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.72e-14	Coronary artery disease;
LGG	cis	rs988958	0.958	rs13419617	chr2:42280854	C/T	cg19376973	chr2:42229025	NA	0.46	7.66	0.34	1.07e-13	Hypospadias;
LGG	cis	rs6728642	1.000	rs59178801	chr2:97604455	C/T	cg26665480	chr2:98280029	ACTR1B	-0.7	-7.45	-0.33	4.59e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs12931792	0.712	rs56399904	chr16:30166183	C/T	cg17640201	chr16:30407289	ZNF48	0.48	8.27	0.36	1.48e-15	Tonsillectomy;
LGG	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg11995313	chr8:8860691	ERI1	-0.44	-7.47	-0.33	4.02e-13	Joint mobility (Beighton score);
LGG	cis	rs67133203	0.851	rs12811658	chr12:51481623	T/A	cg14688905	chr12:51403056	SLC11A2	0.66	9.95	0.42	2.81e-21	Urinary tract infection frequency;
LGG	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg00531865	chr16:30841666	NA	-0.54	-10.87	-0.45	1.11e-24	Multiple myeloma;
LGG	cis	rs847649	0.699	rs7794668	chr7:102510416	C/T	cg18108683	chr7:102477205	FBXL13	0.64	14.31	0.55	1.06e-38	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg21775007	chr8:11205619	TDH	0.81	14.32	0.55	9.29e-39	Retinal vascular caliber;
LGG	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg06885757	chr1:42089581	HIVEP3	-0.58	-13.56	-0.53	1.67e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg07157834	chr1:205819609	PM20D1	0.41	7.0	0.31	9.12e-12	Parkinson's disease;
LGG	cis	rs3748682	0.861	rs28411034	chr1:38276997	G/A	cg12658694	chr1:38397304	INPP5B	0.38	7.06	0.31	6.2e-12	Hypothyroidism;
LGG	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg05973401	chr12:123451056	ABCB9	0.51	8.14	0.35	3.79e-15	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.41	-0.47	9.89e-27	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9650657	0.737	rs2409669	chr8:10623969	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.89	-0.34	2.14e-14	Neuroticism;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg08621203	chr6:150244597	RAET1G	-0.45	-7.73	-0.34	6.53e-14	Lung cancer;
LGG	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg08847533	chr14:75593920	NEK9	-0.54	-10.08	-0.42	9.47e-22	Height;
LGG	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	12.99	0.52	4.27e-33	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10178094	0.528	rs62175963	chr2:161339964	T/C	cg03641300	chr2:160917029	PLA2R1	-0.51	-9.03	-0.39	4.62e-18	White blood cell count;
LGG	cis	rs12681287	0.640	rs8635	chr8:87479810	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.73	-0.34	6.59e-14	Caudate activity during reward;
LGG	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg00405596	chr8:11794950	NA	-0.42	-6.96	-0.31	1.2e-11	Neuroticism;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs571497	0.583	rs62128261	chr19:7837989	G/C	cg09310891	chr19:7854403	CLEC4GP1	0.63	7.42	0.33	5.5e-13	Monocyte count;
LGG	trans	rs61931739	0.963	rs12307606	chr12:34016365	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-8.08	-0.35	5.83e-15	Morning vs. evening chronotype;
LGG	trans	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg21659725	chr3:3221576	CRBN	0.56	7.51	0.33	3.05e-13	Menarche (age at onset);
LGG	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	6e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg19507638	chr5:93509721	C5orf36	0.69	9.55	0.41	7.78e-20	Diabetic retinopathy;
LGG	cis	rs8014204	0.762	rs10139018	chr14:75274292	T/C	cg06637938	chr14:75390232	RPS6KL1	0.65	11.84	0.48	1.87e-28	Caffeine consumption;
LGG	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg25356066	chr3:128598488	ACAD9	0.44	6.7	0.3	6.14e-11	IgG glycosylation;
LGG	trans	rs3858145	0.588	rs78041174	chr10:70038771	G/A	cg04882175	chr6:131122610	NA	-0.55	-7.87	-0.34	2.57e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg05941027	chr17:61774174	LIMD2	-0.36	-9.13	-0.39	2.15e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9849248	0.627	rs4858939	chr3:88250125	T/A	cg14530983	chr3:88190749	ZNF654	-0.56	-7.73	-0.34	6.92e-14	Menarche (age at onset);
LGG	cis	rs1577917	0.958	rs12215265	chr6:86443969	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.66	-0.37	8.07e-17	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg18681998	chr4:17616180	MED28	0.85	18.91	0.66	1.63e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9486715	0.867	rs3849199	chr6:97049191	T/C	cg18709589	chr6:96969512	KIAA0776	-0.44	-8.69	-0.37	6.43e-17	Headache;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24017516	chr10:105677985	OBFC1	-0.43	-7.01	-0.31	8.52e-12	Pancreatic cancer;
LGG	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg04455712	chr21:45112962	RRP1B	0.54	10.11	0.43	7.36e-22	Mean corpuscular volume;
LGG	cis	rs7444	0.941	rs2266961	chr22:21928597	C/G	cg15846791	chr22:21984385	YDJC	-0.47	-7.01	-0.31	8.41e-12	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg04568710	chr12:38710424	ALG10B	-0.41	-8.89	-0.38	1.37e-17	Bladder cancer;
LGG	cis	rs12765878	0.580	rs4918058	chr10:105596641	G/C	cg11005552	chr10:105648138	OBFC1	-0.71	-11.99	-0.49	4.86e-29	Coronary artery disease;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg11301795	chr4:187892539	NA	-0.94	-25.61	-0.77	9.03e-91	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4423214	0.840	rs1792224	chr11:71176141	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg00717180	chr2:96193071	NA	-0.45	-8.32	-0.36	9.91e-16	HDL cholesterol;
LGG	cis	rs68170813	0.641	rs77397573	chr7:107006892	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-10.09	-0.42	9.27e-22	Coronary artery disease;
LGG	cis	rs883115	0.846	rs1566386	chr1:224803800	T/C	cg01808320	chr1:224927238	CNIH3	-0.41	-7.58	-0.33	1.86e-13	Cancer;
LGG	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg06115741	chr20:33292138	TP53INP2	0.59	9.77	0.41	1.29e-20	Coronary artery disease;
LGG	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg07303275	chr16:75499416	TMEM170A	0.38	6.88	0.3	1.92e-11	Dupuytren's disease;
LGG	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg06916706	chr16:4465613	CORO7	-0.9	-17.06	-0.62	5.63e-51	Schizophrenia;
LGG	cis	rs4774899	0.932	rs11637955	chr15:57528131	T/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.21	-0.32	2.29e-12	Urinary tract infection frequency;
LGG	cis	rs283228	0.798	rs550690	chr6:101754020	A/G	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs208520	0.954	rs1468153	chr6:67009054	A/C	cg07460842	chr6:66804631	NA	0.72	10.63	0.44	9.58e-24	Exhaled nitric oxide output;
LGG	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg20813462	chr7:2646259	IQCE	0.54	7.0	0.31	8.85e-12	Urate levels in lean individuals;
LGG	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg06885757	chr1:42089581	HIVEP3	0.56	12.82	0.51	2.09e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9914988	0.943	rs4794836	chr17:27082710	C/G	cg20469991	chr17:27169893	C17orf63	0.55	6.83	0.3	2.66e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1.05e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08677398	chr8:58056175	NA	0.55	8.32	0.36	9.65e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7191700	0.836	rs10163410	chr16:11430615	G/C	cg00044050	chr16:11439710	C16orf75	0.48	7.47	0.33	4.05e-13	Multiple sclerosis;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg08888203	chr3:10149979	C3orf24	0.56	8.01	0.35	9.23e-15	Alzheimer's disease;
LGG	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg25019033	chr10:957182	NA	-0.58	-10.45	-0.44	4.13e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.43	-0.33	5.11e-13	Mood instability;
LGG	trans	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19894588	chr14:64061835	NA	-0.6	-9.72	-0.41	1.94e-20	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs79349575	0.715	rs4793997	chr17:47019672	C/A	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.91	-0.57	2.45e-41	Hair morphology;
LGG	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg04226714	chr8:49833948	SNAI2	0.48	8.6	0.37	1.2e-16	Life satisfaction;
LGG	trans	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.06	-0.35	6.64e-15	Heart rate;
LGG	cis	rs2708240	1.000	rs2538985	chr7:147580902	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.38e-11	QT interval (drug interaction);
LGG	cis	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg06521331	chr12:34319734	NA	-0.64	-11.71	-0.48	6.52e-28	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.32	-0.43	1.31e-22	Alzheimer's disease;
LGG	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg19455335	chr8:22457658	C8orf58	-0.39	-7.96	-0.35	1.33e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs17030434	1.000	rs78249279	chr4:154718783	C/T	cg14289246	chr4:154710475	SFRP2	-0.73	-11.06	-0.46	2.26e-25	Electrocardiographic conduction measures;
LGG	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg03160526	chr17:80928410	B3GNTL1	0.4	6.82	0.3	2.92e-11	Glycated hemoglobin levels;
LGG	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg04733989	chr22:42467013	NAGA	0.57	9.8	0.41	1.02e-20	Schizophrenia;
LGG	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg03315344	chr16:75512273	CHST6	0.58	11.53	0.47	3.2e-27	Dupuytren's disease;
LGG	cis	rs6495367	1.000	rs3851677	chr15:79380869	C/T	cg17916960	chr15:79447300	NA	0.53	9.22	0.39	1.01e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.27	0.5	3.66e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.71	-0.34	8.03e-14	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.91	-0.34	1.92e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg02269571	chr22:50332266	NA	-0.7	-11.26	-0.46	3.64e-26	Schizophrenia;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.9	-0.38	1.3e-17	Neuroticism;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.48	0.4	1.33e-19	Longevity;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg04156016	chr5:1868137	NA	0.32	7.14	0.32	3.58e-12	Cardiovascular disease risk factors;
LGG	cis	rs6456156	0.586	rs2285148	chr6:167490999	G/T	cg07741184	chr6:167504864	NA	0.41	9.04	0.39	4.39e-18	Primary biliary cholangitis;
LGG	trans	rs9929218	0.529	rs8060790	chr16:68729112	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	26.33	0.77	4.62e-94	Colorectal cancer;
LGG	cis	rs11718455	0.960	rs35711021	chr3:44004791	G/A	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.63e-11	Coronary artery disease;
LGG	cis	rs17767392	0.958	rs10483836	chr14:72001614	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.96	-0.38	8.04e-18	Mitral valve prolapse;
LGG	cis	rs4906332	1.000	rs12889703	chr14:103872951	T/A	cg26031613	chr14:104095156	KLC1	-0.54	-8.13	-0.35	3.92e-15	Coronary artery disease;
LGG	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.94	-0.38	9e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg08677398	chr8:58056175	NA	0.56	9.02	0.39	5.01e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg08344181	chr3:125677491	NA	-0.91	-8.65	-0.37	8.37e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.05	-0.31	6.41e-12	IgG glycosylation;
LGG	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.93	-0.57	2.07e-41	Aortic root size;
LGG	trans	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg09048205	chr5:1608656	LOC728613	-0.5	-8.44	-0.37	4.05e-16	Breast cancer;
LGG	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.67	-0.34	1.01e-13	Testicular germ cell tumor;
LGG	cis	rs887829	0.588	rs6715325	chr2:234635241	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.91	-0.34	1.96e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10937275	0.590	rs116050195	chr3:186672937	G/A	cg26193484	chr3:186648175	ST6GAL1	0.8	8.5	0.37	2.72e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg18129748	chr3:49941408	MST1R	0.22	6.89	0.31	1.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.657	rs6107073	chr20:25716363	T/C	cg06421707	chr20:25228305	PYGB	0.37	7.73	0.34	6.59e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg06092702	chr1:163392909	NA	-0.41	-7.36	-0.32	8.25e-13	Motion sickness;
LGG	cis	rs2235649	0.746	rs113666107	chr16:1848642	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs8032158	0.892	rs2089636	chr15:56236314	T/C	cg02198044	chr15:56286336	NEDD4	-0.73	-12.7	-0.51	6.47e-32	Keloid;
LGG	cis	rs910187	0.537	rs1417452	chr20:45763350	T/C	cg27589058	chr20:45804311	EYA2	-0.29	-6.84	-0.3	2.47e-11	Migraine;
LGG	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.34	0.36	8.77e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs3820928	1.000	rs4673173	chr2:227769493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.34	-0.32	9.78e-13	Pulmonary function;
LGG	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg06611532	chr13:114900021	NA	0.27	6.73	0.3	4.88e-11	Schizophrenia;
LGG	cis	rs704795	0.805	rs1728926	chr2:27612937	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.56	0.41	6.92e-20	Menopause (age at onset);
LGG	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.86	-9.57	-0.41	6.36e-20	Diabetic retinopathy;
LGG	cis	rs4740619	0.810	rs2175080	chr9:15714465	A/G	cg14451791	chr9:16040625	NA	0.33	8.54	0.37	1.99e-16	Body mass index;
LGG	cis	rs2637030	0.515	rs449160	chr5:53005969	A/G	cg06476337	chr5:52856530	NDUFS4	0.44	6.9	0.31	1.66e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02825527	chr7:2087843	MAD1L1	-0.53	-8.97	-0.38	7.54e-18	Neuroticism;
LGG	cis	rs7113850	0.541	rs7118538	chr11:24223615	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	10.17	0.43	4.49e-22	Bone fracture in osteoporosis;
LGG	cis	rs4538187	0.950	rs12996866	chr2:64130965	G/A	cg02541582	chr2:64069798	UGP2	-0.6	-14.08	-0.55	1.02e-37	Systolic blood pressure;
LGG	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg00376283	chr12:123451042	ABCB9	0.62	9.43	0.4	1.98e-19	Neutrophil percentage of white cells;
LGG	cis	rs4740619	0.544	rs9406537	chr9:15815246	T/C	cg14451791	chr9:16040625	NA	0.32	7.86	0.34	2.81e-14	Body mass index;
LGG	cis	rs3790455	0.610	rs1171563	chr1:156456529	T/G	cg14087168	chr1:156450669	MEF2D	-0.65	-9.42	-0.4	2.13e-19	Migraine;
LGG	cis	rs2439831	0.867	rs12324572	chr15:43636200	G/A	cg15269541	chr15:43626905	ADAL	-0.42	-7.02	-0.31	7.92e-12	Lung cancer in ever smokers;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9796	0.870	rs8023345	chr15:41338348	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.06	-0.35	6.49e-15	Menopause (age at onset);
LGG	cis	rs72848980	0.706	rs11191732	chr10:105331761	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.76	11.55	0.47	2.83e-27	White matter hyperintensity burden;
LGG	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.38	0.53	9.56e-35	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg07870213	chr5:140052090	DND1	-0.67	-13.07	-0.52	1.95e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg12070911	chr6:150209640	RAET1E	0.28	6.8	0.3	3.34e-11	Lung cancer;
LGG	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-7.75	-0.34	5.75e-14	Vitiligo;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg08621203	chr6:150244597	RAET1G	0.41	6.97	0.31	1.09e-11	Lung cancer;
LGG	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg26384229	chr12:38710491	ALG10B	0.99	23.23	0.73	1.05e-79	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2274273	0.662	rs67092614	chr14:55672055	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.83	0.48	2.21e-28	Protein biomarker;
LGG	cis	rs7572263	0.724	rs11676550	chr2:209053775	T/C	cg00164906	chr2:209055251	C2orf80	0.73	9.85	0.42	6.81e-21	Glioma;Non-glioblastoma glioma;
LGG	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.08	0.49	2.18e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg22482690	chr17:47019901	SNF8	0.36	6.99	0.31	9.53e-12	Coronary heart disease;
LGG	cis	rs1018836	0.608	rs7821069	chr8:91465548	C/G	cg16814680	chr8:91681699	NA	-0.59	-9.93	-0.42	3.44e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07833019	chr5:38258007	EGFLAM	0.48	7.33	0.32	1.06e-12	Gut microbiome composition (summer);
LGG	cis	rs4851254	0.961	rs13022707	chr2:100734946	C/A	cg17356467	chr2:100759845	AFF3	0.4	6.66	0.3	7.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6901004	0.803	rs1322214	chr6:111480045	T/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.64	-0.33	1.24e-13	Blood metabolite levels;
LGG	cis	rs4740619	0.782	rs276444	chr9:15582252	G/C	cg14451791	chr9:16040625	NA	-0.34	-8.65	-0.37	8.34e-17	Body mass index;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.16	-0.32	3.21e-12	Longevity;Endometriosis;
LGG	cis	rs4363385	0.510	rs11577384	chr1:152899728	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.28	-0.4	6.4e-19	Inflammatory skin disease;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg15665833	chr6:26285013	NA	0.42	8.13	0.35	4.07e-15	Educational attainment;
LGG	cis	rs9951602	0.512	rs9953258	chr18:76651199	A/C	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg07936489	chr17:37558343	FBXL20	-0.55	-9.2	-0.39	1.23e-18	Asthma;
LGG	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg26695010	chr11:65641043	EFEMP2	-0.54	-9.19	-0.39	1.31e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-9.6	-0.41	4.95e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.88	-0.3	1.9e-11	Daytime sleep phenotypes;
LGG	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs9849248	0.627	rs56185750	chr3:88154533	A/T	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs17039065	0.920	rs35607957	chr4:109470787	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Triglycerides;
LGG	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg22681709	chr2:178499509	PDE11A	-0.47	-6.79	-0.3	3.46e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg07343612	chr16:622815	PIGQ	-0.77	-15.76	-0.59	4.1e-45	Height;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg10150615	chr22:24372951	LOC391322	-0.41	-6.78	-0.3	3.68e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg17830980	chr10:43048298	ZNF37B	-0.41	-9.26	-0.4	7.43e-19	Extrinsic epigenetic age acceleration;
LGG	cis	rs8133932	0.736	rs2839020	chr21:47280001	A/G	cg13695288	chr21:47294981	PCBP3	-0.37	-7.35	-0.32	8.77e-13	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg11494091	chr17:61959527	GH2	1.01	25.08	0.76	2.74e-88	Prudent dietary pattern;
LGG	cis	rs7215564	0.818	rs34929663	chr17:78617212	C/T	cg16980736	chr17:78789706	RPTOR	-0.67	-8.66	-0.37	7.76e-17	Myopia (pathological);
LGG	cis	rs7215564	0.543	rs78457522	chr17:78520896	G/T	cg16980736	chr17:78789706	RPTOR	-0.56	-7.79	-0.34	4.44e-14	Myopia (pathological);
LGG	cis	rs295140	1.000	rs7584810	chr2:201167772	G/A	cg25099087	chr2:201172481	SPATS2L	0.28	6.96	0.31	1.14e-11	QT interval;
LGG	cis	rs283228	0.678	rs2852508	chr6:101844329	A/T	cg27451362	chr6:101846650	GRIK2	-0.7	-11.39	-0.47	1.16e-26	Coenzyme Q10 levels;
LGG	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg00149659	chr3:10157352	C3orf10	0.55	8.12	0.35	4.29e-15	Alzheimer's disease;
LGG	cis	rs12765878	1.000	rs3814220	chr10:105647300	A/G	cg11005552	chr10:105648138	OBFC1	1.03	26.86	0.78	1.72e-96	Coronary artery disease;
LGG	cis	rs9816226	0.587	rs9863591	chr3:185841624	C/G	cg00760338	chr3:185826511	ETV5	-0.81	-13.81	-0.54	1.47e-36	Obesity;Body mass index;
LGG	cis	rs11718455	0.960	rs11917885	chr3:44008013	A/G	cg21419209	chr3:44054225	NA	0.41	6.81	0.3	3.1e-11	Coronary artery disease;
LGG	cis	rs17373728	0.526	rs10957753	chr8:76133428	T/C	cg07016329	chr8:76221503	NA	0.46	8.6	0.37	1.26e-16	Diabetic kidney disease;
LGG	cis	rs9810089	0.706	rs521746	chr3:136103920	C/T	cg21827317	chr3:136751795	NA	-0.41	-7.2	-0.32	2.38e-12	Gestational age at birth (child effect);
LGG	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.0	-0.31	8.77e-12	Vitiligo;
LGG	cis	rs981844	0.857	rs62325139	chr4:154712213	C/T	cg14289246	chr4:154710475	SFRP2	0.74	12.34	0.5	1.93e-30	Response to statins (LDL cholesterol change);
LGG	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs9649465	1.000	rs2896334	chr7:123367705	A/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.86	-0.38	1.73e-17	Migraine;
LGG	cis	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg24232236	chr22:38142998	TRIOBP	0.35	6.83	0.3	2.68e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg16583315	chr14:65563665	MAX	-0.41	-8.36	-0.36	7.15e-16	Obesity-related traits;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg07061783	chr6:25882402	NA	-0.49	-8.5	-0.37	2.65e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg00340584	chr1:149512963	NA	0.25	7.41	0.33	6.01e-13	Hip geometry;
LGG	cis	rs5753037	0.547	rs140140	chr22:30166437	G/A	cg01021169	chr22:30184971	ASCC2	-0.42	-8.6	-0.37	1.22e-16	Type 1 diabetes;
LGG	cis	rs6445975	0.715	rs3773006	chr3:58269539	C/T	cg24175188	chr3:58374923	PXK	0.4	7.38	0.32	7.4e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.32	0.36	1e-15	Lung cancer;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg07120314	chr15:79043507	NA	-0.68	-12.24	-0.49	4.97e-30	Coronary artery disease or large artery stroke;
LGG	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.35	-0.32	8.98e-13	Cognitive ability;
LGG	cis	rs4919044	0.641	rs7914449	chr10:94723370	G/T	cg05127821	chr10:94822908	CYP26C1	-0.4	-7.0	-0.31	9.23e-12	Coronary artery disease;
LGG	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg04117972	chr1:227635322	NA	0.57	9.37	0.4	3.12e-19	Major depressive disorder;
LGG	cis	rs11785693	0.862	rs1156861	chr8:4984434	G/C	cg26367366	chr8:4980734	NA	1.01	15.81	0.59	2.59e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.89	-19.86	-0.68	6.13e-64	Schizophrenia;
LGG	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg22232500	chr2:134024266	NCKAP5	0.46	6.79	0.3	3.46e-11	Bipolar disorder;
LGG	cis	rs12681288	0.676	rs4565481	chr8:1001944	C/T	cg04851639	chr8:1020857	NA	-0.44	-9.07	-0.39	3.5e-18	Schizophrenia;
LGG	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg02227867	chr8:22457446	C8orf58	-0.43	-8.03	-0.35	7.98e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15644404	chr18:77186268	NFATC1	-0.8	-9.74	-0.41	1.6e-20	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14634336	chr6:111804804	REV3L	0.5	7.78	0.34	4.65e-14	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.45	-0.33	4.75e-13	Neuroticism;
LGG	cis	rs11074306	0.561	rs6497243	chr15:28072596	C/T	cg26402630	chr15:28053930	OCA2	0.35	7.03	0.31	7.39e-12	Uveal melanoma;
LGG	cis	rs4938534	0.559	rs1944918	chr11:111261995	A/G	cg18316498	chr11:111250196	POU2AF1	0.3	6.67	0.3	7.13e-11	Primary biliary cholangitis;
LGG	cis	rs300774	0.925	rs300801	chr2:105259	C/T	cg04617936	chr2:214353	NA	-0.51	-7.48	-0.33	3.79e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs988958	0.526	rs7604662	chr2:42243943	A/G	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Hypospadias;
LGG	cis	rs8017423	1.000	rs8011810	chr14:90685669	A/G	cg04374321	chr14:90722782	PSMC1	0.85	18.23	0.65	2.19e-56	Mortality in heart failure;
LGG	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg27489772	chr12:121021490	NA	0.55	7.38	0.32	7.43e-13	Type 1 diabetes nephropathy;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2072499	0.838	rs2758619	chr1:156162559	A/G	cg25208724	chr1:156163844	SLC25A44	1.27	32.35	0.83	6.52e-121	Testicular germ cell tumor;
LGG	cis	rs7226408	0.857	rs56391099	chr18:34478627	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.98	-0.31	1.03e-11	Obesity-related traits;
LGG	cis	rs6728642	0.908	rs11901495	chr2:98017804	A/G	cg26665480	chr2:98280029	ACTR1B	0.77	9.27	0.4	6.86e-19	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg02462569	chr6:150064036	NUP43	-0.38	-7.95	-0.35	1.47e-14	Lung cancer;
LGG	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.5	-0.37	2.66e-16	Total body bone mineral density;
LGG	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg02002194	chr4:3960332	NA	0.45	8.16	0.35	3.11e-15	Neuroticism;
LGG	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg23601095	chr6:26197514	HIST1H3D	0.69	8.73	0.38	4.72e-17	Gout;Renal underexcretion gout;
LGG	trans	rs1032833	0.732	rs10497533	chr2:179999215	A/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs722599	0.748	rs731952	chr14:75366447	A/G	cg06637938	chr14:75390232	RPS6KL1	0.56	9.23	0.39	9.54e-19	IgG glycosylation;
LGG	cis	rs68170813	0.559	rs4730231	chr7:106942039	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	9.76e-24	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02095752	chr6:150262961	ULBP2	0.44	6.93	0.31	1.39e-11	Gut microbiome composition (summer);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06784845	chr3:133614993	RAB6B	-0.44	-7.5	-0.33	3.18e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg17462356	chr17:80056334	FASN	0.44	6.66	0.3	7.77e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg01657329	chr11:68192670	LRP5	-0.58	-9.27	-0.4	7.14e-19	Total body bone mineral density (age 45-60);
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.84e-28	Intelligence (multi-trait analysis);
LGG	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg17644776	chr2:200775616	C2orf69	-0.5	-8.38	-0.36	6.54e-16	Asthma (bronchodilator response);
LGG	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-12.38	-0.5	1.27e-30	Height;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.92	0.42	3.75e-21	Tonsillectomy;
LGG	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	10.86	0.45	1.31e-24	Mood instability;
LGG	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg16414030	chr3:133502952	NA	0.63	10.64	0.44	8.55e-24	Iron status biomarkers;
LGG	cis	rs6714710	0.603	rs34149969	chr2:98342323	C/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.78	0.41	1.14e-20	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6860806	0.507	rs635620	chr5:131720263	A/G	cg07395648	chr5:131743802	NA	0.48	9.91	0.42	4.17e-21	Breast cancer;
LGG	trans	rs225245	0.782	rs321617	chr17:33915246	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.08	-0.31	5.24e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4888262	0.508	rs7189123	chr16:74540097	C/A	cg01733217	chr16:74700730	RFWD3	0.82	16.05	0.6	2.05e-46	Testicular germ cell tumor;
LGG	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.77	-0.34	5.18e-14	Calcium levels;
LGG	cis	rs9788682	0.747	rs2958719	chr15:78743029	G/A	cg06917634	chr15:78832804	PSMA4	0.53	8.15	0.35	3.31e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2204008	0.594	rs11531211	chr12:37998007	T/G	cg13010199	chr12:38710504	ALG10B	-0.61	-12.79	-0.51	2.74e-32	Bladder cancer;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs4478858	0.735	rs6425737	chr1:31790288	T/C	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.27e-11	Alcohol dependence;
LGG	cis	rs11683229	0.598	rs13023873	chr2:64039567	C/T	cg19915305	chr2:64069682	UGP2	-0.57	-10.53	-0.44	2.17e-23	Protein quantitative trait loci;
LGG	cis	rs4700695	0.925	rs10069614	chr5:65396530	A/C	cg21114390	chr5:65439923	SFRS12	-0.55	-6.89	-0.3	1.89e-11	Facial morphology (factor 19);
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08645402	chr16:4508243	NA	0.49	9.32	0.4	4.6e-19	Schizophrenia;
LGG	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg04450456	chr4:17643702	FAM184B	0.33	6.98	0.31	1.06e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4690686	0.769	rs7656505	chr4:177274867	A/T	cg17059388	chr4:177262070	NA	0.75	16.22	0.6	3.49e-47	Essential tremor;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg04267008	chr7:1944627	MAD1L1	-0.62	-10.67	-0.44	6.28e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs9462027	0.628	rs9462023	chr6:34769410	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs60871478	0.545	rs35400476	chr7:795686	A/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.71	-0.34	8e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg20703242	chr1:230279135	GALNT2	-0.37	-7.2	-0.32	2.5e-12	Coronary artery disease;
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg11608241	chr8:8085544	FLJ10661	-0.33	-7.53	-0.33	2.74e-13	Triglycerides;
LGG	cis	rs3206736	0.548	rs329236	chr7:35056266	C/A	cg13400248	chr7:35225412	NA	0.55	9.6	0.41	5.05e-20	Diastolic blood pressure;
LGG	cis	rs7085104	0.632	rs4290163	chr10:104610926	G/T	cg04362960	chr10:104952993	NT5C2	0.47	8.61	0.37	1.19e-16	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.76	-0.34	5.66e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs12643440	0.538	rs2314599	chr4:17139624	A/G	cg22650099	chr4:17144496	NA	-0.51	-8.73	-0.38	4.66e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs9487094	0.922	rs9487098	chr6:109743392	A/T	cg16315928	chr6:109776240	MICAL1	0.48	8.03	0.35	8.3e-15	Height;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.39	-6.92	-0.31	1.51e-11	Schizophrenia;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs9547996	1.000	rs9547994	chr13:38219448	A/C	cg17979426	chr13:38220150	TRPC4	-0.44	-8.34	-0.36	8.78e-16	Diastolic blood pressure;
LGG	cis	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg13647721	chr17:30228624	UTP6	0.66	6.78	0.3	3.59e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg12046867	chr14:103022105	NA	-0.7	-13.48	-0.53	3.53e-35	Platelet count;
LGG	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08045932	chr20:61659980	NA	0.5	9.33	0.4	4.44e-19	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	6.74	0.3	4.58e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.3	0.4	5.46e-19	Coronary artery disease;
LGG	cis	rs11168854	0.719	rs11168890	chr12:49543913	A/G	cg24176009	chr12:49580217	TUBA1A	0.66	12.83	0.51	1.88e-32	Body mass index;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg14789911	chr21:47582049	C21orf56	-0.41	-7.1	-0.31	4.88e-12	Testicular germ cell tumor;
LGG	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg25309564	chr22:51001381	C22orf41	0.62	9.81	0.41	9.37e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9658691	0.607	rs9658786	chr10:90776349	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.68	8.37	0.36	6.97e-16	Mosquito bite size;
LGG	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	8.06	0.35	6.34e-15	Response to antipsychotic treatment;
LGG	trans	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg27411982	chr8:10470053	RP1L1	0.43	7.33	0.32	1.04e-12	Mean corpuscular volume;
LGG	cis	rs2953174	1.000	rs2953176	chr2:241520754	T/A	cg07929629	chr2:241523174	NA	0.57	6.98	0.31	1.02e-11	Bipolar disorder;
LGG	cis	rs2018055	0.618	rs6568979	chr6:117796443	C/T	cg14611402	chr6:117803162	DCBLD1	0.31	8.96	0.38	7.77e-18	Diastolic blood pressure;
LGG	cis	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg11502198	chr6:26597334	ABT1	-0.86	-7.4	-0.33	6.52e-13	Small cell lung carcinoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05577173	chr5:78908678	PAPD4	0.45	7.45	0.33	4.46e-13	Cognitive performance;
LGG	cis	rs6456156	0.742	rs2022000	chr6:167529611	A/G	cg07741184	chr6:167504864	NA	-0.3	-6.71	-0.3	5.71e-11	Primary biliary cholangitis;
LGG	cis	rs1816752	0.704	rs7995968	chr13:24966892	C/T	cg02811702	chr13:24901961	NA	-0.37	-6.75	-0.3	4.32e-11	Obesity-related traits;
LGG	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg01448562	chr3:133502909	NA	-0.81	-15.52	-0.59	4.72e-44	Iron status biomarkers;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg15948088	chr11:109293068	C11orf87	0.5	8.66	0.37	7.73e-17	Schizophrenia;
LGG	cis	rs10979	0.964	rs35205240	chr6:143898676	T/C	cg25407410	chr6:143891975	LOC285740	-0.71	-12.09	-0.49	1.89e-29	Hypospadias;
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg27400746	chr16:89904261	SPIRE2	0.85	14.56	0.56	8.55e-40	Skin colour saturation;
LGG	cis	rs9359856	0.636	rs1179896	chr6:90318610	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.88	-0.34	2.34e-14	Bipolar disorder;
LGG	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	12.69	0.51	6.91e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.44	0.33	4.85e-13	Triglycerides;
LGG	cis	rs4478037	0.822	rs4528891	chr3:33121392	G/T	cg19404215	chr3:33155277	CRTAP	0.72	9.06	0.39	3.54e-18	Major depressive disorder;
LGG	cis	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs11190604	0.767	rs4919459	chr10:102200371	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.64	0.33	1.24e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.1	0.52	1.39e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs644148	0.803	rs2686771	chr19:44999494	T/C	cg15540054	chr19:45004280	ZNF180	-0.56	-10.72	-0.45	4.12e-24	Personality dimensions;
LGG	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg08297393	chr2:100937505	LONRF2	-0.46	-8.13	-0.35	3.84e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6815814	0.950	rs5743563	chr4:38806019	A/G	cg06935464	chr4:38784597	TLR10	0.6	8.24	0.36	1.76e-15	Breast cancer;
LGG	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg27147174	chr7:100797783	AP1S1	-0.7	-13.25	-0.52	3.43e-34	Life satisfaction;
LGG	cis	rs4950322	0.570	rs17360443	chr1:146751410	G/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.43	-0.36	4.45e-16	Protein quantitative trait loci;
LGG	cis	rs35110281	0.591	rs162390	chr21:44936826	C/T	cg04455712	chr21:45112962	RRP1B	0.46	8.67	0.37	7.35e-17	Mean corpuscular volume;
LGG	cis	rs11997175	0.574	rs12541661	chr8:33649856	T/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.09e-12	Body mass index;
LGG	cis	rs897984	0.568	rs67264578	chr16:30879395	G/A	cg00531865	chr16:30841666	NA	-0.53	-10.01	-0.42	1.78e-21	Dementia with Lewy bodies;
LGG	cis	rs365132	0.846	rs184784	chr5:176440229	G/T	cg16309518	chr5:176445507	NA	-0.51	-11.19	-0.46	6.76e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.06e-12	Electroencephalogram traits;
LGG	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-16.39	-0.61	5.83e-48	Asthma;
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-7.21	-0.32	2.34e-12	Vitiligo;
LGG	cis	rs6740322	0.895	rs11684601	chr2:43574242	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.21	-0.39	1.15e-18	Coronary artery disease;
LGG	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg03342759	chr3:160939853	NMD3	0.58	9.59	0.41	5.45e-20	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.82	0.38	2.36e-17	Obesity-related traits;
LGG	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg26408565	chr15:76604113	ETFA	0.38	6.67	0.3	7.34e-11	Blood metabolite levels;
LGG	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.66	0.3	7.57e-11	Sudden cardiac arrest;
LGG	trans	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg08344181	chr3:125677491	NA	-0.74	-6.67	-0.3	7.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7914558	0.966	rs10786745	chr10:104956827	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.7	0.45	4.97e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs72781680	0.846	rs72782114	chr2:24025740	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs2708240	1.000	rs7806519	chr7:147574574	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.77	-0.3	4.03e-11	QT interval (drug interaction);
LGG	cis	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-14.18	-0.55	3.75e-38	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.818	rs2152994	chr1:152991060	C/T	cg13444842	chr1:152974279	SPRR3	0.42	8.66	0.37	7.65e-17	Inflammatory skin disease;
LGG	cis	rs8170	0.603	rs1544940	chr19:17414843	A/T	cg04749549	chr19:17459798	NA	-0.39	-7.18	-0.32	2.81e-12	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	trans	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg25482853	chr8:67687455	SGK3	0.98	11.13	0.46	1.2e-25	Lung disease severity in cystic fibrosis;
LGG	trans	rs931812	0.757	rs35569317	chr8:101907971	T/C	cg20993868	chr7:22813445	NA	0.61	11.98	0.49	5.39e-29	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2901460	0.509	rs66481227	chr2:62117600	C/T	cg02183531	chr2:62113199	CCT4	-0.47	-8.23	-0.36	1.99e-15	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.92e-13	Restless legs syndrome;
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg04911050	chr16:677664	RAB40C	0.35	6.94	0.31	1.33e-11	Height;
LGG	cis	rs9815354	0.761	rs12635286	chr3:42051836	T/C	cg03022575	chr3:42003672	ULK4	0.66	7.92	0.35	1.75e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.72	0.34	7.12e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.5	9.64	0.41	3.53e-20	Ovarian reserve;
LGG	cis	rs7147624	0.766	rs11158597	chr14:65913536	T/G	cg03016385	chr14:66212404	NA	-0.76	-9.97	-0.42	2.41e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.28	0.36	1.35e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg02158880	chr13:53174818	NA	0.67	15.39	0.58	1.92e-43	Lewy body disease;
LGG	cis	rs1595825	0.891	rs73058867	chr2:198891568	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.82	-0.3	2.77e-11	Ulcerative colitis;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg17178900	chr1:205818956	PM20D1	-0.5	-11.59	-0.47	1.83e-27	Monocyte percentage of white cells;
LGG	cis	rs9902453	0.765	rs3102562	chr17:28040403	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.16	0.55	4.42e-38	Coffee consumption (cups per day);
LGG	cis	rs7166081	1.000	rs34699563	chr15:67514217	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.72	-0.3	5.3e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg06640241	chr16:89574553	SPG7	0.71	12.25	0.49	4.47e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg06886374	chr16:1844152	IGFALS	0.44	7.89	0.34	2.2e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2415984	0.579	rs2817548	chr14:46969149	A/T	cg14871534	chr14:47121158	RPL10L	0.58	10.22	0.43	2.93e-22	Number of children ever born;
LGG	cis	rs9462027	0.628	rs6905393	chr6:34776626	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25010444	chr12:123717480	C12orf65	0.51	7.48	0.33	3.89e-13	Gut microbiome composition (summer);
LGG	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg15145296	chr3:125709740	NA	-0.61	-7.92	-0.35	1.78e-14	Blood pressure (smoking interaction);
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.07e-11	Menopause (age at onset);
LGG	cis	rs6834538	0.744	rs11936846	chr4:113409270	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.46	7.8	0.34	4.19e-14	Free thyroxine concentration;
LGG	cis	rs17001868	1.000	rs17001868	chr22:40778231	A/C	cg07138101	chr22:40742427	ADSL	0.63	6.92	0.31	1.54e-11	Mammographic density (dense area);
LGG	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg12310025	chr6:25882481	NA	-0.62	-11.61	-0.47	1.6e-27	Intelligence (multi-trait analysis);
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg13009111	chr11:71350975	NA	-0.31	-6.74	-0.3	4.84e-11	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg12395012	chr8:11607386	GATA4	0.42	7.51	0.33	3.04e-13	Monocyte count;
LGG	cis	rs2820315	1.000	rs2644122	chr1:201810407	A/G	cg10061532	chr1:201886748	LMOD1	0.33	6.86	0.3	2.21e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs883565	0.606	rs883349	chr3:39067925	T/C	cg01426195	chr3:39028469	NA	-0.67	-15.21	-0.58	1.13e-42	Handedness;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs4776059	1.000	rs12914047	chr15:52970993	G/A	cg22715398	chr15:52968154	KIAA1370	-0.51	-8.51	-0.37	2.44e-16	Schizophrenia;
LGG	cis	rs2274273	0.588	rs9919923	chr14:55813899	A/G	cg04306507	chr14:55594613	LGALS3	0.53	12.49	0.5	4.75e-31	Protein biomarker;
LGG	cis	rs9814567	1.000	rs9841212	chr3:134191938	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.58	-0.5	2e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.66	-12.03	-0.49	3.47e-29	Mean corpuscular volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26057840	chr20:62677629	NA	-0.38	-7.68	-0.34	9.29e-14	Pancreatic cancer;
LGG	cis	rs4959677	0.725	rs879097	chr6:2507392	A/G	cg23817096	chr6:1620687	NA	-0.33	-8.0	-0.35	9.79e-15	Orthostatic hypotension;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.05	-0.42	1.26e-21	Total body bone mineral density;
LGG	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg09596252	chr17:78655493	RPTOR	0.44	7.97	0.35	1.23e-14	Obesity;
LGG	trans	rs8002861	0.781	rs9525857	chr13:44437072	T/C	cg17145862	chr1:211918768	LPGAT1	0.96	24.56	0.75	7.04e-86	Leprosy;
LGG	cis	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg21775007	chr8:11205619	TDH	-0.61	-9.88	-0.42	4.94e-21	Retinal vascular caliber;
LGG	cis	rs11064837	0.523	rs7310266	chr12:120098409	T/C	cg25937854	chr12:120150414	CIT	-0.68	-11.34	-0.47	1.85e-26	Schizophrenia;
LGG	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg18424134	chr6:126068038	NA	0.21	6.68	0.3	6.81e-11	Brugada syndrome;
LGG	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Vitiligo;
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.8	-0.34	4.1e-14	Bipolar disorder;
LGG	cis	rs10220309	0.501	rs4899764	chr14:80642939	G/T	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.12e-11	Lung function (FEV1);
LGG	cis	rs6964587	0.626	rs6972945	chr7:91549576	C/G	cg17063962	chr7:91808500	NA	-0.47	-8.73	-0.38	4.57e-17	Breast cancer;
LGG	trans	rs1941687	0.527	rs1493914	chr18:31362327	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.7	-0.37	6.03e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg12698349	chr2:225449008	CUL3	1.03	26.68	0.78	1.2e-95	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs6577655	0.517	rs11998030	chr8:135585325	C/T	cg17885191	chr8:135476712	NA	0.59	8.82	0.38	2.28e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.73	0.3	5.18e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg13770153	chr20:60521292	NA	-0.54	-8.49	-0.37	2.74e-16	Body mass index;
LGG	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg11871910	chr12:69753446	YEATS4	0.71	8.44	0.37	4.03e-16	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6764363	0.527	rs4685490	chr3:283854	A/G	cg02057681	chr3:285234	CHL1	-0.42	-7.4	-0.33	6.68e-13	Sudden cardiac arrest;
LGG	cis	rs975722	0.638	rs7796168	chr7:117327595	A/C	cg10524701	chr7:117356490	CTTNBP2	0.48	9.72	0.41	1.86e-20	Coronary artery disease;
LGG	cis	rs7617480	0.648	rs4974088	chr3:48898749	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.11	0.35	4.56e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg04672837	chr16:48644449	N4BP1	-0.52	-8.58	-0.37	1.39e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs503734	0.653	rs6771561	chr3:101196087	C/T	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg11301795	chr4:187892539	NA	-0.94	-25.93	-0.77	3.22e-92	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg21890820	chr11:65308645	LTBP3	0.71	7.57	0.33	2.07e-13	Height;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg26384229	chr12:38710491	ALG10B	0.91	20.28	0.69	6.57e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg10224037	chr5:178157518	ZNF354A	0.75	11.66	0.48	1.05e-27	Neutrophil percentage of white cells;
LGG	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.55	8.7	0.37	5.94e-17	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12545109	0.800	rs2670053	chr8:57421998	A/T	cg19413350	chr8:57351067	NA	-0.42	-6.9	-0.31	1.66e-11	Obesity-related traits;
LGG	cis	rs883565	0.568	rs6599004	chr3:39095678	C/T	cg01426195	chr3:39028469	NA	-0.73	-16.96	-0.62	1.62e-50	Handedness;
LGG	cis	rs787274	0.543	rs10116897	chr9:115633479	C/T	cg13803584	chr9:115635662	SNX30	-0.65	-10.0	-0.42	1.88e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.79	17.66	0.63	1.01e-53	Obesity-related traits;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18252515	chr7:66147081	NA	-0.41	-6.92	-0.31	1.48e-11	Aortic root size;
LGG	cis	rs2239547	0.522	rs9865094	chr3:52985319	G/C	cg11645453	chr3:52864694	ITIH4	-0.65	-10.21	-0.43	3.22e-22	Schizophrenia;
LGG	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg23422044	chr7:1970798	MAD1L1	-0.76	-13.5	-0.53	2.98e-35	Bipolar disorder;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19524238	chr7:2802976	GNA12	0.41	9.02	0.39	4.99e-18	Height;
LGG	cis	rs12369635	1.000	rs73159540	chr12:129559421	C/T	cg01909103	chr12:129572610	TMEM132D	-0.7	-7.0	-0.31	8.84e-12	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg05677249	chr15:77158041	SCAPER	-0.31	-6.66	-0.3	7.61e-11	Blood metabolite levels;
LGG	trans	rs7939886	0.920	rs7124734	chr11:55960339	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.71	0.34	7.99e-14	Myopia (pathological);
LGG	cis	rs10274279	0.614	rs12669148	chr7:157404930	T/C	cg09270525	chr7:157391030	PTPRN2	0.87	11.27	0.46	3.48e-26	Myopia (pathological);
LGG	cis	rs12447804	0.871	rs2304488	chr16:58074210	A/G	cg03859792	chr16:58121049	NA	0.47	7.24	0.32	1.88e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2456568	0.803	rs10831142	chr11:93640781	A/G	cg26875233	chr11:93583750	C11orf90	0.34	6.7	0.3	6.05e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg24231037	chr15:68117551	LBXCOR1	0.32	7.77	0.34	5.17e-14	Restless legs syndrome;
LGG	cis	rs9290877	0.667	rs9816134	chr3:188462321	T/G	cg17392043	chr3:188495102	LPP	-0.45	-7.91	-0.34	1.94e-14	IgE levels;
LGG	cis	rs4262150	0.883	rs111770575	chr5:152242327	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.06	-0.49	2.65e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9357271	0.956	rs4711546	chr6:38366186	A/G	cg07362130	chr6:38359646	BTBD9	-0.44	-10.05	-0.42	1.24e-21	Restless legs syndrome;
LGG	cis	rs1832871	0.538	rs6924801	chr6:158718805	A/G	cg07215822	chr6:158701037	NA	0.47	9.18	0.39	1.39e-18	Height;
LGG	cis	rs6577655	0.517	rs6999469	chr8:135577530	G/A	cg17885191	chr8:135476712	NA	0.59	8.86	0.38	1.66e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4148087	0.929	rs4148098	chr21:43639553	T/A	cg10192877	chr21:43641690	ABCG1	-0.4	-6.97	-0.31	1.07e-11	Eating disorder in bipolar disorder;
LGG	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg04287289	chr16:89883240	FANCA	-0.45	-7.99	-0.35	1.11e-14	Vitiligo;
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.1	0.49	1.74e-29	Prudent dietary pattern;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg00713939	chr8:144660590	NAPRT1	0.89	7.27	0.32	1.57e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg00405596	chr8:11794950	NA	-0.44	-7.28	-0.32	1.43e-12	Neuroticism;
LGG	cis	rs9287719	0.967	rs7566875	chr2:10754792	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg12179176	chr11:130786555	SNX19	0.84	17.52	0.63	4.22e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg06598544	chr20:61472147	COL9A3	-0.91	-10.43	-0.44	5e-23	Obesity-related traits;
LGG	cis	rs7646881	0.812	rs7624161	chr3:158459914	C/G	cg19483011	chr3:158453295	NA	-0.59	-8.11	-0.35	4.46e-15	Tetralogy of Fallot;
LGG	cis	rs763121	0.657	rs5995603	chr22:39040733	G/A	cg06022373	chr22:39101656	GTPBP1	0.85	15.65	0.59	1.24e-44	Menopause (age at onset);
LGG	cis	rs778371	0.723	rs12619195	chr2:233678326	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-12.3	-0.5	2.78e-30	Schizophrenia;
LGG	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.95	-0.31	1.23e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8133932	0.554	rs11089028	chr21:47298312	T/C	cg11214348	chr21:47283868	PCBP3	0.44	7.87	0.34	2.56e-14	Schizophrenia;
LGG	cis	rs1957429	0.808	rs11628910	chr14:65332392	A/G	cg23373153	chr14:65346875	NA	1.06	13.48	0.53	3.6e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs7236492	0.935	rs11659416	chr18:77226973	C/T	cg15532942	chr18:77220712	NFATC1	0.47	7.4	0.33	6.27e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg09873164	chr1:152488093	CRCT1	0.63	15.6	0.59	2.21e-44	Hair morphology;
LGG	trans	rs10107145	0.509	rs73209953	chr8:10760112	G/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.76	-0.3	4.28e-11	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg08677398	chr8:58056175	NA	0.5	7.96	0.35	1.36e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	1.000	rs72843619	chr6:27154830	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.46	-0.33	4.21e-13	Hip circumference adjusted for BMI;
LGG	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg00405596	chr8:11794950	NA	-0.61	-10.59	-0.44	1.27e-23	Monocyte count;
LGG	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg20476274	chr7:133979776	SLC35B4	0.66	11.67	0.48	8.92e-28	Mean platelet volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18715511	chr12:1058965	RAD52	0.41	6.81	0.3	2.97e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15344021	chr17:2240169	TSR1;SGSM2	0.53	8.64	0.37	8.91e-17	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.02e-20	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.35e-12	Lung cancer;
LGG	cis	rs2870946	0.826	rs4997558	chr12:68597902	C/T	cg01673780	chr12:68619593	IL26	-0.86	-7.92	-0.35	1.73e-14	Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06527865	chr1:234746497	IRF2BP2	0.43	7.14	0.31	3.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg00424166	chr6:150045504	NUP43	-0.34	-7.17	-0.32	3.06e-12	Lung cancer;
LGG	cis	rs4731207	0.596	rs6964090	chr7:124667116	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.08	-0.31	5.26e-12	Cutaneous malignant melanoma;
LGG	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-14.17	-0.55	3.87e-38	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.12e-19	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg15971980	chr6:150254442	NA	0.44	8.36	0.36	7.61e-16	Lung cancer;
LGG	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.82e-22	Motion sickness;
LGG	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	cis	rs6456156	0.586	rs911632	chr6:167471461	T/C	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Primary biliary cholangitis;
LGG	cis	rs4788570	0.545	rs8044144	chr16:71783121	T/C	cg06353428	chr16:71660113	MARVELD3	1.27	21.06	0.7	1.48e-69	Intelligence (multi-trait analysis);
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg15537850	chr8:144661051	NAPRT1	1.01	7.66	0.34	1.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs4906332	1.000	rs34479426	chr14:103881823	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.89	-0.34	2.22e-14	Coronary artery disease;
LGG	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg27432699	chr2:27873401	GPN1	-0.42	-6.99	-0.31	9.76e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg18876405	chr7:65276391	NA	0.66	12.52	0.5	3.48e-31	Calcium levels;
LGG	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.72e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg07148914	chr20:33460835	GGT7	0.43	6.88	0.3	1.94e-11	Height;
LGG	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg01411142	chr8:19674711	INTS10	0.46	7.31	0.32	1.2e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg01620082	chr3:125678407	NA	-0.87	-8.64	-0.37	9.04e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-16.24	-0.6	2.9e-47	Asthma;
LGG	cis	rs60695258	0.512	rs2053770	chr4:87908085	C/T	cg11209507	chr4:87813803	C4orf36	-0.49	-8.23	-0.36	1.95e-15	Hematocrit;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg00149659	chr3:10157352	C3orf10	0.84	10.56	0.44	1.62e-23	Alzheimer's disease;
LGG	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg03929089	chr4:120376271	NA	0.69	9.5	0.4	1.1e-19	Axial length;
LGG	cis	rs7301826	0.651	rs10734981	chr12:131297895	C/G	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg05491587	chr18:77659695	KCNG2	-0.52	-7.03	-0.31	7.57e-12	Opioid sensitivity;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg09441152	chr18:77712293	PQLC1	0.43	7.42	0.33	5.64e-13	Schizophrenia;
LGG	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg05887092	chr17:76393375	PGS1	0.72	15.74	0.59	5.32e-45	HDL cholesterol levels;
LGG	cis	rs4948275	0.550	rs10994749	chr10:63156222	G/C	cg03237606	chr10:63212265	TMEM26	0.46	8.33	0.36	8.99e-16	Night sleep phenotypes;
LGG	cis	rs8027181	0.617	rs6495017	chr15:73089625	T/A	cg01955962	chr15:73089536	NA	-0.47	-7.74	-0.34	6.51e-14	Triglyceride levels;
LGG	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.29	0.32	1.33e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9513627	1.000	rs7317330	chr13:100119876	T/G	cg25919922	chr13:100150906	NA	-0.71	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg25358565	chr5:93447407	FAM172A	1.34	16.26	0.6	2.26e-47	Diabetic retinopathy;
LGG	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg22643751	chr7:855365	UNC84A	0.36	6.93	0.31	1.42e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg15595755	chr5:1867978	NA	0.43	7.34	0.32	9.79e-13	Cardiovascular disease risk factors;
LGG	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg27129171	chr3:47204927	SETD2	0.77	15.02	0.57	8.21e-42	Colorectal cancer;
LGG	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg24634471	chr8:143751801	JRK	0.49	7.55	0.33	2.4e-13	Schizophrenia;
LGG	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.5	-0.33	3.32e-13	Morning vs. evening chronotype;
LGG	cis	rs1728785	1.000	rs11642045	chr16:68583892	A/G	cg02972257	chr16:68554789	NA	-0.5	-6.85	-0.3	2.35e-11	Ulcerative colitis;
LGG	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg27446573	chr6:127587934	RNF146	0.93	17.75	0.64	3.89e-54	Breast cancer;
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19524238	chr7:2802976	GNA12	0.32	7.75	0.34	5.69e-14	Height;
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs8141529	0.687	rs6005867	chr22:29165120	T/C	cg02153584	chr22:29168773	CCDC117	0.69	11.75	0.48	4.52e-28	Lymphocyte counts;
LGG	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.65	0.48	1.15e-27	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24208426	chr11:3819031	PGAP2;NUP98	0.42	6.74	0.3	4.67e-11	Cognitive performance;
LGG	cis	rs2224391	0.911	rs6925249	chr6:5262510	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.95	-0.35	1.41e-14	Height;
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg11584989	chr19:19387371	SF4	0.75	12.2	0.49	7.01e-30	Bipolar disorder;
LGG	cis	rs7582720	1.000	rs72932554	chr2:203845828	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9287719	0.934	rs4629131	chr2:10744159	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg24675658	chr1:53192096	ZYG11B	0.49	9.85	0.42	6.32e-21	Monocyte count;
LGG	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.94	-0.35	1.5e-14	Bladder cancer;
LGG	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.09	-0.39	2.96e-18	Vitiligo;
LGG	cis	rs10267417	0.603	rs10239480	chr7:19882806	T/A	cg07541023	chr7:19748670	TWISTNB	0.5	6.76	0.3	4.19e-11	Night sleep phenotypes;
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg16885296	chr6:26284938	NA	-0.36	-7.62	-0.33	1.42e-13	Educational attainment;
LGG	cis	rs9467773	0.620	rs2504571	chr6:26643435	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.92	0.54	4.71e-37	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs10779751	1.000	rs2024627	chr1:11298790	T/C	cg08854313	chr1:11322531	MTOR	0.74	16.13	0.6	9.28e-47	Body mass index;
LGG	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.07	-0.31	5.63e-12	Educational attainment;
LGG	cis	rs807029	0.577	rs3740488	chr10:102754033	A/T	cg04662943	chr10:102668895	NA	0.46	6.8	0.3	3.28e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9487094	0.689	rs9487069	chr6:109679855	A/C	cg01125227	chr6:109776195	MICAL1	0.44	7.79	0.34	4.47e-14	Height;
LGG	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg14668632	chr7:2872130	GNA12	0.32	6.72	0.3	5.43e-11	Height;
LGG	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.91	0.35	1.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7122539	0.722	rs11600959	chr11:66631892	G/A	cg01599099	chr11:66649832	PC	0.47	9.25	0.39	8.24e-19	HIV-1 susceptibility;
LGG	cis	rs7246760	1.000	rs56357664	chr19:9903399	C/T	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.51e-11	Pursuit maintenance gain;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg02825527	chr7:2087843	MAD1L1	-0.44	-7.98	-0.35	1.17e-14	Neuroticism;
LGG	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.33	0.65	8.02e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1493916	0.837	rs8088362	chr18:31413016	A/G	cg27147174	chr7:100797783	AP1S1	-0.62	-11.25	-0.46	4.15e-26	Life satisfaction;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.46	8.77	0.38	3.39e-17	Obesity-related traits;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg02002194	chr4:3960332	NA	0.43	7.7	0.34	8.21e-14	Neuroticism;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg19455335	chr8:22457658	C8orf58	-0.36	-7.27	-0.32	1.54e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg00106254	chr7:1943704	MAD1L1	0.44	7.76	0.34	5.4e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07677032	chr17:61819896	STRADA	0.66	12.11	0.49	1.65e-29	Prudent dietary pattern;
LGG	cis	rs498079	0.544	rs509904	chr6:133517082	A/T	cg05493394	chr6:133562035	EYA4	-0.27	-7.57	-0.33	2.08e-13	Total body bone mineral density;
LGG	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.41	-0.33	6.16e-13	IgG glycosylation;
LGG	cis	rs1003719	0.591	rs1053984	chr21:38574018	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.68	-12.28	-0.5	3.2e-30	Eye color traits;
LGG	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg02772935	chr3:125709198	NA	-0.52	-6.65	-0.3	8.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs28374715	0.681	rs11629979	chr15:41626579	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-26.33	-0.77	4.71e-94	Ulcerative colitis;
LGG	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg17145862	chr1:211918768	LPGAT1	0.98	25.23	0.76	5.54e-89	Leprosy;
LGG	trans	rs656319	0.702	rs587328	chr8:9809722	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.34	-0.32	9.87e-13	Myopia (pathological);
LGG	cis	rs10876993	0.928	rs10877008	chr12:58103592	A/G	cg18357645	chr12:58087776	OS9	0.67	11.76	0.48	4.1e-28	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg12193833	chr17:30244370	NA	-0.27	-7.08	-0.31	5.31e-12	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07693657	chr11:67797975	NDUFS8	0.44	6.71	0.3	5.58e-11	Gut microbiome composition (summer);
LGG	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg06453172	chr10:134556979	INPP5A	-0.55	-8.14	-0.35	3.62e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-13.55	-0.53	1.91e-35	Cognitive function;
LGG	cis	rs11650494	0.516	rs2233660	chr17:47492366	C/T	cg08112188	chr17:47440006	ZNF652	-0.95	-10.87	-0.45	1.18e-24	Prostate cancer;
LGG	cis	rs11096990	0.634	rs60016848	chr4:39283056	A/G	cg24403649	chr4:39172243	NA	-0.4	-7.0	-0.31	8.83e-12	Cognitive function;
LGG	trans	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg13565492	chr6:43139072	SRF	-0.9	-15.41	-0.58	1.53e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.53	0.33	2.6e-13	Rheumatoid arthritis;
LGG	trans	rs9409565	0.559	rs9409562	chr9:97246817	G/A	cg05679027	chr9:99775184	HIATL2	-0.47	-6.98	-0.31	1.01e-11	Colorectal cancer (alcohol consumption interaction);
LGG	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg27147174	chr7:100797783	AP1S1	0.61	10.92	0.45	7.14e-25	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg12081754	chr8:22256438	SLC39A14	0.72	13.77	0.54	2.19e-36	Verbal declarative memory;
LGG	cis	rs17401966	0.931	rs11587854	chr1:10447622	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-10.05	-0.42	1.21e-21	Hepatocellular carcinoma;
LGG	cis	rs7241530	0.662	rs6506754	chr18:75904989	A/G	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	7e-19	Educational attainment (years of education);
LGG	cis	rs758324	0.947	rs13154286	chr5:131160189	A/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg08508325	chr11:3079039	CARS	-0.6	-13.13	-0.52	1.11e-33	Longevity;
LGG	cis	rs6456042	1.000	rs3127416	chr6:166537412	G/A	cg11088901	chr6:166572345	T	-0.35	-7.29	-0.32	1.33e-12	Asthma;
LGG	cis	rs9911578	0.967	rs302843	chr17:56727986	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	12.35	0.5	1.77e-30	Cognitive test performance;
LGG	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg24112000	chr20:60950667	NA	-0.36	-7.85	-0.34	2.93e-14	Colorectal cancer;
LGG	cis	rs7551222	0.752	rs12566957	chr1:204556958	C/T	cg20240347	chr1:204465584	NA	-0.48	-9.71	-0.41	2.14e-20	Schizophrenia;
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-0.59	-7.79	-0.34	4.32e-14	Lung function (FEV1/FVC);
LGG	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg17809284	chr5:56205270	C5orf35	-0.49	-8.11	-0.35	4.53e-15	Initial pursuit acceleration;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.19	-0.32	2.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	9.58e-21	Common traits (Other);
LGG	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg25019033	chr10:957182	NA	-0.55	-10.05	-0.42	1.25e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs4690686	0.760	rs1377838	chr4:177282547	G/T	cg17059388	chr4:177262070	NA	0.74	16.08	0.6	1.57e-46	Essential tremor;
LGG	cis	rs4731207	0.596	rs1600741	chr7:124692292	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs4851266	0.865	rs11695996	chr2:100854336	C/T	cg21926883	chr2:100939477	LONRF2	-0.47	-8.34	-0.36	8.37e-16	Educational attainment;
LGG	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.6	0.53	1.11e-35	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg22968622	chr17:43663579	NA	1.1	21.79	0.71	5.72e-73	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.59e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg11859384	chr17:80120422	CCDC57	-0.44	-7.61	-0.33	1.55e-13	Life satisfaction;
LGG	cis	rs9663711	1	rs9663711	chr10:104547628	C/A	cg04362960	chr10:104952993	NT5C2	0.49	8.93	0.38	1.04e-17	Carotid plaque burden;
LGG	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg13385521	chr17:29058706	SUZ12P	0.69	8.18	0.36	2.83e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.91	-0.31	1.58e-11	Blood metabolite levels;
LGG	cis	rs4919694	1.000	rs12261040	chr10:104665397	T/C	cg04362960	chr10:104952993	NT5C2	1.05	14.68	0.56	2.58e-40	Arsenic metabolism;
LGG	cis	rs7219021	1.000	rs2032844	chr17:46847364	C/A	cg16584676	chr17:46985605	UBE2Z	-0.44	-6.99	-0.31	9.72e-12	Schizophrenia or bipolar disorder;
LGG	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg03929089	chr4:120376271	NA	-0.62	-7.76	-0.34	5.46e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7226408	0.857	rs17652454	chr18:34476108	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.27	-0.4	6.84e-19	Aortic root size;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg04829994	chr22:45636317	C22orf9	-0.39	-6.77	-0.3	3.89e-11	Blood metabolite levels;
LGG	cis	rs2694528	0.844	rs16878376	chr5:60059132	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.7	-7.51	-0.33	3.01e-13	Parkinson's disease;
LGG	cis	rs11758351	0.500	rs74974409	chr6:26194402	A/G	cg03181300	chr6:26195995	NA	0.87	6.67	0.3	7.09e-11	Gout;Renal underexcretion gout;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg23978390	chr7:1156363	C7orf50	0.51	8.57	0.37	1.54e-16	Longevity;Endometriosis;
LGG	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg00717180	chr2:96193071	NA	0.43	7.66	0.34	1.06e-13	HDL cholesterol;
LGG	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg00857998	chr1:205179979	DSTYK	-0.5	-7.86	-0.34	2.63e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20529126	chr8:28559781	EXTL3	0.41	6.79	0.3	3.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs61935443	0.832	rs10859778	chr12:95268010	C/G	cg21533806	chr12:95267307	NA	0.51	7.07	0.31	5.67e-12	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04315863	chr15:34330588	AVEN;CHRM5	0.47	7.47	0.33	4.09e-13	Gut microbiome composition (summer);
LGG	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg04111992	chr7:158790115	NA	0.37	7.5	0.33	3.3e-13	Facial morphology (factor 20);
LGG	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg14829360	chr17:73884958	NA	-0.53	-10.0	-0.42	1.83e-21	White matter hyperintensity burden;
LGG	cis	rs8067545	0.611	rs2703786	chr17:20156369	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.22	-0.43	3.05e-22	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07967851	chr16:1833553	NUBP2;SPSB3	0.42	6.73	0.3	5.05e-11	Cognitive performance;
LGG	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg24112000	chr20:60950667	NA	-0.38	-7.66	-0.34	1.09e-13	Colorectal cancer;
LGG	cis	rs9486715	0.867	rs211159	chr6:97023026	G/A	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.29	-0.36	1.2e-15	Headache;
LGG	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg09417038	chr21:47716443	C21orf57	-0.39	-7.73	-0.34	6.9e-14	Testicular germ cell tumor;
LGG	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg08470875	chr2:26401718	FAM59B	-0.38	-7.12	-0.31	4.27e-12	Gut microbiome composition (summer);
LGG	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg03894339	chr8:19674705	INTS10	0.66	10.6	0.44	1.22e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.08	-0.35	5.51e-15	IgG glycosylation;
LGG	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg00495681	chr13:53174319	NA	0.81	17.5	0.63	5.48e-53	Lewy body disease;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	7.54	0.33	2.47e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg25811766	chr13:21894605	NA	-0.56	-7.52	-0.33	2.96e-13	White matter hyperintensity burden;
LGG	cis	rs858239	0.601	rs11982002	chr7:23163270	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.27	0.32	1.55e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6669919	0.655	rs6540686	chr1:211683025	G/T	cg10512769	chr1:211675356	NA	-0.72	-15.11	-0.57	3.09e-42	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg09038676	chr11:67351608	GSTP1	0.36	7.07	0.31	5.68e-12	Mean corpuscular volume;
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.6	10.6	0.44	1.14e-23	Birth weight;
LGG	cis	rs763121	0.853	rs5750627	chr22:38982321	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.25	0.65	1.83e-56	Menopause (age at onset);
LGG	cis	rs9807841	0.592	rs10419865	chr19:10772685	C/G	cg17710535	chr19:10819994	QTRT1	0.49	7.95	0.35	1.48e-14	Inflammatory skin disease;
LGG	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.47	0.4	1.39e-19	Lung cancer in ever smokers;
LGG	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs6762644	0.507	rs9809576	chr3:4765211	A/T	cg11584376	chr3:4789075	ITPR1	-0.39	-8.37	-0.36	7.03e-16	Breast cancer;
LGG	cis	rs9349203	1	rs9349203	chr6:41893323	G/A	cg17623882	chr6:41773611	USP49	-0.46	-7.97	-0.35	1.23e-14	Menarche (age at onset);
LGG	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg04117972	chr1:227635322	NA	0.72	11.74	0.48	4.71e-28	Major depressive disorder;
LGG	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg14673194	chr17:80132900	CCDC57	-0.46	-8.39	-0.36	5.82e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg16339924	chr4:17578868	LAP3	0.5	8.45	0.37	3.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00294572	chr6:26285232	NA	0.4	7.23	0.32	1.96e-12	Educational attainment;
LGG	cis	rs10892173	0.765	rs1892902	chr11:117669794	T/G	cg21640587	chr11:117668038	DSCAML1	0.47	7.86	0.34	2.68e-14	Myopia;
LGG	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg21366198	chr4:185655624	MLF1IP	-0.41	-7.09	-0.31	4.92e-12	Kawasaki disease;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.67	0.37	7.21e-17	Bipolar disorder;
LGG	trans	rs826838	0.834	rs826874	chr12:39122599	C/A	cg06521331	chr12:34319734	NA	0.44	8.09	0.35	5.45e-15	Heart rate;
LGG	cis	rs42648	0.869	rs42614	chr7:89950363	C/G	cg25739043	chr7:89950458	NA	-0.44	-9.55	-0.41	7.54e-20	Homocysteine levels;
LGG	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg15103426	chr22:29168792	CCDC117	0.67	9.78	0.41	1.14e-20	Lymphocyte counts;
LGG	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.15e-12	HDL cholesterol;
LGG	cis	rs2649	0.518	rs28531781	chr15:63879235	T/C	cg22599514	chr15:63798201	USP3	0.44	7.25	0.32	1.7e-12	Aortic root size;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg05091796	chr16:4465799	CORO7	-0.77	-12.73	-0.51	4.8e-32	Schizophrenia;
LGG	cis	rs1497828	0.956	rs1007736	chr1:217547852	C/T	cg04411442	chr1:217543379	NA	0.48	8.03	0.35	8.21e-15	Dialysis-related mortality;
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.34	-0.53	1.34e-34	Personality dimensions;
LGG	cis	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg02002194	chr4:3960332	NA	0.39	6.9	0.31	1.7e-11	Joint mobility (Beighton score);
LGG	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.05	-0.35	7.08e-15	Neuroticism;
LGG	cis	rs7945705	0.837	rs10769966	chr11:8847041	C/A	cg00186954	chr11:8933980	ST5;C11orf17	0.38	7.89	0.34	2.12e-14	Hemoglobin concentration;
LGG	cis	rs11074306	0.561	rs2311467	chr15:28069026	T/C	cg26402630	chr15:28053930	OCA2	0.36	7.29	0.32	1.36e-12	Uveal melanoma;
LGG	cis	rs12431410	0.516	rs12888478	chr14:60208308	A/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.42	-0.33	5.69e-13	Schizophrenia;
LGG	cis	rs2862064	0.932	rs2221267	chr5:156401533	G/C	cg12943317	chr5:156479607	HAVCR1	-0.82	-10.35	-0.43	1.01e-22	Platelet count;
LGG	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-6.89	-0.31	1.78e-11	Neuroticism;
LGG	cis	rs7580658	0.864	rs34832797	chr2:128119441	T/C	cg10021288	chr2:128175891	PROC	-0.63	-12.87	-0.51	1.27e-32	Protein C levels;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg18402987	chr7:1209562	NA	0.49	8.29	0.36	1.2e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg19442545	chr10:75533431	FUT11	-0.46	-7.49	-0.33	3.62e-13	Inflammatory bowel disease;
LGG	cis	rs17253792	0.822	rs79483507	chr14:56164718	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.16e-29	Putamen volume;
LGG	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg24558204	chr6:135376177	HBS1L	0.62	10.58	0.44	1.41e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1707322	0.686	rs1541131	chr1:46084934	G/A	cg03146154	chr1:46216737	IPP	-0.56	-10.9	-0.45	8.68e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs75804782	0.625	rs13421922	chr2:239467430	T/C	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs58616815	0.819	rs72824615	chr10:92157069	A/G	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg14227996	chr4:17616232	MED28	-0.6	-7.16	-0.32	3.11e-12	Opioid sensitivity;
LGG	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.52	-0.4	9.46e-20	Body mass index;
LGG	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg22771759	chr13:24902376	NA	-0.41	-7.08	-0.31	5.31e-12	Obesity-related traits;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21963583	chr11:68658836	MRPL21	-0.58	-10.27	-0.43	2.03e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7937612	0.897	rs1893261	chr11:120198093	A/G	cg24566217	chr11:120254723	ARHGEF12	0.49	11.49	0.47	4.81e-27	Intraocular pressure;
LGG	cis	rs2522056	1.000	rs10900807	chr5:131757480	G/C	cg07395648	chr5:131743802	NA	0.42	7.11	0.31	4.44e-12	Lymphocyte counts;Fibrinogen;
LGG	cis	rs12497850	0.829	rs8926	chr3:49052785	T/A	cg07636037	chr3:49044803	WDR6	1.09	27.78	0.79	1.17e-100	Parkinson's disease;
LGG	cis	rs7010267	0.805	rs6992497	chr8:119980069	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.41	10.56	0.44	1.67e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg02931644	chr1:25747376	RHCE	0.41	9.17	0.39	1.57e-18	Erythrocyte sedimentation rate;
LGG	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.43e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.52	-0.33	2.94e-13	Rheumatoid arthritis;
LGG	cis	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs9868809	0.772	rs9821797	chr3:48718253	T/A	cg00383909	chr3:49044727	WDR6	0.8	9.99	0.42	2.14e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs74781061	0.932	rs2198843	chr15:75001230	C/G	cg02384859	chr15:74862662	ARID3B	-0.33	-7.0	-0.31	9.2e-12	Endometriosis;
LGG	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg15522984	chr1:182991683	LAMC1	-0.46	-9.16	-0.39	1.73e-18	Colorectal cancer;
LGG	cis	rs10048158	0.585	rs2215413	chr17:64249497	G/T	cg19474267	chr17:64306194	PRKCA	0.62	12.43	0.5	8.57e-31	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs2415984	0.579	rs1389608	chr14:46957777	C/A	cg14871534	chr14:47121158	RPL10L	-0.57	-10.1	-0.42	8.14e-22	Number of children ever born;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.43	-0.36	4.5e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7727544	0.547	rs56083751	chr5:131664638	T/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs12580194	0.593	rs61957936	chr12:55745719	A/G	cg19537932	chr12:55886519	OR6C68	-0.52	-9.31	-0.4	4.99e-19	Cancer;
LGG	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg03653399	chr8:142233436	SLC45A4	0.42	8.32	0.36	1.01e-15	Immature fraction of reticulocytes;
LGG	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	10.18	0.43	4.11e-22	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs283228	0.535	rs2852512	chr6:101846554	G/A	cg27451362	chr6:101846650	GRIK2	0.92	14.35	0.55	6.53e-39	Coenzyme Q10 levels;
LGG	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg20283391	chr11:68216788	NA	-0.49	-8.14	-0.35	3.56e-15	Total body bone mineral density;
LGG	cis	rs644799	0.896	rs4430471	chr11:95646774	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.4	6.73	0.3	5.09e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17102423	0.652	rs4902361	chr14:65548470	G/T	cg26396452	chr14:65542826	MAX	0.48	9.87	0.42	5.67e-21	Obesity-related traits;
LGG	cis	rs9309473	1.000	rs6715819	chr2:73772309	T/G	cg20560298	chr2:73613845	ALMS1	-0.42	-6.76	-0.3	4.23e-11	Metabolite levels;
LGG	cis	rs9811920	0.893	rs720688	chr3:99880569	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	7.82	0.34	3.58e-14	Axial length;
LGG	trans	rs9388451	0.772	rs1268064	chr6:126042578	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.48	8.56	0.37	1.7e-16	Brugada syndrome;
LGG	cis	rs9944715	0.954	rs4890629	chr18:43797564	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.37	-6.94	-0.31	1.32e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg13013644	chr5:502571	SLC9A3	0.33	7.3	0.32	1.27e-12	Cystic fibrosis severity;
LGG	cis	rs4774899	0.902	rs11636919	chr15:57465955	G/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.29	-0.32	1.39e-12	Urinary tract infection frequency;
LGG	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg18681998	chr4:17616180	MED28	-0.71	-14.2	-0.55	3.05e-38	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.91	0.34	1.93e-14	Rheumatoid arthritis;
LGG	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg02574844	chr11:5959923	NA	-0.62	-9.46	-0.4	1.59e-19	DNA methylation (variation);
LGG	cis	rs3087591	0.919	rs11080148	chr17:29609922	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-13.9	-0.54	6.05e-37	Hip circumference;
LGG	trans	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg21775007	chr8:11205619	TDH	0.45	7.44	0.33	4.84e-13	Neuroticism;
LGG	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg05234568	chr11:5960015	NA	-0.75	-12.2	-0.49	7.13e-30	DNA methylation (variation);
LGG	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg13385794	chr1:248469461	NA	0.5	8.42	0.36	4.61e-16	Common traits (Other);
LGG	cis	rs4356203	0.870	rs214926	chr11:17231802	T/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.29	-0.32	1.34e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg09238746	chr17:78121135	EIF4A3	-0.81	-14.22	-0.55	2.51e-38	Yeast infection;
LGG	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg04672837	chr16:48644449	N4BP1	0.52	8.42	0.36	4.63e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs41342147	0.591	rs3771547	chr2:242296273	G/C	cg10173475	chr2:242152697	ANO7	-0.58	-9.05	-0.39	3.95e-18	Vitiligo;
LGG	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg05692746	chr2:100937584	LONRF2	0.57	9.86	0.42	5.95e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12458462	0.859	rs35493271	chr18:77448793	G/T	cg11879182	chr18:77439856	CTDP1	0.8	15.15	0.58	2.03e-42	Monocyte count;
LGG	trans	rs11088226	0.692	rs1123142	chr21:33893738	G/A	cg09050820	chr6:167586206	TCP10L2	0.48	7.33	0.32	1.06e-12	Gastritis;
LGG	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.35	-0.47	1.66e-26	Total body bone mineral density;
LGG	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.74	0.51	4.58e-32	Motion sickness;
LGG	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.29	0.43	1.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.11	0.46	1.38e-25	Homoarginine levels;
LGG	cis	rs9916302	0.904	rs34363096	chr17:37594294	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs1712517	0.525	rs2271751	chr10:105175131	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-7.97	-0.35	1.24e-14	Migraine;
LGG	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.55	-0.33	2.32e-13	Other erythrocyte phenotypes;
LGG	cis	rs2354432	1.000	rs6680778	chr1:146747153	T/C	cg25205988	chr1:146714368	CHD1L	1.38	21.82	0.71	4.21e-73	Mitochondrial DNA levels;
LGG	trans	rs877282	0.853	rs7083589	chr10:754494	G/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.1	-0.42	8.53e-22	Lung cancer;
LGG	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg21972741	chr5:435613	AHRR	0.5	8.93	0.38	1.01e-17	Cystic fibrosis severity;
LGG	cis	rs6912958	0.781	rs4707376	chr6:88270947	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.59	-0.37	1.3e-16	Monocyte percentage of white cells;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.07	-0.46	2.06e-25	Neuroticism;
LGG	cis	rs4950322	0.547	rs56864370	chr1:146583429	A/G	cg22381352	chr1:146742008	CHD1L	-0.42	-7.19	-0.32	2.67e-12	Protein quantitative trait loci;
LGG	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs283228	1.000	rs2518179	chr6:101833529	A/G	cg27451362	chr6:101846650	GRIK2	0.55	9.14	0.39	2.05e-18	Coenzyme Q10 levels;
LGG	cis	rs295140	1.000	rs7580924	chr2:201172628	G/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg22875332	chr1:76189707	ACADM	-0.58	-9.41	-0.4	2.37e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.33	-0.32	1.04e-12	Inflammatory bowel disease;
LGG	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.38	5.63e-17	Aortic root size;
LGG	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg16512390	chr1:228756714	NA	0.61	8.06	0.35	6.67e-15	Chronic lymphocytic leukemia;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.7	-0.3	6.09e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg27476859	chr7:2772710	GNA12	0.4	6.87	0.3	2.08e-11	Height;
LGG	cis	rs28595532	0.920	rs55985953	chr4:119764971	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg12591125	chr7:1885375	MAD1L1	0.47	7.39	0.32	7.03e-13	Bipolar disorder;
LGG	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.67	0.41	2.77e-20	Height;
LGG	cis	rs3540	0.513	rs1072879	chr15:90922038	C/T	cg22089800	chr15:90895588	ZNF774	0.76	14.25	0.55	1.89e-38	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.46	-0.37	3.59e-16	Life satisfaction;
LGG	cis	rs7166081	1.000	rs12911370	chr15:67546321	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.73	-0.3	5.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4237845	0.680	rs10877033	chr12:58283731	T/C	cg02175503	chr12:58329896	NA	0.67	12.32	0.5	2.28e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.740	rs4435674	chr3:17794200	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.22	-0.32	2.18e-12	Schizophrenia;
LGG	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.17	-0.39	1.58e-18	Life satisfaction;
LGG	cis	rs7399018	0.643	rs6580810	chr12:51610478	C/T	cg25754956	chr12:51612065	POU6F1	0.63	10.23	0.43	2.77e-22	Cisplatin-induced ototoxicity;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	11.95	0.49	6.84e-29	Colorectal cancer;
LGG	cis	rs6460942	0.915	rs62448599	chr7:12453764	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-7.04	-0.31	6.98e-12	Coronary artery disease;
LGG	cis	rs77372450	0.636	rs11465222	chr5:157004167	C/T	cg25387487	chr5:157003181	ADAM19	-0.58	-7.29	-0.32	1.37e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7737355	0.812	rs2549011	chr5:130657418	G/C	cg06307176	chr5:131281290	NA	-0.48	-8.09	-0.35	5.3e-15	Life satisfaction;
LGG	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	16.46	0.61	2.9e-48	Smoking behavior;
LGG	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.52	-0.4	9.68e-20	Coronary artery disease;
LGG	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg16141378	chr3:129829833	LOC729375	-0.33	-7.13	-0.31	3.77e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg03959625	chr15:84868606	LOC388152	0.55	8.69	0.37	6.42e-17	Schizophrenia;
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg23302884	chr18:44338147	ST8SIA5	0.35	6.77	0.3	3.96e-11	Personality dimensions;
LGG	cis	rs244899	0.935	rs244896	chr5:167918663	G/T	cg06604206	chr5:167912465	RARS	-0.56	-12.51	-0.5	3.99e-31	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.08	0.46	1.8e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg00198680	chr16:28758506	NA	0.3	7.41	0.33	5.91e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg23649088	chr2:200775458	C2orf69	-0.47	-8.21	-0.36	2.21e-15	QT interval;
LGG	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg14541582	chr5:601475	NA	-0.56	-9.01	-0.39	5.62e-18	Obesity-related traits;
LGG	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg24375607	chr4:120327624	NA	0.67	11.14	0.46	1.09e-25	Corneal astigmatism;
LGG	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.23	0.36	1.99e-15	Diabetic kidney disease;
LGG	cis	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg12486710	chr1:178512616	C1orf220	0.51	10.46	0.44	4.05e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs528418	0.592	rs2202849	chr6:145737140	T/C	cg03642472	chr6:145670687	NA	0.55	7.26	0.32	1.63e-12	Methadone dose in opioid dependence;
LGG	cis	rs10504073	0.647	rs10504072	chr8:49993083	G/A	cg00325661	chr8:49890786	NA	0.75	14.62	0.56	4.51e-40	Blood metabolite ratios;
LGG	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-10.54	-0.44	2.07e-23	Chronic sinus infection;
LGG	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg14664628	chr15:75095509	CSK	0.6	9.94	0.42	3.03e-21	Systemic lupus erythematosus;
LGG	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg20673091	chr1:2541236	MMEL1	-0.78	-20.07	-0.68	6.69e-65	Ulcerative colitis;
LGG	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.01	-0.49	4.06e-29	Height;
LGG	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg17971929	chr21:40555470	PSMG1	0.54	9.1	0.39	2.64e-18	Menarche (age at onset);
LGG	cis	rs2273669	0.588	rs79465564	chr6:109350290	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.62	-15.46	-0.58	9.13e-44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-19.67	-0.67	4.83e-63	Heart rate;
LGG	cis	rs17122278	0.929	rs73023341	chr11:118445585	A/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.74	-0.3	4.63e-11	Total cholesterol levels;
LGG	cis	rs2239908	0.718	rs241776	chr17:26644308	C/T	cg10342447	chr17:26645325	TMEM97	0.52	9.83	0.42	8.06e-21	Blood protein levels;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg13010199	chr12:38710504	ALG10B	0.59	10.74	0.45	3.6e-24	Morning vs. evening chronotype;
LGG	trans	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg02002194	chr4:3960332	NA	0.39	6.99	0.31	9.81e-12	Mood instability;
LGG	cis	rs9902453	0.780	rs57037139	chr17:28173283	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.71	0.54	3.89e-36	Coffee consumption (cups per day);
LGG	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg11584989	chr19:19387371	SF4	0.7	11.56	0.47	2.56e-27	Bipolar disorder;
LGG	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg04851639	chr8:1020857	NA	-0.35	-7.39	-0.32	6.82e-13	Schizophrenia;
LGG	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg18105134	chr13:113819100	PROZ	-0.78	-15.71	-0.59	6.65e-45	Platelet distribution width;
LGG	cis	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg15596359	chr8:11213517	TDH	0.41	8.46	0.37	3.65e-16	Retinal vascular caliber;
LGG	cis	rs262150	0.567	rs2040897	chr7:158803848	C/T	cg19418458	chr7:158789849	NA	-0.49	-10.19	-0.43	3.85e-22	Facial morphology (factor 20);
LGG	trans	rs62103177	0.608	rs4442895	chr18:77826399	C/G	cg05926928	chr17:57297772	GDPD1	-0.73	-9.41	-0.4	2.31e-19	Opioid sensitivity;
LGG	cis	rs774359	0.797	rs2492817	chr9:27511151	A/G	cg21249376	chr9:27528432	MOBKL2B	0.43	8.85	0.38	1.85e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14232643	chr2:97481853	CNNM3	0.47	6.83	0.3	2.71e-11	Hip circumference;
LGG	cis	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg20368463	chr18:77673604	PQLC1	-0.5	-7.71	-0.34	7.69e-14	Opioid sensitivity;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.43	-0.36	4.36e-16	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg23815491	chr16:72088622	HP	0.48	10.83	0.45	1.64e-24	Fibrinogen levels;
LGG	trans	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg24247370	chr13:99142703	STK24	-0.42	-7.56	-0.33	2.11e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4774830	0.744	rs62046397	chr15:56321302	G/A	cg24530489	chr15:56299380	NA	-0.81	-7.29	-0.32	1.32e-12	Delta-5 desaturase activity;
LGG	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.92e-11	Bipolar disorder;
LGG	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	12.31	0.5	2.42e-30	Parkinson's disease;
LGG	cis	rs2235649	0.833	rs9939694	chr16:1852760	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.39	-6.72	-0.3	5.41e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs35343117	1	rs35343117	chr15:86079115	C/G	cg10818794	chr15:86012489	AKAP13	-0.39	-7.81	-0.34	3.75e-14	Psoriasis;
LGG	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg02700894	chr3:12045449	SYN2	0.56	9.89	0.42	4.78e-21	Plateletcrit;Lymphocyte counts;White blood cell count;
LGG	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.86	-0.3	2.28e-11	Arsenic metabolism;
LGG	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg06634786	chr22:41940651	POLR3H	0.67	10.85	0.45	1.33e-24	Vitiligo;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg12458913	chr13:53173898	NA	0.63	12.29	0.5	2.97e-30	Lewy body disease;
LGG	cis	rs2859741	0.565	rs12031540	chr1:37513757	C/T	cg09363841	chr1:37513479	NA	-0.56	-12.29	-0.5	2.99e-30	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg21435375	chr2:172878103	MAP1D	-0.33	-7.5	-0.33	3.18e-13	Schizophrenia;
LGG	cis	rs3219090	0.962	rs1417765	chr1:226591243	T/G	cg17127702	chr1:226594323	PARP1	0.38	12.09	0.49	1.89e-29	Melanoma;
LGG	cis	rs4704846	1.000	rs1036199	chr5:156531736	C/A	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.4	-0.33	6.3e-13	Blood protein levels;
LGG	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.74	-0.38	4.35e-17	Breast cancer;
LGG	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06156847	chr2:113672199	IL1F7	0.38	7.62	0.33	1.48e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg06521331	chr12:34319734	NA	-0.48	-8.47	-0.37	3.27e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg21918786	chr6:109611834	NA	-0.48	-9.01	-0.39	5.4e-18	Reticulocyte fraction of red cells;
LGG	cis	rs11920090	0.932	rs11928798	chr3:170727408	A/G	cg09710316	chr3:170744871	SLC2A2	0.61	8.6	0.37	1.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.23e-13	Testicular germ cell tumor;
LGG	cis	rs7582720	0.945	rs72936875	chr2:203791912	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs7241530	0.662	rs7230384	chr18:75908189	A/G	cg14642773	chr18:75888474	NA	0.45	8.74	0.38	4.41e-17	Educational attainment (years of education);
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg05313129	chr8:58192883	C8orf71	0.73	10.08	0.42	9.4e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg20368463	chr18:77673604	PQLC1	0.48	7.36	0.32	8.37e-13	Opioid sensitivity;
LGG	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg07395648	chr5:131743802	NA	0.56	13.26	0.52	3.16e-34	Blood metabolite levels;
LGG	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.58	-0.69	2.57e-67	Intelligence (multi-trait analysis);
LGG	cis	rs8017423	0.935	rs7154695	chr14:90795705	C/G	cg04374321	chr14:90722782	PSMC1	0.75	13.5	0.53	3.03e-35	Mortality in heart failure;
LGG	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.79	-0.34	4.32e-14	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.13	0.43	6.4e-22	Motion sickness;
LGG	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg13385794	chr1:248469461	NA	0.45	7.7	0.34	8.13e-14	Common traits (Other);
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs57502260	0.790	rs7129320	chr11:68388220	G/A	cg01657329	chr11:68192670	LRP5	-0.53	-7.07	-0.31	5.81e-12	Total body bone mineral density (age 45-60);
LGG	trans	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg18187862	chr3:45730750	SACM1L	0.58	9.48	0.4	1.32e-19	Primary sclerosing cholangitis;
LGG	cis	rs986417	0.901	rs1950313	chr14:60997782	A/G	cg27398547	chr14:60952738	C14orf39	0.73	7.31	0.32	1.14e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11112613	0.775	rs12305225	chr12:105963266	G/C	cg03607813	chr12:105948248	NA	0.52	8.89	0.38	1.4e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg27205649	chr11:78285834	NARS2	-0.43	-7.17	-0.32	2.97e-12	Testicular germ cell tumor;
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg20387954	chr3:183756860	HTR3D	-0.66	-13.25	-0.52	3.43e-34	Anterior chamber depth;
LGG	cis	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg15440763	chr7:158190612	PTPRN2	-0.43	-9.11	-0.39	2.5e-18	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13129662	chr17:48227708	PPP1R9B	0.5	8.07	0.35	6.08e-15	Cognitive performance;
LGG	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.32e-31	Motion sickness;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg04503457	chr17:41445688	NA	-0.39	-8.96	-0.38	7.84e-18	Menopause (age at onset);
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg01262667	chr19:19385393	TM6SF2	-0.47	-11.77	-0.48	3.78e-28	Tonsillectomy;
LGG	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg16724585	chr3:197361211	NA	-0.47	-8.22	-0.36	2.12e-15	Pancreatic cancer;
LGG	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.51	-0.4	1.07e-19	Sudden cardiac arrest;
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg09060608	chr5:178986726	RUFY1	0.5	8.93	0.38	1.02e-17	Lung cancer;
LGG	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg05585630	chr7:157510462	PTPRN2	-0.66	-13.71	-0.54	3.88e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	0.698	rs10499	chr16:28915527	G/A	cg07382826	chr16:28625726	SULT1A1	-0.38	-7.33	-0.32	1.01e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4417704	0.551	rs11688859	chr2:241904001	G/C	cg26818257	chr2:241905806	NA	0.49	10.62	0.44	1.02e-23	Joint mobility (Beighton score);
LGG	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.45	-0.33	4.72e-13	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03497419	chr3:37034654	EPM2AIP1;MLH1	0.46	6.72	0.3	5.45e-11	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs1395	0.710	rs11674947	chr2:27471996	A/G	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.02	-0.35	8.9e-15	Blood metabolite levels;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg02733842	chr7:1102375	C7orf50	0.68	10.16	0.43	4.83e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs240764	0.579	rs9386233	chr6:101149540	C/T	cg09795085	chr6:101329169	ASCC3	0.42	7.13	0.31	3.91e-12	Neuroticism;
LGG	cis	rs758324	0.741	rs10075660	chr5:131240843	C/A	cg06307176	chr5:131281290	NA	-0.57	-9.63	-0.41	4.02e-20	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg16301924	chr13:53314226	LECT1	-0.43	-8.49	-0.37	2.78e-16	Lewy body disease;
LGG	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg14829155	chr15:31115871	NA	-0.54	-9.45	-0.4	1.65e-19	Huntington's disease progression;
LGG	cis	rs6504108	0.647	rs12150533	chr17:46287541	T/C	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.62e-15	Body mass index;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.93	-0.59	7.23e-46	Longevity;
LGG	cis	rs60180747	1.000	rs8033122	chr15:66820455	T/A	cg07575407	chr15:66541975	MEGF11	0.34	6.66	0.3	7.79e-11	Testicular germ cell tumor;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg07606381	chr6:8435919	SLC35B3	0.66	12.06	0.49	2.48e-29	Motion sickness;
LGG	cis	rs896543	0.702	rs12692189	chr2:237496112	A/G	cg25295825	chr2:237489920	CXCR7	-0.9	-13.67	-0.54	5.88e-36	Alcohol dependence (age at onset);
LGG	cis	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg24375607	chr4:120327624	NA	0.68	11.19	0.46	7.14e-26	Corneal astigmatism;
LGG	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg21972741	chr5:435613	AHRR	0.5	8.99	0.39	6.13e-18	Cystic fibrosis severity;
LGG	cis	rs17767392	0.794	rs61989259	chr14:71733506	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.76	-0.38	3.62e-17	Mitral valve prolapse;
LGG	trans	rs61931739	0.649	rs864173	chr12:33721422	A/C	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.88	-0.59	1.23e-45	Tonsillectomy;
LGG	cis	rs5762813	0.510	rs35814864	chr22:29285148	T/C	cg15103426	chr22:29168792	CCDC117	0.64	6.7	0.3	6.21e-11	Hematocrit;Hemoglobin concentration;
LGG	trans	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.16e-27	Corneal astigmatism;
LGG	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg08508325	chr11:3079039	CARS	0.39	7.25	0.32	1.81e-12	Calcium levels;
LGG	cis	rs721399	0.614	rs4646246	chr8:18248661	A/G	cg18736775	chr8:18248649	NAT2	-0.81	-12.76	-0.51	3.6e-32	Blood metabolite levels;
LGG	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs6450176	0.904	rs6889847	chr5:53303452	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.54	-0.47	2.91e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.73	-0.3	4.89e-11	Retinal vascular caliber;
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.13e-66	Alzheimer's disease;
LGG	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg07936489	chr17:37558343	FBXL20	-0.86	-15.98	-0.6	4.36e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.42e-11	Obesity-related traits;
LGG	cis	rs9796	0.611	rs691672	chr15:41444438	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.58	-0.41	5.71e-20	Menopause (age at onset);
LGG	cis	rs9400467	0.537	rs12213248	chr6:111499394	G/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.12	0.31	4.08e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg00035636	chr13:21900591	NA	0.35	7.13	0.31	3.81e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.670	rs10880258	chr12:42547531	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.01	0.31	8.61e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09914581	chr2:11606494	E2F6	0.39	6.82	0.3	2.92e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.27	0.4	7.13e-19	Mean corpuscular volume;
LGG	trans	rs57046232	0.552	rs6038443	chr20:6328844	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.89	0.3	1.82e-11	Colorectal cancer;
LGG	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs6594499	0.872	rs1379300	chr5:110441439	A/G	cg04022379	chr5:110408740	TSLP	0.4	7.45	0.33	4.47e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.16	-0.39	1.68e-18	Response to antipsychotic treatment;
LGG	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.39	0.43	7.16e-23	Diabetic retinopathy;
LGG	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.22	-0.43	3.04e-22	Hemoglobin concentration;
LGG	cis	rs6665290	0.904	rs2297415	chr1:227172903	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-44.87	-0.9	1.1e-170	Myeloid white cell count;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg07701084	chr6:150067640	NUP43	0.64	12.06	0.49	2.53e-29	Lung cancer;
LGG	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg27490568	chr2:178487706	NA	0.38	7.59	0.33	1.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7395662	1.000	rs4882132	chr11:48593125	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.18	-0.32	2.86e-12	HDL cholesterol;
LGG	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15214069	chr9:139333582	INPP5E	0.56	8.83	0.38	2.24e-17	Gut microbiome composition (summer);
LGG	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.61	-0.41	4.58e-20	Common traits (Other);
LGG	cis	rs67366981	1.000	rs59262654	chr14:77712261	A/G	cg22824376	chr14:77648248	TMEM63C	0.68	7.29	0.32	1.36e-12	Obsessive-compulsive symptoms;
LGG	cis	rs568617	1.000	rs656980	chr11:65656282	G/A	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.73	-0.3	5.08e-11	Crohn's disease;
LGG	trans	rs75804782	0.521	rs72982598	chr2:239455052	G/A	cg01134436	chr17:81009848	B3GNTL1	0.73	8.3	0.36	1.18e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg22398616	chr13:53314203	LECT1	-0.44	-8.86	-0.38	1.7e-17	Lewy body disease;
LGG	cis	rs2916247	1.000	rs6986430	chr8:93048104	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12107643	chr19:5231603	PTPRS	0.34	6.69	0.3	6.39e-11	Electrocardiographic conduction measures;
LGG	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.69	0.51	7.38e-32	Prudent dietary pattern;
LGG	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg20891283	chr12:69753455	YEATS4	0.78	12.97	0.52	4.98e-33	Response to diuretic therapy;
LGG	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg20573242	chr4:122745356	CCNA2	0.54	10.05	0.42	1.29e-21	Type 2 diabetes;
LGG	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.56	0.41	6.93e-20	Bipolar disorder;
LGG	cis	rs7172689	0.529	rs17875492	chr15:81587086	A/C	cg19620333	chr15:81596332	IL16	0.61	9.48	0.4	1.38e-19	Inattentive symptoms;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg13880726	chr7:1868755	MAD1L1	0.39	6.65	0.3	8.5e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg06392426	chr19:10676186	KRI1	0.62	9.95	0.42	2.86e-21	Red cell distribution width;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg13628971	chr7:2884303	GNA12	0.55	11.71	0.48	6.54e-28	Height;
LGG	cis	rs6665290	0.901	rs61834004	chr1:227202782	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.85	-0.34	2.85e-14	Myeloid white cell count;
LGG	cis	rs7216064	1.000	rs62085992	chr17:65923083	T/A	cg12091567	chr17:66097778	LOC651250	-0.62	-9.07	-0.39	3.52e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.92	0.42	3.71e-21	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg09448879	chr15:79043637	NA	-0.56	-14.58	-0.56	7.1e-40	Coronary artery disease or large artery stroke;
LGG	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	8.94	0.38	9.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg18681998	chr4:17616180	MED28	0.88	20.18	0.68	2.04e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg23625390	chr15:77176239	SCAPER	0.69	14.1	0.55	7.98e-38	Blood metabolite levels;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	4.95e-22	Menopause (age at onset);
LGG	cis	rs972578	0.791	rs5759042	chr22:43324183	C/T	cg01576275	chr22:43409880	NA	-0.23	-7.08	-0.31	5.25e-12	Mean platelet volume;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21862992	chr11:68658383	NA	0.49	8.4	0.36	5.62e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9397585	0.857	rs9478384	chr6:153392908	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.33	0.55	8.06e-39	Body mass index;
LGG	cis	rs1878931	0.531	rs9635548	chr16:3417156	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	13.93	0.54	4.19e-37	Body mass index (adult);
LGG	trans	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg24247370	chr13:99142703	STK24	-0.37	-6.88	-0.3	1.95e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17169635	0.524	rs10231387	chr7:134545091	T/G	cg02516134	chr7:134575187	CALD1	-0.34	-7.57	-0.33	2e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs2224391	0.955	rs2773322	chr6:5263065	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-8.05	-0.35	7.03e-15	Height;
LGG	cis	rs9388451	0.531	rs9375414	chr6:126154475	G/A	cg05901451	chr6:126070800	HEY2	-0.59	-10.46	-0.44	3.79e-23	Brugada syndrome;
LGG	cis	rs6669919	0.597	rs10863905	chr1:211684429	A/G	cg10512769	chr1:211675356	NA	-0.69	-14.43	-0.56	3.17e-39	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-19.66	-0.67	5.48e-63	Cognitive function;
LGG	cis	rs7219021	0.961	rs3901705	chr17:46865760	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.77	-0.3	3.92e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg25319279	chr11:5960081	NA	-0.45	-7.57	-0.33	2.1e-13	DNA methylation (variation);
LGG	cis	rs9399135	0.844	rs13209789	chr6:135367916	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.08e-19	Red blood cell count;
LGG	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.81	0.54	1.37e-36	Colorectal cancer;
LGG	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg02428538	chr16:24856791	SLC5A11	-0.71	-10.87	-0.45	1.14e-24	Intelligence (multi-trait analysis);
LGG	trans	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.75	0.59	4.59e-45	Longevity;
LGG	cis	rs9487094	0.670	rs2277114	chr6:109827716	C/T	cg16315928	chr6:109776240	MICAL1	0.46	7.94	0.35	1.5e-14	Height;
LGG	cis	rs68170813	0.559	rs76299183	chr7:106904859	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-10.28	-0.43	1.79e-22	Coronary artery disease;
LGG	cis	rs6912958	0.559	rs242267	chr6:88061837	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.74	-13.95	-0.54	3.76e-37	Monocyte percentage of white cells;
LGG	cis	rs2273669	0.667	rs76430494	chr6:109350128	C/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg07701084	chr6:150067640	NUP43	0.71	13.76	0.54	2.4e-36	Lung cancer;
LGG	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg00405596	chr8:11794950	NA	-0.6	-10.54	-0.44	2.07e-23	Monocyte count;
LGG	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.88	9.25	0.39	8.2e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg20477318	chr10:51623047	TIMM23	0.72	8.28	0.36	1.3e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg11245990	chr11:68621969	NA	0.43	9.08	0.39	3.07e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7572733	0.534	rs700685	chr2:198715972	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.3	0.46	2.54e-26	Dermatomyositis;
LGG	cis	rs4363385	0.747	rs2225919	chr1:152969603	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.81e-18	Inflammatory skin disease;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg04234412	chr22:24373322	LOC391322	-0.71	-14.13	-0.55	6.09e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10794915	chr17:33569985	SLFN5	0.46	7.57	0.33	2.05e-13	Cognitive performance;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.75	-0.3	4.46e-11	Personality dimensions;
LGG	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg06374794	chr16:88002281	BANP	0.42	7.97	0.35	1.27e-14	Menopause (age at onset);
LGG	cis	rs10463554	0.927	rs62362489	chr5:102245545	C/T	cg23492399	chr5:102201601	PAM	-0.54	-8.29	-0.36	1.23e-15	Parkinson's disease;
LGG	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.81	0.38	2.63e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.21	0.55	2.62e-38	IgG glycosylation;
LGG	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.48	-0.5	4.95e-31	Morning vs. evening chronotype;
LGG	cis	rs9814567	0.806	rs55835132	chr3:134325256	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg19307003	chr11:60775715	CD6	0.51	8.36	0.36	7.59e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg27432699	chr2:27873401	GPN1	-0.5	-8.48	-0.37	3.08e-16	Total body bone mineral density;
LGG	cis	rs7851660	0.506	rs1912996	chr9:100598261	G/T	cg13688889	chr9:100608707	NA	-0.83	-16.19	-0.6	4.95e-47	Strep throat;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14932684	chr12:42632001	YAF2	0.41	7.42	0.33	5.48e-13	Obesity-related traits;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.53	-10.29	-0.43	1.74e-22	Prudent dietary pattern;
LGG	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg13010199	chr12:38710504	ALG10B	0.74	15.59	0.59	2.26e-44	Heart rate;
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg26513180	chr16:89883248	FANCA	0.79	8.58	0.37	1.48e-16	Skin colour saturation;
LGG	cis	rs2377585	0.653	rs59449904	chr12:8846270	A/G	cg03761649	chr12:8850719	RIMKLB	0.49	8.2	0.36	2.36e-15	Reticulocyte fraction of red cells;
LGG	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg21665744	chr7:39171113	POU6F2	0.43	8.83	0.38	2.2e-17	IgG glycosylation;
LGG	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg07636037	chr3:49044803	WDR6	0.78	13.6	0.53	1.16e-35	Menarche (age at onset);
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	11.71	0.48	6.26e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	13.29	0.53	2.33e-34	Total body bone mineral density;
LGG	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs7666738	0.830	rs62321597	chr4:99014221	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.19e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg21724239	chr8:58056113	NA	0.44	6.92	0.31	1.51e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4919087	0.962	rs3740522	chr10:99019144	C/T	cg25902810	chr10:99078978	FRAT1	0.5	9.31	0.4	5.22e-19	Monocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12576700	chr9:123342680	CDK5RAP2	0.4	7.03	0.31	7.54e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg23173402	chr1:227635558	NA	-0.52	-9.09	-0.39	2.89e-18	Major depressive disorder;
LGG	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg14416269	chr4:6271139	WFS1	-0.49	-8.9	-0.38	1.29e-17	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg16507663	chr6:150244633	RAET1G	0.45	8.39	0.36	5.93e-16	Lung cancer;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs9462027	0.628	rs2395598	chr6:34640686	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.25e-24	Systemic lupus erythematosus;
LGG	cis	rs1125355	0.655	rs11683568	chr2:159619202	T/C	cg02251393	chr2:159651559	DAPL1	0.41	7.97	0.35	1.26e-14	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7226408	0.600	rs9945251	chr18:34551343	G/A	cg15022739	chr18:34823045	BRUNOL4	0.42	9.12	0.39	2.39e-18	Obesity-related traits;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13012494	chr21:47604986	C21orf56	0.49	8.22	0.36	2.11e-15	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04389422	chr12:24715564	SOX5	0.38	6.67	0.3	7.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs4474465	1.000	rs2373199	chr11:78142982	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.53	-0.37	2.15e-16	Alzheimer's disease (survival time);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02759489	chr4:55098483	PDGFRA	-0.46	-6.83	-0.3	2.74e-11	Systemic lupus erythematosus;
LGG	cis	rs6495367	1.000	rs1007366	chr15:79379541	G/A	cg17916960	chr15:79447300	NA	0.5	8.99	0.39	6.3e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg00717180	chr2:96193071	NA	-0.42	-7.46	-0.33	4.37e-13	HDL cholesterol;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg24607181	chr17:41446203	NA	0.3	7.08	0.31	5.49e-12	Menopause (age at onset);
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg06221963	chr1:154839813	KCNN3	-0.49	-9.91	-0.42	3.95e-21	Prostate cancer;
LGG	cis	rs2213920	0.749	rs4637918	chr9:118258247	G/T	cg13918206	chr9:118159781	DEC1	0.56	7.47	0.33	3.9e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs3784262	0.904	rs12901462	chr15:58316487	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.2	-0.36	2.43e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg16797656	chr11:68205561	LRP5	-0.46	-8.79	-0.38	2.95e-17	Bone mineral density (spine);
LGG	cis	rs2860975	0.666	rs1891073	chr10:96804911	G/A	cg09036531	chr10:96991505	NA	-0.47	-8.23	-0.36	1.97e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-14.06	-0.55	1.26e-37	Response to antipsychotic treatment;
LGG	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-8.88	-0.38	1.49e-17	Menarche (age at onset);
LGG	cis	rs11971779	0.941	rs1127424	chr7:139107660	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	10.13	0.43	6.34e-22	Diisocyanate-induced asthma;
LGG	cis	rs3741151	0.686	rs12277924	chr11:73219678	T/C	cg17517138	chr11:73019481	ARHGEF17	0.67	7.05	0.31	6.75e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.16	0.52	8.18e-34	Colorectal cancer;
LGG	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg08125733	chr17:73851984	WBP2	0.87	13.29	0.53	2.2e-34	Psoriasis;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.88	-0.34	2.32e-14	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg15971980	chr6:150254442	NA	0.44	8.24	0.36	1.76e-15	Lung cancer;
LGG	cis	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg21775007	chr8:11205619	TDH	-0.56	-8.78	-0.38	3.16e-17	Retinal vascular caliber;
LGG	trans	rs3206736	0.548	rs59505449	chr7:35065852	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.31	0.32	1.19e-12	Diastolic blood pressure;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg18876405	chr7:65276391	NA	-0.67	-12.55	-0.5	2.77e-31	Aortic root size;
LGG	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg15501526	chr10:2543763	NA	0.81	15.89	0.59	1.03e-45	Age-related hearing impairment;
LGG	cis	rs4780401	1.000	rs4780401	chr16:11839326	G/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.22	-0.32	2.13e-12	Rheumatoid arthritis;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg02524346	chr8:600233	NA	1.14	11.37	0.47	1.33e-26	IgG glycosylation;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.44e-12	Electroencephalogram traits;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.53	0.37	2.05e-16	Prostate cancer;
LGG	cis	rs7192750	0.586	rs2288031	chr16:71902142	C/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.81	0.45	1.99e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg27661571	chr11:113659931	NA	-0.73	-9.73	-0.41	1.7e-20	Hip circumference adjusted for BMI;
LGG	trans	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg10756647	chr7:56101905	PSPH	0.8	9.44	0.4	1.83e-19	Diabetic kidney disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10185519	chr16:30621987	ZNF689	-0.45	-6.68	-0.3	7.01e-11	Systemic lupus erythematosus;
LGG	cis	rs657075	0.595	rs3749753	chr5:131587131	C/T	cg14196790	chr5:131705035	SLC22A5	0.5	6.95	0.31	1.25e-11	Rheumatoid arthritis;
LGG	cis	rs6867032	1.000	rs4246753	chr5:2014721	G/A	cg26168224	chr5:2018326	NA	1.26	30.19	0.81	1.9e-111	Gut microbiome composition (winter);
LGG	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.85	0.34	3e-14	Eosinophil percentage of white cells;
LGG	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg25457927	chr22:38595422	NA	-0.41	-10.15	-0.43	5.67e-22	Cutaneous nevi;
LGG	cis	rs526231	0.543	rs34766	chr5:102510923	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.39	-0.36	5.72e-16	Primary biliary cholangitis;
LGG	cis	rs368123	0.961	rs378629	chr6:160737987	T/A	cg07349212	chr6:160770346	SLC22A3	-0.36	-7.8	-0.34	4.04e-14	Waist circumference;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.54	9.84	0.42	7.22e-21	Depressive symptoms;
LGG	cis	rs4771450	0.925	rs877505	chr13:103980230	T/C	cg02987523	chr13:103978230	NA	-0.33	-7.02	-0.31	8.19e-12	Uric acid levels;
LGG	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.21	0.39	1.16e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg21427119	chr20:30132790	HM13	-0.42	-7.16	-0.32	3.14e-12	Mean corpuscular hemoglobin;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-7.19	-0.32	2.65e-12	Longevity;Endometriosis;
LGG	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14154082	chr13:112174009	NA	0.41	9.13	0.39	2.08e-18	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.67	0.3	7.15e-11	Alzheimer's disease;
LGG	cis	rs9790314	0.502	rs2404342	chr3:161092562	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-10.09	-0.42	8.84e-22	Morning vs. evening chronotype;
LGG	cis	rs2777491	0.915	rs7178634	chr15:41634587	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.46	-0.67	4.67e-62	Ulcerative colitis;
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.96e-21	Tonsillectomy;
LGG	cis	rs17767392	0.813	rs12891975	chr14:71789862	T/C	cg02058870	chr14:72053146	SIPA1L1	0.4	8.23	0.36	1.93e-15	Mitral valve prolapse;
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg12310025	chr6:25882481	NA	-0.51	-9.8	-0.41	1.03e-20	Height;
LGG	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg06532163	chr17:45867833	NA	0.51	8.48	0.37	2.96e-16	IgG glycosylation;
LGG	cis	rs10751667	0.577	rs7946461	chr11:974035	A/G	cg22143635	chr11:980567	AP2A2	0.44	8.18	0.36	2.7e-15	Alzheimer's disease (late onset);
LGG	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg02227867	chr8:22457446	C8orf58	-0.44	-8.5	-0.37	2.61e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7255436	0.965	rs28729307	chr19:8452742	A/G	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.68	-0.3	6.78e-11	HDL cholesterol;
LGG	cis	rs498079	0.544	rs509685	chr6:133517005	A/G	cg06181518	chr6:133562196	EYA4	0.43	7.55	0.33	2.33e-13	Total body bone mineral density;
LGG	cis	rs2011503	1.000	rs11670687	chr19:19621752	A/G	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg03342759	chr3:160939853	NMD3	0.46	7.67	0.34	1.03e-13	Morning vs. evening chronotype;
LGG	cis	rs4006360	0.646	rs9902561	chr17:39295384	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.11	-0.43	7.32e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6032067	0.598	rs2741500	chr20:43944958	G/T	cg10761708	chr20:43804764	PI3	0.57	8.53	0.37	2.15e-16	Blood protein levels;
LGG	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.64	0.33	1.25e-13	Neuroticism;
LGG	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg12633918	chr20:23549525	CST9L	-0.35	-7.03	-0.31	7.21e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs17221829	0.617	rs11018677	chr11:89362820	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.3e-18	Anxiety in major depressive disorder;
LGG	trans	rs783540	0.774	rs28415133	chr15:83264713	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.68	-0.3	6.87e-11	Schizophrenia;
LGG	cis	rs8072100	0.967	rs8074149	chr17:45583375	A/C	cg19784903	chr17:45786737	TBKBP1	0.37	8.08	0.35	5.66e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs171408	0.895	rs165172	chr3:8616128	T/C	cg03557445	chr3:8615444	LOH3CR2A	-0.49	-8.82	-0.38	2.26e-17	Mitral valve prolapse;
LGG	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11890956	chr21:40555474	PSMG1	1.16	28.4	0.8	1.73e-103	Cognitive function;
LGG	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	cg07245641	chr1:182991651	LAMC1	0.39	8.65	0.37	8.64e-17	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg11764359	chr7:65958608	NA	0.56	9.25	0.4	8e-19	Aortic root size;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.65	11.9	0.48	1.16e-28	Obesity-related traits;
LGG	cis	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg06521331	chr12:34319734	NA	-0.64	-12.61	-0.51	1.52e-31	Morning vs. evening chronotype;
LGG	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg13902645	chr11:5959945	NA	-0.74	-11.53	-0.47	3.33e-27	DNA methylation (variation);
LGG	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.64e-20	Hypertriglyceridemia;
LGG	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg13802316	chr11:70253460	CTTN	-0.59	-7.63	-0.33	1.35e-13	Coronary artery disease;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg23985595	chr17:80112537	CCDC57	-0.46	-8.99	-0.39	6.35e-18	Life satisfaction;
LGG	cis	rs7769051	1.000	rs3813347	chr6:133119778	G/A	cg22852734	chr6:133119734	C6orf192	1.19	15.82	0.59	2.13e-45	Type 2 diabetes nephropathy;
LGG	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg24450063	chr1:156163899	SLC25A44	1.21	29.71	0.81	2.36e-109	Testicular germ cell tumor;
LGG	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.66	-0.51	9.87e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs10876993	0.928	rs2169988	chr12:58071165	G/A	cg18357645	chr12:58087776	OS9	0.68	12.4	0.5	1.1e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.39	-0.61	6.35e-48	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.7	-0.59	7.31e-45	Platelet count;
LGG	cis	rs8064299	0.597	rs2166703	chr17:72781812	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.98	23.01	0.73	1.1e-78	Monocyte count;
LGG	cis	rs4780355	0.776	rs9936459	chr16:11437779	C/T	cg00044050	chr16:11439710	C16orf75	-0.46	-7.46	-0.33	4.26e-13	Crohn's disease and psoriasis;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg19077165	chr18:44547161	KATNAL2	0.65	12.49	0.5	4.58e-31	Personality dimensions;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg15537850	chr8:144661051	NAPRT1	1.01	7.66	0.34	1.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Bone mineral density;
LGG	cis	rs7168353	1.000	rs7168353	chr15:93638401	C/G	cg20899253	chr15:93632619	RGMA	0.38	6.96	0.31	1.19e-11	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LGG	cis	rs34172651	0.876	rs2112785	chr16:24781176	C/T	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.53	-0.33	2.73e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg18898632	chr2:242989856	NA	-0.81	-10.1	-0.42	8.49e-22	Obesity-related traits;
LGG	cis	rs1650123	0.645	rs703619	chr12:104022088	A/G	cg23227824	chr12:103980017	STAB2	-0.36	-8.32	-0.36	9.87e-16	IgG glycosylation;
LGG	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg10503236	chr1:231470652	EXOC8	0.37	7.21	0.32	2.26e-12	Hemoglobin concentration;
LGG	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg19507638	chr5:93509721	C5orf36	-0.71	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg16230307	chr14:35515116	FAM177A1	0.91	13.2	0.52	5.48e-34	Psoriasis;
LGG	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.27	0.32	1.56e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1568889	0.667	rs16917914	chr11:28459909	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.59	9.93	0.42	3.35e-21	Bipolar disorder;
LGG	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs72792276	0.818	rs57249773	chr5:127463166	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.75	0.3	4.57e-11	Red cell distribution width;
LGG	cis	rs1620921	0.594	rs12153845	chr6:161273987	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10083830	0.566	rs7503407	chr17:19980772	T/G	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Immature fraction of reticulocytes;
LGG	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-9.17	-0.39	1.61e-18	Diabetic retinopathy;
LGG	trans	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg09048205	chr5:1608656	LOC728613	-0.52	-8.44	-0.37	4.15e-16	Breast cancer;
LGG	cis	rs62400317	0.826	rs62436781	chr6:45142068	G/A	cg20913747	chr6:44695427	NA	-0.58	-8.64	-0.37	9.13e-17	Total body bone mineral density;
LGG	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg06212747	chr3:49208901	KLHDC8B	0.68	11.58	0.47	1.99e-27	Parkinson's disease;
LGG	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg09044154	chr16:88155775	NA	-0.52	-7.73	-0.34	6.62e-14	Menopause (age at onset);
LGG	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.1	0.35	4.75e-15	Fuchs's corneal dystrophy;
LGG	cis	rs28588043	1.000	rs11487418	chr1:170996229	C/T	cg03458344	chr1:170964477	C1orf129	-0.48	-7.2	-0.32	2.45e-12	Number of children (6+ vs. 0 or 1);
LGG	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	trans	rs34421088	0.506	rs4841519	chr8:11146228	A/T	cg02002194	chr4:3960332	NA	-0.39	-7.04	-0.31	6.89e-12	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22493809	chr1:120838387	FAM72B	0.4	7.03	0.31	7.21e-12	Obesity-related traits;
LGG	cis	rs757110	0.868	rs5219	chr11:17409572	T/C	cg04705435	chr11:17411270	KCNJ11	0.48	9.18	0.39	1.44e-18	Type 2 diabetes;
LGG	cis	rs7226408	0.600	rs9948487	chr18:34559879	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-8.87	-0.38	1.56e-17	Obesity-related traits;
LGG	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.59	0.56	6.19e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg02269571	chr22:50332266	NA	-0.8	-9.78	-0.41	1.16e-20	Mean platelet volume;
LGG	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	14.97	0.57	1.26e-41	Nonalcoholic fatty liver disease;
LGG	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg26384229	chr12:38710491	ALG10B	0.88	19.88	0.68	4.87e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.37	-0.47	1.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	20.86	0.7	1.31e-68	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.65	-0.33	1.17e-13	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.89	-0.42	4.9e-21	Lung cancer;
LGG	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg08305652	chr11:111469057	NA	0.43	8.19	0.36	2.63e-15	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg15971980	chr6:150254442	NA	0.44	8.29	0.36	1.2e-15	Lung cancer;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg01059449	chr18:44338099	ST8SIA5	0.36	7.81	0.34	3.83e-14	Personality dimensions;
LGG	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg21475434	chr5:93447410	FAM172A	0.71	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs3735485	0.738	rs10951788	chr7:45047919	T/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9849248	0.627	rs74983372	chr3:88158096	C/T	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg13736514	chr6:26305472	NA	-0.48	-9.76	-0.41	1.41e-20	Educational attainment;
LGG	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg09818912	chr17:20140352	CYTSB	0.31	7.18	0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs7143963	0.636	rs9324052	chr14:103344307	C/A	cg23020514	chr14:103360112	TRAF3	0.4	8.35	0.36	8.14e-16	Body mass index;
LGG	cis	rs9487094	0.644	rs3757230	chr6:109704442	T/C	cg01125227	chr6:109776195	MICAL1	0.38	6.69	0.3	6.58e-11	Height;
LGG	cis	rs7129556	0.859	rs11605638	chr11:77239334	C/T	cg12586386	chr11:77299805	AQP11	0.5	8.03	0.35	8.37e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs963731	0.649	rs2278912	chr2:39199702	C/T	cg04010122	chr2:39346883	SOS1	-0.83	-7.24	-0.32	1.92e-12	Corticobasal degeneration;
LGG	cis	rs7717393	0.786	rs72798948	chr5:155800893	G/A	cg04435420	chr5:155754009	SGCD	0.79	9.7	0.41	2.33e-20	Egg allergy;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.1	0.52	1.43e-33	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg18279126	chr7:2041391	MAD1L1	0.32	6.66	0.3	7.85e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg15971980	chr6:150254442	NA	0.44	8.4	0.36	5.45e-16	Lung cancer;
LGG	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg15268244	chr15:77196840	NA	0.47	9.95	0.42	2.99e-21	Blood metabolite levels;
LGG	cis	rs1595825	0.891	rs73061069	chr2:198908825	A/G	cg00982548	chr2:198649783	BOLL	-0.53	-7.12	-0.31	4.25e-12	Ulcerative colitis;
LGG	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg27511599	chr7:32358540	NA	0.64	6.85	0.3	2.4e-11	Body mass index;
LGG	cis	rs835154	0.845	rs835155	chr5:14875868	A/G	cg27316798	chr5:14870666	ANKH	0.48	9.7	0.41	2.25e-20	Blood metabolite levels;
LGG	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	cg15522984	chr1:182991683	LAMC1	0.44	8.77	0.38	3.5e-17	Colorectal cancer;
LGG	cis	rs9790314	0.846	rs4290817	chr3:160967354	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9290877	0.714	rs9815758	chr3:188431954	T/C	cg17392043	chr3:188495102	LPP	-0.4	-6.84	-0.3	2.49e-11	IgE levels;
LGG	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg24331049	chr13:111365604	ING1	-0.83	-14.59	-0.56	6.22e-40	Coronary artery disease;
LGG	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg02487422	chr3:49467188	NICN1	0.57	10.66	0.44	6.93e-24	Resting heart rate;
LGG	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg23029597	chr12:123009494	RSRC2	-0.88	-16.22	-0.6	3.58e-47	Body mass index;
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg13607699	chr17:42295918	UBTF	0.54	9.11	0.39	2.55e-18	Total body bone mineral density;
LGG	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg15309053	chr8:964076	NA	0.37	7.36	0.32	8.63e-13	Schizophrenia;
LGG	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg15532942	chr18:77220712	NFATC1	0.51	7.37	0.32	7.67e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1018836	0.923	rs13267989	chr8:91581648	C/T	cg16814680	chr8:91681699	NA	-0.81	-14.79	-0.57	8.29e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7635838	0.590	rs2256773	chr3:11386329	C/G	cg00170343	chr3:11313890	ATG7	0.5	8.63	0.37	9.98e-17	HDL cholesterol;
LGG	cis	rs1062746	0.544	rs8059287	chr16:87332956	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-7.76	-0.34	5.41e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.16	-0.35	3.25e-15	Obesity;
LGG	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg08999081	chr20:33150536	PIGU	0.38	9.68	0.41	2.62e-20	Coronary artery disease;
LGG	cis	rs718857	0.553	rs7851978	chr9:106715989	C/T	cg14250997	chr9:106856677	SMC2	0.35	6.73	0.3	5.18e-11	Breast cancer;
LGG	cis	rs789852	0.867	rs789846	chr3:194322999	T/C	cg18000598	chr3:194342907	TMEM44	-0.85	-8.05	-0.35	7.06e-15	QT interval;
LGG	cis	rs2516739	1.000	rs2516739	chr16:2097158	A/G	cg04515572	chr16:2107413	TSC2	0.41	6.92	0.31	1.55e-11	Longevity;
LGG	cis	rs12681287	0.640	rs13269259	chr8:87470453	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg04989706	chr14:50066350	PPIL5	-0.53	-8.27	-0.36	1.45e-15	Carotid intima media thickness;
LGG	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg03929089	chr4:120376271	NA	-0.51	-8.47	-0.37	3.34e-16	Height;
LGG	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.79	-0.38	3.04e-17	Kawasaki disease;
LGG	cis	rs9314323	0.798	rs2019239	chr8:26217354	G/A	cg11498726	chr8:26250323	BNIP3L	-0.53	-11.02	-0.46	3.04e-25	Red cell distribution width;
LGG	cis	rs2131877	0.956	rs2279632	chr3:194869285	G/A	cg07250128	chr3:194833983	C3orf21	0.41	7.62	0.33	1.43e-13	Non-small cell lung cancer;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.06	-0.42	1.14e-21	Type 2 diabetes;
LGG	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg23625390	chr15:77176239	SCAPER	-0.69	-14.02	-0.55	1.84e-37	Blood metabolite levels;
LGG	cis	rs7523273	0.526	rs2952	chr1:208049077	C/T	cg22525895	chr1:207977042	MIR29B2	0.47	8.66	0.37	7.85e-17	Schizophrenia;
LGG	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg18551225	chr6:44695536	NA	-0.72	-12.78	-0.51	3.1e-32	Chin dimples;
LGG	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg00898013	chr13:113819073	PROZ	-0.4	-8.18	-0.36	2.75e-15	Platelet distribution width;
LGG	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg12473912	chr3:136751656	NA	0.44	7.82	0.34	3.63e-14	Neuroticism;
LGG	trans	rs73411413	0.661	rs11599981	chr11:1520063	C/T	cg13381631	chr10:46776799	NA	-0.53	-9.45	-0.4	1.73e-19	Myringotomy;
LGG	cis	rs6028335	0.610	rs67621213	chr20:37582553	G/A	cg16355469	chr20:37678765	NA	0.56	7.5	0.33	3.29e-13	Alcohol and nicotine co-dependence;
LGG	cis	rs2245368	0.523	rs67814714	chr7:76517422	T/C	cg15770687	chr7:76625569	PMS2L11	0.53	7.15	0.32	3.49e-12	Body mass index in physically inactive individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg00717180	chr2:96193071	NA	-0.38	-6.81	-0.3	3.1e-11	Coronary artery disease;
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	15.94	0.6	6.15e-46	Personality dimensions;
LGG	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg06640241	chr16:89574553	SPG7	0.82	14.61	0.56	5.23e-40	Multiple myeloma (IgH translocation);
LGG	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg08851530	chr6:28072375	NA	0.84	6.68	0.3	6.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs981844	1.000	rs981844	chr4:154652028	A/G	cg14289246	chr4:154710475	SFRP2	0.64	8.78	0.38	3.12e-17	Response to statins (LDL cholesterol change);
LGG	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs7635838	0.539	rs430353	chr3:11254071	G/A	cg00170343	chr3:11313890	ATG7	0.43	7.3	0.32	1.28e-12	HDL cholesterol;
LGG	cis	rs988958	0.526	rs13424176	chr2:42239532	A/G	cg27428208	chr2:42229179	NA	0.47	7.45	0.33	4.73e-13	Hypospadias;
LGG	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg10621924	chr7:39171070	POU6F2	0.45	9.12	0.39	2.29e-18	IgG glycosylation;
LGG	cis	rs41005	1.000	rs798449	chr2:8106533	G/A	cg03155496	chr2:8117019	LOC339788	0.88	19.19	0.67	8.24e-61	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.32	0.58	3.62e-43	Coronary artery disease;
LGG	cis	rs6582630	0.537	rs1949611	chr12:38373092	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-13.31	-0.53	1.8e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03517284	chr6:25882590	NA	0.63	12.03	0.49	3.5e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg01181863	chr3:195395398	SDHAP2	0.48	7.24	0.32	1.92e-12	Mean corpuscular volume;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg18429434	chr2:203499731	FAM117B	-0.4	-7.02	-0.31	7.84e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.73e-48	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.689	rs4535075	chr2:3481716	T/C	cg15506890	chr2:3487001	NA	-0.54	-10.45	-0.44	4.45e-23	Neurofibrillary tangles;
LGG	cis	rs2721811	0.738	rs2521759	chr7:24764655	C/G	cg06301139	chr7:24798175	DFNA5	-0.4	-7.33	-0.32	1.02e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg24803719	chr17:45855879	NA	-0.31	-8.87	-0.38	1.55e-17	IgG glycosylation;
LGG	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.4e-17	Fuchs's corneal dystrophy;
LGG	cis	rs1909881	0.935	rs56157129	chr8:96521109	A/G	cg04203453	chr8:96504381	NA	-1.09	-18.6	-0.65	4.27e-58	Obesity-related traits;
LGG	cis	rs9463078	0.774	rs3923353	chr6:45256482	C/G	cg25276700	chr6:44698697	NA	-0.4	-8.53	-0.37	2.08e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg16701003	chr16:89028210	CBFA2T3	0.6	10.15	0.43	5.64e-22	Social autistic-like traits;
LGG	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07080220	chr10:102295463	HIF1AN	-0.58	-10.13	-0.43	6.66e-22	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs12545912	0.517	rs10110146	chr8:9685362	G/T	cg16141378	chr3:129829833	LOC729375	0.32	6.68	0.3	7.02e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs3857747	0.895	rs10236169	chr7:40408314	T/C	cg00420559	chr7:40367873	C7orf10	0.39	7.84	0.34	3.07e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg09307838	chr4:120376055	NA	0.8	13.51	0.53	2.73e-35	Corneal astigmatism;
LGG	cis	rs9534288	0.731	rs4942461	chr13:46551023	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.17	-0.52	7.26e-34	Blood protein levels;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg11062466	chr8:58055876	NA	0.47	7.78	0.34	4.73e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6504108	0.624	rs882380	chr17:46294236	C/A	cg02219949	chr17:45927392	SP6	0.42	7.57	0.33	2.11e-13	Body mass index;
LGG	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg22630939	chr7:1135958	C7orf50	0.33	6.77	0.3	3.97e-11	Bronchopulmonary dysplasia;
LGG	cis	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.44	-0.4	1.79e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg01620082	chr3:125678407	NA	0.65	7.15	0.32	3.33e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg01448562	chr3:133502909	NA	-0.51	-8.36	-0.36	7.62e-16	Iron status biomarkers;
LGG	cis	rs701145	0.585	rs1727946	chr3:153826470	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.4	0.33	6.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.03e-11	Aortic root size;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg05896524	chr21:47604654	C21orf56	0.56	9.61	0.41	4.54e-20	Testicular germ cell tumor;
LGG	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg26384229	chr12:38710491	ALG10B	0.88	19.88	0.68	4.87e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03576123	chr11:487126	PTDSS2	0.94	13.83	0.54	1.13e-36	Body mass index;
LGG	cis	rs9287719	0.674	rs11684157	chr2:10827157	C/A	cg02196655	chr2:10830764	NOL10	0.5	8.79	0.38	2.96e-17	Prostate cancer;
LGG	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs7444	0.941	rs878825	chr22:21982249	A/G	cg15846791	chr22:21984385	YDJC	-0.46	-7.34	-0.32	9.67e-13	Systemic lupus erythematosus;
LGG	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	9.13	0.39	2.13e-18	Gout;Renal underexcretion gout;
LGG	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg17644776	chr2:200775616	C2orf69	-0.47	-7.73	-0.34	6.72e-14	QT interval;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg14196790	chr5:131705035	SLC22A5	0.59	7.37	0.32	8.03e-13	Rheumatoid arthritis;
LGG	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg14346243	chr4:90757452	SNCA	0.35	6.8	0.3	3.33e-11	Dementia with Lewy bodies;
LGG	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.45	-0.33	4.7e-13	Systemic lupus erythematosus;
LGG	cis	rs2413583	0.591	rs115038091	chr22:39728575	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.65	0.33	1.2e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.85	-0.34	2.89e-14	Iron status biomarkers;
LGG	trans	rs3206736	0.549	rs57221424	chr7:35215670	C/G	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.44	0.33	4.95e-13	Diastolic blood pressure;
LGG	trans	rs9929218	0.861	rs8056206	chr16:68802072	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.82	-0.51	2.09e-32	Colorectal cancer;
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22963979	chr7:1858916	MAD1L1	-0.48	-9.3	-0.4	5.68e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.9e-14	Resting heart rate;
LGG	cis	rs6907340	0.517	rs9465531	chr6:19798649	A/T	cg02682789	chr6:19804855	NA	0.53	7.72	0.34	7.08e-14	Endometriosis;
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg13565492	chr6:43139072	SRF	-0.78	-10.51	-0.44	2.53e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.17	-0.49	8.98e-30	Cognitive function;
LGG	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.69e-22	DNA methylation (variation);
LGG	trans	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg11441553	chr12:57614120	NXPH4	-0.57	-7.31	-0.32	1.15e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2070488	1.000	rs4147024	chr3:38456664	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.48	0.63	6.33e-53	Electrocardiographic conduction measures;
LGG	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg21775007	chr8:11205619	TDH	-0.57	-9.56	-0.41	7.1e-20	Neuroticism;
LGG	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	cis	rs9815354	0.953	rs1613233	chr3:41945144	A/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-13.58	-0.53	1.37e-35	Menarche (age at onset);
LGG	cis	rs67478160	0.643	rs3742369	chr14:104251276	T/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.44	-0.33	5.03e-13	Schizophrenia;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2415984	0.579	rs28636061	chr14:46959848	T/C	cg14871534	chr14:47121158	RPL10L	-0.57	-10.11	-0.43	7.59e-22	Number of children ever born;
LGG	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg18709589	chr6:96969512	KIAA0776	0.42	8.21	0.36	2.19e-15	Headache;
LGG	cis	rs9486715	0.867	rs11152924	chr6:96877383	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs4144743	0.938	rs7225134	chr17:45326932	C/T	cg18085866	chr17:45331354	ITGB3	-0.81	-9.69	-0.41	2.49e-20	Body mass index;
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg24101359	chr6:42928495	GNMT	0.53	14.63	0.56	4e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01341218	chr17:43662625	NA	0.65	11.85	0.48	1.76e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs910187	0.605	rs6124960	chr20:45803866	G/C	cg27589058	chr20:45804311	EYA2	-0.37	-10.02	-0.42	1.58e-21	Migraine;
LGG	cis	rs4973397	0.668	rs4973393	chr2:232289526	G/T	cg18859089	chr2:232277014	NA	0.42	6.65	0.3	8.19e-11	Anti-saccade response;
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg05335186	chr13:53173507	NA	0.53	11.2	0.46	6.34e-26	Lewy body disease;
LGG	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg11366901	chr6:160182831	ACAT2	1.04	15.92	0.59	8.31e-46	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs138249	0.898	rs138232	chr22:50559838	C/G	cg18875453	chr22:50517795	MLC1	0.26	6.73	0.3	5.13e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs9309711	0.736	rs13409102	chr2:3496321	G/A	cg10845886	chr2:3471009	TTC15	-0.66	-11.9	-0.48	1.17e-28	Neurofibrillary tangles;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg22398616	chr13:53314203	LECT1	-0.5	-10.74	-0.45	3.68e-24	Lewy body disease;
LGG	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg21100191	chr22:23484243	RTDR1	1.0	23.1	0.73	4.22e-79	Bone mineral density;
LGG	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg26384229	chr12:38710491	ALG10B	0.91	20.34	0.69	3.61e-66	Bladder cancer;
LGG	cis	rs4919694	1.000	rs79254677	chr10:104691567	A/G	cg04362960	chr10:104952993	NT5C2	1.01	14.65	0.56	3.34e-40	Arsenic metabolism;
LGG	cis	rs6547631	0.622	rs1561284	chr2:85924295	C/A	cg24620635	chr2:85921963	GNLY	0.5	10.07	0.42	1.1e-21	Blood protein levels;
LGG	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14275779	chr17:40830236	PLEKHH3	0.5	7.78	0.34	4.86e-14	Gut microbiome composition (summer);
LGG	cis	rs8028182	0.636	rs28610581	chr15:75812474	A/G	cg20655648	chr15:75932815	IMP3	0.45	7.48	0.33	3.89e-13	Sudden cardiac arrest;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.5e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg24623649	chr8:11872141	NA	0.29	6.76	0.3	4.12e-11	Myopia (pathological);
LGG	cis	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg24130564	chr14:104152367	KLC1	-0.39	-7.16	-0.32	3.28e-12	Reticulocyte count;
LGG	cis	rs490234	0.812	rs12341150	chr9:128340770	C/T	cg14078157	chr9:128172775	NA	-0.48	-8.92	-0.38	1.1e-17	Mean arterial pressure;
LGG	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.41	-0.61	5.12e-48	Height;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg16405210	chr4:1374714	KIAA1530	-0.46	-7.69	-0.34	9.04e-14	Obesity-related traits;
LGG	cis	rs17092148	1.000	rs2425004	chr20:33405956	G/T	cg12302830	chr20:33297742	TP53INP2	0.47	7.88	0.34	2.34e-14	Neuroticism;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.58	0.33	1.86e-13	Rheumatoid arthritis;
LGG	cis	rs9937943	0.667	rs35126294	chr16:74651005	T/C	cg01733217	chr16:74700730	RFWD3	0.65	9.09	0.39	2.83e-18	Neutrophil percentage of white cells;
LGG	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	7.88e-18	Motion sickness;
LGG	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg13959647	chr9:123605229	PSMD5;LOC253039	0.44	7.08	0.31	5.55e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7503807	0.515	rs12946217	chr17:78686566	C/A	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.2	0.7	3.2e-70	Alzheimer's disease;
LGG	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg12183467	chr14:104352244	NA	-0.4	-6.91	-0.31	1.58e-11	Bipolar disorder;
LGG	cis	rs2692947	0.655	rs60090597	chr2:96406266	G/A	cg22654517	chr2:96458247	NA	0.38	7.5	0.33	3.24e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg12046867	chr14:103022105	NA	0.44	8.84	0.38	2.06e-17	Platelet count;
LGG	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	13.97	0.54	2.86e-37	Cognitive test performance;
LGG	cis	rs755249	0.567	rs61779274	chr1:39816941	C/G	cg18385671	chr1:39797026	MACF1	0.44	7.46	0.33	4.28e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2862064	0.932	rs6870977	chr5:156446249	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.79	-0.45	2.21e-24	Platelet count;
LGG	cis	rs11690935	0.959	rs10174525	chr2:172635697	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.19	-0.78	5.4e-98	Schizophrenia;
LGG	cis	rs9486719	1.000	rs2499816	chr6:96878206	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.69	-0.34	9.15e-14	Calcium levels;
LGG	cis	rs228437	1.000	rs73775366	chr6:134963061	T/C	cg24504307	chr6:134963096	NA	-0.45	-8.28	-0.36	1.28e-15	Melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02325679	chr20:34542290	SCAND1	0.44	6.71	0.3	5.62e-11	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05165339	chr4:1420672	NA	-0.35	-9.0	-0.39	5.83e-18	Longevity;
LGG	cis	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg19399532	chr1:178512495	C1orf220	-0.54	-10.79	-0.45	2.24e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg10523679	chr1:76189770	ACADM	-0.69	-11.02	-0.46	3.2e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.94	0.49	7.64e-29	Mean corpuscular volume;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.4	-0.47	1.09e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs3857536	0.813	rs2093253	chr6:66937702	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs62400317	0.859	rs17209636	chr6:45142517	T/G	cg20913747	chr6:44695427	NA	-0.62	-10.41	-0.44	6.18e-23	Total body bone mineral density;
LGG	cis	rs4474465	0.646	rs7937417	chr11:78284470	A/G	cg27205649	chr11:78285834	NARS2	0.61	11.36	0.47	1.5e-26	Alzheimer's disease (survival time);
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs1595825	0.891	rs16826895	chr2:198901642	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.91	-0.31	1.62e-11	Ulcerative colitis;
LGG	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg24011408	chr12:48396354	COL2A1	0.45	7.02	0.31	7.9e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs9443189	0.703	rs2748950	chr6:76442985	A/G	cg01950844	chr6:76311363	SENP6	-0.53	-7.05	-0.31	6.68e-12	Prostate cancer;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg06654118	chr4:1303317	MAEA	0.4	6.98	0.31	1.02e-11	Obesity-related traits;
LGG	cis	rs7914558	0.752	rs7896519	chr10:104866863	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.29	0.43	1.69e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2415984	0.644	rs1669808	chr14:46930473	A/G	cg14871534	chr14:47121158	RPL10L	0.59	10.22	0.43	3.15e-22	Number of children ever born;
LGG	cis	rs67133203	0.632	rs706802	chr12:51373742	C/T	cg14688905	chr12:51403056	SLC11A2	-0.59	-10.07	-0.42	1.08e-21	Urinary tract infection frequency;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg21926883	chr2:100939477	LONRF2	0.69	16.08	0.6	1.45e-46	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	13.03	0.52	2.83e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg13385794	chr1:248469461	NA	0.49	8.23	0.36	1.95e-15	Common traits (Other);
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21963583	chr11:68658836	MRPL21	0.61	10.57	0.44	1.55e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9788682	0.747	rs7177514	chr15:78907406	C/G	cg06917634	chr15:78832804	PSMA4	-0.52	-8.17	-0.36	2.93e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg21926883	chr2:100939477	LONRF2	-0.68	-16.23	-0.6	3.27e-47	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg13010199	chr12:38710504	ALG10B	-0.66	-12.5	-0.5	4.31e-31	Morning vs. evening chronotype;
LGG	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	9.98e-14	Neutrophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.32	3.07e-12	Lung cancer;
LGG	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.93	-0.31	1.43e-11	Type 2 diabetes;
LGG	cis	rs644799	0.672	rs61902245	chr11:95517737	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.24	0.58	8.61e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7945718	0.967	rs2241857	chr11:12815831	C/T	cg25843174	chr11:12811716	TEAD1	-0.4	-8.26	-0.36	1.52e-15	Educational attainment (years of education);
LGG	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs1801251	0.752	rs4144796	chr2:233562210	T/C	cg25237894	chr2:233734115	C2orf82	0.5	9.27	0.4	6.83e-19	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07557355	chr1:155904306	KIAA0907	0.41	6.78	0.3	3.58e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4538187	1.000	rs7590399	chr2:64081466	C/A	cg19915305	chr2:64069682	UGP2	0.68	15.31	0.58	4.37e-43	Systolic blood pressure;
LGG	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg01411142	chr8:19674711	INTS10	0.46	7.31	0.32	1.2e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7944735	0.508	rs6485783	chr11:47829345	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.89	0.3	1.77e-11	Intraocular pressure;
LGG	cis	rs2797369	0.824	rs2797371	chr6:101687025	A/G	cg27451362	chr6:101846650	GRIK2	0.84	11.37	0.47	1.37e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs368123	1.000	rs316161	chr6:160753983	G/A	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg15485101	chr11:133734466	NA	0.6	10.55	0.44	1.83e-23	Childhood ear infection;
LGG	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg15103426	chr22:29168792	CCDC117	0.64	8.81	0.38	2.5e-17	Lymphocyte counts;
LGG	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg01221209	chr5:554886	NA	-0.45	-6.7	-0.3	6.1e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.93	0.35	1.64e-14	Birth weight;
LGG	cis	rs36051895	0.664	rs884132	chr9:5114522	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.23	-0.58	9.86e-43	Pediatric autoimmune diseases;
LGG	cis	rs4689642	0.507	rs10008988	chr4:7222560	A/G	cg21353189	chr4:7228343	SORCS2	0.33	7.05	0.31	6.53e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg02985541	chr2:219472218	PLCD4	0.28	6.69	0.3	6.5500000000000006e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7927771	1.000	rs11039426	chr11:47863119	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg07636037	chr3:49044803	WDR6	1.11	28.42	0.8	1.43e-103	Parkinson's disease;
LGG	cis	rs1568889	0.938	rs1464898	chr11:28034748	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	15.51	0.58	5.29e-44	Bipolar disorder;
LGG	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg14983838	chr19:29218262	NA	0.71	11.42	0.47	8.53e-27	Methadone dose in opioid dependence;
LGG	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03576123	chr11:487126	PTDSS2	-1.21	-14.81	-0.57	6.4e-41	Body mass index;
LGG	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg15979348	chr13:112237479	NA	0.47	8.0	0.35	9.83e-15	Menarche (age at onset);
LGG	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.35	8.7	0.37	5.99e-17	Systemic lupus erythematosus;
LGG	cis	rs4794202	0.534	rs8078688	chr17:45919869	T/C	cg02219949	chr17:45927392	SP6	0.54	7.08	0.31	5.22e-12	Alzheimer's disease (cognitive decline);
LGG	cis	rs4740619	1.000	rs4740620	chr9:15638387	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.59	-0.44	1.31e-23	Body mass index;
LGG	cis	rs4696584	0.818	rs6844895	chr4:155397991	T/C	cg13738195	chr4:155413469	DCHS2	0.38	7.76	0.34	5.63e-14	Folding of antihelix;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg15971980	chr6:150254442	NA	0.42	6.72	0.3	5.38e-11	Lung cancer;
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.7	-0.37	5.99e-17	Response to antipsychotic treatment;
LGG	cis	rs858239	0.665	rs858306	chr7:23242754	A/T	cg23682824	chr7:23144976	KLHL7	0.4	6.8	0.3	3.22e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg00198680	chr16:28758506	NA	0.28	6.87	0.3	2.03e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1572438	0.931	rs13215634	chr6:866545	C/T	cg21062780	chr6:887772	NA	0.36	6.69	0.3	6.27e-11	Aging;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg00149659	chr3:10157352	C3orf10	1.19	14.13	0.55	6.27e-38	Alzheimer's disease;
LGG	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.46	-0.37	3.56e-16	Bone mineral density;
LGG	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg24851651	chr11:66362959	CCS	-0.41	-7.43	-0.33	5.4e-13	Bipolar disorder;
LGG	cis	rs4919087	0.892	rs10882880	chr10:99008068	G/A	cg25902810	chr10:99078978	FRAT1	0.51	9.48	0.4	1.29e-19	Monocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14092529	chr5:21459600	LOC728411	0.43	7.24	0.32	1.88e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg04733989	chr22:42467013	NAGA	0.61	10.69	0.45	5.34e-24	Schizophrenia;
LGG	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg11366901	chr6:160182831	ACAT2	1.01	15.2	0.58	1.31e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg02825527	chr7:2087843	MAD1L1	-0.37	-6.93	-0.31	1.41e-11	Bipolar disorder;
LGG	cis	rs77972916	0.536	rs7589361	chr2:43589328	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.95	-0.35	1.44e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.34	0.43	1.1e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2820315	0.540	rs10920259	chr1:201797696	C/T	cg06775570	chr1:201857621	SHISA4	-0.33	-6.8	-0.3	3.26e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg24642844	chr7:1081250	C7orf50	-0.53	-9.78	-0.41	1.17e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7072216	0.727	rs942807	chr10:100168219	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs735539	0.521	rs693814	chr13:21422910	A/T	cg04906043	chr13:21280425	IL17D	-0.5	-7.83	-0.34	3.37e-14	Dental caries;
LGG	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.46	0.33	4.29e-13	Neuroticism;
LGG	cis	rs10979	0.928	rs6924967	chr6:143906235	C/T	cg25407410	chr6:143891975	LOC285740	-0.7	-11.64	-0.48	1.2e-27	Hypospadias;
LGG	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.01	0.31	8.68e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg07061783	chr6:25882402	NA	-0.45	-7.72	-0.34	7.31e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg02227867	chr8:22457446	C8orf58	-0.41	-7.8	-0.34	4.28e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7945718	0.934	rs4553350	chr11:12759834	A/G	cg25843174	chr11:12811716	TEAD1	-0.41	-8.35	-0.36	8.05e-16	Educational attainment (years of education);
LGG	cis	rs9443645	0.901	rs9352664	chr6:79566162	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.59	-0.37	1.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg19455335	chr8:22457658	C8orf58	-0.38	-7.89	-0.34	2.18e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26897989	chr16:1907736	C16orf73	-0.81	-13.3	-0.53	2.01e-34	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.34	-0.4	4.02e-19	Response to antipsychotic treatment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11826116	chr22:39916314	ATF4	0.43	6.88	0.3	1.92e-11	Cognitive performance;
LGG	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.3	-0.32	1.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.7	0.45	5.09e-24	Personality dimensions;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg04861929	chr11:109293070	C11orf87	0.52	9.16	0.39	1.72e-18	Schizophrenia;
LGG	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg02466173	chr16:30829666	NA	-0.52	-8.59	-0.37	1.31e-16	Dementia with Lewy bodies;
LGG	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.79	-0.38	2.93e-17	Morning vs. evening chronotype;
LGG	cis	rs7044106	0.708	rs2416760	chr9:123374639	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.0	0.6	3.61e-46	Hip circumference adjusted for BMI;
LGG	cis	rs7474896	0.559	rs10740949	chr10:37978435	A/G	cg25427524	chr10:38739819	LOC399744	-0.46	-7.1	-0.31	4.81e-12	Obesity (extreme);
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.82	-0.34	3.51e-14	Skin colour saturation;
LGG	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg13010199	chr12:38710504	ALG10B	0.58	11.28	0.46	3.06e-26	Morning vs. evening chronotype;
LGG	cis	rs10865541	0.869	rs6747916	chr2:3451704	G/C	cg11642891	chr2:3452563	TTC15	-0.4	-7.59	-0.33	1.74e-13	Obesity-related traits;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg01485645	chr17:36862199	MLLT6	0.41	7.0	0.31	9.06e-12	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.83	-0.45	1.61e-24	Triglycerides;
LGG	cis	rs244899	1.000	rs244899	chr5:167911040	C/T	cg06604206	chr5:167912465	RARS	-0.52	-11.19	-0.46	6.58e-26	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22455342	chr2:225449267	CUL3	-0.82	-13.95	-0.54	3.41e-37	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23221052	chr5:179740743	GFPT2	-0.63	-11.58	-0.47	2.08e-27	Height;
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.53	-0.53	2.19e-35	Total body bone mineral density;
LGG	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg01620082	chr3:125678407	NA	-0.97	-9.36	-0.4	3.6e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg03060546	chr3:49711283	APEH	0.6	7.91	0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs11877825	0.826	rs3748425	chr18:10581762	A/C	cg07277756	chr18:10589357	NA	0.58	10.42	0.44	5.63e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs7106204	0.534	rs77470639	chr11:24250082	C/T	ch.11.24196551F	chr11:24239977	NA	0.86	8.77	0.38	3.54e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs10463554	0.963	rs3776860	chr5:102349970	G/C	cg23492399	chr5:102201601	PAM	-0.51	-7.56	-0.33	2.16e-13	Parkinson's disease;
LGG	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg04662567	chr6:169592167	NA	0.67	13.06	0.52	2.04e-33	Pulse pressure;
LGG	cis	rs698833	0.962	rs786409	chr2:44731344	C/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	6.71	0.3	5.74e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs13314892	0.764	rs17638538	chr3:69880673	A/T	cg17445875	chr3:69859618	MITF	0.4	7.84	0.34	3.17e-14	QRS complex (12-leadsum);
LGG	cis	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg00086871	chr4:6988644	TBC1D14	0.84	8.33	0.36	9.23e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg03342759	chr3:160939853	NMD3	-0.75	-13.3	-0.53	2.11e-34	Parkinson's disease;
LGG	cis	rs11608355	1.000	rs9669684	chr12:109860644	C/T	cg19025524	chr12:109796872	NA	-0.49	-9.29	-0.4	6.26e-19	Neuroticism;
LGG	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg04733989	chr22:42467013	NAGA	-0.59	-10.7	-0.45	5.21e-24	Schizophrenia;
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.37	0.36	6.93e-16	Prostate cancer;
LGG	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg01448562	chr3:133502909	NA	0.42	7.08	0.31	5.37e-12	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs4731207	0.596	rs9640828	chr7:124655481	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs8032158	0.963	rs7182397	chr15:56181052	A/T	cg05129572	chr15:56138634	NEDD4	-0.41	-6.67	-0.3	7.51e-11	Keloid;
LGG	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg00343986	chr7:65444356	GUSB	0.49	8.66	0.37	7.96e-17	Aortic root size;
LGG	cis	rs7927771	0.542	rs7122217	chr11:47777920	G/C	cg20307385	chr11:47447363	PSMC3	-0.56	-10.93	-0.45	6.72e-25	Subjective well-being;
LGG	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.13	-0.35	3.93e-15	Bone mineral density;
LGG	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg12560992	chr17:57184187	TRIM37	-0.88	-15.47	-0.58	8.36e-44	Intelligence (multi-trait analysis);
LGG	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg02931644	chr1:25747376	RHCE	0.41	9.12	0.39	2.27e-18	Erythrocyte sedimentation rate;
LGG	trans	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg13565492	chr6:43139072	SRF	-0.89	-14.94	-0.57	1.82e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.6	-0.33	1.68e-13	Eosinophil percentage of white cells;
LGG	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg16141378	chr3:129829833	LOC729375	-0.54	-13.98	-0.54	2.75e-37	Neuroticism;
LGG	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.46	0.53	4.32e-35	Psoriasis;
LGG	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.87	0.38	1.62e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs1519814	0.668	rs7836786	chr8:121006826	G/A	cg22335954	chr8:121166405	COL14A1	-0.46	-8.08	-0.35	5.5e-15	Breast cancer;
LGG	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs10924309	0.737	rs1538957	chr1:245855639	A/G	cg00036263	chr1:245852353	KIF26B	-0.44	-6.84	-0.3	2.49e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg22433210	chr17:43662623	NA	0.64	11.11	0.46	1.42e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.56	-0.37	1.7e-16	Personality dimensions;
LGG	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg10661904	chr17:79619235	PDE6G	-0.49	-10.04	-0.42	1.36e-21	Eye color traits;
LGG	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs892961	0.932	rs6501954	chr17:75414398	G/C	cg05865280	chr17:75406074	SEPT9	0.43	10.19	0.43	3.85e-22	Airflow obstruction;
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg09818912	chr17:20140352	CYTSB	-0.34	-8.01	-0.35	9.69e-15	Schizophrenia;
LGG	cis	rs7737355	0.773	rs7720194	chr5:130837077	T/C	cg06307176	chr5:131281290	NA	0.51	8.59	0.37	1.36e-16	Life satisfaction;
LGG	cis	rs818427	0.927	rs7213	chr5:112203564	T/A	cg07820702	chr5:112228657	REEP5	0.36	6.69	0.3	6.49e-11	Total body bone mineral density;
LGG	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.9	-14.33	-0.55	8e-39	Cognitive test performance;
LGG	trans	rs7615952	0.611	rs2947646	chr3:125593602	C/T	cg07211511	chr3:129823064	LOC729375	1.3	15.82	0.59	2.32e-45	Blood pressure (smoking interaction);
LGG	cis	rs782590	0.935	rs782652	chr2:55862775	C/A	cg18811423	chr2:55921094	PNPT1	0.91	21.12	0.7	8.14e-70	Metabolic syndrome;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.34	-0.36	8.62e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.02	0.46	3.18e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg14952266	chr13:112191215	NA	0.51	10.78	0.45	2.49e-24	Hepatitis;
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg10587741	chr22:38071170	LGALS1	0.82	21.87	0.71	2.34e-73	Fat distribution (HIV);
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.46	0.67	4.51e-62	Platelet count;
LGG	trans	rs9409565	0.658	rs2809768	chr9:97128369	G/A	cg05679027	chr9:99775184	HIATL2	0.5	8.19	0.36	2.52e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg06885757	chr1:42089581	HIVEP3	0.63	14.99	0.57	1.04e-41	Airway imaging phenotypes;
LGG	cis	rs774359	0.789	rs2492823	chr9:27502005	A/G	cg14173147	chr9:27528300	MOBKL2B	0.46	8.86	0.38	1.79e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.73	-0.48	5.1e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg03894339	chr8:19674705	INTS10	0.66	10.6	0.44	1.22e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.59	9.88	0.42	5.33e-21	Obesity-related traits;
LGG	cis	rs17445240	1.000	rs80212323	chr2:3703959	C/T	cg13452994	chr2:3699195	NA	0.67	7.2	0.32	2.43e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg13872356	chr11:62341519	EEF1G	-0.42	-6.8	-0.3	3.28e-11	Leprosy;
LGG	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg00717180	chr2:96193071	NA	-0.42	-7.46	-0.33	4.37e-13	HDL cholesterol;
LGG	cis	rs7301826	0.966	rs4759795	chr12:131300900	G/A	cg11011512	chr12:131303247	STX2	0.34	7.46	0.33	4.37e-13	Plasma plasminogen activator levels;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.96	-0.35	1.37e-14	Schizophrenia;
LGG	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.36	0.43	9.08e-23	Diabetic retinopathy;
LGG	cis	rs2377585	0.653	rs6487333	chr12:8848929	A/T	cg03761649	chr12:8850719	RIMKLB	-0.47	-8.08	-0.35	5.83e-15	Reticulocyte fraction of red cells;
LGG	trans	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg02002194	chr4:3960332	NA	-0.38	-6.82	-0.3	2.82e-11	Neuroticism;
LGG	cis	rs9790314	0.663	rs778642	chr3:160705819	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-9.12	-0.39	2.24e-18	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.07	-0.52	1.97e-33	Gut microbiome composition (summer);
LGG	cis	rs7527798	0.571	rs7531923	chr1:207833336	T/G	cg09232269	chr1:207846808	CR1L	-0.36	-6.74	-0.3	4.72e-11	Erythrocyte sedimentation rate;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-8.7	-0.37	5.81e-17	Electroencephalogram traits;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg02158880	chr13:53174818	NA	0.42	8.42	0.36	4.64e-16	Lewy body disease;
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg26850624	chr5:429559	AHRR	0.29	6.96	0.31	1.18e-11	Cystic fibrosis severity;
LGG	cis	rs5744897	0.708	rs34504371	chr12:133279469	G/A	cg17341477	chr12:133246679	POLE	0.58	6.66	0.3	7.79e-11	Urate levels in overweight individuals;
LGG	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg02002194	chr4:3960332	NA	-0.52	-9.65	-0.41	3.47e-20	Retinal vascular caliber;
LGG	cis	rs1465370	0.644	rs1558919	chr7:130029508	A/T	cg06917763	chr7:130033247	NA	0.35	7.59	0.33	1.73e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-16.49	-0.61	2.16e-48	Vitiligo;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg01879757	chr17:41196368	BRCA1	-0.4	-8.19	-0.36	2.61e-15	Menopause (age at onset);
LGG	cis	rs9309473	1.000	rs6710438	chr2:73820108	C/G	cg20560298	chr2:73613845	ALMS1	0.44	7.25	0.32	1.81e-12	Metabolite levels;
LGG	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg11812906	chr14:75593930	NEK9	-0.51	-9.49	-0.4	1.26e-19	Height;
LGG	cis	rs12681287	0.640	rs4490816	chr8:87384938	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg26248373	chr2:1572462	NA	-0.8	-11.73	-0.48	5.27e-28	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.65	0.61	3.97e-49	Platelet count;
LGG	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.44	7.74	0.34	6.35e-14	Total body bone mineral density;
LGG	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg21045802	chr8:109455806	TTC35	0.53	10.09	0.42	8.98e-22	Dupuytren's disease;
LGG	cis	rs1707322	1.000	rs4134387	chr1:46395158	A/T	cg03146154	chr1:46216737	IPP	0.55	10.08	0.42	1.02e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7444	1.000	rs7444	chr22:21976934	T/C	cg15846791	chr22:21984385	YDJC	-0.45	-7.07	-0.31	5.84e-12	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.84	0.3	2.44e-11	Retinal vascular caliber;
LGG	cis	rs9902453	0.765	rs8079209	chr17:28186773	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.38	0.56	4.82e-39	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.570	rs10954055	chr7:124589232	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg07157834	chr1:205819609	PM20D1	-0.6	-13.71	-0.54	3.74e-36	Monocyte percentage of white cells;
LGG	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg20891558	chr2:74357851	NA	0.49	9.52	0.4	9.87e-20	Gestational age at birth (maternal effect);
LGG	cis	rs10779751	1.000	rs7549109	chr1:11278813	C/G	cg08854313	chr1:11322531	MTOR	-0.81	-18.93	-0.66	1.3e-59	Body mass index;
LGG	cis	rs4363385	0.818	rs436621	chr1:153005492	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg18551225	chr6:44695536	NA	0.62	9.82	0.42	8.21e-21	Total body bone mineral density;
LGG	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12893428	chr3:195717962	SDHAP1	0.51	10.69	0.45	5.32e-24	Pancreatic cancer;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.89	-0.42	4.55e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13401104	0.680	rs11680714	chr2:237142605	A/G	cg15742758	chr2:237126235	ASB18	0.49	7.89	0.34	2.27e-14	Educational attainment;
LGG	cis	rs12200782	0.932	rs72844476	chr6:26574150	C/T	cg11502198	chr6:26597334	ABT1	-0.87	-7.53	-0.33	2.73e-13	Small cell lung carcinoma;
LGG	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.02	-0.39	5.04e-18	Mean corpuscular volume;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.88	-0.3	1.89e-11	Personality dimensions;
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.564	rs10260039	chr7:124603546	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs56283067	0.810	rs10948155	chr6:44687957	T/C	cg20913747	chr6:44695427	NA	-0.64	-11.83	-0.48	2.07e-28	Total body bone mineral density;
LGG	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg16473166	chr22:50639996	SELO	0.65	11.4	0.47	1.1e-26	Obesity-related traits;
LGG	cis	rs4356203	0.905	rs7396382	chr11:17151472	G/C	cg15432903	chr11:17409602	KCNJ11	0.38	7.25	0.32	1.74e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg02269571	chr22:50332266	NA	-0.54	-8.37	-0.36	6.97e-16	Schizophrenia;
LGG	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg20891283	chr12:69753455	YEATS4	0.97	22.99	0.73	1.43e-78	Blood protein levels;
LGG	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg25358565	chr5:93447407	FAM172A	1.32	16.4	0.61	5.75e-48	Diabetic retinopathy;
LGG	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg11984989	chr7:158649758	WDR60	-1.01	-14.36	-0.56	5.91e-39	Height;
LGG	trans	rs75804782	0.515	rs11897824	chr2:239311445	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.34e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.35	0.43	9.72e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7666738	0.830	rs13122456	chr4:98936011	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg18404041	chr3:52824283	ITIH1	-0.38	-7.2	-0.32	2.39e-12	Electroencephalogram traits;
LGG	cis	rs9534288	1.000	rs9534288	chr13:46605441	T/C	cg15192986	chr13:46630673	CPB2	-0.71	-15.77	-0.59	3.64e-45	Blood protein levels;
LGG	cis	rs12493885	0.818	rs11928425	chr3:153773565	G/T	cg12800244	chr3:153838788	SGEF	-0.79	-9.49	-0.4	1.26e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg19223190	chr17:80058835	NA	-0.49	-9.81	-0.41	9.19e-21	Life satisfaction;
LGG	cis	rs244899	0.967	rs244903	chr5:167913510	G/A	cg06604206	chr5:167912465	RARS	-0.52	-11.56	-0.47	2.47e-27	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg13647721	chr17:30228624	UTP6	0.68	7.22	0.32	2.1e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1046896	0.961	rs7208565	chr17:80696692	C/T	cg16060761	chr17:80687452	NA	-0.44	-7.66	-0.34	1.08e-13	Glycated hemoglobin levels;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg04503457	chr17:41445688	NA	-0.4	-8.18	-0.36	2.78e-15	Menopause (age at onset);
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.12	-0.31	4.27e-12	Obesity-related traits;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg14926445	chr8:58193284	C8orf71	-0.79	-12.17	-0.49	9.1e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs975722	0.540	rs10953846	chr7:117077110	T/C	cg10524701	chr7:117356490	CTTNBP2	0.39	8.23	0.36	1.99e-15	Coronary artery disease;
LGG	cis	rs2133450	0.967	rs949731	chr3:7352379	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.41	-0.36	4.96e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs4731207	0.671	rs4397336	chr7:124503196	C/T	cg05630886	chr7:124431682	NA	0.33	7.42	0.33	5.63e-13	Cutaneous malignant melanoma;
LGG	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.29	-0.4	6.01e-19	Systemic lupus erythematosus;
LGG	cis	rs2354432	0.505	rs3737845	chr1:146724408	A/G	cg25205988	chr1:146714368	CHD1L	1.45	14.81	0.57	6.39e-41	Mitochondrial DNA levels;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25172604	chr17:41446521	NA	-0.29	-6.66	-0.3	7.63e-11	Menopause (age at onset);
LGG	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.43	-0.4	1.97e-19	Height;
LGG	cis	rs6489882	0.966	rs6489880	chr12:113380271	C/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg05793240	chr7:2802953	GNA12	0.35	8.01	0.35	9.28e-15	Height;
LGG	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs7649275	0.938	rs2680651	chr3:53773609	A/G	cg21503701	chr3:53781065	CACNA1D	-0.52	-8.0	-0.35	9.88e-15	Trans fatty acid levels;
LGG	cis	rs3806843	0.547	rs246010	chr5:140336635	A/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7264396	0.635	rs6058375	chr20:34531997	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.26	0.32	1.65e-12	Total cholesterol levels;
LGG	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg16586182	chr3:47516702	SCAP	-0.78	-15.48	-0.58	7.62e-44	Colorectal cancer;
LGG	cis	rs7639513	0.737	rs13070228	chr3:12706914	G/A	cg23032965	chr3:12705835	RAF1	0.85	16.8	0.62	8.47e-50	Itch intensity from mosquito bite;
LGG	trans	rs3206736	0.583	rs1649233	chr7:35000459	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.39	6.83	0.3	2.64e-11	Diastolic blood pressure;
LGG	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg26384229	chr12:38710491	ALG10B	0.91	20.42	0.69	1.46e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6142618	0.562	rs3787369	chr20:30740434	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.46	0.33	4.44e-13	Inflammatory bowel disease;
LGG	cis	rs6754311	0.593	rs4954280	chr2:136420690	C/T	cg07169764	chr2:136633963	MCM6	-0.75	-13.1	-0.52	1.4e-33	Mosquito bite size;
LGG	cis	rs17818399	0.788	rs17818315	chr2:46818992	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.45	6.72	0.3	5.39e-11	Height;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.1e-19	Aortic root size;
LGG	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg01324343	chr3:183735012	ABCC5	0.76	14.49	0.56	1.62e-39	Anterior chamber depth;
LGG	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg00850481	chr1:228891306	NA	-0.5	-8.66	-0.37	8.02e-17	Chronic lymphocytic leukemia;
LGG	cis	rs10991814	0.920	rs7857020	chr9:94035272	G/T	cg14446406	chr9:93919335	NA	-0.72	-8.12	-0.35	4.4e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs2133450	0.712	rs28368666	chr3:7367258	C/G	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.64e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg13010199	chr12:38710504	ALG10B	0.58	11.28	0.46	3.06e-26	Morning vs. evening chronotype;
LGG	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg25427524	chr10:38739819	LOC399744	0.51	7.55	0.33	2.37e-13	Obesity (extreme);
LGG	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.31	-0.32	1.21e-12	Testicular germ cell tumor;
LGG	cis	rs7647973	0.848	rs4955411	chr3:49145304	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.0	0.35	1e-14	Menarche (age at onset);
LGG	cis	rs3771570	1.000	rs59496049	chr2:242260756	G/C	cg21155796	chr2:242212141	HDLBP	0.64	8.57	0.37	1.61e-16	Prostate cancer;
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.33	-0.47	1.89e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9512730	0.553	rs1040986	chr13:28051352	G/T	cg04070771	chr13:27998621	GTF3A	0.47	7.2	0.32	2.49e-12	Schizophrenia;
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.68	0.34	9.6e-14	Morning vs. evening chronotype;
LGG	cis	rs2371030	1.000	rs10211079	chr2:211575735	C/G	cg18417063	chr2:211583084	NA	-0.63	-12.01	-0.49	4.02e-29	Non-small cell lung cancer;
LGG	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.71	-0.34	7.53e-14	Bladder cancer;
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14893161	chr1:205819251	PM20D1	0.61	11.79	0.48	2.99e-28	Menarche (age at onset);
LGG	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.19e-13	HDL cholesterol;
LGG	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg09818912	chr17:20140352	CYTSB	-0.35	-8.16	-0.35	3.15e-15	Schizophrenia;
LGG	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg00806126	chr19:22604979	ZNF98	0.6	9.13	0.39	2.21e-18	Pain;
LGG	cis	rs1707322	1.000	rs11211239	chr1:46451947	A/G	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg07142201	chr11:109293216	C11orf87	0.82	16.13	0.6	9.26e-47	Schizophrenia;
LGG	cis	rs36093844	0.605	rs79719453	chr11:85582217	C/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.45	8.1	0.35	4.79e-15	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg23205692	chr1:25664452	TMEM50A	0.45	9.22	0.39	1.04e-18	Erythrocyte sedimentation rate;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg11764359	chr7:65958608	NA	-0.75	-13.27	-0.53	2.66e-34	Aortic root size;
LGG	cis	rs2115630	0.967	rs28595395	chr15:85334952	T/C	cg12501888	chr15:85177176	SCAND2	-0.41	-6.66	-0.3	7.56e-11	P wave terminal force;
LGG	trans	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.44	-0.4	1.77e-19	Diabetic kidney disease;
LGG	cis	rs78487399	0.808	rs7581586	chr2:43668176	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg12070911	chr6:150209640	RAET1E	0.31	7.64	0.33	1.26e-13	Lung cancer;
LGG	cis	rs7558370	0.737	rs77200948	chr2:3710169	C/T	cg17046650	chr2:3699563	NA	0.91	9.19	0.39	1.36e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.34	0.47	1.88e-26	Colorectal cancer;
LGG	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg02002194	chr4:3960332	NA	0.43	8.12	0.35	4.15e-15	Retinal vascular caliber;
LGG	trans	rs2048656	0.605	rs13249234	chr8:9650401	T/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.72	-0.3	5.3e-11	Schizophrenia;
LGG	cis	rs4538187	1.000	rs6710763	chr2:64068788	G/T	cg19915305	chr2:64069682	UGP2	0.65	14.71	0.56	1.86e-40	Systolic blood pressure;
LGG	cis	rs3845702	1.000	rs3738943	chr2:180846743	G/T	cg01881094	chr2:180872142	CWC22	-0.9	-13.84	-0.54	1.09e-36	Schizophrenia;
LGG	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.75e-23	Hip circumference adjusted for BMI;
LGG	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.32	0.47	2.09e-26	Schizophrenia;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg10189774	chr4:17578691	LAP3	0.43	7.67	0.34	1.02e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7113850	0.541	rs7102578	chr11:24244671	G/T	ch.11.24196551F	chr11:24239977	NA	0.92	10.52	0.44	2.42e-23	Bone fracture in osteoporosis;
LGG	cis	rs5756391	0.568	rs11705504	chr22:37317493	G/A	cg21209356	chr22:37319042	CSF2RB	0.41	9.48	0.4	1.35e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg26384229	chr12:38710491	ALG10B	0.74	14.85	0.57	4.29e-41	Heart rate;
LGG	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg24189917	chr7:1970923	MAD1L1	-0.47	-7.89	-0.34	2.22e-14	Bipolar disorder;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18737667	chr14:74551505	LIN52;ALDH6A1	0.4	6.79	0.3	3.54e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7301826	0.651	rs7956851	chr12:131319099	C/T	cg11011512	chr12:131303247	STX2	0.38	8.12	0.35	4.35e-15	Plasma plasminogen activator levels;
LGG	cis	rs137603	0.562	rs470080	chr22:39712368	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.6	-10.85	-0.45	1.4e-24	Primary biliary cholangitis;
LGG	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.55e-28	Intelligence (multi-trait analysis);
LGG	cis	rs62064224	0.666	rs7224683	chr17:30642262	A/G	cg25809561	chr17:30822961	MYO1D	0.37	8.37	0.36	6.68e-16	Schizophrenia;
LGG	cis	rs4478037	0.731	rs9835090	chr3:33107671	G/T	cg19404215	chr3:33155277	CRTAP	0.69	8.31	0.36	1.06e-15	Major depressive disorder;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg14912033	chr15:79043428	NA	-0.37	-8.86	-0.38	1.79e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg05368731	chr17:41323189	NBR1	0.97	19.13	0.66	1.62e-60	Menopause (age at onset);
LGG	cis	rs3796352	1.000	rs2336540	chr3:52974589	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg06346307	chr22:19949965	COMT	0.37	9.78	0.41	1.12e-20	Blood metabolite levels;
LGG	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg27661571	chr11:113659931	NA	-0.65	-9.22	-0.39	1.03e-18	Hip circumference adjusted for BMI;
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg16434002	chr17:42200994	HDAC5	-0.55	-10.18	-0.43	4.18e-22	Total body bone mineral density;
LGG	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg04568710	chr12:38710424	ALG10B	0.33	7.14	0.32	3.57e-12	Heart rate;
LGG	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg08085267	chr17:45401833	C17orf57	-0.48	-8.74	-0.38	4.31e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10979	1.000	rs11155300	chr6:143894576	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg00405596	chr8:11794950	NA	-0.44	-7.03	-0.31	7.25e-12	Neuroticism;
LGG	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	cg07928641	chr1:182991847	LAMC1	0.44	8.88	0.38	1.49e-17	Colorectal cancer;
LGG	trans	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.37	0.4	3.17e-19	Diabetic kidney disease;
LGG	trans	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.32	0.4	4.84e-19	Coronary artery disease;
LGG	cis	rs9611565	0.921	rs5751077	chr22:41720728	G/C	cg06481639	chr22:41940642	POLR3H	-0.45	-6.83	-0.3	2.68e-11	Vitiligo;
LGG	cis	rs7917772	0.503	rs746552	chr10:104342501	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.47	0.56	2.1e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs368123	1.000	rs471490	chr6:160718711	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs17030434	1.000	rs1456391	chr4:154720485	A/G	cg14289246	chr4:154710475	SFRP2	-0.72	-11.02	-0.46	2.95e-25	Electrocardiographic conduction measures;
LGG	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg17545662	chr6:170176663	C6orf70	0.66	6.72	0.3	5.52e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg19773385	chr1:10388646	KIF1B	-0.33	-7.48	-0.33	3.86e-13	Hepatocellular carcinoma;
LGG	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.07	0.39	3.34e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs16937	0.711	rs3851289	chr1:205149657	G/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.63	-0.33	1.34e-13	Schizophrenia;
LGG	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.91	0.54	5.26e-37	Bladder cancer;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22037798	chr1:231473786	C1orf124;EXOC8	0.42	7.28	0.32	1.47e-12	Lung adenocarcinoma;
LGG	cis	rs6062302	0.522	rs2282157	chr20:62227180	C/G	cg16989086	chr20:62203971	PRIC285	0.49	7.11	0.31	4.32e-12	Glioblastoma;
LGG	cis	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg12486710	chr1:178512616	C1orf220	0.41	8.33	0.36	9.41e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-16.6	-0.61	6.75e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg16590910	chr6:42928470	GNMT	0.46	13.23	0.52	4.24e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10130446	chr14:55658398	DLGAP5	0.45	7.28	0.32	1.44e-12	Cognitive performance;
LGG	cis	rs758324	0.797	rs82125	chr5:131322241	A/G	cg06307176	chr5:131281290	NA	-0.51	-7.42	-0.33	5.55e-13	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg25214090	chr10:38739885	LOC399744	0.65	11.65	0.48	1.09e-27	Corneal astigmatism;
LGG	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-9.14	-0.39	1.96e-18	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21575558	chr1:222763513	TAF1A	-0.49	-7.46	-0.33	4.46e-13	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.49	0.5	4.54e-31	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03732293	chr1:179335087	C1orf125	0.39	6.7	0.3	5.92e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6032067	0.641	rs34919068	chr20:43755830	C/A	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg18225595	chr11:63971243	STIP1	0.48	9.31	0.4	5.27e-19	Platelet count;
LGG	cis	rs727505	0.865	rs10253613	chr7:124508929	G/A	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs10883723	0.737	rs7074444	chr10:104249922	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.83	0.57	5.26e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9788682	0.747	rs28511883	chr15:78783683	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-7.98	-0.35	1.14e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9944715	1.000	rs4890628	chr18:43788045	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.68	-0.3	7.02e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11758351	0.500	rs79697629	chr6:26196512	A/G	cg23601095	chr6:26197514	HIST1H3D	0.89	6.73	0.3	5.12e-11	Gout;Renal underexcretion gout;
LGG	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs13394619	0.562	rs34532804	chr2:11746003	G/A	cg07314298	chr2:11723111	GREB1	0.39	7.88	0.34	2.42e-14	Endometriosis;
LGG	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg22232500	chr2:134024266	NCKAP5	0.65	9.27	0.4	7.22e-19	Bipolar disorder;
LGG	cis	rs981844	1.000	rs72731672	chr4:154664925	G/T	cg14289246	chr4:154710475	SFRP2	0.69	11.52	0.47	3.72e-27	Response to statins (LDL cholesterol change);
LGG	trans	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg21659725	chr3:3221576	CRBN	0.56	7.4	0.33	6.31e-13	Menarche (age at onset);
LGG	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg17108064	chr15:78857060	CHRNA5	-0.39	-7.72	-0.34	7.41e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg12395012	chr8:11607386	GATA4	0.42	7.48	0.33	3.66e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2455799	0.502	rs2470532	chr3:15696909	A/C	cg16303742	chr3:15540471	COLQ	0.44	8.65	0.37	8.51e-17	Mean platelet volume;
LGG	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.86	-0.3	2.21e-11	Joint mobility (Beighton score);
LGG	cis	rs72720396	0.803	rs115552537	chr1:91190856	C/A	cg13456504	chr1:91191583	NA	0.65	9.26	0.4	7.52e-19	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg21775007	chr8:11205619	TDH	0.52	8.36	0.36	7.56e-16	Triglycerides;
LGG	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg13852791	chr20:30311386	BCL2L1	0.91	17.51	0.63	4.56e-53	Mean corpuscular hemoglobin;
LGG	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.69e-123	Prudent dietary pattern;
LGG	cis	rs7737355	1.000	rs27663	chr5:130741438	T/G	cg06307176	chr5:131281290	NA	-0.52	-8.71	-0.38	5.55e-17	Life satisfaction;
LGG	cis	rs7647973	1.000	rs1982861	chr3:49577665	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	7.92	0.35	1.83e-14	Menarche (age at onset);
LGG	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.63	0.61	4.79e-49	Anterior chamber depth;
LGG	trans	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg27349345	chr7:35225932	NA	0.52	7.48	0.33	3.64e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs6964587	0.626	rs2188841	chr7:91522641	A/G	cg17063962	chr7:91808500	NA	-0.44	-8.01	-0.35	9.44e-15	Breast cancer;
LGG	cis	rs425535	0.757	rs13117734	chr4:74787503	T/C	cg01447579	chr4:74847100	PF4	0.54	7.08	0.31	5.51e-12	Blood protein levels;
LGG	cis	rs13082711	0.595	rs4973762	chr3:27364789	A/T	cg02860705	chr3:27208620	NA	0.91	17.28	0.63	5.37e-52	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg03060546	chr3:49711283	APEH	0.56	8.72	0.38	5e-17	Resting heart rate;
LGG	cis	rs6063312	0.935	rs6095256	chr20:47340806	C/T	cg18078177	chr20:47281410	PREX1	0.77	9.29	0.4	6.22e-19	Tonometry;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg11062466	chr8:58055876	NA	0.44	7.16	0.32	3.2e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg13207630	chr7:32358064	NA	0.79	8.14	0.35	3.78e-15	Body mass index;
LGG	cis	rs4330281	0.647	rs4431138	chr3:17749777	G/C	cg20981856	chr3:17787350	NA	-0.39	-7.38	-0.32	7.33e-13	Schizophrenia;
LGG	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21659725	chr3:3221576	CRBN	0.61	9.8	0.41	1.03e-20	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg08344181	chr3:125677491	NA	-0.66	-7.59	-0.33	1.76e-13	Depression;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg13206674	chr6:150067644	NUP43	0.67	15.34	0.58	3.23e-43	Lung cancer;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.66	11.9	0.48	1.17e-28	Obesity-related traits;
LGG	cis	rs283228	1.000	rs2518328	chr6:101813766	T/C	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs11588062	0.601	rs11579255	chr1:46806959	C/T	cg08947153	chr1:46664340	POMGNT1	0.41	7.28	0.32	1.48e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs12220238	1.000	rs2279648	chr10:75867193	G/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	10.78	0.45	2.51e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.19	-0.32	2.54e-12	Schizophrenia;
LGG	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.96	0.38	8.3e-18	Chronic sinus infection;
LGG	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.79	0.73	1.18e-77	Homoarginine levels;
LGG	cis	rs11877825	0.568	rs1442689	chr18:10566345	T/C	cg07277756	chr18:10589357	NA	0.49	9.06	0.39	3.58e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.0	0.62	1.03e-50	Tonsillectomy;
LGG	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg00129232	chr17:37814104	STARD3	0.6	11.29	0.46	2.84e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg27129171	chr3:47204927	SETD2	0.83	15.96	0.6	5.28e-46	Colorectal cancer;
LGG	cis	rs4742903	0.935	rs10820616	chr9:106945991	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.06	0.35	6.75e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg03078520	chr22:18463400	MICAL3	-0.52	-10.25	-0.43	2.3e-22	Presence of antiphospholipid antibodies;
LGG	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg14784868	chr12:69753453	YEATS4	0.7	13.1	0.52	1.47e-33	Blood protein levels;
LGG	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg07150166	chr2:30669952	LCLAT1	0.69	9.2	0.39	1.22e-18	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg22432760	chr17:80829718	TBCD	-0.37	-6.66	-0.3	7.75e-11	Breast cancer;
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06481639	chr22:41940642	POLR3H	0.59	8.56	0.37	1.66e-16	Vitiligo;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22857025	chr5:266934	NA	-1.55	-25.44	-0.76	5.97e-90	Breast cancer;
LGG	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.1	0.35	5.06e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg06212747	chr3:49208901	KLHDC8B	0.66	11.48	0.47	5.25e-27	Parkinson's disease;
LGG	cis	rs4243971	0.557	rs1984792	chr20:30867268	A/C	cg00028034	chr20:30779307	TSPYL3	0.33	6.95	0.31	1.28e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	trans	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs4330281	0.626	rs34892692	chr3:17448866	G/A	cg20981856	chr3:17787350	NA	0.35	6.77	0.3	3.89e-11	Schizophrenia;
LGG	cis	rs7582720	1.000	rs72934513	chr2:203927587	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.34	0.4	3.94e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg22857025	chr5:266934	NA	-1.51	-25.51	-0.76	2.72e-90	Breast cancer;
LGG	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03517284	chr6:25882590	NA	0.66	12.72	0.51	5.15e-32	Blood metabolite levels;
LGG	trans	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.34	0.55	7.44e-39	Exhaled nitric oxide output;
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg18252515	chr7:66147081	NA	0.44	7.32	0.32	1.12e-12	Aortic root size;
LGG	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg05623727	chr3:50126028	RBM5	0.4	8.35	0.36	7.89e-16	Menarche (age at onset);
LGG	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg24812749	chr6:127587940	RNF146	0.94	15.78	0.59	3.37e-45	Breast cancer;
LGG	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7408868	1.000	rs2074618	chr19:15276143	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs10791323	0.572	rs4353292	chr11:133742656	A/G	cg06766960	chr11:133703094	NA	-0.54	-10.69	-0.44	5.5e-24	Childhood ear infection;
LGG	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-6.79	-0.3	3.42e-11	Lung cancer in ever smokers;
LGG	cis	rs7551222	0.752	rs16853958	chr1:204528344	A/C	cg20240347	chr1:204465584	NA	-0.57	-11.47	-0.47	5.8e-27	Schizophrenia;
LGG	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg23625390	chr15:77176239	SCAPER	0.51	9.97	0.42	2.37e-21	Blood metabolite levels;
LGG	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.26	-0.32	1.69e-12	Neuroticism;
LGG	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg26396452	chr14:65542826	MAX	0.41	7.94	0.35	1.49e-14	Obesity-related traits;
LGG	cis	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.81	0.38	2.59e-17	Neuroticism;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg02725872	chr8:58115012	NA	-0.85	-11.61	-0.47	1.59e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02091366	chr17:16342131	NCRNA00188;SNORD49B;SNORD49A	-0.53	-7.88	-0.34	2.3e-14	Systemic lupus erythematosus;
LGG	cis	rs6594713	0.837	rs7714221	chr5:112751378	A/C	cg12552261	chr5:112820674	MCC	0.5	7.17	0.32	3.06e-12	Brain cytoarchitecture;
LGG	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg02175503	chr12:58329896	NA	0.55	9.34	0.4	3.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs17023223	0.537	rs12086686	chr1:119689084	T/A	cg05756136	chr1:119680316	WARS2	-0.43	-9.11	-0.39	2.42e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg11062466	chr8:58055876	NA	0.48	7.9	0.34	2.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg27490568	chr2:178487706	NA	-0.64	-11.69	-0.48	7.95e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg07460842	chr6:66804631	NA	0.92	15.94	0.6	6.28e-46	Exhaled nitric oxide output;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05591758	chr2:74685531	WBP1	0.4	6.88	0.3	2.01e-11	Bilirubin levels;
LGG	cis	rs12579753	0.879	rs11115002	chr12:82153090	C/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.41	-0.5	1.04e-30	Resting heart rate;
LGG	cis	rs58616815	0.890	rs1935251	chr10:92158056	T/A	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.37e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg13607699	chr17:42295918	UBTF	0.64	11.08	0.46	1.89e-25	Total body bone mineral density;
LGG	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.16	-0.39	1.68e-18	Response to antipsychotic treatment;
LGG	cis	rs12143943	0.738	rs11240750	chr1:204459786	T/C	cg20240347	chr1:204465584	NA	-0.33	-7.13	-0.31	3.76e-12	Cognitive performance;
LGG	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs10744422	0.858	rs4759389	chr12:123308615	A/G	cg25930673	chr12:123319894	HIP1R	-0.72	-9.24	-0.39	8.77e-19	Schizophrenia;
LGG	cis	rs6450176	0.909	rs3776712	chr5:53304179	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.26	-0.46	3.66e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg08847533	chr14:75593920	NEK9	-0.46	-8.08	-0.35	5.6e-15	Height;
LGG	cis	rs2011503	0.509	rs10403579	chr19:19770329	T/C	cg11584989	chr19:19387371	SF4	0.59	8.41	0.36	5.08e-16	Bipolar disorder;
LGG	cis	rs4774899	0.966	rs2414497	chr15:57493993	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.86	-0.3	2.2e-11	Urinary tract infection frequency;
LGG	trans	rs7181230	0.848	rs75509561	chr15:40333469	A/G	cg22705835	chr10:65332833	REEP3	-0.61	-9.92	-0.42	3.55e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg09165964	chr15:75287851	SCAMP5	0.64	11.97	0.49	5.97e-29	Breast cancer;
LGG	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.98	0.35	1.14e-14	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04252558	chr8:74884436	TCEB1	0.41	6.92	0.31	1.5e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg15704280	chr7:45808275	SEPT13	0.77	8.96	0.38	8.01e-18	Axial length;
LGG	cis	rs9287719	0.839	rs7600695	chr2:10739945	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs28595532	0.920	rs115738062	chr4:119725490	C/T	cg21605333	chr4:119757512	SEC24D	1.44	14.37	0.56	5.29e-39	Cannabis dependence symptom count;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg04787325	chr16:19179251	SYT17	-0.41	-7.07	-0.31	5.65e-12	Iris color (L* coordinate);
LGG	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg03352830	chr11:487213	PTDSS2	-0.6	-8.7	-0.37	5.9e-17	Body mass index;
LGG	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg18876405	chr7:65276391	NA	0.68	13.0	0.52	3.82e-33	Calcium levels;
LGG	cis	rs77741769	0.571	rs11065311	chr12:121324115	A/T	cg02419362	chr12:121203948	SPPL3	-0.53	-8.99	-0.39	6.41e-18	Mean corpuscular volume;
LGG	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg18357526	chr6:26021779	HIST1H4A	0.94	18.45	0.65	2.3e-57	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.775	rs12191655	chr6:25803095	G/T	cg17691542	chr6:26056736	HIST1H1C	0.88	11.45	0.47	6.81e-27	Iron status biomarkers;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-12.94	-0.52	6.62e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg12011299	chr4:100065546	ADH4	-0.42	-8.66	-0.37	7.76e-17	Alcohol dependence;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	9.66	0.41	3.2e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs4308124	0.708	rs6749633	chr2:111988016	A/G	cg04571233	chr2:111982156	NA	0.6	9.79	0.41	1.06e-20	Vitiligo;
LGG	cis	rs7267979	0.833	rs4619688	chr20:25244101	C/G	cg06421707	chr20:25228305	PYGB	0.48	10.52	0.44	2.27e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7590368	1.000	rs7576898	chr2:10958956	A/G	cg15705551	chr2:10952987	PDIA6	0.62	9.15	0.39	1.84e-18	Educational attainment (years of education);
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.81	0.82	3.5e-114	Prudent dietary pattern;
LGG	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg24231037	chr15:68117551	LBXCOR1	0.31	7.52	0.33	2.78e-13	Restless legs syndrome;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.76e-16	Life satisfaction;
LGG	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1775715	0.737	rs55859032	chr10:32213239	C/T	cg14930904	chr10:32216787	ARHGAP12	0.34	6.66	0.3	7.98e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg07817883	chr1:32538562	TMEM39B	0.85	7.64	0.33	1.3e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6537837	1.000	rs6682956	chr1:110130264	G/A	cg05049280	chr1:110155535	GNAT2	0.35	7.2	0.32	2.47e-12	Major depressive disorder;
LGG	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg10845886	chr2:3471009	TTC15	-0.49	-9.77	-0.41	1.3e-20	Neurofibrillary tangles;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21866054	chr4:103748674	UBE2D3	0.52	8.06	0.35	6.75e-15	Gut microbiome composition (summer);
LGG	cis	rs4356203	0.870	rs1979603	chr11:17283386	A/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.55	-0.33	2.4e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10979	0.562	rs9399446	chr6:143874639	G/C	cg25407410	chr6:143891975	LOC285740	-0.49	-7.88	-0.34	2.36e-14	Hypospadias;
LGG	cis	rs35771425	0.529	rs12743163	chr1:211491963	G/A	cg10512769	chr1:211675356	NA	-0.61	-7.11	-0.31	4.47e-12	Educational attainment (years of education);
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.42	-0.33	5.61e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs61931739	0.649	rs860088	chr12:33721807	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg01043669	chr3:72786069	NA	0.43	7.05	0.31	6.6e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg25801113	chr15:45476975	SHF	0.88	19.29	0.67	2.87e-61	Uric acid levels;
LGG	cis	rs644799	1.000	rs611020	chr11:95567905	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.9	0.54	5.74e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg24634471	chr8:143751801	JRK	0.49	7.52	0.33	2.79e-13	Schizophrenia;
LGG	cis	rs736801	0.891	rs10900809	chr5:131826322	G/A	cg07395648	chr5:131743802	NA	-0.46	-8.6	-0.37	1.21e-16	Breast cancer;Mosquito bite size;
LGG	cis	rs34929064	0.846	rs2905342	chr7:22731044	C/T	cg18045685	chr7:22629474	NA	-0.51	-9.09	-0.39	2.93e-18	Major depression and alcohol dependence;
LGG	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg12454169	chr2:30669597	LCLAT1	0.6	8.16	0.35	3.29e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg21926883	chr2:100939477	LONRF2	0.68	16.06	0.6	1.94e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg13010199	chr12:38710504	ALG10B	0.71	14.1	0.55	8.24e-38	Bladder cancer;
LGG	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-7.23	-0.32	2.06e-12	Acne (severe);
LGG	cis	rs8040855	0.644	rs4635318	chr15:85726737	C/A	cg10818794	chr15:86012489	AKAP13	0.37	7.43	0.33	5.19e-13	Bulimia nervosa;
LGG	cis	rs6456156	0.586	rs13195158	chr6:167481392	G/A	cg07741184	chr6:167504864	NA	0.41	9.21	0.39	1.16e-18	Primary biliary cholangitis;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14159672	chr1:205819179	PM20D1	-0.64	-13.93	-0.54	4.27e-37	Monocyte percentage of white cells;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg22398616	chr13:53314203	LECT1	-0.46	-9.72	-0.41	1.96e-20	Lewy body disease;
LGG	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg11764359	chr7:65958608	NA	-0.7	-12.06	-0.49	2.57e-29	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27109971	chr18:267637	THOC1	0.5	7.6	0.33	1.67e-13	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs7255045	0.752	rs55730975	chr19:12973039	G/A	cg07955356	chr19:12992479	DNASE2	0.42	7.09	0.31	5.05e-12	Mean corpuscular volume;
LGG	cis	rs6800768	0.604	rs76298099	chr3:24155775	G/T	cg10674438	chr3:24145617	LOC152024	-0.52	-9.06	-0.39	3.82e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.73	-0.45	3.88e-24	Primary sclerosing cholangitis;
LGG	cis	rs870825	0.520	rs10022842	chr4:185649459	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.63	-10.78	-0.45	2.56e-24	Platelet count;
LGG	cis	rs6694672	0.557	rs6671696	chr1:197083196	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.99	0.31	9.77e-12	Asthma;
LGG	cis	rs9814567	1.000	rs9827987	chr3:134272621	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	4.08e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7241530	0.662	rs7235625	chr18:75906500	G/A	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01896579	chr4:76599597	G3BP2	0.35	6.97	0.31	1.08e-11	Gut microbiome composition (summer);
LGG	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.35	-0.32	8.87e-13	Height;
LGG	cis	rs3806843	0.548	rs246055	chr5:140325662	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.58	-0.37	1.44e-16	Mood instability;
LGG	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg13256891	chr4:100009986	ADH5	0.55	9.6	0.41	4.99e-20	Alcohol dependence;
LGG	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg21100191	chr22:23484243	RTDR1	1.0	22.97	0.73	1.8e-78	Bone mineral density;
LGG	cis	rs13082711	0.871	rs7624790	chr3:27468601	C/A	cg02860705	chr3:27208620	NA	0.69	12.53	0.5	3.33e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-8.14	-0.35	3.73e-15	Schizophrenia;
LGG	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg09845145	chr15:78292470	TBC1D2B	-0.64	-10.19	-0.43	3.97e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg02023728	chr11:77925099	USP35	0.45	7.79	0.34	4.31e-14	Testicular germ cell tumor;
LGG	cis	rs240764	0.853	rs12206945	chr6:101018032	C/T	cg21058520	chr6:100914733	NA	-0.42	-7.37	-0.32	7.86e-13	Neuroticism;
LGG	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.28	-0.43	1.76e-22	Diabetic kidney disease;
LGG	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg12386194	chr3:101231763	SENP7	0.45	8.2	0.36	2.39e-15	Colorectal cancer;
LGG	cis	rs35771425	0.619	rs7529900	chr1:211442661	C/T	cg10512769	chr1:211675356	NA	-0.44	-7.71	-0.34	7.67e-14	Educational attainment (years of education);
LGG	cis	rs7100689	0.646	rs11202724	chr10:82136190	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs965513	1.000	rs7028661	chr9:100538470	A/G	cg13688889	chr9:100608707	NA	-0.53	-9.56	-0.41	7.09e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg24397884	chr7:158709396	WDR60	1.07	15.86	0.59	1.52e-45	Height;
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg18402987	chr7:1209562	NA	0.67	7.35	0.32	9.13e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.68	-0.51	8.12e-32	Uric acid levels;
LGG	cis	rs6121246	0.609	rs6060627	chr20:30262159	C/T	cg13852791	chr20:30311386	BCL2L1	0.9	17.27	0.63	5.96e-52	Mean corpuscular hemoglobin;
LGG	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg23505145	chr19:12996616	KLF1	0.41	7.33	0.32	1.06e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg03788504	chr6:150331562	NA	-0.58	-12.86	-0.51	1.36e-32	Alopecia areata;
LGG	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg03877680	chr5:178157825	ZNF354A	0.57	8.45	0.37	3.92e-16	Neutrophil percentage of white cells;
LGG	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs939658	0.805	rs35291410	chr15:79438660	C/T	cg17916960	chr15:79447300	NA	-0.66	-13.03	-0.52	2.8e-33	Refractive error;
LGG	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.85	0.3	2.31e-11	Electroencephalogram traits;
LGG	cis	rs209489	0.792	rs60809294	chr6:53113570	A/G	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2074193	0.627	rs215368	chr12:47742003	C/T	cg02516419	chr12:47771422	NA	-0.65	-9.23	-0.39	9.86e-19	Migraine with aura;
LGG	cis	rs758324	0.704	rs40401	chr5:131396478	C/T	cg06307176	chr5:131281290	NA	-0.45	-7.36	-0.32	8.6e-13	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs72781680	0.898	rs7569424	chr2:24036222	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.21e-18	Lymphocyte counts;
LGG	cis	rs7166081	1.000	rs12595736	chr15:67582602	T/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19671926	chr4:122722719	EXOSC9	0.53	8.2	0.36	2.41e-15	Type 2 diabetes;
LGG	cis	rs9807841	0.592	rs10415961	chr19:10759981	G/C	cg17710535	chr19:10819994	QTRT1	0.49	7.84	0.34	3.12e-14	Inflammatory skin disease;
LGG	cis	rs2865126	0.779	rs4796905	chr18:10755251	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-7.41	-0.33	5.92e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs4917300	0.605	rs7820768	chr8:143110823	C/T	cg26003909	chr8:143102224	NA	-0.39	-8.66	-0.37	8.12e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2130392	0.886	rs2077205	chr4:185637418	C/T	cg04058563	chr4:185651563	MLF1IP	0.44	9.36	0.4	3.33e-19	Kawasaki disease;
LGG	cis	rs61906588	0.595	rs693192	chr11:116355678	G/A	cg12564567	chr11:116371188	NA	-0.37	-6.88	-0.3	1.94e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs1386478	0.522	rs7643104	chr3:113809373	C/T	cg14431476	chr3:113822413	NA	0.52	8.63	0.37	1.03e-16	Crohn's disease and psoriasis;
LGG	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg25986240	chr4:9926439	SLC2A9	-0.54	-9.88	-0.42	5.17e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2439831	0.850	rs3825783	chr15:44102309	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	9.82	0.42	8.67e-21	Lung cancer in ever smokers;
LGG	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg13986417	chr12:110012484	MVK;MMAB	-0.49	-11.11	-0.46	1.39e-25	HDL cholesterol levels;
LGG	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg17749961	chr2:30669863	LCLAT1	0.78	10.26	0.43	2.24e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6942756	0.715	rs6467242	chr7:129001173	T/A	cg02491457	chr7:128862824	NA	-0.63	-11.45	-0.47	6.96e-27	White matter hyperintensity burden;
LGG	cis	rs11122272	0.735	rs2437150	chr1:231488524	A/G	cg10503236	chr1:231470652	EXOC8	0.35	7.0	0.31	9.15e-12	Hemoglobin concentration;
LGG	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg14829155	chr15:31115871	NA	-0.59	-10.3	-0.43	1.6e-22	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15710205	chr19:1401492	GAMT	0.46	6.96	0.31	1.16e-11	Gut microbiome composition (summer);
LGG	trans	rs6787172	0.702	rs827110	chr3:157980930	A/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg05890377	chr2:74357713	NA	0.49	9.76	0.41	1.33e-20	Gestational age at birth (maternal effect);
LGG	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg02297831	chr4:17616191	MED28	0.5	9.4	0.4	2.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs498079	0.544	rs509685	chr6:133517005	A/G	cg05493394	chr6:133562035	EYA4	0.27	7.44	0.33	5.07e-13	Total body bone mineral density;
LGG	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg04727924	chr7:799746	HEATR2	-0.45	-6.98	-0.31	1.05e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.74	0.3	4.76e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9486719	0.857	rs11751075	chr6:97065751	G/A	cg18709589	chr6:96969512	KIAA0776	-0.51	-8.28	-0.36	1.3e-15	Migraine;Coronary artery disease;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg03188948	chr7:1209495	NA	0.71	10.02	0.42	1.58e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7219021	0.634	rs9905428	chr17:46948709	C/G	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.84	-0.3	2.47e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.51	10.13	0.43	6.49e-22	Personality dimensions;
LGG	cis	rs6547631	0.622	rs10180451	chr2:85926238	G/T	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	cis	rs6087990	1.000	rs1007124	chr20:31345752	G/C	cg13636640	chr20:31349939	DNMT3B	1.02	22.18	0.72	8.23e-75	Ulcerative colitis;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg02127607	chr17:61920694	SMARCD2	0.43	7.79	0.34	4.4e-14	Prudent dietary pattern;
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs11718455	0.960	rs34019365	chr3:44004735	G/A	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.63e-11	Coronary artery disease;
LGG	cis	rs10937275	0.826	rs35508867	chr3:186643240	C/T	cg13419791	chr3:186648285	ST6GAL1	0.77	7.9	0.34	2e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg16141378	chr3:129829833	LOC729375	0.48	11.11	0.46	1.39e-25	Mood instability;
LGG	trans	rs9354308	0.764	rs2351722	chr6:66602809	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs3126085	0.935	rs4845734	chr1:152167473	T/C	cg26876637	chr1:152193138	HRNR	0.56	9.06	0.39	3.76e-18	Atopic dermatitis;
LGG	cis	rs10421328	0.784	rs28635562	chr19:19769690	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.74	0.34	6.35e-14	Parental longevity (combined parental age at death);
LGG	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg25174290	chr11:3078921	CARS	-0.52	-9.5	-0.4	1.1e-19	Calcium levels;
LGG	cis	rs4073221	0.520	rs1108439	chr3:18201319	A/G	cg07694806	chr3:18168406	NA	-0.68	-8.09	-0.35	5.15e-15	Parkinson's disease;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg11062466	chr8:58055876	NA	0.48	8.21	0.36	2.29e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7582720	1.000	rs72934710	chr2:203709776	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1003719	0.679	rs2246285	chr21:38582431	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-13.98	-0.54	2.6e-37	Eye color traits;
LGG	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg02811702	chr13:24901961	NA	0.39	7.35	0.32	9.22e-13	Obesity-related traits;
LGG	cis	rs2213920	0.679	rs10759786	chr9:118241188	A/G	cg13918206	chr9:118159781	DEC1	0.54	7.65	0.33	1.21e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.18	0.39	1.38e-18	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08990198	chr1:202318195	PPP1R12B	0.56	9.03	0.39	4.78e-18	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg08400814	chr5:56204995	C5orf35	-0.41	-7.29	-0.32	1.32e-12	Initial pursuit acceleration;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg16507663	chr6:150244633	RAET1G	0.41	7.6	0.33	1.65e-13	Lung cancer;
LGG	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.96	0.49	6.57e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26250093	chr2:24397649	C2orf84	-0.36	-6.81	-0.3	3.09e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2074585	0.647	rs2601178	chr15:90919333	T/C	cg22089800	chr15:90895588	ZNF774	0.73	13.48	0.53	3.54e-35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02018176	chr4:1364513	KIAA1530	0.65	16.12	0.6	1.01e-46	Longevity;
LGG	cis	rs10911457	0.542	rs4650	chr1:183896961	T/C	cg18131582	chr1:183912305	GLT25D2	0.27	6.77	0.3	3.83e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg25566285	chr7:158114605	PTPRN2	0.91	20.6	0.69	2.1e-67	Calcium levels;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.06	-0.35	6.55e-15	Skin colour saturation;
LGG	cis	rs9318086	0.663	rs2312295	chr13:24457744	A/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.48	9.28	0.4	6.48e-19	Myopia (pathological);
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg16270222	chr17:41446396	NA	-0.31	-7.34	-0.32	9.68e-13	Menopause (age at onset);
LGG	cis	rs9783347	1.000	rs4150651	chr11:18374425	T/C	cg15585147	chr11:18324498	HPS5	0.41	8.8	0.38	2.74e-17	Pancreatic cancer;
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	trans	rs12310956	0.532	rs2171534	chr12:33838998	C/T	cg13010199	chr12:38710504	ALG10B	0.43	7.98	0.35	1.14e-14	Morning vs. evening chronotype;
LGG	cis	rs9815354	1.000	rs2272007	chr3:41996136	A/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg01657329	chr11:68192670	LRP5	0.56	10.56	0.44	1.64e-23	Total body bone mineral density;
LGG	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.2	-0.46	6.06e-26	Morning vs. evening chronotype;
LGG	cis	rs9463078	0.625	rs12190136	chr6:44767072	A/G	cg25276700	chr6:44698697	NA	-0.38	-7.97	-0.35	1.24e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6961069	0.777	rs2366855	chr7:80253455	A/T	cg04458919	chr7:80252533	CD36	-0.28	-6.76	-0.3	4.1e-11	Platelet count;
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg06558623	chr16:89946397	TCF25	0.92	11.95	0.49	7.34e-29	Skin colour saturation;
LGG	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg26655873	chr3:72818019	SHQ1	0.34	6.82	0.3	2.82e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03150474	chr6:10695108	C6orf52;PAK1IP1	0.46	7.42	0.33	5.58e-13	Cognitive performance;
LGG	cis	rs1497406	0.744	rs4537547	chr1:16510798	C/T	cg20430773	chr1:16534157	ARHGEF19	-0.3	-8.49	-0.37	2.75e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg21775007	chr8:11205619	TDH	-0.46	-7.5	-0.33	3.35e-13	Schizophrenia;
LGG	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg04608330	chr12:45269318	NELL2	-0.63	-11.21	-0.46	5.65e-26	Gut microbiome composition (summer);
LGG	cis	rs870825	0.616	rs2090589	chr4:185647731	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs8064024	0.676	rs9926458	chr16:4872628	G/A	cg08329684	chr16:4932620	PPL	0.4	8.58	0.37	1.49e-16	Cancer;
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg07936489	chr17:37558343	FBXL20	-0.51	-8.57	-0.37	1.54e-16	Asthma;
LGG	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg17145862	chr1:211918768	LPGAT1	0.8	17.34	0.63	2.79e-52	Leprosy;
LGG	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg26695010	chr11:65641043	EFEMP2	0.47	7.41	0.33	6.19e-13	Breast cancer;
LGG	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg05468064	chr22:46423449	NA	-0.41	-7.42	-0.33	5.57e-13	Dupuytren's disease;
LGG	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg06028605	chr16:24865363	SLC5A11	0.5	8.33	0.36	9.42e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg23758822	chr17:41437982	NA	0.84	15.1	0.57	3.65e-42	Menopause (age at onset);
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.04	-0.31	6.93e-12	Triglycerides;
LGG	cis	rs6764363	0.683	rs408644	chr3:298213	C/T	cg02057681	chr3:285234	CHL1	0.38	6.89	0.3	1.86e-11	Sudden cardiac arrest;
LGG	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-14.02	-0.55	1.82e-37	Gut microbiome composition (summer);
LGG	trans	rs937213	0.781	rs28515996	chr15:40297219	T/A	cg22705835	chr10:65332833	REEP3	-0.42	-7.05	-0.31	6.49e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs12410462	0.502	rs115241368	chr1:227795465	A/G	cg04117972	chr1:227635322	NA	0.79	11.82	0.48	2.25e-28	Major depressive disorder;
LGG	cis	rs981844	0.683	rs1037653	chr4:154749992	A/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg12473912	chr3:136751656	NA	0.43	7.57	0.33	2e-13	Neuroticism;
LGG	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg15440763	chr7:158190612	PTPRN2	-0.43	-9.11	-0.39	2.47e-18	Obesity-related traits;
LGG	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg18446336	chr7:2847575	GNA12	-0.4	-10.73	-0.45	3.83e-24	Plateletcrit;
LGG	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01259104	chr12:133340965	NA	0.39	6.86	0.3	2.2e-11	Body fat percentage;
LGG	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-8.04	-0.35	7.69e-15	Body mass index;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00587304	chr3:172468157	NA	0.52	7.98	0.35	1.16e-14	Gut microbiome composition (summer);
LGG	cis	rs11877825	0.826	rs4643401	chr18:10579303	G/C	cg07277756	chr18:10589357	NA	0.58	10.3	0.43	1.54e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs11690935	0.959	rs10207085	chr2:172585885	T/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg08700190	chr5:6636046	SRD5A1	-0.35	-7.5	-0.33	3.38e-13	Response to amphetamines;
LGG	cis	rs9393777	0.502	rs3823427	chr6:27256346	G/C	cg12292205	chr6:26970375	C6orf41	-0.49	-7.65	-0.34	1.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9987353	0.544	rs2929469	chr8:9062656	T/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.99	0.31	9.57e-12	Recombination measurement;
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg16434002	chr17:42200994	HDAC5	-0.53	-9.82	-0.42	8.62e-21	Total body bone mineral density;
LGG	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg00578828	chr5:131826934	IRF1	-0.41	-7.33	-0.32	1.03e-12	Asthma (sex interaction);
LGG	cis	rs2976388	0.566	rs2585141	chr8:143806343	G/A	cg06565975	chr8:143823917	SLURP1	-0.52	-12.82	-0.51	2.12e-32	Urinary tract infection frequency;
LGG	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg21475434	chr5:93447410	FAM172A	0.68	7.11	0.31	4.43e-12	Diabetic retinopathy;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg04703951	chr17:43578652	NA	0.29	6.67	0.3	7.48e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1333657	0.554	rs9465751	chr6:10272211	A/G	cg03826642	chr6:10268858	NA	0.36	7.3	0.32	1.29e-12	Orofacial clefts;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.34	-8.75	-0.38	3.94e-17	IgG glycosylation;
LGG	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg17644776	chr2:200775616	C2orf69	0.63	10.11	0.43	7.43e-22	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs9300255	0.739	rs2337934	chr12:123745359	A/G	cg00376283	chr12:123451042	ABCB9	0.64	10.25	0.43	2.29e-22	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg21724239	chr8:58056113	NA	0.61	9.08	0.39	3.04e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11239187	0.530	rs11239144	chr10:45063401	G/T	cg03916630	chr10:45065415	NA	0.37	9.01	0.39	5.3e-18	Body mass index;
LGG	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.48	-0.44	3.46e-23	Hepatocellular carcinoma;
LGG	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.6	-0.37	1.2e-16	Body mass index;
LGG	cis	rs2455799	0.613	rs2470538	chr3:15717124	G/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.9	-0.34	1.98e-14	Mean platelet volume;
LGG	cis	rs881375	0.933	rs7028641	chr9:123691141	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.83	0.48	2.17e-28	Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13813623	chr9:111774895	CTNNAL1	0.42	7.01	0.31	8.36e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3784262	0.967	rs12910752	chr15:58314679	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.24	-0.36	1.74e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg24375607	chr4:120327624	NA	0.55	9.14	0.39	1.98e-18	Corneal astigmatism;
LGG	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.18	0.7	4.2e-70	Chronic sinus infection;
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg18681998	chr4:17616180	MED28	0.84	18.67	0.66	2.16e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4474465	0.541	rs10736814	chr11:78286462	C/G	cg27205649	chr11:78285834	NARS2	0.61	11.11	0.46	1.34e-25	Alzheimer's disease (survival time);
LGG	cis	rs7215564	0.818	rs1872431	chr17:78635200	T/C	cg16980736	chr17:78789706	RPTOR	-0.7	-9.21	-0.39	1.18e-18	Myopia (pathological);
LGG	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.29	-0.32	1.31e-12	IgG glycosylation;
LGG	cis	rs6882046	0.513	rs185291	chr5:88006764	T/C	cg22951263	chr5:87985283	NA	-0.55	-10.21	-0.43	3.19e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs4917300	0.571	rs2029620	chr8:143111294	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.77	-0.3	3.84e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg04166393	chr7:2884313	GNA12	0.45	8.41	0.36	4.99e-16	Height;
LGG	cis	rs9828933	0.766	rs3774725	chr3:63974258	T/G	cg17941049	chr3:63904683	ATXN7	0.65	7.63	0.33	1.36e-13	Type 2 diabetes;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26453990	chr11:65655486	FIBP	0.46	6.82	0.3	2.85e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs17767392	0.846	rs35151594	chr14:71808583	G/A	cg02058870	chr14:72053146	SIPA1L1	0.38	7.71	0.34	7.7e-14	Mitral valve prolapse;
LGG	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg16141378	chr3:129829833	LOC729375	0.35	7.32	0.32	1.1e-12	Triglycerides;
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-19.57	-0.67	1.42e-62	Vitiligo;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.99	-0.35	1.1e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.56	-7.95	-0.35	1.46e-14	Diabetic retinopathy;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.71	-0.3	5.78e-11	Obesity-related traits;
LGG	cis	rs847649	0.731	rs2298854	chr7:102729631	T/G	cg18108683	chr7:102477205	FBXL13	0.52	10.27	0.43	1.91e-22	Morning vs. evening chronotype;
LGG	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg24565620	chr2:194026	NA	-0.72	-9.07	-0.39	3.51e-18	Blood protein levels;
LGG	cis	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg01851573	chr8:8652454	MFHAS1	0.4	6.68	0.3	6.8e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7666738	0.830	rs35235971	chr4:98999833	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4959677	0.934	rs1891198	chr6:2501828	A/C	cg23817096	chr6:1620687	NA	-0.31	-7.32	-0.32	1.08e-12	Orthostatic hypotension;
LGG	cis	rs12931792	0.720	rs12102320	chr16:30178516	A/C	cg17640201	chr16:30407289	ZNF48	0.53	9.09	0.39	2.89e-18	Tonsillectomy;
LGG	cis	rs236352	0.576	rs2303993	chr6:36842427	C/G	cg03410223	chr6:36853544	C6orf89	0.44	8.4	0.36	5.69e-16	Heart rate;
LGG	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg03433033	chr1:76189801	ACADM	0.81	14.72	0.56	1.72e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1003719	0.715	rs7277820	chr21:38580309	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-14.05	-0.55	1.29e-37	Eye color traits;
LGG	cis	rs282587	0.597	rs1278659	chr13:113386497	G/T	cg04656015	chr13:113407548	ATP11A	0.42	6.7	0.3	5.95e-11	Glycated hemoglobin levels;
LGG	cis	rs17122278	1.000	rs11216925	chr11:118471423	T/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.44	-6.98	-0.31	1e-11	Schizophrenia;
LGG	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg26384229	chr12:38710491	ALG10B	0.71	14.25	0.55	1.86e-38	Morning vs. evening chronotype;
LGG	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg20573242	chr4:122745356	CCNA2	-0.41	-7.11	-0.31	4.4e-12	Type 2 diabetes;
LGG	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg19168338	chr16:4465731	CORO7	0.89	16.31	0.6	1.41e-47	Schizophrenia;
LGG	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs7937612	1.000	rs11217852	chr11:120261187	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.86	-0.51	1.41e-32	Intraocular pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18424841	chr20:61315444	NA	0.4	7.02	0.31	8.14e-12	Pancreatic cancer;
LGG	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg09021430	chr5:549028	NA	-0.72	-10.18	-0.43	4.06e-22	Lung disease severity in cystic fibrosis;
LGG	trans	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.5	0.47	4.37e-27	Corneal astigmatism;
LGG	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg09307838	chr4:120376055	NA	0.8	13.14	0.52	9.94e-34	Corneal astigmatism;
LGG	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07080220	chr10:102295463	HIF1AN	0.74	12.37	0.5	1.41e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9467773	0.620	rs9467810	chr6:26608261	A/C	cg09904177	chr6:26538194	HMGN4	0.68	13.95	0.54	3.65e-37	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg12463550	chr7:65579703	CRCP	0.51	8.54	0.37	2.01e-16	Aortic root size;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg23057284	chr9:131938815	IER5L	-0.4	-6.84	-0.3	2.5e-11	Iris color (L* coordinate);
LGG	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg08048268	chr3:133502702	NA	-0.6	-11.19	-0.46	7.13e-26	Iron status biomarkers;
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	15.05	0.57	5.76e-42	Alzheimer's disease;
LGG	cis	rs2594989	0.887	rs7640360	chr3:11584889	T/G	cg01796438	chr3:11312864	ATG7	0.54	7.23	0.32	2.03e-12	Circulating chemerin levels;
LGG	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.2e-12	HDL cholesterol;
LGG	cis	rs7000551	0.715	rs1879793	chr8:22313986	G/A	cg12081754	chr8:22256438	SLC39A14	0.69	13.72	0.54	3.43e-36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.52	0.33	2.85e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1021993	0.587	rs78609792	chr1:209546014	G/A	cg24446417	chr1:209558027	NA	-0.71	-10.8	-0.45	2.18e-24	Gut microbiome composition (winter);
LGG	cis	rs7000551	0.715	rs2469745	chr8:22343464	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	12.37	0.5	1.51e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2287838	0.692	rs7254989	chr19:10006618	G/A	cg07950397	chr19:10022659	OLFM2	0.3	6.81	0.3	2.96e-11	Sleep duration;
LGG	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-7.46	-0.33	4.24e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg01003211	chr7:1472830	NA	-0.61	-9.12	-0.39	2.3e-18	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs362272	0.525	rs2857849	chr4:3043638	A/T	cg13731523	chr4:3047190	NA	-0.43	-9.68	-0.41	2.57e-20	Serum sulfate level;
LGG	cis	rs6754311	0.517	rs60453613	chr2:136527120	G/C	cg07169764	chr2:136633963	MCM6	1.0	19.13	0.66	1.53e-60	Mosquito bite size;
LGG	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06481639	chr22:41940642	POLR3H	0.61	8.69	0.37	6.3e-17	Vitiligo;
LGG	cis	rs8141529	0.692	rs2239828	chr22:29358802	C/T	cg02153584	chr22:29168773	CCDC117	-0.56	-8.96	-0.38	7.91e-18	Lymphocyte counts;
LGG	cis	rs12282928	0.743	rs1354294	chr11:48232548	C/A	cg26585981	chr11:48327164	OR4S1	-0.4	-7.0	-0.31	9.13e-12	Migraine - clinic-based;
LGG	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.32	0.4	4.77e-19	Height;
LGG	cis	rs9460578	0.537	rs4373348	chr6:20810731	G/A	cg13405222	chr6:20811065	CDKAL1	0.78	17.67	0.63	9.26e-54	Breast cancer;
LGG	cis	rs4642101	0.560	rs4535210	chr3:12839617	T/G	cg24848339	chr3:12840334	CAND2	0.43	9.79	0.41	1.08e-20	QRS complex (12-leadsum);
LGG	cis	rs7659604	0.540	rs11098643	chr4:122701507	C/A	cg19748678	chr4:122722346	EXOSC9	-0.55	-10.06	-0.42	1.14e-21	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.61e-37	Prudent dietary pattern;
LGG	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg14703610	chr5:56206110	C5orf35	0.46	8.06	0.35	6.46e-15	Coronary artery disease;
LGG	cis	rs3784262	1.000	rs4646640	chr15:58247563	C/G	cg12031962	chr15:58353849	ALDH1A2	0.38	8.31	0.36	1.09e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.5e-11	Myopia (pathological);
LGG	cis	rs17508449	0.547	rs11582409	chr1:114399433	C/T	cg26035817	chr1:114414802	PTPN22	-0.46	-6.77	-0.3	3.85e-11	Leprosy;
LGG	cis	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg20368463	chr18:77673604	PQLC1	0.69	14.05	0.55	1.37e-37	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.9	0.31	1.68e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs10991814	0.920	rs76309414	chr9:94104882	T/C	cg14446406	chr9:93919335	NA	-0.69	-7.79	-0.34	4.29e-14	Neutrophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17482706	chr9:77643371	C9orf41	0.45	6.72	0.3	5.28e-11	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg02002194	chr4:3960332	NA	0.52	10.23	0.43	2.7e-22	Neuroticism;
LGG	cis	rs477692	0.637	rs7098627	chr10:131315866	C/T	cg05714579	chr10:131428358	MGMT	0.45	8.47	0.37	3.19e-16	Response to temozolomide;
LGG	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg25554036	chr4:6271136	WFS1	0.53	9.03	0.39	4.61e-18	Cisplatin-induced ototoxicity;
LGG	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg19455335	chr8:22457658	C8orf58	-0.45	-9.23	-0.39	9.35e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg08297393	chr2:100937505	LONRF2	-0.53	-9.86	-0.42	5.89e-21	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs12912251	0.947	rs12899449	chr15:38995491	A/G	cg01338139	chr15:38987640	C15orf53	-0.56	-9.08	-0.39	3.19e-18	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	trans	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.32	0.4	4.91e-19	Height;
LGG	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg14210321	chr2:106509881	NCK2	-0.53	-9.3	-0.4	5.63e-19	Addiction;
LGG	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg14019146	chr3:50243930	SLC38A3	-0.34	-7.26	-0.32	1.6e-12	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-9.94	-0.42	3.25e-21	Diabetic retinopathy;
LGG	cis	rs3820068	0.603	rs17448778	chr1:15985306	A/G	cg05660106	chr1:15850417	CASP9	0.87	17.34	0.63	2.78e-52	Systolic blood pressure;
LGG	trans	rs1997103	0.906	rs6593232	chr7:55402916	C/T	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4671458	0.948	rs72815371	chr2:63583236	A/T	cg17519650	chr2:63277830	OTX1	-0.61	-7.81	-0.34	3.89e-14	Subjective well-being;
LGG	cis	rs8014204	0.657	rs2884668	chr14:75281576	T/A	cg06637938	chr14:75390232	RPS6KL1	0.64	11.81	0.48	2.52e-28	Caffeine consumption;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg16207974	chr18:12431241	SLMO1	-0.4	-8.05	-0.35	7.25e-15	Migraine with aura;
LGG	cis	rs11997175	0.574	rs4538830	chr8:33653741	C/G	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	cis	rs7617773	0.817	rs9837228	chr3:48324466	A/T	cg11946769	chr3:48343235	NME6	-0.65	-10.77	-0.45	2.68e-24	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg12463550	chr7:65579703	CRCP	-0.79	-8.73	-0.38	4.83e-17	Diabetic kidney disease;
LGG	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs975739	1.000	rs1759977	chr13:78385208	G/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs10861342	0.786	rs12303948	chr12:105591569	G/A	cg23923672	chr12:105501055	KIAA1033	0.9	6.68	0.3	6.97e-11	IgG glycosylation;
LGG	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	9.16	0.39	1.69e-18	Aortic root size;
LGG	cis	rs9358372	0.671	rs10946416	chr6:20883616	T/G	cg13405222	chr6:20811065	CDKAL1	-0.54	-9.68	-0.41	2.55e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35110281	0.517	rs11701973	chr21:44979671	G/A	cg04455712	chr21:45112962	RRP1B	0.5	9.3	0.4	5.65e-19	Mean corpuscular volume;
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg16590910	chr6:42928470	GNMT	0.37	10.58	0.44	1.47e-23	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg00198680	chr16:28758506	NA	0.29	6.96	0.31	1.17e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg03433033	chr1:76189801	ACADM	0.75	13.57	0.53	1.45e-35	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg15558759	chr11:118478939	PHLDB1	0.38	6.65	0.3	8.05e-11	Cholesterol, total;
LGG	cis	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg06521331	chr12:34319734	NA	0.41	7.43	0.33	5.19e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.6	0.53	1.1e-35	Lung cancer;
LGG	cis	rs73416724	1.000	rs76649578	chr6:43388024	A/G	cg26312998	chr6:43337775	ZNF318	0.6	8.43	0.36	4.34e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.56	0.69	3.31e-67	Alzheimer's disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg09586080	chr16:86543543	FOXF1	-0.37	-6.73	-0.3	4.98e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg09904177	chr6:26538194	HMGN4	0.79	18.43	0.65	2.75e-57	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23809679	chr4:71554125	UTP3	0.42	6.98	0.31	1.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg11764359	chr7:65958608	NA	0.6	9.17	0.39	1.54e-18	Aortic root size;
LGG	cis	rs6456042	0.965	rs3127411	chr6:166534776	A/G	cg11088901	chr6:166572345	T	-0.35	-7.33	-0.32	1.02e-12	Asthma;
LGG	cis	rs9878978	0.964	rs34966409	chr3:2488889	C/G	cg21928760	chr3:2462534	CNTN4	0.39	8.71	0.38	5.28e-17	Blood pressure (smoking interaction);
LGG	cis	rs1562242	0.653	rs2441112	chr5:57601615	T/C	cg09002358	chr5:57541568	NA	1.1	14.39	0.56	4.41e-39	Educational attainment (years of education);
LGG	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.48	-0.37	3.07e-16	Menarche (age at onset);
LGG	cis	rs17253792	0.822	rs10137885	chr14:56173590	A/G	cg01858014	chr14:56050164	KTN1	-0.87	-12.02	-0.49	3.67e-29	Putamen volume;
LGG	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg06637938	chr14:75390232	RPS6KL1	0.57	10.62	0.44	1.02e-23	Height;
LGG	cis	rs7717393	1.000	rs1857769	chr5:155769363	A/G	cg01474424	chr5:155754231	SGCD	0.81	7.74	0.34	6.39e-14	Egg allergy;
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg06719900	chr11:109292894	C11orf87	0.74	15.2	0.58	1.23e-42	Schizophrenia;
LGG	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg27476859	chr7:2772710	GNA12	0.53	10.52	0.44	2.4e-23	Height;
LGG	cis	rs7586879	0.828	rs13387053	chr2:25103025	G/A	cg04586622	chr2:25135609	ADCY3	0.35	8.54	0.37	1.89e-16	Body mass index;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs4684776	1.000	rs35854631	chr3:11523382	C/A	cg24705426	chr3:11550659	ATG7	-0.47	-8.7	-0.37	5.73e-17	Small vessel stroke;
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg02002194	chr4:3960332	NA	-0.47	-8.83	-0.38	2.13e-17	Neuroticism;
LGG	cis	rs7781557	0.646	rs12113759	chr7:102440914	C/T	cg18108683	chr7:102477205	FBXL13	-0.55	-8.69	-0.37	6.3e-17	Colorectal adenoma (advanced);
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg24503407	chr1:205819492	PM20D1	0.95	26.72	0.78	7.76e-96	Menarche (age at onset);
LGG	cis	rs11018904	0.861	rs12786959	chr11:89943676	A/T	cg27158573	chr11:89632121	NA	-0.42	-7.66	-0.34	1.07e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg11520003	chr13:113540631	ATP11A	-0.39	-7.84	-0.34	3.08e-14	Interstitial lung disease;
LGG	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.02	-0.46	3.15e-25	Migraine;Coronary artery disease;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Electroencephalogram traits;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.72	0.41	1.91e-20	Prudent dietary pattern;
LGG	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg02428538	chr16:24856791	SLC5A11	0.72	11.09	0.46	1.68e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs894344	0.812	rs894359	chr8:135600805	T/G	cg17885191	chr8:135476712	NA	0.39	6.66	0.3	7.56e-11	Systolic blood pressure;
LGG	trans	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg18187862	chr3:45730750	SACM1L	0.65	10.67	0.44	6.77e-24	Primary sclerosing cholangitis;
LGG	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg05082376	chr22:42548792	NA	0.38	8.21	0.36	2.23e-15	Schizophrenia;
LGG	cis	rs9879311	0.932	rs7427473	chr3:10413197	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	7.11	0.31	4.31e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs17767392	0.813	rs61989386	chr14:71986545	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.98	-0.39	7.01e-18	Mitral valve prolapse;
LGG	trans	rs12543645	0.525	rs4349986	chr8:10278851	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.36	-0.32	8.72e-13	Schizophrenia;
LGG	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg08528231	chr16:12997261	SHISA9	-0.33	-6.73	-0.3	5.08e-11	Positive affect;Subjective well-being;
LGG	cis	rs2797369	0.713	rs943909	chr6:101579289	A/C	cg27451362	chr6:101846650	GRIK2	0.81	11.16	0.46	8.61e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.69	0.34	9.03e-14	Depressive symptoms;
LGG	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.96	0.38	7.74e-18	Hypertriglyceridemia;
LGG	cis	rs4799461	0.542	rs1539844	chr18:35120132	G/A	cg27332583	chr18:35150602	NA	0.53	8.23	0.36	1.98e-15	Neuroticism;
LGG	cis	rs9457247	0.663	rs2237274	chr6:167442995	C/G	cg07741184	chr6:167504864	NA	0.38	8.45	0.37	3.69e-16	Crohn's disease;
LGG	trans	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg25214090	chr10:38739885	LOC399744	0.58	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	trans	rs3857536	0.730	rs2157962	chr6:66966203	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.19e-12	Blood trace element (Cu levels);
LGG	cis	rs11630290	0.592	rs1017531	chr15:64158650	G/A	cg12036633	chr15:63758958	NA	0.49	7.01	0.31	8.4e-12	Iris characteristics;
LGG	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg26248373	chr2:1572462	NA	-0.88	-15.18	-0.58	1.58e-42	IgG glycosylation;
LGG	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg00666640	chr1:248458726	OR2T12	0.53	8.86	0.38	1.74e-17	Common traits (Other);
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22433210	chr17:43662623	NA	-0.88	-14.31	-0.55	9.81e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs56397034	1	rs56397034	chr19:13000550	G/C	cg04657146	chr19:12876947	HOOK2	-0.44	-7.34	-0.32	9.42e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.2	0.32	2.46e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1009647	0.645	rs17672298	chr14:55700284	T/C	cg04306507	chr14:55594613	LGALS3	0.46	7.73	0.34	6.77e-14	Testicular germ cell tumor;
LGG	trans	rs2235573	0.657	rs4821731	chr22:38445214	C/A	cg19894588	chr14:64061835	NA	0.5	8.41	0.36	5.18e-16	Glioblastoma;Glioma;
LGG	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11890956	chr21:40555474	PSMG1	1.15	27.03	0.78	2.8e-97	Cognitive function;
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.6	-0.53	1.17e-35	Alzheimer's disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09924173	chr13:32526671	EEF1DP3	0.4	7.25	0.32	1.72e-12	Menarche (age at onset);
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.53	-9.55	-0.41	7.35e-20	Longevity;Endometriosis;
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.53	9.08	0.39	3.08e-18	Birth weight;
LGG	cis	rs1577917	0.959	rs16876540	chr6:86612519	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.23	-0.43	2.67e-22	Response to antipsychotic treatment;
LGG	cis	rs804280	0.662	rs11784693	chr8:11610674	C/T	cg12395012	chr8:11607386	GATA4	0.62	10.12	0.43	6.92e-22	Myopia (pathological);
LGG	cis	rs55665837	0.540	rs10219313	chr11:14749849	C/T	cg18937875	chr11:14930189	NA	-0.48	-7.83	-0.34	3.31e-14	Vitamin D levels;
LGG	cis	rs9398803	0.865	rs9388494	chr6:126776094	G/T	cg19875578	chr6:126661172	C6orf173	0.57	10.41	0.44	5.91e-23	Male-pattern baldness;
LGG	cis	rs9393777	0.557	rs6933999	chr6:27074929	G/A	cg12292205	chr6:26970375	C6orf41	-0.55	-8.81	-0.38	2.6e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	1.000	rs7599132	chr2:26279810	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.83	13.53	0.53	2.22e-35	Gut microbiome composition (summer);
LGG	cis	rs2067615	0.524	rs4275715	chr12:107062246	C/T	cg15890332	chr12:107067104	RFX4	0.41	12.15	0.49	1.13e-29	Heart rate;
LGG	cis	rs1961637	0.514	rs1595821	chr2:223899108	G/A	cg02552189	chr2:223891284	NA	-0.47	-8.54	-0.37	1.92e-16	Oropharynx cancer;
LGG	trans	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.7	0.48	7.06e-28	Corneal astigmatism;
LGG	trans	rs931812	0.825	rs13271753	chr8:101895491	T/C	cg20993868	chr7:22813445	NA	0.69	12.86	0.51	1.44e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg13770153	chr20:60521292	NA	0.61	9.4	0.4	2.48e-19	Body mass index;
LGG	cis	rs7818345	1.000	rs7818345	chr8:19306618	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.66	0.3	7.96e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg05484376	chr2:27715224	FNDC4	0.46	9.85	0.42	6.7e-21	Total body bone mineral density;
LGG	cis	rs1904096	0.506	rs3113863	chr4:95147827	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.95	-0.45	5.52e-25	Type 2 diabetes;
LGG	cis	rs9583531	0.527	rs3818496	chr13:111358488	G/A	cg24331049	chr13:111365604	ING1	0.84	15.36	0.58	2.63e-43	Coronary artery disease;
LGG	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg16586182	chr3:47516702	SCAP	0.78	15.33	0.58	3.33e-43	Colorectal cancer;
LGG	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03264133	chr6:25882463	NA	-0.56	-10.36	-0.43	9.05e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6087990	0.669	rs2424929	chr20:31389518	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	17.38	0.63	1.84e-52	Ulcerative colitis;
LGG	cis	rs193541	0.632	rs415417	chr5:122322884	G/A	cg19412675	chr5:122181750	SNX24	-0.52	-8.36	-0.36	7.61e-16	Glucose homeostasis traits;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.76	0.34	5.63e-14	Menopause (age at onset);
LGG	cis	rs1957429	0.614	rs380741	chr14:65322027	C/T	cg23373153	chr14:65346875	NA	-1.02	-11.0	-0.46	3.7e-25	Pediatric areal bone mineral density (radius);
LGG	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg27053975	chr1:166958233	MAEL	-0.49	-7.05	-0.31	6.7e-12	Obesity-related traits;
LGG	cis	rs2341534	1.000	rs2341534	chr14:55784737	C/G	cg04306507	chr14:55594613	LGALS3	0.39	8.42	0.36	4.6e-16	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.951	rs17063653	chr3:41863817	A/G	cg03022575	chr3:42003672	ULK4	0.67	8.59	0.37	1.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00761968	chr13:53314142	LECT1	-0.36	-7.11	-0.31	4.34e-12	Lewy body disease;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg04234412	chr22:24373322	LOC391322	-0.72	-14.15	-0.55	4.72e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.38	0.36	6.57e-16	Obesity-related traits;
LGG	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.63	-0.37	9.86e-17	Retinal vascular caliber;
LGG	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg22232500	chr2:134024266	NCKAP5	-0.55	-7.78	-0.34	4.81e-14	Bipolar disorder;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13126279	chr21:47581558	C21orf56	0.53	9.49	0.4	1.22e-19	Testicular germ cell tumor;
LGG	cis	rs75920871	0.660	rs7930783	chr11:116959039	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-8.0	-0.35	1.04e-14	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07458698	chr2:67624494	ETAA1	0.43	6.8	0.3	3.18e-11	Cognitive performance;
LGG	trans	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.93	0.42	3.34e-21	Mean corpuscular volume;
LGG	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.76	0.3	4.04e-11	Bladder cancer;
LGG	cis	rs9400467	0.506	rs73530915	chr6:111457448	A/G	cg15721981	chr6:111408429	SLC16A10	0.56	6.84	0.3	2.48e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.12	0.43	6.83e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11112613	0.713	rs73184081	chr12:105951745	C/T	cg03607813	chr12:105948248	NA	0.58	10.69	0.44	5.61e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg24375607	chr4:120327624	NA	0.69	11.11	0.46	1.4e-25	Corneal astigmatism;
LGG	trans	rs330048	0.545	rs7002693	chr8:9148830	G/C	cg06636001	chr8:8085503	FLJ10661	0.45	7.68	0.34	9.42e-14	Systemic lupus erythematosus;
LGG	cis	rs7512552	0.724	rs7002	chr1:150445819	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.07	0.39	3.42e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg23202291	chr11:1979235	NA	0.39	7.46	0.33	4.3e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs116139393	0.656	rs10244591	chr7:6771098	G/C	cg09896999	chr7:6746977	ZNF12	-0.51	-7.13	-0.31	3.96e-12	Alzheimer's disease (APOE e4 interaction);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18492839	chr13:20138761	NA	0.41	7.4	0.33	6.47e-13	Menarche (age at onset);
LGG	cis	rs9354308	0.764	rs9342509	chr6:66586197	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	4.01e-13	Schizophrenia;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.78e-21	Lung cancer;
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.29	-0.43	1.61e-22	Bipolar disorder;
LGG	cis	rs787274	0.764	rs787299	chr9:115542369	A/G	cg13803584	chr9:115635662	SNX30	-0.58	-7.44	-0.33	4.84e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs2760061	0.819	rs708112	chr1:228192452	G/A	cg02753203	chr1:228287806	NA	0.76	14.83	0.57	5.19e-41	Diastolic blood pressure;
LGG	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.91	-0.35	1.84e-14	Morning vs. evening chronotype;
LGG	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.22	-0.36	2.1e-15	Schizophrenia;
LGG	cis	rs10751667	0.666	rs10902241	chr11:949129	G/A	cg22143635	chr11:980567	AP2A2	0.43	7.91	0.35	1.89e-14	Alzheimer's disease (late onset);
LGG	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg13010199	chr12:38710504	ALG10B	-0.53	-10.52	-0.44	2.34e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg11766577	chr21:47581405	C21orf56	0.5	8.33	0.36	9.28e-16	Testicular germ cell tumor;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg05091796	chr16:4465799	CORO7	-0.61	-9.91	-0.42	4.08e-21	Schizophrenia;
LGG	cis	rs2236918	0.622	rs1776177	chr1:242012149	C/T	cg17736920	chr1:242011382	EXO1	0.41	7.5	0.33	3.26e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg23782820	chr8:58130467	NA	0.54	7.46	0.33	4.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6743376	0.556	rs2251876	chr2:113818727	A/G	cg05949173	chr2:113825882	IL1F10	0.5	9.69	0.41	2.39e-20	Inflammatory biomarkers;
LGG	trans	rs7939886	0.920	rs17150038	chr11:55863414	A/T	cg15704280	chr7:45808275	SEPT13	0.85	8.87	0.38	1.62e-17	Myopia (pathological);
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.57	-10.54	-0.44	1.99e-23	Total body bone mineral density;
LGG	cis	rs4330281	0.647	rs9821955	chr3:17650745	A/G	cg20981856	chr3:17787350	NA	0.4	7.52	0.33	2.89e-13	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25707994	chr7:157129685	DNAJB6	-0.4	-6.81	-0.3	3.13e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs66573146	0.831	rs6832482	chr4:7023433	A/T	cg00086871	chr4:6988644	TBC1D14	0.92	8.35	0.36	7.97e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1577917	0.655	rs7766485	chr6:86263555	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.11	0.46	1.43e-25	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-8.63	-0.37	1e-16	Skin colour saturation;
LGG	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.65	-0.33	1.2e-13	Testicular germ cell tumor;
LGG	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs9357271	1.000	rs7766214	chr6:38363168	A/G	cg07362130	chr6:38359646	BTBD9	-0.45	-10.25	-0.43	2.38e-22	Restless legs syndrome;
LGG	cis	rs4132509	1.000	rs12049228	chr1:243995271	C/A	cg25706552	chr1:244017396	NA	0.54	8.75	0.38	3.91e-17	RR interval (heart rate);
LGG	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.41	-0.4	2.35e-19	Common traits (Other);
LGG	cis	rs4740619	0.544	rs1572978	chr9:15824678	A/T	cg14451791	chr9:16040625	NA	0.32	7.89	0.34	2.13e-14	Body mass index;
LGG	cis	rs1018836	0.923	rs6986689	chr8:91626709	A/C	cg16814680	chr8:91681699	NA	-0.85	-16.0	-0.6	3.41e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg20703242	chr1:230279135	GALNT2	0.37	7.54	0.33	2.42e-13	Coronary artery disease;
LGG	cis	rs2594989	0.943	rs62245870	chr3:11439838	G/A	cg01796438	chr3:11312864	ATG7	-0.51	-6.94	-0.31	1.33e-11	Circulating chemerin levels;
LGG	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	2.02e-13	Colorectal cancer;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg15763984	chr4:1342303	KIAA1530	0.38	6.76	0.3	4.16e-11	Obesity-related traits;
LGG	cis	rs965513	1.000	rs7030256	chr9:100535203	C/G	cg13688889	chr9:100608707	NA	-0.53	-9.67	-0.41	2.76e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs4906332	1.000	rs1951389	chr14:103898525	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.93	-0.35	1.6e-14	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.69	-0.37	6.43e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08142263	chr19:17420206	DDA1	0.41	7.31	0.32	1.16e-12	Obesity-related traits;
LGG	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.24	0.36	1.74e-15	Type 2 diabetes;
LGG	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg08727972	chr1:148025634	NBPF14	-0.39	-6.86	-0.3	2.18e-11	Hip geometry;
LGG	cis	rs7572733	0.935	rs6734561	chr2:198725076	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.59e-16	Dermatomyositis;
LGG	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg24253500	chr15:84953950	NA	-0.45	-7.55	-0.33	2.38e-13	Schizophrenia;
LGG	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg13147721	chr7:65941812	NA	-0.81	-9.61	-0.41	4.53e-20	Diabetic kidney disease;
LGG	cis	rs919433	0.926	rs12618567	chr2:198148191	A/T	cg00792783	chr2:198669748	PLCL1	-0.44	-6.89	-0.3	1.87e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6693295	0.625	rs6697670	chr1:246347944	A/G	cg11798871	chr1:246315928	SMYD3	-0.42	-6.95	-0.31	1.23e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs708547	0.599	rs2948348	chr4:57848772	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	10.31	0.43	1.44e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.05	0.42	1.26e-21	Prudent dietary pattern;
LGG	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07440826	chr16:89882328	FANCA	-0.28	-7.37	-0.32	7.82e-13	Vitiligo;
LGG	trans	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.19	-0.32	2.65e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.82	0.34	3.52e-14	Lung cancer;
LGG	cis	rs7084402	0.905	rs7098329	chr10:60276915	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.93	-0.64	5.74e-55	Refractive error;
LGG	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg02711726	chr17:80685570	FN3KRP	0.39	7.64	0.33	1.22e-13	Breast cancer;
LGG	trans	rs11976180	1.000	rs1533268	chr7:143766358	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.85	-0.3	2.4e-11	Obesity-related traits;
LGG	cis	rs921968	0.541	rs6710383	chr2:219359685	T/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs793278	0.520	rs1077686	chr11:19208611	C/A	cg14704941	chr11:19224659	CSRP3	0.47	7.28	0.32	1.42e-12	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs2120019	0.935	rs34913788	chr15:75372617	A/C	cg17294928	chr15:75287854	SCAMP5	-0.91	-16.75	-0.61	1.46e-49	Blood trace element (Zn levels);
LGG	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg08079166	chr15:68083412	MAP2K5	-0.35	-7.91	-0.35	1.92e-14	Restless legs syndrome;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7011049	1.000	rs7818958	chr8:53870354	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.58	0.33	1.9e-13	Lung cancer;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg05025164	chr4:1340916	KIAA1530	0.45	7.51	0.33	2.99e-13	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs9914988	0.943	rs9303621	chr17:27161138	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17377491	chr11:112096999	PTS	0.44	6.67	0.3	7.23e-11	Gut microbiome composition (summer);
LGG	cis	rs738322	0.870	rs2277844	chr22:38577515	G/A	cg03162506	chr22:38580953	NA	-0.41	-10.68	-0.44	5.74e-24	Cutaneous nevi;
LGG	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg18551225	chr6:44695536	NA	0.65	10.71	0.45	4.6e-24	Total body bone mineral density;
LGG	cis	rs77741769	0.529	rs525425	chr12:121195625	A/G	cg02419362	chr12:121203948	SPPL3	0.57	9.78	0.41	1.12e-20	Mean corpuscular volume;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg20607798	chr8:58055168	NA	0.62	7.27	0.32	1.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.28e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.02e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg17764715	chr19:33622953	WDR88	0.59	11.07	0.46	1.95e-25	Bone properties (heel);
LGG	trans	rs12517041	1.000	rs10072527	chr5:23318246	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.1e-25	Calcium levels;
LGG	cis	rs10083830	0.628	rs35244101	chr17:19973453	G/A	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Immature fraction of reticulocytes;
LGG	trans	rs7615952	0.641	rs60839048	chr3:125807938	G/A	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.15e-16	Blood pressure (smoking interaction);
LGG	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg06532163	chr17:45867833	NA	0.54	9.11	0.39	2.4e-18	IgG glycosylation;
LGG	trans	rs8073060	0.519	rs8065286	chr17:33864479	A/G	cg19694781	chr19:47549865	TMEM160	0.48	8.07	0.35	6.02e-15	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg25801113	chr15:45476975	SHF	0.88	20.25	0.69	9.31e-66	Uric acid levels;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg21724239	chr8:58056113	NA	0.5	7.57	0.33	2.07e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg08885076	chr2:99613938	TSGA10	-0.43	-8.04	-0.35	7.78e-15	Chronic sinus infection;
LGG	cis	rs367615	0.731	rs58241713	chr5:108853664	G/A	cg17395555	chr5:108820864	NA	0.82	14.94	0.57	1.76e-41	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2901460	0.509	rs10165560	chr2:62059398	A/C	cg02183531	chr2:62113199	CCT4	-0.42	-7.14	-0.32	3.56e-12	Mean corpuscular volume;
LGG	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.98	-0.49	5.6e-29	Breast cancer;
LGG	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg02227867	chr8:22457446	C8orf58	0.42	7.97	0.35	1.24e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6504108	0.624	rs7223867	chr17:46230156	T/A	cg02219949	chr17:45927392	SP6	0.44	8.24	0.36	1.85e-15	Body mass index;
LGG	cis	rs11239187	0.775	rs1480605	chr10:45109619	C/G	cg03916630	chr10:45065415	NA	0.34	7.55	0.33	2.27e-13	Body mass index;
LGG	trans	rs11976180	1.000	rs2951368	chr7:143752821	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.88	-0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs963731	0.579	rs297134	chr2:39304764	G/C	cg04010122	chr2:39346883	SOS1	-0.7	-7.2	-0.32	2.4e-12	Corticobasal degeneration;
LGG	cis	rs185694	1.000	rs200505	chr13:30900868	G/T	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.67	-0.3	7.26e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg12373951	chr3:133503437	NA	0.39	6.94	0.31	1.3e-11	Iron status biomarkers;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.1	-0.31	4.74e-12	Iron status biomarkers;
LGG	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-14.79	-0.57	8.31e-41	Chronic sinus infection;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.59	-0.63	2.15e-53	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.41	0.36	4.98e-16	Lung cancer;
LGG	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	7.15	0.32	3.37e-12	Total cholesterol levels;
LGG	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22857025	chr5:266934	NA	-1.51	-26.53	-0.78	5.74e-95	Breast cancer;
LGG	cis	rs2721811	0.593	rs2521768	chr7:24784403	C/T	cg19706795	chr7:24797839	DFNA5	-0.26	-6.76	-0.3	4.22e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4639966	0.836	rs10892282	chr11:118627778	C/G	cg19182353	chr11:118479428	PHLDB1	0.52	8.65	0.37	8.49e-17	Systemic lupus erythematosus;
LGG	trans	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.08	-0.31	5.44e-12	Neuroticism;
LGG	cis	rs9611565	0.571	rs7364123	chr22:42216326	A/G	cg03806693	chr22:41940476	POLR3H	-0.83	-13.6	-0.53	1.14e-35	Vitiligo;
LGG	cis	rs2455799	0.613	rs11920540	chr3:15854608	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.83	-0.34	3.32e-14	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10775894	chr20:45318455	TP53RK	0.4	6.84	0.3	2.48e-11	Gut microbiome composition (summer);
LGG	trans	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg16011800	chr17:1958478	HIC1	0.65	9.85	0.42	6.76e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg00006948	chr4:1768889	NA	-0.48	-6.71	-0.3	5.55e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg03160526	chr17:80928410	B3GNTL1	0.49	7.79	0.34	4.36e-14	Glycated hemoglobin levels;
LGG	cis	rs617791	0.530	rs735942	chr11:65749337	A/G	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	8.59	0.37	1.37e-16	Breast cancer;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.79	15.82	0.59	2.32e-45	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg02127607	chr17:61920694	SMARCD2	-0.46	-8.51	-0.37	2.45e-16	Prudent dietary pattern;
LGG	cis	rs7216064	1.000	rs62084214	chr17:65843325	C/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs283228	0.583	rs689073	chr6:101782173	T/A	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg24232236	chr22:38142998	TRIOBP	0.37	7.23	0.32	2.06e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs6598955	0.640	rs1577507	chr1:26547179	C/T	cg04990556	chr1:26633338	UBXN11	-0.69	-14.02	-0.55	1.72e-37	Obesity-related traits;
LGG	cis	rs13082711	0.555	rs73038733	chr3:27263537	C/G	cg02860705	chr3:27208620	NA	0.94	18.44	0.65	2.51e-57	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs12474201	0.832	rs4952843	chr2:46957845	A/G	cg06386533	chr2:46925753	SOCS5	0.81	15.3	0.58	4.7e-43	Height;
LGG	cis	rs13191362	0.507	rs7772787	chr6:163190981	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.49	7.02	0.31	8.1e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.09	0.31	5.01e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg26396452	chr14:65542826	MAX	-0.38	-7.43	-0.33	5.15e-13	Obesity-related traits;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.96	-0.31	1.21e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg14092571	chr14:90743983	NA	-0.81	-16.51	-0.61	1.79e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs112158604	1	rs112158604	chr1:150696792	TCTTCTGCAG/T	cg13175981	chr1:150552382	MCL1	0.54	9.19	0.39	1.31e-18	Lymphocyte counts;
LGG	cis	rs55883249	1.000	rs57234614	chr2:9756379	T/C	cg23886495	chr2:9695866	ADAM17	0.69	9.81	0.41	8.86e-21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs607541	0.850	rs8036651	chr15:45935024	G/A	cg26924012	chr15:45694286	SPATA5L1	0.53	7.4	0.33	6.58e-13	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.66	0.37	8.19e-17	Personality dimensions;
LGG	cis	rs977987	0.806	rs34021527	chr16:75474090	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.17	0.43	4.78e-22	Dupuytren's disease;
LGG	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg12463550	chr7:65579703	CRCP	-0.46	-7.21	-0.32	2.23e-12	Aortic root size;
LGG	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06470251	chr20:60548479	NA	0.41	7.19	0.32	2.69e-12	Body mass index;
LGG	cis	rs1670533	1.000	rs10084889	chr4:1053815	G/A	cg27284194	chr4:1044797	NA	0.54	9.72	0.41	1.84e-20	Recombination rate (females);
LGG	cis	rs7945705	0.776	rs11042069	chr11:8817315	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	8.57	0.37	1.55e-16	Hemoglobin concentration;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05025164	chr4:1340916	KIAA1530	0.59	10.71	0.45	4.43e-24	Obesity-related traits;
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg02002194	chr4:3960332	NA	0.42	7.7	0.34	8.28e-14	Neuroticism;
LGG	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg01528321	chr10:82214614	TSPAN14	0.67	12.03	0.49	3.41e-29	Post bronchodilator FEV1;
LGG	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg16576597	chr16:28551801	NUPR1	0.43	9.91	0.42	4.08e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg09307838	chr4:120376055	NA	0.64	10.29	0.43	1.66e-22	Corneal astigmatism;
LGG	cis	rs7945718	0.806	rs7480572	chr11:12787048	T/C	cg25843174	chr11:12811716	TEAD1	0.39	8.2	0.36	2.32e-15	Educational attainment (years of education);
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.15	0.32	3.5e-12	Prudent dietary pattern;
LGG	cis	rs9287719	0.967	rs12995159	chr2:10753323	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs6430585	0.583	rs59243420	chr2:136584538	A/T	cg07169764	chr2:136633963	MCM6	1.31	26.5	0.78	7.77e-95	Corneal structure;
LGG	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.0	0.31	9.33e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.18	0.32	2.74e-12	Prudent dietary pattern;
LGG	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg01620082	chr3:125678407	NA	-0.88	-7.46	-0.33	4.3e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9443645	0.901	rs1354831	chr6:79613576	T/C	cg18132916	chr6:79620363	NA	-0.32	-8.79	-0.38	2.85e-17	Intelligence (multi-trait analysis);
LGG	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg26695010	chr11:65641043	EFEMP2	0.47	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg27471124	chr11:109292789	C11orf87	0.48	9.59	0.41	5.27e-20	Schizophrenia;
LGG	cis	rs7799006	0.964	rs3757440	chr7:2272936	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.78	-0.34	4.69e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1062177	0.855	rs62395861	chr5:151269270	A/G	cg00977110	chr5:151150581	G3BP1	0.5	7.87	0.34	2.58e-14	Preschool internalizing problems;
LGG	cis	rs9308731	0.644	rs4627572	chr2:111873378	T/C	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.02	-0.31	7.86e-12	Chronic lymphocytic leukemia;
LGG	trans	rs1941687	0.797	rs9965563	chr18:31398985	T/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.77	-0.38	3.47e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg23758822	chr17:41437982	NA	0.88	16.23	0.6	3.28e-47	Menopause (age at onset);
LGG	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg03929089	chr4:120376271	NA	0.81	11.19	0.46	6.58e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg02023728	chr11:77925099	USP35	0.41	7.5	0.33	3.21e-13	Testicular germ cell tumor;
LGG	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg03576123	chr11:487126	PTDSS2	-0.48	-6.66	-0.3	7.91e-11	Systemic lupus erythematosus;
LGG	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs4356203	0.905	rs635802	chr11:17204793	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg22398616	chr13:53314203	LECT1	0.43	8.9	0.38	1.25e-17	Lewy body disease;
LGG	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg18105134	chr13:113819100	PROZ	0.76	16.46	0.61	2.97e-48	Platelet distribution width;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00292047	chr11:33279899	HIPK3	0.46	7.75	0.34	5.78e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02825527	chr7:2087843	MAD1L1	-0.45	-7.98	-0.35	1.16e-14	Bipolar disorder;
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg19223190	chr17:80058835	NA	0.45	8.74	0.38	4.47e-17	Life satisfaction;
LGG	cis	rs4233802	1.000	rs4577299	chr2:151138798	A/C	cg25300694	chr2:151184358	NA	-0.79	-10.19	-0.43	3.84e-22	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs36051895	0.664	rs3780381	chr9:5114523	A/C	cg02405213	chr9:5042618	JAK2	-0.81	-15.3	-0.58	4.49e-43	Pediatric autoimmune diseases;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25072359	chr17:41440525	NA	0.51	9.6	0.41	5.2e-20	Menopause (age at onset);
LGG	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg22643751	chr7:855365	UNC84A	0.36	6.86	0.3	2.21e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs208520	1.000	rs12216109	chr6:66987488	C/G	cg07460842	chr6:66804631	NA	0.9	14.84	0.57	5.02e-41	Exhaled nitric oxide output;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12110529	chr3:141030588	NA	0.39	6.89	0.3	1.87e-11	Obesity-related traits;
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg21017887	chr14:105400489	NA	0.41	8.21	0.36	2.25e-15	Rheumatoid arthritis;
LGG	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg12292205	chr6:26970375	C6orf41	-0.76	-14.79	-0.57	7.84e-41	Autism spectrum disorder or schizophrenia;
LGG	cis	rs5756391	0.546	rs2899276	chr22:37312173	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	8.54	0.37	1.88e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18721605	chr18:44676421	HDHD2	0.44	7.21	0.32	2.33e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg25937216	chr8:58172855	NA	-0.58	-9.36	-0.4	3.53e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg03452623	chr4:187889614	NA	-1.05	-30.2	-0.81	1.69e-111	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs67133203	0.851	rs11169626	chr12:51342099	A/T	cg14688905	chr12:51403056	SLC11A2	0.7	10.32	0.43	1.27e-22	Urinary tract infection frequency;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	6.76	0.3	4.11e-11	Schizophrenia;
LGG	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg06634786	chr22:41940651	POLR3H	0.79	12.43	0.5	8.24e-31	Vitiligo;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg26513180	chr16:89883248	FANCA	0.93	9.92	0.42	3.64e-21	Interleukin-17 levels;
LGG	cis	rs2742417	0.603	rs2673032	chr3:45756927	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.27	-0.4	7.09e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.25	-0.32	1.77e-12	Skin colour saturation;
LGG	cis	rs741702	0.928	rs116374652	chr19:13014235	T/C	cg23899408	chr19:12877188	HOOK2	-0.48	-7.73	-0.34	6.75e-14	Red blood cell traits;
LGG	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	trans	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg06521331	chr12:34319734	NA	-0.48	-8.44	-0.37	4.03e-16	Bladder cancer;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.27	-0.32	1.57e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.735	rs4886495	chr15:76738959	C/T	cg15268244	chr15:77196840	NA	-0.44	-9.66	-0.41	3.06e-20	Blood metabolite levels;
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.87	-0.34	2.61e-14	Triglycerides;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg07701084	chr6:150067640	NUP43	0.68	12.88	0.51	1.19e-32	Lung cancer;
LGG	cis	rs17491951	0.735	rs13014742	chr2:2886795	A/G	cg02105481	chr2:2853515	NA	-0.43	-8.97	-0.38	7.43e-18	White matter integrity (bipolar disorder risk interaction);
LGG	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg04990556	chr1:26633338	UBXN11	-0.71	-14.53	-0.56	1.09e-39	Obesity-related traits;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06028808	chr11:68637592	NA	0.73	11.92	0.48	9.77e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg11494091	chr17:61959527	GH2	0.6	9.57	0.41	6.61e-20	Height;
LGG	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2694528	0.609	rs1379112	chr5:59995742	C/A	cg11474532	chr5:59995715	DEPDC1B	0.91	9.1	0.39	2.73e-18	Parkinson's disease;
LGG	cis	rs11605275	1.000	rs11605704	chr11:20032096	A/G	cg14835545	chr11:20032148	NAV2	0.96	11.37	0.47	1.33e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs921968	0.541	rs647990	chr2:219441428	T/C	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.05	0.39	3.9e-18	Motion sickness;
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg09263875	chr16:632152	PIGQ	0.67	13.41	0.53	7.18e-35	Height;
LGG	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg02403541	chr12:121454288	C12orf43	0.53	8.68	0.37	7.06e-17	N-glycan levels;
LGG	cis	rs3796352	0.892	rs2581807	chr3:53088844	G/A	cg12962167	chr3:53033115	SFMBT1	-0.7	-7.14	-0.32	3.58e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg18357526	chr6:26021779	HIST1H4A	0.91	17.27	0.63	5.96e-52	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.3	0.32	1.23e-12	Skin colour saturation;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.22	-0.32	2.08e-12	Lung cancer;
LGG	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.54	-0.63	3.39e-53	Refractive error;
LGG	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs17014483	1.000	rs72870517	chr4:89667065	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.65	0.3	8.24e-11	Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.16	-0.32	3.15e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6772849	0.930	rs4857912	chr3:128329224	G/A	cg08795948	chr3:128337044	NA	0.67	11.28	0.46	3.09e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg04450456	chr4:17643702	FAM184B	0.33	7.25	0.32	1.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9863	0.861	rs7961449	chr12:124437215	A/T	cg13487667	chr12:124434373	CCDC92	0.34	6.93	0.31	1.43e-11	White blood cell count;
LGG	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg27129171	chr3:47204927	SETD2	0.57	9.4	0.4	2.43e-19	Birth weight;
LGG	cis	rs2952156	1.000	rs1810132	chr17:37866005	C/T	cg00129232	chr17:37814104	STARD3	-0.67	-13.4	-0.53	8.02e-35	Asthma;
LGG	cis	rs3789045	0.913	rs55678522	chr1:204573481	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-8.5	-0.37	2.57e-16	Educational attainment (college completion);
LGG	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.7	-0.3	6.18e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9341808	0.739	rs4706831	chr6:81007699	T/C	cg08355045	chr6:80787529	NA	0.41	8.16	0.35	3.13e-15	Sitting height ratio;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.67	-0.37	7.22e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9329289	0.510	rs10903785	chr10:2550063	C/T	cg15501526	chr10:2543763	NA	0.49	9.35	0.4	3.78e-19	Age-related hearing impairment;
LGG	cis	rs7659604	1.000	rs28618203	chr4:122663935	T/C	cg20573242	chr4:122745356	CCNA2	0.44	8.25	0.36	1.66e-15	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg11062466	chr8:58055876	NA	0.54	8.78	0.38	3.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11864453	0.682	rs10852509	chr16:72026010	G/A	cg23815491	chr16:72088622	HP	0.37	7.48	0.33	3.89e-13	Fibrinogen levels;
LGG	cis	rs1034435	0.755	rs5768680	chr22:48892919	T/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.74	-0.61	1.49e-49	Late-onset Alzheimer's disease;
LGG	cis	rs10870270	0.912	rs7079991	chr10:133736130	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.84	-0.51	1.72e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs16837677	0.826	rs3795737	chr1:156697056	A/G	cg14991358	chr1:156767203	PRCC	0.73	7.89	0.34	2.21e-14	Sjögren's syndrome;
LGG	cis	rs16867321	0.639	rs13028421	chr2:181444035	G/T	cg23363182	chr2:181467187	NA	0.43	8.6	0.37	1.26e-16	Obesity;
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg24623649	chr8:11872141	NA	-0.3	-7.12	-0.31	4.21e-12	Systolic blood pressure;
LGG	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg21775007	chr8:11205619	TDH	0.48	7.84	0.34	3.1e-14	Mood instability;
LGG	cis	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg04691961	chr3:161091175	C3orf57	0.43	9.02	0.39	5.2e-18	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.647	rs56412380	chr1:153000705	T/C	cg13444842	chr1:152974279	SPRR3	-0.49	-9.94	-0.42	3.18e-21	Inflammatory skin disease;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05165339	chr4:1420672	NA	-0.36	-9.02	-0.39	4.86e-18	Longevity;
LGG	cis	rs11122272	0.735	rs11122280	chr1:231519816	T/C	cg10503236	chr1:231470652	EXOC8	-0.39	-7.47	-0.33	4.16e-13	Hemoglobin concentration;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.21	0.67	6.27e-61	Platelet count;
LGG	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg15704280	chr7:45808275	SEPT13	-0.98	-21.5	-0.71	1.33e-71	Coronary artery disease;
LGG	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg18451016	chr1:38461880	NA	0.48	9.74	0.41	1.59e-20	Coronary artery disease;
LGG	trans	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg02705964	chr17:66097276	LOC651250	-0.47	-8.39	-0.36	5.96e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg23131131	chr22:24373011	LOC391322	-0.49	-7.94	-0.35	1.57e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.15	-0.32	3.34e-12	Blood metabolite levels;
LGG	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg04455712	chr21:45112962	RRP1B	0.53	9.89	0.42	4.83e-21	Mean corpuscular volume;
LGG	cis	rs644799	0.735	rs10831432	chr11:95516040	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.27	0.58	6.14e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.07e-33	Response to antipsychotic treatment;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg06916706	chr16:4465613	CORO7	-0.86	-14.97	-0.57	1.28e-41	Schizophrenia;
LGG	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.13	0.39	2.07e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7666738	0.830	rs13148363	chr4:98847498	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.7	0.34	8.05e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg03929089	chr4:120376271	NA	-0.94	-19.77	-0.68	1.53e-63	Height;
LGG	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg21385522	chr1:16154831	NA	-1.02	-25.55	-0.76	1.76e-90	Dilated cardiomyopathy;
LGG	cis	rs11700980	0.636	rs35497275	chr21:30275022	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-7.71	-0.34	7.83e-14	QRS complex (12-leadsum);
LGG	cis	rs6960043	0.818	rs10950546	chr7:15050391	C/T	cg19272540	chr7:15055459	NA	0.33	7.25	0.32	1.76e-12	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs1776421	0.507	rs6672280	chr1:53901342	A/G	cg10892335	chr1:53966318	NA	0.43	8.09	0.35	5.13e-15	PR interval in Tripanosoma cruzi seropositivity;
LGG	cis	rs4689388	0.609	rs4688988	chr4:6287456	C/T	cg25554036	chr4:6271136	WFS1	0.52	8.56	0.37	1.67e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.03	0.39	4.82e-18	Diabetic retinopathy;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg13880726	chr7:1868755	MAD1L1	0.41	7.27	0.32	1.51e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9534288	0.912	rs9534297	chr13:46624630	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-16.04	-0.6	2.23e-46	Blood protein levels;
LGG	cis	rs67385638	1.000	rs10837697	chr11:5281018	G/C	cg12559170	chr11:5275217	HBG2	0.59	13.63	0.54	8.66e-36	Hemoglobin levels;
LGG	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	9.07	0.39	3.5e-18	Eosinophil percentage of white cells;
LGG	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg16325326	chr1:53192061	ZYG11B	-0.75	-17.97	-0.64	3.7e-55	Monocyte count;
LGG	cis	rs78487399	0.519	rs11124929	chr2:43582103	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-7.68	-0.34	9.24e-14	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs9393777	0.513	rs34388707	chr6:27050396	A/G	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.07	-0.31	5.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs427394	0.582	rs274662	chr5:6704860	G/A	cg15145174	chr5:6755386	POLS	-0.41	-7.65	-0.34	1.15e-13	Menopause (age at onset);
LGG	cis	rs7646881	1.000	rs73015652	chr3:158451383	A/G	cg19483011	chr3:158453295	NA	-0.62	-9.2	-0.39	1.24e-18	Tetralogy of Fallot;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg07701084	chr6:150067640	NUP43	0.7	13.58	0.53	1.3e-35	Lung cancer;
LGG	cis	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg12395012	chr8:11607386	GATA4	-0.41	-7.37	-0.32	8.04e-13	Monocyte count;
LGG	cis	rs1008375	0.966	rs12503517	chr4:17698725	G/A	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg05082376	chr22:42548792	NA	0.36	7.61	0.33	1.5e-13	Schizophrenia;
LGG	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.71	-9.55	-0.41	7.75e-20	Diabetic retinopathy;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg03665457	chr10:38645376	HSD17B7P2	0.44	7.1	0.31	4.66e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.9	0.59	1e-45	Headache;
LGG	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg16096631	chr1:42092165	HIVEP3	0.47	10.99	0.45	4.06e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	trans	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.6	0.44	1.2e-23	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg17718321	chr1:152188247	HRNR	-0.41	-8.59	-0.37	1.34e-16	Inflammatory skin disease;
LGG	trans	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg23762105	chr12:34175262	ALG10	0.34	6.85	0.3	2.43e-11	Morning vs. evening chronotype;
LGG	cis	rs4293296	0.830	rs1955463	chr14:54854386	C/G	cg11186706	chr14:54815745	NA	0.42	6.71	0.3	5.85e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.97	-14.91	-0.57	2.39e-41	Chronic sinus infection;
LGG	cis	rs9487094	0.553	rs11968891	chr6:109869850	C/T	cg16315928	chr6:109776240	MICAL1	0.49	7.58	0.33	1.94e-13	Height;
LGG	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg21058520	chr6:100914733	NA	0.43	7.48	0.33	3.64e-13	Neuroticism;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg15704280	chr7:45808275	SEPT13	0.74	8.69	0.37	6.53e-17	Intraocular pressure;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	21.2	0.7	3.26e-70	Platelet count;
LGG	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.98	-0.31	1.02e-11	Neuroticism;
LGG	cis	rs6504108	0.624	rs4793779	chr17:46306597	G/A	cg02219949	chr17:45927392	SP6	0.43	7.97	0.35	1.23e-14	Body mass index;
LGG	cis	rs4330281	0.647	rs7632240	chr3:17711352	C/A	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg11366901	chr6:160182831	ACAT2	1.0	15.27	0.58	6.14e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg06115741	chr20:33292138	TP53INP2	0.6	9.92	0.42	3.82e-21	Coronary artery disease;
LGG	trans	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg12575136	chr18:32820987	ZNF397	0.47	8.63	0.37	9.58e-17	White blood cell count;
LGG	trans	rs3960554	0.696	rs10952869	chr7:75846453	A/G	cg19862616	chr7:65841803	NCRNA00174	0.86	13.92	0.54	4.69e-37	Eotaxin levels;
LGG	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-10.91	-0.45	7.79e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.76e-31	Motion sickness;
LGG	cis	rs883565	0.568	rs4381879	chr3:39028460	G/C	cg01426195	chr3:39028469	NA	-0.78	-18.52	-0.65	1.1e-57	Handedness;
LGG	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	8.61	0.37	1.14e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7572733	0.840	rs700653	chr2:198637433	A/G	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs2070488	0.775	rs6794397	chr3:38559307	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.6	0.56	5.64e-40	Electrocardiographic conduction measures;
LGG	cis	rs11690935	0.632	rs34531723	chr2:172564094	A/C	cg13550731	chr2:172543902	DYNC1I2	0.71	14.66	0.56	3e-40	Schizophrenia;
LGG	cis	rs600550	0.588	rs12225299	chr11:60084465	C/T	cg05040360	chr11:60102449	MS4A6E	-0.35	-7.57	-0.33	2.01e-13	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.68	-0.41	2.73e-20	Morning vs. evening chronotype;
LGG	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.9	-0.31	1.75e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02717437	chr18:14132207	ZNF519	-0.5	-7.3	-0.32	1.23e-12	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.24	-0.43	2.64e-22	Bipolar disorder;
LGG	trans	rs36715	0.904	rs36701	chr5:127552529	C/T	cg16011800	chr17:1958478	HIC1	-0.48	-7.13	-0.31	3.93e-12	Breast cancer;
LGG	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.76	0.3	4.27e-11	Bone mineral density;
LGG	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14019695	chr9:139328340	INPP5E	0.42	7.48	0.33	3.75e-13	Monocyte percentage of white cells;
LGG	trans	rs61931739	0.649	rs708139	chr12:33733265	C/A	cg13010199	chr12:38710504	ALG10B	0.36	6.67	0.3	7.36e-11	Morning vs. evening chronotype;
LGG	cis	rs1018836	0.923	rs9693182	chr8:91621876	T/C	cg16814680	chr8:91681699	NA	-0.85	-16.02	-0.6	2.81e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9398803	0.865	rs9372839	chr6:126809870	G/A	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg22044901	chr15:68126292	NA	-0.42	-7.27	-0.32	1.58e-12	Obesity;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-7.69	-0.34	8.95e-14	Life satisfaction;
LGG	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg13010199	chr12:38710504	ALG10B	0.47	9.34	0.4	4.05e-19	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00166722	chr3:10149974	C3orf24	0.57	8.13	0.35	3.95e-15	Alzheimer's disease;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.45	-0.37	3.88e-16	Obesity-related traits;
LGG	cis	rs2050392	1.000	rs7077496	chr10:30692028	G/A	cg25182066	chr10:30743637	MAP3K8	0.5	10.35	0.43	1.01e-22	Inflammatory bowel disease;
LGG	cis	rs12586317	0.534	rs2273157	chr14:35438836	A/G	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.25	-0.43	2.4e-22	Psoriasis;
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs12681287	0.546	rs11539113	chr8:87497176	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.61	-0.33	1.55e-13	Caudate activity during reward;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs6956675	0.874	rs6968344	chr7:62574533	A/G	cg01314568	chr7:57830625	NA	-0.51	-8.02	-0.35	8.71e-15	Obesity-related traits;
LGG	cis	rs12765878	1.000	rs10883943	chr10:105651416	G/T	cg11005552	chr10:105648138	OBFC1	1.02	27.04	0.78	2.56e-97	Coronary artery disease;
LGG	cis	rs317689	0.658	rs490872	chr12:69645864	A/G	cg20891283	chr12:69753455	YEATS4	0.45	6.83	0.3	2.63e-11	Response to diuretic therapy;
LGG	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg24634471	chr8:143751801	JRK	0.5	7.63	0.33	1.38e-13	Schizophrenia;
LGG	cis	rs16976116	0.901	rs28449712	chr15:55500681	A/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg15596359	chr8:11213517	TDH	0.42	8.56	0.37	1.74e-16	Retinal vascular caliber;
LGG	trans	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg18187862	chr3:45730750	SACM1L	-0.42	-6.9	-0.31	1.7e-11	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg23782820	chr8:58130467	NA	0.44	7.0	0.31	9.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs42648	0.518	rs12535435	chr7:89830817	G/A	cg25739043	chr7:89950458	NA	-0.33	-6.71	-0.3	5.66e-11	Homocysteine levels;
LGG	cis	rs4604732	0.578	rs7525209	chr1:247627404	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.29e-39	Tonsillectomy;
LGG	trans	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg06521331	chr12:34319734	NA	-0.52	-9.04	-0.39	4.43e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg24375607	chr4:120327624	NA	0.62	10.25	0.43	2.44e-22	Corneal astigmatism;
LGG	cis	rs4919694	1.000	rs76255497	chr10:104651955	T/C	cg04362960	chr10:104952993	NT5C2	1.09	14.99	0.57	1.08e-41	Arsenic metabolism;
LGG	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg06360820	chr2:242988706	NA	-0.98	-12.89	-0.51	1.09e-32	Obesity-related traits;
LGG	cis	rs17767392	1.000	rs35621718	chr14:71780758	C/G	cg02058870	chr14:72053146	SIPA1L1	0.47	9.52	0.4	9.68e-20	Mitral valve prolapse;
LGG	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg15665833	chr6:26285013	NA	0.37	6.9	0.31	1.73e-11	Educational attainment;
LGG	trans	rs941408	1.000	rs1736182	chr19:2798686	T/G	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.54	-0.44	1.99e-23	Total cholesterol levels;
LGG	cis	rs11098499	0.754	rs1980025	chr4:120252806	A/G	cg24375607	chr4:120327624	NA	-0.62	-10.63	-0.44	9.59e-24	Corneal astigmatism;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.45	0.33	4.51e-13	Schizophrenia;
LGG	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg24692254	chr21:30365293	RNF160	0.65	11.86	0.48	1.62e-28	Pancreatic cancer;
LGG	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg14042143	chr7:2646782	IQCE	-0.8	-12.48	-0.5	5.1e-31	Urate levels in lean individuals;
LGG	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6735179	0.603	rs736868	chr2:1748429	T/C	cg08534653	chr2:1747700	PXDN	0.49	7.44	0.33	5.03e-13	Response to antipsychotic treatment;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg21724239	chr8:58056113	NA	0.44	6.7	0.3	6.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6032067	0.759	rs2868239	chr20:43873368	T/G	cg10761708	chr20:43804764	PI3	0.58	8.98	0.39	6.86e-18	Blood protein levels;
LGG	trans	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg16141378	chr3:129829833	LOC729375	0.45	10.6	0.44	1.18e-23	Mood instability;
LGG	cis	rs7582720	1.000	rs72934519	chr2:203939640	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.44	0.4	1.82e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs208520	0.874	rs208469	chr6:66915891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.37	-0.58	2.23e-43	Exhaled nitric oxide output;
LGG	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg16141378	chr3:129829833	LOC729375	0.32	7.16	0.32	3.14e-12	Monocyte count;
LGG	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06156847	chr2:113672199	IL1F7	-0.36	-7.32	-0.32	1.11e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.02	-0.42	1.58e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	1.000	rs6804242	chr3:183659463	A/T	cg01324343	chr3:183735012	ABCC5	0.87	18.59	0.65	4.98e-58	Anterior chamber depth;
LGG	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs2735413	0.750	rs67126435	chr16:78066437	C/T	cg04733911	chr16:78082701	NA	0.62	9.94	0.42	3.21e-21	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg18876405	chr7:65276391	NA	0.55	9.98	0.42	2.3e-21	Aortic root size;
LGG	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg10523679	chr1:76189770	ACADM	-0.71	-11.16	-0.46	8.58e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs782590	0.582	rs2627767	chr2:55926815	A/T	cg18811423	chr2:55921094	PNPT1	0.87	19.38	0.67	1.02e-61	Metabolic syndrome;
LGG	cis	rs17767392	0.829	rs56363446	chr14:71761577	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg15103426	chr22:29168792	CCDC117	0.57	8.63	0.37	9.96e-17	Lymphocyte counts;
LGG	trans	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg21659725	chr3:3221576	CRBN	0.54	8.23	0.36	1.88e-15	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg26384229	chr12:38710491	ALG10B	0.79	15.22	0.58	1.09e-42	Morning vs. evening chronotype;
LGG	cis	rs2073300	0.609	rs6137907	chr20:23344511	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11105306	1	rs11105306	chr12:89897388	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.58	0.41	6.15e-20	NT-proBNP levels in acute coronary syndrome;
LGG	cis	rs7000551	0.725	rs7430	chr8:22398414	C/G	cg12081754	chr8:22256438	SLC39A14	0.65	12.31	0.5	2.61e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.78	-0.34	4.8e-14	Testicular germ cell tumor;
LGG	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg01200585	chr1:228362443	C1orf69	-0.45	-7.89	-0.34	2.22e-14	Diastolic blood pressure;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg03528353	chr17:61819722	STRADA	0.47	7.9	0.34	2.01e-14	Prudent dietary pattern;
LGG	cis	rs911263	0.961	rs1950897	chr14:68760141	C/T	cg18825221	chr14:68749962	RAD51L1	0.52	11.11	0.46	1.44e-25	Primary biliary cholangitis;
LGG	cis	rs4900538	0.892	rs4906208	chr14:102956489	G/C	cg18135206	chr14:102964638	TECPR2	0.83	16.25	0.6	2.5e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9788721	0.802	rs56219465	chr15:78742579	A/G	cg18825076	chr15:78729989	IREB2	-0.57	-9.55	-0.41	7.8e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg23202291	chr11:1979235	NA	0.41	7.76	0.34	5.42e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg02475777	chr4:1388615	CRIPAK	-0.48	-8.82	-0.38	2.35e-17	Obesity-related traits;
LGG	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg00990874	chr7:1149470	C7orf50	-0.68	-10.96	-0.45	5.27e-25	Bronchopulmonary dysplasia;
LGG	cis	rs2066819	1.000	rs74496027	chr12:56726340	C/T	cg26714650	chr12:56694279	CS	-1.59	-16.49	-0.61	2.05e-48	Psoriasis vulgaris;
LGG	trans	rs2270927	0.510	rs2937749	chr5:75571564	T/G	cg13563193	chr19:33072644	PDCD5	0.82	9.22	0.39	1.03e-18	Mean corpuscular volume;
LGG	cis	rs975722	0.671	rs43027	chr7:117105361	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	9.32	0.4	4.75e-19	Coronary artery disease;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg11301795	chr4:187892539	NA	0.94	24.69	0.75	1.61e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7781557	0.591	rs56314487	chr7:102535721	G/T	cg18108683	chr7:102477205	FBXL13	-0.55	-8.14	-0.35	3.76e-15	Colorectal adenoma (advanced);
LGG	cis	rs11608355	0.545	rs12819658	chr12:109907670	A/T	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	trans	rs35110281	0.607	rs4819212	chr21:44977455	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.15	0.49	1.12e-29	Mean corpuscular volume;
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg00166722	chr3:10149974	C3orf24	0.53	8.92	0.38	1.13e-17	Alzheimer's disease;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.79e-31	Lymphocyte counts;
LGG	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3540	0.513	rs2601181	chr15:90924702	C/T	cg22089800	chr15:90895588	ZNF774	0.73	13.55	0.53	1.81e-35	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04828509	chr7:98923380	ARPC1A	-0.43	-7.06	-0.31	6.21e-12	Pancreatic cancer;
LGG	trans	rs6601327	0.635	rs7821575	chr8:9665955	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.64	0.33	1.28e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg12292205	chr6:26970375	C6orf41	-0.41	-7.08	-0.31	5.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-14.19	-0.55	3.39e-38	Colorectal cancer;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.45e-21	Intelligence (multi-trait analysis);
LGG	cis	rs896854	0.936	rs10108430	chr8:95961794	C/T	cg16049864	chr8:95962084	TP53INP1	-0.41	-8.92	-0.38	1.13e-17	Type 2 diabetes;
LGG	cis	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.37	0.32	8.14e-13	Morning vs. evening chronotype;
LGG	cis	rs1010254	0.510	rs1035401	chr5:151709678	T/C	cg12297329	chr5:152029980	NA	-0.47	-6.89	-0.3	1.82e-11	Optic nerve measurement (cup area);
LGG	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.79	0.3	3.49e-11	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25179291	chr9:132805739	FNBP1	0.45	6.99	0.31	9.42e-12	Gut microbiome composition (summer);
LGG	cis	rs6450176	1.000	rs5024170	chr5:53300827	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.72	-0.34	7.46e-14	Systemic lupus erythematosus;
LGG	cis	rs9788682	1.000	rs57064725	chr15:78833036	C/A	cg24631222	chr15:78858424	CHRNA5	0.45	6.83	0.3	2.7e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg14952266	chr13:112191215	NA	0.41	8.11	0.35	4.55e-15	Hepatitis;
LGG	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg14186256	chr22:23484241	RTDR1	0.51	7.91	0.34	1.94e-14	Serum parathyroid hormone levels;
LGG	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.58	-0.41	6.17e-20	Retinal vascular caliber;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg23782820	chr8:58130467	NA	0.51	7.09	0.31	5.09e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1534166	0.540	rs56245543	chr3:133516364	T/C	cg27366882	chr3:133540807	NA	-0.44	-6.76	-0.3	4.3e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs372883	0.901	rs407463	chr21:30722440	G/A	cg24692254	chr21:30365293	RNF160	-0.45	-7.87	-0.34	2.62e-14	Pancreatic cancer;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg18000306	chr6:288505	NA	0.49	9.1	0.39	2.67e-18	Menopause (age at onset);
LGG	cis	rs67385638	1.000	rs2855036	chr11:5272682	C/T	cg12559170	chr11:5275217	HBG2	0.58	13.38	0.53	9.41e-35	Hemoglobin levels;
LGG	cis	rs11771526	0.901	rs10223907	chr7:32297813	G/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg06046430	chr4:77819534	ANKRD56	0.54	11.05	0.46	2.37e-25	Emphysema distribution in smoking;
LGG	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg05338066	chr1:7812865	CAMTA1	0.47	7.28	0.32	1.47e-12	Inflammatory bowel disease;
LGG	cis	rs3925075	0.764	rs8044482	chr16:31345752	T/C	cg02846316	chr16:31340340	ITGAM	0.4	7.96	0.35	1.34e-14	IgA nephropathy;
LGG	cis	rs7666738	0.830	rs34212748	chr4:99068708	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs225245	0.610	rs321607	chr17:33880584	A/G	cg19694781	chr19:47549865	TMEM160	-0.48	-8.35	-0.36	7.88e-16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg13939156	chr17:80058883	NA	-0.46	-9.01	-0.39	5.4e-18	Life satisfaction;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg01493318	chr18:8705700	NA	-0.38	-6.75	-0.3	4.34e-11	Iris color (L* coordinate);
LGG	cis	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	7.94	0.35	1.51e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.57	10.79	0.45	2.33e-24	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2916247	0.954	rs28625919	chr8:93030325	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.49	-0.37	2.93e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2562456	0.917	rs2562466	chr19:21714204	C/T	cg00806126	chr19:22604979	ZNF98	0.64	9.53	0.4	9.2e-20	Pain;
LGG	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg18709589	chr6:96969512	KIAA0776	0.41	8.18	0.36	2.84e-15	Headache;
LGG	cis	rs12348691	0.503	rs7048394	chr9:100605433	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.18	-0.6	5.35e-47	Alopecia areata;
LGG	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg24253500	chr15:84953950	NA	0.58	10.41	0.44	5.96e-23	Schizophrenia;
LGG	cis	rs8056893	0.775	rs6499172	chr16:68376570	A/G	cg07273125	chr16:68295692	NA	0.36	6.86	0.3	2.24e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg05425664	chr17:57184151	TRIM37	0.71	11.5	0.47	4.16e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06915872	chr16:87998081	BANP	0.46	6.89	0.31	1.81e-11	Menopause (age at onset);
LGG	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg06917634	chr15:78832804	PSMA4	0.82	17.09	0.62	3.96e-51	Sudden cardiac arrest;
LGG	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	14.43	0.56	3.12e-39	Total body bone mineral density;
LGG	cis	rs965513	1.000	rs965513	chr9:100556109	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.88	-0.42	5.17e-21	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs6540556	0.723	rs6540550	chr1:209925251	A/G	cg23920097	chr1:209922102	NA	-0.49	-8.8	-0.38	2.8e-17	Red blood cell count;
LGG	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-7.03	-0.31	7.67e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.77	0.38	3.34e-17	Mood instability;
LGG	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	17.16	0.62	1.91e-51	Chronic sinus infection;
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg13009111	chr11:71350975	NA	-0.31	-6.84	-0.3	2.46e-11	Neuroticism;
LGG	cis	rs2708240	0.905	rs2538984	chr7:147581460	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.84	-0.3	2.48e-11	QT interval (drug interaction);
LGG	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg03254818	chr6:169586852	NA	-0.52	-7.95	-0.35	1.43e-14	Pulse pressure;
LGG	cis	rs10895140	0.756	rs2155000	chr11:101517503	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.05	-0.31	6.67e-12	Menarche (age at onset);
LGG	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg04490037	chr7:50633773	DDC	0.31	6.95	0.31	1.28e-11	Systemic sclerosis;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.07	0.55	1.06e-37	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	4.17e-44	Lung cancer;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	11.16	0.46	9.31e-26	Longevity;
LGG	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg21827317	chr3:136751795	NA	0.53	9.91	0.42	4.09e-21	Neuroticism;
LGG	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg06532163	chr17:45867833	NA	0.54	9.05	0.39	3.94e-18	IgG glycosylation;
LGG	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.09	0.57	3.98e-42	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg02002194	chr4:3960332	NA	0.43	8.33	0.36	9.55e-16	Mood instability;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg21775007	chr8:11205619	TDH	-0.41	-6.67	-0.3	7.28e-11	Joint mobility (Beighton score);
LGG	cis	rs1819436	1	rs1819436	chr13:78580283	T/C	cg07847733	chr13:78271382	SLAIN1	0.66	8.34	0.36	8.52e-16	Birth weight;
LGG	cis	rs4924935	0.887	rs2428380	chr17:18843089	C/A	cg26378065	chr17:18585709	ZNF286B	-0.46	-7.11	-0.31	4.4e-12	Pancreatic cancer;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg20309703	chr11:118481025	PHLDB1	0.56	10.45	0.44	4.24e-23	Cholesterol, total;
LGG	cis	rs738321	0.757	rs4820315	chr22:38518731	C/T	cg25457927	chr22:38595422	NA	-0.41	-9.62	-0.41	4.2e-20	Breast cancer;
LGG	trans	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg02800362	chr5:177631904	HNRNPAB	0.96	11.94	0.49	7.78e-29	Obesity-related traits;
LGG	cis	rs28830936	0.966	rs28451764	chr15:42126583	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.28	-0.53	2.44e-34	Diastolic blood pressure;
LGG	cis	rs988958	0.526	rs13424159	chr2:42239495	A/G	cg27252766	chr2:42229092	NA	0.47	6.72	0.3	5.28e-11	Hypospadias;
LGG	cis	rs4481887	0.927	rs9651176	chr1:248447343	A/G	cg13385794	chr1:248469461	NA	0.46	7.87	0.34	2.56e-14	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21613905	chr4:26585903	TBC1D19	0.44	6.69	0.3	6.36e-11	Gut microbiome composition (summer);
LGG	cis	rs763121	0.785	rs6001203	chr22:39099602	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.69	0.3	6.38e-11	Menopause (age at onset);
LGG	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs8054556	0.647	rs4787488	chr16:29995803	G/T	cg06326092	chr16:30034487	C16orf92	-0.35	-7.07	-0.31	5.77e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	cis	rs7077256	0.526	rs35386465	chr10:65274839	G/A	cg02276361	chr10:65351566	REEP3	-0.33	-6.78	-0.3	3.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7633787	0.571	rs9877498	chr3:23140670	C/A	cg00327796	chr3:23032191	NA	-0.39	-7.28	-0.32	1.43e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs8064299	0.597	rs6501736	chr17:72775358	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.98	22.78	0.73	1.3e-77	Monocyte count;
LGG	cis	rs6665290	0.669	rs7552783	chr1:227174145	T/C	cg05696931	chr1:227175867	NA	-0.41	-8.32	-0.36	1.02e-15	Myeloid white cell count;
LGG	cis	rs2188554	0.570	rs17451754	chr7:117256712	G/A	cg10524701	chr7:117356490	CTTNBP2	0.48	6.91	0.31	1.59e-11	Esophageal adenocarcinoma;
LGG	cis	rs8008758	1.000	rs12432879	chr14:101688977	A/G	cg26224664	chr14:101693935	NA	0.56	9.59	0.41	5.45e-20	Body mass index (alcohol intake interaction);
LGG	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-7.21	-0.32	2.32e-12	Subjective well-being;
LGG	cis	rs988958	0.567	rs13005448	chr2:42267903	A/C	cg19376973	chr2:42229025	NA	0.59	9.58	0.41	5.95e-20	Hypospadias;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13012494	chr21:47604986	C21orf56	-0.63	-10.46	-0.44	4.03e-23	Testicular germ cell tumor;
LGG	cis	rs11122272	0.735	rs2256908	chr1:231506557	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs4849975	0.510	rs13432750	chr2:3708503	G/A	cg20720597	chr2:3699334	NA	0.55	7.09	0.31	4.94e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg14092988	chr3:52407081	DNAH1	0.25	6.87	0.3	2.09e-11	Bipolar disorder;
LGG	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg07777115	chr5:623756	CEP72	-0.55	-6.85	-0.3	2.33e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.83	-0.42	7.51e-21	Retinal vascular caliber;
LGG	cis	rs9916302	0.808	rs6503515	chr17:37606433	G/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.24	-0.46	4.21e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg14675211	chr2:100938903	LONRF2	0.66	11.69	0.48	7.7e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg20813462	chr7:2646259	IQCE	-0.54	-7.0	-0.31	8.85e-12	Urate levels in lean individuals;
LGG	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg16850897	chr7:100343110	ZAN	0.44	7.0	0.31	8.86e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg02002194	chr4:3960332	NA	0.4	7.05	0.31	6.43e-12	Neuroticism;
LGG	cis	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg16876255	chr19:9731953	ZNF561	0.76	7.13	0.31	3.92e-12	Pursuit maintenance gain;
LGG	cis	rs8016982	0.531	rs2241622	chr14:81737290	A/G	cg01989461	chr14:81687754	GTF2A1	0.5	7.52	0.33	2.87e-13	Schizophrenia;
LGG	cis	rs6754311	0.550	rs12994270	chr2:136518103	T/A	cg07169764	chr2:136633963	MCM6	-0.78	-13.63	-0.54	8.6e-36	Mosquito bite size;
LGG	cis	rs4713675	0.565	rs9368773	chr6:33682541	C/A	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.63e-11	Plateletcrit;
LGG	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg14926445	chr8:58193284	C8orf71	-0.53	-7.47	-0.33	4.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.27	-0.43	2e-22	Longevity;Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07900786	chr7:45151525	TBRG4	-0.52	-7.69	-0.34	8.68e-14	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs638893	0.578	rs4508234	chr11:118662203	G/C	cg22253036	chr11:118662786	DDX6	0.49	7.35	0.32	8.79e-13	Vitiligo;
LGG	cis	rs7113850	0.541	rs80243979	chr11:24231811	A/C	ch.11.24196551F	chr11:24239977	NA	0.89	10.14	0.43	5.8e-22	Bone fracture in osteoporosis;
LGG	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg19812747	chr11:111475976	SIK2	-0.5	-10.67	-0.44	6.37e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg12437481	chr16:420112	MRPL28	-0.56	-8.65	-0.37	8.76e-17	Body mass index;
LGG	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.41	0.33	5.85e-13	Refractive error;
LGG	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-10.09	-0.42	9.31e-22	Vitiligo;
LGG	trans	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg21659725	chr3:3221576	CRBN	0.66	12.43	0.5	8.47e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.26	0.32	1.6e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg25174290	chr11:3078921	CARS	0.75	16.2	0.6	4.25e-47	Longevity;
LGG	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs6450176	0.625	rs56193151	chr5:53287790	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-13.38	-0.53	9.59e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg09307838	chr4:120376055	NA	0.5	8.22	0.36	2.03e-15	Diastolic blood pressure;
LGG	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06915872	chr16:87998081	BANP	0.47	7.06	0.31	6.32e-12	Menopause (age at onset);
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg12070911	chr6:150209640	RAET1E	0.33	8.15	0.35	3.4e-15	Lung cancer;
LGG	cis	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg14019146	chr3:50243930	SLC38A3	-0.34	-7.13	-0.31	3.97e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08280861	chr8:58055591	NA	0.6	7.74	0.34	6.13e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.68	-9.74	-0.41	1.61e-20	Schizophrenia;
LGG	cis	rs4664308	1.000	rs925410	chr2:160912652	C/T	cg03641300	chr2:160917029	PLA2R1	0.85	17.64	0.63	1.22e-53	Idiopathic membranous nephropathy;
LGG	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21659725	chr3:3221576	CRBN	0.57	9.7	0.41	2.3e-20	Body mass index;
LGG	cis	rs4690686	0.500	rs2168032	chr4:177272957	A/G	cg17059388	chr4:177262070	NA	1.03	24.29	0.75	1.2e-84	Essential tremor;
LGG	cis	rs4665809	0.590	rs72809668	chr2:26467653	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg12486710	chr1:178512616	C1orf220	-0.5	-10.55	-0.44	1.8e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs757278	0.591	rs34331324	chr7:117300188	A/C	cg10524701	chr7:117356490	CTTNBP2	0.41	7.33	0.32	1.04e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg24375607	chr4:120327624	NA	0.65	10.52	0.44	2.39e-23	Corneal astigmatism;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.59	-0.33	1.84e-13	Monocyte count;
LGG	cis	rs4253772	0.744	rs9627278	chr22:46643432	C/G	cg24881330	chr22:46731750	TRMU	0.55	7.01	0.31	8.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7428	1.000	rs7428	chr2:85545490	C/T	cg24342717	chr2:85555507	TGOLN2	0.46	7.27	0.32	1.58e-12	Ear protrusion;
LGG	cis	rs1863824	0.625	rs7091192	chr10:88167456	A/G	cg07322936	chr10:88137208	NA	-0.51	-8.37	-0.36	7.13e-16	Schizophrenia;
LGG	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg00701064	chr4:6280414	WFS1	0.62	12.26	0.5	3.9e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs1728785	1.000	rs1615609	chr16:68596401	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs240764	0.717	rs10872622	chr6:101165017	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.54	-0.33	2.57e-13	Neuroticism;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg02018176	chr4:1364513	KIAA1530	0.47	11.38	0.47	1.27e-26	Longevity;
LGG	cis	rs35306767	0.855	rs12761180	chr10:872086	C/T	cg25019033	chr10:957182	NA	-0.53	-9.13	-0.39	2.07e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.84e-12	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.16	0.35	3.14e-15	Diabetic kidney disease;
LGG	cis	rs7617773	0.539	rs11130165	chr3:48384721	G/T	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs2302729	0.578	rs7315556	chr12:2773855	G/A	cg19945202	chr12:2788847	CACNA1C	-0.74	-12.83	-0.51	1.8e-32	Sleep quality;
LGG	trans	rs629535	0.862	rs654604	chr8:70048939	C/A	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg00149659	chr3:10157352	C3orf10	0.57	8.2	0.36	2.45e-15	Alzheimer's disease;
LGG	cis	rs3126085	0.935	rs11204980	chr1:152296191	G/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.1	-0.35	4.76e-15	Atopic dermatitis;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg15665833	chr6:26285013	NA	0.41	7.79	0.34	4.43e-14	Educational attainment;
LGG	cis	rs798766	0.830	rs8389	chr4:1746844	A/T	cg00006948	chr4:1768889	NA	-0.48	-6.69	-0.3	6.56e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg27476859	chr7:2772710	GNA12	0.43	7.39	0.32	7.03e-13	Height;
LGG	cis	rs1408799	0.732	rs7036011	chr9:12757959	A/G	cg05274944	chr9:12693694	TYRP1	0.34	8.15	0.35	3.52e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs67478160	0.571	rs1155751	chr14:104286547	C/G	cg26031613	chr14:104095156	KLC1	-0.46	-7.55	-0.33	2.4e-13	Schizophrenia;
LGG	cis	rs6547741	0.775	rs11692692	chr2:27861707	G/A	cg22903471	chr2:27725779	GCKR	-0.38	-8.38	-0.36	6.3e-16	Oral cavity cancer;
LGG	cis	rs3789045	0.560	rs2271424	chr1:204403311	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.58	-11.12	-0.46	1.24e-25	Educational attainment (college completion);
LGG	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.86	-0.34	2.77e-14	Body mass index;
LGG	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg03758011	chr19:46294482	DMWD	-0.36	-6.67	-0.3	7.13e-11	Coronary artery disease;
LGG	cis	rs12615966	1.000	rs6744707	chr2:105371087	G/A	cg16465502	chr2:105461796	NA	0.89	10.59	0.44	1.28e-23	Pancreatic cancer;
LGG	trans	rs11088226	0.692	rs28709516	chr21:33890366	G/A	cg09050820	chr6:167586206	TCP10L2	0.48	7.47	0.33	4.15e-13	Gastritis;
LGG	cis	rs17767392	1.000	rs34674149	chr14:71777093	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.34e-18	Mitral valve prolapse;
LGG	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.92	0.42	3.82e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-9.63	-0.41	3.86e-20	Schizophrenia;
LGG	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-9.77	-0.41	1.25e-20	Motion sickness;
LGG	cis	rs2635047	0.542	rs2668768	chr18:44783447	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.12	0.35	4.3e-15	Educational attainment;
LGG	cis	rs12135191	0.967	rs962486	chr1:236472163	G/A	cg21399712	chr1:236511386	NA	-0.4	-7.72	-0.34	7.33e-14	Urate levels (BMI interaction);
LGG	cis	rs892961	0.867	rs312909	chr17:75413954	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.26	0.43	2.09e-22	Airflow obstruction;
LGG	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.42	-0.58	1.3e-43	Chronic sinus infection;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.93e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.49	-0.33	3.44e-13	Colorectal cancer;
LGG	cis	rs7659604	0.643	rs6839054	chr4:122663628	C/T	cg19748678	chr4:122722346	EXOSC9	0.46	8.06	0.35	6.78e-15	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg00800038	chr16:89945340	TCF25	0.55	7.85	0.34	2.96e-14	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.52	0.37	2.21e-16	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg04287289	chr16:89883240	FANCA	0.86	8.46	0.37	3.53e-16	Skin colour saturation;
LGG	cis	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg09307838	chr4:120376055	NA	0.72	12.43	0.5	8.46e-31	Corneal astigmatism;
LGG	trans	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg20587970	chr11:113659929	NA	-0.75	-12.07	-0.49	2.42e-29	Height;
LGG	cis	rs7551222	0.634	rs11801289	chr1:204528969	G/C	cg20240347	chr1:204465584	NA	-0.56	-10.99	-0.45	3.99e-25	Schizophrenia;
LGG	cis	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg00405596	chr8:11794950	NA	-0.61	-10.72	-0.45	4.28e-24	Monocyte count;
LGG	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.35e-32	Uric acid levels;
LGG	cis	rs6963495	0.818	rs117028299	chr7:105162310	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00510787	chr6:151772946	C6orf211;RMND1	0.45	7.53	0.33	2.67e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.74	0.38	4.41e-17	Alzheimer's disease;
LGG	cis	rs8017423	0.967	rs6575120	chr14:90725094	C/T	cg04374321	chr14:90722782	PSMC1	0.91	19.82	0.68	9.85e-64	Mortality in heart failure;
LGG	trans	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg21659725	chr3:3221576	CRBN	0.62	11.69	0.48	7.57e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1800562	1	rs1800562	chr6:26093141	C/T	cg16482183	chr6:26056742	HIST1H1C	1.0	7.59	0.33	1.76e-13	Hematocrit;Iron status biomarkers (transferrin levels);Diastolic blood pressure;Hemoglobin;Red blood cell count;Cholesterol, total;Hematology traits;Alcohol consumption (transferrin glycosylation);Iron status biomarkers (ferritin levels);LDL cholesterol;Iron status biomarkers;Mean corpuscular hemoglobin;Iron status biomarkers (transferrin saturation);Mean corpuscular volume;Iron status biomarkers (iron levels);Red blood cell traits;Iron status biomarkers (total iron binding capacity);Glycated hemoglobin levels;Hematological parameters;Hepcidin levels;Cardiovascular disease risk factors;
LGG	cis	rs300703	0.935	rs4241316	chr2:252197	A/G	cg21211680	chr2:198530	NA	-1.25	-15.85	-0.59	1.7e-45	Blood protein levels;
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-8.33	-0.36	9.56e-16	Personality dimensions;
LGG	trans	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg23484912	chr5:273055	PDCD6	-0.4	-7.84	-0.34	3.23e-14	Mean corpuscular volume;
LGG	cis	rs1904096	0.506	rs10034781	chr4:95169682	A/C	cg11021082	chr4:95130006	SMARCAD1	0.6	11.45	0.47	6.6e-27	Type 2 diabetes;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg05861140	chr6:150128134	PCMT1	-0.45	-10.19	-0.43	3.97e-22	Lung cancer;
LGG	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg24642439	chr20:33292090	TP53INP2	0.51	8.32	0.36	9.88e-16	Height;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg01988459	chr11:68622903	NA	-0.62	-12.57	-0.5	2.17e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	cis	rs2072732	0.904	rs12044831	chr1:2964397	A/C	cg08733933	chr1:2954429	NA	-0.46	-8.87	-0.38	1.65e-17	Plateletcrit;
LGG	trans	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs61989804	0.826	rs4899171	chr14:65721641	G/A	cg15999311	chr14:65749247	NA	0.65	6.97	0.31	1.06e-11	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03625951	chr6:149867442	PPIL4	0.46	6.96	0.31	1.14e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg07005078	chr4:17578674	LAP3	0.38	6.96	0.31	1.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	6.89	0.31	1.79e-11	Resting heart rate;
LGG	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.53	0.44	2.22e-23	Height;
LGG	cis	rs8017423	0.967	rs12889636	chr14:90689953	A/C	cg04374321	chr14:90722782	PSMC1	-0.91	-18.84	-0.66	3.37e-59	Mortality in heart failure;
LGG	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg03563238	chr19:33554763	RHPN2	-0.45	-10.59	-0.44	1.35e-23	Bone properties (heel);
LGG	cis	rs5769765	0.837	rs4824110	chr22:50271631	T/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs6784615	0.744	rs4687621	chr3:52524974	A/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.53	-0.33	2.76e-13	Waist-hip ratio;
LGG	cis	rs424971	0.688	rs7185022	chr16:85952929	G/T	cg10334323	chr16:85945517	IRF8	0.33	6.71	0.3	5.7e-11	Monocyte count;
LGG	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.17	-0.35	3.02e-15	Retinal vascular caliber;
LGG	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-11.21	-0.46	5.49e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg02493740	chr2:85810744	VAMP5	-0.39	-7.16	-0.32	3.28e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg14675211	chr2:100938903	LONRF2	0.64	11.2	0.46	6.28e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg00376283	chr12:123451042	ABCB9	0.61	8.89	0.38	1.38e-17	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10825011	chr8:117778719	UTP23	0.49	6.97	0.31	1.13e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg11050988	chr7:1952600	MAD1L1	0.31	6.99	0.31	9.62e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg09222892	chr1:25734099	RHCE	0.45	9.31	0.4	5.27e-19	Erythrocyte sedimentation rate;
LGG	cis	rs897080	0.553	rs1067338	chr2:44624708	G/A	cg00619915	chr2:44497795	NA	-0.49	-6.96	-0.31	1.17e-11	Height;
LGG	cis	rs526231	0.543	rs158244	chr5:102410766	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg16141378	chr3:129829833	LOC729375	0.4	9.19	0.39	1.34e-18	Triglycerides;
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg00631329	chr6:26305371	NA	-0.54	-9.88	-0.42	5.28e-21	Educational attainment;
LGG	cis	rs34172651	0.876	rs2547033	chr16:24743657	C/T	cg02428538	chr16:24856791	SLC5A11	-0.43	-7.41	-0.33	6.04e-13	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.83	0.59	1.94e-45	Longevity;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.58	-0.37	1.45e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7923609	0.756	rs12768534	chr10:65340897	A/G	cg02276361	chr10:65351566	REEP3	0.3	6.87	0.3	2.04e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1372520	0.935	rs2245801	chr4:90757840	T/C	cg15133208	chr4:90757351	SNCA	-0.41	-7.94	-0.35	1.58e-14	Neuroticism;
LGG	cis	rs793571	0.502	rs387812	chr15:59074786	T/C	cg05156742	chr15:59063176	FAM63B	0.66	12.3	0.5	2.83e-30	Schizophrenia;
LGG	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg15017067	chr4:17643749	FAM184B	0.29	6.71	0.3	5.8200000000000003e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs751728	0.638	rs4713686	chr6:33787506	C/T	cg25922239	chr6:33757077	LEMD2	0.55	8.27	0.36	1.47e-15	Crohn's disease;
LGG	cis	rs889398	0.741	rs7190013	chr16:69908248	G/A	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.8	-0.3	3.26e-11	Body mass index;
LGG	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg19507638	chr5:93509721	C5orf36	0.53	6.72	0.3	5.26e-11	Diabetic retinopathy;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg03060546	chr3:49711283	APEH	-0.61	-8.23	-0.36	1.86e-15	Menarche (age at onset);
LGG	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg03342759	chr3:160939853	NMD3	-0.44	-7.36	-0.32	8.5e-13	Morning vs. evening chronotype;
LGG	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg20913747	chr6:44695427	NA	-0.54	-8.17	-0.35	3.06e-15	Total body bone mineral density;
LGG	trans	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg25214090	chr10:38739885	LOC399744	0.56	10.24	0.43	2.49e-22	Corneal astigmatism;
LGG	cis	rs368123	1.000	rs665885	chr6:160702859	G/C	cg07349212	chr6:160770346	SLC22A3	-0.33	-7.06	-0.31	6.07e-12	Waist circumference;
LGG	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg09165964	chr15:75287851	SCAMP5	-0.64	-7.21	-0.32	2.26e-12	Lung cancer;
LGG	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.44	-0.33	4.88e-13	Testicular germ cell tumor;
LGG	cis	rs755249	0.567	rs72661927	chr1:39675322	A/G	cg18385671	chr1:39797026	MACF1	0.44	7.24	0.32	1.92e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs858239	0.601	rs6461693	chr7:23160133	A/G	cg23682824	chr7:23144976	KLHL7	-0.42	-7.02	-0.31	8.06e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6714710	0.603	rs2044458	chr2:98377512	A/T	cg26665480	chr2:98280029	ACTR1B	0.58	9.39	0.4	2.63e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs11166927	0.967	rs12680346	chr8:140814379	C/T	cg16909799	chr8:140841666	TRAPPC9	0.54	11.53	0.47	3.33e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs10463554	0.892	rs464591	chr5:102447304	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg20891283	chr12:69753455	YEATS4	0.96	22.42	0.72	6.46e-76	Blood protein levels;
LGG	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg09021430	chr5:549028	NA	-0.7	-9.16	-0.39	1.75e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg04772025	chr11:68637568	NA	0.74	13.02	0.52	3.01e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.46	-0.33	4.41e-13	Neuroticism;
LGG	trans	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg24247370	chr13:99142703	STK24	-0.37	-6.66	-0.3	7.67e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg26513180	chr16:89883248	FANCA	0.93	20.11	0.68	4.34e-65	Vitiligo;
LGG	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg03961551	chr1:25251730	RUNX3	0.47	12.11	0.49	1.7e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7017914	0.902	rs1373480	chr8:71686967	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.83	-0.38	2.21e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg05527609	chr1:210001259	C1orf107	-0.58	-9.3	-0.4	5.57e-19	Orofacial clefts;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.01	-0.31	8.35e-12	Lung cancer;
LGG	cis	rs4917385	1	rs4917385	chr10:105003721	T/G	cg04362960	chr10:104952993	NT5C2	0.48	8.02	0.35	8.82e-15	Systemic lupus erythematosus;
LGG	cis	rs3008870	1.000	rs2755248	chr1:67492624	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	22.64	0.72	5.96e-77	Lymphocyte percentage of white cells;
LGG	cis	rs7216064	1.000	rs12602912	chr17:65870073	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg04727924	chr7:799746	HEATR2	-0.47	-7.57	-0.33	2.01e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg04568710	chr12:38710424	ALG10B	0.36	7.64	0.33	1.23e-13	Bladder cancer;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs12586317	0.576	rs10130047	chr14:35633580	C/A	cg05294307	chr14:35346193	BAZ1A	-0.36	-6.94	-0.31	1.37e-11	Psoriasis;
LGG	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg25554036	chr4:6271136	WFS1	0.61	11.45	0.47	6.92e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs947474	0.540	rs2181622	chr10:6391061	G/A	cg19837174	chr10:6389707	NA	0.46	7.19	0.32	2.6e-12	Type 1 diabetes;Rheumatoid arthritis;
LGG	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg26338869	chr17:61819248	STRADA	-0.48	-7.62	-0.33	1.46e-13	Prudent dietary pattern;
LGG	trans	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.77	-0.38	3.38e-17	Bladder cancer;
LGG	cis	rs281408	0.559	rs281381	chr19:49214748	C/T	cg13540341	chr19:49222985	MAMSTR	-0.52	-13.18	-0.52	6.52e-34	Urinary metabolites (H-NMR features);
LGG	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg12395012	chr8:11607386	GATA4	0.38	7.08	0.31	5.51e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6681460	0.625	rs4488004	chr1:67073314	T/C	cg20812318	chr1:67072952	SGIP1	-0.32	-7.6	-0.33	1.62e-13	Presence of antiphospholipid antibodies;
LGG	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs911263	0.603	rs3784104	chr14:68773469	A/G	cg18825221	chr14:68749962	RAD51L1	0.36	7.94	0.35	1.59e-14	Primary biliary cholangitis;
LGG	cis	rs919433	0.783	rs2565158	chr2:198236103	T/A	cg00792783	chr2:198669748	PLCL1	0.46	7.3	0.32	1.25e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg18131467	chr2:239335373	ASB1	1.0	22.64	0.72	6.15e-77	Multiple system atrophy;
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-10.85	-0.45	1.37e-24	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg02127607	chr17:61920694	SMARCD2	0.46	7.89	0.34	2.18e-14	Prudent dietary pattern;
LGG	cis	rs6772849	0.930	rs4857916	chr3:128376014	C/G	cg08795948	chr3:128337044	NA	0.66	11.36	0.47	1.57e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.43e-26	Corneal astigmatism;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07659893	chr17:61819838	STRADA	0.48	7.96	0.35	1.37e-14	Prudent dietary pattern;
LGG	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	15.08	0.57	4.42e-42	Menarche (age at onset);
LGG	cis	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.43	-0.47	7.74e-27	Morning vs. evening chronotype;
LGG	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg22601191	chr20:60968625	CABLES2	0.38	7.21	0.32	2.37e-12	Colorectal cancer;
LGG	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.38	7.66	0.34	1.08e-13	Hemoglobin concentration;
LGG	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg16414030	chr3:133502952	NA	-0.58	-10.07	-0.42	1.11e-21	Iron status biomarkers;
LGG	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg21479132	chr6:26055353	NA	0.74	7.29	0.32	1.34e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-13.03	-0.52	2.77e-33	Parkinson's disease;
LGG	cis	rs9487094	0.689	rs9480949	chr6:109728441	T/C	cg16315928	chr6:109776240	MICAL1	0.45	7.83	0.34	3.41e-14	Height;
LGG	cis	rs7646881	0.812	rs73017536	chr3:158460602	C/T	cg19483011	chr3:158453295	NA	-0.62	-8.34	-0.36	8.53e-16	Tetralogy of Fallot;
LGG	cis	rs6831352	0.959	rs6532796	chr4:100042242	C/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.7	-0.41	2.26e-20	Alcohol dependence;
LGG	trans	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	9.39	0.4	2.83e-19	Mean corpuscular volume;
LGG	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.72	0.3	5.38e-11	Bipolar disorder;
LGG	cis	rs3796352	0.568	rs11713376	chr3:52958927	A/G	cg04865290	chr3:52927548	TMEM110	-0.5	-7.86	-0.34	2.78e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs16937	1.000	rs16937	chr1:205035455	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.26	-0.32	1.63e-12	Schizophrenia;
LGG	cis	rs6920372	0.731	rs2357124	chr6:109872263	T/G	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs4843185	0.699	rs8571	chr16:85709610	G/A	cg26571870	chr16:85723150	GINS2	-0.39	-7.29	-0.32	1.34e-12	Platelet distribution width;
LGG	cis	rs9557207	0.853	rs9513563	chr13:99789223	A/G	cg24509225	chr13:100037070	UBAC2	-0.65	-11.37	-0.47	1.39e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg04691961	chr3:161091175	C3orf57	-0.4	-8.41	-0.36	5.09e-16	Morning vs. evening chronotype;
LGG	cis	rs9911578	0.835	rs2301867	chr17:56480074	T/A	cg12560992	chr17:57184187	TRIM37	-0.8	-13.67	-0.54	5.9e-36	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg04455712	chr21:45112962	RRP1B	0.53	9.97	0.42	2.52e-21	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg18379455	chr17:41446167	NA	-0.33	-7.81	-0.34	3.91e-14	Menopause (age at onset);
LGG	trans	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.69e-12	Retinal vascular caliber;
LGG	cis	rs3126085	0.935	rs1858478	chr1:152257457	C/T	cg26876637	chr1:152193138	HRNR	-0.54	-8.79	-0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg14784868	chr12:69753453	YEATS4	0.54	10.08	0.42	9.72e-22	Blood protein levels;
LGG	cis	rs758324	0.853	rs10051653	chr5:131248894	G/A	cg06307176	chr5:131281290	NA	-0.53	-8.76	-0.38	3.62e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7215564	0.908	rs35363308	chr17:78687190	A/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs9863	0.896	rs4930722	chr12:124423275	C/G	cg13487667	chr12:124434373	CCDC92	-0.37	-7.23	-0.32	2.07e-12	White blood cell count;
LGG	cis	rs7226408	0.600	rs8088772	chr18:34647560	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.18	-0.39	1.4e-18	Obesity-related traits;
LGG	trans	rs9354308	0.838	rs9363453	chr6:66544051	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	trans	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.86	0.45	1.29e-24	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16104446	chr8:48873951	MCM4;PRKDC	0.5	7.97	0.35	1.27e-14	Gut microbiome composition (summer);
LGG	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-10.8	-0.45	2.02e-24	Schizophrenia;
LGG	cis	rs6834538	0.597	rs4834291	chr4:113482718	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.52	8.75	0.38	4.07e-17	Free thyroxine concentration;
LGG	cis	rs7507204	0.723	rs62125964	chr19:3414742	C/A	cg08380311	chr19:3435252	NFIC	0.83	12.03	0.49	3.53e-29	Height;
LGG	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs701145	0.585	rs1727920	chr3:153788588	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.4	0.4	2.51e-19	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.72e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.89	-9.69	-0.41	2.44e-20	Corneal curvature;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg16145211	chr17:75695378	NA	-0.65	-6.65	-0.3	8.45e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs7923452	0.938	rs34560372	chr10:30773831	G/A	cg25182066	chr10:30743637	MAP3K8	0.44	6.69	0.3	6.52e-11	Itch intensity from mosquito bite;
LGG	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg22022881	chr2:105853494	NA	-0.36	-7.42	-0.33	5.52e-13	Type 2 diabetes;
LGG	cis	rs17767392	0.813	rs61991243	chr14:71847117	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.62	-0.37	1.06e-16	Mitral valve prolapse;
LGG	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg08603382	chr10:743973	NA	-0.45	-8.32	-0.36	1.02e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs7904368	0.754	rs66491181	chr10:16849430	T/C	cg14835575	chr10:16859367	RSU1	0.81	15.1	0.57	3.45e-42	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2070488	0.965	rs6599209	chr3:38558197	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.54	-0.63	3.34e-53	Electrocardiographic conduction measures;
LGG	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg11693508	chr17:37793320	STARD3	0.52	7.42	0.33	5.67e-13	Bipolar disorder;
LGG	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg16576597	chr16:28551801	NUPR1	0.37	8.66	0.37	8e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	8.01	0.35	9.53e-15	Response to antipsychotic treatment;
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-10.97	-0.45	4.65e-25	Neuroticism;
LGG	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg19913688	chr11:428466	ANO9	-0.64	-8.05	-0.35	7.05e-15	Body mass index;
LGG	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.47	0.33	3.95e-13	Cystic fibrosis severity;
LGG	cis	rs11864453	0.611	rs1050361	chr16:72130203	C/G	cg01557791	chr16:72042693	DHODH	-0.45	-8.17	-0.36	2.86e-15	Fibrinogen levels;
LGG	cis	rs2304069	0.826	rs245076	chr5:149350648	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.65	10.79	0.45	2.35e-24	HIV-1 control;
LGG	cis	rs4924935	0.770	rs4924946	chr17:18846525	A/T	cg26378065	chr17:18585709	ZNF286B	-0.48	-8.64	-0.37	8.93e-17	Pancreatic cancer;
LGG	cis	rs10214930	0.647	rs6966587	chr7:27690363	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs10751667	0.666	rs10902248	chr11:957742	A/G	cg22143635	chr11:980567	AP2A2	0.44	8.27	0.36	1.47e-15	Alzheimer's disease (late onset);
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.73	0.69	5.08e-68	Alzheimer's disease;
LGG	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg04398451	chr17:18023971	MYO15A	-0.61	-12.05	-0.49	2.88e-29	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg18681998	chr4:17616180	MED28	0.83	18.36	0.65	5.58e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.26	-0.32	1.7e-12	Mood instability;
LGG	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg06618935	chr21:46677482	NA	-0.42	-8.31	-0.36	1.04e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3806843	0.576	rs246066	chr5:140323147	T/G	cg19875535	chr5:140030758	IK	0.38	7.47	0.33	4.13e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.64	-0.41	3.69e-20	Aortic root size;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.56e-12	Lung cancer;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg15681038	chr19:37064156	ZNF529	-0.32	-6.83	-0.3	2.73e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg00383909	chr3:49044727	WDR6	0.99	12.39	0.5	1.24e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4900538	0.963	rs1190554	chr14:102918686	T/C	cg18135206	chr14:102964638	TECPR2	0.82	16.3	0.6	1.58e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg26338869	chr17:61819248	STRADA	0.57	9.56	0.41	6.95e-20	Prudent dietary pattern;
LGG	cis	rs58649573	0.509	rs917782	chr9:126790666	T/C	cg14112217	chr9:126806003	NA	0.39	7.55	0.33	2.37e-13	Post-traumatic stress disorder;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg01262667	chr19:19385393	TM6SF2	0.45	11.63	0.48	1.37e-27	Tonsillectomy;
LGG	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg03806693	chr22:41940476	POLR3H	0.88	15.3	0.58	4.8e-43	Vitiligo;
LGG	trans	rs9467711	0.591	rs9295675	chr6:25918473	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-6.9	-0.31	1.68e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg12641515	chr19:46296257	DMWD	-0.5	-8.2	-0.36	2.42e-15	Coronary artery disease;
LGG	cis	rs7312933	0.567	rs11181399	chr12:42666412	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.66	0.34	1.11e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04579211	chr15:41221939	DLL4	0.43	6.79	0.3	3.55e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.8	0.3	3.15e-11	Alzheimer's disease;
LGG	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24503272	chr6:160210831	MRPL18;TCP1	0.42	6.66	0.3	7.7e-11	Cognitive performance;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-7.98	-0.35	1.16e-14	Skin colour saturation;
LGG	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg08344181	chr3:125677491	NA	-0.64	-7.86	-0.34	2.74e-14	Depression;
LGG	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.75	-0.41	1.52e-20	Common traits (Other);
LGG	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg18681998	chr4:17616180	MED28	0.82	18.21	0.65	2.8e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg12163867	chr12:51592794	POU6F1	-0.53	-11.53	-0.47	3.18e-27	Cisplatin-induced ototoxicity;
LGG	cis	rs17253792	0.731	rs74823888	chr14:56049800	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.02	-0.49	3.91e-29	Putamen volume;
LGG	cis	rs174551	1	rs174551	chr11:61573684	T/C	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	LDL cholesterol;
LGG	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg06026331	chr20:60912101	LAMA5	0.74	13.2	0.52	5.5e-34	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs67133203	0.796	rs11169644	chr12:51366535	T/G	cg14688905	chr12:51403056	SLC11A2	0.79	12.17	0.49	9.48e-30	Urinary tract infection frequency;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.79	-0.48	3.11e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.34	-0.32	9.76e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg03162506	chr22:38580953	NA	0.31	7.36	0.32	8.49e-13	Cutaneous nevi;
LGG	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.41	0.36	5.03e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg20587970	chr11:113659929	NA	-1.41	-24.32	-0.75	9e-85	Hip circumference adjusted for BMI;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg24249734	chr3:127872125	EEFSEC	0.4	7.24	0.32	1.91e-12	Body mass index;
LGG	cis	rs7737355	0.738	rs10051609	chr5:130877080	G/C	cg06307176	chr5:131281290	NA	0.51	8.58	0.37	1.46e-16	Life satisfaction;
LGG	cis	rs9636252	0.886	rs6728716	chr2:9269386	C/T	cg20341998	chr2:9276514	NA	0.39	7.6	0.33	1.68e-13	IgG glycosylation;
LGG	cis	rs2502399	0.898	rs774570	chr6:113513922	A/C	cg20413948	chr6:113544930	NA	0.29	6.86	0.3	2.18e-11	Plasma clusterin levels;
LGG	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.45	-0.33	4.48e-13	Monocyte count;
LGG	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg19171272	chr22:38449367	NA	0.4	6.69	0.3	6.48e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg23029597	chr12:123009494	RSRC2	-0.94	-18.37	-0.65	5.14e-57	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08098457	chr2:63815963	MDH1;C2orf86	0.45	7.64	0.33	1.23e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs1707322	1.000	rs10789485	chr1:46407308	C/T	cg03146154	chr1:46216737	IPP	0.55	10.18	0.43	4.41e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg18709589	chr6:96969512	KIAA0776	0.41	7.7	0.34	8.28e-14	Headache;
LGG	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	7.3	0.32	1.3e-12	Type 2 diabetes;
LGG	trans	rs7904321	1.000	rs7904321	chr10:64840665	C/T	cg07856758	chr19:37861652	ZNF527	0.4	6.89	0.3	1.88e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg06521331	chr12:34319734	NA	-0.5	-8.81	-0.38	2.59e-17	Bladder cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg01512265	chr20:34359908	PHF20	-0.37	-6.86	-0.3	2.21e-11	Iris color (L* coordinate);
LGG	cis	rs10089	1.000	rs77086350	chr5:127494431	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.58	0.47	2.05e-27	Ileal carcinoids;
LGG	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.86	-20.89	-0.7	8.98e-69	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00149659	chr3:10157352	C3orf10	0.85	11.05	0.46	2.46e-25	Alzheimer's disease;
LGG	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg07541023	chr7:19748670	TWISTNB	0.52	7.72	0.34	7.38e-14	Thyroid stimulating hormone;
LGG	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03352830	chr11:487213	PTDSS2	0.89	11.28	0.46	2.95e-26	Body mass index;
LGG	cis	rs6860806	0.507	rs169256	chr5:131688533	A/G	cg07395648	chr5:131743802	NA	-0.42	-8.16	-0.35	3.24e-15	Breast cancer;
LGG	cis	rs12477438	0.539	rs2309576	chr2:99972355	C/T	cg23527387	chr2:100056660	REV1	0.44	9.81	0.41	9.41e-21	Chronic sinus infection;
LGG	cis	rs7011049	1.000	rs72643585	chr8:53847651	A/G	cg26025543	chr8:53854495	NA	0.75	9.92	0.42	3.71e-21	Systolic blood pressure;
LGG	cis	rs17776563	0.593	rs28407106	chr15:89142332	C/A	cg05013243	chr15:89149849	MIR1179	-0.34	-7.07	-0.31	5.84e-12	Thyroid hormone levels;
LGG	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.59	-0.37	1.35e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.26e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.37	0.43	8.68e-23	Personality dimensions;
LGG	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg07303275	chr16:75499416	TMEM170A	0.38	6.79	0.3	3.36e-11	Dupuytren's disease;
LGG	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.7	-0.37	5.75e-17	Neuroticism;
LGG	cis	rs7192380	0.729	rs11648335	chr16:69597317	A/G	cg00738113	chr16:70207722	CLEC18C	-0.3	-8.32	-0.36	1e-15	Sjögren's syndrome;
LGG	trans	rs4714291	0.963	rs761801	chr6:39997176	G/A	cg02267698	chr19:7991119	CTXN1	0.59	9.1	0.39	2.75e-18	Strep throat;
LGG	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	9.91	0.42	4.11e-21	Retinal vascular caliber;
LGG	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg13010199	chr12:38710504	ALG10B	0.63	12.63	0.51	1.28e-31	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg05791153	chr7:19748676	TWISTNB	0.74	9.85	0.42	6.51e-21	Thyroid stimulating hormone;
LGG	cis	rs17453880	0.700	rs34967219	chr5:152032949	C/T	cg12297329	chr5:152029980	NA	0.9	23.52	0.74	4.78e-81	Subjective well-being;
LGG	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg19773385	chr1:10388646	KIF1B	-0.45	-9.84	-0.42	6.91e-21	Hepatocellular carcinoma;
LGG	cis	rs9487094	0.961	rs11153174	chr6:109674055	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.96	0.38	8.15e-18	Height;
LGG	cis	rs11971779	0.941	rs7802779	chr7:139122579	G/T	cg07862535	chr7:139043722	LUC7L2	0.6	9.17	0.39	1.62e-18	Diisocyanate-induced asthma;
LGG	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.39	-0.33	6.7e-13	Testicular germ cell tumor;
LGG	trans	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg00938859	chr5:1591904	SDHAP3	0.82	7.55	0.33	2.26e-13	Breast cancer;
LGG	cis	rs892961	0.899	rs72896163	chr17:75412525	C/T	cg05865280	chr17:75406074	SEPT9	0.43	10.25	0.43	2.26e-22	Airflow obstruction;
LGG	cis	rs11169552	0.510	rs876079	chr12:51030709	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.71	-0.34	7.63e-14	Colorectal cancer;
LGG	cis	rs9457247	1.000	rs430097	chr6:167405073	A/G	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	trans	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-11.37	-0.47	1.42e-26	Brugada syndrome;
LGG	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	25.75	0.77	2.07e-91	Chronic sinus infection;
LGG	trans	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs2455799	0.613	rs2470537	chr3:15716898	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.77	-0.34	5e-14	Mean platelet volume;
LGG	cis	rs4742903	0.935	rs10991166	chr9:106974096	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.2	0.36	2.4e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7649275	0.882	rs7373113	chr3:53790054	A/C	cg21503701	chr3:53781065	CACNA1D	-0.44	-6.9	-0.31	1.67e-11	Trans fatty acid levels;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11245990	chr11:68621969	NA	0.43	8.99	0.39	6.11e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg07636037	chr3:49044803	WDR6	0.77	13.75	0.54	2.66e-36	Menarche (age at onset);
LGG	cis	rs2735413	0.918	rs12598024	chr16:78079114	G/A	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg01631408	chr1:248437212	OR2T33	-0.55	-9.89	-0.42	4.63e-21	Common traits (Other);
LGG	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg27205649	chr11:78285834	NARS2	0.44	7.27	0.32	1.53e-12	Testicular germ cell tumor;
LGG	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg08468577	chr11:2973342	NAP1L4	-0.39	-8.27	-0.36	1.42e-15	Calcium levels;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	9.73	0.41	1.69e-20	Bipolar disorder;
LGG	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg03929089	chr4:120376271	NA	0.43	6.94	0.31	1.34e-11	HDL cholesterol;
LGG	trans	rs6956675	0.957	rs10236165	chr7:62596446	T/A	cg01314568	chr7:57830625	NA	-0.51	-8.16	-0.35	3.19e-15	Obesity-related traits;
LGG	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg05925327	chr15:68127851	NA	-0.35	-8.2	-0.36	2.32e-15	Restless legs syndrome;
LGG	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg08847533	chr14:75593920	NEK9	0.63	12.29	0.5	3.03e-30	Height;
LGG	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.56	10.81	0.45	1.92e-24	Lymphocyte percentage of white cells;
LGG	cis	rs1010254	0.559	rs55920366	chr5:151741037	G/A	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.73e-11	Optic nerve measurement (cup area);
LGG	cis	rs700651	0.789	rs5007118	chr2:198909738	G/C	cg00792783	chr2:198669748	PLCL1	0.62	9.76	0.41	1.38e-20	Intracranial aneurysm;
LGG	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.8	0.3	3.34e-11	Cognitive function;
LGG	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	13.65	0.54	7.04e-36	Mean platelet volume;
LGG	cis	rs10504073	0.545	rs4406405	chr8:49957261	G/C	cg00325661	chr8:49890786	NA	0.78	15.32	0.58	3.87e-43	Blood metabolite ratios;
LGG	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs6815814	0.950	rs5743789	chr4:38833173	A/T	cg06935464	chr4:38784597	TLR10	0.58	7.92	0.35	1.78e-14	Breast cancer;
LGG	cis	rs4704187	0.687	rs6453112	chr5:74389901	A/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.65	-0.59	1.27e-44	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08695707	chr1:197871847	C1orf53	0.48	7.32	0.32	1.13e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg15921436	chr17:44337874	NA	-0.44	-10.36	-0.43	9.46e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg13010199	chr12:38710504	ALG10B	0.58	11.4	0.47	1.05e-26	Heart rate;
LGG	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.91	0.38	1.22e-17	Aortic root size;
LGG	cis	rs113835537	0.529	rs2305535	chr11:66272237	A/G	cg24851651	chr11:66362959	CCS	-0.44	-7.74	-0.34	6.46e-14	Airway imaging phenotypes;
LGG	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg13010199	chr12:38710504	ALG10B	0.37	7.03	0.31	7.61e-12	Morning vs. evening chronotype;
LGG	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg25823085	chr7:87105416	ABCB4	0.31	7.69	0.34	8.86e-14	Gallbladder cancer;
LGG	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03517284	chr6:25882590	NA	0.51	9.55	0.41	7.78e-20	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs35391607	chr7:65360829	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs909674	0.731	rs4821897	chr22:39835587	A/G	cg04986931	chr22:39850128	NA	0.41	9.05	0.39	4.01e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7084402	0.565	rs11006188	chr10:60333471	G/C	cg07615347	chr10:60278583	BICC1	0.51	12.6	0.51	1.74e-31	Refractive error;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27343304	chr14:64972179	ZBTB1	0.42	6.93	0.31	1.39e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs12517041	1.000	rs12697619	chr5:23288772	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	trans	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.89	0.48	1.24e-28	Resting heart rate;
LGG	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg22980697	chr10:16874865	CUBN	0.42	7.76	0.34	5.33e-14	Platelet distribution width;
LGG	cis	rs4740619	0.689	rs9969791	chr9:15956164	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.36	-0.43	9.37e-23	Body mass index;
LGG	trans	rs11976180	1.000	rs1919951	chr7:143768891	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.41	-7.31	-0.32	1.2e-12	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg11473876	chr11:109292803	C11orf87	0.46	9.37	0.4	3.11e-19	Schizophrenia;
LGG	cis	rs920590	1.000	rs6995371	chr8:19650268	A/G	cg01411142	chr8:19674711	INTS10	0.43	7.13	0.31	3.89e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11608355	1.000	rs7970482	chr12:109862335	G/A	cg19025524	chr12:109796872	NA	-0.49	-9.17	-0.39	1.52e-18	Neuroticism;
LGG	cis	rs910316	1.000	rs175442	chr14:75603564	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.85	-0.45	1.33e-24	Height;
LGG	cis	rs4936891	0.557	rs55954258	chr11:123914759	A/G	cg22125253	chr11:123886957	OR10G4	-0.53	-8.85	-0.38	1.8e-17	Male fertility;
LGG	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-10.13	-0.43	6.71e-22	Aortic root size;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg22437258	chr11:111473054	SIK2	-0.48	-8.1	-0.35	4.75e-15	Primary sclerosing cholangitis;
LGG	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.33	-0.36	9.01e-16	Educational attainment;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs35425515	0.571	rs71486109	chr10:98887437	G/A	cg09122387	chr10:98855762	SLIT1	0.63	6.78	0.3	3.78e-11	Bipolar disorder;
LGG	cis	rs9811920	0.666	rs793456	chr3:99525631	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.41	-0.36	4.99e-16	Axial length;
LGG	cis	rs12704876	0.509	rs6966856	chr7:96367627	G/A	cg03808172	chr7:96339361	SHFM1	0.56	9.88	0.42	5.05e-21	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17227506	0.543	rs6981209	chr8:13416666	A/G	cg03566418	chr8:13424080	C8orf48	-0.54	-8.2	-0.36	2.3e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg22980697	chr10:16874865	CUBN	0.59	9.59	0.41	5.57e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.17e-18	Motion sickness;
LGG	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs4794106	0.792	rs11365	chr17:48211533	T/G	cg13127421	chr17:48202128	SAMD14	-0.57	-11.82	-0.48	2.38e-28	Temporomandibular joint disorder;
LGG	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs804280	0.662	rs810738	chr8:11611206	A/G	cg12395012	chr8:11607386	GATA4	-0.67	-11.08	-0.46	1.87e-25	Myopia (pathological);
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg15971980	chr6:150254442	NA	0.45	8.29	0.36	1.26e-15	Lung cancer;
LGG	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg05692746	chr2:100937584	LONRF2	-0.57	-9.46	-0.4	1.59e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.66	-0.3	7.77e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs477692	0.571	rs10764890	chr10:131347163	G/A	cg05714579	chr10:131428358	MGMT	0.47	9.08	0.39	3.23e-18	Response to temozolomide;
LGG	cis	rs2916247	0.954	rs6988521	chr8:93167504	A/G	cg10183463	chr8:93005414	RUNX1T1	0.35	7.04	0.31	6.89e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.23	-0.43	2.74e-22	Lymphocyte counts;
LGG	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg04986931	chr22:39850128	NA	0.32	7.25	0.32	1.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.735	rs6849	chr5:140086191	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.7	-0.3	5.93e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-8.96	-0.38	8.13e-18	Lung function (FEV1/FVC);
LGG	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg03929089	chr4:120376271	NA	0.71	9.94	0.42	3.08e-21	Axial length;
LGG	cis	rs58688157	0.883	rs7936397	chr11:577534	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-8.49	-0.37	2.78e-16	Systemic lupus erythematosus;
LGG	trans	rs783540	1.000	rs803688	chr15:83216793	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.77	-0.3	3.86e-11	Schizophrenia;
LGG	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg24675658	chr1:53192096	ZYG11B	-0.54	-10.08	-0.42	1e-21	Monocyte count;
LGG	cis	rs17767392	0.813	rs11848785	chr14:72057355	G/A	cg13720639	chr14:72061746	SIPA1L1	0.36	8.01	0.35	9.06e-15	Mitral valve prolapse;
LGG	cis	rs67133203	0.904	rs12824958	chr12:51334075	A/G	cg14688905	chr12:51403056	SLC11A2	0.7	10.47	0.44	3.75e-23	Urinary tract infection frequency;
LGG	cis	rs4975616	0.843	rs4975615	chr5:1315343	C/T	cg06550200	chr5:1325588	CLPTM1L	0.61	10.82	0.45	1.73e-24	Lung cancer;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.85	0.38	1.92e-17	Platelet count;
LGG	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs11209002	1.000	rs11209002	chr1:67590461	C/T	cg02640540	chr1:67518911	SLC35D1	-0.46	-6.88	-0.3	1.94e-11	Crohn's disease;
LGG	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.91	0.54	5.22e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.07e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs924607	1.000	rs11746907	chr5:598224	G/A	cg09021430	chr5:549028	NA	0.54	10.44	0.44	4.72e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg19812747	chr11:111475976	SIK2	-0.41	-8.53	-0.37	2.08e-16	Primary sclerosing cholangitis;
LGG	cis	rs36071027	0.615	rs34569927	chr5:158421240	A/C	cg04248271	chr5:158524404	EBF1	0.41	7.29	0.32	1.34e-12	Carotid intima media thickness;
LGG	cis	rs71403859	0.502	rs7195767	chr16:71464943	A/G	cg08717414	chr16:71523259	ZNF19	-1.27	-16.23	-0.6	3.04e-47	Post bronchodilator FEV1;
LGG	cis	rs6489882	0.902	rs4767037	chr12:113372804	A/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs36051895	0.632	rs10118789	chr9:5141178	G/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.21	-0.58	1.21e-42	Pediatric autoimmune diseases;
LGG	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-12.3	-0.5	2.82e-30	Menarche (age at onset);
LGG	cis	rs11792861	0.890	rs3750465	chr9:111900677	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.03	0.39	4.71e-18	Menarche (age at onset);
LGG	trans	rs10506458	0.915	rs17738485	chr12:63394932	T/C	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9581943	0.967	rs7999100	chr13:28477401	C/A	cg16302790	chr13:28498334	PDX1	0.5	8.51	0.37	2.45e-16	Pancreatic cancer;
LGG	cis	rs11690935	1.000	rs12053003	chr2:172537350	A/C	cg21435375	chr2:172878103	MAP1D	0.3	6.72	0.3	5.4e-11	Schizophrenia;
LGG	cis	rs7712401	0.562	rs30062	chr5:122296376	C/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg12756686	chr19:29218302	NA	0.71	11.52	0.47	3.61e-27	Methadone dose in opioid dependence;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs16866061	0.962	rs3845840	chr2:225359100	G/A	cg12698349	chr2:225449008	CUL3	0.92	19.16	0.67	1.09e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9341808	0.754	rs10733162	chr6:81023389	G/A	cg08355045	chr6:80787529	NA	0.4	7.74	0.34	6.51e-14	Sitting height ratio;
LGG	cis	rs6840360	0.615	rs72728173	chr4:152469373	C/T	cg25486957	chr4:152246857	NA	-0.52	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25352856	chr1:180472145	ACBD6	-0.45	-7.58	-0.33	1.91e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg00277334	chr10:82204260	NA	-0.45	-9.61	-0.41	4.75e-20	Post bronchodilator FEV1;
LGG	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.13	-0.77	3.95e-93	Height;
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg21798802	chr22:38057573	PDXP	0.61	14.09	0.55	9.33e-38	Fat distribution (HIV);
LGG	cis	rs1417569	0.519	rs3011601	chr10:31245329	C/T	cg00428179	chr10:31322131	ZNF438	-0.39	-9.12	-0.39	2.31e-18	Tuberculosis;
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.09	-0.39	2.89e-18	Prostate cancer;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.92	0.31	1.47e-11	Longevity;
LGG	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06481639	chr22:41940642	POLR3H	-0.56	-7.72	-0.34	7.06e-14	Vitiligo;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg22105103	chr4:187893119	NA	0.57	10.88	0.45	1.04e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg04935436	chr20:30431758	NA	0.41	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg14979609	chr8:8086686	FLJ10661	0.37	9.58	0.41	5.76e-20	Schizophrenia;
LGG	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg16586182	chr3:47516702	SCAP	0.73	13.18	0.52	6.48e-34	Colorectal cancer;
LGG	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg12856521	chr11:46389249	DGKZ	0.44	7.72	0.34	7.03e-14	Leprosy;
LGG	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg13256891	chr4:100009986	ADH5	0.57	9.79	0.41	1.06e-20	Smoking initiation;
LGG	cis	rs4650994	0.593	rs12568310	chr1:178514622	C/T	cg19399532	chr1:178512495	C1orf220	-0.4	-7.5	-0.33	3.23e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg25174290	chr11:3078921	CARS	0.75	16.11	0.6	1.07e-46	Longevity;
LGG	cis	rs4423214	1.000	rs3750997	chr11:71158841	A/C	cg05163923	chr11:71159392	DHCR7	0.7	13.74	0.54	2.94e-36	Vitamin D levels;
LGG	cis	rs8044868	0.586	rs3844425	chr16:72194325	T/C	cg23815491	chr16:72088622	HP	0.36	7.78	0.34	4.87e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg25809561	chr17:30822961	MYO1D	0.36	8.45	0.37	3.8e-16	Schizophrenia;
LGG	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs11718455	0.960	rs11720974	chr3:43999111	G/C	cg21419209	chr3:44054225	NA	-0.4	-6.68	-0.3	7.07e-11	Coronary artery disease;
LGG	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg06565975	chr8:143823917	SLURP1	0.29	6.97	0.31	1.08e-11	Urinary tract infection frequency;
LGG	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.89	0.38	1.41e-17	Cognitive test performance;
LGG	cis	rs3092073	0.624	rs34293711	chr20:44587186	C/T	cg27529037	chr20:44575021	PCIF1	0.38	7.32	0.32	1.11e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.881	rs35680546	chr14:71940619	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.18	-0.39	1.47e-18	Mitral valve prolapse;
LGG	trans	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg26043149	chr18:55253948	FECH	0.4	6.68	0.3	7.07e-11	Bone mineral density;
LGG	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg09307838	chr4:120376055	NA	0.73	12.32	0.5	2.31e-30	Corneal astigmatism;
LGG	cis	rs2455799	0.573	rs924753	chr3:15706124	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.79	-0.34	4.35e-14	Mean platelet volume;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.21e-13	Personality dimensions;
LGG	cis	rs7945705	0.967	rs10769970	chr11:8917937	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.14	0.46	1.08e-25	Hemoglobin concentration;
LGG	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg17885191	chr8:135476712	NA	-0.99	-17.59	-0.63	2.02e-53	Educational attainment;
LGG	cis	rs6964587	0.869	rs11769294	chr7:91549937	C/T	cg17063962	chr7:91808500	NA	0.42	7.4	0.33	6.59e-13	Breast cancer;
LGG	cis	rs9875589	0.957	rs66716710	chr3:13938728	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.42	-8.29	-0.36	1.25e-15	Ovarian reserve;
LGG	cis	rs11157436	0.602	rs10872984	chr14:22639142	C/T	cg00994629	chr14:22694547	NA	0.33	7.14	0.31	3.68e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19524238	chr7:2802976	GNA12	0.38	8.56	0.37	1.72e-16	Height;
LGG	cis	rs4774899	0.966	rs4774910	chr15:57410217	T/C	cg08128148	chr15:57256372	TCF12	-0.32	-7.59	-0.33	1.77e-13	Urinary tract infection frequency;
LGG	cis	rs17152411	0.652	rs1046373	chr10:126674689	A/C	cg06432487	chr10:126623651	NA	0.4	6.75	0.3	4.36e-11	Height;
LGG	cis	rs12505749	0.542	rs12509542	chr4:57357244	T/C	cg07846311	chr4:57371927	ARL9	-0.32	-7.76	-0.34	5.49e-14	Airflow obstruction;
LGG	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs17253792	0.822	rs76205307	chr14:56166038	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.16e-29	Putamen volume;
LGG	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.32	-0.32	1.07e-12	HDL cholesterol;
LGG	cis	rs12190007	0.810	rs12216263	chr6:169767163	G/A	cg16388071	chr6:169726476	NA	-0.37	-6.66	-0.3	8.01e-11	Obesity-related traits;
LGG	cis	rs748404	0.578	rs507178	chr15:43610135	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	8.1	0.35	4.82e-15	Lung cancer;
LGG	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg15557168	chr22:42548783	NA	0.4	8.5	0.37	2.67e-16	Schizophrenia;
LGG	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg08603382	chr10:743973	NA	-0.63	-11.77	-0.48	3.71e-28	Psychosis in Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.67	-0.34	1.02e-13	Life satisfaction;
LGG	cis	rs9583531	1.000	rs9583531	chr13:111385161	T/G	cg24331049	chr13:111365604	ING1	-0.82	-11.64	-0.48	1.22e-27	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.6	-0.33	1.62e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9359856	0.529	rs72919922	chr6:90492997	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.92	-0.42	3.63e-21	Bipolar disorder;
LGG	trans	rs2574985	0.777	rs2983347	chr10:52279350	G/C	cg18558237	chr10:81444220	LOC650623	0.44	6.72	0.3	5.4e-11	Subjective well-being;
LGG	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg09021430	chr5:549028	NA	-0.81	-12.73	-0.51	4.69e-32	Obesity-related traits;
LGG	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-12.03	-0.49	3.25e-29	Body mass index;
LGG	cis	rs6120849	0.754	rs6120828	chr20:33674460	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	6.8	0.3	3.15e-11	Protein C levels;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	9.07	0.39	3.47e-18	Platelet count;
LGG	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg12046867	chr14:103022105	NA	-0.8	-15.27	-0.58	6.15e-43	Platelet count;
LGG	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg06027949	chr8:82754900	SNX16	-0.55	-8.55	-0.37	1.8e-16	Diastolic blood pressure;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.66	9.12	0.39	2.3e-18	Lung function (FEV1/FVC);
LGG	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg01191920	chr7:158217561	PTPRN2	0.72	16.59	0.61	7.47e-49	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg00908189	chr16:619842	PIGQ	0.86	16.18	0.6	5.61e-47	Height;
LGG	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg25019033	chr10:957182	NA	-0.55	-10.08	-0.42	9.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19524238	chr7:2802976	GNA12	0.39	8.92	0.38	1.06e-17	Height;
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.72	-0.56	1.68e-40	Platelet count;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg11494091	chr17:61959527	GH2	-0.69	-12.18	-0.49	8.32e-30	Height;
LGG	cis	rs59104589	0.920	rs59916403	chr2:242370751	G/T	cg10021735	chr2:242295487	FARP2	0.43	7.69	0.34	9.11e-14	Fibrinogen levels;
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.5	-0.61	2.03e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7212938	0.509	rs56199421	chr17:38090808	C/T	cg17467752	chr17:38218738	THRA	0.49	8.01	0.35	9.71e-15	Asthma and hay fever;
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs6554196	0.508	rs2237038	chr4:55525833	C/T	cg18836493	chr4:55524333	KIT	0.41	7.49	0.33	3.49e-13	Monocyte count;
LGG	cis	rs9463078	0.665	rs227849	chr6:44698708	C/T	cg25276700	chr6:44698697	NA	0.45	9.4	0.4	2.5e-19	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg24397884	chr7:158709396	WDR60	1.11	17.08	0.62	4.38e-51	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15355387	chr3:85007817	CADM2	0.41	6.65	0.3	8.13e-11	Cognitive performance;
LGG	cis	rs372883	0.935	rs10460703	chr21:30623109	C/T	cg24692254	chr21:30365293	RNF160	-0.42	-7.31	-0.32	1.2e-12	Pancreatic cancer;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg11494091	chr17:61959527	GH2	0.59	9.52	0.4	9.74e-20	Height;
LGG	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	9.05	0.39	4.01e-18	Eosinophil percentage of white cells;
LGG	cis	rs7927771	0.864	rs755555	chr11:47431966	C/T	cg20307385	chr11:47447363	PSMC3	-0.57	-10.29	-0.43	1.69e-22	Subjective well-being;
LGG	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg16070123	chr10:51489643	NA	-0.4	-7.17	-0.32	2.9e-12	Prostate-specific antigen levels;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.75	-0.38	3.9e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs35740288	0.731	rs35085180	chr15:86102612	T/C	cg04173714	chr15:86211321	AKAP13	0.48	8.65	0.37	8.73e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg24253500	chr15:84953950	NA	0.58	10.46	0.44	4.04e-23	Schizophrenia;
LGG	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-10.1	-0.42	8.29e-22	Educational attainment;
LGG	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs6860806	0.507	rs272892	chr5:131664349	C/T	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Breast cancer;
LGG	cis	rs1577917	0.958	rs12202712	chr6:86578541	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.65	-0.48	1.07e-27	Response to antipsychotic treatment;
LGG	cis	rs151997	0.925	rs27847	chr5:50176197	G/T	cg06027927	chr5:50259733	NA	0.67	11.09	0.46	1.7e-25	Callous-unemotional behaviour;
LGG	cis	rs1018836	0.663	rs12674903	chr8:91475774	T/C	cg16814680	chr8:91681699	NA	-0.68	-11.68	-0.48	8.78e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs477692	0.569	rs871028	chr10:131293478	C/T	cg05714579	chr10:131428358	MGMT	-0.49	-9.72	-0.41	1.87e-20	Response to temozolomide;
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.4	0.53	8.12e-35	Obesity-related traits;
LGG	cis	rs7599312	0.586	rs7571561	chr2:213386267	T/C	cg20637307	chr2:213403960	ERBB4	0.5	8.77	0.38	3.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg23625390	chr15:77176239	SCAPER	-0.4	-7.54	-0.33	2.46e-13	Blood metabolite levels;
LGG	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg16141378	chr3:129829833	LOC729375	0.39	8.84	0.38	1.94e-17	Retinal vascular caliber;
LGG	trans	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg08847533	chr14:75593920	NEK9	0.55	10.11	0.43	7.65e-22	Height;
LGG	cis	rs6787391	0.897	rs13313995	chr3:4747360	G/A	cg11584376	chr3:4789075	ITPR1	-0.33	-6.75	-0.3	4.49e-11	Breast cancer;
LGG	trans	rs970548	0.688	rs2082111	chr10:45931060	A/C	cg14222797	chr10:16859974	RSU1	-0.65	-7.71	-0.34	7.62e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.1	-0.39	2.78e-18	Triglycerides;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18051346	chr17:43238278	HEXIM2	-0.46	-7.46	-0.33	4.31e-13	Pancreatic cancer;
LGG	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg24375607	chr4:120327624	NA	0.4	6.68	0.3	6.67e-11	Diastolic blood pressure;
LGG	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg19920283	chr7:105172520	RINT1	0.59	8.08	0.35	5.58e-15	Bipolar disorder (body mass index interaction);
LGG	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.44	-0.4	1.83e-19	Mood instability;
LGG	cis	rs735539	0.521	rs2585906	chr13:21407492	C/G	cg04906043	chr13:21280425	IL17D	-0.47	-7.39	-0.32	7.05e-13	Dental caries;
LGG	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.47	-0.37	3.21e-16	Blood metabolite levels;
LGG	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg16141378	chr3:129829833	LOC729375	0.36	8.61	0.37	1.11e-16	Neuroticism;
LGG	trans	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.99	0.42	2.13e-21	Mean corpuscular volume;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.72	-0.38	4.92e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg06521331	chr12:34319734	NA	0.43	7.74	0.34	6.21e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1018836	0.545	rs4236827	chr8:91688943	A/T	cg16814680	chr8:91681699	NA	-1.09	-27.93	-0.79	2.38e-101	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2413583	0.591	rs17000979	chr22:39700758	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.63	7.45	0.33	4.55e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg08677398	chr8:58056175	NA	0.48	7.01	0.31	8.66e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg19920283	chr7:105172520	RINT1	-0.61	-8.48	-0.37	3.04e-16	Bipolar disorder (body mass index interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01583365	chr2:172778734	HAT1	0.41	6.96	0.31	1.17e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs459571	0.959	rs2073818	chr9:136918662	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-11.56	-0.47	2.39e-27	Platelet distribution width;
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00292662	chr22:38071168	LGALS1	0.89	24.24	0.75	2.1e-84	Fat distribution (HIV);
LGG	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.29	0.32	1.31e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.44	-0.5	7.76e-31	Lymphocyte counts;
LGG	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg03469862	chr11:68924853	NA	0.44	6.79	0.3	3.39e-11	Blond vs. brown hair color;
LGG	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg21479132	chr6:26055353	NA	0.82	8.04	0.35	7.68e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17253792	0.822	rs78432811	chr14:56051545	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-11.34	-0.47	1.78e-26	Putamen volume;
LGG	trans	rs9585327	0.584	rs4772260	chr13:100645723	A/G	cg26821758	chr2:55515029	CCDC88A	-0.29	-6.93	-0.31	1.42e-11	Myopia;
LGG	cis	rs35160687	0.644	rs11676515	chr2:86496057	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.77	0.3	3.9e-11	Night sleep phenotypes;
LGG	cis	rs9463078	0.625	rs1360197	chr6:44949630	T/C	cg25276700	chr6:44698697	NA	-0.33	-6.8	-0.3	3.22e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg12395012	chr8:11607386	GATA4	-0.39	-6.94	-0.31	1.33e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.46	7.29	0.32	1.37e-12	Hip circumference adjusted for BMI;
LGG	cis	rs55883249	0.957	rs17453675	chr2:9754407	A/G	cg23886495	chr2:9695866	ADAM17	0.69	9.91	0.42	3.92e-21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs9814567	0.752	rs4318591	chr3:134328333	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.59	-0.44	1.33e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7113850	0.541	rs80336897	chr11:24224545	G/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.23	0.43	2.88e-22	Bone fracture in osteoporosis;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.07	0.39	3.4e-18	Mean corpuscular volume;
LGG	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1461503	0.934	rs7119533	chr11:122832683	A/T	cg27398637	chr11:122830231	C11orf63	-0.69	-14.07	-0.55	1.12e-37	Menarche (age at onset);
LGG	cis	rs11785400	1.000	rs4297023	chr8:143733307	C/A	cg24634471	chr8:143751801	JRK	0.52	8.4	0.36	5.62e-16	Schizophrenia;
LGG	cis	rs17428076	0.834	rs6749895	chr2:172875442	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.95	0.42	2.98e-21	Myopia;
LGG	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg16077055	chr2:106428750	NCK2	0.33	8.67	0.37	7.24e-17	Addiction;
LGG	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs7267979	0.903	rs6115109	chr20:25239667	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.52	0.44	2.27e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg16141378	chr3:129829833	LOC729375	0.34	7.38	0.32	7.19e-13	Joint mobility (Beighton score);
LGG	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.23	0.55	2.33e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg20673091	chr1:2541236	MMEL1	-0.76	-18.28	-0.65	1.32e-56	Ulcerative colitis;
LGG	cis	rs12210905	0.925	rs72838228	chr6:26945920	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.25e-13	Hip circumference adjusted for BMI;
LGG	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg17644776	chr2:200775616	C2orf69	-0.6	-6.82	-0.3	2.93e-11	Schizophrenia;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg23034840	chr1:205782522	SLC41A1	0.53	8.66	0.37	8.03e-17	Menarche (age at onset);
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg20821713	chr7:1055600	C7orf50	-0.54	-10.01	-0.42	1.69e-21	Bronchopulmonary dysplasia;
LGG	cis	rs11792861	0.566	rs1003346	chr9:111815340	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.41	6.66	0.3	7.61e-11	Menarche (age at onset);
LGG	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg09165964	chr15:75287851	SCAMP5	0.54	10.02	0.42	1.63e-21	Breast cancer;
LGG	cis	rs11096990	0.634	rs3733287	chr4:39217352	A/G	cg24403649	chr4:39172243	NA	0.42	7.51	0.33	3.11e-13	Cognitive function;
LGG	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-12.57	-0.5	2.22e-31	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.7	-0.34	8.25e-14	Personality dimensions;
LGG	cis	rs56146971	0.703	rs76533089	chr14:91863973	G/T	cg14409461	chr14:91925021	SMEK1	-0.42	-6.91	-0.31	1.66e-11	Alzheimer disease and age of onset;
LGG	cis	rs8032158	1.000	rs8029247	chr15:56273446	C/T	cg02198044	chr15:56286336	NEDD4	0.73	12.98	0.52	4.54e-33	Keloid;
LGG	cis	rs225245	0.817	rs225284	chr17:33933006	A/C	cg05299278	chr17:33885742	SLFN14	0.42	8.17	0.36	2.91e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9398803	0.830	rs9401885	chr6:126825837	C/G	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs17428076	0.830	rs62183852	chr2:172926211	T/G	cg21435375	chr2:172878103	MAP1D	0.46	9.65	0.41	3.4e-20	Myopia;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg11878867	chr6:150167359	LRP11	-0.49	-10.13	-0.43	6.28e-22	Lung cancer;
LGG	cis	rs9400467	0.537	rs77212954	chr6:111445381	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.68	0.3	6.71e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs3815700	0.764	rs259234	chr19:33121729	A/C	cg02997394	chr19:33096574	ANKRD27	-0.71	-7.35	-0.32	9.02e-13	Eosinophilic esophagitis;
LGG	cis	rs796364	0.951	rs12463436	chr2:201061962	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.52	0.33	2.87e-13	Schizophrenia;
LGG	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg16339924	chr4:17578868	LAP3	-0.64	-10.71	-0.45	4.41e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs752010	0.841	rs58737163	chr1:42079821	G/T	cg16096631	chr1:42092165	HIVEP3	0.72	19.42	0.67	6.7e-62	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2916247	0.908	rs2958718	chr8:93180160	C/T	cg10183463	chr8:93005414	RUNX1T1	0.35	7.14	0.31	3.62e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.811	rs12120747	chr1:183042531	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.71	0.3	5.68e-11	Fuchs's corneal dystrophy;
LGG	cis	rs17776563	0.887	rs8024142	chr15:89132693	G/A	cg05013243	chr15:89149849	MIR1179	-0.5	-10.4	-0.44	6.52e-23	Thyroid hormone levels;
LGG	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg05692746	chr2:100937584	LONRF2	-0.67	-11.86	-0.48	1.58e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9462027	0.628	rs7745097	chr6:34794434	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.39	-0.47	1.16e-26	Systemic lupus erythematosus;
LGG	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg04058563	chr4:185651563	MLF1IP	-0.45	-9.56	-0.41	6.82e-20	Kawasaki disease;
LGG	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.09	0.39	2.82e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs13394619	0.936	rs9789414	chr2:11724684	A/G	cg07314298	chr2:11723111	GREB1	-0.48	-9.91	-0.42	3.99e-21	Endometriosis;
LGG	cis	rs4268898	0.636	rs72787371	chr2:24570073	T/A	cg06627628	chr2:24431161	ITSN2	-0.77	-12.52	-0.5	3.52e-31	Asthma;
LGG	cis	rs11966931	0.948	rs112065868	chr6:108088207	C/T	cg04749840	chr6:108095067	SCML4	0.45	7.73	0.34	6.63e-14	Neutrophil percentage of white cells;
LGG	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg03351412	chr1:154909251	PMVK	0.66	12.35	0.5	1.78e-30	Prostate cancer;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg10295955	chr4:187884368	NA	-1.14	-29.7	-0.81	2.65e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg15309053	chr8:964076	NA	0.42	9.07	0.39	3.29e-18	Schizophrenia;
LGG	cis	rs7937890	0.559	rs4369365	chr11:14444515	C/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.91	-0.35	1.89e-14	Mitochondrial DNA levels;
LGG	cis	rs67133203	0.851	rs7954140	chr12:51490408	A/G	cg14688905	chr12:51403056	SLC11A2	-0.67	-10.58	-0.44	1.37e-23	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10465746	0.725	rs6694752	chr1:84389960	C/T	cg10977910	chr1:84465055	TTLL7	0.59	10.94	0.45	6.21e-25	Obesity-related traits;
LGG	cis	rs9308433	0.505	rs6695148	chr1:214497861	G/T	cg06198575	chr1:214491504	SMYD2	0.52	7.85	0.34	2.97e-14	IgG glycosylation;
LGG	cis	rs9849248	0.627	rs56211058	chr3:88155627	A/G	cg14530983	chr3:88190749	ZNF654	0.56	7.82	0.34	3.59e-14	Menarche (age at onset);
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg07701084	chr6:150067640	NUP43	-0.46	-6.91	-0.31	1.57e-11	Lung cancer;
LGG	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg21775007	chr8:11205619	TDH	0.52	8.3	0.36	1.11e-15	Triglycerides;
LGG	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg23583168	chr7:148888333	NA	-0.85	-16.05	-0.6	2.17e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11696845	1.000	rs13037759	chr20:43370692	C/T	cg25301532	chr20:43378953	KCNK15	0.37	8.11	0.35	4.67e-15	Obesity-related traits;
LGG	cis	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg12486710	chr1:178512616	C1orf220	0.52	10.82	0.45	1.77e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs8016982	0.698	rs8011097	chr14:81702736	T/C	cg01989461	chr14:81687754	GTF2A1	0.76	17.85	0.64	1.32e-54	Schizophrenia;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg26513180	chr16:89883248	FANCA	0.73	8.02	0.35	8.58e-15	Skin colour saturation;
LGG	trans	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg02269571	chr22:50332266	NA	-0.61	-9.48	-0.4	1.37e-19	Schizophrenia;
LGG	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.97	-0.31	1.12e-11	Joint mobility (Beighton score);
LGG	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg04565464	chr8:145669602	NFKBIL2	0.38	6.85	0.3	2.33e-11	Schizophrenia;
LGG	cis	rs7572733	0.534	rs770657	chr2:198674184	C/A	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Dermatomyositis;
LGG	trans	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.7	14.63	0.56	4.18e-40	Lymphocyte percentage of white cells;
LGG	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2594989	0.887	rs2442797	chr3:11555935	C/T	cg01796438	chr3:11312864	ATG7	-0.53	-7.34	-0.32	9.43e-13	Circulating chemerin levels;
LGG	cis	rs6964587	0.810	rs408	chr7:91556284	A/G	cg17063962	chr7:91808500	NA	-0.43	-7.77	-0.34	5.15e-14	Breast cancer;
LGG	cis	rs1801251	0.928	rs737028	chr2:233640750	T/C	cg25237894	chr2:233734115	C2orf82	0.65	12.46	0.5	6.44e-31	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.85	0.3	2.37e-11	Schizophrenia;
LGG	cis	rs17221829	0.645	rs4002142	chr11:89374013	G/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14968603	chr10:102046143	BLOC1S2	0.41	7.11	0.31	4.31e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.52e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2273669	0.915	rs6941125	chr6:109287209	T/A	cg05315195	chr6:109294784	ARMC2	-0.52	-7.33	-0.32	1.03e-12	Prostate cancer;
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.75	14.7	0.56	1.99e-40	Personality dimensions;
LGG	trans	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.39	0.4	2.64e-19	Diabetic kidney disease;
LGG	trans	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg14791747	chr16:20752902	THUMPD1	0.51	7.83	0.34	3.29e-14	Cognitive test performance;
LGG	cis	rs138229	0.506	rs9628282	chr22:50534952	G/T	cg16473166	chr22:50639996	SELO	0.51	7.89	0.34	2.24e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg11494091	chr17:61959527	GH2	0.62	10.71	0.45	4.81e-24	Height;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg18446336	chr7:2847575	GNA12	-0.28	-6.78	-0.3	3.71e-11	Height;
LGG	cis	rs7166081	1.000	rs12900708	chr15:67535440	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.1	-0.31	4.6e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22618164	chr12:122356400	WDR66	-0.36	-10.74	-0.45	3.6e-24	Mean corpuscular volume;
LGG	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04935121	chr11:63775413	MACROD1	0.3	7.11	0.31	4.45e-12	Pulse pressure;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg17016394	chr21:34442360	OLIG1	0.46	6.67	0.3	7.29e-11	Hip circumference;
LGG	cis	rs2285947	0.838	rs976516	chr7:21581561	A/G	cg04471919	chr7:21584483	DNAH11	0.44	11.24	0.46	4.33e-26	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs36051895	0.664	rs11788834	chr9:5092466	G/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.03	-0.57	6.93e-42	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg20607798	chr8:58055168	NA	0.64	7.5	0.33	3.37e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.89	-0.51	1.09e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.83	0.42	7.69e-21	Menopause (age at onset);
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19717773	chr7:2847554	GNA12	-0.32	-6.69	-0.3	6.3e-11	Height;
LGG	cis	rs9863	0.828	rs12827409	chr12:124476706	C/G	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.99e-12	White blood cell count;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.34	-0.36	8.87e-16	Life satisfaction;
LGG	cis	rs2120019	1.000	rs7162900	chr15:75368017	T/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.53	-0.61	1.45e-48	Blood trace element (Zn levels);
LGG	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg14055004	chr2:241860995	NA	0.28	7.52	0.33	2.86e-13	Joint mobility (Beighton score);
LGG	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13102973	0.965	rs6535050	chr4:135874115	A/C	cg14419869	chr4:135874104	NA	-0.57	-11.02	-0.46	3.16e-25	Subjective well-being;
LGG	cis	rs4356203	0.840	rs214911	chr11:17242238	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13065560	0.534	rs4318494	chr3:38886804	A/G	cg01426195	chr3:39028469	NA	-0.4	-8.36	-0.36	7.36e-16	Interleukin-18 levels;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19233923	chr11:63753598	OTUB1	0.4	6.68	0.3	6.92e-11	Lung adenocarcinoma;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg05091796	chr16:4465799	CORO7	0.6	9.87	0.42	5.62e-21	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02608596	chr19:4343422	MPND	0.6	6.74	0.3	4.82e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg00933542	chr6:150070202	PCMT1	0.39	6.91	0.31	1.66e-11	Lung cancer;
LGG	cis	rs57994353	0.861	rs34302850	chr9:139327064	A/G	cg14169450	chr9:139327907	INPP5E	0.4	6.9	0.31	1.72e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LGG	cis	rs300774	0.925	rs432750	chr2:147456	A/G	cg04617936	chr2:214353	NA	-0.5	-7.5	-0.33	3.25e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs490234	0.691	rs1472467	chr9:128173121	C/G	cg14078157	chr9:128172775	NA	-0.5	-9.46	-0.4	1.6e-19	Mean arterial pressure;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg08621203	chr6:150244597	RAET1G	0.46	8.08	0.35	5.7e-15	Lung cancer;
LGG	trans	rs9329221	0.716	rs11989640	chr8:10256054	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.36	-0.32	8.61e-13	Neuroticism;
LGG	cis	rs10193935	0.901	rs1390609	chr2:42666230	G/T	cg27598129	chr2:42591480	NA	0.65	9.74	0.41	1.58e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.79	-0.3	3.42e-11	Total body bone mineral density;
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg16578609	chr1:2399051	NA	-0.42	-8.86	-0.38	1.78e-17	Non-obstructive azoospermia;
LGG	cis	rs4731207	0.596	rs13233978	chr7:124587620	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs4481887	0.927	rs4517383	chr1:248426484	C/T	cg13385794	chr1:248469461	NA	0.48	8.09	0.35	5.48e-15	Common traits (Other);
LGG	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg14541582	chr5:601475	NA	-0.68	-10.66	-0.44	7.01e-24	Obesity-related traits;
LGG	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg04731861	chr2:219085781	ARPC2	0.44	10.5	0.44	2.71e-23	Colorectal cancer;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04008888	chr11:68622739	NA	-0.55	-11.8	-0.48	2.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3106136	0.934	rs34396188	chr4:95191292	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.84	-0.34	3.23e-14	Capecitabine sensitivity;
LGG	cis	rs12453935	0.708	rs72843731	chr17:59920876	G/T	cg14757157	chr17:59911755	BRIP1	0.34	6.67	0.3	7.26e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg18681998	chr4:17616180	MED28	0.73	14.94	0.57	1.87e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg03806693	chr22:41940476	POLR3H	1.04	19.29	0.67	2.66e-61	Vitiligo;
LGG	cis	rs10751667	0.666	rs4074231	chr11:978219	G/C	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs4132509	0.793	rs10803161	chr1:243990770	T/C	cg21452805	chr1:244014465	NA	0.64	7.67	0.34	1.03e-13	RR interval (heart rate);
LGG	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.56	-8.14	-0.35	3.79e-15	IgG glycosylation;
LGG	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg15440763	chr7:158190612	PTPRN2	0.5	10.38	0.43	7.57e-23	Obesity-related traits;
LGG	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg17757837	chr7:157058334	UBE3C	-0.78	-15.73	-0.59	5.73e-45	Body mass index;
LGG	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Breast cancer;
LGG	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.14e-29	Aortic root size;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg25214090	chr10:38739885	LOC399744	-0.56	-9.97	-0.42	2.52e-21	Corneal astigmatism;
LGG	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg07541023	chr7:19748670	TWISTNB	0.61	8.48	0.37	3.11e-16	Thyroid stimulating hormone;
LGG	cis	rs733592	0.524	rs10875741	chr12:48492922	A/C	cg24011408	chr12:48396354	COL2A1	-0.68	-11.86	-0.48	1.63e-28	Plateletcrit;
LGG	cis	rs2016266	0.859	rs10783575	chr12:53742885	C/T	cg04065151	chr12:53682969	ESPL1	0.54	8.67	0.37	7.52e-17	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.77	-0.41	1.29e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg00531865	chr16:30841666	NA	-0.54	-11.01	-0.46	3.46e-25	Multiple myeloma;
LGG	cis	rs4889855	0.511	rs9908700	chr17:78466594	A/G	cg16591659	chr17:78472290	NA	-0.4	-8.99	-0.39	6.1e-18	Fractional excretion of uric acid;
LGG	cis	rs9914988	0.887	rs62066838	chr17:27184533	C/T	cg20469991	chr17:27169893	C17orf63	0.53	6.69	0.3	6.47e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs60515486	0.702	rs61000762	chr11:47431961	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.78	0.3	3.74e-11	Lymphocyte counts;
LGG	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg14979609	chr8:8086686	FLJ10661	-0.32	-7.95	-0.35	1.49e-14	Neuroticism;
LGG	cis	rs806215	0.526	rs3808078	chr7:127581677	G/A	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	7.12e-12	Type 2 diabetes;
LGG	cis	rs755249	0.567	rs41270811	chr1:39815344	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.46	0.33	4.28e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg15921436	chr17:44337874	NA	-0.54	-11.45	-0.47	6.78e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.41	10.66	0.44	6.81e-24	IgG glycosylation;
LGG	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.83	0.45	1.57e-24	Mean platelet volume;
LGG	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.07	-0.35	6.27e-15	HDL cholesterol;
LGG	cis	rs3126085	1.000	rs3126095	chr1:152309683	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.85	-0.34	3.02e-14	Atopic dermatitis;
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg23958373	chr8:599963	NA	1.21	12.26	0.5	4.01e-30	IgG glycosylation;
LGG	cis	rs2463822	0.583	rs72919472	chr11:62040655	C/T	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.36	-0.5	1.58e-30	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg26597838	chr10:835615	NA	0.94	12.72	0.51	5.47e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs5771225	0.563	rs1129880	chr22:50694297	A/G	cg16473166	chr22:50639996	SELO	0.64	9.56	0.41	6.98e-20	Late-onset Alzheimer's disease;
LGG	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.82	0.3	2.78e-11	Type 2 diabetes;
LGG	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.55	-0.33	2.32e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg04979063	chr2:113191202	RGPD5;RGPD8	0.75	9.38	0.4	2.9e-19	Yeast infection;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg21139845	chr12:7053993	C12orf57	0.43	7.33	0.32	1.03e-12	Bipolar disorder;
LGG	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg10113582	chr4:905918	GAK	-0.48	-8.88	-0.38	1.48e-17	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs3862435	0.518	rs2444061	chr15:90909439	T/G	cg22089800	chr15:90895588	ZNF774	0.53	6.74	0.3	4.76e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg13880726	chr7:1868755	MAD1L1	0.46	8.07	0.35	6.04e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg12193833	chr17:30244370	NA	-0.29	-6.78	-0.3	3.62e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9815354	0.767	rs73081341	chr3:41900335	A/T	cg03022575	chr3:42003672	ULK4	0.75	9.41	0.4	2.37e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs7945718	0.622	rs4643058	chr11:12689454	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs16976116	0.901	rs9920220	chr15:55503982	T/C	cg11288833	chr15:55489084	RSL24D1	0.57	7.73	0.34	6.53e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg23762105	chr12:34175262	ALG10	0.34	6.66	0.3	7.83e-11	Morning vs. evening chronotype;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg07870213	chr5:140052090	DND1	0.68	13.33	0.53	1.51e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.82	-0.3	2.87e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg22467129	chr15:76604101	ETFA	-0.44	-7.33	-0.32	1.05e-12	Blood metabolite levels;
LGG	cis	rs28830936	0.509	rs6493005	chr15:41859152	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.38	-7.87	-0.34	2.47e-14	Diastolic blood pressure;
LGG	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg15733309	chr7:157513707	PTPRN2	0.62	14.91	0.57	2.44e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	0.901	rs11237459	chr11:78056273	A/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.47	-0.33	3.92e-13	Testicular germ cell tumor;
LGG	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg08528231	chr16:12997261	SHISA9	-0.33	-6.73	-0.3	5.15e-11	Positive affect;Subjective well-being;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.65	0.37	8.5e-17	Obesity-related traits;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.0	0.42	1.96e-21	Tonsillectomy;
LGG	cis	rs7408868	0.908	rs62113794	chr19:15277337	C/A	cg14696996	chr19:15285081	NOTCH3	1.07	12.9	0.51	9.39e-33	Pulse pressure;
LGG	cis	rs1949733	0.701	rs2631754	chr4:8449233	A/G	cg11789530	chr4:8429930	ACOX3	0.73	14.51	0.56	1.33e-39	Response to antineoplastic agents;
LGG	cis	rs3741151	0.773	rs7115055	chr11:73227827	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.87	0.34	2.57e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg14228332	chr4:119757509	SEC24D	-0.75	-8.65	-0.37	8.78e-17	Cannabis dependence symptom count;
LGG	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg22852734	chr6:133119734	C6orf192	1.16	14.66	0.56	2.9e-40	Type 2 diabetes nephropathy;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs78487399	0.808	rs28700209	chr2:43667465	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs10489202	1.000	rs4657727	chr1:167965241	T/C	cg24449463	chr1:168025552	DCAF6	-0.61	-10.02	-0.42	1.56e-21	Schizophrenia;
LGG	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg05484376	chr2:27715224	FNDC4	0.42	9.17	0.39	1.58e-18	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs4330281	0.669	rs12497320	chr3:17754558	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.31e-13	Schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02249930	chr10:70166207	RUFY2	0.42	7.19	0.32	2.65e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	13.84	0.54	1.06e-36	Subjective well-being;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.66e-21	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg08621203	chr6:150244597	RAET1G	0.46	7.91	0.34	1.98e-14	Lung cancer;
LGG	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg13173536	chr2:3403300	TTC15	-0.33	-6.95	-0.31	1.22e-11	Obesity-related traits;
LGG	cis	rs28830936	1.000	rs11629485	chr15:41904569	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.64	-0.51	1.09e-31	Diastolic blood pressure;
LGG	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg24375607	chr4:120327624	NA	0.6	10.27	0.43	1.91e-22	Corneal astigmatism;
LGG	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.66e-25	Parkinson's disease;
LGG	trans	rs9354308	0.764	rs9342513	chr6:66591068	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02182803	chr16:29823685	PRRT2	0.45	6.8	0.3	3.27e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04322344	chr3:131221642	MRPL3	0.49	7.36	0.32	8.55e-13	Gut microbiome composition (summer);
LGG	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg02733842	chr7:1102375	C7orf50	-0.45	-7.42	-0.33	5.73e-13	Bronchopulmonary dysplasia;
LGG	cis	rs490234	0.902	rs7038668	chr9:128239920	T/C	cg14078157	chr9:128172775	NA	-0.37	-7.01	-0.31	8.57e-12	Mean arterial pressure;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg24250549	chr1:154909240	PMVK	0.75	15.06	0.57	5.44e-42	Prostate cancer;
LGG	cis	rs7638995	0.878	rs17005384	chr3:69181552	A/G	cg26574240	chr3:69171822	LMOD3	0.73	11.43	0.47	7.76e-27	Alzheimer's disease (late onset);
LGG	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs6740322	0.696	rs10188539	chr2:43484675	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.65	-0.44	7.47e-24	Coronary artery disease;
LGG	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.87	-0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.47	-9.0	-0.39	6.09e-18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs503734	0.504	rs348873	chr3:100930665	C/T	cg27318481	chr3:100970896	IMPG2	-0.57	-13.24	-0.52	3.66e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9309711	0.922	rs11679058	chr2:3483813	C/G	cg10845886	chr2:3471009	TTC15	-0.73	-14.57	-0.56	7.41e-40	Neurofibrillary tangles;
LGG	cis	rs2735413	0.837	rs4888734	chr16:78083685	C/G	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs6692729	0.966	rs8383	chr1:227083550	C/T	cg08708961	chr1:227070630	PSEN2	0.31	7.8	0.34	4.09e-14	Electrodermal activity;
LGG	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.3	0.4	5.7e-19	Height;
LGG	trans	rs7246760	0.867	rs10410379	chr19:9902197	G/A	cg02900749	chr2:68251473	NA	-0.98	-11.03	-0.46	2.82e-25	Pursuit maintenance gain;
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00142150	chr22:38071001	LGALS1	0.92	19.75	0.68	1.93e-63	Fat distribution (HIV);
LGG	cis	rs4423214	0.592	rs7130829	chr11:71237702	A/T	cg05163923	chr11:71159392	DHCR7	-0.54	-8.0	-0.35	1.04e-14	Vitamin D levels;
LGG	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.56	-0.33	2.21e-13	Mood instability;
LGG	cis	rs503734	0.875	rs9816469	chr3:100950470	A/C	cg27318481	chr3:100970896	IMPG2	-0.37	-7.92	-0.35	1.79e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11096990	0.929	rs55976583	chr4:39224491	A/G	cg24403649	chr4:39172243	NA	-0.45	-7.45	-0.33	4.63e-13	Cognitive function;
LGG	cis	rs6743226	0.603	rs67625947	chr2:242227400	C/A	cg10021735	chr2:242295487	FARP2	0.4	7.08	0.31	5.49e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.39	-0.47	1.2e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14154082	chr13:112174009	NA	0.41	9.05	0.39	3.97e-18	Menarche (age at onset);
LGG	cis	rs9463078	0.605	rs10948188	chr6:44926212	G/A	cg25276700	chr6:44698697	NA	0.34	7.07	0.31	5.69e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg14773178	chr5:1868261	NA	0.36	7.93	0.35	1.61e-14	Cardiovascular disease risk factors;
LGG	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg04731861	chr2:219085781	ARPC2	0.43	10.76	0.45	3.01e-24	Colorectal cancer;
LGG	cis	rs721917	0.525	rs10788338	chr10:81733022	A/C	cg25562619	chr10:81652821	NA	-0.32	-7.18	-0.32	2.79e-12	Chronic obstructive pulmonary disease;
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg16301924	chr13:53314226	LECT1	-0.45	-8.93	-0.38	1.03e-17	Lewy body disease;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg19635926	chr16:89946313	TCF25	0.68	6.87	0.3	2.07e-11	Skin colour saturation;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs5015933	0.832	rs2841332	chr9:128129857	G/T	cg14078157	chr9:128172775	NA	-0.36	-6.81	-0.3	3.07e-11	Body mass index;
LGG	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg01620082	chr3:125678407	NA	-0.84	-9.72	-0.41	1.84e-20	Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23924007	chr4:140099401	NA	0.41	7.01	0.31	8.44e-12	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs877282	0.853	rs7092805	chr10:756246	G/A	cg22713356	chr15:30763199	NA	0.48	7.35	0.32	8.95e-13	Uric acid levels;
LGG	cis	rs4750440	0.671	rs10796149	chr10:14025859	C/T	cg00551146	chr10:14014579	FRMD4A	0.28	6.77	0.3	3.96e-11	Adiponectin levels;
LGG	cis	rs763121	0.819	rs5750629	chr22:38985065	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	17.99	0.64	2.97e-55	Menopause (age at onset);
LGG	cis	rs4740619	0.846	rs7036875	chr9:15653868	G/T	cg14451791	chr9:16040625	NA	0.35	9.11	0.39	2.41e-18	Body mass index;
LGG	cis	rs12153243	0.714	rs17342167	chr5:142895830	A/G	cg13907255	chr5:142895549	NA	-0.49	-8.75	-0.38	4.07e-17	Migraine;
LGG	cis	rs4716602	0.828	rs10270046	chr7:156159047	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.93	-0.31	1.39e-11	Anti-saccade response;
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.08	0.31	5.46e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4727027	0.704	rs12535154	chr7:148895304	G/A	cg23583168	chr7:148888333	NA	-0.94	-19.33	-0.67	1.77e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg00031303	chr3:195681400	NA	-0.44	-6.77	-0.3	3.95e-11	Mean corpuscular volume;
LGG	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg11707556	chr5:10655725	ANKRD33B	0.46	8.48	0.37	2.98e-16	Height;
LGG	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg23029597	chr12:123009494	RSRC2	-0.96	-17.42	-0.63	1.21e-52	Body mass index;
LGG	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg06634786	chr22:41940651	POLR3H	-0.7	-11.74	-0.48	4.77e-28	Vitiligo;
LGG	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg18446336	chr7:2847575	GNA12	-0.38	-10.25	-0.43	2.42e-22	Height;
LGG	cis	rs72960926	1.000	rs11756716	chr6:75097407	T/C	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg05623727	chr3:50126028	RBM5	0.34	7.33	0.32	1.02e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1372520	0.684	rs356162	chr4:90697157	T/C	cg15133208	chr4:90757351	SNCA	0.38	7.58	0.33	1.97e-13	Neuroticism;
LGG	cis	rs700651	0.821	rs700666	chr2:198673544	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Intracranial aneurysm;
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg18245976	chr7:158708271	WDR60	-0.55	-9.52	-0.4	9.77e-20	Height;
LGG	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs561341	0.941	rs550213	chr17:30317518	C/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.21	-0.43	3.17e-22	Hip circumference adjusted for BMI;
LGG	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg02002194	chr4:3960332	NA	-0.52	-9.71	-0.41	2.07e-20	Retinal vascular caliber;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg13939156	chr17:80058883	NA	-0.48	-9.36	-0.4	3.5e-19	Life satisfaction;
LGG	cis	rs12681287	0.547	rs9942823	chr8:87509177	A/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs1580019	0.563	rs2392071	chr7:32572536	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	9.52	0.4	9.26e-20	Cognitive ability;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg06138931	chr13:21896616	NA	-0.47	-7.62	-0.33	1.4e-13	White matter hyperintensity burden;
LGG	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.4	-0.47	1.06e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.05e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26397172	chr17:27047272	RPL23A;SNORD42B	0.45	6.76	0.3	4.1e-11	Gut microbiome composition (summer);
LGG	cis	rs1806153	0.611	rs1806159	chr11:31836627	C/T	cg11990419	chr11:31841155	NA	0.35	8.09	0.35	5.39e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs981844	1.000	rs17299041	chr4:154673127	T/C	cg14289246	chr4:154710475	SFRP2	0.7	11.71	0.48	6.55e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg15369054	chr17:80825471	TBCD	0.58	10.5	0.44	2.8e-23	Breast cancer;
LGG	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg22920501	chr2:26401640	FAM59B	0.45	9.35	0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg00745463	chr17:30367425	LRRC37B	0.54	7.33	0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.18	-0.39	1.4e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg25919922	chr13:100150906	NA	-0.71	-7.58	-0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs35160687	0.644	rs4832036	chr2:86551302	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.96	0.31	1.13e-11	Night sleep phenotypes;
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.41	-0.4	2.24e-19	Retinal vascular caliber;
LGG	cis	rs9487051	0.773	rs351749	chr6:109533353	A/T	cg21918786	chr6:109611834	NA	-0.37	-6.75	-0.3	4.33e-11	Reticulocyte fraction of red cells;
LGG	cis	rs9462027	0.628	rs9462019	chr6:34748730	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.08	-0.35	5.58e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg02466173	chr16:30829666	NA	-0.63	-12.59	-0.5	1.86e-31	Dementia with Lewy bodies;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs2287838	0.704	rs12979606	chr19:9999998	A/T	cg07950397	chr19:10022659	OLFM2	0.29	6.68	0.3	7.03e-11	Sleep duration;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-16.03	-0.6	2.59e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.74	0.3	4.58e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.89	17.42	0.63	1.3e-52	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs62084913	0.511	rs895690	chr17:72784649	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.64	11.64	0.48	1.17e-27	Breast cancer;
LGG	cis	rs6740322	0.748	rs13420649	chr2:43463637	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-10.4	-0.44	6.87e-23	Coronary artery disease;
LGG	cis	rs1650123	0.538	rs2673654	chr12:104027086	A/T	cg23227824	chr12:103980017	STAB2	0.37	8.33	0.36	9.23e-16	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	6.84e-37	Prudent dietary pattern;
LGG	trans	rs208520	1.000	rs208521	chr6:66953625	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs7737355	1.000	rs248652	chr5:130654837	A/T	cg06307176	chr5:131281290	NA	-0.51	-8.62	-0.37	1.04e-16	Life satisfaction;
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg00713939	chr8:144660590	NAPRT1	0.88	7.2	0.32	2.45e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs758324	0.797	rs71970	chr5:131324119	T/G	cg06307176	chr5:131281290	NA	0.5	7.41	0.33	6.18e-13	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg09873164	chr1:152488093	CRCT1	0.64	15.92	0.59	8.03e-46	Hair morphology;
LGG	trans	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg00953403	chr17:74099816	EXOC7	0.41	6.86	0.3	2.2e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg01262667	chr19:19385393	TM6SF2	0.45	11.45	0.47	6.6e-27	Tonsillectomy;
LGG	cis	rs1152591	1.000	rs1152591	chr14:64680848	A/G	cg23250157	chr14:64679961	SYNE2	0.43	8.1	0.35	4.93e-15	Atrial fibrillation;
LGG	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15664640	chr17:80829946	TBCD	-0.8	-15.24	-0.58	8.11e-43	Breast cancer;
LGG	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg25237894	chr2:233734115	C2orf82	0.65	12.4	0.5	1.1e-30	Coronary artery disease;
LGG	cis	rs368123	1.000	rs316169	chr6:160755657	A/C	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.32e-13	Waist circumference;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00346009	chr12:118541298	VSIG10	0.4	6.7	0.3	6.09e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.78e-48	Intelligence (multi-trait analysis);
LGG	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg14664628	chr15:75095509	CSK	-1.13	-25.85	-0.77	7.48e-92	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs10937275	1.000	rs35102841	chr3:186649683	A/G	cg16751732	chr3:186648392	ST6GAL1	0.72	7.32	0.32	1.1e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg23985595	chr17:80112537	CCDC57	0.38	7.58	0.33	1.95e-13	Life satisfaction;
LGG	cis	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.28e-13	Menopause (age at onset);
LGG	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg27129171	chr3:47204927	SETD2	0.81	15.44	0.58	1.11e-43	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	cis	rs3126085	0.515	rs2275264	chr1:152331533	T/G	cg26876637	chr1:152193138	HRNR	-0.44	-6.81	-0.3	3.01e-11	Atopic dermatitis;
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.58	10.09	0.42	9.03e-22	Birth weight;
LGG	cis	rs2905347	0.591	rs12155285	chr7:22678637	G/A	cg18045685	chr7:22629474	NA	-0.73	-15.86	-0.59	1.54e-45	Major depression and alcohol dependence;
LGG	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg11887960	chr12:57824829	NA	0.6	7.33	0.32	1.07e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03647317	chr4:187891568	NA	-0.41	-9.02	-0.39	5.12e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8017423	0.967	rs1959002	chr14:90670994	T/A	cg04374321	chr14:90722782	PSMC1	0.86	18.22	0.65	2.5e-56	Mortality in heart failure;
LGG	cis	rs2377585	0.653	rs10505735	chr12:8841741	A/G	cg03761649	chr12:8850719	RIMKLB	0.49	7.86	0.34	2.73e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.09	-0.49	1.88e-29	Response to antipsychotic treatment;
LGG	cis	rs6694672	1.000	rs2026429	chr1:197079671	A/C	cg13682187	chr1:196946512	CFHR5	-0.49	-6.86	-0.3	2.18e-11	Asthma;
LGG	cis	rs757081	0.637	rs34941502	chr11:17155432	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.02	-0.39	5.12e-18	Systolic blood pressure;
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg00684032	chr4:1343700	KIAA1530	0.39	7.33	0.32	1.02e-12	Obesity-related traits;
LGG	cis	rs921968	0.643	rs524902	chr2:219433357	A/C	cg01130898	chr2:219473002	PLCD4	-0.4	-6.85	-0.3	2.3e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg10587741	chr22:38071170	LGALS1	0.59	13.65	0.54	6.98e-36	Fat distribution (HIV);
LGG	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg10840412	chr1:235813424	GNG4	0.51	6.89	0.3	1.82e-11	Bipolar disorder;
LGG	cis	rs4740619	0.836	rs7027202	chr9:15894495	C/G	cg14451791	chr9:16040625	NA	0.4	10.11	0.43	7.74e-22	Body mass index;
LGG	cis	rs138249	0.934	rs138228	chr22:50557120	A/C	cg18875453	chr22:50517795	MLC1	-0.26	-6.8	-0.3	3.34e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs1348850	0.874	rs13013752	chr2:178456862	A/G	cg22681709	chr2:178499509	PDE11A	-0.42	-7.59	-0.33	1.74e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2905347	0.696	rs2905319	chr7:22697141	G/C	cg18045685	chr7:22629474	NA	-0.69	-14.38	-0.56	4.83e-39	Major depression and alcohol dependence;
LGG	cis	rs1535500	1.000	rs35099099	chr6:39284857	G/A	cg06347083	chr6:39282316	KCNK17	0.44	12.63	0.51	1.25e-31	Type 2 diabetes;
LGG	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05901451	chr6:126070800	HEY2	-0.78	-15.85	-0.59	1.66e-45	Brugada syndrome;
LGG	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.27	-42.87	-0.89	2.59e-163	Myeloid white cell count;
LGG	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg06618935	chr21:46677482	NA	-0.5	-9.72	-0.41	1.8899999999999998e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-9.69	-0.41	2.4e-20	Blood protein levels;
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg19847130	chr8:10466454	RP1L1	-0.31	-6.72	-0.3	5.19e-11	Neuroticism;
LGG	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26011156	chr1:156183096	PMF1	0.47	7.37	0.32	7.83e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.632	rs35716467	chr3:143684993	C/A	cg06585982	chr3:143692056	C3orf58	0.67	11.89	0.48	1.22e-28	Economic and political preferences (feminism/equality);
LGG	cis	rs8060686	0.641	rs118035472	chr16:68242311	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg08305652	chr11:111469057	NA	-0.45	-9.12	-0.39	2.32e-18	Primary sclerosing cholangitis;
LGG	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.67	-0.37	7.46e-17	Initial pursuit acceleration;
LGG	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs6594713	0.717	rs9326891	chr5:112873928	C/T	cg12552261	chr5:112820674	MCC	0.64	8.59	0.37	1.29e-16	Brain cytoarchitecture;
LGG	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg11890956	chr21:40555474	PSMG1	0.75	12.96	0.52	5.21e-33	Cognitive function;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02018176	chr4:1364513	KIAA1530	0.65	15.99	0.6	4.03e-46	Longevity;
LGG	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.14	-0.35	3.65e-15	Bone mineral density;
LGG	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg02461776	chr11:598696	PHRF1	0.54	8.7	0.37	5.69e-17	Systemic lupus erythematosus;
LGG	cis	rs2860975	1.000	rs2860975	chr10:96766934	G/T	cg09036531	chr10:96991505	NA	0.48	8.93	0.38	1.02e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2153535	0.580	rs4140586	chr6:8503192	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.06	0.39	3.8e-18	Motion sickness;
LGG	cis	rs12681366	0.734	rs28641679	chr8:95406693	G/A	cg13257157	chr8:95487014	RAD54B	0.38	6.79	0.3	3.42e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9818758	0.607	rs73082362	chr3:49113729	C/T	cg00383909	chr3:49044727	WDR6	1.1	11.71	0.48	6.55e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg16141378	chr3:129829833	LOC729375	0.32	7.25	0.32	1.72e-12	Recombination measurement;
LGG	cis	rs1728785	0.901	rs698715	chr16:68560896	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.33	-0.36	9.25e-16	Ulcerative colitis;
LGG	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg12165864	chr7:66369176	NA	-0.58	-9.33	-0.4	4.54e-19	Corneal structure;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg07541023	chr7:19748670	TWISTNB	0.45	6.69	0.3	6.59e-11	Thyroid stimulating hormone;
LGG	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	12.67	0.51	8.94e-32	Coronary artery disease;
LGG	cis	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18404041	chr3:52824283	ITIH1	0.37	7.38	0.32	7.34e-13	Bipolar disorder;
LGG	cis	rs9834373	0.553	rs12491264	chr3:78497118	T/C	cg06138941	chr3:78371609	NA	-0.47	-8.62	-0.37	1.07e-16	Protein quantitative trait loci;
LGG	trans	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg08344181	chr3:125677491	NA	-0.58	-7.15	-0.32	3.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.83	-0.3	2.6e-11	Menopause (age at onset);
LGG	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.91	-0.48	9.99e-29	Height;
LGG	cis	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg06609049	chr19:2785107	THOP1	0.62	9.57	0.41	6.5e-20	Total cholesterol levels;
LGG	cis	rs8013055	0.846	rs8003942	chr14:105971670	A/G	cg25008857	chr14:105974488	NA	0.56	9.9	0.42	4.53e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6997458	0.713	rs703	chr8:86389403	T/C	cg02393479	chr8:86352350	CA3	-0.3	-6.67	-0.3	7.24e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg00745463	chr17:30367425	LRRC37B	-0.54	-7.56	-0.33	2.23e-13	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg11502198	chr6:26597334	ABT1	-0.87	-6.66	-0.3	7.67e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12681287	0.547	rs35871312	chr8:87543219	T/C	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg25100604	chr2:70314404	PCBP1	-0.43	-7.31	-0.32	1.15e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	Neuroticism;
LGG	cis	rs2963155	0.518	rs258748	chr5:142656454	C/G	cg17617527	chr5:142782415	NR3C1	0.96	12.67	0.51	8.95e-32	Breast cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25882709	chr1:224517832	NVL	-0.4	-6.81	-0.3	3.11e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2735413	0.918	rs12924772	chr16:78083115	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	15.75	0.59	4.68e-45	Tonsillectomy;
LGG	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg06392426	chr19:10676186	KRI1	0.72	12.01	0.49	4.19e-29	Red cell distribution width;
LGG	cis	rs2011503	0.943	rs1529745	chr19:19517325	C/G	cg11584989	chr19:19387371	SF4	0.71	11.53	0.47	3.22e-27	Bipolar disorder;
LGG	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg16583315	chr14:65563665	MAX	-0.36	-6.91	-0.31	1.58e-11	Obesity-related traits;
LGG	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg17971929	chr21:40555470	PSMG1	0.86	16.59	0.61	7.24e-49	Cognitive function;
LGG	cis	rs59197085	0.636	rs56377531	chr7:128460745	C/T	cg00734629	chr7:128471146	FLNC	0.36	7.24	0.32	1.92e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg19774624	chr17:42201019	HDAC5	-0.84	-16.52	-0.61	1.5e-48	Total body bone mineral density;
LGG	cis	rs3771570	1.000	rs62193221	chr2:242354632	T/C	cg21155796	chr2:242212141	HDLBP	0.75	9.88	0.42	4.98e-21	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24810637	chr10:64564243	ADO	0.48	7.59	0.33	1.8e-13	Gut microbiome composition (summer);
LGG	cis	rs2953174	0.786	rs2953145	chr2:241515596	C/G	cg07929629	chr2:241523174	NA	-0.55	-7.83	-0.34	3.47e-14	Bipolar disorder;
LGG	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg01043669	chr3:72786069	NA	0.42	7.12	0.31	4.12e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg18963800	chr10:38644991	HSD17B7P2	0.42	6.93	0.31	1.39e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg06046430	chr4:77819534	ANKRD56	0.56	11.36	0.47	1.49e-26	Emphysema distribution in smoking;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10053473	chr17:62856997	LRRC37A3	0.79	13.85	0.54	9.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs78487399	0.808	rs17030889	chr2:43702829	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.03	-0.31	7.41e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs2735413	0.918	rs4887932	chr16:78078350	C/A	cg04733911	chr16:78082701	NA	-0.78	-18.66	-0.66	2.23e-58	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg06766960	chr11:133703094	NA	-0.56	-11.01	-0.46	3.23e-25	Childhood ear infection;
LGG	cis	rs1318772	1.000	rs26965	chr5:112739017	A/G	cg12552261	chr5:112820674	MCC	-0.63	-7.5	-0.33	3.29e-13	F-cell distribution;
LGG	cis	rs9790314	0.521	rs13084746	chr3:161086038	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-10.47	-0.44	3.7e-23	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs4938330	0.608	rs4938358	chr11:117084091	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-7.51	-0.33	3.13e-13	Blood protein levels;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.81e-18	Skin colour saturation;
LGG	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.58	9.88	0.42	4.96e-21	Cognitive ability;
LGG	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.54	0.33	2.51e-13	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.85	-0.45	1.42e-24	Hemoglobin concentration;
LGG	cis	rs76419734	0.510	rs2216516	chr4:106749857	G/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.57	-7.86	-0.34	2.69e-14	Post bronchodilator FEV1;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg10360139	chr7:1886902	MAD1L1	-0.44	-7.8	-0.34	4.17e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.5	-8.57	-0.37	1.55e-16	Personality dimensions;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg07157834	chr1:205819609	PM20D1	0.48	9.09	0.39	2.82e-18	Prostate cancer;
LGG	cis	rs1691799	0.867	rs961049	chr12:66762591	A/C	cg16791601	chr12:66731901	HELB	0.63	14.04	0.55	1.49e-37	White blood cell count (basophil);
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.38	6.65	0.3	8.23e-11	Vitiligo;
LGG	cis	rs7572733	1.000	rs1541953	chr2:198898344	A/T	cg00792783	chr2:198669748	PLCL1	-0.41	-6.89	-0.31	1.8e-11	Dermatomyositis;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.63	0.61	5.11e-49	Platelet count;
LGG	cis	rs6121246	0.512	rs45443696	chr20:30311396	A/C	cg13852791	chr20:30311386	BCL2L1	0.96	19.21	0.67	6.42e-61	Mean corpuscular hemoglobin;
LGG	trans	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.42	-0.53	6.52e-35	Alzheimer's disease;
LGG	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg19507638	chr5:93509721	C5orf36	0.68	9.61	0.41	4.75e-20	Diabetic retinopathy;
LGG	cis	rs7577696	0.597	rs2280968	chr2:32290040	G/T	cg02381751	chr2:32503542	YIPF4	-0.46	-6.75	-0.3	4.5e-11	Inflammatory biomarkers;
LGG	cis	rs2115630	0.846	rs8024538	chr15:85368419	A/T	cg12501888	chr15:85177176	SCAND2	-0.5	-8.1	-0.35	4.89e-15	P wave terminal force;
LGG	cis	rs2640806	0.505	rs34269813	chr8:97367524	A/G	cg22138393	chr8:97340270	PTDSS1	0.28	7.3	0.32	1.26e-12	Obesity-related traits;
LGG	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.16	-0.35	3.28e-15	Mood instability;
LGG	cis	rs9875589	0.509	rs7651599	chr3:14010974	C/G	cg19554555	chr3:13937349	NA	-0.56	-10.02	-0.42	1.57e-21	Ovarian reserve;
LGG	cis	rs7582720	0.945	rs2351524	chr2:203880992	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.71	-8.6	-0.37	1.26e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs709400	0.663	rs9671911	chr14:103967343	T/C	cg26031613	chr14:104095156	KLC1	0.78	13.71	0.54	3.91e-36	Body mass index;
LGG	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg00343986	chr7:65444356	GUSB	0.44	7.58	0.33	1.9e-13	Aortic root size;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg08621203	chr6:150244597	RAET1G	0.49	9.15	0.39	1.84e-18	Testicular germ cell tumor;
LGG	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.24	0.43	2.54e-22	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6960043	0.782	rs1558317	chr7:15065564	T/A	cg19272540	chr7:15055459	NA	-0.35	-7.79	-0.34	4.49e-14	Type 2 diabetes;
LGG	cis	rs9682041	0.877	rs9682908	chr3:170072010	C/T	cg11886554	chr3:170076028	SKIL	0.67	8.88	0.38	1.45e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs638893	0.636	rs526850	chr11:118605127	G/T	cg13782932	chr11:118662891	DDX6	0.37	6.71	0.3	5.72e-11	Vitiligo;
LGG	cis	rs13064447	0.874	rs13058951	chr3:12752381	C/T	cg23032965	chr3:12705835	RAF1	0.51	7.8	0.34	4.21e-14	Major depression and alcohol dependence;
LGG	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg11764359	chr7:65958608	NA	0.62	10.69	0.44	5.55e-24	Aortic root size;
LGG	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg06565975	chr8:143823917	SLURP1	-0.57	-13.78	-0.54	1.94e-36	Urinary tract infection frequency;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.05e-21	Electroencephalogram traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07822143	chr4:146019674	ABCE1;ANAPC10	0.49	7.94	0.35	1.56e-14	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg19147804	chr7:1989927	MAD1L1	-0.59	-12.04	-0.49	3.16e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.2	-0.36	2.33e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs785830	0.749	rs487275	chr9:257349	G/A	cg14500300	chr9:211689	NA	0.31	7.77	0.34	5.19e-14	Platelet distribution width;
LGG	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg12011299	chr4:100065546	ADH4	0.42	8.71	0.38	5.46e-17	Alcohol dependence;
LGG	cis	rs6772849	0.896	rs61112519	chr3:128338176	T/A	cg08795948	chr3:128337044	NA	0.65	11.13	0.46	1.18e-25	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs11758351	0.500	rs4593350	chr6:26184800	T/C	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.82e-12	Gout;Renal underexcretion gout;
LGG	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg01448562	chr3:133502909	NA	0.71	13.43	0.53	5.88e-35	Iron status biomarkers;
LGG	trans	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs4478858	0.735	rs11576621	chr1:31795460	A/G	cg19084893	chr1:31688959	NA	0.32	6.87	0.3	2.07e-11	Alcohol dependence;
LGG	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg09624528	chr10:1369823	ADARB2	0.55	10.78	0.45	2.49e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg18335740	chr13:41363409	SLC25A15	-0.57	-11.2	-0.46	6.39e-26	Lewy body disease;
LGG	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg11252792	chr3:125932053	NA	0.56	11.74	0.48	5.04e-28	Metabolite levels;
LGG	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg15704280	chr7:45808275	SEPT13	-0.71	-9.8	-0.41	1.03e-20	Axial length;
LGG	cis	rs9457247	1.000	rs385863	chr6:167386615	C/G	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.33	-0.36	8.97e-16	Neuroticism;
LGG	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.49e-13	Type 2 diabetes;
LGG	cis	rs2599510	0.744	rs2254106	chr2:32768797	G/A	cg02381751	chr2:32503542	YIPF4	0.45	7.34	0.32	9.8e-13	Interleukin-18 levels;
LGG	cis	rs3820068	0.705	rs72645804	chr1:15868387	A/C	cg05660106	chr1:15850417	CASP9	1.14	27.09	0.78	1.6e-97	Systolic blood pressure;
LGG	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg22643751	chr7:855365	UNC84A	0.43	7.62	0.33	1.4e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg18258770	chr4:90757814	SNCA	-0.39	-7.12	-0.31	4.28e-12	Dementia with Lewy bodies;
LGG	cis	rs7944584	1.000	rs7944584	chr11:47336320	A/T	cg20307385	chr11:47447363	PSMC3	0.66	12.59	0.5	1.84e-31	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg03060546	chr3:49711283	APEH	-0.62	-10.27	-0.43	2.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg01819759	chr13:79234251	RNF219	0.54	8.34	0.36	8.86e-16	Large artery stroke;
LGG	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs4740619	0.905	rs4146290	chr9:15782874	A/G	cg14451791	chr9:16040625	NA	-0.38	-9.75	-0.41	1.55e-20	Body mass index;
LGG	cis	rs1707322	0.752	rs3811435	chr1:46125790	C/A	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.85	-0.3	2.36e-11	Monocyte count;
LGG	cis	rs8114671	0.804	rs6060139	chr20:33566499	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	8.37	0.36	6.99e-16	Height;
LGG	cis	rs7582720	1.000	rs72934737	chr2:203740798	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.57	0.41	6.4e-20	Fuchs's corneal dystrophy;
LGG	cis	rs7937612	0.931	rs7121779	chr11:120213360	A/T	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.51	-0.5	3.92e-31	Intraocular pressure;
LGG	trans	rs11875185	0.510	rs77718791	chr18:55646214	G/A	cg15513957	chr14:69354734	ACTN1	-0.99	-9.57	-0.41	6.39e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg13206674	chr6:150067644	NUP43	0.66	15.13	0.58	2.72e-42	Lung cancer;
LGG	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg27189623	chr16:705930	WDR90	0.4	7.52	0.33	2.79e-13	Height;
LGG	cis	rs394563	0.517	rs385303	chr6:149779064	C/T	cg14343457	chr6:149716235	MAP3K7IP2	-0.39	-7.06	-0.31	6.12e-12	Dupuytren's disease;
LGG	cis	rs243505	0.737	rs243538	chr7:148404379	G/A	cg18940274	chr7:148469757	CUL1	0.37	6.98	0.31	1.01e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs503734	0.846	rs1471738	chr3:100915962	G/A	cg27318481	chr3:100970896	IMPG2	-0.43	-9.59	-0.41	5.3e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9368481	0.524	rs12530345	chr6:26884243	T/C	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1682825	1.000	rs1434605	chr3:10770849	C/T	cg23512531	chr3:10780469	NA	-0.57	-8.03	-0.35	8.23e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs113835537	0.627	rs11227534	chr11:66336171	C/A	cg24851651	chr11:66362959	CCS	0.48	8.21	0.36	2.22e-15	Airway imaging phenotypes;
LGG	cis	rs6032067	0.929	rs17424474	chr20:43804797	C/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.54e-28	Blood protein levels;
LGG	cis	rs11945232	1.000	rs6854710	chr4:88334640	A/G	cg23841344	chr4:88312519	HSD17B11	-0.53	-9.51	-0.4	1.04e-19	Intelligence (multi-trait analysis);
LGG	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg24759859	chr6:86352639	SYNCRIP	0.42	6.76	0.3	4.29e-11	Smooth-surface caries;
LGG	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg12395012	chr8:11607386	GATA4	-0.39	-7.08	-0.31	5.28e-12	Monocyte count;
LGG	cis	rs2549003	1.000	rs9282762	chr5:131822055	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg05863683	chr7:1912471	MAD1L1	-0.43	-8.43	-0.36	4.47e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg04863758	chr4:1303710	MAEA	0.41	7.06	0.31	5.96e-12	Obesity-related traits;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.79	-15.55	-0.59	3.68e-44	Longevity;Endometriosis;
LGG	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs2735413	0.564	rs7193020	chr16:78106440	A/G	cg04733911	chr16:78082701	NA	0.57	7.96	0.35	1.32e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7633770	0.805	rs11130098	chr3:46661926	A/G	cg11219411	chr3:46661640	NA	-0.62	-15.06	-0.57	5.53e-42	Coronary artery disease;
LGG	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.81	0.34	3.73e-14	Eosinophil percentage of white cells;
LGG	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg25019033	chr10:957182	NA	-0.53	-9.65	-0.41	3.43e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg06221963	chr1:154839813	KCNN3	-0.4	-7.79	-0.34	4.36e-14	Prostate cancer;
LGG	cis	rs2952156	0.920	rs12150298	chr17:37834541	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.44	-0.61	3.47e-48	Asthma;
LGG	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg19812747	chr11:111475976	SIK2	-0.49	-10.27	-0.43	1.97e-22	Primary sclerosing cholangitis;
LGG	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.39	0.4	2.67e-19	Rheumatoid arthritis;
LGG	cis	rs6901004	0.570	rs783084	chr6:111477887	T/C	cg15721981	chr6:111408429	SLC16A10	0.66	11.02	0.46	3e-25	Blood metabolite levels;
LGG	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg16077055	chr2:106428750	NCK2	0.28	7.42	0.33	5.72e-13	Addiction;
LGG	trans	rs12579753	0.810	rs10862350	chr12:82156202	G/A	cg07923666	chr12:49932857	KCNH3	-0.45	-7.29	-0.32	1.35e-12	Resting heart rate;
LGG	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg13010199	chr12:38710504	ALG10B	0.51	9.74	0.41	1.59e-20	Morning vs. evening chronotype;
LGG	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.81	-0.38	2.52e-17	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.65	0.3	8.35e-11	Schizophrenia;
LGG	cis	rs6963495	0.769	rs11556986	chr7:105177041	A/T	cg21420622	chr7:105162941	PUS7	-0.44	-6.67	-0.3	7.39e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg08250081	chr4:10125330	NA	-0.36	-6.92	-0.31	1.55e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg27286337	chr10:134555280	INPP5A	0.9	15.19	0.58	1.44e-42	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9644630	0.672	rs12542081	chr8:19317786	G/T	cg01280390	chr8:19363452	CSGALNACT1	0.47	11.79	0.48	3.17e-28	Oropharynx cancer;
LGG	cis	rs2133450	0.526	rs12489441	chr3:7346788	C/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.35	-0.4	3.8e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg09307838	chr4:120376055	NA	0.79	12.96	0.52	5.65e-33	Corneal astigmatism;
LGG	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.05	0.49	2.9e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg19875535	chr5:140030758	IK	0.57	11.85	0.48	1.79e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg11764359	chr7:65958608	NA	-0.62	-10.79	-0.45	2.25e-24	Aortic root size;
LGG	cis	rs9814567	0.762	rs13079012	chr3:134247706	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.15	0.46	1.02e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.71	0.54	3.76e-36	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs72625777	chr15:67503808	G/C	cg05925327	chr15:68127851	NA	-0.32	-6.84	-0.3	2.44e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.93	0.38	9.91e-18	Platelet count;
LGG	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.16	0.52	7.62e-34	Colorectal cancer;
LGG	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2901460	0.509	rs56944298	chr2:62090001	A/G	cg02183531	chr2:62113199	CCT4	-0.45	-8.02	-0.35	8.94e-15	Mean corpuscular volume;
LGG	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg22974920	chr21:40686053	BRWD1	-0.43	-6.96	-0.31	1.15e-11	Cognitive function;
LGG	cis	rs1451375	0.617	rs10267323	chr7:50591424	A/G	cg20336341	chr7:50628841	DDC	0.43	7.61	0.33	1.52e-13	Malaria;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.23e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg04455712	chr21:45112962	RRP1B	0.49	9.25	0.4	7.98e-19	Mean corpuscular volume;
LGG	trans	rs7939886	0.920	rs1031978	chr11:55965641	G/T	cg03929089	chr4:120376271	NA	0.73	6.79	0.3	3.52e-11	Myopia (pathological);
LGG	cis	rs17767392	0.918	rs34725136	chr14:71760422	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.67e-18	Mitral valve prolapse;
LGG	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg08975724	chr8:8085496	FLJ10661	0.48	9.48	0.4	1.38e-19	Mood instability;
LGG	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-10.18	-0.43	4.2e-22	Lung cancer in ever smokers;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg18402987	chr7:1209562	NA	0.63	8.83	0.38	2.23e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg15596359	chr8:11213517	TDH	-0.38	-7.87	-0.34	2.52e-14	Retinal vascular caliber;
LGG	cis	rs4650994	0.816	rs2811301	chr1:178594196	T/C	cg12486710	chr1:178512616	C1orf220	-0.4	-8.05	-0.35	6.82e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg23188684	chr11:67383651	NA	-0.41	-6.78	-0.3	3.65e-11	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23000464	chr19:633785	POLRMT	0.48	7.8	0.34	4.11e-14	Cognitive performance;
LGG	cis	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.65	-0.3	8.44e-11	Neuroticism;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg23758822	chr17:41437982	NA	0.84	15.12	0.57	2.97e-42	Menopause (age at onset);
LGG	cis	rs9308731	0.666	rs4849402	chr2:111873932	G/A	cg19992207	chr2:111874495	ACOXL	-0.37	-6.75	-0.3	4.51e-11	Chronic lymphocytic leukemia;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.45	-0.4	1.73e-19	Life satisfaction;
LGG	cis	rs1010254	0.510	rs56019388	chr5:151706225	T/G	cg12297329	chr5:152029980	NA	-0.51	-7.3	-0.32	1.3e-12	Optic nerve measurement (cup area);
LGG	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg03929089	chr4:120376271	NA	-1.02	-22.54	-0.72	1.68e-76	Height;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg09303159	chr6:26284866	NA	0.34	7.84	0.34	3.09e-14	Educational attainment;
LGG	cis	rs13102973	0.720	rs7672296	chr4:135890056	C/G	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.24	0.32	1.94e-12	Neuroticism;
LGG	cis	rs1682825	0.591	rs350662	chr3:10778894	A/C	cg23512531	chr3:10780469	NA	0.61	7.18	0.32	2.88e-12	Economic and political preferences (feminism/equality);
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg12419862	chr22:24373484	LOC391322	-0.88	-17.33	-0.63	3.16e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.98	-0.74	3.42e-83	Height;
LGG	cis	rs9308433	0.553	rs11120299	chr1:214509407	C/A	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.27e-14	IgG glycosylation;
LGG	cis	rs727505	0.866	rs67132333	chr7:124719801	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07856758	chr19:37861652	ZNF527	0.47	8.09	0.35	5.42e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00149659	chr3:10157352	C3orf10	0.96	11.12	0.46	1.27e-25	Alzheimer's disease;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	-0.23	-6.73	-0.3	5.09e-11	IgG glycosylation;
LGG	trans	rs35110281	0.517	rs11701973	chr21:44979671	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.97	0.45	4.92e-25	Mean corpuscular volume;
LGG	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg18876405	chr7:65276391	NA	0.55	9.83	0.42	7.52e-21	Aortic root size;
LGG	cis	rs2933343	0.909	rs1683817	chr3:128651536	G/A	cg25356066	chr3:128598488	ACAD9	0.46	6.68	0.3	6.86e-11	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03627896	chr16:30934334	NCRNA00095	0.49	8.0	0.35	1.01e-14	Cognitive performance;
LGG	cis	rs9811920	0.683	rs793502	chr3:99588417	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	7.5	0.33	3.22e-13	Axial length;
LGG	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07269724	chr19:12904655	NA	0.53	7.95	0.35	1.43e-14	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg23129478	chr18:44337922	ST8SIA5	0.37	7.05	0.31	6.69e-12	Personality dimensions;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg01673284	chr16:4527211	HMOX2	0.34	6.72	0.3	5.51e-11	Schizophrenia;
LGG	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06481639	chr22:41940642	POLR3H	-0.46	-7.19	-0.32	2.64e-12	Vitiligo;
LGG	cis	rs12367572	0.501	rs7975969	chr12:45468749	T/C	cg03114573	chr12:45410052	DBX2	-0.51	-8.71	-0.38	5.31e-17	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.48	-0.4	1.33e-19	Blood metabolite levels;
LGG	cis	rs6835098	1.000	rs9990666	chr4:174083150	G/T	cg08422745	chr4:174089978	GALNT7	-0.84	-15.28	-0.58	5.66e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-10.0	-0.42	1.93e-21	Hepatocellular carcinoma;
LGG	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg04617936	chr2:214353	NA	-0.39	-7.15	-0.32	3.35e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22618164	chr12:122356400	WDR66	0.33	9.94	0.42	3.1e-21	Mean corpuscular volume;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg06916706	chr16:4465613	CORO7	-1.1	-21.36	-0.7	6.07e-71	Schizophrenia;
LGG	cis	rs7215564	0.908	rs2316062	chr17:78663558	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.23	-0.36	1.96e-15	Myopia (pathological);
LGG	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg04851639	chr8:1020857	NA	-0.44	-8.96	-0.38	8.08e-18	Schizophrenia;
LGG	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg19131313	chr8:1704013	NA	-0.3	-6.73	-0.3	5.07e-11	Systolic blood pressure;
LGG	cis	rs9487094	0.645	rs34292461	chr6:109673480	C/T	cg01125227	chr6:109776195	MICAL1	0.46	7.09	0.31	5.19e-12	Height;
LGG	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	trans	rs7395662	0.658	rs2865610	chr11:48772617	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.23e-14	HDL cholesterol;
LGG	cis	rs4566357	0.615	rs2396445	chr2:227917726	C/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.93e-18	Coronary artery disease;
LGG	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg13802316	chr11:70253460	CTTN	-0.6	-7.63	-0.33	1.31e-13	Coronary artery disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10532262	chr3:172428426	NCEH1	0.39	6.77	0.3	3.93e-11	Bipolar disorder;
LGG	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg19901468	chr14:105411992	AHNAK2	0.71	13.53	0.53	2.31e-35	Rheumatoid arthritis;
LGG	cis	rs9952991	0.883	rs2847260	chr18:12775591	C/T	cg23544223	chr18:12777786	NA	0.61	9.26	0.4	7.39e-19	Inflammatory skin disease;
LGG	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.81e-32	Motion sickness;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.74	15.4	0.58	1.69e-43	Obesity-related traits;
LGG	cis	rs9354352	0.935	rs7766730	chr6:66697003	C/A	cg07460842	chr6:66804631	NA	0.74	13.97	0.54	2.85e-37	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-8.84	-0.38	2.07e-17	Lung function (FEV1/FVC);
LGG	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg27454842	chr22:32027588	PISD	-0.61	-6.81	-0.3	3e-11	Age-related hearing impairment;
LGG	cis	rs503734	0.666	rs1918405	chr3:101269038	A/C	cg27318481	chr3:100970896	IMPG2	0.37	7.4	0.33	6.52e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg00795024	chr1:214157026	NA	0.26	7.41	0.33	6.01e-13	Schizophrenia;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7566780	0.602	rs6742067	chr2:16685148	C/G	cg09580478	chr2:16689509	NA	-0.48	-7.4	-0.33	6.52e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	trans	rs28595532	0.720	rs72670231	chr4:119312908	C/T	cg26518628	chr1:97050305	NA	-0.82	-7.06	-0.31	5.98e-12	Cannabis dependence symptom count;
LGG	cis	rs9443189	0.570	rs504446	chr6:76326939	T/C	cg01950844	chr6:76311363	SENP6	0.76	10.1	0.43	8.06e-22	Prostate cancer;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19524238	chr7:2802976	GNA12	0.32	7.83	0.34	3.29e-14	Height;
LGG	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg27053975	chr1:166958233	MAEL	-0.48	-6.65	-0.3	8.2e-11	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg20607798	chr8:58055168	NA	0.7	8.08	0.35	5.5e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg00976097	chr5:421733	AHRR	-0.43	-6.98	-0.31	1.04e-11	Cystic fibrosis severity;
LGG	cis	rs12586317	0.547	rs77262907	chr14:35495734	C/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.76	-0.34	5.64e-14	Psoriasis;
LGG	cis	rs6546550	0.868	rs12713682	chr2:70154134	G/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.95	-0.35	1.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg00339695	chr16:24857497	SLC5A11	0.4	6.94	0.31	1.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-12.06	-0.49	2.5e-29	Chronic sinus infection;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06873352	chr17:61820015	STRADA	0.74	13.8	0.54	1.55e-36	Prudent dietary pattern;
LGG	cis	rs12618769	0.597	rs3769715	chr2:99146855	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.47e-16	Bipolar disorder;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.04e-12	Bipolar disorder;
LGG	trans	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	9.2	0.39	1.21e-18	Lung function (FEV1/FVC);
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.93	-0.45	6.69e-25	Bipolar disorder;
LGG	cis	rs9910055	0.529	rs615070	chr17:42176591	A/G	cg19774624	chr17:42201019	HDAC5	-0.66	-11.67	-0.48	9.25e-28	Total body bone mineral density;
LGG	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.71e-21	Monocyte count;
LGG	cis	rs6748734	0.581	rs4234092	chr2:241866389	T/C	cg14055004	chr2:241860995	NA	0.31	7.61	0.33	1.52e-13	Urinary metabolites;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg04008888	chr11:68622739	NA	-0.56	-11.93	-0.48	8.4e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.61	0.63	1.75e-53	Cognitive function;
LGG	cis	rs7512552	0.839	rs4581308	chr1:150276872	A/G	cg15654264	chr1:150340011	RPRD2	-0.44	-9.07	-0.39	3.39e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7394190	0.935	rs4746140	chr10:75417249	G/C	cg07699608	chr10:75541558	CHCHD1	0.52	7.59	0.33	1.81e-13	Incident atrial fibrillation;
LGG	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.1	0.42	8.4e-22	Lung cancer in ever smokers;
LGG	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg21100191	chr22:23484243	RTDR1	1.02	23.72	0.74	5.19e-82	Bone mineral density;
LGG	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4460629	0.680	rs10796938	chr1:155072055	C/A	cg13808842	chr1:155066096	NA	-0.29	-7.04	-0.31	6.98e-12	Serum magnesium levels;
LGG	cis	rs7923609	1.000	rs10822161	chr10:65118203	G/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.66	-0.3	7.61e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.34	0.36	8.81e-16	Neuroticism;
LGG	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.03	-0.66	4.65e-60	Height;
LGG	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.4	0.47	1.04e-26	Bone mineral density;
LGG	cis	rs17253792	0.822	rs79873916	chr14:56172631	G/C	cg01858014	chr14:56050164	KTN1	-0.89	-12.03	-0.49	3.41e-29	Putamen volume;
LGG	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg08885076	chr2:99613938	TSGA10	-0.61	-12.41	-0.5	9.75e-31	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24701985	chr7:149535383	ZNF862	0.52	8.33	0.36	9.25e-16	Gut microbiome composition (summer);
LGG	cis	rs7666738	0.830	rs10516426	chr4:99035827	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs77633900	0.881	rs113134510	chr15:76667396	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-7.58	-0.33	1.87e-13	Non-glioblastoma glioma;Glioma;
LGG	trans	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.64	0.48	1.22e-27	Obesity-related traits;
LGG	cis	rs151997	0.629	rs152808	chr5:50207382	G/C	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg15162869	chr22:32027605	PISD	-0.69	-7.26	-0.32	1.64e-12	Age-related hearing impairment;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg06074448	chr4:187884817	NA	-0.58	-12.71	-0.51	5.79e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs853679	0.517	rs9380047	chr6:28037893	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.6	-0.33	1.71e-13	Depression;
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg23625390	chr15:77176239	SCAPER	-0.77	-15.97	-0.6	4.83e-46	Blood metabolite levels;
LGG	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg24209194	chr3:40518798	ZNF619	-0.42	-6.74	-0.3	4.6e-11	Renal cell carcinoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12485212	chr8:61565947	NA	0.46	7.61	0.33	1.51e-13	Cognitive performance;
LGG	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.57	0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs763121	0.853	rs5750671	chr22:39094619	A/C	cg06022373	chr22:39101656	GTPBP1	0.91	19.1	0.66	2.18e-60	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg04064380	chr11:117688259	NA	-0.52	-7.33	-0.32	1.01e-12	Myopia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07164266	chr3:149470245	COMMD2	0.45	6.94	0.31	1.37e-11	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg06212747	chr3:49208901	KLHDC8B	0.53	8.14	0.35	3.6e-15	Menarche (age at onset);
LGG	cis	rs300774	0.858	rs423038	chr2:129486	A/C	cg04617936	chr2:214353	NA	-0.49	-7.54	-0.33	2.47e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	5.9e-49	Hip circumference adjusted for BMI;
LGG	cis	rs36051895	0.659	rs7045491	chr9:5045658	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.44	-0.61	3.55e-48	Pediatric autoimmune diseases;
LGG	cis	rs72781680	0.898	rs72780111	chr2:23991146	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs6909430	0.901	rs2450521	chr6:98568517	C/T	cg12860156	chr6:98744658	NA	-0.44	-7.45	-0.33	4.74e-13	Quantitative traits;
LGG	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	trans	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17712092	chr4:129076599	LARP1B	0.75	14.42	0.56	3.29e-39	Eosinophil percentage of white cells;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14123153	chr12:6602654	NCAPD2;MRPL51	0.4	6.84	0.3	2.49e-11	Bipolar disorder;
LGG	cis	rs709400	0.663	rs55723020	chr14:103991401	G/A	cg26031613	chr14:104095156	KLC1	0.82	14.06	0.55	1.25e-37	Body mass index;
LGG	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg12310025	chr6:25882481	NA	0.53	9.84	0.42	7.17e-21	Blood metabolite levels;
LGG	cis	rs11971779	0.680	rs6960876	chr7:139112176	C/T	cg07862535	chr7:139043722	LUC7L2	-0.43	-7.15	-0.32	3.31e-12	Diisocyanate-induced asthma;
LGG	cis	rs11971779	0.680	rs7805767	chr7:139111415	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs7267979	0.528	rs6076366	chr20:25564626	G/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.72	-0.34	7.41e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6546550	0.933	rs1454498	chr2:70149225	C/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.05	0.52	2.4e-33	Rheumatoid arthritis;
LGG	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg01017244	chr2:74357527	NA	0.49	8.79	0.38	2.97e-17	Gestational age at birth (maternal effect);
LGG	cis	rs732765	0.909	rs709887	chr14:75369379	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.0	-0.31	9.03e-12	Non-small cell lung cancer;
LGG	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12477438	1.000	rs11897712	chr2:99735697	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-10.7	-0.45	4.82e-24	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg14926445	chr8:58193284	C8orf71	0.81	10.62	0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs7432375	0.610	rs7633629	chr3:136517028	T/A	cg21827317	chr3:136751795	NA	0.44	7.96	0.35	1.33e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg05692746	chr2:100937584	LONRF2	0.58	9.34	0.4	3.91e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.79	0.38	3e-17	Bipolar disorder;
LGG	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg18357526	chr6:26021779	HIST1H4A	0.49	8.13	0.35	3.83e-15	Height;
LGG	trans	rs1422110	0.819	rs1422114	chr5:85483880	A/G	cg01787110	chr1:109008453	NBPF6	0.6	9.65	0.41	3.44e-20	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg21605333	chr4:119757512	SEC24D	0.76	8.33	0.36	9.08e-16	Cannabis dependence symptom count;
LGG	cis	rs7635838	0.654	rs346086	chr3:11272932	G/T	cg00170343	chr3:11313890	ATG7	0.56	9.17	0.39	1.6e-18	HDL cholesterol;
LGG	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg08250081	chr4:10125330	NA	-0.37	-7.25	-0.32	1.72e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs57590327	0.503	rs7426937	chr3:81881360	T/C	cg07356753	chr3:81810745	GBE1	-0.43	-6.97	-0.31	1.07e-11	Extraversion;
LGG	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	7.78	0.34	4.69e-14	Platelet count;
LGG	cis	rs11168618	1.000	rs3961921	chr12:48943499	G/A	cg24011408	chr12:48396354	COL2A1	0.49	7.88	0.34	2.36e-14	Adiponectin levels;
LGG	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg03929089	chr4:120376271	NA	0.73	8.44	0.37	4.1e-16	Axial length;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10622271	chr12:50236974	BCDIN3D	0.48	7.14	0.31	3.75e-12	Gut microbiome composition (summer);
LGG	cis	rs7928758	0.767	rs1866768	chr11:134274710	A/G	cg25213107	chr11:134282864	B3GAT1	0.71	10.12	0.43	6.79e-22	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1816752	0.875	rs59531061	chr13:25081435	C/T	cg22771759	chr13:24902376	NA	0.42	7.0	0.31	9.02e-12	Obesity-related traits;
LGG	trans	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg25214090	chr10:38739885	LOC399744	0.64	11.58	0.47	2.11e-27	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25822402	chr13:39260877	FREM2	0.44	7.02	0.31	7.73e-12	Gut microbiome composition (summer);
LGG	cis	rs603424	0.597	rs574122	chr10:102089174	C/A	cg10365880	chr10:102089681	PKD2L1	0.52	7.99	0.35	1.07e-14	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LGG	cis	rs10504130	0.569	rs11775587	chr8:52820165	C/T	cg24946253	chr8:52722146	PXDNL	0.45	6.65	0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7928758	0.887	rs55751035	chr11:134265723	C/T	cg25213107	chr11:134282864	B3GAT1	1.25	14.86	0.57	3.94e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg02951883	chr7:2050386	MAD1L1	0.46	6.81	0.3	3.04e-11	Bipolar disorder;
LGG	cis	rs7215564	0.818	rs7214465	chr17:78566792	G/A	cg16980736	chr17:78789706	RPTOR	-0.68	-8.52	-0.37	2.23e-16	Myopia (pathological);
LGG	cis	rs9915657	0.870	rs4140903	chr17:70133771	C/T	cg09344028	chr17:70110421	NA	0.47	10.38	0.43	7.67e-23	Thyroid hormone levels;
LGG	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg13385521	chr17:29058706	SUZ12P	0.89	10.01	0.42	1.82e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg15049968	chr18:44337910	ST8SIA5	-0.36	-6.73	-0.3	5.16e-11	Personality dimensions;
LGG	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.21	0.43	3.36e-22	Motion sickness;
LGG	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg21926883	chr2:100939477	LONRF2	-0.7	-16.71	-0.61	2.08e-49	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.76	-0.34	5.44e-14	Neuroticism;
LGG	cis	rs7615952	0.546	rs11711150	chr3:125315663	C/T	cg21696256	chr3:125484277	NA	-0.45	-6.73	-0.3	4.96e-11	Blood pressure (smoking interaction);
LGG	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg08468577	chr11:2973342	NAP1L4	-0.39	-8.08	-0.35	5.67e-15	Calcium levels;
LGG	cis	rs9640161	0.659	rs11974980	chr7:150009838	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.71	-14.74	-0.57	1.31e-40	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.31	0.5	2.48e-30	Prudent dietary pattern;
LGG	cis	rs3850699	0.926	rs2002916	chr10:104432053	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.41	-6.7	-0.3	6.16e-11	Prostate cancer;
LGG	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.72	-0.34	7.43e-14	Iron status biomarkers;
LGG	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26306683	chr17:18585705	ZNF286B	0.46	8.7	0.37	5.93e-17	Educational attainment (years of education);
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.44	0.33	5.03e-13	Morning vs. evening chronotype;
LGG	trans	rs2945232	1	rs2945232	chr8:8098038	T/C	cg02002194	chr4:3960332	NA	-0.59	-11.87	-0.48	1.49e-28	Schizophrenia;
LGG	cis	rs3806843	1.000	rs1030165	chr5:140185448	G/A	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13012494	chr21:47604986	C21orf56	0.5	8.55	0.37	1.84e-16	Testicular germ cell tumor;
LGG	cis	rs12143943	0.966	rs4951410	chr1:204563817	G/A	cg20240347	chr1:204465584	NA	-0.33	-6.97	-0.31	1.11e-11	Cognitive performance;
LGG	cis	rs11190604	1.000	rs12354411	chr10:102294537	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	12.05	0.49	2.88e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg24253500	chr15:84953950	NA	0.6	11.36	0.47	1.56e-26	Schizophrenia;
LGG	cis	rs9309473	0.687	rs11693531	chr2:73608614	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-9.37	-0.4	3.19e-19	Metabolite levels;
LGG	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.2	-0.46	6.35e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg12927641	chr6:109611667	NA	-0.38	-7.29	-0.32	1.39e-12	Reticulocyte fraction of red cells;
LGG	cis	rs7177699	0.557	rs12898452	chr15:79112628	C/A	cg00540400	chr15:79124168	NA	0.54	11.48	0.47	5.23e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9300255	0.602	rs884548	chr12:123634122	A/G	cg00376283	chr12:123451042	ABCB9	0.65	10.67	0.44	6.51e-24	Neutrophil percentage of white cells;
LGG	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg02733842	chr7:1102375	C7orf50	-0.46	-7.34	-0.32	9.5e-13	Bronchopulmonary dysplasia;
LGG	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-21.48	-0.71	1.6e-71	Vitiligo;
LGG	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12681288	0.523	rs6983944	chr8:955147	A/G	cg04851639	chr8:1020857	NA	-0.33	-6.94	-0.31	1.36e-11	Schizophrenia;
LGG	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg10621924	chr7:39171070	POU6F2	0.47	9.72	0.41	1.92e-20	IgG glycosylation;
LGG	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.58	-0.41	6.16e-20	Neuroticism;
LGG	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg02002194	chr4:3960332	NA	0.37	6.67	0.3	7.32e-11	Triglycerides;
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19524238	chr7:2802976	GNA12	0.37	8.68	0.37	6.85e-17	Height;
LGG	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg25726756	chr21:47582351	C21orf56	-0.32	-6.92	-0.31	1.48e-11	Testicular germ cell tumor;
LGG	cis	rs1801251	1.000	rs12478564	chr2:233598340	C/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	5.14e-19	Coronary artery disease;
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.33	-0.53	1.52e-34	Personality dimensions;
LGG	cis	rs7582720	1.000	rs72932777	chr2:203689914	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.74	0.41	1.65e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.67	-10.0	-0.42	1.87e-21	Body mass index;
LGG	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg21775007	chr8:11205619	TDH	0.49	7.94	0.35	1.58e-14	Neuroticism;
LGG	trans	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg06521331	chr12:34319734	NA	0.42	7.06	0.31	6.04e-12	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs6871536	1.000	rs6596087	chr5:131968609	G/A	cg04303330	chr5:131992430	IL13	0.28	6.84	0.3	2.46e-11	Asthma (childhood onset);
LGG	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.21	0.49	6.41e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.48	0.33	3.85e-13	Neutrophil percentage of white cells;
LGG	cis	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.56	-0.33	2.15e-13	Total cholesterol levels;
LGG	cis	rs10262624	0.967	rs35988560	chr7:23918180	G/A	cg09690326	chr7:23720549	C7orf46	-0.33	-6.86	-0.3	2.21e-11	Schizophrenia;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.14	0.43	5.92e-22	Schizophrenia;
LGG	cis	rs4474465	0.915	rs12274873	chr11:78183015	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.61	-0.37	1.12e-16	Alzheimer's disease (survival time);
LGG	cis	rs638893	0.898	rs587816	chr11:118689871	A/C	cg22253036	chr11:118662786	DDX6	0.44	7.54	0.33	2.58e-13	Vitiligo;
LGG	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg00012203	chr2:219082015	ARPC2	-0.68	-12.24	-0.49	4.8e-30	Colorectal cancer;
LGG	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03517284	chr6:25882590	NA	0.52	9.62	0.41	4.3e-20	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs12618769	0.597	rs72821930	chr2:99127525	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg09873164	chr1:152488093	CRCT1	0.63	15.52	0.59	4.68e-44	Hair morphology;
LGG	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	8.52e-63	Diabetic kidney disease;
LGG	cis	rs9649213	0.614	rs9641236	chr7:97998124	T/A	cg09267113	chr7:98030324	BAIAP2L1	-0.46	-7.7	-0.34	8.31e-14	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs936229	0.861	rs11634474	chr15:75116184	C/G	cg14664628	chr15:75095509	CSK	-1.15	-27.73	-0.79	2e-100	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs1707322	1.000	rs34694458	chr1:46332696	G/A	cg03146154	chr1:46216737	IPP	0.55	10.48	0.44	3.45e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg06521331	chr12:34319734	NA	-0.49	-8.63	-0.37	9.68e-17	Bladder cancer;
LGG	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg01528321	chr10:82214614	TSPAN14	1.19	24.43	0.75	2.8e-85	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg22535103	chr8:58192502	C8orf71	-0.87	-11.15	-0.46	9.71e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs745080	0.519	rs4901282	chr14:52980598	C/T	cg23333723	chr14:53022898	GPR137C	-0.41	-8.19	-0.36	2.58e-15	Orofacial clefts;
LGG	cis	rs1124376	0.882	rs7639282	chr3:20133873	G/A	cg05072819	chr3:20081367	KAT2B	0.6	7.98	0.35	1.14e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07685180	chr8:600429	NA	1.12	10.59	0.44	1.35e-23	IgG glycosylation;
LGG	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg13072238	chr3:49761600	GMPPB	-0.54	-6.88	-0.3	2e-11	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00166722	chr3:10149974	C3orf24	0.55	7.97	0.35	1.28e-14	Alzheimer's disease;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.57	9.43	0.4	2e-19	Longevity;
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-8.49	-0.37	2.78e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	8.75	0.38	4.08e-17	Platelet count;
LGG	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg15736062	chr7:158136485	PTPRN2	-0.39	-7.75	-0.34	6.07e-14	Calcium levels;
LGG	cis	rs2629540	0.924	rs1545910	chr10:126428145	G/C	cg08799069	chr10:126477246	METTL10	-0.65	-12.96	-0.52	5.56e-33	Cocaine dependence;
LGG	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-8.89	-0.38	1.36e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg01238044	chr22:24384105	GSTT1	-0.44	-7.54	-0.33	2.46e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.99	-0.31	9.68e-12	Mood instability;
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17554472	chr22:41940697	POLR3H	0.46	6.73	0.3	4.94e-11	Vitiligo;
LGG	cis	rs7666738	1.000	rs2865983	chr4:99033352	C/T	cg05340658	chr4:99064831	C4orf37	0.44	6.97	0.31	1.1e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg13560919	chr6:33536144	NA	-0.39	-7.03	-0.31	7.47e-12	Crohn's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18154422	chr10:31609200	ZEB1;LOC220930	0.46	7.82	0.34	3.7e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg25100604	chr2:70314404	PCBP1	0.41	6.77	0.3	3.95e-11	Coronary artery disease;
LGG	cis	rs2880765	0.545	rs17553734	chr15:86013059	C/G	cg19183879	chr15:85880815	NA	0.49	9.28	0.4	6.52e-19	Coronary artery disease;
LGG	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg10621924	chr7:39171070	POU6F2	0.48	10.03	0.42	1.53e-21	IgG glycosylation;
LGG	cis	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg01579765	chr21:45077557	HSF2BP	0.36	8.23	0.36	1.96e-15	Mean corpuscular volume;
LGG	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg05985134	chr18:33552581	C18orf21	0.66	10.29	0.43	1.61e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs75920871	0.528	rs1531706	chr11:116943952	C/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.52	-0.33	2.92e-13	Subjective well-being;
LGG	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg11693508	chr17:37793320	STARD3	-0.69	-10.1	-0.42	8.5e-22	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7188861	0.813	rs2867936	chr16:11398698	C/T	cg01510278	chr16:11456238	NA	0.29	7.15	0.32	3.31e-12	HDL cholesterol;
LGG	cis	rs8014204	0.935	rs1799900	chr14:75367740	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.86	-18.21	-0.65	2.75e-56	Caffeine consumption;
LGG	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg17971929	chr21:40555470	PSMG1	0.71	13.42	0.53	6.33e-35	Cognitive function;
LGG	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	cis	rs7188861	1.000	rs889648	chr16:11455816	G/C	cg01510278	chr16:11456238	NA	0.35	8.43	0.36	4.31e-16	HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16826753	chr21:34915507	GART;SON	0.43	7.1	0.31	4.87e-12	Cognitive performance;
LGG	cis	rs911555	0.504	rs745079	chr14:104073551	G/A	cg24130564	chr14:104152367	KLC1	-0.76	-16.92	-0.62	2.27e-50	Intelligence (multi-trait analysis);
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg20120463	chr17:44301886	NA	-0.45	-6.81	-0.3	3.13e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.47	-0.37	3.39e-16	Aortic root size;
LGG	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg16980736	chr17:78789706	RPTOR	-0.64	-8.41	-0.36	5.04e-16	Myopia (pathological);
LGG	cis	rs4746059	0.541	rs10999480	chr10:72477261	T/C	cg18679544	chr10:72432482	ADAMTS14	0.51	8.57	0.37	1.58e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7202877	0.706	rs2059257	chr16:75396376	G/A	cg03315344	chr16:75512273	CHST6	0.54	7.48	0.33	3.85e-13	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg05425664	chr17:57184151	TRIM37	-0.43	-6.89	-0.3	1.86e-11	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg03806693	chr22:41940476	POLR3H	-0.65	-10.65	-0.44	7.68e-24	Neuroticism;
LGG	cis	rs6754311	0.773	rs666407	chr2:136640233	A/G	cg07169764	chr2:136633963	MCM6	0.76	12.94	0.52	6.81e-33	Mosquito bite size;
LGG	trans	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg08847335	chr10:891726	LARP4B	-0.48	-8.14	-0.35	3.63e-15	Eosinophil percentage of granulocytes;
LGG	cis	rs10940138	0.779	rs991123	chr5:67246171	G/A	ch.5.1281357F	chr5:67228439	NA	0.74	12.94	0.52	6.52e-33	Menarche (age at onset);
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05025164	chr4:1340916	KIAA1530	0.85	16.82	0.62	6.88e-50	Longevity;
LGG	cis	rs55883249	0.958	rs113937820	chr2:9746668	A/G	cg23886495	chr2:9695866	ADAM17	0.66	9.69	0.41	2.47e-20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs701145	0.537	rs446144	chr3:153922154	T/C	cg17054900	chr3:154042577	DHX36	0.85	9.59	0.41	5.6e-20	Coronary artery disease;
LGG	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	cis	rs921968	0.643	rs3845836	chr2:219504955	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.3	-0.32	1.27e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.92e-15	Life satisfaction;
LGG	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg27205649	chr11:78285834	NARS2	0.45	7.52	0.33	2.84e-13	Testicular germ cell tumor;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.38	7.84	0.34	3.14e-14	Schizophrenia;
LGG	cis	rs10744422	0.748	rs2292138	chr12:123339712	A/G	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	5.17e-19	Schizophrenia;
LGG	cis	rs2221894	0.506	rs79113316	chr8:28882437	C/T	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.75	-0.34	5.93e-14	Obesity-related traits;
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.01	-0.6	3.29e-46	Intelligence (multi-trait analysis);
LGG	cis	rs7937890	0.531	rs2575859	chr11:14510736	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg00933542	chr6:150070202	PCMT1	0.37	6.78	0.3	3.63e-11	Lung cancer;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg26513180	chr16:89883248	FANCA	0.8	8.45	0.37	3.74e-16	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.86e-13	Life satisfaction;
LGG	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs758324	0.617	rs77938	chr5:131322494	C/T	cg06307176	chr5:131281290	NA	0.45	6.84	0.3	2.58e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	8.85e-13	Lung cancer;
LGG	trans	rs12478296	0.591	rs12719765	chr2:242997202	C/G	cg01596870	chr19:55963115	NA	-0.5	-7.54	-0.33	2.48e-13	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs972578	0.715	rs4822202	chr22:43235156	C/A	cg01576275	chr22:43409880	NA	-0.23	-6.86	-0.3	2.17e-11	Mean platelet volume;
LGG	cis	rs258892	0.895	rs34658	chr5:72148496	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07659893	chr17:61819838	STRADA	0.48	8.01	0.35	9.14e-15	Prudent dietary pattern;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg02018176	chr4:1364513	KIAA1530	-0.49	-11.78	-0.48	3.26e-28	Obesity-related traits;
LGG	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.24	0.39	8.66e-19	Fuchs's corneal dystrophy;
LGG	cis	rs17604090	1.000	rs114892953	chr7:29676298	G/A	cg19413766	chr7:29689036	LOC646762	-0.57	-6.87	-0.3	2.06e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs6868223	0.585	rs4129122	chr5:33646300	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	cis	rs10870270	0.784	rs10430614	chr10:133748640	C/T	cg17892150	chr10:133769511	PPP2R2D	0.58	11.47	0.47	5.6e-27	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.92	0.38	1.05e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.18	-0.32	2.77e-12	Systolic blood pressure;
LGG	cis	rs9549367	0.713	rs4907593	chr13:113830459	C/T	cg00898013	chr13:113819073	PROZ	0.48	9.85	0.42	6.47e-21	Platelet distribution width;
LGG	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.97	-0.42	2.54e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg25846022	chr1:78444909	FUBP1	-0.43	-7.13	-0.31	3.89e-12	Leprosy;
LGG	cis	rs6546550	0.803	rs10165883	chr2:70117015	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.2	-0.36	2.47e-15	Prevalent atrial fibrillation;
LGG	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg21100191	chr22:23484243	RTDR1	1.0	22.93	0.73	2.58e-78	Bone mineral density;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2708240	0.577	rs13235812	chr7:147556653	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.29	6.86	0.3	2.28e-11	QT interval (drug interaction);
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg22044901	chr15:68126292	NA	-0.43	-7.86	-0.34	2.73e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.29e-11	Cognitive ability;
LGG	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg16586182	chr3:47516702	SCAP	0.78	15.57	0.59	2.98e-44	Colorectal cancer;
LGG	cis	rs7149337	1.000	rs35567150	chr14:51725944	A/G	cg23942311	chr14:51606299	NA	0.33	7.29	0.32	1.36e-12	Cancer;
LGG	cis	rs4954585	0.708	rs13034241	chr2:137021263	G/A	cg07169764	chr2:136633963	MCM6	-0.46	-7.32	-0.32	1.12e-12	Colorectal cancer;
LGG	cis	rs4330281	0.647	rs13061771	chr3:17743799	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.46	-0.33	4.24e-13	Schizophrenia;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg05272556	chr6:34360624	NUDT3	0.41	7.03	0.31	7.38e-12	Coronary artery disease;
LGG	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.51	-0.37	2.51e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs66887589	1.000	rs66887589	chr4:120509279	T/C	cg09307838	chr4:120376055	NA	-0.47	-8.15	-0.35	3.4e-15	Diastolic blood pressure;
LGG	cis	rs7617773	0.746	rs4130995	chr3:48358255	C/T	cg11946769	chr3:48343235	NME6	0.6	10.23	0.43	2.79e-22	Coronary artery disease;
LGG	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.89	-0.45	9.99e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7027203	0.828	rs10122041	chr9:96615517	A/G	cg14598338	chr9:96623480	NA	-0.54	-9.61	-0.41	4.74e-20	DNA methylation (variation);
LGG	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.14	0.31	3.64e-12	Refractive error;
LGG	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg02023728	chr11:77925099	USP35	-0.39	-6.9	-0.31	1.69e-11	Alzheimer's disease (survival time);
LGG	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg13010199	chr12:38710504	ALG10B	0.72	13.96	0.54	3.34e-37	Bladder cancer;
LGG	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg14582100	chr15:45693742	SPATA5L1	-0.4	-6.77	-0.3	4.03e-11	Homoarginine levels;
LGG	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg04989706	chr14:50066350	PPIL5	-0.6	-9.86	-0.42	5.94e-21	Carotid intima media thickness;
LGG	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg08822215	chr16:89438651	ANKRD11	-0.36	-7.07	-0.31	5.86e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg08621203	chr6:150244597	RAET1G	0.44	6.65	0.3	8.04e-11	Lung cancer;
LGG	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.06	-0.31	6.19e-12	Diastolic blood pressure;
LGG	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg03517284	chr6:25882590	NA	-0.43	-6.98	-0.31	1.05e-11	Iron status biomarkers;
LGG	cis	rs17604090	0.887	rs7795109	chr7:29666244	G/A	cg19413766	chr7:29689036	LOC646762	-0.61	-8.3	-0.36	1.12e-15	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.74	-0.3	4.69e-11	Sudden cardiac arrest;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19066141	chr12:48395868	COL2A1	0.38	6.7	0.3	6.12e-11	Obesity-related traits;
LGG	cis	rs1904096	0.506	rs2865350	chr4:95212813	A/T	cg11021082	chr4:95130006	SMARCAD1	0.59	10.65	0.44	7.79e-24	Type 2 diabetes;
LGG	cis	rs8017423	0.967	rs11621045	chr14:90714003	C/T	cg04374321	chr14:90722782	PSMC1	0.88	18.87	0.66	2.61e-59	Mortality in heart failure;
LGG	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	cis	rs9393777	0.513	rs13215020	chr6:26656073	G/A	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg25566285	chr7:158114605	PTPRN2	0.88	19.9	0.68	4.07e-64	Calcium levels;
LGG	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.71	0.79	2.38e-100	Height;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg21775007	chr8:11205619	TDH	-0.44	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs9916302	0.904	rs2303316	chr17:37704217	A/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.55	-0.47	2.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg24642844	chr7:1081250	C7orf50	-0.59	-9.33	-0.4	4.47e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22838674	chr8:37619818	PROSC	0.44	7.25	0.32	1.73e-12	Cognitive performance;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-17.67	-0.63	8.58e-54	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg04861929	chr11:109293070	C11orf87	0.48	8.27	0.36	1.4e-15	Schizophrenia;
LGG	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.78	-0.41	1.13e-20	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg00490583	chr16:1843685	IGFALS	0.44	9.75	0.41	1.46e-20	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg03867377	chr3:184289145	EPHB3	-0.35	-6.8	-0.3	3.15e-11	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs9914544	0.545	rs4290526	chr17:18772967	T/C	cg21372672	chr17:16614065	CCDC144A	-0.34	-7.36	-0.32	8.63e-13	Educational attainment (years of education);
LGG	cis	rs17253792	0.915	rs28537145	chr14:56179119	G/A	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.4	-0.4	2.49e-19	Lung cancer;
LGG	cis	rs986417	0.901	rs1955697	chr14:61028435	T/C	cg27398547	chr14:60952738	C14orf39	0.71	6.96	0.31	1.19e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9657904	0.774	rs10804442	chr3:105519212	C/T	cg14088669	chr1:158435396	OR10K1	0.4	7.41	0.33	6.11e-13	Multiple sclerosis;
LGG	trans	rs2562456	0.833	rs62110426	chr19:21602926	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg12395012	chr8:11607386	GATA4	-0.39	-7.1	-0.31	4.78e-12	Monocyte count;
LGG	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.87	-0.54	7.99e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs875971	0.545	rs66594357	chr7:65792784	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.54	0.44	2.03e-23	Aortic root size;
LGG	cis	rs11203032	0.831	rs10887930	chr10:90950094	C/T	cg16672925	chr10:90967113	CH25H	-0.48	-7.61	-0.33	1.5700000000000001e-13	Heart failure;
LGG	cis	rs9879311	0.966	rs28113	chr3:10400643	G/A	cg21387009	chr3:10280255	IRAK2	-0.36	-6.67	-0.3	7.14e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.92	-14.0	-0.55	2.11e-37	Platelet count;
LGG	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	7.53	0.33	2.6e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg12458913	chr13:53173898	NA	-0.61	-11.47	-0.47	5.43e-27	Lewy body disease;
LGG	cis	rs8078723	0.738	rs8066582	chr17:38146929	A/G	cg17467752	chr17:38218738	THRA	-0.62	-11.32	-0.47	2.09e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg00830817	chr11:109293614	C11orf87	0.58	9.46	0.4	1.5e-19	Schizophrenia;
LGG	cis	rs7572733	0.555	rs1435569	chr2:198718667	G/C	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs41005	0.597	rs35400177	chr2:8101757	C/T	cg03155496	chr2:8117019	LOC339788	-0.54	-9.42	-0.4	2.2e-19	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg21775007	chr8:11205619	TDH	-0.78	-13.57	-0.53	1.53e-35	Retinal vascular caliber;
LGG	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.56	-0.33	2.16e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2404618	0.593	rs7815979	chr8:1484887	A/G	cg13402656	chr8:1511478	DLGAP2	-0.72	-13.42	-0.53	6.35e-35	Lung cancer;
LGG	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg07120314	chr15:79043507	NA	-0.35	-6.74	-0.3	4.63e-11	Sudden cardiac arrest;
LGG	cis	rs9487094	0.670	rs12198938	chr6:109822632	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.03	0.35	8.17e-15	Height;
LGG	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.35e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs921968	0.509	rs10932782	chr2:219353195	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7639513	0.767	rs9878151	chr3:12703714	G/C	cg23032965	chr3:12705835	RAF1	0.84	16.12	0.6	1.04e-46	Itch intensity from mosquito bite;
LGG	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-13.28	-0.53	2.42e-34	Morning vs. evening chronotype;
LGG	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg25706552	chr1:244017396	NA	0.51	8.46	0.37	3.44e-16	RR interval (heart rate);
LGG	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg08824895	chr13:115047677	UPF3A	0.41	6.95	0.31	1.25e-11	Schizophrenia;
LGG	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg23594656	chr7:65796392	TPST1	-0.37	-8.34	-0.36	8.38e-16	Aortic root size;
LGG	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.44	0.4	1.88e-19	Bone mineral density;
LGG	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.48	-0.37	3.15e-16	Aortic root size;
LGG	trans	rs1478898	0.526	rs1478897	chr8:11395232	A/T	cg02002194	chr4:3960332	NA	-0.4	-7.21	-0.32	2.27e-12	Morning vs. evening chronotype;
LGG	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg16414030	chr3:133502952	NA	-0.48	-7.92	-0.35	1.81e-14	Iron status biomarkers;
LGG	cis	rs9517320	0.515	rs61969456	chr13:99174799	C/G	cg07423050	chr13:99094983	FARP1	-0.55	-10.71	-0.45	4.69e-24	Longevity;
LGG	cis	rs208346	1.000	rs208346	chr7:2799686	G/T	cg27476859	chr7:2772710	GNA12	-0.41	-7.63	-0.33	1.31e-13	Loneliness (linear analysis);
LGG	cis	rs1005224	0.963	rs12887886	chr14:76167846	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-6.88	-0.3	1.98e-11	Large artery stroke;
LGG	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg18850127	chr7:39170497	POU6F2	0.37	8.44	0.37	4.09e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10896135	0.526	rs12795774	chr11:66381517	T/C	cg01599099	chr11:66649832	PC	-0.4	-7.5	-0.33	3.29e-13	Bipolar disorder;
LGG	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs9929218	1.000	rs8044058	chr16:68807088	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.19	-0.52	5.96e-34	Colorectal cancer;
LGG	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.67	0.41	2.83e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg09264619	chr17:80180166	NA	0.37	7.33	0.32	1.03e-12	Life satisfaction;
LGG	cis	rs9849248	0.627	rs6419868	chr3:88248527	A/G	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs2070433	0.539	rs721131	chr21:47957767	T/C	cg02959939	chr21:47813025	PCNT	-0.31	-6.93	-0.31	1.44e-11	Lymphocyte counts;
LGG	cis	rs11239187	0.927	rs12242079	chr10:45106589	A/C	cg03916630	chr10:45065415	NA	0.34	7.58	0.33	1.86e-13	Body mass index;
LGG	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg15704280	chr7:45808275	SEPT13	-1.01	-21.77	-0.71	6.82e-73	Coronary artery disease;
LGG	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg14829155	chr15:31115871	NA	-0.56	-9.07	-0.39	3.43e-18	Huntington's disease progression;
LGG	cis	rs9323205	1.000	rs12589519	chr14:51596684	C/G	cg23942311	chr14:51606299	NA	-0.38	-6.77	-0.3	3.99e-11	Cancer;
LGG	trans	rs561341	1.000	rs560132	chr17:30320019	C/T	cg20587970	chr11:113659929	NA	-1.35	-23.88	-0.74	9.93e-83	Hip circumference adjusted for BMI;
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg13699009	chr12:122356056	WDR66	0.57	15.18	0.58	1.5e-42	Mean corpuscular volume;
LGG	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.41	0.47	9.46e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-9.48	-0.4	1.3e-19	Prudent dietary pattern;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	15.0	0.57	9.87e-42	Obesity-related traits;
LGG	cis	rs174601	0.861	rs174581	chr11:61606683	G/A	cg19610905	chr11:61596333	FADS2	-0.75	-13.58	-0.53	1.39e-35	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.45e-29	Total body bone mineral density;
LGG	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg25019033	chr10:957182	NA	-0.51	-9.3	-0.4	5.65e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2816316	0.731	rs1853433	chr1:192513661	T/C	cg02586212	chr1:192544902	RGS1	0.33	6.77	0.3	3.86e-11	Celiac disease;
LGG	trans	rs6787172	0.592	rs6788703	chr3:158067237	C/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.27	-0.32	1.49e-12	Subjective well-being;
LGG	cis	rs1620921	0.505	rs1344731	chr6:161205037	G/A	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs17767392	0.595	rs11844320	chr14:71659298	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.06	-0.31	6.31e-12	Mitral valve prolapse;
LGG	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24786176	chr4:113153431	AP1AR	0.46	6.86	0.3	2.25e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg08999081	chr20:33150536	PIGU	0.39	9.77	0.41	1.26e-20	Coronary artery disease;
LGG	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg00129232	chr17:37814104	STARD3	-0.44	-8.18	-0.36	2.85e-15	Self-reported allergy;
LGG	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg13147721	chr7:65941812	NA	-0.83	-10.09	-0.42	8.77e-22	Diabetic kidney disease;
LGG	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg03060546	chr3:49711283	APEH	0.49	7.73	0.34	6.99e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.57	9.3	0.4	5.59e-19	Longevity;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg13939156	chr17:80058883	NA	0.47	9.18	0.39	1.5e-18	Life satisfaction;
LGG	cis	rs17253792	0.915	rs17832389	chr14:56185836	A/G	cg01858014	chr14:56050164	KTN1	-0.8	-10.37	-0.43	8.67e-23	Putamen volume;
LGG	trans	rs6787172	0.622	rs939114	chr3:158115253	C/A	cg23275840	chr4:47708675	CORIN	-0.36	-7.46	-0.33	4.36e-13	Subjective well-being;
LGG	cis	rs6942756	0.806	rs2694572	chr7:128911721	A/G	cg02491457	chr7:128862824	NA	0.64	12.06	0.49	2.69e-29	White matter hyperintensity burden;
LGG	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.15	0.35	3.5e-15	Obesity-related traits;
LGG	cis	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.61	-0.37	1.15e-16	Retinal vascular caliber;
LGG	cis	rs853679	0.517	rs6922063	chr6:28094366	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.52	-0.33	2.93e-13	Depression;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	14.69	0.56	2.22e-40	Platelet count;
LGG	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg11693508	chr17:37793320	STARD3	0.75	10.75	0.45	3.35e-24	Bipolar disorder;
LGG	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg05556477	chr5:131705319	SLC22A5	0.85	10.23	0.43	2.86e-22	Rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.8e-21	Prudent dietary pattern;
LGG	cis	rs9849248	0.627	rs73132512	chr3:88156194	C/A	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-11.47	-0.47	5.43e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg12654349	chr5:56205094	C5orf35	0.56	9.65	0.41	3.31e-20	Initial pursuit acceleration;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg11062466	chr8:58055876	NA	-0.6	-10.02	-0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.706	rs11078894	chr17:37396805	C/G	cg00129232	chr17:37814104	STARD3	-0.57	-8.5	-0.37	2.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs897080	0.515	rs1067319	chr2:44633458	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.78	-0.3	3.67e-11	Height;
LGG	cis	rs7428	0.545	rs17026212	chr2:85551696	T/G	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.87	-0.54	8.16e-37	Ear protrusion;
LGG	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg21775007	chr8:11205619	TDH	-0.7	-11.94	-0.49	7.45e-29	Neuroticism;
LGG	cis	rs7666738	0.830	rs28802909	chr4:99039410	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg16325326	chr1:53192061	ZYG11B	-0.86	-22.93	-0.73	2.72e-78	Monocyte count;
LGG	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs600550	0.517	rs11525457	chr11:60089299	G/T	cg05040360	chr11:60102449	MS4A6E	-0.34	-7.76	-0.34	5.48e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg21466736	chr12:48725269	NA	-0.36	-7.24	-0.32	1.85e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs9837602	0.507	rs1059905	chr3:99516879	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-8.17	-0.35	3e-15	Breast cancer;
LGG	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.61e-15	Common traits (Other);
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg08589960	chr16:83986755	OSGIN1	0.6	11.53	0.47	3.14e-27	Pursuit maintenance gain;
LGG	cis	rs1894633	0.574	rs56259646	chr1:172330739	A/G	cg01573306	chr1:172330400	DNM3	-0.4	-7.08	-0.31	5.32e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6032067	0.929	rs8126178	chr20:43822581	A/C	cg10761708	chr20:43804764	PI3	0.58	8.88	0.38	1.51e-17	Blood protein levels;
LGG	cis	rs6988985	0.678	rs10087214	chr8:143999726	G/A	cg10324643	chr8:143916377	GML	0.45	9.4	0.4	2.58e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2832191	0.716	rs1888439	chr21:30454457	A/G	cg08807101	chr21:30365312	RNF160	0.9	18.93	0.66	1.28e-59	Dental caries;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23166955	chr16:30077191	ALDOA	0.4	6.95	0.31	1.27e-11	Bilirubin levels;
LGG	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg14416269	chr4:6271139	WFS1	0.45	8.16	0.35	3.22e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg00938859	chr5:1591904	SDHAP3	0.91	12.46	0.5	6.22e-31	Breast cancer;
LGG	cis	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg21775007	chr8:11205619	TDH	0.81	14.26	0.55	1.74e-38	Retinal vascular caliber;
LGG	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg09461388	chr22:46763229	CELSR1	-0.59	-6.78	-0.3	3.6e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs62400317	0.826	rs62400330	chr6:45321455	G/A	cg20913747	chr6:44695427	NA	-0.6	-10.13	-0.43	6.5600000000000005e-22	Total body bone mineral density;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.15	0.32	3.45e-12	Schizophrenia;
LGG	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2587949	0.615	rs1385486	chr3:4228745	C/T	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg20608306	chr11:116969690	SIK3	0.4	12.62	0.51	1.36e-31	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23529139	chr3:138048838	TXNDC6	0.46	6.69	0.3	6.48e-11	Gut microbiome composition (summer);
LGG	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	Neuroticism;
LGG	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.62e-20	Colorectal cancer;
LGG	trans	rs9657904	0.813	rs7647955	chr3:105583046	T/C	cg14088669	chr1:158435396	OR10K1	0.42	8.0	0.35	1.03e-14	Multiple sclerosis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04711526	chr14:92582519	NDUFB1	-0.53	-6.66	-0.3	7.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2073300	1.000	rs6132621	chr20:23442180	C/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7119	0.717	rs12901471	chr15:77818992	A/G	cg10437265	chr15:77819839	NA	0.24	6.89	0.31	1.78e-11	Type 2 diabetes;
LGG	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg25986240	chr4:9926439	SLC2A9	0.37	7.73	0.34	6.58e-14	Bone mineral density;
LGG	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg03160526	chr17:80928410	B3GNTL1	0.5	7.75	0.34	6.01e-14	Glycated hemoglobin levels;
LGG	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg14979609	chr8:8086686	FLJ10661	-0.34	-8.66	-0.37	7.95e-17	Neuroticism;
LGG	cis	rs9534288	0.552	rs2840241	chr13:46658903	T/G	cg15192986	chr13:46630673	CPB2	-0.7	-14.36	-0.56	5.93e-39	Blood protein levels;
LGG	cis	rs3820928	0.874	rs7421491	chr2:227839278	C/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.81	-0.34	3.95e-14	Pulmonary function;
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.56	-7.82	-0.34	3.65e-14	Response to haloperidol in psychosis;
LGG	cis	rs2404602	0.647	rs11072620	chr15:77048770	T/A	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.33e-22	Blood metabolite levels;
LGG	cis	rs2933343	0.601	rs1680758	chr3:128594897	T/C	cg25356066	chr3:128598488	ACAD9	0.45	6.95	0.31	1.24e-11	IgG glycosylation;
LGG	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg12923728	chr3:195709715	SDHAP1	0.56	9.55	0.41	7.72e-20	Mean corpuscular volume;
LGG	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg07882059	chr11:68924751	NA	0.38	6.67	0.3	7.18e-11	Blond vs. brown hair color;
LGG	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.96	0.52	5.19e-33	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg00531865	chr16:30841666	NA	0.38	7.9	0.34	2.01e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4919044	0.674	rs115089490	chr10:94793496	G/C	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.59	-0.33	1.72e-13	Coronary artery disease;
LGG	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-8.41	-0.36	5.17e-16	Bronchopulmonary dysplasia;
LGG	cis	rs2494938	0.730	rs417399	chr6:40516762	A/C	cg14084896	chr6:40530702	LRFN2	-0.3	-6.69	-0.3	6.4e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg02466173	chr16:30829666	NA	-0.43	-7.59	-0.33	1.73e-13	Dementia with Lewy bodies;
LGG	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.12	0.46	1.24e-25	Morning vs. evening chronotype;
LGG	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.3e-17	Height;
LGG	cis	rs2346160	1.000	rs6937935	chr6:167670223	T/C	cg20683250	chr6:167653907	NA	0.42	6.92	0.31	1.51e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg22875332	chr1:76189707	ACADM	-0.57	-9.66	-0.41	3.06e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg11822372	chr1:151115635	SEMA6C	0.49	8.69	0.37	6.49e-17	Childhood ear infection;
LGG	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-14.03	-0.55	1.71e-37	Platelet distribution width;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9381107	0.932	rs34030781	chr6:9451449	C/T	cg14735645	chr6:9486422	NA	-0.43	-7.29	-0.32	1.35e-12	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs947612	0.541	rs7747368	chr6:73717568	T/C	cg13494037	chr12:24737079	C12orf67	-0.35	-7.05	-0.31	6.62e-12	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.01	0.42	1.69e-21	Longevity;
LGG	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	19.89	0.68	4.54e-64	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg05941027	chr17:61774174	LIMD2	0.36	8.86	0.38	1.69e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.64	-0.41	3.66e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.15	-0.35	3.45e-15	Joint mobility (Beighton score);
LGG	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	8.17	0.35	3.04e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.73	0.34	6.92e-14	Triglycerides;
LGG	cis	rs9581857	0.579	rs118061689	chr13:27974499	A/T	cg01674679	chr13:27998804	GTF3A	-0.76	-8.58	-0.37	1.46e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs858239	0.539	rs7791200	chr7:23182121	A/T	cg23682824	chr7:23144976	KLHL7	0.41	6.79	0.3	3.38e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.4e-21	Hypertriglyceridemia;
LGG	cis	rs7166081	1.000	rs10152913	chr15:67647328	A/T	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.89e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs701145	0.585	rs1612933	chr3:153786119	G/A	cg12800244	chr3:153838788	SGEF	-0.84	-10.01	-0.42	1.76e-21	Coronary artery disease;
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg18446336	chr7:2847575	GNA12	-0.28	-6.65	-0.3	8.11e-11	Height;
LGG	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg00031303	chr3:195681400	NA	0.53	8.41	0.36	5.3e-16	Pancreatic cancer;
LGG	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg09764611	chr12:132620959	NA	-0.57	-8.55	-0.37	1.82e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg10950524	chr7:2139216	MAD1L1	0.32	7.17	0.32	2.93e-12	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10101463	chr1:202780506	NA	0.44	7.07	0.31	5.59e-12	Cognitive performance;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.57	-0.44	1.55e-23	Prostate cancer;
LGG	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-15.29	-0.58	4.98e-43	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg24675658	chr1:53192096	ZYG11B	-0.56	-11.76	-0.48	4.14e-28	Monocyte count;
LGG	cis	rs10911232	0.507	rs10797821	chr1:183012559	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs7011049	0.778	rs6981132	chr8:53866250	T/C	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg04398451	chr17:18023971	MYO15A	-0.81	-17.09	-0.62	4.07e-51	Total body bone mineral density;
LGG	cis	rs36051895	0.632	rs11791281	chr9:5172540	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-14.79	-0.57	8.4e-41	Pediatric autoimmune diseases;
LGG	cis	rs9912468	0.933	rs35512343	chr17:64310575	T/A	cg19474267	chr17:64306194	PRKCA	0.94	25.05	0.76	3.5e-88	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2073300	0.609	rs6137945	chr20:23406136	C/T	cg12062639	chr20:23401060	NAPB	0.92	8.72	0.38	4.86e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-9.06	-0.39	3.74e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4731207	0.698	rs727506	chr7:124462027	A/G	cg05630886	chr7:124431682	NA	0.33	7.65	0.34	1.14e-13	Cutaneous malignant melanoma;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.51	-0.4	1.07e-19	Obesity-related traits;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs7192750	0.535	rs152826	chr16:72126180	A/G	cg06353428	chr16:71660113	MARVELD3	0.8	7.36	0.32	8.4e-13	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg05925327	chr15:68127851	NA	-0.4	-8.1	-0.35	5e-15	Restless legs syndrome;
LGG	cis	rs1620921	0.967	rs1084656	chr6:161181292	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.49	-0.33	3.61e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2481665	0.772	rs6668600	chr1:62536683	C/G	cg18591186	chr1:62594603	INADL	0.49	9.83	0.42	7.87e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs911555	0.504	rs8006526	chr14:104075015	T/C	cg24130564	chr14:104152367	KLC1	-0.77	-17.21	-0.62	1.14e-51	Intelligence (multi-trait analysis);
LGG	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg21665744	chr7:39171113	POU6F2	0.35	7.16	0.32	3.16e-12	IgG glycosylation;
LGG	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg08773314	chr2:239334832	ASB1	0.43	8.22	0.36	2.03e-15	Multiple system atrophy;
LGG	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg21972741	chr5:435613	AHRR	0.5	8.98	0.39	6.77e-18	Cystic fibrosis severity;
LGG	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg05692746	chr2:100937584	LONRF2	-0.57	-9.47	-0.4	1.42e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg11859384	chr17:80120422	CCDC57	0.46	8.07	0.35	6.05e-15	Life satisfaction;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14368592	chr20:61981657	CHRNA4	0.35	7.12	0.31	4.04e-12	Menarche (age at onset);
LGG	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.4	-0.44	6.35e-23	Subjective well-being;
LGG	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg18681998	chr4:17616180	MED28	0.88	20.24	0.69	1.02e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg27532560	chr4:187881888	NA	0.59	13.01	0.52	3.3e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.25	0.32	1.78e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg01324343	chr3:183735012	ABCC5	0.76	14.41	0.56	3.76e-39	Anterior chamber depth;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg16141378	chr3:129829833	LOC729375	0.32	7.06	0.31	6.31e-12	Triglycerides;
LGG	cis	rs459571	0.606	rs456793	chr9:136903683	G/A	cg13789015	chr9:136890014	NCRNA00094	0.38	6.97	0.31	1.08e-11	Platelet distribution width;
LGG	cis	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg06521331	chr12:34319734	NA	0.64	12.0	0.49	4.6e-29	Morning vs. evening chronotype;
LGG	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg25208724	chr1:156163844	SLC25A44	1.15	20.51	0.69	5.8e-67	Testicular germ cell tumor;
LGG	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.71	-0.34	7.87e-14	Body mass index;
LGG	cis	rs7614311	0.681	rs6776209	chr3:63858633	G/C	cg22134162	chr3:63841271	THOC7	-0.42	-7.74	-0.34	6.31e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs2120243	0.539	rs1568609	chr3:157066839	G/A	cg24825693	chr3:157122686	VEPH1	-0.48	-10.8	-0.45	2.17e-24	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs11169552	0.510	rs4768906	chr12:51106823	T/G	cg12884762	chr12:50931848	DIP2B	-0.42	-7.99	-0.35	1.08e-14	Colorectal cancer;
LGG	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg16208657	chr15:68119293	LBXCOR1	-0.34	-6.74	-0.3	4.72e-11	Obesity;
LGG	cis	rs4450131	0.898	rs3824805	chr10:126320721	C/T	cg08799069	chr10:126477246	METTL10	0.31	6.64	0.3	8.56e-11	White blood cell count (basophil);
LGG	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs9914988	0.943	rs9913801	chr17:27132105	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs504918	0.588	rs11719349	chr3:123978022	A/G	cg05766129	chr3:123988013	KALRN	-0.61	-10.99	-0.45	3.93e-25	Schizophrenia;
LGG	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg17294928	chr15:75287854	SCAMP5	0.56	10.18	0.43	4.1e-22	Breast cancer;
LGG	cis	rs7590368	1.000	rs55771723	chr2:10961902	T/C	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs7503807	0.515	rs34388940	chr17:78663350	G/T	cg18469159	chr17:78755841	RPTOR	-0.65	-11.28	-0.46	3.02e-26	Obesity;
LGG	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs17742757	0.905	rs6993930	chr8:11330365	T/C	cg26274995	chr8:11302983	FAM167A	0.35	6.71	0.3	5.66e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg21017887	chr14:105400489	NA	0.43	8.61	0.37	1.12e-16	Rheumatoid arthritis;
LGG	cis	rs4330281	0.647	rs7651278	chr3:17443745	C/T	cg20981856	chr3:17787350	NA	0.36	6.81	0.3	3.03e-11	Schizophrenia;
LGG	cis	rs7166081	1.000	rs12900708	chr15:67535440	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.75	-0.3	4.52e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg15485101	chr11:133734466	NA	0.52	9.25	0.39	8.57e-19	Childhood ear infection;
LGG	cis	rs7568458	0.870	rs6719046	chr2:85757371	G/A	cg17127132	chr2:85788382	GGCX	0.44	7.72	0.34	7.02e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg00666640	chr1:248458726	OR2T12	0.59	9.42	0.4	2.07e-19	Common traits (Other);
LGG	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg02574844	chr11:5959923	NA	-0.59	-9.17	-0.39	1.52e-18	DNA methylation (variation);
LGG	cis	rs258892	0.842	rs10060065	chr5:72065830	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs2304069	0.545	rs11167492	chr5:149403101	G/A	cg12661370	chr5:149340060	SLC26A2	0.5	8.5	0.37	2.69e-16	HIV-1 control;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.33	-0.4	4.5e-19	Lung cancer;
LGG	cis	rs1920116	0.778	rs2421830	chr3:169554129	G/A	cg08193579	chr3:169529701	LRRC34	0.42	7.34	0.32	9.92e-13	Glioma (high-grade);
LGG	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg07150166	chr2:30669952	LCLAT1	0.6	8.46	0.37	3.43e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	11.21	0.46	5.79e-26	Parkinson's disease;
LGG	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.09	0.35	5.32e-15	Menarche (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.37	6.8	0.3	3.18e-11	Obesity-related traits;
LGG	cis	rs870825	0.616	rs7682677	chr4:185640717	C/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.57	0.72	1.32e-76	Blood protein levels;
LGG	cis	rs7659604	0.539	rs11098646	chr4:122729301	T/C	cg20573242	chr4:122745356	CCNA2	0.55	10.14	0.43	5.69e-22	Type 2 diabetes;
LGG	cis	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.87	-0.3	2.13e-11	Retinal vascular caliber;
LGG	cis	rs73086581	1.000	rs73086512	chr20:3922772	C/A	cg02187196	chr20:3869020	PANK2	0.83	11.6	0.47	1.66e-27	Response to antidepressants in depression;
LGG	cis	rs868036	0.958	rs11635424	chr15:68037578	C/T	cg05925327	chr15:68127851	NA	-0.36	-8.53	-0.37	2.06e-16	Restless legs syndrome;
LGG	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg27411982	chr8:10470053	RP1L1	-0.48	-8.12	-0.35	4.31e-15	Retinal vascular caliber;
LGG	cis	rs2862064	0.818	rs1979870	chr5:156481383	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.64	-0.44	8.12e-24	Platelet count;
LGG	cis	rs12144044	1.000	rs12144044	chr1:113248791	G/T	cg19507217	chr1:113251308	RHOC	-0.56	-10.43	-0.44	5.19e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	7.82	0.34	3.58e-14	Personality dimensions;
LGG	cis	rs1697139	0.583	rs11739727	chr5:66540940	G/A	cg11553311	chr5:66541588	NA	0.45	10.05	0.42	1.24e-21	Breast cancer;
LGG	cis	rs2997447	0.600	rs1335759	chr1:26471743	G/T	cg20415053	chr1:26527928	CATSPER4	-0.32	-7.47	-0.33	3.91e-13	QRS complex (12-leadsum);
LGG	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg22681709	chr2:178499509	PDE11A	-0.48	-8.93	-0.38	1.03e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg13939156	chr17:80058883	NA	0.5	9.85	0.42	6.54e-21	Life satisfaction;
LGG	cis	rs3126085	1.000	rs2011331	chr1:152286002	T/C	cg26876637	chr1:152193138	HRNR	-0.53	-8.64	-0.37	8.98e-17	Atopic dermatitis;
LGG	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg08847533	chr14:75593920	NEK9	-0.54	-9.99	-0.42	2.03e-21	Height;
LGG	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg05535760	chr7:792225	HEATR2	0.97	14.63	0.56	3.95e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs8073060	0.586	rs4796100	chr17:33997657	G/T	cg19694781	chr19:47549865	TMEM160	1.16	18.06	0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7598759	0.527	rs7571691	chr2:232369401	C/T	cg19187155	chr2:232395269	NMUR1	0.53	9.8	0.41	9.54e-21	Noise-induced hearing loss;
LGG	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.58	-11.37	-0.47	1.35e-26	Obesity-related traits;
LGG	cis	rs11190604	1.000	rs3750630	chr10:102275780	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.18	0.32	2.89e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13126279	chr21:47581558	C21orf56	-0.55	-10.02	-0.42	1.67e-21	Testicular germ cell tumor;
LGG	cis	rs9487094	0.961	rs752262	chr6:109770999	G/C	cg01125227	chr6:109776195	MICAL1	0.56	9.55	0.41	7.28e-20	Height;
LGG	cis	rs8053891	0.614	rs34235351	chr16:71987875	G/A	cg00732059	chr16:71740210	PHLPP2	-0.35	-6.71	-0.3	5.75e-11	Coronary artery disease;
LGG	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg26297688	chr12:107349093	C12orf23	-0.38	-7.05	-0.31	6.63e-12	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg14926445	chr8:58193284	C8orf71	-0.85	-10.38	-0.43	8.11e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9443189	0.526	rs9359124	chr6:76200514	G/A	cg01950844	chr6:76311363	SENP6	0.73	8.78	0.38	3.12e-17	Prostate cancer;
LGG	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.41e-14	Myopia (pathological);
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.15	-0.32	3.46e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10267417	0.673	rs2190413	chr7:19958386	A/G	cg05791153	chr7:19748676	TWISTNB	-0.47	-6.67	-0.3	7.18e-11	Night sleep phenotypes;
LGG	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg17644776	chr2:200775616	C2orf69	-0.67	-8.48	-0.37	3.05e-16	Schizophrenia;
LGG	cis	rs858239	0.539	rs10225608	chr7:23188908	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.46e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	9.08e-24	Aortic root size;
LGG	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg17376030	chr22:41985996	PMM1	0.54	9.08	0.39	3.08e-18	Vitiligo;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-6.91	-0.31	1.59e-11	Height;
LGG	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg26248373	chr2:1572462	NA	-0.73	-9.62	-0.41	4.15e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7017914	0.967	rs13272523	chr8:71641472	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs8114671	0.647	rs945959	chr20:33734905	G/C	cg24642439	chr20:33292090	TP53INP2	0.53	8.7	0.37	5.8e-17	Height;
LGG	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg08048268	chr3:133502702	NA	0.61	11.43	0.47	8.28e-27	Iron status biomarkers;
LGG	trans	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg20290983	chr6:43655470	MRPS18A	1.02	17.04	0.62	7.09e-51	IgG glycosylation;
LGG	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.75	0.3	4.58e-11	Bipolar disorder;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.18	-0.52	6.65e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs7100689	0.784	rs7895042	chr10:82095276	G/A	cg01528321	chr10:82214614	TSPAN14	0.89	15.9	0.59	9.43e-46	Post bronchodilator FEV1;
LGG	cis	rs12681288	0.676	rs2701913	chr8:999982	A/T	cg15309053	chr8:964076	NA	0.38	7.48	0.33	3.71e-13	Schizophrenia;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg27661571	chr11:113659931	NA	-0.69	-7.57	-0.33	2.03e-13	Height;
LGG	cis	rs9399135	0.967	rs6902954	chr6:135313994	C/A	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.97e-20	Red blood cell count;
LGG	cis	rs10463554	0.927	rs468844	chr5:102423576	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg06494592	chr3:125709126	NA	-0.53	-6.73	-0.3	5.17e-11	Blood pressure (smoking interaction);
LGG	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg27129171	chr3:47204927	SETD2	0.58	9.67	0.41	2.85e-20	Birth weight;
LGG	cis	rs17767392	0.836	rs17178387	chr14:71997723	A/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.34	0.36	8.31e-16	Mitral valve prolapse;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00290607	chr11:67383545	NA	0.61	11.74	0.48	4.88e-28	Mean corpuscular volume;
LGG	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg19729930	chr2:74357872	NA	0.57	11.67	0.48	8.91e-28	Gestational age at birth (maternal effect);
LGG	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.21	-0.39	1.12e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1568889	0.775	rs35243076	chr11:28250618	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.2	0.67	7.09e-61	Bipolar disorder;
LGG	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	6.06e-14	Testicular germ cell tumor;
LGG	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg12658694	chr1:38397304	INPP5B	-0.47	-9.34	-0.4	3.99e-19	Coronary artery disease;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05665937	chr4:1216051	CTBP1	-0.41	-7.25	-0.32	1.72e-12	Obesity-related traits;
LGG	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg07117364	chr1:16154769	NA	-0.49	-9.4	-0.4	2.57e-19	Dilated cardiomyopathy;
LGG	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-7.48	-0.33	3.88e-13	Longevity;Endometriosis;
LGG	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg22920501	chr2:26401640	FAM59B	-0.41	-8.05	-0.35	7.28e-15	Gut microbiome composition (summer);
LGG	cis	rs7552167	1.000	rs7552167	chr1:24518643	A/G	cg01960748	chr1:24522592	NA	-0.48	-7.38	-0.32	7.52e-13	Psoriasis vulgaris;
LGG	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg12165864	chr7:66369176	NA	-0.58	-9.28	-0.4	6.69e-19	Corneal structure;
LGG	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg26384229	chr12:38710491	ALG10B	0.64	11.56	0.47	2.46e-27	Morning vs. evening chronotype;
LGG	cis	rs12505749	0.542	rs56099714	chr4:57363161	A/C	cg07846311	chr4:57371927	ARL9	-0.31	-7.71	-0.34	7.92e-14	Airflow obstruction;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.49	-8.67	-0.37	7.48e-17	Obesity-related traits;
LGG	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.45e-15	Common traits (Other);
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6963495	0.818	rs73192143	chr7:105202415	A/G	cg19920283	chr7:105172520	RINT1	0.64	8.34	0.36	8.51e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs367943	0.723	rs1965429	chr5:112679373	G/T	cg12552261	chr5:112820674	MCC	-0.56	-10.04	-0.42	1.35e-21	Type 2 diabetes;
LGG	trans	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg14791747	chr16:20752902	THUMPD1	0.49	7.44	0.33	4.98e-13	Cognitive test performance;
LGG	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg18854424	chr1:2615690	NA	-0.33	-7.01	-0.31	8.43e-12	Multiple sclerosis;
LGG	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg05044414	chr3:183734942	ABCC5	-0.72	-13.72	-0.54	3.62e-36	Anterior chamber depth;
LGG	cis	rs6723226	0.557	rs62136260	chr2:32575447	T/C	cg02381751	chr2:32503542	YIPF4	-0.52	-8.51	-0.37	2.38e-16	Intelligence (multi-trait analysis);
LGG	cis	rs8056064	1.000	rs8056064	chr16:82787053	A/G	cg08271366	chr16:82816457	CDH13	-0.37	-6.68	-0.3	6.98e-11	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs3857067	0.967	rs1472984	chr4:95036553	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.74	-0.34	6.18e-14	QT interval;
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.94	14.09	0.55	9.05e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8017423	0.967	rs4904657	chr14:90721600	A/G	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs9815354	1.000	rs1717000	chr3:41930219	A/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs490234	0.691	rs1250505	chr9:128193456	G/T	cg14078157	chr9:128172775	NA	-0.46	-8.75	-0.38	3.94e-17	Mean arterial pressure;
LGG	cis	rs943466	0.956	rs1075379	chr6:33737800	T/C	cg07519485	chr6:33762594	MLN	0.53	11.02	0.46	3.03e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg12395012	chr8:11607386	GATA4	0.44	8.57	0.37	1.58e-16	Neuroticism;
LGG	cis	rs9557207	0.602	rs9557165	chr13:99802974	C/T	cg24509225	chr13:100037070	UBAC2	0.6	11.19	0.46	6.84e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs61612642	0.590	rs6931028	chr6:42193064	A/T	cg01092361	chr6:42185687	MRPS10	0.87	11.63	0.48	1.31e-27	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	cis	rs3925075	1.000	rs55742763	chr16:31340368	G/A	cg02846316	chr16:31340340	ITGAM	0.4	7.78	0.34	4.93e-14	IgA nephropathy;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.63	-11.67	-0.48	8.82e-28	Total body bone mineral density;
LGG	cis	rs10911363	0.592	rs2702205	chr1:183457198	A/G	cg23894439	chr1:183413866	NA	0.49	9.2	0.39	1.27e-18	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06634786	chr22:41940651	POLR3H	0.73	12.17	0.49	9.16e-30	Vitiligo;
LGG	cis	rs10857712	0.703	rs1056521	chr10:135235890	T/C	cg19904058	chr10:135279010	LOC619207	-0.28	-6.86	-0.3	2.19e-11	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg16405210	chr4:1374714	KIAA1530	0.42	7.0	0.31	9.14e-12	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13287668	chr18:8718597	KIAA0802	-0.34	-7.01	-0.31	8.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg21775007	chr8:11205619	TDH	-0.55	-9.03	-0.39	4.57e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg12395012	chr8:11607386	GATA4	0.41	7.49	0.33	3.48e-13	Monocyte count;
LGG	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg25358565	chr5:93447407	FAM172A	1.41	17.32	0.63	3.65e-52	Diabetic retinopathy;
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg18402987	chr7:1209562	NA	0.7	10.52	0.44	2.28e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg08297393	chr2:100937505	LONRF2	-0.51	-9.04	-0.39	4.45e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	9.15	0.39	1.78e-18	Rheumatoid arthritis;
LGG	cis	rs7172677	1.000	rs1021382	chr15:75417398	A/G	cg14664628	chr15:75095509	CSK	-0.45	-6.96	-0.31	1.17e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs74417235	0.684	rs7723312	chr5:154053249	A/G	cg08754654	chr5:154026448	NA	-0.53	-10.76	-0.45	2.96e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.19e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg27523141	chr10:43048294	ZNF37B	-0.44	-8.73	-0.38	4.54e-17	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg11764359	chr7:65958608	NA	-0.74	-13.41	-0.53	7.13e-35	Aortic root size;
LGG	cis	rs7122539	0.646	rs6591222	chr11:66551143	C/T	cg01599099	chr11:66649832	PC	0.48	9.74	0.41	1.59e-20	HIV-1 susceptibility;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.39	0.36	6.13e-16	Tonsillectomy;
LGG	trans	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg06521331	chr12:34319734	NA	-0.41	-7.31	-0.32	1.15e-12	Heart rate;
LGG	cis	rs12438659	1	rs12438659	chr15:78824924	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-9.76	-0.41	1.33e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00933542	chr6:150070202	PCMT1	0.38	7.01	0.31	8.39e-12	Lung cancer;
LGG	cis	rs9393777	0.588	rs3799380	chr6:26467182	C/T	cg12826209	chr6:26865740	GUSBL1	-0.79	-11.5	-0.47	4.46e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.961	rs6911838	chr6:109799923	C/T	cg01125227	chr6:109776195	MICAL1	0.49	8.18	0.36	2.67e-15	Height;
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg00717180	chr2:96193071	NA	0.44	7.75	0.34	5.92e-14	HDL cholesterol;
LGG	cis	rs12765878	1.000	rs11191865	chr10:105672842	G/A	cg11005552	chr10:105648138	OBFC1	1.04	27.14	0.78	9.3e-98	Coronary artery disease;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg19847130	chr8:10466454	RP1L1	0.31	6.83	0.3	2.63e-11	Joint mobility (Beighton score);
LGG	cis	rs651907	0.967	rs694936	chr3:101587793	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.37	7.28	0.32	1.48e-12	Colorectal cancer;
LGG	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.63	0.33	1.35e-13	Neutrophil percentage of white cells;
LGG	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg17031739	chr1:67600172	NA	-0.37	-7.65	-0.33	1.18e-13	Psoriasis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08965527	chr16:84178213	HSDL1;LRRC50	0.48	8.26	0.36	1.51e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg12623918	chr2:306882	NA	0.49	9.31	0.4	5.27e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.55e-22	Motion sickness;
LGG	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.86	-0.34	2.67e-14	Diastolic blood pressure;
LGG	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs694739	1.000	rs499425	chr11:64105929	A/G	cg23796481	chr11:64053134	BAD;GPR137	-0.76	-14.49	-0.56	1.69e-39	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg05926928	chr17:57297772	GDPD1	1.36	21.68	0.71	1.93e-72	Opioid sensitivity;
LGG	cis	rs9886651	0.935	rs4582525	chr8:128800947	A/G	cg24514600	chr8:128805414	PVT1	-0.55	-12.69	-0.51	7.24e-32	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	trans	rs62103177	0.513	rs9945153	chr18:77598450	C/T	cg14227996	chr4:17616232	MED28	0.72	8.81	0.38	2.56e-17	Opioid sensitivity;
LGG	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg25358565	chr5:93447407	FAM172A	1.31	15.98	0.6	4.4e-46	Diabetic retinopathy;
LGG	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg23161317	chr6:28129485	ZNF389	-0.33	-6.67	-0.3	7.25e-11	Depression;
LGG	cis	rs4740619	0.619	rs10810520	chr9:16029467	G/T	cg14451791	chr9:16040625	NA	-0.42	-11.16	-0.46	9.24e-26	Body mass index;
LGG	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.69	0.3	6.58e-11	Homoarginine levels;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg16507663	chr6:150244633	RAET1G	0.44	8.0	0.35	9.78e-15	Lung cancer;
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg18404041	chr3:52824283	ITIH1	-0.61	-11.5	-0.47	4.45e-27	Bipolar disorder;
LGG	cis	rs11677416	1.000	rs6542091	chr2:113525311	G/A	cg27083787	chr2:113543245	IL1A	0.53	8.8	0.38	2.8e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg06654118	chr4:1303317	MAEA	0.5	8.93	0.38	9.93e-18	Obesity-related traits;
LGG	trans	rs3942852	0.688	rs10742834	chr11:48169717	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg00376283	chr12:123451042	ABCB9	0.64	10.33	0.43	1.24e-22	Neutrophil percentage of white cells;
LGG	trans	rs12517041	1.000	rs10066885	chr5:23296872	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg17847044	chr15:42102381	MAPKBP1	0.54	12.62	0.51	1.37e-31	Diastolic blood pressure;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05900347	chr2:105461392	NA	-0.41	-6.86	-0.3	2.24e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg23057051	chr16:89984268	MC1R	-0.37	-7.29	-0.32	1.38e-12	Vitiligo;
LGG	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.74	0.3	4.7e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.25	-0.36	1.64e-15	Breast cancer;
LGG	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg21827317	chr3:136751795	NA	0.47	8.54	0.37	1.88e-16	Gestational age at birth (child effect);
LGG	cis	rs9324022	0.929	rs1004574	chr14:101178067	C/G	cg18089426	chr14:101175970	NA	0.68	11.5	0.47	4.2e-27	Plateletcrit;
LGG	cis	rs861020	0.771	rs654470	chr1:210014093	A/T	cg05527609	chr1:210001259	C1orf107	0.71	10.75	0.45	3.19e-24	Orofacial clefts;
LGG	cis	rs17767392	0.748	rs57204407	chr14:71704261	C/G	cg02058870	chr14:72053146	SIPA1L1	0.35	7.02	0.31	7.96e-12	Mitral valve prolapse;
LGG	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-14.68	-0.56	2.57e-40	Chronic sinus infection;
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.75e-12	Bipolar disorder;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.04	-0.31	6.97e-12	Electroencephalogram traits;
LGG	cis	rs1003719	0.591	rs13046303	chr21:38551976	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-12.34	-0.5	1.88e-30	Eye color traits;
LGG	cis	rs9487051	0.872	rs6924815	chr6:109612344	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.95	-0.38	8.73e-18	Reticulocyte fraction of red cells;
LGG	cis	rs11105298	0.891	rs6538190	chr12:89885942	T/C	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7412746	0.658	rs4537557	chr1:150734436	A/G	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.31e-11	Melanoma;
LGG	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg27129171	chr3:47204927	SETD2	0.51	8.37	0.36	6.63e-16	Birth weight;
LGG	cis	rs6088580	0.634	rs4911153	chr20:32961547	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.26	-0.4	7.7e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.23	0.32	2e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg13047869	chr3:10149882	C3orf24	0.48	7.87	0.34	2.6e-14	Alzheimer's disease;
LGG	cis	rs2373794	0.925	rs4614975	chr2:40353970	C/G	cg17740179	chr2:40377776	SLC8A1	0.88	18.38	0.65	4.88e-57	Asthma;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg14004847	chr7:1930337	MAD1L1	-0.43	-7.5	-0.33	3.26e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.800	rs11920354	chr3:47262246	C/A	cg16586182	chr3:47516702	SCAP	0.75	13.56	0.53	1.6e-35	Colorectal cancer;
LGG	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg13385794	chr1:248469461	NA	-0.48	-8.27	-0.36	1.43e-15	Common traits (Other);
LGG	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg15627072	chr1:2432621	PLCH2	-0.37	-8.42	-0.36	4.78e-16	Multiple sclerosis;
LGG	cis	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg00383909	chr3:49044727	WDR6	0.98	12.39	0.5	1.24e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs62238980	0.614	rs75074953	chr22:32374314	C/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs9828933	0.701	rs7621544	chr3:63928681	C/A	cg17941049	chr3:63904683	ATXN7	0.72	9.13	0.39	2.1e-18	Type 2 diabetes;
LGG	cis	rs9790314	0.663	rs796609	chr3:160705600	C/G	cg04691961	chr3:161091175	C3orf57	-0.42	-9.11	-0.39	2.58e-18	Morning vs. evening chronotype;
LGG	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg24998770	chr7:37888106	TXNDC3	0.68	11.86	0.48	1.57e-28	Alzheimer's disease (late onset);
LGG	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg21775007	chr8:11205619	TDH	0.47	7.72	0.34	7.26e-14	Neuroticism;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.12	-0.49	1.44e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg14541582	chr5:601475	NA	-0.49	-8.75	-0.38	3.98e-17	Obesity-related traits;
LGG	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.77	-0.51	3.38e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	19.79	0.68	1.25e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6964587	0.869	rs10241720	chr7:91527367	G/T	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs8170	0.603	rs8110408	chr19:17440542	C/G	cg04749549	chr19:17459798	NA	-0.41	-7.57	-0.33	1.97e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs367615	0.918	rs115145487	chr5:108888146	A/G	cg17395555	chr5:108820864	NA	0.63	9.09	0.39	2.93e-18	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs12200782	0.649	rs7775720	chr6:26381357	A/C	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05800723	chr4:79103126	FRAS1	-0.41	-7.96	-0.35	1.35e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg25823085	chr7:87105416	ABCB4	0.3	7.35	0.32	8.96e-13	Gallbladder cancer;
LGG	cis	rs9916302	0.706	rs9891892	chr17:37479856	A/C	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.97e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9733	0.650	rs9803935	chr1:150552622	T/G	cg13175981	chr1:150552382	MCL1	0.61	10.58	0.44	1.45e-23	Tonsillectomy;
LGG	cis	rs79146658	0.646	rs10803920	chr2:179728163	A/G	cg17765952	chr2:179737173	CCDC141	-0.59	-8.71	-0.38	5.3e-17	Diastolic blood pressure;
LGG	cis	rs258892	0.947	rs266448	chr5:72182229	G/A	cg21869765	chr5:72125136	TNPO1	0.42	6.77	0.3	3.84e-11	Small cell lung carcinoma;
LGG	cis	rs503734	0.666	rs2682391	chr3:101101361	G/A	cg27318481	chr3:100970896	IMPG2	-0.36	-7.22	-0.32	2.11e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.15	-0.35	3.48e-15	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg23782820	chr8:58130467	NA	0.53	7.51	0.33	3.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs317865	0.737	rs73234668	chr4:16240306	T/C	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.77	7.62	0.33	1.45e-13	Kidney disease (early stage) in type 1 diabetes;
LGG	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	8.14	0.35	3.75e-15	Cognitive test performance;
LGG	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg22232500	chr2:134024266	NCKAP5	0.55	7.83	0.34	3.37e-14	Bipolar disorder;
LGG	cis	rs78487399	0.808	rs17039133	chr2:43694570	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.02	-0.31	8.13e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg05941027	chr17:61774174	LIMD2	0.34	8.76	0.38	3.76e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7940866	0.804	rs10894287	chr11:130808483	C/T	cg12179176	chr11:130786555	SNX19	0.77	15.02	0.57	7.7e-42	Schizophrenia;
LGG	cis	rs7089973	0.604	rs765173	chr10:116601675	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	7.72	0.34	7.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs61931739	0.649	rs864614	chr12:33725409	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs593982	0.920	rs488170	chr11:65481544	T/C	cg08755490	chr11:65554678	OVOL1	0.7	8.61	0.37	1.19e-16	Atopic dermatitis;
LGG	cis	rs4795419	1	rs4795419	chr17:38166003	G/A	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	Monocyte percentage of white cells;
LGG	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.99	-0.31	9.73e-12	Educational attainment;
LGG	trans	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg18187862	chr3:45730750	SACM1L	-0.43	-6.98	-0.31	9.96e-12	Primary sclerosing cholangitis;
LGG	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs13260300	0.571	rs2588305	chr8:75542950	A/C	cg22993706	chr8:75542856	NA	0.54	11.63	0.48	1.36e-27	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.54	-0.53	2.05e-35	Coronary artery disease;
LGG	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.47	0.33	4.06e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-9.08	-0.39	3.11e-18	Menopause (age at onset);
LGG	cis	rs6665290	0.935	rs11588904	chr1:227196211	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.58	-0.37	1.44e-16	Mean corpuscular volume;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg24623649	chr8:11872141	NA	-0.3	-6.78	-0.3	3.58e-11	Neuroticism;
LGG	cis	rs9902453	0.765	rs2874505	chr17:28037923	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.01	0.55	1.93e-37	Coffee consumption (cups per day);
LGG	cis	rs13421350	0.579	rs75669437	chr2:173395373	G/A	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg25817165	chr18:72167213	CNDP2	-0.64	-13.62	-0.53	8.94e-36	Refractive error;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.82	0.3	2.8e-11	Dupuytren's disease;
LGG	cis	rs11608355	0.545	rs11615336	chr12:109914802	C/A	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.95	-0.31	1.25e-11	Lung cancer;
LGG	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-7.83	-0.34	3.31e-14	Osteoporosis;
LGG	cis	rs477692	1.000	rs522891	chr10:131430916	T/C	cg05714579	chr10:131428358	MGMT	-0.56	-11.55	-0.47	2.74e-27	Response to temozolomide;
LGG	cis	rs6882046	0.513	rs254779	chr5:88019629	T/C	cg22951263	chr5:87985283	NA	-0.57	-10.49	-0.44	3.17e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	11.95	0.49	7.01e-29	Longevity;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg19143629	chr17:61920732	SMARCD2	0.39	6.7	0.3	6.13e-11	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7315438	0.512	rs7961787	chr12:115947796	T/C	cg18639984	chr12:115943877	NA	-0.42	-9.11	-0.39	2.5e-18	Colorectal cancer;
LGG	cis	rs1920116	0.778	rs35510081	chr3:169549774	A/T	cg08193579	chr3:169529701	LRRC34	0.41	6.66	0.3	7.6e-11	Glioma (high-grade);
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.88	-0.3	1.96e-11	Bipolar disorder;
LGG	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg27490568	chr2:178487706	NA	0.71	12.62	0.51	1.32e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg26513180	chr16:89883248	FANCA	0.94	20.96	0.7	4.22e-69	Vitiligo;
LGG	cis	rs1620921	0.901	rs783165	chr6:161177842	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.5	-0.33	3.38e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10463316	0.862	rs11740475	chr5:150777997	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.31	-0.43	1.43e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs75059851	0.756	rs11223648	chr11:133840412	C/T	cg17703048	chr11:133852993	NA	-0.87	-16.04	-0.6	2.25e-46	Schizophrenia;
LGG	cis	rs9902453	0.845	rs58575982	chr17:28221776	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.39	0.53	8.73e-35	Coffee consumption (cups per day);
LGG	trans	rs1459104	0.925	rs17157459	chr11:55141418	A/C	cg15704280	chr7:45808275	SEPT13	0.69	6.85	0.3	2.41e-11	Body mass index;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	6.97	0.31	1.12e-11	Renal function-related traits (BUN);
LGG	cis	rs7945718	0.839	rs11022512	chr11:12835952	G/A	cg25843174	chr11:12811716	TEAD1	0.4	7.94	0.35	1.55e-14	Educational attainment (years of education);
LGG	cis	rs514024	0.729	rs4837172	chr9:130384703	A/C	cg13643465	chr9:130375613	STXBP1	0.64	12.06	0.49	2.56e-29	Eating disorders (purging via substances);
LGG	cis	rs6426558	0.537	rs6692080	chr1:227390162	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.6	-9.9	-0.42	4.49e-21	Neutrophil percentage of white cells;
LGG	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg25427524	chr10:38739819	LOC399744	-0.5	-7.42	-0.33	5.68e-13	Obesity (extreme);
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg22437258	chr11:111473054	SIK2	-0.57	-9.79	-0.41	1.04e-20	Primary sclerosing cholangitis;
LGG	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg01620082	chr3:125678407	NA	-0.61	-7.51	-0.33	2.98e-13	Depression;
LGG	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg00599393	chr8:22457479	C8orf58	0.45	7.99	0.35	1.1e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10078	1.000	rs10078	chr5:438102	G/T	cg07599136	chr5:415885	AHRR	0.52	8.12	0.35	4.31e-15	Fat distribution (HIV);
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.44	-0.69	1.19e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.66	-0.34	1.11e-13	Colorectal cancer;
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg05793240	chr7:2802953	GNA12	0.32	7.35	0.32	9.28e-13	Height;
LGG	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg16576597	chr16:28551801	NUPR1	-0.34	-7.47	-0.33	3.92e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.41	-0.33	6.01e-13	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00424166	chr6:150045504	NUP43	-0.36	-7.75	-0.34	5.94e-14	Lung cancer;
LGG	cis	rs848	0.587	rs2040704	chr5:131973177	A/G	cg04303330	chr5:131992430	IL13	0.28	6.79	0.3	3.43e-11	Alopecia areata;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14240646	chr10:27532245	ACBD5	0.74	10.21	0.43	3.29e-22	Breast cancer;
LGG	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.61	-0.56	5.03e-40	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.68e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg12310025	chr6:25882481	NA	-0.44	-7.98	-0.35	1.2e-14	Height;
LGG	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.13	-0.43	6.58e-22	Morning vs. evening chronotype;
LGG	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.84	-9.8	-0.41	9.65e-21	Response to haloperidol in psychosis;
LGG	cis	rs1670533	1.000	rs629261	chr4:1086763	A/C	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg18876405	chr7:65276391	NA	0.49	8.73	0.38	4.51e-17	Aortic root size;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.18	-0.39	1.41e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	10.71	0.45	4.5e-24	Educational attainment;
LGG	cis	rs1620921	0.505	rs11758404	chr6:161210455	A/G	cg01280913	chr6:161186852	NA	-0.49	-9.91	-0.42	4.13e-21	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs36051895	0.623	rs10975031	chr9:5253153	G/T	cg02405213	chr9:5042618	JAK2	-0.73	-13.18	-0.52	6.84e-34	Pediatric autoimmune diseases;
LGG	cis	rs10489202	1.000	rs12407660	chr1:167954363	C/T	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg05165339	chr4:1420672	NA	-0.35	-8.95	-0.38	8.31e-18	Longevity;
LGG	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.1	-0.31	4.66e-12	Testicular germ cell tumor;
LGG	cis	rs4722166	0.645	rs1404006	chr7:22795077	T/C	cg05265849	chr7:22767390	IL6	0.37	7.29	0.32	1.35e-12	Lung cancer;
LGG	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg11062466	chr8:58055876	NA	0.44	7.37	0.32	7.89e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs12517041	1.000	rs35380017	chr5:23310237	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23522427	chr7:150675308	KCNH2	0.47	7.0	0.31	9.19e-12	Hip circumference;
LGG	cis	rs7762018	1.000	rs4716378	chr6:170086568	G/C	cg15038512	chr6:170123185	PHF10	0.51	6.67	0.3	7.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4302748	0.862	rs58221920	chr7:36181963	C/A	cg24442661	chr7:36192818	EEPD1	0.56	7.47	0.33	4.16e-13	Platelet count;
LGG	cis	rs7927771	0.524	rs7943464	chr11:47886639	T/A	cg20307385	chr11:47447363	PSMC3	0.57	11.14	0.46	1.05e-25	Subjective well-being;
LGG	cis	rs4595586	0.679	rs11169992	chr12:39317207	C/T	cg26384229	chr12:38710491	ALG10B	0.47	8.73	0.38	4.8e-17	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.57	-0.33	2.1e-13	Tonsillectomy;
LGG	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.96	0.45	5.2e-25	Parkinson's disease;
LGG	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg12193833	chr17:30244370	NA	0.28	7.01	0.31	8.26e-12	Hip circumference adjusted for BMI;
LGG	cis	rs80282103	0.618	rs11250252	chr10:1124939	G/C	cg08668510	chr10:1095578	IDI1	0.75	7.39	0.32	7.06e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs4629710	0.592	rs11759926	chr6:131571269	G/T	cg12606694	chr6:131520996	AKAP7	0.51	8.33	0.36	9.12e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7129556	0.621	rs663674	chr11:77592522	A/G	cg12586386	chr11:77299805	AQP11	0.44	7.2	0.32	2.5e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs854765	0.583	rs8073001	chr17:17831716	A/C	cg04398451	chr17:18023971	MYO15A	0.59	11.92	0.48	9.71e-29	Total body bone mineral density;
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19717773	chr7:2847554	GNA12	-0.35	-8.11	-0.35	4.6e-15	Height;
LGG	cis	rs9636252	0.887	rs13399442	chr2:9267494	C/T	cg20341998	chr2:9276514	NA	0.37	7.15	0.32	3.5e-12	IgG glycosylation;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg11878867	chr6:150167359	LRP11	-0.5	-9.93	-0.42	3.32e-21	Lung cancer;
LGG	cis	rs4891159	0.756	rs55763305	chr18:74161249	G/C	cg24786174	chr18:74118243	ZNF516	-0.53	-12.09	-0.49	1.87e-29	Longevity;
LGG	cis	rs721917	0.506	rs2758561	chr10:81669474	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.89	-0.34	2.18e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg06951627	chr6:26196580	NA	0.52	7.85	0.34	2.98e-14	Gout;Renal underexcretion gout;
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg12458913	chr13:53173898	NA	-0.54	-10.2	-0.43	3.55e-22	Lewy body disease;
LGG	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg18681998	chr4:17616180	MED28	0.82	18.34	0.65	6.84e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg13010199	chr12:38710504	ALG10B	0.72	14.74	0.57	1.32e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9649213	0.614	rs12539761	chr7:98013839	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.47	-8.04	-0.35	7.37e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7666738	0.830	rs4699600	chr4:99019429	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg16041611	chr6:43139680	SRF	0.39	6.69	0.3	6.27e-11	Body mass index;
LGG	cis	rs8067545	0.611	rs2703812	chr17:20114803	A/G	cg13482628	chr17:19912719	NA	-0.53	-10.14	-0.43	6.1e-22	Schizophrenia;
LGG	cis	rs72848980	0.512	rs56033495	chr10:105383611	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.81	13.6	0.53	1.06e-35	White matter hyperintensity burden;
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.08	-0.52	1.72e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg19077165	chr18:44547161	KATNAL2	0.54	9.8	0.41	1.03e-20	Personality dimensions;
LGG	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12229367	chr17:55822335	NA	0.45	8.63	0.37	9.89e-17	Schizophrenia;
LGG	cis	rs888194	0.714	rs2058804	chr12:109909011	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.21	-0.32	2.36e-12	Neuroticism;
LGG	cis	rs2859741	0.587	rs516139	chr1:37471617	C/G	cg09363841	chr1:37513479	NA	-0.53	-11.15	-0.46	1.01e-25	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs9326248	0.861	rs7931335	chr11:117036805	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.82	0.34	3.71e-14	Blood protein levels;
LGG	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg13147721	chr7:65941812	NA	0.84	10.19	0.43	4.03e-22	Diabetic kidney disease;
LGG	cis	rs2287838	0.716	rs7256625	chr19:10007171	C/G	cg07950397	chr19:10022659	OLFM2	0.29	6.8	0.3	3.17e-11	Sleep duration;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg18379455	chr17:41446167	NA	-0.33	-8.02	-0.35	8.92e-15	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.2	0.36	2.31e-15	Prudent dietary pattern;
LGG	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4684776	0.867	rs1470612	chr3:11336966	C/T	cg24705426	chr3:11550659	ATG7	-0.44	-8.21	-0.36	2.23e-15	Small vessel stroke;
LGG	cis	rs5742933	0.817	rs3816196	chr2:190640475	A/G	cg04003228	chr2:190539410	ANKAR	-0.5	-7.22	-0.32	2.11e-12	Ferritin levels;
LGG	trans	rs7644516	0.646	rs2052761	chr3:25924669	A/G	cg06864853	chr7:134143971	AKR1B1	-0.47	-6.94	-0.31	1.3e-11	DNA methylation (variation);
LGG	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg05623727	chr3:50126028	RBM5	0.33	7.25	0.32	1.81e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg18681998	chr4:17616180	MED28	0.87	20.33	0.69	3.74e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9878978	0.754	rs6774579	chr3:2436262	C/A	cg21928760	chr3:2462534	CNTN4	0.39	7.8	0.34	4.21e-14	Blood pressure (smoking interaction);
LGG	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.31	-7.78	-0.34	4.93e-14	Pulse pressure;
LGG	cis	rs9972944	0.756	rs4791132	chr17:63769124	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs9814567	0.806	rs7648616	chr3:134318074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9611519	1.000	rs4820433	chr22:41607065	C/G	cg03806693	chr22:41940476	POLR3H	-0.51	-8.14	-0.35	3.69e-15	Neuroticism;
LGG	cis	rs7312933	0.737	rs10880261	chr12:42573822	T/C	cg19980929	chr12:42632907	YAF2	0.37	8.29	0.36	1.25e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03264133	chr6:25882463	NA	-0.58	-11.08	-0.46	1.86e-25	Blood metabolite levels;
LGG	cis	rs72925845	0.577	rs618324	chr17:76429546	T/C	cg03830375	chr17:76426088	DNAH17	0.5	7.11	0.31	4.35e-12	Triglycerides;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.91	-0.31	1.61e-11	Longevity;
LGG	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.72	-0.41	1.83e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg09307838	chr4:120376055	NA	0.79	13.12	0.52	1.21e-33	Corneal astigmatism;
LGG	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg23029597	chr12:123009494	RSRC2	0.8	14.93	0.57	1.93e-41	Body mass index;
LGG	trans	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg05059571	chr16:84539110	KIAA1609	-0.57	-11.09	-0.46	1.64e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg26318627	chr11:63887540	MACROD1	0.4	7.39	0.32	6.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg20587970	chr11:113659929	NA	-1.23	-21.57	-0.71	5.86e-72	Hip circumference adjusted for BMI;
LGG	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.24	0.32	1.86e-12	Birth weight;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg00689492	chr4:1303491	MAEA	0.51	8.62	0.37	1.05e-16	Obesity-related traits;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12016809	chr21:47604291	C21orf56	0.59	9.88	0.42	5.11e-21	Testicular germ cell tumor;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06112835	chr11:68658793	MRPL21	0.59	9.81	0.41	9.13e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg04173714	chr15:86211321	AKAP13	-0.47	-8.6	-0.37	1.27e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg15948088	chr11:109293068	C11orf87	0.46	8.28	0.36	1.32e-15	Schizophrenia;
LGG	cis	rs739401	0.611	rs7130841	chr11:3043658	A/G	cg05729581	chr11:3078854	CARS	-0.54	-9.53	-0.4	9.04e-20	Longevity;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.23	0.49	5.35e-30	Prudent dietary pattern;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg13537196	chr9:15553060	C9orf93	0.42	7.43	0.33	5.37e-13	Body mass index;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10779751	1.000	rs1135172	chr1:11301714	C/T	cg08854313	chr1:11322531	MTOR	-0.75	-16.45	-0.61	3.4e-48	Body mass index;
LGG	cis	rs9788721	0.934	rs55676755	chr15:78898932	C/G	cg18825076	chr15:78729989	IREB2	-0.45	-7.32	-0.32	1.1e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1801251	0.727	rs7557607	chr2:233557073	G/T	cg25237894	chr2:233734115	C2orf82	0.51	9.39	0.4	2.81e-19	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg11494091	chr17:61959527	GH2	0.51	8.04	0.35	7.61e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs4665809	1.000	rs4665304	chr2:26313406	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.55e-14	Gut microbiome composition (summer);
LGG	cis	rs12579753	0.667	rs7486325	chr12:82302291	G/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.24	-0.32	1.87e-12	Resting heart rate;
LGG	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.9	-0.34	2.04e-14	Caffeine consumption;
LGG	cis	rs1665650	0.914	rs7096380	chr10:118488416	C/G	cg14919929	chr10:118506882	NA	-0.49	-8.66	-0.37	7.64e-17	Colorectal cancer;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-9.87	-0.42	5.43e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7077256	0.564	rs12766208	chr10:65022022	G/C	cg02276361	chr10:65351566	REEP3	-0.33	-6.75	-0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.85	0.42	6.78e-21	Schizophrenia;
LGG	cis	rs8133932	0.654	rs413517	chr21:47347545	C/G	cg11214348	chr21:47283868	PCBP3	-0.45	-7.85	-0.34	2.88e-14	Schizophrenia;
LGG	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg24812749	chr6:127587940	RNF146	0.64	10.79	0.45	2.28e-24	Breast cancer;
LGG	cis	rs12765878	0.580	rs11191829	chr10:105614452	G/T	cg11005552	chr10:105648138	OBFC1	-0.71	-12.47	-0.5	5.93e-31	Coronary artery disease;
LGG	cis	rs7216064	1.000	rs59950564	chr17:65860859	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg06212747	chr3:49208901	KLHDC8B	0.61	10.07	0.42	1.08e-21	Parkinson's disease;
LGG	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg02187348	chr16:89574699	SPG7	0.46	7.37	0.32	7.78e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs8062405	0.755	rs4788076	chr16:28570005	C/T	cg16576597	chr16:28551801	NUPR1	0.43	10.22	0.43	3.03e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs701145	0.585	rs1624917	chr3:153827300	T/A	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06470251	chr20:60548479	NA	0.49	8.35	0.36	8.15e-16	Body mass index;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.38	-0.43	8.08e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs10849893	0.557	rs10849890	chr12:121902725	T/C	cg01154721	chr12:121881891	KDM2B	-0.4	-6.97	-0.31	1.06e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg08975724	chr8:8085496	FLJ10661	0.51	9.34	0.4	3.91e-19	Red cell distribution width;
LGG	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.34	-0.32	9.95e-13	Hemoglobin concentration;
LGG	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg15440763	chr7:158190612	PTPRN2	0.42	8.62	0.37	1.07e-16	Obesity-related traits;
LGG	trans	rs75804782	0.572	rs74979875	chr2:239302568	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	6.75	0.3	4.31e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs807669	0.903	rs1780640	chr22:19174597	C/T	cg02655711	chr22:19163373	SLC25A1	0.8	16.31	0.6	1.4e-47	Metabolite levels;
LGG	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.06	-0.42	1.13e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg17802220	chr15:77601643	NA	0.54	12.17	0.49	9.73e-30	Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	15.82	0.59	2.34e-45	Personality dimensions;
LGG	cis	rs1971256	0.500	rs9479050	chr6:151806338	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-7.36	-0.32	8.57e-13	Endometriosis;
LGG	cis	rs7493	1.000	rs7786401	chr7:95034001	G/T	cg17330251	chr7:94953956	PON1	-0.43	-8.47	-0.37	3.25e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.51	-10.1	-0.42	8.35e-22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs3617	0.573	rs56383738	chr3:52908398	T/C	cg11645453	chr3:52864694	ITIH4	-0.47	-7.87	-0.34	2.54e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg14541582	chr5:601475	NA	-0.68	-10.63	-0.44	8.86e-24	Obesity-related traits;
LGG	cis	rs907683	0.584	rs12991025	chr2:220284779	C/T	cg15015639	chr2:220282977	DES	0.36	10.29	0.43	1.66e-22	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18222582	chr1:232765331	NA	0.49	7.58	0.33	1.85e-13	Gut microbiome composition (summer);
LGG	cis	rs7811417	0.505	rs1473119	chr7:21564835	A/G	cg04471919	chr7:21584483	DNAH11	-0.35	-8.96	-0.38	8.07e-18	Schizophrenia;
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg12310025	chr6:25882481	NA	0.48	8.73	0.38	4.73e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg27400746	chr16:89904261	SPIRE2	-0.79	-12.77	-0.51	3.2e-32	Skin colour saturation;
LGG	trans	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg13565492	chr6:43139072	SRF	-0.56	-7.4	-0.33	6.2800000000000005e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg07395648	chr5:131743802	NA	0.44	8.53	0.37	2.16e-16	Breast cancer;Mosquito bite size;
LGG	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22174410	chr3:42641766	NKTR	0.48	8.22	0.36	2.1e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.87	-0.3	2.07e-11	Neuroticism;
LGG	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.24	0.49	5.04e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg04226714	chr8:49833948	SNAI2	-0.49	-8.98	-0.39	6.65e-18	Life satisfaction;
LGG	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg27490568	chr2:178487706	NA	0.69	12.95	0.52	6.18e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08555112	chr17:48942811	TOB1	0.5	8.14	0.35	3.75e-15	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.501	rs7563462	chr2:100063708	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.96	-0.31	1.19e-11	Chronic sinus infection;
LGG	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg14092571	chr14:90743983	NA	-0.81	-16.42	-0.61	4.62e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs787274	1.000	rs787295	chr9:115541606	C/G	cg13803584	chr9:115635662	SNX30	0.51	7.11	0.31	4.38e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17767392	0.670	rs59697713	chr14:71729257	T/C	cg02058870	chr14:72053146	SIPA1L1	0.36	7.69	0.34	8.92e-14	Mitral valve prolapse;
LGG	cis	rs13314892	0.764	rs1430604	chr3:69876319	G/T	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg02462569	chr6:150064036	NUP43	-0.37	-7.84	-0.34	3.03e-14	Lung cancer;
LGG	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg11366901	chr6:160182831	ACAT2	-1.06	-16.94	-0.62	1.88e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1962636	1	rs1962636	chr16:22064395	A/C	cg09370801	chr16:22207107	NA	0.66	11.64	0.48	1.19e-27	Schizophrenia;
LGG	cis	rs7928758	0.945	rs113328990	chr11:134278010	G/T	cg15243474	chr11:134282918	B3GAT1	1.08	14.18	0.55	3.81e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs5756391	0.546	rs4821560	chr22:37311806	G/T	cg21209356	chr22:37319042	CSF2RB	-0.39	-8.84	-0.38	2.04e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18252515	chr7:66147081	NA	0.42	7.1	0.31	4.59e-12	Aortic root size;
LGG	trans	rs61931739	0.517	rs12816423	chr12:34067736	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.58e-45	Morning vs. evening chronotype;
LGG	cis	rs12354486	1	rs12354486	chr10:104124055	C/G	cg15320455	chr10:103880129	LDB1	0.5	6.85	0.3	2.3e-11	Educational attainment (college completion);
LGG	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.35	0.4	3.84e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs6582630	0.555	rs10880544	chr12:38473464	G/C	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7715811	0.913	rs73749951	chr5:13762514	G/A	cg07548982	chr5:13769939	DNAH5	-0.45	-9.13	-0.39	2.1e-18	Subclinical atherosclerosis traits (other);
LGG	cis	rs4538187	0.502	rs11683408	chr2:64193684	C/T	cg02541582	chr2:64069798	UGP2	-0.58	-9.42	-0.4	2.18e-19	Systolic blood pressure;
LGG	trans	rs2562456	0.833	rs55756795	chr19:21510059	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg15596359	chr8:11213517	TDH	0.34	6.89	0.31	1.8e-11	Retinal vascular caliber;
LGG	cis	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.14	0.72	1.26e-74	Bladder cancer;
LGG	cis	rs4740619	0.616	rs10756734	chr9:16026444	T/C	cg14451791	chr9:16040625	NA	-0.43	-11.27	-0.46	3.41e-26	Body mass index;
LGG	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06470251	chr20:60548479	NA	0.47	8.32	0.36	9.97e-16	Body mass index;
LGG	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg11871910	chr12:69753446	YEATS4	1.05	28.86	0.8	1.55e-105	Cerebrospinal fluid biomarker levels;
LGG	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21582582	chr3:182698605	DCUN1D1	0.52	9.64	0.41	3.6e-20	Intelligence (multi-trait analysis);
LGG	cis	rs798554	1.000	rs798536	chr7:2766383	G/A	cg27476859	chr7:2772710	GNA12	0.43	7.33	0.32	1.06e-12	Height;
LGG	cis	rs2243480	0.708	rs35825036	chr7:65986502	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.19	-0.43	4.05e-22	Diabetic kidney disease;
LGG	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg01059449	chr18:44338099	ST8SIA5	0.32	7.12	0.31	4.16e-12	Personality dimensions;
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg23302884	chr18:44338147	ST8SIA5	0.36	7.17	0.32	2.98e-12	Personality dimensions;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg01620082	chr3:125678407	NA	-0.82	-8.98	-0.39	6.82e-18	Depression;
LGG	cis	rs10979	0.838	rs12208649	chr6:143893321	G/T	cg25407410	chr6:143891975	LOC285740	-0.73	-12.48	-0.5	5.14e-31	Hypospadias;
LGG	cis	rs7737355	0.812	rs13173941	chr5:130623232	T/A	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs7794364	0.658	rs2193255	chr7:117520009	A/C	cg21880328	chr7:117514017	CTTNBP2	-0.34	-7.04	-0.31	7.12e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.7e-17	Lung cancer;
LGG	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg26384229	chr12:38710491	ALG10B	0.6	11.83	0.48	2.23e-28	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs11771526	0.686	rs77847042	chr7:32277207	A/G	cg13207630	chr7:32358064	NA	0.62	6.81	0.3	2.97e-11	Body mass index;
LGG	cis	rs12643440	0.538	rs882315	chr4:17149123	A/T	cg22650099	chr4:17144496	NA	-0.54	-9.41	-0.4	2.41e-19	Metabolite levels (Pyroglutamine);
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg02002194	chr4:3960332	NA	0.38	6.84	0.3	2.58e-11	Mean corpuscular volume;
LGG	cis	rs2635047	1.000	rs2684825	chr18:44666415	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.0	0.31	9.02e-12	Educational attainment;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-8.88	-0.38	1.48e-17	Schizophrenia;
LGG	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg01017244	chr2:74357527	NA	0.46	8.6	0.37	1.24e-16	Gestational age at birth (maternal effect);
LGG	trans	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg00938859	chr5:1591904	SDHAP3	0.83	8.82	0.38	2.41e-17	Breast cancer;
LGG	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg17077180	chr1:38461687	NA	-0.39	-7.31	-0.32	1.17e-12	Coronary artery disease;
LGG	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.96	-0.45	5.15e-25	Body mass index;
LGG	cis	rs8133932	0.654	rs369245	chr21:47337821	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.98	-0.35	1.17e-14	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26452244	chr6:10695099	C6orf52;PAK1IP1	-0.47	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg19554555	chr3:13937349	NA	-0.54	-9.78	-0.41	1.14e-20	Ovarian reserve;
LGG	trans	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	cis	rs975722	0.638	rs718829	chr7:117207860	C/A	cg10524701	chr7:117356490	CTTNBP2	0.45	9.76	0.41	1.33e-20	Coronary artery disease;
LGG	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg14683738	chr19:37701593	ZNF585B	0.45	6.68	0.3	6.94e-11	Coronary artery calcification;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07440826	chr16:89882328	FANCA	-0.26	-6.89	-0.3	1.82e-11	Vitiligo;
LGG	cis	rs9612	1.000	rs8105041	chr19:44258458	A/G	cg08581076	chr19:44259116	C19orf61	0.48	8.02	0.35	8.81e-15	Exhaled nitric oxide output;
LGG	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg02836325	chr17:76403955	PGS1	-0.79	-17.41	-0.63	1.37e-52	HDL cholesterol;
LGG	trans	rs6787172	0.702	rs1630304	chr3:157991354	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs597583	0.806	rs1941390	chr11:117396991	G/A	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.27	-0.36	1.4e-15	Putamen volume;
LGG	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg23920097	chr1:209922102	NA	-0.49	-8.31	-0.36	1.08e-15	Red blood cell count;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg05861140	chr6:150128134	PCMT1	0.44	9.99	0.42	2.07e-21	Lung cancer;
LGG	cis	rs8044868	0.541	rs7202268	chr16:72086746	A/G	cg23815491	chr16:72088622	HP	0.38	7.88	0.34	2.4e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs9649465	1.000	rs2109725	chr7:123325459	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-9.09	-0.39	2.85e-18	Colorectal cancer;
LGG	trans	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg18187862	chr3:45730750	SACM1L	-0.69	-11.5	-0.47	4.2e-27	Primary sclerosing cholangitis;
LGG	cis	rs55665837	1.000	rs10832278	chr11:14496619	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.81	-0.38	2.59e-17	Vitamin D levels;
LGG	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg19723775	chr5:179050963	HNRNPH1	0.44	7.31	0.32	1.22e-12	Lung cancer;
LGG	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg08344181	chr3:125677491	NA	-0.68	-8.04	-0.35	7.6e-15	Depression;
LGG	cis	rs13217239	0.646	rs10946888	chr6:26951678	A/G	cg12292205	chr6:26970375	C6orf41	0.55	10.87	0.45	1.1e-24	Schizophrenia;
LGG	cis	rs3087591	1.000	rs7220483	chr17:29577248	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.84	-0.57	5.11e-41	Hip circumference;
LGG	cis	rs1034435	0.547	rs743846	chr22:48900819	C/T	cg05992904	chr22:48892994	FAM19A5	-0.69	-11.89	-0.48	1.2e-28	Late-onset Alzheimer's disease;
LGG	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg20302533	chr7:39170763	POU6F2	0.54	13.28	0.53	2.62e-34	IgG glycosylation;
LGG	cis	rs854037	0.551	rs11744848	chr5:57137499	C/T	cg08523694	chr5:57076192	NA	0.52	7.06	0.31	6.09e-12	Birth weight;
LGG	cis	rs3741151	0.773	rs61345051	chr11:73112305	T/C	cg17517138	chr11:73019481	ARHGEF17	0.87	8.64	0.37	9.24e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg22852734	chr6:133119734	C6orf192	1.35	11.33	0.47	1.95e-26	Type 2 diabetes nephropathy;
LGG	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs977987	0.806	rs8056236	chr16:75448273	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg01657329	chr11:68192670	LRP5	0.61	11.0	0.46	3.78e-25	Total body bone mineral density;
LGG	cis	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.31	0.32	1.19e-12	Bladder cancer;
LGG	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.52	-0.33	2.96e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4363385	0.719	rs6587714	chr1:152933023	T/C	cg07796016	chr1:152779584	LCE1C	-0.45	-7.22	-0.32	2.2e-12	Inflammatory skin disease;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.0	-0.42	1.9e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg00666640	chr1:248458726	OR2T12	0.59	9.5	0.4	1.1e-19	Common traits (Other);
LGG	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.49	6.9	0.31	1.69e-11	Birth weight;
LGG	cis	rs10504130	0.597	rs34058697	chr8:52794952	G/A	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.56e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09209002	chr4:71554199	UTP3	0.63	7.56	0.33	2.22e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg00198680	chr16:28758506	NA	0.29	7.14	0.31	3.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs453301	0.506	rs686189	chr8:8623637	A/G	cg02002194	chr4:3960332	NA	0.36	6.82	0.3	2.87e-11	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26859901	chr19:35759185	USF2	0.4	6.73	0.3	5.08e-11	Gut microbiome composition (summer);
LGG	cis	rs113835537	0.529	rs117112180	chr11:66293273	A/G	cg24851651	chr11:66362959	CCS	0.45	7.63	0.33	1.34e-13	Airway imaging phenotypes;
LGG	trans	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.85	0.42	6.5e-21	Mean corpuscular volume;
LGG	cis	rs9309473	0.950	rs6546854	chr2:73834034	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.79	-0.34	4.55e-14	Metabolite levels;
LGG	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.68	-13.79	-0.54	1.77e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9341808	0.500	rs2322629	chr6:80811540	C/T	cg08355045	chr6:80787529	NA	0.38	7.38	0.32	7.42e-13	Sitting height ratio;
LGG	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg22535103	chr8:58192502	C8orf71	-0.58	-9.64	-0.41	3.64e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg07930552	chr6:133119739	C6orf192	-0.84	-11.75	-0.48	4.33e-28	Type 2 diabetes nephropathy;
LGG	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04004882	chr2:215674386	BARD1	-0.66	-11.4	-0.47	1.07e-26	Neuroblastoma (high-risk);
LGG	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg18898632	chr2:242989856	NA	-0.73	-8.79	-0.38	2.98e-17	Obesity-related traits;
LGG	cis	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg06521331	chr12:34319734	NA	-0.62	-11.88	-0.48	1.41e-28	Morning vs. evening chronotype;
LGG	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00166722	chr3:10149974	C3orf24	-0.51	-8.55	-0.37	1.8e-16	Alzheimer's disease;
LGG	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg08601574	chr20:25228251	PYGB	0.37	7.65	0.34	1.15e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-14.96	-0.57	1.49e-41	Morning vs. evening chronotype;
LGG	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg24623649	chr8:11872141	NA	0.29	6.77	0.3	3.94e-11	Myopia (pathological);
LGG	cis	rs8030485	0.536	rs12595749	chr15:79432359	A/G	cg17916960	chr15:79447300	NA	0.55	10.47	0.44	3.75e-23	Left ventricle wall thickness;
LGG	cis	rs2354432	0.556	rs11239964	chr1:146753902	G/C	cg25205988	chr1:146714368	CHD1L	-1.47	-14.82	-0.57	5.75e-41	Mitochondrial DNA levels;
LGG	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.33	-0.32	1.03e-12	Cognitive ability;
LGG	cis	rs950169	0.610	rs34529571	chr15:84691807	A/G	cg24253500	chr15:84953950	NA	0.47	7.49	0.33	3.52e-13	Schizophrenia;
LGG	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg10326726	chr10:51549505	MSMB	0.64	12.8	0.51	2.4e-32	Prostate-specific antigen levels;
LGG	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.01	0.83	1.98e-119	Chronic sinus infection;
LGG	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg12310025	chr6:25882481	NA	0.52	9.74	0.41	1.56e-20	Blood metabolite levels;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg25937216	chr8:58172855	NA	-0.57	-9.14	-0.39	2e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.554	rs6762397	chr3:10007840	C/T	cg00149659	chr3:10157352	C3orf10	0.56	8.09	0.35	5.35e-15	Alzheimer's disease;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.94	0.54	3.77e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17428076	0.749	rs62181741	chr2:172541075	C/T	cg21435375	chr2:172878103	MAP1D	0.38	6.9	0.31	1.73e-11	Myopia;
LGG	trans	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg27661571	chr11:113659931	NA	0.57	7.86	0.34	2.75e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4919694	0.572	rs4917995	chr10:104845443	A/T	cg04362960	chr10:104952993	NT5C2	-0.86	-13.41	-0.53	7.26e-35	Arsenic metabolism;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	cis	rs12780845	0.540	rs3780962	chr10:17193346	A/G	cg01003015	chr10:17271136	VIM	-0.45	-7.69	-0.34	8.68e-14	Homocysteine levels;
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.41	0.36	4.93e-16	Life satisfaction;
LGG	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg03528353	chr17:61819722	STRADA	0.45	7.61	0.33	1.5700000000000001e-13	Prudent dietary pattern;
LGG	cis	rs4268898	0.686	rs2042468	chr2:24398446	A/T	cg06627628	chr2:24431161	ITSN2	0.48	7.89	0.34	2.25e-14	Asthma;
LGG	cis	rs9527	0.590	rs12415388	chr10:104796345	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-7.17	-0.32	3.08e-12	Arsenic metabolism;
LGG	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.35	-0.36	8.06e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1355223	0.506	rs11032898	chr11:34870111	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.36	-0.36	7.56e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2133450	0.683	rs9849706	chr3:7370444	C/G	cg19930620	chr3:7340148	GRM7	-0.36	-7.8	-0.34	4.13e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs13132184	0.507	rs17579610	chr4:38078571	C/G	cg24826020	chr4:38070998	TBC1D1	-0.5	-8.43	-0.36	4.42e-16	Verbal declarative memory;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.87	-0.42	5.39e-21	Personality dimensions;
LGG	cis	rs6754311	0.834	rs12465802	chr2:136381348	A/G	cg07169764	chr2:136633963	MCM6	-0.58	-9.18	-0.39	1.49e-18	Mosquito bite size;
LGG	trans	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg16141378	chr3:129829833	LOC729375	0.33	7.43	0.33	5.38e-13	Joint mobility (Beighton score);
LGG	cis	rs4740619	0.967	rs4741528	chr9:15655978	C/T	cg14451791	chr9:16040625	NA	0.38	9.76	0.41	1.35e-20	Body mass index;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg27411982	chr8:10470053	RP1L1	0.46	7.8	0.34	4.08e-14	Joint mobility (Beighton score);
LGG	cis	rs151997	0.671	rs152099	chr5:50210091	A/G	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.78e-25	Corneal astigmatism;
LGG	cis	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.69	-0.3	6.28e-11	Neuroticism;
LGG	cis	rs6815814	0.898	rs73236646	chr4:38871385	T/C	cg06935464	chr4:38784597	TLR10	0.56	7.68	0.34	9.59e-14	Breast cancer;
LGG	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg01804193	chr12:63026212	NA	0.55	7.15	0.32	3.3e-12	IgG glycosylation;
LGG	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg13073564	chr4:8508604	NA	0.42	7.2	0.32	2.38e-12	Response to antineoplastic agents;
LGG	cis	rs9463078	0.585	rs7754378	chr6:44863106	A/G	cg25276700	chr6:44698697	NA	0.33	6.9	0.31	1.77e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs17014483	0.749	rs2924936	chr4:89641514	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.58	6.65	0.3	8.44e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg16386425	chr10:429943	DIP2C	-0.46	-9.44	-0.4	1.88e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.78	-0.57	8.88e-41	Calcium levels;
LGG	cis	rs17209837	1.000	rs6465116	chr7:87113001	G/A	cg00919237	chr7:87102261	ABCB4	-0.72	-11.51	-0.47	4.09e-27	Gallbladder cancer;
LGG	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs7614311	0.731	rs3774727	chr3:63977875	A/G	cg22134162	chr3:63841271	THOC7	-0.4	-7.16	-0.32	3.23e-12	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs3862030	0.694	rs2025712	chr10:104230064	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.13e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs9976767	1.000	rs3761378	chr21:43832918	C/T	cg23042151	chr21:43824109	UBASH3A	0.34	6.66	0.3	7.66e-11	Type 1 diabetes;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.86	-0.42	5.9e-21	Lung cancer;
LGG	cis	rs11225247	1.000	rs11605066	chr11:102296688	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.68	0.3	7.05e-11	Renal cell carcinoma;
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg19635926	chr16:89946313	TCF25	0.68	8.18	0.36	2.72e-15	Skin colour saturation;
LGG	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.36	0.32	8.38e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg00080972	chr5:178986291	RUFY1	0.52	8.98	0.39	6.79e-18	Lung cancer;
LGG	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.76	-0.38	3.73e-17	HDL cholesterol;
LGG	cis	rs4481887	0.538	rs6697831	chr1:248392205	C/T	cg00666640	chr1:248458726	OR2T12	0.49	7.35	0.32	9.17e-13	Common traits (Other);
LGG	cis	rs3770081	1.000	rs2278086	chr2:86281905	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.66	7.15	0.32	3.51e-12	Facial emotion recognition (sad faces);
LGG	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.59	-0.37	1.35e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.31e-11	Aortic root size;
LGG	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg24558204	chr6:135376177	HBS1L	-0.48	-8.16	-0.35	3.1e-15	Red blood cell count;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.98	-17.66	-0.63	9.77e-54	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg07636037	chr3:49044803	WDR6	-1.01	-21.45	-0.71	2.1e-71	Parkinson's disease;
LGG	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg11812906	chr14:75593930	NEK9	0.55	10.21	0.43	3.29e-22	Height;
LGG	cis	rs17767392	0.813	rs61991243	chr14:71847117	A/G	cg02058870	chr14:72053146	SIPA1L1	0.39	8.08	0.35	5.69e-15	Mitral valve prolapse;
LGG	cis	rs13082711	0.911	rs7650165	chr3:27462440	C/T	cg02860705	chr3:27208620	NA	0.72	13.08	0.52	1.67e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.88	-0.42	5.1e-21	Lung cancer;
LGG	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg15596359	chr8:11213517	TDH	-0.33	-6.72	-0.3	5.27e-11	Retinal vascular caliber;
LGG	cis	rs75920871	0.920	rs7128071	chr11:116968798	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.83	-0.3	2.66e-11	Subjective well-being;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-11.33	-0.47	2.01e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	0.505	rs548298	chr17:30297494	C/A	cg13647721	chr17:30228624	UTP6	0.6	7.72	0.34	7.01e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3857067	0.967	rs1509942	chr4:95013440	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs6087990	0.899	rs6087999	chr20:31363774	A/G	cg13636640	chr20:31349939	DNMT3B	0.98	21.83	0.71	3.59e-73	Ulcerative colitis;
LGG	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg15823100	chr22:32027580	PISD	0.75	8.68	0.37	6.9e-17	Age-related hearing impairment;
LGG	cis	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.74	-0.3	4.65e-11	Neuroticism;
LGG	cis	rs9596863	0.898	rs12860689	chr13:54315805	A/G	ch.13.53330881F	chr13:54432880	NA	0.5	6.91	0.31	1.62e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4716602	0.572	rs10271030	chr7:156159796	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.57	-0.41	6.41e-20	Anti-saccade response;
LGG	cis	rs7010267	0.935	rs7463176	chr8:119957625	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.43	0.44	5.18e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg18876405	chr7:65276391	NA	-0.53	-8.91	-0.38	1.15e-17	Aortic root size;
LGG	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg09163369	chr1:210001066	C1orf107	0.35	7.0	0.31	8.76e-12	Orofacial clefts;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-11.01	-0.46	3.39e-25	Personality dimensions;
LGG	cis	rs977987	0.835	rs7200616	chr16:75366089	G/A	cg03315344	chr16:75512273	CHST6	0.52	10.58	0.44	1.47e-23	Dupuytren's disease;
LGG	cis	rs9303401	0.659	rs34818467	chr17:56643109	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.88	-14.35	-0.55	6.82e-39	Cognitive test performance;
LGG	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-27.82	-0.79	7.5e-101	Heart rate;
LGG	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.98	0.54	2.68e-37	Colorectal cancer;
LGG	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg26597838	chr10:835615	NA	0.78	10.99	0.45	3.9e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.89e-21	Cannabis dependence symptom count;
LGG	cis	rs3008870	0.959	rs2985810	chr1:67376162	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.05	22.83	0.73	7.75e-78	Lymphocyte percentage of white cells;
LGG	cis	rs10050311	0.746	rs17454662	chr4:87673764	G/A	cg11209507	chr4:87813803	C4orf36	0.54	6.99	0.31	9.43e-12	Insulin-related traits;
LGG	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg03959625	chr15:84868606	LOC388152	0.58	9.08	0.39	3.22e-18	Schizophrenia;
LGG	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg10760299	chr15:45669010	GATM	0.37	7.1	0.31	4.65e-12	Homoarginine levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20549080	chr10:103892662	PPRC1	0.51	8.49	0.37	2.92e-16	Cognitive performance;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg05091796	chr16:4465799	CORO7	-0.76	-12.47	-0.5	5.66e-31	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.16	-0.46	9.25e-26	Personality dimensions;
LGG	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.22	-0.32	2.11e-12	Neuroticism;
LGG	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg04617936	chr2:214353	NA	-0.4	-7.34	-0.32	9.77e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3820068	0.603	rs3766163	chr1:15986547	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.64	0.61	4.31e-49	Systolic blood pressure;
LGG	cis	rs2274273	0.967	rs10137409	chr14:55611441	A/C	cg04306507	chr14:55594613	LGALS3	0.61	17.22	0.62	9.69e-52	Protein biomarker;
LGG	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg14664628	chr15:75095509	CSK	-0.45	-8.08	-0.35	5.56e-15	Caffeine consumption;
LGG	cis	rs34599045	0.522	rs12753609	chr1:153034230	T/C	cg07796016	chr1:152779584	LCE1C	-0.93	-7.75	-0.34	5.96e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg22072935	chr14:105399595	NA	0.52	10.21	0.43	3.25e-22	Rheumatoid arthritis;
LGG	cis	rs7084783	0.507	rs10883893	chr10:105413643	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.4	7.44	0.33	4.9e-13	Fear of pain;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg12105860	chr12:31742801	DENND5B	0.38	6.99	0.31	9.41e-12	Eye color traits;
LGG	cis	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg07460842	chr6:66804631	NA	-1.14	-31.77	-0.83	2.22e-118	Exhaled nitric oxide output;
LGG	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg07537917	chr2:241836409	C2orf54	-0.38	-7.55	-0.33	2.26e-13	Urinary metabolites;
LGG	cis	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg19399532	chr1:178512495	C1orf220	0.55	11.04	0.46	2.65e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06677660	chr19:49140777	SEC1;DBP	-0.51	-8.8	-0.38	2.68e-17	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.73e-13	Testicular germ cell tumor;
LGG	cis	rs68170813	0.641	rs74451547	chr7:107078435	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.21	-0.43	3.2e-22	Coronary artery disease;
LGG	cis	rs3857747	0.931	rs11771964	chr7:40386172	C/A	cg00420559	chr7:40367873	C7orf10	-0.41	-8.34	-0.36	8.7e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs8032158	1.000	rs2288344	chr15:56122347	T/G	cg02198044	chr15:56286336	NEDD4	-0.68	-11.83	-0.48	2.21e-28	Keloid;
LGG	cis	rs2976388	0.935	rs2976386	chr8:143757409	G/A	cg06565975	chr8:143823917	SLURP1	-0.43	-10.75	-0.45	3.35e-24	Urinary tract infection frequency;
LGG	cis	rs10227331	0.846	rs10807647	chr7:157298007	A/G	cg06076350	chr7:157294107	NA	-0.35	-6.86	-0.3	2.18e-11	Inattentive symptoms;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18110333	chr6:292329	DUSP22	0.69	11.95	0.49	7e-29	Menopause (age at onset);
LGG	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg13263691	chr18:77568018	NA	0.82	14.31	0.55	9.63e-39	Intelligence (multi-trait analysis);
LGG	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg09165964	chr15:75287851	SCAMP5	0.64	12.23	0.49	5.24e-30	Breast cancer;
LGG	cis	rs72781680	1.000	rs72796328	chr2:24141343	A/G	cg08917208	chr2:24149416	ATAD2B	0.94	10.2	0.43	3.71e-22	Lymphocyte counts;
LGG	cis	rs7772486	0.875	rs13204280	chr6:146415368	T/C	cg23711669	chr6:146136114	FBXO30	0.39	6.78	0.3	3.76e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs68170813	0.559	rs11761181	chr7:106954879	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.6	-0.44	1.15e-23	Coronary artery disease;
LGG	cis	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg26384229	chr12:38710491	ALG10B	-0.7	-13.97	-0.54	3.03e-37	Heart rate;
LGG	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg12046867	chr14:103022105	NA	-0.79	-15.95	-0.6	5.94e-46	Platelet count;
LGG	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg14664628	chr15:75095509	CSK	0.47	9.04	0.39	4.19e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs7267979	0.844	rs6083824	chr20:25363057	G/A	cg06421707	chr20:25228305	PYGB	-0.43	-9.11	-0.39	2.58e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02018176	chr4:1364513	KIAA1530	0.46	11.11	0.46	1.41e-25	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24108286	chr13:114238719	TFDP1	-0.45	-8.04	-0.35	7.6e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg12437481	chr16:420112	MRPL28	-0.43	-7.15	-0.32	3.37e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7586879	0.681	rs6756609	chr2:25121125	C/A	cg04586622	chr2:25135609	ADCY3	0.46	12.76	0.51	3.81e-32	Body mass index;
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	7.12	0.31	4.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.18	0.39	1.49e-18	Motion sickness;
LGG	cis	rs4363385	0.747	rs6668215	chr1:152964498	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.08	-0.39	3.08e-18	Inflammatory skin disease;
LGG	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.15	0.35	3.49e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	8.93	0.38	1.01e-17	Gout;Renal underexcretion gout;
LGG	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg02269571	chr22:50332266	NA	-0.71	-10.95	-0.45	5.58e-25	Schizophrenia;
LGG	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.52	-0.37	2.19e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs4466137	0.951	rs336958	chr5:82973396	A/G	cg16102102	chr5:83017553	HAPLN1	-0.6	-10.93	-0.45	7.03e-25	Prostate cancer;
LGG	cis	rs2444240	1.000	rs494965	chr11:120053650	C/T	cg16005559	chr11:120040616	NA	-0.34	-7.76	-0.34	5.47e-14	Corneal curvature;
LGG	cis	rs9672608	0.687	rs5019044	chr15:78796282	T/A	cg06917634	chr15:78832804	PSMA4	-0.52	-7.73	-0.34	6.57e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg07303275	chr16:75499416	TMEM170A	0.41	7.37	0.32	8.01e-13	Dupuytren's disease;
LGG	cis	rs10463554	0.853	rs458598	chr5:102569378	C/G	cg23492399	chr5:102201601	PAM	-0.5	-7.29	-0.32	1.38e-12	Parkinson's disease;
LGG	cis	rs17208368	0.628	rs16954198	chr16:55093518	T/C	cg09947736	chr16:55091198	NA	0.68	12.92	0.51	8.16e-33	Hypospadias;
LGG	cis	rs12618769	0.652	rs2230388	chr2:99193496	C/T	cg18455616	chr2:99124870	INPP4A	0.26	7.52	0.33	2.78e-13	Bipolar disorder;
LGG	cis	rs11690935	0.921	rs7355523	chr2:172744421	T/C	cg21435375	chr2:172878103	MAP1D	-0.33	-7.24	-0.32	1.94e-12	Schizophrenia;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg06916706	chr16:4465613	CORO7	0.7	11.97	0.49	6.15e-29	Schizophrenia;
LGG	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg02772935	chr3:125709198	NA	-0.53	-6.73	-0.3	4.99e-11	Blood pressure (smoking interaction);
LGG	cis	rs17092148	0.731	rs35507767	chr20:33361364	A/T	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.65	-0.34	1.16e-13	Neuroticism;
LGG	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg24112000	chr20:60950667	NA	-0.38	-7.64	-0.33	1.26e-13	Colorectal cancer;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg16507663	chr6:150244633	RAET1G	0.46	8.66	0.37	8.03e-17	Lung cancer;
LGG	cis	rs7236492	0.572	rs7237333	chr18:77178511	G/A	cg15644404	chr18:77186268	NFATC1	-0.82	-8.84	-0.38	2.03e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7615952	0.546	rs4428131	chr3:125346479	C/T	cg21696256	chr3:125484277	NA	-0.46	-6.89	-0.31	1.79e-11	Blood pressure (smoking interaction);
LGG	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg04450456	chr4:17643702	FAM184B	-0.33	-7.3	-0.32	1.25e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.18	-0.39	1.49e-18	Menopause (age at onset);
LGG	cis	rs17169635	0.836	rs3800739	chr7:134538147	A/G	cg02516134	chr7:134575187	CALD1	0.37	8.2	0.36	2.35e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs2153535	0.542	rs6912740	chr6:8439959	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.11e-31	Motion sickness;
LGG	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.53	-0.37	2.05e-16	Schizophrenia;
LGG	cis	rs1978968	0.956	rs4992882	chr22:18445021	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2587949	0.615	rs2587909	chr3:4199376	C/T	cg16519197	chr3:4211558	NA	0.33	6.77	0.3	3.97e-11	Periodontitis (DPAL);
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg04025307	chr7:1156635	C7orf50	0.81	14.73	0.56	1.5e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.25	-0.36	1.7e-15	Blood trace element (Zn levels);
LGG	cis	rs1348850	0.540	rs6737342	chr2:178419117	G/A	cg27490568	chr2:178487706	NA	0.74	11.81	0.48	2.58e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg22676075	chr6:135203613	NA	0.42	7.3	0.32	1.25e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg14500267	chr11:67383377	NA	0.45	8.35	0.36	8.1e-16	Mean corpuscular volume;
LGG	cis	rs12039371	1.000	rs10911492	chr1:183985203	C/T	cg01436608	chr1:184005534	GLT25D2	0.51	6.66	0.3	7.69e-11	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.84	0.3	2.48e-11	Schizophrenia;
LGG	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg13293535	chr8:11597251	GATA4	0.3	7.21	0.32	2.26e-12	Morning vs. evening chronotype;
LGG	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg22643751	chr7:855365	UNC84A	0.39	6.66	0.3	7.98e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg03060546	chr3:49711283	APEH	0.57	8.79	0.38	2.9e-17	Resting heart rate;
LGG	cis	rs3735485	0.562	rs28630972	chr7:45091012	A/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg22907277	chr7:1156413	C7orf50	0.81	11.29	0.46	2.69e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2444240	0.902	rs626225	chr11:120034115	G/A	cg16005559	chr11:120040616	NA	0.32	7.09	0.31	5.15e-12	Corneal curvature;
LGG	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg19913688	chr11:428466	ANO9	-0.69	-8.39	-0.36	5.77e-16	Body mass index;
LGG	cis	rs7911264	0.739	rs7900689	chr10:94395748	A/C	cg25093409	chr10:94429542	NA	0.49	9.51	0.4	1.06e-19	Inflammatory bowel disease;
LGG	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg00757033	chr12:89920650	WDR51B	0.64	9.24	0.39	8.71e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg08048268	chr3:133502702	NA	-0.47	-7.77	-0.34	5.07e-14	Iron status biomarkers;
LGG	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.75	-0.38	4.06e-17	Neuroticism;
LGG	cis	rs10766496	0.917	rs10766495	chr11:18738603	G/A	cg02515468	chr11:18743222	IGSF22	-0.47	-7.85	-0.34	2.83e-14	Diabetic kidney disease;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg12826209	chr6:26865740	GUSBL1	0.8	6.89	0.3	1.82e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3806843	0.583	rs408652	chr5:140330013	T/G	cg19875535	chr5:140030758	IK	0.38	7.53	0.33	2.63e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9487094	0.961	rs11153175	chr6:109682521	T/C	cg16315928	chr6:109776240	MICAL1	0.53	9.0	0.39	5.76e-18	Height;
LGG	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg07148914	chr20:33460835	GGT7	0.57	9.32	0.4	4.72e-19	Height;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs2587949	0.615	rs2256269	chr3:4216172	C/G	cg16519197	chr3:4211558	NA	-0.32	-6.7	-0.3	5.91e-11	Periodontitis (DPAL);
LGG	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.45	-0.33	4.76e-13	Monocyte count;
LGG	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg16386425	chr10:429943	DIP2C	-0.47	-9.54	-0.41	8.42e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.5e-13	Life satisfaction;
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.66e-25	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg05313129	chr8:58192883	C8orf71	-0.76	-9.97	-0.42	2.36e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.676	rs12465955	chr2:128007074	A/T	cg10021288	chr2:128175891	PROC	-0.61	-12.25	-0.49	4.45e-30	Protein C levels;
LGG	cis	rs4356975	0.563	rs6600887	chr4:69969788	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.65	0.3	8.1e-11	Obesity-related traits;
LGG	cis	rs12681287	0.640	rs2953516	chr8:87332545	C/T	cg27223183	chr8:87520930	FAM82B	-0.48	-7.04	-0.31	6.93e-12	Caudate activity during reward;
LGG	cis	rs4774899	0.901	rs960946	chr15:57549054	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.17	-0.32	2.89e-12	Urinary tract infection frequency;
LGG	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg13010199	chr12:38710504	ALG10B	0.48	9.07	0.39	3.28e-18	Morning vs. evening chronotype;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg05556477	chr5:131705319	SLC22A5	0.79	9.61	0.41	4.58e-20	Rheumatoid arthritis;
LGG	cis	rs7584262	0.513	rs34163130	chr2:42263449	A/C	cg27428208	chr2:42229179	NA	0.51	10.54	0.44	2.04e-23	Bone mineral density;
LGG	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg00701064	chr4:6280414	WFS1	0.76	17.7	0.64	6.56e-54	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg08807101	chr21:30365312	RNF160	-0.56	-9.48	-0.4	1.28e-19	Pancreatic cancer;
LGG	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg15557168	chr22:42548783	NA	0.43	8.93	0.38	1.03e-17	Schizophrenia;
LGG	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg16325326	chr1:53192061	ZYG11B	-0.72	-17.07	-0.62	5.03e-51	Monocyte count;
LGG	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.0	11.17	0.46	8.13e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.79	-0.34	4.43e-14	Neuroticism;
LGG	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg00409905	chr10:38381863	ZNF37A	0.62	12.71	0.51	5.91e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg05535760	chr7:792225	HEATR2	0.8	12.25	0.49	4.47e-30	Cerebrospinal P-tau181p levels;
LGG	cis	rs17030434	0.911	rs75822357	chr4:154738258	T/C	cg14289246	chr4:154710475	SFRP2	-0.69	-10.89	-0.45	9.38e-25	Electrocardiographic conduction measures;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.73	-0.34	6.81e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg18196295	chr10:418757	DIP2C	-0.47	-8.31	-0.36	1.09e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs1707322	0.721	rs10890333	chr1:46100322	T/C	cg03146154	chr1:46216737	IPP	0.58	11.14	0.46	1.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6882046	0.513	rs618298	chr5:88038390	A/G	cg22951263	chr5:87985283	NA	-0.55	-10.22	-0.43	3.08e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs6450176	0.625	rs3776725	chr5:53290138	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-13.62	-0.53	9.21e-36	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7216064	1.000	rs34872586	chr17:65863466	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.38	0.32	7.39e-13	Intraocular pressure;
LGG	cis	rs6121246	0.609	rs6089054	chr20:30323141	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	17.86	0.64	1.13e-54	Mean corpuscular hemoglobin;
LGG	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg18709589	chr6:96969512	KIAA0776	-0.45	-8.92	-0.38	1.11e-17	Headache;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02295156	chr5:60626281	NA	0.44	6.86	0.3	2.24e-11	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.59e-11	Type 2 diabetes;
LGG	cis	rs3803915	0.852	rs7256735	chr19:2169121	G/T	cg27073066	chr19:2169160	DOT1L	-1.03	-13.26	-0.52	3.16e-34	Body mass index;Myocardial infarction;
LGG	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg08400814	chr5:56204995	C5orf35	0.39	7.04	0.31	7.14e-12	Initial pursuit acceleration;
LGG	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg04935436	chr20:30431758	NA	0.43	7.39	0.32	6.91e-13	Mean corpuscular hemoglobin;
LGG	cis	rs1577917	1.000	rs12213740	chr6:86656733	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.81	-0.51	2.25e-32	Response to antipsychotic treatment;
LGG	cis	rs3771570	0.901	rs35256094	chr2:242439938	A/C	cg21155796	chr2:242212141	HDLBP	0.71	8.97	0.38	7.53e-18	Prostate cancer;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	cis	rs7607369	0.648	rs55983650	chr2:219654932	T/C	cg01130898	chr2:219473002	PLCD4	0.41	6.76	0.3	4.14e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	trans	rs1814175	0.645	rs7123448	chr11:49764865	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.1	-0.6	1.21e-46	Height;
LGG	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.76	-0.34	5.63e-14	Sudden cardiac arrest;
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg05941027	chr17:61774174	LIMD2	0.37	9.19	0.39	1.36e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg04000281	chr11:63949212	NA	-0.46	-8.49	-0.37	2.88e-16	Platelet count;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.44	0.56	2.65e-39	Obesity-related traits;
LGG	cis	rs17453880	0.929	rs7731459	chr5:152032506	C/T	cg10931792	chr5:152022470	NA	0.41	8.88	0.38	1.53e-17	Subjective well-being;
LGG	cis	rs17001868	0.568	rs909669	chr22:40742417	C/T	cg07138101	chr22:40742427	ADSL	0.64	8.37	0.36	6.63e-16	Mammographic density (dense area);
LGG	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-12.86	-0.51	1.42e-32	Parkinson's disease;
LGG	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12775980	0.737	rs74129718	chr10:29845415	G/T	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs7524258	0.868	rs1304711	chr1:7270320	G/T	cg07173049	chr1:7289937	CAMTA1	-0.69	-16.4	-0.61	5.62e-48	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.67	-0.59	1.03e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs6496044	0.568	rs2880765	chr15:86056462	A/T	cg13263323	chr15:86062960	AKAP13	0.37	8.1	0.35	4.97e-15	Interstitial lung disease;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.1	-0.31	4.86e-12	Neuroticism;
LGG	cis	rs8064024	0.590	rs2219271	chr16:4898120	C/G	cg08329684	chr16:4932620	PPL	0.52	11.72	0.48	5.74e-28	Cancer;
LGG	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.39	-0.47	1.2e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3857067	1.000	rs2865332	chr4:95013858	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.5	-0.33	3.38e-13	QT interval;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg04503457	chr17:41445688	NA	-0.39	-8.96	-0.38	7.84e-18	Menopause (age at onset);
LGG	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg10253484	chr15:75165896	SCAMP2	-0.44	-7.09	-0.31	5.09e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs3749056	0.512	rs479909	chr2:40432470	C/A	cg17740179	chr2:40377776	SLC8A1	-0.49	-6.8	-0.3	3.24e-11	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs9636202	1.000	rs66978877	chr19:18455657	T/C	cg02383626	chr19:18455508	PGPEP1	0.91	17.93	0.64	5.39e-55	Life satisfaction;
LGG	cis	rs11969893	0.737	rs9498439	chr6:101404768	A/T	cg12253828	chr6:101329408	ASCC3	1.12	9.68	0.41	2.62e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs17401966	0.838	rs4846197	chr1:10282166	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.83	0.34	3.3e-14	Hepatocellular carcinoma;
LGG	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.77	-0.51	3.27e-32	Bladder cancer;
LGG	cis	rs2071403	0.933	rs11685159	chr2:1412282	A/C	cg06500727	chr2:1417164	TPO	-0.51	-9.65	-0.41	3.44e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs751728	0.965	rs9394165	chr6:33731408	G/A	cg25922239	chr6:33757077	LEMD2	0.67	11.58	0.47	2.02e-27	Crohn's disease;
LGG	cis	rs1580019	0.922	rs1466147	chr7:32486262	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	16.06	0.6	1.93e-46	Cognitive ability;
LGG	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg03806693	chr22:41940476	POLR3H	-0.65	-10.51	-0.44	2.64e-23	Neuroticism;
LGG	trans	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.39	0.56	4.47e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs611744	0.625	rs6469168	chr8:109288399	G/T	cg18478394	chr8:109455254	TTC35	0.45	9.09	0.39	2.89e-18	Dupuytren's disease;
LGG	cis	rs6977660	0.660	rs10224938	chr7:19816227	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	7.97	0.35	1.22e-14	Thyroid stimulating hormone;
LGG	cis	rs372883	0.935	rs1153294	chr21:30701096	A/G	cg24692254	chr21:30365293	RNF160	-0.4	-6.9	-0.31	1.76e-11	Pancreatic cancer;
LGG	cis	rs10814247	1.000	rs10758308	chr9:35509782	G/C	cg18130437	chr9:35658183	CCDC107;RMRP	-0.4	-6.68	-0.3	6.96e-11	Psoriasis;
LGG	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.34	-0.32	9.4e-13	Inflammatory bowel disease;
LGG	cis	rs12464483	0.591	rs4952171	chr2:30886903	G/A	cg03795903	chr2:30669940	LCLAT1	0.61	7.95	0.35	1.46e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs877282	1.000	rs12219807	chr10:772870	A/C	cg17470449	chr10:769945	NA	0.65	8.35	0.36	8.26e-16	Uric acid levels;
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg22862634	chr11:62369728	EML3;MTA2	0.61	14.05	0.55	1.28e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7159888	0.514	rs12893094	chr14:65789077	G/A	cg15999311	chr14:65749247	NA	-0.4	-7.08	-0.31	5.47e-12	IgG glycosylation;N-glycan levels;
LGG	cis	rs55692411	0.537	rs7648652	chr3:50135412	A/C	cg24110177	chr3:50126178	RBM5	-0.55	-8.33	-0.36	9.08e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	16.68	0.61	3.09e-49	Platelet count;
LGG	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg17211192	chr8:82754475	SNX16	-0.68	-12.05	-0.49	2.94e-29	Diastolic blood pressure;
LGG	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg17691542	chr6:26056736	HIST1H1C	0.67	11.23	0.46	4.74e-26	Iron status biomarkers;
LGG	cis	rs16937	0.711	rs6682400	chr1:205173519	T/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	trans	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.54	0.33	2.58e-13	Schizophrenia;
LGG	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg00086871	chr4:6988644	TBC1D14	0.81	8.02	0.35	8.95e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg17376030	chr22:41985996	PMM1	-0.56	-9.18	-0.39	1.42e-18	Vitiligo;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07498778	chr8:38325092	FGFR1	-0.46	-6.75	-0.3	4.53e-11	Systemic lupus erythematosus;
LGG	cis	rs7586879	0.789	rs13398155	chr2:25128550	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.28	0.32	1.43e-12	Menopause (age at onset);
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.57	9.8	0.41	1.02e-20	Prudent dietary pattern;
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg11764359	chr7:65958608	NA	0.73	13.2	0.52	5.46e-34	Aortic root size;
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg21775007	chr8:11205619	TDH	-0.49	-8.24	-0.36	1.77e-15	Mood instability;
LGG	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg02023728	chr11:77925099	USP35	0.39	7.07	0.31	5.86e-12	Alzheimer's disease (survival time);
LGG	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.08	0.35	5.67e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg03806693	chr22:41940476	POLR3H	-0.74	-12.97	-0.52	4.91e-33	Vitiligo;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg23422044	chr7:1970798	MAD1L1	-0.68	-11.85	-0.48	1.73e-28	Bipolar disorder;
LGG	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.61	-0.71	3.77e-72	Height;
LGG	cis	rs6032067	0.759	rs2206889	chr20:43886487	C/A	cg10761708	chr20:43804764	PI3	0.58	8.89	0.38	1.34e-17	Blood protein levels;
LGG	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg16590910	chr6:42928470	GNMT	0.29	6.94	0.31	1.36e-11	Blood protein levels;
LGG	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg05044414	chr3:183734942	ABCC5	-0.52	-7.3	-0.32	1.27e-12	Body mass index;
LGG	cis	rs2074193	0.569	rs215392	chr12:47765063	G/A	cg02516419	chr12:47771422	NA	-0.58	-8.61	-0.37	1.18e-16	Migraine with aura;
LGG	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg05985134	chr18:33552581	C18orf21	0.63	9.9	0.42	4.46e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7659604	0.540	rs4075065	chr4:122683906	A/G	cg19671926	chr4:122722719	EXOSC9	0.46	7.06	0.31	6.18e-12	Type 2 diabetes;
LGG	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.85	20.19	0.68	1.68e-65	Systemic lupus erythematosus;
LGG	cis	rs9303280	0.685	rs9916765	chr17:38005595	T/C	cg00129232	chr17:37814104	STARD3	-0.46	-8.6	-0.37	1.2e-16	Self-reported allergy;
LGG	cis	rs7727544	0.684	rs2631363	chr5:131707095	A/G	cg24060327	chr5:131705240	SLC22A5	0.48	8.25	0.36	1.68e-15	Blood metabolite levels;
LGG	cis	rs738322	0.718	rs2899297	chr22:38594668	A/G	cg03162506	chr22:38580953	NA	0.42	11.01	0.46	3.46e-25	Cutaneous nevi;
LGG	cis	rs9419702	0.614	rs4373847	chr10:133532408	C/T	cg20568497	chr10:133558893	NA	0.35	7.3	0.32	1.25e-12	Survival in rectal cancer;
LGG	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg10518543	chr12:38710700	ALG10B	0.42	6.68	0.3	7.05e-11	Morning vs. evening chronotype;
LGG	trans	rs10838798	0.607	rs11039537	chr11:48154603	A/G	cg15704280	chr7:45808275	SEPT13	-0.43	-6.69	-0.3	6.48e-11	Height;
LGG	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.47	0.4	1.42e-19	Height;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg05091796	chr16:4465799	CORO7	-0.81	-13.6	-0.53	1.1e-35	Schizophrenia;
LGG	cis	rs701145	0.585	rs1727923	chr3:153786303	C/T	cg12800244	chr3:153838788	SGEF	-0.81	-9.0	-0.39	6.07e-18	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27577023	chr18:24236500	NA	-0.42	-6.65	-0.3	8.38e-11	Pancreatic cancer;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg21724239	chr8:58056113	NA	0.44	6.82	0.3	2.85e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1493916	0.592	rs1389068	chr18:31312738	G/T	cg04226714	chr8:49833948	SNAI2	-0.42	-7.3	-0.32	1.3e-12	Life satisfaction;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg15665833	chr6:26285013	NA	0.38	7.5	0.33	3.32e-13	Educational attainment;
LGG	cis	rs2242116	0.592	rs2290545	chr3:46967040	C/T	cg16586182	chr3:47516702	SCAP	-0.57	-8.67	-0.37	7.55e-17	Birth weight;
LGG	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.62	0.33	1.46e-13	Electroencephalogram traits;
LGG	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg21058520	chr6:100914733	NA	0.39	6.66	0.3	8.01e-11	Neuroticism;
LGG	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12893428	chr3:195717962	SDHAP1	0.5	10.37	0.43	8.66e-23	Pancreatic cancer;
LGG	trans	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.42	-0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg06238570	chr21:40685208	BRWD1	0.42	6.66	0.3	7.61e-11	Cognitive function;
LGG	trans	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19894588	chr14:64061835	NA	0.5	8.41	0.36	4.95e-16	Glioblastoma;Glioma;
LGG	cis	rs283228	0.535	rs62421963	chr6:101836326	G/A	cg02011392	chr6:101847541	GRIK2	0.55	7.51	0.33	3.05e-13	Coenzyme Q10 levels;
LGG	trans	rs9951602	0.512	rs8084836	chr18:76647841	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	13.39	0.53	8.38e-35	Obesity-related traits;
LGG	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg05234568	chr11:5960015	NA	0.7	11.11	0.46	1.4e-25	DNA methylation (variation);
LGG	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.92	0.54	4.67e-37	Total body bone mineral density;
LGG	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg05044414	chr3:183734942	ABCC5	0.71	13.23	0.52	4.05e-34	Anterior chamber depth;
LGG	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8112449	0.822	rs4804133	chr19:10550932	T/A	cg21868191	chr19:10515988	NA	-0.48	-8.03	-0.35	8.07e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs7590720	1.000	rs1991533	chr2:216908910	T/C	cg12620499	chr2:216877984	MREG	0.75	13.7	0.54	4.22e-36	Alcohol dependence;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.39	7.5	0.33	3.4e-13	Longevity;
LGG	trans	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg18187862	chr3:45730750	SACM1L	-0.68	-10.87	-0.45	1.17e-24	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.69	0.48	7.94e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs3784262	0.669	rs3204690	chr15:58246768	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.78	-0.3	3.56e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.53	0.53	2.29e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg01599099	chr11:66649832	PC	-0.39	-7.34	-0.32	9.46e-13	Bipolar disorder;
LGG	cis	rs503734	0.666	rs497953	chr3:101043565	T/C	cg27318481	chr3:100970896	IMPG2	-0.36	-7.33	-0.32	1.02e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4595586	1.000	rs4595586	chr12:39225991	A/T	cg26384229	chr12:38710491	ALG10B	-0.44	-7.92	-0.35	1.73e-14	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-13.89	-0.54	6.71e-37	Cognitive function;
LGG	cis	rs509477	0.962	rs562412	chr18:32576305	T/C	cg23791764	chr18:32556832	MAPRE2	-0.52	-8.9	-0.38	1.31e-17	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg22437258	chr11:111473054	SIK2	0.56	9.91	0.42	3.87e-21	Primary sclerosing cholangitis;
LGG	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg04450456	chr4:17643702	FAM184B	0.33	7.35	0.32	9.27e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs12142240	0.698	rs17361805	chr1:46813967	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.1	0.35	5.1e-15	Menopause (age at onset);
LGG	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg08297393	chr2:100937505	LONRF2	-0.52	-9.56	-0.41	6.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2840044	0.534	rs2124246	chr17:33885431	G/A	cg05299278	chr17:33885742	SLFN14	0.45	8.96	0.38	7.78e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs912057	0.797	rs1294430	chr6:6744698	A/G	cg06612196	chr6:6737390	NA	0.46	9.39	0.4	2.8e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg11473876	chr11:109292803	C11orf87	0.63	12.32	0.5	2.35e-30	Schizophrenia;
LGG	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg18198730	chr1:247681584	NA	0.71	12.26	0.49	4.16e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg06453172	chr10:134556979	INPP5A	0.55	8.58	0.37	1.48e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1707322	0.721	rs10890336	chr1:46111056	C/T	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	4.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.4	-0.4	2.47e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Vitiligo;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.3	0.32	1.23e-12	Skin colour saturation;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.52	-0.33	2.96e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs12618769	0.625	rs72819970	chr2:99034554	C/G	cg18455616	chr2:99124870	INPP4A	0.29	8.53	0.37	2.13e-16	Bipolar disorder;
LGG	cis	rs4704846	0.861	rs4704849	chr5:156532928	A/G	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.27	-0.32	1.57e-12	Blood protein levels;
LGG	cis	rs10936602	0.527	rs9878316	chr3:169533717	T/A	cg08193579	chr3:169529701	LRRC34	0.37	7.48	0.33	3.77e-13	Renal cell carcinoma;
LGG	cis	rs13126513	0.708	rs1491233	chr4:100476060	C/T	cg05468953	chr4:100565104	NA	0.39	7.76	0.34	5.31e-14	Metabolite levels (MHPG);
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.3	-0.32	1.24e-12	Electroencephalogram traits;
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.86	-0.3	2.15e-11	Aortic root size;
LGG	cis	rs9308433	0.529	rs6660335	chr1:214501855	C/T	cg06198575	chr1:214491504	SMYD2	0.51	7.73	0.34	6.8e-14	IgG glycosylation;
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.77	0.41	1.25e-20	Height;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.98	-0.31	1.02e-11	Aortic root size;
LGG	cis	rs10779751	0.922	rs11121708	chr1:11307253	G/C	cg08854313	chr1:11322531	MTOR	0.75	16.6	0.61	6.45e-49	Body mass index;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.38	-0.32	7.58e-13	Prostate cancer;
LGG	cis	rs7789940	0.904	rs7459185	chr7:75934640	C/G	cg10167463	chr7:75959203	YWHAG	0.41	6.77	0.3	3.9e-11	Multiple sclerosis;
LGG	cis	rs12956009	0.518	rs4574017	chr18:44891703	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.45	0.33	4.72e-13	Educational attainment (years of education);
LGG	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg11846333	chr4:119757529	SEC24D	0.85	7.36	0.32	8.48e-13	Cannabis dependence symptom count;
LGG	cis	rs67133203	0.799	rs12810596	chr12:51505898	C/T	cg14688905	chr12:51403056	SLC11A2	0.67	9.87	0.42	5.45e-21	Urinary tract infection frequency;
LGG	cis	rs9790314	0.779	rs1599374	chr3:160891727	G/A	cg04691961	chr3:161091175	C3orf57	-0.6	-13.23	-0.52	4.15e-34	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02461391	chr16:80838265	CDYL2	0.44	6.71	0.3	5.71e-11	Gut microbiome composition (summer);
LGG	cis	rs963731	0.579	rs4643520	chr2:39229464	T/C	cg04010122	chr2:39346883	SOS1	-0.8	-6.83	-0.3	2.61e-11	Corticobasal degeneration;
LGG	cis	rs9911578	0.967	rs4932693	chr17:57110327	T/C	cg05425664	chr17:57184151	TRIM37	0.71	11.5	0.47	4.16e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7011049	1.000	rs79536146	chr8:53853526	G/A	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg21782813	chr7:2030301	MAD1L1	-0.47	-11.43	-0.47	8.39e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.47	-0.33	4.1e-13	Psoriasis;
LGG	cis	rs3825932	0.961	rs11072815	chr15:79232319	C/T	cg25744700	chr15:79237217	CTSH	-0.35	-6.85	-0.3	2.43e-11	Type 1 diabetes;
LGG	cis	rs9886651	0.935	rs4427135	chr8:128802021	A/C	cg24514600	chr8:128805414	PVT1	-0.55	-12.87	-0.51	1.27e-32	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs9783347	1.000	rs10741741	chr11:18342081	C/T	cg03595886	chr11:18357587	GTF2H1	0.37	7.93	0.35	1.71e-14	Pancreatic cancer;
LGG	cis	rs13065560	0.659	rs4234135	chr3:38882479	C/T	cg01426195	chr3:39028469	NA	-0.43	-8.94	-0.38	9.22e-18	Interleukin-18 levels;
LGG	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg06636001	chr8:8085503	FLJ10661	0.56	10.28	0.43	1.83e-22	Retinal vascular caliber;
LGG	cis	rs6964587	1.000	rs7811873	chr7:91751120	G/A	cg17063962	chr7:91808500	NA	0.51	9.17	0.39	1.58e-18	Breast cancer;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs910316	0.967	rs12890371	chr14:75593839	T/C	cg08847533	chr14:75593920	NEK9	0.63	12.05	0.49	2.92e-29	Height;
LGG	trans	rs629535	0.773	rs72654090	chr8:70118666	G/A	cg21567404	chr3:27674614	NA	-0.4	-6.69	-0.3	6.61e-11	Dupuytren's disease;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14893161	chr1:205819251	PM20D1	0.88	20.45	0.69	1.12e-66	Menarche (age at onset);
LGG	cis	rs12431410	0.550	rs10150849	chr14:60211444	C/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.31	-0.32	1.21e-12	Schizophrenia;
LGG	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg16576597	chr16:28551801	NUPR1	0.37	8.82	0.38	2.28e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21659725	chr3:3221576	CRBN	0.75	11.86	0.48	1.7e-28	Resting heart rate;
LGG	cis	rs7666738	0.687	rs6839454	chr4:99073914	T/C	cg05340658	chr4:99064831	C4orf37	0.46	7.41	0.33	6.15e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12220238	1.000	rs11000888	chr10:75901929	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.72	0.48	6.04e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg11062466	chr8:58055876	NA	0.49	7.89	0.34	2.19e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18876405	chr7:65276391	NA	0.59	10.95	0.45	5.68e-25	Aortic root size;
LGG	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg26384229	chr12:38710491	ALG10B	0.6	11.21	0.46	5.53e-26	Morning vs. evening chronotype;
LGG	cis	rs9911578	1.000	rs6503866	chr17:56619581	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs73787773	0.644	rs17134153	chr5:111480324	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.19	-0.32	2.69e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6546550	0.935	rs10202159	chr2:70062454	G/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.01	-0.35	9.64e-15	Prevalent atrial fibrillation;
LGG	cis	rs7717393	1.000	rs17053447	chr5:155769694	A/T	cg12904904	chr5:155754151	SGCD	-0.91	-8.65	-0.37	8.66e-17	Egg allergy;
LGG	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg02151108	chr14:50098012	C14orf104	0.47	10.09	0.42	9.24e-22	Carotid intima media thickness;
LGG	cis	rs9318086	0.776	rs1326130	chr13:24447664	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.36	7.0	0.31	9.18e-12	Myopia (pathological);
LGG	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg06360820	chr2:242988706	NA	-1.1	-12.68	-0.51	7.95e-32	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.76	-0.3	4.3e-11	Personality dimensions;
LGG	cis	rs12431410	0.927	rs1957987	chr14:60158269	G/A	cg07950296	chr14:60194823	RTN1	0.37	7.12	0.31	4.04e-12	Schizophrenia;
LGG	cis	rs9815354	0.951	rs73830511	chr3:41864643	G/T	cg03022575	chr3:42003672	ULK4	0.67	8.59	0.37	1.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs896854	0.738	rs509594	chr8:95967156	C/G	cg16049864	chr8:95962084	TP53INP1	0.4	8.7	0.37	5.74e-17	Type 2 diabetes;
LGG	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.52	0.33	2.84e-13	Cystic fibrosis severity;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	16.82	0.62	6.71e-50	Platelet count;
LGG	cis	rs7538876	0.935	rs2526827	chr1:17730825	G/A	cg10329579	chr1:17754830	RCC2	-0.48	-9.31	-0.4	5.27e-19	Basal cell carcinoma;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs6964587	0.869	rs401	chr7:91527945	T/G	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg03264133	chr6:25882463	NA	-0.43	-7.75	-0.34	5.82e-14	Height;
LGG	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg20637307	chr2:213403960	ERBB4	-0.45	-8.79	-0.38	3.03e-17	QT interval (ambient particulate matter interaction);
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11645453	chr3:52864694	ITIH4	0.43	7.19	0.32	2.66e-12	Bipolar disorder;
LGG	cis	rs2013441	1.000	rs2526472	chr17:20137888	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.1	0.31	4.8e-12	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg05941027	chr17:61774174	LIMD2	0.36	9.05	0.39	3.95e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg17370700	chr17:5401814	NA	-0.4	-6.73	-0.3	5.14e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.42	-0.47	9.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.89	-0.34	2.25e-14	Personality dimensions;
LGG	cis	rs10936602	0.520	rs12486767	chr3:169550759	A/G	cg00832555	chr3:169529716	LRRC34	-0.35	-7.01	-0.31	8.43e-12	Renal cell carcinoma;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00586367	chr8:74790437	UBE2W	0.41	7.35	0.32	9e-13	Bipolar disorder;
LGG	cis	rs926392	0.640	rs7268716	chr20:37693214	C/T	cg16355469	chr20:37678765	NA	0.59	9.24	0.39	8.72e-19	Dialysis-related mortality;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg16507663	chr6:150244633	RAET1G	0.45	8.39	0.36	5.78e-16	Lung cancer;
LGG	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg11266682	chr4:10021025	SLC2A9	0.51	10.21	0.43	3.33e-22	Bone mineral density;
LGG	cis	rs2251666	0.514	rs56159834	chr16:4918732	A/T	cg04440724	chr16:4920505	UBN1	-0.58	-8.25	-0.36	1.63e-15	Cancer;
LGG	cis	rs62238980	0.614	rs4820058	chr22:32345733	A/G	cg00543991	chr22:32367038	NA	0.82	8.98	0.38	7.09e-18	Childhood ear infection;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8016982	0.520	rs17111601	chr14:81717808	C/T	cg01989461	chr14:81687754	GTF2A1	-0.59	-8.62	-0.37	1.06e-16	Schizophrenia;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.54	-0.33	2.46e-13	Menopause (age at onset);
LGG	cis	rs10991814	0.764	rs75062481	chr9:94094222	G/A	cg14446406	chr9:93919335	NA	-0.69	-7.84	-0.34	3.23e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs1978968	1.000	rs28434757	chr22:18451554	G/A	cg03078520	chr22:18463400	MICAL3	-0.64	-12.84	-0.51	1.74e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg26174226	chr8:58114915	NA	-0.46	-6.73	-0.3	4.98e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.15	-0.43	5.66e-22	Schizophrenia;
LGG	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg13047869	chr3:10149882	C3orf24	0.54	9.02	0.39	4.94e-18	Alzheimer's disease;
LGG	cis	rs7241530	0.610	rs34543415	chr18:75891645	C/G	cg14642773	chr18:75888474	NA	0.47	9.08	0.39	3.22e-18	Educational attainment (years of education);
LGG	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg04672837	chr16:48644449	N4BP1	0.53	8.61	0.37	1.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6546550	0.867	rs6738174	chr2:70150215	A/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26306683	chr17:18585705	ZNF286B	0.44	7.3	0.32	1.23e-12	Pancreatic cancer;
LGG	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg21775007	chr8:11205619	TDH	0.47	7.46	0.33	4.27e-13	Neuroticism;
LGG	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs4132509	1.000	rs4565696	chr1:243918083	C/T	cg25706552	chr1:244017396	NA	0.53	8.12	0.35	4.31e-15	RR interval (heart rate);
LGG	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg21452805	chr1:244014465	NA	0.68	8.12	0.35	4.31e-15	RR interval (heart rate);
LGG	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.34	0.36	8.53e-16	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg16339924	chr4:17578868	LAP3	0.65	11.18	0.46	7.3e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg05444541	chr17:17804740	TOM1L2	-0.78	-20.64	-0.69	1.38e-67	Total body bone mineral density;
LGG	trans	rs7746199	0.736	rs72845070	chr6:27668300	A/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.19	-0.46	6.8e-26	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18404041	chr3:52824283	ITIH1	0.52	9.94	0.42	3.18e-21	Bipolar disorder;
LGG	cis	rs1358748	0.522	rs1830513	chr1:67575549	A/G	cg02640540	chr1:67518911	SLC35D1	0.55	6.69	0.3	6.43e-11	Tuberculosis;
LGG	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7107174	1.000	rs10899475	chr11:78051610	T/C	cg02023728	chr11:77925099	USP35	0.47	8.17	0.35	2.97e-15	Testicular germ cell tumor;
LGG	cis	rs1816752	0.638	rs9578730	chr13:24999683	G/A	cg22771759	chr13:24902376	NA	0.42	7.24	0.32	1.86e-12	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00166722	chr3:10149974	C3orf24	0.5	8.43	0.36	4.52e-16	Alzheimer's disease;
LGG	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs7566780	0.700	rs1430052	chr2:16667742	C/G	cg09580478	chr2:16689509	NA	0.47	6.84	0.3	2.48e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs2066819	1.000	rs78121408	chr12:56684798	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg09448879	chr15:79043637	NA	0.4	7.1	0.31	4.65e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs3806843	0.576	rs265316	chr5:140290843	T/C	cg19875535	chr5:140030758	IK	0.38	7.52	0.33	2.81e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg03175030	chr11:2018143	H19;MIR675	-0.53	-9.72	-0.41	1.84e-20	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg03264133	chr6:25882463	NA	-0.43	-7.61	-0.33	1.52e-13	Height;
LGG	cis	rs9894429	0.546	rs55917554	chr17:79608776	T/C	cg10661904	chr17:79619235	PDE6G	-0.45	-8.86	-0.38	1.68e-17	Eye color traits;
LGG	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg22643751	chr7:855365	UNC84A	0.36	6.83	0.3	2.71e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs12586317	0.547	rs28589276	chr14:35478865	A/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs11229555	0.645	rs11229436	chr11:58186009	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.28	-0.58	5.53e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4561483	0.556	rs11570136	chr16:12058832	T/A	cg08843971	chr16:11963173	GSPT1	-0.59	-12.84	-0.51	1.65e-32	Testicular germ cell tumor;
LGG	cis	rs2075466	0.514	rs78766103	chr16:4898252	G/C	cg04440724	chr16:4920505	UBN1	-0.61	-8.86	-0.38	1.78e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6547631	0.622	rs10210321	chr2:85928128	A/C	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.82e-11	Blood protein levels;
LGG	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg22771759	chr13:24902376	NA	0.47	7.88	0.34	2.43e-14	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg12654349	chr5:56205094	C5orf35	-0.66	-10.48	-0.44	3.31e-23	Initial pursuit acceleration;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.54	0.41	8.47e-20	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13129888	chr1:28415099	EYA3	0.49	8.34	0.36	8.89e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs11382616	1	rs11382616	chr14:103081465	G/GC	cg12046867	chr14:103022105	NA	-0.4	-7.46	-0.33	4.27e-13	Plateletcrit;Platelet count;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01449415	chr16:3184811	ZNF213	0.42	7.42	0.33	5.48e-13	Obesity-related traits;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.1	0.35	4.79e-15	Schizophrenia;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg05025164	chr4:1340916	KIAA1530	-0.54	-9.87	-0.42	5.45e-21	Obesity-related traits;
LGG	trans	rs853679	1.000	rs13200462	chr6:28218199	A/C	cg01620082	chr3:125678407	NA	-0.62	-7.59	-0.33	1.78e-13	Depression;
LGG	cis	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs36051895	0.658	rs7875265	chr9:5033882	C/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.4	-0.61	5.73e-48	Pediatric autoimmune diseases;
LGG	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8064024	0.681	rs7194890	chr16:4883781	T/A	cg08329684	chr16:4932620	PPL	0.52	11.76	0.48	4.08e-28	Cancer;
LGG	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.59	0.53	1.28e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.5	0.37	2.53e-16	Systemic lupus erythematosus;
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.11	-0.52	1.34e-33	Aortic root size;
LGG	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg25811766	chr13:21894605	NA	0.63	8.45	0.37	3.86e-16	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25220896	chr1:11004296	NA	0.44	7.44	0.33	4.81e-13	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg06916706	chr16:4465613	CORO7	0.75	13.13	0.52	1.11e-33	Schizophrenia;
LGG	cis	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg26384229	chr12:38710491	ALG10B	-0.88	-19.24	-0.67	4.73e-61	Morning vs. evening chronotype;
LGG	cis	rs9815354	1.000	rs9882329	chr3:41767154	T/C	cg03022575	chr3:42003672	ULK4	0.6	7.74	0.34	6.27e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7945705	0.870	rs1109305	chr11:8955272	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	11.67	0.48	9.39e-28	Hemoglobin concentration;
LGG	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg07395648	chr5:131743802	NA	-0.55	-13.19	-0.52	6.22e-34	Blood metabolite levels;
LGG	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg01570182	chr17:44337453	NA	0.51	9.18	0.39	1.43e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs62458065	0.513	rs787220	chr7:32581139	C/G	cg00845942	chr12:64062724	DPY19L2	-0.59	-7.74	-0.34	6.49e-14	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.33	-0.36	9.56e-16	Menopause (age at onset);
LGG	cis	rs644799	0.582	rs1727149	chr11:95497171	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.69	-12.1	-0.49	1.77e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg05014952	chr14:35873130	NFKBIA	-0.4	-6.8	-0.3	3.22e-11	Hematological and biochemical traits;
LGG	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.18	-0.32	2.73e-12	Neuroticism;
LGG	cis	rs11628318	0.588	rs12892602	chr14:103114091	T/C	cg12046867	chr14:103022105	NA	0.45	8.88	0.38	1.48e-17	Platelet count;
LGG	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg16006841	chr5:176797999	RGS14	0.6	9.3	0.4	5.51e-19	Hemoglobin concentration;Hematocrit;
LGG	cis	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg03511173	chr18:77590860	NA	0.66	8.33	0.36	9.56e-16	Opioid sensitivity;
LGG	cis	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg21775007	chr8:11205619	TDH	0.52	7.93	0.35	1.62e-14	Neuroticism;
LGG	cis	rs6912958	0.684	rs2787893	chr6:88387359	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.35	-0.36	7.82e-16	Monocyte percentage of white cells;
LGG	cis	rs6988985	0.765	rs4483134	chr8:143978646	G/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05351302	chr7:87563908	ADAM22	0.44	7.31	0.32	1.19e-12	Cognitive performance;
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.67	-0.3	7.28e-11	Aortic root size;
LGG	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg04455712	chr21:45112962	RRP1B	0.51	9.78	0.41	1.14e-20	Mean corpuscular volume;
LGG	cis	rs3617	0.625	rs7652667	chr3:52866535	C/A	cg11645453	chr3:52864694	ITIH4	-0.43	-7.28	-0.32	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg06606381	chr12:133084897	FBRSL1	-1.27	-11.3	-0.46	2.56e-26	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6993813	0.620	rs12056346	chr8:120042191	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.8	0.34	4.05e-14	Bone mineral density (hip);
LGG	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg01411142	chr8:19674711	INTS10	0.48	7.35	0.32	9.21e-13	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg02002194	chr4:3960332	NA	-0.47	-9.0	-0.39	5.86e-18	Neuroticism;
LGG	cis	rs3845702	0.736	rs6722147	chr2:180829704	G/A	cg01881094	chr2:180872142	CWC22	-1.26	-16.57	-0.61	9.27e-49	Schizophrenia;
LGG	cis	rs881375	0.967	rs7848332	chr9:123669496	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	trans	rs17685	0.753	rs1637051	chr7:75730659	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.85	0.77	7.24e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg20607798	chr8:58055168	NA	0.62	7.19	0.32	2.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg09029085	chr17:47094198	IGF2BP1	0.31	8.35	0.36	8.11e-16	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg21775007	chr8:11205619	TDH	-0.54	-8.38	-0.36	6.63e-16	Neuroticism;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-15.99	-0.6	4.04e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7712401	0.541	rs42537	chr5:122274688	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.85	0.3	2.4e-11	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17187048	chr2:122407283	CLASP1	0.41	6.8	0.3	3.17e-11	Cognitive performance;
LGG	cis	rs3816183	0.626	rs4444592	chr2:42899759	C/T	cg14631114	chr2:43023945	NA	0.36	6.98	0.31	1.01e-11	Hypospadias;
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.59	9.78	0.41	1.15e-20	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg18681998	chr4:17616180	MED28	0.84	17.71	0.64	5.92e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2073300	0.609	rs6132615	chr20:23413200	T/C	cg12062639	chr20:23401060	NAPB	0.92	8.71	0.38	5.28e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs72827839	0.846	rs16954078	chr17:46306127	T/A	cg02219949	chr17:45927392	SP6	0.52	7.74	0.34	6.08e-14	Ease of getting up in the morning;
LGG	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg03733263	chr8:22462867	KIAA1967	0.97	23.29	0.73	5.59e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.17	0.32	3.02e-12	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.817	rs7481230	chr11:49772235	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.91	-0.78	1.05e-96	Height;
LGG	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg14979609	chr8:8086686	FLJ10661	-0.32	-8.1	-0.35	4.88e-15	Mood instability;
LGG	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg10402321	chr1:26617780	UBXN11	-0.44	-7.41	-0.33	6.16e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18867708	chr6:26865862	GUSBL1	0.49	8.22	0.36	2.08e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs963731	0.649	rs10172714	chr2:39197543	C/G	cg04010122	chr2:39346883	SOS1	-0.82	-7.23	-0.32	2.07e-12	Corticobasal degeneration;
LGG	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	trans	rs6787172	0.592	rs9867152	chr3:158098163	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg23985595	chr17:80112537	CCDC57	0.46	9.38	0.4	3.01e-19	Life satisfaction;
LGG	cis	rs2274273	0.743	rs7161656	chr14:55524530	A/G	cg04306507	chr14:55594613	LGALS3	0.43	10.89	0.45	9.32e-25	Protein biomarker;
LGG	cis	rs1577917	1.000	rs10944163	chr6:86658693	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.17	-0.43	4.64e-22	Response to antipsychotic treatment;
LGG	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-8.43	-0.36	4.4e-16	Oral cavity cancer;
LGG	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	14.18	0.55	3.6e-38	Cognitive test performance;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg23129478	chr18:44337922	ST8SIA5	-0.37	-7.13	-0.31	3.99e-12	Personality dimensions;
LGG	cis	rs4788570	0.667	rs4788557	chr16:71804802	C/T	cg06353428	chr16:71660113	MARVELD3	1.26	20.52	0.69	5.03e-67	Intelligence (multi-trait analysis);
LGG	cis	rs9314323	0.558	rs7828560	chr8:26188998	G/A	cg11498726	chr8:26250323	BNIP3L	-0.44	-9.45	-0.4	1.7e-19	Red cell distribution width;
LGG	trans	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg02002194	chr4:3960332	NA	0.43	6.81	0.3	2.95e-11	Myopia (pathological);
LGG	trans	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg19862616	chr7:65841803	NCRNA00174	0.72	7.69	0.34	8.78e-14	Mononucleosis;
LGG	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg01043669	chr3:72786069	NA	0.43	6.98	0.31	1.03e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	cis	rs735539	0.645	rs7326068	chr13:21209512	A/G	cg04906043	chr13:21280425	IL17D	0.54	8.67	0.37	7.53e-17	Dental caries;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg21171335	chr12:122356390	WDR66	0.29	8.1	0.35	5.07e-15	Mean corpuscular volume;
LGG	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg04733989	chr22:42467013	NAGA	0.53	9.36	0.4	3.59e-19	Schizophrenia;
LGG	trans	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg21659725	chr3:3221576	CRBN	-0.56	-8.38	-0.36	6.31e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	1.000	rs714238	chr7:19803925	C/T	cg05791153	chr7:19748676	TWISTNB	0.57	8.33	0.36	9.46e-16	Thyroid stimulating hormone;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.79	-0.34	4.3e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg00928816	chr10:63809098	ARID5B	-0.37	-7.34	-0.32	9.54e-13	Systemic lupus erythematosus;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22450146	chr17:74733660	MIR636;SFRS2;MFSD11	0.4	6.81	0.3	3.01e-11	Bipolar disorder;
LGG	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg02772935	chr3:125709198	NA	-0.52	-6.65	-0.3	8.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg17347104	chr14:75034677	LTBP2	-0.38	-6.91	-0.31	1.64e-11	Caffeine consumption;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.85	17.72	0.64	5.2e-54	Personality dimensions;
LGG	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg13010199	chr12:38710504	ALG10B	0.7	14.46	0.56	2.2e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-7.65	-0.34	1.16e-13	Blood pressure (smoking interaction);
LGG	cis	rs12153243	0.659	rs72806725	chr5:142936181	T/C	cg13907255	chr5:142895549	NA	-0.47	-8.2	-0.36	2.35e-15	Migraine;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.36	-0.32	8.74e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs4714291	0.855	rs1743971	chr6:40095927	A/C	cg02267698	chr19:7991119	CTXN1	0.6	9.51	0.4	1.05e-19	Strep throat;
LGG	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg15485101	chr11:133734466	NA	0.62	10.93	0.45	6.73e-25	Childhood ear infection;
LGG	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg16141378	chr3:129829833	LOC729375	0.32	7.07	0.31	5.76e-12	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26840318	chr1:234745203	IRF2BP2	0.49	7.2	0.32	2.39e-12	Gut microbiome composition (summer);
LGG	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.07	-0.42	1.03e-21	Prostate cancer;
LGG	cis	rs12780845	0.540	rs11254424	chr10:17218554	T/C	cg01003015	chr10:17271136	VIM	-0.45	-7.52	-0.33	2.93e-13	Homocysteine levels;
LGG	trans	rs9650657	0.683	rs7005905	chr8:10585144	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	7.35	0.32	9.12e-13	Neuroticism;
LGG	cis	rs6142618	0.562	rs6142622	chr20:30738978	A/G	cg00028034	chr20:30779307	TSPYL3	0.36	7.86	0.34	2.71e-14	Inflammatory bowel disease;
LGG	cis	rs1957429	0.614	rs62621845	chr14:65403525	T/A	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs7512552	0.839	rs7523428	chr1:150430472	G/A	cg15654264	chr1:150340011	RPRD2	0.46	9.36	0.4	3.54e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg02002194	chr4:3960332	NA	0.41	7.65	0.33	1.19e-13	Neuroticism;
LGG	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21582582	chr3:182698605	DCUN1D1	0.51	9.39	0.4	2.78e-19	Intelligence (multi-trait analysis);
LGG	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg02536541	chr18:77568900	NA	-0.56	-8.97	-0.38	7.28e-18	Schizophrenia;
LGG	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg12463550	chr7:65579703	CRCP	-0.74	-8.28	-0.36	1.33e-15	Diabetic kidney disease;
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg26513180	chr16:89883248	FANCA	0.98	9.25	0.39	8.38e-19	Skin colour saturation;
LGG	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.59	-0.33	1.8e-13	Retinal vascular caliber;
LGG	cis	rs3126085	0.935	rs6670717	chr1:152249956	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.09	-0.35	5.16e-15	Atopic dermatitis;
LGG	cis	rs6712932	1.000	rs6712932	chr2:105837598	C/T	cg22878388	chr2:105853796	NA	0.41	7.36	0.32	8.5e-13	Type 2 diabetes;
LGG	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg19223190	chr17:80058835	NA	0.44	8.55	0.37	1.81e-16	Life satisfaction;
LGG	cis	rs4319547	0.955	rs6489159	chr12:123112806	G/A	cg23029597	chr12:123009494	RSRC2	-0.98	-17.99	-0.64	2.82e-55	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04910183	chr1:193090988	CDC73	0.41	6.76	0.3	4.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9290877	0.564	rs9883953	chr3:188474856	A/C	cg17392043	chr3:188495102	LPP	0.45	7.94	0.35	1.52e-14	IgE levels;
LGG	cis	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.39	0.7	4.43e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2470578	0.792	rs283938	chr3:17343457	T/C	cg20981856	chr3:17787350	NA	0.35	6.65	0.3	8.22e-11	Schizophrenia;
LGG	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg12463550	chr7:65579703	CRCP	-0.76	-8.39	-0.36	5.82e-16	Gout;
LGG	cis	rs1210638	0.756	rs2518800	chr22:18973471	C/T	cg14259594	chr22:18958660	DGCR5	0.54	9.21	0.39	1.16e-18	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/TA	cg12826209	chr6:26865740	GUSBL1	0.84	11.78	0.48	3.25e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	1.000	rs28494082	chr21:43634547	A/G	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.66	0.48	1.05e-27	Bipolar disorder;
LGG	cis	rs4824093	0.610	rs4824113	chr22:50284974	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.11	-0.31	4.51e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg05775895	chr3:12838266	CAND2	0.66	11.87	0.48	1.5e-28	QRS complex (12-leadsum);
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg11062466	chr8:58055876	NA	0.47	8.15	0.35	3.47e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs350251	0.934	rs350209	chr16:12212818	G/C	cg02910054	chr16:12241554	SNX29	0.44	8.13	0.35	4.1e-15	Intelligence (multi-trait analysis);
LGG	cis	rs36093844	0.800	rs78681528	chr11:85588156	T/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17368114	chr5:138268312	CTNNA1	-0.59	-6.81	-0.3	3.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.779	rs17271767	chr6:25886921	C/T	cg03517284	chr6:25882590	NA	-0.46	-6.76	-0.3	4.07e-11	Iron status biomarkers;
LGG	trans	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.26	-0.4	7.67e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2224391	0.628	rs2753222	chr6:5242075	T/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.9	-0.31	1.76e-11	Height;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg14926445	chr8:58193284	C8orf71	-0.71	-9.23	-0.39	9.4e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg27490568	chr2:178487706	NA	-0.48	-9.54	-0.41	8.23e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7181230	1.000	rs9972424	chr15:40365851	A/G	cg22705835	chr10:65332833	REEP3	-0.6	-10.67	-0.44	6.69e-24	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.71	13.34	0.53	1.37e-34	Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.35e-16	Life satisfaction;
LGG	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.85	0.34	2.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1978968	0.833	rs5992941	chr22:18463747	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-13.8	-0.54	1.6e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs7107174	0.748	rs7105835	chr11:78075725	T/C	cg02023728	chr11:77925099	USP35	0.47	8.35	0.36	7.92e-16	Testicular germ cell tumor;
LGG	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4789294	0.950	rs4789295	chr17:74419180	C/A	cg27112972	chr17:74378252	NA	-0.29	-7.14	-0.31	3.74e-12	Lymphocyte percentage of white cells;
LGG	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.66	-0.37	7.64e-17	Platelet distribution width;
LGG	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg05623727	chr3:50126028	RBM5	0.32	6.89	0.31	1.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.7	-0.34	8.1e-14	Obesity-related traits;
LGG	cis	rs77106637	0.585	rs12292949	chr11:72457531	C/T	cg04827223	chr11:72435913	ARAP1	-0.47	-7.88	-0.34	2.3e-14	Type 2 diabetes;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg05368731	chr17:41323189	NBR1	0.85	16.55	0.61	1.11e-48	Menopause (age at onset);
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg13880726	chr7:1868755	MAD1L1	0.44	7.79	0.34	4.51e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4917300	1.000	rs7834925	chr8:143123731	T/C	cg06573787	chr8:143070187	NA	0.49	8.99	0.39	6.44e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs4919694	1.000	rs75219158	chr10:104747594	C/T	cg04362960	chr10:104952993	NT5C2	1.06	13.4	0.53	7.79e-35	Arsenic metabolism;
LGG	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.52	0.61	1.64e-48	Hip circumference adjusted for BMI;
LGG	cis	rs9640161	0.658	rs74348353	chr7:150053655	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-11.17	-0.46	7.96e-26	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4917300	0.571	rs4917288	chr8:143114054	C/T	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.32e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs4268898	0.662	rs74470633	chr2:24438712	A/G	cg06627628	chr2:24431161	ITSN2	-0.79	-12.9	-0.51	9.41e-33	Asthma;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs2692947	0.644	rs772154	chr2:97021664	G/T	cg22654517	chr2:96458247	NA	0.35	7.16	0.32	3.13e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	7.12	0.31	4.13e-12	Schizophrenia;
LGG	cis	rs1620921	0.594	rs9355845	chr6:161269097	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg04398451	chr17:18023971	MYO15A	-0.85	-18.91	-0.66	1.54e-59	Total body bone mineral density;
LGG	cis	rs7236492	0.748	rs11663202	chr18:77209180	T/C	cg15532942	chr18:77220712	NFATC1	0.46	7.44	0.33	4.86e-13	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11815991	chr20:30193098	ID1	0.47	7.59	0.33	1.8e-13	Cognitive performance;
LGG	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg02725872	chr8:58115012	NA	-1.03	-14.08	-0.55	9.84e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.74	0.73	2.04e-77	Homoarginine levels;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg04008888	chr11:68622739	NA	-0.55	-11.8	-0.48	2.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg23029597	chr12:123009494	RSRC2	-0.88	-16.27	-0.6	2.19e-47	Body mass index;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	12.21	0.49	6.62e-30	Lymphocyte counts;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg21775007	chr8:11205619	TDH	0.51	8.57	0.37	1.53e-16	Mood instability;
LGG	cis	rs7250872	0.568	rs10405979	chr19:1840267	A/G	cg18850929	chr19:1828978	REXO1	0.49	7.88	0.34	2.33e-14	Bipolar disorder;
LGG	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg23845249	chr11:68861649	NA	0.44	7.56	0.33	2.24e-13	Blond vs. brown hair color;
LGG	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg14952266	chr13:112191215	NA	0.41	7.94	0.35	1.5e-14	Hepatitis;
LGG	cis	rs11877825	0.826	rs8098954	chr18:10578697	A/G	cg25239095	chr18:10589360	NA	0.48	8.63	0.37	1e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs1185460	0.565	rs2276060	chr11:118919132	G/A	cg12636538	chr11:118901039	SLC37A4	-0.65	-13.35	-0.53	1.31e-34	Coronary artery disease;
LGG	cis	rs7572733	0.534	rs700692	chr2:198728500	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.53e-25	Dermatomyositis;
LGG	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg04731861	chr2:219085781	ARPC2	0.49	12.57	0.5	2.26e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg02002194	chr4:3960332	NA	0.43	7.82	0.34	3.55e-14	Triglycerides;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg05084668	chr3:125655381	ALG1L	-0.54	-7.34	-0.32	9.49e-13	Blood pressure (smoking interaction);
LGG	cis	rs2197308	0.740	rs11182967	chr12:37935140	A/C	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs1639906	0.560	rs1624785	chr7:2258139	T/C	cg08027265	chr7:2291960	NA	-0.54	-10.77	-0.45	2.76e-24	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg06875740	chr19:51307921	C19orf48	-0.52	-8.16	-0.35	3.24e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs258892	0.947	rs266443	chr5:72180377	C/T	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg07915516	chr16:377344	AXIN1	0.3	7.88	0.34	2.44e-14	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9715521	0.775	rs11723682	chr4:59851969	C/T	cg11281224	chr4:60001000	NA	-0.5	-8.46	-0.37	3.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg09222892	chr1:25734099	RHCE	0.49	10.7	0.45	4.83e-24	Erythrocyte sedimentation rate;
LGG	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.92e-13	Restless legs syndrome;
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg15556689	chr8:8085844	FLJ10661	0.44	7.74	0.34	6.39e-14	Myopia (pathological);
LGG	cis	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.44	-0.4	1.85e-19	Mean corpuscular volume;
LGG	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs35740288	0.822	rs34734963	chr15:86217644	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.09	0.35	5.21e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg07537917	chr2:241836409	C2orf54	-0.4	-7.81	-0.34	3.77e-14	Urinary metabolites;
LGG	cis	rs6998277	0.830	rs6468838	chr8:103609336	T/C	cg10187029	chr8:103597600	NA	1.02	19.52	0.67	2.27e-62	Migraine;
LGG	cis	rs6772849	0.775	rs67105978	chr3:128415180	C/A	cg08795948	chr3:128337044	NA	0.63	9.82	0.42	8.33e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs735539	0.521	rs716480	chr13:21418094	T/G	cg04906043	chr13:21280425	IL17D	-0.46	-7.24	-0.32	1.85e-12	Dental caries;
LGG	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.47	-0.37	3.19e-16	Skin colour saturation;
LGG	cis	rs9300255	0.639	rs941306	chr12:123715113	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1e-13	Neutrophil percentage of white cells;
LGG	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg07537917	chr2:241836409	C2orf54	-0.41	-8.2	-0.36	2.4e-15	Urinary metabolites;
LGG	cis	rs67311347	1.000	rs7641495	chr3:40494690	T/C	cg24209194	chr3:40518798	ZNF619	-0.44	-7.05	-0.31	6.64e-12	Renal cell carcinoma;
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg12310025	chr6:25882481	NA	-0.72	-13.75	-0.54	2.68e-36	Intelligence (multi-trait analysis);
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg14773178	chr5:1868261	NA	0.36	7.82	0.34	3.68e-14	Cardiovascular disease risk factors;
LGG	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs2354432	0.607	rs7511989	chr1:146720160	A/G	cg25205988	chr1:146714368	CHD1L	-1.45	-15.1	-0.57	3.61e-42	Mitochondrial DNA levels;
LGG	cis	rs3816183	0.756	rs4953669	chr2:43069976	A/C	cg14631114	chr2:43023945	NA	-0.45	-8.3	-0.36	1.18e-15	Hypospadias;
LGG	cis	rs4423214	0.840	rs4435028	chr11:71183690	C/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg09307838	chr4:120376055	NA	0.64	11.56	0.47	2.48e-27	Corneal astigmatism;
LGG	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg01028140	chr2:1542097	TPO	-0.55	-8.54	-0.37	1.89e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.96	-0.31	1.17e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4430311	0.688	rs11578459	chr1:243770727	A/G	cg25706552	chr1:244017396	NA	-0.64	-15.5	-0.58	6.18e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03274991	chr11:120207803	ARHGEF12	0.48	7.93	0.35	1.71e-14	Cognitive performance;
LGG	cis	rs12210905	1.000	rs114337870	chr6:27254937	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2798269	0.668	rs1200055	chr13:22086127	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.45	-7.83	-0.34	3.33e-14	PR segment;
LGG	cis	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.32	0.36	1.02e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg25517755	chr10:38738941	LOC399744	-0.39	-6.75	-0.3	4.4e-11	Corneal astigmatism;
LGG	cis	rs9902453	0.904	rs12936302	chr17:28349476	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.51	-0.53	2.64e-35	Coffee consumption (cups per day);
LGG	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg23594656	chr7:65796392	TPST1	0.38	8.36	0.36	7.32e-16	Aortic root size;
LGG	cis	rs897984	0.609	rs1108431	chr16:31054607	C/T	cg00531865	chr16:30841666	NA	-0.5	-9.93	-0.42	3.35e-21	Dementia with Lewy bodies;
LGG	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	7.9	0.34	2.01e-14	Menarche (age at onset);
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.02	-0.35	8.79e-15	IgG glycosylation;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.36	7.09	0.31	4.91e-12	Aortic root size;
LGG	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.55	7.06	0.31	6.1e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.84	-0.3	2.46e-11	Fear of minor pain;
LGG	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg18825076	chr15:78729989	IREB2	-0.61	-9.83	-0.42	7.58e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg05623727	chr3:50126028	RBM5	0.41	8.82	0.38	2.38e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg16141378	chr3:129829833	LOC729375	0.4	9.05	0.39	3.98e-18	Triglycerides;
LGG	cis	rs4740619	0.544	rs2153727	chr9:15829503	A/G	cg14451791	chr9:16040625	NA	0.31	7.39	0.32	6.87e-13	Body mass index;
LGG	cis	rs1577917	1.000	rs12196037	chr6:86694631	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.27	-0.43	2.05e-22	Response to antipsychotic treatment;
LGG	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.4	8.06e-19	Diabetic retinopathy;
LGG	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg16482183	chr6:26056742	HIST1H1C	0.93	13.51	0.53	2.81e-35	Iron status biomarkers;
LGG	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.1	-0.39	2.64e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9463078	1.000	rs9463078	chr6:45181340	G/A	cg25276700	chr6:44698697	NA	-0.37	-7.4	-0.33	6.39e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18402987	chr7:1209562	NA	0.37	6.65	0.3	8.28e-11	Longevity;Endometriosis;
LGG	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03576123	chr11:487126	PTDSS2	-1.29	-17.29	-0.63	4.64e-52	Body mass index;
LGG	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.96	-0.31	1.2e-11	Fear of minor pain;
LGG	cis	rs8048589	0.612	rs2869808	chr16:12176864	A/C	cg02910054	chr16:12241554	SNX29	0.41	6.78	0.3	3.63e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs7932354	0.528	rs7125807	chr11:47041163	G/T	cg03339077	chr11:47165057	C11orf49	0.53	9.95	0.42	2.88e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg20607798	chr8:58055168	NA	0.68	7.68	0.34	9.49e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1983891	0.955	rs6917270	chr6:41548755	A/G	cg20194872	chr6:41519635	FOXP4	0.59	10.15	0.43	5.54e-22	Prostate cancer;
LGG	cis	rs11601602	0.531	rs35031414	chr11:28545563	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.57	7.91	0.35	1.89e-14	Obesity-related traits;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg03452623	chr4:187889614	NA	-1.05	-31.91	-0.83	5.36e-119	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs561341	0.843	rs879945	chr17:30242796	G/A	cg27661571	chr11:113659931	NA	-0.56	-8.3	-0.36	1.13e-15	Hip circumference adjusted for BMI;
LGG	cis	rs11920090	0.872	rs5400	chr3:170732300	G/A	cg09710316	chr3:170744871	SLC2A2	0.58	8.27	0.36	1.46e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg27661571	chr11:113659931	NA	-0.56	-8.27	-0.36	1.41e-15	Hip circumference adjusted for BMI;
LGG	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg21435375	chr2:172878103	MAP1D	0.3	6.9	0.31	1.76e-11	Schizophrenia;
LGG	trans	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs10046574	0.561	rs10215176	chr7:135198589	A/G	cg27474649	chr7:135195673	CNOT4	0.75	8.97	0.38	7.2e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17221829	0.764	rs6483020	chr11:89386384	A/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs4268898	0.717	rs3731626	chr2:24427864	G/A	cg06627628	chr2:24431161	ITSN2	-0.73	-11.81	-0.48	2.54e-28	Asthma;
LGG	cis	rs10743315	0.908	rs7297169	chr12:19466956	G/T	cg02471346	chr12:19282374	PLEKHA5	0.62	6.88	0.3	1.91e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs36051895	0.553	rs16922773	chr9:5197436	T/G	cg02405213	chr9:5042618	JAK2	-0.75	-12.78	-0.51	3.12e-32	Pediatric autoimmune diseases;
LGG	cis	rs10489202	1.000	rs67600256	chr1:167972357	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs963731	0.649	rs78421201	chr2:39339424	C/A	cg04010122	chr2:39346883	SOS1	0.93	8.24	0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs6942756	0.876	rs7789697	chr7:129060386	T/A	cg02491457	chr7:128862824	NA	-0.66	-11.97	-0.49	6.02e-29	White matter hyperintensity burden;
LGG	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs3206736	0.548	rs10278195	chr7:35064459	G/T	cg13400248	chr7:35225412	NA	0.55	9.59	0.41	5.59e-20	Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.46	-0.4	1.56e-19	Menopause (age at onset);
LGG	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.5	0.44	2.92e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs12358475	0.954	rs11596144	chr10:11847184	G/A	cg02074763	chr10:11825795	NA	-0.4	-6.66	-0.3	7.76e-11	Breast cancer (survival);
LGG	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.29	0.4	6.2800000000000005e-19	Lung cancer in ever smokers;
LGG	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg09238746	chr17:78121135	EIF4A3	-0.54	-9.81	-0.41	9.16e-21	Yeast infection;
LGG	cis	rs193541	0.632	rs34486978	chr5:122312543	G/A	cg19412675	chr5:122181750	SNX24	-0.56	-8.96	-0.38	8.17e-18	Glucose homeostasis traits;
LGG	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.56	-0.47	2.56e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6735179	0.566	rs13416067	chr2:1755898	C/T	cg20311673	chr2:1746207	PXDN	-0.45	-7.32	-0.32	1.09e-12	Response to antipsychotic treatment;
LGG	cis	rs7614311	0.681	rs57766205	chr3:63895303	G/C	cg22134162	chr3:63841271	THOC7	-0.43	-8.06	-0.35	6.46e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg13607699	chr17:42295918	UBTF	0.55	9.11	0.39	2.53e-18	Total body bone mineral density;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs7766436	0.961	rs6922960	chr6:22570189	T/C	cg13666174	chr6:22585274	NA	-0.43	-9.96	-0.42	2.73e-21	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11815991	chr20:30193098	ID1	0.4	6.85	0.3	2.4e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg24846343	chr22:24311635	DDTL	0.53	10.03	0.42	1.54e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7000551	0.715	rs1530874	chr8:22347777	G/C	cg12081754	chr8:22256438	SLC39A14	0.68	13.07	0.52	1.91e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg26384229	chr12:38710491	ALG10B	0.71	14.41	0.56	3.67e-39	Heart rate;
LGG	cis	rs6868223	0.651	rs6861589	chr5:33642492	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.64	0.59	1.43e-44	Mortality in heart failure;
LGG	cis	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg12395012	chr8:11607386	GATA4	-0.37	-6.7	-0.3	6.15e-11	Retinal vascular caliber;
LGG	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg18825076	chr15:78729989	IREB2	-0.61	-9.72	-0.41	1.93e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg03929089	chr4:120376271	NA	0.69	9.58	0.41	5.82e-20	Axial length;
LGG	trans	rs526821	0.595	rs4938937	chr11:55305507	T/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.74	-0.3	4.58e-11	Pediatric bone mineral density (spine);
LGG	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg00383909	chr3:49044727	WDR6	-0.45	-7.05	-0.31	6.38e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs584438	1.000	rs584438	chr17:38599172	A/C	cg09358481	chr17:38600305	IGFBP4	0.44	8.29	0.36	1.25e-15	Height;
LGG	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.72e-13	Aortic root size;
LGG	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg25703541	chr22:24373054	LOC391322	-0.62	-9.36	-0.4	3.49e-19	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs4363385	0.553	rs61813181	chr1:152942177	T/C	cg13444842	chr1:152974279	SPRR3	-0.51	-10.37	-0.43	8.85e-23	Inflammatory skin disease;
LGG	cis	rs12220238	0.722	rs7921187	chr10:76377501	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.51	6.71	0.3	5.8200000000000003e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6460942	0.915	rs62447641	chr7:12488764	G/A	cg06484146	chr7:12443880	VWDE	-0.39	-6.83	-0.3	2.6e-11	Coronary artery disease;
LGG	cis	rs926938	0.527	rs360678	chr1:115493902	T/A	cg12756093	chr1:115239321	AMPD1	0.45	8.37	0.36	6.88e-16	Autism;
LGG	cis	rs2692947	0.770	rs62153678	chr2:96558346	C/T	cg22654517	chr2:96458247	NA	0.38	7.54	0.33	2.48e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs3816183	0.585	rs4355164	chr2:42858862	C/G	cg14631114	chr2:43023945	NA	0.35	6.93	0.31	1.43e-11	Hypospadias;
LGG	cis	rs6460942	0.687	rs74753576	chr7:12463926	G/A	cg06484146	chr7:12443880	VWDE	-0.36	-6.94	-0.31	1.32e-11	Coronary artery disease;
LGG	cis	rs4731207	0.661	rs6466956	chr7:124520366	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	trans	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg16141378	chr3:129829833	LOC729375	-0.29	-6.74	-0.3	4.85e-11	Joint mobility (Beighton score);
LGG	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg02788857	chr8:22132959	PIWIL2	0.51	12.07	0.49	2.26e-29	Hypertriglyceridemia;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05665937	chr4:1216051	CTBP1	0.54	9.93	0.42	3.44e-21	Obesity-related traits;
LGG	cis	rs3770081	1.000	rs1561328	chr2:86272758	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-7.04	-0.31	7.09e-12	Facial emotion recognition (sad faces);
LGG	cis	rs6912958	0.525	rs586771	chr6:88064971	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.05	0.52	2.23e-33	Monocyte percentage of white cells;
LGG	cis	rs611744	0.967	rs678387	chr8:109242730	G/C	cg21045802	chr8:109455806	TTC35	0.38	6.79	0.3	3.38e-11	Dupuytren's disease;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg13453750	chr1:205783389	SLC41A1	-0.48	-9.45	-0.4	1.75e-19	Menarche (age at onset);
LGG	cis	rs11971779	0.648	rs6974099	chr7:139098566	A/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs3816183	0.805	rs2304657	chr2:43019927	T/C	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.24e-18	Hypospadias;
LGG	cis	rs3796352	1.000	rs75217232	chr3:53132373	A/C	cg12962167	chr3:53033115	SFMBT1	0.62	6.71	0.3	5.68e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2635047	0.638	rs2668777	chr18:44748683	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.96	0.31	1.18e-11	Educational attainment;
LGG	cis	rs7011049	0.573	rs114491022	chr8:53867161	T/G	cg26025543	chr8:53854495	NA	0.59	8.37	0.36	6.86e-16	Systolic blood pressure;
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg05793240	chr7:2802953	GNA12	0.34	7.74	0.34	6.15e-14	Height;
LGG	trans	rs7869550	1.000	rs7869550	chr9:119134796	A/G	cg20043202	chr10:124765622	IKZF5	0.36	6.84	0.3	2.54e-11	Height;
LGG	cis	rs2764980	1.000	rs2764979	chr10:3283882	T/C	cg11630169	chr10:3283847	NA	-0.44	-10.51	-0.44	2.67e-23	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26306683	chr17:18585705	ZNF286B	0.49	9.31	0.4	5.34e-19	Educational attainment (years of education);
LGG	cis	rs9487094	0.922	rs13204500	chr6:109961885	G/A	cg01125227	chr6:109776195	MICAL1	0.52	8.86	0.38	1.75e-17	Height;
LGG	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.32	-0.32	1.08e-12	Breast cancer;
LGG	cis	rs6445975	0.666	rs3922713	chr3:58383788	C/T	cg24175188	chr3:58374923	PXK	-0.55	-8.93	-0.38	9.96e-18	Systemic lupus erythematosus;
LGG	cis	rs11711311	1.000	rs6792447	chr3:113508335	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.57	-0.33	2.1e-13	IgG glycosylation;
LGG	cis	rs10851411	0.697	rs11636209	chr15:42788107	A/G	cg21293051	chr15:42870591	STARD9	0.5	6.95	0.31	1.22e-11	Glucose homeostasis traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24486960	chr6:44225443	SLC35B2	-0.46	-7.31	-0.32	1.19e-12	Pancreatic cancer;
LGG	cis	rs9487094	0.961	rs34202013	chr6:109674558	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.99	0.39	6.22e-18	Height;
LGG	trans	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.12e-11	Retinal vascular caliber;
LGG	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg21665744	chr7:39171113	POU6F2	-0.36	-6.96	-0.31	1.14e-11	IgG glycosylation;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19720917	chr19:36606221	POLR2I;TBCB	-0.43	-7.09	-0.31	5.1e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.13	-0.31	3.86e-12	Blood metabolite levels;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06028808	chr11:68637592	NA	0.69	11.86	0.48	1.56e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6011368	0.740	rs6062357	chr20:62892739	C/T	cg13869341	chr1:15865	WASH5P	0.54	9.59	0.41	5.57e-20	Clozapine-induced cytotoxicity;
LGG	cis	rs9788682	0.747	rs8042059	chr15:78907859	A/C	cg06917634	chr15:78832804	PSMA4	-0.51	-7.79	-0.34	4.31e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.27	-0.5	3.66e-30	Alzheimer's disease;
LGG	cis	rs9815354	0.638	rs56008529	chr3:42026755	A/T	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6088590	1.000	rs3787222	chr20:33333040	T/A	cg24642439	chr20:33292090	TP53INP2	0.84	15.41	0.58	1.51e-43	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg21545522	chr1:205238299	TMCC2	0.41	7.92	0.35	1.77e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.84	0.54	1.01e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs8056893	0.686	rs4783558	chr16:68403966	A/G	cg07273125	chr16:68295692	NA	0.37	7.13	0.31	3.76e-12	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs10504130	0.518	rs6473654	chr8:52671514	C/A	cg24946253	chr8:52722146	PXDNL	0.47	6.99	0.31	9.72e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg12623918	chr2:306882	NA	0.5	9.49	0.4	1.2e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs629922	0.507	rs583331	chr11:114057007	G/C	cg01914181	chr11:114070210	ZBTB16	-0.54	-6.84	-0.3	2.49e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg07460842	chr6:66804631	NA	0.51	8.85	0.38	1.83e-17	Metabolite levels;
LGG	cis	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg21479132	chr6:26055353	NA	0.81	7.17	0.32	2.96e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg02002194	chr4:3960332	NA	0.4	6.85	0.3	2.42e-11	Neuroticism;
LGG	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg16208657	chr15:68119293	LBXCOR1	-0.35	-6.73	-0.3	4.97e-11	Obesity;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.57	0.41	6.29e-20	Total body bone mineral density;
LGG	trans	rs11039798	0.687	rs11499938	chr11:48957297	G/A	cg02254774	chr11:50257496	LOC441601	0.52	6.71	0.3	5.72e-11	Axial length;
LGG	cis	rs7818345	0.613	rs13261732	chr8:19330215	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.89	0.38	1.41e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7917772	0.582	rs10883753	chr10:104372441	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.59	11.4	0.47	1.03e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg05555928	chr11:63887634	MACROD1	-0.77	-10.25	-0.43	2.26e-22	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.62	-0.33	1.41e-13	Personality dimensions;
LGG	cis	rs10884984	0.710	rs2282239	chr10:112262125	C/T	cg18756771	chr10:112261994	DUSP5	-0.7	-13.25	-0.52	3.26e-34	Facial morphology (factor 22);
LGG	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.11	0.39	2.45e-18	Morning vs. evening chronotype;
LGG	cis	rs701145	0.938	rs1086056	chr3:154088411	T/G	cg17054900	chr3:154042577	DHX36	0.98	12.32	0.5	2.23e-30	Coronary artery disease;
LGG	cis	rs10739695	0.513	rs7864230	chr9:130379799	T/C	cg13643465	chr9:130375613	STXBP1	0.5	8.83	0.38	2.19e-17	Monocyte percentage of white cells;
LGG	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08109568	chr15:31115862	NA	-0.53	-9.46	-0.4	1.62e-19	Huntington's disease progression;
LGG	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg15704280	chr7:45808275	SEPT13	-0.53	-8.81	-0.38	2.62e-17	HDL cholesterol;
LGG	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg27129171	chr3:47204927	SETD2	0.79	15.17	0.58	1.8e-42	Colorectal cancer;
LGG	cis	rs9964724	0.758	rs12455348	chr18:35197842	A/G	cg27332583	chr18:35150602	NA	0.37	7.83	0.34	3.27e-14	Educational attainment (years of education);
LGG	cis	rs62400317	0.762	rs12190313	chr6:44903902	T/G	cg18551225	chr6:44695536	NA	-0.68	-11.36	-0.47	1.51e-26	Total body bone mineral density;
LGG	cis	rs72901758	0.669	rs17641275	chr17:76247796	A/C	cg26068271	chr17:76253126	NA	-0.45	-10.21	-0.43	3.24e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2235642	0.582	rs2072990	chr16:1567651	A/G	cg04525384	chr16:1557733	TELO2	0.48	8.46	0.37	3.67e-16	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg02227867	chr8:22457446	C8orf58	-0.45	-8.46	-0.37	3.49e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10892173	0.782	rs6421566	chr11:117671398	G/A	cg21640587	chr11:117668038	DSCAML1	0.47	7.8	0.34	4.17e-14	Myopia;
LGG	cis	rs4662750	0.828	rs2248519	chr2:128377833	C/G	cg10021288	chr2:128175891	PROC	0.39	7.09	0.31	4.99e-12	Renal cell carcinoma;
LGG	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg20913747	chr6:44695427	NA	-0.65	-11.01	-0.46	3.34e-25	Total body bone mineral density;
LGG	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg00129232	chr17:37814104	STARD3	-0.57	-8.48	-0.37	3.06e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs3870371	0.955	rs10091828	chr8:122697607	T/A	cg15679747	chr8:122755315	NA	-0.35	-6.75	-0.3	4.39e-11	Periodontal disease-related phenotypes;
LGG	cis	rs7444	0.941	rs140498	chr22:21927064	G/A	cg22858872	chr22:21984481	YDJC	-0.36	-6.72	-0.3	5.51e-11	Systemic lupus erythematosus;
LGG	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.68	-0.34	9.87e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg08888203	chr3:10149979	C3orf24	0.57	7.99	0.35	1.07e-14	Alzheimer's disease;
LGG	cis	rs7208859	0.623	rs9906957	chr17:29157755	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.57	-6.87	-0.3	2.04e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4774899	1.000	rs12914410	chr15:57429837	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.44	-0.33	5.05e-13	Urinary tract infection frequency;
LGG	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-8.9	-0.38	1.24e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg05084668	chr3:125655381	ALG1L	-1.06	-12.23	-0.49	5.23e-30	Blood pressure (smoking interaction);
LGG	trans	rs9929218	0.507	rs62057805	chr16:68742390	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	24.4	0.75	3.86e-85	Colorectal cancer;
LGG	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs477692	0.905	rs509041	chr10:131424948	A/G	cg05714579	chr10:131428358	MGMT	0.66	14.06	0.55	1.24e-37	Response to temozolomide;
LGG	cis	rs986417	0.901	rs6573315	chr14:60996831	A/C	cg27398547	chr14:60952738	C14orf39	0.72	6.91	0.31	1.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	18.88	0.66	2.18e-59	Platelet count;
LGG	cis	rs17221829	0.965	rs10830363	chr11:89458468	A/G	cg02982614	chr11:89391479	FOLH1B	-0.33	-7.32	-0.32	1.12e-12	Anxiety in major depressive disorder;
LGG	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs6430585	0.583	rs3754689	chr2:136590746	C/T	cg07169764	chr2:136633963	MCM6	1.22	24.06	0.75	1.37e-83	Corneal structure;
LGG	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.68	-0.74	8.28e-82	Primary sclerosing cholangitis;
LGG	cis	rs10779751	0.734	rs910660	chr1:11130643	C/T	cg08854313	chr1:11322531	MTOR	-0.74	-16.38	-0.61	6.82e-48	Body mass index;
LGG	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg17133734	chr15:86042851	AKAP13	0.28	6.74	0.3	4.67e-11	Coronary artery disease;
LGG	cis	rs883565	0.543	rs784488	chr3:39173135	C/G	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	9.66e-38	Handedness;
LGG	cis	rs2658782	0.526	rs3020062	chr11:93061159	T/C	cg15737290	chr11:93063684	CCDC67	0.66	11.02	0.46	2.99e-25	Pulmonary function decline;
LGG	cis	rs427394	0.664	rs274696	chr5:6732213	A/C	cg15145174	chr5:6755386	POLS	-0.38	-7.21	-0.32	2.37e-12	Menopause (age at onset);
LGG	cis	rs2114646	1.000	rs2114646	chr2:170624221	C/T	cg17598339	chr2:170624727	NA	0.47	8.46	0.37	3.63e-16	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs2865981	chr4:99031493	G/A	cg05340658	chr4:99064831	C4orf37	0.49	8.26	0.36	1.59e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10227331	1.000	rs11979293	chr7:157293586	C/T	cg04156418	chr7:157293606	NA	0.62	14.57	0.56	7.74e-40	Inattentive symptoms;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06916706	chr16:4465613	CORO7	-0.89	-15.65	-0.59	1.22e-44	Schizophrenia;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg17202724	chr17:61916730	SMARCD2	0.55	12.69	0.51	7.11e-32	Prudent dietary pattern;
LGG	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg09263875	chr16:632152	PIGQ	0.66	12.96	0.52	5.41e-33	Height;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg26513180	chr16:89883248	FANCA	0.92	9.78	0.41	1.15e-20	Skin colour saturation;
LGG	cis	rs2479724	0.870	rs3747753	chr6:41753380	G/T	cg17623882	chr6:41773611	USP49	0.52	9.1	0.39	2.72e-18	Menarche (age at onset);
LGG	cis	rs3812565	0.530	rs10781538	chr9:139320929	C/G	cg14019695	chr9:139328340	INPP5E	-0.43	-7.96	-0.35	1.33e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg25019033	chr10:957182	NA	-0.52	-9.51	-0.4	1.01e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs10979	0.557	rs9403517	chr6:143909400	T/C	cg25407410	chr6:143891975	LOC285740	-0.56	-8.24	-0.36	1.8e-15	Hypospadias;
LGG	cis	rs7843479	0.601	rs1058486	chr8:21862551	A/G	cg17168535	chr8:21777572	XPO7	0.82	16.03	0.6	2.59e-46	Mean corpuscular volume;
LGG	cis	rs16854884	0.632	rs35629416	chr3:143748424	C/T	cg06585982	chr3:143692056	C3orf58	0.56	9.6	0.41	5.16e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg26695010	chr11:65641043	EFEMP2	0.64	11.34	0.47	1.73e-26	Eosinophil percentage of white cells;
LGG	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg04362960	chr10:104952993	NT5C2	-0.57	-10.76	-0.45	2.99e-24	Arsenic metabolism;
LGG	cis	rs4704187	0.687	rs4360021	chr5:74421962	A/G	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.46	7.52	0.33	2.95e-13	Lymphocyte counts;
LGG	cis	rs4740619	0.905	rs10962098	chr9:15611407	G/C	cg14451791	chr9:16040625	NA	-0.37	-9.37	-0.4	3.15e-19	Body mass index;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg04287289	chr16:89883240	FANCA	0.83	9.01	0.39	5.45e-18	Interleukin-17 levels;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg15971980	chr6:150254442	NA	0.45	8.63	0.37	9.97e-17	Lung cancer;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg00149659	chr3:10157352	C3orf10	1.18	13.62	0.53	8.8e-36	Alzheimer's disease;
LGG	trans	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.6	0.53	1.14e-35	Obesity-related traits;
LGG	cis	rs4740619	0.604	rs9650685	chr9:15808994	T/A	cg14451791	chr9:16040625	NA	-0.38	-9.55	-0.41	7.3e-20	Body mass index;
LGG	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.69	-0.34	8.81e-14	Testicular germ cell tumor;
LGG	trans	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg07817883	chr1:32538562	TMEM39B	-0.63	-8.1	-0.35	4.92e-15	Monocyte percentage of white cells;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.75	-0.34	5.96e-14	Life satisfaction;
LGG	cis	rs11696845	0.965	rs13038381	chr20:43370747	A/G	cg25301532	chr20:43378953	KCNK15	0.37	8.11	0.35	4.67e-15	Obesity-related traits;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg11360546	chr7:1094263	C7orf50	-0.42	-7.81	-0.34	4e-14	Longevity;Endometriosis;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.91	-0.34	1.96e-14	Schizophrenia;
LGG	cis	rs1062177	0.855	rs1346489	chr5:151266534	C/T	cg00977110	chr5:151150581	G3BP1	0.42	6.73	0.3	5.08e-11	Preschool internalizing problems;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-8.06	-0.35	6.55e-15	Life satisfaction;
LGG	cis	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.18e-20	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.85	-0.34	2.88e-14	Total body bone mineral density;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.77	-0.41	1.24e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg24110177	chr3:50126178	RBM5	0.44	7.35	0.32	9.1e-13	Body mass index;
LGG	cis	rs1957429	0.520	rs72625641	chr14:65335761	C/T	cg23373153	chr14:65346875	NA	-1.04	-9.94	-0.42	3.2e-21	Pediatric areal bone mineral density (radius);
LGG	trans	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg25214090	chr10:38739885	LOC399744	0.56	10.25	0.43	2.27e-22	Corneal astigmatism;
LGG	cis	rs1728785	0.688	rs698718	chr16:68560185	A/G	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs17067123	0.614	rs2383271	chr4:180071469	G/A	cg26610307	chr4:180072759	NA	-0.48	-6.99	-0.31	9.88e-12	Response to hepatitis C treatment;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	2.03e-57	Platelet count;
LGG	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.81	-0.51	2.25e-32	Response to antipsychotic treatment;
LGG	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg01631408	chr1:248437212	OR2T33	-0.58	-10.34	-0.43	1.11e-22	Common traits (Other);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24783322	chr8:49834643	SNAI2	0.42	7.15	0.32	3.48e-12	Cognitive performance;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg23978390	chr7:1156363	C7orf50	0.58	10.04	0.42	1.38e-21	Longevity;Endometriosis;
LGG	cis	rs4740619	0.544	rs9407657	chr9:15832935	C/T	cg14451791	chr9:16040625	NA	0.32	7.57	0.33	2.09e-13	Body mass index;
LGG	cis	rs12464559	0.649	rs4664496	chr2:152522556	T/C	cg01189475	chr2:152685088	ARL5A	-0.61	-6.96	-0.31	1.17e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg07460842	chr6:66804631	NA	-0.49	-8.23	-0.36	1.91e-15	Metabolite levels;
LGG	cis	rs4262150	0.672	rs72806790	chr5:152355258	T/C	cg12297329	chr5:152029980	NA	-0.56	-8.73	-0.38	4.71e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs72799341	1.000	rs1458201	chr16:30916129	G/A	cg00531865	chr16:30841666	NA	-0.5	-8.89	-0.38	1.37e-17	Diastolic blood pressure;
LGG	cis	rs7589342	0.628	rs11893695	chr2:106401300	C/G	cg16077055	chr2:106428750	NCK2	-0.3	-7.14	-0.31	3.72e-12	Addiction;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.7e-13	Menopause (age at onset);
LGG	cis	rs283228	0.550	rs2629976	chr6:101812654	G/T	cg02011392	chr6:101847541	GRIK2	0.49	6.84	0.3	2.58e-11	Coenzyme Q10 levels;
LGG	cis	rs208520	0.754	rs851593	chr6:66875783	C/T	cg07460842	chr6:66804631	NA	0.97	17.75	0.64	3.7e-54	Exhaled nitric oxide output;
LGG	cis	rs61990749	0.544	rs2544566	chr14:78181738	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.34	0.32	9.85e-13	Fibroblast growth factor basic levels;
LGG	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg15704280	chr7:45808275	SEPT13	0.71	8.79	0.38	2.86e-17	Intraocular pressure;
LGG	cis	rs7937890	0.504	rs2575822	chr11:14519851	C/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg00012203	chr2:219082015	ARPC2	0.78	14.74	0.57	1.39e-40	Colorectal cancer;
LGG	cis	rs72960926	1.000	rs16884858	chr6:75107741	C/A	cg03266952	chr6:74778945	NA	-0.68	-6.8	-0.3	3.25e-11	Metabolite levels (MHPG);
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.33	0.4	4.32e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06056004	chr5:44809616	MRPS30	0.45	7.04	0.31	6.84e-12	Gut microbiome composition (summer);
LGG	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg05791153	chr7:19748676	TWISTNB	0.77	10.22	0.43	3.11e-22	Thyroid stimulating hormone;
LGG	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg02353165	chr6:42928485	GNMT	-0.5	-15.7	-0.59	7.42e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs151234	0.676	rs554206	chr16:28576369	G/A	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.94	-0.42	3.01e-21	Platelet distribution width;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg07142201	chr11:109293216	C11orf87	0.53	9.47	0.4	1.48e-19	Schizophrenia;
LGG	cis	rs763121	0.853	rs8138996	chr22:39047435	G/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg20848291	chr7:100343083	ZAN	-0.66	-9.83	-0.42	7.62e-21	Other erythrocyte phenotypes;
LGG	cis	rs36051895	0.632	rs9657576	chr9:5183028	T/G	cg02405213	chr9:5042618	JAK2	-0.75	-14.46	-0.56	2.17e-39	Pediatric autoimmune diseases;
LGG	cis	rs9527	0.615	rs10883804	chr10:104706520	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7215564	0.908	rs34084509	chr17:78696577	C/A	cg16980736	chr17:78789706	RPTOR	-0.71	-9.07	-0.39	3.47e-18	Myopia (pathological);
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.55	-0.37	1.85e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg17646820	chr3:66848679	NA	0.5	7.79	0.34	4.53e-14	Type 2 diabetes;
LGG	cis	rs7928758	0.945	rs113328990	chr11:134278010	G/T	cg25213107	chr11:134282864	B3GAT1	1.03	12.4	0.5	1.12e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg14926445	chr8:58193284	C8orf71	-0.87	-12.2	-0.49	6.99e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg07701084	chr6:150067640	NUP43	0.68	11.98	0.49	5.26e-29	Lung cancer;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.96e-19	Menopause (age at onset);
LGG	cis	rs4919694	1.000	rs12245779	chr10:104645944	C/A	cg04362960	chr10:104952993	NT5C2	1.11	15.3	0.58	4.59e-43	Arsenic metabolism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08951907	chr17:18218556	TOP3A;SMCR8	0.47	7.67	0.34	1.05e-13	Cognitive performance;
LGG	cis	rs10743315	0.732	rs75285724	chr12:19454688	T/G	cg02471346	chr12:19282374	PLEKHA5	0.6	6.88	0.3	2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs67478160	0.679	rs8011109	chr14:104279974	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-7.49	-0.33	3.56e-13	Schizophrenia;
LGG	cis	rs7267979	0.565	rs3752273	chr20:25594783	A/T	cg06421707	chr20:25228305	PYGB	-0.36	-7.5	-0.33	3.28e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg16606324	chr3:10149918	C3orf24	-0.62	-7.25	-0.32	1.8e-12	Alzheimer's disease;
LGG	cis	rs4144743	1.000	rs4144743	chr17:45323125	A/G	cg18085866	chr17:45331354	ITGB3	-0.76	-9.67	-0.41	2.88e-20	Body mass index;
LGG	cis	rs7215564	0.818	rs756076	chr17:78662918	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.23	-0.36	1.96e-15	Myopia (pathological);
LGG	cis	rs921968	0.541	rs41461846	chr2:219313354	A/G	cg01130898	chr2:219473002	PLCD4	0.47	7.97	0.35	1.22e-14	Mean corpuscular hemoglobin concentration;
LGG	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.72	0.56	1.61e-40	Morning vs. evening chronotype;
LGG	cis	rs4538187	1.000	rs4538187	chr2:64103741	C/T	cg14150252	chr2:64069583	UGP2	0.5	10.09	0.42	9.28e-22	Systolic blood pressure;
LGG	cis	rs28647808	0.881	rs7029386	chr9:136263736	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26076054	chr5:421317	AHRR	-0.46	-7.59	-0.33	1.82e-13	Cystic fibrosis severity;
LGG	cis	rs57502260	0.704	rs72936570	chr11:68307139	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-7.34	-0.32	9.46e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.44	7.53	0.33	2.77e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9462027	0.628	rs7756405	chr6:34722659	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg18187862	chr3:45730750	SACM1L	0.58	9.58	0.41	5.85e-20	Primary sclerosing cholangitis;
LGG	cis	rs698813	0.774	rs1085492	chr2:44609371	C/G	cg00619915	chr2:44497795	NA	-0.48	-6.85	-0.3	2.39e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2635047	0.747	rs9956387	chr18:44773382	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.47	0.37	3.2e-16	Educational attainment;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs7394190	0.748	rs11000777	chr10:75545063	G/C	cg07699608	chr10:75541558	CHCHD1	0.55	7.37	0.32	7.9e-13	Incident atrial fibrillation;
LGG	cis	rs80282103	0.618	rs74120451	chr10:1126866	T/C	cg08668510	chr10:1095578	IDI1	0.75	7.39	0.32	7.06e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg02466173	chr16:30829666	NA	-0.56	-10.12	-0.43	6.81e-22	Multiple myeloma;
LGG	cis	rs7534801	0.656	rs2134268	chr1:244915579	A/C	cg20597013	chr1:244894274	NA	-0.26	-7.17	-0.32	3.02e-12	Longitudinal change in brain amyloid plaque burden;
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg00666640	chr1:248458726	OR2T12	0.62	9.93	0.42	3.52e-21	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27006027	chr19:33165562	ANKRD27;RGS9BP	0.4	6.76	0.3	4.18e-11	Gut microbiome composition (summer);
LGG	cis	rs703842	0.963	rs923829	chr12:58174306	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	7.72	0.34	7.1e-14	Multiple sclerosis;
LGG	cis	rs1712517	0.526	rs113528138	chr10:105125451	C/A	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.46e-15	Migraine;
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.53	0.84	5.72e-126	Prudent dietary pattern;
LGG	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	trans	rs9409565	0.576	rs73653460	chr9:97065301	C/A	cg05679027	chr9:99775184	HIATL2	0.52	8.61	0.37	1.14e-16	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg15485101	chr11:133734466	NA	0.61	10.78	0.45	2.45e-24	Childhood ear infection;
LGG	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg11766577	chr21:47581405	C21orf56	-0.41	-7.02	-0.31	7.8e-12	Testicular germ cell tumor;
LGG	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.48	12.24	0.49	4.79e-30	Oropharynx cancer;
LGG	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg01028140	chr2:1542097	TPO	-0.56	-8.4	-0.36	5.54e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg07928641	chr1:182991847	LAMC1	0.48	9.71	0.41	2.1e-20	Hypertriglyceridemia;
LGG	cis	rs2075371	1.000	rs2598297	chr7:133993001	T/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.22	0.58	1.09e-42	Mean platelet volume;
LGG	trans	rs3206736	0.548	rs328940	chr7:35050364	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.0	0.31	8.84e-12	Diastolic blood pressure;
LGG	cis	rs10214930	0.697	rs10951171	chr7:27611607	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.68	0.3	6.99e-11	Hypospadias;
LGG	cis	rs1015291	0.708	rs1586838	chr12:19998182	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.24	-0.32	1.87e-12	Diastolic blood pressure;
LGG	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs3806843	0.576	rs246020	chr5:140334771	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg00409905	chr10:38381863	ZNF37A	0.48	7.1	0.31	4.81e-12	Obesity (extreme);
LGG	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg23815491	chr16:72088622	HP	0.5	11.07	0.46	1.99e-25	Fibrinogen levels;
LGG	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg22875332	chr1:76189707	ACADM	-0.6	-8.95	-0.38	8.31e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg18105134	chr13:113819100	PROZ	-0.7	-14.24	-0.55	2.07e-38	Platelet distribution width;
LGG	cis	rs8060686	0.641	rs73612208	chr16:68206844	G/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.22	-0.32	2.12e-12	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19894588	chr14:64061835	NA	0.48	8.02	0.35	8.57e-15	Glioblastoma;Glioma;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05165339	chr4:1420672	NA	-0.35	-8.8	-0.38	2.71e-17	Longevity;
LGG	cis	rs9309711	0.737	rs9284795	chr2:3492065	G/A	cg10845886	chr2:3471009	TTC15	-0.68	-12.99	-0.52	3.91e-33	Neurofibrillary tangles;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg01966878	chr4:90757139	SNCA	-0.33	-6.7	-0.3	5.94e-11	Dementia with Lewy bodies;
LGG	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg03538708	chr1:25844672	NA	0.36	6.81	0.3	3.11e-11	Erythrocyte sedimentation rate;
LGG	cis	rs7100689	0.697	rs4934084	chr10:82116960	T/C	cg01528321	chr10:82214614	TSPAN14	0.94	16.77	0.61	1.15e-49	Post bronchodilator FEV1;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.04e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg03453431	chr7:157225567	NA	-0.6	-11.02	-0.46	3.17e-25	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg26513180	chr16:89883248	FANCA	0.62	11.26	0.46	3.82e-26	Vitiligo;
LGG	cis	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg02972257	chr16:68554789	NA	-0.57	-8.41	-0.36	5.1e-16	Ulcerative colitis;
LGG	cis	rs2836950	0.501	rs2836985	chr21:40701169	A/G	cg11644478	chr21:40555479	PSMG1	-0.58	-9.51	-0.4	1.01e-19	Menarche (age at onset);
LGG	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg11859384	chr17:80120422	CCDC57	0.39	6.77	0.3	3.82e-11	Life satisfaction;
LGG	cis	rs4474465	1.000	rs908003	chr11:78190340	A/T	cg02023728	chr11:77925099	USP35	0.39	6.9	0.31	1.73e-11	Alzheimer's disease (survival time);
LGG	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.43	-0.4	2.01e-19	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11672037	chr15:48010808	SEMA6D	0.47	7.05	0.31	6.35e-12	Gut microbiome composition (summer);
LGG	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00198680	chr16:28758506	NA	0.3	7.37	0.32	7.72e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6692729	0.901	rs1295643	chr1:227071364	G/A	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11890956	chr21:40555474	PSMG1	1.05	21.08	0.7	1.24e-69	Cognitive function;
LGG	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg22517653	chr1:2918612	NA	-0.5	-7.01	-0.31	8.74e-12	Plateletcrit;
LGG	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.9	-0.74	7.95e-83	Lymphocyte percentage of white cells;
LGG	cis	rs80130819	0.748	rs1387255	chr12:48648943	C/T	cg24011408	chr12:48396354	COL2A1	0.58	6.75	0.3	4.51e-11	Prostate cancer;
LGG	cis	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.05	-0.35	6.99e-15	Mood instability;
LGG	cis	rs9815354	0.767	rs73071337	chr3:41822518	G/C	cg03022575	chr3:42003672	ULK4	0.79	9.06	0.39	3.61e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10170846	0.893	rs12614976	chr2:223542896	A/T	cg25565276	chr2:223520875	FARSB	0.65	11.11	0.46	1.4e-25	Schizophrenia (inflammation and infection response interaction);
LGG	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-8.05	-0.35	7.01e-15	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg14926445	chr8:58193284	C8orf71	-0.79	-9.68	-0.41	2.54e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg21775007	chr8:11205619	TDH	-0.47	-7.5	-0.33	3.23e-13	Morning vs. evening chronotype;
LGG	cis	rs13421350	0.579	rs9636257	chr2:173344128	G/A	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs4481887	0.508	rs4916115	chr1:248383316	T/G	cg00666640	chr1:248458726	OR2T12	0.46	6.93	0.31	1.41e-11	Common traits (Other);
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg08621203	chr6:150244597	RAET1G	0.47	8.21	0.36	2.24e-15	Lung cancer;
LGG	cis	rs13082711	0.906	rs34775440	chr3:27447333	G/T	cg02860705	chr3:27208620	NA	0.75	13.96	0.54	3.27e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs745080	0.764	rs6572849	chr14:52977289	C/G	cg23333723	chr14:53022898	GPR137C	-0.29	-6.82	-0.3	2.84e-11	Orofacial clefts;
LGG	cis	rs12618769	0.597	rs11888595	chr2:99084708	T/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs6714710	0.580	rs55886305	chr2:98495661	T/G	cg26665480	chr2:98280029	ACTR1B	0.59	9.47	0.4	1.4e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.26	-0.32	1.69e-12	Life satisfaction;
LGG	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15128208	chr22:42549153	NA	-0.46	-8.87	-0.38	1.55e-17	Cognitive function;
LGG	cis	rs7619833	0.658	rs633157	chr3:27335350	A/T	cg02860705	chr3:27208620	NA	0.39	7.56	0.33	2.15e-13	Breast cancer;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.5	0.44	2.78e-23	Personality dimensions;
LGG	cis	rs4849975	0.510	rs28548099	chr2:3710938	G/A	cg14882966	chr2:3699353	NA	0.61	7.51	0.33	3e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4253772	0.513	rs9615345	chr22:46713631	C/T	cg24881330	chr22:46731750	TRMU	0.83	9.94	0.42	3.11e-21	LDL cholesterol;Cholesterol, total;
LGG	cis	rs8038465	0.638	rs12594175	chr15:73973186	C/T	cg15420318	chr15:73925796	NPTN	0.41	7.02	0.31	7.74e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6912958	0.781	rs9444524	chr6:88311260	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.68	-0.37	6.91e-17	Monocyte percentage of white cells;
LGG	cis	rs34172651	0.797	rs12920941	chr16:24830866	T/A	cg02428538	chr16:24856791	SLC5A11	-0.43	-7.44	-0.33	4.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.37	0.32	7.81e-13	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	12.54	0.5	2.88e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.67	-0.34	1.05e-13	Lung cancer;
LGG	cis	rs4919087	1.000	rs7078288	chr10:99086361	C/T	cg25902810	chr10:99078978	FRAT1	-0.49	-8.95	-0.38	8.88e-18	Monocyte count;
LGG	cis	rs1152591	0.967	rs1152589	chr14:64683926	A/T	cg23250157	chr14:64679961	SYNE2	-0.45	-8.54	-0.37	1.9e-16	Atrial fibrillation;
LGG	cis	rs1707322	1.000	rs785468	chr1:46521517	G/A	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	9.3e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7172689	1.000	rs6495554	chr15:81548381	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.71	-0.45	4.53e-24	Inattentive symptoms;
LGG	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg21775007	chr8:11205619	TDH	-0.5	-8.03	-0.35	8.2e-15	Triglycerides;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-8.05	-0.35	7.11e-15	Personality dimensions;
LGG	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11644478	chr21:40555479	PSMG1	-0.6	-10.09	-0.42	8.79e-22	Menarche (age at onset);
LGG	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.25	0.32	1.72e-12	Systemic lupus erythematosus;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg21045802	chr8:109455806	TTC35	-0.52	-9.83	-0.42	7.71e-21	Dupuytren's disease;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg11062466	chr8:58055876	NA	0.6	9.65	0.41	3.44e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	cis	rs9815354	0.812	rs73073233	chr3:42010550	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.28	0.4	6.36e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg07615347	chr10:60278583	BICC1	-0.61	-17.25	-0.63	7.62e-52	Refractive error;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg00814883	chr7:100076585	TSC22D4	-0.73	-10.57	-0.44	1.48e-23	Platelet count;
LGG	cis	rs6908034	0.660	rs7750716	chr6:19804839	C/T	cg02682789	chr6:19804855	NA	0.84	9.58	0.41	5.94e-20	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.4	-6.91	-0.31	1.62e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg05925327	chr15:68127851	NA	-0.44	-8.95	-0.38	8.46e-18	Restless legs syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26035463	chr12:117627651	FBXO21	0.59	9.38	0.4	2.88e-19	Gut microbiome composition (summer);
LGG	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg03647239	chr10:116582469	FAM160B1	0.41	7.23	0.32	2e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.9	0.57	2.63e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs981844	0.921	rs2606336	chr4:154656792	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	8.26e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs11971779	0.680	rs6467840	chr7:139065401	A/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg24955955	chr5:415729	AHRR	0.76	10.37	0.43	8.72e-23	Fat distribution (HIV);
LGG	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg02002194	chr4:3960332	NA	-0.46	-8.6	-0.37	1.21e-16	Neuroticism;
LGG	cis	rs9443645	0.901	rs55755815	chr6:79607121	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs12539231	chr7:91634963	G/A	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.39	-0.43	6.9e-23	Lung cancer;
LGG	cis	rs10791097	0.653	rs11222362	chr11:130731425	T/C	cg09137382	chr11:130731461	NA	0.43	8.38	0.36	6.36e-16	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg04863758	chr4:1303710	MAEA	0.42	7.24	0.32	1.84e-12	Obesity-related traits;
LGG	cis	rs1185460	0.546	rs17075	chr11:118959331	A/G	cg12636538	chr11:118901039	SLC37A4	-0.56	-11.67	-0.48	9.37e-28	Coronary artery disease;
LGG	cis	rs2421770	0.532	rs3847615	chr11:35347929	A/C	cg10331829	chr11:35343789	SLC1A2	-0.35	-7.68	-0.34	9.79e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs7091068	0.671	rs588912	chr10:95402929	T/C	cg20715218	chr10:95462985	C10orf4	-0.57	-8.98	-0.39	6.76e-18	Urinary tract infection frequency;
LGG	cis	rs2050392	0.630	rs303426	chr10:30740379	A/G	cg25182066	chr10:30743637	MAP3K8	0.56	11.73	0.48	5.34e-28	Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04968835	chr1:143913847	FAM72D	0.45	7.18	0.32	2.82e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs3806843	0.741	rs2563293	chr5:140110536	T/C	cg19875535	chr5:140030758	IK	-0.58	-11.84	-0.48	2e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4740619	0.870	rs2382539	chr9:15793592	A/T	cg14451791	chr9:16040625	NA	-0.36	-9.02	-0.39	5.12e-18	Body mass index;
LGG	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg02297831	chr4:17616191	MED28	0.47	8.51	0.37	2.46e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2732480	0.500	rs2450986	chr12:48661688	G/A	cg24011408	chr12:48396354	COL2A1	0.49	7.7	0.34	8.42e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg19143629	chr17:61920732	SMARCD2	0.43	7.36	0.32	8.57e-13	Prudent dietary pattern;
LGG	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg12310025	chr6:25882481	NA	-0.37	-6.71	-0.3	5.78e-11	Height;
LGG	cis	rs981844	0.712	rs897611	chr4:154755519	T/C	cg14289246	chr4:154710475	SFRP2	-0.56	-9.63	-0.41	4.07e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.94	-0.52	6.71e-33	Diastolic blood pressure;
LGG	cis	rs7828089	0.522	rs4872484	chr8:22255859	C/T	cg12081754	chr8:22256438	SLC39A14	1.09	25.67	0.77	4.75e-91	Verbal declarative memory;
LGG	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-11.53	-0.47	3.41e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	0.714	rs13230381	chr7:19833896	T/C	cg05791153	chr7:19748676	TWISTNB	0.74	9.81	0.41	9.23e-21	Thyroid stimulating hormone;
LGG	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs9443645	0.901	rs4147183	chr6:79557046	C/G	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs780096	0.967	rs1260334	chr2:27748597	C/A	cg22903471	chr2:27725779	GCKR	-0.35	-7.39	-0.33	6.69e-13	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24465118	chr20:47895107	C20orf199;SNORD12C;ZNFX1	0.44	7.52	0.33	2.88e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	19.72	0.68	2.67e-63	Alzheimer's disease;
LGG	cis	rs6573604	1.000	rs8012054	chr14:65774762	A/C	cg15999311	chr14:65749247	NA	0.46	6.69	0.3	6.26e-11	N-glycan levels;
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.94	0.38	9.13e-18	Alzheimer's disease;
LGG	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.41e-12	Schizophrenia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12995410	chr6:151712734	ZBTB2	0.41	6.74	0.3	4.86e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg26116260	chr4:7069785	GRPEL1	-1.07	-15.93	-0.59	7.43e-46	Monocyte percentage of white cells;
LGG	cis	rs804280	1.000	rs804280	chr8:11612698	G/T	cg12395012	chr8:11607386	GATA4	-0.69	-14.3	-0.55	1.06e-38	Myopia (pathological);
LGG	cis	rs2273669	0.667	rs78714994	chr6:109350351	G/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg16586182	chr3:47516702	SCAP	-0.43	-6.96	-0.31	1.2e-11	Birth weight;
LGG	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg02002194	chr4:3960332	NA	0.5	9.47	0.4	1.41e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg05335186	chr13:53173507	NA	-0.78	-18.63	-0.65	3.39e-58	Lewy body disease;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg20255370	chr15:40268687	EIF2AK4	0.61	8.92	0.38	1.12e-17	Response to haloperidol in psychosis;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg05313129	chr8:58192883	C8orf71	-0.61	-8.33	-0.36	9.49e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg15948088	chr11:109293068	C11orf87	0.49	8.32	0.36	1.02e-15	Schizophrenia;
LGG	cis	rs2230307	0.536	rs7518943	chr1:100463422	G/T	cg24955406	chr1:100503596	HIAT1	0.55	8.29	0.36	1.22e-15	Carotid intima media thickness;
LGG	cis	rs4851266	0.966	rs12987662	chr2:100821548	C/A	cg21926883	chr2:100939477	LONRF2	-0.43	-7.86	-0.34	2.72e-14	Educational attainment;
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs7084402	0.817	rs7099496	chr10:60265242	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.29	-0.63	5.09e-52	Refractive error;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.958	rs3784066	chr14:72007454	A/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.03	0.39	4.48e-18	Mitral valve prolapse;
LGG	cis	rs10463554	0.927	rs257308	chr5:102418261	A/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.43	7.06	0.31	6.24e-12	Carotid intima media thickness;
LGG	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs6456042	0.965	rs1900056	chr6:166545910	A/G	cg11088901	chr6:166572345	T	-0.34	-7.18	-0.32	2.75e-12	Asthma;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08645402	chr16:4508243	NA	0.51	9.83	0.42	7.5e-21	Schizophrenia;
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg06925179	chr17:43578568	NA	0.42	10.06	0.42	1.19e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg03709012	chr19:19516395	GATAD2A	0.79	14.84	0.57	4.87e-41	Tonsillectomy;
LGG	cis	rs4474465	1.000	rs10899505	chr11:78165343	T/C	cg02023728	chr11:77925099	USP35	0.4	7.15	0.32	3.31e-12	Alzheimer's disease (survival time);
LGG	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg04731861	chr2:219085781	ARPC2	0.52	13.46	0.53	4.17e-35	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.87	-0.45	1.11e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.54e-11	Aortic root size;
LGG	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg18825076	chr15:78729989	IREB2	-0.47	-7.62	-0.33	1.45e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs34172651	0.917	rs11642302	chr16:24770856	G/A	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.63	-0.33	1.35e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11225247	1.000	rs11225242	chr11:102274181	G/C	cg06323957	chr11:102217781	BIRC2	0.78	6.9	0.31	1.72e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs7402982	0.525	rs11247361	chr15:99207392	C/G	cg03437748	chr15:99193247	IGF1R	-0.66	-10.7	-0.45	4.82e-24	Birth weight;
LGG	cis	rs727505	1.000	rs3925331	chr7:124446137	C/G	cg23710748	chr7:124431027	NA	-0.51	-9.7	-0.41	2.19e-20	Lewy body disease;
LGG	cis	rs4363385	0.588	rs11205180	chr1:153022070	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-9.93	-0.42	3.35e-21	Inflammatory skin disease;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.15	-0.39	1.89e-18	Life satisfaction;
LGG	cis	rs2117029	0.727	rs10875910	chr12:49402393	G/C	cg24176009	chr12:49580217	TUBA1A	0.46	8.33	0.36	9.53e-16	Intelligence (multi-trait analysis);
LGG	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg16096631	chr1:42092165	HIVEP3	0.57	13.69	0.54	4.5e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs6964587	1.000	rs10243241	chr7:91705696	A/G	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.13e-16	Breast cancer;
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05923184	chr19:38878861	GGN	0.43	6.8	0.3	3.24e-11	Cognitive performance;
LGG	cis	rs7222240	0.904	rs57499268	chr17:43132378	G/A	cg24806326	chr17:43207588	PLCD3	0.44	7.41	0.33	6.13e-13	Craniofacial microsomia;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.49	-0.37	2.89e-16	Life satisfaction;
LGG	cis	rs35306767	0.715	rs1250891	chr10:1040159	G/C	cg25019033	chr10:957182	NA	-0.61	-11.16	-0.46	9.04e-26	Eosinophil percentage of granulocytes;
LGG	cis	rs28595532	0.720	rs72670224	chr4:119301885	G/T	cg21605333	chr4:119757512	SEC24D	0.9	8.55	0.37	1.84e-16	Cannabis dependence symptom count;
LGG	trans	rs9650657	0.836	rs11250067	chr8:10606954	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.79	-0.3	3.45e-11	Neuroticism;
LGG	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg18252515	chr7:66147081	NA	-0.46	-7.98	-0.35	1.2e-14	Aortic root size;
LGG	cis	rs72949976	0.898	rs6732233	chr2:214022834	C/T	cg08319019	chr2:214017104	IKZF2	-0.62	-10.71	-0.45	4.54e-24	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg03929089	chr4:120376271	NA	0.8	11.08	0.46	1.74e-25	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.64	-0.37	9.52e-17	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg22535103	chr8:58192502	C8orf71	-0.77	-10.34	-0.43	1.12e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6743376	0.532	rs2515403	chr2:113820732	T/C	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.68	-0.37	6.63e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.38	0.36	6.38e-16	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.76	-0.38	3.8e-17	Menopause (age at onset);
LGG	cis	rs6466055	0.674	rs6967587	chr7:104744041	C/T	cg04380332	chr7:105027541	SRPK2	-0.39	-7.37	-0.32	7.96e-13	Schizophrenia;
LGG	cis	rs834603	0.546	rs1534138	chr7:47482750	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.93	0.35	1.65e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	15.06	0.57	5.18e-42	Menarche (age at onset);
LGG	cis	rs6032067	0.777	rs979641	chr20:43786336	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs1256531	0.661	rs17102845	chr14:66144630	A/C	cg15999311	chr14:65749247	NA	0.86	7.2	0.32	2.43e-12	Conduct disorder (symptom count);
LGG	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs9815354	0.767	rs115702638	chr3:42058594	C/T	cg03022575	chr3:42003672	ULK4	0.66	7.91	0.34	1.96e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	9.09e-48	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs7927771	0.524	rs7114813	chr11:47801101	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.09	0.46	1.65e-25	Subjective well-being;
LGG	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.49	9.24	0.39	8.69e-19	IgG glycosylation;
LGG	cis	rs17453880	0.890	rs4958563	chr5:151981337	A/G	cg12297329	chr5:152029980	NA	-0.87	-22.03	-0.72	4.29e-74	Subjective well-being;
LGG	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg00277334	chr10:82204260	NA	0.36	7.88	0.34	2.37e-14	Post bronchodilator FEV1;
LGG	cis	rs7911264	0.967	rs2497318	chr10:94432000	C/T	cg25093409	chr10:94429542	NA	-0.57	-11.28	-0.46	3.16e-26	Inflammatory bowel disease;
LGG	cis	rs888194	0.688	rs1543896	chr12:109920071	G/T	cg19025524	chr12:109796872	NA	-0.36	-7.14	-0.32	3.54e-12	Neuroticism;
LGG	trans	rs9467603	0.547	rs4712936	chr6:25417423	G/T	cg06606381	chr12:133084897	FBRSL1	0.91	7.3	0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2693698	0.649	rs3994992	chr14:99679507	C/T	cg07440398	chr14:99712966	BCL11B	0.57	11.76	0.48	4.01e-28	Schizophrenia;
LGG	cis	rs72949976	0.707	rs62186571	chr2:214038673	C/G	cg08319019	chr2:214017104	IKZF2	-0.5	-7.9	-0.34	2.12e-14	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.88	0.42	4.98e-21	Primary sclerosing cholangitis;
LGG	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.03	-0.49	3.46e-29	Vitiligo;
LGG	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.79	-0.34	4.49e-14	Response to antipsychotic treatment;
LGG	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs6740322	0.895	rs6760797	chr2:43559612	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.62	-0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06112835	chr11:68658793	MRPL21	0.61	10.2	0.43	3.45e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs34172651	0.517	rs12920774	chr16:24830750	T/C	cg02428538	chr16:24856791	SLC5A11	-0.69	-10.48	-0.44	3.22e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2802728	0.881	rs79105724	chr1:243566645	A/G	cg05593162	chr1:243577377	SDCCAG8	0.51	7.18	0.32	2.73e-12	Toenail selenium levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg18125208	chr1:228297275	MRPL55	0.49	7.14	0.31	3.66e-12	Hip circumference;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs947474	0.838	rs2146900	chr10:6403050	G/C	cg19837174	chr10:6389707	NA	0.61	8.51	0.37	2.44e-16	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs12545109	0.800	rs2221919	chr8:57412541	A/C	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs17453880	0.895	rs4610448	chr5:152019865	A/T	cg10931792	chr5:152022470	NA	0.4	8.68	0.37	6.78e-17	Subjective well-being;
LGG	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg26384229	chr12:38710491	ALG10B	0.63	12.27	0.5	3.69e-30	Morning vs. evening chronotype;
LGG	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg22903471	chr2:27725779	GCKR	-0.54	-11.91	-0.48	1.07e-28	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs7010267	0.669	rs2073617	chr8:119964283	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.92	0.35	1.82e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs10193935	0.901	rs62142561	chr2:42477808	G/C	cg27598129	chr2:42591480	NA	-0.63	-9.48	-0.4	1.31e-19	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03031660	chr17:73257791	MRPS7;GGA3	0.44	7.44	0.33	5.01e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg16301924	chr13:53314226	LECT1	-0.41	-7.8	-0.34	4.09e-14	Lewy body disease;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.57	-0.33	2.05e-13	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg23625390	chr15:77176239	SCAPER	0.5	9.87	0.42	5.63e-21	Blood metabolite levels;
LGG	cis	rs709400	0.663	rs3742458	chr14:103950368	A/G	cg26031613	chr14:104095156	KLC1	0.79	14.01	0.55	1.96e-37	Body mass index;
LGG	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.66	-0.41	2.99e-20	Response to antipsychotic treatment;
LGG	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg21775007	chr8:11205619	TDH	-0.51	-8.23	-0.36	1.93e-15	Triglycerides;
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03517284	chr6:25882590	NA	-0.51	-9.83	-0.42	7.68e-21	Height;
LGG	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg08528231	chr16:12997261	SHISA9	-0.33	-6.78	-0.3	3.68e-11	Positive affect;Subjective well-being;
LGG	cis	rs4268898	0.662	rs72793213	chr2:24524725	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-12.57	-0.5	2.15e-31	Asthma;
LGG	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14240646	chr10:27532245	ACBD5	-0.75	-10.33	-0.43	1.18e-22	Breast cancer;
LGG	cis	rs2624839	0.704	rs12632110	chr3:50224225	A/G	cg24110177	chr3:50126178	RBM5	0.43	6.99	0.31	9.46e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg00717180	chr2:96193071	NA	0.41	7.3	0.32	1.24e-12	HDL cholesterol;
LGG	trans	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.47e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg25019033	chr10:957182	NA	-0.51	-9.27	-0.4	7.01e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg21948465	chr5:131705150	SLC22A5	0.65	7.17	0.32	2.94e-12	Rheumatoid arthritis;
LGG	trans	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.46	0.5	6.41e-31	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg00198680	chr16:28758506	NA	0.29	7.19	0.32	2.64e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg05926928	chr17:57297772	GDPD1	-0.86	-13.35	-0.53	1.23e-34	Opioid sensitivity;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-6.95	-0.31	1.27e-11	Height;
LGG	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.32	-0.32	1.13e-12	Inflammatory bowel disease;
LGG	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg04398451	chr17:18023971	MYO15A	-0.82	-18.26	-0.65	1.63e-56	Total body bone mineral density;
LGG	cis	rs1941023	0.567	rs955019	chr11:60174250	C/T	cg08716584	chr11:60157161	MS4A7	-0.36	-7.14	-0.31	3.61e-12	Congenital heart disease (maternal effect);
LGG	cis	rs7428	0.545	rs9248	chr2:85537312	G/A	cg24342717	chr2:85555507	TGOLN2	-0.71	-13.37	-0.53	1.06e-34	Ear protrusion;
LGG	cis	rs644799	0.562	rs1313288	chr11:95520695	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.25	0.52	3.34e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7100689	0.622	rs10736344	chr10:82133955	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs9487094	0.645	rs12529505	chr6:109946561	A/G	cg01125227	chr6:109776195	MICAL1	-0.47	-7.41	-0.33	5.98e-13	Height;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00864171	chr11:67383662	NA	0.61	10.57	0.44	1.52e-23	Mean corpuscular volume;
LGG	cis	rs2735413	0.564	rs73580826	chr16:78110889	G/T	cg04733911	chr16:78082701	NA	0.58	8.09	0.35	5.29e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg19223190	chr17:80058835	NA	0.44	8.38	0.36	6.21e-16	Life satisfaction;
LGG	cis	rs12476592	0.602	rs2604613	chr2:63832776	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.48e-11	Childhood ear infection;
LGG	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.37	0.32	7.89e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9443189	0.855	rs2842554	chr6:76455557	C/A	cg01950844	chr6:76311363	SENP6	-0.53	-6.98	-0.31	1.01e-11	Prostate cancer;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg23743428	chr13:21893420	NA	-0.46	-10.53	-0.44	2.12e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg00564723	chr10:75632066	CAMK2G	0.33	7.36	0.32	8.41e-13	Inflammatory bowel disease;
LGG	cis	rs2153535	0.580	rs9393033	chr6:8521446	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.81e-22	Motion sickness;
LGG	cis	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.58	-0.44	1.41e-23	Bladder cancer;
LGG	cis	rs1021993	0.545	rs76438740	chr1:209539726	G/A	cg24446417	chr1:209558027	NA	-0.72	-10.73	-0.45	3.78e-24	Gut microbiome composition (winter);
LGG	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg20991723	chr1:152506922	NA	-0.71	-14.37	-0.56	5.47e-39	Hair morphology;
LGG	cis	rs1909881	0.935	rs11783284	chr8:96521423	A/T	cg04203453	chr8:96504381	NA	1.1	19.7	0.68	3.33e-63	Obesity-related traits;
LGG	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-11.02	-0.46	3.06e-25	Presence of antiphospholipid antibodies;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10445487	chr16:75599896	GABARAPL2	0.41	6.74	0.3	4.59e-11	Cognitive performance;
LGG	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.53	-0.33	2.76e-13	Morning vs. evening chronotype;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg22903471	chr2:27725779	GCKR	-0.57	-12.92	-0.51	8.19e-33	Total body bone mineral density;
LGG	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15128208	chr22:42549153	NA	0.5	10.16	0.43	5.08e-22	Cognitive function;
LGG	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg02493740	chr2:85810744	VAMP5	-0.41	-7.39	-0.32	6.74e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg03036210	chr16:89904091	SPIRE2	-0.6	-7.22	-0.32	2.08e-12	Skin colour saturation;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.74	0.34	6.38e-14	Testicular germ cell tumor;
LGG	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg03929089	chr4:120376271	NA	0.84	8.71	0.38	5.6e-17	Myopia (pathological);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05669157	chr7:72742156	TRIM50;FKBP6	0.42	7.15	0.32	3.51e-12	Pancreatic cancer;
LGG	trans	rs931812	0.825	rs55818461	chr8:101899229	T/C	cg20993868	chr7:22813445	NA	0.71	13.42	0.53	6.28e-35	Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg12395012	chr8:11607386	GATA4	0.43	7.41	0.33	5.89e-13	Myopia (pathological);
LGG	cis	rs7444	0.941	rs73166622	chr22:21938863	G/C	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.57e-11	Systemic lupus erythematosus;
LGG	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg07636037	chr3:49044803	WDR6	0.6	10.47	0.44	3.68e-23	Resting heart rate;
LGG	cis	rs4938330	0.608	rs2239012	chr11:117088362	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-7.54	-0.33	2.51e-13	Blood protein levels;
LGG	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.76	-0.3	4.17e-11	Educational attainment;
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.61	-0.41	4.67e-20	Systolic blood pressure;
LGG	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg14703610	chr5:56206110	C5orf35	0.42	7.44	0.33	4.9e-13	Breast cancer;Breast cancer (early onset);
LGG	cis	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.73	-0.56	1.49e-40	Extrinsic epigenetic age acceleration;
LGG	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.38	0.47	1.3e-26	Hemoglobin concentration;
LGG	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg25174290	chr11:3078921	CARS	0.68	13.47	0.53	4.08e-35	Type 2 diabetes;
LGG	cis	rs9796	0.870	rs4244584	chr15:41259523	A/G	cg18705301	chr15:41695430	NDUFAF1	0.47	8.29	0.36	1.22e-15	Menopause (age at onset);
LGG	cis	rs7568458	0.636	rs11126995	chr2:85792408	A/T	cg17127132	chr2:85788382	GGCX	0.49	7.75	0.34	5.88e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs11628318	0.515	rs12435280	chr14:103125059	A/C	cg12046867	chr14:103022105	NA	0.42	8.03	0.35	7.89e-15	Platelet count;
LGG	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-16.52	-0.61	1.55e-48	Asthma;
LGG	cis	rs2247341	0.965	rs2854921	chr4:1715250	C/T	cg07465881	chr4:1713556	SLBP	-0.47	-7.63	-0.33	1.33e-13	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14829155	chr15:31115871	NA	0.67	11.3	0.46	2.61e-26	Huntington's disease progression;
LGG	cis	rs7107174	1.000	rs2511157	chr11:77972632	G/A	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg06028605	chr16:24865363	SLC5A11	0.51	8.57	0.37	1.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.649	rs6713281	chr2:39235330	G/T	cg04010122	chr2:39346883	SOS1	-0.79	-7.08	-0.31	5.48e-12	Corticobasal degeneration;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg09307838	chr4:120376055	NA	0.79	12.96	0.52	5.65e-33	Corneal astigmatism;
LGG	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.42	-0.36	4.93e-16	Type 2 diabetes;
LGG	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.76	0.3	4.04e-11	Glomerular filtration rate;
LGG	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg02811702	chr13:24901961	NA	0.4	7.48	0.33	3.87e-13	Obesity-related traits;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg05665937	chr4:1216051	CTBP1	-0.56	-10.37	-0.43	8.56e-23	Obesity-related traits;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12379764	chr21:47803548	PCNT	-0.48	-7.68	-0.34	9.41e-14	Testicular germ cell tumor;
LGG	cis	rs9640161	0.789	rs4554381	chr7:150025567	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.76	-15.94	-0.6	6.25e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg13206674	chr6:150067644	NUP43	0.65	14.64	0.56	3.8e-40	Lung cancer;
LGG	cis	rs897984	0.646	rs9938088	chr16:30830004	G/A	cg00531865	chr16:30841666	NA	-0.68	-16.17	-0.6	5.89e-47	Dementia with Lewy bodies;
LGG	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg23815491	chr16:72088622	HP	0.52	11.78	0.48	3.41e-28	Fibrinogen levels;
LGG	cis	rs7394190	0.630	rs4746150	chr10:75565935	A/G	cg07699608	chr10:75541558	CHCHD1	0.54	6.87	0.3	2.13e-11	Incident atrial fibrillation;
LGG	cis	rs3820068	0.705	rs59502343	chr1:15872617	T/C	cg05660106	chr1:15850417	CASP9	1.14	26.95	0.78	6.62e-97	Systolic blood pressure;
LGG	cis	rs4417704	0.551	rs4315517	chr2:241894906	T/G	cg14055004	chr2:241860995	NA	0.28	7.35	0.32	9.34e-13	Joint mobility (Beighton score);
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg07120314	chr15:79043507	NA	-0.71	-15.82	-0.59	2.21e-45	Coronary artery disease or large artery stroke;
LGG	cis	rs511515	1	rs511515	chr6:33541507	A/G	cg07679836	chr6:33548423	BAK1	0.61	10.06	0.42	1.14e-21	Eosinophil counts;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LGG	cis	rs7107174	1.000	rs10899476	chr11:78051794	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.41	-0.33	5.87e-13	Testicular germ cell tumor;
LGG	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg05535760	chr7:792225	HEATR2	0.93	14.46	0.56	2.34e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.44	-0.33	5.04e-13	Prostate cancer;
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs78456975	0.739	rs13405352	chr2:1518726	C/T	cg26248373	chr2:1572462	NA	-0.73	-9.73	-0.41	1.8e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg17376030	chr22:41985996	PMM1	-0.62	-10.22	-0.43	2.98e-22	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg25237894	chr2:233734115	C2orf82	0.5	9.58	0.41	5.76e-20	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg13010199	chr12:38710504	ALG10B	-0.53	-10.6	-0.44	1.2e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4743820	0.620	rs55934624	chr9:93917285	T/G	cg14446406	chr9:93919335	NA	-0.9	-15.15	-0.58	2.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9880211	0.800	rs9819856	chr3:136492149	T/C	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs870825	0.616	rs6552808	chr4:185642865	G/T	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg18187862	chr3:45730750	SACM1L	0.55	9.09	0.39	2.99e-18	Primary sclerosing cholangitis;
LGG	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg16583315	chr14:65563665	MAX	-0.36	-6.99	-0.31	9.81e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.69	-0.41	2.41e-20	Lung cancer;
LGG	trans	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.46	0.4	1.54e-19	Gout;
LGG	cis	rs6087990	0.735	rs6058891	chr20:31386347	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	16.83	0.62	5.9e-50	Ulcerative colitis;
LGG	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg04851639	chr8:1020857	NA	-0.45	-8.88	-0.38	1.5e-17	Schizophrenia;
LGG	cis	rs17767392	0.670	rs11849508	chr14:71723064	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.79	-0.34	4.5e-14	Mitral valve prolapse;
LGG	cis	rs10173297	0.686	rs13392120	chr2:3708685	C/T	cg17046650	chr2:3699563	NA	0.67	9.35	0.4	3.8e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg08885076	chr2:99613938	TSGA10	-0.36	-7.28	-0.32	1.48e-12	Chronic sinus infection;
LGG	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.57	9.52	0.4	1e-19	Cognitive ability;
LGG	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.27	0.4	7.29e-19	Blood metabolite levels;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg02640540	chr1:67518911	SLC35D1	0.38	7.4	0.33	6.26e-13	Lymphocyte percentage of white cells;
LGG	cis	rs3206736	0.729	rs6972730	chr7:35190409	A/G	cg13400248	chr7:35225412	NA	0.44	8.01	0.35	9.24e-15	Diastolic blood pressure;
LGG	trans	rs11039798	0.844	rs11040177	chr11:48976211	G/C	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12654349	chr5:56205094	C5orf35	0.79	11.39	0.47	1.16e-26	Initial pursuit acceleration;
LGG	cis	rs6546550	0.835	rs3755389	chr2:70119469	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.05	-0.35	6.9e-15	Prevalent atrial fibrillation;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg05896524	chr21:47604654	C21orf56	-0.59	-10.65	-0.44	8.02e-24	Testicular germ cell tumor;
LGG	cis	rs6838801	1.000	rs7694630	chr4:77556983	C/T	cg17476223	chr4:77663285	SHROOM3	0.38	6.72	0.3	5.51e-11	Cleft lip with or without cleft palate;
LGG	cis	rs1580019	0.563	rs896137	chr7:32579345	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.56	9.41	0.4	2.41e-19	Cognitive ability;
LGG	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg18200150	chr17:30822561	MYO1D	0.74	15.29	0.58	5.19e-43	Schizophrenia;
LGG	cis	rs10197940	0.662	rs4335940	chr2:152275304	A/G	cg19508488	chr2:152266495	RIF1	-0.58	-10.52	-0.44	2.45e-23	Lung cancer;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg11473876	chr11:109292803	C11orf87	0.49	9.66	0.41	3.22e-20	Schizophrenia;
LGG	trans	rs1032833	0.732	rs76649196	chr2:180127956	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.39	0.36	5.92e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	14.19	0.55	3.32e-38	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3762637	1.000	rs7615673	chr3:122125544	G/C	cg24169773	chr3:122142474	KPNA1	-0.57	-9.42	-0.4	2.07e-19	LDL cholesterol levels;
LGG	cis	rs7666738	0.581	rs34205844	chr4:98887494	C/A	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.72e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs453301	0.506	rs476845	chr8:8622877	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.5	0.33	3.31e-13	Joint mobility (Beighton score);
LGG	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	7.79	0.34	4.6e-14	Schizophrenia;
LGG	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg22852734	chr6:133119734	C6orf192	1.17	16.06	0.6	1.87e-46	Type 2 diabetes nephropathy;
LGG	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1256061	0.654	rs1256033	chr14:64745399	A/G	cg23250157	chr14:64679961	SYNE2	0.37	6.81	0.3	3.06e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs59918340	0.764	rs9324542	chr8:142227854	A/T	cg23750338	chr8:142222470	SLC45A4	-0.58	-11.65	-0.48	1.1e-27	Immature fraction of reticulocytes;
LGG	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg05535760	chr7:792225	HEATR2	0.8	12.87	0.51	1.26e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs7169223	0.653	rs8042170	chr15:79096599	G/A	cg03762349	chr15:79060523	ADAMTS7	-0.34	-6.89	-0.3	1.88e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs10504073	0.647	rs4493918	chr8:50015937	C/G	cg00325661	chr8:49890786	NA	0.74	14.19	0.55	3.39e-38	Blood metabolite ratios;
LGG	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.64e-13	HDL cholesterol;
LGG	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg21775007	chr8:11205619	TDH	-0.42	-6.67	-0.3	7.32e-11	Triglycerides;
LGG	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.39	-0.32	7.15e-13	Retinal vascular caliber;
LGG	cis	rs6772849	0.775	rs66822528	chr3:128415097	G/A	cg08795948	chr3:128337044	NA	0.63	9.82	0.42	8.33e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.55e-27	Blood metabolite levels;
LGG	trans	rs1422110	0.681	rs35625401	chr5:85465408	G/A	cg01787110	chr1:109008453	NBPF6	0.72	11.77	0.48	3.59e-28	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7818345	0.569	rs4484715	chr8:19358296	T/G	cg06699216	chr8:19333253	CSGALNACT1	-0.39	-8.43	-0.36	4.53e-16	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.07	0.31	5.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg02002194	chr4:3960332	NA	0.44	8.15	0.35	3.36e-15	Triglycerides;
LGG	cis	rs745570	0.502	rs4889898	chr17:77798404	C/A	cg25456068	chr17:77800718	NA	-0.54	-11.24	-0.46	4.46e-26	Breast cancer;
LGG	cis	rs295140	1.000	rs3739121	chr2:201171014	G/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	cis	rs9310709	0.517	rs616006	chr3:23037791	T/C	cg00327796	chr3:23032191	NA	-0.48	-9.67	-0.41	2.76e-20	Chronic kidney disease and serum creatinine levels;
LGG	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg09873164	chr1:152488093	CRCT1	0.65	15.97	0.6	4.99e-46	Hair morphology;
LGG	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26378065	chr17:18585709	ZNF286B	0.5	9.24	0.39	9.23e-19	Educational attainment (years of education);
LGG	trans	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.0	-0.31	9.29e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs870825	0.929	rs72689256	chr4:185590174	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	18.88	0.66	2.14e-59	Blood protein levels;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.7	-0.48	7.11e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-9.23	-0.39	9.81e-19	Schizophrenia;
LGG	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-8.67	-0.37	7.35e-17	Height;
LGG	cis	rs17767392	1.000	rs34746156	chr14:71752360	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.01	-0.39	5.29e-18	Mitral valve prolapse;
LGG	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.48e-16	Aortic root size;
LGG	cis	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg21775007	chr8:11205619	TDH	0.81	14.18	0.55	3.62e-38	Retinal vascular caliber;
LGG	cis	rs74781061	0.929	rs4887153	chr15:74777042	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.16	-0.32	3.29e-12	Endometriosis;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.32	-0.5	2.23e-30	Lymphocyte counts;
LGG	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg07701084	chr6:150067640	NUP43	-0.48	-7.35	-0.32	9.19e-13	Lung cancer;
LGG	trans	rs1032833	0.660	rs17454458	chr2:180058043	T/G	cg23654767	chr2:101192981	PDCL3	0.67	8.03	0.35	8.02e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs12210905	1.000	rs12196084	chr6:27198204	A/C	cg15325629	chr6:28072465	NA	0.79	6.9	0.31	1.7e-11	Hip circumference adjusted for BMI;
LGG	cis	rs975722	0.613	rs13222797	chr7:117100046	G/T	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.0	-0.39	5.85e-18	Coronary artery disease;
LGG	cis	rs9394152	0.845	rs769051	chr6:33473894	T/G	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.86e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7000551	0.556	rs12674913	chr8:22263617	G/C	cg12081754	chr8:22256438	SLC39A14	1.16	26.61	0.78	2.37e-95	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg09173681	chr1:183549694	NCF2	0.36	8.3	0.36	1.13e-15	Systemic lupus erythematosus;
LGG	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg02023728	chr11:77925099	USP35	0.44	7.65	0.34	1.17e-13	Testicular germ cell tumor;
LGG	cis	rs9733	0.566	rs878471	chr1:150547747	G/A	cg13175981	chr1:150552382	MCL1	0.58	9.81	0.41	8.84e-21	Tonsillectomy;
LGG	cis	rs7614311	0.681	rs6796317	chr3:63927739	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-8.07	-0.35	6.32e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.89	-0.57	3.07e-41	IgG glycosylation;
LGG	cis	rs11874712	0.545	rs9950234	chr18:43653200	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.11	-0.39	2.41e-18	Migraine - clinic-based;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs7309	0.622	rs4664396	chr2:161901650	C/T	cg22496339	chr2:162101262	NA	0.35	6.94	0.31	1.35e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs7937612	0.561	rs10892568	chr11:120252828	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.38	-8.66	-0.37	7.93e-17	Intraocular pressure;
LGG	cis	rs1957429	0.634	rs7143541	chr14:65419777	G/T	cg23373153	chr14:65346875	NA	-0.93	-12.22	-0.49	5.96e-30	Pediatric areal bone mineral density (radius);
LGG	cis	rs2916247	1.000	rs2976506	chr8:92998874	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.32	-0.36	1.03e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg25319279	chr11:5960081	NA	-0.53	-8.51	-0.37	2.43e-16	DNA methylation (variation);
LGG	cis	rs988958	0.675	rs34863191	chr2:42217615	G/A	cg19376973	chr2:42229025	NA	0.6	9.34	0.4	4.17e-19	Hypospadias;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs13424612	0.930	rs4149545	chr2:240942818	G/T	cg01812947	chr2:240904978	NDUFA10	0.44	7.27	0.32	1.59e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs3741151	1.000	rs61037777	chr11:73046663	A/G	cg17517138	chr11:73019481	ARHGEF17	0.94	9.87	0.42	5.66e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	cis	rs526231	0.511	rs1826673	chr5:102345916	G/A	cg23492399	chr5:102201601	PAM	-0.56	-8.38	-0.36	6.52e-16	Primary biliary cholangitis;
LGG	trans	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07923666	chr12:49932857	KCNH3	0.5	7.47	0.33	4.02e-13	Resting heart rate;
LGG	cis	rs7264396	0.635	rs6060720	chr20:34548336	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.89	-0.3	1.83e-11	Total cholesterol levels;
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg10523679	chr1:76189770	ACADM	0.8	14.34	0.55	7.33e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4538187	1.000	rs34122334	chr2:64169309	A/G	cg19915305	chr2:64069682	UGP2	-0.68	-15.3	-0.58	4.47e-43	Systolic blood pressure;
LGG	cis	rs6977660	0.714	rs10228783	chr7:19789290	C/T	cg05791153	chr7:19748676	TWISTNB	0.76	10.23	0.43	2.72e-22	Thyroid stimulating hormone;
LGG	cis	rs9557207	0.653	rs9557171	chr13:99817289	G/A	cg24509225	chr13:100037070	UBAC2	0.63	11.35	0.47	1.71e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs4740619	0.685	rs9298740	chr9:15837289	T/A	cg14451791	chr9:16040625	NA	0.33	8.0	0.35	9.88e-15	Body mass index;
LGG	cis	rs9810089	0.843	rs838202	chr3:136035217	G/A	cg12473912	chr3:136751656	NA	0.41	6.96	0.31	1.19e-11	Gestational age at birth (child effect);
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg21970626	chr13:21893289	NA	-0.4	-9.13	-0.39	2.05e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.1	0.31	4.7e-12	Homoarginine levels;
LGG	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg12658982	chr7:29603541	PRR15	-0.4	-8.46	-0.37	3.54e-16	Facial emotion recognition (angry faces);
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg04287289	chr16:89883240	FANCA	0.83	8.99	0.39	6.18e-18	Skin colour saturation;
LGG	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg22467129	chr15:76604101	ETFA	-0.43	-7.17	-0.32	2.92e-12	Blood metabolite levels;
LGG	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg13010199	chr12:38710504	ALG10B	0.51	10.05	0.42	1.21e-21	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7241530	0.585	rs12455145	chr18:75893361	A/T	cg14642773	chr18:75888474	NA	0.48	9.13	0.39	2.11e-18	Educational attainment (years of education);
LGG	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.64	-0.33	1.22e-13	Testicular germ cell tumor;
LGG	cis	rs2693698	0.525	rs2693674	chr14:99732416	C/G	cg07440398	chr14:99712966	BCL11B	0.47	9.71	0.41	2.05e-20	Schizophrenia;
LGG	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00631329	chr6:26305371	NA	-0.54	-9.63	-0.41	4.03e-20	Educational attainment;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg27471124	chr11:109292789	C11orf87	0.55	10.08	0.42	1e-21	Schizophrenia;
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	cis	rs6993813	0.843	rs28621599	chr8:120030694	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	cis	rs1670533	1.000	rs11247971	chr4:1053580	A/G	cg27284194	chr4:1044797	NA	0.54	9.72	0.41	1.84e-20	Recombination rate (females);
LGG	cis	rs528418	0.592	rs7771768	chr6:145670042	T/C	cg03642472	chr6:145670687	NA	0.55	7.02	0.31	7.75e-12	Methadone dose in opioid dependence;
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.19e-12	Bipolar disorder;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.28	0.32	1.49e-12	Schizophrenia;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.4	0.33	6.52e-13	Prudent dietary pattern;
LGG	cis	rs4936891	0.577	rs11219422	chr11:123920178	C/T	cg22125253	chr11:123886957	OR10G4	-0.52	-8.78	-0.38	3.23e-17	Male fertility;
LGG	cis	rs651907	0.535	rs13085776	chr3:101505507	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	8.72	0.38	5e-17	Colorectal cancer;
LGG	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.55	-0.53	1.75e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg15997130	chr1:24165203	NA	0.47	13.09	0.52	1.61e-33	Immature fraction of reticulocytes;
LGG	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg13736514	chr6:26305472	NA	-0.49	-9.63	-0.41	3.83e-20	Educational attainment;
LGG	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.59	0.37	1.3e-16	Coronary artery disease;
LGG	cis	rs4764124	1.000	rs4764124	chr12:14966604	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.5	9.35	0.4	3.62e-19	Pubertal anthropometrics;
LGG	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg06108461	chr20:60628389	TAF4	-0.68	-12.18	-0.49	8.31e-30	Body mass index;
LGG	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.49	-0.33	3.42e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs17039065	1.000	rs72889396	chr4:109400426	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.83	0.3	2.65e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs1395	0.744	rs1122227	chr2:27544285	C/T	cg22903471	chr2:27725779	GCKR	-0.41	-6.96	-0.31	1.13e-11	Blood metabolite levels;
LGG	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.6	8.27	0.36	1.4e-15	Diabetic retinopathy;
LGG	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg19748678	chr4:122722346	EXOSC9	0.49	9.19	0.39	1.37e-18	Type 2 diabetes;
LGG	cis	rs7129556	0.701	rs11237280	chr11:77456906	A/G	cg12586386	chr11:77299805	AQP11	0.46	7.53	0.33	2.7e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.87	0.34	2.61e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.23	-0.32	2.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs300774	1.000	rs378456	chr2:119346	C/G	cg04617936	chr2:214353	NA	-0.48	-7.05	-0.31	6.6e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg07148914	chr20:33460835	GGT7	0.57	9.5	0.4	1.12e-19	Height;
LGG	cis	rs888194	0.738	rs2241213	chr12:109938857	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-6.69	-0.3	6.6e-11	Neuroticism;
LGG	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg07636037	chr3:49044803	WDR6	-0.8	-13.9	-0.54	5.95e-37	Menarche (age at onset);
LGG	cis	rs77741769	0.529	rs909053	chr12:121237668	G/A	cg02419362	chr12:121203948	SPPL3	0.54	9.42	0.4	2.14e-19	Mean corpuscular volume;
LGG	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg16576597	chr16:28551801	NUPR1	-0.3	-6.78	-0.3	3.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4722166	0.598	rs4722171	chr7:22785717	A/G	cg05265849	chr7:22767390	IL6	0.42	7.83	0.34	3.44e-14	Lung cancer;
LGG	trans	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg23484912	chr5:273055	PDCD6	0.47	9.61	0.41	4.51e-20	Pancreatic cancer;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg14092988	chr3:52407081	DNAH1	0.29	7.88	0.34	2.29e-14	Bipolar disorder;
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19524238	chr7:2802976	GNA12	0.37	8.83	0.38	2.17e-17	Height;
LGG	cis	rs283228	0.535	rs2852512	chr6:101846554	G/A	cg02011392	chr6:101847541	GRIK2	0.48	6.96	0.31	1.2e-11	Coenzyme Q10 levels;
LGG	cis	rs7927771	0.864	rs60075622	chr11:47449101	T/G	cg20307385	chr11:47447363	PSMC3	-0.58	-10.61	-0.44	1.14e-23	Subjective well-being;
LGG	cis	rs17739167	0.569	rs11638621	chr15:42228226	C/T	cg20935245	chr15:42234343	EHD4	0.45	8.81	0.38	2.51e-17	Monocyte count;
LGG	cis	rs6942756	1.000	rs6467233	chr7:128868656	C/T	cg02491457	chr7:128862824	NA	-0.77	-14.22	-0.55	2.56e-38	White matter hyperintensity burden;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg20308403	chr7:2120281	MAD1L1	0.35	7.32	0.32	1.08e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg20746552	chr10:63809108	ARID5B	0.39	7.52	0.33	2.83e-13	Systemic lupus erythematosus;
LGG	cis	rs225245	0.782	rs321618	chr17:33912404	A/G	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00149659	chr3:10157352	C3orf10	1.19	13.96	0.54	3.35e-37	Alzheimer's disease;
LGG	trans	rs2235573	0.594	rs4821730	chr22:38441587	A/G	cg19894588	chr14:64061835	NA	0.51	8.68	0.37	6.79e-17	Glioblastoma;Glioma;
LGG	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-23.12	-0.73	3.4e-79	Coronary artery disease;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg06221963	chr1:154839813	KCNN3	-0.52	-10.74	-0.45	3.56e-24	Prostate cancer;
LGG	cis	rs1580019	0.961	rs11765387	chr7:32494790	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs9467773	1.000	rs1078679	chr6:26568741	C/T	cg11502198	chr6:26597334	ABT1	0.59	10.11	0.43	7.78e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	5.9e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03517284	chr6:25882590	NA	-0.49	-9.31	-0.4	5.17e-19	Blood metabolite levels;
LGG	cis	rs921968	0.643	rs612874	chr2:219492924	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.05	-0.31	6.54e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg07511668	chr11:68622177	NA	-0.36	-7.29	-0.32	1.36e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9398803	0.687	rs12208811	chr6:126926898	T/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg26384229	chr12:38710491	ALG10B	0.64	12.17	0.49	9.11e-30	Morning vs. evening chronotype;
LGG	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.52	0.56	1.21e-39	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg26116260	chr4:7069785	GRPEL1	-1.11	-10.93	-0.45	6.96e-25	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17253792	0.822	rs10139905	chr14:56170031	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-12.83	-0.51	1.87e-32	Putamen volume;
LGG	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	7.78	0.34	4.91e-14	Retinal vascular caliber;
LGG	cis	rs5769707	0.632	rs135871	chr22:50008969	A/G	cg06623630	chr22:50017776	C22orf34	-0.47	-9.42	-0.4	2.16e-19	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7166081	1.000	rs12910062	chr15:67537210	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.75	-0.3	4.52e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9354308	0.764	rs13203686	chr6:66607161	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg06271696	chr7:157225062	NA	0.39	7.74	0.34	6.14e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.14	0.39	1.95e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.25	-0.46	4.12e-26	Prostate cancer;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.66	0.34	1.06e-13	Longevity;
LGG	cis	rs7106204	0.620	rs16912295	chr11:24260162	T/C	ch.11.24196551F	chr11:24239977	NA	0.86	9.48	0.4	1.34e-19	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.4	7.03	0.31	7.53e-12	Bipolar disorder;
LGG	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg27284194	chr4:1044797	NA	0.56	11.71	0.48	6.33e-28	Recombination rate (males);
LGG	cis	rs367615	0.660	rs4632850	chr5:108832883	C/G	cg17395555	chr5:108820864	NA	0.87	15.71	0.59	6.78e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-10.27	-0.43	2.03e-22	Personality dimensions;
LGG	trans	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-31.88	-0.83	7.02e-119	Exhaled nitric oxide output;
LGG	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg18258770	chr4:90757814	SNCA	-0.38	-6.99	-0.31	9.84e-12	Dementia with Lewy bodies;
LGG	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.88	-0.42	5.05e-21	Multiple myeloma;
LGG	cis	rs258892	0.793	rs61141607	chr5:72056883	T/A	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg02951883	chr7:2050386	MAD1L1	0.45	7.25	0.32	1.75e-12	Neuroticism;
LGG	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg06634786	chr22:41940651	POLR3H	-0.54	-8.73	-0.38	4.57e-17	Neuroticism;
LGG	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.41	0.4	2.32e-19	Lung cancer in ever smokers;
LGG	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg09696939	chr10:60272079	BICC1	0.37	7.17	0.32	3e-12	Refractive error;
LGG	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg26597838	chr10:835615	NA	0.52	6.82	0.3	2.81e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs9951602	0.512	rs4799244	chr18:76649763	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.23	-0.36	1.94e-15	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg08807101	chr21:30365312	RNF160	0.63	10.46	0.44	3.79e-23	Pancreatic cancer;
LGG	cis	rs2066819	1.000	rs11575232	chr12:56744422	G/A	cg26714650	chr12:56694279	CS	-1.59	-15.54	-0.59	4.08e-44	Psoriasis vulgaris;
LGG	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg25319279	chr11:5960081	NA	-0.47	-7.7	-0.34	8.21e-14	DNA methylation (variation);
LGG	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg24101359	chr6:42928495	GNMT	0.38	8.7	0.37	5.89e-17	Blood protein levels;
LGG	cis	rs10214930	0.606	rs4719900	chr7:27568121	T/A	cg22168087	chr7:27702803	HIBADH	0.45	6.77	0.3	3.84e-11	Hypospadias;
LGG	cis	rs2120243	0.539	rs2085315	chr3:157112622	T/G	cg24825693	chr3:157122686	VEPH1	-0.58	-13.53	-0.53	2.17e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.46	0.37	3.55e-16	Mean corpuscular hemoglobin;
LGG	cis	rs2302729	0.625	rs12228313	chr12:2831297	C/T	cg19945202	chr12:2788847	CACNA1C	0.7	9.1	0.39	2.65e-18	Sleep quality;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg20607798	chr8:58055168	NA	0.68	7.77	0.34	5.28e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg22920501	chr2:26401640	FAM59B	-0.43	-8.71	-0.38	5.41e-17	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.857	rs55811995	chr18:34622341	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs2832191	1.000	rs8131214	chr21:30483386	T/G	cg24692254	chr21:30365293	RNF160	-0.88	-19.92	-0.68	3.12e-64	Dental caries;
LGG	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Calcium levels;
LGG	cis	rs7662987	0.517	rs1154405	chr4:100008750	G/A	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.79e-20	Smoking initiation;
LGG	cis	rs500492	0.542	rs449295	chr16:1074443	G/A	cg08273874	chr16:1060765	NA	-0.57	-8.17	-0.35	3.05e-15	Polycystic ovary syndrome;
LGG	cis	rs4330281	0.715	rs11128849	chr3:17764670	T/C	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs9398803	0.687	rs9491652	chr6:126943620	G/C	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.65	-0.3	8.37e-11	Mood instability;
LGG	cis	rs34172651	0.917	rs11646987	chr16:24832408	G/T	cg02428538	chr16:24856791	SLC5A11	-0.43	-7.3	-0.32	1.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg07120314	chr15:79043507	NA	-0.68	-12.48	-0.5	5.1e-31	Coronary artery disease or large artery stroke;
LGG	cis	rs7444	0.941	rs2266959	chr22:21922904	G/T	cg22858872	chr22:21984481	YDJC	-0.37	-6.73	-0.3	4.94e-11	Systemic lupus erythematosus;
LGG	cis	rs4888262	0.526	rs12921903	chr16:74625575	C/T	cg01733217	chr16:74700730	RFWD3	0.88	17.99	0.64	2.93e-55	Testicular germ cell tumor;
LGG	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg26384229	chr12:38710491	ALG10B	0.72	14.35	0.55	6.88e-39	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg08344181	chr3:125677491	NA	-0.65	-7.73	-0.34	6.73e-14	Depression;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11875185	0.510	rs76522780	chr18:55595203	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9596863	0.898	rs9568924	chr13:54360952	T/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.13	0.31	3.99e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.97	0.45	4.82e-25	Morning vs. evening chronotype;
LGG	cis	rs17384381	0.863	rs12140272	chr1:85789757	G/A	cg16011679	chr1:85725395	C1orf52	0.61	10.27	0.43	2.01e-22	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg02030672	chr11:45687055	CHST1	0.5	8.79	0.38	3.03e-17	Obesity-related traits;
LGG	cis	rs490234	0.627	rs4838276	chr9:128364901	A/G	cg14078157	chr9:128172775	NA	0.53	9.97	0.42	2.36e-21	Mean arterial pressure;
LGG	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.36	-0.58	2.63e-43	Chronic sinus infection;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.41	-8.44	-0.37	3.97e-16	Schizophrenia;
LGG	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg04673462	chr1:38461896	NA	0.46	8.96	0.38	8.17e-18	Coronary artery disease;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg05863683	chr7:1912471	MAD1L1	-0.45	-9.35	-0.4	3.71e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg23920097	chr1:209922102	NA	0.43	7.25	0.32	1.81e-12	Red blood cell count;
LGG	cis	rs4149577	0.630	rs4149570	chr12:6451590	A/C	cg11268190	chr12:6442526	TNFRSF1A	0.32	8.08	0.35	5.68e-15	Monocyte count;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.11	-0.57	3.1e-42	Platelet count;
LGG	cis	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg06521331	chr12:34319734	NA	-0.63	-11.43	-0.47	7.74e-27	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg05368731	chr17:41323189	NBR1	0.92	17.95	0.64	4.51e-55	Menopause (age at onset);
LGG	cis	rs12474201	0.630	rs897529	chr2:46948175	T/C	cg06386533	chr2:46925753	SOCS5	0.61	10.66	0.44	7.19e-24	Height;
LGG	cis	rs6456156	1.000	rs9457274	chr6:167520865	G/T	cg07741184	chr6:167504864	NA	0.33	7.44	0.33	4.86e-13	Primary biliary cholangitis;
LGG	cis	rs2274273	0.870	rs8018110	chr14:55641714	C/T	cg04306507	chr14:55594613	LGALS3	0.65	17.95	0.64	4.29e-55	Protein biomarker;
LGG	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs2120243	0.534	rs35004310	chr3:157113800	C/T	cg24825693	chr3:157122686	VEPH1	-0.58	-13.49	-0.53	3.16e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs733592	0.507	rs56129148	chr12:48485530	T/C	cg24011408	chr12:48396354	COL2A1	-0.69	-12.22	-0.49	5.77e-30	Plateletcrit;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.78	-0.48	3.28e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg17294928	chr15:75287854	SCAMP5	-0.99	-19.24	-0.67	4.87e-61	Blood trace element (Zn levels);
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg06654118	chr4:1303317	MAEA	0.49	8.59	0.37	1.33e-16	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs2592102	chr2:233726772	G/T	cg25237894	chr2:233734115	C2orf82	-0.66	-12.53	-0.5	3.35e-31	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs28465658	chr4:99035866	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7267979	1.000	rs404394	chr20:25447896	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3106136	0.967	rs3113862	chr4:95143122	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.96	-0.35	1.38e-14	Capecitabine sensitivity;
LGG	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg11342453	chr6:26196699	NA	0.49	6.81	0.3	3.06e-11	Gout;Renal underexcretion gout;
LGG	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-10.13	-0.43	6.21e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg21775007	chr8:11205619	TDH	-0.56	-8.78	-0.38	3.16e-17	Retinal vascular caliber;
LGG	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-7.76	-0.34	5.4e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.93	0.38	9.93e-18	Colorectal cancer;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg14789911	chr21:47582049	C21orf56	-0.49	-8.68	-0.37	6.95e-17	Testicular germ cell tumor;
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.5	-8.05	-0.35	6.92e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	2.11e-13	Menarche (age at onset);
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg09264619	chr17:80180166	NA	-0.37	-7.44	-0.33	4.94e-13	Life satisfaction;
LGG	cis	rs1707322	0.721	rs9793568	chr1:46130373	G/A	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg02462569	chr6:150064036	NUP43	0.41	8.85	0.38	1.91e-17	Lung cancer;
LGG	trans	rs12517041	1.000	rs12520032	chr5:23285074	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.9	-0.45	8.86e-25	Calcium levels;
LGG	cis	rs9462027	0.628	rs6929567	chr6:34692735	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg26396452	chr14:65542826	MAX	0.49	10.23	0.43	2.71e-22	Obesity-related traits;
LGG	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06470251	chr20:60548479	NA	0.42	7.28	0.32	1.43e-12	Body mass index;
LGG	cis	rs8067545	0.750	rs7208635	chr17:19990990	T/C	cg13482628	chr17:19912719	NA	0.61	12.13	0.49	1.38e-29	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.39	0.36	5.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg22676075	chr6:135203613	NA	0.42	7.17	0.32	2.91e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.49e-12	Prudent dietary pattern;
LGG	cis	rs7172689	1.000	rs11634673	chr15:81535789	G/A	cg11808699	chr15:81528661	IL16	-0.51	-10.19	-0.43	3.74e-22	Inattentive symptoms;
LGG	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg00198680	chr16:28758506	NA	0.28	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11122272	0.701	rs2883799	chr1:231531166	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.34	-0.36	8.54e-16	Breast cancer;
LGG	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Colorectal cancer;
LGG	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	Cognitive function;
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-9.13	-0.39	2.06e-18	Vitiligo;
LGG	cis	rs9534288	0.797	rs7989351	chr13:46534080	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-12.86	-0.51	1.37e-32	Blood protein levels;
LGG	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg12395012	chr8:11607386	GATA4	0.39	7.25	0.32	1.75e-12	Neuroticism;
LGG	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.41	-0.36	5.13e-16	Neuroticism;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.7e-12	Lung cancer;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.71	-0.34	7.98e-14	Personality dimensions;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20590175	chr12:132530165	EP400	0.38	7.35	0.32	8.81e-13	Electrocardiographic conduction measures;
LGG	cis	rs17384381	1.000	rs12129502	chr1:85900727	T/C	cg16011679	chr1:85725395	C1orf52	0.62	10.64	0.44	8.33e-24	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.12	0.31	4.23e-12	Retinal vascular caliber;
LGG	cis	rs7717393	0.786	rs7714142	chr5:155771022	C/T	cg04435420	chr5:155754009	SGCD	0.77	9.5	0.4	1.11e-19	Egg allergy;
LGG	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg19507638	chr5:93509721	C5orf36	0.4	7.15	0.32	3.4e-12	Diabetic retinopathy;
LGG	cis	rs9287719	0.904	rs55738250	chr2:10757132	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08704884	chr19:59070524	UBE2M;LOC100131691	0.49	7.11	0.31	4.4e-12	Gut microbiome composition (summer);
LGG	cis	rs10089	0.857	rs7718286	chr5:127459414	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs2084898	1.000	rs55920307	chr11:120042846	A/G	cg07435449	chr11:120005650	TRIM29	-0.68	-7.89	-0.34	2.24e-14	Stroke (pediatric);
LGG	cis	rs757081	0.636	rs664382	chr11:17206519	A/T	cg15432903	chr11:17409602	KCNJ11	-0.49	-8.3	-0.36	1.19e-15	Systolic blood pressure;
LGG	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg11814155	chr7:99998594	ZCWPW1	0.45	6.65	0.3	8.11e-11	Lung function (FEV1/FVC);
LGG	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg20935368	chr5:178288625	ZNF354B	0.36	7.2	0.32	2.38e-12	Sleep duration;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25172604	chr17:41446521	NA	-0.3	-6.98	-0.31	9.96e-12	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10189230	0.935	rs1864461	chr2:222347615	A/G	cg14652038	chr2:222343519	EPHA4	0.61	12.63	0.51	1.28e-31	Urate levels in lean individuals;
LGG	cis	rs873946	0.648	rs1548281	chr10:134552982	C/T	cg13271783	chr10:134563150	INPP5A	-0.53	-7.7	-0.34	8.48e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7412746	0.658	rs12405726	chr1:150956128	G/A	cg15448220	chr1:150897856	SETDB1	0.38	6.88	0.3	2e-11	Melanoma;
LGG	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg03806693	chr22:41940476	POLR3H	1.01	17.0	0.62	1.04e-50	Vitiligo;
LGG	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	trans	rs783540	1.000	rs11637433	chr15:83321336	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.31	-0.32	1.17e-12	Schizophrenia;
LGG	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs751728	0.605	rs1535950	chr6:33785827	A/G	cg25922239	chr6:33757077	LEMD2	0.5	7.9	0.34	2.02e-14	Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01302669	chr3:49824110	IP6K1	0.41	6.67	0.3	7.25e-11	Cognitive performance;
LGG	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg26513180	chr16:89883248	FANCA	-0.52	-9.23	-0.39	9.36e-19	Vitiligo;
LGG	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg18850127	chr7:39170497	POU6F2	0.35	8.15	0.35	3.55e-15	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07786668	chr16:73092391	ZFHX3	-0.5	-7.26	-0.32	1.62e-12	Systemic lupus erythematosus;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.36	6.69	0.3	6.56e-11	Longevity;
LGG	cis	rs3762318	0.806	rs1321156	chr1:67604702	C/G	cg17031739	chr1:67600172	NA	-0.49	-7.09	-0.31	4.89e-12	Leprosy;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-13.5	-0.53	3.03e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4740619	0.905	rs10962167	chr9:15800846	T/A	cg14451791	chr9:16040625	NA	-0.4	-10.18	-0.43	4.38e-22	Body mass index;
LGG	cis	rs10463554	0.655	rs152138	chr5:102559428	C/G	cg23492399	chr5:102201601	PAM	-0.52	-7.58	-0.33	1.91e-13	Parkinson's disease;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg25437947	chr8:17941982	ASAH1	-0.42	-7.04	-0.31	6.9e-12	Brain structure;
LGG	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg06951627	chr6:26196580	NA	0.51	7.82	0.34	3.53e-14	Gout;Renal underexcretion gout;
LGG	cis	rs17534004	1.000	rs17534137	chr13:31471920	G/A	cg00367615	chr13:31480979	C13orf33	0.36	7.22	0.32	2.12e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs250677	0.687	rs36048	chr5:148441713	G/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.67e-12	Breast cancer;
LGG	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg24209194	chr3:40518798	ZNF619	-0.43	-7.16	-0.32	3.29e-12	Renal cell carcinoma;
LGG	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg24692254	chr21:30365293	RNF160	0.82	16.81	0.62	7.5e-50	Selective IgA deficiency;
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg02002194	chr4:3960332	NA	-0.44	-8.46	-0.37	3.65e-16	Monocyte count;
LGG	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg11871910	chr12:69753446	YEATS4	0.72	14.31	0.55	1.01e-38	Blood protein levels;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06028808	chr11:68637592	NA	0.64	11.07	0.46	1.94e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.87	-0.34	2.49e-14	Menarche (age at onset);
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11905131	chr22:24372483	LOC391322	0.45	7.62	0.33	1.41e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg18240062	chr17:79603768	NPLOC4	0.72	13.49	0.53	3.41e-35	Eye color traits;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06250734	chr16:46723432	ORC6L;VPS35	0.41	6.98	0.31	1.06e-11	Bipolar disorder;
LGG	cis	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.39	-0.36	6.04e-16	Ulcerative colitis;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	trans	rs3960554	0.932	rs11971220	chr7:75842792	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	11.56	0.47	2.57e-27	Eotaxin levels;
LGG	cis	rs4535700	0.501	rs6943341	chr7:55975182	A/T	cg17215666	chr7:56131930	SUMF2	-0.46	-6.94	-0.31	1.35e-11	Macular telangiectasia type 2;
LGG	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.25	0.32	1.73e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.48	0.53	3.56e-35	Anterior chamber depth;
LGG	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.41	0.53	7.18e-35	Breast cancer;
LGG	cis	rs6977660	1.000	rs13230910	chr7:19806003	A/G	cg07541023	chr7:19748670	TWISTNB	-0.47	-7.38	-0.32	7.18e-13	Thyroid stimulating hormone;
LGG	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg25039879	chr17:56429692	SUPT4H1	0.62	8.54	0.37	1.99e-16	Cognitive test performance;
LGG	cis	rs9393777	0.513	rs7740197	chr6:26663478	C/T	cg12826209	chr6:26865740	GUSBL1	-0.83	-12.49	-0.5	4.69e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06470251	chr20:60548479	NA	0.4	6.94	0.31	1.35e-11	Body mass index;
LGG	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg08344181	chr3:125677491	NA	-0.6	-6.96	-0.31	1.14e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2077654	0.818	rs4148636	chr11:17427363	A/G	cg25308976	chr11:17434268	ABCC8	-0.74	-9.56	-0.41	7.02e-20	Gout;
LGG	cis	rs2013441	1.000	rs2526464	chr17:20075052	A/G	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg23625390	chr15:77176239	SCAPER	0.52	10.45	0.44	4.34e-23	Blood metabolite levels;
LGG	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg14829360	chr17:73884958	NA	-0.56	-10.76	-0.45	3.06e-24	White matter hyperintensity burden;
LGG	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg16414030	chr3:133502952	NA	-0.49	-7.98	-0.35	1.18e-14	Iron status biomarkers;
LGG	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg19507638	chr5:93509721	C5orf36	0.4	7.19	0.32	2.62e-12	Diabetic retinopathy;
LGG	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs35160687	0.865	rs10189492	chr2:86478902	G/A	cg10973622	chr2:86423274	IMMT	0.41	7.01	0.31	8.54e-12	Night sleep phenotypes;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.96	0.35	1.35e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg04398451	chr17:18023971	MYO15A	-0.64	-10.81	-0.45	2.01e-24	Total body bone mineral density;
LGG	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg24130564	chr14:104152367	KLC1	-0.39	-7.21	-0.32	2.32e-12	Reticulocyte count;
LGG	cis	rs9815354	0.767	rs17281182	chr3:41817263	C/T	cg03022575	chr3:42003672	ULK4	0.78	8.96	0.38	7.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.92	-0.31	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18876405	chr7:65276391	NA	0.64	11.81	0.48	2.62e-28	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24727343	chr7:121418840	NA	0.42	7.99	0.35	1.05e-14	Gut microbiome composition (summer);
LGG	cis	rs459571	0.959	rs467379	chr9:136905474	C/T	cg13789015	chr9:136890014	NCRNA00094	0.58	10.6	0.44	1.14e-23	Platelet distribution width;
LGG	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs56235845	0.694	rs12055081	chr5:176757191	C/T	cg17509989	chr5:176798049	RGS14	0.65	10.85	0.45	1.41e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs7568458	0.846	rs6743030	chr2:85763520	C/T	cg17127132	chr2:85788382	GGCX	0.47	8.13	0.35	3.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg08975724	chr8:8085496	FLJ10661	0.52	9.6	0.41	5.24e-20	Red cell distribution width;
LGG	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	7.89	0.34	2.19e-14	Menarche (age at onset);
LGG	cis	rs9549367	0.673	rs575453	chr13:113837871	C/A	cg00898013	chr13:113819073	PROZ	0.48	9.85	0.42	6.6e-21	Platelet distribution width;
LGG	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg19680485	chr15:31195859	MTMR15	-0.44	-6.72	-0.3	5.33e-11	Huntington's disease progression;
LGG	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-6.7	-0.3	5.97e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg23834254	chr4:169931521	CBR4	0.64	6.67	0.3	7.36e-11	Kashin-Beck disease;
LGG	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg05527609	chr1:210001259	C1orf107	0.6	9.68	0.41	2.65e-20	Orofacial clefts;
LGG	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.35	-0.53	1.32e-34	Personality dimensions;
LGG	cis	rs42648	0.567	rs12669304	chr7:89891040	T/C	cg25739043	chr7:89950458	NA	-0.35	-7.39	-0.32	6.8e-13	Homocysteine levels;
LGG	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-7.7	-0.34	8.1e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-9.91	-0.42	3.93e-21	Colorectal cancer;
LGG	cis	rs5742933	0.652	rs10210345	chr2:190619486	G/C	cg10453823	chr2:190539512	ANKAR	-0.47	-6.84	-0.3	2.48e-11	Ferritin levels;
LGG	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.08	-0.31	5.23e-12	Iron status biomarkers;
LGG	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg00129232	chr17:37814104	STARD3	-0.69	-13.95	-0.54	3.63e-37	Asthma;
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	cis	rs2932538	0.961	rs3013441	chr1:113192605	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-10.39	-0.43	6.96e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg07005078	chr4:17578674	LAP3	-0.37	-6.72	-0.3	5.34e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs514406	0.683	rs6588440	chr1:53209587	C/T	cg24675658	chr1:53192096	ZYG11B	0.62	13.13	0.52	1.08e-33	Monocyte count;
LGG	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg22903471	chr2:27725779	GCKR	-0.53	-12.14	-0.49	1.27e-29	Total body bone mineral density;
LGG	cis	rs774359	1.000	rs774356	chr9:27559721	T/C	cg21249376	chr9:27528432	MOBKL2B	0.4	7.47	0.33	3.97e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg02023728	chr11:77925099	USP35	0.46	7.88	0.34	2.31e-14	Testicular germ cell tumor;
LGG	cis	rs7236492	0.505	rs11663549	chr18:77181989	A/G	cg15644404	chr18:77186268	NFATC1	0.78	8.81	0.38	2.56e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2075371	0.931	rs1646697	chr7:133999930	G/A	cg20476274	chr7:133979776	SLC35B4	0.76	14.94	0.57	1.78e-41	Mean platelet volume;
LGG	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg08085267	chr17:45401833	C17orf57	-0.75	-14.97	-0.57	1.37e-41	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8016982	0.674	rs2288499	chr14:81660997	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	19.73	0.68	2.53e-63	Schizophrenia;
LGG	cis	rs12780845	0.505	rs10795459	chr10:17244124	C/T	cg01003015	chr10:17271136	VIM	-0.43	-7.51	-0.33	3.15e-13	Homocysteine levels;
LGG	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.96	-0.42	2.7e-21	Sudden cardiac arrest;
LGG	cis	rs11608355	1.000	rs7958625	chr12:109869218	A/T	cg19025524	chr12:109796872	NA	-0.49	-9.18	-0.39	1.39e-18	Neuroticism;
LGG	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg04503457	chr17:41445688	NA	-0.38	-8.71	-0.38	5.46e-17	Menopause (age at onset);
LGG	cis	rs8064024	0.508	rs2037912	chr16:4933939	G/C	cg04440724	chr16:4920505	UBN1	0.56	11.96	0.49	6.38e-29	Cancer;
LGG	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg02023728	chr11:77925099	USP35	0.44	7.64	0.33	1.25e-13	Testicular germ cell tumor;
LGG	cis	rs4974559	1.000	rs1882099	chr4:1352685	A/G	cg02980000	chr4:1222292	CTBP1	0.64	9.34	0.4	4.03e-19	Systolic blood pressure;
LGG	trans	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg06606381	chr12:133084897	FBRSL1	-0.79	-8.55	-0.37	1.77e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg20673091	chr1:2541236	MMEL1	0.78	19.03	0.66	4.69e-60	Ulcerative colitis;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg13264159	chr8:625131	ERICH1	0.72	7.63	0.33	1.38e-13	IgG glycosylation;
LGG	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg26655873	chr3:72818019	SHQ1	0.37	7.61	0.33	1.52e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg19894588	chr14:64061835	NA	-0.58	-9.0	-0.39	6.04e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg04733989	chr22:42467013	NAGA	0.6	10.21	0.43	3.38e-22	Schizophrenia;
LGG	cis	rs7011049	1.000	rs72643580	chr8:53846710	T/G	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg18681998	chr4:17616180	MED28	0.84	18.26	0.65	1.64e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg09307838	chr4:120376055	NA	0.72	12.42	0.5	9.37e-31	Corneal astigmatism;
LGG	cis	rs921968	0.643	rs4674324	chr2:219523433	T/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.1	-0.31	4.69e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg16608652	chr1:193155390	B3GALT2;CDC73	-0.29	-7.04	-0.31	6.91e-12	Height;
LGG	cis	rs4950322	0.543	rs2883324	chr1:146788870	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs7635838	0.617	rs347590	chr3:11289561	G/A	cg00170343	chr3:11313890	ATG7	0.55	9.67	0.41	2.9e-20	HDL cholesterol;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07157834	chr1:205819609	PM20D1	0.81	19.23	0.67	5.18e-61	Menarche (age at onset);
LGG	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg21775007	chr8:11205619	TDH	-0.78	-13.67	-0.54	5.79e-36	Retinal vascular caliber;
LGG	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg15704280	chr7:45808275	SEPT13	0.73	9.98	0.42	2.24e-21	Axial length;
LGG	cis	rs11229555	0.645	rs11530830	chr11:58252992	C/G	cg15696309	chr11:58395628	NA	0.97	15.66	0.59	1.17e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9790314	0.690	rs7617204	chr3:160821969	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.68	-0.48	8.72e-28	Morning vs. evening chronotype;
LGG	cis	rs11920090	0.789	rs7617707	chr3:170758765	A/G	cg09710316	chr3:170744871	SLC2A2	0.7	8.58	0.37	1.45e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs17253792	0.822	rs76164147	chr14:56140369	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	cis	rs258892	0.793	rs34657	chr5:72148196	G/A	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs7818345	0.540	rs4623445	chr8:19347184	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.4	-8.59	-0.37	1.31e-16	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs10504073	0.647	rs4873317	chr8:50021111	C/T	cg00325661	chr8:49890786	NA	0.74	14.19	0.55	3.39e-38	Blood metabolite ratios;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02184643	chr11:10879647	ZBED5	0.42	6.96	0.31	1.16e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg04935436	chr20:30431758	NA	0.41	7.25	0.32	1.74e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg05368731	chr17:41323189	NBR1	0.86	16.71	0.61	2.07e-49	Menopause (age at onset);
LGG	cis	rs80282103	0.867	rs7099063	chr10:1078547	C/G	cg08668510	chr10:1095578	IDI1	0.71	7.45	0.33	4.51e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs1062177	1.000	rs2964585	chr5:151141895	C/T	cg00977110	chr5:151150581	G3BP1	0.49	7.91	0.34	1.96e-14	Preschool internalizing problems;
LGG	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg02187348	chr16:89574699	SPG7	0.46	7.43	0.33	5.32e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6665290	0.669	rs6426558	chr1:227175367	G/T	cg05696931	chr1:227175867	NA	-0.41	-8.35	-0.36	8.03e-16	Myeloid white cell count;
LGG	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg05775895	chr3:12838266	CAND2	0.62	10.95	0.45	5.48e-25	QRS complex (12-leadsum);
LGG	cis	rs10751667	0.643	rs7942693	chr11:957832	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.27	0.36	1.47e-15	Alzheimer's disease (late onset);
LGG	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg06885757	chr1:42089581	HIVEP3	-0.64	-15.11	-0.57	3.34e-42	Airway imaging phenotypes;
LGG	cis	rs3768617	0.811	rs12138053	chr1:182979560	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.74	0.3	4.73e-11	Fuchs's corneal dystrophy;
LGG	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg25358565	chr5:93447407	FAM172A	1.27	15.62	0.59	1.67e-44	Diabetic retinopathy;
LGG	cis	rs9398803	0.698	rs853970	chr6:127063983	A/G	cg19875578	chr6:126661172	C6orf173	-0.49	-8.93	-0.38	9.94e-18	Male-pattern baldness;
LGG	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.78	-0.45	2.59e-24	Hemoglobin concentration;
LGG	cis	rs12579753	1.000	rs7300900	chr12:82166821	G/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.21	-0.46	5.66e-26	Resting heart rate;
LGG	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-10.57	-0.44	1.49e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9649465	0.935	rs7780086	chr7:123378471	C/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.84	-0.38	2.07e-17	Migraine;
LGG	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg20503657	chr10:835505	NA	0.78	10.98	0.45	4.53e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.72	-13.62	-0.53	8.83e-36	Personality dimensions;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg22916017	chr11:64110731	CCDC88B	-0.46	-6.74	-0.3	4.66e-11	Mean platelet volume;
LGG	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs977987	0.806	rs11648176	chr16:75456423	C/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	7.6	0.33	1.68e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg13206674	chr6:150067644	NUP43	0.66	14.76	0.57	1.16e-40	Lung cancer;
LGG	cis	rs17122278	1.000	rs11216904	chr11:118440863	A/G	cg19182353	chr11:118479428	PHLDB1	-0.51	-6.67	-0.3	7.42e-11	Total cholesterol levels;
LGG	cis	rs231513	1.000	rs231518	chr17:41961451	C/T	cg26893861	chr17:41843967	DUSP3	0.59	6.91	0.31	1.63e-11	Cognitive function;
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg00292662	chr22:38071168	LGALS1	0.89	24.16	0.75	4.76e-84	Fat distribution (HIV);
LGG	cis	rs16937	0.711	rs12129162	chr1:205164650	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.5e-13	Schizophrenia;
LGG	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg05527609	chr1:210001259	C1orf107	0.48	6.68	0.3	6.92e-11	Red blood cell count;
LGG	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg11502198	chr6:26597334	ABT1	0.58	10.02	0.42	1.6e-21	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg06521331	chr12:34319734	NA	0.52	9.55	0.41	7.28e-20	Bladder cancer;
LGG	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.72	0.34	7.26e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.75	-0.41	1.47e-20	Glomerular filtration rate;
LGG	cis	rs7166081	1.000	rs10152913	chr15:67647328	A/T	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.8	-0.3	3.3e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.39e-17	Mean corpuscular volume;
LGG	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.51e-17	DNA methylation (variation);
LGG	cis	rs4700695	0.764	rs27701	chr5:65377526	G/C	cg21114390	chr5:65439923	SFRS12	-0.56	-7.03	-0.31	7.34e-12	Facial morphology (factor 19);
LGG	cis	rs2237234	0.580	rs7763910	chr6:26472655	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-9.43	-0.4	1.97e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg10546459	chr2:36825355	FEZ2	-0.48	-7.36	-0.32	8.71e-13	Height;
LGG	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg11657817	chr20:23433608	CST11	0.45	9.25	0.39	8.51e-19	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-7.91	-0.34	1.94e-14	Vitiligo;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.31e-19	Lung cancer;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg11693508	chr17:37793320	STARD3	-0.63	-9.39	-0.4	2.78e-19	Bipolar disorder;
LGG	cis	rs9287719	0.934	rs12692418	chr2:10745870	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7508	0.694	rs12541181	chr8:17923499	C/G	cg18067069	chr8:17937731	ASAH1	-0.38	-8.8	-0.38	2.78e-17	Atrial fibrillation;
LGG	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	4.88e-18	Lung cancer;
LGG	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg24110177	chr3:50126178	RBM5	0.51	8.56	0.37	1.65e-16	Menarche (age at onset);
LGG	cis	rs754466	1.000	rs12220902	chr10:79682918	C/T	cg17075019	chr10:79541650	NA	-0.81	-13.8	-0.54	1.63e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.09	0.35	5.16e-15	Neuroticism;
LGG	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg08305652	chr11:111469057	NA	-0.39	-7.5	-0.33	3.32e-13	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg26396452	chr14:65542826	MAX	0.49	10.37	0.43	8.39e-23	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg06623918	chr6:96969491	KIAA0776	0.74	10.83	0.45	1.66e-24	Migraine;Coronary artery disease;
LGG	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.37	-0.36	6.8e-16	Educational attainment (years of education);
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.18	-0.39	1.42e-18	Obesity-related traits;
LGG	cis	rs4728302	0.608	rs6967856	chr7:133727304	C/T	cg10665199	chr7:133106180	EXOC4	0.42	7.28	0.32	1.41e-12	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs2354432	0.505	rs72691009	chr1:146708397	C/T	cg25205988	chr1:146714368	CHD1L	-1.42	-13.71	-0.54	3.83e-36	Mitochondrial DNA levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04139300	chr20:40247070	CHD6	0.4	7.07	0.31	5.62e-12	Body mass index;
LGG	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.7	-0.37	5.99e-17	Aortic root size;
LGG	cis	rs4474465	1.000	rs10899518	chr11:78180508	A/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.65	-0.37	8.27e-17	Alzheimer's disease (survival time);
LGG	cis	rs912057	0.932	rs1294406	chr6:6737737	A/G	cg06612196	chr6:6737390	NA	0.43	8.83	0.38	2.19e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg09998033	chr7:158218633	PTPRN2	-0.46	-8.59	-0.37	1.35e-16	Obesity-related traits;
LGG	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg22852734	chr6:133119734	C6orf192	1.39	11.69	0.48	7.39e-28	Type 2 diabetes nephropathy;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.48	0.37	3.02e-16	Schizophrenia;
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.14	0.43	6.11e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11969893	0.850	rs9498409	chr6:101299966	G/A	cg12253828	chr6:101329408	ASCC3	1.23	10.42	0.44	5.74e-23	Economic and political preferences (immigration/crime);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17060249	chr3:10029235	TMEM111	-0.48	-7.24	-0.32	1.82e-12	Systemic lupus erythematosus;
LGG	cis	rs4888262	0.508	rs6564153	chr16:74658723	A/C	cg01733217	chr16:74700730	RFWD3	0.9	17.83	0.64	1.59e-54	Testicular germ cell tumor;
LGG	cis	rs16912285	0.748	rs12786638	chr11:24346006	A/G	ch.11.24196551F	chr11:24239977	NA	0.92	13.04	0.52	2.5e-33	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg18252515	chr7:66147081	NA	0.4	6.91	0.31	1.61e-11	Calcium levels;
LGG	cis	rs9513627	1.000	rs7334274	chr13:100120801	G/A	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg15971980	chr6:150254442	NA	0.46	8.53	0.37	2.13e-16	Lung cancer;
LGG	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg02733842	chr7:1102375	C7orf50	-0.49	-7.84	-0.34	3.05e-14	Bronchopulmonary dysplasia;
LGG	trans	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg07393940	chr7:158741817	NA	-0.58	-10.61	-0.44	1.06e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg07142201	chr11:109293216	C11orf87	0.61	10.28	0.43	1.86e-22	Schizophrenia;
LGG	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg03264133	chr6:25882463	NA	-0.38	-6.71	-0.3	5.53e-11	Height;
LGG	cis	rs2635047	0.967	rs2247784	chr18:44746997	G/A	cg19077165	chr18:44547161	KATNAL2	-0.44	-7.41	-0.33	5.85e-13	Educational attainment;
LGG	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.12	-0.31	4.03e-12	Iron status biomarkers;
LGG	cis	rs2294693	0.891	rs1072119	chr6:40993072	G/A	cg14769373	chr6:40998127	UNC5CL	-0.44	-7.43	-0.33	5.39e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs870825	0.616	rs12512839	chr4:185610347	G/A	cg04058563	chr4:185651563	MLF1IP	1.07	22.12	0.72	1.64e-74	Blood protein levels;
LGG	cis	rs4538187	0.951	rs17562177	chr2:64160385	A/G	cg19915305	chr2:64069682	UGP2	-0.67	-14.93	-0.57	2e-41	Systolic blood pressure;
LGG	cis	rs62400317	0.859	rs6927213	chr6:45206283	A/G	cg18551225	chr6:44695536	NA	0.57	8.42	0.36	4.63e-16	Total body bone mineral density;
LGG	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg18089519	chr11:763339	TALDO1	0.46	7.34	0.32	9.36e-13	Breast cancer;
LGG	cis	rs1790761	0.505	rs7938563	chr11:67304131	A/G	cg00290607	chr11:67383545	NA	-0.51	-8.97	-0.38	7.41e-18	Mean corpuscular volume;
LGG	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg10057126	chr4:77819792	ANKRD56	0.36	6.94	0.31	1.34e-11	Emphysema distribution in smoking;
LGG	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg27284194	chr4:1044797	NA	0.57	11.88	0.48	1.4e-28	Recombination rate (males);
LGG	cis	rs709400	0.628	rs7150317	chr14:103921691	C/G	cg26031613	chr14:104095156	KLC1	0.78	13.99	0.55	2.38e-37	Body mass index;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.22e-26	Personality dimensions;
LGG	cis	rs7166081	1.000	rs12443472	chr15:67555958	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.94	-0.31	1.34e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7945705	0.902	rs2012696	chr11:8995818	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.78	0.3	3.62e-11	Hemoglobin concentration;
LGG	cis	rs2282300	0.739	rs1717775	chr11:30350254	T/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.9	-0.34	2.04e-14	Morning vs. evening chronotype;
LGG	cis	rs9354308	0.753	rs10944854	chr6:66604806	T/A	cg07460842	chr6:66804631	NA	0.43	7.08	0.31	5.43e-12	Metabolite levels;
LGG	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg08250081	chr4:10125330	NA	-0.34	-6.75	-0.3	4.53e-11	Bone mineral density;
LGG	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Aortic root size;
LGG	cis	rs11190604	1.000	rs10883507	chr10:102291275	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg03804240	chr11:118481350	PHLDB1	0.41	8.41	0.36	5.25e-16	Cholesterol, total;
LGG	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.82	-0.34	3.6e-14	Pancreatic cancer;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.51	0.53	2.66e-35	Height;
LGG	cis	rs7951870	0.645	rs57804402	chr11:46729872	T/C	cg03339077	chr11:47165057	C11orf49	0.43	7.28	0.32	1.46e-12	Schizophrenia;
LGG	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg15147215	chr3:52552868	STAB1	0.39	7.53	0.33	2.65e-13	Electroencephalogram traits;
LGG	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg23335576	chr14:104009727	NA	0.49	8.56	0.37	1.66e-16	Reticulocyte count;
LGG	cis	rs17767392	0.881	rs35971049	chr14:72012219	T/A	cg02058870	chr14:72053146	SIPA1L1	0.43	8.92	0.38	1.12e-17	Mitral valve prolapse;
LGG	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs3845702	1.000	rs9989852	chr2:180839707	G/A	cg01881094	chr2:180872142	CWC22	-0.91	-14.19	-0.55	3.37e-38	Schizophrenia;
LGG	cis	rs17253792	0.731	rs79483151	chr14:56048851	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.02	-0.49	3.91e-29	Putamen volume;
LGG	cis	rs17162190	0.590	rs10902748	chr1:26817825	G/A	cg23229016	chr1:26872525	RPS6KA1	0.25	6.65	0.3	8.3e-11	Mean corpuscular volume;
LGG	cis	rs7582720	1.000	rs114155121	chr2:203718682	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.66	0.41	3.14e-20	Lung cancer in ever smokers;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg04080417	chr5:1859792	NA	-0.53	-8.74	-0.38	4.42e-17	Cardiovascular disease risk factors;
LGG	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg04568710	chr12:38710424	ALG10B	0.4	8.59	0.37	1.35e-16	Morning vs. evening chronotype;
LGG	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06915872	chr16:87998081	BANP	0.45	6.69	0.3	6.56e-11	Menopause (age at onset);
LGG	cis	rs10895140	0.756	rs4633432	chr11:101514325	A/G	cg23650423	chr11:101454676	TRPC6	0.44	7.13	0.31	3.95e-12	Menarche (age at onset);
LGG	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg12439423	chr8:41522721	ANK1	0.42	7.63	0.33	1.33e-13	Type 2 diabetes;
LGG	cis	rs12618769	0.625	rs3769709	chr2:99187433	A/T	cg18455616	chr2:99124870	INPP4A	0.27	7.6	0.33	1.67e-13	Bipolar disorder;
LGG	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg11752832	chr7:134001865	SLC35B4	0.61	11.04	0.46	2.51e-25	Mean platelet volume;
LGG	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg23625390	chr15:77176239	SCAPER	0.41	7.78	0.34	4.75e-14	Blood metabolite levels;
LGG	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg08250081	chr4:10125330	NA	-0.36	-6.65	-0.3	8.32e-11	Bone mineral density;
LGG	cis	rs7113019	1	rs7113019	chr11:122819119	A/C	cg27398637	chr11:122830231	C11orf63	-0.69	-13.45	-0.53	4.69e-35	Menarche (age at onset);
LGG	cis	rs28719689	0.655	rs17063833	chr8:1275384	A/G	cg22761795	chr8:1265118	NA	0.81	9.11	0.39	2.42e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25742201	chr17:35306863	AATF	0.46	7.89	0.34	2.22e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs4948523	0.530	rs11006182	chr10:60309128	G/A	cg07615347	chr10:60278583	BICC1	-0.52	-12.67	-0.51	8.5e-32	Myopia;
LGG	cis	rs651907	0.640	rs771578	chr3:101613434	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	8.32	0.36	9.98e-16	Colorectal cancer;
LGG	trans	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.31	0.36	1.09e-15	Joint mobility (Beighton score);
LGG	cis	rs4330281	0.647	rs6782889	chr3:17692938	G/T	cg20981856	chr3:17787350	NA	-0.38	-7.0	-0.31	8.98e-12	Schizophrenia;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg07701084	chr6:150067640	NUP43	0.68	11.52	0.47	3.47e-27	Lung cancer;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg18538332	chr22:24372958	LOC391322	-0.47	-7.87	-0.34	2.62e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg20691617	chr2:85142974	NA	-0.36	-7.29	-0.32	1.35e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.89	0.31	1.81e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7301826	0.627	rs4325342	chr12:131312482	G/A	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.42	0.63	1.29e-52	Obesity-related traits;
LGG	cis	rs12928939	0.723	rs28501298	chr16:71855133	C/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-11.41	-0.47	9.55e-27	Post bronchodilator FEV1;
LGG	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg24110177	chr3:50126178	RBM5	0.57	10.46	0.44	4.02e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.41e-18	Lung cancer;
LGG	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg16414030	chr3:133502952	NA	0.55	9.74	0.41	1.56e-20	Iron status biomarkers;
LGG	cis	rs2303319	1.000	rs16845830	chr2:162258195	A/G	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.19	0.52	6.23e-34	Lung cancer in ever smokers;
LGG	cis	rs1333657	0.582	rs4712502	chr6:10279331	A/T	cg03826642	chr6:10268858	NA	0.36	6.95	0.31	1.25e-11	Orofacial clefts;
LGG	cis	rs9397585	0.857	rs7763717	chr6:153367347	T/G	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg20891283	chr12:69753455	YEATS4	0.81	13.23	0.52	4.09e-34	Response to diuretic therapy;
LGG	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs113835537	0.529	rs10501397	chr11:66272976	G/T	cg24851651	chr11:66362959	CCS	0.44	7.62	0.33	1.46e-13	Airway imaging phenotypes;
LGG	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg02753203	chr1:228287806	NA	-0.76	-14.42	-0.56	3.28e-39	Parkinson's disease;
LGG	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg02985381	chr13:37494744	SMAD9	0.69	12.15	0.49	1.17e-29	Coronary artery disease;
LGG	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-18.91	-0.66	1.59e-59	Vitiligo;
LGG	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.23	-0.32	1.98e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.1e-50	Platelet distribution width;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg05868516	chr6:26286170	HIST1H4H	0.45	7.67	0.34	9.93e-14	Educational attainment;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.44	-0.37	4.17e-16	Aortic root size;
LGG	cis	rs7010267	0.902	rs4242592	chr8:119968975	T/G	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.38	0.43	7.69e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs9828933	0.626	rs73119018	chr3:63975328	A/G	cg17941049	chr3:63904683	ATXN7	0.71	7.55	0.33	2.27e-13	Type 2 diabetes;
LGG	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.45	-0.37	3.91e-16	Myopia (pathological);
LGG	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.96	-0.35	1.33e-14	Obesity-related traits;
LGG	cis	rs7226408	0.600	rs6507189	chr18:34572061	C/G	cg15022739	chr18:34823045	BRUNOL4	0.42	9.02	0.39	4.89e-18	Obesity-related traits;
LGG	cis	rs2455799	0.613	rs13078485	chr3:15883236	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-7.81	-0.34	3.91e-14	Mean platelet volume;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16218610	chr6:26124417	HIST1H2AC;HIST1H2BC	0.42	6.88	0.3	1.9e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg01631408	chr1:248437212	OR2T33	-0.5	-9.18	-0.39	1.48e-18	Common traits (Other);
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.02	-0.31	7.86e-12	Life satisfaction;
LGG	cis	rs9937943	0.615	rs35495670	chr16:74610422	T/C	cg01733217	chr16:74700730	RFWD3	0.66	9.03	0.39	4.59e-18	Neutrophil percentage of white cells;
LGG	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06133097	chr7:32552212	AVL9	-0.38	-7.2	-0.32	2.42e-12	Cognitive ability;
LGG	trans	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.42	7.12	0.31	4.22e-12	Endometrial cancer;
LGG	cis	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg14795047	chr12:38710433	ALG10B	-0.4	-6.66	-0.3	7.63e-11	Leprosy;
LGG	cis	rs9457247	0.602	rs2157388	chr6:167481912	G/A	cg07741184	chr6:167504864	NA	0.46	10.39	0.43	7.46e-23	Crohn's disease;
LGG	cis	rs9467711	0.606	rs16891725	chr6:26479150	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	7.77	0.34	5.13e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg08847533	chr14:75593920	NEK9	-0.47	-8.7	-0.37	5.85e-17	Coronary artery disease;
LGG	cis	rs2880765	0.835	rs4281668	chr15:86047286	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.41	-0.33	6.2e-13	Coronary artery disease;
LGG	cis	rs7432375	0.901	rs1681817	chr3:136473728	C/T	cg21827317	chr3:136751795	NA	-0.45	-8.15	-0.35	3.44e-15	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs76070545	0.551	rs10096999	chr8:104230267	A/G	cg03923813	chr8:104230441	BAALC	-1.19	-13.41	-0.53	6.84e-35	Alzheimer disease and age of onset;
LGG	cis	rs6460942	0.915	rs62448596	chr7:12446869	C/T	cg06484146	chr7:12443880	VWDE	-0.41	-7.22	-0.32	2.15e-12	Coronary artery disease;
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.09	-0.46	1.67e-25	Neuroticism;
LGG	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs6445975	0.747	rs9852465	chr3:58465183	A/G	cg24175188	chr3:58374923	PXK	0.43	7.97	0.35	1.27e-14	Systemic lupus erythematosus;
LGG	cis	rs9916302	0.904	rs1077715	chr17:37683548	A/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.56	-0.47	2.56e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg17211192	chr8:82754475	SNX16	-0.73	-11.24	-0.46	4.23e-26	Diastolic blood pressure;
LGG	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08045932	chr20:61659980	NA	0.6	13.17	0.52	7.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs58785573	0.504	rs3860067	chr4:38611905	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.41	6.77	0.3	3.8e-11	Lymphocyte percentage of white cells;
LGG	cis	rs4132509	1.000	rs2881275	chr1:243918313	G/C	cg21452805	chr1:244014465	NA	0.66	7.88	0.34	2.36e-14	RR interval (heart rate);
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.39	-0.32	7.04e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg01640437	chr11:65405484	SIPA1	0.39	6.67	0.3	7.12e-11	Blood pressure (age interaction);
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg25811766	chr13:21894605	NA	-0.59	-7.74	-0.34	6.42e-14	White matter hyperintensity burden;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg10950524	chr7:2139216	MAD1L1	0.34	7.4	0.33	6.6e-13	Schizophrenia;
LGG	cis	rs3126085	0.935	rs3126062	chr1:152272352	G/A	cg26876637	chr1:152193138	HRNR	-0.54	-8.68	-0.37	6.92e-17	Atopic dermatitis;
LGG	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs9381107	0.858	rs6458230	chr6:9465363	G/A	cg14735645	chr6:9486422	NA	-0.45	-7.29	-0.32	1.34e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg24611264	chr11:120008944	TRIM29	0.37	9.25	0.4	8e-19	Stroke (pediatric);
LGG	cis	rs6430585	0.702	rs1042712	chr2:136545844	C/G	cg07169764	chr2:136633963	MCM6	-1.26	-23.8	-0.74	2.35e-82	Corneal structure;
LGG	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg02002194	chr4:3960332	NA	-0.5	-9.27	-0.4	6.88e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg11062466	chr8:58055876	NA	0.62	9.69	0.41	2.4e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11229555	0.645	rs4517537	chr11:58213695	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.38	-0.58	2.05e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg00383909	chr3:49044727	WDR6	1.07	12.79	0.51	2.84e-32	Blood protein levels;
LGG	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg09029085	chr17:47094198	IGF2BP1	0.31	8.25	0.36	1.66e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs972578	0.967	rs926353	chr22:43371507	T/A	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-15.86	-0.59	1.52e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg26384229	chr12:38710491	ALG10B	0.99	24.81	0.76	4.56e-87	Heart rate;
LGG	cis	rs599083	0.502	rs113307519	chr11:68212641	C/T	cg16797656	chr11:68205561	LRP5	0.54	7.83	0.34	3.39e-14	Bone mineral density (spine);
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.14	-0.35	3.77e-15	Total body bone mineral density;
LGG	cis	rs17092148	1.000	rs6088579	chr20:33284624	A/G	cg12302830	chr20:33297742	TP53INP2	-0.48	-7.6	-0.33	1.61e-13	Neuroticism;
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg11062466	chr8:58055876	NA	0.48	7.85	0.34	2.85e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2073300	0.609	rs6137930	chr20:23376732	G/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg18252515	chr7:66147081	NA	1.43	20.52	0.69	5e-67	Diabetic kidney disease;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	13.35	0.53	1.25e-34	Obesity-related traits;
LGG	cis	rs7607369	0.572	rs629177	chr2:219454801	T/G	cg01130898	chr2:219473002	PLCD4	-0.43	-7.48	-0.33	3.8e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	cis	rs12681287	0.547	rs56752411	chr8:87515156	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.59	-0.33	1.82e-13	Caudate activity during reward;
LGG	cis	rs2455799	0.613	rs1345157	chr3:15895581	C/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.94	-0.35	1.52e-14	Mean platelet volume;
LGG	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg16434002	chr17:42200994	HDAC5	-0.52	-9.69	-0.41	2.49e-20	Total body bone mineral density;
LGG	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg09467607	chr2:36825704	FEZ2	0.49	9.53	0.4	9.19e-20	Height;
LGG	cis	rs4770433	0.503	rs943242	chr13:23916533	T/C	cg16923290	chr13:23949747	SACS	0.52	7.0	0.31	8.97e-12	Protein quantitative trait loci;
LGG	trans	rs11976180	1.000	rs13243677	chr7:143746572	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.9	-0.31	1.7e-11	Obesity-related traits;
LGG	cis	rs4742903	0.935	rs9942894	chr9:106914905	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.11e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.49	0.61	2.21e-48	Obesity-related traits;
LGG	cis	rs2531992	1.000	rs710893	chr16:4014964	A/G	cg05927578	chr16:4029543	ADCY9	0.68	9.41	0.4	2.41e-19	Waist circumference;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg16301924	chr13:53314226	LECT1	0.48	9.73	0.41	1.8e-20	Lewy body disease;
LGG	cis	rs6815814	0.861	rs73142654	chr4:38785697	T/A	cg06935464	chr4:38784597	TLR10	0.54	8.82	0.38	2.3e-17	Breast cancer;
LGG	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.3	0.36	1.14e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04464219	chr8:98657199	MTDH	0.4	6.88	0.3	1.94e-11	Bipolar disorder;
LGG	trans	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg10756647	chr7:56101905	PSPH	0.82	9.55	0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg10150615	chr22:24372951	LOC391322	-0.4	-6.66	-0.3	7.75e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg18709589	chr6:96969512	KIAA0776	-0.52	-7.86	-0.34	2.69e-14	Migraine;Coronary artery disease;
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17376030	chr22:41985996	PMM1	0.48	7.85	0.34	2.83e-14	Vitiligo;
LGG	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-12.61	-0.51	1.46e-31	Cognitive function;
LGG	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08109568	chr15:31115862	NA	-0.47	-8.48	-0.37	2.99e-16	Huntington's disease progression;
LGG	trans	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg25214090	chr10:38739885	LOC399744	0.68	11.89	0.48	1.25e-28	Corneal astigmatism;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.13	-0.43	6.4e-22	Tonsillectomy;
LGG	cis	rs11676855	0.927	rs4341884	chr2:235918504	G/T	cg06431347	chr2:235935754	SH3BP4	-0.46	-10.55	-0.44	1.89e-23	Dialysis-related mortality;
LGG	cis	rs4478037	1.000	rs58864038	chr3:33161355	G/A	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg08621203	chr6:150244597	RAET1G	0.44	7.29	0.32	1.37e-12	Lung cancer;
LGG	cis	rs6964587	0.967	rs34574955	chr7:91847550	A/C	cg17063962	chr7:91808500	NA	0.53	9.59	0.41	5.35e-20	Breast cancer;
LGG	cis	rs758324	0.947	rs4705900	chr5:131140241	G/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg26850624	chr5:429559	AHRR	-0.37	-8.13	-0.35	3.94e-15	Cystic fibrosis severity;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg11050988	chr7:1952600	MAD1L1	-0.4	-9.85	-0.42	6.76e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs6882046	0.513	rs34318	chr5:88027149	G/A	cg22951263	chr5:87985283	NA	-0.56	-10.38	-0.43	7.9e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.87	13.57	0.53	1.46e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg22676075	chr6:135203613	NA	0.45	7.87	0.34	2.47e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.16	0.32	3.17e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg13802316	chr11:70253460	CTTN	-0.57	-7.41	-0.33	5.85e-13	Coronary artery disease;
LGG	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg20587970	chr11:113659929	NA	-1.15	-20.17	-0.68	2.08e-65	Hip circumference adjusted for BMI;
LGG	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.06	0.39	3.65e-18	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24594292	chr6:111179867	NA	0.4	7.73	0.34	6.9e-14	Menarche (age at onset);
LGG	cis	rs10979	0.931	rs9403509	chr6:143888691	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.5	-0.44	2.89e-23	Systemic lupus erythematosus;
LGG	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg04986931	chr22:39850128	NA	0.4	9.01	0.39	5.43e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7267979	0.714	rs6132825	chr20:25238309	A/T	cg08601574	chr20:25228251	PYGB	0.35	7.1	0.31	4.64e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs71403859	0.667	rs12149264	chr16:71720921	T/G	cg08717414	chr16:71523259	ZNF19	-1.0	-12.85	-0.51	1.52e-32	Post bronchodilator FEV1;
LGG	cis	rs3126085	0.778	rs9887901	chr1:152248552	A/C	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs11169552	0.510	rs11169487	chr12:50937105	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.92	-0.35	1.75e-14	Colorectal cancer;
LGG	cis	rs6762644	0.507	rs9311401	chr3:4764177	A/G	cg11584376	chr3:4789075	ITPR1	-0.4	-8.52	-0.37	2.31e-16	Breast cancer;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg02462569	chr6:150064036	NUP43	-0.42	-8.68	-0.37	6.88e-17	Lung cancer;
LGG	cis	rs523522	0.847	rs11065132	chr12:120908459	C/T	cg12219531	chr12:120966889	COQ5	0.66	11.02	0.46	3.02e-25	High light scatter reticulocyte count;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs2289125	0.597	rs595518	chr11:89220222	A/C	cg01436723	chr11:89220647	NOX4	0.51	7.36	0.32	8.33e-13	Pulse pressure;
LGG	cis	rs55665837	0.539	rs10500804	chr11:14910273	A/C	cg18937875	chr11:14930189	NA	-0.48	-6.99	-0.31	9.48e-12	Vitamin D levels;
LGG	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg15704280	chr7:45808275	SEPT13	-0.81	-13.62	-0.53	9.06e-36	Coronary artery disease;
LGG	cis	rs8044868	0.548	rs12930702	chr16:72077000	C/G	cg23815491	chr16:72088622	HP	0.36	7.71	0.34	7.89e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs500492	0.527	rs445815	chr16:1075847	C/T	cg08273874	chr16:1060765	NA	-0.59	-8.35	-0.36	7.89e-16	Polycystic ovary syndrome;
LGG	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.09	0.35	5.3e-15	Neuroticism;
LGG	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg17294928	chr15:75287854	SCAMP5	-0.55	-9.96	-0.42	2.57e-21	Breast cancer;
LGG	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.18	0.39	1.49e-18	Motion sickness;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07623702	chr17:15902660	ZSWIM7;TTC19	0.46	7.53	0.33	2.63e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.63	14.47	0.56	2.08e-39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs139371	0.684	rs139339	chr22:39505581	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.71	-0.3	5.55e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.6	0.51	1.65e-31	Prudent dietary pattern;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-6.99	-0.31	9.9e-12	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06811360	chr17:8089327	NA	0.46	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	cis	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.56	-10.44	-0.44	4.61e-23	Platelet distribution width;
LGG	cis	rs10189230	0.507	rs6737671	chr2:222386932	T/C	cg14652038	chr2:222343519	EPHA4	-0.36	-6.72	-0.3	5.44e-11	Urate levels in lean individuals;
LGG	cis	rs4845570	1.000	rs4845356	chr1:151759223	T/A	cg07092448	chr1:151763213	TDRKH	1.11	18.67	0.66	2.06e-58	Coronary artery disease;
LGG	cis	rs4919694	1.000	rs12253284	chr10:104665145	G/C	cg04362960	chr10:104952993	NT5C2	1.05	14.68	0.56	2.58e-40	Arsenic metabolism;
LGG	cis	rs2013441	0.508	rs4925078	chr17:19982473	A/G	cg13482628	chr17:19912719	NA	-0.42	-7.26	-0.32	1.65e-12	Obesity-related traits;
LGG	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg07150166	chr2:30669952	LCLAT1	0.71	9.47	0.4	1.45e-19	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4148883	0.628	rs34195655	chr4:100073795	C/T	cg13256891	chr4:100009986	ADH5	0.38	6.69	0.3	6.43e-11	Alcohol dependence;
LGG	cis	rs4950322	0.543	rs115392281	chr1:146790018	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.55	0.37	1.77e-16	Response to antipsychotic treatment;
LGG	cis	rs75920871	0.588	rs6589587	chr11:116875338	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.32	-0.36	9.66e-16	Subjective well-being;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21518151	chr13:112631009	NA	0.38	6.84	0.3	2.52e-11	Menarche (age at onset);
LGG	cis	rs2798269	0.901	rs12860947	chr13:22149336	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.94	-0.31	1.29e-11	PR segment;
LGG	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.81	-0.45	1.93e-24	Resting heart rate;
LGG	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg07382826	chr16:28625726	SULT1A1	0.38	7.84	0.34	3.06e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2769264	0.649	rs9436029	chr1:151367378	C/T	cg18801370	chr1:151430492	POGZ	-0.94	-12.2	-0.49	6.92e-30	Blood trace element (Cu levels);
LGG	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs735860	0.726	rs209517	chr6:53206989	A/T	cg10236188	chr6:53219634	NA	0.35	6.85	0.3	2.36e-11	Glaucoma;
LGG	cis	rs12912251	0.500	rs2643204	chr15:39007171	C/T	cg10631289	chr15:39006617	NA	-0.42	-7.09	-0.31	5.1e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs1372520	0.684	rs10008964	chr4:90744721	G/A	cg15133208	chr4:90757351	SNCA	-0.4	-8.16	-0.35	3.25e-15	Neuroticism;
LGG	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.74	-0.3	4.73e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.96	0.38	8.19e-18	Vitiligo;
LGG	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs6429082	0.818	rs704714	chr1:235632094	T/C	cg26050004	chr1:235667680	B3GALNT2	0.61	10.15	0.43	5.4e-22	Adiposity;
LGG	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.58	0.33	1.96e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06112835	chr11:68658793	MRPL21	0.57	9.65	0.41	3.51e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg00290607	chr11:67383545	NA	-0.52	-9.26	-0.4	7.43e-19	Mean corpuscular volume;
LGG	cis	rs2797160	1.000	rs1739354	chr6:126017808	G/C	cg05901451	chr6:126070800	HEY2	0.44	7.45	0.33	4.67e-13	Endometrial cancer;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.37	-7.55	-0.33	2.32e-13	Longevity;Endometriosis;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg05896524	chr21:47604654	C21orf56	-0.65	-10.97	-0.45	4.58e-25	Testicular germ cell tumor;
LGG	cis	rs12479064	0.666	rs11887935	chr2:100127570	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-8.36	-0.36	7.58e-16	Chronic sinus infection;
LGG	cis	rs4727027	0.933	rs917123	chr7:148848358	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.18	-0.62	1.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg18379455	chr17:41446167	NA	-0.32	-7.55	-0.33	2.32e-13	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs62318503	chr4:98935479	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs806215	0.526	rs12668077	chr7:127476253	T/C	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	6.96e-12	Type 2 diabetes;
LGG	cis	rs6871536	0.901	rs2706374	chr5:131937845	T/A	cg04303330	chr5:131992430	IL13	0.28	6.87	0.3	2.06e-11	Asthma (childhood onset);
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	7.31	0.32	1.16e-12	Schizophrenia;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.59	0.47	1.91e-27	Electroencephalogram traits;
LGG	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.53	-9.3	-0.4	5.64e-19	Hemoglobin concentration;
LGG	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg16583315	chr14:65563665	MAX	-0.42	-8.66	-0.37	8.1e-17	Obesity-related traits;
LGG	cis	rs10839968	1.000	rs7112892	chr11:8059109	G/A	cg14064503	chr11:8094152	TUB	0.62	6.93	0.31	1.38e-11	Left  ventricle systolic dysfunction;
LGG	trans	rs459571	0.585	rs378569	chr9:136902415	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.45	-7.44	-0.33	4.94e-13	Platelet distribution width;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs637571	0.558	rs10896064	chr11:65641033	G/C	cg26695010	chr11:65641043	EFEMP2	0.65	11.75	0.48	4.64e-28	Eosinophil percentage of white cells;
LGG	cis	rs881301	1.000	rs881299	chr8:38332249	T/C	cg17120578	chr8:38329836	NA	-0.4	-8.64	-0.37	9.44e-17	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6065	0.618	rs16942618	chr17:4877358	G/A	cg16045459	chr17:4872488	CAMTA2;SPAG7	-0.53	-7.11	-0.31	4.38e-12	Platelet count;
LGG	cis	rs2124969	0.562	rs13393480	chr2:161058790	G/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-11.89	-0.48	1.24e-28	Waist circumference adjusted for body mass index;
LGG	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs4430311	0.723	rs10927075	chr1:243956120	A/T	cg25706552	chr1:244017396	NA	-0.64	-15.67	-0.59	1e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs629535	0.773	rs655299	chr8:70074534	C/T	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs2011503	0.882	rs72999053	chr19:19375372	G/A	cg11584989	chr19:19387371	SF4	0.78	13.03	0.52	2.73e-33	Bipolar disorder;
LGG	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.95	0.42	2.97e-21	Dupuytren's disease;
LGG	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.75	0.51	3.99e-32	IgG glycosylation;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg01519584	chr16:3060971	CLDN9	-0.33	-6.69	-0.3	6.3e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs783540	0.967	rs1259183	chr15:83279433	C/T	cg16105309	chr15:79090380	ADAMTS7	0.42	7.36	0.32	8.19e-13	Schizophrenia;
LGG	cis	rs897984	0.722	rs12445568	chr16:31004812	T/C	cg02466173	chr16:30829666	NA	-0.47	-8.13	-0.35	4.09e-15	Dementia with Lewy bodies;
LGG	cis	rs10214930	0.697	rs6958467	chr7:27603812	T/C	cg22168087	chr7:27702803	HIBADH	0.45	6.65	0.3	8.31e-11	Hypospadias;
LGG	trans	rs4714291	0.963	rs1304602	chr6:40013471	T/G	cg02267698	chr19:7991119	CTXN1	0.59	9.12	0.39	2.22e-18	Strep throat;
LGG	trans	rs75804782	0.521	rs113497020	chr2:239370813	C/T	cg01134436	chr17:81009848	B3GNTL1	0.83	8.48	0.37	3.01e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.87	-0.34	2.5e-14	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20566420	chr12:122327043	PSMD9	0.52	8.42	0.36	4.72e-16	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg02002194	chr4:3960332	NA	-0.43	-8.2	-0.36	2.43e-15	Mood instability;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15128208	chr22:42549153	NA	-0.46	-9.08	-0.39	3.06e-18	Cognitive function;
LGG	cis	rs7511006	0.858	rs2294402	chr22:50654428	T/G	cg16473166	chr22:50639996	SELO	0.66	11.85	0.48	1.79e-28	Obesity-related traits;
LGG	cis	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg04990556	chr1:26633338	UBXN11	0.61	8.21	0.36	2.27e-15	Obesity-related traits;
LGG	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg14983838	chr19:29218262	NA	0.75	10.45	0.44	4.14e-23	Methadone dose in opioid dependence;
LGG	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15128208	chr22:42549153	NA	-0.38	-7.55	-0.33	2.4e-13	Cognitive function;
LGG	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.74	0.3	4.81e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.24	0.32	1.89e-12	Menopause (age at onset);
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg11252792	chr3:125932053	NA	0.67	12.58	0.5	2e-31	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs12410462	0.591	rs2814061	chr1:227735114	C/T	cg04117972	chr1:227635322	NA	0.48	8.9	0.38	1.23e-17	Major depressive disorder;
LGG	cis	rs35146811	0.695	rs858509	chr7:99821470	A/G	cg13334819	chr7:99746414	C7orf59	0.51	7.83	0.34	3.45e-14	Coronary artery disease;
LGG	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg10160682	chr2:1713001	PXDN	-0.54	-9.72	-0.41	1.96e-20	Response to antipsychotic treatment;
LGG	cis	rs1707322	1.000	rs4660889	chr1:46297331	C/T	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.4e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7635838	0.819	rs2454482	chr3:11534031	C/T	cg00170343	chr3:11313890	ATG7	0.41	6.77	0.3	3.95e-11	HDL cholesterol;
LGG	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg09904177	chr6:26538194	HMGN4	0.7	14.49	0.56	1.67e-39	Intelligence (multi-trait analysis);
LGG	cis	rs9543976	1.000	rs2328964	chr13:76138830	G/T	cg01531495	chr13:76123901	UCHL3	0.61	7.47	0.33	3.99e-13	Diabetic retinopathy;
LGG	cis	rs4538187	0.585	rs329478	chr2:64257746	A/G	cg02541582	chr2:64069798	UGP2	0.56	11.68	0.48	8.7e-28	Systolic blood pressure;
LGG	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg09085632	chr11:111637200	PPP2R1B	0.98	18.91	0.66	1.58e-59	Primary sclerosing cholangitis;
LGG	cis	rs16976116	0.901	rs28589609	chr15:55503630	C/T	cg11288833	chr15:55489084	RSL24D1	0.57	7.64	0.33	1.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6594499	0.872	rs2112541	chr5:110449346	T/C	cg04022379	chr5:110408740	TSLP	0.4	7.38	0.32	7.42e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg13010199	chr12:38710504	ALG10B	0.4	7.35	0.32	9.24e-13	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1816752	0.870	rs9581025	chr13:24997825	T/C	cg22771759	chr13:24902376	NA	0.42	7.22	0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg10756647	chr7:56101905	PSPH	0.46	6.94	0.31	1.36e-11	Corneal structure;
LGG	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg25801113	chr15:45476975	SHF	0.88	19.29	0.67	2.87e-61	Uric acid levels;
LGG	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6787172	0.702	rs1724652	chr3:157981572	G/C	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs4262150	0.726	rs4958318	chr5:151943054	C/T	cg12297329	chr5:152029980	NA	-0.73	-13.92	-0.54	4.97e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg06951627	chr6:26196580	NA	0.52	7.51	0.33	3.1400000000000003e-13	Gout;Renal underexcretion gout;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.64	8.9	0.38	1.23e-17	Lung function (FEV1/FVC);
LGG	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg00343986	chr7:65444356	GUSB	-0.48	-8.4	-0.36	5.66e-16	Aortic root size;
LGG	cis	rs4926611	1.000	rs10888801	chr1:54108777	C/T	cg23596471	chr1:54105337	GLIS1	0.41	8.47	0.37	3.36e-16	Hand grip strength;
LGG	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.65	0.33	1.18e-13	Depressive symptoms;
LGG	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg07382826	chr16:28625726	SULT1A1	-0.33	-7.08	-0.31	5.25e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7551222	0.752	rs10900596	chr1:204522457	T/C	cg20240347	chr1:204465584	NA	-0.56	-11.16	-0.46	8.74e-26	Schizophrenia;
LGG	cis	rs17092148	1.000	rs62211617	chr20:33400355	C/G	cg12302830	chr20:33297742	TP53INP2	0.47	7.82	0.34	3.56e-14	Neuroticism;
LGG	cis	rs9487051	1.000	rs9400272	chr6:109616762	A/G	cg21918786	chr6:109611834	NA	-0.43	-8.17	-0.36	2.92e-15	Reticulocyte fraction of red cells;
LGG	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg21605333	chr4:119757512	SEC24D	1.37	12.93	0.51	7.48e-33	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs8077059	1.000	rs9303396	chr17:55825118	A/G	cg12582317	chr17:55822272	NA	0.38	6.98	0.31	1e-11	Sex hormone-binding globulin levels;
LGG	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg26597838	chr10:835615	NA	0.74	10.11	0.43	7.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	-0.53	-9.29	-0.4	6.12e-19	Resistin levels;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07677032	chr17:61819896	STRADA	-0.55	-9.57	-0.41	6.34e-20	Prudent dietary pattern;
LGG	cis	rs7617773	0.563	rs13082269	chr3:48392274	G/A	cg11946769	chr3:48343235	NME6	0.51	8.68	0.37	6.8e-17	Coronary artery disease;
LGG	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg20587970	chr11:113659929	NA	0.9	14.02	0.55	1.8e-37	Hip circumference adjusted for BMI;
LGG	cis	rs524281	0.861	rs10750780	chr11:65974592	G/A	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.49e-11	Electroencephalogram traits;
LGG	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg26585981	chr11:48327164	OR4S1	0.41	7.15	0.32	3.43e-12	Migraine - clinic-based;
LGG	trans	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.5	-0.37	2.67e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs57920188	0.640	rs4311852	chr1:4085353	C/A	cg20703997	chr1:4087676	NA	0.5	6.69	0.3	6.53e-11	Interleukin-17 levels;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.78	-0.34	4.61e-14	Menarche (age at onset);
LGG	cis	rs6032067	0.852	rs17333103	chr20:43803613	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06634786	chr22:41940651	POLR3H	0.76	12.2	0.49	6.91e-30	Vitiligo;
LGG	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.46	-0.44	3.86e-23	Morning vs. evening chronotype;
LGG	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	13.01	0.52	3.29e-33	High light scatter reticulocyte count;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg03647317	chr4:187891568	NA	-0.42	-9.18	-0.39	1.49e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10744422	1.000	rs4759381	chr12:123348480	G/A	cg25930673	chr12:123319894	HIP1R	-0.73	-8.52	-0.37	2.34e-16	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs6076065	0.748	rs2236023	chr20:23373043	A/C	cg11657817	chr20:23433608	CST11	0.4	8.15	0.35	3.42e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg23625390	chr15:77176239	SCAPER	0.51	10.12	0.43	7.05e-22	Blood metabolite levels;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.39	6.65	0.3	8.45e-11	Schizophrenia;
LGG	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg18850127	chr7:39170497	POU6F2	0.35	8.11	0.35	4.51e-15	Intelligence (multi-trait analysis);
LGG	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg12623918	chr2:306882	NA	0.51	9.39	0.4	2.68e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09957386	chr7:134144062	AKR1B1	0.49	7.53	0.33	2.75e-13	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.74	0.3	4.58e-11	Vitiligo;
LGG	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.62	0.53	8.82e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs35771425	1.000	rs12740755	chr1:211591669	C/G	cg10512769	chr1:211675356	NA	-0.74	-11.85	-0.48	1.81e-28	Educational attainment (years of education);
LGG	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07570687	chr10:102243282	WNT8B	-0.41	-6.98	-0.31	1.04e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4936894	0.500	rs12795997	chr11:124171574	G/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.84	-0.45	1.46e-24	Aging (time to death);
LGG	cis	rs9771228	0.536	rs4141108	chr7:32266959	A/G	cg27532318	chr7:32358331	NA	-0.51	-7.37	-0.32	8.05e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg11764359	chr7:65958608	NA	0.77	14.38	0.56	4.98e-39	Aortic root size;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg22398616	chr13:53314203	LECT1	-0.48	-9.85	-0.42	6.42e-21	Lewy body disease;
LGG	cis	rs12134040	0.646	rs11801269	chr1:236506676	C/T	cg21399712	chr1:236511386	NA	-0.43	-8.52	-0.37	2.19e-16	Urate levels (BMI interaction);
LGG	cis	rs7010267	0.602	rs11995824	chr8:120012700	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.75	0.38	3.97e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	trans	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg06521331	chr12:34319734	NA	0.44	7.86	0.34	2.8e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17767392	0.595	rs8010203	chr14:71653031	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.04	-0.31	7.16e-12	Mitral valve prolapse;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg03647317	chr4:187891568	NA	-0.4	-8.73	-0.38	4.69e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.36	0.32	8.34e-13	Menopause (age at onset);
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg09033563	chr22:24373618	LOC391322	0.49	8.09	0.35	5.22e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1707322	0.721	rs6429575	chr1:46134216	G/C	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	7.79	0.34	4.6e-14	Schizophrenia;
LGG	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg25457927	chr22:38595422	NA	-0.41	-10.54	-0.44	1.91e-23	Cutaneous nevi;
LGG	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg12923728	chr3:195709715	SDHAP1	0.56	9.47	0.4	1.41e-19	Mean corpuscular volume;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07685180	chr8:600429	NA	1.04	10.66	0.44	6.84e-24	IgG glycosylation;
LGG	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.78	-0.3	3.58e-11	Bipolar disorder;
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-9.04	-0.39	4.14e-18	Total body bone mineral density;
LGG	cis	rs5769707	0.681	rs8140095	chr22:50043795	A/G	cg06623630	chr22:50017776	C22orf34	-0.5	-9.89	-0.42	4.81e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg13073564	chr4:8508604	NA	-0.58	-11.25	-0.46	4.05e-26	Response to antineoplastic agents;
LGG	trans	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg02002194	chr4:3960332	NA	0.4	7.15	0.32	3.45e-12	Mood instability;
LGG	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg12011299	chr4:100065546	ADH4	0.4	8.23	0.36	1.89e-15	Alcohol dependence;
LGG	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.62	10.48	0.44	3.3e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.29	0.43	1.71e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2346160	1.000	rs7753298	chr6:167664193	G/A	cg20683250	chr6:167653907	NA	0.42	6.99	0.31	9.37e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs283228	0.798	rs11156003	chr6:101769638	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.63e-23	Coenzyme Q10 levels;
LGG	trans	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs939658	1.000	rs4778935	chr15:79453282	T/C	cg17916960	chr15:79447300	NA	0.63	12.34	0.5	1.97e-30	Refractive error;
LGG	cis	rs7928758	0.887	rs11825120	chr11:134271805	A/G	cg22777979	chr11:134283252	B3GAT1	0.98	13.21	0.52	4.73e-34	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs68170813	0.652	rs11532774	chr7:107201579	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.42	-0.36	4.92e-16	Coronary artery disease;
LGG	cis	rs4740619	0.619	rs1410451	chr9:16039579	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.48	-0.47	5.22e-27	Body mass index;
LGG	cis	rs7241530	0.662	rs55694606	chr18:75902149	A/G	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg21045802	chr8:109455806	TTC35	0.56	10.67	0.44	6.51e-24	Dupuytren's disease;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.57	8.87	0.38	1.56e-17	Renal function-related traits (BUN);
LGG	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8180040	0.966	rs6790763	chr3:47572585	C/A	cg16586182	chr3:47516702	SCAP	-0.77	-14.8	-0.57	7.44e-41	Colorectal cancer;
LGG	cis	rs4474465	0.646	rs10899556	chr11:78278986	C/T	cg27205649	chr11:78285834	NARS2	0.6	11.17	0.46	8.52e-26	Alzheimer's disease (survival time);
LGG	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.31	0.36	1.11e-15	Personality dimensions;
LGG	cis	rs9549367	0.789	rs71446682	chr13:113894908	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.56	-0.37	1.66e-16	Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17293641	chr8:119964144	TNFRSF11B	0.54	8.17	0.35	3.05e-15	Gut microbiome composition (summer);
LGG	cis	rs9326248	0.581	rs10892076	chr11:116988936	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.71	12.63	0.51	1.24e-31	Blood protein levels;
LGG	trans	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg25214090	chr10:38739885	LOC399744	0.68	11.95	0.49	7.12e-29	Corneal astigmatism;
LGG	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg02931644	chr1:25747376	RHCE	0.42	9.36	0.4	3.34e-19	Plateletcrit;Mean corpuscular volume;
LGG	trans	rs10242455	0.571	rs7805661	chr7:99171522	A/C	cg09045935	chr12:6379348	NA	0.88	7.83	0.34	3.28e-14	Blood metabolite levels;
LGG	cis	rs7267979	0.966	rs6083855	chr20:25405118	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.53	-0.44	2.26e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg19338460	chr6:170058176	WDR27	-0.64	-8.65	-0.37	8.45e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.61	-0.41	4.7e-20	Life satisfaction;
LGG	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.91	-0.48	1.06e-28	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs739401	0.611	rs12284275	chr11:3024384	T/C	cg05729581	chr11:3078854	CARS	-0.52	-8.97	-0.38	7.4e-18	Longevity;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.79	-0.38	3.04e-17	Personality dimensions;
LGG	cis	rs2278491	0.502	rs10095889	chr8:117758844	C/T	cg23513447	chr8:117778558	UTP23	-0.51	-6.81	-0.3	3.12e-11	Body mass index;
LGG	cis	rs968567	0.817	rs61896141	chr11:61556039	A/C	cg19610905	chr11:61596333	FADS2	-0.68	-8.33	-0.36	9.56e-16	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-6.7	-0.3	6.1e-11	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09369316	chr1:85462700	MCOLN2	0.45	6.87	0.3	2.07e-11	Gut microbiome composition (summer);
LGG	cis	rs10489202	1.000	rs34192847	chr1:168064317	A/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.13	-0.43	6.53e-22	Schizophrenia;
LGG	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.03e-13	Schizophrenia;
LGG	cis	rs3219090	0.861	rs1341333	chr1:226604638	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.33	0.5	2.01e-30	Melanoma;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg27532560	chr4:187881888	NA	0.59	12.69	0.51	6.98e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4988958	0.527	rs11465641	chr2:103000868	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg24558204	chr6:135376177	HBS1L	-0.49	-8.37	-0.36	6.69e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs2270875	1.000	rs78340057	chr8:132927607	T/G	cg24184792	chr8:132919238	EFR3A	-0.44	-6.82	-0.3	2.8e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	trans	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg21659725	chr3:3221576	CRBN	-0.65	-7.06	-0.31	6.32e-12	Cognitive function;
LGG	trans	rs7944735	0.702	rs60515486	chr11:47682725	A/T	cg15704280	chr7:45808275	SEPT13	0.58	7.42	0.33	5.62e-13	Intraocular pressure;
LGG	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg13902645	chr11:5959945	NA	-0.66	-11.15	-0.46	9.89e-26	DNA methylation (variation);
LGG	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07570687	chr10:102243282	WNT8B	0.44	7.57	0.33	2.04e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2033908	0.589	rs4757060	chr11:12842990	G/A	cg25843174	chr11:12811716	TEAD1	-0.35	-7.19	-0.32	2.59e-12	Sitting height ratio;
LGG	cis	rs3106136	0.967	rs2664892	chr4:95154186	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.05	-0.35	7.04e-15	Capecitabine sensitivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00639289	chr2:213403734	ERBB4	0.44	6.73	0.3	4.96e-11	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7512552	0.809	rs2794685	chr1:150312268	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.43	0.4	1.95e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg10402321	chr1:26617780	UBXN11	-0.45	-7.6	-0.33	1.63e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg20913747	chr6:44695427	NA	-0.66	-11.24	-0.46	4.56e-26	Total body bone mineral density;
LGG	trans	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg16141378	chr3:129829833	LOC729375	0.35	7.88	0.34	2.3e-14	Joint mobility (Beighton score);
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.87	0.3	2.13e-11	Cystic fibrosis severity;
LGG	cis	rs4987668	0.786	rs10952540	chr7:142634912	G/C	cg19410471	chr7:142636507	C7orf34	0.57	8.89	0.38	1.33e-17	Cancer;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg05313129	chr8:58192883	C8orf71	-0.85	-12.24	-0.49	4.89e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.2	0.36	2.37e-15	Colorectal cancer;
LGG	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg21775007	chr8:11205619	TDH	-0.54	-9.12	-0.39	2.39e-18	Neuroticism;
LGG	cis	rs2071403	0.622	rs4076290	chr2:1378969	C/T	cg02514003	chr2:1378035	NA	-0.38	-6.82	-0.3	2.82e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.32	0.67	2.12e-61	Platelet count;
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg16141378	chr3:129829833	LOC729375	0.38	8.96	0.38	7.74e-18	Systolic blood pressure;
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg16096631	chr1:42092165	HIVEP3	-0.42	-9.12	-0.39	2.28e-18	Airway imaging phenotypes;
LGG	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg25358565	chr5:93447407	FAM172A	0.85	11.64	0.48	1.18e-27	Diabetic retinopathy;
LGG	cis	rs7572263	1.000	rs7572263	chr2:209051586	A/G	cg00164906	chr2:209055251	C2orf80	0.55	8.81	0.38	2.51e-17	Glioma;Non-glioblastoma glioma;
LGG	cis	rs78545713	0.536	rs11755618	chr6:26215802	C/T	cg01420254	chr6:26195488	NA	-0.78	-7.45	-0.33	4.59e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.75	-0.3	4.43e-11	Blood metabolite levels;
LGG	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg03060546	chr3:49711283	APEH	0.58	8.9	0.38	1.27e-17	Resting heart rate;
LGG	cis	rs3806843	0.576	rs246002	chr5:140341104	A/G	cg19875535	chr5:140030758	IK	0.37	7.44	0.33	4.97e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs755249	0.567	rs4660751	chr1:39905873	C/T	cg18385671	chr1:39797026	MACF1	0.45	7.47	0.33	3.91e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24073613	chr1:210424721	NA	-0.42	-6.8	-0.3	3.31e-11	Pancreatic cancer;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs931812	0.557	rs4734498	chr8:101946548	T/G	cg20993868	chr7:22813445	NA	0.39	7.36	0.32	8.68e-13	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs6694672	0.867	rs4915327	chr1:197079130	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.93	0.31	1.45e-11	Asthma;
LGG	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg19913688	chr11:428466	ANO9	-0.69	-8.43	-0.36	4.5e-16	Body mass index;
LGG	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg13010199	chr12:38710504	ALG10B	-0.6	-11.71	-0.48	6.39e-28	Morning vs. evening chronotype;
LGG	cis	rs6594499	0.542	rs7722241	chr5:110460747	T/A	cg04022379	chr5:110408740	TSLP	0.42	7.47	0.33	4.02e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs329674	0.556	rs484210	chr11:133762767	G/A	cg06766960	chr11:133703094	NA	-0.63	-7.19	-0.32	2.64e-12	Bipolar disorder;
LGG	trans	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.55	-0.41	7.84e-20	Mood instability;
LGG	cis	rs6087990	0.735	rs1040554	chr20:31380073	C/T	cg13636640	chr20:31349939	DNMT3B	0.81	16.31	0.6	1.4e-47	Ulcerative colitis;
LGG	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg03806693	chr22:41940476	POLR3H	-1.08	-17.88	-0.64	9.24e-55	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17875496	0.828	rs11073001	chr15:81592802	A/G	cg19620333	chr15:81596332	IL16	0.48	9.3	0.4	5.79e-19	Number of common colds;
LGG	trans	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg06636001	chr8:8085503	FLJ10661	0.44	7.59	0.33	1.73e-13	Retinal vascular caliber;
LGG	cis	rs35146811	0.695	rs1623264	chr7:99811204	G/C	cg13334819	chr7:99746414	C7orf59	0.48	7.55	0.33	2.32e-13	Coronary artery disease;
LGG	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg11752832	chr7:134001865	SLC35B4	0.62	11.29	0.46	2.91e-26	Mean platelet volume;
LGG	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13012494	chr21:47604986	C21orf56	0.52	8.7	0.37	5.7e-17	Testicular germ cell tumor;
LGG	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg23029597	chr12:123009494	RSRC2	-0.92	-18.38	-0.65	4.75e-57	Body mass index;
LGG	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs7100689	0.784	rs6585986	chr10:82171559	T/C	cg01528321	chr10:82214614	TSPAN14	1.02	19.82	0.68	9.41e-64	Post bronchodilator FEV1;
LGG	cis	rs13191362	1.000	rs2156257	chr6:163100710	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.98	10.11	0.43	7.44e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6912958	1.000	rs6933587	chr6:88175577	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-10.33	-0.43	1.24e-22	Monocyte percentage of white cells;
LGG	cis	rs7617773	0.780	rs4511916	chr3:48350366	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs117517889	chr22:32469452	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs4720575	1.000	rs4724535	chr7:47100396	G/A	cg00036614	chr7:47093842	NA	-0.49	-9.76	-0.41	1.34e-20	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs7428	0.527	rs1554110	chr2:85547963	C/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.74	-0.54	2.91e-36	Ear protrusion;
LGG	trans	rs1997103	1.000	rs11238364	chr7:55407632	G/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04350249	chr20:18488833	SEC23B	0.41	6.86	0.3	2.18e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg21724239	chr8:58056113	NA	0.49	7.33	0.32	1.01e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.589	rs2041306	chr17:30665675	T/C	cg25809561	chr17:30822961	MYO1D	0.38	9.18	0.39	1.46e-18	Schizophrenia;
LGG	cis	rs42648	0.869	rs42617	chr7:89952046	T/A	cg25739043	chr7:89950458	NA	-0.41	-8.56	-0.37	1.66e-16	Homocysteine levels;
LGG	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg17809284	chr5:56205270	C5orf35	0.54	10.12	0.43	6.76e-22	Initial pursuit acceleration;
LGG	cis	rs72827839	0.846	rs113187178	chr17:46117471	G/A	cg02219949	chr17:45927392	SP6	0.54	8.12	0.35	4.13e-15	Ease of getting up in the morning;
LGG	cis	rs5756813	0.635	rs11089856	chr22:38205784	A/C	cg24232236	chr22:38142998	TRIOBP	0.35	6.83	0.3	2.68e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3806843	0.706	rs1089305	chr5:140066306	T/C	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7812879	0.636	rs2618457	chr8:11369177	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.15	-0.32	3.33e-12	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25046584	chr21:32932016	TIAM1	0.54	8.31	0.36	1.05e-15	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-8.31	-0.36	1.11e-15	Body mass index;
LGG	cis	rs7660883	1.000	rs3775221	chr4:88011793	T/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.3	-0.4	5.47e-19	HDL cholesterol levels;
LGG	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg18876405	chr7:65276391	NA	-0.66	-12.05	-0.49	2.94e-29	Calcium levels;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg23758822	chr17:41437982	NA	0.88	15.32	0.58	3.8e-43	Menopause (age at onset);
LGG	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24308560	chr3:49941425	MST1R	-0.23	-7.24	-0.32	1.85e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg02951883	chr7:2050386	MAD1L1	-0.6	-11.49	-0.47	4.71e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs10895140	0.756	rs2508728	chr11:101491011	C/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg27489772	chr12:121021490	NA	-0.56	-7.58	-0.33	1.91e-13	Type 1 diabetes nephropathy;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07677032	chr17:61819896	STRADA	0.6	11.05	0.46	2.36e-25	Prudent dietary pattern;
LGG	cis	rs7615952	0.736	rs11921945	chr3:125643719	A/G	cg05084668	chr3:125655381	ALG1L	-0.88	-11.03	-0.46	2.84e-25	Blood pressure (smoking interaction);
LGG	cis	rs854037	0.698	rs62360073	chr5:57072508	G/C	cg08523694	chr5:57076192	NA	0.51	7.12	0.31	4.03e-12	Birth weight;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg26338869	chr17:61819248	STRADA	0.55	9.03	0.39	4.81e-18	Prudent dietary pattern;
LGG	cis	rs17014483	0.749	rs2860422	chr4:89644931	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.58	6.65	0.3	8.44e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs36051895	0.664	rs7852755	chr9:5100862	C/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.74	-0.59	5.24e-45	Pediatric autoimmune diseases;
LGG	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs9914988	0.725	rs66531973	chr17:27125993	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg25319279	chr11:5960081	NA	-0.53	-8.37	-0.36	6.7e-16	DNA methylation (variation);
LGG	cis	rs113835537	0.529	rs79798028	chr11:66199362	T/G	cg24851651	chr11:66362959	CCS	0.44	7.71	0.34	7.89e-14	Airway imaging phenotypes;
LGG	cis	rs1707322	0.752	rs12047629	chr1:46162802	G/A	cg03146154	chr1:46216737	IPP	0.56	10.61	0.44	1.13e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04772025	chr11:68637568	NA	0.75	13.43	0.53	5.97e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2976388	0.967	rs2976387	chr8:143759364	G/A	cg06565975	chr8:143823917	SLURP1	-0.42	-10.42	-0.44	5.46e-23	Urinary tract infection frequency;
LGG	cis	rs4950322	0.529	rs11809327	chr1:146578261	A/C	cg22381352	chr1:146742008	CHD1L	-0.42	-7.24	-0.32	1.82e-12	Protein quantitative trait loci;
LGG	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.93	-0.35	1.63e-14	HDL cholesterol;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs703842	1.000	rs11172335	chr12:58175201	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.24	0.36	1.78e-15	Multiple sclerosis;
LGG	trans	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.59	-0.33	1.76e-13	Mood instability;
LGG	cis	rs7927771	0.965	rs56400411	chr11:47586376	T/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.73	-0.38	4.72e-17	Subjective well-being;
LGG	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg00204512	chr16:28754710	NA	0.26	7.47	0.33	4.16e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.06	-0.35	6.61e-15	Total body bone mineral density;
LGG	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg08885076	chr2:99613938	TSGA10	0.34	7.24	0.32	1.93e-12	Chronic sinus infection;
LGG	trans	rs853679	0.607	rs56189111	chr6:28271973	C/A	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14240646	chr10:27532245	ACBD5	0.7	10.04	0.42	1.41e-21	Breast cancer;
LGG	cis	rs4900069	0.764	rs4243689	chr14:91592036	C/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.45	-7.61	-0.33	1.5e-13	Resting heart rate;
LGG	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg00531865	chr16:30841666	NA	-0.48	-9.57	-0.41	6.43e-20	Dementia with Lewy bodies;
LGG	cis	rs1816752	0.905	rs13428	chr13:25009441	C/G	cg22771759	chr13:24902376	NA	0.42	7.13	0.31	3.86e-12	Obesity-related traits;
LGG	cis	rs2635047	0.682	rs4534948	chr18:44793419	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.54	0.33	2.46e-13	Educational attainment;
LGG	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg23029597	chr12:123009494	RSRC2	-0.97	-18.92	-0.66	1.51e-59	Body mass index;
LGG	cis	rs7106204	0.543	rs16912423	chr11:24322678	C/G	ch.11.24196551F	chr11:24239977	NA	-0.87	-9.46	-0.4	1.61e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg06598544	chr20:61472147	COL9A3	-0.91	-10.22	-0.43	3.1e-22	Obesity-related traits;
LGG	cis	rs9357271	1.000	rs4714156	chr6:38361112	A/G	cg07362130	chr6:38359646	BTBD9	0.47	10.68	0.44	5.77e-24	Restless legs syndrome;
LGG	cis	rs12282928	0.959	rs11039635	chr11:48299098	T/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg23758822	chr17:41437982	NA	0.88	16.34	0.6	1e-47	Menopause (age at onset);
LGG	cis	rs12738007	0.717	rs12021667	chr1:29311074	A/G	cg11747820	chr1:29584023	PTPRU	-0.36	-8.38	-0.36	6.37e-16	Schizophrenia;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg13732083	chr21:47605072	C21orf56	-0.56	-9.83	-0.42	7.75e-21	Testicular germ cell tumor;
LGG	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	9.69	0.41	2.53e-20	Iron status biomarkers;
LGG	cis	rs2798269	0.966	rs1044090	chr13:22090066	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.14	-0.32	3.54e-12	PR segment;
LGG	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	12.99	0.52	4e-33	Rheumatoid arthritis;
LGG	cis	rs13191362	1.000	rs34344906	chr6:162993378	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.95	10.48	0.44	3.21e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04565464	chr8:145669602	NFKBIL2	0.38	6.68	0.3	6.83e-11	Schizophrenia;
LGG	cis	rs2964802	0.505	rs13180011	chr5:10824615	T/C	cg14521931	chr5:10832172	NA	-0.75	-16.33	-0.6	1.17e-47	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs6500395	0.926	rs8057164	chr16:48563466	A/G	cg04672837	chr16:48644449	N4BP1	0.55	8.84	0.38	1.99e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.88e-17	Life satisfaction;
LGG	cis	rs17604090	0.878	rs4457221	chr7:29701774	C/T	cg19413766	chr7:29689036	LOC646762	-0.56	-7.0	-0.31	8.79e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7264396	0.580	rs2425181	chr20:34447709	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.72	0.3	5.36e-11	Total cholesterol levels;
LGG	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.18	-0.32	2.79e-12	Iron status biomarkers;
LGG	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg07549998	chr6:150325970	RAET1K	-0.38	-7.27	-0.32	1.52e-12	Alopecia areata;
LGG	cis	rs9534288	0.763	rs34175925	chr13:46611800	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.46	-0.33	4.4e-13	Prostate cancer;
LGG	cis	rs1467026	0.584	rs9880453	chr3:12804060	C/T	cg05775895	chr3:12838266	CAND2	0.71	12.63	0.51	1.3e-31	P wave duration;
LGG	cis	rs2721811	0.738	rs2721795	chr7:24766614	G/T	cg06301139	chr7:24798175	DFNA5	-0.42	-7.62	-0.33	1.41e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.69	-0.34	8.73e-14	Total body bone mineral density;
LGG	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.28	0.4	6.47e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2803122	0.502	rs1854552	chr9:19235047	C/T	cg13469590	chr9:19229767	NA	0.36	7.37	0.32	8.03e-13	Pulse pressure;
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg02002194	chr4:3960332	NA	0.43	7.76	0.34	5.4e-14	Neuroticism;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	10.5	0.44	2.77e-23	Obesity-related traits;
LGG	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg22857025	chr5:266934	NA	-1.47	-24.58	-0.75	5.51e-86	Breast cancer;
LGG	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.34	-0.32	9.74e-13	Restless legs syndrome;
LGG	trans	rs9354308	0.868	rs9363465	chr6:66557802	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.65	-0.37	8.59e-17	Metabolite levels;
LGG	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg03315344	chr16:75512273	CHST6	0.5	10.08	0.42	9.91e-22	Dupuytren's disease;
LGG	cis	rs1670533	1.000	rs2014318	chr4:1068778	C/T	cg27284194	chr4:1044797	NA	-0.55	-9.98	-0.42	2.3e-21	Recombination rate (females);
LGG	cis	rs7301826	0.651	rs12228957	chr12:131296066	T/C	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs2795502	0.873	rs3121327	chr10:43388285	G/A	cg27426351	chr10:43362370	NA	0.58	8.12	0.35	4.23e-15	Blood protein levels;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg05368731	chr17:41323189	NBR1	0.85	16.36	0.61	8.36e-48	Menopause (age at onset);
LGG	cis	rs858239	0.600	rs10266123	chr7:23136487	G/C	cg23682824	chr7:23144976	KLHL7	0.43	7.48	0.33	3.67e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg24110177	chr3:50126178	RBM5	0.46	7.79	0.34	4.32e-14	Menarche (age at onset);
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg19168338	chr16:4465731	CORO7	0.72	13.27	0.53	2.68e-34	Schizophrenia;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.54	-0.37	1.92e-16	Personality dimensions;
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.7	-0.54	4.3e-36	Alzheimer's disease;
LGG	cis	rs7914558	0.966	rs943035	chr10:104839152	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.73	0.45	3.79e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg02524346	chr8:600233	NA	0.99	10.01	0.42	1.72e-21	IgG glycosylation;
LGG	cis	rs172166	0.694	rs9295760	chr6:28147385	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.18	-0.32	2.84e-12	Cardiac Troponin-T levels;
LGG	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20707008	chr6:160210612	MRPL18;TCP1	0.39	6.81	0.3	3.12e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg04025307	chr7:1156635	C7orf50	0.89	19.49	0.67	3.23e-62	Longevity;Endometriosis;
LGG	cis	rs7084402	0.967	rs2917949	chr10:60329166	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.29	-0.32	1.38e-12	Refractive error;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.71	0.38	5.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12912251	0.947	rs7165988	chr15:38988815	C/G	cg01338139	chr15:38987640	C15orf53	-0.55	-8.71	-0.38	5.55e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg02002194	chr4:3960332	NA	0.51	9.73	0.41	1.78e-20	Neuroticism;
LGG	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg04617936	chr2:214353	NA	-0.4	-7.33	-0.32	1.06e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03517284	chr6:25882590	NA	0.65	12.6	0.51	1.72e-31	Blood metabolite levels;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg05368731	chr17:41323189	NBR1	0.9	17.94	0.64	4.96e-55	Menopause (age at onset);
LGG	cis	rs1790761	0.967	rs1808279	chr11:67211569	T/C	cg24690094	chr11:67383802	NA	-0.39	-6.76	-0.3	4.19e-11	Mean corpuscular volume;
LGG	cis	rs9427116	0.502	rs9427100	chr1:154583762	G/A	cg11650704	chr1:154556575	ADAR	-0.48	-9.5	-0.4	1.15e-19	Blood protein levels;
LGG	trans	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.79	-11.94	-0.49	7.59e-29	Obesity-related traits;
LGG	cis	rs7444	0.882	rs5754387	chr22:21974703	C/G	cg05046821	chr22:21984468	YDJC	0.37	6.76	0.3	4.09e-11	Systemic lupus erythematosus;
LGG	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg07936489	chr17:37558343	FBXL20	-0.98	-15.06	-0.57	5.52e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs6964587	0.934	rs7798973	chr7:91588360	G/A	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.92	-0.31	1.51e-11	Longevity;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.33	-0.32	1.05e-12	Longevity;Endometriosis;
LGG	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	9.08e-24	Aortic root size;
LGG	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-13.65	-0.54	6.58e-36	Blood metabolite levels;
LGG	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-11.01	-0.46	3.5e-25	Presence of antiphospholipid antibodies;
LGG	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg09873164	chr1:152488093	CRCT1	0.64	16.04	0.6	2.2e-46	Hair morphology;
LGG	cis	rs933688	1.000	rs2059208	chr5:90732065	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	17.7	0.64	6.11e-54	Smoking behavior;
LGG	cis	rs7607369	0.580	rs17573731	chr2:219652153	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.15	0.32	3.51e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg07460842	chr6:66804631	NA	0.9	14.76	0.57	1.14e-40	Exhaled nitric oxide output;
LGG	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg00405596	chr8:11794950	NA	-0.61	-10.67	-0.44	6.55e-24	Monocyte count;
LGG	cis	rs929596	0.564	rs2602364	chr2:234524229	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.28	-0.4	6.64e-19	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg13397359	chr6:42928475	GNMT	0.51	13.93	0.54	4.41e-37	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg17178900	chr1:205818956	PM20D1	0.6	13.47	0.53	4.05e-35	Menarche (age at onset);
LGG	cis	rs26232	0.583	rs26434	chr5:102363402	C/T	cg23492399	chr5:102201601	PAM	0.51	7.62	0.33	1.48e-13	Rheumatoid arthritis;
LGG	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.84	0.34	3.22e-14	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4750440	0.712	rs11258776	chr10:14031709	G/T	cg27542038	chr10:14027202	FRMD4A	-0.7	-13.73	-0.54	3.22e-36	Adiponectin levels;
LGG	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2797369	0.542	rs4840179	chr6:101516987	G/A	cg27451362	chr6:101846650	GRIK2	-0.51	-7.82	-0.34	3.63e-14	Renal function-related traits (eGRFcrea);
LGG	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg27476859	chr7:2772710	GNA12	0.54	10.58	0.44	1.39e-23	Height;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.94	0.35	1.53e-14	Bipolar disorder;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.54	8.46	0.37	3.67e-16	Renal function-related traits (BUN);
LGG	cis	rs17767392	0.914	rs28859432	chr14:72010693	C/T	cg02058870	chr14:72053146	SIPA1L1	0.43	8.63	0.37	9.58e-17	Mitral valve prolapse;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg24846343	chr22:24311635	DDTL	-0.57	-10.98	-0.45	4.38e-25	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs4665809	1.000	rs6546766	chr2:26328680	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs929596	0.561	rs11891311	chr2:234639310	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.58	10.51	0.44	2.63e-23	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg19748678	chr4:122722346	EXOSC9	0.69	13.7	0.54	4.1e-36	Type 2 diabetes;
LGG	cis	rs6784615	0.744	rs123598	chr3:52435860	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.88	0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs4722166	0.695	rs7808122	chr7:22798080	A/G	cg05265849	chr7:22767390	IL6	0.37	7.19	0.32	2.62e-12	Lung cancer;
LGG	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg00631329	chr6:26305371	NA	-0.45	-7.21	-0.32	2.34e-12	Educational attainment;
LGG	cis	rs3850699	0.683	rs67481356	chr10:104317811	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.71	-0.3	5.81e-11	Prostate cancer;
LGG	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.43e-13	HDL cholesterol;
LGG	cis	rs701145	0.643	rs7647694	chr3:153851535	C/G	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs1007190	0.881	rs34854300	chr17:42969013	T/C	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	cis	rs6840360	1.000	rs1864300	chr4:152663326	T/C	cg22705602	chr4:152727874	NA	-0.27	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.33	0.53	1.48e-34	Anterior chamber depth;
LGG	cis	rs4771450	0.924	rs9518974	chr13:103970094	A/C	cg02987523	chr13:103978230	NA	-0.32	-6.86	-0.3	2.19e-11	Uric acid levels;
LGG	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-6.64	-0.3	8.61e-11	Blood metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07077115	chr13:28024429	MTIF3	0.37	6.67	0.3	7.51e-11	Bipolar disorder;
LGG	cis	rs1775715	0.707	rs2808079	chr10:32167385	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.7	0.3	5.97e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg26924012	chr15:45694286	SPATA5L1	0.47	8.07	0.35	5.99e-15	Uric acid levels;
LGG	cis	rs2285947	1.000	rs10229224	chr7:21583921	G/A	cg03697024	chr7:21583438	DNAH11	0.35	8.62	0.37	1.06e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.69	0.37	6.32e-17	Platelet count;
LGG	cis	rs9388451	0.626	rs1739384	chr6:126099246	C/A	cg05901451	chr6:126070800	HEY2	-0.68	-12.92	-0.51	8.22e-33	Brugada syndrome;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg11141652	chr22:24348549	GSTTP1	0.46	7.84	0.34	3.1e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.44	4.43e-23	Bipolar disorder;
LGG	cis	rs972578	0.765	rs8141000	chr22:43215470	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.97	-0.31	1.1e-11	Mean platelet volume;
LGG	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.58	-0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.59	-8.98	-0.39	6.82e-18	Body mass index;
LGG	cis	rs870825	0.616	rs9631783	chr4:185626511	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.83	0.34	3.33e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.0	-0.39	6.02e-18	Life satisfaction;
LGG	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00204512	chr16:28754710	NA	0.25	7.22	0.32	2.12e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg13385794	chr1:248469461	NA	0.5	8.34	0.36	8.83e-16	Common traits (Other);
LGG	trans	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg06521331	chr12:34319734	NA	-0.39	-6.66	-0.3	7.72e-11	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.73e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9443645	0.901	rs9352666	chr6:79572184	C/G	cg18132916	chr6:79620363	NA	-0.31	-8.57	-0.37	1.5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs2816316	1.000	rs2816315	chr1:192536886	C/T	cg10861751	chr1:192544716	RGS1	0.34	6.91	0.31	1.62e-11	Celiac disease;
LGG	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-6.85	-0.3	2.35e-11	Large artery stroke;
LGG	cis	rs477692	0.563	rs12266634	chr10:131412659	G/C	cg05714579	chr10:131428358	MGMT	-0.86	-21.39	-0.71	4.2e-71	Response to temozolomide;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg14968603	chr10:102046143	BLOC1S2	0.47	6.85	0.3	2.34e-11	Breast cancer;
LGG	cis	rs6594713	0.921	rs7714760	chr5:112735231	T/C	cg12552261	chr5:112820674	MCC	0.49	7.0	0.31	9.17e-12	Brain cytoarchitecture;
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.69	0.41	2.52e-20	Mean corpuscular volume;
LGG	cis	rs887829	0.569	rs3755319	chr2:234667582	A/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.41	-7.48	-0.33	3.8e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15980492	chr1:29508159	SFRS4	0.39	6.71	0.3	5.77e-11	Gut microbiome composition (summer);
LGG	cis	rs7215564	0.908	rs2340772	chr17:78752017	C/A	cg06153925	chr17:78755379	RPTOR	-0.42	-7.3	-0.32	1.26e-12	Myopia (pathological);
LGG	cis	rs12410462	0.551	rs66471275	chr1:227824312	T/C	cg04117972	chr1:227635322	NA	0.42	7.8	0.34	4.05e-14	Major depressive disorder;
LGG	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg13010199	chr12:38710504	ALG10B	0.69	14.52	0.56	1.27e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.86e-13	Joint mobility (Beighton score);
LGG	cis	rs9333075	0.507	rs11575603	chr10:15754920	A/G	cg14364212	chr10:15760690	ITGA8	-0.46	-9.6	-0.41	4.88e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7945705	0.747	rs1123936	chr11:9003306	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.32	-0.47	2.2e-26	Hemoglobin concentration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07001481	chr17:5389669	DERL2;MIS12	0.47	7.6	0.33	1.69e-13	Cognitive performance;
LGG	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	9.57	0.41	6.37e-20	Multiple sclerosis;
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7765175	0.698	rs3851200	chr6:113674422	C/T	cg26552650	chr6:113682475	NA	0.33	7.17	0.32	2.99e-12	Coronary artery calcification;
LGG	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.49	-9.61	-0.41	4.72e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg19223190	chr17:80058835	NA	0.45	8.69	0.37	6.39e-17	Life satisfaction;
LGG	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg16586182	chr3:47516702	SCAP	-0.75	-13.85	-0.54	9.32e-37	Colorectal cancer;
LGG	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.35e-16	Neuroticism;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-7.44	-0.33	4.87e-13	Life satisfaction;
LGG	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.06	-0.35	6.47e-15	Retinal vascular caliber;
LGG	cis	rs113835537	0.529	rs4930378	chr11:66255515	T/C	cg24851651	chr11:66362959	CCS	0.44	7.79	0.34	4.51e-14	Airway imaging phenotypes;
LGG	cis	rs727505	1.000	rs1541416	chr7:124450345	T/C	cg23710748	chr7:124431027	NA	-0.5	-9.5	-0.4	1.12e-19	Lewy body disease;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg08742575	chr21:47604166	C21orf56	0.53	8.8	0.38	2.66e-17	Testicular germ cell tumor;
LGG	cis	rs4378355	1	rs4378355	chr11:34783417	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.43	7.15	0.32	3.47e-12	Prostate-specific antigen levels;
LGG	cis	rs4727027	0.801	rs12666337	chr7:148796253	C/T	cg23583168	chr7:148888333	NA	-0.83	-15.79	-0.59	2.89e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	6.11e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12200782	0.578	rs9467739	chr6:26382573	A/T	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.32	-0.32	1.11e-12	Menopause (age at onset);
LGG	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg05925327	chr15:68127851	NA	-0.36	-8.44	-0.37	4.12e-16	Restless legs syndrome;
LGG	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg21211680	chr2:198530	NA	0.59	7.47	0.33	3.99e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg00149659	chr3:10157352	C3orf10	0.85	10.89	0.45	9.71e-25	Alzheimer's disease;
LGG	cis	rs2070433	0.752	rs11701058	chr21:47776382	T/C	cg12379764	chr21:47803548	PCNT	0.67	9.36	0.4	3.47e-19	Lymphocyte counts;
LGG	cis	rs9400467	0.506	rs17539875	chr6:111674350	C/T	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19412076	chr19:12661732	ZNF564	-0.43	-7.42	-0.33	5.64e-13	Pancreatic cancer;
LGG	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg22630939	chr7:1135958	C7orf50	0.32	6.68	0.3	6.72e-11	Bronchopulmonary dysplasia;
LGG	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg15704280	chr7:45808275	SEPT13	-0.51	-8.22	-0.36	2.01e-15	HDL cholesterol;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg16141378	chr3:129829833	LOC729375	0.4	9.25	0.39	8.33e-19	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21108767	chr7:99933721	PILRB;PMS2L1	0.42	6.72	0.3	5.44e-11	Cognitive performance;
LGG	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg06028605	chr16:24865363	SLC5A11	0.5	8.46	0.37	3.45e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg17050807	chr22:42548356	NA	0.39	7.59	0.33	1.83e-13	Schizophrenia;
LGG	cis	rs7412746	0.658	rs8444	chr1:150938571	G/A	cg15448220	chr1:150897856	SETDB1	0.39	7.18	0.32	2.73e-12	Melanoma;
LGG	cis	rs7666738	0.753	rs13120995	chr4:98972762	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1065852	0.526	rs56234624	chr22:42388826	A/G	cg15128208	chr22:42549153	NA	0.41	7.04	0.31	7.16e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs3806843	1.000	rs4451093	chr5:140158542	A/G	cg19875535	chr5:140030758	IK	-0.5	-10.21	-0.43	3.43e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg14835575	chr10:16859367	RSU1	0.43	7.8	0.34	4.15e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg27624424	chr6:160112604	SOD2	0.63	9.39	0.4	2.62e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg18357526	chr6:26021779	HIST1H4A	0.86	15.73	0.59	5.88e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg05234568	chr11:5960015	NA	-0.72	-11.8	-0.48	2.9e-28	DNA methylation (variation);
LGG	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22022881	chr2:105853494	NA	-0.38	-7.93	-0.35	1.66e-14	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18418962	chr18:2571633	METTL4;NDC80	0.48	8.05	0.35	7.21e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08219700	chr8:58056026	NA	0.45	6.92	0.31	1.53e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg10840412	chr1:235813424	GNG4	0.69	9.31	0.4	5.33e-19	Bipolar disorder;
LGG	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	trans	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.51	-8.29	-0.36	1.21e-15	Mean corpuscular hemoglobin;
LGG	cis	rs11583043	0.708	rs3861735	chr1:101530191	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.48	0.37	3.12e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.89	-0.34	2.17e-14	Total cholesterol levels;
LGG	cis	rs7843479	0.562	rs2127206	chr8:21786989	C/T	cg17168535	chr8:21777572	XPO7	0.8	15.27	0.58	5.99e-43	Mean corpuscular volume;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Electroencephalogram traits;
LGG	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg12438819	chr7:158236134	PTPRN2	0.32	8.12	0.35	4.2e-15	Obesity-related traits;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.37	-0.32	7.86e-13	Iron status biomarkers;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg05313129	chr8:58192883	C8orf71	-0.78	-12.2	-0.49	6.86e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2249694	0.520	rs10857730	chr10:135326822	T/G	cg20169779	chr10:135381914	SYCE1	-0.56	-7.58	-0.33	1.94e-13	Obesity-related traits;
LGG	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg16141378	chr3:129829833	LOC729375	0.32	6.88	0.3	1.98e-11	Triglycerides;
LGG	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg13939156	chr17:80058883	NA	0.46	8.09	0.35	5.4e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs367943	0.698	rs7728525	chr5:112972215	C/G	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs994014	0.640	rs11942269	chr4:82210926	A/G	cg07938847	chr4:82126349	PRKG2	0.29	6.97	0.31	1.08e-11	Height;
LGG	cis	rs7766436	0.885	rs13220769	chr6:22596464	T/A	cg13666174	chr6:22585274	NA	-0.52	-12.23	-0.49	5.43e-30	Coronary artery disease;
LGG	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	11.6	0.47	1.69e-27	Lung cancer in ever smokers;
LGG	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg15268244	chr15:77196840	NA	0.48	10.31	0.43	1.41e-22	Blood metabolite levels;
LGG	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg08125733	chr17:73851984	WBP2	0.95	13.91	0.54	5.49e-37	Psoriasis;
LGG	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg19992207	chr2:111874495	ACOXL	-0.37	-6.78	-0.3	3.78e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg18681998	chr4:17616180	MED28	0.87	19.94	0.68	2.7e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.19	-0.36	2.5e-15	Schizophrenia;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs854765	0.505	rs4924832	chr17:17897739	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-15.4	-0.58	1.61e-43	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04451703	chr10:70231397	DNA2	0.46	6.8	0.3	3.28e-11	Gut microbiome composition (summer);
LGG	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg20891283	chr12:69753455	YEATS4	0.5	7.83	0.34	3.47e-14	Response to diuretic therapy;
LGG	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg13114125	chr14:105738426	BRF1	0.83	16.5	0.61	1.84e-48	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7432375	0.804	rs6764567	chr3:136425514	A/C	cg21827317	chr3:136751795	NA	-0.47	-8.48	-0.37	3.04e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg11839771	chr15:80205821	ST20	-0.39	-8.58	-0.37	1.43e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.34	-0.32	9.37e-13	Bipolar disorder;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg00166722	chr3:10149974	C3orf24	0.49	8.29	0.36	1.28e-15	Alzheimer's disease;
LGG	cis	rs2011503	0.941	rs55765017	chr19:19368264	G/A	cg11584989	chr19:19387371	SF4	0.78	13.02	0.52	3.18e-33	Bipolar disorder;
LGG	cis	rs1385374	0.858	rs12298615	chr12:129286756	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	6.87	0.3	2.08e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07362569	chr17:61921086	SMARCD2	0.49	9.51	0.4	1.08e-19	Prudent dietary pattern;
LGG	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.64e-23	Chronic sinus infection;
LGG	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.14	-0.58	2.4e-42	Chronic sinus infection;
LGG	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg08923054	chr8:41654455	ANK1	0.84	14.76	0.57	1.14e-40	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg21775007	chr8:11205619	TDH	0.8	14.17	0.55	4.03e-38	Retinal vascular caliber;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.35	0.5	1.8e-30	Obesity-related traits;
LGG	cis	rs9517313	0.897	rs4772087	chr13:99115041	A/G	cg07423050	chr13:99094983	FARP1	0.57	11.48	0.47	4.96e-27	Neuroticism;
LGG	cis	rs4880487	0.505	rs883660	chr10:1206834	A/G	cg03183215	chr10:1252341	ADARB2	-0.37	-6.84	-0.3	2.53e-11	Migraine;
LGG	cis	rs2731664	0.792	rs2544809	chr5:176885499	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-12.93	-0.51	7.44e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg27400746	chr16:89904261	SPIRE2	-0.92	-15.4	-0.58	1.65e-43	Skin colour saturation;
LGG	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg06634786	chr22:41940651	POLR3H	0.68	11.1	0.46	1.49e-25	Vitiligo;
LGG	cis	rs992157	0.585	rs62182795	chr2:219100202	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.77	-0.38	3.32e-17	Colorectal cancer;
LGG	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg13010199	chr12:38710504	ALG10B	-0.62	-12.87	-0.51	1.31e-32	Morning vs. evening chronotype;
LGG	cis	rs9463078	0.774	rs10948222	chr6:45244415	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.39	-0.36	5.95e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-8.39	-0.36	6.1e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.47	0.37	3.38e-16	Prudent dietary pattern;
LGG	cis	rs3126085	0.935	rs6587651	chr1:152193121	G/T	cg26876637	chr1:152193138	HRNR	0.54	8.97	0.38	7.31e-18	Atopic dermatitis;
LGG	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg11040518	chr10:102331378	NA	-0.36	-6.76	-0.3	4.29e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35079168	0.961	rs66475113	chr9:137284381	C/T	cg00753924	chr9:137298813	RXRA	-0.37	-6.89	-0.3	1.84e-11	Intelligence;
LGG	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg26384229	chr12:38710491	ALG10B	0.63	12.53	0.5	3.19e-31	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg03929089	chr4:120376271	NA	0.78	8.1	0.35	4.95e-15	Myopia (pathological);
LGG	cis	rs11190604	1.000	rs11190557	chr10:102209369	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg00106254	chr7:1943704	MAD1L1	0.43	7.56	0.33	2.11e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs432925	0.576	rs11866815	chr16:387867	C/T	cg07915516	chr16:377344	AXIN1	-0.29	-7.35	-0.32	8.78e-13	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6787172	0.651	rs6806702	chr3:158138728	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.72	0.45	4.27e-24	Lung cancer in ever smokers;
LGG	cis	rs9815354	0.953	rs1629462	chr3:41927452	G/C	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg02743256	chr7:2109353	MAD1L1	-0.37	-7.36	-0.32	8.56e-13	Neuroticism;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg00908189	chr16:619842	PIGQ	0.88	16.88	0.62	3.59e-50	Height;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	9.86e-36	Lung cancer;
LGG	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.14	0.55	5.53e-38	Cognitive test performance;
LGG	trans	rs12517041	0.872	rs1896723	chr5:23303194	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs12679857	0.686	rs1032129	chr8:119951900	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.27	0.36	1.44e-15	Type 1 diabetes;
LGG	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg11584989	chr19:19387371	SF4	0.57	9.85	0.42	6.35e-21	Tonsillectomy;
LGG	cis	rs4604732	0.536	rs12049066	chr1:247642655	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.65	10.45	0.44	4.32e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg02187348	chr16:89574699	SPG7	0.5	8.09	0.35	5.24e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.54	-0.41	7.96e-20	Aortic root size;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.66	-0.3	7.62e-11	Personality dimensions;
LGG	cis	rs367943	1.000	rs348952	chr5:112821990	G/T	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg25356066	chr3:128598488	ACAD9	0.45	6.93	0.31	1.39e-11	IgG glycosylation;
LGG	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	cis	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg19338460	chr6:170058176	WDR27	-0.62	-8.39	-0.36	5.99e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7927771	0.524	rs11039377	chr11:47789776	C/T	cg20307385	chr11:47447363	PSMC3	0.56	10.99	0.45	4.16e-25	Subjective well-being;
LGG	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg25237894	chr2:233734115	C2orf82	-0.66	-12.57	-0.5	2.17e-31	Coronary artery disease;
LGG	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg11693508	chr17:37793320	STARD3	0.53	7.7	0.34	8.17e-14	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg25019033	chr10:957182	NA	-0.55	-10.12	-0.43	7.26e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7945705	0.875	rs10769947	chr11:8758114	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.42	8.76	0.38	3.71e-17	Hemoglobin concentration;
LGG	cis	rs4819052	0.851	rs12626188	chr21:46669258	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.07	0.39	3.49e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.82	-0.3	2.79e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg27411982	chr8:10470053	RP1L1	-0.47	-8.05	-0.35	7.11e-15	Retinal vascular caliber;
LGG	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08704250	chr15:31115839	NA	0.49	9.0	0.39	6.06e-18	Huntington's disease progression;
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg04861929	chr11:109293070	C11orf87	0.67	11.98	0.49	5.64e-29	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.76	-14.21	-0.55	2.72e-38	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg16507663	chr6:150244633	RAET1G	0.44	7.13	0.31	3.98e-12	Lung cancer;
LGG	cis	rs6714710	0.603	rs4311104	chr2:98424802	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7503807	0.651	rs901065	chr17:78599655	G/T	cg18469159	chr17:78755841	RPTOR	-0.38	-7.07	-0.31	5.74e-12	Obesity;
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg13628971	chr7:2884303	GNA12	0.55	11.91	0.48	1.07e-28	Height;
LGG	cis	rs1978968	0.750	rs13053880	chr22:18443500	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-9.59	-0.41	5.43e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg14689365	chr7:158441557	NCAPG2	0.56	6.75	0.3	4.31e-11	Height;
LGG	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg16141378	chr3:129829833	LOC729375	0.31	7.09	0.31	5.04e-12	Triglycerides;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.6e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1010254	0.510	rs888877	chr5:151760425	C/T	cg12297329	chr5:152029980	NA	-0.51	-7.24	-0.32	1.91e-12	Optic nerve measurement (cup area);
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.69	-0.3	6.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8078723	0.866	rs11078934	chr17:38189793	C/T	cg17467752	chr17:38218738	THRA	0.81	15.91	0.59	9.01e-46	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.84	12.37	0.5	1.4e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs614226	0.516	rs1794748	chr12:120953758	A/G	cg01236616	chr12:121019343	POP5	1.29	23.46	0.74	8.77e-81	Type 1 diabetes nephropathy;
LGG	cis	rs7586879	0.964	rs6545795	chr2:25116783	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.88	0.42	5.02e-21	Body mass index;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg04287289	chr16:89883240	FANCA	0.67	7.47	0.33	4.16e-13	Skin colour saturation;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.03	-0.39	4.7e-18	Neuroticism;
LGG	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-14.34	-0.55	7.57e-39	Response to antipsychotic treatment;
LGG	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg03929089	chr4:120376271	NA	-0.7	-9.56	-0.41	7.08e-20	Axial length;
LGG	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg18876405	chr7:65276391	NA	-0.64	-11.91	-0.48	1.05e-28	Aortic root size;
LGG	cis	rs6489785	0.689	rs538785	chr12:121291505	C/G	cg02419362	chr12:121203948	SPPL3	-0.44	-6.85	-0.3	2.42e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs5750830	0.649	rs6001588	chr22:39819049	G/C	cg04986931	chr22:39850128	NA	0.34	7.66	0.34	1.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg19507638	chr5:93509721	C5orf36	0.42	6.92	0.31	1.54e-11	Diabetic retinopathy;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg12310025	chr6:25882481	NA	0.49	9.09	0.39	2.93e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.64	0.41	3.75e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6964587	0.782	rs13221571	chr7:91500236	C/T	cg17063962	chr7:91808500	NA	-0.4	-6.99	-0.31	9.65e-12	Breast cancer;
LGG	cis	rs7020830	0.830	rs17487601	chr9:37213641	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	29.7	0.81	2.74e-109	Schizophrenia;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg17911788	chr17:44343683	NA	0.61	9.2	0.39	1.23e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7659604	1.000	rs7689722	chr4:122665955	T/C	cg06713675	chr4:122721982	EXOSC9	-0.44	-6.99	-0.31	9.74e-12	Type 2 diabetes;
LGG	cis	rs340874	0.703	rs340835	chr1:214163675	C/T	cg05052969	chr1:214156842	NA	-0.46	-8.66	-0.37	7.63e-17	Type 2 diabetes;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg23758822	chr17:41437982	NA	0.87	15.4	0.58	1.61e-43	Menopause (age at onset);
LGG	cis	rs295140	1.000	rs10931899	chr2:201176901	A/G	cg25099087	chr2:201172481	SPATS2L	-0.27	-6.8	-0.3	3.23e-11	QT interval;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg21226059	chr5:178986404	RUFY1	0.52	9.45	0.4	1.76e-19	Lung cancer;
LGG	cis	rs6087990	0.806	rs4911259	chr20:31376282	A/C	cg13636640	chr20:31349939	DNMT3B	0.86	17.34	0.63	2.96e-52	Ulcerative colitis;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.6e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg23057051	chr16:89984268	MC1R	-0.36	-6.98	-0.31	1.01e-11	Vitiligo;
LGG	cis	rs7572644	0.699	rs1902966	chr2:28189280	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg25174290	chr11:3078921	CARS	-0.47	-8.24	-0.36	1.84e-15	Calcium levels;
LGG	cis	rs10193935	1.000	rs58962161	chr2:42400278	T/A	cg27598129	chr2:42591480	NA	-0.6	-8.95	-0.38	8.96e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg21775007	chr8:11205619	TDH	0.43	7.08	0.31	5.33e-12	Systolic blood pressure;
LGG	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg08085267	chr17:45401833	C17orf57	-0.6	-12.16	-0.49	1.01e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14240646	chr10:27532245	ACBD5	-0.74	-10.36	-0.43	9.52e-23	Breast cancer;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.86	-0.48	1.64e-28	Alzheimer's disease;
LGG	cis	rs9534288	0.797	rs7982998	chr13:46601535	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg11941060	chr3:133502564	NA	0.47	8.28	0.36	1.3e-15	Iron status biomarkers;
LGG	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg02023728	chr11:77925099	USP35	0.44	7.58	0.33	1.89e-13	Testicular germ cell tumor;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.75	0.3	4.49e-11	Personality dimensions;
LGG	cis	rs1691799	0.867	rs1495497	chr12:66770020	A/T	cg16791601	chr12:66731901	HELB	-0.66	-15.62	-0.59	1.83e-44	White blood cell count (basophil);
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg13206674	chr6:150067644	NUP43	0.63	14.3	0.55	1.12e-38	Lung cancer;
LGG	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg05555928	chr11:63887634	MACROD1	-0.63	-8.88	-0.38	1.48e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.56	-0.44	1.73e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	9.15	0.39	1.77e-18	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07714657	chr2:219724408	WNT6	-0.45	-7.09	-0.31	4.97e-12	Pancreatic cancer;
LGG	cis	rs11203032	0.831	rs4511206	chr10:90968759	C/T	cg16672925	chr10:90967113	CH25H	0.84	11.38	0.47	1.22e-26	Heart failure;
LGG	cis	rs8064024	0.590	rs2219271	chr16:4898120	C/G	cg04440724	chr16:4920505	UBN1	-0.54	-11.85	-0.48	1.71e-28	Cancer;
LGG	cis	rs926938	0.541	rs360623	chr1:115407268	G/C	cg12756093	chr1:115239321	AMPD1	0.44	8.32	0.36	1.03e-15	Autism;
LGG	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.8	-0.3	3.31e-11	Neuroticism;
LGG	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg23601095	chr6:26197514	HIST1H3D	0.72	9.25	0.39	8.42e-19	Gout;Renal underexcretion gout;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg03188948	chr7:1209495	NA	0.71	10.31	0.43	1.43e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg00830817	chr11:109293614	C11orf87	0.42	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs2901460	0.509	rs35056428	chr2:62061943	A/T	cg02183531	chr2:62113199	CCT4	-0.43	-7.34	-0.32	1e-12	Mean corpuscular volume;
LGG	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.86	-0.38	1.75e-17	High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22168525	chr7:87505499	SLC25A40;DBF4	0.46	6.78	0.3	3.79e-11	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg21911579	chr5:131705225	SLC22A5	0.67	7.49	0.33	3.41e-13	Rheumatoid arthritis;
LGG	cis	rs3789045	0.866	rs61817482	chr1:204570347	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.47	-9.09	-0.39	2.84e-18	Educational attainment (college completion);
LGG	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg20283391	chr11:68216788	NA	-0.5	-8.3	-0.36	1.17e-15	Total body bone mineral density;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08997444	chr20:57464970	GNAS	-0.39	-6.82	-0.3	2.79e-11	Brain structure;
LGG	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.6	-12.95	-0.52	5.82e-33	Multiple sclerosis;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	3.9e-17	Lung cancer;
LGG	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06449863	chr20:25388049	GINS1	-0.38	-6.65	-0.3	8.38e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg07817883	chr1:32538562	TMEM39B	0.71	8.91	0.38	1.21e-17	Monocyte percentage of white cells;
LGG	cis	rs4423214	0.592	rs11233977	chr11:71221605	C/T	cg05163923	chr11:71159392	DHCR7	-0.55	-8.1	-0.35	4.77e-15	Vitamin D levels;
LGG	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg26384229	chr12:38710491	ALG10B	0.76	15.34	0.58	3.14e-43	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2798269	1.000	rs2761912	chr13:22134037	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs2742417	1.000	rs2742454	chr3:45766222	T/A	cg04837898	chr3:45731254	SACM1L	-0.36	-7.06	-0.31	5.97e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.13	0.68	3.48e-65	Smoking behavior;
LGG	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg26150922	chr2:100937072	LONRF2	-0.52	-9.16	-0.39	1.65e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7589342	0.628	rs9646959	chr2:106412191	A/G	cg16077055	chr2:106428750	NCK2	-0.28	-6.77	-0.3	3.87e-11	Addiction;
LGG	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg10664184	chr19:17420304	DDA1	0.55	8.38	0.36	6.22e-16	Systemic lupus erythematosus;
LGG	cis	rs3790455	1.000	rs4450010	chr1:156448209	T/G	cg14087168	chr1:156450669	MEF2D	0.48	7.94	0.35	1.58e-14	Migraine;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg02466173	chr16:30829666	NA	0.42	7.41	0.33	5.91e-13	Dementia with Lewy bodies;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg22398616	chr13:53314203	LECT1	0.49	10.18	0.43	4.09e-22	Lewy body disease;
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg10523679	chr1:76189770	ACADM	0.82	14.08	0.55	1.02e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg14042143	chr7:2646782	IQCE	0.79	12.01	0.49	3.97e-29	Urate levels in lean individuals;
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14550338	chr10:106097511	NA	0.37	6.84	0.3	2.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.31	-0.32	1.15e-12	Alzheimer's disease (late onset);
LGG	cis	rs1620921	0.711	rs2565724	chr6:161241889	A/G	cg01280913	chr6:161186852	NA	-0.34	-6.92	-0.31	1.51e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6838801	0.892	rs10029193	chr4:77576894	G/A	cg17476223	chr4:77663285	SHROOM3	0.38	6.84	0.3	2.51e-11	Cleft lip with or without cleft palate;
LGG	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.97	0.38	7.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg09165964	chr15:75287851	SCAMP5	0.65	12.38	0.5	1.34e-30	Breast cancer;
LGG	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.79e-16	Bone mineral density;
LGG	cis	rs11753937	0.887	rs954917	chr6:133617735	T/C	cg05493394	chr6:133562035	EYA4	-0.26	-7.11	-0.31	4.39e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg24231037	chr15:68117551	LBXCOR1	0.31	7.64	0.33	1.26e-13	Restless legs syndrome;
LGG	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg24829409	chr8:58192753	C8orf71	-0.66	-9.62	-0.41	4.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg22552966	chr17:19620595	SLC47A2	-0.4	-7.86	-0.34	2.73e-14	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg19508488	chr2:152266495	RIF1	0.7	13.66	0.54	6.12e-36	Lung cancer;
LGG	cis	rs7666738	0.830	rs13116691	chr4:98929771	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg15596359	chr8:11213517	TDH	-0.4	-8.1	-0.35	4.94e-15	Retinal vascular caliber;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg05863683	chr7:1912471	MAD1L1	0.48	9.65	0.41	3.4e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.692	rs34181263	chr15:77065388	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.83	-0.3	2.62e-11	Blood metabolite levels;
LGG	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg04691961	chr3:161091175	C3orf57	-0.45	-8.72	-0.38	4.9e-17	Parkinson's disease;
LGG	cis	rs11190604	0.767	rs10786590	chr10:102164604	T/C	cg07570687	chr10:102243282	WNT8B	0.4	7.04	0.31	6.83e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4760636	0.512	rs11168170	chr12:47995078	C/T	cg12761788	chr12:48120090	P11	0.49	7.84	0.34	3.18e-14	Urate levels;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.48	-0.33	3.66e-13	Lung cancer;
LGG	cis	rs7308134	0.550	rs7299904	chr12:2000098	T/G	cg19708984	chr12:1973340	CACNA2D4	0.41	7.21	0.32	2.35e-12	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg09307838	chr4:120376055	NA	0.79	13.09	0.52	1.62e-33	Corneal astigmatism;
LGG	cis	rs7084402	0.902	rs1346300	chr10:60287635	G/C	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs12765878	1.000	rs2067832	chr10:105643134	G/A	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs7241530	0.610	rs980492	chr18:75895710	G/A	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs2708240	0.577	rs10233374	chr7:147566772	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.31	7.39	0.33	6.69e-13	QT interval (drug interaction);
LGG	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs34366173	1	rs34366173	chr15:63998914	CTT/C	cg12036633	chr15:63758958	NA	-0.4	-6.82	-0.3	2.77e-11	Reticulocyte fraction of red cells;
LGG	cis	rs1007190	0.881	rs75199539	chr17:42930246	A/C	cg15406952	chr17:42872593	NA	1.15	14.64	0.56	3.58e-40	DNA methylation (variation);
LGG	cis	rs9487094	0.885	rs2208209	chr6:109903003	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.74	0.38	4.25e-17	Height;
LGG	cis	rs1014246	0.813	rs11197797	chr10:118454499	C/T	cg14919929	chr10:118506882	NA	0.6	11.39	0.47	1.15e-26	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg00409905	chr10:38381863	ZNF37A	0.52	10.3	0.43	1.5e-22	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11792861	0.591	rs2275641	chr9:111696389	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	11.71	0.48	6.34e-28	Menarche (age at onset);
LGG	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg21775007	chr8:11205619	TDH	-0.46	-6.94	-0.31	1.31e-11	Neuroticism;
LGG	cis	rs36051895	0.732	rs7046736	chr9:5015732	C/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.55	-0.59	3.63e-44	Pediatric autoimmune diseases;
LGG	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.72	-0.3	5.3e-11	Schizophrenia;
LGG	cis	rs4538187	0.585	rs34765999	chr2:64252793	G/A	cg14150252	chr2:64069583	UGP2	-0.46	-9.09	-0.39	3e-18	Systolic blood pressure;
LGG	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg13298116	chr11:62369859	EML3;MTA2	0.69	17.27	0.63	6.09e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.29	0.43	1.65e-22	Diabetic retinopathy;
LGG	cis	rs8016982	0.630	rs61980900	chr14:81686436	T/C	cg01989461	chr14:81687754	GTF2A1	0.79	19.71	0.68	3e-63	Schizophrenia;
LGG	cis	rs2797369	0.665	rs9485443	chr6:101507885	G/T	cg27451362	chr6:101846650	GRIK2	-0.85	-11.38	-0.47	1.3e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs7666738	0.830	rs62321570	chr4:98984276	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.3	-0.32	1.27e-12	Bipolar disorder;
LGG	cis	rs6860806	0.507	rs2631362	chr5:131707293	A/G	cg07395648	chr5:131743802	NA	0.49	10.13	0.43	6.38e-22	Breast cancer;
LGG	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-7.54	-0.33	2.51e-13	Eosinophil percentage of white cells;
LGG	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg10792982	chr14:105748885	BRF1	0.65	13.26	0.52	2.97e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2535633	0.631	rs9823697	chr3:53002150	A/G	cg11645453	chr3:52864694	ITIH4	0.48	8.07	0.35	6.09e-15	Body mass index;
LGG	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg11984989	chr7:158649758	WDR60	-0.95	-18.76	-0.66	8.33e-59	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26268843	chr7:64467056	NA	0.48	6.92	0.31	1.51e-11	Gut microbiome composition (summer);
LGG	cis	rs73416724	1.000	rs76658194	chr6:43357601	C/T	cg26312998	chr6:43337775	ZNF318	0.59	8.32	0.36	9.94e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg15394860	chr11:2017084	H19	0.63	13.76	0.54	2.23e-36	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.51	-0.61	1.77e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg08250081	chr4:10125330	NA	-0.51	-9.83	-0.42	7.53e-21	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-13.85	-0.54	1e-36	Menarche (age at onset);
LGG	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.5e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg13010199	chr12:38710504	ALG10B	-0.45	-7.99	-0.35	1.1e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9814567	1.000	rs6765505	chr3:134208132	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.36	-0.53	1.2e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.54	-10.64	-0.44	8.75e-24	Prudent dietary pattern;
LGG	cis	rs709400	0.628	rs7146506	chr14:103924477	A/G	cg26031613	chr14:104095156	KLC1	0.78	13.76	0.54	2.41e-36	Body mass index;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg27398817	chr8:82754497	SNX16	-0.72	-11.11	-0.46	1.37e-25	Diastolic blood pressure;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.37	7.08	0.31	5.39e-12	Longevity;
LGG	cis	rs7523273	0.526	rs12132968	chr1:207884292	T/C	cg22525895	chr1:207977042	MIR29B2	0.45	8.61	0.37	1.13e-16	Schizophrenia;
LGG	cis	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg13789015	chr9:136890014	NCRNA00094	0.59	10.99	0.45	4.02e-25	Platelet distribution width;
LGG	cis	rs4474465	0.688	rs10501429	chr11:78279790	T/G	cg27205649	chr11:78285834	NARS2	0.6	11.31	0.47	2.34e-26	Alzheimer's disease (survival time);
LGG	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.43	7.54	0.33	2.49e-13	Depressive symptoms;
LGG	cis	rs3540	0.533	rs2256097	chr15:90971331	A/T	cg22089800	chr15:90895588	ZNF774	0.68	12.37	0.5	1.42e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg13607699	chr17:42295918	UBTF	-0.57	-9.47	-0.4	1.43e-19	Total body bone mineral density;
LGG	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg26818010	chr10:134567672	INPP5A	0.66	10.3	0.43	1.56e-22	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6938	0.618	rs2044157	chr15:75225808	G/C	cg09165964	chr15:75287851	SCAMP5	0.69	13.03	0.52	2.81e-33	Breast cancer;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg03528353	chr17:61819722	STRADA	0.43	7.14	0.31	3.64e-12	Prudent dietary pattern;
LGG	cis	rs758324	0.812	rs11750031	chr5:131171251	G/A	cg06307176	chr5:131281290	NA	0.53	8.87	0.38	1.58e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13732083	chr21:47605072	C21orf56	0.56	9.58	0.41	5.79e-20	Testicular germ cell tumor;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17208368	0.657	rs12448373	chr16:55094232	T/C	cg09947736	chr16:55091198	NA	0.67	12.84	0.51	1.67e-32	Hypospadias;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs870825	0.616	rs6419939	chr4:185642869	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	cis	rs365132	1.000	rs353464	chr5:176403023	A/G	cg16309518	chr5:176445507	NA	-0.55	-12.3	-0.5	2.87e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs6438424	0.521	rs12634615	chr3:117748947	A/G	cg07910724	chr3:117604411	NA	0.34	9.11	0.39	2.41e-18	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18252515	chr7:66147081	NA	0.41	6.94	0.31	1.32e-11	Aortic root size;
LGG	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg08807101	chr21:30365312	RNF160	-0.58	-7.97	-0.35	1.27e-14	Cognitive test performance;
LGG	cis	rs6835098	1.000	rs10011724	chr4:174088865	A/G	cg08422745	chr4:174089978	GALNT7	-0.87	-15.5	-0.58	6.15e-44	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg09904177	chr6:26538194	HMGN4	-0.52	-7.26	-0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg12458913	chr13:53173898	NA	0.93	23.04	0.73	8.15e-79	Lewy body disease;
LGG	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.46	-0.33	4.36e-13	Refractive error;
LGG	cis	rs675828	0.765	rs661614	chr13:103351552	G/C	cg19359983	chr13:103346900	C13orf39	0.39	7.12	0.31	4.05e-12	Borderline personality disorder;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg06221963	chr1:154839813	KCNN3	-0.5	-10.0	-0.42	1.89e-21	Prostate cancer;
LGG	cis	rs4948275	0.742	rs2650694	chr10:63286827	C/T	cg03237606	chr10:63212265	TMEM26	-0.37	-6.76	-0.3	4.26e-11	Night sleep phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09920427	chr19:12777674	MORG1;MAN2B1	0.52	8.2	0.36	2.4e-15	Gut microbiome composition (summer);
LGG	cis	rs735860	0.712	rs2294864	chr6:53140928	T/A	cg10236188	chr6:53219634	NA	-0.39	-7.59	-0.33	1.82e-13	Glaucoma;
LGG	cis	rs2307022	0.586	rs3785129	chr16:68401377	G/A	cg07273125	chr16:68295692	NA	0.45	10.08	0.42	9.68e-22	Body mass index;
LGG	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg12658694	chr1:38397304	INPP5B	0.41	8.78	0.38	3.29e-17	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.78	0.41	1.15e-20	Bipolar disorder;
LGG	cis	rs1775715	0.707	rs2808087	chr10:32146444	C/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.98	0.31	1.04e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs12477438	0.501	rs2122748	chr2:100065369	T/A	cg23527387	chr2:100056660	REV1	0.42	9.49	0.4	1.24e-19	Chronic sinus infection;
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.12	-0.6	9.81e-47	Intelligence (multi-trait analysis);
LGG	trans	rs7980799	0.935	rs12301124	chr12:33543024	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-8.69	-0.37	6.53e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg12395012	chr8:11607386	GATA4	0.41	7.41	0.33	5.96e-13	Monocyte count;
LGG	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11890956	chr21:40555474	PSMG1	-0.95	-19.54	-0.67	1.85e-62	Cognitive function;
LGG	cis	rs6688613	0.759	rs61815132	chr1:166920911	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.46	6.92	0.31	1.55e-11	Refractive astigmatism;
LGG	cis	rs34172651	0.617	rs9922436	chr16:24704490	C/G	cg02428538	chr16:24856791	SLC5A11	-0.57	-9.13	-0.39	2.08e-18	Intelligence (multi-trait analysis);
LGG	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg27119904	chr13:114814333	RASA3	0.35	7.14	0.31	3.72e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs6694672	0.867	rs10922166	chr1:197080036	G/C	cg13682187	chr1:196946512	CFHR5	0.5	6.93	0.31	1.45e-11	Asthma;
LGG	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.08	-0.35	5.6e-15	Retinal vascular caliber;
LGG	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	12.55	0.5	2.6e-31	Menarche (age at onset);
LGG	trans	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg18187862	chr3:45730750	SACM1L	-0.57	-9.26	-0.4	7.61e-19	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg25358565	chr5:93447407	FAM172A	1.22	15.22	0.58	1.06e-42	Diabetic retinopathy;
LGG	trans	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.69	11.86	0.48	1.63e-28	Platelet distribution width;
LGG	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-15.97	-0.6	4.85e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2251381	0.565	rs2832279	chr21:30613466	G/T	cg08807101	chr21:30365312	RNF160	0.64	10.59	0.44	1.33e-23	Selective IgA deficiency;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.38e-12	Aortic root size;
LGG	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg00405596	chr8:11794950	NA	-0.44	-7.28	-0.32	1.43e-12	Neuroticism;
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg25019033	chr10:957182	NA	-0.58	-10.63	-0.44	9.5e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg13207630	chr7:32358064	NA	0.68	7.21	0.32	2.33e-12	Body mass index;
LGG	trans	rs2840044	1.000	rs11080357	chr17:33898933	G/A	cg19694781	chr19:47549865	TMEM160	0.53	8.83	0.38	2.24e-17	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00684032	chr4:1343700	KIAA1530	-0.52	-10.79	-0.45	2.27e-24	Obesity-related traits;
LGG	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg19628046	chr18:33552617	C18orf21	0.53	7.7	0.34	8.09e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7267979	0.932	rs6115215	chr20:25562500	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.23	0.43	2.75e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3204270	0.759	rs8071492	chr17:79682650	G/A	cg18367735	chr17:79674897	NA	0.61	7.95	0.35	1.48e-14	Dental caries;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.85	-0.34	2.99e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg26338869	chr17:61819248	STRADA	0.59	10.02	0.42	1.58e-21	Prudent dietary pattern;
LGG	cis	rs6964587	1.000	rs2282975	chr7:91761638	A/G	cg17063962	chr7:91808500	NA	0.51	9.15	0.39	1.76e-18	Breast cancer;
LGG	cis	rs4704187	0.687	rs115403098	chr5:74397384	A/G	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.47	0.4	1.4e-19	Mood instability;
LGG	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg03060546	chr3:49711283	APEH	0.73	13.14	0.52	9.68e-34	Resting heart rate;
LGG	cis	rs9788682	0.747	rs2915695	chr15:78739471	T/C	cg06917634	chr15:78832804	PSMA4	0.53	8.06	0.35	6.39e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2797160	1.000	rs2797154	chr6:126005197	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-7.31	-0.32	1.18e-12	Endometrial cancer;
LGG	cis	rs1707322	0.752	rs28812624	chr1:46203736	T/A	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12643440	0.574	rs1581400	chr4:17139504	A/G	cg22650099	chr4:17144496	NA	-0.5	-8.52	-0.37	2.34e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs7010267	0.935	rs6469788	chr8:119952750	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.32	0.43	1.34e-22	Total body bone mineral density (age 45-60);
LGG	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg03060546	chr3:49711283	APEH	0.59	8.35	0.36	7.71e-16	Menarche (age at onset);
LGG	cis	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg12826209	chr6:26865740	GUSBL1	0.78	8.16	0.35	3.27e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg24764310	chr7:157512201	PTPRN2	-0.46	-10.1	-0.42	8.15e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.68e-12	Morning vs. evening chronotype;
LGG	cis	rs9487094	0.620	rs7768973	chr6:109745325	T/A	cg01125227	chr6:109776195	MICAL1	0.39	6.81	0.3	2.96e-11	Height;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3820068	0.603	rs16851884	chr1:15961871	A/G	cg05660106	chr1:15850417	CASP9	0.83	16.72	0.61	1.94e-49	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00346009	chr12:118541298	VSIG10	0.41	6.81	0.3	3.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2213920	0.749	rs6478172	chr9:118251281	C/T	cg13918206	chr9:118159781	DEC1	0.56	7.4	0.33	6.3e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg26384229	chr12:38710491	ALG10B	-1.08	-29.25	-0.81	2.86e-107	Heart rate;
LGG	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg06623630	chr22:50017776	C22orf34	-0.36	-7.73	-0.34	6.65e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg10483660	chr13:112241077	NA	0.36	7.05	0.31	6.68e-12	Menarche (age at onset);
LGG	trans	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.4	-0.33	6.63e-13	Cognitive ability;
LGG	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg10407489	chr4:1043616	NA	-0.29	-6.65	-0.3	8.22e-11	Recombination rate (males);
LGG	cis	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg14019146	chr3:50243930	SLC38A3	0.54	11.7	0.48	6.8e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs10198293	chr2:99602929	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.45	-0.63	9.34e-53	Chronic sinus infection;
LGG	cis	rs12282928	0.714	rs1354295	chr11:48232547	A/T	cg20307385	chr11:47447363	PSMC3	-0.42	-6.95	-0.31	1.21e-11	Migraine - clinic-based;
LGG	cis	rs62158211	1.000	rs62158211	chr2:114106139	G/T	cg17784749	chr2:114082611	LOC440839	0.63	8.89	0.38	1.37e-17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg16301924	chr13:53314226	LECT1	-0.55	-11.97	-0.49	5.66e-29	Lewy body disease;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20887711	chr4:1340912	KIAA1530	0.94	21.14	0.7	5.98e-70	Longevity;
LGG	cis	rs9290877	0.667	rs6444324	chr3:188457961	C/G	cg17392043	chr3:188495102	LPP	-0.42	-7.22	-0.32	2.13e-12	IgE levels;
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg23730037	chr7:158596552	ESYT2	-0.47	-8.64	-0.37	9.06e-17	Height;
LGG	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg17971929	chr21:40555470	PSMG1	-0.71	-13.6	-0.53	1.1e-35	Cognitive function;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08677398	chr8:58056175	NA	0.5	7.93	0.35	1.7e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs13190888	chr6:28285985	G/A	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs9472414	0.771	rs4714825	chr6:44761546	C/T	cg20913747	chr6:44695427	NA	0.47	7.09	0.31	5.2e-12	Height;
LGG	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg03162506	chr22:38580953	NA	0.28	6.79	0.3	3.35e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg16400903	chr5:693638	TPPP	0.45	6.89	0.3	1.86e-11	Obesity-related traits;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14159672	chr1:205819179	PM20D1	0.65	13.86	0.54	8.69e-37	Monocyte percentage of white cells;
LGG	cis	rs7166081	1.000	rs35151633	chr15:67568265	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.89e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1127311	0.905	rs6702449	chr1:154583210	A/C	cg11650704	chr1:154556575	ADAR	-0.49	-9.53	-0.41	8.8e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2180341	0.781	rs877102	chr6:127587086	T/C	cg24812749	chr6:127587940	RNF146	0.78	12.92	0.51	7.61e-33	Breast cancer;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg20887711	chr4:1340912	KIAA1530	0.47	8.27	0.36	1.42e-15	Obesity-related traits;
LGG	cis	rs67133203	0.904	rs11169652	chr12:51379384	C/T	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg10483660	chr13:112241077	NA	0.44	9.09	0.39	3.02e-18	Menarche (age at onset);
LGG	cis	rs2735413	0.918	rs11150037	chr16:78075774	A/G	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg09427745	chr16:71932006	KIAA0174	-0.51	-7.52	-0.33	2.92e-13	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs875971	0.545	rs12673308	chr7:65631361	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.57e-23	Aortic root size;
LGG	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.64	-0.33	1.26e-13	Mood instability;
LGG	cis	rs11229555	0.645	rs34350060	chr11:58184902	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10824796	0.638	rs10740519	chr10:54517687	A/G	cg27418851	chr10:54531653	MBL2	0.41	7.68	0.34	9.39e-14	Blood protein levels;
LGG	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg02836325	chr17:76403955	PGS1	-0.71	-14.43	-0.56	3e-39	HDL cholesterol levels;
LGG	cis	rs7091068	0.802	rs10786121	chr10:95419796	G/A	cg20715218	chr10:95462985	C10orf4	0.66	10.06	0.42	1.2e-21	Urinary tract infection frequency;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg09264619	chr17:80180166	NA	0.34	6.84	0.3	2.46e-11	Life satisfaction;
LGG	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg11757124	chr7:157526947	PTPRN2	-0.81	-16.47	-0.61	2.73e-48	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.81	-0.38	2.53e-17	Bladder cancer;
LGG	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.15	0.43	5.35e-22	Morning vs. evening chronotype;
LGG	cis	rs2077654	0.822	rs1805036	chr11:17434284	G/A	cg25308976	chr11:17434268	ABCC8	0.85	10.29	0.43	1.68e-22	Gout;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.89	-0.31	1.78e-11	Lung cancer;
LGG	cis	rs7666738	0.830	rs1869082	chr4:98841254	T/A	cg05340658	chr4:99064831	C4orf37	0.47	7.71	0.34	7.8e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.84	0.34	3.05e-14	Myopia (pathological);
LGG	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.51	-9.75	-0.41	1.55e-20	Obesity-related traits;
LGG	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg19442545	chr10:75533431	FUT11	-0.44	-7.36	-0.32	8.68e-13	Inflammatory bowel disease;
LGG	cis	rs4664308	0.692	rs13009231	chr2:160964057	G/T	cg03641300	chr2:160917029	PLA2R1	-0.69	-13.16	-0.52	7.72e-34	Idiopathic membranous nephropathy;
LGG	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg20637307	chr2:213403960	ERBB4	-0.46	-8.95	-0.38	8.6e-18	QT interval (ambient particulate matter interaction);
LGG	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg13010199	chr12:38710504	ALG10B	-0.57	-10.74	-0.45	3.43e-24	Morning vs. evening chronotype;
LGG	cis	rs17227506	0.583	rs56355780	chr8:13483647	A/T	cg03566418	chr8:13424080	C8orf48	0.55	8.21	0.36	2.29e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg11040518	chr10:102331378	NA	-0.37	-6.88	-0.3	1.99e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.17	-0.32	2.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	1.96e-17	Alzheimer's disease;
LGG	cis	rs6546537	1.000	rs6546537	chr2:69839633	T/C	cg10773587	chr2:69614142	GFPT1	-0.45	-7.5	-0.33	3.3e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs7647973	1.000	rs74471041	chr3:49542543	T/G	cg07636037	chr3:49044803	WDR6	-0.78	-13.85	-0.54	1e-36	Menarche (age at onset);
LGG	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22857025	chr5:266934	NA	-1.56	-25.51	-0.76	2.62e-90	Breast cancer;
LGG	cis	rs9443189	0.526	rs9359132	chr6:76289553	G/A	cg01950844	chr6:76311363	SENP6	0.75	9.86	0.42	5.97e-21	Prostate cancer;
LGG	cis	rs7799006	0.527	rs73039284	chr7:2221583	C/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-11.44	-0.47	7.63e-27	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11252926	0.800	rs2209625	chr10:747115	A/C	cg16386425	chr10:429943	DIP2C	0.35	6.7	0.3	6.1e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg21479132	chr6:26055353	NA	0.83	8.09	0.35	5.36e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg08344181	chr3:125677491	NA	-0.65	-7.62	-0.33	1.48e-13	Depression;
LGG	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg22705602	chr4:152727874	NA	-0.33	-7.93	-0.35	1.71e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7572644	0.640	rs4583413	chr2:28074824	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg16141378	chr3:129829833	LOC729375	0.36	8.29	0.36	1.22e-15	Neuroticism;
LGG	cis	rs67311347	1.000	rs9833430	chr3:40459043	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-26.62	-0.78	2.1e-95	Renal cell carcinoma;
LGG	cis	rs1497828	1.000	rs2810777	chr1:217559619	A/C	cg04411442	chr1:217543379	NA	0.46	8.07	0.35	6.21e-15	Dialysis-related mortality;
LGG	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg13902645	chr11:5959945	NA	-0.7	-13.0	-0.52	3.66e-33	DNA methylation (variation);
LGG	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg09818912	chr17:20140352	CYTSB	-0.3	-6.89	-0.31	1.81e-11	Schizophrenia;
LGG	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17830980	chr10:43048298	ZNF37B	0.44	9.96	0.42	2.73e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.44	0.37	4.12e-16	Prostate cancer;
LGG	cis	rs1044826	0.642	rs176983	chr3:139213755	G/A	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs6598955	0.502	rs6683157	chr1:26545865	G/A	cg04990556	chr1:26633338	UBXN11	0.71	10.44	0.44	4.57e-23	Obesity-related traits;
LGG	trans	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.64	9.75	0.41	1.46e-20	Ulcerative colitis;
LGG	trans	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs910187	1.000	rs4555399	chr20:45837896	G/A	cg27589058	chr20:45804311	EYA2	-0.31	-7.49	-0.33	3.59e-13	Migraine;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25072359	chr17:41440525	NA	-0.51	-10.06	-0.42	1.15e-21	Menopause (age at onset);
LGG	cis	rs2797160	1.000	rs1739375	chr6:126012013	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.36	0.32	8.25e-13	Endometrial cancer;
LGG	cis	rs4731207	0.698	rs7811608	chr7:124447848	T/C	cg05630886	chr7:124431682	NA	0.34	7.89	0.34	2.15e-14	Cutaneous malignant melanoma;
LGG	cis	rs9309473	0.950	rs17009149	chr2:73790368	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.71	-0.34	7.97e-14	Metabolite levels;
LGG	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg26150922	chr2:100937072	LONRF2	-0.57	-9.9	-0.42	4.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.37	0.56	5.39e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs8032158	0.927	rs7179116	chr15:56174827	A/G	cg02198044	chr15:56286336	NEDD4	-0.59	-9.11	-0.39	2.43e-18	Keloid;
LGG	cis	rs7649275	1.000	rs2680664	chr3:53765663	A/G	cg21503701	chr3:53781065	CACNA1D	-0.48	-6.83	-0.3	2.7e-11	Trans fatty acid levels;
LGG	cis	rs7177699	0.557	rs12442476	chr15:79117856	G/A	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg13206674	chr6:150067644	NUP43	0.68	15.41	0.58	1.56e-43	Lung cancer;
LGG	cis	rs941873	0.803	rs5015119	chr10:81101609	G/C	cg09469691	chr10:81107165	PPIF	0.57	10.08	0.42	9.47e-22	Height;
LGG	cis	rs3816183	0.797	rs6544599	chr2:43031319	C/A	cg14631114	chr2:43023945	NA	0.5	9.05	0.39	4.1e-18	Hypospadias;
LGG	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg06197492	chr11:2016605	H19	0.45	8.87	0.38	1.64e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs8002861	0.555	rs4942245	chr13:44389479	T/G	cg12856521	chr11:46389249	DGKZ	0.44	7.26	0.32	1.65e-12	Leprosy;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg05863683	chr7:1912471	MAD1L1	0.48	9.07	0.39	3.35e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.62e-12	Prudent dietary pattern;
LGG	cis	rs2916247	1.000	rs9297901	chr8:93036795	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.32	-0.36	9.65e-16	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg00405596	chr8:11794950	NA	-0.46	-7.66	-0.34	1.07e-13	Triglycerides;
LGG	cis	rs10504130	0.666	rs7833668	chr8:52853886	A/G	cg22653915	chr8:52722023	PXDNL	0.43	7.27	0.32	1.52e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11971779	0.666	rs6467847	chr7:139079436	T/C	cg07862535	chr7:139043722	LUC7L2	0.52	8.48	0.37	2.98e-16	Diisocyanate-induced asthma;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg17178900	chr1:205818956	PM20D1	0.51	11.74	0.48	4.91e-28	Monocyte percentage of white cells;
LGG	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg20891283	chr12:69753455	YEATS4	0.7	13.56	0.53	1.63e-35	Blood protein levels;
LGG	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg11742103	chr11:62369870	EML3;MTA2	-0.55	-12.23	-0.49	5.45e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs877426	0.667	rs9525231	chr13:114829711	G/A	cg00571178	chr13:114841904	RASA3	-0.46	-8.45	-0.37	3.8e-16	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs7944735	0.817	rs7924699	chr11:47893120	A/T	cg03929089	chr4:120376271	NA	0.54	6.79	0.3	3.49e-11	Intraocular pressure;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.52e-17	Prudent dietary pattern;
LGG	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg12573674	chr2:1569213	NA	-0.55	-7.44	-0.33	4.85e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg01262667	chr19:19385393	TM6SF2	0.36	7.25	0.32	1.71e-12	Bipolar disorder;
LGG	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg21775007	chr8:11205619	TDH	0.44	6.99	0.31	9.64e-12	Neuroticism;
LGG	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.02	0.68	1.09e-64	Alzheimer's disease;
LGG	cis	rs4731207	0.596	rs3900363	chr7:124667961	C/A	cg05630886	chr7:124431682	NA	-0.31	-7.09	-0.31	5.01e-12	Cutaneous malignant melanoma;
LGG	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg02187348	chr16:89574699	SPG7	0.46	7.42	0.33	5.52e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7929679	0.602	rs10836310	chr11:34808920	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.85	0.3	2.33e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs9357271	0.955	rs9349076	chr6:38345763	A/G	cg07362130	chr6:38359646	BTBD9	-0.45	-9.46	-0.4	1.61e-19	Restless legs syndrome;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.57	10.03	0.42	1.49e-21	Longevity;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg03709012	chr19:19516395	GATAD2A	-0.85	-17.08	-0.62	4.67e-51	Tonsillectomy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26959380	chr12:130498820	NA	0.39	6.76	0.3	4.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg09021430	chr5:549028	NA	0.74	10.57	0.44	1.58e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.26	-0.43	2.22e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg20476274	chr7:133979776	SLC35B4	0.73	13.77	0.54	2.07e-36	Mean platelet volume;
LGG	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg04362960	chr10:104952993	NT5C2	-0.56	-10.75	-0.45	3.36e-24	Arsenic metabolism;
LGG	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.36	-0.43	8.94e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10929925	0.966	rs7584076	chr2:6157693	G/A	cg00493617	chr2:6141445	NA	0.32	7.2	0.32	2.39e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	trans	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg16141378	chr3:129829833	LOC729375	0.34	7.0	0.31	8.89e-12	Triglycerides;
LGG	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.24	-0.43	2.53e-22	Bone mineral density;
LGG	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg17885191	chr8:135476712	NA	0.44	7.0	0.31	8.93e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs36051895	0.664	rs10117501	chr9:5094246	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.48	-0.58	7.19e-44	Pediatric autoimmune diseases;
LGG	cis	rs1620921	0.524	rs4440440	chr6:161183424	A/C	cg01280913	chr6:161186852	NA	-0.51	-10.46	-0.44	4.02e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7567389	0.504	rs5937	chr2:128184770	T/C	cg10021288	chr2:128175891	PROC	0.39	6.99	0.31	9.53e-12	Self-rated health;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.31	-8.3	-0.36	1.12e-15	IgG glycosylation;
LGG	cis	rs668210	0.793	rs586921	chr11:65747701	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-9.48	-0.4	1.34e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg22509189	chr2:225307070	NA	-0.6	-9.3	-0.4	5.6e-19	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7917772	0.582	rs3977756	chr10:104398582	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.12	-0.39	2.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg02711726	chr17:80685570	FN3KRP	-0.38	-7.38	-0.32	7.58e-13	Breast cancer;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg13206674	chr6:150067644	NUP43	0.68	15.97	0.6	4.92e-46	Lung cancer;
LGG	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-7.96	-0.35	1.3e-14	Diabetic retinopathy;
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs55633855	0.516	rs72953019	chr11:88165661	G/T	cg08522340	chr11:88068493	CTSC	-0.4	-6.95	-0.31	1.25e-11	Body mass index;
LGG	cis	rs175714	0.845	rs175702	chr14:75971133	G/T	cg01624173	chr14:75981868	NA	-0.49	-11.57	-0.47	2.26e-27	Lymphocyte counts;
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg00976097	chr5:421733	AHRR	-0.4	-6.68	-0.3	6.72e-11	Cystic fibrosis severity;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg07511668	chr11:68622177	NA	0.47	9.09	0.39	2.81e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.75	-0.38	3.86e-17	Obesity-related traits;
LGG	cis	rs943466	1.000	rs2395400	chr6:33770076	G/A	cg07519485	chr6:33762594	MLN	0.55	10.87	0.45	1.12e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg07677032	chr17:61819896	STRADA	0.42	6.69	0.3	6.5500000000000006e-11	Height;
LGG	trans	rs58106596	0.747	rs10166046	chr2:232560984	C/T	cg01370599	chr3:116745421	NA	-0.57	-8.96	-0.38	8.12e-18	White blood cell count;Lymphocyte counts;
LGG	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg20821713	chr7:1055600	C7orf50	-0.46	-6.65	-0.3	8.26e-11	Bronchopulmonary dysplasia;
LGG	cis	rs6032067	1.000	rs13041304	chr20:43811697	G/A	cg10761708	chr20:43804764	PI3	0.76	11.9	0.48	1.11e-28	Blood protein levels;
LGG	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs3806843	0.933	rs10069930	chr5:140163328	T/A	cg19875535	chr5:140030758	IK	0.5	10.18	0.43	4.25e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7523273	0.606	rs2488255	chr1:207941741	C/T	cg22525895	chr1:207977042	MIR29B2	0.61	12.06	0.49	2.53e-29	Schizophrenia;
LGG	cis	rs972578	0.765	rs7073	chr22:43266363	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.98	-0.31	1.01e-11	Mean platelet volume;
LGG	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12756686	chr19:29218302	NA	0.71	11.56	0.47	2.4200000000000002e-27	Methadone dose in opioid dependence;
LGG	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg15325629	chr6:28072465	NA	0.94	7.24	0.32	1.93e-12	Parkinson's disease;
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.68	-0.34	9.44e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg07636037	chr3:49044803	WDR6	0.99	22.08	0.72	2.54e-74	Menarche (age at onset);
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg04234412	chr22:24373322	LOC391322	-0.73	-14.87	-0.57	3.49e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9863	0.794	rs7133378	chr12:124409502	G/A	cg13487667	chr12:124434373	CCDC92	-0.35	-6.79	-0.3	3.52e-11	White blood cell count;
LGG	cis	rs7192380	0.767	rs11641686	chr16:69580399	A/G	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.36	-0.36	7.31e-16	Sjögren's syndrome;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg07142201	chr11:109293216	C11orf87	0.53	9.33	0.4	4.32e-19	Schizophrenia;
LGG	cis	rs11627756	0.918	rs2403070	chr14:103093432	T/C	cg12046867	chr14:103022105	NA	-0.4	-7.56	-0.33	2.2e-13	Mean platelet volume;
LGG	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg05673287	chr15:77411982	SGK269	-0.44	-9.49	-0.4	1.2e-19	Type 2 diabetes;
LGG	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.47	0.37	3.39e-16	Menarche (age at onset);
LGG	trans	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg20573242	chr4:122745356	CCNA2	0.49	8.92	0.38	1.05e-17	Type 2 diabetes;
LGG	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg06026331	chr20:60912101	LAMA5	0.45	8.35	0.36	7.68e-16	Colorectal cancer;
LGG	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs6964587	0.967	rs10953063	chr7:91576958	A/G	cg17063962	chr7:91808500	NA	-0.49	-8.65	-0.37	8.56e-17	Breast cancer;
LGG	cis	rs9513627	1.000	rs7321381	chr13:100126156	G/A	cg25919922	chr13:100150906	NA	-0.73	-7.54	-0.33	2.46e-13	Obesity-related traits;
LGG	cis	rs17001868	0.568	rs2280790	chr22:40745181	T/C	cg07138101	chr22:40742427	ADSL	0.7	9.05	0.39	4.03e-18	Mammographic density (dense area);
LGG	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg07636037	chr3:49044803	WDR6	1.09	27.78	0.79	1.12e-100	Parkinson's disease;
LGG	cis	rs9818758	0.607	rs34343820	chr3:49309534	C/G	cg00383909	chr3:49044727	WDR6	1.01	12.54	0.5	3.02e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06028808	chr11:68637592	NA	0.73	12.21	0.49	6.7e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	cis	rs6430585	0.528	rs309165	chr2:136667301	T/C	cg07169764	chr2:136633963	MCM6	1.17	22.63	0.72	6.54e-77	Corneal structure;
LGG	cis	rs4851266	1.000	rs11123817	chr2:100835032	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg13482628	chr17:19912719	NA	0.54	10.13	0.43	6.61e-22	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.44	-0.5	7.48e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	0.521	rs1450523	chr3:161077270	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-11.32	-0.47	2.1e-26	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.52	10.19	0.43	3.89e-22	Obesity-related traits;
LGG	cis	rs10849893	0.538	rs7961855	chr12:121829943	C/T	cg01154721	chr12:121881891	KDM2B	-0.41	-6.98	-0.31	1.06e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6940638	0.688	rs9393791	chr6:27132529	C/G	cg12826209	chr6:26865740	GUSBL1	0.44	7.26	0.32	1.69e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.73	-0.38	4.54e-17	Neuroticism;
LGG	cis	rs4731207	0.564	rs6466992	chr7:124692166	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg23752985	chr2:85803571	VAMP8	0.44	8.54	0.37	1.95e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs75920871	0.502	rs10790166	chr11:116779499	A/G	cg20608306	chr11:116969690	SIK3	-0.32	-8.62	-0.37	1.05e-16	Subjective well-being;
LGG	cis	rs4891159	0.790	rs8098821	chr18:74140345	T/C	cg24786174	chr18:74118243	ZNF516	-0.57	-13.08	-0.52	1.8e-33	Longevity;
LGG	cis	rs7590368	0.962	rs13431633	chr2:10960225	T/C	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg01966878	chr4:90757139	SNCA	-0.37	-7.64	-0.33	1.26e-13	Dementia with Lewy bodies;
LGG	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-9.27	-0.4	7.27e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.72	-0.34	7.2e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2579519	0.547	rs11683523	chr2:96544855	T/C	cg22654517	chr2:96458247	NA	0.38	7.57	0.33	1.98e-13	Diastolic blood pressure;
LGG	cis	rs7106204	0.764	rs79362440	chr11:24212972	G/A	ch.11.24196551F	chr11:24239977	NA	0.93	11.03	0.46	2.74e-25	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg08250081	chr4:10125330	NA	0.65	11.82	0.48	2.44e-28	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6121246	0.697	rs6060912	chr20:30325755	C/A	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1044573	0.514	rs2268879	chr20:25177805	C/T	cg06421707	chr20:25228305	PYGB	-0.35	-7.37	-0.32	7.96e-13	Allergic rhinitis;
LGG	cis	rs7312933	0.703	rs10880264	chr12:42586535	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.89	0.31	1.79e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs514406	0.861	rs554760	chr1:53266749	G/A	cg24675658	chr1:53192096	ZYG11B	0.49	9.69	0.41	2.47e-20	Monocyte count;
LGG	cis	rs4851254	0.660	rs17023468	chr2:100694091	A/G	cg17356467	chr2:100759845	AFF3	0.45	7.42	0.33	5.7e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11225247	0.892	rs61123589	chr11:102265467	T/C	cg06323957	chr11:102217781	BIRC2	0.77	6.7	0.3	6.21e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.35	0.32	8.77e-13	Monocyte count;
LGG	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg11789530	chr4:8429930	ACOX3	-0.65	-10.53	-0.44	2.16e-23	Response to antineoplastic agents;
LGG	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg23625390	chr15:77176239	SCAPER	0.39	7.34	0.32	9.63e-13	Blood metabolite levels;
LGG	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.56	7.74	0.34	6.2e-14	Schizophrenia;
LGG	cis	rs6807915	0.603	rs13077979	chr3:12297922	T/G	cg15873301	chr3:12045459	SYN2	-0.42	-7.14	-0.32	3.57e-12	Leprosy;
LGG	cis	rs1003719	0.788	rs4817849	chr21:38469796	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.26	0.4	7.72e-19	Lung cancer;
LGG	cis	rs240764	0.817	rs239246	chr6:101089134	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg19847130	chr8:10466454	RP1L1	0.31	6.95	0.31	1.26e-11	Neuroticism;
LGG	trans	rs2018683	0.523	rs1499227	chr7:29025615	C/T	cg19402173	chr7:128379420	CALU	-0.52	-8.45	-0.37	3.94e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs10267417	0.651	rs10229420	chr7:19935229	G/C	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs6831352	0.840	rs35073321	chr4:100053276	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs13401104	0.716	rs6737755	chr2:237125171	A/G	cg15742758	chr2:237126235	ASB18	0.38	6.77	0.3	3.89e-11	Educational attainment;
LGG	cis	rs4601821	0.635	rs2303380	chr11:113200709	G/A	cg14373873	chr11:113211441	TTC12	0.39	7.74	0.34	6.38e-14	Alcoholic chronic pancreatitis;
LGG	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.09	-0.35	5.2e-15	Bone mineral density;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.3	-7.93	-0.35	1.63e-14	IgG glycosylation;
LGG	trans	rs11088226	0.750	rs2833885	chr21:33923161	A/G	cg09050820	chr6:167586206	TCP10L2	0.67	9.79	0.41	1.04e-20	Gastritis;
LGG	cis	rs17767392	0.918	rs17767499	chr14:71867275	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.67e-18	Mitral valve prolapse;
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs9902453	0.808	rs1986555	chr17:28014448	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.98	0.54	2.72e-37	Coffee consumption (cups per day);
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.48	0.63	6.33e-53	Obesity-related traits;
LGG	cis	rs9311474	1.000	rs1060330	chr3:52288945	T/C	cg14092988	chr3:52407081	DNAH1	0.28	7.45	0.33	4.54e-13	Electroencephalogram traits;
LGG	cis	rs9902453	0.691	rs140701	chr17:28538532	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.61	11.89	0.48	1.25e-28	Coffee consumption (cups per day);
LGG	cis	rs870825	0.929	rs1405941	chr4:185591518	A/C	cg04058563	chr4:185651563	MLF1IP	-0.98	-17.5	-0.63	5.19e-53	Blood protein levels;
LGG	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.59	-0.33	1.73e-13	Calcium levels;
LGG	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg13628971	chr7:2884303	GNA12	0.51	10.45	0.44	4.14e-23	Height;
LGG	cis	rs629922	0.507	rs606942	chr11:114061889	A/T	cg01914181	chr11:114070210	ZBTB16	-0.54	-6.9	-0.31	1.68e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs1707322	0.506	rs2991983	chr1:46079391	T/C	cg03146154	chr1:46216737	IPP	-0.56	-10.62	-0.44	9.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6976053	0.875	rs7783543	chr7:100468398	T/C	cg03098644	chr7:100410630	EPHB4	-0.44	-7.8	-0.34	4.24e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg17376030	chr22:41985996	PMM1	0.55	9.07	0.39	3.49e-18	Vitiligo;
LGG	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg05784532	chr1:230284198	GALNT2	0.52	9.25	0.39	8.48e-19	Coronary artery disease;
LGG	cis	rs7412746	0.658	rs57818453	chr1:150763139	G/A	cg15448220	chr1:150897856	SETDB1	0.38	7.01	0.31	8.61e-12	Melanoma;
LGG	cis	rs9815354	0.909	rs6794477	chr3:41920401	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.3	-0.36	1.13e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs701145	0.617	rs7426835	chr3:154049539	C/T	cg12800244	chr3:153838788	SGEF	0.55	7.55	0.33	2.28e-13	Coronary artery disease;
LGG	cis	rs7091068	0.671	rs514120	chr10:95404400	G/A	cg20715218	chr10:95462985	C10orf4	-0.59	-9.3	-0.4	5.69e-19	Urinary tract infection frequency;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08677398	chr8:58056175	NA	0.55	8.32	0.36	9.65e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21659725	chr3:3221576	CRBN	-0.55	-9.61	-0.41	4.61e-20	Body mass index;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg08621203	chr6:150244597	RAET1G	0.45	7.77	0.34	5.01e-14	Lung cancer;
LGG	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg03162506	chr22:38580953	NA	0.38	8.99	0.39	6.56e-18	Breast cancer;
LGG	cis	rs12422267	0.536	rs11246933	chr12:132610314	G/A	cg08270023	chr12:132619174	NA	-0.41	-6.8	-0.3	3.33e-11	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg10911889	chr6:126070802	HEY2	0.42	7.19	0.32	2.56e-12	Brugada syndrome;
LGG	cis	rs2303319	1.000	rs62188139	chr2:162269775	G/T	cg13806767	chr2:162164127	PSMD14	-0.68	-7.87	-0.34	2.55e-14	Cognitive function;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05665937	chr4:1216051	CTBP1	0.55	10.27	0.43	2.07e-22	Obesity-related traits;
LGG	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.62e-12	Retinal vascular caliber;
LGG	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg03060546	chr3:49711283	APEH	-0.62	-10.24	-0.43	2.5e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7172689	1.000	rs59254248	chr15:81541673	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg27189623	chr16:705930	WDR90	0.4	7.62	0.33	1.44e-13	Height;
LGG	cis	rs11700980	0.636	rs73190119	chr21:30303685	C/A	cg24692254	chr21:30365293	RNF160	-0.59	-7.07	-0.31	5.69e-12	QRS complex (12-leadsum);
LGG	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.41	7.25	0.32	1.81e-12	Depressive symptoms;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg00830817	chr11:109293614	C11orf87	0.42	6.83	0.3	2.63e-11	Schizophrenia;
LGG	trans	rs7819412	0.558	rs11777486	chr8:10908287	C/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.33	-0.32	1.06e-12	Triglycerides;
LGG	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg00198680	chr16:28758506	NA	0.29	7.3	0.32	1.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	23.82	0.74	1.96e-82	Lymphocyte percentage of white cells;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg07142201	chr11:109293216	C11orf87	0.51	9.29	0.4	6.02e-19	Schizophrenia;
LGG	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.41	-7.33	-0.32	1.06e-12	Colorectal cancer;
LGG	cis	rs7619833	0.658	rs1579817	chr3:27310595	C/T	cg02860705	chr3:27208620	NA	0.39	7.45	0.33	4.57e-13	Breast cancer;
LGG	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.32	-0.32	1.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg26578617	chr4:90757533	SNCA	-0.42	-8.69	-0.37	6.08e-17	Dementia with Lewy bodies;
LGG	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	8.01	0.35	9.43e-15	Cognitive test performance;
LGG	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.59	-0.61	7.35e-49	Blood trace element (Zn levels);
LGG	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg22491629	chr6:157744540	C6orf35	-0.97	-13.36	-0.53	1.2e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs17428076	0.958	rs62183762	chr2:172828798	A/G	cg21435375	chr2:172878103	MAP1D	0.45	9.79	0.41	1.04e-20	Myopia;
LGG	cis	rs17039065	0.920	rs11097992	chr4:109468554	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg02975922	chr3:195473998	MUC4	-0.54	-8.96	-0.38	7.89e-18	Pancreatic cancer;
LGG	cis	rs7289126	1.000	rs7290309	chr22:38630287	C/T	cg25457927	chr22:38595422	NA	-0.3	-7.31	-0.32	1.16e-12	Mammographic density (dense area);Percent mammographic density;
LGG	trans	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg05059571	chr16:84539110	KIAA1609	0.42	7.81	0.34	3.89e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg04851639	chr8:1020857	NA	-0.43	-8.56	-0.37	1.62e-16	Schizophrenia;
LGG	cis	rs721917	0.525	rs4281433	chr10:81742660	A/T	cg25562619	chr10:81652821	NA	-0.32	-7.17	-0.32	3.07e-12	Chronic obstructive pulmonary disease;
LGG	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.55	7.16	0.32	3.25e-12	Blood protein levels;
LGG	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg19524238	chr7:2802976	GNA12	0.33	7.99	0.35	1.12e-14	Height;
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.89	-0.51	1.03e-32	Alzheimer's disease;
LGG	trans	rs72991	0.644	rs297486	chr11:121257399	G/A	cg27192990	chr6:129479024	LAMA2	-0.39	-6.67	-0.3	7.45e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg08999081	chr20:33150536	PIGU	-0.39	-9.72	-0.41	1.9e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.57	-0.41	6.66e-20	Height;
LGG	cis	rs6759839	0.761	rs4832443	chr2:16626887	C/T	cg09580478	chr2:16689509	NA	0.49	7.56	0.33	2.19e-13	Mean platelet volume;
LGG	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg05234568	chr11:5960015	NA	-0.74	-12.06	-0.49	2.61e-29	DNA methylation (variation);
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg22398616	chr13:53314203	LECT1	-0.49	-9.88	-0.42	5.05e-21	Lewy body disease;
LGG	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-7.02	-0.31	7.87e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13108043	0.509	rs28533631	chr4:87818090	T/C	cg11209507	chr4:87813803	C4orf36	0.68	9.25	0.39	8.23e-19	Red blood cell count;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.73e-13	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.38	-0.32	7.6e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6089584	0.587	rs13041784	chr20:60561671	T/C	cg06108461	chr20:60628389	TAF4	-0.63	-10.96	-0.45	5.44e-25	Body mass index;
LGG	cis	rs2629540	0.847	rs12762597	chr10:126387043	G/A	cg08799069	chr10:126477246	METTL10	0.64	12.94	0.52	6.75e-33	Cocaine dependence;
LGG	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg01181863	chr3:195395398	SDHAP2	-0.68	-10.37	-0.43	8.55e-23	Pancreatic cancer;
LGG	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10504130	0.502	rs877248	chr8:52851634	G/A	cg24946253	chr8:52722146	PXDNL	-0.49	-7.91	-0.35	1.9e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg01028140	chr2:1542097	TPO	-0.55	-8.38	-0.36	6.17e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.51	-0.44	2.49e-23	Lung cancer;
LGG	cis	rs6546324	0.625	rs4260227	chr2:67843537	G/A	cg18237512	chr2:67827392	NA	-0.4	-7.18	-0.32	2.86e-12	Endometriosis;
LGG	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.64	-0.33	1.22e-13	Testicular germ cell tumor;
LGG	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg02002194	chr4:3960332	NA	0.41	7.49	0.33	3.58e-13	Morning vs. evening chronotype;
LGG	trans	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg11441553	chr12:57614120	NXPH4	-0.58	-7.2	-0.32	2.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4243830	1.000	rs10158949	chr1:6583701	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-10.6	-0.44	1.21e-23	Body mass index;
LGG	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg26384229	chr12:38710491	ALG10B	0.65	12.48	0.5	5.14e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2587949	0.593	rs1444051	chr3:4200013	G/T	cg16519197	chr3:4211558	NA	0.34	6.96	0.31	1.14e-11	Periodontitis (DPAL);
LGG	cis	rs4731207	0.698	rs10250202	chr7:124465509	A/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs7928758	0.943	rs11826381	chr11:134273304	A/G	cg25213107	chr11:134282864	B3GAT1	1.0	13.02	0.52	3.11e-33	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9611519	0.929	rs71327107	chr22:41418229	T/G	cg03806693	chr22:41940476	POLR3H	-0.5	-7.26	-0.32	1.64e-12	Neuroticism;
LGG	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg15704280	chr7:45808275	SEPT13	-0.91	-16.35	-0.61	9.23e-48	Height;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.64	0.67	6.31e-63	Platelet count;
LGG	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg14227996	chr4:17616232	MED28	0.54	7.58	0.33	1.91e-13	Opioid sensitivity;
LGG	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg27147174	chr7:100797783	AP1S1	-0.66	-12.62	-0.51	1.34e-31	Life satisfaction;
LGG	cis	rs9486719	1.000	rs4343922	chr6:96876903	C/T	cg18709589	chr6:96969512	KIAA0776	0.44	6.84	0.3	2.44e-11	Migraine;Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21379008	chr1:154297555	ATP8B2;AQP10	0.46	6.72	0.3	5.31e-11	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.86	0.3	2.25e-11	Longevity;
LGG	cis	rs61931739	0.500	rs11052990	chr12:34058647	T/A	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.11e-25	Morning vs. evening chronotype;
LGG	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07080220	chr10:102295463	HIF1AN	0.6	10.41	0.44	6.01e-23	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg26338869	chr17:61819248	STRADA	-0.59	-10.02	-0.42	1.56e-21	Prudent dietary pattern;
LGG	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg05973401	chr12:123451056	ABCB9	0.5	7.45	0.33	4.49e-13	Neutrophil percentage of white cells;
LGG	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-9.19	-0.39	1.32e-18	Neuroticism;
LGG	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.21	-0.72	6.16e-75	Total body bone mineral density;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10883723	0.810	rs1884929	chr10:104275418	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.96e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs35740288	0.685	rs12899481	chr15:86308970	C/T	cg04173714	chr15:86211321	AKAP13	0.41	7.17	0.32	3.07e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1109114	0.738	rs10073851	chr5:148623217	C/T	cg06539116	chr5:148597365	ABLIM3	-0.49	-11.91	-0.48	1.05e-28	Body mass index;
LGG	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg21055462	chr7:100276975	NA	0.39	7.68	0.34	9.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	14.18	0.55	3.6e-38	Cognitive test performance;
LGG	cis	rs12534701	0.904	rs3817518	chr7:154672809	C/T	cg24255201	chr7:154684926	DPP6	0.53	9.7	0.41	2.21e-20	Colorectal cancer (diet interaction);
LGG	cis	rs9309473	1.000	rs10169714	chr2:73808773	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.62	-0.33	1.43e-13	Metabolite levels;
LGG	cis	rs2587949	0.532	rs2587910	chr3:4198891	A/G	cg16519197	chr3:4211558	NA	-0.35	-7.06	-0.31	6.08e-12	Periodontitis (DPAL);
LGG	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg24130564	chr14:104152367	KLC1	-0.39	-7.14	-0.31	3.64e-12	Reticulocyte count;
LGG	cis	rs881375	0.967	rs1930778	chr9:123641369	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.5	0.47	4.1e-27	Rheumatoid arthritis;
LGG	trans	rs61931739	0.578	rs12426748	chr12:33596654	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.98	-0.35	1.15e-14	Morning vs. evening chronotype;
LGG	cis	rs9309473	1.000	rs1403284	chr2:73726662	A/G	cg20560298	chr2:73613845	ALMS1	0.49	8.0	0.35	1.01e-14	Metabolite levels;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg12741488	chr16:2933841	FLYWCH2	-0.46	-6.85	-0.3	2.35e-11	Beard thickness;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg19168338	chr16:4465731	CORO7	-0.89	-16.65	-0.61	3.84e-49	Schizophrenia;
LGG	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	10.12	0.43	6.98e-22	Height;
LGG	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg13263323	chr15:86062960	AKAP13	-0.39	-8.45	-0.37	3.84e-16	Interstitial lung disease;
LGG	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg20573242	chr4:122745356	CCNA2	0.52	9.53	0.4	9.03e-20	Type 2 diabetes;
LGG	cis	rs7756236	0.521	rs9462208	chr6:36627890	T/C	cg08179530	chr6:36648295	CDKN1A	0.42	6.69	0.3	6.59e-11	QRS duration;
LGG	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg26816564	chr1:7831052	VAMP3	0.8	11.33	0.47	2.01e-26	Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs1920116	0.778	rs12494201	chr3:169559856	T/C	cg08193579	chr3:169529701	LRRC34	0.42	7.28	0.32	1.46e-12	Glioma (high-grade);
LGG	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.45	-0.33	4.61e-13	Neuroticism;
LGG	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.36	-0.32	8.48e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.05	0.35	7.14e-15	Homoarginine levels;
LGG	cis	rs11771526	1.000	rs10231440	chr7:32299435	C/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.16	-0.39	1.68e-18	Response to antipsychotic treatment;
LGG	cis	rs4356932	0.935	rs6532160	chr4:76978199	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs11920090	0.860	rs6780208	chr3:170686066	A/T	cg09710316	chr3:170744871	SLC2A2	0.58	8.37	0.36	7.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs367615	0.704	rs60538082	chr5:108829101	A/G	cg17395555	chr5:108820864	NA	0.87	15.8	0.59	2.72e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg04861929	chr11:109293070	C11orf87	-0.6	-10.73	-0.45	3.99e-24	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg05941027	chr17:61774174	LIMD2	0.37	9.61	0.41	4.7e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12478296	1.000	rs6732595	chr2:243035338	T/C	cg18898632	chr2:242989856	NA	-0.82	-10.17	-0.43	4.73e-22	Obesity-related traits;
LGG	trans	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg16141378	chr3:129829833	LOC729375	0.34	7.66	0.34	1.07e-13	Mood instability;
LGG	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.66	-0.34	1.13e-13	Total cholesterol levels;
LGG	cis	rs6120849	0.754	rs6120813	chr20:33642112	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs8114671	0.967	rs2069948	chr20:33762489	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs74781061	0.860	rs4887147	chr15:74736204	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-6.98	-0.31	1.04e-11	Endometriosis;
LGG	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg15704280	chr7:45808275	SEPT13	0.49	7.96	0.35	1.38e-14	HDL cholesterol;
LGG	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg08603382	chr10:743973	NA	0.41	7.47	0.33	4.03e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs10197940	0.532	rs13425170	chr2:152387112	A/C	cg19508488	chr2:152266495	RIF1	0.55	9.0	0.39	5.81e-18	Lung cancer;
LGG	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.44	-0.63	9.53e-53	Bladder cancer;
LGG	cis	rs5758511	0.680	rs5758682	chr22:42645202	C/T	cg15128208	chr22:42549153	NA	0.75	11.5	0.47	4.15e-27	Birth weight;
LGG	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg12560992	chr17:57184187	TRIM37	-0.86	-15.31	-0.58	4.36e-43	Intelligence (multi-trait analysis);
LGG	cis	rs3862030	0.694	rs41306870	chr10:104229785	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.13e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.91	-19.52	-0.67	2.23e-62	Personality dimensions;
LGG	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs701145	0.585	rs401162	chr3:153905988	T/A	cg12800244	chr3:153838788	SGEF	0.82	8.45	0.37	3.91e-16	Coronary artery disease;
LGG	cis	rs12519773	0.550	rs4242242	chr5:92519387	G/A	cg18783429	chr5:92414398	NA	0.31	7.52	0.33	2.9e-13	Migraine;
LGG	cis	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg03060546	chr3:49711283	APEH	-0.62	-8.17	-0.35	2.95e-15	Menarche (age at onset);
LGG	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.66	0.44	7.28e-24	Morning vs. evening chronotype;
LGG	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg07148914	chr20:33460835	GGT7	0.51	8.13	0.35	4.08e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs1065852	0.526	rs2097562	chr22:42389500	T/C	cg15128208	chr22:42549153	NA	0.41	7.03	0.31	7.51e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.6	0.44	1.16e-23	Lung cancer in ever smokers;
LGG	cis	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.82	-0.48	2.33e-28	Morning vs. evening chronotype;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08115387	chr20:709194	NA	-0.42	-6.82	-0.3	2.82e-11	Electrocardiographic conduction measures;
LGG	cis	rs13260300	0.613	rs2553717	chr8:75531964	T/C	cg22993706	chr8:75542856	NA	0.41	7.93	0.35	1.67e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg21459583	chr1:227974177	NA	-0.45	-6.98	-0.31	1.03e-11	Major depressive disorder;
LGG	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg19507638	chr5:93509721	C5orf36	-0.4	-6.79	-0.3	3.56e-11	Diabetic retinopathy;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.65	-0.33	1.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.83	-0.42	8.05e-21	Eosinophil percentage of white cells;
LGG	cis	rs17428076	0.793	rs3770448	chr2:172692265	A/G	cg21435375	chr2:172878103	MAP1D	0.39	8.39	0.36	5.77e-16	Myopia;
LGG	cis	rs1348850	0.632	rs13009207	chr2:178501632	A/G	cg27490568	chr2:178487706	NA	0.51	9.96	0.42	2.56e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	6.64	0.3	8.63e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.61	0.37	1.12e-16	Neuroticism;
LGG	cis	rs6840360	0.582	rs6813735	chr4:152326990	T/G	cg17217059	chr4:152329364	FAM160A1	0.2	6.88	0.3	1.96e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.52	-0.33	2.83e-13	Neuroticism;
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg16141378	chr3:129829833	LOC729375	0.37	7.9	0.34	2.08e-14	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10668512	chr15:42565522	GANC;TMEM87A	0.54	8.63	0.37	9.56e-17	Gut microbiome composition (summer);
LGG	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	5.95e-19	Coronary artery disease;
LGG	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg00599393	chr8:22457479	C8orf58	-0.43	-8.0	-0.35	1.03e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2692947	0.683	rs62153700	chr2:96581338	C/T	cg22654517	chr2:96458247	NA	0.37	7.07	0.31	5.62e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6882716	0.591	rs10044607	chr5:10806058	G/A	cg14521931	chr5:10832172	NA	-1.07	-18.97	-0.66	8.93e-60	Alcohol consumption (maxi-drinks);
LGG	cis	rs1018836	0.892	rs10103198	chr8:91579436	A/T	cg16814680	chr8:91681699	NA	-0.71	-12.66	-0.51	9.56e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.91	0.35	1.9e-14	Lung cancer;
LGG	cis	rs2860975	0.620	rs7077618	chr10:96793457	T/A	cg09036531	chr10:96991505	NA	-0.47	-8.12	-0.35	4.34e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2186369	0.681	rs9608186	chr22:24142978	C/T	cg10122452	chr22:24128767	SMARCB1	-0.4	-7.98	-0.35	1.16e-14	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.4	0.4	2.58e-19	Bipolar disorder;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg06654118	chr4:1303317	MAEA	-0.42	-7.03	-0.31	7.28e-12	Obesity-related traits;
LGG	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg11901034	chr3:128598214	ACAD9	0.46	6.98	0.31	1.06e-11	IgG glycosylation;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.94e-21	Educational attainment;
LGG	cis	rs2806731	0.600	rs9568877	chr13:54198174	T/C	ch.13.53330881F	chr13:54432880	NA	0.43	7.0	0.31	9.07e-12	Obesity-related traits;
LGG	cis	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.36	-0.4	3.41e-19	Morning vs. evening chronotype;
LGG	cis	rs1010254	0.559	rs17447016	chr5:151737559	A/C	cg12297329	chr5:152029980	NA	-0.47	-6.78	-0.3	3.75e-11	Optic nerve measurement (cup area);
LGG	cis	rs7106204	1.000	rs12798139	chr11:24220907	A/G	ch.11.24196551F	chr11:24239977	NA	0.94	12.23	0.49	5.37e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg08610935	chr16:1836813	NUBP2	0.55	9.55	0.41	7.49e-20	Insulin-like growth factors;
LGG	cis	rs7980687	0.628	rs1727332	chr12:123718301	C/T	cg00376283	chr12:123451042	ABCB9	0.66	11.46	0.47	6.04e-27	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs5753037	0.809	rs5997530	chr22:30203599	C/G	cg27665648	chr22:30112403	NA	0.29	6.69	0.3	6.33e-11	Type 1 diabetes;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg23782820	chr8:58130467	NA	-0.56	-8.35	-0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-12.74	-0.51	4.62e-32	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	12.11	0.49	1.57e-29	Type 2 diabetes;
LGG	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8014204	0.816	rs28426374	chr14:75346740	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.69	-12.89	-0.51	1.11e-32	Caffeine consumption;
LGG	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-9.89	-0.42	4.73e-21	Common traits (Other);
LGG	cis	rs12210905	0.610	rs72845033	chr6:27546262	C/T	cg10122326	chr6:28072925	NA	0.85	6.9	0.31	1.69e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg24558204	chr6:135376177	HBS1L	0.61	10.79	0.45	2.26e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9915657	0.773	rs9894696	chr17:70099487	C/T	cg09344028	chr17:70110421	NA	0.59	14.12	0.55	6.89e-38	Thyroid hormone levels;
LGG	cis	rs8180040	0.652	rs13077398	chr3:47011120	G/C	cg16586182	chr3:47516702	SCAP	-0.76	-14.19	-0.55	3.39e-38	Colorectal cancer;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.93	-9.96	-0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs7851660	0.679	rs7033765	chr9:100591705	A/T	cg13688889	chr9:100608707	NA	0.65	13.55	0.53	1.84e-35	Strep throat;
LGG	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg26874229	chr2:105853672	NA	-0.32	-6.94	-0.31	1.34e-11	Type 2 diabetes;
LGG	cis	rs4642101	0.662	rs9874893	chr3:12833079	C/G	cg24848339	chr3:12840334	CAND2	0.44	10.16	0.43	5.04e-22	QRS complex (12-leadsum);
LGG	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg23815491	chr16:72088622	HP	0.46	7.63	0.33	1.39e-13	Coronary artery disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12891498	chr12:117319246	HRK	0.44	7.35	0.32	8.94e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2455799	0.553	rs2262664	chr3:15768097	A/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.98	-0.35	1.14e-14	Mean platelet volume;
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04063615	chr12:132293388	NA	-0.39	-8.26	-0.36	1.5e-15	Migraine;
LGG	cis	rs3820928	0.874	rs55959848	chr2:227805426	C/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs7928758	0.887	rs76369658	chr11:134268110	C/T	cg15243474	chr11:134282918	B3GAT1	1.24	16.07	0.6	1.72e-46	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg13009111	chr11:71350975	NA	-0.33	-7.34	-0.32	9.87e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7660883	1.000	rs3775223	chr4:88000446	A/T	cg21988461	chr4:88008667	AFF1	-0.33	-9.08	-0.39	3.06e-18	HDL cholesterol levels;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.5	0.33	3.37e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12477438	0.520	rs6542864	chr2:99725223	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs4654899	0.865	rs4654891	chr1:21286391	T/C	cg05370193	chr1:21551575	ECE1	0.3	7.0	0.31	9.04e-12	Superior frontal gyrus grey matter volume;
LGG	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg11822372	chr1:151115635	SEMA6C	0.5	8.77	0.38	3.5e-17	Childhood ear infection;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-12.75	-0.51	3.93e-32	Vitiligo;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10064886	chr14:58764945	FLJ31306;ARID4A	-0.46	-6.66	-0.3	7.86e-11	Systemic lupus erythematosus;
LGG	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.77	0.45	2.82e-24	Diabetic retinopathy;
LGG	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.34	-0.32	9.77e-13	Height;
LGG	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.76	0.54	2.22e-36	Lung cancer in ever smokers;
LGG	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg09307838	chr4:120376055	NA	0.78	12.68	0.51	7.77e-32	Corneal astigmatism;
LGG	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.45	0.33	4.69e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg04995300	chr3:66848608	NA	0.56	8.12	0.35	4.25e-15	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-8.34	-0.36	8.83e-16	Vitiligo;
LGG	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg20712883	chr12:51590929	POU6F1	0.64	10.82	0.45	1.81e-24	Cisplatin-induced ototoxicity;
LGG	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.99	0.39	6.51e-18	Cognitive test performance;
LGG	cis	rs2274273	0.662	rs4525413	chr14:55661138	A/T	cg04306507	chr14:55594613	LGALS3	0.51	12.06	0.49	2.57e-29	Protein biomarker;
LGG	cis	rs4363385	0.818	rs558363	chr1:153010431	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs8062405	0.723	rs62031562	chr16:28609329	A/T	cg16576597	chr16:28551801	NUPR1	0.43	9.84	0.42	6.95e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs36051895	0.589	rs7874785	chr9:5196695	C/T	cg02405213	chr9:5042618	JAK2	0.81	14.66	0.56	3.03e-40	Pediatric autoimmune diseases;
LGG	cis	rs12477438	0.798	rs13393860	chr2:99590397	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.8	-16.38	-0.61	6.9e-48	Lymphocyte counts;
LGG	cis	rs2404602	0.575	rs11633309	chr15:76962349	C/A	cg15268244	chr15:77196840	NA	0.44	8.4	0.36	5.54e-16	Blood metabolite levels;
LGG	trans	rs7830371	0.545	rs2978508	chr8:62108954	C/T	cg09864156	chr10:70939728	SUPV3L1	-0.4	-6.7	-0.3	5.93e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg02227867	chr8:22457446	C8orf58	0.42	7.87	0.34	2.45e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg15971980	chr6:150254442	NA	0.44	8.14	0.35	3.75e-15	Lung cancer;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.03	-0.35	8.13e-15	Skin colour saturation;
LGG	cis	rs5758511	0.637	rs5751244	chr22:42617411	T/C	cg15128208	chr22:42549153	NA	0.73	11.13	0.46	1.17e-25	Birth weight;
LGG	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg18681998	chr4:17616180	MED28	0.82	17.79	0.64	2.43e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg24011408	chr12:48396354	COL2A1	0.5	7.92	0.35	1.83e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs208515	0.556	rs12214562	chr6:66681011	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.09	0.62	4.12e-51	Exhaled nitric oxide levels;
LGG	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.11	-0.46	1.44e-25	Hemoglobin concentration;
LGG	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg26248373	chr2:1572462	NA	-0.87	-15.29	-0.58	4.95e-43	IgG glycosylation;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.93	-0.35	1.67e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg02158880	chr13:53174818	NA	0.37	6.75	0.3	4.54e-11	Lewy body disease;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	ch.10.132646605F	chr10:132756615	NA	-0.43	-6.9	-0.31	1.76e-11	Body fat percentage;
LGG	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg15479754	chr10:1447082	ADARB2	-0.34	-6.95	-0.31	1.28e-11	Radiation response;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.91	0.35	1.87e-14	Lung cancer;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg06719900	chr11:109292894	C11orf87	0.44	8.61	0.37	1.15e-16	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.25	-0.32	1.8e-12	Iron status biomarkers;
LGG	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs4819388	0.751	rs2838533	chr21:45640260	T/C	cg01992765	chr21:45622493	NA	0.47	8.98	0.39	6.9e-18	Celiac disease;
LGG	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg14664628	chr15:75095509	CSK	0.59	9.49	0.4	1.19e-19	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs28374715	0.578	rs10518717	chr15:41623368	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.33	-32.91	-0.84	2.55e-123	Ulcerative colitis;
LGG	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg00405596	chr8:11794950	NA	-0.44	-6.99	-0.31	9.55e-12	Retinal vascular caliber;
LGG	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.35	0.43	9.75e-23	Height;
LGG	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg04287289	chr16:89883240	FANCA	0.49	8.51	0.37	2.37e-16	Vitiligo;
LGG	cis	rs513349	0.964	rs210139	chr6:33543409	A/C	cg13560919	chr6:33536144	NA	0.41	7.16	0.32	3.16e-12	Platelet count;
LGG	cis	rs2463822	0.583	rs72919467	chr11:62040102	G/A	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.36	-0.5	1.58e-30	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs4268898	0.662	rs2303291	chr2:24431184	C/T	cg06627628	chr2:24431161	ITSN2	-0.8	-12.49	-0.5	4.85e-31	Asthma;
LGG	cis	rs6912958	0.712	rs4707383	chr6:88330602	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.71	-0.38	5.28e-17	Monocyte percentage of white cells;
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg11764359	chr7:65958608	NA	-0.73	-13.03	-0.52	2.7e-33	Aortic root size;
LGG	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.63	0.63	1.41e-53	Cognitive function;
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg24623649	chr8:11872141	NA	0.31	6.85	0.3	2.35e-11	Myopia (pathological);
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg13628971	chr7:2884303	GNA12	0.51	10.1	0.42	8.12e-22	Height;
LGG	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg16141378	chr3:129829833	LOC729375	-0.45	-10.97	-0.45	4.67e-25	Mood instability;
LGG	cis	rs741702	0.892	rs11085824	chr19:13001547	A/G	cg04657146	chr19:12876947	HOOK2	-0.44	-7.28	-0.32	1.42e-12	Red blood cell traits;
LGG	trans	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs3820928	0.874	rs10174073	chr2:227794944	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.65	-0.34	1.17e-13	Pulmonary function;
LGG	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg26655873	chr3:72818019	SHQ1	0.34	6.81	0.3	3.02e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.68	0.34	9.66e-14	Educational attainment;
LGG	cis	rs16867335	0.625	rs7573877	chr2:181478111	A/G	cg23363182	chr2:181467187	NA	-0.41	-7.98	-0.35	1.16e-14	Survival in rectal cancer;
LGG	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4363385	0.510	rs11588463	chr1:152901984	T/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.39	-0.4	2.79e-19	Inflammatory skin disease;
LGG	trans	rs3960554	0.808	rs78340819	chr7:75673833	C/G	cg19862616	chr7:65841803	NCRNA00174	0.85	12.27	0.5	3.53e-30	Eotaxin levels;
LGG	trans	rs12545912	0.908	rs10465002	chr8:9582217	G/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg26384229	chr12:38710491	ALG10B	-0.69	-14.17	-0.55	4.17e-38	Morning vs. evening chronotype;
LGG	cis	rs988958	1.000	rs988958	chr2:42287306	A/G	cg27252766	chr2:42229092	NA	-0.43	-6.96	-0.31	1.16e-11	Hypospadias;
LGG	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg24623649	chr8:11872141	NA	-0.32	-7.6	-0.33	1.69e-13	Neuroticism;
LGG	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg24565620	chr2:194026	NA	-0.71	-8.67	-0.37	7.61e-17	Blood protein levels;
LGG	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg15309053	chr8:964076	NA	0.43	8.5	0.37	2.72e-16	Schizophrenia;
LGG	cis	rs11920090	0.789	rs7638027	chr3:170756706	G/C	cg09710316	chr3:170744871	SLC2A2	0.69	8.64	0.37	8.87e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6665290	0.836	rs12593	chr1:227172290	A/G	cg05696931	chr1:227175867	NA	0.39	7.63	0.33	1.31e-13	Myeloid white cell count;
LGG	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-15.43	-0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg08677398	chr8:58056175	NA	0.48	7.01	0.31	8.66e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16099496	chr7:139476910	TBXAS1;HIPK2	0.51	8.02	0.35	8.69e-15	Gut microbiome composition (summer);
LGG	cis	rs73787773	0.867	rs73227496	chr5:111480685	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.23	-0.36	1.96e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg23958373	chr8:599963	NA	0.89	9.71	0.41	2.03e-20	IgG glycosylation;
LGG	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.14	0.39	1.9e-18	Lung cancer in ever smokers;
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	17.52	0.63	4.24e-53	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17248495	chr5:126114298	LMNB1	0.49	7.45	0.33	4.75e-13	Gut microbiome composition (summer);
LGG	cis	rs1832871	0.578	rs262820	chr6:158663101	G/T	cg07215822	chr6:158701037	NA	-0.49	-9.73	-0.41	1.83e-20	Height;
LGG	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg00383909	chr3:49044727	WDR6	0.44	7.08	0.31	5.53e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg08302650	chr8:145750040	LRRC24;LRRC14	0.39	8.33	0.36	9.58e-16	Age at first birth;
LGG	cis	rs72945132	0.882	rs947781	chr11:70212755	G/A	cg14191688	chr11:70257035	CTTN	0.55	8.09	0.35	5.38e-15	Coronary artery disease;
LGG	cis	rs10492096	0.783	rs11064220	chr12:6592574	C/T	cg13857086	chr12:6580257	VAMP1	0.52	7.51	0.33	3.12e-13	Hip geometry;
LGG	cis	rs7512552	0.646	rs1694367	chr1:150329469	T/A	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12286929	0.609	rs11601751	chr11:115094117	C/T	cg04055981	chr11:115044050	NA	0.36	6.72	0.3	5.27e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg27624424	chr6:160112604	SOD2	0.65	9.51	0.4	1.08e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg08888203	chr3:10149979	C3orf24	0.56	9.43	0.4	2.04e-19	Alzheimer's disease;
LGG	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg21045802	chr8:109455806	TTC35	0.5	9.32	0.4	4.95e-19	Dupuytren's disease;
LGG	cis	rs5769765	0.908	rs9616388	chr22:50313438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.66	-0.56	2.94e-40	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.95e-17	Menopause (age at onset);
LGG	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-9.29	-0.4	6.27e-19	HDL cholesterol;
LGG	cis	rs2229238	0.911	rs4390168	chr1:154509096	A/G	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.31e-12	Coronary heart disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16854524	chr4:83931902	LIN54	-0.41	-7.0	-0.31	9.3e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06558623	chr16:89946397	TCF25	1.2	14.08	0.55	1e-37	Skin colour saturation;
LGG	cis	rs1355223	0.525	rs12280958	chr11:34872799	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.36	-0.36	7.56e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.67	-0.34	1.01e-13	Educational attainment (years of education);
LGG	cis	rs9473924	0.505	rs9463664	chr6:50902570	T/A	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs17106184	1.000	rs1474784	chr1:50944634	C/G	cg07174182	chr1:51127561	FAF1	0.53	8.05	0.35	7.09e-15	Type 2 diabetes;
LGG	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg01620082	chr3:125678407	NA	-1.09	-10.5	-0.44	2.9e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.45	8.26	0.36	1.54e-15	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2250704	chr1:231486647	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.41	-0.33	6.24e-13	Hemoglobin concentration;
LGG	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-17.3	-0.63	4.26e-52	Vitiligo;
LGG	cis	rs975739	1.000	rs1766341	chr13:78384264	A/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	3.81e-11	Hair color;
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg02158880	chr13:53174818	NA	0.47	9.0	0.39	5.85e-18	Lewy body disease;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg13628971	chr7:2884303	GNA12	0.48	9.53	0.4	8.84e-20	Height;
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg25660036	chr4:7070649	GRPEL1	-0.51	-7.41	-0.33	6.01e-13	Monocyte percentage of white cells;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg16507663	chr6:150244633	RAET1G	0.47	8.75	0.38	3.99e-17	Lung cancer;
LGG	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs8017423	0.935	rs3742667	chr14:90767856	T/C	cg04374321	chr14:90722782	PSMC1	-0.85	-17.19	-0.62	1.35e-51	Mortality in heart failure;
LGG	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.12	-0.39	2.26e-18	Vitiligo;
LGG	cis	rs1408799	0.772	rs927869	chr9:12748962	A/G	cg05274944	chr9:12693694	TYRP1	0.35	8.39	0.36	5.81e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07080220	chr10:102295463	HIF1AN	0.69	11.75	0.48	4.42e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12681287	0.547	rs7837569	chr8:87507366	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg13647721	chr17:30228624	UTP6	0.64	7.88	0.34	2.35e-14	Hip circumference adjusted for BMI;
LGG	cis	rs61990749	0.597	rs1549119	chr14:78219812	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.15e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg14092988	chr3:52407081	DNAH1	0.31	8.08	0.35	5.67e-15	Bipolar disorder;
LGG	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg07117364	chr1:16154769	NA	-0.5	-9.46	-0.4	1.58e-19	Dilated cardiomyopathy;
LGG	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9818758	0.882	rs74926817	chr3:49378833	C/G	cg00383909	chr3:49044727	WDR6	0.57	8.18	0.36	2.69e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.71	0.48	6.56e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4919044	0.740	rs73319304	chr10:94777045	A/G	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.07	-0.31	5.73e-12	Coronary artery disease;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg16920238	chr17:80076378	CCDC57	0.35	8.07	0.35	6.25e-15	Life satisfaction;
LGG	cis	rs4253772	0.720	rs4253778	chr22:46630634	C/G	cg24881330	chr22:46731750	TRMU	0.58	7.45	0.33	4.76e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	8.88	0.38	1.52e-17	Obesity-related traits;
LGG	cis	rs7552404	0.883	rs11161493	chr1:76206254	T/A	cg22875332	chr1:76189707	ACADM	0.6	10.42	0.44	5.78e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	trans	rs637571	0.544	rs500161	chr11:65695438	C/T	cg17712092	chr4:129076599	LARP1B	0.87	17.63	0.63	1.29e-53	Eosinophil percentage of white cells;
LGG	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg01796438	chr3:11312864	ATG7	-0.61	-8.24	-0.36	1.82e-15	Circulating chemerin levels;
LGG	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg00647317	chr7:50633725	DDC	-0.32	-7.17	-0.32	3.02e-12	Malaria;
LGG	cis	rs7166081	1.000	rs34310656	chr15:67599975	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg00530320	chr1:46809349	NSUN4	0.46	8.48	0.37	3.01e-16	Menopause (age at onset);
LGG	trans	rs561341	0.700	rs886223	chr17:30229877	G/T	cg20587970	chr11:113659929	NA	-0.75	-11.85	-0.48	1.77e-28	Hip circumference adjusted for BMI;
LGG	cis	rs1010254	0.559	rs1592896	chr5:151746085	G/T	cg12297329	chr5:152029980	NA	-0.46	-6.76	-0.3	4.2e-11	Optic nerve measurement (cup area);
LGG	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.53	-0.33	2.65e-13	Myopia (pathological);
LGG	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg12591125	chr7:1885375	MAD1L1	-0.47	-7.29	-0.32	1.39e-12	Bipolar disorder;
LGG	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.83	-0.45	1.59e-24	Height;
LGG	cis	rs4740619	0.836	rs7859780	chr9:15622520	G/C	cg14451791	chr9:16040625	NA	-0.38	-9.89	-0.42	4.82e-21	Body mass index;
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.69	-0.3	6.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08677398	chr8:58056175	NA	0.56	9.02	0.39	5.01e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12200560	0.505	rs59296768	chr6:97075535	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg03929089	chr4:120376271	NA	-1.03	-24.32	-0.75	8.95e-85	Height;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-7.12	-0.31	4.01e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.5	-0.33	3.19e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg17294928	chr15:75287854	SCAMP5	0.66	11.97	0.49	6.12e-29	Caffeine consumption;
LGG	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg21775007	chr8:11205619	TDH	-0.51	-8.39	-0.36	6.07e-16	Triglycerides;
LGG	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg08508325	chr11:3079039	CARS	0.42	8.0	0.35	9.91e-15	Calcium levels;
LGG	trans	rs7395662	0.963	rs11039773	chr11:48513931	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.52	-0.33	2.88e-13	HDL cholesterol;
LGG	cis	rs972578	0.765	rs5751402	chr22:43311523	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.12e-11	Mean platelet volume;
LGG	cis	rs2692947	0.616	rs2301707	chr2:96931846	T/C	cg22654517	chr2:96458247	NA	0.37	7.29	0.32	1.35e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6732160	0.588	rs72841902	chr2:73372212	T/A	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.832	rs896816	chr11:47394338	T/C	cg20307385	chr11:47447363	PSMC3	0.57	10.45	0.44	4.48e-23	Subjective well-being;
LGG	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg01017244	chr2:74357527	NA	0.47	7.96	0.35	1.29e-14	Gestational age at birth (maternal effect);
LGG	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	13.73	0.54	3.19e-36	Response to antipsychotic treatment;
LGG	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.65	-7.67	-0.34	1.01e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11150038	0.536	rs2735416	chr16:78046507	C/G	cg04733911	chr16:78082701	NA	-0.67	-11.01	-0.46	3.24e-25	Colorectal or endometrial cancer;
LGG	cis	rs9329289	0.510	rs9733402	chr10:2551532	G/A	cg15501526	chr10:2543763	NA	0.49	9.28	0.4	6.34e-19	Age-related hearing impairment;
LGG	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07570687	chr10:102243282	WNT8B	0.45	7.88	0.34	2.33e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg07511668	chr11:68622177	NA	0.51	9.86	0.42	6.01e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10354764	chr16:3285464	ZNF200	0.45	7.54	0.33	2.44e-13	Gut microbiome composition (summer);
LGG	cis	rs10861661	0.963	rs10778511	chr12:107225331	A/T	cg15890332	chr12:107067104	RFX4	0.32	7.76	0.34	5.38e-14	Triglyceride levels;
LGG	cis	rs12586317	0.547	rs2254990	chr14:35465565	T/C	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs4950322	0.570	rs116339673	chr1:146800654	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.25e-17	Lung cancer;
LGG	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg12070911	chr6:150209640	RAET1E	0.3	7.24	0.32	1.89e-12	Lung cancer;
LGG	cis	rs9398803	0.965	rs2027299	chr6:126685827	G/C	cg19875578	chr6:126661172	C6orf173	0.55	9.98	0.42	2.18e-21	Male-pattern baldness;
LGG	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg25427524	chr10:38739819	LOC399744	-0.62	-12.48	-0.5	5.06e-31	Extrinsic epigenetic age acceleration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26567249	chr8:97247842	UQCRB	0.47	7.96	0.35	1.38e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs9929218	0.953	rs12920562	chr16:68737512	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-15.14	-0.58	2.25e-42	Colorectal cancer;
LGG	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg20891283	chr12:69753455	YEATS4	1.1	29.0	0.8	3.51e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4253772	0.591	rs6007748	chr22:46657798	A/G	cg24881330	chr22:46731750	TRMU	0.7	8.6	0.37	1.29e-16	LDL cholesterol;Cholesterol, total;
LGG	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg13009111	chr11:71350975	NA	-0.33	-7.34	-0.32	9.51e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12780845	0.540	rs10490962	chr10:17200363	A/G	cg01003015	chr10:17271136	VIM	-0.45	-7.61	-0.33	1.54e-13	Homocysteine levels;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.76	-0.41	1.39e-20	Lung cancer;
LGG	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg20302533	chr7:39170763	POU6F2	0.5	11.52	0.47	3.69e-27	IgG glycosylation;
LGG	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.01	0.42	1.78e-21	Height;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs4820539	0.966	rs2301554	chr22:23484254	A/C	cg21100191	chr22:23484243	RTDR1	1.03	25.21	0.76	6.37e-89	Bone mineral density;
LGG	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.99	-0.31	9.93e-12	Mean corpuscular volume;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24475210	chr4:6642433	MRFAP1	0.4	7.1	0.31	4.73e-12	Obesity-related traits;
LGG	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs77972916	0.505	rs6719754	chr2:43526386	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.2	-0.43	3.45e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08280861	chr8:58055591	NA	0.64	7.97	0.35	1.26e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4865875	1.000	rs10036257	chr5:54107324	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.37	-0.36	6.66e-16	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg12386194	chr3:101231763	SENP7	0.59	10.44	0.44	4.64e-23	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg26174226	chr8:58114915	NA	-0.51	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg11062466	chr8:58055876	NA	0.45	7.5	0.33	3.23e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs4750440	0.585	rs35982189	chr10:14029875	T/C	cg27542038	chr10:14027202	FRMD4A	-0.77	-14.46	-0.56	2.19e-39	Adiponectin levels;
LGG	cis	rs10193935	0.901	rs222479	chr2:42656857	T/G	cg27598129	chr2:42591480	NA	-0.66	-9.84	-0.42	7.02e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.13	-0.6	9.48e-47	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.706	rs11636753	chr15:78928946	G/T	cg03762349	chr15:79060523	ADAMTS7	0.32	7.03	0.31	7.44e-12	Sudden cardiac arrest;
LGG	trans	rs36715	0.953	rs185177	chr5:127547810	A/G	cg16011800	chr17:1958478	HIC1	-0.47	-6.83	-0.3	2.63e-11	Breast cancer;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.7	-0.59	7.31e-45	Platelet count;
LGG	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg16339924	chr4:17578868	LAP3	0.67	11.47	0.47	5.45e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg09044154	chr16:88155775	NA	-0.5	-7.51	-0.33	3.02e-13	Menopause (age at onset);
LGG	trans	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg15704280	chr7:45808275	SEPT13	0.75	7.89	0.34	2.13e-14	Axial length;
LGG	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg05791153	chr7:19748676	TWISTNB	-0.75	-10.42	-0.44	5.57e-23	Thyroid stimulating hormone;
LGG	cis	rs7630877	0.719	rs73057311	chr3:179664197	A/G	cg18765712	chr3:179670323	PEX5L	0.43	6.74	0.3	4.65e-11	Type 2 diabetes;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.48	-0.33	3.88e-13	Tonsillectomy;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11245990	chr11:68621969	NA	0.42	9.04	0.39	4.45e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg02640540	chr1:67518911	SLC35D1	-0.36	-7.18	-0.32	2.85e-12	Lymphocyte percentage of white cells;
LGG	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg16301924	chr13:53314226	LECT1	-0.35	-6.9	-0.31	1.73e-11	Lewy body disease;
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.74	-0.41	1.61e-20	Aortic root size;
LGG	cis	rs8179	0.761	rs42034	chr7:92239144	A/G	cg15732164	chr7:92237376	CDK6	-0.56	-10.35	-0.43	9.9e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg24829409	chr8:58192753	C8orf71	-0.62	-8.34	-0.36	8.71e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	0.966	rs12898844	chr15:57358508	A/T	cg08128148	chr15:57256372	TCF12	-0.33	-7.76	-0.34	5.35e-14	Urinary tract infection frequency;
LGG	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg16049864	chr8:95962084	TP53INP1	-0.43	-9.44	-0.4	1.89e-19	Type 2 diabetes;
LGG	trans	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.66	-0.34	1.11e-13	Joint mobility (Beighton score);
LGG	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg02002194	chr4:3960332	NA	0.38	6.84	0.3	2.49e-11	Morning vs. evening chronotype;
LGG	cis	rs3820928	1.000	rs10197757	chr2:227763244	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.16	-0.32	3.17e-12	Pulmonary function;
LGG	cis	rs10484885	0.759	rs56230212	chr6:90234654	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.66	-7.88	-0.34	2.32e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.73	0.34	6.95e-14	Blood protein levels;
LGG	cis	rs1978968	0.750	rs13053880	chr22:18443500	G/A	cg03078520	chr22:18463400	MICAL3	-0.64	-9.78	-0.41	1.13e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg02725872	chr8:58115012	NA	0.92	12.98	0.52	4.28e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4253772	0.591	rs73886791	chr22:46687212	A/G	cg24881330	chr22:46731750	TRMU	0.78	9.49	0.4	1.18e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12200782	1.000	rs12201802	chr6:26398664	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.1	-0.31	4.59e-12	Small cell lung carcinoma;
LGG	cis	rs12135191	0.741	rs12728000	chr1:236500839	T/C	cg21399712	chr1:236511386	NA	-0.41	-7.75	-0.34	5.77e-14	Urate levels (BMI interaction);
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.72	-0.34	7.32e-14	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs892961	0.932	rs3987887	chr17:75414862	T/C	cg05865280	chr17:75406074	SEPT9	0.42	9.7	0.41	2.18e-20	Airflow obstruction;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg16325326	chr1:53192061	ZYG11B	0.74	17.09	0.62	3.81e-51	Monocyte count;
LGG	cis	rs10197940	0.550	rs77233070	chr2:152416477	G/A	cg19508488	chr2:152266495	RIF1	0.54	8.98	0.38	7.06e-18	Lung cancer;
LGG	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg08975724	chr8:8085496	FLJ10661	0.5	9.35	0.4	3.71e-19	Red cell distribution width;
LGG	cis	rs6793245	0.810	rs7429945	chr3:38591689	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-8.77	-0.38	3.43e-17	QT interval;
LGG	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg02023728	chr11:77925099	USP35	0.46	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg14673194	chr17:80132900	CCDC57	-0.44	-7.72	-0.34	7.15e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs5769707	0.632	rs135872	chr22:50009300	T/C	cg06623630	chr22:50017776	C22orf34	-0.47	-9.38	-0.4	3.05e-19	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs17373728	0.526	rs9298251	chr8:76155416	C/A	cg07016329	chr8:76221503	NA	0.46	8.45	0.37	3.85e-16	Diabetic kidney disease;
LGG	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg16400903	chr5:693638	TPPP	0.46	6.83	0.3	2.68e-11	Obesity-related traits;
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.82	0.38	2.42e-17	Triglycerides;
LGG	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-9.34	-0.4	4.22e-19	Height;
LGG	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg15440763	chr7:158190612	PTPRN2	0.5	10.43	0.44	4.97e-23	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg13010199	chr12:38710504	ALG10B	-0.63	-12.57	-0.5	2.22e-31	Morning vs. evening chronotype;
LGG	cis	rs17253792	0.731	rs3736876	chr14:56120178	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs8180040	0.966	rs11914795	chr3:47557722	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-14.58	-0.56	6.45e-40	Colorectal cancer;
LGG	trans	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs2050392	0.517	rs656600	chr10:30765654	G/A	cg25182066	chr10:30743637	MAP3K8	-0.64	-13.16	-0.52	7.7e-34	Inflammatory bowel disease;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg11494091	chr17:61959527	GH2	0.51	8.16	0.35	3.23e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg04719120	chr6:96025338	MANEA	0.52	7.85	0.34	2.98e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg23302884	chr18:44338147	ST8SIA5	0.45	9.01	0.39	5.32e-18	Personality dimensions;
LGG	cis	rs7853377	0.760	rs2576362	chr9:86572575	G/T	cg12437157	chr9:86433764	GKAP1	0.39	6.7	0.3	6.01e-11	Height;
LGG	cis	rs13420028	0.675	rs28673587	chr2:133193034	C/T	cg02570563	chr2:133174168	GPR39	0.42	6.97	0.31	1.12e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06481639	chr22:41940642	POLR3H	-0.54	-7.88	-0.34	2.32e-14	Vitiligo;
LGG	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.54e-24	Lung cancer in ever smokers;
LGG	cis	rs41005	0.967	rs1974696	chr2:8115782	A/G	cg03155496	chr2:8117019	LOC339788	0.92	22.18	0.72	8.22e-75	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs4919087	0.590	rs78376466	chr10:99034835	G/A	cg25902810	chr10:99078978	FRAT1	-0.42	-6.8	-0.3	3.29e-11	Monocyte count;
LGG	cis	rs9487094	0.670	rs12528781	chr6:109929308	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.97e-14	Height;
LGG	cis	rs11693319	1.000	rs62177297	chr2:179751771	G/A	cg17765952	chr2:179737173	CCDC141	0.59	9.08	0.39	3.21e-18	Blood pressure measurement (cold pressor test);
LGG	cis	rs939658	1.000	rs11072826	chr15:79461516	C/T	cg17916960	chr15:79447300	NA	0.64	12.52	0.5	3.63e-31	Refractive error;
LGG	cis	rs10781543	0.845	rs10781542	chr9:139327439	A/G	cg14169450	chr9:139327907	INPP5E	0.41	7.54	0.33	2.59e-13	Monocyte percentage of white cells;
LGG	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg14456004	chr13:21872349	NA	1.36	25.83	0.77	8.85e-92	White matter hyperintensity burden;
LGG	cis	rs6163	0.588	rs67506723	chr10:104509064	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-7.51	-0.33	2.99e-13	Waist circumference;Hip circumference;
LGG	cis	rs4851254	0.660	rs77023845	chr2:100712346	G/A	cg17356467	chr2:100759845	AFF3	0.46	7.35	0.32	9.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg05484376	chr2:27715224	FNDC4	0.46	9.94	0.42	3.1e-21	Total body bone mineral density;
LGG	cis	rs4363385	0.818	rs382653	chr1:153006761	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg22771759	chr13:24902376	NA	0.42	6.92	0.31	1.55e-11	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs2274273	0.901	rs17674563	chr14:55831125	G/A	cg04306507	chr14:55594613	LGALS3	0.6	16.51	0.61	1.74e-48	Protein biomarker;
LGG	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	cis	rs888194	0.738	rs2241215	chr12:109925489	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.14	-0.32	3.54e-12	Neuroticism;
LGG	cis	rs4900538	0.927	rs8005804	chr14:102957803	A/G	cg18135206	chr14:102964638	TECPR2	0.83	16.25	0.6	2.5e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg06968155	chr5:131705112	SLC22A5	0.72	8.32	0.36	9.6e-16	Rheumatoid arthritis;
LGG	cis	rs815815	0.608	rs815809	chr2:47380203	T/C	cg27223769	chr2:47403360	CALM2	-0.57	-8.57	-0.37	1.59e-16	Dialysis-related mortality;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04180460	chr3:41240962	CTNNB1	0.49	7.49	0.33	3.43e-13	Gut microbiome composition (summer);
LGG	cis	rs4417704	0.551	rs13009903	chr2:241900756	A/G	cg14055004	chr2:241860995	NA	0.28	7.23	0.32	1.98e-12	Joint mobility (Beighton score);
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.04e-12	Bipolar disorder;
LGG	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.79	-0.41	1.1e-20	Menarche (age at onset);
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg02951883	chr7:2050386	MAD1L1	-0.82	-17.75	-0.64	3.62e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg02725872	chr8:58115012	NA	-0.85	-12.22	-0.49	6.06e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.59	-0.33	1.72e-13	Schizophrenia;
LGG	cis	rs2239547	0.522	rs6445550	chr3:52983434	G/A	cg11645453	chr3:52864694	ITIH4	0.69	10.7	0.45	5.13e-24	Schizophrenia;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs858239	0.600	rs6956595	chr7:23134256	A/G	cg23682824	chr7:23144976	KLHL7	0.42	7.26	0.32	1.7e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg05863683	chr7:1912471	MAD1L1	-0.44	-8.44	-0.37	4.15e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7089973	0.872	rs7909657	chr10:116629096	C/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs3008870	0.755	rs3736905	chr1:67392614	A/G	cg02640540	chr1:67518911	SLC35D1	0.38	7.25	0.32	1.78e-12	Lymphocyte percentage of white cells;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.54	0.44	2.03e-23	Obesity-related traits;
LGG	cis	rs3857067	0.806	rs2171384	chr4:95103545	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.9	-0.34	2.09e-14	QT interval;
LGG	cis	rs12618769	0.597	rs55900716	chr2:99109132	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.36	0.32	8.71e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg22907277	chr7:1156413	C7orf50	0.7	13.25	0.52	3.48e-34	Longevity;Endometriosis;
LGG	cis	rs6693567	0.545	rs1932934	chr1:150449195	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.72	0.3	5.52e-11	Migraine;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07362569	chr17:61921086	SMARCD2	0.45	8.75	0.38	4.02e-17	Prudent dietary pattern;
LGG	cis	rs12493885	0.585	rs787812	chr3:153622217	A/G	cg12800244	chr3:153838788	SGEF	0.65	7.5	0.33	3.38e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.66	12.3	0.5	2.77e-30	Lymphocyte counts;
LGG	cis	rs7582720	1.000	rs72932746	chr2:203663498	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6120849	0.754	rs6120793	chr20:33604407	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg13397359	chr6:42928475	GNMT	0.43	9.54	0.41	8.48e-20	Blood protein levels;
LGG	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.54	-0.44	1.95e-23	Corneal structure;
LGG	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs9771228	0.560	rs4723147	chr7:32398156	G/A	cg27532318	chr7:32358331	NA	0.48	6.86	0.3	2.17e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.44	-9.02	-0.39	5.16e-18	Colorectal cancer;
LGG	trans	rs36715	0.868	rs2546147	chr5:127552590	G/A	cg16011800	chr17:1958478	HIC1	-0.48	-7.3	-0.32	1.24e-12	Breast cancer;
LGG	cis	rs2749592	0.918	rs11011388	chr10:38155210	C/T	cg25427524	chr10:38739819	LOC399744	0.56	9.71	0.41	2.01e-20	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg02023728	chr11:77925099	USP35	0.38	6.72	0.3	5.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs11748327	0.881	rs66682948	chr5:4075775	T/C	cg01025095	chr5:4101132	NA	-0.6	-9.71	-0.41	2.1e-20	Myocardial infarction;
LGG	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg27189623	chr16:705930	WDR90	0.4	7.63	0.33	1.34e-13	Height;
LGG	cis	rs4684776	1.000	rs11128552	chr3:11539955	T/G	cg24705426	chr3:11550659	ATG7	-0.48	-8.46	-0.37	3.59e-16	Small vessel stroke;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2735413	0.875	rs12924402	chr16:78083477	C/G	cg04733911	chr16:78082701	NA	-0.77	-18.55	-0.65	7.78e-58	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7226408	0.857	rs72887084	chr18:34503982	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2124969	0.527	rs56040145	chr2:160983850	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.15	-0.39	1.87e-18	Waist circumference adjusted for body mass index;
LGG	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	cis	rs9612	1.000	rs2277745	chr19:44259077	C/T	cg08581076	chr19:44259116	C19orf61	0.51	8.3	0.36	1.18e-15	Exhaled nitric oxide output;
LGG	cis	rs12681287	0.604	rs6471316	chr8:87403587	G/C	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg05090351	chr10:126851162	NA	0.28	6.77	0.3	3.9e-11	Menarche (age at onset);
LGG	cis	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.17	0.35	3.02e-15	Diabetic kidney disease;
LGG	cis	rs7143963	0.666	rs8008502	chr14:103359492	G/A	cg23020514	chr14:103360112	TRAF3	0.4	8.08	0.35	5.72e-15	Body mass index;
LGG	cis	rs1966248	0.656	rs11154745	chr6:134123832	G/A	cg25632230	chr6:134101081	NA	-0.32	-6.76	-0.3	4.12e-11	Coronary artery disease;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg14675211	chr2:100938903	LONRF2	0.69	12.48	0.5	5.33e-31	Intelligence (multi-trait analysis);
LGG	cis	rs11690935	0.589	rs62182403	chr2:172747182	G/A	cg13550731	chr2:172543902	DYNC1I2	0.64	12.22	0.49	5.8e-30	Schizophrenia;
LGG	cis	rs12282928	0.959	rs2870509	chr11:48284109	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.08	-0.31	5.37e-12	Migraine - clinic-based;
LGG	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg11764359	chr7:65958608	NA	0.8	14.96	0.57	1.43e-41	Aortic root size;
LGG	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg02461776	chr11:598696	PHRF1	0.42	6.87	0.3	2.02e-11	Systemic lupus erythematosus;
LGG	trans	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.8	-0.34	4.19e-14	Joint mobility (Beighton score);
LGG	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg25600027	chr14:23388339	RBM23	-0.44	-7.25	-0.32	1.8e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg13206674	chr6:150067644	NUP43	0.68	15.96	0.6	5.39e-46	Lung cancer;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs941873	0.868	rs2233718	chr10:81108956	A/G	cg09469691	chr10:81107165	PPIF	0.6	10.46	0.44	4.05e-23	Height;
LGG	cis	rs526231	0.543	rs246900	chr5:102534629	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.32	-0.36	9.95e-16	Primary biliary cholangitis;
LGG	trans	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg06875740	chr19:51307921	C19orf48	-0.69	-6.97	-0.31	1.12e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4006360	0.575	rs436266	chr17:39313798	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.61	-13.68	-0.54	5.17e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg02631450	chr22:32366979	NA	1.01	9.67	0.41	2.84e-20	Childhood ear infection;
LGG	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg18709589	chr6:96969512	KIAA0776	0.4	7.77	0.34	4.97e-14	Headache;
LGG	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg14835575	chr10:16859367	RSU1	0.35	6.89	0.31	1.77e-11	Platelet distribution width;
LGG	cis	rs1345301	0.518	rs2110661	chr2:102863221	C/T	cg05295703	chr2:102895712	NA	0.49	9.72	0.41	1.91e-20	Waist circumference;
LGG	cis	rs700651	0.789	rs10497812	chr2:198911245	A/G	cg00792783	chr2:198669748	PLCL1	-0.62	-9.8	-0.41	9.79e-21	Intracranial aneurysm;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg25064146	chr11:111957872	TIMM8B;SDHD	-0.43	-6.68	-0.3	6.9e-11	Coronary artery disease;
LGG	trans	rs9818758	0.607	rs9862483	chr3:49195441	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-6.98	-0.31	1.03e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.95e-17	Menopause (age at onset);
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00166722	chr3:10149974	C3orf24	-0.54	-8.96	-0.38	7.74e-18	Alzheimer's disease;
LGG	cis	rs6500637	0.860	rs11644917	chr16:4940387	G/A	cg04440724	chr16:4920505	UBN1	0.63	13.53	0.53	2.3e-35	Cancer;
LGG	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	13.94	0.54	4.01e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	9.74e-36	Lung cancer;
LGG	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-8.87	-0.38	1.6e-17	Gut microbiome composition (summer);
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07791516	chr6:150247246	NA	0.31	6.83	0.3	2.74e-11	Testicular germ cell tumor;
LGG	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	10.9	0.45	9.14e-25	Mean platelet volume;
LGG	cis	rs1719271	0.831	rs1719285	chr15:65182223	T/A	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.25	-0.32	1.78e-12	Platelet count;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.27	-8.04	-0.35	7.78e-15	IgG glycosylation;
LGG	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg07884673	chr3:53033167	SFMBT1	0.66	6.66	0.3	7.86e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg00745463	chr17:30367425	LRRC37B	0.54	7.33	0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg02151108	chr14:50098012	C14orf104	0.39	7.8	0.34	4.02e-14	Carotid intima media thickness;
LGG	cis	rs112591243	0.685	rs74671132	chr21:47963485	T/C	cg10657630	chr21:48055338	PRMT2	0.87	7.53	0.33	2.64e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4950322	0.570	rs79810882	chr1:146707223	G/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.12	-0.35	4.4e-15	Protein quantitative trait loci;
LGG	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07080220	chr10:102295463	HIF1AN	-0.69	-11.88	-0.48	1.3e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15664640	chr17:80829946	TBCD	-0.79	-15.31	-0.58	4.28e-43	Breast cancer;
LGG	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	19.41	0.67	7.43e-62	Smoking behavior;
LGG	trans	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg21659725	chr3:3221576	CRBN	0.74	11.9	0.48	1.17e-28	Resting heart rate;
LGG	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg27411982	chr8:10470053	RP1L1	-0.47	-8.01	-0.35	9.6e-15	Neuroticism;
LGG	trans	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg19894588	chr14:64061835	NA	-0.6	-9.39	-0.4	2.75e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs80282103	0.764	rs12247818	chr10:1110464	G/A	cg08668510	chr10:1095578	IDI1	0.76	8.37	0.36	7.07e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg27446573	chr6:127587934	RNF146	0.74	13.31	0.53	1.93e-34	Breast cancer;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg11211951	chr8:145729740	GPT	-0.6	-14.17	-0.55	4.22e-38	Age at first birth;
LGG	cis	rs11967485	0.534	rs72998909	chr6:157167848	G/A	cg23222435	chr6:157204239	ARID1B	-0.78	-7.44	-0.33	5.07e-13	Calcium levels;
LGG	cis	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg00745463	chr17:30367425	LRRC37B	-0.49	-7.02	-0.31	7.99e-12	Hip circumference adjusted for BMI;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00544901	chr19:49999417	RPS11	0.44	6.98	0.31	1.04e-11	Cognitive performance;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg14668821	chr17:77704760	ENPP7	0.42	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg19507638	chr5:93509721	C5orf36	0.68	9.59	0.41	5.61e-20	Diabetic retinopathy;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.69	-0.3	6.65e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1707322	0.963	rs12145287	chr1:46325002	C/G	cg03146154	chr1:46216737	IPP	0.55	10.52	0.44	2.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg24846343	chr22:24311635	DDTL	-0.46	-6.98	-0.31	1.01e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs1408799	0.720	rs7853779	chr9:12612893	A/G	cg05274944	chr9:12693694	TYRP1	0.33	7.66	0.34	1.07e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs6456156	0.586	rs12213801	chr6:167474084	T/A	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.54e-18	Primary biliary cholangitis;
LGG	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs2976388	0.609	rs2572908	chr8:143802636	A/G	cg06565975	chr8:143823917	SLURP1	0.37	9.43	0.4	2.01e-19	Urinary tract infection frequency;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.7	-0.41	2.28e-20	Obesity-related traits;
LGG	cis	rs61931739	0.649	rs815037	chr12:33725193	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs708547	0.766	rs781545	chr4:57732025	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.54	-0.33	2.56e-13	Response to bleomycin (chromatid breaks);
LGG	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.5	-6.94	-0.31	1.32e-11	Crohn's disease;
LGG	trans	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9397585	0.857	rs6935593	chr6:153378090	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg13397898	chr9:133768931	QRFP	0.36	8.12	0.35	4.16e-15	Response to amphetamines;
LGG	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.64e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.46	-0.37	3.45e-16	Schizophrenia;
LGG	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.2	-0.32	2.4e-12	Joint mobility (Beighton score);
LGG	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.92	-0.38	1.09e-17	Neuroticism;
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26617929	chr16:1858877	NA	-0.66	-9.35	-0.4	3.86e-19	Ankle injury;
LGG	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg21211680	chr2:198530	NA	0.6	7.5	0.33	3.27e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs9914988	0.887	rs11652710	chr17:27145075	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg22907277	chr7:1156413	C7orf50	0.82	11.83	0.48	2.18e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	0.56	8.0	0.35	1.02e-14	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3219090	1.000	rs2666428	chr1:226589709	C/T	cg17127702	chr1:226594323	PARP1	0.38	12.05	0.49	2.89e-29	Melanoma;
LGG	cis	rs9880211	1.000	rs9869630	chr3:136248019	A/C	cg21827317	chr3:136751795	NA	-0.48	-7.19	-0.32	2.64e-12	Body mass index;Height;
LGG	cis	rs7932354	0.528	rs12796744	chr11:47132724	A/T	cg03339077	chr11:47165057	C11orf49	0.55	10.38	0.43	7.55e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.5	-0.33	3.31e-13	Lung cancer;
LGG	cis	rs2070677	0.935	rs2864985	chr10:135348757	C/G	cg20169779	chr10:135381914	SYCE1	0.94	12.16	0.49	9.8e-30	Gout;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17417191	chr1:218458683	RRP15	0.4	7.17	0.32	2.99e-12	Obesity-related traits;
LGG	cis	rs3126085	0.935	rs4326625	chr1:152223996	C/T	cg26876637	chr1:152193138	HRNR	0.52	8.4	0.36	5.54e-16	Atopic dermatitis;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.58	0.65	5.77e-58	Personality dimensions;
LGG	cis	rs1497828	0.956	rs2815240	chr1:217549651	A/T	cg04411442	chr1:217543379	NA	0.48	8.15	0.35	3.32e-15	Dialysis-related mortality;
LGG	cis	rs6028335	0.867	rs59736162	chr20:37709541	A/G	cg16355469	chr20:37678765	NA	0.54	6.75	0.3	4.38e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs12493885	0.725	rs11718646	chr3:153741996	C/T	cg17054900	chr3:154042577	DHX36	-0.72	-8.85	-0.38	1.82e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg01943577	chr7:158741284	NA	-0.46	-8.18	-0.36	2.8e-15	Height;
LGG	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.28	-6.82	-0.3	2.87e-11	Systemic lupus erythematosus;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05447186	chr20:3869454	PANK2	0.41	6.87	0.3	2.08e-11	Bipolar disorder;
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg26897989	chr16:1907736	C16orf73	0.67	10.2	0.43	3.47e-22	Insulin-like growth factors;
LGG	trans	rs12339094	0.591	rs9410969	chr9:90414334	T/A	cg24436365	chr6:63940138	NA	0.47	6.75	0.3	4.45e-11	Smoking quantity;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.73	-0.3	4.93e-11	Bipolar disorder;
LGG	cis	rs11209002	0.592	rs6672126	chr1:67558063	C/G	cg02640540	chr1:67518911	SLC35D1	0.41	7.04	0.31	6.9e-12	Crohn's disease;
LGG	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg08392591	chr16:89556376	ANKRD11	0.59	9.42	0.4	2.12e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg02297831	chr4:17616191	MED28	0.47	8.78	0.38	3.07e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg19223190	chr17:80058835	NA	-0.5	-9.97	-0.42	2.49e-21	Life satisfaction;
LGG	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg08885076	chr2:99613938	TSGA10	-0.39	-8.14	-0.35	3.59e-15	Chronic sinus infection;
LGG	cis	rs28830936	1.000	rs11637341	chr15:41955825	G/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.79	-0.3	3.4e-11	Diastolic blood pressure;
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg13009111	chr11:71350975	NA	-0.32	-7.11	-0.31	4.55e-12	Neuroticism;
LGG	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg19784903	chr17:45786737	TBKBP1	0.32	6.88	0.3	1.94e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg02002194	chr4:3960332	NA	0.45	8.21	0.36	2.19e-15	Neuroticism;
LGG	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Neuroticism;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-8.09	-0.35	5.36e-15	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18500714	chr14:100706288	YY1	-0.44	-7.31	-0.32	1.17e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.18	-0.32	2.83e-12	Prostate-specific antigen levels;
LGG	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-14.18	-0.55	3.71e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs2742417	1.000	rs2742421	chr3:45732515	G/T	cg04837898	chr3:45731254	SACM1L	0.39	7.84	0.34	3.12e-14	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6558530	0.666	rs4242538	chr8:1694010	G/C	cg08198773	chr8:1697536	NA	0.42	7.51	0.33	3.1e-13	Systolic blood pressure;
LGG	cis	rs778371	0.723	rs12105766	chr2:233617647	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	11.84	0.48	2.01e-28	Schizophrenia;
LGG	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg03806693	chr22:41940476	POLR3H	-0.98	-16.76	-0.61	1.28e-49	Vitiligo;
LGG	cis	rs151997	0.777	rs3846500	chr5:50254488	A/T	cg06027927	chr5:50259733	NA	-0.65	-11.48	-0.47	5.15e-27	Callous-unemotional behaviour;
LGG	cis	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg22437258	chr11:111473054	SIK2	-0.42	-6.91	-0.31	1.59e-11	Primary sclerosing cholangitis;
LGG	cis	rs35771425	0.626	rs11119744	chr1:211644575	C/T	cg10512769	chr1:211675356	NA	-0.85	-17.56	-0.63	2.77e-53	Educational attainment (years of education);
LGG	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg23335576	chr14:104009727	NA	0.5	9.18	0.39	1.44e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg15352829	chr14:105391018	PLD4	-0.47	-11.53	-0.47	3.21e-27	Rheumatoid arthritis;
LGG	cis	rs7107174	0.901	rs901105	chr11:77924607	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.86e-13	Testicular germ cell tumor;
LGG	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.4	-0.33	6.65e-13	Life satisfaction;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.2	0.32	2.41e-12	Lung cancer;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg18357526	chr6:26021779	HIST1H4A	0.57	9.75	0.41	1.44e-20	Height;
LGG	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg03788504	chr6:150331562	NA	-0.5	-10.78	-0.45	2.62e-24	Alopecia areata;
LGG	cis	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs2880765	0.743	rs16940052	chr15:86006674	G/A	cg10818794	chr15:86012489	AKAP13	-0.36	-7.54	-0.33	2.44e-13	Coronary artery disease;
LGG	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg08048268	chr3:133502702	NA	-0.51	-8.82	-0.38	2.4e-17	Iron status biomarkers;
LGG	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs698813	0.604	rs7606004	chr2:44479983	G/A	cg00619915	chr2:44497795	NA	-0.61	-8.91	-0.38	1.14e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs300774	0.925	rs300726	chr2:132490	C/G	cg04617936	chr2:214353	NA	-0.51	-7.67	-0.34	1.01e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg14784868	chr12:69753453	YEATS4	0.9	20.16	0.68	2.39e-65	Blood protein levels;
LGG	cis	rs4430311	1.000	rs3008659	chr1:244023962	G/C	cg25706552	chr1:244017396	NA	-0.68	-17.58	-0.63	2.33e-53	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg12070911	chr6:150209640	RAET1E	0.3	7.16	0.32	3.21e-12	Lung cancer;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg22044901	chr15:68126292	NA	-0.43	-7.83	-0.34	3.32e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	13.93	0.54	4.27e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg16797656	chr11:68205561	LRP5	0.52	10.12	0.43	7.24e-22	Total body bone mineral density;
LGG	cis	rs17776563	0.593	rs10852106	chr15:89143115	C/T	cg05013243	chr15:89149849	MIR1179	-0.35	-7.23	-0.32	2.02e-12	Thyroid hormone levels;
LGG	cis	rs9354308	0.764	rs4031877	chr6:66604405	A/G	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.8	-15.96	-0.6	5.46e-46	Longevity;Endometriosis;
LGG	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg17127132	chr2:85788382	GGCX	0.44	7.7	0.34	8.11e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg19336497	chr11:14380999	RRAS2	-0.57	-11.72	-0.48	5.66e-28	Sense of smell;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1957429	0.520	rs12433757	chr14:65296598	T/C	cg23373153	chr14:65346875	NA	-0.78	-8.05	-0.35	7.1e-15	Pediatric areal bone mineral density (radius);
LGG	cis	rs16937	0.711	rs10900461	chr1:205153208	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.55	-0.33	2.34e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14893128	chr20:32077794	CBFA2T2	0.48	7.52	0.33	2.85e-13	Gut microbiome composition (summer);
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg00490583	chr16:1843685	IGFALS	0.42	7.15	0.32	3.37e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg19077165	chr18:44547161	KATNAL2	0.7	13.44	0.53	5.37e-35	Personality dimensions;
LGG	cis	rs9287719	0.967	rs6432121	chr2:10753804	G/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg14210321	chr2:106509881	NCK2	0.45	7.66	0.34	1.12e-13	Addiction;
LGG	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.93	0.31	1.43e-11	Educational attainment;
LGG	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg20673091	chr1:2541236	MMEL1	-0.77	-18.04	-0.64	1.8e-55	Ulcerative colitis;
LGG	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.74	16.15	0.6	7.65e-47	Lymphocyte percentage of white cells;
LGG	cis	rs25645	0.502	rs9895948	chr17:38108363	T/C	cg17467752	chr17:38218738	THRA	0.45	6.94	0.31	1.36e-11	Myeloid white cell count;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18876405	chr7:65276391	NA	-0.55	-9.67	-0.41	2.92e-20	Aortic root size;
LGG	trans	rs853679	0.607	rs13199772	chr6:27834085	A/G	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	cis	rs9596863	1.000	rs1379831	chr13:54418506	C/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.6	0.33	1.7e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs774359	0.750	rs2453565	chr9:27551040	C/T	cg21249376	chr9:27528432	MOBKL2B	0.42	7.11	0.31	4.53e-12	Amyotrophic lateral sclerosis;
LGG	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg20578329	chr17:80767326	TBCD	-0.79	-11.89	-0.48	1.19e-28	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg25706552	chr1:244017396	NA	0.48	6.78	0.3	3.79e-11	RR interval (heart rate);
LGG	cis	rs7267979	1.000	rs6076345	chr20:25381895	T/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.85	0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs62380364	0.507	rs34321	chr5:88020319	C/G	cg22951263	chr5:87985283	NA	-0.57	-10.49	-0.44	3.17e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg11861562	chr11:117069780	TAGLN	0.25	6.85	0.3	2.34e-11	Blood protein levels;
LGG	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg01262667	chr19:19385393	TM6SF2	0.36	7.19	0.32	2.57e-12	Bipolar disorder;
LGG	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg26384229	chr12:38710491	ALG10B	0.93	20.95	0.7	4.7e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg25114630	chr15:101792522	CHSY1	0.54	9.22	0.39	1.06e-18	Corneal structure;
LGG	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg05639522	chr1:247681581	NA	-0.62	-10.49	-0.44	3.04e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs428668	0.523	rs3926389	chr5:150677806	C/T	cg11125805	chr5:150678162	SLC36A3	0.32	6.86	0.3	2.2e-11	Skin aging (microtopography measurement);
LGG	cis	rs4818225	0.804	rs9975388	chr21:42626362	C/A	cg21268422	chr21:42620091	BACE2	0.47	8.52	0.37	2.29e-16	Educational attainment;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg07701084	chr6:150067640	NUP43	0.68	13.12	0.52	1.18e-33	Lung cancer;
LGG	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg23029597	chr12:123009494	RSRC2	-0.84	-15.89	-0.59	1.11e-45	Body mass index;
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-7.28	-0.32	1.47e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7089973	0.872	rs41284358	chr10:116622339	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7949030	0.523	rs67308910	chr11:62377359	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.59	12.49	0.5	4.58e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7789940	0.904	rs61294900	chr7:75937212	A/T	cg10167463	chr7:75959203	YWHAG	-0.44	-7.24	-0.32	1.83e-12	Multiple sclerosis;
LGG	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.9	-0.48	1.16e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.21	-0.43	3.22e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3008870	1.000	rs2985797	chr1:67431499	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-21.92	-0.71	1.45e-73	Lymphocyte percentage of white cells;
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-8.06	-0.35	6.56e-15	Personality dimensions;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7566780	0.630	rs6705856	chr2:16698235	C/T	cg09580478	chr2:16689509	NA	0.51	7.97	0.35	1.2e-14	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.56	0.41	6.77e-20	Bipolar disorder;
LGG	cis	rs3789045	0.819	rs16854023	chr1:204551830	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.5	-9.81	-0.41	9.12e-21	Educational attainment (college completion);
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.0	-0.31	8.79e-12	Menopause (age at onset);
LGG	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg22980697	chr10:16874865	CUBN	0.61	9.84	0.42	7.12e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Aortic root size;
LGG	cis	rs2236293	0.965	rs10758327	chr9:35837284	G/T	cg12876594	chr9:35791798	NPR2	0.4	7.45	0.33	4.47e-13	Blood protein levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25917893	chr19:45458573	CLPTM1	-0.35	-6.69	-0.3	6.53e-11	Pancreatic cancer;
LGG	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg02002194	chr4:3960332	NA	0.38	6.73	0.3	4.93e-11	Morning vs. evening chronotype;
LGG	cis	rs7769051	1.000	rs58832890	chr6:133127139	C/T	cg07930552	chr6:133119739	C6orf192	0.87	12.16	0.49	9.89e-30	Type 2 diabetes nephropathy;
LGG	cis	rs11771526	0.901	rs11761481	chr7:32293994	C/T	cg27532318	chr7:32358331	NA	0.62	6.8	0.3	3.21e-11	Body mass index;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg21782813	chr7:2030301	MAD1L1	0.55	14.43	0.56	2.98e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs28588043	0.818	rs72710571	chr1:170986343	C/T	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg14949292	chr17:78079608	GAA	-0.27	-7.11	-0.31	4.32e-12	Yeast infection;
LGG	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg23625390	chr15:77176239	SCAPER	0.49	9.61	0.41	4.73e-20	Blood metabolite levels;
LGG	cis	rs1451375	0.617	rs10271341	chr7:50591583	A/C	cg20336341	chr7:50628841	DDC	0.42	7.38	0.32	7.51e-13	Malaria;
LGG	trans	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg16141378	chr3:129829833	LOC729375	0.46	11.19	0.46	6.84e-26	Mood instability;
LGG	cis	rs6546537	1.000	rs4852868	chr2:69831636	C/T	cg10773587	chr2:69614142	GFPT1	-0.4	-6.69	-0.3	6.49e-11	Serum thyroid-stimulating hormone levels;
LGG	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg13385794	chr1:248469461	NA	0.48	8.1	0.35	5.01e-15	Common traits (Other);
LGG	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg07150166	chr2:30669952	LCLAT1	-0.61	-8.59	-0.37	1.31e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4474465	0.920	rs7944485	chr11:78225261	T/C	cg27205649	chr11:78285834	NARS2	0.46	7.84	0.34	3.05e-14	Alzheimer's disease (survival time);
LGG	cis	rs4919087	0.810	rs10736115	chr10:99031685	A/G	cg25902810	chr10:99078978	FRAT1	0.45	8.15	0.35	3.44e-15	Monocyte count;
LGG	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg21100191	chr22:23484243	RTDR1	0.54	8.19	0.36	2.64e-15	Serum parathyroid hormone levels;
LGG	cis	rs11239177	0.625	rs10160108	chr10:45061923	T/G	cg03916630	chr10:45065415	NA	0.37	8.91	0.38	1.15e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	trans	rs877282	0.733	rs11253342	chr10:765072	A/G	cg22713356	chr15:30763199	NA	0.52	7.68	0.34	9.24e-14	Uric acid levels;
LGG	cis	rs139371	0.657	rs139301	chr22:39497811	A/G	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.75	-0.3	4.51e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.79	0.3	3.39e-11	Longevity;
LGG	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs17780086	0.529	rs7406406	chr17:30220153	T/G	cg00745463	chr17:30367425	LRRC37B	-0.45	-7.18	-0.32	2.77e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14563165	chr9:130214037	LRSAM1;RPL12	0.43	6.8	0.3	3.32e-11	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg16507663	chr6:150244633	RAET1G	0.45	8.54	0.37	1.88e-16	Lung cancer;
LGG	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg08847335	chr10:891726	LARP4B	-0.37	-7.04	-0.31	7.19e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg26811252	chr16:29126840	RRN3P2	0.76	12.1	0.49	1.72e-29	Menopause (age at onset);
LGG	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24308560	chr3:49941425	MST1R	0.23	7.07	0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7523273	0.925	rs6540443	chr1:208002010	T/A	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.36	-0.47	1.52e-26	Schizophrenia;
LGG	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg25566285	chr7:158114605	PTPRN2	0.91	20.67	0.69	9.56e-68	Calcium levels;
LGG	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-8.66	-0.37	7.91e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2016266	0.929	rs11170495	chr12:53665202	G/A	cg19049858	chr12:53661747	ESPL1	-0.38	-6.82	-0.3	2.9100000000000002e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7107174	1.000	rs1385601	chr11:77936064	A/C	cg02023728	chr11:77925099	USP35	0.46	8.18	0.36	2.66e-15	Testicular germ cell tumor;
LGG	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	10.83	0.45	1.67e-24	Hemoglobin concentration;
LGG	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg12081754	chr8:22256438	SLC39A14	0.72	13.77	0.54	2.19e-36	Verbal declarative memory;
LGG	trans	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg11887960	chr12:57824829	NA	0.6	7.26	0.32	1.64e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg23649088	chr2:200775458	C2orf69	0.54	8.95	0.38	8.71e-18	Osteoporosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12560154	chr19:11925149	ZNF440	0.52	8.02	0.35	8.76e-15	Gut microbiome composition (summer);
LGG	cis	rs787274	0.764	rs4979157	chr9:115571791	T/C	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg26031613	chr14:104095156	KLC1	0.43	6.98	0.31	1.02e-11	Blood metabolite levels;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	9.29	0.4	6.03e-19	Iron status biomarkers;
LGG	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg20673091	chr1:2541236	MMEL1	0.75	18.27	0.65	1.45e-56	Ulcerative colitis;
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06481639	chr22:41940642	POLR3H	0.56	8.2	0.36	2.45e-15	Vitiligo;
LGG	cis	rs9796	0.870	rs2306083	chr15:41347658	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.16	-0.35	3.14e-15	Menopause (age at onset);
LGG	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg10513866	chr5:139070639	NA	0.4	7.87	0.34	2.49e-14	Schizophrenia;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg24503407	chr1:205819492	PM20D1	-0.47	-8.73	-0.38	4.7e-17	Menarche (age at onset);
LGG	cis	rs537930	0.580	rs31201	chr5:134349974	A/C	cg24576358	chr5:134350122	NA	0.44	9.71	0.41	2.15e-20	Height;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.58	-0.47	2.15e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	7.44	0.33	4.89e-13	Obesity-related traits;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs1577917	0.958	rs13213551	chr6:86608701	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.37	-0.4	3.3e-19	Response to antipsychotic treatment;
LGG	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.26	-0.43	2.24e-22	Colorectal cancer;
LGG	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg23495837	chr4:3480318	DOK7	-0.51	-9.57	-0.41	6.21e-20	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs10463316	0.894	rs3846711	chr5:150740749	A/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.37	-0.43	8.15e-23	Metabolite levels (Pyroglutamine);
LGG	trans	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.42	0.4	2.15e-19	Aortic root size;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.26e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17221829	0.733	rs72971009	chr11:89358840	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs6977660	0.660	rs13225400	chr7:19817016	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs986417	0.901	rs10134736	chr14:60998540	A/T	cg27398547	chr14:60952738	C14orf39	0.73	7.02	0.31	7.96e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07570687	chr10:102243282	WNT8B	0.44	7.44	0.33	4.82e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg04733989	chr22:42467013	NAGA	0.59	10.7	0.45	5.21e-24	Schizophrenia;
LGG	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg09021430	chr5:549028	NA	-0.67	-9.21	-0.39	1.17e-18	Obesity-related traits;
LGG	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs6542838	0.702	rs6419564	chr2:99534113	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.1	-0.31	4.74e-12	Fear of minor pain;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.37e-19	Height;
LGG	cis	rs10979	0.597	rs10782290	chr6:143906340	T/C	cg25407410	chr6:143891975	LOC285740	-0.56	-8.3	-0.36	1.19e-15	Hypospadias;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.72	0.41	1.91e-20	Prudent dietary pattern;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00684032	chr4:1343700	KIAA1530	0.45	8.68	0.37	6.62e-17	Obesity-related traits;
LGG	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg20040747	chr15:74715105	SEMA7A	0.4	8.67	0.37	7.49e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	trans	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg02002194	chr4:3960332	NA	0.38	6.75	0.3	4.51e-11	Joint mobility (Beighton score);
LGG	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg07061783	chr6:25882402	NA	0.45	7.89	0.34	2.25e-14	Blood metabolite levels;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg11141652	chr22:24348549	GSTTP1	0.46	7.89	0.34	2.15e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.47	-0.4	1.44e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2479724	1.000	rs2479724	chr6:41890982	T/C	cg17623882	chr6:41773611	USP49	-0.46	-7.97	-0.35	1.22e-14	Menarche (age at onset);
LGG	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg18551225	chr6:44695536	NA	-0.67	-11.11	-0.46	1.36e-25	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg04450456	chr4:17643702	FAM184B	0.33	7.17	0.32	2.92e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4727027	0.866	rs3735311	chr7:148877737	T/C	cg23583168	chr7:148888333	NA	-0.85	-16.47	-0.61	2.56e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10929925	0.832	rs2609190	chr2:6159057	T/C	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs988958	0.565	rs35033846	chr2:42237228	G/A	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg19774624	chr17:42201019	HDAC5	0.65	11.35	0.47	1.66e-26	Total body bone mineral density;
LGG	cis	rs9790314	0.581	rs6806054	chr3:160724978	C/T	cg04691961	chr3:161091175	C3orf57	-0.41	-8.62	-0.37	1.07e-16	Morning vs. evening chronotype;
LGG	cis	rs9513627	1.000	rs3928270	chr13:100184268	A/G	cg15490075	chr13:100150979	NA	0.63	6.73	0.3	5.14e-11	Obesity-related traits;
LGG	cis	rs888194	0.934	rs12314392	chr12:110010866	A/G	cg19025524	chr12:109796872	NA	-0.38	-7.59	-0.33	1.79e-13	Neuroticism;
LGG	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.59	0.37	1.3e-16	Systemic lupus erythematosus;
LGG	cis	rs12410462	0.579	rs78343168	chr1:227621090	G/A	cg23173402	chr1:227635558	NA	0.74	11.39	0.47	1.16e-26	Major depressive disorder;
LGG	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14373873	chr11:113211441	TTC12	0.54	11.69	0.48	7.94e-28	Neuroticism;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.29	0.5	2.99e-30	Obesity-related traits;
LGG	cis	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg26306683	chr17:18585705	ZNF286B	0.38	7.39	0.32	7.14e-13	Educational attainment (years of education);
LGG	cis	rs870825	0.698	rs7673203	chr4:185625397	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs10991814	0.920	rs7852934	chr9:94112399	T/C	cg14446406	chr9:93919335	NA	-0.74	-8.29	-0.36	1.21e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg06951627	chr6:26196580	NA	0.48	7.07	0.31	5.82e-12	Gout;Renal underexcretion gout;
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-10.12	-0.43	6.91e-22	Bipolar disorder;
LGG	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg20913747	chr6:44695427	NA	-0.61	-10.21	-0.43	3.15e-22	Total body bone mineral density;
LGG	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg05791153	chr7:19748676	TWISTNB	0.77	10.45	0.44	4.21e-23	Thyroid stimulating hormone;
LGG	cis	rs7511006	0.859	rs7292228	chr22:50649560	C/G	cg16473166	chr22:50639996	SELO	0.67	11.66	0.48	1.05e-27	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg08677398	chr8:58056175	NA	0.4	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg11890956	chr21:40555474	PSMG1	0.73	12.7	0.51	6.64e-32	Menarche (age at onset);
LGG	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg08477640	chr19:41863820	B9D2	0.42	7.55	0.33	2.3e-13	Colorectal cancer;
LGG	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-13.16	-0.52	7.82e-34	Presence of antiphospholipid antibodies;
LGG	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg08400814	chr5:56204995	C5orf35	0.52	7.68	0.34	9.7e-14	Initial pursuit acceleration;
LGG	cis	rs4748857	1.000	rs4633356	chr10:23548027	T/C	cg18853376	chr10:23633759	C10orf67	0.37	6.77	0.3	3.84e-11	Systemic lupus erythematosus;
LGG	cis	rs9796	0.553	rs7171437	chr15:41315168	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.61	-10.69	-0.44	5.59e-24	Menopause (age at onset);
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.01	-0.31	8.68e-12	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10344404	chr17:35969756	SYNRG	0.43	7.01	0.31	8.63e-12	Cognitive performance;
LGG	cis	rs11785693	0.862	rs6990234	chr8:4996812	A/G	cg26367366	chr8:4980734	NA	1.02	15.57	0.59	2.95e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08624063	chr15:45879286	PLDN	-0.38	-6.91	-0.31	1.63e-11	Brain structure;
LGG	cis	rs7651039	1.000	rs7651039	chr3:15648004	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.52	-0.33	2.88e-13	Coronary heart disease;
LGG	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs10089	0.680	rs3805616	chr5:127520897	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	7.77	0.34	5.23e-14	Ileal carcinoids;
LGG	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-10.09	-0.42	9.08e-22	Body mass index;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg13264159	chr8:625131	ERICH1	-1.05	-12.27	-0.5	3.75e-30	IgG glycosylation;
LGG	cis	rs2377585	0.653	rs10842130	chr12:8847053	C/G	cg03761649	chr12:8850719	RIMKLB	0.49	8.2	0.36	2.36e-15	Reticulocyte fraction of red cells;
LGG	cis	rs2479106	0.824	rs1752169	chr9:126586563	C/A	cg16191174	chr9:126692580	DENND1A	0.45	6.8	0.3	3.26e-11	Polycystic ovary syndrome;
LGG	cis	rs12210905	0.925	rs4541737	chr6:27002821	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg23306229	chr2:178417860	TTC30B	0.63	7.01	0.31	8.64e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg19168338	chr16:4465731	CORO7	-0.9	-17.35	-0.63	2.46e-52	Schizophrenia;
LGG	cis	rs9902453	0.868	rs12944395	chr17:28323499	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.5	-0.53	2.9e-35	Coffee consumption (cups per day);
LGG	cis	rs2235649	0.833	rs9939766	chr16:1852808	C/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.39	-6.72	-0.3	5.41e-11	Blood metabolite levels;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16405210	chr4:1374714	KIAA1530	0.8	14.55	0.56	9.09e-40	Longevity;
LGG	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.44	-0.33	4.82e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.59	-0.37	1.32e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs8032158	0.963	rs16976600	chr15:56154635	C/T	cg02198044	chr15:56286336	NEDD4	-0.69	-11.96	-0.49	6.79e-29	Keloid;
LGG	cis	rs9611519	0.929	rs9611465	chr22:41426139	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-8.0	-0.35	9.92e-15	Neuroticism;
LGG	cis	rs3741151	1.000	rs7125978	chr11:73039229	G/A	cg17517138	chr11:73019481	ARHGEF17	0.95	9.85	0.42	6.56e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11229555	0.609	rs4598685	chr11:58216864	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg13010199	chr12:38710504	ALG10B	0.58	11.26	0.46	3.54e-26	Morning vs. evening chronotype;
LGG	trans	rs12517041	1.000	rs10074124	chr5:23318235	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.1e-25	Calcium levels;
LGG	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.57	-0.33	1.99e-13	Mood instability;
LGG	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg04287289	chr16:89883240	FANCA	0.54	10.22	0.43	3.04e-22	Vitiligo;
LGG	cis	rs2718058	0.630	rs2722359	chr7:37839764	T/C	cg24998770	chr7:37888106	TXNDC3	0.46	7.38	0.32	7.36e-13	Alzheimer's disease (late onset);
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-19.57	-0.67	1.32e-62	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.04	-0.39	4.14e-18	Educational attainment;
LGG	cis	rs7255045	0.788	rs1124820	chr19:12957114	G/A	cg07955356	chr19:12992479	DNASE2	0.43	7.18	0.32	2.8e-12	Mean corpuscular volume;
LGG	cis	rs3126085	0.935	rs12144058	chr1:152170216	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.84	0.38	1.98e-17	Atopic dermatitis;
LGG	cis	rs10789491	0.951	rs35050319	chr1:47103886	C/A	cg15501359	chr1:47185051	KIAA0494	-0.78	-14.33	-0.55	7.94e-39	Response to hepatitis C treatment;
LGG	cis	rs7666738	0.830	rs4323111	chr4:98952276	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.85	0.34	2.88e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.76	-14.23	-0.55	2.26e-38	Platelet count;
LGG	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs17401966	0.931	rs11584023	chr1:10302596	A/G	cg15208524	chr1:10270712	KIF1B	0.44	7.71	0.34	7.71e-14	Hepatocellular carcinoma;
LGG	cis	rs4843747	0.636	rs4075597	chr16:88107590	C/A	cg06374794	chr16:88002281	BANP	0.45	8.34	0.36	8.52e-16	Menopause (age at onset);
LGG	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg02002194	chr4:3960332	NA	0.38	6.97	0.31	1.08e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2282802	0.685	rs2436391	chr5:139557385	C/T	cg26211634	chr5:139558579	C5orf32	-0.35	-7.63	-0.33	1.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.18	0.32	2.84e-12	Lung cancer;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.14e-12	Lung cancer;
LGG	cis	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19171272	chr22:38449367	NA	-0.48	-8.74	-0.38	4.38e-17	Glioblastoma;Glioma;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.73	0.54	3.12e-36	Prudent dietary pattern;
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg00290607	chr11:67383545	NA	-0.65	-11.09	-0.46	1.64e-25	Mean corpuscular volume;
LGG	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.44	-0.44	4.85e-23	Retinal vascular caliber;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg02462569	chr6:150064036	NUP43	-0.45	-9.14	-0.39	1.96e-18	Lung cancer;
LGG	cis	rs2120243	0.539	rs12629552	chr3:157086630	T/A	cg24825693	chr3:157122686	VEPH1	-0.51	-11.1	-0.46	1.54e-25	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10715637	chr10:90751534	FAS;ACTA2	-0.49	-7.84	-0.34	3.16e-14	Gut microbiome composition (summer);
LGG	cis	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19171272	chr22:38449367	NA	-0.57	-11.0	-0.46	3.55e-25	Glioblastoma;Glioma;
LGG	cis	rs1018836	0.663	rs2205151	chr8:91483468	A/C	cg16814680	chr8:91681699	NA	-0.68	-11.84	-0.48	1.96e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg15627072	chr1:2432621	PLCH2	-0.36	-8.14	-0.35	3.75e-15	Multiple sclerosis;
LGG	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg26384229	chr12:38710491	ALG10B	1.06	28.23	0.8	1.09e-102	Heart rate;
LGG	cis	rs2239547	0.522	rs4519686	chr3:52997871	C/T	cg11645453	chr3:52864694	ITIH4	0.66	10.65	0.44	7.84e-24	Schizophrenia;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08280861	chr8:58055591	NA	0.55	6.97	0.31	1.12e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.591	rs3748806	chr1:227751112	A/C	cg04117972	chr1:227635322	NA	-0.45	-8.45	-0.37	3.95e-16	Major depressive disorder;
LGG	cis	rs9783347	1.000	rs2061164	chr11:18329006	T/C	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.27	-0.32	1.5e-12	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10243681	chr15:73925924	NPTN	0.44	6.74	0.3	4.59e-11	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-14.0	-0.55	2.29e-37	Bladder cancer;
LGG	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.11	0.52	1.25e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs858239	0.600	rs2014768	chr7:23122440	C/A	cg23682824	chr7:23144976	KLHL7	0.45	7.81	0.34	3.96e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg03342759	chr3:160939853	NMD3	-0.45	-7.72	-0.34	7.09e-14	Morning vs. evening chronotype;
LGG	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.7	-0.34	8.52e-14	Mood instability;
LGG	trans	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.5	-9.21	-0.39	1.12e-18	Brugada syndrome;
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.97e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg13736514	chr6:26305472	NA	-0.47	-9.66	-0.41	3.19e-20	Educational attainment;
LGG	cis	rs3820928	0.874	rs13385711	chr2:227830414	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.52e-14	Pulmonary function;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.92	0.45	7.21e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10274279	1.000	rs73163814	chr7:157388012	A/G	cg09270525	chr7:157391030	PTPRN2	0.73	9.47	0.4	1.49e-19	Myopia (pathological);
LGG	cis	rs7166081	1.000	rs34221449	chr15:67644263	C/T	cg05925327	chr15:68127851	NA	-0.34	-7.14	-0.31	3.67e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg09873164	chr1:152488093	CRCT1	0.56	11.13	0.46	1.16e-25	Hair morphology;
LGG	cis	rs8056064	0.739	rs12932553	chr16:82820632	G/C	cg08271366	chr16:82816457	CDH13	-0.46	-8.18	-0.36	2.68e-15	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs6784615	0.744	rs3774409	chr3:52496229	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg22676075	chr6:135203613	NA	0.43	7.46	0.33	4.44e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg20608306	chr11:116969690	SIK3	0.33	8.44	0.37	4.09e-16	Blood protein levels;
LGG	trans	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg13565492	chr6:43139072	SRF	-0.76	-9.11	-0.39	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03627896	chr16:30934334	NCRNA00095	0.42	7.01	0.31	8.73e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg19980929	chr12:42632907	YAF2	0.39	8.94	0.38	9.14e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg00405596	chr8:11794950	NA	0.44	7.37	0.32	8.04e-13	Monocyte count;
LGG	cis	rs61931739	0.649	rs861526	chr12:33726434	A/G	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs66573146	0.656	rs111560662	chr4:6952766	C/T	cg02503808	chr4:7069936	GRPEL1	-0.99	-8.6	-0.37	1.27e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	trans	rs7395662	0.745	rs10838830	chr11:48233932	A/G	cg00717180	chr2:96193071	NA	0.43	7.55	0.33	2.31e-13	HDL cholesterol;
LGG	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg20368463	chr18:77673604	PQLC1	-0.61	-11.85	-0.48	1.75e-28	Schizophrenia;
LGG	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	8.42	0.36	4.76e-16	Diabetic retinopathy;
LGG	cis	rs6977660	1.000	rs10279525	chr7:19822305	C/T	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg24675658	chr1:53192096	ZYG11B	-0.62	-13.79	-0.54	1.65e-36	Monocyte count;
LGG	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg22482690	chr17:47019901	SNF8	0.34	6.72	0.3	5.44e-11	Type 2 diabetes;
LGG	cis	rs13401104	0.716	rs11682806	chr2:237138825	A/T	cg15742758	chr2:237126235	ASB18	0.49	7.89	0.34	2.26e-14	Educational attainment;
LGG	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg00277334	chr10:82204260	NA	-0.38	-8.14	-0.35	3.64e-15	Post bronchodilator FEV1;
LGG	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.73	0.34	6.85e-14	Glycated hemoglobin levels;
LGG	cis	rs4242434	0.597	rs1877675	chr8:22533947	C/T	cg19455335	chr8:22457658	C8orf58	0.41	8.21	0.36	2.17e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg05484376	chr2:27715224	FNDC4	0.45	9.66	0.41	2.99e-20	Total body bone mineral density;
LGG	cis	rs300774	0.844	rs300729	chr2:131788	C/G	cg04617936	chr2:214353	NA	0.5	7.55	0.33	2.41e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg23978390	chr7:1156363	C7orf50	-0.54	-9.26	-0.4	7.42e-19	Longevity;Endometriosis;
LGG	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg16096631	chr1:42092165	HIVEP3	0.74	21.76	0.71	8.27e-73	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.58	-10.22	-0.43	2.99e-22	Educational attainment;
LGG	cis	rs1978968	0.717	rs35645198	chr22:18408322	C/T	cg03078520	chr22:18463400	MICAL3	-0.52	-9.96	-0.42	2.71e-21	Presence of antiphospholipid antibodies;
LGG	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg13010199	chr12:38710504	ALG10B	0.43	7.64	0.33	1.25e-13	Morning vs. evening chronotype;
LGG	cis	rs35771425	0.600	rs6667063	chr1:211660746	G/A	cg10512769	chr1:211675356	NA	-0.9	-18.76	-0.66	7.76e-59	Educational attainment (years of education);
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.25e-25	Aortic root size;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	9.29e-19	Menopause (age at onset);
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.3	-0.36	1.12e-15	Longevity;Endometriosis;
LGG	cis	rs7084402	0.967	rs1658463	chr10:60298208	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs17672112	0.512	rs673119	chr6:101371999	T/C	cg27451362	chr6:101846650	GRIK2	0.55	8.0	0.35	9.92e-15	Putamen volume;
LGG	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg20487152	chr13:99095054	FARP1	-0.35	-6.77	-0.3	4e-11	Neuroticism;
LGG	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg06360820	chr2:242988706	NA	-1.08	-12.33	-0.5	2.11e-30	Obesity-related traits;
LGG	cis	rs7945718	1.000	rs7945719	chr11:12748820	A/C	cg25843174	chr11:12811716	TEAD1	0.41	8.43	0.36	4.37e-16	Educational attainment (years of education);
LGG	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-13.5	-0.53	2.84e-35	Parkinson's disease;
LGG	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg03959625	chr15:84868606	LOC388152	0.55	8.71	0.38	5.43e-17	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13600149	chr9:98079129	FANCC	0.46	7.69	0.34	9.04e-14	Cognitive performance;
LGG	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg03258749	chr1:151040405	MLLT11	0.53	9.29	0.4	6.08e-19	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14242042	chr12:24715250	SOX5	0.46	7.76	0.34	5.5e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg22437258	chr11:111473054	SIK2	0.39	6.75	0.3	4.53e-11	Primary sclerosing cholangitis;
LGG	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-11.91	-0.48	9.91e-29	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	trans	rs11976180	1.000	rs6464574	chr7:143748257	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.91	-0.31	1.59e-11	Obesity-related traits;
LGG	cis	rs12220238	1.000	rs10824130	chr10:76008931	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.43	0.47	7.69e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg20503657	chr10:835505	NA	0.62	9.32	0.4	4.63e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11997175	0.574	rs4364597	chr8:33653729	G/C	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg20673091	chr1:2541236	MMEL1	0.76	17.46	0.63	7.96e-53	Multiple sclerosis;
LGG	cis	rs9916302	0.851	rs6503502	chr17:37501855	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs115344852	0.598	rs2531815	chr6:28436060	C/T	cg13525197	chr6:28411240	ZSCAN23	-0.49	-7.44	-0.33	5e-13	Epithelial ovarian cancer;
LGG	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.73	-0.41	1.76e-20	Common traits (Other);
LGG	cis	rs1348850	0.567	rs4893838	chr2:178531436	T/C	cg27490568	chr2:178487706	NA	0.52	10.07	0.42	1.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9463078	0.764	rs9395051	chr6:44825715	C/A	cg25276700	chr6:44698697	NA	-0.41	-8.64	-0.37	8.95e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.46	-0.33	4.24e-13	Body mass index;
LGG	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg06916706	chr16:4465613	CORO7	0.71	12.28	0.5	3.34e-30	Schizophrenia;
LGG	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg05169160	chr2:178484487	TTC30A	-0.34	-6.66	-0.3	7.92e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg08621203	chr6:150244597	RAET1G	0.39	6.67	0.3	7.36e-11	Lung cancer;
LGG	cis	rs72925845	0.577	rs691061	chr17:76429847	C/T	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg14675211	chr2:100938903	LONRF2	-0.64	-11.12	-0.46	1.26e-25	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.83e-12	Menopause (age at onset);
LGG	cis	rs11711311	0.955	rs9851812	chr3:113412362	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.57	-0.33	1.99e-13	IgG glycosylation;
LGG	cis	rs6032067	0.641	rs34811768	chr20:43765800	T/C	cg10761708	chr20:43804764	PI3	0.74	11.11	0.46	1.4e-25	Blood protein levels;
LGG	cis	rs1555322	0.530	rs6058224	chr20:33881774	C/T	cg03689076	chr20:33865952	NA	0.56	8.0	0.35	1.03e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.59	0.53	1.18e-35	Cognitive test performance;
LGG	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg11812906	chr14:75593930	NEK9	-0.43	-7.54	-0.33	2.46e-13	Height;
LGG	cis	rs28595532	0.920	rs114223775	chr4:119775091	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs4849845	0.584	rs3896630	chr2:121037018	A/G	cg15425061	chr2:121036351	RALB	0.37	6.97	0.31	1.12e-11	Mean platelet volume;
LGG	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs367943	1.000	rs348930	chr5:112814763	T/C	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	trans	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8044868	0.586	rs6499557	chr16:72082654	A/G	cg23815491	chr16:72088622	HP	0.36	7.61	0.33	1.56e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6594713	0.679	rs66572866	chr5:112761470	G/A	cg12552261	chr5:112820674	MCC	0.65	8.23	0.36	1.86e-15	Brain cytoarchitecture;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg14653418	chr10:32217953	ARHGAP12	-0.45	-6.67	-0.3	7.49e-11	Educational attainment (years of education);
LGG	cis	rs283228	0.550	rs687497	chr6:101792897	G/A	cg27451362	chr6:101846650	GRIK2	1.02	15.5	0.58	6.11e-44	Coenzyme Q10 levels;
LGG	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg13147721	chr7:65941812	NA	-0.79	-9.58	-0.41	5.9e-20	Diabetic kidney disease;
LGG	cis	rs4918072	0.917	rs12571879	chr10:105663346	G/A	cg11005552	chr10:105648138	OBFC1	0.72	12.28	0.5	3.31e-30	Coronary artery disease;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.63	-0.33	1.32e-13	Schizophrenia;
LGG	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg11984989	chr7:158649758	WDR60	-0.96	-19.86	-0.68	6.08e-64	Height;
LGG	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg26441486	chr22:50317300	CRELD2	0.41	7.77	0.34	5.04e-14	Schizophrenia;
LGG	cis	rs8044868	0.566	rs3812984	chr16:72207797	C/T	cg23815491	chr16:72088622	HP	0.35	7.37	0.32	7.96e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg25356066	chr3:128598488	ACAD9	0.45	6.95	0.31	1.24e-11	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.27	-0.36	1.43e-15	Life satisfaction;
LGG	trans	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.26	0.4	7.81e-19	Primary sclerosing cholangitis;
LGG	cis	rs3796352	0.667	rs11720228	chr3:52877270	G/A	cg12962167	chr3:53033115	SFMBT1	0.64	7.24	0.32	1.88e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg18225595	chr11:63971243	STIP1	0.57	7.58	0.33	1.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6028335	0.674	rs3829696	chr20:37634704	C/T	cg16355469	chr20:37678765	NA	-0.52	-7.27	-0.32	1.5e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4771122	0.740	rs1006353	chr13:28047269	A/G	cg01674679	chr13:27998804	GTF3A	0.58	8.69	0.37	6.26e-17	Body mass index;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.75	-0.59	4.51e-45	Platelet count;
LGG	cis	rs2718058	0.589	rs7779539	chr7:37795566	G/A	cg24998770	chr7:37888106	TXNDC3	-0.41	-7.0	-0.31	8.91e-12	Alzheimer's disease (late onset);
LGG	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.18	-0.52	6.42e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg03563238	chr19:33554763	RHPN2	0.4	7.66	0.34	1.07e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.46	-0.47	6.25e-27	Hemoglobin concentration;
LGG	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.46	-0.37	3.53e-16	Restless legs syndrome;
LGG	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.62e-12	Cognitive ability;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg16359550	chr11:109292809	C11orf87	0.4	7.93	0.35	1.66e-14	Schizophrenia;
LGG	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg19637330	chr1:19110922	NA	-0.41	-6.7	-0.3	6.12e-11	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs9783347	0.890	rs11024634	chr11:18392074	G/A	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.04	-0.31	6.81e-12	Pancreatic cancer;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg12708336	chr17:41446283	NA	-0.33	-8.0	-0.35	1.04e-14	Menopause (age at onset);
LGG	cis	rs4671458	0.948	rs1517403	chr2:63540324	A/G	cg17519650	chr2:63277830	OTX1	-0.61	-7.84	-0.34	3.13e-14	Subjective well-being;
LGG	cis	rs1957429	0.614	rs17883073	chr14:65404059	G/A	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg05793240	chr7:2802953	GNA12	0.29	7.1	0.31	4.77e-12	Height;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25072359	chr17:41440525	NA	0.51	9.7	0.41	2.29e-20	Menopause (age at onset);
LGG	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg15268244	chr15:77196840	NA	-0.33	-7.22	-0.32	2.11e-12	Blood metabolite levels;
LGG	cis	rs6964587	0.773	rs12740	chr7:92029302	A/G	cg17063962	chr7:91808500	NA	0.48	8.24	0.36	1.81e-15	Breast cancer;
LGG	cis	rs7582720	1.000	rs72934735	chr2:203740010	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4268898	1.000	rs6746005	chr2:24434345	G/A	cg06627628	chr2:24431161	ITSN2	0.52	8.86	0.38	1.73e-17	Asthma;
LGG	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.07e-11	Blood metabolite levels;
LGG	cis	rs3091242	0.933	rs9438904	chr1:25756860	T/C	cg02931644	chr1:25747376	RHCE	0.42	9.18	0.39	1.49e-18	Erythrocyte sedimentation rate;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg19635926	chr16:89946313	TCF25	0.75	7.32	0.32	1.14e-12	Skin colour saturation;
LGG	cis	rs8067545	0.750	rs9897246	chr17:19965702	T/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.45e-11	Schizophrenia;
LGG	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.42	0.33	5.59e-13	Hemoglobin concentration;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.05	0.46	2.38e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg07061783	chr6:25882402	NA	-0.61	-10.66	-0.44	7.39e-24	Urate levels;
LGG	cis	rs1318772	0.932	rs2914152	chr5:112895674	A/G	cg12552261	chr5:112820674	MCC	0.69	7.36	0.32	8.74e-13	F-cell distribution;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg00789671	chr3:195488493	MUC4	0.67	9.28	0.4	6.48e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs7851660	0.967	rs6478437	chr9:100607497	A/G	cg13688889	chr9:100608707	NA	-0.69	-14.61	-0.56	5.17e-40	Strep throat;
LGG	cis	rs10155981	0.510	rs28673155	chr7:22593935	C/T	cg06110297	chr7:22589830	NA	-0.66	-6.65	-0.3	8.27e-11	Bilirubin levels;
LGG	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg01620082	chr3:125678407	NA	-0.59	-6.74	-0.3	4.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs75059851	1.000	rs73036065	chr11:133830067	G/T	cg17703048	chr11:133852993	NA	-0.82	-14.56	-0.56	8.21e-40	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.53e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs34638952	0.577	rs1994663	chr17:27437710	C/G	cg27392559	chr17:27410759	MYO18A	-0.37	-7.04	-0.31	7.13e-12	Sitting height ratio;
LGG	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg06092702	chr1:163392909	NA	0.45	8.02	0.35	8.58e-15	Motion sickness;
LGG	trans	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg10756647	chr7:56101905	PSPH	0.81	9.59	0.41	5.36e-20	Diabetic kidney disease;
LGG	trans	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.7e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3762637	0.941	rs7653592	chr3:122218371	G/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.96	-0.45	5.27e-25	LDL cholesterol levels;
LGG	cis	rs5758659	1.000	rs5751255	chr22:42648408	C/T	cg15128208	chr22:42549153	NA	-0.46	-9.08	-0.39	3.07e-18	Cognitive function;
LGG	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.92	-0.31	1.56e-11	Common traits (Other);
LGG	cis	rs36051895	0.632	rs12337480	chr9:5134567	T/A	cg02405213	chr9:5042618	JAK2	-0.79	-15.33	-0.58	3.3400000000000002e-43	Pediatric autoimmune diseases;
LGG	trans	rs7395662	0.591	rs4882138	chr11:48619321	A/G	cg00717180	chr2:96193071	NA	-0.46	-8.38	-0.36	6.2e-16	HDL cholesterol;
LGG	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg18032289	chr17:61959525	GH2	-0.38	-6.67	-0.3	7.51e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7089973	0.844	rs10510007	chr10:116636721	A/G	cg08188268	chr10:116634841	FAM160B1	0.31	6.77	0.3	4e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09699651	chr6:150184138	LRP11	0.55	10.51	0.44	2.63e-23	Testicular germ cell tumor;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg04008888	chr11:68622739	NA	-0.54	-11.56	-0.47	2.45e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg14403583	chr14:105418241	AHNAK2	-0.78	-15.51	-0.58	5.2e-44	Rheumatoid arthritis;
LGG	cis	rs4950322	0.542	rs72692942	chr1:146790180	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs6866344	0.568	rs10516147	chr5:178094484	A/G	cg03877680	chr5:178157825	ZNF354A	0.57	8.43	0.36	4.35e-16	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg27400746	chr16:89904261	SPIRE2	-0.99	-16.92	-0.62	2.43e-50	Skin colour saturation;
LGG	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg23029597	chr12:123009494	RSRC2	-0.97	-18.68	-0.66	1.85e-58	Body mass index;
LGG	cis	rs250677	0.958	rs36068	chr5:148417512	C/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.12	-0.31	4.08e-12	Breast cancer;
LGG	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.18	-0.36	2.86e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9911578	0.967	rs1267542	chr17:56654690	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-15.84	-0.59	1.77e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs745821	0.879	rs58000211	chr18:48138375	A/G	cg18923635	chr18:48083994	NA	0.4	6.91	0.31	1.6e-11	Diastolic blood pressure;
LGG	cis	rs9912468	0.870	rs4433842	chr17:64322683	T/C	cg19474267	chr17:64306194	PRKCA	0.94	25.49	0.76	3.45e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs9911578	1.000	rs12940681	chr17:56933622	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs11969893	0.649	rs1321204	chr6:101468591	A/G	cg12253828	chr6:101329408	ASCC3	0.86	7.81	0.34	3.91e-14	Economic and political preferences (immigration/crime);
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.81	-0.34	3.82e-14	Life satisfaction;
LGG	trans	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg18187862	chr3:45730750	SACM1L	-0.69	-11.6	-0.47	1.69e-27	Primary sclerosing cholangitis;
LGG	cis	rs6840360	0.571	rs4696101	chr4:152528513	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.24	-0.36	1.74e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2371030	1.000	rs10211086	chr2:211575748	C/G	cg18417063	chr2:211583084	NA	-0.63	-12.3	-0.5	2.68e-30	Non-small cell lung cancer;
LGG	trans	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-16.72	-0.61	1.99e-49	Exhaled nitric oxide output;
LGG	cis	rs4380275	0.809	rs6753699	chr2:766081	A/C	cg14072418	chr2:740025	NA	-0.36	-7.19	-0.32	2.55e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.6	-10.19	-0.43	3.92e-22	Longevity;Endometriosis;
LGG	cis	rs7635838	0.617	rs2122031	chr3:11314143	G/A	cg00170343	chr3:11313890	ATG7	0.55	9.45	0.4	1.73e-19	HDL cholesterol;
LGG	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg16141378	chr3:129829833	LOC729375	0.43	10.63	0.44	9.53e-24	Mood instability;
LGG	cis	rs11168618	0.810	rs35338015	chr12:48839401	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.98	0.35	1.16e-14	Adiponectin levels;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02018176	chr4:1364513	KIAA1530	0.46	10.91	0.45	8.01e-25	Longevity;
LGG	cis	rs7565124	1.000	rs7608391	chr2:20261167	T/C	cg24657347	chr2:20261756	NA	-0.76	-15.04	-0.57	6.27e-42	Major depressive disorder;
LGG	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.57	0.44	1.56e-23	Cognitive test performance;
LGG	cis	rs2247341	0.965	rs11736125	chr4:1744939	C/T	cg07465881	chr4:1713556	SLBP	-0.44	-6.93	-0.31	1.41e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19171272	chr22:38449367	NA	-0.51	-9.5	-0.4	1.13e-19	Glioblastoma;Glioma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17987601	chr16:30389834	SEPT1	0.48	7.39	0.32	6.9e-13	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg09085632	chr11:111637200	PPP2R1B	1.19	28.63	0.8	1.69e-104	Primary sclerosing cholangitis;
LGG	cis	rs72949976	0.934	rs1922794	chr2:214026181	G/A	cg08319019	chr2:214017104	IKZF2	-0.61	-10.2	-0.43	3.71e-22	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.82	0.51	1.99e-32	Obesity-related traits;
LGG	cis	rs6496044	0.547	rs1564719	chr15:86054266	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.08	-0.35	5.81e-15	Interstitial lung disease;
LGG	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg06917634	chr15:78832804	PSMA4	0.43	7.09	0.31	5.04e-12	Sudden cardiac arrest;
LGG	cis	rs7546668	1.000	rs10803388	chr1:15850097	G/A	cg21858823	chr1:15850916	CASP9	0.38	7.0	0.31	8.83e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7572733	0.840	rs700650	chr2:198624285	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.75	0.54	2.61e-36	Cognitive test performance;
LGG	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.45	-7.99	-0.35	1.11e-14	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg10760299	chr15:45669010	GATM	0.39	7.41	0.33	5.85e-13	Homoarginine levels;
LGG	cis	rs7737355	0.812	rs13167908	chr5:131083829	T/C	cg06307176	chr5:131281290	NA	0.51	8.37	0.36	7.13e-16	Life satisfaction;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.81	-0.38	2.59e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg16060761	chr17:80687452	NA	0.43	7.52	0.33	2.8e-13	Glycated hemoglobin levels;
LGG	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs2273669	0.667	rs11153153	chr6:109356104	A/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.73e-16	Prostate cancer;
LGG	trans	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.35	-0.36	7.83e-16	Breast cancer;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs1862618	0.853	rs2548664	chr5:56133555	G/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02775028	chr4:184580387	C4orf41;RWDD4A	-0.48	-6.98	-0.31	1.06e-11	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.4	-0.36	5.57e-16	Triglycerides;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg22702949	chr19:56739731	ZSCAN5A	-0.32	-6.68	-0.3	6.74e-11	Migraine with aura;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	8.98	0.39	6.89e-18	Platelet count;
LGG	cis	rs78487399	0.808	rs13405076	chr2:43735353	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.66	-0.3	7.69e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg16102102	chr5:83017553	HAPLN1	0.59	11.65	0.48	1.1e-27	Prostate cancer;
LGG	cis	rs9462027	0.607	rs205259	chr6:34564066	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.36	-0.43	9.24e-23	Systemic lupus erythematosus;
LGG	cis	rs7918232	0.941	rs1775350	chr10:27441973	C/T	cg14442939	chr10:27389572	ANKRD26	-0.75	-11.2	-0.46	6.34e-26	Breast cancer;
LGG	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg03060546	chr3:49711283	APEH	-0.61	-8.02	-0.35	8.48e-15	Menarche (age at onset);
LGG	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.39	-0.47	1.11e-26	Type 2 diabetes;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg02733842	chr7:1102375	C7orf50	0.69	11.11	0.46	1.4e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.97	0.42	2.53e-21	Dupuytren's disease;
LGG	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg17145862	chr1:211918768	LPGAT1	0.8	16.6	0.61	6.79e-49	Leprosy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	ch.9.130720330F	chr9:131680509	NA	0.46	7.46	0.33	4.17e-13	Cognitive performance;
LGG	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14240646	chr10:27532245	ACBD5	-0.7	-9.81	-0.41	9.18e-21	Breast cancer;
LGG	cis	rs2274273	0.840	rs6573013	chr14:55735873	A/C	cg04306507	chr14:55594613	LGALS3	0.63	17.9	0.64	7.58e-55	Protein biomarker;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg25703541	chr22:24373054	LOC391322	-0.86	-16.16	-0.6	6.39e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4689642	0.709	rs35194996	chr4:7226477	G/C	cg21353189	chr4:7228343	SORCS2	0.39	9.02	0.39	5.02e-18	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg11266682	chr4:10021025	SLC2A9	0.48	9.5	0.4	1.13e-19	Bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02949864	chr19:8553760	HNRNPM	-0.4	-7.3	-0.32	1.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs881375	0.967	rs7034653	chr9:123687372	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.26	0.4	7.37e-19	Rheumatoid arthritis;
LGG	cis	rs67133203	0.851	rs12811777	chr12:51332000	C/T	cg14688905	chr12:51403056	SLC11A2	0.73	10.77	0.45	2.64e-24	Urinary tract infection frequency;
LGG	trans	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.18e-19	Diabetic kidney disease;
LGG	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg04935436	chr20:30431758	NA	0.41	7.05	0.31	6.47e-12	Mean corpuscular hemoglobin;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs6062302	0.522	rs2297428	chr20:62221766	C/T	cg16989086	chr20:62203971	PRIC285	0.49	7.16	0.32	3.14e-12	Glioblastoma;
LGG	trans	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg07817883	chr1:32538562	TMEM39B	0.68	8.5	0.37	2.63e-16	Monocyte percentage of white cells;
LGG	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg03060546	chr3:49711283	APEH	-0.64	-10.59	-0.44	1.32e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.77	-9.24	-0.39	9.12e-19	Schizophrenia;
LGG	cis	rs4006360	0.601	rs349785	chr17:39254557	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-9.94	-0.42	3.07e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg24634471	chr8:143751801	JRK	0.54	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs4732038	0.718	rs4732037	chr7:134227299	A/G	cg06906464	chr7:134288099	NA	-0.34	-7.65	-0.33	1.19e-13	Longevity;
LGG	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22509189	chr2:225307070	NA	-0.61	-9.91	-0.42	4.1e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg20913747	chr6:44695427	NA	-0.62	-10.41	-0.44	6.18e-23	Total body bone mineral density;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.02	0.39	4.94e-18	Alzheimer's disease;
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg26513180	chr16:89883248	FANCA	0.84	8.94	0.38	9.1e-18	Skin colour saturation;
LGG	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.85	0.38	1.92e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6860806	0.507	rs274572	chr5:131710917	T/G	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Breast cancer;
LGG	cis	rs9649465	0.967	rs6950373	chr7:123361773	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs4148087	0.860	rs4148102	chr21:43641347	A/G	cg08841829	chr21:43638893	ABCG1	0.59	8.62	0.37	1.1e-16	Eating disorder in bipolar disorder;
LGG	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg12591125	chr7:1885375	MAD1L1	0.47	7.24	0.32	1.84e-12	Bipolar disorder;
LGG	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.42	-7.26	-0.32	1.66e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs2635047	0.625	rs1836259	chr18:44732389	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.71	0.34	7.61e-14	Educational attainment;
LGG	cis	rs2562456	0.793	rs2562474	chr19:21646282	A/C	cg00806126	chr19:22604979	ZNF98	0.56	7.97	0.35	1.22e-14	Pain;
LGG	cis	rs1707322	0.721	rs10890337	chr1:46124527	C/T	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4132509	0.947	rs7517340	chr1:243710190	T/C	cg25706552	chr1:244017396	NA	-0.52	-8.06	-0.35	6.55e-15	RR interval (heart rate);
LGG	cis	rs7301826	0.560	rs12829294	chr12:131309972	A/G	cg11011512	chr12:131303247	STX2	-0.39	-8.4	-0.36	5.59e-16	Plasma plasminogen activator levels;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-20.59	-0.69	2.39e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg02023728	chr11:77925099	USP35	0.39	6.77	0.3	4.02e-11	Alzheimer's disease (survival time);
LGG	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg00012203	chr2:219082015	ARPC2	-0.69	-12.87	-0.51	1.27e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs2224391	0.628	rs9504365	chr6:5256116	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.36	-0.32	8.62e-13	Height;
LGG	cis	rs17166499	0.803	rs73070145	chr7:12898313	T/C	cg12945054	chr7:12841881	NA	-0.7	-7.5	-0.33	3.36e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	19.47	0.67	4.18e-62	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs787274	0.867	rs6477959	chr9:115554296	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.03	-0.52	2.71e-33	Response to antipsychotic treatment;
LGG	cis	rs56235845	0.694	rs36102285	chr5:176774018	C/T	cg17509989	chr5:176798049	RGS14	0.65	10.74	0.45	3.41e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.09	0.42	8.73e-22	Iron status biomarkers;
LGG	cis	rs6496044	0.568	rs11636764	chr15:86079751	G/A	cg13263323	chr15:86062960	AKAP13	-0.37	-7.95	-0.35	1.44e-14	Interstitial lung disease;
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.74	0.38	4.42e-17	Bipolar disorder;
LGG	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.25e-22	Cognitive ability;
LGG	cis	rs926392	0.896	rs1569538	chr20:37685216	A/G	cg16355469	chr20:37678765	NA	-0.46	-7.62	-0.33	1.4e-13	Dialysis-related mortality;
LGG	cis	rs9393777	0.513	rs13219181	chr6:27136225	A/G	cg12826209	chr6:26865740	GUSBL1	0.58	7.14	0.31	3.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg24642439	chr20:33292090	TP53INP2	0.82	15.28	0.58	5.88e-43	Coronary artery disease;
LGG	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.22	0.7	2.57e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs77972916	0.505	rs1322	chr2:43521167	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.67	-10.11	-0.43	7.38e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10193935	0.892	rs13413028	chr2:42394865	C/G	cg27598129	chr2:42591480	NA	-0.62	-9.13	-0.39	2.08e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs7681440	0.605	rs1372509	chr4:90817311	A/G	cg26578617	chr4:90757533	SNCA	-0.35	-6.89	-0.31	1.78e-11	Dementia with Lewy bodies;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.79	-0.51	2.86e-32	Schizophrenia;
LGG	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg02975922	chr3:195473998	MUC4	-0.45	-6.94	-0.31	1.31e-11	Pancreatic cancer;
LGG	cis	rs1878931	0.501	rs28735976	chr16:3418419	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	14.0	0.55	2.17e-37	Body mass index (adult);
LGG	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs17253792	0.822	rs10148983	chr14:56051879	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg10847948	chr11:71163743	NADSYN1	0.59	8.78	0.38	3.07e-17	Vitamin D levels;
LGG	cis	rs2046867	0.862	rs58538718	chr3:72800563	C/A	cg25664220	chr3:72788482	NA	-0.32	-8.83	-0.38	2.09e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.61	7.34	0.32	9.41e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6735179	0.647	rs749089	chr2:1763213	T/C	cg08534653	chr2:1747700	PXDN	0.43	6.77	0.3	4.01e-11	Response to antipsychotic treatment;
LGG	cis	rs2898279	0.933	rs13259219	chr8:11297277	T/C	cg26274995	chr8:11302983	FAM167A	0.49	9.42	0.4	2.09e-19	Small cell lung carcinoma;
LGG	cis	rs4740619	0.557	rs1328296	chr9:16046292	G/C	cg14451791	chr9:16040625	NA	-0.44	-11.43	-0.47	7.9e-27	Body mass index;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.53	-0.33	2.65e-13	Longevity;Endometriosis;
LGG	cis	rs8056893	0.569	rs12924125	chr16:68299781	T/C	cg07273125	chr16:68295692	NA	0.46	10.17	0.43	4.64e-22	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg02825527	chr7:2087843	MAD1L1	-0.34	-6.78	-0.3	3.71e-11	Neuroticism;
LGG	cis	rs240764	0.687	rs1336245	chr6:101197640	A/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg05692746	chr2:100937584	LONRF2	0.65	12.0	0.49	4.43e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.17	-0.32	2.98e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2481665	0.617	rs12732781	chr1:62518459	T/C	cg18591186	chr1:62594603	INADL	-0.38	-7.31	-0.32	1.2e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	cis	rs7666738	0.791	rs1896156	chr4:99020882	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03284175	chr1:146643471	PRKAB2	0.47	7.65	0.34	1.15e-13	Cognitive performance;
LGG	cis	rs8017423	0.935	rs11628952	chr14:90734953	T/C	cg04374321	chr14:90722782	PSMC1	-0.87	-17.81	-0.64	2.06e-54	Mortality in heart failure;
LGG	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11644478	chr21:40555479	PSMG1	-0.71	-12.39	-0.5	1.2e-30	Cognitive function;
LGG	cis	rs12042938	0.600	rs823163	chr1:231771108	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	10.36	0.43	9.25e-23	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs3780378	0.967	rs7857730	chr9:5084049	G/T	cg02405213	chr9:5042618	JAK2	-0.53	-9.22	-0.39	1.06e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	7.3	0.32	1.25e-12	Longevity;
LGG	cis	rs2587949	0.593	rs1872416	chr3:4211269	G/T	cg16519197	chr3:4211558	NA	0.32	6.76	0.3	4.24e-11	Periodontitis (DPAL);
LGG	cis	rs17253792	0.598	rs12880362	chr14:56017929	G/C	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg26656751	chr17:43910226	CRHR1	0.49	9.03	0.39	4.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2072732	0.861	rs3795262	chr1:2938697	A/C	cg08733933	chr1:2954429	NA	-0.42	-8.48	-0.37	2.98e-16	Plateletcrit;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22968622	chr17:43663579	NA	-1.01	-18.96	-0.66	9.41e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.12	0.57	2.96e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg03188948	chr7:1209495	NA	0.48	7.8	0.34	4.17e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4921915	0.519	rs35583283	chr8:18254509	G/C	cg18736775	chr8:18248649	NAT2	-0.78	-11.85	-0.48	1.78e-28	Iron status biomarkers (transferrin levels);
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg02725872	chr8:58115012	NA	-0.92	-12.26	-0.49	4.23e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20195957	chr2:68694673	APLF;FBXO48	0.45	7.24	0.32	1.88e-12	Gut microbiome composition (summer);
LGG	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg23422044	chr7:1970798	MAD1L1	-0.73	-11.82	-0.48	2.3e-28	Bipolar disorder;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg16606324	chr3:10149918	C3orf24	0.6	6.91	0.31	1.61e-11	Alzheimer's disease;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg25214090	chr10:38739885	LOC399744	0.46	8.31	0.36	1.08e-15	Diastolic blood pressure;
LGG	cis	rs2985684	0.841	rs2281836	chr14:50065717	G/C	cg02151108	chr14:50098012	C14orf104	-0.44	-9.33	-0.4	4.57e-19	Carotid intima media thickness;
LGG	cis	rs6976053	1.000	rs6976053	chr7:100512119	C/T	cg03098644	chr7:100410630	EPHB4	-0.39	-6.78	-0.3	3.75e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7246760	1.000	rs113915533	chr19:9881379	A/C	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.98	0.39	6.7e-18	Height;
LGG	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07377341	chr1:160068584	IGSF8	-0.48	-7.61	-0.33	1.58e-13	Pancreatic cancer;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.28	0.58	5.81e-43	Longevity;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.48e-17	Life satisfaction;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg05941027	chr17:61774174	LIMD2	0.38	9.56	0.41	7.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg06640241	chr16:89574553	SPG7	0.85	15.24	0.58	8.7e-43	Multiple myeloma (IgH translocation);
LGG	trans	rs62103177	0.525	rs1835410	chr18:77702025	T/C	cg05926928	chr17:57297772	GDPD1	-1.15	-16.11	-0.6	1.11e-46	Opioid sensitivity;
LGG	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	8.69	0.37	6.21e-17	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg08470875	chr2:26401718	FAM59B	0.42	8.04	0.35	7.44e-15	Gut microbiome composition (summer);
LGG	cis	rs11122272	0.735	rs2790885	chr1:231529925	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg20887711	chr4:1340912	KIAA1530	0.46	7.95	0.35	1.39e-14	Obesity-related traits;
LGG	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg27165867	chr14:105738592	BRF1	-0.45	-7.51	-0.33	3.02e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16405210	chr4:1374714	KIAA1530	-0.49	-8.59	-0.37	1.38e-16	Longevity;
LGG	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.25e-12	Morning vs. evening chronotype;
LGG	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	10.59	0.44	1.26e-23	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg02733842	chr7:1102375	C7orf50	-0.46	-7.3	-0.32	1.29e-12	Bronchopulmonary dysplasia;
LGG	cis	rs7523273	0.606	rs7144	chr1:207967719	A/G	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.46	-0.47	6.3e-27	Schizophrenia;
LGG	cis	rs7737355	0.947	rs3776007	chr5:130875085	C/G	cg06307176	chr5:131281290	NA	-0.55	-9.14	-0.39	2.02e-18	Life satisfaction;
LGG	cis	rs2066819	1.000	rs79824801	chr12:56728137	T/C	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09440289	chr12:15475990	PTPRO	0.38	6.79	0.3	3.38e-11	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.29	-0.32	1.32e-12	Initial pursuit acceleration;
LGG	cis	rs9815354	1.000	rs6768128	chr3:41865080	G/A	cg03022575	chr3:42003672	ULK4	0.68	8.7	0.37	5.68e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.5	-0.37	2.62e-16	Lung cancer;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs73198271	1.000	rs73198279	chr8:8608504	A/G	cg16141378	chr3:129829833	LOC729375	0.37	6.9	0.31	1.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg11266682	chr4:10021025	SLC2A9	0.54	10.97	0.45	4.82e-25	Bone mineral density;
LGG	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg10326726	chr10:51549505	MSMB	-0.62	-12.7	-0.51	6.23e-32	Prostate-specific antigen levels;
LGG	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg12856521	chr11:46389249	DGKZ	0.43	7.52	0.33	2.94e-13	Leprosy;
LGG	cis	rs1801251	0.752	rs709938	chr2:233746457	C/T	cg08000102	chr2:233561755	GIGYF2	-0.43	-7.09	-0.31	5.14e-12	Coronary artery disease;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg18379455	chr17:41446167	NA	-0.33	-7.9	-0.34	2.01e-14	Menopause (age at onset);
LGG	trans	rs6921919	1.000	rs35875412	chr6:28331818	C/T	cg06606381	chr12:133084897	FBRSL1	-0.53	-7.35	-0.32	9.29e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-9.72	-0.41	1.88e-20	Colorectal cancer;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08645402	chr16:4508243	NA	0.53	9.69	0.41	2.5e-20	Schizophrenia;
LGG	cis	rs3106136	0.609	rs11097407	chr4:95146135	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-6.98	-0.31	1.04e-11	Capecitabine sensitivity;
LGG	cis	rs2274273	0.967	rs8009670	chr14:55583477	G/A	cg04306507	chr14:55594613	LGALS3	0.65	18.64	0.65	2.83e-58	Protein biomarker;
LGG	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg18850127	chr7:39170497	POU6F2	0.64	16.39	0.61	6e-48	IgG glycosylation;
LGG	cis	rs10979	1.000	rs9496678	chr6:143896664	C/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.58	-0.5	2.1e-31	Hypospadias;
LGG	cis	rs975739	0.931	rs1279393	chr13:78377597	C/T	cg07847733	chr13:78271382	SLAIN1	0.36	6.65	0.3	8.12e-11	Hair color;
LGG	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg09359103	chr1:154839909	KCNN3	0.51	10.63	0.44	8.85e-24	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17257175	chr1:155163542	MUC1;MIR92B	0.48	7.08	0.31	5.27e-12	Gut microbiome composition (summer);
LGG	cis	rs6460942	0.915	rs1595802	chr7:12439672	C/T	cg06484146	chr7:12443880	VWDE	-0.42	-7.31	-0.32	1.16e-12	Coronary artery disease;
LGG	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.57	0.59	2.91e-44	Diabetic retinopathy;
LGG	cis	rs4959677	0.698	rs2325963	chr6:2479402	T/C	cg20147862	chr6:2634573	C6orf195	-0.38	-8.24	-0.36	1.83e-15	Orthostatic hypotension;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg23034840	chr1:205782522	SLC41A1	0.53	8.62	0.37	1.07e-16	Menarche (age at onset);
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.33e-13	Educational attainment;
LGG	trans	rs3942852	0.774	rs2279823	chr11:48146092	T/C	cg03929089	chr4:120376271	NA	-0.63	-8.77	-0.38	3.38e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg09904177	chr6:26538194	HMGN4	-0.76	-17.09	-0.62	3.94e-51	Intelligence (multi-trait analysis);
LGG	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	8.74	0.38	4.44e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs12517041	1.000	rs10054768	chr5:23278161	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-10.79	-0.45	2.32e-24	Calcium levels;
LGG	cis	rs6964587	1.000	rs6970277	chr7:91680655	T/C	cg17063962	chr7:91808500	NA	0.49	8.62	0.37	1.03e-16	Breast cancer;
LGG	cis	rs9487051	0.768	rs458185	chr6:109524074	A/G	cg21918786	chr6:109611834	NA	-0.37	-6.78	-0.3	3.69e-11	Reticulocyte fraction of red cells;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.49	0.33	3.41e-13	Height;
LGG	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	cg15522984	chr1:182991683	LAMC1	0.44	8.66	0.37	8.1e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg25986240	chr4:9926439	SLC2A9	-0.4	-8.43	-0.36	4.56e-16	Bone mineral density;
LGG	cis	rs36093844	0.706	rs1445503	chr11:85585011	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs2224391	0.628	rs2773299	chr6:5242169	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-6.9	-0.31	1.76e-11	Height;
LGG	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg06453172	chr10:134556979	INPP5A	-0.58	-8.74	-0.38	4.42e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11650494	0.901	rs117087923	chr17:47364913	G/A	cg08112188	chr17:47440006	ZNF652	1.33	15.73	0.59	5.36e-45	Prostate cancer;
LGG	cis	rs6141769	0.542	rs2064933	chr20:31314625	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs9486719	1.000	rs11757063	chr6:96884886	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.3	-0.43	1.6e-22	Migraine;Coronary artery disease;
LGG	cis	rs3087591	0.922	rs9892839	chr17:29618990	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.52	-0.56	1.2e-39	Hip circumference;
LGG	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg15440763	chr7:158190612	PTPRN2	0.49	10.44	0.44	4.71e-23	Obesity-related traits;
LGG	cis	rs8060686	0.516	rs12599238	chr16:68276235	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.7	-0.3	6.06e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs17221829	0.673	rs10741307	chr11:89367271	G/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.19	-0.39	1.3e-18	Anxiety in major depressive disorder;
LGG	cis	rs7766436	0.767	rs6456496	chr6:22599386	G/C	cg13666174	chr6:22585274	NA	-0.36	-8.62	-0.37	1.1e-16	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02360337	chr11:65627185	MUS81;CFL1	0.46	7.31	0.32	1.2e-12	Gut microbiome composition (summer);
LGG	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	2.05e-14	Coronary artery disease;
LGG	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg17809284	chr5:56205270	C5orf35	-0.53	-8.67	-0.37	7.46e-17	Initial pursuit acceleration;
LGG	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg13852791	chr20:30311386	BCL2L1	0.87	15.44	0.58	1.05e-43	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs4363385	0.818	rs435633	chr1:153011811	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.85e-13	Retinal vascular caliber;
LGG	cis	rs8077889	0.917	rs4793037	chr17:41914826	C/T	cg26893861	chr17:41843967	DUSP3	0.92	15.61	0.59	1.85e-44	Triglycerides;
LGG	cis	rs864537	0.622	rs2949661	chr1:167424924	C/T	cg09179987	chr1:167433047	CD247	0.43	9.41	0.4	2.39e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14373873	chr11:113211441	TTC12	0.4	8.33	0.36	9.34e-16	Information processing speed;
LGG	cis	rs2481665	0.680	rs2481671	chr1:62611666	A/C	cg18591186	chr1:62594603	INADL	-0.52	-11.41	-0.47	9.57e-27	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01767202	chr14:36789886	MBIP	0.43	7.03	0.31	7.26e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs1018836	0.892	rs4140680	chr8:91584157	G/A	cg16814680	chr8:91681699	NA	-0.75	-13.22	-0.52	4.33e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs1014246	0.769	rs10886006	chr10:118486038	C/G	cg14919929	chr10:118506882	NA	0.67	13.09	0.52	1.52e-33	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg02463440	chr8:22132932	PIWIL2	0.49	10.9	0.45	8.67e-25	Hypertriglyceridemia;
LGG	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg08508325	chr11:3079039	CARS	-0.62	-13.34	-0.53	1.38e-34	Longevity;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg04503457	chr17:41445688	NA	-0.4	-9.46	-0.4	1.56e-19	Menopause (age at onset);
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg26338869	chr17:61819248	STRADA	-0.45	-7.24	-0.32	1.86e-12	Prudent dietary pattern;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.84	0.3	2.53e-11	Lung cancer;
LGG	cis	rs12464559	0.579	rs11682909	chr2:152651592	A/G	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg13939156	chr17:80058883	NA	0.41	7.28	0.32	1.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	cis	rs7765175	0.598	rs2842840	chr6:113630776	C/G	cg26552650	chr6:113682475	NA	0.34	7.36	0.32	8.25e-13	Coronary artery calcification;
LGG	cis	rs4740619	0.689	rs10810506	chr9:15955190	C/A	cg14451791	chr9:16040625	NA	-0.4	-10.17	-0.43	4.69e-22	Body mass index;
LGG	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg12046867	chr14:103022105	NA	-0.76	-13.2	-0.52	5.46e-34	Platelet count;
LGG	cis	rs17767392	0.595	rs10130213	chr14:71652127	C/G	cg13720639	chr14:72061746	SIPA1L1	0.35	7.19	0.32	2.57e-12	Mitral valve prolapse;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg04503457	chr17:41445688	NA	-0.37	-8.8	-0.38	2.76e-17	Menopause (age at onset);
LGG	cis	rs16866061	1.000	rs7588380	chr2:225341304	A/T	cg12698349	chr2:225449008	CUL3	-0.93	-19.03	-0.66	4.29e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1034435	0.962	rs1894542	chr22:48890335	G/C	cg05992904	chr22:48892994	FAM19A5	-0.79	-15.56	-0.59	3.39e-44	Late-onset Alzheimer's disease;
LGG	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs1003719	0.614	rs1053808	chr21:38525356	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-13.0	-0.52	3.79e-33	Eye color traits;
LGG	cis	rs28655083	0.529	rs589002	chr16:77104044	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.43	7.38	0.32	7.35e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg13047869	chr3:10149882	C3orf24	0.52	8.57	0.37	1.58e-16	Alzheimer's disease;
LGG	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg15596359	chr8:11213517	TDH	0.39	8.06	0.35	6.48e-15	Retinal vascular caliber;
LGG	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg15103426	chr22:29168792	CCDC117	-0.58	-8.73	-0.38	4.82e-17	Lymphocyte counts;
LGG	trans	rs6598955	0.670	rs12733645	chr1:26540356	G/T	cg07461501	chr17:79650226	HGS;ARL16	0.36	7.49	0.33	3.47e-13	Obesity-related traits;
LGG	cis	rs26949	0.511	rs11740327	chr5:59899413	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	6.68	0.3	6.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg02462569	chr6:150064036	NUP43	-0.42	-9.1	-0.39	2.76e-18	Lung cancer;
LGG	cis	rs433406	1.000	rs433406	chr11:131371019	A/G	cg27203895	chr11:131369037	NTM	0.58	12.57	0.5	2.28e-31	Male fertility;
LGG	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.0	-0.31	9.01e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4321325	0.733	rs13421996	chr2:127934812	G/T	cg11380483	chr2:127933992	NA	0.64	8.87	0.38	1.58e-17	Protein C levels;
LGG	cis	rs7975161	0.624	rs11111943	chr12:104632418	T/C	cg25273343	chr12:104657179	TXNRD1	-0.74	-7.46	-0.33	4.2e-13	Toenail selenium levels;
LGG	cis	rs7084402	0.967	rs1621227	chr10:60327734	C/G	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	2e-54	Refractive error;
LGG	cis	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg03060546	chr3:49711283	APEH	-0.6	-8.12	-0.35	4.12e-15	Menarche (age at onset);
LGG	cis	rs3762637	1.000	rs7645862	chr3:122221139	C/T	cg24169773	chr3:122142474	KPNA1	-0.59	-9.82	-0.42	8.29e-21	LDL cholesterol levels;
LGG	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg00405596	chr8:11794950	NA	0.46	7.59	0.33	1.72e-13	Myopia (pathological);
LGG	cis	rs17221323	1.000	rs17221323	chr10:618685	A/G	cg16386425	chr10:429943	DIP2C	-0.43	-6.77	-0.3	4e-11	Immune reponse to smallpox (secreted IFN-alpha);
LGG	cis	rs9583531	0.760	rs11843661	chr13:111390990	T/C	cg24331049	chr13:111365604	ING1	-0.88	-13.08	-0.52	1.69e-33	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg06654118	chr4:1303317	MAEA	0.47	8.16	0.35	3.13e-15	Obesity-related traits;
LGG	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg19455335	chr8:22457658	C8orf58	-0.43	-8.85	-0.38	1.84e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg12310025	chr6:25882481	NA	-0.61	-11.23	-0.46	4.76e-26	Intelligence (multi-trait analysis);
LGG	cis	rs888194	0.738	rs7956536	chr12:109980516	A/G	cg08884029	chr12:110012500	MVK;MMAB	0.32	6.67	0.3	7.09e-11	Neuroticism;
LGG	cis	rs556990	0.760	rs3024739	chr13:113819948	G/A	cg18105134	chr13:113819100	PROZ	-0.8	-16.1	-0.6	1.19e-46	Blood protein levels;
LGG	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg07537917	chr2:241836409	C2orf54	-0.42	-8.09	-0.35	5.29e-15	Urinary metabolites;
LGG	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.76	-0.3	4.25e-11	Nose size;
LGG	cis	rs1957429	0.614	rs7144637	chr14:65349709	A/G	cg23373153	chr14:65346875	NA	-1.08	-12.1	-0.49	1.76e-29	Pediatric areal bone mineral density (radius);
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg25938646	chr13:84456681	SLITRK1	0.4	7.12	0.31	4.02e-12	Migraine with aura;
LGG	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg26384229	chr12:38710491	ALG10B	0.7	12.99	0.52	4.12e-33	Resting heart rate;
LGG	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	7.94	0.35	1.51e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs17767392	0.881	rs61991199	chr14:71762542	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs1949733	1.000	rs2140337	chr4:8502112	A/G	cg13073564	chr4:8508604	NA	-0.6	-11.96	-0.49	6.74e-29	Response to antineoplastic agents;
LGG	cis	rs6728642	0.572	rs2872686	chr2:97601024	A/G	cg26665480	chr2:98280029	ACTR1B	-0.87	-11.5	-0.47	4.4e-27	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs1408799	0.772	rs10960775	chr9:12742172	C/A	cg05274944	chr9:12693694	TYRP1	0.34	8.08	0.35	5.67e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.28	0.32	1.44e-12	Prudent dietary pattern;
LGG	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06850241	chr22:41845214	NA	-0.43	-6.67	-0.3	7.27e-11	Vitiligo;
LGG	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.26	0.52	2.91e-34	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg15704280	chr7:45808275	SEPT13	-0.83	-16.29	-0.6	1.8e-47	Height;
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg11473876	chr11:109292803	C11orf87	0.78	17.4	0.63	1.56e-52	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12174276	chr6:166401921	LOC441177;C6orf176	0.46	7.46	0.33	4.21e-13	Cognitive performance;
LGG	cis	rs2916247	1.000	rs7844067	chr8:93026078	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.59	-0.37	1.38e-16	Intelligence (multi-trait analysis);
LGG	cis	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.67	0.34	1.03e-13	Breast cancer;
LGG	trans	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg17712092	chr4:129076599	LARP1B	-0.83	-16.64	-0.61	4.31e-49	Eosinophil percentage of white cells;
LGG	cis	rs12476592	0.602	rs6546009	chr2:63745742	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.77	-0.3	3.98e-11	Childhood ear infection;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.41	0.36	4.97e-16	Lung cancer;
LGG	cis	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg06521331	chr12:34319734	NA	-0.41	-7.08	-0.31	5.54e-12	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.764	rs9363474	chr6:66587868	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.73	0.3	5.04e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.92	0.38	1.06e-17	Myopia (pathological);
LGG	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	19.18	0.67	8.77e-61	Gut microbiome composition (summer);
LGG	cis	rs11874712	1.000	rs11874712	chr18:43688576	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.53	-11.52	-0.47	3.49e-27	Migraine - clinic-based;
LGG	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-11.8	-0.48	2.7e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg05335186	chr13:53173507	NA	0.89	23.65	0.74	1.2e-81	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07220085	chr15:52971596	KIAA1370	0.4	6.75	0.3	4.58e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.32	0.32	1.1e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs13421350	0.579	rs16860478	chr2:173334716	T/G	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.79	15.1	0.57	3.55e-42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs17767392	0.918	rs12894016	chr14:71883088	G/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs9398803	0.723	rs853972	chr6:127068293	C/G	cg19875578	chr6:126661172	C6orf173	-0.49	-8.9	-0.38	1.22e-17	Male-pattern baldness;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg13628971	chr7:2884303	GNA12	0.48	9.5	0.4	1.15e-19	Height;
LGG	cis	rs4906332	1.000	rs12896612	chr14:103877868	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-8.07	-0.35	6.01e-15	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.47	-0.37	3.38e-16	Obesity-related traits;
LGG	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg11040518	chr10:102331378	NA	-0.37	-6.67	-0.3	7.39e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg09596252	chr17:78655493	RPTOR	0.42	7.4	0.33	6.48e-13	Obesity;
LGG	cis	rs6908034	0.556	rs79028848	chr6:19783153	G/A	cg02682789	chr6:19804855	NA	0.9	7.98	0.35	1.2e-14	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg16099169	chr2:106886729	NA	-0.32	-8.29	-0.36	1.24e-15	Facial morphology (factor 23);
LGG	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs362272	0.525	rs1313768	chr4:3054017	T/C	cg13731523	chr4:3047190	NA	-0.43	-9.67	-0.41	2.87e-20	Serum sulfate level;
LGG	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.31e-19	Aortic root size;
LGG	cis	rs1869026	1.000	rs1869026	chr2:121341281	G/T	cg13274077	chr2:121334614	NA	-0.31	-7.44	-0.33	4.98e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13126279	chr21:47581558	C21orf56	0.42	6.78	0.3	3.63e-11	Testicular germ cell tumor;
LGG	cis	rs2055942	0.639	rs3792211	chr4:46994495	G/T	cg09812070	chr4:46995689	GABRA4	0.47	8.83	0.38	2.16e-17	Type 2 diabetes;
LGG	cis	rs10178409	1	rs10178409	chr2:73855507	G/T	cg20560298	chr2:73613845	ALMS1	-0.43	-6.87	-0.3	2.12e-11	Urinary metabolites;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.16	0.43	5.03e-22	Prudent dietary pattern;
LGG	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs882300	0.934	rs58085003	chr2:136930556	A/G	cg07169764	chr2:136633963	MCM6	0.46	7.52	0.33	2.82e-13	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.23	-0.43	2.78e-22	Chronic sinus infection;
LGG	cis	rs975722	0.646	rs43036	chr7:117114478	C/T	cg10524701	chr7:117356490	CTTNBP2	0.43	9.48	0.4	1.35e-19	Coronary artery disease;
LGG	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg14456004	chr13:21872349	NA	1.38	25.87	0.77	5.81e-92	White matter hyperintensity burden;
LGG	cis	rs4262150	0.846	rs113655983	chr5:152128093	T/C	cg12297329	chr5:152029980	NA	-0.7	-13.16	-0.52	7.62e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs7589342	0.929	rs2060036	chr2:106436101	G/A	cg14210321	chr2:106509881	NCK2	-0.51	-8.81	-0.38	2.47e-17	Addiction;
LGG	cis	rs79387448	0.655	rs79144324	chr2:102932814	G/A	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.92	-0.31	1.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.96	-0.45	5.41e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7929679	0.551	rs11032849	chr11:34785740	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs9296092	0.560	rs3846854	chr6:33528466	T/C	cg13560919	chr6:33536144	NA	-1.06	-22.16	-0.72	1.01e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07080220	chr10:102295463	HIF1AN	-0.56	-9.89	-0.42	4.89e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.59	0.37	1.32e-16	Alzheimer's disease;
LGG	cis	rs9644630	0.672	rs12542081	chr8:19317786	G/T	cg06562184	chr8:19319451	CSGALNACT1	0.37	7.35	0.32	8.93e-13	Oropharynx cancer;
LGG	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg25457927	chr22:38595422	NA	-0.35	-8.51	-0.37	2.45e-16	Cutaneous nevi;
LGG	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg06481639	chr22:41940642	POLR3H	0.52	7.95	0.35	1.41e-14	Vitiligo;
LGG	cis	rs2640806	0.505	rs7820029	chr8:97352787	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.28	0.32	1.46e-12	Obesity-related traits;
LGG	trans	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.93	-0.6	7e-46	Colorectal cancer;
LGG	cis	rs4262150	0.810	rs72797203	chr5:151952877	C/T	cg12297329	chr5:152029980	NA	-0.81	-15.87	-0.59	1.37e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs2708977	1.000	rs10184209	chr2:97337491	G/T	cg01950434	chr2:97203154	ARID5A	0.55	8.64	0.37	9.3e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9549367	0.577	rs513479	chr13:113815200	C/T	cg18105134	chr13:113819100	PROZ	-0.81	-14.06	-0.55	1.18e-37	Platelet distribution width;
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg03517284	chr6:25882590	NA	-0.7	-13.49	-0.53	3.24e-35	Blood metabolite levels;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg02466173	chr16:30829666	NA	-0.52	-9.26	-0.4	7.8e-19	Multiple myeloma;
LGG	cis	rs7666738	0.830	rs11931166	chr4:99054187	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.08e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs638893	0.717	rs622690	chr11:118704265	T/C	cg22253036	chr11:118662786	DDX6	0.41	6.93	0.31	1.44e-11	Vitiligo;
LGG	cis	rs71403859	0.730	rs12931191	chr16:71621373	A/T	cg08717414	chr16:71523259	ZNF19	1.13	14.88	0.57	3.38e-41	Post bronchodilator FEV1;
LGG	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.38	-0.36	6.16e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg14088196	chr11:70211408	PPFIA1	0.92	13.0	0.52	3.77e-33	Coronary artery disease;
LGG	cis	rs6835098	1.000	rs10031414	chr4:174084953	A/C	cg08422745	chr4:174089978	GALNT7	-0.86	-15.25	-0.58	7.98e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08382705	chr11:45687319	CHST1	0.43	7.1	0.31	4.84e-12	Height;
LGG	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21862992	chr11:68658383	NA	0.5	8.46	0.37	3.49e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg18171855	chr10:2543474	NA	0.41	8.08	0.35	5.87e-15	Age-related hearing impairment;
LGG	cis	rs11096990	0.855	rs2566177	chr4:39156178	G/C	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.8	-0.45	2.08e-24	Prostate cancer;
LGG	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.91	0.35	1.88e-14	Colorectal cancer;
LGG	trans	rs12517041	1.000	rs7734125	chr5:23300072	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.05	-0.46	2.33e-25	Calcium levels;
LGG	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg22535103	chr8:58192502	C8orf71	-0.74	-9.59	-0.41	5.32e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7215564	0.730	rs2171023	chr17:78608913	A/T	cg16980736	chr17:78789706	RPTOR	-0.65	-8.35	-0.36	8.24e-16	Myopia (pathological);
LGG	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	8.74	0.38	4.2e-17	Gout;Renal underexcretion gout;
LGG	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg04691961	chr3:161091175	C3orf57	-0.56	-12.92	-0.51	7.76e-33	Morning vs. evening chronotype;
LGG	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.95	-0.35	1.47e-14	Asthma;
LGG	cis	rs11630290	0.774	rs57085979	chr15:64133689	T/C	cg12036633	chr15:63758958	NA	-0.56	-7.74	-0.34	6.48e-14	Iris characteristics;
LGG	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Vitiligo;
LGG	cis	rs1577917	1.000	rs12207610	chr6:86688016	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.81	-0.51	2.25e-32	Response to antipsychotic treatment;
LGG	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg13770153	chr20:60521292	NA	0.44	7.42	0.33	5.78e-13	Body mass index;
LGG	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.29	0.36	1.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.67	0.34	1.06e-13	Schizophrenia;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg13206674	chr6:150067644	NUP43	0.62	14.04	0.55	1.48e-37	Lung cancer;
LGG	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg03160526	chr17:80928410	B3GNTL1	0.52	8.44	0.37	4.08e-16	Glycated hemoglobin levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16261398	chr11:1410750	BRSK2	0.57	6.68	0.3	6.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-10.41	-0.44	5.81e-23	Response to antipsychotic treatment;
LGG	trans	rs9908158	1	rs9908158	chr17:33890083	T/C	cg19694781	chr19:47549865	TMEM160	0.54	9.07	0.39	3.44e-18	Platelet count;Platelet distribution width;
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg22348356	chr13:114891224	RASA3	0.4	7.89	0.34	2.14e-14	Schizophrenia;
LGG	cis	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26376749	chr17:30677620	ZNF207	0.5	7.9	0.34	2.02e-14	Gut microbiome composition (summer);
LGG	cis	rs11245387	0.633	rs2086945	chr10:126543993	C/T	cg08799069	chr10:126477246	METTL10	0.54	10.51	0.44	2.59e-23	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.09	-0.31	5.15e-12	Personality dimensions;
LGG	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.54e-15	Bone mineral density;
LGG	trans	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg11887960	chr12:57824829	NA	0.59	7.24	0.32	1.88e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2224391	0.628	rs2753224	chr6:5244864	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.39	-0.32	6.96e-13	Height;
LGG	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs735860	0.726	rs209500	chr6:53188137	A/C	cg10236188	chr6:53219634	NA	-0.35	-6.85	-0.3	2.36e-11	Glaucoma;
LGG	cis	rs9359856	0.564	rs76069351	chr6:90425043	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-10.1	-0.42	8.4e-22	Bipolar disorder;
LGG	cis	rs503734	0.653	rs9843186	chr3:101161330	A/C	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg12458913	chr13:53173898	NA	0.56	10.19	0.43	4e-22	Lewy body disease;
LGG	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg04455712	chr21:45112962	RRP1B	0.51	9.41	0.4	2.35e-19	Mean corpuscular volume;
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg09263875	chr16:632152	PIGQ	0.64	12.67	0.51	8.29e-32	Height;
LGG	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg25706552	chr1:244017396	NA	0.53	8.7	0.37	5.96e-17	RR interval (heart rate);
LGG	cis	rs6594713	0.837	rs17327964	chr5:112729116	C/G	cg12552261	chr5:112820674	MCC	-0.52	-6.76	-0.3	4.29e-11	Brain cytoarchitecture;
LGG	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.33	-0.32	1.01e-12	Mood instability;
LGG	cis	rs1707322	0.682	rs12041197	chr1:46104464	T/C	cg03146154	chr1:46216737	IPP	0.57	10.95	0.45	5.86e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg05623727	chr3:50126028	RBM5	0.39	8.4	0.36	5.67e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	0.612	rs2237273	chr6:167443017	T/C	cg07741184	chr6:167504864	NA	0.39	8.46	0.37	3.47e-16	Crohn's disease;
LGG	cis	rs6938	0.534	rs59945415	chr15:75228427	C/A	cg17294928	chr15:75287854	SCAMP5	0.63	11.56	0.47	2.43e-27	Breast cancer;
LGG	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg12773197	chr13:112238673	NA	-0.35	-7.18	-0.32	2.71e-12	Hepatitis;
LGG	cis	rs2370759	1.000	rs11594459	chr10:32561858	A/C	cg01819863	chr10:32635814	EPC1	1.06	14.71	0.56	1.86e-40	Sexual dysfunction (female);
LGG	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg13385794	chr1:248469461	NA	0.5	8.33	0.36	9.35e-16	Common traits (Other);
LGG	cis	rs2463822	0.920	rs72923207	chr11:62117959	A/G	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.37	-0.58	2.36e-43	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1018836	0.884	rs7008765	chr8:91632589	C/T	cg16814680	chr8:91681699	NA	-0.84	-15.55	-0.59	3.68e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg03805757	chr16:71968109	PKD1L3	-0.48	-8.87	-0.38	1.59e-17	Post bronchodilator FEV1;
LGG	cis	rs755249	0.567	rs16825887	chr1:39643382	A/G	cg18385671	chr1:39797026	MACF1	-0.43	-7.34	-0.32	9.53e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs240764	0.817	rs6938440	chr6:101152009	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-7.48	-0.33	3.72e-13	Neuroticism;
LGG	cis	rs2180341	0.595	rs7771391	chr6:127749656	C/G	cg24812749	chr6:127587940	RNF146	0.65	10.25	0.43	2.32e-22	Breast cancer;
LGG	cis	rs9534288	0.797	rs2104515	chr13:46569846	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg27286069	chr11:118481882	PHLDB1	-0.55	-10.14	-0.43	6.16e-22	Cholesterol, total;
LGG	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg02002194	chr4:3960332	NA	0.45	8.11	0.35	4.69e-15	Retinal vascular caliber;
LGG	cis	rs721917	0.506	rs4322333	chr10:81651096	T/C	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs7045138	1	rs7045138	chr9:100591463	C/T	cg13688889	chr9:100608707	NA	-0.66	-13.64	-0.54	7.3e-36	Thyroid hormone levels;
LGG	cis	rs2658782	0.547	rs4344448	chr11:93047047	T/C	cg15737290	chr11:93063684	CCDC67	0.66	10.95	0.45	5.65e-25	Pulmonary function decline;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg00684032	chr4:1343700	KIAA1530	0.46	8.97	0.38	7.68e-18	Obesity-related traits;
LGG	cis	rs7617773	0.817	rs936426	chr3:48215253	C/T	cg11946769	chr3:48343235	NME6	0.62	10.12	0.43	6.9e-22	Coronary artery disease;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-12.49	-0.5	4.67e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg03188948	chr7:1209495	NA	0.64	8.27	0.36	1.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg02297831	chr4:17616191	MED28	0.47	8.5	0.37	2.64e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7940866	0.845	rs1991899	chr11:130801649	C/T	cg12179176	chr11:130786555	SNX19	-0.76	-14.57	-0.56	7.61e-40	Schizophrenia;
LGG	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.59	-0.41	5.52e-20	Neuroticism;
LGG	cis	rs7577696	0.554	rs34835885	chr2:32325414	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-6.77	-0.3	4.03e-11	Inflammatory biomarkers;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.63	-0.33	1.33e-13	Psoriasis;
LGG	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.0	-0.35	1e-14	Initial pursuit acceleration;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs7241530	0.610	rs7235552	chr18:75892776	T/G	cg14642773	chr18:75888474	NA	0.47	8.98	0.39	6.65e-18	Educational attainment (years of education);
LGG	trans	rs1032833	0.732	rs6433759	chr2:180015053	C/T	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs3219090	0.962	rs2666427	chr1:226601874	G/A	cg17127702	chr1:226594323	PARP1	0.38	12.34	0.5	1.85e-30	Melanoma;
LGG	cis	rs7607369	0.714	rs4674332	chr2:219604326	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.03	-0.31	7.28e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs9296092	0.538	rs7761464	chr6:33519417	C/A	cg13560919	chr6:33536144	NA	-1.04	-21.54	-0.71	8.12e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7717393	0.786	rs17053462	chr5:155780558	C/T	cg12904904	chr5:155754151	SGCD	-0.64	-7.46	-0.33	4.4e-13	Egg allergy;
LGG	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg14675211	chr2:100938903	LONRF2	0.5	8.12	0.35	4.41e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.85	-0.57	4.35e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.6	-0.33	1.71e-13	Triglycerides;
LGG	cis	rs4732038	0.510	rs6948744	chr7:134278163	A/G	cg06906464	chr7:134288099	NA	-0.67	-17.35	-0.63	2.46e-52	Longevity;
LGG	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg03929089	chr4:120376271	NA	-1.04	-24.4	-0.75	3.67e-85	Height;
LGG	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.22	0.32	2.2e-12	Schizophrenia;
LGG	cis	rs6964587	0.610	rs6465338	chr7:91450624	T/C	cg17063962	chr7:91808500	NA	0.4	7.19	0.32	2.6e-12	Breast cancer;
LGG	trans	rs2727020	0.894	rs3862342	chr11:49357043	C/T	cg03929089	chr4:120376271	NA	-0.8	-13.29	-0.53	2.32e-34	Coronary artery disease;
LGG	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	10.47	0.44	3.57e-23	Bone mineral density;
LGG	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6815814	0.898	rs6848423	chr4:38887933	C/T	cg06935464	chr4:38784597	TLR10	0.55	7.89	0.34	2.13e-14	Breast cancer;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.13	-0.31	3.85e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg27471124	chr11:109292789	C11orf87	0.55	10.29	0.43	1.74e-22	Schizophrenia;
LGG	cis	rs12472274	0.648	rs67102443	chr2:239084602	A/G	cg17459225	chr2:239074497	NA	0.66	11.68	0.48	8.7e-28	Phospholipid levels (plasma);
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.33	-0.4	4.39e-19	Monocyte percentage of white cells;
LGG	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.62	0.44	9.61e-24	Lung cancer in ever smokers;
LGG	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg15028436	chr7:37888078	TXNDC3	0.89	15.93	0.59	7.38e-46	Alzheimer's disease (late onset);
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.18	-20.06	-0.68	6.79e-65	Platelet count;
LGG	cis	rs2559856	1.000	rs10860771	chr12:102087242	A/G	cg12924262	chr12:102091054	CHPT1	0.66	13.11	0.52	1.32e-33	Blood protein levels;
LGG	cis	rs4689388	0.856	rs4308430	chr4:6294095	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.81e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg06092702	chr1:163392909	NA	-0.47	-8.3	-0.36	1.16e-15	Motion sickness;
LGG	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg13770153	chr20:60521292	NA	-0.49	-7.95	-0.35	1.47e-14	Body mass index;
LGG	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	10.79	0.45	2.2e-24	Mood instability;
LGG	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.66	-0.41	3e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs950169	0.580	rs11634320	chr15:85172183	A/C	cg03959625	chr15:84868606	LOC388152	-0.48	-7.14	-0.32	3.55e-12	Schizophrenia;
LGG	cis	rs6740322	1.000	rs4128209	chr2:43554729	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.76	-0.38	3.72e-17	Coronary artery disease;
LGG	trans	rs146671954	1	rs146671954	chr9:136934203	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-7.66	-0.34	1.1e-13	Red cell distribution width;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg01114163	chr5:1856713	NA	-0.42	-6.9	-0.31	1.68e-11	Cardiovascular disease risk factors;
LGG	cis	rs708547	0.581	rs781661	chr4:57780307	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.44	-7.22	-0.32	2.13e-12	Response to bleomycin (chromatid breaks);
LGG	cis	rs4917300	0.606	rs4917292	chr8:143115553	T/C	cg06573787	chr8:143070187	NA	0.6	9.85	0.42	6.33e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg07274523	chr3:49395745	GPX1	0.56	8.9	0.38	1.23e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11169552	0.510	rs876078	chr12:51029835	G/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.54	-0.33	2.56e-13	Colorectal cancer;
LGG	cis	rs861020	0.883	rs680331	chr1:209959872	G/A	cg05527609	chr1:210001259	C1orf107	0.7	9.51	0.4	1.03e-19	Orofacial clefts;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.37	0.69	2.63e-66	Alzheimer's disease;
LGG	cis	rs7215564	0.908	rs34199628	chr17:78661675	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg19680485	chr15:31195859	MTMR15	-0.46	-7.58	-0.33	1.93e-13	Huntington's disease progression;
LGG	cis	rs28374715	0.662	rs72737792	chr15:41515589	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.0	-17.9	-0.64	7.55e-55	Ulcerative colitis;
LGG	cis	rs1497406	0.773	rs7538833	chr1:16504381	T/C	cg20430773	chr1:16534157	ARHGEF19	0.3	8.27	0.36	1.49e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.54e-24	Lung cancer in ever smokers;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg18402987	chr7:1209562	NA	0.7	9.53	0.41	8.77e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3806843	0.576	rs155361	chr5:140307284	G/A	cg19875535	chr5:140030758	IK	0.37	7.32	0.32	1.1e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4789378	1.000	rs4789376	chr17:74929998	G/T	cg02841895	chr17:74942714	MGAT5B	0.34	7.18	0.32	2.72e-12	Colorectal or endometrial cancer;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.16e-14	Total body bone mineral density;
LGG	cis	rs67478160	0.619	rs12437066	chr14:104236844	A/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.49e-13	Schizophrenia;
LGG	cis	rs888194	0.651	rs10850380	chr12:110002819	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.11	-0.31	4.37e-12	Neuroticism;
LGG	cis	rs9807841	0.538	rs892086	chr19:10837677	C/T	cg17710535	chr19:10819994	QTRT1	0.54	9.58	0.41	5.8e-20	Inflammatory skin disease;
LGG	cis	rs1371867	0.875	rs1788176	chr8:101332112	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs7717393	1.000	rs11950100	chr5:155755768	G/A	cg19569526	chr5:155754265	SGCD	0.83	7.96	0.35	1.38e-14	Egg allergy;
LGG	cis	rs2346177	0.875	rs4413204	chr2:46647092	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.42	-0.44	5.49e-23	HDL cholesterol;
LGG	cis	rs10979	1.000	rs6570566	chr6:143899534	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-11.7	-0.48	6.92e-28	Hypospadias;
LGG	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg08200770	chr17:80723486	TBCD	-0.46	-8.22	-0.36	2.03e-15	Glycated hemoglobin levels;
LGG	cis	rs7666738	0.830	rs13119995	chr4:99026790	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.48	0.37	3.01e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg08888203	chr3:10149979	C3orf24	0.55	9.39	0.4	2.81e-19	Alzheimer's disease;
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg04876069	chr12:132293656	NA	-0.35	-6.86	-0.3	2.21e-11	Migraine;
LGG	cis	rs2346177	0.875	rs12986585	chr2:46644121	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.46	-0.44	3.83e-23	HDL cholesterol;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	8.3	0.36	1.18e-15	Diabetic retinopathy;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13012494	chr21:47604986	C21orf56	0.59	10.4	0.44	6.84e-23	Testicular germ cell tumor;
LGG	cis	rs8028182	0.666	rs4886708	chr15:75762608	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.49	0.33	3.49e-13	Sudden cardiac arrest;
LGG	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg13628971	chr7:2884303	GNA12	-0.49	-10.06	-0.42	1.19e-21	Height;
LGG	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.84	-0.3	2.48e-11	Systolic blood pressure;
LGG	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg20891283	chr12:69753455	YEATS4	1.08	29.19	0.8	4.91e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs981844	0.775	rs17299519	chr4:154762123	C/T	cg14289246	chr4:154710475	SFRP2	0.68	11.09	0.46	1.62e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-7.71	-0.34	7.87e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17491951	0.735	rs67495046	chr2:2889271	G/A	cg02105481	chr2:2853515	NA	-0.43	-8.83	-0.38	2.18e-17	White matter integrity (bipolar disorder risk interaction);
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg04911050	chr16:677664	RAB40C	0.33	6.69	0.3	6.49e-11	Height;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg11317459	chr13:21872234	NA	-1.17	-18.82	-0.66	4.33e-59	White matter hyperintensity burden;
LGG	cis	rs10461617	0.541	rs832575	chr5:56161787	C/T	cg12654349	chr5:56205094	C5orf35	-0.64	-8.67	-0.37	7.2e-17	Type 2 diabetes;
LGG	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.88	-0.66	2.14e-59	Blood trace element (Zn levels);
LGG	cis	rs11771526	0.901	rs62457469	chr7:32303052	T/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.29	-0.4	5.94e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg18402987	chr7:1209562	NA	0.68	9.38	0.4	3.02e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg05863683	chr7:1912471	MAD1L1	0.46	9.09	0.39	2.84e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg22852734	chr6:133119734	C6orf192	1.3	10.2	0.43	3.55e-22	Type 2 diabetes nephropathy;
LGG	cis	rs7851660	0.844	rs10119853	chr9:100624981	G/A	cg13688889	chr9:100608707	NA	-0.63	-12.56	-0.5	2.39e-31	Strep throat;
LGG	cis	rs4974559	0.947	rs28711287	chr4:1346682	G/C	cg02980000	chr4:1222292	CTBP1	0.64	7.74	0.34	6.29e-14	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04047827	chr16:24740859	TNRC6A	0.47	7.18	0.32	2.79e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg02725872	chr8:58115012	NA	-0.98	-13.09	-0.52	1.53e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.77	-0.3	3.84e-11	Triglycerides;
LGG	cis	rs1318772	0.867	rs13171389	chr5:112907818	C/T	cg12552261	chr5:112820674	MCC	0.65	7.71	0.34	7.5e-14	F-cell distribution;
LGG	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg12253571	chr8:8283032	NA	-0.31	-6.79	-0.3	3.53e-11	Mood instability;
LGG	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-8.04	-0.35	7.31e-15	Ovarian reserve;
LGG	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs1707322	0.928	rs7527244	chr1:46368772	A/G	cg03146154	chr1:46216737	IPP	0.55	10.46	0.44	3.9699999999999997e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2073300	0.609	rs6137913	chr20:23357725	C/T	cg12062639	chr20:23401060	NAPB	0.84	8.38	0.36	6.2e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14172283	chr9:37592468	TOMM5	0.43	7.09	0.31	4.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2274273	0.624	rs7159824	chr14:55772536	C/T	cg04306507	chr14:55594613	LGALS3	0.54	12.61	0.51	1.51e-31	Protein biomarker;
LGG	trans	rs12682352	0.602	rs4841044	chr8:8664940	A/G	cg02002194	chr4:3960332	NA	0.38	7.02	0.31	8.17e-12	Neuroticism;
LGG	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18252515	chr7:66147081	NA	-0.41	-7.04	-0.31	7.04e-12	Aortic root size;
LGG	cis	rs60695258	0.550	rs340641	chr4:87951393	C/T	cg11209507	chr4:87813803	C4orf36	-0.47	-7.99	-0.35	1.11e-14	Hematocrit;
LGG	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.96	-0.35	1.29e-14	Depression;
LGG	cis	rs7220401	0.512	rs2289629	chr17:27959903	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.59	9.87	0.42	5.52e-21	Coronary artery disease;
LGG	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg17376030	chr22:41985996	PMM1	0.58	9.15	0.39	1.77e-18	Vitiligo;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.81	0.38	2.47e-17	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22621994	chr19:41869702	B9D2;TMEM91	-0.4	-7.25	-0.32	1.8e-12	Pancreatic cancer;
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg23188684	chr11:67383651	NA	0.51	8.66	0.37	7.79e-17	Mean corpuscular volume;
LGG	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg15823100	chr22:32027580	PISD	-0.74	-8.42	-0.36	4.8e-16	Age-related hearing impairment;
LGG	cis	rs12431410	0.550	rs2350136	chr14:60186498	T/C	cg07950296	chr14:60194823	RTN1	-0.39	-7.47	-0.33	4.01e-13	Schizophrenia;
LGG	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.75	-0.34	5.86e-14	Psoriasis;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.4	-0.33	6.52e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs854765	0.520	rs9899355	chr17:17898243	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-14.62	-0.56	4.35e-40	Total body bone mineral density;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg23978390	chr7:1156363	C7orf50	0.5	8.69	0.37	6.22e-17	Longevity;Endometriosis;
LGG	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg14664628	chr15:75095509	CSK	-1.01	-21.43	-0.71	2.69e-71	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18252515	chr7:66147081	NA	0.4	6.86	0.3	2.27e-11	Aortic root size;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24774154	chr11:34127519	NAT10	-0.41	-6.81	-0.3	3.1e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs62117911	1	rs62117911	chr19:16241886	G/A	cg07665718	chr19:16244068	HSH2D;RAB8A	0.56	7.52	0.33	2.79e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.91	-0.31	1.65e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg23815491	chr16:72088622	HP	0.51	11.54	0.47	2.89e-27	Fibrinogen levels;
LGG	cis	rs9902453	0.967	rs4325622	chr17:28526475	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.57	0.5	2.23e-31	Coffee consumption (cups per day);
LGG	cis	rs1371867	0.846	rs1788204	chr8:101303936	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs4865875	0.901	rs1073709	chr5:54115868	T/C	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg10189774	chr4:17578691	LAP3	0.41	7.46	0.33	4.38e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg16096631	chr1:42092165	HIVEP3	0.52	12.13	0.49	1.34e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg20607798	chr8:58055168	NA	0.64	7.12	0.31	4.17e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.43	-0.4	2e-19	Bladder cancer;
LGG	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.42	-0.36	4.92e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.02	-0.31	8.05e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4662750	0.743	rs1835431	chr2:128375943	A/G	cg10021288	chr2:128175891	PROC	0.39	7.17	0.32	2.98e-12	Renal cell carcinoma;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.52	-0.44	2.3e-23	Lung cancer;
LGG	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg26513180	chr16:89883248	FANCA	-0.64	-12.03	-0.49	3.46e-29	Vitiligo;
LGG	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg13647721	chr17:30228624	UTP6	0.66	9.01	0.39	5.23e-18	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.22	0.55	2.43e-38	Obesity-related traits;
LGG	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg06766960	chr11:133703094	NA	-0.55	-10.91	-0.45	8.14e-25	Childhood ear infection;
LGG	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg25486957	chr4:152246857	NA	-0.52	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2117029	0.561	rs7957983	chr12:49508987	C/T	cg24176009	chr12:49580217	TUBA1A	0.6	11.73	0.48	5.36e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22144125	chr7:100209665	MOSPD3	0.46	7.34	0.32	9.98e-13	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15069926	chr1:160001653	PIGM	0.48	7.15	0.32	3.42e-12	Gut microbiome composition (summer);
LGG	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	10.96	0.45	5.04e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7911264	1.000	rs10882100	chr10:94460687	C/G	cg25093409	chr10:94429542	NA	0.59	12.51	0.5	3.9e-31	Inflammatory bowel disease;
LGG	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg19875535	chr5:140030758	IK	-0.57	-11.82	-0.48	2.26e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.9	0.42	4.44e-21	Prudent dietary pattern;
LGG	cis	rs11214589	0.774	rs7116782	chr11:113250938	A/G	cg14159747	chr11:113255604	NA	0.32	8.57	0.37	1.5e-16	Neuroticism;
LGG	cis	rs7586879	0.638	rs13035244	chr2:25134009	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.88	0.51	1.12e-32	Body mass index;
LGG	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.1	-0.42	8.13e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs11608355	0.515	rs61941592	chr12:109930497	G/A	cg05360138	chr12:110035743	NA	0.84	12.24	0.49	4.93e-30	Neuroticism;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg11644478	chr21:40555479	PSMG1	-0.7	-12.47	-0.5	5.93e-31	Cognitive function;
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs4671458	0.948	rs72813476	chr2:63523174	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-7.84	-0.34	3.13e-14	Subjective well-being;
LGG	cis	rs911263	0.561	rs1810623	chr14:68805725	T/C	cg18825221	chr14:68749962	RAD51L1	0.42	7.27	0.32	1.53e-12	Primary biliary cholangitis;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg25706552	chr1:244017396	NA	0.53	8.52	0.37	2.21e-16	RR interval (heart rate);
LGG	cis	rs9902453	0.765	rs2447935	chr17:28057524	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.38	-0.56	5.01e-39	Coffee consumption (cups per day);
LGG	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg13114125	chr14:105738426	BRF1	-0.84	-16.97	-0.62	1.44e-50	Platelet count;
LGG	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-18.72	-0.66	1.3e-58	Chronic sinus infection;
LGG	cis	rs2386661	0.547	rs72781996	chr10:5646485	C/G	cg17085576	chr10:5658249	NA	-0.43	-7.91	-0.35	1.86e-14	Breast cancer;
LGG	cis	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg12486710	chr1:178512616	C1orf220	-0.51	-10.65	-0.44	7.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9899728	0.764	rs9660	chr17:73038746	A/G	cg27626185	chr17:73056755	KCTD2	-0.69	-9.41	-0.4	2.41e-19	Alzheimer's disease or small vessel stroke;
LGG	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg09904177	chr6:26538194	HMGN4	0.68	13.95	0.54	3.56e-37	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs516946	1.000	rs750625	chr8:41525914	C/T	cg01678292	chr8:41522873	ANK1	0.35	8.21	0.36	2.19e-15	Type 2 diabetes;
LGG	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg26248373	chr2:1572462	NA	-0.68	-9.09	-0.39	2.98e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	8.31	0.36	1.03e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg08807101	chr21:30365312	RNF160	0.58	9.68	0.41	2.66e-20	Pancreatic cancer;
LGG	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg01831904	chr17:28903510	LRRC37B2	0.85	10.42	0.44	5.77e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11771526	0.792	rs11770580	chr7:32305009	T/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs360798	0.512	rs9973612	chr2:63019815	G/C	cg17519650	chr2:63277830	OTX1	-0.5	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg17376030	chr22:41985996	PMM1	0.5	8.14	0.35	3.65e-15	Vitiligo;
LGG	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs75920871	1.000	rs11820814	chr11:116765700	T/C	cg20608306	chr11:116969690	SIK3	-0.32	-6.83	-0.3	2.73e-11	Subjective well-being;
LGG	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg19676328	chr12:49525230	TUBA1B	-0.63	-10.34	-0.43	1.07e-22	Total cholesterol levels;
LGG	trans	rs3206736	0.548	rs328891	chr7:35013517	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.39	6.8	0.3	3.23e-11	Diastolic blood pressure;
LGG	trans	rs66573146	0.656	rs66517061	chr4:6935163	C/G	cg07817883	chr1:32538562	TMEM39B	1.43	13.15	0.52	9.04e-34	Granulocyte percentage of myeloid white cells;
LGG	cis	rs240764	0.658	rs9377214	chr6:101212146	G/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs62432291	0.681	rs365045	chr6:159632250	A/G	cg14500486	chr6:159655392	FNDC1	0.62	6.95	0.31	1.24e-11	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg05313129	chr8:58192883	C8orf71	-0.67	-8.72	-0.38	5.19e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10463554	0.853	rs2432177	chr5:102571873	A/G	cg23492399	chr5:102201601	PAM	-0.53	-7.66	-0.34	1.07e-13	Parkinson's disease;
LGG	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	10.57	0.44	1.6e-23	Lung cancer in ever smokers;
LGG	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.87	0.42	5.52e-21	Common traits (Other);
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg22753661	chr15:79092743	ADAMTS7	0.39	6.77	0.3	4.03e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg11161011	chr14:65562177	MAX	-0.64	-12.48	-0.5	5.05e-31	Obesity-related traits;
LGG	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg11871910	chr12:69753446	YEATS4	0.42	6.71	0.3	5.65e-11	Response to diuretic therapy;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg18379455	chr17:41446167	NA	-0.34	-8.08	-0.35	5.86e-15	Menopause (age at onset);
LGG	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg04935436	chr20:30431758	NA	-0.4	-7.04	-0.31	7.06e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg04234412	chr22:24373322	LOC391322	-0.8	-16.68	-0.61	2.83e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.24	0.69	1.06e-65	Alzheimer's disease;
LGG	cis	rs2013441	0.613	rs888424	chr17:19985427	C/T	cg13482628	chr17:19912719	NA	0.51	9.63	0.41	3.92e-20	Obesity-related traits;
LGG	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg24110177	chr3:50126178	RBM5	0.58	10.46	0.44	4.06e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4308124	0.708	rs6727313	chr2:111971540	G/A	cg04571233	chr2:111982156	NA	-0.6	-9.85	-0.42	6.38e-21	Vitiligo;
LGG	cis	rs11122272	0.735	rs2739513	chr1:231515201	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg07870213	chr5:140052090	DND1	-0.67	-13.07	-0.52	1.95e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-9.06	-0.39	3.54e-18	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.71	0.45	4.76e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg00701064	chr4:6280414	WFS1	0.68	13.26	0.52	3.06e-34	Cisplatin-induced ototoxicity;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-11.83	-0.48	2.18e-28	Prudent dietary pattern;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg04743933	chr7:129844923	TMEM209	-0.46	-7.2	-0.32	2.53e-12	Sitting height ratio;
LGG	cis	rs2050392	0.517	rs619864	chr10:30750950	A/G	cg25182066	chr10:30743637	MAP3K8	0.66	14.57	0.56	7.72e-40	Inflammatory bowel disease;
LGG	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.29	-7.6	-0.33	1.65e-13	IgG glycosylation;
LGG	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg14829155	chr15:31115871	NA	-0.56	-9.81	-0.41	9.13e-21	Huntington's disease progression;
LGG	cis	rs12765878	0.692	rs10883926	chr10:105608838	G/A	cg11005552	chr10:105648138	OBFC1	0.78	15.09	0.57	3.75e-42	Coronary artery disease;
LGG	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg26076054	chr5:421317	AHRR	-0.48	-7.95	-0.35	1.48e-14	Cystic fibrosis severity;
LGG	cis	rs6430585	0.528	rs7606267	chr2:136668123	T/C	cg07169764	chr2:136633963	MCM6	1.26	25.06	0.76	3.41e-88	Corneal structure;
LGG	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs600231	0.706	rs11227221	chr11:65319265	T/C	cg17120908	chr11:65337727	SSSCA1	0.61	10.87	0.45	1.17e-24	Bone mineral density;
LGG	cis	rs12476592	0.602	rs262472	chr2:63833616	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.48e-11	Childhood ear infection;
LGG	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.82	-0.3	2.77e-11	Schizophrenia;
LGG	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs3219090	0.861	rs2570370	chr1:226607385	T/C	cg17127702	chr1:226594323	PARP1	0.4	12.41	0.5	9.69e-31	Melanoma;
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg10505658	chr17:80084571	CCDC57	-0.4	-8.15	-0.35	3.53e-15	Life satisfaction;
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg16339924	chr4:17578868	LAP3	0.66	11.27	0.46	3.43e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs1961637	0.603	rs895772	chr2:223892964	C/T	cg02552189	chr2:223891284	NA	0.36	7.18	0.32	2.88e-12	Oropharynx cancer;
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg11764359	chr7:65958608	NA	0.71	12.86	0.51	1.44e-32	Aortic root size;
LGG	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11626933	0.885	rs6575125	chr14:90802463	C/T	cg04374321	chr14:90722782	PSMC1	0.45	7.33	0.32	1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg04234412	chr22:24373322	LOC391322	-0.79	-16.22	-0.6	3.57e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg11707556	chr5:10655725	ANKRD33B	0.45	7.1	0.31	4.7e-12	Intraocular pressure;
LGG	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs7617773	0.780	rs13081169	chr3:48356797	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs793571	0.669	rs714696	chr15:58962987	C/G	cg05156742	chr15:59063176	FAM63B	0.49	7.9	0.34	2.06e-14	Schizophrenia;
LGG	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg10483660	chr13:112241077	NA	-0.36	-7.17	-0.32	2.96e-12	Menarche (age at onset);
LGG	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg18105134	chr13:113819100	PROZ	-0.7	-14.05	-0.55	1.31e-37	Platelet distribution width;
LGG	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17818399	0.708	rs13000706	chr2:46838247	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.75	0.3	4.39e-11	Height;
LGG	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.33	0.65	7.89e-57	Refractive error;
LGG	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg26384229	chr12:38710491	ALG10B	0.89	19.7	0.68	3.43e-63	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.597	rs2185358	chr1:248585259	T/A	cg00666640	chr1:248458726	OR2T12	0.5	7.02	0.31	7.76e-12	Common traits (Other);
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.36	-0.32	8.7e-13	Lung cancer;
LGG	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.37	-0.32	8.04e-13	HDL cholesterol;
LGG	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg25173405	chr17:45401733	C17orf57	0.47	8.01	0.35	9.27e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.99e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.752	rs11078895	chr17:37401051	A/G	cg00129232	chr17:37814104	STARD3	-0.54	-8.13	-0.35	3.84e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs78487399	0.808	rs13417883	chr2:43700154	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs709400	0.628	rs11621510	chr14:103869620	T/C	cg26031613	chr14:104095156	KLC1	0.78	13.44	0.53	5.08e-35	Body mass index;
LGG	cis	rs34929064	0.560	rs62449491	chr7:22748954	C/T	cg18045685	chr7:22629474	NA	0.53	7.16	0.32	3.13e-12	Major depression and alcohol dependence;
LGG	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.37	6.65	0.3	8.53e-11	Parkinson's disease;
LGG	cis	rs6750047	0.625	rs59363818	chr2:38261973	A/C	cg07380506	chr2:38303506	CYP1B1	-0.43	-7.11	-0.31	4.36e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs4481887	0.893	rs1934543	chr1:248505602	C/G	cg01631408	chr1:248437212	OR2T33	-0.5	-9.18	-0.39	1.48e-18	Common traits (Other);
LGG	cis	rs4653767	1.000	rs708773	chr1:226920730	T/C	cg00279406	chr1:226924739	ITPKB	0.27	6.95	0.31	1.25e-11	Parkinson's disease;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg07142201	chr11:109293216	C11orf87	0.61	10.52	0.44	2.33e-23	Schizophrenia;
LGG	cis	rs9473924	0.580	rs60100577	chr6:50816134	C/T	cg14470998	chr6:50812995	TFAP2B	0.65	7.75	0.34	5.74e-14	Body mass index;
LGG	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	Neuroticism;
LGG	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg20555477	chr9:86594889	HNRNPK;RMI1	0.4	6.8	0.3	3.32e-11	Lung adenocarcinoma;
LGG	cis	rs2669010	1.000	rs2669010	chr12:77009060	A/G	cg14998926	chr12:77026162	NA	-0.38	-6.83	-0.3	2.69e-11	Systemic lupus erythematosus;
LGG	cis	rs67311347	0.956	rs9822870	chr3:40514890	A/C	cg13683864	chr3:40499215	RPL14	1.15	28.0	0.79	1.18e-101	Renal cell carcinoma;
LGG	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	13.09	0.52	1.52e-33	Menarche (age at onset);
LGG	cis	rs3008870	0.755	rs4655662	chr1:67416432	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.83e-44	Lymphocyte percentage of white cells;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg07648498	chr16:89883185	FANCA	0.41	6.94	0.31	1.31e-11	Vitiligo;
LGG	cis	rs12580194	0.556	rs12099811	chr12:55731200	T/A	cg19537932	chr12:55886519	OR6C68	-0.52	-9.33	-0.4	4.35e-19	Cancer;
LGG	cis	rs2933343	0.601	rs1680759	chr3:128594896	C/G	cg25356066	chr3:128598488	ACAD9	0.45	6.95	0.31	1.24e-11	IgG glycosylation;
LGG	cis	rs283228	0.617	rs542923	chr6:101740974	T/C	cg27451362	chr6:101846650	GRIK2	0.84	13.16	0.52	8.32e-34	Coenzyme Q10 levels;
LGG	trans	rs66887589	0.616	rs13113885	chr4:120221176	G/C	cg25214090	chr10:38739885	LOC399744	0.44	7.79	0.34	4.37e-14	Diastolic blood pressure;
LGG	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg18404041	chr3:52824283	ITIH1	-0.49	-9.16	-0.39	1.75e-18	Electroencephalogram traits;
LGG	cis	rs7646881	0.904	rs112493023	chr3:158448276	A/G	cg19483011	chr3:158453295	NA	-0.62	-9.18	-0.39	1.45e-18	Tetralogy of Fallot;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.21	0.32	2.32e-12	Childhood ear infection;
LGG	cis	rs4262150	0.846	rs72799185	chr5:152182070	C/A	cg12297329	chr5:152029980	NA	-0.69	-12.79	-0.51	2.82e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg25801113	chr15:45476975	SHF	0.86	19.64	0.67	6.64e-63	Uric acid levels;
LGG	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg18252515	chr7:66147081	NA	-1.35	-18.68	-0.66	1.89e-58	Diabetic kidney disease;
LGG	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg17971929	chr21:40555470	PSMG1	-0.53	-8.95	-0.38	8.55e-18	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14509921	chr1:184357113	C1orf21	0.47	7.24	0.32	1.88e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs4671458	0.948	rs12471038	chr2:63484639	C/A	cg17519650	chr2:63277830	OTX1	-0.63	-8.08	-0.35	5.58e-15	Subjective well-being;
LGG	cis	rs2916247	1.000	rs2976502	chr8:92980734	A/G	cg10183463	chr8:93005414	RUNX1T1	0.41	8.36	0.36	7.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg01200585	chr1:228362443	C1orf69	0.47	8.14	0.35	3.72e-15	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg11494091	chr17:61959527	GH2	0.5	8.03	0.35	8.28e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg20673091	chr1:2541236	MMEL1	0.78	19.17	0.67	9.53e-61	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7246760	0.867	rs56377135	chr19:9820116	C/T	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg13395646	chr4:1353034	KIAA1530	0.49	8.29	0.36	1.28e-15	Obesity-related traits;
LGG	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg12395012	chr8:11607386	GATA4	0.44	8.21	0.36	2.3e-15	Morning vs. evening chronotype;
LGG	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg25208724	chr1:156163844	SLC25A44	1.16	24.23	0.75	2.25e-84	Testicular germ cell tumor;
LGG	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg12636538	chr11:118901039	SLC37A4	-0.56	-11.56	-0.47	2.4200000000000002e-27	Coronary artery disease;
LGG	cis	rs10262624	0.967	rs10229233	chr7:23907519	C/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.7	-0.3	6.17e-11	Schizophrenia;
LGG	cis	rs7077256	0.542	rs67453614	chr10:65157708	A/C	cg02276361	chr10:65351566	REEP3	-0.34	-7.0	-0.31	9.16e-12	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg26384229	chr12:38710491	ALG10B	0.94	20.61	0.69	1.92e-67	Morning vs. evening chronotype;
LGG	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08109568	chr15:31115862	NA	-0.54	-9.52	-0.4	9.67e-20	Huntington's disease progression;
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg06494592	chr3:125709126	NA	-0.55	-7.0	-0.31	9.02e-12	Blood pressure (smoking interaction);
LGG	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19171272	chr22:38449367	NA	-0.54	-10.41	-0.44	6.08e-23	Glioblastoma;Glioma;
LGG	cis	rs477692	1.000	rs569235	chr10:131411620	T/C	cg05714579	chr10:131428358	MGMT	0.56	11.42	0.47	9.16e-27	Response to temozolomide;
LGG	trans	rs637571	0.607	rs574586	chr11:65697083	G/A	cg17712092	chr4:129076599	LARP1B	0.87	17.44	0.63	1.03e-52	Eosinophil percentage of white cells;
LGG	cis	rs7567389	0.534	rs2069904	chr2:128175779	G/A	cg10021288	chr2:128175891	PROC	0.38	6.71	0.3	5.85e-11	Self-rated health;
LGG	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg25809561	chr17:30822961	MYO1D	0.42	10.11	0.43	7.68e-22	Schizophrenia;
LGG	cis	rs870825	0.616	rs12498890	chr4:185636096	C/G	cg04058563	chr4:185651563	MLF1IP	-0.97	-21.04	-0.7	1.94e-69	Blood protein levels;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.831	rs34592564	chr21:40516288	G/C	cg11890956	chr21:40555474	PSMG1	1.18	25.78	0.77	1.51e-91	Cognitive function;
LGG	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg06360820	chr2:242988706	NA	-0.89	-11.49	-0.47	4.54e-27	Obesity-related traits;
LGG	cis	rs6579956	0.517	rs2961750	chr5:152020985	T/C	cg12297329	chr5:152029980	NA	-0.53	-9.66	-0.41	3.17e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs709400	0.597	rs1013650	chr14:103909203	G/A	cg26031613	chr14:104095156	KLC1	0.77	13.82	0.54	1.3e-36	Body mass index;
LGG	trans	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.47	-0.4	1.43e-19	Bladder cancer;
LGG	cis	rs68170813	0.559	rs1548523	chr7:106944408	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.55	-0.44	1.88e-23	Coronary artery disease;
LGG	trans	rs7939886	0.920	rs7124734	chr11:55960339	C/T	cg03929089	chr4:120376271	NA	0.72	6.68	0.3	6.83e-11	Myopia (pathological);
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg06916706	chr16:4465613	CORO7	0.86	14.67	0.56	2.68e-40	Schizophrenia;
LGG	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.28	-0.32	1.47e-12	Testicular germ cell tumor;
LGG	cis	rs16854884	0.657	rs7642774	chr3:143723272	T/A	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.16e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg20219074	chr11:18656078	SPTY2D1	0.84	15.97	0.6	4.59e-46	Breast cancer;
LGG	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572733	0.905	rs6718039	chr2:198761642	C/G	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.66e-16	Dermatomyositis;
LGG	cis	rs7222240	0.680	rs58219619	chr17:43207624	G/A	cg24806326	chr17:43207588	PLCD3	0.54	9.47	0.4	1.4e-19	Craniofacial microsomia;
LGG	cis	rs4356932	1.000	rs7670789	chr4:76940381	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs757081	0.648	rs1488933	chr11:17267029	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.73	-0.34	6.84e-14	Systolic blood pressure;
LGG	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg22044901	chr15:68126292	NA	-0.4	-6.78	-0.3	3.71e-11	Restless legs syndrome;
LGG	cis	rs4731207	0.509	rs6977699	chr7:124617109	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.84	-0.3	2.55e-11	Cutaneous malignant melanoma;
LGG	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg00031303	chr3:195681400	NA	0.51	8.08	0.35	5.75e-15	Pancreatic cancer;
LGG	cis	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg19399532	chr1:178512495	C1orf220	0.54	10.81	0.45	1.94e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14014525	chr17:42148052	G6PC3	0.51	7.53	0.33	2.66e-13	Gut microbiome composition (summer);
LGG	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg00405596	chr8:11794950	NA	-0.4	-6.66	-0.3	7.72e-11	Triglycerides;
LGG	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-20.25	-0.69	9.11e-66	Gut microbiome composition (summer);
LGG	cis	rs10463554	0.892	rs72783889	chr5:102274539	A/G	cg23492399	chr5:102201601	PAM	-0.55	-8.48	-0.37	3.05e-16	Parkinson's disease;
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.72	-0.61	1.98e-49	Intelligence (multi-trait analysis);
LGG	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg04731861	chr2:219085781	ARPC2	0.45	11.04	0.46	2.55e-25	Colorectal cancer;
LGG	cis	rs867371	1.000	rs9944197	chr15:82450602	G/A	cg00614314	chr15:82944287	LOC80154	0.6	10.14	0.43	5.94e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs1165472	1.000	rs6700588	chr1:56099371	A/C	cg11523071	chr1:56160889	NA	0.43	9.22	0.39	1.02e-18	Paclitaxel-induced neuropathy;
LGG	cis	rs9303280	0.836	rs12453507	chr17:38053207	C/G	cg00129232	chr17:37814104	STARD3	-0.5	-9.26	-0.4	7.94e-19	Self-reported allergy;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg08677398	chr8:58056175	NA	0.44	7.41	0.33	6.07e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03452623	chr4:187889614	NA	0.85	18.43	0.65	2.72e-57	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg11984989	chr7:158649758	WDR60	0.96	19.68	0.67	4.18e-63	Height;
LGG	cis	rs898097	0.627	rs3785514	chr17:80888905	A/G	cg15664640	chr17:80829946	TBCD	0.7	12.74	0.51	4.44e-32	Breast cancer;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13012494	chr21:47604986	C21orf56	-0.55	-9.69	-0.41	2.34e-20	Testicular germ cell tumor;
LGG	cis	rs950169	0.579	rs12912716	chr15:84664263	A/T	cg24253500	chr15:84953950	NA	0.45	7.2	0.32	2.51e-12	Schizophrenia;
LGG	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.78	-0.51	2.95e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs6429082	0.683	rs2131920	chr1:235579912	T/A	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	cis	rs4803468	1.000	rs878083	chr19:41897688	G/A	cg09537434	chr19:41945824	ATP5SL	-0.86	-22.14	-0.72	1.35e-74	Height;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-9.19	-0.39	1.37e-18	Skin colour saturation;
LGG	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.89	-18.41	-0.65	3.26e-57	Hip circumference adjusted for BMI;
LGG	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg16511985	chr3:153974050	SGEF	0.5	8.41	0.36	5.23e-16	Coronary artery disease;
LGG	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg07537917	chr2:241836409	C2orf54	-0.39	-7.41	-0.33	6e-13	Urinary metabolites;
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg11965913	chr1:205819406	PM20D1	0.49	8.63	0.37	1.02e-16	Menarche (age at onset);
LGG	cis	rs7226408	0.600	rs7227303	chr18:34521293	C/T	cg15022739	chr18:34823045	BRUNOL4	0.41	8.82	0.38	2.32e-17	Obesity-related traits;
LGG	cis	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg21479132	chr6:26055353	NA	0.79	7.13	0.31	3.9e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00166722	chr3:10149974	C3orf24	0.51	8.51	0.37	2.39e-16	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25072359	chr17:41440525	NA	-0.52	-10.14	-0.43	5.98e-22	Menopause (age at onset);
LGG	cis	rs2540226	0.539	rs2716694	chr2:39911336	A/G	cg18968196	chr2:39892502	TMEM178	0.29	8.06	0.35	6.34e-15	Personality dimensions;
LGG	cis	rs10416265	0.527	rs11084699	chr19:33538393	A/T	cg27124370	chr19:33622961	WDR88	0.54	10.23	0.43	2.88e-22	Bone properties (heel);
LGG	cis	rs1729951	0.575	rs835642	chr3:136703365	A/T	cg21827317	chr3:136751795	NA	0.52	9.71	0.41	2.03e-20	Neuroticism;
LGG	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.06	0.46	2.24e-25	Mean platelet volume;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.84	16.46	0.61	2.83e-48	Lymphocyte counts;
LGG	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.55	-0.33	2.36e-13	Bone mineral density;
LGG	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg18963800	chr10:38644991	HSD17B7P2	0.44	7.27	0.32	1.52e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.45e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg23468128	chr2:61108270	REL	-0.43	-6.78	-0.3	3.64e-11	Educational attainment (years of education);
LGG	cis	rs701145	0.585	rs1713798	chr3:153807407	G/A	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg05973401	chr12:123451056	ABCB9	0.45	7.7	0.34	8.34e-14	Platelet count;
LGG	cis	rs883565	0.792	rs813669	chr3:39181723	C/T	cg01426195	chr3:39028469	NA	0.61	10.63	0.44	8.87e-24	Handedness;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg05484376	chr2:27715224	FNDC4	0.44	9.45	0.4	1.67e-19	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.48	7.63	0.33	1.31e-13	Hip circumference adjusted for BMI;
LGG	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg09873164	chr1:152488093	CRCT1	0.61	14.76	0.57	1.13e-40	Hair morphology;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05025164	chr4:1340916	KIAA1530	0.88	17.16	0.62	1.95e-51	Longevity;
LGG	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.85	-9.55	-0.41	7.69e-20	Diabetic retinopathy;
LGG	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg01529538	chr14:23388837	RBM23	0.37	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs1697139	0.710	rs6888412	chr5:66526800	G/C	cg11553311	chr5:66541588	NA	0.53	11.19	0.46	6.57e-26	Breast cancer;
LGG	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.7	0.41	2.31e-20	Diabetic retinopathy;
LGG	cis	rs2371030	0.509	rs2287412	chr2:211617598	G/A	cg18417063	chr2:211583084	NA	0.52	8.71	0.38	5.48e-17	Non-small cell lung cancer;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07234876	chr8:600039	NA	-1.37	-11.56	-0.47	2.48e-27	IgG glycosylation;
LGG	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg17218041	chr13:113365319	ATP11A	-0.44	-7.19	-0.32	2.59e-12	Glycated hemoglobin levels;
LGG	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.61	0.51	1.49e-31	Motion sickness;
LGG	cis	rs6489785	0.775	rs1718211	chr12:121347713	G/A	cg02419362	chr12:121203948	SPPL3	-0.43	-6.78	-0.3	3.73e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15853374	chr22:38245447	EIF3L	0.47	7.02	0.31	7.88e-12	Gut microbiome composition (summer);
LGG	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs2188561	0.697	rs7782475	chr7:107386251	A/G	cg16793755	chr7:107334138	SLC26A4	-0.38	-6.8	-0.3	3.27e-11	Alcohol consumption;
LGG	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg06872548	chr17:78716983	RPTOR	0.45	10.63	0.44	9.58e-24	Obesity;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg16359550	chr11:109292809	C11orf87	0.43	8.41	0.36	5.29e-16	Schizophrenia;
LGG	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs8028182	0.636	rs11634863	chr15:75766672	C/A	cg20655648	chr15:75932815	IMP3	0.46	7.78	0.34	4.76e-14	Sudden cardiac arrest;
LGG	cis	rs2276314	0.857	rs8097597	chr18:33619448	A/G	cg19628046	chr18:33552617	C18orf21	0.5	7.3	0.32	1.27e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs12220238	0.841	rs12098284	chr10:76047464	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.95	0.38	8.48e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs79911532	0.515	rs117690214	chr7:75718237	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-8.0	-0.35	9.72e-15	Mononucleosis;
LGG	cis	rs7808935	0.628	rs9791862	chr7:27950760	G/A	cg22168087	chr7:27702803	HIBADH	0.69	9.54	0.41	8.47e-20	Prostate cancer;
LGG	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg17201900	chr20:34330562	RBM39	0.52	7.07	0.31	5.59e-12	Total cholesterol levels;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.62	-0.53	9.47e-36	Schizophrenia;
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg13607699	chr17:42295918	UBTF	0.64	11.1	0.46	1.55e-25	Total body bone mineral density;
LGG	cis	rs1707322	0.893	rs9919275	chr1:46441360	A/C	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15369054	chr17:80825471	TBCD	0.54	7.49	0.33	3.56e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.28e-17	Schizophrenia;
LGG	cis	rs2820315	1.000	rs2172935	chr1:201826340	A/G	cg10061532	chr1:201886748	LMOD1	-0.34	-7.04	-0.31	7.11e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.82	-0.34	3.56e-14	Joint mobility (Beighton score);
LGG	cis	rs9487094	0.614	rs13191444	chr6:110084064	A/G	cg16315928	chr6:109776240	MICAL1	0.48	7.8	0.34	4.11e-14	Height;
LGG	cis	rs1010254	0.510	rs17446143	chr5:151697650	C/T	cg12297329	chr5:152029980	NA	-0.47	-6.82	-0.3	2.8e-11	Optic nerve measurement (cup area);
LGG	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.74	-17.08	-0.62	4.24e-51	Multiple sclerosis;
LGG	cis	rs3784262	1.000	rs12910113	chr15:58248373	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.15	-0.35	3.34e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg26384229	chr12:38710491	ALG10B	0.99	23.52	0.74	4.63e-81	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg04986931	chr22:39850128	NA	0.34	7.75	0.34	5.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.515	rs12945216	chr17:78670642	C/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.46	-0.47	6.02e-27	Obesity;
LGG	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.6e-22	Total body bone mineral density;
LGG	cis	rs4948275	0.773	rs2787732	chr10:63247599	A/G	cg03237606	chr10:63212265	TMEM26	0.37	6.71	0.3	5.79e-11	Night sleep phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08413153	chr17:46185283	SNX11	0.55	8.38	0.36	6.5e-16	Gut microbiome composition (summer);
LGG	cis	rs113835537	0.529	rs17580784	chr11:66214859	T/A	cg24851651	chr11:66362959	CCS	0.43	7.36	0.32	8.6e-13	Airway imaging phenotypes;
LGG	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg18128536	chr17:47092178	IGF2BP1	-0.54	-10.41	-0.44	5.92e-23	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs7851660	0.967	rs4743135	chr9:100599493	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.56	-0.56	8.14e-40	Strep throat;
LGG	cis	rs4662945	0.504	rs35568023	chr2:130251812	A/T	cg05962382	chr2:130345044	NA	-0.45	-7.83	-0.34	3.28e-14	Response to cytidine analogues (gemcitabine);
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03647317	chr4:187891568	NA	-0.41	-8.91	-0.38	1.17e-17	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg15704280	chr7:45808275	SEPT13	0.67	8.42	0.36	4.75e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.31	0.43	1.45e-22	Prudent dietary pattern;
LGG	cis	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg06521331	chr12:34319734	NA	-0.58	-10.1	-0.42	8.28e-22	Morning vs. evening chronotype;
LGG	cis	rs490234	0.934	rs12553637	chr9:128277258	A/G	cg14078157	chr9:128172775	NA	-0.4	-7.56	-0.33	2.22e-13	Mean arterial pressure;
LGG	cis	rs11025559	0.812	rs11025583	chr11:20513260	C/T	cg19653624	chr11:20408972	PRMT3	0.5	8.58	0.37	1.48e-16	Pursuit maintenance gain;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.61e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.967	rs55748380	chr17:28469782	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.82e-34	Coffee consumption (cups per day);
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg07157834	chr1:205819609	PM20D1	-0.73	-16.73	-0.61	1.66e-49	Menarche (age at onset);
LGG	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg13852791	chr20:30311386	BCL2L1	0.87	15.43	0.58	1.23e-43	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs504918	0.556	rs11719623	chr3:123978818	A/C	cg05766129	chr3:123988013	KALRN	-0.59	-10.65	-0.44	7.85e-24	Schizophrenia;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.52	0.37	2.35e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11250097	0.543	rs68164957	chr8:10799489	A/C	cg21775007	chr8:11205619	TDH	-0.47	-7.03	-0.31	7.35e-12	Neuroticism;
LGG	cis	rs6815814	0.851	rs5743551	chr4:38807654	T/C	cg06935464	chr4:38784597	TLR10	0.5	8.14	0.35	3.68e-15	Breast cancer;
LGG	trans	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg02002194	chr4:3960332	NA	-0.42	-7.79	-0.34	4.54e-14	Neuroticism;
LGG	cis	rs3768617	1.000	rs1360704	chr1:183099380	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.35	-6.78	-0.3	3.67e-11	Fuchs's corneal dystrophy;
LGG	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg16070123	chr10:51489643	NA	-0.4	-7.24	-0.32	1.83e-12	Prostate-specific antigen levels;
LGG	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg20503657	chr10:835505	NA	-0.59	-8.84	-0.38	2.02e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg25019033	chr10:957182	NA	-0.6	-11.02	-0.46	3.16e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg18681998	chr4:17616180	MED28	0.85	18.31	0.65	9.33e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.95	0.31	1.21e-11	Lung cancer;
LGG	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.44	0.44	4.84e-23	Calcium levels;
LGG	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg05182265	chr7:156933206	UBE3C	0.38	7.66	0.34	1.09e-13	Body mass index;
LGG	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg03511173	chr18:77590860	NA	0.62	7.79	0.34	4.41e-14	Opioid sensitivity;
LGG	cis	rs1143633	0.530	rs2723163	chr2:113694339	A/G	cg06771106	chr2:113671356	IL1F7	-0.35	-6.75	-0.3	4.49e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg15537850	chr8:144661051	NAPRT1	0.99	7.53	0.33	2.71e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs3733585	0.699	rs7663097	chr4:9966791	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.03e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg00864171	chr11:67383662	NA	-0.45	-7.37	-0.32	7.67e-13	Mean corpuscular volume;
LGG	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg14689365	chr7:158441557	NCAPG2	0.54	6.69	0.3	6.6e-11	Height;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	cis	rs17767392	0.918	rs17767499	chr14:71867275	T/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.07	0.39	3.33e-18	Mitral valve prolapse;
LGG	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg08999081	chr20:33150536	PIGU	-0.28	-6.67	-0.3	7.4e-11	Height;
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg00405596	chr8:11794950	NA	-0.41	-6.69	-0.3	6.37e-11	Neuroticism;
LGG	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-10.52	-0.44	2.32e-23	Chronic sinus infection;
LGG	cis	rs7587476	0.784	rs13008641	chr2:215698033	T/C	cg04004882	chr2:215674386	BARD1	0.57	8.23	0.36	1.88e-15	Neuroblastoma;
LGG	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	12.71	0.51	6.09e-32	Lung cancer in ever smokers;
LGG	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-14.15	-0.55	5.16e-38	Platelet distribution width;
LGG	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.64	-0.33	1.26e-13	Mood instability;
LGG	cis	rs7572733	0.846	rs1518359	chr2:198847383	C/T	cg00792783	chr2:198669748	PLCL1	0.48	7.96	0.35	1.3e-14	Dermatomyositis;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg06848047	chr4:90757629	SNCA	-0.42	-7.88	-0.34	2.37e-14	Dementia with Lewy bodies;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg04703951	chr17:43578652	NA	0.35	7.31	0.32	1.2e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg17734273	chr15:78292508	TBC1D2B	0.36	8.77	0.38	3.52e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg14664628	chr15:75095509	CSK	0.62	10.29	0.43	1.61e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs61332075	0.504	rs7596847	chr2:239321118	T/A	cg18131467	chr2:239335373	ASB1	-0.58	-7.66	-0.34	1.08e-13	Lung function (FEV1/FVC);
LGG	trans	rs3960554	0.808	rs4728587	chr7:75803132	C/T	cg19862616	chr7:65841803	NCRNA00174	0.87	12.3	0.5	2.76e-30	Eotaxin levels;
LGG	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg08975724	chr8:8085496	FLJ10661	0.42	8.08	0.35	5.7e-15	Mood instability;
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.88	0.34	2.28e-14	Personality dimensions;
LGG	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.96	0.31	1.15e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs3857067	0.967	rs899135	chr4:95019816	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.58	-0.33	1.91e-13	QT interval;
LGG	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg20302533	chr7:39170763	POU6F2	0.47	11.04	0.46	2.69e-25	IgG glycosylation;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg23188684	chr11:67383651	NA	0.61	10.51	0.44	2.49e-23	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.51	-0.33	3.03e-13	Lung cancer;
LGG	cis	rs7928758	0.887	rs76956658	chr11:134272144	G/A	cg15243474	chr11:134282918	B3GAT1	1.24	16.7	0.61	2.31e-49	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg00599393	chr8:22457479	C8orf58	-0.46	-7.73	-0.34	6.68e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12912251	0.591	rs4924291	chr15:39000484	A/C	cg10631289	chr15:39006617	NA	0.42	7.09	0.31	4.91e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg26384229	chr12:38710491	ALG10B	1.0	25.1	0.76	2.2e-88	Heart rate;
LGG	cis	rs2274273	0.624	rs7151754	chr14:55788501	C/T	cg04306507	chr14:55594613	LGALS3	0.54	12.52	0.5	3.68e-31	Protein biomarker;
LGG	cis	rs1710278	0.967	rs1278264	chr10:127746893	G/A	cg08295661	chr10:127769903	ADAM12	-0.33	-6.93	-0.31	1.44e-11	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg24846343	chr22:24311635	DDTL	0.61	12.13	0.49	1.31e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg03188948	chr7:1209495	NA	0.45	8.11	0.35	4.71e-15	Longevity;Endometriosis;
LGG	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.54e-19	Childhood ear infection;
LGG	cis	rs13314892	0.692	rs57788691	chr3:69897450	G/T	cg17445875	chr3:69859618	MITF	-0.41	-7.94	-0.35	1.54e-14	QRS complex (12-leadsum);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20080320	chr15:28363860	HERC2	0.39	7.03	0.31	7.64e-12	Electrocardiographic conduction measures;
LGG	cis	rs62400317	0.859	rs72869118	chr6:45064626	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.55e-22	Total body bone mineral density;
LGG	cis	rs6504108	0.624	rs3805363	chr17:46241622	C/T	cg02219949	chr17:45927392	SP6	0.43	8.16	0.35	3.18e-15	Body mass index;
LGG	cis	rs35771425	0.600	rs12754747	chr1:211470827	C/T	cg10512769	chr1:211675356	NA	-0.59	-7.93	-0.35	1.6e-14	Educational attainment (years of education);
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg05623727	chr3:50126028	RBM5	0.39	8.51	0.37	2.39e-16	Body mass index;
LGG	cis	rs17818399	0.684	rs62134759	chr2:46791849	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.73	-12.14	-0.49	1.18e-29	Height;
LGG	cis	rs2540226	0.655	rs1978327	chr2:39933267	A/C	cg18968196	chr2:39892502	TMEM178	0.26	6.89	0.31	1.78e-11	Personality dimensions;
LGG	cis	rs7119	0.717	rs12902912	chr15:77809170	A/G	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg16606324	chr3:10149918	C3orf24	0.54	7.07	0.31	5.64e-12	Alzheimer's disease;
LGG	cis	rs35740288	0.822	rs11630549	chr15:86275796	C/T	cg07943548	chr15:86304357	KLHL25	-0.36	-7.04	-0.31	7.04e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.93	0.35	1.62e-14	Schizophrenia;
LGG	cis	rs6032067	0.929	rs35869085	chr20:43805134	G/C	cg10761708	chr20:43804764	PI3	0.76	11.88	0.48	1.33e-28	Blood protein levels;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg06916706	chr16:4465613	CORO7	-0.84	-14.81	-0.57	6.58e-41	Schizophrenia;
LGG	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs807669	0.807	rs712948	chr22:19206499	A/G	cg02655711	chr22:19163373	SLC25A1	0.78	15.3	0.58	4.74e-43	Metabolite levels;
LGG	cis	rs9902453	0.904	rs10853136	chr17:28406018	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.75	-0.54	2.68e-36	Coffee consumption (cups per day);
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.44	-0.53	5.25e-35	Personality dimensions;
LGG	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-8.41	-0.36	5.01e-16	Body mass index;
LGG	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg06138931	chr13:21896616	NA	-0.45	-7.36	-0.32	8.35e-13	White matter hyperintensity burden;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg13484946	chr2:61293354	KIAA1841	-0.39	-6.69	-0.3	6.49e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg08499158	chr17:42289980	UBTF	0.57	10.77	0.45	2.74e-24	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg08888203	chr3:10149979	C3orf24	0.55	9.24	0.39	8.88e-19	Alzheimer's disease;
LGG	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04682192	chr12:110561945	IFT81	0.43	6.67	0.3	7.3e-11	Gut microbiome composition (summer);
LGG	cis	rs2180341	0.513	rs12196828	chr6:127696864	C/T	cg27446573	chr6:127587934	RNF146	0.74	13.31	0.53	1.91e-34	Breast cancer;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.15e-12	Menopause (age at onset);
LGG	cis	rs11039216	1	rs11039216	chr11:47406592	C/T	cg20307385	chr11:47447363	PSMC3	0.68	13.96	0.54	3.28e-37	Neuroticism;
LGG	cis	rs6840360	0.642	rs12647555	chr4:152401098	A/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.21	0.32	2.35e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg18129748	chr3:49941408	MST1R	-0.22	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.95	-0.35	1.45e-14	Triglycerides;
LGG	cis	rs240764	0.604	rs4840153	chr6:101213723	C/T	cg21058520	chr6:100914733	NA	0.39	6.77	0.3	3.8e-11	Neuroticism;
LGG	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg26384229	chr12:38710491	ALG10B	0.96	20.83	0.7	1.75e-68	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg15971980	chr6:150254442	NA	0.44	8.31	0.36	1.09e-15	Lung cancer;
LGG	cis	rs13082711	1.000	rs35944308	chr3:27536356	G/A	cg02860705	chr3:27208620	NA	0.83	14.63	0.56	4.27e-40	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4728302	0.559	rs7779409	chr7:133158475	A/G	cg10665199	chr7:133106180	EXOC4	0.6	10.28	0.43	1.86e-22	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.54e-24	Aortic root size;
LGG	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg18225595	chr11:63971243	STIP1	-0.43	-8.05	-0.35	7.11e-15	Platelet count;
LGG	cis	rs7106204	0.609	rs72874176	chr11:24330205	C/T	ch.11.24196551F	chr11:24239977	NA	0.89	9.67	0.41	2.91e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.12	-0.35	4.35e-15	Height;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	trans	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg00938859	chr5:1591904	SDHAP3	0.88	12.04	0.49	3.14e-29	Breast cancer;
LGG	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.54	-0.5	2.87e-31	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.98	-21.81	-0.71	4.65e-73	Schizophrenia;
LGG	trans	rs2562456	0.916	rs1967182	chr19:21603139	C/G	cg00806126	chr19:22604979	ZNF98	-0.54	-7.28	-0.32	1.48e-12	Pain;
LGG	cis	rs11676348	0.783	rs4674252	chr2:218984478	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-9.87	-0.42	5.57e-21	Ulcerative colitis;
LGG	cis	rs870825	0.616	rs2003994	chr4:185636568	G/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.67	0.73	4.11e-77	Blood protein levels;
LGG	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-7.86	-0.34	2.63e-14	Self-reported allergy;
LGG	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26734620	chr12:56694298	CS	0.77	6.87	0.3	2.13e-11	Psoriasis vulgaris;
LGG	cis	rs754466	0.580	rs11002301	chr10:79574078	G/A	cg17075019	chr10:79541650	NA	-0.98	-22.15	-0.72	1.13e-74	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.75	0.41	1.45e-20	Blood metabolite levels;
LGG	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg24375607	chr4:120327624	NA	0.67	11.05	0.46	2.41e-25	Corneal astigmatism;
LGG	cis	rs360798	0.532	rs360800	chr2:62954326	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-7.01	-0.31	8.36e-12	Coronary artery disease;
LGG	cis	rs7568458	0.709	rs11895399	chr2:85753806	C/A	cg17127132	chr2:85788382	GGCX	0.49	7.94	0.35	1.54e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg05926928	chr17:57297772	GDPD1	0.97	15.54	0.59	3.91e-44	Opioid sensitivity;
LGG	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg14784868	chr12:69753453	YEATS4	0.76	13.14	0.52	9.65e-34	Response to diuretic therapy;
LGG	cis	rs7412746	0.658	rs7528773	chr1:150915875	G/A	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-10.07	-0.42	1.1e-21	Schizophrenia;
LGG	trans	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.0	-0.35	1.03e-14	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27218469	chr2:7005960	CMPK2	0.46	6.91	0.31	1.65e-11	Gut microbiome composition (summer);
LGG	cis	rs7814319	1.000	rs2643338	chr8:97247469	A/G	cg20787634	chr8:97240163	UQCRB	-0.74	-17.35	-0.63	2.54e-52	Lung function (FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08938475	chr2:70313833	PCBP1	0.51	7.47	0.33	3.97e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17672112	0.541	rs705620	chr6:101364555	T/C	cg27451362	chr6:101846650	GRIK2	0.54	7.87	0.34	2.61e-14	Putamen volume;
LGG	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg07173049	chr1:7289937	CAMTA1	0.39	7.61	0.33	1.55e-13	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1862618	0.671	rs2591957	chr5:56243146	A/T	cg12654349	chr5:56205094	C5orf35	0.57	9.87	0.42	5.39e-21	Initial pursuit acceleration;
LGG	cis	rs7917772	0.636	rs7897384	chr10:104529042	T/G	cg04362960	chr10:104952993	NT5C2	0.48	8.01	0.35	9.35e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2439831	1.000	rs2601014	chr15:43756013	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.94	11.02	0.46	3.19e-25	Lung cancer in ever smokers;
LGG	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	9.02	0.39	5.05e-18	Response to antipsychotic treatment;
LGG	cis	rs2777491	0.872	rs61037359	chr15:41585926	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.94	-18.57	-0.65	6.16e-58	Ulcerative colitis;
LGG	cis	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg08257133	chr12:52711352	KRT83	0.55	7.6	0.33	1.66e-13	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg09517075	chr8:22133004	PIWIL2	0.43	9.38	0.4	2.91e-19	Hypertriglyceridemia;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11792861	0.926	rs1044905	chr9:111781495	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.48	0.4	1.36e-19	Menarche (age at onset);
LGG	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.38	-8.12	-0.35	4.28e-15	Bacteremia;
LGG	cis	rs10743315	0.732	rs7960486	chr12:19441082	C/A	cg02471346	chr12:19282374	PLEKHA5	0.6	6.85	0.3	2.39e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.65	0.37	8.59e-17	Mood instability;
LGG	cis	rs6500395	1.000	rs8059905	chr16:48629934	C/T	cg04672837	chr16:48644449	N4BP1	0.57	9.34	0.4	4.05e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs123509	0.645	rs73077238	chr3:42858666	T/C	cg12982090	chr3:42733453	KBTBD5	-0.92	-13.64	-0.54	7.89e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17428076	0.801	rs62182392	chr2:172721762	G/A	cg21435375	chr2:172878103	MAP1D	0.41	8.76	0.38	3.78e-17	Myopia;
LGG	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.51	8.74	0.38	4.42e-17	Menarche (age at onset);
LGG	trans	rs629535	0.821	rs650267	chr8:70029160	C/T	cg21567404	chr3:27674614	NA	0.4	6.69	0.3	6.5500000000000006e-11	Dupuytren's disease;
LGG	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg27205649	chr11:78285834	NARS2	-0.49	-8.37	-0.36	6.65e-16	Alzheimer's disease (survival time);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26446827	chr20:18268978	ZNF133	0.48	8.2	0.36	2.47e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.04	0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg05313129	chr8:58192883	C8orf71	-0.58	-7.71	-0.34	7.75e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs308971	0.656	rs307606	chr3:12067126	A/T	cg02700894	chr3:12045449	SYN2	0.48	6.97	0.31	1.12e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs9880211	0.948	rs34913797	chr3:136127570	G/A	cg21827317	chr3:136751795	NA	-0.48	-7.11	-0.31	4.29e-12	Body mass index;Height;
LGG	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg27398817	chr8:82754497	SNX16	-0.78	-13.61	-0.53	1.06e-35	Diastolic blood pressure;
LGG	trans	rs4942242	0.663	rs17460812	chr13:44215504	A/G	cg19169023	chr15:41853346	TYRO3	-0.42	-8.17	-0.35	2.98e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg16680214	chr1:154839983	KCNN3	-0.46	-8.46	-0.37	3.51e-16	Prostate cancer;
LGG	cis	rs7572733	1.000	rs10196612	chr2:198894139	T/C	cg00792783	chr2:198669748	PLCL1	0.45	7.48	0.33	3.84e-13	Dermatomyositis;
LGG	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	7.1	0.31	4.59e-12	Platelet count;
LGG	cis	rs10207628	1.000	rs10207628	chr2:127852021	C/G	cg06223080	chr2:127868745	NA	-0.76	-14.71	-0.56	1.81e-40	Psychosis and Alzheimer's disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg19543068	chr14:92573078	ATXN3	-0.4	-6.88	-0.3	1.95e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg13010199	chr12:38710504	ALG10B	0.57	10.63	0.44	9.1e-24	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.19e-18	Motion sickness;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00689492	chr4:1303491	MAEA	-0.45	-7.52	-0.33	2.8e-13	Obesity-related traits;
LGG	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg13009111	chr11:71350975	NA	0.35	7.52	0.33	2.82e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7666738	0.830	rs13139078	chr4:99020774	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.830	rs28795113	chr4:98951331	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2282300	0.667	rs10734405	chr11:30273750	T/C	cg25418670	chr11:30344373	C11orf46	0.56	7.82	0.34	3.51e-14	Morning vs. evening chronotype;
LGG	cis	rs793571	0.521	rs12594872	chr15:58912749	T/C	cg05156742	chr15:59063176	FAM63B	0.55	9.54	0.41	8.09e-20	Schizophrenia;
LGG	cis	rs11608355	0.545	rs11609019	chr12:109895958	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg25730555	chr22:47059586	GRAMD4	0.39	6.67	0.3	7.12e-11	Urate levels in obese individuals;
LGG	cis	rs7091068	0.616	rs10748611	chr10:95482761	A/C	cg20715218	chr10:95462985	C10orf4	0.7	10.98	0.45	4.3e-25	Urinary tract infection frequency;
LGG	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.11	0.39	2.4e-18	Aortic root size;
LGG	trans	rs9354308	0.764	rs4529284	chr6:66603919	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.68	-0.3	6.97e-11	Metabolite levels;
LGG	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.61	-6.96	-0.31	1.14e-11	Schizophrenia;
LGG	cis	rs2735413	0.507	rs72798886	chr16:78038466	T/G	cg04733911	chr16:78082701	NA	0.51	6.85	0.3	2.41e-11	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg07148914	chr20:33460835	GGT7	0.54	9.06	0.39	3.68e-18	Height;
LGG	trans	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg10840412	chr1:235813424	GNG4	-0.54	-7.46	-0.33	4.22e-13	Bipolar disorder;
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg07061783	chr6:25882402	NA	0.39	6.93	0.31	1.44e-11	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg19789848	chr17:30454741	NA	0.41	6.72	0.3	5.34e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs642803	0.527	rs1647570	chr11:65568256	A/T	cg08755490	chr11:65554678	OVOL1	-0.37	-6.89	-0.31	1.79e-11	Urate levels;
LGG	cis	rs17767392	0.846	rs17767398	chr14:71770485	C/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.83	0.38	2.17e-17	Mitral valve prolapse;
LGG	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.56	9.25	0.39	8.48e-19	Colorectal cancer;
LGG	cis	rs7301826	0.610	rs9668291	chr12:131296908	C/G	cg11011512	chr12:131303247	STX2	0.41	8.87	0.38	1.61e-17	Plasma plasminogen activator levels;
LGG	cis	rs600231	0.508	rs11227202	chr11:65242717	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.65	-0.37	8.55e-17	Bone mineral density;
LGG	cis	rs7241530	0.585	rs7233393	chr18:75888229	G/A	cg14642773	chr18:75888474	NA	0.48	9.31	0.4	5.28e-19	Educational attainment (years of education);
LGG	cis	rs7666738	0.830	rs13101766	chr4:98957696	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg27523141	chr10:43048294	ZNF37B	0.37	7.47	0.33	3.91e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.61	10.8	0.45	2.14e-24	Birth weight;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-7.65	-0.34	1.15e-13	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.78	-0.41	1.16e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17152411	0.652	rs3845	chr10:126674093	T/C	cg06432487	chr10:126623651	NA	0.39	6.65	0.3	8.17e-11	Height;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-9.19	-0.39	1.36e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.19	-0.43	3.88e-22	Colorectal cancer;
LGG	cis	rs9399135	0.967	rs9389256	chr6:135331254	A/C	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.06e-19	Red blood cell count;
LGG	cis	rs3741151	1.000	rs79038783	chr11:73038746	C/G	cg17517138	chr11:73019481	ARHGEF17	1.07	10.8	0.45	2.19e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7666738	0.830	rs7667796	chr4:99071415	G/T	cg05340658	chr4:99064831	C4orf37	-0.5	-8.39	-0.36	5.76e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs8180040	0.620	rs11715121	chr3:47072621	T/A	cg16586182	chr3:47516702	SCAP	0.73	13.25	0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs11018904	0.608	rs35700249	chr11:89931927	A/C	cg27158573	chr11:89632121	NA	-0.5	-7.99	-0.35	1.09e-14	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg21963583	chr11:68658836	MRPL21	0.57	9.51	0.4	1.06e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8063761	1.000	rs8063761	chr16:90027626	A/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.63	10.68	0.44	5.93e-24	Squamous cell carcinoma;
LGG	cis	rs1127311	1.000	rs1127313	chr1:154556425	A/G	cg11650704	chr1:154556575	ADAR	0.5	9.94	0.42	3.16e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg18351406	chr4:77819688	ANKRD56	0.46	7.95	0.35	1.47e-14	Emphysema distribution in smoking;
LGG	trans	rs6787172	0.702	rs1095638	chr3:157969918	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs185694	1.000	rs672233	chr13:30899601	G/A	cg07600127	chr13:30881527	KATNAL1	-0.51	-6.79	-0.3	3.44e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg11235426	chr6:292522	DUSP22	-0.41	-6.97	-0.31	1.07e-11	Menopause (age at onset);
LGG	cis	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	7.85e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg11766577	chr21:47581405	C21orf56	0.57	10.45	0.44	4.34e-23	Testicular germ cell tumor;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07685180	chr8:600429	NA	1.08	10.96	0.45	5.21e-25	IgG glycosylation;
LGG	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg05973401	chr12:123451056	ABCB9	0.48	8.0	0.35	1.04e-14	Platelet count;
LGG	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-14.18	-0.55	3.73e-38	Platelet distribution width;
LGG	trans	rs7474896	0.616	rs2505239	chr10:38440765	A/G	cg17830980	chr10:43048298	ZNF37B	-0.46	-7.09	-0.31	5.02e-12	Obesity (extreme);
LGG	cis	rs35146811	0.735	rs1727130	chr7:99811464	C/G	cg22906224	chr7:99728672	NA	-0.58	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg08446824	chr4:1720184	TMEM129	-0.64	-11.83	-0.48	2.16e-28	Hip circumference adjusted for BMI;Height;
LGG	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg13010199	chr12:38710504	ALG10B	0.69	13.56	0.53	1.6e-35	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg00938859	chr5:1591904	SDHAP3	0.88	12.08	0.49	2.18e-29	Breast cancer;
LGG	trans	rs12517041	1.000	rs2081953	chr5:23295682	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg06654118	chr4:1303317	MAEA	0.45	7.93	0.35	1.61e-14	Obesity-related traits;
LGG	cis	rs209489	0.892	rs80176274	chr6:53111712	G/C	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00347862	chr15:71184758	LRRC49;THAP10	-0.49	-7.13	-0.31	3.87e-12	Systemic lupus erythematosus;
LGG	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg05768032	chr16:30646687	NA	0.4	6.69	0.3	6.56e-11	Multiple myeloma;
LGG	cis	rs9790314	0.669	rs7630768	chr3:160864879	T/A	cg04691961	chr3:161091175	C3orf57	-0.46	-10.21	-0.43	3.24e-22	Morning vs. evening chronotype;
LGG	cis	rs4936894	0.519	rs10893203	chr11:124167628	C/A	cg27160556	chr11:124181099	OR8D1	-0.46	-10.63	-0.44	9.1e-24	Aging (time to death);
LGG	cis	rs78456975	0.506	rs13384333	chr2:1555531	A/C	cg26248373	chr2:1572462	NA	-0.87	-14.46	-0.56	2.3e-39	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs832540	0.564	rs33329	chr5:56145068	T/C	cg12654349	chr5:56205094	C5orf35	-0.42	-7.37	-0.32	8.13e-13	Coronary artery disease;
LGG	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg07636037	chr3:49044803	WDR6	0.91	16.81	0.62	7.87e-50	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs11239187	0.530	rs11239145	chr10:45063631	C/T	cg03916630	chr10:45065415	NA	0.37	8.98	0.39	6.66e-18	Body mass index;
LGG	cis	rs9411298	0.550	rs4880192	chr9:139927062	A/G	cg14024893	chr9:139943146	ENTPD2	0.53	9.42	0.4	2.1e-19	Monocyte percentage of white cells;
LGG	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.66	-0.3	7.72e-11	Retinal vascular caliber;
LGG	cis	rs10214930	0.697	rs12155430	chr7:27671296	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.74	0.3	4.79e-11	Hypospadias;
LGG	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg01620082	chr3:125678407	NA	-0.92	-8.25	-0.36	1.67e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12220238	0.818	rs10430521	chr10:75913590	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.1	0.46	1.58e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.04	0.39	4.38e-18	Motion sickness;
LGG	cis	rs7715811	0.913	rs6869474	chr5:13768691	C/T	cg07548982	chr5:13769939	DNAH5	-0.45	-9.12	-0.39	2.24e-18	Subclinical atherosclerosis traits (other);
LGG	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg23649088	chr2:200775458	C2orf69	0.52	8.86	0.38	1.74e-17	Osteoporosis;
LGG	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg15704280	chr7:45808275	SEPT13	-0.88	-15.61	-0.59	1.91e-44	Coronary artery disease;
LGG	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg16885296	chr6:26284938	NA	0.36	7.78	0.34	4.78e-14	Educational attainment;
LGG	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.67	-0.51	8.82e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09217309	chr6:150244204	RAET1G	0.44	8.1	0.35	4.75e-15	Testicular germ cell tumor;
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg15556689	chr8:8085844	FLJ10661	0.4	7.23	0.32	2.07e-12	Monocyte count;
LGG	cis	rs7107174	1.000	rs2512547	chr11:77960888	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.56	-0.33	2.12e-13	Testicular germ cell tumor;
LGG	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg19455335	chr8:22457658	C8orf58	0.44	9.02	0.39	4.91e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.73	-0.41	1.77e-20	Parkinson's disease;
LGG	cis	rs1003719	0.591	rs1053966	chr21:38568009	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.67	-11.86	-0.48	1.61e-28	Eye color traits;
LGG	cis	rs7937682	0.681	rs2156580	chr11:111394328	C/G	cg09085632	chr11:111637200	PPP2R1B	0.67	11.61	0.47	1.63e-27	Primary sclerosing cholangitis;
LGG	cis	rs11800820	0.557	rs12045741	chr1:246664634	A/T	cg16700716	chr1:246684329	NA	-0.43	-7.81	-0.34	3.85e-14	Obesity-related traits;
LGG	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.77	-0.38	3.32e-17	Colorectal cancer;
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg27189623	chr16:705930	WDR90	0.41	7.84	0.34	3.03e-14	Height;
LGG	cis	rs1021993	0.597	rs10494921	chr1:209513501	A/G	cg24446417	chr1:209558027	NA	-0.67	-9.9	-0.42	4.29e-21	Gut microbiome composition (winter);
LGG	cis	rs3816183	1.000	rs10193013	chr2:43017416	T/C	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs11225247	0.881	rs12282486	chr11:102253554	C/G	cg06323957	chr11:102217781	BIRC2	0.82	7.17	0.32	2.99e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.52	-0.37	2.2e-16	Platelet distribution width;
LGG	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.93e-22	Asthma (sex interaction);
LGG	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg02002194	chr4:3960332	NA	-0.39	-6.69	-0.3	6.28e-11	Neuroticism;
LGG	cis	rs1862618	0.671	rs2591965	chr5:56236176	T/C	cg17809284	chr5:56205270	C5orf35	0.53	9.77	0.41	1.31e-20	Initial pursuit acceleration;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg00800038	chr16:89945340	TCF25	-0.73	-8.76	-0.38	3.72e-17	Skin colour saturation;
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg13047869	chr3:10149882	C3orf24	0.45	7.44	0.33	4.97e-13	Alzheimer's disease;
LGG	cis	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05901451	chr6:126070800	HEY2	0.62	11.37	0.47	1.38e-26	Endometrial cancer;
LGG	cis	rs1371867	0.875	rs962451	chr8:101331010	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.12e-17	Atrioventricular conduction;
LGG	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.37e-11	Dupuytren's disease;
LGG	trans	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.7	-0.64	6.43e-54	Exhaled nitric oxide output;
LGG	cis	rs6429082	0.818	rs167092	chr1:235642359	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	10.3	0.43	1.59e-22	Adiposity;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg07636037	chr3:49044803	WDR6	0.79	14.17	0.55	3.91e-38	Menarche (age at onset);
LGG	cis	rs6429082	0.818	rs291381	chr1:235641924	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.21	0.43	3.41e-22	Adiposity;
LGG	cis	rs7168592	1.000	rs12593277	chr15:101730860	C/T	cg24254196	chr15:101719523	CHSY1	-0.66	-7.28	-0.32	1.42e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07080220	chr10:102295463	HIF1AN	0.64	11.01	0.46	3.37e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4363385	0.720	rs6672735	chr1:152981086	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.2	-0.39	1.27e-18	Inflammatory skin disease;
LGG	cis	rs4704187	0.617	rs2035192	chr5:74407231	T/A	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs7737355	0.812	rs13172003	chr5:131087656	T/C	cg06307176	chr5:131281290	NA	0.51	8.5	0.37	2.65e-16	Life satisfaction;
LGG	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg02297831	chr4:17616191	MED28	0.47	8.79	0.38	2.86e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.25e-13	Educational attainment;
LGG	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg11812906	chr14:75593930	NEK9	0.48	8.77	0.38	3.54e-17	Height;
LGG	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg22491629	chr6:157744540	C6orf35	-0.78	-11.71	-0.48	6.48e-28	Hemostatic factors and hematological phenotypes;
LGG	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.03	0.52	2.71e-33	Colorectal cancer;
LGG	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg17971929	chr21:40555470	PSMG1	-0.53	-8.97	-0.38	7.64e-18	Menarche (age at onset);
LGG	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	6.97	0.31	1.09e-11	Height;
LGG	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg19524238	chr7:2802976	GNA12	0.4	9.21	0.39	1.16e-18	Height;
LGG	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg15704280	chr7:45808275	SEPT13	-0.88	-13.64	-0.54	7.44e-36	Coronary artery disease;
LGG	cis	rs9878978	1.000	rs35941126	chr3:2477382	A/G	cg21928760	chr3:2462534	CNTN4	0.41	8.99	0.39	6.18e-18	Blood pressure (smoking interaction);
LGG	cis	rs9595066	1.000	rs9595066	chr13:44706268	C/T	cg04068111	chr13:44716778	NA	-0.5	-7.63	-0.33	1.33e-13	Schizophrenia;
LGG	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs17689437	0.647	rs12921494	chr16:68582861	A/G	cg02972257	chr16:68554789	NA	-0.45	-7.63	-0.33	1.33e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.88	0.3	2e-11	Lung cancer;
LGG	cis	rs7927771	0.524	rs10838760	chr11:47786414	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs11096990	0.750	rs2465242	chr4:39155416	A/T	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg16141378	chr3:129829833	LOC729375	-0.36	-7.91	-0.35	1.88e-14	Myopia (pathological);
LGG	cis	rs12681366	0.762	rs7824722	chr8:95350851	A/T	cg13257157	chr8:95487014	RAD54B	0.39	6.73	0.3	5.12e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6728642	0.572	rs1320147	chr2:97600626	A/C	cg26665480	chr2:98280029	ACTR1B	0.85	11.36	0.47	1.48e-26	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9362426	0.503	rs34977536	chr6:88112368	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.37	-7.34	-0.32	9.78e-13	Depressive episodes in bipolar disorder;
LGG	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg01191920	chr7:158217561	PTPRN2	-0.92	-24.53	-0.75	9.47e-86	Obesity-related traits;
LGG	cis	rs7107174	1.000	rs10899455	chr11:77999163	T/C	cg02023728	chr11:77925099	USP35	0.45	7.93	0.35	1.61e-14	Testicular germ cell tumor;
LGG	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11644478	chr21:40555479	PSMG1	-0.7	-12.26	-0.49	4.17e-30	Cognitive function;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05025164	chr4:1340916	KIAA1530	0.44	7.74	0.34	6.2e-14	Obesity-related traits;
LGG	cis	rs2985684	1.000	rs1952012	chr14:50098896	T/A	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs12618769	0.652	rs3754877	chr2:99184019	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.55	0.33	2.33e-13	Bipolar disorder;
LGG	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg26384229	chr12:38710491	ALG10B	0.97	22.01	0.72	5.45e-74	Bladder cancer;
LGG	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg24675658	chr1:53192096	ZYG11B	-0.62	-13.48	-0.53	3.43e-35	Monocyte count;
LGG	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg21926883	chr2:100939477	LONRF2	-0.54	-10.47	-0.44	3.63e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg25554036	chr4:6271136	WFS1	0.53	9.31	0.4	5.23e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg14703610	chr5:56206110	C5orf35	0.4	6.9	0.31	1.76e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6988985	0.703	rs6995180	chr8:143946429	C/G	cg10324643	chr8:143916377	GML	0.38	7.52	0.33	2.89e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.3	-0.53	2.15e-34	Response to antipsychotic treatment;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg18963800	chr10:38644991	HSD17B7P2	0.48	7.69	0.34	8.61e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg04733989	chr22:42467013	NAGA	-0.58	-9.96	-0.42	2.69e-21	Schizophrenia;
LGG	cis	rs2652834	1.000	rs68088462	chr15:63397617	T/C	cg05507819	chr15:63340323	TPM1	0.58	7.72	0.34	7.24e-14	HDL cholesterol;
LGG	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.91	0.35	1.85e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9596863	0.633	rs8000651	chr13:54234870	G/A	ch.13.53330881F	chr13:54432880	NA	0.46	7.01	0.31	8.57e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2070677	0.932	rs2987786	chr10:135365303	C/T	cg20169779	chr10:135381914	SYCE1	-0.89	-11.86	-0.48	1.63e-28	Gout;
LGG	cis	rs9814567	0.896	rs6775611	chr3:134358947	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.17	0.49	9.06e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg04166393	chr7:2884313	GNA12	0.46	8.67	0.37	7.13e-17	Height;
LGG	cis	rs8067545	0.532	rs17759041	chr17:19959966	A/G	cg13482628	chr17:19912719	NA	0.53	8.8	0.38	2.78e-17	Schizophrenia;
LGG	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg13798912	chr7:905769	UNC84A	0.56	6.9	0.31	1.71e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg17757837	chr7:157058334	UBE3C	-0.9	-20.1	-0.68	4.67e-65	Body mass index;
LGG	cis	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg19338460	chr6:170058176	WDR27	-0.73	-9.5	-0.4	1.11e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.22	-0.36	2.06e-15	Joint mobility (Beighton score);
LGG	cis	rs220324	0.954	rs456358	chr21:43583649	C/G	cg08841829	chr21:43638893	ABCG1	0.42	6.78	0.3	3.7e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs6445975	0.715	rs4681835	chr3:58263351	T/G	cg24175188	chr3:58374923	PXK	0.4	7.5	0.33	3.23e-13	Systemic lupus erythematosus;
LGG	cis	rs7215564	0.818	rs1872431	chr17:78635200	T/C	cg06153925	chr17:78755379	RPTOR	0.4	6.79	0.3	3.54e-11	Myopia (pathological);
LGG	cis	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg21775007	chr8:11205619	TDH	-0.77	-13.22	-0.52	4.58e-34	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs986417	0.818	rs7156107	chr14:61059153	C/G	cg27398547	chr14:60952738	C14orf39	-0.56	-6.92	-0.31	1.51e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg02002194	chr4:3960332	NA	0.45	8.43	0.36	4.42e-16	Mood instability;
LGG	cis	rs986417	0.818	rs6573319	chr14:61091913	C/G	cg27398547	chr14:60952738	C14orf39	0.75	7.49	0.33	3.47e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg18032289	chr17:61959525	GH2	-0.41	-7.0	-0.31	8.87e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6815814	0.731	rs4513579	chr4:38773816	T/C	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.79e-20	Alcohol dependence;
LGG	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg09361094	chr10:834503	NA	-0.3	-8.0	-0.35	1.03e-14	Survival in rectal cancer;
LGG	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.32	3.54e-12	Obesity-related traits;
LGG	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg08079166	chr15:68083412	MAP2K5	0.35	8.11	0.35	4.59e-15	Restless legs syndrome;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg09264619	chr17:80180166	NA	0.37	7.42	0.33	5.76e-13	Life satisfaction;
LGG	trans	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg01620082	chr3:125678407	NA	-0.86	-7.33	-0.32	1e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12482904	0.943	rs77546520	chr21:43840089	T/G	cg23042151	chr21:43824109	UBASH3A	-0.41	-6.84	-0.3	2.52e-11	Vitiligo;
LGG	cis	rs2798269	0.933	rs2315545	chr13:22076491	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.13	-0.31	3.99e-12	PR segment;
LGG	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg24253500	chr15:84953950	NA	0.6	11.39	0.47	1.19e-26	Schizophrenia;
LGG	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg24675658	chr1:53192096	ZYG11B	0.48	9.95	0.42	2.86e-21	Monocyte count;
LGG	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg22044901	chr15:68126292	NA	-0.42	-7.9	-0.34	2.03e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg27422857	chr2:105853526	NA	-0.38	-7.01	-0.31	8.37e-12	Type 2 diabetes;
LGG	cis	rs2046867	0.908	rs6779684	chr3:72787586	G/A	cg25664220	chr3:72788482	NA	-0.32	-8.98	-0.39	6.64e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9788721	0.836	rs1504550	chr15:78766250	A/G	cg16751781	chr15:78858589	CHRNA5	-0.39	-6.91	-0.31	1.63e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.07	0.39	3.28e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2836974	0.583	rs2776306	chr21:40713754	A/G	cg17971929	chr21:40555470	PSMG1	0.59	10.2	0.43	3.54e-22	Cognitive function;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07362569	chr17:61921086	SMARCD2	0.51	9.38	0.4	2.9e-19	Prudent dietary pattern;
LGG	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg08807101	chr21:30365312	RNF160	0.91	19.33	0.67	1.81e-61	Dental caries;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02580604	chr1:63250136	ATG4C	-0.39	-6.78	-0.3	3.72e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs9358372	0.711	rs4131667	chr6:20885514	C/T	cg13405222	chr6:20811065	CDKAL1	0.57	11.96	0.49	6.62e-29	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7113874	0.524	rs11041981	chr11:8579208	T/C	cg23764900	chr11:8616102	STK33	-0.39	-7.01	-0.31	8.3e-12	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11700980	0.636	rs11702742	chr21:30254022	T/C	cg08807101	chr21:30365312	RNF160	-0.65	-7.35	-0.32	8.84e-13	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	trans	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg24247370	chr13:99142703	STK24	-0.43	-7.78	-0.34	4.83e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.87	0.45	1.15e-24	Obesity-related traits;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.32	0.32	1.07e-12	Schizophrenia;
LGG	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.2	-0.39	1.2e-18	Erythrocyte sedimentation rate;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg05665937	chr4:1216051	CTBP1	0.61	11.39	0.47	1.17e-26	Obesity-related traits;
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.43	0.36	4.48e-16	Aortic root size;
LGG	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.48	-0.4	1.29e-19	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18911943	chr2:677677	TMEM18	0.51	7.74	0.34	6.49e-14	Gut microbiome composition (summer);
LGG	cis	rs751728	0.965	rs756137	chr6:33755890	T/C	cg25922239	chr6:33757077	LEMD2	0.67	11.02	0.46	3.2e-25	Crohn's disease;
LGG	cis	rs7619833	0.685	rs3920005	chr3:27368884	T/C	cg02860705	chr3:27208620	NA	-0.42	-7.92	-0.35	1.81e-14	Breast cancer;
LGG	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.89e-41	Vitiligo;
LGG	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.49	-0.4	1.2e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.65e-12	HDL cholesterol;
LGG	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2652822	1.000	rs2652822	chr15:63422772	C/T	cg02713581	chr15:63449717	RPS27L	-0.47	-8.04	-0.35	7.74e-15	Metabolic traits;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg05491587	chr18:77659695	KCNG2	-0.52	-7.03	-0.31	7.57e-12	Opioid sensitivity;
LGG	cis	rs10489167	1.000	rs34837468	chr1:41141660	G/A	cg11417323	chr1:41160271	NFYC	-0.48	-6.67	-0.3	7.52e-11	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	8.53	0.37	2.16e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs877282	0.898	rs34490091	chr10:765800	A/C	cg17470449	chr10:769945	NA	0.56	6.68	0.3	6.88e-11	Uric acid levels;
LGG	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.46e-22	Iron status biomarkers;
LGG	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg03060546	chr3:49711283	APEH	-0.61	-8.41	-0.36	5.26e-16	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.82	-0.3	2.89e-11	Neuroticism;
LGG	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg11161011	chr14:65562177	MAX	-0.67	-12.59	-0.51	1.76e-31	Obesity-related traits;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg20309703	chr11:118481025	PHLDB1	0.55	10.11	0.43	7.52e-22	Cholesterol, total;
LGG	cis	rs6977660	0.714	rs17141882	chr7:19790217	C/T	cg07541023	chr7:19748670	TWISTNB	0.61	8.47	0.37	3.17e-16	Thyroid stimulating hormone;
LGG	cis	rs4950322	0.580	rs7541393	chr1:146588768	C/T	cg22381352	chr1:146742008	CHD1L	-0.43	-7.37	-0.32	8.15e-13	Protein quantitative trait loci;
LGG	cis	rs7598759	0.712	rs10933372	chr2:232332325	G/A	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.49e-14	Noise-induced hearing loss;
LGG	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg00631329	chr6:26305371	NA	-0.44	-7.06	-0.31	6.16e-12	Educational attainment;
LGG	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg04455712	chr21:45112962	RRP1B	0.54	9.98	0.42	2.21e-21	Mean corpuscular volume;
LGG	cis	rs17539620	0.624	rs117591255	chr6:154839118	G/A	cg17771515	chr6:154831774	CNKSR3	0.62	7.63	0.33	1.4e-13	Lipoprotein (a) levels;
LGG	cis	rs6920372	0.748	rs2025147	chr6:110070767	A/G	cg01125227	chr6:109776195	MICAL1	0.43	7.53	0.33	2.69e-13	Height;
LGG	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg27366882	chr3:133540807	NA	-0.47	-9.8	-0.41	9.59e-21	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.56	0.87	1.13e-146	Chronic sinus infection;
LGG	cis	rs7267979	1.000	rs7020	chr20:25278600	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.28	0.43	1.87e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2862064	1.000	rs6867207	chr5:156450106	G/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.8	-0.45	2.05e-24	Platelet count;
LGG	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg04166393	chr7:2884313	GNA12	-0.4	-7.67	-0.34	1.05e-13	Height;
LGG	cis	rs300703	0.654	rs401364	chr2:119493	G/A	cg21211680	chr2:198530	NA	-1.25	-19.07	-0.66	3.01e-60	Blood protein levels;
LGG	cis	rs41342147	0.660	rs77576057	chr2:242289843	A/T	cg10173475	chr2:242152697	ANO7	-0.6	-9.39	-0.4	2.8e-19	Vitiligo;
LGG	trans	rs7939886	0.841	rs11227582	chr11:55995736	C/A	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs227833	0.729	rs687878	chr6:44706790	T/C	cg20913747	chr6:44695427	NA	0.4	6.85	0.3	2.33e-11	Monobrow;
LGG	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs7589342	0.862	rs12613864	chr2:106515869	G/A	cg16077055	chr2:106428750	NCK2	0.26	6.79	0.3	3.35e-11	Addiction;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg25173464	chr15:68126554	NA	-0.32	-6.83	-0.3	2.76e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg15736062	chr7:158136485	PTPRN2	0.37	7.35	0.32	9.24e-13	Calcium levels;
LGG	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.19	0.36	2.48e-15	Birth weight;
LGG	cis	rs994014	0.572	rs7662037	chr4:82290839	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.8	-0.3	3.19e-11	Height;
LGG	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.52	-0.4	9.49e-20	Menarche (age at onset);
LGG	cis	rs4911253	0.509	rs66499347	chr20:31448696	C/T	cg13636640	chr20:31349939	DNMT3B	-0.61	-10.9	-0.45	8.63e-25	Lymphocyte counts;
LGG	cis	rs709400	0.520	rs28583452	chr14:103938664	C/A	cg26031613	chr14:104095156	KLC1	0.79	14.02	0.55	1.89e-37	Body mass index;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs56283067	0.578	rs1321079	chr6:45358403	T/A	cg20913747	chr6:44695427	NA	-0.53	-7.97	-0.35	1.22e-14	Total body bone mineral density;
LGG	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6961069	0.806	rs11770907	chr7:80258630	G/A	cg04458919	chr7:80252533	CD36	0.28	6.81	0.3	3.01e-11	Platelet count;
LGG	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.65	0.37	8.58e-17	Mood instability;
LGG	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs9790314	0.690	rs7651087	chr3:160821929	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.55	-0.47	2.7e-27	Morning vs. evening chronotype;
LGG	cis	rs2652822	0.615	rs7174466	chr15:63425019	A/C	cg05507819	chr15:63340323	TPM1	0.52	7.29	0.32	1.35e-12	Metabolic traits;
LGG	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs757978	1.000	rs73116396	chr2:242368693	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.57	-0.37	1.61e-16	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.590	rs10786738	chr10:104869451	C/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.7	-0.3	6.02e-11	Arsenic metabolism;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-8.34	-0.36	8.39e-16	Prostate cancer;
LGG	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.54	-0.63	3.54e-53	Morning vs. evening chronotype;
LGG	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg03060546	chr3:49711283	APEH	-0.63	-10.46	-0.44	3.81e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg08250081	chr4:10125330	NA	0.67	12.42	0.5	9.11e-31	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs314370	0.904	rs13244629	chr7:100509253	A/C	cg10426581	chr7:100472382	SRRT	0.51	7.02	0.31	7.95e-12	Resting heart rate;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg06558623	chr16:89946397	TCF25	1.13	12.3	0.5	2.8e-30	Skin colour saturation;
LGG	cis	rs2290402	0.505	rs9328759	chr4:882845	C/T	cg09237302	chr4:906077	GAK	0.46	7.86	0.34	2.72e-14	Type 2 diabetes;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.6	-0.41	5.16e-20	Aortic root size;
LGG	cis	rs1620921	0.967	rs1247570	chr6:161208957	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.36	-0.32	8.59e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg05623727	chr3:50126028	RBM5	0.32	6.88	0.3	1.99e-11	Intelligence (multi-trait analysis);
LGG	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg21095983	chr6:86352623	SYNCRIP	0.59	10.79	0.45	2.26e-24	Smooth-surface caries;
LGG	cis	rs9341808	0.935	rs942381	chr6:80880150	T/G	cg08355045	chr6:80787529	NA	0.38	7.55	0.33	2.3e-13	Sitting height ratio;
LGG	cis	rs3806843	0.771	rs2563334	chr5:140107065	C/G	cg19875535	chr5:140030758	IK	-0.59	-11.94	-0.49	8.03e-29	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg02725872	chr8:58115012	NA	-0.78	-11.14	-0.46	1.1e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1580019	0.961	rs6949851	chr7:32493807	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	14.9	0.57	2.63e-41	Cognitive ability;
LGG	cis	rs721917	0.565	rs7476563	chr10:81735074	A/C	cg25562619	chr10:81652821	NA	-0.32	-7.08	-0.31	5.5e-12	Chronic obstructive pulmonary disease;
LGG	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-27.19	-0.78	5.51e-98	Height;
LGG	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg01599099	chr11:66649832	PC	-0.39	-7.51	-0.33	3.07e-13	Bipolar disorder;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs1335587	0.550	rs9518407	chr13:102086687	G/T	cg13538571	chr13:102108074	ITGBL1	0.36	6.85	0.3	2.29e-11	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18404041	chr3:52824283	ITIH1	0.5	9.73	0.41	1.81e-20	Bipolar disorder;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg24846343	chr22:24311635	DDTL	0.6	11.77	0.48	3.67e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg03735888	chr19:58951602	ZNF132	0.41	8.32	0.36	9.76e-16	Uric acid clearance;
LGG	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.19	-0.32	2.56e-12	Blood metabolite levels;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg07511668	chr11:68622177	NA	0.51	9.37	0.4	3.18e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs11608355	0.846	rs4766598	chr12:109853306	A/G	cg19025524	chr12:109796872	NA	-0.4	-6.8	-0.3	3.27e-11	Neuroticism;
LGG	cis	rs7077256	0.564	rs72837076	chr10:65278764	G/T	cg02276361	chr10:65351566	REEP3	-0.33	-6.78	-0.3	3.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11764359	chr7:65958608	NA	-0.55	-9.2	-0.39	1.25e-18	Aortic root size;
LGG	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg15325629	chr6:28072465	NA	1.01	7.69	0.34	9.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.6	-0.37	1.26e-16	Alcohol dependence;
LGG	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg08498830	chr11:832797	CD151	-0.44	-7.05	-0.31	6.42e-12	Mean platelet volume;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.25	0.32	1.81e-12	Schizophrenia;
LGG	cis	rs972578	0.651	rs5759002	chr22:43263432	C/T	cg01576275	chr22:43409880	NA	0.23	6.95	0.31	1.22e-11	Mean platelet volume;
LGG	cis	rs921968	0.509	rs556468	chr2:219355794	G/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs763121	0.819	rs3747173	chr22:39069045	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg07636037	chr3:49044803	WDR6	1.02	22.69	0.73	3.59e-77	Parkinson's disease;
LGG	cis	rs1461503	0.868	rs7126785	chr11:122839564	C/A	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs4865875	0.892	rs9292073	chr5:54096229	G/T	cg22421804	chr5:54100067	NA	0.5	7.31	0.32	1.2e-12	Sense of smell;
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19524238	chr7:2802976	GNA12	0.41	9.3	0.4	5.61e-19	Height;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg19635926	chr16:89946313	TCF25	0.75	7.33	0.32	1.04e-12	Skin colour saturation;
LGG	cis	rs972578	0.791	rs738383	chr22:43315393	A/G	cg01576275	chr22:43409880	NA	-0.22	-6.67	-0.3	7.44e-11	Mean platelet volume;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.57	0.63	2.67e-53	Longevity;
LGG	cis	rs17767392	0.846	rs61991213	chr14:71796441	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.75	-0.38	4.06e-17	Mitral valve prolapse;
LGG	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg03477792	chr4:77819574	ANKRD56	0.52	9.08	0.39	3.03e-18	Emphysema distribution in smoking;
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.55	-0.41	7.82e-20	Personality dimensions;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg07701084	chr6:150067640	NUP43	0.71	13.82	0.54	1.26e-36	Lung cancer;
LGG	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg26578617	chr4:90757533	SNCA	-0.45	-9.17	-0.39	1.52e-18	Dementia with Lewy bodies;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.38	0.32	7.18e-13	Schizophrenia;
LGG	cis	rs9443189	0.570	rs523465	chr6:76330434	G/C	cg01950844	chr6:76311363	SENP6	0.76	10.1	0.43	8.06e-22	Prostate cancer;
LGG	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg13010199	chr12:38710504	ALG10B	0.68	14.0	0.55	2.24e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2742417	1.000	rs2673036	chr3:45752471	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs1005224	0.819	rs10147492	chr14:76155309	T/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.74	-0.3	4.68e-11	Large artery stroke;
LGG	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg12046867	chr14:103022105	NA	-0.76	-13.04	-0.52	2.61e-33	Platelet count;
LGG	cis	rs6087771	0.747	rs6058261	chr20:30235470	C/A	cg21427119	chr20:30132790	HM13	-0.4	-7.05	-0.31	6.68e-12	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2735413	0.881	rs4888732	chr16:78080505	A/G	cg04733911	chr16:78082701	NA	-0.76	-17.62	-0.63	1.53e-53	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.53	-0.37	2.04e-16	Longevity;
LGG	cis	rs4330281	0.654	rs4908965	chr3:17768038	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.19	-0.32	2.7e-12	Schizophrenia;
LGG	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg00405596	chr8:11794950	NA	0.64	11.3	0.46	2.58e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg26850624	chr5:429559	AHRR	-0.38	-8.39	-0.36	5.81e-16	Cystic fibrosis severity;
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg16339924	chr4:17578868	LAP3	0.63	10.99	0.45	4.16e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg24623649	chr8:11872141	NA	0.3	7.01	0.31	8.5e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg13009111	chr11:71350975	NA	0.35	7.63	0.33	1.37e-13	Neuroticism;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg16524936	chr4:1340807	KIAA1530	-0.47	-7.71	-0.34	7.55e-14	Longevity;
LGG	cis	rs9397585	0.637	rs589019	chr6:153411380	C/T	cg17707550	chr6:153380415	RGS17	-0.41	-8.84	-0.38	2e-17	Body mass index;
LGG	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.91	0.42	3.86e-21	Height;
LGG	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg25919922	chr13:100150906	NA	-0.73	-7.63	-0.33	1.38e-13	Obesity-related traits;
LGG	cis	rs9389248	0.690	rs6939543	chr6:135255143	A/G	cg22676075	chr6:135203613	NA	-0.48	-8.4	-0.36	5.62e-16	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2898279	0.966	rs9693089	chr8:11298385	A/G	cg26274995	chr8:11302983	FAM167A	0.52	10.12	0.43	6.99e-22	Small cell lung carcinoma;
LGG	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs4750440	0.706	rs4750443	chr10:14019865	A/T	cg00551146	chr10:14014579	FRMD4A	0.29	6.96	0.31	1.13e-11	Adiponectin levels;
LGG	cis	rs9362426	0.526	rs7773804	chr6:88116150	T/A	cg06087457	chr6:88040249	C6orf162;GJB7	-0.37	-7.27	-0.32	1.5e-12	Depressive episodes in bipolar disorder;
LGG	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg26384229	chr12:38710491	ALG10B	-0.68	-13.52	-0.53	2.44e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg15971980	chr6:150254442	NA	0.46	8.61	0.37	1.12e-16	Lung cancer;
LGG	cis	rs17039065	0.920	rs61327329	chr4:109447407	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.32	-0.32	1.14e-12	Retinal vascular caliber;
LGG	cis	rs2816316	0.731	rs10754012	chr1:192492895	C/T	cg02586212	chr1:192544902	RGS1	-0.34	-7.19	-0.32	2.67e-12	Celiac disease;
LGG	cis	rs8051149	0.625	rs28483765	chr16:87882509	C/T	cg01412419	chr16:87856264	NA	0.45	8.61	0.37	1.18e-16	Blood metabolite levels;
LGG	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.9	0.57	2.59e-41	Colorectal cancer;
LGG	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.35	-0.36	7.73e-16	Neurofibrillary tangles;
LGG	cis	rs4363385	1.000	rs10888527	chr1:153001363	G/T	cg13444842	chr1:152974279	SPRR3	0.36	7.26	0.32	1.63e-12	Inflammatory skin disease;
LGG	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg00198680	chr16:28758506	NA	0.28	6.82	0.3	2.8e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg27489772	chr12:121021490	NA	0.57	7.52	0.33	2.96e-13	Type 1 diabetes nephropathy;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.68e-36	Lung cancer;
LGG	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg04691961	chr3:161091175	C3orf57	-0.49	-10.83	-0.45	1.65e-24	Morning vs. evening chronotype;
LGG	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg20476274	chr7:133979776	SLC35B4	0.71	13.14	0.52	9.69e-34	Mean platelet volume;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-20.02	-0.68	1.05e-64	Prudent dietary pattern;
LGG	cis	rs12210905	0.925	rs11961179	chr6:26994157	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6732160	0.691	rs4536673	chr2:73413462	A/T	cg01422370	chr2:73384389	NA	0.47	9.12	0.39	2.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs34311866	0.752	rs11725653	chr4:963397	C/T	cg07828340	chr4:882639	GAK	0.84	9.1	0.39	2.73e-18	Parkinson's disease;
LGG	trans	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.76	-0.34	5.33e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00933542	chr6:150070202	PCMT1	0.36	6.72	0.3	5.3e-11	Lung cancer;
LGG	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.9	-0.42	4.39e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg16434002	chr17:42200994	HDAC5	0.56	10.43	0.44	5.3e-23	Total body bone mineral density;
LGG	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.3	-0.43	1.49e-22	Depression;
LGG	cis	rs9914988	0.943	rs28847895	chr17:27172520	T/C	cg20469991	chr17:27169893	C17orf63	-0.54	-6.76	-0.3	4.16e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs2033732	0.706	rs1437512	chr8:85064763	T/G	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg24110177	chr3:50126178	RBM5	-0.63	-11.48	-0.47	4.93e-27	Body mass index;
LGG	cis	rs60180747	1.000	rs74397736	chr15:66701500	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	10.95	0.45	5.52e-25	Testicular germ cell tumor;
LGG	cis	rs2463822	0.925	rs72923272	chr11:62166832	G/A	cg06239285	chr11:62104954	ASRGL1	-1.14	-14.82	-0.57	5.83e-41	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1419980	0.722	rs752452	chr12:7781021	G/A	cg10578777	chr12:7781093	NA	0.63	8.58	0.37	1.42e-16	HDL cholesterol levels;
LGG	cis	rs10915437	0.536	rs6663939	chr1:4197256	C/T	cg27165836	chr1:4193882	NA	0.48	9.81	0.41	9.14e-21	Migraine - clinic-based;
LGG	cis	rs7617773	0.780	rs4130522	chr3:48352313	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg10760299	chr15:45669010	GATM	0.4	8.01	0.35	9.16e-15	Homoarginine levels;
LGG	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs36051895	0.695	rs60221565	chr9:5029077	T/G	cg02405213	chr9:5042618	JAK2	-0.82	-15.08	-0.57	4.14e-42	Pediatric autoimmune diseases;
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg02503808	chr4:7069936	GRPEL1	0.91	14.07	0.55	1.13e-37	Monocyte percentage of white cells;
LGG	trans	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg02030672	chr11:45687055	CHST1	0.49	8.91	0.38	1.19e-17	Obesity-related traits;
LGG	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg11752832	chr7:134001865	SLC35B4	-0.59	-10.83	-0.45	1.6e-24	Mean platelet volume;
LGG	cis	rs7100689	0.646	rs1047952	chr10:82126808	C/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg18898632	chr2:242989856	NA	-0.8	-9.85	-0.42	6.73e-21	Obesity-related traits;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg00495681	chr13:53174319	NA	0.5	8.55	0.37	1.83e-16	Lewy body disease;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs6546550	0.867	rs726920	chr2:70152027	G/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs4799461	0.874	rs1539853	chr18:35131444	A/G	cg27332583	chr18:35150602	NA	-0.54	-10.74	-0.45	3.53e-24	Neuroticism;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg03188948	chr7:1209495	NA	0.62	8.14	0.35	3.73e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg04731861	chr2:219085781	ARPC2	0.49	12.52	0.5	3.61e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.96	0.38	8e-18	Height;
LGG	cis	rs10276381	0.786	rs73300665	chr7:28227024	G/A	cg23620719	chr7:28220237	JAZF1	0.83	10.32	0.43	1.25e-22	Crohn's disease;
LGG	cis	rs2729354	0.953	rs2848625	chr11:57330650	G/C	cg24343310	chr11:57249947	NA	0.37	6.82	0.3	2.81e-11	Blood protein levels;
LGG	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg14917874	chr2:235941519	SH3BP4	0.52	9.39	0.4	2.83e-19	Dialysis-related mortality;
LGG	cis	rs4787491	0.729	rs11642399	chr16:30059593	T/G	cg06326092	chr16:30034487	C16orf92	0.42	8.5	0.37	2.65e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7166081	1.000	rs12443472	chr15:67555958	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.79	-0.3	3.47e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11920090	0.932	rs2292621	chr3:170723668	C/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.36	0.36	7.33e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg06656553	chr16:89960601	TCF25	-0.7	-6.93	-0.31	1.42e-11	Skin colour saturation;
LGG	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg26116260	chr4:7069785	GRPEL1	-0.93	-16.58	-0.61	8.37e-49	Monocyte percentage of white cells;
LGG	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg08297393	chr2:100937505	LONRF2	-0.45	-8.08	-0.35	5.5e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9581857	0.725	rs9319366	chr13:28017722	C/T	cg01674679	chr13:27998804	GTF3A	-0.66	-7.72	-0.34	7.35e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11890956	chr21:40555474	PSMG1	1.16	29.07	0.8	1.73e-106	Cognitive function;
LGG	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg24558204	chr6:135376177	HBS1L	-0.59	-10.08	-0.42	1.01e-21	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs8067545	0.641	rs203482	chr17:19827210	G/A	cg13482628	chr17:19912719	NA	0.54	9.92	0.42	3.63e-21	Schizophrenia;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg06521331	chr12:34319734	NA	-0.55	-9.38	-0.4	2.95e-19	Morning vs. evening chronotype;
LGG	cis	rs7617480	0.558	rs12715430	chr3:48942855	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.4	0.36	5.7e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs3820068	0.581	rs59684759	chr1:15919893	A/G	cg05660106	chr1:15850417	CASP9	0.87	17.71	0.64	6e-54	Systolic blood pressure;
LGG	cis	rs2797160	1.000	rs1578794	chr6:126015469	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.44	-7.87	-0.34	2.61e-14	Caffeine consumption;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg21948465	chr5:131705150	SLC22A5	0.65	7.17	0.32	2.94e-12	Rheumatoid arthritis;
LGG	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg01130898	chr2:219473002	PLCD4	-0.39	-6.67	-0.3	7.17e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.38	0.47	1.29e-26	Coronary artery disease;
LGG	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg05044414	chr3:183734942	ABCC5	-0.78	-17.04	-0.62	6.47e-51	Anterior chamber depth;
LGG	trans	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg18335740	chr13:41363409	SLC25A15	-0.52	-9.3	-0.4	5.63e-19	Lewy body disease;
LGG	trans	rs12517041	1.000	rs7734577	chr5:23290864	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.55e-17	Aortic root size;
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00294572	chr6:26285232	NA	-0.4	-7.22	-0.32	2.15e-12	Educational attainment;
LGG	cis	rs4595586	0.545	rs6580894	chr12:39371951	A/G	cg13010199	chr12:38710504	ALG10B	0.4	7.17	0.32	3.04e-12	Morning vs. evening chronotype;
LGG	cis	rs17301259	0.564	rs4727185	chr7:88428840	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.77	-0.3	3.88e-11	Heschl's gyrus morphology;
LGG	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg02002194	chr4:3960332	NA	-0.42	-7.6	-0.33	1.67e-13	Retinal vascular caliber;
LGG	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.93	-14.96	-0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg04861929	chr11:109293070	C11orf87	0.48	8.35	0.36	7.83e-16	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16075209	chr5:44808992	MRPS30	0.41	6.75	0.3	4.55e-11	Cognitive performance;
LGG	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg18196295	chr10:418757	DIP2C	-0.41	-7.41	-0.33	5.88e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs3741151	0.773	rs11820577	chr11:73261424	C/G	cg17517138	chr11:73019481	ARHGEF17	0.81	7.79	0.34	4.54e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg05692746	chr2:100937584	LONRF2	-0.59	-9.67	-0.41	2.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2133450	0.526	rs13327304	chr3:7341120	C/G	cg19930620	chr3:7340148	GRM7	-0.41	-9.32	-0.4	4.75e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs9790314	0.967	rs339101	chr3:161064193	A/T	cg04691961	chr3:161091175	C3orf57	-0.66	-16.11	-0.6	1.1e-46	Morning vs. evening chronotype;
LGG	cis	rs11229555	0.957	rs10896796	chr11:58394256	A/G	cg15696309	chr11:58395628	NA	-0.98	-17.28	-0.63	5.44e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg09624528	chr10:1369823	ADARB2	-0.41	-6.93	-0.31	1.45e-11	Radiation response;
LGG	cis	rs7100689	0.753	rs4934125	chr10:82147466	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	17.55	0.63	3e-53	Post bronchodilator FEV1;
LGG	cis	rs7635838	0.523	rs9873503	chr3:11396100	T/C	cg00170343	chr3:11313890	ATG7	0.5	8.23	0.36	1.95e-15	HDL cholesterol;
LGG	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs10979	1.000	rs9373394	chr6:143890776	A/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.42	-0.5	9.26e-31	Hypospadias;
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg13009111	chr11:71350975	NA	0.33	7.25	0.32	1.76e-12	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08483876	chr8:145910754	NA	0.51	8.24	0.36	1.74e-15	Cognitive performance;
LGG	cis	rs12230513	0.732	rs61956300	chr12:55812640	T/G	cg19537932	chr12:55886519	OR6C68	-0.61	-11.05	-0.46	2.39e-25	Contrast sensitivity;
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg00405596	chr8:11794950	NA	-0.45	-6.96	-0.31	1.18e-11	Systemic lupus erythematosus;
LGG	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg06138931	chr13:21896616	NA	0.45	7.29	0.32	1.35e-12	White matter hyperintensity burden;
LGG	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.24	-0.52	3.59e-34	Diastolic blood pressure;
LGG	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg20720597	chr2:3699334	NA	0.53	6.72	0.3	5.39e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg18135555	chr8:22132992	PIWIL2	0.39	10.35	0.43	1.01e-22	Hypertriglyceridemia;
LGG	cis	rs3762637	0.941	rs9810999	chr3:122074391	G/A	cg24169773	chr3:122142474	KPNA1	-0.56	-8.84	-0.38	1.97e-17	LDL cholesterol levels;
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg08888203	chr3:10149979	C3orf24	0.52	8.85	0.38	1.87e-17	Alzheimer's disease;
LGG	cis	rs13314892	0.734	rs74491124	chr3:69854510	C/G	cg17445875	chr3:69859618	MITF	-0.38	-7.19	-0.32	2.65e-12	QRS complex (12-leadsum);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg23305440	chr4:99529282	TSPAN5	-0.43	-6.89	-0.3	1.84e-11	Apolipoprotein A-IV levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27188447	chr15:67358130	SMAD3	-0.44	-6.94	-0.31	1.3e-11	Pancreatic cancer;
LGG	cis	rs2916247	0.954	rs7014794	chr8:93164893	A/C	cg10183463	chr8:93005414	RUNX1T1	0.35	7.09	0.31	4.93e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.99	-0.6	3.93e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg17788362	chr6:86352627	SYNCRIP	-0.53	-9.27	-0.4	6.96e-19	Smooth-surface caries;
LGG	cis	rs11792861	0.532	rs10979659	chr9:111788975	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.4	6.7	0.3	5.9e-11	Menarche (age at onset);
LGG	cis	rs60180747	1.000	rs16953563	chr15:66686770	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	-0.6	-10.79	-0.45	2.34e-24	Testicular germ cell tumor;
LGG	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg11502198	chr6:26597334	ABT1	0.53	9.23	0.39	1.01e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg20573242	chr4:122745356	CCNA2	0.52	9.53	0.4	9.03e-20	Type 2 diabetes;
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.65e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.74	0.59	4.98e-45	Breast cancer;
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.33e-11	Aortic root size;
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs283228	0.550	rs503387	chr6:101805331	C/T	cg27451362	chr6:101846650	GRIK2	0.99	14.98	0.57	1.23e-41	Coenzyme Q10 levels;
LGG	cis	rs17102423	0.594	rs942628	chr14:65539463	C/G	cg16583315	chr14:65563665	MAX	-0.39	-7.96	-0.35	1.38e-14	Obesity-related traits;
LGG	cis	rs2033908	0.620	rs1371753	chr11:12853703	G/A	cg25843174	chr11:12811716	TEAD1	-0.34	-7.22	-0.32	2.12e-12	Sitting height ratio;
LGG	cis	rs653465	0.709	rs1609978	chr3:27203626	G/A	cg02860705	chr3:27208620	NA	-0.42	-8.17	-0.35	3.06e-15	Breast cancer (early onset);
LGG	cis	rs6964587	0.934	rs7793861	chr7:91742728	C/G	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.4e-18	Breast cancer;
LGG	cis	rs79839061	0.610	rs34006051	chr4:847445	C/T	cg07828340	chr4:882639	GAK	0.88	9.44	0.4	1.83e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.66	-0.37	7.88e-17	Initial pursuit acceleration;
LGG	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg12179176	chr11:130786555	SNX19	0.84	17.66	0.63	1.02e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.52	-0.5	3.51e-31	Alzheimer's disease;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	1.000	rs1962716	chr6:86648436	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.94e-20	Response to antipsychotic treatment;
LGG	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg00745463	chr17:30367425	LRRC37B	-0.6	-8.79	-0.38	2.97e-17	Hip circumference adjusted for BMI;
LGG	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg15704280	chr7:45808275	SEPT13	0.64	9.02	0.39	5.02e-18	Intraocular pressure;
LGG	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs2797369	0.882	rs2797368	chr6:101672809	T/C	cg27451362	chr6:101846650	GRIK2	-0.78	-9.68	-0.41	2.58e-20	Renal function-related traits (eGRFcrea);
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg13206674	chr6:150067644	NUP43	-0.4	-6.81	-0.3	2.98e-11	Lung cancer;
LGG	cis	rs7192750	0.586	rs12447045	chr16:71914617	C/G	cg06353428	chr16:71660113	MARVELD3	0.65	10.63	0.44	9.47e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6546537	0.868	rs62133967	chr2:69891708	G/C	cg10773587	chr2:69614142	GFPT1	-0.45	-7.31	-0.32	1.16e-12	Serum thyroid-stimulating hormone levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02879267	chr19:45349558	PVRL2	0.39	6.68	0.3	6.91e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg04503457	chr17:41445688	NA	-0.4	-9.7	-0.41	2.16e-20	Menopause (age at onset);
LGG	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg25174290	chr11:3078921	CARS	-0.72	-14.9	-0.57	2.78e-41	Longevity;
LGG	cis	rs6088580	0.505	rs6142219	chr20:33256345	G/A	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18252515	chr7:66147081	NA	0.43	7.26	0.32	1.66e-12	Aortic root size;
LGG	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg19980929	chr12:42632907	YAF2	0.34	7.61	0.33	1.59e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg00933542	chr6:150070202	PCMT1	0.37	6.69	0.3	6.32e-11	Lung cancer;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg04166393	chr7:2884313	GNA12	0.46	8.57	0.37	1.51e-16	Height;
LGG	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg13147721	chr7:65941812	NA	-0.83	-9.95	-0.42	2.81e-21	Diabetic kidney disease;
LGG	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.07	0.39	3.36e-18	Diabetic retinopathy;
LGG	cis	rs1971762	0.527	rs784568	chr12:53927554	C/A	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.88	-0.3	1.9e-11	Height;
LGG	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg10818794	chr15:86012489	AKAP13	-0.37	-7.81	-0.34	3.76e-14	Coronary artery disease;
LGG	trans	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg02800362	chr5:177631904	HNRNPAB	-0.78	-13.51	-0.53	2.77e-35	Obesity-related traits;
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs28647808	0.881	rs4962047	chr9:136262916	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.72	6.94	0.31	1.35e-11	Blood protein levels;
LGG	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg26818010	chr10:134567672	INPP5A	-0.68	-10.38	-0.43	7.75e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9399137	0.507	rs7748708	chr6:135275142	G/A	cg24558204	chr6:135376177	HBS1L	0.61	10.67	0.44	6.44e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs981844	0.796	rs13140722	chr4:154712203	T/A	cg14289246	chr4:154710475	SFRP2	-0.67	-11.44	-0.47	7.59e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs2241941	0.879	rs7109418	chr11:20623007	C/T	cg05572763	chr11:20631898	SLC6A5	-0.43	-7.94	-0.35	1.5e-14	Obesity-related traits;
LGG	cis	rs28647808	0.618	rs7025970	chr9:136267173	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.74	7.05	0.31	6.36e-12	Blood protein levels;
LGG	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg09165964	chr15:75287851	SCAMP5	0.65	12.26	0.49	4.23e-30	Breast cancer;
LGG	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg00129232	chr17:37814104	STARD3	0.57	8.47	0.37	3.32e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.95	0.38	8.89e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs758324	0.648	rs152126	chr5:131383667	A/C	cg06307176	chr5:131281290	NA	-0.44	-7.13	-0.31	3.96e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs8180040	0.726	rs7628747	chr3:47001990	A/T	cg16586182	chr3:47516702	SCAP	-0.74	-13.75	-0.54	2.67e-36	Colorectal cancer;
LGG	cis	rs2075371	1.000	rs2598296	chr7:133992985	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.35	0.58	2.8e-43	Mean platelet volume;
LGG	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs919433	0.713	rs11900232	chr2:198466273	T/C	cg00792783	chr2:198669748	PLCL1	0.51	7.99	0.35	1.1e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.94	0.54	3.91e-37	IgG glycosylation;
LGG	cis	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06869971	chr15:69706519	KIF23	0.4	6.76	0.3	4.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg20283391	chr11:68216788	NA	-0.5	-8.3	-0.36	1.18e-15	Total body bone mineral density;
LGG	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11644478	chr21:40555479	PSMG1	-0.62	-10.42	-0.44	5.61e-23	Menarche (age at onset);
LGG	cis	rs2859741	0.967	rs507460	chr1:37493206	C/G	cg09363841	chr1:37513479	NA	0.64	15.65	0.59	1.34e-44	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.05e-12	Bipolar disorder;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg23131131	chr22:24373011	LOC391322	0.43	6.86	0.3	2.26e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3126085	0.935	rs11204981	chr1:152298212	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-8.11	-0.35	4.48e-15	Atopic dermatitis;
LGG	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg13647721	chr17:30228624	UTP6	-0.76	-10.94	-0.45	5.95e-25	Hip circumference adjusted for BMI;
LGG	cis	rs6976053	0.818	rs13241786	chr7:100486656	T/G	cg03098644	chr7:100410630	EPHB4	-0.42	-7.4	-0.33	6.67e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25072359	chr17:41440525	NA	0.53	10.03	0.42	1.44e-21	Menopause (age at onset);
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg02002194	chr4:3960332	NA	0.41	7.56	0.33	2.23e-13	Neuroticism;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-11.91	-0.48	1.06e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs28735056	0.967	rs4799092	chr18:77608203	C/G	cg05926928	chr17:57297772	GDPD1	-0.52	-8.27	-0.36	1.45e-15	Schizophrenia;
LGG	cis	rs9581943	0.967	rs7995917	chr13:28472724	T/C	cg16302790	chr13:28498334	PDX1	0.52	8.8	0.38	2.78e-17	Pancreatic cancer;
LGG	cis	rs4650994	0.789	rs2811300	chr1:178590394	T/C	cg19399532	chr1:178512495	C1orf220	-0.37	-6.97	-0.31	1.09e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg07964753	chr8:142112622	NA	-0.48	-7.26	-0.32	1.66e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg26116260	chr4:7069785	GRPEL1	1.15	22.53	0.72	2.05e-76	Monocyte percentage of white cells;
LGG	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg27624424	chr6:160112604	SOD2	0.66	9.54	0.41	8.1e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.99	-0.31	9.36e-12	Lung cancer;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12016809	chr21:47604291	C21orf56	0.5	8.4	0.36	5.33e-16	Testicular germ cell tumor;
LGG	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-16.01	-0.6	3.03e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.77	-0.45	2.77e-24	Primary sclerosing cholangitis;
LGG	cis	rs4689388	0.793	rs4234731	chr4:6299914	A/G	cg00701064	chr4:6280414	WFS1	0.75	16.48	0.61	2.46e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.77	-0.41	1.27e-20	Retinal vascular caliber;
LGG	cis	rs7851660	0.870	rs55960649	chr9:100598695	C/A	cg13688889	chr9:100608707	NA	-0.69	-14.58	-0.56	6.52e-40	Strep throat;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg05313129	chr8:58192883	C8orf71	0.84	12.53	0.5	3.35e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs7727544	0.582	rs3792894	chr5:131547271	C/T	cg07395648	chr5:131743802	NA	-0.39	-8.5	-0.37	2.62e-16	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07660663	chr8:117886887	RAD21	0.46	6.81	0.3	2.95e-11	Gut microbiome composition (summer);
LGG	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg02487422	chr3:49467188	NICN1	0.43	7.0	0.31	9.06e-12	Resting heart rate;
LGG	cis	rs55863869	0.748	rs2291309	chr2:179623577	G/T	cg02880032	chr2:179629472	TTN	0.47	6.71	0.3	5.75e-11	QT interval;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9911578	1.000	rs12947785	chr17:57045160	A/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4262150	0.739	rs3890802	chr5:152081927	G/A	cg12297329	chr5:152029980	NA	-0.76	-14.23	-0.55	2.27e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-7.3	-0.32	1.3e-12	Smoking behavior;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg03351412	chr1:154909251	PMVK	0.64	11.86	0.48	1.7e-28	Prostate cancer;
LGG	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg02002194	chr4:3960332	NA	0.44	7.76	0.34	5.44e-14	Retinal vascular caliber;
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.2	0.39	1.22e-18	Bipolar disorder;
LGG	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	trans	rs12517041	1.000	rs6868335	chr5:23316641	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.08	-0.46	1.85e-25	Calcium levels;
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.45e-12	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg18252515	chr7:66147081	NA	-1.37	-18.71	-0.66	1.37e-58	Diabetic kidney disease;
LGG	cis	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.44	-0.47	7.25e-27	Resting heart rate;
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.45	-0.33	4.52e-13	Prostate cancer;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	1.000	rs10791097	chr11:130718630	G/T	cg12179176	chr11:130786555	SNX19	-0.74	-14.3	-0.55	1.06e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg24565620	chr2:194026	NA	-0.73	-9.12	-0.39	2.27e-18	Blood protein levels;
LGG	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg09818912	chr17:20140352	CYTSB	-0.33	-7.78	-0.34	4.74e-14	Schizophrenia;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg15971980	chr6:150254442	NA	0.45	8.41	0.36	5.15e-16	Lung cancer;
LGG	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.74	-10.88	-0.45	1.02e-24	Schizophrenia;
LGG	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg24375607	chr4:120327624	NA	-0.4	-6.64	-0.3	8.58e-11	Diastolic blood pressure;
LGG	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.58	10.07	0.42	1.03e-21	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7395662	0.611	rs7478698	chr11:48549139	T/C	cg03929089	chr4:120376271	NA	-0.53	-8.89	-0.38	1.39e-17	HDL cholesterol;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg05091796	chr16:4465799	CORO7	-0.6	-9.85	-0.42	6.31e-21	Schizophrenia;
LGG	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg13877915	chr19:58951672	ZNF132	1.0	26.81	0.78	2.99e-96	Uric acid clearance;
LGG	cis	rs2470578	0.792	rs2733501	chr3:17274801	T/C	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Electroencephalogram traits;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08219700	chr8:58056026	NA	0.57	12.6	0.51	1.62e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.86	-17.35	-0.63	2.48e-52	Lung cancer;
LGG	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-10.99	-0.45	3.88e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11738604	chr10:7573562	NA	0.35	6.81	0.3	3.05e-11	Electrocardiographic conduction measures;
LGG	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg07777115	chr5:623756	CEP72	-0.63	-7.92	-0.35	1.76e-14	Obesity-related traits;
LGG	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg09165964	chr15:75287851	SCAMP5	0.66	12.06	0.49	2.63e-29	Caffeine consumption;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.42	-0.33	5.78e-13	Menopause (age at onset);
LGG	trans	rs225245	0.531	rs321609	chr17:33880676	G/T	cg19694781	chr19:47549865	TMEM160	-0.54	-9.34	-0.4	4.11e-19	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-8.66	-0.37	7.73e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.36	-7.73	-0.34	6.78e-14	Personality dimensions;
LGG	cis	rs6460942	0.749	rs62448592	chr7:12435985	A/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.99	-0.31	9.51e-12	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg15971980	chr6:150254442	NA	0.44	8.36	0.36	7.14e-16	Lung cancer;
LGG	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg18225595	chr11:63971243	STIP1	0.5	7.24	0.32	1.84e-12	Mean platelet volume;
LGG	cis	rs2180341	0.618	rs12210968	chr6:127596985	A/G	cg27446573	chr6:127587934	RNF146	0.72	12.98	0.52	4.37e-33	Breast cancer;
LGG	cis	rs8141529	0.732	rs11556025	chr22:29168755	T/C	cg15103426	chr22:29168792	CCDC117	0.7	11.24	0.46	4.55e-26	Lymphocyte counts;
LGG	cis	rs3816183	0.558	rs11692987	chr2:42790564	T/A	cg14631114	chr2:43023945	NA	0.35	6.76	0.3	4.15e-11	Hypospadias;
LGG	trans	rs7944735	0.508	rs1474056	chr11:47632707	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.24e-11	Intraocular pressure;
LGG	trans	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg06521331	chr12:34319734	NA	0.43	7.84	0.34	3.12e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12431410	0.782	rs9323353	chr14:60171047	A/G	cg07950296	chr14:60194823	RTN1	-0.35	-6.82	-0.3	2.78e-11	Schizophrenia;
LGG	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-10.52	-0.44	2.29e-23	Hepatocellular carcinoma;
LGG	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11096990	0.855	rs2465243	chr4:39155656	G/T	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg01420254	chr6:26195488	NA	0.6	8.69	0.37	6.29e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg05308233	chr10:104796373	CNNM2	-0.33	-7.29	-0.32	1.39e-12	Arsenic metabolism;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs2072499	0.750	rs7534339	chr1:156156219	A/G	cg25208724	chr1:156163844	SLC25A44	1.15	20.44	0.69	1.2e-66	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg13939156	chr17:80058883	NA	-0.46	-8.97	-0.38	7.18e-18	Life satisfaction;
LGG	cis	rs3820928	0.874	rs4144328	chr2:227790187	A/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.74	-0.34	6.4e-14	Pulmonary function;
LGG	cis	rs12922317	0.964	rs16958789	chr16:12075648	G/A	cg08843971	chr16:11963173	GSPT1	-0.32	-6.67	-0.3	7.51e-11	Schizophrenia;
LGG	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg25817165	chr18:72167213	CNDP2	-0.69	-15.6	-0.59	2.22e-44	Refractive error;
LGG	cis	rs477692	1.000	rs538969	chr10:131410608	C/T	cg05714579	chr10:131428358	MGMT	0.56	11.42	0.47	8.47e-27	Response to temozolomide;
LGG	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg03128534	chr1:43423976	SLC2A1	0.62	13.17	0.52	7.32e-34	Red cell distribution width;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09412808	chr4:57180590	KIAA1211	0.44	7.17	0.32	2.93e-12	Pancreatic cancer;
LGG	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs4561483	0.832	rs171656	chr16:11953167	C/T	cg08843971	chr16:11963173	GSPT1	-0.67	-17.48	-0.63	6.91e-53	Testicular germ cell tumor;
LGG	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg26031613	chr14:104095156	KLC1	1.15	27.82	0.79	7.71e-101	Body mass index;
LGG	cis	rs4474465	0.915	rs7123060	chr11:78208634	A/G	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs12410462	0.551	rs2819502	chr1:227712652	T/C	cg04117972	chr1:227635322	NA	0.46	8.35	0.36	7.99e-16	Major depressive disorder;
LGG	cis	rs7727544	0.582	rs2278398	chr5:131530441	C/T	cg07395648	chr5:131743802	NA	0.39	8.56	0.37	1.66e-16	Blood metabolite levels;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.21e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8028182	0.636	rs12909863	chr15:75825822	G/C	cg20655648	chr15:75932815	IMP3	0.45	7.44	0.33	4.78e-13	Sudden cardiac arrest;
LGG	cis	rs1371867	0.817	rs1788208	chr8:101312515	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs1801251	1.000	rs4973054	chr2:233710713	G/C	cg25237894	chr2:233734115	C2orf82	-0.66	-12.47	-0.5	5.76e-31	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg26338869	chr17:61819248	STRADA	0.58	9.75	0.41	1.44e-20	Prudent dietary pattern;
LGG	trans	rs6575793	0.532	rs11849489	chr14:101037762	C/G	cg22806444	chr17:72968764	C17orf28	0.5	8.27	0.36	1.48e-15	Menarche (age at onset);
LGG	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg02187348	chr16:89574699	SPG7	0.65	11.09	0.46	1.68e-25	Multiple myeloma (IgH translocation);
LGG	cis	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.79	-0.3	3.55e-11	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02475777	chr4:1388615	CRIPAK	0.43	7.96	0.35	1.37e-14	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16970804	chr5:43042108	LOC153684	0.49	8.21	0.36	2.27e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg02030672	chr11:45687055	CHST1	-0.5	-9.0	-0.39	5.86e-18	Obesity-related traits;
LGG	trans	rs7812879	0.602	rs2736353	chr8:11367038	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.93	-0.31	1.44e-11	Systemic lupus erythematosus;
LGG	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg24634471	chr8:143751801	JRK	0.53	8.56	0.37	1.62e-16	Schizophrenia;
LGG	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.25	-0.32	1.71e-12	Neuroticism;
LGG	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.21	0.55	2.62e-38	IgG glycosylation;
LGG	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs28595532	0.920	rs114963870	chr4:119758099	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg16414030	chr3:133502952	NA	-0.6	-10.47	-0.44	3.62e-23	Iron status biomarkers;
LGG	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg13147721	chr7:65941812	NA	-0.76	-8.96	-0.38	8.06e-18	Diabetic kidney disease;
LGG	cis	rs9715521	0.775	rs62301191	chr4:59842587	T/G	cg11281224	chr4:60001000	NA	-0.51	-8.48	-0.37	2.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.35	0.32	8.81e-13	Schizophrenia;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg01236616	chr12:121019343	POP5	1.26	22.23	0.72	4.94e-75	Type 1 diabetes nephropathy;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.7	-0.34	8.23e-14	Lung cancer;
LGG	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg15704280	chr7:45808275	SEPT13	-0.98	-21.5	-0.71	1.33e-71	Coronary artery disease;
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.07	-0.52	1.97e-33	Gut microbiome composition (summer);
LGG	cis	rs7737355	0.947	rs6859469	chr5:130962546	C/T	cg06307176	chr5:131281290	NA	0.58	9.52	0.4	9.39e-20	Life satisfaction;
LGG	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg11812906	chr14:75593930	NEK9	-0.45	-8.09	-0.35	5.22e-15	Height;
LGG	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg07599136	chr5:415885	AHRR	0.85	11.55	0.47	2.73e-27	Fat distribution (HIV);
LGG	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.31	-0.53	1.92e-34	Personality dimensions;
LGG	cis	rs1318772	0.536	rs13355330	chr5:113001735	C/T	cg12552261	chr5:112820674	MCC	0.53	6.82	0.3	2.81e-11	F-cell distribution;
LGG	trans	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg23762105	chr12:34175262	ALG10	0.34	6.66	0.3	8e-11	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg04025307	chr7:1156635	C7orf50	0.89	19.52	0.67	2.37e-62	Longevity;Endometriosis;
LGG	cis	rs4076764	0.914	rs6704467	chr1:163364512	A/G	cg24596788	chr1:163392923	NA	-0.71	-13.39	-0.53	8.35e-35	Motion sickness;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs12476592	0.516	rs196124	chr2:63854138	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.75	-0.3	4.39e-11	Childhood ear infection;
LGG	cis	rs11711311	0.955	rs67550112	chr3:113401988	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.73	0.54	3.21e-36	IgG glycosylation;
LGG	cis	rs12579753	0.667	rs11115071	chr12:82284926	G/A	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.23	-0.32	1.98e-12	Resting heart rate;
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg23985595	chr17:80112537	CCDC57	-0.46	-9.34	-0.4	3.92e-19	Life satisfaction;
LGG	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.7e-51	Morning vs. evening chronotype;
LGG	cis	rs240764	0.507	rs11155661	chr6:101229025	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.06	0.31	6.03e-12	Neuroticism;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg18446336	chr7:2847575	GNA12	-0.31	-7.19	-0.32	2.56e-12	Height;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-9.15	-0.39	1.81e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10046574	0.561	rs17403528	chr7:135195531	C/T	cg27474649	chr7:135195673	CNOT4	0.76	9.0	0.39	5.71e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4595586	0.525	rs3914597	chr12:39388693	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg12437481	chr16:420112	MRPL28	-0.48	-8.22	-0.36	2e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.16	0.35	3.15e-15	Obesity-related traits;
LGG	cis	rs9972944	0.902	rs9972885	chr17:63771264	G/T	cg07283582	chr17:63770753	CCDC46	0.43	8.41	0.36	5.23e-16	Total body bone mineral density;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg11965913	chr1:205819406	PM20D1	0.85	18.61	0.65	3.81e-58	Menarche (age at onset);
LGG	cis	rs17767392	0.881	rs35589413	chr14:71991676	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.6	-0.37	1.25e-16	Mitral valve prolapse;
LGG	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-14.06	-0.55	1.16e-37	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg16507663	chr6:150244633	RAET1G	0.46	7.94	0.35	1.51e-14	Lung cancer;
LGG	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg25427524	chr10:38739819	LOC399744	0.49	7.01	0.31	8.43e-12	Obesity (extreme);
LGG	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg14829155	chr15:31115871	NA	0.49	8.52	0.37	2.2e-16	Huntington's disease progression;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.27	-0.43	1.98e-22	Bipolar disorder;
LGG	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg21775007	chr8:11205619	TDH	-0.76	-13.15	-0.52	8.59e-34	Retinal vascular caliber;
LGG	cis	rs4740619	0.810	rs7037662	chr9:15701630	C/T	cg14451791	chr9:16040625	NA	0.33	8.44	0.37	3.98e-16	Body mass index;
LGG	cis	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg02972257	chr16:68554789	NA	0.44	6.81	0.3	3.11e-11	Colorectal cancer;
LGG	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.46	-0.4	1.5700000000000001e-19	Height;
LGG	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg25309564	chr22:51001381	C22orf41	0.62	9.79	0.41	1.07e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg16885296	chr6:26284938	NA	0.34	7.46	0.33	4.42e-13	Educational attainment;
LGG	cis	rs9467160	0.511	rs796984	chr6:24440600	T/A	cg20631270	chr6:24437470	GPLD1	0.39	6.69	0.3	6.49e-11	Liver enzyme levels;
LGG	cis	rs36093844	0.752	rs7121363	chr11:85575110	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.29	-0.32	1.39e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg13647721	chr17:30228624	UTP6	0.78	10.35	0.43	1.01e-22	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs8013055	0.796	rs8005568	chr14:105971794	A/G	cg25008857	chr14:105974488	NA	0.57	10.09	0.42	8.96e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6977660	1.000	rs6959591	chr7:19821824	A/G	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	trans	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg07817883	chr1:32538562	TMEM39B	1.15	12.08	0.49	2.08e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4363385	0.693	rs368076	chr1:153046514	A/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs10504073	0.647	rs55920380	chr8:50026353	G/A	cg00325661	chr8:49890786	NA	0.74	14.05	0.55	1.3e-37	Blood metabolite ratios;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg25811766	chr13:21894605	NA	0.74	13.58	0.53	1.33e-35	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs11203032	0.831	rs2902445	chr10:90934154	A/G	cg16672925	chr10:90967113	CH25H	0.76	10.95	0.45	5.8e-25	Heart failure;
LGG	cis	rs12447804	0.871	rs12928392	chr16:58070964	T/A	cg03859792	chr16:58121049	NA	0.44	6.7	0.3	6.03e-11	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs4629710	0.592	rs66533103	chr6:131531016	C/T	cg12606694	chr6:131520996	AKAP7	0.53	8.67	0.37	7.19e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg08645402	chr16:4508243	NA	-0.5	-8.88	-0.38	1.53e-17	Schizophrenia;
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg26513180	chr16:89883248	FANCA	0.94	20.96	0.7	4.57e-69	Vitiligo;
LGG	cis	rs10504130	0.666	rs7813414	chr8:52860205	C/T	cg13492337	chr8:52722140	PXDNL	-0.5	-7.4	-0.33	6.38e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.44	-0.33	4.86e-13	Red cell distribution width;
LGG	cis	rs4901847	0.577	rs11158199	chr14:58585354	T/C	cg15908186	chr14:58618357	C14orf37	0.67	12.29	0.5	3.16e-30	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	0.4	6.97	0.31	1.07e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.9	-0.34	2.11e-14	Longevity;Endometriosis;
LGG	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04881214	chr2:44395864	PPM1B	0.38	6.77	0.3	3.93e-11	Gut microbiome composition (summer);
LGG	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg19992207	chr2:111874495	ACOXL	-0.38	-6.92	-0.31	1.5e-11	Chronic lymphocytic leukemia;
LGG	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg07636037	chr3:49044803	WDR6	1.1	28.13	0.79	2.93e-102	Parkinson's disease;
LGG	cis	rs17092148	0.887	rs6142199	chr20:33162298	G/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.94	-0.31	1.35e-11	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10282920	chr2:95831790	ZNF2	0.42	6.83	0.3	2.63e-11	Cognitive performance;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.17e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg05308233	chr10:104796373	CNNM2	-0.33	-7.3	-0.32	1.28e-12	Arsenic metabolism;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg04025307	chr7:1156635	C7orf50	0.9	19.86	0.68	5.83e-64	Longevity;Endometriosis;
LGG	cis	rs17711722	0.585	rs6942660	chr7:65302406	C/T	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Calcium levels;
LGG	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.53	-0.4	9.11e-20	Mood instability;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg10950524	chr7:2139216	MAD1L1	0.32	6.91	0.31	1.63e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.99	10.41	0.44	6.29e-23	Diabetic retinopathy;
LGG	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.25	0.32	1.81e-12	Triglycerides;
LGG	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs6840360	0.573	rs10024721	chr4:152265331	G/A	cg25486957	chr4:152246857	NA	-0.41	-7.31	-0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Breast cancer;
LGG	cis	rs79390637	1	rs79390637	chr11:47456867	C/A	cg20307385	chr11:47447363	PSMC3	0.47	7.59	0.33	1.78e-13	Intraocular pressure;
LGG	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg12310025	chr6:25882481	NA	-0.4	-7.17	-0.32	2.92e-12	Height;
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	trans	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06529181	chr19:52193933	NA	-0.43	-6.65	-0.3	8.29e-11	IgG glycosylation;
LGG	cis	rs2303319	1.000	rs57090160	chr2:162179197	G/A	cg13806767	chr2:162164127	PSMD14	-0.66	-7.65	-0.33	1.21e-13	Cognitive function;
LGG	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg26031613	chr14:104095156	KLC1	-0.58	-9.16	-0.39	1.64e-18	Reticulocyte count;
LGG	cis	rs60180747	1.000	rs11631448	chr15:66757961	T/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.6	10.71	0.45	4.61e-24	Testicular germ cell tumor;
LGG	cis	rs7226408	0.857	rs72885302	chr18:34453491	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2030746	0.521	rs2311598	chr2:121331102	A/G	cg13274077	chr2:121334614	NA	-0.38	-9.63	-0.41	4.06e-20	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs11074306	0.561	rs8023306	chr15:28075500	G/T	cg26402630	chr15:28053930	OCA2	0.35	7.01	0.31	8.38e-12	Uveal melanoma;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-9.78	-0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.810	rs66921603	chr6:162996982	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs806215	0.906	rs806195	chr7:127249178	A/G	cg25922125	chr7:127225783	GCC1	0.75	10.3	0.43	1.48e-22	Type 2 diabetes;
LGG	cis	rs8180040	0.701	rs11917474	chr3:47010491	G/A	cg27129171	chr3:47204927	SETD2	0.82	15.19	0.58	1.38e-42	Colorectal cancer;
LGG	cis	rs9308062	1	rs9308062	chr4:164438200	T/C	cg01736356	chr4:164465789	MARCH1	0.38	10.17	0.43	4.6e-22	Small cell lung carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07509094	chr11:60674167	PRPF19	0.53	8.51	0.37	2.43e-16	Gut microbiome composition (summer);
LGG	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg02896835	chr1:92012615	NA	0.43	9.32	0.4	4.74e-19	Breast cancer;
LGG	trans	rs61931739	0.649	rs815047	chr12:33726459	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs8078723	0.714	rs2241245	chr17:38151014	C/T	cg17467752	chr17:38218738	THRA	-0.62	-11.2	-0.46	6e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17975002	chr19:36347691	KIRREL2	0.39	6.9	0.31	1.72e-11	Gut microbiome composition (summer);
LGG	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.99	0.42	2.14e-21	Ovarian reserve;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg26554054	chr8:600488	NA	1.0	10.52	0.44	2.36e-23	IgG glycosylation;
LGG	cis	rs2070488	0.775	rs2300669	chr3:38541318	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.28	-0.55	1.34e-38	Electrocardiographic conduction measures;
LGG	trans	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.54	0.33	2.47e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.4	-7.05	-0.31	6.39e-12	Alzheimer's disease (late onset);
LGG	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.46	-0.37	3.54e-16	Alcohol dependence;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg18332480	chr10:55587200	PCDH15	0.36	6.84	0.3	2.45e-11	Pancreatic cancer;
LGG	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg17330273	chr5:96107758	CAST;ERAP1	0.58	8.86	0.38	1.77e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14893161	chr1:205819251	PM20D1	0.88	20.44	0.69	1.13e-66	Menarche (age at onset);
LGG	cis	rs227833	0.826	rs227854	chr6:44701035	C/T	cg20913747	chr6:44695427	NA	-0.39	-6.75	-0.3	4.41e-11	Monobrow;
LGG	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg06718696	chr17:78121285	EIF4A3	0.4	6.69	0.3	6.49e-11	Yeast infection;
LGG	trans	rs1456305	0.550	rs2392733	chr8:128100672	C/T	cg22517681	chr1:24995876	SRRM1	0.49	7.85	0.34	2.91e-14	Prostate cancer;
LGG	cis	rs79839061	0.520	rs6842808	chr4:906903	C/T	cg07828340	chr4:882639	GAK	0.93	9.78	0.41	1.2e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8030485	0.964	rs8032861	chr15:79412728	A/C	cg17916960	chr15:79447300	NA	0.42	7.06	0.31	5.95e-12	Left ventricle wall thickness;
LGG	cis	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg05623727	chr3:50126028	RBM5	0.39	8.42	0.36	4.73e-16	Body mass index;
LGG	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.98	-0.39	6.61e-18	Response to antipsychotic treatment;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg19168338	chr16:4465731	CORO7	0.72	13.4	0.53	7.99e-35	Schizophrenia;
LGG	cis	rs7945718	0.967	rs10741602	chr11:12761699	A/T	cg25843174	chr11:12811716	TEAD1	0.42	8.53	0.37	2.06e-16	Educational attainment (years of education);
LGG	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg04143929	chr2:100879511	NA	-0.49	-7.56	-0.33	2.11e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.559	rs6060932	chr20:30350545	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.17	0.67	1.04e-60	Mean corpuscular hemoglobin;
LGG	cis	rs10766496	1.000	rs10766496	chr11:18738718	C/T	cg02515468	chr11:18743222	IGSF22	0.46	7.75	0.34	5.7e-14	Diabetic kidney disease;
LGG	cis	rs4731207	0.564	rs6967420	chr7:124609360	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs360798	0.512	rs11893131	chr2:63079528	C/A	cg17519650	chr2:63277830	OTX1	0.47	7.73	0.34	6.92e-14	Coronary artery disease;
LGG	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs1806153	0.611	rs1806155	chr11:31841125	G/T	cg11990419	chr11:31841155	NA	0.35	8.02	0.35	8.48e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs11971779	0.618	rs13068	chr7:139104141	G/C	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.39e-12	Diisocyanate-induced asthma;
LGG	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg04691961	chr3:161091175	C3orf57	-0.46	-9.77	-0.41	1.23e-20	Morning vs. evening chronotype;
LGG	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg14952266	chr13:112191215	NA	-0.5	-10.49	-0.44	2.94e-23	Hepatitis;
LGG	cis	rs698833	0.859	rs1067360	chr2:44661817	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.46	6.91	0.31	1.66e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-8.19	-0.36	2.51e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12580194	0.556	rs61957898	chr12:55730423	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-9.37	-0.4	3.1e-19	Cancer;
LGG	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg08250081	chr4:10125330	NA	0.66	12.29	0.5	2.94e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.07	0.57	4.77e-42	Lung cancer;
LGG	cis	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg14668632	chr7:2872130	GNA12	-0.34	-7.14	-0.32	3.55e-12	Height;
LGG	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.29	-0.36	1.2e-15	Aortic root size;
LGG	cis	rs12643440	0.538	rs62296726	chr4:17143914	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.76	-13.86	-0.54	9.13e-37	Intelligence (multi-trait analysis);
LGG	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg14835575	chr10:16859367	RSU1	0.79	14.44	0.56	2.84e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg20026190	chr17:76395443	PGS1	0.44	7.41	0.33	6.09e-13	HDL cholesterol levels;
LGG	cis	rs1062177	1.000	rs12515762	chr5:151209922	G/T	cg00977110	chr5:151150581	G3BP1	0.51	7.98	0.35	1.19e-14	Preschool internalizing problems;
LGG	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg10167378	chr1:228756711	NA	0.55	7.95	0.35	1.48e-14	Chronic lymphocytic leukemia;
LGG	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.7	12.78	0.51	3.06e-32	Colorectal cancer;
LGG	cis	rs4740619	0.905	rs4146291	chr9:15783266	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.42	-0.44	5.7e-23	Body mass index;
LGG	cis	rs4930561	0.739	rs10896303	chr11:67974292	C/A	cg16338278	chr11:67432957	ALDH3B2	0.41	7.52	0.33	2.94e-13	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs9880211	1.000	rs9837158	chr3:136073163	C/T	cg21827317	chr3:136751795	NA	-0.47	-6.99	-0.31	9.57e-12	Body mass index;Height;
LGG	cis	rs7301826	0.571	rs4759788	chr12:131296314	T/C	cg11011512	chr12:131303247	STX2	0.42	8.92	0.38	1.1e-17	Plasma plasminogen activator levels;
LGG	cis	rs8013055	0.846	rs12893999	chr14:105970842	C/G	cg19700328	chr14:106028568	NA	-0.6	-10.13	-0.43	6.42e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2797369	0.656	rs617365	chr6:101351365	A/G	cg27451362	chr6:101846650	GRIK2	0.76	10.31	0.43	1.43e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs1920116	0.778	rs6785618	chr3:169562797	G/A	cg08193579	chr3:169529701	LRRC34	0.42	7.36	0.32	8.71e-13	Glioma (high-grade);
LGG	cis	rs4363385	0.818	rs4845512	chr1:152995241	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.71	-0.38	5.4e-17	Inflammatory skin disease;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	4.95e-12	Prudent dietary pattern;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.46	-0.37	3.53e-16	Personality dimensions;
LGG	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg19847130	chr8:10466454	RP1L1	0.32	6.99	0.31	9.78e-12	Triglycerides;
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg11764359	chr7:65958608	NA	-0.71	-12.86	-0.51	1.43e-32	Aortic root size;
LGG	trans	rs7762018	1.000	rs6904601	chr6:170131905	T/G	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs655029	1.000	rs655029	chr2:31477838	G/A	cg14018959	chr2:31480232	EHD3	-0.37	-7.27	-0.32	1.51e-12	Mean platelet volume;Platelet distribution width;Platelet count;Plateletcrit;
LGG	cis	rs4538187	0.547	rs12713498	chr2:64112428	C/T	cg14150252	chr2:64069583	UGP2	0.36	7.64	0.33	1.29e-13	Systolic blood pressure;
LGG	cis	rs2354432	0.607	rs57078845	chr1:146722222	G/A	cg25205988	chr1:146714368	CHD1L	-1.46	-15.06	-0.57	5.08e-42	Mitochondrial DNA levels;
LGG	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg24759859	chr6:86352639	SYNCRIP	0.42	6.81	0.3	3.08e-11	Smooth-surface caries;
LGG	cis	rs3916	0.955	rs34030695	chr12:121156496	G/A	cg21892295	chr12:121157589	UNC119B	-0.41	-7.26	-0.32	1.6e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs737693	1.000	rs737693	chr11:102726142	A/T	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg02018176	chr4:1364513	KIAA1530	-0.42	-9.41	-0.4	2.3e-19	Obesity-related traits;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg13732589	chr9:135457339	BARHL1	-0.37	-6.83	-0.3	2.72e-11	Iris color (L* coordinate);
LGG	cis	rs920590	0.573	rs6986456	chr8:19680562	A/G	cg03894339	chr8:19674705	INTS10	0.55	9.42	0.4	2.15e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg22398616	chr13:53314203	LECT1	-0.4	-7.57	-0.33	2.04e-13	Lewy body disease;
LGG	cis	rs1670533	0.932	rs4690214	chr4:1054636	T/C	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	cis	rs9596863	0.898	rs9568919	chr13:54352229	T/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.21	0.32	2.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs8018808	0.935	rs1061629	chr14:77926011	A/G	cg20045696	chr14:77926864	AHSA1	-0.41	-6.67	-0.3	7.13e-11	Myeloid white cell count;
LGG	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.11	-0.46	1.36e-25	Blood trace element (Zn levels);
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.3	0.46	2.54e-26	Tonsillectomy;
LGG	cis	rs7726354	0.793	rs16886164	chr5:56022907	G/A	cg27303933	chr5:56029418	NA	0.49	6.93	0.31	1.39e-11	Breast cancer (early onset);
LGG	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg27129171	chr3:47204927	SETD2	0.78	15.19	0.58	1.47e-42	Colorectal cancer;
LGG	trans	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg16141378	chr3:129829833	LOC729375	-0.31	-7.22	-0.32	2.09e-12	Joint mobility (Beighton score);
LGG	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg05677249	chr15:77158041	SCAPER	-0.31	-6.74	-0.3	4.74e-11	Blood metabolite levels;
LGG	cis	rs11734570	0.581	rs73808504	chr4:38600593	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.32	0.36	1.01e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.06	-0.31	5.95e-12	Bipolar disorder;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03452623	chr4:187889614	NA	-1.04	-29.29	-0.81	1.82e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs977987	0.806	rs1364077	chr16:75396991	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs6835098	0.692	rs7657374	chr4:174065756	A/T	cg08422745	chr4:174089978	GALNT7	-0.67	-11.73	-0.48	5.38e-28	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs4740619	0.967	rs6474942	chr9:15666712	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.38	-0.43	7.59e-23	Body mass index;
LGG	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11890956	chr21:40555474	PSMG1	1.18	27.02	0.78	3.3e-97	Cognitive function;
LGG	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs8068544	0.818	rs75771390	chr17:40194054	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-13.72	-0.54	3.3e-36	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs6963495	0.745	rs73190169	chr7:105160500	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02788857	chr8:22132959	PIWIL2	0.5	11.78	0.48	3.33e-28	Hypertriglyceridemia;
LGG	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.78	0.34	4.91e-14	Retinal vascular caliber;
LGG	cis	rs4794202	0.629	rs7214694	chr17:45895353	C/T	cg02219949	chr17:45927392	SP6	0.52	6.69	0.3	6.6e-11	Alzheimer's disease (cognitive decline);
LGG	cis	rs10197940	0.624	rs10497082	chr2:152355258	T/C	cg06191203	chr2:152266755	RIF1	-0.46	-7.86	-0.34	2.73e-14	Lung cancer;
LGG	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg25706552	chr1:244017396	NA	0.49	7.54	0.33	2.55e-13	RR interval (heart rate);
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg12395012	chr8:11607386	GATA4	0.4	6.92	0.31	1.55e-11	Neuroticism;
LGG	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg02461776	chr11:598696	PHRF1	0.42	6.97	0.31	1.1e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.78e-17	Lung cancer;
LGG	cis	rs8053891	0.673	rs35338546	chr16:72022156	C/T	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.67	-0.3	7.32e-11	Coronary artery disease;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg17911788	chr17:44343683	NA	0.62	9.46	0.4	1.58e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg02463440	chr8:22132932	PIWIL2	0.47	10.12	0.43	6.86e-22	Hypertriglyceridemia;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs13421350	0.579	rs78181761	chr2:173303531	A/G	cg15021238	chr2:173305865	ITGA6	-0.83	-9.33	-0.4	4.5e-19	Diabetic kidney disease;
LGG	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.17	0.72	9.91e-75	Homoarginine levels;
LGG	trans	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs9462027	0.606	rs412392	chr6:34549699	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.54	-0.44	2.03e-23	Systemic lupus erythematosus;
LGG	cis	rs3106136	0.527	rs10016806	chr4:95158495	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.05	-0.46	2.36e-25	Capecitabine sensitivity;
LGG	cis	rs9487094	0.670	rs13220915	chr6:109824826	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.12e-15	Height;
LGG	cis	rs6087990	0.836	rs2424909	chr20:31361861	T/C	cg13636640	chr20:31349939	DNMT3B	0.98	21.48	0.71	1.56e-71	Ulcerative colitis;
LGG	cis	rs2742417	1.000	rs1877932	chr3:45753539	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.64	-0.56	3.74e-40	Schizophrenia;
LGG	cis	rs721917	0.506	rs2493725	chr10:81657882	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs870825	0.616	rs7667449	chr4:185641711	T/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.16	0.72	1.03e-74	Blood protein levels;
LGG	cis	rs7586879	0.789	rs17046737	chr2:25127835	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	cis	rs7582720	1.000	rs72926794	chr2:203827432	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11700980	0.748	rs17734876	chr21:30260144	C/T	cg08807101	chr21:30365312	RNF160	-0.65	-6.9	-0.31	1.75e-11	QRS complex (12-leadsum);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23000464	chr19:633785	POLRMT	0.39	6.93	0.31	1.38e-11	Obesity-related traits;
LGG	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg10950924	chr17:47092072	IGF2BP1	0.46	8.94	0.38	9.25e-18	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg04374321	chr14:90722782	PSMC1	0.5	8.22	0.36	2.03e-15	Longevity;
LGG	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Lung cancer in ever smokers;
LGG	cis	rs4622507	0.618	rs12935747	chr16:55070160	G/A	cg09947736	chr16:55091198	NA	0.77	11.65	0.48	1.12e-27	Social communication problems;
LGG	cis	rs3857067	1.000	rs3857068	chr4:95026494	C/G	cg11021082	chr4:95130006	SMARCAD1	0.42	7.76	0.34	5.36e-14	QT interval;
LGG	cis	rs11885103	0.692	rs2685247	chr2:554788	G/C	cg21195176	chr2:593345	NA	0.39	7.2	0.32	2.51e-12	Heschl's gyrus morphology;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.09	-0.35	5.11e-15	Prudent dietary pattern;
LGG	cis	rs9911578	1.000	rs4636974	chr17:56965373	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	3.05e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2270450	0.580	rs9395208	chr6:46703319	G/C	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.53e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs3849046	0.680	rs34858014	chr5:137944006	C/T	cg10920316	chr5:137946599	NA	-0.45	-7.1	-0.31	4.72e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9309473	0.687	rs6706409	chr2:73606508	G/T	cg20560298	chr2:73613845	ALMS1	0.47	8.56	0.37	1.64e-16	Metabolite levels;
LGG	cis	rs2186369	0.681	rs5760023	chr22:24138301	C/T	cg10122452	chr22:24128767	SMARCB1	-0.41	-8.11	-0.35	4.69e-15	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg10802521	chr3:52805072	NEK4	-0.38	-6.96	-0.31	1.19e-11	Bipolar disorder;
LGG	cis	rs4780401	0.609	rs9924522	chr16:11816852	C/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.87	-0.51	1.27e-32	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04962738	chr7:86974741	CROT;TP53TG1	0.44	6.66	0.3	7.75e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg14541582	chr5:601475	NA	-0.7	-10.83	-0.45	1.59e-24	Obesity-related traits;
LGG	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg26354017	chr1:205819088	PM20D1	-0.42	-7.42	-0.33	5.72e-13	Menarche (age at onset);
LGG	trans	rs9987353	1.000	rs9987353	chr8:9116349	C/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.0	-0.31	9.11e-12	Recombination measurement;
LGG	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg24558204	chr6:135376177	HBS1L	0.61	10.53	0.44	2.21e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg01448562	chr3:133502909	NA	0.62	10.35	0.43	1.05e-22	Iron status biomarkers;
LGG	cis	rs9660992	0.674	rs12122105	chr1:205256818	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.7	0.3	6.1e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00689492	chr4:1303491	MAEA	0.45	7.76	0.34	5.57e-14	Obesity-related traits;
LGG	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.39	0.53	8.48e-35	Bladder cancer;
LGG	cis	rs11096990	0.593	rs35937374	chr4:39186355	C/T	cg24403649	chr4:39172243	NA	0.42	7.51	0.33	3.03e-13	Cognitive function;
LGG	cis	rs9810089	0.814	rs866758	chr3:136117870	G/C	cg21827317	chr3:136751795	NA	0.46	8.02	0.35	8.86e-15	Gestational age at birth (child effect);
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg22907277	chr7:1156413	C7orf50	0.63	11.64	0.48	1.17e-27	Longevity;Endometriosis;
LGG	cis	rs35160687	0.644	rs4832036	chr2:86551302	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-6.99	-0.31	9.47e-12	Night sleep phenotypes;
LGG	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg21775007	chr8:11205619	TDH	0.84	15.43	0.58	1.2e-43	Retinal vascular caliber;
LGG	cis	rs6912958	0.754	rs1051131	chr6:88221546	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.85e-16	Monocyte percentage of white cells;
LGG	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs853679	0.546	rs35017208	chr6:28345282	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs7928758	0.943	rs75184941	chr11:134277750	G/A	cg15243474	chr11:134282918	B3GAT1	1.08	14.19	0.55	3.41e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.19	-0.36	2.59e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6456156	0.811	rs975822	chr6:167516458	C/T	cg07741184	chr6:167504864	NA	-0.35	-7.62	-0.33	1.4e-13	Primary biliary cholangitis;
LGG	cis	rs10905065	0.931	rs11255228	chr10:5837671	T/C	cg11519256	chr10:5708881	ASB13	0.41	7.06	0.31	6.08e-12	Menopause (age at onset);
LGG	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.42	-8.35	-0.36	7.96e-16	Schizophrenia;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg15971980	chr6:150254442	NA	0.41	6.74	0.3	4.75e-11	Lung cancer;
LGG	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	cis	rs6456156	0.692	rs9457270	chr6:167512928	A/G	cg07741184	chr6:167504864	NA	0.44	9.92	0.42	3.82e-21	Primary biliary cholangitis;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.34	0.32	9.42e-13	Renal function-related traits (BUN);
LGG	cis	rs9640161	0.789	rs34495356	chr7:150057791	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-11.25	-0.46	4.2e-26	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7267979	0.903	rs6115118	chr20:25246734	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.52	0.44	2.27e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg10483660	chr13:112241077	NA	0.45	9.4	0.4	2.54e-19	Menarche (age at onset);
LGG	trans	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.61	-0.41	4.81e-20	Primary sclerosing cholangitis;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12200782	1.000	rs12200782	chr6:26403036	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.48	-0.33	3.69e-13	Small cell lung carcinoma;
LGG	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.7	0.34	8.19e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg21724239	chr8:58056113	NA	0.62	9.07	0.39	3.33e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.79	-0.38	2.95e-17	Self-reported allergy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05014952	chr14:35873130	NFKBIA	0.43	7.71	0.34	7.54e-14	Obesity-related traits;
LGG	cis	rs7561149	0.528	rs10497523	chr2:179652802	A/G	cg17765952	chr2:179737173	CCDC141	-0.31	-6.71	-0.3	5.77e-11	QT interval;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.71	-0.34	7.52e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.84	0.64	1.44e-54	Alzheimer's disease;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg13047869	chr3:10149882	C3orf24	-0.54	-9.0	-0.39	6.05e-18	Alzheimer's disease;
LGG	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	10.0	0.42	1.96e-21	Body mass index;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg07142201	chr11:109293216	C11orf87	-0.49	-8.11	-0.35	4.73e-15	Schizophrenia;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.03	-0.31	7.63e-12	Prostate cancer;
LGG	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-8.42	-0.36	4.64e-16	Carotid intima media thickness;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg02951883	chr7:2050386	MAD1L1	0.78	17.35	0.63	2.63e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs4728302	0.643	rs6978605	chr7:133720125	T/C	cg10665199	chr7:133106180	EXOC4	0.41	7.03	0.31	7.58e-12	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	21.24	0.7	2.24e-70	Alzheimer's disease;
LGG	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg23625390	chr15:77176239	SCAPER	-0.66	-13.46	-0.53	4.58e-35	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06221470	chr7:2353869	SNX8	0.44	6.87	0.3	2.09e-11	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.22	-0.39	1.04e-18	Neuroticism;
LGG	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg25237894	chr2:233734115	C2orf82	-0.73	-15.41	-0.58	1.45e-43	Coronary artery disease;
LGG	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg26597838	chr10:835615	NA	0.74	10.39	0.43	7.3e-23	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12012146	chr6:139094629	CCDC28A	0.5	7.65	0.33	1.17e-13	Gut microbiome composition (summer);
LGG	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg04117972	chr1:227635322	NA	0.9	14.03	0.55	1.6e-37	Major depressive disorder;
LGG	cis	rs4917300	0.606	rs13250335	chr8:143096061	G/C	cg26003909	chr8:143102224	NA	-0.33	-6.66	-0.3	7.83e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg00166722	chr3:10149974	C3orf24	0.53	9.17	0.39	1.61e-18	Alzheimer's disease;
LGG	cis	rs8020289	0.957	rs10136525	chr14:77287433	A/G	cg23436960	chr14:77239540	VASH1	-0.26	-6.77	-0.3	4.03e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs2976388	0.578	rs4736324	chr8:143830462	G/A	cg06565975	chr8:143823917	SLURP1	-0.54	-14.05	-0.55	1.3e-37	Urinary tract infection frequency;
LGG	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs372883	0.648	rs2832296	chr21:30741454	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-11.7	-0.48	7.25e-28	Pancreatic cancer;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25172604	chr17:41446521	NA	-0.32	-7.47	-0.33	4.13e-13	Menopause (age at onset);
LGG	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs7177699	0.550	rs7182716	chr15:79123753	T/C	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg01570182	chr17:44337453	NA	0.52	9.54	0.41	8.5e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg02002194	chr4:3960332	NA	0.44	8.01	0.35	9.26e-15	Neuroticism;
LGG	cis	rs3806843	0.900	rs2531340	chr5:140131046	C/T	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg19147804	chr7:1989927	MAD1L1	-0.6	-11.92	-0.48	9.3e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7927771	1.000	rs12419692	chr11:47624714	A/C	cg20307385	chr11:47447363	PSMC3	0.48	8.53	0.37	2.09e-16	Subjective well-being;
LGG	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg07537917	chr2:241836409	C2orf54	-0.4	-7.87	-0.34	2.58e-14	Urinary metabolites;
LGG	cis	rs16957091	0.908	rs1915241	chr15:43054042	T/G	cg07484255	chr15:43025164	CDAN1	-0.46	-6.72	-0.3	5.43e-11	MGMT methylation in smokers;
LGG	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg15704280	chr7:45808275	SEPT13	0.87	13.76	0.54	2.25e-36	Coronary artery disease;
LGG	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg07648498	chr16:89883185	FANCA	-0.41	-7.0	-0.31	8.88e-12	Vitiligo;
LGG	cis	rs2798269	0.902	rs11616720	chr13:22115822	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.09	-0.31	5e-12	PR segment;
LGG	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg04226714	chr8:49833948	SNAI2	0.44	7.88	0.34	2.37e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs11088226	0.692	rs2833861	chr21:33882345	C/T	cg09050820	chr6:167586206	TCP10L2	0.49	7.53	0.33	2.59e-13	Gastritis;
LGG	trans	rs3960554	0.808	rs13438599	chr7:75768022	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.43	0.5	7.87e-31	Eotaxin levels;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg04267008	chr7:1944627	MAD1L1	-0.52	-8.68	-0.37	6.89e-17	Schizophrenia;
LGG	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg24209194	chr3:40518798	ZNF619	-0.39	-6.68	-0.3	6.69e-11	Renal cell carcinoma;
LGG	cis	rs7927771	0.965	rs17788930	chr11:47752775	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs9964724	0.865	rs12956949	chr18:35171653	G/A	cg27332583	chr18:35150602	NA	-0.42	-9.03	-0.39	4.6e-18	Educational attainment (years of education);
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg07308232	chr7:1071921	C7orf50	-0.72	-14.32	-0.55	9.27e-39	Longevity;Endometriosis;
LGG	cis	rs981844	0.740	rs7653960	chr4:154697430	T/G	cg14289246	chr4:154710475	SFRP2	-0.59	-10.41	-0.44	6.21e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs17336368	1.000	rs17336368	chr6:44751668	G/A	cg20913747	chr6:44695427	NA	-0.67	-12.05	-0.49	2.73e-29	Chin dimples;
LGG	trans	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.36	-0.32	8.64e-13	Triglycerides;
LGG	cis	rs503734	0.666	rs2682384	chr3:101112472	A/C	cg27318481	chr3:100970896	IMPG2	-0.36	-7.24	-0.32	1.84e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	15.43	0.58	1.21e-43	Hip circumference adjusted for BMI;
LGG	cis	rs6835098	0.887	rs12644699	chr4:174142874	A/G	cg08422745	chr4:174089978	GALNT7	0.8	13.5	0.53	3.04e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs7107174	0.892	rs2512540	chr11:77979299	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg24642844	chr7:1081250	C7orf50	-0.72	-13.05	-0.52	2.36e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-8.21	-0.36	2.24e-15	Height;
LGG	cis	rs9790314	0.690	rs1599390	chr3:160833246	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.29	-0.43	1.71e-22	Morning vs. evening chronotype;
LGG	cis	rs17221829	0.703	rs12418019	chr11:89391757	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.16e-18	Anxiety in major depressive disorder;
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg23302884	chr18:44338147	ST8SIA5	0.35	6.77	0.3	3.83e-11	Personality dimensions;
LGG	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg08250081	chr4:10125330	NA	-0.38	-7.42	-0.33	5.76e-13	Bone mineral density;
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18099408	chr3:52552593	STAB1	0.36	7.23	0.32	2.01e-12	Bipolar disorder;
LGG	cis	rs7712401	0.601	rs144597	chr5:122223232	A/C	cg19412675	chr5:122181750	SNX24	0.42	6.97	0.31	1.13e-11	Mean platelet volume;
LGG	trans	rs9650657	0.655	rs10093774	chr8:10703293	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.5	0.33	3.27e-13	Neuroticism;
LGG	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg16141378	chr3:129829833	LOC729375	0.37	8.29	0.36	1.27e-15	Multiple myeloma (hyperdiploidy);
LGG	trans	rs12579753	1.000	rs2401004	chr12:82214822	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.77	-0.34	5.21e-14	Resting heart rate;
LGG	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	11.06	0.46	2.09e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.58	-0.5	2e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10802521	chr3:52805072	NEK4	-0.44	-7.63	-0.33	1.34e-13	Bipolar disorder;
LGG	cis	rs41005	1.000	rs42357	chr2:8110896	C/T	cg03155496	chr2:8117019	LOC339788	0.89	20.03	0.68	9.89e-65	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs514024	0.729	rs10819303	chr9:130392954	G/A	cg13643465	chr9:130375613	STXBP1	-0.64	-11.94	-0.49	7.76e-29	Eating disorders (purging via substances);
LGG	trans	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-9.52	-0.4	9.45e-20	Neuroticism;
LGG	cis	rs11696845	0.787	rs6017408	chr20:43363529	A/G	cg25301532	chr20:43378953	KCNK15	0.45	10.76	0.45	3.04e-24	Obesity-related traits;
LGG	trans	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg02002194	chr4:3960332	NA	0.39	7.24	0.32	1.85e-12	Joint mobility (Beighton score);
LGG	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.34	0.4	3.94e-19	Blood protein levels;
LGG	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg24006582	chr15:45444508	DUOX1	-0.65	-12.29	-0.5	3.14e-30	Uric acid levels;
LGG	cis	rs10504130	0.569	rs7820177	chr8:52836933	A/T	cg13492337	chr8:52722140	PXDNL	-0.51	-7.91	-0.35	1.85e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.27	0.43	1.93e-22	Arsenic metabolism;
LGG	cis	rs2033732	0.706	rs7835031	chr8:85076187	C/T	cg05716166	chr8:85095498	RALYL	0.46	7.34	0.32	9.96e-13	Body mass index;
LGG	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.65	-0.37	8.38e-17	Granulocyte percentage of myeloid white cells;
LGG	trans	rs9467711	0.606	rs9393707	chr6:26362486	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg23594656	chr7:65796392	TPST1	0.41	9.1	0.39	2.7e-18	Aortic root size;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg00631329	chr6:26305371	NA	-0.54	-9.76	-0.41	1.34e-20	Educational attainment;
LGG	cis	rs6430585	0.527	rs2254780	chr2:136435526	C/T	cg07169764	chr2:136633963	MCM6	0.97	16.24	0.6	2.89e-47	Corneal structure;
LGG	cis	rs9512730	0.527	rs11619722	chr13:27998600	T/C	cg04070771	chr13:27998621	GTF3A	0.6	9.31	0.4	5.16e-19	Schizophrenia;
LGG	cis	rs2573652	0.722	rs12908133	chr15:100544405	G/A	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.23	-0.32	2.04e-12	Height;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.48	0.33	3.64e-13	Renal function-related traits (BUN);
LGG	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.44	-0.33	5.04e-13	Prostate cancer;
LGG	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg10204951	chr7:910479	UNC84A	-0.52	-6.88	-0.3	1.89e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06873352	chr17:61820015	STRADA	0.72	13.38	0.53	9.92e-35	Prudent dietary pattern;
LGG	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg10223061	chr2:219282414	VIL1	0.31	6.84	0.3	2.55e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9814567	1.000	rs55913793	chr3:134285968	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.66e-25	Intelligence (multi-trait analysis);
LGG	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg00850481	chr1:228891306	NA	-0.5	-8.66	-0.37	8.02e-17	Chronic lymphocytic leukemia;
LGG	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg03605463	chr16:89740564	NA	0.61	11.03	0.46	2.89e-25	Vitiligo;
LGG	cis	rs2860975	0.620	rs2275622	chr10:96827178	T/C	cg09036531	chr10:96991505	NA	-0.5	-8.65	-0.37	8.7e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs4321325	0.733	rs79208542	chr2:127935686	G/C	cg11380483	chr2:127933992	NA	0.69	9.42	0.4	2.07e-19	Protein C levels;
LGG	cis	rs3735485	0.800	rs4724349	chr7:45059247	T/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4315565	0.688	rs6546478	chr2:69282132	C/T	cg13358873	chr2:69271042	ANTXR1	0.51	7.7	0.34	8.44e-14	Height;
LGG	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg24558204	chr6:135376177	HBS1L	0.55	9.61	0.41	4.82e-20	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.15	0.52	8.83e-34	Bladder cancer;
LGG	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.23	-0.36	1.92e-15	Retinal vascular caliber;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg19318889	chr4:1322082	MAEA	-0.46	-7.87	-0.34	2.45e-14	Longevity;
LGG	cis	rs2540226	0.539	rs6711206	chr2:39919736	A/G	cg02886589	chr2:39892450	TMEM178	0.3	8.23	0.36	1.93e-15	Personality dimensions;
LGG	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg02264733	chr16:588086	SOLH	-0.47	-7.58	-0.33	1.95e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg13010199	chr12:38710504	ALG10B	0.54	9.66	0.41	3.07e-20	Resting heart rate;
LGG	cis	rs36051895	0.589	rs7038763	chr9:5076399	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-16.27	-0.6	2.18e-47	Pediatric autoimmune diseases;
LGG	cis	rs4665809	0.590	rs3806515	chr2:26466975	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-25.19	-0.76	8.35e-89	Height;
LGG	cis	rs7633770	0.965	rs6804112	chr3:46686248	C/T	cg11219411	chr3:46661640	NA	0.53	12.06	0.49	2.53e-29	Coronary artery disease;
LGG	cis	rs4684776	0.935	rs35166981	chr3:11385356	G/T	cg24705426	chr3:11550659	ATG7	-0.45	-8.49	-0.37	2.91e-16	Small vessel stroke;
LGG	cis	rs4959677	0.725	rs879097	chr6:2507392	A/G	cg20147862	chr6:2634573	C6orf195	-0.36	-8.01	-0.35	9.5e-15	Orthostatic hypotension;
LGG	cis	rs4926611	0.729	rs17382457	chr1:54071428	A/G	cg23596471	chr1:54105337	GLIS1	0.39	7.92	0.35	1.77e-14	Hand grip strength;
LGG	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg13647721	chr17:30228624	UTP6	0.67	9.36	0.4	3.51e-19	Hip circumference adjusted for BMI;
LGG	cis	rs758324	0.783	rs253941	chr5:131320293	C/T	cg06307176	chr5:131281290	NA	-0.6	-9.48	-0.4	1.38e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7011049	0.778	rs114842851	chr8:53867405	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg07142201	chr11:109293216	C11orf87	0.53	9.12	0.39	2.27e-18	Schizophrenia;
LGG	cis	rs3820928	0.967	rs4675118	chr2:227773157	C/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.22	-0.32	2.14e-12	Pulmonary function;
LGG	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg19774624	chr17:42201019	HDAC5	0.67	11.97	0.49	6.12e-29	Total body bone mineral density;
LGG	cis	rs9660992	0.710	rs1151787	chr1:205254238	G/A	cg21545522	chr1:205238299	TMCC2	0.48	8.58	0.37	1.48e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.49	-0.37	2.9e-16	Life satisfaction;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg13126279	chr21:47581558	C21orf56	0.55	10.05	0.42	1.27e-21	Testicular germ cell tumor;
LGG	cis	rs1941023	0.503	rs7944025	chr11:60142538	C/A	cg08716584	chr11:60157161	MS4A7	-0.43	-8.49	-0.37	2.85e-16	Congenital heart disease (maternal effect);
LGG	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg09307838	chr4:120376055	NA	0.67	11.64	0.48	1.23e-27	Educational attainment;
LGG	cis	rs10791097	0.547	rs1050078	chr11:130746146	T/C	cg12179176	chr11:130786555	SNX19	0.88	17.77	0.64	3.1e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	10.04	0.42	1.33e-21	Height;
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg27400746	chr16:89904261	SPIRE2	-0.98	-16.72	-0.61	1.96e-49	Skin colour saturation;
LGG	cis	rs6435862	0.636	rs717548	chr2:215676905	G/A	cg04530015	chr2:215796436	ABCA12	0.52	10.37	0.43	8.22e-23	Neuroblastoma (high-risk);
LGG	cis	rs6728642	0.561	rs62152901	chr2:97564898	A/G	cg26665480	chr2:98280029	ACTR1B	-0.65	-8.37	-0.36	6.67e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg00343986	chr7:65444356	GUSB	0.41	6.9	0.31	1.72e-11	Aortic root size;
LGG	cis	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg21775007	chr8:11205619	TDH	-0.52	-8.37	-0.36	6.83e-16	Retinal vascular caliber;
LGG	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg12458913	chr13:53173898	NA	-0.44	-7.53	-0.33	2.63e-13	Lewy body disease;
LGG	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg02002194	chr4:3960332	NA	-0.43	-8.23	-0.36	1.93e-15	Joint mobility (Beighton score);
LGG	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg26384229	chr12:38710491	ALG10B	0.79	15.57	0.59	2.88e-44	Morning vs. evening chronotype;
LGG	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg24675658	chr1:53192096	ZYG11B	0.62	13.32	0.53	1.78e-34	Monocyte count;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg00405596	chr8:11794950	NA	-0.43	-6.72	-0.3	5.24e-11	Retinal vascular caliber;
LGG	cis	rs4148883	0.645	rs1154404	chr4:100009004	A/T	cg12011299	chr4:100065546	ADH4	0.4	8.37	0.36	7.03e-16	Alcohol dependence;
LGG	cis	rs7402982	0.625	rs7179841	chr15:99204652	C/T	cg03437748	chr15:99193247	IGF1R	0.79	13.12	0.52	1.19e-33	Birth weight;
LGG	cis	rs4478037	0.822	rs9868526	chr3:33124269	A/G	cg19404215	chr3:33155277	CRTAP	-0.73	-9.16	-0.39	1.65e-18	Major depressive disorder;
LGG	cis	rs2735413	0.563	rs8046446	chr16:78049586	C/G	cg04733911	chr16:78082701	NA	0.57	7.46	0.33	4.19e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs240764	0.619	rs9399656	chr6:101127124	C/T	cg09795085	chr6:101329169	ASCC3	0.41	6.79	0.3	3.41e-11	Neuroticism;
LGG	cis	rs11971779	0.680	rs2355787	chr7:139089928	G/T	cg07862535	chr7:139043722	LUC7L2	-0.41	-6.93	-0.31	1.42e-11	Diisocyanate-induced asthma;
LGG	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.46	-0.47	5.89e-27	Schizophrenia;
LGG	trans	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg02800362	chr5:177631904	HNRNPAB	0.79	13.84	0.54	1.01e-36	Obesity-related traits;
LGG	cis	rs72781680	0.800	rs6718635	chr2:24066183	A/C	cg08917208	chr2:24149416	ATAD2B	0.9	9.56	0.41	6.81e-20	Lymphocyte counts;
LGG	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg21045802	chr8:109455806	TTC35	0.52	9.86	0.42	5.82e-21	Dupuytren's disease;
LGG	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg02640540	chr1:67518911	SLC35D1	0.38	7.4	0.33	6.26e-13	Lymphocyte percentage of white cells;
LGG	cis	rs6912958	1.000	rs9294380	chr6:88152667	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.61	-0.44	1.09e-23	Monocyte percentage of white cells;
LGG	cis	rs8114671	0.967	rs34515766	chr20:33785221	C/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.4	-0.33	6.5e-13	Height;
LGG	cis	rs1018836	0.632	rs9642910	chr8:91475724	G/T	cg16814680	chr8:91681699	NA	-0.66	-11.27	-0.46	3.26e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.4	-0.58	1.6e-43	Chronic sinus infection;
LGG	cis	rs9443189	0.570	rs6903448	chr6:76173832	C/T	cg01950844	chr6:76311363	SENP6	0.67	8.74	0.38	4.18e-17	Prostate cancer;
LGG	cis	rs9359856	0.510	rs6937789	chr6:90468775	C/G	cg13799429	chr6:90582589	CASP8AP2	0.85	12.57	0.5	2.24e-31	Bipolar disorder;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	cis	rs2976388	1.000	rs2976394	chr8:143763622	C/T	cg06565975	chr8:143823917	SLURP1	-0.4	-10.27	-0.43	1.99e-22	Urinary tract infection frequency;
LGG	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg00666640	chr1:248458726	OR2T12	0.61	9.76	0.41	1.37e-20	Common traits (Other);
LGG	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-7.68	-0.34	9.59e-14	Self-reported allergy;
LGG	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg04662567	chr6:169592167	NA	-0.78	-11.41	-0.47	9.83e-27	Pulse pressure;
LGG	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg03433033	chr1:76189801	ACADM	-0.63	-9.39	-0.4	2.82e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.27	-0.5	3.84e-30	Obesity-related traits;
LGG	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22857025	chr5:266934	NA	1.3	21.67	0.71	2.14e-72	Breast cancer;
LGG	cis	rs7695597	0.643	rs1217953	chr4:185167708	A/G	cg12654155	chr4:185238627	NA	0.42	7.65	0.34	1.17e-13	Night sleep phenotypes;
LGG	cis	rs721399	0.719	rs12674710	chr8:18263663	A/C	cg18736775	chr8:18248649	NAT2	-0.77	-12.13	-0.49	1.34e-29	Blood metabolite levels;
LGG	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg10523679	chr1:76189770	ACADM	0.73	11.87	0.48	1.49e-28	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs240764	0.717	rs151640	chr6:101111521	A/C	cg09795085	chr6:101329169	ASCC3	0.44	7.6	0.33	1.62e-13	Neuroticism;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg13384949	chr1:2383501	NA	-0.6	-14.07	-0.55	1.05e-37	Non-obstructive azoospermia;
LGG	cis	rs367943	0.698	rs728915	chr5:112995748	C/T	cg12552261	chr5:112820674	MCC	0.54	9.64	0.41	3.74e-20	Type 2 diabetes;
LGG	cis	rs2070677	1.000	rs1329149	chr10:135349801	T/C	cg20169779	chr10:135381914	SYCE1	0.96	12.75	0.51	4.11e-32	Gout;
LGG	cis	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg15105060	chr4:7024189	TBC1D14	-0.72	-6.99	-0.31	9.38e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6732160	0.657	rs10171459	chr2:73434728	A/C	cg01422370	chr2:73384389	NA	0.48	9.15	0.39	1.81e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2180341	0.814	rs6569488	chr6:127726256	C/T	cg24812749	chr6:127587940	RNF146	0.71	11.39	0.47	1.14e-26	Breast cancer;
LGG	cis	rs6121246	0.609	rs6060652	chr20:30266845	A/G	cg13852791	chr20:30311386	BCL2L1	0.91	17.22	0.62	9.93e-52	Mean corpuscular hemoglobin;
LGG	cis	rs3820928	1.000	rs978909	chr2:227771389	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.14	-0.32	3.53e-12	Pulmonary function;
LGG	cis	rs6669008	1.000	rs6669008	chr1:114166561	A/G	cg26035817	chr1:114414802	PTPN22	0.5	10.29	0.43	1.73e-22	Bacteremia;
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.16	-0.49	9.99e-30	Alzheimer's disease;
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.26e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg27471124	chr11:109292789	C11orf87	0.49	9.53	0.41	8.75e-20	Schizophrenia;
LGG	cis	rs8072100	0.666	rs6503804	chr17:45772447	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-9.93	-0.42	3.39e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg11366901	chr6:160182831	ACAT2	1.05	16.27	0.6	2.18e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg07157834	chr1:205819609	PM20D1	0.4	6.84	0.3	2.5e-11	Parkinson's disease;
LGG	trans	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.63	0.48	1.37e-27	Mean corpuscular volume;
LGG	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg23752985	chr2:85803571	VAMP8	0.4	7.76	0.34	5.29e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg06138931	chr13:21896616	NA	0.46	10.06	0.42	1.12e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11920090	0.800	rs67190441	chr3:170754048	T/C	cg09710316	chr3:170744871	SLC2A2	0.64	8.38	0.36	6.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg07511668	chr11:68622177	NA	0.51	9.86	0.42	6.01e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg15212455	chr7:39170539	POU6F2	0.51	12.04	0.49	3.18e-29	IgG glycosylation;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.45	-0.4	1.74e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg23978390	chr7:1156363	C7orf50	0.53	8.99	0.39	6.16e-18	Longevity;Endometriosis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01235203	chr3:187461998	BCL6	0.41	6.78	0.3	3.72e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10871290	1.000	rs11149710	chr16:74472546	G/T	cg01733217	chr16:74700730	RFWD3	-0.69	-13.0	-0.52	3.57e-33	Breast cancer;
LGG	cis	rs7666738	0.680	rs11097613	chr4:99079991	G/T	cg05340658	chr4:99064831	C4orf37	0.46	7.45	0.33	4.62e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs748404	0.578	rs573615	chr15:43614281	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	7.88	0.34	2.32e-14	Lung cancer;
LGG	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg02959939	chr21:47813025	PCNT	-0.38	-6.98	-0.31	1e-11	Lymphocyte counts;
LGG	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg21535247	chr6:8435926	SLC35B3	-0.53	-8.83	-0.38	2.14e-17	Motion sickness;
LGG	cis	rs2041895	0.509	rs10861676	chr12:107311235	G/A	cg13944111	chr12:107296891	NA	0.27	7.0	0.31	8.82e-12	Glaucoma (low intraocular pressure);
LGG	cis	rs3784262	0.904	rs17820823	chr15:58239358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.39	-0.32	7.07e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	cg15522984	chr1:182991683	LAMC1	0.44	8.88	0.38	1.51e-17	Colorectal cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10445487	chr16:75599896	GABARAPL2	0.39	6.7	0.3	5.9e-11	Bipolar disorder;
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg05793240	chr7:2802953	GNA12	0.33	7.92	0.35	1.74e-14	Height;
LGG	cis	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg15596359	chr8:11213517	TDH	-0.4	-8.08	-0.35	5.83e-15	Retinal vascular caliber;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg00106254	chr7:1943704	MAD1L1	0.44	7.83	0.34	3.29e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs977987	0.843	rs17696749	chr16:75403062	C/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.68	0.3	6.89e-11	Dupuytren's disease;
LGG	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.35	0.36	7.78e-16	Alzheimer's disease (survival time);
LGG	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg12379764	chr21:47803548	PCNT	0.67	9.32	0.4	4.68e-19	Lymphocyte counts;
LGG	trans	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg00953403	chr17:74099816	EXOC7	0.41	6.78	0.3	3.57e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs8067545	0.611	rs6587219	chr17:20034531	T/G	cg13482628	chr17:19912719	NA	0.54	10.26	0.43	2.19e-22	Schizophrenia;
LGG	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg24623649	chr8:11872141	NA	0.3	7.05	0.31	6.59e-12	Neuroticism;
LGG	cis	rs7172689	1.000	rs67766197	chr15:81539951	A/G	cg11808699	chr15:81528661	IL16	-0.51	-10.11	-0.43	7.8e-22	Inattentive symptoms;
LGG	trans	rs61931739	0.534	rs4931770	chr12:34044479	G/T	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.84e-46	Morning vs. evening chronotype;
LGG	cis	rs2251260	1.000	rs1092095	chr14:62018292	A/G	cg23386212	chr14:62041363	NA	-0.62	-9.36	-0.4	3.54e-19	Yeast infection;
LGG	trans	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg06875740	chr19:51307921	C19orf48	-0.66	-6.83	-0.3	2.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2030746	0.899	rs2030745	chr2:121309282	A/G	cg03661458	chr2:121334411	NA	0.29	6.68	0.3	6.85e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs3816183	1.000	rs11124892	chr2:43014304	C/A	cg27299406	chr2:43020013	HAAO	-0.27	-6.79	-0.3	3.44e-11	Hypospadias;
LGG	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg25174290	chr11:3078921	CARS	0.75	16.09	0.6	1.4300000000000001e-46	Longevity;
LGG	cis	rs7267979	1.000	rs11087521	chr20:25440648	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.18	0.43	4.27e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs75920871	0.588	rs1871756	chr11:116953645	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.38	-0.36	6.33e-16	Subjective well-being;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg06494592	chr3:125709126	NA	-0.54	-6.91	-0.31	1.56e-11	Blood pressure (smoking interaction);
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.33e-11	Aortic root size;
LGG	cis	rs17767392	0.846	rs61991213	chr14:71796441	C/T	cg02058870	chr14:72053146	SIPA1L1	0.4	8.23	0.36	1.93e-15	Mitral valve prolapse;
LGG	cis	rs12997796	0.556	rs35129240	chr2:86929217	G/A	cg25203885	chr2:87302643	LOC285074	-0.64	-7.44	-0.33	5e-13	Schizophrenia;
LGG	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg24189917	chr7:1970923	MAD1L1	-0.54	-7.9	-0.34	1.99e-14	Bipolar disorder;
LGG	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	7.0	0.31	8.8e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9296092	0.538	rs62405953	chr6:33524760	C/T	cg13560919	chr6:33536144	NA	-1.05	-21.92	-0.71	1.47e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7940866	0.838	rs10750455	chr11:130800330	C/T	cg12179176	chr11:130786555	SNX19	0.78	14.91	0.57	2.52e-41	Schizophrenia;
LGG	cis	rs7851660	0.772	rs6478471	chr9:100664382	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.78	-0.51	3.07e-32	Strep throat;
LGG	cis	rs9296092	0.500	rs4376348	chr6:33521097	A/G	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg20573242	chr4:122745356	CCNA2	0.42	7.6	0.33	1.68e-13	Type 2 diabetes;
LGG	cis	rs72781680	0.706	rs72794290	chr2:23896106	A/T	cg08917208	chr2:24149416	ATAD2B	0.85	8.81	0.38	2.62e-17	Lymphocyte counts;
LGG	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14952266	chr13:112191215	NA	-0.41	-7.55	-0.33	2.31e-13	Menarche (age at onset);
LGG	cis	rs4268898	0.931	rs55642516	chr2:24502305	A/G	cg06627628	chr2:24431161	ITSN2	-0.53	-8.9	-0.38	1.27e-17	Asthma;
LGG	cis	rs4330281	0.647	rs4435673	chr3:17749125	A/G	cg20981856	chr3:17787350	NA	-0.38	-6.94	-0.31	1.34e-11	Schizophrenia;
LGG	cis	rs6784615	0.744	rs613519	chr3:52468940	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.69	-7.76	-0.34	5.37e-14	Waist-hip ratio;
LGG	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg04608330	chr12:45269318	NELL2	-0.6	-10.57	-0.44	1.6e-23	Gut microbiome composition (summer);
LGG	cis	rs6429082	0.634	rs3856245	chr1:235571428	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.93	-0.38	9.71e-18	Adiposity;
LGG	cis	rs933688	0.509	rs2973472	chr5:90519496	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.49	-6.69	-0.3	6.29e-11	Smoking behavior;
LGG	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.37	-0.56	5.44e-39	Headache;
LGG	cis	rs6942756	0.758	rs13226649	chr7:128977598	C/T	cg02491457	chr7:128862824	NA	-0.61	-11.33	-0.47	1.99e-26	White matter hyperintensity burden;
LGG	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.38	-0.32	7.57e-13	Tonsillectomy;
LGG	cis	rs2976388	0.573	rs1529865	chr8:143789171	C/T	cg06565975	chr8:143823917	SLURP1	0.37	9.53	0.4	8.89e-20	Urinary tract infection frequency;
LGG	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.95	0.45	5.71e-25	Orofacial clefts;
LGG	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	9.22	0.39	1.06e-18	Mood instability;
LGG	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg01620082	chr3:125678407	NA	-1.01	-9.68	-0.41	2.75e-20	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07157834	chr1:205819609	PM20D1	0.5	9.98	0.42	2.31e-21	Menarche (age at onset);
LGG	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg24558204	chr6:135376177	HBS1L	0.61	10.56	0.44	1.65e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-6.87	-0.3	2.14e-11	Huntington's disease progression;
LGG	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs4417704	0.551	rs6754171	chr2:241896013	G/C	cg26818257	chr2:241905806	NA	0.5	10.93	0.45	6.9e-25	Joint mobility (Beighton score);
LGG	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	trans	rs35094601	0.625	rs72858187	chr2:139227315	G/A	cg25299176	chr17:1303341	YWHAE	-0.64	-8.21	-0.36	2.29e-15	Schizophrenia;
LGG	cis	rs9948	1.000	rs1320149	chr2:97493877	T/C	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.68	-0.34	9.76e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs793571	0.590	rs618684	chr15:59115922	A/G	cg05156742	chr15:59063176	FAM63B	0.57	9.65	0.41	3.36e-20	Schizophrenia;
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg21775007	chr8:11205619	TDH	0.44	7.1	0.31	4.57e-12	Mood instability;
LGG	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg12046867	chr14:103022105	NA	-0.75	-12.39	-0.5	1.21e-30	Platelet count;
LGG	cis	rs9660992	0.649	rs12128229	chr1:205268014	C/A	cg21545522	chr1:205238299	TMCC2	0.46	7.98	0.35	1.16e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs919433	0.680	rs7590010	chr2:198400668	C/T	cg00792783	chr2:198669748	PLCL1	0.5	7.77	0.34	5.19e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs7975161	0.630	rs4964257	chr12:104633262	T/C	cg25273343	chr12:104657179	TXNRD1	-0.74	-7.46	-0.33	4.2e-13	Toenail selenium levels;
LGG	cis	rs7312933	0.934	rs11181289	chr12:42402342	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.49	0.33	3.55e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs7246760	0.500	rs7250760	chr19:9989298	C/T	cg02900749	chr2:68251473	NA	-0.61	-7.06	-0.31	6.07e-12	Pursuit maintenance gain;
LGG	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg13512537	chr8:22265999	SLC39A14	-0.44	-7.11	-0.31	4.36e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs514406	0.861	rs1749907	chr1:53259658	C/T	cg24675658	chr1:53192096	ZYG11B	0.48	9.69	0.41	2.42e-20	Monocyte count;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.87	-0.42	5.54e-21	Lung cancer;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.812	rs11250073	chr8:10632236	G/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.06	-0.31	6.31e-12	Neuroticism;
LGG	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg04226714	chr8:49833948	SNAI2	-0.46	-8.16	-0.35	3.22e-15	Life satisfaction;
LGG	cis	rs1109114	0.764	rs2918276	chr5:148598681	T/C	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.65	-0.59	1.23e-44	Body mass index;
LGG	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg15704280	chr7:45808275	SEPT13	0.85	8.83	0.38	2.16e-17	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg11812906	chr14:75593930	NEK9	-0.5	-9.13	-0.39	2.08e-18	Height;
LGG	trans	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg26043149	chr18:55253948	FECH	-0.42	-6.96	-0.31	1.16e-11	Bone mineral density;
LGG	cis	rs9818758	0.607	rs3923475	chr3:49055788	G/T	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg15971980	chr6:150254442	NA	0.46	8.76	0.38	3.62e-17	Lung cancer;
LGG	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg08949735	chr16:89699720	DPEP1	-0.48	-10.0	-0.42	1.94e-21	Vitiligo;
LGG	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.39	0.32	6.81e-13	Birth weight;
LGG	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg17246694	chr1:24480847	IL28RA	-0.51	-6.65	-0.3	8.04e-11	Psoriasis vulgaris;
LGG	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.5	-0.33	3.25e-13	Restless legs syndrome;
LGG	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg03788504	chr6:150331562	NA	-0.56	-12.78	-0.51	2.94e-32	Alopecia areata;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg13939156	chr17:80058883	NA	0.47	9.14	0.39	1.98e-18	Life satisfaction;
LGG	cis	rs2708977	0.933	rs2579502	chr2:97198800	A/G	cg01950434	chr2:97203154	ARID5A	-0.58	-9.31	-0.4	5.32e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7246760	1.000	rs73507215	chr19:9887312	C/T	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	cis	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.89	-0.48	1.21e-28	Morning vs. evening chronotype;
LGG	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs4006360	0.545	rs365738	chr17:39279082	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.39	-8.2	-0.36	2.45e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs26868	0.740	rs26869	chr16:2248786	T/C	cg02248941	chr16:2239361	CASKIN1	0.48	9.55	0.41	7.52e-20	Height;
LGG	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.97	0.35	1.26e-14	Height;
LGG	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.27	-0.36	1.38e-15	Lung cancer;
LGG	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.44	-0.47	7.41e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg20240347	chr1:204465584	NA	-0.55	-11.12	-0.46	1.33e-25	Schizophrenia;
LGG	cis	rs9549367	0.789	rs9577218	chr13:113894911	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.65	-0.37	8.66e-17	Platelet distribution width;
LGG	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg24812749	chr6:127587940	RNF146	0.65	10.93	0.45	6.86e-25	Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13600149	chr9:98079129	FANCC	0.39	6.81	0.3	3.12e-11	Bipolar disorder;
LGG	cis	rs2692947	0.727	rs893173	chr2:96789787	T/C	cg22654517	chr2:96458247	NA	0.38	8.3	0.36	1.12e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1816752	0.875	rs59686377	chr13:25050007	C/T	cg22771759	chr13:24902376	NA	0.42	7.15	0.32	3.5e-12	Obesity-related traits;
LGG	cis	rs11662586	1.000	rs8093291	chr18:77701294	G/A	cg20368463	chr18:77673604	PQLC1	0.47	7.34	0.32	9.52e-13	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs8067287	0.724	rs35380019	chr17:16826904	G/A	cg26910001	chr17:16838321	NA	-0.47	-8.77	-0.38	3.51e-17	Diabetic kidney disease;
LGG	cis	rs4740619	0.619	rs4741557	chr9:16031080	C/T	cg14451791	chr9:16040625	NA	0.42	11.21	0.46	5.97e-26	Body mass index;
LGG	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-14.18	-0.55	3.77e-38	Headache;
LGG	cis	rs6840360	0.582	rs11732918	chr4:152319045	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.1	0.31	4.85e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4561483	0.801	rs33640	chr16:11986874	C/T	cg08843971	chr16:11963173	GSPT1	-0.67	-18.1	-0.64	9.67e-56	Testicular germ cell tumor;
LGG	cis	rs59197085	0.534	rs2307039	chr7:128449355	A/G	cg00734629	chr7:128471146	FLNC	0.35	7.11	0.31	4.56e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.61	-0.37	1.15e-16	Alzheimer's disease (survival time);
LGG	cis	rs9473924	0.542	rs9473946	chr6:50892950	G/A	cg14470998	chr6:50812995	TFAP2B	0.66	7.99	0.35	1.05e-14	Body mass index;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg08621203	chr6:150244597	RAET1G	0.46	6.87	0.3	2.11e-11	Lung cancer;
LGG	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.24	0.46	4.37e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13191362	0.935	rs13215748	chr6:163010710	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg07747251	chr5:1868357	NA	0.44	8.75	0.38	4.15e-17	Cardiovascular disease risk factors;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08677398	chr8:58056175	NA	0.51	7.95	0.35	1.45e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.28	-0.36	1.29e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg14773178	chr5:1868261	NA	0.37	7.98	0.35	1.15e-14	Cardiovascular disease risk factors;
LGG	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.44	-0.5	7.43e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19524238	chr7:2802976	GNA12	0.3	7.2	0.32	2.44e-12	Height;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg14668632	chr7:2872130	GNA12	-0.37	-7.63	-0.33	1.31e-13	Height;
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg03709012	chr19:19516395	GATAD2A	-0.85	-16.56	-0.61	1.08e-48	Tonsillectomy;
LGG	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg26384229	chr12:38710491	ALG10B	0.59	10.71	0.45	4.49e-24	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.62	0.63	1.57e-53	Cognitive function;
LGG	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg09307838	chr4:120376055	NA	0.73	12.54	0.5	2.97e-31	Corneal astigmatism;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg22535103	chr8:58192502	C8orf71	-0.87	-11.16	-0.46	9.12e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7717393	0.881	rs10074370	chr5:155765956	A/G	cg04435420	chr5:155754009	SGCD	0.69	8.72	0.38	5.01e-17	Egg allergy;
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.75	-0.3	4.56e-11	Aortic root size;
LGG	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg00531865	chr16:30841666	NA	-0.49	-10.23	-0.43	2.77e-22	Dementia with Lewy bodies;
LGG	cis	rs77633900	0.772	rs2957612	chr15:76703688	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-8.32	-0.36	9.76e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg00990874	chr7:1149470	C7orf50	-0.71	-11.17	-0.46	8.3e-26	Bronchopulmonary dysplasia;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07612497	chr3:48672985	SLC26A6	0.45	6.69	0.3	6.48e-11	Hip circumference;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.88	-0.42	5.26e-21	Monocyte count;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs7586879	0.663	rs6760328	chr2:25077991	T/C	cg04586622	chr2:25135609	ADCY3	0.33	7.74	0.34	6.17e-14	Body mass index;
LGG	trans	rs62458065	0.640	rs28587905	chr7:32533054	C/T	cg00845942	chr12:64062724	DPY19L2	-0.62	-7.75	-0.34	5.68e-14	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs2386661	0.516	rs61832676	chr10:5646337	G/A	cg12223502	chr10:5658492	NA	-0.37	-6.98	-0.31	1.01e-11	Breast cancer;
LGG	cis	rs774359	0.789	rs774349	chr9:27521908	T/A	cg21249376	chr9:27528432	MOBKL2B	0.45	8.47	0.37	3.4e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs17685	0.753	rs7804598	chr7:75702578	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	26.08	0.77	6.23e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4664304	0.802	rs1511224	chr2:160750861	C/T	cg03641300	chr2:160917029	PLA2R1	-0.39	-6.79	-0.3	3.51e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg07636037	chr3:49044803	WDR6	1.03	23.37	0.74	2.22e-80	Parkinson's disease;
LGG	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg22852734	chr6:133119734	C6orf192	1.31	10.34	0.43	1.11e-22	Type 2 diabetes nephropathy;
LGG	trans	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.11	0.43	7.57e-22	Mean corpuscular volume;
LGG	cis	rs2735413	0.564	rs73578755	chr16:78108809	T/A	cg04733911	chr16:78082701	NA	0.57	7.98	0.35	1.19e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6142618	0.562	rs4911548	chr20:30735339	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg02725872	chr8:58115012	NA	-0.78	-10.66	-0.44	7.37e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1805008	0.535	rs4785621	chr16:90130735	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.69	-7.29	-0.32	1.35e-12	Skin colour saturation;
LGG	cis	rs6963495	0.818	rs73190183	chr7:105163022	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg11812906	chr14:75593930	NEK9	-0.44	-7.92	-0.35	1.72e-14	Height;
LGG	cis	rs714515	0.900	rs991790	chr1:172340917	C/G	cg01573306	chr1:172330400	DNM3	0.34	7.44	0.33	4.93e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs2798269	1.000	rs2798269	chr13:22131897	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg15665833	chr6:26285013	NA	0.39	7.66	0.34	1.07e-13	Educational attainment;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.33	0.4	4.52e-19	Lung cancer;
LGG	cis	rs12893597	0.580	rs35068962	chr14:76818804	G/A	cg20290672	chr14:76816747	NA	-0.42	-7.02	-0.31	8.12e-12	Maximal oxygen uptake response;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg27400746	chr16:89904261	SPIRE2	-1.12	-16.9	-0.62	2.99e-50	Skin colour saturation;
LGG	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg09873164	chr1:152488093	CRCT1	0.63	15.32	0.58	3.73e-43	Hair morphology;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg12458913	chr13:53173898	NA	0.6	11.3	0.46	2.62e-26	Lewy body disease;
LGG	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.24	-0.52	3.7e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2797369	1.000	rs2764267	chr6:101679914	C/T	cg27451362	chr6:101846650	GRIK2	0.75	9.9	0.42	4.41e-21	Renal function-related traits (eGRFcrea);
LGG	cis	rs7647973	1.000	rs9871024	chr3:49554241	T/C	cg07636037	chr3:49044803	WDR6	-0.78	-13.99	-0.54	2.54e-37	Menarche (age at onset);
LGG	cis	rs17428076	0.556	rs12692976	chr2:172684403	G/T	cg21435375	chr2:172878103	MAP1D	-0.38	-9.75	-0.41	1.44e-20	Myopia;
LGG	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	26.98	0.78	4.88e-97	Height;
LGG	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.46	-0.33	4.27e-13	Testicular germ cell tumor;
LGG	cis	rs2672886	0.747	rs2672887	chr17:78781804	A/T	cg16015295	chr17:78793479	RPTOR	0.32	7.61	0.33	1.5700000000000001e-13	Airway responsiveness in chronic obstructive pulmonary disease;
LGG	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg05925327	chr15:68127851	NA	0.4	8.22	0.36	2.13e-15	Restless legs syndrome;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg24110177	chr3:50126178	RBM5	0.47	7.57	0.33	2.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7444	0.941	rs2266964	chr22:21958304	A/G	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg04989706	chr14:50066350	PPIL5	-0.58	-9.14	-0.39	2e-18	Carotid intima media thickness;
LGG	cis	rs75920871	0.925	rs61903399	chr11:116942475	A/T	cg20608306	chr11:116969690	SIK3	-0.33	-6.85	-0.3	2.39e-11	Subjective well-being;
LGG	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg01620082	chr3:125678407	NA	-0.64	-6.95	-0.31	1.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9457247	0.967	rs447042	chr6:167405435	C/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs763121	0.815	rs9306328	chr22:39028913	C/T	cg06022373	chr22:39101656	GTPBP1	0.77	15.49	0.58	6.49e-44	Menopause (age at onset);
LGG	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs887829	0.641	rs10179094	chr2:234597825	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.44	-0.37	4.15e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.92	-0.38	1.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09155575	chr17:38084037	ORMDL3	0.48	7.89	0.34	2.15e-14	Cognitive performance;
LGG	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.52	-0.44	2.34e-23	Bladder cancer;
LGG	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg19468946	chr17:37922297	IKZF3	-0.38	-6.86	-0.3	2.2e-11	Self-reported allergy;
LGG	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg07382826	chr16:28625726	SULT1A1	0.43	9.02	0.39	5.03e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.69	0.34	8.87e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.68	0.37	6.56e-17	Obesity-related traits;
LGG	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg01447254	chr11:429437	ANO9	0.45	6.83	0.3	2.75e-11	Body mass index;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.41	0.33	5.99e-13	Renal function-related traits (BUN);
LGG	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg06636001	chr8:8085503	FLJ10661	-0.68	-14.21	-0.55	2.6e-38	Neuroticism;
LGG	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.47	0.33	3.95e-13	Cystic fibrosis severity;
LGG	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg11764359	chr7:65958608	NA	0.63	9.47	0.4	1.4e-19	Aortic root size;
LGG	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg22437258	chr11:111473054	SIK2	0.55	9.51	0.4	1.09e-19	Primary sclerosing cholangitis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13129662	chr17:48227708	PPP1R9B	-0.48	-6.99	-0.31	9.91e-12	Systemic lupus erythematosus;
LGG	cis	rs17221829	0.673	rs4753228	chr11:89369157	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs6840360	0.571	rs72730104	chr4:152543857	A/G	cg25486957	chr4:152246857	NA	-0.49	-8.09	-0.35	5.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08280861	chr8:58055591	NA	-0.64	-8.23	-0.36	1.91e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs9427116	0.502	rs3766922	chr1:154577055	A/C	cg11650704	chr1:154556575	ADAR	-0.5	-9.81	-0.41	8.99e-21	Blood protein levels;
LGG	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.71	-0.38	5.43e-17	Mean corpuscular volume;
LGG	cis	rs10824796	0.638	rs11003120	chr10:54522634	C/T	cg27418851	chr10:54531653	MBL2	-0.46	-7.85	-0.34	2.99e-14	Blood protein levels;
LGG	cis	rs2071403	1.000	rs2298876	chr2:1416037	G/A	cg06500727	chr2:1417164	TPO	-0.49	-9.44	-0.4	1.87e-19	Thyroid peroxidase antibody positivity;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg04703951	chr17:43578652	NA	0.4	8.02	0.35	8.74e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7474896	0.515	rs2505233	chr10:38340265	C/T	cg00409905	chr10:38381863	ZNF37A	-0.47	-7.07	-0.31	5.77e-12	Obesity (extreme);
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.06	0.57	5.58e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.4	-0.36	5.49e-16	Hemoglobin concentration;
LGG	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.23e-56	White matter hyperintensity burden;
LGG	cis	rs9878978	0.964	rs17786885	chr3:2488667	A/T	cg21928760	chr3:2462534	CNTN4	0.39	8.71	0.38	5.28e-17	Blood pressure (smoking interaction);
LGG	cis	rs7188861	0.768	rs529866	chr16:11373320	A/G	cg01510278	chr16:11456238	NA	-0.29	-7.07	-0.31	5.69e-12	HDL cholesterol;
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.35e-16	Aortic root size;
LGG	cis	rs1547553	1	rs1547553	chr18:77926197	C/A	cg14906638	chr18:78001859	PARD6G	-0.91	-13.5	-0.53	3.04e-35	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7617773	0.780	rs11710257	chr3:48373214	T/G	cg11946769	chr3:48343235	NME6	0.7	11.6	0.47	1.66e-27	Coronary artery disease;
LGG	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg24611264	chr11:120008944	TRIM29	0.37	9.52	0.4	1e-19	Stroke (pediatric);
LGG	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg13902645	chr11:5959945	NA	-0.65	-10.08	-0.42	9.39e-22	DNA methylation (variation);
LGG	cis	rs2290159	0.800	rs7636754	chr3:12678725	C/G	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.03e-20	Cholesterol, total;
LGG	cis	rs12477438	0.501	rs4851206	chr2:100068069	T/C	cg23527387	chr2:100056660	REV1	0.43	9.55	0.41	7.51e-20	Chronic sinus infection;
LGG	cis	rs2361710	0.611	rs12451471	chr17:78102517	C/T	cg06718696	chr17:78121285	EIF4A3	0.64	10.54	0.44	1.99e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg22732515	chr19:44031385	ETHE1	0.54	9.41	0.4	2.27e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs9296092	0.517	rs7743064	chr6:33470529	C/T	cg13560919	chr6:33536144	NA	-0.92	-16.58	-0.61	8.08e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.64	0.33	1.3e-13	Obesity-related traits;
LGG	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg11161011	chr14:65562177	MAX	0.63	11.93	0.49	8.18e-29	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.06	-0.31	6.13e-12	HDL cholesterol;
LGG	cis	rs6735179	0.565	rs73182756	chr2:1747826	A/G	cg20570797	chr2:1712800	PXDN	-0.46	-7.99	-0.35	1.1e-14	Response to antipsychotic treatment;
LGG	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg03709012	chr19:19516395	GATAD2A	1.06	17.26	0.63	6.47e-52	Nonalcoholic fatty liver disease;
LGG	cis	rs977987	0.806	rs12930768	chr16:75464500	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs17401966	0.931	rs3748579	chr1:10420937	C/T	cg19773385	chr1:10388646	KIF1B	-0.5	-10.59	-0.44	1.27e-23	Hepatocellular carcinoma;
LGG	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6547631	0.622	rs61191323	chr2:85928631	G/A	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.59e-22	Blood protein levels;
LGG	cis	rs1784581	0.588	rs10945792	chr6:162423484	C/T	cg17173639	chr6:162384350	PARK2	0.64	13.5	0.53	2.92e-35	Itch intensity from mosquito bite;
LGG	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-12.15	-0.49	1.16e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7107174	1.000	rs4945270	chr11:78068216	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.07	0.39	3.39e-18	Morning vs. evening chronotype;
LGG	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg03517284	chr6:25882590	NA	-0.57	-10.77	-0.45	2.8e-24	Intelligence (multi-trait analysis);
LGG	cis	rs72772090	0.710	rs1559085	chr5:96078702	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-8.2	-0.36	2.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18099408	chr3:52552593	STAB1	0.37	7.09	0.31	5.02e-12	Bipolar disorder;
LGG	cis	rs868036	0.958	rs12593813	chr15:68036852	C/T	cg05925327	chr15:68127851	NA	-0.36	-8.4	-0.36	5.63e-16	Restless legs syndrome;
LGG	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg15704280	chr7:45808275	SEPT13	-0.67	-12.1	-0.49	1.84e-29	Height;
LGG	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.1	0.31	4.86e-12	Aortic root size;
LGG	cis	rs9972944	0.756	rs9894010	chr17:63760156	T/G	cg07283582	chr17:63770753	CCDC46	-0.4	-7.78	-0.34	4.68e-14	Total body bone mineral density;
LGG	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg06886374	chr16:1844152	IGFALS	-0.44	-8.01	-0.35	9.55e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6032067	0.929	rs6032063	chr20:43854475	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs7119	0.717	rs12917314	chr15:77818285	T/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs1784581	0.674	rs1789989	chr6:162408138	C/T	cg17173639	chr6:162384350	PARK2	0.66	14.36	0.56	6.09e-39	Itch intensity from mosquito bite;
LGG	cis	rs11072804	1	rs11072804	chr15:79078486	T/G	cg00540400	chr15:79124168	NA	-0.37	-7.1	-0.31	4.73e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg07791516	chr6:150247246	NA	0.36	6.71	0.3	5.6e-11	Lung cancer;
LGG	cis	rs12493885	0.818	rs10935971	chr3:153773945	C/T	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs854765	0.583	rs62064158	chr17:17826935	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs7208859	0.573	rs79505916	chr17:29062326	C/T	cg13385521	chr17:29058706	SUZ12P	0.93	10.78	0.45	2.44e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.31	-0.32	1.19e-12	Lung cancer;
LGG	cis	rs9796	0.870	rs10851402	chr15:41263438	C/T	cg18705301	chr15:41695430	NDUFAF1	0.46	7.96	0.35	1.38e-14	Menopause (age at onset);
LGG	cis	rs6087990	0.584	rs6058897	chr20:31398105	G/T	cg13636640	chr20:31349939	DNMT3B	-0.75	-14.8	-0.57	7.56e-41	Ulcerative colitis;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg12458913	chr13:53173898	NA	0.56	9.97	0.42	2.38e-21	Lewy body disease;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg00800038	chr16:89945340	TCF25	0.6	8.06	0.35	6.76e-15	Skin colour saturation;
LGG	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.64	-0.37	9.35e-17	Joint mobility (Beighton score);
LGG	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.9	-0.54	5.6e-37	Morning vs. evening chronotype;
LGG	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg09624528	chr10:1369823	ADARB2	-0.41	-7.2	-0.32	2.44e-12	Radiation response;
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15320075	chr8:145703422	NA	-0.72	-14.06	-0.55	1.2e-37	Age at first birth;
LGG	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg20891283	chr12:69753455	YEATS4	0.95	21.77	0.71	6.82e-73	Blood protein levels;
LGG	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs9467773	0.873	rs9295698	chr6:26566099	T/A	cg11502198	chr6:26597334	ABT1	0.58	10.02	0.42	1.67e-21	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114210107	chr4:119734491	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs2050392	0.590	rs694346	chr10:30711929	C/T	cg25182066	chr10:30743637	MAP3K8	-0.59	-12.12	-0.49	1.42e-29	Inflammatory bowel disease;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.4	-0.33	6.48e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7077256	0.564	rs17741131	chr10:65201926	T/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2916247	0.865	rs2920467	chr8:93001261	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.68	-0.37	6.62e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.74	14.78	0.57	8.96e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs73198271	0.562	rs79296712	chr8:8659978	G/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.36	0.36	7.34e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg09044154	chr16:88155775	NA	-0.49	-7.44	-0.33	5.06e-13	Menopause (age at onset);
LGG	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs9790314	0.582	rs6796201	chr3:160634313	A/G	cg03342759	chr3:160939853	NMD3	0.43	7.28	0.32	1.45e-12	Morning vs. evening chronotype;
LGG	cis	rs2074193	0.569	rs215360	chr12:47739549	A/C	cg02516419	chr12:47771422	NA	-0.5	-7.34	-0.32	9.55e-13	Migraine with aura;
LGG	cis	rs10078	0.571	rs2241597	chr5:480509	A/G	cg24955955	chr5:415729	AHRR	0.78	10.77	0.45	2.66e-24	Fat distribution (HIV);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.41	7.12	0.31	4.27e-12	Longevity;
LGG	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg10253484	chr15:75165896	SCAMP2	0.44	7.05	0.31	6.39e-12	Systemic lupus erythematosus;
LGG	cis	rs2836950	0.509	rs4816618	chr21:40599529	G/A	cg17971929	chr21:40555470	PSMG1	-0.52	-8.87	-0.38	1.63e-17	Menarche (age at onset);
LGG	cis	rs2816316	1.000	rs2816305	chr1:192524269	A/G	cg02586212	chr1:192544902	RGS1	-0.41	-8.38	-0.36	6.37e-16	Celiac disease;
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg13206674	chr6:150067644	NUP43	-0.4	-6.95	-0.31	1.25e-11	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04912466	chr11:63742028	COX8A	0.42	6.87	0.3	2.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg23188684	chr11:67383651	NA	0.53	8.93	0.38	1.01e-17	Mean corpuscular volume;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24095088	chr6:160210874	MRPL18;TCP1	-0.43	-7.11	-0.31	4.49e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.93	-0.31	1.45e-11	Schizophrenia;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg13397359	chr6:42928475	GNMT	-0.57	-15.71	-0.59	6.84e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-9.58	-0.41	5.77e-20	Schizophrenia;
LGG	cis	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg20368463	chr18:77673604	PQLC1	-0.54	-7.81	-0.34	3.74e-14	Opioid sensitivity;
LGG	cis	rs1595825	0.786	rs74652956	chr2:198754247	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.83	-0.3	2.65e-11	Ulcerative colitis;
LGG	cis	rs17253792	0.545	rs75276278	chr14:56024341	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-9.35	-0.4	3.69e-19	Putamen volume;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06916706	chr16:4465613	CORO7	-0.88	-15.39	-0.58	1.91e-43	Schizophrenia;
LGG	cis	rs4846580	0.598	rs7555048	chr1:219895380	C/T	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.54	0.67	1.86e-62	Platelet count;
LGG	cis	rs3008870	0.959	rs2985816	chr1:67387750	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs11971779	0.648	rs6967836	chr7:139079944	C/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.02	0.31	8.12e-12	Diisocyanate-induced asthma;
LGG	cis	rs2224391	0.737	rs36117780	chr6:5262233	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs4888262	0.526	rs7205992	chr16:74590578	T/A	cg01733217	chr16:74700730	RFWD3	0.82	16.35	0.61	8.85e-48	Testicular germ cell tumor;
LGG	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.82	17.5	0.63	5.08e-53	Menarche (age at onset);
LGG	cis	rs7568458	0.709	rs2592551	chr2:85780131	G/A	cg17127132	chr2:85788382	GGCX	0.52	8.17	0.36	2.88e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg12179176	chr11:130786555	SNX19	0.82	17.09	0.62	3.95e-51	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs12230513	0.732	rs61957763	chr12:55867540	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-10.98	-0.45	4.45e-25	Contrast sensitivity;
LGG	cis	rs9810089	0.843	rs696081	chr3:136047189	C/T	cg12473912	chr3:136751656	NA	-0.41	-6.92	-0.31	1.54e-11	Gestational age at birth (child effect);
LGG	cis	rs9916302	0.706	rs12947506	chr17:37707592	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-15.31	-0.58	4.39e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs425535	0.817	rs1821623	chr4:74804846	C/G	cg01447579	chr4:74847100	PF4	0.54	6.84	0.3	2.56e-11	Blood protein levels;
LGG	trans	rs11976180	1.000	rs6464573	chr7:143748098	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	0.37	6.8	0.3	3.28e-11	Obesity-related traits;
LGG	trans	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg25214090	chr10:38739885	LOC399744	0.57	10.25	0.43	2.44e-22	Corneal astigmatism;
LGG	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg19773385	chr1:10388646	KIF1B	-0.51	-10.52	-0.44	2.29e-23	Hepatocellular carcinoma;
LGG	cis	rs4690686	0.509	rs61482060	chr4:177264465	A/G	cg17059388	chr4:177262070	NA	1.03	24.07	0.75	1.23e-83	Essential tremor;
LGG	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06470251	chr20:60548479	NA	0.49	8.56	0.37	1.67e-16	Body mass index;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.8e-26	Bipolar disorder;
LGG	cis	rs3736594	0.513	rs56725354	chr2:27824168	G/C	cg27432699	chr2:27873401	GPN1	0.56	8.44	0.37	3.97e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs7301016	1.000	rs11520127	chr12:62906965	C/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.27e-17	IgG glycosylation;
LGG	cis	rs9911578	1.000	rs1057068	chr17:56598439	T/C	cg05425664	chr17:57184151	TRIM37	0.59	9.49	0.4	1.18e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.34	-0.36	8.62e-16	Glycated hemoglobin levels;
LGG	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg14673194	chr17:80132900	CCDC57	0.46	8.48	0.37	2.96e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25072359	chr17:41440525	NA	0.51	9.73	0.41	1.7e-20	Menopause (age at onset);
LGG	cis	rs629922	0.671	rs1184748	chr11:114037061	A/G	cg25009965	chr11:114031120	ZBTB16	0.48	6.68	0.3	6.68e-11	Paneth cell defects in Crohn's disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21393713	chr7:69064801	AUTS2	0.59	6.67	0.3	7.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg00376283	chr12:123451042	ABCB9	-0.63	-10.19	-0.43	3.87e-22	Neutrophil percentage of white cells;
LGG	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg05333889	chr7:157238977	NA	-0.5	-9.51	-0.4	1.07e-19	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.5	7.95	0.35	1.47e-14	Renal function-related traits (BUN);
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg00495681	chr13:53174319	NA	0.67	12.75	0.51	4.08e-32	Lewy body disease;
LGG	trans	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.74	0.34	6.38e-14	Eosinophil percentage of white cells;
LGG	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg26396452	chr14:65542826	MAX	-0.51	-10.5	-0.44	2.92e-23	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg12573674	chr2:1569213	NA	-0.66	-10.45	-0.44	4.23e-23	IgG glycosylation;
LGG	cis	rs1978968	1.000	rs11705221	chr22:18443287	T/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg27471124	chr11:109292789	C11orf87	0.48	9.54	0.41	7.91e-20	Schizophrenia;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg19635926	chr16:89946313	TCF25	0.72	8.42	0.36	4.86e-16	Skin colour saturation;
LGG	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs2131877	0.956	rs13315459	chr3:194871995	A/G	cg07250128	chr3:194833983	C3orf21	0.4	7.45	0.33	4.66e-13	Non-small cell lung cancer;
LGG	cis	rs2370759	1.000	rs79578760	chr10:32611264	C/A	cg01819863	chr10:32635814	EPC1	1.1	15.3	0.58	4.45e-43	Sexual dysfunction (female);
LGG	cis	rs367615	0.552	rs10042721	chr5:108713970	C/T	cg17395555	chr5:108820864	NA	-0.71	-11.58	-0.47	2.01e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg08027265	chr7:2291960	NA	0.38	6.73	0.3	5.03e-11	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18000306	chr6:288505	NA	0.61	10.84	0.45	1.47e-24	Menopause (age at onset);
LGG	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg00405596	chr8:11794950	NA	0.65	11.47	0.47	5.62e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg25173405	chr17:45401733	C17orf57	0.51	8.6	0.37	1.24e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg18551225	chr6:44695536	NA	-0.63	-10.25	-0.43	2.32e-22	Total body bone mineral density;
LGG	cis	rs1475718	0.563	rs1041608	chr9:137116205	C/T	cg21243944	chr9:137118148	NA	-0.35	-9.06	-0.39	3.7e-18	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09398166	chr15:74666346	NA	0.51	7.58	0.33	1.96e-13	Gut microbiome composition (summer);
LGG	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg12560992	chr17:57184187	TRIM37	-0.86	-15.1	-0.57	3.6e-42	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.62	0.53	9.62e-36	Bladder cancer;
LGG	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg22920501	chr2:26401640	FAM59B	-0.43	-8.9	-0.38	1.27e-17	Gut microbiome composition (summer);
LGG	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg00677455	chr12:58241039	CTDSP2	0.44	8.04	0.35	7.36e-15	Multiple sclerosis;
LGG	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.85	0.38	1.9e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7781557	0.525	rs114762765	chr7:102595160	G/A	cg18108683	chr7:102477205	FBXL13	-0.53	-8.0	-0.35	1.01e-14	Colorectal adenoma (advanced);
LGG	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg08610935	chr16:1836813	NUBP2	0.43	6.84	0.3	2.46e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17776563	0.853	rs57761829	chr15:89150488	C/G	cg05013243	chr15:89149849	MIR1179	-0.51	-10.59	-0.44	1.34e-23	Thyroid hormone levels;
LGG	trans	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.77	0.34	4.95e-14	Intelligence (multi-trait analysis);
LGG	cis	rs367943	0.547	rs2081926	chr5:113004021	G/T	cg12552261	chr5:112820674	MCC	0.47	7.95	0.35	1.44e-14	Type 2 diabetes;
LGG	cis	rs972578	0.691	rs2179260	chr22:43357072	A/G	cg01576275	chr22:43409880	NA	0.24	7.26	0.32	1.61e-12	Mean platelet volume;
LGG	cis	rs4268898	0.636	rs9636438	chr2:24460566	C/T	cg06627628	chr2:24431161	ITSN2	0.77	12.49	0.5	4.59e-31	Asthma;
LGG	cis	rs9359856	0.564	rs17584108	chr6:90458209	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.69	-0.41	2.52e-20	Bipolar disorder;
LGG	cis	rs9790314	0.690	rs7633857	chr3:160844942	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg23978390	chr7:1156363	C7orf50	0.5	7.93	0.35	1.68e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg16301924	chr13:53314226	LECT1	-0.44	-9.05	-0.39	4.05e-18	Lewy body disease;
LGG	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.92	0.45	7.34e-25	Lung cancer in ever smokers;
LGG	cis	rs2742417	0.603	rs2531755	chr3:45772742	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.38	-0.4	3.04e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg00166722	chr3:10149974	C3orf24	0.57	8.05	0.35	6.97e-15	Alzheimer's disease;
LGG	cis	rs861020	0.959	rs641348	chr1:209992043	A/G	cg05527609	chr1:210001259	C1orf107	0.72	9.73	0.41	1.74e-20	Orofacial clefts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17543885	chr6:151562429	AKAP12	0.46	7.45	0.33	4.53e-13	Gut microbiome composition (summer);
LGG	cis	rs6860806	0.507	rs270606	chr5:131650867	A/G	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Breast cancer;
LGG	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg08700190	chr5:6636046	SRD5A1	-0.32	-6.71	-0.3	5.78e-11	Response to amphetamines;
LGG	cis	rs9308731	0.966	rs6753785	chr2:111923630	T/G	cg26001287	chr2:111877753	BCL2L11	-0.38	-7.71	-0.34	7.68e-14	Chronic lymphocytic leukemia;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19626725	chr5:178986131	RUFY1	-0.42	-6.84	-0.3	2.44e-11	Lung cancer;
LGG	cis	rs6964587	0.626	rs4729014	chr7:91550707	A/G	cg17063962	chr7:91808500	NA	-0.47	-8.76	-0.38	3.66e-17	Breast cancer;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs4818225	0.895	rs2837996	chr21:42626706	C/T	cg21268422	chr21:42620091	BACE2	-0.46	-8.27	-0.36	1.42e-15	Educational attainment;
LGG	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg22771759	chr13:24902376	NA	0.41	6.83	0.3	2.75e-11	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.58	0.67	1.29e-62	Platelet count;
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-7.22	-0.32	2.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg04455712	chr21:45112962	RRP1B	0.49	9.14	0.39	1.9e-18	Mean corpuscular volume;
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.08	-0.6	1.56e-46	Intelligence (multi-trait analysis);
LGG	cis	rs17039065	0.748	rs17039088	chr4:109403528	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.95	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg02002194	chr4:3960332	NA	0.42	7.33	0.32	1.04e-12	Mood instability;
LGG	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg03160526	chr17:80928410	B3GNTL1	0.43	6.92	0.31	1.54e-11	Glycated hemoglobin levels;
LGG	cis	rs6032067	0.777	rs34916007	chr20:43782952	T/G	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg18129748	chr3:49941408	MST1R	-0.21	-6.69	-0.3	6.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.62	0.33	1.43e-13	Total cholesterol levels;
LGG	cis	rs7980687	0.527	rs28533432	chr12:123873242	C/T	cg00376283	chr12:123451042	ABCB9	0.52	9.1	0.39	2.69e-18	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.13e-17	Cognitive test performance;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.21	-0.36	2.18e-15	Obesity-related traits;
LGG	cis	rs9890032	0.570	rs8068504	chr17:29112070	C/A	cg13385521	chr17:29058706	SUZ12P	0.47	7.01	0.31	8.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4740619	0.967	rs1553728	chr9:15667702	G/T	cg14451791	chr9:16040625	NA	-0.4	-10.58	-0.44	1.38e-23	Body mass index;
LGG	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25517755	chr10:38738941	LOC399744	-0.36	-6.83	-0.3	2.71e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg18478394	chr8:109455254	TTC35	-0.42	-8.32	-0.36	9.93e-16	Dupuytren's disease;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg04863758	chr4:1303710	MAEA	0.43	7.33	0.32	1.03e-12	Obesity-related traits;
LGG	cis	rs2371030	1.000	rs2193616	chr2:211573706	C/A	cg18417063	chr2:211583084	NA	-0.63	-11.99	-0.49	4.95e-29	Non-small cell lung cancer;
LGG	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-11.95	-0.49	6.91e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg03264133	chr6:25882463	NA	-0.69	-12.85	-0.51	1.53e-32	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07685180	chr8:600429	NA	1.04	10.7	0.45	5.17e-24	IgG glycosylation;
LGG	cis	rs9815354	0.812	rs73071212	chr3:41981856	C/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg22852734	chr6:133119734	C6orf192	1.15	14.08	0.55	9.91e-38	Type 2 diabetes nephropathy;
LGG	cis	rs6500395	1.000	rs3848321	chr16:48620780	A/T	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg23649088	chr2:200775458	C2orf69	-0.56	-8.84	-0.38	2.06e-17	Schizophrenia;
LGG	cis	rs60180747	1.000	rs112981358	chr15:66653446	G/A	cg07575407	chr15:66541975	MEGF11	0.36	7.4	0.33	6.33e-13	Testicular germ cell tumor;
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.58	-0.37	1.43e-16	Aortic root size;
LGG	trans	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg06521331	chr12:34319734	NA	0.46	7.8	0.34	4.18e-14	Heart rate;
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10802521	chr3:52805072	NEK4	-0.44	-7.4	-0.33	6.42e-13	Bipolar disorder;
LGG	cis	rs523522	0.962	rs4767905	chr12:120930835	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.7	-0.48	6.74e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg17201900	chr20:34330562	RBM39	0.53	7.09	0.31	4.96e-12	Total cholesterol levels;
LGG	cis	rs2742417	0.603	rs6807438	chr3:45778623	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.29	-0.4	6e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg03188948	chr7:1209495	NA	0.6	7.81	0.34	3.84e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19894588	chr14:64061835	NA	0.59	9.96	0.42	2.69e-21	Glioblastoma;Glioma;
LGG	cis	rs10479542	0.766	rs6894980	chr5:178974592	C/T	cg21226059	chr5:178986404	RUFY1	0.45	8.04	0.35	7.34e-15	Lung cancer;
LGG	cis	rs12927351	1.000	rs12927351	chr16:74596618	C/A	cg01733217	chr16:74700730	RFWD3	0.52	6.94	0.31	1.31e-11	Granulocyte percentage of myeloid white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09650667	chr3:139108740	COPB2	0.44	7.64	0.33	1.28e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg24110177	chr3:50126178	RBM5	0.63	11.43	0.47	8.03e-27	Body mass index;
LGG	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.94	-0.31	1.31e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.91	-0.35	1.88e-14	Life satisfaction;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg22283653	chr8:49824208	NA	0.51	9.44	0.4	1.87e-19	Sudden cardiac arrest;
LGG	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg19507638	chr5:93509721	C5orf36	-0.65	-9.12	-0.39	2.27e-18	Diabetic retinopathy;
LGG	cis	rs36051895	0.659	rs57204002	chr9:5062610	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-15.06	-0.57	5.44e-42	Pediatric autoimmune diseases;
LGG	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg04025307	chr7:1156635	C7orf50	-0.46	-8.15	-0.35	3.52e-15	Longevity;Endometriosis;
LGG	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.25	-0.36	1.61e-15	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.09	-0.39	3.02e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.96	-0.31	1.17e-11	Bipolar disorder;
LGG	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg27476859	chr7:2772710	GNA12	-0.53	-10.58	-0.44	1.46e-23	Height;
LGG	cis	rs2978263	0.628	rs17626807	chr8:30310481	C/T	cg05780722	chr8:30327988	RBPMS	-0.33	-6.65	-0.3	8.48e-11	Cognitive performance;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06873684	chr19:4472059	HDGF2	-0.53	-7.8	-0.34	4.13e-14	Systemic lupus erythematosus;
LGG	cis	rs4804815	1.000	rs4804815	chr19:7842669	C/G	cg00970558	chr19:7854469	CLEC4GP1	0.7	10.83	0.45	1.68e-24	Neutrophil count;
LGG	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	14.4	0.56	4.22e-39	Cognitive test performance;
LGG	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.77e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs209489	0.892	rs17543833	chr6:53125994	G/T	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1355223	0.833	rs11032804	chr11:34680598	C/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.77	-0.3	3.96e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg11846333	chr4:119757529	SEC24D	0.85	7.36	0.32	8.48e-13	Cannabis dependence symptom count;
LGG	cis	rs5742933	0.817	rs1233265	chr2:190661116	G/T	cg04003228	chr2:190539410	ANKAR	0.48	7.1	0.31	4.59e-12	Ferritin levels;
LGG	cis	rs6719977	0.569	rs6756258	chr2:42969028	C/T	cg14631114	chr2:43023945	NA	0.45	9.34	0.4	4.22e-19	Hyperactive-impulsive symptoms;
LGG	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12229367	chr17:55822335	NA	0.45	8.63	0.37	9.89e-17	Schizophrenia;
LGG	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Vitiligo;
LGG	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15557168	chr22:42548783	NA	0.38	8.37	0.36	6.76e-16	Cognitive function;
LGG	cis	rs10937275	0.623	rs34421968	chr3:186645080	T/C	cg16751732	chr3:186648392	ST6GAL1	0.7	7.08	0.31	5.4e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg22980697	chr10:16874865	CUBN	0.6	9.66	0.41	2.99e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs747782	0.536	rs6485772	chr11:47728074	A/T	cg15704280	chr7:45808275	SEPT13	0.63	6.85	0.3	2.31e-11	Intraocular pressure;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg11062466	chr8:58055876	NA	0.58	9.01	0.39	5.39e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg13537196	chr9:15553060	C9orf93	0.45	7.85	0.34	3.02e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs10940138	0.774	rs57209938	chr5:67234233	A/G	ch.5.1281357F	chr5:67228439	NA	0.76	13.46	0.53	4.17e-35	Menarche (age at onset);
LGG	cis	rs9868809	0.772	rs9877501	chr3:48718390	C/G	cg00383909	chr3:49044727	WDR6	0.81	10.19	0.43	3.8e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2421770	0.532	rs7130967	chr11:35374008	A/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.64	-0.33	1.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs933688	0.536	rs332537	chr5:90794973	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.76	-10.51	-0.44	2.53e-23	Smoking behavior;
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-13.2	-0.52	5.22e-34	Life satisfaction;
LGG	cis	rs12681288	0.550	rs58295701	chr8:962136	T/C	cg04851639	chr8:1020857	NA	-0.34	-7.15	-0.32	3.41e-12	Schizophrenia;
LGG	trans	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg10756647	chr7:56101905	PSPH	0.76	8.73	0.38	4.71e-17	Diabetic kidney disease;
LGG	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg26384229	chr12:38710491	ALG10B	0.86	18.54	0.65	8.22e-58	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09217309	chr6:150244204	RAET1G	0.4	7.17	0.32	2.93e-12	Testicular germ cell tumor;
LGG	cis	rs12908161	0.920	rs35738019	chr15:85280210	T/C	cg03959625	chr15:84868606	LOC388152	0.5	7.41	0.33	6.23e-13	Schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19125715	chr8:67525489	MYBL1	0.41	7.13	0.31	3.87e-12	Bilirubin levels;
LGG	cis	rs8060686	0.544	rs1124993	chr16:68114626	T/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.91e-12	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.75	-0.68	1.89e-63	Height;
LGG	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-10.56	-0.44	1.74e-23	Total body bone mineral density;
LGG	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg02002194	chr4:3960332	NA	0.38	6.68	0.3	7.05e-11	Triglycerides;
LGG	cis	rs12042938	0.600	rs1094655	chr1:231774362	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	10.38	0.43	7.76e-23	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs11608355	1.000	rs930356	chr12:109852372	T/C	cg19025524	chr12:109796872	NA	-0.49	-9.26	-0.4	7.55e-19	Neuroticism;
LGG	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg17376030	chr22:41985996	PMM1	0.47	7.82	0.34	3.57e-14	Vitiligo;
LGG	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg04851639	chr8:1020857	NA	-0.42	-8.72	-0.38	4.99e-17	Schizophrenia;
LGG	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.35	0.36	7.75e-16	Educational attainment;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg02733842	chr7:1102375	C7orf50	0.43	7.47	0.33	3.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.63	-0.33	1.35e-13	Menarche (age at onset);
LGG	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg07928641	chr1:182991847	LAMC1	0.48	9.73	0.41	1.75e-20	Hypertriglyceridemia;
LGG	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-11.87	-0.48	1.52e-28	Migraine;Coronary artery disease;
LGG	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg25811766	chr13:21894605	NA	-0.56	-7.4	-0.33	6.27e-13	White matter hyperintensity burden;
LGG	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.48	0.4	1.29e-19	Mood instability;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-10.42	-0.44	5.48e-23	Lung cancer;
LGG	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7077256	0.542	rs67586772	chr10:65067003	T/C	cg02276361	chr10:65351566	REEP3	-0.32	-6.65	-0.3	8.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11722228	0.508	rs9732	chr4:10076658	T/C	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.19	-0.43	4.04e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11866815	0.512	rs12719804	chr16:392275	G/A	cg07915516	chr16:377344	AXIN1	-0.49	-10.93	-0.45	6.64e-25	Body mass index;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg18225595	chr11:63971243	STIP1	0.52	10.27	0.43	1.99e-22	Platelet count;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg27532560	chr4:187881888	NA	-0.6	-13.13	-0.52	1.01e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs4704846	0.646	rs6879197	chr5:156502878	G/A	cg12943317	chr5:156479607	HAVCR1	-0.58	-7.94	-0.35	1.59e-14	Blood protein levels;
LGG	cis	rs714515	0.934	rs12404665	chr1:172357433	T/C	cg01573306	chr1:172330400	DNM3	0.33	7.38	0.32	7.17e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	7.84e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11096990	0.634	rs2276888	chr4:39279907	C/T	cg24403649	chr4:39172243	NA	-0.41	-7.4	-0.33	6.39e-13	Cognitive function;
LGG	cis	rs1966248	0.543	rs4895992	chr6:134118263	T/A	cg25632230	chr6:134101081	NA	-0.35	-7.52	-0.33	2.89e-13	Coronary artery disease;
LGG	trans	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.23	0.49	5.31e-30	Type 2 diabetes;
LGG	cis	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg00745463	chr17:30367425	LRRC37B	-0.71	-7.95	-0.35	1.44e-14	Height;
LGG	cis	rs718857	0.508	rs1443829	chr9:106717273	G/C	cg14250997	chr9:106856677	SMC2	0.36	6.86	0.3	2.24e-11	Breast cancer;
LGG	cis	rs9952991	0.566	rs34846641	chr18:12875975	A/G	cg23598886	chr18:12777645	NA	-0.52	-7.5	-0.33	3.18e-13	Inflammatory skin disease;
LGG	cis	rs7727544	0.735	rs274557	chr5:131721204	T/C	cg07395648	chr5:131743802	NA	0.56	13.26	0.52	3.16e-34	Blood metabolite levels;
LGG	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg27426351	chr10:43362370	NA	0.54	7.67	0.34	1.05e-13	Blood protein levels;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg23422044	chr7:1970798	MAD1L1	-0.66	-11.25	-0.46	3.97e-26	Neuroticism;
LGG	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg21535247	chr6:8435926	SLC35B3	0.61	10.29	0.43	1.69e-22	Motion sickness;
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.98	0.62	1.29e-50	Hip circumference adjusted for BMI;
LGG	cis	rs12410462	0.551	rs67511833	chr1:227838514	G/A	cg23173402	chr1:227635558	NA	0.35	6.68	0.3	6.84e-11	Major depressive disorder;
LGG	cis	rs3806843	0.576	rs246036	chr5:140331886	T/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7951870	0.617	rs7932354	chr11:46722221	T/C	cg03339077	chr11:47165057	C11orf49	-0.41	-7.11	-0.31	4.5e-12	Schizophrenia;
LGG	cis	rs10875746	0.669	rs11168516	chr12:48702065	C/T	cg24011408	chr12:48396354	COL2A1	-0.56	-7.29	-0.32	1.34e-12	Longevity (90 years and older);
LGG	cis	rs6909752	0.629	rs4712695	chr6:22556680	C/T	cg13666174	chr6:22585274	NA	0.29	6.72	0.3	5.33e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs6430585	0.591	rs1374330	chr2:136420908	A/C	cg07169764	chr2:136633963	MCM6	1.04	16.91	0.62	2.57e-50	Corneal structure;
LGG	cis	rs7584262	0.573	rs11891679	chr2:42275726	C/G	cg27252766	chr2:42229092	NA	0.49	7.54	0.33	2.52e-13	Bone mineral density;
LGG	cis	rs3815700	1.000	rs3815700	chr19:33093252	T/C	cg02997394	chr19:33096574	ANKRD27	0.87	12.88	0.51	1.13e-32	Eosinophilic esophagitis;
LGG	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg27205649	chr11:78285834	NARS2	-0.43	-7.19	-0.32	2.56e-12	Testicular germ cell tumor;
LGG	cis	rs1847505	0.562	rs11840753	chr13:61451581	C/T	cg25164009	chr13:61490935	NA	0.6	10.29	0.43	1.62e-22	Polychlorinated biphenyl levels;
LGG	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.14e-54	Cognitive function;
LGG	cis	rs1670533	1.000	rs10003009	chr4:1050849	G/A	cg27284194	chr4:1044797	NA	0.55	9.84	0.42	6.95e-21	Recombination rate (females);
LGG	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg03929089	chr4:120376271	NA	0.84	8.7	0.37	5.63e-17	Myopia (pathological);
LGG	cis	rs1978968	0.763	rs8137857	chr22:18465616	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.72	-0.54	3.6e-36	Presence of antiphospholipid antibodies;
LGG	trans	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg02800362	chr5:177631904	HNRNPAB	0.97	12.31	0.5	2.57e-30	Obesity-related traits;
LGG	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.75	-0.48	4.44e-28	Hemoglobin concentration;
LGG	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg24634471	chr8:143751801	JRK	0.52	8.26	0.36	1.57e-15	Schizophrenia;
LGG	cis	rs2346160	0.899	rs206977	chr6:167690746	G/C	cg20683250	chr6:167653907	NA	-0.43	-7.04	-0.31	6.77e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.38	-0.32	7.28e-13	Mean corpuscular volume;
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.14	-0.31	3.74e-12	Triglycerides;
LGG	cis	rs2013441	0.866	rs2526473	chr17:20137478	G/C	cg13482628	chr17:19912719	NA	-0.41	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg01620082	chr3:125678407	NA	-1.04	-10.0	-0.42	1.93e-21	Breast cancer;
LGG	cis	rs8016982	0.674	rs11850714	chr14:81662993	C/G	cg01989461	chr14:81687754	GTF2A1	0.79	19.58	0.67	1.24e-62	Schizophrenia;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs727505	1.000	rs59294613	chr7:124554267	C/A	cg23710748	chr7:124431027	NA	-0.47	-8.94	-0.38	9.36e-18	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16611736	chr16:25123254	LCMT1	0.48	7.94	0.35	1.51e-14	Cognitive performance;
LGG	cis	rs2415984	0.622	rs61993296	chr14:46934216	C/T	cg14871534	chr14:47121158	RPL10L	-0.59	-10.3	-0.43	1.58e-22	Number of children ever born;
LGG	cis	rs13382275	1.000	rs6734008	chr2:963597	C/T	cg10902693	chr2:875509	NA	0.39	6.82	0.3	2.92e-11	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7572733	0.935	rs1518360	chr2:198815303	A/G	cg00792783	chr2:198669748	PLCL1	-0.49	-8.25	-0.36	1.66e-15	Dermatomyositis;
LGG	cis	rs2361710	0.669	rs12940486	chr17:78118569	T/C	cg09238746	chr17:78121135	EIF4A3	-0.59	-10.27	-0.43	1.95e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7737355	0.947	rs10463887	chr5:130776854	C/G	cg06307176	chr5:131281290	NA	-0.54	-9.07	-0.39	3.28e-18	Life satisfaction;
LGG	cis	rs9911578	1.000	rs6503887	chr17:56993320	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.73	0.59	5.9e-45	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27144592	chr16:783916	NARFL	0.4	6.67	0.3	7.14e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11339840	chr1:203596058	ATP2B4	0.46	7.29	0.32	1.35e-12	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.18	-0.39	1.39e-18	Personality dimensions;
LGG	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg06885757	chr1:42089581	HIVEP3	0.49	10.49	0.44	3.08e-23	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9362426	0.608	rs6912875	chr6:88133503	A/T	cg06087457	chr6:88040249	C6orf162;GJB7	-0.46	-8.71	-0.38	5.36e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	7.64	0.33	1.28e-13	Schizophrenia;
LGG	cis	rs1461503	0.512	rs3816621	chr11:122818311	A/G	cg27398637	chr11:122830231	C11orf63	-0.67	-13.29	-0.53	2.3e-34	Menarche (age at onset);
LGG	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	0.899	rs13104539	chr4:135904385	G/A	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22624255	chr19:19779476	ZNF101	0.38	6.65	0.3	8.53e-11	Obesity-related traits;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg22398616	chr13:53314203	LECT1	-0.49	-10.02	-0.42	1.56e-21	Lewy body disease;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs17221829	0.673	rs1962257	chr11:89380737	G/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26422134	chr7:43909318	MRPS24	0.41	6.88	0.3	1.98e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7619833	0.658	rs6551184	chr3:27299001	A/G	cg02860705	chr3:27208620	NA	0.39	7.44	0.33	4.98e-13	Breast cancer;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg02002194	chr4:3960332	NA	0.52	10.35	0.43	1.05e-22	Neuroticism;
LGG	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg00376283	chr12:123451042	ABCB9	0.65	11.29	0.46	2.74e-26	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg01960748	chr1:24522592	NA	-0.52	-7.91	-0.35	1.92e-14	Psoriasis vulgaris;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.24	-0.43	2.45e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.967	rs2299902	chr7:124397814	G/T	cg05630886	chr7:124431682	NA	0.31	7.34	0.32	9.75e-13	Cutaneous malignant melanoma;
LGG	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg26655873	chr3:72818019	SHQ1	-0.4	-8.17	-0.35	3.05e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.23e-18	Motion sickness;
LGG	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg22643751	chr7:855365	UNC84A	0.36	6.92	0.31	1.51e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.44e-16	Life satisfaction;
LGG	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg03929089	chr4:120376271	NA	-0.86	-13.73	-0.54	3.18e-36	Height;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg16606324	chr3:10149918	C3orf24	0.52	6.8	0.3	3.21e-11	Alzheimer's disease;
LGG	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg26031613	chr14:104095156	KLC1	-0.68	-10.83	-0.45	1.61e-24	Reticulocyte count;
LGG	cis	rs12586317	0.547	rs4982234	chr14:35460106	T/A	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs4845570	1.000	rs4845570	chr1:151759104	C/T	cg07092448	chr1:151763213	TDRKH	1.12	18.51	0.65	1.12e-57	Coronary artery disease;
LGG	cis	rs924607	0.583	rs12516251	chr5:608939	C/T	cg07001201	chr5:642380	CEP72	0.6	11.08	0.46	1.79e-25	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.65	-11.49	-0.47	4.77e-27	Renal function-related traits (BUN);
LGG	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg19774624	chr17:42201019	HDAC5	0.64	11.32	0.47	2.24e-26	Total body bone mineral density;
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.6	-0.33	1.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1209950	0.901	rs1209953	chr21:40180383	T/A	cg01359822	chr21:40176597	ETS2	0.36	8.1	0.35	4.92e-15	Non-small cell lung cancer (survival);
LGG	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg27624424	chr6:160112604	SOD2	0.65	9.27	0.4	6.84e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2692947	0.637	rs1168967	chr2:96826016	A/G	cg22654517	chr2:96458247	NA	0.4	8.76	0.38	3.82e-17	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7828089	0.504	rs4872505	chr8:22337996	A/T	cg12081754	chr8:22256438	SLC39A14	0.7	13.42	0.53	6.74e-35	Verbal declarative memory;
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg08499158	chr17:42289980	UBTF	-0.57	-10.8	-0.45	2.05e-24	Total body bone mineral density;
LGG	cis	rs4243830	0.571	rs60256927	chr1:6614747	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	11.97	0.49	5.74e-29	Body mass index;
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg14675211	chr2:100938903	LONRF2	0.65	11.63	0.48	1.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.664	rs12344629	chr9:5109208	C/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.26	-0.58	6.81e-43	Pediatric autoimmune diseases;
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.67	-0.41	2.77e-20	Retinal vascular caliber;
LGG	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg26597838	chr10:835615	NA	0.75	10.44	0.44	4.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs5769765	1.000	rs5769765	chr22:50271176	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7917772	0.582	rs10883738	chr10:104321721	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.63	0.48	1.35e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-9.91	-0.42	4.14e-21	Schizophrenia;
LGG	cis	rs9914988	0.943	rs11658884	chr17:27132742	A/G	cg20469991	chr17:27169893	C17orf63	0.59	7.28	0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs638893	0.685	rs486651	chr11:118649859	A/T	cg13782932	chr11:118662891	DDX6	0.37	6.8	0.3	3.25e-11	Vitiligo;
LGG	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg03060546	chr3:49711283	APEH	0.74	13.33	0.53	1.57e-34	Resting heart rate;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg22105103	chr4:187893119	NA	0.58	11.12	0.46	1.22e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.93	0.45	7.04e-25	Personality dimensions;
LGG	cis	rs6028335	0.867	rs67114385	chr20:37696401	C/T	cg16355469	chr20:37678765	NA	0.56	7.1	0.31	4.82e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg18032289	chr17:61959525	GH2	-0.38	-6.68	-0.3	6.93e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9309711	0.961	rs11890651	chr2:3482796	T/G	cg10845886	chr2:3471009	TTC15	-0.66	-13.43	-0.53	5.79e-35	Neurofibrillary tangles;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg18402987	chr7:1209562	NA	0.49	8.15	0.35	3.39e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.67	-0.34	9.89e-14	Menopause (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06322639	chr15:80883928	ARNT2	0.42	6.68	0.3	6.66e-11	Pancreatic cancer;
LGG	cis	rs7712401	0.601	rs13155907	chr5:122334633	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	trans	rs9650657	0.571	rs2409672	chr8:10598780	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.43	-0.33	5.42e-13	Neuroticism;
LGG	cis	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg15596359	chr8:11213517	TDH	-0.41	-8.62	-0.37	1.04e-16	Retinal vascular caliber;
LGG	cis	rs61897795	0.628	rs174579	chr11:61605613	C/T	cg19610905	chr11:61596333	FADS2	-0.69	-10.16	-0.43	5e-22	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg08885076	chr2:99613938	TSGA10	-0.43	-7.87	-0.34	2.58e-14	Chronic sinus infection;
LGG	cis	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg04990556	chr1:26633338	UBXN11	-0.68	-13.93	-0.54	4.33e-37	Obesity-related traits;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg19168338	chr16:4465731	CORO7	-1.14	-24.86	-0.76	2.82e-87	Schizophrenia;
LGG	cis	rs4750440	0.614	rs7921866	chr10:14030161	C/T	cg27542038	chr10:14027202	FRMD4A	-0.77	-15.27	-0.58	6.46e-43	Adiponectin levels;
LGG	cis	rs986417	0.892	rs57925468	chr14:60816129	G/A	cg27398547	chr14:60952738	C14orf39	-0.72	-6.92	-0.31	1.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.19	-0.39	1.33e-18	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07564927	chr11:65479383	KAT5	0.43	6.65	0.3	8.13e-11	Gut microbiome composition (summer);
LGG	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg09818912	chr17:20140352	CYTSB	0.31	7.3	0.32	1.28e-12	Schizophrenia;
LGG	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg06360820	chr2:242988706	NA	-0.92	-12.01	-0.49	4.04e-29	Obesity-related traits;
LGG	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg09461388	chr22:46763229	CELSR1	-0.67	-7.05	-0.31	6.38e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10883969	0.504	rs805701	chr10:105819956	G/A	cg13448625	chr10:105845238	COL17A1	-0.4	-8.89	-0.38	1.36e-17	Preeclampsia;
LGG	cis	rs9831754	0.906	rs9869812	chr3:78385679	G/A	cg06138941	chr3:78371609	NA	-0.9	-18.86	-0.66	2.89e-59	Calcium levels;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.69	-0.3	6.32e-11	Lung cancer;
LGG	cis	rs240764	0.612	rs6929748	chr6:100929394	C/T	cg21058520	chr6:100914733	NA	-0.48	-8.48	-0.37	3.06e-16	Neuroticism;
LGG	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg11861562	chr11:117069780	TAGLN	-0.25	-6.92	-0.31	1.49e-11	Blood protein levels;
LGG	cis	rs7715811	1.000	rs7446025	chr5:13773800	T/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.95	-0.42	2.94e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg12165864	chr7:66369176	NA	-0.58	-9.39	-0.4	2.8e-19	Corneal structure;
LGG	cis	rs11190604	1.000	rs9420785	chr10:102240451	C/G	cg07570687	chr10:102243282	WNT8B	0.44	7.75	0.34	5.83e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg24642439	chr20:33292090	TP53INP2	0.78	12.78	0.51	3.12e-32	Coronary artery disease;
LGG	cis	rs807669	0.525	rs2282684	chr22:19184244	C/T	cg02655711	chr22:19163373	SLC25A1	0.51	9.24	0.39	9.31e-19	Metabolite levels;
LGG	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.64	8.7	0.37	5.73e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8133932	0.521	rs1625244	chr21:47364499	C/T	cg11214348	chr21:47283868	PCBP3	-0.42	-7.33	-0.32	1.07e-12	Schizophrenia;
LGG	cis	rs270601	0.710	rs4705852	chr5:131602807	A/G	cg07395648	chr5:131743802	NA	-0.36	-7.37	-0.32	7.76e-13	Acylcarnitine levels;
LGG	cis	rs4665809	1.000	rs1470097	chr2:26312840	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.22	-0.52	4.3e-34	Gut microbiome composition (summer);
LGG	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.89e-22	Cannabis dependence symptom count;
LGG	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs193541	0.632	rs26370	chr5:122235192	T/C	cg19412675	chr5:122181750	SNX24	0.55	8.67	0.37	7.41e-17	Glucose homeostasis traits;
LGG	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg14019146	chr3:50243930	SLC38A3	0.54	11.79	0.48	3.19e-28	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs2689330	chr3:153929990	T/C	cg17054900	chr3:154042577	DHX36	0.91	10.03	0.42	1.43e-21	Coronary artery disease;
LGG	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg25309564	chr22:51001381	C22orf41	-0.61	-9.58	-0.41	5.76e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg11871910	chr12:69753446	YEATS4	1.04	28.61	0.8	2.12e-104	Cerebrospinal fluid biomarker levels;
LGG	trans	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg02030672	chr11:45687055	CHST1	0.56	10.14	0.43	6.01e-22	Obesity-related traits;
LGG	cis	rs7851660	0.967	rs12348304	chr9:100611233	T/C	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.58e-40	Strep throat;
LGG	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-13.07	-0.52	1.82e-33	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg08975724	chr8:8085496	FLJ10661	0.45	8.8	0.38	2.73e-17	Mood instability;
LGG	cis	rs3789045	1.000	rs61817485	chr1:204595592	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.4	-8.13	-0.35	3.96e-15	Educational attainment (college completion);
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.94	-0.42	3.17e-21	Bipolar disorder;
LGG	cis	rs9354308	0.838	rs9363453	chr6:66544051	G/A	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19063972	chr13:95364908	SOX21	0.45	6.94	0.31	1.32e-11	Gut microbiome composition (summer);
LGG	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-9.36	-0.4	3.5e-19	Self-reported allergy;
LGG	cis	rs208520	0.770	rs2153941	chr6:66885521	A/T	cg07460842	chr6:66804631	NA	-0.95	-17.33	-0.63	3.31e-52	Exhaled nitric oxide output;
LGG	trans	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg18187862	chr3:45730750	SACM1L	0.43	7.01	0.31	8.21e-12	Primary sclerosing cholangitis;
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg08835221	chr22:38071607	LGALS1	0.27	7.48	0.33	3.89e-13	Fat distribution (HIV);
LGG	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg12463550	chr7:65579703	CRCP	-0.79	-8.51	-0.37	2.4e-16	Diabetic kidney disease;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.47	-0.44	3.69e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg01145232	chr6:150245071	RAET1G	0.48	8.72	0.38	5.03e-17	Lung cancer;
LGG	cis	rs10861342	1.000	rs7136344	chr12:105528268	A/G	cg23923672	chr12:105501055	KIAA1033	0.83	7.85	0.34	2.96e-14	IgG glycosylation;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.6	8.99	0.39	6.54e-18	Renal function-related traits (BUN);
LGG	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg21453758	chr17:80185943	SLC16A3	0.34	7.41	0.33	6.03e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4774899	0.902	rs12909696	chr15:57572133	C/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.58e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05025164	chr4:1340916	KIAA1530	0.54	9.7	0.41	2.17e-20	Longevity;
LGG	cis	rs4851266	0.966	rs13018640	chr2:100821545	T/C	cg21926883	chr2:100939477	LONRF2	-0.43	-7.86	-0.34	2.72e-14	Educational attainment;
LGG	cis	rs13177180	0.523	rs256980	chr5:114902807	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.32	-6.83	-0.3	2.74e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs2071403	0.901	rs11211644	chr2:1404495	C/T	cg06500727	chr2:1417164	TPO	-0.53	-10.1	-0.42	8.45e-22	Thyroid peroxidase antibody positivity;
LGG	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg03788504	chr6:150331562	NA	-0.59	-13.38	-0.53	9.14e-35	Alopecia areata;
LGG	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18760324	chr15:49103180	CEP152	0.41	6.76	0.3	4.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg23758822	chr17:41437982	NA	-0.84	-15.22	-0.58	1.04e-42	Menopause (age at onset);
LGG	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg05096777	chr10:104283225	SUFU	0.32	6.99	0.31	9.48e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	20.74	0.69	4.82e-68	Homoarginine levels;
LGG	cis	rs11971779	0.938	rs11981688	chr7:139088895	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	10.27	0.43	1.96e-22	Diisocyanate-induced asthma;
LGG	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.25	0.32	1.75e-12	Bladder cancer;
LGG	cis	rs6772849	0.930	rs4857914	chr3:128350684	C/T	cg08795948	chr3:128337044	NA	0.68	11.48	0.47	5.25e-27	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	7.29	0.32	1.34e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg18681998	chr4:17616180	MED28	0.83	18.26	0.65	1.74e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg02951883	chr7:2050386	MAD1L1	0.74	15.29	0.58	5.3800000000000004e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	11.27	0.46	3.34e-26	Bone mineral density;
LGG	cis	rs9815354	0.951	rs17060961	chr3:41763711	A/G	cg03022575	chr3:42003672	ULK4	0.6	7.59	0.33	1.72e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg03342759	chr3:160939853	NMD3	-0.56	-9.53	-0.4	9.08e-20	Morning vs. evening chronotype;
LGG	cis	rs698813	0.604	rs1988663	chr2:44492753	C/T	cg00619915	chr2:44497795	NA	-0.61	-8.82	-0.38	2.33e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs4851266	0.898	rs10496346	chr2:100853267	A/G	cg21926883	chr2:100939477	LONRF2	0.47	8.48	0.37	2.95e-16	Educational attainment;
LGG	cis	rs752010	1.000	rs752010	chr1:42093015	C/T	cg16096631	chr1:42092165	HIVEP3	0.7	18.47	0.65	1.79e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17125944	0.686	rs2025634	chr14:53336017	C/T	cg00686598	chr14:53173677	PSMC6	-0.64	-6.86	-0.3	2.17e-11	Alzheimer's disease (late onset);
LGG	cis	rs773506	0.655	rs10991796	chr9:93930243	G/T	cg14446406	chr9:93919335	NA	0.63	11.21	0.46	5.66e-26	Type 2 diabetes nephropathy;
LGG	cis	rs7602441	0.521	rs78292972	chr2:14766128	G/C	cg06545361	chr2:14773388	FAM84A	0.78	7.11	0.31	4.45e-12	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.58	-0.44	1.48e-23	Aortic root size;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.6	0.37	1.24e-16	Lung cancer;
LGG	cis	rs3780378	0.875	rs7861599	chr9:5067298	C/T	cg02405213	chr9:5042618	JAK2	-0.53	-9.57	-0.41	6.68e-20	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	7.84	0.34	3.15e-14	Renal function-related traits (BUN);
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2119480	0.762	rs418935	chr13:111309267	C/G	cg16216153	chr13:111290848	CARKD	0.35	6.82	0.3	2.88e-11	Diastolic blood pressure;
LGG	cis	rs11239187	0.530	rs11239141	chr10:45063228	A/G	cg03916630	chr10:45065415	NA	-0.35	-8.18	-0.36	2.74e-15	Body mass index;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg21171335	chr12:122356390	WDR66	-0.29	-8.56	-0.37	1.64e-16	Mean corpuscular volume;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03276167	chr6:86388360	SNHG5;SNORD50B;SNORD50A	0.37	6.73	0.3	4.95e-11	Body mass index;
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg27219399	chr15:67835830	MAP2K5	0.33	7.21	0.32	2.34e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg01448562	chr3:133502909	NA	-0.74	-13.66	-0.54	6.4e-36	Iron status biomarkers;
LGG	cis	rs16854884	0.657	rs35959290	chr3:143725566	T/A	cg06585982	chr3:143692056	C3orf58	0.57	9.48	0.4	1.38e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg23306229	chr2:178417860	TTC30B	-0.71	-8.49	-0.37	2.79e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01534423	chr17:18965556	NA	0.46	7.68	0.34	9.57e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs240764	0.621	rs6925840	chr6:101209386	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-7.9	-0.34	2.11e-14	Neuroticism;
LGG	cis	rs7647973	1.000	rs11710434	chr3:49346130	T/C	cg07636037	chr3:49044803	WDR6	0.76	13.37	0.53	1.07e-34	Menarche (age at onset);
LGG	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg06046430	chr4:77819534	ANKRD56	0.54	11.05	0.46	2.37e-25	Emphysema distribution in smoking;
LGG	cis	rs13191362	0.935	rs67889271	chr6:163045753	T/G	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.67	0.48	9.62e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg09361094	chr10:834503	NA	-0.28	-7.35	-0.32	9.18e-13	Survival in rectal cancer;
LGG	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg03929089	chr4:120376271	NA	0.68	7.46	0.33	4.37e-13	Axial length;
LGG	cis	rs3790515	1.000	rs12145375	chr1:151785229	T/C	cg07092448	chr1:151763213	TDRKH	-0.89	-10.38	-0.43	7.9e-23	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs4671458	0.656	rs4671518	chr2:63820219	T/G	cg17519650	chr2:63277830	OTX1	-0.55	-7.52	-0.33	2.81e-13	Subjective well-being;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs2051211	0.947	rs60479981	chr3:38568611	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-9.44	-0.4	1.82e-19	QRS duration;
LGG	cis	rs9486719	0.857	rs2983897	chr6:97033780	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-12.41	-0.5	9.59e-31	Migraine;Coronary artery disease;
LGG	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg14598338	chr9:96623480	NA	-0.54	-9.64	-0.41	3.65e-20	DNA methylation (variation);
LGG	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg10167378	chr1:228756711	NA	0.57	8.1	0.35	5.08e-15	Chronic lymphocytic leukemia;
LGG	cis	rs6754311	0.689	rs192822	chr2:136682274	A/T	cg07169764	chr2:136633963	MCM6	0.77	12.9	0.51	9.6e-33	Mosquito bite size;
LGG	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg23057051	chr16:89984268	MC1R	0.37	7.11	0.31	4.35e-12	Vitiligo;
LGG	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg24692254	chr21:30365293	RNF160	-0.63	-11.03	-0.46	2.76e-25	Cognitive test performance;
LGG	cis	rs4662945	0.525	rs10174479	chr2:130296287	A/C	cg05962382	chr2:130345044	NA	-0.44	-7.83	-0.34	3.43e-14	Response to cytidine analogues (gemcitabine);
LGG	cis	rs7937612	0.861	rs4245213	chr11:120273597	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.58	-0.5	2.02e-31	Intraocular pressure;
LGG	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg15454534	chr1:248569605	OR2T1	0.39	6.89	0.3	1.87e-11	Common traits (Other);
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.8e-15	Obesity-related traits;
LGG	cis	rs3740909	1.000	rs74545052	chr11:125885001	C/A	cg24940576	chr11:125904314	CDON	-0.48	-7.53	-0.33	2.63e-13	Blood protein levels;
LGG	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg04455712	chr21:45112962	RRP1B	0.54	10.27	0.43	2.04e-22	Mean corpuscular volume;
LGG	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg16141378	chr3:129829833	LOC729375	0.33	7.07	0.31	5.69e-12	Myopia (pathological);
LGG	cis	rs1580019	0.844	rs4723159	chr7:32512804	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.87	16.07	0.6	1.61e-46	Cognitive ability;
LGG	cis	rs986417	0.551	rs4901991	chr14:61065025	T/C	cg27398547	chr14:60952738	C14orf39	0.76	7.05	0.31	6.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs9463078	0.764	rs9369513	chr6:44789476	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.55	-0.37	1.84e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9611519	1.000	rs9611510	chr22:41569124	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-8.49	-0.37	2.89e-16	Neuroticism;
LGG	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg04455712	chr21:45112962	RRP1B	0.5	8.93	0.38	1.02e-17	Mean corpuscular volume;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg11062466	chr8:58055876	NA	0.61	10.13	0.43	6.43e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1983891	1.000	rs2104506	chr6:41533579	C/A	cg20194872	chr6:41519635	FOXP4	0.58	9.92	0.42	3.61e-21	Prostate cancer;
LGG	cis	rs12282928	1.000	rs1503169	chr11:48271287	C/T	cg26585981	chr11:48327164	OR4S1	-0.44	-7.23	-0.32	1.96e-12	Migraine - clinic-based;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.85	-0.38	1.8e-17	Triglycerides;
LGG	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg24253500	chr15:84953950	NA	0.6	11.36	0.47	1.56e-26	Schizophrenia;
LGG	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-11.07	-0.46	2.04e-25	Neuroticism;
LGG	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.87	0.54	8.08e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Iron status biomarkers;
LGG	cis	rs6882076	1.000	rs6882076	chr5:156390297	T/C	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.58	-0.47	2.03e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg19223190	chr17:80058835	NA	0.43	8.4	0.36	5.62e-16	Life satisfaction;
LGG	cis	rs8180040	0.726	rs4234465	chr3:47026885	C/G	cg27129171	chr3:47204927	SETD2	0.78	14.29	0.55	1.24e-38	Colorectal cancer;
LGG	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg24565620	chr2:194026	NA	0.64	9.77	0.41	1.3e-20	Blood protein levels;
LGG	cis	rs239198	0.602	rs11758174	chr6:101322595	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.16	0.32	3.21e-12	Menarche (age at onset);
LGG	cis	rs7647973	0.769	rs11130181	chr3:49109919	G/A	cg06212747	chr3:49208901	KLHDC8B	0.49	7.43	0.33	5.33e-13	Menarche (age at onset);
LGG	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg01181863	chr3:195395398	SDHAP2	0.48	7.35	0.32	8.79e-13	Mean corpuscular volume;
LGG	cis	rs1256061	0.630	rs1256030	chr14:64747170	A/G	cg23250157	chr14:64679961	SYNE2	0.37	6.77	0.3	3.82e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs17767294	0.541	rs72845044	chr6:27572479	G/A	cg10122326	chr6:28072925	NA	0.88	6.78	0.3	3.61e-11	Parkinson's disease;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.43	-0.33	5.15e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.08	-0.57	4.37e-42	Platelet count;
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg11984989	chr7:158649758	WDR60	0.94	20.24	0.69	1.02e-65	Height;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg05025164	chr4:1340916	KIAA1530	0.43	7.16	0.32	3.27e-12	Obesity-related traits;
LGG	cis	rs990171	0.721	rs6543115	chr2:102927641	C/G	cg05295703	chr2:102895712	NA	-0.65	-11.89	-0.48	1.29e-28	Lymphocyte counts;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03000485	chr8:144973638	NA	0.36	6.95	0.31	1.27e-11	Electrocardiographic conduction measures;
LGG	cis	rs9463078	0.774	rs7451423	chr6:45241343	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.41	-0.36	5.01e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.21	-0.32	2.35e-12	Total body bone mineral density;
LGG	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg16386425	chr10:429943	DIP2C	-0.46	-9.31	-0.4	5.04e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.15	0.32	3.31e-12	Lung cancer;
LGG	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg08847335	chr10:891726	LARP4B	-0.49	-8.88	-0.38	1.46e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs9354308	0.932	rs1938061	chr6:66545581	A/C	cg07460842	chr6:66804631	NA	-0.51	-8.74	-0.38	4.19e-17	Metabolite levels;
LGG	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg08250081	chr4:10125330	NA	0.37	7.19	0.32	2.62e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.98	0.35	1.13e-14	Triglycerides;
LGG	cis	rs1056053	0.514	rs3099269	chr6:166572242	T/A	cg11088901	chr6:166572345	T	-0.52	-9.95	-0.42	2.88e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs7980799	0.649	rs7972688	chr12:33653477	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-12.22	-0.49	6.01e-30	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7580658	0.637	rs4580338	chr2:127974937	T/C	cg10021288	chr2:128175891	PROC	-0.6	-12.11	-0.49	1.65e-29	Protein C levels;
LGG	cis	rs818427	0.826	rs153565	chr5:112250376	A/T	cg07820702	chr5:112228657	REEP5	-0.36	-6.71	-0.3	5.73e-11	Total body bone mineral density;
LGG	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16516785	chr7:100291438	NA	0.44	6.76	0.3	4.15e-11	Gut microbiome composition (summer);
LGG	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg22633769	chr20:60982531	CABLES2	0.5	6.89	0.3	1.83e-11	Colorectal cancer;
LGG	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg25358565	chr5:93447407	FAM172A	1.29	15.45	0.58	1.02e-43	Diabetic retinopathy;
LGG	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg14228332	chr4:119757509	SEC24D	0.92	9.41	0.4	2.34e-19	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg15971980	chr6:150254442	NA	0.45	8.31	0.36	1.1e-15	Lung cancer;
LGG	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg19723775	chr5:179050963	HNRNPH1	0.45	7.48	0.33	3.86e-13	Lung cancer;
LGG	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg04657146	chr19:12876947	HOOK2	0.46	7.57	0.33	2.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-11.53	-0.47	3.36e-27	Prudent dietary pattern;
LGG	cis	rs968451	0.789	rs1569501	chr22:39683534	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	11.36	0.47	1.46e-26	Primary biliary cholangitis;
LGG	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg06636001	chr8:8085503	FLJ10661	0.42	7.33	0.32	1.04e-12	Retinal vascular caliber;
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg14675211	chr2:100938903	LONRF2	0.63	11.2	0.46	6.23e-26	Intelligence (multi-trait analysis);
LGG	trans	rs2898857	0.504	rs35822701	chr17:47422317	C/T	cg11430096	chr6:110968061	CDK19	-0.48	-8.2	-0.36	2.42e-15	Cancer;
LGG	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg24846343	chr22:24311635	DDTL	0.47	8.38	0.36	6.36e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-11.56	-0.47	2.53e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26991812	chr17:27621123	NUFIP2	0.45	6.69	0.3	6.56e-11	Gut microbiome composition (summer);
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg06925179	chr17:43578568	NA	0.43	10.12	0.43	6.76e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg19913688	chr11:428466	ANO9	-0.68	-8.31	-0.36	1.1e-15	Body mass index;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg05313129	chr8:58192883	C8orf71	-0.6	-7.6	-0.33	1.72e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg22437258	chr11:111473054	SIK2	0.51	8.89	0.38	1.38e-17	Primary sclerosing cholangitis;
LGG	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg04731861	chr2:219085781	ARPC2	0.45	10.93	0.45	6.6e-25	Colorectal cancer;
LGG	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.79	14.96	0.57	1.51e-41	Hip circumference adjusted for BMI;
LGG	cis	rs9487094	0.689	rs9487064	chr6:109667763	G/A	cg16315928	chr6:109776240	MICAL1	0.44	7.83	0.34	3.47e-14	Height;
LGG	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg09324608	chr17:30823087	MYO1D	0.31	7.6	0.33	1.68e-13	Schizophrenia;
LGG	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg02269571	chr22:50332266	NA	-0.58	-8.98	-0.39	6.88e-18	Schizophrenia;
LGG	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg04842962	chr6:43655489	MRPS18A	1.08	22.96	0.73	1.9e-78	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.46	-0.37	3.41e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2249694	1.000	rs4363513	chr10:135355534	A/G	cg20169779	chr10:135381914	SYCE1	0.51	7.83	0.34	3.38e-14	Obesity-related traits;
LGG	cis	rs2916247	0.954	rs13252280	chr8:93088151	C/T	cg10183463	chr8:93005414	RUNX1T1	0.37	7.55	0.33	2.27e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg25214090	chr10:38739885	LOC399744	0.63	11.19	0.46	6.6e-26	Corneal astigmatism;
LGG	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg20573242	chr4:122745356	CCNA2	-0.46	-8.04	-0.35	7.35e-15	Type 2 diabetes;
LGG	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487051	0.676	rs1608042	chr6:109595631	G/A	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.01e-14	Reticulocyte fraction of red cells;
LGG	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg24112000	chr20:60950667	NA	-0.37	-7.44	-0.33	5.01e-13	Colorectal cancer;
LGG	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.58	-0.41	5.77e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-8.59	-0.37	1.31e-16	Diabetic retinopathy;
LGG	cis	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg24375607	chr4:120327624	NA	0.53	9.01	0.39	5.51e-18	Corneal astigmatism;
LGG	cis	rs9834373	0.853	rs2314126	chr3:78474658	A/C	cg06138941	chr3:78371609	NA	-0.52	-9.33	-0.4	4.58e-19	Protein quantitative trait loci;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15984612	chr8:145514624	BOP1;HSF1	0.44	7.15	0.32	3.34e-12	Cognitive performance;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg14893161	chr1:205819251	PM20D1	-0.56	-8.96	-0.38	8.27e-18	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg22705602	chr4:152727874	NA	-0.32	-7.71	-0.34	7.91e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.13	0.43	6.49e-22	Schizophrenia;
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19524238	chr7:2802976	GNA12	0.37	8.74	0.38	4.21e-17	Height;
LGG	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg00149659	chr3:10157352	C3orf10	0.57	8.12	0.35	4.33e-15	Alzheimer's disease;
LGG	cis	rs1461503	0.511	rs4129007	chr11:122811812	T/C	cg27398637	chr11:122830231	C11orf63	-0.67	-12.98	-0.52	4.4e-33	Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg00434991	chr10:134504552	INPP5A	0.38	6.8	0.3	3.17e-11	Menarche (age at onset);
LGG	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg13385794	chr1:248469461	NA	0.43	7.5	0.33	3.22e-13	Common traits (Other);
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs2115630	0.936	rs8033459	chr15:85253258	C/T	cg12501888	chr15:85177176	SCAND2	-0.43	-7.08	-0.31	5.45e-12	P wave terminal force;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	7.71	0.34	7.84e-14	Schizophrenia;
LGG	cis	rs2742540	0.503	rs2653556	chr11:8906636	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.53	-11.74	-0.48	5.08e-28	Hematocrit;
LGG	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg14784868	chr12:69753453	YEATS4	-0.68	-10.59	-0.44	1.35e-23	Response to diuretic therapy;
LGG	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg10494973	chr17:80897199	TBCD	0.38	6.75	0.3	4.44e-11	Breast cancer;
LGG	cis	rs11250097	0.501	rs2409665	chr8:10736233	G/C	cg21775007	chr8:11205619	TDH	-0.47	-7.16	-0.32	3.21e-12	Neuroticism;
LGG	cis	rs2742417	1.000	rs2251954	chr3:45731784	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.44	-0.33	5e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs787274	1.000	rs4979155	chr9:115560134	G/A	cg13803584	chr9:115635662	SNX30	-0.61	-7.72	-0.34	7.03e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.8	0.48	2.7e-28	Tonsillectomy;
LGG	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg11366901	chr6:160182831	ACAT2	1.06	17.1	0.62	3.67e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs67460515	0.563	rs35914913	chr3:160826561	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-11.85	-0.48	1.71e-28	Parkinson's disease;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.24	-0.36	1.73e-15	Skin colour saturation;
LGG	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg18854424	chr1:2615690	NA	-0.35	-7.45	-0.33	4.48e-13	Ulcerative colitis;
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg06565975	chr8:143823917	SLURP1	-0.56	-13.58	-0.53	1.32e-35	Urinary tract infection frequency;
LGG	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.55	-0.37	1.74e-16	Retinal vascular caliber;
LGG	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg05425664	chr17:57184151	TRIM37	-0.59	-9.6	-0.41	4.98e-20	Intelligence (multi-trait analysis);
LGG	cis	rs258892	0.841	rs34665	chr5:72158396	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	trans	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.17	-0.43	4.6e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg22232500	chr2:134024266	NCKAP5	0.57	8.1	0.35	5.06e-15	Bipolar disorder;
LGG	cis	rs2415984	0.558	rs754960	chr14:46962969	C/T	cg14871534	chr14:47121158	RPL10L	0.56	9.92	0.42	3.74e-21	Number of children ever born;
LGG	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs10267417	0.603	rs10226787	chr7:19946542	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	trans	rs1941687	0.702	rs10460050	chr18:31413671	G/T	cg27147174	chr7:100797783	AP1S1	-0.53	-8.99	-0.39	6.4e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.6	-0.33	1.66e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7177699	0.525	rs56076311	chr15:79115120	A/G	cg00540400	chr15:79124168	NA	-0.54	-11.46	-0.47	6.13e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.95	10.48	0.44	3.21e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6708331	0.517	rs12999042	chr2:70366811	C/T	cg01613454	chr2:70366299	NA	0.54	10.87	0.45	1.12e-24	Obesity-related traits;
LGG	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17808011	chr17:36761852	SRCIN1	0.59	9.13	0.39	2.17e-18	Gut microbiome composition (summer);
LGG	cis	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg09044154	chr16:88155775	NA	-0.48	-7.41	-0.33	5.92e-13	Menopause (age at onset);
LGG	cis	rs908922	0.887	rs6587688	chr1:152529622	C/T	cg09873164	chr1:152488093	CRCT1	-0.53	-10.89	-0.45	9.23e-25	Hair morphology;
LGG	cis	rs2688608	0.836	rs2675668	chr10:75636148	G/A	cg10168709	chr10:75599394	CAMK2G	-0.34	-6.66	-0.3	7.63e-11	Inflammatory bowel disease;
LGG	cis	rs730566	1.000	rs730566	chr3:48487048	G/T	cg07636037	chr3:49044803	WDR6	-0.56	-9.06	-0.39	3.73e-18	Prion diseases;
LGG	cis	rs3736594	0.513	rs62138968	chr2:27824485	C/G	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4315565	0.541	rs11126214	chr2:69272116	C/T	cg13358873	chr2:69271042	ANTXR1	0.49	6.73	0.3	5.18e-11	Height;
LGG	cis	rs7727544	0.735	rs274566	chr5:131715011	A/G	cg07395648	chr5:131743802	NA	0.56	13.27	0.53	2.68e-34	Blood metabolite levels;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg10360139	chr7:1886902	MAD1L1	-0.44	-7.68	-0.34	9.46e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg03315344	chr16:75512273	CHST6	0.5	9.98	0.42	2.27e-21	Dupuytren's disease;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg08866814	chr16:89351500	ANKRD11	0.36	6.72	0.3	5.41e-11	Body fat percentage;
LGG	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14159747	chr11:113255604	NA	0.29	7.76	0.34	5.59e-14	Neuroticism;
LGG	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg03929089	chr4:120376271	NA	0.88	15.45	0.58	9.51e-44	Height;
LGG	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.47e-25	Corneal astigmatism;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.79	-0.34	4.36e-14	Neuroticism;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg10852096	chr15:79043040	NA	-0.3	-8.65	-0.37	8.41e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs500492	0.542	rs2573148	chr16:1073372	C/T	cg05970874	chr16:1061053	NA	-0.52	-6.68	-0.3	6.87e-11	Polycystic ovary syndrome;
LGG	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg17108064	chr15:78857060	CHRNA5	-0.43	-8.91	-0.38	1.2e-17	Sudden cardiac arrest;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17318645	chr14:77787612	GSTZ1;POMT2	0.43	7.03	0.31	7.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03576123	chr11:487126	PTDSS2	-1.22	-15.03	-0.57	7.37e-42	Body mass index;
LGG	cis	rs62025270	0.632	rs7163838	chr15:86207621	T/C	cg25843651	chr15:86329602	KLHL25	0.55	8.35	0.36	7.77e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg06521331	chr12:34319734	NA	0.51	8.72	0.38	5.09e-17	Resting heart rate;
LGG	cis	rs9863	0.828	rs12311848	chr12:124486851	A/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.27	-0.32	1.59e-12	White blood cell count;
LGG	cis	rs4731207	0.698	rs4279518	chr7:124528086	G/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg07061783	chr6:25882402	NA	0.4	7.02	0.31	7.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2729354	0.953	rs1846567	chr11:57357593	T/C	cg24343310	chr11:57249947	NA	0.36	6.68	0.3	7.02e-11	Blood protein levels;
LGG	cis	rs11630290	0.592	rs11634436	chr15:64158394	T/G	cg12036633	chr15:63758958	NA	0.48	6.88	0.3	1.97e-11	Iris characteristics;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg12293132	chr7:23720668	C7orf46	0.35	8.25	0.36	1.61e-15	Schizophrenia;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.27	-0.32	1.58e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4731207	0.596	rs1842615	chr7:124582871	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	3.82e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3798221	1.000	rs34620808	chr6:161015406	C/T	cg04181478	chr6:161122748	PLG	0.44	6.77	0.3	3.99e-11	Lipoprotein (a) levels;
LGG	cis	rs6750047	0.625	rs336036	chr2:38261143	C/T	cg07380506	chr2:38303506	CYP1B1	-0.42	-6.93	-0.31	1.43e-11	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.889	rs1043402	chr22:38879688	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	16.75	0.61	1.41e-49	Menopause (age at onset);
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg05368731	chr17:41323189	NBR1	0.88	17.42	0.63	1.24e-52	Menopause (age at onset);
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14893161	chr1:205819251	PM20D1	0.88	20.51	0.69	5.55e-67	Menarche (age at onset);
LGG	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg15704280	chr7:45808275	SEPT13	0.78	9.03	0.39	4.79e-18	Axial length;
LGG	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg25664220	chr3:72788482	NA	-0.33	-9.01	-0.39	5.46e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6598955	0.543	rs881578	chr1:26536141	G/A	cg04990556	chr1:26633338	UBXN11	0.72	10.74	0.45	3.41e-24	Obesity-related traits;
LGG	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg09173681	chr1:183549694	NCF2	0.38	8.58	0.37	1.46e-16	Systemic lupus erythematosus;
LGG	cis	rs7508	0.612	rs35305827	chr8:17918335	C/T	cg18067069	chr8:17937731	ASAH1	0.37	8.49	0.37	2.9e-16	Atrial fibrillation;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02071572	chr4:1403502	NA	0.38	6.92	0.31	1.48e-11	Longevity;
LGG	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg05791153	chr7:19748676	TWISTNB	0.57	8.61	0.37	1.18e-16	Thyroid stimulating hormone;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.33	-0.36	8.99e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14829155	chr15:31115871	NA	-0.58	-10.13	-0.43	6.47e-22	Huntington's disease progression;
LGG	cis	rs972578	0.715	rs13433641	chr22:43268009	A/G	cg01576275	chr22:43409880	NA	-0.22	-6.72	-0.3	5.5e-11	Mean platelet volume;
LGG	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-10.56	-0.44	1.68e-23	Dental caries;
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg16885296	chr6:26284938	NA	0.37	7.75	0.34	5.85e-14	Educational attainment;
LGG	trans	rs2840044	1.000	rs11653310	chr17:33893378	C/G	cg19694781	chr19:47549865	TMEM160	-0.54	-9.02	-0.39	4.94e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.64	-0.41	3.7799999999999997e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.06	-0.31	5.96e-12	Uric acid levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09658342	chr2:70476000	TIA1	-0.41	-6.94	-0.31	1.33e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9814567	1.000	rs6439484	chr3:134249899	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg08677398	chr8:58056175	NA	0.46	7.11	0.31	4.54e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7011049	1.000	rs72640857	chr8:53839067	T/A	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs1707322	1.000	rs4641257	chr1:46353589	G/A	cg03146154	chr1:46216737	IPP	0.54	10.41	0.44	5.88e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.31	6.66e-12	Intelligence (multi-trait analysis);
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg17734273	chr15:78292508	TBC1D2B	-0.34	-8.33	-0.36	9.32e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs4740619	0.810	rs10756691	chr9:15699078	C/T	cg14451791	chr9:16040625	NA	0.33	8.44	0.37	3.98e-16	Body mass index;
LGG	cis	rs367943	0.712	rs13188946	chr5:112722855	C/T	cg12552261	chr5:112820674	MCC	0.57	10.35	0.43	1.02e-22	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10484885	0.757	rs72912535	chr6:90159762	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.03	-0.31	7.65e-12	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7928758	0.832	rs56007027	chr11:134270955	G/A	cg15243474	chr11:134282918	B3GAT1	1.09	14.95	0.57	1.59e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7818345	0.712	rs13261442	chr8:19352333	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.44	10.59	0.44	1.27e-23	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs870825	0.655	rs2310104	chr4:185619967	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs432925	0.576	rs11866815	chr16:387867	C/T	cg26913058	chr16:419975	MRPL28	-0.52	-8.19	-0.36	2.64e-15	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.91e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg07959490	chr17:80112427	CCDC57	0.45	8.88	0.38	1.53e-17	Life satisfaction;
LGG	cis	rs6918586	0.681	rs198831	chr6:26116996	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.61	-0.41	4.69e-20	Schizophrenia;
LGG	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs13392177	0.647	rs6718220	chr2:219066518	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.8	-0.34	4.17e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs1459104	0.925	rs34245100	chr11:55211191	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.67	0.3	7.28e-11	Body mass index;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg02725872	chr8:58115012	NA	-1.05	-15.42	-0.58	1.35e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg11502198	chr6:26597334	ABT1	0.59	10.11	0.43	7.78e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg07701084	chr6:150067640	NUP43	0.7	13.39	0.53	9e-35	Lung cancer;
LGG	cis	rs4780401	0.728	rs7188511	chr16:11773743	G/T	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.1	-0.31	4.86e-12	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs896854	0.846	rs13254283	chr8:95914103	G/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.24	-0.36	1.78e-15	Type 2 diabetes;
LGG	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg14088196	chr11:70211408	PPFIA1	0.92	12.97	0.52	4.93e-33	Coronary artery disease;
LGG	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg02466173	chr16:30829666	NA	-0.39	-6.81	-0.3	2.96e-11	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.41e-14	Lung cancer;
LGG	cis	rs13260300	0.688	rs7008779	chr8:75531121	A/T	cg22993706	chr8:75542856	NA	0.41	7.94	0.35	1.54e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg23029597	chr12:123009494	RSRC2	-0.83	-15.67	-0.59	1.01e-44	Body mass index;
LGG	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.16	0.39	1.74e-18	Lung cancer in ever smokers;
LGG	cis	rs735539	0.521	rs2762991	chr13:21394071	T/A	cg04906043	chr13:21280425	IL17D	-0.5	-7.88	-0.34	2.43e-14	Dental caries;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	3.08e-12	Bipolar disorder;
LGG	cis	rs3087591	0.639	rs7223589	chr17:29728284	T/C	cg24425628	chr17:29625626	OMG;NF1	0.56	11.41	0.47	9.3e-27	Hip circumference;
LGG	cis	rs4808199	0.843	rs10402308	chr19:19657500	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	8.39	0.36	5.94e-16	Nonalcoholic fatty liver disease;
LGG	cis	rs16837677	1.000	rs76734003	chr1:156738676	G/T	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs72781680	0.566	rs6713865	chr2:23899807	A/G	cg08917208	chr2:24149416	ATAD2B	0.59	7.05	0.31	6.43e-12	Lymphocyte counts;
LGG	cis	rs9325144	0.505	rs7138977	chr12:38642109	G/A	cg13010199	chr12:38710504	ALG10B	0.64	12.92	0.51	7.74e-33	Morning vs. evening chronotype;
LGG	cis	rs9296092	0.538	rs62405942	chr6:33517346	G/A	cg13560919	chr6:33536144	NA	-1.05	-21.67	-0.71	2.07e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg04703951	chr17:43578652	NA	0.4	8.05	0.35	6.88e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12519773	0.526	rs7714485	chr5:92515301	A/C	cg18783429	chr5:92414398	NA	0.31	7.63	0.33	1.36e-13	Migraine;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22613905	chr2:240039481	HDAC4	0.41	6.71	0.3	5.6e-11	Pancreatic cancer;
LGG	cis	rs46522	0.585	rs79049364	chr17:47014991	T/A	cg16584676	chr17:46985605	UBE2Z	0.49	8.25	0.36	1.69e-15	Coronary heart disease;
LGG	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-10.95	-0.45	5.82e-25	Pulmonary function;
LGG	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg00599393	chr8:22457479	C8orf58	-0.48	-8.88	-0.38	1.43e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12517041	1.000	rs1428621	chr5:23283431	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs2153535	0.580	rs1414346	chr6:8471574	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs10193935	0.792	rs222472	chr2:42662911	C/T	cg27598129	chr2:42591480	NA	-0.66	-9.87	-0.42	5.72e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs490234	0.718	rs2819622	chr9:128173724	T/C	cg14078157	chr9:128172775	NA	-0.5	-9.58	-0.41	5.92e-20	Mean arterial pressure;
LGG	trans	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs11945232	1.000	rs28406846	chr4:88343468	C/G	cg23841344	chr4:88312519	HSD17B11	-0.51	-9.07	-0.39	3.39e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg19539972	chr4:7069911	GRPEL1	0.68	9.93	0.42	3.32e-21	Monocyte percentage of white cells;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.44	0.33	4.98e-13	Lung cancer;
LGG	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.44e-33	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.4e-12	Lung cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg12891197	chr22:38902464	DDX17	-0.34	-6.77	-0.3	3.92e-11	Iris color (L* coordinate);
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.7	0.37	6.02e-17	Schizophrenia;
LGG	cis	rs2070488	0.699	rs13078966	chr3:38517914	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.78	0.57	8.79e-41	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs9359856	0.510	rs3736984	chr6:90408589	C/T	cg13799429	chr6:90582589	CASP8AP2	0.85	12.87	0.51	1.25e-32	Bipolar disorder;
LGG	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.05	0.46	2.36e-25	Mood instability;
LGG	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.53	0.33	2.75e-13	Schizophrenia;
LGG	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg17809284	chr5:56205270	C5orf35	-0.68	-10.86	-0.45	1.25e-24	Initial pursuit acceleration;
LGG	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.62	0.37	1.08e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs250677	1.000	rs190378	chr5:148434275	G/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.78	-0.34	4.7e-14	Breast cancer;
LGG	cis	rs4148883	0.651	rs10020052	chr4:100086331	C/G	cg12011299	chr4:100065546	ADH4	0.4	8.54	0.37	1.9e-16	Alcohol dependence;
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.51	0.56	1.38e-39	Platelet count;
LGG	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	10.65	0.44	7.55e-24	Menopause (age at onset);
LGG	cis	rs34172651	0.917	rs200538	chr16:24735736	C/T	cg02428538	chr16:24856791	SLC5A11	0.44	7.52	0.33	2.89e-13	Intelligence (multi-trait analysis);
LGG	cis	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	trans	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg02002194	chr4:3960332	NA	0.42	7.54	0.33	2.51e-13	Mood instability;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs2933343	0.630	rs75824035	chr3:128652985	T/C	cg25356066	chr3:128598488	ACAD9	0.45	6.83	0.3	2.61e-11	IgG glycosylation;
LGG	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg14541582	chr5:601475	NA	-0.69	-10.64	-0.44	8.45e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs11158026	0.722	rs2840268	chr14:55471983	C/G	cg04306507	chr14:55594613	LGALS3	0.31	6.93	0.31	1.38e-11	Parkinson's disease;
LGG	cis	rs981844	0.816	rs62325145	chr4:154725687	G/C	cg14289246	chr4:154710475	SFRP2	0.72	11.65	0.48	1.12e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs56283067	0.886	rs12205657	chr6:44680615	C/T	cg20913747	chr6:44695427	NA	-0.64	-11.41	-0.47	9.37e-27	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17859882	chr6:58287694	GUSBL2	0.42	6.97	0.31	1.08e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6450176	1.000	rs3776703	chr5:53305259	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24454698	chr1:24126991	GALE	0.48	7.37	0.32	8.13e-13	Gut microbiome composition (summer);
LGG	trans	rs3942852	0.869	rs4752806	chr11:48118199	G/C	cg03929089	chr4:120376271	NA	-0.64	-8.09	-0.35	5.14e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1008375	0.966	rs4235389	chr4:17696280	A/G	cg02297831	chr4:17616191	MED28	0.42	7.81	0.34	3.76e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10489202	1.000	rs34058770	chr1:168057399	C/A	cg24449463	chr1:168025552	DCAF6	-0.63	-10.13	-0.43	6.49e-22	Schizophrenia;
LGG	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg21095983	chr6:86352623	SYNCRIP	0.56	9.89	0.42	4.87e-21	Smooth-surface caries;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg14004847	chr7:1930337	MAD1L1	-0.58	-10.22	-0.43	2.95e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg11441379	chr12:63026424	NA	0.7	9.71	0.41	2.14e-20	IgG glycosylation;
LGG	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	14.39	0.56	4.68e-39	Cognitive test performance;
LGG	cis	rs73086581	0.838	rs11907416	chr20:4005619	G/C	cg02187196	chr20:3869020	PANK2	0.71	9.64	0.41	3.71e-20	Response to antidepressants in depression;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg23985595	chr17:80112537	CCDC57	0.48	9.58	0.41	5.74e-20	Life satisfaction;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg19673125	chr6:150240577	RAET1G	0.35	8.7	0.37	5.78e-17	Lung cancer;
LGG	cis	rs4330281	0.669	rs11128838	chr3:17697368	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.25	-0.32	1.78e-12	Schizophrenia;
LGG	cis	rs4650994	0.935	rs2811290	chr1:178572978	C/T	cg12486710	chr1:178512616	C1orf220	-0.43	-8.74	-0.38	4.29e-17	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs12410462	0.591	rs72632830	chr1:227728897	G/T	cg23173402	chr1:227635558	NA	0.38	7.27	0.32	1.52e-12	Major depressive disorder;
LGG	cis	rs778371	0.723	rs6710294	chr2:233579634	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.89	0.48	1.18e-28	Schizophrenia;
LGG	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg08200770	chr17:80723486	TBCD	-0.47	-8.39	-0.36	5.91e-16	Glycated hemoglobin levels;
LGG	cis	rs6882076	0.925	rs4704826	chr5:156392082	C/A	cg12943317	chr5:156479607	HAVCR1	-0.66	-11.88	-0.48	1.37e-28	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg02733842	chr7:1102375	C7orf50	0.42	7.36	0.32	8.55e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4780401	0.755	rs2868981	chr16:11765518	T/C	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.24	-0.32	1.88e-12	Rheumatoid arthritis;
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.57	-0.41	6.65e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg10523679	chr1:76189770	ACADM	-0.84	-14.32	-0.55	8.85e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg08564027	chr20:61660810	NA	1.02	25.08	0.76	2.73e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg04568710	chr12:38710424	ALG10B	-0.4	-8.26	-0.36	1.5e-15	Morning vs. evening chronotype;
LGG	cis	rs911555	0.662	rs4906322	chr14:103879032	A/G	cg24130564	chr14:104152367	KLC1	0.38	6.93	0.31	1.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02071572	chr4:1403502	NA	0.39	6.7	0.3	6.18e-11	Longevity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08870933	chr16:71879943	ATXN1L	0.62	7.09	0.31	5.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	10.5	0.44	2.77e-23	Obesity-related traits;
LGG	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg12386194	chr3:101231763	SENP7	0.47	8.31	0.36	1.06e-15	Colorectal cancer;
LGG	cis	rs9534288	0.797	rs1134071	chr13:46562935	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.25	-0.52	3.41e-34	Blood protein levels;
LGG	cis	rs17227506	0.704	rs6530649	chr8:13448112	A/G	cg03566418	chr8:13424080	C8orf48	-0.62	-9.89	-0.42	4.84e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6772849	1.000	rs9839508	chr3:128310794	A/T	cg08795948	chr3:128337044	NA	-0.52	-8.49	-0.37	2.87e-16	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs7107174	1.000	rs2511180	chr11:77937255	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.2	-0.32	2.45e-12	Testicular germ cell tumor;
LGG	cis	rs72925845	0.519	rs72916819	chr17:76425874	A/C	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg10167378	chr1:228756711	NA	0.56	8.08	0.35	5.53e-15	Chronic lymphocytic leukemia;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24596836	chr15:52472025	GNB5	0.46	6.7	0.3	6.06e-11	Hip circumference;
LGG	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.22e-32	Uric acid levels;
LGG	cis	rs2288073	0.965	rs6545335	chr2:24422011	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-10.65	-0.44	7.94e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.59	0.37	1.3e-16	Bipolar disorder;
LGG	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg19980929	chr12:42632907	YAF2	-0.35	-7.94	-0.35	1.56e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7091068	0.518	rs1409337	chr10:95439822	T/C	cg20715218	chr10:95462985	C10orf4	0.67	12.07	0.49	2.44e-29	Urinary tract infection frequency;
LGG	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	7.13	0.31	3.87e-12	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	7.36e-37	Prudent dietary pattern;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26748024	chr6:42420298	TRERF1	0.4	6.69	0.3	6.64e-11	Hip circumference;
LGG	cis	rs910187	0.605	rs2235907	chr20:45809652	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.22	-0.39	1.09e-18	Migraine;
LGG	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg09359103	chr1:154839909	KCNN3	-0.52	-10.83	-0.45	1.69e-24	Prostate cancer;
LGG	trans	rs11875185	0.510	rs17692986	chr18:55621594	C/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.71	-0.38	5.52e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs1348850	0.598	rs12616259	chr2:178503803	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-9.59	-0.41	5.4e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg11040518	chr10:102331378	NA	-0.4	-7.2	-0.32	2.5e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg18854424	chr1:2615690	NA	0.33	7.29	0.32	1.37e-12	Ulcerative colitis;
LGG	cis	rs7011049	0.778	rs7843363	chr8:53874753	C/T	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs9880211	0.800	rs13314357	chr3:136487559	A/G	cg21827317	chr3:136751795	NA	-0.47	-6.85	-0.3	2.39e-11	Body mass index;Height;
LGG	trans	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.71	-0.3	5.67e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6838801	0.892	rs28515950	chr4:77575939	A/G	cg17476223	chr4:77663285	SHROOM3	0.37	6.77	0.3	3.82e-11	Cleft lip with or without cleft palate;
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg11814155	chr7:99998594	ZCWPW1	0.64	9.84	0.42	7.1e-21	Platelet count;
LGG	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.11e-11	Blood metabolite levels;
LGG	cis	rs9815354	0.812	rs7652506	chr3:42060235	C/T	cg03022575	chr3:42003672	ULK4	0.64	7.76	0.34	5.57e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs701145	0.537	rs1713847	chr3:153791107	C/A	cg12800244	chr3:153838788	SGEF	0.81	8.82	0.38	2.32e-17	Coronary artery disease;
LGG	trans	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.78	-0.3	3.71e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.75	-0.69	4.13e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg00405596	chr8:11794950	NA	0.44	6.99	0.31	9.79e-12	Systolic blood pressure;
LGG	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg04149295	chr10:70884716	VPS26A	0.48	7.09	0.31	4.99e-12	Left atrial antero-posterior diameter;
LGG	cis	rs7843479	0.965	rs17616085	chr8:21857267	C/T	cg17168535	chr8:21777572	XPO7	0.59	9.52	0.4	9.69e-20	Mean corpuscular volume;
LGG	cis	rs11971779	0.646	rs58682779	chr7:139084712	C/T	cg07862535	chr7:139043722	LUC7L2	0.67	10.13	0.43	6.34e-22	Diisocyanate-induced asthma;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg13206674	chr6:150067644	NUP43	0.4	8.61	0.37	1.19e-16	Testicular germ cell tumor;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs16976116	0.851	rs13380400	chr15:55490518	A/G	cg11288833	chr15:55489084	RSL24D1	0.56	7.7	0.34	8.12e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6988985	0.594	rs4513950	chr8:143941391	C/T	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.66	-12.07	-0.49	2.35e-29	Obesity-related traits;
LGG	cis	rs11083475	0.714	rs1471432	chr19:39260282	G/A	cg07403899	chr19:39283540	NA	-0.23	-6.78	-0.3	3.61e-11	Heart rate;
LGG	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.76	-0.34	5.64e-14	Psoriasis;
LGG	cis	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.11	-0.35	4.44e-15	Height;
LGG	cis	rs6763768	0.705	rs312483	chr3:53524051	A/G	cg16894138	chr3:53270350	TKT	-0.44	-7.87	-0.34	2.47e-14	Bacterial meningitis;
LGG	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14373873	chr11:113211441	TTC12	0.45	9.51	0.4	1.03e-19	Neuroticism;
LGG	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg15704280	chr7:45808275	SEPT13	0.77	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.28	0.43	1.81e-22	Height;
LGG	cis	rs4262150	0.544	rs72795336	chr5:151903469	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.76	-0.48	4.13e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00290607	chr11:67383545	NA	0.66	12.88	0.51	1.19e-32	Mean corpuscular volume;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.97	0.35	1.24e-14	Renal function-related traits (BUN);
LGG	cis	rs9513627	1.000	rs2147625	chr13:100140645	G/T	cg15490075	chr13:100150979	NA	0.61	6.66	0.3	7.93e-11	Obesity-related traits;
LGG	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14829155	chr15:31115871	NA	0.67	11.32	0.47	2.19e-26	Huntington's disease progression;
LGG	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg27124370	chr19:33622961	WDR88	0.45	7.95	0.35	1.48e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10991814	0.920	rs79799877	chr9:94036245	G/A	cg14446406	chr9:93919335	NA	-0.72	-8.12	-0.35	4.4e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-14.24	-0.55	2.01e-38	Dental caries;
LGG	cis	rs17739794	0.517	rs4439155	chr8:781047	C/T	cg01971667	chr8:817044	NA	-0.35	-6.92	-0.31	1.53e-11	Clozapine-induced cytotoxicity;
LGG	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.29	-0.4	6.25e-19	Systemic lupus erythematosus;
LGG	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs2562456	0.833	rs2562487	chr19:21651382	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.99	-0.35	1.08e-14	Pain;
LGG	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg09408571	chr1:101003634	GPR88	0.34	8.11	0.35	4.47e-15	Breast cancer;
LGG	trans	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.26e-19	Morning vs. evening chronotype;
LGG	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg04362960	chr10:104952993	NT5C2	0.56	10.58	0.44	1.38e-23	Arsenic metabolism;
LGG	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.52	-0.71	1.05e-71	Height;
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.53	-0.33	2.64e-13	Skin colour saturation;
LGG	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg13009111	chr11:71350975	NA	0.35	7.64	0.33	1.25e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7945718	0.967	rs7927470	chr11:12748899	A/T	cg25843174	chr11:12811716	TEAD1	0.41	8.35	0.36	7.92e-16	Educational attainment (years of education);
LGG	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.75	-0.34	5.72e-14	Mean corpuscular hemoglobin;
LGG	cis	rs7267979	0.966	rs2257712	chr20:25264910	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03576123	chr11:487126	PTDSS2	-1.24	-14.62	-0.56	4.53e-40	Body mass index;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg12395012	chr8:11607386	GATA4	0.4	6.94	0.31	1.35e-11	Neuroticism;
LGG	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.43	-0.36	4.41e-16	Mean corpuscular volume;
LGG	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.83e-22	Axial length;
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg13770153	chr20:60521292	NA	1.09	20.03	0.68	1.02e-64	Obesity-related traits;
LGG	cis	rs2066819	1.000	rs117683816	chr12:56638267	T/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg02574844	chr11:5959923	NA	0.52	9.16	0.39	1.71e-18	DNA methylation (variation);
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg15971980	chr6:150254442	NA	0.45	8.57	0.37	1.6e-16	Lung cancer;
LGG	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg01191920	chr7:158217561	PTPRN2	-0.78	-17.75	-0.64	3.86e-54	Obesity-related traits;
LGG	cis	rs975722	0.663	rs11975114	chr7:117096645	C/A	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.26	-0.4	7.88e-19	Coronary artery disease;
LGG	cis	rs9368481	0.761	rs9357030	chr6:26985026	G/T	cg18867708	chr6:26865862	GUSBL1	-0.47	-7.81	-0.34	3.89e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.805	rs10185599	chr2:42283886	A/G	cg27252766	chr2:42229092	NA	0.46	7.61	0.33	1.56e-13	Hypospadias;
LGG	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	trans	rs72991	0.639	rs297527	chr11:121243468	G/C	cg27192990	chr6:129479024	LAMA2	-0.55	-8.39	-0.36	5.73e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs35146811	0.586	rs10267231	chr7:99595480	T/C	cg22906224	chr7:99728672	NA	0.55	8.74	0.38	4.37e-17	Coronary artery disease;
LGG	cis	rs4722166	0.597	rs1554606	chr7:22768707	T/G	cg05265849	chr7:22767390	IL6	0.41	8.14	0.35	3.67e-15	Lung cancer;
LGG	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.87	-0.42	5.4e-21	Carotid intima media thickness;
LGG	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.09	0.52	1.52e-33	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.7.2194789F	chr7:102039835	PRKRIP1	0.45	7.57	0.33	2.03e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs11235843	0.602	rs1830069	chr11:73433229	C/G	cg18195628	chr11:73498948	MRPL48	-0.53	-7.5	-0.33	3.3e-13	Hand grip strength;
LGG	cis	rs9457247	0.935	rs427824	chr6:167403918	T/G	cg07741184	chr6:167504864	NA	0.32	7.15	0.32	3.34e-12	Crohn's disease;
LGG	cis	rs55883249	1.000	rs62119429	chr2:9743585	G/C	cg23886495	chr2:9695866	ADAM17	0.66	9.57	0.41	6.56e-20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-15.05	-0.57	6.12e-42	Schizophrenia;
LGG	cis	rs12472274	0.817	rs12621791	chr2:239104061	G/A	cg17459225	chr2:239074497	NA	0.79	13.19	0.52	6.15e-34	Phospholipid levels (plasma);
LGG	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.4	0.36	5.38e-16	Neuroticism;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.53	10.39	0.43	7.38e-23	Longevity;
LGG	cis	rs7940866	0.809	rs11222410	chr11:130833994	A/G	cg12179176	chr11:130786555	SNX19	0.75	14.04	0.55	1.52e-37	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg22089800	chr15:90895588	ZNF774	-0.68	-12.4	-0.5	1.1e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.67	-0.3	7.1e-11	Mood instability;
LGG	cis	rs17384381	0.953	rs12138621	chr1:85783970	T/C	cg16011679	chr1:85725395	C1orf52	0.63	10.38	0.43	8.01e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg05313129	chr8:58192883	C8orf71	-0.47	-8.06	-0.35	6.5e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg07148914	chr20:33460835	GGT7	0.55	9.18	0.39	1.46e-18	Height;
LGG	cis	rs858239	0.601	rs1558313	chr7:23156079	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.15e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs875971	1.000	rs12698523	chr7:65968113	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.07e-11	Total body bone mineral density;
LGG	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg24812749	chr6:127587940	RNF146	0.95	15.82	0.59	2.29e-45	Breast cancer;
LGG	cis	rs6763768	0.719	rs3755815	chr3:53527293	T/G	cg16894138	chr3:53270350	TKT	0.4	7.09	0.31	5.02e-12	Bacterial meningitis;
LGG	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-16.62	-0.61	5.51e-49	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg12310025	chr6:25882481	NA	0.48	8.89	0.38	1.36e-17	Blood metabolite levels;
LGG	cis	rs2117029	1.000	rs10875913	chr12:49419308	T/C	cg24176009	chr12:49580217	TUBA1A	0.44	8.14	0.35	3.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3008870	0.959	rs2985826	chr1:67412918	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.35	0.74	2.84e-80	Lymphocyte percentage of white cells;
LGG	trans	rs57046232	0.552	rs1887412	chr20:6340856	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.92	0.31	1.51e-11	Colorectal cancer;
LGG	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.83e-22	Motion sickness;
LGG	cis	rs2742417	1.000	rs9821974	chr3:45784963	T/C	cg04837898	chr3:45731254	SACM1L	-0.35	-6.82	-0.3	2.9e-11	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	6.2e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2652834	1.000	rs2729781	chr15:63404265	T/A	cg05507819	chr15:63340323	TPM1	0.61	8.32	0.36	1.03e-15	HDL cholesterol;
LGG	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg02187348	chr16:89574699	SPG7	0.51	7.74	0.34	6.12e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs7523273	0.597	rs4844619	chr1:207960708	C/T	cg22525895	chr1:207977042	MIR29B2	-0.44	-6.68	-0.3	6.7e-11	Schizophrenia;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg04166393	chr7:2884313	GNA12	0.45	8.61	0.37	1.13e-16	Height;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg08621203	chr6:150244597	RAET1G	0.46	7.82	0.34	3.61e-14	Lung cancer;
LGG	cis	rs858239	0.601	rs10278700	chr7:23160529	T/C	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.15e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2013441	1.000	rs2526472	chr17:20137888	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs2282802	0.685	rs2337082	chr5:139649201	G/A	cg26211634	chr5:139558579	C5orf32	0.34	7.52	0.33	2.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs77633900	0.772	rs2460161	chr15:76640430	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-8.03	-0.35	8.2e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10870270	1.000	rs11146324	chr10:133767445	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.56	-0.5	2.39e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	8.16	0.35	3.13e-15	Cognitive test performance;
LGG	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg25986240	chr4:9926439	SLC2A9	0.37	7.45	0.33	4.51e-13	Bone mineral density;
LGG	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg03929089	chr4:120376271	NA	-0.56	-9.76	-0.41	1.32e-20	HDL cholesterol;
LGG	cis	rs62244186	1.000	rs62244186	chr3:44739783	G/A	cg02073558	chr3:44770973	ZNF501	0.71	14.16	0.55	4.32e-38	Depressive symptoms;
LGG	cis	rs7614311	0.681	rs55917937	chr3:63894829	A/C	cg22134162	chr3:63841271	THOC7	-0.37	-6.98	-0.31	1.03e-11	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg20368463	chr18:77673604	PQLC1	0.49	7.43	0.33	5.18e-13	Opioid sensitivity;
LGG	cis	rs7617773	0.780	rs11716848	chr3:48378500	G/A	cg11946769	chr3:48343235	NME6	0.71	11.88	0.48	1.42e-28	Coronary artery disease;
LGG	trans	rs1459104	1.000	rs35525598	chr11:55157701	A/G	cg15704280	chr7:45808275	SEPT13	0.71	7.09	0.31	5.06e-12	Body mass index;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg10150615	chr22:24372951	LOC391322	-0.39	-6.68	-0.3	6.79e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg09085632	chr11:111637200	PPP2R1B	1.02	19.21	0.67	6.35e-61	Primary sclerosing cholangitis;
LGG	cis	rs778371	0.723	rs35491427	chr2:233688542	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.24	-0.46	4.33e-26	Schizophrenia;
LGG	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06634786	chr22:41940651	POLR3H	-0.67	-11.31	-0.47	2.39e-26	Vitiligo;
LGG	cis	rs9457247	0.565	rs55873403	chr6:167511800	C/T	cg07741184	chr6:167504864	NA	0.45	10.09	0.42	8.72e-22	Crohn's disease;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.55	0.41	7.51e-20	Bipolar disorder;
LGG	cis	rs922107	0.713	rs6702712	chr1:89947493	T/C	cg01128109	chr1:89989507	LRRC8B	0.31	6.71	0.3	5.77e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs2084898	1.000	rs76841836	chr11:120051217	G/C	cg07435449	chr11:120005650	TRIM29	-0.67	-7.9	-0.34	2.05e-14	Stroke (pediatric);
LGG	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg20891283	chr12:69753455	YEATS4	0.85	15.18	0.58	1.56e-42	Response to diuretic therapy;
LGG	cis	rs7927771	0.524	rs9633830	chr11:47849470	T/G	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.33	-0.47	1.93e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg23782820	chr8:58130467	NA	0.5	6.93	0.31	1.42e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	1.000	rs6494696	chr15:68103206	C/G	cg05925327	chr15:68127851	NA	0.38	8.95	0.38	8.64e-18	Restless legs syndrome;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg06719900	chr11:109292894	C11orf87	0.44	8.12	0.35	4.38e-15	Schizophrenia;
LGG	cis	rs11675119	0.501	rs9309716	chr2:3493355	A/G	cg15541040	chr2:3486749	NA	-0.43	-7.49	-0.33	3.59e-13	Neurofibrillary tangles;
LGG	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.79e-27	Neuroticism;
LGG	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg02023728	chr11:77925099	USP35	0.39	6.82	0.3	2.79e-11	Alzheimer's disease (survival time);
LGG	cis	rs7717393	1.000	rs72798937	chr5:155796766	T/C	cg19569526	chr5:155754265	SGCD	0.76	7.16	0.32	3.2e-12	Egg allergy;
LGG	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg03929089	chr4:120376271	NA	-0.72	-8.37	-0.36	7e-16	Intraocular pressure;
LGG	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg16980736	chr17:78789706	RPTOR	0.59	7.77	0.34	5.23e-14	Myopia (pathological);
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00166722	chr3:10149974	C3orf24	0.5	7.98	0.35	1.13e-14	Alzheimer's disease;
LGG	cis	rs9487094	0.922	rs10782162	chr6:109806263	A/T	cg01125227	chr6:109776195	MICAL1	-0.51	-8.56	-0.37	1.64e-16	Height;
LGG	cis	rs755249	0.567	rs3768301	chr1:39870793	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.5	0.33	3.32e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg02002194	chr4:3960332	NA	-0.37	-6.81	-0.3	3e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.44	-0.33	4.78e-13	Retinal vascular caliber;
LGG	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg11317459	chr13:21872234	NA	-1.22	-20.15	-0.68	2.62e-65	White matter hyperintensity burden;
LGG	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.14e-29	Aortic root size;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04008888	chr11:68622739	NA	-0.55	-11.77	-0.48	3.64e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs2798269	0.867	rs1539562	chr13:22117071	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.09	-0.31	5e-12	PR segment;
LGG	cis	rs2467099	0.732	rs2168855	chr17:73943350	C/T	cg23806715	chr17:73775811	H3F3B	0.49	7.3	0.32	1.28e-12	Systolic blood pressure;
LGG	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.82e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg21399703	chr1:247681439	NA	0.57	6.8	0.3	3.15e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4774899	0.752	rs28514688	chr15:57399988	C/G	cg08128148	chr15:57256372	TCF12	0.28	6.85	0.3	2.39e-11	Urinary tract infection frequency;
LGG	cis	rs17384381	1.000	rs12743049	chr1:85897386	G/A	cg16011679	chr1:85725395	C1orf52	0.59	10.12	0.43	6.88e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2797160	1.000	rs1612249	chr6:126014916	C/A	cg05901451	chr6:126070800	HEY2	0.44	7.36	0.32	8.37e-13	Endometrial cancer;
LGG	cis	rs1355223	0.545	rs7106831	chr11:34879542	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.39	-0.36	5.82e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs3820068	0.705	rs74054769	chr1:15860147	A/C	cg05660106	chr1:15850417	CASP9	1.13	27.4	0.79	5.98e-99	Systolic blood pressure;
LGG	cis	rs7103648	0.695	rs12223593	chr11:47789082	T/G	cg20307385	chr11:47447363	PSMC3	0.81	16.48	0.61	2.27e-48	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs7714584	1.000	rs73282209	chr5:150174959	G/A	cg22134413	chr5:150180641	NA	0.69	6.82	0.3	2.81e-11	Crohn's disease;
LGG	cis	rs11885103	0.692	rs2683968	chr2:573207	A/G	cg21195176	chr2:593345	NA	0.42	7.84	0.34	3.07e-14	Heschl's gyrus morphology;
LGG	cis	rs9300255	0.679	rs28583837	chr12:123863620	G/A	cg00376283	chr12:123451042	ABCB9	-0.56	-8.25	-0.36	1.66e-15	Neutrophil percentage of white cells;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg05863683	chr7:1912471	MAD1L1	0.48	9.41	0.4	2.29e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs315122	0.588	rs548240	chr12:69756291	A/T	cg20891283	chr12:69753455	YEATS4	0.69	7.86	0.34	2.74e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs8067545	0.611	rs2703775	chr17:20134466	A/G	cg13482628	chr17:19912719	NA	-0.54	-10.29	-0.43	1.71e-22	Schizophrenia;
LGG	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg12463550	chr7:65579703	CRCP	0.54	9.02	0.39	4.99e-18	Aortic root size;
LGG	cis	rs9287719	0.967	rs4284804	chr2:10722124	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9513627	0.573	rs4771336	chr13:100210610	T/G	cg15490075	chr13:100150979	NA	0.52	7.42	0.33	5.64e-13	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05797656	chr17:61851352	DDX42;CCDC47	0.43	7.09	0.31	5.17e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7084402	0.967	rs10826198	chr10:60274182	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.83	-0.64	1.69e-54	Refractive error;
LGG	cis	rs73198271	0.531	rs3748142	chr8:8655355	G/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.16	0.35	3.26e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.37	-0.32	7.94e-13	Coronary artery disease;
LGG	cis	rs157093	0.626	rs157087	chr20:56248964	A/C	cg04055238	chr20:56251166	PMEPA1	-0.46	-7.8	-0.34	4.27e-14	Verbal declarative memory;
LGG	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg16141378	chr3:129829833	LOC729375	-0.45	-10.94	-0.45	6.22e-25	Retinal vascular caliber;
LGG	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.34	-0.36	8.66e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg13010199	chr12:38710504	ALG10B	0.59	11.56	0.47	2.48e-27	Morning vs. evening chronotype;
LGG	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.76	0.3	4.29e-11	Sudden cardiac arrest;
LGG	cis	rs4330281	0.647	rs6442683	chr3:17462945	G/A	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.79e-11	Schizophrenia;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14159672	chr1:205819179	PM20D1	0.85	19.41	0.67	7.89e-62	Menarche (age at onset);
LGG	cis	rs2249694	0.520	rs7095379	chr10:135328532	C/T	cg20169779	chr10:135381914	SYCE1	-0.55	-7.66	-0.34	1.13e-13	Obesity-related traits;
LGG	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.87	-0.3	2.04e-11	Joint mobility (Beighton score);
LGG	cis	rs6840360	0.582	rs1372976	chr4:152451453	G/A	cg17217059	chr4:152329364	FAM160A1	0.21	7.1	0.31	4.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7100689	0.753	rs1361458	chr10:82090339	A/T	cg01528321	chr10:82214614	TSPAN14	0.89	15.9	0.59	9.43e-46	Post bronchodilator FEV1;
LGG	cis	rs13202913	0.609	rs13205308	chr6:151753440	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.57	6.69	0.3	6.54e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs9868809	0.505	rs11708786	chr3:48752654	C/T	cg00383909	chr3:49044727	WDR6	0.9	11.34	0.47	1.75e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg04863758	chr4:1303710	MAEA	0.41	7.26	0.32	1.67e-12	Obesity-related traits;
LGG	cis	rs1784581	0.588	rs1789988	chr6:162408472	C/T	cg17173639	chr6:162384350	PARK2	-0.65	-13.81	-0.54	1.45e-36	Itch intensity from mosquito bite;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg21862992	chr11:68658383	NA	0.51	8.59	0.37	1.36e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg18854424	chr1:2615690	NA	0.35	7.09	0.31	5.02e-12	Ulcerative colitis;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs13108705	chr4:99044438	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg09038676	chr11:67351608	GSTP1	-0.35	-7.14	-0.32	3.52e-12	Mean corpuscular volume;
LGG	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg00666640	chr1:248458726	OR2T12	0.53	9.07	0.39	3.42e-18	Common traits (Other);
LGG	cis	rs10937275	0.624	rs17774519	chr3:186665247	G/A	cg26193484	chr3:186648175	ST6GAL1	0.84	8.63	0.37	9.73e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs34783982	0.510	rs12909922	chr15:89529353	G/T	cg09489435	chr15:89561491	NA	-0.38	-7.21	-0.32	2.37e-12	Squamous cell lung carcinoma;
LGG	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg06481639	chr22:41940642	POLR3H	0.57	7.92	0.35	1.78e-14	Vitiligo;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.74e-26	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.46	0.37	3.47e-16	Obesity-related traits;
LGG	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg23752985	chr2:85803571	VAMP8	0.43	8.53	0.37	2.08e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10924309	0.737	rs1122736	chr1:245852695	A/G	cg00036263	chr1:245852353	KIF26B	-0.46	-7.18	-0.32	2.89e-12	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-14.18	-0.55	3.76e-38	Alzheimer's disease;
LGG	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg00564723	chr10:75632066	CAMK2G	-0.31	-6.81	-0.3	2.98e-11	Inflammatory bowel disease;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg15595755	chr5:1867978	NA	0.51	10.29	0.43	1.73e-22	Cardiovascular disease risk factors;
LGG	cis	rs490234	0.702	rs4838277	chr9:128367886	C/T	cg14078157	chr9:128172775	NA	-0.54	-10.11	-0.43	7.43e-22	Mean arterial pressure;
LGG	cis	rs270601	0.690	rs162904	chr5:131595784	C/T	cg07395648	chr5:131743802	NA	0.36	7.0	0.31	9.04e-12	Acylcarnitine levels;
LGG	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg18252515	chr7:66147081	NA	1.31	18.72	0.66	1.19e-58	Diabetic kidney disease;
LGG	cis	rs61990749	0.597	rs11624101	chr14:78138059	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-6.96	-0.31	1.14e-11	Fibroblast growth factor basic levels;
LGG	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg26248373	chr2:1572462	NA	-0.72	-9.03	-0.39	4.66e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1018697	1.000	rs6584525	chr10:104551981	G/A	cg04362960	chr10:104952993	NT5C2	0.49	8.93	0.38	1.04e-17	Colorectal adenoma (advanced);
LGG	trans	rs17154702	0.524	rs2664041	chr8:8593144	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.86	0.3	2.28e-11	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs9443645	0.527	rs2063123	chr6:79658535	T/C	cg18132916	chr6:79620363	NA	-0.28	-7.29	-0.32	1.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg04287289	chr16:89883240	FANCA	0.84	8.04	0.35	7.52e-15	Skin colour saturation;
LGG	cis	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs350251	0.899	rs350285	chr16:12228735	G/A	cg02910054	chr16:12241554	SNX29	0.46	8.49	0.37	2.92e-16	Intelligence (multi-trait analysis);
LGG	cis	rs714515	0.967	rs9425590	chr1:172358664	A/C	cg01573306	chr1:172330400	DNM3	0.34	7.42	0.33	5.49e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.73	0.45	3.99e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7940866	0.903	rs7130842	chr11:130836269	A/G	cg12179176	chr11:130786555	SNX19	0.73	13.7	0.54	4.07e-36	Schizophrenia;
LGG	cis	rs6964587	0.872	rs57969083	chr7:91665627	A/T	cg17063962	chr7:91808500	NA	0.49	8.68	0.37	6.66e-17	Breast cancer;
LGG	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg23594656	chr7:65796392	TPST1	0.38	8.39	0.36	5.79e-16	Aortic root size;
LGG	trans	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg03647239	chr10:116582469	FAM160B1	0.41	7.33	0.32	1.06e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19695335	chr20:25604759	NANP	0.41	7.23	0.32	2.03e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9326248	0.652	rs7128382	chr11:117023487	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.81	0.34	3.77e-14	Blood protein levels;
LGG	cis	rs17818399	0.620	rs7598578	chr2:46857085	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-7.98	-0.35	1.15e-14	Height;
LGG	cis	rs9815354	1.000	rs6801343	chr3:41767234	C/T	cg03022575	chr3:42003672	ULK4	0.6	7.71	0.34	7.62e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg14416269	chr4:6271139	WFS1	0.53	9.9	0.42	4.3e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg17644776	chr2:200775616	C2orf69	-0.68	-9.22	-0.39	1.09e-18	Schizophrenia;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00495681	chr13:53174319	NA	0.6	11.37	0.47	1.36e-26	Lewy body disease;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg00933542	chr6:150070202	PCMT1	0.37	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.01	-0.31	8.47e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3087591	1.000	rs4795579	chr17:29458682	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	14.12	0.55	6.44e-38	Hip circumference;
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg20120463	chr17:44301886	NA	0.46	7.12	0.31	4.06e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg14036092	chr11:66035641	RAB1B	0.45	7.79	0.34	4.55e-14	Gout;
LGG	cis	rs2862064	0.799	rs4704835	chr5:156443251	G/A	cg12943317	chr5:156479607	HAVCR1	-0.78	-10.35	-0.43	1.01e-22	Platelet count;
LGG	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.25	0.36	1.67e-15	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg10818794	chr15:86012489	AKAP13	-0.38	-7.96	-0.35	1.36e-14	Coronary artery disease;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg24101359	chr6:42928495	GNMT	-0.45	-12.52	-0.5	3.43e-31	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg10587741	chr22:38071170	LGALS1	0.34	6.97	0.31	1.07e-11	Glioblastoma;Glioma;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03517284	chr6:25882590	NA	-0.98	-21.82	-0.71	3.97e-73	Urate levels;
LGG	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg06827562	chr3:125932279	NA	0.71	17.4	0.63	1.58e-52	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	0.715	rs2435907	chr15:57333416	A/G	cg08128148	chr15:57256372	TCF12	0.29	6.98	0.31	9.96e-12	Urinary tract infection frequency;
LGG	cis	rs4919044	0.808	rs860669	chr10:94796031	T/C	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs1978968	0.717	rs34740481	chr22:18401620	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.55	-0.41	7.31e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.91e-60	Menopause (age at onset);
LGG	cis	rs75920871	0.588	rs7112111	chr11:116980858	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-8.8	-0.38	2.68e-17	Subjective well-being;
LGG	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg20848291	chr7:100343083	ZAN	0.45	7.14	0.31	3.65e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs897984	0.542	rs7197717	chr16:31083075	A/C	cg02466173	chr16:30829666	NA	-0.42	-7.69	-0.34	8.81e-14	Dementia with Lewy bodies;
LGG	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg16359550	chr11:109292809	C11orf87	0.4	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	9.26	0.4	7.72e-19	Schizophrenia;
LGG	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg09855544	chr8:135498122	ZFAT	-0.45	-7.71	-0.34	7.93e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs9912789	0.807	rs9896850	chr17:79191726	C/T	cg25342872	chr17:79175132	AZI1	-0.59	-10.62	-0.44	1.04e-23	Frontotemporal dementia;
LGG	cis	rs12586317	0.547	rs74462850	chr14:35500093	G/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.66	-0.34	1.09e-13	Psoriasis;
LGG	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs10876993	0.890	rs799575	chr12:58069107	A/G	cg18357645	chr12:58087776	OS9	0.69	12.51	0.5	3.85e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.74	0.34	6.28e-14	Homoarginine levels;
LGG	cis	rs834603	0.611	rs2692540	chr7:47465325	C/G	cg09696706	chr7:47479511	TNS3	0.36	7.87	0.34	2.49e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg08017756	chr2:100939284	LONRF2	-0.31	-7.31	-0.32	1.19e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.05	0.35	6.96e-15	Retinal vascular caliber;
LGG	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.99e-12	Calcium levels;
LGG	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.19	-0.32	2.64e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs35160687	0.640	rs13015186	chr2:86485578	A/G	cg10973622	chr2:86423274	IMMT	0.46	7.77	0.34	5.12e-14	Night sleep phenotypes;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg18350739	chr11:68623251	NA	-0.85	-21.49	-0.71	1.48e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs5756391	1.000	rs5756391	chr22:37298344	C/T	cg21209356	chr22:37319042	CSF2RB	-0.35	-7.73	-0.34	6.78e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04798930	chr2:37193060	STRN	-0.4	-6.69	-0.3	6.59e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.66	-0.34	1.1e-13	Joint mobility (Beighton score);
LGG	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	10.78	0.45	2.42e-24	Lung cancer in ever smokers;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07659893	chr17:61819838	STRADA	0.48	7.94	0.35	1.5e-14	Prudent dietary pattern;
LGG	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg02002194	chr4:3960332	NA	0.4	7.11	0.31	4.48e-12	Neuroticism;
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg24101359	chr6:42928495	GNMT	0.57	16.9	0.62	3.08e-50	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4006360	0.511	rs7503699	chr17:39258027	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.4	-8.34	-0.36	8.3e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg26578617	chr4:90757533	SNCA	0.45	8.78	0.38	3.26e-17	Dementia with Lewy bodies;
LGG	cis	rs11203032	0.831	rs4269843	chr10:90944216	G/A	cg16672925	chr10:90967113	CH25H	0.51	8.09	0.35	5.14e-15	Heart failure;
LGG	cis	rs56399783	0.803	rs7811164	chr7:2822416	G/A	cg23009067	chr7:2775923	GNA12	0.35	6.65	0.3	8.15e-11	Childhood ear infection;
LGG	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.86	-17.21	-0.62	1.15e-51	Lung cancer;
LGG	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg15890332	chr12:107067104	RFX4	0.32	8.44	0.37	4.09e-16	Total body bone mineral density;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10205287	chr4:100815590	MAPKSP1	0.39	6.94	0.31	1.32e-11	Obesity-related traits;
LGG	cis	rs17039065	1.000	rs72889375	chr4:109387798	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.75	0.3	4.55e-11	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27322228	chr8:23145479	R3HCC1	0.44	7.19	0.32	2.7e-12	Cognitive performance;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04723886	chr5:1468204	LPCAT1	0.41	7.29	0.32	1.33e-12	Electrocardiographic conduction measures;
LGG	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.24e-14	HDL cholesterol;
LGG	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg00129232	chr17:37814104	STARD3	-0.59	-10.96	-0.45	5.04e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.63e-26	Hemoglobin concentration;
LGG	cis	rs4144743	1.000	rs34182248	chr17:45321359	T/C	cg18085866	chr17:45331354	ITGB3	-0.77	-9.77	-0.41	1.25e-20	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21292152	chr19:37406949	ZNF829;ZNF568	0.46	7.57	0.33	2e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg21518248	chr2:162101506	NA	0.24	7.4	0.33	6.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs912057	0.601	rs1294405	chr6:6737591	A/G	cg06612196	chr6:6737390	NA	0.51	11.51	0.47	4.09e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs10927875	0.757	rs4661679	chr1:16321010	C/T	cg21385522	chr1:16154831	NA	0.56	10.0	0.42	1.94e-21	Dilated cardiomyopathy;
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.28	0.43	1.81e-22	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24823832	chr8:67974235	COPS5	0.43	7.59	0.33	1.76e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg25319279	chr11:5960081	NA	0.55	9.85	0.42	6.46e-21	DNA methylation (variation);
LGG	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.47	-6.99	-0.31	9.55e-12	Childhood ear infection;
LGG	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg16414030	chr3:133502952	NA	-0.6	-10.31	-0.43	1.37e-22	Iron status biomarkers;
LGG	cis	rs3008870	1.000	rs11208979	chr1:67442275	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg08355456	chr11:67383691	NA	0.5	8.51	0.37	2.44e-16	Mean corpuscular volume;
LGG	cis	rs56235845	0.694	rs9313758	chr5:176773091	T/G	cg17509989	chr5:176798049	RGS14	0.67	11.04	0.46	2.53e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs3784262	0.669	rs12148281	chr15:58311061	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.82	-0.3	2.86e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19524238	chr7:2802976	GNA12	0.31	7.62	0.33	1.41e-13	Height;
LGG	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg27476859	chr7:2772710	GNA12	0.64	13.06	0.52	2.01e-33	Height;
LGG	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg12560992	chr17:57184187	TRIM37	0.54	8.64	0.37	9.35e-17	Testicular germ cell tumor;
LGG	cis	rs6997458	0.742	rs10091566	chr8:86341559	A/C	cg02393479	chr8:86352350	CA3	-0.31	-6.8	-0.3	3.24e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.97	0.42	2.35e-21	Lung cancer in ever smokers;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.71	-0.45	4.52e-24	Neuroticism;
LGG	cis	rs6977660	0.714	rs10270204	chr7:19819544	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	7.86	0.34	2.64e-14	Thyroid stimulating hormone;
LGG	cis	rs3206736	0.634	rs329546	chr7:35111358	T/C	cg13400248	chr7:35225412	NA	0.45	8.17	0.35	2.99e-15	Diastolic blood pressure;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg15133208	chr4:90757351	SNCA	-0.35	-7.92	-0.35	1.77e-14	Dementia with Lewy bodies;
LGG	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg23422044	chr7:1970798	MAD1L1	-0.47	-8.47	-0.37	3.33e-16	Neuroticism;
LGG	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.68	0.3	6.77e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg03894339	chr8:19674705	INTS10	1.17	16.82	0.62	6.5e-50	Lipid metabolism phenotypes;
LGG	cis	rs4474465	1.000	rs10899517	chr11:78180507	A/T	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.5e-11	Alzheimer's disease (survival time);
LGG	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg03806693	chr22:41940476	POLR3H	1.05	17.72	0.64	5.43e-54	Vitiligo;
LGG	cis	rs9457247	0.555	rs2247325	chr6:167369992	A/G	cg18261144	chr6:167370276	RNASET2	-0.34	-6.92	-0.31	1.47e-11	Crohn's disease;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg02023728	chr11:77925099	USP35	0.44	7.8	0.34	4.02e-14	Testicular germ cell tumor;
LGG	trans	rs2562456	0.793	rs57299552	chr19:21504128	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs4851254	0.961	rs11677607	chr2:100751150	C/T	cg17356467	chr2:100759845	AFF3	0.4	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg14791747	chr16:20752902	THUMPD1	0.51	7.78	0.34	4.65e-14	Cognitive test performance;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg23758822	chr17:41437982	NA	0.86	14.73	0.56	1.52e-40	Menopause (age at onset);
LGG	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg04317338	chr11:64019027	PLCB3	-0.66	-8.29	-0.36	1.23e-15	Mean platelet volume;
LGG	cis	rs5744897	0.581	rs35235926	chr12:133304126	G/A	cg17341477	chr12:133246679	POLE	0.57	6.67	0.3	7.13e-11	Urate levels in overweight individuals;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg00166722	chr3:10149974	C3orf24	0.41	7.35	0.32	9.1e-13	Alzheimer's disease;
LGG	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.84	0.45	1.51e-24	Morning vs. evening chronotype;
LGG	cis	rs1467026	0.589	rs9876483	chr3:12803792	G/T	cg24848339	chr3:12840334	CAND2	0.34	7.58	0.33	1.93e-13	P wave duration;
LGG	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg26150922	chr2:100937072	LONRF2	-0.5	-9.25	-0.39	8.29e-19	Intelligence (multi-trait analysis);
LGG	cis	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg07460842	chr6:66804631	NA	-0.5	-8.83	-0.38	2.15e-17	Blood trace element (Cu levels);
LGG	cis	rs7191439	0.789	rs4433802	chr16:88784964	A/G	cg02389323	chr16:88786976	FAM38A	1.09	12.72	0.51	5.23e-32	Plateletcrit;
LGG	cis	rs11700980	0.551	rs11701759	chr21:30115571	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.17	0.46	7.97e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Vitiligo;
LGG	cis	rs8014204	0.604	rs12147862	chr14:75384471	C/T	cg06637938	chr14:75390232	RPS6KL1	-1.06	-25.1	-0.76	2.17e-88	Caffeine consumption;
LGG	cis	rs8008758	1.000	rs8008758	chr14:101690045	A/C	cg26224664	chr14:101693935	NA	0.56	9.72	0.41	1.9e-20	Body mass index (alcohol intake interaction);
LGG	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg25358565	chr5:93447407	FAM172A	-0.82	-11.35	-0.47	1.58e-26	Diabetic retinopathy;
LGG	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.96	-0.42	2.73e-21	Morning vs. evening chronotype;
LGG	cis	rs4918072	0.754	rs4918065	chr10:105617578	T/C	cg11005552	chr10:105648138	OBFC1	0.72	10.77	0.45	2.77e-24	Coronary artery disease;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg22398616	chr13:53314203	LECT1	-0.46	-9.69	-0.41	2.41e-20	Lewy body disease;
LGG	cis	rs11920090	0.932	rs16847990	chr3:170702422	A/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.45	0.37	3.83e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9796	0.870	rs2925345	chr15:41311799	T/C	cg18705301	chr15:41695430	NDUFAF1	0.49	8.36	0.36	7.16e-16	Menopause (age at onset);
LGG	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg24692254	chr21:30365293	RNF160	-0.56	-8.1	-0.35	4.9e-15	Cognitive test performance;
LGG	cis	rs2797160	1.000	rs1418951	chr6:125996185	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-7.04	-0.31	7.15e-12	Endometrial cancer;
LGG	cis	rs6815814	0.861	rs10012017	chr4:38784633	G/T	cg06935464	chr4:38784597	TLR10	0.54	8.81	0.38	2.45e-17	Breast cancer;
LGG	trans	rs12517041	1.000	rs6894144	chr5:23312635	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-10.28	-0.43	1.89e-22	Schizophrenia;
LGG	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.56	-10.05	-0.42	1.23e-21	Height;
LGG	cis	rs883565	0.740	rs11925218	chr3:39081171	C/A	cg01426195	chr3:39028469	NA	-0.71	-16.0	-0.6	3.44e-46	Handedness;
LGG	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg04568710	chr12:38710424	ALG10B	-0.39	-8.33	-0.36	9.04e-16	Bladder cancer;
LGG	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg24692254	chr21:30365293	RNF160	-0.58	-8.49	-0.37	2.9e-16	Cognitive test performance;
LGG	cis	rs832540	0.603	rs6870175	chr5:56093371	A/G	cg12654349	chr5:56205094	C5orf35	-0.42	-7.28	-0.32	1.45e-12	Coronary artery disease;
LGG	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.35	-0.4	3.84e-19	Headache;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg20308403	chr7:2120281	MAD1L1	-0.35	-7.4	-0.33	6.26e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-11.09	-0.46	1.66e-25	Morning vs. evening chronotype;
LGG	cis	rs3206736	0.556	rs1649235	chr7:35003882	G/A	cg13400248	chr7:35225412	NA	0.54	9.43	0.4	2.05e-19	Diastolic blood pressure;
LGG	cis	rs1355223	0.545	rs12278318	chr11:34876507	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.34	-0.36	8.35e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.33	0.58	3.28e-43	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg16507663	chr6:150244633	RAET1G	0.46	8.78	0.38	3.17e-17	Lung cancer;
LGG	cis	rs7222240	0.857	rs8066395	chr17:43147582	A/G	cg24806326	chr17:43207588	PLCD3	0.44	7.41	0.33	5.86e-13	Craniofacial microsomia;
LGG	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.86	-0.34	2.81e-14	IgG glycosylation;
LGG	trans	rs35110281	0.693	rs4819290	chr21:45122713	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.13	0.43	6.32e-22	Mean corpuscular volume;
LGG	cis	rs17092148	0.848	rs6060030	chr20:33340313	C/T	cg12302830	chr20:33297742	TP53INP2	-0.42	-7.18	-0.32	2.73e-12	Neuroticism;
LGG	cis	rs10489202	0.683	rs7515429	chr1:168066659	A/G	cg24449463	chr1:168025552	DCAF6	-0.59	-10.34	-0.43	1.08e-22	Schizophrenia;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg12708336	chr17:41446283	NA	-0.33	-8.03	-0.35	8.19e-15	Menopause (age at onset);
LGG	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg26384229	chr12:38710491	ALG10B	0.47	8.75	0.38	4.06e-17	Morning vs. evening chronotype;
LGG	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg06637938	chr14:75390232	RPS6KL1	0.78	15.52	0.59	4.84e-44	Caffeine consumption;
LGG	cis	rs2274273	0.870	rs1952087	chr14:55683211	A/C	cg04306507	chr14:55594613	LGALS3	0.63	17.61	0.63	1.62e-53	Protein biomarker;
LGG	cis	rs7216064	1.000	rs9915591	chr17:65826090	C/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.54	-0.37	1.93e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs16933812	0.510	rs10114416	chr9:36990635	T/C	cg13738729	chr9:36989127	PAX5	0.42	9.32	0.4	4.86e-19	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.36	-0.32	8.32e-13	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Vitiligo;
LGG	cis	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11062677	chr19:13976917	NA	0.56	9.07	0.39	3.29e-18	Gut microbiome composition (summer);
LGG	trans	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.93	0.31	1.42e-11	Joint mobility (Beighton score);
LGG	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg25706552	chr1:244017396	NA	0.53	8.58	0.37	1.4e-16	RR interval (heart rate);
LGG	cis	rs17253792	0.732	rs75796044	chr14:56034128	C/T	cg01858014	chr14:56050164	KTN1	-0.87	-11.22	-0.46	5.26e-26	Putamen volume;
LGG	cis	rs6840360	0.550	rs7675818	chr4:152690777	C/G	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg16583315	chr14:65563665	MAX	-0.42	-8.58	-0.37	1.41e-16	Obesity-related traits;
LGG	cis	rs6817170	0.617	rs7687559	chr4:154385925	G/C	cg24020152	chr4:154419554	KIAA0922	0.34	7.49	0.33	3.57e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs1568889	1.000	rs12796293	chr11:28177723	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.78	-14.8	-0.57	7.12e-41	Bipolar disorder;
LGG	cis	rs9486719	0.895	rs12527021	chr6:97025496	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg21366198	chr4:185655624	MLF1IP	0.45	7.8	0.34	4.26e-14	Kawasaki disease;
LGG	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg03961551	chr1:25251730	RUNX3	0.47	12.3	0.5	2.82e-30	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs13082711	0.555	rs73149363	chr3:27265394	C/A	cg02860705	chr3:27208620	NA	0.93	18.31	0.65	1.03e-56	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg12751644	chr20:60527061	NA	-0.3	-6.99	-0.31	9.9e-12	Body mass index;
LGG	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg21226059	chr5:178986404	RUFY1	-0.46	-8.4	-0.36	5.41e-16	Lung cancer;
LGG	cis	rs1620921	1.000	rs1740442	chr6:161197558	A/G	cg01280913	chr6:161186852	NA	-0.33	-6.86	-0.3	2.17e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg14074117	chr16:1909714	C16orf73	-0.51	-7.62	-0.33	1.42e-13	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs9929218	0.954	rs4485355	chr16:68754730	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-14.23	-0.55	2.19e-38	Colorectal cancer;
LGG	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.02	24.79	0.76	5.83e-87	Chronic sinus infection;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20786246	chr2:72377174	NA	0.38	6.9	0.31	1.67e-11	Body mass index;
LGG	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-10.62	-0.44	1e-23	Morning vs. evening chronotype;
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07685180	chr8:600429	NA	1.23	11.98	0.49	5.41e-29	IgG glycosylation;
LGG	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.3	-0.4	5.6e-19	Mean corpuscular volume;
LGG	trans	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.13	0.43	6.66e-22	Metabolite levels;
LGG	cis	rs13260300	0.599	rs1425775	chr8:75535793	T/C	cg22993706	chr8:75542856	NA	0.33	6.79	0.3	3.43e-11	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.75	0.34	5.76e-14	Height;
LGG	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.85	-0.59	1.64e-45	Colorectal cancer;
LGG	cis	rs3106136	0.872	rs2016476	chr4:95229004	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.33	-0.32	1.06e-12	Capecitabine sensitivity;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg11766577	chr21:47581405	C21orf56	-0.52	-9.28	-0.4	6.3e-19	Testicular germ cell tumor;
LGG	cis	rs2976388	0.967	rs2976393	chr8:143763618	C/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.13	-0.43	6.36e-22	Urinary tract infection frequency;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.26e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6752107	0.967	rs10210302	chr2:234158839	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.25	0.52	3.23e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13040088	0.935	rs62200158	chr20:61557906	C/T	cg23096297	chr20:61557774	DIDO1	0.88	12.32	0.5	2.35e-30	Menopause (age at onset);
LGG	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.79	0.38	2.94e-17	Eosinophil percentage of white cells;
LGG	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	trans	rs8129326	0.664	rs2834479	chr21:35783219	A/G	cg07474852	chr4:123073612	NA	0.5	9.06	0.39	3.58e-18	Cancer;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg09426994	chr11:118478258	PHLDB1	-0.43	-7.49	-0.33	3.61e-13	Cholesterol, total;
LGG	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg12081754	chr8:22256438	SLC39A14	0.72	13.8	0.54	1.63e-36	Verbal declarative memory;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg12070911	chr6:150209640	RAET1E	0.3	7.29	0.32	1.37e-12	Lung cancer;
LGG	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.22	-0.39	1.06e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6684428	0.505	rs6588581	chr1:56393537	C/T	cg11651538	chr1:56320950	NA	-0.43	-8.28	-0.36	1.32e-15	Airflow obstruction;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg05368731	chr17:41323189	NBR1	0.89	17.62	0.63	1.42e-53	Menopause (age at onset);
LGG	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg13271783	chr10:134563150	INPP5A	-0.49	-7.25	-0.32	1.73e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4662750	0.536	rs4662744	chr2:128350965	C/T	cg10021288	chr2:128175891	PROC	0.37	6.98	0.31	1.01e-11	Renal cell carcinoma;
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg19774624	chr17:42201019	HDAC5	0.84	16.46	0.61	3.02e-48	Total body bone mineral density;
LGG	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	8.22	0.36	2.12e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7565124	1.000	rs12471796	chr2:20256192	G/A	cg24657347	chr2:20261756	NA	-0.76	-14.88	-0.57	3.21e-41	Major depressive disorder;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.2	-0.46	6.3e-26	Obesity-related traits;
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg06494592	chr3:125709126	NA	-0.55	-7.06	-0.31	6.13e-12	Blood pressure (smoking interaction);
LGG	cis	rs1862618	0.853	rs33326	chr5:56142601	G/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg26384229	chr12:38710491	ALG10B	0.93	21.17	0.7	4.6e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg08250081	chr4:10125330	NA	0.41	8.0	0.35	1.03e-14	Bone mineral density;
LGG	cis	rs35771425	0.600	rs1020336	chr1:211661016	C/T	cg10512769	chr1:211675356	NA	-0.9	-18.76	-0.66	7.76e-59	Educational attainment (years of education);
LGG	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg24812749	chr6:127587940	RNF146	0.64	10.89	0.45	1.01e-24	Breast cancer;
LGG	cis	rs72925845	0.519	rs72907440	chr17:76425989	T/G	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs3839234	1	rs3839234	chr5:148596693	TG/T	cg06539116	chr5:148597365	ABLIM3	-0.6	-16.03	-0.6	2.66e-46	Lung function (FEV1);
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg05861140	chr6:150128134	PCMT1	0.45	10.02	0.42	1.56e-21	Lung cancer;
LGG	cis	rs17818399	0.712	rs13008088	chr2:46781580	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-10.99	-0.45	3.92e-25	Height;
LGG	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.09	-0.46	1.6e-25	Migraine;Coronary artery disease;
LGG	cis	rs9398803	0.661	rs853985	chr6:127020173	C/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.66	-0.41	3.15e-20	Male-pattern baldness;
LGG	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg16583315	chr14:65563665	MAX	-0.37	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.42e-27	Rheumatoid arthritis;
LGG	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-16.87	-0.62	4.13e-50	Height;
LGG	cis	rs9896933	0.615	rs2379354	chr17:80704385	G/A	cg20578329	chr17:80767326	TBCD	-0.84	-11.94	-0.49	7.55e-29	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9807841	0.617	rs2360944	chr19:10769974	T/C	cg17710535	chr19:10819994	QTRT1	0.44	6.72	0.3	5.27e-11	Inflammatory skin disease;
LGG	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs514406	0.861	rs7524476	chr1:53240212	C/T	cg24675658	chr1:53192096	ZYG11B	0.49	9.74	0.41	1.58e-20	Monocyte count;
LGG	cis	rs4700695	0.668	rs253214	chr5:65499401	A/G	cg21114390	chr5:65439923	SFRS12	-0.65	-9.37	-0.4	3.25e-19	Facial morphology (factor 19);
LGG	cis	rs2640806	0.505	rs35834070	chr8:97362101	A/G	cg22138393	chr8:97340270	PTDSS1	0.28	7.24	0.32	1.92e-12	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg24253500	chr15:84953950	NA	0.57	10.16	0.43	4.89e-22	Schizophrenia;
LGG	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.45	-6.81	-0.3	3.01e-11	Parkinson's disease;
LGG	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.34e-17	DNA methylation (variation);
LGG	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg16486109	chr11:613632	IRF7	0.42	6.93	0.31	1.39e-11	Systemic lupus erythematosus;
LGG	cis	rs72772090	0.710	rs17479052	chr5:96065636	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.52	-8.01	-0.35	9.25e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg24623649	chr8:11872141	NA	0.31	7.41	0.33	6.03e-13	Triglycerides;
LGG	cis	rs3735485	0.843	rs1557934	chr7:45022257	A/G	cg03440944	chr7:45023329	C7orf40	0.58	9.84	0.42	6.86e-21	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg22920501	chr2:26401640	FAM59B	0.43	8.28	0.36	1.29e-15	Gut microbiome composition (summer);
LGG	cis	rs807669	0.868	rs762529	chr22:19170205	C/G	cg02655711	chr22:19163373	SLC25A1	0.79	16.13	0.6	9.15e-47	Metabolite levels;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	8.91e-16	Personality dimensions;
LGG	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg06808227	chr14:105710500	BRF1	-0.62	-11.38	-0.47	1.23e-26	Platelet count;
LGG	cis	rs17092148	0.887	rs6059915	chr20:33147737	C/G	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.77	-0.3	3.93e-11	Neuroticism;
LGG	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg27205649	chr11:78285834	NARS2	0.49	8.48	0.37	3.1e-16	Alzheimer's disease (survival time);
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg23422044	chr7:1970798	MAD1L1	0.6	10.27	0.43	1.91e-22	Bipolar disorder;
LGG	cis	rs7572733	0.534	rs1435568	chr2:198762879	T/C	cg00792783	chr2:198669748	PLCL1	0.69	11.19	0.46	7.05e-26	Dermatomyositis;
LGG	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg02772935	chr3:125709198	NA	-0.53	-6.73	-0.3	4.9e-11	Blood pressure (smoking interaction);
LGG	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.15	-0.35	3.47e-15	Height;
LGG	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.37e-16	IgG glycosylation;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.13	-0.46	1.16e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg07777115	chr5:623756	CEP72	-0.51	-6.78	-0.3	3.74e-11	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11014794	chr10:93999688	CPEB3	0.43	7.05	0.31	6.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs5998509	1	rs5998509	chr22:21917479	C/T	cg05046821	chr22:21984468	YDJC	-0.4	-7.12	-0.31	4.1e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs1008375	0.966	rs1860591	chr4:17577329	A/G	cg16339924	chr4:17578868	LAP3	0.64	11.16	0.46	9.25e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7927771	0.524	rs7942074	chr11:47720509	T/C	cg20307385	chr11:47447363	PSMC3	0.58	11.29	0.46	2.89e-26	Subjective well-being;
LGG	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg03929089	chr4:120376271	NA	0.43	6.93	0.31	1.45e-11	HDL cholesterol;
LGG	cis	rs698813	0.604	rs768007	chr2:44487486	G/A	cg00619915	chr2:44497795	NA	-0.6	-8.84	-0.38	2.04e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs1620921	0.533	rs9347447	chr6:161269371	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.39	-0.43	7.4e-23	Subjective well-being;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs6546537	0.550	rs2312202	chr2:69775104	A/C	cg10773587	chr2:69614142	GFPT1	0.42	7.3	0.32	1.25e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.66	-11.23	-0.46	4.73e-26	Mean platelet volume;
LGG	cis	rs6580649	0.657	rs57863747	chr12:48470425	G/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs4740619	0.692	rs7036775	chr9:15762716	T/C	cg14451791	chr9:16040625	NA	0.34	8.85	0.38	1.86e-17	Body mass index;
LGG	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19748678	chr4:122722346	EXOSC9	-0.52	-9.36	-0.4	3.41e-19	Type 2 diabetes;
LGG	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	11.07	0.46	2.05e-25	Mean corpuscular hemoglobin;
LGG	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg13072238	chr3:49761600	GMPPB	0.52	6.91	0.31	1.58e-11	Menarche (age at onset);
LGG	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	trans	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg06521331	chr12:34319734	NA	-0.48	-8.46	-0.37	3.51e-16	Bladder cancer;
LGG	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg08648136	chr8:956695	NA	0.44	9.41	0.4	2.38e-19	Schizophrenia;
LGG	cis	rs988958	0.562	rs13397376	chr2:42221417	A/G	cg19376973	chr2:42229025	NA	0.61	8.96	0.38	7.82e-18	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04326040	chr17:617519	VPS53	0.41	6.91	0.31	1.57e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg07648498	chr16:89883185	FANCA	0.41	7.03	0.31	7.46e-12	Vitiligo;
LGG	trans	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-6.91	-0.31	1.64e-11	Triglycerides;
LGG	cis	rs12477438	0.520	rs4851204	chr2:99991182	A/G	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-9.03	-0.39	4.79e-18	Blood metabolite levels;
LGG	trans	rs629535	0.773	rs568159	chr8:70032908	C/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg02158880	chr13:53174818	NA	0.42	8.32	0.36	9.62e-16	Lewy body disease;
LGG	cis	rs7927592	0.731	rs10896350	chr11:68386373	A/C	cg16797656	chr11:68205561	LRP5	0.51	10.0	0.42	1.92e-21	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08501054	chr8:9413133	TNKS	0.4	6.68	0.3	6.83e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6977660	0.714	rs34451907	chr7:19824538	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.16	0.35	3.29e-15	Thyroid stimulating hormone;
LGG	cis	rs9549367	0.789	rs7999579	chr13:113879357	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-13.96	-0.54	3.34e-37	Platelet distribution width;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs832540	0.519	rs6450411	chr5:56265771	A/G	cg12654349	chr5:56205094	C5orf35	-0.38	-6.65	-0.3	8.52e-11	Coronary artery disease;
LGG	cis	rs9972944	0.902	rs59009755	chr17:63772263	C/T	cg07283582	chr17:63770753	CCDC46	0.43	8.34	0.36	8.32e-16	Total body bone mineral density;
LGG	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.58	-0.33	1.96e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg11813489	chr14:105363835	NA	-0.45	-8.76	-0.38	3.73e-17	IgG glycosylation;
LGG	cis	rs34929064	0.718	rs17302823	chr7:22719409	C/G	cg18045685	chr7:22629474	NA	0.6	8.77	0.38	3.56e-17	Major depression and alcohol dependence;
LGG	cis	rs2816316	0.945	rs2984919	chr1:192541172	A/T	cg10861751	chr1:192544716	RGS1	0.34	7.0	0.31	9.1e-12	Celiac disease;
LGG	cis	rs2247341	0.965	rs11248073	chr4:1737502	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.74	-0.45	3.67e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9513627	1.000	rs7338537	chr13:100119581	C/A	cg15490075	chr13:100150979	NA	-0.68	-7.07	-0.31	5.58e-12	Obesity-related traits;
LGG	cis	rs9467773	0.572	rs2076029	chr6:26390830	T/C	cg09904177	chr6:26538194	HMGN4	-0.43	-7.68	-0.34	9.36e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25267526	chr19:12777743	MORG1;MAN2B1	0.43	7.45	0.33	4.48e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00567479	chr2:242295999	FARP2	0.45	6.87	0.3	2.12e-11	Gut microbiome composition (summer);
LGG	cis	rs8180040	1.000	rs295428	chr3:47359262	G/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.17	-0.58	1.82e-42	Colorectal cancer;
LGG	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg18681998	chr4:17616180	MED28	0.85	18.24	0.65	1.97e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.63	-0.33	1.37e-13	Life satisfaction;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg03188948	chr7:1209495	NA	0.42	7.23	0.32	2.04e-12	Longevity;Endometriosis;
LGG	cis	rs7772486	0.875	rs6913797	chr6:146413758	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.7	0.3	5.94e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.89	14.03	0.55	1.58e-37	Cognitive test performance;
LGG	cis	rs9473924	0.542	rs2857514	chr6:50811283	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	7.28	0.32	1.43e-12	Body mass index;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.82	-0.42	8.23e-21	IgG glycosylation;
LGG	cis	rs6141769	0.518	rs6057631	chr20:31319149	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.75	-0.3	4.49e-11	Subjective well-being;
LGG	cis	rs2862064	0.932	rs1995378	chr5:156421132	G/A	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.72	-0.45	4.12e-24	Platelet count;
LGG	cis	rs1355223	0.966	rs11602318	chr11:34766983	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.45	0.33	4.54e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs559928	1.000	rs471584	chr11:64149252	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.54	-7.15	-0.32	3.42e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg26031613	chr14:104095156	KLC1	0.82	14.81	0.57	6.49e-41	Body mass index;
LGG	cis	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg06521331	chr12:34319734	NA	-0.59	-11.02	-0.46	3.03e-25	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.58	0.44	1.41e-23	Prudent dietary pattern;
LGG	cis	rs28655083	0.550	rs598340	chr16:77102504	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	7.02	0.31	7.82e-12	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg06521331	chr12:34319734	NA	0.47	8.37	0.36	6.66e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9388451	0.626	rs2875881	chr6:126072853	C/G	cg05901451	chr6:126070800	HEY2	-0.68	-12.91	-0.51	9.16e-33	Brugada syndrome;
LGG	trans	rs8073060	0.586	rs2523116	chr17:34025460	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1467026	0.589	rs9876483	chr3:12803792	G/T	cg05775895	chr3:12838266	CAND2	0.57	9.79	0.41	1.07e-20	P wave duration;
LGG	cis	rs7512552	0.803	rs13294	chr1:150484987	G/A	cg15654264	chr1:150340011	RPRD2	0.44	9.02	0.39	4.98e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11169552	0.510	rs4768852	chr12:50960289	A/C	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.68e-14	Colorectal cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg14694896	chr8:104427370	SLC25A32;DCAF13	0.42	6.88	0.3	1.99e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs6968355	0.745	rs2430485	chr7:104583091	G/T	cg03782966	chr7:104585482	NA	0.49	9.1	0.39	2.71e-18	Myopia (pathological);
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg17809284	chr5:56205270	C5orf35	0.65	9.89	0.42	4.84e-21	Initial pursuit acceleration;
LGG	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.39	-0.36	5.85e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg08727972	chr1:148025634	NBPF14	0.38	6.8	0.3	3.22e-11	Hip geometry;
LGG	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg09264619	chr17:80180166	NA	0.51	10.11	0.43	7.88e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs67133203	0.904	rs2301529	chr12:51389747	G/A	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs593982	1.000	rs1941746	chr11:65502413	A/G	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs216026	0.689	rs216048	chr12:2766700	A/C	cg19945202	chr12:2788847	CACNA1C	0.64	9.44	0.4	1.86e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg03733263	chr8:22462867	KIAA1967	0.9	20.16	0.68	2.35e-65	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09227533	chr4:186945339	NA	0.36	6.76	0.3	4.1e-11	Electrocardiographic conduction measures;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-12.04	-0.49	3.24e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg18350739	chr11:68623251	NA	-0.85	-21.64	-0.71	2.95e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.99	-0.35	1.07e-14	Life satisfaction;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.57	-0.33	1.98e-13	Personality dimensions;
LGG	cis	rs4262150	0.764	rs4958561	chr5:151930231	A/G	cg12297329	chr5:152029980	NA	-0.72	-13.9	-0.54	5.82e-37	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-10.75	-0.45	3.21e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3824867	0.920	rs10742805	chr11:47454701	A/G	cg20307385	chr11:47447363	PSMC3	0.47	7.61	0.33	1.56e-13	Mean corpuscular hemoglobin;
LGG	trans	rs617791	0.508	rs10896074	chr11:65776304	C/T	cg17712092	chr4:129076599	LARP1B	-0.57	-9.56	-0.41	7.05e-20	Breast cancer;
LGG	cis	rs4268898	0.662	rs72793967	chr2:24422902	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-12.68	-0.51	8.11e-32	Asthma;
LGG	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg04362960	chr10:104952993	NT5C2	0.57	10.85	0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.68	0.37	6.57e-17	Platelet count;
LGG	cis	rs9814567	0.806	rs2293294	chr3:134322814	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.77	0.45	2.85e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4919694	0.808	rs4918001	chr10:105013147	G/T	cg04362960	chr10:104952993	NT5C2	-0.98	-13.04	-0.52	2.44e-33	Arsenic metabolism;
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.56	-0.33	2.22e-13	Prostate cancer;
LGG	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg20302533	chr7:39170763	POU6F2	0.57	14.73	0.56	1.51e-40	IgG glycosylation;
LGG	cis	rs1801251	0.778	rs2675967	chr2:233736133	C/G	cg25237894	chr2:233734115	C2orf82	-0.75	-15.58	-0.59	2.69e-44	Coronary artery disease;
LGG	cis	rs1270639	0.778	rs1638021	chr7:157438037	A/G	cg13357408	chr7:157437802	PTPRN2	0.61	9.96	0.42	2.64e-21	Colorectal cancer;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg09699651	chr6:150184138	LRP11	0.46	7.0	0.31	9.14e-12	Lung cancer;
LGG	cis	rs12997796	0.556	rs35594332	chr2:86982651	G/A	cg25203885	chr2:87302643	LOC285074	-0.64	-7.28	-0.32	1.41e-12	Schizophrenia;
LGG	cis	rs2153535	0.580	rs6941771	chr6:8494452	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.36e-31	Motion sickness;
LGG	cis	rs6489882	0.966	rs7955267	chr12:113379039	C/T	cg25319449	chr12:113376135	OAS3	-0.38	-7.08	-0.31	5.36e-12	Chronic lymphocytic leukemia;
LGG	cis	rs9814567	0.896	rs2177602	chr3:134245866	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs209489	0.786	rs9463890	chr6:53111466	T/C	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg07435449	chr11:120005650	TRIM29	0.74	13.83	0.54	1.14e-36	Stroke (pediatric);
LGG	cis	rs4319547	0.737	rs11058226	chr12:122938958	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.6	-9.21	-0.39	1.14e-18	Body mass index;
LGG	cis	rs2797369	0.713	rs2813653	chr6:101585895	C/T	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06470251	chr20:60548479	NA	0.4	6.94	0.31	1.35e-11	Body mass index;
LGG	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg14416269	chr4:6271139	WFS1	0.45	7.22	0.32	2.13e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg06623918	chr6:96969491	KIAA0776	-0.79	-15.71	-0.59	6.7e-45	Headache;
LGG	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg03806693	chr22:41940476	POLR3H	-1.16	-21.49	-0.71	1.48e-71	Vitiligo;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.48	-0.33	3.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.6	0.33	1.66e-13	Retinal vascular caliber;
LGG	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	12.91	0.51	9.06e-33	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs9929218	0.551	rs2281850	chr16:68718750	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.13	-32.53	-0.83	1.12e-121	Colorectal cancer;
LGG	cis	rs67385638	0.792	rs16912979	chr11:5309695	T/C	cg12559170	chr11:5275217	HBG2	0.49	10.97	0.45	4.59e-25	Hemoglobin levels;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg13263323	chr15:86062960	AKAP13	-0.34	-7.2	-0.32	2.5e-12	Coronary artery disease;
LGG	cis	rs2693698	0.550	rs1257443	chr14:99686970	A/T	cg07440398	chr14:99712966	BCL11B	0.51	10.76	0.45	3.01e-24	Schizophrenia;
LGG	cis	rs2070433	0.756	rs2839295	chr21:47917871	A/T	cg12379764	chr21:47803548	PCNT	0.51	7.32	0.32	1.1e-12	Lymphocyte counts;
LGG	cis	rs17253792	0.822	rs10083499	chr14:56066590	T/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16587623	chr1:47184894	KIAA0494	0.42	6.96	0.31	1.18e-11	Gut microbiome composition (summer);
LGG	cis	rs523522	0.962	rs2393590	chr12:120913900	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.78e-25	High light scatter reticulocyte count;
LGG	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.39	-0.36	6.07e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs798766	1.000	rs11729657	chr4:1737585	T/C	cg05874882	chr4:1763078	NA	-0.47	-6.69	-0.3	6.5500000000000006e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg05775895	chr3:12838266	CAND2	0.79	15.92	0.59	7.93e-46	QRS complex (12-leadsum);
LGG	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg22878388	chr2:105853796	NA	-0.49	-9.15	-0.39	1.89e-18	Type 2 diabetes;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00166722	chr3:10149974	C3orf24	-0.52	-8.77	-0.38	3.33e-17	Alzheimer's disease;
LGG	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	cg15522984	chr1:182991683	LAMC1	0.43	8.74	0.38	4.32e-17	Colorectal cancer;
LGG	cis	rs2251666	0.514	rs12444761	chr16:4927285	C/T	cg04440724	chr16:4920505	UBN1	-0.6	-8.43	-0.36	4.38e-16	Cancer;
LGG	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg16096631	chr1:42092165	HIVEP3	0.7	18.38	0.65	4.76e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.9	-0.34	1.99e-14	Mood instability;
LGG	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.71	-0.34	7.5e-14	Colorectal cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg10651618	chr6:90122152	RRAGD	-0.37	-6.85	-0.3	2.37e-11	Iris color (L* coordinate);
LGG	cis	rs10489202	0.954	rs3820399	chr1:168062053	C/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.16	-0.43	5.07e-22	Schizophrenia;
LGG	cis	rs42235	0.571	rs42042	chr7:92247112	A/G	cg15732164	chr7:92237376	CDK6	0.34	7.36	0.32	8.57e-13	Hip circumference adjusted for BMI;Height;
LGG	trans	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg02002194	chr4:3960332	NA	-0.41	-7.18	-0.32	2.78e-12	Retinal vascular caliber;
LGG	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg18937875	chr11:14930189	NA	0.45	7.54	0.33	2.57e-13	Adiponectin levels;Vitamin D levels;
LGG	cis	rs2011503	1.000	rs756999	chr19:19448200	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.28	-0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg10189774	chr4:17578691	LAP3	0.42	7.53	0.33	2.61e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9463078	0.526	rs9472337	chr6:44711576	C/A	cg25276700	chr6:44698697	NA	0.4	8.01	0.35	9.21e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2708377	0.858	rs68045377	chr12:11294452	T/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.4	0.33	6.58e-13	Bitter taste perception;
LGG	cis	rs2860975	1.000	rs12781471	chr10:96765362	T/C	cg09036531	chr10:96991505	NA	-0.49	-9.08	-0.39	3.05e-18	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	7.08	0.31	5.51e-12	Coronary artery disease;
LGG	cis	rs45544231	0.544	rs1420533	chr16:52563626	G/A	cg09051775	chr16:52580266	TOX3	-0.43	-7.18	-0.32	2.77e-12	Restless legs syndrome;
LGG	cis	rs870825	0.616	rs7678849	chr4:185648868	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.4	0.36	5.34e-16	Prudent dietary pattern;
LGG	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.01	-0.35	9.14e-15	HDL cholesterol;
LGG	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.94	0.52	6.71e-33	Alzheimer's disease;
LGG	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.63	-0.37	9.61e-17	Triglycerides;
LGG	cis	rs6988985	0.728	rs6471572	chr8:143965264	G/C	cg10324643	chr8:143916377	GML	0.4	8.0	0.35	1.03e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg03060546	chr3:49711283	APEH	0.73	13.2	0.52	5.67e-34	Resting heart rate;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg05863683	chr7:1912471	MAD1L1	0.45	8.86	0.38	1.68e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg17178900	chr1:205818956	PM20D1	0.6	13.55	0.53	1.81e-35	Menarche (age at onset);
LGG	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg02227867	chr8:22457446	C8orf58	-0.46	-8.42	-0.36	4.9e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg20368463	chr18:77673604	PQLC1	0.57	7.48	0.33	3.79e-13	Opioid sensitivity;
LGG	cis	rs9811920	0.683	rs7650727	chr3:99688976	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-7.42	-0.33	5.64e-13	Axial length;
LGG	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg13259177	chr13:114761607	RASA3	-0.78	-11.08	-0.46	1.81e-25	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg08355456	chr11:67383691	NA	-0.43	-7.42	-0.33	5.81e-13	Mean corpuscular volume;
LGG	cis	rs17221829	0.764	rs7930024	chr11:89386038	G/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.26	-0.4	7.46e-19	Anxiety in major depressive disorder;
LGG	cis	rs526231	0.543	rs257302	chr5:102416130	G/T	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg23422044	chr7:1970798	MAD1L1	-0.62	-10.63	-0.44	8.99e-24	Bipolar disorder;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg15971980	chr6:150254442	NA	0.45	8.39	0.36	6.16e-16	Lung cancer;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03324837	chr17:61044407	NA	0.39	6.79	0.3	3.53e-11	Body mass index;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs1997103	0.871	rs6956733	chr7:55393032	A/C	cg20935933	chr6:143382018	AIG1	0.54	7.51	0.33	3.1400000000000003e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.51	-0.44	2.61e-23	Hepatocellular carcinoma;
LGG	cis	rs745821	0.701	rs11873590	chr18:48100355	A/G	cg18923635	chr18:48083994	NA	0.42	7.57	0.33	2.02e-13	Diastolic blood pressure;
LGG	cis	rs4722166	0.630	rs12700390	chr7:22777129	G/T	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	8.91e-16	Lung cancer;
LGG	cis	rs4919044	0.641	rs11187232	chr10:94737477	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.09	-0.31	4.92e-12	Coronary artery disease;
LGG	cis	rs9354308	0.764	rs9345711	chr6:66591447	C/T	cg07460842	chr6:66804631	NA	0.41	6.97	0.31	1.13e-11	Metabolite levels;
LGG	cis	rs10751667	0.643	rs10794350	chr11:946070	A/G	cg22143635	chr11:980567	AP2A2	0.44	8.11	0.35	4.65e-15	Alzheimer's disease (late onset);
LGG	cis	rs9398803	0.687	rs1417572	chr6:126958727	T/C	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.89e-20	Male-pattern baldness;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg02353165	chr6:42928485	GNMT	-0.47	-14.22	-0.55	2.47e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg19761014	chr17:28927070	LRRC37B2	0.61	7.32	0.32	1.09e-12	Body mass index;
LGG	cis	rs7113850	0.541	rs76874215	chr11:24235158	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.47	0.44	3.72e-23	Bone fracture in osteoporosis;
LGG	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.87	-0.38	1.64e-17	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21963583	chr11:68658836	MRPL21	0.58	9.91	0.42	4.07e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6582630	0.519	rs12368889	chr12:38315160	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.11	-0.39	2.55e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.62	0.37	1.05e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2694528	0.764	rs1816862	chr5:60011636	G/A	cg11474532	chr5:59995715	DEPDC1B	0.79	8.09	0.35	5.22e-15	Parkinson's disease;
LGG	cis	rs7000551	0.725	rs2461486	chr8:22392008	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	11.93	0.48	8.86e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs67311347	1.000	rs9841335	chr3:40475858	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	8.67	0.37	7.43e-17	Thyroid stimulating hormone;
LGG	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg18851795	chr1:204543875	NA	-0.37	-6.94	-0.31	1.32e-11	Schizophrenia;
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg20798164	chr1:3347577	PRDM16	0.38	6.91	0.31	1.66e-11	Monocyte count;
LGG	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg09818912	chr17:20140352	CYTSB	-0.32	-7.41	-0.33	6.25e-13	Schizophrenia;
LGG	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.2	-0.46	6.23e-26	Bipolar disorder;
LGG	cis	rs11229555	0.645	rs34054511	chr11:58204943	A/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.14	-0.46	1.06e-25	Morning vs. evening chronotype;
LGG	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg02002194	chr4:3960332	NA	0.46	9.23	0.39	1.01e-18	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.64e-14	Lung cancer;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg24829409	chr8:58192753	C8orf71	0.75	10.45	0.44	4.18e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12519773	0.549	rs11738974	chr5:92537336	G/A	cg18783429	chr5:92414398	NA	0.31	7.58	0.33	1.93e-13	Migraine;
LGG	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.85e-21	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg17644776	chr2:200775616	C2orf69	0.6	8.38	0.36	6.17e-16	Schizophrenia;
LGG	trans	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.76	-0.38	3.81e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.53	-10.36	-0.43	9.4e-23	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.95	-10.79	-0.45	2.33e-24	Diabetic retinopathy;
LGG	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.76	-0.78	5.01e-96	Schizophrenia;
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	19.57	0.67	1.37e-62	Platelet count;
LGG	cis	rs6681460	0.625	rs12127199	chr1:67103742	T/C	cg13052034	chr1:66999238	SGIP1	0.35	6.91	0.31	1.63e-11	Presence of antiphospholipid antibodies;
LGG	cis	rs1003719	0.788	rs9981226	chr21:38452127	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.54	0.63	3.59e-53	Eye color traits;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.74	-0.3	4.69e-11	Lung cancer;
LGG	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg26513180	chr16:89883248	FANCA	0.94	21.56	0.71	6.54e-72	Vitiligo;
LGG	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg10580341	chr11:889148	CHID1	-0.38	-6.89	-0.31	1.79e-11	Mean platelet volume;
LGG	cis	rs1318772	0.800	rs4410636	chr5:112935406	A/T	cg12552261	chr5:112820674	MCC	0.67	7.44	0.33	4.78e-13	F-cell distribution;
LGG	cis	rs1878931	0.582	rs40633	chr16:3425325	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-11.29	-0.46	2.72e-26	Body mass index (adult);
LGG	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.42e-16	Retinal vascular caliber;
LGG	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg20913747	chr6:44695427	NA	-0.6	-10.23	-0.43	2.7e-22	Total body bone mineral density;
LGG	cis	rs9427116	0.502	rs9426829	chr1:154592201	T/C	cg11650704	chr1:154556575	ADAR	-0.49	-9.7	-0.41	2.31e-20	Blood protein levels;
LGG	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19717773	chr7:2847554	GNA12	-0.38	-8.71	-0.38	5.43e-17	Height;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg14789911	chr21:47582049	C21orf56	-0.52	-9.17	-0.39	1.52e-18	Testicular germ cell tumor;
LGG	cis	rs427394	0.659	rs274725	chr5:6717408	C/G	cg15145174	chr5:6755386	POLS	-0.44	-8.13	-0.35	3.92e-15	Menopause (age at onset);
LGG	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs4150161	0.591	rs3759977	chr16:84221170	T/A	cg10106505	chr16:84220380	TAF1C	-0.88	-7.46	-0.33	4.18e-13	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	trans	rs12517041	1.000	rs7721619	chr5:23292676	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.98	0.49	5.24e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2976388	0.647	rs1048831	chr8:143781858	G/A	cg06565975	chr8:143823917	SLURP1	0.35	8.9	0.38	1.28e-17	Urinary tract infection frequency;
LGG	cis	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg24623649	chr8:11872141	NA	-0.32	-7.56	-0.33	2.19e-13	Retinal vascular caliber;
LGG	cis	rs12143943	0.866	rs12032618	chr1:204532659	C/T	cg20240347	chr1:204465584	NA	-0.34	-7.51	-0.33	3e-13	Cognitive performance;
LGG	cis	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.82	-0.38	2.41e-17	Resting heart rate;
LGG	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.73	0.34	6.69e-14	Menopause (age at onset);
LGG	cis	rs10743315	0.557	rs117033327	chr12:19373040	G/T	cg02471346	chr12:19282374	PLEKHA5	0.85	7.99	0.35	1.11e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg12728061	chr1:2383438	NA	-0.46	-11.28	-0.46	3.01e-26	Non-obstructive azoospermia;
LGG	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.89	0.57	2.87e-41	Cannabis dependence symptom count;
LGG	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg09165964	chr15:75287851	SCAMP5	0.55	10.13	0.43	6.44e-22	Breast cancer;
LGG	cis	rs17125944	0.686	rs7147258	chr14:53337664	G/T	cg00686598	chr14:53173677	PSMC6	-0.68	-7.44	-0.33	4.96e-13	Alzheimer's disease (late onset);
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg07142201	chr11:109293216	C11orf87	0.54	9.6	0.41	5.06e-20	Schizophrenia;
LGG	cis	rs28374715	0.681	rs7163989	chr15:41614621	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-26.2	-0.77	1.83e-93	Ulcerative colitis;
LGG	cis	rs12580194	0.593	rs61956275	chr12:55786423	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.24	-0.43	2.52e-22	Cancer;
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.75	-0.3	4.54e-11	Total body bone mineral density;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg19233923	chr11:63753598	OTUB1	-0.43	-7.29	-0.32	1.38e-12	Hematological and biochemical traits;
LGG	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	cis	rs11168618	0.626	rs11514105	chr12:48820934	G/C	cg24011408	chr12:48396354	COL2A1	0.47	7.57	0.33	2.03e-13	Adiponectin levels;
LGG	cis	rs870825	0.616	rs28672716	chr4:185647345	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04530015	chr2:215796436	ABCA12	-0.46	-7.81	-0.34	3.86e-14	Neuroblastoma;
LGG	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.32	-0.32	1.08e-12	Breast cancer;
LGG	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg06238570	chr21:40685208	BRWD1	-0.53	-8.71	-0.38	5.62e-17	Cognitive function;
LGG	cis	rs514406	0.621	rs928452	chr1:53195926	G/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-25.63	-0.77	7.69e-91	Monocyte count;
LGG	trans	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg25214090	chr10:38739885	LOC399744	0.64	11.55	0.47	2.69e-27	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11644478	chr21:40555479	PSMG1	0.9	17.28	0.63	5.24e-52	Cognitive function;
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.28	-0.32	1.48e-12	Bipolar disorder;
LGG	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg27129171	chr3:47204927	SETD2	0.71	11.3	0.46	2.57e-26	Birth weight;
LGG	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs2048656	0.523	rs1976673	chr8:9679780	T/A	cg06636001	chr8:8085503	FLJ10661	0.48	8.12	0.35	4.27e-15	Schizophrenia;
LGG	cis	rs2131877	0.830	rs62290347	chr3:194852620	A/G	cg07250128	chr3:194833983	C3orf21	0.41	6.72	0.3	5.44e-11	Non-small cell lung cancer;
LGG	cis	rs9359856	0.564	rs61739327	chr6:90340446	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.71	-0.41	2.15e-20	Bipolar disorder;
LGG	cis	rs7444	0.941	rs5998619	chr22:21945851	G/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.64	-0.33	1.28e-13	Systemic lupus erythematosus;
LGG	cis	rs7089973	0.604	rs7919649	chr10:116609576	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	7.27	0.32	1.56e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg10950524	chr7:2139216	MAD1L1	-0.32	-6.86	-0.3	2.18e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13268671	chr2:166810585	TTC21B	0.43	7.33	0.32	1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg18942110	chr15:91072797	CRTC3	-0.29	-6.68	-0.3	7.09e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg03477792	chr4:77819574	ANKRD56	0.51	8.95	0.38	8.44e-18	Emphysema distribution in smoking;
LGG	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.73	0.34	6.62e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9287719	0.967	rs6759740	chr2:10747271	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs72781680	0.716	rs2712056	chr2:23959131	C/T	cg08917208	chr2:24149416	ATAD2B	0.65	8.48	0.37	2.99e-16	Lymphocyte counts;
LGG	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg03342759	chr3:160939853	NMD3	-0.45	-7.78	-0.34	4.83e-14	Morning vs. evening chronotype;
LGG	cis	rs7424096	0.527	rs4670637	chr2:37164857	T/G	cg14987922	chr2:37194071	STRN	0.49	8.01	0.35	9.7e-15	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6665290	0.901	rs11580229	chr1:227210820	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.25	-38.64	-0.87	5.49e-147	Myeloid white cell count;
LGG	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg08600765	chr20:34638493	LOC647979	-0.62	-7.9	-0.34	2.09e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg19920283	chr7:105172520	RINT1	0.6	7.97	0.35	1.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4774899	1.000	rs4774902	chr15:57240760	A/C	cg08128148	chr15:57256372	TCF12	-0.33	-7.89	-0.34	2.22e-14	Urinary tract infection frequency;
LGG	cis	rs6063312	0.667	rs9679994	chr20:47281853	T/C	cg18078177	chr20:47281410	PREX1	0.9	15.53	0.59	4.51e-44	Tonometry;
LGG	cis	rs1595825	0.945	rs6736825	chr2:198854224	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.87	-0.3	2.1e-11	Ulcerative colitis;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7717393	0.881	rs10056289	chr5:155776066	A/T	cg04435420	chr5:155754009	SGCD	-0.67	-8.31	-0.36	1.06e-15	Egg allergy;
LGG	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg03060546	chr3:49711283	APEH	0.76	13.84	0.54	1.11e-36	Resting heart rate;
LGG	cis	rs7219021	0.674	rs11656939	chr17:46964406	G/C	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.91	-0.31	1.63e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs907683	0.546	rs1058261	chr2:220285309	C/T	cg15015639	chr2:220282977	DES	-0.35	-10.14	-0.43	5.81e-22	Resting heart rate;
LGG	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg00405596	chr8:11794950	NA	0.42	7.08	0.31	5.49e-12	Mood instability;
LGG	trans	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg18187862	chr3:45730750	SACM1L	0.66	10.9	0.45	8.68e-25	Primary sclerosing cholangitis;
LGG	cis	rs2227564	0.678	rs2242257	chr10:75597605	A/G	cg00564723	chr10:75632066	CAMK2G	0.52	11.05	0.46	2.35e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg19507638	chr5:93509721	C5orf36	-0.44	-7.7	-0.34	8.22e-14	Diabetic retinopathy;
LGG	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg06618935	chr21:46677482	NA	0.49	9.6	0.41	5.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.17e-25	Aortic root size;
LGG	cis	rs9399135	1.000	rs4895435	chr6:135293463	C/A	cg24558204	chr6:135376177	HBS1L	0.53	9.41	0.4	2.3e-19	Red blood cell count;
LGG	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg07636037	chr3:49044803	WDR6	0.93	17.09	0.62	4.02e-51	Menarche (age at onset);
LGG	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg08305652	chr11:111469057	NA	0.41	7.95	0.35	1.45e-14	Primary sclerosing cholangitis;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.29	-0.46	2.9e-26	Extrinsic epigenetic age acceleration;
LGG	cis	rs2859741	0.528	rs59729868	chr1:37493710	G/A	cg09363841	chr1:37513479	NA	-0.56	-11.61	-0.47	1.59e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs10504130	0.569	rs11775611	chr8:52820274	A/G	cg24946253	chr8:52722146	PXDNL	-0.45	-6.65	-0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg02002194	chr4:3960332	NA	0.46	8.3	0.36	1.18e-15	Retinal vascular caliber;
LGG	cis	rs4889911	1.000	rs4889911	chr17:77839811	C/T	cg07923794	chr17:77834237	NA	0.63	7.91	0.34	1.94e-14	Electroencephalogram traits;
LGG	trans	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg06521331	chr12:34319734	NA	0.42	7.44	0.33	4.88e-13	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg03929089	chr4:120376271	NA	-0.72	-13.02	-0.52	3.03e-33	Coronary artery disease;
LGG	cis	rs6088590	0.735	rs6060001	chr20:33294353	C/T	cg07148914	chr20:33460835	GGT7	-0.41	-6.97	-0.31	1.07e-11	Coronary artery disease;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21963583	chr11:68658836	MRPL21	0.55	9.66	0.41	3.18e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.35	0.32	9.26e-13	Bladder cancer;
LGG	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	cis	rs11920090	0.932	rs12486792	chr3:170677123	C/G	cg09710316	chr3:170744871	SLC2A2	-0.57	-8.02	-0.35	8.61e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg03605463	chr16:89740564	NA	-0.44	-7.31	-0.32	1.2e-12	Vitiligo;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg13395646	chr4:1353034	KIAA1530	-0.54	-9.45	-0.4	1.65e-19	Obesity-related traits;
LGG	cis	rs7760949	0.889	rs9382688	chr6:13926746	A/T	cg27413430	chr6:13925136	RNF182	0.49	7.38	0.32	7.42e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs950027	0.787	rs1153845	chr15:45724729	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.67	-11.93	-0.48	8.59e-29	Response to fenofibrate (adiponectin levels);
LGG	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg27523141	chr10:43048294	ZNF37B	0.4	7.83	0.34	3.28e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9912468	1.000	rs9890911	chr17:64315569	T/C	cg19474267	chr17:64306194	PRKCA	-0.97	-28.04	-0.79	7.55e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg05313129	chr8:58192883	C8orf71	-0.76	-10.6	-0.44	1.22e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7011049	1.000	rs117708010	chr8:53844026	G/A	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg00290607	chr11:67383545	NA	-0.49	-8.49	-0.37	2.77e-16	Mean corpuscular volume;
LGG	trans	rs941408	1.000	rs1640266	chr19:2787832	T/G	cg22153745	chr1:153894579	GATAD2B	-0.66	-10.56	-0.44	1.63e-23	Total cholesterol levels;
LGG	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg08994789	chr17:28903642	LRRC37B2	0.61	7.29	0.32	1.31e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07233135	chr10:33623121	NRP1	0.39	6.9	0.31	1.73e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.86	-0.45	1.23e-24	Migraine;Coronary artery disease;
LGG	cis	rs3820928	0.874	rs10177995	chr2:227781600	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.83	-0.34	3.47e-14	Pulmonary function;
LGG	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg06028605	chr16:24865363	SLC5A11	-0.48	-7.88	-0.34	2.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.06e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.89	-0.34	2.22e-14	Total cholesterol levels;
LGG	cis	rs3806843	0.676	rs1583005	chr5:140031537	G/A	cg19875535	chr5:140030758	IK	-0.59	-12.41	-0.5	9.79e-31	Depressive symptoms (multi-trait analysis);
LGG	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.14	0.55	5.36e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2932538	0.922	rs6668533	chr1:113064468	C/T	cg22162597	chr1:113214053	CAPZA1	0.61	11.53	0.47	3.4e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg08621203	chr6:150244597	RAET1G	0.46	8.02	0.35	8.7e-15	Lung cancer;
LGG	cis	rs6120849	0.707	rs6088694	chr20:33652371	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.87	0.48	1.47e-28	Response to antipsychotic treatment;
LGG	cis	rs554111	0.891	rs604645	chr1:21043926	T/C	cg15613048	chr1:21044031	KIF17	-0.35	-6.87	-0.3	2.08e-11	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg17376030	chr22:41985996	PMM1	0.67	10.9	0.45	8.58e-25	Vitiligo;
LGG	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg26384229	chr12:38710491	ALG10B	1.04	26.58	0.78	3.2e-95	Heart rate;
LGG	cis	rs17253792	0.749	rs17747301	chr14:56125030	C/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg08120226	chr3:195531633	MUC4	0.48	7.93	0.35	1.66e-14	Lung disease severity in cystic fibrosis;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.08	0.31	5.38e-12	Schizophrenia;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.19	0.32	2.58e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg16339924	chr4:17578868	LAP3	0.62	10.52	0.44	2.34e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.35	0.32	9.35e-13	Bladder cancer;
LGG	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg12310025	chr6:25882481	NA	0.46	7.48	0.33	3.74e-13	Iron status biomarkers;
LGG	trans	rs11722228	0.508	rs3796825	chr4:10092879	T/A	cg26043149	chr18:55253948	FECH	0.95	16.63	0.61	5.01e-49	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg00599393	chr8:22457479	C8orf58	-0.43	-7.97	-0.35	1.23e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs67311347	0.544	rs2123998	chr3:40359005	C/G	cg13683864	chr3:40499215	RPL14	0.79	15.51	0.58	5.34e-44	Renal cell carcinoma;
LGG	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg03342759	chr3:160939853	NMD3	0.45	7.56	0.33	2.21e-13	Morning vs. evening chronotype;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg15971980	chr6:150254442	NA	0.44	8.34	0.36	8.33e-16	Lung cancer;
LGG	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg02390115	chr1:21767211	NBPF3	0.58	11.1	0.46	1.46e-25	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12971120	0.685	rs34780792	chr18:72173278	G/A	cg26446133	chr18:72167187	CNDP2	-0.68	-13.61	-0.53	1.05e-35	Refractive error;
LGG	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg26384229	chr12:38710491	ALG10B	1.05	27.9	0.79	3.32e-101	Heart rate;
LGG	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.09	-0.35	5.2e-15	Bone mineral density;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg16141378	chr3:129829833	LOC729375	0.38	8.68	0.37	6.85e-17	Triglycerides;
LGG	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg21459583	chr1:227974177	NA	-0.46	-6.95	-0.31	1.27e-11	Major depressive disorder;
LGG	cis	rs4689642	0.507	rs11728393	chr4:7223566	A/G	cg21353189	chr4:7228343	SORCS2	0.35	7.33	0.32	1.04e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs1983891	0.874	rs2395779	chr6:41511950	C/T	cg20194872	chr6:41519635	FOXP4	0.57	10.0	0.42	1.91e-21	Prostate cancer;
LGG	cis	rs1620921	0.505	rs4708878	chr6:161203026	A/G	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs701145	0.585	rs1727919	chr3:153788757	G/A	cg12800244	chr3:153838788	SGEF	0.81	8.82	0.38	2.32e-17	Coronary artery disease;
LGG	cis	rs853679	0.517	rs36078605	chr6:28078032	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15369054	chr17:80825471	TBCD	0.58	10.6	0.44	1.16e-23	Breast cancer;
LGG	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg11861562	chr11:117069780	TAGLN	0.26	7.0	0.31	9.18e-12	Blood protein levels;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.01	-0.6	2.99e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg22105103	chr4:187893119	NA	0.56	10.69	0.44	5.52e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs9815354	0.767	rs73069245	chr3:41951452	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-6.91	-0.31	1.57e-11	Common traits (Other);
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg01943577	chr7:158741284	NA	-0.44	-8.11	-0.35	4.69e-15	Height;
LGG	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg14882966	chr2:3699353	NA	0.57	7.14	0.31	3.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12618769	0.570	rs116051325	chr2:99056836	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.56e-17	Bipolar disorder;
LGG	cis	rs3771570	0.901	rs869943	chr2:242431585	C/G	cg21155796	chr2:242212141	HDLBP	0.7	9.17	0.39	1.55e-18	Prostate cancer;
LGG	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg20336341	chr7:50628841	DDC	-0.42	-7.33	-0.32	1.07e-12	Malaria;
LGG	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.32	0.47	2.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg22916017	chr11:64110731	CCDC88B	-0.49	-6.68	-0.3	7.05e-11	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.7	0.41	2.3e-20	Lung cancer in ever smokers;
LGG	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg23920097	chr1:209922102	NA	-0.48	-8.52	-0.37	2.24e-16	Red blood cell count;
LGG	cis	rs4629180	0.586	rs7583526	chr2:102124665	G/A	cg16435561	chr2:102091048	RFX8	0.49	9.01	0.39	5.38e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg12395012	chr8:11607386	GATA4	-0.41	-7.42	-0.33	5.79e-13	Neuroticism;
LGG	cis	rs8017423	0.967	rs2149655	chr14:90707246	T/C	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.73e-57	Mortality in heart failure;
LGG	cis	rs10766496	1.000	rs10766494	chr11:18738281	C/T	cg02515468	chr11:18743222	IGSF22	-0.46	-7.74	-0.34	6.19e-14	Diabetic kidney disease;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg16680214	chr1:154839983	KCNN3	-0.49	-9.61	-0.41	4.49e-20	Prostate cancer;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg01673284	chr16:4527211	HMOX2	0.32	6.81	0.3	3.07e-11	Schizophrenia;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg04287289	chr16:89883240	FANCA	-0.71	-7.89	-0.34	2.2e-14	Skin colour saturation;
LGG	cis	rs9354308	0.764	rs9342518	chr6:66606606	A/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs4917300	1.000	rs13268779	chr8:143120421	G/A	cg06573787	chr8:143070187	NA	0.5	9.03	0.39	4.58e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs6748734	0.779	rs6437371	chr2:241797424	G/C	cg04034577	chr2:241836375	C2orf54	-0.48	-10.18	-0.43	4.15e-22	Urinary metabolites;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.25e-13	Educational attainment;
LGG	cis	rs8017423	0.904	rs11622257	chr14:90715014	C/T	cg04374321	chr14:90722782	PSMC1	-0.9	-18.38	-0.65	4.53e-57	Mortality in heart failure;
LGG	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs12618769	0.597	rs11902825	chr2:99129137	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.6	10.25	0.43	2.31e-22	Birth weight;
LGG	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg03160526	chr17:80928410	B3GNTL1	0.42	6.73	0.3	5.1e-11	Glycated hemoglobin levels;
LGG	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg11266682	chr4:10021025	SLC2A9	-0.51	-9.96	-0.42	2.76e-21	Bone mineral density;
LGG	cis	rs2307022	0.530	rs3826166	chr16:68388781	C/G	cg07273125	chr16:68295692	NA	0.45	10.07	0.42	1.04e-21	Body mass index;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs4679904	0.960	rs12639488	chr3:160259367	T/C	cg20378687	chr3:160281681	KPNA4	-0.35	-6.69	-0.3	6.48e-11	Primary biliary cholangitis;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg14092988	chr3:52407081	DNAH1	0.28	7.58	0.33	1.9e-13	Electroencephalogram traits;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6456156	0.792	rs2039321	chr6:167516299	C/T	cg07741184	chr6:167504864	NA	0.41	9.09	0.39	2.87e-18	Primary biliary cholangitis;
LGG	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.94	0.52	6.87e-33	Hip circumference adjusted for BMI;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg08742575	chr21:47604166	C21orf56	0.49	8.48	0.37	3.15e-16	Testicular germ cell tumor;
LGG	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg25319279	chr11:5960081	NA	-0.56	-8.57	-0.37	1.58e-16	DNA methylation (variation);
LGG	cis	rs17401966	1.000	rs3748578	chr1:10420918	A/G	cg15208524	chr1:10270712	KIF1B	-0.42	-7.18	-0.32	2.8e-12	Hepatocellular carcinoma;
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.11	0.39	2.56e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs644799	0.662	rs35793328	chr11:95490896	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	11.77	0.48	3.56e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs74781061	0.929	rs8029215	chr15:74853488	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.12	-0.31	4.26e-12	Endometriosis;
LGG	cis	rs4330281	0.608	rs9847477	chr3:17607991	C/G	cg20981856	chr3:17787350	NA	0.4	7.22	0.32	2.1e-12	Schizophrenia;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg08621203	chr6:150244597	RAET1G	0.47	8.22	0.36	2.12e-15	Lung cancer;
LGG	cis	rs4919694	1.000	rs12266291	chr10:104806884	G/A	cg04362960	chr10:104952993	NT5C2	1.07	15.29	0.58	5.26e-43	Arsenic metabolism;
LGG	cis	rs10876993	1.000	rs10876993	chr12:58062667	C/T	cg18357645	chr12:58087776	OS9	0.71	13.06	0.52	2.01e-33	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg03929089	chr4:120376271	NA	-1.02	-22.5	-0.72	2.6e-76	Height;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.25	0.36	1.69e-15	Schizophrenia;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.26	-0.32	1.63e-12	Neuroticism;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.75	14.09	0.55	8.83e-38	Obesity-related traits;
LGG	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs990171	0.540	rs759381	chr2:103094323	A/T	cg05295703	chr2:102895712	NA	-0.43	-7.15	-0.32	3.49e-12	Lymphocyte counts;
LGG	trans	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg02800362	chr5:177631904	HNRNPAB	0.75	12.97	0.52	4.76e-33	Obesity-related traits;
LGG	cis	rs2033732	0.706	rs7839360	chr8:85069719	G/T	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg14456004	chr13:21872349	NA	1.27	19.65	0.67	5.8e-63	White matter hyperintensity burden;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg05091796	chr16:4465799	CORO7	-0.78	-13.07	-0.52	1.95e-33	Schizophrenia;
LGG	cis	rs240764	0.697	rs239194	chr6:101131959	G/A	cg09795085	chr6:101329169	ASCC3	0.41	6.7	0.3	6.24e-11	Neuroticism;
LGG	cis	rs8048589	0.526	rs71388721	chr16:12212164	G/A	cg02910054	chr16:12241554	SNX29	0.62	10.66	0.44	7.29e-24	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg22301664	chr6:74072820	C6orf221	-0.37	-6.72	-0.3	5.44e-11	Emphysema imaging phenotypes;
LGG	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg08305652	chr11:111469057	NA	-0.44	-8.61	-0.37	1.18e-16	Primary sclerosing cholangitis;
LGG	trans	rs208520	0.837	rs208471	chr6:66916749	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.58	-0.59	2.52e-44	Exhaled nitric oxide output;
LGG	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg02820901	chr13:113351484	ATP11A	0.57	6.73	0.3	5.01e-11	Glycated hemoglobin levels;
LGG	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg19997662	chr15:101784653	CHSY1	-0.91	-20.3	-0.69	5.18e-66	Corneal structure;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg07511668	chr11:68622177	NA	0.51	9.85	0.42	6.72e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.13e-30	Intelligence (multi-trait analysis);
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg07332563	chr6:291687	DUSP22	-0.57	-9.47	-0.4	1.42e-19	Menopause (age at onset);
LGG	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs17209837	0.607	rs117917293	chr7:87114824	G/C	cg00919237	chr7:87102261	ABCB4	-0.8	-16.07	-0.6	1.68e-46	Gallbladder cancer;
LGG	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg06494592	chr3:125709126	NA	-0.52	-6.7	-0.3	5.91e-11	Blood pressure (smoking interaction);
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs950027	0.620	rs1719246	chr15:45625479	T/A	cg26924012	chr15:45694286	SPATA5L1	0.68	12.23	0.49	5.34e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs12681287	0.547	rs7459877	chr8:87505660	G/A	cg27223183	chr8:87520930	FAM82B	-0.49	-7.46	-0.33	4.17e-13	Caudate activity during reward;
LGG	cis	rs4727027	0.865	rs62505077	chr7:148849656	T/A	cg23583168	chr7:148888333	NA	-0.88	-17.1	-0.62	3.63e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6961069	0.745	rs3212160	chr7:80273308	A/C	cg04458919	chr7:80252533	CD36	0.28	6.75	0.3	4.54e-11	Platelet count;
LGG	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg09754948	chr16:28834200	ATXN2L	0.49	7.73	0.34	6.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.31	-0.36	1.11e-15	Tonsillectomy;
LGG	cis	rs7917772	0.582	rs10786683	chr10:104320476	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.63	0.48	1.35e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6835098	0.924	rs1991727	chr4:174163169	A/G	cg08422745	chr4:174089978	GALNT7	-0.78	-14.04	-0.55	1.43e-37	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.54	-0.44	2.04e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg00405596	chr8:11794950	NA	-0.6	-10.69	-0.45	5.33e-24	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10911363	0.592	rs12117885	chr1:183494214	C/T	cg23894439	chr1:183413866	NA	-0.47	-8.82	-0.38	2.39e-17	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg11890956	chr21:40555474	PSMG1	-0.95	-19.14	-0.66	1.44e-60	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06544198	chr6:10723702	TMEM14C	0.42	7.03	0.31	7.25e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg24879335	chr3:133465180	TF	0.43	7.08	0.31	5.54e-12	Iron status biomarkers (transferrin levels);
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.87	-0.3	2.08e-11	Lung cancer;
LGG	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg01028140	chr2:1542097	TPO	-0.47	-8.65	-0.37	8.81e-17	IgG glycosylation;
LGG	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg22437258	chr11:111473054	SIK2	-0.39	-6.85	-0.3	2.34e-11	Primary sclerosing cholangitis;
LGG	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg00405596	chr8:11794950	NA	0.64	11.4	0.47	1.05e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.35	-0.43	1.02e-22	Total body bone mineral density;
LGG	cis	rs7173743	0.756	rs12903668	chr15:79129320	A/G	cg00540400	chr15:79124168	NA	0.39	8.04	0.35	7.64e-15	Coronary artery disease;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2976388	0.556	rs2572876	chr8:143830599	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-14.38	-0.56	4.79e-39	Urinary tract infection frequency;
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-13.44	-0.53	5.55e-35	Gut microbiome composition (summer);
LGG	cis	rs847649	0.767	rs7796678	chr7:102778447	C/T	cg18108683	chr7:102477205	FBXL13	0.54	11.28	0.46	3.15e-26	Morning vs. evening chronotype;
LGG	cis	rs2116941	1.000	rs8104426	chr19:10338676	G/T	cg01850179	chr19:10340795	S1PR2	0.62	9.91	0.42	4.02e-21	Pulse pressure;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.626	rs4855833	chr3:49657441	A/G	cg03060546	chr3:49711283	APEH	0.62	8.66	0.37	8.11e-17	Menarche (age at onset);
LGG	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg17764715	chr19:33622953	WDR88	-0.55	-9.53	-0.41	8.66e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6787172	0.622	rs2362968	chr3:158125946	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs7091068	0.567	rs1572773	chr10:95432968	T/C	cg20715218	chr10:95462985	C10orf4	0.68	12.35	0.5	1.78e-30	Urinary tract infection frequency;
LGG	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg03264133	chr6:25882463	NA	-0.45	-7.29	-0.32	1.33e-12	Iron status biomarkers;
LGG	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24110177	chr3:50126178	RBM5	-0.57	-10.44	-0.44	4.5e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.44	-0.47	7.26e-27	Personality dimensions;
LGG	cis	rs12912292	1	rs12912292	chr15:56038707	G/A	cg17396834	chr15:56014697	PRTG	-0.38	-8.46	-0.37	3.47e-16	Testicular germ cell tumor;
LGG	cis	rs3126085	0.935	rs7550106	chr1:152197202	C/T	cg26876637	chr1:152193138	HRNR	-0.55	-9.03	-0.39	4.52e-18	Atopic dermatitis;
LGG	trans	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg25482853	chr8:67687455	SGK3	0.97	11.88	0.48	1.4e-28	Obesity-related traits;
LGG	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21659725	chr3:3221576	CRBN	-0.92	-20.41	-0.69	1.63e-66	Intelligence (multi-trait analysis);
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.49	-8.29	-0.36	1.25e-15	Renal function-related traits (BUN);
LGG	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.81	0.54	1.37e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs477692	1.000	rs554792	chr10:131423181	A/G	cg05714579	chr10:131428358	MGMT	0.56	11.5	0.47	4.42e-27	Response to temozolomide;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.42	-6.9	-0.31	1.75e-11	Renal function-related traits (BUN);
LGG	cis	rs12042938	0.622	rs12030517	chr1:231808385	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	8.67	0.37	7.18e-17	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs11700980	0.551	rs2832035	chr21:30115032	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-12.14	-0.49	1.18e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-7.07	-0.31	5.85e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.48	-0.33	3.81e-13	Morning vs. evening chronotype;
LGG	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg14784868	chr12:69753453	YEATS4	0.72	13.81	0.54	1.37e-36	Blood protein levels;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg12070911	chr6:150209640	RAET1E	0.28	6.8	0.3	3.3e-11	Lung cancer;
LGG	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg11189052	chr15:85197271	WDR73	-0.55	-9.11	-0.39	2.43e-18	P wave terminal force;
LGG	cis	rs6997458	0.785	rs2548281	chr8:86310776	A/G	cg02393479	chr8:86352350	CA3	-0.31	-6.75	-0.3	4.47e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg12864912	chr4:6988209	TBC1D14	-0.46	-8.7	-0.37	5.89e-17	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.2e-12	HDL cholesterol;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg27476859	chr7:2772710	GNA12	0.52	10.23	0.43	2.69e-22	Height;
LGG	cis	rs7551222	0.646	rs6594015	chr1:204461622	C/T	cg20240347	chr1:204465584	NA	-0.49	-9.23	-0.39	9.95e-19	Schizophrenia;
LGG	cis	rs10463554	0.963	rs40322	chr5:102446957	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.5e-13	Parkinson's disease;
LGG	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg20573242	chr4:122745356	CCNA2	-0.44	-7.53	-0.33	2.6e-13	Type 2 diabetes;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg21963583	chr11:68658836	MRPL21	0.37	6.67	0.3	7.29e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.59	-0.33	1.76e-13	Mean corpuscular hemoglobin;
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg12473912	chr3:136751656	NA	0.43	7.63	0.33	1.34e-13	Neuroticism;
LGG	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg20302533	chr7:39170763	POU6F2	0.56	14.41	0.56	3.7e-39	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.83	-0.3	2.63e-11	Total cholesterol levels;
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg13009111	chr11:71350975	NA	-0.31	-6.92	-0.31	1.47e-11	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14754491	chr12:50677585	LIMA1	0.43	7.22	0.32	2.18e-12	Cognitive performance;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg25072359	chr17:41440525	NA	0.51	9.53	0.4	8.96e-20	Menopause (age at onset);
LGG	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.82e-13	HDL cholesterol;
LGG	cis	rs11239187	0.530	rs11239146	chr10:45064837	C/G	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg08250081	chr4:10125330	NA	0.39	7.55	0.33	2.31e-13	Bone mineral density;
LGG	cis	rs6445975	0.639	rs2037125	chr3:58241231	G/A	cg24175188	chr3:58374923	PXK	0.39	7.24	0.32	1.89e-12	Systemic lupus erythematosus;
LGG	cis	rs7107174	1.000	rs2512538	chr11:77972461	T/G	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg18105134	chr13:113819100	PROZ	0.72	15.38	0.58	2.11e-43	Platelet distribution width;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.84	0.59	1.83e-45	Lung cancer;
LGG	cis	rs9354308	0.738	rs1499706	chr6:66593415	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.84	-0.3	2.44e-11	Metabolite levels;
LGG	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.36	-0.5	1.59e-30	Cognitive function;
LGG	cis	rs1682825	0.591	rs1836293	chr3:10765253	T/G	cg23512531	chr3:10780469	NA	0.57	6.86	0.3	2.22e-11	Economic and political preferences (feminism/equality);
LGG	trans	rs8073060	0.859	rs17550268	chr17:33874678	T/C	cg19694781	chr19:47549865	TMEM160	0.85	13.37	0.53	1.08e-34	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6546550	0.901	rs12613947	chr2:70161342	A/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.88	-0.34	2.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg26354017	chr1:205819088	PM20D1	0.94	24.99	0.76	7.18e-88	Menarche (age at onset);
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.59	-0.33	1.76e-13	Personality dimensions;
LGG	cis	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg07460842	chr6:66804631	NA	0.73	12.6	0.51	1.65e-31	Type 2 diabetes;
LGG	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-12.13	-0.49	1.39e-29	Menarche (age at onset);
LGG	cis	rs244899	0.935	rs2432645	chr5:167936423	A/G	cg06604206	chr5:167912465	RARS	-0.52	-11.45	-0.47	6.92e-27	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg17927777	chr20:33865990	NA	0.73	9.83	0.42	7.89e-21	Attention deficit hyperactivity disorder;
LGG	cis	rs12410462	0.591	rs965942	chr1:227772974	A/G	cg04117972	chr1:227635322	NA	0.47	8.5	0.37	2.69e-16	Major depressive disorder;
LGG	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.45	7.6	0.33	1.67e-13	Cognitive test performance;
LGG	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.0	11.19	0.46	6.9e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.81	0.41	9.09e-21	Mean corpuscular volume;
LGG	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs7301826	1.000	rs2001483	chr12:131318645	A/G	cg11011512	chr12:131303247	STX2	0.34	7.43	0.33	5.37e-13	Plasma plasminogen activator levels;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02539911	chr17:58677246	PPM1D	0.46	7.34	0.32	9.4e-13	Gut microbiome composition (summer);
LGG	cis	rs2117029	0.586	rs11168882	chr12:49537343	G/A	cg24176009	chr12:49580217	TUBA1A	0.63	12.27	0.5	3.52e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.761	rs7225637	chr17:80059758	A/G	cg19223190	chr17:80058835	NA	0.49	9.78	0.41	1.14e-20	Life satisfaction;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.11	-0.31	4.53e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs514024	0.729	rs557630	chr9:130491998	C/T	cg13643465	chr9:130375613	STXBP1	-0.6	-11.14	-0.46	1.03e-25	Eating disorders (purging via substances);
LGG	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg20587970	chr11:113659929	NA	1.06	16.27	0.6	2.03e-47	Hip circumference adjusted for BMI;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.48	-8.25	-0.36	1.69e-15	Longevity;Endometriosis;
LGG	cis	rs28374715	0.681	rs77187862	chr15:41619276	A/T	cg18705301	chr15:41695430	NDUFAF1	-1.18	-24.76	-0.75	7.8e-87	Ulcerative colitis;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg06885757	chr1:42089581	HIVEP3	-0.56	-12.79	-0.51	2.75e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04681579	chr7:75027559	TRIM73;TRIM74	0.44	7.46	0.33	4.17e-13	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.89	-0.51	1.03e-32	Gut microbiome composition (summer);
LGG	trans	rs1997103	1.000	rs6966183	chr7:55407546	A/C	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg00784671	chr22:46762841	CELSR1	-0.56	-7.31	-0.32	1.18e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg15971980	chr6:150254442	NA	-0.45	-7.26	-0.32	1.61e-12	Lung cancer;
LGG	cis	rs6121246	0.697	rs6088864	chr20:30228157	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.21	0.43	3.38e-22	Mean corpuscular hemoglobin;
LGG	cis	rs754466	0.606	rs55854323	chr10:79589904	C/T	cg17075019	chr10:79541650	NA	-0.96	-20.91	-0.7	7.14e-69	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg04731861	chr2:219085781	ARPC2	-0.44	-10.85	-0.45	1.36e-24	Colorectal cancer;
LGG	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg13679303	chr9:96623674	NA	-0.39	-6.88	-0.3	1.9e-11	DNA methylation (variation);
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.71	-0.48	6.25e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs11645898	0.935	rs72787077	chr16:72156674	C/T	cg14768367	chr16:72042858	DHODH	-0.82	-11.17	-0.46	8.06e-26	Blood protein levels;
LGG	cis	rs9513627	1.000	rs7338335	chr13:100125296	G/C	cg15490075	chr13:100150979	NA	-0.66	-6.92	-0.31	1.52e-11	Obesity-related traits;
LGG	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg15268244	chr15:77196840	NA	-0.34	-7.59	-0.33	1.78e-13	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.48	-0.53	3.42e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg11693508	chr17:37793320	STARD3	0.51	7.31	0.32	1.2e-12	Bipolar disorder;
LGG	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg07150166	chr2:30669952	LCLAT1	0.61	8.6	0.37	1.22e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00292435	chr9:91925643	CKS2	0.39	6.86	0.3	2.16e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02304285	chr10:102747340	C10orf2;MRPL43	0.44	6.68	0.3	6.71e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18146873	chr5:142782827	NR3C1	0.5	7.57	0.33	2.08e-13	Gut microbiome composition (summer);
LGG	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.72	0.41	1.91e-20	Hypertriglyceridemia;
LGG	cis	rs6594713	0.921	rs6594714	chr5:112738620	C/G	cg12552261	chr5:112820674	MCC	0.5	7.23	0.32	2.06e-12	Brain cytoarchitecture;
LGG	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.69	-0.45	5.36e-24	IgG glycosylation;
LGG	cis	rs9790314	0.613	rs6809177	chr3:160630477	G/T	cg03342759	chr3:160939853	NMD3	0.44	7.38	0.32	7.52e-13	Morning vs. evening chronotype;
LGG	cis	rs6743376	0.556	rs2515391	chr2:113815997	C/T	cg05949173	chr2:113825882	IL1F10	0.49	9.64	0.41	3.59e-20	Inflammatory biomarkers;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg23782820	chr8:58130467	NA	0.51	7.21	0.32	2.24e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7326068	0.610	rs9552275	chr13:21337389	G/A	cg04906043	chr13:21280425	IL17D	-0.44	-7.15	-0.32	3.46e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.54	-0.53	2.02e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs611744	0.669	rs13251024	chr8:109258333	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg06108461	chr20:60628389	TAF4	-0.66	-9.54	-0.41	8.48e-20	Obesity-related traits;
LGG	cis	rs3813359	0.545	rs62431197	chr6:130550896	C/T	cg23281432	chr6:130554730	NA	0.51	7.36	0.32	8.38e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06470251	chr20:60548479	NA	0.42	7.25	0.32	1.8e-12	Body mass index;
LGG	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg09904177	chr6:26538194	HMGN4	0.68	14.0	0.55	2.08e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg18245976	chr7:158708271	WDR60	-0.55	-9.82	-0.42	8.11e-21	Height;
LGG	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg08704250	chr15:31115839	NA	0.5	8.89	0.38	1.36e-17	Huntington's disease progression;
LGG	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.24	-0.36	1.83e-15	Restless legs syndrome;
LGG	cis	rs11792861	0.816	rs11790105	chr9:111731785	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	10.01	0.42	1.74e-21	Menarche (age at onset);
LGG	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.49	-0.37	2.89e-16	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg23758822	chr17:41437982	NA	0.89	13.3	0.53	2.09e-34	Menopause (age at onset);
LGG	cis	rs9790314	1.000	rs459697	chr3:161093420	G/A	cg03342759	chr3:160939853	NMD3	-0.64	-11.25	-0.46	4.1e-26	Morning vs. evening chronotype;
LGG	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg02023728	chr11:77925099	USP35	-0.42	-7.52	-0.33	2.92e-13	Testicular germ cell tumor;
LGG	cis	rs4849975	0.510	rs28548099	chr2:3710938	G/A	cg16123090	chr2:3699210	NA	0.6	7.8	0.34	4.26e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.3	0.47	2.49e-26	Vitamin D levels;
LGG	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg02931644	chr1:25747376	RHCE	0.46	10.55	0.44	1.85e-23	Erythrocyte sedimentation rate;
LGG	cis	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg11764359	chr7:65958608	NA	-0.61	-10.1	-0.43	8.08e-22	Aortic root size;
LGG	trans	rs1032833	0.732	rs78129581	chr2:180040691	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg25039879	chr17:56429692	SUPT4H1	0.64	9.01	0.39	5.31e-18	Cognitive test performance;
LGG	cis	rs60695258	0.529	rs340630	chr4:87958395	G/A	cg01323104	chr4:87958903	AFF1	-0.24	-6.95	-0.31	1.24e-11	Hematocrit;
LGG	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg02002194	chr4:3960332	NA	0.4	7.18	0.32	2.75e-12	Neuroticism;
LGG	trans	rs11782517	0.920	rs13266832	chr8:10107068	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-6.92	-0.31	1.49e-11	Nose size;
LGG	cis	rs9790314	1.000	rs9846756	chr3:160983809	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs12347191	0.500	rs907579	chr9:100622723	G/T	cg13688889	chr9:100608707	NA	-0.82	-16.1	-0.6	1.18e-46	Orofacial clefts;
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.66	0.41	3.1e-20	Bipolar disorder;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg05552183	chr6:42928497	GNMT	0.44	13.0	0.52	3.87e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.59	-0.33	1.78e-13	Depression;
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.15	-0.35	3.44e-15	Personality dimensions;
LGG	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg22681709	chr2:178499509	PDE11A	-0.47	-8.66	-0.37	7.71e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs240764	0.528	rs964223	chr6:101250982	T/A	cg09795085	chr6:101329169	ASCC3	0.43	6.9	0.31	1.67e-11	Neuroticism;
LGG	cis	rs12220238	1.000	rs11000924	chr10:75972311	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9467773	0.526	rs12199613	chr6:26367218	C/T	cg09904177	chr6:26538194	HMGN4	-0.42	-7.41	-0.33	6.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.69	0.61	2.63e-49	Platelet count;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg02002194	chr4:3960332	NA	0.51	9.73	0.41	1.78e-20	Neuroticism;
LGG	cis	rs6540556	0.723	rs10863783	chr1:209889802	T/C	cg23920097	chr1:209922102	NA	-0.43	-6.92	-0.31	1.52e-11	Red blood cell count;
LGG	cis	rs7294478	0.738	rs11050917	chr12:7264406	C/T	cg01074767	chr12:7262137	C1RL;LOC283314	-0.37	-10.0	-0.42	1.97e-21	Neuritic plaque;
LGG	cis	rs4380275	0.809	rs6753699	chr2:766081	A/C	cg02758766	chr2:740531	NA	-0.39	-6.9	-0.31	1.76e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs367615	0.680	rs253247	chr5:108983966	A/G	cg17395555	chr5:108820864	NA	0.53	6.79	0.3	3.35e-11	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg20628663	chr10:43360327	NA	-0.4	-8.07	-0.35	5.93e-15	Blood protein levels;
LGG	cis	rs7615952	0.800	rs11914298	chr3:125643772	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-10.97	-0.45	4.74e-25	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs367943	0.556	rs7709820	chr5:112991327	G/A	cg12552261	chr5:112820674	MCC	0.5	8.84	0.38	2.05e-17	Type 2 diabetes;
LGG	cis	rs4262150	0.883	rs56269251	chr5:152194094	A/G	cg12297329	chr5:152029980	NA	-0.68	-12.82	-0.51	2.03e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs7927771	0.524	rs754434	chr11:47814280	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.08	0.46	1.89e-25	Subjective well-being;
LGG	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.32	0.32	1.12e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg04568710	chr12:38710424	ALG10B	0.34	7.04	0.31	6.99e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05306546	chr7:100076560	TSC22D4	0.44	6.81	0.3	3.01e-11	Gut microbiome composition (summer);
LGG	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg16105309	chr15:79090380	ADAMTS7	0.43	7.5	0.33	3.31e-13	Schizophrenia;
LGG	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg24110177	chr3:50126178	RBM5	0.61	11.26	0.46	3.54e-26	Body mass index;
LGG	cis	rs7751419	0.651	rs1864059	chr6:39105177	T/G	cg08089693	chr6:39098871	NA	-0.44	-8.07	-0.35	6.3e-15	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs782590	0.902	rs2586947	chr2:55854009	C/G	cg18811423	chr2:55921094	PNPT1	0.86	19.81	0.68	1.07e-63	Metabolic syndrome;
LGG	cis	rs1497828	1.000	rs2815241	chr1:217549909	G/A	cg04411442	chr1:217543379	NA	0.47	8.09	0.35	5.17e-15	Dialysis-related mortality;
LGG	trans	rs7944735	0.767	rs1017875	chr11:47999218	C/T	cg03929089	chr4:120376271	NA	0.67	8.26	0.36	1.59e-15	Intraocular pressure;
LGG	cis	rs6764363	0.654	rs455239	chr3:299025	C/G	cg02057681	chr3:285234	CHL1	0.39	6.97	0.31	1.12e-11	Sudden cardiac arrest;
LGG	cis	rs6686643	0.868	rs9333461	chr1:165618320	G/T	cg19407955	chr1:165599744	MGST3	-0.54	-8.01	-0.35	9.45e-15	Total ventricular volume;
LGG	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.67	-0.3	7.21e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6430585	0.591	rs72970243	chr2:136484232	G/A	cg07169764	chr2:136633963	MCM6	0.95	15.78	0.59	3.37e-45	Corneal structure;
LGG	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg03114573	chr12:45410052	DBX2	-0.68	-12.21	-0.49	6.53e-30	Gut microbiome composition (summer);
LGG	trans	rs12579753	0.917	rs12822036	chr12:82183009	C/T	cg07923666	chr12:49932857	KCNH3	-0.51	-7.89	-0.34	2.27e-14	Resting heart rate;
LGG	cis	rs4148087	0.929	rs2381037	chr21:43612608	C/A	cg08841829	chr21:43638893	ABCG1	-0.54	-7.26	-0.32	1.67e-12	Eating disorder in bipolar disorder;
LGG	cis	rs2952156	0.920	rs8078228	chr17:37834998	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.87e-16	Asthma;
LGG	cis	rs514406	0.607	rs6696940	chr1:53203427	C/T	cg16325326	chr1:53192061	ZYG11B	-0.89	-24.19	-0.75	3.54e-84	Monocyte count;
LGG	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg21058520	chr6:100914733	NA	0.41	7.07	0.31	5.82e-12	Neuroticism;
LGG	cis	rs832540	0.931	rs832536	chr5:56212595	C/T	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.78e-11	Coronary artery disease;
LGG	cis	rs2235573	0.836	rs12162647	chr22:38490801	G/C	cg19171272	chr22:38449367	NA	0.44	8.39	0.36	6.15e-16	Glioblastoma;Glioma;
LGG	cis	rs9300255	0.602	rs2695476	chr12:123694206	T/C	cg00376283	chr12:123451042	ABCB9	0.62	9.43	0.4	1.98e-19	Neutrophil percentage of white cells;
LGG	cis	rs9486719	0.948	rs11153059	chr6:97014537	T/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg03806693	chr22:41940476	POLR3H	1.07	18.28	0.65	1.33e-56	Vitiligo;
LGG	cis	rs8141529	0.764	rs5752807	chr22:29223169	A/G	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.7e-28	Lymphocyte counts;
LGG	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg06453172	chr10:134556979	INPP5A	0.53	8.3	0.36	1.15e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg15208524	chr1:10270712	KIF1B	0.43	7.69	0.34	8.86e-14	Hepatocellular carcinoma;
LGG	cis	rs8048589	0.948	rs11648228	chr16:12181702	G/T	cg02910054	chr16:12241554	SNX29	0.42	6.68	0.3	6.69e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg12473912	chr3:136751656	NA	0.43	7.62	0.33	1.42e-13	Neuroticism;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg13206674	chr6:150067644	NUP43	0.67	15.3	0.58	4.67e-43	Lung cancer;
LGG	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg26396452	chr14:65542826	MAX	0.43	8.44	0.37	4.03e-16	Obesity-related traits;
LGG	cis	rs9354308	0.764	rs9342511	chr6:66589672	C/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs75804782	0.625	rs72984535	chr2:239470022	T/C	cg01134436	chr17:81009848	B3GNTL1	0.75	7.92	0.35	1.74e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg06916706	chr16:4465613	CORO7	-0.87	-14.93	-0.57	1.94e-41	Schizophrenia;
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg25660036	chr4:7070649	GRPEL1	-0.48	-7.27	-0.32	1.58e-12	Monocyte percentage of white cells;
LGG	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg13010199	chr12:38710504	ALG10B	0.77	16.53	0.61	1.4e-48	Heart rate;
LGG	cis	rs9443645	0.901	rs9361488	chr6:79782874	T/C	cg18132916	chr6:79620363	NA	-0.3	-8.21	-0.36	2.28e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.2	-0.49	6.82e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06470251	chr20:60548479	NA	0.5	8.74	0.38	4.33e-17	Body mass index;
LGG	cis	rs3087591	0.960	rs10512433	chr17:29600564	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	14.66	0.56	2.9e-40	Hip circumference;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.51	0.33	3.16e-13	Schizophrenia;
LGG	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.55	9.84	0.42	6.88e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2229238	0.866	rs59741504	chr1:154504601	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.11e-11	Coronary heart disease;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg23188684	chr11:67383651	NA	-0.5	-7.33	-0.32	1.02e-12	Mean corpuscular volume;
LGG	cis	rs7241530	0.636	rs34068602	chr18:75898236	C/T	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg25664220	chr3:72788482	NA	-0.33	-9.45	-0.4	1.63e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg09818912	chr17:20140352	CYTSB	-0.32	-7.54	-0.33	2.49e-13	Schizophrenia;
LGG	cis	rs2270450	0.650	rs9369632	chr6:46713394	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.51e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs2871865	0.841	rs28410907	chr15:99206835	G/A	cg03437748	chr15:99193247	IGF1R	0.64	6.66	0.3	7.66e-11	Height;
LGG	cis	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6960043	1.000	rs6972333	chr7:15051643	G/A	cg19272540	chr7:15055459	NA	-0.36	-8.09	-0.35	5.44e-15	Type 2 diabetes;
LGG	cis	rs9487051	0.676	rs6568568	chr6:109597048	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.38e-14	Reticulocyte fraction of red cells;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.48	-0.47	5.31e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs8077889	1.000	rs17742905	chr17:41891143	C/A	cg26893861	chr17:41843967	DUSP3	0.94	15.83	0.59	2.09e-45	Triglycerides;
LGG	cis	rs4330281	0.626	rs13327810	chr3:17464911	C/A	cg20981856	chr3:17787350	NA	0.35	6.77	0.3	4.03e-11	Schizophrenia;
LGG	cis	rs12210905	0.920	rs9379975	chr6:27295808	T/A	cg15325629	chr6:28072465	NA	0.87	6.77	0.3	3.84e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.85	-18.68	-0.66	1.95e-58	Chronic sinus infection;
LGG	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg18129748	chr3:49941408	MST1R	-0.23	-7.31	-0.32	1.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13421350	0.579	rs79474289	chr2:173362046	C/A	cg15021238	chr2:173305865	ITGA6	-0.79	-8.48	-0.37	3.07e-16	Diabetic kidney disease;
LGG	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-7.01	-0.31	8.56e-12	Type 2 diabetes;
LGG	cis	rs4671458	0.739	rs72806056	chr2:63837680	T/C	cg17519650	chr2:63277830	OTX1	-0.55	-7.18	-0.32	2.84e-12	Subjective well-being;
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg02524346	chr8:600233	NA	1.36	12.92	0.51	8e-33	IgG glycosylation;
LGG	cis	rs3206736	0.548	rs328891	chr7:35013517	C/T	cg13400248	chr7:35225412	NA	0.54	9.21	0.39	1.12e-18	Diastolic blood pressure;
LGG	cis	rs17039065	0.920	rs17039103	chr4:109434995	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.64	0.33	1.3e-13	Gut microbiome composition (summer);
LGG	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg27432699	chr2:27873401	GPN1	-0.76	-15.8	-0.59	2.71e-45	Oral cavity cancer;
LGG	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg24011408	chr12:48396354	COL2A1	0.48	7.69	0.34	8.97e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs3008870	1.000	rs2815351	chr1:67477980	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	21.71	0.71	1.28e-72	Lymphocyte percentage of white cells;
LGG	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg15704280	chr7:45808275	SEPT13	-0.45	-7.21	-0.32	2.34e-12	HDL cholesterol;
LGG	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg02297831	chr4:17616191	MED28	0.4	7.07	0.31	5.76e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs751728	1.000	rs9380378	chr6:33765479	T/C	cg25922239	chr6:33757077	LEMD2	0.69	12.13	0.49	1.3e-29	Crohn's disease;
LGG	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg00666640	chr1:248458726	OR2T12	0.55	9.1	0.39	2.7e-18	Common traits (Other);
LGG	cis	rs953387	1.000	rs950176	chr2:136898078	A/G	cg07169764	chr2:136633963	MCM6	0.55	9.27	0.4	7.05e-19	Arthritis (juvenile idiopathic);
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09217309	chr6:150244204	RAET1G	-0.44	-8.17	-0.36	2.88e-15	Testicular germ cell tumor;
LGG	cis	rs35883536	0.626	rs10493933	chr1:101111282	A/G	cg06223162	chr1:101003688	GPR88	-0.38	-9.03	-0.39	4.51e-18	Monocyte count;
LGG	cis	rs4727027	0.704	rs12704070	chr7:148902789	G/A	cg23583168	chr7:148888333	NA	-0.94	-19.37	-0.67	1.16e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.37	0.43	8.42e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21252276	chr9:135037801	NTNG2	0.44	6.88	0.3	1.99e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.59e-12	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06207852	chr22:41033162	MKL1	0.4	6.72	0.3	5.52e-11	Bipolar disorder;
LGG	cis	rs2404602	0.583	rs2469542	chr15:76557476	A/G	cg22467129	chr15:76604101	ETFA	0.43	7.18	0.32	2.84e-12	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.48	-0.53	3.61e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs941873	0.805	rs10824747	chr10:81118464	T/C	cg09469691	chr10:81107165	PPIF	0.56	9.57	0.41	6.37e-20	Height;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg23758822	chr17:41437982	NA	0.9	15.27	0.58	5.98e-43	Menopause (age at onset);
LGG	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg16586182	chr3:47516702	SCAP	0.72	12.81	0.51	2.18e-32	QT interval;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg04503457	chr17:41445688	NA	0.41	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21659725	chr3:3221576	CRBN	-0.65	-12.04	-0.49	3.23e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.08	-0.31	5.51e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg06191203	chr2:152266755	RIF1	0.37	6.73	0.3	4.94e-11	Lung cancer;
LGG	cis	rs4771450	0.962	rs9300802	chr13:103974558	C/A	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.27	0.58	6.14e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.82	-0.42	8.68e-21	Coronary artery disease;
LGG	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.97	-0.45	4.81e-25	Hemoglobin concentration;
LGG	cis	rs4948275	0.741	rs2787695	chr10:63291845	G/T	cg03237606	chr10:63212265	TMEM26	-0.39	-7.01	-0.31	8.41e-12	Night sleep phenotypes;
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.88	-0.34	2.41e-14	Menopause (age at onset);
LGG	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg03162506	chr22:38580953	NA	0.34	8.31	0.36	1.08e-15	Melanoma;
LGG	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs2476847	1.000	rs2473490	chr6:549364	G/A	cg13471009	chr6:564609	EXOC2	0.34	7.4	0.33	6.52e-13	Inflammatory skin disease;
LGG	trans	rs9914544	0.545	rs8069826	chr17:18765490	G/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.53	-0.33	2.7e-13	Educational attainment (years of education);
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg26338869	chr17:61819248	STRADA	-0.47	-7.49	-0.33	3.42e-13	Prudent dietary pattern;
LGG	cis	rs5769707	0.521	rs5769719	chr22:50062101	G/A	cg06623630	chr22:50017776	C22orf34	-0.46	-9.05	-0.39	4.03e-18	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg21775007	chr8:11205619	TDH	0.61	10.14	0.43	6.06e-22	Retinal vascular caliber;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg21910821	chr19:52407881	ZNF649	0.4	7.04	0.31	7.16e-12	Body mass index;
LGG	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg19680485	chr15:31195859	MTMR15	-0.44	-6.73	-0.3	5.09e-11	Huntington's disease progression;
LGG	cis	rs7107174	1.000	rs2292572	chr11:78052864	G/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.44	-0.33	4.9e-13	Testicular germ cell tumor;
LGG	cis	rs13421350	0.579	rs16860513	chr2:173342367	T/A	cg15021238	chr2:173305865	ITGA6	-0.7	-8.0	-0.35	1.02e-14	Diabetic kidney disease;
LGG	cis	rs6547631	0.622	rs10180451	chr2:85926238	G/T	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22168489	chr12:122356033	WDR66	-0.41	-9.96	-0.42	2.64e-21	Mean corpuscular volume;
LGG	trans	rs6787172	0.622	rs12633594	chr3:158124944	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs67133203	0.808	rs6580792	chr12:51530796	A/G	cg14688905	chr12:51403056	SLC11A2	0.7	10.53	0.44	2.15e-23	Urinary tract infection frequency;
LGG	cis	rs10191773	0.584	rs72831633	chr2:112945932	T/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.54	-7.95	-0.35	1.4e-14	Yeast infection;
LGG	trans	rs634534	0.562	rs661335	chr11:65754061	G/A	cg17712092	chr4:129076599	LARP1B	0.74	14.15	0.55	4.83e-38	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs16854884	0.789	rs34096668	chr3:143794483	C/T	cg06585982	chr3:143692056	C3orf58	0.57	9.48	0.4	1.33e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs1915146	1.000	rs1915146	chr10:126846214	A/G	cg05090351	chr10:126851162	NA	0.32	7.99	0.35	1.06e-14	Menarche (age at onset);
LGG	cis	rs11715604	1	rs11715604	chr3:136589549	A/T	cg21827317	chr3:136751795	NA	-0.55	-6.93	-0.31	1.42e-11	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07167872	chr1:205819463	PM20D1	0.57	11.4	0.47	1.04e-26	Menarche (age at onset);
LGG	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.23	0.55	2.23e-38	Cognitive test performance;
LGG	cis	rs3087591	0.960	rs2952999	chr17:29509801	G/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.41	0.56	3.54e-39	Hip circumference;
LGG	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg13628971	chr7:2884303	GNA12	0.51	10.1	0.42	8.15e-22	Height;
LGG	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg14101638	chr12:121416612	HNF1A	-0.44	-9.65	-0.41	3.45e-20	Metabolic traits;LDL cholesterol;
LGG	trans	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg25214090	chr10:38739885	LOC399744	0.7	12.48	0.5	4.99e-31	Corneal astigmatism;
LGG	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.43	-0.44	5.12e-23	Hemoglobin concentration;
LGG	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg14689365	chr7:158441557	NCAPG2	0.58	7.01	0.31	8.26e-12	Height;
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg19524238	chr7:2802976	GNA12	0.38	8.74	0.38	4.32e-17	Height;
LGG	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg09462578	chr12:12878428	APOLD1	0.46	7.6	0.33	1.68e-13	Pulse pressure;
LGG	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg01620082	chr3:125678407	NA	-0.83	-9.62	-0.41	4.35e-20	Breast cancer;
LGG	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	4.95e-12	Prudent dietary pattern;
LGG	cis	rs2354432	0.607	rs66486822	chr1:146802653	T/A	cg25205988	chr1:146714368	CHD1L	-1.43	-14.5	-0.56	1.55e-39	Mitochondrial DNA levels;
LGG	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs2071403	0.933	rs938326	chr2:1401781	C/T	cg06500727	chr2:1417164	TPO	-0.49	-9.43	-0.4	2.04e-19	Thyroid peroxidase antibody positivity;
LGG	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg24375607	chr4:120327624	NA	0.66	10.98	0.45	4.43e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg21724239	chr8:58056113	NA	-0.5	-7.38	-0.32	7.48e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.49	-8.3	-0.36	1.19e-15	Menarche (age at onset);
LGG	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg25143771	chr10:104629124	AS3MT	0.39	6.72	0.3	5.31e-11	Arsenic metabolism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14741666	chr17:34842576	ZNHIT3	0.53	7.99	0.35	1.09e-14	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg13009111	chr11:71350975	NA	-0.31	-6.79	-0.3	3.45e-11	Neuroticism;
LGG	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.54	-7.65	-0.33	1.21e-13	Diabetic retinopathy;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	12.35	0.5	1.68e-30	Longevity;
LGG	cis	rs11690935	0.921	rs3770445	chr2:172708919	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-25.58	-0.77	1.26e-90	Schizophrenia;
LGG	cis	rs4363385	0.510	rs61811902	chr1:153053464	A/G	cg13444842	chr1:152974279	SPRR3	-0.47	-9.22	-0.39	1.05e-18	Inflammatory skin disease;
LGG	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg01448562	chr3:133502909	NA	-0.72	-13.29	-0.53	2.21e-34	Iron status biomarkers;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg06074448	chr4:187884817	NA	-0.58	-12.76	-0.51	3.64e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg18876405	chr7:65276391	NA	-0.52	-8.78	-0.38	3.2e-17	Aortic root size;
LGG	trans	rs8073060	0.586	rs11080356	chr17:33895309	T/C	cg19694781	chr19:47549865	TMEM160	1.11	17.31	0.63	4.15e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg01221209	chr5:554886	NA	-0.45	-6.73	-0.3	5.19e-11	Obesity-related traits;
LGG	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg16339924	chr4:17578868	LAP3	-0.65	-11.08	-0.46	1.76e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg15208524	chr1:10270712	KIF1B	0.44	7.86	0.34	2.68e-14	Hepatocellular carcinoma;
LGG	cis	rs3784262	0.669	rs12915508	chr15:58302036	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.76	-0.3	4.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.19	-0.36	2.59e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7617773	0.817	rs6806112	chr3:48276077	A/T	cg11946769	chr3:48343235	NME6	0.57	9.53	0.4	8.95e-20	Coronary artery disease;
LGG	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg10636054	chr15:40330586	SRP14	1.22	14.03	0.55	1.65e-37	Corneal curvature;
LGG	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.76	-0.41	1.41e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11168618	0.846	rs11168577	chr12:48842592	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.96	0.35	1.37e-14	Adiponectin levels;
LGG	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.62	-0.41	4.33e-20	Response to antipsychotic treatment;
LGG	cis	rs7586879	0.828	rs12986610	chr2:25106265	A/G	cg04586622	chr2:25135609	ADCY3	-0.33	-7.92	-0.35	1.76e-14	Body mass index;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.67	-0.54	5.8e-36	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26161780	chr14:61448269	TRMT5;SLC38A6	0.44	7.03	0.31	7.61e-12	Cognitive performance;
LGG	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	10.23	0.43	2.83e-22	Iron status biomarkers;
LGG	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	6.64	0.3	8.57e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg02811702	chr13:24901961	NA	0.38	7.13	0.31	3.85e-12	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg04672837	chr16:48644449	N4BP1	0.56	9.31	0.4	5.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10982213	0.830	rs7861409	chr9:117181190	A/G	cg00969271	chr9:117093052	ORM2	0.42	7.15	0.32	3.46e-12	Interleukin-6 levels;
LGG	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg11247378	chr22:39784982	NA	-0.32	-9.15	-0.39	1.8e-18	Intelligence (multi-trait analysis);
LGG	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg08344181	chr3:125677491	NA	-0.53	-7.1	-0.31	4.6e-12	Depression;
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg11984989	chr7:158649758	WDR60	1.04	23.01	0.73	1.07e-78	Height;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.45	-0.44	4.24e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg06885757	chr1:42089581	HIVEP3	0.56	12.75	0.51	3.89e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs362296	0.698	rs3135168	chr4:3262699	T/C	cg06533319	chr4:3265114	C4orf44	0.52	10.79	0.45	2.36e-24	Parental longevity (mother's age at death);
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg12310025	chr6:25882481	NA	0.49	9.06	0.39	3.78e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg25664220	chr3:72788482	NA	-0.33	-9.19	-0.39	1.33e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg02725872	chr8:58115012	NA	-0.95	-13.07	-0.52	1.82e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4804815	0.780	rs4804231	chr19:7839803	C/A	cg00970558	chr19:7854469	CLEC4GP1	0.63	9.6	0.41	5.03e-20	Neutrophil count;
LGG	cis	rs9463078	0.547	rs4449629	chr6:44717808	T/C	cg25276700	chr6:44698697	NA	0.44	9.12	0.39	2.38e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs926938	0.618	rs3121506	chr1:115363207	T/G	cg12756093	chr1:115239321	AMPD1	0.46	8.55	0.37	1.76e-16	Autism;
LGG	cis	rs28595532	1.000	rs11938970	chr4:119660152	A/G	cg21605333	chr4:119757512	SEC24D	1.22	12.15	0.49	1.11e-29	Cannabis dependence symptom count;
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.34	-0.43	1.14e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg02297831	chr4:17616191	MED28	-0.48	-8.71	-0.38	5.52e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg25072359	chr17:41440525	NA	0.5	9.71	0.41	2.14e-20	Menopause (age at onset);
LGG	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg14952266	chr13:112191215	NA	0.52	11.01	0.46	3.31e-25	Hepatitis;
LGG	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs3816183	0.585	rs4953528	chr2:42870156	C/T	cg14631114	chr2:43023945	NA	0.35	6.85	0.3	2.31e-11	Hypospadias;
LGG	cis	rs4959677	0.935	rs7758842	chr6:2496664	A/G	cg20147862	chr6:2634573	C6orf195	0.37	8.03	0.35	7.89e-15	Orthostatic hypotension;
LGG	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg03213289	chr20:61660250	NA	0.66	14.48	0.56	1.81e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs209489	0.892	rs17544110	chr6:53130222	T/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21659725	chr3:3221576	CRBN	-0.67	-12.41	-0.5	9.5e-31	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg08885076	chr2:99613938	TSGA10	0.43	9.25	0.4	8.05e-19	Chronic sinus infection;
LGG	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg26597838	chr10:835615	NA	-0.53	-8.67	-0.37	7.36e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.78	0.34	4.88e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13314892	0.689	rs62252226	chr3:69885246	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.87	-0.34	2.49e-14	QRS complex (12-leadsum);
LGG	cis	rs4356975	0.563	rs4541594	chr4:69972272	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg13395646	chr4:1353034	KIAA1530	0.53	9.28	0.4	6.6e-19	Obesity-related traits;
LGG	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg13010199	chr12:38710504	ALG10B	0.46	8.94	0.38	9.21e-18	Morning vs. evening chronotype;
LGG	trans	rs2562456	0.754	rs11673320	chr19:21507603	G/A	cg00806126	chr19:22604979	ZNF98	-0.55	-7.28	-0.32	1.42e-12	Pain;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.07e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs946100	chr1:152971663	C/T	cg13444842	chr1:152974279	SPRR3	0.45	9.3	0.4	5.67e-19	Inflammatory skin disease;
LGG	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.16	0.32	3.16e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg25214090	chr10:38739885	LOC399744	0.57	10.42	0.44	5.63e-23	Corneal astigmatism;
LGG	cis	rs2012796	1.000	rs10450939	chr14:81825202	A/T	cg02996355	chr14:81879375	NA	0.52	8.3	0.36	1.18e-15	Night sleep phenotypes;
LGG	cis	rs13082711	0.911	rs34422761	chr3:27513366	C/A	cg02860705	chr3:27208620	NA	0.69	12.3	0.5	2.66e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs593982	0.858	rs663797	chr11:65552740	A/G	cg08755490	chr11:65554678	OVOL1	0.76	11.71	0.48	6.6e-28	Atopic dermatitis;
LGG	cis	rs4698433	1.000	rs4698432	chr4:15964763	A/G	cg15380744	chr4:15964812	FGFBP2	0.24	6.73	0.3	5.13e-11	QT interval;
LGG	cis	rs6997458	0.904	rs725605	chr8:86266886	C/T	cg02393479	chr8:86352350	CA3	-0.3	-6.66	-0.3	7.77e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.27	0.4	6.91e-19	Platelet count;
LGG	cis	rs2130392	0.924	rs873687	chr4:185638853	G/A	cg21366198	chr4:185655624	MLF1IP	0.44	7.71	0.34	7.76e-14	Kawasaki disease;
LGG	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.44	0.47	7.41e-27	Coronary artery disease;
LGG	cis	rs3741151	1.000	rs75109191	chr11:73023532	T/C	cg17517138	chr11:73019481	ARHGEF17	1.05	10.51	0.44	2.64e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7084402	0.764	rs2393455	chr10:60374898	C/A	cg07615347	chr10:60278583	BICC1	0.58	14.97	0.57	1.31e-41	Refractive error;
LGG	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	12.94	0.52	6.3e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg07959490	chr17:80112427	CCDC57	0.47	9.3	0.4	5.46e-19	Life satisfaction;
LGG	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg00990874	chr7:1149470	C7orf50	-0.84	-13.49	-0.53	3.11e-35	Bronchopulmonary dysplasia;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	8.26	0.36	1.55e-15	Menarche (age at onset);
LGG	cis	rs3735485	0.760	rs868191	chr7:45064187	T/G	cg03440944	chr7:45023329	C7orf40	0.55	9.4	0.4	2.62e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	7.4	0.33	6.26e-13	Systemic lupus erythematosus;
LGG	cis	rs28595532	0.925	rs28627331	chr4:119665345	T/C	cg21605333	chr4:119757512	SEC24D	1.39	12.82	0.51	2.04e-32	Cannabis dependence symptom count;
LGG	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg02002194	chr4:3960332	NA	-0.57	-11.46	-0.47	6.35e-27	Systolic blood pressure;
LGG	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs17453880	0.929	rs7731459	chr5:152032506	C/T	cg12297329	chr5:152029980	NA	-0.9	-23.59	-0.74	2.26e-81	Subjective well-being;
LGG	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg23815491	chr16:72088622	HP	0.51	11.68	0.48	8.35e-28	Fibrinogen levels;
LGG	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg06606381	chr12:133084897	FBRSL1	-1.17	-10.1	-0.42	8.27e-22	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9649465	1.000	rs11765478	chr7:123362872	A/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.86	-0.38	1.76e-17	Migraine;
LGG	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg08603382	chr10:743973	NA	0.38	7.0	0.31	8.89e-12	Psychosis in Alzheimer's disease;
LGG	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg12395012	chr8:11607386	GATA4	0.37	6.86	0.3	2.15e-11	Myopia (pathological);
LGG	cis	rs6784615	0.590	rs4687618	chr3:52513940	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg27661571	chr11:113659931	NA	0.59	7.15	0.32	3.36e-12	Hip circumference adjusted for BMI;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg07511668	chr11:68622177	NA	0.51	9.68	0.41	2.59e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6725041	0.819	rs10048819	chr2:213090681	T/G	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs10911232	0.507	rs4483371	chr1:182988352	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs7226408	0.802	rs72885272	chr18:34437656	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs4302748	0.862	rs57133121	chr7:36182859	G/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	trans	rs12517041	0.938	rs10045757	chr5:23270469	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.98	-0.39	6.79e-18	Calcium levels;
LGG	cis	rs6964587	0.626	rs6951795	chr7:91543764	T/C	cg17063962	chr7:91808500	NA	-0.45	-8.21	-0.36	2.19e-15	Breast cancer;
LGG	cis	rs7250872	0.647	rs2304615	chr19:1826112	A/G	cg18850929	chr19:1828978	REXO1	0.49	8.06	0.35	6.4e-15	Bipolar disorder;
LGG	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg22920501	chr2:26401640	FAM59B	-0.41	-8.11	-0.35	4.65e-15	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.85	0.59	1.63e-45	Lung cancer;
LGG	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg05555928	chr11:63887634	MACROD1	-0.62	-8.96	-0.38	7.76e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs6840360	0.615	rs55932132	chr4:152463897	G/T	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg03351412	chr1:154909251	PMVK	0.65	12.53	0.5	3.3e-31	Prostate cancer;
LGG	cis	rs4363385	0.818	rs4284210	chr1:152985711	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.08e-16	Inflammatory skin disease;
LGG	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg01620082	chr3:125678407	NA	0.63	6.98	0.31	1.03e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.68	-0.37	6.71e-17	Triglycerides;
LGG	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1790761	0.967	rs7110021	chr11:67253564	T/C	cg23188684	chr11:67383651	NA	-0.42	-6.78	-0.3	3.61e-11	Mean corpuscular volume;
LGG	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.79e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg08888203	chr3:10149979	C3orf24	0.53	9.14	0.39	1.99e-18	Alzheimer's disease;
LGG	cis	rs73198271	0.641	rs34473848	chr8:8649837	C/T	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	cg07928641	chr1:182991847	LAMC1	0.45	9.1	0.39	2.74e-18	Colorectal cancer;
LGG	cis	rs6763768	0.606	rs11707463	chr3:53362565	A/G	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg23782820	chr8:58130467	NA	0.44	7.35	0.32	8.83e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg18350739	chr11:68623251	NA	-0.89	-22.6	-0.72	9.4e-77	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7474896	0.583	rs4934898	chr10:37990395	G/C	cg00409905	chr10:38381863	ZNF37A	-0.49	-7.72	-0.34	7.27e-14	Obesity (extreme);
LGG	cis	rs9557207	0.703	rs1923894	chr13:100022758	C/T	cg24509225	chr13:100037070	UBAC2	0.64	11.72	0.48	6.06e-28	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs472402	0.580	rs8192186	chr5:6652009	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.77	-0.3	3.95e-11	Response to amphetamines;
LGG	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.43e-38	IgG glycosylation;
LGG	cis	rs9902453	0.791	rs62068629	chr17:28187596	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-6.83	-0.3	2.63e-11	Prostate cancer;
LGG	trans	rs877282	0.945	rs10904554	chr10:786768	T/C	cg22713356	chr15:30763199	NA	0.57	8.59	0.37	1.31e-16	Uric acid levels;
LGG	cis	rs6141769	0.542	rs6119932	chr20:31263802	G/T	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.89	-0.31	1.81e-11	Subjective well-being;
LGG	cis	rs9300255	0.739	rs4759371	chr12:123742563	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.2e-22	Neutrophil percentage of white cells;
LGG	cis	rs643506	1.000	rs612345	chr11:111639122	G/A	cg09085632	chr11:111637200	PPP2R1B	0.58	9.29	0.4	5.82e-19	Breast cancer;
LGG	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg08200770	chr17:80723486	TBCD	-0.47	-8.3	-0.36	1.13e-15	Glycated hemoglobin levels;
LGG	cis	rs3849570	1.000	rs13088000	chr3:81839404	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-7.79	-0.34	4.59e-14	Waist circumference;Body mass index;
LGG	cis	rs17767392	0.958	rs2214836	chr14:72025078	G/T	cg13720639	chr14:72061746	SIPA1L1	0.38	8.27	0.36	1.39e-15	Mitral valve prolapse;
LGG	cis	rs7566780	0.568	rs1965731	chr2:16687183	A/G	cg09580478	chr2:16689509	NA	0.49	7.48	0.33	3.77e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg11859384	chr17:80120422	CCDC57	0.45	7.89	0.34	2.28e-14	Life satisfaction;
LGG	cis	rs2354432	0.607	rs6658763	chr1:146692373	C/T	cg25205988	chr1:146714368	CHD1L	-1.45	-13.65	-0.54	6.99e-36	Mitochondrial DNA levels;
LGG	cis	rs6723226	0.750	rs762019	chr2:32688601	A/C	cg02381751	chr2:32503542	YIPF4	0.61	10.43	0.44	5.19e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg09021430	chr5:549028	NA	-0.81	-12.83	-0.51	1.8e-32	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.55e-15	Bipolar disorder;
LGG	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg13385521	chr17:29058706	SUZ12P	0.8	9.55	0.41	7.4e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg22852734	chr6:133119734	C6orf192	1.16	14.71	0.56	1.77e-40	Type 2 diabetes nephropathy;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.8	-16.05	-0.6	2.02e-46	Obesity-related traits;
LGG	cis	rs4919087	0.926	rs7072078	chr10:99026509	G/A	cg25902810	chr10:99078978	FRAT1	0.49	9.01	0.39	5.24e-18	Monocyte count;
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.48	-0.4	1.32e-19	Retinal vascular caliber;
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg26554054	chr8:600488	NA	0.96	10.05	0.42	1.2e-21	IgG glycosylation;
LGG	cis	rs1728785	0.901	rs11075688	chr16:68655924	A/G	cg02972257	chr16:68554789	NA	0.53	7.94	0.35	1.54e-14	Ulcerative colitis;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg11062466	chr8:58055876	NA	0.58	9.11	0.39	2.43e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs785830	0.636	rs601023	chr9:224693	A/G	cg14500300	chr9:211689	NA	0.29	7.17	0.32	3.07e-12	Platelet distribution width;
LGG	cis	rs7444	0.941	rs2266961	chr22:21928597	C/G	cg11654148	chr22:21984483	YDJC	-0.41	-7.79	-0.34	4.53e-14	Systemic lupus erythematosus;
LGG	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03264133	chr6:25882463	NA	0.71	13.74	0.54	2.85e-36	Blood metabolite levels;
LGG	cis	rs10464366	0.843	rs13242209	chr7:39110241	C/T	cg15212455	chr7:39170539	POU6F2	0.37	8.03	0.35	8.17e-15	IgG glycosylation;
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg24397884	chr7:158709396	WDR60	0.87	17.28	0.63	5.64e-52	Height;
LGG	cis	rs17767392	0.881	rs35866366	chr14:71849185	A/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.4	0.36	5.38e-16	Mitral valve prolapse;
LGG	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg07636037	chr3:49044803	WDR6	0.95	20.5	0.69	6.54e-67	Menarche (age at onset);
LGG	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg20913747	chr6:44695427	NA	-0.67	-11.34	-0.47	1.78e-26	Total body bone mineral density;
LGG	cis	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg05084668	chr3:125655381	ALG1L	-1.13	-13.0	-0.52	3.83e-33	Blood pressure (smoking interaction);
LGG	cis	rs68170813	0.559	rs6963917	chr7:106953427	T/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.7	-0.45	5.22e-24	Coronary artery disease;
LGG	cis	rs3816183	0.680	rs6715170	chr2:43088304	A/G	cg14631114	chr2:43023945	NA	-0.43	-7.81	-0.34	3.79e-14	Hypospadias;
LGG	cis	rs3820881	0.516	rs842824	chr2:201254277	C/T	cg23516759	chr2:201153734	NA	-0.59	-8.68	-0.37	6.93e-17	Chickenpox;
LGG	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08109568	chr15:31115862	NA	-0.54	-9.38	-0.4	3.04e-19	Huntington's disease progression;
LGG	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg06848047	chr4:90757629	SNCA	-0.35	-6.65	-0.3	8.51e-11	Dementia with Lewy bodies;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.45e-15	Lymphocyte counts;
LGG	cis	rs4629180	0.701	rs10202801	chr2:102106670	T/C	cg16435561	chr2:102091048	RFX8	0.46	8.6	0.37	1.24e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.34	0.32	9.48e-13	Menopause (age at onset);
LGG	cis	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.82	-0.34	3.48e-14	Neuroticism;
LGG	cis	rs804292	0.800	rs36018280	chr8:11619397	G/A	cg26752888	chr8:11627280	NEIL2	1.11	17.13	0.62	2.63e-51	Alcohol dependence;Nicotine use;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg09699651	chr6:150184138	LRP11	0.48	8.53	0.37	2.08e-16	Lung cancer;
LGG	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg21926883	chr2:100939477	LONRF2	-0.49	-9.45	-0.4	1.63e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg16270222	chr17:41446396	NA	-0.3	-7.25	-0.32	1.71e-12	Menopause (age at onset);
LGG	trans	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.01	-0.39	5.46e-18	Bladder cancer;
LGG	cis	rs7572733	0.534	rs7557203	chr2:198795650	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.14	0.46	1.07e-25	Dermatomyositis;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6466055	0.669	rs2003506	chr7:104761741	A/G	cg04380332	chr7:105027541	SRPK2	-0.35	-6.72	-0.3	5.25e-11	Schizophrenia;
LGG	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg14191688	chr11:70257035	CTTN	0.6	8.49	0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs8078723	1.000	rs3213762	chr17:38178627	A/G	cg17467752	chr17:38218738	THRA	0.72	13.5	0.53	2.97e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg12856521	chr11:46389249	DGKZ	0.43	7.51	0.33	3.01e-13	Leprosy;
LGG	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg25358565	chr5:93447407	FAM172A	1.27	15.43	0.58	1.18e-43	Diabetic retinopathy;
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.4	6.69	0.3	6.66e-11	Personality dimensions;
LGG	cis	rs2916247	0.954	rs1126063	chr8:93120861	C/T	cg10183463	chr8:93005414	RUNX1T1	0.4	8.23	0.36	1.87e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg22348356	chr13:114891224	RASA3	0.4	7.81	0.34	3.99e-14	Schizophrenia;
LGG	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg26384229	chr12:38710491	ALG10B	0.85	19.09	0.66	2.28e-60	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	9.36	0.4	3.41e-19	Tonsillectomy;
LGG	cis	rs6764363	0.693	rs7433836	chr3:306640	A/C	cg02057681	chr3:285234	CHL1	0.38	6.99	0.31	9.7e-12	Sudden cardiac arrest;
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg19847130	chr8:10466454	RP1L1	0.33	7.22	0.32	2.21e-12	Triglycerides;
LGG	cis	rs2415984	0.579	rs2642091	chr14:46972754	A/G	cg14871534	chr14:47121158	RPL10L	0.54	9.52	0.4	9.74e-20	Number of children ever born;
LGG	cis	rs17453880	0.890	rs61070048	chr5:151964713	A/C	cg12297329	chr5:152029980	NA	-0.86	-21.98	-0.71	7.27e-74	Subjective well-being;
LGG	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.05	0.52	2.37e-33	Psoriasis;
LGG	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg27297192	chr10:134578999	INPP5A	0.32	7.0	0.31	9.15e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg23533926	chr12:111358616	MYL2	0.4	6.65	0.3	8.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.77	-0.48	3.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.859	rs17288250	chr6:45192022	T/A	cg18551225	chr6:44695536	NA	-0.63	-9.91	-0.42	3.96e-21	Total body bone mineral density;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-9.16	-0.39	1.63e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg15556689	chr8:8085844	FLJ10661	0.41	7.14	0.32	3.53e-12	Systolic blood pressure;
LGG	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg18245976	chr7:158708271	WDR60	-0.56	-7.16	-0.32	3.11e-12	Height;
LGG	cis	rs4671458	0.656	rs12470478	chr2:63769308	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.11	-0.31	4.41e-12	Subjective well-being;
LGG	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg24375607	chr4:120327624	NA	0.53	9.03	0.39	4.53e-18	Educational attainment;
LGG	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg24848339	chr3:12840334	CAND2	0.38	8.6	0.37	1.21e-16	QRS complex (12-leadsum);
LGG	trans	rs2736340	0.539	rs9644687	chr8:11323025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-6.86	-0.3	2.18e-11	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs897984	0.542	rs3751855	chr16:31091209	T/C	cg00531865	chr16:30841666	NA	-0.48	-10.14	-0.43	5.93e-22	Dementia with Lewy bodies;
LGG	cis	rs7267979	1.000	rs4815408	chr20:25346678	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg16590910	chr6:42928470	GNMT	0.42	11.97	0.49	5.96e-29	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg05484376	chr2:27715224	FNDC4	0.46	9.91	0.42	3.85e-21	Total body bone mineral density;
LGG	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg15028436	chr7:37888078	TXNDC3	0.53	8.29	0.36	1.22e-15	Alzheimer's disease (late onset);
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs7927771	0.864	rs2293580	chr11:47440283	T/A	cg20307385	chr11:47447363	PSMC3	0.58	10.73	0.45	3.73e-24	Subjective well-being;
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs2247341	0.893	rs743569	chr4:1719620	T/G	cg07465881	chr4:1713556	SLBP	-0.46	-7.37	-0.32	8.18e-13	Hip circumference adjusted for BMI;Height;
LGG	trans	rs11782517	0.924	rs35222693	chr8:10108790	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-6.97	-0.31	1.11e-11	Nose size;
LGG	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.71e-12	Aortic root size;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.79	-15.9	-0.59	9.35e-46	Longevity;Endometriosis;
LGG	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.2	0.52	5.17e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1973993	0.603	rs3912027	chr1:96993603	G/T	cg10631902	chr5:14652156	NA	-0.37	-7.06	-0.31	6.32e-12	Weight;
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs919433	0.963	rs4850428	chr2:198169772	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-6.84	-0.3	2.49e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.33	0.43	1.19e-22	Diabetic retinopathy;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.84	0.42	7.34e-21	Prudent dietary pattern;
LGG	cis	rs17381785	0.586	rs1874205	chr4:14971155	T/C	cg12377275	chr4:15005593	CPEB2	0.7	13.41	0.53	7.23e-35	Urate levels in overweight individuals;
LGG	cis	rs3816183	0.571	rs11679371	chr2:42910919	G/A	cg14631114	chr2:43023945	NA	0.35	7.1	0.31	4.65e-12	Hypospadias;
LGG	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-9.01	-0.39	5.63e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06634786	chr22:41940651	POLR3H	-0.72	-11.54	-0.47	2.88e-27	Vitiligo;
LGG	cis	rs35849525	0.776	rs7615318	chr3:49987475	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.93	-0.35	1.67e-14	Intelligence (multi-trait analysis);
LGG	cis	rs876084	0.505	rs11988495	chr8:121128487	A/G	cg06265175	chr8:121136014	COL14A1	0.46	9.25	0.39	8.19e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg21775007	chr8:11205619	TDH	0.4	6.72	0.3	5.38e-11	Mood instability;
LGG	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg07274523	chr3:49395745	GPX1	0.55	9.1	0.39	2.61e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg19673125	chr6:150240577	RAET1G	-0.35	-8.72	-0.38	4.97e-17	Testicular germ cell tumor;
LGG	cis	rs77106637	0.932	rs7109082	chr11:72707441	A/C	cg03878208	chr11:72483293	STARD10	0.5	7.16	0.32	3.15e-12	Type 2 diabetes;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	9.88	0.42	5.3e-21	Obesity-related traits;
LGG	cis	rs11158026	0.757	rs6572994	chr14:55427103	C/G	cg04306507	chr14:55594613	LGALS3	0.31	6.94	0.31	1.34e-11	Parkinson's disease;
LGG	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg25986240	chr4:9926439	SLC2A9	0.35	7.16	0.32	3.27e-12	Bone mineral density;
LGG	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2013441	1.000	rs2080673	chr17:20062395	C/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.68	-0.3	6.7e-11	Obesity-related traits;
LGG	cis	rs34172651	0.687	rs8044992	chr16:24811207	T/C	cg02428538	chr16:24856791	SLC5A11	-0.45	-7.73	-0.34	6.74e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4689642	0.507	rs4689652	chr4:7223260	C/G	cg21353189	chr4:7228343	SORCS2	0.34	7.25	0.32	1.73e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs4740619	0.870	rs10962065	chr9:15545807	C/T	cg14451791	chr9:16040625	NA	-0.39	-9.67	-0.41	2.86e-20	Body mass index;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg23758822	chr17:41437982	NA	0.88	15.69	0.59	8.2e-45	Menopause (age at onset);
LGG	cis	rs4423214	0.802	rs4402322	chr11:71184015	C/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	cis	rs11190604	1.000	rs3763695	chr10:102269206	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.45	0.33	4.61e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg03806693	chr22:41940476	POLR3H	-1.01	-17.3	-0.63	4.26e-52	Vitiligo;
LGG	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.64	-0.33	1.29e-13	Obesity (extreme);
LGG	cis	rs3087591	0.683	rs7502556	chr17:29642430	T/C	cg24425628	chr17:29625626	OMG;NF1	0.6	12.38	0.5	1.32e-30	Hip circumference;
LGG	cis	rs7727544	0.506	rs10040809	chr5:131343017	A/C	cg07395648	chr5:131743802	NA	-0.41	-8.86	-0.38	1.77e-17	Blood metabolite levels;
LGG	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg15997130	chr1:24165203	NA	0.47	12.73	0.51	4.73e-32	Immature fraction of reticulocytes;
LGG	cis	rs804292	0.600	rs3729851	chr8:11612842	G/A	cg12395012	chr8:11607386	GATA4	0.61	6.78	0.3	3.62e-11	Alcohol dependence;Nicotine use;
LGG	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg18252515	chr7:66147081	NA	1.43	20.48	0.69	7.66e-67	Diabetic kidney disease;
LGG	cis	rs968451	0.865	rs5757611	chr22:39708357	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	11.61	0.47	1.57e-27	Primary biliary cholangitis;
LGG	cis	rs2901331	0.533	rs34860122	chr2:125418079	A/T	cg07771321	chr2:125368595	CNTNAP5	-0.46	-8.07	-0.35	6.19e-15	Response to statin therapy;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.11	-0.35	4.72e-15	IgG glycosylation;
LGG	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.38	-0.5	1.33e-30	Chronic sinus infection;
LGG	cis	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg06521331	chr12:34319734	NA	-0.59	-10.95	-0.45	5.8e-25	Morning vs. evening chronotype;
LGG	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.63e-13	Platelet count;
LGG	cis	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg26384229	chr12:38710491	ALG10B	0.92	20.46	0.69	9.17e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.6	-0.33	1.71e-13	Testicular germ cell tumor;
LGG	cis	rs9517313	0.591	rs9554480	chr13:99221138	T/A	cg03701759	chr13:99174930	STK24	-0.38	-7.38	-0.32	7.4e-13	Neuroticism;
LGG	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.36	6.94	0.31	1.35e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	9.95	0.42	2.98e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs9354308	0.764	rs9345706	chr6:66586915	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs12731740	1.000	rs35720264	chr1:208004782	G/A	cg22525895	chr1:207977042	MIR29B2	-0.66	-7.48	-0.33	3.74e-13	Biomedical quantitative traits;
LGG	trans	rs2018683	1.000	rs160837	chr7:29012732	C/G	cg19402173	chr7:128379420	CALU	-0.76	-14.54	-0.56	1.01e-39	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-6.76	-0.3	4.08e-11	Blood metabolite levels;
LGG	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs12447804	0.645	rs12930038	chr16:58115941	C/T	cg03859792	chr16:58121049	NA	0.63	9.92	0.42	3.55e-21	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg07701084	chr6:150067640	NUP43	0.65	12.39	0.5	1.18e-30	Lung cancer;
LGG	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.54	-8.62	-0.37	1.05e-16	Menarche (age at onset);
LGG	cis	rs1062177	0.826	rs2915822	chr5:151130901	G/T	cg00977110	chr5:151150581	G3BP1	-0.46	-7.4	-0.33	6.33e-13	Preschool internalizing problems;
LGG	cis	rs13108043	0.605	rs767314	chr4:87960139	C/T	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs7193541	0.684	rs4888265	chr16:74683737	T/C	cg01733217	chr16:74700730	RFWD3	1.1	34.98	0.85	4.78e-132	Multiple myeloma;
LGG	cis	rs12195424	0.558	rs75807762	chr6:56305880	G/C	cg07152817	chr6:56299822	NA	-0.99	-9.97	-0.42	2.46e-21	Cerebrospinal fluid clusterin levels;
LGG	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg07027305	chr7:2059796	MAD1L1	-0.35	-8.92	-0.38	1.06e-17	Neuroticism;
LGG	cis	rs919433	0.783	rs805497	chr2:198222548	A/T	cg00792783	chr2:198669748	PLCL1	0.45	6.96	0.31	1.2e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4924935	1.000	rs9905565	chr17:18758641	C/T	cg26378065	chr17:18585709	ZNF286B	0.49	8.02	0.35	8.6e-15	Pancreatic cancer;
LGG	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.18e-19	Chronic lymphocytic leukemia;
LGG	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg12395012	chr8:11607386	GATA4	0.39	7.17	0.32	2.95e-12	Neuroticism;
LGG	trans	rs12517041	1.000	rs12514453	chr5:23289951	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	0.76	10.88	0.45	1.03e-24	Calcium levels;
LGG	cis	rs1728785	1.000	rs1728784	chr16:68591156	T/A	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs910187	0.678	rs3818006	chr20:45816328	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.05	-0.39	4.09e-18	Migraine;
LGG	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-8.44	-0.37	3.98e-16	Schizophrenia;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.9	-0.38	1.28e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13082711	0.911	rs13075550	chr3:27427618	A/G	cg02860705	chr3:27208620	NA	0.75	13.67	0.54	5.53e-36	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs709400	0.567	rs28496120	chr14:103897899	C/T	cg26031613	chr14:104095156	KLC1	0.78	13.77	0.54	2.15e-36	Body mass index;
LGG	trans	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.55	-9.7	-0.41	2.3e-20	Metabolite levels;
LGG	trans	rs3942852	0.568	rs7479361	chr11:48109793	C/T	cg03929089	chr4:120376271	NA	-0.68	-10.71	-0.45	4.61e-24	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.5	-0.37	2.63e-16	Retinal vascular caliber;
LGG	cis	rs2845885	0.793	rs35927325	chr11:63882495	C/T	cg18375707	chr11:64034959	PLCB3	-0.67	-7.26	-0.32	1.64e-12	Body mass index;
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg01966878	chr4:90757139	SNCA	-0.33	-6.75	-0.3	4.39e-11	Dementia with Lewy bodies;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg13939156	chr17:80058883	NA	0.47	9.14	0.39	1.98e-18	Life satisfaction;
LGG	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg12486710	chr1:178512616	C1orf220	0.51	10.68	0.44	6.03e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9443645	0.901	rs2174742	chr6:79610101	G/T	cg18132916	chr6:79620363	NA	-0.32	-8.92	-0.38	1.13e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg12463550	chr7:65579703	CRCP	-0.78	-8.44	-0.37	4.2e-16	Diabetic kidney disease;
LGG	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg04617936	chr2:214353	NA	-0.4	-7.39	-0.32	6.9e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg12560992	chr17:57184187	TRIM37	-0.88	-15.64	-0.59	1.41e-44	Intelligence (multi-trait analysis);
LGG	cis	rs7617773	0.638	rs7644414	chr3:48299079	A/T	cg11946769	chr3:48343235	NME6	0.64	10.35	0.43	9.67e-23	Coronary artery disease;
LGG	cis	rs7226408	0.857	rs57233384	chr18:34546721	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.76e-12	Obesity-related traits;
LGG	cis	rs721917	0.646	rs2819096	chr10:81707613	A/C	cg25562619	chr10:81652821	NA	-0.3	-6.72	-0.3	5.36e-11	Chronic obstructive pulmonary disease;
LGG	cis	rs11650494	0.710	rs11651666	chr17:47474571	C/T	cg08112188	chr17:47440006	ZNF652	1.16	12.52	0.5	3.7e-31	Prostate cancer;
LGG	cis	rs847649	0.692	rs6949391	chr7:102446863	C/T	cg18108683	chr7:102477205	FBXL13	-0.7	-15.64	-0.59	1.4e-44	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.64e-21	Corneal astigmatism;
LGG	cis	rs11587400	0.574	rs2268696	chr1:115219083	T/A	cg12756093	chr1:115239321	AMPD1	-0.4	-6.99	-0.31	9.83e-12	Autism;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg19318889	chr4:1322082	MAEA	0.47	8.01	0.35	9.32e-15	Longevity;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16784092	chr12:53400507	EIF4B	0.4	6.95	0.31	1.23e-11	Bilirubin levels;
LGG	cis	rs9581857	0.579	rs9581846	chr13:27987953	A/G	cg01674679	chr13:27998804	GTF3A	-0.7	-8.1	-0.35	5.09e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.33	-0.36	9.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2742417	0.967	rs6800556	chr3:45752229	G/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	9.39	0.4	2.81e-19	Mean corpuscular volume;
LGG	trans	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg07211511	chr3:129823064	LOC729375	-1.39	-21.25	-0.7	1.96e-70	Blood pressure (smoking interaction);
LGG	trans	rs6981523	0.553	rs11989369	chr8:11055385	A/G	cg06636001	chr8:8085503	FLJ10661	0.47	7.92	0.35	1.77e-14	Neuroticism;
LGG	trans	rs9951602	0.512	rs9946123	chr18:76654557	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	13.56	0.53	1.64e-35	Obesity-related traits;
LGG	cis	rs6578985	0.520	rs7924316	chr11:2173447	G/T	cg04484994	chr11:2181039	INS-IGF2;INS	0.44	9.14	0.39	2.02e-18	Femoral neck bone geometry and menarche (age at onset);
LGG	cis	rs1829883	0.898	rs1464639	chr5:98786821	A/G	cg08333243	chr5:99726346	NA	-0.36	-6.65	-0.3	8.28e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs16837677	1.000	rs16837660	chr1:156765384	A/T	cg14991358	chr1:156767203	PRCC	-0.75	-7.57	-0.33	2.07e-13	Sjögren's syndrome;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg24247370	chr13:99142703	STK24	-0.39	-7.11	-0.31	4.29e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg16606324	chr3:10149918	C3orf24	0.54	7.26	0.32	1.66e-12	Alzheimer's disease;
LGG	cis	rs78487399	0.808	rs111812200	chr2:43674278	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg19784903	chr17:45786737	TBKBP1	0.33	6.97	0.31	1.09e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg21775007	chr8:11205619	TDH	0.84	15.43	0.58	1.22e-43	Retinal vascular caliber;
LGG	cis	rs600231	0.708	rs1784860	chr11:65240712	C/A	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.16	-0.39	1.63e-18	Bone mineral density;
LGG	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.31	-0.36	1.05e-15	Schizophrenia;
LGG	cis	rs7928758	0.887	rs60337613	chr11:134264255	T/C	cg22777979	chr11:134283252	B3GAT1	1.0	12.86	0.51	1.43e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1816854	1.000	rs1816854	chr12:44205018	A/G	cg20956634	chr12:44200518	TWF1	0.52	7.59	0.33	1.77e-13	Inflammatory bowel disease;
LGG	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg07080220	chr10:102295463	HIF1AN	0.68	11.67	0.48	9.17e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.54	0.56	9.75e-40	Lung cancer;
LGG	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.47e-18	Motion sickness;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg11062466	chr8:58055876	NA	0.6	10.01	0.42	1.74e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.846	rs9834659	chr3:160980947	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg09580153	chr6:41068724	NFYA;LOC221442	0.44	7.6	0.33	1.63e-13	Alzheimer's disease (late onset);
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.73	-0.45	3.74e-24	Lung cancer;
LGG	cis	rs10979	1.000	rs13197332	chr6:143888095	T/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.48	-0.5	5.3e-31	Hypospadias;
LGG	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg15103426	chr22:29168792	CCDC117	-0.63	-9.67	-0.41	2.75e-20	Lymphocyte counts;
LGG	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.88	0.51	1.19e-32	Hip circumference adjusted for BMI;
LGG	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.55	-0.41	7.81e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6594499	0.872	rs6881147	chr5:110451936	G/C	cg04022379	chr5:110408740	TSLP	0.4	7.29	0.32	1.33e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11890956	chr21:40555474	PSMG1	1.17	28.11	0.79	3.76e-102	Cognitive function;
LGG	cis	rs7020830	0.867	rs563132	chr9:37245476	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	29.56	0.81	1.12e-108	Schizophrenia;
LGG	cis	rs6076065	0.723	rs6137924	chr20:23366171	C/G	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs208520	0.690	rs851458	chr6:66813279	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.46	-0.65	2.06e-57	Exhaled nitric oxide output;
LGG	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	7.12	0.31	4.05e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg24011408	chr12:48396354	COL2A1	0.49	7.71	0.34	7.92e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg22535103	chr8:58192502	C8orf71	0.94	13.17	0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	0.593	rs6676155	chr1:178508360	C/A	cg19399532	chr1:178512495	C1orf220	-0.41	-7.9	-0.34	2.12e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6988985	0.589	rs57219141	chr8:143987619	G/T	cg10324643	chr8:143916377	GML	0.41	8.17	0.35	3e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs10779751	0.960	rs6661859	chr1:11301063	T/C	cg08854313	chr1:11322531	MTOR	0.73	16.2	0.6	4.28e-47	Body mass index;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05665937	chr4:1216051	CTBP1	0.59	11.0	0.46	3.58e-25	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25072359	chr17:41440525	NA	0.54	10.22	0.43	3e-22	Menopause (age at onset);
LGG	cis	rs7444	0.941	rs4821112	chr22:21964761	G/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.54	-0.33	2.53e-13	Systemic lupus erythematosus;
LGG	trans	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg25214090	chr10:38739885	LOC399744	0.6	11.0	0.46	3.69e-25	Corneal astigmatism;
LGG	cis	rs911263	0.961	rs7148416	chr14:68747868	A/T	cg18825221	chr14:68749962	RAD51L1	0.54	11.67	0.48	9.34e-28	Primary biliary cholangitis;
LGG	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg00898013	chr13:113819073	PROZ	-0.46	-7.85	-0.34	2.93e-14	Platelet distribution width;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg12310025	chr6:25882481	NA	-0.38	-6.74	-0.3	4.72e-11	Height;
LGG	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.22e-19	Fuchs's corneal dystrophy;
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.37	7.43	0.33	5.26e-13	Aortic root size;
LGG	cis	rs7512552	0.809	rs828783	chr1:150376977	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.43	0.4	1.95e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.96	0.52	5.65e-33	IgG glycosylation;
LGG	cis	rs774359	0.744	rs7019351	chr9:27491262	A/C	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.01	-0.35	9.58e-15	Amyotrophic lateral sclerosis;
LGG	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg02002194	chr4:3960332	NA	-0.51	-10.23	-0.43	2.87e-22	Mood instability;
LGG	trans	rs7246760	1.000	rs10419915	chr19:9890957	G/A	cg02900749	chr2:68251473	NA	-0.98	-11.03	-0.46	2.82e-25	Pursuit maintenance gain;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg20493526	chr2:3714936	ALLC	0.45	9.8	0.41	1.02e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05719877	chr11:114271629	C11orf71;RBM7	-0.47	-6.76	-0.3	4.22e-11	Systemic lupus erythematosus;
LGG	cis	rs75059851	0.756	rs11223646	chr11:133839560	C/T	cg17703048	chr11:133852993	NA	-0.88	-16.21	-0.6	3.75e-47	Schizophrenia;
LGG	cis	rs9547996	0.879	rs17197908	chr13:38175744	G/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.88	-0.3	1.95e-11	Diastolic blood pressure;
LGG	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg18709589	chr6:96969512	KIAA0776	-0.44	-7.1	-0.31	4.86e-12	Migraine;Coronary artery disease;
LGG	cis	rs2692947	0.644	rs1168970	chr2:96816606	C/T	cg22654517	chr2:96458247	NA	0.37	7.55	0.33	2.38e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25072359	chr17:41440525	NA	0.54	9.92	0.42	3.71e-21	Menopause (age at onset);
LGG	cis	rs73086581	1.000	rs73086597	chr20:3983571	G/A	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.43e-26	Response to antidepressants in depression;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg03036210	chr16:89904091	SPIRE2	-0.58	-8.08	-0.35	5.71e-15	Skin colour saturation;
LGG	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.98	0.35	1.15e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20887711	chr4:1340912	KIAA1530	0.59	11.26	0.46	3.79e-26	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4774830	0.744	rs73420376	chr15:56283648	T/C	cg24530489	chr15:56299380	NA	-0.85	-7.84	-0.34	3.22e-14	Delta-5 desaturase activity;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg04166393	chr7:2884313	GNA12	-0.42	-7.76	-0.34	5.57e-14	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11367841	chr11:47270567	NR1H3;ACP2	0.46	6.82	0.3	2.92e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.750	rs6765270	chr3:160899974	A/G	cg04691961	chr3:161091175	C3orf57	-0.58	-12.95	-0.52	6.15e-33	Morning vs. evening chronotype;
LGG	cis	rs889398	0.617	rs55887947	chr16:69893343	G/A	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.55	-0.33	2.39e-13	Body mass index;
LGG	cis	rs7301016	0.846	rs11174571	chr12:63022329	C/T	cg01804193	chr12:63026212	NA	0.54	7.1	0.31	4.65e-12	IgG glycosylation;
LGG	cis	rs7326068	0.596	rs4505167	chr13:21341096	T/C	cg04906043	chr13:21280425	IL17D	-0.51	-8.15	-0.35	3.5e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg03709012	chr19:19516395	GATAD2A	0.86	17.46	0.63	8.32e-53	Tonsillectomy;
LGG	cis	rs7770628	0.622	rs1965091	chr6:161120648	G/A	cg04181478	chr6:161122748	PLG	-0.42	-8.35	-0.36	7.77e-16	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	cis	rs6450176	0.564	rs6874524	chr5:53343529	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.68	11.26	0.46	3.56e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9463078	0.683	rs227855	chr6:44702352	T/C	cg25276700	chr6:44698697	NA	0.42	8.62	0.37	1.07e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9814567	0.964	rs1534028	chr3:134284639	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.4	-0.33	6.6e-13	Body mass index;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg19635926	chr16:89946313	TCF25	0.82	9.31	0.4	5.04e-19	Skin colour saturation;
LGG	cis	rs17301259	0.548	rs2519948	chr7:88398729	T/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.87	-0.3	2.04e-11	Heschl's gyrus morphology;
LGG	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg26031613	chr14:104095156	KLC1	1.13	25.21	0.76	6.89e-89	Body mass index;
LGG	cis	rs17767392	0.881	rs61991199	chr14:71762542	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03517284	chr6:25882590	NA	-0.58	-10.47	-0.44	3.64e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2806561	0.695	rs67238799	chr1:23335012	G/A	cg19743168	chr1:23544995	NA	0.36	7.25	0.32	1.82e-12	Height;
LGG	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg05313129	chr8:58192883	C8orf71	-0.55	-7.36	-0.32	8.7e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg22433210	chr17:43662623	NA	-0.87	-14.21	-0.55	2.67e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.74	-14.82	-0.57	6.07e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6504950	0.566	rs12937360	chr17:53046298	C/T	cg19360675	chr17:53046073	COX11;STXBP4	0.4	6.84	0.3	2.48e-11	Breast cancer;
LGG	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.16	-0.35	3.22e-15	Joint mobility (Beighton score);
LGG	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-12.88	-0.51	1.19e-32	Menarche (age at onset);
LGG	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg15268244	chr15:77196840	NA	-0.32	-7.03	-0.31	7.28e-12	Blood metabolite levels;
LGG	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.3	0.4	5.78e-19	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.02e-34	Skin colour saturation;
LGG	cis	rs74781061	0.929	rs11072490	chr15:74807510	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs896854	0.967	rs896853	chr8:95960855	G/C	cg13393036	chr8:95962371	TP53INP1	-0.26	-7.02	-0.31	7.93e-12	Type 2 diabetes;
LGG	cis	rs9783347	1.000	rs4150661	chr11:18379629	C/A	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.17	-0.32	2.93e-12	Pancreatic cancer;
LGG	cis	rs12195424	0.558	rs80061842	chr6:56304126	G/T	cg07152817	chr6:56299822	NA	-0.82	-8.56	-0.37	1.66e-16	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg02503808	chr4:7069936	GRPEL1	0.9	14.07	0.55	1.11e-37	Monocyte percentage of white cells;
LGG	cis	rs9487094	0.626	rs1322124	chr6:110062873	A/C	cg01125227	chr6:109776195	MICAL1	0.41	7.24	0.32	1.94e-12	Height;
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg23594656	chr7:65796392	TPST1	0.4	8.74	0.38	4.29e-17	Aortic root size;
LGG	cis	rs892961	1.000	rs1075457	chr17:75400737	A/G	cg05865280	chr17:75406074	SEPT9	-0.41	-9.97	-0.42	2.37e-21	Airflow obstruction;
LGG	cis	rs1552244	0.515	rs6768768	chr3:10177653	C/T	cg00149659	chr3:10157352	C3orf10	0.88	11.56	0.47	2.6e-27	Alzheimer's disease;
LGG	cis	rs1018836	0.663	rs4735190	chr8:91509601	A/G	cg16814680	chr8:91681699	NA	-0.7	-11.92	-0.48	9.32e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg06026331	chr20:60912101	LAMA5	0.4	7.51	0.33	3.11e-13	Colorectal cancer;
LGG	cis	rs778371	0.788	rs4973569	chr2:233767037	A/G	cg08000102	chr2:233561755	GIGYF2	-0.59	-8.88	-0.38	1.46e-17	Schizophrenia;
LGG	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg25358565	chr5:93447407	FAM172A	1.34	16.45	0.61	3.13e-48	Diabetic retinopathy;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-9.37	-0.4	3.1400000000000002e-19	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg10760299	chr15:45669010	GATM	0.38	7.4	0.33	6.32e-13	Homoarginine levels;
LGG	cis	rs4846580	0.660	rs1416006	chr1:219908948	G/A	cg08034750	chr1:219919793	NA	0.41	7.26	0.32	1.61e-12	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.96	0.31	1.15e-11	Total cholesterol levels;
LGG	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg16662043	chr16:48846231	NA	0.35	6.87	0.3	2.14e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1062746	0.544	rs17770933	chr16:87325729	C/T	cg02258303	chr16:87377426	FBXO31	-0.43	-7.75	-0.34	5.73e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs2652822	0.901	rs4775622	chr15:63408179	A/C	cg02713581	chr15:63449717	RPS27L	0.44	7.47	0.33	4.09e-13	Metabolic traits;
LGG	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg07615347	chr10:60278583	BICC1	0.63	17.85	0.64	1.3e-54	Refractive error;
LGG	trans	rs3206736	0.548	rs328901	chr7:35020451	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.21	0.32	2.27e-12	Diastolic blood pressure;
LGG	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs12915845	0.545	rs4407042	chr15:89077885	T/A	cg05013243	chr15:89149849	MIR1179	0.35	7.11	0.31	4.56e-12	Menarche (age at onset);
LGG	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg02002194	chr4:3960332	NA	0.48	8.7	0.37	5.65e-17	Retinal vascular caliber;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg16590910	chr6:42928470	GNMT	-0.44	-12.93	-0.52	7.13e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg18335740	chr13:41363409	SLC25A15	0.66	13.65	0.54	6.58e-36	Lewy body disease;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.15	0.35	3.36e-15	Lung cancer;
LGG	cis	rs7929679	0.521	rs1509667	chr11:34791303	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs56399783	0.901	rs73051444	chr7:2866529	G/A	cg19731401	chr7:2775893	GNA12	0.35	6.94	0.31	1.33e-11	Childhood ear infection;
LGG	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6912958	0.559	rs107690	chr6:88069352	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-13.06	-0.52	2.18e-33	Monocyte percentage of white cells;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.77	-0.3	3.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2213920	0.915	rs980176	chr9:118260408	T/G	cg13918206	chr9:118159781	DEC1	0.51	6.85	0.3	2.41e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21738971	chr2:106810986	UXS1	0.47	6.85	0.3	2.37e-11	Gut microbiome composition (summer);
LGG	cis	rs2070488	0.775	rs2070489	chr3:38519424	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.5	0.56	1.46e-39	Electrocardiographic conduction measures;
LGG	cis	rs73198271	0.653	rs10087633	chr8:8660444	A/G	cg01851573	chr8:8652454	MFHAS1	0.36	6.72	0.3	5.25e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg26513180	chr16:89883248	FANCA	0.98	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	cis	rs9287719	0.967	rs12995602	chr2:10753542	C/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7589342	0.862	rs6745887	chr2:106468039	G/A	cg16077055	chr2:106428750	NCK2	0.3	7.91	0.34	1.96e-14	Addiction;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg06112835	chr11:68658793	MRPL21	0.64	10.79	0.45	2.34e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02653800	chr10:60095305	UBE2D1	0.42	6.69	0.3	6.28e-11	Cognitive performance;
LGG	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs6696846	0.765	rs3738155	chr1:205074424	C/T	cg00857998	chr1:205179979	DSTYK	0.57	9.25	0.4	8.07e-19	Red blood cell count;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg26384229	chr12:38710491	ALG10B	0.64	12.29	0.5	3.15e-30	Morning vs. evening chronotype;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.5	0.4	1.09e-19	Neuroticism;
LGG	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.24e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6964587	1.000	rs6961928	chr7:91669808	C/T	cg17063962	chr7:91808500	NA	0.48	8.55	0.37	1.85e-16	Breast cancer;
LGG	cis	rs4356932	1.000	rs4257674	chr4:76945685	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg01673284	chr16:4527211	HMOX2	0.33	6.84	0.3	2.52e-11	Schizophrenia;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg11905131	chr22:24372483	LOC391322	-0.45	-7.71	-0.34	7.66e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4478858	0.735	rs4949205	chr1:31800579	A/G	cg19084893	chr1:31688959	NA	0.32	6.84	0.3	2.5e-11	Alcohol dependence;
LGG	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-9.64	-0.41	3.59e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg03909863	chr11:638404	DRD4	-0.41	-6.86	-0.3	2.24e-11	Systemic lupus erythematosus;
LGG	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg07424592	chr7:64974309	NA	0.76	7.34	0.32	9.74e-13	Diabetic kidney disease;
LGG	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg05887092	chr17:76393375	PGS1	0.79	18.65	0.66	2.55e-58	HDL cholesterol levels;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg01879757	chr17:41196368	BRCA1	-0.42	-8.45	-0.37	3.88e-16	Menopause (age at onset);
LGG	cis	rs4356932	1.000	rs4241580	chr4:76956188	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs12410462	0.681	rs6681096	chr1:227609720	G/A	cg23173402	chr1:227635558	NA	0.72	11.59	0.47	1.91e-27	Major depressive disorder;
LGG	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.25	-40.89	-0.88	9.25e-156	Myeloid white cell count;
LGG	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.08	-0.35	5.83e-15	Mean corpuscular volume;
LGG	cis	rs4740619	0.774	rs4741548	chr9:15921622	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.86	-0.42	6.17e-21	Body mass index;
LGG	cis	rs4917300	0.571	rs4917288	chr8:143114054	C/T	cg06573787	chr8:143070187	NA	0.6	10.02	0.42	1.57e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	6.91e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.2e-28	Tonsillectomy;
LGG	cis	rs8017423	0.522	rs12887028	chr14:90819605	A/G	cg04374321	chr14:90722782	PSMC1	-0.65	-12.75	-0.51	4.07e-32	Mortality in heart failure;
LGG	cis	rs4557101	0.625	rs11128341	chr3:73535591	A/C	cg24173753	chr3:73529447	PDZRN3	-0.34	-7.06	-0.31	6.18e-12	QT interval;
LGG	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg04450456	chr4:17643702	FAM184B	0.34	7.61	0.33	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.07	-0.42	1.07e-21	Glomerular filtration rate;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs9972944	0.651	rs9906040	chr17:63840825	A/G	cg07283582	chr17:63770753	CCDC46	-0.38	-6.91	-0.31	1.57e-11	Total body bone mineral density;
LGG	cis	rs858239	0.600	rs10256361	chr7:23123885	C/T	cg23682824	chr7:23144976	KLHL7	0.46	7.89	0.34	2.14e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs12220238	1.000	rs7096553	chr10:75957835	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.47	0.47	5.85e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs68170813	0.559	rs75154004	chr7:106903326	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.56	-0.44	1.67e-23	Coronary artery disease;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.42	-0.36	4.84e-16	Tonsillectomy;
LGG	cis	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-7.84	-0.34	3.21e-14	Mean corpuscular volume;
LGG	trans	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg05926928	chr17:57297772	GDPD1	-0.5	-7.95	-0.35	1.42e-14	Schizophrenia;
LGG	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26076054	chr5:421317	AHRR	-0.43	-6.97	-0.31	1.06e-11	Cystic fibrosis severity;
LGG	cis	rs6912958	0.559	rs445434	chr6:88041849	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	13.24	0.52	3.79e-34	Monocyte percentage of white cells;
LGG	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27297192	chr10:134578999	INPP5A	0.31	6.73	0.3	4.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2153535	0.541	rs7774752	chr6:8468978	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9527	0.545	rs12784384	chr10:104957594	G/C	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.16e-12	Arsenic metabolism;
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22618164	chr12:122356400	WDR66	0.38	11.29	0.46	2.88e-26	Mean corpuscular volume;
LGG	cis	rs17504614	0.634	rs56316058	chr2:51060931	C/A	cg23851515	chr2:51057218	NRXN1	0.47	7.73	0.34	6.56e-14	Educational attainment (years of education);
LGG	cis	rs6743376	0.556	rs2515399	chr2:113819451	G/T	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.16e-18	Inflammatory biomarkers;
LGG	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	13.44	0.53	5.31e-35	Colorectal cancer;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg04772025	chr11:68637568	NA	0.72	12.55	0.5	2.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7717393	1.000	rs11950100	chr5:155755768	G/A	cg01474424	chr5:155754231	SGCD	0.79	7.69	0.34	8.85e-14	Egg allergy;
LGG	cis	rs2070488	0.775	rs2186457	chr3:38553965	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.36	0.56	5.91e-39	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.44	0.58	1.09e-43	Lung cancer;
LGG	trans	rs1728785	1.000	rs1728764	chr16:68572292	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03324837	chr17:61044407	NA	0.4	7.29	0.32	1.36e-12	Obesity-related traits;
LGG	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg03806693	chr22:41940476	POLR3H	0.99	16.35	0.6	9.46e-48	Vitiligo;
LGG	cis	rs6500395	1.000	rs7184144	chr16:48606077	C/T	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.46e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10850519	0.744	rs9971698	chr12:115948936	T/A	cg18639984	chr12:115943877	NA	-0.41	-8.91	-0.38	1.15e-17	Diastolic blood pressure;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs6750795	0.569	rs1667313	chr2:232408018	A/C	cg19187155	chr2:232395269	NMUR1	0.51	9.56	0.41	7.23e-20	Height;
LGG	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg11871910	chr12:69753446	YEATS4	1.06	28.69	0.8	9.09e-105	Cerebrospinal fluid biomarker levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07686248	chr19:8455013	RAB11B	0.49	7.43	0.33	5.28e-13	Gut microbiome composition (summer);
LGG	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs28374715	0.528	rs28492932	chr15:41624397	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.68	-0.84	1.36e-126	Ulcerative colitis;
LGG	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs16973500	0.808	rs61523290	chr16:71943556	A/G	cg09427745	chr16:71932006	KIAA0174	-0.51	-7.52	-0.33	2.92e-13	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg13009111	chr11:71350975	NA	0.35	7.62	0.33	1.45e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.54	0.33	2.57e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg20913747	chr6:44695427	NA	0.64	11.03	0.46	2.87e-25	Total body bone mineral density;
LGG	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg14598338	chr9:96623480	NA	-0.52	-9.44	-0.4	1.76e-19	DNA methylation (variation);
LGG	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.23	0.6	3.04e-47	Smoking behavior;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.89	0.34	2.16e-14	Personality dimensions;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07362569	chr17:61921086	SMARCD2	-0.48	-9.15	-0.39	1.76e-18	Prudent dietary pattern;
LGG	cis	rs703842	0.928	rs724834	chr12:58180416	G/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.29	0.36	1.22e-15	Multiple sclerosis;
LGG	trans	rs12517041	1.000	rs113660280	chr5:23302289	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.61	0.37	1.15e-16	Neuroticism;
LGG	cis	rs9393777	0.588	rs9467772	chr6:26496578	A/T	cg12826209	chr6:26865740	GUSBL1	0.85	12.73	0.51	4.9e-32	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Colorectal cancer;
LGG	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.63	11.16	0.46	8.84e-26	Hip circumference adjusted for BMI;
LGG	cis	rs911119	0.954	rs35966482	chr20:23620716	G/T	cg16589663	chr20:23618590	CST3	0.47	6.66	0.3	7.83e-11	Chronic kidney disease;
LGG	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg15704280	chr7:45808275	SEPT13	0.67	9.63	0.41	3.83e-20	Intraocular pressure;
LGG	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.84	-0.3	2.47e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg02002194	chr4:3960332	NA	-0.5	-9.36	-0.4	3.49e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10950821	0.519	rs12667658	chr7:20659545	T/A	cg21202529	chr7:20656503	ABCB5	-0.34	-6.71	-0.3	5.65e-11	Response to statin therapy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06012509	chr6:43027269	KLC4;MRPL2	0.38	6.75	0.3	4.57e-11	Obesity-related traits;
LGG	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg16576597	chr16:28551801	NUPR1	0.37	8.89	0.38	1.41e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7572733	0.935	rs1878732	chr2:198809545	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.2	0.36	2.39e-15	Dermatomyositis;
LGG	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.01	-19.56	-0.67	1.6e-62	Homoarginine levels;
LGG	cis	rs1790761	0.967	rs7110021	chr11:67253564	T/C	cg00290607	chr11:67383545	NA	-0.5	-8.84	-0.38	2.04e-17	Mean corpuscular volume;
LGG	cis	rs17039065	0.920	rs1595195	chr4:109470367	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.17	0.32	3.08e-12	Gut microbiome composition (summer);
LGG	cis	rs11225247	0.881	rs11604271	chr11:102250601	A/C	cg06323957	chr11:102217781	BIRC2	0.8	6.81	0.3	3.11e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24478630	chr2:74692696	MOGS	0.44	7.31	0.32	1.16e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg02002194	chr4:3960332	NA	-0.48	-9.19	-0.39	1.35e-18	Neuroticism;
LGG	cis	rs2455799	0.613	rs4685258	chr3:15792315	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs17453880	0.611	rs2964242	chr5:151923981	T/C	cg12297329	chr5:152029980	NA	-0.57	-11.63	-0.48	1.28e-27	Subjective well-being;
LGG	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-10.15	-0.43	5.25e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg15309053	chr8:964076	NA	0.34	6.91	0.31	1.63e-11	Schizophrenia;
LGG	cis	rs13065560	0.714	rs4280575	chr3:38937645	C/T	cg01426195	chr3:39028469	NA	0.46	9.56	0.41	7.05e-20	Interleukin-18 levels;
LGG	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.29	-0.4	5.89e-19	Common traits (Other);
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	11.56	0.47	2.4e-27	Total body bone mineral density;
LGG	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg02811702	chr13:24901961	NA	0.42	7.79	0.34	4.6e-14	Obesity-related traits;
LGG	cis	rs9818758	0.556	rs9813813	chr3:49207093	T/A	cg00383909	chr3:49044727	WDR6	1.12	13.81	0.54	1.49e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs8018808	1.000	rs12435136	chr14:77856184	G/A	cg20045696	chr14:77926864	AHSA1	-0.42	-6.97	-0.31	1.07e-11	Myeloid white cell count;
LGG	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-8.1	-0.35	5.05e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9814567	1.000	rs7619451	chr3:134233238	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-11.81	-0.48	2.48e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs5758511	0.573	rs5996069	chr22:42201185	T/G	cg15128208	chr22:42549153	NA	-0.42	-7.27	-0.32	1.53e-12	Birth weight;
LGG	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg03476357	chr21:30257390	N6AMT1	-0.55	-8.41	-0.36	5.07e-16	Cognitive test performance;
LGG	cis	rs6768930	0.509	rs6445928	chr3:57758655	T/C	cg01571842	chr3:57934672	NA	0.3	6.66	0.3	7.73e-11	Obesity-related traits;
LGG	cis	rs1465370	0.720	rs7811463	chr7:130017488	G/A	cg06917763	chr7:130033247	NA	0.33	7.14	0.31	3.68e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.14	0.49	1.19e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs57046232	0.552	rs6139968	chr20:6319606	A/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.89	0.3	1.82e-11	Colorectal cancer;
LGG	cis	rs6807915	0.647	rs310756	chr3:12277612	C/T	cg02700894	chr3:12045449	SYN2	0.4	6.77	0.3	3.93e-11	Leprosy;
LGG	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg08344181	chr3:125677491	NA	-0.71	-7.67	-0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2237234	0.813	rs34565965	chr6:26350810	T/A	cg09904177	chr6:26538194	HMGN4	-0.49	-6.8	-0.3	3.28e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs883565	0.655	rs4676628	chr3:39095965	G/A	cg01426195	chr3:39028469	NA	-0.73	-16.96	-0.62	1.62e-50	Handedness;
LGG	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.51	0.5	3.86e-31	IgG glycosylation;
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.32	0.36	9.61e-16	Aortic root size;
LGG	cis	rs2074193	0.569	rs215358	chr12:47737789	T/G	cg02516419	chr12:47771422	NA	-0.52	-7.52	-0.33	2.87e-13	Migraine with aura;
LGG	cis	rs7927771	0.690	rs35496532	chr11:47450338	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-10.57	-0.44	1.55e-23	Subjective well-being;
LGG	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.12	-0.43	6.87e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs72949976	0.864	rs13389834	chr2:214025112	G/A	cg08319019	chr2:214017104	IKZF2	-0.63	-10.74	-0.45	3.45e-24	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs9354308	0.868	rs9363464	chr6:66557759	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.1	-0.35	5.08e-15	Metabolite levels;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg03188948	chr7:1209495	NA	0.64	8.26	0.36	1.53e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4731207	0.672	rs11983251	chr7:124459925	G/A	cg05630886	chr7:124431682	NA	0.34	7.85	0.34	2.99e-14	Cutaneous malignant melanoma;
LGG	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg13852791	chr20:30311386	BCL2L1	0.87	15.43	0.58	1.23e-43	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs10849893	0.595	rs6489811	chr12:121893626	C/T	cg01154721	chr12:121881891	KDM2B	0.4	6.95	0.31	1.27e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs12318506	1.000	rs35383953	chr12:75660182	A/G	cg04728562	chr12:75699417	CAPS2	-1.12	-9.42	-0.4	2.1e-19	Coronary artery calcification;
LGG	cis	rs2133450	0.717	rs1400165	chr3:7268362	C/G	cg19930620	chr3:7340148	GRM7	0.33	7.27	0.32	1.5e-12	Early response to risperidone in schizophrenia;
LGG	trans	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg20587970	chr11:113659929	NA	-1.33	-23.21	-0.73	1.31e-79	Hip circumference adjusted for BMI;
LGG	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs7537765	0.696	rs72640267	chr1:11897286	G/T	cg02448276	chr1:11845238	NA	-0.56	-7.62	-0.33	1.47e-13	QRS complex (12-leadsum);
LGG	cis	rs12291225	0.545	rs11023187	chr11:14345559	T/G	cg19336497	chr11:14380999	RRAS2	-0.63	-13.46	-0.53	4.57e-35	Sense of smell;
LGG	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg16339924	chr4:17578868	LAP3	0.65	11.12	0.46	1.29e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24903225	chr12:108956097	SART3;ISCU	0.43	7.27	0.32	1.51e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg02297831	chr4:17616191	MED28	0.47	8.68	0.37	7.03e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs742614	0.533	rs2747541	chr20:32418772	G/T	cg06304546	chr20:32448765	NA	-0.7	-14.19	-0.55	3.26e-38	Stearic acid (18:0) levels;
LGG	cis	rs10089	1.000	rs10060181	chr5:127475573	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.77	0.48	3.58e-28	Ileal carcinoids;
LGG	cis	rs113835537	0.529	rs75003264	chr11:66256099	G/A	cg24851651	chr11:66362959	CCS	0.44	7.47	0.33	4e-13	Airway imaging phenotypes;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.31	3.69e-12	Life satisfaction;
LGG	cis	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg03517284	chr6:25882590	NA	0.52	9.72	0.41	1.96e-20	Intelligence (multi-trait analysis);
LGG	cis	rs60695258	0.550	rs4693800	chr4:87915620	C/G	cg01323104	chr4:87958903	AFF1	-0.24	-6.86	-0.3	2.23e-11	Hematocrit;
LGG	cis	rs80282103	0.618	rs11819230	chr10:1128812	A/G	cg08668510	chr10:1095578	IDI1	0.76	7.57	0.33	2.1e-13	Glomerular filtration rate (creatinine);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07087116	chr3:39447931	RPSA	-0.4	-6.71	-0.3	5.68e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9640161	0.830	rs12703061	chr7:150062545	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-10.21	-0.43	3.2e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10484885	0.824	rs72919981	chr6:90528977	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.74	-0.45	3.7e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-11.91	-0.48	1e-28	Morning vs. evening chronotype;
LGG	cis	rs1018836	0.923	rs13254212	chr8:91582355	T/C	cg16814680	chr8:91681699	NA	-0.81	-14.79	-0.57	8.29e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs7178375	1.000	rs10163148	chr15:31212684	C/G	cg04373760	chr16:53404718	NA	0.55	7.88	0.34	2.29e-14	Hypertriglyceridemia;
LGG	cis	rs2658782	0.654	rs2605623	chr11:93249359	A/G	cg15737290	chr11:93063684	CCDC67	0.45	6.73	0.3	4.9e-11	Pulmonary function decline;
LGG	trans	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg25214090	chr10:38739885	LOC399744	-0.68	-11.85	-0.48	1.74e-28	Corneal astigmatism;
LGG	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06156847	chr2:113672199	IL1F7	0.39	7.7	0.34	8.45e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17453880	0.890	rs28749810	chr5:152048630	C/A	cg10931792	chr5:152022470	NA	0.42	9.01	0.39	5.63e-18	Subjective well-being;
LGG	cis	rs6831352	0.729	rs4699718	chr4:100067791	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg13010199	chr12:38710504	ALG10B	0.47	8.89	0.38	1.39e-17	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs28485415	chr4:99060340	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs73198271	0.562	rs35432123	chr8:8671018	G/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.03	0.35	8.32e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg13939156	chr17:80058883	NA	-0.46	-9.02	-0.39	5.15e-18	Life satisfaction;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	cis	rs7193541	0.673	rs12716769	chr16:74652537	T/C	cg01733217	chr16:74700730	RFWD3	1.09	32.98	0.84	1.3e-123	Multiple myeloma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26612088	chr17:74722779	JMJD6;C17orf95	0.46	6.71	0.3	5.58e-11	Gut microbiome composition (summer);
LGG	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.97	-0.31	1.13e-11	Breast cancer;
LGG	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg21640587	chr11:117668038	DSCAML1	0.92	15.22	0.58	1.05e-42	Myopia;
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg05484376	chr2:27715224	FNDC4	0.46	9.85	0.42	6.85e-21	Total body bone mineral density;
LGG	cis	rs9814567	1.000	rs3846056	chr3:134227292	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.35e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6938	0.618	rs12911254	chr15:75166335	G/A	cg17294928	chr15:75287854	SCAMP5	0.66	12.24	0.49	4.82e-30	Breast cancer;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg09359103	chr1:154839909	KCNN3	-0.53	-10.52	-0.44	2.38e-23	Prostate cancer;
LGG	cis	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-6.92	-0.31	1.54e-11	Neuroticism;
LGG	cis	rs7523050	0.643	rs7551142	chr1:109399710	G/T	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs12464559	0.579	rs1523181	chr2:152679462	T/C	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg11301795	chr4:187892539	NA	0.79	17.21	0.62	1.1e-51	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg16511985	chr3:153974050	SGEF	0.5	8.49	0.37	2.9e-16	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.49	-8.06	-0.35	6.79e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg21427119	chr20:30132790	HM13	0.42	6.95	0.31	1.22e-11	Mean corpuscular hemoglobin;
LGG	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg16096631	chr1:42092165	HIVEP3	0.76	22.86	0.73	5.32e-78	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.68	-0.34	9.68e-14	Bone mineral density;
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.17	0.35	2.97e-15	Tonsillectomy;
LGG	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.88	0.42	5.03e-21	Ovarian reserve;
LGG	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12923728	chr3:195709715	SDHAP1	-0.77	-14.56	-0.56	8.32e-40	Pancreatic cancer;
LGG	trans	rs6787172	0.702	rs1730040	chr3:158030962	A/G	cg23275840	chr4:47708675	CORIN	0.4	8.57	0.37	1.54e-16	Subjective well-being;
LGG	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.56	0.44	1.7e-23	Lung cancer in ever smokers;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14986359	chr19:59085030	MZF1;LOC100131691	-0.47	-6.85	-0.3	2.38e-11	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.02	-0.57	8.06e-42	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17059624	chr11:85358760	TMEM126A	-0.47	-7.32	-0.32	1.11e-12	Systemic lupus erythematosus;
LGG	cis	rs9814567	0.896	rs1357764	chr3:134344928	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.55	0.5	2.7e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg08305652	chr11:111469057	NA	-0.45	-9.05	-0.39	3.9e-18	Primary sclerosing cholangitis;
LGG	cis	rs908922	0.651	rs10888493	chr1:152503913	G/A	cg20991723	chr1:152506922	NA	-0.73	-15.0	-0.57	9.89e-42	Hair morphology;
LGG	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg24759859	chr6:86352639	SYNCRIP	0.41	6.93	0.31	1.46e-11	Smooth-surface caries;
LGG	cis	rs4423214	0.592	rs10898186	chr11:71188800	G/A	cg10847948	chr11:71163743	NADSYN1	0.6	8.76	0.38	3.62e-17	Vitamin D levels;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg05941027	chr17:61774174	LIMD2	0.38	9.71	0.41	2.12e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.57	0.53	1.53e-35	Lung cancer;
LGG	cis	rs4986172	0.700	rs71373536	chr17:43221808	G/A	cg10701640	chr17:43249399	NA	0.43	7.44	0.33	4.97e-13	Height;
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg16339924	chr4:17578868	LAP3	0.5	8.45	0.37	3.9e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs988958	0.566	rs7599890	chr2:42247958	A/G	cg27252766	chr2:42229092	NA	0.52	7.86	0.34	2.64e-14	Hypospadias;
LGG	cis	rs826838	0.709	rs4882355	chr12:38721462	A/T	cg04568710	chr12:38710424	ALG10B	0.39	8.38	0.36	6.35e-16	Heart rate;
LGG	cis	rs10895140	0.665	rs717098	chr11:101466848	A/G	cg04553838	chr11:101454733	TRPC6	-0.41	-6.67	-0.3	7.18e-11	Menarche (age at onset);
LGG	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg06138931	chr13:21896616	NA	0.54	9.19	0.39	1.37e-18	White matter hyperintensity burden;
LGG	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg00666640	chr1:248458726	OR2T12	0.54	8.66	0.37	8.16e-17	Common traits (Other);
LGG	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg16096631	chr1:42092165	HIVEP3	0.68	17.83	0.64	1.63e-54	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Bladder cancer;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.12	-0.31	4.23e-12	Obesity-related traits;
LGG	cis	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.86	-0.38	1.74e-17	Response to antipsychotic treatment;
LGG	cis	rs1670533	1.000	rs935972	chr4:1045171	A/G	cg27284194	chr4:1044797	NA	0.56	8.95	0.38	8.82e-18	Recombination rate (females);
LGG	cis	rs7465272	0.957	rs11994668	chr8:143687392	G/T	cg10104451	chr8:143696006	ARC	-0.75	-11.06	-0.46	2.13e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs8002861	0.664	rs4942246	chr13:44404853	A/G	cg17145862	chr1:211918768	LPGAT1	0.8	17.18	0.62	1.6e-51	Leprosy;
LGG	cis	rs283228	0.517	rs1832416	chr6:101807024	T/A	cg02011392	chr6:101847541	GRIK2	0.52	7.3	0.32	1.28e-12	Coenzyme Q10 levels;
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg02733842	chr7:1102375	C7orf50	0.68	8.01	0.35	9.69e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg12288994	chr5:1860383	NA	0.69	11.28	0.46	3.09e-26	Cardiovascular disease risk factors;
LGG	cis	rs10875746	0.669	rs10875792	chr12:48697423	T/A	cg24011408	chr12:48396354	COL2A1	-0.57	-7.23	-0.32	1.95e-12	Longevity (90 years and older);
LGG	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg24623649	chr8:11872141	NA	-0.31	-7.47	-0.33	4.11e-13	Neuroticism;
LGG	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg04469686	chr1:162760199	HSD17B7	-0.48	-7.73	-0.34	6.89e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg08621203	chr6:150244597	RAET1G	0.53	9.96	0.42	2.62e-21	Testicular germ cell tumor;
LGG	cis	rs2470578	0.792	rs2247106	chr3:17308770	A/G	cg20981856	chr3:17787350	NA	0.37	7.07	0.31	5.81e-12	Schizophrenia;
LGG	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg21427119	chr20:30132790	HM13	-0.58	-9.16	-0.39	1.65e-18	Mean corpuscular hemoglobin;
LGG	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg13770153	chr20:60521292	NA	-0.43	-7.11	-0.31	4.42e-12	Body mass index;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg04861929	chr11:109293070	C11orf87	0.51	9.41	0.4	2.31e-19	Schizophrenia;
LGG	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg01620082	chr3:125678407	NA	-0.76	-7.62	-0.33	1.43e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg08975724	chr8:8085496	FLJ10661	0.53	10.59	0.44	1.3e-23	Mood instability;
LGG	cis	rs9640161	0.702	rs1962004	chr7:150020381	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.78	-16.05	-0.6	2.09e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	6.72	0.3	5.48e-11	Homoarginine levels;
LGG	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg17691542	chr6:26056736	HIST1H1C	0.76	13.03	0.52	2.66e-33	Height;
LGG	cis	rs3126085	0.935	rs34188926	chr1:152293481	A/C	cg26876637	chr1:152193138	HRNR	-0.51	-8.02	-0.35	8.96e-15	Atopic dermatitis;
LGG	cis	rs977987	0.843	rs8056080	chr16:75410798	C/A	cg03315344	chr16:75512273	CHST6	0.51	10.36	0.43	9.54e-23	Dupuytren's disease;
LGG	cis	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs701145	0.585	rs401162	chr3:153905988	T/A	cg17054900	chr3:154042577	DHX36	0.87	10.04	0.42	1.34e-21	Coronary artery disease;
LGG	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg25019033	chr10:957182	NA	-0.53	-9.07	-0.39	3.44e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs11966931	1.000	rs11962140	chr6:108121326	A/T	cg04749840	chr6:108095067	SCML4	0.45	7.67	0.34	1.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg23461800	chr14:103021989	NA	-0.51	-8.23	-0.36	1.86e-15	Platelet count;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs55665837	1.000	rs11023229	chr11:14461001	G/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.7	-0.37	5.87e-17	Vitamin D levels;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.25	-0.43	2.42e-22	Lymphocyte counts;
LGG	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg10189774	chr4:17578691	LAP3	0.4	7.13	0.31	3.77e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg06654118	chr4:1303317	MAEA	-0.43	-7.37	-0.32	8.12e-13	Obesity-related traits;
LGG	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg16583315	chr14:65563665	MAX	-0.4	-8.13	-0.35	4.04e-15	Obesity-related traits;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.9	0.34	2.08e-14	Longevity;
LGG	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg24565620	chr2:194026	NA	-0.7	-10.7	-0.45	4.91e-24	Blood protein levels;
LGG	cis	rs6089584	0.546	rs4925337	chr20:60637637	T/C	cg13770153	chr20:60521292	NA	-0.43	-7.2	-0.32	2.47e-12	Body mass index;
LGG	cis	rs4566357	1.000	rs6721237	chr2:227923357	T/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.36	7.24	0.32	1.94e-12	Oropharynx cancer;
LGG	cis	rs7241530	0.636	rs11875760	chr18:75897285	C/G	cg14642773	chr18:75888474	NA	0.47	8.99	0.39	6.4e-18	Educational attainment (years of education);
LGG	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.41	0.44	5.87e-23	Arsenic metabolism;
LGG	cis	rs7572644	0.640	rs13027666	chr2:28058433	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.92	0.31	1.49e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2470578	0.729	rs2733523	chr3:17322432	G/A	cg20981856	chr3:17787350	NA	0.35	6.69	0.3	6.59e-11	Schizophrenia;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg22535103	chr8:58192502	C8orf71	-0.74	-9.41	-0.4	2.24e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.932	rs372678	chr20:25465248	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.9	0.42	4.27e-21	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg27411982	chr8:10470053	RP1L1	0.42	7.21	0.32	2.36e-12	Mood instability;
LGG	cis	rs7572733	0.534	rs700664	chr2:198671145	C/T	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Dermatomyositis;
LGG	cis	rs7103648	0.735	rs3824869	chr11:47378245	T/C	cg20307385	chr11:47447363	PSMC3	-0.92	-19.82	-0.68	9.32e-64	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.34	0.32	9.54e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs116095464	0.558	rs10462755	chr5:246748	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.43	0.53	6.09e-35	Breast cancer;
LGG	cis	rs4474465	1.000	rs10899508	chr11:78170708	T/G	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs6840360	0.642	rs4263379	chr4:152399131	G/A	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg26818257	chr2:241905806	NA	0.51	11.6	0.47	1.74e-27	Joint mobility (Beighton score);
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.12	0.43	7.18e-22	Height;
LGG	cis	rs13177180	0.563	rs2546487	chr5:114853836	A/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.32	6.84	0.3	2.56e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs2976388	0.590	rs10110970	chr8:143820410	G/C	cg06565975	chr8:143823917	SLURP1	-0.53	-13.45	-0.53	4.75e-35	Urinary tract infection frequency;
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg07142201	chr11:109293216	C11orf87	0.51	9.41	0.4	2.25e-19	Schizophrenia;
LGG	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.24	0.39	8.77e-19	Sudden cardiac arrest;
LGG	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg02002194	chr4:3960332	NA	-0.51	-10.27	-0.43	2.01e-22	Mood instability;
LGG	cis	rs36051895	0.587	rs7019418	chr9:5259847	G/C	cg02405213	chr9:5042618	JAK2	-0.72	-12.99	-0.52	4.24e-33	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg12070911	chr6:150209640	RAET1E	0.31	7.67	0.34	1.04e-13	Lung cancer;
LGG	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	8.49	0.37	2.9e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs10754283	0.967	rs2002883	chr1:90105838	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.29	-0.32	1.38e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg00990874	chr7:1149470	C7orf50	-0.68	-10.92	-0.45	7.64e-25	Bronchopulmonary dysplasia;
LGG	cis	rs9783347	0.643	rs2305565	chr11:18317699	C/T	cg15585147	chr11:18324498	HPS5	0.33	7.66	0.34	1.07e-13	Pancreatic cancer;
LGG	cis	rs1971762	0.545	rs7485472	chr12:54044438	T/C	cg06632207	chr12:54070931	ATP5G2	0.24	7.48	0.33	3.87e-13	Height;
LGG	cis	rs6430585	0.583	rs2322813	chr2:136582809	A/G	cg07169764	chr2:136633963	MCM6	1.3	26.45	0.78	1.32e-94	Corneal structure;
LGG	trans	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg07211511	chr3:129823064	LOC729375	-0.77	-11.23	-0.46	4.74e-26	Blood pressure (smoking interaction);
LGG	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg06108461	chr20:60628389	TAF4	-0.71	-12.97	-0.52	5.04e-33	Body mass index;
LGG	cis	rs6694672	0.717	rs10733087	chr1:197055782	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs150647904	1	rs150647904	chr1:54839485	T/TCAG	cg17417004	chr1:54819992	SSBP3	0.48	6.93	0.31	1.42e-11	Platelet distribution width;
LGG	cis	rs6912958	0.559	rs2985039	chr6:88041757	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	13.27	0.52	2.85e-34	Monocyte percentage of white cells;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg06916706	chr16:4465613	CORO7	0.87	14.79	0.57	8.1e-41	Schizophrenia;
LGG	cis	rs7717393	0.786	rs10039835	chr5:155764666	G/A	cg04435420	chr5:155754009	SGCD	0.78	9.67	0.41	2.89e-20	Egg allergy;
LGG	cis	rs10214930	0.697	rs10951169	chr7:27555914	C/T	cg22168087	chr7:27702803	HIBADH	-0.44	-6.67	-0.3	7.52e-11	Hypospadias;
LGG	cis	rs73193808	0.590	rs2832244	chr21:30554034	T/C	cg03476357	chr21:30257390	N6AMT1	0.4	6.71	0.3	5.84e-11	Coronary artery disease;
LGG	cis	rs17253792	0.822	rs8006705	chr14:56171283	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-12.81	-0.51	2.18e-32	Putamen volume;
LGG	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg14926445	chr8:58193284	C8orf71	-0.8	-9.74	-0.41	1.63e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.24	-0.32	1.93e-12	Mean corpuscular volume;
LGG	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg07930552	chr6:133119739	C6orf192	0.68	8.2	0.36	2.36e-15	Type 2 diabetes nephropathy;
LGG	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.78	0.38	3.29e-17	Fuchs's corneal dystrophy;
LGG	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg09696939	chr10:60272079	BICC1	0.39	7.5	0.33	3.23e-13	Refractive error;
LGG	cis	rs74781061	0.860	rs4887149	chr15:74736449	A/T	cg02384859	chr15:74862662	ARID3B	-0.33	-6.81	-0.3	2.95e-11	Endometriosis;
LGG	cis	rs3735485	0.800	rs1294969	chr7:45075483	C/G	cg03440944	chr7:45023329	C7orf40	0.55	9.38	0.4	2.97e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg11987759	chr7:65425863	GUSB	0.4	7.55	0.33	2.26e-13	Aortic root size;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs6430585	0.591	rs3098103	chr2:136656094	T/C	cg07169764	chr2:136633963	MCM6	1.22	22.23	0.72	4.83e-75	Corneal structure;
LGG	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg13010199	chr12:38710504	ALG10B	0.42	7.64	0.33	1.27e-13	Morning vs. evening chronotype;
LGG	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg09029085	chr17:47094198	IGF2BP1	0.31	8.25	0.36	1.66e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg10483660	chr13:112241077	NA	-0.36	-8.0	-0.35	1.04e-14	Hepatitis;
LGG	cis	rs9905704	0.671	rs4337355	chr17:56950920	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-6.75	-0.3	4.32e-11	Testicular germ cell tumor;
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg15556689	chr8:8085844	FLJ10661	0.4	7.07	0.31	5.86e-12	Retinal vascular caliber;
LGG	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.35	0.47	1.71e-26	Response to antipsychotic treatment;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07557355	chr1:155904306	KIAA0907	0.4	6.79	0.3	3.38e-11	Bipolar disorder;
LGG	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg04617936	chr2:214353	NA	-0.39	-7.21	-0.32	2.26e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg24692254	chr21:30365293	RNF160	0.62	11.17	0.46	8.35e-26	Pancreatic cancer;
LGG	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg21045802	chr8:109455806	TTC35	0.53	9.96	0.42	2.56e-21	Dupuytren's disease;
LGG	cis	rs7572733	0.773	rs7601762	chr2:198529237	G/T	cg00792783	chr2:198669748	PLCL1	0.4	6.65	0.3	8.37e-11	Dermatomyositis;
LGG	cis	rs2153535	0.580	rs9406172	chr6:8515464	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	trans	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg25482853	chr8:67687455	SGK3	0.98	11.9	0.48	1.1e-28	Lung disease severity in cystic fibrosis;
LGG	cis	rs10870270	0.500	rs9419217	chr10:133758379	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.45	-9.45	-0.4	1.66e-19	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs9354308	0.834	rs12212376	chr6:66598879	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	9.8	0.41	1.01e-20	Metabolite levels;
LGG	cis	rs397969	0.570	rs62066349	chr17:19899940	C/G	cg13482628	chr17:19912719	NA	0.52	8.51	0.37	2.4e-16	Platelet count;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20887711	chr4:1340912	KIAA1530	0.63	12.16	0.49	1.01e-29	Obesity-related traits;
LGG	cis	rs2380220	0.576	rs7751219	chr6:96018915	G/A	cg04719120	chr6:96025338	MANEA	0.56	7.9	0.34	2.12e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.39	-7.09	-0.31	5.17e-12	Longevity;Endometriosis;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.59	-0.33	1.72e-13	Prostate cancer;
LGG	cis	rs9912468	1.000	rs4328478	chr17:64307982	C/T	cg19474267	chr17:64306194	PRKCA	-0.96	-27.76	-0.79	1.37e-100	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.29	-0.46	2.86e-26	Resting heart rate;
LGG	cis	rs314370	0.951	rs6706	chr7:100471044	C/T	cg10426581	chr7:100472382	SRRT	0.51	7.09	0.31	5.02e-12	Resting heart rate;
LGG	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	11.22	0.46	5.29e-26	Lung cancer in ever smokers;
LGG	cis	rs10937275	0.826	rs13061952	chr3:186658866	C/G	cg26193484	chr3:186648175	ST6GAL1	0.78	8.39	0.36	6.07e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7077256	0.564	rs6479911	chr10:65351581	C/T	cg02276361	chr10:65351566	REEP3	0.33	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.31	-0.79	1.52e-98	Primary sclerosing cholangitis;
LGG	cis	rs2439831	0.702	rs3759791	chr15:44090798	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	9.94	0.42	3.25e-21	Lung cancer in ever smokers;
LGG	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg04568710	chr12:38710424	ALG10B	-0.35	-7.47	-0.33	4.04e-13	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs4731207	0.596	rs10257712	chr7:124598079	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.85	-0.3	2.43e-11	Cutaneous malignant melanoma;
LGG	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg02649063	chr16:55794731	CES4	-0.48	-8.16	-0.35	3.11e-15	Response to dabigatran etexilate treatment;
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.51	-0.61	1.81e-48	Intelligence (multi-trait analysis);
LGG	cis	rs7226408	0.576	rs12454417	chr18:34516841	A/G	cg15022739	chr18:34823045	BRUNOL4	0.41	8.83	0.38	2.2e-17	Obesity-related traits;
LGG	cis	rs7666738	0.791	rs6840669	chr4:99016020	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg15763984	chr4:1342303	KIAA1530	0.37	6.73	0.3	5.01e-11	Obesity-related traits;
LGG	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg09222892	chr1:25734099	RHCE	0.47	9.99	0.42	2.14e-21	Erythrocyte sedimentation rate;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02054479	chr16:20911997	LYRM1;DCUN1D3	-0.52	-7.67	-0.34	1.01e-13	Systemic lupus erythematosus;
LGG	cis	rs4671458	0.948	rs12466601	chr2:63556348	T/G	cg17519650	chr2:63277830	OTX1	-0.61	-7.79	-0.34	4.38e-14	Subjective well-being;
LGG	cis	rs897984	0.762	rs8062719	chr16:31002664	A/G	cg02466173	chr16:30829666	NA	0.43	7.45	0.33	4.58e-13	Dementia with Lewy bodies;
LGG	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg24110177	chr3:50126178	RBM5	-0.44	-6.97	-0.31	1.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04772025	chr11:68637568	NA	0.72	12.77	0.51	3.41e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg23131131	chr22:24373011	LOC391322	-0.49	-7.98	-0.35	1.2e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs1620921	0.934	rs1740432	chr6:161210470	A/G	cg01280913	chr6:161186852	NA	-0.37	-7.59	-0.33	1.81e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.37	0.32	8.05e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6960043	0.818	rs10950550	chr7:15063923	T/G	cg19272540	chr7:15055459	NA	0.35	7.79	0.34	4.4e-14	Type 2 diabetes;
LGG	trans	rs7939886	0.764	rs12282595	chr11:55933084	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.88	0.3	2e-11	Myopia (pathological);
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg07870213	chr5:140052090	DND1	0.69	13.44	0.53	5.5e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs2011503	1.000	rs80007081	chr19:19626734	A/G	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg24011408	chr12:48396354	COL2A1	0.5	8.07	0.35	6.21e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg21100191	chr22:23484243	RTDR1	-1.0	-24.04	-0.75	1.71e-83	Bone mineral density;
LGG	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	trans	rs34421088	0.506	rs10091637	chr8:11144314	T/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.71	-0.3	5.77e-11	Neuroticism;
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9486719	0.656	rs6924957	chr6:96853579	G/T	cg06623918	chr6:96969491	KIAA0776	0.71	11.33	0.47	2.04e-26	Migraine;Coronary artery disease;
LGG	cis	rs990171	1.000	rs6727306	chr2:102981644	A/C	cg05295703	chr2:102895712	NA	-0.56	-9.67	-0.41	2.76e-20	Lymphocyte counts;
LGG	cis	rs10464366	0.843	rs13242209	chr7:39110241	C/T	cg10621924	chr7:39171070	POU6F2	0.42	8.31	0.36	1.07e-15	IgG glycosylation;
LGG	trans	rs75804782	0.630	rs11895642	chr2:239308280	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	6.71	0.3	5.76e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.89	-0.42	4.61e-21	Prostate cancer;
LGG	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg01324343	chr3:183735012	ABCC5	0.86	18.28	0.65	1.39e-56	Anterior chamber depth;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	cis	rs758324	0.947	rs10052255	chr5:131173106	C/T	cg06307176	chr5:131281290	NA	0.57	9.43	0.4	1.95e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg12856521	chr11:46389249	DGKZ	0.89	14.64	0.56	3.74e-40	Crohn's disease;
LGG	cis	rs13102973	0.867	rs12501608	chr4:135896365	T/C	cg14419869	chr4:135874104	NA	0.47	8.41	0.36	5.27e-16	Subjective well-being;
LGG	trans	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.64	-11.29	-0.46	2.78e-26	Mean corpuscular volume;
LGG	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs6426558	0.572	rs2670471	chr1:227454328	T/C	cg10327440	chr1:227177885	CDC42BPA	0.61	10.19	0.43	3.74e-22	Neutrophil percentage of white cells;
LGG	cis	rs926392	0.572	rs6129158	chr20:37673967	A/G	cg16355469	chr20:37678765	NA	0.63	10.29	0.43	1.61e-22	Dialysis-related mortality;
LGG	cis	rs975739	0.872	rs1279666	chr13:78367657	A/T	cg07847733	chr13:78271382	SLAIN1	0.38	6.85	0.3	2.39e-11	Hair color;
LGG	cis	rs1465370	0.711	rs10265824	chr7:130005092	G/T	cg04743876	chr7:130013617	NA	0.33	7.08	0.31	5.38e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.32	-0.32	1.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18876405	chr7:65276391	NA	0.59	10.87	0.45	1.19e-24	Aortic root size;
LGG	trans	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.55	-0.33	2.36e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg03188948	chr7:1209495	NA	0.49	7.16	0.32	3.16e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg27490568	chr2:178487706	NA	0.81	14.28	0.55	1.42e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs477692	0.618	rs7080419	chr10:131455235	A/G	cg05714579	chr10:131428358	MGMT	0.42	8.0	0.35	9.87e-15	Response to temozolomide;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs4948102	0.667	rs7811270	chr7:56139990	A/G	cg17215666	chr7:56131930	SUMF2	0.46	7.51	0.33	3.11e-13	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg26384229	chr12:38710491	ALG10B	0.73	14.71	0.56	1.83e-40	Morning vs. evening chronotype;
LGG	cis	rs11166927	1.000	rs13260415	chr8:140805137	A/C	cg16909799	chr8:140841666	TRAPPC9	0.59	12.37	0.5	1.51e-30	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs4622507	0.618	rs34298210	chr16:55061600	C/T	cg09947736	chr16:55091198	NA	0.77	11.24	0.46	4.56e-26	Social communication problems;
LGG	cis	rs11229555	0.874	rs11605269	chr11:58350872	A/G	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	9.25e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs870825	0.616	rs4443323	chr4:185629805	C/A	cg04058563	chr4:185651563	MLF1IP	1.06	22.06	0.72	3.13e-74	Blood protein levels;
LGG	cis	rs637571	0.780	rs653914	chr11:65676516	A/G	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.59	-0.41	5.35e-20	Eosinophil percentage of white cells;
LGG	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg27165867	chr14:105738592	BRF1	0.45	7.36	0.32	8.37e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg27476859	chr7:2772710	GNA12	0.53	10.36	0.43	9.61e-23	Height;
LGG	cis	rs6728642	0.572	rs13403225	chr2:97600827	A/G	cg26665480	chr2:98280029	ACTR1B	-0.86	-11.48	-0.47	4.92e-27	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg19847130	chr8:10466454	RP1L1	0.34	7.29	0.32	1.36e-12	Neuroticism;
LGG	cis	rs1371867	0.875	rs28595052	chr8:101327553	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.45	0.33	4.57e-13	Tonsillectomy;
LGG	cis	rs7267979	1.000	rs1047171	chr20:25428786	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9948	0.655	rs6758151	chr2:97388884	A/G	cg01990225	chr2:97406019	LMAN2L	-0.77	-8.11	-0.35	4.65e-15	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg21479132	chr6:26055353	NA	0.81	8.15	0.35	3.34e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg00405596	chr8:11794950	NA	0.66	11.76	0.48	4.2e-28	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg04317338	chr11:64019027	PLCB3	0.67	8.04	0.35	7.64e-15	Mean platelet volume;
LGG	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg27478167	chr7:817139	HEATR2	0.47	7.34	0.32	9.44e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.8	-0.34	4.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07458698	chr2:67624494	ETAA1	-0.41	-6.67	-0.3	7.39e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs240764	0.658	rs2132169	chr6:101177663	C/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.72	-0.34	7.02e-14	Neuroticism;
LGG	cis	rs7011049	1.000	rs77668788	chr8:53856407	C/T	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg08198773	chr8:1697536	NA	0.36	7.0	0.31	9.18e-12	Systolic blood pressure;
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.24	-0.39	9.07e-19	Life satisfaction;
LGG	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg03929089	chr4:120376271	NA	-0.64	-9.09	-0.39	2.87e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09833538	chr9:123605306	PSMD5;LOC253039	0.44	7.23	0.32	2.08e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9486719	0.901	rs760619	chr6:96857431	A/G	cg06623918	chr6:96969491	KIAA0776	0.76	10.59	0.44	1.33e-23	Migraine;Coronary artery disease;
LGG	cis	rs950169	0.649	rs12911612	chr15:84691014	T/C	cg24253500	chr15:84953950	NA	0.47	7.47	0.33	4e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21317132	chr2:65215566	SLC1A4	0.45	7.18	0.32	2.81e-12	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg18681998	chr4:17616180	MED28	0.88	20.3	0.69	5.26e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs472402	0.507	rs8192139	chr5:6636973	C/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.42	-6.69	-0.3	6.47e-11	Response to amphetamines;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.82	0.42	8.72e-21	Longevity;
LGG	cis	rs4262150	0.883	rs72799153	chr5:152112858	A/T	cg12297329	chr5:152029980	NA	-0.7	-12.9	-0.51	9.38e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs7226408	0.857	rs56364983	chr18:34430275	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2013441	1.000	rs34712254	chr17:20049308	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs975722	0.902	rs214152	chr7:117325184	C/T	cg10524701	chr7:117356490	CTTNBP2	0.5	11.41	0.47	9.27e-27	Coronary artery disease;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg18379455	chr17:41446167	NA	-0.32	-7.39	-0.32	7e-13	Menopause (age at onset);
LGG	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg16576597	chr16:28551801	NUPR1	0.34	7.57	0.33	2.05e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	9.09	0.39	2.91e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	1.000	rs9825741	chr3:41761828	A/T	cg03022575	chr3:42003672	ULK4	-0.59	-7.71	-0.34	7.58e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.9	0.57	2.72e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9487094	0.885	rs12524273	chr6:109716964	T/C	cg16315928	chr6:109776240	MICAL1	0.53	9.09	0.39	2.84e-18	Height;
LGG	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.04	0.31	7.19e-12	Educational attainment;
LGG	cis	rs1568889	1.000	rs12804198	chr11:28143114	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	14.15	0.55	4.94e-38	Bipolar disorder;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.646	rs10793337	chr11:78285875	A/T	cg27205649	chr11:78285834	NARS2	0.6	11.24	0.46	4.37e-26	Alzheimer's disease (survival time);
LGG	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.97	-0.38	7.45e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9902453	0.765	rs2250320	chr17:28128657	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg12623918	chr2:306882	NA	0.38	7.1	0.31	4.67e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-8.03	-0.35	8.38e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.36	0.4	3.43e-19	Parkinson's disease;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.72	-0.3	5.26e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	8.9	0.38	1.3e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg13628971	chr7:2884303	GNA12	0.38	7.84	0.34	3.19e-14	Height;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg14004847	chr7:1930337	MAD1L1	0.58	10.39	0.43	7.18e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg06875740	chr19:51307921	C19orf48	-0.69	-6.97	-0.31	1.12e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8017423	0.565	rs4904681	chr14:90835566	A/T	cg04374321	chr14:90722782	PSMC1	-0.62	-11.63	-0.48	1.35e-27	Mortality in heart failure;
LGG	cis	rs7336332	0.628	rs9581855	chr13:28018014	G/A	cg01674679	chr13:27998804	GTF3A	-0.67	-8.75	-0.38	4.12e-17	Weight;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg06916706	chr16:4465613	CORO7	-0.71	-12.24	-0.49	4.67e-30	Schizophrenia;
LGG	cis	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg06521331	chr12:34319734	NA	-0.58	-10.13	-0.43	6.34e-22	Morning vs. evening chronotype;
LGG	cis	rs77633900	0.614	rs7162982	chr15:76961559	G/A	cg21673338	chr15:77095150	SCAPER	0.48	7.8	0.34	4.19e-14	Non-glioblastoma glioma;Glioma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09636849	chr2:96658648	NA	0.51	7.44	0.33	5.05e-13	Gut microbiome composition (summer);
LGG	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.98	-0.39	6.67e-18	Mean corpuscular volume;
LGG	cis	rs7179456	0.545	rs2250583	chr15:59050382	C/T	cg05156742	chr15:59063176	FAM63B	-0.59	-9.61	-0.41	4.65e-20	Asperger disorder;
LGG	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs737693	0.831	rs72981684	chr11:102724211	C/T	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs457717	0.730	rs457054	chr5:75946971	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.84	0.3	2.44e-11	Hearing impairment;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.38	-0.36	6.45e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.17	0.43	4.44e-22	Colorectal cancer;
LGG	cis	rs3096299	0.754	rs3102382	chr16:89409742	C/G	cg06640241	chr16:89574553	SPG7	0.59	9.62	0.41	4.36e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg22398616	chr13:53314203	LECT1	-0.4	-8.11	-0.35	4.48e-15	Lewy body disease;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9611519	0.929	rs9611474	chr22:41434858	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-7.91	-0.34	1.97e-14	Neuroticism;
LGG	cis	rs28655083	1.000	rs7197078	chr16:77072735	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.71	-0.34	7.58e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26076054	chr5:421317	AHRR	-0.54	-8.89	-0.38	1.34e-17	Cystic fibrosis severity;
LGG	cis	rs344364	0.602	rs12325217	chr16:1887108	A/T	cg00490583	chr16:1843685	IGFALS	-0.45	-9.88	-0.42	5.11e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.54	-9.22	-0.39	1.07e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg26384229	chr12:38710491	ALG10B	0.89	20.28	0.69	6.33e-66	Bladder cancer;
LGG	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg02002194	chr4:3960332	NA	-0.41	-7.73	-0.34	6.6e-14	Neuroticism;
LGG	cis	rs11608355	1.000	rs10774690	chr12:109859682	G/A	cg19025524	chr12:109796872	NA	-0.49	-9.3	-0.4	5.73e-19	Neuroticism;
LGG	cis	rs11885103	0.669	rs2724889	chr2:551146	G/T	cg21195176	chr2:593345	NA	0.37	6.87	0.3	2.04e-11	Heschl's gyrus morphology;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg23958373	chr8:599963	NA	1.21	12.26	0.5	4.01e-30	IgG glycosylation;
LGG	cis	rs6964587	1.000	rs10270598	chr7:91700827	T/C	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	trans	rs12517041	1.000	rs2081950	chr5:23287505	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs7737355	1.000	rs12521320	chr5:130755920	A/G	cg06307176	chr5:131281290	NA	-0.54	-9.13	-0.39	2.13e-18	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg07701084	chr6:150067640	NUP43	0.7	13.51	0.53	2.64e-35	Lung cancer;
LGG	cis	rs6430585	0.591	rs61187091	chr2:136468238	G/A	cg07169764	chr2:136633963	MCM6	1.09	18.2	0.65	3.14e-56	Corneal structure;
LGG	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg14092571	chr14:90743983	NA	-0.81	-16.39	-0.61	5.89e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs9868809	0.881	rs2310996	chr3:48671834	T/C	cg00383909	chr3:49044727	WDR6	0.76	9.13	0.39	2.19e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.28	-0.69	6.87e-66	Diabetic kidney disease;
LGG	cis	rs3816183	0.626	rs13023683	chr2:42908951	A/G	cg14631114	chr2:43023945	NA	0.36	7.03	0.31	7.52e-12	Hypospadias;
LGG	cis	rs4330281	0.608	rs34502358	chr3:17377815	T/C	cg20981856	chr3:17787350	NA	0.36	6.82	0.3	2.83e-11	Schizophrenia;
LGG	cis	rs4363385	0.620	rs4388644	chr1:152983674	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.05	-0.39	4.02e-18	Inflammatory skin disease;
LGG	cis	rs9868809	0.772	rs9811318	chr3:48702606	A/G	cg00383909	chr3:49044727	WDR6	0.78	9.52	0.4	9.37e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.69	-9.32	-0.4	4.72e-19	Diabetic retinopathy;
LGG	cis	rs4845570	1.000	rs7542898	chr1:151753622	T/G	cg07092448	chr1:151763213	TDRKH	-1.1	-17.41	-0.63	1.37e-52	Coronary artery disease;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg07414643	chr4:187882934	NA	-0.48	-9.28	-0.4	6.71e-19	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.06	0.31	6.11e-12	Morning vs. evening chronotype;
LGG	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg21055462	chr7:100276975	NA	0.35	6.78	0.3	3.71e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs1566085	0.704	rs73713410	chr8:142655567	G/A	cg26331504	chr8:142652174	NA	-0.3	-6.93	-0.31	1.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg02725872	chr8:58115012	NA	-0.86	-11.65	-0.48	1.1e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.669	rs1341734	chr9:15763124	A/G	cg14451791	chr9:16040625	NA	0.34	8.85	0.38	1.86e-17	Body mass index;
LGG	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.26e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1034435	0.662	rs10460766	chr22:48896580	G/A	cg05992904	chr22:48892994	FAM19A5	-0.55	-8.42	-0.36	4.88e-16	Late-onset Alzheimer's disease;
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg26513180	chr16:89883248	FANCA	0.95	22.1	0.72	1.95e-74	Vitiligo;
LGG	cis	rs6429082	0.715	rs2172718	chr1:235580727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.78	0.3	3.78e-11	Cognitive ability;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg16606324	chr3:10149918	C3orf24	0.54	7.19	0.32	2.62e-12	Alzheimer's disease;
LGG	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg06640241	chr16:89574553	SPG7	0.79	14.03	0.55	1.65e-37	Multiple myeloma (IgH translocation);
LGG	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg10847948	chr11:71163743	NADSYN1	0.58	8.73	0.38	4.66e-17	Vitamin D levels;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg25540816	chr5:148928885	CSNK1A1	-0.37	-6.77	-0.3	3.85e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg18681998	chr4:17616180	MED28	0.88	20.18	0.68	1.93e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg02931644	chr1:25747376	RHCE	0.42	9.53	0.4	8.88e-20	Erythrocyte sedimentation rate;
LGG	cis	rs12579753	1.000	rs12580330	chr12:82241280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.05	-0.46	2.38e-25	Resting heart rate;
LGG	cis	rs17221829	0.521	rs12366176	chr11:89316998	A/C	cg02982614	chr11:89391479	FOLH1B	0.38	8.26	0.36	1.59e-15	Anxiety in major depressive disorder;
LGG	cis	rs911555	0.692	rs60235428	chr14:103904350	T/C	cg24130564	chr14:104152367	KLC1	0.37	7.04	0.31	7.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg23758822	chr17:41437982	NA	-0.86	-15.72	-0.59	5.98e-45	Menopause (age at onset);
LGG	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg21827317	chr3:136751795	NA	0.53	9.9	0.42	4.3e-21	Neuroticism;
LGG	cis	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg21775007	chr8:11205619	TDH	0.83	15.65	0.59	1.35e-44	Retinal vascular caliber;
LGG	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	Neuroticism;
LGG	cis	rs7474896	0.609	rs11011336	chr10:37985316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.5	-7.96	-0.35	1.35e-14	Obesity (extreme);
LGG	cis	rs10193935	0.901	rs13375	chr2:42559288	A/G	cg27598129	chr2:42591480	NA	-0.58	-8.93	-0.38	9.8e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4330281	0.669	rs9821318	chr3:17567220	C/T	cg20981856	chr3:17787350	NA	0.38	7.12	0.31	4.16e-12	Schizophrenia;
LGG	cis	rs963731	0.579	rs3796038	chr2:39239572	G/C	cg04010122	chr2:39346883	SOS1	-0.75	-7.92	-0.35	1.79e-14	Corticobasal degeneration;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs11748327	0.580	rs10056229	chr5:4012356	C/G	cg01025095	chr5:4101132	NA	-0.43	-7.07	-0.31	5.58e-12	Myocardial infarction;
LGG	cis	rs2735413	0.750	rs75500355	chr16:78075396	A/T	cg04733911	chr16:78082701	NA	0.61	9.85	0.42	6.5e-21	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs929354	0.772	rs6954050	chr7:156978554	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.35e-13	Body mass index;
LGG	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg27205649	chr11:78285834	NARS2	0.47	7.82	0.34	3.59e-14	Alzheimer's disease (survival time);
LGG	cis	rs11920090	0.800	rs5393	chr3:170744920	T/G	cg09710316	chr3:170744871	SLC2A2	0.64	8.76	0.38	3.72e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg13647721	chr17:30228624	UTP6	0.64	7.97	0.35	1.25e-14	Hip circumference adjusted for BMI;
LGG	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg19508488	chr2:152266495	RIF1	-0.59	-10.23	-0.43	2.71e-22	Lung cancer;
LGG	cis	rs2235649	0.663	rs113908028	chr16:1848915	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.91	-0.31	1.65e-11	Blood metabolite levels;
LGG	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg21130718	chr4:1044621	NA	0.39	7.46	0.33	4.23e-13	Recombination rate (males);
LGG	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21659725	chr3:3221576	CRBN	0.75	11.86	0.48	1.7e-28	Resting heart rate;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg13047869	chr3:10149882	C3orf24	0.53	8.9	0.38	1.22e-17	Alzheimer's disease;
LGG	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg05025159	chr2:241905733	NA	0.49	10.0	0.42	1.9e-21	Urinary metabolites;
LGG	cis	rs9818758	0.607	rs34580506	chr3:49113713	C/A	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs1878931	0.582	rs27225	chr16:3428060	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.71	-11.3	-0.46	2.59e-26	Body mass index (adult);
LGG	cis	rs2694528	0.925	rs76339698	chr5:60372588	A/G	cg11474532	chr5:59995715	DEPDC1B	0.69	7.4	0.33	6.31e-13	Parkinson's disease;
LGG	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg08975724	chr8:8085496	FLJ10661	0.38	7.01	0.31	8.43e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.27	0.4	6.92e-19	Diabetic retinopathy;
LGG	cis	rs11971779	0.680	rs10274480	chr7:139052428	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	6.83	0.3	2.68e-11	Diisocyanate-induced asthma;
LGG	cis	rs7666738	0.830	rs6831925	chr4:98947401	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.545	rs3735147	chr7:65970528	A/C	cg11764359	chr7:65958608	NA	0.63	9.77	0.41	1.23e-20	Aortic root size;
LGG	trans	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.86	-0.3	2.16e-11	Retinal vascular caliber;
LGG	cis	rs2294693	0.947	rs10456496	chr6:40988840	A/G	cg14769373	chr6:40998127	UNC5CL	0.41	7.2	0.32	2.49e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08223748	chr5:88179260	MEF2C	0.44	7.32	0.32	1.11e-12	Cognitive performance;
LGG	cis	rs1927790	0.727	rs7320065	chr13:96937738	C/G	cg02571835	chr13:96230311	CLDN10	-0.35	-7.16	-0.32	3.17e-12	Body mass index;
LGG	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg00405596	chr8:11794950	NA	0.44	7.64	0.33	1.24e-13	Mood instability;
LGG	trans	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs1691799	0.899	rs1168303	chr12:66738586	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.53	-0.59	4.4e-44	White blood cell count (basophil);
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04911050	chr16:677664	RAB40C	0.33	6.73	0.3	5.09e-11	Height;
LGG	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg01324343	chr3:183735012	ABCC5	0.85	18.33	0.65	7.91e-57	Anterior chamber depth;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.57	-0.41	6.31e-20	Joint mobility (Beighton score);
LGG	cis	rs41005	0.967	rs13430914	chr2:8114648	A/G	cg03155496	chr2:8117019	LOC339788	0.88	19.56	0.67	1.54e-62	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.38	-0.43	7.7e-23	Tonsillectomy;
LGG	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5e-12	Leprosy;
LGG	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.37	0.4	3.12e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7937890	0.559	rs2597200	chr11:14485600	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs4919044	0.688	rs59539045	chr10:94776594	C/A	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.07	-0.31	5.73e-12	Coronary artery disease;
LGG	trans	rs208520	0.690	rs851468	chr6:66825875	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.34	-0.65	7.39e-57	Exhaled nitric oxide output;
LGG	cis	rs476633	0.691	rs2164996	chr15:41536624	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.61	-10.73	-0.45	3.92e-24	Glomerular filtration rate (creatinine);
LGG	cis	rs68170813	0.652	rs77056542	chr7:107089751	G/C	cg02696742	chr7:106810147	HBP1	-0.68	-8.72	-0.38	5.03e-17	Coronary artery disease;
LGG	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.18	-0.36	2.8e-15	HDL cholesterol;
LGG	cis	rs4356203	0.905	rs511119	chr11:17215117	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs283228	0.617	rs496165	chr6:101777796	A/T	cg27451362	chr6:101846650	GRIK2	0.86	13.43	0.53	5.77e-35	Coenzyme Q10 levels;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg21911579	chr5:131705225	SLC22A5	-0.67	-7.48	-0.33	3.66e-13	Rheumatoid arthritis;
LGG	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg01200585	chr1:228362443	C1orf69	-0.45	-8.06	-0.35	6.78e-15	Diastolic blood pressure;
LGG	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg11812906	chr14:75593930	NEK9	0.47	8.34	0.36	8.33e-16	Height;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg09264619	chr17:80180166	NA	0.39	7.82	0.34	3.6e-14	Life satisfaction;
LGG	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg02227867	chr8:22457446	C8orf58	0.46	8.8	0.38	2.7e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11168618	0.810	rs11168595	chr12:48868211	C/T	cg24011408	chr12:48396354	COL2A1	0.49	8.04	0.35	7.5e-15	Adiponectin levels;
LGG	trans	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg13013644	chr5:502571	SLC9A3	-0.35	-6.73	-0.3	4.92e-11	Cystic fibrosis severity;
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg17328964	chr8:145687451	CYHR1	0.66	12.66	0.51	9.2e-32	Age at first birth;
LGG	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12016809	chr21:47604291	C21orf56	-0.55	-9.71	-0.41	2.14e-20	Testicular germ cell tumor;
LGG	trans	rs941408	0.515	rs759067	chr19:2775668	C/T	cg22153745	chr1:153894579	GATAD2B	-0.57	-8.62	-0.37	1.07e-16	Total cholesterol levels;
LGG	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg12623918	chr2:306882	NA	0.52	9.76	0.41	1.38e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs1997103	1.000	rs2331065	chr7:55408392	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs3087591	1.000	rs2952978	chr17:29474744	A/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg17652424	chr22:38574118	PLA2G6	0.27	6.93	0.31	1.41e-11	Cutaneous nevi;
LGG	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.92	0.38	1.12e-17	Motion sickness;
LGG	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17453880	0.929	rs4958321	chr5:152020604	G/T	cg12297329	chr5:152029980	NA	-0.9	-23.82	-0.74	1.89e-82	Subjective well-being;
LGG	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs9878978	0.890	rs35104429	chr3:2481559	C/T	cg21928760	chr3:2462534	CNTN4	0.41	8.94	0.38	9.02e-18	Blood pressure (smoking interaction);
LGG	cis	rs4262150	0.883	rs72799198	chr5:152190705	A/G	cg12297329	chr5:152029980	NA	-0.68	-12.84	-0.51	1.71e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs3087591	0.639	rs757378	chr17:29722619	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.57	-11.9	-0.48	1.09e-28	Hip circumference;
LGG	cis	rs929596	0.606	rs10178992	chr2:234657877	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.9	-0.45	9.1e-25	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4774899	0.752	rs2264904	chr15:57373739	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.75	-0.3	4.33e-11	Urinary tract infection frequency;
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg12654349	chr5:56205094	C5orf35	0.57	9.72	0.41	1.87e-20	Initial pursuit acceleration;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg21963583	chr11:68658836	MRPL21	0.5	8.57	0.37	1.56e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6460942	0.915	rs62448619	chr7:12457743	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs13323323	0.842	rs56377787	chr3:44293513	A/G	cg02073558	chr3:44770973	ZNF501	0.51	7.06	0.31	6.01e-12	IgG glycosylation;
LGG	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg18854424	chr1:2615690	NA	-0.35	-7.45	-0.33	4.48e-13	Ulcerative colitis;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg14773178	chr5:1868261	NA	0.37	7.99	0.35	1.1e-14	Cardiovascular disease risk factors;
LGG	cis	rs4430311	0.723	rs2034915	chr1:243878503	A/G	cg25706552	chr1:244017396	NA	-0.64	-15.66	-0.59	1.14e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg19847130	chr8:10466454	RP1L1	-0.3	-6.72	-0.3	5.42e-11	Mood instability;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg08885076	chr2:99613938	TSGA10	-0.54	-9.64	-0.41	3.59e-20	Chronic sinus infection;
LGG	cis	rs9796	0.576	rs13329511	chr15:41299121	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.46	-0.44	3.98e-23	Menopause (age at onset);
LGG	cis	rs10992471	0.756	rs7848055	chr9:95115492	A/C	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.1	-0.31	4.75e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4132509	0.793	rs12037013	chr1:243784207	G/A	cg21452805	chr1:244014465	NA	0.88	8.46	0.37	3.63e-16	RR interval (heart rate);
LGG	cis	rs7712401	0.601	rs442911	chr5:122325551	T/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs4423214	0.569	rs12806918	chr11:71119018	G/T	cg10847948	chr11:71163743	NADSYN1	-0.53	-9.98	-0.42	2.19e-21	Vitamin D levels;
LGG	trans	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg16141378	chr3:129829833	LOC729375	0.31	7.1	0.31	4.7e-12	Recombination measurement;
LGG	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs1018836	0.923	rs2105967	chr8:91587522	A/G	cg16814680	chr8:91681699	NA	-0.83	-15.53	-0.59	4.52e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4722166	0.695	rs6946509	chr7:22809490	T/C	cg05265849	chr7:22767390	IL6	0.37	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg18551225	chr6:44695536	NA	-0.65	-11.27	-0.46	3.33e-26	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	trans	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg21659725	chr3:3221576	CRBN	-0.67	-6.72	-0.3	5.48e-11	Cognitive function;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg05091796	chr16:4465799	CORO7	-0.6	-9.95	-0.42	2.97e-21	Schizophrenia;
LGG	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg19761014	chr17:28927070	LRRC37B2	0.64	8.08	0.35	5.56e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg22437258	chr11:111473054	SIK2	-0.58	-9.85	-0.42	6.33e-21	Primary sclerosing cholangitis;
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg00405596	chr8:11794950	NA	-0.43	-6.9	-0.31	1.72e-11	Neuroticism;
LGG	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg24699146	chr1:24152579	HMGCL	-0.26	-7.79	-0.34	4.46e-14	Immature fraction of reticulocytes;
LGG	cis	rs17208368	0.628	rs12598595	chr16:55093224	A/C	cg11181171	chr16:55090946	NA	0.46	7.59	0.33	1.77e-13	Hypospadias;
LGG	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18252515	chr7:66147081	NA	-0.4	-6.89	-0.3	1.85e-11	Aortic root size;
LGG	cis	rs7716219	0.751	rs1983189	chr5:54886681	C/T	cg14753740	chr5:54468940	CDC20B;MIR449C	-0.43	-6.66	-0.3	7.87e-11	Height;
LGG	cis	rs1801251	0.778	rs812383	chr2:233737132	C/A	cg25237894	chr2:233734115	C2orf82	-0.72	-15.29	-0.58	4.87e-43	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19819145	chr3:35681147	NA	0.38	6.83	0.3	2.62e-11	Obesity-related traits;
LGG	cis	rs703842	1.000	rs11172343	chr12:58188157	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.36	0.36	7.45e-16	Multiple sclerosis;
LGG	cis	rs2285947	0.935	rs10258022	chr7:21583667	A/G	cg23045935	chr7:21583304	DNAH11	0.43	9.38	0.4	2.85e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11625487	0.915	rs11845826	chr14:77966145	C/A	cg20045696	chr14:77926864	AHSA1	0.57	7.34	0.32	9.98e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	cis	rs963731	0.649	rs6544191	chr2:39266384	C/T	cg04010122	chr2:39346883	SOS1	-0.89	-7.59	-0.33	1.76e-13	Corticobasal degeneration;
LGG	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs5769765	1.000	rs34774661	chr22:50267508	C/G	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg18402987	chr7:1209562	NA	0.67	9.13	0.39	2.15e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.33	6.87	0.3	2.13e-11	Bipolar disorder;
LGG	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg04287289	chr16:89883240	FANCA	0.5	8.75	0.38	3.9e-17	Vitiligo;
LGG	cis	rs174601	0.861	rs174550	chr11:61571478	T/C	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs11718455	0.960	rs13082990	chr3:44005172	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.73	-0.3	4.95e-11	Coronary artery disease;
LGG	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.88	-0.34	2.32e-14	IgG glycosylation;
LGG	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.7e-11	Coronary artery disease;
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg05793240	chr7:2802953	GNA12	0.33	7.92	0.35	1.77e-14	Height;
LGG	cis	rs2075064	0.500	rs10986190	chr9:126818818	A/G	cg14112217	chr9:126806003	NA	0.48	8.86	0.38	1.75e-17	Waist circumference;
LGG	cis	rs9900972	0.918	rs2889530	chr17:76878706	C/T	cg00961940	chr17:76876995	TIMP2	0.46	9.04	0.39	4.39e-18	Obesity-related traits;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.01	0.55	2.07e-37	Bladder cancer;
LGG	cis	rs2694528	1.000	rs158937	chr5:60236206	A/G	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.57	-0.33	2e-13	Parkinson's disease;
LGG	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.64	-0.37	9.07e-17	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	13.35	0.53	1.25e-34	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg23782820	chr8:58130467	NA	0.56	8.31	0.36	1.03e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10779751	1.000	rs7544489	chr1:11299511	A/G	cg08854313	chr1:11322531	MTOR	-0.78	-17.17	-0.62	1.7e-51	Body mass index;
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg02002194	chr4:3960332	NA	0.44	8.04	0.35	7.63e-15	Triglycerides;
LGG	cis	rs9354308	0.738	rs1392148	chr6:66613162	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg18876405	chr7:65276391	NA	0.45	7.86	0.34	2.81e-14	Calcium levels;
LGG	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg00717180	chr2:96193071	NA	-0.48	-9.12	-0.39	2.22e-18	Coronary artery disease;
LGG	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg03806693	chr22:41940476	POLR3H	1.02	18.05	0.64	1.58e-55	Vitiligo;
LGG	trans	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs981844	0.775	rs72733610	chr4:154732336	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.1	0.46	1.48e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg21775007	chr8:11205619	TDH	-0.51	-8.25	-0.36	1.68e-15	Retinal vascular caliber;
LGG	cis	rs2439831	1.000	rs2439841	chr15:43734749	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.9	0.45	9.1e-25	Lung cancer in ever smokers;
LGG	cis	rs6752107	0.503	rs2304774	chr2:234235749	G/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.49	8.54	0.37	1.96e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10861661	1.000	rs10861661	chr12:107174646	A/C	cg15890332	chr12:107067104	RFX4	0.32	7.63	0.33	1.31e-13	Triglyceride levels;
LGG	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg00700412	chr12:58011837	NA	0.41	8.39	0.36	6.02e-16	Multiple sclerosis;
LGG	trans	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg02002194	chr4:3960332	NA	-0.39	-7.02	-0.31	7.71e-12	Mood instability;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg18926786	chr6:150244388	RAET1G	0.31	6.72	0.3	5.32e-11	Lung cancer;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg12379764	chr21:47803548	PCNT	-0.46	-7.93	-0.35	1.62e-14	Testicular germ cell tumor;
LGG	cis	rs4330281	0.608	rs17043422	chr3:17383881	C/T	cg20981856	chr3:17787350	NA	0.36	6.88	0.3	1.96e-11	Schizophrenia;
LGG	cis	rs36051895	0.695	rs62541532	chr9:5017384	C/A	cg02405213	chr9:5042618	JAK2	-0.83	-14.64	-0.56	3.82e-40	Pediatric autoimmune diseases;
LGG	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg08297393	chr2:100937505	LONRF2	-0.52	-9.54	-0.41	8.19e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2298450	0.550	rs3827184	chr21:37661686	T/G	cg02919814	chr21:37666008	DOPEY2	-0.45	-9.12	-0.39	2.31e-18	Schizophrenia;
LGG	cis	rs4330281	0.608	rs2592099	chr3:17369313	G/T	cg20981856	chr3:17787350	NA	0.36	6.87	0.3	2.08e-11	Schizophrenia;
LGG	cis	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs2377058	0.803	rs13332439	chr16:89730479	A/T	cg07835443	chr16:89734986	C16orf55	-0.46	-7.83	-0.34	3.34e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg20503657	chr10:835505	NA	0.52	6.75	0.3	4.57e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs4356932	0.902	rs28548768	chr4:76972755	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.07e-11	Blood protein levels;
LGG	cis	rs8077889	0.956	rs61608877	chr17:41848713	A/C	cg26893861	chr17:41843967	DUSP3	0.96	17.07	0.62	5.13e-51	Triglycerides;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg11766577	chr21:47581405	C21orf56	-0.49	-8.56	-0.37	1.74e-16	Testicular germ cell tumor;
LGG	cis	rs4242434	0.672	rs7846476	chr8:22479461	T/C	cg03733263	chr8:22462867	KIAA1967	1.01	24.45	0.75	2.21e-85	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs2898857	0.524	rs2072153	chr17:47390014	C/G	cg11430096	chr6:110968061	CDK19	-0.49	-8.39	-0.36	6.1e-16	Cancer;
LGG	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg20503657	chr10:835505	NA	0.95	13.04	0.52	2.6e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	15.06	0.57	5.34e-42	Cognitive test performance;
LGG	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg12463550	chr7:65579703	CRCP	-0.74	-7.42	-0.33	5.6e-13	Diabetic kidney disease;
LGG	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg08742575	chr21:47604166	C21orf56	0.56	10.34	0.43	1.1e-22	Testicular germ cell tumor;
LGG	trans	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg26043149	chr18:55253948	FECH	0.6	9.86	0.42	6.3e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.0	-0.35	9.94e-15	Coronary artery disease;
LGG	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.74e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3845702	0.877	rs12693216	chr2:180839793	T/A	cg01881094	chr2:180872142	CWC22	-0.91	-14.19	-0.55	3.37e-38	Schizophrenia;
LGG	trans	rs931812	0.757	rs13276100	chr8:101908345	G/A	cg20993868	chr7:22813445	NA	0.62	11.56	0.47	2.48e-27	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs7119	0.689	rs11630557	chr15:77820712	A/G	cg10437265	chr15:77819839	NA	0.25	6.97	0.31	1.09e-11	Type 2 diabetes;
LGG	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.78	-0.3	3.69e-11	HDL cholesterol;
LGG	cis	rs2084898	0.891	rs501021	chr11:120000872	T/C	cg13907859	chr11:120009124	TRIM29	-0.87	-12.44	-0.5	7.76e-31	Stroke (pediatric);
LGG	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg21435375	chr2:172878103	MAP1D	0.32	7.26	0.32	1.7e-12	Schizophrenia;
LGG	trans	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.19	0.49	8.07e-30	Type 2 diabetes;
LGG	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg23625390	chr15:77176239	SCAPER	0.51	9.99	0.42	2.14e-21	Blood metabolite levels;
LGG	cis	rs7580658	0.545	rs885276	chr2:127950904	A/T	cg10021288	chr2:128175891	PROC	-0.46	-8.82	-0.38	2.26e-17	Protein C levels;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03324837	chr17:61044407	NA	0.39	6.95	0.31	1.23e-11	Bilirubin levels;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.38	-0.32	7.63e-13	Electroencephalogram traits;
LGG	cis	rs977747	0.966	rs741959	chr1:47676233	C/T	cg03885399	chr1:47691550	TAL1	0.33	6.97	0.31	1.12e-11	Body mass index;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.61	-0.44	1.06e-23	Platelet count;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.8	0.3	3.18e-11	Longevity;
LGG	cis	rs11209002	0.592	rs7551197	chr1:67588090	A/T	cg02640540	chr1:67518911	SLC35D1	0.4	6.69	0.3	6.38e-11	Crohn's disease;
LGG	cis	rs919433	0.680	rs12621129	chr2:198265350	T/C	cg00792783	chr2:198669748	PLCL1	-0.53	-8.0	-0.35	9.83e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs8032158	1.000	rs8026172	chr15:56125182	T/A	cg02198044	chr15:56286336	NEDD4	-0.69	-11.82	-0.48	2.44e-28	Keloid;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27397625	chr6:42952298	PPP2R5D	0.43	6.92	0.31	1.49e-11	Gut microbiome composition (summer);
LGG	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.33	0.32	1.01e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7017914	0.967	rs13261712	chr8:71732264	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.77	-0.3	3.85e-11	Bone mineral density;
LGG	cis	rs11971779	0.590	rs59602547	chr7:139117023	G/A	cg07862535	chr7:139043722	LUC7L2	0.46	7.66	0.34	1.12e-13	Diisocyanate-induced asthma;
LGG	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg03929089	chr4:120376271	NA	0.74	7.83	0.34	3.41e-14	Axial length;
LGG	cis	rs9815354	0.812	rs73077386	chr3:41857652	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg07274523	chr3:49395745	GPX1	0.57	9.56	0.41	7.02e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4888262	0.526	rs7201105	chr16:74590603	A/G	cg01733217	chr16:74700730	RFWD3	0.82	16.35	0.61	8.85e-48	Testicular germ cell tumor;
LGG	cis	rs56146971	0.714	rs17804071	chr14:91852876	C/T	cg14409461	chr14:91925021	SMEK1	-0.4	-6.66	-0.3	7.67e-11	Alzheimer disease and age of onset;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.02	-0.39	5.13e-18	Life satisfaction;
LGG	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.15	0.32	3.31e-12	Homoarginine levels;
LGG	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg01448562	chr3:133502909	NA	-0.8	-15.65	-0.59	1.26e-44	Iron status biomarkers;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.14	0.31	3.61e-12	Schizophrenia;
LGG	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg15971980	chr6:150254442	NA	0.42	6.88	0.3	2e-11	Lung cancer;
LGG	cis	rs13082711	0.522	rs6790344	chr3:27336531	G/C	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.48	0.5	5.27e-31	Coronary artery disease;
LGG	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg06917634	chr15:78832804	PSMA4	0.44	7.39	0.32	6.81e-13	Sudden cardiac arrest;
LGG	cis	rs832540	0.898	rs331497	chr5:56251660	G/T	cg14703610	chr5:56206110	C5orf35	-0.4	-6.87	-0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs11718455	1.000	rs11917515	chr3:44020237	A/G	cg21419209	chr3:44054225	NA	-0.42	-6.9	-0.31	1.73e-11	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.49	-0.44	3.13e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11583043	1.000	rs34915449	chr1:101476786	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	7.88	0.34	2.34e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg02527881	chr3:46936655	PTH1R	-0.33	-8.04	-0.35	7.82e-15	Birth weight;
LGG	cis	rs6032067	0.632	rs35632684	chr20:43802889	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs10791097	0.667	rs4937584	chr11:130741761	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg15128208	chr22:42549153	NA	-0.37	-7.41	-0.33	5.97e-13	Cognitive function;
LGG	cis	rs7226408	0.857	rs72887045	chr18:34481737	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	Neuroticism;
LGG	trans	rs1997103	1.000	rs1997098	chr7:55405594	G/T	cg20935933	chr6:143382018	AIG1	0.56	8.84	0.38	2.04e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs11645898	0.935	rs72787091	chr16:72190184	C/T	cg14768367	chr16:72042858	DHODH	-0.8	-10.94	-0.45	6.38e-25	Blood protein levels;
LGG	cis	rs9308731	0.931	rs616130	chr2:111912681	C/A	cg26001287	chr2:111877753	BCL2L11	-0.39	-7.73	-0.34	6.99e-14	Chronic lymphocytic leukemia;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg21963583	chr11:68658836	MRPL21	0.6	10.15	0.43	5.53e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-9.41	-0.4	2.42e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4430311	0.571	rs1486475	chr1:243868398	T/C	cg25706552	chr1:244017396	NA	-0.61	-13.53	-0.53	2.14e-35	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08800530	chr5:175788722	KIAA1191	-0.51	-7.39	-0.32	6.85e-13	Systemic lupus erythematosus;
LGG	trans	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg08553999	chr16:79633724	MAF	0.39	6.69	0.3	6.36e-11	Lung adenocarcinoma;
LGG	cis	rs2658782	0.615	rs2605615	chr11:93233068	G/A	cg15737290	chr11:93063684	CCDC67	0.47	7.0	0.31	9.03e-12	Pulmonary function decline;
LGG	cis	rs892085	0.681	rs3826803	chr19:10883126	C/G	cg17710535	chr19:10819994	QTRT1	-0.49	-8.88	-0.38	1.44e-17	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg07936489	chr17:37558343	FBXL20	0.85	15.98	0.6	4.27e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg14159672	chr1:205819179	PM20D1	0.77	16.44	0.61	3.53e-48	Menarche (age at onset);
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.62	-0.37	1.05e-16	Aortic root size;
LGG	cis	rs892961	0.932	rs9646396	chr17:75416755	G/A	cg05865280	chr17:75406074	SEPT9	0.42	9.58	0.41	6.06e-20	Airflow obstruction;
LGG	cis	rs4132509	1.000	rs6681863	chr1:243982709	C/G	cg25706552	chr1:244017396	NA	0.52	8.44	0.37	4.13e-16	RR interval (heart rate);
LGG	cis	rs972578	0.715	rs2273142	chr22:43230140	C/G	cg01576275	chr22:43409880	NA	-0.23	-6.9	-0.31	1.71e-11	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.31e-18	Lung cancer;
LGG	cis	rs950027	0.620	rs2486274	chr15:45666228	G/T	cg26924012	chr15:45694286	SPATA5L1	0.67	12.11	0.49	1.63e-29	Response to fenofibrate (adiponectin levels);
LGG	cis	rs10751667	0.643	rs10794343	chr11:925493	C/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.85e-14	Alzheimer's disease (late onset);
LGG	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg03342759	chr3:160939853	NMD3	-0.75	-13.28	-0.53	2.43e-34	Parkinson's disease;
LGG	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg13147721	chr7:65941812	NA	-0.81	-9.92	-0.42	3.69e-21	Gout;
LGG	cis	rs9287719	0.901	rs55861579	chr2:10763340	T/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.48	-0.33	3.67e-13	Prostate cancer;
LGG	cis	rs7712401	0.562	rs384483	chr5:122261573	G/T	cg19412675	chr5:122181750	SNX24	-0.39	-6.79	-0.3	3.45e-11	Mean platelet volume;
LGG	cis	rs7584262	0.737	rs7578091	chr2:42243480	G/C	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Bone mineral density;
LGG	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg24397884	chr7:158709396	WDR60	1.04	15.37	0.58	2.37e-43	Height;
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25072359	chr17:41440525	NA	0.54	10.19	0.43	4.05e-22	Menopause (age at onset);
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.16	-0.32	3.2e-12	Bipolar disorder;
LGG	cis	rs427394	0.632	rs377137	chr5:6740468	T/G	cg15145174	chr5:6755386	POLS	-0.44	-8.05	-0.35	6.87e-15	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg01620082	chr3:125678407	NA	-0.66	-7.12	-0.31	4.01e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12580194	0.593	rs11171435	chr12:55758053	T/C	cg19537932	chr12:55886519	OR6C68	-0.55	-10.03	-0.42	1.48e-21	Cancer;
LGG	cis	rs58616815	0.963	rs10881789	chr10:92148449	A/G	cg17905462	chr10:92153495	NA	-0.26	-6.83	-0.3	2.68e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4604732	0.603	rs4546958	chr1:247639478	G/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.55	0.37	1.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12135191	0.801	rs7554436	chr1:236474797	T/C	cg21399712	chr1:236511386	NA	-0.42	-7.97	-0.35	1.22e-14	Urate levels (BMI interaction);
LGG	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-15.84	-0.59	1.72e-45	Menarche (age at onset);
LGG	cis	rs11971779	0.688	rs1862880	chr7:139020100	T/C	cg07862535	chr7:139043722	LUC7L2	0.51	8.14	0.35	3.81e-15	Diisocyanate-induced asthma;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.61	-0.44	1.1e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs77669868	0.703	rs61904685	chr11:114072659	G/A	cg01914181	chr11:114070210	ZBTB16	0.69	8.15	0.35	3.4e-15	Monocyte percentage of white cells;
LGG	cis	rs7089973	0.604	rs11196952	chr10:116607592	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.36	-7.41	-0.33	6.21e-13	Neuroticism;
LGG	trans	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.08	-0.35	5.74e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.19	0.32	2.58e-12	Hip circumference adjusted for BMI;
LGG	cis	rs283228	0.617	rs584655	chr6:101739160	T/C	cg27451362	chr6:101846650	GRIK2	0.84	13.16	0.52	8.32e-34	Coenzyme Q10 levels;
LGG	cis	rs368123	1.000	rs377197	chr6:160720991	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18500431	chr7:1709489	NA	0.49	7.88	0.34	2.32e-14	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.86	0.42	5.99e-21	Morning vs. evening chronotype;
LGG	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg11693508	chr17:37793320	STARD3	0.63	9.59	0.41	5.55e-20	Bipolar disorder;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.49e-22	Tonsillectomy;
LGG	cis	rs12410462	0.681	rs12401677	chr1:227608577	T/C	cg21459583	chr1:227974177	NA	0.47	6.92	0.31	1.55e-11	Major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21160151	chr5:131131930	FNIP1	0.41	7.08	0.31	5.38e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.26	-0.36	1.49e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg21782813	chr7:2030301	MAD1L1	0.49	11.73	0.48	5.41e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg07636037	chr3:49044803	WDR6	1.1	28.22	0.8	1.19e-102	Parkinson's disease;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.15	0.43	5.36e-22	Obesity-related traits;
LGG	cis	rs3806843	0.733	rs801181	chr5:140092814	C/T	cg19875535	chr5:140030758	IK	-0.53	-10.93	-0.45	6.54e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.47	-0.4	1.39e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4731207	0.844	rs12673697	chr7:124395006	G/C	cg05630886	chr7:124431682	NA	0.31	6.83	0.3	2.7e-11	Cutaneous malignant melanoma;
LGG	cis	rs1568889	1.000	rs78140392	chr11:28203231	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	14.27	0.55	1.51e-38	Bipolar disorder;
LGG	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg18225595	chr11:63971243	STIP1	-0.62	-11.81	-0.48	2.47e-28	Platelet count;
LGG	cis	rs7649275	0.541	rs898419	chr3:53783785	A/C	cg21503701	chr3:53781065	CACNA1D	-0.41	-6.77	-0.3	3.87e-11	Trans fatty acid levels;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg02725872	chr8:58115012	NA	-0.86	-12.41	-0.5	9.62e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg02733842	chr7:1102375	C7orf50	-0.44	-7.14	-0.31	3.75e-12	Bronchopulmonary dysplasia;
LGG	cis	rs6430585	0.759	rs12467770	chr2:136536095	G/A	cg07169764	chr2:136633963	MCM6	1.27	24.09	0.75	1e-83	Corneal structure;
LGG	cis	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg07777115	chr5:623756	CEP72	-0.56	-6.83	-0.3	2.72e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs3784262	0.765	rs8026952	chr15:58276950	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.01	-0.31	8.5e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7072216	0.691	rs3829853	chr10:100171174	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.16	-0.32	3.11e-12	Metabolite levels;
LGG	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.31	-0.32	1.18e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.52	-0.44	2.27e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg15971980	chr6:150254442	NA	0.45	8.52	0.37	2.2e-16	Lung cancer;
LGG	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg13647721	chr17:30228624	UTP6	-0.76	-10.94	-0.45	5.95e-25	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg17951613	chr5:131705445	SLC22A5	0.63	7.22	0.32	2.14e-12	Rheumatoid arthritis;
LGG	cis	rs638893	1.000	rs636736	chr11:118705145	G/A	cg22253036	chr11:118662786	DDX6	0.41	7.08	0.31	5.52e-12	Vitiligo;
LGG	cis	rs9400467	0.537	rs73528983	chr6:111433641	A/G	cg15721981	chr6:111408429	SLC16A10	0.58	7.09	0.31	4.94e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg03188948	chr7:1209495	NA	0.48	7.72	0.34	7.31e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg01420254	chr6:26195488	NA	0.85	11.09	0.46	1.71e-25	Gout;Renal underexcretion gout;
LGG	cis	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg06521331	chr12:34319734	NA	-0.61	-11.75	-0.48	4.58e-28	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	8.93	0.38	9.8e-18	Bone mineral density;
LGG	cis	rs2933343	0.951	rs789251	chr3:128576770	G/A	cg25356066	chr3:128598488	ACAD9	0.47	6.81	0.3	3.09e-11	IgG glycosylation;
LGG	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg20713898	chr8:124780851	FAM91A1	-0.48	-7.59	-0.33	1.75e-13	Pancreatic cancer;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.01	0.46	3.48e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg16606324	chr3:10149918	C3orf24	0.55	7.39	0.32	7.14e-13	Alzheimer's disease;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.16	-0.7	5.18e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11626933	1.000	rs7149083	chr14:90754006	G/A	cg04374321	chr14:90722782	PSMC1	0.43	6.76	0.3	4.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg11878867	chr6:150167359	LRP11	-0.53	-10.87	-0.45	1.13e-24	Lung cancer;
LGG	cis	rs34638952	0.577	rs877492	chr17:27449059	C/A	cg13672501	chr17:27410685	MYO18A	-0.39	-7.16	-0.32	3.16e-12	Sitting height ratio;
LGG	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg05084668	chr3:125655381	ALG1L	-0.59	-8.04	-0.35	7.55e-15	Blood pressure (smoking interaction);
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06850241	chr22:41845214	NA	-0.45	-6.98	-0.31	1.02e-11	Vitiligo;
LGG	cis	rs975722	0.516	rs7784156	chr7:117066718	C/G	cg10524701	chr7:117356490	CTTNBP2	0.4	8.62	0.37	1.07e-16	Coronary artery disease;
LGG	cis	rs7172689	1.000	rs8030065	chr15:81536683	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.59	-0.44	1.35e-23	Inattentive symptoms;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.39e-15	Lymphocyte counts;
LGG	trans	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg25214090	chr10:38739885	LOC399744	0.71	12.62	0.51	1.41e-31	Corneal astigmatism;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg24690094	chr11:67383802	NA	0.5	8.94	0.38	9.39e-18	Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.3	0.36	1.13e-15	Aortic root size;
LGG	trans	rs9929218	0.551	rs3785135	chr16:68728976	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.03	-25.06	-0.76	3.12e-88	Colorectal cancer;
LGG	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	5.92e-13	HDL cholesterol;
LGG	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.71	-0.38	5.46e-17	Chronic sinus infection;
LGG	cis	rs10861342	1.000	rs11112374	chr12:105510285	G/T	cg23923672	chr12:105501055	KIAA1033	0.76	7.25	0.32	1.77e-12	IgG glycosylation;
LGG	cis	rs10875746	0.587	rs9788082	chr12:48752056	C/A	cg24011408	chr12:48396354	COL2A1	-0.55	-6.93	-0.31	1.44e-11	Longevity (90 years and older);
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15320075	chr8:145703422	NA	-0.79	-16.05	-0.6	2.08e-46	Age at first birth;
LGG	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg14952266	chr13:112191215	NA	-0.37	-6.66	-0.3	7.68e-11	Menarche (age at onset);
LGG	cis	rs3784262	0.669	rs12909979	chr15:58241022	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.15e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg04503457	chr17:41445688	NA	-0.41	-9.94	-0.42	3.24e-21	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg05044414	chr3:183734942	ABCC5	0.72	14.74	0.57	1.33e-40	Anterior chamber depth;
LGG	cis	rs6988985	0.678	rs28491316	chr8:143992661	C/T	cg10324643	chr8:143916377	GML	0.45	9.4	0.4	2.49e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg21775007	chr8:11205619	TDH	0.43	6.87	0.3	2.14e-11	Systolic blood pressure;
LGG	cis	rs71403859	0.502	rs71403849	chr16:71484365	T/C	cg08717414	chr16:71523259	ZNF19	-1.29	-18.01	-0.64	2.5e-55	Post bronchodilator FEV1;
LGG	cis	rs4936891	0.645	rs896891	chr11:123910740	C/T	cg22125253	chr11:123886957	OR10G4	0.68	13.58	0.53	1.3e-35	Male fertility;
LGG	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.56	0.56	8.59e-40	Colorectal cancer;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03183872	chr20:3140552	FASTKD5;UBOX5	0.39	6.76	0.3	4.27e-11	Lung adenocarcinoma;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	2.98e-15	Testicular germ cell tumor;
LGG	cis	rs6430585	0.528	rs309119	chr2:136710372	T/C	cg07169764	chr2:136633963	MCM6	1.14	20.01	0.68	1.15e-64	Corneal structure;
LGG	cis	rs9487094	0.626	rs12195904	chr6:109815963	A/T	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.96	0.38	7.73e-18	Height;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.57	-8.77	-0.38	3.31e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2976388	1.000	rs2294010	chr8:143762430	A/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg04287289	chr16:89883240	FANCA	0.81	17.35	0.63	2.71e-52	Vitiligo;
LGG	cis	rs10808265	0.594	rs10954384	chr7:132264224	G/A	cg05950570	chr7:132261418	PLXNA4	0.54	10.0	0.42	1.93e-21	Pulmonary function decline;
LGG	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg20387954	chr3:183756860	HTR3D	0.65	13.43	0.53	5.82e-35	Anterior chamber depth;
LGG	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs7444	0.941	rs140498	chr22:21927064	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.55e-14	Systemic lupus erythematosus;
LGG	cis	rs12681288	0.578	rs10503154	chr8:969343	C/G	cg15309053	chr8:964076	NA	0.43	9.13	0.39	2.13e-18	Schizophrenia;
LGG	cis	rs12780845	0.540	rs11254411	chr10:17201701	A/G	cg01003015	chr10:17271136	VIM	-0.45	-7.61	-0.33	1.54e-13	Homocysteine levels;
LGG	cis	rs1003719	0.788	rs2156076	chr21:38452634	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.84	17.33	0.63	3.23e-52	Eye color traits;
LGG	cis	rs10492096	1.000	rs10492096	chr12:6580582	A/G	cg13857086	chr12:6580257	VAMP1	0.64	9.19	0.39	1.29e-18	Hip geometry;
LGG	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg00898013	chr13:113819073	PROZ	-0.48	-9.34	-0.4	4.06e-19	Platelet distribution width;
LGG	cis	rs735539	0.521	rs2818990	chr13:21388724	A/G	cg04906043	chr13:21280425	IL17D	0.44	7.13	0.31	3.93e-12	Dental caries;
LGG	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	10.02	0.42	1.6e-21	Schizophrenia;
LGG	cis	rs912057	0.601	rs1294411	chr6:6739034	T/C	cg06612196	chr6:6737390	NA	0.51	11.67	0.48	8.8e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7192750	0.586	rs8054175	chr16:71990424	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.85	0.45	1.31e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.56e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9300255	0.602	rs1727313	chr12:123640853	C/G	cg05973401	chr12:123451056	ABCB9	0.47	6.84	0.3	2.51e-11	Neutrophil percentage of white cells;
LGG	cis	rs9300255	0.602	rs1617434	chr12:123649486	A/G	cg00376283	chr12:123451042	ABCB9	0.55	8.57	0.37	1.59e-16	Neutrophil percentage of white cells;
LGG	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.8	-0.3	3.2e-11	Schizophrenia;
LGG	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg14036092	chr11:66035641	RAB1B	0.46	7.97	0.35	1.23e-14	Gout;
LGG	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg17971929	chr21:40555470	PSMG1	0.87	16.82	0.62	6.5e-50	Cognitive function;
LGG	cis	rs6121246	0.909	rs6060644	chr20:30265652	G/A	cg13852791	chr20:30311386	BCL2L1	0.77	12.46	0.5	6.17e-31	Mean corpuscular hemoglobin;
LGG	cis	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg26384229	chr12:38710491	ALG10B	0.89	20.09	0.68	5.23e-65	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg22963979	chr7:1858916	MAD1L1	0.51	10.11	0.43	7.75e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11587400	0.532	rs2268700	chr1:115228879	T/G	cg12756093	chr1:115239321	AMPD1	-0.43	-8.02	-0.35	8.9e-15	Autism;
LGG	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg24881330	chr22:46731750	TRMU	0.7	7.2	0.32	2.39e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg25173405	chr17:45401733	C17orf57	0.52	8.72	0.38	4.98e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg00745463	chr17:30367425	LRRC37B	0.48	7.03	0.31	7.25e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7928758	0.887	rs74639401	chr11:134264213	C/T	cg25213107	chr11:134282864	B3GAT1	1.26	14.98	0.57	1.2e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs17286411	0.750	rs35619990	chr16:71949266	C/T	cg06353428	chr16:71660113	MARVELD3	0.41	7.36	0.32	8.24e-13	Blood protein levels;
LGG	trans	rs4714291	0.802	rs911818	chr6:39988816	C/A	cg02267698	chr19:7991119	CTXN1	-0.59	-9.5	-0.4	1.12e-19	Strep throat;
LGG	cis	rs1003719	1.000	rs2154536	chr21:38492147	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.79	15.51	0.58	5.56e-44	Eye color traits;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.0500000000000001e-23	Lymphocyte counts;
LGG	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg20368463	chr18:77673604	PQLC1	0.49	7.6	0.33	1.62e-13	Opioid sensitivity;
LGG	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg23335576	chr14:104009727	NA	0.49	8.57	0.37	1.52e-16	Reticulocyte count;
LGG	cis	rs1385374	0.858	rs11059923	chr12:129293057	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg15148918	chr7:75625777	STYXL1	-0.7	-7.88	-0.34	2.36e-14	Mononucleosis;
LGG	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg19913688	chr11:428466	ANO9	-0.68	-8.27	-0.36	1.48e-15	Body mass index;
LGG	cis	rs7552404	0.731	rs10732723	chr1:76392437	C/T	cg03433033	chr1:76189801	ACADM	-0.63	-8.94	-0.38	9.27e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7267979	0.545	rs6050426	chr20:25178265	C/G	cg06421707	chr20:25228305	PYGB	0.44	8.88	0.38	1.52e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9487094	0.696	rs11153188	chr6:109879450	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg16070123	chr10:51489643	NA	-0.42	-7.74	-0.34	6.19e-14	Prostate-specific antigen levels;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.79	-0.3	3.55e-11	Lung cancer;
LGG	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.85e-12	Schizophrenia;
LGG	cis	rs9487094	0.961	rs1923725	chr6:109708888	T/G	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.75e-18	Height;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.32	0.4	4.89e-19	Obesity-related traits;
LGG	cis	rs6735179	0.648	rs6706107	chr2:1761661	C/A	cg08534653	chr2:1747700	PXDN	0.45	6.97	0.31	1.11e-11	Response to antipsychotic treatment;
LGG	cis	rs12753569	0.720	rs4381138	chr1:76509783	G/A	cg00791851	chr1:76518896	NA	0.43	10.17	0.43	4.74e-22	Personality dimensions;
LGG	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.6	0.33	1.7e-13	Initial pursuit acceleration;
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.78e-16	Aortic root size;
LGG	cis	rs3008870	0.709	rs62883160	chr1:67392889	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.75	15.34	0.58	3e-43	Lymphocyte percentage of white cells;
LGG	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg16070123	chr10:51489643	NA	0.4	7.25	0.32	1.73e-12	Prostate-specific antigen levels;
LGG	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.27e-23	Resting heart rate;
LGG	trans	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg02030672	chr11:45687055	CHST1	-0.49	-8.77	-0.38	3.32e-17	Obesity-related traits;
LGG	cis	rs9309473	0.898	rs7587577	chr2:73832786	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.8	-0.34	4.19e-14	Metabolite levels;
LGG	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg12463550	chr7:65579703	CRCP	0.74	8.42	0.36	4.77e-16	Diabetic kidney disease;
LGG	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg00666640	chr1:248458726	OR2T12	0.53	8.95	0.38	8.65e-18	Common traits (Other);
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg06916706	chr16:4465613	CORO7	-0.89	-16.1	-0.6	1.25e-46	Schizophrenia;
LGG	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg15394860	chr11:2017084	H19	-0.43	-8.8	-0.38	2.79e-17	DNA methylation (variation);
LGG	cis	rs9790314	0.631	rs2061804	chr3:161102474	C/A	cg03342759	chr3:160939853	NMD3	-0.56	-9.69	-0.41	2.38e-20	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg07701084	chr6:150067640	NUP43	0.71	13.79	0.54	1.68e-36	Lung cancer;
LGG	cis	rs4065321	0.522	rs34648856	chr17:38149411	G/A	cg17467752	chr17:38218738	THRA	-0.59	-9.8	-0.41	9.62e-21	White blood cell count (basophil);White blood cell count;
LGG	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs7666738	0.791	rs11729596	chr4:99045461	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs972578	0.715	rs5758956	chr22:43217955	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.86	-0.3	2.25e-11	Mean platelet volume;
LGG	cis	rs3806843	1.000	rs3733707	chr5:140181892	T/C	cg19875535	chr5:140030758	IK	0.51	10.4	0.44	6.34e-23	Depressive symptoms (multi-trait analysis);
LGG	trans	rs208520	0.634	rs3909071	chr6:66836947	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.56	-0.63	2.95e-53	Exhaled nitric oxide output;
LGG	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.05	0.39	3.87e-18	Eosinophil percentage of white cells;
LGG	cis	rs10779751	0.960	rs12739368	chr1:11288247	T/C	cg08854313	chr1:11322531	MTOR	0.74	16.2	0.6	4.26e-47	Body mass index;
LGG	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.58	7.92	0.35	1.76e-14	Schizophrenia;
LGG	cis	rs12431410	0.550	rs28529862	chr14:60181498	A/G	cg07950296	chr14:60194823	RTN1	-0.4	-7.64	-0.33	1.29e-13	Schizophrenia;
LGG	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.1e-11	Schizophrenia;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.6	0.47	1.73e-27	Lymphocyte counts;
LGG	cis	rs62238980	0.614	rs76161060	chr22:32383153	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs209489	0.892	rs59581894	chr6:53113554	T/C	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.16	-0.32	3.13e-12	Personality dimensions;
LGG	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg04267008	chr7:1944627	MAD1L1	0.67	11.72	0.48	5.61e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.09	-0.31	5.02e-12	Menopause (age at onset);
LGG	cis	rs921968	0.510	rs620887	chr2:219465594	C/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.75	-0.41	1.44e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg26384229	chr12:38710491	ALG10B	0.79	15.7	0.59	7.53e-45	Morning vs. evening chronotype;
LGG	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg24006582	chr15:45444508	DUOX1	0.68	12.33	0.5	2.04e-30	Uric acid levels;
LGG	cis	rs2342371	0.883	rs11185542	chr3:196187927	G/C	cg15048948	chr3:196158458	UBXN7	-0.46	-7.57	-0.33	2.06e-13	Fat distribution (HIV);
LGG	cis	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg24110177	chr3:50126178	RBM5	0.4	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg14154082	chr13:112174009	NA	0.43	9.33	0.4	4.47e-19	Menarche (age at onset);
LGG	cis	rs6840360	0.606	rs2709814	chr4:152360870	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	6.76	0.3	4.27e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg13206674	chr6:150067644	NUP43	0.43	7.49	0.33	3.62e-13	Lung cancer;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.78	0.38	3.21e-17	Lung cancer;
LGG	cis	rs2294693	0.947	rs9381025	chr6:40986623	C/T	cg14769373	chr6:40998127	UNC5CL	-0.42	-7.4	-0.33	6.49e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs9287719	0.901	rs4555317	chr2:10744247	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.51	-0.53	2.65e-35	Bladder cancer;
LGG	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.37	-0.61	7.42e-48	Blood trace element (Zn levels);
LGG	trans	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg11441553	chr12:57614120	NXPH4	-0.58	-7.2	-0.32	2.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.07	-0.35	6.24e-15	Mood instability;
LGG	cis	rs11885103	0.692	rs2954999	chr2:556454	T/C	cg21195176	chr2:593345	NA	0.39	7.31	0.32	1.2e-12	Heschl's gyrus morphology;
LGG	cis	rs12410462	1.000	rs75637482	chr1:227622944	A/T	cg23173402	chr1:227635558	NA	0.62	10.36	0.43	9e-23	Major depressive disorder;
LGG	trans	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.09	-0.31	5.18e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09230442	chr15:65809997	DPP8	0.48	7.24	0.32	1.9e-12	Pancreatic cancer;
LGG	cis	rs6964587	1.000	rs411	chr7:91557758	C/G	cg17063962	chr7:91808500	NA	-0.49	-8.68	-0.37	6.57e-17	Breast cancer;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg16507663	chr6:150244633	RAET1G	0.44	7.15	0.32	3.49e-12	Lung cancer;
LGG	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	cis	rs7666738	0.830	rs7678250	chr4:98922109	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.53	-0.4	9.22e-20	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.11	-0.31	4.4e-12	Longevity;Endometriosis;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg10189774	chr4:17578691	LAP3	0.39	6.77	0.3	3.88e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg00129232	chr17:37814104	STARD3	-0.49	-9.29	-0.4	6.23e-19	Self-reported allergy;
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.55	-0.37	1.79e-16	Aortic root size;
LGG	cis	rs4474465	0.833	rs11606128	chr11:78156960	T/C	cg02023728	chr11:77925099	USP35	0.39	6.83	0.3	2.75e-11	Alzheimer's disease (survival time);
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg23758822	chr17:41437982	NA	0.87	15.43	0.58	1.28e-43	Menopause (age at onset);
LGG	cis	rs7572733	0.576	rs1865586	chr2:198758868	C/T	cg00792783	chr2:198669748	PLCL1	-0.68	-11.33	-0.47	1.91e-26	Dermatomyositis;
LGG	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-15.75	-0.59	4.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs7523050	0.643	rs17621851	chr1:109400835	C/T	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.44	-7.75	-0.34	6.02e-14	Caffeine consumption;
LGG	cis	rs7241530	0.610	rs7241666	chr18:75892405	C/G	cg14642773	chr18:75888474	NA	0.47	9.05	0.39	4.07e-18	Educational attainment (years of education);
LGG	cis	rs11864453	0.826	rs12325142	chr16:72138112	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-10.02	-0.42	1.61e-21	Fibrinogen levels;
LGG	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4363385	0.765	rs11205165	chr1:152986928	G/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.92	-0.38	1.07e-17	Inflammatory skin disease;
LGG	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg21045802	chr8:109455806	TTC35	0.55	10.44	0.44	4.58e-23	Dupuytren's disease;
LGG	cis	rs9902453	1.000	rs9906340	chr17:28398977	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.29	-0.53	2.24e-34	Coffee consumption (cups per day);
LGG	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg04362960	chr10:104952993	NT5C2	0.57	10.55	0.44	1.78e-23	Arsenic metabolism;
LGG	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg13009111	chr11:71350975	NA	0.36	7.87	0.34	2.48e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6909430	0.901	rs34894675	chr6:98631150	A/G	cg12860156	chr6:98744658	NA	-0.46	-7.32	-0.32	1.07e-12	Quantitative traits;
LGG	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.04	-0.31	6.86e-12	Testicular germ cell tumor;
LGG	cis	rs1568889	1.000	rs12794100	chr11:28332785	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.83	0.54	1.12e-36	Bipolar disorder;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.54	-0.47	2.97e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	0.961	rs17587071	chr1:76225083	A/C	cg03433033	chr1:76189801	ACADM	0.75	12.68	0.51	8.07e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg13736514	chr6:26305472	NA	-0.49	-9.62	-0.41	4.33e-20	Educational attainment;
LGG	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.92	9.87	0.42	5.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9790314	0.645	rs9879687	chr3:160874938	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.68	-0.48	8.68e-28	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg06636001	chr8:8085503	FLJ10661	0.45	7.92	0.35	1.81e-14	Retinal vascular caliber;
LGG	cis	rs7589342	0.628	rs35482041	chr2:106409436	A/G	cg16077055	chr2:106428750	NCK2	0.3	7.18	0.32	2.73e-12	Addiction;
LGG	cis	rs11074306	0.561	rs28504269	chr15:28070772	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	trans	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg08344181	chr3:125677491	NA	-0.58	-7.18	-0.32	2.77e-12	Intelligence (multi-trait analysis);
LGG	trans	rs877282	1.000	rs71494928	chr10:769134	A/G	cg22713356	chr15:30763199	NA	0.55	8.13	0.35	3.84e-15	Uric acid levels;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg19318889	chr4:1322082	MAEA	0.46	8.0	0.35	1.02e-14	Longevity;
LGG	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	9.58	0.41	5.82e-20	Menarche (age at onset);
LGG	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg14675211	chr2:100938903	LONRF2	0.67	12.21	0.49	6.64e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2251260	0.685	rs2246609	chr14:62007872	G/A	cg23386212	chr14:62041363	NA	0.6	8.41	0.36	5.25e-16	Yeast infection;
LGG	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.12	0.39	2.22e-18	Educational attainment;
LGG	cis	rs751728	0.643	rs12173787	chr6:33735471	G/C	cg07519485	chr6:33762594	MLN	-0.31	-6.65	-0.3	8.25e-11	Crohn's disease;
LGG	cis	rs7084402	0.967	rs1649069	chr10:60303695	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.27	-0.65	1.51e-56	Refractive error;
LGG	cis	rs9354352	0.967	rs9354351	chr6:66696271	G/A	cg07460842	chr6:66804631	NA	0.74	13.97	0.54	2.85e-37	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs11718455	0.960	rs34179760	chr3:44002303	A/G	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.58e-11	Coronary artery disease;
LGG	cis	rs7107174	0.681	rs10793301	chr11:78020913	G/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6908034	0.607	rs77753186	chr6:19812980	G/C	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg23958373	chr8:599963	NA	1.21	11.85	0.48	1.75e-28	IgG glycosylation;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg16282993	chr6:26204765	HIST1H4E	0.73	6.78	0.3	3.56e-11	Plasma thyroid-stimulating hormone levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11877270	chr2:65658583	SPRED2	0.4	7.1	0.31	4.78e-12	Obesity-related traits;
LGG	cis	rs8020289	0.560	rs4903492	chr14:77264528	G/A	cg23436960	chr14:77239540	VASH1	-0.36	-10.82	-0.45	1.78e-24	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs6577655	0.517	rs6983560	chr8:135584553	C/T	cg17885191	chr8:135476712	NA	-0.58	-8.69	-0.37	6.47e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg05861140	chr6:150128134	PCMT1	-0.3	-7.01	-0.31	8.27e-12	Testicular germ cell tumor;
LGG	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.43	-0.71	2.8e-71	Height;
LGG	trans	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg06521331	chr12:34319734	NA	0.42	7.68	0.34	9.7e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7927771	0.832	rs4992357	chr11:47393638	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-10.3	-0.43	1.54e-22	Subjective well-being;
LGG	cis	rs714031	0.967	rs5757763	chr22:40065005	A/G	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.56	-0.56	8.64e-40	Schizophrenia;
LGG	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.24	-0.58	8.17e-43	Chronic sinus infection;
LGG	cis	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.37	-0.36	6.88e-16	Mean corpuscular volume;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg06719900	chr11:109292894	C11orf87	0.45	8.34	0.36	8.87e-16	Schizophrenia;
LGG	cis	rs921968	0.643	rs497983	chr2:219415189	A/G	cg01130898	chr2:219473002	PLCD4	-0.39	-6.7	-0.3	5.95e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.48e-17	Bipolar disorder;
LGG	cis	rs11209002	0.567	rs2815385	chr1:67542083	A/G	cg02640540	chr1:67518911	SLC35D1	0.41	6.93	0.31	1.39e-11	Crohn's disease;
LGG	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg05768032	chr16:30646687	NA	0.42	7.15	0.32	3.47e-12	Multiple myeloma;
LGG	cis	rs60695258	0.572	rs375795	chr4:87972465	C/T	cg11209507	chr4:87813803	C4orf36	0.46	7.89	0.34	2.27e-14	Hematocrit;
LGG	cis	rs921968	0.541	rs3731867	chr2:219472734	G/A	cg01130898	chr2:219473002	PLCD4	0.48	8.28	0.36	1.34e-15	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4566357	0.595	rs10206912	chr2:227921095	A/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-8.86	-0.38	1.78e-17	Coronary artery disease;
LGG	cis	rs1198430	0.562	rs7546989	chr1:23789698	C/G	cg01000553	chr1:23811582	ASAP3	-0.36	-6.91	-0.31	1.64e-11	Total cholesterol levels;
LGG	cis	rs36093844	0.615	rs77258124	chr11:85578081	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.04e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.5	-0.33	3.39e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11098499	0.955	rs35197422	chr4:120169314	T/G	cg25214090	chr10:38739885	LOC399744	0.64	11.57	0.47	2.26e-27	Corneal astigmatism;
LGG	cis	rs7666738	0.962	rs2865985	chr4:99068009	T/C	cg05340658	chr4:99064831	C4orf37	0.44	7.1	0.31	4.63e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7923609	0.561	rs68187821	chr10:65311032	C/A	cg02276361	chr10:65351566	REEP3	-0.31	-6.83	-0.3	2.68e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12579753	0.956	rs7309624	chr12:82204266	C/A	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.34	-0.47	1.87e-26	Resting heart rate;
LGG	cis	rs9810089	0.802	rs10935182	chr3:136137422	G/A	cg12473912	chr3:136751656	NA	0.4	6.79	0.3	3.49e-11	Gestational age at birth (child effect);
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg08355456	chr11:67383691	NA	0.5	8.46	0.37	3.56e-16	Mean corpuscular volume;
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg04287289	chr16:89883240	FANCA	0.81	16.82	0.62	6.5e-50	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01954107	chr1:100731633	RTCD1	0.43	6.83	0.3	2.66e-11	Gut microbiome composition (summer);
LGG	cis	rs9472414	0.680	rs9463020	chr6:44713432	G/A	cg20913747	chr6:44695427	NA	0.46	7.23	0.32	2.05e-12	Height;
LGG	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg00490583	chr16:1843685	IGFALS	0.45	9.83	0.42	7.53e-21	Insulin-like growth factors;
LGG	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg08392591	chr16:89556376	ANKRD11	0.65	10.42	0.44	5.44e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg26513180	chr16:89883248	FANCA	0.49	8.55	0.37	1.84e-16	Vitiligo;
LGG	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.16	-0.39	1.64e-18	Joint mobility (Beighton score);
LGG	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.88e-11	Type 2 diabetes;
LGG	cis	rs17253792	0.822	rs77315200	chr14:56072643	C/A	cg01858014	chr14:56050164	KTN1	-0.86	-11.88	-0.48	1.41e-28	Putamen volume;
LGG	cis	rs701145	0.824	rs355767	chr3:154045895	G/A	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg26597838	chr10:835615	NA	0.64	9.49	0.4	1.24e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2072732	0.821	rs12038530	chr1:2946726	T/A	cg08733933	chr1:2954429	NA	-0.41	-8.34	-0.36	8.48e-16	Plateletcrit;
LGG	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg01631408	chr1:248437212	OR2T33	-0.44	-7.36	-0.32	8.48e-13	Common traits (Other);
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg03188948	chr7:1209495	NA	0.51	7.99	0.35	1.08e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2247341	0.965	rs1530588	chr4:1742779	G/A	cg05026014	chr4:1749153	NA	-0.33	-9.27	-0.4	7.25e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8078723	0.677	rs8073254	chr17:38149350	C/G	cg17467752	chr17:38218738	THRA	-0.61	-11.1	-0.46	1.48e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg23505145	chr19:12996616	KLF1	0.38	6.68	0.3	7.03e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3825932	0.778	rs1369324	chr15:79239719	C/T	cg25744700	chr15:79237217	CTSH	-0.36	-6.88	-0.3	1.99e-11	Type 1 diabetes;
LGG	trans	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg06521331	chr12:34319734	NA	-0.51	-8.91	-0.38	1.14e-17	Bladder cancer;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.61	-0.37	1.16e-16	Personality dimensions;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.37	-0.36	6.7e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg00745463	chr17:30367425	LRRC37B	0.54	7.33	0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-6.98	-0.31	1.04e-11	Diastolic blood pressure;
LGG	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2067615	0.524	rs10778504	chr12:107120424	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.85	0.51	1.53e-32	Heart rate;
LGG	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.85	-0.57	4.35e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg26354017	chr1:205819088	PM20D1	0.59	11.49	0.47	4.72e-27	Menarche (age at onset);
LGG	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.68	-0.34	9.44e-14	Height;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.66	-0.54	6.33e-36	Personality dimensions;
LGG	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg01324343	chr3:183735012	ABCC5	0.65	12.64	0.51	1.17e-31	Anterior chamber depth;
LGG	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg25427524	chr10:38739819	LOC399744	-0.5	-7.61	-0.33	1.5700000000000001e-13	Obesity (extreme);
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04008888	chr11:68622739	NA	-0.57	-12.13	-0.49	1.4e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-13.43	-0.53	5.72e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2011503	1.000	rs17684164	chr19:19626769	C/T	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27461200	chr16:89926104	SPIRE2	0.36	6.71	0.3	5.6e-11	Electrocardiographic conduction measures;
LGG	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg03929089	chr4:120376271	NA	0.89	18.07	0.64	1.29e-55	Coronary artery disease;
LGG	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.94	0.31	1.31e-11	Cognitive ability;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg09303159	chr6:26284866	NA	0.37	8.18	0.36	2.8e-15	Educational attainment;
LGG	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg08847533	chr14:75593920	NEK9	-0.59	-11.11	-0.46	1.37e-25	Height;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.53	0.4	9.09e-20	Lung cancer;
LGG	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-9.5	-0.4	1.11e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9547996	0.879	rs61957469	chr13:38133006	C/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.91	-0.31	1.6e-11	Diastolic blood pressure;
LGG	cis	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1707322	0.963	rs10789484	chr1:46406978	G/C	cg03146154	chr1:46216737	IPP	0.54	10.2	0.43	3.54e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11969893	0.737	rs6930051	chr6:101406108	A/G	cg12253828	chr6:101329408	ASCC3	1.12	9.71	0.41	2.1e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.78	0.41	1.16e-20	Schizophrenia;
LGG	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.56	-0.41	6.99e-20	Height;
LGG	cis	rs9403521	0.898	rs10872562	chr6:143974930	A/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-9.68	-0.41	2.56e-20	Obesity-related traits;
LGG	trans	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg16141378	chr3:129829833	LOC729375	0.45	10.63	0.44	9.53e-24	Mood instability;
LGG	cis	rs921968	0.541	rs832798	chr2:219464810	G/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs929596	0.564	rs2741038	chr2:234563998	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-9.14	-0.39	2.04e-18	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs10504130	0.569	rs12681734	chr8:52806195	T/A	cg24946253	chr8:52722146	PXDNL	-0.45	-6.64	-0.3	8.56e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6121246	0.559	rs6058465	chr20:30397691	G/A	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg04568710	chr12:38710424	ALG10B	0.33	6.75	0.3	4.33e-11	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27323780	chr13:28024626	MTIF3	0.54	8.03	0.35	7.94e-15	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.67	-0.37	7.54e-17	Personality dimensions;
LGG	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg19774624	chr17:42201019	HDAC5	0.66	11.6	0.47	1.8e-27	Bone mineral density (hip);Bone mineral density (spine);
LGG	trans	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg06636001	chr8:8085503	FLJ10661	0.41	7.12	0.31	4.23e-12	Retinal vascular caliber;
LGG	cis	rs7103648	0.838	rs2293576	chr11:47434986	A/G	cg20307385	chr11:47447363	PSMC3	-0.89	-19.73	-0.68	2.53e-63	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs7226408	0.625	rs7241317	chr18:34453333	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.41	-8.8	-0.38	2.78e-17	Obesity-related traits;
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg18876405	chr7:65276391	NA	0.55	9.88	0.42	5.22e-21	Aortic root size;
LGG	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg24623649	chr8:11872141	NA	-0.31	-7.09	-0.31	5.12e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7166081	1.000	rs8031500	chr15:67519040	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.94	-0.31	1.36e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.36	0.36	7.21e-16	Life satisfaction;
LGG	cis	rs2239815	0.515	rs9625600	chr22:29244395	T/C	cg15103426	chr22:29168792	CCDC117	0.66	7.62	0.33	1.45e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs6964587	0.869	rs10256780	chr7:91527176	T/A	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	-0.32	-6.67	-0.3	7.14e-11	Schizophrenia;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.76	-0.3	4.23e-11	Personality dimensions;
LGG	cis	rs17776563	0.853	rs57192577	chr15:89150965	T/C	cg05013243	chr15:89149849	MIR1179	-0.51	-10.48	-0.44	3.35e-23	Thyroid hormone levels;
LGG	trans	rs9354308	0.738	rs9453464	chr6:66584927	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs9815354	0.767	rs60764195	chr3:41812522	G/C	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg26384229	chr12:38710491	ALG10B	0.74	14.67	0.56	2.71e-40	Morning vs. evening chronotype;
LGG	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.29e-11	Parkinson's disease;
LGG	cis	rs17092148	0.887	rs6059916	chr20:33148861	T/G	cg12302830	chr20:33297742	TP53INP2	-0.44	-6.99	-0.31	9.44e-12	Neuroticism;
LGG	cis	rs17373728	0.585	rs1912709	chr8:76178563	C/T	cg07016329	chr8:76221503	NA	0.61	10.94	0.45	6.15e-25	Diabetic kidney disease;
LGG	cis	rs1577917	0.958	rs12205492	chr6:86475976	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.7	-0.45	5.24e-24	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs727505	1.000	rs2286175	chr7:124431032	G/A	cg23710748	chr7:124431027	NA	-0.55	-10.34	-0.43	1.11e-22	Lewy body disease;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.13	-0.31	3.92e-12	Personality dimensions;
LGG	trans	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.88	0.34	2.41e-14	Obesity-related traits;
LGG	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg26513180	chr16:89883248	FANCA	0.95	21.39	0.71	4.05e-71	Vitiligo;
LGG	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.48	-0.44	3.27e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg27490568	chr2:178487706	NA	0.5	9.74	0.41	1.62e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4774899	0.832	rs2703596	chr15:57492360	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.87	-0.3	2.02e-11	Urinary tract infection frequency;
LGG	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg00495681	chr13:53174319	NA	-0.46	-7.61	-0.33	1.51e-13	Lewy body disease;
LGG	cis	rs7192380	0.964	rs8055756	chr16:69648653	A/G	cg00738113	chr16:70207722	CLEC18C	0.26	7.48	0.33	3.81e-13	Sjögren's syndrome;
LGG	cis	rs1670533	1.000	rs633556	chr4:1092405	A/G	cg27284194	chr4:1044797	NA	0.54	9.9	0.42	4.21e-21	Recombination rate (females);
LGG	cis	rs4851266	0.966	rs11689199	chr2:100820421	A/G	cg21926883	chr2:100939477	LONRF2	-0.43	-7.86	-0.34	2.72e-14	Educational attainment;
LGG	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs4917300	0.606	rs7015050	chr8:143100960	T/A	cg06573787	chr8:143070187	NA	0.6	10.04	0.42	1.38e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.41	6.73	0.3	5.16e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7301826	0.651	rs10848210	chr12:131312020	G/A	cg11011512	chr12:131303247	STX2	0.41	8.88	0.38	1.5e-17	Plasma plasminogen activator levels;
LGG	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg27165867	chr14:105738592	BRF1	-0.44	-7.46	-0.33	4.32e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9828933	0.938	rs3816157	chr3:63999322	G/A	cg17941049	chr3:63904683	ATXN7	0.68	8.05	0.35	7.09e-15	Type 2 diabetes;
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg12463550	chr7:65579703	CRCP	-0.44	-6.85	-0.3	2.32e-11	Aortic root size;
LGG	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.75	-0.41	1.46e-20	Oropharynx cancer;
LGG	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.39	0.36	5.91e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7945718	0.621	rs6485992	chr11:12697359	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.09	0.31	5.08e-12	Educational attainment (years of education);
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.44	0.47	7.33e-27	Bipolar disorder;
LGG	cis	rs9863	0.861	rs11057393	chr12:124403769	C/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.0	-0.31	9.16e-12	White blood cell count;
LGG	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11245990	chr11:68621969	NA	0.43	9.06	0.39	3.75e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg07701084	chr6:150067640	NUP43	0.69	13.07	0.52	1.87e-33	Lung cancer;
LGG	cis	rs7580658	0.637	rs4662710	chr2:127976817	C/G	cg10021288	chr2:128175891	PROC	-0.6	-12.11	-0.49	1.69e-29	Protein C levels;
LGG	cis	rs7444	0.825	rs2266963	chr22:21947467	C/G	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.53e-14	Systemic lupus erythematosus;
LGG	cis	rs7100689	0.784	rs3802637	chr10:82179699	G/C	cg01528321	chr10:82214614	TSPAN14	1.07	20.4	0.69	1.9e-66	Post bronchodilator FEV1;
LGG	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg23933602	chr10:16859644	RSU1	0.86	16.07	0.6	1.64e-46	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs7100689	0.646	rs7077854	chr10:82124070	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg14703610	chr5:56206110	C5orf35	0.46	8.01	0.35	9.51e-15	Coronary artery disease;
LGG	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg00757033	chr12:89920650	WDR51B	0.62	8.96	0.38	8.25e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg20744362	chr22:50050164	C22orf34	0.42	7.67	0.34	1.01e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg03060546	chr3:49711283	APEH	-0.67	-11.17	-0.46	8.37e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2742417	0.935	rs1468543	chr3:45776900	A/G	cg04837898	chr3:45731254	SACM1L	-0.36	-7.06	-0.31	5.97e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs6787172	0.702	rs827108	chr3:157982997	G/A	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	8.47	0.37	3.37e-16	Lung function (FEV1/FVC);
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg02462569	chr6:150064036	NUP43	-0.42	-9.1	-0.39	2.76e-18	Lung cancer;
LGG	cis	rs7975161	0.671	rs10861180	chr12:104650999	T/C	cg25273343	chr12:104657179	TXNRD1	-0.55	-8.49	-0.37	2.91e-16	Toenail selenium levels;
LGG	cis	rs6708331	0.504	rs2169837	chr2:70551907	C/T	cg01613454	chr2:70366299	NA	0.37	6.81	0.3	3.13e-11	Obesity-related traits;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg00080972	chr5:178986291	RUFY1	-0.5	-8.74	-0.38	4.19e-17	Lung cancer;
LGG	trans	rs9650657	0.596	rs2409675	chr8:10595259	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.44	-0.33	5.04e-13	Neuroticism;
LGG	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.2	-0.32	2.45e-12	Multiple myeloma (IgH translocation);
LGG	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg01620082	chr3:125678407	NA	-0.59	-7.4	-0.33	6.65e-13	Depression;
LGG	cis	rs4950322	0.518	rs114226486	chr1:146801833	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg04662567	chr6:169592167	NA	-0.8	-11.67	-0.48	9.22e-28	Pulse pressure;
LGG	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.23	-0.46	4.85e-26	Life satisfaction;
LGG	cis	rs1883415	0.534	rs2760143	chr6:24479472	C/T	cg20631270	chr6:24437470	GPLD1	0.49	8.52	0.37	2.19e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9880211	1.000	rs28750366	chr3:136361055	T/C	cg21827317	chr3:136751795	NA	-0.48	-7.2	-0.32	2.49e-12	Body mass index;Height;
LGG	cis	rs2688608	0.672	rs2688622	chr10:75688981	C/A	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.07	-0.31	5.73e-12	Inflammatory bowel disease;
LGG	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.96	-0.54	3.18e-37	Response to antipsychotic treatment;
LGG	cis	rs2177596	0.549	rs4592846	chr2:227948866	G/A	cg11843606	chr2:227700838	RHBDD1	-0.52	-9.22	-0.39	1.05e-18	Body mass index;
LGG	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.12	-0.43	7.22e-22	Schizophrenia;
LGG	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.83	0.34	3.28e-14	Coronary artery disease;
LGG	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.14	-0.35	3.79e-15	Bipolar disorder;
LGG	cis	rs2832191	1.000	rs9984793	chr21:30486471	T/C	cg08807101	chr21:30365312	RNF160	-0.8	-15.72	-0.59	6.07e-45	Dental caries;
LGG	cis	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg05623727	chr3:50126028	RBM5	-0.39	-8.43	-0.36	4.39e-16	Body mass index;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	ch.1.3571010R	chr1:182824678	DHX9	-0.43	-7.75	-0.34	6e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9308731	0.863	rs17558117	chr2:111940996	A/T	cg26001287	chr2:111877753	BCL2L11	-0.35	-6.87	-0.3	2.04e-11	Chronic lymphocytic leukemia;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	29.73	0.81	1.93e-109	Prudent dietary pattern;
LGG	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs7166081	1.000	rs8042007	chr15:67652976	C/T	cg02273617	chr15:68117586	LBXCOR1	0.29	6.75	0.3	4.35e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7717393	1.000	rs9313897	chr5:155791181	A/C	cg04435420	chr5:155754009	SGCD	0.97	11.12	0.46	1.27e-25	Egg allergy;
LGG	cis	rs9487094	0.626	rs11153215	chr6:110053721	T/G	cg01125227	chr6:109776195	MICAL1	0.43	7.46	0.33	4.21e-13	Height;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.56	-0.33	2.17e-13	Prostate cancer;
LGG	cis	rs3617	0.625	rs6445541	chr3:52880128	G/T	cg11645453	chr3:52864694	ITIH4	0.41	7.04	0.31	6.79e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2070488	0.965	rs2051215	chr3:38560345	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.83	-0.64	1.67e-54	Electrocardiographic conduction measures;
LGG	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.74	-0.3	4.62e-11	Schizophrenia;
LGG	cis	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05901451	chr6:126070800	HEY2	-0.68	-12.91	-0.51	9.16e-33	Brugada syndrome;
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.87	-0.34	2.46e-14	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg12708336	chr17:41446283	NA	-0.33	-7.92	-0.35	1.76e-14	Menopause (age at onset);
LGG	cis	rs877282	0.583	rs10904564	chr10:819459	C/G	cg15764593	chr10:829463	NA	-0.67	-9.9	-0.42	4.38e-21	Uric acid levels;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg14646974	chr10:38645378	HSD17B7P2	0.45	7.27	0.32	1.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7107174	1.000	rs4945274	chr11:78109260	G/A	cg02023728	chr11:77925099	USP35	0.43	7.7	0.34	8.37e-14	Testicular germ cell tumor;
LGG	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg12292205	chr6:26970375	C6orf41	0.77	15.66	0.59	1.16e-44	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10876993	0.928	rs1678532	chr12:58055197	T/G	cg18357645	chr12:58087776	OS9	0.69	12.35	0.5	1.79e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.16	0.39	1.63e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs62238980	0.614	rs117112619	chr22:32508140	G/A	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs10819861	0.621	rs4742839	chr9:98847910	C/T	cg14508093	chr9:98862825	NA	0.29	6.73	0.3	4.95e-11	Electrocardiographic traits;
LGG	cis	rs2251381	0.606	rs8129515	chr21:30520167	C/G	cg08807101	chr21:30365312	RNF160	0.75	13.04	0.52	2.53e-33	Selective IgA deficiency;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg20453264	chr5:131705742	SLC22A5	0.61	7.87	0.34	2.5e-14	Rheumatoid arthritis;
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.85	0.48	1.86e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg12193833	chr17:30244370	NA	-0.29	-6.73	-0.3	5.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-7.3	-0.32	1.28e-12	Schizophrenia;
LGG	cis	rs10908458	0.743	rs7367207	chr1:155079477	C/T	cg13808842	chr1:155066096	NA	-0.33	-8.15	-0.35	3.49e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg16141378	chr3:129829833	LOC729375	0.43	10.04	0.42	1.32e-21	Triglycerides;
LGG	cis	rs9912468	0.629	rs62069916	chr17:64280503	C/T	cg19474267	chr17:64306194	PRKCA	-0.77	-16.04	-0.6	2.32e-46	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg25019033	chr10:957182	NA	0.33	7.25	0.32	1.74e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg26384229	chr12:38710491	ALG10B	0.83	18.85	0.66	3.16e-59	Heart rate;
LGG	cis	rs10193935	0.792	rs72794590	chr2:42378392	G/A	cg27598129	chr2:42591480	NA	-0.59	-8.44	-0.37	4.01e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3741151	0.773	rs73544716	chr11:73170061	C/T	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs16854884	0.538	rs61359084	chr3:143738362	T/C	cg06585982	chr3:143692056	C3orf58	0.6	10.36	0.43	9.36e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg18252515	chr7:66147081	NA	0.44	7.46	0.33	4.29e-13	Aortic root size;
LGG	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.58e-15	Homoarginine levels;
LGG	cis	rs6960043	0.818	rs1974619	chr7:15065300	C/T	cg19272540	chr7:15055459	NA	-0.36	-7.87	-0.34	2.56e-14	Type 2 diabetes;
LGG	cis	rs7666738	0.830	rs13122054	chr4:98972974	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9354308	0.764	rs2154330	chr6:66567872	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs5769707	0.732	rs135865	chr22:50004829	G/A	cg20744362	chr22:50050164	C22orf34	0.41	7.47	0.33	4.06e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs17767392	0.846	rs61991200	chr14:71762569	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.76	-0.38	3.78e-17	Mitral valve prolapse;
LGG	cis	rs11190604	0.767	rs10748794	chr10:102175918	G/T	cg07080220	chr10:102295463	HIF1AN	-0.56	-9.75	-0.41	1.54e-20	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4409675	0.912	rs11247730	chr1:28270737	A/G	cg07233700	chr1:28261706	SMPDL3B	-0.32	-7.05	-0.31	6.72e-12	Corneal astigmatism;
LGG	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23598886	chr18:12777645	NA	-0.65	-8.55	-0.37	1.85e-16	Inflammatory skin disease;
LGG	trans	rs5756813	0.635	rs12160750	chr22:38199054	A/G	cg19894588	chr14:64061835	NA	-0.64	-10.23	-0.43	2.8e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2798269	0.789	rs3886357	chr13:22085965	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.73	-0.3	5.1e-11	PR segment;
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg22044901	chr15:68126292	NA	-0.41	-7.31	-0.32	1.2e-12	Obesity;
LGG	cis	rs7843479	0.544	rs4872110	chr8:21784989	A/G	cg17168535	chr8:21777572	XPO7	0.78	14.55	0.56	8.87e-40	Mean corpuscular volume;
LGG	cis	rs7568458	0.684	rs7579147	chr2:85805654	G/A	cg17127132	chr2:85788382	GGCX	0.53	8.4	0.36	5.39e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9354308	0.764	rs2211636	chr6:66596815	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg14456004	chr13:21872349	NA	-1.21	-19.25	-0.67	4.34e-61	White matter hyperintensity burden;
LGG	cis	rs9911578	0.934	rs58092632	chr17:57111101	T/C	cg12560992	chr17:57184187	TRIM37	-0.93	-16.53	-0.61	1.46e-48	Intelligence (multi-trait analysis);
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg11598736	chr3:195384522	SDHAP2	0.7	9.82	0.42	8.51e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.18e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs10089	1.000	rs7703634	chr5:127509223	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.58	0.47	2.05e-27	Ileal carcinoids;
LGG	cis	rs727505	1.000	rs28622327	chr7:124526213	C/T	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs250677	1.000	rs36079	chr5:148430504	G/A	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.71	-0.34	7.51e-14	Breast cancer;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg22535103	chr8:58192502	C8orf71	-0.95	-12.57	-0.5	2.21e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7973719	0.833	rs3825405	chr12:7360143	G/T	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.8	-0.34	4.1e-14	IgG glycosylation;
LGG	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.2	0.32	2.42e-12	Hemoglobin concentration;
LGG	cis	rs7103648	0.643	rs12365079	chr11:47696596	A/T	cg20307385	chr11:47447363	PSMC3	0.82	16.72	0.61	1.87e-49	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.31	4.65e-12	Lung cancer;
LGG	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs6138458	1.000	rs227630	chr20:24913584	A/G	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs12617721	0.718	rs1857745	chr2:99016975	T/C	cg18455616	chr2:99124870	INPP4A	0.3	7.72	0.34	7.47e-14	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs2354432	0.607	rs6685775	chr1:146744294	A/G	cg25205988	chr1:146714368	CHD1L	-1.48	-15.04	-0.57	6.37e-42	Mitochondrial DNA levels;
LGG	cis	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg21775007	chr8:11205619	TDH	-0.51	-8.06	-0.35	6.36e-15	Triglycerides;
LGG	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs4689388	0.926	rs5018648	chr4:6292818	C/G	cg00701064	chr4:6280414	WFS1	-0.72	-15.73	-0.59	5.38e-45	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.09	-0.64	1.02e-55	Refractive error;
LGG	cis	rs963731	0.649	rs78510010	chr2:39348662	T/C	cg04010122	chr2:39346883	SOS1	0.93	8.24	0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg20673091	chr1:2541236	MMEL1	-0.77	-18.04	-0.64	1.8e-55	Ulcerative colitis;
LGG	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.58	-0.33	1.87e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3824867	0.920	rs3740685	chr11:47468791	C/T	cg20307385	chr11:47447363	PSMC3	0.5	8.0	0.35	1.01e-14	Mean corpuscular hemoglobin;
LGG	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.08	-0.49	2.14e-29	Cognitive function;
LGG	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg12310025	chr6:25882481	NA	-0.4	-7.17	-0.32	2.93e-12	Height;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9287719	0.967	rs728134	chr2:10745187	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.84	-0.3	2.57e-11	Triglycerides;
LGG	cis	rs5758659	0.714	rs2284087	chr22:42485671	T/C	cg04733989	chr22:42467013	NAGA	-0.38	-6.72	-0.3	5.25e-11	Cognitive function;
LGG	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.67	-0.3	7.18e-11	Neuroticism;
LGG	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs17604090	0.878	rs10262227	chr7:29704073	G/A	cg19413766	chr7:29689036	LOC646762	-0.56	-6.99	-0.31	9.61e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.25	0.49	4.47e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12580194	0.593	rs4448777	chr12:55724981	T/C	cg19537932	chr12:55886519	OR6C68	-0.56	-9.89	-0.42	4.75e-21	Cancer;
LGG	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg02297831	chr4:17616191	MED28	0.49	9.39	0.4	2.78e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.77	-0.57	1.04e-40	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg12310025	chr6:25882481	NA	-0.44	-7.31	-0.32	1.19e-12	Iron status biomarkers;
LGG	cis	rs9470366	0.883	rs7756236	chr6:36627053	A/G	cg08179530	chr6:36648295	CDKN1A	0.6	8.87	0.38	1.55e-17	QRS duration;
LGG	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg14675211	chr2:100938903	LONRF2	0.64	11.27	0.46	3.51e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg15440763	chr7:158190612	PTPRN2	0.42	8.55	0.37	1.81e-16	Obesity-related traits;
LGG	cis	rs7089973	0.872	rs7074729	chr10:116632257	C/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7737355	0.947	rs4705894	chr5:131079288	A/G	cg06307176	chr5:131281290	NA	0.57	9.36	0.4	3.5e-19	Life satisfaction;
LGG	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	8.01e-13	Platelet count;
LGG	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.49	10.13	0.43	6.33e-22	Ovarian reserve;
LGG	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1.05e-12	Neuroticism;
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg07701084	chr6:150067640	NUP43	0.63	11.92	0.48	9.33e-29	Lung cancer;
LGG	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg01601518	chr4:2404284	ZFYVE28	0.73	7.13	0.31	3.94e-12	Influenza A (H1N1) severity;
LGG	cis	rs1961637	0.642	rs895774	chr2:223886563	A/G	cg02552189	chr2:223891284	NA	-0.38	-7.56	-0.33	2.25e-13	Oropharynx cancer;
LGG	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg09238746	chr17:78121135	EIF4A3	-0.6	-10.28	-0.43	1.82e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs2916247	0.954	rs7006836	chr8:93167342	C/T	cg10183463	chr8:93005414	RUNX1T1	0.35	7.11	0.31	4.33e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.781	rs14030	chr14:71956141	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.87	-0.38	1.65e-17	Mitral valve prolapse;
LGG	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg27297192	chr10:134578999	INPP5A	0.31	6.81	0.3	3.06e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7267979	1.000	rs4815404	chr20:25301845	T/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.86e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs988958	0.675	rs35637955	chr2:42217686	A/C	cg19376973	chr2:42229025	NA	0.57	9.21	0.39	1.14e-18	Hypospadias;
LGG	cis	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg07460842	chr6:66804631	NA	0.73	12.46	0.5	5.98e-31	Type 2 diabetes;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.12	-0.39	2.32e-18	Menopause (age at onset);
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg07243736	chr16:783730	NARFL	0.42	7.18	0.32	2.74e-12	Height;
LGG	trans	rs11875185	0.510	rs80190539	chr18:55632404	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08208917	chr15:42565872	GANC;TMEM87A	0.41	6.83	0.3	2.63e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21086891	chr3:192635035	C3orf59	0.57	9.42	0.4	2.22e-19	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.44	7.2	0.32	2.44e-12	Longevity;
LGG	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.56	-7.91	-0.35	1.85e-14	Diabetic retinopathy;
LGG	cis	rs35771425	0.529	rs34355723	chr1:211379129	G/C	cg10512769	chr1:211675356	NA	-0.64	-8.34	-0.36	8.69e-16	Educational attainment (years of education);
LGG	cis	rs1620921	0.625	rs2465864	chr6:161273785	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.71	0.45	4.79e-24	Blood protein levels;
LGG	cis	rs17221829	0.702	rs2075536	chr11:89407391	G/T	cg02982614	chr11:89391479	FOLH1B	0.39	8.66	0.37	7.88e-17	Anxiety in major depressive disorder;
LGG	cis	rs537930	0.734	rs31198	chr5:134372685	A/G	cg24576358	chr5:134350122	NA	0.36	6.87	0.3	2.07e-11	Height;
LGG	cis	rs10463554	0.927	rs185387	chr5:102420019	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.58e-13	Parkinson's disease;
LGG	trans	rs11039798	0.541	rs11040166	chr11:48965449	T/C	cg03929089	chr4:120376271	NA	0.72	7.69	0.34	8.91e-14	Axial length;
LGG	cis	rs9863	0.694	rs11837287	chr12:124470059	C/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.99e-12	White blood cell count;
LGG	cis	rs853679	0.517	rs9468286	chr6:28079428	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs1355223	0.902	rs865070	chr11:34742497	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.0	-0.31	8.91e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4474465	0.850	rs10793330	chr11:78269985	T/C	cg02023728	chr11:77925099	USP35	-0.38	-6.73	-0.3	5.06e-11	Alzheimer's disease (survival time);
LGG	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg08508325	chr11:3079039	CARS	0.42	7.78	0.34	4.83e-14	Calcium levels;
LGG	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg05775895	chr3:12838266	CAND2	0.72	13.15	0.52	8.87e-34	P wave duration;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.11	0.6	1.11e-46	Lung cancer;
LGG	cis	rs738321	0.725	rs5756926	chr22:38542613	T/C	cg25457927	chr22:38595422	NA	-0.4	-9.5	-0.4	1.09e-19	Breast cancer;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg20607798	chr8:58055168	NA	0.65	7.16	0.32	3.28e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs242577	chr3:153941208	G/A	cg17054900	chr3:154042577	DHX36	0.91	10.03	0.42	1.43e-21	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs2270450	0.650	rs9296509	chr6:46701037	C/A	cg10156739	chr6:46714674	LOC100287718	-0.47	-10.42	-0.44	5.48e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.14	0.32	3.58e-12	Longevity;
LGG	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.3	0.4	5.73e-19	Gout;Renal underexcretion gout;
LGG	cis	rs9788721	0.836	rs72738736	chr15:78765122	G/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.48	-0.4	1.32e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.92	-0.54	4.95e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07234876	chr8:600039	NA	1.03	10.33	0.43	1.22e-22	IgG glycosylation;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg16141378	chr3:129829833	LOC729375	-0.48	-12.07	-0.49	2.32e-29	Mood instability;
LGG	cis	rs9517320	1.000	rs9645890	chr13:99126637	C/T	cg07423050	chr13:99094983	FARP1	0.4	8.14	0.35	3.7e-15	Longevity;
LGG	cis	rs7103648	0.669	rs10437655	chr11:47391948	G/A	cg20307385	chr11:47447363	PSMC3	0.94	22.52	0.72	2.11e-76	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg00677455	chr12:58241039	CTDSP2	-0.44	-8.03	-0.35	7.85e-15	Multiple sclerosis;
LGG	cis	rs11586313	0.935	rs4845496	chr1:152888178	A/G	cg07796016	chr1:152779584	LCE1C	-0.62	-9.92	-0.42	3.67e-21	Vitamin D levels;
LGG	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg20503657	chr10:835505	NA	0.95	13.04	0.52	2.6e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07308232	chr7:1071921	C7orf50	-0.45	-8.35	-0.36	8.16e-16	Longevity;Endometriosis;
LGG	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg18225595	chr11:63971243	STIP1	-0.52	-10.53	-0.44	2.12e-23	Platelet count;
LGG	cis	rs13314892	0.728	rs62251025	chr3:69862189	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg03330168	chr4:9382066	NA	-0.37	-6.7	-0.3	6.13e-11	Neuroticism;
LGG	trans	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.32	0.43	1.32e-22	Ulcerative colitis;
LGG	cis	rs6429082	1.000	rs6429082	chr1:235600129	C/T	cg26050004	chr1:235667680	B3GALNT2	0.46	7.72	0.34	7.19e-14	Adiposity;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.71	0.61	2.13e-49	Personality dimensions;
LGG	cis	rs9462027	0.628	rs4601124	chr6:34776910	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.71e-18	Cognitive test performance;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg18402987	chr7:1209562	NA	0.76	10.83	0.45	1.61e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg22920501	chr2:26401640	FAM59B	-0.42	-8.35	-0.36	8.12e-16	Gut microbiome composition (summer);
LGG	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.75	8.35	0.36	8e-16	Yeast infection;
LGG	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08280861	chr8:58055591	NA	0.62	7.77	0.34	4.96e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg20578329	chr17:80767326	TBCD	-0.77	-10.93	-0.45	6.72e-25	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07636362	chr8:79717261	IL7	0.45	7.66	0.34	1.07e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.02	0.52	3e-33	Tonsillectomy;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg21092834	chr11:107462721	LOC643923;ELMOD1	0.45	6.74	0.3	4.83e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg19875535	chr5:140030758	IK	-0.56	-11.5	-0.47	4.37e-27	Depressive symptoms (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07657236	chr3:19190202	KCNH8	0.36	6.86	0.3	2.28e-11	Obesity-related traits;
LGG	cis	rs6565180	0.962	rs11642676	chr16:30371655	C/G	cg17640201	chr16:30407289	ZNF48	-0.85	-16.33	-0.6	1.17e-47	Tonsillectomy;
LGG	cis	rs6960043	0.818	rs4719433	chr7:15065003	A/G	cg19272540	chr7:15055459	NA	-0.36	-7.89	-0.34	2.21e-14	Type 2 diabetes;
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21627589	chr17:45899047	OSBPL7	0.45	6.72	0.3	5.41e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.09	0.39	2.86e-18	Lung cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	-0.49	-7.33	-0.32	1.02e-12	Systemic lupus erythematosus;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg23758822	chr17:41437982	NA	-0.86	-15.55	-0.59	3.4e-44	Menopause (age at onset);
LGG	cis	rs11214589	0.747	rs7939992	chr11:113229665	T/C	cg14159747	chr11:113255604	NA	0.28	7.51	0.33	3e-13	Neuroticism;
LGG	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg07636037	chr3:49044803	WDR6	0.91	17.41	0.63	1.36e-52	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.16	-0.39	1.68e-18	Response to antipsychotic treatment;
LGG	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-14.0	-0.55	2.27e-37	Bladder cancer;
LGG	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg11764359	chr7:65958608	NA	-0.8	-14.88	-0.57	3.28e-41	Aortic root size;
LGG	cis	rs11608355	0.960	rs10774691	chr12:109859830	C/T	cg19025524	chr12:109796872	NA	-0.49	-9.29	-0.4	6.26e-19	Neuroticism;
LGG	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24110177	chr3:50126178	RBM5	0.59	10.85	0.45	1.42e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.614	rs2388202	chr11:89374231	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs11098499	0.863	rs7699064	chr4:120428309	A/G	cg24375607	chr4:120327624	NA	-0.67	-10.78	-0.45	2.54e-24	Corneal astigmatism;
LGG	cis	rs4481887	0.927	rs6689193	chr1:248482900	T/A	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs7666738	0.761	rs13136913	chr4:98998031	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs73198271	0.960	rs11776546	chr8:8609181	T/G	cg16141378	chr3:129829833	LOC729375	0.37	6.95	0.31	1.25e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg07615347	chr10:60278583	BICC1	0.61	16.56	0.61	1.07e-48	Refractive error;
LGG	cis	rs4774899	0.752	rs2957574	chr15:57336825	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.8	-0.3	3.21e-11	Urinary tract infection frequency;
LGG	cis	rs701145	0.585	rs959376	chr3:153866707	A/T	cg17054900	chr3:154042577	DHX36	0.75	9.07	0.39	3.31e-18	Coronary artery disease;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.16	-0.32	3.16e-12	Schizophrenia;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg12432903	chr7:1882776	MAD1L1	0.54	8.17	0.35	3.07e-15	Bipolar disorder;
LGG	trans	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.11	28.6	0.8	2.17e-104	Exhaled nitric oxide output;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08795962	chr11:93862716	PANX1	-0.48	-6.98	-0.31	1.04e-11	Systemic lupus erythematosus;
LGG	cis	rs2249694	0.919	rs10857769	chr10:135405047	T/C	cg20169779	chr10:135381914	SYCE1	-0.5	-7.71	-0.34	7.66e-14	Obesity-related traits;
LGG	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg18135555	chr8:22132992	PIWIL2	0.39	10.25	0.43	2.38e-22	Hypertriglyceridemia;
LGG	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg09307838	chr4:120376055	NA	0.81	13.65	0.54	6.83e-36	Corneal astigmatism;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.55	-0.59	3.7e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs2587949	0.615	rs2587911	chr3:4198140	A/G	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	trans	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg10756647	chr7:56101905	PSPH	0.46	7.0	0.31	8.88e-12	Corneal structure;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	8.87	0.38	1.61e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs61990749	0.597	rs2267761	chr14:78147849	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.16	-0.32	3.15e-12	Fibroblast growth factor basic levels;
LGG	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	17.51	0.63	4.72e-53	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	trans	rs9650657	0.737	rs4504595	chr8:10655505	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.28	-0.32	1.46e-12	Neuroticism;
LGG	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	7.9	0.34	2.06e-14	Triglycerides;
LGG	cis	rs9467773	0.869	rs1796521	chr6:26421392	T/C	cg09904177	chr6:26538194	HMGN4	-0.62	-12.25	-0.49	4.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg14186256	chr22:23484241	RTDR1	1.0	25.91	0.77	3.76e-92	Bone mineral density;
LGG	cis	rs9640161	0.658	rs60467296	chr7:150015471	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.72	-14.53	-0.56	1.09e-39	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg16434002	chr17:42200994	HDAC5	0.44	7.86	0.34	2.8e-14	Total body bone mineral density;
LGG	cis	rs9467711	0.591	rs17586553	chr6:25928775	C/T	cg21479132	chr6:26055353	NA	0.78	7.15	0.32	3.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg11062466	chr8:58055876	NA	0.52	7.95	0.35	1.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg14926445	chr8:58193284	C8orf71	-0.73	-8.49	-0.37	2.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs227833	1.000	rs227830	chr6:44680555	G/C	cg20913747	chr6:44695427	NA	0.46	7.72	0.34	7.02e-14	Monobrow;
LGG	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg05925327	chr15:68127851	NA	-0.37	-7.31	-0.32	1.17e-12	Restless legs syndrome;
LGG	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg22643751	chr7:855365	UNC84A	0.39	6.72	0.3	5.49e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg27490568	chr2:178487706	NA	-0.81	-13.34	-0.53	1.44e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.35	0.36	7.76e-16	Thyroid stimulating hormone;
LGG	cis	rs7084402	1.000	rs717452	chr10:60268270	A/G	cg07615347	chr10:60278583	BICC1	0.62	17.52	0.63	4.24e-53	Refractive error;
LGG	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg10760299	chr15:45669010	GATM	-0.38	-7.15	-0.32	3.37e-12	Homoarginine levels;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg13264159	chr8:625131	ERICH1	-0.94	-10.44	-0.44	4.6e-23	IgG glycosylation;
LGG	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	14.47	0.56	1.97e-39	Nonalcoholic fatty liver disease;
LGG	cis	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg24006582	chr15:45444508	DUOX1	0.67	12.2	0.49	7.1e-30	Uric acid levels;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg17734273	chr15:78292508	TBC1D2B	0.31	6.82	0.3	2.87e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg11764359	chr7:65958608	NA	-0.7	-11.97	-0.49	6.07e-29	Aortic root size;
LGG	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.24	-0.32	1.85e-12	Neuroticism;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs3857747	0.931	rs4613890	chr7:40381031	A/C	cg00420559	chr7:40367873	C7orf10	-0.41	-8.34	-0.36	8.7e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs4774899	0.869	rs2733174	chr15:57331666	C/T	cg08128148	chr15:57256372	TCF12	0.31	7.52	0.33	2.77e-13	Urinary tract infection frequency;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20601096	chr14:93799719	KIAA1409;BTBD7	0.44	7.41	0.33	6.23e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg13944838	chr5:179740914	GFPT2	-0.67	-12.44	-0.5	7.36e-31	Height;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.79	-0.34	4.45e-14	Life satisfaction;
LGG	cis	rs4538187	1.000	rs6755646	chr2:64091533	A/G	cg14150252	chr2:64069583	UGP2	0.5	9.99	0.42	1.99e-21	Systolic blood pressure;
LGG	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.48	-0.37	3.12e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9287719	0.967	rs9287720	chr2:10752664	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs457717	0.730	rs463147	chr5:75947711	T/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs7129556	0.954	rs6592738	chr11:77323126	C/T	cg12586386	chr11:77299805	AQP11	0.52	8.68	0.37	6.93e-17	Weight loss (gastric bypass surgery);
LGG	cis	rs2415984	0.579	rs2254846	chr14:46973394	G/A	cg14871534	chr14:47121158	RPL10L	0.57	10.01	0.42	1.7e-21	Number of children ever born;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs9300255	0.663	rs7953929	chr12:123758235	C/G	cg00376283	chr12:123451042	ABCB9	0.57	8.54	0.37	1.95e-16	Neutrophil percentage of white cells;
LGG	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg01028140	chr2:1542097	TPO	-0.44	-8.23	-0.36	1.98e-15	IgG glycosylation;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.52	0.37	2.32e-16	Obesity-related traits;
LGG	cis	rs240764	0.631	rs6932158	chr6:101246010	T/C	cg21058520	chr6:100914733	NA	0.4	6.89	0.31	1.81e-11	Neuroticism;
LGG	cis	rs9715521	0.803	rs62301188	chr4:59840423	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.33	-0.32	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2072153	0.738	rs9895945	chr17:47329255	A/G	cg08112188	chr17:47440006	ZNF652	0.43	6.9	0.31	1.72e-11	Height;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg12310025	chr6:25882481	NA	-0.72	-13.9	-0.54	6.12e-37	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.590	rs9642120	chr7:139083971	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.55	-9.1	-0.39	2.68e-18	Bipolar disorder;
LGG	cis	rs6460942	1.000	rs6460938	chr7:12406808	T/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.88	-0.3	1.99e-11	Coronary artery disease;
LGG	cis	rs17039065	0.834	rs17039112	chr4:109439739	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.83	0.34	3.47e-14	Gut microbiome composition (summer);
LGG	cis	rs7246760	0.867	rs68041339	chr19:9818851	A/G	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs7216064	1.000	rs9915108	chr17:65874463	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.47e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs752010	0.523	rs10890158	chr1:42117985	C/T	cg06885757	chr1:42089581	HIVEP3	0.61	14.11	0.55	7.61e-38	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4561483	0.801	rs33660	chr16:11961858	A/G	cg08843971	chr16:11963173	GSPT1	-0.68	-18.33	-0.65	7.94e-57	Testicular germ cell tumor;
LGG	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.11	0.35	4.56e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg07659893	chr17:61819838	STRADA	-0.42	-6.87	-0.3	2.07e-11	Prudent dietary pattern;
LGG	cis	rs4330281	0.608	rs28408438	chr3:17384023	T/C	cg20981856	chr3:17787350	NA	0.36	6.88	0.3	1.96e-11	Schizophrenia;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.29	-7.38	-0.32	7.37e-13	IgG glycosylation;
LGG	cis	rs7940866	0.845	rs2324314	chr11:130834589	A/C	cg12179176	chr11:130786555	SNX19	0.74	13.82	0.54	1.24e-36	Schizophrenia;
LGG	cis	rs2273669	0.667	rs11755471	chr6:109342169	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg18402987	chr7:1209562	NA	0.46	8.73	0.38	4.58e-17	Longevity;Endometriosis;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02071572	chr4:1403502	NA	0.37	6.77	0.3	3.98e-11	Longevity;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.33	0.32	1.03e-12	Longevity;
LGG	cis	rs6800768	0.633	rs59715267	chr3:24100414	C/A	cg10674438	chr3:24145617	LOC152024	-0.48	-8.7	-0.37	6.02e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.45	-0.71	2.26e-71	Monocyte count;
LGG	cis	rs7786808	0.504	rs10949725	chr7:158196003	C/T	cg01191920	chr7:158217561	PTPRN2	0.7	15.14	0.58	2.36e-42	Obesity-related traits;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.66	-0.41	3.02e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.879	rs29001208	chr4:100052539	A/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.63	-0.37	9.63e-17	Alcohol dependence;
LGG	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06470251	chr20:60548479	NA	0.51	8.51	0.37	2.53e-16	Body mass index;
LGG	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.4	-0.36	5.4e-16	Restless legs syndrome;
LGG	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.87	-0.42	5.64e-21	Primary sclerosing cholangitis;
LGG	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg25019033	chr10:957182	NA	0.52	12.13	0.49	1.36e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.25	-0.36	1.69e-15	Mood instability;
LGG	cis	rs9462027	0.651	rs9469884	chr6:34758703	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.24	-0.46	4.47e-26	Systemic lupus erythematosus;
LGG	cis	rs7296418	0.922	rs12425009	chr12:123502044	C/T	cg05973401	chr12:123451056	ABCB9	0.48	8.02	0.35	8.74e-15	Platelet count;
LGG	cis	rs283228	0.550	rs2852495	chr6:101827044	C/T	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs7808935	0.958	rs17156041	chr7:27975745	C/T	cg22168087	chr7:27702803	HIBADH	0.64	8.56	0.37	1.63e-16	Prostate cancer;
LGG	cis	rs8078723	0.802	rs9303283	chr17:38192633	A/G	cg17467752	chr17:38218738	THRA	0.86	18.45	0.65	2.1e-57	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg00204512	chr16:28754710	NA	0.25	7.08	0.31	5.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3784262	1.000	rs7170896	chr15:58252393	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.36	-0.36	7.41e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7394190	0.748	rs12573448	chr10:75504512	T/G	cg07699608	chr10:75541558	CHCHD1	0.56	7.21	0.32	2.35e-12	Incident atrial fibrillation;
LGG	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg14664628	chr15:75095509	CSK	-1.15	-27.85	-0.79	5.68e-101	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg15369054	chr17:80825471	TBCD	0.58	10.29	0.43	1.63e-22	Breast cancer;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.53	-6.69	-0.3	6.42e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08613513	chr1:52870060	ORC1L;PRPF38A	0.45	7.41	0.33	5.96e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg05863683	chr7:1912471	MAD1L1	0.38	7.48	0.33	3.75e-13	Schizophrenia;
LGG	cis	rs765787	0.530	rs1706834	chr15:45517854	G/A	cg25801113	chr15:45476975	SHF	0.89	20.4	0.69	1.85e-66	Uric acid levels;
LGG	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.21e-25	Corneal astigmatism;
LGG	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.27e-14	Huntington's disease progression;
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22968622	chr17:43663579	NA	0.79	15.29	0.58	5.12e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-10.86	-0.45	1.21e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08564027	chr20:61660810	NA	1.02	25.72	0.77	3.06e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg00343986	chr7:65444356	GUSB	0.44	7.58	0.33	1.9e-13	Calcium levels;
LGG	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg23625390	chr15:77176239	SCAPER	0.52	10.31	0.43	1.36e-22	Blood metabolite levels;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.11	-0.7	8.96e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23030894	chr19:37701637	ZNF585B	0.43	7.13	0.31	3.88e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7765175	0.698	rs9488154	chr6:113664674	G/A	cg26552650	chr6:113682475	NA	0.33	7.48	0.33	3.72e-13	Coronary artery calcification;
LGG	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg14675211	chr2:100938903	LONRF2	0.48	7.38	0.32	7.21e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.13	-0.55	6.07e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3858145	0.588	rs76854765	chr10:70037456	C/T	cg04882175	chr6:131122610	NA	-0.56	-8.0	-0.35	1.04e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.74	13.69	0.54	4.7e-36	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.47e-24	Aortic root size;
LGG	cis	rs6580649	0.598	rs1793913	chr12:48387025	T/A	cg24011408	chr12:48396354	COL2A1	0.63	7.63	0.33	1.31e-13	Lung cancer;
LGG	cis	rs7599312	0.963	rs6735267	chr2:213403863	C/T	cg16329650	chr2:213403929	ERBB4	0.61	10.07	0.42	1.03e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7072216	0.763	rs942805	chr10:100168372	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.17	-0.32	3.03e-12	Metabolite levels;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg07883762	chr3:176914208	TBL1XR1	0.49	8.21	0.36	2.18e-15	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg06521331	chr12:34319734	NA	-0.55	-9.38	-0.4	2.95e-19	Morning vs. evening chronotype;
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10053473	chr17:62856997	LRRC37A3	0.79	13.85	0.54	9.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4538187	0.906	rs17619753	chr2:63943616	G/A	cg19915305	chr2:64069682	UGP2	-0.63	-13.95	-0.54	3.57e-37	Systolic blood pressure;
LGG	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg15556689	chr8:8085844	FLJ10661	0.49	8.63	0.37	9.65e-17	Retinal vascular caliber;
LGG	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg01181863	chr3:195395398	SDHAP2	0.47	7.28	0.32	1.45e-12	Mean corpuscular volume;
LGG	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg19748678	chr4:122722346	EXOSC9	0.51	9.67	0.41	2.78e-20	Type 2 diabetes;
LGG	cis	rs9487094	0.626	rs12201444	chr6:110059954	G/A	cg01125227	chr6:109776195	MICAL1	0.42	7.41	0.33	6.2e-13	Height;
LGG	cis	rs8141529	0.748	rs2064261	chr22:29287730	C/T	cg02153584	chr22:29168773	CCDC117	0.59	9.41	0.4	2.25e-19	Lymphocyte counts;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg15017067	chr4:17643749	FAM184B	0.31	6.89	0.3	1.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04095345	chr6:34857663	ANKS1A	0.44	6.77	0.3	3.94e-11	Gut microbiome composition (summer);
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg21963583	chr11:68658836	MRPL21	0.61	10.57	0.44	1.55e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4409675	0.576	rs6691656	chr1:28221130	C/G	cg23691781	chr1:28212827	C1orf38	0.43	11.63	0.48	1.37e-27	Corneal astigmatism;
LGG	cis	rs1344694	0.566	rs13029765	chr2:216894976	A/T	cg12620499	chr2:216877984	MREG	0.61	11.59	0.47	1.93e-27	Alcohol dependence;
LGG	cis	rs3816183	0.557	rs7558422	chr2:42883025	A/G	cg14631114	chr2:43023945	NA	0.34	6.74	0.3	4.78e-11	Hypospadias;
LGG	cis	rs883115	0.846	rs7529774	chr1:224794206	A/T	cg01808320	chr1:224927238	CNIH3	-0.38	-7.01	-0.31	8.66e-12	Cancer;
LGG	cis	rs4917300	0.606	rs6583570	chr8:143115783	A/G	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.29e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg26031613	chr14:104095156	KLC1	1.15	27.64	0.79	4.76e-100	Body mass index;
LGG	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg26924012	chr15:45694286	SPATA5L1	1.04	22.37	0.72	1.06e-75	Homoarginine levels;
LGG	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg16414030	chr3:133502952	NA	-0.6	-10.44	-0.44	4.81e-23	Iron status biomarkers;
LGG	cis	rs11608355	0.545	rs56144717	chr12:109902304	T/C	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg14675211	chr2:100938903	LONRF2	0.61	10.75	0.45	3.38e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg11752832	chr7:134001865	SLC35B4	0.57	10.2	0.43	3.67e-22	Mean platelet volume;
LGG	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.23	-0.39	9.56e-19	Myopia (pathological);
LGG	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg02002194	chr4:3960332	NA	0.48	9.41	0.4	2.38e-19	Joint mobility (Beighton score);
LGG	cis	rs10940138	1.000	rs10940138	chr5:67194469	C/T	ch.5.1281357F	chr5:67228439	NA	0.74	12.77	0.51	3.26e-32	Menarche (age at onset);
LGG	cis	rs977987	0.750	rs4888407	chr16:75432390	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.48	0.44	3.46e-23	Dupuytren's disease;
LGG	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg25482853	chr8:67687455	SGK3	0.95	12.17	0.49	9.15e-30	Obesity-related traits;
LGG	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg03929089	chr4:120376271	NA	0.64	7.65	0.33	1.16e-13	Intraocular pressure;
LGG	cis	rs7584330	0.657	rs10211024	chr2:238353776	A/T	cg16989719	chr2:238392110	NA	-0.32	-6.81	-0.3	3e-11	Prostate cancer;
LGG	cis	rs7100689	0.577	rs1340385	chr10:82058851	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	14.98	0.57	1.26e-41	Post bronchodilator FEV1;
LGG	cis	rs2718058	0.613	rs1562767	chr7:37758187	G/A	cg15028436	chr7:37888078	TXNDC3	-0.58	-9.68	-0.41	2.56e-20	Alzheimer's disease (late onset);
LGG	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.46	0.37	3.63e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4803468	1.000	rs2288871	chr19:41917868	C/T	cg09537434	chr19:41945824	ATP5SL	-0.88	-23.09	-0.73	4.53e-79	Height;
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg13009111	chr11:71350975	NA	-0.38	-8.77	-0.38	3.35e-17	Monocyte count;
LGG	cis	rs1021993	0.545	rs79960084	chr1:209556170	C/A	cg24446417	chr1:209558027	NA	-0.76	-11.77	-0.48	3.71e-28	Gut microbiome composition (winter);
LGG	cis	rs13053817	1.000	rs13055259	chr22:29856892	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.73	-0.3	5.16e-11	Carotid atherosclerosis in HIV infection;
LGG	trans	rs4942242	0.617	rs9590778	chr13:44199007	C/G	cg19169023	chr15:41853346	TYRO3	-0.45	-8.86	-0.38	1.79e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7639513	0.545	rs9874557	chr3:12720967	A/G	cg23032965	chr3:12705835	RAF1	0.73	11.67	0.48	9.55e-28	Itch intensity from mosquito bite;
LGG	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg01130898	chr2:219473002	PLCD4	0.44	7.66	0.34	1.1e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg05863683	chr7:1912471	MAD1L1	0.46	9.16	0.39	1.65e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.84	-0.38	2.02e-17	Mean corpuscular volume;
LGG	cis	rs1572438	0.811	rs6916731	chr6:880428	G/C	cg21062780	chr6:887772	NA	0.36	6.76	0.3	4.26e-11	Aging;
LGG	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg26769984	chr7:1090371	C7orf50	0.42	7.42	0.33	5.83e-13	Bronchopulmonary dysplasia;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg22907277	chr7:1156413	C7orf50	0.51	7.21	0.32	2.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg06693505	chr8:141057453	TRAPPC9	-0.31	-6.68	-0.3	6.9e-11	Pulse pressure;
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg00166722	chr3:10149974	C3orf24	0.48	8.05	0.35	7.11e-15	Alzheimer's disease;
LGG	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.65	-7.6	-0.33	1.63e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9534288	0.797	rs9534279	chr13:46584999	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs4820539	1.000	rs5751589	chr22:23475762	A/G	cg21100191	chr22:23484243	RTDR1	-1.02	-23.4	-0.74	1.69e-80	Bone mineral density;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.31	5.36e-12	Lung cancer;
LGG	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg26597838	chr10:835615	NA	0.67	9.93	0.42	3.52e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg12395012	chr8:11607386	GATA4	0.39	7.19	0.32	2.68e-12	Neuroticism;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.28	-0.36	1.32e-15	Lymphocyte counts;
LGG	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg27489772	chr12:121021490	NA	0.56	7.25	0.32	1.77e-12	Type 1 diabetes nephropathy;
LGG	cis	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg10402321	chr1:26617780	UBXN11	-0.45	-7.6	-0.33	1.63e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.57	-0.33	2.02e-13	IgG glycosylation;
LGG	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.3	-0.32	1.27e-12	Mood instability;
LGG	cis	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg21775007	chr8:11205619	TDH	-0.52	-8.12	-0.35	4.41e-15	Triglycerides;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg05091796	chr16:4465799	CORO7	0.59	9.49	0.4	1.23e-19	Schizophrenia;
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg04166393	chr7:2884313	GNA12	0.47	9.37	0.4	3.17e-19	Height;
LGG	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg19455335	chr8:22457658	C8orf58	-0.47	-9.31	-0.4	5.25e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.46	-0.47	6.39e-27	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg24375607	chr4:120327624	NA	0.62	10.35	0.43	9.9e-23	Corneal astigmatism;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg06558623	chr16:89946397	TCF25	1.15	14.68	0.56	2.5e-40	Skin colour saturation;
LGG	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	10.55	0.44	1.89e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7712401	0.525	rs2910150	chr5:122296745	G/T	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs35740288	0.857	rs11630274	chr15:86288387	C/T	cg04173714	chr15:86211321	AKAP13	0.42	7.28	0.32	1.43e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	8.8e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg21096502	chr7:56174374	CHCHD2	-0.61	-7.63	-0.33	1.38e-13	PR interval in Tripanosoma cruzi seropositivity;
LGG	cis	rs6912958	0.935	rs2179844	chr6:88165773	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-10.45	-0.44	4.25e-23	Monocyte percentage of white cells;
LGG	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.14	-0.39	2.01e-18	Educational attainment;
LGG	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.58	0.33	1.97e-13	Neutrophil percentage of white cells;
LGG	cis	rs3816183	1.000	rs6724265	chr2:43020236	G/C	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.24e-18	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06845991	chr7:90032834	CLDN12	0.42	7.03	0.31	7.51e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg21775007	chr8:11205619	TDH	0.6	10.09	0.42	8.79e-22	Retinal vascular caliber;
LGG	cis	rs7107174	0.688	rs11237489	chr11:78130325	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.62	-0.33	1.45e-13	Testicular germ cell tumor;
LGG	trans	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg06521331	chr12:34319734	NA	0.45	8.14	0.35	3.57e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8133932	0.576	rs2839039	chr21:47321499	T/G	cg11214348	chr21:47283868	PCBP3	0.45	7.9	0.34	1.98e-14	Schizophrenia;
LGG	cis	rs2901460	0.527	rs10167456	chr2:62112839	G/A	cg02183531	chr2:62113199	CCT4	-0.48	-8.33	-0.36	9.39e-16	Mean corpuscular volume;
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.09	-0.31	4.97e-12	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04643103	chr1:150039325	VPS45	0.43	6.94	0.31	1.33e-11	Cognitive performance;
LGG	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg26396452	chr14:65542826	MAX	-0.48	-10.12	-0.43	7.21e-22	Obesity-related traits;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg24503407	chr1:205819492	PM20D1	-0.41	-8.41	-0.36	5.11e-16	Prostate-specific antigen levels;
LGG	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg02297831	chr4:17616191	MED28	0.42	7.78	0.34	4.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg12081754	chr8:22256438	SLC39A14	0.76	15.13	0.58	2.74e-42	Verbal declarative memory;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	cis	rs2334880	0.678	rs57821244	chr16:71553791	G/C	cg06353428	chr16:71660113	MARVELD3	-1.03	-13.85	-0.54	9.66e-37	Malaria;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.03e-19	Obesity-related traits;
LGG	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg05425664	chr17:57184151	TRIM37	0.68	11.04	0.46	2.67e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2708977	0.637	rs654224	chr2:97080123	A/C	cg01950434	chr2:97203154	ARID5A	-0.47	-7.21	-0.32	2.34e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg05941027	chr17:61774174	LIMD2	0.35	8.79	0.38	2.85e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg03609598	chr5:56110824	MAP3K1	-0.5	-7.47	-0.33	4.15e-13	Initial pursuit acceleration;
LGG	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.5	-0.33	3.36e-13	Personality dimensions;
LGG	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14645526	chr11:91959086	NA	0.42	6.7	0.3	6.26e-11	Cognitive performance;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.39	7.05	0.31	6.42e-12	Longevity;
LGG	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24308560	chr3:49941425	MST1R	0.22	6.88	0.3	1.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2652834	1.000	rs2729833	chr15:63397044	G/A	cg05507819	chr15:63340323	TPM1	0.6	8.06	0.35	6.72e-15	HDL cholesterol;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs2188554	0.527	rs7795896	chr7:117086613	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.42	-8.64	-0.37	9.51e-17	Esophageal adenocarcinoma;
LGG	cis	rs7191700	0.511	rs8058983	chr16:11360849	A/G	cg00044050	chr16:11439710	C16orf75	-0.56	-9.39	-0.4	2.72e-19	Multiple sclerosis;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg26384229	chr12:38710491	ALG10B	1.07	29.39	0.81	6.76e-108	Heart rate;
LGG	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	trans	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.8	-0.3	3.22e-11	Body mass index;
LGG	cis	rs6694672	0.850	rs4915316	chr1:197059928	A/G	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.31	1.54e-11	Asthma;
LGG	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.17	-0.32	3e-12	Arsenic metabolism;
LGG	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.72	-12.66	-0.51	9.8e-32	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03584288	chr19:37407041	ZNF829;ZNF568	0.45	7.19	0.32	2.62e-12	Cognitive performance;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.56	-0.44	1.69e-23	IgG glycosylation;
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg19901468	chr14:105411992	AHNAK2	-0.89	-19.28	-0.67	3.16e-61	Rheumatoid arthritis;
LGG	trans	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.78	0.3	3.68e-11	Vitiligo;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg22232500	chr2:134024266	NCKAP5	0.57	8.06	0.35	6.43e-15	Bipolar disorder;
LGG	trans	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg21775007	chr8:11205619	TDH	0.45	7.27	0.32	1.55e-12	Joint mobility (Beighton score);
LGG	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	trans	rs747782	0.528	rs11039674	chr11:48336116	C/T	cg15704280	chr7:45808275	SEPT13	0.72	8.59	0.37	1.38e-16	Intraocular pressure;
LGG	cis	rs10904908	1.000	rs7903259	chr10:17259642	C/G	cg01003015	chr10:17271136	VIM	0.53	8.64	0.37	9.12e-17	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.23	0.32	2e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2371030	0.632	rs13422990	chr2:211567790	A/G	cg18417063	chr2:211583084	NA	-0.54	-8.61	-0.37	1.18e-16	Non-small cell lung cancer;
LGG	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12826209	chr6:26865740	GUSBL1	0.59	7.3	0.32	1.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.64	0.37	9.49e-17	Bipolar disorder;
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg06848047	chr4:90757629	SNCA	-0.4	-7.59	-0.33	1.83e-13	Dementia with Lewy bodies;
LGG	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25517755	chr10:38738941	LOC399744	-0.39	-6.69	-0.3	6.48e-11	Corneal astigmatism;
LGG	trans	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg26043149	chr18:55253948	FECH	0.41	6.72	0.3	5.3e-11	Bone mineral density;
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg10207240	chr12:122356781	WDR66	0.27	8.2	0.36	2.33e-15	Mean corpuscular volume;
LGG	cis	rs9878978	0.722	rs35775662	chr3:2437223	T/C	cg21928760	chr3:2462534	CNTN4	0.39	7.79	0.34	4.37e-14	Blood pressure (smoking interaction);
LGG	cis	rs2274273	0.712	rs9806049	chr14:55525589	C/A	cg04306507	chr14:55594613	LGALS3	0.44	10.79	0.45	2.34e-24	Protein biomarker;
LGG	cis	rs977987	0.778	rs1109341	chr16:75445605	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.1	0.42	8.51e-22	Dupuytren's disease;
LGG	cis	rs17253792	0.822	rs113692713	chr14:56087424	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.07	-0.49	2.4e-29	Putamen volume;
LGG	cis	rs1909881	0.935	rs55736309	chr8:96521287	T/C	cg04203453	chr8:96504381	NA	-1.09	-18.6	-0.65	4.27e-58	Obesity-related traits;
LGG	cis	rs2797369	0.713	rs2813655	chr6:101586319	T/G	cg27451362	chr6:101846650	GRIK2	0.78	10.88	0.45	1.01e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.35	0.36	7.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg24623649	chr8:11872141	NA	-0.3	-7.03	-0.31	7.3e-12	Triglycerides;
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg26116260	chr4:7069785	GRPEL1	1.15	21.91	0.71	1.5e-73	Monocyte percentage of white cells;
LGG	cis	rs41005	1.000	rs41005	chr2:8111231	A/G	cg03155496	chr2:8117019	LOC339788	-0.88	-19.68	-0.67	4.15e-63	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg08048268	chr3:133502702	NA	0.38	6.76	0.3	4.2e-11	Alcohol consumption (transferrin glycosylation);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg19434433	chr17:44849214	WNT3	-0.4	-6.65	-0.3	8.29e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs12410462	0.591	rs3748806	chr1:227751112	A/C	cg23173402	chr1:227635558	NA	-0.36	-6.89	-0.31	1.81e-11	Major depressive disorder;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.79	-0.41	1.04e-20	Lung cancer;
LGG	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.76	-0.38	3.82e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg13514129	chr1:39547527	MACF1	-0.68	-12.68	-0.51	7.9e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg06808227	chr14:105710500	BRF1	0.65	11.37	0.47	1.32e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg01200585	chr1:228362443	C1orf69	0.48	8.06	0.35	6.76e-15	Diastolic blood pressure;
LGG	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg02269571	chr22:50332266	NA	-0.71	-10.93	-0.45	6.82e-25	Schizophrenia;
LGG	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs1185460	0.967	rs1786684	chr11:118938435	G/A	cg23280166	chr11:118938394	VPS11	0.6	11.23	0.46	4.71e-26	Coronary artery disease;
LGG	cis	rs2285947	1.000	rs2285950	chr7:21584432	C/T	cg04471919	chr7:21584483	DNAH11	-0.5	-14.13	-0.55	6.16e-38	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.45	-0.44	4.28e-23	Body mass index;
LGG	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg13939156	chr17:80058883	NA	-0.4	-7.19	-0.32	2.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg21366198	chr4:185655624	MLF1IP	-0.44	-7.59	-0.33	1.83e-13	Kawasaki disease;
LGG	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg01557791	chr16:72042693	DHODH	0.7	14.04	0.55	1.49e-37	Prostate cancer;
LGG	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg08499158	chr17:42289980	UBTF	-0.38	-7.08	-0.31	5.45e-12	Red cell distribution width;Reticulocyte count;
LGG	cis	rs12210905	0.748	rs6901225	chr6:26670491	A/G	cg11502198	chr6:26597334	ABT1	-0.96	-9.66	-0.41	3.22e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1966248	0.543	rs12206782	chr6:134103192	C/A	cg25632230	chr6:134101081	NA	-0.35	-7.65	-0.33	1.19e-13	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-15.92	-0.59	7.83e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.2e-20	Aortic root size;
LGG	cis	rs2587949	0.638	rs10865900	chr3:4193041	C/T	cg16519197	chr3:4211558	NA	0.34	7.15	0.32	3.35e-12	Periodontitis (DPAL);
LGG	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg14784868	chr12:69753453	YEATS4	0.44	6.8	0.3	3.29e-11	Response to diuretic therapy;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.632	rs62541916	chr9:5151904	C/A	cg02405213	chr9:5042618	JAK2	-0.77	-14.89	-0.57	2.93e-41	Pediatric autoimmune diseases;
LGG	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg15212455	chr7:39170539	POU6F2	0.3	6.78	0.3	3.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	0.967	rs12602065	chr17:28482488	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.59	0.53	1.18e-35	Coffee consumption (cups per day);
LGG	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg17809284	chr5:56205270	C5orf35	0.54	10.02	0.42	1.59e-21	Initial pursuit acceleration;
LGG	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg02002194	chr4:3960332	NA	-0.38	-6.66	-0.3	7.65e-11	Neuroticism;
LGG	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg04117972	chr1:227635322	NA	0.9	13.72	0.54	3.58e-36	Major depressive disorder;
LGG	cis	rs6546550	0.901	rs6546559	chr2:70145833	G/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.95	-0.35	1.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.11e-25	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.0	0.52	3.59e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-8.31	-0.36	1.08e-15	Lung cancer;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg15763984	chr4:1342303	KIAA1530	0.37	6.73	0.3	5.09e-11	Obesity-related traits;
LGG	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-11.15	-0.46	9.51e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18252515	chr7:66147081	NA	-0.41	-6.93	-0.31	1.44e-11	Aortic root size;
LGG	cis	rs11971779	0.648	rs10230407	chr7:139103893	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.78	0.3	3.6e-11	Diisocyanate-induced asthma;
LGG	cis	rs7794364	0.658	rs7807677	chr7:117502574	C/T	cg21880328	chr7:117514017	CTTNBP2	-0.36	-7.49	-0.33	3.56e-13	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs4746818	0.711	rs4745976	chr10:70845181	A/G	cg11621586	chr10:70884670	VPS26A	0.76	11.52	0.47	3.73e-27	Left atrial antero-posterior diameter;
LGG	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs10426930	0.738	rs2620815	chr19:5051840	C/G	cg08036796	chr19:5034282	KDM4B	-0.3	-6.85	-0.3	2.39e-11	Monocyte percentage of white cells;
LGG	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg12386194	chr3:101231763	SENP7	0.4	7.24	0.32	1.86e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg03162506	chr22:38580953	NA	0.41	9.84	0.42	7.26e-21	Breast cancer;
LGG	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.45	-7.19	-0.32	2.64e-12	Eosinophil percentage of white cells;
LGG	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg25486957	chr4:152246857	NA	-0.4	-7.0	-0.31	8.92e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg02297831	chr4:17616191	MED28	0.5	9.4	0.4	2.56e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.830	rs13108871	chr4:98803872	T/C	cg05340658	chr4:99064831	C4orf37	0.49	8.06	0.35	6.8e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.46	-0.33	4.31e-13	Lung cancer;
LGG	cis	rs1577917	0.572	rs911927	chr6:86327860	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	9.95e-16	Response to antipsychotic treatment;
LGG	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	6.75	0.3	4.54e-11	Neuroticism;
LGG	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-12.49	-0.5	4.91e-31	Vitiligo;
LGG	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs11792861	0.589	rs75742991	chr9:111929624	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	7.81	0.34	3.96e-14	Menarche (age at onset);
LGG	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	1.000	rs10838954	chr11:48579323	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.51	-0.33	3.07e-13	HDL cholesterol;
LGG	cis	rs1707322	0.721	rs10789470	chr1:46158331	T/G	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6939532	0.597	rs2273558	chr6:26466035	A/C	cg12826209	chr6:26865740	GUSBL1	0.46	7.34	0.32	9.88e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6840360	0.571	rs10026670	chr4:152539212	C/T	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9356171	0.572	rs2281407	chr6:164325926	C/T	cg25752492	chr6:164341247	NA	-0.46	-9.16	-0.39	1.65e-18	Diisocyanate-induced asthma;
LGG	cis	rs9443645	0.869	rs2095724	chr6:79742101	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.46	-0.37	3.47e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2797369	1.000	rs2797369	chr6:101674290	C/T	cg27451362	chr6:101846650	GRIK2	-0.72	-9.75	-0.41	1.47e-20	Renal function-related traits (eGRFcrea);
LGG	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.76	-0.3	4.11e-11	Iron status biomarkers;
LGG	cis	rs367943	0.637	rs6859521	chr5:113007423	C/T	cg12552261	chr5:112820674	MCC	0.49	7.99	0.35	1.06e-14	Type 2 diabetes;
LGG	cis	rs11771526	1.000	rs117890465	chr7:32351009	A/C	cg13207630	chr7:32358064	NA	0.67	7.03	0.31	7.21e-12	Body mass index;
LGG	cis	rs6429082	0.807	rs4659857	chr1:235581411	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09823679	chr13:53425813	NA	0.51	8.29	0.36	1.23e-15	Cognitive performance;
LGG	cis	rs12210905	1.000	rs9348758	chr6:27255238	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs8064024	0.870	rs6500635	chr16:4867565	A/G	cg08329684	chr16:4932620	PPL	0.43	9.35	0.4	3.9e-19	Cancer;
LGG	cis	rs9611519	0.558	rs8137906	chr22:41442566	A/G	cg03806693	chr22:41940476	POLR3H	-0.49	-8.12	-0.35	4.33e-15	Neuroticism;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs11239187	0.586	rs1383376	chr10:45101196	G/A	cg03916630	chr10:45065415	NA	0.35	8.39	0.36	5.99e-16	Body mass index;
LGG	cis	rs9948	0.655	rs78424221	chr2:97410399	A/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.62e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.4	-7.99	-0.35	1.11e-14	Platelet count;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg01516881	chr6:292596	DUSP22	-0.51	-8.79	-0.38	2.93e-17	Menopause (age at onset);
LGG	cis	rs78487399	0.808	rs12105399	chr2:43676939	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg03606772	chr1:152487856	CRCT1	0.3	7.04	0.31	6.9e-12	Plantar warts;
LGG	cis	rs727505	0.607	rs67313231	chr7:124804532	T/A	cg23710748	chr7:124431027	NA	-0.42	-8.14	-0.35	3.63e-15	Lewy body disease;
LGG	cis	rs9894429	0.683	rs112612275	chr17:79552604	C/A	cg10661904	chr17:79619235	PDE6G	0.42	8.42	0.36	4.75e-16	Eye color traits;
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg01341218	chr17:43662625	NA	0.96	16.83	0.62	6.41e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9311474	1.000	rs9311474	chr3:52338852	T/C	cg14092988	chr3:52407081	DNAH1	0.28	7.35	0.32	9.13e-13	Electroencephalogram traits;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01516881	chr6:292596	DUSP22	-0.69	-11.78	-0.48	3.26e-28	Menopause (age at onset);
LGG	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	13.01	0.52	3.46e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9397585	0.857	rs1338065	chr6:153380434	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs9527	0.662	rs4919687	chr10:104595248	G/A	cg04362960	chr10:104952993	NT5C2	0.5	8.94	0.38	9.28e-18	Arsenic metabolism;
LGG	cis	rs7172677	0.732	rs55922358	chr15:75313967	G/C	cg10253484	chr15:75165896	SCAMP2	0.6	8.78	0.38	3.25e-17	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.08	-0.46	1.89e-25	Mean platelet volume;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg24110177	chr3:50126178	RBM5	0.4	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg23985595	chr17:80112537	CCDC57	0.48	9.56	0.41	6.87e-20	Life satisfaction;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-9.94	-0.42	3.2e-21	Bladder cancer;
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg05793240	chr7:2802953	GNA12	0.34	7.88	0.34	2.43e-14	Height;
LGG	cis	rs881375	1.000	rs1609810	chr9:123642351	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.11	0.39	2.48e-18	Rheumatoid arthritis;
LGG	cis	rs644799	0.965	rs602512	chr11:95561682	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.96	0.54	3.37e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs7945718	0.781	rs10741604	chr11:12840940	C/A	cg25843174	chr11:12811716	TEAD1	0.39	7.62	0.33	1.42e-13	Educational attainment (years of education);
LGG	cis	rs55871839	0.559	rs66954327	chr8:59825133	A/G	cg07426533	chr8:59803705	TOX	0.59	12.47	0.5	5.77e-31	Pneumonia;
LGG	cis	rs6750047	0.585	rs336033	chr2:38263808	A/G	cg07380506	chr2:38303506	CYP1B1	-0.43	-7.08	-0.31	5.53e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs5753037	0.543	rs140128	chr22:30150140	T/C	cg01021169	chr22:30184971	ASCC2	-0.38	-7.53	-0.33	2.7e-13	Type 1 diabetes;
LGG	cis	rs10876993	0.806	rs1689598	chr12:58050500	G/C	cg18357645	chr12:58087776	OS9	0.68	12.22	0.49	5.97e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.4	-0.58	1.64e-43	Colorectal cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02625641	chr15:59041175	ADAM10	0.4	6.8	0.3	3.26e-11	Bipolar disorder;
LGG	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg24812749	chr6:127587940	RNF146	0.79	13.35	0.53	1.33e-34	Breast cancer;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg18926786	chr6:150244388	RAET1G	0.32	6.79	0.3	3.46e-11	Testicular germ cell tumor;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg11814155	chr7:99998594	ZCWPW1	0.53	8.08	0.35	5.74e-15	Platelet count;
LGG	cis	rs752010	0.714	rs10789403	chr1:42085869	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	13.79	0.54	1.66e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7945718	0.591	rs10831892	chr11:12676272	T/A	cg25843174	chr11:12811716	TEAD1	0.34	7.2	0.32	2.46e-12	Educational attainment (years of education);
LGG	cis	rs7681423	1.000	rs12644950	chr4:155537321	G/A	cg20735720	chr4:155535218	FGG	-0.59	-10.92	-0.45	7.67e-25	Fibrinogen;
LGG	cis	rs55883249	1.000	rs11692112	chr2:9723732	G/T	cg23886495	chr2:9695866	ADAM17	0.65	9.4	0.4	2.49e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.58	0.53	1.38e-35	Cognitive test performance;
LGG	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg06606381	chr12:133084897	FBRSL1	0.88	9.38	0.4	2.89e-19	Autism spectrum disorder or schizophrenia;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	11.75	0.48	4.35e-28	Neuroticism;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.78	0.57	8.91e-41	Platelet count;
LGG	cis	rs35740288	0.822	rs10520599	chr15:86223097	C/T	cg07943548	chr15:86304357	KLHL25	-0.34	-6.77	-0.3	4.02e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs882300	0.934	rs2102895	chr2:136906692	G/A	cg07169764	chr2:136633963	MCM6	-0.49	-7.78	-0.34	4.75e-14	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs17767392	1.000	rs61991205	chr14:71771921	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	cis	rs7715806	0.500	rs3797581	chr5:75002895	G/T	cg19683494	chr5:74908142	NA	0.49	6.68	0.3	6.95e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg10756647	chr7:56101905	PSPH	-0.81	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs7188861	0.768	rs62023605	chr16:11380861	A/C	cg01510278	chr16:11456238	NA	0.29	7.11	0.31	4.55e-12	HDL cholesterol;
LGG	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg25019033	chr10:957182	NA	-0.6	-11.48	-0.47	4.94e-27	Eosinophil percentage of granulocytes;
LGG	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	7.02	0.31	8.05e-12	Cognitive ability;
LGG	trans	rs3942852	0.806	rs1503188	chr11:48117478	C/T	cg03929089	chr4:120376271	NA	-0.66	-9.26	-0.4	7.88e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6554196	0.508	rs7695300	chr4:55512066	T/C	cg18836493	chr4:55524333	KIT	-0.43	-8.07	-0.35	5.97e-15	Monocyte count;
LGG	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg21665744	chr7:39171113	POU6F2	0.36	7.23	0.32	2.02e-12	IgG glycosylation;
LGG	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg02023728	chr11:77925099	USP35	-0.44	-7.61	-0.33	1.52e-13	Testicular germ cell tumor;
LGG	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg07120314	chr15:79043507	NA	0.38	7.39	0.32	6.76e-13	Sudden cardiac arrest;
LGG	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg05887092	chr17:76393375	PGS1	0.72	15.84	0.59	1.89e-45	HDL cholesterol levels;
LGG	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg14088196	chr11:70211408	PPFIA1	0.95	13.37	0.53	1.01e-34	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.35	0.36	8.23e-16	Schizophrenia;
LGG	cis	rs17023223	0.537	rs12081198	chr1:119686104	A/C	cg05756136	chr1:119680316	WARS2	-0.43	-9.09	-0.39	2.91e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2016266	1.000	rs2016266	chr12:53727955	A/G	cg04065151	chr12:53682969	ESPL1	0.49	8.51	0.37	2.49e-16	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs13191362	1.000	rs66594243	chr6:163169024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.92	9.21	0.39	1.16e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg18279126	chr7:2041391	MAD1L1	0.31	6.66	0.3	7.77e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.61e-11	Total body bone mineral density;
LGG	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg22437258	chr11:111473054	SIK2	0.56	9.76	0.41	1.39e-20	Primary sclerosing cholangitis;
LGG	cis	rs11585357	0.895	rs72633823	chr1:17630779	G/A	cg08277548	chr1:17600880	PADI3	-0.74	-8.34	-0.36	8.36e-16	Hair shape;
LGG	cis	rs806215	0.547	rs12539411	chr7:127468928	C/T	cg25922125	chr7:127225783	GCC1	-0.5	-7.27	-0.32	1.5e-12	Type 2 diabetes;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.75	-0.41	1.54e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.35	-0.43	1.03e-22	Lymphocyte counts;
LGG	cis	rs300774	0.858	rs300718	chr2:136579	G/A	cg04617936	chr2:214353	NA	-0.5	-7.58	-0.33	1.96e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs72960926	0.590	rs56343698	chr6:74749564	C/T	cg03266952	chr6:74778945	NA	-0.68	-7.01	-0.31	8.24e-12	Metabolite levels (MHPG);
LGG	cis	rs2916247	0.908	rs6471321	chr8:93162098	G/A	cg10183463	chr8:93005414	RUNX1T1	0.37	7.56	0.33	2.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.16	-0.46	8.56e-26	Migraine;Coronary artery disease;
LGG	cis	rs7666738	0.830	rs4619898	chr4:98959646	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10744422	1.000	rs2343108	chr12:123331301	C/T	cg25930673	chr12:123319894	HIP1R	-0.77	-9.82	-0.42	8.2e-21	Schizophrenia;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg04234412	chr22:24373322	LOC391322	-0.72	-14.18	-0.55	3.5e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11866815	0.590	rs7186323	chr16:402078	C/T	cg07915516	chr16:377344	AXIN1	-0.44	-9.45	-0.4	1.75e-19	Body mass index;
LGG	cis	rs7512552	0.966	rs2274127	chr1:150252984	T/G	cg15654264	chr1:150340011	RPRD2	-0.4	-8.05	-0.35	7.09e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6066825	0.644	rs761272	chr20:47315581	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.07	0.35	5.97e-15	Colorectal cancer;
LGG	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg20991723	chr1:152506922	NA	0.73	14.93	0.57	2.01e-41	Hair morphology;
LGG	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9875589	0.509	rs7636901	chr3:14030958	G/A	cg19554555	chr3:13937349	NA	-0.53	-9.62	-0.41	4.44e-20	Ovarian reserve;
LGG	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.9	0.38	1.29e-17	Systolic blood pressure;
LGG	cis	rs2000999	0.514	rs17604662	chr16:72221464	A/G	cg04254540	chr16:71951199	KIAA0174	-0.57	-6.79	-0.3	3.47e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs4262150	0.810	rs72797251	chr5:152010999	G/A	cg12297329	chr5:152029980	NA	-0.8	-15.43	-0.58	1.22e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg23978390	chr7:1156363	C7orf50	0.56	9.44	0.4	1.78e-19	Longevity;Endometriosis;
LGG	cis	rs11874712	0.966	rs8093880	chr18:43666786	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs9557207	1.000	rs34647286	chr13:99865252	G/A	cg24509225	chr13:100037070	UBAC2	0.71	12.65	0.51	1.04e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg19761014	chr17:28927070	LRRC37B2	0.56	6.66	0.3	7.57e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg11502198	chr6:26597334	ABT1	0.86	11.83	0.48	2.2e-28	Small cell lung carcinoma;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.94	-0.31	1.3e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg03036210	chr16:89904091	SPIRE2	-0.63	-7.49	-0.33	3.61e-13	Skin colour saturation;
LGG	trans	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg00953403	chr17:74099816	EXOC7	-0.48	-8.03	-0.35	8.03e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg08949735	chr16:89699720	DPEP1	-0.36	-7.18	-0.32	2.77e-12	Hemoglobin concentration;
LGG	cis	rs208520	0.526	rs7771233	chr6:66819784	A/G	cg07460842	chr6:66804631	NA	-1.11	-29.84	-0.81	6.84e-110	Exhaled nitric oxide output;
LGG	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26913058	chr16:419975	MRPL28	0.38	6.65	0.3	8.13e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20073686	chr11:105481863	GRIA4	0.41	6.68	0.3	7.07e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.11e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg23461800	chr14:103021989	NA	-0.52	-8.39	-0.36	5.9e-16	Platelet count;
LGG	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg05926928	chr17:57297772	GDPD1	1.36	21.78	0.71	6.66e-73	Opioid sensitivity;
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.65	0.37	8.21e-17	Bipolar disorder;
LGG	cis	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.43	-0.56	2.91e-39	IgG glycosylation;
LGG	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-11.44	-0.47	7.59e-27	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.933	rs10810434	chr9:15713775	G/C	cg14451791	chr9:16040625	NA	-0.37	-9.42	-0.4	2.08e-19	Body mass index;
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg05484376	chr2:27715224	FNDC4	0.46	9.97	0.42	2.37e-21	Total body bone mineral density;
LGG	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg19774624	chr17:42201019	HDAC5	0.95	20.54	0.69	3.96e-67	Total body bone mineral density;
LGG	cis	rs4631830	0.683	rs11004409	chr10:51498019	G/C	cg16070123	chr10:51489643	NA	0.41	7.42	0.33	5.59e-13	Prostate-specific antigen levels;
LGG	cis	rs953387	0.869	rs1519525	chr2:136965117	C/T	cg07169764	chr2:136633963	MCM6	0.52	8.77	0.38	3.53e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg12310025	chr6:25882481	NA	-0.46	-7.44	-0.33	4.97e-13	Iron status biomarkers;
LGG	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.65e-19	Neuroticism;
LGG	cis	rs3806843	0.966	rs1030163	chr5:140185132	G/A	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2299587	0.552	rs10503644	chr8:17697376	A/G	cg18067069	chr8:17937731	ASAH1	-0.29	-6.89	-0.31	1.79e-11	Economic and political preferences;
LGG	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.84	0.51	1.65e-32	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.66	-0.34	1.13e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.746	rs10839429	chr11:49906845	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	cis	rs6540556	0.723	rs11119336	chr1:209930585	G/C	cg23920097	chr1:209922102	NA	-0.48	-8.15	-0.35	3.42e-15	Red blood cell count;
LGG	cis	rs896854	1.000	rs7003387	chr8:95961979	C/G	cg13393036	chr8:95962371	TP53INP1	-0.26	-6.89	-0.3	1.82e-11	Type 2 diabetes;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg24642844	chr7:1081250	C7orf50	-0.67	-8.56	-0.37	1.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-12.78	-0.51	2.95e-32	Chronic sinus infection;
LGG	cis	rs67478160	0.608	rs11160760	chr14:104248938	G/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.54	-0.33	2.55e-13	Schizophrenia;
LGG	cis	rs7166081	1.000	rs12324222	chr15:67581282	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	16.63	0.61	4.85e-49	Alzheimer's disease;
LGG	trans	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg25482853	chr8:67687455	SGK3	1.0	12.95	0.52	6.15e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.34	0.32	9.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs283228	0.550	rs541637	chr6:101783232	T/C	cg02011392	chr6:101847541	GRIK2	0.53	7.32	0.32	1.07e-12	Coenzyme Q10 levels;
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg18099408	chr3:52552593	STAB1	0.36	7.12	0.31	4.04e-12	Bipolar disorder;
LGG	cis	rs4622507	0.618	rs12917781	chr16:55070285	G/A	cg09947736	chr16:55091198	NA	0.77	11.65	0.48	1.12e-27	Social communication problems;
LGG	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs975722	0.516	rs7805063	chr7:117041069	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	8.5	0.37	2.66e-16	Coronary artery disease;
LGG	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.75	-0.51	4.04e-32	Response to antipsychotic treatment;
LGG	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs208520	1.000	rs208535	chr6:66962286	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs12200782	1.000	rs12204145	chr6:26600156	C/T	cg11502198	chr6:26597334	ABT1	-0.9	-7.91	-0.35	1.85e-14	Small cell lung carcinoma;
LGG	cis	rs4845570	0.749	rs11586446	chr1:151712488	A/G	cg07092448	chr1:151763213	TDRKH	-1.05	-14.67	-0.56	2.65e-40	Coronary artery disease;
LGG	cis	rs6032067	0.673	rs36019441	chr20:43892401	G/A	cg10761708	chr20:43804764	PI3	0.61	9.3	0.4	5.48e-19	Blood protein levels;
LGG	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.24	0.32	1.93e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs526231	0.543	rs62362541	chr5:102322448	G/A	cg23492399	chr5:102201601	PAM	-0.58	-9.05	-0.39	4.04e-18	Primary biliary cholangitis;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	8.11	0.35	4.49e-15	Longevity;
LGG	cis	rs10492096	1.000	rs11064218	chr12:6586261	C/T	cg13857086	chr12:6580257	VAMP1	0.64	9.17	0.39	1.57e-18	Hip geometry;
LGG	cis	rs7241530	0.595	rs36084769	chr18:75899991	C/T	cg14642773	chr18:75888474	NA	0.47	8.88	0.38	1.43e-17	Educational attainment (years of education);
LGG	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.4	0.58	1.59e-43	Total body bone mineral density;
LGG	cis	rs4742903	0.935	rs3818626	chr9:106856633	C/T	cg14250997	chr9:106856677	SMC2	0.41	8.67	0.37	7.25e-17	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1966248	0.543	rs6909803	chr6:134111198	C/T	cg25632230	chr6:134101081	NA	-0.34	-7.46	-0.33	4.31e-13	Coronary artery disease;
LGG	cis	rs1953600	0.870	rs2788295	chr10:81941007	C/G	cg04850286	chr10:81895943	PLAC9	0.44	9.94	0.42	3.02e-21	Sarcoidosis;
LGG	cis	rs11971779	0.617	rs66652773	chr7:139109573	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05025164	chr4:1340916	KIAA1530	0.58	10.42	0.44	5.43e-23	Obesity-related traits;
LGG	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg20848291	chr7:100343083	ZAN	0.45	7.14	0.31	3.65e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg03605463	chr16:89740564	NA	-0.4	-6.82	-0.3	2.85e-11	Vitiligo;
LGG	cis	rs4268898	0.662	rs2288074	chr2:24413595	C/T	cg06627628	chr2:24431161	ITSN2	-0.78	-12.7	-0.51	6.51e-32	Asthma;
LGG	cis	rs1555133	0.652	rs6141304	chr20:30989210	C/T	cg00028034	chr20:30779307	TSPYL3	0.33	6.73	0.3	5.18e-11	Monocyte count;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6460942	0.915	rs79232243	chr7:12459494	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-7.25	-0.32	1.75e-12	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	trans	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs1783925	0.959	rs671789	chr11:125294614	C/A	cg03464685	chr11:125439445	EI24	-0.59	-9.33	-0.4	4.46e-19	Formal thought disorder in schizophrenia;
LGG	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg16141378	chr3:129829833	LOC729375	0.35	7.88	0.34	2.41e-14	Neuroticism;
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg14092988	chr3:52407081	DNAH1	-0.27	-7.11	-0.31	4.56e-12	Electroencephalogram traits;
LGG	cis	rs6929812	0.605	rs12526495	chr6:27393871	G/A	cg18711553	chr6:27366782	ZNF391	-0.48	-9.25	-0.39	8.44e-19	Neuroticism (multi-trait analysis);
LGG	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.72	-0.38	4.9e-17	Cognitive function;
LGG	cis	rs66561647	0.895	rs9649959	chr8:128972721	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	-0.45	-7.87	-0.34	2.45e-14	Hemoglobin concentration;
LGG	cis	rs7546668	1.000	rs6685648	chr1:15825195	T/C	cg21858823	chr1:15850916	CASP9	0.37	7.05	0.31	6.75e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg11644478	chr21:40555479	PSMG1	-0.73	-13.19	-0.52	6.01e-34	Cognitive function;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg23758822	chr17:41437982	NA	0.86	15.72	0.59	5.98e-45	Menopause (age at onset);
LGG	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg24642439	chr20:33292090	TP53INP2	0.64	11.29	0.46	2.79e-26	Coronary artery disease;
LGG	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	15.42	0.58	1.33e-43	Smoking behavior;
LGG	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg19338460	chr6:170058176	WDR27	-0.83	-9.81	-0.41	9.17e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg24011408	chr12:48396354	COL2A1	0.48	7.69	0.34	8.97e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7917772	0.503	rs56397707	chr10:104302693	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17148978	chr1:151584446	SNX27	0.45	6.72	0.3	5.46e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg20607798	chr8:58055168	NA	0.67	7.32	0.32	1.1e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs9911578	1.000	rs9901181	chr17:56964271	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.77	0.59	3.9e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.66	-0.34	1.11e-13	Height;
LGG	cis	rs4919044	0.641	rs11187231	chr10:94736462	T/A	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.09	-0.31	4.92e-12	Coronary artery disease;
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg16359550	chr11:109292809	C11orf87	0.49	8.9	0.38	1.25e-17	Schizophrenia;
LGG	cis	rs2795502	1.000	rs2473119	chr10:43339038	A/T	cg27426351	chr10:43362370	NA	-0.55	-7.87	-0.34	2.55e-14	Blood protein levels;
LGG	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg03511173	chr18:77590860	NA	0.62	7.77	0.34	5.16e-14	Opioid sensitivity;
LGG	cis	rs7149337	1.000	rs8006432	chr14:51731306	A/T	cg23942311	chr14:51606299	NA	0.34	7.53	0.33	2.65e-13	Cancer;
LGG	trans	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg06521331	chr12:34319734	NA	0.44	7.66	0.34	1.09e-13	Bladder cancer;
LGG	cis	rs3862030	0.720	rs3740415	chr10:104232716	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.48	-0.4	1.36e-19	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.11e-49	Obesity-related traits;
LGG	trans	rs73198271	1.000	rs11776513	chr8:8609057	T/C	cg16141378	chr3:129829833	LOC729375	0.37	6.9	0.31	1.74e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4363385	0.818	rs11205174	chr1:153001230	C/T	cg13444842	chr1:152974279	SPRR3	0.43	8.89	0.38	1.4e-17	Inflammatory skin disease;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs7503807	0.515	rs12946217	chr17:78686566	C/A	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs10991814	1.000	rs79808025	chr9:93953419	C/A	cg14446406	chr9:93919335	NA	-0.75	-8.26	-0.36	1.51e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg02524346	chr8:600233	NA	0.99	10.02	0.42	1.62e-21	IgG glycosylation;
LGG	cis	rs11971779	0.680	rs10085901	chr7:139108989	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4601790	0.601	rs4930295	chr11:65390554	C/G	cg27068330	chr11:65405492	SIPA1	0.47	7.45	0.33	4.76e-13	Blood pressure (age interaction);
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg14668632	chr7:2872130	GNA12	-0.34	-6.81	-0.3	3.14e-11	Height;
LGG	cis	rs9486715	0.867	rs9373887	chr6:96957004	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.78	0.59	3.26e-45	Headache;
LGG	cis	rs283228	0.798	rs556996	chr6:101770479	A/C	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs758324	0.947	rs72793241	chr5:131240885	C/T	cg06307176	chr5:131281290	NA	-0.56	-9.32	-0.4	4.69e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7940866	0.770	rs10791104	chr11:130814893	A/T	cg12179176	chr11:130786555	SNX19	0.77	14.8	0.57	7.1e-41	Schizophrenia;
LGG	cis	rs17683430	0.702	rs116989257	chr22:32378613	A/G	cg00543991	chr22:32367038	NA	0.77	7.37	0.32	7.94e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.14e-27	Height;
LGG	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.18	0.32	2.83e-12	Lung cancer;
LGG	cis	rs3824867	0.879	rs4752837	chr11:47465955	G/A	cg20307385	chr11:47447363	PSMC3	0.48	7.59	0.33	1.77e-13	Mean corpuscular hemoglobin;
LGG	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg08885076	chr2:99613938	TSGA10	0.58	10.43	0.44	5.24e-23	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08280861	chr8:58055591	NA	0.62	7.81	0.34	3.99e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2455799	0.574	rs2455800	chr3:15701589	T/G	cg16303742	chr3:15540471	COLQ	-0.42	-8.34	-0.36	8.71e-16	Mean platelet volume;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs13191362	0.935	rs67673890	chr6:163107647	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.11	0.31	4.41e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs76419734	0.510	rs12504088	chr4:106662004	A/G	cg11477892	chr4:106580295	NA	-0.42	-6.89	-0.3	1.87e-11	Post bronchodilator FEV1;
LGG	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg16586182	chr3:47516702	SCAP	0.71	12.26	0.49	4.14e-30	Colorectal cancer;
LGG	cis	rs2408955	0.521	rs10875753	chr12:48557141	C/T	cg24011408	chr12:48396354	COL2A1	0.56	9.33	0.4	4.37e-19	Glycated hemoglobin levels;
LGG	cis	rs1909881	0.605	rs968962	chr8:96482283	T/C	cg04203453	chr8:96504381	NA	-0.62	-11.38	-0.47	1.26e-26	Obesity-related traits;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19723775	chr5:179050963	HNRNPH1	0.47	7.41	0.33	5.9e-13	Lung cancer;
LGG	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.26	-0.43	2.16e-22	Retinal vascular caliber;
LGG	cis	rs7267979	0.565	rs4815437	chr20:25584788	C/G	cg06421707	chr20:25228305	PYGB	-0.37	-7.61	-0.33	1.5700000000000001e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg21782813	chr7:2030301	MAD1L1	0.52	13.03	0.52	2.84e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	12.91	0.51	8.68e-33	Coronary artery disease;
LGG	cis	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg09307838	chr4:120376055	NA	0.8	13.51	0.53	2.73e-35	Corneal astigmatism;
LGG	cis	rs6032067	0.516	rs6032087	chr20:43902305	A/G	cg10761708	chr20:43804764	PI3	0.47	7.41	0.33	6.11e-13	Blood protein levels;
LGG	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.47	-0.37	3.22e-16	Cognitive function;
LGG	cis	rs68170813	0.559	rs58663672	chr7:106949444	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.58	-0.44	1.43e-23	Coronary artery disease;
LGG	cis	rs11785400	1.000	rs11785400	chr8:143730456	C/T	cg10596483	chr8:143751796	JRK	0.57	9.42	0.4	2.12e-19	Schizophrenia;
LGG	cis	rs11608355	0.846	rs35393419	chr12:109881809	C/T	cg05360138	chr12:110035743	NA	0.53	7.35	0.32	9.22e-13	Neuroticism;
LGG	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	7.44	0.33	4.93e-13	Thyroid stimulating hormone;
LGG	cis	rs11168618	0.846	rs11168586	chr12:48854012	C/T	cg24011408	chr12:48396354	COL2A1	0.5	8.12	0.35	4.38e-15	Adiponectin levels;
LGG	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg17201900	chr20:34330562	RBM39	-0.51	-6.88	-0.3	2e-11	Total cholesterol levels;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.04	-17.63	-0.63	1.32e-53	Alzheimer's disease;
LGG	trans	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg22232500	chr2:134024266	NCKAP5	0.55	7.83	0.34	3.31e-14	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg19223190	chr17:80058835	NA	0.44	8.57	0.37	1.51e-16	Life satisfaction;
LGG	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg17333051	chr19:2783644	SGTA	0.4	6.7	0.3	6.25e-11	Total cholesterol levels;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.77	0.3	3.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg20368463	chr18:77673604	PQLC1	-0.48	-8.49	-0.37	2.88e-16	Schizophrenia;
LGG	cis	rs4851266	1.000	rs13034176	chr2:100833913	G/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	2.07e-31	Motion sickness;
LGG	cis	rs73416724	1.000	rs70953680	chr6:43267831	G/A	cg26312998	chr6:43337775	ZNF318	0.59	7.99	0.35	1.07e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00986762	chr1:36107072	PSMB2	0.46	6.97	0.31	1.06e-11	Gut microbiome composition (summer);
LGG	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg14055004	chr2:241860995	NA	0.28	7.52	0.33	2.96e-13	Joint mobility (Beighton score);
LGG	cis	rs3859192	0.599	rs34933056	chr17:38162983	G/A	cg17467752	chr17:38218738	THRA	-0.58	-9.62	-0.41	4.25e-20	White blood cell count;
LGG	cis	rs7918232	0.882	rs10829190	chr10:27409555	C/T	cg14240646	chr10:27532245	ACBD5	-0.74	-10.6	-0.44	1.19e-23	Breast cancer;
LGG	cis	rs2404602	0.647	rs11852395	chr15:77087785	T/C	cg15268244	chr15:77196840	NA	0.49	10.4	0.44	6.81e-23	Blood metabolite levels;
LGG	cis	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg24375607	chr4:120327624	NA	0.41	6.77	0.3	3.83e-11	Diastolic blood pressure;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04353771	chr1:42928952	NA	0.44	7.81	0.34	3.94e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs72901758	0.768	rs11659046	chr17:76245718	G/A	cg26068271	chr17:76253126	NA	0.54	11.29	0.46	2.79e-26	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.18	0.32	2.75e-12	Longevity;
LGG	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg14227996	chr4:17616232	MED28	-0.52	-6.73	-0.3	5.14e-11	Opioid sensitivity;
LGG	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.79	-0.45	2.27e-24	Primary sclerosing cholangitis;
LGG	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.35e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg06532163	chr17:45867833	NA	0.55	8.39	0.36	6.15e-16	IgG glycosylation;
LGG	cis	rs6546550	0.901	rs10167142	chr2:70062360	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.01	-0.35	9.64e-15	Prevalent atrial fibrillation;
LGG	trans	rs6787172	0.728	rs1104289	chr3:157970694	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	3.06e-17	Subjective well-being;
LGG	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg08603382	chr10:743973	NA	0.4	7.41	0.33	6.05e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.5	-0.33	3.32e-13	Personality dimensions;
LGG	trans	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg11441553	chr12:57614120	NXPH4	-0.61	-7.64	-0.33	1.22e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs60180747	1.000	rs11636809	chr15:66729927	T/C	cg07575407	chr15:66541975	MEGF11	0.35	6.97	0.31	1.09e-11	Testicular germ cell tumor;
LGG	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg09998033	chr7:158218633	PTPRN2	-0.5	-8.99	-0.39	6.56e-18	Obesity-related traits;
LGG	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.45	0.37	3.81e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07157834	chr1:205819609	PM20D1	0.74	16.71	0.61	2.26e-49	Menarche (age at onset);
LGG	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.93	-0.54	4.4e-37	Extrinsic epigenetic age acceleration;
LGG	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21659725	chr3:3221576	CRBN	0.75	11.86	0.48	1.66e-28	Resting heart rate;
LGG	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.93e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	trans	rs2562456	0.876	rs2681395	chr19:21738140	T/C	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg26138144	chr22:38071188	LGALS1	0.67	15.44	0.58	1.15e-43	Fat distribution (HIV);
LGG	cis	rs9287719	0.781	rs6732671	chr2:10759149	T/G	cg02196655	chr2:10830764	NOL10	-0.47	-8.16	-0.35	3.12e-15	Prostate cancer;
LGG	trans	rs11875185	0.510	rs75398401	chr18:55649386	C/G	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.9	-0.42	4.46e-21	Body mass index;
LGG	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00204512	chr16:28754710	NA	0.25	6.91	0.31	1.64e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg18681998	chr4:17616180	MED28	0.88	18.8	0.66	5.5099999999999996e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.02	-0.49	3.81e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.68	-0.44	6.19e-24	Vitiligo;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.38	-0.53	9.48e-35	Personality dimensions;
LGG	cis	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg21775007	chr8:11205619	TDH	0.82	14.49	0.56	1.66e-39	Retinal vascular caliber;
LGG	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02475777	chr4:1388615	CRIPAK	-0.6	-10.83	-0.45	1.62e-24	Longevity;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg04025307	chr7:1156635	C7orf50	0.55	10.3	0.43	1.57e-22	Longevity;Endometriosis;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg06719900	chr11:109292894	C11orf87	0.44	8.53	0.37	2.11e-16	Schizophrenia;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.598	rs793470	chr3:99548274	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	8.3	0.36	1.13e-15	Axial length;
LGG	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.58	-0.5	1.92e-31	Bipolar disorder;
LGG	cis	rs919433	0.713	rs55642934	chr2:198491110	C/T	cg00792783	chr2:198669748	PLCL1	0.54	8.38	0.36	6.27e-16	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.67	-0.37	7.61e-17	Aortic root size;
LGG	cis	rs1008375	0.966	rs6449325	chr4:17699509	C/T	cg02297831	chr4:17616191	MED28	-0.4	-7.32	-0.32	1.09e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs894344	0.748	rs16905190	chr8:135598265	C/T	cg17885191	chr8:135476712	NA	-0.39	-6.72	-0.3	5.32e-11	Systolic blood pressure;
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs9515201	0.859	rs9515199	chr13:111033704	C/T	cg06243866	chr13:111019493	COL4A2	0.58	11.29	0.46	2.77e-26	White matter hyperintensity burden;
LGG	cis	rs11771526	0.792	rs17161105	chr7:32299187	T/C	cg27532318	chr7:32358331	NA	0.73	7.59	0.33	1.75e-13	Body mass index;
LGG	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg24110177	chr3:50126178	RBM5	-0.58	-8.85	-0.38	1.91e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg07148914	chr20:33460835	GGT7	-0.48	-7.84	-0.34	3.1e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs17433780	0.964	rs10493821	chr1:89475135	C/T	cg09516651	chr1:89888402	LOC400759	0.73	16.86	0.62	4.43e-50	Carotid intima media thickness;
LGG	cis	rs7927592	0.763	rs7129248	chr11:68263276	A/T	cg16797656	chr11:68205561	LRP5	0.52	10.09	0.42	9.18e-22	Total body bone mineral density;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg24846343	chr22:24311635	DDTL	0.57	10.76	0.45	3.06e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.84	-0.45	1.45e-24	Morning vs. evening chronotype;
LGG	cis	rs12367572	0.965	rs10785539	chr12:45233023	G/C	cg04608330	chr12:45269318	NELL2	-0.62	-11.1	-0.46	1.57e-25	Gut microbiome composition (summer);
LGG	trans	rs4942242	0.763	rs7326281	chr13:44233186	G/A	cg19169023	chr15:41853346	TYRO3	-0.46	-9.15	-0.39	1.82e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1568889	0.838	rs3812738	chr11:28129982	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.4	0.67	8.45e-62	Bipolar disorder;
LGG	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.32	-0.4	4.69e-19	Height;
LGG	cis	rs7617773	0.925	rs35942721	chr3:48173069	C/T	cg11946769	chr3:48343235	NME6	0.66	10.23	0.43	2.78e-22	Coronary artery disease;
LGG	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-10.99	-0.45	4.07e-25	Morning vs. evening chronotype;
LGG	cis	rs8017423	0.904	rs11623741	chr14:90804474	C/T	cg04374321	chr14:90722782	PSMC1	0.85	17.31	0.63	3.87e-52	Mortality in heart failure;
LGG	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	23.81	0.74	1.98e-82	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1712517	0.566	rs1163073	chr10:105022934	C/T	cg04362960	chr10:104952993	NT5C2	0.48	8.33	0.36	9.52e-16	Migraine;
LGG	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24182603	chr12:111843578	SH2B3	0.49	7.33	0.32	1.02e-12	Hip circumference;
LGG	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg15316289	chr22:50310904	ALG12;CRELD2	0.45	6.83	0.3	2.73e-11	Schizophrenia;
LGG	cis	rs7143963	0.636	rs2180393	chr14:103293845	T/C	cg23020514	chr14:103360112	TRAF3	0.41	8.39	0.36	6.12e-16	Body mass index;
LGG	cis	rs2040771	0.774	rs9604935	chr22:19211665	C/T	cg02655711	chr22:19163373	SLC25A1	0.47	8.39	0.36	5.85e-16	Metabolite levels (small molecules and protein measures);
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.24	0.36	1.73e-15	Prudent dietary pattern;
LGG	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg24375607	chr4:120327624	NA	0.51	8.68	0.37	7.02e-17	Corneal astigmatism;
LGG	cis	rs10479542	0.559	rs9885443	chr5:178962918	G/A	cg14851468	chr5:179071604	C5orf60	0.47	7.28	0.32	1.42e-12	Lung cancer;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3092073	0.624	rs3848714	chr20:44547176	T/C	cg27529037	chr20:44575021	PCIF1	0.4	7.47	0.33	4.01e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06470251	chr20:60548479	NA	0.47	8.01	0.35	9.09e-15	Body mass index;
LGG	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg26655873	chr3:72818019	SHQ1	0.34	6.77	0.3	3.88e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg04166393	chr7:2884313	GNA12	0.47	9.39	0.4	2.8e-19	Height;
LGG	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg02002194	chr4:3960332	NA	-0.44	-8.0	-0.35	9.9e-15	Monocyte count;
LGG	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg26384229	chr12:38710491	ALG10B	0.94	22.15	0.72	1.21e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg06453172	chr10:134556979	INPP5A	-0.42	-7.01	-0.31	8.68e-12	Migraine;
LGG	trans	rs7210837	0.591	rs12944244	chr17:16790430	T/C	cg11294312	chr17:28900046	NA	-0.73	-9.1	-0.39	2.8e-18	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg01059449	chr18:44338099	ST8SIA5	0.32	7.11	0.31	4.29e-12	Personality dimensions;
LGG	trans	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg09048205	chr5:1608656	LOC728613	-0.52	-8.44	-0.37	4.15e-16	Breast cancer;
LGG	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg00290607	chr11:67383545	NA	0.5	8.79	0.38	2.98e-17	Mean corpuscular volume;
LGG	cis	rs7226408	0.857	rs72887044	chr18:34481573	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02398342	chr17:80708632	TBCD;FN3K	-0.51	-9.91	-0.42	3.95e-21	Glycated hemoglobin levels;
LGG	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg21366198	chr4:185655624	MLF1IP	-0.45	-7.93	-0.35	1.61e-14	Kawasaki disease;
LGG	cis	rs7666738	0.830	rs10005120	chr4:99038200	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.1e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs11225247	0.881	rs77227803	chr11:102255684	T/C	cg06323957	chr11:102217781	BIRC2	0.8	6.81	0.3	3.11e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg13607699	chr17:42295918	UBTF	0.61	10.29	0.43	1.62e-22	Total body bone mineral density;
LGG	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.53	0.72	1.89e-76	Breast cancer;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-10.58	-0.44	1.43e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	7.02	0.31	7.95e-12	Height;
LGG	cis	rs4888262	0.514	rs8048239	chr16:74578317	A/T	cg01733217	chr16:74700730	RFWD3	0.82	16.38	0.61	6.42e-48	Testicular germ cell tumor;
LGG	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg24011408	chr12:48396354	COL2A1	0.5	8.0	0.35	1.02e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7226408	0.857	rs2166295	chr18:34488481	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2412208	0.796	rs3986512	chr1:7090699	C/T	cg20434152	chr1:7120926	CAMTA1	0.42	7.17	0.32	3.02e-12	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs709400	0.628	rs1989565	chr14:103862193	G/A	cg26031613	chr14:104095156	KLC1	-0.79	-13.98	-0.54	2.62e-37	Body mass index;
LGG	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg19748678	chr4:122722346	EXOSC9	0.66	13.23	0.52	4.05e-34	Type 2 diabetes;
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg01765077	chr12:122356316	WDR66	0.29	7.59	0.33	1.78e-13	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs258892	0.895	rs10052974	chr5:72067869	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg23815491	chr16:72088622	HP	0.5	11.26	0.46	3.58e-26	Fibrinogen levels;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.24	-0.39	9.07e-19	Life satisfaction;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg11473876	chr11:109292803	C11orf87	0.48	9.52	0.4	9.57e-20	Schizophrenia;
LGG	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg04398451	chr17:18023971	MYO15A	0.86	19.99	0.68	1.55e-64	Total body bone mineral density;
LGG	cis	rs10744422	0.800	rs2343110	chr12:123343571	T/G	cg25930673	chr12:123319894	HIP1R	-0.75	-9.39	-0.4	2.8e-19	Schizophrenia;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1062177	1.000	rs2915869	chr5:151171509	C/T	cg00977110	chr5:151150581	G3BP1	0.5	8.03	0.35	7.96e-15	Preschool internalizing problems;
LGG	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.71e-28	Intelligence (multi-trait analysis);
LGG	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg15704280	chr7:45808275	SEPT13	-0.65	-9.16	-0.39	1.7e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg12310025	chr6:25882481	NA	-0.6	-11.35	-0.47	1.65e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.25	0.32	1.8e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	cis	rs1386478	0.669	rs13094677	chr3:113818348	A/G	cg14431476	chr3:113822413	NA	-0.49	-7.72	-0.34	7.07e-14	Crohn's disease and psoriasis;
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.13	0.39	2.17e-18	Colorectal cancer;
LGG	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg09307838	chr4:120376055	NA	0.67	11.06	0.46	2.25e-25	Corneal astigmatism;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg11473876	chr11:109292803	C11orf87	-0.46	-9.1	-0.39	2.74e-18	Schizophrenia;
LGG	cis	rs9649213	0.614	rs1006169	chr7:97938443	A/G	cg09267113	chr7:98030324	BAIAP2L1	0.47	8.05	0.35	7.2e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6426558	0.559	rs2813947	chr1:227459413	G/T	cg10327440	chr1:227177885	CDC42BPA	0.62	10.23	0.43	2.77e-22	Neutrophil percentage of white cells;
LGG	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg03342759	chr3:160939853	NMD3	0.45	7.42	0.33	5.54e-13	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Bladder cancer;
LGG	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.38	-0.36	6.31e-16	Neuroticism;
LGG	trans	rs1814175	0.562	rs1794130	chr11:49903764	T/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.85	-0.54	9.95e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs3087591	0.919	rs2953004	chr17:29502723	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	13.94	0.54	3.88e-37	Hip circumference;
LGG	cis	rs13260300	0.571	rs3750238	chr8:75540855	T/C	cg22993706	chr8:75542856	NA	0.52	10.72	0.45	4.14e-24	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg13880726	chr7:1868755	MAD1L1	0.44	7.54	0.33	2.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10227331	0.521	rs17667159	chr7:157296065	A/C	cg24455158	chr7:157314073	NA	0.4	7.03	0.31	7.69e-12	Inattentive symptoms;
LGG	cis	rs68170813	0.523	rs75999022	chr7:107017135	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.05	-0.42	1.26e-21	Coronary artery disease;
LGG	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11229555	0.609	rs12286421	chr11:58174898	A/G	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2307022	0.586	rs1124585	chr16:68401740	C/T	cg07273125	chr16:68295692	NA	0.44	9.91	0.42	3.87e-21	Body mass index;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.09	-0.42	8.7e-22	Obesity-related traits;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg02297831	chr4:17616191	MED28	0.54	9.89	0.42	4.88e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs250677	0.687	rs1422581	chr5:148437386	C/T	cg18129178	chr5:148520854	ABLIM3	0.42	6.96	0.31	1.19e-11	Breast cancer;
LGG	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg12011299	chr4:100065546	ADH4	0.4	8.51	0.37	2.52e-16	Alcohol dependence;
LGG	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.5	-12.36	-0.5	1.57e-30	Tonsillectomy;
LGG	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.98	-0.35	1.16e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07219400	chr15:31664460	KLF13	0.4	6.69	0.3	6.6e-11	Pancreatic cancer;
LGG	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.32	-0.32	1.12e-12	HDL cholesterol;
LGG	cis	rs11785400	0.793	rs2976399	chr8:143746050	C/T	cg10596483	chr8:143751796	JRK	0.53	8.17	0.35	3e-15	Schizophrenia;
LGG	cis	rs9810089	0.843	rs650326	chr3:136037707	G/A	cg21827317	chr3:136751795	NA	0.47	8.25	0.36	1.66e-15	Gestational age at birth (child effect);
LGG	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.82	-0.3	2.78e-11	Mood instability;
LGG	trans	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg08344181	chr3:125677491	NA	-0.81	-8.03	-0.35	8.13e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9486719	0.895	rs12190520	chr6:96928620	A/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.7e-23	Migraine;Coronary artery disease;
LGG	cis	rs56399783	0.901	rs73047393	chr7:2775879	C/T	cg19731401	chr7:2775893	GNA12	0.37	7.61	0.33	1.51e-13	Childhood ear infection;
LGG	trans	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg10756647	chr7:56101905	PSPH	-0.79	-9.56	-0.41	6.99e-20	Diabetic kidney disease;
LGG	cis	rs3784262	0.740	rs2119859	chr15:58254745	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.24	-0.32	1.93e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs897984	0.762	rs2305880	chr16:30999462	T/C	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs714031	0.902	rs4820388	chr22:40070642	C/G	cg21377881	chr22:40064566	CACNA1I	-0.62	-14.76	-0.57	1.07e-40	Schizophrenia;
LGG	cis	rs7394190	1.000	rs10824026	chr10:75421208	A/G	cg07699608	chr10:75541558	CHCHD1	0.45	6.66	0.3	7.78e-11	Incident atrial fibrillation;
LGG	cis	rs1577917	0.958	rs4707223	chr6:86509802	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.17	-0.39	1.57e-18	Response to antipsychotic treatment;
LGG	cis	rs17767392	0.881	rs10138557	chr14:72061718	C/T	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.25	-0.39	8.42e-19	Mitral valve prolapse;
LGG	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg09222892	chr1:25734099	RHCE	-0.42	-8.64	-0.37	9.07e-17	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.81	-0.3	2.99e-11	Menopause (age at onset);
LGG	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.21e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1957429	0.520	rs2181127	chr14:65336455	C/T	cg23373153	chr14:65346875	NA	-1.04	-9.94	-0.42	3.2e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs7169223	0.653	rs1564499	chr15:79084808	C/T	cg03762349	chr15:79060523	ADAMTS7	0.37	7.42	0.33	5.55e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg26384229	chr12:38710491	ALG10B	0.97	22.0	0.71	6.12e-74	Bladder cancer;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25072359	chr17:41440525	NA	0.51	10.07	0.42	1.02e-21	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs10892173	0.904	rs10892172	chr11:117672474	C/A	cg07621104	chr11:117668040	DSCAML1	0.46	6.99	0.31	9.83e-12	Myopia;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg00689492	chr4:1303491	MAEA	-0.42	-7.44	-0.33	4.97e-13	Obesity-related traits;
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.51	9.07	0.39	3.31e-18	Total body bone mineral density;
LGG	cis	rs7552404	0.656	rs11161792	chr1:76336746	C/T	cg10523679	chr1:76189770	ACADM	0.7	10.99	0.46	3.85e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg06074448	chr4:187884817	NA	-0.59	-13.18	-0.52	6.83e-34	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs747782	0.527	rs2270993	chr11:48145166	G/A	cg15704280	chr7:45808275	SEPT13	0.7	7.24	0.32	1.85e-12	Intraocular pressure;
LGG	trans	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26306683	chr17:18585705	ZNF286B	0.49	9.31	0.4	5.34e-19	Educational attainment (years of education);
LGG	cis	rs1829883	1.000	rs2461991	chr5:98793332	C/G	cg08333243	chr5:99726346	NA	-0.39	-7.48	-0.33	3.65e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg24130564	chr14:104152367	KLC1	-0.36	-6.69	-0.3	6.47e-11	Reticulocyte count;
LGG	cis	rs3126085	0.935	rs12407156	chr1:152295942	A/G	cg26876637	chr1:152193138	HRNR	-0.49	-7.07	-0.31	5.75e-12	Atopic dermatitis;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg06873352	chr17:61820015	STRADA	-0.59	-10.31	-0.43	1.39e-22	Prudent dietary pattern;
LGG	cis	rs7572733	0.534	rs7572123	chr2:198769637	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.19	0.46	7.05e-26	Dermatomyositis;
LGG	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg18131467	chr2:239335373	ASB1	0.99	21.55	0.71	7.88e-72	Multiple system atrophy;
LGG	trans	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg06521331	chr12:34319734	NA	0.51	9.41	0.4	2.33e-19	Morning vs. evening chronotype;
LGG	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg20913747	chr6:44695427	NA	0.65	10.99	0.45	4.13e-25	Total body bone mineral density;
LGG	cis	rs7853377	0.723	rs4147133	chr9:86559104	C/T	cg12437157	chr9:86433764	GKAP1	0.4	7.05	0.31	6.72e-12	Height;
LGG	cis	rs6964587	0.867	rs12704637	chr7:91874686	C/T	cg17063962	chr7:91808500	NA	0.53	9.26	0.4	7.69e-19	Breast cancer;
LGG	cis	rs1467026	0.563	rs12629928	chr3:12811796	C/T	cg05775895	chr3:12838266	CAND2	0.73	13.32	0.53	1.67e-34	P wave duration;
LGG	cis	rs1107366	0.722	rs35331719	chr3:125907392	C/A	cg06827562	chr3:125932279	NA	0.58	13.52	0.53	2.5e-35	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09755102	chr1:33283495	S100PBP;YARS	0.58	9.22	0.39	1.06e-18	Gut microbiome composition (summer);
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26897989	chr16:1907736	C16orf73	-0.85	-13.94	-0.54	3.89e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Vitiligo;
LGG	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.07	-25.8	-0.77	1.25e-91	Cognitive ability;
LGG	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.39	0.36	5.94e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs10489202	0.908	rs6692861	chr1:168079553	G/C	cg24449463	chr1:168025552	DCAF6	-0.65	-10.31	-0.43	1.39e-22	Schizophrenia;
LGG	cis	rs2070433	0.534	rs2839269	chr21:47891491	A/G	cg12379764	chr21:47803548	PCNT	0.46	7.1	0.31	4.83e-12	Lymphocyte counts;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg09873164	chr1:152488093	CRCT1	0.64	15.68	0.59	9.05e-45	Hair morphology;
LGG	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg09021430	chr5:549028	NA	-0.81	-12.83	-0.51	1.8e-32	Obesity-related traits;
LGG	cis	rs7236492	0.935	rs60115988	chr18:77226571	G/A	cg15644404	chr18:77186268	NFATC1	-0.76	-9.39	-0.4	2.72e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg22907277	chr7:1156413	C7orf50	0.45	7.52	0.33	2.78e-13	Longevity;Endometriosis;
LGG	cis	rs8114671	0.740	rs3761141	chr20:33737824	A/C	cg24642439	chr20:33292090	TP53INP2	0.52	8.43	0.36	4.28e-16	Height;
LGG	cis	rs35306767	0.715	rs12777801	chr10:1036285	T/A	cg26597838	chr10:835615	NA	0.54	6.92	0.31	1.52e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs34599045	0.522	rs71626743	chr1:152941289	A/G	cg07796016	chr1:152779584	LCE1C	-0.89	-7.67	-0.34	1.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18455759	chr8:126443767	TRIB1	0.44	7.57	0.33	2.01e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6909430	0.731	rs6569342	chr6:98613835	C/T	cg12860156	chr6:98744658	NA	-0.39	-7.07	-0.31	5.84e-12	Quantitative traits;
LGG	cis	rs12367572	1.000	rs7295923	chr12:45269284	C/T	cg03114573	chr12:45410052	DBX2	-0.52	-8.86	-0.38	1.74e-17	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg08344181	chr3:125677491	NA	-0.82	-7.62	-0.33	1.48e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg06848047	chr4:90757629	SNCA	-0.4	-7.62	-0.33	1.43e-13	Dementia with Lewy bodies;
LGG	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg23920097	chr1:209922102	NA	0.5	8.92	0.38	1.06e-17	Red blood cell count;
LGG	trans	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-7.82	-0.34	3.53e-14	Joint mobility (Beighton score);
LGG	cis	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg06521331	chr12:34319734	NA	-0.51	-8.66	-0.37	7.81e-17	Resting heart rate;
LGG	cis	rs12496230	1.000	rs12496230	chr3:66829908	A/G	cg04995300	chr3:66848608	NA	0.52	7.71	0.34	7.81e-14	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6735179	1.000	rs59771193	chr2:1778157	C/T	cg10160682	chr2:1713001	PXDN	-0.44	-7.4	-0.33	6.67e-13	Response to antipsychotic treatment;
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg20003494	chr4:90757398	SNCA	-0.41	-8.07	-0.35	6.11e-15	Dementia with Lewy bodies;
LGG	cis	rs3617	0.625	rs2071042	chr3:52864584	A/G	cg11645453	chr3:52864694	ITIH4	0.43	7.31	0.32	1.14e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4740619	0.933	rs11789563	chr9:15699817	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.34	-0.43	1.07e-22	Body mass index;
LGG	cis	rs17221829	0.733	rs10765227	chr11:89385116	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.12	-0.39	2.26e-18	Anxiety in major depressive disorder;
LGG	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg04731861	chr2:219085781	ARPC2	0.46	11.22	0.46	5.38e-26	Colorectal cancer;
LGG	cis	rs9894429	0.738	rs8077038	chr17:79577127	T/G	cg18240062	chr17:79603768	NPLOC4	-0.82	-15.45	-0.58	1.02e-43	Eye color traits;
LGG	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg03894339	chr8:19674705	INTS10	0.63	10.33	0.43	1.17e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13294100	0.894	rs10810811	chr9:17584225	G/A	cg11213383	chr9:17579734	SH3GL2	-0.63	-11.58	-0.47	2.15e-27	Parkinson's disease;
LGG	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg24308560	chr3:49941425	MST1R	-0.22	-6.9	-0.31	1.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6546550	0.901	rs7573442	chr2:70154037	G/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.95	-0.35	1.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs858239	0.600	rs7799422	chr7:23128413	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.45	0.33	4.48e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg03264133	chr6:25882463	NA	0.48	8.0	0.35	1.01e-14	Iron status biomarkers;
LGG	cis	rs735396	0.770	rs2464196	chr12:121435427	G/A	cg14101638	chr12:121416612	HNF1A	0.39	7.99	0.35	1.05e-14	N-glycan levels;
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.45e-12	Bipolar disorder;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.35	-6.77	-0.3	4.01e-11	Longevity;Endometriosis;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.47	-8.09	-0.35	5.12e-15	Renal function-related traits (BUN);
LGG	cis	rs11514810	1.000	rs57444112	chr7:1430892	T/C	cg01003211	chr7:1472830	NA	-0.59	-8.26	-0.36	1.57e-15	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg14926445	chr8:58193284	C8orf71	-0.7	-9.16	-0.39	1.65e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.865	rs28634456	chr4:120375778	A/G	cg09307838	chr4:120376055	NA	0.82	13.53	0.53	2.1e-35	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27211345	chr12:31227271	DDX11	0.46	7.09	0.31	4.92e-12	Gut microbiome composition (summer);
LGG	cis	rs7119	0.717	rs12910975	chr15:77817487	C/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg06697600	chr4:7070879	GRPEL1	0.51	7.94	0.35	1.54e-14	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.69	12.81	0.51	2.18e-32	Obesity-related traits;
LGG	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.94	-0.38	9.63e-18	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19229622	chr11:47291485	MADD	0.55	8.74	0.38	4.32e-17	Gut microbiome composition (summer);
LGG	cis	rs876084	0.505	rs7840588	chr8:121108256	G/T	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.29	0.5	3.13e-30	Lung cancer in ever smokers;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.37	0.36	7.1e-16	Personality dimensions;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg06558623	chr16:89946397	TCF25	1.18	12.92	0.51	8.28e-33	Skin colour saturation;
LGG	cis	rs708547	0.836	rs781554	chr4:57717537	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.16	-0.32	3.1e-12	Response to bleomycin (chromatid breaks);
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.13	-0.43	6.31e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.06	-0.31	6.31e-12	Neuroticism;
LGG	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg04132472	chr17:19861366	AKAP10	0.26	7.28	0.32	1.45e-12	Schizophrenia;
LGG	cis	rs7215564	0.908	rs35434628	chr17:78714760	C/T	cg06153925	chr17:78755379	RPTOR	0.38	6.9	0.31	1.74e-11	Myopia (pathological);
LGG	trans	rs1997103	0.911	rs11238361	chr7:55395981	A/G	cg20935933	chr6:143382018	AIG1	0.58	9.08	0.39	3.17e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3782089	1.000	rs3782089	chr11:65336819	C/T	cg21890820	chr11:65308645	LTBP3	0.71	7.76	0.34	5.38e-14	Height;
LGG	cis	rs4727027	0.704	rs2269972	chr7:148914047	C/T	cg23583168	chr7:148888333	NA	0.9	18.2	0.65	3.13e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs537930	0.885	rs299371	chr5:134339715	T/C	cg24576358	chr5:134350122	NA	0.48	10.19	0.43	3.79e-22	Height;
LGG	cis	rs7215564	0.818	rs4889878	chr17:78662479	G/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.04	-0.35	7.33e-15	Myopia (pathological);
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	11.06	0.46	2.11e-25	Total body bone mineral density;
LGG	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.4	-0.33	6.43e-13	Testicular germ cell tumor;
LGG	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg27087555	chr16:88793112	FAM38A	-1.35	-20.79	-0.69	2.64e-68	Plateletcrit;
LGG	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg20891283	chr12:69753455	YEATS4	0.5	7.81	0.34	3.97e-14	Response to diuretic therapy;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg14893161	chr1:205819251	PM20D1	0.89	20.49	0.69	7.15e-67	Menarche (age at onset);
LGG	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg02228329	chr11:64053129	BAD;GPR137	-0.53	-6.97	-0.31	1.07e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg16586182	chr3:47516702	SCAP	0.77	15.09	0.57	3.83e-42	Colorectal cancer;
LGG	cis	rs9902453	0.740	rs2244247	chr17:28110174	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs74781061	0.585	rs8041068	chr15:74730206	G/A	cg02384859	chr15:74862662	ARID3B	-0.38	-6.67	-0.3	7.17e-11	Endometriosis;
LGG	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg26408565	chr15:76604113	ETFA	-0.38	-6.64	-0.3	8.61e-11	Blood metabolite levels;
LGG	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.22	0.58	1.06e-42	Mean platelet volume;
LGG	trans	rs2562456	0.833	rs62110367	chr19:21548631	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.6	-0.33	1.66e-13	Pain;
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg19847130	chr8:10466454	RP1L1	-0.31	-7.08	-0.31	5.53e-12	Neuroticism;
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	4.94e-22	Intelligence (multi-trait analysis);
LGG	trans	rs10432169	1	rs10432169	chr18:31347098	C/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.66	-0.37	7.83e-17	Subjective well-being;
LGG	trans	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg24174307	chr17:73043075	ATP5H;KCTD2	0.37	6.88	0.3	1.96e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg09165964	chr15:75287851	SCAMP5	-1.05	-22.68	-0.73	3.91e-77	Blood trace element (Zn levels);
LGG	cis	rs12493885	0.725	rs61793489	chr3:153731156	T/C	cg12800244	chr3:153838788	SGEF	-0.8	-8.96	-0.38	8.18e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg08601574	chr20:25228251	PYGB	0.37	7.36	0.32	8.6e-13	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg21775007	chr8:11205619	TDH	0.46	7.62	0.33	1.49e-13	Mood instability;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.63	-0.41	4.07e-20	Lung cancer;
LGG	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg25986240	chr4:9926439	SLC2A9	-0.57	-10.64	-0.44	8.26e-24	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00149659	chr3:10157352	C3orf10	0.82	10.5	0.44	2.84e-23	Alzheimer's disease;
LGG	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.71	0.3	5.73e-11	Parkinson's disease;
LGG	cis	rs6456042	0.965	rs3127425	chr6:166539227	A/G	cg11088901	chr6:166572345	T	-0.35	-7.38	-0.32	7.56e-13	Asthma;
LGG	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg02227867	chr8:22457446	C8orf58	0.43	8.0	0.35	1.03e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3747547	0.892	rs72724200	chr9:37952144	G/A	cg13774184	chr9:37916125	SHB	-0.7	-6.85	-0.3	2.38e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.75	-0.45	3.25e-24	Lung cancer;
LGG	cis	rs9831754	0.756	rs6548554	chr3:78423185	C/T	cg06138941	chr3:78371609	NA	-0.79	-15.48	-0.58	7.06e-44	Calcium levels;
LGG	cis	rs1800788	0.945	rs6536022	chr4:155453460	A/G	cg20735720	chr4:155535218	FGG	-0.48	-6.65	-0.3	8.34e-11	Fibrinogen;
LGG	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg03175030	chr11:2018143	H19;MIR675	-0.42	-7.69	-0.34	8.88e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs13177180	0.671	rs10079000	chr5:114940200	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.45	10.02	0.42	1.67e-21	Conotruncal heart defects (inherited effects);
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg13264159	chr8:625131	ERICH1	-1.05	-11.0	-0.46	3.61e-25	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs818427	0.964	rs351767	chr5:112200098	A/G	cg07820702	chr5:112228657	REEP5	0.36	6.73	0.3	5.13e-11	Total body bone mineral density;
LGG	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg24110177	chr3:50126178	RBM5	-0.45	-7.11	-0.31	4.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.04	0.72	3.85e-74	Bladder cancer;
LGG	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg17691542	chr6:26056736	HIST1H1C	0.86	13.78	0.54	1.9e-36	Iron status biomarkers;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03517284	chr6:25882590	NA	-0.49	-9.32	-0.4	4.79e-19	Blood metabolite levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07017284	chr1:173684020	KLHL20	-0.47	-7.29	-0.32	1.36e-12	Systemic lupus erythematosus;
LGG	cis	rs28735056	0.592	rs2277725	chr18:77694168	A/C	cg20368463	chr18:77673604	PQLC1	-0.62	-11.43	-0.47	8.1e-27	Schizophrenia;
LGG	cis	rs17221829	0.733	rs11018686	chr11:89365241	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.13	-0.39	2.19e-18	Anxiety in major depressive disorder;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.13	0.52	1.09e-33	Prudent dietary pattern;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12379764	chr21:47803548	PCNT	0.43	7.37	0.32	7.81e-13	Testicular germ cell tumor;
LGG	cis	rs988958	0.679	rs10171410	chr2:42224842	A/G	cg27252766	chr2:42229092	NA	0.58	8.66	0.37	7.87e-17	Hypospadias;
LGG	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg08344181	chr3:125677491	NA	-0.69	-7.3	-0.32	1.28e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs3780486	0.757	rs10758189	chr9:33125804	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	24.61	0.75	3.96e-86	IgG glycosylation;
LGG	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.51	-0.47	3.97e-27	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg04166393	chr7:2884313	GNA12	0.47	9.36	0.4	3.45e-19	Height;
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg26818010	chr10:134567672	INPP5A	-0.63	-9.87	-0.42	5.52e-21	Migraine;
LGG	cis	rs4472734	1.000	rs4615815	chr1:214604236	A/G	cg00063699	chr1:214624242	PTPN14	-0.35	-6.97	-0.31	1.1e-11	Height;
LGG	trans	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.38	8.04	0.35	7.45e-15	Obesity-related traits;
LGG	cis	rs504918	1.000	rs11710228	chr3:124112105	G/A	cg05766129	chr3:123988013	KALRN	-0.39	-6.98	-0.31	1.02e-11	Schizophrenia;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12432903	chr7:1882776	MAD1L1	0.55	8.9	0.38	1.25e-17	Bipolar disorder;
LGG	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg02002194	chr4:3960332	NA	-0.51	-9.54	-0.41	8.5e-20	Retinal vascular caliber;
LGG	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg19183879	chr15:85880815	NA	0.41	7.42	0.33	5.71e-13	Bulimia nervosa;
LGG	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg23796481	chr11:64053134	BAD;GPR137	-0.68	-12.53	-0.5	3.36e-31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.22	-0.36	2.01e-15	Personality dimensions;
LGG	cis	rs36051895	0.632	rs7469563	chr9:5139489	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-15.76	-0.59	3.96e-45	Pediatric autoimmune diseases;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg06685724	chr7:23720386	C7orf46	0.41	9.64	0.41	3.57e-20	Schizophrenia;
LGG	cis	rs950027	0.620	rs35861938	chr15:45637343	T/C	cg26924012	chr15:45694286	SPATA5L1	0.69	12.48	0.5	4.96e-31	Response to fenofibrate (adiponectin levels);
LGG	cis	rs6860806	0.507	rs2631371	chr5:131703691	G/A	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Breast cancer;
LGG	cis	rs7572733	0.935	rs7558450	chr2:198837766	C/T	cg00792783	chr2:198669748	PLCL1	0.5	8.3	0.36	1.19e-15	Dermatomyositis;
LGG	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.75	-0.34	5.77e-14	Height;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-12.59	-0.51	1.76e-31	Total body bone mineral density;
LGG	cis	rs3206736	0.548	rs329233	chr7:35055831	T/C	cg13400248	chr7:35225412	NA	0.55	9.45	0.4	1.7e-19	Diastolic blood pressure;
LGG	cis	rs13191362	0.507	rs2846535	chr6:163034019	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-8.8	-0.38	2.82e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs888194	0.677	rs2075431	chr12:109874621	C/T	cg19025524	chr12:109796872	NA	-0.46	-9.13	-0.39	2.14e-18	Neuroticism;
LGG	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg02002194	chr4:3960332	NA	0.47	8.62	0.37	1.03e-16	Retinal vascular caliber;
LGG	cis	rs7091068	0.518	rs913045	chr10:95431535	C/T	cg20715218	chr10:95462985	C10orf4	0.67	12.29	0.5	3.01e-30	Urinary tract infection frequency;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg13939156	chr17:80058883	NA	-0.46	-8.89	-0.38	1.38e-17	Life satisfaction;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.5	0.37	2.68e-16	Lung cancer;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg08742575	chr21:47604166	C21orf56	0.54	9.83	0.42	7.56e-21	Testicular germ cell tumor;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00495681	chr13:53174319	NA	0.76	15.37	0.58	2.21e-43	Lewy body disease;
LGG	cis	rs7301016	0.846	rs73124315	chr12:62970437	C/T	cg11441379	chr12:63026424	NA	0.63	8.96	0.38	8.15e-18	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16784092	chr12:53400507	EIF4B	0.48	7.72	0.34	7.35e-14	Cognitive performance;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg00689492	chr4:1303491	MAEA	0.5	8.67	0.37	7.16e-17	Obesity-related traits;
LGG	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg27490568	chr2:178487706	NA	0.51	10.17	0.43	4.42e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg25208724	chr1:156163844	SLC25A44	0.78	6.89	0.31	1.81e-11	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs7191700	1.000	rs7191700	chr16:11406803	C/T	cg00044050	chr16:11439710	C16orf75	0.5	7.94	0.35	1.56e-14	Multiple sclerosis;
LGG	cis	rs972578	0.715	rs8141676	chr22:43275968	G/C	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.21e-11	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01083340	chr11:66176265	NA	0.5	7.65	0.33	1.16e-13	Gut microbiome composition (summer);
LGG	cis	rs4891159	0.536	rs11664190	chr18:74107920	T/C	cg24786174	chr18:74118243	ZNF516	-0.62	-14.76	-0.57	1.15e-40	Longevity;
LGG	cis	rs6704644	0.651	rs56266844	chr2:234360007	G/A	cg27060346	chr2:234359958	DGKD	-0.6	-7.07	-0.31	5.76e-12	Bilirubin levels;
LGG	cis	rs12681288	0.963	rs7822955	chr8:1029090	C/T	cg04851639	chr8:1020857	NA	0.35	7.52	0.33	2.83e-13	Schizophrenia;
LGG	cis	rs2221894	0.506	rs17525359	chr8:28829417	C/A	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.83	-0.34	3.32e-14	Obesity-related traits;
LGG	cis	rs1620921	0.624	rs13219765	chr6:161275516	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs75920871	0.528	rs7484045	chr11:116946890	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.52	-0.33	2.92e-13	Subjective well-being;
LGG	cis	rs2735413	0.564	rs78769909	chr16:78104002	G/A	cg04733911	chr16:78082701	NA	0.57	7.67	0.34	9.94e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.55	-8.71	-0.38	5.48e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11748327	0.959	rs1389321	chr5:4054849	G/C	cg01025095	chr5:4101132	NA	-0.57	-9.28	-0.4	6.29e-19	Myocardial infarction;
LGG	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg18200150	chr17:30822561	MYO1D	0.5	9.58	0.41	5.77e-20	Schizophrenia;
LGG	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg02269571	chr22:50332266	NA	0.64	10.17	0.43	4.62e-22	Schizophrenia;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg11584989	chr19:19387371	SF4	-0.44	-8.06	-0.35	6.64e-15	Tonsillectomy;
LGG	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.76	-0.3	4.23e-11	Alzheimer's disease (survival time);
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.53	-0.4	8.89e-20	Neuroticism;
LGG	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg01191920	chr7:158217561	PTPRN2	-0.73	-15.65	-0.59	1.24e-44	Obesity-related traits;
LGG	cis	rs7666738	0.791	rs13146909	chr4:98934198	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg03538708	chr1:25844672	NA	-0.36	-6.81	-0.3	3.11e-11	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg00294572	chr6:26285232	NA	0.39	6.8	0.3	3.32e-11	Educational attainment;
LGG	cis	rs977987	0.735	rs166013	chr16:75434146	C/T	cg07303275	chr16:75499416	TMEM170A	-0.45	-8.19	-0.36	2.48e-15	Dupuytren's disease;
LGG	cis	rs7301826	0.651	rs7299281	chr12:131303132	G/A	cg11011512	chr12:131303247	STX2	-0.38	-8.07	-0.35	6.14e-15	Plasma plasminogen activator levels;
LGG	cis	rs2115536	0.692	rs8036559	chr15:80170563	C/T	cg11839771	chr15:80205821	ST20	-0.39	-8.66	-0.37	7.97e-17	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.2e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg17007872	chr7:129251834	NRF1	0.46	7.0	0.31	8.75e-12	Hip circumference;
LGG	cis	rs10861661	0.569	rs10778514	chr12:107303577	G/A	cg15890332	chr12:107067104	RFX4	0.29	6.8	0.3	3.2e-11	Triglyceride levels;
LGG	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.95e-13	Uric acid levels;
LGG	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg03433033	chr1:76189801	ACADM	0.77	12.5	0.5	4.41e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11834862	0.765	rs10902511	chr12:132689436	C/T	cg16245054	chr12:132698494	GALNT9	-0.45	-6.86	-0.3	2.2e-11	Anti-saccade response;
LGG	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-9.97	-0.42	2.4e-21	Bladder cancer;
LGG	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg18225595	chr11:63971243	STIP1	0.48	9.31	0.4	5.27e-19	Platelet count;
LGG	cis	rs7017914	0.967	rs10089583	chr8:71849484	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.89	-0.31	1.81e-11	Bone mineral density;
LGG	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.22	0.55	2.53e-38	Cognitive test performance;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.37	4.05e-16	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.28	0.53	2.48e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.04	0.39	4.43e-18	Resting heart rate;
LGG	cis	rs2070997	0.756	rs3134875	chr9:133710072	G/C	cg13397898	chr9:133768931	QRFP	0.38	7.7	0.34	8.4e-14	Response to amphetamines;
LGG	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.93e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg21130718	chr4:1044621	NA	-0.46	-9.21	-0.39	1.14e-18	Recombination rate (males);
LGG	cis	rs1018836	0.892	rs13267237	chr8:91550820	T/C	cg16814680	chr8:91681699	NA	-0.72	-13.05	-0.52	2.2e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg05182265	chr7:156933206	UBE3C	0.37	7.64	0.33	1.25e-13	Body mass index;
LGG	cis	rs11785693	0.862	rs7009771	chr8:4990189	C/T	cg26367366	chr8:4980734	NA	0.95	14.9	0.57	2.68e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-15.26	-0.58	7.26e-43	Total body bone mineral density;
LGG	cis	rs1719271	1.000	rs2013555	chr15:65170949	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.55	-7.43	-0.33	5.45e-13	Platelet count;
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg19077165	chr18:44547161	KATNAL2	-0.54	-9.84	-0.42	7.21e-21	Personality dimensions;
LGG	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.61	-0.63	1.6e-53	Breast cancer;
LGG	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.21e-18	Corneal astigmatism;
LGG	cis	rs17102423	0.558	rs11628664	chr14:65615651	C/T	cg11161011	chr14:65562177	MAX	-0.67	-11.93	-0.48	8.84e-29	Obesity-related traits;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-11.57	-0.47	2.26e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs17221829	0.733	rs12281810	chr11:89409595	C/T	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.6	-0.37	1.29e-16	Anxiety in major depressive disorder;
LGG	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg19635926	chr16:89946313	TCF25	0.75	7.32	0.32	1.08e-12	Skin colour saturation;
LGG	cis	rs16937	0.711	rs12130817	chr1:205140305	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.63	-0.33	1.34e-13	Schizophrenia;
LGG	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg26769984	chr7:1090371	C7orf50	0.43	7.6	0.33	1.69e-13	Bronchopulmonary dysplasia;
LGG	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg08875078	chr22:50639485	SELO	0.51	8.76	0.38	3.84e-17	Obesity-related traits;
LGG	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg09448879	chr15:79043637	NA	0.47	10.23	0.43	2.77e-22	Coronary artery disease or large artery stroke;
LGG	trans	rs877282	0.891	rs12767043	chr10:797943	C/T	cg22713356	chr15:30763199	NA	0.58	8.69	0.37	6.18e-17	Uric acid levels;
LGG	trans	rs629535	0.773	rs681534	chr8:70056964	A/C	cg21567404	chr3:27674614	NA	0.4	6.68	0.3	6.84e-11	Dupuytren's disease;
LGG	cis	rs1978968	1.000	rs2099945	chr22:18438642	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.46	-0.5	6.32e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.5	-8.82	-0.38	2.3e-17	Diastolic blood pressure;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg16301924	chr13:53314226	LECT1	-0.44	-9.06	-0.39	3.63e-18	Lewy body disease;
LGG	trans	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg07393940	chr7:158741817	NA	0.57	10.57	0.44	1.53e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11225247	1.000	rs11605010	chr11:102266343	T/G	cg06323957	chr11:102217781	BIRC2	0.79	6.81	0.3	3.09e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg09426994	chr11:118478258	PHLDB1	0.43	7.91	0.35	1.9e-14	Cholesterol, total;
LGG	cis	rs963731	0.579	rs1377863	chr2:39238854	T/C	cg04010122	chr2:39346883	SOS1	-0.79	-7.59	-0.33	1.72e-13	Corticobasal degeneration;
LGG	trans	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.79	-0.41	1.08e-20	Primary sclerosing cholangitis;
LGG	cis	rs11785693	0.774	rs62489516	chr8:4946015	T/C	cg26367366	chr8:4980734	NA	0.77	10.32	0.43	1.25e-22	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.65e-12	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg15242686	chr22:24348715	GSTTP1	-0.4	-7.35	-0.32	8.93e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs887829	0.570	rs4347832	chr2:234593041	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.09	-0.35	5.3e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg23594656	chr7:65796392	TPST1	0.37	8.3	0.36	1.14e-15	Aortic root size;
LGG	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg00405596	chr8:11794950	NA	0.61	10.57	0.44	1.53e-23	Monocyte count;
LGG	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg19680485	chr15:31195859	MTMR15	0.54	9.36	0.4	3.38e-19	Huntington's disease progression;
LGG	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg08648136	chr8:956695	NA	0.43	9.46	0.4	1.56e-19	Schizophrenia;
LGG	cis	rs1595825	1.000	rs73058834	chr2:198873779	T/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.79	-0.3	3.54e-11	Ulcerative colitis;
LGG	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg10760299	chr15:45669010	GATM	0.38	7.18	0.32	2.77e-12	Homoarginine levels;
LGG	cis	rs10870270	0.956	rs7894	chr10:133769482	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.71	-0.51	5.88e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs75804782	0.521	rs72993073	chr2:239412925	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.51	0.37	2.48e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	trans	rs7246760	1.000	rs2287839	chr19:9940814	C/G	cg02900749	chr2:68251473	NA	-1.06	-11.44	-0.47	7.53e-27	Pursuit maintenance gain;
LGG	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Metabolite levels (small molecules and protein measures);
LGG	cis	rs1003719	0.788	rs2835593	chr21:38465873	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.52	0.63	4.3e-53	Eye color traits;
LGG	cis	rs28588043	0.877	rs9426925	chr1:170982001	A/G	cg03458344	chr1:170964477	C1orf129	-0.53	-7.12	-0.31	4.24e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs1927790	0.759	rs12866328	chr13:96986656	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.88	-0.3	1.95e-11	Body mass index;
LGG	cis	rs881301	1.000	rs881301	chr8:38332318	A/G	cg17120578	chr8:38329836	NA	-0.4	-8.51	-0.37	2.53e-16	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs7572733	0.840	rs7340470	chr2:198545462	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-7.51	-0.33	3e-13	Dermatomyositis;
LGG	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg16123090	chr2:3699210	NA	0.81	8.75	0.38	4.1e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9399135	0.967	rs7766189	chr6:135353851	A/C	cg24558204	chr6:135376177	HBS1L	0.54	9.85	0.42	6.56e-21	Red blood cell count;
LGG	cis	rs634534	0.622	rs531612	chr11:65705432	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.45	-7.39	-0.32	7.01e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs5758511	0.514	rs9607885	chr22:42578596	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.84	0.3	2.46e-11	Birth weight;
LGG	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg11752832	chr7:134001865	SLC35B4	0.62	11.48	0.47	5.27e-27	Mean platelet volume;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.22	-0.32	2.18e-12	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.29	-0.5	3.11e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.616	rs203477	chr17:19831819	A/C	cg13482628	chr17:19912719	NA	0.52	9.53	0.4	8.89e-20	Schizophrenia;
LGG	cis	rs701145	0.640	rs357499	chr3:153946463	C/G	cg12800244	chr3:153838788	SGEF	0.85	8.16	0.35	3.31e-15	Coronary artery disease;
LGG	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-9.22	-0.39	1.09e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg06521331	chr12:34319734	NA	0.51	8.8	0.38	2.75e-17	Bladder cancer;
LGG	cis	rs6163	0.508	rs11191381	chr10:104493444	C/T	cg25143771	chr10:104629124	AS3MT	0.4	6.75	0.3	4.33e-11	Waist circumference;Hip circumference;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.37	0.32	7.85e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2456568	0.709	rs1546400	chr11:93639203	G/A	cg26875233	chr11:93583750	C11orf90	0.36	7.02	0.31	7.82e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg15068132	chr12:102092402	CHPT1	-0.36	-6.71	-0.3	5.7e-11	Blood protein levels;
LGG	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg08344181	chr3:125677491	NA	-0.8	-8.05	-0.35	7.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6142618	0.562	rs4589835	chr20:30756614	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.12	0.35	4.15e-15	Inflammatory bowel disease;
LGG	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg08508325	chr11:3079039	CARS	0.39	7.25	0.32	1.81e-12	Calcium levels;
LGG	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg02269571	chr22:50332266	NA	-0.71	-10.9	-0.45	8.73e-25	Schizophrenia;
LGG	cis	rs1978968	0.731	rs9605462	chr22:18459859	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.73	-0.54	3.14e-36	Presence of antiphospholipid antibodies;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00734800	chr3:50388182	TUSC4;CYB561D2	0.52	8.17	0.35	2.87e-15	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg02002194	chr4:3960332	NA	0.46	8.07	0.35	6.28e-15	Triglycerides;
LGG	cis	rs6728642	0.519	rs4260285	chr2:97570081	A/G	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.52	-0.37	2.33e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02886208	chr11:14281011	SPON1	-0.42	-8.35	-0.36	7.89e-16	Mitochondrial DNA levels;
LGG	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.91	0.57	2.41e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs6575793	0.512	rs1888581	chr14:101042715	A/C	cg09399377	chr6:136611038	BCLAF1	0.48	7.2	0.32	2.4e-12	Menarche (age at onset);
LGG	trans	rs7937682	0.564	rs4938723	chr11:111382565	T/C	cg18187862	chr3:45730750	SACM1L	-0.42	-6.73	-0.3	4.93e-11	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-7.84	-0.34	3.02e-14	Lung cancer;
LGG	cis	rs17401966	0.838	rs12120191	chr1:10345772	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-10.23	-0.43	2.87e-22	Hepatocellular carcinoma;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg22903471	chr2:27725779	GCKR	-0.58	-13.27	-0.52	2.78e-34	Total body bone mineral density;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07132326	chr6:150258058	NA	0.36	7.68	0.34	9.38e-14	Testicular germ cell tumor;
LGG	cis	rs10089	0.953	rs114881127	chr5:127369661	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.47	0.47	5.79e-27	Ileal carcinoids;
LGG	cis	rs11785693	0.909	rs62489556	chr8:4968149	G/A	cg26367366	chr8:4980734	NA	1.02	15.33	0.58	3.31e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.66e-12	Bipolar disorder;
LGG	cis	rs11671005	0.735	rs45617039	chr19:58951096	G/A	cg13877915	chr19:58951672	ZNF132	0.61	8.45	0.37	3.87e-16	Mean platelet volume;
LGG	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg14088196	chr11:70211408	PPFIA1	0.88	11.32	0.47	2.13e-26	Coronary artery disease;
LGG	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg18240062	chr17:79603768	NPLOC4	0.81	15.43	0.58	1.23e-43	Eye color traits;
LGG	cis	rs3820068	0.608	rs6668919	chr1:16049893	A/G	cg05660106	chr1:15850417	CASP9	-0.72	-13.48	-0.53	3.51e-35	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg05368731	chr17:41323189	NBR1	0.96	18.91	0.66	1.61e-59	Menopause (age at onset);
LGG	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg20891283	chr12:69753455	YEATS4	0.85	15.07	0.57	4.62e-42	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg02725872	chr8:58115012	NA	-0.93	-12.34	-0.5	1.87e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-12.61	-0.51	1.58e-31	Total body bone mineral density;
LGG	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg23324259	chr8:82754387	SNX16	-0.46	-7.34	-0.32	9.47e-13	Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17518778	chr5:140071088	HARS;HARS2	0.4	6.87	0.3	2.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4965869	0.866	rs11856811	chr15:101976322	A/G	cg12371147	chr15:101978424	PCSK6	-0.42	-7.65	-0.33	1.17e-13	Platelet-derived growth factor BB levels;
LGG	cis	rs17122278	0.577	rs537975	chr11:118362869	T/C	cg19182353	chr11:118479428	PHLDB1	0.44	6.88	0.3	1.95e-11	Total cholesterol levels;
LGG	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg06115741	chr20:33292138	TP53INP2	0.57	9.19	0.39	1.28e-18	Coronary artery disease;
LGG	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg20673091	chr1:2541236	MMEL1	-0.55	-11.7	-0.48	7.11e-28	Ulcerative colitis;
LGG	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.59	9.07	0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg01620082	chr3:125678407	NA	-0.74	-7.34	-0.32	9.88e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4819052	0.959	rs9976074	chr21:46655638	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.6	9.25	0.39	8.54e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.85	-0.51	1.62e-32	Response to antipsychotic treatment;
LGG	trans	rs35847492	1.000	rs17730481	chr8:9276163	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.02	-0.35	8.69e-15	Neuroticism;
LGG	cis	rs10220309	0.501	rs4903903	chr14:80634365	T/C	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.12e-11	Lung function (FEV1);
LGG	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg04362960	chr10:104952993	NT5C2	-0.54	-10.01	-0.42	1.74e-21	Arsenic metabolism;
LGG	cis	rs12200560	0.505	rs9400166	chr6:97077101	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg05890377	chr2:74357713	NA	0.38	7.43	0.33	5.32e-13	Gestational age at birth (maternal effect);
LGG	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg24110177	chr3:50126178	RBM5	-0.59	-10.61	-0.44	1.1e-23	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-11.67	-0.48	8.9e-28	Prudent dietary pattern;
LGG	cis	rs7932354	0.528	rs4752967	chr11:47169376	T/C	cg03339077	chr11:47165057	C11orf49	0.55	10.42	0.44	5.39e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg07148914	chr20:33460835	GGT7	0.58	9.49	0.4	1.22e-19	Height;
LGG	cis	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg06609049	chr19:2785107	THOP1	0.6	9.41	0.4	2.4e-19	Total cholesterol levels;
LGG	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg01152986	chr16:58549298	SETD6	0.84	7.28	0.32	1.44e-12	Schizophrenia;
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.81	-0.41	9.28e-21	Triglycerides;
LGG	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg21772509	chr8:41503840	NKX6-3	0.87	19.59	0.67	1.06e-62	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.51	-0.47	3.97e-27	Intelligence (multi-trait analysis);
LGG	cis	rs911263	0.603	rs61985136	chr14:68769199	C/T	cg18825221	chr14:68749962	RAD51L1	0.38	8.2	0.36	2.44e-15	Primary biliary cholangitis;
LGG	trans	rs7939886	0.920	rs10431119	chr11:55977069	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	trans	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg18187862	chr3:45730750	SACM1L	-0.64	-10.59	-0.44	1.31e-23	Primary sclerosing cholangitis;
LGG	cis	rs17208368	0.689	rs11861573	chr16:55091114	A/T	cg09947736	chr16:55091198	NA	0.77	13.57	0.53	1.43e-35	Hypospadias;
LGG	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.29	0.6	1.79e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg02733842	chr7:1102375	C7orf50	0.45	7.66	0.34	1.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg02002194	chr4:3960332	NA	0.48	8.81	0.38	2.56e-17	Retinal vascular caliber;
LGG	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg19774624	chr17:42201019	HDAC5	-0.56	-9.86	-0.42	6.27e-21	Total body bone mineral density;
LGG	cis	rs11264213	0.901	rs74879824	chr1:36413117	T/A	cg27506609	chr1:36549197	TEKT2	0.74	7.71	0.34	8.02e-14	Schizophrenia;
LGG	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg24848339	chr3:12840334	CAND2	-0.43	-10.15	-0.43	5.55e-22	QRS complex (12-leadsum);
LGG	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg16797656	chr11:68205561	LRP5	0.41	7.26	0.32	1.61e-12	Total body bone mineral density;
LGG	cis	rs4740619	0.619	rs1410452	chr9:16042120	G/C	cg14451791	chr9:16040625	NA	-0.42	-11.37	-0.47	1.34e-26	Body mass index;
LGG	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg07936489	chr17:37558343	FBXL20	0.85	16.0	0.6	3.49e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg06808227	chr14:105710500	BRF1	-0.63	-11.35	-0.47	1.61e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	trans	rs8073060	0.586	rs2011897	chr17:34054408	A/T	cg19694781	chr19:47549865	TMEM160	1.16	17.6	0.63	1.89e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg18937875	chr11:14930189	NA	-0.49	-7.99	-0.35	1.05e-14	Vitamin D levels;
LGG	cis	rs782590	0.935	rs2586954	chr2:55892261	A/C	cg18811423	chr2:55921094	PNPT1	0.91	20.93	0.7	6.05e-69	Metabolic syndrome;
LGG	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg03060546	chr3:49711283	APEH	0.57	8.57	0.37	1.6e-16	Resting heart rate;
LGG	trans	rs8105895	0.935	rs62112920	chr19:22227149	A/G	cg19945060	chr8:41508779	NA	0.45	6.69	0.3	6.5e-11	Body mass index (change over time);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22373181	chr2:39893080	TMEM178	-0.42	-7.16	-0.32	3.24e-12	Pancreatic cancer;
LGG	trans	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.37	0.4	3.17e-19	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25877086	chr17:45726922	KPNB1	0.42	7.1	0.31	4.84e-12	Gut microbiome composition (summer);
LGG	trans	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg25482853	chr8:67687455	SGK3	1.03	13.24	0.52	3.71e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs35740288	0.857	rs11632034	chr15:86284072	C/T	cg04173714	chr15:86211321	AKAP13	0.42	7.28	0.32	1.43e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg23131131	chr22:24373011	LOC391322	-0.5	-8.32	-0.36	9.61e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg02753203	chr1:228287806	NA	-0.64	-11.94	-0.49	7.54e-29	Diastolic blood pressure;
LGG	cis	rs1577917	0.771	rs9294337	chr6:86248460	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	17.16	0.62	1.89e-51	Response to antipsychotic treatment;
LGG	cis	rs17854409	0.881	rs1046784	chr20:61472808	G/C	cg05147244	chr20:61493195	TCFL5	0.77	7.42	0.33	5.81e-13	Obesity-related traits;
LGG	cis	rs3849570	0.925	rs6798680	chr3:81905441	C/A	cg07356753	chr3:81810745	GBE1	-0.43	-7.01	-0.31	8.73e-12	Waist circumference;Body mass index;
LGG	cis	rs7851660	0.874	rs7037175	chr9:100631662	G/C	cg13688889	chr9:100608707	NA	-0.59	-11.65	-0.48	1.14e-27	Strep throat;
LGG	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg20498895	chr3:12883366	SNORA7A;RPL32	0.44	6.66	0.3	7.81e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg03188948	chr7:1209495	NA	0.41	7.18	0.32	2.81e-12	Longevity;Endometriosis;
LGG	cis	rs7312774	0.618	rs28716736	chr12:107364410	A/G	cg16260113	chr12:107380972	MTERFD3	0.97	8.73	0.38	4.83e-17	Severe influenza A (H1N1) infection;
LGG	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.16	-0.35	3.2e-15	Retinal vascular caliber;
LGG	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg03929089	chr4:120376271	NA	0.44	7.18	0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25517755	chr10:38738941	LOC399744	-0.38	-6.86	-0.3	2.24e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.96	-0.31	1.18e-11	Bipolar disorder;
LGG	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg00571178	chr13:114841904	RASA3	-0.55	-9.72	-0.41	1.84e-20	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg12395012	chr8:11607386	GATA4	0.4	6.95	0.31	1.26e-11	Neuroticism;
LGG	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg07389463	chr12:132296394	NA	0.54	11.78	0.48	3.32e-28	Migraine;
LGG	cis	rs7511006	0.893	rs760743	chr22:50647375	C/T	cg08875078	chr22:50639485	SELO	0.51	8.55	0.37	1.82e-16	Obesity-related traits;
LGG	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg26597838	chr10:835615	NA	0.92	12.26	0.5	3.87e-30	Eosinophil percentage of granulocytes;
LGG	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg10840412	chr1:235813424	GNG4	0.65	8.71	0.38	5.38e-17	Bipolar disorder;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11169552	0.510	rs10747587	chr12:51105300	T/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.4	-0.33	6.35e-13	Colorectal cancer;
LGG	cis	rs9807989	0.507	rs7605284	chr2:103044175	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.58	0.41	5.74e-20	Asthma;
LGG	cis	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg07460842	chr6:66804631	NA	0.73	12.52	0.5	3.54e-31	Type 2 diabetes;
LGG	cis	rs9309711	0.922	rs7561600	chr2:3486093	G/C	cg10845886	chr2:3471009	TTC15	-0.65	-12.65	-0.51	1.03e-31	Neurofibrillary tangles;
LGG	cis	rs8014204	0.901	rs6574200	chr14:75364451	C/T	cg03030879	chr14:75389066	RPS6KL1	0.37	6.7	0.3	5.9e-11	Caffeine consumption;
LGG	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-12.81	-0.51	2.2e-32	Menarche (age at onset);
LGG	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg17376030	chr22:41985996	PMM1	0.55	9.12	0.39	2.28e-18	Vitiligo;
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg05313129	chr8:58192883	C8orf71	-0.78	-12.05	-0.49	2.95e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7818345	0.637	rs13280711	chr8:19353600	T/A	cg01280390	chr8:19363452	CSGALNACT1	0.44	10.76	0.45	3.08e-24	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg19338460	chr6:170058176	WDR27	-0.64	-8.59	-0.37	1.35e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg03161606	chr19:29218774	NA	0.63	8.25	0.36	1.7e-15	Methadone dose in opioid dependence;
LGG	cis	rs9972944	0.756	rs6504350	chr17:63764336	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg11752832	chr7:134001865	SLC35B4	0.64	11.69	0.48	7.78e-28	Mean platelet volume;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs7766436	0.553	rs62391069	chr6:22610835	C/T	cg13666174	chr6:22585274	NA	-0.4	-7.11	-0.31	4.45e-12	Coronary artery disease;
LGG	cis	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg08112188	chr17:47440006	ZNF652	1.26	13.39	0.53	8.61e-35	Prostate cancer;
LGG	cis	rs9372253	0.934	rs9320327	chr6:110715194	T/A	cg01119278	chr6:110721349	DDO	-0.3	-7.31	-0.32	1.2e-12	Platelet distribution width;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.74e-13	Blood metabolite levels;
LGG	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.86	-0.34	2.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.773	rs8006525	chr14:55813394	T/G	cg04306507	chr14:55594613	LGALS3	0.63	17.99	0.64	2.88e-55	Protein biomarker;
LGG	cis	rs12534701	0.534	rs13235571	chr7:154686531	G/C	cg24255201	chr7:154684926	DPP6	0.61	11.52	0.47	3.45e-27	Colorectal cancer (diet interaction);
LGG	cis	rs6430585	0.528	rs12474975	chr2:136702118	A/T	cg07169764	chr2:136633963	MCM6	1.23	22.62	0.72	7.26e-77	Corneal structure;
LGG	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg26597838	chr10:835615	NA	0.64	9.33	0.4	4.47e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs4660214	0.666	rs7414381	chr1:39741520	A/T	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7666738	0.716	rs35195511	chr4:98859660	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.68	0.34	9.34e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs9549367	0.737	rs71446680	chr13:113894846	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.58	-0.37	1.47e-16	Platelet distribution width;
LGG	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.72	0.34	7.11e-14	Coronary artery disease;
LGG	cis	rs62025270	0.547	rs338540	chr15:86195731	C/T	cg25843651	chr15:86329602	KLHL25	-0.54	-8.98	-0.39	6.67e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs6938	0.534	rs11072512	chr15:75204026	C/T	cg14664628	chr15:75095509	CSK	-0.54	-10.39	-0.43	7.12e-23	Breast cancer;
LGG	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg09021430	chr5:549028	NA	-0.69	-11.74	-0.48	4.75e-28	Obesity-related traits;
LGG	cis	rs698813	0.604	rs768006	chr2:44487612	C/G	cg00619915	chr2:44497795	NA	-0.6	-8.82	-0.38	2.36e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.61	-0.33	1.53e-13	Total cholesterol levels;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.73	-0.38	4.68e-17	Lung cancer;
LGG	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.48	0.71	1.58e-71	Morning vs. evening chronotype;
LGG	cis	rs1395	0.744	rs7600932	chr2:27474869	G/A	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg07701084	chr6:150067640	NUP43	0.68	12.86	0.51	1.37e-32	Lung cancer;
LGG	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.52e-35	Anterior chamber depth;
LGG	cis	rs7587476	0.861	rs17488049	chr2:215651750	G/A	cg04004882	chr2:215674386	BARD1	0.53	6.95	0.31	1.25e-11	Neuroblastoma;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.56	-0.53	1.65e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs607541	1.000	rs688967	chr15:45936127	T/G	cg26924012	chr15:45694286	SPATA5L1	0.53	7.38	0.32	7.37e-13	Obesity-related traits;
LGG	cis	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.74	-0.34	6.51e-14	Blood trace element (Cu levels);
LGG	cis	rs4747241	0.739	rs4747245	chr10:74077308	A/T	cg25082487	chr10:74091975	NA	-0.38	-7.07	-0.31	5.75e-12	Heschl's gyrus morphology;
LGG	cis	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg00745463	chr17:30367425	LRRC37B	-0.59	-8.78	-0.38	3.19e-17	Hip circumference adjusted for BMI;
LGG	cis	rs17428076	0.710	rs62181740	chr2:172540401	A/G	cg21435375	chr2:172878103	MAP1D	0.38	6.9	0.31	1.73e-11	Myopia;
LGG	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg00204512	chr16:28754710	NA	0.26	7.2	0.32	2.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg21775007	chr8:11205619	TDH	-0.44	-7.14	-0.31	3.69e-12	Systolic blood pressure;
LGG	cis	rs9358372	0.537	rs9368242	chr6:20826168	G/A	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.28	-0.4	6.7e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9790314	0.645	rs6778254	chr3:160892792	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-11.59	-0.47	1.84e-27	Morning vs. evening chronotype;
LGG	cis	rs12580194	0.593	rs7485979	chr12:55789043	A/T	cg19537932	chr12:55886519	OR6C68	0.56	10.13	0.43	6.62e-22	Cancer;
LGG	cis	rs12477438	0.501	rs7589365	chr2:99990324	C/T	cg23527387	chr2:100056660	REV1	0.41	9.23	0.39	9.34e-19	Chronic sinus infection;
LGG	cis	rs6964587	0.869	rs405	chr7:91546327	G/C	cg17063962	chr7:91808500	NA	-0.45	-7.84	-0.34	3.13e-14	Breast cancer;
LGG	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg24101359	chr6:42928495	GNMT	-0.41	-9.13	-0.39	2.05e-18	Blood protein levels;
LGG	cis	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs1784581	0.532	rs7767219	chr6:162423088	T/C	cg17173639	chr6:162384350	PARK2	0.64	13.5	0.53	2.92e-35	Itch intensity from mosquito bite;
LGG	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg03342759	chr3:160939853	NMD3	0.44	7.44	0.33	4.87e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg05861140	chr6:150128134	PCMT1	0.41	9.2	0.39	1.22e-18	Lung cancer;
LGG	cis	rs6815814	0.950	rs5743571	chr4:38805489	C/T	cg06935464	chr4:38784597	TLR10	0.61	8.39	0.36	5.74e-16	Breast cancer;
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg18681998	chr4:17616180	MED28	0.89	19.16	0.67	1.09e-60	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10832963	1.000	rs7943121	chr11:18656062	G/C	cg09201001	chr11:18656081	SPTY2D1	0.99	20.76	0.69	3.83e-68	Breast cancer;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-12.44	-0.5	7.27e-31	Cognitive function;
LGG	trans	rs12517041	1.000	rs2081954	chr5:23295705	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs2072732	0.821	rs7412983	chr1:2943183	A/C	cg22517653	chr1:2918612	NA	-0.5	-7.01	-0.31	8.74e-12	Plateletcrit;
LGG	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg21545522	chr1:205238299	TMCC2	0.37	7.22	0.32	2.12e-12	Red blood cell count;
LGG	cis	rs7113850	0.541	rs61875405	chr11:24376359	G/A	ch.11.24196551F	chr11:24239977	NA	0.6	6.71	0.3	5.83e-11	Bone fracture in osteoporosis;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs7940866	0.774	rs7480903	chr11:130832276	A/G	cg12179176	chr11:130786555	SNX19	0.74	13.68	0.54	5.22e-36	Schizophrenia;
LGG	cis	rs9397585	0.857	rs1338067	chr6:153380668	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs7123876	0.553	rs10898868	chr11:72431679	A/G	cg04827223	chr11:72435913	ARAP1	-0.37	-6.77	-0.3	3.81e-11	Body mass index;
LGG	cis	rs3617	0.591	rs11918800	chr3:52868145	G/A	cg11645453	chr3:52864694	ITIH4	-0.43	-7.28	-0.32	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	cg07245641	chr1:182991651	LAMC1	0.41	9.16	0.39	1.7e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg07005078	chr4:17578674	LAP3	0.36	6.66	0.3	7.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg12386194	chr3:101231763	SENP7	0.7	11.97	0.49	5.81e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08219700	chr8:58056026	NA	0.53	6.93	0.31	1.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.55	-7.27	-0.32	1.5e-12	HIV-1 control;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.35e-16	Testicular germ cell tumor;
LGG	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg04226714	chr8:49833948	SNAI2	-0.48	-8.63	-0.37	9.95e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10895140	0.718	rs1938836	chr11:101493608	A/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg25358565	chr5:93447407	FAM172A	1.39	16.98	0.62	1.29e-50	Diabetic retinopathy;
LGG	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.07	0.42	1.07e-21	Aortic root size;
LGG	cis	rs7192750	0.586	rs12444521	chr16:71941698	A/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24838063	chr12:130822603	PIWIL1	-0.65	-12.28	-0.5	3.46e-30	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.79	0.38	2.91e-17	Obesity-related traits;
LGG	cis	rs7106204	0.514	rs12805363	chr11:24258357	T/G	ch.11.24196551F	chr11:24239977	NA	0.86	9.48	0.4	1.34e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg22875332	chr1:76189707	ACADM	0.62	11.0	0.46	3.75e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs490234	0.756	rs6478705	chr9:128216326	G/T	cg14078157	chr9:128172775	NA	-0.44	-8.1	-0.35	4.81e-15	Mean arterial pressure;
LGG	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.91	0.42	3.86e-21	Height;
LGG	cis	rs4787491	0.729	rs4788215	chr16:30047930	G/A	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs36715	1.000	rs251386	chr5:127547298	A/G	cg16011800	chr17:1958478	HIC1	-0.47	-6.82	-0.3	2.94e-11	Breast cancer;
LGG	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg26031613	chr14:104095156	KLC1	0.55	8.73	0.38	4.82e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg26769984	chr7:1090371	C7orf50	0.46	7.22	0.32	2.13e-12	Bronchopulmonary dysplasia;
LGG	cis	rs9403521	1.000	rs117303301	chr6:143999003	C/T	cg18240653	chr6:144019428	PHACTR2	-0.64	-10.05	-0.42	1.26e-21	Obesity-related traits;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20887711	chr4:1340912	KIAA1530	-0.76	-16.08	-0.6	1.58e-46	Obesity-related traits;
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10802521	chr3:52805072	NEK4	0.42	7.04	0.31	6.91e-12	Bipolar disorder;
LGG	cis	rs17270561	0.609	rs9348694	chr6:25753640	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.74	-0.34	6.1e-14	Iron status biomarkers;
LGG	cis	rs9790314	0.663	rs12639128	chr3:160639645	A/G	cg04691961	chr3:161091175	C3orf57	0.4	8.44	0.37	4.23e-16	Morning vs. evening chronotype;
LGG	trans	rs253959	0.607	rs1396497	chr5:115427416	C/T	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.71	0.3	5.55e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18850918	chr19:18633063	ELL	0.49	7.29	0.32	1.31e-12	Gut microbiome composition (summer);
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.18	-0.39	1.46e-18	Morning vs. evening chronotype;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg23034840	chr1:205782522	SLC41A1	0.61	10.08	0.42	9.46e-22	Menarche (age at onset);
LGG	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	9.62	0.41	4.22e-20	Body mass index;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.08	0.46	1.89e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01698708	chr1:28100000	STX12	0.46	7.01	0.31	8.73e-12	Gut microbiome composition (summer);
LGG	cis	rs3106136	0.967	rs61514245	chr4:95165053	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	4.02e-15	Capecitabine sensitivity;
LGG	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.7	-12.77	-0.51	3.36e-32	Obesity-related traits;
LGG	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-9.09	-0.39	2.91e-18	Chronic sinus infection;
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.1	-0.39	2.73e-18	Triglycerides;
LGG	cis	rs9649465	0.967	rs3779261	chr7:123315174	A/G	cg03229431	chr7:123269106	ASB15	-0.39	-8.8	-0.38	2.81e-17	Migraine;
LGG	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.9	-0.42	4.37e-21	Height;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg27336068	chr10:1336103	ADARB2	-0.41	-9.24	-0.39	8.81e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26434800	chr1:245848928	KIF26B	0.4	6.72	0.3	5.29e-11	Pancreatic cancer;
LGG	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.56e-14	Neuroticism;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.93	-0.54	4.37e-37	Alzheimer's disease;
LGG	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg13009111	chr11:71350975	NA	-0.33	-7.29	-0.32	1.33e-12	Monocyte count;
LGG	cis	rs11096990	0.551	rs2060005	chr4:39162521	A/G	cg24403649	chr4:39172243	NA	0.41	7.26	0.32	1.64e-12	Cognitive function;
LGG	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.52	-0.4	9.87e-20	Neuroticism;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.01	-0.39	5.26e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg02023728	chr11:77925099	USP35	0.47	8.38	0.36	6.46e-16	Testicular germ cell tumor;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg07701084	chr6:150067640	NUP43	0.69	12.74	0.51	4.57e-32	Lung cancer;
LGG	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg14186256	chr22:23484241	RTDR1	0.98	23.94	0.74	5.1e-83	Bone mineral density;
LGG	cis	rs9914544	0.602	rs4924929	chr17:18714241	G/A	cg26306683	chr17:18585705	ZNF286B	0.37	7.21	0.32	2.36e-12	Educational attainment (years of education);
LGG	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.66	0.34	1.11e-13	Schizophrenia;
LGG	cis	rs3857067	0.806	rs9307137	chr4:95135712	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.42	-0.36	4.82e-16	QT interval;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg13282195	chr8:144660772	NAPRT1	0.94	7.34	0.32	9.73e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.09	-0.57	4.01e-42	Chronic sinus infection;
LGG	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.52	-0.33	2.84e-13	Testicular germ cell tumor;
LGG	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.32	0.47	2.11e-26	Vitamin D levels;
LGG	cis	rs11997175	0.550	rs7459534	chr8:33836623	G/C	ch.8.33884649F	chr8:33765107	NA	0.39	7.33	0.32	1.02e-12	Body mass index;
LGG	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.0	0.31	9.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2976388	0.609	rs2164308	chr8:143785659	A/G	cg06565975	chr8:143823917	SLURP1	-0.35	-9.12	-0.39	2.36e-18	Urinary tract infection frequency;
LGG	cis	rs4731207	0.698	rs34014883	chr7:124480577	C/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	trans	rs11134654	0.627	rs4868033	chr5:170234264	A/T	cg20034712	chr19:52675470	ZNF836	-0.56	-10.59	-0.44	1.28e-23	Smooth-surface caries;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00689492	chr4:1303491	MAEA	0.52	9.03	0.39	4.66e-18	Obesity-related traits;
LGG	cis	rs61990749	0.597	rs176952	chr14:78180736	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.34	0.32	9.85e-13	Fibroblast growth factor basic levels;
LGG	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg00376283	chr12:123451042	ABCB9	-0.57	-8.68	-0.37	7.01e-17	Neutrophil percentage of white cells;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs9453476	chr6:66603836	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.72	-0.34	7.49e-14	Systemic lupus erythematosus;
LGG	cis	rs72925845	0.519	rs1631200	chr17:76426512	C/T	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg02487422	chr3:49467188	NICN1	0.44	7.2	0.32	2.5e-12	Resting heart rate;
LGG	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg27624424	chr6:160112604	SOD2	0.65	9.78	0.41	1.21e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11190604	1.000	rs3750627	chr10:102275642	G/T	cg07080220	chr10:102295463	HIF1AN	0.71	12.17	0.49	9.74e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs72843166	0.545	rs1588368	chr17:61016209	C/T	cg06641342	chr17:61514920	CYB561	-0.46	-7.38	-0.32	7.62e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17021463	0.902	rs11097413	chr4:95249286	C/T	cg11021082	chr4:95130006	SMARCAD1	0.52	9.62	0.41	4.18e-20	Testicular germ cell tumor;
LGG	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg06889755	chr6:150326021	RAET1K	-0.38	-7.83	-0.34	3.31e-14	Alopecia areata;
LGG	cis	rs4774830	0.744	rs62046383	chr15:56303623	C/T	cg05129572	chr15:56138634	NEDD4	0.68	6.68	0.3	6.81e-11	Delta-5 desaturase activity;
LGG	cis	rs2154319	0.836	rs6669737	chr1:41525890	T/C	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.84	-0.38	1.98e-17	Height;
LGG	cis	rs10254118	0.757	rs6467491	chr7:133138761	A/G	cg10665199	chr7:133106180	EXOC4	0.57	9.45	0.4	1.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17376030	chr22:41985996	PMM1	0.59	9.2	0.39	1.22e-18	Vitiligo;
LGG	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg08645402	chr16:4508243	NA	0.44	8.04	0.35	7.64e-15	Schizophrenia;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14795047	chr12:38710433	ALG10B	0.42	7.02	0.31	8.12e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9547996	0.879	rs61957468	chr13:38132914	G/A	cg17979426	chr13:38220150	TRPC4	-0.35	-6.84	-0.3	2.51e-11	Diastolic blood pressure;
LGG	cis	rs3793683	0.928	rs2148666	chr10:134553785	A/G	cg27286337	chr10:134555280	INPP5A	1.04	23.98	0.74	3.43e-83	Migraine;
LGG	cis	rs1055129	0.560	rs9302994	chr17:73906934	G/A	cg08125733	chr17:73851984	WBP2	0.43	7.19	0.32	2.63e-12	White matter hyperintensity burden;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs231513	0.911	rs124720	chr17:41960141	A/G	cg26893861	chr17:41843967	DUSP3	-0.58	-6.79	-0.3	3.54e-11	Cognitive function;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg02953029	chr4:95128914	SMARCAD1	0.71	6.68	0.3	6.68e-11	Plasma thyroid-stimulating hormone levels;
LGG	trans	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.23	0.55	2.31e-38	Exhaled nitric oxide output;
LGG	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5e-17	Aortic root size;
LGG	cis	rs4730779	0.869	rs12534129	chr7:117018135	T/C	cg10524701	chr7:117356490	CTTNBP2	0.39	8.38	0.36	6.53e-16	Waist circumference;
LGG	cis	rs17776563	0.887	rs12324548	chr15:89130155	G/A	cg05013243	chr15:89149849	MIR1179	-0.48	-9.89	-0.42	4.61e-21	Thyroid hormone levels;
LGG	cis	rs58688157	0.921	rs12805435	chr11:612355	T/C	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs236352	0.504	rs4714018	chr6:36812717	C/T	cg03410223	chr6:36853544	C6orf89	0.39	6.94	0.31	1.29e-11	Heart rate;
LGG	cis	rs7246865	0.954	rs3745348	chr19:17212410	C/T	cg19418318	chr19:17219073	MYO9B	0.35	9.54	0.41	8.28e-20	Reticulocyte fraction of red cells;
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg26354017	chr1:205819088	PM20D1	-0.52	-10.01	-0.42	1.79e-21	Menarche (age at onset);
LGG	cis	rs1348850	0.597	rs13014417	chr2:178417835	T/G	cg27490568	chr2:178487706	NA	0.75	13.74	0.54	2.78e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg18200150	chr17:30822561	MYO1D	0.87	20.93	0.7	6.27e-69	Schizophrenia;
LGG	cis	rs4363385	0.693	rs608509	chr1:153034650	G/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg00071950	chr4:10020882	SLC2A9	0.37	7.67	0.34	1.05e-13	Bone mineral density;
LGG	trans	rs208520	1.000	rs12193164	chr6:66978962	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.918	rs8007068	chr14:71770710	T/A	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.35	-0.43	9.86e-23	Chronic sinus infection;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-13.94	-0.54	3.85e-37	Alzheimer's disease;
LGG	cis	rs2905347	0.726	rs2905321	chr7:22704587	A/G	cg18045685	chr7:22629474	NA	0.65	13.69	0.54	4.4e-36	Major depression and alcohol dependence;
LGG	cis	rs13191362	1.000	rs73035025	chr6:163000988	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg17545662	chr6:170176663	C6orf70	0.67	8.7	0.37	5.76e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2717559	0.542	rs2585156	chr8:143879795	G/A	cg06565975	chr8:143823917	SLURP1	-0.29	-6.89	-0.3	1.88e-11	Urinary tract infection frequency;
LGG	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg12439423	chr8:41522721	ANK1	-0.46	-8.56	-0.37	1.69e-16	Type 2 diabetes;
LGG	cis	rs4789294	0.950	rs567009	chr17:74434817	A/G	cg27112972	chr17:74378252	NA	-0.26	-6.8	-0.3	3.2e-11	Lymphocyte percentage of white cells;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.35	6.68	0.3	6.8e-11	Schizophrenia;
LGG	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22496380	chr5:211416	CCDC127	-1.14	-10.66	-0.44	7.04e-24	Breast cancer;
LGG	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.15	-0.32	3.33e-12	Total cholesterol levels;
LGG	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.47	6.95	0.31	1.25e-11	Cystic fibrosis severity;
LGG	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg12561776	chr17:30844705	MYO1D	-0.27	-6.8	-0.3	3.23e-11	Schizophrenia;
LGG	cis	rs4819852	0.752	rs2238781	chr22:19970547	G/T	cg07821417	chr22:19972146	ARVCF	0.5	10.79	0.45	2.26e-24	Pulse pressure;
LGG	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22857025	chr5:266934	NA	-1.11	-9.05	-0.39	3.95e-18	Asthma (childhood onset);
LGG	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg19824325	chr16:58548873	SETD6	1.21	11.07	0.46	1.93e-25	Schizophrenia;
LGG	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg05234568	chr11:5960015	NA	-0.66	-10.59	-0.44	1.35e-23	DNA methylation (variation);
LGG	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg04617936	chr2:214353	NA	-0.39	-7.18	-0.32	2.85e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10785877	0.717	rs7848602	chr9:137120763	T/C	cg21243944	chr9:137118148	NA	-0.31	-7.61	-0.33	1.56e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg09699651	chr6:150184138	LRP11	0.48	8.58	0.37	1.41e-16	Lung cancer;
LGG	cis	rs881375	0.933	rs7859805	chr9:123664123	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg16507663	chr6:150244633	RAET1G	0.41	7.6	0.33	1.65e-13	Lung cancer;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.37	0.36	6.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2282978	0.557	rs2040494	chr7:92256905	C/T	cg15732164	chr7:92237376	CDK6	-0.34	-7.23	-0.32	1.97e-12	Height;
LGG	cis	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg00409905	chr10:38381863	ZNF37A	0.41	7.91	0.35	1.88e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs250677	0.958	rs36070	chr5:148417240	T/C	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.12	-0.31	4.08e-12	Breast cancer;
LGG	cis	rs2694528	0.858	rs80154095	chr5:60378204	C/T	cg11474532	chr5:59995715	DEPDC1B	0.69	7.4	0.33	6.31e-13	Parkinson's disease;
LGG	cis	rs9527	0.590	rs7089680	chr10:104802071	C/T	cg05308233	chr10:104796373	CNNM2	0.32	7.16	0.32	3.29e-12	Arsenic metabolism;
LGG	cis	rs1497828	0.956	rs2454117	chr1:217552823	T/C	cg04411442	chr1:217543379	NA	0.47	7.88	0.34	2.33e-14	Dialysis-related mortality;
LGG	cis	rs9486719	1.000	rs12190507	chr6:96898265	T/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg19774624	chr17:42201019	HDAC5	0.83	16.43	0.61	4.08e-48	Total body bone mineral density;
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.4e-16	Aortic root size;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg09307838	chr4:120376055	NA	0.49	8.38	0.36	6.56e-16	Corneal astigmatism;
LGG	cis	rs6740322	1.000	rs11693666	chr2:43562479	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.57	8.9	0.38	1.24e-17	Coronary artery disease;
LGG	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.97	-0.42	2.54e-21	Sudden cardiac arrest;
LGG	trans	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.42	-0.33	5.55e-13	Educational attainment (years of education);
LGG	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-8.66	-0.37	7.76e-17	Aortic root size;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12148488	0.966	rs12899062	chr15:75347641	A/C	cg14664628	chr15:75095509	CSK	0.48	9.18	0.39	1.45e-18	Caffeine consumption;
LGG	cis	rs6964587	0.655	rs6965864	chr7:91595596	A/G	cg17063962	chr7:91808500	NA	0.49	9.2	0.39	1.24e-18	Breast cancer;
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.53	0.33	2.6e-13	Rheumatoid arthritis;
LGG	cis	rs881375	0.967	rs1860823	chr9:123659304	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.76	0.48	3.89e-28	Rheumatoid arthritis;
LGG	cis	rs1550582	0.548	rs7828645	chr8:135497385	A/G	cg17885191	chr8:135476712	NA	-1.01	-17.55	-0.63	3.21e-53	Educational attainment;
LGG	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg01557791	chr16:72042693	DHODH	-0.45	-8.25	-0.36	1.69e-15	Fibrinogen levels;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	8.79	0.38	3.03e-17	Personality dimensions;
LGG	cis	rs6759839	0.761	rs7563815	chr2:16624337	C/T	cg09580478	chr2:16689509	NA	0.47	7.36	0.32	8.55e-13	Mean platelet volume;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.45	-0.4	1.64e-19	Personality dimensions;
LGG	cis	rs6088580	0.524	rs11167241	chr20:33250835	C/T	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs11088226	0.681	rs9622	chr21:33951068	T/C	cg09050820	chr6:167586206	TCP10L2	0.94	13.81	0.54	1.38e-36	Gastritis;
LGG	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.74	0.34	6.28e-14	Homoarginine levels;
LGG	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg02753203	chr1:228287806	NA	0.76	14.7	0.56	2.01e-40	Diastolic blood pressure;
LGG	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.6	13.02	0.52	2.96e-33	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-10.03	-0.42	1.46e-21	Coronary artery disease;
LGG	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg21055462	chr7:100276975	NA	0.46	9.84	0.42	7.15e-21	Other erythrocyte phenotypes;
LGG	cis	rs6076065	0.722	rs6048760	chr20:23345844	G/T	cg11657817	chr20:23433608	CST11	-0.39	-7.93	-0.35	1.6e-14	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg07148914	chr20:33460835	GGT7	0.41	6.74	0.3	4.7e-11	Coronary artery disease;
LGG	cis	rs11758351	0.660	rs77337633	chr6:26233610	T/C	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7917772	0.545	rs3934960	chr10:104355275	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.46	-0.47	5.88e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2562456	0.917	rs2562471	chr19:21715819	C/T	cg00806126	chr19:22604979	ZNF98	0.64	9.53	0.4	9.2e-20	Pain;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg19182353	chr11:118479428	PHLDB1	-0.55	-10.98	-0.45	4.36e-25	Cholesterol, total;
LGG	cis	rs4731207	0.698	rs11979724	chr7:124451045	G/T	cg05630886	chr7:124431682	NA	0.34	7.88	0.34	2.29e-14	Cutaneous malignant melanoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01449415	chr16:3184811	ZNF213	-0.42	-6.87	-0.3	2.11e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs36051895	0.589	rs12682672	chr9:5187941	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-13.49	-0.53	3.2e-35	Pediatric autoimmune diseases;
LGG	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg06611532	chr13:114900021	NA	0.29	7.15	0.32	3.4e-12	Schizophrenia;
LGG	cis	rs9911578	0.967	rs2643124	chr17:56741672	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.26e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09663530	chr15:41953829	MGA	0.43	6.72	0.3	5.4e-11	Cognitive performance;
LGG	cis	rs7312933	0.703	rs1059360	chr12:42554505	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.95	0.31	1.27e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs72772090	0.539	rs72775809	chr5:96183556	C/T	cg00188032	chr5:96141721	ERAP1	0.56	7.29	0.32	1.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg14541582	chr5:601475	NA	-0.69	-10.89	-0.45	9.93e-25	Obesity-related traits;
LGG	cis	rs7635838	0.587	rs347591	chr3:11290122	G/T	cg00170343	chr3:11313890	ATG7	0.52	9.06	0.39	3.75e-18	HDL cholesterol;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07853992	chr17:49197496	SPAG9	-0.44	-7.44	-0.33	5.08e-13	Brain structure;
LGG	trans	rs9929218	0.906	rs33965787	chr16:68828173	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.85	-0.48	1.77e-28	Colorectal cancer;
LGG	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.32e-17	Diabetic kidney disease;
LGG	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.34	-0.4	4.03e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg07747251	chr5:1868357	NA	0.47	9.61	0.41	4.83e-20	Cardiovascular disease risk factors;
LGG	cis	rs5769765	0.908	rs9616216	chr22:50318927	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.99	-0.52	4.18e-33	Schizophrenia;
LGG	cis	rs4740619	0.507	rs10810512	chr9:16009911	A/G	cg14451791	chr9:16040625	NA	-0.28	-6.79	-0.3	3.42e-11	Body mass index;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg26338869	chr17:61819248	STRADA	-0.58	-9.9	-0.42	4.44e-21	Prudent dietary pattern;
LGG	trans	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg07211511	chr3:129823064	LOC729375	-0.65	-9.01	-0.39	5.47e-18	Blood pressure (smoking interaction);
LGG	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg20387954	chr3:183756860	HTR3D	0.52	9.98	0.42	2.32e-21	Anterior chamber depth;
LGG	cis	rs12410462	0.792	rs994666	chr1:227651454	C/T	cg04117972	chr1:227635322	NA	-0.61	-10.29	-0.43	1.62e-22	Major depressive disorder;
LGG	cis	rs8017423	0.967	rs2282030	chr14:90730265	G/A	cg04374321	chr14:90722782	PSMC1	0.9	19.5	0.67	2.92e-62	Mortality in heart failure;
LGG	cis	rs4948275	0.530	rs2393853	chr10:63167688	C/G	cg03237606	chr10:63212265	TMEM26	0.44	8.21	0.36	2.15e-15	Night sleep phenotypes;
LGG	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg09461388	chr22:46763229	CELSR1	-0.67	-6.82	-0.3	2.87e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7246760	0.748	rs111564896	chr19:9722672	C/T	cg16876255	chr19:9731953	ZNF561	0.84	7.5	0.33	3.26e-13	Pursuit maintenance gain;
LGG	cis	rs11074306	0.561	rs931664	chr15:28069983	C/T	cg26402630	chr15:28053930	OCA2	0.36	7.26	0.32	1.66e-12	Uveal melanoma;
LGG	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg08717414	chr16:71523259	ZNF19	-0.52	-7.76	-0.34	5.56e-14	Post bronchodilator FEV1;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg18446336	chr7:2847575	GNA12	-0.3	-7.14	-0.31	3.73e-12	Height;
LGG	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.5	-0.33	3.23e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.75	0.34	5.72e-14	Mood instability;
LGG	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg06917634	chr15:78832804	PSMA4	-0.71	-14.42	-0.56	3.4e-39	Sudden cardiac arrest;
LGG	cis	rs8133932	0.654	rs7280405	chr21:47275611	C/T	cg11214348	chr21:47283868	PCBP3	0.42	7.36	0.32	8.7e-13	Schizophrenia;
LGG	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg09307838	chr4:120376055	NA	0.72	12.17	0.49	9.64e-30	Corneal astigmatism;
LGG	cis	rs897080	0.552	rs1067320	chr2:44633122	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg16141378	chr3:129829833	LOC729375	0.42	9.79	0.41	1.1e-20	Neuroticism;
LGG	cis	rs4148087	0.719	rs9978956	chr21:43599950	T/C	cg08841829	chr21:43638893	ABCG1	-0.52	-6.87	-0.3	2.05e-11	Eating disorder in bipolar disorder;
LGG	cis	rs60180747	0.909	rs78136741	chr15:66728310	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.59	10.01	0.42	1.77e-21	Testicular germ cell tumor;
LGG	trans	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg23762105	chr12:34175262	ALG10	0.34	7.01	0.31	8.73e-12	Morning vs. evening chronotype;
LGG	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg25554036	chr4:6271136	WFS1	0.61	11.39	0.47	1.16e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10463316	0.832	rs246484	chr5:150730938	T/C	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.35	-0.43	1.05e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs10155981	0.510	rs4719704	chr7:22588827	T/G	cg05062323	chr7:22590069	NA	-0.83	-10.08	-0.42	9.64e-22	Bilirubin levels;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg05163923	chr11:71159392	DHCR7	-0.57	-8.38	-0.36	6.49e-16	Vitamin D levels;
LGG	cis	rs9462027	0.588	rs13215181	chr6:34759881	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.26	-0.46	3.62e-26	Systemic lupus erythematosus;
LGG	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs10904908	1.000	rs10795465	chr10:17260525	C/T	cg01003015	chr10:17271136	VIM	-0.54	-8.97	-0.38	7.68e-18	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg21211680	chr2:198530	NA	-1.16	-19.05	-0.66	3.67e-60	Blood protein levels;
LGG	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	8.81	0.38	2.49e-17	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg14926445	chr8:58193284	C8orf71	-0.71	-8.43	-0.36	4.4e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.682	rs7141975	chr14:55542216	G/C	cg04306507	chr14:55594613	LGALS3	0.45	11.01	0.46	3.29e-25	Protein biomarker;
LGG	cis	rs28830936	0.966	rs28432037	chr15:42126779	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.93	-0.52	7.38e-33	Diastolic blood pressure;
LGG	cis	rs6480314	0.636	rs34888891	chr10:70002108	A/G	cg06988349	chr10:69991859	ATOH7	0.35	6.71	0.3	5.61e-11	Optic nerve measurement (disc area);
LGG	cis	rs1152591	0.524	rs1255991	chr14:64661642	G/A	cg21174375	chr14:64681225	SYNE2	0.44	8.34	0.36	8.3e-16	Atrial fibrillation;
LGG	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	9.54	0.41	8.2e-20	Iron status biomarkers;
LGG	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg07615347	chr10:60278583	BICC1	0.62	17.39	0.63	1.7e-52	Refractive error;
LGG	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs2599510	0.807	rs176416	chr2:32652223	A/G	cg02381751	chr2:32503542	YIPF4	-0.51	-8.32	-0.36	1.01e-15	Interleukin-18 levels;
LGG	cis	rs56161922	0.908	rs113826410	chr1:207849815	C/T	cg09557387	chr1:207818395	CR1L	0.95	9.51	0.4	1.03e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs1018836	0.923	rs11784529	chr8:91640956	C/A	cg16814680	chr8:91681699	NA	-0.83	-15.31	-0.58	4.06e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.95	0.42	2.84e-21	Bone mineral density;
LGG	trans	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.97	0.35	1.29e-14	Joint mobility (Beighton score);
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.94e-21	Educational attainment;
LGG	cis	rs2797369	0.609	rs1740477	chr6:101409069	T/C	cg27451362	chr6:101846650	GRIK2	0.76	10.29	0.43	1.68e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.12	0.35	4.19e-15	Prudent dietary pattern;
LGG	cis	rs12540874	0.698	rs13234331	chr7:50560314	G/T	cg04490037	chr7:50633773	DDC	0.31	6.89	0.3	1.85e-11	Systemic sclerosis;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg19223190	chr17:80058835	NA	-0.46	-8.91	-0.38	1.19e-17	Life satisfaction;
LGG	cis	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg04455712	chr21:45112962	RRP1B	0.49	9.07	0.39	3.34e-18	Mean corpuscular volume;
LGG	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg21775007	chr8:11205619	TDH	-0.53	-8.62	-0.37	1.1e-16	Retinal vascular caliber;
LGG	cis	rs6540556	0.643	rs2236903	chr1:209883480	A/T	cg23920097	chr1:209922102	NA	-0.39	-6.91	-0.31	1.58e-11	Red blood cell count;
LGG	cis	rs75920871	1.000	rs1473324	chr11:116821918	T/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.66e-12	Subjective well-being;
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.39	-0.43	7.33e-23	Bipolar disorder;
LGG	cis	rs972578	1.000	rs738379	chr22:43400764	G/T	cg01576275	chr22:43409880	NA	0.23	6.74	0.3	4.67e-11	Mean platelet volume;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.84	0.48	1.91e-28	Obesity-related traits;
LGG	cis	rs7394190	0.748	rs78985317	chr10:75514465	C/T	cg07699608	chr10:75541558	CHCHD1	0.55	7.07	0.31	5.61e-12	Incident atrial fibrillation;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg23131131	chr22:24373011	LOC391322	-0.47	-7.65	-0.33	1.21e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6997458	1.000	rs1532423	chr8:86268313	A/G	cg02393479	chr8:86352350	CA3	-0.31	-6.87	-0.3	2.1e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	cis	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.04	-0.35	7.84e-15	Mood instability;
LGG	cis	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg06360820	chr2:242988706	NA	-0.52	-7.15	-0.32	3.35e-12	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26339992	chr1:28241106	RPA2	-0.42	-6.72	-0.3	5.25e-11	Pancreatic cancer;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg06654118	chr4:1303317	MAEA	0.43	7.33	0.32	1.05e-12	Obesity-related traits;
LGG	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg03929089	chr4:120376271	NA	-0.48	-7.98	-0.35	1.17e-14	HDL cholesterol;
LGG	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22496380	chr5:211416	CCDC127	-1.31	-18.01	-0.64	2.46e-55	Breast cancer;
LGG	trans	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg25214090	chr10:38739885	LOC399744	0.57	10.37	0.43	8.75e-23	Corneal astigmatism;
LGG	cis	rs9296092	0.517	rs55683509	chr6:33471077	A/G	cg13560919	chr6:33536144	NA	-0.92	-16.58	-0.61	8.08e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg15440763	chr7:158190612	PTPRN2	-0.54	-11.77	-0.48	3.59e-28	Obesity-related traits;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg04166393	chr7:2884313	GNA12	0.43	8.43	0.36	4.3e-16	Height;
LGG	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.42e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00769072	chr9:5629304	KIAA1432	0.46	6.91	0.31	1.66e-11	Gut microbiome composition (summer);
LGG	cis	rs35160687	0.644	rs7595785	chr2:86556405	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-7.0	-0.31	8.89e-12	Night sleep phenotypes;
LGG	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg18129748	chr3:49941408	MST1R	0.22	7.12	0.31	4.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.602	rs2682431	chr12:123703226	T/A	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs6141769	0.569	rs6058807	chr20:31264608	T/C	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.05	-0.31	6.35e-12	Subjective well-being;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg18032289	chr17:61959525	GH2	-0.41	-7.02	-0.31	8.03e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs72827839	0.739	rs16953235	chr17:46244948	A/G	cg02219949	chr17:45927392	SP6	0.55	8.21	0.36	2.28e-15	Ease of getting up in the morning;
LGG	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg08344181	chr3:125677491	NA	-0.56	-7.3	-0.32	1.25e-12	Depression;
LGG	cis	rs7246760	0.867	rs73011937	chr19:9832530	T/C	cg16876255	chr19:9731953	ZNF561	0.73	6.91	0.31	1.57e-11	Pursuit maintenance gain;
LGG	cis	rs72843166	0.545	rs1107041	chr17:61005950	C/G	cg27279583	chr17:61514753	CYB561	0.4	6.7	0.3	6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs12282928	0.959	rs12790767	chr11:48332171	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	2.06e-12	Migraine - clinic-based;
LGG	cis	rs5756391	0.782	rs735562	chr22:37296946	C/G	cg21209356	chr22:37319042	CSF2RB	0.33	7.35	0.32	9.29e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.0	-0.52	3.76e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs459193	1.000	rs256903	chr5:55809138	C/A	cg26646659	chr5:55776364	NA	0.3	6.78	0.3	3.65e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg05665937	chr4:1216051	CTBP1	0.4	7.29	0.32	1.32e-12	Longevity;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg23758822	chr17:41437982	NA	0.85	14.81	0.57	6.54e-41	Menopause (age at onset);
LGG	cis	rs1620921	0.621	rs9458046	chr6:161262133	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs12188164	0.965	rs77101200	chr5:443059	G/T	cg26850624	chr5:429559	AHRR	-0.36	-7.83	-0.34	3.46e-14	Cystic fibrosis severity;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg02158880	chr13:53174818	NA	0.41	8.18	0.36	2.81e-15	Lewy body disease;
LGG	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg26446133	chr18:72167187	CNDP2	-0.74	-17.01	-0.62	9.77e-51	Refractive error;
LGG	trans	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24440854	chr1:98386913	DPYD	-0.46	-6.75	-0.3	4.43e-11	Systemic lupus erythematosus;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg11494091	chr17:61959527	GH2	0.53	8.58	0.37	1.45e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg00666640	chr1:248458726	OR2T12	0.49	7.32	0.32	1.11e-12	Autism spectrum disorder;
LGG	cis	rs4253772	0.550	rs6007761	chr22:46670394	C/T	cg24881330	chr22:46731750	TRMU	-0.72	-9.11	-0.39	2.4e-18	LDL cholesterol;Cholesterol, total;
LGG	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg25358565	chr5:93447407	FAM172A	1.4	17.18	0.62	1.52e-51	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	9.12e-12	Lung cancer;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs9486719	1.000	rs2472895	chr6:96870387	A/T	cg06623918	chr6:96969491	KIAA0776	0.74	10.36	0.43	9.25e-23	Migraine;Coronary artery disease;
LGG	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.52	0.44	2.32e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg16724585	chr3:197361211	NA	-0.47	-8.16	-0.35	3.14e-15	Pancreatic cancer;
LGG	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg25237894	chr2:233734115	C2orf82	0.65	12.52	0.5	3.47e-31	Coronary artery disease;
LGG	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg13770153	chr20:60521292	NA	-0.47	-7.81	-0.34	3.75e-14	Body mass index;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg12395012	chr8:11607386	GATA4	0.38	6.7	0.3	6.08e-11	Neuroticism;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg26116260	chr4:7069785	GRPEL1	1.15	22.29	0.72	2.49e-75	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08405073	chr19:11456857	CCDC159;TMEM205	0.43	7.01	0.31	8.27e-12	Gut microbiome composition (summer);
LGG	cis	rs2693698	0.591	rs7152190	chr14:99681012	T/A	cg07440398	chr14:99712966	BCL11B	0.58	11.57	0.47	2.29e-27	Schizophrenia;
LGG	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg19539972	chr4:7069911	GRPEL1	-0.79	-10.7	-0.45	5.16e-24	Monocyte percentage of white cells;
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-17.01	-0.62	9.12e-51	Skin colour saturation;
LGG	cis	rs67311347	0.713	rs4974018	chr3:40307419	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-15.26	-0.58	6.72e-43	Renal cell carcinoma;
LGG	cis	rs2046867	0.628	rs1393584	chr3:72917193	G/T	cg01043669	chr3:72786069	NA	0.4	7.24	0.32	1.91e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10929925	0.966	rs78580465	chr2:6160161	G/A	cg00493617	chr2:6141445	NA	0.32	7.13	0.31	3.91e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs9677476	0.821	rs6731682	chr2:232106245	G/C	cg23338755	chr2:231921595	PSMD1	0.48	7.26	0.32	1.66e-12	Food antigen IgG levels;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg20295408	chr7:1910781	MAD1L1	0.47	8.13	0.35	4.01e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs453301	0.652	rs2043129	chr8:8825504	C/G	cg27411982	chr8:10470053	RP1L1	0.41	7.28	0.32	1.46e-12	Joint mobility (Beighton score);
LGG	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.85	0.38	1.81e-17	Eosinophil percentage of white cells;
LGG	cis	rs8017423	0.647	rs12589952	chr14:90821364	T/C	cg04374321	chr14:90722782	PSMC1	-0.64	-12.76	-0.51	3.59e-32	Mortality in heart failure;
LGG	cis	rs7011049	0.841	rs117219249	chr8:53871963	G/A	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs8056893	0.589	rs2863978	chr16:68343969	C/T	cg07273125	chr16:68295692	NA	-0.37	-7.94	-0.35	1.57e-14	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg02725872	chr8:58115012	NA	-1.04	-15.17	-0.58	1.71e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg01130898	chr2:219473002	PLCD4	0.42	7.2	0.32	2.42e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg09977064	chr17:26684993	TMEM199;POLDIP2	0.51	6.73	0.3	4.92e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg10523679	chr1:76189770	ACADM	-0.69	-10.92	-0.45	7.49e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg13207630	chr7:32358064	NA	0.76	7.57	0.33	2.01e-13	Body mass index;
LGG	cis	rs35740288	0.822	rs2016517	chr15:86229618	C/T	cg07943548	chr15:86304357	KLHL25	-0.35	-6.94	-0.31	1.29e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1620921	0.625	rs28711930	chr6:161272157	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4740619	0.901	rs10756692	chr9:15710207	T/C	cg14451791	chr9:16040625	NA	-0.39	-9.68	-0.41	2.62e-20	Body mass index;
LGG	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.35	-0.4	3.79e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	0.901	rs2450140	chr11:77924388	T/C	cg02023728	chr11:77925099	USP35	0.46	7.94	0.35	1.57e-14	Testicular germ cell tumor;
LGG	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg04156418	chr7:157293606	NA	0.63	14.63	0.56	4.17e-40	Inattentive symptoms;
LGG	cis	rs12724450	0.793	rs71622698	chr1:150404973	G/A	cg03818307	chr1:150480534	ECM1	0.5	7.16	0.32	3.23e-12	Blood protein levels;
LGG	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg26513180	chr16:89883248	FANCA	0.93	20.56	0.69	3.14e-67	Vitiligo;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	trans	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-7.13	-0.31	3.88e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs138024639	1	rs138024639	chr6:28436014	TAAACATA/T	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Breast cancer;
LGG	cis	rs3857067	0.772	rs10516947	chr4:95110897	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.41	-0.33	5.92e-13	Skin colour saturation;
LGG	cis	rs2455799	0.613	rs13071730	chr3:15891035	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.95	-0.35	1.44e-14	Mean platelet volume;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.59	-9.96	-0.42	2.65e-21	Obesity-related traits;
LGG	cis	rs78487399	0.808	rs77527404	chr2:43678387	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs7166081	1.000	rs8042007	chr15:67652976	C/T	cg05925327	chr15:68127851	NA	0.32	6.65	0.3	8.31e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg20336341	chr7:50628841	DDC	0.42	7.34	0.32	9.65e-13	Malaria;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15664640	chr17:80829946	TBCD	0.57	11.45	0.47	6.7399999999999993e-27	Breast cancer;
LGG	cis	rs854037	0.698	rs10052232	chr5:57045167	C/T	cg08523694	chr5:57076192	NA	0.51	7.2	0.32	2.4e-12	Birth weight;
LGG	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg23625390	chr15:77176239	SCAPER	-0.71	-13.91	-0.54	5.16e-37	Blood metabolite levels;
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	18.08	0.64	1.16e-55	Platelet count;
LGG	cis	rs1707322	1.000	rs10158032	chr1:46332701	T/C	cg03146154	chr1:46216737	IPP	0.54	10.44	0.44	4.61e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7527798	0.592	rs10863437	chr1:207817612	T/C	cg09232269	chr1:207846808	CR1L	-0.36	-6.89	-0.3	1.82e-11	Erythrocyte sedimentation rate;
LGG	cis	rs9354308	0.727	rs9363468	chr6:66566692	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.75	-0.3	4.54e-11	Metabolite levels;
LGG	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.81	-0.51	2.25e-32	Response to antipsychotic treatment;
LGG	cis	rs1355223	0.583	rs1396881	chr11:34870506	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.74	14.78	0.57	8.96e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg18876405	chr7:65276391	NA	-0.66	-12.73	-0.51	5.09e-32	Aortic root size;
LGG	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg13010199	chr12:38710504	ALG10B	0.7	14.62	0.56	4.55e-40	Heart rate;
LGG	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg19784903	chr17:45786737	TBKBP1	0.33	7.3	0.32	1.24e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11792861	0.855	rs72607165	chr9:111814498	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.6	0.41	5e-20	Menarche (age at onset);
LGG	cis	rs5769765	0.773	rs7290751	chr22:50318312	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.73	-0.41	1.76e-20	Schizophrenia;
LGG	trans	rs656319	0.580	rs13272793	chr8:10002027	C/T	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.44e-12	Myopia (pathological);
LGG	cis	rs7647973	0.925	rs7429661	chr3:49228800	G/A	cg07636037	chr3:49044803	WDR6	0.77	13.32	0.53	1.78e-34	Menarche (age at onset);
LGG	cis	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg04455712	chr21:45112962	RRP1B	0.53	9.92	0.42	3.68e-21	Mean corpuscular volume;
LGG	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg06618935	chr21:46677482	NA	-0.53	-9.37	-0.4	3.19e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9457247	1.000	rs1819333	chr6:167373547	G/T	cg07741184	chr6:167504864	NA	0.31	6.9	0.31	1.71e-11	Crohn's disease;
LGG	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg12463550	chr7:65579703	CRCP	0.49	8.18	0.36	2.83e-15	Aortic root size;
LGG	cis	rs10189230	0.868	rs5002064	chr2:222353508	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.85e-32	Urate levels in lean individuals;
LGG	cis	rs774359	0.797	rs7046653	chr9:27490967	A/G	cg14173147	chr9:27528300	MOBKL2B	-0.39	-8.19	-0.36	2.48e-15	Amyotrophic lateral sclerosis;
LGG	trans	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg02002194	chr4:3960332	NA	0.39	7.04	0.31	7.01e-12	Mood instability;
LGG	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg16395133	chr6:150326394	RAET1K	0.27	6.77	0.3	4e-11	Alopecia areata;
LGG	cis	rs4906332	0.782	rs12891288	chr14:103999750	C/T	cg23335576	chr14:104009727	NA	0.49	7.68	0.34	9.8e-14	Coronary artery disease;
LGG	cis	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.45	0.53	4.68e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs709400	0.663	rs1022736	chr14:103998423	G/C	cg26031613	chr14:104095156	KLC1	0.82	14.03	0.55	1.59e-37	Body mass index;
LGG	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg13852791	chr20:30311386	BCL2L1	0.73	11.63	0.48	1.38e-27	Mean corpuscular hemoglobin;
LGG	cis	rs4730250	0.707	rs257381	chr7:106803963	T/C	cg02696742	chr7:106810147	HBP1	-0.81	-11.7	-0.48	7.27e-28	Osteoarthritis;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.83	-0.34	3.39e-14	Menarche (age at onset);
LGG	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs17376456	0.877	rs10065056	chr5:93380123	G/T	cg19507638	chr5:93509721	C5orf36	-0.69	-9.56	-0.41	6.95e-20	Diabetic retinopathy;
LGG	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg13334819	chr7:99746414	C7orf59	-0.46	-7.08	-0.31	5.33e-12	Coronary artery disease;
LGG	cis	rs12980942	0.872	rs12974420	chr19:41798660	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.6	7.42	0.33	5.65e-13	Coronary artery disease;
LGG	cis	rs981844	0.712	rs62325150	chr4:154728117	T/G	cg14289246	chr4:154710475	SFRP2	0.64	10.66	0.44	6.8e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs4774899	0.869	rs2733176	chr15:57336589	G/A	cg08128148	chr15:57256372	TCF12	0.31	7.46	0.33	4.22e-13	Urinary tract infection frequency;
LGG	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg00012203	chr2:219082015	ARPC2	0.76	14.49	0.56	1.73e-39	Colorectal cancer;
LGG	cis	rs6764363	0.506	rs4685489	chr3:283807	T/G	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.72e-13	Sudden cardiac arrest;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg21724239	chr8:58056113	NA	0.6	9.25	0.39	8.24e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg07636037	chr3:49044803	WDR6	0.91	16.48	0.61	2.5e-48	Menarche (age at onset);
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg04986931	chr22:39850128	NA	0.39	8.72	0.38	4.85e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	7.26e-22	Axial length;
LGG	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg03970086	chr16:88974840	CBFA2T3	0.4	7.77	0.34	5.24e-14	Social autistic-like traits;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.55e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.7	-12.62	-0.51	1.37e-31	Lymphocyte counts;
LGG	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg08344181	chr3:125677491	NA	-0.68	-7.12	-0.31	4.16e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.58	7.4	0.33	6.34e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg03469862	chr11:68924853	NA	0.45	6.91	0.31	1.6e-11	Blond vs. brown hair color;
LGG	cis	rs892961	0.932	rs747481	chr17:75412143	A/G	cg05865280	chr17:75406074	SEPT9	0.44	10.38	0.43	7.61e-23	Airflow obstruction;
LGG	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.44	-0.33	4.91e-13	Joint mobility (Beighton score);
LGG	cis	rs8044868	0.512	rs4788461	chr16:72156000	C/A	cg23815491	chr16:72088622	HP	0.37	7.92	0.35	1.77e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs12209877	0.788	rs10946425	chr6:21018655	C/T	cg13405222	chr6:20811065	CDKAL1	0.39	7.46	0.33	4.27e-13	Cognitive function;
LGG	cis	rs9381107	1.000	rs9381107	chr6:9469238	G/A	cg14735645	chr6:9486422	NA	-0.47	-7.64	-0.33	1.27e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs3617	0.572	rs2245538	chr3:52852060	T/C	cg11645453	chr3:52864694	ITIH4	0.42	7.09	0.31	5.11e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg12011299	chr4:100065546	ADH4	0.43	8.58	0.37	1.46e-16	Alcohol dependence;
LGG	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg01262667	chr19:19385393	TM6SF2	-0.34	-7.9	-0.34	2.12e-14	Tonsillectomy;
LGG	cis	rs10504130	0.569	rs9650305	chr8:52824673	T/C	cg22653915	chr8:52722023	PXDNL	-0.43	-6.89	-0.3	1.88e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg16885296	chr6:26284938	NA	0.35	7.34	0.32	9.64e-13	Educational attainment;
LGG	cis	rs9894429	1.000	rs7406003	chr17:79597597	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.81	0.54	1.46e-36	Eye color traits;
LGG	cis	rs2640806	0.505	rs7833617	chr8:97355080	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.27	0.32	1.59e-12	Obesity-related traits;
LGG	cis	rs7312774	0.748	rs10492214	chr12:107294758	T/C	cg16260113	chr12:107380972	MTERFD3	0.65	6.79	0.3	3.4e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs9354308	0.764	rs6929536	chr6:66614101	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs7107174	0.786	rs4945266	chr11:78027488	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg25706552	chr1:244017396	NA	0.53	8.57	0.37	1.52e-16	RR interval (heart rate);
LGG	cis	rs9467773	1.000	rs9467773	chr6:26498426	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.32	0.63	3.61e-52	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	0.551	rs2819516	chr1:227637092	A/G	cg04117972	chr1:227635322	NA	0.36	6.64	0.3	8.62e-11	Major depressive disorder;
LGG	cis	rs2013441	1.000	rs3850784	chr17:20185030	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs9341835	0.772	rs9294206	chr6:64141201	A/G	cg00787780	chr6:64151745	NA	0.41	7.45	0.33	4.46e-13	Schizophrenia;
LGG	cis	rs1620921	0.594	rs9365216	chr6:161268818	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.86e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.14	0.32	3.55e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg03517284	chr6:25882590	NA	-0.4	-7.08	-0.31	5.35e-12	Height;
LGG	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg25486957	chr4:152246857	NA	-0.38	-6.67	-0.3	7.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg25019033	chr10:957182	NA	-0.6	-12.68	-0.51	7.58e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs4363385	0.747	rs1415959	chr1:152973690	C/T	cg13444842	chr1:152974279	SPRR3	0.44	9.17	0.39	1.55e-18	Inflammatory skin disease;
LGG	cis	rs2404602	0.692	rs12437733	chr15:77155562	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.8	-0.3	3.34e-11	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03267400	chr2:27273215	AGBL5	0.45	6.86	0.3	2.18e-11	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg04851639	chr8:1020857	NA	-0.43	-9.23	-0.39	9.49e-19	Schizophrenia;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08280861	chr8:58055591	NA	0.5	6.69	0.3	6.31e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg19761014	chr17:28927070	LRRC37B2	0.68	7.9	0.34	2.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg13009111	chr11:71350975	NA	0.32	6.95	0.31	1.27e-11	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16513467	chr10:28822500	WAC	0.47	7.65	0.33	1.17e-13	Cognitive performance;
LGG	cis	rs7216064	1.000	rs9912084	chr17:65868035	A/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.9	-0.38	1.23e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2070488	1.000	rs2268758	chr3:38514049	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.1	0.64	8.75e-56	Electrocardiographic conduction measures;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg09033563	chr22:24373618	LOC391322	0.5	8.32	0.36	9.92e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06759117	chr16:53088791	CHD9	0.46	6.74	0.3	4.7e-11	Gut microbiome composition (summer);
LGG	cis	rs16854884	1.000	rs13068298	chr3:143772247	T/C	cg06585982	chr3:143692056	C3orf58	0.53	8.24	0.36	1.81e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg17971929	chr21:40555470	PSMG1	-0.9	-17.8	-0.64	2.25e-54	Cognitive function;
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg00292662	chr22:38071168	LGALS1	0.89	24.41	0.75	3.45e-85	Fat distribution (HIV);
LGG	cis	rs787274	0.850	rs10733598	chr9:115615329	G/A	cg13803584	chr9:115635662	SNX30	-0.65	-7.91	-0.35	1.85e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4423214	0.592	rs10898191	chr11:71194601	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-8.55	-0.37	1.85e-16	Vitamin D levels;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg07870213	chr5:140052090	DND1	-0.86	-15.64	-0.59	1.4e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15505141	chr4:154388378	KIAA0922	0.44	7.23	0.32	2e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg05941027	chr17:61774174	LIMD2	0.34	8.54	0.37	1.94e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10053473	chr17:62856997	LRRC37A3	0.87	13.71	0.54	3.63e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1.05e-12	Neuroticism;
LGG	trans	rs75804782	0.625	rs10929279	chr2:239468667	A/G	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg14227996	chr4:17616232	MED28	0.53	7.35	0.32	9.33e-13	Opioid sensitivity;
LGG	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.21	-0.32	2.24e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs35160687	0.644	rs4832276	chr2:86545018	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.37	-6.83	-0.3	2.64e-11	Night sleep phenotypes;
LGG	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg18196295	chr10:418757	DIP2C	-0.57	-10.5	-0.44	2.8e-23	Psychosis in Alzheimer's disease;
LGG	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.41	7.25	0.32	1.79e-12	Total cholesterol levels;
LGG	cis	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01300546	chr3:3841853	LRRN1	0.46	6.9	0.31	1.67e-11	Gut microbiome composition (summer);
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg04166393	chr7:2884313	GNA12	0.45	8.38	0.36	6.39e-16	Height;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg25566285	chr7:158114605	PTPRN2	0.67	11.22	0.46	5.39e-26	Response to amphetamines;
LGG	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg07636037	chr3:49044803	WDR6	0.95	20.32	0.69	4.23e-66	Menarche (age at onset);
LGG	cis	rs2274273	0.870	rs13379169	chr14:55741287	C/T	cg04306507	chr14:55594613	LGALS3	0.63	17.74	0.64	4.09e-54	Protein biomarker;
LGG	cis	rs57502260	0.704	rs2186937	chr11:68256847	G/A	cg01657329	chr11:68192670	LRP5	-0.58	-7.42	-0.33	5.61e-13	Total body bone mineral density (age 45-60);
LGG	trans	rs7777677	0.925	rs73543808	chr7:142367857	T/C	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.13	-0.35	3.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg22072935	chr14:105399595	NA	0.52	10.12	0.43	7.21e-22	Rheumatoid arthritis;
LGG	cis	rs2228479	0.702	rs12600151	chr16:89831558	C/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs9287719	0.967	rs6744854	chr2:10747246	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs4293296	0.525	rs12323811	chr14:54811735	C/A	cg11186706	chr14:54815745	NA	0.59	8.09	0.35	5.22e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.85	0.38	1.9e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg02002194	chr4:3960332	NA	-0.4	-7.05	-0.31	6.46e-12	Retinal vascular caliber;
LGG	trans	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg02002194	chr4:3960332	NA	0.43	7.51	0.33	3.16e-13	Retinal vascular caliber;
LGG	cis	rs35538253	0.522	rs10492823	chr16:72018860	G/C	cg03805757	chr16:71968109	PKD1L3	-0.69	-9.46	-0.4	1.51e-19	Post bronchodilator FEV1;
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.93	-0.38	1.04e-17	Aortic root size;
LGG	cis	rs208520	0.545	rs10944874	chr6:66752080	C/T	cg07460842	chr6:66804631	NA	-1.11	-28.97	-0.8	4.85e-106	Exhaled nitric oxide output;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.0	-0.52	3.67e-33	Aortic root size;
LGG	cis	rs516946	0.797	rs11995075	chr8:41534068	T/C	cg01678292	chr8:41522873	ANK1	0.34	7.23	0.32	2.02e-12	Type 2 diabetes;
LGG	cis	rs787274	0.718	rs7869100	chr9:115628533	T/C	cg13803584	chr9:115635662	SNX30	-0.68	-7.75	-0.34	5.85e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg13010199	chr12:38710504	ALG10B	0.77	16.73	0.61	1.82e-49	Heart rate;
LGG	cis	rs9457247	1.000	rs408918	chr6:167399282	G/T	cg07741184	chr6:167504864	NA	0.32	7.02	0.31	7.92e-12	Crohn's disease;
LGG	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-21.39	-0.71	4.39e-71	Hemostatic factors and hematological phenotypes;
LGG	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg27279351	chr12:120934652	DYNLL1	0.81	13.01	0.52	3.22e-33	High light scatter reticulocyte count;
LGG	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg26818257	chr2:241905806	NA	0.38	7.45	0.33	4.68e-13	Urinary metabolites;
LGG	cis	rs2204008	0.665	rs11179830	chr12:38220966	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.45	0.53	5.01e-35	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16677955	chr1:32930380	ZBTB8B	0.45	7.37	0.32	8.1e-13	Cognitive performance;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg00960700	chr17:80709150	TBCD	0.38	6.69	0.3	6.57e-11	Glycated hemoglobin levels;
LGG	cis	rs10504130	0.569	rs12680128	chr8:52679243	A/G	cg22653915	chr8:52722023	PXDNL	-0.43	-6.83	-0.3	2.73e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.94	-0.38	9.12e-18	Self-reported allergy;
LGG	cis	rs2797160	1.000	rs1832979	chr6:125997436	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-7.47	-0.33	3.96e-13	Endometrial cancer;
LGG	cis	rs4740619	0.935	rs7863088	chr9:15623163	A/G	cg14451791	chr9:16040625	NA	-0.38	-9.89	-0.42	4.82e-21	Body mass index;
LGG	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs9783347	1.000	rs4150615	chr11:18365028	A/G	cg03595886	chr11:18357587	GTF2H1	0.37	7.48	0.33	3.71e-13	Pancreatic cancer;
LGG	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.69	-0.51	6.78e-32	Cognitive function;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.89	-0.3	1.89e-11	Lung cancer;
LGG	cis	rs2013441	0.508	rs35124809	chr17:19973338	T/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs7572733	1.000	rs1595823	chr2:198891799	C/T	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg26513180	chr16:89883248	FANCA	0.98	9.2	0.39	1.18e-18	Skin colour saturation;
LGG	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.01e-18	Menarche (age at onset);
LGG	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.83	0.3	2.6e-11	Sjögren's syndrome;
LGG	cis	rs758324	0.580	rs35566767	chr5:131606049	C/G	cg14196790	chr5:131705035	SLC22A5	0.54	6.94	0.31	1.29e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs807669	0.586	rs5746671	chr22:19160899	A/G	cg02655711	chr22:19163373	SLC25A1	0.56	10.35	0.43	9.98e-23	Metabolite levels;
LGG	cis	rs911186	0.812	rs6932590	chr6:27248931	T/C	cg12292205	chr6:26970375	C6orf41	-0.5	-7.99	-0.35	1.05e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg21926883	chr2:100939477	LONRF2	0.7	16.6	0.61	7.06e-49	Intelligence (multi-trait analysis);
LGG	cis	rs11650494	0.570	rs9901650	chr17:47513127	A/G	cg08112188	chr17:47440006	ZNF652	0.95	10.45	0.44	4.27e-23	Prostate cancer;
LGG	cis	rs4356932	0.967	rs4478212	chr4:76958899	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg00405596	chr8:11794950	NA	-0.44	-7.26	-0.32	1.7e-12	Neuroticism;
LGG	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg21775007	chr8:11205619	TDH	0.41	6.91	0.31	1.57e-11	Mood instability;
LGG	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg15208524	chr1:10270712	KIF1B	0.41	7.29	0.32	1.39e-12	Hepatocellular carcinoma;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.48	0.37	2.98e-16	Schizophrenia;
LGG	cis	rs2274273	0.638	rs3825614	chr14:55729387	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.86	0.48	1.68e-28	Protein biomarker;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg03528353	chr17:61819722	STRADA	-0.42	-7.01	-0.31	8.22e-12	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.56	-10.14	-0.43	5.84e-22	Height;
LGG	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg02002194	chr4:3960332	NA	-0.51	-9.98	-0.42	2.22e-21	Retinal vascular caliber;
LGG	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.09	-0.31	5.09e-12	Blood metabolite levels;
LGG	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg07636037	chr3:49044803	WDR6	1.09	27.79	0.79	1.04e-100	Parkinson's disease;
LGG	cis	rs11190604	0.673	rs10883498	chr10:102228709	T/A	cg07570687	chr10:102243282	WNT8B	0.45	7.9	0.34	2.1e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg03264133	chr6:25882463	NA	0.62	11.45	0.47	6.56e-27	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg25019033	chr10:957182	NA	-0.53	-9.09	-0.39	2.86e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02018176	chr4:1364513	KIAA1530	0.49	11.99	0.49	4.89e-29	Longevity;
LGG	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg25664220	chr3:72788482	NA	-0.27	-8.01	-0.35	9.63e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg08975724	chr8:8085496	FLJ10661	0.36	6.8	0.3	3.28e-11	Mood instability;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.02	0.31	8.02e-12	Prudent dietary pattern;
LGG	cis	rs7715811	1.000	rs7715811	chr5:13769974	C/T	cg07548982	chr5:13769939	DNAH5	-0.48	-10.2	-0.43	3.64e-22	Subclinical atherosclerosis traits (other);
LGG	cis	rs752010	0.655	rs10890145	chr1:42086290	A/G	cg16096631	chr1:42092165	HIVEP3	0.76	22.09	0.72	2.12e-74	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.96e-46	Morning vs. evening chronotype;
LGG	cis	rs6694672	1.000	rs4915345	chr1:197102839	A/C	cg13682187	chr1:196946512	CFHR5	0.5	7.07	0.31	5.71e-12	Asthma;
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.92e-14	Bipolar disorder;
LGG	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.57	0.33	2.1e-13	Birth weight;
LGG	trans	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg25214090	chr10:38739885	LOC399744	0.62	10.44	0.44	4.52e-23	Corneal astigmatism;
LGG	cis	rs7107174	0.892	rs7115850	chr11:78045071	C/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.35	-0.32	9.23e-13	Testicular germ cell tumor;
LGG	cis	rs4262150	0.544	rs56346646	chr5:151915603	G/A	cg12297329	chr5:152029980	NA	-0.64	-11.46	-0.47	5.9e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.38	0.61	6.9e-48	Lymphocyte counts;
LGG	cis	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg22857025	chr5:266934	NA	-1.53	-24.6	-0.75	4.44e-86	Breast cancer;
LGG	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg20503657	chr10:835505	NA	0.95	12.89	0.51	1.02e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.95	-0.31	1.25e-11	Bipolar disorder;
LGG	cis	rs2201728	0.702	rs17583939	chr4:100187381	A/G	cg07219303	chr4:100140905	ADH6	-0.37	-6.89	-0.31	1.82e-11	Cardiac Troponin-T levels;
LGG	cis	rs11945232	0.624	rs35607673	chr4:88363217	C/T	cg23841344	chr4:88312519	HSD17B11	-0.43	-6.7	-0.3	6.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs972578	0.668	rs4822207	chr22:43257261	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.98	-0.31	1.01e-11	Mean platelet volume;
LGG	cis	rs2050392	1.000	rs2050392	chr10:30691503	G/A	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.69	-0.44	5.56e-24	Inflammatory bowel disease;
LGG	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg25174290	chr11:3078921	CARS	0.73	15.77	0.59	3.59e-45	Longevity;
LGG	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.77	16.57	0.61	8.85e-49	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg16339924	chr4:17578868	LAP3	0.63	10.56	0.44	1.66e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7291412	1.000	rs7291412	chr22:46459132	G/T	cg23564243	chr22:46441127	LOC100271722	-0.39	-6.66	-0.3	7.67e-11	Dupuytren's disease;Subjective well-being;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg02725872	chr8:58115012	NA	-0.97	-12.92	-0.51	7.73e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg15971980	chr6:150254442	NA	0.46	8.57	0.37	1.51e-16	Lung cancer;
LGG	cis	rs439731	0.628	rs384344	chr16:1078084	C/T	cg08273874	chr16:1060765	NA	-0.44	-6.68	-0.3	6.88e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.84	0.38	2.04e-17	Lung cancer;
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00149659	chr3:10157352	C3orf10	0.72	8.79	0.38	3.01e-17	Alzheimer's disease;
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg18681998	chr4:17616180	MED28	0.84	18.36	0.65	5.95e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12016809	chr21:47604291	C21orf56	0.4	6.79	0.3	3.38e-11	Testicular germ cell tumor;
LGG	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18252515	chr7:66147081	NA	-0.41	-7.18	-0.32	2.8e-12	Aortic root size;
LGG	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg15128208	chr22:42549153	NA	-0.39	-7.81	-0.34	3.82e-14	Cognitive function;
LGG	cis	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs877282	1.000	rs12775643	chr10:773242	G/A	cg22713356	chr15:30763199	NA	0.56	8.67	0.37	7.53e-17	Uric acid levels;
LGG	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg00579200	chr11:133705235	NA	-0.56	-10.41	-0.44	6.3e-23	Childhood ear infection;
LGG	cis	rs72960926	1.000	rs72956984	chr6:75109496	G/A	cg03266952	chr6:74778945	NA	-0.68	-6.8	-0.3	3.25e-11	Metabolite levels (MHPG);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07682378	chr3:150128910	TSC22D2	0.5	8.14	0.35	3.65e-15	Gut microbiome composition (summer);
LGG	cis	rs12282928	1.000	rs6485822	chr11:48292801	C/G	cg26585981	chr11:48327164	OR4S1	0.44	7.27	0.32	1.54e-12	Migraine - clinic-based;
LGG	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg02187348	chr16:89574699	SPG7	0.63	10.48	0.44	3.2e-23	Multiple myeloma (IgH translocation);
LGG	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	cis	rs10089	0.953	rs7713860	chr5:127428789	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.97	0.49	5.87e-29	Ileal carcinoids;
LGG	cis	rs9323205	0.954	rs9672122	chr14:51582391	A/G	cg23942311	chr14:51606299	NA	-0.37	-6.84	-0.3	2.56e-11	Cancer;
LGG	cis	rs9290877	0.637	rs9290879	chr3:188450208	A/G	cg17392043	chr3:188495102	LPP	-0.43	-7.37	-0.32	7.97e-13	IgE levels;
LGG	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.54	0.44	2.07e-23	Neutrophil percentage of white cells;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg01988459	chr11:68622903	NA	-0.63	-12.61	-0.51	1.53e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-7.54	-0.33	2.44e-13	Neuroticism;
LGG	cis	rs7010267	0.570	rs1485295	chr8:120039462	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03298364	chr17:17495252	PEMT	0.48	6.98	0.31	1.03e-11	Gut microbiome composition (summer);
LGG	cis	rs16910800	0.731	rs56768542	chr11:23191946	A/G	cg20040320	chr11:23191996	NA	-0.6	-6.91	-0.31	1.58e-11	Cancer;
LGG	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg10523679	chr1:76189770	ACADM	0.81	14.76	0.57	1.14e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg19507638	chr5:93509721	C5orf36	-0.67	-9.38	-0.4	3.05e-19	Diabetic retinopathy;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.34	0.4	4.21e-19	Bipolar disorder;
LGG	cis	rs9463078	0.605	rs9472409	chr6:44926431	A/G	cg25276700	chr6:44698697	NA	0.35	7.17	0.32	2.93e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2688608	0.592	rs10762559	chr10:75486453	G/C	cg19442545	chr10:75533431	FUT11	-0.44	-7.22	-0.32	2.18e-12	Inflammatory bowel disease;
LGG	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.78	-0.3	3.68e-11	Blood metabolite levels;
LGG	cis	rs17376456	0.825	rs1470150	chr5:93138654	C/T	cg25358565	chr5:93447407	FAM172A	-1.17	-14.61	-0.56	5.23e-40	Diabetic retinopathy;
LGG	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11890956	chr21:40555474	PSMG1	-0.96	-19.58	-0.67	1.25e-62	Cognitive function;
LGG	cis	rs9952991	0.883	rs2847293	chr18:12782448	A/T	cg23598886	chr18:12777645	NA	0.71	9.96	0.42	2.55e-21	Inflammatory skin disease;
LGG	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-7.24	-0.32	1.86e-12	Aortic root size;
LGG	cis	rs3815148	0.569	rs12705406	chr7:106792554	A/G	cg02696742	chr7:106810147	HBP1	0.65	7.56	0.33	2.24e-13	Osteoarthritis;
LGG	cis	rs13294100	0.929	rs8181077	chr9:17580616	A/T	cg11213383	chr9:17579734	SH3GL2	-0.62	-12.02	-0.49	3.76e-29	Parkinson's disease;
LGG	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21659725	chr3:3221576	CRBN	-0.93	-20.85	-0.7	1.43e-68	Intelligence (multi-trait analysis);
LGG	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00889227	chr1:205173544	DSTYK	-0.28	-6.81	-0.3	2.98e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.26	0.69	8.5e-66	Alzheimer's disease;
LGG	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg09021430	chr5:549028	NA	-0.72	-10.11	-0.43	7.65e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.73	8.17	0.35	3e-15	Initial pursuit acceleration;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.51	0.37	2.47e-16	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05602212	chr5:79703393	ZFYVE16	0.43	6.76	0.3	4.25e-11	Gut microbiome composition (summer);
LGG	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	31.32	0.82	1.93e-116	Prudent dietary pattern;
LGG	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs620875	0.920	rs615586	chr11:126848667	A/T	cg06504925	chr11:126872760	NA	-0.55	-7.73	-0.34	6.61e-14	Response to antipsychotic treatment;
LGG	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg18479299	chr3:125709523	NA	-0.56	-7.2	-0.32	2.42e-12	Blood pressure (smoking interaction);
LGG	cis	rs2635047	0.638	rs28718304	chr18:44632830	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	7.03	0.31	7.47e-12	Educational attainment;
LGG	cis	rs12493885	0.818	rs61791541	chr3:153758155	G/T	cg12800244	chr3:153838788	SGEF	-0.8	-9.4	-0.4	2.43e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg05085101	chr17:4890696	CAMTA2	-0.38	-6.7	-0.3	6.19e-11	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.1	-0.39	2.8e-18	Diabetic kidney disease;
LGG	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg21153622	chr11:89784906	NA	-0.4	-6.74	-0.3	4.71e-11	Height;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.37	7.01	0.31	8.51e-12	Schizophrenia;
LGG	cis	rs72634258	0.699	rs2493214	chr1:7994420	A/G	cg00042356	chr1:8021962	PARK7	0.48	7.66	0.34	1.06e-13	Inflammatory bowel disease;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg25706552	chr1:244017396	NA	0.52	8.56	0.37	1.7e-16	RR interval (heart rate);
LGG	cis	rs4696584	0.816	rs55810732	chr4:155410667	G/A	cg04517429	chr4:155413618	DCHS2	-0.33	-7.47	-0.33	4e-13	Folding of antihelix;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-7.04	-0.31	7.08e-12	Height;
LGG	cis	rs6831352	0.918	rs34805407	chr4:100050786	C/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg25237894	chr2:233734115	C2orf82	0.46	7.23	0.32	1.98e-12	Schizophrenia;
LGG	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.75	0.38	4.07e-17	Eosinophil percentage of white cells;
LGG	cis	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.1e-17	Mean corpuscular volume;
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg23422044	chr7:1970798	MAD1L1	-0.66	-11.33	-0.47	1.91e-26	Bipolar disorder;
LGG	cis	rs757110	0.866	rs5215	chr11:17408630	C/T	cg04705435	chr11:17411270	KCNJ11	0.44	8.63	0.37	9.67e-17	Type 2 diabetes;
LGG	cis	rs7267979	0.668	rs4815398	chr20:25237338	C/T	cg06421707	chr20:25228305	PYGB	-0.44	-9.24	-0.39	9.19e-19	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7188861	0.768	rs1646026	chr16:11382695	C/T	cg01510278	chr16:11456238	NA	0.3	7.16	0.32	3.2e-12	HDL cholesterol;
LGG	cis	rs7712401	0.623	rs30057	chr5:122298118	C/T	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs9399135	0.967	rs9376085	chr6:135371224	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg08621203	chr6:150244597	RAET1G	0.45	6.67	0.3	7.24e-11	Lung cancer;
LGG	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg27478167	chr7:817139	HEATR2	-0.43	-6.96	-0.31	1.15e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg02023728	chr11:77925099	USP35	0.45	8.02	0.35	8.76e-15	Testicular germ cell tumor;
LGG	trans	rs225245	0.817	rs225284	chr17:33933006	A/C	cg19694781	chr19:47549865	TMEM160	-0.41	-7.04	-0.31	7.06e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1451375	0.617	rs7790758	chr7:50561544	G/A	cg14593290	chr7:50529359	DDC	-0.66	-11.87	-0.48	1.53e-28	Malaria;
LGG	cis	rs7011049	0.778	rs73601272	chr8:53866659	T/G	cg26025543	chr8:53854495	NA	0.59	8.29	0.36	1.26e-15	Systolic blood pressure;
LGG	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg04374321	chr14:90722782	PSMC1	0.44	6.87	0.3	2.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg18446336	chr7:2847575	GNA12	-0.29	-6.77	-0.3	3.82e-11	Height;
LGG	cis	rs1829883	1.000	rs2460683	chr5:98778568	A/G	cg08333243	chr5:99726346	NA	-0.39	-7.69	-0.34	8.94e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	8.01	0.35	9.22e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06133097	chr7:32552212	AVL9	-0.4	-7.61	-0.33	1.59e-13	Cognitive ability;
LGG	trans	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17712092	chr4:129076599	LARP1B	0.72	14.02	0.55	1.78e-37	Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.44	-0.33	4.8e-13	Lung cancer;
LGG	cis	rs9815354	0.812	rs794890	chr3:42062339	G/T	cg03022575	chr3:42003672	ULK4	-0.59	-7.34	-0.32	9.55e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs7799006	0.634	rs34502289	chr7:2311266	G/A	cg02951883	chr7:2050386	MAD1L1	-0.38	-6.7	-0.3	6.19e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7017914	0.967	rs2100908	chr8:71583310	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.39	-7.1	-0.31	4.88e-12	Bone mineral density;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00495681	chr13:53174319	NA	0.56	10.41	0.44	6.3e-23	Lewy body disease;
LGG	cis	rs7666738	0.830	rs6840766	chr4:99016260	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg12588763	chr5:139555533	C5orf32	0.53	6.92	0.31	1.48e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1670533	1.000	rs2100411	chr4:1074412	T/C	cg27284194	chr4:1044797	NA	0.54	9.92	0.42	3.6e-21	Recombination rate (females);
LGG	cis	rs939658	1.000	rs34286854	chr15:79454374	C/T	cg17916960	chr15:79447300	NA	-0.63	-12.32	-0.5	2.32e-30	Refractive error;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg18379455	chr17:41446167	NA	-0.32	-7.55	-0.33	2.32e-13	Menopause (age at onset);
LGG	cis	rs9487094	0.689	rs9487064	chr6:109667763	G/A	cg01125227	chr6:109776195	MICAL1	0.45	7.97	0.35	1.24e-14	Height;
LGG	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs35123781	1.000	rs13436896	chr5:139067098	G/A	cg21230503	chr5:139085173	NA	0.32	7.68	0.34	9.38e-14	Schizophrenia;
LGG	cis	rs1506636	0.886	rs6945841	chr7:123266094	G/A	cg03229431	chr7:123269106	ASB15	-0.75	-18.61	-0.65	4.01e-58	Plateletcrit;Platelet count;
LGG	cis	rs35740288	0.640	rs11632164	chr15:86109539	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.95	0.38	8.76e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1030877	0.515	rs2679893	chr2:105909554	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.34	0.43	1.08e-22	Obesity-related traits;
LGG	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg08508325	chr11:3079039	CARS	-0.59	-12.97	-0.52	5.02e-33	Longevity;
LGG	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg27490568	chr2:178487706	NA	0.56	11.0	0.46	3.63e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.33	-0.32	1.03e-12	Calcium levels;
LGG	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15369054	chr17:80825471	TBCD	-0.53	-10.09	-0.42	8.68e-22	Breast cancer;
LGG	cis	rs6582630	0.502	rs8186661	chr12:38380781	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.21	0.72	6.42e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2717559	0.522	rs2585158	chr8:143875832	C/T	cg06565975	chr8:143823917	SLURP1	0.29	6.86	0.3	2.26e-11	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs763121	0.815	rs4821799	chr22:39021326	T/G	cg06022373	chr22:39101656	GTPBP1	0.78	15.76	0.59	4.13e-45	Menopause (age at onset);
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.59	-9.82	-0.42	8.55e-21	Longevity;Endometriosis;
LGG	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg20712883	chr12:51590929	POU6F1	0.49	8.34	0.36	8.71e-16	Cisplatin-induced ototoxicity;
LGG	cis	rs2613964	0.548	rs9870733	chr3:112849254	A/G	cg16248390	chr3:112854924	NA	-0.34	-6.73	-0.3	4.96e-11	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs9790314	1.000	rs6794601	chr3:160946769	C/T	cg04691961	chr3:161091175	C3orf57	-0.62	-14.6	-0.56	5.77e-40	Morning vs. evening chronotype;
LGG	cis	rs10193935	1.000	rs4048	chr2:42424595	A/C	cg27598129	chr2:42591480	NA	-0.62	-9.11	-0.39	2.41e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg12661370	chr5:149340060	SLC26A2	-0.49	-6.71	-0.3	5.67e-11	HIV-1 control;
LGG	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg02023728	chr11:77925099	USP35	0.43	7.29	0.32	1.36e-12	Testicular germ cell tumor;
LGG	cis	rs8133932	0.654	rs2839041	chr21:47322616	T/C	cg11214348	chr21:47283868	PCBP3	0.46	8.16	0.35	3.09e-15	Schizophrenia;
LGG	cis	rs1355223	0.583	rs2941057	chr11:34882220	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.46	-0.33	4.32e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2120019	0.935	rs8043181	chr15:75380424	T/C	cg09165964	chr15:75287851	SCAMP5	-0.99	-20.13	-0.68	3.23e-65	Blood trace element (Zn levels);
LGG	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg26031613	chr14:104095156	KLC1	0.49	7.94	0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs922107	0.713	rs359942	chr1:89975959	C/T	cg01128109	chr1:89989507	LRRC8B	0.32	6.7	0.3	6.17e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	trans	rs1459104	0.850	rs1847548	chr11:55355624	C/G	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.62e-11	Body mass index;
LGG	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg01324343	chr3:183735012	ABCC5	0.85	18.33	0.65	7.91e-57	Anterior chamber depth;
LGG	cis	rs12701220	0.553	rs9639882	chr7:1133731	G/A	cg00990874	chr7:1149470	C7orf50	-0.82	-14.5	-0.56	1.48e-39	Bronchopulmonary dysplasia;
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	7.81	0.34	3.75e-14	Tonsillectomy;
LGG	cis	rs1405069	0.506	rs2296934	chr6:36931162	A/G	cg24661236	chr6:36930062	PI16	0.43	9.65	0.41	3.48e-20	Chemerin levels;
LGG	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg18681998	chr4:17616180	MED28	0.73	14.94	0.57	1.87e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs629535	0.862	rs655028	chr8:70049047	T/C	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg24687543	chr11:63912206	MACROD1	0.61	8.46	0.37	3.41e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.4	0.44	6.32e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2153535	0.580	rs2143354	chr6:8517907	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs8017423	0.740	rs7152196	chr14:90703900	G/T	cg04374321	chr14:90722782	PSMC1	0.88	18.47	0.65	1.73e-57	Mortality in heart failure;
LGG	trans	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.65	-0.3	8.17e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1395	0.778	rs60631624	chr2:27497815	T/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.0	-0.31	9.2e-12	Blood metabolite levels;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00689492	chr4:1303491	MAEA	-0.47	-7.97	-0.35	1.22e-14	Obesity-related traits;
LGG	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14373873	chr11:113211441	TTC12	-0.41	-8.52	-0.37	2.32e-16	Neuroticism;
LGG	cis	rs990171	0.955	rs3817465	chr2:103039584	A/T	cg05295703	chr2:102895712	NA	-0.55	-9.69	-0.41	2.53e-20	Lymphocyte counts;
LGG	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg11494091	chr17:61959527	GH2	0.61	10.19	0.43	3.94e-22	Height;
LGG	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg12751644	chr20:60527061	NA	-0.29	-6.93	-0.31	1.41e-11	Body mass index;
LGG	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg06238570	chr21:40685208	BRWD1	-0.51	-8.38	-0.36	6.5e-16	Cognitive function;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.57	0.37	1.51e-16	Obesity-related traits;
LGG	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg02227867	chr8:22457446	C8orf58	-0.46	-8.42	-0.36	4.74e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs977987	0.806	rs4146809	chr16:75415775	A/G	cg03315344	chr16:75512273	CHST6	-0.5	-9.98	-0.42	2.19e-21	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9399135	0.967	rs4896122	chr6:135295081	T/C	cg22676075	chr6:135203613	NA	0.37	6.69	0.3	6.52e-11	Red blood cell count;
LGG	cis	rs283228	0.535	rs2852507	chr6:101844253	G/A	cg27451362	chr6:101846650	GRIK2	0.98	15.33	0.58	3.49e-43	Coenzyme Q10 levels;
LGG	cis	rs763121	0.853	rs3761454	chr22:39066820	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	18.0	0.64	2.53e-55	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.55	0.53	1.76e-35	Obesity-related traits;
LGG	trans	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg05059571	chr16:84539110	KIAA1609	0.53	10.14	0.43	5.68e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg06521331	chr12:34319734	NA	-0.42	-7.72	-0.34	7.42e-14	Morning vs. evening chronotype;
LGG	cis	rs3820928	0.874	rs4675131	chr2:227836742	T/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.8	-0.34	4.26e-14	Pulmonary function;
LGG	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg03701759	chr13:99174930	STK24	-0.38	-7.34	-0.32	9.69e-13	Longevity;
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00761968	chr13:53314142	LECT1	-0.39	-8.09	-0.35	5.15e-15	Lewy body disease;
LGG	cis	rs4926611	1.000	rs4927021	chr1:54107026	C/G	cg23596471	chr1:54105337	GLIS1	0.4	8.18	0.36	2.68e-15	Hand grip strength;
LGG	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.2e-14	HDL cholesterol;
LGG	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg10560079	chr2:191398806	TMEM194B	0.36	7.96	0.35	1.33e-14	Pulse pressure;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.99	-0.42	2.08e-21	Platelet count;
LGG	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg05673287	chr15:77411982	SGK269	-0.44	-9.7	-0.41	2.32e-20	Type 2 diabetes;
LGG	cis	rs7607369	0.679	rs6751527	chr2:219630965	C/G	cg01130898	chr2:219473002	PLCD4	-0.41	-6.93	-0.31	1.44e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs4808199	0.649	rs12983940	chr19:19516431	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	17.58	0.63	2.18e-53	Nonalcoholic fatty liver disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01141237	chr2:198175400	NA	0.44	7.1	0.31	4.85e-12	Cognitive performance;
LGG	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.95	-0.38	8.31e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.94	-0.6	6.27e-46	Platelet count;
LGG	cis	rs2247341	0.965	rs11736125	chr4:1744939	C/T	cg05026014	chr4:1749153	NA	-0.33	-9.27	-0.4	7.25e-19	Hip circumference adjusted for BMI;Height;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.29	-0.4	6.04e-19	Neuroticism;
LGG	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg23205692	chr1:25664452	TMEM50A	0.49	10.71	0.45	4.46e-24	Erythrocyte sedimentation rate;
LGG	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg00990874	chr7:1149470	C7orf50	-0.64	-9.07	-0.39	3.51e-18	Bronchopulmonary dysplasia;
LGG	trans	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.73	13.53	0.53	2.31e-35	Initial pursuit acceleration in psychotic disorders;
LGG	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg20368463	chr18:77673604	PQLC1	0.58	7.54	0.33	2.45e-13	Opioid sensitivity;
LGG	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg20821713	chr7:1055600	C7orf50	-0.46	-6.66	-0.3	7.64e-11	Bronchopulmonary dysplasia;
LGG	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg09238746	chr17:78121135	EIF4A3	-0.89	-15.09	-0.57	3.84e-42	Yeast infection;
LGG	cis	rs7301016	0.846	rs17732182	chr12:63026131	C/T	cg01804193	chr12:63026212	NA	0.55	7.15	0.32	3.3e-12	IgG glycosylation;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.42	-0.47	8.65e-27	Personality dimensions;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.27	0.58	6.3e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.24	0.32	1.91e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1595825	0.838	rs6742343	chr2:198666752	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.3	6.85e-11	Ulcerative colitis;
LGG	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg06636001	chr8:8085503	FLJ10661	0.65	12.81	0.51	2.2e-32	Mood instability;
LGG	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg17644776	chr2:200775616	C2orf69	0.57	8.61	0.37	1.16e-16	Schizophrenia;
LGG	cis	rs870825	0.548	rs12513029	chr4:185665118	G/A	cg04058563	chr4:185651563	MLF1IP	0.9	15.57	0.59	3.01e-44	Blood protein levels;
LGG	cis	rs7666738	0.830	rs13147195	chr4:98893334	G/T	cg05340658	chr4:99064831	C4orf37	0.47	7.79	0.34	4.4e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.52	0.5	3.59e-31	Alzheimer's disease;
LGG	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.12	-0.49	1.54e-29	Height;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.05	0.6	2e-46	Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg11859384	chr17:80120422	CCDC57	0.47	8.19	0.36	2.57e-15	Life satisfaction;
LGG	cis	rs7674212	0.541	rs2720464	chr4:104073201	G/A	cg16532752	chr4:104119610	CENPE	-0.38	-6.7	-0.3	6.16e-11	Type 2 diabetes;
LGG	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg26677194	chr12:130822605	PIWIL1	0.56	9.99	0.42	1.98e-21	Menopause (age at onset);
LGG	cis	rs8020289	1.000	rs74068872	chr14:77291214	G/T	cg23436960	chr14:77239540	VASH1	-0.26	-6.82	-0.3	2.93e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs26949	0.511	rs2898287	chr5:59884233	C/G	cg02684056	chr5:59996105	DEPDC1B	-0.4	-6.71	-0.3	5.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	1.000	rs12250013	chr10:60265957	C/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.64	-0.63	1.27e-53	Refractive error;
LGG	cis	rs7666738	0.830	rs6818045	chr4:99049374	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.43e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg19168338	chr16:4465731	CORO7	-0.92	-19.1	-0.66	2.06e-60	Schizophrenia;
LGG	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.25	0.7	1.92e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg14893161	chr1:205819251	PM20D1	0.48	7.74	0.34	6.29e-14	Parkinson's disease;
LGG	cis	rs806215	0.547	rs3757778	chr7:127456607	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	6.76e-12	Type 2 diabetes;
LGG	cis	rs240764	0.817	rs239190	chr6:101129067	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.61	0.33	1.5700000000000001e-13	Neuroticism;
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.62	0.37	1.05e-16	Coronary artery disease;
LGG	cis	rs61990749	0.597	rs28534379	chr14:78172140	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.34	-0.32	9.85e-13	Fibroblast growth factor basic levels;
LGG	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg21174375	chr14:64681225	SYNE2	0.43	8.15	0.35	3.45e-15	Atrial fibrillation;
LGG	cis	rs2742417	1.000	rs2673034	chr3:45755138	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs12195424	0.730	rs78734435	chr6:56303666	A/G	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs7412746	0.658	rs6657388	chr1:150748786	A/G	cg15448220	chr1:150897856	SETDB1	0.38	6.95	0.31	1.23e-11	Melanoma;
LGG	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	15.74	0.59	5.03e-45	Alzheimer's disease;
LGG	cis	rs7301016	0.948	rs10877870	chr12:62923955	A/G	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.43	-0.33	5.28e-13	Lung cancer;
LGG	cis	rs6688613	0.579	rs4657609	chr1:166839174	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.56	8.22	0.36	2.12e-15	Refractive astigmatism;
LGG	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.87	-0.3	2.14e-11	Schizophrenia;
LGG	cis	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg20368463	chr18:77673604	PQLC1	0.58	8.14	0.35	3.7e-15	Opioid sensitivity;
LGG	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg27476859	chr7:2772710	GNA12	0.51	10.22	0.43	2.97e-22	Height;
LGG	cis	rs9677476	0.818	rs9973675	chr2:232095484	G/A	cg23338755	chr2:231921595	PSMD1	0.44	6.67	0.3	7.43e-11	Food antigen IgG levels;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.67	0.59	1.01e-44	Obesity-related traits;
LGG	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.44	-7.11	-0.31	4.54e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs9894429	0.646	rs58398000	chr17:79576923	G/A	cg10661904	chr17:79619235	PDE6G	0.49	10.09	0.42	9.02e-22	Eye color traits;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg06916706	chr16:4465613	CORO7	-0.85	-15.85	-0.59	1.68e-45	Schizophrenia;
LGG	cis	rs757081	0.667	rs12420958	chr11:17100432	G/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.84	-0.38	1.96e-17	Systolic blood pressure;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg27286069	chr11:118481882	PHLDB1	0.5	9.35	0.4	3.89e-19	Systemic lupus erythematosus;
LGG	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.75	0.59	4.55e-45	HDL cholesterol levels;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.51	0.37	2.35e-16	Prostate cancer;
LGG	cis	rs10170846	0.800	rs10194743	chr2:223518151	A/G	cg25565276	chr2:223520875	FARSB	0.7	12.61	0.51	1.52e-31	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg08847335	chr10:891726	LARP4B	-0.54	-9.07	-0.39	3.5e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.43	0.4	2.06e-19	Bone mineral density;
LGG	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg09307838	chr4:120376055	NA	0.81	13.34	0.53	1.46e-34	Corneal astigmatism;
LGG	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg23029597	chr12:123009494	RSRC2	0.93	17.25	0.63	7.34e-52	Body mass index;
LGG	cis	rs701145	0.938	rs2971446	chr3:154073445	G/C	cg17054900	chr3:154042577	DHX36	0.98	12.3	0.5	2.66e-30	Coronary artery disease;
LGG	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg10847948	chr11:71163743	NADSYN1	0.57	8.56	0.37	1.69e-16	Vitamin D levels;
LGG	cis	rs4478858	0.735	rs6679360	chr1:31817936	G/T	cg19084893	chr1:31688959	NA	0.32	6.67	0.3	7.21e-11	Alcohol dependence;
LGG	cis	rs17023223	0.537	rs17023171	chr1:119593268	A/C	cg05756136	chr1:119680316	WARS2	-0.41	-8.02	-0.35	8.79e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2953174	0.529	rs3997219	chr2:241541619	T/C	cg07929629	chr2:241523174	NA	0.61	9.17	0.39	1.57e-18	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00292047	chr11:33279899	HIPK3	0.45	7.16	0.32	3.26e-12	Cognitive performance;
LGG	cis	rs919433	0.680	rs1563340	chr2:198414713	A/T	cg00792783	chr2:198669748	PLCL1	0.51	8.05	0.35	6.95e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.55	0.59	3.61e-44	Prostate cancer;
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.3	0.4	5.42e-19	Bipolar disorder;
LGG	cis	rs854765	0.565	rs4072738	chr17:17884547	A/C	cg05444541	chr17:17804740	TOM1L2	-0.67	-15.07	-0.57	4.67e-42	Total body bone mineral density;
LGG	cis	rs8114671	0.562	rs6088642	chr20:33483186	G/T	cg07148914	chr20:33460835	GGT7	0.55	9.13	0.39	2.07e-18	Height;
LGG	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-8.12	-0.35	4.19e-15	Neuroticism;
LGG	trans	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg06521331	chr12:34319734	NA	0.44	7.6	0.33	1.61e-13	Heart rate;
LGG	cis	rs9814567	0.712	rs4245905	chr3:134328864	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.6	-0.44	1.2e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg00343986	chr7:65444356	GUSB	0.42	7.19	0.32	2.69e-12	Aortic root size;
LGG	cis	rs11676348	0.791	rs4133195	chr2:218951245	A/G	cg00012203	chr2:219082015	ARPC2	0.55	9.94	0.42	3.11e-21	Ulcerative colitis;
LGG	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg11995313	chr8:8860691	ERI1	0.42	6.94	0.31	1.34e-11	Joint mobility (Beighton score);
LGG	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg11752832	chr7:134001865	SLC35B4	0.63	11.55	0.47	2.63e-27	Mean platelet volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19819145	chr3:35681147	NA	0.47	7.65	0.33	1.14e-13	Cognitive performance;
LGG	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg03788504	chr6:150331562	NA	-0.6	-13.75	-0.54	2.56e-36	Alopecia areata;
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00049323	chr5:472564	LOC25845	0.39	8.62	0.37	1.07e-16	Cystic fibrosis severity;
LGG	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg27532318	chr7:32358331	NA	-0.72	-7.39	-0.32	6.74e-13	Body mass index;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs13102973	0.965	rs4640720	chr4:135850050	G/T	cg14419869	chr4:135874104	NA	0.56	10.7	0.45	5.24e-24	Subjective well-being;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.09e-13	Tonsillectomy;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg27129171	chr3:47204927	SETD2	-0.6	-9.98	-0.42	2.33e-21	Birth weight;
LGG	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.98	-0.35	1.16e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2688608	0.647	rs2461863	chr10:75680236	C/T	cg10168709	chr10:75599394	CAMK2G	-0.37	-7.38	-0.32	7.46e-13	Inflammatory bowel disease;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg21427119	chr20:30132790	HM13	-0.42	-7.17	-0.32	2.93e-12	Mean corpuscular hemoglobin;
LGG	cis	rs8077889	0.750	rs231533	chr17:41945588	A/G	cg26893861	chr17:41843967	DUSP3	-0.85	-11.79	-0.48	2.96e-28	Triglycerides;
LGG	cis	rs35740288	0.770	rs35348278	chr15:86200340	G/A	cg07943548	chr15:86304357	KLHL25	-0.33	-6.66	-0.3	7.64e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-7.88	-0.34	2.33e-14	Obesity-related traits;
LGG	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg11266682	chr4:10021025	SLC2A9	0.55	10.9	0.45	8.98e-25	Bone mineral density;
LGG	cis	rs62238980	0.520	rs62238975	chr22:32569545	C/G	cg02631450	chr22:32366979	NA	0.8	8.08	0.35	5.53e-15	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs615632	0.530	rs10092464	chr8:9804185	C/G	cg21775007	chr8:11205619	TDH	-0.46	-7.12	-0.31	4.22e-12	Neuroticism;
LGG	cis	rs2976388	0.609	rs2717602	chr8:143805683	G/A	cg06565975	chr8:143823917	SLURP1	0.37	9.43	0.4	2.01e-19	Urinary tract infection frequency;
LGG	cis	rs17001868	0.568	rs470113	chr22:40729614	A/G	cg07138101	chr22:40742427	ADSL	0.64	8.09	0.35	5.14e-15	Mammographic density (dense area);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg00586367	chr8:74790437	UBE2W	0.39	6.99	0.31	9.94e-12	Body mass index;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	trans	rs561341	0.941	rs550213	chr17:30317518	C/G	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.61e-81	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.47	-0.33	3.97e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10267417	0.522	rs34452666	chr7:19936665	T/G	cg05791153	chr7:19748676	TWISTNB	0.53	6.76	0.3	4.08e-11	Night sleep phenotypes;
LGG	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg13047869	chr3:10149882	C3orf24	0.53	8.76	0.38	3.65e-17	Alzheimer's disease;
LGG	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Vitiligo;
LGG	trans	rs7777677	0.925	rs4726540	chr7:142366268	C/T	cg18540325	chr9:33795118	PRSS3	-0.42	-7.31	-0.32	1.2e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs7301016	0.652	rs2270732	chr12:62965149	T/C	cg11441379	chr12:63026424	NA	0.51	7.77	0.34	5.19e-14	IgG glycosylation;
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg06558623	chr16:89946397	TCF25	-0.9	-11.78	-0.48	3.38e-28	Skin colour saturation;
LGG	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg27211696	chr2:191398769	TMEM194B	0.4	9.43	0.4	1.96e-19	Pulse pressure;
LGG	cis	rs1371867	0.726	rs1660333	chr8:101309989	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.75	-0.38	4.03e-17	Atrioventricular conduction;
LGG	cis	rs787274	1.000	rs4304397	chr9:115598154	C/T	cg13803584	chr9:115635662	SNX30	0.55	7.02	0.31	7.81e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.89e-12	Bipolar disorder;
LGG	cis	rs7247513	0.897	rs12972944	chr19:12713808	G/A	cg01871581	chr19:12707946	ZNF490	-0.45	-9.14	-0.39	1.99e-18	Bipolar disorder;
LGG	cis	rs975722	0.663	rs9792104	chr7:117087142	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.39	-8.86	-0.38	1.76e-17	Coronary artery disease;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg13395646	chr4:1353034	KIAA1530	-0.39	-6.71	-0.3	5.56e-11	Longevity;
LGG	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.86	0.62	4.61e-50	Anterior chamber depth;
LGG	cis	rs6868223	1.000	rs4263503	chr5:33638872	A/T	cg10594543	chr5:33649717	ADAMTS12	-0.56	-12.57	-0.5	2.24e-31	Mortality in heart failure;
LGG	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg02002194	chr4:3960332	NA	0.49	9.49	0.4	1.27e-19	Systolic blood pressure;
LGG	cis	rs9880211	0.800	rs9865995	chr3:136513350	G/A	cg21827317	chr3:136751795	NA	-0.49	-7.13	-0.31	3.79e-12	Body mass index;Height;
LGG	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg17145862	chr1:211918768	LPGAT1	0.65	8.89	0.38	1.35e-17	Crohn's disease;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs9682041	0.932	rs7631221	chr3:170069893	A/G	cg11886554	chr3:170076028	SKIL	0.76	9.84	0.42	7.25e-21	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs807669	0.935	rs712963	chr22:19156543	A/G	cg02655711	chr22:19163373	SLC25A1	0.67	13.21	0.52	4.89e-34	Metabolite levels;
LGG	cis	rs6708331	0.517	rs11692018	chr2:70369154	A/C	cg01613454	chr2:70366299	NA	0.55	11.06	0.46	2.26e-25	Obesity-related traits;
LGG	cis	rs2239815	0.545	rs5762855	chr22:29246605	A/T	cg02153584	chr22:29168773	CCDC117	0.61	7.29	0.32	1.33e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs8133932	0.727	rs2150453	chr21:47253215	C/T	cg13695288	chr21:47294981	PCBP3	0.36	6.81	0.3	2.98e-11	Schizophrenia;
LGG	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.4	0.4	2.54e-19	Bone mineral density;
LGG	trans	rs1459104	0.570	rs56152290	chr11:54858073	C/T	cg15704280	chr7:45808275	SEPT13	0.74	7.57	0.33	2e-13	Body mass index;
LGG	cis	rs11645898	0.687	rs56129242	chr16:72098260	C/G	cg14768367	chr16:72042858	DHODH	-0.71	-9.73	-0.41	1.77e-20	Blood protein levels;
LGG	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg23625390	chr15:77176239	SCAPER	0.49	9.56	0.41	6.92e-20	Blood metabolite levels;
LGG	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg23625390	chr15:77176239	SCAPER	0.47	9.25	0.4	8.09e-19	Blood metabolite levels;
LGG	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.14	-0.31	3.63e-12	Blood metabolite levels;
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg10587741	chr22:38071170	LGALS1	0.82	21.45	0.71	2.14e-71	Fat distribution (HIV);
LGG	cis	rs2286885	1.000	rs2286885	chr9:129246487	A/C	cg14319473	chr9:129242481	FAM125B	0.45	8.41	0.36	5.19e-16	Intraocular pressure;
LGG	cis	rs4742903	0.904	rs1333941	chr9:106996386	C/G	cg14250997	chr9:106856677	SMC2	0.37	7.85	0.34	2.98e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	2.99e-20	Hypertriglyceridemia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00085830	chr1:182808254	DHX9	0.41	6.9	0.31	1.76e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg21827317	chr3:136751795	NA	0.47	8.54	0.37	1.88e-16	Gestational age at birth (child effect);
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg11878867	chr6:150167359	LRP11	-0.49	-10.02	-0.42	1.61e-21	Lung cancer;
LGG	cis	rs6866344	0.570	rs56236920	chr5:178144617	C/T	cg10224037	chr5:178157518	ZNF354A	0.8	13.21	0.52	4.81e-34	Neutrophil percentage of white cells;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.41	-7.33	-0.32	1.02e-12	Longevity;
LGG	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs1971256	0.500	rs17081284	chr6:151800796	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-7.45	-0.33	4.66e-13	Endometriosis;
LGG	cis	rs1355223	0.525	rs7129533	chr11:34872292	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.36	-0.36	7.56e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1210638	1.000	rs2518806	chr22:18976603	A/G	cg12798833	chr22:18958832	DGCR5	-0.52	-8.54	-0.37	1.94e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.33	4.17e-13	Height;
LGG	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg08603382	chr10:743973	NA	0.43	7.8	0.34	4.2e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs3126085	0.935	rs4845736	chr1:152175551	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.81	0.38	2.49e-17	Atopic dermatitis;
LGG	cis	rs11239187	0.586	rs11239159	chr10:45079665	A/T	cg03916630	chr10:45065415	NA	0.35	8.45	0.37	3.86e-16	Body mass index;
LGG	cis	rs4740619	0.870	rs4740627	chr9:15857875	T/C	cg14451791	chr9:16040625	NA	-0.39	-9.96	-0.42	2.72e-21	Body mass index;
LGG	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg12046867	chr14:103022105	NA	-0.43	-8.48	-0.37	2.95e-16	Platelet count;
LGG	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.55	-0.37	1.87e-16	Neuroticism;
LGG	cis	rs16957091	0.908	rs12906497	chr15:43030660	G/C	cg07484255	chr15:43025164	CDAN1	-0.48	-6.87	-0.3	2.12e-11	MGMT methylation in smokers;
LGG	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg18681998	chr4:17616180	MED28	0.82	18.09	0.64	1.05e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9472414	0.771	rs3799965	chr6:44798617	G/T	cg20913747	chr6:44695427	NA	0.46	6.82	0.3	2.8e-11	Height;
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.86e-28	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.44	0.37	4.07e-16	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg27490568	chr2:178487706	NA	0.51	10.05	0.42	1.27e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg11707556	chr5:10655725	ANKRD33B	0.48	7.06	0.31	6.21e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg23920097	chr1:209922102	NA	-0.49	-8.33	-0.36	9.2e-16	Red blood cell count;
LGG	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg04935436	chr20:30431758	NA	0.41	7.14	0.31	3.62e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.22	-0.43	3.01e-22	Menarche (age at onset);
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs367943	0.698	rs9326900	chr5:112972859	A/G	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs698833	0.506	rs4952705	chr2:44499867	T/C	cg00619915	chr2:44497795	NA	-0.61	-8.62	-0.37	1.05e-16	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1665650	0.789	rs11197806	chr10:118481766	A/G	cg14919929	chr10:118506882	NA	0.41	6.73	0.3	5.03e-11	Colorectal cancer;
LGG	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	cis	rs12681287	0.640	rs10098356	chr8:87442667	A/G	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs9308731	0.644	rs7577824	chr2:111876763	G/A	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.82	-0.3	2.79e-11	Chronic lymphocytic leukemia;
LGG	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg27478167	chr7:817139	HEATR2	-0.43	-6.92	-0.31	1.52e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs3849046	0.817	rs9327813	chr5:137864421	A/T	cg10920316	chr5:137946599	NA	0.43	6.78	0.3	3.73e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg15971980	chr6:150254442	NA	0.46	8.65	0.37	8.32e-17	Lung cancer;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	1.000	rs2269727	chr7:91752690	C/A	cg17063962	chr7:91808500	NA	0.51	9.2	0.39	1.21e-18	Breast cancer;
LGG	cis	rs4740619	0.544	rs9406540	chr9:15824469	T/C	cg14451791	chr9:16040625	NA	0.32	8.03	0.35	8.15e-15	Body mass index;
LGG	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.8e-22	Neutrophil percentage of white cells;
LGG	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg12292205	chr6:26970375	C6orf41	-0.56	-11.09	-0.46	1.64e-25	Schizophrenia;
LGG	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg08603382	chr10:743973	NA	-0.36	-6.66	-0.3	7.74e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-9.78	-0.41	1.2e-20	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.71	0.38	5.55e-17	Longevity;
LGG	cis	rs7918232	0.941	rs1753413	chr10:27397112	T/C	cg14240646	chr10:27532245	ACBD5	-0.74	-10.27	-0.43	1.95e-22	Breast cancer;
LGG	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	9.55	0.41	7.82e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg13012494	chr21:47604986	C21orf56	0.57	9.77	0.41	1.25e-20	Testicular germ cell tumor;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg14926445	chr8:58193284	C8orf71	-0.82	-10.6	-0.44	1.17e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.724	rs6712551	chr2:127998485	G/A	cg10021288	chr2:128175891	PROC	-0.62	-12.62	-0.51	1.4e-31	Protein C levels;
LGG	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg25427524	chr10:38739819	LOC399744	-0.54	-9.15	-0.39	1.89e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12282928	1.000	rs11039668	chr11:48326479	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg00149659	chr3:10157352	C3orf10	0.57	8.12	0.35	4.33e-15	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10234952	chr20:55926623	RAE1	0.44	7.36	0.32	8.36e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg24846343	chr22:24311635	DDTL	0.61	12.26	0.5	3.98e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg04861929	chr11:109293070	C11orf87	0.55	10.09	0.42	9.03e-22	Schizophrenia;
LGG	cis	rs1555322	0.872	rs2425048	chr20:33872723	C/T	cg17927777	chr20:33865990	NA	0.76	8.13	0.35	3.84e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg08508325	chr11:3079039	CARS	-0.59	-12.5	-0.5	4.43e-31	Longevity;
LGG	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg11584989	chr19:19387371	SF4	0.44	7.84	0.34	3.09e-14	Tonsillectomy;
LGG	cis	rs4774899	0.934	rs11632069	chr15:57474756	C/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.44	-0.33	4.84e-13	Urinary tract infection frequency;
LGG	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg03433033	chr1:76189801	ACADM	0.65	10.03	0.42	1.47e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg14191688	chr11:70257035	CTTN	0.6	8.56	0.37	1.7e-16	Coronary artery disease;
LGG	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1506636	0.720	rs633590	chr7:123442156	G/A	cg03229431	chr7:123269106	ASB15	0.57	12.78	0.51	3.15e-32	Plateletcrit;Platelet count;
LGG	trans	rs79911532	0.515	rs117892182	chr7:75805689	C/A	cg19862616	chr7:65841803	NCRNA00174	0.69	7.2	0.32	2.49e-12	Mononucleosis;
LGG	cis	rs785830	0.717	rs617453	chr9:223339	A/G	cg14500300	chr9:211689	NA	0.31	7.76	0.34	5.31e-14	Platelet distribution width;
LGG	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs2708377	0.929	rs73053785	chr12:11162411	T/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.46	7.04	0.31	7.18e-12	Bitter taste perception;
LGG	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg00409905	chr10:38381863	ZNF37A	0.66	13.34	0.53	1.45e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg12438819	chr7:158236134	PTPRN2	0.32	8.46	0.37	3.57e-16	Obesity-related traits;
LGG	cis	rs1670533	1.000	rs6858612	chr4:1053353	C/T	cg27284194	chr4:1044797	NA	0.54	9.69	0.41	2.45e-20	Recombination rate (females);
LGG	cis	rs2117029	0.619	rs2241727	chr12:49525008	G/C	cg24176009	chr12:49580217	TUBA1A	0.63	12.29	0.5	3.05e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2624839	0.704	rs2624838	chr3:50205642	C/G	cg14019146	chr3:50243930	SLC38A3	-0.43	-8.83	-0.38	2.17e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2131877	0.830	rs77855194	chr3:194879589	T/C	cg07250128	chr3:194833983	C3orf21	0.46	7.58	0.33	1.84e-13	Non-small cell lung cancer;
LGG	cis	rs9398803	0.932	rs9401876	chr6:126669479	C/A	cg19875578	chr6:126661172	C6orf173	0.56	10.29	0.43	1.65e-22	Male-pattern baldness;
LGG	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.85	-0.59	1.7e-45	Chronic sinus infection;
LGG	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg18171855	chr10:2543474	NA	0.46	8.21	0.36	2.21e-15	Age-related hearing impairment;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.67	-0.34	1.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs701145	0.938	rs2596630	chr3:153992586	A/G	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.51	-0.33	2.98e-13	Obesity;
LGG	cis	rs9419702	0.639	rs4367873	chr10:133533485	C/T	cg20568497	chr10:133558893	NA	0.35	7.4	0.33	6.52e-13	Survival in rectal cancer;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg04287289	chr16:89883240	FANCA	0.72	8.15	0.35	3.39e-15	Skin colour saturation;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.57	10.5	0.44	2.81e-23	Longevity;
LGG	cis	rs13102973	0.931	rs12643821	chr4:135859614	A/G	cg14419869	chr4:135874104	NA	-0.57	-11.02	-0.46	3.04e-25	Subjective well-being;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.82	15.27	0.58	6.07e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.49	-0.37	2.88e-16	Total body bone mineral density;
LGG	cis	rs9815354	1.000	rs9846634	chr3:41894049	G/A	cg03022575	chr3:42003672	ULK4	0.74	9.29	0.4	6.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg05555928	chr11:63887634	MACROD1	-0.78	-10.58	-0.44	1.37e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6088590	0.648	rs6058105	chr20:33271719	C/T	cg08999081	chr20:33150536	PIGU	0.39	9.73	0.41	1.76e-20	Coronary artery disease;
LGG	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg04691961	chr3:161091175	C3orf57	0.42	8.79	0.38	2.93e-17	Kawasaki disease;
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg17691542	chr6:26056736	HIST1H1C	0.59	10.48	0.44	3.43e-23	Height;
LGG	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg03433033	chr1:76189801	ACADM	0.81	14.72	0.56	1.72e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg13263323	chr15:86062960	AKAP13	-0.39	-8.43	-0.36	4.31e-16	Interstitial lung disease;
LGG	trans	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg06521331	chr12:34319734	NA	-0.4	-6.99	-0.31	9.44e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg05194412	chr2:137003533	NA	0.37	8.07	0.35	6.29e-15	Colorectal cancer;
LGG	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-8.44	-0.37	4.22e-16	Oral cavity cancer;
LGG	cis	rs12153243	0.714	rs2895168	chr5:142895518	A/G	cg13907255	chr5:142895549	NA	-0.49	-8.49	-0.37	2.82e-16	Migraine;
LGG	cis	rs459571	0.606	rs457420	chr9:136909261	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.49	-9.41	-0.4	2.39e-19	Platelet distribution width;
LGG	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25355226	chr3:150320980	SELT	0.51	7.63	0.33	1.35e-13	Gut microbiome composition (summer);
LGG	cis	rs2070997	0.715	rs11244164	chr9:133736116	A/G	cg03924115	chr9:133768966	QRFP	0.41	7.18	0.32	2.78e-12	Response to amphetamines;
LGG	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.33	-0.5	2.16e-30	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.660	rs62465434	chr7:66005152	A/C	cg18876405	chr7:65276391	NA	0.63	11.92	0.48	9.12e-29	Aortic root size;
LGG	cis	rs9849248	0.585	rs73146095	chr3:88130136	C/T	cg14530983	chr3:88190749	ZNF654	0.57	7.86	0.34	2.63e-14	Menarche (age at onset);
LGG	cis	rs9814567	0.858	rs4955548	chr3:134341060	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.34	-0.5	1.93e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg11266682	chr4:10021025	SLC2A9	0.45	8.96	0.38	7.73e-18	Bone mineral density;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.76	0.59	4.21e-45	Lung cancer;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	17.69	0.64	6.98e-54	Platelet count;
LGG	cis	rs1348850	0.914	rs2121430	chr2:178318375	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.63	-0.37	9.56e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg06219351	chr7:158114137	PTPRN2	-0.78	-15.0	-0.57	9.86e-42	Calcium levels;
LGG	cis	rs7267979	1.000	rs2258066	chr20:25271326	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.73e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg04455712	chr21:45112962	RRP1B	0.53	9.73	0.41	1.82e-20	Mean corpuscular volume;
LGG	cis	rs11657217	0.677	rs8071194	chr17:77698458	A/C	cg06901238	chr17:77706717	ENPP7	0.48	10.18	0.43	4.24e-22	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg11494091	chr17:61959527	GH2	-1.11	-32.41	-0.83	3.63e-121	Prudent dietary pattern;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg16141378	chr3:129829833	LOC729375	0.42	9.7	0.41	2.23e-20	Triglycerides;
LGG	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg17809284	chr5:56205270	C5orf35	0.54	10.12	0.43	6.76e-22	Initial pursuit acceleration;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg26338869	chr17:61819248	STRADA	0.47	7.7	0.34	8.51e-14	Prudent dietary pattern;
LGG	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg00717180	chr2:96193071	NA	0.41	7.35	0.32	9.28e-13	HDL cholesterol;
LGG	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg21775007	chr8:11205619	TDH	0.43	6.84	0.3	2.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg27165867	chr14:105738592	BRF1	-0.44	-7.06	-0.31	6.09e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7106204	0.609	rs75825327	chr11:24356616	A/T	ch.11.24196551F	chr11:24239977	NA	0.86	8.85	0.38	1.93e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg16980736	chr17:78789706	RPTOR	-0.61	-7.98	-0.35	1.16e-14	Myopia (pathological);
LGG	cis	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg21775007	chr8:11205619	TDH	-0.59	-9.81	-0.41	9.3e-21	Retinal vascular caliber;
LGG	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg19812747	chr11:111475976	SIK2	0.47	9.6	0.41	5.09e-20	Primary sclerosing cholangitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10726394	chr6:157098467	ARID1B	0.42	6.91	0.31	1.6e-11	Cognitive performance;
LGG	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg15704280	chr7:45808275	SEPT13	-0.71	-11.04	-0.46	2.69e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg03709012	chr19:19516395	GATAD2A	0.97	15.03	0.57	7.26e-42	Nonalcoholic fatty liver disease;
LGG	trans	rs61931739	0.513	rs1486889	chr12:33901229	A/G	cg26384229	chr12:38710491	ALG10B	0.65	12.6	0.51	1.68e-31	Morning vs. evening chronotype;
LGG	cis	rs2737618	0.651	rs2249172	chr1:200082955	A/G	cg21825944	chr1:200113062	NR5A2	0.57	11.33	0.47	1.98e-26	Uric acid levels;
LGG	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.17	0.68	2.17e-65	Smoking behavior;
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg13939156	chr17:80058883	NA	0.56	11.46	0.47	6.11e-27	Life satisfaction;
LGG	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg23933602	chr10:16859644	RSU1	0.63	9.38	0.4	3.03e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg11742103	chr11:62369870	EML3;MTA2	0.62	15.54	0.59	3.98e-44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1032833	0.732	rs79532902	chr2:180046666	G/T	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg07308232	chr7:1071921	C7orf50	-0.71	-14.38	-0.56	5.02e-39	Longevity;Endometriosis;
LGG	cis	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg26384229	chr12:38710491	ALG10B	0.93	20.81	0.7	2.27e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg16680214	chr1:154839983	KCNN3	-0.47	-8.47	-0.37	3.19e-16	Prostate cancer;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg16141378	chr3:129829833	LOC729375	0.41	9.81	0.41	9.49e-21	Joint mobility (Beighton score);
LGG	cis	rs1816752	0.789	rs7986037	chr13:25012853	A/G	cg02811702	chr13:24901961	NA	0.4	7.68	0.34	9.81e-14	Obesity-related traits;
LGG	cis	rs2905347	0.520	rs2905309	chr7:22648542	C/T	cg18045685	chr7:22629474	NA	-0.73	-15.33	-0.58	3.56e-43	Major depression and alcohol dependence;
LGG	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg15454534	chr1:248569605	OR2T1	0.38	6.85	0.3	2.38e-11	Common traits (Other);
LGG	cis	rs11864453	0.713	rs9925763	chr16:72142595	C/A	cg23815491	chr16:72088622	HP	0.5	11.33	0.47	2.02e-26	Fibrinogen levels;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.55	-0.41	7.42e-20	Lung cancer;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg13009111	chr11:71350975	NA	0.31	6.67	0.3	7.52e-11	Neuroticism;
LGG	cis	rs7000551	0.606	rs11780055	chr8:22268929	T/A	cg13512537	chr8:22265999	SLC39A14	-0.48	-7.53	-0.33	2.61e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.77	-0.48	3.73e-28	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03786924	chr6:73331680	KCNQ5	0.41	6.71	0.3	5.7e-11	Cognitive performance;
LGG	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg08035479	chr8:58172643	NA	-0.53	-8.16	-0.35	3.1e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2249694	0.538	rs2026047	chr10:135329616	C/T	cg20169779	chr10:135381914	SYCE1	0.62	8.8	0.38	2.72e-17	Obesity-related traits;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg00830817	chr11:109293614	C11orf87	0.42	6.79	0.3	3.54e-11	Schizophrenia;
LGG	cis	rs2180341	1.000	rs2144743	chr6:127633810	A/T	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	cis	rs7827545	1.000	rs9644456	chr8:135568656	G/T	cg09855544	chr8:135498122	ZFAT	0.46	7.6	0.33	1.65e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.78	0.34	4.83e-14	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07953670	chr7:86781583	DMTF1	0.45	7.22	0.32	2.18e-12	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18500714	chr14:100706288	YY1	0.53	9.01	0.39	5.34e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg05973401	chr12:123451056	ABCB9	0.48	8.13	0.35	3.97e-15	Platelet count;
LGG	cis	rs7507204	0.767	rs62125962	chr19:3410852	A/G	cg08380311	chr19:3435252	NFIC	0.81	11.94	0.49	7.76e-29	Height;
LGG	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg06640241	chr16:89574553	SPG7	0.71	12.23	0.49	5.53e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.32	-0.32	1.07e-12	Bipolar disorder;
LGG	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg02228329	chr11:64053129	BAD;GPR137	-0.51	-6.75	-0.3	4.32e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.54	-9.77	-0.41	1.31e-20	Personality dimensions;
LGG	cis	rs4481887	1.000	rs6671789	chr1:248482931	G/A	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	6.99e-21	Common traits (Other);
LGG	cis	rs4535700	0.501	rs10245725	chr7:55976548	C/T	cg17215666	chr7:56131930	SUMF2	0.43	6.71	0.3	5.56e-11	Macular telangiectasia type 2;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg20991723	chr1:152506922	NA	0.73	14.83	0.57	5.34e-41	Hair morphology;
LGG	cis	rs4803468	1.000	rs10409485	chr19:41920765	C/T	cg14132834	chr19:41945861	ATP5SL	0.5	9.25	0.39	8.22e-19	Height;
LGG	cis	rs546131	0.642	rs508062	chr11:34843820	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	6.99	0.31	9.76e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.9	0.34	2.05e-14	Homoarginine levels;
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg11764359	chr7:65958608	NA	-0.71	-12.48	-0.5	5.34e-31	Aortic root size;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg08645402	chr16:4508243	NA	0.54	9.87	0.42	5.73e-21	Schizophrenia;
LGG	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg27432699	chr2:27873401	GPN1	-0.74	-15.28	-0.58	5.58e-43	Oral cavity cancer;
LGG	cis	rs758324	0.812	rs494349	chr5:131260452	C/A	cg06307176	chr5:131281290	NA	-0.53	-8.73	-0.38	4.52e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02931753	chr4:154074737	TRIM2	0.43	6.98	0.31	1.05e-11	Cognitive performance;
LGG	cis	rs4731207	0.564	rs7776821	chr7:124657504	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7107174	1.000	rs1485483	chr11:77930138	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.5	-0.33	3.37e-13	Testicular germ cell tumor;
LGG	trans	rs12439619	0.693	rs28665836	chr15:82511296	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-8.29	-0.36	1.26e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.538	rs1190339	chr14:103103876	C/T	cg01864069	chr14:103024347	NA	-0.45	-7.95	-0.35	1.44e-14	Platelet count;
LGG	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.68	-0.37	6.8e-17	Initial pursuit acceleration;
LGG	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg02269571	chr22:50332266	NA	-0.67	-10.04	-0.42	1.33e-21	Schizophrenia;
LGG	trans	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.01	0.52	3.47e-33	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs6752107	0.967	rs3792109	chr2:234184417	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.86	0.34	2.78e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2916247	1.000	rs2920464	chr8:92987753	C/T	cg10183463	chr8:93005414	RUNX1T1	0.39	8.16	0.35	3.3e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7639513	0.767	rs9861271	chr3:12707620	A/C	cg23032965	chr3:12705835	RAF1	0.85	16.72	0.61	2.04e-49	Itch intensity from mosquito bite;
LGG	cis	rs17221829	0.965	rs12292340	chr11:89461273	C/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.5	-0.33	3.18e-13	Anxiety in major depressive disorder;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg13453750	chr1:205783389	SLC41A1	0.38	7.68	0.34	9.76e-14	Monocyte percentage of white cells;
LGG	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg11984989	chr7:158649758	WDR60	1.0	13.9	0.54	5.76e-37	Height;
LGG	cis	rs6784615	0.744	rs353548	chr3:52269491	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.71	-7.72	-0.34	7.43e-14	Waist-hip ratio;
LGG	cis	rs7799006	0.789	rs4719468	chr7:2285019	G/C	cg02951883	chr7:2050386	MAD1L1	-0.42	-7.23	-0.32	2.05e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg11366901	chr6:160182831	ACAT2	0.99	14.75	0.57	1.19e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Cannabis dependence symptom count;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg09448879	chr15:79043637	NA	0.55	14.18	0.55	3.7e-38	Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08219700	chr8:58056026	NA	0.45	7.06	0.31	5.99e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.97	0.49	6.06e-29	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg17757837	chr7:157058334	UBE3C	-0.91	-20.45	-0.69	1.12e-66	Body mass index;
LGG	trans	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13065938	chr1:186344998	TPR;C1orf27;MIR548F1	0.42	6.83	0.3	2.73e-11	Cognitive performance;
LGG	cis	rs250677	1.000	rs28173	chr5:148423573	C/T	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.55	-0.33	2.39e-13	Breast cancer;
LGG	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.5	0.33	3.18e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2117029	0.521	rs2114845	chr12:49558533	T/C	cg24176009	chr12:49580217	TUBA1A	0.62	12.19	0.49	8.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	trans	rs2018683	0.745	rs917217	chr7:28975025	G/T	cg19402173	chr7:128379420	CALU	0.56	9.65	0.41	3.39e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg02269571	chr22:50332266	NA	-0.71	-10.91	-0.45	8.39e-25	Schizophrenia;
LGG	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg00666640	chr1:248458726	OR2T12	0.56	8.9	0.38	1.28e-17	Common traits (Other);
LGG	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg22044901	chr15:68126292	NA	-0.42	-6.96	-0.31	1.15e-11	Restless legs syndrome;
LGG	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.53	-0.41	8.61e-20	Common traits (Other);
LGG	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg14092988	chr3:52407081	DNAH1	0.26	6.88	0.3	1.91e-11	Electroencephalogram traits;
LGG	cis	rs56161922	1.000	rs55821028	chr1:207843000	G/A	cg09557387	chr1:207818395	CR1L	0.99	9.66	0.41	3.18e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	trans	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.3	-0.32	1.27e-12	Mood instability;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22779765	chr14:103369786	TRAF3	0.42	7.52	0.33	2.91e-13	Menarche (age at onset);
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	trans	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg08888203	chr3:10149979	C3orf24	0.55	7.92	0.35	1.78e-14	Alzheimer's disease;
LGG	cis	rs2587949	0.615	rs1121798	chr3:4243602	T/C	cg16519197	chr3:4211558	NA	0.33	6.68	0.3	6.92e-11	Periodontitis (DPAL);
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg26838691	chr2:24397539	C2orf84	-0.51	-7.15	-0.32	3.37e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06771106	chr2:113671356	IL1F7	0.38	7.19	0.32	2.56e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg08355456	chr11:67383691	NA	0.52	8.97	0.38	7.62e-18	Mean corpuscular volume;
LGG	cis	rs1595825	0.891	rs892513	chr2:198905874	A/G	cg00982548	chr2:198649783	BOLL	0.52	6.87	0.3	2.14e-11	Ulcerative colitis;
LGG	cis	rs3791406	1.000	rs3791405	chr2:240030284	G/A	cg14550559	chr2:240039617	HDAC4	-0.45	-8.06	-0.35	6.73e-15	Skin aging (microtopography measurement);
LGG	cis	rs7769051	0.803	rs59740783	chr6:133231711	G/A	cg07930552	chr6:133119739	C6orf192	0.69	8.26	0.36	1.56e-15	Type 2 diabetes nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16909824	chr1:151299438	PI4KB	0.48	7.19	0.32	2.54e-12	Gut microbiome composition (summer);
LGG	cis	rs7133214	0.680	rs11049129	chr12:27923119	A/T	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.68	-0.3	6.77e-11	Gut microbiota (functional units);
LGG	trans	rs111706465	1	rs111706465	chr2:239452382	A/C	cg01134436	chr17:81009848	B3GNTL1	0.74	8.22	0.36	2e-15	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg13206674	chr6:150067644	NUP43	0.42	8.99	0.39	6.13e-18	Testicular germ cell tumor;
LGG	cis	rs9814567	0.896	rs6763188	chr3:134349995	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.68	0.51	8.03e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg11494091	chr17:61959527	GH2	1.0	24.03	0.74	1.96e-83	Prudent dietary pattern;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-19.83	-0.68	8.44e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08219700	chr8:58056026	NA	0.46	6.96	0.31	1.15e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.51	9.94	0.42	3.14e-21	Obesity-related traits;
LGG	trans	rs61931739	1.000	rs1852223	chr12:34013251	C/T	cg26384229	chr12:38710491	ALG10B	-0.59	-10.79	-0.45	2.28e-24	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.73	13.99	0.55	2.4e-37	Obesity-related traits;
LGG	cis	rs41005	1.000	rs798450	chr2:8107093	C/T	cg03155496	chr2:8117019	LOC339788	0.88	19.95	0.68	2.25e-64	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs4268898	0.862	rs11125549	chr2:24576240	C/T	cg06627628	chr2:24431161	ITSN2	0.51	8.45	0.37	3.92e-16	Asthma;
LGG	cis	rs12421382	0.543	rs11213094	chr11:109357926	G/A	cg27471124	chr11:109292789	C11orf87	0.8	17.76	0.64	3.51e-54	Schizophrenia;
LGG	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs897080	0.515	rs1067337	chr2:44624859	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.85	-0.3	2.4e-11	Height;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.69	0.51	7.39e-32	Obesity-related traits;
LGG	cis	rs6882716	0.534	rs7719906	chr5:10809586	G/A	cg14521931	chr5:10832172	NA	-1.06	-18.63	-0.65	3.27e-58	Alcohol consumption (maxi-drinks);
LGG	cis	rs4006360	0.531	rs7502102	chr17:39307041	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.66	-14.8	-0.57	7.55e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg13902645	chr11:5959945	NA	-0.66	-10.75	-0.45	3.28e-24	DNA methylation (variation);
LGG	cis	rs4891159	0.584	rs689878	chr18:74152017	C/T	cg24786174	chr18:74118243	ZNF516	0.68	16.9	0.62	3.05e-50	Longevity;
LGG	cis	rs4731207	0.623	rs1600744	chr7:124585960	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2832191	0.967	rs2251377	chr21:30530599	T/C	cg24692254	chr21:30365293	RNF160	0.85	19.15	0.66	1.23e-60	Dental caries;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02379684	chr5:154181831	LARP1	0.37	7.33	0.32	1.05e-12	Menarche (age at onset);
LGG	cis	rs3126085	0.935	rs10749670	chr1:152220467	G/A	cg26876637	chr1:152193138	HRNR	0.55	9.14	0.39	2.01e-18	Atopic dermatitis;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.51	-0.47	4.06e-27	Personality dimensions;
LGG	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg18551225	chr6:44695536	NA	-0.7	-12.4	-0.5	1.11e-30	Total body bone mineral density;
LGG	cis	rs11920090	0.789	rs55977330	chr3:170756897	A/G	cg09710316	chr3:170744871	SLC2A2	0.69	8.66	0.37	7.93e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	cis	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg12826209	chr6:26865740	GUSBL1	0.8	6.88	0.3	2e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs977987	1.000	rs977985	chr16:75506947	C/G	cg03315344	chr16:75512273	CHST6	0.58	11.48	0.47	5.33e-27	Dupuytren's disease;
LGG	trans	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg06521331	chr12:34319734	NA	-0.5	-8.87	-0.38	1.54e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06966887	chr5:443603	EXOC3;C5orf55	0.48	7.47	0.33	3.94e-13	Gut microbiome composition (summer);
LGG	cis	rs7215564	0.908	rs34267318	chr17:78664619	G/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs6540556	0.682	rs2282741	chr1:209900609	G/C	cg23920097	chr1:209922102	NA	-0.4	-7.34	-0.32	9.78e-13	Red blood cell count;
LGG	cis	rs6087990	0.806	rs6088008	chr20:31382860	A/G	cg13636640	chr20:31349939	DNMT3B	0.94	19.77	0.68	1.61e-63	Ulcerative colitis;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.48	-0.44	3.44e-23	Lymphocyte counts;
LGG	cis	rs7666738	0.830	rs7680909	chr4:98934604	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14928532	chr9:133454630	LOC100272217;FUBP3	0.44	7.47	0.33	4.1e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs721399	0.539	rs2410561	chr8:18266774	G/A	cg18736775	chr8:18248649	NAT2	-0.76	-11.7	-0.48	7.03e-28	Blood metabolite levels;
LGG	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg07395648	chr5:131743802	NA	0.51	10.68	0.44	6.16e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg09307838	chr4:120376055	NA	0.81	13.57	0.53	1.48e-35	Corneal astigmatism;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.12	-0.31	4.13e-12	Personality dimensions;
LGG	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg06598544	chr20:61472147	COL9A3	-0.9	-9.84	-0.42	6.9299999999999992e-21	Obesity-related traits;
LGG	cis	rs1843834	0.898	rs12623277	chr2:225548072	T/G	cg22455342	chr2:225449267	CUL3	0.57	9.78	0.41	1.18e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs55986470	0.763	rs10188853	chr2:239430558	G/C	cg18131467	chr2:239335373	ASB1	-0.55	-6.76	-0.3	4.19e-11	Chronotype;
LGG	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	8.94	0.38	9.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3849046	0.738	rs57958956	chr5:137926641	G/T	cg10920316	chr5:137946599	NA	0.43	6.86	0.3	2.2e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03066081	chr17:77784036	NA	0.43	7.08	0.31	5.22e-12	Gut microbiome composition (summer);
LGG	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg04851639	chr8:1020857	NA	-0.39	-7.98	-0.35	1.18e-14	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11116429	chr5:36607417	SLC1A3	0.41	7.01	0.31	8.51e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17830980	chr10:43048298	ZNF37B	0.45	9.86	0.42	6.26e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs36051895	0.659	rs7856912	chr9:5184449	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-14.56	-0.56	7.9e-40	Pediatric autoimmune diseases;
LGG	cis	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg19399532	chr1:178512495	C1orf220	0.51	10.13	0.43	6.32e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7766436	0.885	rs13199041	chr6:22577718	A/G	cg13666174	chr6:22585274	NA	-0.51	-11.89	-0.48	1.2e-28	Coronary artery disease;
LGG	trans	rs4295623	0.507	rs2256241	chr8:11494657	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.72	-0.34	7.48e-14	Morning vs. evening chronotype;
LGG	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg05555928	chr11:63887634	MACROD1	-0.64	-9.13	-0.39	2.16e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13418717	1.000	rs10496658	chr2:127663497	C/T	cg25501666	chr2:127640322	NA	1.05	8.25	0.36	1.64e-15	Heart failure;
LGG	trans	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg26384229	chr12:38710491	ALG10B	0.79	15.7	0.59	7.53e-45	Morning vs. evening chronotype;
LGG	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg06917634	chr15:78832804	PSMA4	0.49	7.71	0.34	7.88e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs897984	0.542	rs11865038	chr16:31095171	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.28e-14	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.52e-14	Lung cancer;
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg14154082	chr13:112174009	NA	0.37	8.03	0.35	8.35e-15	Menarche (age at onset);
LGG	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg18825076	chr15:78729989	IREB2	-0.48	-7.63	-0.33	1.38e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.49	-9.16	-0.39	1.68e-18	Lymphocyte counts;
LGG	cis	rs59197085	0.636	rs57573379	chr7:128465646	A/G	cg00734629	chr7:128471146	FLNC	0.34	7.05	0.31	6.49e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11890956	chr21:40555474	PSMG1	-0.95	-19.02	-0.66	5.06e-60	Cognitive function;
LGG	cis	rs12079745	0.793	rs12067139	chr1:169254507	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.99	-7.24	-0.32	1.85e-12	QT interval;
LGG	cis	rs59104589	0.959	rs60624480	chr2:242297118	G/A	cg10021735	chr2:242295487	FARP2	0.42	7.69	0.34	8.93e-14	Fibrinogen levels;
LGG	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.54	-0.33	2.56e-13	Colorectal cancer;
LGG	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg25338242	chr13:114786047	RASA3	0.4	7.31	0.32	1.21e-12	Schizophrenia;
LGG	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	16.96	0.62	1.49e-50	Smoking behavior;
LGG	trans	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg07211511	chr3:129823064	LOC729375	-1.37	-21.84	-0.71	3.26e-73	Blood pressure (smoking interaction);
LGG	trans	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.02	-0.31	7.92e-12	Joint mobility (Beighton score);
LGG	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	8.96	0.38	7.8e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.11	-0.39	2.46e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17125944	0.615	rs1998779	chr14:53295950	T/A	cg00686598	chr14:53173677	PSMC6	-0.75	-7.95	-0.35	1.43e-14	Alzheimer's disease (late onset);
LGG	cis	rs17253792	0.822	rs10483650	chr14:56145312	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg07148914	chr20:33460835	GGT7	0.51	8.52	0.37	2.33e-16	Height;
LGG	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.73	0.59	5.41e-45	Intelligence (multi-trait analysis);
LGG	cis	rs977747	0.872	rs10890471	chr1:47676525	C/A	cg03885399	chr1:47691550	TAL1	-0.37	-7.77	-0.34	5.09e-14	Body mass index;
LGG	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg15128208	chr22:42549153	NA	0.75	11.76	0.48	4.09e-28	Birth weight;
LGG	cis	rs1419980	0.556	rs11054516	chr12:7724875	C/T	cg14906510	chr12:7781169	NA	-0.56	-7.23	-0.32	2.06e-12	HDL cholesterol levels;
LGG	cis	rs3087591	0.960	rs12940303	chr17:29604862	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	14.61	0.56	5.19e-40	Hip circumference;
LGG	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.68	-0.75	1.83e-86	Height;
LGG	trans	rs75804782	0.641	rs72987315	chr2:239348474	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	7.99	0.35	1.08e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg18551225	chr6:44695536	NA	-0.62	-10.11	-0.43	7.58e-22	Total body bone mineral density;
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs61990749	0.597	rs10136053	chr14:78155205	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.36	-0.32	8.35e-13	Fibroblast growth factor basic levels;
LGG	cis	rs2153535	0.580	rs9406169	chr6:8509470	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.46	0.5	6.34e-31	Motion sickness;
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-7.05	-0.31	6.75e-12	Bipolar disorder;
LGG	trans	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg26043149	chr18:55253948	FECH	-0.47	-8.11	-0.35	4.73e-15	Bone mineral density;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.29	0.32	1.38e-12	Lung cancer;
LGG	cis	rs5750830	0.569	rs5750809	chr22:39791491	T/G	cg04986931	chr22:39850128	NA	0.35	7.99	0.35	1.07e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg23625390	chr15:77176239	SCAPER	-0.62	-12.09	-0.49	2.03e-29	Blood metabolite levels;
LGG	trans	rs826838	0.934	rs10875647	chr12:38856995	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.27e-14	Heart rate;
LGG	cis	rs3742264	0.656	rs741669	chr13:46516021	C/T	cg15192986	chr13:46630673	CPB2	0.36	7.03	0.31	7.4e-12	Blood protein levels;
LGG	cis	rs2354432	0.599	rs4950423	chr1:146854539	T/C	cg25205988	chr1:146714368	CHD1L	1.19	11.59	0.47	1.98e-27	Mitochondrial DNA levels;
LGG	cis	rs62400317	0.859	rs10456542	chr6:45107579	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.12	-0.43	6.85e-22	Total body bone mineral density;
LGG	cis	rs4780401	0.755	rs8191285	chr16:11765408	A/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.24	-0.32	1.88e-12	Rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.75e-13	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg18252515	chr7:66147081	NA	1.32	18.42	0.65	3.11e-57	Diabetic kidney disease;
LGG	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg07061783	chr6:25882402	NA	-0.44	-7.48	-0.33	3.89e-13	Intelligence (multi-trait analysis);
LGG	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-7.14	-0.31	3.66e-12	Joint mobility (Beighton score);
LGG	cis	rs17818399	1.000	rs62136864	chr2:46829124	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.47	7.92	0.35	1.72e-14	Height;
LGG	cis	rs10782582	0.609	rs1001160	chr1:76358591	A/C	cg10523679	chr1:76189770	ACADM	-0.41	-6.72	-0.3	5.4e-11	Daytime sleep phenotypes;
LGG	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs4774899	0.752	rs7173936	chr15:57418815	A/C	cg08128148	chr15:57256372	TCF12	0.28	6.81	0.3	2.98e-11	Urinary tract infection frequency;
LGG	cis	rs308971	0.611	rs307598	chr3:12102273	T/C	cg15873301	chr3:12045459	SYN2	0.54	7.85	0.34	2.86e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs1712517	0.503	rs72846198	chr10:105098024	G/A	cg04362960	chr10:104952993	NT5C2	-0.5	-8.28	-0.36	1.38e-15	Migraine;
LGG	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs262150	0.731	rs2657388	chr7:158763428	A/G	cg19418458	chr7:158789849	NA	0.42	8.6	0.37	1.28e-16	Facial morphology (factor 20);
LGG	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11890956	chr21:40555474	PSMG1	-1.05	-21.64	-0.71	2.77e-72	Cognitive function;
LGG	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg12615879	chr12:58013172	SLC26A10	0.37	8.62	0.37	1.06e-16	Multiple sclerosis;
LGG	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg11366901	chr6:160182831	ACAT2	1.07	16.29	0.6	1.67e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14893161	chr1:205819251	PM20D1	-0.86	-19.14	-0.66	1.44e-60	Menarche (age at onset);
LGG	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg11890956	chr21:40555474	PSMG1	1.18	29.59	0.81	8.22e-109	Cognitive function;
LGG	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg16511985	chr3:153974050	SGEF	0.49	8.38	0.36	6.24e-16	Coronary artery disease;
LGG	cis	rs10895140	0.756	rs2226560	chr11:101502427	T/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.85	-0.3	2.37e-11	Menarche (age at onset);
LGG	cis	rs526231	0.543	rs34770	chr5:102447646	A/C	cg23492399	chr5:102201601	PAM	-0.57	-8.34	-0.36	8.82e-16	Primary biliary cholangitis;
LGG	cis	rs679087	0.640	rs79708380	chr12:29909457	G/A	cg14258853	chr12:29935411	TMTC1	-0.41	-7.69	-0.34	8.8e-14	Schizophrenia;
LGG	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg15128208	chr22:42549153	NA	0.75	11.48	0.47	5.3e-27	Birth weight;
LGG	cis	rs4819052	0.851	rs2838833	chr21:46665160	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.59	-0.41	5.47e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs72781680	0.716	rs2551343	chr2:24027002	C/G	cg08917208	chr2:24149416	ATAD2B	0.63	8.23	0.36	1.94e-15	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg14088196	chr11:70211408	PPFIA1	0.83	11.16	0.46	9.26e-26	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs113034745	chr4:119750044	T/C	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.9e-21	Cannabis dependence symptom count;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg13206674	chr6:150067644	NUP43	0.63	13.87	0.54	7.9e-37	Lung cancer;
LGG	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg11812906	chr14:75593930	NEK9	0.47	8.36	0.36	7.35e-16	Height;
LGG	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg19729930	chr2:74357872	NA	0.54	11.58	0.47	2.05e-27	Gestational age at birth (maternal effect);
LGG	cis	rs1682825	0.585	rs34139283	chr3:10766079	A/T	cg23512531	chr3:10780469	NA	0.59	9.29	0.4	6.16e-19	Economic and political preferences (feminism/equality);
LGG	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.06	-0.31	6.03e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.36e-23	Bipolar disorder;
LGG	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs990171	1.000	rs3755267	chr2:103038587	G/T	cg05295703	chr2:102895712	NA	0.56	9.52	0.4	9.45e-20	Lymphocyte counts;
LGG	trans	rs8002861	0.905	rs6561150	chr13:44460470	C/T	cg12856521	chr11:46389249	DGKZ	0.41	7.12	0.31	4.08e-12	Leprosy;
LGG	cis	rs2463822	0.925	rs74692811	chr11:62156572	G/A	cg06239285	chr11:62104954	ASRGL1	-1.15	-15.91	-0.59	9.05e-46	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg16512390	chr1:228756714	NA	0.49	6.84	0.3	2.52e-11	Chronic lymphocytic leukemia;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg05793240	chr7:2802953	GNA12	0.37	8.38	0.36	6.2e-16	Height;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs11748327	0.881	rs1353102	chr5:4069616	G/C	cg01025095	chr5:4101132	NA	-0.59	-9.45	-0.4	1.65e-19	Myocardial infarction;
LGG	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.18	-0.77	2.34e-93	Primary sclerosing cholangitis;
LGG	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg08807101	chr21:30365312	RNF160	0.6	8.35	0.36	8.13e-16	Cognitive test performance;
LGG	cis	rs1497406	0.802	rs11588341	chr1:16498048	A/G	cg20430773	chr1:16534157	ARHGEF19	0.26	7.66	0.34	1.11e-13	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	cis	rs1620921	0.742	rs1652463	chr6:161237204	C/A	cg01280913	chr6:161186852	NA	-0.34	-6.93	-0.31	1.39e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9487094	0.626	rs1980591	chr6:109939823	C/T	cg16315928	chr6:109776240	MICAL1	0.46	8.1	0.35	5.09e-15	Height;
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg09845145	chr15:78292470	TBC1D2B	0.69	13.91	0.54	5.3e-37	Coronary artery disease or large artery stroke;
LGG	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg09855544	chr8:135498122	ZFAT	0.46	7.85	0.34	3.01e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg16434002	chr17:42200994	HDAC5	0.44	7.89	0.34	2.25e-14	Total body bone mineral density;
LGG	cis	rs8017423	1.000	rs8017423	chr14:90679910	A/G	cg04374321	chr14:90722782	PSMC1	0.86	17.97	0.64	3.55e-55	Mortality in heart failure;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20786246	chr2:72377174	NA	0.39	6.84	0.3	2.52e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.11	-0.31	4.4e-12	Personality dimensions;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg15763984	chr4:1342303	KIAA1530	0.37	6.74	0.3	4.69e-11	Obesity-related traits;
LGG	cis	rs220324	1.000	rs467990	chr21:43582861	G/A	cg15319517	chr21:43638949	ABCG1	0.45	7.27	0.32	1.5e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.1	-0.43	8.01e-22	Sudden cardiac arrest;
LGG	cis	rs73001065	0.901	rs73004962	chr19:19713069	A/T	cg03709012	chr19:19516395	GATAD2A	0.79	6.96	0.31	1.18e-11	LDL cholesterol;
LGG	cis	rs734999	0.588	rs60520190	chr1:2533706	G/A	cg18854424	chr1:2615690	NA	0.35	7.17	0.32	2.97e-12	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04626574	chr22:26879726	HPS4;SRRD	0.49	7.36	0.32	8.44e-13	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg24375607	chr4:120327624	NA	-0.68	-11.03	-0.46	2.87e-25	Corneal astigmatism;
LGG	trans	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg10756647	chr7:56101905	PSPH	0.84	10.24	0.43	2.45e-22	Diabetic kidney disease;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.87	-10.96	-0.45	5.26e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.5	9.65	0.41	3.41e-20	Longevity;
LGG	cis	rs953387	1.000	rs2102896	chr2:136906640	T/C	cg07169764	chr2:136633963	MCM6	0.53	8.88	0.38	1.45e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.44	0.33	5.08e-13	Lung cancer;
LGG	cis	rs6988985	0.765	rs7011830	chr8:143982392	G/T	cg10324643	chr8:143916377	GML	-0.4	-7.83	-0.34	3.29e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg17108064	chr15:78857060	CHRNA5	-0.41	-8.39	-0.36	6.11e-16	Sudden cardiac arrest;
LGG	cis	rs7617773	0.539	rs12486944	chr3:48390016	G/A	cg11946769	chr3:48343235	NME6	0.51	8.7	0.37	5.81e-17	Coronary artery disease;
LGG	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.32	-0.32	1.14e-12	Fear of minor pain;
LGG	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg17691542	chr6:26056736	HIST1H1C	1.09	16.83	0.62	5.88e-50	Iron status biomarkers;
LGG	cis	rs9397585	0.857	rs6903981	chr6:153379664	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.38	0.56	4.86e-39	Body mass index;
LGG	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg17294928	chr15:75287854	SCAMP5	-0.92	-16.82	-0.62	6.78e-50	Blood trace element (Zn levels);
LGG	cis	rs10892173	0.846	rs2298647	chr11:117671641	A/T	cg21640587	chr11:117668038	DSCAML1	0.45	7.64	0.33	1.29e-13	Myopia;
LGG	cis	rs17767392	0.958	rs34454371	chr14:71881502	C/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.11	0.39	2.59e-18	Mitral valve prolapse;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg19168338	chr16:4465731	CORO7	-1.11	-24.3	-0.75	1.15e-84	Schizophrenia;
LGG	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27297192	chr10:134578999	INPP5A	-0.3	-7.01	-0.31	8.25e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-10.01	-0.42	1.74e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg13443165	chr9:33130375	B4GALT1	-0.6	-9.08	-0.39	3.17e-18	IgG glycosylation;
LGG	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg11871910	chr12:69753446	YEATS4	0.72	14.31	0.55	1.01e-38	Blood protein levels;
LGG	cis	rs12497850	0.644	rs11928552	chr3:48739883	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.86	0.3	2.24e-11	Parkinson's disease;
LGG	cis	rs7937890	0.706	rs7115393	chr11:14268378	T/A	cg22961513	chr11:14280813	SPON1	0.29	6.78	0.3	3.68e-11	Mitochondrial DNA levels;
LGG	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.9	-0.34	2.11e-14	HDL cholesterol;
LGG	cis	rs16854884	0.586	rs6440212	chr3:143748526	T/C	cg06585982	chr3:143692056	C3orf58	0.69	12.43	0.5	7.99e-31	Economic and political preferences (feminism/equality);
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	4.02e-21	Bipolar disorder;
LGG	trans	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg01620082	chr3:125678407	NA	-0.63	-7.0	-0.31	8.97e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500395	1.000	rs1386040	chr16:48631207	A/G	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.23	0.32	2.04e-12	Retinal vascular caliber;
LGG	cis	rs12470837	1	rs12470837	chr2:132582511	T/C	cg16789863	chr2:132589606	NA	0.57	8.65	0.37	8.32e-17	Cerebrospinal fluid clusterin levels in APOEe4+ carriers;Cerebrospinal fluid clusterin levels;
LGG	trans	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	trans	rs11039798	0.764	rs7294013	chr11:48762416	G/A	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg18926786	chr6:150244388	RAET1G	0.32	6.88	0.3	1.93e-11	Testicular germ cell tumor;
LGG	cis	rs9486715	0.838	rs9386473	chr6:96873341	C/A	cg18709589	chr6:96969512	KIAA0776	0.4	7.7	0.34	8.21e-14	Headache;
LGG	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-10.04	-0.42	1.37e-21	Common traits (Other);
LGG	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg15103426	chr22:29168792	CCDC117	-0.58	-6.94	-0.31	1.32e-11	Lymphocyte counts;
LGG	cis	rs4144027	0.967	rs4900601	chr14:104358076	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.12	-0.31	4.26e-12	Blood metabolite levels;
LGG	cis	rs975722	0.516	rs4730779	chr7:117023535	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.4	-8.52	-0.37	2.28e-16	Coronary artery disease;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg02273617	chr15:68117586	LBXCOR1	0.33	7.71	0.34	7.68e-14	Obesity;
LGG	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg08125733	chr17:73851984	WBP2	0.44	7.25	0.32	1.77e-12	White matter hyperintensity burden;
LGG	cis	rs68170813	0.596	rs76888321	chr7:106945926	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-10.42	-0.44	5.56e-23	Coronary artery disease;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21862992	chr11:68658383	NA	0.49	8.3	0.36	1.19e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg07541023	chr7:19748670	TWISTNB	0.58	7.86	0.34	2.64e-14	Thyroid stimulating hormone;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.18e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg07511668	chr11:68622177	NA	0.51	9.68	0.41	2.69e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg22643751	chr7:855365	UNC84A	0.36	6.9	0.31	1.74e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs8017423	0.845	rs8005870	chr14:90723172	A/C	cg04374321	chr14:90722782	PSMC1	0.88	18.73	0.66	1.11e-58	Mortality in heart failure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05603623	chr19:8008081	TIMM44	0.41	6.71	0.3	5.53e-11	Cognitive performance;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg01341218	chr17:43662625	NA	-0.65	-11.77	-0.48	3.61e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.19	-0.32	2.64e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs61931739	0.500	rs28692887	chr12:34457075	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.52	-0.33	2.95e-13	Vitamin D levels;
LGG	cis	rs9660992	0.674	rs72745221	chr1:205262337	G/A	cg21545522	chr1:205238299	TMCC2	0.47	8.44	0.37	4.2e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg09303159	chr6:26284866	NA	0.32	7.21	0.32	2.23e-12	Educational attainment;
LGG	cis	rs225245	0.687	rs321614	chr17:33881734	A/G	cg05299278	chr17:33885742	SLFN14	0.38	7.25	0.32	1.73e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg19455335	chr8:22457658	C8orf58	0.42	8.53	0.37	2.1e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12615966	0.790	rs72830459	chr2:105387628	T/G	cg16465502	chr2:105461796	NA	0.87	10.49	0.44	3.02e-23	Pancreatic cancer;
LGG	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-7.74	-0.34	6.49e-14	Self-reported allergy;
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg07234876	chr8:600039	NA	1.17	11.7	0.48	6.98e-28	IgG glycosylation;
LGG	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.75	-0.34	5.7e-14	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00330464	chr19:50143474	RRAS	0.4	6.68	0.3	6.92e-11	Gut microbiome composition (summer);
LGG	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.37	0.53	1.08e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11696845	1.000	rs1555299	chr20:43370106	T/C	cg25301532	chr20:43378953	KCNK15	0.37	8.12	0.35	4.31e-15	Obesity-related traits;
LGG	cis	rs61931739	0.517	rs12367881	chr12:34175508	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs4561483	0.798	rs33629	chr16:11997490	G/A	cg08843971	chr16:11963173	GSPT1	-0.63	-15.56	-0.59	3.08e-44	Testicular germ cell tumor;
LGG	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg03929089	chr4:120376271	NA	-0.97	-21.59	-0.71	5.17e-72	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.81	-0.3	3.1e-11	Lung cancer;
LGG	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.03	-0.31	7.5e-12	Neuroticism;
LGG	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg13482628	chr17:19912719	NA	0.63	12.53	0.5	3.09e-31	Schizophrenia;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-10.89	-0.45	1e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04772025	chr11:68637568	NA	0.73	12.8	0.51	2.49e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2985684	0.901	rs2354448	chr14:50098296	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	cis	rs1003719	0.646	rs9985082	chr21:38501021	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.06	-0.57	5.36e-42	Eye color traits;
LGG	cis	rs17384381	0.834	rs11161614	chr1:85898160	A/C	cg16011679	chr1:85725395	C1orf52	0.53	9.48	0.4	1.31e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3087591	0.960	rs12603885	chr17:29466722	C/T	cg24425628	chr17:29625626	OMG;NF1	0.68	13.89	0.54	6.49e-37	Hip circumference;
LGG	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15128208	chr22:42549153	NA	-0.45	-8.8	-0.38	2.75e-17	Cognitive function;
LGG	cis	rs57590327	0.503	rs11706976	chr3:81899653	C/T	cg07356753	chr3:81810745	GBE1	-0.46	-7.35	-0.32	8.91e-13	Extraversion;
LGG	trans	rs9657904	0.826	rs10933833	chr3:105598185	A/T	cg14088669	chr1:158435396	OR10K1	0.43	8.0	0.35	9.73e-15	Multiple sclerosis;
LGG	cis	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.54	-0.63	3.54e-53	Breast cancer;
LGG	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs13082711	0.554	rs9310843	chr3:27371260	A/G	cg02860705	chr3:27208620	NA	0.63	11.96	0.49	6.73e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg23625390	chr15:77176239	SCAPER	-0.64	-11.58	-0.47	2e-27	Blood metabolite levels;
LGG	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg15145174	chr5:6755386	POLS	-0.4	-7.6	-0.33	1.65e-13	Menopause (age at onset);
LGG	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22601191	chr20:60968625	CABLES2	0.55	9.42	0.4	2.12e-19	Colorectal cancer;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.73	-0.41	1.75e-20	Pancreatic cancer;
LGG	cis	rs17776563	0.593	rs4100934	chr15:89143378	G/C	cg05013243	chr15:89149849	MIR1179	-0.34	-7.08	-0.31	5.45e-12	Thyroid hormone levels;
LGG	cis	rs8014204	0.736	rs2111705	chr14:75261641	G/A	cg06637938	chr14:75390232	RPS6KL1	0.63	11.51	0.47	3.79e-27	Caffeine consumption;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg04503457	chr17:41445688	NA	-0.38	-9.02	-0.39	4.87e-18	Menopause (age at onset);
LGG	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg04058563	chr4:185651563	MLF1IP	-0.47	-10.0	-0.42	1.86e-21	Kawasaki disease;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.07	-0.39	3.37e-18	Neuroticism;
LGG	trans	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.92	-0.38	1.07e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg07667977	chr2:32236247	MEMO1	-0.39	-6.91	-0.31	1.64e-11	Iris color (L* coordinate);
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg06719900	chr11:109292894	C11orf87	0.57	10.54	0.44	2.04e-23	Schizophrenia;
LGG	cis	rs9640161	0.750	rs3735169	chr7:150034378	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.78	-16.07	-0.6	1.62e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg05425664	chr17:57184151	TRIM37	0.68	10.16	0.43	4.94e-22	Intelligence (multi-trait analysis);
LGG	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.43	0.36	4.46e-16	Resting heart rate;
LGG	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.19	-0.39	1.35e-18	Erythrocyte sedimentation rate;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18404041	chr3:52824283	ITIH1	-0.51	-10.02	-0.42	1.57e-21	Bipolar disorder;
LGG	cis	rs4727027	0.865	rs12154368	chr7:148862041	C/T	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg24209194	chr3:40518798	ZNF619	-0.41	-6.67	-0.3	7.4e-11	Renal cell carcinoma;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs509477	0.718	rs273358	chr18:32596784	C/T	cg23791764	chr18:32556832	MAPRE2	0.44	7.33	0.32	1.04e-12	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg12573674	chr2:1569213	NA	-0.64	-9.54	-0.41	8.06e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg06654118	chr4:1303317	MAEA	0.44	7.65	0.33	1.17e-13	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.74	0.66	1.01e-58	Menopause (age at onset);
LGG	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg06421707	chr20:25228305	PYGB	0.5	10.72	0.45	4.12e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg08112188	chr17:47440006	ZNF652	1.33	15.72	0.59	6.2e-45	Prostate cancer;
LGG	trans	rs9354308	0.764	rs9363475	chr6:66588340	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg05775895	chr3:12838266	CAND2	0.56	9.37	0.4	3.23e-19	QRS complex (12-leadsum);
LGG	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg02461776	chr11:598696	PHRF1	0.54	8.66	0.37	7.82e-17	Systemic lupus erythematosus;
LGG	cis	rs35160687	0.644	rs11676515	chr2:86496057	A/G	cg10973622	chr2:86423274	IMMT	-0.41	-7.19	-0.32	2.66e-12	Night sleep phenotypes;
LGG	cis	rs2285947	1.000	rs2285947	chr7:21584088	A/G	cg03697024	chr7:21583438	DNAH11	-0.34	-8.49	-0.37	2.92e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.63	0.54	8.56e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3736594	0.513	rs76013440	chr2:27816315	G/A	cg27432699	chr2:27873401	GPN1	0.57	8.48	0.37	3.02e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs240764	0.817	rs6907240	chr6:101153782	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-7.48	-0.33	3.74e-13	Neuroticism;
LGG	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg12458913	chr13:53173898	NA	1.04	25.95	0.77	2.64e-92	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25880573	chr1:24073129	TCEB3	-0.36	-8.15	-0.35	3.5e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg25566285	chr7:158114605	PTPRN2	0.7	11.57	0.47	2.22e-27	Response to amphetamines;
LGG	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg21153622	chr11:89784906	NA	-0.38	-6.8	-0.3	3.32e-11	HDL cholesterol;
LGG	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg13271783	chr10:134563150	INPP5A	-0.51	-8.24	-0.36	1.79e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs564799	0.966	rs522127	chr3:159734668	A/C	cg04855961	chr3:159719849	NA	-0.28	-7.48	-0.33	3.85e-13	Systemic lupus erythematosus;
LGG	cis	rs9443645	0.527	rs4706743	chr6:79615793	G/T	cg18132916	chr6:79620363	NA	-0.27	-7.25	-0.32	1.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2120019	0.938	rs13056	chr15:75312187	A/G	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.47	-0.65	1.75e-57	Blood trace element (Zn levels);
LGG	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg15596359	chr8:11213517	TDH	-0.41	-8.31	-0.36	1.09e-15	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs6787172	0.593	rs9876322	chr3:158119238	A/C	cg23275840	chr4:47708675	CORIN	0.36	7.39	0.32	6.94e-13	Subjective well-being;
LGG	cis	rs17445240	1.000	rs80212323	chr2:3703959	C/T	cg20720597	chr2:3699334	NA	0.88	9.25	0.4	8e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.28	-0.32	1.47e-12	Schizophrenia;
LGG	cis	rs1014246	1.000	rs2240706	chr10:118466297	C/G	cg14919929	chr10:118506882	NA	0.55	10.14	0.43	5.72e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg21479132	chr6:26055353	NA	0.77	7.58	0.33	1.92e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg00717180	chr2:96193071	NA	-0.42	-7.49	-0.33	3.59e-13	HDL cholesterol;
LGG	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.18e-24	Vitiligo;
LGG	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg17376030	chr22:41985996	PMM1	0.54	8.68	0.37	7.01e-17	Vitiligo;
LGG	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg09441152	chr18:77712293	PQLC1	0.39	6.69	0.3	6.34e-11	Schizophrenia;
LGG	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	17.02	0.62	8.79e-51	Smoking behavior;
LGG	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.72	-0.75	1.22e-86	Height;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg19168338	chr16:4465731	CORO7	0.9	16.67	0.61	3.3e-49	Schizophrenia;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg21782813	chr7:2030301	MAD1L1	0.4	9.66	0.41	3.03e-20	Schizophrenia;
LGG	trans	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg10840412	chr1:235813424	GNG4	0.52	7.0	0.31	9.25e-12	Bipolar disorder;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05665937	chr4:1216051	CTBP1	0.51	9.32	0.4	4.7e-19	Obesity-related traits;
LGG	cis	rs9878978	0.722	rs11706424	chr3:2459623	G/A	cg21928760	chr3:2462534	CNTN4	0.47	9.12	0.39	2.28e-18	Blood pressure (smoking interaction);
LGG	cis	rs3857067	1.000	rs3846291	chr4:95026735	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.79	-0.34	4.31e-14	QT interval;
LGG	cis	rs9300255	0.602	rs941305	chr12:123715266	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1e-13	Neutrophil percentage of white cells;
LGG	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg09021430	chr5:549028	NA	-0.72	-9.92	-0.42	3.57e-21	Obesity-related traits;
LGG	cis	rs9549367	0.713	rs3024757	chr13:113823186	G/T	cg00898013	chr13:113819073	PROZ	-0.49	-9.36	-0.4	3.4e-19	Platelet distribution width;
LGG	cis	rs9308731	0.644	rs1837366	chr2:111874629	C/T	cg18081430	chr2:111878091	BCL2L11	-0.31	-6.68	-0.3	6.7e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.28	-0.58	5.95e-43	Glomerular filtration rate (creatinine);
LGG	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg20587970	chr11:113659929	NA	-1.36	-24.28	-0.75	1.34e-84	Hip circumference adjusted for BMI;
LGG	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	cg15522984	chr1:182991683	LAMC1	0.45	9.38	0.4	3.03e-19	Colorectal cancer;
LGG	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg19455335	chr8:22457658	C8orf58	-0.45	-9.13	-0.39	2.06e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9503598	0.783	rs9503599	chr6:3451048	T/C	cg00476032	chr6:3446245	SLC22A23	0.67	14.48	0.56	1.83e-39	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9534288	0.740	rs7989892	chr13:46630641	C/T	cg15192986	chr13:46630673	CPB2	-0.8	-17.39	-0.63	1.69e-52	Blood protein levels;
LGG	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.54	-7.16	-0.32	3.2e-12	Schizophrenia;
LGG	cis	rs7113874	0.524	rs4929943	chr11:8625354	G/A	cg23764900	chr11:8616102	STK33	0.4	6.89	0.3	1.83e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.41	-0.33	6.11e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.23e-15	Dementia with Lewy bodies;
LGG	cis	rs6835098	0.962	rs10014010	chr4:174083230	C/T	cg08422745	chr4:174089978	GALNT7	-0.84	-15.28	-0.58	5.66e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	17.3	0.63	4.6e-52	Hip circumference adjusted for BMI;
LGG	cis	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg05084668	chr3:125655381	ALG1L	-0.88	-10.99	-0.45	4.12e-25	Blood pressure (smoking interaction);
LGG	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg11366901	chr6:160182831	ACAT2	1.01	16.04	0.6	2.33e-46	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg00290607	chr11:67383545	NA	-0.5	-9.13	-0.39	2.12e-18	Mean corpuscular volume;
LGG	cis	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg26384229	chr12:38710491	ALG10B	1.07	29.05	0.8	2.16e-106	Heart rate;
LGG	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg24565620	chr2:194026	NA	0.64	10.2	0.43	3.54e-22	Blood protein levels;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg27286069	chr11:118481882	PHLDB1	0.6	11.42	0.47	9.05e-27	Systemic lupus erythematosus;
LGG	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg21659725	chr3:3221576	CRBN	0.58	7.66	0.34	1.07e-13	Menarche (age at onset);
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26897989	chr16:1907736	C16orf73	0.91	15.17	0.58	1.8e-42	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.85	0.38	1.84e-17	Lung cancer;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.08	-0.39	3.16e-18	Longevity;Endometriosis;
LGG	cis	rs4938330	0.552	rs3882895	chr11:117090545	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.63	-0.33	1.39e-13	Blood protein levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21156836	chr7:16623139	NA	0.44	7.87	0.34	2.55e-14	Menarche (age at onset);
LGG	cis	rs79146658	0.736	rs4894060	chr2:179751817	T/A	cg17765952	chr2:179737173	CCDC141	-0.61	-8.83	-0.38	2.2e-17	Diastolic blood pressure;
LGG	trans	rs6575793	0.532	rs6575794	chr14:101039724	C/T	cg22806444	chr17:72968764	C17orf28	0.52	8.33	0.36	9.17e-16	Menarche (age at onset);
LGG	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.36e-13	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.79	0.41	1.11e-20	Prudent dietary pattern;
LGG	cis	rs34783982	0.510	rs11073824	chr15:89530760	T/C	cg09489435	chr15:89561491	NA	-0.39	-7.34	-0.32	9.81e-13	Squamous cell lung carcinoma;
LGG	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg16127683	chr15:40268777	EIF2AK4	-0.98	-10.76	-0.45	2.99e-24	Response to haloperidol in psychosis;
LGG	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg04362960	chr10:104952993	NT5C2	0.56	10.5	0.44	2.76e-23	Arsenic metabolism;
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17554472	chr22:41940697	POLR3H	-0.51	-7.23	-0.32	2.04e-12	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01999652	chr6:28220110	ZKSCAN4	0.51	7.79	0.34	4.46e-14	Gut microbiome composition (summer);
LGG	cis	rs9398803	0.865	rs9398808	chr6:126758791	G/T	cg19875578	chr6:126661172	C6orf173	0.58	10.56	0.44	1.65e-23	Male-pattern baldness;
LGG	cis	rs7267979	0.844	rs2424703	chr20:25270124	G/A	cg06421707	chr20:25228305	PYGB	0.43	8.88	0.38	1.51e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg14784868	chr12:69753453	YEATS4	0.73	12.47	0.5	5.83e-31	Response to diuretic therapy;
LGG	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.45	-0.44	4.28e-23	Bone mineral density;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg19524238	chr7:2802976	GNA12	0.39	8.86	0.38	1.66e-17	Height;
LGG	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-9.15	-0.39	1.87e-18	Triglycerides;
LGG	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.5	0.4	1.13e-19	Lung cancer in ever smokers;
LGG	cis	rs9513627	1.000	rs4294655	chr13:100216696	A/G	cg25919922	chr13:100150906	NA	0.69	7.12	0.31	4.16e-12	Obesity-related traits;
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg02772935	chr3:125709198	NA	0.54	6.85	0.3	2.31e-11	Blood pressure (smoking interaction);
LGG	cis	rs2412208	0.839	rs2412214	chr1:7089674	C/T	cg20434152	chr1:7120926	CAMTA1	-0.46	-8.07	-0.35	5.91e-15	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.51	-0.33	3.12e-13	Morning vs. evening chronotype;
LGG	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg00701064	chr4:6280414	WFS1	0.59	10.73	0.45	3.92e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26897989	chr16:1907736	C16orf73	-0.85	-14.04	-0.55	1.54e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.12e-44	Lung cancer;
LGG	cis	rs9902453	0.845	rs12602426	chr17:28158815	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.85	0.54	9.72e-37	Coffee consumption (cups per day);
LGG	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.14	-0.43	6.07e-22	Total body bone mineral density;
LGG	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.95	-0.31	1.26e-11	Colorectal cancer;
LGG	trans	rs75804782	0.572	rs112551758	chr2:239299770	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	6.75	0.3	4.31e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg00405596	chr8:11794950	NA	-0.42	-7.12	-0.31	4.22e-12	Morning vs. evening chronotype;
LGG	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs7539542	0.556	rs10732292	chr1:202891366	T/C	cg19681188	chr1:202830198	LOC148709	0.51	8.51	0.37	2.49e-16	Mean platelet volume;
LGG	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg20757019	chr2:95873242	NA	-0.43	-8.01	-0.35	9.15e-15	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.52	0.37	2.35e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.57	-0.47	2.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs3784262	0.631	rs4646560	chr15:58353546	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.78	-0.3	3.75e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2018055	0.618	rs13205986	chr6:117791674	A/G	cg14611402	chr6:117803162	DCBLD1	-0.29	-8.67	-0.37	7.49e-17	Diastolic blood pressure;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg08219700	chr8:58056026	NA	-0.44	-6.94	-0.31	1.36e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.75	0.48	4.39e-28	Mean corpuscular volume;
LGG	cis	rs6725041	0.792	rs11694300	chr2:213092028	T/C	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs11255291	1.000	rs11255291	chr10:7736904	C/T	cg13340899	chr10:7670827	ITIH5	0.38	6.66	0.3	7.88e-11	Ovarian reserve;
LGG	cis	rs11190604	0.767	rs4559620	chr10:102199935	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.53	0.33	2.63e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	6.73	0.3	5.18e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg15556689	chr8:8085844	FLJ10661	0.61	11.76	0.48	4.24e-28	Schizophrenia;
LGG	trans	rs28595532	0.557	rs28657902	chr4:119305491	C/T	cg26518628	chr1:97050305	NA	-0.92	-12.45	-0.5	6.8e-31	Cannabis dependence symptom count;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg03351412	chr1:154909251	PMVK	0.63	11.92	0.48	8.99e-29	Prostate cancer;
LGG	cis	rs6942756	1.000	rs2012919	chr7:128890812	C/T	cg02491457	chr7:128862824	NA	-0.77	-14.06	-0.55	1.22e-37	White matter hyperintensity burden;
LGG	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	10.52	0.44	2.32e-23	Homoarginine levels;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg22535103	chr8:58192502	C8orf71	-0.97	-15.68	-0.59	9.24e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs8048589	0.559	rs35542345	chr16:12210618	T/C	cg02910054	chr16:12241554	SNX29	0.54	8.39	0.36	5.81e-16	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs7113874	0.569	rs4620720	chr11:8615939	G/A	cg23764900	chr11:8616102	STK33	0.38	6.74	0.3	4.84e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.83	-0.34	3.32e-14	Neuroticism;
LGG	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-7.55	-0.33	2.28e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6462411	0.877	rs28633761	chr7:3914754	A/G	cg18022346	chr7:3920534	SDK1	-0.36	-6.99	-0.31	9.47e-12	Quantitative traits;
LGG	cis	rs1555895	0.656	rs7919815	chr10:842062	C/G	cg09361094	chr10:834503	NA	-0.29	-7.81	-0.34	3.97e-14	Survival in rectal cancer;
LGG	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg00262122	chr8:11665843	FDFT1	0.48	7.69	0.34	9.2e-14	Morning vs. evening chronotype;
LGG	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg18850127	chr7:39170497	POU6F2	0.63	15.99	0.6	4.01e-46	IgG glycosylation;
LGG	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg02951883	chr7:2050386	MAD1L1	0.45	7.18	0.32	2.73e-12	Neuroticism;
LGG	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg06212747	chr3:49208901	KLHDC8B	0.52	8.1	0.35	5.01e-15	Childhood ear infection;
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.3	0.4	5.6e-19	Triglycerides;
LGG	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg08079166	chr15:68083412	MAP2K5	-0.36	-7.98	-0.35	1.17e-14	Restless legs syndrome;
LGG	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14154082	chr13:112174009	NA	0.42	9.28	0.4	6.41e-19	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27310449	chr2:27592944	EIF2B4;SNX17	0.47	6.78	0.3	3.57e-11	Gut microbiome composition (summer);
LGG	trans	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg02002194	chr4:3960332	NA	0.43	8.34	0.36	8.65e-16	Joint mobility (Beighton score);
LGG	cis	rs12368653	0.534	rs923828	chr12:58015494	G/A	cg20892847	chr12:58011875	NA	0.39	8.12	0.35	4.29e-15	Multiple sclerosis;
LGG	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs1847505	0.832	rs1967223	chr13:61520309	C/T	cg25164009	chr13:61490935	NA	-0.61	-9.79	-0.41	1.09e-20	Polychlorinated biphenyl levels;
LGG	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg25174290	chr11:3078921	CARS	-0.44	-7.7	-0.34	8.48e-14	Calcium levels;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs77633900	0.614	rs279999	chr15:76945466	C/T	cg21673338	chr15:77095150	SCAPER	-0.65	-10.17	-0.43	4.62e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1003719	0.679	rs2835674	chr21:38581522	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-14.45	-0.56	2.55e-39	Eye color traits;
LGG	cis	rs9462027	0.628	rs2764211	chr6:34704613	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.65e-24	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.18	-0.43	4.12e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg16606324	chr3:10149918	C3orf24	0.58	7.7	0.34	8.38e-14	Alzheimer's disease;
LGG	cis	rs11792861	0.781	rs2297581	chr9:111755008	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.19	0.43	4.04e-22	Menarche (age at onset);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg08295258	chr5:102455984	GIN1	-0.45	-7.16	-0.32	3.27e-12	Coronary artery disease;
LGG	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg14689365	chr7:158441557	NCAPG2	0.56	6.8	0.3	3.15e-11	Height;
LGG	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg26513180	chr16:89883248	FANCA	0.95	20.76	0.69	3.95e-68	Vitiligo;
LGG	cis	rs6997458	0.785	rs713489	chr8:86342573	G/A	cg02393479	chr8:86352350	CA3	-0.32	-7.13	-0.31	3.93e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg08468577	chr11:2973342	NAP1L4	-0.37	-7.51	-0.33	2.98e-13	Calcium levels;
LGG	cis	rs17221829	0.673	rs10830330	chr11:89392799	G/A	cg02982614	chr11:89391479	FOLH1B	-0.44	-9.45	-0.4	1.66e-19	Anxiety in major depressive disorder;
LGG	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.27e-12	Cystic fibrosis severity;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg17951613	chr5:131705445	SLC22A5	0.66	7.42	0.33	5.74e-13	Rheumatoid arthritis;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg02733842	chr7:1102375	C7orf50	0.73	10.93	0.45	6.67e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg08847533	chr14:75593920	NEK9	0.59	10.9	0.45	8.8e-25	Height;
LGG	cis	rs9287719	0.934	rs4622695	chr2:10744327	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	4.16e-13	Prostate cancer;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.45e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2797369	0.600	rs600653	chr6:101370944	C/T	cg27451362	chr6:101846650	GRIK2	0.77	10.51	0.44	2.68e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs478607	0.749	rs2022050	chr11:64367651	G/A	cg19395706	chr11:64412079	NRXN2	0.42	6.76	0.3	4.04e-11	Urate levels;
LGG	cis	rs4936894	0.519	rs4272792	chr11:124109058	C/G	cg27160556	chr11:124181099	OR8D1	-0.45	-10.43	-0.44	5.17e-23	Aging (time to death);
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg17178900	chr1:205818956	PM20D1	0.41	7.43	0.33	5.16e-13	Prostate-specific antigen levels;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.15	0.52	8.53e-34	Prudent dietary pattern;
LGG	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg18681998	chr4:17616180	MED28	0.73	14.84	0.57	5.13e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg13565492	chr6:43139072	SRF	-0.79	-10.34	-0.43	1.08e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs727505	0.754	rs56012154	chr7:124781250	A/G	cg23710748	chr7:124431027	NA	-0.44	-8.5	-0.37	2.64e-16	Lewy body disease;
LGG	cis	rs4671458	0.512	rs76298426	chr2:63287328	T/C	cg17519650	chr2:63277830	OTX1	-0.7	-6.85	-0.3	2.38e-11	Subjective well-being;
LGG	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4727027	0.899	rs6464942	chr7:148826368	T/C	cg23583168	chr7:148888333	NA	-0.87	-16.92	-0.62	2.38e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1790761	0.505	rs34721562	chr11:67312708	T/C	cg00864171	chr11:67383662	NA	-0.43	-6.9	-0.31	1.69e-11	Mean corpuscular volume;
LGG	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg01493522	chr13:37497338	NA	-0.5	-8.57	-0.37	1.51e-16	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.24	-0.43	2.56e-22	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg18379455	chr17:41446167	NA	-0.34	-8.07	-0.35	6.03e-15	Menopause (age at onset);
LGG	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-13.15	-0.52	8.44e-34	Cognitive function;
LGG	cis	rs2236267	0.726	rs2755075	chr14:88579279	A/G	cg02175263	chr14:88627849	NA	0.31	6.8	0.3	3.25e-11	Food antigen IgG levels;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg15971980	chr6:150254442	NA	0.45	8.52	0.37	2.31e-16	Lung cancer;
LGG	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg20290983	chr6:43655470	MRPS18A	1.11	24.54	0.75	8.82e-86	IgG glycosylation;
LGG	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg06121193	chr1:90282411	NA	-0.37	-7.25	-0.32	1.71e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.954	rs11098525	chr4:120390152	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.53e-30	Corneal astigmatism;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26188571	chr5:179050811	HNRNPH1	0.4	6.83	0.3	2.69e-11	Bipolar disorder;
LGG	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs7586879	0.789	rs13428763	chr2:25132855	T/G	cg04586622	chr2:25135609	ADCY3	0.38	9.25	0.4	7.98e-19	Body mass index;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg02018176	chr4:1364513	KIAA1530	0.39	8.6	0.37	1.29e-16	Obesity-related traits;
LGG	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg27411982	chr8:10470053	RP1L1	0.44	7.2	0.32	2.51e-12	Neuroticism;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs758324	0.947	rs4705903	chr5:131206594	A/C	cg06307176	chr5:131281290	NA	0.56	9.38	0.4	2.99e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs17767392	0.670	rs11627918	chr14:71724408	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.36	-8.28	-0.36	1.36e-15	Mitral valve prolapse;
LGG	cis	rs1594829	0.553	rs2046226	chr8:26152050	G/A	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs78456975	0.607	rs72776258	chr2:1530732	C/G	cg26248373	chr2:1572462	NA	-0.67	-7.93	-0.35	1.61e-14	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg18105134	chr13:113819100	PROZ	0.67	13.64	0.54	7.26e-36	Platelet distribution width;
LGG	cis	rs7572733	0.576	rs1368989	chr2:198937082	T/C	cg00792783	chr2:198669748	PLCL1	0.6	9.43	0.4	2.04e-19	Dermatomyositis;
LGG	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg12654349	chr5:56205094	C5orf35	0.4	7.24	0.32	1.83e-12	Coronary artery disease;
LGG	cis	rs300774	0.920	rs378161	chr2:192983	A/T	cg21211680	chr2:198530	NA	0.58	7.35	0.32	9.16e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs12618769	0.652	rs3754875	chr2:99202747	C/G	cg18455616	chr2:99124870	INPP4A	0.26	7.33	0.32	1.06e-12	Bipolar disorder;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg07005078	chr4:17578674	LAP3	-0.36	-6.74	-0.3	4.85e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.41	6.75	0.3	4.43e-11	Prudent dietary pattern;
LGG	cis	rs4917300	1.000	rs7829749	chr8:143122493	T/C	cg06573787	chr8:143070187	NA	0.52	9.41	0.4	2.27e-19	Amyotrophic lateral sclerosis;
LGG	cis	rs10262624	1.000	rs17347692	chr7:23918367	A/G	cg09690326	chr7:23720549	C7orf46	-0.33	-6.8	-0.3	3.34e-11	Schizophrenia;
LGG	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg12501888	chr15:85177176	SCAND2	-0.56	-9.12	-0.39	2.25e-18	P wave terminal force;
LGG	cis	rs9902453	0.933	rs1128156	chr17:28513176	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.53	0.53	2.23e-35	Coffee consumption (cups per day);
LGG	cis	rs2404602	0.647	rs12440511	chr15:76993135	A/G	cg15268244	chr15:77196840	NA	0.49	10.56	0.44	1.64e-23	Blood metabolite levels;
LGG	cis	rs711245	1.000	rs711245	chr2:36768875	G/A	cg09467607	chr2:36825704	FEZ2	0.43	8.16	0.35	3.29e-15	Height;
LGG	cis	rs11229555	0.574	rs72919749	chr11:58323467	T/C	cg15696309	chr11:58395628	NA	-0.91	-12.22	-0.49	5.69e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7582720	1.000	rs72934573	chr2:204005072	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.33	0.4	4.51e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13389575	chr13:48890413	RB1	0.41	6.76	0.3	4.29e-11	Gut microbiome composition (summer);
LGG	cis	rs10504073	0.584	rs72641612	chr8:49947986	C/T	cg00325661	chr8:49890786	NA	0.8	15.74	0.59	4.98e-45	Blood metabolite ratios;
LGG	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.67	-0.34	1.03e-13	IgG glycosylation;
LGG	cis	rs1401999	1.000	rs6800217	chr3:183685893	T/C	cg20387954	chr3:183756860	HTR3D	0.66	13.59	0.53	1.21e-35	Anterior chamber depth;
LGG	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg06092702	chr1:163392909	NA	-0.44	-7.81	-0.34	3.96e-14	Motion sickness;
LGG	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg19336497	chr11:14380999	RRAS2	-0.39	-7.48	-0.33	3.81e-13	Vitamin D levels;
LGG	cis	rs17253792	0.822	rs10483645	chr14:56103766	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs13382862	0.895	rs13385499	chr2:20882413	A/G	cg27141850	chr2:20869434	GDF7	-0.23	-6.95	-0.31	1.27e-11	Abdominal aortic aneurysm;
LGG	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg14593290	chr7:50529359	DDC	-0.67	-12.03	-0.49	3.29e-29	Malaria;
LGG	cis	rs209489	1.000	rs209499	chr6:53186203	C/T	cg15607103	chr6:53167650	ELOVL5	-0.54	-7.63	-0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1983891	0.865	rs10947980	chr6:41525739	A/G	cg20194872	chr6:41519635	FOXP4	0.55	8.93	0.38	9.73e-18	Prostate cancer;
LGG	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg14541582	chr5:601475	NA	-0.7	-10.84	-0.45	1.46e-24	Obesity-related traits;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg07157834	chr1:205819609	PM20D1	-0.45	-7.39	-0.32	7.14e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs11920090	0.860	rs7646014	chr3:170740071	G/C	cg09710316	chr3:170744871	SLC2A2	0.65	8.84	0.38	1.97e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs643506	0.874	rs4245045	chr11:111659924	A/G	cg09085632	chr11:111637200	PPP2R1B	0.43	6.95	0.31	1.25e-11	Breast cancer;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg10935494	chr17:80760059	TBCD	-0.39	-7.35	-0.32	9.15e-13	Glycated hemoglobin levels;
LGG	cis	rs2735413	0.813	rs11644471	chr16:78077237	A/T	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7614311	0.681	rs73117042	chr3:63896543	T/C	cg22134162	chr3:63841271	THOC7	-0.45	-8.13	-0.35	3.98e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg15557168	chr22:42548783	NA	0.35	7.92	0.35	1.72e-14	Cognitive function;
LGG	cis	rs77972916	0.505	rs6753197	chr2:43527962	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.27	-0.43	1.95e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1949733	1.000	rs6858542	chr4:8511547	C/G	cg11789530	chr4:8429930	ACOX3	-0.89	-16.9	-0.62	3.06e-50	Response to antineoplastic agents;
LGG	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.66e-22	DNA methylation (variation);
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07856758	chr19:37861652	ZNF527	0.38	6.72	0.3	5.19e-11	Bilirubin levels;
LGG	cis	rs317865	0.737	rs28516589	chr4:16234111	C/T	cg04764131	chr4:16228633	TAPT1;FLJ39653	0.75	7.38	0.32	7.34e-13	Kidney disease (early stage) in type 1 diabetes;
LGG	cis	rs1519814	0.696	rs7813264	chr8:121032753	C/T	cg22335954	chr8:121166405	COL14A1	-0.48	-8.77	-0.38	3.52e-17	Breast cancer;
LGG	trans	rs11875185	0.510	rs17754588	chr18:55605119	A/C	cg15513957	chr14:69354734	ACTN1	-0.82	-8.29	-0.36	1.26e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg01620082	chr3:125678407	NA	-0.97	-8.96	-0.38	8.07e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6541297	0.941	rs6665258	chr1:230279058	G/A	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs12153243	0.714	rs72804744	chr5:142917084	G/C	cg13907255	chr5:142895549	NA	-0.47	-8.2	-0.36	2.44e-15	Migraine;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00657582	chr14:21904906	CHD8	0.42	6.88	0.3	1.89e-11	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06558623	chr16:89946397	TCF25	1.2	14.05	0.55	1.33e-37	Skin colour saturation;
LGG	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg03433033	chr1:76189801	ACADM	0.61	8.59	0.37	1.38e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	13.0	0.52	3.89e-33	Response to antipsychotic treatment;
LGG	cis	rs273218	1.000	rs156385	chr5:53370749	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.62	9.03	0.39	4.8e-18	Migraine;
LGG	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs1801251	1.000	rs13013142	chr2:233600606	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.33	0.4	4.25e-19	Coronary artery disease;
LGG	cis	rs7582720	0.832	rs114139737	chr2:203721733	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.7e-18	Motion sickness;
LGG	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.27	-0.36	1.4e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.81	0.48	2.55e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg04553112	chr3:125709451	NA	-0.54	-6.89	-0.3	1.85e-11	Blood pressure (smoking interaction);
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg14668632	chr7:2872130	GNA12	-0.32	-6.9	-0.31	1.67e-11	Height;
LGG	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.81	0.38	2.51e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg00149659	chr3:10157352	C3orf10	0.86	10.85	0.45	1.38e-24	Alzheimer's disease;
LGG	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg17201900	chr20:34330562	RBM39	0.56	7.56	0.33	2.25e-13	Total cholesterol levels;
LGG	cis	rs950173	1.000	rs950173	chr2:172570419	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.9	-9.95	-0.42	2.9e-21	Hippocampal volume;
LGG	cis	rs11967485	0.609	rs62435816	chr6:157153186	C/T	cg23222435	chr6:157204239	ARID1B	-0.81	-7.36	-0.32	8.19e-13	Calcium levels;
LGG	cis	rs953387	1.000	rs4954564	chr2:136895508	A/G	cg07169764	chr2:136633963	MCM6	0.56	9.47	0.4	1.43e-19	Arthritis (juvenile idiopathic);
LGG	cis	rs13191362	1.000	rs13214516	chr6:163121583	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	6.89	0.3	1.82e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.54	-0.37	2.02e-16	Life satisfaction;
LGG	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.11	-0.35	4.7e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.27	0.43	1.91e-22	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.32	-0.58	3.7e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	1.000	rs11722746	chr4:135850567	A/T	cg14419869	chr4:135874104	NA	0.56	10.7	0.45	5.24e-24	Subjective well-being;
LGG	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.86	-0.34	2.75e-14	Height;
LGG	cis	rs74781061	0.585	rs7161990	chr15:74735664	C/T	cg02384859	chr15:74862662	ARID3B	-0.38	-6.69	-0.3	6.37e-11	Endometriosis;
LGG	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg27446573	chr6:127587934	RNF146	1.16	22.82	0.73	9.07e-78	Breast cancer;
LGG	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg27165867	chr14:105738592	BRF1	-0.48	-8.2	-0.36	2.35e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1620921	0.967	rs1247555	chr6:161189018	A/C	cg01280913	chr6:161186852	NA	-0.33	-6.82	-0.3	2.85e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.56	-0.37	1.69e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.27	-0.32	1.53e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.13e-11	Parkinson's disease;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.49	-9.56	-0.41	7.2e-20	Obesity-related traits;
LGG	cis	rs911263	1.000	rs911263	chr14:68753593	C/T	cg18825221	chr14:68749962	RAD51L1	0.52	11.32	0.47	2.21e-26	Primary biliary cholangitis;
LGG	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg06766960	chr11:133703094	NA	-0.5	-10.06	-0.42	1.16e-21	Childhood ear infection;
LGG	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.98	0.57	1.14e-41	Cognitive test performance;
LGG	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg15664640	chr17:80829946	TBCD	0.57	8.69	0.37	6.16e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs41271473	0.687	rs2295256	chr1:228874049	C/T	cg16512390	chr1:228756714	NA	0.45	7.03	0.31	7.33e-12	Chronic lymphocytic leukemia;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg13206674	chr6:150067644	NUP43	0.42	8.89	0.38	1.42e-17	Testicular germ cell tumor;
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg21926883	chr2:100939477	LONRF2	-0.69	-15.77	-0.59	3.64e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.663	rs778653	chr3:160716041	G/T	cg04691961	chr3:161091175	C3orf57	-0.4	-8.59	-0.37	1.38e-16	Morning vs. evening chronotype;
LGG	cis	rs16854884	0.710	rs6782558	chr3:143817462	G/C	cg06585982	chr3:143692056	C3orf58	0.48	7.81	0.34	3.85e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.66	-0.44	7.08e-24	Initial pursuit acceleration;
LGG	cis	rs12368653	0.544	rs11172304	chr12:58097862	T/C	cg18357645	chr12:58087776	OS9	0.49	8.5	0.37	2.54e-16	Multiple sclerosis;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg06925179	chr17:43578568	NA	0.42	9.76	0.41	1.37e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs10242455	0.702	rs2293256	chr7:99057701	A/G	cg09045935	chr12:6379348	NA	-0.68	-6.68	-0.3	6.95e-11	Blood metabolite levels;
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.68e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg03788504	chr6:150331562	NA	-0.59	-13.67	-0.54	5.61e-36	Alopecia areata;
LGG	trans	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg18187862	chr3:45730750	SACM1L	-0.63	-10.35	-0.43	1.03e-22	Primary sclerosing cholangitis;
LGG	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg08999081	chr20:33150536	PIGU	0.44	11.43	0.47	8.09e-27	Coronary artery disease;
LGG	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg16339924	chr4:17578868	LAP3	0.58	10.07	0.42	1.09e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11753937	0.735	rs572004	chr6:133580411	G/T	cg05493394	chr6:133562035	EYA4	0.26	7.05	0.31	6.73e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs6754311	0.731	rs309160	chr2:136685228	C/T	cg07169764	chr2:136633963	MCM6	0.77	12.79	0.51	2.71e-32	Mosquito bite size;
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24440854	chr1:98386913	DPYD	0.43	7.26	0.32	1.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-12.89	-0.51	1.11e-32	Vitiligo;
LGG	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs2467099	0.679	rs59867239	chr17:73931787	G/A	cg23806715	chr17:73775811	H3F3B	0.49	7.32	0.32	1.1e-12	Systolic blood pressure;
LGG	cis	rs972578	0.715	rs9611914	chr22:43206587	A/T	cg01576275	chr22:43409880	NA	-0.23	-6.84	-0.3	2.55e-11	Mean platelet volume;
LGG	cis	rs9783347	0.621	rs4150589	chr11:18360251	C/T	cg15585147	chr11:18324498	HPS5	0.31	7.11	0.31	4.3e-12	Pancreatic cancer;
LGG	cis	rs17221829	0.703	rs10830347	chr11:89415165	C/T	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.53	-0.37	2.05e-16	Anxiety in major depressive disorder;
LGG	cis	rs13177180	0.749	rs1015812	chr5:114906948	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.38	-8.37	-0.36	6.67e-16	Conotruncal heart defects (inherited effects);
LGG	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg24848339	chr3:12840334	CAND2	0.37	8.41	0.36	5e-16	P wave duration;
LGG	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.56	0.79	1.16e-99	Height;
LGG	cis	rs13108043	0.605	rs62306505	chr4:87936842	A/G	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs9303401	0.646	rs7213269	chr17:57237796	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	8.01	0.35	9.43e-15	Cognitive test performance;
LGG	cis	rs6960043	0.652	rs6461149	chr7:15044103	C/T	cg19272540	chr7:15055459	NA	0.31	6.78	0.3	3.67e-11	Type 2 diabetes;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.16	0.35	3.17e-15	Bipolar disorder;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg17911788	chr17:44343683	NA	0.62	9.4	0.4	2.55e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg03162506	chr22:38580953	NA	0.28	6.84	0.3	2.59e-11	Mammographic density (dense area);Percent mammographic density;
LGG	trans	rs7246760	1.000	rs57736549	chr19:9937558	A/G	cg02900749	chr2:68251473	NA	-1.08	-11.46	-0.47	6.09e-27	Pursuit maintenance gain;
LGG	cis	rs4746059	0.655	rs35253454	chr10:72454449	A/T	cg18679544	chr10:72432482	ADAMTS14	0.55	9.21	0.39	1.17e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs8064029	1.000	rs3813750	chr16:4919253	C/T	cg04440724	chr16:4920505	UBN1	0.61	7.48	0.33	3.75e-13	Cancer;
LGG	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg06346307	chr22:19949965	COMT	0.35	9.33	0.4	4.39e-19	Blood metabolite levels;
LGG	cis	rs7769051	1.000	rs9493443	chr6:133121349	C/T	cg07930552	chr6:133119739	C6orf192	0.85	11.79	0.48	3.21e-28	Type 2 diabetes nephropathy;
LGG	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg22432760	chr17:80829718	TBCD	0.43	7.3	0.32	1.28e-12	Breast cancer;
LGG	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg24759859	chr6:86352639	SYNCRIP	0.44	7.41	0.33	5.85e-13	Smooth-surface caries;
LGG	cis	rs4771450	0.962	rs7318846	chr13:103975445	G/C	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs4671458	1.000	rs72813411	chr2:63364225	G/C	cg17519650	chr2:63277830	OTX1	-0.62	-7.85	-0.34	2.82e-14	Subjective well-being;
LGG	trans	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg20587970	chr11:113659929	NA	-0.9	-13.78	-0.54	1.86e-36	Hip circumference adjusted for BMI;
LGG	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg10847948	chr11:71163743	NADSYN1	0.63	11.14	0.46	1.09e-25	Vitamin D levels;
LGG	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg13009111	chr11:71350975	NA	-0.34	-7.39	-0.32	6.88e-13	Monocyte count;
LGG	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.72e-22	Cannabis dependence symptom count;
LGG	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-6.66	-0.3	7.86e-11	Schizophrenia;
LGG	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg08305652	chr11:111469057	NA	-0.41	-8.04	-0.35	7.58e-15	Primary sclerosing cholangitis;
LGG	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg02153584	chr22:29168773	CCDC117	0.59	7.13	0.31	3.86e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg02931644	chr1:25747376	RHCE	0.42	9.32	0.4	4.93e-19	Erythrocyte sedimentation rate;
LGG	trans	rs61931739	0.500	rs7979769	chr12:34509522	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.46	0.53	4.41e-35	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg20887711	chr4:1340912	KIAA1530	-0.6	-11.35	-0.47	1.66e-26	Obesity-related traits;
LGG	cis	rs747650	0.961	rs7945315	chr11:47110652	A/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.99	-0.42	2.09e-21	Acne (severe);
LGG	cis	rs525304	0.868	rs10899361	chr11:70511900	T/C	cg07091154	chr11:70562728	SHANK2	0.37	7.01	0.31	8.39e-12	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1670533	0.932	rs6599276	chr4:1056827	T/C	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs16854884	0.770	rs7621093	chr3:143814542	C/G	cg06585982	chr3:143692056	C3orf58	0.52	8.08	0.35	5.6e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs2084898	1.000	rs76841836	chr11:120051217	G/C	cg13907859	chr11:120009124	TRIM29	0.89	12.08	0.49	2.16e-29	Stroke (pediatric);
LGG	cis	rs1580019	0.961	rs958217	chr7:32493417	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.77	14.63	0.56	4.18e-40	Cognitive ability;
LGG	cis	rs7274811	0.744	rs55651102	chr20:32188068	A/T	cg21523528	chr20:32077966	CBFA2T2	0.4	6.66	0.3	7.9e-11	Height;
LGG	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.91	0.35	1.91e-14	Platelet count;
LGG	cis	rs2404602	0.735	rs2957614	chr15:76696635	C/T	cg15268244	chr15:77196840	NA	-0.42	-9.23	-0.39	9.54e-19	Blood metabolite levels;
LGG	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14829155	chr15:31115871	NA	-0.57	-9.6	-0.41	4.99e-20	Huntington's disease progression;
LGG	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg11266682	chr4:10021025	SLC2A9	0.42	8.14	0.35	3.72e-15	Bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21341150	chr3:171178963	TNIK	-0.41	-6.86	-0.3	2.27e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs9354308	0.678	rs2000383	chr6:66597419	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs28595532	0.841	rs55744948	chr4:119769243	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.09	0.42	9e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.79	-0.38	3.01e-17	Lung cancer;
LGG	cis	rs2797160	1.000	rs1418948	chr6:126007018	C/T	cg05901451	chr6:126070800	HEY2	0.44	7.46	0.33	4.39e-13	Endometrial cancer;
LGG	cis	rs10463554	0.963	rs12655592	chr5:102379419	A/G	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs745821	0.701	rs73959979	chr18:48122758	G/A	cg18923635	chr18:48083994	NA	0.47	8.23	0.36	1.93e-15	Diastolic blood pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17300391	chr3:116164035	LSAMP	-0.45	-6.83	-0.3	2.6e-11	Pancreatic cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21350283	chr14:69445743	ACTN1	-0.46	-7.75	-0.34	5.77e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg27624424	chr6:160112604	SOD2	-0.66	-9.83	-0.42	7.87e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7538876	0.903	rs1324367	chr1:17752451	C/G	cg10329579	chr1:17754830	RCC2	-0.53	-10.12	-0.43	6.8e-22	Basal cell carcinoma;
LGG	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg08885076	chr2:99613938	TSGA10	-0.43	-8.02	-0.35	8.6e-15	Chronic sinus infection;
LGG	cis	rs10484885	0.887	rs17707738	chr6:90602735	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-11.29	-0.46	2.93e-26	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg06453172	chr10:134556979	INPP5A	-0.58	-8.65	-0.37	8.54e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7267005	0.661	rs41293084	chr20:34192340	C/G	cg17201900	chr20:34330562	RBM39	0.99	7.18	0.32	2.74e-12	Response to paliperidone in schizophrenia (Multivariate);
LGG	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg17127132	chr2:85788382	GGCX	-0.45	-7.87	-0.34	2.52e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.43	-0.4	1.99e-19	Coronary artery disease;
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.19	-0.32	2.63e-12	Bipolar disorder;
LGG	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg03563238	chr19:33554763	RHPN2	-0.44	-10.12	-0.43	7.25e-22	Bone properties (heel);
LGG	cis	rs4330281	0.669	rs11128837	chr3:17697175	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.29e-13	Schizophrenia;
LGG	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg25801113	chr15:45476975	SHF	-0.88	-19.15	-0.66	1.2e-60	Uric acid levels;
LGG	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.9e-11	Intelligence (multi-trait analysis);
LGG	cis	rs868036	1.000	rs1871307	chr15:68100623	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.76	-0.34	5.37e-14	Restless legs syndrome;
LGG	cis	rs9460578	0.537	rs4712555	chr6:20825504	A/G	cg13405222	chr6:20811065	CDKAL1	0.76	17.27	0.63	6.07e-52	Breast cancer;
LGG	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.59	0.53	1.21e-35	Anterior chamber depth;
LGG	cis	rs9916302	0.610	rs11078902	chr17:37631883	C/G	cg00129232	chr17:37814104	STARD3	-0.59	-10.94	-0.45	6.08e-25	Glomerular filtration rate (creatinine);
LGG	trans	rs7178375	0.678	rs798112	chr15:31110279	G/A	cg04373760	chr16:53404718	NA	0.59	9.16	0.39	1.74e-18	Hypertriglyceridemia;
LGG	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg18681998	chr4:17616180	MED28	-0.81	-17.99	-0.64	3.09e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1878931	0.597	rs37816	chr16:3456371	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-11.67	-0.48	9.2e-28	Body mass index (adult);
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07362569	chr17:61921086	SMARCD2	0.48	9.32	0.4	4.69e-19	Prudent dietary pattern;
LGG	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs7666738	0.830	rs11097605	chr4:98985167	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.86	0.34	2.79e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg04503457	chr17:41445688	NA	-0.39	-9.22	-0.39	1.07e-18	Menopause (age at onset);
LGG	cis	rs4262150	0.695	rs72804798	chr5:152329436	G/T	cg12297329	chr5:152029980	NA	-0.67	-11.46	-0.47	5.94e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	7.37	0.32	8.05e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9815354	0.903	rs7373694	chr3:42012719	G/A	cg03022575	chr3:42003672	ULK4	-0.63	-8.14	-0.35	3.79e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-9.39	-0.4	2.72e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.9	0.34	2e-14	Homoarginine levels;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-11.19	-0.46	6.73e-26	Obesity-related traits;
LGG	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg25174290	chr11:3078921	CARS	0.74	15.78	0.59	3.5e-45	Longevity;
LGG	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg17927777	chr20:33865990	NA	0.74	10.89	0.45	9.61e-25	Attention deficit hyperactivity disorder;
LGG	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg03929089	chr4:120376271	NA	0.76	11.98	0.49	5.52e-29	Coronary artery disease;
LGG	cis	rs78456975	1.000	rs13413096	chr2:1553588	G/A	cg26248373	chr2:1572462	NA	-0.71	-8.83	-0.38	2.25e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	7.14	0.32	3.58e-12	Resting heart rate;
LGG	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg14088196	chr11:70211408	PPFIA1	0.82	11.25	0.46	4.08e-26	Coronary artery disease;
LGG	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg16141378	chr3:129829833	LOC729375	0.32	7.23	0.32	2.06e-12	Triglycerides;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.72	0.3	5.33e-11	Longevity;
LGG	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg24675658	chr1:53192096	ZYG11B	0.5	10.32	0.43	1.34e-22	Monocyte count;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs6066825	0.554	rs4809711	chr20:47235811	T/C	cg18078177	chr20:47281410	PREX1	0.5	8.24	0.36	1.81e-15	Colorectal cancer;
LGG	cis	rs6787391	0.933	rs6765702	chr3:4742745	T/C	cg11584376	chr3:4789075	ITPR1	-0.34	-7.12	-0.31	4.02e-12	Breast cancer;
LGG	cis	rs8064024	0.681	rs7189135	chr16:4884368	G/C	cg08329684	chr16:4932620	PPL	0.51	11.26	0.46	3.69e-26	Cancer;
LGG	cis	rs4917300	0.606	rs6583565	chr8:143114379	C/T	cg06573787	chr8:143070187	NA	0.6	10.02	0.42	1.57e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg07460842	chr6:66804631	NA	-0.97	-18.06	-0.64	1.47e-55	Exhaled nitric oxide output;
LGG	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.52	-10.18	-0.43	4.24e-22	Ovarian reserve;
LGG	cis	rs4750440	0.670	rs7917314	chr10:14029682	G/A	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.93	-0.54	4.2e-37	Adiponectin levels;
LGG	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg13385794	chr1:248469461	NA	0.46	7.47	0.33	4.09e-13	Common traits (Other);
LGG	cis	rs7917772	0.582	rs3936017	chr10:104354424	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.39e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs977987	0.843	rs4888427	chr16:75478447	A/G	cg03315344	chr16:75512273	CHST6	0.53	10.53	0.44	2.2e-23	Dupuytren's disease;
LGG	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg04705435	chr11:17411270	KCNJ11	0.42	8.33	0.36	9.16e-16	Type 2 diabetes;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.66	0.41	3.1e-20	Obesity-related traits;
LGG	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg04568710	chr12:38710424	ALG10B	0.33	6.79	0.3	3.39e-11	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg13010199	chr12:38710504	ALG10B	0.48	9.08	0.39	3.07e-18	Morning vs. evening chronotype;
LGG	cis	rs4696584	0.581	rs1552639	chr4:155402499	G/A	cg04517429	chr4:155413618	DCHS2	-0.32	-7.33	-0.32	1.06e-12	Folding of antihelix;
LGG	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.62e-14	Testicular germ cell tumor;
LGG	cis	rs4664308	0.875	rs60908067	chr2:161004983	T/G	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.1	-0.62	3.5e-51	Idiopathic membranous nephropathy;
LGG	cis	rs7737355	0.947	rs9327619	chr5:130921781	A/G	cg06307176	chr5:131281290	NA	0.54	8.98	0.39	6.79e-18	Life satisfaction;
LGG	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-15.82	-0.59	2.28e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg17178900	chr1:205818956	PM20D1	0.68	16.42	0.61	4.41e-48	Menarche (age at onset);
LGG	cis	rs7633787	0.571	rs13315592	chr3:23143676	C/T	cg00327796	chr3:23032191	NA	-0.39	-7.33	-0.32	1.05e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs171408	0.895	rs164967	chr3:8619179	C/T	cg03557445	chr3:8615444	LOH3CR2A	-0.48	-8.58	-0.37	1.44e-16	Mitral valve prolapse;
LGG	cis	rs3135063	0.847	rs1138690	chr4:3291401	G/T	cg06533319	chr4:3265114	C4orf44	-0.35	-6.78	-0.3	3.6e-11	Blood protein levels;
LGG	cis	rs12188164	0.812	rs10072668	chr5:422752	T/C	cg21972741	chr5:435613	AHRR	0.38	7.06	0.31	6e-12	Cystic fibrosis severity;
LGG	cis	rs16937	0.711	rs10751431	chr1:205128059	C/T	cg00889227	chr1:205173544	DSTYK	-0.3	-7.62	-0.33	1.46e-13	Schizophrenia;
LGG	cis	rs7558370	0.737	rs77681530	chr2:3712062	C/G	cg20720597	chr2:3699334	NA	0.76	7.09	0.31	4.99e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg10760299	chr15:45669010	GATM	-0.41	-8.02	-0.35	8.7e-15	Homoarginine levels;
LGG	cis	rs6489785	0.643	rs2015462	chr12:121238204	G/C	cg02419362	chr12:121203948	SPPL3	0.54	9.4	0.4	2.45e-19	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs75804782	0.522	rs11889150	chr2:239324542	A/G	cg18131467	chr2:239335373	ASB1	-0.58	-7.77	-0.34	5.18e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg21827317	chr3:136751795	NA	0.5	9.25	0.39	8.47e-19	Gestational age at birth (child effect);
LGG	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg16339924	chr4:17578868	LAP3	0.64	10.96	0.45	5.08e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7928758	0.767	rs746431	chr11:134267093	A/G	cg15243474	chr11:134282918	B3GAT1	0.83	12.47	0.5	5.49e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4740619	0.782	rs10119975	chr9:15708140	C/A	cg14451791	chr9:16040625	NA	0.31	7.83	0.34	3.38e-14	Body mass index;
LGG	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.32	0.4	4.64e-19	Height;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03647317	chr4:187891568	NA	-0.42	-9.07	-0.39	3.54e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.85	0.38	1.89e-17	Alzheimer's disease;
LGG	trans	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg03929089	chr4:120376271	NA	0.68	6.9	0.31	1.71e-11	Intraocular pressure;
LGG	cis	rs2597513	0.860	rs2597522	chr3:13568415	T/C	cg24006715	chr3:13568212	NA	0.63	10.24	0.43	2.63e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9815354	0.812	rs17283677	chr3:41926148	C/T	cg03022575	chr3:42003672	ULK4	-0.76	-8.74	-0.38	4.18e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.41	0.4	2.39e-19	Longevity;
LGG	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.48	-7.97	-0.35	1.24e-14	Colorectal cancer;
LGG	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg20891283	chr12:69753455	YEATS4	1.09	29.06	0.8	2.03e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8179	0.593	rs7804722	chr7:92288106	C/T	cg15732164	chr7:92237376	CDK6	0.5	9.44	0.4	1.87e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7717393	0.786	rs10039835	chr5:155764666	G/A	cg12904904	chr5:155754151	SGCD	0.63	6.86	0.3	2.26e-11	Egg allergy;
LGG	trans	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg11161011	chr14:65562177	MAX	-0.73	-14.61	-0.56	5.06e-40	Obesity-related traits;
LGG	cis	rs12497850	0.931	rs6446253	chr3:48911443	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	11.09	0.46	1.7e-25	Parkinson's disease;
LGG	cis	rs1318772	0.800	rs11746529	chr5:112934164	T/C	cg12552261	chr5:112820674	MCC	0.68	7.3	0.32	1.23e-12	F-cell distribution;
LGG	cis	rs2013441	1.000	rs9325894	chr17:20197101	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.91e-19	Obesity-related traits;
LGG	cis	rs34638952	0.577	rs8080082	chr17:27456591	A/G	cg27392559	chr17:27410759	MYO18A	-0.38	-7.11	-0.31	4.34e-12	Sitting height ratio;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg13009111	chr11:71350975	NA	0.34	7.37	0.32	7.84e-13	Myopia (pathological);
LGG	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.25	0.43	2.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg08112188	chr17:47440006	ZNF652	0.4	6.65	0.3	8.37e-11	Cancer;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.28e-17	Prudent dietary pattern;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg13163269	chr11:122933012	HSPA8	-0.36	-6.92	-0.31	1.48e-11	Iris color (L* coordinate);
LGG	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.41	-0.33	6e-13	Restless legs syndrome;
LGG	cis	rs9863	0.536	rs4765568	chr12:124479161	C/T	cg13487667	chr12:124434373	CCDC92	0.4	6.86	0.3	2.28e-11	White blood cell count;
LGG	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.65	-0.71	2.69e-72	Coronary artery disease;
LGG	cis	rs8072100	0.537	rs9912450	chr17:45402208	C/T	cg25173405	chr17:45401733	C17orf57	-0.71	-12.16	-0.49	1.01e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9486719	0.948	rs2472904	chr6:96874962	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs701145	0.585	rs1727958	chr3:153824800	G/A	cg17054900	chr3:154042577	DHX36	0.82	9.82	0.42	8.71e-21	Coronary artery disease;
LGG	cis	rs1387259	0.931	rs11168474	chr12:48621384	A/C	cg24011408	chr12:48396354	COL2A1	0.51	8.07	0.35	6.06e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4319547	0.656	rs7397299	chr12:122821649	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-10.03	-0.42	1.48e-21	Body mass index;
LGG	cis	rs17776563	0.959	rs1348002	chr15:89113138	C/G	cg05013243	chr15:89149849	MIR1179	-0.48	-9.72	-0.41	1.95e-20	Thyroid hormone levels;
LGG	cis	rs9487094	0.710	rs71558370	chr6:109776903	G/T	cg16315928	chr6:109776240	MICAL1	0.52	7.78	0.34	4.8e-14	Height;
LGG	trans	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.81	-15.0	-0.57	9.43e-42	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	9.34	0.4	4.06e-19	Ovarian reserve;
LGG	cis	rs10908907	0.874	rs11265853	chr9:92263349	C/T	cg01515543	chr9:92254510	LOC100129066	0.42	7.63	0.33	1.34e-13	Alcoholism (heaviness of drinking);
LGG	cis	rs7110818	0.510	rs2226612	chr11:76281219	A/G	cg17647271	chr11:76299819	NA	-0.39	-6.9	-0.31	1.73e-11	Gut microbiota (functional units);
LGG	cis	rs11758351	1.000	rs76329209	chr6:26196430	A/G	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.36	0.36	7.34e-16	Type 2 diabetes;
LGG	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg09029085	chr17:47094198	IGF2BP1	0.31	8.28	0.36	1.36e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg19635926	chr16:89946313	TCF25	0.81	8.37	0.36	7.06e-16	Skin colour saturation;
LGG	cis	rs5756391	0.546	rs9607398	chr22:37316041	C/T	cg21209356	chr22:37319042	CSF2RB	0.42	9.59	0.41	5.6e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg09467607	chr2:36825704	FEZ2	-0.57	-12.07	-0.49	2.44e-29	Height;
LGG	cis	rs7089973	0.872	rs34683721	chr10:116619849	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11096990	0.892	rs7680520	chr4:39220633	A/T	cg24403649	chr4:39172243	NA	-0.45	-7.43	-0.33	5.16e-13	Cognitive function;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7975161	0.572	rs4964226	chr12:104570489	A/G	cg25273343	chr12:104657179	TXNRD1	-0.73	-8.35	-0.36	7.98e-16	Toenail selenium levels;
LGG	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.14	0.35	3.69e-15	Colorectal cancer;
LGG	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.81	0.54	1.37e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62027291	0.654	rs11634136	chr15:77063039	A/G	cg23625390	chr15:77176239	SCAPER	-0.63	-6.79	-0.3	3.54e-11	Plateletcrit;
LGG	cis	rs4959677	0.804	rs7751264	chr6:2477490	G/A	cg23817096	chr6:1620687	NA	-0.32	-7.65	-0.33	1.19e-13	Orthostatic hypotension;
LGG	trans	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg16359550	chr11:109292809	C11orf87	0.42	8.19	0.36	2.58e-15	Schizophrenia;
LGG	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg19508488	chr2:152266495	RIF1	0.6	10.82	0.45	1.7e-24	Lung cancer;
LGG	cis	rs4757645	0.571	rs3781945	chr11:18306272	A/G	cg03595886	chr11:18357587	GTF2H1	0.35	8.0	0.35	1.04e-14	Survival in pancreatic cancer;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg06654118	chr4:1303317	MAEA	0.46	7.85	0.34	2.97e-14	Obesity-related traits;
LGG	cis	rs362272	0.545	rs3129308	chr4:3309272	C/T	cg06533319	chr4:3265114	C4orf44	-0.32	-6.67	-0.3	7.54e-11	Serum sulfate level;
LGG	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg27165867	chr14:105738592	BRF1	-0.43	-6.94	-0.31	1.32e-11	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12681287	0.577	rs10481197	chr8:87546551	A/T	cg27223183	chr8:87520930	FAM82B	0.49	7.41	0.33	5.98e-13	Caudate activity during reward;
LGG	cis	rs7945718	0.875	rs9888179	chr11:12782601	G/T	cg25843174	chr11:12811716	TEAD1	0.39	8.11	0.35	4.74e-15	Educational attainment (years of education);
LGG	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.9	-0.34	2.1e-14	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06451949	chr17:48942959	NA	0.47	7.2	0.32	2.39e-12	Gut microbiome composition (summer);
LGG	cis	rs9517320	1.000	rs9517320	chr13:99126303	G/T	cg07423050	chr13:99094983	FARP1	-0.4	-8.26	-0.36	1.52e-15	Longevity;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.91	-0.42	3.95e-21	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19057882	chr20:37101373	RALGAPB	0.44	7.37	0.32	7.91e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12681288	0.676	rs2701914	chr8:999935	C/T	cg04851639	chr8:1020857	NA	-0.43	-8.99	-0.39	6.55e-18	Schizophrenia;
LGG	trans	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg07549590	chr16:15018862	NA	-0.47	-8.13	-0.35	3.96e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4243971	0.516	rs6141299	chr20:30970070	A/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.17	-0.46	7.85e-26	Tonsillectomy;
LGG	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg13385521	chr17:29058706	SUZ12P	0.9	10.22	0.43	2.96e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9914544	0.545	rs1037037	chr17:18765021	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.48	-0.33	3.77e-13	Educational attainment (years of education);
LGG	cis	rs2173063	1.000	rs74029107	chr15:93125751	G/A	cg07052004	chr15:93132129	NA	0.62	6.99	0.31	9.58e-12	Subcutaneous adipose tissue;
LGG	cis	rs9790314	0.586	rs1839491	chr3:161126429	C/A	cg03342759	chr3:160939853	NMD3	-0.64	-11.2	-0.46	6.4e-26	Morning vs. evening chronotype;
LGG	cis	rs7168592	1.000	rs7168592	chr15:101723499	C/T	cg24254196	chr15:101719523	CHSY1	-0.66	-7.31	-0.32	1.2e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs209489	0.892	rs7768167	chr6:53110684	T/C	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.18	-0.32	2.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10463316	0.894	rs954339	chr5:150752161	C/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.24	-0.43	2.51e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg26513180	chr16:89883248	FANCA	1.02	9.83	0.42	7.96e-21	Skin colour saturation;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg07870213	chr5:140052090	DND1	0.91	16.21	0.6	3.87e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.42	0.58	1.38e-43	Chronic sinus infection;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg19673125	chr6:150240577	RAET1G	0.36	8.77	0.38	3.55e-17	Testicular germ cell tumor;
LGG	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg01262667	chr19:19385393	TM6SF2	0.35	7.18	0.32	2.88e-12	Bipolar disorder;
LGG	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg11252792	chr3:125932053	NA	0.9	18.97	0.66	8.98e-60	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs28595532	0.920	rs115500312	chr4:119752551	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-12.31	-0.5	2.46e-30	Vitiligo;
LGG	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.28	-0.36	1.34e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.77	-0.41	1.27e-20	Lung cancer;
LGG	cis	rs2470578	0.792	rs283941	chr3:17344551	G/T	cg20981856	chr3:17787350	NA	0.36	6.78	0.3	3.62e-11	Schizophrenia;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-24.49	-0.75	1.36e-85	Prudent dietary pattern;
LGG	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.74	-0.3	4.61e-11	Obesity-related traits;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg00960700	chr17:80709150	TBCD	-0.46	-8.86	-0.38	1.67e-17	Glycated hemoglobin levels;
LGG	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg16512390	chr1:228756714	NA	0.49	6.82	0.3	2.88e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.18	-0.43	4.3e-22	Longevity;Endometriosis;
LGG	cis	rs72772090	0.539	rs56213813	chr5:96112284	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs67133203	0.554	rs10099	chr12:51487882	T/C	cg14688905	chr12:51403056	SLC11A2	-0.52	-8.9	-0.38	1.31e-17	Urinary tract infection frequency;
LGG	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg09165964	chr15:75287851	SCAMP5	-1.06	-22.3	-0.72	2.34e-75	Blood trace element (Zn levels);
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg25025879	chr12:53359317	NA	-0.51	-8.91	-0.38	1.17e-17	Cancer (pleiotropy);
LGG	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.2	0.43	3.59e-22	Diabetic retinopathy;
LGG	cis	rs2229238	0.911	rs6672087	chr1:154516122	A/C	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.7e-12	Coronary heart disease;
LGG	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs3820068	0.655	rs72645826	chr1:15889741	A/G	cg05660106	chr1:15850417	CASP9	1.13	23.72	0.74	5.7e-82	Systolic blood pressure;
LGG	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.2	-0.32	2.43e-12	Joint mobility (Beighton score);
LGG	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg11657817	chr20:23433608	CST11	0.39	8.01	0.35	9.29e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.94	0.31	1.35e-11	Resting heart rate;
LGG	cis	rs6692729	0.966	rs6674701	chr1:227007182	A/G	cg08708961	chr1:227070630	PSEN2	-0.28	-7.35	-0.32	8.88e-13	Electrodermal activity;
LGG	cis	rs4253772	0.678	rs9627281	chr22:46644168	A/G	cg24881330	chr22:46731750	TRMU	0.58	7.47	0.33	4.02e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs17253792	0.749	rs74979160	chr14:56097568	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs2802728	0.786	rs72759858	chr1:243551844	C/T	cg05593162	chr1:243577377	SDCCAG8	0.53	7.31	0.32	1.2e-12	Toenail selenium levels;
LGG	cis	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg09307838	chr4:120376055	NA	0.8	13.21	0.52	4.83e-34	Corneal astigmatism;
LGG	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg26384229	chr12:38710491	ALG10B	-0.73	-13.91	-0.54	5.54e-37	Morning vs. evening chronotype;
LGG	cis	rs77633900	0.614	rs280005	chr15:77009185	G/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.39	-0.43	7.11e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.92	-16.87	-0.62	3.94e-50	Platelet count;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.53	-0.44	2.1e-23	Personality dimensions;
LGG	cis	rs584438	0.803	rs56394376	chr17:38589733	C/T	cg09358481	chr17:38600305	IGFBP4	-0.45	-8.6	-0.37	1.22e-16	Height;
LGG	cis	rs9398803	0.799	rs1538170	chr6:126752874	C/T	cg19875578	chr6:126661172	C6orf173	0.58	10.57	0.44	1.49e-23	Male-pattern baldness;
LGG	trans	rs7937682	0.593	rs1113851	chr11:111354161	G/A	cg18187862	chr3:45730750	SACM1L	-0.43	-6.98	-0.31	1.01e-11	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.72	0.3	5.47e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12200782	0.649	rs12189870	chr6:26382765	T/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs1318772	0.577	rs6863445	chr5:112955331	G/T	cg12552261	chr5:112820674	MCC	0.54	6.74	0.3	4.84e-11	F-cell distribution;
LGG	cis	rs8058578	1.000	rs13338946	chr16:30700858	T/C	cg00531865	chr16:30841666	NA	-0.55	-11.07	-0.46	1.98e-25	Multiple myeloma;
LGG	cis	rs7301016	0.846	rs11174576	chr12:63026436	C/T	cg11441379	chr12:63026424	NA	0.7	9.71	0.41	2.14e-20	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg21724239	chr8:58056113	NA	0.51	7.63	0.33	1.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.85	0.3	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9868809	0.881	rs57334642	chr3:48666795	C/T	cg00383909	chr3:49044727	WDR6	0.83	9.59	0.41	5.61e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2197308	0.765	rs11182964	chr12:37935052	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.39	-0.36	6.13e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2735413	0.918	rs11646244	chr16:78082453	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg00960700	chr17:80709150	TBCD	-0.48	-9.19	-0.39	1.38e-18	Glycated hemoglobin levels;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.7	-0.41	2.33e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25545336	chr2:223520958	FARSB	-0.49	-7.23	-0.32	1.97e-12	Systemic lupus erythematosus;
LGG	cis	rs7945718	0.967	rs10765989	chr11:12769397	A/G	cg25843174	chr11:12811716	TEAD1	-0.38	-7.83	-0.34	3.37e-14	Educational attainment (years of education);
LGG	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18404041	chr3:52824283	ITIH1	-0.38	-7.25	-0.32	1.73e-12	Electroencephalogram traits;
LGG	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg22348356	chr13:114891224	RASA3	0.4	7.72	0.34	7.26e-14	Schizophrenia;
LGG	cis	rs17208368	0.628	rs56318516	chr16:55095572	C/G	cg09947736	chr16:55091198	NA	0.66	12.5	0.5	4.38e-31	Hypospadias;
LGG	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg13256891	chr4:100009986	ADH5	0.53	9.55	0.41	7.76e-20	Alcohol dependence;
LGG	cis	rs17039065	0.920	rs59486913	chr4:109384333	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.05	0.31	6.75e-12	Gut microbiome composition (summer);
LGG	cis	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg05084668	chr3:125655381	ALG1L	-0.67	-8.5	-0.37	2.67e-16	Blood pressure (smoking interaction);
LGG	cis	rs4740619	0.689	rs1328283	chr9:15926469	T/G	cg14451791	chr9:16040625	NA	-0.41	-10.28	-0.43	1.85e-22	Body mass index;
LGG	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg09165964	chr15:75287851	SCAMP5	0.7	13.11	0.52	1.33e-33	Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12458207	chr3:85008991	CADM2	0.47	7.65	0.33	1.18e-13	Cognitive performance;
LGG	cis	rs4077515	0.874	rs3812575	chr9:139293259	T/C	cg21253087	chr9:139290292	SNAPC4	0.37	7.61	0.33	1.5e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6594713	0.605	rs11241213	chr5:112851088	T/A	cg12552261	chr5:112820674	MCC	0.63	7.81	0.34	3.81e-14	Brain cytoarchitecture;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04600792	chr7:29256702	CHN2	0.35	6.92	0.31	1.48e-11	Gut microbiome composition (summer);
LGG	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.07	-0.35	5.93e-15	Monocyte count;
LGG	cis	rs17030434	1.000	rs17030434	chr4:154703596	A/G	cg14289246	chr4:154710475	SFRP2	-0.75	-11.79	-0.48	2.98e-28	Electrocardiographic conduction measures;
LGG	trans	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.14	-0.31	3.75e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg21138405	chr5:131827807	IRF1	-0.39	-10.25	-0.43	2.34e-22	Asthma (sex interaction);
LGG	cis	rs12643440	0.538	rs6818238	chr4:17140193	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	trans	rs9354308	0.771	rs2814100	chr6:66528107	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	9.31	0.4	5.16e-19	Metabolite levels;
LGG	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg05044414	chr3:183734942	ABCC5	0.76	16.7	0.61	2.35e-49	Anterior chamber depth;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs911263	0.603	rs7150988	chr14:68793704	C/T	cg18825221	chr14:68749962	RAD51L1	0.36	7.87	0.34	2.53e-14	Primary biliary cholangitis;
LGG	cis	rs559928	0.524	rs4963222	chr11:64184735	T/C	cg26318627	chr11:63887540	MACROD1	-0.38	-6.86	-0.3	2.26e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9398803	0.713	rs9401891	chr6:126894135	G/T	cg19875578	chr6:126661172	C6orf173	0.52	9.58	0.41	5.78e-20	Male-pattern baldness;
LGG	trans	rs1728785	1.000	rs1069288	chr16:68585285	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.33	0.43	1.19e-22	Ulcerative colitis;
LGG	cis	rs7572733	0.534	rs700672	chr2:198691455	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs477692	0.692	rs12265758	chr10:131445144	A/G	cg05714579	chr10:131428358	MGMT	-0.7	-15.62	-0.59	1.74e-44	Response to temozolomide;
LGG	trans	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	trans	rs12517041	1.000	rs6889753	chr5:23304559	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	0.73	10.91	0.45	8.37e-25	Calcium levels;
LGG	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg00908189	chr16:619842	PIGQ	0.83	15.04	0.57	6.36e-42	Height;
LGG	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs977987	0.806	rs7185640	chr16:75394399	A/G	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.66e-21	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13881405	chr9:92220388	GADD45G	0.42	6.71	0.3	5.7e-11	Gut microbiome composition (summer);
LGG	cis	rs4742903	1.000	rs4742903	chr9:106856793	G/C	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-8.16	-0.35	3.1e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1816752	0.905	rs7571	chr13:25000617	C/G	cg22771759	chr13:24902376	NA	0.43	7.34	0.32	9.85e-13	Obesity-related traits;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23139473	chr8:30890632	WRN;PURG	0.41	6.85	0.3	2.34e-11	Hip circumference;
LGG	cis	rs12368653	0.641	rs7311632	chr12:58086340	A/C	cg20892847	chr12:58011875	NA	0.35	7.15	0.32	3.31e-12	Multiple sclerosis;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg05313129	chr8:58192883	C8orf71	-0.81	-11.87	-0.48	1.5e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.66	-0.63	9.78e-54	Refractive error;
LGG	cis	rs988958	0.675	rs12712816	chr2:42224048	G/C	cg19376973	chr2:42229025	NA	0.62	9.81	0.41	8.84e-21	Hypospadias;
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg00761968	chr13:53314142	LECT1	-0.38	-8.06	-0.35	6.49e-15	Lewy body disease;
LGG	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.18	-0.39	1.41e-18	Educational attainment;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20887711	chr4:1340912	KIAA1530	0.72	15.34	0.58	3.04e-43	Longevity;
LGG	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg08085267	chr17:45401833	C17orf57	-0.63	-12.83	-0.51	1.94e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2213920	0.523	rs7857923	chr9:118176789	A/G	cg13918206	chr9:118159781	DEC1	0.63	8.87	0.38	1.56e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs2188561	0.697	rs12539555	chr7:107404473	A/G	cg16793755	chr7:107334138	SLC26A4	0.41	7.2	0.32	2.38e-12	Alcohol consumption;
LGG	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg26396452	chr14:65542826	MAX	0.41	7.93	0.35	1.71e-14	Obesity-related traits;
LGG	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	15.19	0.58	1.41e-42	Menarche (age at onset);
LGG	cis	rs350251	0.614	rs17805158	chr16:12160328	G/T	cg02910054	chr16:12241554	SNX29	-0.39	-6.65	-0.3	8.48e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.93	-0.48	8.81e-29	Alzheimer's disease;
LGG	cis	rs365132	0.846	rs353470	chr5:176444861	C/T	cg16309518	chr5:176445507	NA	-0.51	-11.27	-0.46	3.23e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2070488	0.775	rs6599211	chr3:38558830	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.34	-0.55	7.72e-39	Electrocardiographic conduction measures;
LGG	cis	rs7674212	0.570	rs2711899	chr4:104062414	T/C	cg16532752	chr4:104119610	CENPE	-0.39	-6.82	-0.3	2.82e-11	Type 2 diabetes;
LGG	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg02487422	chr3:49467188	NICN1	0.39	7.05	0.31	6.72e-12	Menarche (age at onset);
LGG	cis	rs972578	0.668	rs5758990	chr22:43252280	A/G	cg01576275	chr22:43409880	NA	-0.23	-7.08	-0.31	5.54e-12	Mean platelet volume;
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg18357526	chr6:26021779	HIST1H4A	0.45	7.2	0.32	2.51e-12	Height;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.84	-0.3	2.59e-11	Total body bone mineral density;
LGG	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg04287289	chr16:89883240	FANCA	0.59	9.79	0.41	1.08e-20	Vitiligo;
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg13384949	chr1:2383501	NA	-0.6	-13.59	-0.53	1.21e-35	Non-obstructive azoospermia;
LGG	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg03433033	chr1:76189801	ACADM	0.8	13.96	0.54	3.38e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17221829	0.733	rs2200750	chr11:89416160	G/A	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.42	-0.36	4.63e-16	Anxiety in major depressive disorder;
LGG	cis	rs7726354	0.793	rs73756772	chr5:56002136	G/C	cg27303933	chr5:56029418	NA	0.48	6.77	0.3	3.83e-11	Breast cancer (early onset);
LGG	cis	rs2224391	0.784	rs35048711	chr6:5262235	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs858239	0.508	rs7805085	chr7:23190243	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.49e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2562456	0.876	rs11085465	chr19:21751790	A/G	cg00806126	chr19:22604979	ZNF98	0.64	9.57	0.41	6.28e-20	Pain;
LGG	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg09307838	chr4:120376055	NA	0.73	12.36	0.5	1.58e-30	Corneal astigmatism;
LGG	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg25039879	chr17:56429692	SUPT4H1	0.56	7.93	0.35	1.69e-14	Cognitive test performance;
LGG	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.51	-0.53	2.71e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg27490568	chr2:178487706	NA	0.53	10.36	0.43	9.18e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg24565620	chr2:194026	NA	-0.66	-10.42	-0.44	5.75e-23	Blood protein levels;
LGG	cis	rs67311347	0.544	rs2278927	chr3:40350447	G/A	cg13683864	chr3:40499215	RPL14	-0.81	-15.88	-0.59	1.21e-45	Renal cell carcinoma;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16524936	chr4:1340807	KIAA1530	-0.41	-6.66	-0.3	8.02e-11	Longevity;
LGG	cis	rs7712401	0.601	rs34233716	chr5:122316365	C/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.78	-0.3	3.74e-11	Mean platelet volume;
LGG	cis	rs4919694	1.000	rs112240253	chr10:104753726	C/T	cg04362960	chr10:104952993	NT5C2	1.07	13.73	0.54	3.03e-36	Arsenic metabolism;
LGG	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg16395133	chr6:150326394	RAET1K	0.27	6.76	0.3	4.16e-11	Alopecia areata;
LGG	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.53	0.37	2.14e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg14789911	chr21:47582049	C21orf56	-0.52	-9.38	-0.4	2.97e-19	Testicular germ cell tumor;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg15971980	chr6:150254442	NA	0.46	8.46	0.37	3.56e-16	Lung cancer;
LGG	cis	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.44	-0.37	4.22e-16	Resting heart rate;
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg13282195	chr8:144660772	NAPRT1	0.98	7.59	0.33	1.83e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06634786	chr22:41940651	POLR3H	0.78	12.8	0.51	2.52e-32	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17270561	0.609	rs1892255	chr6:25750354	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	8.29	0.36	1.21e-15	Iron status biomarkers;
LGG	cis	rs988958	0.565	rs13417438	chr2:42237876	A/G	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg26318627	chr11:63887540	MACROD1	-0.37	-6.74	-0.3	4.65e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs12517041	1.000	rs1428624	chr5:23290393	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.03e-25	Calcium levels;
LGG	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25172604	chr17:41446521	NA	-0.3	-6.84	-0.3	2.45e-11	Menopause (age at onset);
LGG	cis	rs2717559	0.503	rs62523781	chr8:143870981	A/G	cg06565975	chr8:143823917	SLURP1	0.28	6.86	0.3	2.19e-11	Urinary tract infection frequency;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg27471124	chr11:109292789	C11orf87	0.81	17.88	0.64	9.14e-55	Schizophrenia;
LGG	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.69	-9.61	-0.41	4.8e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2011503	0.941	rs76944848	chr19:19417512	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	6.87	0.3	2.06e-11	Bipolar disorder;
LGG	cis	rs4262150	0.667	rs13160798	chr5:152276252	A/G	cg12297329	chr5:152029980	NA	0.61	11.94	0.49	7.89e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg05091796	chr16:4465799	CORO7	1.03	18.76	0.66	7.85e-59	Schizophrenia;
LGG	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg20283391	chr11:68216788	NA	-0.49	-8.04	-0.35	7.57e-15	Total body bone mineral density;
LGG	cis	rs9354308	0.868	rs9345692	chr6:66544714	T/A	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.86	0.38	1.73e-17	Aortic root size;
LGG	cis	rs10744625	0.836	rs12426322	chr12:3865413	T/C	cg22221074	chr12:3862810	EFCAB4B	0.35	7.46	0.33	4.21e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs3204270	0.810	rs62077191	chr17:79678063	A/G	cg18367735	chr17:79674897	NA	0.58	7.31	0.32	1.2e-12	Dental caries;
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg18764438	chr3:125238508	SNX4	-0.5	-6.78	-0.3	3.56e-11	Leprosy;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg10505658	chr17:80084571	CCDC57	0.43	8.69	0.37	6.11e-17	Life satisfaction;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg01988459	chr11:68622903	NA	-0.58	-11.93	-0.49	8.22e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg03342759	chr3:160939853	NMD3	-0.66	-12.0	-0.49	4.51e-29	Morning vs. evening chronotype;
LGG	cis	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.82	-0.3	2.85e-11	Neuroticism;
LGG	cis	rs10888329	0.708	rs6587435	chr1:248355585	T/C	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Autism spectrum disorder;
LGG	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.91	0.35	1.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12580194	0.593	rs67015069	chr12:55759968	T/A	cg19537932	chr12:55886519	OR6C68	-0.57	-10.4	-0.44	6.78e-23	Cancer;
LGG	cis	rs2737618	0.722	rs2258675	chr1:200091548	G/C	cg21825944	chr1:200113062	NR5A2	-0.61	-11.84	-0.48	1.9e-28	Uric acid levels;
LGG	trans	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg00938859	chr5:1591904	SDHAP3	0.8	7.74	0.34	6.3e-14	Breast cancer;
LGG	cis	rs4925386	0.765	rs6142737	chr20:60919800	C/G	cg22307297	chr20:60903441	LAMA5	0.42	8.25	0.36	1.62e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs9463078	0.739	rs6458425	chr6:45173857	C/G	cg25276700	chr6:44698697	NA	-0.33	-6.77	-0.3	3.84e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.65	-0.3	8.15e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs870825	0.616	rs28444118	chr4:185621692	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs780096	1.000	rs780096	chr2:27741072	C/G	cg22903471	chr2:27725779	GCKR	-0.37	-7.77	-0.34	5.04e-14	Total body bone mineral density;
LGG	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg12179176	chr11:130786555	SNX19	0.84	17.75	0.64	3.75e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-11.82	-0.48	2.26e-28	Colorectal cancer;
LGG	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08468577	chr11:2973342	NAP1L4	-0.33	-6.77	-0.3	3.86e-11	Calcium levels;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg14668632	chr7:2872130	GNA12	-0.37	-7.7	-0.34	8.24e-14	Height;
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg08499158	chr17:42289980	UBTF	-0.58	-11.21	-0.46	5.73e-26	Total body bone mineral density;
LGG	cis	rs883565	0.528	rs4428122	chr3:38972603	C/A	cg01426195	chr3:39028469	NA	0.6	12.77	0.51	3.33e-32	Handedness;
LGG	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11864453	0.680	rs8047377	chr16:72148339	T/C	cg23815491	chr16:72088622	HP	0.51	11.63	0.48	1.34e-27	Fibrinogen levels;
LGG	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg15212455	chr7:39170539	POU6F2	0.47	10.76	0.45	3e-24	IgG glycosylation;
LGG	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg07936489	chr17:37558343	FBXL20	0.76	12.99	0.52	4.19e-33	Glomerular filtration rate (creatinine);
LGG	cis	rs12367572	0.501	rs7969381	chr12:45476934	C/G	cg03114573	chr12:45410052	DBX2	-0.5	-8.31	-0.36	1.06e-15	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg12310025	chr6:25882481	NA	-0.51	-9.39	-0.4	2.69e-19	Height;
LGG	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg23034840	chr1:205782522	SLC41A1	-0.73	-8.39	-0.36	5.92e-16	Prostate-specific antigen levels;
LGG	trans	rs2018683	0.899	rs10269454	chr7:28978400	C/T	cg19402173	chr7:128379420	CALU	-0.66	-11.77	-0.48	3.74e-28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg03517284	chr6:25882590	NA	-0.38	-6.8	-0.3	3.25e-11	Height;
LGG	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg19143629	chr17:61920732	SMARCD2	0.4	6.8	0.3	3.31e-11	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18347762	chr13:91499567	NA	0.37	7.22	0.32	2.19e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg09307838	chr4:120376055	NA	0.72	12.46	0.5	6.22e-31	Corneal astigmatism;
LGG	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg02023728	chr11:77925099	USP35	0.46	8.1	0.35	4.97e-15	Testicular germ cell tumor;
LGG	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	trans	rs3857536	0.813	rs2040591	chr6:66945915	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	10.02	0.42	1.6e-21	Schizophrenia;
LGG	cis	rs4517514	0.509	rs10830411	chr11:89865532	A/G	cg21153622	chr11:89784906	NA	-0.6	-6.71	-0.3	5.66e-11	Trans fatty acid levels;
LGG	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.25	0.39	8.53e-19	Height;
LGG	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.51	-7.01	-0.31	8.51e-12	HIV-1 control;
LGG	cis	rs2717559	0.522	rs2949872	chr8:143872904	T/C	cg07661805	chr8:143867942	LY6D	0.3	8.06	0.35	6.77e-15	Urinary tract infection frequency;
LGG	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg06219351	chr7:158114137	PTPRN2	0.71	13.84	0.54	1.05e-36	Calcium levels;
LGG	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.9	0.38	1.31e-17	Motion sickness;
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg09699651	chr6:150184138	LRP11	0.47	7.46	0.33	4.22e-13	Lung cancer;
LGG	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg01221209	chr5:554886	NA	-0.46	-6.89	-0.3	1.85e-11	Obesity-related traits;
LGG	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.47	0.37	3.16e-16	Mood instability;
LGG	cis	rs2712184	0.683	rs2541403	chr2:217637885	A/G	cg05032264	chr2:217675019	NA	0.41	8.96	0.38	7.74e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs11096990	0.656	rs7693837	chr4:39303101	T/C	cg24403649	chr4:39172243	NA	0.38	6.73	0.3	5.06e-11	Cognitive function;
LGG	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.88	0.34	2.4e-14	Neuroticism;
LGG	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg23815491	chr16:72088622	HP	0.47	8.78	0.38	3.08e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs921968	0.542	rs588182	chr2:219412335	C/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.17	-0.32	2.92e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg03929089	chr4:120376271	NA	-0.63	-7.93	-0.35	1.65e-14	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs12579753	0.917	rs12372724	chr12:82193628	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg00684032	chr4:1343700	KIAA1530	0.45	8.68	0.37	6.58e-17	Obesity-related traits;
LGG	cis	rs4430311	0.723	rs11586029	chr1:243910067	C/T	cg25706552	chr1:244017396	NA	-0.65	-15.89	-0.59	1.03e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.69	-0.37	6.33e-17	Initial pursuit acceleration;
LGG	cis	rs72781680	0.566	rs72794293	chr2:23898149	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	6.98	0.31	1.05e-11	Lymphocyte counts;
LGG	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg14541582	chr5:601475	NA	-0.69	-10.96	-0.45	5.19e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs6594713	0.642	rs6890874	chr5:112787813	C/A	cg12552261	chr5:112820674	MCC	0.64	8.06	0.35	6.67e-15	Brain cytoarchitecture;
LGG	cis	rs6694672	1.000	rs1412634	chr1:197023156	T/C	cg13682187	chr1:196946512	CFHR5	0.51	7.0	0.31	9.28e-12	Asthma;
LGG	cis	rs3806843	0.547	rs246054	chr5:140326159	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs783540	0.967	rs17158390	chr15:83293028	A/G	cg16105309	chr15:79090380	ADAMTS7	0.41	7.26	0.32	1.65e-12	Schizophrenia;
LGG	cis	rs7106204	0.534	rs74650605	chr11:24253414	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	9.49	0.4	1.22e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-9.45	-0.4	1.73e-19	Blood metabolite levels;
LGG	cis	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg06521331	chr12:34319734	NA	0.39	6.71	0.3	5.7e-11	Morning vs. evening chronotype;
LGG	cis	rs7766436	0.648	rs6908475	chr6:22572798	A/G	cg13666174	chr6:22585274	NA	-0.4	-9.72	-0.41	1.86e-20	Coronary artery disease;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg08677398	chr8:58056175	NA	0.58	9.25	0.4	8.13e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4959677	0.901	rs7776061	chr6:2487061	G/T	cg23817096	chr6:1620687	NA	-0.31	-7.38	-0.32	7.57e-13	Orthostatic hypotension;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	cis	rs2153535	0.584	rs9502723	chr6:8541504	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.34	0.43	1.11e-22	Motion sickness;
LGG	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-14.52	-0.56	1.21e-39	Presence of antiphospholipid antibodies;
LGG	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg27661571	chr11:113659931	NA	-0.68	-9.55	-0.41	7.86e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4148883	0.689	rs1869458	chr4:100024728	C/G	cg13256891	chr4:100009986	ADH5	0.37	6.64	0.3	8.55e-11	Alcohol dependence;
LGG	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-11.0	-0.46	3.68e-25	Personality dimensions;
LGG	cis	rs4409675	0.576	rs6679432	chr1:28227665	T/C	cg23691781	chr1:28212827	C1orf38	0.4	10.87	0.45	1.17e-24	Corneal astigmatism;
LGG	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg14664628	chr15:75095509	CSK	-0.47	-8.62	-0.37	1.11e-16	Caffeine consumption;
LGG	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.29e-11	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.32	0.32	1.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10791097	0.739	rs11222358	chr11:130730497	G/A	cg12179176	chr11:130786555	SNX19	0.77	14.74	0.57	1.36e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs457717	0.706	rs2432186	chr5:75945066	T/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs9487051	0.735	rs455839	chr6:109524221	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.85	-0.3	2.35e-11	Reticulocyte fraction of red cells;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg19168338	chr16:4465731	CORO7	-0.74	-13.66	-0.54	6.43e-36	Schizophrenia;
LGG	cis	rs7241530	0.636	rs28491529	chr18:75889301	A/G	cg14642773	chr18:75888474	NA	0.46	9.38	0.4	2.9e-19	Educational attainment (years of education);
LGG	cis	rs4731207	0.596	rs7778875	chr7:124645446	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg18129748	chr3:49941408	MST1R	-0.22	-6.95	-0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg09771049	chr17:66031798	KPNA2	0.4	6.91	0.31	1.66e-11	Bilirubin levels;
LGG	cis	rs7107174	1.000	rs4134379	chr11:77992588	A/G	cg02023728	chr11:77925099	USP35	0.43	7.65	0.34	1.14e-13	Testicular germ cell tumor;
LGG	cis	rs1018697	0.518	rs2790914	chr10:104568018	C/T	cg04362960	chr10:104952993	NT5C2	-0.65	-10.16	-0.43	4.99e-22	Colorectal adenoma (advanced);
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg12379764	chr21:47803548	PCNT	0.43	7.49	0.33	3.57e-13	Testicular germ cell tumor;
LGG	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.35	-0.47	1.67e-26	Lung cancer;
LGG	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg22834771	chr12:69754056	YEATS4	-0.51	-8.81	-0.38	2.46e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg21475434	chr5:93447410	FAM172A	0.66	6.72	0.3	5.42e-11	Diabetic retinopathy;
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg16141378	chr3:129829833	LOC729375	0.39	9.23	0.39	9.73e-19	Neuroticism;
LGG	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg00647317	chr7:50633725	DDC	0.49	12.22	0.49	5.77e-30	Systemic sclerosis;
LGG	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.75	-0.3	4.54e-11	Pancreatic cancer;
LGG	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg11738485	chr19:12877000	HOOK2	0.43	6.9	0.31	1.68e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs9354308	0.764	rs4710547	chr6:66605906	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	trans	rs826838	0.868	rs12322306	chr12:39130021	A/G	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs6693567	0.565	rs1260374	chr1:150331593	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.74	0.3	4.75e-11	Migraine;
LGG	cis	rs758324	0.704	rs493829	chr5:131297043	T/C	cg06307176	chr5:131281290	NA	-0.56	-9.13	-0.39	2.05e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs10048158	0.585	rs9890748	chr17:64248521	T/C	cg19474267	chr17:64306194	PRKCA	-0.64	-13.12	-0.52	1.2e-33	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg18252515	chr7:66147081	NA	0.43	7.04	0.31	6.98e-12	Aortic root size;
LGG	cis	rs4924935	0.781	rs2472694	chr17:18848498	A/G	cg26378065	chr17:18585709	ZNF286B	0.47	7.22	0.32	2.2e-12	Pancreatic cancer;
LGG	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.52	8.66	0.37	8.04e-17	Colorectal cancer;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.31	0.32	1.17e-12	Menopause (age at onset);
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg11814155	chr7:99998594	ZCWPW1	0.53	8.09	0.35	5.15e-15	Platelet count;
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12618769	0.652	rs4851144	chr2:99220707	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.7	0.34	8.26e-14	Bipolar disorder;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg05091796	chr16:4465799	CORO7	-0.6	-9.9	-0.42	4.27e-21	Schizophrenia;
LGG	cis	rs7166081	1.000	rs7182798	chr15:67535212	C/G	cg05925327	chr15:68127851	NA	-0.32	-6.83	-0.3	2.68e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.61	-12.39	-0.5	1.15e-30	Prudent dietary pattern;
LGG	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-9.05	-0.39	4.13e-18	Triglycerides;
LGG	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	9.24	0.39	9.11e-19	Menarche (age at onset);
LGG	cis	rs7192750	0.652	rs150617	chr16:72139396	T/C	cg06353428	chr16:71660113	MARVELD3	0.76	7.24	0.32	1.87e-12	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg02403541	chr12:121454288	C12orf43	0.53	8.8	0.38	2.75e-17	N-glycan levels;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg03528353	chr17:61819722	STRADA	0.45	7.64	0.33	1.23e-13	Prudent dietary pattern;
LGG	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg09818912	chr17:20140352	CYTSB	-0.3	-6.91	-0.31	1.58e-11	Schizophrenia;
LGG	cis	rs6598955	0.543	rs12122527	chr1:26549748	C/T	cg04990556	chr1:26633338	UBXN11	0.69	10.36	0.43	9.14e-23	Obesity-related traits;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07167872	chr1:205819463	PM20D1	0.53	10.63	0.44	9.5e-24	Menarche (age at onset);
LGG	cis	rs4776059	1.000	rs8026800	chr15:52933548	C/G	cg22715398	chr15:52968154	KIAA1370	-0.53	-8.77	-0.38	3.45e-17	Schizophrenia;
LGG	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.63	-9.62	-0.41	4.39e-20	Blood protein levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg15023313	chr10:37414759	ANKRD30A	-0.57	-7.02	-0.31	8.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.6	10.63	0.44	8.91e-24	Birth weight;
LGG	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg00666640	chr1:248458726	OR2T12	-0.57	-8.94	-0.38	9.47e-18	Common traits (Other);
LGG	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.66	-0.41	3.01e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg24690094	chr11:67383802	NA	0.47	8.19	0.36	2.59e-15	Mean corpuscular volume;
LGG	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg14829155	chr15:31115871	NA	0.67	11.4	0.47	1.08e-26	Huntington's disease progression;
LGG	trans	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs6754311	0.731	rs309164	chr2:136691825	T/C	cg07169764	chr2:136633963	MCM6	0.82	13.88	0.54	6.84e-37	Mosquito bite size;
LGG	cis	rs7586879	0.639	rs2033656	chr2:25100902	C/G	cg04586622	chr2:25135609	ADCY3	0.44	11.93	0.48	8.73e-29	Body mass index;
LGG	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg00319359	chr11:70116639	PPFIA1	0.76	7.68	0.34	9.35e-14	Coronary artery disease;
LGG	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.49	-0.37	2.88e-16	Retinal vascular caliber;
LGG	cis	rs3741151	0.686	rs7114009	chr11:73115314	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.71	-7.77	-0.34	4.95e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.12	-0.49	1.48e-29	Bladder cancer;
LGG	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg11941060	chr3:133502564	NA	-0.48	-8.08	-0.35	5.59e-15	Iron status biomarkers;
LGG	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg08847335	chr10:891726	LARP4B	-0.51	-9.17	-0.39	1.54e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.23e-14	Life satisfaction;
LGG	cis	rs4622507	0.618	rs4784458	chr16:55056685	G/T	cg09947736	chr16:55091198	NA	0.77	11.02	0.46	3.06e-25	Social communication problems;
LGG	cis	rs787274	0.543	rs10114623	chr9:115631360	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-9.9	-0.42	4.41e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs806215	0.547	rs17151377	chr7:127458009	G/T	cg25922125	chr7:127225783	GCC1	-0.5	-7.37	-0.32	8.16e-13	Type 2 diabetes;
LGG	trans	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.4	-0.33	6.29e-13	Heart rate;
LGG	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25517755	chr10:38738941	LOC399744	0.35	6.75	0.3	4.37e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs477692	0.673	rs487120	chr10:131367552	C/T	cg05714579	chr10:131428358	MGMT	0.46	8.79	0.38	2.84e-17	Response to temozolomide;
LGG	cis	rs858239	0.537	rs10279691	chr7:23228387	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.83	0.3	2.63e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.06	0.35	6.63e-15	Iron status biomarkers;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg16590910	chr6:42928470	GNMT	0.42	11.81	0.48	2.49e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6504108	0.647	rs7210149	chr17:46297622	A/G	cg02219949	chr17:45927392	SP6	0.43	7.99	0.35	1.06e-14	Body mass index;
LGG	cis	rs7619833	0.653	rs2100006	chr3:27273415	G/A	cg02860705	chr3:27208620	NA	0.4	7.74	0.34	6.34e-14	Breast cancer;
LGG	cis	rs17767392	0.958	rs12896986	chr14:71922893	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs28655083	0.529	rs285027	chr16:77100932	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.96	0.31	1.19e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs193541	0.642	rs42538	chr5:122292352	A/T	cg19412675	chr5:122181750	SNX24	0.55	8.72	0.38	5.04e-17	Glucose homeostasis traits;
LGG	cis	rs6580649	0.941	rs4760677	chr12:48449163	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg05784532	chr1:230284198	GALNT2	0.56	9.08	0.39	3.18e-18	Coronary artery disease;
LGG	cis	rs6489882	1.000	rs6489882	chr12:113381376	G/A	cg25319449	chr12:113376135	OAS3	-0.39	-7.05	-0.31	6.54e-12	Chronic lymphocytic leukemia;
LGG	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.05	0.35	7.17e-15	Iron status biomarkers;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02071572	chr4:1403502	NA	0.39	6.7	0.3	6.21e-11	Longevity;
LGG	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg00686598	chr14:53173677	PSMC6	1.38	15.13	0.58	2.7e-42	Alzheimer's disease (late onset);
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26617929	chr16:1858877	NA	-0.62	-8.51	-0.37	2.41e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs367615	0.552	rs7720036	chr5:108710699	A/G	cg17395555	chr5:108820864	NA	-0.75	-12.18	-0.49	8.83e-30	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs61931739	0.890	rs694706	chr12:34135323	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.5	0.4	1.16e-19	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg26384229	chr12:38710491	ALG10B	0.95	21.48	0.71	1.6e-71	Bladder cancer;
LGG	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.59	-0.51	1.8e-31	Chronic sinus infection;
LGG	trans	rs2898290	0.532	rs4841566	chr8:11432438	C/G	cg02002194	chr4:3960332	NA	0.44	7.31	0.32	1.18e-12	Systolic blood pressure;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg15948088	chr11:109293068	C11orf87	0.45	7.41	0.33	6.23e-13	Schizophrenia;
LGG	cis	rs367943	0.698	rs9764191	chr5:112961088	T/C	cg12552261	chr5:112820674	MCC	0.52	9.02	0.39	4.86e-18	Type 2 diabetes;
LGG	cis	rs68170813	0.559	rs80212020	chr7:106957596	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.79	-0.45	2.3e-24	Coronary artery disease;
LGG	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg20578329	chr17:80767326	TBCD	-0.79	-11.69	-0.48	7.77e-28	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs2131877	0.830	rs62285228	chr3:194880965	T/C	cg07250128	chr3:194833983	C3orf21	0.43	7.31	0.32	1.17e-12	Non-small cell lung cancer;
LGG	cis	rs7712401	0.601	rs28892	chr5:122283826	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.9	-0.31	1.67e-11	Mean platelet volume;
LGG	cis	rs4711350	0.678	rs658087	chr6:33665020	A/T	cg06471254	chr6:33690276	IP6K3	0.52	7.4	0.33	6.49e-13	Schizophrenia;
LGG	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.15	-0.35	3.55e-15	Neuroticism;
LGG	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17767392	0.846	rs4453405	chr14:71757251	A/T	cg02058870	chr14:72053146	SIPA1L1	0.4	8.58	0.37	1.41e-16	Mitral valve prolapse;
LGG	cis	rs6723226	0.767	rs10172308	chr2:32555760	G/A	cg02381751	chr2:32503542	YIPF4	-0.75	-12.6	-0.51	1.7e-31	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.67	-0.41	2.81e-20	Neuroticism;
LGG	cis	rs72772090	0.539	rs11748795	chr5:96168056	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.44	-0.37	4.02e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.41	0.44	5.9e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2798269	0.966	rs2040059	chr13:22143100	C/G	cg18095732	chr13:22033692	ZDHHC20	0.4	6.96	0.31	1.17e-11	PR segment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05852623	chr17:42219219	C17orf53	0.44	7.17	0.32	3.01e-12	Cognitive performance;
LGG	cis	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg06521331	chr12:34319734	NA	0.41	6.87	0.3	2.08e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	10.36	0.43	9.42e-23	Height;
LGG	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.34	-0.32	9.77e-13	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg08847533	chr14:75593920	NEK9	-0.59	-11.44	-0.47	7.42e-27	Height;
LGG	cis	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg08250081	chr4:10125330	NA	0.67	12.14	0.49	1.28e-29	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs3767633	0.925	rs924777	chr1:161848904	G/A	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg08521684	chr3:195488725	MUC4	0.54	7.17	0.32	3.01e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs62432291	0.681	rs438853	chr6:159630352	A/C	cg14500486	chr6:159655392	FNDC1	-0.63	-7.03	-0.31	7.24e-12	Joint mobility (Beighton score);
LGG	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg25664220	chr3:72788482	NA	-0.33	-8.88	-0.38	1.44e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Colorectal cancer;
LGG	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg08250081	chr4:10125330	NA	0.38	7.44	0.33	4.78e-13	Bone mineral density;
LGG	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg25173405	chr17:45401733	C17orf57	0.48	8.07	0.35	5.93e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4727027	0.705	rs10952803	chr7:148890091	T/G	cg23583168	chr7:148888333	NA	-0.91	-18.24	-0.65	2.15e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04054012	chr13:52980262	THSD1	0.63	7.26	0.32	1.68e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12738007	0.745	rs6702335	chr1:29411250	A/G	cg11747820	chr1:29584023	PTPRU	-0.31	-7.02	-0.31	7.86e-12	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06558623	chr16:89946397	TCF25	1.2	14.06	0.55	1.21e-37	Skin colour saturation;
LGG	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs992157	0.932	rs56109829	chr2:219149740	G/A	cg00012203	chr2:219082015	ARPC2	0.76	14.36	0.56	6.01e-39	Colorectal cancer;
LGG	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.68e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12618769	0.597	rs3769716	chr2:99133305	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.89	9.69	0.41	2.48e-20	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	0.821	rs72796401	chr2:24180078	T/A	cg08917208	chr2:24149416	ATAD2B	0.65	8.61	0.37	1.14e-16	Lymphocyte counts;
LGG	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg23461800	chr14:103021989	NA	-0.53	-8.33	-0.36	8.99e-16	Platelet count;
LGG	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg04568710	chr12:38710424	ALG10B	0.42	9.33	0.4	4.41e-19	Heart rate;
LGG	cis	rs3806843	1.000	rs1548701	chr5:140164557	T/C	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs870825	0.616	rs4444873	chr4:185628406	A/G	cg04058563	chr4:185651563	MLF1IP	1.04	22.68	0.73	3.93e-77	Blood protein levels;
LGG	cis	rs113084984	0.816	rs4669749	chr2:11692664	A/C	cg07314298	chr2:11723111	GREB1	-0.44	-8.67	-0.37	7.52e-17	Breast cancer;
LGG	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.69	-0.37	6.35e-17	Cognitive function;
LGG	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.78	0.38	3.27e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2354432	0.607	rs3766524	chr1:146729093	A/G	cg25205988	chr1:146714368	CHD1L	-1.47	-14.92	-0.57	2.13e-41	Mitochondrial DNA levels;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.65	-0.37	8.43e-17	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg05444541	chr17:17804740	TOM1L2	0.79	21.87	0.71	2.4e-73	Total body bone mineral density;
LGG	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg27661571	chr11:113659931	NA	-0.69	-9.57	-0.41	6.32e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7937612	0.965	rs10892570	chr11:120274501	G/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.8	-0.51	2.39e-32	Intraocular pressure;
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg02772935	chr3:125709198	NA	-0.55	-7.08	-0.31	5.34e-12	Blood pressure (smoking interaction);
LGG	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg01601518	chr4:2404284	ZFYVE28	-0.49	-8.45	-0.37	3.76e-16	Cognitive function;
LGG	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg12386194	chr3:101231763	SENP7	0.45	7.92	0.35	1.72e-14	Colorectal cancer;
LGG	cis	rs62025270	0.688	rs56388190	chr15:86314896	C/G	cg25843651	chr15:86329602	KLHL25	0.64	10.7	0.45	5.17e-24	Idiopathic pulmonary fibrosis;
LGG	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg07148914	chr20:33460835	GGT7	-0.5	-8.21	-0.36	2.26e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg02023728	chr11:77925099	USP35	0.44	7.84	0.34	3.02e-14	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02366587	chr6:42531991	UBR2	0.53	7.9	0.34	2.05e-14	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.934	rs455386	chr3:161102495	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-10.22	-0.43	3.1e-22	Morning vs. evening chronotype;
LGG	cis	rs7172677	0.960	rs4334268	chr15:75407298	A/G	cg14664628	chr15:75095509	CSK	-0.47	-7.08	-0.31	5.52e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg23752985	chr2:85803571	VAMP8	0.43	8.63	0.37	9.65e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.84	0.38	2.08e-17	Total body bone mineral density;
LGG	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	7.94	0.35	1.5e-14	Thyroid stimulating hormone;
LGG	trans	rs2018683	0.707	rs2391718	chr7:28974988	T/C	cg19402173	chr7:128379420	CALU	-0.53	-9.26	-0.4	7.64e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg13607699	chr17:42295918	UBTF	0.55	9.13	0.39	2.18e-18	Total body bone mineral density;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs7590720	0.840	rs705648	chr2:216933792	C/T	cg12620499	chr2:216877984	MREG	0.73	12.3	0.5	2.76e-30	Alcohol dependence;
LGG	cis	rs4722166	0.630	rs7781534	chr7:22778592	A/C	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	8.91e-16	Lung cancer;
LGG	cis	rs2797160	1.000	rs1832938	chr6:125988964	G/C	cg05901451	chr6:126070800	HEY2	-0.41	-6.9	-0.31	1.72e-11	Endometrial cancer;
LGG	cis	rs13260300	1.000	rs13260300	chr8:75479624	C/T	cg22993706	chr8:75542856	NA	0.4	8.3	0.36	1.17e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12402495	chr1:154192844	C1orf43;UBAP2L	0.47	7.26	0.32	1.7e-12	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00208153	chr13:58206058	PCDH17	0.42	6.65	0.3	8.06e-11	Cognitive performance;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.31	-0.63	4.08e-52	Skin colour saturation;
LGG	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13102973	0.965	rs28769289	chr4:135878230	T/C	cg14419869	chr4:135874104	NA	-0.56	-10.74	-0.45	3.54e-24	Subjective well-being;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg27165867	chr14:105738592	BRF1	-0.47	-7.38	-0.32	7.36e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6784615	0.744	rs9867823	chr3:52513027	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.53	-0.33	2.76e-13	Waist-hip ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16418163	chr3:140950828	ACPL2	0.46	6.85	0.3	2.41e-11	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.72	-0.54	3.48e-36	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.94	0.31	1.36e-11	Bipolar disorder;
LGG	cis	rs10193935	0.786	rs72796504	chr2:42406728	T/C	cg27598129	chr2:42591480	NA	-0.62	-9.14	-0.39	1.92e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg11062466	chr8:58055876	NA	0.48	8.26	0.36	1.49e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg25457927	chr22:38595422	NA	-0.38	-9.39	-0.4	2.72e-19	Cutaneous nevi;
LGG	cis	rs7618501	0.633	rs6446189	chr3:50008566	A/G	cg24308560	chr3:49941425	MST1R	0.22	6.88	0.3	1.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg27129171	chr3:47204927	SETD2	0.78	15.19	0.58	1.47e-42	Colorectal cancer;
LGG	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg18681998	chr4:17616180	MED28	-0.84	-17.72	-0.64	5.21e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.09	-0.55	8.76e-38	Alzheimer's disease;
LGG	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg19761014	chr17:28927070	LRRC37B2	0.6	7.2	0.32	2.47e-12	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01089095	chr10:75541668	CHCHD1	0.42	6.77	0.3	3.97e-11	Cognitive performance;
LGG	cis	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg06521331	chr12:34319734	NA	-0.65	-12.06	-0.49	2.61e-29	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.91e-14	Rheumatoid arthritis;
LGG	cis	rs9875589	0.509	rs1873005	chr3:14060223	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.57	-0.53	1.47e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12667521	chr19:29218732	NA	0.61	9.37	0.4	3.09e-19	Methadone dose in opioid dependence;
LGG	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	15.44	0.58	1.09e-43	Alzheimer's disease;
LGG	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg03098644	chr7:100410630	EPHB4	0.47	7.18	0.32	2.83e-12	Other erythrocyte phenotypes;
LGG	cis	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.67e-15	Retinal vascular caliber;
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15320075	chr8:145703422	NA	-0.62	-11.86	-0.48	1.58e-28	Age at first birth;
LGG	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.7	-0.3	5.99e-11	Neuroticism;
LGG	cis	rs4862307	0.836	rs13107384	chr4:185004073	C/T	cg06737308	chr4:185021514	ENPP6	-0.42	-7.28	-0.32	1.44e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs6445975	0.612	rs6763103	chr3:58437345	C/T	cg24175188	chr3:58374923	PXK	-0.53	-8.52	-0.37	2.29e-16	Systemic lupus erythematosus;
LGG	cis	rs2486288	0.656	rs11632752	chr15:45551140	A/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18252515	chr7:66147081	NA	0.41	6.92	0.31	1.48e-11	Aortic root size;
LGG	cis	rs55863869	0.748	rs77841333	chr2:179624788	A/T	cg02880032	chr2:179629472	TTN	0.47	6.71	0.3	5.75e-11	QT interval;
LGG	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.46	-0.33	4.38e-13	Iron status biomarkers;
LGG	cis	rs7072216	0.727	rs942808	chr10:100168102	C/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.31e-11	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13930080	chr1:23494472	LUZP1	0.42	7.5	0.33	3.36e-13	Gut microbiome composition (summer);
LGG	cis	rs6732160	0.656	rs2043093	chr2:73407342	G/C	cg01422370	chr2:73384389	NA	0.5	9.37	0.4	3.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1185460	0.546	rs592190	chr11:118955314	G/A	cg12636538	chr11:118901039	SLC37A4	-0.57	-11.41	-0.47	9.4e-27	Coronary artery disease;
LGG	cis	rs6866344	0.697	rs17184281	chr5:178127563	G/A	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg18825076	chr15:78729989	IREB2	-0.46	-7.44	-0.33	5.08e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.09	-0.39	2.83e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg20503657	chr10:835505	NA	0.76	10.48	0.44	3.4e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs6466055	0.777	rs2237613	chr7:104845253	G/C	cg04380332	chr7:105027541	SRPK2	-0.35	-6.76	-0.3	4.06e-11	Schizophrenia;
LGG	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.61	-0.51	1.47e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7737355	0.947	rs11242081	chr5:130908135	T/C	cg06307176	chr5:131281290	NA	0.56	9.38	0.4	2.87e-19	Life satisfaction;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg19147804	chr7:1989927	MAD1L1	-0.6	-12.16	-0.49	1.04e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.77	-0.38	3.41e-17	Menopause (age at onset);
LGG	cis	rs9377188	0.593	rs10872629	chr6:149375647	T/C	cg21368479	chr6:149415018	NA	0.27	6.89	0.3	1.85e-11	Cancer;
LGG	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03352830	chr11:487213	PTDSS2	0.86	11.27	0.46	3.47e-26	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20774646	chr1:149858164	HIST2H2BE;HIST2H2AC	0.47	7.9	0.34	2.07e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs68170813	0.559	rs9641378	chr7:106868003	T/C	cg02696742	chr7:106810147	HBP1	-0.78	-10.94	-0.45	5.95e-25	Coronary artery disease;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.48	0.37	3.03e-16	Personality dimensions;
LGG	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.01	-0.42	1.79e-21	Menarche (age at onset);
LGG	cis	rs6940638	0.662	rs7759694	chr6:27240956	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-7.42	-0.33	5.62e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2688608	0.592	rs11000757	chr10:75486815	T/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.35	-0.32	9.01e-13	Inflammatory bowel disease;
LGG	cis	rs6867032	1.000	rs28392808	chr5:2013477	A/G	cg26168224	chr5:2018326	NA	1.26	28.43	0.8	1.33e-103	Gut microbiome composition (winter);
LGG	cis	rs11023332	0.706	rs11023380	chr11:14930058	A/G	cg18937875	chr11:14930189	NA	-0.56	-9.46	-0.4	1.55e-19	Adiponectin levels;Vitamin D levels;
LGG	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-8.01	-0.35	9.68e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg24011408	chr12:48396354	COL2A1	0.52	8.31	0.36	1.09e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg11764359	chr7:65958608	NA	0.73	13.18	0.52	6.73e-34	Aortic root size;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.57e-12	Lung cancer;
LGG	cis	rs1371867	0.875	rs1962901	chr8:101326428	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.59	-0.37	1.36e-16	Atrioventricular conduction;
LGG	cis	rs4789693	0.544	rs4789770	chr17:80376655	C/T	cg19579500	chr17:80346614	NA	0.51	8.9	0.38	1.24e-17	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg01448562	chr3:133502909	NA	-0.64	-10.59	-0.44	1.29e-23	Iron status biomarkers;
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.13	0.31	3.84e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06112835	chr11:68658793	MRPL21	0.62	10.33	0.43	1.24e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9399135	0.967	rs6569990	chr6:135365818	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg21427119	chr20:30132790	HM13	-0.42	-7.1	-0.31	4.71e-12	Mean corpuscular hemoglobin;
LGG	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.63	-0.33	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg19338460	chr6:170058176	WDR27	-0.61	-8.27	-0.36	1.4e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs9472414	0.830	rs34776198	chr6:44760255	C/G	cg20913747	chr6:44695427	NA	0.47	7.0	0.31	9.21e-12	Height;
LGG	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg16586182	chr3:47516702	SCAP	-0.79	-15.19	-0.58	1.47e-42	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	6.12e-20	Life satisfaction;
LGG	cis	rs35160687	0.623	rs11689971	chr2:86474471	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	7.06	0.31	6.16e-12	Night sleep phenotypes;
LGG	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg13072238	chr3:49761600	GMPPB	0.52	7.08	0.31	5.44e-12	Menarche (age at onset);
LGG	cis	rs72781680	0.752	rs72796110	chr2:23905658	T/A	cg08917208	chr2:24149416	ATAD2B	0.84	8.87	0.38	1.61e-17	Lymphocyte counts;
LGG	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg21605333	chr4:119757512	SEC24D	0.79	8.63	0.37	1.01e-16	Cannabis dependence symptom count;
LGG	cis	rs4851266	0.898	rs12615145	chr2:100853116	C/T	cg21926883	chr2:100939477	LONRF2	-0.47	-8.58	-0.37	1.47e-16	Educational attainment;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.34	-0.32	9.73e-13	Menopause (age at onset);
LGG	cis	rs68170813	0.641	rs75639044	chr7:107092631	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-9.94	-0.42	3.25e-21	Coronary artery disease;
LGG	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.06	-0.46	2.26e-25	Coronary artery disease;
LGG	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15664640	chr17:80829946	TBCD	-0.8	-15.74	-0.59	4.98e-45	Breast cancer;
LGG	cis	rs79349575	0.783	rs4294857	chr17:46983391	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs12410462	0.591	rs903692	chr1:227732721	A/G	cg23173402	chr1:227635558	NA	0.36	6.89	0.3	1.86e-11	Major depressive disorder;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg07511668	chr11:68622177	NA	0.46	8.9	0.38	1.22e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg00857998	chr1:205179979	DSTYK	0.57	9.29	0.4	5.96e-19	Red blood cell count;
LGG	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg06623630	chr22:50017776	C22orf34	-0.36	-7.7	-0.34	8.59e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06481639	chr22:41940642	POLR3H	0.52	7.77	0.34	5.05e-14	Vitiligo;
LGG	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.29	-0.32	1.38e-12	Triglycerides;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2692947	0.794	rs2692893	chr2:96756547	C/T	cg22654517	chr2:96458247	NA	0.35	7.09	0.31	5.01e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs35771425	1.000	rs35332498	chr1:211559243	A/C	cg10512769	chr1:211675356	NA	-0.74	-11.74	-0.48	4.81e-28	Educational attainment (years of education);
LGG	cis	rs7647973	1.000	rs974495	chr3:49400482	T/C	cg07636037	chr3:49044803	WDR6	0.77	13.79	0.54	1.8e-36	Menarche (age at onset);
LGG	cis	rs6456042	0.893	rs2277093	chr6:166570766	C/T	cg11088901	chr6:166572345	T	-0.38	-7.89	-0.34	2.28e-14	Asthma;
LGG	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg15017067	chr4:17643749	FAM184B	0.29	6.71	0.3	5.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.14	-0.35	3.66e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2213920	0.516	rs71505548	chr9:118169753	G/A	cg13918206	chr9:118159781	DEC1	-0.77	-10.38	-0.43	7.54e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg21775007	chr8:11205619	TDH	-0.52	-8.35	-0.36	8.27e-16	Neuroticism;
LGG	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs892961	0.932	rs3987885	chr17:75414990	A/G	cg05865280	chr17:75406074	SEPT9	0.43	9.9	0.42	4.21e-21	Airflow obstruction;
LGG	cis	rs1395	0.710	rs72817533	chr2:27482612	A/G	cg23587288	chr2:27483067	SLC30A3	-0.33	-7.43	-0.33	5.31e-13	Blood metabolite levels;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg25811766	chr13:21894605	NA	-0.57	-7.48	-0.33	3.78e-13	White matter hyperintensity burden;
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.7	12.31	0.5	2.48e-30	Blood protein levels;
LGG	cis	rs1497828	0.956	rs1497836	chr1:217562407	T/C	cg04411442	chr1:217543379	NA	0.47	8.04	0.35	7.45e-15	Dialysis-related mortality;
LGG	cis	rs3204270	0.714	rs7503307	chr17:79674929	C/G	cg18367735	chr17:79674897	NA	0.61	8.04	0.35	7.58e-15	Dental caries;
LGG	trans	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg03433033	chr1:76189801	ACADM	-0.71	-9.33	-0.4	4.29e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7781557	0.582	rs2411061	chr7:102613490	T/A	cg18108683	chr7:102477205	FBXL13	-0.52	-7.79	-0.34	4.39e-14	Colorectal adenoma (advanced);
LGG	cis	rs13065560	0.594	rs4398365	chr3:38878804	C/G	cg01426195	chr3:39028469	NA	-0.45	-9.41	-0.4	2.39e-19	Interleukin-18 levels;
LGG	cis	rs9790314	0.905	rs7611367	chr3:161003182	A/G	cg03342759	chr3:160939853	NMD3	0.6	10.21	0.43	3.3e-22	Morning vs. evening chronotype;
LGG	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg11366901	chr6:160182831	ACAT2	1.09	17.26	0.63	6.76e-52	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg20503657	chr10:835505	NA	0.63	9.04	0.39	4.2e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7394190	0.810	rs7394152	chr10:75421446	C/T	cg07699608	chr10:75541558	CHCHD1	0.53	7.26	0.32	1.65e-12	Incident atrial fibrillation;
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg03806693	chr22:41940476	POLR3H	1.09	19.91	0.68	3.64e-64	Vitiligo;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	-0.39	-7.05	-0.31	6.41e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs571497	0.583	rs4804809	chr19:7835977	G/A	cg00371453	chr19:7854482	CLEC4GP1	0.8	8.93	0.38	1.04e-17	Monocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11053966	chr12:51476537	CSRNP2	0.43	6.96	0.31	1.17e-11	Cognitive performance;
LGG	cis	rs11264213	0.901	rs72661643	chr1:36451599	A/G	cg27506609	chr1:36549197	TEKT2	0.83	8.38	0.36	6.37e-16	Schizophrenia;
LGG	cis	rs1497828	1.000	rs1391286	chr1:217561510	C/T	cg04411442	chr1:217543379	NA	0.46	7.89	0.34	2.13e-14	Dialysis-related mortality;
LGG	trans	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.71e-11	Depression;
LGG	cis	rs3857067	1.000	rs6532463	chr4:95027048	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.81	-0.34	3.75e-14	QT interval;
LGG	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.56	0.37	1.64e-16	Aortic root size;
LGG	cis	rs2742417	1.000	rs2673025	chr3:45760483	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs1107366	0.722	rs35331719	chr3:125907392	C/A	cg01346077	chr3:125931526	NA	0.41	9.95	0.42	2.92e-21	Metabolite levels;
LGG	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg11871910	chr12:69753446	YEATS4	0.79	13.22	0.52	4.42e-34	Response to diuretic therapy;
LGG	trans	rs587242	0.823	rs12025601	chr1:97024285	A/G	cg10631902	chr5:14652156	NA	-0.44	-7.52	-0.33	2.89e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LGG	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.93	0.38	1.02e-17	Mood instability;
LGG	cis	rs36051895	0.672	rs12353218	chr9:5162828	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-15.07	-0.57	4.61e-42	Pediatric autoimmune diseases;
LGG	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg13334819	chr7:99746414	C7orf59	-0.53	-8.2	-0.36	2.41e-15	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg07615347	chr10:60278583	BICC1	0.63	18.18	0.65	3.87e-56	Refractive error;
LGG	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.49	7.56	0.33	2.23e-13	Huntington's disease progression;
LGG	cis	rs9914544	0.966	rs7210746	chr17:18798593	T/C	cg26378065	chr17:18585709	ZNF286B	0.51	9.58	0.41	6.07e-20	Educational attainment (years of education);
LGG	cis	rs4740619	0.836	rs10283865	chr9:15894943	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.9	-0.42	4.46e-21	Body mass index;
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.11	0.43	7.91e-22	Height;
LGG	cis	rs2016266	0.859	rs56225815	chr12:53740090	C/G	cg04065151	chr12:53682969	ESPL1	0.58	9.05	0.39	4.03e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-8.78	-0.38	3.3e-17	Blood protein levels;
LGG	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg04025307	chr7:1156635	C7orf50	0.47	8.29	0.36	1.2e-15	Longevity;Endometriosis;
LGG	cis	rs922692	0.744	rs2277545	chr15:79083591	T/C	cg00540400	chr15:79124168	NA	-0.39	-7.58	-0.33	1.9e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08733086	chr1:154947035	CKS1B;SHC1	0.38	6.8	0.3	3.26e-11	Obesity-related traits;
LGG	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs477692	0.789	rs568166	chr10:131400088	G/A	cg05714579	chr10:131428358	MGMT	0.52	10.53	0.44	2.12e-23	Response to temozolomide;
LGG	cis	rs7649275	0.655	rs898420	chr3:53783784	T/G	cg21503701	chr3:53781065	CACNA1D	-0.41	-6.77	-0.3	3.87e-11	Trans fatty acid levels;
LGG	cis	rs34929064	0.914	rs61336419	chr7:22740925	G/A	cg18045685	chr7:22629474	NA	0.52	7.93	0.35	1.7e-14	Major depression and alcohol dependence;
LGG	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06108461	chr20:60628389	TAF4	-0.68	-12.16	-0.49	1.03e-29	Body mass index;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.609	rs2376998	chr20:30340663	T/C	cg13852791	chr20:30311386	BCL2L1	0.93	17.83	0.64	1.57e-54	Mean corpuscular hemoglobin;
LGG	cis	rs4268898	0.662	rs714531	chr2:24399877	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-12.42	-0.5	8.83e-31	Asthma;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.77	-0.34	5.18e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1978968	1.000	rs1076541	chr22:18440026	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-12.61	-0.51	1.45e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs7222240	0.951	rs7220212	chr17:43100566	C/G	cg24806326	chr17:43207588	PLCD3	0.47	7.82	0.34	3.54e-14	Craniofacial microsomia;
LGG	cis	rs13314892	0.728	rs1367370	chr3:69887656	A/G	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg03477792	chr4:77819574	ANKRD56	0.53	9.25	0.39	8.6e-19	Emphysema distribution in smoking;
LGG	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.89	0.3	1.83e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9611565	0.512	rs8141103	chr22:42136930	T/C	cg06481639	chr22:41940642	POLR3H	0.55	7.7	0.34	8.59e-14	Vitiligo;
LGG	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.78	0.45	2.61e-24	Arsenic metabolism;
LGG	cis	rs10262624	1.000	rs13244265	chr7:23917903	A/G	cg09690326	chr7:23720549	C7orf46	-0.33	-6.82	-0.3	2.93e-11	Schizophrenia;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg16405210	chr4:1374714	KIAA1530	0.52	8.81	0.38	2.6e-17	Obesity-related traits;
LGG	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14169450	chr9:139327907	INPP5E	0.38	6.97	0.31	1.08e-11	Monocyte percentage of white cells;
LGG	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg01130898	chr2:219473002	PLCD4	0.44	7.66	0.34	1.1e-13	Mean corpuscular hemoglobin concentration;
LGG	trans	rs12517041	0.572	rs34757351	chr5:23303772	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-8.9	-0.38	1.31e-17	Calcium levels;
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-11.71	-0.48	6.35e-28	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00174466	chr20:30945677	ASXL1	0.51	7.48	0.33	3.83e-13	Gut microbiome composition (summer);
LGG	cis	rs4330281	0.669	rs4909012	chr3:17756467	C/A	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.31e-13	Schizophrenia;
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg14346243	chr4:90757452	SNCA	-0.37	-7.66	-0.34	1.11e-13	Dementia with Lewy bodies;
LGG	cis	rs1018836	0.828	rs10086462	chr8:91558089	A/G	cg16814680	chr8:91681699	NA	-0.73	-13.21	-0.52	4.97e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4731207	0.596	rs6967707	chr7:124609355	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs2180341	0.782	rs6912006	chr6:127722631	C/T	cg24812749	chr6:127587940	RNF146	0.65	11.32	0.47	2.23e-26	Breast cancer;
LGG	trans	rs13256369	0.511	rs7012395	chr8:8538009	T/C	cg21775007	chr8:11205619	TDH	-0.44	-6.66	-0.3	7.64e-11	Obesity-related traits;
LGG	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06562184	chr8:19319451	CSGALNACT1	0.37	7.54	0.33	2.53e-13	Oropharynx cancer;
LGG	cis	rs6784615	0.744	rs2335929	chr3:52498966	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.77	0.57	9.61e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg19077165	chr18:44547161	KATNAL2	0.47	8.28	0.36	1.34e-15	Educational attainment;
LGG	cis	rs367943	0.604	rs10477502	chr5:113007126	C/T	cg12552261	chr5:112820674	MCC	0.51	8.31	0.36	1.1e-15	Type 2 diabetes;
LGG	cis	rs6500395	0.584	rs8059077	chr16:48742029	T/C	cg16662043	chr16:48846231	NA	0.46	8.23	0.36	1.95e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.93	-0.45	6.65e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg18252515	chr7:66147081	NA	1.43	20.72	0.69	5.87e-68	Diabetic kidney disease;
LGG	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg11846333	chr4:119757529	SEC24D	0.84	7.74	0.34	6.21e-14	Cannabis dependence symptom count;
LGG	cis	rs300703	0.654	rs300771	chr2:117241	A/G	cg24565620	chr2:194026	NA	0.66	9.76	0.41	1.39e-20	Blood protein levels;
LGG	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg04207632	chr4:6986609	TBC1D14	-0.43	-8.19	-0.36	2.5e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs6032067	0.929	rs34412950	chr20:43805132	C/A	cg10761708	chr20:43804764	PI3	0.76	11.88	0.48	1.33e-28	Blood protein levels;
LGG	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg22437258	chr11:111473054	SIK2	-0.52	-9.05	-0.39	3.86e-18	Primary sclerosing cholangitis;
LGG	cis	rs13382862	0.895	rs2289082	chr2:20881958	A/T	cg27141850	chr2:20869434	GDF7	0.22	7.05	0.31	6.72e-12	Abdominal aortic aneurysm;
LGG	trans	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg25214090	chr10:38739885	LOC399744	0.61	11.09	0.46	1.64e-25	Corneal astigmatism;
LGG	cis	rs4144743	0.938	rs35069360	chr17:45321270	C/T	cg18085866	chr17:45331354	ITGB3	-0.77	-9.77	-0.41	1.25e-20	Body mass index;
LGG	cis	rs55871839	0.708	rs10098750	chr8:59813205	T/G	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs524281	1.000	rs527897	chr11:65900777	C/T	cg14541915	chr11:65894463	PACS1	0.3	7.06	0.31	5.94e-12	Electroencephalogram traits;
LGG	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg02002194	chr4:3960332	NA	-0.6	-12.55	-0.5	2.75e-31	Mood instability;
LGG	cis	rs17021463	0.676	rs17311887	chr4:95313228	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.07	0.31	5.83e-12	Testicular germ cell tumor;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg05527609	chr1:210001259	C1orf107	-0.52	-6.66	-0.3	8e-11	Red blood cell count;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg27400746	chr16:89904261	SPIRE2	-1.05	-15.39	-0.58	1.92e-43	Skin colour saturation;
LGG	cis	rs11748327	0.514	rs9313069	chr5:4093896	A/G	cg01025095	chr5:4101132	NA	-0.64	-10.23	-0.43	2.74e-22	Myocardial infarction;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg07870213	chr5:140052090	DND1	0.93	17.73	0.64	4.55e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18110333	chr6:292329	DUSP22	-0.52	-9.0	-0.39	5.68e-18	Menopause (age at onset);
LGG	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06634786	chr22:41940651	POLR3H	0.75	11.91	0.48	1.03e-28	Vitiligo;
LGG	cis	rs620875	0.660	rs587590	chr11:126861960	A/G	cg06504925	chr11:126872760	NA	-0.49	-7.08	-0.31	5.51e-12	Response to antipsychotic treatment;
LGG	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.14	-0.31	3.72e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7017914	1.000	rs7007450	chr8:71640269	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs6831352	0.879	rs56272995	chr4:100060882	A/G	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg00700412	chr12:58011837	NA	0.41	8.25	0.36	1.7e-15	Multiple sclerosis;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg00405596	chr8:11794950	NA	-0.43	-6.82	-0.3	2.8e-11	Retinal vascular caliber;
LGG	cis	rs6032067	0.714	rs6032076	chr20:43887682	T/C	cg10761708	chr20:43804764	PI3	0.58	8.65	0.37	8.46e-17	Blood protein levels;
LGG	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg16325326	chr1:53192061	ZYG11B	-0.85	-22.87	-0.73	4.86e-78	Monocyte count;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg26617929	chr16:1858877	NA	-0.61	-8.65	-0.37	8.3e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg08621203	chr6:150244597	RAET1G	0.46	8.01	0.35	9.64e-15	Lung cancer;
LGG	cis	rs17767392	0.914	rs10139519	chr14:72109270	C/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.48	-0.4	1.37e-19	Mitral valve prolapse;
LGG	cis	rs6732160	0.588	rs13403748	chr2:73371475	T/C	cg01422370	chr2:73384389	NA	0.56	9.66	0.41	3.01e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.77	0.41	1.3e-20	Bipolar disorder;
LGG	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg02549819	chr16:58548995	SETD6	1.43	13.68	0.54	5.3e-36	Schizophrenia;
LGG	trans	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg00953403	chr17:74099816	EXOC7	0.4	6.66	0.3	7.69e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs747650	0.892	rs7937101	chr11:47226488	A/G	cg03339077	chr11:47165057	C11orf49	-0.53	-9.94	-0.42	3.24e-21	Acne (severe);
LGG	cis	rs77741769	0.529	rs7137504	chr12:121221628	C/T	cg02419362	chr12:121203948	SPPL3	0.56	9.61	0.41	4.57e-20	Mean corpuscular volume;
LGG	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg03477792	chr4:77819574	ANKRD56	0.54	9.46	0.4	1.53e-19	Emphysema distribution in smoking;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.94	0.49	7.62e-29	Tonsillectomy;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs11122272	0.735	rs2437147	chr1:231516756	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19436567	chr6:157099375	ARID1B	0.5	7.51	0.33	3.15e-13	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.737	rs4841436	chr8:10594474	A/C	cg08975724	chr8:8085496	FLJ10661	0.36	6.69	0.3	6.65e-11	Neuroticism;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-7.11	-0.31	4.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.4e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg20336341	chr7:50628841	DDC	0.51	9.51	0.4	1e-19	Malaria;
LGG	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.95	-0.31	1.25e-11	Blood metabolite levels;
LGG	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg25457927	chr22:38595422	NA	0.44	11.17	0.46	8.33e-26	Cutaneous nevi;
LGG	cis	rs754423	0.532	rs941625	chr14:52547735	A/G	cg12071775	chr14:52591786	NA	0.5	8.86	0.38	1.71e-17	Craniofacial microsomia;
LGG	cis	rs12618769	0.597	rs72821907	chr2:99085296	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.52	0.37	2.28e-16	Bipolar disorder;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg13453750	chr1:205783389	SLC41A1	-0.4	-7.64	-0.33	1.27e-13	Menarche (age at onset);
LGG	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg26597838	chr10:835615	NA	-0.7	-9.59	-0.41	5.46e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs9660992	0.674	rs17345816	chr1:205262868	A/T	cg00857998	chr1:205179979	DSTYK	-0.48	-6.97	-0.31	1.13e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs17208368	0.628	rs61446595	chr16:55093788	A/C	cg09947736	chr16:55091198	NA	0.67	12.82	0.51	2.03e-32	Hypospadias;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg05313129	chr8:58192883	C8orf71	-0.74	-9.81	-0.41	8.95e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs2270450	0.704	rs953062	chr6:46626353	A/G	cg10156739	chr6:46714674	LOC100287718	-0.34	-8.01	-0.35	9.33e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs12477438	0.501	rs2122748	chr2:100065369	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.95	-0.31	1.26e-11	Chronic sinus infection;
LGG	cis	rs6840360	0.571	rs72728182	chr4:152487027	T/C	cg25486957	chr4:152246857	NA	-0.51	-8.52	-0.37	2.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.594	rs12526352	chr6:101113781	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.89	0.3	1.83e-11	Neuroticism;
LGG	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg27205649	chr11:78285834	NARS2	-0.42	-6.88	-0.3	1.93e-11	Testicular germ cell tumor;
LGG	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg12011299	chr4:100065546	ADH4	0.4	8.15	0.35	3.41e-15	Alcohol dependence;
LGG	cis	rs4917300	0.606	rs1492367	chr8:143103498	T/C	cg06573787	chr8:143070187	NA	0.59	9.98	0.42	2.29e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg08280861	chr8:58055591	NA	0.57	7.25	0.32	1.72e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs611744	0.967	rs584555	chr8:109218612	C/G	cg21045802	chr8:109455806	TTC35	0.38	6.75	0.3	4.55e-11	Dupuytren's disease;
LGG	cis	rs2243480	1.000	rs1638734	chr7:66097539	A/C	cg12463550	chr7:65579703	CRCP	0.75	7.95	0.35	1.43e-14	Diabetic kidney disease;
LGG	cis	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.05	-0.31	6.68e-12	Triglycerides;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23046897	chr19:55851104	SUV420H2	-0.37	-6.82	-0.3	2.79e-11	Pancreatic cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03888520	chr22:42978243	RRP7B	0.44	7.02	0.31	7.98e-12	Cognitive performance;
LGG	trans	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-9.59	-0.41	5.43e-20	Brugada syndrome;
LGG	cis	rs8017423	0.967	rs11623275	chr14:90721335	C/T	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.52	0.61	1.63e-48	Obesity-related traits;
LGG	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg09517075	chr8:22133004	PIWIL2	0.43	9.38	0.4	2.91e-19	Hypertriglyceridemia;
LGG	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg11952622	chr19:58962976	ZNF324B	-0.46	-6.87	-0.3	2.08e-11	Mean platelet volume;
LGG	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.41	-0.44	6.29e-23	Hemoglobin concentration;
LGG	cis	rs17767392	0.834	rs55863348	chr14:71724293	C/T	cg02058870	chr14:72053146	SIPA1L1	0.4	7.67	0.34	9.95e-14	Mitral valve prolapse;
LGG	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg18567174	chr15:68126065	LBXCOR1	-0.39	-6.98	-0.31	1e-11	Restless legs syndrome;
LGG	cis	rs193541	0.564	rs407230	chr5:122345727	G/A	cg19412675	chr5:122181750	SNX24	-0.52	-8.3	-0.36	1.11e-15	Glucose homeostasis traits;
LGG	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg02002194	chr4:3960332	NA	0.38	7.0	0.31	9.08e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11864453	0.616	rs9938025	chr16:72022041	A/G	cg14768367	chr16:72042858	DHODH	-0.42	-7.61	-0.33	1.5700000000000001e-13	Fibrinogen levels;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.94	10.29	0.43	1.6400000000000001e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs653465	0.739	rs56259835	chr3:27166202	C/T	cg02860705	chr3:27208620	NA	-0.41	-7.96	-0.35	1.35e-14	Breast cancer (early onset);
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.41	0.36	5.14e-16	Platelet count;
LGG	cis	rs2712184	0.756	rs2712161	chr2:217662384	G/A	cg05032264	chr2:217675019	NA	-0.43	-9.27	-0.4	7.09e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs6489882	0.703	rs10774672	chr12:113360737	G/T	cg25319449	chr12:113376135	OAS3	-0.37	-6.7	-0.3	6.06e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.41	0.33	5.94e-13	Menopause (age at onset);
LGG	trans	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg16006296	chr10:38738647	LOC399744	0.34	6.69	0.3	6.31e-11	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08263361	chr15:77713262	HMG20A	-0.53	-7.82	-0.34	3.56e-14	Systemic lupus erythematosus;
LGG	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.14	0.31	3.7e-12	Neuroticism;
LGG	cis	rs240764	0.578	rs6928418	chr6:101175347	T/C	cg09795085	chr6:101329169	ASCC3	0.42	7.08	0.31	5.24e-12	Neuroticism;
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	11.04	0.46	2.56e-25	Total body bone mineral density;
LGG	cis	rs12282928	1.000	rs10769336	chr11:48292339	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.04	-0.31	6.8e-12	Migraine - clinic-based;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg18538332	chr22:24372958	LOC391322	0.52	8.61	0.37	1.19e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg26441486	chr22:50317300	CRELD2	0.41	7.18	0.32	2.72e-12	Schizophrenia;
LGG	cis	rs79349575	0.715	rs62075844	chr17:47002389	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.51e-11	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg00800038	chr16:89945340	TCF25	-0.67	-7.91	-0.35	1.86e-14	Skin colour saturation;
LGG	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg08344181	chr3:125677491	NA	-0.56	-7.33	-0.32	1e-12	Depression;
LGG	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-11.05	-0.46	2.34e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11229555	1.000	rs10896795	chr11:58366561	A/G	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs11711311	1.000	rs12695295	chr3:113474866	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.03	-0.35	8.26e-15	IgG glycosylation;
LGG	trans	rs5750339	0.666	rs2413435	chr22:37312264	A/C	cg19147129	chr2:74230310	NA	-0.36	-7.22	-0.32	2.19e-12	Itch intensity from mosquito bite adjusted by bite size;Mosquito bite size;Perceived unattractiveness to mosquitoes;Itch intensity from mosquito bite;
LGG	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04850017	chr11:63683019	RCOR2	0.31	7.92	0.35	1.75e-14	Pulse pressure;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg08677398	chr8:58056175	NA	0.56	12.31	0.5	2.6e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	1.000	rs72796358	chr2:24160132	T/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.31	0.4	5.34e-19	Lymphocyte counts;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.51	0.37	2.47e-16	Platelet count;
LGG	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.52	0.37	2.18e-16	Retinal vascular caliber;
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs4356932	0.935	rs116135606	chr4:76967942	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	5.17e-11	Blood protein levels;
LGG	cis	rs62380364	0.565	rs13158247	chr5:88030670	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27482856	chr7:99214447	ZNF498	0.51	8.25	0.36	1.71e-15	Cognitive performance;
LGG	cis	rs7681440	0.715	rs17016251	chr4:90742639	G/C	cg15133208	chr4:90757351	SNCA	-0.3	-6.85	-0.3	2.3e-11	Dementia with Lewy bodies;
LGG	cis	rs6909430	0.803	rs6938289	chr6:98566974	G/T	cg12860156	chr6:98744658	NA	-0.44	-7.33	-0.32	1.05e-12	Quantitative traits;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	9.1	0.39	2.67e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2898279	0.815	rs2003423	chr8:11303011	A/G	cg26274995	chr8:11302983	FAM167A	0.54	11.14	0.46	1.11e-25	Small cell lung carcinoma;
LGG	cis	rs8072100	1.000	rs11870935	chr17:45732605	G/A	cg08085267	chr17:45401833	C17orf57	0.62	12.94	0.52	6.45e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12580194	0.593	rs7489047	chr12:55759851	A/G	cg19537932	chr12:55886519	OR6C68	-0.57	-10.4	-0.44	6.78e-23	Cancer;
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22968622	chr17:43663579	NA	1.1	21.3	0.7	1.09e-70	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7236492	0.627	rs76032846	chr18:77198322	G/A	cg15644404	chr18:77186268	NFATC1	-0.81	-9.8	-0.41	9.96e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9305556	0.857	rs2000436	chr21:36029025	C/T	cg24523685	chr21:36062813	CLIC6	-0.35	-6.73	-0.3	4.94e-11	Psoriasis;
LGG	cis	rs525592	1	rs525592	chr11:68195104	C/T	cg16797656	chr11:68205561	LRP5	0.56	10.52	0.44	2.39e-23	Bone mineral density;
LGG	cis	rs17826219	0.733	rs7221691	chr17:28723619	C/T	cg01831904	chr17:28903510	LRRC37B2	0.65	8.16	0.35	3.08e-15	Body mass index;
LGG	trans	rs826838	1.000	rs851934	chr12:39104453	G/T	cg06521331	chr12:34319734	NA	0.44	8.05	0.35	7.18e-15	Heart rate;
LGG	cis	rs7851660	0.844	rs10759975	chr9:100625193	C/T	cg13688889	chr9:100608707	NA	0.63	12.57	0.5	2.23e-31	Strep throat;
LGG	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg11789530	chr4:8429930	ACOX3	0.74	14.54	0.56	9.84e-40	Response to antineoplastic agents;
LGG	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg04691961	chr3:161091175	C3orf57	-0.47	-10.06	-0.42	1.12e-21	Morning vs. evening chronotype;
LGG	cis	rs877282	1.000	rs11253362	chr10:770979	G/T	cg17470449	chr10:769945	NA	0.62	7.91	0.35	1.9e-14	Uric acid levels;
LGG	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg23280166	chr11:118938394	VPS11	-0.49	-8.44	-0.37	4.11e-16	Coronary artery disease;
LGG	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.87e-19	Menarche (age at onset);
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22433210	chr17:43662623	NA	0.91	15.07	0.57	4.94e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg13397359	chr6:42928475	GNMT	0.52	14.27	0.55	1.57e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	12.48	0.5	4.96e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.71	0.3	5.52e-11	Bladder cancer;
LGG	cis	rs1983891	0.779	rs4714475	chr6:41509901	G/T	cg20194872	chr6:41519635	FOXP4	0.54	8.8	0.38	2.7e-17	Prostate cancer;
LGG	cis	rs12135062	0.851	rs2651927	chr1:3101762	A/C	cg21609526	chr1:3105151	PRDM16	-0.65	-11.81	-0.48	2.65e-28	Migraine;
LGG	cis	rs1010254	0.510	rs2881985	chr5:151700329	C/G	cg12297329	chr5:152029980	NA	0.5	7.22	0.32	2.09e-12	Optic nerve measurement (cup area);
LGG	trans	rs877282	0.842	rs12357963	chr10:757562	C/T	cg22713356	chr15:30763199	NA	0.48	7.24	0.32	1.93e-12	Uric acid levels;
LGG	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg03605463	chr16:89740564	NA	0.5	8.8	0.38	2.78e-17	Hemoglobin concentration;
LGG	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15369054	chr17:80825471	TBCD	0.35	6.7	0.3	6.02e-11	Breast cancer;
LGG	cis	rs6430585	0.793	rs11684545	chr2:136539122	G/T	cg07169764	chr2:136633963	MCM6	-0.78	-13.82	-0.54	1.26e-36	Corneal structure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10513696	chr12:27863634	MRPS35	0.5	7.54	0.33	2.45e-13	Gut microbiome composition (summer);
LGG	cis	rs7614311	0.639	rs73119035	chr3:63993966	A/G	cg22134162	chr3:63841271	THOC7	-0.41	-6.99	-0.31	9.46e-12	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs283228	0.617	rs608847	chr6:101736144	T/G	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg24829409	chr8:58192753	C8orf71	0.77	10.43	0.44	5.31e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.93	-0.45	6.84e-25	Longevity;
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.48	-8.37	-0.36	6.95e-16	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17218495	chr19:11071743	SMARCA4	0.48	7.68	0.34	9.81e-14	Cognitive performance;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	0.57	7.32	0.32	1.07e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7071206	0.947	rs4979902	chr10:79399946	C/T	cg07817648	chr10:79422355	NA	0.8	14.95	0.57	1.64e-41	Bone mineral density;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6998277	1.000	rs4734648	chr8:103635994	G/A	cg10187029	chr8:103597600	NA	0.81	11.82	0.48	2.33e-28	Migraine;
LGG	cis	rs7107174	1.000	rs10899454	chr11:77997513	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.38	-0.32	7.39e-13	Testicular germ cell tumor;
LGG	cis	rs7737355	0.947	rs79018835	chr5:130798461	C/A	cg06307176	chr5:131281290	NA	-0.56	-9.31	-0.4	5.3e-19	Life satisfaction;
LGG	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs6496667	0.557	rs2526002	chr15:90965655	C/T	cg22089800	chr15:90895588	ZNF774	0.5	8.16	0.35	3.29e-15	Rheumatoid arthritis;
LGG	cis	rs9815354	1.000	rs9826058	chr3:41762062	A/G	cg03022575	chr3:42003672	ULK4	0.58	7.45	0.33	4.49e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs6840360	0.607	rs1561918	chr4:152446832	T/A	cg17217059	chr4:152329364	FAM160A1	0.21	7.3	0.32	1.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9543976	1.000	rs7339146	chr13:76173719	G/A	cg01531495	chr13:76123901	UCHL3	-0.63	-7.66	-0.34	1.09e-13	Diabetic retinopathy;
LGG	cis	rs911555	0.755	rs12436729	chr14:103929889	G/C	cg24130564	chr14:104152367	KLC1	0.39	7.31	0.32	1.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs3790455	0.585	rs3790460	chr1:156465029	C/G	cg14087168	chr1:156450669	MEF2D	-0.66	-9.66	-0.41	3.11e-20	Migraine;
LGG	cis	rs7412746	0.658	rs1027699	chr1:150811712	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.11	0.31	4.56e-12	Melanoma;
LGG	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg08923054	chr8:41654455	ANK1	0.78	13.71	0.54	3.7e-36	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.22	-0.36	2.09e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2836974	0.932	rs2150415	chr21:40615367	A/G	cg11890956	chr21:40555474	PSMG1	1.13	24.83	0.76	3.64e-87	Cognitive function;
LGG	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg14186256	chr22:23484241	RTDR1	0.92	20.53	0.69	4.56e-67	Bone mineral density;
LGG	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg13147721	chr7:65941812	NA	-0.57	-7.11	-0.31	4.47e-12	Diabetic kidney disease;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.88	0.38	1.53e-17	Colorectal cancer;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.94	-0.45	6.22e-25	Longevity;Endometriosis;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.23	0.49	5.46e-30	Vitiligo;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.11	-0.43	7.67e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg12432903	chr7:1882776	MAD1L1	-0.52	-7.93	-0.35	1.67e-14	Bipolar disorder;
LGG	trans	rs8002861	0.875	rs11616803	chr13:44457109	A/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-22.07	-0.72	2.7e-74	Leprosy;
LGG	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg13010199	chr12:38710504	ALG10B	0.66	13.29	0.53	2.18e-34	Bladder cancer;
LGG	cis	rs36051895	0.589	rs11790596	chr9:5198335	T/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.16	-0.58	1.92e-42	Pediatric autoimmune diseases;
LGG	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-10.83	-0.45	1.58e-24	Bronchopulmonary dysplasia;
LGG	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg14773178	chr5:1868261	NA	0.37	6.93	0.31	1.43e-11	Cardiovascular disease risk factors;
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.06e-12	Aortic root size;
LGG	cis	rs9398803	0.678	rs3861456	chr6:126898660	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.69e-20	Male-pattern baldness;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg11062466	chr8:58055876	NA	-0.54	-8.81	-0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg20913747	chr6:44695427	NA	-0.6	-10.23	-0.43	2.7e-22	Total body bone mineral density;
LGG	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-10.64	-0.44	8.75e-24	Mean platelet volume;Platelet distribution width;
LGG	trans	rs2548003	0.966	rs1862559	chr5:28733753	T/C	cg12623145	chr2:97778927	ANKRD36	0.45	6.96	0.31	1.17e-11	Hip geometry;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg22535103	chr8:58192502	C8orf71	-0.8	-9.7	-0.41	2.2e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg02811702	chr13:24901961	NA	0.4	7.32	0.32	1.07e-12	Obesity-related traits;
LGG	cis	rs4722585	0.533	rs2049843	chr7:26196963	G/A	cg07876897	chr7:26191696	NFE2L3	0.36	7.05	0.31	6.5e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs607541	1.000	rs4270120	chr15:45936234	G/C	cg26924012	chr15:45694286	SPATA5L1	0.53	7.37	0.32	7.83e-13	Obesity-related traits;
LGG	cis	rs10193935	0.901	rs6733914	chr2:42674741	A/G	cg27598129	chr2:42591480	NA	0.67	10.07	0.42	1.09e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg26174226	chr8:58114915	NA	-0.5	-7.02	-0.31	8.15e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	0.678	rs11125293	chr2:24102423	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	8.19	0.36	2.64e-15	Lymphocyte counts;
LGG	cis	rs1790761	0.967	rs7110021	chr11:67253564	T/C	cg24690094	chr11:67383802	NA	-0.4	-6.92	-0.31	1.48e-11	Mean corpuscular volume;
LGG	cis	rs698833	0.780	rs11124986	chr2:44508835	G/A	cg00619915	chr2:44497795	NA	-0.45	-6.79	-0.3	3.35e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Vitiligo;
LGG	cis	rs17221829	0.645	rs10830325	chr11:89389068	G/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	trans	rs11039798	1.000	rs10769383	chr11:48592510	C/G	cg03929089	chr4:120376271	NA	0.74	8.65	0.37	8.74e-17	Axial length;
LGG	cis	rs7789940	0.904	rs12531348	chr7:75937191	G/C	cg10167463	chr7:75959203	YWHAG	-0.44	-7.24	-0.32	1.83e-12	Multiple sclerosis;
LGG	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.46e-12	Blood metabolite levels;
LGG	cis	rs644799	0.542	rs10831415	chr11:95466159	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	8.81	0.38	2.56e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-10.41	-0.44	6.02e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs12519773	0.534	rs2453763	chr5:92376460	T/A	cg18783429	chr5:92414398	NA	-0.31	-7.42	-0.33	5.74e-13	Migraine;
LGG	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.93	0.52	6.92e-33	Colorectal cancer;
LGG	cis	rs8017423	0.935	rs716122	chr14:90792313	A/C	cg04374321	chr14:90722782	PSMC1	-0.86	-17.48	-0.63	6.55e-53	Mortality in heart failure;
LGG	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg03511173	chr18:77590860	NA	0.44	7.23	0.32	2.06e-12	Schizophrenia;
LGG	cis	rs887829	0.569	rs4124874	chr2:234665659	T/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.64	-0.33	1.24e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg12310025	chr6:25882481	NA	-0.41	-7.36	-0.32	8.65e-13	Height;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg27286069	chr11:118481882	PHLDB1	0.51	9.17	0.39	1.58e-18	Cholesterol, total;
LGG	cis	rs12780845	0.540	rs12770238	chr10:17209570	C/G	cg01003015	chr10:17271136	VIM	0.41	7.02	0.31	8.1e-12	Homocysteine levels;
LGG	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg08305652	chr11:111469057	NA	-0.44	-8.61	-0.37	1.12e-16	Primary sclerosing cholangitis;
LGG	cis	rs7923609	0.841	rs10761786	chr10:65336207	T/C	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.71	-0.3	5.58e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.43	6.96	0.31	1.16e-11	Cystic fibrosis severity;
LGG	cis	rs7937682	0.961	rs7106104	chr11:111635655	T/C	cg08305652	chr11:111469057	NA	0.39	7.57	0.33	2.01e-13	Primary sclerosing cholangitis;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs6688613	0.545	rs10800270	chr1:166827602	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.57	8.87	0.38	1.64e-17	Refractive astigmatism;
LGG	trans	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg25482853	chr8:67687455	SGK3	0.93	11.68	0.48	8.29e-28	Obesity-related traits;
LGG	cis	rs6704644	0.656	rs11694654	chr2:234332343	G/A	cg27060346	chr2:234359958	DGKD	-0.61	-7.38	-0.32	7.33e-13	Bilirubin levels;
LGG	cis	rs6445975	0.715	rs17059125	chr3:58268750	C/A	cg24175188	chr3:58374923	PXK	0.4	7.57	0.33	1.98e-13	Systemic lupus erythematosus;
LGG	cis	rs9314323	0.698	rs1064807	chr8:26236978	C/T	cg11498726	chr8:26250323	BNIP3L	-0.54	-11.32	-0.47	2.22e-26	Red cell distribution width;
LGG	cis	rs2274273	0.870	rs10147434	chr14:55674847	C/T	cg04306507	chr14:55594613	LGALS3	0.64	17.77	0.64	2.95e-54	Protein biomarker;
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	trans	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg01620082	chr3:125678407	NA	-1.01	-9.08	-0.39	3.15e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.86	-0.34	2.73e-14	Life satisfaction;
LGG	cis	rs472402	0.560	rs6874005	chr5:6624371	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.18	-0.32	2.84e-12	Response to amphetamines;
LGG	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg23221052	chr5:179740743	GFPT2	-0.6	-11.04	-0.46	2.69e-25	Height;
LGG	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg00204512	chr16:28754710	NA	0.24	6.66	0.3	7.62e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-7.56	-0.33	2.2e-13	Total body bone mineral density;
LGG	cis	rs4460629	0.742	rs7368345	chr1:155080090	C/T	cg13808842	chr1:155066096	NA	0.29	7.09	0.31	5.1e-12	Serum magnesium levels;
LGG	cis	rs13191362	0.935	rs35537826	chr6:163145867	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.08	11.87	0.48	1.55e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.76	-0.3	4.08e-11	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00629816	chr9:37784931	EXOSC3	0.52	8.08	0.35	5.67e-15	Gut microbiome composition (summer);
LGG	cis	rs61192259	0.840	rs6899746	chr6:38412788	G/A	cg07362130	chr6:38359646	BTBD9	-0.29	-6.73	-0.3	5.18e-11	Restless legs syndrome;
LGG	cis	rs2274273	0.870	rs4496026	chr14:55790512	A/G	cg04306507	chr14:55594613	LGALS3	0.62	17.17	0.62	1.69e-51	Protein biomarker;
LGG	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs12049351	0.665	rs10916477	chr1:229576965	C/T	cg13547644	chr1:229569608	ACTA1	0.31	6.76	0.3	4.13e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg21724239	chr8:58056113	NA	0.47	7.07	0.31	5.88e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12016809	chr21:47604291	C21orf56	0.54	9.67	0.41	2.85e-20	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7241530	0.636	rs4799271	chr18:75898539	C/T	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	trans	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg18187862	chr3:45730750	SACM1L	0.57	9.2	0.39	1.23e-18	Primary sclerosing cholangitis;
LGG	cis	rs6840360	0.642	rs10857260	chr4:152424056	C/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.26	0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg24253500	chr15:84953950	NA	0.59	10.82	0.45	1.84e-24	Schizophrenia;
LGG	cis	rs6062302	0.522	rs2297427	chr20:62221364	G/A	cg16989086	chr20:62203971	PRIC285	0.48	7.07	0.31	5.57e-12	Glioblastoma;
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19524238	chr7:2802976	GNA12	0.33	7.96	0.35	1.34e-14	Height;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg08198773	chr8:1697536	NA	0.44	7.73	0.34	6.8e-14	Systolic blood pressure;
LGG	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs526231	0.543	rs75913944	chr5:102479503	G/C	cg23492399	chr5:102201601	PAM	-0.58	-8.53	-0.37	2.05e-16	Primary biliary cholangitis;
LGG	cis	rs185694	0.947	rs202079	chr13:30879154	C/T	cg07600127	chr13:30881527	KATNAL1	-0.55	-7.04	-0.31	7.15e-12	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs988958	0.637	rs7595175	chr2:42220015	T/C	cg19376973	chr2:42229025	NA	0.63	9.88	0.42	5.23e-21	Hypospadias;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg08742575	chr21:47604166	C21orf56	0.54	9.05	0.39	3.91e-18	Testicular germ cell tumor;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg13945301	chr2:157190182	NR4A2	-0.43	-7.15	-0.32	3.5e-12	Body fat mass;
LGG	cis	rs2832270	0.562	rs17814339	chr21:30543443	G/A	cg24692254	chr21:30365293	RNF160	-0.67	-7.02	-0.31	8.05e-12	Response to mTOR inhibitor (everolimus);
LGG	cis	rs2236918	1.000	rs1635511	chr1:242026172	C/T	cg17736920	chr1:242011382	EXO1	0.53	9.55	0.41	7.29e-20	Menopause (age at onset);
LGG	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg02466173	chr16:30829666	NA	-0.43	-7.71	-0.34	7.59e-14	Dementia with Lewy bodies;
LGG	cis	rs12579753	0.719	rs4384447	chr12:82268069	G/C	cg07988820	chr12:82153109	PPFIA2	-0.56	-8.21	-0.36	2.22e-15	Resting heart rate;
LGG	trans	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg14791747	chr16:20752902	THUMPD1	0.5	7.59	0.33	1.82e-13	Cognitive test performance;
LGG	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.04	-0.35	7.77e-15	Neuroticism;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg27471124	chr11:109292789	C11orf87	0.49	9.27	0.4	6.84e-19	Schizophrenia;
LGG	cis	rs1577917	0.958	rs12209668	chr6:86566517	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs4842666	0.850	rs11105328	chr12:89942390	A/G	cg00757033	chr12:89920650	WDR51B	0.53	6.76	0.3	4.23e-11	Blood pressure;
LGG	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg02297831	chr4:17616191	MED28	0.51	9.67	0.41	2.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg21775007	chr8:11205619	TDH	0.43	6.78	0.3	3.67e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg06481639	chr22:41940642	POLR3H	0.53	7.91	0.35	1.88e-14	Vitiligo;
LGG	cis	rs9814567	0.806	rs1880375	chr3:134322163	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.56	0.41	6.93e-20	Bipolar disorder;
LGG	cis	rs1344694	0.548	rs12468812	chr2:216905867	C/T	cg12620499	chr2:216877984	MREG	0.58	10.87	0.45	1.19e-24	Alcohol dependence;
LGG	cis	rs362272	0.545	rs2236052	chr4:3318413	C/T	cg06533319	chr4:3265114	C4orf44	0.33	6.65	0.3	8.44e-11	Serum sulfate level;
LGG	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15128208	chr22:42549153	NA	-0.41	-8.12	-0.35	4.17e-15	Cognitive function;
LGG	cis	rs7546668	1.000	rs6686890	chr1:15835414	C/G	cg21858823	chr1:15850916	CASP9	0.37	6.86	0.3	2.23e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9463078	0.764	rs9367208	chr6:44830180	G/A	cg25276700	chr6:44698697	NA	-0.4	-8.58	-0.37	1.41e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs952623	0.717	rs12669446	chr7:39046908	A/G	cg18850127	chr7:39170497	POU6F2	-0.32	-7.47	-0.33	4.03e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6800768	0.633	rs58523227	chr3:24116856	C/A	cg10674438	chr3:24145617	LOC152024	-0.5	-8.86	-0.38	1.77e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4959677	0.698	rs9501849	chr6:2479770	A/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.21	-0.36	2.28e-15	Orthostatic hypotension;
LGG	cis	rs3820068	0.581	rs72645888	chr1:15929922	C/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.67	0.51	8.42e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6466055	0.720	rs12668097	chr7:104996472	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.29	0.32	1.31e-12	Schizophrenia;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.6	-0.51	1.6e-31	Vitiligo;
LGG	cis	rs1957429	0.614	rs17767870	chr14:65321737	G/A	cg23373153	chr14:65346875	NA	-1.02	-9.76	-0.41	1.43e-20	Pediatric areal bone mineral density (radius);
LGG	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg00198680	chr16:28758506	NA	0.31	7.45	0.33	4.57e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg09904177	chr6:26538194	HMGN4	0.59	8.5	0.37	2.72e-16	Small cell lung carcinoma;
LGG	cis	rs12410462	0.591	rs2644162	chr1:227703397	C/T	cg23173402	chr1:227635558	NA	0.38	7.11	0.31	4.56e-12	Major depressive disorder;
LGG	cis	rs644799	1.000	rs632388	chr11:95563775	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg15485101	chr11:133734466	NA	0.59	10.21	0.43	3.41e-22	Childhood ear infection;
LGG	cis	rs10504073	0.669	rs62507253	chr8:50028836	C/T	cg00325661	chr8:49890786	NA	0.74	13.97	0.54	2.91e-37	Blood metabolite ratios;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg09033563	chr22:24373618	LOC391322	-0.52	-8.5	-0.37	2.57e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg13010199	chr12:38710504	ALG10B	0.62	12.08	0.49	2.22e-29	Heart rate;
LGG	cis	rs4262150	0.883	rs11167589	chr5:152098705	C/G	cg12297329	chr5:152029980	NA	-0.74	-13.77	-0.54	2.03e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg25823085	chr7:87105416	ABCB4	0.29	7.26	0.32	1.66e-12	Gallbladder cancer;
LGG	cis	rs7937890	0.532	rs2256884	chr11:14476402	A/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.89	-0.34	2.15e-14	Mitochondrial DNA levels;
LGG	cis	rs6558530	0.666	rs6558526	chr8:1702572	A/G	cg25947184	chr8:1697459	NA	0.42	7.34	0.32	9.66e-13	Systolic blood pressure;
LGG	cis	rs9815354	0.812	rs4264702	chr3:41952539	T/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg18196295	chr10:418757	DIP2C	0.44	8.03	0.35	8.18e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs11206510	0.585	rs2495505	chr1:55484810	A/G	cg20245116	chr1:55522013	PCSK9	0.39	7.08	0.31	5.29e-12	Coronary heart disease;LDL cholesterol;Myocardial infarction (early onset);Myocardial infarction;Coronary artery disease;
LGG	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg13010199	chr12:38710504	ALG10B	0.73	14.91	0.57	2.43e-41	Bladder cancer;
LGG	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs6831352	0.879	rs7672728	chr4:100055173	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs620875	0.660	rs602920	chr11:126860868	T/C	cg06504925	chr11:126872760	NA	-0.49	-7.11	-0.31	4.48e-12	Response to antipsychotic treatment;
LGG	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg20368463	chr18:77673604	PQLC1	0.43	7.53	0.33	2.59e-13	Schizophrenia;
LGG	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs17453880	0.676	rs2961761	chr5:151953547	A/G	cg12297329	chr5:152029980	NA	-0.67	-14.56	-0.56	8.51e-40	Subjective well-being;
LGG	cis	rs1707322	0.964	rs10437063	chr1:46273666	G/A	cg03146154	chr1:46216737	IPP	0.54	10.28	0.43	1.78e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2251381	0.750	rs2255055	chr21:30537045	C/T	cg08807101	chr21:30365312	RNF160	0.76	13.74	0.54	2.73e-36	Selective IgA deficiency;
LGG	cis	rs9517313	0.615	rs4772079	chr13:99090837	C/G	cg07423050	chr13:99094983	FARP1	-0.63	-12.39	-0.5	1.17e-30	Neuroticism;
LGG	cis	rs7654585	0.962	rs2309289	chr4:25947094	T/A	cg10409131	chr4:25915609	C4orf52	0.51	8.45	0.37	3.85e-16	Obesity-related traits;
LGG	cis	rs60180747	0.544	rs12908529	chr15:66571968	T/G	cg07575407	chr15:66541975	MEGF11	0.63	13.64	0.54	7.88e-36	Testicular germ cell tumor;
LGG	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg12395012	chr8:11607386	GATA4	0.39	6.84	0.3	2.48e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9487094	0.670	rs12199154	chr6:109822996	C/T	cg16315928	chr6:109776240	MICAL1	-0.45	-7.89	-0.34	2.18e-14	Height;
LGG	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg00666640	chr1:248458726	OR2T12	0.58	8.84	0.38	2.05e-17	Common traits (Other);
LGG	cis	rs11229555	0.645	rs7929028	chr11:58188258	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.29	-0.58	5.13e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.97	-12.71	-0.51	5.85e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg16006841	chr5:176797999	RGS14	-0.6	-9.67	-0.41	2.78e-20	Hemoglobin concentration;Hematocrit;
LGG	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg04568710	chr12:38710424	ALG10B	-0.36	-7.9	-0.34	2.01e-14	Bladder cancer;
LGG	cis	rs4774899	0.966	rs12902099	chr15:57568789	A/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.3	-0.32	1.22e-12	Urinary tract infection frequency;
LGG	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.11	-0.31	4.37e-12	Blood metabolite levels;
LGG	cis	rs11771526	0.901	rs28631129	chr7:32305044	G/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs7851660	0.967	rs3758248	chr9:100614601	G/A	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg03060546	chr3:49711283	APEH	-0.69	-12.06	-0.49	2.55e-29	Resting heart rate;
LGG	cis	rs9341808	0.718	rs9352803	chr6:80864667	G/T	cg08355045	chr6:80787529	NA	0.42	8.02	0.35	8.98e-15	Sitting height ratio;
LGG	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg10483660	chr13:112241077	NA	0.36	6.96	0.31	1.13e-11	Menarche (age at onset);
LGG	cis	rs6964587	1.000	rs2299239	chr7:91654617	C/T	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.16e-13	HDL cholesterol;
LGG	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	9.61	0.41	4.62e-20	Retinal vascular caliber;
LGG	cis	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg06521331	chr12:34319734	NA	0.4	7.19	0.32	2.57e-12	Morning vs. evening chronotype;
LGG	cis	rs2916247	0.954	rs7841406	chr8:93156120	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.38	-7.99	-0.35	1.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg07061783	chr6:25882402	NA	-0.5	-8.66	-0.37	8.19e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.86	0.48	1.7e-28	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg26513180	chr16:89883248	FANCA	0.6	10.68	0.44	6.21e-24	Vitiligo;
LGG	cis	rs854765	0.583	rs11656840	chr17:17837354	C/T	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.45e-29	Total body bone mineral density;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg05213609	chr16:51185407	SALL1	0.4	6.66	0.3	7.67e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs3540	0.597	rs11639150	chr15:91042071	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-12.44	-0.5	7.67e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06481639	chr22:41940642	POLR3H	0.58	8.41	0.36	5.17e-16	Vitiligo;
LGG	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.62	11.22	0.46	5.3e-26	Menarche (age at onset);
LGG	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.43e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	trans	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg26043149	chr18:55253948	FECH	0.4	6.65	0.3	8.21e-11	Bone mineral density;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg17951613	chr5:131705445	SLC22A5	0.62	7.08	0.31	5.27e-12	Rheumatoid arthritis;
LGG	cis	rs6964587	1.000	rs7800582	chr7:91701346	G/A	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.37	0.5	1.42e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg26354017	chr1:205819088	PM20D1	0.96	25.47	0.76	3.96e-90	Menarche (age at onset);
LGG	cis	rs12681287	0.640	rs13267782	chr8:87481887	G/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.67	-0.34	1.05e-13	Caudate activity during reward;
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg18252515	chr7:66147081	NA	-0.44	-7.66	-0.34	1.09e-13	Aortic root size;
LGG	cis	rs7617480	0.544	rs6442129	chr3:48735256	T/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.73	0.3	5.17e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg20325280	chr12:8324153	ZNF705A	-0.61	-7.15	-0.32	3.5e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg01620082	chr3:125678407	NA	-0.7	-6.92	-0.31	1.55e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg22484793	chr3:52261325	TLR9	0.34	8.08	0.35	5.65e-15	Bipolar disorder;
LGG	cis	rs6977660	0.714	rs28605851	chr7:19815219	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.57	0.44	1.48e-23	Thyroid stimulating hormone;
LGG	cis	rs9815354	1.000	rs17061431	chr3:41792655	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.56	0.33	2.13e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1957429	0.614	rs79411360	chr14:65378856	T/C	cg23373153	chr14:65346875	NA	-1.05	-9.96	-0.42	2.63e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.87	-0.42	5.44e-21	Body mass index;
LGG	cis	rs7737355	1.000	rs6872972	chr5:130621533	C/T	cg06307176	chr5:131281290	NA	0.51	8.49	0.37	2.83e-16	Life satisfaction;
LGG	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg17108064	chr15:78857060	CHRNA5	0.45	9.63	0.41	3.93e-20	Sudden cardiac arrest;
LGG	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg16141378	chr3:129829833	LOC729375	0.32	6.92	0.31	1.49e-11	Myopia (pathological);
LGG	cis	rs11920090	0.932	rs12487589	chr3:170718253	G/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.47	0.37	3.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg02002194	chr4:3960332	NA	0.49	9.08	0.39	3.03e-18	Mood instability;
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg05793240	chr7:2802953	GNA12	0.34	8.59	0.37	1.33e-16	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15798279	chr7:6523691	KDELR2	0.46	6.81	0.3	3.09e-11	Gut microbiome composition (summer);
LGG	cis	rs912057	0.560	rs1294416	chr6:6741327	A/G	cg06612196	chr6:6737390	NA	0.52	11.73	0.48	5.47e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20620272	chr3:167968129	C3orf50	-0.57	-8.97	-0.38	7.66e-18	Systemic lupus erythematosus;
LGG	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg00129232	chr17:37814104	STARD3	-0.6	-11.24	-0.46	4.21e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs35123781	1.000	rs2336880	chr5:139063728	A/G	cg10513866	chr5:139070639	NA	-0.34	-6.8	-0.3	3.27e-11	Schizophrenia;
LGG	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.17	-0.32	2.99e-12	Mood instability;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg14228332	chr4:119757509	SEC24D	0.99	10.56	0.44	1.67e-23	Cannabis dependence symptom count;
LGG	cis	rs6908034	0.607	rs75060331	chr6:19812956	C/T	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs944722	1.000	rs4796034	chr17:26093792	G/A	cg07704981	chr17:26127537	NOS2	-0.49	-8.56	-0.37	1.63e-16	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs9457247	0.508	rs9457268	chr6:167503639	A/T	cg07741184	chr6:167504864	NA	0.37	8.81	0.38	2.49e-17	Crohn's disease;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg21782813	chr7:2030301	MAD1L1	0.36	8.6	0.37	1.23e-16	Schizophrenia;
LGG	cis	rs17039065	0.920	rs56988845	chr4:109458114	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.67	0.34	1.03e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.8	0.3	3.15e-11	Alzheimer's disease;
LGG	cis	rs1014246	1.000	rs2240705	chr10:118467334	C/T	cg14919929	chr10:118506882	NA	0.54	9.89	0.42	4.81e-21	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg18105134	chr13:113819100	PROZ	-0.76	-15.86	-0.59	1.41e-45	Platelet distribution width;
LGG	cis	rs9649465	1.000	rs6963231	chr7:123374766	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.23	-0.55	2.27e-38	Heart rate;
LGG	cis	rs9467711	0.651	rs13206443	chr6:26119245	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	7.54	0.33	2.47e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.9	0.45	9.11e-25	Personality dimensions;
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06850241	chr22:41845214	NA	-0.44	-6.77	-0.3	3.87e-11	Vitiligo;
LGG	cis	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg06360820	chr2:242988706	NA	-0.57	-8.71	-0.38	5.49e-17	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.834	rs10839166	chr11:6002464	T/C	cg05234568	chr11:5960015	NA	-0.63	-10.15	-0.43	5.54e-22	DNA methylation (variation);
LGG	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.11	0.31	4.3e-12	Homoarginine levels;
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg02503808	chr4:7069936	GRPEL1	0.9	14.17	0.55	4.16e-38	Monocyte percentage of white cells;
LGG	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg21827317	chr3:136751795	NA	0.53	10.01	0.42	1.71e-21	Neuroticism;
LGG	cis	rs7539542	0.577	rs6662398	chr1:202888456	T/G	cg19681188	chr1:202830198	LOC148709	0.51	8.55	0.37	1.82e-16	Mean platelet volume;
LGG	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg22044901	chr15:68126292	NA	-0.4	-7.12	-0.31	4.15e-12	Obesity;
LGG	cis	rs10267417	0.603	rs10271293	chr7:19932427	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-12.65	-0.51	1.01e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg09307838	chr4:120376055	NA	0.82	13.59	0.53	1.19e-35	Corneal astigmatism;
LGG	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.97	0.35	1.22e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.3e-14	Tonsillectomy;
LGG	trans	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.2	0.39	1.23e-18	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.18	-0.32	2.73e-12	Menopause (age at onset);
LGG	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg20608306	chr11:116969690	SIK3	0.34	8.96	0.38	8.18e-18	Blood protein levels;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	11.11	0.46	1.34e-25	Lung cancer in ever smokers;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg06558623	chr16:89946397	TCF25	1.08	11.43	0.47	7.98e-27	Skin colour saturation;
LGG	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg20283391	chr11:68216788	NA	-0.49	-8.0	-0.35	1.01e-14	Total body bone mineral density;
LGG	cis	rs2692947	0.864	rs2579518	chr2:96675259	G/A	cg22654517	chr2:96458247	NA	0.37	8.01	0.35	9.46e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11771526	0.681	rs79578813	chr7:32308867	G/T	cg13207630	chr7:32358064	NA	0.65	6.94	0.31	1.3e-11	Body mass index;
LGG	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs4774899	0.932	rs17239508	chr15:57553990	T/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.15	-0.32	3.44e-12	Urinary tract infection frequency;
LGG	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg23057051	chr16:89984268	MC1R	-0.38	-7.09	-0.31	5.19e-12	Vitiligo;
LGG	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-13.43	-0.53	5.94e-35	Extrinsic epigenetic age acceleration;
LGG	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg26384229	chr12:38710491	ALG10B	0.8	16.15	0.6	7.52e-47	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.13	-0.52	1.03e-33	Aortic root size;
LGG	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.23	0.36	1.96e-15	Neuroticism;
LGG	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.62	-10.95	-0.45	5.7e-25	Blood metabolite levels;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-13.44	-0.53	5.29e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg20913747	chr6:44695427	NA	0.6	11.01	0.46	3.38e-25	Total body bone mineral density;
LGG	cis	rs745821	0.701	rs11878165	chr18:48091748	G/C	cg18923635	chr18:48083994	NA	0.44	7.78	0.34	4.62e-14	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15094636	chr3:125094397	ZNF148	-0.46	-6.71	-0.3	5.81e-11	Systemic lupus erythematosus;
LGG	cis	rs2742417	1.000	rs2673065	chr3:45771222	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.39	-0.32	6.88e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6815814	0.851	rs9715769	chr4:38774489	A/C	cg06935464	chr4:38784597	TLR10	0.54	7.36	0.32	8.22e-13	Breast cancer;
LGG	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg07117364	chr1:16154769	NA	-0.48	-7.28	-0.32	1.4e-12	Dilated cardiomyopathy;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg03032015	chr1:142618752	NA	-0.36	-6.69	-0.3	6.48e-11	Iris color (L* coordinate);
LGG	cis	rs6748734	0.519	rs9973362	chr2:241898198	T/C	cg14055004	chr2:241860995	NA	0.31	7.76	0.34	5.67e-14	Urinary metabolites;
LGG	cis	rs7129556	0.737	rs2154972	chr11:77488825	G/A	cg12586386	chr11:77299805	AQP11	0.45	7.4	0.33	6.52e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg21911579	chr5:131705225	SLC22A5	0.64	7.21	0.32	2.27e-12	Rheumatoid arthritis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24399406	chr17:33895357	NA	0.38	6.72	0.3	5.42e-11	Bilirubin levels;
LGG	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg14456004	chr13:21872349	NA	-1.21	-19.25	-0.67	4.34e-61	White matter hyperintensity burden;
LGG	cis	rs6840360	0.571	rs28454076	chr4:152520083	G/T	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12643440	0.718	rs629542	chr4:17137284	C/A	cg22650099	chr4:17144496	NA	0.39	7.2	0.32	2.38e-12	Metabolite levels (Pyroglutamine);
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00495681	chr13:53174319	NA	0.55	9.78	0.41	1.21e-20	Lewy body disease;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg19784903	chr17:45786737	TBKBP1	-0.33	-7.2	-0.32	2.41e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2708977	0.671	rs582014	chr2:97075826	A/G	cg01950434	chr2:97203154	ARID5A	-0.46	-7.02	-0.31	8.03e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1620921	0.622	rs2489965	chr6:161262607	C/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.78	-0.3	3.57e-11	Longevity;Endometriosis;
LGG	trans	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg01134436	chr17:81009848	B3GNTL1	0.83	8.68	0.37	6.89e-17	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17787366	chr7:75369077	HIP1	0.42	6.69	0.3	6.35e-11	Gut microbiome composition (summer);
LGG	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg08461772	chr7:95026248	PON3	0.39	8.39	0.36	6.13e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6500395	1.000	rs9933314	chr16:48676608	T/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg13736514	chr6:26305472	NA	-0.49	-10.3	-0.43	1.54e-22	Educational attainment;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg16359550	chr11:109292809	C11orf87	0.42	8.14	0.35	3.64e-15	Schizophrenia;
LGG	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg04568710	chr12:38710424	ALG10B	0.33	6.82	0.3	2.79e-11	Bladder cancer;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg21724239	chr8:58056113	NA	0.42	6.69	0.3	6.39e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.901	rs12701710	chr7:1090396	A/G	cg00990874	chr7:1149470	C7orf50	0.69	11.44	0.47	7.31e-27	Bronchopulmonary dysplasia;
LGG	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg11965913	chr1:205819406	PM20D1	0.41	6.86	0.3	2.22e-11	Menarche (age at onset);
LGG	cis	rs6940638	0.531	rs12211984	chr6:26986054	G/C	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.967	rs6428561	chr1:90102619	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.25	0.49	4.47e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg03806693	chr22:41940476	POLR3H	1.04	19.58	0.67	1.28e-62	Vitiligo;
LGG	cis	rs6908034	0.607	rs77386860	chr6:19814755	A/C	cg02682789	chr6:19804855	NA	0.92	8.65	0.37	8.82e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24378470	chr17:9478950	WDR16;STX8	0.41	7.03	0.31	7.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg05665937	chr4:1216051	CTBP1	0.37	6.66	0.3	7.96e-11	Longevity;
LGG	cis	rs4959677	0.586	rs3924452	chr6:2476910	C/G	cg20147862	chr6:2634573	C6orf195	-0.34	-7.59	-0.33	1.73e-13	Orthostatic hypotension;
LGG	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.4	-0.36	5.72e-16	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg26384229	chr12:38710491	ALG10B	0.82	16.47	0.61	2.7e-48	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06558623	chr16:89946397	TCF25	0.96	12.34	0.5	1.93e-30	Skin colour saturation;
LGG	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg12223502	chr10:5658492	NA	-0.37	-7.1	-0.31	4.69e-12	Breast cancer;
LGG	cis	rs11711311	0.955	rs9881563	chr3:113414031	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.42	7.42	0.33	5.51e-13	IgG glycosylation;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg17712092	chr4:129076599	LARP1B	-0.71	-13.39	-0.53	8.79e-35	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	12.67	0.51	8.76e-32	High light scatter reticulocyte count;
LGG	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21659725	chr3:3221576	CRBN	0.93	20.77	0.69	3.33e-68	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02475777	chr4:1388615	CRIPAK	-0.57	-10.22	-0.43	2.95e-22	Longevity;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg05313129	chr8:58192883	C8orf71	-0.76	-9.96	-0.42	2.72e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg25237894	chr2:233734115	C2orf82	-0.65	-12.34	-0.5	1.95e-30	Coronary artery disease;
LGG	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.31	0.53	1.89e-34	Colorectal cancer;
LGG	cis	rs12478296	0.786	rs6721704	chr2:242994923	A/G	cg06360820	chr2:242988706	NA	-0.97	-12.71	-0.51	6.1e-32	Obesity-related traits;
LGG	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.76	-0.51	3.82e-32	HDL cholesterol;
LGG	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg13114125	chr14:105738426	BRF1	-0.87	-18.1	-0.64	9.6e-56	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg19445457	chr11:5799446	OR52N5	-0.42	-6.89	-0.3	1.83e-11	DNA methylation (variation);
LGG	cis	rs4474465	0.646	rs10751297	chr11:78278567	C/T	cg27205649	chr11:78285834	NARS2	0.59	10.95	0.45	5.64e-25	Alzheimer's disease (survival time);
LGG	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg07615347	chr10:60278583	BICC1	0.62	17.65	0.63	1.13e-53	Refractive error;
LGG	cis	rs2718058	0.540	rs2722331	chr7:37816055	G/T	cg15028436	chr7:37888078	TXNDC3	0.5	8.31	0.36	1.11e-15	Alzheimer's disease (late onset);
LGG	cis	rs2354432	1.000	rs11239944	chr1:146691015	C/T	cg25205988	chr1:146714368	CHD1L	1.19	16.36	0.61	8.36e-48	Mitochondrial DNA levels;
LGG	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1595825	0.891	rs73056811	chr2:198766642	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.97	-0.31	1.1e-11	Ulcerative colitis;
LGG	cis	rs1829883	0.866	rs1523391	chr5:98794214	A/C	cg08333243	chr5:99726346	NA	-0.36	-6.69	-0.3	6.6e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.35	0.36	7.73e-16	Schizophrenia;
LGG	cis	rs17221829	0.627	rs12421880	chr11:89391713	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.09e-18	Anxiety in major depressive disorder;
LGG	cis	rs7155454	0.935	rs11627531	chr14:65487796	T/C	cg26396452	chr14:65542826	MAX	0.35	6.67	0.3	7.22e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06850241	chr22:41845214	NA	-0.44	-6.97	-0.31	1.11e-11	Vitiligo;
LGG	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.96	0.35	1.37e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07234876	chr8:600039	NA	-1.24	-10.73	-0.45	3.82e-24	IgG glycosylation;
LGG	cis	rs2735413	0.563	rs72800918	chr16:78060731	C/T	cg04733911	chr16:78082701	NA	0.57	7.49	0.33	3.44e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs877282	0.853	rs11595510	chr10:756757	C/G	cg22713356	chr15:30763199	NA	0.48	7.41	0.33	5.85e-13	Uric acid levels;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs2486288	0.656	rs1719236	chr15:45577783	G/T	cg09092052	chr15:45571596	NA	0.45	6.7	0.3	6.17e-11	Glomerular filtration rate;
LGG	cis	rs9811920	0.683	rs793439	chr3:99637783	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	7.5	0.33	3.4e-13	Axial length;
LGG	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg08610935	chr16:1836813	NUBP2	0.44	6.87	0.3	2.11e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4650994	0.593	rs16853043	chr1:178545926	A/G	cg19399532	chr1:178512495	C1orf220	-0.39	-7.44	-0.33	5.09e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg21772509	chr8:41503840	NKX6-3	0.88	19.67	0.67	4.46e-63	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	trans	rs783540	0.681	rs1259178	chr15:83271876	T/C	cg16105309	chr15:79090380	ADAMTS7	0.48	8.2	0.36	2.34e-15	Schizophrenia;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.65e-12	Mean corpuscular hemoglobin;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05665937	chr4:1216051	CTBP1	0.59	11.0	0.46	3.63e-25	Obesity-related traits;
LGG	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.71	-0.34	7.49e-14	Testicular germ cell tumor;
LGG	cis	rs2916247	1.000	rs6995893	chr8:93034861	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.39	-0.36	6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.82	-0.48	2.26e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg05623727	chr3:50126028	RBM5	0.34	7.33	0.32	1.02e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.99	-0.35	1.08e-14	Retinal vascular caliber;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg11905131	chr22:24372483	LOC391322	-0.41	-7.05	-0.31	6.54e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg08824895	chr13:115047677	UPF3A	-0.41	-7.15	-0.32	3.32e-12	Schizophrenia;
LGG	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg03929089	chr4:120376271	NA	0.88	14.57	0.56	7.7e-40	Height;
LGG	cis	rs7129220	0.528	rs10840368	chr11:10126480	A/G	cg01453529	chr11:10209919	SBF2	-0.39	-6.66	-0.3	7.55e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6598955	0.671	rs10159433	chr1:26618370	A/G	cg04990556	chr1:26633338	UBXN11	0.58	7.9	0.34	2e-14	Obesity-related traits;
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03452623	chr4:187889614	NA	-1.02	-27.62	-0.79	6.33e-100	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg26174226	chr8:58114915	NA	-0.53	-7.46	-0.33	4.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs6960043	0.689	rs12538003	chr7:15058692	G/A	cg19272540	chr7:15055459	NA	0.36	7.83	0.34	3.35e-14	Type 2 diabetes;
LGG	cis	rs9611565	0.592	rs28750375	chr22:41990644	A/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.27	-0.46	3.5e-26	Vitiligo;
LGG	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.67	-0.34	1e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg27129171	chr3:47204927	SETD2	0.83	15.73	0.59	5.66e-45	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.64e-13	Prudent dietary pattern;
LGG	cis	rs75920871	1.000	rs1473325	chr11:116822034	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.66e-12	Subjective well-being;
LGG	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg17425144	chr1:10567563	PEX14	0.42	9.61	0.41	4.66e-20	Hepatocellular carcinoma;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg00149659	chr3:10157352	C3orf10	0.86	11.17	0.46	8.53e-26	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg08888203	chr3:10149979	C3orf24	-0.56	-9.57	-0.41	6.37e-20	Alzheimer's disease;
LGG	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.28	0.36	1.33e-15	Type 2 diabetes;
LGG	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg04173714	chr15:86211321	AKAP13	0.48	8.72	0.38	5.1e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs11039571	0.544	rs7947811	chr11:48167738	C/T	cg03929089	chr4:120376271	NA	-0.62	-7.91	-0.35	1.92e-14	D-dimer levels;
LGG	cis	rs4865875	0.901	rs10073662	chr5:54097504	C/T	cg22421804	chr5:54100067	NA	0.5	7.3	0.32	1.3e-12	Sense of smell;
LGG	cis	rs2599510	0.811	rs2710628	chr2:32758353	A/C	cg02381751	chr2:32503542	YIPF4	0.45	7.31	0.32	1.21e-12	Interleukin-18 levels;
LGG	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.05	0.39	4.03e-18	Motion sickness;
LGG	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg09307838	chr4:120376055	NA	0.82	13.83	0.54	1.23e-36	Corneal astigmatism;
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	8.07e-43	Height;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.73	0.51	4.67e-32	Obesity-related traits;
LGG	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg07120314	chr15:79043507	NA	-0.59	-9.39	-0.4	2.76e-19	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.36	0.32	8.5e-13	Homoarginine levels;
LGG	cis	rs6967414	0.605	rs7786706	chr7:6747267	C/T	cg09896999	chr7:6746977	ZNF12	-0.51	-6.77	-0.3	3.95e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.28	-0.36	1.35e-15	Total body bone mineral density;
LGG	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg10596483	chr8:143751796	JRK	0.58	9.49	0.4	1.27e-19	Schizophrenia;
LGG	cis	rs12724450	0.546	rs34448981	chr1:150435577	C/A	cg03818307	chr1:150480534	ECM1	0.51	7.17	0.32	2.94e-12	Blood protein levels;
LGG	cis	rs11792861	0.816	rs3763643	chr9:111695607	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.21	0.43	3.34e-22	Menarche (age at onset);
LGG	cis	rs7615952	0.866	rs1976459	chr3:125647486	A/T	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	trans	rs17685	0.725	rs4728548	chr7:75654632	A/T	cg19862616	chr7:65841803	NCRNA00174	-0.96	-19.86	-0.68	6.11e-64	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg24846343	chr22:24311635	DDTL	-0.48	-7.31	-0.32	1.21e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs4917300	0.606	rs13261328	chr8:143096137	T/C	cg06573787	chr8:143070187	NA	0.59	9.85	0.42	6.32e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs755249	0.588	rs2275767	chr1:39945297	C/T	cg18385671	chr1:39797026	MACF1	-0.39	-8.75	-0.38	4.01e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg04287289	chr16:89883240	FANCA	0.59	6.76	0.3	4.18e-11	Skin colour saturation;
LGG	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg21387009	chr3:10280255	IRAK2	-0.36	-6.64	-0.3	8.63e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg27400746	chr16:89904261	SPIRE2	-0.97	-15.43	-0.58	1.25e-43	Skin colour saturation;
LGG	cis	rs12458462	1.000	rs12458462	chr18:77472436	C/A	cg11879182	chr18:77439856	CTDP1	0.8	14.54	0.56	1.04e-39	Monocyte count;
LGG	cis	rs6964587	1.000	rs35653487	chr7:91745441	C/G	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.48e-18	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24091570	chr5:110428036	WDR36	0.43	7.09	0.31	4.94e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2204008	0.774	rs11520237	chr12:38266978	G/A	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg02487422	chr3:49467188	NICN1	0.42	7.18	0.32	2.81e-12	Parkinson's disease;
LGG	cis	rs2073300	1.000	rs6137959	chr20:23442640	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg22232500	chr2:134024266	NCKAP5	0.66	9.03	0.39	4.6e-18	Bipolar disorder;
LGG	cis	rs1497828	0.913	rs2810778	chr1:217542793	G/A	cg04411442	chr1:217543379	NA	0.48	8.24	0.36	1.85e-15	Dialysis-related mortality;
LGG	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg04455712	chr21:45112962	RRP1B	0.51	9.65	0.41	3.28e-20	Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	6.26e-19	Life satisfaction;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.15	0.58	2.16e-42	Cognitive test performance;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg16507663	chr6:150244633	RAET1G	0.48	8.98	0.39	6.78e-18	Lung cancer;
LGG	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg12310025	chr6:25882481	NA	0.71	14.2	0.55	2.91e-38	Blood metabolite levels;
LGG	cis	rs17641971	0.708	rs974781	chr8:49931055	T/A	cg00325661	chr8:49890786	NA	0.52	9.43	0.4	1.93e-19	Blood metabolite levels;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs17453880	0.929	rs4385197	chr5:152047146	G/A	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs896854	0.530	rs10956934	chr8:95992473	C/A	cg16049864	chr8:95962084	TP53INP1	-0.37	-8.38	-0.36	6.62e-16	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.698	rs6977407	chr7:124499002	A/C	cg05630886	chr7:124431682	NA	-0.33	-7.76	-0.34	5.53e-14	Cutaneous malignant melanoma;
LGG	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg15208524	chr1:10270712	KIF1B	0.45	7.54	0.33	2.49e-13	Hepatocellular carcinoma;
LGG	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg08400814	chr5:56204995	C5orf35	-0.41	-6.65	-0.3	8.47e-11	Initial pursuit acceleration;
LGG	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg07343612	chr16:622815	PIGQ	0.49	8.4	0.36	5.69e-16	Height;
LGG	cis	rs690037	0.641	rs538525	chr3:16376279	A/G	cg23474789	chr3:16306055	DPH3;OXNAD1	0.51	8.61	0.37	1.17e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LGG	cis	rs1371867	0.875	rs7830342	chr8:101327738	T/A	cg06636551	chr8:101224915	SPAG1	-0.46	-8.58	-0.37	1.43e-16	Atrioventricular conduction;
LGG	cis	rs6807915	0.603	rs13077979	chr3:12297922	T/G	cg22839075	chr3:12045461	SYN2	-0.4	-6.87	-0.3	2.11e-11	Leprosy;
LGG	cis	rs7523273	0.526	rs2745975	chr1:208013620	C/T	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.98	-0.49	5.48e-29	Schizophrenia;
LGG	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	8.64	0.37	9.43e-17	Lung cancer in ever smokers;
LGG	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg03352830	chr11:487213	PTDSS2	0.83	10.01	0.42	1.78e-21	Body mass index;
LGG	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg04568710	chr12:38710424	ALG10B	-0.34	-6.94	-0.31	1.32e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg08198773	chr8:1697536	NA	0.46	8.11	0.35	4.42e-15	Systolic blood pressure;
LGG	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs78456975	1.000	rs6730391	chr2:1566838	A/C	cg01028140	chr2:1542097	TPO	-0.53	-8.39	-0.36	5.93e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.95e-17	Menopause (age at onset);
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12016809	chr21:47604291	C21orf56	0.48	8.24	0.36	1.81e-15	Testicular germ cell tumor;
LGG	cis	rs4731207	0.662	rs10246553	chr7:124494934	A/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.84	0.59	1.82e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12893668	0.703	rs4906335	chr14:104021141	C/A	cg26031613	chr14:104095156	KLC1	-0.59	-9.17	-0.39	1.58e-18	Reticulocyte count;
LGG	cis	rs1847202	0.963	rs34317383	chr3:72946652	A/C	cg25664220	chr3:72788482	NA	-0.24	-7.39	-0.32	7.07e-13	Motion sickness;
LGG	cis	rs9487051	0.652	rs13210424	chr6:109598737	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.29e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1978968	1.000	rs2099943	chr22:18438559	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.18	-0.49	8.12e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs4889855	1.000	rs4889855	chr17:78513280	G/A	cg16591659	chr17:78472290	NA	-0.42	-8.66	-0.37	8.06e-17	Fractional excretion of uric acid;
LGG	cis	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg25894440	chr7:65020034	NA	-0.81	-7.29	-0.32	1.33e-12	Diabetic kidney disease;
LGG	cis	rs752010	0.523	rs10890159	chr1:42118282	A/G	cg16096631	chr1:42092165	HIVEP3	0.53	12.28	0.5	3.38e-30	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg25019033	chr10:957182	NA	-0.55	-10.06	-0.42	1.15e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg08250081	chr4:10125330	NA	-0.48	-9.4	-0.4	2.54e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg25174290	chr11:3078921	CARS	-0.49	-8.99	-0.39	6.21e-18	Calcium levels;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg26917462	chr1:234745804	IRF2BP2	-0.38	-6.7	-0.3	6.23e-11	Blood metabolite levels;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg03709012	chr19:19516395	GATAD2A	0.84	16.94	0.62	2e-50	Tonsillectomy;
LGG	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.08e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.65	0.3	8.44e-11	Cognitive ability;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19983627	chr4:108852959	CYP2U1	-0.44	-7.33	-0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg22431228	chr1:16359049	CLCNKA	-0.4	-7.33	-0.32	1e-12	Systolic blood pressure;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg02475777	chr4:1388615	CRIPAK	0.42	7.72	0.34	7.17e-14	Longevity;
LGG	cis	rs537930	0.925	rs31203	chr5:134351470	C/T	cg24576358	chr5:134350122	NA	-0.44	-9.05	-0.39	3.83e-18	Height;
LGG	cis	rs4690686	0.538	rs11730551	chr4:177259182	A/G	cg17059388	chr4:177262070	NA	0.96	21.31	0.7	9.53e-71	Essential tremor;
LGG	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg08125733	chr17:73851984	WBP2	0.43	7.21	0.32	2.36e-12	White matter hyperintensity burden;
LGG	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.09	0.68	5.23e-65	Resting heart rate;
LGG	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.02	-0.31	8.13e-12	Joint mobility (Beighton score);
LGG	cis	rs4740619	0.619	rs4741561	chr9:16045827	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.45	-0.47	6.86e-27	Body mass index;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg13206674	chr6:150067644	NUP43	0.6	13.29	0.53	2.36e-34	Lung cancer;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.06e-13	Bipolar disorder;
LGG	cis	rs12476592	0.602	rs262506	chr2:63863022	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.84	-0.3	2.58e-11	Childhood ear infection;
LGG	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg00405596	chr8:11794950	NA	-0.62	-10.76	-0.45	2.96e-24	Monocyte count;
LGG	cis	rs2117029	0.586	rs6580701	chr12:49557265	C/G	cg24176009	chr12:49580217	TUBA1A	0.66	12.89	0.51	1.03e-32	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-9.3	-0.4	5.38e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.77	-0.48	3.73e-28	Height;
LGG	cis	rs9300255	0.770	rs7980687	chr12:123822711	G/A	cg05973401	chr12:123451056	ABCB9	-0.46	-6.65	-0.3	8.08e-11	Neutrophil percentage of white cells;
LGG	cis	rs1018836	0.884	rs7823461	chr8:91581075	T/C	cg16814680	chr8:91681699	NA	-0.8	-14.71	-0.56	1.8e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-9.61	-0.41	4.78e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg10911889	chr6:126070802	HEY2	0.45	7.49	0.33	3.54e-13	Brugada syndrome;
LGG	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.58	-8.32	-0.36	9.87e-16	Schizophrenia;
LGG	cis	rs6138458	0.620	rs914314	chr20:24897355	C/T	cg26195577	chr20:24973756	C20orf3	-1.15	-14.18	-0.55	3.77e-38	Blood protein levels;
LGG	trans	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	9.75	0.41	1.54e-20	Aortic root size;
LGG	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg25237894	chr2:233734115	C2orf82	-0.66	-12.57	-0.5	2.19e-31	Coronary artery disease;
LGG	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg12654349	chr5:56205094	C5orf35	0.66	10.2	0.43	3.73e-22	Initial pursuit acceleration;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg02725872	chr8:58115012	NA	-0.75	-10.84	-0.45	1.47e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg24623649	chr8:11872141	NA	-0.32	-7.36	-0.32	8.2e-13	Triglycerides;
LGG	cis	rs12458462	0.892	rs2242174	chr18:77458037	T/C	cg11879182	chr18:77439856	CTDP1	0.8	14.95	0.57	1.66e-41	Monocyte count;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.0	-0.31	9.27e-12	Height;
LGG	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06481639	chr22:41940642	POLR3H	0.5	7.02	0.31	7.71e-12	Vitiligo;
LGG	cis	rs7918232	0.830	rs7915902	chr10:27410734	T/C	cg14240646	chr10:27532245	ACBD5	-0.73	-10.36	-0.43	9.22e-23	Breast cancer;
LGG	cis	rs7975161	0.572	rs10861163	chr12:104568613	C/A	cg25273343	chr12:104657179	TXNRD1	-0.75	-8.36	-0.36	7.29e-16	Toenail selenium levels;
LGG	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg03469862	chr11:68924853	NA	0.45	6.83	0.3	2.73e-11	Blond vs. brown hair color;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19708343	chr22:26986233	TPST2	0.46	7.02	0.31	8.2e-12	Gut microbiome composition (summer);
LGG	cis	rs477692	1.000	rs516704	chr10:131419879	G/A	cg05714579	chr10:131428358	MGMT	0.56	11.63	0.48	1.36e-27	Response to temozolomide;
LGG	cis	rs11105298	0.891	rs10858854	chr12:89835728	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.69	-9.45	-0.4	1.71e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6061231	1.000	rs6061231	chr20:60956917	C/A	cg22601191	chr20:60968625	CABLES2	0.51	9.44	0.4	1.76e-19	Colorectal cancer;
LGG	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.71	-0.41	2.1e-20	Carotid intima media thickness;
LGG	cis	rs755249	0.567	rs113214136	chr1:39874539	G/T	cg18385671	chr1:39797026	MACF1	0.44	7.45	0.33	4.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-15.88	-0.59	1.16e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg09307838	chr4:120376055	NA	0.74	12.19	0.49	8.09e-30	Corneal astigmatism;
LGG	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.35	-0.53	1.24e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg05313129	chr8:58192883	C8orf71	-0.59	-7.4	-0.33	6.56e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs17641971	0.684	rs7011891	chr8:49983538	A/C	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg00717180	chr2:96193071	NA	-0.44	-7.8	-0.34	4.25e-14	HDL cholesterol;
LGG	trans	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.22	0.39	1.07e-18	Resting heart rate;
LGG	cis	rs7717393	0.582	rs17556534	chr5:155809735	C/G	cg19569526	chr5:155754265	SGCD	0.69	6.72	0.3	5.24e-11	Egg allergy;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg00409905	chr10:38381863	ZNF37A	0.55	10.71	0.45	4.62e-24	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg00290607	chr11:67383545	NA	0.66	12.76	0.51	3.75e-32	Mean corpuscular volume;
LGG	cis	rs10186029	0.509	rs2371793	chr2:213945082	G/C	cg08319019	chr2:214017104	IKZF2	-0.39	-6.66	-0.3	7.95e-11	Systemic sclerosis;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg16507663	chr6:150244633	RAET1G	0.44	8.26	0.36	1.54e-15	Lung cancer;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.77	-0.38	3.45e-17	Alcohol dependence;
LGG	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.28	0.53	2.42e-34	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg25214090	chr10:38739885	LOC399744	0.57	10.4	0.44	6.55e-23	Corneal astigmatism;
LGG	cis	rs7027203	1.000	rs7856374	chr9:96529791	G/A	cg14598338	chr9:96623480	NA	0.5	8.74	0.38	4.38e-17	DNA methylation (variation);
LGG	cis	rs6784615	0.744	rs2215466	chr3:52489074	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.65	-7.51	-0.33	3.09e-13	Waist-hip ratio;
LGG	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-11.65	-0.48	1.15e-27	Morning vs. evening chronotype;
LGG	cis	rs796364	0.806	rs76112266	chr2:201087157	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.57	-0.37	1.54e-16	Schizophrenia;
LGG	cis	rs757110	0.648	rs12146443	chr11:17384498	T/C	cg15432903	chr11:17409602	KCNJ11	0.8	16.3	0.6	1.53e-47	Type 2 diabetes;
LGG	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.73	0.34	6.92e-14	Neuroticism;
LGG	cis	rs4132509	0.947	rs10927041	chr1:243731890	T/C	cg25706552	chr1:244017396	NA	0.51	8.04	0.35	7.49e-15	RR interval (heart rate);
LGG	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg19992207	chr2:111874495	ACOXL	-0.37	-6.75	-0.3	4.45e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg06951627	chr6:26196580	NA	0.52	7.85	0.34	2.91e-14	Gout;Renal underexcretion gout;
LGG	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs6499244	0.508	rs11642008	chr16:69928639	G/A	cg00738113	chr16:70207722	CLEC18C	-0.28	-7.93	-0.35	1.62e-14	Menarche (age at onset);
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg03647317	chr4:187891568	NA	0.42	8.94	0.38	9.04e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4262150	0.764	rs3923209	chr5:151937593	A/T	cg12297329	chr5:152029980	NA	-0.72	-13.79	-0.54	1.67e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.93	-0.42	3.48e-21	Lung cancer;
LGG	cis	rs4959677	0.689	rs1994124	chr6:2509443	C/T	cg20147862	chr6:2634573	C6orf195	-0.36	-7.82	-0.34	3.62e-14	Orthostatic hypotension;
LGG	cis	rs422249	0.512	rs1535	chr11:61597972	A/G	cg19610905	chr11:61596333	FADS2	-0.8	-14.56	-0.56	8.43e-40	Trans fatty acid levels;
LGG	cis	rs763121	0.853	rs5757234	chr22:39072686	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	19.23	0.67	5.33e-61	Menopause (age at onset);
LGG	cis	rs2456568	0.709	rs7942444	chr11:93637160	G/A	cg26875233	chr11:93583750	C11orf90	0.36	7.02	0.31	7.7e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg11366901	chr6:160182831	ACAT2	0.99	15.32	0.58	3.95e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6547631	0.622	rs2366807	chr2:85926598	G/A	cg24620635	chr2:85921963	GNLY	0.5	10.07	0.42	1.09e-21	Blood protein levels;
LGG	trans	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg07817883	chr1:32538562	TMEM39B	1.08	10.22	0.43	3.01e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.29	-0.36	1.21e-15	Educational attainment;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07264062	chr8:1785958	ARHGEF10	0.4	7.1	0.31	4.83e-12	Electrocardiographic conduction measures;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg09771049	chr17:66031798	KPNA2	-0.42	-6.91	-0.31	1.6e-11	Leprosy;
LGG	cis	rs1867631	0.585	rs11208922	chr1:67080226	T/C	cg13052034	chr1:66999238	SGIP1	0.33	6.77	0.3	3.82e-11	Menopause (age at onset);
LGG	cis	rs10861342	1.000	rs11112397	chr12:105568381	T/C	cg23923672	chr12:105501055	KIAA1033	0.79	7.5	0.33	3.33e-13	IgG glycosylation;
LGG	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg12573674	chr2:1569213	NA	-0.65	-10.04	-0.42	1.38e-21	IgG glycosylation;
LGG	cis	rs6728642	0.572	rs13387563	chr2:97600916	C/A	cg26665480	chr2:98280029	ACTR1B	-0.85	-11.48	-0.47	5.2e-27	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs897080	0.552	rs1067374	chr2:44650250	A/G	cg00619915	chr2:44497795	NA	0.48	6.8	0.3	3.19e-11	Height;
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg16141378	chr3:129829833	LOC729375	0.4	9.28	0.4	6.6e-19	Neuroticism;
LGG	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg08733933	chr1:2954429	NA	-0.39	-8.67	-0.37	7.5e-17	Plateletcrit;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg19168338	chr16:4465731	CORO7	-0.86	-15.9	-0.59	9.28e-46	Schizophrenia;
LGG	cis	rs2802728	0.881	rs4658562	chr1:243546516	A/G	cg05593162	chr1:243577377	SDCCAG8	0.51	7.12	0.31	4.14e-12	Toenail selenium levels;
LGG	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg21100191	chr22:23484243	RTDR1	-0.56	-8.33	-0.36	8.96e-16	Serum parathyroid hormone levels;
LGG	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.95	-0.52	6.16e-33	Gut microbiome composition (summer);
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg12458913	chr13:53173898	NA	0.54	9.82	0.42	8.32e-21	Lewy body disease;
LGG	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg20978937	chr14:105399321	PLD4	0.49	11.19	0.46	6.96e-26	Rheumatoid arthritis;
LGG	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03878208	chr11:72483293	STARD10	0.53	7.32	0.32	1.11e-12	Type 2 diabetes;
LGG	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.64	9.22	0.39	1.05e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg08508325	chr11:3079039	CARS	0.53	11.4	0.47	1.05e-26	Longevity;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.01	-0.55	2.01e-37	Alzheimer's disease;
LGG	cis	rs7589342	0.894	rs7557976	chr2:106435061	C/A	cg14210321	chr2:106509881	NCK2	-0.51	-8.81	-0.38	2.47e-17	Addiction;
LGG	cis	rs3813359	0.545	rs75184378	chr6:130553720	C/T	cg23281432	chr6:130554730	NA	0.5	6.93	0.31	1.43e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg12070911	chr6:150209640	RAET1E	0.27	6.73	0.3	5.19e-11	Testicular germ cell tumor;
LGG	cis	rs4132509	1.000	rs10927067	chr1:243923244	C/T	cg25706552	chr1:244017396	NA	0.55	8.88	0.38	1.43e-17	RR interval (heart rate);
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg21724239	chr8:58056113	NA	0.56	8.19	0.36	2.52e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03517284	chr6:25882590	NA	-0.38	-6.79	-0.3	3.47e-11	Height;
LGG	cis	rs7474896	0.583	rs11011347	chr10:38019264	G/A	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.71	-0.34	7.95e-14	Obesity (extreme);
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg06197492	chr11:2016605	H19	0.5	10.14	0.43	6.03e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01341218	chr17:43662625	NA	-0.88	-14.84	-0.57	4.83e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7177699	0.557	rs55870734	chr15:79117917	A/T	cg00540400	chr15:79124168	NA	-0.54	-11.4	-0.47	1.02e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2692947	0.683	rs2315416	chr2:96558477	C/T	cg22654517	chr2:96458247	NA	0.38	8.03	0.35	8.01e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.95	-17.26	-0.63	6.78e-52	Homoarginine levels;
LGG	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs9296092	0.538	rs9461882	chr6:33520221	A/C	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg08355456	chr11:67383691	NA	-0.5	-8.01	-0.35	9.36e-15	Mean corpuscular volume;
LGG	cis	rs228769	0.792	rs454192	chr17:42171206	T/C	cg19774624	chr17:42201019	HDAC5	0.57	8.52	0.37	2.2e-16	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg25319279	chr11:5960081	NA	-0.54	-8.48	-0.37	3.08e-16	DNA methylation (variation);
LGG	cis	rs7717393	1.000	rs9313897	chr5:155791181	A/C	cg19569526	chr5:155754265	SGCD	0.78	7.76	0.34	5.4e-14	Egg allergy;
LGG	cis	rs6912958	0.512	rs910563	chr6:88058885	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	12.82	0.51	2.14e-32	Monocyte percentage of white cells;
LGG	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg00129232	chr17:37814104	STARD3	0.57	8.05	0.35	7.03e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4006360	0.540	rs9915780	chr17:39301074	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.14	-0.43	5.76e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs834603	0.575	rs2665775	chr7:47465387	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.74	0.34	6.32e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs244731	0.959	rs11740250	chr5:176721272	G/C	cg17509989	chr5:176798049	RGS14	0.59	8.14	0.35	3.66e-15	Urate levels in lean individuals;
LGG	cis	rs4474465	1.000	rs7933612	chr11:78209366	G/T	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.56e-15	Alzheimer's disease (survival time);
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.93	-0.42	3.42e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg03733263	chr8:22462867	KIAA1967	0.98	23.42	0.74	1.41e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs11718455	1.000	rs13092460	chr3:44057995	G/A	cg21419209	chr3:44054225	NA	-0.45	-7.09	-0.31	5.01e-12	Coronary artery disease;
LGG	cis	rs4901847	0.574	rs60055365	chr14:58582693	G/A	cg15908186	chr14:58618357	C14orf37	0.64	11.57	0.47	2.28e-27	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs490234	0.702	rs4838275	chr9:128352785	C/T	cg14078157	chr9:128172775	NA	-0.54	-10.2	-0.43	3.48e-22	Mean arterial pressure;
LGG	cis	rs9807841	0.538	rs714307	chr19:10835405	C/T	cg17710535	chr19:10819994	QTRT1	0.48	7.92	0.35	1.74e-14	Inflammatory skin disease;
LGG	cis	rs17818399	0.781	rs13024534	chr2:46859386	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-9.15	-0.39	1.76e-18	Height;
LGG	cis	rs1707322	0.928	rs61785614	chr1:46446047	A/G	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg18252515	chr7:66147081	NA	-1.37	-19.11	-0.66	1.82e-60	Diabetic kidney disease;
LGG	trans	rs9329221	0.662	rs12541491	chr8:10250048	C/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.7	0.3	6.04e-11	Neuroticism;
LGG	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.96	0.42	2.73e-21	Height;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.9e-28	Intelligence (multi-trait analysis);
LGG	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg01093212	chr22:39715156	SNORD43;RPL3	-0.4	-6.73	-0.3	4.91e-11	Primary biliary cholangitis;
LGG	cis	rs34421088	0.564	rs6983129	chr8:11591136	A/C	cg12395012	chr8:11607386	GATA4	-0.51	-10.18	-0.43	4.33e-22	Neuroticism;
LGG	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.2	-0.36	2.34e-15	Retinal vascular caliber;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.98e-12	Electroencephalogram traits;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13732083	chr21:47605072	C21orf56	0.45	7.36	0.32	8.58e-13	Testicular germ cell tumor;
LGG	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg26677194	chr12:130822605	PIWIL1	0.56	9.99	0.42	1.98e-21	Menopause (age at onset);
LGG	cis	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg13072238	chr3:49761600	GMPPB	0.52	6.65	0.3	8.1e-11	Menarche (age at onset);
LGG	cis	rs5744897	1.000	rs5744897	chr12:133226831	C/T	cg16945633	chr12:133170342	NA	0.6	6.87	0.3	2.08e-11	Urate levels in overweight individuals;
LGG	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg24450063	chr1:156163899	SLC25A44	1.14	24.36	0.75	5.89e-85	Testicular germ cell tumor;
LGG	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg26150922	chr2:100937072	LONRF2	0.55	9.64	0.41	3.62e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg00071950	chr4:10020882	SLC2A9	0.33	6.65	0.3	8.2e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	14.11	0.55	7.59e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2976388	0.609	rs2257796	chr8:143808667	T/C	cg06565975	chr8:143823917	SLURP1	0.38	9.66	0.41	3.22e-20	Urinary tract infection frequency;
LGG	cis	rs7010267	0.570	rs35746859	chr8:120039139	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs73198271	0.740	rs1039911	chr8:8648206	G/A	cg01851573	chr8:8652454	MFHAS1	0.37	6.65	0.3	8.12e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs774359	0.789	rs2764332	chr9:27492522	T/A	cg22262168	chr9:27528999	MOBKL2B	0.45	6.91	0.31	1.64e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.85	0.45	1.32e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12182343	chr17:75955921	NA	-0.45	-6.73	-0.3	4.98e-11	Systemic lupus erythematosus;
LGG	cis	rs9287719	0.967	rs6744599	chr2:10747013	C/G	cg02196655	chr2:10830764	NOL10	0.42	7.11	0.31	4.41e-12	Prostate cancer;
LGG	trans	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.45	-9.11	-0.39	2.59e-18	Obesity-related traits;
LGG	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg12310025	chr6:25882481	NA	0.46	8.25	0.36	1.62e-15	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.837	rs12627667	chr21:45071396	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.13	0.43	6.64e-22	Mean corpuscular volume;
LGG	cis	rs4561483	0.549	rs6498251	chr16:11952290	A/G	cg08843971	chr16:11963173	GSPT1	0.61	15.2	0.58	1.33e-42	Testicular germ cell tumor;
LGG	cis	rs6964587	0.967	rs6980247	chr7:91594228	T/A	cg17063962	chr7:91808500	NA	0.49	8.75	0.38	4.09e-17	Breast cancer;
LGG	cis	rs2718058	0.606	rs2718054	chr7:37835854	T/A	cg15028436	chr7:37888078	TXNDC3	0.51	8.55	0.37	1.75e-16	Alzheimer's disease (late onset);
LGG	cis	rs4589502	0.800	rs1498499	chr15:67202620	C/T	cg18595228	chr15:67193261	NA	-0.49	-6.68	-0.3	6.98e-11	Lung cancer (smoking interaction);
LGG	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.18	0.39	1.47e-18	Cognitive test performance;
LGG	cis	rs2273669	0.667	rs6899723	chr6:109362749	T/G	cg05315195	chr6:109294784	ARMC2	-0.63	-8.18	-0.36	2.85e-15	Prostate cancer;
LGG	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.29e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg12091567	chr17:66097778	LOC651250	0.78	12.93	0.51	7.42e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4774899	0.869	rs8037901	chr15:57421355	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.61	-0.33	1.59e-13	Urinary tract infection frequency;
LGG	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg16141378	chr3:129829833	LOC729375	0.42	9.26	0.4	7.89e-19	Retinal vascular caliber;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.29	0.58	5.29e-43	Colorectal cancer;
LGG	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg02002194	chr4:3960332	NA	-0.37	-6.72	-0.3	5.36e-11	Retinal vascular caliber;
LGG	cis	rs9796	0.870	rs1001341	chr15:41261491	T/A	cg18705301	chr15:41695430	NDUFAF1	0.48	8.38	0.36	6.49e-16	Menopause (age at onset);
LGG	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg27511599	chr7:32358540	NA	0.65	7.15	0.32	3.34e-12	Body mass index;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.67e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14804635	chr15:75747750	SIN3A	0.41	6.67	0.3	7.42e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs8073060	0.586	rs6505484	chr17:33993152	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.79	-0.64	2.42e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.46	-0.37	3.64e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9815354	1.000	rs9874513	chr3:41909508	G/A	cg03022575	chr3:42003672	ULK4	0.74	9.27	0.4	6.95e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2213920	0.516	rs34302658	chr9:118168158	T/A	cg13918206	chr9:118159781	DEC1	-0.77	-10.5	-0.44	2.8e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg05863683	chr7:1912471	MAD1L1	0.39	7.21	0.32	2.25e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10193935	0.892	rs6744964	chr2:42441088	A/G	cg27598129	chr2:42591480	NA	-0.62	-9.44	-0.4	1.79e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7605378	0.964	rs2689763	chr2:200689555	G/A	cg17644776	chr2:200775616	C2orf69	0.53	8.5	0.37	2.58e-16	Osteoporosis;
LGG	cis	rs79149102	0.579	rs7342591	chr15:75306863	C/T	cg17294928	chr15:75287854	SCAMP5	0.78	9.09	0.39	2.91e-18	Lung cancer;
LGG	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg27523141	chr10:43048294	ZNF37B	0.37	7.49	0.33	3.49e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.78	-0.34	4.61e-14	Menarche (age at onset);
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg00631329	chr6:26305371	NA	-0.52	-9.26	-0.4	7.45e-19	Educational attainment;
LGG	trans	rs7939886	0.920	rs10792448	chr11:55804542	C/G	cg15704280	chr7:45808275	SEPT13	0.87	9.18	0.39	1.4e-18	Myopia (pathological);
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.26	0.69	7.94e-66	Alzheimer's disease;
LGG	cis	rs9557207	0.853	rs9585006	chr13:99805193	T/C	cg24509225	chr13:100037070	UBAC2	0.67	12.1	0.49	1.78e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.03	0.31	7.62e-12	Height;
LGG	cis	rs4363385	0.747	rs1415962	chr1:152958731	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.91	-0.38	1.14e-17	Inflammatory skin disease;
LGG	trans	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg02002194	chr4:3960332	NA	-0.4	-7.44	-0.33	4.83e-13	Neuroticism;
LGG	cis	rs17428076	0.629	rs72892859	chr2:172904889	T/C	cg21435375	chr2:172878103	MAP1D	0.46	9.63	0.41	4e-20	Myopia;
LGG	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg18681998	chr4:17616180	MED28	0.83	17.81	0.64	1.98e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs504918	0.524	rs2272486	chr3:123988039	T/C	cg05766129	chr3:123988013	KALRN	0.62	11.66	0.48	1.05e-27	Schizophrenia;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg23034840	chr1:205782522	SLC41A1	0.6	9.9	0.42	4.28e-21	Menarche (age at onset);
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	8.14	0.35	3.8e-15	Lymphocyte counts;
LGG	cis	rs883565	0.528	rs9818979	chr3:38963835	C/G	cg01426195	chr3:39028469	NA	0.59	12.39	0.5	1.23e-30	Handedness;
LGG	cis	rs2637030	0.515	rs439552	chr5:52978517	G/A	cg06476337	chr5:52856530	NDUFS4	0.44	6.84	0.3	2.54e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs12261331	1	rs12261331	chr10:82287527	C/T	cg01528321	chr10:82214614	TSPAN14	-0.97	-11.83	-0.48	2.09e-28	Post bronchodilator FEV1;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg07120314	chr15:79043507	NA	0.73	17.54	0.63	3.45e-53	Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg04529724	chr6:150244392	RAET1G	0.33	6.7	0.3	6.18e-11	Lung cancer;
LGG	cis	rs9916302	0.904	rs9898170	chr17:37510092	T/C	cg07936489	chr17:37558343	FBXL20	0.84	15.6	0.59	2.08e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs2865126	0.818	rs4519388	chr18:10762275	T/C	cg21165219	chr18:10698044	FAM38B	-0.45	-7.28	-0.32	1.44e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg02631450	chr22:32366979	NA	0.8	8.42	0.36	4.64e-16	Childhood ear infection;
LGG	cis	rs711245	0.796	rs848606	chr2:36770736	G/T	cg01206211	chr2:36825736	FEZ2	0.41	7.85	0.34	2.94e-14	Height;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.47	-0.37	3.35e-16	Personality dimensions;
LGG	cis	rs7264396	0.635	rs6058378	chr20:34546658	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.47e-12	Total cholesterol levels;
LGG	cis	rs6964587	0.839	rs6949881	chr7:91433827	C/T	cg17063962	chr7:91808500	NA	0.39	6.71	0.3	5.57e-11	Breast cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01811882	chr13:22493739	NA	0.37	7.02	0.31	8.2e-12	Electrocardiographic conduction measures;
LGG	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs17428076	0.831	rs3821093	chr2:172694587	C/T	cg21435375	chr2:172878103	MAP1D	0.43	9.25	0.4	8.06e-19	Myopia;
LGG	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg25817165	chr18:72167213	CNDP2	-0.67	-15.04	-0.57	6.41e-42	Refractive error;
LGG	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.95	-0.35	1.48e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.12	-0.35	4.14e-15	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11028409	chr10:104192462	CUEDC2	0.48	7.29	0.32	1.33e-12	Gut microbiome composition (summer);
LGG	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg23324259	chr8:82754387	SNX16	-0.39	-6.75	-0.3	4.54e-11	Diastolic blood pressure;
LGG	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04004882	chr2:215674386	BARD1	0.55	8.06	0.35	6.78e-15	Neuroblastoma;
LGG	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.44	-0.37	4.19e-16	Total body bone mineral density;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg05091796	chr16:4465799	CORO7	0.78	12.58	0.5	2.1e-31	Schizophrenia;
LGG	cis	rs10819861	0.645	rs4743535	chr9:98857953	C/T	cg14508093	chr9:98862825	NA	0.3	6.98	0.31	1.02e-11	Electrocardiographic traits;
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg07440826	chr16:89882328	FANCA	-0.26	-6.81	-0.3	2.96e-11	Vitiligo;
LGG	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg05096777	chr10:104283225	SUFU	0.32	6.98	0.31	1.05e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg09165964	chr15:75287851	SCAMP5	1.04	21.08	0.7	1.16e-69	Blood trace element (Zn levels);
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg08807101	chr21:30365312	RNF160	-0.82	-16.23	-0.6	3.18e-47	Dental caries;
LGG	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs11864453	0.826	rs6499559	chr16:72132064	G/C	cg23815491	chr16:72088622	HP	0.53	11.65	0.48	1.11e-27	Fibrinogen levels;
LGG	cis	rs9443189	0.570	rs276687	chr6:76429995	G/T	cg01950844	chr6:76311363	SENP6	-0.67	-7.99	-0.35	1.05e-14	Prostate cancer;
LGG	cis	rs6764363	0.504	rs4684333	chr3:278661	A/C	cg02057681	chr3:285234	CHL1	-0.42	-7.64	-0.33	1.29e-13	Sudden cardiac arrest;
LGG	cis	rs537930	0.560	rs31202	chr5:134350794	A/G	cg24576358	chr5:134350122	NA	0.41	9.1	0.39	2.79e-18	Height;
LGG	cis	rs3820928	0.935	rs12151597	chr2:227859224	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.42	-0.33	5.79e-13	Pulmonary function;
LGG	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg06718696	chr17:78121285	EIF4A3	0.88	14.09	0.55	9.26e-38	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23598886	chr18:12777645	NA	0.75	10.48	0.44	3.41e-23	Inflammatory skin disease;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg04503457	chr17:41445688	NA	-0.38	-9.35	-0.4	3.89e-19	Menopause (age at onset);
LGG	cis	rs7586879	1.000	rs6736711	chr2:25116456	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg15704280	chr7:45808275	SEPT13	-1.09	-27.25	-0.78	2.74e-98	Height;
LGG	cis	rs11098499	0.754	rs1511025	chr4:120240238	T/C	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07677032	chr17:61819896	STRADA	0.68	12.61	0.51	1.5e-31	Prudent dietary pattern;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-6.99	-0.31	9.48e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.06	-0.42	1.17e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg00717180	chr2:96193071	NA	0.42	7.5	0.33	3.27e-13	HDL cholesterol;
LGG	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg06138931	chr13:21896616	NA	-0.44	-7.22	-0.32	2.17e-12	White matter hyperintensity burden;
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07648498	chr16:89883185	FANCA	0.41	7.06	0.31	6.21e-12	Vitiligo;
LGG	cis	rs571497	0.697	rs62128260	chr19:7833876	T/A	cg09310891	chr19:7854403	CLEC4GP1	0.58	6.65	0.3	8.27e-11	Monocyte count;
LGG	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	cis	rs9341808	0.718	rs9443735	chr6:80820474	G/T	cg08355045	chr6:80787529	NA	0.42	8.11	0.35	4.49e-15	Sitting height ratio;
LGG	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg25427524	chr10:38739819	LOC399744	0.52	7.68	0.34	9.5e-14	Obesity (extreme);
LGG	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg11502198	chr6:26597334	ABT1	-0.69	-12.51	-0.5	3.78e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4788570	0.543	rs4788820	chr16:71660115	G/C	cg06353428	chr16:71660113	MARVELD3	1.28	21.75	0.71	8.58e-73	Intelligence (multi-trait analysis);
LGG	cis	rs9517313	0.565	rs9556978	chr13:99234648	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.75	-0.45	3.2e-24	Neuroticism;
LGG	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg11878867	chr6:150167359	LRP11	-0.47	-9.7	-0.41	2.31e-20	Lung cancer;
LGG	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg03806693	chr22:41940476	POLR3H	1.0	17.1	0.62	3.49e-51	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.38e-16	Lung cancer;
LGG	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg02002194	chr4:3960332	NA	-0.4	-7.32	-0.32	1.09e-12	Retinal vascular caliber;
LGG	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.55e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg00129232	chr17:37814104	STARD3	-0.76	-16.52	-0.61	1.59e-48	Asthma;
LGG	cis	rs950027	0.549	rs11636114	chr15:45601412	C/G	cg26924012	chr15:45694286	SPATA5L1	0.59	10.03	0.42	1.45e-21	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs4788570	0.527	rs72791971	chr16:71477297	C/G	cg06353428	chr16:71660113	MARVELD3	-1.02	-13.44	-0.53	5.32e-35	Intelligence (multi-trait analysis);
LGG	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.98	0.49	5.27e-29	Rheumatoid arthritis;
LGG	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.34	0.4	4.03e-19	Gout;Renal underexcretion gout;
LGG	cis	rs6580649	0.941	rs3742074	chr12:48457385	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg10483660	chr13:112241077	NA	0.44	8.82	0.38	2.28e-17	Menarche (age at onset);
LGG	cis	rs9790314	0.613	rs56665329	chr3:160590858	T/A	cg03342759	chr3:160939853	NMD3	0.45	7.41	0.33	6.05e-13	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg15269541	chr15:43626905	ADAL	-0.45	-7.94	-0.35	1.52e-14	Lung cancer in ever smokers;
LGG	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg12179176	chr11:130786555	SNX19	0.84	17.61	0.63	1.58e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.41	-0.33	6e-13	Restless legs syndrome;
LGG	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.52e-12	Neuroticism;
LGG	cis	rs7923609	1.000	rs4379723	chr10:64963449	T/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.8	-0.3	3.23e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7444	0.941	rs2266964	chr22:21958304	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.519	rs10880194	chr12:38302836	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.17e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs75920871	1.000	rs4938325	chr11:116898479	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.7e-12	Subjective well-being;
LGG	trans	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.53	-0.33	2.66e-13	Menarche (age at onset);
LGG	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.05	0.39	4.13e-18	Blood metabolite levels;
LGG	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.73	-8.65	-0.37	8.8e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10489202	1.000	rs17556487	chr1:167889094	T/A	cg24449463	chr1:168025552	DCAF6	-0.58	-9.39	-0.4	2.76e-19	Schizophrenia;
LGG	cis	rs7715811	1.000	rs2173980	chr5:13767116	A/T	cg07548982	chr5:13769939	DNAH5	-0.47	-9.69	-0.41	2.42e-20	Subclinical atherosclerosis traits (other);
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	cg07928641	chr1:182991847	LAMC1	0.46	9.16	0.39	1.68e-18	Hypertriglyceridemia;
LGG	cis	rs10155981	0.510	rs41398948	chr7:22591226	A/T	cg06110297	chr7:22589830	NA	0.72	6.98	0.31	1.06e-11	Bilirubin levels;
LGG	cis	rs4595586	0.545	rs7970850	chr12:39397878	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs8072100	0.512	rs9674670	chr17:45386157	G/A	cg08085267	chr17:45401833	C17orf57	-0.63	-12.6	-0.51	1.59e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg07777115	chr5:623756	CEP72	0.63	8.08	0.35	5.57e-15	Obesity-related traits;
LGG	cis	rs4595586	0.505	rs12823590	chr12:39399750	A/T	cg26384229	chr12:38710491	ALG10B	0.6	10.55	0.44	1.85e-23	Morning vs. evening chronotype;
LGG	cis	rs17169635	0.601	rs4732062	chr7:134547955	G/A	cg02516134	chr7:134575187	CALD1	-0.33	-6.94	-0.31	1.35e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.49	0.37	2.81e-16	Lung cancer;
LGG	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22857025	chr5:266934	NA	-1.43	-12.22	-0.49	6.09e-30	Breast cancer;
LGG	cis	rs12950390	0.853	rs55745341	chr17:45855778	G/C	cg00777063	chr17:45855553	NA	-0.32	-6.76	-0.3	4.12e-11	IgG glycosylation;
LGG	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.89	0.54	6.41e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg21427119	chr20:30132790	HM13	-0.43	-7.37	-0.32	7.84e-13	Mean corpuscular hemoglobin;
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.92	-0.31	1.53e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg20332930	chr11:82997207	CCDC90B	-0.44	-7.01	-0.31	8.41e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
LGG	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.6	-0.41	5.08e-20	Height;
LGG	cis	rs10463316	0.894	rs7718085	chr5:150742957	G/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.17	-0.43	4.73e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg26174226	chr8:58114915	NA	0.5	7.06	0.31	6.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg22842854	chr12:123319900	HIP1R	-0.53	-6.65	-0.3	8.37e-11	Schizophrenia;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.33	0.53	1.58e-34	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	cis	rs7246760	0.748	rs113745845	chr19:9736226	G/A	cg16876255	chr19:9731953	ZNF561	0.9	8.17	0.36	2.92e-15	Pursuit maintenance gain;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg01570551	chr7:23719851	C7orf46	0.35	7.58	0.33	1.92e-13	Schizophrenia;
LGG	cis	rs1707322	0.752	rs28719889	chr1:46202283	C/T	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7027203	0.717	rs7869328	chr9:96588782	A/G	cg14598338	chr9:96623480	NA	-0.52	-9.4	-0.4	2.57e-19	DNA methylation (variation);
LGG	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg08499158	chr17:42289980	UBTF	0.4	7.21	0.32	2.26e-12	Red cell distribution width;Reticulocyte count;
LGG	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.89	0.31	1.78e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7296418	0.699	rs11608297	chr12:123826642	T/C	cg05973401	chr12:123451056	ABCB9	0.44	7.51	0.33	3.01e-13	Platelet count;
LGG	cis	rs11785693	0.862	rs11774842	chr8:4979769	A/C	cg26367366	chr8:4980734	NA	0.99	15.37	0.58	2.17e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg05555928	chr11:63887634	MACROD1	-0.79	-10.81	-0.45	1.94e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.41	-0.44	6.23e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg18854424	chr1:2615690	NA	-0.32	-6.85	-0.3	2.41e-11	Ulcerative colitis;
LGG	cis	rs4262150	0.764	rs4580766	chr5:151939939	A/G	cg12297329	chr5:152029980	NA	-0.72	-13.72	-0.54	3.39e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-13.39	-0.53	8.92e-35	Cognitive function;
LGG	cis	rs2071403	0.933	rs10180405	chr2:1404850	A/G	cg06500727	chr2:1417164	TPO	-0.5	-9.53	-0.41	8.61e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs7747724	0.715	rs6936840	chr6:20775451	A/G	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.37	-0.4	3.1400000000000002e-19	Bladder cancer;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg19673125	chr6:150240577	RAET1G	0.36	8.85	0.38	1.81e-17	Testicular germ cell tumor;
LGG	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg19524238	chr7:2802976	GNA12	0.32	7.75	0.34	5.87e-14	Height;
LGG	cis	rs4727443	0.691	rs6975827	chr7:99585798	C/G	cg12813108	chr7:99719912	CNPY4	0.41	7.85	0.34	2.88e-14	Interstitial lung disease;
LGG	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg22875332	chr1:76189707	ACADM	0.6	9.58	0.41	6.08e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs68170813	0.617	rs17481842	chr7:107121862	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-8.56	-0.37	1.73e-16	Coronary artery disease;
LGG	cis	rs10128251	0.625	rs9424204	chr10:5726376	C/G	cg09072322	chr10:5726702	C10orf18	0.44	6.75	0.3	4.39e-11	Childhood ear infection;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg05313129	chr8:58192883	C8orf71	0.73	10.29	0.43	1.66e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.630	rs3739070	chr2:239306268	A/C	cg01134436	chr17:81009848	B3GNTL1	0.78	6.75	0.3	4.31e-11	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs9929218	0.911	rs1075959	chr16:68832750	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.28	-0.5	3.26e-30	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs78487399	0.808	rs6746632	chr2:43712163	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.81	-0.3	2.98e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs113835537	0.529	rs17065	chr11:66277035	G/A	cg24851651	chr11:66362959	CCS	0.44	7.53	0.33	2.7e-13	Airway imaging phenotypes;
LGG	cis	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg18252515	chr7:66147081	NA	-1.31	-19.07	-0.66	3e-60	Diabetic kidney disease;
LGG	cis	rs4662945	0.525	rs28819474	chr2:130264623	T/C	cg05962382	chr2:130345044	NA	-0.45	-7.83	-0.34	3.37e-14	Response to cytidine analogues (gemcitabine);
LGG	cis	rs6743376	0.556	rs12475161	chr2:113823626	T/C	cg05949173	chr2:113825882	IL1F10	0.51	9.78	0.41	1.18e-20	Inflammatory biomarkers;
LGG	cis	rs11711311	0.911	rs9831422	chr3:113398195	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.3	-0.32	1.25e-12	IgG glycosylation;
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg08017756	chr2:100939284	LONRF2	-0.29	-7.11	-0.31	4.34e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs55788414	0.932	rs57461213	chr16:81185419	G/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg11887960	chr12:57824829	NA	0.56	6.89	0.3	1.79e-11	Obesity-related traits;
LGG	cis	rs68170813	0.559	rs7794965	chr7:106826439	A/G	cg02696742	chr7:106810147	HBP1	0.76	11.01	0.46	3.34e-25	Coronary artery disease;
LGG	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg18446336	chr7:2847575	GNA12	-0.4	-10.67	-0.44	6.72e-24	Height;
LGG	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	9.42	0.4	2.13e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg26248373	chr2:1572462	NA	-0.89	-14.47	-0.56	2.08e-39	IgG glycosylation;
LGG	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg12615879	chr12:58013172	SLC26A10	0.3	6.73	0.3	5.08e-11	Multiple sclerosis;
LGG	cis	rs7945705	0.846	rs11042055	chr11:8756856	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.45	9.05	0.39	4.09e-18	Hemoglobin concentration;
LGG	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg06965744	chr5:177196865	FAM153A	0.35	7.82	0.34	3.57e-14	Methadone dose in opioid dependence;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.21	-0.43	3.34e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs73787773	0.668	rs56071312	chr5:111481600	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.58	-7.6	-0.33	1.63e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-8.06	-0.35	6.51e-15	Parkinson's disease;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg26513180	chr16:89883248	FANCA	0.85	9.13	0.39	2.18e-18	Skin colour saturation;
LGG	cis	rs6988985	0.728	rs56400819	chr8:143925374	A/G	cg10324643	chr8:143916377	GML	0.39	7.74	0.34	6.37e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4595586	0.655	rs7958206	chr12:39329294	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.88	0.38	1.53e-17	Morning vs. evening chronotype;
LGG	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.72	-0.38	5.18e-17	Menopause (age at onset);
LGG	cis	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg00405596	chr8:11794950	NA	0.63	11.21	0.46	5.57e-26	Myopia (pathological);
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	trans	rs629535	0.735	rs525610	chr8:70074535	A/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs4926611	1.000	rs1526907	chr1:54110087	T/C	cg23596471	chr1:54105337	GLIS1	0.41	8.46	0.37	3.45e-16	Hand grip strength;
LGG	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.51	0.37	2.47e-16	Morning vs. evening chronotype;
LGG	cis	rs7149242	0.696	rs7141210	chr14:101182470	T/C	cg18089426	chr14:101175970	NA	-0.42	-9.41	-0.4	2.4e-19	Platelet count;
LGG	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg14191688	chr11:70257035	CTTN	0.54	7.93	0.35	1.67e-14	Coronary artery disease;
LGG	cis	rs6138458	1.000	rs6114988	chr20:24977586	C/T	cg26195577	chr20:24973756	C20orf3	1.24	25.88	0.77	5.13e-92	Blood protein levels;
LGG	cis	rs1249910	0.660	rs9818848	chr3:112394340	C/T	cg02954903	chr3:112359935	CCDC80	0.41	7.26	0.32	1.61e-12	Diabetic kidney disease;
LGG	trans	rs1941687	0.797	rs8086041	chr18:31402756	G/A	cg27147174	chr7:100797783	AP1S1	-0.51	-8.55	-0.37	1.82e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs8020289	0.560	rs4903491	chr14:77263609	A/G	cg23436960	chr14:77239540	VASH1	-0.37	-11.15	-0.46	1.01e-25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg11995313	chr8:8860691	ERI1	0.46	7.86	0.34	2.79e-14	Myopia;Myopia (pathological);
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.93	-0.35	1.66e-14	IgG glycosylation;
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg06221963	chr1:154839813	KCNN3	-0.53	-11.27	-0.46	3.4e-26	Prostate cancer;
LGG	cis	rs7666738	0.830	rs28887893	chr4:98963006	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.05	0.49	2.73e-29	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1682825	0.858	rs1836292	chr3:10761255	A/T	cg23512531	chr3:10780469	NA	0.56	7.87	0.34	2.56e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.16	-0.49	1.02e-29	Corneal structure;
LGG	cis	rs4538187	1.000	rs11676710	chr2:64173754	A/G	cg19915305	chr2:64069682	UGP2	-0.7	-15.77	-0.59	3.56e-45	Systolic blood pressure;
LGG	cis	rs73086581	1.000	rs17287822	chr20:3978536	C/T	cg02187196	chr20:3869020	PANK2	0.75	10.62	0.44	1.03e-23	Response to antidepressants in depression;
LGG	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.41e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg05527609	chr1:210001259	C1orf107	0.59	9.56	0.41	6.89e-20	Orofacial clefts;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg02811702	chr13:24901961	NA	0.42	7.79	0.34	4.39e-14	Obesity-related traits;
LGG	cis	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg19399532	chr1:178512495	C1orf220	-0.54	-10.77	-0.45	2.71e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9815354	0.767	rs12185934	chr3:41836558	A/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2180341	1.000	rs9398837	chr6:127635217	G/A	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.09e-47	Breast cancer;
LGG	cis	rs8060686	0.641	rs59708959	chr16:68123916	A/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.64	-0.33	1.25e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4321325	0.733	rs111245735	chr2:127942522	A/C	cg11380483	chr2:127933992	NA	0.65	8.91	0.38	1.14e-17	Protein C levels;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg22535103	chr8:58192502	C8orf71	-1.05	-15.92	-0.59	7.92e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2456568	0.548	rs6483280	chr11:93661592	T/C	cg26875233	chr11:93583750	C11orf90	-0.44	-8.48	-0.37	3.12e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs3540	0.597	rs4932346	chr15:91048991	T/C	cg18942110	chr15:91072797	CRTC3	-0.29	-6.64	-0.3	8.63e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.7	-0.48	6.84e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9357271	1.000	rs7759078	chr6:38351291	C/T	cg07362130	chr6:38359646	BTBD9	-0.47	-10.74	-0.45	3.59e-24	Restless legs syndrome;
LGG	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.78	0.41	1.16e-20	Height;
LGG	cis	rs9397585	0.857	rs4599660	chr6:153367910	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11764359	chr7:65958608	NA	-0.59	-10.02	-0.42	1.6e-21	Aortic root size;
LGG	cis	rs3806843	0.576	rs155360	chr5:140309016	C/T	cg19875535	chr5:140030758	IK	0.37	7.44	0.33	4.92e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.18	-0.36	2.73e-15	Response to antipsychotic treatment;
LGG	cis	rs12802200	0.535	rs12282299	chr11:570009	T/C	cg16486109	chr11:613632	IRF7	0.41	7.37	0.32	7.98e-13	Systemic lupus erythematosus;
LGG	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg13647721	chr17:30228624	UTP6	0.66	8.84	0.38	2.03e-17	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.39	0.36	5.82e-16	Tonsillectomy;
LGG	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg27316798	chr5:14870666	ANKH	-0.5	-10.0	-0.42	1.83e-21	Blood metabolite levels;
LGG	cis	rs6598955	0.670	rs4659366	chr1:26542572	G/A	cg04990556	chr1:26633338	UBXN11	-0.7	-14.08	-0.55	9.61e-38	Obesity-related traits;
LGG	cis	rs6977660	0.714	rs10249635	chr7:19787090	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.2	0.43	3.72e-22	Thyroid stimulating hormone;
LGG	cis	rs28580297	1	rs28580297	chr4:119427957	C/G	cg21605333	chr4:119757512	SEC24D	0.58	7.0	0.31	9.29e-12	Body mass index;
LGG	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg15596359	chr8:11213517	TDH	0.42	8.48	0.37	2.97e-16	Retinal vascular caliber;
LGG	cis	rs7192750	0.562	rs9934803	chr16:71981630	T/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.71	0.45	4.59e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.74	-9.36	-0.4	3.52e-19	Gout;Renal underexcretion gout;
LGG	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg03709012	chr19:19516395	GATAD2A	0.94	12.18	0.49	8.37e-30	Nonalcoholic fatty liver disease;
LGG	cis	rs61990749	0.597	rs7147516	chr14:78153980	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.15	-0.32	3.38e-12	Fibroblast growth factor basic levels;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06028808	chr11:68637592	NA	0.71	12.26	0.49	4.21e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16978263	chr3:160118452	SMC4;IFT80	0.39	7.03	0.31	7.28e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26594331	chr5:178053244	CLK4	0.44	7.34	0.32	9.91e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.02	0.39	4.92e-18	Resting heart rate;
LGG	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg26384229	chr12:38710491	ALG10B	0.81	16.35	0.61	9.5e-48	Morning vs. evening chronotype;
LGG	cis	rs72777070	0.895	rs12615784	chr2:9789403	A/G	cg14973360	chr2:9800511	NA	-0.49	-6.76	-0.3	4.28e-11	Platelet-derived growth factor BB levels;
LGG	cis	rs9557207	1.000	rs9300537	chr13:99988491	C/T	cg24509225	chr13:100037070	UBAC2	0.71	12.71	0.51	6.12e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg04455712	chr21:45112962	RRP1B	0.54	10.31	0.43	1.36e-22	Mean corpuscular volume;
LGG	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg12310025	chr6:25882481	NA	-0.58	-11.31	-0.47	2.32e-26	Blood metabolite levels;
LGG	cis	rs6964587	1.000	rs13231238	chr7:91653851	T/G	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg06618935	chr21:46677482	NA	-0.43	-8.47	-0.37	3.2e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg05665937	chr4:1216051	CTBP1	0.57	10.49	0.44	3.13e-23	Obesity-related traits;
LGG	cis	rs77972916	0.536	rs62137421	chr2:43594091	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.58	-7.98	-0.35	1.18e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg26384229	chr12:38710491	ALG10B	0.97	22.06	0.72	3.15e-74	Bladder cancer;
LGG	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg14829360	chr17:73884958	NA	-0.78	-12.88	-0.51	1.13e-32	Psoriasis;
LGG	cis	rs9964724	0.559	rs62081465	chr18:35154196	T/C	cg27332583	chr18:35150602	NA	0.64	12.51	0.5	3.76e-31	Educational attainment (years of education);
LGG	trans	rs6787172	0.702	rs827128	chr3:158012346	T/G	cg23275840	chr4:47708675	CORIN	0.4	8.65	0.37	8.5e-17	Subjective well-being;
LGG	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15128208	chr22:42549153	NA	-0.39	-7.69	-0.34	9.07e-14	Cognitive function;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.51	-0.53	2.66e-35	Testicular germ cell tumor;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	8.35	0.36	8.07e-16	Lung function (FEV1/FVC);
LGG	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs4742903	0.935	rs4587392	chr9:106972508	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.04	0.35	7.4e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs17221829	0.610	rs1844195	chr11:89389332	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs7717393	1.000	rs13358340	chr5:155757872	C/T	cg01474424	chr5:155754231	SGCD	0.79	7.69	0.34	8.85e-14	Egg allergy;
LGG	cis	rs11696845	0.666	rs6103849	chr20:43365687	C/T	cg25301532	chr20:43378953	KCNK15	-0.47	-11.65	-0.48	1.13e-27	Obesity-related traits;
LGG	cis	rs11096990	0.634	rs4975001	chr4:39266464	T/C	cg24403649	chr4:39172243	NA	-0.39	-6.91	-0.31	1.57e-11	Cognitive function;
LGG	cis	rs4888262	0.526	rs7193508	chr16:74628630	G/T	cg01733217	chr16:74700730	RFWD3	0.89	18.21	0.65	2.89e-56	Testicular germ cell tumor;
LGG	cis	rs6121246	0.559	rs6121243	chr20:30415094	C/G	cg21427119	chr20:30132790	HM13	-0.37	-6.75	-0.3	4.38e-11	Mean corpuscular hemoglobin;
LGG	cis	rs10463554	0.963	rs32840	chr5:102479150	A/C	cg23492399	chr5:102201601	PAM	-0.51	-7.59	-0.33	1.8e-13	Parkinson's disease;
LGG	cis	rs1620921	0.624	rs13200798	chr6:161275510	C/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg24006582	chr15:45444508	DUOX1	-0.7	-13.47	-0.53	3.81e-35	Uric acid levels;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.16	-0.32	3.28e-12	Skin colour saturation;
LGG	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.81	0.34	3.78e-14	Height;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg09359103	chr1:154839909	KCNN3	-0.47	-9.41	-0.4	2.25e-19	Prostate cancer;
LGG	cis	rs870825	0.616	rs4610378	chr4:185624220	C/T	cg04058563	chr4:185651563	MLF1IP	-1.01	-22.31	-0.72	2.18e-75	Blood protein levels;
LGG	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26605046	chr4:2439731	NA	-0.35	-6.86	-0.3	2.25e-11	Cognitive function;
LGG	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg05784532	chr1:230284198	GALNT2	0.52	9.3	0.4	5.77e-19	Coronary artery disease;
LGG	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg20587970	chr11:113659929	NA	-1.16	-20.3	-0.69	5.36e-66	Hip circumference adjusted for BMI;
LGG	cis	rs17067123	0.539	rs79352031	chr4:180066810	C/T	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04530015	chr2:215796436	ABCA12	0.44	7.27	0.32	1.53e-12	Neuroblastoma;
LGG	cis	rs7635838	0.684	rs2594968	chr3:11352442	T/C	cg00170343	chr3:11313890	ATG7	0.51	8.77	0.38	3.55e-17	HDL cholesterol;
LGG	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg16512390	chr1:228756714	NA	0.61	8.37	0.36	6.71e-16	Chronic lymphocytic leukemia;
LGG	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.51	0.37	2.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs920590	0.758	rs2898491	chr8:19661883	C/T	cg03894339	chr8:19674705	INTS10	0.63	10.23	0.43	2.8e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2074193	0.627	rs11183918	chr12:47772256	C/T	cg02516419	chr12:47771422	NA	0.73	10.84	0.45	1.48e-24	Migraine with aura;
LGG	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.12e-14	Colorectal cancer;
LGG	cis	rs6977660	0.652	rs10267417	chr7:19843797	C/T	cg07541023	chr7:19748670	TWISTNB	0.6	7.71	0.34	7.81e-14	Thyroid stimulating hormone;
LGG	cis	rs10791097	0.694	rs4456262	chr11:130755813	C/T	cg12179176	chr11:130786555	SNX19	-0.85	-17.39	-0.63	1.63e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.67	-0.44	6.68e-24	Longevity;Endometriosis;
LGG	cis	rs4919694	1.000	rs12268849	chr10:104737682	G/A	cg04362960	chr10:104952993	NT5C2	1.04	14.75	0.57	1.28e-40	Arsenic metabolism;
LGG	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.62	0.51	1.43e-31	Motion sickness;
LGG	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg11266682	chr4:10021025	SLC2A9	-0.39	-7.32	-0.32	1.11e-12	Bone mineral density;
LGG	cis	rs7173389	1.000	rs60512978	chr15:73653502	T/C	cg01796676	chr15:73680284	NA	0.5	8.37	0.36	7.1e-16	Resting heart rate;
LGG	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg00376283	chr12:123451042	ABCB9	0.66	12.19	0.49	7.86e-30	Platelet count;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg05863683	chr7:1912471	MAD1L1	0.45	8.62	0.37	1.03e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs8141529	0.529	rs5752803	chr22:29205004	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Lymphocyte counts;
LGG	trans	rs7246760	1.000	rs10421336	chr19:9939831	A/G	cg02900749	chr2:68251473	NA	-0.94	-10.42	-0.44	5.53e-23	Pursuit maintenance gain;
LGG	cis	rs1934953	0.556	rs7909236	chr10:96829430	A/C	cg09036531	chr10:96991505	NA	-0.44	-6.79	-0.3	3.39e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs3206736	0.548	rs1186721	chr7:34974602	G/A	cg13400248	chr7:35225412	NA	0.53	9.25	0.39	8.18e-19	Diastolic blood pressure;
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-8.94	-0.38	9.38e-18	Total body bone mineral density;
LGG	cis	rs6831352	0.918	rs13138294	chr4:100062675	T/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.67	-0.41	2.82e-20	Alcohol dependence;
LGG	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg26597838	chr10:835615	NA	-0.95	-12.67	-0.51	8.32e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs4960433	chr6:8523697	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.84	0.38	1.95e-17	Motion sickness;
LGG	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs6908034	0.607	rs12527834	chr6:19821781	A/G	cg02682789	chr6:19804855	NA	0.9	8.41	0.36	4.95e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9462027	0.606	rs12201281	chr6:34681091	T/C	cg07306190	chr6:34760872	UHRF1BP1	0.54	10.79	0.45	2.25e-24	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.34	-0.32	9.73e-13	Menopause (age at onset);
LGG	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg22875332	chr1:76189707	ACADM	0.62	11.09	0.46	1.67e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg04617936	chr2:214353	NA	0.4	7.38	0.32	7.36e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.42	-6.99	-0.31	9.53e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg08250081	chr4:10125330	NA	0.44	8.57	0.37	1.58e-16	Bone mineral density;
LGG	cis	rs4262150	0.767	rs6579993	chr5:152329479	C/T	cg12297329	chr5:152029980	NA	0.62	10.68	0.44	5.84e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9879311	0.966	rs775018	chr3:10400145	A/G	cg11030744	chr3:10328490	GHRL;GHRLOS	0.35	6.92	0.31	1.5e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg01804193	chr12:63026212	NA	-0.54	-7.2	-0.32	2.42e-12	IgG glycosylation;
LGG	cis	rs9788721	1.000	rs9788721	chr15:78802869	C/T	cg18825076	chr15:78729989	IREB2	0.46	7.6	0.33	1.62e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs709400	1.000	rs861531	chr14:104172807	C/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.3	-0.36	1.14e-15	Body mass index;
LGG	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	trans	rs57046232	0.552	rs4402836	chr20:6338026	G/A	cg21095983	chr6:86352623	SYNCRIP	0.42	7.04	0.31	6.91e-12	Colorectal cancer;
LGG	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg13560919	chr6:33536144	NA	-0.42	-7.79	-0.34	4.31e-14	Crohn's disease;
LGG	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.62	0.33	1.44e-13	Bipolar disorder;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.15	-0.35	3.54e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.01	0.35	9.62e-15	Prostate cancer;
LGG	cis	rs9916302	0.904	rs6503507	chr17:37525274	C/T	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs3806843	1.000	rs4151682	chr5:140201264	C/T	cg19875535	chr5:140030758	IK	0.5	10.32	0.43	1.27e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg23750338	chr8:142222470	SLC45A4	0.6	12.44	0.5	7.83e-31	Immature fraction of reticulocytes;
LGG	cis	rs7572263	0.724	rs35551278	chr2:209056128	A/G	cg00164906	chr2:209055251	C2orf80	0.75	9.68	0.41	2.6e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs11025559	0.812	rs10833338	chr11:20514709	A/G	cg19653624	chr11:20408972	PRMT3	-0.48	-7.99	-0.35	1.1e-14	Pursuit maintenance gain;
LGG	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.42	-0.44	5.73e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8073060	0.521	rs225254	chr17:33953384	G/A	cg05299278	chr17:33885742	SLFN14	0.38	6.76	0.3	4.12e-11	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg05484508	chr16:89589025	SPG7	0.47	7.65	0.33	1.21e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg06521331	chr12:34319734	NA	0.54	9.77	0.41	1.31e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.25	0.32	1.73e-12	Tonsillectomy;
LGG	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.62	0.44	1.03e-23	Lung cancer in ever smokers;
LGG	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.06	0.42	1.2e-21	Motion sickness;
LGG	cis	rs1105228	0.644	rs9457059	chr6:165699810	G/A	cg12582777	chr6:165658423	NA	-0.26	-6.84	-0.3	2.55e-11	Number of pregnancies;Number of children;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13732083	chr21:47605072	C21orf56	-0.52	-8.43	-0.36	4.52e-16	Testicular germ cell tumor;
LGG	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.6	-12.11	-0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg03060546	chr3:49711283	APEH	0.63	8.54	0.37	2.01e-16	Menarche (age at onset);
LGG	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10170846	0.626	rs9288575	chr2:223495133	A/C	cg25565276	chr2:223520875	FARSB	1.21	20.53	0.69	4.53e-67	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.26	-0.46	3.64e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3206736	0.548	rs1186716	chr7:34970685	C/G	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.11	0.31	4.48e-12	Diastolic blood pressure;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.4	0.63	1.48e-52	Obesity-related traits;
LGG	cis	rs7973719	1.000	rs7973719	chr12:7334813	C/T	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.76	-0.34	5.63e-14	IgG glycosylation;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.38	-0.47	1.24e-26	Testicular germ cell tumor;
LGG	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-27.19	-0.78	5.4e-98	Height;
LGG	cis	rs9487094	0.666	rs7751582	chr6:109748847	T/C	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.18e-11	Height;
LGG	trans	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg26043149	chr18:55253948	FECH	-0.46	-7.61	-0.33	1.52e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-8.67	-0.37	7.19e-17	Hip circumference adjusted for BMI;
LGG	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.72	0.45	4.06e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs9427116	0.502	rs9426830	chr1:154594690	A/G	cg11650704	chr1:154556575	ADAR	-0.48	-9.5	-0.4	1.14e-19	Blood protein levels;
LGG	cis	rs883565	0.655	rs6777651	chr3:39143599	G/C	cg01426195	chr3:39028469	NA	-0.74	-17.39	-0.63	1.76e-52	Handedness;
LGG	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg00405596	chr8:11794950	NA	0.64	11.41	0.47	9.3e-27	Neuroticism;
LGG	cis	rs2540226	0.515	rs2716693	chr2:39895556	A/G	cg18968196	chr2:39892502	TMEM178	0.31	8.54	0.37	1.94e-16	Personality dimensions;
LGG	cis	rs7444	0.941	rs181359	chr22:21928641	C/T	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.83e-11	Systemic lupus erythematosus;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg10004079	chr17:26372530	NLK	-0.42	-6.67	-0.3	7.41e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1497828	0.956	rs2646803	chr1:217522466	A/G	cg04411442	chr1:217543379	NA	0.48	8.15	0.35	3.39e-15	Dialysis-related mortality;
LGG	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.88	-0.45	1.03e-24	Hemoglobin concentration;
LGG	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.78	-0.3	3.74e-11	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg05793240	chr7:2802953	GNA12	0.31	7.55	0.33	2.32e-13	Height;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6693295	0.877	rs2787970	chr1:246231670	T/C	cg11798871	chr1:246315928	SMYD3	-0.42	-6.76	-0.3	4.05e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs2273669	0.667	rs12216104	chr6:109317635	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	trans	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg21659725	chr3:3221576	CRBN	-0.66	-12.39	-0.5	1.25e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg12463550	chr7:65579703	CRCP	0.8	8.78	0.38	3.18e-17	Diabetic kidney disease;
LGG	cis	rs4917300	0.606	rs2029621	chr8:143111165	T/C	cg06573787	chr8:143070187	NA	0.6	10.06	0.42	1.2e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg14926445	chr8:58193284	C8orf71	-0.88	-12.48	-0.5	5.01e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03145290	chr16:32857923	NA	0.37	7.41	0.33	6.11e-13	Menarche (age at onset);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.22	-0.32	2.15e-12	Obesity-related traits;
LGG	cis	rs587080	0.559	rs12364730	chr11:65228278	C/T	cg17120908	chr11:65337727	SSSCA1	-0.6	-8.64	-0.37	8.97e-17	Plateletcrit;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00761968	chr13:53314142	LECT1	0.33	7.05	0.31	6.56e-12	Lewy body disease;
LGG	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.65e-11	Bladder cancer;
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.21	-0.43	3.29e-22	Neuroticism;
LGG	cis	rs1904096	0.506	rs7697827	chr4:95184748	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.6	-11.36	-0.47	1.46e-26	Type 2 diabetes;
LGG	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg03433033	chr1:76189801	ACADM	-0.66	-9.94	-0.42	3.22e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4253772	0.591	rs7291444	chr22:46656246	T/G	cg24881330	chr22:46731750	TRMU	0.71	8.85	0.38	1.81e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg02158880	chr13:53174818	NA	-0.4	-8.03	-0.35	8.35e-15	Lewy body disease;
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.72	0.38	4.93e-17	Bipolar disorder;
LGG	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7647973	0.593	rs1799844	chr3:49847642	G/A	cg21659725	chr3:3221576	CRBN	0.56	7.3	0.32	1.24e-12	Menarche (age at onset);
LGG	cis	rs17453880	0.929	rs4391148	chr5:152026986	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	trans	rs9354308	0.764	rs9345706	chr6:66586915	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.62e-12	IgG glycosylation;
LGG	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg00409905	chr10:38381863	ZNF37A	0.39	6.93	0.31	1.4e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.82	12.59	0.5	1.85e-31	HIV-1 control;
LGG	cis	rs7103648	0.712	rs10838703	chr11:47422861	C/G	cg20307385	chr11:47447363	PSMC3	0.88	19.04	0.66	4.05e-60	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs10929925	0.897	rs4670029	chr2:6158148	C/T	cg00493617	chr2:6141445	NA	0.32	7.2	0.32	2.39e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs494459	0.838	rs12796102	chr11:118662028	C/T	cg20110707	chr11:118481992	PHLDB1	0.31	6.68	0.3	6.77e-11	Height;
LGG	cis	rs11122272	0.735	rs973254	chr1:231521149	T/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.26	-0.32	1.7e-12	Hemoglobin concentration;
LGG	cis	rs7766436	0.727	rs6908574	chr6:22610165	T/C	cg13666174	chr6:22585274	NA	-0.36	-8.54	-0.37	2.01e-16	Coronary artery disease;
LGG	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08564027	chr20:61660810	NA	1.03	25.29	0.76	2.74e-89	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10861342	0.892	rs10459207	chr12:105531072	C/T	cg23923672	chr12:105501055	KIAA1033	0.79	7.44	0.33	5.04e-13	IgG glycosylation;
LGG	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg24110177	chr3:50126178	RBM5	0.65	12.0	0.49	4.63e-29	Body mass index;
LGG	cis	rs11190604	1.000	rs10883492	chr10:102206089	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11169552	0.510	rs11613488	chr12:50978255	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.62	-0.33	1.47e-13	Colorectal cancer;
LGG	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.4	0.33	6.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9308731	0.644	rs56952027	chr2:111877104	C/T	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.88	-0.3	1.91e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10492096	0.947	rs12371184	chr12:6632925	A/G	cg13857086	chr12:6580257	VAMP1	0.5	7.31	0.32	1.16e-12	Hip geometry;
LGG	cis	rs6539288	0.803	rs2374651	chr12:107328124	A/G	cg26297688	chr12:107349093	C12orf23	-0.37	-7.05	-0.31	6.67e-12	Total body bone mineral density;
LGG	cis	rs12618769	0.625	rs76362434	chr2:99118005	C/T	cg18455616	chr2:99124870	INPP4A	0.28	7.52	0.33	2.89e-13	Bipolar disorder;
LGG	cis	rs12908161	1.000	rs60957376	chr15:85280792	T/G	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg07169764	chr2:136633963	MCM6	-0.46	-7.32	-0.32	1.11e-12	Colorectal cancer;
LGG	cis	rs7091068	0.518	rs4144098	chr10:95432600	C/T	cg20715218	chr10:95462985	C10orf4	0.67	12.29	0.5	3.01e-30	Urinary tract infection frequency;
LGG	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg00405596	chr8:11794950	NA	-0.66	-11.66	-0.48	1.05e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4242434	0.757	rs4872531	chr8:22529695	A/G	cg03733263	chr8:22462867	KIAA1967	-1.01	-23.79	-0.74	2.5e-82	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg13385521	chr17:29058706	SUZ12P	0.9	10.23	0.43	2.69e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.64	0.33	1.23e-13	Rheumatoid arthritis;
LGG	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg15103426	chr22:29168792	CCDC117	0.59	8.95	0.38	8.58e-18	Lymphocyte counts;
LGG	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg14664628	chr15:75095509	CSK	-0.89	-18.11	-0.64	8.44e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg20892847	chr12:58011875	NA	0.36	7.56	0.33	2.15e-13	Multiple sclerosis;
LGG	cis	rs826838	0.935	rs1684407	chr12:39127270	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg04546413	chr19:29218101	NA	0.63	8.59	0.37	1.32e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg18551225	chr6:44695536	NA	-0.61	-10.1	-0.42	8.35e-22	Total body bone mineral density;
LGG	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg04132472	chr17:19861366	AKAP10	0.26	7.24	0.32	1.92e-12	Schizophrenia;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	6.73e-13	Lung cancer;
LGG	cis	rs870825	0.616	rs28649620	chr4:185648997	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs79349575	0.721	rs1008834	chr17:46968008	G/C	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.07e-14	Type 2 diabetes;
LGG	cis	rs999943	0.846	rs999942	chr6:33624902	G/C	cg14003231	chr6:33640908	ITPR3	0.63	14.48	0.56	1.92e-39	Obesity (extreme);
LGG	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24991452	chr6:35996059	MAPK14	0.47	7.12	0.31	4.23e-12	Gut microbiome composition (summer);
LGG	cis	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	8.63	0.37	9.79e-17	Breast cancer;
LGG	trans	rs11976180	1.000	rs2371247	chr7:143764179	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs8180040	0.966	rs17476234	chr3:47326298	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-15.85	-0.59	1.67e-45	Colorectal cancer;
LGG	cis	rs9457247	0.663	rs9459839	chr6:167431829	T/C	cg07741184	chr6:167504864	NA	0.38	8.45	0.37	3.82e-16	Crohn's disease;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	trans	rs7395662	0.864	rs10838951	chr11:48571088	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs6743226	0.603	rs62186419	chr2:242246865	C/T	cg10021735	chr2:242295487	FARP2	0.4	7.07	0.31	5.63e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6693567	0.565	rs834235	chr1:150362154	C/T	cg15654264	chr1:150340011	RPRD2	0.32	6.69	0.3	6.47e-11	Migraine;
LGG	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg16751781	chr15:78858589	CHRNA5	-0.42	-8.58	-0.37	1.49e-16	Sudden cardiac arrest;
LGG	cis	rs6964587	0.626	rs2106745	chr7:91506635	C/T	cg17063962	chr7:91808500	NA	-0.43	-7.86	-0.34	2.77e-14	Breast cancer;
LGG	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.41e-20	Heart rate;
LGG	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-10.23	-0.43	2.87e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9443645	1.000	rs9443645	chr6:79822924	C/T	cg18132916	chr6:79620363	NA	-0.28	-7.44	-0.33	5.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg22947322	chr17:47091978	IGF2BP1	0.45	8.01	0.35	9.38e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.49	-0.33	3.43e-13	Restless legs syndrome;
LGG	cis	rs4740619	0.905	rs10962157	chr9:15786817	A/T	cg14451791	chr9:16040625	NA	-0.4	-10.35	-0.43	1.05e-22	Body mass index;
LGG	cis	rs4731207	0.533	rs1481326	chr7:124625984	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs8002861	0.905	rs12430629	chr13:44415919	T/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.28	-0.7	1.44e-70	Leprosy;
LGG	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15369054	chr17:80825471	TBCD	0.53	7.38	0.32	7.62e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs2404602	0.692	rs12904198	chr15:77146978	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs67133203	0.659	rs407135	chr12:51411353	G/T	cg14688905	chr12:51403056	SLC11A2	-0.6	-10.3	-0.43	1.5e-22	Urinary tract infection frequency;
LGG	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg22348356	chr13:114891224	RASA3	0.44	8.88	0.38	1.45e-17	Schizophrenia;
LGG	cis	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.96	-0.31	1.14e-11	Morning vs. evening chronotype;
LGG	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg27572855	chr1:25598939	RHD	0.52	12.03	0.49	3.52e-29	Erythrocyte sedimentation rate;
LGG	cis	rs9290065	0.538	rs9860182	chr3:160768962	T/C	cg03342759	chr3:160939853	NMD3	-0.58	-9.84	-0.42	7.41e-21	Kawasaki disease;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.51	0.56	1.38e-39	Platelet count;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.14	0.58	2.36e-42	Lung cancer;
LGG	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-16.52	-0.61	1.54e-48	Vitiligo;
LGG	cis	rs6120849	0.754	rs6120804	chr20:33623701	C/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg06112835	chr11:68658793	MRPL21	0.64	10.23	0.43	2.85e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17976829	chr10:131934431	GLRX3	0.43	6.8	0.3	3.17e-11	Gut microbiome composition (summer);
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg14789911	chr21:47582049	C21orf56	-0.41	-7.04	-0.31	6.93e-12	Testicular germ cell tumor;
LGG	cis	rs9296092	0.538	rs9296094	chr6:33520064	A/G	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-10.05	-0.42	1.27e-21	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg04672837	chr16:48644449	N4BP1	0.53	8.61	0.37	1.13e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs920590	0.758	rs7012358	chr8:19662498	C/T	cg01411142	chr8:19674711	INTS10	0.47	7.34	0.32	9.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.9	0.34	2.1e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11626933	1.000	rs7146724	chr14:90766092	C/T	cg14092571	chr14:90743983	NA	-0.82	-16.89	-0.62	3.19e-50	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs2862064	1.000	rs2902128	chr5:156421347	C/T	cg12943317	chr5:156479607	HAVCR1	-0.84	-10.57	-0.44	1.56e-23	Platelet count;
LGG	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12826209	chr6:26865740	GUSBL1	0.58	7.03	0.31	7.66e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.8e-12	Aortic root size;
LGG	cis	rs2635047	0.638	rs55730206	chr18:44608230	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.71	0.3	5.76e-11	Educational attainment;
LGG	trans	rs12517041	0.872	rs28839222	chr5:23312044	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.11	-0.46	1.4e-25	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10880863	chr7:132937862	EXOC4	0.49	7.81	0.34	3.89e-14	Gut microbiome composition (summer);
LGG	cis	rs4865875	1.000	rs10805463	chr5:54100354	A/G	cg22421804	chr5:54100067	NA	-0.51	-7.72	-0.34	7.13e-14	Sense of smell;
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.69	-0.37	6.5e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs9486719	1.000	rs2472882	chr6:96863474	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.26	-0.49	4.11e-30	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.66	-0.34	1.08e-13	Iron status biomarkers;
LGG	cis	rs78487399	0.710	rs7567685	chr2:43668169	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs67311347	0.955	rs6599100	chr3:40447362	C/T	cg13683864	chr3:40499215	RPL14	-0.98	-20.56	-0.69	3.26e-67	Renal cell carcinoma;
LGG	cis	rs9486719	1.000	rs2205755	chr6:96864704	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.23	0.32	1.99e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg14664628	chr15:75095509	CSK	-0.56	-10.57	-0.44	1.6e-23	Breast cancer;
LGG	cis	rs4704187	0.663	rs28448485	chr5:74425775	G/A	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs7584330	0.617	rs28725355	chr2:238372824	T/G	cg16989719	chr2:238392110	NA	-0.36	-7.35	-0.32	8.95e-13	Prostate cancer;
LGG	cis	rs4144743	0.938	rs55677902	chr17:45322572	G/T	cg18085866	chr17:45331354	ITGB3	-0.8	-9.92	-0.42	3.57e-21	Body mass index;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg26174226	chr8:58114915	NA	-0.58	-8.06	-0.35	6.65e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg24759859	chr6:86352639	SYNCRIP	0.43	7.06	0.31	6.02e-12	Smooth-surface caries;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.41	-6.83	-0.3	2.69e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19671926	chr4:122722719	EXOSC9	0.53	8.19	0.36	2.56e-15	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.71	-9.81	-0.41	8.83e-21	Lung function (FEV1/FVC);
LGG	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg15327641	chr2:3715039	ALLC	0.33	7.3	0.32	1.3e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs6912958	0.712	rs7755167	chr6:88338752	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.73	-0.38	4.67e-17	Monocyte percentage of white cells;
LGG	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11722228	0.522	rs2241468	chr4:10113905	G/A	cg25986240	chr4:9926439	SLC2A9	-0.53	-9.61	-0.41	4.51e-20	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg06521331	chr12:34319734	NA	-0.42	-7.38	-0.32	7.5e-13	Morning vs. evening chronotype;
LGG	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.01	0.42	1.75e-21	Height;
LGG	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.56	11.53	0.47	3.16e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg02002194	chr4:3960332	NA	0.45	8.13	0.35	3.88e-15	Retinal vascular caliber;
LGG	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg13385794	chr1:248469461	NA	0.45	7.94	0.35	1.51e-14	Common traits (Other);
LGG	cis	rs477692	0.905	rs555545	chr10:131411586	G/A	cg05714579	chr10:131428358	MGMT	0.64	13.53	0.53	2.13e-35	Response to temozolomide;
LGG	trans	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.49	-0.33	3.55e-13	Educational attainment (years of education);
LGG	cis	rs6598955	0.671	rs11247904	chr1:26621804	G/A	cg04990556	chr1:26633338	UBXN11	0.6	7.98	0.35	1.15e-14	Obesity-related traits;
LGG	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg16797656	chr11:68205561	LRP5	-0.46	-7.67	-0.34	1.05e-13	Bone mineral density (spine);
LGG	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.63	0.41	3.87e-20	Hypertriglyceridemia;
LGG	cis	rs4268898	0.760	rs11125535	chr2:24528114	T/C	cg06627628	chr2:24431161	ITSN2	0.43	7.3	0.32	1.24e-12	Asthma;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs7172677	1.000	rs7166695	chr15:75404402	C/T	cg14664628	chr15:75095509	CSK	0.53	8.18	0.36	2.82e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-7.99	-0.35	1.07e-14	Self-reported allergy;
LGG	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.32e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg25517755	chr10:38738941	LOC399744	-0.35	-6.69	-0.3	6.39e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg03433033	chr1:76189801	ACADM	0.65	9.14	0.39	1.93e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg07520810	chr10:63809149	ARID5B	-0.39	-7.66	-0.34	1.1e-13	Systemic lupus erythematosus;
LGG	cis	rs4750440	0.671	rs1809305	chr10:14026780	G/A	cg27542038	chr10:14027202	FRMD4A	-0.7	-13.37	-0.53	1.04e-34	Adiponectin levels;
LGG	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg07835443	chr16:89734986	C16orf55	0.4	7.13	0.31	3.81e-12	Hemoglobin concentration;
LGG	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg21775007	chr8:11205619	TDH	-0.52	-7.9	-0.34	2.12e-14	Neuroticism;
LGG	cis	rs9467711	0.651	rs9467623	chr6:25860580	G/A	cg21479132	chr6:26055353	NA	0.75	6.66	0.3	7.7e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg22834771	chr12:69754056	YEATS4	-0.42	-7.39	-0.32	6.75e-13	Blood protein levels;
LGG	trans	rs62458065	0.513	rs7805536	chr7:32573570	T/C	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.67	-0.34	1.02e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs727505	0.721	rs11534064	chr7:124767997	G/T	cg23710748	chr7:124431027	NA	0.41	8.13	0.35	3.82e-15	Lewy body disease;
LGG	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg26384229	chr12:38710491	ALG10B	-0.83	-18.17	-0.65	4.52e-56	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16680214	chr1:154839983	KCNN3	-0.48	-9.54	-0.41	8.1e-20	Prostate cancer;
LGG	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-8.07	-0.35	6.01e-15	Psoriasis;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg14789911	chr21:47582049	C21orf56	-0.43	-7.13	-0.31	3.83e-12	Testicular germ cell tumor;
LGG	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg24812749	chr6:127587940	RNF146	0.88	13.54	0.53	2.02e-35	Breast cancer;
LGG	cis	rs8017423	0.967	rs11627528	chr14:90719697	C/A	cg04374321	chr14:90722782	PSMC1	-0.89	-18.42	-0.65	3.2e-57	Mortality in heart failure;
LGG	cis	rs10861342	1.000	rs7305712	chr12:105519188	A/T	cg23923672	chr12:105501055	KIAA1033	-0.71	-6.91	-0.31	1.63e-11	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01148728	chr11:117198424	CEP164	0.5	8.4	0.36	5.64e-16	Cognitive performance;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg03808351	chr9:123631620	PHF19	-0.27	-7.01	-0.31	8.49e-12	Birth weight;
LGG	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg15103426	chr22:29168792	CCDC117	0.65	7.81	0.34	3.98e-14	Pancreatic cancer;
LGG	cis	rs1371867	0.875	rs1660344	chr8:101324659	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs36093844	0.752	rs79734467	chr11:85571953	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.17	-0.32	3.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs11771526	0.901	rs7357161	chr7:32302475	A/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg13047869	chr3:10149882	C3orf24	0.5	7.92	0.35	1.81e-14	Alzheimer's disease;
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg27400746	chr16:89904261	SPIRE2	-0.93	-14.81	-0.57	6.96e-41	Skin colour saturation;
LGG	cis	rs9486715	0.867	rs4839828	chr6:96863326	G/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.0	0.35	1.02e-14	Headache;
LGG	cis	rs73198271	1.000	rs55971558	chr8:8614403	G/T	cg01851573	chr8:8652454	MFHAS1	0.4	6.66	0.3	7.92e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.65	-0.3	8.15e-11	Total body bone mineral density;
LGG	cis	rs8017423	0.967	rs12589808	chr14:90719236	C/T	cg04374321	chr14:90722782	PSMC1	-0.89	-18.36	-0.65	5.9e-57	Mortality in heart failure;
LGG	cis	rs6087990	0.899	rs1333469	chr20:31361249	C/T	cg13636640	chr20:31349939	DNMT3B	0.97	21.41	0.71	3.31e-71	Ulcerative colitis;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg07685180	chr8:600429	NA	1.04	10.66	0.44	6.84e-24	IgG glycosylation;
LGG	cis	rs240764	0.764	rs10457800	chr6:100936628	C/T	cg21058520	chr6:100914733	NA	0.5	8.67	0.37	7.22e-17	Neuroticism;
LGG	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.2	-0.39	1.2e-18	Erythrocyte sedimentation rate;
LGG	cis	rs7615952	0.546	rs111812401	chr3:125361495	G/A	cg21696256	chr3:125484277	NA	-0.45	-6.87	-0.3	2.06e-11	Blood pressure (smoking interaction);
LGG	cis	rs8056893	0.807	rs7203220	chr16:68356187	A/C	cg07273125	chr16:68295692	NA	0.36	6.9	0.31	1.68e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs3789045	0.774	rs11801299	chr1:204529084	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.47	-9.33	-0.4	4.45e-19	Educational attainment (college completion);
LGG	cis	rs9677476	0.909	rs7573577	chr2:232104079	C/T	cg23338755	chr2:231921595	PSMD1	0.47	7.0	0.31	9.13e-12	Food antigen IgG levels;
LGG	cis	rs977987	0.778	rs4888413	chr16:75443223	C/A	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	32.46	0.83	2.3e-121	Prudent dietary pattern;
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg26513180	chr16:89883248	FANCA	0.89	8.49	0.37	2.77e-16	Skin colour saturation;
LGG	cis	rs965513	1.000	rs4743130	chr9:100546040	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.49	-0.4	1.23e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs6719977	0.543	rs6544595	chr2:42977870	T/G	cg14631114	chr2:43023945	NA	0.48	10.14	0.43	6.11e-22	Hyperactive-impulsive symptoms;
LGG	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	7.87	0.34	2.45e-14	Bone mineral density;
LGG	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg13009111	chr11:71350975	NA	-0.34	-7.61	-0.33	1.6e-13	Neuroticism;
LGG	cis	rs8016982	0.674	rs1951614	chr14:81672106	A/G	cg01989461	chr14:81687754	GTF2A1	-0.78	-19.51	-0.67	2.73e-62	Schizophrenia;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg19168338	chr16:4465731	CORO7	0.73	13.41	0.53	7.44e-35	Schizophrenia;
LGG	cis	rs1977876	0.777	rs11119769	chr1:211713769	C/G	cg01575408	chr1:211752895	SLC30A1	-0.48	-6.71	-0.3	5.83e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg18252515	chr7:66147081	NA	-1.42	-20.51	-0.69	5.3e-67	Diabetic kidney disease;
LGG	cis	rs734999	0.545	rs6698817	chr1:2564183	T/C	cg15627072	chr1:2432621	PLCH2	-0.35	-7.85	-0.34	3.01e-14	Ulcerative colitis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06642177	chr6:134496341	SGK1	0.4	6.72	0.3	5.43e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05950833	chr1:32688296	C1orf91;EIF3I	0.45	6.79	0.3	3.54e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06850241	chr22:41845214	NA	-0.45	-7.1	-0.31	4.87e-12	Vitiligo;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08219700	chr8:58056026	NA	0.46	7.02	0.31	8.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3849046	0.934	rs7714751	chr5:137849066	G/A	cg10920316	chr5:137946599	NA	-0.41	-6.78	-0.3	3.64e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg00333364	chr11:8704802	RPL27A;SNORA3	0.44	7.88	0.34	2.42e-14	Menarche (age at onset);
LGG	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg18451016	chr1:38461880	NA	-0.61	-14.26	-0.55	1.72e-38	Coronary artery disease;
LGG	cis	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs12422267	0.609	rs10128884	chr12:132621624	C/T	cg09764611	chr12:132620959	NA	-0.53	-8.12	-0.35	4.21e-15	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6088580	0.561	rs3761147	chr20:32996689	G/T	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.35	2.95e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26149167	chr19:16187889	TPM4	0.39	6.75	0.3	4.49e-11	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.32	0.58	3.66e-43	Lung cancer;
LGG	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg08704250	chr15:31115839	NA	-0.42	-7.26	-0.32	1.61e-12	Huntington's disease progression;
LGG	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg01411142	chr8:19674711	INTS10	0.47	7.55	0.33	2.41e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg21724239	chr8:58056113	NA	0.53	7.53	0.33	2.67e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.61	-0.44	1.06e-23	Prostate cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05577173	chr5:78908678	PAPD4	0.41	6.97	0.31	1.07e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg05868516	chr6:26286170	HIST1H4H	0.45	7.67	0.34	9.93e-14	Educational attainment;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg02725872	chr8:58115012	NA	-0.91	-11.94	-0.49	7.79e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg11901034	chr3:128598214	ACAD9	-0.46	-6.94	-0.31	1.31e-11	IgG glycosylation;
LGG	cis	rs755249	0.532	rs61779277	chr1:39833535	G/A	cg18385671	chr1:39797026	MACF1	0.43	7.41	0.33	6.19e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13082711	0.689	rs34946790	chr3:27345170	G/A	cg02860705	chr3:27208620	NA	1.03	18.9	0.66	1.74e-59	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg08648136	chr8:956695	NA	0.38	7.72	0.34	7.41e-14	Schizophrenia;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.58	8.67	0.37	7.51e-17	Renal function-related traits (BUN);
LGG	trans	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg16006296	chr10:38738647	LOC399744	0.35	6.78	0.3	3.59e-11	Diastolic blood pressure;
LGG	cis	rs870825	0.616	rs3184982	chr4:185615768	T/G	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs3735485	0.800	rs17548523	chr7:45084446	T/C	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg06112835	chr11:68658793	MRPL21	-0.41	-7.37	-0.32	7.79e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg21918786	chr6:109611834	NA	0.48	9.02	0.39	4.9e-18	Reticulocyte fraction of red cells;
LGG	cis	rs12410462	0.591	rs2132366	chr1:227787102	C/T	cg23173402	chr1:227635558	NA	0.39	7.31	0.32	1.18e-12	Major depressive disorder;
LGG	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg12463550	chr7:65579703	CRCP	0.81	9.03	0.39	4.51e-18	Diabetic kidney disease;
LGG	cis	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.43	-0.33	5.16e-13	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg06212747	chr3:49208901	KLHDC8B	0.44	7.09	0.31	4.99e-12	Resting heart rate;
LGG	cis	rs35740288	0.770	rs1382538	chr15:86165896	G/C	cg04173714	chr15:86211321	AKAP13	0.44	7.54	0.33	2.48e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2013441	1.000	rs2120282	chr17:20209474	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs6998277	0.830	rs6981007	chr8:103598257	G/C	cg10187029	chr8:103597600	NA	1.01	19.09	0.66	2.41e-60	Migraine;
LGG	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.86	-0.34	2.74e-14	Height;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs4132509	1.000	rs2291410	chr1:243716654	A/C	cg25706552	chr1:244017396	NA	-0.52	-8.25	-0.36	1.69e-15	RR interval (heart rate);
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg19168338	chr16:4465731	CORO7	0.85	15.52	0.58	4.97e-44	Schizophrenia;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs300774	0.925	rs300779	chr2:111486	G/A	cg04617936	chr2:214353	NA	-0.49	-7.29	-0.32	1.35e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs10875746	0.669	rs11168459	chr12:48596241	A/G	cg24011408	chr12:48396354	COL2A1	-0.57	-7.5	-0.33	3.37e-13	Longevity (90 years and older);
LGG	cis	rs6871536	1.000	rs6871536	chr5:131969874	T/C	cg04303330	chr5:131992430	IL13	0.29	6.98	0.31	1.06e-11	Asthma (childhood onset);
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg15664640	chr17:80829946	TBCD	0.46	8.43	0.36	4.52e-16	Glycated hemoglobin levels;
LGG	trans	rs116095464	0.558	rs12173015	chr5:269967	A/C	cg00938859	chr5:1591904	SDHAP3	-0.57	-8.08	-0.35	5.77e-15	Breast cancer;
LGG	cis	rs11122272	0.735	rs2739516	chr1:231505527	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.18	-0.46	7.46e-26	Hemoglobin concentration;
LGG	trans	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg23649088	chr2:200775458	C2orf69	0.78	15.65	0.59	1.29e-44	Osteoporosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19635869	chr6:90121153	RRAGD	0.49	7.83	0.34	3.39e-14	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.825	rs56108532	chr5:93276342	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.82	9.26	0.4	7.65e-19	Diabetic retinopathy;
LGG	cis	rs4242434	0.672	rs7846476	chr8:22479461	T/C	cg02227867	chr8:22457446	C8orf58	-0.37	-6.96	-0.31	1.2e-11	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs62103177	0.565	rs473119	chr18:77849459	T/G	cg05926928	chr17:57297772	GDPD1	-0.93	-11.8	-0.48	2.78e-28	Opioid sensitivity;
LGG	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg07928641	chr1:182991847	LAMC1	0.45	8.9	0.38	1.26e-17	Colorectal cancer;
LGG	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg10661904	chr17:79619235	PDE6G	-0.51	-10.41	-0.44	5.82e-23	Eye color traits;
LGG	cis	rs300774	0.925	rs384286	chr2:128345	C/T	cg04617936	chr2:214353	NA	-0.49	-7.46	-0.33	4.2e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg11693508	chr17:37793320	STARD3	0.67	9.26	0.4	7.46e-19	Bipolar disorder;
LGG	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.6	-11.85	-0.48	1.76e-28	Menarche (age at onset);
LGG	cis	rs5756391	0.568	rs2075940	chr22:37318446	G/A	cg21209356	chr22:37319042	CSF2RB	0.42	9.55	0.41	7.52e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs17767392	0.670	rs11620632	chr14:71729438	A/G	cg13720639	chr14:72061746	SIPA1L1	0.35	8.17	0.35	3.03e-15	Mitral valve prolapse;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg00945038	chr17:61921165	SMARCD2	-0.39	-6.67	-0.3	7.4e-11	Prudent dietary pattern;
LGG	cis	rs34929064	0.525	rs1880243	chr7:22759655	C/A	cg18045685	chr7:22629474	NA	0.54	7.6	0.33	1.64e-13	Major depression and alcohol dependence;
LGG	cis	rs806215	0.526	rs2058457	chr7:127493657	A/T	cg25922125	chr7:127225783	GCC1	-0.49	-7.18	-0.32	2.72e-12	Type 2 diabetes;
LGG	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.02	-0.39	4.92e-18	Bone mineral density;
LGG	cis	rs72781680	0.898	rs72786270	chr2:24059049	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.21e-18	Lymphocyte counts;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg23034840	chr1:205782522	SLC41A1	0.53	8.62	0.37	1.04e-16	Menarche (age at onset);
LGG	cis	rs7508	0.694	rs2073572	chr8:17921666	C/T	cg18067069	chr8:17937731	ASAH1	-0.37	-8.6	-0.37	1.26e-16	Atrial fibrillation;
LGG	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg15704280	chr7:45808275	SEPT13	0.88	12.43	0.5	8.41e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6787391	0.933	rs9877680	chr3:4751160	G/T	cg11584376	chr3:4789075	ITPR1	-0.33	-6.78	-0.3	3.69e-11	Breast cancer;
LGG	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg15704280	chr7:45808275	SEPT13	-0.75	-9.24	-0.39	8.92e-19	Height;
LGG	trans	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	3.97e-16	Retinal vascular caliber;
LGG	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.67	-0.3	7.3e-11	Blood metabolite levels;
LGG	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg27129171	chr3:47204927	SETD2	-0.81	-14.87	-0.57	3.69e-41	Colorectal cancer;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.53	-0.44	2.14e-23	Prostate cancer;
LGG	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	10.37	0.43	8.68e-23	Educational attainment;
LGG	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9487094	0.813	rs3799835	chr6:109693287	A/G	cg01125227	chr6:109776195	MICAL1	0.5	8.49	0.37	2.81e-16	Height;
LGG	cis	rs35740288	0.895	rs3743332	chr15:86303751	T/C	cg04173714	chr15:86211321	AKAP13	0.41	7.16	0.32	3.1e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg20891283	chr12:69753455	YEATS4	0.5	7.81	0.34	3.97e-14	Response to diuretic therapy;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.32e-16	Total body bone mineral density;
LGG	cis	rs763121	0.853	rs5757203	chr22:39044152	G/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	trans	rs12517041	1.000	rs10056180	chr5:23261881	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.8	-0.38	2.78e-17	Calcium levels;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.18e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02071572	chr4:1403502	NA	0.38	7.0	0.31	8.79e-12	Longevity;
LGG	cis	rs11166927	0.901	rs7014257	chr8:140802694	G/T	cg16909799	chr8:140841666	TRAPPC9	0.58	12.15	0.49	1.08e-29	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs9354308	0.702	rs9345713	chr6:66591842	A/T	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.42	-0.36	4.78e-16	Total body bone mineral density;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7119	0.717	rs11629835	chr15:77787469	G/T	cg17802220	chr15:77601643	NA	-0.54	-12.23	-0.49	5.57e-30	Type 2 diabetes;
LGG	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg08847533	chr14:75593920	NEK9	-0.61	-11.39	-0.47	1.2e-26	Height;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.89e-31	Lymphocyte counts;
LGG	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs12681366	0.573	rs2470740	chr8:95399551	A/T	cg13257157	chr8:95487014	RAD54B	-0.37	-6.67	-0.3	7.29e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg00677455	chr12:58241039	CTDSP2	0.37	6.66	0.3	7.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.665	rs11495668	chr12:38221018	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.06	0.72	3.15e-74	Bladder cancer;
LGG	cis	rs988958	0.567	rs11887431	chr2:42267462	C/T	cg19376973	chr2:42229025	NA	0.6	10.04	0.42	1.42e-21	Hypospadias;
LGG	cis	rs9420907	0.892	rs11591710	chr10:105687632	A/C	cg11005552	chr10:105648138	OBFC1	-0.65	-8.22	-0.36	2.05e-15	Telomere length;
LGG	cis	rs920590	0.523	rs4464983	chr8:19680979	C/T	cg03894339	chr8:19674705	INTS10	-0.53	-8.95	-0.38	8.55e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg11878867	chr6:150167359	LRP11	-0.54	-11.28	-0.46	2.98e-26	Lung cancer;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	16.57	0.61	9.01e-49	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7010267	0.570	rs6469804	chr8:120044829	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.86	0.38	1.77e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs76935404	0.811	rs12151139	chr19:41433543	A/G	cg01409498	chr19:41429786	CYP2B7P1	0.37	8.77	0.38	3.4e-17	nicotine metabolite ratio in current smokers;
LGG	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg10122326	chr6:28072925	NA	-0.92	-7.31	-0.32	1.19e-12	Parkinson's disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07856758	chr19:37861652	ZNF527	0.41	7.0	0.31	9.28e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg03538708	chr1:25844672	NA	0.35	6.71	0.3	5.8200000000000003e-11	Erythrocyte sedimentation rate;
LGG	cis	rs16912285	0.688	rs12279442	chr11:24317174	C/G	ch.11.24196551F	chr11:24239977	NA	0.87	12.74	0.51	4.32e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs6087990	0.731	rs2424897	chr20:31338098	A/T	cg13636640	chr20:31349939	DNMT3B	0.91	19.15	0.66	1.29e-60	Ulcerative colitis;
LGG	cis	rs12549902	0.932	rs6981607	chr8:41508168	A/C	cg25883020	chr8:41504993	NKX6-3	0.32	7.09	0.31	5.16e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.61	-0.33	1.5e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.17e-12	Cystic fibrosis severity;
LGG	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg20818283	chr2:191399100	TMEM194B	0.31	7.4	0.33	6.67e-13	Pulse pressure;
LGG	cis	rs12549902	0.897	rs12549294	chr8:41506380	A/G	cg25883020	chr8:41504993	NKX6-3	0.31	6.91	0.31	1.57e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg17764715	chr19:33622953	WDR88	0.57	7.91	0.35	1.88e-14	Bone properties (heel);
LGG	trans	rs561341	1.000	rs554078	chr17:30330109	A/C	cg27661571	chr11:113659931	NA	-0.7	-9.64	-0.41	3.6e-20	Hip circumference adjusted for BMI;
LGG	trans	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg00531865	chr16:30841666	NA	0.52	10.45	0.44	4.19e-23	Mean corpuscular hemoglobin;
LGG	cis	rs528418	0.560	rs2328655	chr6:145676244	T/C	cg03642472	chr6:145670687	NA	0.55	7.15	0.32	3.3e-12	Methadone dose in opioid dependence;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.84	-0.42	7.33e-21	Lung cancer;
LGG	cis	rs1465370	0.760	rs10263705	chr7:130027633	C/T	cg06917763	chr7:130033247	NA	-0.36	-7.79	-0.34	4.33e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg04000281	chr11:63949212	NA	0.42	7.9	0.34	2.02e-14	Platelet count;
LGG	cis	rs2073300	0.609	rs1076776	chr20:23427399	C/T	cg12062639	chr20:23401060	NAPB	-0.89	-8.31	-0.36	1.11e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg07075026	chr17:47091521	IGF2BP1	-0.39	-6.97	-0.31	1.11e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs1109114	0.816	rs2918275	chr5:148600424	T/C	cg06539116	chr5:148597365	ABLIM3	-0.61	-16.02	-0.6	2.85e-46	Body mass index;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg03804240	chr11:118481350	PHLDB1	-0.4	-7.84	-0.34	3.17e-14	Cholesterol, total;
LGG	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg15212455	chr7:39170539	POU6F2	0.48	11.09	0.46	1.71e-25	IgG glycosylation;
LGG	trans	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.68	-0.41	2.62e-20	Bladder cancer;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.83	-17.36	-0.63	2.37e-52	Personality dimensions;
LGG	trans	rs9944715	0.954	rs12962307	chr18:43815420	A/T	cg01718231	chr17:29326311	RNF135	-0.41	-6.66	-0.3	7.56e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg05535760	chr7:792225	HEATR2	0.78	12.49	0.5	4.91e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs490234	0.841	rs13291593	chr9:128228483	A/G	cg14078157	chr9:128172775	NA	-0.42	-7.75	-0.34	5.93e-14	Mean arterial pressure;
LGG	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.9	-0.51	9.68e-33	Menarche (age at onset);
LGG	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg26384229	chr12:38710491	ALG10B	0.67	12.1	0.49	1.75e-29	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs17169635	0.765	rs1014832	chr7:134572672	C/T	cg02516134	chr7:134575187	CALD1	0.42	8.88	0.38	1.44e-17	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg09845145	chr15:78292470	TBC1D2B	0.66	12.26	0.5	3.92e-30	Coronary artery disease or large artery stroke;
LGG	cis	rs8016982	0.520	rs7160599	chr14:81713739	C/T	cg01989461	chr14:81687754	GTF2A1	0.57	8.52	0.37	2.29e-16	Schizophrenia;
LGG	cis	rs6963495	0.745	rs68153235	chr7:105184832	A/C	cg19920283	chr7:105172520	RINT1	0.61	8.49	0.37	2.87e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs911263	0.524	rs1956526	chr14:68799787	G/T	cg18825221	chr14:68749962	RAD51L1	-0.37	-8.05	-0.35	7.17e-15	Primary biliary cholangitis;
LGG	trans	rs7395662	1.000	rs4882123	chr11:48575739	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg17757837	chr7:157058334	UBE3C	0.76	14.99	0.57	1.1e-41	Body mass index;
LGG	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.49	-0.4	1.27e-19	Height;
LGG	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg26384229	chr12:38710491	ALG10B	0.51	9.54	0.41	8.23e-20	Morning vs. evening chronotype;
LGG	cis	rs2282802	0.685	rs1347143	chr5:139669386	A/G	cg26211634	chr5:139558579	C5orf32	-0.35	-7.69	-0.34	9.07e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.44	0.33	4.95e-13	Schizophrenia;
LGG	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs365132	0.902	rs353489	chr5:176461974	T/C	cg16309518	chr5:176445507	NA	-0.55	-12.27	-0.5	3.81e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.72	-0.51	5.43e-32	Bipolar disorder;
LGG	cis	rs3784262	0.869	rs12903792	chr15:58261280	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.25	-0.36	1.61e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.91e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.767	rs11920853	chr3:47308183	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6e-39	Colorectal cancer;
LGG	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg26924012	chr15:45694286	SPATA5L1	0.41	6.68	0.3	6.93e-11	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03385696	chr7:75988425	YWHAG	0.46	7.12	0.31	4.21e-12	Gut microbiome composition (summer);
LGG	cis	rs1348850	0.914	rs1348849	chr2:178358072	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.45	-0.37	3.84e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg08999081	chr20:33150536	PIGU	-0.31	-7.24	-0.32	1.92e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.72	0.34	7.11e-14	Coronary artery disease;
LGG	trans	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.03	-0.39	4.82e-18	Bladder cancer;
LGG	cis	rs12477438	0.871	rs13396584	chr2:99611768	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.76	12.31	0.5	2.61e-30	Chronic sinus infection;
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.09	0.55	8.97e-38	Tonsillectomy;
LGG	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg23231163	chr10:75533350	FUT11	0.39	6.82	0.3	2.88e-11	Inflammatory bowel disease;
LGG	cis	rs72634501	0.716	rs4660165	chr1:39578532	C/T	cg18385671	chr1:39797026	MACF1	-0.39	-6.99	-0.31	9.52e-12	HDL cholesterol;
LGG	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02463440	chr8:22132932	PIWIL2	0.48	10.56	0.44	1.68e-23	Hypertriglyceridemia;
LGG	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg15704280	chr7:45808275	SEPT13	-1.01	-22.81	-0.73	9.2e-78	Coronary artery disease;
LGG	cis	rs11122272	0.735	rs2790880	chr1:231534259	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.18	-0.32	2.75e-12	Hemoglobin concentration;
LGG	cis	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg17545662	chr6:170176663	C6orf70	0.68	8.81	0.38	2.46e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg11062466	chr8:58055876	NA	0.44	7.3	0.32	1.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg00343986	chr7:65444356	GUSB	0.4	6.76	0.3	4.07e-11	Aortic root size;
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg01059449	chr18:44338099	ST8SIA5	0.36	7.71	0.34	7.6e-14	Personality dimensions;
LGG	cis	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg14593290	chr7:50529359	DDC	-0.43	-8.14	-0.35	3.66e-15	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.85	13.6	0.53	1.1e-35	Cognitive test performance;
LGG	cis	rs12477438	0.501	rs3792144	chr2:100056736	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.96	-0.31	1.19e-11	Chronic sinus infection;
LGG	cis	rs950169	0.509	rs71395455	chr15:85153804	A/G	cg03959625	chr15:84868606	LOC388152	0.55	8.45	0.37	3.83e-16	Schizophrenia;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg22947322	chr17:47091978	IGF2BP1	0.43	7.57	0.33	1.99e-13	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs6089829	0.925	rs2277767	chr20:61666937	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.98e-17	Bladder cancer;
LGG	cis	rs9807841	0.670	rs2010492	chr19:10803395	A/G	cg17710535	chr19:10819994	QTRT1	0.45	6.98	0.31	1.05e-11	Inflammatory skin disease;
LGG	cis	rs9534288	0.797	rs7995256	chr13:46579414	A/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs7737355	0.773	rs4706027	chr5:130932972	T/C	cg06307176	chr5:131281290	NA	0.53	8.77	0.38	3.48e-17	Life satisfaction;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4144743	1.000	rs67923812	chr17:45326151	T/G	cg18085866	chr17:45331354	ITGB3	-0.8	-9.59	-0.41	5.27e-20	Body mass index;
LGG	cis	rs8018808	0.935	rs11623826	chr14:77912862	A/C	cg20045696	chr14:77926864	AHSA1	0.39	6.7	0.3	6.01e-11	Myeloid white cell count;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00313498	chr4:7787944	AFAP1	0.36	7.1	0.31	4.65e-12	Electrocardiographic conduction measures;
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg11608241	chr8:8085544	FLJ10661	0.29	6.73	0.3	5.06e-11	Systolic blood pressure;
LGG	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg21775007	chr8:11205619	TDH	-0.48	-7.86	-0.34	2.77e-14	Systolic blood pressure;
LGG	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg16325326	chr1:53192061	ZYG11B	-0.9	-26.42	-0.78	1.78e-94	Monocyte count;
LGG	cis	rs9463078	0.764	rs494982	chr6:44937255	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.58	-0.37	1.4e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2030746	0.899	rs940688	chr2:121311000	C/G	cg03661458	chr2:121334411	NA	-0.29	-6.76	-0.3	4.29e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15893127	chr1:153756397	NA	-0.45	-6.82	-0.3	2.9e-11	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11620996	chr4:39368162	RFC1	0.46	6.87	0.3	2.1e-11	Gut microbiome composition (summer);
LGG	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg15704280	chr7:45808275	SEPT13	0.73	7.61	0.33	1.59e-13	Intraocular pressure;
LGG	cis	rs7503807	0.967	rs4889867	chr17:78593058	C/T	cg06872548	chr17:78716983	RPTOR	0.46	11.13	0.46	1.18e-25	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10796467	chr19:11546103	CCDC151;PRKCSH	0.47	7.13	0.31	3.86e-12	Gut microbiome composition (summer);
LGG	cis	rs1420338	0.967	rs10271544	chr7:34147159	C/T	cg01275685	chr7:34179230	BMPER	-0.5	-9.24	-0.39	8.87e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg13206674	chr6:150067644	NUP43	0.39	8.16	0.35	3.23e-15	Testicular germ cell tumor;
LGG	cis	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-8.87	-0.38	1.6e-17	Bladder cancer;
LGG	cis	rs17854409	0.881	rs68091818	chr20:61479882	A/C	cg05147244	chr20:61493195	TCFL5	0.76	7.56	0.33	2.19e-13	Obesity-related traits;
LGG	cis	rs9557207	1.000	rs9557205	chr13:100035272	C/G	cg24509225	chr13:100037070	UBAC2	0.71	12.8	0.51	2.39e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg11380483	chr2:127933992	NA	-0.35	-6.72	-0.3	5.41e-11	Self-rated health;
LGG	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	12.09	0.49	2.04e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs11169552	0.510	rs4238108	chr12:51059691	T/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.4	-0.33	6.41e-13	Colorectal cancer;
LGG	cis	rs2133450	0.524	rs56209862	chr3:7349037	G/A	cg19930620	chr3:7340148	GRM7	-0.42	-9.42	-0.4	2.22e-19	Early response to risperidone in schizophrenia;
LGG	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg11693508	chr17:37793320	STARD3	0.73	10.53	0.44	2.08e-23	Bipolar disorder;
LGG	cis	rs283228	0.605	rs589469	chr6:101726763	A/G	cg27451362	chr6:101846650	GRIK2	0.74	11.1	0.46	1.58e-25	Coenzyme Q10 levels;
LGG	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs2342371	1.000	rs13094241	chr3:196190893	G/T	cg15048948	chr3:196158458	UBXN7	0.43	7.21	0.32	2.3e-12	Fat distribution (HIV);
LGG	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg05147244	chr20:61493195	TCFL5	0.78	7.45	0.33	4.73e-13	Obesity-related traits;
LGG	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.34	-0.47	1.82e-26	Morning vs. evening chronotype;
LGG	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg25482853	chr8:67687455	SGK3	1.0	12.85	0.51	1.52e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs283228	0.959	rs283222	chr6:101758839	T/G	cg27451362	chr6:101846650	GRIK2	0.53	8.89	0.38	1.39e-17	Coenzyme Q10 levels;
LGG	cis	rs36051895	0.659	rs7025540	chr9:5043152	T/C	cg02405213	chr9:5042618	JAK2	-0.82	-16.19	-0.6	4.68e-47	Pediatric autoimmune diseases;
LGG	cis	rs7226408	0.857	rs11081985	chr18:34682970	A/G	cg15022739	chr18:34823045	BRUNOL4	0.43	7.0	0.31	9.23e-12	Obesity-related traits;
LGG	cis	rs7523273	1.000	rs12184327	chr1:207978780	A/G	cg22525895	chr1:207977042	MIR29B2	-0.63	-11.87	-0.48	1.48e-28	Schizophrenia;
LGG	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg18128536	chr17:47092178	IGF2BP1	0.49	9.48	0.4	1.32e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25281171	chr1:111149507	KCNA2	0.53	7.94	0.35	1.55e-14	Gut microbiome composition (summer);
LGG	cis	rs6831352	0.879	rs4699716	chr4:100066125	G/A	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.61e-12	Life satisfaction;
LGG	cis	rs2708377	0.858	rs115781584	chr12:11304560	C/T	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.7	-0.3	6.13e-11	Bitter taste perception;
LGG	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg27490568	chr2:178487706	NA	0.49	9.57	0.41	6.65e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg26384229	chr12:38710491	ALG10B	0.71	14.23	0.55	2.15e-38	Morning vs. evening chronotype;
LGG	cis	rs10267417	0.603	rs10081258	chr7:19934237	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs4363385	0.747	rs1999886	chr1:152955522	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	trans	rs6787172	0.622	rs6791431	chr3:158094357	A/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.31	-0.32	1.21e-12	Subjective well-being;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg19168338	chr16:4465731	CORO7	-0.86	-16.12	-0.6	9.84e-47	Schizophrenia;
LGG	cis	rs36093844	0.848	rs55836023	chr11:85566157	A/G	cg16165120	chr11:85566439	CCDC83	-0.5	-8.52	-0.37	2.29e-16	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs972578	0.765	rs5751396	chr22:43272085	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.87	-0.3	2.08e-11	Mean platelet volume;
LGG	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg25173405	chr17:45401733	C17orf57	0.47	8.29	0.36	1.24e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg18446336	chr7:2847575	GNA12	-0.29	-6.92	-0.31	1.52e-11	Height;
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg18252515	chr7:66147081	NA	0.44	7.32	0.32	1.14e-12	Aortic root size;
LGG	cis	rs9462027	0.628	rs2492860	chr6:34705530	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.92	-0.45	7.12e-25	Systemic lupus erythematosus;
LGG	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2562456	0.833	rs62107531	chr19:21509065	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs1395	0.710	rs2083363	chr2:27475318	G/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	cis	rs943466	0.955	rs11757524	chr6:33766212	A/G	cg07519485	chr6:33762594	MLN	0.56	11.5	0.47	4.13e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs9314323	0.964	rs2304300	chr8:26249018	G/A	cg11498726	chr8:26250323	BNIP3L	-0.55	-11.58	-0.47	2.12e-27	Red cell distribution width;
LGG	cis	rs13177180	0.671	rs9326970	chr5:114965602	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-9.47	-0.4	1.43e-19	Conotruncal heart defects (inherited effects);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20000940	chr14:52327486	GNG2	0.45	7.23	0.32	2.02e-12	Gut microbiome composition (summer);
LGG	cis	rs2797369	0.546	rs705602	chr6:101314358	G/A	cg27451362	chr6:101846650	GRIK2	0.65	8.96	0.38	8.27e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-12.14	-0.49	1.28e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg16583315	chr14:65563665	MAX	-0.42	-8.65	-0.37	8.71e-17	Obesity-related traits;
LGG	trans	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg10756647	chr7:56101905	PSPH	0.45	6.69	0.3	6.44e-11	Corneal structure;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.51	-0.56	1.4e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs4862307	0.762	rs28584149	chr4:184996482	C/T	cg06737308	chr4:185021514	ENPP6	0.41	7.27	0.32	1.57e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.37	-0.56	5.71e-39	Tonsillectomy;
LGG	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24110177	chr3:50126178	RBM5	-0.55	-10.0	-0.42	1.88e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12780845	0.540	rs2356829	chr10:17223625	C/T	cg01003015	chr10:17271136	VIM	0.43	7.29	0.32	1.34e-12	Homocysteine levels;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg21798802	chr22:38057573	PDXP	0.6	13.76	0.54	2.41e-36	Fat distribution (HIV);
LGG	cis	rs6088580	0.524	rs1321306	chr20:33266379	T/A	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.31	0.6	1.39e-47	Hip circumference adjusted for BMI;
LGG	cis	rs2718058	0.630	rs2722359	chr7:37839764	T/C	cg15028436	chr7:37888078	TXNDC3	0.52	8.21	0.36	2.18e-15	Alzheimer's disease (late onset);
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg13880726	chr7:1868755	MAD1L1	0.48	8.33	0.36	9.19e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs11055034	0.560	rs2024385	chr12:12888438	A/T	cg04607235	chr12:12878440	APOLD1	0.6	10.85	0.45	1.35e-24	Birth weight;
LGG	cis	rs2404602	1.000	rs12594541	chr15:76834368	G/A	cg15268244	chr15:77196840	NA	-0.33	-7.32	-0.32	1.11e-12	Blood metabolite levels;
LGG	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg27411982	chr8:10470053	RP1L1	-0.41	-7.02	-0.31	8.02e-12	Systolic blood pressure;
LGG	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.75	-0.34	5.75e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4789452	0.934	rs3987888	chr17:75370274	T/C	cg06761530	chr17:75373219	SEPT9	-0.38	-7.4	-0.33	6.42e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg07636037	chr3:49044803	WDR6	0.91	17.36	0.63	2.26e-52	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.66	0.34	1.13e-13	Homoarginine levels;
LGG	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.73	0.41	1.69e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9543976	1.000	rs73223968	chr13:76141721	C/A	cg01531495	chr13:76123901	UCHL3	-0.62	-7.39	-0.32	7.1e-13	Diabetic retinopathy;
LGG	cis	rs3093024	0.595	rs4458654	chr6:167476068	A/C	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Rheumatoid arthritis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	0.46	7.62	0.33	1.41e-13	Cognitive performance;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07243736	chr16:783730	NARFL	0.39	6.75	0.3	4.44e-11	Height;
LGG	cis	rs67478160	0.643	rs4900600	chr14:104291839	A/G	cg26031613	chr14:104095156	KLC1	-0.46	-7.55	-0.33	2.38e-13	Schizophrenia;
LGG	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.85e-12	Menopause (age at onset);
LGG	cis	rs7566780	0.516	rs12710703	chr2:16665425	C/G	cg09580478	chr2:16689509	NA	-0.43	-6.72	-0.3	5.52e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs6815814	0.851	rs17582921	chr4:38892649	T/C	cg06935464	chr4:38784597	TLR10	0.56	7.83	0.34	3.41e-14	Breast cancer;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg11878867	chr6:150167359	LRP11	-0.53	-11.19	-0.46	6.99e-26	Lung cancer;
LGG	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.04	0.35	7.77e-15	Colorectal cancer;
LGG	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg12395012	chr8:11607386	GATA4	-0.38	-6.77	-0.3	4e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs721399	0.752	rs35570672	chr8:18272635	T/C	cg18736775	chr8:18248649	NAT2	0.49	8.4	0.36	5.72e-16	Blood metabolite levels;
LGG	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg01017244	chr2:74357527	NA	0.49	9.13	0.39	2.12e-18	Gestational age at birth (maternal effect);
LGG	cis	rs12643440	0.538	rs1522080	chr4:17135354	G/C	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21881859	chr17:3749224	C17orf85	-0.44	-6.89	-0.3	1.82e-11	Pancreatic cancer;
LGG	cis	rs4950322	0.570	rs17356184	chr1:146734601	A/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs329674	0.556	rs55807834	chr11:133769957	T/C	cg06766960	chr11:133703094	NA	-0.65	-7.54	-0.33	2.54e-13	Bipolar disorder;
LGG	trans	rs61931739	0.517	rs11053063	chr12:34181011	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg26554054	chr8:600488	NA	-0.85	-8.5	-0.37	2.59e-16	IgG glycosylation;
LGG	cis	rs9393777	0.528	rs34843552	chr6:27241915	A/G	cg12292205	chr6:26970375	C6orf41	-0.59	-9.69	-0.41	2.37e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.666	rs7748669	chr6:109745342	A/G	cg16315928	chr6:109776240	MICAL1	0.42	7.19	0.32	2.6e-12	Height;
LGG	cis	rs7633770	0.786	rs1520488	chr3:46677459	C/T	cg11219411	chr3:46661640	NA	0.57	13.77	0.54	2.1e-36	Coronary artery disease;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg03709012	chr19:19516395	GATAD2A	0.82	15.59	0.59	2.34e-44	Tonsillectomy;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23446514	chr15:66797150	ZWILCH;SNORD18A;RPL4	0.59	6.68	0.3	6.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg06074448	chr4:187884817	NA	-0.58	-12.72	-0.51	5.16e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	cis	rs2658782	0.547	rs3020052	chr11:93055184	C/G	cg15737290	chr11:93063684	CCDC67	0.66	10.92	0.45	7.25e-25	Pulmonary function decline;
LGG	cis	rs8077889	0.871	rs11079838	chr17:41898971	G/A	cg26893861	chr17:41843967	DUSP3	0.9	15.65	0.59	1.3e-44	Triglycerides;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01044731	chr13:24554006	NA	0.41	7.16	0.32	3.26e-12	Bilirubin levels;
LGG	cis	rs13053817	0.948	rs67613029	chr22:29836569	T/A	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.43	-6.71	-0.3	5.62e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs368123	1.000	rs442426	chr6:160721106	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs9543976	1.000	rs9573592	chr13:76197843	G/A	cg01531495	chr13:76123901	UCHL3	-0.64	-7.42	-0.33	5.53e-13	Diabetic retinopathy;
LGG	cis	rs62238980	0.614	rs74450300	chr22:32403780	C/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4787491	0.729	rs11150584	chr16:30039678	C/A	cg06326092	chr16:30034487	C16orf92	0.42	8.37	0.36	6.99e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg05091796	chr16:4465799	CORO7	-0.75	-12.53	-0.5	3.29e-31	Schizophrenia;
LGG	cis	rs9425766	0.640	rs61827925	chr1:173831757	A/T	cg06124660	chr1:173389066	NA	-0.43	-7.23	-0.32	1.99e-12	Life satisfaction;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg23302884	chr18:44338147	ST8SIA5	0.44	8.7	0.37	5.88e-17	Personality dimensions;
LGG	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.03	0.39	4.75e-18	Motion sickness;
LGG	cis	rs7216064	1.000	rs8079754	chr17:65887896	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.11	-0.39	2.56e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs3617	0.573	rs6795646	chr3:52922621	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-7.81	-0.34	3.9e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4595586	0.545	rs12815047	chr12:39380901	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-20.26	-0.69	8.11e-66	Cognitive function;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg17202724	chr17:61916730	SMARCD2	0.62	15.36	0.58	2.61e-43	Prudent dietary pattern;
LGG	cis	rs67478160	0.643	rs11160762	chr14:104255083	A/G	cg26031613	chr14:104095156	KLC1	0.44	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg18446336	chr7:2847575	GNA12	-0.31	-8.2	-0.36	2.46e-15	Height;
LGG	cis	rs7619833	0.542	rs35536598	chr3:27518167	C/A	cg02860705	chr3:27208620	NA	0.45	8.59	0.37	1.35e-16	Breast cancer;
LGG	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.81	-0.38	2.46e-17	Eosinophil percentage of white cells;
LGG	cis	rs7789940	0.904	rs6948661	chr7:75961647	T/C	cg10167463	chr7:75959203	YWHAG	-0.47	-7.91	-0.35	1.89e-14	Multiple sclerosis;
LGG	cis	rs577948	0.770	rs488062	chr11:122050913	A/G	cg27212940	chr11:122074089	LOC399959	-0.34	-6.83	-0.3	2.72e-11	Myopia (pathological);
LGG	cis	rs2635047	0.542	rs1512235	chr18:44781569	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	7.81	0.34	3.76e-14	Educational attainment;
LGG	cis	rs9309473	1.000	rs6711033	chr2:73746643	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.54	-0.33	2.48e-13	Metabolite levels;
LGG	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg10523679	chr1:76189770	ACADM	-0.81	-17.3	-0.63	4.59e-52	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-9.09	-0.39	2.82e-18	Bipolar disorder;
LGG	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg01557791	chr16:72042693	DHODH	-0.55	-8.53	-0.37	2.15e-16	Blood protein levels;
LGG	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	17.39	0.63	1.64e-52	Smoking behavior;
LGG	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg11693508	chr17:37793320	STARD3	0.62	9.35	0.4	3.88e-19	Bipolar disorder;
LGG	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.16	-0.35	3.3e-15	Neuroticism;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.7e-12	Electroencephalogram traits;
LGG	trans	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.7	7.71	0.34	7.5e-14	Initial pursuit acceleration;
LGG	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg11644478	chr21:40555479	PSMG1	-0.6	-10.14	-0.43	5.83e-22	Menarche (age at onset);
LGG	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg05623727	chr3:50126028	RBM5	-0.38	-8.44	-0.37	4.15e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00761968	chr13:53314142	LECT1	0.35	7.33	0.32	1e-12	Lewy body disease;
LGG	cis	rs2247341	0.928	rs2854916	chr4:1721348	G/A	cg08629884	chr4:1719983	TMEM129	-0.57	-11.11	-0.46	1.38e-25	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs60695258	1.000	rs17605615	chr4:87996745	G/A	cg11209507	chr4:87813803	C4orf36	0.43	6.94	0.31	1.3e-11	Hematocrit;
LGG	cis	rs8016982	0.662	rs7144005	chr14:81656437	C/T	cg01989461	chr14:81687754	GTF2A1	0.58	9.07	0.39	3.45e-18	Schizophrenia;
LGG	cis	rs9394152	0.845	rs9366823	chr6:33471059	C/T	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.75e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.33e-23	Bipolar disorder;
LGG	cis	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg04455712	chr21:45112962	RRP1B	-0.53	-9.91	-0.42	3.9e-21	Mean corpuscular volume;
LGG	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg08344181	chr3:125677491	NA	-0.67	-8.06	-0.35	6.64e-15	Depression;
LGG	trans	rs9467711	0.651	rs16891261	chr6:26062631	A/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.27	-0.32	1.49e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg00717180	chr2:96193071	NA	0.4	7.13	0.31	3.83e-12	Coronary artery disease;
LGG	cis	rs12200560	0.505	rs2015196	chr6:97075331	G/C	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg26384229	chr12:38710491	ALG10B	0.73	14.34	0.55	7.66e-39	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs17711722	0.565	rs4275112	chr7:65198619	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.61	-13.81	-0.54	1.37e-36	Calcium levels;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg27286069	chr11:118481882	PHLDB1	-0.52	-9.35	-0.4	3.89e-19	Cholesterol, total;
LGG	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg05768032	chr16:30646687	NA	0.43	7.19	0.32	2.62e-12	Multiple myeloma;
LGG	cis	rs6912958	0.712	rs6454641	chr6:88371060	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.46	-0.37	3.57e-16	Monocyte percentage of white cells;
LGG	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.16e-13	Height;
LGG	cis	rs7394190	0.748	rs12572278	chr10:75504513	C/A	cg07699608	chr10:75541558	CHCHD1	0.56	7.21	0.32	2.35e-12	Incident atrial fibrillation;
LGG	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg24060327	chr5:131705240	SLC22A5	-0.46	-7.76	-0.34	5.39e-14	Blood metabolite levels;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg00830817	chr11:109293614	C11orf87	-0.6	-9.83	-0.42	7.46e-21	Schizophrenia;
LGG	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg16473166	chr22:50639996	SELO	0.64	9.71	0.41	2.01e-20	Late-onset Alzheimer's disease;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg18105134	chr13:113819100	PROZ	-0.69	-14.17	-0.55	4.22e-38	Platelet distribution width;
LGG	cis	rs10904908	1.000	rs7920112	chr10:17259863	T/C	cg01003015	chr10:17271136	VIM	-0.54	-8.86	-0.38	1.68e-17	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07570687	chr10:102243282	WNT8B	0.44	7.42	0.33	5.57e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg21782813	chr7:2030301	MAD1L1	0.56	14.51	0.56	1.32e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs1595825	0.891	rs73054827	chr2:198649905	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg26031613	chr14:104095156	KLC1	0.58	9.2	0.39	1.23e-18	Reticulocyte count;
LGG	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg11764359	chr7:65958608	NA	0.64	9.85	0.42	6.65e-21	Aortic root size;
LGG	cis	rs4771450	0.925	rs7327351	chr13:103986195	A/C	cg02987523	chr13:103978230	NA	-0.33	-7.08	-0.31	5.53e-12	Uric acid levels;
LGG	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-13.19	-0.52	6.05e-34	Morning vs. evening chronotype;
LGG	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs439731	0.518	rs2260241	chr16:1075147	G/A	cg08273874	chr16:1060765	NA	-0.79	-10.07	-0.42	1.08e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg17211192	chr8:82754475	SNX16	-0.73	-12.35	-0.5	1.82e-30	Diastolic blood pressure;
LGG	cis	rs9419702	0.538	rs9322837	chr10:133539229	G/A	cg04492858	chr10:133558786	NA	0.39	7.45	0.33	4.55e-13	Survival in rectal cancer;
LGG	cis	rs2522056	0.808	rs1016988	chr5:131744574	T/C	cg07395648	chr5:131743802	NA	0.41	6.85	0.3	2.31e-11	Lymphocyte counts;Fibrinogen;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg04287289	chr16:89883240	FANCA	0.75	7.24	0.32	1.86e-12	Skin colour saturation;
LGG	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg20587970	chr11:113659929	NA	-1.35	-24.2	-0.75	3.28e-84	Hip circumference adjusted for BMI;
LGG	trans	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg21775007	chr8:11205619	TDH	-0.41	-6.73	-0.3	5.07e-11	Systolic blood pressure;
LGG	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg03264133	chr6:25882463	NA	-0.68	-12.72	-0.51	5.15e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.812	rs73073337	chr3:41837497	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs17767392	0.670	rs2159145	chr14:71726351	T/C	cg02058870	chr14:72053146	SIPA1L1	0.34	7.18	0.32	2.82e-12	Mitral valve prolapse;
LGG	cis	rs13314892	0.843	rs58529025	chr3:69843262	T/C	cg17445875	chr3:69859618	MITF	-0.37	-7.45	-0.33	4.52e-13	QRS complex (12-leadsum);
LGG	cis	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg08807101	chr21:30365312	RNF160	-0.68	-11.67	-0.48	8.89e-28	Cognitive test performance;
LGG	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg20503657	chr10:835505	NA	0.95	12.76	0.51	3.58e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.48e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg10523679	chr1:76189770	ACADM	0.72	10.83	0.45	1.62e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.04	0.46	2.49e-25	Tonsillectomy;
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg03808351	chr9:123631620	PHF19	0.29	7.21	0.32	2.37e-12	Birth weight;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg24253500	chr15:84953950	NA	0.42	7.1	0.31	4.88e-12	Schizophrenia;
LGG	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27286337	chr10:134555280	INPP5A	0.83	12.07	0.49	2.39e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg14055004	chr2:241860995	NA	0.29	7.75	0.34	5.81e-14	Joint mobility (Beighton score);
LGG	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22857025	chr5:266934	NA	-1.49	-26.17	-0.77	2.46e-93	Breast cancer;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.68	-0.37	6.73e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7584330	0.704	rs7598954	chr2:238364776	C/T	cg16989719	chr2:238392110	NA	-0.34	-6.71	-0.3	5.85e-11	Prostate cancer;
LGG	cis	rs8180040	0.966	rs11711824	chr3:47468261	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.57	-0.59	3.03e-44	Colorectal cancer;
LGG	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.81	-0.48	2.51e-28	Response to antipsychotic treatment;
LGG	cis	rs11264213	0.901	rs72661641	chr1:36448130	A/G	cg27506609	chr1:36549197	TEKT2	0.83	8.38	0.36	6.37e-16	Schizophrenia;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg11211951	chr8:145729740	GPT	-0.58	-13.63	-0.53	8.7e-36	Age at first birth;
LGG	cis	rs6430585	0.528	rs115553816	chr2:136692893	G/A	cg07169764	chr2:136633963	MCM6	1.23	22.62	0.72	7.26e-77	Corneal structure;
LGG	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg06917634	chr15:78832804	PSMA4	-0.82	-17.35	-0.63	2.62e-52	Sudden cardiac arrest;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08280861	chr8:58055591	NA	0.64	8.1	0.35	4.95e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg19774624	chr17:42201019	HDAC5	0.85	16.54	0.61	1.21e-48	Total body bone mineral density;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg20887711	chr4:1340912	KIAA1530	0.91	20.24	0.69	1.04e-65	Longevity;
LGG	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2120243	0.539	rs4679793	chr3:157122661	A/C	cg24825693	chr3:157122686	VEPH1	0.58	13.37	0.53	1.09e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg13770153	chr20:60521292	NA	-0.47	-7.76	-0.34	5.56e-14	Body mass index;
LGG	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs7077256	0.564	rs12772006	chr10:65117845	A/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.95	-0.31	1.27e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.89	0.42	4.88e-21	Common traits (Other);
LGG	cis	rs3820068	0.705	rs4646031	chr1:15834648	A/G	cg05660106	chr1:15850417	CASP9	1.09	26.9	0.78	1.09e-96	Systolic blood pressure;
LGG	cis	rs11098499	0.863	rs11731756	chr4:120478696	T/G	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.92e-26	Corneal astigmatism;
LGG	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg08000102	chr2:233561755	GIGYF2	-0.62	-9.37	-0.4	3.32e-19	Schizophrenia;
LGG	cis	rs6809651	0.524	rs1356291	chr3:185824644	C/T	cg00760338	chr3:185826511	ETV5	0.93	15.55	0.59	3.69e-44	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs1719271	0.908	rs1684050	chr15:65198172	C/G	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.14	-0.32	3.58e-12	Platelet count;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg05313129	chr8:58192883	C8orf71	-0.79	-12.04	-0.49	3.19e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09823679	chr13:53425813	NA	-0.47	-6.79	-0.3	3.55e-11	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.18e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6426558	0.537	rs12139758	chr1:227260519	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	10.21	0.43	3.43e-22	Neutrophil percentage of white cells;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg07511668	chr11:68622177	NA	0.52	9.95	0.42	2.89e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg00578828	chr5:131826934	IRF1	0.41	7.43	0.33	5.3e-13	Asthma (sex interaction);
LGG	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.47	-11.32	-0.47	2.07e-26	Oropharynx cancer;
LGG	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-8.97	-0.38	7.25e-18	Kawasaki disease;
LGG	trans	rs3942852	0.774	rs924715	chr11:48181060	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs698833	0.813	rs3768919	chr2:44512971	C/T	cg00619915	chr2:44497795	NA	-0.45	-6.77	-0.3	3.84e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.67	0.63	8.48e-54	Platelet count;
LGG	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.98	-0.74	3.25e-83	Height;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.94	-0.35	1.53e-14	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.3e-12	Lung cancer;
LGG	cis	rs7572644	0.640	rs4666015	chr2:28019367	G/A	cg27432699	chr2:27873401	GPN1	0.48	6.86	0.3	2.28e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs6539288	0.803	rs7305715	chr12:107326552	G/A	cg26297688	chr12:107349093	C12orf23	-0.37	-7.05	-0.31	6.67e-12	Total body bone mineral density;
LGG	cis	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg06521331	chr12:34319734	NA	-0.4	-6.92	-0.31	1.5e-11	Morning vs. evening chronotype;
LGG	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.82	-0.3	2.92e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs62400317	0.762	rs62436375	chr6:44875818	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs7246760	0.867	rs67634928	chr19:9802397	C/G	cg16876255	chr19:9731953	ZNF561	0.84	7.84	0.34	3.06e-14	Pursuit maintenance gain;
LGG	cis	rs892085	0.654	rs8106691	chr19:10889469	C/A	cg17710535	chr19:10819994	QTRT1	0.5	8.96	0.38	8.12e-18	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs2455601	0.786	rs2568070	chr11:8976893	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-10.0	-0.42	1.83e-21	Schizophrenia;
LGG	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.82	-0.78	2.62e-96	Height;
LGG	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.85	-0.48	1.75e-28	Total body bone mineral density;
LGG	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.15	-26.01	-0.77	1.35e-92	Primary sclerosing cholangitis;
LGG	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg25174290	chr11:3078921	CARS	0.75	15.8	0.59	2.81e-45	Longevity;
LGG	cis	rs7301826	1.000	rs7301826	chr12:131291101	C/T	cg11011512	chr12:131303247	STX2	0.35	7.58	0.33	1.85e-13	Plasma plasminogen activator levels;
LGG	cis	rs968451	0.547	rs738331	chr22:39714216	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.97	22.61	0.72	7.84e-77	Primary biliary cholangitis;
LGG	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.45	6.67	0.3	7.34e-11	Gut microbiome composition (summer);
LGG	cis	rs1003719	0.788	rs59637309	chr21:38475398	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs4973397	0.509	rs10191571	chr2:232279975	C/A	cg18859089	chr2:232277014	NA	0.56	9.78	0.41	1.19e-20	Anti-saccade response;
LGG	cis	rs35160687	0.644	rs2367232	chr2:86541491	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.72	0.3	5.47e-11	Night sleep phenotypes;
LGG	cis	rs6901004	0.716	rs35312643	chr6:111574536	C/A	cg15721981	chr6:111408429	SLC16A10	0.45	7.87	0.34	2.5e-14	Blood metabolite levels;
LGG	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg19847130	chr8:10466454	RP1L1	-0.32	-7.27	-0.32	1.55e-12	Mood instability;
LGG	cis	rs7552404	0.731	rs1770887	chr1:76401812	A/G	cg22875332	chr1:76189707	ACADM	-0.58	-8.87	-0.38	1.63e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6062788	0.811	rs6011581	chr20:61698889	G/A	cg04883260	chr20:61718941	NA	0.31	6.83	0.3	2.6e-11	Body mass index;
LGG	cis	rs4851266	1.000	rs11686280	chr2:100827718	C/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	5.09e-15	Educational attainment;
LGG	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	11.97	0.49	5.72e-29	Systolic blood pressure;
LGG	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg24642439	chr20:33292090	TP53INP2	0.66	11.58	0.47	2.16e-27	Coronary artery disease;
LGG	cis	rs10504073	0.584	rs115370638	chr8:49916452	A/G	cg00325661	chr8:49890786	NA	0.81	16.31	0.6	1.42e-47	Blood metabolite ratios;
LGG	cis	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg15148918	chr7:75625777	STYXL1	-0.7	-8.0	-0.35	9.72e-15	Mononucleosis;
LGG	cis	rs6977660	0.714	rs2390156	chr7:19786138	A/T	cg07541023	chr7:19748670	TWISTNB	0.59	8.18	0.36	2.71e-15	Thyroid stimulating hormone;
LGG	cis	rs6028335	0.674	rs66476511	chr20:37605303	T/A	cg16355469	chr20:37678765	NA	0.6	7.92	0.35	1.75e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs6466055	0.748	rs9640686	chr7:104867330	T/G	cg04380332	chr7:105027541	SRPK2	0.38	7.03	0.31	7.65e-12	Schizophrenia;
LGG	cis	rs2070488	0.965	rs2366123	chr3:38493153	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.19	0.65	3.66e-56	Electrocardiographic conduction measures;
LGG	cis	rs8061903	0.682	rs12596722	chr16:9417288	G/T	cg03762483	chr16:10274847	GRIN2A	-0.41	-7.4	-0.33	6.49e-13	HIV-1 viral setpoint;
LGG	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg05535760	chr7:792225	HEATR2	0.93	14.46	0.56	2.34e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs2354432	0.546	rs11240030	chr1:146882616	G/A	cg25205988	chr1:146714368	CHD1L	1.24	14.67	0.56	2.66e-40	Mitochondrial DNA levels;
LGG	cis	rs7166081	1.000	rs8030620	chr15:67620665	G/A	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.81e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs571497	0.583	rs4804809	chr19:7835977	G/A	cg00970558	chr19:7854469	CLEC4GP1	0.69	7.64	0.33	1.23e-13	Monocyte count;
LGG	cis	rs1111571	0.557	rs1868157	chr16:68403654	G/C	cg07273125	chr16:68295692	NA	0.37	8.1	0.35	4.78e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.64	-0.33	1.25e-13	Longevity;Endometriosis;
LGG	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg05147244	chr20:61493195	TCFL5	0.77	7.52	0.33	2.89e-13	Obesity-related traits;
LGG	cis	rs35771425	1.000	rs12569232	chr1:211553064	G/C	cg10512769	chr1:211675356	NA	-0.74	-11.77	-0.48	3.66e-28	Educational attainment (years of education);
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.6	0.59	2.1e-44	Prostate cancer;
LGG	cis	rs11671005	0.735	rs11668420	chr19:58937836	G/A	cg13877915	chr19:58951672	ZNF132	0.61	8.67	0.37	7.3e-17	Mean platelet volume;
LGG	cis	rs6942756	1.000	rs2103232	chr7:128951232	G/T	cg02491457	chr7:128862824	NA	-0.75	-13.63	-0.54	8.66e-36	White matter hyperintensity burden;
LGG	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs1950500	0.545	rs1950501	chr14:24806800	C/G	cg22990158	chr14:24802150	ADCY4	-0.3	-6.69	-0.3	6.44e-11	Height;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	6.69	0.3	6.64e-11	Schizophrenia;
LGG	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs806215	0.547	rs10487497	chr7:127400667	C/T	cg25922125	chr7:127225783	GCC1	0.48	7.09	0.31	5.18e-12	Type 2 diabetes;
LGG	cis	rs367943	0.712	rs10062004	chr5:112694914	T/C	cg12552261	chr5:112820674	MCC	0.58	10.43	0.44	5.16e-23	Type 2 diabetes;
LGG	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg25866889	chr13:114914595	NA	-0.34	-6.77	-0.3	3.94e-11	Schizophrenia;
LGG	cis	rs758324	0.947	rs6596041	chr5:131198860	C/T	cg06307176	chr5:131281290	NA	0.59	9.69	0.41	2.38e-20	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.01	0.31	8.57e-12	Personality dimensions;
LGG	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg02753203	chr1:228287806	NA	0.78	15.08	0.57	4.2e-42	Diastolic blood pressure;
LGG	cis	rs2708377	0.929	rs73066828	chr12:11270654	A/C	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.79	-0.3	3.42e-11	Bitter taste perception;
LGG	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.32	0.55	8.72e-39	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12681287	0.640	rs13252046	chr8:87477751	G/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg00701064	chr4:6280414	WFS1	0.74	16.12	0.6	9.68e-47	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25437947	chr8:17941982	ASAH1	0.45	6.76	0.3	4.14e-11	Gut microbiome composition (summer);
LGG	cis	rs4256922	0.752	rs4497350	chr10:52499880	A/G	cg12289553	chr10:52500425	ASAH2B	-0.45	-8.47	-0.37	3.26e-16	Urate levels in lean individuals;
LGG	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg24375607	chr4:120327624	NA	0.68	11.2	0.46	6.05e-26	Corneal astigmatism;
LGG	cis	rs3771570	0.901	rs56129392	chr2:242242439	C/T	cg21155796	chr2:242212141	HDLBP	0.76	9.87	0.42	5.65e-21	Prostate cancer;
LGG	cis	rs11190604	0.767	rs11190520	chr10:102175309	T/C	cg07570687	chr10:102243282	WNT8B	0.4	7.06	0.31	6.08e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg20503657	chr10:835505	NA	0.75	10.35	0.43	1.03e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1801251	1.000	rs6437074	chr2:233712296	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-8.58	-0.37	1.48e-16	Coronary artery disease;
LGG	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06254406	chr13:103450982	BIVM;KDELC1	0.53	7.89	0.34	2.12e-14	Gut microbiome composition (summer);
LGG	cis	rs7666738	0.830	rs6819177	chr4:99040907	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17221829	0.733	rs10830326	chr11:89389110	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg11502198	chr6:26597334	ABT1	-0.92	-7.87	-0.34	2.46e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg14500267	chr11:67383377	NA	0.43	7.77	0.34	5.21e-14	Mean corpuscular volume;
LGG	cis	rs3540	0.597	rs1978149	chr15:91036976	A/G	cg22089800	chr15:90895588	ZNF774	0.69	12.75	0.51	4.06e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg17911788	chr17:44343683	NA	-0.6	-9.21	-0.39	1.12e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs4430311	0.723	rs2125231	chr1:243762299	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.51	-0.58	5.67e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1915146	0.546	rs2681919	chr10:126859029	A/G	cg23000734	chr10:126850823	CTBP2	0.25	7.31	0.32	1.16e-12	Menarche (age at onset);
LGG	cis	rs8017423	1.000	rs59052550	chr14:90665098	C/T	cg04374321	chr14:90722782	PSMC1	0.85	17.87	0.64	1.06e-54	Mortality in heart failure;
LGG	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg11812906	chr14:75593930	NEK9	0.53	9.72	0.41	1.91e-20	Height;
LGG	cis	rs12505749	0.542	rs12505939	chr4:57364210	T/C	cg07846311	chr4:57371927	ARL9	-0.32	-7.94	-0.35	1.53e-14	Airflow obstruction;
LGG	cis	rs4740619	0.716	rs7019851	chr9:15769551	A/G	cg14451791	chr9:16040625	NA	-0.35	-9.18	-0.39	1.49e-18	Body mass index;
LGG	trans	rs459571	0.959	rs465724	chr9:136910097	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.63	-10.37	-0.43	8.63e-23	Platelet distribution width;
LGG	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg22546130	chr22:19950026	COMT	0.42	9.98	0.42	2.2e-21	Blood metabolite levels;
LGG	cis	rs151997	1.000	rs152854	chr5:50223206	G/A	cg06027927	chr5:50259733	NA	-0.67	-10.71	-0.45	4.8e-24	Callous-unemotional behaviour;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01532694	chr8:8243576	NA	0.49	7.92	0.35	1.75e-14	Cognitive performance;
LGG	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg26384229	chr12:38710491	ALG10B	0.93	21.66	0.71	2.22e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6547741	0.874	rs58737572	chr2:27852118	A/C	cg22903471	chr2:27725779	GCKR	0.38	8.65	0.37	8.71e-17	Oral cavity cancer;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg00355188	chr10:134053962	STK32C	0.37	7.1	0.31	4.85e-12	Parkinson's disease (motor and cognition);
LGG	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg03264133	chr6:25882463	NA	-0.41	-7.19	-0.32	2.67e-12	Height;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs1015291	0.670	rs10841386	chr12:20010785	A/C	cg25401612	chr12:20009446	NA	0.35	7.43	0.33	5.45e-13	Diastolic blood pressure;
LGG	cis	rs9341808	0.718	rs9343978	chr6:80971978	A/G	cg08355045	chr6:80787529	NA	0.39	7.51	0.33	3.04e-13	Sitting height ratio;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg21821990	chr11:64795449	SNX15	0.41	6.76	0.3	4.27e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg00277334	chr10:82204260	NA	-0.35	-7.67	-0.34	1e-13	Post bronchodilator FEV1;
LGG	cis	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.7	-0.3	6.2e-11	Triglycerides;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg26655873	chr3:72818019	SHQ1	0.37	7.13	0.31	3.85e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg18196295	chr10:418757	DIP2C	0.62	12.28	0.5	3.5e-30	Psychosis in Alzheimer's disease;
LGG	cis	rs4330281	0.586	rs2596652	chr3:17368197	C/A	cg20981856	chr3:17787350	NA	0.36	6.94	0.31	1.29e-11	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26187219	chr5:52095812	ITGA1;PELO	0.48	8.07	0.35	5.99e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2717559	0.542	rs10956986	chr8:143886601	C/T	cg07661805	chr8:143867942	LY6D	-0.28	-7.72	-0.34	7.32e-14	Urinary tract infection frequency;
LGG	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg21055462	chr7:100276975	NA	0.45	9.36	0.4	3.38e-19	Other erythrocyte phenotypes;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.78	-13.82	-0.54	1.25e-36	Age at first birth;
LGG	cis	rs2762353	0.526	rs6901027	chr6:25709042	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.4	-6.9	-0.31	1.76e-11	Blood metabolite levels;
LGG	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.91	-0.35	1.9e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7172677	0.960	rs12917304	chr15:75406875	G/A	cg14664628	chr15:75095509	CSK	-0.47	-7.1	-0.31	4.76e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	10.93	0.45	6.68e-25	Lung cancer in ever smokers;
LGG	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg08989290	chr16:615782	NHLRC4	0.34	6.77	0.3	3.81e-11	Height;
LGG	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	11.27	0.46	3.23e-26	Menarche (age at onset);
LGG	cis	rs10875746	0.768	rs10875724	chr12:48420253	C/A	cg24011408	chr12:48396354	COL2A1	-0.51	-6.86	-0.3	2.21e-11	Longevity (90 years and older);
LGG	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg06634786	chr22:41940651	POLR3H	0.72	12.03	0.49	3.29e-29	Vitiligo;
LGG	cis	rs6835098	1.000	rs4695826	chr4:174089426	T/G	cg08422745	chr4:174089978	GALNT7	-0.87	-15.51	-0.58	5.32e-44	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.23	0.46	4.97e-26	Lymphocyte counts;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg21926883	chr2:100939477	LONRF2	-0.48	-9.41	-0.4	2.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs653465	0.739	rs11129263	chr3:27143527	A/G	cg02860705	chr3:27208620	NA	-0.4	-7.68	-0.34	9.77e-14	Breast cancer (early onset);
LGG	cis	rs9815354	1.000	rs1564716	chr3:41862613	A/G	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.67	-0.34	1.02e-13	Menarche (age at onset);
LGG	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.1	-0.43	8e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.52	-0.44	2.37e-23	Bladder cancer;
LGG	trans	rs79911532	0.515	rs116006876	chr7:75775918	G/C	cg19862616	chr7:65841803	NCRNA00174	0.73	7.63	0.33	1.32e-13	Mononucleosis;
LGG	trans	rs9650657	0.601	rs10903330	chr8:10673104	C/T	cg06636001	chr8:8085503	FLJ10661	0.38	6.92	0.31	1.5e-11	Neuroticism;
LGG	cis	rs2011503	1.000	rs16996127	chr19:19627310	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.23	0.32	2.03e-12	Bipolar disorder;
LGG	cis	rs6930083	0.527	rs9470367	chr6:36626932	G/C	cg08179530	chr6:36648295	CDKN1A	-0.57	-9.65	-0.41	3.31e-20	Coronary artery disease;
LGG	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.81	-0.34	3.93e-14	Triglycerides;
LGG	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg03060546	chr3:49711283	APEH	0.49	7.83	0.34	3.37e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs629535	0.814	rs614050	chr8:70065642	G/A	cg21567404	chr3:27674614	NA	0.4	6.74	0.3	4.86e-11	Dupuytren's disease;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04772025	chr11:68637568	NA	0.75	13.24	0.52	3.68e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg08280861	chr8:58055591	NA	0.54	6.9	0.31	1.73e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs858239	0.699	rs955187	chr7:23194605	A/G	cg23682824	chr7:23144976	KLHL7	-0.43	-7.36	-0.32	8.59e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7241530	0.585	rs12967211	chr18:75890753	A/G	cg14642773	chr18:75888474	NA	-0.45	-9.04	-0.39	4.22e-18	Educational attainment (years of education);
LGG	cis	rs8067545	0.750	rs4924805	chr17:19997205	C/G	cg09818912	chr17:20140352	CYTSB	-0.3	-6.91	-0.31	1.57e-11	Schizophrenia;
LGG	cis	rs9354308	0.764	rs9345703	chr6:66583609	G/A	cg07460842	chr6:66804631	NA	-0.41	-7.01	-0.31	8.6e-12	Metabolite levels;
LGG	cis	rs3796352	1.000	rs13072818	chr3:53074263	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	7.16	0.32	3.09e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg02466173	chr16:30829666	NA	-0.54	-9.78	-0.41	1.14e-20	Multiple myeloma;
LGG	cis	rs2953174	0.744	rs2975748	chr2:241518989	A/G	cg07929629	chr2:241523174	NA	0.56	7.78	0.34	4.72e-14	Bipolar disorder;
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg02297831	chr4:17616191	MED28	0.48	8.83	0.38	2.15e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.26e-23	Ulcerative colitis;
LGG	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs10751667	0.621	rs4075990	chr11:976614	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg06360820	chr2:242988706	NA	-0.88	-10.95	-0.45	5.82e-25	Obesity-related traits;
LGG	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.28e-13	HDL cholesterol;
LGG	cis	rs9354308	0.764	rs9345712	chr6:66591479	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11416447	chr7:86781551	DMTF1	0.37	6.71	0.3	5.8e-11	Bipolar disorder;
LGG	cis	rs3857067	0.806	rs4693374	chr4:95086164	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.76	-0.34	5.39e-14	QT interval;
LGG	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18252515	chr7:66147081	NA	0.46	7.59	0.33	1.76e-13	Aortic root size;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.48	-0.69	7.5e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2075371	0.966	rs1901204	chr7:133985896	A/G	cg11752832	chr7:134001865	SLC35B4	0.62	11.32	0.47	2.17e-26	Mean platelet volume;
LGG	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.34	7.25	0.32	1.72e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs1371614	0.610	rs12615509	chr2:27098766	G/A	cg12045002	chr2:27069975	DPYSL5	-0.31	-6.66	-0.3	7.75e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg24375607	chr4:120327624	NA	0.4	6.65	0.3	8.13e-11	Diastolic blood pressure;
LGG	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg23173402	chr1:227635558	NA	0.57	8.98	0.39	7.02e-18	Major depressive disorder;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg22907277	chr7:1156413	C7orf50	0.64	11.41	0.47	9.29e-27	Longevity;Endometriosis;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7267979	1.000	rs6083844	chr20:25386832	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.12	-0.43	7.09e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21963583	chr11:68658836	MRPL21	-0.55	-9.61	-0.41	4.57e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.77	14.26	0.55	1.62e-38	Alzheimer's disease;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg09623771	chr7:99717157	TAF6;CNPY4	-0.44	-6.79	-0.3	3.38e-11	Alzheimer's disease (survival time);
LGG	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs4470077	1.000	rs7156648	chr14:55898399	A/G	cg04306507	chr14:55594613	LGALS3	0.37	6.7	0.3	6.23e-11	Platelet count;
LGG	cis	rs4919087	0.748	rs701816	chr10:98977250	C/T	cg25902810	chr10:99078978	FRAT1	-0.43	-7.29	-0.32	1.35e-12	Monocyte count;
LGG	cis	rs9398803	0.678	rs4380768	chr6:126867351	G/C	cg19875578	chr6:126661172	C6orf173	0.51	9.32	0.4	4.79e-19	Male-pattern baldness;
LGG	cis	rs11203032	0.831	rs10788635	chr10:90927063	A/G	cg16672925	chr10:90967113	CH25H	0.52	8.09	0.35	5.41e-15	Heart failure;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.31	-0.43	1.38e-22	Lung cancer;
LGG	cis	rs600550	0.588	rs10897049	chr11:60100581	C/T	cg05040360	chr11:60102449	MS4A6E	-0.35	-7.68	-0.34	9.8e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs34599045	0.522	rs77702899	chr1:152968025	C/G	cg07796016	chr1:152779584	LCE1C	-0.91	-7.56	-0.33	2.12e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg16077055	chr2:106428750	NCK2	0.33	8.75	0.38	3.99e-17	Addiction;
LGG	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg05775895	chr3:12838266	CAND2	0.66	11.87	0.48	1.5e-28	QRS complex (12-leadsum);
LGG	cis	rs17767392	0.918	rs3784062	chr14:72090505	T/G	cg02058870	chr14:72053146	SIPA1L1	-0.48	-9.3	-0.4	5.42e-19	Mitral valve prolapse;
LGG	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg27205649	chr11:78285834	NARS2	-0.44	-7.26	-0.32	1.62e-12	Testicular germ cell tumor;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg22907277	chr7:1156413	C7orf50	0.68	12.56	0.5	2.46e-31	Longevity;Endometriosis;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7224668	0.647	rs8070092	chr17:79246818	A/C	cg03823431	chr17:79229385	SLC38A10	0.35	7.59	0.33	1.75e-13	IgG glycosylation;
LGG	cis	rs1348850	0.526	rs1345138	chr2:178387100	A/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.61	-0.33	1.54e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg00857998	chr1:205179979	DSTYK	0.47	7.55	0.33	2.36e-13	Red blood cell count;
LGG	cis	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg21775007	chr8:11205619	TDH	-0.6	-9.5	-0.4	1.16e-19	Retinal vascular caliber;
LGG	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.4	0.33	6.3e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs62380364	0.542	rs2247885	chr5:88047999	T/C	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs13202913	0.837	rs9397054	chr6:151789912	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.62	7.13	0.31	3.91e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.62	0.41	4.14e-20	Colorectal cancer;
LGG	cis	rs6430585	0.528	rs56064699	chr2:136595706	G/A	cg07169764	chr2:136633963	MCM6	1.29	26.01	0.77	1.32e-92	Corneal structure;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9487051	0.837	rs9480920	chr6:109605322	C/A	cg12927641	chr6:109611667	NA	-0.37	-7.16	-0.32	3.15e-12	Reticulocyte fraction of red cells;
LGG	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.28	-0.4	6.64e-19	Body mass index;
LGG	cis	rs6087990	0.965	rs2424899	chr20:31343543	A/C	cg13636640	chr20:31349939	DNMT3B	1.01	21.96	0.71	8.89e-74	Ulcerative colitis;
LGG	cis	rs6430585	0.697	rs7607174	chr2:136513670	T/A	cg07169764	chr2:136633963	MCM6	1.27	24.14	0.75	5.96e-84	Corneal structure;
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg02725872	chr8:58115012	NA	-0.76	-10.87	-0.45	1.11e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg07636037	chr3:49044803	WDR6	1.1	28.22	0.8	1.19e-102	Parkinson's disease;
LGG	cis	rs7010267	0.602	rs7822098	chr8:120020129	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.87	0.38	1.61e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs55788414	0.932	rs34444956	chr16:81185412	C/T	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2693698	0.502	rs807734	chr14:99688670	C/T	cg07440398	chr14:99712966	BCL11B	0.48	9.85	0.42	6.71e-21	Schizophrenia;
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg11494091	chr17:61959527	GH2	0.51	8.33	0.36	9.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4774899	0.934	rs12910832	chr15:57471792	A/C	cg08128148	chr15:57256372	TCF12	-0.32	-7.64	-0.33	1.28e-13	Urinary tract infection frequency;
LGG	cis	rs10463316	0.894	rs6891252	chr5:150762807	G/T	cg03212797	chr5:150827313	SLC36A1	-0.61	-10.8	-0.45	2.19e-24	Metabolite levels (Pyroglutamine);
LGG	cis	rs4731207	0.698	rs10228682	chr7:124538036	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs35740288	0.787	rs11637768	chr15:86223410	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.09	0.35	5.21e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs847577	0.748	rs940431	chr7:97716495	C/T	cg13397024	chr7:97797637	LMTK2	-0.36	-6.88	-0.3	2.01e-11	Breast cancer;
LGG	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg26384229	chr12:38710491	ALG10B	0.85	18.43	0.65	2.76e-57	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	31.82	0.83	1.38e-118	Chronic sinus infection;
LGG	cis	rs12618769	0.656	rs3769735	chr2:99092302	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.41e-16	Bipolar disorder;
LGG	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg21452805	chr1:244014465	NA	-0.59	-7.24	-0.32	1.94e-12	RR interval (heart rate);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg19318889	chr4:1322082	MAEA	-0.48	-8.35	-0.36	8e-16	Longevity;
LGG	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.97	0.42	2.39e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-7.31	-0.32	1.22e-12	Subjective well-being;
LGG	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	4.97e-87	Height;
LGG	cis	rs2692947	0.702	rs6717101	chr2:96505552	C/T	cg22654517	chr2:96458247	NA	0.36	7.6	0.33	1.65e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs174601	0.582	rs108499	chr11:61547237	C/T	cg19610905	chr11:61596333	FADS2	-0.72	-12.55	-0.5	2.79e-31	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	trans	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-15.47	-0.58	8.04e-44	Blood pressure (smoking interaction);
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg02002194	chr4:3960332	NA	0.4	6.97	0.31	1.12e-11	Triglycerides;
LGG	cis	rs1577917	0.518	rs2475787	chr6:86415236	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	7.15	0.32	3.39e-12	Response to antipsychotic treatment;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg17663101	chr3:49131524	QRICH1	0.39	6.77	0.3	3.84e-11	Bilirubin levels;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.8	-0.48	2.8e-28	Height;
LGG	cis	rs72925845	0.519	rs1627621	chr17:76426988	A/G	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg19992207	chr2:111874495	ACOXL	-0.4	-7.46	-0.33	4.28e-13	Chronic lymphocytic leukemia;
LGG	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg10326726	chr10:51549505	MSMB	-0.64	-12.75	-0.51	3.89e-32	Prostate-specific antigen levels;
LGG	trans	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-13.07	-0.52	1.84e-33	Obesity-related traits;
LGG	cis	rs9309473	1.000	rs9653557	chr2:73795962	A/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg05863683	chr7:1912471	MAD1L1	-0.38	-7.24	-0.32	1.94e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg11859384	chr17:80120422	CCDC57	0.46	8.02	0.35	8.48e-15	Life satisfaction;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.61	-0.44	1.08e-23	Intelligence (multi-trait analysis);
LGG	cis	rs365132	0.715	rs181330	chr5:176404962	A/G	cg16309518	chr5:176445507	NA	-0.5	-11.08	-0.46	1.74e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.23	0.46	4.82e-26	Lymphocyte counts;
LGG	cis	rs6467136	0.540	rs56216302	chr7:127180679	G/A	cg25922125	chr7:127225783	GCC1	-0.45	-6.83	-0.3	2.61e-11	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg27400746	chr16:89904261	SPIRE2	-1.05	-15.41	-0.58	1.53e-43	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08515713	chr11:64037528	BAD	0.44	7.06	0.31	6.07e-12	Cognitive performance;
LGG	cis	rs7168592	1.000	rs34748909	chr15:101731509	A/C	cg24254196	chr15:101719523	CHSY1	-0.68	-7.6	-0.33	1.61e-13	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.08e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg03352830	chr11:487213	PTDSS2	-0.62	-8.98	-0.39	6.86e-18	Body mass index;
LGG	cis	rs9733	0.687	rs11204735	chr1:150841667	T/C	cg13175981	chr1:150552382	MCL1	0.53	8.58	0.37	1.43e-16	Tonsillectomy;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.89	-0.38	1.36e-17	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.77	0.84	1.05e-122	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-8.03	-0.35	8.12e-15	Skin colour saturation;
LGG	cis	rs62244186	0.566	rs6766221	chr3:44882784	C/T	cg02073558	chr3:44770973	ZNF501	0.84	18.24	0.65	1.99e-56	Depressive symptoms;
LGG	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs5744897	0.708	rs4883582	chr12:133242733	C/A	cg17341477	chr12:133246679	POLE	0.58	6.87	0.3	2.07e-11	Urate levels in overweight individuals;
LGG	cis	rs1451375	1.000	rs921450	chr7:50623260	A/G	cg00647317	chr7:50633725	DDC	0.34	7.56	0.33	2.19e-13	Malaria;
LGG	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.18	0.39	1.4e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg00757033	chr12:89920650	WDR51B	0.64	9.4	0.4	2.45e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-7.29	-0.32	1.35e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4363385	0.667	rs6675352	chr1:152936749	A/G	cg07796016	chr1:152779584	LCE1C	-0.46	-7.29	-0.32	1.35e-12	Inflammatory skin disease;
LGG	cis	rs721399	0.752	rs4921914	chr8:18272438	A/G	cg18736775	chr8:18248649	NAT2	-0.5	-8.38	-0.36	6.29e-16	Blood metabolite levels;
LGG	cis	rs12447804	0.871	rs2118018	chr16:58076422	A/G	cg03859792	chr16:58121049	NA	0.46	7.06	0.31	5.95e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg12070911	chr6:150209640	RAET1E	0.32	7.75	0.34	6.08e-14	Lung cancer;
LGG	trans	rs6787172	0.702	rs827179	chr3:157965389	T/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Vitiligo;
LGG	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg11693508	chr17:37793320	STARD3	-0.66	-9.7	-0.41	2.21e-20	Bipolar disorder;
LGG	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12505749	0.542	rs4340842	chr4:57338188	A/G	cg07846311	chr4:57371927	ARL9	-0.31	-7.73	-0.34	6.8e-14	Airflow obstruction;
LGG	trans	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.67	-12.52	-0.5	3.47e-31	Blood trace element (Cu levels);
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg06766960	chr11:133703094	NA	-0.57	-11.12	-0.46	1.23e-25	Childhood ear infection;
LGG	cis	rs9467773	0.620	rs2494692	chr6:26615223	G/A	cg11502198	chr6:26597334	ABT1	0.7	12.63	0.51	1.31e-31	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.19	-0.36	2.64e-15	Aortic root size;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg19507638	chr5:93509721	C5orf36	-0.64	-9.15	-0.39	1.75e-18	Diabetic retinopathy;
LGG	cis	rs2764208	0.535	rs9368829	chr6:34668442	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.44	7.61	0.33	1.56e-13	Systemic lupus erythematosus;
LGG	cis	rs921968	0.541	rs55996799	chr2:219558193	C/G	cg01130898	chr2:219473002	PLCD4	0.49	8.33	0.36	9.55e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg00405596	chr8:11794950	NA	0.64	11.13	0.46	1.13e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg01236616	chr12:121019343	POP5	-1.26	-21.99	-0.71	6.92e-74	Type 1 diabetes nephropathy;
LGG	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg11752832	chr7:134001865	SLC35B4	-0.52	-9.09	-0.39	2.86e-18	Mean platelet volume;
LGG	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg19812747	chr11:111475976	SIK2	-0.41	-8.66	-0.37	7.77e-17	Primary sclerosing cholangitis;
LGG	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.06	0.42	1.15e-21	Thyroid stimulating hormone;
LGG	trans	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg10756647	chr7:56101905	PSPH	0.78	8.59	0.37	1.37e-16	Diabetic kidney disease;
LGG	cis	rs9357271	0.955	rs9296249	chr6:38365841	C/T	cg07362130	chr6:38359646	BTBD9	0.43	9.27	0.4	7.02e-19	Restless legs syndrome;
LGG	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.94	-0.42	3.03e-21	Response to antipsychotic treatment;
LGG	trans	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg06521331	chr12:34319734	NA	0.5	9.25	0.39	8.15e-19	Bladder cancer;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25172604	chr17:41446521	NA	-0.31	-7.23	-0.32	2e-12	Menopause (age at onset);
LGG	cis	rs12949688	0.967	rs9905938	chr17:55824351	G/A	cg12582317	chr17:55822272	NA	0.69	19.53	0.67	2.07e-62	Schizophrenia;
LGG	trans	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg25214090	chr10:38739885	LOC399744	0.64	11.57	0.47	2.26e-27	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16362983	chr14:50335243	NA	0.45	7.18	0.32	2.72e-12	Cognitive performance;
LGG	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg02023728	chr11:77925099	USP35	0.45	8.04	0.35	7.81e-15	Testicular germ cell tumor;
LGG	cis	rs4950322	0.570	rs11800580	chr1:146732707	A/G	cg22381352	chr1:146742008	CHD1L	0.48	7.93	0.35	1.63e-14	Protein quantitative trait loci;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg06916706	chr16:4465613	CORO7	-0.84	-14.46	-0.56	2.22e-39	Schizophrenia;
LGG	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg00701064	chr4:6280414	WFS1	0.68	13.42	0.53	6.15e-35	Cisplatin-induced ototoxicity;
LGG	cis	rs6426558	0.537	rs6682642	chr1:227244600	G/T	cg10327440	chr1:227177885	CDC42BPA	0.62	10.44	0.44	4.71e-23	Neutrophil percentage of white cells;
LGG	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.15e-25	Homoarginine levels;
LGG	cis	rs6424115	1.000	rs34477640	chr1:24154067	T/C	cg15997130	chr1:24165203	NA	-0.48	-13.1	-0.52	1.43e-33	Immature fraction of reticulocytes;
LGG	cis	rs751728	1.000	rs6920075	chr6:33731797	C/T	cg25922239	chr6:33757077	LEMD2	0.67	11.55	0.47	2.65e-27	Crohn's disease;
LGG	cis	rs12586317	0.514	rs61100068	chr14:35400232	A/T	cg05294307	chr14:35346193	BAZ1A	-0.56	-7.61	-0.33	1.54e-13	Psoriasis;
LGG	cis	rs209489	1.000	rs209511	chr6:53203007	G/A	cg15607103	chr6:53167650	ELOVL5	-0.49	-7.17	-0.32	2.91e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.45e-12	Vitiligo;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	7.29	0.32	1.32e-12	Schizophrenia;
LGG	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg13207630	chr7:32358064	NA	0.73	7.89	0.34	2.18e-14	Body mass index;
LGG	cis	rs243505	0.660	rs243488	chr7:148446649	G/A	cg18940274	chr7:148469757	CUL1	0.37	6.79	0.3	3.38e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg25358565	chr5:93447407	FAM172A	1.28	15.96	0.6	5.5e-46	Diabetic retinopathy;
LGG	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.32	0.43	1.29e-22	Height;
LGG	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg06138931	chr13:21896616	NA	-0.45	-7.38	-0.32	7.34e-13	White matter hyperintensity burden;
LGG	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.54	-0.33	2.59e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1003719	0.751	rs10154032	chr21:38453459	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs7927771	0.832	rs1317164	chr11:47419757	G/T	cg20307385	chr11:47447363	PSMC3	-0.58	-10.59	-0.44	1.34e-23	Subjective well-being;
LGG	cis	rs17401966	0.838	rs12125535	chr1:10350849	T/A	cg19773385	chr1:10388646	KIF1B	-0.45	-9.77	-0.41	1.26e-20	Hepatocellular carcinoma;
LGG	cis	rs9816226	0.591	rs1516725	chr3:185824004	T/C	cg00760338	chr3:185826511	ETV5	0.84	10.42	0.44	5.44e-23	Obesity;Body mass index;
LGG	cis	rs10896135	0.554	rs3741364	chr11:66451178	C/T	cg01599099	chr11:66649832	PC	0.47	8.35	0.36	7.89e-16	Bipolar disorder;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03452623	chr4:187889614	NA	1.03	30.72	0.82	8.23e-114	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	12.96	0.52	5.59e-33	Mean platelet volume;
LGG	cis	rs7444	0.941	rs59391722	chr22:21920817	G/C	cg22858872	chr22:21984481	YDJC	-0.37	-6.73	-0.3	4.94e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-8.45	-0.37	3.68e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg24623649	chr8:11872141	NA	-0.31	-7.2	-0.32	2.39e-12	Triglycerides;
LGG	cis	rs35146811	0.844	rs13223792	chr7:99675659	T/G	cg13334819	chr7:99746414	C7orf59	-0.48	-7.54	-0.33	2.43e-13	Coronary artery disease;
LGG	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.38e-11	Schizophrenia;
LGG	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.67	-0.37	7.4e-17	Cognitive function;
LGG	cis	rs7095944	0.554	rs11245344	chr10:126418782	C/T	cg08799069	chr10:126477246	METTL10	-0.45	-10.46	-0.44	4.11e-23	Asthma;
LGG	cis	rs11025559	0.812	rs10766679	chr11:20509190	T/C	cg19653624	chr11:20408972	PRMT3	-0.5	-8.42	-0.36	4.6e-16	Pursuit maintenance gain;
LGG	cis	rs7444	0.825	rs738129	chr22:21971041	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs910316	0.967	rs2268619	chr14:75640354	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-9.74	-0.41	1.59e-20	Height;
LGG	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg08999081	chr20:33150536	PIGU	-0.4	-10.11	-0.43	7.93e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03452623	chr4:187889614	NA	-1.05	-28.3	-0.8	4.81e-103	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4664308	0.658	rs12987602	chr2:160960788	G/T	cg03641300	chr2:160917029	PLA2R1	-0.7	-13.38	-0.53	9.36e-35	Idiopathic membranous nephropathy;
LGG	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg03342759	chr3:160939853	NMD3	0.44	7.24	0.32	1.89e-12	Morning vs. evening chronotype;
LGG	cis	rs3087591	0.960	rs7212264	chr17:29454766	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	14.54	0.56	9.81e-40	Hip circumference;
LGG	cis	rs9300255	0.544	rs1716174	chr12:123660717	T/C	cg00376283	chr12:123451042	ABCB9	0.6	8.59	0.37	1.31e-16	Neutrophil percentage of white cells;
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22618164	chr12:122356400	WDR66	0.37	10.53	0.44	2.13e-23	Mean corpuscular volume;
LGG	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg17145862	chr1:211918768	LPGAT1	0.97	24.89	0.76	1.91e-87	Leprosy;
LGG	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg03929089	chr4:120376271	NA	-0.42	-6.69	-0.3	6.57e-11	HDL cholesterol;
LGG	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.27	-44.15	-0.9	4.77e-168	Myeloid white cell count;
LGG	cis	rs62238980	0.614	rs75426883	chr22:32434795	C/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7129556	0.954	rs2032395	chr11:77314503	A/G	cg12586386	chr11:77299805	AQP11	0.52	8.69	0.37	6.45e-17	Weight loss (gastric bypass surgery);
LGG	cis	rs13102973	0.965	rs4535381	chr4:135861313	A/T	cg14419869	chr4:135874104	NA	0.57	10.92	0.45	7.1e-25	Subjective well-being;
LGG	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg21211680	chr2:198530	NA	-1.17	-19.83	-0.68	8.61e-64	Blood protein levels;
LGG	cis	rs9921192	0.967	rs3747571	chr16:4323983	A/G	cg13035052	chr16:4323854	TFAP4	0.45	7.94	0.35	1.56e-14	Prostate-specific antigen levels;
LGG	cis	rs55788414	0.932	rs34110030	chr16:81185211	G/A	cg06400318	chr16:81190750	PKD1L2	-0.92	-10.96	-0.45	5.4e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg00599393	chr8:22457479	C8orf58	-0.41	-7.52	-0.33	2.91e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.31	0.36	1.04e-15	Personality dimensions;
LGG	trans	rs6011368	0.765	rs6062681	chr20:62891803	A/G	cg13869341	chr1:15865	WASH5P	0.53	9.54	0.41	7.88e-20	Clozapine-induced cytotoxicity;
LGG	cis	rs2013441	1.000	rs2526460	chr17:20086352	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.91	-0.31	1.63e-11	Caffeine consumption;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.62	0.56	4.48e-40	Platelet count;
LGG	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.75	0.54	2.54e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg13647721	chr17:30228624	UTP6	-0.76	-9.87	-0.42	5.36e-21	Hip circumference adjusted for BMI;
LGG	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.34	0.6	9.94e-48	Hip circumference adjusted for BMI;
LGG	cis	rs2236918	0.710	rs1635507	chr1:242028358	G/T	cg17736920	chr1:242011382	EXO1	0.51	9.29	0.4	5.97e-19	Menopause (age at onset);
LGG	cis	rs1451375	0.572	rs896309	chr7:50545022	A/G	cg20336341	chr7:50628841	DDC	-0.41	-7.12	-0.31	4.2e-12	Malaria;
LGG	cis	rs7264396	0.790	rs6060519	chr20:34217383	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.66	-0.34	1.12e-13	Total cholesterol levels;
LGG	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.35e-12	Schizophrenia;
LGG	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg00204512	chr16:28754710	NA	0.26	7.16	0.32	3.12e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs6598955	0.724	rs12096059	chr1:26596709	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.96	0.35	1.35e-14	Obesity-related traits;
LGG	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg21427119	chr20:30132790	HM13	-0.42	-6.97	-0.31	1.09e-11	Mean corpuscular hemoglobin;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.84e-21	Prudent dietary pattern;
LGG	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.39	7.87	0.34	2.45e-14	Hemoglobin concentration;
LGG	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	11.59	0.47	1.93e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.2	0.49	6.83e-30	Mean corpuscular volume;
LGG	cis	rs9393692	0.577	rs9358914	chr6:26262063	G/T	cg13736514	chr6:26305472	NA	-0.47	-8.67	-0.37	7.3e-17	Educational attainment;
LGG	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg18681998	chr4:17616180	MED28	0.82	17.89	0.64	8.99e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.15.979660F	chr15:65855109	PTPLAD1	0.37	6.8	0.3	3.27e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs826838	1.000	rs826888	chr12:39104719	C/G	cg26384229	chr12:38710491	ALG10B	-0.88	-20.81	-0.7	2.31e-68	Heart rate;
LGG	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg18196295	chr10:418757	DIP2C	0.64	13.03	0.52	2.85e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg12923728	chr3:195709715	SDHAP1	-0.8	-15.2	-0.58	1.27e-42	Pancreatic cancer;
LGG	cis	rs7843479	0.526	rs34802507	chr8:21773853	C/T	cg17168535	chr8:21777572	XPO7	0.74	14.04	0.55	1.51e-37	Mean corpuscular volume;
LGG	trans	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg00953403	chr17:74099816	EXOC7	-0.45	-7.39	-0.32	6.77e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs2991971	0.967	rs7526665	chr1:46005832	G/T	cg24296786	chr1:45957014	TESK2	0.4	6.97	0.31	1.11e-11	High light scatter reticulocyte count;
LGG	cis	rs7312933	1.000	rs3229	chr12:42475888	G/A	cg19980929	chr12:42632907	YAF2	0.35	7.77	0.34	5.19e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1538970	0.669	rs3219476	chr1:45802670	A/C	cg05343316	chr1:45956843	TESK2	-0.45	-7.68	-0.34	9.65e-14	Platelet count;
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg02353165	chr6:42928485	GNMT	0.48	13.94	0.54	3.99e-37	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg11887960	chr12:57824829	NA	0.56	6.91	0.31	1.61e-11	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs7659604	1.000	rs7659604	chr4:122665514	A/G	cg19748678	chr4:122722346	EXOSC9	-0.49	-9.18	-0.39	1.43e-18	Type 2 diabetes;
LGG	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg20336341	chr7:50628841	DDC	0.43	7.55	0.33	2.35e-13	Malaria;
LGG	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg04672837	chr16:48644449	N4BP1	0.55	9.11	0.39	2.53e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg12561776	chr17:30844705	MYO1D	-0.27	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06873352	chr17:61820015	STRADA	0.74	13.85	0.54	9.8e-37	Prudent dietary pattern;
LGG	cis	rs7814319	0.700	rs871798	chr8:97257982	T/C	cg20787634	chr8:97240163	UQCRB	-0.67	-13.64	-0.54	7.87e-36	Lung function (FVC);
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg09699651	chr6:150184138	LRP11	0.53	9.42	0.4	2.16e-19	Lung cancer;
LGG	cis	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.62	-0.44	9.66e-24	Mood instability;
LGG	cis	rs7747724	0.720	rs9465890	chr6:20774759	C/T	cg13405222	chr6:20811065	CDKAL1	0.4	7.57	0.33	2e-13	Bladder cancer;
LGG	cis	rs11229555	0.645	rs11229549	chr11:58395914	T/C	cg15696309	chr11:58395628	NA	-0.9	-12.09	-0.49	1.91e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00891011	chr1:150487740	NA	0.39	6.99	0.31	9.53e-12	Obesity-related traits;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.33	-0.4	4.38e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg15948088	chr11:109293068	C11orf87	0.46	7.84	0.34	3.05e-14	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.06	0.42	1.11e-21	Iron status biomarkers;
LGG	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.88	0.38	1.52e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6764363	0.587	rs7646675	chr3:276273	C/T	cg02057681	chr3:285234	CHL1	-0.44	-8.01	-0.35	9.25e-15	Sudden cardiac arrest;
LGG	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15128208	chr22:42549153	NA	-0.43	-8.03	-0.35	8.09e-15	Cognitive function;
LGG	cis	rs8064299	0.597	rs9893035	chr17:72783798	A/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.98	22.02	0.72	4.81e-74	Monocyte count;
LGG	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg13073564	chr4:8508604	NA	-0.6	-11.96	-0.49	6.74e-29	Response to antineoplastic agents;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg04863758	chr4:1303710	MAEA	0.42	7.13	0.31	3.92e-12	Obesity-related traits;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg04025307	chr7:1156635	C7orf50	0.82	14.2	0.55	3.03e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg22643751	chr7:855365	UNC84A	0.36	6.87	0.3	2.04e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg11757124	chr7:157526947	PTPRN2	-0.52	-9.39	-0.4	2.76e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs11214589	0.807	rs2155463	chr11:113242301	T/C	cg14373873	chr11:113211441	TTC12	0.44	9.21	0.39	1.18e-18	Neuroticism;
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.98	-0.31	1.03e-11	Triglycerides;
LGG	cis	rs977987	0.806	rs11149832	chr16:75462713	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.93	0.42	3.42e-21	Dupuytren's disease;
LGG	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg12310025	chr6:25882481	NA	-0.59	-11.63	-0.48	1.28e-27	Blood metabolite levels;
LGG	cis	rs9807841	0.592	rs3810155	chr19:10764867	C/G	cg17710535	chr19:10819994	QTRT1	0.48	7.79	0.34	4.45e-14	Inflammatory skin disease;
LGG	cis	rs2371030	1.000	rs1019393	chr2:211593081	C/G	cg18417063	chr2:211583084	NA	-0.64	-12.32	-0.5	2.23e-30	Non-small cell lung cancer;
LGG	cis	rs8064024	0.680	rs2063101	chr16:4916348	A/G	cg08329684	chr16:4932620	PPL	0.52	11.77	0.48	3.59e-28	Cancer;
LGG	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2073300	0.609	rs3746737	chr20:23424638	C/T	cg12062639	chr20:23401060	NAPB	0.89	8.19	0.36	2.58e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4805272	1.000	rs8104550	chr19:29331733	A/G	cg04546413	chr19:29218101	NA	0.41	6.75	0.3	4.4e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.37	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7000551	0.751	rs2443505	chr8:22375341	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	12.3	0.5	2.72e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg05044414	chr3:183734942	ABCC5	0.57	11.37	0.47	1.34e-26	Anterior chamber depth;
LGG	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.95	0.31	1.27e-11	Schizophrenia;
LGG	cis	rs9660992	0.573	rs1318187	chr1:205206172	T/A	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.47	0.37	3.19e-16	Schizophrenia;
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.02	16.84	0.62	5.61e-50	Alzheimer's disease;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.77	-0.48	3.79e-28	Tonsillectomy;
LGG	cis	rs9354308	0.868	rs4392709	chr6:66547178	G/A	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.96	-0.35	1.38e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg08250081	chr4:10125330	NA	0.36	6.93	0.31	1.41e-11	Bone mineral density;
LGG	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg04450456	chr4:17643702	FAM184B	0.32	7.14	0.31	3.61e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-6.65	-0.3	8.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs7762018	0.621	rs3823465	chr6:170068180	A/G	cg15038512	chr6:170123185	PHF10	0.5	7.44	0.33	4.77e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	7.52	0.33	2.88e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs607541	1.000	rs4271550	chr15:45936266	G/C	cg26924012	chr15:45694286	SPATA5L1	0.54	7.45	0.33	4.57e-13	Obesity-related traits;
LGG	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg22681709	chr2:178499509	PDE11A	-0.39	-7.35	-0.32	9.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9467160	0.953	rs13205577	chr6:24448648	A/T	cg20631270	chr6:24437470	GPLD1	0.52	7.5	0.33	3.35e-13	Liver enzyme levels;
LGG	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs1707322	0.758	rs10789474	chr1:46250040	G/T	cg03146154	chr1:46216737	IPP	0.58	10.69	0.44	5.7e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.6	-0.33	1.66e-13	Morning vs. evening chronotype;
LGG	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg02151108	chr14:50098012	C14orf104	-0.46	-9.96	-0.42	2.57e-21	Carotid intima media thickness;
LGG	cis	rs10463554	0.927	rs55641526	chr5:102251005	G/A	cg23492399	chr5:102201601	PAM	-0.56	-8.56	-0.37	1.68e-16	Parkinson's disease;
LGG	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.22	0.55	2.36e-38	Colorectal cancer;
LGG	cis	rs2066819	1.000	rs11575231	chr12:56744445	T/C	cg26714650	chr12:56694279	CS	-1.59	-15.54	-0.59	4.08e-44	Psoriasis vulgaris;
LGG	cis	rs2797369	0.883	rs2350099	chr6:101699107	A/G	cg27451362	chr6:101846650	GRIK2	0.82	11.06	0.46	2.23e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg08085267	chr17:45401833	C17orf57	-0.58	-11.33	-0.47	1.94e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-13.35	-0.53	1.28e-34	Colorectal cancer;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.62	12.52	0.5	3.58e-31	Obesity-related traits;
LGG	cis	rs6429082	0.660	rs10737818	chr1:235542023	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.9	-0.38	1.29e-17	Adiposity;
LGG	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg12310025	chr6:25882481	NA	0.37	6.72	0.3	5.43e-11	Blood metabolite levels;
LGG	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg01063088	chr1:162760584	HSD17B7	-0.41	-6.65	-0.3	8.15e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13394619	0.655	rs7578132	chr2:11718858	C/T	cg07314298	chr2:11723111	GREB1	-0.46	-9.27	-0.4	7.01e-19	Endometriosis;
LGG	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-8.01	-0.35	9.14e-15	Self-reported allergy;
LGG	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg06108461	chr20:60628389	TAF4	-0.76	-13.74	-0.54	2.7e-36	Body mass index;
LGG	cis	rs754466	0.580	rs10824571	chr10:79531931	G/A	cg17075019	chr10:79541650	NA	-0.99	-21.94	-0.71	1.16e-73	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4595586	0.545	rs12811619	chr12:39392196	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs12971120	0.891	rs12605820	chr18:72167802	G/A	cg25817165	chr18:72167213	CNDP2	-0.66	-13.54	-0.53	2.01e-35	Refractive error;
LGG	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg06470251	chr20:60548479	NA	0.41	7.19	0.32	2.69e-12	Body mass index;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.93	0.54	4.24e-37	Lung cancer;
LGG	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg01831904	chr17:28903510	LRRC37B2	0.86	10.12	0.43	6.89e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg05793240	chr7:2802953	GNA12	0.33	7.76	0.34	5.39e-14	Height;
LGG	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs490234	0.775	rs12341245	chr9:128340941	C/T	cg14078157	chr9:128172775	NA	-0.5	-9.15	-0.39	1.86e-18	Mean arterial pressure;
LGG	cis	rs9810089	0.711	rs711972	chr3:136110018	C/T	cg21827317	chr3:136751795	NA	0.42	7.42	0.33	5.76e-13	Gestational age at birth (child effect);
LGG	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg05191792	chr6:2765113	WRNIP1	0.39	6.67	0.3	7.48e-11	Body mass index;
LGG	cis	rs34546498	1	rs34546498	chr6:26961280	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	6.67	0.3	7.45e-11	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01568846	chr3:179281462	ACTL6A	0.5	7.3	0.32	1.23e-12	Gut microbiome composition (summer);
LGG	cis	rs7209395	0.959	rs62063583	chr17:64164326	C/T	cg19474267	chr17:64306194	PRKCA	0.51	7.97	0.35	1.23e-14	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs41271473	0.687	rs35832347	chr1:228883738	G/C	cg16512390	chr1:228756714	NA	0.44	6.88	0.3	1.9e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg14186256	chr22:23484241	RTDR1	1.01	25.07	0.76	2.89e-88	Bone mineral density;
LGG	trans	rs78049276	0.688	rs61075980	chr4:148374767	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.36	-0.32	8.53e-13	Pulse pressure;
LGG	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg20891283	chr12:69753455	YEATS4	0.97	22.99	0.73	1.43e-78	Blood protein levels;
LGG	cis	rs7193541	0.695	rs7199490	chr16:74716026	G/A	cg01733217	chr16:74700730	RFWD3	0.85	16.79	0.62	9.72e-50	Multiple myeloma;
LGG	cis	rs6693567	0.545	rs1694386	chr1:150377965	C/G	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs9916302	0.784	rs4795382	chr17:37700860	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.79	-0.59	2.94e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7937890	0.531	rs2597216	chr11:14533916	G/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs5769707	0.967	rs9616701	chr22:50025546	G/A	cg20744362	chr22:50050164	C22orf34	0.4	7.8	0.34	4.09e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs55665837	0.540	rs10766192	chr11:14811686	A/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.33	-0.32	1.06e-12	Vitamin D levels;
LGG	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.08	-0.42	9.96e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12843872	chr7:90894352	FZD1	0.45	6.82	0.3	2.85e-11	Gut microbiome composition (summer);
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.55	9.39	0.4	2.83e-19	Birth weight;
LGG	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.3	-0.32	1.25e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06789412	chr3:101405552	RPL24	0.52	8.9	0.38	1.26e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg11062466	chr8:58055876	NA	0.5	8.08	0.35	5.81e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs5753037	0.543	rs140119	chr22:30138149	A/T	cg01021169	chr22:30184971	ASCC2	-0.38	-7.4	-0.33	6.2800000000000005e-13	Type 1 diabetes;
LGG	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg01897796	chr15:59225903	SLTM	-0.34	-6.74	-0.3	4.85e-11	Iris color (L* coordinate);
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.82	-0.3	2.82e-11	Menopause (age at onset);
LGG	trans	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg17712092	chr4:129076599	LARP1B	-0.59	-10.31	-0.43	1.42e-22	DNA methylation (variation);
LGG	cis	rs8170	0.603	rs11086068	chr19:17420165	T/C	cg04749549	chr19:17459798	NA	-0.37	-6.81	-0.3	3e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg08888203	chr3:10149979	C3orf24	0.53	8.8	0.38	2.78e-17	Alzheimer's disease;
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00761968	chr13:53314142	LECT1	-0.37	-7.94	-0.35	1.57e-14	Lewy body disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17621389	chr6:147728290	NA	0.34	6.79	0.3	3.45e-11	Menarche (age at onset);
LGG	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.67	0.37	7.22e-17	Colorectal cancer;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg27476859	chr7:2772710	GNA12	0.42	7.23	0.32	1.98e-12	Height;
LGG	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.26	0.32	1.66e-12	Myopia (pathological);
LGG	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.32	0.32	1.12e-12	Intelligence (multi-trait analysis);
LGG	trans	rs8073060	0.586	rs225256	chr17:33955756	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7432375	0.583	rs1609391	chr3:136615268	G/A	cg21827317	chr3:136751795	NA	0.54	9.43	0.4	2.01e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.52	-0.53	2.54e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg11766577	chr21:47581405	C21orf56	0.49	8.14	0.35	3.72e-15	Testicular germ cell tumor;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.582	rs80273890	chr5:483057	C/T	cg21972741	chr5:435613	AHRR	0.48	7.41	0.33	5.91e-13	Cystic fibrosis severity;
LGG	cis	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg22857025	chr5:266934	NA	-1.49	-26.28	-0.77	8.03e-94	Breast cancer;
LGG	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.07	-0.42	1.08e-21	Hip circumference adjusted for BMI;
LGG	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg00666640	chr1:248458726	OR2T12	-0.53	-8.3	-0.36	1.19e-15	Common traits (Other);
LGG	cis	rs10937275	0.623	rs35166820	chr3:186646140	C/T	cg16751732	chr3:186648392	ST6GAL1	0.71	7.05	0.31	6.42e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg11764359	chr7:65958608	NA	-0.8	-14.94	-0.57	1.73e-41	Aortic root size;
LGG	cis	rs943466	1.000	rs11755593	chr6:33740325	G/C	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	2.04e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.48	0.58	7.61e-44	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26279152	chr13:20356101	PSPC1	0.45	7.2	0.32	2.47e-12	Cognitive performance;
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.69e-14	Height;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.96	-0.38	8e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg10621924	chr7:39171070	POU6F2	0.48	10.03	0.42	1.53e-21	IgG glycosylation;
LGG	cis	rs4363385	0.693	rs576941	chr1:153040165	A/G	cg13444842	chr1:152974279	SPRR3	0.4	8.08	0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs240764	0.619	rs6903665	chr6:101148234	T/C	cg09795085	chr6:101329169	ASCC3	0.43	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs314370	0.951	rs12666989	chr7:100486754	G/C	cg10426581	chr7:100472382	SRRT	0.51	7.02	0.31	7.95e-12	Resting heart rate;
LGG	cis	rs11748327	0.580	rs6555241	chr5:4008448	A/G	cg01025095	chr5:4101132	NA	-0.44	-7.09	-0.31	4.94e-12	Myocardial infarction;
LGG	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.1e-22	Initial pursuit acceleration;
LGG	cis	rs3762637	1.000	rs12633461	chr3:122135897	C/G	cg24169773	chr3:122142474	KPNA1	-0.6	-10.07	-0.42	1.05e-21	LDL cholesterol levels;
LGG	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg12165864	chr7:66369176	NA	-0.57	-9.22	-0.39	1.03e-18	Corneal structure;
LGG	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg13010199	chr12:38710504	ALG10B	-0.63	-12.57	-0.5	2.22e-31	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.67	-12.34	-0.5	1.84e-30	Personality dimensions;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs2635047	0.638	rs2668758	chr18:44685679	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.86	0.34	2.67e-14	Educational attainment;
LGG	cis	rs6908034	0.505	rs77880623	chr6:19819454	T/C	cg02682789	chr6:19804855	NA	0.9	8.42	0.36	4.78e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs4926611	1.000	rs4926611	chr1:54111733	T/C	cg23596471	chr1:54105337	GLIS1	0.41	8.59	0.37	1.34e-16	Hand grip strength;
LGG	cis	rs4604732	0.631	rs7546720	chr1:247627229	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs877282	0.898	rs11253346	chr10:765313	A/G	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.02e-11	Uric acid levels;
LGG	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg27147174	chr7:100797783	AP1S1	0.61	10.8	0.45	2.16e-24	Life satisfaction;
LGG	cis	rs2032447	0.670	rs198834	chr6:26114372	G/A	cg12310025	chr6:25882481	NA	0.5	9.27	0.4	7.31e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.556	rs7108048	chr11:111352299	T/C	cg09085632	chr11:111637200	PPP2R1B	0.65	11.03	0.46	2.78e-25	Primary sclerosing cholangitis;
LGG	cis	rs2235573	0.718	rs4373009	chr22:38490056	A/G	cg19171272	chr22:38449367	NA	-0.45	-8.63	-0.37	9.61e-17	Glioblastoma;Glioma;
LGG	cis	rs503734	0.666	rs520558	chr3:101046933	G/C	cg27318481	chr3:100970896	IMPG2	-0.36	-7.32	-0.32	1.08e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.84	0.34	3.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3008870	0.959	rs2985808	chr1:67367741	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.28	0.72	2.93e-75	Lymphocyte percentage of white cells;
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.36	0.47	1.54e-26	Alzheimer's disease;
LGG	trans	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg06521331	chr12:34319734	NA	-0.43	-7.66	-0.34	1.12e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs367615	0.552	rs2416210	chr5:108741137	C/T	cg17395555	chr5:108820864	NA	-0.71	-11.57	-0.47	2.23e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.79e-12	Blood metabolite levels;
LGG	cis	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg21605333	chr4:119757512	SEC24D	0.98	10.06	0.42	1.17e-21	Cannabis dependence symptom count;
LGG	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg04287289	chr16:89883240	FANCA	-0.55	-10.39	-0.43	7.32e-23	Vitiligo;
LGG	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg01200585	chr1:228362443	C1orf69	-0.43	-7.6	-0.33	1.71e-13	Diastolic blood pressure;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg26174226	chr8:58114915	NA	-0.53	-7.28	-0.32	1.4e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg11050988	chr7:1952600	MAD1L1	-0.4	-9.69	-0.41	2.36e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	11.81	0.48	2.59e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.71	0.3	5.66e-11	Alzheimer's disease;
LGG	cis	rs701145	0.585	rs1727879	chr3:153835819	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.67	0.48	9.61e-28	Mean platelet volume;
LGG	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg19761014	chr17:28927070	LRRC37B2	0.71	8.9	0.38	1.31e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs3960554	0.808	rs2302434	chr7:75630183	C/T	cg19862616	chr7:65841803	NCRNA00174	0.88	13.09	0.52	1.62e-33	Eotaxin levels;
LGG	cis	rs889398	0.802	rs2291959	chr16:69873992	T/G	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.69	-0.3	6.53e-11	Body mass index;
LGG	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg23129478	chr18:44337922	ST8SIA5	0.37	7.15	0.32	3.41e-12	Personality dimensions;
LGG	cis	rs1983891	0.954	rs4714481	chr6:41521110	T/C	cg20194872	chr6:41519635	FOXP4	0.58	9.82	0.42	8.58e-21	Prostate cancer;
LGG	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg04691961	chr3:161091175	C3orf57	0.41	8.61	0.37	1.12e-16	Morning vs. evening chronotype;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg18857889	chr7:23719661	C7orf46	-0.36	-7.42	-0.33	5.83e-13	Schizophrenia;
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg03806693	chr22:41940476	POLR3H	-1.17	-22.11	-0.72	1.76e-74	Vitiligo;
LGG	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg06212747	chr3:49208901	KLHDC8B	0.52	8.04	0.35	7.53e-15	Menarche (age at onset);
LGG	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg21453758	chr17:80185943	SLC16A3	0.34	7.19	0.32	2.69e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg18335740	chr13:41363409	SLC25A15	0.84	19.61	0.67	9.04e-63	Lewy body disease;
LGG	cis	rs12477438	0.520	rs1584648	chr2:100001077	G/A	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg23649088	chr2:200775458	C2orf69	-0.46	-7.97	-0.35	1.26e-14	QT interval;
LGG	cis	rs6752107	1.000	rs6738490	chr2:234161583	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.36	0.53	1.1e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4423214	1.000	rs12806844	chr11:71170770	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.35	-0.32	9.24e-13	Dementia with Lewy bodies;
LGG	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.72	14.5	0.56	1.55e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs151997	1.000	rs152817	chr5:50230879	T/A	cg06027927	chr5:50259733	NA	-0.63	-10.49	-0.44	2.97e-23	Callous-unemotional behaviour;
LGG	cis	rs4716602	0.586	rs13224457	chr7:156161005	G/T	cg16983916	chr7:156159713	NA	-0.49	-9.43	-0.4	1.91e-19	Anti-saccade response;
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg13009111	chr11:71350975	NA	-0.31	-6.83	-0.3	2.72e-11	Systolic blood pressure;
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9381107	0.932	rs2327168	chr6:9437498	G/A	cg14735645	chr6:9486422	NA	-0.42	-7.15	-0.32	3.49e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs3815700	1.000	rs8104729	chr19:33093979	C/T	cg02997394	chr19:33096574	ANKRD27	0.87	13.02	0.52	3.04e-33	Eosinophilic esophagitis;
LGG	cis	rs8180040	0.654	rs4682831	chr3:47027138	A/G	cg27129171	chr3:47204927	SETD2	-0.79	-14.84	-0.57	4.88e-41	Colorectal cancer;
LGG	cis	rs138249	0.505	rs138218	chr22:50547558	T/C	cg07310406	chr22:50524374	MLC1	0.61	11.41	0.47	9.42e-27	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg23594656	chr7:65796392	TPST1	0.3	6.69	0.3	6.57e-11	Aortic root size;
LGG	cis	rs240764	0.746	rs240153	chr6:101067135	A/C	cg09795085	chr6:101329169	ASCC3	0.47	7.62	0.33	1.41e-13	Neuroticism;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9534288	0.699	rs9567621	chr13:46665814	A/G	cg15192986	chr13:46630673	CPB2	-0.62	-12.74	-0.51	4.23e-32	Blood protein levels;
LGG	cis	rs17039065	1.000	rs72889358	chr4:109379790	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.0	0.31	9.09e-12	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20731804	chr6:42858765	C6orf226	0.43	6.81	0.3	2.98e-11	Cognitive performance;
LGG	trans	rs11039798	0.688	rs10839007	chr11:48703442	A/C	cg15704280	chr7:45808275	SEPT13	0.78	9.03	0.39	4.69e-18	Axial length;
LGG	cis	rs9358372	0.519	rs4492184	chr6:20794682	A/C	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.4	-0.4	2.51e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg24110177	chr3:50126178	RBM5	-0.41	-7.12	-0.31	4.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4006360	0.520	rs4986664	chr17:39250248	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.527	rs7128827	chr11:49665644	C/T	cg15704280	chr7:45808275	SEPT13	0.91	15.15	0.58	2.24e-42	Height;
LGG	cis	rs6840360	1.000	rs28637056	chr4:152652501	A/G	cg22705602	chr4:152727874	NA	-0.27	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	trans	rs6787172	0.702	rs827097	chr3:157996636	C/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg06656553	chr16:89960601	TCF25	-0.61	-6.89	-0.3	1.83e-11	Skin colour saturation;
LGG	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg26597838	chr10:835615	NA	0.7	8.95	0.38	8.47e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs1595825	0.891	rs1992313	chr2:198896766	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16680214	chr1:154839983	KCNN3	-0.48	-9.62	-0.41	4.28e-20	Prostate cancer;
LGG	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg12924262	chr12:102091054	CHPT1	0.66	13.27	0.52	2.85e-34	Blood protein levels;
LGG	trans	rs801193	1.000	rs10252765	chr7:66228732	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.61	0.37	1.2e-16	Aortic root size;
LGG	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg08885076	chr2:99613938	TSGA10	0.6	12.14	0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg16316162	chr8:144660157	NAPRT1	0.75	6.81	0.3	3.06e-11	Attention deficit hyperactivity disorder;
LGG	trans	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg02002194	chr4:3960332	NA	0.39	6.93	0.31	1.42e-11	Mood instability;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg04503457	chr17:41445688	NA	-0.39	-9.22	-0.39	1.07e-18	Menopause (age at onset);
LGG	cis	rs490234	0.702	rs13302549	chr9:128284775	T/C	cg14078157	chr9:128172775	NA	-0.55	-10.45	-0.44	4.34e-23	Mean arterial pressure;
LGG	cis	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11080107	0.542	rs894606	chr17:27909352	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	9.47	0.4	1.42e-19	Coronary artery disease;
LGG	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg22517653	chr1:2918612	NA	-0.45	-7.07	-0.31	5.57e-12	Plateletcrit;
LGG	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.69	-0.37	6.22e-17	Neuroticism;
LGG	cis	rs10979	1.000	rs13198159	chr6:143891953	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.26	-0.5	3.99e-30	Hypospadias;
LGG	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.6	-0.37	1.25e-16	Platelet distribution width;
LGG	cis	rs9467711	0.591	rs9461223	chr6:25918335	T/C	cg21479132	chr6:26055353	NA	0.7	6.67	0.3	7.12e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18252515	chr7:66147081	NA	0.44	7.35	0.32	9.03e-13	Aortic root size;
LGG	cis	rs1847202	0.717	rs13063437	chr3:72952388	A/G	cg25664220	chr3:72788482	NA	-0.24	-6.91	-0.31	1.58e-11	Motion sickness;
LGG	cis	rs2933343	0.951	rs789217	chr3:128593201	C/T	cg25356066	chr3:128598488	ACAD9	0.46	6.79	0.3	3.36e-11	IgG glycosylation;
LGG	cis	rs861020	0.606	rs4844903	chr1:210006267	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg11764359	chr7:65958608	NA	-0.74	-13.41	-0.53	7.13e-35	Aortic root size;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.48	0.47	5.16e-27	Bipolar disorder;
LGG	cis	rs5756391	0.568	rs7410682	chr22:37317258	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.57	0.41	6.56e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.23	0.55	2.22e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12505749	0.660	rs7690100	chr4:57344320	C/A	cg07846311	chr4:57371927	ARL9	-0.32	-7.84	-0.34	3.04e-14	Airflow obstruction;
LGG	cis	rs1256061	0.624	rs7229	chr14:64692825	G/A	cg23250157	chr14:64679961	SYNE2	0.38	6.83	0.3	2.7e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg09033563	chr22:24373618	LOC391322	-0.49	-8.08	-0.35	5.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2976388	1.000	rs2294008	chr8:143761931	C/T	cg06565975	chr8:143823917	SLURP1	-0.41	-10.5	-0.44	2.71e-23	Urinary tract infection frequency;
LGG	cis	rs2717559	0.541	rs34497317	chr8:143889053	T/A	cg06565975	chr8:143823917	SLURP1	-0.34	-8.42	-0.36	4.7e-16	Urinary tract infection frequency;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg05335186	chr13:53173507	NA	0.46	9.02	0.39	4.89e-18	Lewy body disease;
LGG	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg26897989	chr16:1907736	C16orf73	-0.49	-9.14	-0.39	2.03e-18	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs13421350	0.579	rs55867175	chr2:173340209	A/C	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs9790314	1.000	rs7653233	chr3:160992033	G/A	cg04691961	chr3:161091175	C3orf57	-0.61	-14.48	-0.56	1.93e-39	Morning vs. evening chronotype;
LGG	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.23	-0.36	1.99e-15	Calcium levels;
LGG	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg09307838	chr4:120376055	NA	0.77	12.67	0.51	8.34e-32	Corneal astigmatism;
LGG	cis	rs4906332	0.811	rs2021965	chr14:103997248	C/A	cg23335576	chr14:104009727	NA	-0.48	-7.69	-0.34	9.06e-14	Coronary artery disease;
LGG	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19717773	chr7:2847554	GNA12	-0.36	-8.19	-0.36	2.59e-15	Height;
LGG	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.99	-21.01	-0.7	2.56e-69	Cognitive ability;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04921814	chr1:145575587	PIAS3	0.47	7.63	0.33	1.34e-13	Cognitive performance;
LGG	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg04743876	chr7:130013617	NA	0.37	8.37	0.36	7.09e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs988958	0.833	rs1440096	chr2:42289736	A/G	cg19376973	chr2:42229025	NA	0.46	6.87	0.3	2.12e-11	Hypospadias;
LGG	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg01864069	chr14:103024347	NA	-0.62	-10.05	-0.42	1.27e-21	Platelet count;
LGG	cis	rs6868223	0.617	rs4621563	chr5:33649905	C/T	cg10594543	chr5:33649717	ADAMTS12	0.65	15.34	0.58	3.22e-43	Mortality in heart failure;
LGG	cis	rs2637030	0.559	rs2637027	chr5:52980471	G/A	cg06476337	chr5:52856530	NDUFS4	0.44	6.88	0.3	1.97e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	-0.4	-6.79	-0.3	3.48e-11	Resistin levels;
LGG	cis	rs7918232	0.830	rs9833	chr10:27400861	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	11.14	0.46	1.11e-25	Breast cancer;
LGG	cis	rs7949566	0.614	rs948055	chr11:126292289	G/C	cg05055844	chr11:126275997	ST3GAL4	0.36	7.25	0.32	1.73e-12	Platelet distribution width;Mean platelet volume;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg16405210	chr4:1374714	KIAA1530	-0.43	-7.01	-0.31	8.44e-12	Obesity-related traits;
LGG	cis	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg23594656	chr7:65796392	TPST1	-0.36	-8.02	-0.35	8.6e-15	Aortic root size;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-6.68	-0.3	7.01e-11	Life satisfaction;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.42	6.72	0.3	5.31e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.31	-0.32	1.18e-12	Height;
LGG	cis	rs7312933	0.558	rs11181467	chr12:42765250	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.17	0.35	2.97e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs80282103	0.618	rs57514701	chr10:1146169	G/A	cg08668510	chr10:1095578	IDI1	0.77	7.63	0.33	1.32e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-11.1	-0.46	1.54e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg23752985	chr2:85803571	VAMP8	0.4	7.67	0.34	1.03e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg12045294	chr17:78518616	RPTOR	-0.47	-7.31	-0.32	1.15e-12	Glycated hemoglobin levels;
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg05552183	chr6:42928497	GNMT	0.44	13.29	0.53	2.16e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs367615	0.661	rs9326775	chr5:108836925	A/T	cg17395555	chr5:108820864	NA	0.88	15.99	0.6	3.69e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs4076764	0.801	rs12046142	chr1:163375247	G/A	cg24596788	chr1:163392923	NA	-0.65	-12.14	-0.49	1.24e-29	Motion sickness;
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg01943577	chr7:158741284	NA	-0.45	-8.36	-0.36	7.3e-16	Height;
LGG	cis	rs7587476	0.501	rs11888027	chr2:215639612	A/C	cg04530015	chr2:215796436	ABCA12	0.36	6.67	0.3	7.51e-11	Neuroblastoma;
LGG	cis	rs17776563	0.853	rs11636283	chr15:89143777	A/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.28	-0.43	1.88e-22	Thyroid hormone levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24926775	chr1:151584391	SNX27	0.48	7.4	0.33	6.37e-13	Gut microbiome composition (summer);
LGG	cis	rs3743102	0.591	rs10520565	chr15:83255074	C/T	cg00614314	chr15:82944287	LOC80154	-0.71	-7.12	-0.31	4.24e-12	Colorectal adenoma (advanced);
LGG	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.72	0.51	5.26e-32	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2117029	0.554	rs12579015	chr12:49556431	T/G	cg24176009	chr12:49580217	TUBA1A	0.63	12.38	0.5	1.37e-30	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg21775007	chr8:11205619	TDH	-0.43	-6.8	-0.3	3.22e-11	Neuroticism;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.72e-13	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19789848	chr17:30454741	NA	0.43	7.26	0.32	1.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg02428538	chr16:24856791	SLC5A11	-0.69	-10.64	-0.44	8.38e-24	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.649	rs422854	chr2:39185048	C/T	cg04010122	chr2:39346883	SOS1	-0.78	-6.8	-0.3	3.27e-11	Corticobasal degeneration;
LGG	cis	rs1978968	0.956	rs35598889	chr22:18450794	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.64	-0.51	1.19e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs76693355	0.512	rs4938807	chr11:120331701	C/A	cg15690696	chr11:120217718	ARHGEF12	-0.42	-6.65	-0.3	8.29e-11	Intraocular pressure;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg23782820	chr8:58130467	NA	0.44	6.77	0.3	3.98e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg11608241	chr8:8085544	FLJ10661	-0.33	-7.51	-0.33	3.05e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9354308	0.764	rs9354331	chr6:66605081	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.02	-0.46	3.16e-25	Migraine;Coronary artery disease;
LGG	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-9.99	-0.42	2.04e-21	Bipolar disorder;
LGG	cis	rs208520	0.690	rs12208310	chr6:66730108	G/C	cg07460842	chr6:66804631	NA	0.96	17.92	0.64	5.89e-55	Exhaled nitric oxide output;
LGG	cis	rs12195424	0.730	rs6941846	chr6:56302621	C/T	cg07152817	chr6:56299822	NA	-0.55	-6.69	-0.3	6.41e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg07701084	chr6:150067640	NUP43	-0.46	-6.86	-0.3	2.26e-11	Lung cancer;
LGG	cis	rs36051895	0.659	rs12348771	chr9:5083634	T/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.19	-0.58	1.46e-42	Pediatric autoimmune diseases;
LGG	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg13147721	chr7:65941812	NA	0.81	9.8	0.41	9.83e-21	Diabetic kidney disease;
LGG	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg26384229	chr12:38710491	ALG10B	-0.7	-13.22	-0.52	4.3e-34	Morning vs. evening chronotype;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg05708079	chr12:90102477	LOC338758	-0.38	-6.83	-0.3	2.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg19168338	chr16:4465731	CORO7	-0.74	-13.72	-0.54	3.43e-36	Schizophrenia;
LGG	cis	rs3093024	0.904	rs3093019	chr6:167539655	C/G	cg07741184	chr6:167504864	NA	-0.34	-7.6	-0.33	1.64e-13	Rheumatoid arthritis;
LGG	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg11502198	chr6:26597334	ABT1	-0.92	-7.86	-0.34	2.77e-14	Small cell lung carcinoma;
LGG	cis	rs6708331	1.000	rs62151174	chr2:70363968	C/G	cg01613454	chr2:70366299	NA	0.53	9.44	0.4	1.8e-19	Obesity-related traits;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.84	-0.42	7.16e-21	Lung cancer;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.12	-0.49	1.42e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.62e-13	Prudent dietary pattern;
LGG	trans	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.61	10.9	0.45	8.72e-25	Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg15971980	chr6:150254442	NA	0.44	7.88	0.34	2.28e-14	Lung cancer;
LGG	cis	rs757278	0.608	rs7804816	chr7:117355509	T/C	cg10524701	chr7:117356490	CTTNBP2	0.47	8.42	0.36	4.89e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg21775007	chr8:11205619	TDH	0.63	10.4	0.44	6.42e-23	Retinal vascular caliber;
LGG	cis	rs67311347	1.000	rs12488805	chr3:40422869	C/T	cg13683864	chr3:40499215	RPL14	-1.15	-25.8	-0.77	1.25e-91	Renal cell carcinoma;
LGG	cis	rs2658782	0.547	rs3020054	chr11:93055556	C/T	cg15737290	chr11:93063684	CCDC67	0.65	11.01	0.46	3.41e-25	Pulmonary function decline;
LGG	cis	rs2735413	0.914	rs1922608	chr16:78065139	A/G	cg04733911	chr16:78082701	NA	-0.76	-17.51	-0.63	4.94e-53	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs2067615	0.524	rs7959062	chr12:107107334	G/T	cg15890332	chr12:107067104	RFX4	0.44	13.17	0.52	6.94e-34	Heart rate;
LGG	cis	rs988958	0.565	rs12712817	chr2:42236230	A/G	cg27428208	chr2:42229179	NA	0.49	7.73	0.34	6.78e-14	Hypospadias;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.95	0.45	5.76e-25	Personality dimensions;
LGG	cis	rs988958	0.565	rs11894536	chr2:42238134	T/A	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs785830	0.689	rs1536608	chr9:223613	T/G	cg14500300	chr9:211689	NA	0.31	7.76	0.34	5.31e-14	Platelet distribution width;
LGG	trans	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.87	0.59	1.31e-45	Morning vs. evening chronotype;
LGG	cis	rs329648	1.000	rs329652	chr11:133769699	A/G	cg15485101	chr11:133734466	NA	0.45	7.09	0.31	5e-12	Parkinson's disease;
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg06026331	chr20:60912101	LAMA5	0.48	8.8	0.38	2.68e-17	Colorectal cancer;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg11473876	chr11:109292803	C11orf87	0.46	9.26	0.4	7.94e-19	Schizophrenia;
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.47e-27	Rheumatoid arthritis;
LGG	cis	rs17227506	0.543	rs35599664	chr8:13483299	C/T	cg03566418	chr8:13424080	C8orf48	0.55	8.11	0.35	4.63e-15	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01449415	chr16:3184811	ZNF213	0.45	7.45	0.33	4.76e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg14664628	chr15:75095509	CSK	-0.49	-8.8	-0.38	2.76e-17	Airflow obstruction;
LGG	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg25809561	chr17:30822961	MYO1D	0.38	9.01	0.39	5.4e-18	Schizophrenia;
LGG	cis	rs6940638	0.956	rs36048693	chr6:27032711	T/G	cg09904177	chr6:26538194	HMGN4	-0.52	-7.19	-0.32	2.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.65	0.48	1.08e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.64	-0.41	3.68e-20	Morning vs. evening chronotype;
LGG	cis	rs6694672	1.000	rs1759008	chr1:197026895	G/T	cg13682187	chr1:196946512	CFHR5	-0.48	-6.78	-0.3	3.75e-11	Asthma;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.36	-0.43	9.42e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs9467773	0.526	rs3734536	chr6:26365346	C/G	cg09904177	chr6:26538194	HMGN4	-0.41	-7.28	-0.32	1.46e-12	Intelligence (multi-trait analysis);
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14893161	chr1:205819251	PM20D1	0.48	7.73	0.34	6.54e-14	Parkinson's disease;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08677398	chr8:58056175	NA	0.6	9.06	0.39	3.77e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg07636037	chr3:49044803	WDR6	0.75	12.95	0.52	6.03e-33	Menarche (age at onset);
LGG	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.28	0.32	1.44e-12	Schizophrenia;
LGG	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg23202291	chr11:1979235	NA	0.54	11.32	0.47	2.2e-26	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.85	-0.3	2.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs986417	1.000	rs1956875	chr14:60846212	T/C	cg27398547	chr14:60952738	C14orf39	-0.71	-7.02	-0.31	7.89e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.45	-0.44	4.49e-23	Total body bone mineral density;
LGG	cis	rs6665290	0.935	rs1929863	chr1:227195728	C/T	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg21427119	chr20:30132790	HM13	-0.58	-9.16	-0.39	1.65e-18	Mean corpuscular hemoglobin;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg16339924	chr4:17578868	LAP3	-0.61	-10.66	-0.44	7.33e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs208520	0.754	rs851592	chr6:66875175	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.18	-0.62	1.54e-51	Exhaled nitric oxide output;
LGG	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.43	0.53	5.73e-35	Bladder cancer;
LGG	cis	rs36051895	0.623	rs1555476	chr9:5233054	T/C	cg02405213	chr9:5042618	JAK2	-0.78	-13.11	-0.52	1.3e-33	Pediatric autoimmune diseases;
LGG	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-7.32	-0.32	1.14e-12	HDL cholesterol;
LGG	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg13147721	chr7:65941812	NA	-0.44	-6.75	-0.3	4.52e-11	Corneal structure;
LGG	cis	rs1829883	0.835	rs10068675	chr5:98890617	C/G	cg08333243	chr5:99726346	NA	-0.37	-6.93	-0.31	1.4e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.47	-7.49	-0.33	3.49e-13	Longevity;
LGG	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	8.9	0.38	1.24e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.39	-0.56	4.75e-39	Platelet count;
LGG	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.5	-0.4	1.09e-19	Breast cancer;
LGG	cis	rs6815814	0.861	rs17616434	chr4:38812876	T/C	cg06935464	chr4:38784597	TLR10	0.47	7.54	0.33	2.43e-13	Breast cancer;
LGG	cis	rs6489785	0.775	rs1732396	chr12:121363598	T/C	cg02419362	chr12:121203948	SPPL3	0.44	6.96	0.31	1.17e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-7.39	-0.32	6.98e-13	Total body bone mineral density;
LGG	cis	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19171272	chr22:38449367	NA	-0.55	-10.85	-0.45	1.39e-24	Glioblastoma;Glioma;
LGG	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg13482628	chr17:19912719	NA	-0.55	-10.41	-0.44	6.25e-23	Schizophrenia;
LGG	cis	rs7568458	0.870	rs6757263	chr2:85803542	A/G	cg17127132	chr2:85788382	GGCX	0.46	8.1	0.35	4.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg24623649	chr8:11872141	NA	-0.34	-7.93	-0.35	1.69e-14	Triglycerides;
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg02002194	chr4:3960332	NA	0.43	7.84	0.34	3.09e-14	Triglycerides;
LGG	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.39	-0.32	7.05e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3540	0.574	rs2657947	chr15:90968977	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-11.95	-0.49	7.15e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs1997103	1.000	rs6958664	chr7:55404958	T/G	cg20935933	chr6:143382018	AIG1	0.56	8.84	0.38	2.04e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs829402	0.836	rs829373	chr1:21988563	C/T	cg14212983	chr1:21985742	RAP1GAP	0.73	12.19	0.49	7.7e-30	High light scatter reticulocyte count;
LGG	cis	rs9341835	0.518	rs9344168	chr6:64169682	G/A	cg00787780	chr6:64151745	NA	0.41	7.17	0.32	3.05e-12	Schizophrenia;
LGG	cis	rs6594713	0.837	rs6594715	chr5:112741593	T/C	cg12552261	chr5:112820674	MCC	0.5	7.23	0.32	2.06e-12	Brain cytoarchitecture;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.53	-0.33	2.72e-13	Lung cancer;
LGG	cis	rs6466055	0.501	rs7776707	chr7:104605530	C/A	cg03782966	chr7:104585482	NA	0.32	6.86	0.3	2.2e-11	Schizophrenia;
LGG	cis	rs10803016	0.564	rs2053191	chr1:242270373	A/T	cg23840812	chr1:242252992	PLD5	0.4	8.16	0.35	3.21e-15	Coronary artery calcification;
LGG	cis	rs10266483	0.515	rs6948710	chr7:63866003	G/A	cg24201672	chr7:64023550	ZNF680	0.46	7.01	0.31	8.27e-12	Response to statin therapy;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg05313129	chr8:58192883	C8orf71	-0.84	-12.54	-0.5	2.89e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs295140	0.507	rs1369842	chr2:201108987	C/A	cg23649088	chr2:200775458	C2orf69	-0.46	-7.94	-0.35	1.53e-14	QT interval;
LGG	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	13.07	0.52	1.91e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg22903471	chr2:27725779	GCKR	0.38	8.42	0.36	4.87e-16	Oral cavity cancer;
LGG	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg14979609	chr8:8086686	FLJ10661	-0.31	-7.97	-0.35	1.26e-14	Mood instability;
LGG	trans	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08862035	chr2:2617432	NA	0.41	6.76	0.3	4.28e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs35661897	0.920	rs62190939	chr2:227336387	C/T	cg03426602	chr2:227312417	NA	-0.44	-6.83	-0.3	2.76e-11	Urinary tract infection frequency;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg24642844	chr7:1081250	C7orf50	-0.64	-10.73	-0.45	3.73e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs806215	0.526	rs3808088	chr7:127526038	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.08	-0.31	5.3e-12	Type 2 diabetes;
LGG	cis	rs2820315	0.867	rs2820318	chr1:201878620	T/C	cg10061532	chr1:201886748	LMOD1	0.32	6.89	0.31	1.8e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs2991971	0.967	rs644915	chr1:46007002	T/C	cg24296786	chr1:45957014	TESK2	0.4	6.97	0.31	1.11e-11	High light scatter reticulocyte count;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-12.41	-0.5	9.8e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs7113850	0.541	rs7129631	chr11:24208560	A/G	ch.11.24196551F	chr11:24239977	NA	0.91	10.1	0.42	8.45e-22	Bone fracture in osteoporosis;
LGG	cis	rs7408868	1.000	rs1548554	chr19:15277938	C/T	cg14696996	chr19:15285081	NOTCH3	1.1	13.17	0.52	7.11e-34	Pulse pressure;
LGG	cis	rs6792151	0.652	rs3850190	chr3:171561608	A/T	cg26441893	chr3:171559851	TMEM212	-0.44	-7.76	-0.34	5.44e-14	Red cell distribution width;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18789337	chr6:114180353	MARCKS	0.41	6.99	0.31	9.66e-12	Cognitive performance;
LGG	cis	rs741702	0.928	rs1010222	chr19:13048608	A/G	cg23899408	chr19:12877188	HOOK2	0.5	8.0	0.35	9.94e-15	Red blood cell traits;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.46	-0.5	6.48e-31	Lymphocyte counts;
LGG	cis	rs1023500	0.573	rs133370	chr22:42465260	T/C	cg15557168	chr22:42548783	NA	-0.4	-8.64	-0.37	9.24e-17	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12407844	chr14:60558421	C14orf135	0.38	6.72	0.3	5.29e-11	Obesity-related traits;
LGG	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg25706552	chr1:244017396	NA	0.53	8.73	0.38	4.62e-17	RR interval (heart rate);
LGG	cis	rs988958	0.526	rs13424159	chr2:42239495	A/G	cg27428208	chr2:42229179	NA	0.47	7.45	0.33	4.73e-13	Hypospadias;
LGG	cis	rs763121	0.925	rs5757251	chr22:39100128	G/A	cg06022373	chr22:39101656	GTPBP1	0.81	16.6	0.61	6.98e-49	Menopause (age at onset);
LGG	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.64	-0.37	8.87e-17	Aortic root size;
LGG	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-7.81	-0.34	3.91e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg17330251	chr7:94953956	PON1	-0.43	-8.34	-0.36	8.73e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg15971980	chr6:150254442	NA	0.46	8.65	0.37	8.83e-17	Lung cancer;
LGG	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.73	-0.34	6.6e-14	Menarche (age at onset);
LGG	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg23029597	chr12:123009494	RSRC2	-0.92	-18.32	-0.65	8.79e-57	Body mass index;
LGG	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg12654349	chr5:56205094	C5orf35	-0.69	-10.29	-0.43	1.61e-22	Initial pursuit acceleration;
LGG	cis	rs12431410	0.550	rs8007076	chr14:60228408	C/G	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00894870	chr1:19578612	MRTO4;KIAA0090	0.46	7.44	0.33	4.86e-13	Gut microbiome composition (summer);
LGG	trans	rs8002861	0.846	rs12869355	chr13:44478193	A/C	cg12856521	chr11:46389249	DGKZ	0.45	7.81	0.34	3.73e-14	Leprosy;
LGG	cis	rs4132509	0.744	rs12047209	chr1:243954407	A/C	cg25706552	chr1:244017396	NA	0.55	6.99	0.31	9.82e-12	RR interval (heart rate);
LGG	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg01620082	chr3:125678407	NA	-0.71	-8.37	-0.36	7.08e-16	Depression;
LGG	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg16141378	chr3:129829833	LOC729375	-0.43	-10.2	-0.43	3.45e-22	Mood instability;
LGG	cis	rs2180341	0.680	rs9388554	chr6:127576234	C/G	cg27446573	chr6:127587934	RNF146	0.9	16.85	0.62	4.81e-50	Breast cancer;
LGG	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg02466173	chr16:30829666	NA	-0.52	-9.31	-0.4	5.34e-19	Multiple myeloma;
LGG	cis	rs7432375	0.901	rs35874192	chr3:136470004	G/C	cg21827317	chr3:136751795	NA	-0.47	-8.43	-0.36	4.58e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs1032833	0.732	rs17454024	chr2:179972833	C/G	cg23654767	chr2:101192981	PDCL3	0.67	8.12	0.35	4.11e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9398803	0.678	rs1155938	chr6:126866472	C/A	cg19875578	chr6:126661172	C6orf173	0.51	9.45	0.4	1.7e-19	Male-pattern baldness;
LGG	cis	rs875971	0.545	rs1909508	chr7:65766353	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.3	0.43	1.6e-22	Aortic root size;
LGG	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs9368481	0.729	rs9379948	chr6:26944783	T/G	cg18867708	chr6:26865862	GUSBL1	0.44	7.2	0.32	2.47e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1953600	0.870	rs2573356	chr10:81949363	C/T	cg04850286	chr10:81895943	PLAC9	0.44	9.79	0.41	1.09e-20	Sarcoidosis;
LGG	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg21466736	chr12:48725269	NA	-0.36	-7.29	-0.32	1.32e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs2018055	0.551	rs13198016	chr6:117797524	A/G	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs870825	0.616	rs28442259	chr4:185646962	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg15485101	chr11:133734466	NA	0.59	10.4	0.44	6.45e-23	Childhood ear infection;
LGG	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg14829155	chr15:31115871	NA	-0.67	-11.29	-0.46	2.74e-26	Huntington's disease progression;
LGG	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg10621924	chr7:39171070	POU6F2	0.45	8.96	0.38	8.07e-18	IgG glycosylation;
LGG	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg18196295	chr10:418757	DIP2C	-0.61	-11.72	-0.48	5.87e-28	Psychosis in Alzheimer's disease;
LGG	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.13	-0.49	1.32e-29	Height;
LGG	cis	rs4919694	1.000	rs80327774	chr10:104656671	T/C	cg04362960	chr10:104952993	NT5C2	1.1	15.11	0.57	3.29e-42	Arsenic metabolism;
LGG	cis	rs2204008	0.569	rs11495449	chr12:37995753	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.24	0.72	4.35e-75	Bladder cancer;
LGG	cis	rs6964587	1.000	rs28584017	chr7:91719168	G/A	cg17063962	chr7:91808500	NA	0.47	8.42	0.36	4.67e-16	Breast cancer;
LGG	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg16141378	chr3:129829833	LOC729375	0.37	8.3	0.36	1.16e-15	Triglycerides;
LGG	cis	rs698813	0.572	rs12712914	chr2:44478649	C/G	cg00619915	chr2:44497795	NA	-0.6	-8.88	-0.38	1.44e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.42	6.89	0.3	1.83e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg06618935	chr21:46677482	NA	-0.51	-8.79	-0.38	2.9e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7945718	0.806	rs7927346	chr11:12835835	C/T	cg25843174	chr11:12811716	TEAD1	0.38	7.65	0.33	1.2e-13	Educational attainment (years of education);
LGG	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg25427524	chr10:38739819	LOC399744	-0.6	-12.2	-0.49	7.08e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg21453758	chr17:80185943	SLC16A3	-0.33	-7.0	-0.31	9.17e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg20503657	chr10:835505	NA	0.57	7.49	0.33	3.56e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg05342682	chr7:94953680	PON1	-0.32	-7.38	-0.32	7.28e-13	Paraoxonase activity;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.92	-15.73	-0.59	5.93e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2905347	1.000	rs2905347	chr7:22620319	C/T	cg18045685	chr7:22629474	NA	0.79	17.6	0.63	1.88e-53	Major depression and alcohol dependence;
LGG	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	11.05	0.46	2.37e-25	Emphysema distribution in smoking;
LGG	cis	rs738322	0.555	rs5750548	chr22:38547016	C/A	cg25457927	chr22:38595422	NA	-0.45	-10.94	-0.45	5.97e-25	Cutaneous nevi;
LGG	cis	rs2933343	0.859	rs789247	chr3:128580585	C/A	cg25356066	chr3:128598488	ACAD9	0.46	6.69	0.3	6.53e-11	IgG glycosylation;
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg07142201	chr11:109293216	C11orf87	0.55	9.76	0.41	1.34e-20	Schizophrenia;
LGG	cis	rs9354308	0.764	rs1938099	chr6:66599750	T/G	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	cis	rs1497828	0.956	rs2815245	chr1:217559982	A/G	cg04411442	chr1:217543379	NA	0.47	8.15	0.35	3.39e-15	Dialysis-related mortality;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg14092988	chr3:52407081	DNAH1	0.31	8.18	0.36	2.8e-15	Bipolar disorder;
LGG	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg07541023	chr7:19748670	TWISTNB	0.58	7.83	0.34	3.28e-14	Thyroid stimulating hormone;
LGG	cis	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg00383909	chr3:49044727	WDR6	-1.02	-12.67	-0.51	8.35e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs73198271	1.000	rs11784958	chr8:8607781	C/A	cg16141378	chr3:129829833	LOC729375	0.37	6.91	0.31	1.63e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-18.91	-0.66	1.59e-59	Vitiligo;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.55	0.37	1.84e-16	Personality dimensions;
LGG	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg05692746	chr2:100937584	LONRF2	0.6	10.65	0.44	7.69e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17253792	0.822	rs75049893	chr14:56089158	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.85	-0.3	2.4e-11	Sudden cardiac arrest;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg22535103	chr8:58192502	C8orf71	-0.98	-15.74	-0.59	5.17e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs1418639	chr6:125999940	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	cis	rs62025270	0.688	rs79083718	chr15:86263529	T/A	cg25843651	chr15:86329602	KLHL25	0.57	8.8	0.38	2.76e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs10463554	0.824	rs3776868	chr5:102298716	T/G	cg23492399	chr5:102201601	PAM	-0.54	-8.19	-0.36	2.57e-15	Parkinson's disease;
LGG	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg02023728	chr11:77925099	USP35	-0.38	-6.76	-0.3	4.25e-11	Alzheimer's disease (survival time);
LGG	cis	rs12681287	0.640	rs6471314	chr8:87400459	G/A	cg27223183	chr8:87520930	FAM82B	0.5	7.7	0.34	8.59e-14	Caudate activity during reward;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg05896524	chr21:47604654	C21orf56	0.58	10.17	0.43	4.42e-22	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.63	0.33	1.31e-13	Menopause (age at onset);
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs9912468	0.933	rs17633401	chr17:64301363	C/T	cg19474267	chr17:64306194	PRKCA	0.94	24.86	0.76	2.69e-87	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs922107	0.934	rs6700967	chr1:90017273	C/G	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.59	-0.33	1.79e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	trans	rs3857536	0.679	rs7740850	chr6:66981033	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.08	-0.31	5.39e-12	Blood trace element (Cu levels);
LGG	cis	rs3087591	1.000	rs1800845	chr17:29703438	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.43	-0.56	2.97e-39	Hip circumference;
LGG	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11764359	chr7:65958608	NA	-0.59	-9.96	-0.42	2.72e-21	Aortic root size;
LGG	cis	rs2587949	0.593	rs588845	chr3:4173839	C/G	cg16519197	chr3:4211558	NA	-0.36	-7.32	-0.32	1.11e-12	Periodontitis (DPAL);
LGG	cis	rs6942756	1.000	rs2402945	chr7:128956256	C/A	cg02491457	chr7:128862824	NA	-0.74	-13.52	-0.53	2.48e-35	White matter hyperintensity burden;
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-9.13	-0.39	2.12e-18	Vitiligo;
LGG	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.54e-21	HDL cholesterol;
LGG	cis	rs11122272	0.735	rs2808592	chr1:231523757	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	17.62	0.63	1.44e-53	Smoking behavior;
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-20.59	-0.69	2.34e-67	Vitiligo;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.39	7.38	0.32	7.49e-13	Longevity;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg01059449	chr18:44338099	ST8SIA5	0.32	7.11	0.31	4.29e-12	Personality dimensions;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.8	0.38	2.77e-17	Schizophrenia;
LGG	cis	rs9300255	0.722	rs11830103	chr12:123823546	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-8.63	-0.37	9.59e-17	Neutrophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04496899	chr1:70820341	HHLA3;ANKRD13C	0.45	7.27	0.32	1.55e-12	Cognitive performance;
LGG	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg01403660	chr11:68851641	TPCN2	0.53	7.44	0.33	4.99e-13	Blond vs. brown hair color;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19312935	chr22:42017417	PPPDE2;XRCC6	0.41	6.81	0.3	3.06e-11	Cognitive performance;
LGG	cis	rs10193935	0.901	rs871045	chr2:42609431	G/C	cg27598129	chr2:42591480	NA	-0.64	-9.61	-0.41	4.53e-20	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10512748	chr1:28844557	SNHG3-RCC1;RCC1	0.54	8.14	0.35	3.74e-15	Gut microbiome composition (summer);
LGG	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.49	-0.33	3.61e-13	Obesity-related traits;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.07e-21	Prudent dietary pattern;
LGG	cis	rs12210905	0.688	rs115030474	chr6:27512220	C/T	cg15325629	chr6:28072465	NA	0.98	7.48	0.33	3.69e-13	Hip circumference adjusted for BMI;
LGG	cis	rs4622507	0.618	rs66471173	chr16:55062304	G/T	cg09947736	chr16:55091198	NA	0.77	11.24	0.46	4.56e-26	Social communication problems;
LGG	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg24375607	chr4:120327624	NA	0.62	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.85	0.34	2.82e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2046867	0.908	rs62251639	chr3:72801214	G/A	cg25664220	chr3:72788482	NA	-0.32	-8.8	-0.38	2.65e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg23202291	chr11:1979235	NA	0.37	7.23	0.32	2.04e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.11	0.31	4.32e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg04691961	chr3:161091175	C3orf57	-0.62	-14.16	-0.55	4.46e-38	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg16482183	chr6:26056742	HIST1H1C	0.92	13.81	0.54	1.39e-36	Iron status biomarkers;
LGG	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg03806693	chr22:41940476	POLR3H	-0.88	-14.65	-0.56	3.19e-40	Vitiligo;
LGG	cis	rs4917300	1.000	rs2220696	chr8:143118812	C/G	cg06573787	chr8:143070187	NA	-0.49	-8.89	-0.38	1.33e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs11700980	0.748	rs11701355	chr21:30285594	A/G	cg24692254	chr21:30365293	RNF160	-0.58	-6.67	-0.3	7.46e-11	QRS complex (12-leadsum);
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.19	0.62	1.37e-51	Alzheimer's disease;
LGG	cis	rs6723226	0.842	rs1901355	chr2:32835664	A/G	cg02381751	chr2:32503542	YIPF4	-0.7	-10.81	-0.45	1.92e-24	Intelligence (multi-trait analysis);
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.44	8.2e-24	Neuroticism;
LGG	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.66	0.54	6.5e-36	IgG glycosylation;
LGG	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg11995313	chr8:8860691	ERI1	0.41	6.9	0.31	1.75e-11	Joint mobility (Beighton score);
LGG	cis	rs778371	0.697	rs6717048	chr2:233586427	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.89	0.48	1.19e-28	Schizophrenia;
LGG	cis	rs537930	0.922	rs660273	chr5:134348564	G/T	cg24576358	chr5:134350122	NA	0.46	9.29	0.4	6.25e-19	Height;
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg00101154	chr16:420108	MRPL28	-0.64	-10.17	-0.43	4.56e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7717393	0.786	rs10038418	chr5:155792943	T/C	cg12904904	chr5:155754151	SGCD	0.64	7.45	0.33	4.53e-13	Egg allergy;
LGG	cis	rs8062405	0.755	rs17707300	chr16:28593347	A/G	cg00198680	chr16:28758506	NA	0.28	6.64	0.3	8.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg19182353	chr11:118479428	PHLDB1	0.56	11.83	0.48	2.2e-28	Cholesterol, total;
LGG	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg08847533	chr14:75593920	NEK9	0.52	9.71	0.41	2.1e-20	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21483842	chr13:49821938	CDADC1	0.38	6.65	0.3	8.51e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg27432699	chr2:27873401	GPN1	0.7	14.4	0.56	4.13e-39	Oral cavity cancer;
LGG	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg03175030	chr11:2018143	H19;MIR675	-0.58	-11.04	-0.46	2.56e-25	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs42648	0.869	rs42611	chr7:89950060	C/A	cg25739043	chr7:89950458	NA	-0.44	-9.35	-0.4	3.73e-19	Homocysteine levels;
LGG	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.64	-0.41	3.52e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg12310025	chr6:25882481	NA	-0.43	-6.9	-0.31	1.74e-11	Iron status biomarkers;
LGG	cis	rs7267979	0.586	rs6050429	chr20:25183058	G/A	cg06421707	chr20:25228305	PYGB	0.39	7.99	0.35	1.12e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg17376030	chr22:41985996	PMM1	-0.65	-10.63	-0.44	9.06e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1018836	0.700	rs4735201	chr8:91528313	C/T	cg16814680	chr8:91681699	NA	-0.75	-12.72	-0.51	5.35e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9397585	0.791	rs9371658	chr6:153368353	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13111919	chr4:185569962	CCDC111;CASP3	0.45	6.97	0.31	1.1e-11	Gut microbiome composition (summer);
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02711726	chr17:80685570	FN3KRP	0.58	10.39	0.43	7.48e-23	Glycated hemoglobin levels;
LGG	cis	rs921968	0.608	rs7598056	chr2:219352511	A/C	cg02985541	chr2:219472218	PLCD4	0.29	6.86	0.3	2.15e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg23978390	chr7:1156363	C7orf50	0.56	9.68	0.41	2.56e-20	Longevity;Endometriosis;
LGG	cis	rs9863	0.827	rs12823740	chr12:124458002	C/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	5.12e-12	White blood cell count;
LGG	trans	rs61931739	1.000	rs12304768	chr12:34000986	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-8.09	-0.35	5.16e-15	Morning vs. evening chronotype;
LGG	cis	rs12049351	0.665	rs3767325	chr1:229590046	C/T	cg13547644	chr1:229569608	ACTA1	0.32	7.17	0.32	2.92e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg12486710	chr1:178512616	C1orf220	0.51	10.42	0.44	5.51e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1577917	0.655	rs2842600	chr6:86325632	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.24	-0.46	4.45e-26	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg24829409	chr8:58192753	C8orf71	-0.58	-7.92	-0.35	1.76e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg27147174	chr7:100797783	AP1S1	0.65	12.0	0.49	4.69e-29	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg06885757	chr1:42089581	HIVEP3	0.59	13.5	0.53	2.91e-35	Airway imaging phenotypes;
LGG	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg23335576	chr14:104009727	NA	0.47	8.19	0.36	2.56e-15	Reticulocyte count;
LGG	cis	rs72781680	0.752	rs72796114	chr2:23906133	C/G	cg08917208	chr2:24149416	ATAD2B	0.84	8.85	0.38	1.88e-17	Lymphocyte counts;
LGG	cis	rs28655083	1.000	rs7198870	chr16:77072963	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.68	-0.34	9.5e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs4330281	0.647	rs6799259	chr3:17427142	T/C	cg20981856	chr3:17787350	NA	0.36	6.77	0.3	3.81e-11	Schizophrenia;
LGG	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg03929089	chr4:120376271	NA	0.77	11.41	0.47	9.55e-27	Coronary artery disease;
LGG	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg07303275	chr16:75499416	TMEM170A	0.41	7.33	0.32	1e-12	Dupuytren's disease;
LGG	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg20891283	chr12:69753455	YEATS4	0.97	22.99	0.73	1.43e-78	Blood protein levels;
LGG	trans	rs4942242	0.663	rs7332737	chr13:44215043	C/T	cg19169023	chr15:41853346	TYRO3	-0.44	-8.8	-0.38	2.82e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7084783	0.532	rs10883894	chr10:105422957	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.4	7.47	0.33	3.94e-13	Fear of pain;
LGG	trans	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg06521331	chr12:34319734	NA	0.43	7.6	0.33	1.62e-13	Bladder cancer;
LGG	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.43	0.33	5.2e-13	Birth weight;
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.8	-0.3	3.21e-11	Bipolar disorder;
LGG	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg13271783	chr10:134563150	INPP5A	-0.46	-7.68	-0.34	9.78e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4820539	0.966	rs5751590	chr22:23486830	A/C	cg14186256	chr22:23484241	RTDR1	1.02	26.18	0.77	2.24e-93	Bone mineral density;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.46	-0.5	5.98e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	1.000	rs4148101	chr21:43640183	G/A	cg08841829	chr21:43638893	ABCG1	-0.67	-9.64	-0.41	3.53e-20	Eating disorder in bipolar disorder;
LGG	cis	rs9649465	0.967	rs1008539	chr7:123305518	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs2274273	0.837	rs56949365	chr14:55790078	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.17	0.62	1.69e-51	Protein biomarker;
LGG	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg23659134	chr10:106035168	GSTO2	-0.38	-8.34	-0.36	8.27e-16	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg09307838	chr4:120376055	NA	-0.59	-9.53	-0.41	8.64e-20	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.82	-0.38	2.39e-17	Lung cancer;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg07701084	chr6:150067640	NUP43	0.5	7.56	0.33	2.22e-13	Lung cancer;
LGG	cis	rs6424115	0.965	rs2502986	chr1:24135292	G/T	cg24699146	chr1:24152579	HMGCL	0.25	7.66	0.34	1.08e-13	Immature fraction of reticulocytes;
LGG	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.11	0.46	1.42e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.78	15.75	0.59	4.7e-45	Obesity-related traits;
LGG	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg01324343	chr3:183735012	ABCC5	0.86	18.39	0.65	4.13e-57	Anterior chamber depth;
LGG	cis	rs7904985	0.813	rs724862	chr10:88100542	C/G	cg07322936	chr10:88137208	NA	-0.51	-7.77	-0.34	5e-14	Barrett's esophagus;
LGG	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg08508325	chr11:3079039	CARS	0.43	8.39	0.36	5.95e-16	Calcium levels;
LGG	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg03213289	chr20:61660250	NA	0.66	14.45	0.56	2.55e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01251444	chr7:99933543	PILRB;PMS2L1	0.45	6.65	0.3	8.11e-11	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.673	rs10257567	chr7:19934505	A/G	cg05791153	chr7:19748676	TWISTNB	0.5	7.2	0.32	2.48e-12	Night sleep phenotypes;
LGG	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	8.57	0.37	1.55e-16	Myopia (pathological);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01585758	chr2:203102753	SUMO1	0.5	7.59	0.33	1.8e-13	Gut microbiome composition (summer);
LGG	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg22563815	chr15:78856949	CHRNA5	0.29	6.96	0.31	1.15e-11	Sudden cardiac arrest;
LGG	cis	rs17767392	0.958	rs7144829	chr14:72066456	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.48	-0.4	1.37e-19	Mitral valve prolapse;
LGG	cis	rs9925964	0.933	rs2303223	chr16:31075175	G/A	cg00531865	chr16:30841666	NA	0.33	6.69	0.3	6.45e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9796	0.866	rs2928148	chr15:41401550	G/A	cg18705301	chr15:41695430	NDUFAF1	0.52	8.94	0.38	9.21e-18	Menopause (age at onset);
LGG	cis	rs7851660	0.874	rs7860144	chr9:100626884	A/G	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg03160526	chr17:80928410	B3GNTL1	0.5	8.01	0.35	9.06e-15	Glycated hemoglobin levels;
LGG	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-9.08	-0.39	3.2e-18	Joint mobility (Beighton score);
LGG	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg04995300	chr3:66848608	NA	0.55	8.11	0.35	4.68e-15	Type 2 diabetes;
LGG	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.18e-13	Dupuytren's disease;
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg02733842	chr7:1102375	C7orf50	0.69	8.26	0.36	1.51e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg00277334	chr10:82204260	NA	-0.34	-7.51	-0.33	3.1400000000000003e-13	Post bronchodilator FEV1;
LGG	trans	rs73198271	0.960	rs73198290	chr8:8616009	A/T	cg16141378	chr3:129829833	LOC729375	0.39	7.12	0.31	4.23e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg06713675	chr4:122721982	EXOSC9	-0.59	-8.23	-0.36	1.85e-15	Type 2 diabetes;
LGG	cis	rs6964587	1.000	rs9969198	chr7:91567492	G/T	cg17063962	chr7:91808500	NA	-0.49	-8.62	-0.37	1.05e-16	Breast cancer;
LGG	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.74	-0.3	4.72e-11	Sudden cardiac arrest;
LGG	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg05941027	chr17:61774174	LIMD2	-0.33	-8.05	-0.35	7.01e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs6489882	0.867	rs6489866	chr12:113363408	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.18e-13	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.12e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg26384229	chr12:38710491	ALG10B	0.8	17.32	0.63	3.64e-52	Bladder cancer;
LGG	cis	rs6456156	0.586	rs9459853	chr6:167465774	C/A	cg07741184	chr6:167504864	NA	0.39	8.8	0.38	2.69e-17	Primary biliary cholangitis;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.02	-0.31	8.14e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs747782	0.582	rs4752843	chr11:47531884	T/G	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.49e-11	Intraocular pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26649251	chr19:44598564	ZNF224	-0.51	-7.55	-0.33	2.27e-13	Systemic lupus erythematosus;
LGG	cis	rs11255291	0.668	rs4749169	chr10:7737661	G/C	cg13340899	chr10:7670827	ITIH5	0.41	7.15	0.32	3.48e-12	Ovarian reserve;
LGG	cis	rs9287719	0.967	rs10191883	chr2:10744136	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27286337	chr10:134555280	INPP5A	0.85	12.34	0.5	1.86e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.5	-0.4	1.09e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15749322	chr11:82905199	ANKRD42	0.43	7.09	0.31	4.88e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17711722	0.523	rs365896	chr7:65510697	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-13.11	-0.52	1.34e-33	Calcium levels;
LGG	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs988958	0.755	rs988263	chr2:42290536	T/C	cg19376973	chr2:42229025	NA	0.45	6.7	0.3	5.9e-11	Hypospadias;
LGG	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg02733842	chr7:1102375	C7orf50	-0.55	-8.27	-0.36	1.43e-15	Bronchopulmonary dysplasia;
LGG	cis	rs1790761	0.967	rs4930427	chr11:67200819	C/T	cg00290607	chr11:67383545	NA	-0.47	-8.35	-0.36	7.8e-16	Mean corpuscular volume;
LGG	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg27205649	chr11:78285834	NARS2	-0.49	-8.31	-0.36	1.07e-15	Alzheimer's disease (survival time);
LGG	cis	rs3762637	1.000	rs7642869	chr3:122190786	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg03823431	chr17:79229385	SLC38A10	0.32	6.93	0.31	1.38e-11	Frontotemporal dementia;
LGG	cis	rs883565	0.655	rs6768957	chr3:39100094	G/A	cg01426195	chr3:39028469	NA	-0.73	-17.06	-0.62	5.46e-51	Handedness;
LGG	cis	rs847577	0.722	rs1013886	chr7:97709861	A/G	cg13397024	chr7:97797637	LMTK2	0.35	6.65	0.3	8.2e-11	Breast cancer;
LGG	cis	rs4144743	0.759	rs4289057	chr17:45321030	G/A	cg18085866	chr17:45331354	ITGB3	-0.75	-8.17	-0.35	2.96e-15	Body mass index;
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg19635926	chr16:89946313	TCF25	0.69	8.34	0.36	8.55e-16	Skin colour saturation;
LGG	cis	rs975722	0.632	rs6466612	chr7:117097922	T/C	cg10524701	chr7:117356490	CTTNBP2	-0.43	-9.55	-0.41	7.71e-20	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg09818912	chr17:20140352	CYTSB	0.29	6.68	0.3	6.98e-11	Obesity-related traits;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.47	-8.38	-0.36	6.57e-16	Longevity;Endometriosis;
LGG	cis	rs6504108	0.624	rs2305433	chr17:46265433	C/G	cg02219949	chr17:45927392	SP6	-0.43	-8.07	-0.35	6.22e-15	Body mass index;
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg16301924	chr13:53314226	LECT1	-0.48	-9.37	-0.4	3.23e-19	Lewy body disease;
LGG	cis	rs503734	0.502	rs348864	chr3:100910127	T/G	cg27318481	chr3:100970896	IMPG2	-0.57	-13.16	-0.52	8.05e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs490234	0.812	rs4838285	chr9:128446888	C/T	cg14078157	chr9:128172775	NA	-0.43	-7.95	-0.35	1.42e-14	Mean arterial pressure;
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.81	-16.62	-0.61	5.53e-49	Personality dimensions;
LGG	cis	rs2729354	0.817	rs2250673	chr11:57268170	T/C	cg24343310	chr11:57249947	NA	0.42	8.27	0.36	1.41e-15	Blood protein levels;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.27e-13	Menopause (age at onset);
LGG	cis	rs6694672	0.764	rs668590	chr1:197220598	A/T	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs8077059	1.000	rs9944404	chr17:55809972	T/A	cg12582317	chr17:55822272	NA	0.39	7.06	0.31	6.21e-12	Sex hormone-binding globulin levels;
LGG	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg16070123	chr10:51489643	NA	-0.39	-7.05	-0.31	6.47e-12	Prostate-specific antigen levels;
LGG	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg20570797	chr2:1712800	PXDN	-0.45	-7.75	-0.34	6.05e-14	Response to antipsychotic treatment;
LGG	cis	rs6582630	0.519	rs11495700	chr12:38288240	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.61	0.71	4.03e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7582720	0.943	rs72934734	chr2:203739970	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg08508325	chr11:3079039	CARS	-0.62	-13.67	-0.54	5.44e-36	Longevity;
LGG	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg03929089	chr4:120376271	NA	-0.98	-21.38	-0.7	4.87e-71	Coronary artery disease;
LGG	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg07636037	chr3:49044803	WDR6	0.68	12.52	0.5	3.7e-31	Parkinson's disease;
LGG	cis	rs2502399	0.898	rs774572	chr6:113512682	T/A	cg20413948	chr6:113544930	NA	0.29	6.85	0.3	2.4e-11	Plasma clusterin levels;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.74	0.34	6.24e-14	Neuroticism;
LGG	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.59	-7.83	-0.34	3.45e-14	Depression;
LGG	cis	rs12220238	1.000	rs11000922	chr10:75969305	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.81	10.9	0.45	8.53e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg25358565	chr5:93447407	FAM172A	-0.68	-9.77	-0.41	1.28e-20	Diabetic retinopathy;
LGG	trans	rs800082	1.000	rs11718059	chr3:144305997	G/A	cg24215973	chr2:240111563	HDAC4	-0.49	-8.66	-0.37	7.84e-17	Smoking behavior;
LGG	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.67	0.41	2.77e-20	Height;
LGG	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg16576597	chr16:28551801	NUPR1	0.3	6.71	0.3	5.56e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6882716	1.000	rs4702730	chr5:10799879	T/A	cg14521931	chr5:10832172	NA	-0.97	-15.17	-0.58	1.77e-42	Alcohol consumption (maxi-drinks);
LGG	cis	rs7017914	0.934	rs78923624	chr8:71677839	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg11584989	chr19:19387371	SF4	-0.74	-12.43	-0.5	7.87e-31	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.13	0.31	3.85e-12	Prudent dietary pattern;
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	cis	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg21775007	chr8:11205619	TDH	-0.51	-8.34	-0.36	8.4e-16	Neuroticism;
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg17691542	chr6:26056736	HIST1H1C	0.55	9.8	0.41	1.03e-20	Height;
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.5	-0.4	1.13e-19	Neuroticism;
LGG	cis	rs61884328	0.713	rs61897791	chr11:47186561	T/G	cg03339077	chr11:47165057	C11orf49	0.65	6.9	0.31	1.67e-11	Total body bone mineral density (age over 60);
LGG	cis	rs2298450	0.550	rs113779114	chr21:37658072	T/A	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.77	-0.38	3.51e-17	Schizophrenia;
LGG	cis	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg20368463	chr18:77673604	PQLC1	-0.48	-8.24	-0.36	1.75e-15	Schizophrenia;
LGG	cis	rs9467773	1.000	rs6930120	chr6:26555484	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg04503457	chr17:41445688	NA	-0.41	-10.09	-0.42	9.34e-22	Menopause (age at onset);
LGG	cis	rs11785400	0.762	rs7460801	chr8:143730972	C/A	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.3e-14	Schizophrenia;
LGG	cis	rs7089973	0.604	rs7897937	chr10:116591318	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.21	0.32	2.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg05793240	chr7:2802953	GNA12	0.34	7.59	0.33	1.77e-13	Height;
LGG	cis	rs77633900	0.772	rs284907	chr15:76741569	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg21055462	chr7:100276975	NA	0.45	9.35	0.4	3.63e-19	Other erythrocyte phenotypes;
LGG	cis	rs80282103	0.618	rs1079390	chr10:1161653	C/A	cg08668510	chr10:1095578	IDI1	0.78	7.61	0.33	1.58e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg16339924	chr4:17578868	LAP3	0.63	11.01	0.46	3.33e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg21548813	chr6:291882	DUSP22	0.74	13.2	0.52	5.25e-34	Menopause (age at onset);
LGG	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs1966248	0.543	rs12193307	chr6:134103250	A/G	cg25632230	chr6:134101081	NA	-0.35	-7.65	-0.33	1.19e-13	Coronary artery disease;
LGG	trans	rs6787172	0.621	rs9823076	chr3:158153560	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg00405596	chr8:11794950	NA	-0.6	-10.67	-0.44	6.56e-24	Monocyte count;
LGG	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg11040518	chr10:102331378	NA	-0.39	-6.96	-0.31	1.14e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.55	-0.33	2.38e-13	Life satisfaction;
LGG	cis	rs7712401	0.601	rs27976	chr5:122206460	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.77	-0.3	3.98e-11	Mean platelet volume;
LGG	cis	rs12493885	0.818	rs6800048	chr3:153766181	T/C	cg17054900	chr3:154042577	DHX36	-0.65	-8.28	-0.36	1.34e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs57590327	0.504	rs13065281	chr3:81693550	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.49	-0.33	3.46e-13	Extraversion;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.596	rs12112909	chr7:124584834	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	trans	rs931812	0.829	rs13266662	chr8:101916156	C/T	cg20993868	chr7:22813445	NA	0.58	11.28	0.46	3.18e-26	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg09699651	chr6:150184138	LRP11	0.51	8.96	0.38	8.15e-18	Lung cancer;
LGG	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg10580341	chr11:889148	CHID1	-0.39	-7.03	-0.31	7.45e-12	Mean platelet volume;
LGG	cis	rs892961	0.965	rs2411111	chr17:75402540	A/T	cg05865280	chr17:75406074	SEPT9	0.41	9.59	0.41	5.52e-20	Airflow obstruction;
LGG	cis	rs12912251	0.591	rs2624272	chr15:39003409	A/G	cg10631289	chr15:39006617	NA	-0.42	-7.1	-0.31	4.84e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs7315438	0.512	rs10850527	chr12:115941263	C/T	cg18639984	chr12:115943877	NA	-0.39	-8.55	-0.37	1.77e-16	Colorectal cancer;
LGG	cis	rs11239187	0.530	rs11239142	chr10:45063329	G/A	cg03916630	chr10:45065415	NA	0.37	9.01	0.39	5.3e-18	Body mass index;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	trans	rs11650494	0.710	rs57030023	chr17:47468546	T/A	cg11430096	chr6:110968061	CDK19	0.65	6.66	0.3	7.64e-11	Prostate cancer;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs4363385	0.747	rs1611759	chr1:152957439	T/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.3	-0.4	5.75e-19	Inflammatory skin disease;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg13282195	chr8:144660772	NAPRT1	0.94	7.47	0.33	3.93e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs911186	0.891	rs6914824	chr6:27139048	C/T	cg12826209	chr6:26865740	GUSBL1	0.57	7.08	0.31	5.42e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs34381861	0.520	rs74382390	chr16:71458526	C/G	cg08717414	chr16:71523259	ZNF19	-1.06	-12.8	-0.51	2.4e-32	Post bronchodilator FEV1;
LGG	cis	rs78456975	1.000	rs11899027	chr2:1560414	G/C	cg26248373	chr2:1572462	NA	-0.69	-8.88	-0.38	1.51e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg02462569	chr6:150064036	NUP43	-0.38	-8.08	-0.35	5.87e-15	Lung cancer;
LGG	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg20488157	chr14:104394430	TDRD9	0.57	9.19	0.39	1.33e-18	Bipolar disorder;
LGG	cis	rs981844	0.740	rs10024619	chr4:154684441	A/T	cg14289246	chr4:154710475	SFRP2	-0.6	-10.74	-0.45	3.42e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	trans	rs208520	0.690	rs12192710	chr6:66718137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.71	0.64	5.77e-54	Exhaled nitric oxide output;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg20295408	chr7:1910781	MAD1L1	0.46	8.21	0.36	2.24e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.583	rs112940751	chr12:33687592	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-8.05	-0.35	7.29e-15	Morning vs. evening chronotype;
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg24578937	chr1:2090814	PRKCZ	-0.33	-8.91	-0.38	1.2e-17	Height;
LGG	trans	rs75804782	0.641	rs55740938	chr2:239332647	G/A	cg01134436	chr17:81009848	B3GNTL1	0.86	8.78	0.38	3.19e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg22906224	chr7:99728672	NA	-0.59	-9.65	-0.41	3.27e-20	Coronary artery disease;
LGG	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg09537434	chr19:41945824	ATP5SL	-0.87	-22.74	-0.73	1.93e-77	Height;
LGG	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg11871910	chr12:69753446	YEATS4	0.8	13.62	0.53	9.01e-36	Response to diuretic therapy;
LGG	cis	rs1375194	0.558	rs13418410	chr2:33800899	C/A	cg04131969	chr2:33951647	MYADML	-0.58	-10.16	-0.43	4.94e-22	Response to antidepressants in depression;
LGG	cis	rs7312774	0.618	rs7304621	chr12:107325888	C/T	cg16260113	chr12:107380972	MTERFD3	0.89	8.35	0.36	7.89e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25172604	chr17:41446521	NA	-0.31	-7.47	-0.33	3.91e-13	Menopause (age at onset);
LGG	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03264133	chr6:25882463	NA	0.55	10.12	0.43	7.28e-22	Blood metabolite levels;
LGG	cis	rs763121	0.853	rs10135	chr22:39082174	C/T	cg06022373	chr22:39101656	GTPBP1	-0.85	-18.79	-0.66	5.95e-59	Menopause (age at onset);
LGG	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg24692254	chr21:30365293	RNF160	0.58	10.5	0.44	2.82e-23	Pancreatic cancer;
LGG	trans	rs9914544	0.545	rs12452289	chr17:18781809	T/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs9914988	0.778	rs4794837	chr17:27110024	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg20290983	chr6:43655470	MRPS18A	-1.09	-23.44	-0.74	1.07e-80	IgG glycosylation;
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.92	-0.35	1.74e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs225245	0.817	rs225255	chr17:33955243	A/G	cg19694781	chr19:47549865	TMEM160	0.41	7.1	0.31	4.74e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.43	0.33	5.28e-13	Menopause (age at onset);
LGG	cis	rs2721811	0.665	rs2108301	chr7:24660345	T/A	cg06301139	chr7:24798175	DFNA5	-0.38	-6.95	-0.31	1.28e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg02733842	chr7:1102375	C7orf50	0.69	10.41	0.44	6.15e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs73086581	1.000	rs17286349	chr20:3914302	G/A	cg02187196	chr20:3869020	PANK2	0.85	11.81	0.48	2.53e-28	Response to antidepressants in depression;
LGG	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.99	-0.55	2.44e-37	Morning vs. evening chronotype;
LGG	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg08198773	chr8:1697536	NA	0.45	7.93	0.35	1.65e-14	Systolic blood pressure;
LGG	cis	rs7584262	0.737	rs12996528	chr2:42239901	T/C	cg27252766	chr2:42229092	NA	0.47	6.72	0.3	5.28e-11	Bone mineral density;
LGG	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg13073564	chr4:8508604	NA	-0.6	-12.05	-0.49	2.79e-29	Response to antineoplastic agents;
LGG	trans	rs7937682	0.575	rs34695265	chr11:111719128	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00198680	chr16:28758506	NA	0.3	7.66	0.34	1.12e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6764363	0.566	rs4003416	chr3:281319	G/A	cg02057681	chr3:285234	CHL1	-0.44	-7.89	-0.34	2.28e-14	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg00933542	chr6:150070202	PCMT1	0.39	6.84	0.3	2.49e-11	Lung cancer;
LGG	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.99	0.45	4.05e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.54	0.33	2.43e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs611744	0.805	rs378515	chr8:109104905	T/G	cg21045802	chr8:109455806	TTC35	0.38	6.66	0.3	7.89e-11	Dupuytren's disease;
LGG	cis	rs17253792	0.822	rs28481586	chr14:56053863	C/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.99	0.57	1.05e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.44	-0.4	1.76e-19	Mean corpuscular volume;
LGG	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg13010199	chr12:38710504	ALG10B	-0.66	-12.61	-0.51	1.46e-31	Morning vs. evening chronotype;
LGG	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg02175503	chr12:58329896	NA	0.49	7.74	0.34	6.12e-14	Multiple sclerosis;
LGG	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.77	0.34	5.16e-14	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.41	0.33	6.17e-13	Lung cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02776251	chr12:62654319	USP15	-0.48	-6.93	-0.31	1.39e-11	Systemic lupus erythematosus;
LGG	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg26578617	chr4:90757533	SNCA	-0.35	-7.02	-0.31	7.82e-12	Dementia with Lewy bodies;
LGG	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg21775007	chr8:11205619	TDH	0.47	7.59	0.33	1.75e-13	Joint mobility (Beighton score);
LGG	cis	rs2984613	1	rs2984613	chr1:156197380	C/T	cg25208724	chr1:156163844	SLC25A44	1.11	22.76	0.73	1.71e-77	Intracerebral hemorrhage;White matter hyperintensity burden;
LGG	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg02151108	chr14:50098012	C14orf104	-0.47	-10.11	-0.43	7.56e-22	Carotid intima media thickness;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04990056	chr1:28099876	STX12	-0.46	-7.3	-0.32	1.27e-12	Pancreatic cancer;
LGG	cis	rs300774	1.000	rs300802	chr2:104762	G/A	cg04617936	chr2:214353	NA	-0.48	-7.18	-0.32	2.85e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg23782820	chr8:58130467	NA	0.49	7.12	0.31	4.06e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06873352	chr17:61820015	STRADA	0.74	13.67	0.54	5.81e-36	Prudent dietary pattern;
LGG	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg06917634	chr15:78832804	PSMA4	-0.71	-14.5	-0.56	1.48e-39	Sudden cardiac arrest;
LGG	cis	rs963731	0.649	rs297135	chr2:39304793	G/A	cg04010122	chr2:39346883	SOS1	-0.8	-7.16	-0.32	3.1e-12	Corticobasal degeneration;
LGG	cis	rs643506	0.845	rs2850245	chr11:111760738	G/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.85	0.3	2.31e-11	Breast cancer;
LGG	cis	rs10789491	1.000	rs35861275	chr1:47171909	A/C	cg15501359	chr1:47185051	KIAA0494	-0.77	-14.1	-0.55	7.78e-38	Response to hepatitis C treatment;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.17	0.55	4.1e-38	Obesity-related traits;
LGG	cis	rs1670533	0.872	rs11727135	chr4:1051803	G/C	cg27284194	chr4:1044797	NA	0.5	9.05	0.39	3.86e-18	Recombination rate (females);
LGG	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg11707556	chr5:10655725	ANKRD33B	0.58	10.24	0.43	2.59e-22	Coronary artery disease;
LGG	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg06453172	chr10:134556979	INPP5A	-0.55	-8.29	-0.36	1.23e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs742614	0.533	rs6059497	chr20:32446960	C/G	cg06304546	chr20:32448765	NA	-0.72	-14.27	-0.55	1.52e-38	Stearic acid (18:0) levels;
LGG	cis	rs9783347	0.621	rs10766469	chr11:18323316	G/C	cg03595886	chr11:18357587	GTF2H1	-0.48	-11.75	-0.48	4.39e-28	Pancreatic cancer;
LGG	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	9.04	0.39	4.18e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2224391	0.628	rs2753239	chr6:5252826	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.07	-0.31	5.93e-12	Height;
LGG	cis	rs7666738	0.830	rs13137859	chr4:99050319	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg18252515	chr7:66147081	NA	-0.75	-12.0	-0.49	4.36e-29	Corneal structure;
LGG	cis	rs12618769	0.597	rs56197140	chr2:99113740	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs36093844	0.752	rs77197861	chr11:85547405	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.26	0.36	1.59e-15	Bipolar disorder;
LGG	cis	rs10932679	0.532	rs2712162	chr2:217661788	C/T	cg05032264	chr2:217675019	NA	-0.43	-8.64	-0.37	9.1e-17	Pulse pressure;
LGG	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	cis	rs240764	0.697	rs846799	chr6:101270345	A/G	cg21058520	chr6:100914733	NA	-0.4	-6.88	-0.3	1.93e-11	Neuroticism;
LGG	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg15522984	chr1:182991683	LAMC1	0.47	9.75	0.41	1.5e-20	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg10295955	chr4:187884368	NA	-1.15	-31.51	-0.83	2.97e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs1318772	1.000	rs26984	chr5:112774425	A/G	cg12552261	chr5:112820674	MCC	0.71	7.94	0.35	1.56e-14	F-cell distribution;
LGG	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg13232821	chr7:50628718	DDC	0.35	6.89	0.3	1.82e-11	Malaria;
LGG	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15504467	chr11:108093238	ATM;NPAT	0.46	6.8	0.3	3.3e-11	Gut microbiome composition (summer);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12703710	chr1:146522416	NA	0.38	7.47	0.33	3.94e-13	Menarche (age at onset);
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2658782	0.789	rs3020073	chr11:93103830	T/C	cg15737290	chr11:93063684	CCDC67	0.51	7.85	0.34	2.82e-14	Pulmonary function decline;
LGG	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs854765	0.547	rs2955380	chr17:17944349	A/G	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.71	-0.38	5.48e-17	Post bronchodilator FEV1;
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg18258770	chr4:90757814	SNCA	-0.4	-7.25	-0.32	1.81e-12	Dementia with Lewy bodies;
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.21	0.32	2.25e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg15105011	chr4:940614	TMEM175	0.41	7.77	0.34	5.09e-14	Sjögren's syndrome;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg11062466	chr8:58055876	NA	0.47	7.78	0.34	4.73e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg23762105	chr12:34175262	ALG10	0.34	6.66	0.3	7.83e-11	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs9300255	0.722	rs28592876	chr12:123866429	G/A	cg00376283	chr12:123451042	ABCB9	-0.53	-7.96	-0.35	1.34e-14	Neutrophil percentage of white cells;
LGG	cis	rs7953249	0.594	rs11065384	chr12:121423285	T/C	cg02403541	chr12:121454288	C12orf43	-0.5	-8.13	-0.35	3.98e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs17401966	0.867	rs61775872	chr1:10279308	T/C	cg15208524	chr1:10270712	KIF1B	0.47	8.02	0.35	8.44e-15	Hepatocellular carcinoma;
LGG	cis	rs1790761	0.967	rs869736	chr11:67205462	C/A	cg00290607	chr11:67383545	NA	-0.47	-8.49	-0.37	2.81e-16	Mean corpuscular volume;
LGG	trans	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.47e-21	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19233923	chr11:63753598	OTUB1	0.53	9.03	0.39	4.7e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	9.38	0.4	2.85e-19	Bone mineral density;
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.22e-13	Personality dimensions;
LGG	cis	rs9397585	0.667	rs9371672	chr6:153422140	C/G	cg17707550	chr6:153380415	RGS17	0.48	10.38	0.43	7.69e-23	Body mass index;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.23	-0.32	2.07e-12	Obesity-related traits;
LGG	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.73	-0.3	4.92e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	6.8	0.3	3.32e-11	Bipolar disorder;
LGG	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.54	-0.5	2.8e-31	Bladder cancer;
LGG	cis	rs1401999	1.000	rs6802849	chr3:183698943	A/C	cg05044414	chr3:183734942	ABCC5	0.78	17.09	0.62	4.17e-51	Anterior chamber depth;
LGG	cis	rs9487051	0.676	rs13210693	chr6:109598964	A/G	cg21918786	chr6:109611834	NA	0.43	7.97	0.35	1.26e-14	Reticulocyte fraction of red cells;
LGG	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	14.92	0.57	2.17e-41	Menarche (age at onset);
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg26076054	chr5:421317	AHRR	0.43	7.88	0.34	2.37e-14	Cystic fibrosis severity;
LGG	cis	rs10262624	1.000	rs10245161	chr7:23907692	T/C	cg09690326	chr7:23720549	C7orf46	-0.32	-6.7	-0.3	6.17e-11	Schizophrenia;
LGG	cis	rs372883	0.597	rs2018956	chr21:30736622	C/A	cg08807101	chr21:30365312	RNF160	0.49	8.02	0.35	8.53e-15	Pancreatic cancer;
LGG	cis	rs6541297	0.878	rs4846905	chr1:230279582	C/T	cg05784532	chr1:230284198	GALNT2	-0.49	-8.05	-0.35	6.89e-15	Coronary artery disease;
LGG	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg12395012	chr8:11607386	GATA4	0.41	7.13	0.31	3.92e-12	Retinal vascular caliber;
LGG	cis	rs4356932	1.000	rs11097212	chr4:76952879	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.7	-0.3	5.99e-11	Blood protein levels;
LGG	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg27446573	chr6:127587934	RNF146	1.12	21.83	0.71	3.72e-73	Breast cancer;
LGG	cis	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg07460842	chr6:66804631	NA	0.94	17.59	0.63	2.12e-53	Exhaled nitric oxide output;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09699651	chr6:150184138	LRP11	0.57	10.97	0.45	4.68e-25	Testicular germ cell tumor;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	10.74	0.45	3.6e-24	Pancreatic cancer;
LGG	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg14416269	chr4:6271139	WFS1	0.54	9.92	0.42	3.77e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-13.08	-0.52	1.67e-33	Morning vs. evening chronotype;
LGG	cis	rs72949976	0.564	rs4673730	chr2:214024836	G/T	cg08319019	chr2:214017104	IKZF2	0.67	12.66	0.51	9.2e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs34929064	0.527	rs2961285	chr7:22654968	A/G	cg18045685	chr7:22629474	NA	-0.78	-16.21	-0.6	3.96e-47	Major depression and alcohol dependence;
LGG	trans	rs7939886	0.920	rs1586014	chr11:55771540	C/T	cg15704280	chr7:45808275	SEPT13	0.88	9.21	0.39	1.1e-18	Myopia (pathological);
LGG	cis	rs9354308	0.868	rs9363457	chr6:66549080	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.85	-0.34	2.86e-14	Metabolite levels;
LGG	cis	rs6580649	0.941	rs72644841	chr12:48411987	A/G	cg24011408	chr12:48396354	COL2A1	-0.6	-7.44	-0.33	4.9e-13	Lung cancer;
LGG	trans	rs6787172	0.622	rs67761009	chr3:158068261	G/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.21	-0.32	2.28e-12	Subjective well-being;
LGG	cis	rs17253792	0.822	rs79538158	chr14:56051365	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs11711311	0.955	rs9830102	chr3:113408302	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.48	-0.33	3.67e-13	IgG glycosylation;
LGG	cis	rs897984	0.806	rs1046276	chr16:30914626	A/G	cg02466173	chr16:30829666	NA	0.41	7.22	0.32	2.09e-12	Dementia with Lewy bodies;
LGG	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg27426351	chr10:43362370	NA	0.59	8.41	0.36	5.14e-16	Blood protein levels;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg18621852	chr3:10150065	C3orf24	-0.41	-6.77	-0.3	3.87e-11	Alzheimer's disease;
LGG	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg24308560	chr3:49941425	MST1R	-0.22	-6.67	-0.3	7.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.22	-0.46	5.34e-26	Morning vs. evening chronotype;
LGG	cis	rs7216064	0.684	rs7406031	chr17:66021753	C/T	cg02705964	chr17:66097276	LOC651250	-0.47	-8.3	-0.36	1.18e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg00383909	chr3:49044727	WDR6	0.44	7.22	0.32	2.18e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.11	0.31	4.38e-12	Resting heart rate;
LGG	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg08807101	chr21:30365312	RNF160	0.77	13.87	0.54	8.23e-37	Selective IgA deficiency;
LGG	cis	rs2247341	0.965	rs798761	chr4:1731126	G/A	cg07465881	chr4:1713556	SLBP	-0.45	-7.05	-0.31	6.41e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg01557791	chr16:72042693	DHODH	-0.55	-10.02	-0.42	1.64e-21	Fibrinogen levels;
LGG	cis	rs7586879	0.658	rs7563204	chr2:25125075	T/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs12200782	0.649	rs3757148	chr6:26381206	C/T	cg27193005	chr6:26382695	BTN2A2	0.52	7.46	0.33	4.28e-13	Small cell lung carcinoma;
LGG	cis	rs67478160	0.643	rs2295145	chr14:104202304	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-7.47	-0.33	3.97e-13	Schizophrenia;
LGG	cis	rs10751667	0.621	rs7394862	chr11:927500	T/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs6831352	0.819	rs1230158	chr4:99990186	T/C	cg13256891	chr4:100009986	ADH5	0.49	8.64	0.37	9.39e-17	Alcohol dependence;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21659397	chr7:155080028	NA	0.37	6.92	0.31	1.54e-11	Electrocardiographic conduction measures;
LGG	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg22437258	chr11:111473054	SIK2	-0.54	-8.99	-0.39	6.39e-18	Primary sclerosing cholangitis;
LGG	cis	rs4846580	0.660	rs17006353	chr1:219874421	A/G	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.39e-12	Total body bone mineral density;
LGG	cis	rs11967485	0.609	rs62434278	chr6:157226031	A/C	cg23222435	chr6:157204239	ARID1B	-0.8	-6.87	-0.3	2.11e-11	Calcium levels;
LGG	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg03060546	chr3:49711283	APEH	0.59	8.35	0.36	7.71e-16	Menarche (age at onset);
LGG	cis	rs2708977	0.965	rs12717781	chr2:97249142	G/A	cg01950434	chr2:97203154	ARID5A	0.57	9.2	0.39	1.27e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.62	-0.59	1.67e-44	Skin colour saturation;
LGG	cis	rs2011503	1.000	rs75582668	chr19:19569023	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.33	0.36	9.21e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs8112449	1.000	rs7253917	chr19:10522176	A/T	cg21868191	chr19:10515988	NA	-0.48	-8.3	-0.36	1.16e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.686	rs3861458	chr6:126912162	G/A	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs2117029	0.619	rs9325145	chr12:49525884	A/G	cg24176009	chr12:49580217	TUBA1A	0.66	12.91	0.51	8.86e-33	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs11763920	chr7:124640880	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg11878867	chr6:150167359	LRP11	-0.56	-10.97	-0.45	4.7e-25	Lung cancer;
LGG	cis	rs4731207	0.537	rs6466974	chr7:124609510	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1728785	0.591	rs10775305	chr16:68656460	A/G	cg02972257	chr16:68554789	NA	-0.53	-7.9	-0.34	1.99e-14	Ulcerative colitis;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg12419862	chr22:24373484	LOC391322	-0.94	-19.76	-0.68	1.83e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.14	-0.35	3.75e-15	Neuroticism;
LGG	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs17021463	0.726	rs62320444	chr4:95261251	C/T	cg11021082	chr4:95130006	SMARCAD1	0.49	8.96	0.38	7.98e-18	Testicular germ cell tumor;
LGG	cis	rs41271473	0.948	rs17437060	chr1:228822374	C/T	cg10167378	chr1:228756711	NA	0.56	7.58	0.33	1.88e-13	Chronic lymphocytic leukemia;
LGG	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.86e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg15242686	chr22:24348715	GSTTP1	-0.39	-7.19	-0.32	2.67e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2153535	0.541	rs5026687	chr6:8473957	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.4e-22	Motion sickness;
LGG	cis	rs1941023	0.584	rs2241921	chr11:60164302	C/T	cg08716584	chr11:60157161	MS4A7	-0.44	-8.92	-0.38	1.07e-17	Congenital heart disease (maternal effect);
LGG	cis	rs11122272	0.766	rs2790872	chr1:231540543	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.65	-0.44	7.52e-24	Hemoglobin concentration;
LGG	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	14.92	0.57	2.29e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg02733842	chr7:1102375	C7orf50	0.57	8.6	0.37	1.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7523273	0.505	rs35438924	chr1:207881489	T/G	cg22525895	chr1:207977042	MIR29B2	0.46	8.7	0.37	5.98e-17	Schizophrenia;
LGG	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14159747	chr11:113255604	NA	0.31	8.45	0.37	3.84e-16	Information processing speed;
LGG	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg00666640	chr1:248458726	OR2T12	0.57	9.15	0.39	1.78e-18	Common traits (Other);
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	7.7e-29	Prudent dietary pattern;
LGG	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg21775007	chr8:11205619	TDH	-0.46	-7.36	-0.32	8.56e-13	Triglycerides;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.77	-0.45	2.79e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.57	-0.33	2.1e-13	Myopia (pathological);
LGG	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg13010199	chr12:38710504	ALG10B	0.77	16.35	0.6	9.35e-48	Heart rate;
LGG	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg02631450	chr22:32366979	NA	0.99	9.33	0.4	4.3e-19	Childhood ear infection;
LGG	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.85	0.34	2.92e-14	Retinal vascular caliber;
LGG	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg01620082	chr3:125678407	NA	0.64	6.89	0.3	1.77e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11123610	0.520	rs12711962	chr2:3717985	C/T	cg26344334	chr2:3718215	ALLC	-0.49	-8.52	-0.37	2.23e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Colorectal cancer;
LGG	cis	rs7119	0.717	rs12916515	chr15:77818518	G/T	cg10437265	chr15:77819839	NA	0.25	6.97	0.31	1.1e-11	Type 2 diabetes;
LGG	cis	rs17776563	0.959	rs11857151	chr15:89112877	C/G	cg05013243	chr15:89149849	MIR1179	-0.51	-10.33	-0.43	1.24e-22	Thyroid hormone levels;
LGG	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.24e-24	Corneal astigmatism;
LGG	cis	rs4538187	0.760	rs11558741	chr2:64124722	C/A	cg14150252	chr2:64069583	UGP2	-0.51	-9.34	-0.4	4.1e-19	Systolic blood pressure;
LGG	cis	rs2540226	0.550	rs13401182	chr2:39932807	G/A	cg18968196	chr2:39892502	TMEM178	0.26	6.74	0.3	4.79e-11	Personality dimensions;
LGG	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg09324608	chr17:30823087	MYO1D	-0.32	-7.75	-0.34	5.84e-14	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.19	0.36	2.58e-15	Lung cancer;
LGG	cis	rs12931792	0.712	rs2887799	chr16:30163833	G/A	cg17640201	chr16:30407289	ZNF48	0.48	8.09	0.35	5.33e-15	Tonsillectomy;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg15971980	chr6:150254442	NA	0.46	8.54	0.37	1.95e-16	Lung cancer;
LGG	cis	rs11785693	0.862	rs62491191	chr8:4993460	G/A	cg26367366	chr8:4980734	NA	1.05	16.56	0.61	1.01e-48	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg26408565	chr15:76604113	ETFA	-0.4	-6.89	-0.3	1.85e-11	Blood metabolite levels;
LGG	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg20503657	chr10:835505	NA	0.63	9.27	0.4	6.93e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg19077165	chr18:44547161	KATNAL2	-0.54	-9.67	-0.41	2.92e-20	Educational attainment;
LGG	cis	rs4639966	0.836	rs7943039	chr11:118603030	G/A	cg27286069	chr11:118481882	PHLDB1	-0.49	-7.1	-0.31	4.71e-12	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg21775007	chr8:11205619	TDH	-0.52	-8.65	-0.37	8.81e-17	Retinal vascular caliber;
LGG	cis	rs5756931	0.503	rs5750542	chr22:38534507	T/C	cg25457927	chr22:38595422	NA	-0.33	-7.73	-0.34	6.58e-14	Triglycerides;
LGG	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.773	rs9616382	chr22:50312979	C/T	cg26441486	chr22:50317300	CRELD2	0.42	7.34	0.32	9.7e-13	Schizophrenia;
LGG	cis	rs72925845	0.548	rs680027	chr17:76426216	G/A	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs4481887	0.538	rs10888328	chr1:248378777	G/A	cg01631408	chr1:248437212	OR2T33	-0.43	-7.44	-0.33	4.86e-13	Common traits (Other);
LGG	cis	rs6426558	0.515	rs7521110	chr1:227384459	T/A	cg10327440	chr1:227177885	CDC42BPA	-0.61	-10.04	-0.42	1.39e-21	Neutrophil percentage of white cells;
LGG	cis	rs2201728	0.739	rs1497376	chr4:100161887	C/T	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs9815354	1.000	rs73069396	chr3:41787236	A/T	cg03022575	chr3:42003672	ULK4	0.58	7.42	0.33	5.56e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.65	-0.37	8.38e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9660992	0.736	rs72745207	chr1:205251991	C/G	cg00857998	chr1:205179979	DSTYK	0.47	6.74	0.3	4.86e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2033732	0.674	rs1866087	chr8:85071289	T/A	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg14926445	chr8:58193284	C8orf71	0.84	10.4	0.44	6.72e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11971779	0.715	rs6954219	chr7:139065110	G/C	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.35e-12	Diisocyanate-induced asthma;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-9.19	-0.39	1.33e-18	Obesity-related traits;
LGG	cis	rs7017914	0.811	rs4272413	chr8:71636187	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.7	-0.3	6.24e-11	Bone mineral density;
LGG	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg27446573	chr6:127587934	RNF146	0.92	16.19	0.6	5.1e-47	Breast cancer;
LGG	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12923728	chr3:195709715	SDHAP1	-0.8	-15.09	-0.57	4.01e-42	Pancreatic cancer;
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg08297393	chr2:100937505	LONRF2	-0.57	-10.81	-0.45	1.87e-24	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.927	rs34776	chr5:102451794	C/G	cg23492399	chr5:102201601	PAM	-0.52	-7.71	-0.34	7.75e-14	Parkinson's disease;
LGG	cis	rs4356203	0.905	rs7938820	chr11:17077452	C/T	cg15432903	chr11:17409602	KCNJ11	0.4	7.53	0.33	2.75e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs2279817	0.863	rs12757678	chr1:17983680	G/C	cg21791023	chr1:18019539	ARHGEF10L	-0.65	-9.24	-0.39	9.28e-19	Neuroticism;
LGG	cis	rs11750568	0.967	rs6879226	chr5:178513371	A/G	cg10208897	chr5:178548229	ADAMTS2	0.42	6.87	0.3	2.07e-11	Height;
LGG	cis	rs701145	0.585	rs1612933	chr3:153786119	G/A	cg17054900	chr3:154042577	DHX36	-0.68	-8.56	-0.37	1.62e-16	Coronary artery disease;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg20120463	chr17:44301886	NA	-0.46	-7.17	-0.32	2.93e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg00092383	chr7:157075207	NA	0.39	6.78	0.3	3.58e-11	Body mass index;
LGG	cis	rs4948102	0.686	rs7801467	chr7:56160977	A/G	cg17215666	chr7:56131930	SUMF2	0.45	7.24	0.32	1.91e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs308971	0.611	rs387152	chr3:12076032	G/C	cg15873301	chr3:12045459	SYN2	0.54	7.92	0.35	1.77e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs490647	0.652	rs507249	chr1:37254339	T/C	cg24672014	chr1:37203461	NA	0.35	7.41	0.33	5.9e-13	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27542512	chr1:153963550	RPS27	-0.48	-7.02	-0.31	7.71e-12	Systemic lupus erythematosus;
LGG	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg27490568	chr2:178487706	NA	0.53	10.3	0.43	1.49e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6735179	0.601	rs114382205	chr2:1747539	G/A	cg08534653	chr2:1747700	PXDN	0.49	7.36	0.32	8.27e-13	Response to antipsychotic treatment;
LGG	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg13009111	chr11:71350975	NA	0.35	7.66	0.34	1.11e-13	Myopia (pathological);
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.8	-0.34	4.02e-14	IgG glycosylation;
LGG	cis	rs6840360	0.571	rs17275577	chr4:152519899	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	cis	rs7216064	1.000	rs62084251	chr17:65878736	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.13	0.31	3.86e-12	Menopause (age at onset);
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg22963979	chr7:1858916	MAD1L1	0.44	8.86	0.38	1.77e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg03351412	chr1:154909251	PMVK	0.48	8.36	0.36	7.53e-16	Prostate cancer;
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.37e-12	Height;
LGG	cis	rs4466137	0.904	rs6887104	chr5:83003535	G/A	cg16102102	chr5:83017553	HAPLN1	-0.6	-11.07	-0.46	2e-25	Prostate cancer;
LGG	cis	rs1801251	0.964	rs12997185	chr2:233560587	A/T	cg08000102	chr2:233561755	GIGYF2	0.57	8.86	0.38	1.71e-17	Coronary artery disease;
LGG	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg15704280	chr7:45808275	SEPT13	0.7	9.71	0.41	2.08e-20	Axial length;
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg04287289	chr16:89883240	FANCA	0.73	7.76	0.34	5.44e-14	Skin colour saturation;
LGG	cis	rs7444	0.883	rs7445	chr22:21977047	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-6.68	-0.3	6.87e-11	Systemic lupus erythematosus;
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.72	-0.51	5.56e-32	Total body bone mineral density;
LGG	cis	rs2742417	0.967	rs2742427	chr3:45736423	C/T	cg04837898	chr3:45731254	SACM1L	0.34	6.77	0.3	4e-11	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9682041	0.660	rs34158232	chr3:170115360	T/C	cg11886554	chr3:170076028	SKIL	0.66	8.43	0.36	4.3e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg17467752	chr17:38218738	THRA	-0.45	-7.26	-0.32	1.6e-12	Self-reported allergy;
LGG	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.98	0.35	1.16e-14	Myopia (pathological);
LGG	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg15268244	chr15:77196840	NA	-0.34	-7.37	-0.32	7.96e-13	Blood metabolite levels;
LGG	cis	rs4642101	0.793	rs56082700	chr3:12833833	T/C	cg24848339	chr3:12840334	CAND2	0.42	9.78	0.41	1.2e-20	QRS complex (12-leadsum);
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.0	-0.49	4.31e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg15147215	chr3:52552868	STAB1	0.38	7.19	0.32	2.66e-12	Bipolar disorder;
LGG	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg05234568	chr11:5960015	NA	-0.63	-10.47	-0.44	3.67e-23	DNA methylation (variation);
LGG	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.37e-11	Blood metabolite levels;
LGG	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-11.68	-0.48	8.19e-28	Hemoglobin concentration;
LGG	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg07005078	chr4:17578674	LAP3	-0.37	-6.86	-0.3	2.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs656319	0.729	rs471480	chr8:9812462	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.81	-0.3	2.97e-11	Myopia (pathological);
LGG	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.35e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg22963979	chr7:1858916	MAD1L1	-0.55	-10.73	-0.45	3.76e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs10463554	0.927	rs158403	chr5:102415768	C/G	cg23492399	chr5:102201601	PAM	-0.52	-7.73	-0.34	6.8e-14	Parkinson's disease;
LGG	cis	rs4731207	0.698	rs11978628	chr7:124449897	C/T	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs1978968	0.826	rs34596632	chr22:18463254	A/C	cg03078520	chr22:18463400	MICAL3	-0.73	-15.19	-0.58	1.44e-42	Presence of antiphospholipid antibodies;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07167872	chr1:205819463	PM20D1	0.57	11.49	0.47	4.76e-27	Menarche (age at onset);
LGG	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg06219351	chr7:158114137	PTPRN2	0.7	13.79	0.54	1.71e-36	Calcium levels;
LGG	cis	rs6963495	0.745	rs73192152	chr7:105212258	A/C	cg19920283	chr7:105172520	RINT1	0.64	8.24	0.36	1.78e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.07	-0.31	5.83e-12	Neuroticism;
LGG	cis	rs953387	1.000	rs953387	chr2:136907170	A/C	cg07169764	chr2:136633963	MCM6	0.53	8.9	0.38	1.24e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.87	-18.26	-0.65	1.73e-56	Prudent dietary pattern;
LGG	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.03	-0.31	7.34e-12	HDL cholesterol;
LGG	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.42	-0.33	5.49e-13	Retinal vascular caliber;
LGG	cis	rs3820068	0.532	rs6701009	chr1:15935614	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.86	0.62	4.71e-50	Systolic blood pressure;
LGG	cis	rs11074306	0.561	rs28471994	chr15:28067604	G/A	cg26402630	chr15:28053930	OCA2	0.36	7.33	0.32	1.04e-12	Uveal melanoma;
LGG	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.57	0.33	1.99e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg22535103	chr8:58192502	C8orf71	0.93	13.1	0.52	1.41e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg12856521	chr11:46389249	DGKZ	-0.42	-7.51	-0.33	3.06e-13	Leprosy;
LGG	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06108461	chr20:60628389	TAF4	-0.86	-16.47	-0.61	2.67e-48	Body mass index;
LGG	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.79	0.57	8.43e-41	Colorectal cancer;
LGG	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg21466736	chr12:48725269	NA	-0.39	-7.79	-0.34	4.34e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg00409905	chr10:38381863	ZNF37A	-0.52	-9.49	-0.4	1.22e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.01	0.46	3.38e-25	Homoarginine levels;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.59	-0.33	1.73e-13	Personality dimensions;
LGG	trans	rs2562456	0.833	rs62109225	chr19:21536663	G/A	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs7552404	0.883	rs77773255	chr1:76217193	G/A	cg03433033	chr1:76189801	ACADM	0.77	13.14	0.52	9.71e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs16837677	1.000	rs78079642	chr1:156749800	A/T	cg14991358	chr1:156767203	PRCC	0.76	7.91	0.35	1.87e-14	Sjögren's syndrome;
LGG	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.79	0.79	1.03e-100	Cognitive ability;
LGG	cis	rs8135665	0.600	rs6519096	chr22:38451389	C/T	cg19171272	chr22:38449367	NA	-0.46	-8.39	-0.36	5.8e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.19	0.6	4.69e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg02002194	chr4:3960332	NA	-0.38	-6.83	-0.3	2.69e-11	Retinal vascular caliber;
LGG	cis	rs7666738	0.830	rs13125432	chr4:98961253	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17401966	0.838	rs4846207	chr1:10313811	T/C	cg15208524	chr1:10270712	KIF1B	0.45	8.04	0.35	7.47e-15	Hepatocellular carcinoma;
LGG	cis	rs1506636	0.962	rs10243279	chr7:123441262	T/A	cg03229431	chr7:123269106	ASB15	0.71	16.49	0.61	2.2e-48	Plateletcrit;Platelet count;
LGG	cis	rs875971	0.545	rs13311962	chr7:66068129	C/T	cg11764359	chr7:65958608	NA	-0.66	-10.21	-0.43	3.3e-22	Aortic root size;
LGG	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg16414030	chr3:133502952	NA	-0.41	-6.77	-0.3	3.89e-11	Iron status biomarkers;
LGG	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg21699342	chr2:239360505	ASB1	0.38	7.41	0.33	5.98e-13	Multiple system atrophy;
LGG	trans	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.46	0.47	6.3e-27	Mean corpuscular volume;
LGG	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.7	0.54	4.12e-36	IgG glycosylation;
LGG	cis	rs897984	0.542	rs750952	chr16:31093954	C/T	cg02466173	chr16:30829666	NA	-0.41	-7.32	-0.32	1.12e-12	Dementia with Lewy bodies;
LGG	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs12476592	0.602	rs6732791	chr2:63788901	C/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.98	-0.31	1.02e-11	Childhood ear infection;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg04025307	chr7:1156635	C7orf50	0.91	19.48	0.67	3.68e-62	Longevity;Endometriosis;
LGG	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg22643751	chr7:855365	UNC84A	0.42	7.49	0.33	3.42e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg22681709	chr2:178499509	PDE11A	0.5	7.03	0.31	7.62e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs714515	0.868	rs4916253	chr1:172361032	G/T	cg01573306	chr1:172330400	DNM3	0.34	7.34	0.32	9.5e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.79e-16	Body mass index;
LGG	cis	rs972578	0.791	rs732439	chr22:43303417	T/G	cg01576275	chr22:43409880	NA	-0.23	-6.87	-0.3	2.11e-11	Mean platelet volume;
LGG	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.18e-16	Aortic root size;
LGG	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs4262150	0.672	rs72806788	chr5:152355093	T/C	cg12297329	chr5:152029980	NA	-0.56	-8.68	-0.37	6.76e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg19847130	chr8:10466454	RP1L1	0.33	7.12	0.31	4.28e-12	Neuroticism;
LGG	cis	rs77633900	0.614	rs280001	chr15:77003566	C/A	cg21673338	chr15:77095150	SCAPER	-0.65	-10.11	-0.43	7.31e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.87e-16	Bone mineral density;
LGG	cis	rs12220238	1.000	rs7909915	chr10:75960942	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9733	0.650	rs12125672	chr1:150554470	A/T	cg13175981	chr1:150552382	MCL1	0.6	10.42	0.44	5.54e-23	Tonsillectomy;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg14789911	chr21:47582049	C21orf56	-0.41	-7.04	-0.31	6.93e-12	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs62056069	chr16:89912000	C/T	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg02487422	chr3:49467188	NICN1	0.42	7.11	0.31	4.43e-12	Parkinson's disease;
LGG	cis	rs10779751	0.690	rs28729193	chr1:11180151	T/C	cg08854313	chr1:11322531	MTOR	-0.7	-14.32	-0.55	8.8e-39	Body mass index;
LGG	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg20744362	chr22:50050164	C22orf34	0.39	6.94	0.31	1.32e-11	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9290065	0.519	rs2376475	chr3:160708942	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.89	-0.38	1.33e-17	Kawasaki disease;
LGG	cis	rs6866344	0.598	rs34703961	chr5:178147874	A/G	cg10224037	chr5:178157518	ZNF354A	0.78	12.7	0.51	6.69e-32	Neutrophil percentage of white cells;
LGG	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg15556689	chr8:8085844	FLJ10661	0.53	9.14	0.39	1.98e-18	Retinal vascular caliber;
LGG	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg15595755	chr5:1867978	NA	0.49	8.18	0.36	2.69e-15	Cardiovascular disease risk factors;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.45	0.37	3.74e-16	Height;
LGG	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg06885757	chr1:42089581	HIVEP3	-0.48	-9.89	-0.42	4.69e-21	Airway imaging phenotypes;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg16301924	chr13:53314226	LECT1	-0.45	-8.98	-0.39	6.77e-18	Lewy body disease;
LGG	cis	rs2797369	0.656	rs7755696	chr6:101383557	C/T	cg27451362	chr6:101846650	GRIK2	0.76	10.44	0.44	4.69e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs67311347	1.000	rs9842564	chr3:40405810	A/G	cg13683864	chr3:40499215	RPL14	0.97	19.77	0.68	1.55e-63	Renal cell carcinoma;
LGG	cis	rs2131877	0.645	rs75738250	chr3:194880839	T/A	cg07250128	chr3:194833983	C3orf21	0.33	6.94	0.31	1.32e-11	Non-small cell lung cancer;
LGG	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.03	0.31	7.63e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2013441	1.000	rs9904928	chr17:20180536	C/T	cg13482628	chr17:19912719	NA	0.47	8.23	0.36	1.98e-15	Obesity-related traits;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11245990	chr11:68621969	NA	0.42	8.93	0.38	1e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg07636037	chr3:49044803	WDR6	0.45	6.84	0.3	2.51e-11	Resting heart rate;
LGG	cis	rs870825	0.616	rs7683799	chr4:185632164	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.95	0.73	2.07e-78	Blood protein levels;
LGG	cis	rs774359	0.789	rs814030	chr9:27515194	G/C	cg14173147	chr9:27528300	MOBKL2B	0.45	8.77	0.38	3.42e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs10267417	0.603	rs34087364	chr7:19860293	A/C	cg05791153	chr7:19748676	TWISTNB	0.56	7.37	0.32	8.01e-13	Night sleep phenotypes;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.53	-0.44	2.16e-23	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03434872	chr3:186524395	RFC4	0.46	7.08	0.31	5.35e-12	Gut microbiome composition (summer);
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	7.51	0.33	3e-13	Tonsillectomy;
LGG	cis	rs8036030	0.604	rs11852686	chr15:74715205	A/G	cg10253484	chr15:75165896	SCAMP2	-0.55	-9.22	-0.39	1.02e-18	Airflow obstruction;
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg21171335	chr12:122356390	WDR66	0.29	8.34	0.36	8.4e-16	Mean corpuscular volume;
LGG	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg19901468	chr14:105411992	AHNAK2	-0.89	-19.21	-0.67	6.68e-61	Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21795699	chr17:15903687	ZSWIM7;TTC19	0.44	7.39	0.32	6.71e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs738321	0.757	rs9622732	chr22:38524149	G/C	cg25457927	chr22:38595422	NA	-0.42	-9.69	-0.41	2.48e-20	Breast cancer;
LGG	cis	rs12286929	0.661	rs7947402	chr11:115088420	T/C	cg04055981	chr11:115044050	NA	0.37	6.82	0.3	2.83e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7188861	1.000	rs731774	chr16:11456266	C/T	cg01510278	chr16:11456238	NA	-0.35	-8.5	-0.37	2.66e-16	HDL cholesterol;
LGG	cis	rs4716602	0.898	rs10249494	chr7:156159448	G/T	cg16983916	chr7:156159713	NA	-0.38	-6.74	-0.3	4.73e-11	Anti-saccade response;
LGG	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg00170343	chr3:11313890	ATG7	0.52	6.82	0.3	2.92e-11	Circulating chemerin levels;
LGG	trans	rs2270927	0.510	rs6891108	chr5:75579152	C/A	cg13563193	chr19:33072644	PDCD5	0.87	10.31	0.43	1.39e-22	Mean corpuscular volume;
LGG	cis	rs2236918	0.710	rs2526698	chr1:242029101	T/C	cg17736920	chr1:242011382	EXO1	0.39	7.02	0.31	7.75e-12	Menopause (age at onset);
LGG	cis	rs12042938	0.935	rs751229	chr1:231768539	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	11.34	0.47	1.74e-26	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18252515	chr7:66147081	NA	0.42	7.09	0.31	5.02e-12	Aortic root size;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg12751644	chr20:60527061	NA	0.44	9.48	0.4	1.29e-19	Obesity-related traits;
LGG	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg26656751	chr17:43910226	CRHR1	-0.33	-6.77	-0.3	3.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg10483660	chr13:112241077	NA	0.36	7.15	0.32	3.33e-12	Menarche (age at onset);
LGG	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg12046867	chr14:103022105	NA	0.68	10.74	0.45	3.64e-24	Platelet count;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12681366	0.647	rs12545262	chr8:95405041	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.77	0.3	3.82e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs3735485	0.760	rs1294964	chr7:45069687	C/T	cg03440944	chr7:45023329	C7orf40	0.55	9.4	0.4	2.62e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg25358565	chr5:93447407	FAM172A	0.86	11.74	0.48	5.07e-28	Diabetic retinopathy;
LGG	cis	rs9427116	0.532	rs9426828	chr1:154591489	G/A	cg11650704	chr1:154556575	ADAR	-0.47	-9.29	-0.4	6.08e-19	Blood protein levels;
LGG	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg27476859	chr7:2772710	GNA12	0.54	10.42	0.44	5.78e-23	Height;
LGG	trans	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.3	0.32	1.25e-12	Retinal vascular caliber;
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.58	0.33	1.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg24375607	chr4:120327624	NA	-0.52	-8.97	-0.38	7.16e-18	Corneal astigmatism;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-8.9	-0.38	1.28e-17	Bipolar disorder;
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg08888203	chr3:10149979	C3orf24	0.56	8.01	0.35	9.23e-15	Alzheimer's disease;
LGG	cis	rs1014246	0.848	rs10749227	chr10:118468631	G/C	cg14919929	chr10:118506882	NA	0.58	10.4	0.44	6.5e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16854524	chr4:83931902	LIN54	0.48	8.22	0.36	2.07e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg22907277	chr7:1156413	C7orf50	0.64	12.26	0.5	3.96e-30	Longevity;Endometriosis;
LGG	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.62	0.44	1.04e-23	Lung cancer in ever smokers;
LGG	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg26513180	chr16:89883248	FANCA	0.64	11.94	0.49	7.87e-29	Vitiligo;
LGG	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg00376283	chr12:123451042	ABCB9	0.66	11.38	0.47	1.21e-26	Neutrophil percentage of white cells;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg01879757	chr17:41196368	BRCA1	-0.42	-8.31	-0.36	1.05e-15	Menopause (age at onset);
LGG	cis	rs12476592	0.602	rs1348805	chr2:63895673	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.48	-0.5	5.1e-31	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.75	0.64	3.83e-54	Vitiligo;
LGG	cis	rs12195424	0.558	rs76680041	chr6:56305145	C/T	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13012494	chr21:47604986	C21orf56	-0.51	-8.67	-0.37	7.46e-17	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg07606381	chr6:8435919	SLC35B3	-0.65	-12.15	-0.49	1.1e-29	Motion sickness;
LGG	cis	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.8	-0.34	4.2e-14	Blood trace element (Cu levels);
LGG	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.81	-0.3	3.05e-11	Retinal vascular caliber;
LGG	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs708547	0.647	rs1713982	chr4:57881715	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.31	0.36	1.05e-15	Response to bleomycin (chromatid breaks);
LGG	cis	rs10463554	0.963	rs11242484	chr5:102381876	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07318049	chr1:28562181	ATPIF1	-0.44	-6.78	-0.3	3.67e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.63e-12	Lung cancer;
LGG	cis	rs8013055	0.846	rs8013827	chr14:105970176	C/T	cg25008857	chr14:105974488	NA	-0.54	-9.46	-0.4	1.53e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg12982090	chr3:42733453	KBTBD5	0.94	15.59	0.59	2.41e-44	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs131656	1	rs131656	chr22:21917450	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.72	-0.34	7.01e-14	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4732038	0.565	rs12665934	chr7:134281053	A/C	cg06906464	chr7:134288099	NA	0.71	20.61	0.69	1.99e-67	Longevity;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg11518657	chr1:67396239	MIER1	0.49	7.27	0.32	1.54e-12	Lymphocyte percentage of white cells;
LGG	trans	rs62458065	0.513	rs10268149	chr7:32575499	T/C	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.68	-0.34	9.57e-14	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Vitiligo;
LGG	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.66	0.41	3.06e-20	Lung cancer in ever smokers;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	cis	rs7113874	0.524	rs6484485	chr11:8620740	A/G	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.69e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05025164	chr4:1340916	KIAA1530	0.71	13.25	0.52	3.35e-34	Longevity;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg07601598	chr6:14541800	NA	-0.39	-6.76	-0.3	4.28e-11	Apolipoprotein A-IV levels;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.57	0.44	1.56e-23	Cognitive test performance;
LGG	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.31	0.32	1.15e-12	Platelet count;
LGG	cis	rs67311347	0.955	rs2085114	chr3:40497437	T/A	cg24209194	chr3:40518798	ZNF619	0.44	6.86	0.3	2.18e-11	Renal cell carcinoma;
LGG	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg11752832	chr7:134001865	SLC35B4	0.67	12.44	0.5	7.64e-31	Mean platelet volume;
LGG	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg26384229	chr12:38710491	ALG10B	0.95	21.02	0.7	2.18e-69	Morning vs. evening chronotype;
LGG	cis	rs7928758	0.623	rs10894808	chr11:134256805	C/T	cg22777979	chr11:134283252	B3GAT1	0.74	8.35	0.36	7.71e-16	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg05926928	chr17:57297772	GDPD1	1.32	19.13	0.66	1.47e-60	Opioid sensitivity;
LGG	trans	rs947612	0.541	rs9351961	chr6:73678927	A/C	cg13494037	chr12:24737079	C12orf67	-0.37	-7.66	-0.34	1.07e-13	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs1878931	0.697	rs1044390	chr16:3432594	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.03	24.0	0.74	2.85e-83	Body mass index (adult);
LGG	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg14092988	chr3:52407081	DNAH1	0.31	8.18	0.36	2.85e-15	Bipolar disorder;
LGG	cis	rs10484885	0.752	rs72921948	chr6:90582560	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-16.3	-0.6	1.55e-47	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg08885076	chr2:99613938	TSGA10	0.42	8.87	0.38	1.62e-17	Chronic sinus infection;
LGG	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg00198680	chr16:28758506	NA	0.28	6.92	0.31	1.47e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg13114125	chr14:105738426	BRF1	-0.83	-16.33	-0.6	1.1e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg04156016	chr5:1868137	NA	0.32	7.0	0.31	9.06e-12	Cardiovascular disease risk factors;
LGG	trans	rs11989744	1.000	rs11989744	chr8:23567463	A/G	cg03492747	chr16:86543808	FOXF1	-0.51	-7.57	-0.33	2.03e-13	Waist-hip ratio;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.0500000000000001e-23	Lymphocyte counts;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.09	-0.35	5.47e-15	IgG glycosylation;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14123153	chr12:6602654	NCAPD2;MRPL51	-0.43	-7.17	-0.32	3.04e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.42	0.65	3.02e-57	Platelet count;
LGG	cis	rs12788925	0.967	rs12792912	chr11:102801303	T/G	cg19620758	chr11:102826565	MMP13	-0.36	-7.03	-0.31	7.4e-12	Coronary artery disease;
LGG	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg02002194	chr4:3960332	NA	0.45	8.42	0.36	4.63e-16	Monocyte count;
LGG	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg26384229	chr12:38710491	ALG10B	0.47	8.72	0.38	5.16e-17	Morning vs. evening chronotype;
LGG	cis	rs240110	0.548	rs12190574	chr6:101173842	T/G	cg09795085	chr6:101329169	ASCC3	-0.41	-6.82	-0.3	2.78e-11	Neuroticism;
LGG	cis	rs12477438	0.735	rs12474477	chr2:99690408	G/T	cg08885076	chr2:99613938	TSGA10	-0.59	-12.05	-0.49	2.85e-29	Chronic sinus infection;
LGG	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.27	0.32	1.54e-12	Total cholesterol levels;
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22968622	chr17:43663579	NA	1.09	21.76	0.71	7.6499999999999994e-73	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9463078	0.764	rs1854547	chr6:44912366	G/A	cg25276700	chr6:44698697	NA	-0.39	-8.45	-0.37	3.86e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.21	0.36	2.25e-15	Obesity-related traits;
LGG	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg19972287	chr10:38689165	CDC10L	-0.39	-6.7	-0.3	6.19e-11	Testicular germ cell tumor;
LGG	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	trans	rs783540	1.000	rs6603033	chr15:83335875	A/C	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.47	-0.33	4.04e-13	Schizophrenia;
LGG	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.76	-11.15	-0.46	9.81e-26	Cognitive test performance;
LGG	cis	rs17001868	0.568	rs9611312	chr22:40734790	T/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs4474465	0.646	rs7927503	chr11:78280606	G/T	cg27205649	chr11:78285834	NARS2	0.61	11.49	0.47	4.62e-27	Alzheimer's disease (survival time);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	11.42	0.47	9.1e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4253772	0.591	rs6007732	chr22:46652303	A/T	cg24881330	chr22:46731750	TRMU	0.69	8.44	0.37	4.16e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.85	-0.54	9.69e-37	Tonsillectomy;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.84	0.3	2.56e-11	Longevity;
LGG	cis	rs9911578	0.967	rs7503190	chr17:57184162	A/C	cg12560992	chr17:57184187	TRIM37	0.93	16.69	0.61	2.65e-49	Intelligence (multi-trait analysis);
LGG	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg02002194	chr4:3960332	NA	0.52	10.26	0.43	2.24e-22	Neuroticism;
LGG	cis	rs6831352	0.760	rs2602859	chr4:100030583	G/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Alcohol dependence;
LGG	cis	rs7828089	1.000	rs7837521	chr8:22264151	G/T	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.74	-0.3	4.86e-11	Verbal declarative memory;
LGG	cis	rs943466	0.540	rs11752353	chr6:33795628	G/A	cg07519485	chr6:33762594	MLN	0.46	7.02	0.31	8.13e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg22168489	chr12:122356033	WDR66	0.42	10.14	0.43	6.15e-22	Mean corpuscular volume;
LGG	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.97	-0.42	2.35e-21	Rheumatoid arthritis;
LGG	cis	rs34734847	0.787	rs7976497	chr12:121135467	T/C	cg21892295	chr12:121157589	UNC119B	-0.39	-7.38	-0.32	7.17e-13	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2028299	0.920	rs10852123	chr15:90428894	A/C	cg23731826	chr15:90371692	NA	0.36	7.83	0.34	3.25e-14	Type 2 diabetes;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg03709012	chr19:19516395	GATAD2A	-0.82	-15.9	-0.59	9.32e-46	Tonsillectomy;
LGG	cis	rs10861342	1.000	rs11112396	chr12:105568359	T/G	cg23923672	chr12:105501055	KIAA1033	0.79	7.5	0.33	3.33e-13	IgG glycosylation;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.03	-0.49	3.4e-29	Alzheimer's disease;
LGG	cis	rs10992471	0.729	rs6479418	chr9:95064762	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.43	-6.88	-0.3	1.91e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.57	-0.5	2.19e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.724	rs12623948	chr2:128001342	G/A	cg10021288	chr2:128175891	PROC	-0.62	-12.57	-0.5	2.22e-31	Protein C levels;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.12	0.31	4.15e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg03054141	chr12:8234711	NECAP1	-0.49	-7.1	-0.31	4.74e-12	Beard thickness;
LGG	cis	rs7503807	0.515	rs1485330	chr17:78640822	G/A	cg06872548	chr17:78716983	RPTOR	0.37	6.93	0.31	1.4e-11	Obesity;
LGG	cis	rs3733585	0.648	rs7378305	chr4:9954893	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs981844	0.740	rs12644642	chr4:154686550	G/C	cg14289246	chr4:154710475	SFRP2	-0.6	-10.76	-0.45	3.07e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs533581	0.866	rs2968474	chr16:88970566	A/G	cg16701003	chr16:89028210	CBFA2T3	-0.51	-7.99	-0.35	1.11e-14	Social autistic-like traits;
LGG	trans	rs2562456	0.754	rs11673234	chr19:21507602	A/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.28	-0.32	1.42e-12	Pain;
LGG	cis	rs7503807	1.000	rs8079537	chr17:78600818	A/G	cg06872548	chr17:78716983	RPTOR	0.45	11.13	0.46	1.19e-25	Obesity;
LGG	cis	rs4819388	0.751	rs12482807	chr21:45642363	G/A	cg01992765	chr21:45622493	NA	0.46	8.8	0.38	2.64e-17	Celiac disease;
LGG	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.38	0.32	7.3e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12681288	0.676	rs17668031	chr8:1007176	A/G	cg08648136	chr8:956695	NA	0.36	7.0	0.31	9.12e-12	Schizophrenia;
LGG	cis	rs7017914	1.000	rs13253842	chr8:71625503	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg03929089	chr4:120376271	NA	-0.71	-8.22	-0.36	2.07e-15	Axial length;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07071206	chr18:44140466	LOXHD1	0.37	6.83	0.3	2.64e-11	Pancreatic cancer;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.0	0.35	1.04e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg03605463	chr16:89740564	NA	-0.42	-7.07	-0.31	5.85e-12	Vitiligo;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.61	11.88	0.48	1.39e-28	Obesity-related traits;
LGG	trans	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg01134436	chr17:81009848	B3GNTL1	0.84	8.83	0.38	2.14e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs16937	0.618	rs6659069	chr1:205182031	A/G	cg00889227	chr1:205173544	DSTYK	-0.28	-6.96	-0.31	1.14e-11	Schizophrenia;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs8133932	0.667	rs2839033	chr21:47296381	T/C	cg11214348	chr21:47283868	PCBP3	0.45	8.07	0.35	6.29e-15	Schizophrenia;
LGG	cis	rs977987	0.806	rs1109342	chr16:75445675	A/G	cg03315344	chr16:75512273	CHST6	-0.51	-10.26	-0.43	2.12e-22	Dupuytren's disease;
LGG	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg24253500	chr15:84953950	NA	0.58	10.6	0.44	1.14e-23	Schizophrenia;
LGG	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.13e-95	Breast cancer;
LGG	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg07274523	chr3:49395745	GPX1	0.55	9.21	0.39	1.15e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6032067	0.641	rs17423617	chr20:43768050	G/C	cg10761708	chr20:43804764	PI3	0.72	10.61	0.44	1.07e-23	Blood protein levels;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	-0.44	-6.76	-0.3	4.29e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.05e-13	Schizophrenia;
LGG	trans	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs6558530	0.653	rs6984632	chr8:1700434	G/A	cg08198773	chr8:1697536	NA	0.46	8.13	0.35	4.07e-15	Systolic blood pressure;
LGG	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg26174226	chr8:58114915	NA	-0.48	-7.26	-0.32	1.67e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.59	-11.99	-0.49	4.8e-29	Presence of antiphospholipid antibodies;
LGG	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg24253500	chr15:84953950	NA	0.61	11.39	0.47	1.13e-26	Schizophrenia;
LGG	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg02002194	chr4:3960332	NA	-0.46	-9.03	-0.39	4.79e-18	Mood instability;
LGG	cis	rs2802728	1.000	rs2932631	chr1:243521055	G/C	cg05593162	chr1:243577377	SDCCAG8	-0.49	-6.99	-0.31	9.84e-12	Toenail selenium levels;
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.61	-0.37	1.19e-16	Neuroticism;
LGG	cis	rs6964587	0.869	rs13237856	chr7:91551788	G/A	cg17063962	chr7:91808500	NA	-0.43	-7.77	-0.34	5.15e-14	Breast cancer;
LGG	cis	rs36051895	0.625	rs11792531	chr9:5152203	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-13.81	-0.54	1.36e-36	Pediatric autoimmune diseases;
LGG	trans	rs7980799	0.682	rs10161491	chr12:33623806	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-11.96	-0.49	6.7200000000000006e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs17221829	0.673	rs10830324	chr11:89388845	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.89	9.52	0.4	9.84e-20	Diabetic retinopathy;
LGG	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg14500267	chr11:67383377	NA	-0.39	-7.21	-0.32	2.28e-12	Mean corpuscular volume;
LGG	cis	rs12643440	0.538	rs2041441	chr4:17136036	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.58	-0.37	1.45e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs994014	0.572	rs17428097	chr4:82313486	C/A	cg07938847	chr4:82126349	PRKG2	-0.28	-6.67	-0.3	7.2e-11	Height;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.81	0.3	2.97e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg21696256	chr3:125484277	NA	-0.44	-7.44	-0.33	4.87e-13	Blood pressure (smoking interaction);
LGG	trans	rs7246760	0.867	rs16981648	chr19:9804424	A/C	cg02900749	chr2:68251473	NA	-1.01	-10.68	-0.44	5.73e-24	Pursuit maintenance gain;
LGG	cis	rs9393777	0.513	rs6936555	chr6:26640886	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	12.12	0.49	1.53e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2735413	0.918	rs2344494	chr16:78078111	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg04287289	chr16:89883240	FANCA	0.81	17.07	0.62	5.04e-51	Vitiligo;
LGG	cis	rs9611519	1.000	rs5758267	chr22:41619350	A/T	cg03806693	chr22:41940476	POLR3H	0.46	7.2	0.32	2.5e-12	Neuroticism;
LGG	cis	rs4423214	0.592	rs3829251	chr11:71194559	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-8.51	-0.37	2.44e-16	Vitamin D levels;
LGG	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.57	0.33	2.07e-13	Schizophrenia;
LGG	trans	rs783540	0.500	rs7163840	chr15:83398303	A/G	cg16105309	chr15:79090380	ADAMTS7	0.46	7.33	0.32	1.06e-12	Schizophrenia;
LGG	cis	rs4776059	0.958	rs35505902	chr15:52888493	A/G	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.12	-0.35	4.12e-15	Schizophrenia;
LGG	cis	rs9308731	0.966	rs4849442	chr2:111934219	C/T	cg26001287	chr2:111877753	BCL2L11	-0.35	-6.88	-0.3	1.91e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4687717	0.689	rs4687716	chr3:53277094	G/A	cg16894138	chr3:53270350	TKT	0.42	7.9	0.34	2.02e-14	Blood metabolite levels;Blood metabolite ratios;
LGG	cis	rs870825	0.616	rs7683615	chr4:185618373	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs1957429	0.901	rs1951490	chr14:65346957	G/T	cg23373153	chr14:65346875	NA	1.14	15.34	0.58	3.03e-43	Pediatric areal bone mineral density (radius);
LGG	cis	rs4959677	0.868	rs12208100	chr6:2481688	T/A	cg20147862	chr6:2634573	C6orf195	-0.41	-9.0	-0.39	5.85e-18	Orthostatic hypotension;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19862918	chr17:40761350	FAM134C;TUBG1	0.6	9.0	0.39	5.81e-18	Gut microbiome composition (summer);
LGG	cis	rs7615952	0.546	rs2922194	chr3:125332263	G/A	cg21696256	chr3:125484277	NA	-0.44	-6.74	-0.3	4.62e-11	Blood pressure (smoking interaction);
LGG	cis	rs9733	0.650	rs11204684	chr1:150608894	A/G	cg13175981	chr1:150552382	MCL1	0.58	9.89	0.42	4.92e-21	Tonsillectomy;
LGG	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs112591243	0.655	rs7510435	chr21:48059798	G/A	cg10657630	chr21:48055338	PRMT2	0.88	7.38	0.32	7.25e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6665290	0.870	rs1045289	chr1:227178713	C/T	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs1971762	0.545	rs10876466	chr12:53981426	G/C	cg06632207	chr12:54070931	ATP5G2	0.22	6.85	0.3	2.31e-11	Height;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.71	-0.34	7.82e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg16662043	chr16:48846231	NA	0.38	7.44	0.33	4.86e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg15068132	chr12:102092402	CHPT1	0.37	6.81	0.3	3.12e-11	Blood protein levels;
LGG	cis	rs2075371	0.796	rs1643040	chr7:134011703	G/C	cg11752832	chr7:134001865	SLC35B4	0.61	11.14	0.46	1.08e-25	Mean platelet volume;
LGG	cis	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg08112188	chr17:47440006	ZNF652	1.33	15.68	0.59	9.63e-45	Prostate cancer;
LGG	cis	rs7010267	0.692	rs2073618	chr8:119964052	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.24	0.36	1.82e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg04935436	chr20:30431758	NA	0.41	7.18	0.32	2.84e-12	Mean corpuscular hemoglobin;
LGG	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.41	-7.28	-0.32	1.49e-12	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6582630	0.519	rs9738104	chr12:38338459	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.52	-0.4	9.56e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg00071950	chr4:10020882	SLC2A9	0.41	8.5	0.37	2.71e-16	Bone mineral density;
LGG	cis	rs2074585	0.713	rs2589941	chr15:90931457	C/T	cg22089800	chr15:90895588	ZNF774	0.71	13.07	0.52	1.97e-33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs17301259	0.548	rs7801611	chr7:88397641	A/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.3	-6.67	-0.3	7.21e-11	Heschl's gyrus morphology;
LGG	cis	rs9790314	0.638	rs17236746	chr3:160646743	A/G	cg03342759	chr3:160939853	NMD3	0.44	7.33	0.32	1.03e-12	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs858239	0.539	rs4559148	chr7:23185967	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.83	0.3	2.61e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs870825	0.860	rs2705886	chr4:185608591	T/C	cg04058563	chr4:185651563	MLF1IP	-1.01	-19.42	-0.67	6.59e-62	Blood protein levels;
LGG	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.22	0.83	2.56e-120	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg05861140	chr6:150128134	PCMT1	-0.45	-10.24	-0.43	2.5e-22	Lung cancer;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.42	-7.52	-0.33	2.8e-13	Schizophrenia;
LGG	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg00092383	chr7:157075207	NA	0.39	6.71	0.3	5.73e-11	Body mass index;
LGG	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg09640425	chr7:158790006	NA	-0.4	-7.4	-0.33	6.38e-13	Facial morphology (factor 20);
LGG	cis	rs13191362	0.872	rs36069443	chr6:163248701	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.82	9.38	0.4	2.93e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs787274	1.000	rs7859175	chr9:115587160	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11225247	1.000	rs12275185	chr11:102272277	G/T	cg06323957	chr11:102217781	BIRC2	0.8	7.03	0.31	7.51e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs4319547	0.695	rs6488958	chr12:122880704	A/G	cg23029597	chr12:123009494	RSRC2	-0.93	-17.17	-0.62	1.66e-51	Body mass index;
LGG	cis	rs7918232	0.891	rs10443987	chr10:27375377	A/T	cg14240646	chr10:27532245	ACBD5	-0.76	-11.09	-0.46	1.65e-25	Breast cancer;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.71	12.82	0.51	2.15e-32	Obesity-related traits;
LGG	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.77	-0.41	1.3e-20	Response to antipsychotic treatment;
LGG	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg26617929	chr16:1858877	NA	-0.6	-8.56	-0.37	1.73e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3862030	0.533	rs715440	chr10:104258095	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.16	-0.43	5.15e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg26248373	chr2:1572462	NA	-0.87	-14.68	-0.56	2.39e-40	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.64	-0.75	2.82e-86	Height;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.35	-0.36	8.18e-16	IgG glycosylation;
LGG	cis	rs2797160	0.967	rs2797159	chr6:126009557	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs12724450	0.793	rs34233130	chr1:150449766	A/G	cg03818307	chr1:150480534	ECM1	0.53	7.39	0.32	7.13e-13	Blood protein levels;
LGG	cis	rs11920090	0.789	rs7628022	chr3:170756778	A/G	cg09710316	chr3:170744871	SLC2A2	0.68	8.58	0.37	1.46e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4950322	0.570	rs72692904	chr1:146773136	T/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs10089	0.953	rs1036171	chr5:127402798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	11.06	0.46	2.21e-25	Ileal carcinoids;
LGG	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22618164	chr12:122356400	WDR66	0.37	10.56	0.44	1.62e-23	Mean corpuscular volume;
LGG	cis	rs2251381	0.750	rs2251186	chr21:30528880	G/A	cg24692254	chr21:30365293	RNF160	0.83	17.32	0.63	3.51e-52	Selective IgA deficiency;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09440289	chr12:15475990	PTPRO	0.47	7.61	0.33	1.55e-13	Cognitive performance;
LGG	cis	rs6867032	0.958	rs4975797	chr5:2015573	G/A	cg26168224	chr5:2018326	NA	1.28	30.94	0.82	9.35e-115	Gut microbiome composition (winter);
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.2e-16	Personality dimensions;
LGG	cis	rs774359	0.744	rs7019351	chr9:27491262	A/C	cg14173147	chr9:27528300	MOBKL2B	-0.41	-8.0	-0.35	9.98e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs564799	0.966	rs548018	chr3:159732345	A/G	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs67311347	1.000	rs4973993	chr3:40452960	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-26.11	-0.77	4.54e-93	Renal cell carcinoma;
LGG	cis	rs368123	0.961	rs601690	chr6:160754473	C/T	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs990171	1.000	rs6713618	chr2:103048437	A/T	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	trans	rs3857536	0.813	rs9354404	chr6:66948408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6121246	0.512	rs6058384	chr20:30276409	A/T	cg13852791	chr20:30311386	BCL2L1	0.94	18.67	0.66	2.11e-58	Mean corpuscular hemoglobin;
LGG	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg05425664	chr17:57184151	TRIM37	0.61	9.71	0.41	2.15e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg06238570	chr21:40685208	BRWD1	0.44	6.86	0.3	2.25e-11	Cognitive function;
LGG	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.26	0.32	1.63e-12	Retinal vascular caliber;
LGG	cis	rs9916302	0.718	rs7219909	chr17:37706243	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.79	-0.59	2.94e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs654950	0.776	rs2759254	chr1:42035683	G/C	cg16096631	chr1:42092165	HIVEP3	-0.43	-9.01	-0.39	5.34e-18	Airway imaging phenotypes;
LGG	cis	rs2120019	0.567	rs68036747	chr15:75203200	A/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.81	-0.51	2.22e-32	Blood trace element (Zn levels);
LGG	cis	rs9915657	0.966	rs8071725	chr17:70128726	C/T	cg09344028	chr17:70110421	NA	0.49	11.19	0.46	6.82e-26	Thyroid hormone levels;
LGG	cis	rs7215564	0.908	rs55886624	chr17:78658657	G/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.32	-0.36	9.89e-16	Myopia (pathological);
LGG	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg13770153	chr20:60521292	NA	-0.49	-8.12	-0.35	4.11e-15	Body mass index;
LGG	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.37	0.47	1.39e-26	Ovarian reserve;
LGG	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.28	-0.46	3.14e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs6500395	0.609	rs8057605	chr16:48565569	T/C	cg04672837	chr16:48644449	N4BP1	0.5	8.57	0.37	1.52e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6866344	0.561	rs55974982	chr5:178141421	G/A	cg03877680	chr5:178157825	ZNF354A	0.82	14.08	0.55	1.04e-37	Neutrophil percentage of white cells;
LGG	cis	rs2230307	0.536	rs522696	chr1:100476662	G/A	cg24955406	chr1:100503596	HIAT1	0.56	8.0	0.35	1.02e-14	Carotid intima media thickness;
LGG	cis	rs113835537	0.529	rs11227495	chr11:66263243	C/T	cg24851651	chr11:66362959	CCS	0.45	7.83	0.34	3.41e-14	Airway imaging phenotypes;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg01262667	chr19:19385393	TM6SF2	0.43	10.72	0.45	4.34e-24	Tonsillectomy;
LGG	trans	rs6787172	0.702	rs1526193	chr3:158017965	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.7	-13.66	-0.54	6.04e-36	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08889789	chr4:1305886	MAEA	0.39	7.38	0.32	7.28e-13	Electrocardiographic conduction measures;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08219700	chr8:58056026	NA	0.45	6.86	0.3	2.23e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-6.99	-0.31	9.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg06521331	chr12:34319734	NA	-0.63	-11.49	-0.47	4.6e-27	Morning vs. evening chronotype;
LGG	cis	rs2114646	0.731	rs10173676	chr2:170644751	A/G	cg17598339	chr2:170624727	NA	-0.36	-6.9	-0.31	1.69e-11	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg20607798	chr8:58055168	NA	0.57	6.79	0.3	3.38e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs72615157	0.539	rs2261360	chr7:99692993	G/T	cg12813108	chr7:99719912	CNPY4	-0.85	-16.57	-0.61	8.88e-49	Lung function (FEV1/FVC);
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg18404041	chr3:52824283	ITIH1	0.54	10.09	0.42	8.67e-22	Bipolar disorder;
LGG	cis	rs9462027	0.583	rs2814949	chr6:34656722	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.25	-0.43	2.41e-22	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg19635926	chr16:89946313	TCF25	0.75	8.25	0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs60180747	1.000	rs12905354	chr15:66802208	T/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.49	9.44	0.4	1.78e-19	Testicular germ cell tumor;
LGG	cis	rs11628318	0.515	rs12433517	chr14:103126912	T/G	cg12046867	chr14:103022105	NA	0.42	7.95	0.35	1.42e-14	Platelet count;
LGG	cis	rs847577	0.748	rs940432	chr7:97716483	G/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.88	-0.3	2.01e-11	Breast cancer;
LGG	cis	rs701145	0.585	rs62276841	chr3:153783645	C/T	cg12800244	chr3:153838788	SGEF	-0.8	-8.85	-0.38	1.87e-17	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs11941961	chr4:99065654	G/T	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.18e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7091068	0.566	rs7098349	chr10:95514907	A/C	cg20715218	chr10:95462985	C10orf4	0.67	9.88	0.42	5.03e-21	Urinary tract infection frequency;
LGG	cis	rs4363385	0.510	rs6677674	chr1:153037601	A/G	cg13444842	chr1:152974279	SPRR3	-0.46	-9.2	-0.39	1.23e-18	Inflammatory skin disease;
LGG	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg18551225	chr6:44695536	NA	-0.63	-9.98	-0.42	2.16e-21	Total body bone mineral density;
LGG	cis	rs8067545	0.611	rs9902032	chr17:20015178	G/C	cg09818912	chr17:20140352	CYTSB	-0.34	-7.9	-0.34	2.09e-14	Schizophrenia;
LGG	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg15395560	chr15:45543142	SLC28A2	0.42	6.92	0.31	1.51e-11	Glomerular filtration rate;
LGG	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg01324343	chr3:183735012	ABCC5	0.65	12.55	0.5	2.71e-31	Anterior chamber depth;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg17689763	chr4:710664	PCGF3	-0.8	-16.65	-0.61	4.01e-49	White blood cell count;
LGG	cis	rs1882538	0.564	rs10488164	chr7:133106199	A/G	cg10665199	chr7:133106180	EXOC4	0.54	9.69	0.41	2.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg23985595	chr17:80112537	CCDC57	0.47	9.38	0.4	3.04e-19	Life satisfaction;
LGG	cis	rs6664467	1	rs6664467	chr1:151738403	G/A	cg07092448	chr1:151763213	TDRKH	-1.05	-15.41	-0.58	1.5e-43	Carotid plaque burden;
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.04e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg03264133	chr6:25882463	NA	-0.41	-7.22	-0.32	2.17e-12	Height;
LGG	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg16885296	chr6:26284938	NA	-0.36	-7.43	-0.33	5.21e-13	Mosquito bite size;
LGG	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg04842962	chr6:43655489	MRPS18A	1.11	24.16	0.75	4.62e-84	IgG glycosylation;
LGG	cis	rs4356203	0.870	rs214900	chr11:17227762	A/G	cg15432903	chr11:17409602	KCNJ11	0.39	7.34	0.32	9.76e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg06637938	chr14:75390232	RPS6KL1	0.57	10.55	0.44	1.82e-23	Height;
LGG	trans	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.59	-10.07	-0.42	1.04e-21	Mean corpuscular volume;
LGG	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg17644776	chr2:200775616	C2orf69	-0.46	-7.69	-0.34	8.74e-14	QT interval;
LGG	trans	rs479844	0.617	rs12146493	chr11:65547333	G/A	cg17712092	chr4:129076599	LARP1B	0.49	7.96	0.35	1.34e-14	Allergic disease (asthma, hay fever or eczema);Atopic march;Atopic dermatitis;
LGG	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg18876405	chr7:65276391	NA	-0.6	-11.42	-0.47	8.56e-27	Aortic root size;
LGG	cis	rs236373	0.522	rs236349	chr6:36820565	C/T	cg07544796	chr6:36817048	NA	-0.23	-7.02	-0.31	7.78e-12	Heart rate;
LGG	cis	rs6032067	0.538	rs62206429	chr20:43730333	A/G	cg10761708	chr20:43804764	PI3	0.68	10.08	0.42	9.47e-22	Blood protein levels;
LGG	cis	rs12681288	0.862	rs2701899	chr8:1019581	G/A	cg04851639	chr8:1020857	NA	-0.45	-9.46	-0.4	1.53e-19	Schizophrenia;
LGG	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.08	0.39	3.26e-18	Eosinophil percentage of white cells;
LGG	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21582582	chr3:182698605	DCUN1D1	0.52	9.56	0.41	7.03e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3820068	0.705	rs11584398	chr1:15880275	G/A	cg05660106	chr1:15850417	CASP9	1.17	25.15	0.76	1.24e-88	Systolic blood pressure;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08219700	chr8:58056026	NA	0.46	7.02	0.31	8.05e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg19611418	chr2:131851282	FAM168B	-0.44	-7.34	-0.32	9.94e-13	Brain structure;
LGG	cis	rs60695258	0.512	rs2053769	chr4:87908007	T/C	cg01323104	chr4:87958903	AFF1	-0.24	-6.69	-0.3	6.57e-11	Hematocrit;
LGG	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.48	-8.29	-0.36	1.28e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1568889	0.877	rs57202579	chr11:28221677	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	14.67	0.56	2.77e-40	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	6.96	0.31	1.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1707322	0.752	rs11211168	chr1:46163647	C/T	cg03146154	chr1:46216737	IPP	0.56	10.67	0.44	6.72e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg01831904	chr17:28903510	LRRC37B2	0.73	8.63	0.37	1.01e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg22232500	chr2:134024266	NCKAP5	0.67	9.15	0.39	1.79e-18	Bipolar disorder;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.53	-0.33	2.6e-13	Personality dimensions;
LGG	cis	rs12681366	0.663	rs2919660	chr8:95470697	C/A	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg02002194	chr4:3960332	NA	0.44	7.79	0.34	4.52e-14	Retinal vascular caliber;
LGG	cis	rs4478858	0.735	rs11436	chr1:31837320	T/C	cg19084893	chr1:31688959	NA	0.32	6.75	0.3	4.34e-11	Alcohol dependence;
LGG	cis	rs7928758	0.945	rs28625034	chr11:134280504	C/T	cg15243474	chr11:134282918	B3GAT1	1.05	13.44	0.53	5.28e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg04469686	chr1:162760199	HSD17B7	0.46	7.56	0.33	2.25e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3540	0.597	rs3539	chr15:91045419	G/T	cg22089800	chr15:90895588	ZNF774	-0.68	-12.65	-0.51	1.07e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs78366141	0.536	rs78517451	chr4:89650437	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.4	0.36	5.63e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg06654118	chr4:1303317	MAEA	0.45	7.81	0.34	3.95e-14	Obesity-related traits;
LGG	cis	rs2303759	0.515	rs2334867	chr19:49788205	C/T	cg22307029	chr19:49891270	CCDC155	-0.45	-8.29	-0.36	1.28e-15	Multiple sclerosis;
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs17767392	0.958	rs4899398	chr14:72083441	A/G	cg13720639	chr14:72061746	SIPA1L1	0.39	8.25	0.36	1.64e-15	Mitral valve prolapse;
LGG	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11644478	chr21:40555479	PSMG1	-0.53	-9.05	-0.39	3.87e-18	Cognitive function;
LGG	cis	rs9486719	1.000	rs12201449	chr6:96959382	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.65	-0.44	7.68e-24	Migraine;Coronary artery disease;
LGG	cis	rs9790314	0.637	rs7628880	chr3:160743217	C/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.27	-0.4	7.12e-19	Morning vs. evening chronotype;
LGG	cis	rs6866344	0.697	rs11743893	chr5:178125194	C/T	cg03877680	chr5:178157825	ZNF354A	0.78	12.77	0.51	3.28e-32	Neutrophil percentage of white cells;
LGG	cis	rs13160562	0.527	rs25862	chr5:96104835	G/A	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.17	0.32	2.99e-12	Alcohol dependence;
LGG	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs17227506	0.900	rs1105406	chr8:13447025	G/A	cg03566418	chr8:13424080	C8orf48	0.48	7.52	0.33	2.8e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs75059851	0.756	rs11223651	chr11:133841034	A/G	cg20042908	chr11:133852938	NA	0.77	14.43	0.56	3.12e-39	Schizophrenia;
LGG	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg21475434	chr5:93447410	FAM172A	0.66	6.67	0.3	7.16e-11	Diabetic retinopathy;
LGG	cis	rs941873	0.772	rs2000404	chr10:81109708	T/C	cg09469691	chr10:81107165	PPIF	0.56	9.55	0.41	7.53e-20	Height;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.17	-0.46	8.35e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.507	rs9453585	chr6:66796668	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-32.4	-0.83	4.25e-121	Exhaled nitric oxide output;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7267979	0.745	rs6132845	chr20:25547767	A/G	cg06421707	chr20:25228305	PYGB	0.41	8.63	0.37	9.65e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10173297	0.686	rs13392120	chr2:3708685	C/T	cg20720597	chr2:3699334	NA	0.53	6.85	0.3	2.29e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13621184	chr19:7459697	ARHGEF18	0.44	6.77	0.3	3.81e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	15.13	0.58	2.69e-42	Alzheimer's disease;
LGG	cis	rs4930561	0.765	rs7931502	chr11:67959607	A/C	cg16338278	chr11:67432957	ALDH3B2	-0.42	-7.93	-0.35	1.64e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg07167872	chr1:205819463	PM20D1	0.58	11.59	0.47	1.93e-27	Menarche (age at onset);
LGG	cis	rs13082711	0.554	rs7635958	chr3:27385616	A/C	cg02860705	chr3:27208620	NA	0.92	16.83	0.62	6.19e-50	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs2028299	0.920	rs4932261	chr15:90430396	A/G	cg23731826	chr15:90371692	NA	0.34	7.74	0.34	6.35e-14	Type 2 diabetes;
LGG	cis	rs514024	0.700	rs554160	chr9:130491633	T/C	cg13643465	chr9:130375613	STXBP1	0.59	10.97	0.45	4.81e-25	Eating disorders (purging via substances);
LGG	cis	rs4538187	0.901	rs67765474	chr2:64168437	C/T	cg02541582	chr2:64069798	UGP2	-0.61	-14.42	-0.56	3.26e-39	Systolic blood pressure;
LGG	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg08773314	chr2:239334832	ASB1	0.43	8.15	0.35	3.4e-15	Multiple system atrophy;
LGG	cis	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg02972257	chr16:68554789	NA	-0.57	-8.39	-0.36	5.87e-16	Ulcerative colitis;
LGG	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.47	-0.4	1.4e-19	Height;
LGG	trans	rs1459104	1.000	rs12575696	chr11:55057235	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.9	0.31	1.69e-11	Body mass index;
LGG	trans	rs17685	0.753	rs10952840	chr7:75772878	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg14541582	chr5:601475	NA	-0.72	-10.68	-0.44	5.98e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg06212747	chr3:49208901	KLHDC8B	0.58	10.34	0.43	1.14e-22	Menarche (age at onset);
LGG	cis	rs4891159	0.536	rs690392	chr18:74152618	G/A	cg24786174	chr18:74118243	ZNF516	0.69	17.08	0.62	4.38e-51	Longevity;
LGG	cis	rs68170813	0.559	rs7783181	chr7:106977613	A/G	cg02696742	chr7:106810147	HBP1	-0.68	-9.82	-0.42	8.08e-21	Coronary artery disease;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg07243736	chr16:783730	NARFL	0.4	7.01	0.31	8.63e-12	Height;
LGG	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg22307297	chr20:60903441	LAMA5	-0.41	-8.06	-0.35	6.35e-15	Colorectal cancer;
LGG	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg15823100	chr22:32027580	PISD	-0.75	-8.49	-0.37	2.87e-16	Age-related hearing impairment;
LGG	cis	rs4917300	0.606	rs4917291	chr8:143115093	A/G	cg06573787	chr8:143070187	NA	0.57	9.86	0.42	6.29e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg26384229	chr12:38710491	ALG10B	0.92	20.78	0.69	3.01e-68	Bladder cancer;
LGG	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg27286337	chr10:134555280	INPP5A	0.87	13.81	0.54	1.43e-36	Migraine;
LGG	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.12	0.35	4.17e-15	Colorectal cancer;
LGG	cis	rs6445975	1.000	rs2176082	chr3:58331186	G/A	cg24175188	chr3:58374923	PXK	0.52	9.58	0.41	5.95e-20	Systemic lupus erythematosus;
LGG	trans	rs8073060	0.586	rs7214250	chr17:33981704	C/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.0	-0.64	2.54e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg27535305	chr1:53392650	SCP2	-0.31	-7.13	-0.31	3.85e-12	Monocyte count;
LGG	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg18937875	chr11:14930189	NA	-0.48	-7.83	-0.34	3.31e-14	Vitamin D levels;
LGG	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg23205692	chr1:25664452	TMEM50A	0.46	9.7	0.41	2.23e-20	Erythrocyte sedimentation rate;
LGG	cis	rs1978968	0.751	rs5992138	chr22:18458621	A/C	cg03078520	chr22:18463400	MICAL3	-0.69	-14.93	-0.57	1.98e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg03452623	chr4:187889614	NA	-1.02	-26.61	-0.78	2.53e-95	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.67	0.3	7.41e-11	Bladder cancer;
LGG	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg16400903	chr5:693638	TPPP	0.47	6.99	0.31	9.71e-12	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.85	-9.04	-0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs3849570	1.000	rs9826270	chr3:81841869	C/T	cg07356753	chr3:81810745	GBE1	-0.48	-7.86	-0.34	2.63e-14	Waist circumference;Body mass index;
LGG	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.72	-0.51	5.52e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.73	-0.34	6.99e-14	Life satisfaction;
LGG	cis	rs10751667	0.643	rs10902257	chr11:973577	T/C	cg22143635	chr11:980567	AP2A2	0.44	8.18	0.36	2.7e-15	Alzheimer's disease (late onset);
LGG	cis	rs1371867	0.764	rs1020171	chr8:101288610	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.91	-0.38	1.2e-17	Atrioventricular conduction;
LGG	cis	rs10191773	0.589	rs72831634	chr2:112946796	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.72	8.68	0.37	6.55e-17	Yeast infection;
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg10587741	chr22:38071170	LGALS1	0.82	21.87	0.71	2.34e-73	Fat distribution (HIV);
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.52	0.5	3.61e-31	Obesity-related traits;
LGG	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg14228332	chr4:119757509	SEC24D	0.81	8.96	0.38	7.69e-18	Cannabis dependence symptom count;
LGG	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.74	-0.3	4.8e-11	Pediatric bone mineral density (spine);
LGG	cis	rs35740288	0.618	rs11630755	chr15:86108737	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.98	0.39	6.96e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs16854884	0.632	rs4535221	chr3:143658607	A/G	cg06585982	chr3:143692056	C3orf58	0.62	10.72	0.45	4.41e-24	Economic and political preferences (feminism/equality);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg00533923	chr6:116892543	RWDD1	0.41	6.8	0.3	3.25e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg08888203	chr3:10149979	C3orf24	0.52	8.7	0.37	5.97e-17	Alzheimer's disease;
LGG	cis	rs4748857	0.947	rs7075197	chr10:23566045	A/T	cg18853376	chr10:23633759	C10orf67	0.38	7.23	0.32	2e-12	Systemic lupus erythematosus;
LGG	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg27661571	chr11:113659931	NA	-0.67	-9.53	-0.4	8.88e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg14952266	chr13:112191215	NA	0.5	10.49	0.44	2.94e-23	Hepatitis;
LGG	cis	rs758324	0.580	rs35566767	chr5:131606049	C/G	cg05556477	chr5:131705319	SLC22A5	0.68	8.26	0.36	1.5e-15	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs8060686	0.641	rs12598274	chr16:68084099	G/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.17e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs8133932	0.608	rs373267	chr21:47343320	G/T	cg11214348	chr21:47283868	PCBP3	-0.46	-8.22	-0.36	2.06e-15	Schizophrenia;
LGG	cis	rs2708977	0.637	rs583705	chr2:97068754	C/T	cg01950434	chr2:97203154	ARID5A	-0.45	-6.94	-0.31	1.32e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20000342	chr17:56031856	NA	0.39	6.67	0.3	7.11e-11	Cognitive performance;
LGG	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg06138931	chr13:21896616	NA	-0.47	-7.92	-0.35	1.78e-14	White matter hyperintensity burden;
LGG	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg16512390	chr1:228756714	NA	0.48	6.78	0.3	3.77e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg03264133	chr6:25882463	NA	-0.59	-10.38	-0.43	7.6e-23	Intelligence (multi-trait analysis);
LGG	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg12395012	chr8:11607386	GATA4	-0.53	-8.02	-0.35	8.83e-15	Alcohol dependence;Nicotine use;
LGG	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg00343986	chr7:65444356	GUSB	-0.42	-7.29	-0.32	1.39e-12	Aortic root size;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs757278	0.608	rs6967714	chr7:117340986	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.47	-8.43	-0.36	4.27e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs8180040	0.966	rs9683033	chr3:47489820	C/T	cg27129171	chr3:47204927	SETD2	0.79	15.35	0.58	2.88e-43	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs4243830	0.850	rs10779790	chr1:6608435	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.82	-12.71	-0.51	5.75e-32	Body mass index;
LGG	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs4665809	1.000	rs4665306	chr2:26319124	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.13e-33	Gut microbiome composition (summer);
LGG	cis	rs6547631	0.502	rs77067405	chr2:85927739	G/T	cg24620635	chr2:85921963	GNLY	0.5	10.02	0.42	1.62e-21	Blood protein levels;
LGG	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg13147721	chr7:65941812	NA	-0.82	-10.12	-0.43	7.13e-22	Diabetic kidney disease;
LGG	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg14829360	chr17:73884958	NA	-0.51	-9.85	-0.42	6.54e-21	White matter hyperintensity burden;
LGG	cis	rs12431410	0.550	rs8009507	chr14:60230820	G/C	cg07950296	chr14:60194823	RTN1	-0.35	-6.68	-0.3	6.89e-11	Schizophrenia;
LGG	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg21605333	chr4:119757512	SEC24D	-1.45	-14.6	-0.56	5.32e-40	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.84e-13	Menopause (age at onset);
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-14.48	-0.56	1.93e-39	Platelet count;
LGG	trans	rs3206736	0.548	rs328902	chr7:35020843	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.23	0.32	2.06e-12	Diastolic blood pressure;
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg16590910	chr6:42928470	GNMT	0.46	13.49	0.53	3.39e-35	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-15.27	-0.58	6.14e-43	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.76	0.57	1.05e-40	Platelet count;
LGG	cis	rs4262150	0.883	rs4958587	chr5:152251201	T/C	cg12297329	chr5:152029980	NA	-0.66	-12.47	-0.5	5.85e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9547996	0.879	rs7985686	chr13:38128643	C/T	cg17979426	chr13:38220150	TRPC4	0.37	7.16	0.32	3.28e-12	Diastolic blood pressure;
LGG	cis	rs4237845	0.788	rs1962047	chr12:58292707	G/A	cg02175503	chr12:58329896	NA	0.62	10.94	0.45	5.97e-25	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.864	rs3781625	chr11:47443080	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-10.53	-0.44	2.12e-23	Subjective well-being;
LGG	cis	rs35771425	0.711	rs1046690	chr1:211546501	T/A	cg10512769	chr1:211675356	NA	-0.68	-9.46	-0.4	1.5700000000000001e-19	Educational attainment (years of education);
LGG	cis	rs9880211	0.898	rs28877020	chr3:136395716	T/G	cg21827317	chr3:136751795	NA	-0.49	-7.26	-0.32	1.59e-12	Body mass index;Height;
LGG	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.07	0.31	5.75e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9388451	0.626	rs3799708	chr6:126078530	C/T	cg05901451	chr6:126070800	HEY2	-0.67	-12.82	-0.51	2.04e-32	Brugada syndrome;
LGG	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg20570797	chr2:1712800	PXDN	-0.46	-8.34	-0.36	8.42e-16	Response to antipsychotic treatment;
LGG	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg08468577	chr11:2973342	NAP1L4	-0.38	-8.01	-0.35	9.24e-15	Calcium levels;
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.07	-0.35	5.91e-15	Total body bone mineral density;
LGG	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs936229	0.768	rs11072509	chr15:75114374	C/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.29	-0.43	1.73e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs867371	1.000	rs2088858	chr15:82474749	C/T	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	3.2e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg24642844	chr7:1081250	C7orf50	-0.58	-8.76	-0.38	3.64e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg19717773	chr7:2847554	GNA12	-0.36	-8.14	-0.35	3.7e-15	Height;
LGG	cis	rs7241530	0.662	rs6506755	chr18:75905002	A/G	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs6930083	0.713	rs1321308	chr6:36638691	A/C	cg08179530	chr6:36648295	CDKN1A	-0.74	-13.25	-0.52	3.29e-34	Coronary artery disease;
LGG	trans	rs8002861	0.641	rs4942252	chr13:44443039	C/T	cg12856521	chr11:46389249	DGKZ	0.51	9.12	0.39	2.31e-18	Leprosy;
LGG	cis	rs11098499	0.739	rs10031033	chr4:120151452	C/T	cg09307838	chr4:120376055	NA	0.59	9.79	0.41	1.06e-20	Corneal astigmatism;
LGG	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.65	0.41	3.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs698813	0.674	rs4953080	chr2:44500849	C/A	cg00619915	chr2:44497795	NA	-0.62	-8.66	-0.37	7.99e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.98	-0.42	2.25e-21	Intelligence (multi-trait analysis);
LGG	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-7.78	-0.34	4.8e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg18876405	chr7:65276391	NA	0.54	9.73	0.41	1.77e-20	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03315687	chr19:40932206	SERTAD1	0.48	7.68	0.34	9.5e-14	Gut microbiome composition (summer);
LGG	cis	rs4788570	0.615	rs7195059	chr16:71718366	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	20.92	0.7	6.61e-69	Intelligence (multi-trait analysis);
LGG	cis	rs10193935	0.901	rs9808509	chr2:42479644	T/C	cg27598129	chr2:42591480	NA	-0.62	-9.07	-0.39	3.5e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg04672837	chr16:48644449	N4BP1	0.52	8.55	0.37	1.81e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs698813	0.604	rs1596010	chr2:44491804	A/C	cg00619915	chr2:44497795	NA	-0.61	-8.91	-0.38	1.21e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	5.14e-20	Hypertriglyceridemia;
LGG	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.1	0.31	4.61e-12	Schizophrenia;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	7.43	0.33	5.12e-13	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02520519	chr3:4345006	SETMAR	0.43	7.05	0.31	6.73e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg17644776	chr2:200775616	C2orf69	0.61	8.48	0.37	3.1e-16	Schizophrenia;
LGG	cis	rs7166081	1.000	rs12899051	chr15:67573741	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23541273	chr2:27631826	PPM1G	0.45	6.87	0.3	2.08e-11	Gut microbiome composition (summer);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16611736	chr16:25123254	LCMT1	-0.39	-6.7	-0.3	5.99e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg21724239	chr8:58056113	NA	0.49	7.36	0.32	8.24e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	1.000	rs4410378	chr22:18451391	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-13.09	-0.52	1.5e-33	Presence of antiphospholipid antibodies;
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg15394860	chr11:2017084	H19	-0.62	-13.56	-0.53	1.71e-35	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg12654349	chr5:56205094	C5orf35	0.67	10.35	0.43	1.02e-22	Initial pursuit acceleration;
LGG	cis	rs57502260	0.680	rs7104806	chr11:68222188	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-7.32	-0.32	1.13e-12	Total body bone mineral density (age 45-60);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02132458	chr4:57333267	SRP72	0.41	6.88	0.3	1.94e-11	Cognitive performance;
LGG	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg23306229	chr2:178417860	TTC30B	0.75	9.0	0.39	6.06e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7143963	1.000	rs72704726	chr14:103353101	A/G	cg23020514	chr14:103360112	TRAF3	0.49	9.49	0.4	1.19e-19	Body mass index;
LGG	cis	rs7712401	0.584	rs39820	chr5:122299921	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg04568710	chr12:38710424	ALG10B	0.32	6.66	0.3	7.92e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg11644478	chr21:40555479	PSMG1	0.92	17.86	0.64	1.15e-54	Cognitive function;
LGG	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.47	-0.33	4.08e-13	HDL cholesterol;
LGG	cis	rs6554196	0.525	rs12499367	chr4:55505911	C/T	cg18836493	chr4:55524333	KIT	-0.44	-8.33	-0.36	8.93e-16	Monocyte count;
LGG	cis	rs7917772	0.560	rs729023	chr10:104341887	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.58	-11.06	-0.46	2.11e-25	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-7.05	-0.31	6.38e-12	Total body bone mineral density;
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	12.61	0.51	1.49e-31	Total body bone mineral density;
LGG	cis	rs9354308	0.738	rs9453464	chr6:66584927	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg18479299	chr3:125709523	NA	-0.58	-7.59	-0.33	1.75e-13	Blood pressure (smoking interaction);
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg21782813	chr7:2030301	MAD1L1	0.44	10.06	0.42	1.12e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs2540226	0.515	rs2540248	chr2:39909117	G/T	cg18968196	chr2:39892502	TMEM178	0.32	8.69	0.37	6.36e-17	Personality dimensions;
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.81	-0.57	6.4e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10861342	1.000	rs12229846	chr12:105553066	A/C	cg23923672	chr12:105501055	KIAA1033	0.79	7.07	0.31	5.79e-12	IgG glycosylation;
LGG	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg26138144	chr22:38071188	LGALS1	0.67	15.34	0.58	3.08e-43	Fat distribution (HIV);
LGG	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg13010199	chr12:38710504	ALG10B	0.58	11.4	0.47	1.07e-26	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs988958	0.675	rs56140445	chr2:42230317	G/C	cg27428208	chr2:42229179	NA	0.53	9.24	0.39	9.12e-19	Hypospadias;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg13009111	chr11:71350975	NA	-0.31	-7.02	-0.31	7.85e-12	Neuroticism;
LGG	cis	rs16867321	0.694	rs721301	chr2:181387265	A/G	cg23363182	chr2:181467187	NA	0.42	8.19	0.36	2.52e-15	Obesity;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs1065852	0.526	rs9611700	chr22:42401514	C/T	cg15128208	chr22:42549153	NA	0.41	7.15	0.32	3.34e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.88	0.3	1.98e-11	Neuroticism;
LGG	cis	rs7267979	0.966	rs2500433	chr20:25296335	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.13	-0.43	6.64e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2735413	0.881	rs12927515	chr16:78080141	T/G	cg04733911	chr16:78082701	NA	-0.78	-18.87	-0.66	2.54e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg11657817	chr20:23433608	CST11	0.35	7.0	0.31	9.25e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs858239	0.539	rs2390757	chr7:23191492	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.83	0.3	2.69e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg16586182	chr3:47516702	SCAP	0.77	15.4	0.58	1.62e-43	Colorectal cancer;
LGG	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg09044154	chr16:88155775	NA	-0.5	-7.66	-0.34	1.09e-13	Menopause (age at onset);
LGG	cis	rs262150	0.579	rs4909110	chr7:158787332	C/T	cg19418458	chr7:158789849	NA	0.46	7.17	0.32	3.07e-12	Facial morphology (factor 20);
LGG	cis	rs1007190	0.570	rs7224712	chr17:42874218	G/T	cg15406952	chr17:42872593	NA	-1.23	-15.78	-0.59	3.4e-45	DNA methylation (variation);
LGG	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg06634786	chr22:41940651	POLR3H	0.66	10.76	0.45	3.03e-24	Vitiligo;
LGG	cis	rs6430585	0.528	rs309158	chr2:136680534	A/G	cg07169764	chr2:136633963	MCM6	1.17	22.63	0.72	6.54e-77	Corneal structure;
LGG	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg09307838	chr4:120376055	NA	0.82	13.74	0.54	2.87e-36	Corneal astigmatism;
LGG	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.95	-0.31	1.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-8.73	-0.38	4.7e-17	Lung cancer;
LGG	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg26513180	chr16:89883248	FANCA	-0.88	-9.12	-0.39	2.28e-18	Caffeine consumption;
LGG	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg05666200	chr11:89790683	NA	-0.53	-7.11	-0.31	4.5e-12	White blood cell types;
LGG	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg15704280	chr7:45808275	SEPT13	-0.58	-9.88	-0.42	5.2e-21	HDL cholesterol;
LGG	cis	rs96067	0.711	rs4653164	chr1:36627542	A/G	cg24686825	chr1:36642396	MAP7D1	0.45	9.14	0.39	1.94e-18	Corneal structure;
LGG	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg06634786	chr22:41940651	POLR3H	0.79	12.59	0.51	1.82e-31	Cannabis dependence symptom count;
LGG	cis	rs2075371	0.897	rs1646702	chr7:134000177	C/G	cg20476274	chr7:133979776	SLC35B4	0.76	14.95	0.57	1.7e-41	Mean platelet volume;
LGG	cis	rs4538187	1.000	rs6755646	chr2:64091533	A/G	cg19915305	chr2:64069682	UGP2	0.68	15.61	0.59	2.03e-44	Systolic blood pressure;
LGG	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg19784903	chr17:45786737	TBKBP1	0.37	8.14	0.35	3.74e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg25566285	chr7:158114605	PTPRN2	0.7	11.57	0.47	2.22e-27	Response to amphetamines;
LGG	cis	rs9309473	0.950	rs6546847	chr2:73785358	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.77	-0.34	5.25e-14	Metabolite levels;
LGG	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg22852734	chr6:133119734	C6orf192	1.15	14.68	0.56	2.55e-40	Type 2 diabetes nephropathy;
LGG	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.88	-0.42	5.12e-21	Response to antipsychotic treatment;
LGG	cis	rs727505	0.607	rs66478705	chr7:124789211	C/G	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs9796	0.774	rs28866311	chr15:41442195	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-8.92	-0.38	1.1e-17	Menopause (age at onset);
LGG	cis	rs4330281	0.740	rs12488591	chr3:17795931	A/G	cg20981856	chr3:17787350	NA	-0.38	-6.95	-0.31	1.27e-11	Schizophrenia;
LGG	cis	rs7107174	1.000	rs10793295	chr11:77996521	C/G	cg27205649	chr11:78285834	NARS2	0.44	7.24	0.32	1.89e-12	Testicular germ cell tumor;
LGG	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.83	-0.34	3.26e-14	Calcium levels;
LGG	cis	rs6500395	1.000	rs9924078	chr16:48557918	A/C	cg16662043	chr16:48846231	NA	-0.36	-6.94	-0.31	1.34e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17376030	chr22:41985996	PMM1	0.45	7.26	0.32	1.66e-12	Vitiligo;
LGG	trans	rs7980799	0.935	rs2389194	chr12:33529164	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-8.57	-0.37	1.56e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9397585	0.857	rs6557256	chr6:153384633	A/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.28e-38	Body mass index;
LGG	cis	rs4148087	0.860	rs1893589	chr21:43612531	C/T	cg08841829	chr21:43638893	ABCG1	-0.51	-6.85	-0.3	2.3e-11	Eating disorder in bipolar disorder;
LGG	cis	rs7666738	0.830	rs1593570	chr4:99017058	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg27211696	chr2:191398769	TMEM194B	-0.41	-9.66	-0.41	3.06e-20	Pulse pressure;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs2120019	0.505	rs77456790	chr15:75330095	G/T	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.38	-0.36	6.22e-16	Blood trace element (Zn levels);
LGG	cis	rs2658782	0.547	rs4753453	chr11:93041174	T/G	cg15737290	chr11:93063684	CCDC67	0.66	10.94	0.45	6.43e-25	Pulmonary function decline;
LGG	cis	rs9783347	0.621	rs11024606	chr11:18317864	C/A	cg15585147	chr11:18324498	HPS5	0.31	7.03	0.31	7.26e-12	Pancreatic cancer;
LGG	trans	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.65	-11.14	-0.46	1.07e-25	Obesity-related traits;
LGG	cis	rs644799	0.544	rs1527450	chr11:95467777	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	9.03	0.39	4.49e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4665809	0.627	rs13014338	chr2:26463024	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg24829409	chr8:58192753	C8orf71	0.78	11.18	0.46	7.3e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg24503407	chr1:205819492	PM20D1	0.96	26.52	0.78	6.31e-95	Menarche (age at onset);
LGG	cis	rs12618769	0.652	rs72823794	chr2:99216593	T/A	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09378691	chr20:44600971	ZNF335	0.41	6.84	0.3	2.44e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7667	0.919	rs6702374	chr1:19755388	C/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.38	-6.69	-0.3	6.56e-11	Crohn's disease and psoriasis;
LGG	cis	rs7923609	0.561	rs12253452	chr10:65315902	T/A	cg02276361	chr10:65351566	REEP3	-0.31	-6.79	-0.3	3.46e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg07414643	chr4:187882934	NA	0.55	11.29	0.46	2.76e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3219090	1.000	rs1341336	chr1:226596389	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	cis	rs9640161	0.830	rs1051760	chr7:150070630	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.05	-0.42	1.22e-21	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.85	0.42	6.71e-21	Coronary artery disease;
LGG	cis	rs6694672	1.000	rs9726778	chr1:197116754	G/C	cg13682187	chr1:196946512	CFHR5	0.49	6.9	0.31	1.75e-11	Asthma;
LGG	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7851660	0.775	rs7034336	chr9:100661100	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg07148914	chr20:33460835	GGT7	0.55	9.08	0.39	3.15e-18	Height;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg23782820	chr8:58130467	NA	0.5	7.67	0.34	1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs757278	0.704	rs10278481	chr7:117381393	C/T	cg10524701	chr7:117356490	CTTNBP2	0.39	6.78	0.3	3.66e-11	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7394190	0.688	rs76033784	chr10:75535970	A/G	cg07699608	chr10:75541558	CHCHD1	0.55	7.33	0.32	1.03e-12	Incident atrial fibrillation;
LGG	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg08305652	chr11:111469057	NA	0.43	8.3	0.36	1.13e-15	Primary sclerosing cholangitis;
LGG	cis	rs6138458	1.000	rs6707	chr20:24944166	C/T	cg26195577	chr20:24973756	C20orf3	1.24	26.23	0.77	1.29e-93	Blood protein levels;
LGG	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg25173405	chr17:45401733	C17orf57	0.49	8.55	0.37	1.85e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs798766	0.953	rs798751	chr4:1719572	A/G	cg00006948	chr4:1768889	NA	-0.5	-6.97	-0.31	1.11e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs8180040	0.726	rs2061197	chr3:47001350	C/T	cg27129171	chr3:47204927	SETD2	-0.84	-15.54	-0.59	3.95e-44	Colorectal cancer;
LGG	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg17376030	chr22:41985996	PMM1	0.55	8.74	0.38	4.21e-17	Vitiligo;
LGG	cis	rs1964356	0.524	rs7839585	chr8:8854235	C/G	cg11995313	chr8:8860691	ERI1	0.5	8.63	0.37	9.96e-17	Mean corpuscular volume;
LGG	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg01620082	chr3:125678407	NA	-0.99	-9.35	-0.4	3.79e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04530015	chr2:215796436	ABCA12	-0.46	-7.71	-0.34	7.87e-14	Neuroblastoma;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg12288994	chr5:1860383	NA	0.78	15.84	0.59	1.78e-45	Cardiovascular disease risk factors;
LGG	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg04025307	chr7:1156635	C7orf50	0.75	10.76	0.45	2.86e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11190604	1.000	rs2295773	chr10:102265815	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.75e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.52e-23	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg25658980	chr19:49955004	ALDH16A1;PIH1D1	0.44	7.62	0.33	1.45e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs8017423	0.630	rs4900038	chr14:90821677	A/G	cg04374321	chr14:90722782	PSMC1	-0.65	-12.84	-0.51	1.64e-32	Mortality in heart failure;
LGG	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg03929089	chr4:120376271	NA	0.74	8.6	0.37	1.26e-16	Axial length;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg02158880	chr13:53174818	NA	0.41	8.27	0.36	1.45e-15	Lewy body disease;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17253792	0.822	rs75437558	chr14:56066798	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15557168	chr22:42548783	NA	-0.34	-7.69	-0.34	8.76e-14	Cognitive function;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg15704280	chr7:45808275	SEPT13	0.49	8.03	0.35	8.14e-15	HDL cholesterol;
LGG	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg07636037	chr3:49044803	WDR6	0.54	7.32	0.32	1.07e-12	Menarche (age at onset);
LGG	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg07962218	chr7:65219954	SNORA22;CCT6P1	-0.29	-6.87	-0.3	2.09e-11	Calcium levels;
LGG	cis	rs5769765	0.526	rs5770722	chr22:50253220	G/C	cg02269571	chr22:50332266	NA	0.65	8.68	0.37	6.58e-17	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26720338	chr16:87635575	JPH3	0.34	6.65	0.3	8.2e-11	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	cis	rs2629540	0.855	rs12776722	chr10:126469833	G/A	cg08799069	chr10:126477246	METTL10	0.69	14.06	0.55	1.25e-37	Cocaine dependence;
LGG	cis	rs3806933	0.522	rs13186912	chr5:110456704	A/T	cg04022379	chr5:110408740	TSLP	-0.48	-8.03	-0.35	8.24e-15	Eosinophilic esophagitis;
LGG	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg19784903	chr17:45786737	TBKBP1	0.38	8.28	0.36	1.37e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.27	-0.72	3.3e-75	Total body bone mineral density;
LGG	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.41	6.71	0.3	5.69e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg08008072	chr16:1524255	CLCN7	-0.64	-11.26	-0.46	3.82e-26	Bone mineral density;
LGG	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.69	-0.34	8.77e-14	Menarche (age at onset);
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.47	-0.5	5.91e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg02462569	chr6:150064036	NUP43	0.37	7.77	0.34	5.25e-14	Lung cancer;
LGG	cis	rs7193541	0.564	rs4888274	chr16:74706298	A/T	cg01733217	chr16:74700730	RFWD3	1.08	32.38	0.83	4.9e-121	Multiple myeloma;
LGG	cis	rs7649275	0.938	rs898409	chr3:53757159	A/C	cg21503701	chr3:53781065	CACNA1D	-0.46	-6.89	-0.31	1.78e-11	Trans fatty acid levels;
LGG	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	10.95	0.45	5.83e-25	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg07701084	chr6:150067640	NUP43	0.69	12.89	0.51	1.11e-32	Lung cancer;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.58	-0.33	1.89e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2458413	0.543	rs2514658	chr8:105337871	G/A	cg23108931	chr8:105342351	NA	-0.27	-6.97	-0.31	1.08e-11	Paget's disease;
LGG	cis	rs11240074	0.733	rs6685325	chr1:146984386	C/G	cg25205988	chr1:146714368	CHD1L	-0.56	-6.65	-0.3	8.48e-11	Type 2 diabetes;
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-20.39	-0.69	1.96e-66	Vitiligo;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg26174226	chr8:58114915	NA	-0.58	-7.61	-0.33	1.55e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.967	rs2094102	chr14:55591098	T/C	cg04306507	chr14:55594613	LGALS3	0.61	16.99	0.62	1.16e-50	Protein biomarker;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg09818912	chr17:20140352	CYTSB	-0.32	-7.64	-0.33	1.26e-13	Schizophrenia;
LGG	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg03477792	chr4:77819574	ANKRD56	0.52	9.14	0.39	1.99e-18	Emphysema distribution in smoking;
LGG	cis	rs4006360	1.000	rs4006360	chr17:39250639	A/G	cg16985667	chr17:39306289	KRTAP4-5	0.51	11.24	0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg22676075	chr6:135203613	NA	0.42	7.3	0.32	1.25e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg09021430	chr5:549028	NA	-0.82	-12.78	-0.51	3.01e-32	Obesity-related traits;
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	6.76	0.3	4.2e-11	Height;
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	trans	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12505749	0.542	rs66858948	chr4:57334142	C/G	cg07846311	chr4:57371927	ARL9	-0.31	-7.47	-0.33	3.99e-13	Airflow obstruction;
LGG	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.69	0.3	6.45e-11	IgG glycosylation;
LGG	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg23815491	chr16:72088622	HP	-0.42	-8.93	-0.38	1.04e-17	Prostate cancer;
LGG	cis	rs1941023	0.606	rs7946122	chr11:60172770	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-8.58	-0.37	1.46e-16	Congenital heart disease (maternal effect);
LGG	cis	rs9399137	0.507	rs4580893	chr6:135297662	G/A	cg24558204	chr6:135376177	HBS1L	0.62	10.67	0.44	6.42e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs2133450	0.745	rs9868216	chr3:7268077	C/G	cg19930620	chr3:7340148	GRM7	-0.33	-7.38	-0.32	7.26e-13	Early response to risperidone in schizophrenia;
LGG	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11792861	0.591	rs10979632	chr9:111732140	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	11.17	0.46	8.45e-26	Menarche (age at onset);
LGG	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.12	0.62	3.06e-51	Cognitive function;
LGG	trans	rs9914544	0.545	rs2386403	chr17:18769600	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.54	-0.33	2.51e-13	Educational attainment (years of education);
LGG	cis	rs7267979	1.000	rs2258563	chr20:25273435	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1355223	0.902	rs1361645	chr11:34746385	G/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.0	-0.31	8.91e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6764363	0.506	rs13091217	chr3:277778	A/G	cg02057681	chr3:285234	CHL1	-0.42	-7.61	-0.33	1.59e-13	Sudden cardiac arrest;
LGG	cis	rs10743315	0.643	rs75398828	chr12:19340053	T/C	cg02471346	chr12:19282374	PLEKHA5	0.6	6.66	0.3	7.79e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12379764	chr21:47803548	PCNT	-0.4	-6.7	-0.3	5.93e-11	Testicular germ cell tumor;
LGG	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg04455712	chr21:45112962	RRP1B	-0.52	-9.51	-0.4	1.03e-19	Mean corpuscular volume;
LGG	cis	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg07460842	chr6:66804631	NA	-0.97	-18.09	-0.64	9.95e-56	Exhaled nitric oxide output;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg12288994	chr5:1860383	NA	0.79	15.97	0.6	4.74e-46	Cardiovascular disease risk factors;
LGG	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09190325	chr6:26539014	HMGN4	-0.46	-6.84	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg22705602	chr4:152727874	NA	-0.32	-7.75	-0.34	6.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.825	rs497535	chr1:53284677	A/G	cg24675658	chr1:53192096	ZYG11B	0.48	9.63	0.41	4.06e-20	Monocyte count;
LGG	cis	rs7523273	0.568	rs6669384	chr1:208025926	T/C	cg22525895	chr1:207977042	MIR29B2	-0.49	-7.31	-0.32	1.14e-12	Schizophrenia;
LGG	cis	rs9487094	0.961	rs12524639	chr6:109709459	A/G	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.15e-18	Height;
LGG	cis	rs2153535	0.580	rs2184586	chr6:8474182	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.46e-31	Motion sickness;
LGG	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	trans	rs11039798	1.000	rs12281162	chr11:48650491	T/C	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.63e-16	Axial length;
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-9.48	-0.4	1.31e-19	Prostate cancer;
LGG	cis	rs9486719	0.843	rs2472876	chr6:96845723	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs4132509	1.000	rs4553169	chr1:243900640	G/A	cg25706552	chr1:244017396	NA	0.55	8.85	0.38	1.92e-17	RR interval (heart rate);
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.57	-0.33	2.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs600550	0.588	rs10431136	chr11:60074313	A/T	cg05040360	chr11:60102449	MS4A6E	-0.38	-8.18	-0.36	2.73e-15	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg08085267	chr17:45401833	C17orf57	-0.64	-13.27	-0.53	2.65e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg19338460	chr6:170058176	WDR27	-0.78	-8.72	-0.38	5.08e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs72781680	1.000	rs72781631	chr2:24195064	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.28	0.4	6.48e-19	Lymphocyte counts;
LGG	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg16482183	chr6:26056742	HIST1H1C	0.92	13.8	0.54	1.52e-36	Iron status biomarkers;
LGG	cis	rs7084402	0.967	rs10826199	chr10:60274213	T/C	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.85e-12	Refractive error;
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06475006	chr16:89985975	MC1R	-0.6	-7.1	-0.31	4.72e-12	Skin colour saturation;
LGG	cis	rs9810089	0.903	rs7427564	chr3:136274435	G/A	cg21827317	chr3:136751795	NA	0.47	8.56	0.37	1.68e-16	Gestational age at birth (child effect);
LGG	cis	rs4704846	1.000	rs919747	chr5:156531330	A/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.53	-0.33	2.67e-13	Blood protein levels;
LGG	cis	rs4246949	0.597	rs4625397	chr10:125519383	A/G	cg12769705	chr10:125521557	CPXM2	-0.33	-6.77	-0.3	3.83e-11	Ulcerative colitis;
LGG	cis	rs62481355	0.680	rs11563620	chr7:127059236	C/T	cg25922125	chr7:127225783	GCC1	-0.46	-6.73	-0.3	4.97e-11	Type 2 diabetes;
LGG	cis	rs7428	0.502	rs3184781	chr2:85549527	T/C	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.87	-0.54	7.69e-37	Ear protrusion;
LGG	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg00204512	chr16:28754710	NA	0.25	7.27	0.32	1.53e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.44	9.01	0.39	5.33e-18	Schizophrenia;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.02	0.31	7.86e-12	Schizophrenia;
LGG	cis	rs4481887	1.000	rs11204626	chr1:248458974	T/A	cg13385794	chr1:248469461	NA	0.48	8.03	0.35	8.21e-15	Common traits (Other);
LGG	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg00405596	chr8:11794950	NA	-0.41	-6.75	-0.3	4.31e-11	Joint mobility (Beighton score);
LGG	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg08125733	chr17:73851984	WBP2	0.42	7.09	0.31	5.1e-12	White matter hyperintensity burden;
LGG	cis	rs9863	0.898	rs7301953	chr12:124405871	G/A	cg13487667	chr12:124434373	CCDC92	-0.38	-7.25	-0.32	1.82e-12	White blood cell count;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.88	-0.54	7.37e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs11967485	0.609	rs62435822	chr6:157164199	G/A	cg23222435	chr6:157204239	ARID1B	-0.81	-7.38	-0.32	7.46e-13	Calcium levels;
LGG	cis	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg12486710	chr1:178512616	C1orf220	-0.49	-10.22	-0.43	2.99e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2742417	0.967	rs1969625	chr3:45734975	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg00198680	chr16:28758506	NA	0.29	6.96	0.31	1.17e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg12636538	chr11:118901039	SLC37A4	-0.65	-13.65	-0.54	6.83e-36	Coronary artery disease;
LGG	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg01221209	chr5:554886	NA	-0.47	-6.97	-0.31	1.13e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg23750338	chr8:142222470	SLC45A4	0.6	12.48	0.5	4.92e-31	Immature fraction of reticulocytes;
LGG	cis	rs35160687	0.901	rs13020869	chr2:86523360	C/T	cg10973622	chr2:86423274	IMMT	0.39	6.68	0.3	6.71e-11	Night sleep phenotypes;
LGG	cis	rs4950928	0.823	rs4950929	chr1:203160126	A/C	cg17014757	chr1:203156097	CHI3L1	0.38	8.05	0.35	7.19e-15	YKL-40 levels;
LGG	cis	rs2028299	0.920	rs11638138	chr15:90428755	A/G	cg23731826	chr15:90371692	NA	-0.35	-7.87	-0.34	2.54e-14	Type 2 diabetes;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.66	-11.42	-0.47	9.07e-27	Longevity;Endometriosis;
LGG	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg07382826	chr16:28625726	SULT1A1	0.42	8.78	0.38	3.27e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9302635	0.513	rs3902135	chr16:72175820	C/T	cg23815491	chr16:72088622	HP	0.5	8.94	0.38	9.2e-18	Blood protein levels;
LGG	cis	rs4716602	0.542	rs10261485	chr7:156159775	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.57	-0.41	6.41e-20	Anti-saccade response;
LGG	cis	rs5756813	0.635	rs4820301	chr22:38126364	G/A	cg19171272	chr22:38449367	NA	0.41	7.04	0.31	7.07e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.17e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9467773	0.620	rs3800303	chr6:26598188	A/G	cg11502198	chr6:26597334	ABT1	0.71	12.96	0.52	5.27e-33	Intelligence (multi-trait analysis);
LGG	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg05555928	chr11:63887634	MACROD1	-0.76	-10.36	-0.43	9.62e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg18876405	chr7:65276391	NA	0.55	9.98	0.42	2.29e-21	Aortic root size;
LGG	cis	rs796364	0.694	rs1653299	chr2:201075611	A/G	cg23649088	chr2:200775458	C2orf69	0.57	9.53	0.4	9.14e-20	Schizophrenia;
LGG	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg18898632	chr2:242989856	NA	-0.87	-10.48	-0.44	3.34e-23	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03694515	chr18:32870085	ZNF271;ZNF397OS	0.48	7.27	0.32	1.5e-12	Gut microbiome composition (summer);
LGG	cis	rs503734	0.967	rs533852	chr3:100994497	C/T	cg27318481	chr3:100970896	IMPG2	-0.36	-7.78	-0.34	4.93e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.87	-0.51	1.27e-32	Chronic sinus infection;
LGG	cis	rs9814567	0.896	rs4245907	chr3:134347876	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.3	-0.5	2.7e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2108225	0.872	rs2051954	chr7:107441097	G/C	cg18560240	chr7:107437656	SLC26A3	-0.56	-9.96	-0.42	2.61e-21	Ulcerative colitis;
LGG	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg26677194	chr12:130822605	PIWIL1	0.57	10.19	0.43	3.92e-22	Menopause (age at onset);
LGG	cis	rs4474465	0.703	rs10899547	chr11:78254720	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.03e-11	Alzheimer's disease (survival time);
LGG	cis	rs13260300	0.645	rs2114056	chr8:75521619	C/T	cg22993706	chr8:75542856	NA	0.41	8.14	0.35	3.62e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.81e-15	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg17202724	chr17:61916730	SMARCD2	0.61	14.99	0.57	1.11e-41	Prudent dietary pattern;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg06719900	chr11:109292894	C11orf87	0.43	7.8	0.34	4.15e-14	Schizophrenia;
LGG	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.14	-0.35	3.79e-15	Retinal vascular caliber;
LGG	cis	rs17221829	0.549	rs72969202	chr11:89358355	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.04	-0.39	4.44e-18	Anxiety in major depressive disorder;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg05804949	chr7:23719620	C7orf46	0.34	7.84	0.34	3.11e-14	Schizophrenia;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg03395511	chr6:291903	DUSP22	-0.66	-11.17	-0.46	8.47e-26	Menopause (age at onset);
LGG	trans	rs9929218	0.861	rs4783667	chr16:68752878	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.85	-15.46	-0.58	8.83e-44	Colorectal cancer;
LGG	cis	rs240764	0.817	rs6922219	chr6:101153907	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-7.48	-0.33	3.77e-13	Neuroticism;
LGG	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.76	-0.3	4.08e-11	Blood metabolite levels;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.54	0.37	1.97e-16	Triglycerides;
LGG	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg16077055	chr2:106428750	NCK2	0.32	8.39	0.36	6.16e-16	Addiction;
LGG	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2.04e-13	HDL cholesterol;
LGG	trans	rs877282	1.000	rs11253362	chr10:770979	G/T	cg22713356	chr15:30763199	NA	0.56	8.67	0.37	7.45e-17	Uric acid levels;
LGG	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg26850624	chr5:429559	AHRR	-0.33	-6.89	-0.3	1.88e-11	Cystic fibrosis severity;
LGG	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg11752832	chr7:134001865	SLC35B4	0.51	9.11	0.39	2.51e-18	Mean platelet volume;
LGG	cis	rs4704187	0.687	rs4404660	chr5:74422210	T/C	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs2273669	0.588	rs75995854	chr6:109325624	C/A	cg05315195	chr6:109294784	ARMC2	-0.66	-8.73	-0.38	4.78e-17	Prostate cancer;
LGG	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg08847533	chr14:75593920	NEK9	0.63	12.23	0.49	5.47e-30	Height;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs4474465	0.915	rs12277503	chr11:78140373	A/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.49	-0.37	2.76e-16	Alzheimer's disease (survival time);
LGG	cis	rs12643440	0.538	rs10939707	chr4:17146776	G/T	cg22650099	chr4:17144496	NA	-0.51	-8.76	-0.38	3.65e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg18050959	chr15:68126178	NA	0.37	7.05	0.31	6.5e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3087591	0.614	rs3785955	chr17:29647802	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.69	0.34	8.74e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7572733	0.534	rs10211202	chr2:198771941	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.11	0.46	1.36e-25	Dermatomyositis;
LGG	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg12800244	chr3:153838788	SGEF	0.58	8.31	0.36	1.08e-15	Coronary artery disease;
LGG	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.35	-0.36	8.01e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.71	-0.56	1.85e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs12282928	1.000	rs11039676	chr11:48337188	T/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs283228	0.798	rs2852556	chr6:101775010	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs7267979	0.816	rs405822	chr20:25501314	A/G	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.68e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg23583168	chr7:148888333	NA	-0.84	-15.94	-0.6	6.27e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4911259	0.533	rs6058931	chr20:31471012	C/T	cg13636640	chr20:31349939	DNMT3B	-0.66	-11.82	-0.48	2.25e-28	Inflammatory bowel disease;
LGG	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg18856731	chr12:58011764	NA	0.34	7.04	0.31	7.19e-12	Multiple sclerosis;
LGG	cis	rs787274	1.000	rs787301	chr9:115542737	G/T	cg13803584	chr9:115635662	SNX30	0.53	7.54	0.33	2.56e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg01338084	chr22:32026380	PISD	1.49	12.14	0.49	1.22e-29	Age-related hearing impairment;
LGG	cis	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg01851573	chr8:8652454	MFHAS1	0.41	6.82	0.3	2.94e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11574514	1.000	rs7200950	chr16:67689752	C/T	cg09738193	chr16:67926317	PSKH1	-0.71	-6.98	-0.31	1e-11	Crohn's disease;
LGG	cis	rs1408799	0.523	rs10115202	chr9:12764879	C/T	cg05274944	chr9:12693694	TYRP1	0.38	7.06	0.31	6.22e-12	Eye color;Blue vs. green eyes;
LGG	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.65	-11.23	-0.46	5.01e-26	Mean platelet volume;
LGG	cis	rs17453880	0.929	rs12518097	chr5:152030041	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs9287719	0.870	rs10167676	chr2:10753140	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9583531	0.600	rs9555724	chr13:111354110	C/T	cg24331049	chr13:111365604	ING1	-0.82	-15.28	-0.58	5.44e-43	Coronary artery disease;
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg21171335	chr12:122356390	WDR66	0.27	7.75	0.34	5.75e-14	Mean corpuscular volume;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg22105103	chr4:187893119	NA	0.54	10.39	0.43	7.25e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4740619	0.619	rs10810518	chr9:16029175	T/A	cg14451791	chr9:16040625	NA	-0.43	-11.43	-0.47	7.87e-27	Body mass index;
LGG	cis	rs7267979	1.000	rs2258879	chr20:25279213	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4901847	0.933	rs11623561	chr14:58556776	G/T	cg15908186	chr14:58618357	C14orf37	-0.54	-9.67	-0.41	2.91e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg03528353	chr17:61819722	STRADA	-0.42	-7.06	-0.31	6.3e-12	Prudent dietary pattern;
LGG	cis	rs208520	0.661	rs1776361	chr6:66822270	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.41	-0.65	3.45e-57	Exhaled nitric oxide output;
LGG	trans	rs73198271	1.000	rs11775821	chr8:8609153	A/G	cg16141378	chr3:129829833	LOC729375	0.37	6.93	0.31	1.44e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1707322	0.896	rs809774	chr1:46560244	T/A	cg03146154	chr1:46216737	IPP	-0.56	-10.1	-0.42	8.42e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs9886651	0.935	rs4733759	chr8:128804840	C/T	cg24514600	chr8:128805414	PVT1	-0.56	-13.05	-0.52	2.29e-33	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.53	-0.59	4.36e-44	Platelet count;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg23782820	chr8:58130467	NA	0.54	7.5	0.33	3.21e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6121246	0.559	rs6119652	chr20:30259445	C/G	cg13852791	chr20:30311386	BCL2L1	0.94	18.52	0.65	1.08e-57	Mean corpuscular hemoglobin;
LGG	trans	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.99	-0.35	1.08e-14	Resting heart rate;
LGG	cis	rs7582720	0.887	rs115600411	chr2:204121145	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.46	0.4	1.61e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs453301	0.653	rs7853	chr8:8890814	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.99	0.42	2.06e-21	Joint mobility (Beighton score);
LGG	cis	rs6909430	1.000	rs9482508	chr6:98685769	A/G	cg12860156	chr6:98744658	NA	-0.44	-7.56	-0.33	2.24e-13	Quantitative traits;
LGG	cis	rs629922	0.507	rs561099	chr11:114054163	C/A	cg01914181	chr11:114070210	ZBTB16	-0.53	-6.74	-0.3	4.58e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	cis	rs6089584	0.606	rs7270666	chr20:60577598	C/T	cg06470251	chr20:60548479	NA	0.43	7.58	0.33	1.88e-13	Body mass index;
LGG	cis	rs17102423	0.594	rs1271582	chr14:65564703	T/G	cg26396452	chr14:65542826	MAX	0.48	10.1	0.42	8.11e-22	Obesity-related traits;
LGG	cis	rs2613964	0.504	rs2399466	chr3:112848037	C/G	cg16248390	chr3:112854924	NA	0.51	10.73	0.45	3.82e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs6743376	0.556	rs768627	chr2:113821653	C/T	cg05949173	chr2:113825882	IL1F10	-0.5	-9.45	-0.4	1.66e-19	Inflammatory biomarkers;
LGG	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg23335576	chr14:104009727	NA	0.43	7.27	0.32	1.57e-12	Reticulocyte count;
LGG	cis	rs2028299	0.959	rs748508	chr15:90381258	G/T	cg23731826	chr15:90371692	NA	0.37	8.68	0.37	6.64e-17	Type 2 diabetes;
LGG	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.66	-0.34	1.11e-13	Bipolar disorder;
LGG	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg10556349	chr10:835070	NA	-0.34	-8.78	-0.38	3.08e-17	Survival in rectal cancer;
LGG	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg17211192	chr8:82754475	SNX16	-0.66	-11.31	-0.47	2.34e-26	Diastolic blood pressure;
LGG	cis	rs72945132	0.507	rs34612166	chr11:70244400	C/T	cg13802316	chr11:70253460	CTTN	-0.74	-9.98	-0.42	2.23e-21	Coronary artery disease;
LGG	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg03929089	chr4:120376271	NA	0.44	7.18	0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg05556477	chr5:131705319	SLC22A5	0.85	10.19	0.43	3.8e-22	Rheumatoid arthritis;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07243736	chr16:783730	NARFL	0.4	7.01	0.31	8.63e-12	Height;
LGG	cis	rs208520	1.000	rs208520	chr6:66952828	G/T	cg07460842	chr6:66804631	NA	-0.89	-14.62	-0.56	4.71e-40	Exhaled nitric oxide output;
LGG	cis	rs273218	1.000	rs156380	chr5:53378450	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.65	9.08	0.39	3.13e-18	Migraine;
LGG	cis	rs74781061	0.929	rs4886601	chr15:74883851	T/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.22	-0.32	2.1e-12	Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17675882	chr20:35374068	NDRG3	0.57	9.0	0.39	5.95e-18	Gut microbiome composition (summer);
LGG	trans	rs75804782	0.625	rs72984525	chr2:239469318	T/C	cg01134436	chr17:81009848	B3GNTL1	0.69	7.44	0.33	5.01e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7166081	1.000	rs12898685	chr15:67525772	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs193541	0.556	rs30024	chr5:122285160	A/G	cg19412675	chr5:122181750	SNX24	0.55	8.88	0.38	1.45e-17	Glucose homeostasis traits;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.59	-0.33	1.82e-13	Neuroticism;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg25726756	chr21:47582351	C21orf56	-0.32	-6.87	-0.3	2.02e-11	Testicular germ cell tumor;
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.54	-9.15	-0.39	1.76e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.5	-0.33	3.22e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01358551	chr19:47353761	AP2S1	0.43	7.37	0.32	8.16e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs2652834	1.000	rs8032104	chr15:63400584	A/G	cg05507819	chr15:63340323	TPM1	0.6	8.02	0.35	8.62e-15	HDL cholesterol;
LGG	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg01338084	chr22:32026380	PISD	1.42	11.83	0.48	2.21e-28	Age-related hearing impairment;
LGG	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4363385	0.818	rs2879487	chr1:152985360	C/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.52e-17	Inflammatory skin disease;
LGG	trans	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg06521331	chr12:34319734	NA	-0.49	-8.6	-0.37	1.27e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg08085267	chr17:45401833	C17orf57	0.54	10.57	0.44	1.51e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-20.87	-0.7	1.15e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs62238980	0.614	rs76177859	chr22:32390135	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6835098	0.500	rs13112928	chr4:174158132	A/G	cg08422745	chr4:174089978	GALNT7	0.59	10.35	0.43	9.7e-23	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg07959490	chr17:80112427	CCDC57	-0.48	-9.47	-0.4	1.45e-19	Life satisfaction;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg23958373	chr8:599963	NA	1.26	12.22	0.49	5.65e-30	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17474435	chr12:50135167	TMBIM6	0.44	6.73	0.3	4.98e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg15971980	chr6:150254442	NA	0.44	8.14	0.35	3.7e-15	Lung cancer;
LGG	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg23029597	chr12:123009494	RSRC2	-0.91	-16.82	-0.62	7.09e-50	Body mass index;
LGG	cis	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg12395012	chr8:11607386	GATA4	0.41	7.4	0.33	6.54e-13	Monocyte count;
LGG	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	12.43	0.5	7.92e-31	Parkinson's disease;
LGG	cis	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.9	-0.31	1.69e-11	Neuroticism;
LGG	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.84	0.51	1.68e-32	Intelligence (multi-trait analysis);
LGG	cis	rs477692	0.673	rs7909964	chr10:131338714	T/C	cg05714579	chr10:131428358	MGMT	0.46	8.95	0.38	8.62e-18	Response to temozolomide;
LGG	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg18876405	chr7:65276391	NA	0.57	10.69	0.45	5.36e-24	Aortic root size;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg08621203	chr6:150244597	RAET1G	0.46	7.92	0.35	1.72e-14	Lung cancer;
LGG	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg13147721	chr7:65941812	NA	0.84	10.18	0.43	4.21e-22	Diabetic kidney disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17018464	chr11:6411469	SMPD1	-0.46	-7.0	-0.31	8.83e-12	Pancreatic cancer;
LGG	cis	rs738322	0.600	rs5995542	chr22:38558141	C/T	cg03162506	chr22:38580953	NA	0.39	9.97	0.42	2.35e-21	Cutaneous nevi;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg24503407	chr1:205819492	PM20D1	0.79	18.67	0.66	2.05e-58	Menarche (age at onset);
LGG	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.39	-0.36	5.97e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	13.52	0.53	2.54e-35	Calcium levels;
LGG	cis	rs62064224	0.714	rs4795692	chr17:30636688	G/T	cg18200150	chr17:30822561	MYO1D	0.5	9.66	0.41	3.13e-20	Schizophrenia;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.85	0.3	2.33e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02951883	chr7:2050386	MAD1L1	0.45	7.36	0.32	8.62e-13	Neuroticism;
LGG	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg22974920	chr21:40686053	BRWD1	-0.42	-6.65	-0.3	8.22e-11	Cognitive function;
LGG	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.62e-20	Aortic root size;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg19168338	chr16:4465731	CORO7	-0.89	-18.25	-0.65	1.82e-56	Schizophrenia;
LGG	cis	rs4740619	0.792	rs276433	chr9:15621105	T/C	cg14451791	chr9:16040625	NA	-0.31	-7.62	-0.33	1.47e-13	Body mass index;
LGG	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg03060546	chr3:49711283	APEH	0.73	13.14	0.52	9.65e-34	Resting heart rate;
LGG	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.66	-0.37	7.87e-17	Retinal vascular caliber;
LGG	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.14	-0.49	1.18e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg22771759	chr13:24902376	NA	0.42	7.24	0.32	1.88e-12	Obesity-related traits;
LGG	cis	rs6450176	0.585	rs255761	chr5:53321956	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.81	-12.75	-0.51	4.07e-32	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9611565	0.569	rs6002328	chr22:41710034	T/C	cg03806693	chr22:41940476	POLR3H	-0.75	-12.61	-0.51	1.53e-31	Vitiligo;
LGG	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.99e-11	Aortic root size;
LGG	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg12395012	chr8:11607386	GATA4	0.44	8.58	0.37	1.39e-16	Neuroticism;
LGG	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	9.17	0.39	1.53e-18	Diabetic retinopathy;
LGG	trans	rs1459104	0.925	rs12576020	chr11:55221500	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.67	0.3	7.28e-11	Body mass index;
LGG	cis	rs11214589	0.870	rs10789942	chr11:113236199	C/T	cg14159747	chr11:113255604	NA	-0.3	-8.28	-0.36	1.34e-15	Neuroticism;
LGG	cis	rs883565	0.740	rs12631937	chr3:39037652	T/A	cg01426195	chr3:39028469	NA	-0.7	-15.26	-0.58	7.01e-43	Handedness;
LGG	trans	rs1814175	0.791	rs1722011	chr11:49899340	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.29	-0.5	3.11e-30	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22301261	chr13:50655392	DLEU1;DLEU2	0.49	8.27	0.36	1.42e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7084402	0.967	rs1621811	chr10:60320664	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.31	0.63	4e-52	Refractive error;
LGG	cis	rs10875746	0.669	rs10467101	chr12:48607737	T/C	cg24011408	chr12:48396354	COL2A1	-0.56	-7.38	-0.32	7.21e-13	Longevity (90 years and older);
LGG	cis	rs9398803	0.723	rs1022573	chr6:127054914	C/A	cg19875578	chr6:126661172	C6orf173	-0.51	-9.31	-0.4	5.12e-19	Male-pattern baldness;
LGG	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg16141378	chr3:129829833	LOC729375	0.33	7.32	0.32	1.13e-12	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04718306	chr1:68151105	GADD45A	0.43	6.68	0.3	6.79e-11	Gut microbiome composition (summer);
LGG	cis	rs4900538	0.855	rs762105	chr14:102830175	A/G	cg18135206	chr14:102964638	TECPR2	-0.71	-12.72	-0.51	5.24e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.62	-0.51	1.41e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9972944	0.729	rs6504351	chr17:63765275	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs1568889	1.000	rs12797155	chr11:28290866	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.64	0.54	7.54e-36	Bipolar disorder;
LGG	cis	rs4950322	0.570	rs72692917	chr1:146776087	A/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs698833	0.886	rs698802	chr2:44697624	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	7.16	0.32	3.26e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg14668821	chr17:77704760	ENPP7	0.42	8.27	0.36	1.41e-15	Menopause (age at onset);
LGG	cis	rs9596837	0.514	rs61954136	chr13:54262073	G/A	ch.13.53330881F	chr13:54432880	NA	0.41	6.66	0.3	7.81e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg15704280	chr7:45808275	SEPT13	-0.89	-12.56	-0.5	2.32e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg03909863	chr11:638404	DRD4	-0.41	-6.9	-0.31	1.68e-11	Systemic lupus erythematosus;
LGG	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg15268244	chr15:77196840	NA	0.47	10.14	0.43	5.72e-22	Blood metabolite levels;
LGG	cis	rs7113850	0.541	rs4536215	chr11:24245374	C/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.37	0.43	8.76e-23	Bone fracture in osteoporosis;
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.53	-0.37	2.07e-16	Neuroticism;
LGG	cis	rs2033732	0.826	rs12546578	chr8:85085268	A/T	cg05716166	chr8:85095498	RALYL	-0.54	-8.83	-0.38	2.16e-17	Body mass index;
LGG	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg00129232	chr17:37814104	STARD3	-0.76	-16.52	-0.61	1.59e-48	Asthma;
LGG	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.78	-0.38	3.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg13679303	chr9:96623674	NA	-0.38	-6.82	-0.3	2.83e-11	DNA methylation (variation);
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg15103426	chr22:29168792	CCDC117	0.73	11.79	0.48	3.17e-28	Lymphocyte counts;
LGG	cis	rs9814567	1.000	rs9834755	chr3:134206845	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.9	-0.51	9.25e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg13385521	chr17:29058706	SUZ12P	0.94	10.53	0.44	2.19e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg02855558	chr7:158107723	PTPRN2	-0.42	-7.57	-0.33	2.04e-13	Calcium levels;
LGG	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg20891283	chr12:69753455	YEATS4	0.76	14.64	0.56	3.65e-40	Blood protein levels;
LGG	trans	rs7939886	0.844	rs7106504	chr11:55932827	C/T	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.53	-0.44	2.11e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg25214090	chr10:38739885	LOC399744	0.69	12.15	0.49	1.09e-29	Corneal astigmatism;
LGG	cis	rs1010254	0.510	rs2348422	chr5:151759909	G/A	cg08593883	chr5:151785301	NMUR2	-0.45	-6.91	-0.31	1.62e-11	Optic nerve measurement (cup area);
LGG	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14829155	chr15:31115871	NA	0.67	11.3	0.46	2.61e-26	Huntington's disease progression;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg21948465	chr5:131705150	SLC22A5	0.68	7.5	0.33	3.22e-13	Rheumatoid arthritis;
LGG	cis	rs741702	0.892	rs1799918	chr19:13002400	G/C	cg11738485	chr19:12877000	HOOK2	-0.45	-7.15	-0.32	3.51e-12	Red blood cell traits;
LGG	cis	rs273218	1.000	rs274366	chr5:53374636	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.65	9.21	0.39	1.16e-18	Migraine;
LGG	cis	rs642803	0.569	rs44205	chr11:65564786	G/A	cg08755490	chr11:65554678	OVOL1	-0.36	-6.82	-0.3	2.94e-11	Urate levels;
LGG	cis	rs2644899	0.785	rs2604895	chr19:41292263	T/A	cg24958765	chr19:41283667	RAB4B	-0.5	-7.11	-0.31	4.29e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg00761968	chr13:53314142	LECT1	-0.38	-7.69	-0.34	8.92e-14	Lewy body disease;
LGG	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.14	-0.35	3.72e-15	Height;
LGG	cis	rs9863	0.828	rs34114498	chr12:124480373	G/C	cg13487667	chr12:124434373	CCDC92	-0.34	-6.85	-0.3	2.35e-11	White blood cell count;
LGG	cis	rs62400317	0.859	rs12198376	chr6:45153681	G/C	cg20913747	chr6:44695427	NA	-0.6	-10.22	-0.43	3.02e-22	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg01879757	chr17:41196368	BRCA1	-0.41	-8.41	-0.36	5.1e-16	Menopause (age at onset);
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.72	-0.38	4.91e-17	Life satisfaction;
LGG	cis	rs1555895	0.576	rs7071801	chr10:854011	T/C	cg10556349	chr10:835070	NA	-0.31	-7.74	-0.34	6.5e-14	Survival in rectal cancer;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg04503457	chr17:41445688	NA	-0.4	-9.76	-0.41	1.4e-20	Menopause (age at onset);
LGG	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg25986240	chr4:9926439	SLC2A9	-0.54	-9.97	-0.42	2.43e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg16268157	chr7:99778414	STAG3	-0.46	-7.69	-0.34	9.05e-14	Lung function (FEV1/FVC);
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00761968	chr13:53314142	LECT1	-0.39	-8.02	-0.35	8.44e-15	Lewy body disease;
LGG	cis	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg06374794	chr16:88002281	BANP	0.47	8.65	0.37	8.23e-17	Menopause (age at onset);
LGG	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg02462569	chr6:150064036	NUP43	-0.46	-9.56	-0.41	7.02e-20	Lung cancer;
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg16141378	chr3:129829833	LOC729375	0.43	10.06	0.42	1.17e-21	Neuroticism;
LGG	cis	rs7843479	0.601	rs4872209	chr8:21848832	A/T	cg17168535	chr8:21777572	XPO7	0.8	15.79	0.59	3.17e-45	Mean corpuscular volume;
LGG	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.88	0.54	7.06e-37	Colorectal cancer;
LGG	cis	rs3806843	0.546	rs246023	chr5:140333990	G/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4356975	0.563	rs4292394	chr4:69972949	C/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs9811920	0.931	rs7629487	chr3:99860401	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	8.04	0.35	7.37e-15	Axial length;
LGG	cis	rs2635047	0.638	rs9961383	chr18:44604001	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.64	0.37	9.38e-17	Educational attainment;
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.2	-0.32	2.49e-12	Life satisfaction;
LGG	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4684776	0.867	rs60056696	chr3:11331944	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.65	-0.37	8.27e-17	Small vessel stroke;
LGG	cis	rs2247341	0.965	rs13138643	chr4:1740675	G/A	cg08446824	chr4:1720184	TMEM129	-0.67	-12.68	-0.51	7.84e-32	Hip circumference adjusted for BMI;Height;
LGG	trans	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.66	0.37	7.88e-17	Mood instability;
LGG	cis	rs12612619	0.504	rs13405539	chr2:27072209	C/T	cg12045002	chr2:27069975	DPYSL5	-0.34	-7.22	-0.32	2.18e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4e-19	Life satisfaction;
LGG	trans	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.65e-14	Resting heart rate;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.52	0.33	2.88e-13	Prudent dietary pattern;
LGG	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg25809561	chr17:30822961	MYO1D	0.43	10.45	0.44	4.31e-23	Schizophrenia;
LGG	cis	rs35740288	0.770	rs11638278	chr15:86211404	C/T	cg07943548	chr15:86304357	KLHL25	-0.33	-6.73	-0.3	4.95e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-18.45	-0.65	2.25e-57	Chronic sinus infection;
LGG	cis	rs4919087	0.926	rs10882884	chr10:99025611	T/A	cg25902810	chr10:99078978	FRAT1	0.5	9.32	0.4	4.72e-19	Monocyte count;
LGG	cis	rs2274273	0.624	rs7154796	chr14:55771458	T/C	cg04306507	chr14:55594613	LGALS3	0.54	12.57	0.5	2.2e-31	Protein biomarker;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg24846343	chr22:24311635	DDTL	0.55	10.55	0.44	1.87e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2933343	0.621	rs789241	chr3:128585752	G/A	cg11901034	chr3:128598214	ACAD9	-0.45	-6.83	-0.3	2.73e-11	IgG glycosylation;
LGG	cis	rs4795067	0.929	rs10853180	chr17:26117407	A/G	cg07704981	chr17:26127537	NOS2	-0.43	-7.44	-0.33	5e-13	Psoriatic arthritis;Psoriasis;Cutaneous psoriasis;Inflammatory skin disease;
LGG	cis	rs6489785	0.701	rs2649996	chr12:121362280	A/C	cg02419362	chr12:121203948	SPPL3	0.44	6.96	0.31	1.16e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.9	-19.14	-0.66	1.34e-60	Personality dimensions;
LGG	cis	rs58649573	0.509	rs4838093	chr9:126788876	G/T	cg14112217	chr9:126806003	NA	0.39	7.7	0.34	8.15e-14	Post-traumatic stress disorder;
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg26554054	chr8:600488	NA	0.93	10.18	0.43	4.38e-22	IgG glycosylation;
LGG	trans	rs9354308	0.764	rs9363472	chr6:66584142	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2404602	0.684	rs1011083	chr15:77007527	C/T	cg23625390	chr15:77176239	SCAPER	-0.72	-14.44	-0.56	2.78e-39	Blood metabolite levels;
LGG	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.27e-12	Cystic fibrosis severity;
LGG	cis	rs1185460	0.546	rs589925	chr11:118955679	C/T	cg23280166	chr11:118938394	VPS11	-0.46	-7.84	-0.34	3.19e-14	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg15440763	chr7:158190612	PTPRN2	-0.5	-10.63	-0.44	9.08e-24	Obesity-related traits;
LGG	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg00701064	chr4:6280414	WFS1	0.77	17.87	0.64	1.08e-54	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg18245976	chr7:158708271	WDR60	-0.55	-9.53	-0.41	8.73e-20	Height;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.77	0.84	1.05e-122	Prudent dietary pattern;
LGG	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.63	0.54	8.39e-36	Colorectal cancer;
LGG	trans	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg00938859	chr5:1591904	SDHAP3	0.84	8.56	0.37	1.65e-16	Breast cancer;
LGG	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg06481639	chr22:41940642	POLR3H	-0.54	-7.96	-0.35	1.33e-14	Vitiligo;
LGG	cis	rs950027	0.572	rs12910764	chr15:45609360	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.95	-0.42	2.77e-21	Response to fenofibrate (adiponectin levels);
LGG	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.44	-0.37	3.99e-16	Total body bone mineral density;
LGG	trans	rs11246602	1	rs11246602	chr11:51512090	T/C	cg15704280	chr7:45808275	SEPT13	0.87	9.48	0.4	1.34e-19	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11585357	0.947	rs72646795	chr1:17612120	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-8.31	-0.36	1.11e-15	Hair shape;
LGG	cis	rs4665809	0.556	rs1560869	chr2:26417095	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg00149659	chr3:10157352	C3orf10	0.59	8.35	0.36	7.75e-16	Alzheimer's disease;
LGG	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg23029597	chr12:123009494	RSRC2	-0.95	-18.14	-0.64	6.16e-56	Body mass index;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg18538332	chr22:24372958	LOC391322	-0.46	-7.48	-0.33	3.71e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg14668632	chr7:2872130	GNA12	-0.38	-7.84	-0.34	3.2e-14	Height;
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.11e-11	Bipolar disorder;
LGG	cis	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg05084668	chr3:125655381	ALG1L	-0.94	-12.21	-0.49	6.33e-30	Blood pressure (smoking interaction);
LGG	cis	rs7444	0.941	rs2283789	chr22:21944478	T/G	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.57e-11	Systemic lupus erythematosus;
LGG	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-9.96	-0.42	2.72e-21	Kawasaki disease;
LGG	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg06360820	chr2:242988706	NA	-0.89	-11.5	-0.47	4.38e-27	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg17376030	chr22:41985996	PMM1	-0.57	-9.16	-0.39	1.72e-18	Vitiligo;
LGG	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg00325661	chr8:49890786	NA	-0.43	-7.04	-0.31	7.14e-12	Sudden cardiac arrest;
LGG	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg25019033	chr10:957182	NA	-0.59	-12.02	-0.49	3.76e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs2976388	0.647	rs2164307	chr8:143788831	A/T	cg06565975	chr8:143823917	SLURP1	0.37	9.53	0.4	8.89e-20	Urinary tract infection frequency;
LGG	cis	rs7208859	0.573	rs73267829	chr17:29003939	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.22	-0.46	5.14e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3540	0.512	rs3930162	chr15:91075129	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-12.23	-0.49	5.14e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs9650657	0.623	rs6601517	chr8:10603793	T/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.19	-0.32	2.68e-12	Neuroticism;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg25703541	chr22:24373054	LOC391322	-0.87	-17.01	-0.62	9.46e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9783347	1.000	rs12286683	chr11:18348662	G/T	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	trans	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg23484912	chr5:273055	PDCD6	0.47	9.57	0.41	6.52e-20	Pancreatic cancer;
LGG	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg20891558	chr2:74357851	NA	0.5	8.88	0.38	1.5e-17	Gestational age at birth (maternal effect);
LGG	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg11644478	chr21:40555479	PSMG1	-0.72	-12.86	-0.51	1.4e-32	Cognitive function;
LGG	cis	rs35160687	0.798	rs6547674	chr2:86552919	G/T	cg10973622	chr2:86423274	IMMT	-0.4	-7.26	-0.32	1.64e-12	Night sleep phenotypes;
LGG	cis	rs10227331	0.585	rs10240671	chr7:157298637	G/T	cg04156418	chr7:157293606	NA	-0.56	-11.52	-0.47	3.59e-27	Inattentive symptoms;
LGG	cis	rs11650494	0.710	rs11653775	chr17:47472365	A/G	cg08112188	chr17:47440006	ZNF652	1.2	13.19	0.52	5.72e-34	Prostate cancer;
LGG	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg23422044	chr7:1970798	MAD1L1	-0.51	-8.66	-0.37	7.91e-17	Bipolar disorder;
LGG	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.65	-0.3	8.11e-11	Pediatric bone mineral density (spine);
LGG	cis	rs4430311	0.624	rs1074657	chr1:243746634	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.56	-0.59	3.32e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs13191362	1.000	rs13200329	chr6:163004418	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	11.45	0.47	6.63e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg15284433	chr12:132323321	MMP17	-0.39	-7.48	-0.33	3.83e-13	Migraine;
LGG	cis	rs1451375	0.669	rs4512339	chr7:50646977	C/T	cg00647317	chr7:50633725	DDC	0.33	7.39	0.33	6.7e-13	Malaria;
LGG	cis	rs17776563	0.919	rs1348005	chr15:89113482	A/G	cg05013243	chr15:89149849	MIR1179	-0.49	-10.0	-0.42	1.89e-21	Thyroid hormone levels;
LGG	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11890956	chr21:40555474	PSMG1	1.18	25.83	0.77	8.74e-92	Cognitive function;
LGG	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg06951627	chr6:26196580	NA	0.48	7.19	0.32	2.7e-12	Gout;Renal underexcretion gout;
LGG	cis	rs8133932	0.654	rs410902	chr21:47341794	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-8.05	-0.35	6.85e-15	Schizophrenia;
LGG	trans	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1003719	0.751	rs55992706	chr21:38542749	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.27	-0.58	6.49e-43	Eye color traits;
LGG	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg01017244	chr2:74357527	NA	0.43	8.06	0.35	6.53e-15	Gestational age at birth (maternal effect);
LGG	cis	rs55871839	0.533	rs1015794	chr8:59838228	C/T	cg07426533	chr8:59803705	TOX	0.58	12.04	0.49	3.23e-29	Pneumonia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08606075	chr2:677472	TMEM18	0.41	6.75	0.3	4.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg08975724	chr8:8085496	FLJ10661	0.37	6.67	0.3	7.35e-11	Retinal vascular caliber;
LGG	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.55	0.44	1.81e-23	Morning vs. evening chronotype;
LGG	cis	rs9912468	1.000	rs11867573	chr17:64320085	A/G	cg19474267	chr17:64306194	PRKCA	-0.97	-28.4	-0.8	1.77e-103	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1577917	0.523	rs1413724	chr6:86814549	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	9.6e-16	Response to antipsychotic treatment;
LGG	cis	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.1	-0.46	1.49e-25	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg01879757	chr17:41196368	BRCA1	-0.41	-8.53	-0.37	2.11e-16	Menopause (age at onset);
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	cis	rs9964724	0.796	rs35064785	chr18:35197862	G/A	cg27332583	chr18:35150602	NA	0.37	7.83	0.34	3.27e-14	Educational attainment (years of education);
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg04267008	chr7:1944627	MAD1L1	0.6	10.76	0.45	3.1e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg23601095	chr6:26197514	HIST1H3D	0.72	8.77	0.38	3.36e-17	Gout;Renal underexcretion gout;
LGG	cis	rs6032067	0.777	rs34085254	chr20:43786170	T/G	cg10761708	chr20:43804764	PI3	0.74	11.28	0.46	3.19e-26	Blood protein levels;
LGG	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.79	0.38	2.84e-17	Myopia (pathological);
LGG	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg02002194	chr4:3960332	NA	0.39	6.92	0.31	1.48e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17102423	0.588	rs7150646	chr14:65540463	G/T	cg26396452	chr14:65542826	MAX	0.47	10.03	0.42	1.51e-21	Obesity-related traits;
LGG	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg09441152	chr18:77712293	PQLC1	-0.41	-7.24	-0.32	1.9e-12	Schizophrenia;
LGG	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg05234568	chr11:5960015	NA	-0.64	-10.93	-0.45	6.79e-25	DNA methylation (variation);
LGG	cis	rs34599045	0.522	rs17680493	chr1:152972747	G/A	cg07796016	chr1:152779584	LCE1C	-0.88	-7.39	-0.32	6.72e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg17158414	chr2:27665306	KRTCAP3	0.27	6.97	0.31	1.08e-11	Total body bone mineral density;
LGG	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.89	-13.75	-0.54	2.59e-36	HIV-1 control;
LGG	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg23625390	chr15:77176239	SCAPER	0.46	8.93	0.38	1e-17	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg11584989	chr19:19387371	SF4	-0.74	-12.12	-0.49	1.54e-29	Bipolar disorder;
LGG	cis	rs2013441	1.000	rs9897328	chr17:20174852	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.85e-19	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg19442545	chr10:75533431	FUT11	-0.43	-7.04	-0.31	6.77e-12	Inflammatory bowel disease;
LGG	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15506890	chr2:3487001	NA	-0.52	-10.07	-0.42	1.1e-21	Neurofibrillary tangles;
LGG	cis	rs8005677	0.798	rs61977741	chr14:23400979	G/C	cg25600027	chr14:23388339	RBM23	-0.43	-7.29	-0.32	1.35e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.01	0.39	5.61e-18	Motion sickness;
LGG	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg23422044	chr7:1970798	MAD1L1	0.69	11.61	0.47	1.56e-27	Bipolar disorder;
LGG	trans	rs6787172	0.622	rs60336101	chr3:158066295	A/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.41	-0.33	6.08e-13	Subjective well-being;
LGG	cis	rs12887734	0.524	rs4906363	chr14:104210239	G/A	cg26031613	chr14:104095156	KLC1	-0.56	-8.89	-0.38	1.32e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.55	-0.44	1.75e-23	Platelet count;
LGG	cis	rs6831352	0.918	rs34876213	chr4:100062216	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.67	-0.41	2.82e-20	Alcohol dependence;
LGG	cis	rs7529073	1.000	rs7529073	chr1:214147889	T/C	cg05052969	chr1:214156842	NA	0.44	8.48	0.37	2.98e-16	Schizophrenia;
LGG	trans	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg18187862	chr3:45730750	SACM1L	-0.54	-8.46	-0.37	3.59e-16	Primary sclerosing cholangitis;
LGG	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.88	-0.3	1.99e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs7937840	0.581	rs4963462	chr11:61886672	A/T	cg01969543	chr11:61895209	INCENP	0.47	9.56	0.41	7.02e-20	Breast cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17174775	chr7:121784596	AASS	-0.41	-6.83	-0.3	2.64e-11	Electrocardiographic conduction measures;
LGG	trans	rs9393777	0.778	rs35741362	chr6:27007687	T/C	cg08344181	chr3:125677491	NA	-0.61	-7.33	-0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00149659	chr3:10157352	C3orf10	-1.17	-14.0	-0.55	2.22e-37	Alzheimer's disease;
LGG	cis	rs9457247	0.765	rs9459849	chr6:167444160	G/T	cg07741184	chr6:167504864	NA	0.43	9.49	0.4	1.26e-19	Crohn's disease;
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.09	0.46	1.66e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg09359103	chr1:154839909	KCNN3	-0.48	-9.49	-0.4	1.25e-19	Prostate cancer;
LGG	cis	rs72781680	0.752	rs55859418	chr2:23904231	C/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.89	0.38	1.4e-17	Lymphocyte counts;
LGG	cis	rs6430585	0.591	rs309118	chr2:136746224	G/C	cg07169764	chr2:136633963	MCM6	1.17	22.1	0.72	2.04e-74	Corneal structure;
LGG	cis	rs6735179	0.549	rs56066419	chr2:1755649	G/A	cg08534653	chr2:1747700	PXDN	0.46	7.1	0.31	4.69e-12	Response to antipsychotic treatment;
LGG	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg20573242	chr4:122745356	CCNA2	-0.46	-7.89	-0.34	2.17e-14	Type 2 diabetes;
LGG	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg24112000	chr20:60950667	NA	-0.4	-8.01	-0.35	9.5e-15	Colorectal cancer;
LGG	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg03433033	chr1:76189801	ACADM	0.82	14.34	0.55	7.79e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3820068	0.529	rs79570154	chr1:15990912	T/C	cg05660106	chr1:15850417	CASP9	0.82	15.82	0.59	2.32e-45	Systolic blood pressure;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg00933542	chr6:150070202	PCMT1	0.38	6.86	0.3	2.16e-11	Lung cancer;
LGG	cis	rs3820928	0.874	rs4675138	chr2:227884118	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.56	-0.33	2.25e-13	Pulmonary function;
LGG	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg10792982	chr14:105748885	BRF1	-0.55	-11.38	-0.47	1.29e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.86	0.3	2.21e-11	Menarche (age at onset);
LGG	cis	rs9557207	1.000	rs35694871	chr13:100036955	C/T	cg24509225	chr13:100037070	UBAC2	0.72	12.98	0.52	4.43e-33	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2594989	0.779	rs2443702	chr3:11586435	C/T	cg01796438	chr3:11312864	ATG7	0.45	6.66	0.3	7.94e-11	Circulating chemerin levels;
LGG	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.93	-0.38	1.01e-17	Cognitive function;
LGG	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-7.81	-0.34	3.95e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6860806	0.507	rs273917	chr5:131659618	A/G	cg07395648	chr5:131743802	NA	-0.49	-9.99	-0.42	2.01e-21	Breast cancer;
LGG	cis	rs7236492	0.572	rs7242868	chr18:77179564	G/A	cg15644404	chr18:77186268	NFATC1	-0.82	-8.86	-0.38	1.79e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17604090	0.938	rs10241566	chr7:29690179	T/C	cg19413766	chr7:29689036	LOC646762	-0.62	-7.83	-0.34	3.34e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs3779273	0.776	rs4730110	chr7:77832149	T/C	cg05596911	chr5:118502651	DMXL1	-0.5	-10.7	-0.45	5.15e-24	Body mass index;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.3	0.32	1.3e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	7.64	0.33	1.22e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11190604	1.000	rs75063298	chr10:102213600	C/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12410462	0.591	rs12080590	chr1:227759771	C/G	cg23173402	chr1:227635558	NA	-0.38	-7.24	-0.32	1.84e-12	Major depressive disorder;
LGG	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-8.45	-0.37	3.72e-16	Obesity (extreme);
LGG	cis	rs5756391	0.901	rs5750328	chr22:37284219	A/G	cg21209356	chr22:37319042	CSF2RB	0.34	7.33	0.32	1.04e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2692947	0.832	rs2579519	chr2:96675166	T/C	cg22654517	chr2:96458247	NA	0.38	8.14	0.35	3.73e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.4	-0.33	6.2800000000000005e-13	Subjective well-being;
LGG	cis	rs7814319	0.966	rs10955069	chr8:97253788	C/T	cg20787634	chr8:97240163	UQCRB	-0.77	-18.71	-0.66	1.41e-58	Lung function (FVC);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22256960	chr15:77711686	NA	-0.52	-7.74	-0.34	6.39e-14	Systemic lupus erythematosus;
LGG	cis	rs8077889	0.917	rs9894873	chr17:41911832	A/G	cg26893861	chr17:41843967	DUSP3	0.91	15.57	0.59	2.95e-44	Triglycerides;
LGG	cis	rs7463659	1.000	rs7463659	chr8:135432140	T/C	cg17885191	chr8:135476712	NA	-0.43	-7.28	-0.32	1.4e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4743820	0.651	rs16907199	chr9:93923617	A/G	cg14446406	chr9:93919335	NA	-0.88	-15.17	-0.58	1.74e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.41	0.44	6.04e-23	Aortic root size;
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.57	-0.33	2.02e-13	Monocyte count;
LGG	trans	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.49	0.4	1.2e-19	Mean corpuscular volume;
LGG	cis	rs2964802	0.505	rs11133627	chr5:10830474	T/G	cg14521931	chr5:10832172	NA	-0.75	-16.36	-0.61	8.45e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs7106204	0.534	rs56157310	chr11:24260694	A/G	ch.11.24196551F	chr11:24239977	NA	0.86	9.48	0.4	1.34e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	15.81	0.59	2.58e-45	Menarche (age at onset);
LGG	cis	rs9783347	0.714	rs4150644	chr11:18370969	C/T	cg15585147	chr11:18324498	HPS5	0.32	7.43	0.33	5.29e-13	Pancreatic cancer;
LGG	cis	rs7241530	0.585	rs67507908	chr18:75891447	A/G	cg14642773	chr18:75888474	NA	0.46	9.05	0.39	4e-18	Educational attainment (years of education);
LGG	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg03970086	chr16:88974840	CBFA2T3	-0.41	-8.18	-0.36	2.78e-15	Social autistic-like traits;
LGG	cis	rs17221829	0.702	rs72971023	chr11:89363934	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	trans	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs7959452	0.868	rs12812860	chr12:69746671	T/C	cg20891283	chr12:69753455	YEATS4	0.8	16.24	0.6	2.99e-47	Blood protein levels;
LGG	cis	rs7926971	0.655	rs7927422	chr11:12660894	T/C	cg25843174	chr11:12811716	TEAD1	0.31	6.79	0.3	3.43e-11	Height;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.85	-0.3	2.33e-11	Lung cancer;
LGG	cis	rs36051895	0.664	rs10974963	chr9:5101305	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.01	-0.57	8.75e-42	Pediatric autoimmune diseases;
LGG	cis	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg21479132	chr6:26055353	NA	0.79	7.13	0.31	3.9e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg17294928	chr15:75287854	SCAMP5	0.61	10.93	0.45	6.58e-25	Caffeine consumption;
LGG	cis	rs12282928	0.802	rs1105164	chr11:48285025	G/A	cg26585981	chr11:48327164	OR4S1	0.44	7.12	0.31	4.22e-12	Migraine - clinic-based;
LGG	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg23625390	chr15:77176239	SCAPER	-0.71	-13.77	-0.54	2.1e-36	Blood metabolite levels;
LGG	cis	rs11874712	1.000	rs9783887	chr18:43651272	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.93	-0.45	7.07e-25	Migraine - clinic-based;
LGG	cis	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg21775007	chr8:11205619	TDH	-0.49	-7.56	-0.33	2.25e-13	Triglycerides;
LGG	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.62	-0.37	1.11e-16	Neuroticism;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg13206674	chr6:150067644	NUP43	0.63	14.3	0.55	1.11e-38	Lung cancer;
LGG	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.72	-0.34	7.01e-14	Colorectal cancer;
LGG	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg13271783	chr10:134563150	INPP5A	0.48	7.21	0.32	2.3e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.14	-0.32	3.6e-12	Lung cancer;
LGG	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg25986240	chr4:9926439	SLC2A9	-0.57	-10.64	-0.44	8.26e-24	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06141123	chr2:178129829	NFE2L2	0.6	6.73	0.3	5.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.18	0.65	3.87e-56	Refractive error;
LGG	cis	rs986417	0.818	rs8014133	chr14:61104738	A/G	cg27398547	chr14:60952738	C14orf39	0.65	6.68	0.3	6.95e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4727443	0.866	rs12531809	chr7:99620473	G/T	cg12813108	chr7:99719912	CNPY4	-0.58	-11.29	-0.46	2.89e-26	Interstitial lung disease;
LGG	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg16662043	chr16:48846231	NA	-0.35	-6.96	-0.31	1.16e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg22174410	chr3:42641766	NKTR	-0.41	-6.88	-0.3	1.97e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs3204270	0.639	rs62077183	chr17:79658940	C/A	cg18367735	chr17:79674897	NA	0.6	7.99	0.35	1.06e-14	Dental caries;
LGG	cis	rs9948	0.786	rs62156230	chr2:97424915	A/G	cg01990225	chr2:97406019	LMAN2L	-0.65	-7.26	-0.32	1.66e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg27129171	chr3:47204927	SETD2	0.78	15.19	0.58	1.47e-42	Colorectal cancer;
LGG	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.67	-0.3	7.46e-11	HDL cholesterol;
LGG	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg00409905	chr10:38381863	ZNF37A	-0.49	-6.99	-0.31	9.74e-12	Obesity (extreme);
LGG	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs2346177	0.874	rs35462976	chr2:46649049	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.83	0.34	3.35e-14	HDL cholesterol;
LGG	cis	rs36051895	0.623	rs62541543	chr9:5042082	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-15.59	-0.59	2.29e-44	Pediatric autoimmune diseases;
LGG	cis	rs847649	0.699	rs10242028	chr7:102527785	C/G	cg18108683	chr7:102477205	FBXL13	-0.64	-14.11	-0.55	7.19e-38	Morning vs. evening chronotype;
LGG	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg00031303	chr3:195681400	NA	-0.45	-6.99	-0.31	9.89e-12	Mean corpuscular volume;
LGG	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg10189774	chr4:17578691	LAP3	0.42	7.54	0.33	2.46e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11074306	0.561	rs4778189	chr15:28072228	A/G	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs7617773	0.963	rs12493256	chr3:48176747	C/T	cg11946769	chr3:48343235	NME6	-0.5	-8.05	-0.35	6.88e-15	Coronary artery disease;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg11766577	chr21:47581405	C21orf56	0.49	8.14	0.35	3.72e-15	Testicular germ cell tumor;
LGG	cis	rs9472414	0.771	rs7769218	chr6:44783457	A/G	cg20913747	chr6:44695427	NA	0.45	6.75	0.3	4.45e-11	Height;
LGG	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg16586182	chr3:47516702	SCAP	-0.56	-9.49	-0.4	1.18e-19	Birth weight;
LGG	trans	rs208520	0.874	rs208518	chr6:66948501	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.91	15.47	0.58	8.07e-44	Exhaled nitric oxide output;
LGG	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.36e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.76	0.57	1.06e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1983170	0.736	rs4484968	chr1:92012005	C/A	cg25838465	chr1:92012736	NA	0.5	6.78	0.3	3.59e-11	Eosinophil percentage of white cells;
LGG	cis	rs8078723	0.510	rs9898547	chr17:38136026	G/T	cg17467752	chr17:38218738	THRA	-0.55	-9.49	-0.4	1.19e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-10.06	-0.42	1.15e-21	Chronic sinus infection;
LGG	cis	rs2307022	0.586	rs1465467	chr16:68398432	A/G	cg07273125	chr16:68295692	NA	-0.44	-9.91	-0.42	4.04e-21	Body mass index;
LGG	trans	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.67	-0.37	7.58e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4919087	1.000	rs11189132	chr10:99086195	G/C	cg25902810	chr10:99078978	FRAT1	-0.5	-9.03	-0.39	4.67e-18	Monocyte count;
LGG	cis	rs7444	0.825	rs2266963	chr22:21947467	C/G	cg05046821	chr22:21984468	YDJC	-0.39	-7.1	-0.31	4.65e-12	Systemic lupus erythematosus;
LGG	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.38	-0.32	7.51e-13	Blood metabolite levels;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.28	0.58	5.87e-43	Platelet count;
LGG	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg11663600	chr3:49941416	MST1R	0.24	6.74	0.3	4.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.6e-29	Total body bone mineral density;
LGG	cis	rs929354	1.000	rs1182410	chr7:157063837	C/T	cg00092383	chr7:157075207	NA	0.45	7.92	0.35	1.82e-14	Body mass index;
LGG	cis	rs2274273	0.712	rs7144652	chr14:55537718	G/A	cg04306507	chr14:55594613	LGALS3	0.43	10.73	0.45	3.77e-24	Protein biomarker;
LGG	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.5	7.59	0.33	1.81e-13	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7939886	0.920	rs11227598	chr11:56000451	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7246760	1.000	rs57736549	chr19:9937558	A/G	cg16876255	chr19:9731953	ZNF561	0.78	7.18	0.32	2.73e-12	Pursuit maintenance gain;
LGG	cis	rs2046867	0.818	rs17010188	chr3:72870351	T/C	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6050267	0.556	rs62217177	chr20:25012178	A/G	cg26195577	chr20:24973756	C20orf3	0.81	9.46	0.4	1.54e-19	Cognitive performance;
LGG	cis	rs7264396	0.635	rs6060681	chr20:34506147	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.15	-0.32	3.39e-12	Total cholesterol levels;
LGG	cis	rs2201728	0.714	rs13121365	chr4:100218412	T/A	cg07219303	chr4:100140905	ADH6	-0.36	-6.74	-0.3	4.8e-11	Cardiac Troponin-T levels;
LGG	cis	rs4481887	0.508	rs7349159	chr1:248386242	C/T	cg00666640	chr1:248458726	OR2T12	0.47	7.02	0.31	7.95e-12	Common traits (Other);
LGG	trans	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg25482853	chr8:67687455	SGK3	0.99	11.44	0.47	7.23e-27	Ulcerative colitis;
LGG	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg04842962	chr6:43655489	MRPS18A	1.11	23.71	0.74	5.99e-82	IgG glycosylation;
LGG	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg12011299	chr4:100065546	ADH4	0.39	7.55	0.33	2.26e-13	Alcohol dependence;
LGG	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg25730555	chr22:47059586	GRAMD4	0.42	7.17	0.32	3.04e-12	Urate levels in obese individuals;
LGG	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg06138931	chr13:21896616	NA	0.51	8.11	0.35	4.55e-15	White matter hyperintensity burden;
LGG	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.2	-0.36	2.3e-15	Height;
LGG	cis	rs908922	0.676	rs12116609	chr1:152497685	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.4	0.33	6.2800000000000005e-13	Hair morphology;
LGG	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg14154082	chr13:112174009	NA	0.36	7.96	0.35	1.3e-14	Menarche (age at onset);
LGG	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg20283391	chr11:68216788	NA	-0.45	-7.38	-0.32	7.29e-13	Total body bone mineral density;
LGG	cis	rs12731740	1.000	rs34599386	chr1:208034235	G/T	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.06	-0.31	6.29e-12	Biomedical quantitative traits;
LGG	cis	rs778371	0.676	rs7560115	chr2:233709465	T/G	cg08000102	chr2:233561755	GIGYF2	-0.66	-10.69	-0.44	5.68e-24	Schizophrenia;
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg24996263	chr1:31297444	NA	-0.42	-6.92	-0.31	1.51e-11	Breast cancer;
LGG	cis	rs7424096	0.515	rs17497343	chr2:37173032	T/C	cg14987922	chr2:37194071	STRN	0.49	7.82	0.34	3.71e-14	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs61931739	0.620	rs7138912	chr12:33701863	G/C	cg06521331	chr12:34319734	NA	0.4	6.89	0.3	1.82e-11	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.23	-0.36	1.97e-15	Neuroticism;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.92	-0.45	7.67e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg06697600	chr4:7070879	GRPEL1	-0.55	-9.69	-0.41	2.37e-20	Monocyte percentage of white cells;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg24101359	chr6:42928495	GNMT	0.53	14.77	0.57	9.59e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9899728	0.665	rs2307008	chr17:73042682	G/A	cg27626185	chr17:73056755	KCTD2	-0.67	-8.93	-0.38	9.97e-18	Alzheimer's disease or small vessel stroke;
LGG	cis	rs13294100	0.929	rs10435770	chr9:17581168	C/G	cg11213383	chr9:17579734	SH3GL2	-0.61	-11.64	-0.48	1.24e-27	Parkinson's disease;
LGG	trans	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg11887960	chr12:57824829	NA	0.54	6.67	0.3	7.13e-11	Obesity-related traits;
LGG	cis	rs9902453	0.817	rs2729435	chr17:28121532	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.79	-0.54	1.67e-36	Coffee consumption (cups per day);
LGG	cis	rs72949976	1.000	rs62186568	chr2:214033955	G/A	cg08319019	chr2:214017104	IKZF2	-0.6	-10.08	-0.42	9.61e-22	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.79	0.59	2.89e-45	Lung cancer;
LGG	cis	rs7662987	0.517	rs4235436	chr4:100039620	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs2734839	0.964	rs4587762	chr11:113306893	G/A	cg14159747	chr11:113255604	NA	0.28	7.29	0.32	1.38e-12	Information processing speed;
LGG	cis	rs6430585	0.528	rs309167	chr2:136669264	C/T	cg07169764	chr2:136633963	MCM6	1.22	22.35	0.72	1.4e-75	Corneal structure;
LGG	trans	rs7395662	0.963	rs11039774	chr11:48513959	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.04	-0.31	7.14e-12	HDL cholesterol;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.86	-16.25	-0.6	2.73e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg13482628	chr17:19912719	NA	0.59	11.65	0.48	1.08e-27	Schizophrenia;
LGG	cis	rs41271473	0.649	rs11584348	chr1:228901357	T/C	cg00850481	chr1:228891306	NA	-0.46	-7.83	-0.34	3.24e-14	Chronic lymphocytic leukemia;
LGG	cis	rs1270639	0.778	rs2906933	chr7:157450749	T/A	cg13357408	chr7:157437802	PTPRN2	0.7	10.43	0.44	5.15e-23	Colorectal cancer;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg05165339	chr4:1420672	NA	0.36	9.13	0.39	2.08e-18	Longevity;
LGG	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.38	-0.32	7.41e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs283228	1.000	rs2579928	chr6:101830109	T/C	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.83	-0.51	1.85e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg04503457	chr17:41445688	NA	-0.39	-8.96	-0.38	7.84e-18	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12385383	chr13:113951097	LAMP1	0.42	7.01	0.31	8.34e-12	Cognitive performance;
LGG	cis	rs6142618	0.562	rs6061159	chr20:30691922	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.92	0.35	1.75e-14	Inflammatory bowel disease;
LGG	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs858239	0.539	rs6955726	chr7:23186691	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.77	0.3	3.92e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg07701084	chr6:150067640	NUP43	0.7	13.51	0.53	2.58e-35	Lung cancer;
LGG	trans	rs9354308	0.764	rs9453474	chr6:66603577	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs17604090	0.756	rs10249388	chr7:29729135	G/T	cg19413766	chr7:29689036	LOC646762	-0.58	-7.16	-0.32	3.18e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg13385794	chr1:248469461	NA	0.44	7.81	0.34	3.91e-14	Common traits (Other);
LGG	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg18350739	chr11:68623251	NA	-0.86	-22.4	-0.72	8.13e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7236492	0.872	rs112187368	chr18:77236259	G/A	cg15644404	chr18:77186268	NFATC1	-0.76	-8.95	-0.38	8.31e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg21827317	chr3:136751795	NA	0.51	9.4	0.4	2.62e-19	Gestational age at birth (child effect);
LGG	cis	rs7589342	0.628	rs12996286	chr2:106399667	A/G	cg16077055	chr2:106428750	NCK2	0.29	6.99	0.31	9.42e-12	Addiction;
LGG	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg04226714	chr8:49833948	SNAI2	-0.5	-9.06	-0.39	3.63e-18	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05318427	chr2:85199320	KCMF1	0.48	7.67	0.34	1.02e-13	Gut microbiome composition (summer);
LGG	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.9	-0.31	1.66e-11	Multiple myeloma (IgH translocation);
LGG	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg03929089	chr4:120376271	NA	-0.79	-8.15	-0.35	3.38e-15	Myopia (pathological);
LGG	trans	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.29	0.5	3.13e-30	Type 2 diabetes;
LGG	cis	rs174601	0.668	rs174559	chr11:61581656	G/A	cg19610905	chr11:61596333	FADS2	-0.74	-12.1	-0.49	1.72e-29	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs75059851	0.756	rs2000852	chr11:133838221	C/T	cg20042908	chr11:133852938	NA	-0.77	-14.28	-0.55	1.33e-38	Schizophrenia;
LGG	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg18196295	chr10:418757	DIP2C	-0.72	-13.48	-0.53	3.54e-35	Psychosis in Alzheimer's disease;
LGG	cis	rs36051895	0.664	rs10121077	chr9:5098411	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.08	-0.6	1.59e-46	Pediatric autoimmune diseases;
LGG	cis	rs988958	0.958	rs6730389	chr2:42279349	A/C	cg27428208	chr2:42229179	NA	-0.41	-7.42	-0.33	5.82e-13	Hypospadias;
LGG	cis	rs939658	0.683	rs1560895	chr15:79468082	A/G	cg17916960	chr15:79447300	NA	-0.52	-9.59	-0.41	5.32e-20	Refractive error;
LGG	cis	rs7000551	0.700	rs2461480	chr8:22381839	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	12.62	0.51	1.32e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg20431080	chr7:149158239	ZNF777	0.44	6.75	0.3	4.43e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2073300	1.000	rs114718317	chr20:23442620	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.99	-0.39	6.21e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg14541582	chr5:601475	NA	-0.67	-10.47	-0.44	3.59e-23	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.43	0.56	3.1e-39	Cognitive test performance;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.06	-0.31	6.31e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg03647317	chr4:187891568	NA	-0.42	-9.09	-0.39	2.88e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.673	rs73277984	chr17:29196133	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.14	0.31	3.62e-12	Personality dimensions;
LGG	cis	rs10865541	0.902	rs7558487	chr2:3425514	G/C	cg11642891	chr2:3452563	TTC15	-0.43	-8.48	-0.37	3.16e-16	Obesity-related traits;
LGG	trans	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg06521331	chr12:34319734	NA	0.42	7.57	0.33	2e-13	Heart rate;
LGG	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg03929089	chr4:120376271	NA	0.75	8.64	0.37	9.37e-17	Axial length;
LGG	cis	rs9463078	0.774	rs6458441	chr6:45327401	G/T	cg25276700	chr6:44698697	NA	0.4	8.53	0.37	2.14e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.62	0.37	1.06e-16	Prudent dietary pattern;
LGG	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13425677	chr5:56112090	MAP3K1	0.4	6.96	0.31	1.19e-11	Bilirubin levels;
LGG	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg18351406	chr4:77819688	ANKRD56	0.46	8.04	0.35	7.79e-15	Emphysema distribution in smoking;
LGG	cis	rs6586163	0.527	rs3824730	chr10:90752128	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.76	14.97	0.57	1.33e-41	Chronic lymphocytic leukemia;
LGG	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-13.72	-0.54	3.48e-36	Coronary artery disease;
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg06611532	chr13:114900021	NA	-0.29	-7.52	-0.33	2.8e-13	Schizophrenia;
LGG	cis	rs3735485	0.738	rs62458145	chr7:45090911	G/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.47e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.48	8.55	0.37	1.87e-16	Brugada syndrome;
LGG	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg07777115	chr5:623756	CEP72	-0.49	-6.7	-0.3	5.97e-11	Obesity-related traits;
LGG	cis	rs3767633	0.764	rs4657094	chr1:161713826	G/T	cg00160981	chr1:161691911	FCRLB	0.39	6.75	0.3	4.53e-11	IgG glycosylation;
LGG	cis	rs6754311	0.773	rs309125	chr2:136643555	C/T	cg07169764	chr2:136633963	MCM6	0.76	13.01	0.52	3.22e-33	Mosquito bite size;
LGG	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg03606772	chr1:152487856	CRCT1	0.29	6.87	0.3	2.06e-11	Hair morphology;
LGG	cis	rs3862030	0.720	rs7081467	chr10:104231662	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.22	-0.39	1.07e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs9397585	0.857	rs9384074	chr6:153378895	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.43e-39	Body mass index;
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.7	-0.3	6.23e-11	Aortic root size;
LGG	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg06238570	chr21:40685208	BRWD1	0.42	6.66	0.3	7.61e-11	Cognitive function;
LGG	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs9902453	0.845	rs12452201	chr17:28214173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.39	0.53	8.73e-35	Coffee consumption (cups per day);
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.55	0.37	1.85e-16	Obesity-related traits;
LGG	cis	rs11677416	1.000	rs6542092	chr2:113528322	C/G	cg27083787	chr2:113543245	IL1A	0.53	8.78	0.38	3.11e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg09904177	chr6:26538194	HMGN4	-0.39	-6.97	-0.31	1.13e-11	Schizophrenia;
LGG	cis	rs10463316	0.894	rs7703283	chr5:150764904	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.2800000000000002e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs13082711	0.516	rs1388785	chr3:27371843	T/C	cg02860705	chr3:27208620	NA	-0.63	-12.07	-0.49	2.28e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	cg07928641	chr1:182991847	LAMC1	0.46	9.23	0.39	9.77e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.23	0.58	9.89e-43	Platelet count;
LGG	cis	rs10884984	0.739	rs4917567	chr10:112272762	C/T	cg18756771	chr10:112261994	DUSP5	-0.72	-13.36	-0.53	1.16e-34	Facial morphology (factor 22);
LGG	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg18850127	chr7:39170497	POU6F2	0.56	13.66	0.54	6.29e-36	IgG glycosylation;
LGG	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.1	-0.43	7.98e-22	Menarche (age at onset);
LGG	cis	rs4820539	0.902	rs9612237	chr22:23472954	T/C	cg14186256	chr22:23484241	RTDR1	1.0	25.14	0.76	1.46e-88	Bone mineral density;
LGG	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-8.79	-0.38	2.91e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9397585	0.637	rs9479499	chr6:153400279	T/A	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.616	rs41278579	chr4:185622402	A/G	cg04058563	chr4:185651563	MLF1IP	1.06	22.06	0.72	3.13e-74	Blood protein levels;
LGG	cis	rs4481887	1.000	rs4244182	chr1:248471174	A/G	cg13385794	chr1:248469461	NA	0.48	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs12135191	0.869	rs7540507	chr1:236474796	C/T	cg21399712	chr1:236511386	NA	-0.42	-7.97	-0.35	1.22e-14	Urate levels (BMI interaction);
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg23782820	chr8:58130467	NA	0.43	6.67	0.3	7.36e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg21153622	chr11:89784906	NA	-0.39	-6.71	-0.3	5.75e-11	HDL cholesterol;
LGG	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg12463550	chr7:65579703	CRCP	0.47	7.75	0.34	5.74e-14	Aortic root size;
LGG	cis	rs9810089	0.903	rs711975	chr3:136235908	T/C	cg21827317	chr3:136751795	NA	0.48	8.58	0.37	1.43e-16	Gestational age at birth (child effect);
LGG	cis	rs7681440	0.669	rs7693616	chr4:90792230	G/T	cg26578617	chr4:90757533	SNCA	0.36	6.94	0.31	1.34e-11	Dementia with Lewy bodies;
LGG	trans	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg26043149	chr18:55253948	FECH	-0.41	-6.76	-0.3	4.29e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg00933542	chr6:150070202	PCMT1	0.37	6.86	0.3	2.26e-11	Lung cancer;
LGG	cis	rs2742417	0.967	rs9311378	chr3:45763135	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2.07e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs227833	0.586	rs633313	chr6:44644407	T/A	cg18551225	chr6:44695536	NA	0.42	6.96	0.31	1.2e-11	Monobrow;
LGG	cis	rs2404602	0.735	rs11638767	chr15:76655938	T/C	cg15268244	chr15:77196840	NA	0.43	9.41	0.4	2.25e-19	Blood metabolite levels;
LGG	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.96e-14	Common traits (Other);
LGG	cis	rs9487051	0.738	rs449850	chr6:109525045	A/G	cg21918786	chr6:109611834	NA	-0.39	-7.11	-0.31	4.49e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.8	-18.23	-0.65	2.3e-56	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg19812747	chr11:111475976	SIK2	0.46	9.37	0.4	3.16e-19	Primary sclerosing cholangitis;
LGG	cis	rs3087591	0.922	rs2905801	chr17:29524974	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs12200560	0.505	rs211163	chr6:97067654	A/G	cg06623918	chr6:96969491	KIAA0776	0.46	7.75	0.34	5.93e-14	Coronary heart disease;
LGG	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.68	7.27	0.32	1.55e-12	Facial emotion recognition (sad faces);
LGG	cis	rs17826219	0.500	rs28452421	chr17:29083980	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.91	-0.42	4.12e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17125944	0.686	rs78623109	chr14:53383077	G/T	cg00686598	chr14:53173677	PSMC6	0.81	8.17	0.35	2.98e-15	Alzheimer's disease (late onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13505469	chr10:81839053	LOC219347;C10orf57	0.46	7.47	0.33	4.03e-13	Cognitive performance;
LGG	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg24623649	chr8:11872141	NA	-0.28	-6.78	-0.3	3.74e-11	Neuroticism;
LGG	trans	rs71327718	1	rs71327718	chr3:125592857	C/G	cg07211511	chr3:129823064	LOC729375	-1.32	-15.93	-0.6	6.95e-46	Metabolite levels (HVA/5-HIAA ratio);
LGG	cis	rs858239	0.601	rs3735228	chr7:23170427	T/G	cg23682824	chr7:23144976	KLHL7	0.43	7.16	0.32	3.17e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs757978	0.733	rs11684403	chr2:242414874	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.63	-7.14	-0.32	3.53e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2235573	0.527	rs5756853	chr22:38329524	G/A	cg19171272	chr22:38449367	NA	0.51	9.23	0.39	9.41e-19	Glioblastoma;Glioma;
LGG	cis	rs31872	0.678	rs702390	chr5:140442209	G/A	cg19884223	chr5:140554610	PCDHB7	-0.3	-6.68	-0.3	6.91e-11	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg08392591	chr16:89556376	ANKRD11	0.55	8.71	0.38	5.39e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs4742903	0.765	rs4743700	chr9:107005468	C/T	cg14250997	chr9:106856677	SMC2	0.37	7.64	0.33	1.27e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4478858	0.684	rs7528066	chr1:31749092	C/G	cg19084893	chr1:31688959	NA	0.31	6.69	0.3	6.65e-11	Alcohol dependence;
LGG	cis	rs17401966	1.000	rs11578788	chr1:10422958	A/G	cg15208524	chr1:10270712	KIF1B	0.46	7.69	0.34	8.63e-14	Hepatocellular carcinoma;
LGG	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg06951627	chr6:26196580	NA	0.46	6.87	0.3	2.07e-11	Gout;Renal underexcretion gout;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg16507663	chr6:150244633	RAET1G	0.51	10.49	0.44	3.17e-23	Testicular germ cell tumor;
LGG	cis	rs17689437	0.671	rs1728790	chr16:68596308	C/T	cg02972257	chr16:68554789	NA	0.42	6.96	0.31	1.18e-11	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.78	-15.57	-0.59	2.8e-44	Obesity-related traits;
LGG	cis	rs12915845	0.545	rs1583794	chr15:89076644	C/T	cg05013243	chr15:89149849	MIR1179	0.34	7.03	0.31	7.53e-12	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.0	0.35	1.01e-14	Lung cancer;
LGG	cis	rs12410462	0.515	rs1845760	chr1:227714702	A/C	cg04117972	chr1:227635322	NA	-0.41	-7.59	-0.33	1.74e-13	Major depressive disorder;
LGG	cis	rs9300255	0.739	rs1980252	chr12:123745178	C/G	cg05973401	chr12:123451056	ABCB9	0.51	7.65	0.34	1.16e-13	Neutrophil percentage of white cells;
LGG	cis	rs9487051	0.768	rs1269172	chr6:109522080	G/C	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg12486710	chr1:178512616	C1orf220	-0.5	-10.43	-0.44	4.95e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9914988	0.943	rs12951232	chr17:27132638	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg13565492	chr6:43139072	SRF	-0.71	-8.83	-0.38	2.15e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7939886	0.920	rs61742348	chr11:55905078	C/T	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg23758822	chr17:41437982	NA	0.86	15.43	0.58	1.24e-43	Menopause (age at onset);
LGG	cis	rs7503807	0.688	rs7503203	chr17:78590528	G/A	cg06872548	chr17:78716983	RPTOR	0.4	8.76	0.38	3.63e-17	Obesity;
LGG	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	6.06e-14	Testicular germ cell tumor;
LGG	cis	rs74781061	0.929	rs60777494	chr15:74785348	A/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.04	-0.31	7.08e-12	Endometriosis;
LGG	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-10.08	-0.42	9.56e-22	Common traits (Other);
LGG	cis	rs7789940	1.000	rs73140069	chr7:75986790	T/A	cg10167463	chr7:75959203	YWHAG	-0.46	-7.74	-0.34	6.14e-14	Multiple sclerosis;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.79	0.45	2.31e-24	Personality dimensions;
LGG	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-10.82	-0.45	1.8e-24	Personality dimensions;
LGG	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg24642844	chr7:1081250	C7orf50	-0.67	-11.17	-0.46	8.11e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg03160526	chr17:80928410	B3GNTL1	0.5	7.93	0.35	1.64e-14	Glycated hemoglobin levels;
LGG	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg02187348	chr16:89574699	SPG7	0.45	7.32	0.32	1.1e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg03433033	chr1:76189801	ACADM	0.77	12.83	0.51	1.83e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	trans	rs877282	0.947	rs7904978	chr10:768078	C/T	cg22713356	chr15:30763199	NA	0.54	8.19	0.36	2.54e-15	Uric acid levels;
LGG	cis	rs13082711	0.911	rs7637211	chr3:27419868	C/T	cg02860705	chr3:27208620	NA	0.79	14.49	0.56	1.6e-39	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs72781680	1.000	rs72781665	chr2:24223086	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.03	0.39	4.81e-18	Lymphocyte counts;
LGG	cis	rs4684776	0.676	rs3732941	chr3:11304575	A/G	cg24705426	chr3:11550659	ATG7	-0.4	-7.11	-0.31	4.48e-12	Small vessel stroke;
LGG	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17554472	chr22:41940697	POLR3H	-0.44	-6.74	-0.3	4.8e-11	Vitiligo;
LGG	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.27e-17	Retinal vascular caliber;
LGG	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg19920283	chr7:105172520	RINT1	0.61	8.42	0.36	4.63e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg24848339	chr3:12840334	CAND2	0.42	9.69	0.41	2.53e-20	QRS complex (12-leadsum);
LGG	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7617773	0.780	rs7632297	chr3:48348163	A/C	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.47	-0.5	5.73e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.23	-0.39	9.66e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19894588	chr14:64061835	NA	-0.56	-8.8	-0.38	2.81e-17	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg19539972	chr4:7069911	GRPEL1	0.68	10.12	0.43	7.01e-22	Monocyte percentage of white cells;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg04080417	chr5:1859792	NA	-0.51	-8.27	-0.36	1.42e-15	Cardiovascular disease risk factors;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.76	0.3	4.15e-11	Schizophrenia;
LGG	trans	rs1814175	0.781	rs11040681	chr11:49981654	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs1949733	1.000	rs1357481	chr4:8496221	A/T	cg11789530	chr4:8429930	ACOX3	0.87	17.34	0.63	2.99e-52	Response to antineoplastic agents;
LGG	cis	rs2133450	0.933	rs9849119	chr3:7320216	T/C	cg19930620	chr3:7340148	GRM7	-0.37	-8.06	-0.35	6.52e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg05555928	chr11:63887634	MACROD1	-0.63	-9.14	-0.39	1.99e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	8.85	0.38	1.9e-17	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11779988	0.598	rs6980962	chr8:17909992	G/A	cg18067069	chr8:17937731	ASAH1	-0.32	-7.73	-0.34	6.54e-14	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05485520	chr3:45883628	LZTFL1	0.52	8.54	0.37	1.94e-16	Gut microbiome composition (summer);
LGG	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.02	0.57	8.07e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.4	-0.44	6.45e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.27	-0.32	1.56e-12	Obesity;
LGG	cis	rs2235573	0.789	rs4821733	chr22:38449394	A/G	cg19171272	chr22:38449367	NA	0.66	13.94	0.54	3.98e-37	Glioblastoma;Glioma;
LGG	cis	rs870825	0.929	rs72689261	chr4:185590897	C/A	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	cis	rs9814567	0.712	rs9838467	chr3:134332222	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.71	0.61	2.18e-49	Hip circumference adjusted for BMI;
LGG	cis	rs11673344	0.642	rs12462708	chr19:37797578	A/G	cg05280698	chr19:37825388	HKR1	-0.36	-6.9	-0.31	1.68e-11	Obesity-related traits;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18252515	chr7:66147081	NA	0.41	6.94	0.31	1.32e-11	Aortic root size;
LGG	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.52	0.37	2.31e-16	Mood instability;
LGG	trans	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg11441553	chr12:57614120	NXPH4	-0.58	-7.16	-0.32	3.16e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg03806693	chr22:41940476	POLR3H	-0.89	-14.82	-0.57	6.04e-41	Vitiligo;
LGG	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg02002194	chr4:3960332	NA	-0.44	-8.06	-0.35	6.72e-15	Retinal vascular caliber;
LGG	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg13256891	chr4:100009986	ADH5	-0.53	-8.86	-0.38	1.76e-17	Smoking initiation;
LGG	cis	rs2303319	1.000	rs62197078	chr2:162182954	G/A	cg13806767	chr2:162164127	PSMD14	-0.66	-7.7	-0.34	8.26e-14	Cognitive function;
LGG	trans	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-12.5	-0.5	4.36e-31	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg11608241	chr8:8085544	FLJ10661	-0.34	-7.72	-0.34	7e-14	Triglycerides;
LGG	cis	rs6604026	0.883	rs10874745	chr1:93321541	G/A	cg22128645	chr1:93425802	FAM69A	-0.39	-7.4	-0.33	6.43e-13	Multiple sclerosis;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg02018176	chr4:1364513	KIAA1530	0.33	6.99	0.31	9.78e-12	Obesity-related traits;
LGG	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-8.31	-0.36	1.04e-15	Height;
LGG	cis	rs7584262	0.695	rs12712824	chr2:42244325	T/C	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Bone mineral density;
LGG	cis	rs2013441	1.000	rs2189710	chr17:20078964	C/A	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.39	6.88	0.3	2.01e-11	Multiple sclerosis;
LGG	cis	rs4732038	0.510	rs57460017	chr7:134279055	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.29	-0.63	4.85e-52	Longevity;
LGG	cis	rs9914988	0.943	rs9898892	chr17:27150750	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs4262150	0.672	rs72806714	chr5:152342727	G/C	cg12297329	chr5:152029980	NA	-0.57	-9.21	-0.39	1.1e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg10935494	chr17:80760059	TBCD	0.38	7.21	0.32	2.23e-12	Glycated hemoglobin levels;
LGG	cis	rs4660214	0.614	rs10888715	chr1:39699244	C/T	cg18385671	chr1:39797026	MACF1	-0.44	-9.32	-0.4	4.87e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9527	1.000	rs12416687	chr10:104629011	T/C	cg04362960	chr10:104952993	NT5C2	0.58	9.7	0.41	2.21e-20	Arsenic metabolism;
LGG	cis	rs11971779	0.680	rs3924445	chr7:139044172	C/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs7255045	0.788	rs2290689	chr19:12958360	T/C	cg07955356	chr19:12992479	DNASE2	0.43	7.25	0.32	1.74e-12	Mean corpuscular volume;
LGG	cis	rs1318772	0.932	rs13180262	chr5:112881145	A/G	cg12552261	chr5:112820674	MCC	0.65	7.47	0.33	3.92e-13	F-cell distribution;
LGG	cis	rs2120243	0.874	rs9868133	chr3:157151461	G/C	cg24825693	chr3:157122686	VEPH1	-0.34	-7.28	-0.32	1.4e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.77	-0.41	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4731207	0.591	rs28634794	chr7:124614430	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6993813	0.786	rs6469797	chr8:120018159	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.28	7.12	0.31	4.09e-12	Bone mineral density (hip);
LGG	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg18240062	chr17:79603768	NPLOC4	0.75	13.83	0.54	1.22e-36	Eye color traits;
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg08888203	chr3:10149979	C3orf24	0.52	8.87	0.38	1.63e-17	Alzheimer's disease;
LGG	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg05082376	chr22:42548792	NA	0.37	7.84	0.34	3.16e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.23	-0.43	2.89e-22	Bladder cancer;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.28	-0.4	6.43e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg26043149	chr18:55253948	FECH	0.4	6.65	0.3	8.09e-11	Bone mineral density;
LGG	cis	rs11586313	0.507	rs3856026	chr1:152869763	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-7.62	-0.33	1.4e-13	Vitamin D levels;
LGG	cis	rs4660214	0.666	rs663892	chr1:39889677	G/A	cg18385671	chr1:39797026	MACF1	0.47	9.69	0.41	2.5e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs16912285	0.688	rs12801480	chr11:24270146	G/A	ch.11.24196551F	chr11:24239977	NA	0.9	13.16	0.52	8.01e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.88	0.45	1.06e-24	Parkinson's disease;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg16103275	chr6:290800	DUSP22	0.4	6.75	0.3	4.57e-11	Menopause (age at onset);
LGG	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg03030879	chr14:75389066	RPS6KL1	0.37	6.68	0.3	6.81e-11	Caffeine consumption;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs2455799	0.613	rs13080145	chr3:15880060	C/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.86	-0.34	2.77e-14	Mean platelet volume;
LGG	cis	rs9463078	0.605	rs3799984	chr6:44893640	C/G	cg25276700	chr6:44698697	NA	0.33	6.94	0.31	1.34e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7250872	0.568	rs8101970	chr19:1835625	C/T	cg18850929	chr19:1828978	REXO1	0.49	7.98	0.35	1.14e-14	Bipolar disorder;
LGG	cis	rs9810089	0.802	rs833861	chr3:136231067	T/A	cg12473912	chr3:136751656	NA	0.39	6.66	0.3	7.61e-11	Gestational age at birth (child effect);
LGG	cis	rs10089	0.953	rs17164427	chr5:127361736	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.72	-11.07	-0.46	1.93e-25	Ileal carcinoids;
LGG	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/A	cg27121462	chr16:89883253	FANCA	0.47	7.25	0.32	1.73e-12	Vitiligo;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.68	0.37	6.69e-17	Schizophrenia;
LGG	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg18196295	chr10:418757	DIP2C	0.62	12.56	0.5	2.33e-31	Psychosis in Alzheimer's disease;
LGG	cis	rs921968	0.643	rs832802	chr2:219386899	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.09e-17	Lung cancer;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg14668632	chr7:2872130	GNA12	0.32	6.89	0.3	1.87e-11	Height;
LGG	cis	rs11877825	0.737	rs6505572	chr18:10579366	T/C	cg25239095	chr18:10589360	NA	0.47	8.49	0.37	2.76e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17408647	chr7:43769049	C7orf44	0.41	6.71	0.3	5.74e-11	Cognitive performance;
LGG	cis	rs12410462	0.591	rs16847966	chr1:227771014	A/G	cg23173402	chr1:227635558	NA	0.39	7.4	0.33	6.37e-13	Major depressive disorder;
LGG	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.48	0.4	1.38e-19	Gout;Renal underexcretion gout;
LGG	trans	rs61931739	0.500	rs7965679	chr12:34542494	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs929354	1.000	rs1182384	chr7:157040642	A/G	cg00092383	chr7:157075207	NA	0.42	7.38	0.32	7.17e-13	Body mass index;
LGG	cis	rs1109114	1.000	rs13171669	chr5:148601243	A/G	cg06539116	chr5:148597365	ABLIM3	-0.56	-13.47	-0.53	3.94e-35	Body mass index;
LGG	cis	rs7267979	1.000	rs2257808	chr20:25266450	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.28	0.43	1.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6568686	0.592	rs12202987	chr6:111446458	A/C	cg15721981	chr6:111408429	SLC16A10	0.58	7.12	0.31	4.18e-12	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs7173743	0.756	rs6495339	chr15:79128272	T/C	cg00540400	chr15:79124168	NA	0.42	8.62	0.37	1.03e-16	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg06558623	chr16:89946397	TCF25	1.11	12.15	0.49	1.08e-29	Skin colour saturation;
LGG	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg04568710	chr12:38710424	ALG10B	0.32	6.78	0.3	3.67e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg27476859	chr7:2772710	GNA12	-0.39	-6.76	-0.3	4.06e-11	Height;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg23034840	chr1:205782522	SLC41A1	0.58	9.57	0.41	6.23e-20	Menarche (age at onset);
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.57	-9.81	-0.41	9.22e-21	Obesity-related traits;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.31	0.58	4.2e-43	Lung cancer;
LGG	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs1816752	0.870	rs7981337	chr13:25015053	A/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs9359856	0.564	rs72913976	chr6:90390233	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.57	-0.41	6.58e-20	Bipolar disorder;
LGG	cis	rs35160687	0.901	rs12620833	chr2:86472870	T/C	cg10973622	chr2:86423274	IMMT	0.42	7.25	0.32	1.8e-12	Night sleep phenotypes;
LGG	cis	rs593982	0.688	rs3897552	chr11:65560880	C/T	cg08755490	chr11:65554678	OVOL1	-0.71	-9.62	-0.41	4.3e-20	Atopic dermatitis;
LGG	cis	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05901451	chr6:126070800	HEY2	0.59	10.61	0.44	1.11e-23	Endometrial cancer;
LGG	trans	rs853679	0.824	rs1321505	chr6:28052823	A/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.55e-20	Depression;
LGG	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.71	0.45	4.78e-24	Morning vs. evening chronotype;
LGG	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.46	7.58	0.33	1.91e-13	Height;
LGG	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg03433033	chr1:76189801	ACADM	0.71	12.5	0.5	4.26e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7923837	1.000	rs7923866	chr10:94482076	C/T	cg25093409	chr10:94429542	NA	0.39	7.28	0.32	1.47e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs12912251	0.591	rs3104150	chr15:39003585	T/C	cg10631289	chr15:39006617	NA	-0.41	-6.82	-0.3	2.79e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg16876255	chr19:9731953	ZNF561	0.81	7.57	0.33	2.08e-13	Pursuit maintenance gain;
LGG	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg26116260	chr4:7069785	GRPEL1	-0.87	-8.9	-0.38	1.24e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg06565975	chr8:143823917	SLURP1	-0.29	-6.95	-0.31	1.27e-11	Urinary tract infection frequency;
LGG	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg03175030	chr11:2018143	H19;MIR675	-0.53	-9.68	-0.41	2.56e-20	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs4704846	1.000	rs422450	chr5:156546464	C/T	cg12943317	chr5:156479607	HAVCR1	-0.57	-7.26	-0.32	1.66e-12	Blood protein levels;
LGG	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg23601095	chr6:26197514	HIST1H3D	0.7	8.86	0.38	1.7e-17	Gout;Renal underexcretion gout;
LGG	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.37	-0.4	3.08e-19	Educational attainment;
LGG	cis	rs6835098	0.961	rs1574314	chr4:174106663	C/T	cg08422745	chr4:174089978	GALNT7	-0.85	-15.05	-0.57	6.13e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs2354432	1.000	rs7514864	chr1:146690102	T/C	cg25205988	chr1:146714368	CHD1L	1.32	16.67	0.61	3.33e-49	Mitochondrial DNA levels;
LGG	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs4409675	0.576	rs12062621	chr1:28230404	A/G	cg23691781	chr1:28212827	C1orf38	0.4	10.59	0.44	1.27e-23	Corneal astigmatism;
LGG	cis	rs61884328	0.703	rs60201196	chr11:47110592	C/T	cg03339077	chr11:47165057	C11orf49	0.63	6.85	0.3	2.32e-11	Total body bone mineral density (age over 60);
LGG	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.87	-10.58	-0.44	1.43e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg26597838	chr10:835615	NA	0.54	7.07	0.31	5.62e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7241530	0.662	rs1566903	chr18:75901684	T/C	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg18135555	chr8:22132992	PIWIL2	0.39	10.31	0.43	1.39e-22	Hypertriglyceridemia;
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03517284	chr6:25882590	NA	0.51	9.69	0.41	2.51e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg17509989	chr5:176798049	RGS14	0.86	14.6	0.56	5.43e-40	Hemoglobin concentration;Hematocrit;
LGG	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.69	0.34	9.11e-14	Neuroticism;
LGG	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.36	-0.32	8.58e-13	Alzheimer's disease (late onset);
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.37e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11122272	0.735	rs2247132	chr1:231493359	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.17	-0.32	3.06e-12	Hemoglobin concentration;
LGG	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs9354308	0.901	rs12197136	chr6:66590953	T/C	cg07460842	chr6:66804631	NA	0.58	9.65	0.41	3.35e-20	Metabolite levels;
LGG	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg09029085	chr17:47094198	IGF2BP1	0.31	8.26	0.36	1.57e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6918586	0.658	rs198854	chr6:26104057	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.62	-0.41	4.37e-20	Schizophrenia;
LGG	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.58	-9.62	-0.41	4.44e-20	Cognitive ability;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06112835	chr11:68658793	MRPL21	0.6	10.09	0.42	9.22e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-7.95	-0.35	1.4e-14	Subjective well-being;
LGG	cis	rs4642101	0.535	rs55692304	chr3:12840057	C/T	cg05775895	chr3:12838266	CAND2	0.77	15.27	0.58	6.37e-43	QRS complex (12-leadsum);
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg05793240	chr7:2802953	GNA12	0.31	7.66	0.34	1.06e-13	Height;
LGG	cis	rs4704187	0.532	rs75392670	chr5:74394968	A/G	cg03227963	chr5:74354835	NA	0.31	6.69	0.3	6.61e-11	Response to amphetamines;
LGG	cis	rs2236267	0.693	rs6574993	chr14:88606993	G/A	cg02175263	chr14:88627849	NA	0.33	7.42	0.33	5.63e-13	Food antigen IgG levels;
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.59	9.05	0.39	3.94e-18	Renal function-related traits (BUN);
LGG	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg13647721	chr17:30228624	UTP6	0.78	11.18	0.46	7.31e-26	Hip circumference adjusted for BMI;
LGG	cis	rs7503807	0.515	rs12601001	chr17:78681084	T/C	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg07061783	chr6:25882402	NA	0.45	7.8	0.34	4.02e-14	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.608	rs678814	chr2:219359287	T/C	cg02985541	chr2:219472218	PLCD4	0.29	6.86	0.3	2.15e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg14227996	chr4:17616232	MED28	0.72	8.71	0.38	5.44e-17	Opioid sensitivity;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-19.87	-0.68	5.31e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7666738	0.830	rs4699588	chr4:98973789	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2976388	0.609	rs2572904	chr8:143792193	A/C	cg06565975	chr8:143823917	SLURP1	0.35	9.03	0.39	4.78e-18	Urinary tract infection frequency;
LGG	cis	rs36051895	0.658	rs10975029	chr9:5251068	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-12.66	-0.51	9.09e-32	Pediatric autoimmune diseases;
LGG	cis	rs36093844	0.898	rs11234446	chr11:85566169	A/G	cg16165120	chr11:85566439	CCDC83	-0.38	-6.76	-0.3	4.13e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7827545	0.644	rs4909452	chr8:135521053	C/G	cg17885191	chr8:135476712	NA	-0.51	-8.45	-0.37	3.68e-16	Hypertension (SNP x SNP interaction);
LGG	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg03264133	chr6:25882463	NA	-0.38	-6.71	-0.3	5.75e-11	Height;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-15.94	-0.6	6.71e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg17646820	chr3:66848679	NA	0.5	7.62	0.33	1.41e-13	Type 2 diabetes;
LGG	trans	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg24423897	chr19:4723980	DPP9	0.39	6.8	0.3	3.34e-11	Dupuytren's disease;
LGG	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.73	-0.3	5.09e-11	Alzheimer's disease (survival time);
LGG	cis	rs10499694	0.868	rs1470749	chr7:50578023	G/T	cg00647317	chr7:50633725	DDC	0.32	7.54	0.33	2.5e-13	Body mass index;
LGG	cis	rs990171	0.837	rs1568681	chr2:103014696	C/T	cg05295703	chr2:102895712	NA	-0.56	-10.04	-0.42	1.32e-21	Lymphocyte counts;
LGG	cis	rs2171564	0.967	rs9863500	chr3:112440948	C/T	cg06685282	chr3:112453648	NA	0.41	7.69	0.34	8.88e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-11.03	-0.46	2.7e-25	Neuroticism;
LGG	trans	rs1941687	0.563	rs9947894	chr18:31328720	G/T	cg04226714	chr8:49833948	SNAI2	0.47	8.65	0.37	8.38e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg11366901	chr6:160182831	ACAT2	-0.85	-13.75	-0.54	2.48e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	7.28	0.32	1.45e-12	Obesity-related traits;
LGG	cis	rs367943	0.514	rs2081925	chr5:113004028	A/T	cg12552261	chr5:112820674	MCC	0.47	7.93	0.35	1.64e-14	Type 2 diabetes;
LGG	cis	rs7188861	0.723	rs12599908	chr16:11395915	G/A	cg01510278	chr16:11456238	NA	0.31	7.37	0.32	7.69e-13	HDL cholesterol;
LGG	cis	rs2964802	0.505	rs13179252	chr5:10805662	A/G	cg14521931	chr5:10832172	NA	-0.76	-17.06	-0.62	5.46e-51	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg13073564	chr4:8508604	NA	-0.52	-10.63	-0.44	9.47e-24	Response to antineoplastic agents;
LGG	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg25382214	chr1:3105252	PRDM16	-0.41	-7.62	-0.33	1.44e-13	Migraine;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg23034840	chr1:205782522	SLC41A1	0.53	8.66	0.37	7.9e-17	Menarche (age at onset);
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg05793240	chr7:2802953	GNA12	0.37	8.58	0.37	1.47e-16	Height;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg21782813	chr7:2030301	MAD1L1	0.56	14.56	0.56	8.56e-40	Bipolar disorder and schizophrenia;
LGG	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg01620082	chr3:125678407	NA	-1.05	-9.5	-0.4	1.17e-19	Breast cancer;
LGG	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.69e-16	Aortic root size;
LGG	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg00745463	chr17:30367425	LRRC37B	0.45	7.12	0.31	4.12e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg05925327	chr15:68127851	NA	-0.38	-7.75	-0.34	5.99e-14	Restless legs syndrome;
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.58	-0.33	1.87e-13	Prostate cancer;
LGG	cis	rs612683	0.664	rs6702766	chr1:100997635	A/G	cg06223162	chr1:101003688	GPR88	-0.5	-12.64	-0.51	1.16e-31	Breast cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21605986	chr5:175788725	KIAA1191	0.37	6.65	0.3	8.33e-11	Obesity-related traits;
LGG	cis	rs9916302	0.680	rs2271308	chr17:37817482	T/C	cg07936489	chr17:37558343	FBXL20	-0.58	-9.78	-0.41	1.16e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg23815491	chr16:72088622	HP	0.51	11.56	0.47	2.46e-27	Fibrinogen levels;
LGG	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg06618935	chr21:46677482	NA	-0.35	-6.86	-0.3	2.23e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1318772	1.000	rs11748646	chr5:112662479	A/G	cg12552261	chr5:112820674	MCC	0.69	7.99	0.35	1.05e-14	F-cell distribution;
LGG	cis	rs7766436	0.540	rs6922087	chr6:22608798	G/A	cg13666174	chr6:22585274	NA	-0.32	-7.67	-0.34	1.02e-13	Coronary artery disease;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.49	0.4	1.27e-19	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Vitiligo;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08677398	chr8:58056175	NA	0.59	9.11	0.39	2.44e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.32	0.36	9.61e-16	Aortic root size;
LGG	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg21545522	chr1:205238299	TMCC2	0.38	7.24	0.32	1.87e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg20913747	chr6:44695427	NA	-0.59	-9.88	-0.42	5.27e-21	Total body bone mineral density;
LGG	cis	rs67366981	0.841	rs55903932	chr14:77706389	T/C	cg22824376	chr14:77648248	TMEM63C	0.73	7.58	0.33	1.93e-13	Obsessive-compulsive symptoms;
LGG	cis	rs7241530	0.595	rs35856696	chr18:75898218	G/A	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	cis	rs75059851	0.756	rs55747998	chr11:133840793	C/T	cg20042908	chr11:133852938	NA	-0.76	-14.24	-0.55	2.09e-38	Schizophrenia;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.81e-17	Lung cancer;
LGG	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.19	-0.55	3.29e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.99	0.35	1.11e-14	Mean platelet volume;
LGG	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs6669919	0.553	rs11587632	chr1:211668437	T/C	cg10512769	chr1:211675356	NA	-0.93	-23.57	-0.74	2.75e-81	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-6.66	-0.3	7.8e-11	Lung cancer;
LGG	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg22676075	chr6:135203613	NA	0.39	6.81	0.3	3.09e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg12070911	chr6:150209640	RAET1E	0.32	7.82	0.34	3.55e-14	Lung cancer;
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg04025307	chr7:1156635	C7orf50	-0.62	-11.55	-0.47	2.82e-27	Longevity;Endometriosis;
LGG	cis	rs7586879	0.639	rs7567997	chr2:25096952	A/G	cg04586622	chr2:25135609	ADCY3	0.41	11.18	0.46	7.58e-26	Body mass index;
LGG	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg20336341	chr7:50628841	DDC	0.37	7.03	0.31	7.44e-12	Malaria;
LGG	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg08344181	chr3:125677491	NA	-0.83	-8.09	-0.35	5.23e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg10207240	chr12:122356781	WDR66	0.27	8.43	0.36	4.5e-16	Mean corpuscular volume;
LGG	cis	rs11098499	0.564	rs11098507	chr4:120288286	G/A	cg24375607	chr4:120327624	NA	0.59	9.83	0.42	7.7e-21	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.48e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg01528321	chr10:82214614	TSPAN14	0.66	11.84	0.48	1.97e-28	Post bronchodilator FEV1;
LGG	cis	rs3849570	0.732	rs11715625	chr3:81875938	A/T	cg07356753	chr3:81810745	GBE1	-0.47	-7.64	-0.33	1.25e-13	Waist circumference;Body mass index;
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs2898279	1.000	rs2898279	chr8:11295251	C/G	cg26274995	chr8:11302983	FAM167A	0.47	8.91	0.38	1.15e-17	Small cell lung carcinoma;
LGG	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs7143963	0.666	rs7154352	chr14:103323947	T/C	cg23020514	chr14:103360112	TRAF3	0.4	8.47	0.37	3.26e-16	Body mass index;
LGG	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.2	0.65	3.04e-56	Refractive error;
LGG	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.62	13.85	0.54	9.49e-37	Multiple sclerosis;
LGG	cis	rs1783925	1.000	rs610236	chr11:125297925	T/A	cg03464685	chr11:125439445	EI24	-0.6	-9.64	-0.41	3.71e-20	Formal thought disorder in schizophrenia;
LGG	cis	rs74781061	0.789	rs12440654	chr15:74745349	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg12486710	chr1:178512616	C1orf220	0.42	8.53	0.37	2.16e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg12288994	chr5:1860383	NA	0.73	13.93	0.54	4.47e-37	Cardiovascular disease risk factors;
LGG	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg12463550	chr7:65579703	CRCP	0.52	8.65	0.37	8.38e-17	Aortic root size;
LGG	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08045932	chr20:61659980	NA	0.59	12.72	0.51	5.4e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg07677032	chr17:61819896	STRADA	0.66	12.33	0.5	2.12e-30	Prudent dietary pattern;
LGG	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	8.05	0.35	7.05e-15	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09771049	chr17:66031798	KPNA2	0.5	8.11	0.35	4.58e-15	Cognitive performance;
LGG	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg02753203	chr1:228287806	NA	0.92	18.72	0.66	1.3e-58	Diastolic blood pressure;
LGG	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.56e-12	Retinal vascular caliber;
LGG	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.95	0.38	8.81e-18	Colorectal cancer;
LGG	cis	rs35771425	0.529	rs66526219	chr1:211415948	C/T	cg10512769	chr1:211675356	NA	-0.67	-8.64	-0.37	9.02e-17	Educational attainment (years of education);
LGG	cis	rs16912285	0.688	rs7124856	chr11:24324926	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	13.47	0.53	4.15e-35	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9910055	0.762	rs2631299	chr17:42219773	G/T	cg19774624	chr17:42201019	HDAC5	-0.81	-15.81	-0.59	2.56e-45	Total body bone mineral density;
LGG	cis	rs12731740	1.000	rs36092684	chr1:208010992	T/C	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.41	-0.33	6.1e-13	Biomedical quantitative traits;
LGG	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg24101359	chr6:42928495	GNMT	0.52	14.73	0.56	1.47e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg06212747	chr3:49208901	KLHDC8B	0.71	12.44	0.5	7.76e-31	Menarche (age at onset);
LGG	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27286337	chr10:134555280	INPP5A	0.86	14.24	0.55	1.95e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01293313	chr2:122406171	CLASP1	0.44	7.05	0.31	6.65e-12	Cognitive performance;
LGG	cis	rs10267417	0.603	rs4543442	chr7:19911140	G/A	cg05791153	chr7:19748676	TWISTNB	0.61	8.01	0.35	9.1e-15	Night sleep phenotypes;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08677398	chr8:58056175	NA	0.46	7.69	0.34	9.11e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2273669	0.667	rs4509156	chr6:109308952	A/C	cg05315195	chr6:109294784	ARMC2	0.64	8.5	0.37	2.6e-16	Prostate cancer;
LGG	cis	rs4936894	0.500	rs11219567	chr11:124166375	T/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.81	-0.45	1.86e-24	Aging (time to death);
LGG	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg17691542	chr6:26056736	HIST1H1C	0.74	11.92	0.48	9.02e-29	Height;
LGG	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg06623918	chr6:96969491	KIAA0776	0.77	15.02	0.57	8.24e-42	Headache;
LGG	cis	rs981844	0.712	rs4302444	chr4:154745663	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.82e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg15596359	chr8:11213517	TDH	-0.41	-8.37	-0.36	7.11e-16	Retinal vascular caliber;
LGG	cis	rs7572733	0.515	rs1836234	chr2:198882873	T/G	cg00792783	chr2:198669748	PLCL1	0.64	10.35	0.43	9.95e-23	Dermatomyositis;
LGG	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg09855544	chr8:135498122	ZFAT	-0.45	-7.65	-0.33	1.21e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs6867032	1.000	rs61177713	chr5:2017255	G/A	cg26168224	chr5:2018326	NA	1.29	31.13	0.82	1.41e-115	Gut microbiome composition (winter);
LGG	cis	rs4308124	0.708	rs10179596	chr2:111970380	G/A	cg04571233	chr2:111982156	NA	-0.6	-9.85	-0.42	6.38e-21	Vitiligo;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg02725872	chr8:58115012	NA	-0.78	-10.55	-0.44	1.9e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg02975922	chr3:195473998	MUC4	-0.45	-7.19	-0.32	2.68e-12	Mean corpuscular volume;
LGG	cis	rs9902453	0.967	rs12450441	chr17:28495021	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.53	0.53	2.32e-35	Coffee consumption (cups per day);
LGG	cis	rs9814567	0.964	rs9815894	chr3:134282796	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.85	-0.45	1.36e-24	Neuroticism;
LGG	cis	rs2535633	0.631	rs2710326	chr3:52995444	T/C	cg11645453	chr3:52864694	ITIH4	-0.48	-8.0	-0.35	1.01e-14	Body mass index;
LGG	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-21.21	-0.7	2.86e-70	Hemostatic factors and hematological phenotypes;
LGG	cis	rs74781061	0.929	rs2415242	chr15:74839106	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.42e-12	Endometriosis;
LGG	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg18446336	chr7:2847575	GNA12	-0.32	-8.57	-0.37	1.58e-16	Height;
LGG	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.03e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6735179	0.565	rs736870	chr2:1748702	T/C	cg10160682	chr2:1713001	PXDN	-0.55	-9.49	-0.4	1.22e-19	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg16482183	chr6:26056742	HIST1H1C	-0.54	-8.72	-0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.59	-0.37	1.38e-16	Post bronchodilator FEV1;
LGG	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg18898632	chr2:242989856	NA	-0.76	-9.18	-0.39	1.44e-18	Obesity-related traits;
LGG	cis	rs3096299	0.566	rs4129126	chr16:89561475	A/C	cg06640241	chr16:89574553	SPG7	0.71	11.27	0.46	3.25e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.74	0.34	6.13e-14	Testicular germ cell tumor;
LGG	cis	rs975722	0.967	rs6970681	chr7:117346660	C/G	cg10524701	chr7:117356490	CTTNBP2	0.51	11.63	0.48	1.27e-27	Coronary artery disease;
LGG	cis	rs9916302	0.851	rs9904919	chr17:37556431	G/C	cg00129232	chr17:37814104	STARD3	0.61	11.32	0.47	2.09e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs4780401	0.527	rs4780402	chr16:11839809	C/T	cg01061890	chr16:11836724	TXNDC11	-0.61	-10.77	-0.45	2.66e-24	Rheumatoid arthritis;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.44	-9.33	-0.4	4.32e-19	Schizophrenia;
LGG	cis	rs6815814	0.861	rs28393318	chr4:38784267	A/G	cg06935464	chr4:38784597	TLR10	0.53	8.61	0.37	1.12e-16	Breast cancer;
LGG	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06470251	chr20:60548479	NA	0.46	8.19	0.36	2.49e-15	Body mass index;
LGG	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs17401966	1.000	rs12755094	chr1:10305711	T/C	cg15208524	chr1:10270712	KIF1B	0.46	7.86	0.34	2.64e-14	Hepatocellular carcinoma;
LGG	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg21211680	chr2:198530	NA	1.28	22.19	0.72	7.62e-75	Blood protein levels;
LGG	trans	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg02030672	chr11:45687055	CHST1	-0.5	-9.26	-0.4	7.42e-19	Obesity-related traits;
LGG	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs2172802	1.000	rs2172802	chr4:62453209	C/T	cg04118610	chr4:62707027	LPHN3	0.44	6.65	0.3	8.35e-11	Partial epilepsies;
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg14074117	chr16:1909714	C16orf73	-0.53	-7.83	-0.34	3.27e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg02002194	chr4:3960332	NA	0.46	8.53	0.37	2.18e-16	Monocyte count;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg22963979	chr7:1858916	MAD1L1	-0.4	-7.87	-0.34	2.48e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg04204079	chr8:58130323	NA	0.36	6.71	0.3	5.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4689642	0.507	rs4689647	chr4:7221633	T/C	cg21353189	chr4:7228343	SORCS2	0.32	6.72	0.3	5.31e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2227564	0.729	rs2688611	chr10:75653372	G/T	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.14	-0.39	2.02e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2072732	0.861	rs12408197	chr1:2951511	C/T	cg08733933	chr1:2954429	NA	-0.4	-8.72	-0.38	4.92e-17	Plateletcrit;
LGG	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg16576597	chr16:28551801	NUPR1	0.3	6.71	0.3	5.56e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs881375	0.678	rs2269060	chr9:123683569	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.43	0.5	8.61e-31	Rheumatoid arthritis;
LGG	cis	rs113835537	0.529	rs11824771	chr11:66262550	T/C	cg24851651	chr11:66362959	CCS	0.46	7.99	0.35	1.11e-14	Airway imaging phenotypes;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg09699651	chr6:150184138	LRP11	0.54	9.27	0.4	7.11e-19	Lung cancer;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.74	-0.34	6.3e-14	Longevity;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	trans	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg26384229	chr12:38710491	ALG10B	0.73	14.61	0.56	4.97e-40	Morning vs. evening chronotype;
LGG	cis	rs490234	0.676	rs13293034	chr9:128256951	C/T	cg14078157	chr9:128172775	NA	-0.54	-10.31	-0.43	1.46e-22	Mean arterial pressure;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.43	-0.33	5.28e-13	Lung cancer;
LGG	cis	rs7666738	0.830	rs10019087	chr4:99030211	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg02487422	chr3:49467188	NICN1	0.41	6.93	0.31	1.4e-11	Parkinson's disease;
LGG	cis	rs4954585	0.708	rs6430612	chr2:137006198	C/T	cg05194412	chr2:137003533	NA	0.37	7.95	0.35	1.39e-14	Colorectal cancer;
LGG	cis	rs977987	0.931	rs7195161	chr16:75495572	T/C	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.14e-28	Dupuytren's disease;
LGG	cis	rs910316	0.763	rs13712	chr14:75483812	T/C	cg11812906	chr14:75593930	NEK9	0.48	8.58	0.37	1.43e-16	Height;
LGG	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	trans	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg05926928	chr17:57297772	GDPD1	-0.84	-11.6	-0.47	1.7e-27	Opioid sensitivity;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg00166722	chr3:10149974	C3orf24	0.51	8.55	0.37	1.8e-16	Alzheimer's disease;
LGG	cis	rs9547996	0.879	rs9547953	chr13:38138863	C/T	cg13634560	chr13:38173852	POSTN	-0.36	-7.24	-0.32	1.88e-12	Diastolic blood pressure;
LGG	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg11812906	chr14:75593930	NEK9	-0.44	-8.05	-0.35	7.25e-15	Height;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg05096777	chr10:104283225	SUFU	0.32	6.86	0.3	2.27e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	7.18	0.32	2.84e-12	Height;
LGG	cis	rs988958	0.600	rs10205005	chr2:42248713	A/G	cg27252766	chr2:42229092	NA	0.57	8.43	0.36	4.55e-16	Hypospadias;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19243777	chr12:26278767	BHLHE41	0.59	9.17	0.39	1.55e-18	Gut microbiome composition (summer);
LGG	cis	rs9399137	0.507	rs7771310	chr6:135272535	G/A	cg24558204	chr6:135376177	HBS1L	0.6	10.33	0.43	1.25e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6840360	0.967	rs7684350	chr4:152672882	T/G	cg22705602	chr4:152727874	NA	-0.26	-6.66	-0.3	7.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg21724239	chr8:58056113	NA	0.44	6.65	0.3	8.2e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs854765	0.583	rs2350977	chr17:17802779	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	12.9	0.51	9.92e-33	Total body bone mineral density;
LGG	cis	rs9487094	0.922	rs1321328	chr6:109976385	G/C	cg16315928	chr6:109776240	MICAL1	0.54	9.12	0.39	2.36e-18	Height;
LGG	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg04731861	chr2:219085781	ARPC2	0.48	12.21	0.49	6.71e-30	Colorectal cancer;
LGG	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg03162506	chr22:38580953	NA	0.41	9.98	0.42	2.27e-21	Breast cancer;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg03188948	chr7:1209495	NA	0.4	6.94	0.31	1.34e-11	Longevity;Endometriosis;
LGG	cis	rs17221829	0.965	rs28614109	chr11:89460943	A/G	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.5	-0.33	3.18e-13	Anxiety in major depressive disorder;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.565	rs12538641	chr7:124600671	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.91	-0.31	1.6e-11	Cutaneous malignant melanoma;
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.51	-8.56	-0.37	1.72e-16	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.88	-0.51	1.17e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs10493773	0.962	rs6698578	chr1:86236676	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.62	-10.46	-0.44	4.04e-23	Urate levels in overweight individuals;
LGG	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg20503657	chr10:835505	NA	0.96	12.76	0.51	3.54e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs4664308	0.935	rs877200	chr2:160903723	G/C	cg03641300	chr2:160917029	PLA2R1	-0.85	-17.85	-0.64	1.32e-54	Idiopathic membranous nephropathy;
LGG	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.05	-0.35	7.21e-15	Mean corpuscular volume;
LGG	cis	rs7917772	0.582	rs10883736	chr10:104320029	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.68	0.48	8.52e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4665809	0.941	rs1434079	chr2:26284670	C/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.76	-0.34	5.59e-14	Gut microbiome composition (summer);
LGG	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.6	0.37	1.2e-16	Aortic root size;
LGG	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.59	-0.59	2.36e-44	Body mass index;
LGG	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16160182	chr1:2574031	NA	0.42	6.81	0.3	3.03e-11	Cognitive performance;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.9e-17	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04730665	chr2:236403704	AGAP1	0.43	7.45	0.33	4.76e-13	Bipolar disorder;
LGG	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.82e-21	HDL cholesterol;
LGG	cis	rs6088580	0.634	rs6059896	chr20:33111783	T/C	cg08999081	chr20:33150536	PIGU	0.39	9.72	0.41	1.91e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7106204	0.748	rs2403888	chr11:24208071	C/G	ch.11.24196551F	chr11:24239977	NA	-1.01	-16.02	-0.6	2.69e-46	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	trans	rs9929218	0.954	rs2961	chr16:68818903	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-12.28	-0.5	3.25e-30	Colorectal cancer;
LGG	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg27165867	chr14:105738592	BRF1	-0.44	-7.32	-0.32	1.11e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2274273	0.553	rs56166765	chr14:55738018	T/C	cg04306507	chr14:55594613	LGALS3	0.54	12.63	0.51	1.28e-31	Protein biomarker;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.44	0.4	1.82e-19	Longevity;
LGG	cis	rs55788414	0.932	rs9940186	chr16:81182199	A/T	cg06400318	chr16:81190750	PKD1L2	-0.92	-11.0	-0.46	3.83e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Bone mineral density;
LGG	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg07549998	chr6:150325970	RAET1K	-0.37	-7.15	-0.32	3.39e-12	Alopecia areata;
LGG	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.85	0.38	1.9e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg06521331	chr12:34319734	NA	0.43	7.84	0.34	3.13e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.84	0.34	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg16751781	chr15:78858589	CHRNA5	0.38	7.12	0.31	4.22e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	9.34	0.4	4.18e-19	Rheumatoid arthritis;
LGG	trans	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg26043149	chr18:55253948	FECH	0.95	16.33	0.6	1.08e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg18681998	chr4:17616180	MED28	0.84	18.52	0.65	1.05e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9814567	0.731	rs34797591	chr3:134192516	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.66	10.45	0.44	4.48e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg21972741	chr5:435613	AHRR	0.48	8.34	0.36	8.34e-16	Cystic fibrosis severity;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg15440763	chr7:158190612	PTPRN2	0.49	10.65	0.44	7.99e-24	Obesity-related traits;
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg16606324	chr3:10149918	C3orf24	0.59	6.73	0.3	4.88e-11	Alzheimer's disease;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg01673284	chr16:4527211	HMOX2	0.36	7.18	0.32	2.87e-12	Schizophrenia;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg15971980	chr6:150254442	NA	0.45	8.41	0.36	5.11e-16	Lung cancer;
LGG	cis	rs55665837	1.000	rs11023214	chr11:14436259	G/C	cg19336497	chr11:14380999	RRAS2	-0.46	-8.91	-0.38	1.16e-17	Vitamin D levels;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg02023728	chr11:77925099	USP35	0.45	7.99	0.35	1.08e-14	Testicular germ cell tumor;
LGG	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg05147244	chr20:61493195	TCFL5	-0.69	-7.07	-0.31	5.61e-12	Obesity-related traits;
LGG	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.75	0.3	4.34e-11	Schizophrenia;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs1670533	0.932	rs10902753	chr4:1056223	G/A	cg27284194	chr4:1044797	NA	0.55	9.81	0.41	8.99e-21	Recombination rate (females);
LGG	cis	rs7666738	0.830	rs28818218	chr4:98880575	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.3	0.36	1.19e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg18402987	chr7:1209562	NA	0.67	9.29	0.4	5.95e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1982963	0.951	rs56834750	chr14:52509483	T/C	cg05884192	chr14:52515736	NID2	-0.33	-7.08	-0.31	5.34e-12	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg27124370	chr19:33622961	WDR88	-0.5	-8.96	-0.38	7.89e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3806843	0.933	rs2240696	chr5:140168070	A/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs727505	1.000	rs68007199	chr7:124491307	T/C	cg23710748	chr7:124431027	NA	-0.53	-10.0	-0.42	1.83e-21	Lewy body disease;
LGG	cis	rs11676348	0.818	rs1126579	chr2:219000734	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-10.23	-0.43	2.7e-22	Ulcerative colitis;
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg15145296	chr3:125709740	NA	-0.62	-8.09	-0.35	5.13e-15	Blood pressure (smoking interaction);
LGG	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs3857067	1.000	rs1585652	chr4:95014313	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg14403583	chr14:105418241	AHNAK2	-0.76	-15.36	-0.58	2.52e-43	Rheumatoid arthritis;
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg03847636	chr4:7070632	GRPEL1	-0.55	-7.68	-0.34	9.27e-14	Monocyte percentage of white cells;
LGG	cis	rs832540	0.552	rs702681	chr5:56218029	C/T	cg12654349	chr5:56205094	C5orf35	-0.45	-7.96	-0.35	1.36e-14	Coronary artery disease;
LGG	trans	rs9650657	0.707	rs4841452	chr8:10687121	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.37	-0.32	7.86e-13	Neuroticism;
LGG	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	cis	rs11785693	0.862	rs73189843	chr8:5000915	C/T	cg26367366	chr8:4980734	NA	1.0	15.18	0.58	1.58e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg10204951	chr7:910479	UNC84A	-0.52	-6.99	-0.31	9.47e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.81	0.41	8.99e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4356932	0.729	rs6855257	chr4:76964788	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs6032067	0.527	rs6104012	chr20:43734571	A/G	cg10761708	chr20:43804764	PI3	0.55	8.46	0.37	3.58e-16	Blood protein levels;
LGG	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg15490075	chr13:100150979	NA	0.64	6.79	0.3	3.41e-11	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	1.01e-25	Homoarginine levels;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg20295408	chr7:1910781	MAD1L1	-0.4	-6.7	-0.3	6e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-17.46	-0.63	7.93e-53	Vitiligo;
LGG	cis	rs9355814	0.514	rs62442784	chr6:161067992	T/C	cg04181478	chr6:161122748	PLG	0.43	6.94	0.31	1.34e-11	Lipoprotein (a) levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02804564	chr10:112679224	NCRNA00081;SHOC2	0.48	7.32	0.32	1.13e-12	Gut microbiome composition (summer);
LGG	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg01620082	chr3:125678407	NA	-0.66	-7.41	-0.33	5.97e-13	Depression;
LGG	cis	rs34816374	1	rs34816374	chr6:26949672	A/G	cg12826209	chr6:26865740	GUSBL1	0.73	6.7	0.3	5.98e-11	Lung cancer in ever smokers;
LGG	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-12.22	-0.49	5.88e-30	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08908148	chr7:39606013	C7orf36	0.39	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg22968622	chr17:43663579	NA	0.78	15.28	0.58	5.79e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8007846	0.508	rs1256538	chr14:65763026	G/A	cg15999311	chr14:65749247	NA	0.44	7.75	0.34	5.77e-14	Multiple sclerosis--Brain Glutamate Levels;
LGG	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg12046867	chr14:103022105	NA	0.73	12.2	0.49	7.13e-30	Platelet count;
LGG	cis	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg12463550	chr7:65579703	CRCP	0.71	6.83	0.3	2.66e-11	Gout;
LGG	cis	rs1909881	0.515	rs4320522	chr8:96473324	C/G	cg04203453	chr8:96504381	NA	-1.06	-16.21	-0.6	3.77e-47	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.32	0.32	1.09e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.51	-8.58	-0.37	1.47e-16	Menarche (age at onset);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg07432643	chr22:50247581	ZBED4	-0.42	-7.08	-0.31	5.53e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.32	-0.47	2.08e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6540556	0.769	rs12030655	chr1:209922123	G/T	cg23920097	chr1:209922102	NA	-0.5	-8.92	-0.38	1.08e-17	Red blood cell count;
LGG	cis	rs9487051	0.676	rs6903107	chr6:109597711	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.33e-14	Reticulocyte fraction of red cells;
LGG	cis	rs11585357	0.793	rs112597506	chr1:17628832	A/G	cg08277548	chr1:17600880	PADI3	-0.74	-8.18	-0.36	2.79e-15	Hair shape;
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4538187	1.000	rs10183479	chr2:64085114	G/A	cg14150252	chr2:64069583	UGP2	0.5	9.99	0.42	2.11e-21	Systolic blood pressure;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11245990	chr11:68621969	NA	0.41	8.7	0.37	5.69e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.46	7.78	0.34	4.93e-14	Cystic fibrosis severity;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	9.12e-12	Lung cancer;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg21724239	chr8:58056113	NA	0.7	15.65	0.59	1.28e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs6723108	0.603	rs62168897	chr2:135717997	C/T	cg07169764	chr2:136633963	MCM6	0.43	6.7	0.3	6.18e-11	Type 2 diabetes;
LGG	cis	rs73787773	0.866	rs73227493	chr5:111477659	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.65	-7.8	-0.34	4.1e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9393813	0.529	rs73395360	chr6:27457317	A/C	cg18711553	chr6:27366782	ZNF391	-0.47	-9.01	-0.39	5.61e-18	Bipolar disorder;
LGG	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg13334819	chr7:99746414	C7orf59	0.44	6.9	0.31	1.67e-11	Coronary artery disease;
LGG	cis	rs1322639	0.614	rs6925950	chr6:169563958	A/G	cg03254818	chr6:169586852	NA	0.52	8.06	0.35	6.52e-15	Pulse pressure;
LGG	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.15	-0.32	3.48e-12	Joint mobility (Beighton score);
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04008888	chr11:68622739	NA	-0.54	-11.6	-0.47	1.68e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10479542	0.537	rs1344158	chr5:178950761	G/A	cg09060608	chr5:178986726	RUFY1	-0.42	-7.29	-0.32	1.38e-12	Lung cancer;
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg13607699	chr17:42295918	UBTF	0.6	9.22	0.39	1.07e-18	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs9849248	0.574	rs11925988	chr3:88231451	A/C	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs2115630	1.000	rs2879828	chr15:85361977	G/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.67	-0.3	7.51e-11	P wave terminal force;
LGG	cis	rs6500395	1.000	rs9928051	chr16:48557316	T/A	cg04672837	chr16:48644449	N4BP1	0.52	8.55	0.37	1.76e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.32e-16	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs7107174	1.000	rs731600	chr11:77963133	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.38	-0.32	7.21e-13	Testicular germ cell tumor;
LGG	trans	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg17712092	chr4:129076599	LARP1B	0.63	10.56	0.44	1.62e-23	DNA methylation (variation);
LGG	cis	rs7107174	0.792	rs2888465	chr11:77945807	T/C	cg02023728	chr11:77925099	USP35	0.47	8.16	0.35	3.25e-15	Testicular germ cell tumor;
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg06917634	chr15:78832804	PSMA4	0.73	13.42	0.53	6.3e-35	Sudden cardiac arrest;
LGG	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.83	-0.42	7.86e-21	Response to antipsychotic treatment;
LGG	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.48	-0.33	3.83e-13	Neuroticism;
LGG	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-10.11	-0.43	7.74e-22	Chronic sinus infection;
LGG	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg12773197	chr13:112238673	NA	-0.37	-7.61	-0.33	1.59e-13	Hepatitis;
LGG	cis	rs9296092	0.560	rs62407561	chr6:33528103	T/C	cg13560919	chr6:33536144	NA	-1.06	-22.16	-0.72	1.01e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg02018176	chr4:1364513	KIAA1530	0.51	12.42	0.5	8.88e-31	Longevity;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.73e-33	Prudent dietary pattern;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-7.03	-0.31	7.63e-12	Schizophrenia;
LGG	cis	rs300774	0.925	rs7562639	chr2:117690	G/T	cg04617936	chr2:214353	NA	-0.49	-7.32	-0.32	1.14e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg02461776	chr11:598696	PHRF1	0.52	8.1	0.35	4.8e-15	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Vitiligo;
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs10463554	0.892	rs17154859	chr5:102290912	A/C	cg23492399	chr5:102201601	PAM	0.56	8.61	0.37	1.16e-16	Parkinson's disease;
LGG	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs514024	0.765	rs497632	chr9:130475442	A/C	cg13643465	chr9:130375613	STXBP1	0.61	11.59	0.47	1.87e-27	Eating disorders (purging via substances);
LGG	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.25	0.36	1.65e-15	Multiple myeloma (hyperdiploidy);
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg05064044	chr6:292385	DUSP22	-0.64	-10.8	-0.45	2.05e-24	Menopause (age at onset);
LGG	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg11266682	chr4:10021025	SLC2A9	0.47	9.16	0.39	1.65e-18	Bone mineral density;
LGG	cis	rs2735413	0.564	rs74864339	chr16:78095071	C/T	cg04733911	chr16:78082701	NA	0.63	8.96	0.38	7.77e-18	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9329221	0.508	rs6601455	chr8:10273426	A/G	cg12940923	chr8:10282607	MSRA	0.3	6.94	0.31	1.3e-11	Neuroticism;
LGG	cis	rs1801251	0.644	rs283473	chr2:233654847	A/G	cg08000102	chr2:233561755	GIGYF2	0.58	10.11	0.43	7.74e-22	Coronary artery disease;
LGG	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg18473234	chr19:5097819	KDM4B	-0.44	-7.67	-0.34	1.01e-13	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg11062466	chr8:58055876	NA	0.48	8.08	0.35	5.82e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs774359	0.830	rs2477523	chr9:27536894	T/A	cg21249376	chr9:27528432	MOBKL2B	0.44	8.13	0.35	4.05e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs8016982	0.657	rs11625861	chr14:81735001	C/T	cg01989461	chr14:81687754	GTF2A1	-0.75	-17.51	-0.63	4.59e-53	Schizophrenia;
LGG	cis	rs7315438	0.512	rs7962222	chr12:115942219	T/C	cg18639984	chr12:115943877	NA	-0.42	-9.13	-0.39	2.13e-18	Colorectal cancer;
LGG	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg26384229	chr12:38710491	ALG10B	-0.51	-8.98	-0.39	6.99e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg19774624	chr17:42201019	HDAC5	-0.9	-17.55	-0.63	3.08e-53	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg02297831	chr4:17616191	MED28	0.5	9.51	0.4	1.03e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9393777	0.720	rs57713596	chr6:27004098	C/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.31	-0.4	5.08e-19	Intelligence (multi-trait analysis);
LGG	trans	rs28595532	0.557	rs4359977	chr4:119314055	T/C	cg26518628	chr1:97050305	NA	-0.9	-12.08	-0.49	2.18e-29	Cannabis dependence symptom count;
LGG	cis	rs7191439	0.589	rs12709104	chr16:88757940	G/A	cg27087555	chr16:88793112	FAM38A	-1.01	-11.03	-0.46	2.84e-25	Plateletcrit;
LGG	trans	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg02002194	chr4:3960332	NA	0.38	7.04	0.31	7.2e-12	Joint mobility (Beighton score);
LGG	cis	rs250677	0.958	rs36078	chr5:148430567	G/A	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.19	-0.32	2.57e-12	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03626857	chr19:44716492	ZNF227	0.33	6.65	0.3	8.38e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs2945232	1	rs2945232	chr8:8098038	T/C	cg16141378	chr3:129829833	LOC729375	-0.59	-15.82	-0.59	2.33e-45	Schizophrenia;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.19	0.39	1.36e-18	Alzheimer's disease;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.42	-0.4	2.08e-19	Platelet count;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11245990	chr11:68621969	NA	0.41	8.77	0.38	3.56e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10489202	0.632	rs203781	chr1:167880518	A/C	cg24449463	chr1:168025552	DCAF6	-0.57	-9.96	-0.42	2.55e-21	Schizophrenia;
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg02002194	chr4:3960332	NA	0.47	8.96	0.38	7.95e-18	Monocyte count;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg14675211	chr2:100938903	LONRF2	0.63	11.2	0.46	6.31e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg03651054	chr13:50194643	NA	0.3	6.75	0.3	4.31e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs8067545	0.586	rs2703770	chr17:20123928	A/G	cg09818912	chr17:20140352	CYTSB	0.31	6.77	0.3	3.93e-11	Schizophrenia;
LGG	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg13802316	chr11:70253460	CTTN	-0.59	-8.16	-0.35	3.3e-15	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Gut microbiome composition (summer);
LGG	cis	rs758324	0.812	rs11242095	chr5:131152575	A/G	cg06307176	chr5:131281290	NA	0.53	8.79	0.38	2.93e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9325144	0.624	rs7309400	chr12:39150369	G/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.53	-0.33	2.72e-13	Morning vs. evening chronotype;
LGG	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg20608306	chr11:116969690	SIK3	0.4	12.63	0.51	1.27e-31	Blood protein levels;
LGG	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg19223190	chr17:80058835	NA	0.45	8.94	0.38	9.19e-18	Life satisfaction;
LGG	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg10661904	chr17:79619235	PDE6G	-0.39	-7.93	-0.35	1.7e-14	Eye color traits;
LGG	trans	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg01620082	chr3:125678407	NA	-0.68	-6.86	-0.3	2.27e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17321999	0.859	rs72787718	chr2:30474351	G/A	cg05247661	chr2:30472410	LBH	0.55	9.1	0.39	2.78e-18	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg26150922	chr2:100937072	LONRF2	-0.57	-9.97	-0.42	2.53e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg02462569	chr6:150064036	NUP43	-0.39	-8.3	-0.36	1.13e-15	Lung cancer;
LGG	trans	rs61931739	0.620	rs7297316	chr12:33702261	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-8.58	-0.37	1.4e-16	Morning vs. evening chronotype;
LGG	trans	rs6598955	0.612	rs12738188	chr1:26548029	G/C	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.88	0.34	2.3e-14	Obesity-related traits;
LGG	cis	rs11645898	0.574	rs17604349	chr16:72210865	C/T	cg14768367	chr16:72042858	DHODH	-0.57	-8.12	-0.35	4.36e-15	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21088281	chr4:176922637	GPM6A	0.55	8.32	0.36	9.71e-16	Gut microbiome composition (summer);
LGG	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.46	-0.33	4.43e-13	Testicular germ cell tumor;
LGG	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg02297831	chr4:17616191	MED28	0.45	8.28	0.36	1.34e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg14541582	chr5:601475	NA	-0.57	-9.13	-0.39	2.15e-18	Obesity-related traits;
LGG	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg02002194	chr4:3960332	NA	-0.43	-7.81	-0.34	3.99e-14	Neuroticism;
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.41	-0.53	7.13e-35	Aortic root size;
LGG	trans	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg06529181	chr19:52193933	NA	0.51	7.83	0.34	3.34e-14	IgG glycosylation;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg08847335	chr10:891726	LARP4B	-0.54	-9.07	-0.39	3.5e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.38	0.61	6.45e-48	Hip circumference adjusted for BMI;
LGG	cis	rs10504073	0.647	rs28685207	chr8:50003484	A/G	cg00325661	chr8:49890786	NA	0.69	13.58	0.53	1.41e-35	Blood metabolite ratios;
LGG	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg09307838	chr4:120376055	NA	0.7	11.33	0.47	1.92e-26	Corneal astigmatism;
LGG	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	11.49	0.47	4.86e-27	Response to antipsychotic treatment;
LGG	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Calcium levels;
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg05793240	chr7:2802953	GNA12	0.28	6.72	0.3	5.41e-11	Height;
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg19554555	chr3:13937349	NA	-0.57	-10.2	-0.43	3.5e-22	Ovarian reserve;
LGG	cis	rs4363385	0.818	rs1890285	chr1:153015396	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.04e-16	Inflammatory skin disease;
LGG	cis	rs17227506	0.742	rs9650364	chr8:13442279	C/A	cg03566418	chr8:13424080	C8orf48	0.47	7.29	0.32	1.33e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4974559	0.739	rs6845586	chr4:1323070	G/A	cg02980000	chr4:1222292	CTBP1	0.81	9.16	0.39	1.73e-18	Systolic blood pressure;
LGG	cis	rs9487094	0.626	rs12215077	chr6:110052880	A/C	cg16315928	chr6:109776240	MICAL1	-0.43	-7.5	-0.33	3.3e-13	Height;
LGG	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg01448562	chr3:133502909	NA	-0.8	-15.2	-0.58	1.32e-42	Iron status biomarkers;
LGG	cis	rs12210905	1.000	rs12209429	chr6:27054867	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-19.92	-0.68	3.04e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.8	-16.82	-0.62	6.67e-50	Schizophrenia;
LGG	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg04731861	chr2:219085781	ARPC2	0.51	13.47	0.53	4.08e-35	Colorectal cancer;
LGG	trans	rs7618501	1.000	rs2271960	chr3:49878078	A/G	cg21659725	chr3:3221576	CRBN	0.9	19.43	0.67	6.2e-62	Intelligence (multi-trait analysis);
LGG	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg25457927	chr22:38595422	NA	-0.41	-9.62	-0.41	4.28e-20	Breast cancer;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg09307838	chr4:120376055	NA	0.71	11.78	0.48	3.39e-28	Corneal astigmatism;
LGG	cis	rs1707322	1.000	rs10890359	chr1:46336635	A/G	cg03146154	chr1:46216737	IPP	0.55	10.49	0.44	3.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg11494091	chr17:61959527	GH2	0.99	24.23	0.75	2.42e-84	Prudent dietary pattern;
LGG	trans	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg06521331	chr12:34319734	NA	0.43	7.64	0.33	1.27e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs490234	0.586	rs12553548	chr9:128155261	T/G	cg14078157	chr9:128172775	NA	-0.49	-9.21	-0.39	1.14e-18	Mean arterial pressure;
LGG	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg26513180	chr16:89883248	FANCA	0.65	12.43	0.5	8.11e-31	Vitiligo;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.37	-0.36	6.91e-16	Aortic root size;
LGG	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg23750338	chr8:142222470	SLC45A4	-0.58	-11.9	-0.48	1.14e-28	Immature fraction of reticulocytes;
LGG	cis	rs4604732	0.527	rs7539082	chr1:247627260	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.11	0.39	2.5e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg14893161	chr1:205819251	PM20D1	0.85	19.73	0.68	2.52e-63	Menarche (age at onset);
LGG	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg03806693	chr22:41940476	POLR3H	1.05	17.74	0.64	4.31e-54	Vitiligo;
LGG	cis	rs151997	0.508	rs9292165	chr5:50272619	T/C	cg06027927	chr5:50259733	NA	0.62	10.11	0.43	7.76e-22	Callous-unemotional behaviour;
LGG	trans	rs800082	0.839	rs11714177	chr3:144312862	T/C	cg24215973	chr2:240111563	HDAC4	-0.48	-8.21	-0.36	2.27e-15	Smoking behavior;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.86	-18.96	-0.66	9.68e-60	Longevity;Endometriosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04696559	chr5:36152378	SKP2;LMBRD2	0.46	7.63	0.33	1.37e-13	Cognitive performance;
LGG	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg00990874	chr7:1149470	C7orf50	-0.61	-9.21	-0.39	1.17e-18	Bronchopulmonary dysplasia;
LGG	cis	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	cis	rs6489785	0.775	rs2701178	chr12:121337179	T/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.76	-0.3	4.28e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.75	0.3	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg08280861	chr8:58055591	NA	0.55	6.97	0.31	1.12e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.33	3.94e-13	Height;
LGG	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg02175503	chr12:58329896	NA	-0.54	-9.02	-0.39	5e-18	Intelligence (multi-trait analysis);
LGG	cis	rs17428076	0.749	rs788161	chr2:172926671	C/T	cg21435375	chr2:172878103	MAP1D	0.46	9.83	0.42	7.54e-21	Myopia;
LGG	trans	rs7980799	0.649	rs10772088	chr12:33663849	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-8.25	-0.36	1.69e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg12525768	chr7:29689996	LOC646762	0.54	7.73	0.34	6.7e-14	Facial emotion recognition (angry faces);
LGG	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg20570797	chr2:1712800	PXDN	-0.46	-8.36	-0.36	7.68e-16	Response to antipsychotic treatment;
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	11.57	0.47	2.23e-27	Lymphocyte counts;
LGG	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs10751667	0.666	rs7394427	chr11:970405	G/A	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg26384229	chr12:38710491	ALG10B	0.65	12.54	0.5	3.06e-31	Morning vs. evening chronotype;
LGG	cis	rs367943	0.799	rs10057321	chr5:112974729	A/G	cg12552261	chr5:112820674	MCC	0.58	10.04	0.42	1.36e-21	Type 2 diabetes;
LGG	cis	rs11608355	0.545	rs2302706	chr12:109894028	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs3213961	0.744	rs4627543	chr2:33815948	T/C	cg04131969	chr2:33951647	MYADML	0.49	7.19	0.32	2.58e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg09307838	chr4:120376055	NA	-0.72	-11.76	-0.48	3.91e-28	Corneal astigmatism;
LGG	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg01324343	chr3:183735012	ABCC5	-0.74	-12.92	-0.51	8.2e-33	Anterior chamber depth;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.5e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.84	-0.42	7.06e-21	Response to antipsychotic treatment;
LGG	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.66	0.3	7.94e-11	Vitiligo;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18766912	chr15:25683909	UBE3A	0.41	7.32	0.32	1.13e-12	Obesity-related traits;
LGG	cis	rs220324	0.954	rs511045	chr21:43581865	T/C	cg15319517	chr21:43638949	ABCG1	0.45	7.27	0.32	1.5e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs4474465	1.000	rs7935292	chr11:78169885	C/G	cg02023728	chr11:77925099	USP35	0.39	6.77	0.3	4.02e-11	Alzheimer's disease (survival time);
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg16141378	chr3:129829833	LOC729375	0.41	9.54	0.41	8.12e-20	Neuroticism;
LGG	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg11812906	chr14:75593930	NEK9	-0.46	-8.21	-0.36	2.28e-15	Height;
LGG	cis	rs28595532	0.764	rs115011450	chr4:119778171	C/T	cg21605333	chr4:119757512	SEC24D	1.47	13.64	0.54	7.78e-36	Cannabis dependence symptom count;
LGG	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.86	-0.3	2.15e-11	Aortic root size;
LGG	cis	rs12220238	1.000	rs11000916	chr10:75953909	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.26	0.32	1.65e-12	Retinal vascular caliber;
LGG	cis	rs4731207	0.596	rs10231491	chr7:124574091	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs77633900	0.772	rs8031378	chr15:76657874	A/G	cg21673338	chr15:77095150	SCAPER	-0.6	-7.69	-0.34	8.96e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg15268244	chr15:77196840	NA	0.44	9.71	0.41	2.02e-20	Blood metabolite levels;
LGG	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg08999081	chr20:33150536	PIGU	0.3	6.95	0.31	1.25e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg22358067	chr17:16797159	NA	-0.52	-7.32	-0.32	1.1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg15454534	chr1:248569605	OR2T1	0.38	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg00579200	chr11:133705235	NA	-0.59	-11.29	-0.46	2.89e-26	Childhood ear infection;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16475925	chr16:89574613	SPG7	-0.41	-6.86	-0.3	2.25e-11	Brain structure;
LGG	cis	rs9487051	0.676	rs9398196	chr6:109601554	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.17e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.87	-0.34	2.59e-14	Vitiligo;
LGG	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg19847130	chr8:10466454	RP1L1	0.32	7.25	0.32	1.71e-12	Mood instability;
LGG	cis	rs5758659	0.692	rs5751251	chr22:42640606	G/C	cg15128208	chr22:42549153	NA	-0.5	-9.9	-0.42	4.52e-21	Cognitive function;
LGG	cis	rs1461503	0.932	rs7944492	chr11:122838745	G/T	cg27398637	chr11:122830231	C11orf63	-0.72	-14.33	-0.55	7.93e-39	Menarche (age at onset);
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg05793240	chr7:2802953	GNA12	0.34	7.65	0.34	1.15e-13	Height;
LGG	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg02002194	chr4:3960332	NA	0.37	6.7	0.3	6.23e-11	Morning vs. evening chronotype;
LGG	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg27476859	chr7:2772710	GNA12	0.54	10.52	0.44	2.3e-23	Height;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.93	-0.31	1.4e-11	Lung cancer;
LGG	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg07148914	chr20:33460835	GGT7	-0.47	-7.74	-0.34	6.23e-14	Height;
LGG	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg08648136	chr8:956695	NA	0.34	6.77	0.3	3.81e-11	Schizophrenia;
LGG	cis	rs4262150	0.883	rs72799142	chr5:152100732	A/C	cg12297329	chr5:152029980	NA	-0.74	-13.35	-0.53	1.25e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg14912033	chr15:79043428	NA	-0.41	-10.39	-0.43	7.02e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg00343986	chr7:65444356	GUSB	0.4	6.78	0.3	3.72e-11	Aortic root size;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg07701084	chr6:150067640	NUP43	0.69	13.33	0.53	1.57e-34	Lung cancer;
LGG	cis	rs7523273	0.597	rs11118612	chr1:207979577	T/A	cg22525895	chr1:207977042	MIR29B2	-0.45	-6.82	-0.3	2.89e-11	Schizophrenia;
LGG	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.28	-0.32	1.42e-12	Refractive error;
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg00149659	chr3:10157352	C3orf10	0.83	10.68	0.44	5.97e-24	Alzheimer's disease;
LGG	cis	rs9463078	0.625	rs1891412	chr6:44760642	T/C	cg25276700	chr6:44698697	NA	0.38	7.85	0.34	2.82e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08658981	chr10:134578481	INPP5A	0.41	7.07	0.31	5.88e-12	Gut microbiome composition (summer);
LGG	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg04398451	chr17:18023971	MYO15A	0.66	13.83	0.54	1.19e-36	Total body bone mineral density;
LGG	cis	rs2587949	0.593	rs1817576	chr3:4205925	T/C	cg16519197	chr3:4211558	NA	-0.33	-6.91	-0.31	1.59e-11	Periodontitis (DPAL);
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg19635926	chr16:89946313	TCF25	0.82	9.24	0.39	8.87e-19	Skin colour saturation;
LGG	cis	rs3824867	0.920	rs80241400	chr11:47453828	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-7.38	-0.32	7.22e-13	Mean corpuscular hemoglobin;
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg11645453	chr3:52864694	ITIH4	0.41	6.81	0.3	3.09e-11	Bipolar disorder;
LGG	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg08305652	chr11:111469057	NA	-0.45	-8.92	-0.38	1.08e-17	Primary sclerosing cholangitis;
LGG	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg25173405	chr17:45401733	C17orf57	0.49	8.4	0.36	5.55e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs704	0.628	rs7212349	chr17:26733698	T/C	cg10342447	chr17:26645325	TMEM97	-0.41	-7.42	-0.33	5.46e-13	Osteoprotegerin levels;
LGG	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg02297831	chr4:17616191	MED28	0.49	9.31	0.4	5.01e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg18252515	chr7:66147081	NA	-0.6	-9.95	-0.42	2.89e-21	Corneal structure;
LGG	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04633058	chr17:48474099	LRRC59	0.42	6.66	0.3	7.81e-11	Gut microbiome composition (summer);
LGG	cis	rs6704644	1.000	rs10929178	chr2:234396566	C/G	cg27060346	chr2:234359958	DGKD	-0.6	-7.34	-0.32	9.4e-13	Bilirubin levels;
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	cis	rs977987	0.806	rs11862582	chr16:75431295	T/C	cg03315344	chr16:75512273	CHST6	0.5	9.91	0.42	3.96e-21	Dupuytren's disease;
LGG	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg10760299	chr15:45669010	GATM	0.4	7.99	0.35	1.1e-14	Homoarginine levels;
LGG	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg11871910	chr12:69753446	YEATS4	-0.47	-7.75	-0.34	5.82e-14	Response to diuretic therapy;
LGG	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.03	-0.31	7.44e-12	Migraine;Coronary artery disease;
LGG	cis	rs2290159	0.948	rs7956	chr3:12624763	C/T	cg23032965	chr3:12705835	RAF1	-0.54	-8.27	-0.36	1.4e-15	Cholesterol, total;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16351364	chr6:46620676	CYP39A1;SLC25A27	0.46	6.78	0.3	3.67e-11	Gut microbiome composition (summer);
LGG	cis	rs9549367	0.713	rs3024747	chr13:113821787	C/G	cg18105134	chr13:113819100	PROZ	-0.76	-15.87	-0.59	1.34e-45	Platelet distribution width;
LGG	cis	rs7647973	1.000	rs56127630	chr3:49438036	C/G	cg07636037	chr3:49044803	WDR6	-0.75	-13.16	-0.52	8.1e-34	Menarche (age at onset);
LGG	cis	rs4776059	1.000	rs4776065	chr15:52929716	A/G	cg22715398	chr15:52968154	KIAA1370	0.46	7.71	0.34	7.9e-14	Schizophrenia;
LGG	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg01625945	chr7:157512322	PTPRN2	-0.46	-10.61	-0.44	1.1e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg02487422	chr3:49467188	NICN1	0.46	7.42	0.33	5.63e-13	Resting heart rate;
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg12395012	chr8:11607386	GATA4	0.41	7.45	0.33	4.65e-13	Retinal vascular caliber;
LGG	cis	rs7394190	1.000	rs7394190	chr10:75421648	G/A	cg07699608	chr10:75541558	CHCHD1	0.47	6.82	0.3	2.77e-11	Incident atrial fibrillation;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.77	-0.41	1.31e-20	Personality dimensions;
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.48	0.37	2.99e-16	Monocyte count;
LGG	trans	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg25482853	chr8:67687455	SGK3	1.01	12.13	0.49	1.39e-29	Lung disease severity in cystic fibrosis;
LGG	cis	rs74781061	0.860	rs7166701	chr15:74749015	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.29	-0.32	1.32e-12	Endometriosis;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg05368731	chr17:41323189	NBR1	0.93	17.74	0.64	4.29e-54	Menopause (age at onset);
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg18258770	chr4:90757814	SNCA	-0.4	-7.29	-0.32	1.34e-12	Dementia with Lewy bodies;
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.73e-21	Aortic root size;
LGG	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg14952266	chr13:112191215	NA	-0.37	-6.67	-0.3	7.13e-11	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7617773	0.778	rs11715776	chr3:48377611	G/C	cg11946769	chr3:48343235	NME6	0.7	11.65	0.48	1.06e-27	Coronary artery disease;
LGG	cis	rs3845702	1.000	rs262279	chr2:180869145	G/A	cg01881094	chr2:180872142	CWC22	0.92	14.26	0.55	1.65e-38	Schizophrenia;
LGG	cis	rs56146971	0.763	rs2064961	chr14:91868814	A/G	cg14409461	chr14:91925021	SMEK1	-0.4	-6.72	-0.3	5.27e-11	Alzheimer disease and age of onset;
LGG	trans	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	11.06	0.46	2.24e-25	Ulcerative colitis;
LGG	cis	rs1355223	0.506	rs11032894	chr11:34865544	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.41	-0.36	5.08e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs6912958	0.781	rs4464759	chr6:88282621	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.82	16.26	0.6	2.39e-47	Obesity-related traits;
LGG	cis	rs66823261	0.741	rs7841786	chr8:191746	A/C	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.73	-10.71	-0.45	4.66e-24	Breast cancer (estrogen-receptor negative);Breast cancer;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg07701084	chr6:150067640	NUP43	0.64	12.24	0.49	4.78e-30	Lung cancer;
LGG	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg00405596	chr8:11794950	NA	0.41	7.03	0.31	7.62e-12	Mood instability;
LGG	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg20935368	chr5:178288625	ZNF354B	0.34	6.89	0.3	1.84e-11	Sleep duration;
LGG	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.7	0.59	7.45e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg10253484	chr15:75165896	SCAMP2	0.44	6.96	0.31	1.18e-11	Systemic lupus erythematosus;
LGG	cis	rs1062177	1.000	rs892006	chr5:151180890	G/T	cg00977110	chr5:151150581	G3BP1	0.5	7.99	0.35	1.11e-14	Preschool internalizing problems;
LGG	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg20503657	chr10:835505	NA	0.66	9.09	0.39	2.81e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs1506636	1.000	rs2429616	chr7:123406034	C/T	cg03229431	chr7:123269106	ASB15	0.73	18.0	0.64	2.6e-55	Plateletcrit;Platelet count;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.29	0.55	1.29e-38	Platelet count;
LGG	cis	rs2180341	0.920	rs1073931	chr6:127681762	A/T	cg24812749	chr6:127587940	RNF146	0.97	16.03	0.6	2.67e-46	Breast cancer;
LGG	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.97	-0.54	2.82e-37	Gut microbiome composition (summer);
LGG	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg22044901	chr15:68126292	NA	-0.41	-6.94	-0.31	1.34e-11	Restless legs syndrome;
LGG	cis	rs644799	0.710	rs519511	chr11:95538270	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.0	0.64	2.58e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg04490037	chr7:50633773	DDC	0.33	7.2	0.32	2.46e-12	Systemic sclerosis;
LGG	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg24623649	chr8:11872141	NA	-0.31	-7.4	-0.33	6.68e-13	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26477793	chr10:104262085	ACTR1A	0.44	7.1	0.31	4.73e-12	Cognitive performance;
LGG	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg09307838	chr4:120376055	NA	0.72	12.09	0.49	1.95e-29	Corneal astigmatism;
LGG	cis	rs2235642	0.891	rs2281231	chr16:1601879	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	10.18	0.43	4.36e-22	Coronary artery disease;
LGG	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18876405	chr7:65276391	NA	0.59	10.79	0.45	2.4e-24	Aortic root size;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg01059449	chr18:44338099	ST8SIA5	0.38	8.28	0.36	1.36e-15	Personality dimensions;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg06558623	chr16:89946397	TCF25	1.05	13.06	0.52	2.07e-33	Skin colour saturation;
LGG	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-9.99	-0.42	2.09e-21	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs2273669	0.667	rs114481082	chr6:109280932	G/A	cg05315195	chr6:109294784	ARMC2	-0.59	-7.8	-0.34	4.22e-14	Prostate cancer;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg09033563	chr22:24373618	LOC391322	-0.5	-8.41	-0.36	5.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.34e-12	Lung cancer;
LGG	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs2030746	0.521	rs13415147	chr2:121329768	A/G	cg03661458	chr2:121334411	NA	-0.41	-10.44	-0.44	4.87e-23	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs7580658	0.637	rs9636235	chr2:127981551	C/T	cg10021288	chr2:128175891	PROC	-0.6	-12.1	-0.49	1.8e-29	Protein C levels;
LGG	cis	rs10463554	0.927	rs34831	chr5:102444089	C/T	cg23492399	chr5:102201601	PAM	-0.53	-7.82	-0.34	3.61e-14	Parkinson's disease;
LGG	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg23750338	chr8:142222470	SLC45A4	0.6	12.4	0.5	1.08e-30	Immature fraction of reticulocytes;
LGG	trans	rs7980799	0.935	rs7294492	chr12:33548530	C/T	cg26384229	chr12:38710491	ALG10B	-0.51	-9.07	-0.39	3.43e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.05e-13	Rheumatoid arthritis;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.68	-0.41	2.59e-20	Aortic root size;
LGG	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg26031613	chr14:104095156	KLC1	-0.67	-10.83	-0.45	1.56e-24	Reticulocyte count;
LGG	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-11.1	-0.46	1.48e-25	Height;
LGG	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs2070488	1.000	rs36006749	chr3:38443312	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	17.17	0.62	1.66e-51	Electrocardiographic conduction measures;
LGG	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs11168618	0.870	rs7302209	chr12:48895384	T/C	cg24011408	chr12:48396354	COL2A1	0.49	7.85	0.34	2.89e-14	Adiponectin levels;
LGG	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.83	-0.34	3.35e-14	Response to antipsychotic treatment;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.99e-27	Intelligence (multi-trait analysis);
LGG	trans	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg01134436	chr17:81009848	B3GNTL1	0.84	8.9	0.38	1.28e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg06623630	chr22:50017776	C22orf34	-0.45	-9.05	-0.39	3.97e-18	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg24933247	chr19:19729558	PBX4	-0.37	-6.88	-0.3	2e-11	Iris color (L* coordinate);
LGG	cis	rs6840360	0.608	rs2724556	chr4:152341717	G/A	cg17217059	chr4:152329364	FAM160A1	0.21	6.88	0.3	1.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg10523679	chr1:76189770	ACADM	0.61	9.55	0.41	7.81e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7100689	0.516	rs3862532	chr10:82015725	A/C	cg01528321	chr10:82214614	TSPAN14	0.79	13.4	0.53	8.1e-35	Post bronchodilator FEV1;
LGG	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.39	0.63	1.63e-52	Cognitive function;
LGG	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg18854424	chr1:2615690	NA	0.34	7.46	0.33	4.27e-13	Ulcerative colitis;
LGG	cis	rs2737618	0.722	rs2737676	chr1:200086839	T/C	cg21825944	chr1:200113062	NR5A2	-0.59	-11.44	-0.47	7.23e-27	Uric acid levels;
LGG	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg08648136	chr8:956695	NA	0.42	9.03	0.39	4.78e-18	Schizophrenia;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.94	0.35	1.56e-14	Schizophrenia;
LGG	trans	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg22358067	chr17:16797159	NA	-0.52	-7.35	-0.32	9.26e-13	Body mass index;
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg03517284	chr6:25882590	NA	-0.39	-6.96	-0.31	1.16e-11	Height;
LGG	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs1577917	0.771	rs4351223	chr6:86237797	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	17.03	0.62	7.73e-51	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg04851639	chr8:1020857	NA	-0.42	-8.72	-0.38	4.98e-17	Schizophrenia;
LGG	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-10.6	-0.44	1.23e-23	Hepatocellular carcinoma;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg27532560	chr4:187881888	NA	-0.59	-12.94	-0.52	6.31e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6578185	0.810	rs3935446	chr8:142452954	C/T	cg07762003	chr8:142452454	FLJ43860	-0.65	-13.49	-0.53	3.27e-35	Endometriosis;
LGG	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg07636037	chr3:49044803	WDR6	0.77	13.61	0.53	1e-35	Menarche (age at onset);
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg26513180	chr16:89883248	FANCA	0.88	8.59	0.37	1.3e-16	Skin colour saturation;
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.65	-0.33	1.2e-13	Tonsillectomy;
LGG	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg15454534	chr1:248569605	OR2T1	0.37	6.68	0.3	6.77e-11	Common traits (Other);
LGG	cis	rs3858526	0.959	rs10838901	chr11:5959128	G/A	cg13902645	chr11:5959945	NA	-0.76	-11.78	-0.48	3.26e-28	DNA methylation (variation);
LGG	cis	rs367943	0.698	rs7718310	chr5:112970628	A/G	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.17	-0.32	2.92e-12	Personality dimensions;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.04	-0.35	7.35e-15	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs12762955	0.561	rs6560863	chr10:1013535	C/A	cg25019033	chr10:957182	NA	0.33	6.93	0.31	1.39e-11	Response to angiotensin II receptor blocker therapy;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22365431	chr2:122125279	CLASP1	0.37	7.24	0.32	1.85e-12	Menarche (age at onset);
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs4774899	0.752	rs2962992	chr15:57346505	T/C	cg08128148	chr15:57256372	TCF12	-0.29	-7.08	-0.31	5.54e-12	Urinary tract infection frequency;
LGG	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg08344181	chr3:125677491	NA	-0.59	-6.89	-0.3	1.78e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.68	0.3	6.72e-11	Schizophrenia;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	13.79	0.54	1.71e-36	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7712401	0.601	rs13164134	chr5:122337941	T/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs17767392	0.918	rs61991202	chr14:71766675	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs11785400	1.000	rs3735994	chr8:143742683	C/T	cg24634471	chr8:143751801	JRK	0.54	8.62	0.37	1.04e-16	Schizophrenia;
LGG	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg18404041	chr3:52824283	ITIH1	-0.56	-9.99	-0.42	2.11e-21	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg04503457	chr17:41445688	NA	-0.41	-10.13	-0.43	6.71e-22	Menopause (age at onset);
LGG	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg12800244	chr3:153838788	SGEF	0.57	8.23	0.36	1.87e-15	Coronary artery disease;
LGG	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.9	0.31	1.7e-11	Acne (severe);
LGG	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg00376283	chr12:123451042	ABCB9	0.68	12.63	0.51	1.29e-31	Platelet count;
LGG	cis	rs651907	0.817	rs675779	chr3:101599019	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.35	6.71	0.3	5.53e-11	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02396668	chr19:50528878	VRK3;ZNF473	0.48	7.89	0.34	2.15e-14	Gut microbiome composition (summer);
LGG	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.59	-0.37	1.37e-16	Lung cancer;
LGG	cis	rs4865875	0.892	rs4242048	chr5:54130586	A/C	cg22421804	chr5:54100067	NA	0.5	7.35	0.32	9.26e-13	Sense of smell;
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.36	-0.32	8.68e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10779751	1.000	rs4845986	chr1:11288633	G/C	cg08854313	chr1:11322531	MTOR	0.73	16.07	0.6	1.7e-46	Body mass index;
LGG	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.99	0.35	1.07e-14	Mean platelet volume;
LGG	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10974632	chr14:51562381	TRIM9	0.4	7.2	0.32	2.52e-12	Obesity-related traits;
LGG	cis	rs2640806	0.505	rs11990371	chr8:97365928	A/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.27	0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs7635838	0.617	rs13071193	chr3:11284226	G/T	cg00170343	chr3:11313890	ATG7	-0.56	-9.78	-0.41	1.18e-20	HDL cholesterol;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg04267008	chr7:1944627	MAD1L1	0.65	10.87	0.45	1.13e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg11812906	chr14:75593930	NEK9	0.55	10.29	0.43	1.7e-22	Height;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg19524238	chr7:2802976	GNA12	0.32	7.79	0.34	4.29e-14	Height;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg08200770	chr17:80723486	TBCD	0.42	8.26	0.36	1.54e-15	Glycated hemoglobin levels;
LGG	cis	rs858239	0.601	rs2141307	chr7:23191424	G/C	cg23682824	chr7:23144976	KLHL7	0.42	7.01	0.31	8.54e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg01988459	chr11:68622903	NA	-0.64	-12.77	-0.51	3.37e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.66	0.37	8.06e-17	Platelet count;
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg05335186	chr13:53173507	NA	-0.41	-8.15	-0.35	3.5e-15	Lewy body disease;
LGG	cis	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg24110177	chr3:50126178	RBM5	-0.4	-6.83	-0.3	2.64e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00166722	chr3:10149974	C3orf24	0.51	8.8	0.38	2.65e-17	Alzheimer's disease;
LGG	cis	rs3816183	0.626	rs11679377	chr2:42910940	G/C	cg14631114	chr2:43023945	NA	0.35	7.05	0.31	6.63e-12	Hypospadias;
LGG	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs938554	0.744	rs7675964	chr4:9941434	C/T	cg25986240	chr4:9926439	SLC2A9	0.41	8.15	0.35	3.42e-15	Blood metabolite levels;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	19.57	0.67	1.37e-62	Platelet count;
LGG	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.72e-12	Bladder cancer;
LGG	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg09263875	chr16:632152	PIGQ	0.65	13.29	0.53	2.19e-34	Height;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg02625641	chr15:59041175	ADAM10	0.41	6.98	0.31	1.03e-11	Lung adenocarcinoma;
LGG	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14373873	chr11:113211441	TTC12	0.44	8.99	0.39	6.39e-18	Neuroticism;
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg22753661	chr15:79092743	ADAMTS7	0.41	6.94	0.31	1.36e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg23815491	chr16:72088622	HP	0.51	11.46	0.47	5.9e-27	Fibrinogen levels;
LGG	cis	rs763121	0.853	rs6001184	chr22:39052116	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs12908161	1.000	rs17601029	chr15:85347709	A/G	cg03959625	chr15:84868606	LOC388152	0.48	6.97	0.31	1.13e-11	Schizophrenia;
LGG	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg01028140	chr2:1542097	TPO	-0.54	-8.48	-0.37	3.03e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg26600954	chr7:23719792	C7orf46	0.32	6.72	0.3	5.32e-11	Schizophrenia;
LGG	trans	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.52	-0.37	2.28e-16	Neuroticism;
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg18225595	chr11:63971243	STIP1	0.56	7.58	0.33	1.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04330628	chr15:44116879	MFAP1	0.47	7.93	0.35	1.64e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7666738	0.570	rs10032272	chr4:99095601	T/C	cg05340658	chr4:99064831	C4orf37	0.42	6.83	0.3	2.64e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg02524346	chr8:600233	NA	1.14	11.37	0.47	1.33e-26	IgG glycosylation;
LGG	cis	rs7818345	0.569	rs4631483	chr8:19357923	G/C	cg06699216	chr8:19333253	CSGALNACT1	-0.41	-8.96	-0.38	8.2e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs644799	1.000	rs10831431	chr11:95510089	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.33	0.7	8.12e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs832540	0.806	rs10039322	chr5:56260259	A/C	cg14703610	chr5:56206110	C5orf35	0.42	7.2	0.32	2.46e-12	Coronary artery disease;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg21782813	chr7:2030301	MAD1L1	0.52	12.44	0.5	7.59e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9487094	0.689	rs11251	chr6:109689907	G/T	cg16315928	chr6:109776240	MICAL1	0.44	7.7	0.34	8.15e-14	Height;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg11584989	chr19:19387371	SF4	-0.4	-7.3	-0.32	1.28e-12	Tonsillectomy;
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06873352	chr17:61820015	STRADA	0.47	7.25	0.32	1.71e-12	Height;
LGG	cis	rs9807841	0.670	rs1982075	chr19:10787744	C/G	cg17710535	chr19:10819994	QTRT1	0.45	6.89	0.3	1.82e-11	Inflammatory skin disease;
LGG	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg18551225	chr6:44695536	NA	-0.56	-8.01	-0.35	9.37e-15	Total body bone mineral density;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg14338887	chr6:42928500	GNMT	0.27	8.65	0.37	8.31e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10728060	chr13:53029403	CKAP2	0.46	6.74	0.3	4.62e-11	Gut microbiome composition (summer);
LGG	cis	rs3126085	0.935	rs4845421	chr1:152173259	G/T	cg26876637	chr1:152193138	HRNR	0.54	8.75	0.38	3.88e-17	Atopic dermatitis;
LGG	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg02002194	chr4:3960332	NA	0.39	7.09	0.31	5.13e-12	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs929354	0.742	rs7801905	chr7:156940111	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.43	0.44	5.08e-23	Prudent dietary pattern;
LGG	cis	rs7586879	0.639	rs2384058	chr2:25100328	A/G	cg04586622	chr2:25135609	ADCY3	0.42	11.58	0.47	2.06e-27	Body mass index;
LGG	cis	rs2180341	0.924	rs877661	chr6:127587915	T/G	cg24812749	chr6:127587940	RNF146	0.95	15.85	0.59	1.69e-45	Breast cancer;
LGG	cis	rs9906944	0.678	rs56015440	chr17:47136631	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.96	-0.31	1.15e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6977660	0.714	rs10260866	chr7:19793151	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	8.64	0.37	9.35e-17	Thyroid stimulating hormone;
LGG	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	cg07928641	chr1:182991847	LAMC1	0.45	8.86	0.38	1.73e-17	Colorectal cancer;
LGG	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg27661571	chr11:113659931	NA	-0.69	-9.55	-0.41	7.33e-20	Hip circumference adjusted for BMI;
LGG	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg06970220	chr1:156163860	SLC25A44	0.44	6.64	0.3	8.61e-11	Testicular germ cell tumor;
LGG	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.92	-0.38	1.13e-17	Aortic root size;
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg16141378	chr3:129829833	LOC729375	0.35	7.59	0.33	1.82e-13	Neuroticism;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.14	0.58	2.26e-42	Platelet count;
LGG	trans	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg02800362	chr5:177631904	HNRNPAB	0.77	13.56	0.53	1.64e-35	Obesity-related traits;
LGG	cis	rs7715806	0.500	rs888788	chr5:74988336	C/T	cg19683494	chr5:74908142	NA	0.52	6.94	0.31	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.37	0.36	6.87e-16	Mood instability;
LGG	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg21452805	chr1:244014465	NA	0.93	10.39	0.43	7.42e-23	RR interval (heart rate);
LGG	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs10769945	0.605	rs656757	chr11:1966106	G/A	cg23202291	chr11:1979235	NA	0.37	7.13	0.31	3.9e-12	DNA methylation (variation);
LGG	trans	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg02002194	chr4:3960332	NA	0.42	7.54	0.33	2.51e-13	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25740925	chr13:95254690	GPR180	0.45	7.19	0.32	2.62e-12	Gut microbiome composition (summer);
LGG	cis	rs832540	0.629	rs10055224	chr5:56081201	C/T	cg12654349	chr5:56205094	C5orf35	0.38	6.83	0.3	2.69e-11	Coronary artery disease;
LGG	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg18654377	chr3:49208889	KLHDC8B	0.47	7.36	0.32	8.66e-13	Menarche (age at onset);
LGG	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg00666640	chr1:248458726	OR2T12	0.53	8.9	0.38	1.24e-17	Common traits (Other);
LGG	cis	rs240764	0.645	rs240111	chr6:101059499	C/A	cg09795085	chr6:101329169	ASCC3	0.43	7.25	0.32	1.75e-12	Neuroticism;
LGG	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.72	-0.3	5.42e-11	HDL cholesterol;
LGG	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg22681709	chr2:178499509	PDE11A	-0.44	-7.87	-0.34	2.61e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg20040747	chr15:74715105	SEMA7A	-0.36	-6.96	-0.31	1.2e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg15921436	chr17:44337874	NA	-0.54	-11.34	-0.47	1.85e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7149337	0.933	rs28705789	chr14:51713508	C/T	cg23942311	chr14:51606299	NA	0.34	7.5	0.33	3.34e-13	Cancer;
LGG	cis	rs10214930	0.602	rs2098315	chr7:27580645	T/A	cg22168087	chr7:27702803	HIBADH	0.47	7.02	0.31	7.83e-12	Hypospadias;
LGG	cis	rs4974559	0.947	rs28540746	chr4:1352954	G/A	cg02980000	chr4:1222292	CTBP1	0.65	7.9	0.34	2.1e-14	Systolic blood pressure;
LGG	cis	rs7129556	0.954	rs10899387	chr11:77276188	C/T	cg12586386	chr11:77299805	AQP11	0.51	8.5	0.37	2.57e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.01	-0.39	5.46e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9788682	0.747	rs2036533	chr15:78781687	G/A	cg06917634	chr15:78832804	PSMA4	-0.52	-7.92	-0.35	1.75e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7072216	0.727	rs3750603	chr10:100175536	A/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.12	-0.31	4.16e-12	Metabolite levels;
LGG	cis	rs6062788	0.524	rs6122362	chr20:61701245	C/T	cg04883260	chr20:61718941	NA	-0.42	-9.63	-0.41	4.04e-20	Body mass index;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.6	11.07	0.46	2.06e-25	Total body bone mineral density;
LGG	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.8	-0.34	4.22e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg06827562	chr3:125932279	NA	0.51	12.39	0.5	1.15e-30	Metabolite levels;
LGG	cis	rs11920090	0.858	rs61595505	chr3:170693472	C/T	cg09710316	chr3:170744871	SLC2A2	0.65	8.4	0.36	5.47e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg06521331	chr12:34319734	NA	-0.44	-7.7	-0.34	8.32e-14	Heart rate;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg05313129	chr8:58192883	C8orf71	-0.61	-8.57	-0.37	1.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg18876405	chr7:65276391	NA	-0.64	-12.07	-0.49	2.46e-29	Aortic root size;
LGG	cis	rs7250872	0.606	rs4453627	chr19:1829860	T/C	cg18850929	chr19:1828978	REXO1	0.49	8.09	0.35	5.47e-15	Bipolar disorder;
LGG	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg26769984	chr7:1090371	C7orf50	0.55	10.0	0.42	1.94e-21	Bronchopulmonary dysplasia;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.3	0.32	1.3e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg24253500	chr15:84953950	NA	0.57	10.12	0.43	6.84e-22	Bipolar disorder lithium response (categorical) or schizophrenia;
LGG	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg01960748	chr1:24522592	NA	-0.53	-7.98	-0.35	1.18e-14	Psoriasis vulgaris;
LGG	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg13683864	chr3:40499215	RPL14	0.83	17.23	0.63	9.22e-52	Renal cell carcinoma;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.31	-0.43	1.47e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg16141378	chr3:129829833	LOC729375	-0.45	-10.74	-0.45	3.41e-24	Parkinson's disease;
LGG	cis	rs9682041	1.000	rs6773095	chr3:170082181	A/G	cg11886554	chr3:170076028	SKIL	1.01	12.08	0.49	2.21e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs12476592	0.571	rs964903	chr2:63741548	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.96	-0.31	1.17e-11	Childhood ear infection;
LGG	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.46	-0.33	4.39e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.865	rs28753180	chr4:120405367	A/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs7666738	0.830	rs1593572	chr4:98979322	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-8.19	-0.36	2.49e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs992157	0.835	rs6707559	chr2:219142773	C/T	cg00012203	chr2:219082015	ARPC2	0.66	12.0	0.49	4.51e-29	Colorectal cancer;
LGG	cis	rs755249	0.567	rs3768302	chr1:39880319	T/G	cg18385671	chr1:39797026	MACF1	0.44	7.45	0.33	4.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10186029	0.680	rs10179508	chr2:213978526	C/T	cg08319019	chr2:214017104	IKZF2	-0.47	-8.15	-0.35	3.32e-15	Systemic sclerosis;
LGG	cis	rs1348850	0.632	rs1358328	chr2:178517532	G/A	cg05169160	chr2:178484487	TTC30A	0.35	7.04	0.31	6.81e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg21427119	chr20:30132790	HM13	-0.41	-7.12	-0.31	4.21e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7215564	1.000	rs7215564	chr17:78737287	A/G	cg16980736	chr17:78789706	RPTOR	-0.59	-7.83	-0.34	3.3e-14	Myopia (pathological);
LGG	cis	rs11074306	0.561	rs4580105	chr15:28070441	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	13.33	0.53	1.57e-34	Cognitive test performance;
LGG	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14952266	chr13:112191215	NA	-0.42	-7.68	-0.34	9.8e-14	Menarche (age at onset);
LGG	cis	rs546131	0.928	rs535719	chr11:34853382	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.59	10.7	0.45	4.82e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs9951602	0.512	rs1599636	chr18:76643916	G/A	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg16590910	chr6:42928470	GNMT	0.42	11.75	0.48	4.58e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg13009111	chr11:71350975	NA	-0.31	-6.84	-0.3	2.46e-11	Systolic blood pressure;
LGG	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg13647721	chr17:30228624	UTP6	-0.73	-9.34	-0.4	4.21e-19	Hip circumference adjusted for BMI;
LGG	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg17470449	chr10:769945	NA	0.62	7.68	0.34	9.77e-14	Uric acid levels;
LGG	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg06238570	chr21:40685208	BRWD1	-0.5	-8.15	-0.35	3.53e-15	Cognitive function;
LGG	cis	rs5758511	0.689	rs55906806	chr22:42644471	C/T	cg15128208	chr22:42549153	NA	0.79	11.12	0.46	1.25e-25	Birth weight;
LGG	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs477895	0.653	rs66648159	chr11:63899429	G/A	cg04317338	chr11:64019027	PLCB3	0.66	8.2	0.36	2.33e-15	Mean platelet volume;
LGG	cis	rs7980799	0.716	rs1601008	chr12:33611352	A/G	cg06521331	chr12:34319734	NA	0.4	6.8	0.3	3.32e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg01673284	chr16:4527211	HMOX2	0.33	6.89	0.3	1.82e-11	Schizophrenia;
LGG	cis	rs11744848	0.775	rs13156567	chr5:57122376	A/G	cg08523694	chr5:57076192	NA	-0.51	-6.84	-0.3	2.58e-11	Longitudinal change in brain amyloid plaque burden;
LGG	cis	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.61	-0.33	1.51e-13	Restless legs syndrome;
LGG	cis	rs9534338	0.520	rs7317686	chr13:46715616	T/A	cg11274337	chr13:46717068	LCP1	-0.36	-8.26	-0.36	1.54e-15	Blood protein levels;
LGG	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg18937875	chr11:14930189	NA	-0.47	-7.65	-0.34	1.16e-13	Vitamin D levels;
LGG	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs73086581	0.838	rs41398349	chr20:4024439	C/T	cg02187196	chr20:3869020	PANK2	-0.65	-9.26	-0.4	7.61e-19	Response to antidepressants in depression;
LGG	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg01324343	chr3:183735012	ABCC5	0.85	18.03	0.64	1.9e-55	Anterior chamber depth;
LGG	cis	rs943466	0.513	rs755497	chr6:33734419	C/T	cg25922239	chr6:33757077	LEMD2	-0.45	-7.7	-0.34	8.1e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	cis	rs9880211	0.800	rs28390205	chr3:136364850	C/G	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs7635838	0.650	rs1375206	chr3:11339117	C/G	cg00170343	chr3:11313890	ATG7	0.49	8.49	0.37	2.73e-16	HDL cholesterol;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.52	0.63	4.35e-53	Platelet count;
LGG	cis	rs2806561	0.929	rs627304	chr1:23537555	A/G	cg19743168	chr1:23544995	NA	0.39	8.5	0.37	2.7e-16	Height;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.44	-0.37	4.17e-16	Lung cancer;
LGG	cis	rs12586317	0.620	rs2295104	chr14:35579927	A/G	cg16230307	chr14:35515116	FAM177A1	-0.87	-12.56	-0.5	2.52e-31	Psoriasis;
LGG	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.32	0.47	2.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg07659893	chr17:61819838	STRADA	0.46	7.74	0.34	6.19e-14	Prudent dietary pattern;
LGG	cis	rs7945718	0.621	rs6485978	chr11:12678415	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.57e-12	Educational attainment (years of education);
LGG	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.02	-0.31	7.88e-12	Joint mobility (Beighton score);
LGG	cis	rs2415984	0.622	rs8022305	chr14:46946545	C/T	cg14871534	chr14:47121158	RPL10L	-0.59	-10.32	-0.43	1.29e-22	Number of children ever born;
LGG	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-14.73	-0.56	1.49e-40	Colorectal cancer;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg26174226	chr8:58114915	NA	-0.51	-7.4	-0.33	6.52e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg07549590	chr16:15018862	NA	-0.43	-7.79	-0.34	4.42e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg10756647	chr7:56101905	PSPH	0.46	6.97	0.31	1.12e-11	Corneal structure;
LGG	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg16512390	chr1:228756714	NA	0.51	7.26	0.32	1.69e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7666738	0.830	rs7679961	chr4:99000202	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg20290983	chr6:43655470	MRPS18A	-1.12	-24.45	-0.75	2.29e-85	IgG glycosylation;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24108215	chr1:39174820	NA	0.36	6.77	0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.38	-0.32	7.31e-13	Testicular germ cell tumor;
LGG	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg20003494	chr4:90757398	SNCA	0.34	6.7	0.3	6.21e-11	Dementia with Lewy bodies;
LGG	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg05555928	chr11:63887634	MACROD1	0.59	11.45	0.47	6.57e-27	Platelet count;
LGG	cis	rs13082711	0.522	rs3103745	chr3:27342927	T/C	cg02860705	chr3:27208620	NA	0.59	11.27	0.46	3.45e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	7.88	0.34	2.41e-14	Mood instability;
LGG	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg14926445	chr8:58193284	C8orf71	-0.68	-9.0	-0.39	6.01e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7103648	0.630	rs7120548	chr11:47662932	A/G	cg20307385	chr11:47447363	PSMC3	0.87	18.91	0.66	1.68e-59	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9534288	0.763	rs7989605	chr13:46534036	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-12.86	-0.51	1.37e-32	Blood protein levels;
LGG	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg20040747	chr15:74715105	SEMA7A	0.38	7.37	0.32	7.93e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs1451375	0.583	rs7776816	chr7:50583534	G/A	cg20336341	chr7:50628841	DDC	0.43	7.55	0.33	2.31e-13	Malaria;
LGG	cis	rs4363385	0.719	rs6664823	chr1:152933424	A/C	cg07796016	chr1:152779584	LCE1C	-0.47	-7.56	-0.33	2.12e-13	Inflammatory skin disease;
LGG	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.55	-0.69	3.54e-67	Gout;
LGG	cis	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg12463550	chr7:65579703	CRCP	0.77	8.29	0.36	1.27e-15	Diabetic kidney disease;
LGG	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.09e-25	Corneal astigmatism;
LGG	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg08733933	chr1:2954429	NA	0.42	7.9	0.34	2.03e-14	Plateletcrit;
LGG	cis	rs854765	0.583	rs67253360	chr17:17828973	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs240764	0.853	rs17303769	chr6:100967531	G/A	cg21058520	chr6:100914733	NA	0.42	7.28	0.32	1.47e-12	Neuroticism;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03506944	chr4:154074021	TRIM2	-0.42	-6.95	-0.31	1.27e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs526231	0.511	rs6881612	chr5:102377013	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg12395012	chr8:11607386	GATA4	-0.36	-6.65	-0.3	8.22e-11	Neuroticism;
LGG	trans	rs6787172	0.622	rs4680430	chr3:158089089	C/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg02158880	chr13:53174818	NA	-0.5	-10.25	-0.43	2.33e-22	Lewy body disease;
LGG	cis	rs4740619	0.716	rs12378499	chr9:15779259	G/C	cg14451791	chr9:16040625	NA	0.33	8.42	0.36	4.59e-16	Body mass index;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg16141378	chr3:129829833	LOC729375	0.43	9.93	0.42	3.45e-21	Retinal vascular caliber;
LGG	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.18	0.32	2.72e-12	Neuroticism;
LGG	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.33	0.69	4.05e-66	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23649161	chr17:41132662	AARSD1;RUNDC1	0.44	6.91	0.31	1.64e-11	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.857	rs11665258	chr18:34508112	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.4	0.33	6.65e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.2	-0.46	6.28e-26	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2186369	0.681	rs5760020	chr22:24133092	G/A	cg10122452	chr22:24128767	SMARCB1	-0.4	-7.94	-0.35	1.52e-14	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs7975161	0.640	rs10778323	chr12:104746075	A/G	cg25273343	chr12:104657179	TXNRD1	0.75	9.87	0.42	5.64e-21	Toenail selenium levels;
LGG	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg24642439	chr20:33292090	TP53INP2	-0.72	-12.66	-0.51	9.05e-32	Coronary artery disease;
LGG	cis	rs3785574	1.000	rs2955245	chr17:61979845	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.57	-8.91	-0.38	1.15e-17	Height;
LGG	trans	rs12517041	1.000	rs10064195	chr5:23278179	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.87	-0.45	1.18e-24	Calcium levels;
LGG	cis	rs7572263	0.959	rs12995271	chr2:209048136	T/C	cg00164906	chr2:209055251	C2orf80	0.53	8.67	0.37	7.51e-17	Glioma;Non-glioblastoma glioma;
LGG	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11890956	chr21:40555474	PSMG1	1.18	28.65	0.8	1.29e-104	Cognitive function;
LGG	cis	rs3796352	1.000	rs11712653	chr3:53070875	A/C	cg12962167	chr3:53033115	SFMBT1	-0.69	-7.33	-0.32	1.04e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg15208524	chr1:10270712	KIF1B	0.43	7.56	0.33	2.25e-13	Hepatocellular carcinoma;
LGG	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.18	-0.39	1.46e-18	Morning vs. evening chronotype;
LGG	cis	rs1144	0.537	rs2430486	chr7:104584410	C/T	cg03782966	chr7:104585482	NA	0.35	7.98	0.35	1.16e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	trans	rs3857536	0.813	rs4710581	chr6:66939954	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg14835575	chr10:16859367	RSU1	0.78	14.47	0.56	2.13e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg09021430	chr5:549028	NA	-0.69	-9.54	-0.41	8.35e-20	Obesity-related traits;
LGG	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg15704280	chr7:45808275	SEPT13	0.9	18.58	0.65	5.26e-58	Coronary artery disease;
LGG	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg25287198	chr4:183728479	NA	0.48	8.07	0.35	6.23e-15	Pediatric autoimmune diseases;
LGG	cis	rs2188561	0.708	rs9718496	chr7:107370632	G/A	cg16793755	chr7:107334138	SLC26A4	0.42	7.4	0.33	6.57e-13	Alcohol consumption;
LGG	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg10911889	chr6:126070802	HEY2	0.45	7.61	0.33	1.59e-13	Brugada syndrome;
LGG	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg19717773	chr7:2847554	GNA12	0.41	8.31	0.36	1.06e-15	Loneliness (linear analysis);
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs11677416	1.000	rs4848304	chr2:113552737	T/C	cg27083787	chr2:113543245	IL1A	0.53	8.86	0.38	1.7e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg18099408	chr3:52552593	STAB1	-0.35	-7.16	-0.32	3.2e-12	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.82	0.34	3.54e-14	Lung cancer;
LGG	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs2404602	0.647	rs907593	chr15:77196953	G/A	cg15268244	chr15:77196840	NA	0.48	9.92	0.42	3.61e-21	Blood metabolite levels;
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.82	-0.48	2.29e-28	Tonsillectomy;
LGG	cis	rs10504073	0.669	rs341801	chr8:50037784	A/G	cg00325661	chr8:49890786	NA	0.68	13.29	0.53	2.28e-34	Blood metabolite ratios;
LGG	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg00666640	chr1:248458726	OR2T12	0.54	9.14	0.39	2.01e-18	Common traits (Other);
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.33	0.55	8.45e-39	Obesity-related traits;
LGG	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg15704280	chr7:45808275	SEPT13	0.85	13.48	0.53	3.6e-35	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.52	-0.33	2.9e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.17	-0.39	1.54e-18	Aortic root size;
LGG	cis	rs975722	0.663	rs2078967	chr7:117088819	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.04	-0.39	4.14e-18	Coronary artery disease;
LGG	cis	rs7737355	0.681	rs11242094	chr5:131072622	A/G	cg06307176	chr5:131281290	NA	0.52	8.55	0.37	1.8e-16	Life satisfaction;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-13.94	-0.54	3.85e-37	Alzheimer's disease;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.33e-20	Life satisfaction;
LGG	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	2e-82	Dental caries;
LGG	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.59	-8.08	-0.35	5.56e-15	Diabetic retinopathy;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.45	-0.53	4.75e-35	Longevity;Endometriosis;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg11608241	chr8:8085544	FLJ10661	0.32	7.44	0.33	4.89e-13	Neuroticism;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.68e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9658691	0.607	rs3740281	chr10:90772150	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-8.98	-0.39	6.75e-18	Mosquito bite size;
LGG	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.02	0.52	3.15e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4148087	0.860	rs9976024	chr21:43641657	A/G	cg08841829	chr21:43638893	ABCG1	0.63	9.28	0.4	6.58e-19	Eating disorder in bipolar disorder;
LGG	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg03929089	chr4:120376271	NA	-0.68	-9.88	-0.42	5.31e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4900538	0.821	rs8016191	chr14:102825340	G/A	cg18135206	chr14:102964638	TECPR2	-0.7	-12.62	-0.51	1.39e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs836589	0.506	rs10188540	chr2:173569704	C/T	cg06468108	chr2:173539091	NA	-0.47	-6.79	-0.3	3.44e-11	Erectile dysfunction in type 1 diabetes;
LGG	cis	rs6740322	0.748	rs6756625	chr2:43489313	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.67	10.63	0.44	9.39e-24	Coronary artery disease;
LGG	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.89	-0.3	1.83e-11	HDL cholesterol;
LGG	cis	rs7937682	0.564	rs7115263	chr11:111379054	C/A	cg09085632	chr11:111637200	PPP2R1B	0.66	11.18	0.46	7.29e-26	Primary sclerosing cholangitis;
LGG	cis	rs12431410	0.550	rs10131474	chr14:60179275	A/G	cg07950296	chr14:60194823	RTN1	-0.37	-7.2	-0.32	2.46e-12	Schizophrenia;
LGG	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg24375607	chr4:120327624	NA	0.66	10.55	0.44	1.8e-23	Corneal astigmatism;
LGG	cis	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.37e-15	Obesity-related traits;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07677032	chr17:61819896	STRADA	0.66	12.04	0.49	3.22e-29	Prudent dietary pattern;
LGG	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	trans	rs6787172	0.622	rs11706187	chr3:158093173	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg14926445	chr8:58193284	C8orf71	-0.78	-9.6	-0.41	5.15e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs8067287	0.688	rs11651187	chr17:16845402	T/A	cg26910001	chr17:16838321	NA	-0.4	-7.95	-0.35	1.43e-14	Diabetic kidney disease;
LGG	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg05784532	chr1:230284198	GALNT2	0.56	9.11	0.39	2.4e-18	Coronary artery disease;
LGG	cis	rs870825	0.616	rs28524599	chr4:185647414	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9341808	0.718	rs3805920	chr6:80892745	T/C	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.89e-14	Sitting height ratio;
LGG	cis	rs4750440	0.706	rs10906555	chr10:14016879	G/A	cg27542038	chr10:14027202	FRMD4A	-0.66	-12.62	-0.51	1.44e-31	Adiponectin levels;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg11764359	chr7:65958608	NA	-0.73	-13.0	-0.52	3.67e-33	Aortic root size;
LGG	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg15485101	chr11:133734466	NA	0.6	10.55	0.44	1.83e-23	Childhood ear infection;
LGG	cis	rs6076065	0.707	rs2424555	chr20:23417705	A/G	cg11657817	chr20:23433608	CST11	0.43	8.55	0.37	1.81e-16	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.89	0.31	1.77e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4517514	0.509	rs4385851	chr11:89870750	C/T	cg14505434	chr11:89522851	NA	0.64	8.07	0.35	6.3e-15	Trans fatty acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05012946	chr17:35305634	AATF	0.44	6.78	0.3	3.66e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08280861	chr8:58055591	NA	0.64	7.76	0.34	5.58e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg16606324	chr3:10149918	C3orf24	0.62	6.78	0.3	3.78e-11	Alzheimer's disease;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07362569	chr17:61921086	SMARCD2	-0.51	-9.89	-0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs6565180	0.791	rs4247355	chr16:30392099	A/G	cg17640201	chr16:30407289	ZNF48	0.85	16.38	0.61	6.57e-48	Tonsillectomy;
LGG	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.75e-31	Motion sickness;
LGG	cis	rs1595825	0.891	rs1968488	chr2:198721827	C/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.58e-11	Ulcerative colitis;
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	cis	rs11633958	1	rs11633958	chr15:78862064	C/T	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.63	-0.33	1.36e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.85	0.3	2.33e-11	Schizophrenia;
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg15537850	chr8:144661051	NAPRT1	0.95	7.45	0.33	4.63e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2239547	0.522	rs9311485	chr3:52987645	T/G	cg11645453	chr3:52864694	ITIH4	-0.66	-10.42	-0.44	5.36e-23	Schizophrenia;
LGG	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg25427524	chr10:38739819	LOC399744	0.5	7.39	0.32	6.99e-13	Obesity (extreme);
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.52	-8.41	-0.36	5.14e-16	Iron status biomarkers;
LGG	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15532942	chr18:77220712	NFATC1	0.43	6.88	0.3	1.94e-11	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg02002194	chr4:3960332	NA	0.44	7.99	0.35	1.09e-14	Retinal vascular caliber;
LGG	cis	rs372883	0.869	rs2027605	chr21:30726773	A/G	cg24692254	chr21:30365293	RNF160	0.44	7.92	0.35	1.77e-14	Pancreatic cancer;
LGG	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.7	-0.59	8.05e-45	Intelligence (multi-trait analysis);
LGG	cis	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg09307838	chr4:120376055	NA	-0.47	-7.7	-0.34	8.26e-14	Diastolic blood pressure;
LGG	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg00795024	chr1:214157026	NA	-0.3	-8.69	-0.37	6.46e-17	Schizophrenia;
LGG	cis	rs941873	0.900	rs4979862	chr10:81131599	G/A	cg09469691	chr10:81107165	PPIF	0.62	10.76	0.45	3.06e-24	Height;
LGG	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.69	-0.34	8.77e-14	Menarche (age at onset);
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.54	-0.41	8.53e-20	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.34	-0.32	9.49e-13	Hemoglobin concentration;
LGG	cis	rs477895	0.838	rs2070765	chr11:64010085	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.55	0.44	1.79e-23	Mean platelet volume;
LGG	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg12179176	chr11:130786555	SNX19	0.84	17.41	0.63	1.42e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9359856	0.510	rs2768936	chr6:90441851	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-12.93	-0.52	7.21e-33	Bipolar disorder;
LGG	trans	rs67340775	0.541	rs200968	chr6:27859568	T/C	cg01620082	chr3:125678407	NA	-0.66	-8.3	-0.36	1.19e-15	Lung cancer in ever smokers;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg16344026	chr5:149109979	PPARGC1B	0.48	6.76	0.3	4.27e-11	Breast cancer;
LGG	cis	rs6546550	0.835	rs3752781	chr2:70124316	T/A	cg02498382	chr2:70120550	SNRNP27	-0.44	-8.15	-0.35	3.46e-15	Prevalent atrial fibrillation;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	cis	rs9463078	0.838	rs1924662	chr6:45140332	T/A	cg25276700	chr6:44698697	NA	-0.39	-8.32	-0.36	1.01e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2289328	0.882	rs16970633	chr15:40642877	G/T	cg13931752	chr15:40660718	DISP2	0.33	6.71	0.3	5.73e-11	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg14926445	chr8:58193284	C8orf71	-0.79	-9.68	-0.41	2.54e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.13	-0.31	3.78e-12	Inflammatory bowel disease;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg26513180	chr16:89883248	FANCA	1.02	9.63	0.41	4.12e-20	Skin colour saturation;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg15948088	chr11:109293068	C11orf87	-0.82	-15.69	-0.59	8.64e-45	Schizophrenia;
LGG	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.5e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6424115	0.867	rs11588187	chr1:24145047	T/A	cg15997130	chr1:24165203	NA	0.47	12.87	0.51	1.33e-32	Immature fraction of reticulocytes;
LGG	cis	rs876084	0.505	rs4336644	chr8:121136128	G/C	cg06265175	chr8:121136014	COL14A1	0.46	9.25	0.39	8.56e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.69	-0.34	8.86e-14	Testicular germ cell tumor;
LGG	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.88	-0.42	5.31e-21	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1459104	0.789	rs12802739	chr11:54899892	A/G	cg03929089	chr4:120376271	NA	0.71	6.96	0.31	1.16e-11	Body mass index;
LGG	cis	rs4740619	0.967	rs10962110	chr9:15658794	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.16	-0.43	4.9e-22	Body mass index;
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg02725872	chr8:58115012	NA	-0.78	-11.25	-0.46	4.13e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs12474201	0.569	rs13411633	chr2:46932666	A/G	cg06386533	chr2:46925753	SOCS5	0.59	10.39	0.43	7.3e-23	Height;
LGG	cis	rs3849046	0.746	rs1811371	chr5:137936905	G/T	cg10920316	chr5:137946599	NA	-0.46	-7.28	-0.32	1.42e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg01657329	chr11:68192670	LRP5	0.6	10.59	0.44	1.29e-23	Bone mineral density (spine);
LGG	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg22232500	chr2:134024266	NCKAP5	0.55	7.8	0.34	4.22e-14	Bipolar disorder;
LGG	cis	rs7084402	0.967	rs11006170	chr10:60276369	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg03264133	chr6:25882463	NA	-0.39	-6.78	-0.3	3.68e-11	Height;
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.46	-0.37	3.65e-16	Aortic root size;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg19168338	chr16:4465731	CORO7	-0.73	-13.51	-0.53	2.6e-35	Schizophrenia;
LGG	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg11822372	chr1:151115635	SEMA6C	0.49	8.76	0.38	3.82e-17	Childhood ear infection;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg22535103	chr8:58192502	C8orf71	-0.93	-13.15	-0.52	8.7e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg26384229	chr12:38710491	ALG10B	1.01	25.61	0.77	9.69e-91	Heart rate;
LGG	trans	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	cis	rs1007190	0.764	rs758020	chr17:42872579	C/A	cg15406952	chr17:42872593	NA	-1.23	-15.78	-0.59	3.4e-45	DNA methylation (variation);
LGG	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.46	8.14	0.35	3.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02598978	chr16:20817844	LOC81691;ERI2	0.41	7.21	0.32	2.36e-12	Bipolar disorder;
LGG	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	13.88	0.54	7.08e-37	HIV-1 control;
LGG	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg00204512	chr16:28754710	NA	0.25	7.24	0.32	1.88e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10214930	0.697	rs6462026	chr7:27562368	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.7	0.3	6.14e-11	Hypospadias;
LGG	cis	rs151234	0.741	rs151230	chr16:28583215	G/A	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.94	-0.42	3.01e-21	Platelet distribution width;
LGG	cis	rs7191700	0.673	rs12325495	chr16:11418328	C/T	cg00044050	chr16:11439710	C16orf75	0.64	11.19	0.46	7.14e-26	Multiple sclerosis;
LGG	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg00599393	chr8:22457479	C8orf58	0.39	6.9	0.31	1.68e-11	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2074585	0.708	rs2589939	chr15:90930875	C/T	cg22089800	chr15:90895588	ZNF774	0.71	13.2	0.52	5.66e-34	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	7.78	0.34	4.9e-14	Bone mineral density;
LGG	cis	rs2486288	0.656	rs2413768	chr15:45561984	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.42	-0.44	5.6e-23	Glomerular filtration rate;
LGG	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg06532163	chr17:45867833	NA	0.54	9.13	0.39	2.19e-18	IgG glycosylation;
LGG	cis	rs4727443	0.736	rs4727444	chr7:99614851	T/A	cg12813108	chr7:99719912	CNPY4	-0.58	-11.22	-0.46	5.25e-26	Interstitial lung disease;
LGG	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg02463440	chr8:22132932	PIWIL2	0.49	10.96	0.45	5.41e-25	Hypertriglyceridemia;
LGG	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-6.9	-0.31	1.77e-11	Common traits (Other);
LGG	cis	rs10851411	0.697	rs62019315	chr15:42863542	G/C	cg21293051	chr15:42870591	STARD9	0.5	7.19	0.32	2.67e-12	Glucose homeostasis traits;
LGG	cis	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg04455712	chr21:45112962	RRP1B	0.55	10.08	0.42	9.43e-22	Mean corpuscular volume;
LGG	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	5.15e-19	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	cis	rs734999	0.588	rs2843403	chr1:2529097	T/C	cg20673091	chr1:2541236	MMEL1	-0.77	-18.8	-0.66	5.14e-59	Ulcerative colitis;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00684032	chr4:1343700	KIAA1530	0.44	8.49	0.37	2.79e-16	Obesity-related traits;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg23978390	chr7:1156363	C7orf50	0.44	6.66	0.3	7.7e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	22.53	0.72	2.04e-76	Homoarginine levels;
LGG	trans	rs9354308	0.764	rs9351529	chr6:66589556	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.62	-11.92	-0.48	9.73e-29	Obesity-related traits;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs477692	0.905	rs4751106	chr10:131424653	G/T	cg05714579	chr10:131428358	MGMT	-0.67	-14.21	-0.55	2.66e-38	Response to temozolomide;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg24642844	chr7:1081250	C7orf50	-0.71	-9.1	-0.39	2.63e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.02	0.64	2.26e-55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	3.07e-48	Diabetic retinopathy;
LGG	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg21775007	chr8:11205619	TDH	-0.44	-7.21	-0.32	2.25e-12	Systolic blood pressure;
LGG	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg03959625	chr15:84868606	LOC388152	0.56	8.86	0.38	1.72e-17	Schizophrenia;
LGG	trans	rs7916697	0.520	rs10762201	chr10:70040111	A/G	cg04882175	chr6:131122610	NA	0.47	7.09	0.31	4.89e-12	Optic disc area;
LGG	cis	rs1729951	0.575	rs12494558	chr3:136678781	C/G	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	6.24e-21	Neuroticism;
LGG	cis	rs17052344	0.543	rs2342183	chr17:21738349	G/T	cg18423549	chr17:21743878	NA	-0.53	-8.22	-0.36	2.08e-15	Cutaneous psoriasis;
LGG	trans	rs9650657	0.648	rs7833945	chr8:10700266	T/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.21	-0.32	2.27e-12	Neuroticism;
LGG	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.4	-0.36	5.65e-16	Neuroticism;
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg07005078	chr4:17578674	LAP3	0.39	7.12	0.31	4.18e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs77633900	0.614	rs280033	chr15:77023099	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-10.48	-0.44	3.41e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg05775895	chr3:12838266	CAND2	0.57	9.26	0.4	7.57e-19	QRS complex (12-leadsum);
LGG	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.56	0.33	2.23e-13	Electroencephalogram traits;
LGG	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.53	-0.33	2.65e-13	Testicular germ cell tumor;
LGG	cis	rs9905704	0.647	rs6503888	chr17:57028126	T/C	cg12560992	chr17:57184187	TRIM37	0.53	8.54	0.37	1.94e-16	Testicular germ cell tumor;
LGG	cis	rs7503807	0.515	rs1485330	chr17:78640822	G/A	cg22878693	chr17:78755604	RPTOR	-0.56	-9.14	-0.39	2.05e-18	Obesity;
LGG	cis	rs2274273	0.840	rs66486619	chr14:55869555	T/G	cg04306507	chr14:55594613	LGALS3	0.62	17.12	0.62	2.85e-51	Protein biomarker;
LGG	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg08000102	chr2:233561755	GIGYF2	-0.55	-8.94	-0.38	9.55e-18	Coronary artery disease;
LGG	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	3.12e-11	Iron status biomarkers;
LGG	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg00717180	chr2:96193071	NA	-0.46	-8.31	-0.36	1.05e-15	HDL cholesterol;
LGG	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.69	-0.56	2.17e-40	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg09264619	chr17:80180166	NA	-0.39	-7.81	-0.34	3.74e-14	Life satisfaction;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg26513180	chr16:89883248	FANCA	0.83	8.66	0.37	8.16e-17	Skin colour saturation;
LGG	cis	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.03e-25	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13961709	chr14:74486189	C14orf45;ENTPD5	0.42	6.75	0.3	4.36e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs870825	0.616	rs2696037	chr4:185610940	C/T	cg04058563	chr4:185651563	MLF1IP	-1.01	-20.56	-0.69	3.09e-67	Blood protein levels;
LGG	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	11.54	0.47	3e-27	Post bronchodilator FEV1;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07791516	chr6:150247246	NA	0.31	6.67	0.3	7.41e-11	Testicular germ cell tumor;
LGG	cis	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg02972257	chr16:68554789	NA	-0.55	-8.29	-0.36	1.22e-15	Ulcerative colitis;
LGG	trans	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	cis	rs2235573	0.527	rs139878	chr22:38361559	C/T	cg19171272	chr22:38449367	NA	-0.49	-8.8	-0.38	2.72e-17	Glioblastoma;Glioma;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg05064044	chr6:292385	DUSP22	-0.47	-8.09	-0.35	5.23e-15	Menopause (age at onset);
LGG	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg14019146	chr3:50243930	SLC38A3	-0.49	-9.76	-0.41	1.33e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7586879	0.765	rs6545758	chr2:25074874	C/T	cg04586622	chr2:25135609	ADCY3	-0.36	-8.55	-0.37	1.78e-16	Body mass index;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs977987	0.806	rs1030262	chr16:75491327	C/A	cg07303275	chr16:75499416	TMEM170A	0.38	6.81	0.3	2.99e-11	Dupuytren's disease;
LGG	trans	rs6787172	0.702	rs827099	chr3:157996767	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs10744422	1.000	rs937766	chr12:123331094	G/T	cg25930673	chr12:123319894	HIP1R	-0.77	-9.86	-0.42	5.83e-21	Schizophrenia;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg17376030	chr22:41985996	PMM1	-0.55	-8.9	-0.38	1.27e-17	Vitiligo;
LGG	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg13560919	chr6:33536144	NA	-0.42	-7.77	-0.34	5.19e-14	Crohn's disease;
LGG	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg26441486	chr22:50317300	CRELD2	-0.4	-7.52	-0.33	2.92e-13	Schizophrenia;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg06873352	chr17:61820015	STRADA	-0.58	-9.94	-0.42	3.05e-21	Prudent dietary pattern;
LGG	cis	rs10465746	0.780	rs12139191	chr1:84387871	A/C	cg10977910	chr1:84465055	TTLL7	0.58	10.71	0.45	4.8e-24	Obesity-related traits;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg26354017	chr1:205819088	PM20D1	0.99	27.59	0.79	7.95e-100	Menarche (age at onset);
LGG	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.25	0.36	1.66e-15	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.54	-7.22	-0.32	2.15e-12	Schizophrenia;
LGG	cis	rs4730250	0.707	rs6977868	chr7:106790555	T/G	cg02696742	chr7:106810147	HBP1	0.78	10.82	0.45	1.7e-24	Osteoarthritis;
LGG	cis	rs920590	0.679	rs58556504	chr8:19653674	A/G	cg03894339	chr8:19674705	INTS10	0.44	7.54	0.33	2.55e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg09263875	chr16:632152	PIGQ	0.67	13.47	0.53	3.85e-35	Height;
LGG	cis	rs4363385	0.720	rs11205150	chr1:152959266	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.08	-0.39	3.25e-18	Inflammatory skin disease;
LGG	cis	rs2816316	1.000	rs2816317	chr1:192536385	G/A	cg02586212	chr1:192544902	RGS1	0.46	9.21	0.39	1.15e-18	Celiac disease;
LGG	trans	rs62103177	0.568	rs2365388	chr18:77973702	G/T	cg05926928	chr17:57297772	GDPD1	0.88	10.46	0.44	3.9699999999999997e-23	Opioid sensitivity;
LGG	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg08508325	chr11:3079039	CARS	0.5	10.67	0.44	6.24e-24	Longevity;
LGG	cis	rs877282	0.838	rs11253374	chr10:774961	C/T	cg17470449	chr10:769945	NA	0.61	7.68	0.34	9.39e-14	Uric acid levels;
LGG	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg00919237	chr7:87102261	ABCB4	-0.8	-16.12	-0.6	1.05e-46	Gallbladder cancer;
LGG	cis	rs55871839	0.708	rs12114218	chr8:59817454	T/C	cg07426533	chr8:59803705	TOX	-0.55	-12.48	-0.5	5.03e-31	Pneumonia;
LGG	cis	rs6817170	0.692	rs1560941	chr4:154378744	A/G	cg07229402	chr4:154369277	NA	0.34	6.72	0.3	5.3e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs2599510	0.703	rs762023	chr2:32713170	G/A	cg02381751	chr2:32503542	YIPF4	0.5	8.16	0.35	3.13e-15	Interleukin-18 levels;
LGG	cis	rs10791097	0.667	rs2155358	chr11:130740357	T/C	cg12179176	chr11:130786555	SNX19	0.84	17.68	0.63	8.06e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26991296	chr17:20841833	NA	0.39	7.79	0.34	4.58e-14	Menarche (age at onset);
LGG	cis	rs8056893	0.744	rs2307022	chr16:68381978	A/G	cg07273125	chr16:68295692	NA	0.46	9.45	0.4	1.68e-19	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00290607	chr11:67383545	NA	0.66	12.79	0.51	2.63e-32	Mean corpuscular volume;
LGG	cis	rs6594499	0.843	rs1993465	chr5:110433098	A/G	cg04022379	chr5:110408740	TSLP	0.4	7.37	0.32	8.15e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg20587970	chr11:113659929	NA	-1.26	-21.75	-0.71	8.42e-73	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.43	-0.33	5.11e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg04469686	chr1:162760199	HSD17B7	0.4	6.65	0.3	8.09e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467160	0.871	rs9461014	chr6:24449008	T/G	cg20631270	chr6:24437470	GPLD1	0.51	7.64	0.33	1.26e-13	Liver enzyme levels;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05665937	chr4:1216051	CTBP1	0.4	6.96	0.31	1.15e-11	Longevity;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg04234412	chr22:24373322	LOC391322	-0.78	-16.08	-0.6	1.56e-46	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.59	-0.61	7.35e-49	Blood trace element (Zn levels);
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-15.26	-0.58	7.29e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg14926445	chr8:58193284	C8orf71	-0.68	-9.02	-0.39	4.92e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg19077165	chr18:44547161	KATNAL2	-0.53	-10.02	-0.42	1.66e-21	Personality dimensions;
LGG	cis	rs2470578	0.792	rs1449884	chr3:17256687	G/C	cg20981856	chr3:17787350	NA	0.35	6.64	0.3	8.55e-11	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21487830	chr17:48943706	NA	0.58	6.76	0.3	4.14e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg04362960	chr10:104952993	NT5C2	0.44	6.95	0.31	1.24e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9649465	1.000	rs1006764	chr7:123337873	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs6840360	0.615	rs4696097	chr4:152479765	C/T	cg25486957	chr4:152246857	NA	0.5	8.31	0.36	1.04e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.41	-0.36	5.03e-16	Retinal vascular caliber;
LGG	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	7.41	0.33	6.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3790455	0.610	rs746527	chr1:156460511	C/T	cg14087168	chr1:156450669	MEF2D	-0.67	-10.19	-0.43	3.81e-22	Migraine;
LGG	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg20790798	chr5:1857306	NA	-0.43	-7.06	-0.31	6.3e-12	Cardiovascular disease risk factors;
LGG	cis	rs2836950	0.565	rs2150414	chr21:40614988	A/G	cg11890956	chr21:40555474	PSMG1	-0.75	-13.26	-0.52	3.18e-34	Menarche (age at onset);
LGG	cis	rs758324	0.947	rs6886188	chr5:131178252	C/T	cg06307176	chr5:131281290	NA	0.57	9.37	0.4	3.21e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7444	0.660	rs11089637	chr22:21979096	A/G	cg11654148	chr22:21984483	YDJC	-0.37	-7.09	-0.31	5.11e-12	Systemic lupus erythematosus;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg13387826	chr1:2005260	PRKCZ	-0.25	-6.96	-0.31	1.17e-11	Lung adenocarcinoma;
LGG	trans	rs11650494	0.808	rs76366926	chr17:47396628	T/C	cg11430096	chr6:110968061	CDK19	0.68	7.1	0.31	4.76e-12	Prostate cancer;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.49	0.4	1.25e-19	Longevity;
LGG	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg08305652	chr11:111469057	NA	0.45	8.99	0.39	6.55e-18	Primary sclerosing cholangitis;
LGG	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.84	0.79	6.33e-101	Parkinson's disease;
LGG	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.29	-0.32	1.33e-12	Response to amphetamines;
LGG	cis	rs9381107	0.505	rs1001384	chr6:9485556	G/A	cg14735645	chr6:9486422	NA	-0.53	-10.2	-0.43	3.51e-22	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.8	-0.34	4.26e-14	Bipolar disorder;
LGG	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg12081754	chr8:22256438	SLC39A14	1.18	27.44	0.79	4.12e-99	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg14092988	chr3:52407081	DNAH1	0.31	7.94	0.35	1.56e-14	Bipolar disorder;
LGG	cis	rs4474465	0.920	rs10899526	chr11:78206157	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.33	0.36	9.54e-16	Alzheimer's disease (survival time);
LGG	cis	rs3770081	1.000	rs12328085	chr2:86262009	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.93	-0.31	1.38e-11	Facial emotion recognition (sad faces);
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg19143629	chr17:61920732	SMARCD2	-0.41	-6.91	-0.31	1.57e-11	Prudent dietary pattern;
LGG	cis	rs11191205	0.644	rs7874	chr10:103361088	C/T	cg15320455	chr10:103880129	LDB1	0.5	7.3	0.32	1.28e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg00173435	chr12:106696525	TCP11L2	0.66	10.06	0.42	1.2e-21	Tourette syndrome;
LGG	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg24308560	chr3:49941425	MST1R	0.22	6.87	0.3	2.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg00383909	chr3:49044727	WDR6	0.99	12.55	0.5	2.68e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg19635926	chr16:89946313	TCF25	0.76	7.28	0.32	1.4e-12	Skin colour saturation;
LGG	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.67	-0.44	6.34e-24	Primary sclerosing cholangitis;
LGG	cis	rs523522	0.571	rs11065120	chr12:120875456	C/T	cg27279351	chr12:120934652	DYNLL1	0.49	6.72	0.3	5.32e-11	High light scatter reticulocyte count;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.49	-0.4	1.23e-19	Lung cancer;
LGG	cis	rs7917772	0.539	rs12572775	chr10:104285594	A/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.56	-10.5	-0.44	2.86e-23	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10463554	0.963	rs62364875	chr5:102392190	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.64	-0.33	1.25e-13	Parkinson's disease;
LGG	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.82e-44	Colorectal cancer;
LGG	cis	rs7674212	0.541	rs4699051	chr4:104114394	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-7.27	-0.32	1.59e-12	Type 2 diabetes;
LGG	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.48	9.12	0.39	2.39e-18	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs2797160	1.000	rs61299898	chr6:126007651	G/C	cg05901451	chr6:126070800	HEY2	0.44	7.37	0.32	7.67e-13	Endometrial cancer;
LGG	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs9399135	0.636	rs4646871	chr6:135265617	A/G	cg24558204	chr6:135376177	HBS1L	-0.54	-9.5	-0.4	1.17e-19	Red blood cell count;
LGG	cis	rs432925	0.529	rs2885415	chr16:395396	A/G	cg12437481	chr16:420112	MRPL28	0.54	8.49	0.37	2.76e-16	Morning vs. evening chronotype;
LGG	cis	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg20368463	chr18:77673604	PQLC1	0.57	7.47	0.33	3.89e-13	Opioid sensitivity;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24018799	chr5:172744616	STC2	0.37	7.59	0.33	1.76e-13	Electrocardiographic conduction measures;
LGG	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	cis	rs9527	0.590	rs7898770	chr10:104756636	A/G	cg04362960	chr10:104952993	NT5C2	-0.56	-10.69	-0.44	5.62e-24	Arsenic metabolism;
LGG	cis	rs9875589	0.509	rs28865280	chr3:14064958	C/T	cg19554555	chr3:13937349	NA	-0.54	-9.9	-0.42	4.31e-21	Ovarian reserve;
LGG	cis	rs1816752	0.712	rs9507335	chr13:24983904	G/A	cg02811702	chr13:24901961	NA	0.4	7.34	0.32	9.63e-13	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.7	0.34	8.15e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9868809	0.542	rs9873726	chr3:48712367	C/T	cg00383909	chr3:49044727	WDR6	0.8	9.91	0.42	3.97e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg22676075	chr6:135203613	NA	0.42	7.2	0.32	2.42e-12	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg08305652	chr11:111469057	NA	0.42	8.5	0.37	2.56e-16	Primary sclerosing cholangitis;
LGG	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg13647721	chr17:30228624	UTP6	0.63	7.8	0.34	4.1e-14	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.29	0.55	1.21e-38	Obesity-related traits;
LGG	cis	rs6964587	0.934	rs12531561	chr7:91707780	A/G	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.13e-16	Breast cancer;
LGG	cis	rs9472414	0.510	rs227852	chr6:44699559	A/G	cg20913747	chr6:44695427	NA	-0.47	-7.87	-0.34	2.48e-14	Height;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg02002194	chr4:3960332	NA	0.42	7.63	0.33	1.34e-13	Triglycerides;
LGG	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg25173405	chr17:45401733	C17orf57	0.46	7.91	0.35	1.86e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.34	0.36	8.43e-16	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.6	0.37	1.28e-16	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17322444	chr19:33572249	GPATCH1	0.47	7.14	0.31	3.61e-12	Gut microbiome composition (summer);
LGG	cis	rs10751667	0.643	rs7395592	chr11:934094	C/G	cg22143635	chr11:980567	AP2A2	0.42	7.64	0.33	1.24e-13	Alzheimer's disease (late onset);
LGG	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg24692254	chr21:30365293	RNF160	-0.7	-13.1	-0.52	1.45e-33	Cognitive test performance;
LGG	trans	rs8073060	0.544	rs225283	chr17:33934912	A/G	cg19694781	chr19:47549865	TMEM160	-1.15	-17.47	-0.63	6.91e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg07777115	chr5:623756	CEP72	-0.61	-7.79	-0.34	4.41e-14	Obesity-related traits;
LGG	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.34	-0.43	1.11e-22	Bladder cancer;
LGG	cis	rs4430311	1.000	rs3008657	chr1:244023667	A/G	cg25706552	chr1:244017396	NA	0.63	15.98	0.6	4.35e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs61990749	0.597	rs176943	chr14:78175797	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.56	-7.0	-0.31	8.91e-12	Fibroblast growth factor basic levels;
LGG	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs4696584	0.877	rs4696582	chr4:155396138	C/T	cg04517429	chr4:155413618	DCHS2	0.29	6.84	0.3	2.48e-11	Folding of antihelix;
LGG	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-7.09	-0.31	5.2e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4819852	0.958	rs2240716	chr22:19969696	C/T	cg07821417	chr22:19972146	ARVCF	0.59	12.61	0.51	1.46e-31	Pulse pressure;
LGG	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg06636001	chr8:8085503	FLJ10661	0.53	9.74	0.41	1.6e-20	Triglycerides;
LGG	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg08048268	chr3:133502702	NA	-0.46	-7.94	-0.35	1.54e-14	Iron status biomarkers;
LGG	cis	rs11866815	0.744	rs60769452	chr16:379379	G/A	cg07915516	chr16:377344	AXIN1	-0.41	-9.58	-0.41	5.84e-20	Body mass index;
LGG	cis	rs4851266	0.898	rs12614880	chr2:100849341	A/G	cg21926883	chr2:100939477	LONRF2	-0.47	-8.38	-0.36	6.46e-16	Educational attainment;
LGG	cis	rs1568889	1.000	rs34337978	chr11:28136746	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	14.16	0.55	4.63e-38	Bipolar disorder;
LGG	cis	rs3735485	0.738	rs55928218	chr7:45090704	T/C	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg05535760	chr7:792225	HEATR2	0.77	12.4	0.5	1.14e-30	Cerebrospinal P-tau181p levels;
LGG	cis	rs3741798	1.000	rs61922025	chr12:12486263	G/A	cg08615371	chr12:12503544	MANSC1	0.6	6.86	0.3	2.28e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs2018683	0.899	rs10479816	chr7:28978021	G/A	cg19402173	chr7:128379420	CALU	-0.65	-11.77	-0.48	3.77e-28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg27523141	chr10:43048294	ZNF37B	0.43	8.45	0.37	3.87e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs3784262	1.000	rs11855259	chr15:58249377	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.16	-0.35	3.08e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs7980799	0.816	rs1343676	chr12:33537387	T/C	cg26384229	chr12:38710491	ALG10B	-0.46	-8.22	-0.36	2.09e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2456568	0.802	rs10765640	chr11:93636462	C/T	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.26	0.49	4.13e-30	Prudent dietary pattern;
LGG	cis	rs3820928	0.605	rs13410141	chr2:227805529	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-7.47	-0.33	3.91e-13	Pulmonary function;
LGG	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06481639	chr22:41940642	POLR3H	0.57	8.03	0.35	8.28e-15	Vitiligo;
LGG	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.75	-0.59	4.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs10089	0.953	rs1432614	chr5:127416919	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.57	0.47	2.2e-27	Ileal carcinoids;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg22552966	chr17:19620595	SLC47A2	-0.4	-8.29	-0.36	1.25e-15	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	13.38	0.53	9.74e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg10224037	chr5:178157518	ZNF354A	0.77	12.78	0.51	3.15e-32	Neutrophil percentage of white cells;
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.99	-0.52	4.02e-33	Alzheimer's disease;
LGG	cis	rs2573652	0.722	rs8034841	chr15:100541593	G/T	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.28	-0.32	1.4e-12	Height;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs7412746	0.658	rs4970982	chr1:150865084	G/C	cg15448220	chr1:150897856	SETDB1	0.4	7.28	0.32	1.4e-12	Melanoma;
LGG	cis	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg01579765	chr21:45077557	HSF2BP	0.36	8.31	0.36	1.07e-15	Mean corpuscular volume;
LGG	cis	rs4731207	0.698	rs4728012	chr7:124481798	C/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.2	0.49	6.93e-30	Hip circumference adjusted for BMI;
LGG	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg18446336	chr7:2847575	GNA12	-0.3	-7.11	-0.31	4.41e-12	Height;
LGG	cis	rs13053817	1.000	rs13057382	chr22:29850334	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.65	-0.3	8.1e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs4664308	0.870	rs2198918	chr2:161015052	C/T	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.92	-0.59	7.63e-46	Idiopathic membranous nephropathy;
LGG	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg16077055	chr2:106428750	NCK2	0.31	8.26	0.36	1.53e-15	Addiction;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10523193	chr11:93463762	SNORA25	0.37	7.05	0.31	6.54e-12	Gut microbiome composition (summer);
LGG	cis	rs722599	0.748	rs61978932	chr14:75342954	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-9.64	-0.41	3.6e-20	IgG glycosylation;
LGG	trans	rs2281558	0.583	rs11087526	chr20:25648016	A/T	cg25917747	chr17:21561886	NA	0.52	7.24	0.32	1.82e-12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LGG	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	13.6	0.53	1.07e-35	HIV-1 control;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs701145	0.640	rs896016	chr3:153929902	C/T	cg12800244	chr3:153838788	SGEF	0.8	8.17	0.36	2.92e-15	Coronary artery disease;
LGG	cis	rs2273669	0.667	rs12206423	chr6:109353216	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.53	-0.37	2.11e-16	Prostate cancer;
LGG	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg07636037	chr3:49044803	WDR6	0.89	17.44	0.63	1.03e-52	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs975722	0.663	rs6955320	chr7:117097327	C/A	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.25	-0.39	8.61e-19	Coronary artery disease;
LGG	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.35e-12	Mood instability;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7614311	0.594	rs3774709	chr3:63882476	A/G	cg22134162	chr3:63841271	THOC7	-0.39	-7.62	-0.33	1.44e-13	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg19774624	chr17:42201019	HDAC5	0.65	11.36	0.47	1.56e-26	Total body bone mineral density;
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.97	0.45	4.84e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.629	rs17637821	chr12:33701108	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.58	-0.37	1.4e-16	Morning vs. evening chronotype;
LGG	cis	rs9878978	0.722	rs11717960	chr3:2513867	C/A	cg21928760	chr3:2462534	CNTN4	0.35	6.86	0.3	2.27e-11	Blood pressure (smoking interaction);
LGG	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg26384229	chr12:38710491	ALG10B	0.92	21.43	0.71	2.71e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg08645402	chr16:4508243	NA	-0.38	-6.67	-0.3	7.45e-11	Schizophrenia;
LGG	cis	rs988958	0.565	rs11894536	chr2:42238134	T/A	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg07371521	chr5:154026371	NA	0.47	7.62	0.33	1.42e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6032067	0.516	rs761367	chr20:43913317	C/T	cg10761708	chr20:43804764	PI3	0.49	7.87	0.34	2.57e-14	Blood protein levels;
LGG	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6462411	1.000	rs6462412	chr7:3915626	G/C	cg18022346	chr7:3920534	SDK1	-0.35	-6.75	-0.3	4.48e-11	Quantitative traits;
LGG	cis	rs7614311	0.681	rs73130565	chr3:63887135	T/C	cg22134162	chr3:63841271	THOC7	-0.45	-8.13	-0.35	3.98e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs6784615	0.744	rs353545	chr3:52267580	G/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.73	-7.73	-0.34	6.99e-14	Waist-hip ratio;
LGG	cis	rs1707322	1.000	rs12124291	chr1:46432132	G/A	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg04034577	chr2:241836375	C2orf54	-0.53	-11.18	-0.46	7.36e-26	Urinary metabolites;
LGG	trans	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg21659725	chr3:3221576	CRBN	0.63	11.59	0.47	1.94e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.33	-6.66	-0.3	7.64e-11	Schizophrenia;
LGG	cis	rs10463316	0.817	rs906679	chr5:150779302	T/A	cg03212797	chr5:150827313	SLC36A1	-0.57	-9.97	-0.42	2.44e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs4538187	0.951	rs17562177	chr2:64160385	A/G	cg14150252	chr2:64069583	UGP2	-0.48	-9.37	-0.4	3.17e-19	Systolic blood pressure;
LGG	cis	rs10099921	0.743	rs34421889	chr8:41636251	T/C	cg17182837	chr8:41585554	ANK1	0.48	7.5	0.33	3.32e-13	Neutrophil percentage of white cells;
LGG	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg18252515	chr7:66147081	NA	-1.38	-18.83	-0.66	3.82e-59	Diabetic kidney disease;
LGG	cis	rs62209	1.000	rs1291898	chr10:11009127	G/A	cg26901096	chr10:10994189	LOC254312	0.51	8.39	0.36	6.06e-16	Alzheimer's disease (late onset);
LGG	trans	rs6787172	0.622	rs11718056	chr3:158092993	T/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.7e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-10.75	-0.45	3.37e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg03929089	chr4:120376271	NA	0.7	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg00490583	chr16:1843685	IGFALS	-0.41	-7.03	-0.31	7.55e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg15501526	chr10:2543763	NA	0.68	12.45	0.5	6.95e-31	Age-related hearing impairment;
LGG	cis	rs17253792	0.822	rs117050012	chr14:56038729	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg23625390	chr15:77176239	SCAPER	0.49	9.65	0.41	3.31e-20	Blood metabolite levels;
LGG	cis	rs34929064	0.881	rs2961311	chr7:22727538	T/G	cg18045685	chr7:22629474	NA	-0.52	-9.35	-0.4	3.72e-19	Major depression and alcohol dependence;
LGG	cis	rs977987	0.806	rs56343285	chr16:75409797	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg08872617	chr16:4783947	ANKS3;C16orf71	-0.41	-7.06	-0.31	6.28e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs3784262	0.900	rs12911071	chr15:58314848	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.24	-0.36	1.74e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9309473	0.848	rs9750915	chr2:73811880	T/C	cg20560298	chr2:73613845	ALMS1	-0.46	-7.31	-0.32	1.21e-12	Metabolite levels;
LGG	cis	rs11605275	1.000	rs77993017	chr11:20031388	C/G	cg14835545	chr11:20032148	NAV2	-0.97	-11.3	-0.47	2.47e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.95	0.54	3.53e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg18335740	chr13:41363409	SLC25A15	0.61	12.02	0.49	3.66e-29	Lewy body disease;
LGG	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.38	0.4	3.01e-19	Retinal vascular caliber;
LGG	cis	rs7586879	0.861	rs10164466	chr2:25114069	T/C	cg04586622	chr2:25135609	ADCY3	0.37	9.14	0.39	1.93e-18	Body mass index;
LGG	cis	rs7638995	0.651	rs4635707	chr3:69197507	C/T	cg26574240	chr3:69171822	LMOD3	-0.46	-8.07	-0.35	5.99e-15	Alzheimer's disease (late onset);
LGG	cis	rs9972944	0.651	rs8080916	chr17:63816368	G/C	cg07283582	chr17:63770753	CCDC46	-0.39	-6.99	-0.31	9.71e-12	Total body bone mineral density;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3820928	0.874	rs10183633	chr2:227887828	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.64	-0.33	1.28e-13	Pulmonary function;
LGG	cis	rs8048589	0.537	rs4781180	chr16:12192194	C/T	cg02910054	chr16:12241554	SNX29	0.48	8.11	0.35	4.59e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg00686598	chr14:53173677	PSMC6	1.35	14.82	0.57	6.19e-41	Alzheimer's disease (late onset);
LGG	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs701145	0.585	rs1713807	chr3:153883344	C/T	cg17054900	chr3:154042577	DHX36	0.84	9.77	0.41	1.29e-20	Coronary artery disease;
LGG	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg07051648	chr19:49177693	NTN5;SEC1	-0.41	-7.15	-0.32	3.46e-12	Dietary macronutrient intake;
LGG	cis	rs7781557	1.000	rs10487284	chr7:102470275	G/A	cg18108683	chr7:102477205	FBXL13	-0.53	-8.49	-0.37	2.91e-16	Colorectal adenoma (advanced);
LGG	cis	rs763121	0.819	rs6001205	chr22:39100264	T/A	cg06022373	chr22:39101656	GTPBP1	0.91	18.49	0.65	1.41e-57	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.7	-12.54	-0.5	2.93e-31	Obesity-related traits;
LGG	cis	rs921551	1.000	rs921551	chr4:122110975	C/T	cg24215459	chr4:122110906	TNIP3	0.75	7.23	0.32	1.96e-12	Breast cancer;
LGG	trans	rs7939886	0.920	rs12417606	chr11:55750479	C/T	cg03929089	chr4:120376271	NA	0.84	8.71	0.38	5.6e-17	Myopia (pathological);
LGG	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.74	-0.41	1.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4684776	1.000	rs7645555	chr3:11416009	T/G	cg24705426	chr3:11550659	ATG7	-0.41	-7.25	-0.32	1.72e-12	Small vessel stroke;
LGG	trans	rs45509595	0.841	rs2747054	chr6:27783359	A/G	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs8040855	0.599	rs2342123	chr15:85725149	C/G	cg04831495	chr15:85060580	GOLGA6L5	-0.32	-6.72	-0.3	5.41e-11	Bulimia nervosa;
LGG	cis	rs12477438	0.765	rs7607578	chr2:99669771	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs876084	0.966	rs876083	chr8:121101533	C/T	cg22335954	chr8:121166405	COL14A1	-0.32	-7.06	-0.31	6.22e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2303319	1.000	rs78555127	chr2:162271260	G/T	cg13806767	chr2:162164127	PSMD14	-0.69	-7.79	-0.34	4.4e-14	Cognitive function;
LGG	cis	rs193541	0.632	rs168913	chr5:122225793	G/A	cg19412675	chr5:122181750	SNX24	0.53	8.49	0.37	2.8e-16	Glucose homeostasis traits;
LGG	cis	rs77106637	0.585	rs67260737	chr11:72458196	A/G	cg04827223	chr11:72435913	ARAP1	-0.45	-7.51	-0.33	3e-13	Type 2 diabetes;
LGG	cis	rs4262150	0.810	rs72799126	chr5:152084873	T/C	cg12297329	chr5:152029980	NA	-0.76	-14.09	-0.55	8.7e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs8133932	0.654	rs371587	chr21:47348512	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.97	-0.35	1.26e-14	Schizophrenia;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg03709012	chr19:19516395	GATAD2A	0.86	17.45	0.63	9.07e-53	Tonsillectomy;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05855116	chr7:101603335	CUX1	-0.38	-6.93	-0.31	1.44e-11	Bipolar disorder;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.69	12.87	0.51	1.23e-32	Obesity-related traits;
LGG	cis	rs4604732	0.536	rs4925674	chr1:247636906	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.64	10.18	0.43	4.4e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7851660	0.967	rs7860598	chr9:100600702	G/A	cg13688889	chr9:100608707	NA	-0.69	-14.56	-0.56	8.14e-40	Strep throat;
LGG	cis	rs6960043	0.738	rs10950549	chr7:15057829	G/A	cg19272540	chr7:15055459	NA	0.37	8.45	0.37	3.87e-16	Type 2 diabetes;
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg26354017	chr1:205819088	PM20D1	0.49	8.08	0.35	5.82e-15	Parkinson's disease;
LGG	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.75e-13	Prudent dietary pattern;
LGG	cis	rs6740322	0.895	rs13384080	chr2:43557363	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.62	-0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg20120463	chr17:44301886	NA	-0.47	-7.37	-0.32	7.91e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg08994789	chr17:28903642	LRRC37B2	0.68	8.2	0.36	2.36e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg21466736	chr12:48725269	NA	-0.36	-7.29	-0.32	1.32e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	trans	rs2548003	1.000	rs1593020	chr5:28733106	T/C	cg12623145	chr2:97778927	ANKRD36	0.46	6.94	0.31	1.32e-11	Hip geometry;
LGG	cis	rs3540	0.533	rs12708585	chr15:91052285	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-11.92	-0.48	9.53e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs8180040	1.000	rs807936	chr3:47322496	C/T	cg27129171	chr3:47204927	SETD2	0.79	15.3	0.58	4.51e-43	Colorectal cancer;
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.34	-0.4	3.97e-19	Retinal vascular caliber;
LGG	cis	rs1941023	0.584	rs2197236	chr11:60168859	T/C	cg08716584	chr11:60157161	MS4A7	-0.43	-8.58	-0.37	1.46e-16	Congenital heart disease (maternal effect);
LGG	cis	rs3206736	0.632	rs10252277	chr7:35152859	G/A	cg13400248	chr7:35225412	NA	0.44	8.1	0.35	4.98e-15	Diastolic blood pressure;
LGG	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-7.72	-0.34	7.12e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs9393777	0.720	rs56874662	chr6:26985607	C/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-9.25	-0.39	8.61e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2640806	0.645	rs34545432	chr8:97326671	C/A	cg22138393	chr8:97340270	PTDSS1	0.31	7.85	0.34	2.94e-14	Obesity-related traits;
LGG	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.18	-0.39	1.42e-18	Vitiligo;
LGG	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg06618935	chr21:46677482	NA	-0.49	-9.51	-0.4	1.08e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8062405	1.000	rs7187776	chr16:28857645	A/G	cg16576597	chr16:28551801	NUPR1	0.29	6.73	0.3	4.99e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs911263	0.546	rs4902567	chr14:68800600	T/C	cg18825221	chr14:68749962	RAD51L1	0.44	7.43	0.33	5.18e-13	Primary biliary cholangitis;
LGG	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.04	-0.31	7.13e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.11	-0.43	7.84e-22	Lung cancer;
LGG	cis	rs4737010	0.501	rs2032736	chr8:41639266	C/A	cg08923054	chr8:41654455	ANK1	-0.82	-13.49	-0.53	3.38e-35	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.32	-0.32	1.14e-12	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13600149	chr9:98079129	FANCC	0.52	9.15	0.39	1.86e-18	Gut microbiota (bacterial taxa);
LGG	trans	rs8073060	0.963	rs11080353	chr17:33871281	C/T	cg19694781	chr19:47549865	TMEM160	0.64	10.32	0.43	1.29e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg02527881	chr3:46936655	PTH1R	-0.35	-8.53	-0.37	2.03e-16	Birth weight;
LGG	cis	rs13421350	1.000	rs13421350	chr2:173318571	A/G	cg15021238	chr2:173305865	ITGA6	0.45	7.35	0.32	9.34e-13	Diabetic kidney disease;
LGG	cis	rs7227917	0.536	rs4603334	chr18:45523867	T/A	cg22195133	chr18:45534586	NA	0.77	7.31	0.32	1.19e-12	Lung cancer in ever smokers;
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs72634258	0.945	rs12730860	chr1:8132462	T/C	cg00042356	chr1:8021962	PARK7	0.82	10.05	0.42	1.22e-21	Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19954613	chr22:22020219	PPIL2	0.43	6.91	0.31	1.58e-11	Cognitive performance;
LGG	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg11252792	chr3:125932053	NA	0.8	17.24	0.63	8.51e-52	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7565124	0.909	rs6747472	chr2:20252007	C/T	cg24657347	chr2:20261756	NA	-0.73	-14.37	-0.56	5.59e-39	Major depressive disorder;
LGG	cis	rs4740619	0.792	rs7846970	chr9:15795646	T/G	cg14451791	chr9:16040625	NA	0.31	7.78	0.34	4.65e-14	Body mass index;
LGG	cis	rs7122539	0.684	rs10896139	chr11:66650060	C/T	cg01599099	chr11:66649832	PC	0.46	9.11	0.39	2.52e-18	HIV-1 susceptibility;
LGG	trans	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg07211511	chr3:129823064	LOC729375	-1.33	-21.34	-0.7	7.07e-71	Blood pressure (smoking interaction);
LGG	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg20503657	chr10:835505	NA	0.94	12.82	0.51	1.99e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.5	-0.5	4.25e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9517320	1.000	rs912337	chr13:99141272	A/G	cg07423050	chr13:99094983	FARP1	-0.36	-7.36	-0.32	8.7e-13	Longevity;
LGG	cis	rs752010	0.574	rs2148636	chr1:42119844	C/T	cg16096631	chr1:42092165	HIVEP3	-0.47	-10.89	-0.45	9.69e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4929949	0.901	rs9705083	chr11:8586772	G/A	cg23764900	chr11:8616102	STK33	-0.4	-7.06	-0.31	6.02e-12	Body mass index;
LGG	cis	rs9810259	0.508	rs6442309	chr3:12301166	A/G	cg15873301	chr3:12045459	SYN2	-0.42	-7.07	-0.31	5.91e-12	Platelet count;
LGG	cis	rs7216064	0.954	rs9907491	chr17:65949993	G/A	cg12091567	chr17:66097778	LOC651250	0.62	9.02	0.39	4.88e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4538187	0.502	rs11683408	chr2:64193684	C/T	cg14150252	chr2:64069583	UGP2	-0.49	-7.13	-0.31	4e-12	Systolic blood pressure;
LGG	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg05623727	chr3:50126028	RBM5	0.41	8.86	0.38	1.68e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.07e-12	Electroencephalogram traits;
LGG	cis	rs11018904	0.906	rs35286339	chr11:89965679	A/G	cg27158573	chr11:89632121	NA	-0.41	-7.31	-0.32	1.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg03709012	chr19:19516395	GATAD2A	-0.58	-9.66	-0.41	3.12e-20	Tonsillectomy;
LGG	cis	rs2777491	0.915	rs16971767	chr15:41623308	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg18850127	chr7:39170497	POU6F2	-0.35	-8.11	-0.35	4.53e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2073300	1.000	rs6137976	chr20:23463241	C/T	cg12062639	chr20:23401060	NAPB	0.83	6.75	0.3	4.43e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.48	-0.33	3.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs13401104	0.796	rs1466207	chr2:237121350	C/T	cg15742758	chr2:237126235	ASB18	0.41	6.67	0.3	7.28e-11	Educational attainment;
LGG	trans	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg26384229	chr12:38710491	ALG10B	-0.64	-11.8	-0.48	2.7e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs546131	0.600	rs525202	chr11:34821948	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.13	0.31	3.8e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg13482628	chr17:19912719	NA	0.63	12.58	0.5	2.04e-31	Schizophrenia;
LGG	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03517284	chr6:25882590	NA	0.52	9.83	0.42	7.54e-21	Blood metabolite levels;
LGG	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.92	-0.38	1.13e-17	Aortic root size;
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	cis	rs9486719	0.948	rs12203657	chr6:96883285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs11170468	0.697	rs10747659	chr12:39434813	C/T	cg26384229	chr12:38710491	ALG10B	-0.43	-6.84	-0.3	2.44e-11	Body mass index;
LGG	cis	rs3087591	1.000	rs6505235	chr17:29688603	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.69	-0.56	2.26e-40	Hip circumference;
LGG	cis	rs1707322	1.000	rs7526369	chr1:46390560	G/C	cg03146154	chr1:46216737	IPP	0.54	10.12	0.43	6.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24677674	chr10:113943468	GPAM	0.48	7.49	0.33	3.6e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-10.63	-0.44	9.33e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	9.52	0.4	9.35e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1345301	1.000	rs13431601	chr2:102873713	G/A	cg05295703	chr2:102895712	NA	0.38	7.6	0.33	1.67e-13	Waist circumference;
LGG	cis	rs4604732	0.588	rs7549955	chr1:247628321	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.06	0.39	3.56e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2115630	0.755	rs7169629	chr15:85191274	C/G	cg12501888	chr15:85177176	SCAND2	0.44	7.19	0.32	2.69e-12	P wave terminal force;
LGG	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	2.98e-20	Diabetic kidney disease;
LGG	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg09904177	chr6:26538194	HMGN4	0.77	17.11	0.62	3.39e-51	Intelligence (multi-trait analysis);
LGG	cis	rs9398803	0.865	rs1120786	chr6:126808637	T/G	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs12360000	0.797	rs12768776	chr10:1901587	C/T	cg26364871	chr10:1889757	NA	-0.74	-14.12	-0.55	6.71e-38	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs4423214	0.879	rs12803256	chr11:71132868	A/G	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.51	-0.53	2.78e-35	Vitamin D levels;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg06917634	chr15:78832804	PSMA4	-0.72	-14.2	-0.55	2.95e-38	Sudden cardiac arrest;
LGG	cis	rs3816183	1.000	rs12998043	chr2:43018054	T/C	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.57	9.62	0.41	4.34e-20	Colorectal cancer;
LGG	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg05623727	chr3:50126028	RBM5	0.33	7.18	0.32	2.72e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3206736	0.548	rs167893	chr7:35042733	A/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs283228	0.550	rs496596	chr6:101752756	A/T	cg27451362	chr6:101846650	GRIK2	0.99	15.09	0.57	4.03e-42	Coenzyme Q10 levels;
LGG	cis	rs3106136	0.967	rs13132963	chr4:95219780	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.18	-0.36	2.74e-15	Capecitabine sensitivity;
LGG	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.83	-0.34	3.41e-14	Mood instability;
LGG	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.55	0.44	1.91e-23	Mood instability;
LGG	cis	rs3806843	0.966	rs2563267	chr5:140136913	C/T	cg19875535	chr5:140030758	IK	-0.53	-10.95	-0.45	5.89e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.64	-0.37	9.53e-17	Response to antipsychotic treatment;
LGG	cis	rs7666738	0.753	rs35194639	chr4:99053819	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.08e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg07117364	chr1:16154769	NA	-0.53	-8.49	-0.37	2.81e-16	Dilated cardiomyopathy;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg02002194	chr4:3960332	NA	-0.5	-9.55	-0.41	7.83e-20	Neuroticism;
LGG	cis	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg26384229	chr12:38710491	ALG10B	0.91	20.43	0.69	1.3e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7100689	0.516	rs10887711	chr10:82034842	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	13.6	0.53	1.06e-35	Post bronchodilator FEV1;
LGG	cis	rs9557207	0.950	rs11069358	chr13:99868898	A/G	cg24509225	chr13:100037070	UBAC2	0.71	12.78	0.51	2.97e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.11	0.55	7.38e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg06916706	chr16:4465613	CORO7	-0.87	-15.48	-0.58	7.34e-44	Schizophrenia;
LGG	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7605378	0.528	rs7592587	chr2:200786516	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	7.78	0.34	4.75e-14	Osteoporosis;
LGG	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg13385794	chr1:248469461	NA	0.48	8.12	0.35	4.28e-15	Common traits (Other);
LGG	cis	rs6904897	0.538	rs4639353	chr6:135224328	A/G	cg24558204	chr6:135376177	HBS1L	-0.49	-8.53	-0.37	2.17e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs459571	0.959	rs465535	chr9:136910905	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-6.71	-0.3	5.72e-11	Platelet distribution width;
LGG	cis	rs12997796	0.556	rs34353387	chr2:86974834	A/C	cg25203885	chr2:87302643	LOC285074	-0.66	-7.82	-0.34	3.67e-14	Schizophrenia;
LGG	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg18551225	chr6:44695536	NA	0.63	10.05	0.42	1.27e-21	Total body bone mineral density;
LGG	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg04842962	chr6:43655489	MRPS18A	-0.8	-15.35	-0.58	2.71e-43	IgG glycosylation;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg06081371	chr3:32726639	CNOT10	0.39	6.75	0.3	4.41e-11	Corneal astigmatism;
LGG	cis	rs1005224	0.926	rs12892551	chr14:76159902	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.93	-0.31	1.44e-11	Large artery stroke;
LGG	cis	rs773506	0.576	rs943502	chr9:93920745	G/A	cg14446406	chr9:93919335	NA	0.7	12.6	0.51	1.61e-31	Type 2 diabetes nephropathy;
LGG	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg11494091	chr17:61959527	GH2	0.61	10.3	0.43	1.58e-22	Height;
LGG	cis	rs6800768	0.658	rs6766462	chr3:24118122	A/T	cg10674438	chr3:24145617	LOC152024	-0.32	-6.67	-0.3	7.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9463078	0.874	rs7743116	chr6:45142858	T/C	cg25276700	chr6:44698697	NA	-0.39	-8.32	-0.36	1.01e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.35e-13	HDL cholesterol;
LGG	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg12654349	chr5:56205094	C5orf35	0.58	10.04	0.42	1.41e-21	Initial pursuit acceleration;
LGG	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.22	0.36	2.13e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23408836	chr2:170590490	KLHL23	0.44	6.74	0.3	4.86e-11	Gut microbiome composition (summer);
LGG	cis	rs2073300	0.609	rs6137950	chr20:23418722	T/A	cg12062639	chr20:23401060	NAPB	0.92	8.7	0.37	5.96e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg07211511	chr3:129823064	LOC729375	-0.66	-9.09	-0.39	2.82e-18	Blood pressure (smoking interaction);
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.94	0.38	9e-18	Retinal vascular caliber;
LGG	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs73198271	0.562	rs17631052	chr8:8663787	G/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.21	0.36	2.23e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7666738	0.830	rs28497822	chr4:98906873	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17169635	0.551	rs12155483	chr7:134562384	C/T	cg02516134	chr7:134575187	CALD1	-0.35	-7.56	-0.33	2.13e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs2562456	0.550	rs4809143	chr19:21772728	C/A	cg00806126	chr19:22604979	ZNF98	-0.63	-8.67	-0.37	7.58e-17	Pain;
LGG	cis	rs653465	0.739	rs11710255	chr3:27145591	C/G	cg02860705	chr3:27208620	NA	-0.4	-7.68	-0.34	9.77e-14	Breast cancer (early onset);
LGG	cis	rs7928758	0.943	rs79416046	chr11:134270003	C/T	cg15243474	chr11:134282918	B3GAT1	1.16	15.3	0.58	4.78e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9487051	0.898	rs882072	chr6:109611806	A/G	cg21918786	chr6:109611834	NA	-0.48	-9.01	-0.39	5.4e-18	Reticulocyte fraction of red cells;
LGG	cis	rs6694672	0.764	rs672928	chr1:197198558	T/C	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg04166393	chr7:2884313	GNA12	0.43	8.02	0.35	8.44e-15	Height;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg21657780	chr14:105293878	NA	0.54	9.73	0.41	1.7e-20	IgG glycosylation;
LGG	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.48	-0.37	3.09e-16	Neuroticism;
LGG	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.63	6.95	0.31	1.21e-11	Initial pursuit acceleration;
LGG	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.52	0.33	2.84e-13	Cystic fibrosis severity;
LGG	cis	rs4538187	0.865	rs11686956	chr2:63938708	T/G	cg14150252	chr2:64069583	UGP2	-0.46	-9.14	-0.39	2.04e-18	Systolic blood pressure;
LGG	trans	rs35110281	0.807	rs6518301	chr21:45016818	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.93	0.42	3.43e-21	Mean corpuscular volume;
LGG	cis	rs7666738	0.716	rs1426660	chr4:98876792	T/A	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9815354	0.812	rs114034165	chr3:41823297	G/A	cg03022575	chr3:42003672	ULK4	0.79	9.13	0.39	2.05e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs7428	0.527	rs3184780	chr2:85549547	C/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.87	-0.54	7.69e-37	Ear protrusion;
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg02002194	chr4:3960332	NA	-0.44	-8.2	-0.36	2.3e-15	Mood instability;
LGG	trans	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg20587970	chr11:113659929	NA	-1.34	-24.01	-0.74	2.48e-83	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04008888	chr11:68622739	NA	-0.54	-11.66	-0.48	9.87e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	11.88	0.48	1.4e-28	Lymphocyte counts;
LGG	cis	rs9457247	0.602	rs2239827	chr6:167490945	G/A	cg07741184	chr6:167504864	NA	0.47	10.37	0.43	8.32e-23	Crohn's disease;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.36	0.43	9.1e-23	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg14926445	chr8:58193284	C8orf71	-0.9	-13.34	-0.53	1.3600000000000001e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6871536	1.000	rs2706347	chr5:131905117	G/T	cg04303330	chr5:131992430	IL13	0.28	6.75	0.3	4.54e-11	Asthma (childhood onset);
LGG	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs921968	0.643	rs520095	chr2:219329485	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg21926883	chr2:100939477	LONRF2	-0.5	-8.99	-0.39	6.22e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6032067	0.777	rs35434469	chr20:43778544	C/T	cg10761708	chr20:43804764	PI3	0.74	11.23	0.46	4.89e-26	Blood protein levels;
LGG	cis	rs68170813	0.617	rs12535761	chr7:107139275	A/C	cg02696742	chr7:106810147	HBP1	-0.68	-8.67	-0.37	7.27e-17	Coronary artery disease;
LGG	cis	rs950027	0.549	rs11070452	chr15:45594836	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.78	-0.41	1.15e-20	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg00149659	chr3:10157352	C3orf10	0.85	10.83	0.45	1.7e-24	Alzheimer's disease;
LGG	cis	rs7551222	0.716	rs10900601	chr1:204572050	A/G	cg20240347	chr1:204465584	NA	-0.41	-7.08	-0.31	5.24e-12	Schizophrenia;
LGG	cis	rs17253792	0.822	rs76918910	chr14:56058762	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg24623649	chr8:11872141	NA	-0.3	-6.86	-0.3	2.25e-11	Neuroticism;
LGG	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.71	-12.61	-0.51	1.56e-31	Longevity;Endometriosis;
LGG	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg10056627	chr6:42928773	GNMT	0.26	7.04	0.31	6.84e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg21911579	chr5:131705225	SLC22A5	0.7	7.79	0.34	4.45e-14	Rheumatoid arthritis;
LGG	cis	rs2315504	0.509	rs2240076	chr17:39035615	C/T	cg05063374	chr17:38953512	KRT28	-0.38	-7.19	-0.32	2.67e-12	Height;
LGG	trans	rs75804782	0.625	rs13409356	chr2:239468046	C/T	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.78	-0.41	1.13e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg14851468	chr5:179071604	C5orf60	0.48	8.44	0.37	4.13e-16	Lung cancer;
LGG	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.08	-0.31	5.42e-12	Bipolar disorder;
LGG	cis	rs6032067	0.929	rs17334064	chr20:43839197	T/C	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs9486715	1.000	rs3798297	chr6:97062835	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.33	-0.4	4.3e-19	Headache;
LGG	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg24558204	chr6:135376177	HBS1L	0.55	9.63	0.41	3.85e-20	Red blood cell count;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.09	-0.35	5.21e-15	Neuroticism;
LGG	cis	rs6665290	0.669	rs3768419	chr1:227173477	C/G	cg05696931	chr1:227175867	NA	-0.41	-8.16	-0.35	3.22e-15	Myeloid white cell count;
LGG	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.12e-15	Bipolar disorder;
LGG	cis	rs8044868	0.586	rs6499564	chr16:72189655	G/A	cg23815491	chr16:72088622	HP	0.38	8.08	0.35	5.49e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs9287719	0.967	rs6709466	chr2:10748257	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg24503407	chr1:205819492	PM20D1	0.46	7.85	0.34	2.85e-14	Parkinson's disease;
LGG	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.14	-0.35	3.69e-15	Coronary artery disease;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.89	-0.38	1.36e-17	Lymphocyte counts;
LGG	cis	rs7091068	0.550	rs7901909	chr10:95492508	C/T	cg20715218	chr10:95462985	C10orf4	0.74	12.7	0.51	6.41e-32	Urinary tract infection frequency;
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.4	-0.44	6.33e-23	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10101463	chr1:202780506	NA	0.41	6.74	0.3	4.83e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.65	0.3	8.24e-11	Bipolar disorder;
LGG	cis	rs7215564	0.908	rs79961397	chr17:78687146	T/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7017697	0.507	rs10113140	chr8:19684745	A/C	cg03894339	chr8:19674705	INTS10	-0.62	-8.82	-0.38	2.3e-17	Breast cancer;
LGG	cis	rs6163	0.588	rs3818708	chr10:104503584	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-7.44	-0.33	4.83e-13	Waist circumference;Hip circumference;
LGG	cis	rs977987	0.806	rs11864102	chr16:75442360	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.07	0.42	1.08e-21	Dupuytren's disease;
LGG	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg01280390	chr8:19363452	CSGALNACT1	0.56	15.06	0.57	5.57e-42	Oropharynx cancer;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.77	-0.34	5.15e-14	Menopause (age at onset);
LGG	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg26384229	chr12:38710491	ALG10B	-0.85	-19.2	-0.67	7.31e-61	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg04287289	chr16:89883240	FANCA	0.76	8.15	0.35	3.35e-15	Skin colour saturation;
LGG	cis	rs975739	0.630	rs7992650	chr13:78594809	G/A	cg07847733	chr13:78271382	SLAIN1	0.48	8.21	0.36	2.23e-15	Hair color;
LGG	trans	rs17685	0.753	rs10245584	chr7:75745866	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.73	0.77	2.61e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.88	-0.38	1.46e-17	Self-reported allergy;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg10360139	chr7:1886902	MAD1L1	-0.37	-6.68	-0.3	6.76e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg09417038	chr21:47716443	C21orf57	-0.41	-8.3	-0.36	1.13e-15	Testicular germ cell tumor;
LGG	cis	rs77140172	0.677	rs28435799	chr4:89617931	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.9	7.9	0.34	2.12e-14	Post bronchodilator FEV1;
LGG	cis	rs9815354	1.000	rs73069394	chr3:41787233	G/A	cg03022575	chr3:42003672	ULK4	0.58	7.42	0.33	5.56e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs365132	1.000	rs353467	chr5:176445698	T/C	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs12367572	0.620	rs2731054	chr12:45410570	T/C	cg03114573	chr12:45410052	DBX2	-0.69	-12.77	-0.51	3.2e-32	Gut microbiome composition (summer);
LGG	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs7119038	0.509	rs10790261	chr11:118579747	C/T	cg19182353	chr11:118479428	PHLDB1	-0.38	-6.8	-0.3	3.22e-11	Sjögren's syndrome;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.1	0.39	2.73e-18	Alzheimer's disease;
LGG	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg05163923	chr11:71159392	DHCR7	0.73	14.14	0.55	5.25e-38	Vitamin D levels;
LGG	cis	rs6684428	0.536	rs6670350	chr1:56391806	C/T	cg11651538	chr1:56320950	NA	0.47	8.51	0.37	2.43e-16	Airflow obstruction;
LGG	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg23484912	chr5:273055	PDCD6	0.44	8.93	0.38	1.03e-17	Pancreatic cancer;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg12458913	chr13:53173898	NA	0.53	8.66	0.37	7.82e-17	Lewy body disease;
LGG	cis	rs7666738	0.791	rs7377018	chr4:99034962	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25072359	chr17:41440525	NA	0.52	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.07	-0.49	2.45e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7236492	0.872	rs78538334	chr18:77223322	G/A	cg15644404	chr18:77186268	NFATC1	-0.82	-10.06	-0.42	1.17e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-11.34	-0.47	1.78e-26	Hemoglobin concentration;
LGG	trans	rs6956675	0.631	rs4302702	chr7:62556899	A/G	cg01314568	chr7:57830625	NA	-0.55	-7.96	-0.35	1.33e-14	Obesity-related traits;
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg14338887	chr6:42928500	GNMT	0.27	8.76	0.38	3.85e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7769051	0.522	rs10457596	chr6:133169974	T/G	cg22852734	chr6:133119734	C6orf192	0.98	9.9	0.42	4.26e-21	Type 2 diabetes nephropathy;
LGG	cis	rs2486288	0.656	rs8024620	chr15:45574329	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.81	-0.45	1.87e-24	Glomerular filtration rate;
LGG	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs3740909	1.000	rs7101525	chr11:125889990	C/G	cg24940576	chr11:125904314	CDON	-0.46	-7.08	-0.31	5.36e-12	Blood protein levels;
LGG	trans	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs4919694	1.000	rs7099987	chr10:104807926	C/T	cg04362960	chr10:104952993	NT5C2	1.07	15.29	0.58	5.26e-43	Arsenic metabolism;
LGG	cis	rs7923609	0.838	rs7909960	chr10:65239177	T/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.74	-0.3	4.74e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2354432	0.607	rs10453880	chr1:146693689	T/C	cg25205988	chr1:146714368	CHD1L	1.11	9.49	0.4	1.22e-19	Mitochondrial DNA levels;
LGG	cis	rs7017914	0.967	rs7000647	chr8:71688408	C/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs745821	0.541	rs11082832	chr18:48115431	T/A	cg18923635	chr18:48083994	NA	0.41	7.74	0.34	6.33e-14	Diastolic blood pressure;
LGG	trans	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg18335740	chr13:41363409	SLC25A15	0.54	9.78	0.41	1.13e-20	Lewy body disease;
LGG	cis	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.52	-0.44	2.35e-23	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23676114	chr9:33264786	SUGT1P1;CHMP5;BAG1	0.56	8.41	0.36	5.18e-16	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg02753203	chr1:228287806	NA	-0.65	-12.07	-0.49	2.3e-29	Diastolic blood pressure;
LGG	cis	rs2274273	0.624	rs66551709	chr14:55791022	A/T	cg04306507	chr14:55594613	LGALS3	0.53	12.51	0.5	3.74e-31	Protein biomarker;
LGG	cis	rs2273669	0.915	rs3734651	chr6:109295040	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg13263323	chr15:86062960	AKAP13	-0.39	-8.43	-0.36	4.31e-16	Interstitial lung disease;
LGG	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.14	0.31	3.65e-12	Myopia (pathological);
LGG	cis	rs78456975	1.000	rs111935361	chr2:1554192	C/A	cg26248373	chr2:1572462	NA	-0.7	-8.76	-0.38	3.6e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	9.23	0.39	9.34e-19	Iron status biomarkers;
LGG	cis	rs8031584	0.679	rs34017474	chr15:31230611	T/C	cg14829155	chr15:31115871	NA	-0.43	-7.55	-0.33	2.3e-13	Huntington's disease progression;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg14346243	chr4:90757452	SNCA	-0.41	-8.26	-0.36	1.51e-15	Dementia with Lewy bodies;
LGG	cis	rs1059312	0.808	rs10847693	chr12:129292006	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.46	0.37	3.42e-16	Systemic lupus erythematosus;
LGG	cis	rs9796	0.505	rs28665387	chr15:41532869	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.33	-0.43	1.17e-22	Menopause (age at onset);
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg04287289	chr16:89883240	FANCA	0.74	8.03	0.35	8.38e-15	Skin colour saturation;
LGG	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.44	8.11	0.35	4.52e-15	Longevity;
LGG	cis	rs360798	0.553	rs7562734	chr2:63047973	G/C	cg17519650	chr2:63277830	OTX1	-0.49	-8.14	-0.35	3.72e-15	Coronary artery disease;
LGG	cis	rs870825	0.616	rs4615214	chr4:185624129	G/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs2594989	0.943	rs901865	chr3:11300707	T/C	cg00170343	chr3:11313890	ATG7	0.55	7.28	0.32	1.49e-12	Circulating chemerin levels;
LGG	cis	rs6500395	1.000	rs6500397	chr16:48642235	T/C	cg04672837	chr16:48644449	N4BP1	0.55	9.13	0.39	2.11e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07157834	chr1:205819609	PM20D1	0.72	16.57	0.61	8.95e-49	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg15971980	chr6:150254442	NA	0.46	8.81	0.38	2.49e-17	Lung cancer;
LGG	cis	rs2599510	0.811	rs2710625	chr2:32822957	G/A	cg02381751	chr2:32503542	YIPF4	0.47	7.6	0.33	1.65e-13	Interleukin-18 levels;
LGG	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg02733842	chr7:1102375	C7orf50	-0.54	-8.14	-0.35	3.64e-15	Bronchopulmonary dysplasia;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.36	-0.4	3.35e-19	Life satisfaction;
LGG	cis	rs7133214	0.713	rs12369101	chr12:27925311	T/C	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.98	-0.31	1.03e-11	Gut microbiota (functional units);
LGG	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.38	-0.32	7.61e-13	Total cholesterol levels;
LGG	cis	rs7551222	0.752	rs6594016	chr1:204539462	G/A	cg20240347	chr1:204465584	NA	-0.56	-11.19	-0.46	6.59e-26	Schizophrenia;
LGG	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2444240	0.583	rs75389345	chr11:120039924	T/G	cg16005559	chr11:120040616	NA	0.32	7.04	0.31	7.2e-12	Corneal curvature;
LGG	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.51e-16	Obesity-related traits;
LGG	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg14228332	chr4:119757509	SEC24D	0.92	9.41	0.4	2.34e-19	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.44	-0.4	1.76e-19	Lung cancer;
LGG	cis	rs9527	0.545	rs7894588	chr10:104756030	A/T	cg04362960	chr10:104952993	NT5C2	0.54	9.91	0.42	4.08e-21	Arsenic metabolism;
LGG	cis	rs77633900	0.772	rs78181637	chr15:76672569	A/C	cg21673338	chr15:77095150	SCAPER	-0.63	-8.32	-0.36	9.74e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs7084783	0.500	rs10883892	chr10:105397102	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.47	8.03	0.35	8.39e-15	Fear of pain;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	10.04	0.42	1.31e-21	Obesity-related traits;
LGG	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg10402321	chr1:26617780	UBXN11	-0.35	-6.74	-0.3	4.82e-11	Obesity-related traits;
LGG	trans	rs9325144	0.647	rs4616077	chr12:39092364	T/C	cg06521331	chr12:34319734	NA	0.41	6.96	0.31	1.2e-11	Morning vs. evening chronotype;
LGG	cis	rs747650	0.884	rs7128325	chr11:47046554	G/A	cg03339077	chr11:47165057	C11orf49	-0.53	-10.01	-0.42	1.74e-21	Acne (severe);
LGG	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.83	0.3	2.74e-11	Parkinson's disease;
LGG	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg15665833	chr6:26285013	NA	0.36	6.74	0.3	4.7e-11	Educational attainment;
LGG	cis	rs365132	1.000	rs353478	chr5:176370988	T/C	cg16309518	chr5:176445507	NA	-0.54	-11.76	-0.48	4.05e-28	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.3	-0.47	2.49e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9783347	1.000	rs12286683	chr11:18348662	G/T	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs2131877	0.956	rs57750973	chr3:194870093	T/C	cg07250128	chr3:194833983	C3orf21	0.4	7.55	0.33	2.3e-13	Non-small cell lung cancer;
LGG	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.63	0.41	4.11e-20	Lung cancer in ever smokers;
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.94	-0.38	9.41e-18	Aortic root size;
LGG	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.83	-0.3	2.75e-11	Retinal vascular caliber;
LGG	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg08250081	chr4:10125330	NA	0.65	12.19	0.49	7.96e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg15268244	chr15:77196840	NA	0.49	10.22	0.43	3.11e-22	Blood metabolite levels;
LGG	cis	rs1790761	0.806	rs35787427	chr11:67255877	C/T	cg00864171	chr11:67383662	NA	-0.43	-6.96	-0.31	1.17e-11	Mean corpuscular volume;
LGG	cis	rs56161922	1.000	rs12567945	chr1:207841934	T/C	cg09557387	chr1:207818395	CR1L	0.99	9.78	0.41	1.2e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg20503657	chr10:835505	NA	0.95	13.01	0.52	3.47e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs7945705	0.520	rs1984791	chr11:9035027	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.51	9.7	0.41	2.25e-20	Hemoglobin concentration;
LGG	cis	rs896854	0.608	rs6991067	chr8:95875676	A/G	cg16049864	chr8:95962084	TP53INP1	-0.33	-7.16	-0.32	3.22e-12	Type 2 diabetes;
LGG	cis	rs881375	0.933	rs7031096	chr9:123694942	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.73	0.48	5.18e-28	Rheumatoid arthritis;
LGG	trans	rs1941687	0.509	rs7238029	chr18:31317755	A/G	cg27147174	chr7:100797783	AP1S1	-0.65	-11.84	-0.48	1.93e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs79349575	0.783	rs4793991	chr17:47001801	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.91	0.31	1.57e-11	Type 2 diabetes;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg22535103	chr8:58192502	C8orf71	-1.0	-15.97	-0.6	4.76e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.04	-25.15	-0.76	1.21e-88	Schizophrenia;
LGG	cis	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg22857025	chr5:266934	NA	-1.28	-12.31	-0.5	2.43e-30	Breast cancer;
LGG	cis	rs12505749	0.542	rs12646890	chr4:57355262	T/C	cg07846311	chr4:57371927	ARL9	-0.32	-7.94	-0.35	1.52e-14	Airflow obstruction;
LGG	cis	rs151997	0.962	rs27256	chr5:50190264	G/C	cg06027927	chr5:50259733	NA	0.68	11.08	0.46	1.76e-25	Callous-unemotional behaviour;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs3008870	1.000	rs2815371	chr1:67504313	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.97	21.84	0.71	3.29e-73	Lymphocyte percentage of white cells;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg07087116	chr3:39447931	RPSA	0.73	6.95	0.31	1.29e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15506890	chr2:3487001	NA	-0.55	-10.58	-0.44	1.44e-23	Neurofibrillary tangles;
LGG	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs67311347	1.000	rs73078164	chr3:40480289	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.79	0.3	3.39e-11	Renal cell carcinoma;
LGG	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.69	0.34	9.18e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12135062	0.851	rs2651925	chr1:3101863	C/G	cg21609526	chr1:3105151	PRDM16	0.68	12.0	0.49	4.41e-29	Migraine;
LGG	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs17641971	0.783	rs2385127	chr8:49975746	C/T	cg00325661	chr8:49890786	NA	0.44	7.73	0.34	6.88e-14	Blood metabolite levels;
LGG	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg23899408	chr19:12877188	HOOK2	0.5	7.97	0.35	1.24e-14	Red blood cell traits;
LGG	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.59	0.69	2.37e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10876993	0.890	rs1678516	chr12:58047458	G/A	cg18357645	chr12:58087776	OS9	0.67	12.14	0.49	1.27e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7607369	0.596	rs10165754	chr2:219287370	A/G	cg10223061	chr2:219282414	VIL1	0.41	8.86	0.38	1.78e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs730775	0.505	rs325001	chr6:44270936	A/G	cg21130236	chr6:44246755	TMEM151B	0.34	7.5	0.33	3.21e-13	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg23583168	chr7:148888333	NA	-0.85	-16.26	-0.6	2.33e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.7	0.54	4.2e-36	Lung cancer;
LGG	cis	rs12042938	0.507	rs1765778	chr1:231732356	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-14.97	-0.57	1.26e-41	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.43	-0.5	7.93e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs36093844	0.706	rs79814326	chr11:85585573	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.56	10.34	0.43	1.12e-22	Longevity;
LGG	cis	rs11771526	0.786	rs28670858	chr7:32293126	G/A	cg27532318	chr7:32358331	NA	0.72	7.42	0.33	5.82e-13	Body mass index;
LGG	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg15208524	chr1:10270712	KIF1B	-0.4	-6.89	-0.3	1.86e-11	Hepatocellular carcinoma;
LGG	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg02428538	chr16:24856791	SLC5A11	-0.65	-9.74	-0.41	1.65e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs67133203	0.904	rs12369658	chr12:51328359	T/C	cg14688905	chr12:51403056	SLC11A2	0.73	10.77	0.45	2.64e-24	Urinary tract infection frequency;
LGG	cis	rs9964724	0.685	rs6507215	chr18:35195629	C/T	cg27332583	chr18:35150602	NA	0.39	8.37	0.36	6.89e-16	Educational attainment (years of education);
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.36	-0.36	7.66e-16	Total body bone mineral density;
LGG	cis	rs854765	0.647	rs721669	chr17:18005073	A/G	cg05444541	chr17:17804740	TOM1L2	-0.57	-12.37	-0.5	1.48e-30	Total body bone mineral density;
LGG	cis	rs11608355	0.545	rs2302704	chr12:109898797	A/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs6120849	0.617	rs12480442	chr20:33648388	C/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg11764359	chr7:65958608	NA	0.57	9.58	0.41	6.15e-20	Calcium levels;
LGG	cis	rs77956314	0.515	rs10850741	chr12:117432004	A/G	cg02017074	chr12:117425053	FBXW8	0.55	7.64	0.33	1.25e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.85	-0.3	2.37e-11	Migraine;Coronary artery disease;
LGG	trans	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05926928	chr17:57297772	GDPD1	0.56	9.26	0.4	7.74e-19	Schizophrenia;
LGG	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg18196295	chr10:418757	DIP2C	0.63	12.99	0.52	4.07e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg25811766	chr13:21894605	NA	-0.55	-7.33	-0.32	1.03e-12	White matter hyperintensity burden;
LGG	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg06873352	chr17:61820015	STRADA	-0.49	-7.65	-0.33	1.18e-13	Height;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg08888203	chr3:10149979	C3orf24	0.58	8.07	0.35	6.15e-15	Alzheimer's disease;
LGG	cis	rs637571	0.584	rs7107912	chr11:65603252	G/A	cg26695010	chr11:65641043	EFEMP2	0.62	10.81	0.45	1.98e-24	Eosinophil percentage of white cells;
LGG	cis	rs6460942	1.000	rs2053378	chr7:12405564	C/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.86	-0.3	2.19e-11	Coronary artery disease;
LGG	trans	rs3942852	0.568	rs2904315	chr11:48109948	C/T	cg15704280	chr7:45808275	SEPT13	0.7	10.98	0.45	4.21e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg12419862	chr22:24373484	LOC391322	-0.88	-17.25	-0.63	7.2e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	10.17	0.43	4.49e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4474465	0.790	rs12363982	chr11:78229167	C/T	cg27205649	chr11:78285834	NARS2	0.49	8.27	0.36	1.42e-15	Alzheimer's disease (survival time);
LGG	cis	rs4727443	0.866	rs35228488	chr7:99617852	G/C	cg12813108	chr7:99719912	CNPY4	-0.58	-11.31	-0.47	2.39e-26	Interstitial lung disease;
LGG	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.94	-0.42	3.21e-21	Retinal vascular caliber;
LGG	cis	rs6942756	0.876	rs28636722	chr7:129015151	C/T	cg02491457	chr7:128862824	NA	-0.66	-12.09	-0.49	2.04e-29	White matter hyperintensity burden;
LGG	cis	rs41271473	1.000	rs6665334	chr1:228868574	A/C	cg00850481	chr1:228891306	NA	-0.51	-8.66	-0.37	7.94e-17	Chronic lymphocytic leukemia;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs17030434	0.654	rs28640133	chr4:154645926	T/A	cg14289246	chr4:154710475	SFRP2	-0.62	-9.79	-0.41	1.08e-20	Electrocardiographic conduction measures;
LGG	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-8.3	-0.36	1.17e-15	Chronic sinus infection;
LGG	cis	rs2013441	0.866	rs2703784	chr17:20151320	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg11878867	chr6:150167359	LRP11	-0.5	-10.42	-0.44	5.53e-23	Lung cancer;
LGG	cis	rs3916	0.955	rs35771722	chr12:121154000	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-7.26	-0.32	1.6e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19626725	chr5:178986131	RUFY1	-0.44	-7.23	-0.32	1.97e-12	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05201673	chr11:47600596	NDUFS3;KBTBD4	0.44	6.78	0.3	3.66e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.0	0.31	9.25e-12	Lung cancer;
LGG	cis	rs3087591	0.639	rs2342053	chr17:29722196	A/G	cg24425628	chr17:29625626	OMG;NF1	0.58	12.17	0.49	9.31e-30	Hip circumference;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.71	0.34	7.87e-14	Obesity-related traits;
LGG	cis	rs3087591	0.887	rs12150521	chr17:29595108	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.59	0.56	6.31e-40	Hip circumference;
LGG	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg19338460	chr6:170058176	WDR27	-0.61	-8.24	-0.36	1.76e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10106298	0.901	rs13275089	chr8:103662852	T/C	cg10187029	chr8:103597600	NA	0.41	6.74	0.3	4.8e-11	Schizophrenia;
LGG	cis	rs7666738	0.606	rs10006454	chr4:99080361	G/A	cg05340658	chr4:99064831	C4orf37	0.42	6.84	0.3	2.56e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7623687	0.892	rs73088122	chr3:49432404	C/T	cg19401529	chr3:49056140	DALRD3	0.68	7.88	0.34	2.39e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs3741151	0.686	rs12276892	chr11:73283990	A/T	cg17517138	chr11:73019481	ARHGEF17	0.68	7.12	0.31	4.23e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg09222892	chr1:25734099	RHCE	-0.46	-9.59	-0.41	5.53e-20	Erythrocyte sedimentation rate;
LGG	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg19901956	chr11:77921274	USP35	-0.41	-6.84	-0.3	2.58e-11	Testicular germ cell tumor;
LGG	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg08085267	chr17:45401833	C17orf57	-0.73	-14.62	-0.56	4.66e-40	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10421328	0.848	rs867616	chr19:19757682	C/T	cg11584989	chr19:19387371	SF4	0.49	7.36	0.32	8.26e-13	Parental longevity (combined parental age at death);
LGG	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27297192	chr10:134578999	INPP5A	0.29	6.71	0.3	5.59e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07791516	chr6:150247246	NA	-0.32	-6.7	-0.3	5.98e-11	Lung cancer;
LGG	cis	rs9398803	0.636	rs864938	chr6:127022804	A/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.53	-0.41	8.63e-20	Male-pattern baldness;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.71	13.99	0.55	2.44e-37	Obesity-related traits;
LGG	cis	rs7617773	0.778	rs11707997	chr3:48377875	A/G	cg11946769	chr3:48343235	NME6	0.7	11.65	0.48	1.06e-27	Coronary artery disease;
LGG	cis	rs1669338	0.588	rs6784329	chr3:3200013	C/T	cg16797762	chr3:3221439	CRBN	-0.98	-12.99	-0.52	4.19e-33	White matter integrity;
LGG	cis	rs4948102	0.667	rs7811270	chr7:56139990	A/G	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.12	0.31	4.16e-12	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg16141378	chr3:129829833	LOC729375	0.4	9.3	0.4	5.43e-19	Neuroticism;
LGG	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.14	0.35	3.77e-15	Colorectal cancer;
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01341218	chr17:43662625	NA	0.66	11.89	0.48	1.22e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs854765	0.575	rs2955357	chr17:17946401	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-15.17	-0.58	1.75e-42	Total body bone mineral density;
LGG	trans	rs11039798	0.528	rs10769559	chr11:49032446	T/C	cg03929089	chr4:120376271	NA	0.74	10.4	0.44	6.84e-23	Axial length;
LGG	trans	rs17685	0.712	rs1639620	chr7:75704090	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs546131	0.928	rs516228	chr11:34838823	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.6	11.0	0.46	3.64e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg04851639	chr8:1020857	NA	-0.43	-9.0	-0.39	5.69e-18	Schizophrenia;
LGG	cis	rs490234	0.805	rs562004	chr9:128321771	T/C	cg14078157	chr9:128172775	NA	0.46	8.56	0.37	1.71e-16	Mean arterial pressure;
LGG	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg04568710	chr12:38710424	ALG10B	0.39	8.3	0.36	1.14e-15	Morning vs. evening chronotype;
LGG	cis	rs3818285	0.515	rs4918471	chr10:111660500	C/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-10.26	-0.43	2.23e-22	Superior crus of antihelix expression;
LGG	trans	rs78049276	0.688	rs17612693	chr4:148365339	T/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.31	-0.32	1.19e-12	Pulse pressure;
LGG	cis	rs1847505	0.520	rs717048	chr13:61497414	T/C	cg25164009	chr13:61490935	NA	0.55	9.38	0.4	3e-19	Polychlorinated biphenyl levels;
LGG	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.9	-0.38	1.31e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.31	-0.36	1.08e-15	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.4e-22	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09914581	chr2:11606494	E2F6	0.41	6.86	0.3	2.18e-11	Cognitive performance;
LGG	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg24530489	chr15:56299380	NA	-0.84	-7.79	-0.34	4.4e-14	Delta-5 desaturase activity;
LGG	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg15147215	chr3:52552868	STAB1	-0.44	-8.88	-0.38	1.45e-17	Electroencephalogram traits;
LGG	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg08807101	chr21:30365312	RNF160	0.92	19.39	0.67	9.52e-62	Dental caries;
LGG	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg15208524	chr1:10270712	KIF1B	-0.43	-7.57	-0.33	1.99e-13	Hepatocellular carcinoma;
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg06558623	chr16:89946397	TCF25	1.2	14.08	0.55	1e-37	Skin colour saturation;
LGG	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg24803719	chr17:45855879	NA	-0.31	-8.69	-0.37	6.29e-17	IgG glycosylation;
LGG	trans	rs1997103	1.000	rs2177804	chr7:55410302	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2732480	0.577	rs2634693	chr12:48706498	C/T	cg21466736	chr12:48725269	NA	-0.39	-7.73	-0.34	6.9e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg12288994	chr5:1860383	NA	0.76	15.19	0.58	1.38e-42	Cardiovascular disease risk factors;
LGG	cis	rs11920090	1.000	rs7635470	chr3:170696065	G/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.72e-16	Rheumatoid arthritis;
LGG	cis	rs2239547	0.603	rs17304995	chr3:53070755	A/G	cg11645453	chr3:52864694	ITIH4	0.55	8.03	0.35	8.28e-15	Schizophrenia;
LGG	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg09137382	chr11:130731461	NA	0.41	7.91	0.34	1.96e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg07414643	chr4:187882934	NA	0.54	11.29	0.46	2.86e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9399135	0.967	rs6902438	chr6:135336587	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.46	0.4	1.62e-19	Red blood cell count;
LGG	cis	rs1476670	0.710	rs2485993	chr1:44503040	C/T	cg09470012	chr1:44509516	NA	-0.45	-8.74	-0.38	4.22e-17	Eotaxin levels;
LGG	cis	rs4481887	0.538	rs6697831	chr1:248392205	C/T	cg01631408	chr1:248437212	OR2T33	-0.44	-7.34	-0.32	9.55e-13	Common traits (Other);
LGG	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.94e-46	Morning vs. evening chronotype;
LGG	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg05425664	chr17:57184151	TRIM37	0.46	7.4	0.33	6.56e-13	Testicular germ cell tumor;
LGG	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg04989706	chr14:50066350	PPIL5	-0.62	-10.26	-0.43	2.09e-22	Carotid intima media thickness;
LGG	cis	rs537930	0.560	rs501247	chr5:134353547	G/A	cg24576358	chr5:134350122	NA	0.4	8.93	0.38	1.01e-17	Height;
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.72	-0.3	5.31e-11	Total body bone mineral density;
LGG	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg08847533	chr14:75593920	NEK9	-0.52	-9.66	-0.41	3.16e-20	Height;
LGG	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.99	-0.35	1.11e-14	Neuroticism;
LGG	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg20821713	chr7:1055600	C7orf50	-0.41	-8.02	-0.35	8.94e-15	Longevity;Endometriosis;
LGG	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.49	-0.4	1.19e-19	Lung cancer;
LGG	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg15128208	chr22:42549153	NA	0.75	11.73	0.48	5.36e-28	Birth weight;
LGG	cis	rs10499694	0.735	rs2044859	chr7:50612562	A/G	cg14593290	chr7:50529359	DDC	0.4	8.07	0.35	5.97e-15	Body mass index;
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs4974559	0.690	rs28515563	chr4:1315123	G/A	cg02980000	chr4:1222292	CTBP1	0.81	9.24	0.39	9.17e-19	Systolic blood pressure;
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg03264133	chr6:25882463	NA	-0.48	-8.56	-0.37	1.7e-16	Intelligence (multi-trait analysis);
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg15556689	chr8:8085844	FLJ10661	0.39	7.13	0.31	3.94e-12	Monocyte count;
LGG	cis	rs13082711	0.911	rs4973772	chr3:27450234	G/T	cg02860705	chr3:27208620	NA	0.74	13.3	0.53	2.14e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs877282	0.853	rs11595507	chr10:756703	C/T	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs9354308	0.727	rs2351718	chr6:66597295	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs55794721	0.509	rs12027110	chr1:25775682	A/T	cg02931644	chr1:25747376	RHCE	0.44	9.51	0.4	1.03e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs6445975	0.619	rs112015230	chr3:58262204	T/C	cg24175188	chr3:58374923	PXK	0.4	7.56	0.33	2.22e-13	Systemic lupus erythematosus;
LGG	cis	rs3096299	0.967	rs2965830	chr16:89460290	T/C	cg02187348	chr16:89574699	SPG7	0.44	7.04	0.31	6.86e-12	Multiple myeloma (IgH translocation);
LGG	trans	rs2018683	0.803	rs12700920	chr7:28984924	A/G	cg19402173	chr7:128379420	CALU	-0.67	-11.95	-0.49	7.3e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs12493885	0.585	rs701264	chr3:153628080	A/G	cg17054900	chr3:154042577	DHX36	-0.58	-7.23	-0.32	1.95e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1124376	1.000	rs9819739	chr3:20140760	G/A	cg05072819	chr3:20081367	KAT2B	0.63	8.35	0.36	7.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg20608306	chr11:116969690	SIK3	-0.42	-13.57	-0.53	1.48e-35	Blood protein levels;
LGG	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg00717180	chr2:96193071	NA	0.39	6.83	0.3	2.74e-11	Coronary artery disease;
LGG	cis	rs79911532	0.515	rs113244522	chr7:75715307	G/A	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg07541023	chr7:19748670	TWISTNB	0.61	8.57	0.37	1.57e-16	Thyroid stimulating hormone;
LGG	cis	rs4731207	0.535	rs28820311	chr7:124598989	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs7828089	0.561	rs13266541	chr8:22266135	G/A	cg13512537	chr8:22265999	SLC39A14	-0.47	-8.29	-0.36	1.27e-15	Verbal declarative memory;
LGG	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11644478	chr21:40555479	PSMG1	0.83	14.65	0.56	3.31e-40	Cognitive function;
LGG	trans	rs7812879	0.636	rs2252729	chr8:11368219	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-7.04	-0.31	7.17e-12	Systemic lupus erythematosus;
LGG	cis	rs7444	0.941	rs5754422	chr22:21980257	A/G	cg11654148	chr22:21984483	YDJC	-0.38	-7.29	-0.32	1.31e-12	Systemic lupus erythematosus;
LGG	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07243736	chr16:783730	NARFL	0.6	10.17	0.43	4.76e-22	Height;
LGG	cis	rs12618769	0.597	rs55978998	chr2:99049014	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.35e-16	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs12282928	0.917	rs1601046	chr11:48337656	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02841941	chr3:152552615	P2RY1	0.41	6.92	0.31	1.49e-11	Gut microbiome composition (summer);
LGG	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg15704280	chr7:45808275	SEPT13	0.73	10.09	0.42	9.02e-22	Axial length;
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.29	0.4	6.12e-19	Electroencephalogram traits;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-7.0	-0.31	8.77e-12	Bipolar disorder;
LGG	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.65	-0.41	3.27e-20	Coronary artery disease;
LGG	cis	rs2180341	0.722	rs9388555	chr6:127576363	G/A	cg27446573	chr6:127587934	RNF146	0.96	17.88	0.64	9.59e-55	Breast cancer;
LGG	cis	rs7712401	0.601	rs30058	chr5:122297703	A/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27626746	chr11:126081776	RPUSD4;FAM118B	-0.44	-7.16	-0.32	3.12e-12	Pancreatic cancer;
LGG	cis	rs7928758	0.623	rs10894808	chr11:134256805	C/T	cg15243474	chr11:134282918	B3GAT1	1.0	11.32	0.47	2.17e-26	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.33e-13	Educational attainment;
LGG	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg06848047	chr4:90757629	SNCA	-0.35	-6.65	-0.3	8.51e-11	Dementia with Lewy bodies;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.35	-0.36	7.83e-16	Triglycerides;
LGG	cis	rs2070433	0.539	rs2070432	chr21:47957332	G/A	cg02959939	chr21:47813025	PCNT	-0.33	-7.23	-0.32	2.03e-12	Lymphocyte counts;
LGG	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.91	0.38	1.22e-17	Aortic root size;
LGG	cis	rs6977660	1.000	rs57916046	chr7:19800542	T/C	cg07541023	chr7:19748670	TWISTNB	0.46	7.07	0.31	5.63e-12	Thyroid stimulating hormone;
LGG	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.42	0.36	4.78e-16	Educational attainment;
LGG	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg02574844	chr11:5959923	NA	-0.54	-8.61	-0.37	1.17e-16	DNA methylation (variation);
LGG	cis	rs757110	0.770	rs4439492	chr11:17386733	C/T	cg04705435	chr11:17411270	KCNJ11	0.43	8.33	0.36	8.91e-16	Type 2 diabetes;
LGG	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.68	0.44	6.11e-24	Body mass index;
LGG	cis	rs2916247	0.954	rs1484560	chr8:93172236	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.35	-7.22	-0.32	2.08e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4509693	1.000	rs4277047	chr10:102499416	T/A	cg24179445	chr10:102496915	NA	0.38	6.81	0.3	2.96e-11	Alzheimer's disease;
LGG	cis	rs6580649	0.941	rs72644843	chr12:48465061	A/G	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs6908034	0.607	rs34109983	chr6:19808042	G/A	cg02682789	chr6:19804855	NA	0.92	8.74	0.38	4.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.19	-0.36	2.63e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3806843	0.547	rs183679	chr5:140271017	C/T	cg19875535	chr5:140030758	IK	-0.37	-7.26	-0.32	1.62e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs13102973	0.965	rs4331828	chr4:135849100	C/G	cg14419869	chr4:135874104	NA	0.57	10.71	0.45	4.63e-24	Subjective well-being;
LGG	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg25427524	chr10:38739819	LOC399744	0.47	9.11	0.39	2.48e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.07e-22	Colorectal cancer;
LGG	cis	rs3796619	1.000	rs12647929	chr4:1092019	G/T	cg21130718	chr4:1044621	NA	0.39	7.56	0.33	2.16e-13	Recombination rate (males);
LGG	cis	rs9951602	0.512	rs56009939	chr18:76644497	T/G	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07058694	chr12:111909145	ATXN2	0.44	7.92	0.35	1.77e-14	Electrocardiographic conduction measures;
LGG	cis	rs4865169	0.934	rs3796531	chr4:57850846	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.39	-6.78	-0.3	3.6e-11	Breast cancer;
LGG	cis	rs8076336	1	rs8076336	chr17:18212614	A/C	cg00898350	chr17:18164434	SMCR7	-0.31	-8.23	-0.36	1.85e-15	Parental longevity (combined parental age at death);
LGG	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg11764359	chr7:65958608	NA	-0.61	-8.98	-0.39	6.95e-18	Aortic root size;
LGG	cis	rs4566357	0.615	rs12621808	chr2:227909522	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.16	-0.39	1.7e-18	Coronary artery disease;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.75	-0.34	5.91e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	7.36	0.32	8.61e-13	Mood instability;
LGG	cis	rs2133450	1.000	rs12489402	chr3:7346663	C/T	cg19930620	chr3:7340148	GRM7	-0.38	-8.45	-0.37	3.86e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs9487094	0.922	rs59056467	chr6:109767931	C/T	cg16315928	chr6:109776240	MICAL1	0.57	9.57	0.41	6.23e-20	Height;
LGG	cis	rs9354308	0.764	rs1938080	chr6:66611181	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.23e-11	Metabolite levels;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7193541	0.684	rs9923145	chr16:74686166	G/A	cg01733217	chr16:74700730	RFWD3	1.1	34.98	0.85	4.78e-132	Multiple myeloma;
LGG	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg21452805	chr1:244014465	NA	0.62	7.44	0.33	4.91e-13	RR interval (heart rate);
LGG	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg27490568	chr2:178487706	NA	0.7	13.16	0.52	7.89e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs7119	0.717	rs11632729	chr15:77722006	G/A	cg17802220	chr15:77601643	NA	-0.54	-12.1	-0.49	1.85e-29	Type 2 diabetes;
LGG	cis	rs1371867	0.875	rs1612773	chr8:101337818	G/C	cg06636551	chr8:101224915	SPAG1	-0.46	-8.67	-0.37	7.47e-17	Atrioventricular conduction;
LGG	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg08312369	chr19:10679775	CDKN2D	0.49	6.73	0.3	4.89e-11	Red cell distribution width;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7000551	0.581	rs2293145	chr8:22262654	A/T	cg13512537	chr8:22265999	SLC39A14	-0.46	-7.46	-0.33	4.24e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg02254774	chr11:50257496	LOC441601	-0.58	-6.89	-0.3	1.79e-11	Myopia (pathological);
LGG	cis	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg05299278	chr17:33885742	SLFN14	0.43	8.21	0.36	2.18e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs9513627	0.665	rs79036236	chr13:100116405	C/T	cg15490075	chr13:100150979	NA	-0.71	-7.66	-0.34	1.09e-13	Obesity-related traits;
LGG	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.71	-0.3	5.83e-11	Iron status biomarkers;
LGG	cis	rs4262150	0.672	rs72806798	chr5:152357151	T/C	cg12297329	chr5:152029980	NA	-0.55	-8.43	-0.36	4.54e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg13010199	chr12:38710504	ALG10B	0.77	16.59	0.61	7.31e-49	Heart rate;
LGG	cis	rs9354308	0.764	rs62400772	chr6:66607468	C/G	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg12491688	chr15:44580831	CASC4	-0.41	-6.9	-0.31	1.71e-11	Calcium levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17012160	chr1:240255691	FMN2	0.43	6.84	0.3	2.54e-11	Cognitive performance;
LGG	cis	rs6732160	0.967	rs6760964	chr2:73387386	C/G	cg01422370	chr2:73384389	NA	0.53	10.21	0.43	3.25e-22	Intelligence (multi-trait analysis);
LGG	trans	rs1459104	1.000	rs67536351	chr11:55356464	G/A	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.62e-11	Body mass index;
LGG	cis	rs6840360	0.571	rs17360371	chr4:152565374	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.31	-0.36	1.04e-15	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg25019033	chr10:957182	NA	-0.53	-9.64	-0.41	3.62e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02510299	chr8:121457568	MTBP;MRPL13	0.41	6.65	0.3	8.32e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg26818010	chr10:134567672	INPP5A	-0.6	-9.45	-0.4	1.7e-19	Migraine;
LGG	cis	rs4363385	0.530	rs10888529	chr1:153050654	G/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.38	-0.4	3.06e-19	Inflammatory skin disease;
LGG	cis	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.26	0.36	1.55e-15	Mood instability;
LGG	cis	rs7635838	0.617	rs346071	chr3:11305584	A/T	cg00170343	chr3:11313890	ATG7	-0.54	-9.46	-0.4	1.53e-19	HDL cholesterol;
LGG	cis	rs1345301	1.000	rs12475055	chr2:102878891	G/T	cg05295703	chr2:102895712	NA	-0.39	-7.8	-0.34	4.22e-14	Waist circumference;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	4.17e-16	Retinal vascular caliber;
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg14092988	chr3:52407081	DNAH1	-0.33	-8.58	-0.37	1.49e-16	Bipolar disorder;
LGG	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	cg15522984	chr1:182991683	LAMC1	0.44	8.88	0.38	1.51e-17	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.95	-0.38	8.89e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.88	-0.42	4.94e-21	Pancreatic cancer;
LGG	cis	rs9534288	0.797	rs6561278	chr13:46572937	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs17221829	0.733	rs117029483	chr11:89365918	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	trans	rs6076960	0.652	rs6085441	chr20:6211383	A/G	cg21095983	chr6:86352623	SYNCRIP	0.56	10.42	0.44	5.5e-23	Smooth-surface caries;
LGG	cis	rs882632	0.668	rs10495767	chr2:29287192	C/T	cg23429306	chr2:29287725	C2orf71	0.41	8.51	0.37	2.46e-16	Major depressive disorder;
LGG	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-9.2	-0.39	1.27e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.16	0.58	1.89e-42	Lung cancer;
LGG	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.22	-0.32	2.16e-12	Neuroticism;
LGG	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.65	-0.44	7.49e-24	Systemic lupus erythematosus;
LGG	cis	rs7315438	0.512	rs1391711	chr12:115941429	T/A	cg18639984	chr12:115943877	NA	-0.39	-8.59	-0.37	1.39e-16	Colorectal cancer;
LGG	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg16141378	chr3:129829833	LOC729375	-0.39	-9.0	-0.39	5.78e-18	Neuroticism;
LGG	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.87	-0.3	2.08e-11	Bipolar disorder;
LGG	trans	rs11651000	0.625	rs58067360	chr17:45819587	G/C	cg06529181	chr19:52193933	NA	0.45	6.91	0.31	1.61e-11	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26790547	chr11:14542185	PSMA1	0.49	8.21	0.36	2.22e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10463554	0.963	rs6596530	chr5:102371440	C/G	cg23492399	chr5:102201601	PAM	-0.51	-7.67	-0.34	1.03e-13	Parkinson's disease;
LGG	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg06212747	chr3:49208901	KLHDC8B	0.78	13.85	0.54	9.6e-37	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg25986240	chr4:9926439	SLC2A9	0.36	7.42	0.33	5.66e-13	Bone mineral density;
LGG	cis	rs6693567	0.545	rs11205375	chr1:150412474	C/T	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs7134594	0.617	rs9668192	chr12:109860911	T/A	cg19025524	chr12:109796872	NA	-0.48	-9.73	-0.41	1.8e-20	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26166804	chr10:71812612	H2AFY2	0.45	7.09	0.31	4.91e-12	Gut microbiome composition (summer);
LGG	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg08344181	chr3:125677491	NA	-0.79	-8.25	-0.36	1.68e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.91e-60	Menopause (age at onset);
LGG	cis	rs4751006	0.543	rs7899778	chr10:128780419	A/C	cg05702161	chr10:128779687	DOCK1	-0.94	-10.78	-0.45	2.62e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11190604	1.000	rs11190595	chr10:102291761	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs12517041	1.000	rs1428619	chr5:23282426	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg20503657	chr10:835505	NA	0.75	10.43	0.44	5.3e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg13802316	chr11:70253460	CTTN	-0.6	-7.55	-0.33	2.28e-13	Coronary artery disease;
LGG	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.59e-15	Obesity-related traits;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs3816183	0.585	rs4953530	chr2:42873371	C/T	cg14631114	chr2:43023945	NA	0.35	6.88	0.3	1.94e-11	Hypospadias;
LGG	cis	rs6940638	0.513	rs4424065	chr6:27036456	C/T	cg12292205	chr6:26970375	C6orf41	-0.56	-10.73	-0.45	3.82e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7766436	0.813	rs7773580	chr6:22587114	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs12477438	0.501	rs6542881	chr2:100089871	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.24	0.39	9.01e-19	Motion sickness;
LGG	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg13072238	chr3:49761600	GMPPB	0.55	7.44	0.33	4.79e-13	Menarche (age at onset);
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18252515	chr7:66147081	NA	0.44	7.36	0.32	8.42e-13	Aortic root size;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	9.0	0.39	5.87e-18	Renal function-related traits (BUN);
LGG	cis	rs17227506	0.641	rs11780636	chr8:13439673	C/A	cg03566418	chr8:13424080	C8orf48	0.63	9.86	0.42	5.97e-21	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs60695258	0.512	rs2053770	chr4:87908085	C/T	cg01323104	chr4:87958903	AFF1	-0.24	-6.69	-0.3	6.41e-11	Hematocrit;
LGG	cis	rs26232	0.521	rs67019105	chr5:102374163	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.43	-0.36	4.43e-16	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08721324	chr16:89384602	ANKRD11	0.31	7.04	0.31	6.77e-12	Gut microbiome composition (summer);
LGG	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg26396452	chr14:65542826	MAX	0.42	8.44	0.37	4.2e-16	Obesity-related traits;
LGG	cis	rs10089	0.953	rs13358455	chr5:127365786	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.47	0.47	5.79e-27	Ileal carcinoids;
LGG	cis	rs4538187	1.000	rs4671071	chr2:64085638	C/T	cg19915305	chr2:64069682	UGP2	0.68	15.66	0.59	1.18e-44	Systolic blood pressure;
LGG	trans	rs9354308	0.868	rs9345696	chr6:66557641	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-7.92	-0.35	1.72e-14	Metabolite levels;
LGG	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg27490568	chr2:178487706	NA	0.72	13.55	0.53	1.76e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12928939	0.517	rs9940234	chr16:71964805	C/T	cg03805757	chr16:71968109	PKD1L3	-0.66	-13.3	-0.53	2.07e-34	Post bronchodilator FEV1;
LGG	cis	rs8013055	0.699	rs66798104	chr14:105987782	C/G	cg19700328	chr14:106028568	NA	-0.61	-10.05	-0.42	1.24e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.68	0.3	6.85e-11	Cognitive function;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.97	0.35	1.22e-14	Prudent dietary pattern;
LGG	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.84	18.01	0.64	2.3e-55	Chronic sinus infection;
LGG	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg14191688	chr11:70257035	CTTN	0.6	8.61	0.37	1.2e-16	Coronary artery disease;
LGG	trans	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg21659725	chr3:3221576	CRBN	0.56	7.5	0.33	3.36e-13	Intelligence (multi-trait analysis);
LGG	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg02566259	chr4:3043199	NA	0.34	8.82	0.38	2.28e-17	Serum sulfate level;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	trans	rs6787172	0.537	rs9811217	chr3:158117700	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs9976767	0.759	rs9325634	chr21:43818790	A/G	cg23042151	chr21:43824109	UBASH3A	-0.46	-9.42	-0.4	2.09e-19	Type 1 diabetes;
LGG	cis	rs4740619	0.507	rs13298860	chr9:16015384	G/T	cg14451791	chr9:16040625	NA	0.29	7.05	0.31	6.48e-12	Body mass index;
LGG	cis	rs62025270	0.632	rs62022918	chr15:86218284	C/G	cg25843651	chr15:86329602	KLHL25	0.56	8.48	0.37	3.04e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg00701064	chr4:6280414	WFS1	0.73	16.03	0.6	2.62e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs5742933	0.817	rs1055091	chr2:190635143	C/T	cg10453823	chr2:190539512	ANKAR	-0.47	-6.81	-0.3	3.05e-11	Ferritin levels;
LGG	cis	rs7727544	0.508	rs11739935	chr5:131380658	C/T	cg07395648	chr5:131743802	NA	-0.39	-6.95	-0.31	1.21e-11	Blood metabolite levels;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.6	10.6	0.44	1.15e-23	Obesity-related traits;
LGG	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg05925327	chr15:68127851	NA	-0.36	-8.49	-0.37	2.93e-16	Restless legs syndrome;
LGG	cis	rs714515	0.934	rs2227200	chr1:172333448	A/G	cg01573306	chr1:172330400	DNM3	0.35	7.84	0.34	3.17e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs7539542	0.556	rs10753928	chr1:202891045	A/C	cg19681188	chr1:202830198	LOC148709	-0.48	-7.68	-0.34	9.76e-14	Mean platelet volume;
LGG	cis	rs3735485	0.678	rs1132130	chr7:45120248	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.07	-0.39	3.45e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg05941027	chr17:61774174	LIMD2	0.31	7.2	0.32	2.52e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg04731861	chr2:219085781	ARPC2	-0.44	-10.65	-0.44	8.08e-24	Colorectal cancer;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg12070911	chr6:150209640	RAET1E	0.28	7.24	0.32	1.94e-12	Testicular germ cell tumor;
LGG	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg02023728	chr11:77925099	USP35	0.44	7.84	0.34	3.12e-14	Testicular germ cell tumor;
LGG	cis	rs208520	0.802	rs851600	chr6:66893754	T/C	cg07460842	chr6:66804631	NA	-0.95	-17.25	-0.63	7.6900000000000007e-52	Exhaled nitric oxide output;
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11750568	0.967	rs6879775	chr5:178515196	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.44	-7.03	-0.31	7.46e-12	Height;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg06074448	chr4:187884817	NA	-0.57	-12.9	-0.51	9.28e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg27532318	chr7:32358331	NA	0.84	7.98	0.35	1.18e-14	Body mass index;
LGG	cis	rs7191700	0.836	rs12708722	chr16:11428905	T/A	cg00044050	chr16:11439710	C16orf75	0.48	7.47	0.33	4.05e-13	Multiple sclerosis;
LGG	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.67	-0.54	5.85e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg19338460	chr6:170058176	WDR27	-0.88	-10.56	-0.44	1.66e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7717393	0.786	rs10042069	chr5:155764895	C/A	cg12904904	chr5:155754151	SGCD	0.63	6.85	0.3	2.41e-11	Egg allergy;
LGG	cis	rs2133450	0.662	rs9839429	chr3:7275648	G/C	cg19930620	chr3:7340148	GRM7	-0.34	-7.27	-0.32	1.57e-12	Early response to risperidone in schizophrenia;
LGG	cis	rs4356932	1.000	rs10014837	chr4:76941818	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.37	-0.43	8.54e-23	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.09	-0.31	4.89e-12	Menopause (age at onset);
LGG	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg09264619	chr17:80180166	NA	0.52	10.23	0.43	2.82e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs8002861	0.935	rs9533672	chr13:44451180	C/T	cg12856521	chr11:46389249	DGKZ	0.4	6.78	0.3	3.69e-11	Leprosy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05644321	chr20:20693493	RALGAPA2	0.45	7.06	0.31	6e-12	Gut microbiome composition (summer);
LGG	cis	rs6032067	0.516	rs1883829	chr20:43891253	G/C	cg10761708	chr20:43804764	PI3	0.47	7.39	0.32	6.86e-13	Blood protein levels;
LGG	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg24812749	chr6:127587940	RNF146	0.64	10.92	0.45	7.4e-25	Breast cancer;
LGG	cis	rs12493885	0.654	rs61792350	chr3:153712959	A/G	cg17054900	chr3:154042577	DHX36	-0.74	-8.68	-0.37	6.81e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	7.89	0.34	2.14e-14	Menarche (age at onset);
LGG	cis	rs888194	0.677	rs2164743	chr12:109875163	C/T	cg19025524	chr12:109796872	NA	-0.46	-9.34	-0.4	4.19e-19	Neuroticism;
LGG	cis	rs4262150	0.767	rs13182323	chr5:152329944	T/C	cg12297329	chr5:152029980	NA	0.63	11.11	0.46	1.43e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9486719	0.522	rs4839683	chr6:96851933	A/G	cg06623918	chr6:96969491	KIAA0776	0.66	10.22	0.43	3.08e-22	Migraine;Coronary artery disease;
LGG	cis	rs3741151	1.000	rs7949364	chr11:73041077	A/G	cg17517138	chr11:73019481	ARHGEF17	0.96	9.91	0.42	3.88e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9914544	0.628	rs67053020	chr17:18680061	G/C	cg26378065	chr17:18585709	ZNF286B	0.42	7.9	0.34	2.09e-14	Educational attainment (years of education);
LGG	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.7	0.56	2.01e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.56	0.33	2.25e-13	Neuroticism;
LGG	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	10.77	0.45	2.76e-24	Lung cancer in ever smokers;
LGG	cis	rs17401966	0.931	rs12131441	chr1:10428952	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.76	0.34	5.3e-14	Hepatocellular carcinoma;
LGG	cis	rs7017914	0.967	rs62530792	chr8:71618767	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs6466055	0.720	rs6466064	chr7:105024217	T/C	cg04380332	chr7:105027541	SRPK2	-0.4	-7.46	-0.33	4.31e-13	Schizophrenia;
LGG	cis	rs745080	0.519	rs1824258	chr14:52919930	C/T	cg23333723	chr14:53022898	GPR137C	-0.43	-8.55	-0.37	1.77e-16	Orofacial clefts;
LGG	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg00012203	chr2:219082015	ARPC2	-0.84	-17.19	-0.62	1.46e-51	Colorectal cancer;
LGG	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.86	-0.3	2.27e-11	Educational attainment;
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg02297831	chr4:17616191	MED28	0.45	8.21	0.36	2.29e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08645402	chr16:4508243	NA	0.49	9.39	0.4	2.65e-19	Schizophrenia;
LGG	cis	rs7589342	0.839	rs7589790	chr2:106433909	C/G	cg16077055	chr2:106428750	NCK2	-0.31	-8.08	-0.35	5.61e-15	Addiction;
LGG	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg25817165	chr18:72167213	CNDP2	-0.68	-15.23	-0.58	9.2e-43	Refractive error;
LGG	trans	rs7395662	0.895	rs1121000	chr11:48711790	A/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.2	0.39	1.19e-18	Rheumatoid arthritis;
LGG	cis	rs36051895	0.664	rs3780373	chr9:5098223	T/C	cg02405213	chr9:5042618	JAK2	-0.8	-15.49	-0.58	6.75e-44	Pediatric autoimmune diseases;
LGG	cis	rs10186029	0.676	rs10187830	chr2:213964796	C/G	cg08319019	chr2:214017104	IKZF2	0.47	8.28	0.36	1.29e-15	Systemic sclerosis;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg22704520	chr2:200820451	C2orf60;C2orf47	-0.43	-7.22	-0.32	2.09e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.98	-0.31	1.01e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.09	0.57	3.74e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9875589	0.509	rs9824910	chr3:14040136	C/T	cg19554555	chr3:13937349	NA	-0.55	-9.85	-0.42	6.49e-21	Ovarian reserve;
LGG	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs1355223	1.000	rs1396883	chr11:34757447	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-7.63	-0.33	1.32e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7742824	0.602	rs4714753	chr6:44104881	A/G	cg04074908	chr6:44101190	TMEM63B	0.52	10.92	0.45	7.26e-25	Major depressive disorder;
LGG	cis	rs2309757	1	rs2309757	chr2:100807725	T/C	cg21926883	chr2:100939477	LONRF2	-0.42	-7.64	-0.33	1.23e-13	Educational attainment (college completion);
LGG	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.52	0.47	3.51e-27	Bone mineral density;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.27	-0.36	1.48e-15	Neuroticism;
LGG	cis	rs2013441	1.000	rs1373147	chr17:20206645	T/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19727166	chr6:117804670	DCBLD1	0.4	6.71	0.3	5.74e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.8	-0.48	2.76e-28	Alzheimer's disease;
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs7223966	0.691	rs9893518	chr17:62006997	A/G	cg17202724	chr17:61916730	SMARCD2	-0.36	-6.77	-0.3	3.84e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7129556	0.737	rs4344516	chr11:77438059	A/G	cg12586386	chr11:77299805	AQP11	0.45	7.33	0.32	1e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.26	0.36	1.53e-15	Prudent dietary pattern;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.23	-0.32	2.06e-12	Lung cancer;
LGG	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07167872	chr1:205819463	PM20D1	0.38	7.13	0.31	3.81e-12	Menarche (age at onset);
LGG	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	15.6	0.59	2.11e-44	IgG glycosylation;
LGG	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.59	0.37	1.33e-16	Retinal vascular caliber;
LGG	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg09307838	chr4:120376055	NA	0.81	13.07	0.52	1.81e-33	Corneal astigmatism;
LGG	cis	rs7937890	0.587	rs11023204	chr11:14411223	C/A	cg02886208	chr11:14281011	SPON1	-0.41	-8.05	-0.35	7.24e-15	Mitochondrial DNA levels;
LGG	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg01966878	chr4:90757139	SNCA	0.35	7.29	0.32	1.34e-12	Dementia with Lewy bodies;
LGG	cis	rs3816183	1.000	rs3816185	chr2:43015902	G/A	cg27299406	chr2:43020013	HAAO	-0.28	-6.83	-0.3	2.69e-11	Hypospadias;
LGG	cis	rs7512552	0.839	rs11587116	chr1:150451898	A/T	cg15654264	chr1:150340011	RPRD2	0.45	9.18	0.39	1.41e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4631830	0.720	rs2611512	chr10:51515534	A/G	cg10326726	chr10:51549505	MSMB	-0.63	-12.74	-0.51	4.53e-32	Prostate-specific antigen levels;
LGG	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-7.03	-0.31	7.62e-12	Schizophrenia;
LGG	cis	rs151997	0.569	rs62367393	chr5:50270360	C/A	cg06027927	chr5:50259733	NA	0.62	10.18	0.43	4.3e-22	Callous-unemotional behaviour;
LGG	cis	rs1580019	0.961	rs2392056	chr7:32498953	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.8	15.04	0.57	6.57e-42	Cognitive ability;
LGG	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.4	0.33	6.4e-13	Mood instability;
LGG	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg03175030	chr11:2018143	H19;MIR675	-0.61	-11.41	-0.47	9.71e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg24189917	chr7:1970923	MAD1L1	0.49	7.35	0.32	9.14e-13	Bipolar disorder;
LGG	cis	rs490234	0.746	rs1266009	chr9:128192316	A/G	cg14078157	chr9:128172775	NA	-0.46	-8.71	-0.38	5.46e-17	Mean arterial pressure;
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg00800038	chr16:89945340	TCF25	-0.69	-8.11	-0.35	4.55e-15	Skin colour saturation;
LGG	cis	rs6764363	0.587	rs3913285	chr3:281916	C/T	cg02057681	chr3:285234	CHL1	-0.45	-8.17	-0.36	2.89e-15	Sudden cardiac arrest;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.34	-0.63	2.8e-52	Skin colour saturation;
LGG	cis	rs2188561	0.697	rs13242107	chr7:107375245	G/A	cg16793755	chr7:107334138	SLC26A4	0.42	7.39	0.32	6.77e-13	Alcohol consumption;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.59	-9.55	-0.41	7.72e-20	Longevity;
LGG	cis	rs933688	0.639	rs332530	chr5:90789810	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	15.55	0.59	3.57e-44	Smoking behavior;
LGG	cis	rs4604732	0.631	rs10754561	chr1:247622800	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.56	8.5	0.37	2.69e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20296188	chr17:77397067	HRNBP3	0.5	8.34	0.36	8.66e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7107174	1.000	rs11603112	chr11:78073491	G/A	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	8.01e-13	Testicular germ cell tumor;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.95	0.57	1.54e-41	Platelet count;
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs4132509	1.000	rs10927050	chr1:243805907	A/G	cg21452805	chr1:244014465	NA	0.6	7.08	0.31	5.26e-12	RR interval (heart rate);
LGG	cis	rs17453880	0.929	rs4958572	chr5:152031109	C/T	cg12297329	chr5:152029980	NA	-0.9	-23.63	-0.74	1.38e-81	Subjective well-being;
LGG	cis	rs919433	0.680	rs2565161	chr2:198285554	C/G	cg00792783	chr2:198669748	PLCL1	0.51	8.04	0.35	7.4e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg13443165	chr9:33130375	B4GALT1	0.55	7.83	0.34	3.45e-14	IgG glycosylation;
LGG	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg11984989	chr7:158649758	WDR60	1.01	14.27	0.55	1.47e-38	Height;
LGG	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg11752832	chr7:134001865	SLC35B4	0.67	12.47	0.5	5.81e-31	Mean platelet volume;
LGG	cis	rs6466055	0.748	rs1204080	chr7:104988848	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.17	0.32	3.08e-12	Schizophrenia;
LGG	cis	rs2307022	0.586	rs2279539	chr16:68395094	G/A	cg07273125	chr16:68295692	NA	0.44	9.91	0.42	4.05e-21	Body mass index;
LGG	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.6	-0.33	1.69e-13	Joint mobility (Beighton score);
LGG	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg27121462	chr16:89883253	FANCA	0.62	11.44	0.47	7.08e-27	Vitiligo;
LGG	cis	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg01244601	chr4:120671846	NA	-0.37	-6.88	-0.3	1.99e-11	Corneal astigmatism;
LGG	cis	rs13314892	0.806	rs2163326	chr3:69876683	A/C	cg17445875	chr3:69859618	MITF	-0.39	-7.64	-0.33	1.24e-13	QRS complex (12-leadsum);
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg04166393	chr7:2884313	GNA12	0.42	7.86	0.34	2.78e-14	Height;
LGG	cis	rs2479724	0.935	rs7753507	chr6:41784094	C/T	cg17623882	chr6:41773611	USP49	0.52	9.35	0.4	3.66e-19	Menarche (age at onset);
LGG	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.41	7.23	0.32	1.97e-12	Alzheimer's disease (late onset);
LGG	cis	rs1405069	0.562	rs697746	chr6:36926412	A/T	cg24661236	chr6:36930062	PI16	0.42	9.26	0.4	7.71e-19	Chemerin levels;
LGG	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg23505145	chr19:12996616	KLF1	0.4	7.18	0.32	2.73e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg09307838	chr4:120376055	NA	0.74	12.65	0.51	1.07e-31	Corneal astigmatism;
LGG	cis	rs3747547	0.710	rs7864677	chr9:37949969	C/T	cg13774184	chr9:37916125	SHB	-0.72	-7.99	-0.35	1.11e-14	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg12623918	chr2:306882	NA	0.53	9.89	0.42	4.9e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg12182343	chr17:75955921	NA	-0.43	-6.69	-0.3	6.43e-11	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.99	-0.45	3.87e-25	Lung cancer;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.56	-0.37	1.69e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.28	-0.32	1.42e-12	Retinal vascular caliber;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.66	-0.37	7.64e-17	Menopause (age at onset);
LGG	cis	rs7937890	0.904	rs7484197	chr11:14283654	C/T	cg22961513	chr11:14280813	SPON1	-0.38	-9.62	-0.41	4.18e-20	Mitochondrial DNA levels;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.29	-0.36	1.27e-15	Triglycerides;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.17	-0.58	1.71e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs9863	0.862	rs6488912	chr12:124442752	T/C	cg13487667	chr12:124434373	CCDC92	-0.35	-7.03	-0.31	7.41e-12	White blood cell count;
LGG	cis	rs7737355	0.812	rs8180462	chr5:130907189	A/G	cg06307176	chr5:131281290	NA	0.45	7.15	0.32	3.39e-12	Life satisfaction;
LGG	cis	rs4742903	0.935	rs4743692	chr9:106931890	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9916302	0.904	rs587343	chr17:37440603	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-10.76	-0.45	2.9e-24	Prudent dietary pattern;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs74054849	0.850	rs6692555	chr1:16012657	C/T	cg05660106	chr1:15850417	CASP9	-0.66	-6.81	-0.3	3.03e-11	Alcoholic chronic pancreatitis;
LGG	cis	rs4262150	0.810	rs72797233	chr5:151992765	A/G	cg12297329	chr5:152029980	NA	-0.81	-15.95	-0.6	5.57e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg11766577	chr21:47581405	C21orf56	-0.51	-8.77	-0.38	3.43e-17	Testicular germ cell tumor;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.09	-0.31	5.15e-12	Obesity-related traits;
LGG	cis	rs62103177	0.525	rs9949598	chr18:77753037	G/A	cg20368463	chr18:77673604	PQLC1	-0.55	-7.97	-0.35	1.26e-14	Opioid sensitivity;
LGG	trans	rs7246760	1.000	rs28441975	chr19:9897631	C/A	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg18225595	chr11:63971243	STIP1	0.56	7.54	0.33	2.43e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.18	-0.36	2.8e-15	Obesity-related traits;
LGG	cis	rs1620921	0.967	rs783162	chr6:161182954	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.49	-0.33	3.61e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg08888203	chr3:10149979	C3orf24	0.52	8.7	0.37	5.97e-17	Alzheimer's disease;
LGG	trans	rs2898857	0.524	rs2906100	chr17:47372764	C/T	cg11430096	chr6:110968061	CDK19	0.5	8.53	0.37	2.17e-16	Cancer;
LGG	cis	rs10949834	0.878	rs2527839	chr7:73510891	G/C	cg07137043	chr7:73588983	EIF4H	-0.65	-7.37	-0.32	8.07e-13	Verbal memory performance (residualized delayed recall change);
LGG	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.63	-0.41	3.96e-20	Morning vs. evening chronotype;
LGG	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg01864069	chr14:103024347	NA	-0.68	-9.55	-0.41	7.29e-20	Platelet count;
LGG	cis	rs5758659	0.652	rs133313	chr22:42401749	G/T	cg15128208	chr22:42549153	NA	-0.37	-7.36	-0.32	8.41e-13	Cognitive function;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.57e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs8013055	0.846	rs10136015	chr14:105973469	A/C	cg19700328	chr14:106028568	NA	-0.6	-10.14	-0.43	6.09e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs977987	0.800	rs1011121	chr16:75325933	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.75	0.3	4.38e-11	Dupuytren's disease;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg07791516	chr6:150247246	NA	0.34	7.47	0.33	3.97e-13	Testicular germ cell tumor;
LGG	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg06618935	chr21:46677482	NA	-0.5	-9.73	-0.41	1.8e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.66	-0.63	9.42e-54	Breast cancer;
LGG	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg15208524	chr1:10270712	KIF1B	0.41	6.69	0.3	6.47e-11	Hepatocellular carcinoma;
LGG	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg15268244	chr15:77196840	NA	-0.36	-7.97	-0.35	1.26e-14	Blood metabolite levels;
LGG	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.89	0.45	9.96e-25	Aortic root size;
LGG	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg01028140	chr2:1542097	TPO	-0.52	-8.2	-0.36	2.45e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg11878867	chr6:150167359	LRP11	-0.57	-11.77	-0.48	3.83e-28	Lung cancer;
LGG	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.48	0.4	1.3e-19	Schizophrenia;
LGG	cis	rs7666738	0.791	rs62318907	chr4:99037120	C/T	cg05340658	chr4:99064831	C4orf37	0.48	8.07	0.35	6.05e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg21385522	chr1:16154831	NA	0.56	9.99	0.42	2.07e-21	Systolic blood pressure;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg18402987	chr7:1209562	NA	0.38	6.92	0.31	1.54e-11	Longevity;Endometriosis;
LGG	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg18681998	chr4:17616180	MED28	0.86	19.69	0.68	3.72e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9964724	0.929	rs1941955	chr18:35162838	T/C	cg27332583	chr18:35150602	NA	-0.46	-10.04	-0.42	1.36e-21	Educational attainment (years of education);
LGG	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg24130564	chr14:104152367	KLC1	-0.4	-7.47	-0.33	4.16e-13	Body mass index;
LGG	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7173389	1.000	rs4489968	chr15:73665506	T/G	cg01796676	chr15:73680284	NA	0.51	8.63	0.37	1.02e-16	Resting heart rate;
LGG	cis	rs4356932	0.790	rs6532130	chr4:76969190	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs2404602	0.647	rs4886840	chr15:77179002	A/G	cg15268244	chr15:77196840	NA	0.47	10.08	0.42	9.96e-22	Blood metabolite levels;
LGG	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg27205649	chr11:78285834	NARS2	-0.52	-8.64	-0.37	8.95e-17	Alzheimer's disease (survival time);
LGG	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg21385522	chr1:16154831	NA	0.63	10.43	0.44	5.25e-23	Dilated cardiomyopathy;
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg23000734	chr10:126850823	CTBP2	0.31	9.26	0.4	7.97e-19	Menarche (age at onset);
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.72	0.38	5.09e-17	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg08400814	chr5:56204995	C5orf35	-0.47	-7.64	-0.33	1.3e-13	Initial pursuit acceleration;
LGG	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.5	-0.37	2.54e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs11098499	0.618	rs28491261	chr4:120294900	C/A	cg09307838	chr4:120376055	NA	0.8	13.28	0.53	2.39e-34	Corneal astigmatism;
LGG	trans	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg09048205	chr5:1608656	LOC728613	-0.52	-8.44	-0.37	4.08e-16	Breast cancer;
LGG	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.87	-10.78	-0.45	2.43e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.36	0.43	9.61e-23	Aortic root size;
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.46e-17	Life satisfaction;
LGG	cis	rs2224391	0.628	rs9405261	chr6:5249702	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.3	-0.32	1.29e-12	Height;
LGG	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.19	-0.46	6.66e-26	Personality dimensions;
LGG	trans	rs10506458	0.915	rs12423078	chr12:63397529	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.43	-0.53	5.85e-35	Hemostatic factors and hematological phenotypes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07335156	chr7:75947820	NA	0.5	7.79	0.34	4.58e-14	Gut microbiome composition (summer);
LGG	cis	rs1670533	1.000	rs62294756	chr4:1097676	G/A	cg27284194	chr4:1044797	NA	-0.55	-10.06	-0.42	1.2e-21	Recombination rate (females);
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg21782813	chr7:2030301	MAD1L1	0.48	11.45	0.47	6.67e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs9486719	0.895	rs11152960	chr6:96900398	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.53	-0.44	2.11e-23	Migraine;Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26888861	chr11:62521812	ZBTB3	0.41	6.81	0.3	3.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11645898	0.748	rs72791120	chr16:72224583	G/T	cg14768367	chr16:72042858	DHODH	-0.73	-9.83	-0.42	7.73e-21	Blood protein levels;
LGG	cis	rs9487094	0.813	rs3799840	chr6:109702646	A/T	cg16315928	chr6:109776240	MICAL1	0.54	9.05	0.39	4.13e-18	Height;
LGG	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.45	-0.4	1.73e-19	Sudden cardiac arrest;
LGG	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg03264133	chr6:25882463	NA	-0.41	-7.38	-0.32	7.5e-13	Height;
LGG	cis	rs2075371	0.965	rs1862049	chr7:133978344	A/T	cg20476274	chr7:133979776	SLC35B4	0.78	15.64	0.59	1.36e-44	Mean platelet volume;
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg08645402	chr16:4508243	NA	0.43	7.07	0.31	5.92e-12	Schizophrenia;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.01	-0.39	5.29e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg16339924	chr4:17578868	LAP3	-0.59	-9.54	-0.41	8.1e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.19	-0.36	2.63e-15	Neuroticism;
LGG	cis	rs11693319	1.000	rs2130221	chr2:179750087	T/C	cg17765952	chr2:179737173	CCDC141	0.58	9.41	0.4	2.41e-19	Blood pressure measurement (cold pressor test);
LGG	cis	rs9473924	0.505	rs9473931	chr6:50851411	C/G	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs12362504	0.532	rs4334006	chr11:9923276	C/T	cg07197493	chr11:9884649	SBF2	-0.34	-6.66	-0.3	7.85e-11	Survival in pancreatic cancer;
LGG	cis	rs2204008	0.580	rs11174421	chr12:38105138	A/G	cg26384229	chr12:38710491	ALG10B	0.88	18.4	0.65	3.63e-57	Bladder cancer;
LGG	cis	rs77633900	0.614	rs2469241	chr15:76873908	A/G	cg21673338	chr15:77095150	SCAPER	-0.62	-9.76	-0.41	1.32e-20	Non-glioblastoma glioma;Glioma;
LGG	cis	rs231513	0.954	rs231512	chr17:41965831	G/A	cg26893861	chr17:41843967	DUSP3	-0.58	-6.89	-0.3	1.88e-11	Cognitive function;
LGG	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	10.52	0.44	2.31e-23	Iron status biomarkers;
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg27121462	chr16:89883253	FANCA	0.62	11.26	0.46	3.72e-26	Vitiligo;
LGG	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg02297831	chr4:17616191	MED28	0.51	9.85	0.42	6.4e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs240764	0.782	rs151637	chr6:101104191	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs2114646	0.731	rs7577456	chr2:170645805	A/G	cg17598339	chr2:170624727	NA	0.35	6.71	0.3	5.68e-11	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg27523141	chr10:43048294	ZNF37B	-0.43	-8.55	-0.37	1.81e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.58	-0.47	2.02e-27	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.07	-0.31	5.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg15268244	chr15:77196840	NA	0.31	6.91	0.31	1.62e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg16920238	chr17:80076378	CCDC57	-0.33	-7.43	-0.33	5.17e-13	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17323045	chr14:58764804	FLJ31306;ARID4A	0.4	6.69	0.3	6.48e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1577917	0.559	rs2223788	chr6:86811920	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.39	-6.65	-0.3	8.23e-11	Response to antipsychotic treatment;
LGG	cis	rs7928758	0.708	rs11223785	chr11:134275986	G/A	cg22777979	chr11:134283252	B3GAT1	0.62	8.87	0.38	1.66e-17	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6141769	0.518	rs28565102	chr20:31285458	T/G	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.79	-0.3	3.55e-11	Subjective well-being;
LGG	trans	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs258892	0.947	rs266446	chr5:72182030	T/G	cg21869765	chr5:72125136	TNPO1	0.42	6.77	0.3	3.84e-11	Small cell lung carcinoma;
LGG	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.23	-0.49	5.53e-30	Hemoglobin concentration;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs561341	0.681	rs56064462	chr17:30235116	G/A	cg20587970	chr11:113659929	NA	-0.9	-13.76	-0.54	2.39e-36	Hip circumference adjusted for BMI;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg11168104	chr5:1857477	NA	-0.41	-7.15	-0.32	3.38e-12	Cardiovascular disease risk factors;
LGG	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	9.43	0.4	2.05e-19	Coronary artery disease;
LGG	cis	rs4727027	0.901	rs4727017	chr7:148822062	A/G	cg23583168	chr7:148888333	NA	-0.88	-17.14	-0.62	2.44e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg11494091	chr17:61959527	GH2	0.51	8.08	0.35	5.51e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9457247	1.000	rs2769347	chr6:167371737	T/A	cg07741184	chr6:167504864	NA	-0.32	-7.03	-0.31	7.49e-12	Crohn's disease;
LGG	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	8.99	0.39	6.22e-18	Coronary artery disease;
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg13628971	chr7:2884303	GNA12	0.46	9.78	0.41	1.13e-20	Height;
LGG	cis	rs6087990	0.735	rs910083	chr20:31378690	A/C	cg13636640	chr20:31349939	DNMT3B	0.82	17.0	0.62	1.03e-50	Ulcerative colitis;
LGG	cis	rs10421328	0.821	rs10405234	chr19:19756662	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.33	7.17	0.32	3.05e-12	Parental longevity (combined parental age at death);
LGG	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg26818010	chr10:134567672	INPP5A	-0.6	-9.4	-0.4	2.45e-19	Migraine;
LGG	cis	rs701145	0.585	rs357494	chr3:153937753	G/A	cg12800244	chr3:153838788	SGEF	0.84	8.33	0.36	9.55e-16	Coronary artery disease;
LGG	cis	rs2013441	0.965	rs9896221	chr17:20180337	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg03036210	chr16:89904091	SPIRE2	-0.64	-7.77	-0.34	5.26e-14	Skin colour saturation;
LGG	cis	rs4132509	0.592	rs12076373	chr1:243851947	G/C	cg21452805	chr1:244014465	NA	0.92	10.26	0.43	2.12e-22	RR interval (heart rate);
LGG	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.29	-0.55	1.22e-38	Hair morphology;
LGG	trans	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-9.19	-0.39	1.31e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.31	0.32	1.15e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.75	0.3	4.5e-11	Mood instability;
LGG	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg10523679	chr1:76189770	ACADM	-0.82	-14.55	-0.56	9.39e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg20848291	chr7:100343083	ZAN	-0.66	-9.83	-0.42	7.62e-21	Other erythrocyte phenotypes;
LGG	cis	rs1009647	0.645	rs117502961	chr14:55599914	T/G	cg04306507	chr14:55594613	LGALS3	0.47	8.02	0.35	8.61e-15	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs9987353	0.566	rs13260067	chr8:9071033	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.72	0.3	5.51e-11	Recombination measurement;
LGG	cis	rs4417704	0.551	rs4315517	chr2:241894906	T/G	cg05025159	chr2:241905733	NA	0.52	10.58	0.44	1.38e-23	Joint mobility (Beighton score);
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg24575275	chr7:1094737	C7orf50	-0.41	-7.83	-0.34	3.34e-14	Longevity;Endometriosis;
LGG	cis	rs990171	1.000	rs917996	chr2:103082273	C/A	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs7106204	0.513	rs7131144	chr11:24249486	A/G	ch.11.24196551F	chr11:24239977	NA	0.98	14.34	0.55	7.85e-39	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg02353165	chr6:42928485	GNMT	0.48	14.48	0.56	1.89e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7558370	0.737	rs112914737	chr2:3713431	G/A	cg20720597	chr2:3699334	NA	0.8	7.19	0.32	2.63e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg15704280	chr7:45808275	SEPT13	-0.52	-8.74	-0.38	4.18e-17	HDL cholesterol;
LGG	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg26444097	chr4:2432313	NA	-0.38	-9.77	-0.41	1.26e-20	Cognitive function;
LGG	cis	rs793571	0.502	rs688756	chr15:59076272	A/C	cg05156742	chr15:59063176	FAM63B	0.66	12.15	0.49	1.11e-29	Schizophrenia;
LGG	cis	rs9462027	0.628	rs10807141	chr6:34693111	A/G	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg11752832	chr7:134001865	SLC35B4	-0.58	-10.82	-0.45	1.7e-24	Mean platelet volume;
LGG	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg26396452	chr14:65542826	MAX	0.42	8.41	0.36	5.14e-16	Obesity-related traits;
LGG	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg06640241	chr16:89574553	SPG7	0.81	14.32	0.55	9.22e-39	Multiple myeloma (IgH translocation);
LGG	trans	rs62458065	0.568	rs62463963	chr7:32486691	C/T	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.96	-0.31	1.17e-11	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs7098414	0.511	rs10887828	chr10:82151470	T/C	cg00277334	chr10:82204260	NA	-0.34	-7.55	-0.33	2.33e-13	Post bronchodilator FEV1;
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg17328964	chr8:145687451	CYHR1	-0.38	-6.81	-0.3	3.02e-11	Age at first birth;
LGG	cis	rs9467160	0.501	rs1772257	chr6:24441214	C/T	cg20631270	chr6:24437470	GPLD1	-0.39	-6.69	-0.3	6.49e-11	Liver enzyme levels;
LGG	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	8.65	0.37	8.62e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.75	0.34	5.92e-14	Homoarginine levels;
LGG	cis	rs77741769	0.549	rs57697145	chr12:121333552	T/G	cg02419362	chr12:121203948	SPPL3	0.54	9.3	0.4	5.66e-19	Mean corpuscular volume;
LGG	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg02002194	chr4:3960332	NA	0.42	7.99	0.35	1.09e-14	Neuroticism;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg00689492	chr4:1303491	MAEA	-0.5	-8.79	-0.38	3.04e-17	Obesity-related traits;
LGG	cis	rs7394190	0.748	rs1057410	chr10:75574079	G/A	cg07699608	chr10:75541558	CHCHD1	0.57	7.51	0.33	3.16e-13	Incident atrial fibrillation;
LGG	cis	rs2133450	0.967	rs17697287	chr3:7349755	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.6	-0.37	1.24e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.49	0.75	1.36e-85	Chronic sinus infection;
LGG	cis	rs926938	0.527	rs1391484	chr1:115522366	A/G	cg12756093	chr1:115239321	AMPD1	0.41	7.83	0.34	3.47e-14	Autism;
LGG	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.2	-0.36	2.45e-15	Monocyte count;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs4838594	0.715	rs11101340	chr10:49682402	C/T	cg17291251	chr10:49678358	ARHGAP22	0.52	9.91	0.42	3.85e-21	Daytime sleep phenotypes;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg18357526	chr6:26021779	HIST1H4A	0.42	6.85	0.3	2.41e-11	Height;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs9875589	0.509	rs11718142	chr3:14018793	G/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.9	0.42	4.28e-21	Ovarian reserve;
LGG	cis	rs7927771	0.542	rs7108479	chr11:47781460	G/T	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg01620082	chr3:125678407	NA	0.61	7.51	0.33	2.98e-13	Depression;
LGG	cis	rs12579753	0.879	rs12579544	chr12:82164043	A/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-12.14	-0.49	1.19e-29	Resting heart rate;
LGG	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg19847130	chr8:10466454	RP1L1	0.3	6.68	0.3	6.87e-11	Joint mobility (Beighton score);
LGG	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.7	0.3	5.94e-11	Bladder cancer;
LGG	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg21775007	chr8:11205619	TDH	-0.55	-8.97	-0.38	7.13e-18	Triglycerides;
LGG	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21659725	chr3:3221576	CRBN	-0.67	-12.61	-0.51	1.46e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg01145232	chr6:150245071	RAET1G	-0.52	-9.72	-0.41	1.84e-20	Lung cancer;
LGG	cis	rs4363385	0.818	rs382292	chr1:153006641	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.06	0.39	3.8e-18	Motion sickness;
LGG	cis	rs10895140	0.709	rs2154998	chr11:101517377	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.99	-0.31	9.87e-12	Menarche (age at onset);
LGG	cis	rs75920871	0.528	rs10892071	chr11:116954565	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.18	-0.43	4.34e-22	Subjective well-being;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs2880765	0.743	rs8039631	chr15:86007931	A/G	cg10818794	chr15:86012489	AKAP13	-0.36	-7.54	-0.33	2.44e-13	Coronary artery disease;
LGG	trans	rs7980799	0.649	rs11052732	chr12:33657801	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-12.41	-0.5	1.03e-30	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.81	-0.38	2.61e-17	Body mass index;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg18357526	chr6:26021779	HIST1H4A	0.8	13.06	0.52	2.11e-33	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.567	rs7754960	chr6:28346945	G/C	cg06606381	chr12:133084897	FBRSL1	-0.46	-6.78	-0.3	3.78e-11	Depression;
LGG	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg12501888	chr15:85177176	SCAND2	-0.56	-9.1	-0.39	2.79e-18	P wave terminal force;
LGG	cis	rs668210	0.793	rs534201	chr11:65776728	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	9.51	0.4	1.05e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.91	-0.31	1.62e-11	Blood metabolite levels;
LGG	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.69	0.34	8.7e-14	Height;
LGG	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg21724239	chr8:58056113	NA	0.6	9.19	0.39	1.38e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs8177179	0.967	rs4078166	chr3:133435979	C/A	cg24879335	chr3:133465180	TF	0.45	7.42	0.33	5.83e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs1568889	1.000	rs16917687	chr11:28062614	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg18099408	chr3:52552593	STAB1	-0.37	-7.12	-0.31	4.17e-12	Bipolar disorder;
LGG	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4006360	0.575	rs7502215	chr17:39306261	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.65	14.76	0.57	1.09e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs735539	0.521	rs2818995	chr13:21420964	T/G	cg04906043	chr13:21280425	IL17D	-0.5	-7.85	-0.34	3e-14	Dental caries;
LGG	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.59	-11.14	-0.46	1.09e-25	Schizophrenia;
LGG	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg09855544	chr8:135498122	ZFAT	0.45	7.47	0.33	3.89e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs757978	0.810	rs34123564	chr2:242404437	A/G	cg10173475	chr2:242152697	ANO7	-0.54	-6.94	-0.31	1.34e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7998202	0.667	rs408220	chr13:113370267	T/C	cg02820901	chr13:113351484	ATP11A	0.55	6.66	0.3	7.8e-11	Glycated hemoglobin levels;
LGG	cis	rs34599045	0.522	rs34686286	chr1:153008252	A/T	cg07796016	chr1:152779584	LCE1C	-0.88	-7.86	-0.34	2.67e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs36071027	0.615	rs10515785	chr5:158443352	G/T	cg04248271	chr5:158524404	EBF1	0.41	7.2	0.32	2.53e-12	Carotid intima media thickness;
LGG	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15369054	chr17:80825471	TBCD	0.58	10.71	0.45	4.55e-24	Breast cancer;
LGG	cis	rs9309473	1.000	rs7584575	chr2:73666402	C/T	cg20560298	chr2:73613845	ALMS1	-0.43	-7.2	-0.32	2.45e-12	Metabolite levels;
LGG	cis	rs997295	0.554	rs4261477	chr15:68073968	G/T	cg08079166	chr15:68083412	MAP2K5	0.29	6.75	0.3	4.38e-11	Motion sickness;
LGG	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg00717180	chr2:96193071	NA	-0.47	-8.85	-0.38	1.84e-17	HDL cholesterol;
LGG	cis	rs10504073	0.647	rs62507247	chr8:50013554	T/G	cg00325661	chr8:49890786	NA	0.75	14.53	0.56	1.07e-39	Blood metabolite ratios;
LGG	cis	rs826838	1.000	rs11514441	chr12:38775190	C/T	cg26384229	chr12:38710491	ALG10B	1.07	28.64	0.8	1.44e-104	Heart rate;
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg03808351	chr9:123631620	PHF19	0.29	7.24	0.32	1.87e-12	Birth weight;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg11608241	chr8:8085544	FLJ10661	0.32	7.18	0.32	2.78e-12	Neuroticism;
LGG	cis	rs7590720	1.000	rs6435930	chr2:216885852	A/G	cg12620499	chr2:216877984	MREG	0.77	14.53	0.56	1.12e-39	Alcohol dependence;
LGG	cis	rs9517313	0.592	rs11069311	chr13:99202101	G/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.93	-0.45	7.01e-25	Neuroticism;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg24846343	chr22:24311635	DDTL	0.61	12.28	0.5	3.48e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17270561	0.887	rs717551	chr6:25855624	T/C	cg17691542	chr6:26056736	HIST1H1C	0.93	13.53	0.53	2.26e-35	Iron status biomarkers;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.03	-0.39	4.78e-18	Retinal vascular caliber;
LGG	cis	rs10991814	0.925	rs75139635	chr9:93968324	A/G	cg14446406	chr9:93919335	NA	-0.75	-8.29	-0.36	1.25e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg06212747	chr3:49208901	KLHDC8B	0.54	8.46	0.37	3.56e-16	Menarche (age at onset);
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.44	-9.01	-0.39	5.23e-18	Schizophrenia;
LGG	cis	rs9583531	0.657	rs7337126	chr13:111376788	A/G	cg24331049	chr13:111365604	ING1	0.82	14.49	0.56	1.72e-39	Coronary artery disease;
LGG	cis	rs6907340	0.517	rs6939160	chr6:19802317	C/G	cg02682789	chr6:19804855	NA	0.53	7.78	0.34	4.62e-14	Endometriosis;
LGG	trans	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg10756647	chr7:56101905	PSPH	0.82	10.15	0.43	5.38e-22	Diabetic kidney disease;
LGG	cis	rs2133450	0.526	rs12485342	chr3:7349051	G/A	cg19930620	chr3:7340148	GRM7	-0.42	-9.41	-0.4	2.24e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.34	-0.47	1.87e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	11.81	0.48	2.63e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg09060608	chr5:178986726	RUFY1	-0.45	-7.86	-0.34	2.75e-14	Lung cancer;
LGG	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg20703242	chr1:230279135	GALNT2	-0.39	-7.36	-0.32	8.65e-13	Coronary artery disease;
LGG	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.85	-0.38	1.93e-17	Eosinophil percentage of white cells;
LGG	cis	rs10489202	0.657	rs201541	chr1:167992344	T/A	cg24449463	chr1:168025552	DCAF6	-0.58	-10.15	-0.43	5.46e-22	Schizophrenia;
LGG	cis	rs4684776	1.000	rs4377480	chr3:11525500	T/C	cg24705426	chr3:11550659	ATG7	-0.47	-8.7	-0.37	5.73e-17	Small vessel stroke;
LGG	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg19812747	chr11:111475976	SIK2	-0.46	-9.31	-0.4	5.35e-19	Primary sclerosing cholangitis;
LGG	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg10189774	chr4:17578691	LAP3	0.38	6.82	0.3	2.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs9517320	0.534	rs912330	chr13:99131294	C/T	cg07423050	chr13:99094983	FARP1	-0.49	-9.03	-0.39	4.69e-18	Longevity;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg12310025	chr6:25882481	NA	-0.42	-7.5	-0.33	3.36e-13	Height;
LGG	cis	rs11700980	0.551	rs62223678	chr21:30118656	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.7	-0.3	6.09e-11	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.51	0.37	2.49e-16	Lung cancer;
LGG	cis	rs17401966	0.931	rs61778401	chr1:10426474	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.52	-0.44	2.31e-23	Hepatocellular carcinoma;
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg24623649	chr8:11872141	NA	-0.3	-7.07	-0.31	5.65e-12	Neuroticism;
LGG	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg15440763	chr7:158190612	PTPRN2	0.49	10.38	0.43	8.12e-23	Obesity-related traits;
LGG	cis	rs7216064	0.911	rs6504551	chr17:65903326	T/G	cg12091567	chr17:66097778	LOC651250	-0.58	-9.06	-0.39	3.72e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs3806843	0.966	rs2337986	chr5:140160622	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06470251	chr20:60548479	NA	0.5	8.7	0.37	5.88e-17	Body mass index;
LGG	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg21138405	chr5:131827807	IRF1	-0.28	-6.72	-0.3	5.34e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg01114163	chr5:1856713	NA	-0.42	-7.28	-0.32	1.41e-12	Cardiovascular disease risk factors;
LGG	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg26850624	chr5:429559	AHRR	-0.37	-8.14	-0.35	3.82e-15	Cystic fibrosis severity;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs75059851	0.756	rs56241440	chr11:133840830	A/C	cg17703048	chr11:133852993	NA	-0.87	-16.03	-0.6	2.6e-46	Schizophrenia;
LGG	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg09021430	chr5:549028	NA	-0.74	-10.57	-0.44	1.58e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs1904096	0.506	rs13434570	chr4:95168019	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.09	-0.46	1.61e-25	Type 2 diabetes;
LGG	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg04851639	chr8:1020857	NA	-0.45	-9.75	-0.41	1.5e-20	Schizophrenia;
LGG	cis	rs9715521	0.719	rs11936702	chr4:59849081	G/A	cg11281224	chr4:60001000	NA	-0.5	-8.46	-0.37	3.51e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4974559	0.739	rs28411197	chr4:1279781	C/T	cg02980000	chr4:1222292	CTBP1	0.82	9.27	0.4	7.05e-19	Systolic blood pressure;
LGG	cis	rs10048158	0.743	rs2215415	chr17:64215571	G/A	cg19474267	chr17:64306194	PRKCA	-0.74	-15.47	-0.58	8.06e-44	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.11	-0.31	4.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg19678392	chr7:94953810	PON1	-0.45	-11.85	-0.48	1.83e-28	Paraoxonase activity;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.33e-17	Lung cancer;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg22535103	chr8:58192502	C8orf71	-0.85	-11.03	-0.46	2.93e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg18402987	chr7:1209562	NA	0.66	9.0	0.39	5.7e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7911264	0.967	rs9419741	chr10:94430525	A/G	cg25093409	chr10:94429542	NA	-0.56	-11.49	-0.47	4.76e-27	Inflammatory bowel disease;
LGG	cis	rs2463822	1.000	rs2513074	chr11:62100880	A/C	cg06239285	chr11:62104954	ASRGL1	1.16	16.25	0.6	2.59e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg08807101	chr21:30365312	RNF160	-0.68	-11.67	-0.48	8.89e-28	Cognitive test performance;
LGG	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg04731861	chr2:219085781	ARPC2	-0.48	-12.39	-0.5	1.19e-30	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	11.02	0.46	3.13e-25	Crohn's disease;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg26752003	chr8:145688521	CYHR1	0.54	11.65	0.48	1.11e-27	Age at first birth;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.22e-18	Alzheimer's disease;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg15558759	chr11:118478939	PHLDB1	0.38	6.75	0.3	4.57e-11	Cholesterol, total;
LGG	cis	rs9916302	0.808	rs12943928	chr17:37611330	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.83	-0.59	2.11e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs12615966	1.000	rs17030284	chr2:105380921	A/G	cg16465502	chr2:105461796	NA	-0.87	-10.53	-0.44	2.1e-23	Pancreatic cancer;
LGG	cis	rs2120243	0.539	rs2168430	chr3:157120408	T/C	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg20607798	chr8:58055168	NA	0.56	6.81	0.3	3.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.73	0.34	6.81e-14	Electroencephalogram traits;
LGG	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg04226714	chr8:49833948	SNAI2	-0.5	-9.09	-0.39	2.85e-18	Life satisfaction;
LGG	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg17809284	chr5:56205270	C5orf35	-0.54	-8.98	-0.38	7.06e-18	Initial pursuit acceleration;
LGG	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.14	12.34	0.5	1.89e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11150038	0.623	rs7192324	chr16:78018042	G/T	cg04733911	chr16:78082701	NA	-0.54	-7.05	-0.31	6.39e-12	Colorectal or endometrial cancer;
LGG	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg18402987	chr7:1209562	NA	0.62	6.92	0.31	1.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7166081	1.000	rs12594229	chr15:67596084	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12200560	0.505	rs211177	chr6:97074088	C/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.71	0.34	8.02e-14	Coronary heart disease;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg03804240	chr11:118481350	PHLDB1	0.41	7.86	0.34	2.69e-14	Cholesterol, total;
LGG	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.77	0.64	2.93e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.96	-0.31	1.21e-11	Systolic blood pressure;
LGG	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.12e-24	Corneal astigmatism;
LGG	cis	rs4732038	0.528	rs1722903	chr7:134276281	T/G	cg06906464	chr7:134288099	NA	-0.72	-20.93	-0.7	6.34e-69	Longevity;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.57	0.53	1.54e-35	Lung cancer;
LGG	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg25664220	chr3:72788482	NA	-0.33	-9.34	-0.4	4.14e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.49	-0.47	4.63e-27	Type 2 diabetes;
LGG	cis	rs35160687	0.644	rs1863061	chr2:86512907	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.91	0.31	1.66e-11	Night sleep phenotypes;
LGG	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg15325629	chr6:28072465	NA	0.99	7.6	0.33	1.65e-13	Parkinson's disease;
LGG	cis	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg06521331	chr12:34319734	NA	-0.4	-7.07	-0.31	5.86e-12	Morning vs. evening chronotype;
LGG	trans	rs11875185	0.510	rs111420428	chr18:55634303	T/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs599083	0.590	rs10791984	chr11:68407835	T/G	cg01657329	chr11:68192670	LRP5	0.48	8.74	0.38	4.29e-17	Bone mineral density (spine);
LGG	cis	rs4253772	0.637	rs6008339	chr22:46650846	C/T	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs780094	0.500	rs12987055	chr2:27834152	T/C	cg27432699	chr2:27873401	GPN1	0.46	6.85	0.3	2.38e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04008888	chr11:68622739	NA	-0.56	-11.58	-0.47	2.14e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg12458913	chr13:53173898	NA	-0.91	-19.92	-0.68	3.17e-64	Lewy body disease;
LGG	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg05444541	chr17:17804740	TOM1L2	-0.79	-21.9	-0.71	1.78e-73	Total body bone mineral density;
LGG	cis	rs8072100	1.000	rs8065669	chr17:45724996	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-8.81	-0.38	2.45e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg03188948	chr7:1209495	NA	0.49	7.77	0.34	5.26e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg01191920	chr7:158217561	PTPRN2	0.7	15.08	0.57	4.46e-42	Obesity-related traits;
LGG	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-12.32	-0.5	2.3e-30	Mood instability;
LGG	cis	rs4704187	0.595	rs6859176	chr5:74379425	T/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.98	0.31	1.05e-11	Lung cancer;
LGG	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg14055004	chr2:241860995	NA	0.28	7.39	0.32	7.02e-13	Joint mobility (Beighton score);
LGG	cis	rs11690935	0.851	rs6731562	chr2:172798262	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.6	-0.33	1.7e-13	Schizophrenia;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg21782813	chr7:2030301	MAD1L1	0.42	9.9	0.42	4.24e-21	Schizophrenia;
LGG	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg23649088	chr2:200775458	C2orf69	-0.63	-8.24	-0.36	1.75e-15	Schizophrenia;
LGG	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.11	-0.7	8.52e-70	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.44e-31	Motion sickness;
LGG	cis	rs4555082	0.874	rs1882846	chr14:105717448	G/C	cg27165867	chr14:105738592	BRF1	-0.45	-7.46	-0.33	4.33e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.65	0.51	9.99e-32	Motion sickness;
LGG	cis	rs10839968	1.000	rs75947662	chr11:8056953	C/T	cg14064503	chr11:8094152	TUB	0.64	6.72	0.3	5.3e-11	Left  ventricle systolic dysfunction;
LGG	cis	rs7808935	0.914	rs757136	chr7:27988939	C/T	cg22168087	chr7:27702803	HIBADH	-0.67	-9.18	-0.39	1.45e-18	Prostate cancer;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs6728642	0.803	rs11891458	chr2:97632450	G/T	cg26665480	chr2:98280029	ACTR1B	-0.76	-9.18	-0.39	1.46e-18	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg04034577	chr2:241836375	C2orf54	-0.48	-10.24	-0.43	2.54e-22	Urinary metabolites;
LGG	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.97	-0.31	1.11e-11	Breast cancer;
LGG	cis	rs911555	0.723	rs7144010	chr14:103869869	G/A	cg24130564	chr14:104152367	KLC1	0.37	7.01	0.31	8.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs258892	0.895	rs6882092	chr5:72086928	G/A	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs910187	0.641	rs6124966	chr20:45813099	T/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.33	-0.4	4.51e-19	Migraine;
LGG	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-9.61	-0.41	4.78e-20	Lymphocyte counts;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2247341	0.965	rs2236787	chr4:1718883	A/T	cg08629884	chr4:1719983	TMEM129	-0.57	-11.21	-0.46	5.82e-26	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11920090	0.932	rs11720640	chr3:170694237	G/A	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2033732	1.000	rs2033732	chr8:85079709	T/C	cg05716166	chr8:85095498	RALYL	0.53	8.14	0.35	3.76e-15	Body mass index;
LGG	cis	rs6942756	0.747	rs691435	chr7:129097352	C/T	cg02491457	chr7:128862824	NA	0.65	11.42	0.47	9.15e-27	White matter hyperintensity burden;
LGG	cis	rs2640806	0.505	rs13262091	chr8:97365173	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.22	0.32	2.1e-12	Obesity-related traits;
LGG	cis	rs4740619	0.846	rs10810426	chr9:15677078	C/T	cg14451791	chr9:16040625	NA	0.32	8.2	0.36	2.46e-15	Body mass index;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.53	0.37	2.17e-16	Bipolar disorder;
LGG	cis	rs6918586	0.658	rs198826	chr6:26121153	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.5	0.4	1.17e-19	Schizophrenia;
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.97	-0.42	2.5e-21	Rheumatoid arthritis;
LGG	cis	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg06521331	chr12:34319734	NA	0.38	6.78	0.3	3.68e-11	Morning vs. evening chronotype;
LGG	trans	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs1847505	0.559	rs1475496	chr13:61566031	G/C	cg25164009	chr13:61490935	NA	-0.6	-11.73	-0.48	5.29e-28	Polychlorinated biphenyl levels;
LGG	cis	rs9354308	0.764	rs2351724	chr6:66602952	T/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg11360546	chr7:1094263	C7orf50	-0.37	-6.67	-0.3	7.12e-11	Longevity;Endometriosis;
LGG	trans	rs6598955	0.671	rs58038522	chr1:26582713	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.88	-0.51	1.21e-32	Obesity-related traits;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg07511668	chr11:68622177	NA	0.45	8.6	0.37	1.2e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9660992	0.573	rs12140422	chr1:205187981	G/A	cg21545522	chr1:205238299	TMCC2	0.41	7.78	0.34	4.92e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg02711726	chr17:80685570	FN3KRP	0.42	8.37	0.36	7.04e-16	Breast cancer;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg01673284	chr16:4527211	HMOX2	-0.33	-6.74	-0.3	4.7e-11	Schizophrenia;
LGG	cis	rs67133203	0.898	rs12822509	chr12:51439665	G/C	cg14688905	chr12:51403056	SLC11A2	0.72	10.88	0.45	1.09e-24	Urinary tract infection frequency;
LGG	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.85	0.42	6.41e-21	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6800768	0.633	rs59461522	chr3:24100377	G/A	cg10674438	chr3:24145617	LOC152024	-0.5	-8.96	-0.38	7.99e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.94e-13	Neuroticism;
LGG	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg22437258	chr11:111473054	SIK2	-0.42	-6.91	-0.31	1.58e-11	Primary sclerosing cholangitis;
LGG	cis	rs10876993	0.928	rs774890	chr12:58068388	C/T	cg18357645	chr12:58087776	OS9	0.68	12.5	0.5	4.14e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs11150038	0.702	rs4570858	chr16:78071433	G/T	cg04733911	chr16:78082701	NA	-0.68	-9.82	-0.42	8.31e-21	Colorectal or endometrial cancer;
LGG	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.07	-0.31	5.86e-12	IgG glycosylation;
LGG	cis	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.4	-0.36	5.43e-16	IgG glycosylation;
LGG	cis	rs4363385	0.818	rs10788856	chr1:153011517	G/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00495681	chr13:53174319	NA	0.63	12.18	0.49	8.54e-30	Lewy body disease;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13126279	chr21:47581558	C21orf56	-0.42	-7.27	-0.32	1.54e-12	Testicular germ cell tumor;
LGG	cis	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9878978	0.964	rs11718236	chr3:2478632	C/T	cg21928760	chr3:2462534	CNTN4	0.41	8.99	0.39	6.18e-18	Blood pressure (smoking interaction);
LGG	cis	rs877282	0.945	rs11253396	chr10:789754	C/T	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg01221209	chr5:554886	NA	0.46	10.03	0.42	1.47e-21	Obesity-related traits;
LGG	cis	rs17092148	0.945	rs17092080	chr20:33335657	A/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08508337	chr8:144660607	NAPRT1	-0.72	-8.06	-0.35	6.56e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs2952156	0.959	rs2952151	chr17:37828496	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-14.45	-0.56	2.58e-39	Asthma;
LGG	cis	rs13260300	0.657	rs4557675	chr8:75492140	G/A	cg22993706	chr8:75542856	NA	0.37	7.07	0.31	5.66e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs11018904	0.861	rs4589254	chr11:89963355	A/C	cg27158573	chr11:89632121	NA	0.42	7.35	0.32	8.92e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4748857	1.000	rs4748857	chr10:23599558	C/T	cg18853376	chr10:23633759	C10orf67	0.37	7.03	0.31	7.24e-12	Systemic lupus erythematosus;
LGG	cis	rs1372520	0.684	rs356188	chr4:90691537	T/C	cg15133208	chr4:90757351	SNCA	0.38	7.48	0.33	3.74e-13	Neuroticism;
LGG	cis	rs34467563	0.670	rs6990150	chr8:97368622	T/A	cg22138393	chr8:97340270	PTDSS1	0.31	7.7	0.34	8.18e-14	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6787172	0.702	rs865455	chr3:158008001	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.81	0.38	2.6e-17	Subjective well-being;
LGG	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-12.86	-0.51	1.44e-32	Bladder cancer;
LGG	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg00376283	chr12:123451042	ABCB9	0.61	10.76	0.45	2.88e-24	Platelet count;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04772025	chr11:68637568	NA	0.75	13.42	0.53	6.17e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg11812906	chr14:75593930	NEK9	-0.52	-9.73	-0.41	1.73e-20	Height;
LGG	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.38	-0.43	7.51e-23	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.2	-0.32	2.45e-12	Lung cancer;
LGG	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg04617936	chr2:214353	NA	-0.39	-7.27	-0.32	1.58e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg19635926	chr16:89946313	TCF25	-0.64	-7.82	-0.34	3.54e-14	Skin colour saturation;
LGG	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03352830	chr11:487213	PTDSS2	0.86	11.3	0.46	2.63e-26	Body mass index;
LGG	trans	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg12045294	chr17:78518616	RPTOR	-0.46	-7.1	-0.31	4.65e-12	Glycated hemoglobin levels;
LGG	cis	rs12586317	0.534	rs1568200	chr14:35419592	C/T	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.24	-0.43	2.58e-22	Psoriasis;
LGG	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.43	7.04	0.31	7.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg24375607	chr4:120327624	NA	0.64	10.36	0.43	9.44e-23	Corneal astigmatism;
LGG	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	cg07245641	chr1:182991651	LAMC1	0.38	8.6	0.37	1.26e-16	Fuchs's corneal dystrophy;
LGG	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.05e-54	Refractive error;
LGG	cis	rs9359856	0.564	rs10484885	chr6:90395016	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.75	-0.41	1.5e-20	Bipolar disorder;
LGG	cis	rs7762018	0.607	rs75964125	chr6:170054290	T/A	cg17545662	chr6:170176663	C6orf70	0.65	6.89	0.31	1.81e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg09307838	chr4:120376055	NA	0.77	12.67	0.51	8.34e-32	Corneal astigmatism;
LGG	cis	rs12282928	0.917	rs1503175	chr11:48269192	A/G	cg26585981	chr11:48327164	OR4S1	-0.43	-7.09	-0.31	5.18e-12	Migraine - clinic-based;
LGG	cis	rs4684776	1.000	rs13098824	chr3:11454909	G/A	cg24705426	chr3:11550659	ATG7	-0.44	-7.79	-0.34	4.34e-14	Small vessel stroke;
LGG	cis	rs4722166	0.630	rs6461667	chr7:22796743	A/G	cg05265849	chr7:22767390	IL6	0.42	7.67	0.34	1.01e-13	Lung cancer;
LGG	cis	rs2346177	0.875	rs2346178	chr2:46647061	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.3	-0.43	1.54e-22	HDL cholesterol;
LGG	cis	rs8180040	0.593	rs4018905	chr3:47138170	A/G	cg27129171	chr3:47204927	SETD2	0.82	15.04	0.57	6.4e-42	Colorectal cancer;
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg06221963	chr1:154839813	KCNN3	-0.51	-9.92	-0.42	3.84e-21	Prostate cancer;
LGG	cis	rs7216064	1.000	rs2046323	chr17:65849927	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg03060546	chr3:49711283	APEH	0.6	7.9	0.34	2.11e-14	Menarche (age at onset);
LGG	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg13770153	chr20:60521292	NA	0.6	9.23	0.39	9.69e-19	Body mass index;
LGG	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg21775007	chr8:11205619	TDH	-0.5	-8.12	-0.35	4.15e-15	Triglycerides;
LGG	cis	rs7267979	1.000	rs2257988	chr20:25270003	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.75e-31	Motion sickness;
LGG	trans	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg00938859	chr5:1591904	SDHAP3	0.94	13.02	0.52	3.05e-33	Breast cancer;
LGG	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06481639	chr22:41940642	POLR3H	-0.46	-7.19	-0.32	2.64e-12	Vitiligo;
LGG	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg03315344	chr16:75512273	CHST6	0.49	9.82	0.42	8.46e-21	Dupuytren's disease;
LGG	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg15704280	chr7:45808275	SEPT13	-0.7	-10.07	-0.42	1.09e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs989128	0.600	rs898453	chr17:48632401	G/A	cg20467136	chr17:48638190	CACNA1G	0.48	6.8	0.3	3.34e-11	Type 2 diabetes;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg26554054	chr8:600488	NA	0.92	9.67	0.41	2.79e-20	IgG glycosylation;
LGG	trans	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg21659725	chr3:3221576	CRBN	0.46	6.76	0.3	4.2e-11	Menarche (age at onset);
LGG	cis	rs736801	0.607	rs11746555	chr5:131727033	G/A	cg07395648	chr5:131743802	NA	-0.59	-12.9	-0.51	1e-32	Breast cancer;Mosquito bite size;
LGG	cis	rs6735179	0.532	rs6756670	chr2:1761496	A/G	cg10160682	chr2:1713001	PXDN	-0.54	-9.6	-0.41	4.9e-20	Response to antipsychotic treatment;
LGG	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg04568710	chr12:38710424	ALG10B	0.34	7.17	0.32	2.95e-12	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg03647317	chr4:187891568	NA	-0.41	-8.83	-0.38	2.2e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4650994	0.623	rs7534394	chr1:178622760	G/A	cg19399532	chr1:178512495	C1orf220	-0.37	-6.96	-0.31	1.15e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17221829	0.549	rs9666894	chr11:89358359	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.09	-0.39	2.84e-18	Anxiety in major depressive disorder;
LGG	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.870	rs3825616	chr14:55853288	G/C	cg04306507	chr14:55594613	LGALS3	0.63	17.94	0.64	5.2e-55	Protein biomarker;
LGG	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.76	0.38	3.81e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9457247	0.765	rs9457252	chr6:167433925	A/G	cg07741184	chr6:167504864	NA	-0.42	-9.51	-0.4	1.02e-19	Crohn's disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06138683	chr10:38265481	ZNF25	-0.4	-6.77	-0.3	3.94e-11	Pancreatic cancer;
LGG	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.21e-12	HDL cholesterol;
LGG	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.96	0.35	1.34e-14	Personality dimensions;
LGG	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs2011503	1.000	rs74950305	chr19:19639448	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.09	0.6	1.34e-46	Hip circumference adjusted for BMI;
LGG	cis	rs6952809	0.504	rs1978169	chr7:2434522	G/A	cg23289794	chr7:2394357	EIF3B	-0.75	-9.7	-0.41	2.25e-20	Multiple sclerosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10526942	chr3:131753457	CPNE4	0.39	6.67	0.3	7.43e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg02297831	chr4:17616191	MED28	0.5	9.61	0.41	4.64e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7267979	0.509	rs6115218	chr20:25566485	A/G	cg08601574	chr20:25228251	PYGB	0.38	7.14	0.32	3.55e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2032447	0.714	rs199736	chr6:25936787	C/T	cg18357526	chr6:26021779	HIST1H4A	0.84	15.31	0.58	4.06e-43	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1649041	chr10:60328782	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg19554555	chr3:13937349	NA	-0.55	-10.08	-0.42	9.53e-22	Ovarian reserve;
LGG	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs1784581	0.588	rs7758559	chr6:162438635	G/T	cg17173639	chr6:162384350	PARK2	0.65	13.78	0.54	2.01e-36	Itch intensity from mosquito bite;
LGG	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs741702	0.928	rs2009222	chr19:13034543	T/C	cg23899408	chr19:12877188	HOOK2	0.48	7.75	0.34	5.87e-14	Red blood cell traits;
LGG	cis	rs225245	0.817	rs225290	chr17:33927904	C/G	cg05299278	chr17:33885742	SLFN14	0.42	7.94	0.35	1.51e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs975722	0.662	rs214167	chr7:117286524	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	8.88	0.38	1.53e-17	Coronary artery disease;
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg16141378	chr3:129829833	LOC729375	0.41	9.47	0.4	1.42e-19	Neuroticism;
LGG	cis	rs12200782	0.578	rs2237233	chr6:26387535	A/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg14784868	chr12:69753453	YEATS4	0.9	19.54	0.67	1.92e-62	Blood protein levels;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.5	0.37	2.6e-16	Platelet count;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.79	-13.89	-0.54	6.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.46	0.58	8.99e-44	Total body bone mineral density;
LGG	cis	rs6547631	0.622	rs1437745	chr2:85928283	A/G	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg01864069	chr14:103024347	NA	0.67	9.64	0.41	3.67e-20	Platelet count;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.3	-0.32	1.27e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9649465	0.561	rs631445	chr7:123413707	C/T	cg03229431	chr7:123269106	ASB15	-0.59	-13.72	-0.54	3.59e-36	Migraine;
LGG	cis	rs4704846	1.000	rs4704846	chr5:156513344	G/A	cg12943317	chr5:156479607	HAVCR1	-0.54	-7.07	-0.31	5.93e-12	Blood protein levels;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg15971980	chr6:150254442	NA	0.46	8.54	0.37	1.95e-16	Lung cancer;
LGG	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.66	-0.63	9.42e-54	Breast cancer;
LGG	cis	rs11966931	0.790	rs12665630	chr6:108101358	C/T	cg04749840	chr6:108095067	SCML4	0.43	7.36	0.32	8.69e-13	Neutrophil percentage of white cells;
LGG	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg25457927	chr22:38595422	NA	-0.43	-11.03	-0.46	2.78e-25	Cutaneous nevi;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.49	0.53	3.21e-35	Obesity-related traits;
LGG	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.47	0.4	1.41e-19	Bone mineral density;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg18538332	chr22:24372958	LOC391322	0.47	7.67	0.34	1.01e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2204008	0.837	rs11519926	chr12:38348992	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.29e-18	Bladder cancer;
LGG	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.4	0.44	6.67e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.72	-0.34	7.45e-14	Blood metabolite levels;
LGG	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg16576597	chr16:28551801	NUPR1	0.32	7.02	0.31	8.14e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1003719	0.843	rs1003721	chr21:38492657	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.71	13.37	0.53	1.01e-34	Eye color traits;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17612569	chr21:27107221	GABPA;ATP5J	-0.36	-6.68	-0.3	7.04e-11	Brain structure;
LGG	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg22482690	chr17:47019901	SNF8	0.35	6.86	0.3	2.28e-11	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01235203	chr3:187461998	BCL6	0.48	8.12	0.35	4.21e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg14047339	chr6:45345544	RUNX2;SUPT3H	0.4	6.7	0.3	6.18e-11	Corneal astigmatism;
LGG	cis	rs6866344	0.697	rs56159071	chr5:178127246	T/A	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.14	-0.31	3.62e-12	Menopause (age at onset);
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.84	-0.54	1.11e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs758324	0.947	rs56081930	chr5:131235274	T/G	cg06307176	chr5:131281290	NA	-0.56	-9.45	-0.4	1.76e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.54	0.5	2.93e-31	Lung cancer in ever smokers;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.83	-0.57	5.45e-41	Platelet count;
LGG	cis	rs2120019	0.938	rs8028632	chr15:75321262	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-23.48	-0.74	7.17e-81	Blood trace element (Zn levels);
LGG	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg12046867	chr14:103022105	NA	0.73	12.03	0.49	3.39e-29	Platelet count;
LGG	cis	rs4696584	0.877	rs56137436	chr4:155389000	A/C	cg13738195	chr4:155413469	DCHS2	-0.39	-7.27	-0.32	1.56e-12	Folding of antihelix;
LGG	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.66e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.81e-24	Body mass index;
LGG	cis	rs907612	0.638	rs907611	chr11:1874072	G/A	cg05305434	chr11:1874049	LSP1	0.4	10.38	0.43	7.97e-23	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.52	-0.37	2.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs113084984	0.718	rs12994182	chr2:11683898	C/A	cg07314298	chr2:11723111	GREB1	0.36	6.72	0.3	5.24e-11	Breast cancer;
LGG	cis	rs1927790	0.727	rs9556555	chr13:96961482	A/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.96	-0.31	1.19e-11	Body mass index;
LGG	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.91	-0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg10150615	chr22:24372951	LOC391322	-0.4	-6.67	-0.3	7.34e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs883565	0.528	rs11716902	chr3:38958010	G/T	cg01426195	chr3:39028469	NA	0.6	12.94	0.52	6.4e-33	Handedness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14538249	chr22:26962806	TPST2	-0.34	-6.77	-0.3	3.91e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.33	0.47	1.93e-26	Ovarian reserve;
LGG	cis	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg22857025	chr5:266934	NA	-1.51	-26.53	-0.78	5.74e-95	Breast cancer;
LGG	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.81	0.34	3.92e-14	Colorectal cancer;
LGG	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg02886208	chr11:14281011	SPON1	-0.5	-10.4	-0.44	6.32e-23	Mitochondrial DNA levels;
LGG	cis	rs875622	0.556	rs4808047	chr19:16527834	T/C	cg10248733	chr19:16607483	C19orf44;CALR3	-0.5	-6.72	-0.3	5.41e-11	White matter integrity;Neutrophil percentage of white cells;
LGG	cis	rs12348691	0.503	rs894672	chr9:100612185	C/T	cg13688889	chr9:100608707	NA	-0.83	-16.18	-0.6	5.35e-47	Alopecia areata;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg16507663	chr6:150244633	RAET1G	-0.45	-8.28	-0.36	1.34e-15	Lung cancer;
LGG	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.79	-0.45	2.27e-24	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.48	-0.33	3.68e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2268241	0.877	rs17885509	chr21:34779630	C/T	cg14850771	chr21:34775459	IFNGR2	0.76	9.2	0.39	1.24e-18	Obesity-related traits;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg25480799	chr2:184472883	NA	-0.34	-6.69	-0.3	6.63e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-9.08	-0.39	3.16e-18	Psychosis in Alzheimer's disease;
LGG	trans	rs281288	0.666	rs653749	chr15:47644528	A/G	cg03946899	chr15:98503444	ARRDC4	-0.42	-6.83	-0.3	2.61e-11	Positive affect;
LGG	cis	rs757110	0.770	rs11024268	chr11:17387982	A/G	cg15432903	chr11:17409602	KCNJ11	0.81	16.57	0.61	8.92e-49	Type 2 diabetes;
LGG	cis	rs7523273	0.526	rs1204706	chr1:208021060	G/T	cg22525895	chr1:207977042	MIR29B2	-0.63	-11.99	-0.49	5.01e-29	Schizophrenia;
LGG	cis	rs17169635	0.721	rs4732063	chr7:134552028	A/T	cg02516134	chr7:134575187	CALD1	-0.37	-7.31	-0.32	1.19e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs4417704	0.551	rs4610050	chr2:241891914	A/G	cg14055004	chr2:241860995	NA	0.28	7.35	0.32	9.22e-13	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22481606	chr17:56429567	SUPT4H1	0.5	7.96	0.35	1.33e-14	Gut microbiome composition (summer);
LGG	cis	rs74781061	0.929	rs78796673	chr15:74812527	T/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg18225595	chr11:63971243	STIP1	0.62	12.3	0.5	2.65e-30	Platelet count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08352032	chr19:45805935	MARK4	0.34	7.05	0.31	6.52e-12	Pancreatic cancer;
LGG	cis	rs6976053	0.870	rs314372	chr7:100455733	C/T	cg03098644	chr7:100410630	EPHB4	-0.4	-7.15	-0.32	3.31e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26120584	chr12:50795366	LARP4	-0.47	-7.07	-0.31	5.92e-12	Systemic lupus erythematosus;
LGG	cis	rs929596	0.564	rs2741027	chr2:234518011	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.28	-0.4	6.64e-19	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2519796	0.509	rs648353	chr9:136822827	T/C	cg13751417	chr9:136814406	VAV2	-0.45	-8.23	-0.36	1.93e-15	Hematocrit;Hemoglobin concentration;
LGG	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.47	0.4	1.41e-19	Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs897984	0.542	rs35713203	chr16:31090407	G/C	cg02466173	chr16:30829666	NA	-0.39	-6.77	-0.3	3.81e-11	Dementia with Lewy bodies;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg02475777	chr4:1388615	CRIPAK	0.39	6.97	0.31	1.07e-11	Longevity;
LGG	cis	rs806215	1.000	rs712703	chr7:127257498	C/T	cg25922125	chr7:127225783	GCC1	-0.71	-9.9	-0.42	4.22e-21	Type 2 diabetes;
LGG	cis	rs1348850	0.958	rs4893941	chr2:178269531	A/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.59	-0.37	1.34e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.02	-0.35	8.49e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.920	rs10793321	chr11:78237566	A/G	cg27205649	chr11:78285834	NARS2	0.52	8.65	0.37	8.75e-17	Alzheimer's disease (survival time);
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg25173464	chr15:68126554	NA	-0.34	-7.21	-0.32	2.31e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9457247	0.765	rs2237276	chr6:167442115	C/T	cg07741184	chr6:167504864	NA	0.42	9.36	0.4	3.36e-19	Crohn's disease;
LGG	cis	rs7523273	0.586	rs2724359	chr1:207935706	A/G	cg22525895	chr1:207977042	MIR29B2	0.61	11.88	0.48	1.33e-28	Schizophrenia;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg18446336	chr7:2847575	GNA12	-0.28	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg06719900	chr11:109292894	C11orf87	0.45	8.26	0.36	1.56e-15	Schizophrenia;
LGG	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg16339924	chr4:17578868	LAP3	0.51	8.51	0.37	2.36e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7301016	0.846	rs11174569	chr12:63021161	A/C	cg01804193	chr12:63026212	NA	0.53	6.94	0.31	1.33e-11	IgG glycosylation;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg11161011	chr14:65562177	MAX	-0.78	-15.87	-0.59	1.37e-45	Obesity-related traits;
LGG	trans	rs11875185	0.510	rs76038066	chr18:55647085	T/C	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9733	0.744	rs11204725	chr1:150742700	T/C	cg13175981	chr1:150552382	MCL1	0.54	8.73	0.38	4.63e-17	Tonsillectomy;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.18	0.55	3.73e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg15133208	chr4:90757351	SNCA	-0.37	-8.69	-0.37	6.08e-17	Dementia with Lewy bodies;
LGG	cis	rs17039065	1.000	rs57389415	chr4:109389586	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.11	0.31	4.3e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs6120666	chr20:33090718	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.26	0.36	1.59e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.65	0.34	1.14e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4891159	0.526	rs2848961	chr18:74129886	C/G	cg24786174	chr18:74118243	ZNF516	-0.66	-16.37	-0.61	7.8e-48	Longevity;
LGG	cis	rs1451375	0.617	rs11772714	chr7:50542843	G/A	cg14593290	chr7:50529359	DDC	-0.66	-11.9	-0.48	1.13e-28	Malaria;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.5	7.4	0.33	6.4e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs68170813	0.562	rs7810216	chr7:107000353	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-10.09	-0.42	9.27e-22	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-7.29	-0.32	1.38e-12	Electroencephalogram traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14438019	chr17:46702558	HOXB9	0.45	7.02	0.31	8.11e-12	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07791516	chr6:150247246	NA	0.34	6.73	0.3	5.03e-11	Lung cancer;
LGG	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.97	-0.31	1.11e-11	Neuroticism;
LGG	cis	rs4077515	0.967	rs11794847	chr9:139271747	G/A	cg21253087	chr9:139290292	SNAPC4	0.35	7.09	0.31	5.11e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg03894339	chr8:19674705	INTS10	0.93	14.99	0.57	1.05e-41	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-10.94	-0.45	6.17e-25	Mood instability;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08645402	chr16:4508243	NA	-0.51	-9.01	-0.39	5.38e-18	Schizophrenia;
LGG	cis	rs1577917	0.958	rs1545376	chr6:86504582	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.71	0.38	5.32e-17	Response to antipsychotic treatment;
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg11764359	chr7:65958608	NA	0.74	13.34	0.53	1.43e-34	Aortic root size;
LGG	cis	rs7923837	0.964	rs10882106	chr10:94480334	C/T	cg25093409	chr10:94429542	NA	0.38	6.99	0.31	9.73e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs12410462	0.551	rs903694	chr1:227733005	C/G	cg04117972	chr1:227635322	NA	0.46	8.62	0.37	1.04e-16	Major depressive disorder;
LGG	cis	rs1927790	0.759	rs7320054	chr13:96976392	A/G	cg02571835	chr13:96230311	CLDN10	-0.35	-7.04	-0.31	7.17e-12	Body mass index;
LGG	cis	rs6456156	0.774	rs6908364	chr6:167527296	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.88	-0.3	2e-11	Primary biliary cholangitis;
LGG	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg07343612	chr16:622815	PIGQ	-0.73	-14.52	-0.56	1.24e-39	Height;
LGG	cis	rs735539	0.521	rs2585902	chr13:21417636	A/C	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-11.52	-0.47	3.43e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg06521331	chr12:34319734	NA	0.44	8.04	0.35	7.62e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg05091796	chr16:4465799	CORO7	-0.77	-12.97	-0.52	4.96e-33	Schizophrenia;
LGG	cis	rs1010254	0.510	rs72808305	chr5:151719521	C/G	cg12297329	chr5:152029980	NA	-0.47	-6.79	-0.3	3.36e-11	Optic nerve measurement (cup area);
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg19143629	chr17:61920732	SMARCD2	0.4	6.73	0.3	5.05e-11	Prudent dietary pattern;
LGG	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.11e-15	Monocyte count;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06028808	chr11:68637592	NA	0.74	12.93	0.52	7.2e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg26446133	chr18:72167187	CNDP2	-0.7	-14.8	-0.57	7.54e-41	Refractive error;
LGG	cis	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg19399532	chr1:178512495	C1orf220	-0.42	-8.24	-0.36	1.85e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2797160	0.684	rs1832937	chr6:125985934	A/G	cg05901451	chr6:126070800	HEY2	0.5	8.51	0.37	2.45e-16	Endometrial cancer;
LGG	cis	rs4650994	0.525	rs2811295	chr1:178551267	C/T	cg12486710	chr1:178512616	C1orf220	-0.51	-10.65	-0.44	7.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6725041	0.819	rs10048673	chr2:213083282	A/G	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.03	-0.31	7.4e-12	Triglycerides;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3813359	0.545	rs62431206	chr6:130555995	G/T	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.53	-0.53	2.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg25237894	chr2:233734115	C2orf82	-0.66	-12.42	-0.5	9.04e-31	Coronary artery disease;
LGG	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg03060546	chr3:49711283	APEH	-0.69	-11.51	-0.47	3.88e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4740619	0.901	rs10810435	chr9:15719658	T/G	cg14451791	chr9:16040625	NA	-0.39	-9.91	-0.42	3.87e-21	Body mass index;
LGG	cis	rs3771570	1.000	rs73002111	chr2:242277833	C/T	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.57	-0.69	3.04e-67	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10660249	chr9:5833007	ERMP1	0.45	6.88	0.3	1.94e-11	Gut microbiome composition (summer);
LGG	cis	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg13443165	chr9:33130375	B4GALT1	-0.67	-11.51	-0.47	3.94e-27	IgG glycosylation;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21862992	chr11:68658383	NA	0.5	8.42	0.36	4.84e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2071403	0.933	rs11900674	chr2:1406538	G/A	cg06500727	chr2:1417164	TPO	-0.5	-9.58	-0.41	6.12e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg20991723	chr1:152506922	NA	-0.71	-14.5	-0.56	1.47e-39	Hair morphology;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11039798	1.000	rs10838918	chr11:48507449	A/G	cg15704280	chr7:45808275	SEPT13	0.77	8.92	0.38	1.13e-17	Axial length;
LGG	cis	rs1691799	0.899	rs1168328	chr12:66729250	T/C	cg16791601	chr12:66731901	HELB	-0.66	-15.81	-0.59	2.6e-45	White blood cell count (basophil);
LGG	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg14952266	chr13:112191215	NA	-0.42	-7.68	-0.34	9.8e-14	Menarche (age at onset);
LGG	cis	rs4639966	0.797	rs68097885	chr11:118596444	G/A	cg27286069	chr11:118481882	PHLDB1	-0.48	-6.88	-0.3	1.97e-11	Systemic lupus erythematosus;
LGG	cis	rs8112449	1.000	rs35951601	chr19:10521548	G/A	cg21868191	chr19:10515988	NA	-0.48	-8.29	-0.36	1.21e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs2404602	0.647	rs12439141	chr15:77095423	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-13.65	-0.54	6.84e-36	Blood metabolite levels;
LGG	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.09	-0.42	8.8e-22	Response to antipsychotic treatment;
LGG	cis	rs6121246	0.529	rs6060142	chr20:30178028	A/G	cg21427119	chr20:30132790	HM13	-0.56	-8.52	-0.37	2.23e-16	Mean corpuscular hemoglobin;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23633679	chr1:173793655	CENPL;DARS2	0.47	8.34	0.36	8.71e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg06558623	chr16:89946397	TCF25	1.02	12.76	0.51	3.69e-32	Skin colour saturation;
LGG	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.82	16.38	0.61	6.92e-48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6141769	0.542	rs6058833	chr20:31316767	T/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs10193935	0.901	rs222483	chr2:42652184	T/G	cg27598129	chr2:42591480	NA	-0.68	-10.15	-0.43	5.4e-22	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11190604	1.000	rs10786597	chr10:102291287	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8180040	0.966	rs12632132	chr3:47477019	C/T	cg27129171	chr3:47204927	SETD2	0.79	15.35	0.58	2.7e-43	Colorectal cancer;
LGG	cis	rs12580194	0.593	rs12099665	chr12:55731191	G/T	cg19537932	chr12:55886519	OR6C68	-0.56	-9.94	-0.42	3.08e-21	Cancer;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg03575189	chr17:44344142	NA	0.48	7.09	0.31	5.12e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.26	0.4	7.82e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.09	0.55	9.11e-38	Platelet count;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08677398	chr8:58056175	NA	0.56	8.67	0.37	7.16e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg26043149	chr18:55253948	FECH	1.0	18.26	0.65	1.65e-56	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9318086	0.753	rs9553094	chr13:24474613	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.36	-6.89	-0.3	1.87e-11	Myopia (pathological);
LGG	cis	rs1451375	0.642	rs6963996	chr7:50559300	T/C	cg14593290	chr7:50529359	DDC	-0.67	-11.96	-0.49	6.74e-29	Malaria;
LGG	cis	rs79839061	0.610	rs2306252	chr4:892116	T/C	cg07828340	chr4:882639	GAK	0.73	8.36	0.36	7.14e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4851254	0.660	rs60697219	chr2:100699507	G/A	cg17356467	chr2:100759845	AFF3	0.45	7.33	0.32	1.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg23583168	chr7:148888333	NA	-0.81	-15.23	-0.58	9.68e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg15038512	chr6:170123185	PHF10	0.51	6.73	0.3	5.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2074585	0.646	rs2589964	chr15:90922757	A/G	cg22089800	chr15:90895588	ZNF774	0.74	13.56	0.53	1.57e-35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg24375607	chr4:120327624	NA	0.61	10.19	0.43	3.87e-22	Corneal astigmatism;
LGG	cis	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs8179	0.700	rs42040	chr7:92245927	C/T	cg15732164	chr7:92237376	CDK6	-0.55	-10.25	-0.43	2.39e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg13647721	chr17:30228624	UTP6	0.63	7.92	0.35	1.8e-14	Hip circumference adjusted for BMI;
LGG	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg26248373	chr2:1572462	NA	-0.87	-14.68	-0.56	2.39e-40	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg15506890	chr2:3487001	NA	-0.52	-9.74	-0.41	1.59e-20	Neurofibrillary tangles;
LGG	cis	rs3784262	0.669	rs4646645	chr15:58245151	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.75	-0.3	4.46e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07923666	chr12:49932857	KCNH3	-0.44	-6.75	-0.3	4.51e-11	Resting heart rate;
LGG	cis	rs4660214	0.666	rs4617393	chr1:39940223	C/T	cg18385671	chr1:39797026	MACF1	-0.49	-10.03	-0.42	1.47e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7851660	0.527	rs7870540	chr9:100573925	T/C	cg13688889	chr9:100608707	NA	-0.86	-18.74	-0.66	9.72e-59	Strep throat;
LGG	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.28	0.4	6.75e-19	Diabetic retinopathy;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24972080	chr11:65154083	FRMD8	0.61	7.12	0.31	4.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2742417	0.603	rs2742453	chr3:45765858	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.65e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21963583	chr11:68658836	MRPL21	0.61	10.57	0.44	1.55e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs34929064	1.000	rs34929064	chr7:22728272	T/C	cg18045685	chr7:22629474	NA	0.56	8.92	0.38	1.11e-17	Major depression and alcohol dependence;
LGG	cis	rs4731207	0.596	rs1871775	chr7:124674652	G/T	cg05630886	chr7:124431682	NA	-0.33	-7.53	-0.33	2.64e-13	Cutaneous malignant melanoma;
LGG	cis	rs60180747	0.544	rs12913465	chr15:66573234	C/A	cg07575407	chr15:66541975	MEGF11	0.62	13.48	0.53	3.64e-35	Testicular germ cell tumor;
LGG	trans	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg13565492	chr6:43139072	SRF	-0.72	-8.78	-0.38	3.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11018904	0.861	rs12787117	chr11:89943681	A/G	cg16176437	chr11:89678848	NA	0.39	6.68	0.3	7.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12200782	0.649	rs9467745	chr6:26386762	G/A	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs965513	1.000	rs925488	chr9:100546391	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.69	-0.41	2.51e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg14784868	chr12:69753453	YEATS4	0.79	15.34	0.58	3.09e-43	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7666738	0.791	rs6853608	chr4:99047916	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3796352	1.000	rs113995589	chr3:53132372	A/T	cg12962167	chr3:53033115	SFMBT1	0.62	6.71	0.3	5.68e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2247341	0.577	rs2236996	chr4:1703646	A/G	cg08629884	chr4:1719983	TMEM129	-0.38	-6.86	-0.3	2.21e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg18105134	chr13:113819100	PROZ	-0.79	-16.8	-0.62	8.33e-50	Platelet distribution width;
LGG	cis	rs9902453	1.000	rs60967688	chr17:28437052	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.4	0.5	1.1e-30	Coffee consumption (cups per day);
LGG	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg12458913	chr13:53173898	NA	-0.47	-8.02	-0.35	9e-15	Lewy body disease;
LGG	cis	rs13082711	1.000	rs73050029	chr3:27514760	C/A	cg02860705	chr3:27208620	NA	0.82	14.61	0.56	5.09e-40	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7319311	0.899	rs9521729	chr13:111029970	G/A	cg06243866	chr13:111019493	COL4A2	0.5	8.75	0.38	4.04e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg12070911	chr6:150209640	RAET1E	-0.3	-7.25	-0.32	1.8e-12	Lung cancer;
LGG	cis	rs2410601	0.562	rs7846416	chr8:18913273	C/G	cg03215416	chr8:18823341	PSD3	-0.39	-6.8	-0.3	3.32e-11	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.1	0.35	4.77e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs677665	0.537	rs12121476	chr1:9335327	C/G	cg25755851	chr1:9335794	NA	0.29	8.38	0.36	6.4e-16	Eosinophil percentage of white cells;
LGG	cis	rs17122278	1.000	rs11216922	chr11:118465295	A/G	cg19182353	chr11:118479428	PHLDB1	-0.53	-7.04	-0.31	6.99e-12	Total cholesterol levels;
LGG	cis	rs7177699	0.557	rs3971829	chr15:79109052	A/G	cg00540400	chr15:79124168	NA	0.54	11.4	0.47	1.03e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg23166289	chr1:210001082	C1orf107	0.37	7.23	0.32	2.01e-12	Orofacial clefts;
LGG	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.11	-0.35	4.7e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9354308	0.764	rs9294669	chr6:66604668	A/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.87e-13	Menopause (age at onset);
LGG	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.36e-21	Colorectal cancer;
LGG	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.23	-0.32	1.97e-12	Mood instability;
LGG	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg02733842	chr7:1102375	C7orf50	-0.46	-7.41	-0.33	6.07e-13	Bronchopulmonary dysplasia;
LGG	cis	rs7179456	0.654	rs11633839	chr15:59234376	G/A	cg05156742	chr15:59063176	FAM63B	-0.4	-6.8	-0.3	3.23e-11	Asperger disorder;
LGG	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg06347083	chr6:39282316	KCNK17	0.43	12.53	0.5	3.29e-31	Type 2 diabetes;
LGG	trans	rs11039798	0.588	rs10437592	chr11:48598859	G/T	cg03929089	chr4:120376271	NA	0.71	9.77	0.41	1.3e-20	Axial length;
LGG	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg09307838	chr4:120376055	NA	0.72	12.48	0.5	5.3e-31	Corneal astigmatism;
LGG	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1878931	0.597	rs2680221	chr16:3462595	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.78	-12.0	-0.49	4.4e-29	Body mass index (adult);
LGG	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg24253500	chr15:84953950	NA	0.4	6.67	0.3	7.17e-11	Schizophrenia;
LGG	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-10.97	-0.45	4.58e-25	HDL cholesterol;
LGG	cis	rs7444	0.941	rs131665	chr22:21920903	A/G	cg05046821	chr22:21984468	YDJC	-0.39	-7.08	-0.31	5.48e-12	Systemic lupus erythematosus;
LGG	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg10661904	chr17:79619235	PDE6G	0.41	8.15	0.35	3.51e-15	Eye color traits;
LGG	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.45e-13	Body mass index;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03264133	chr6:25882463	NA	-0.5	-9.34	-0.4	4.16e-19	Height;
LGG	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07570687	chr10:102243282	WNT8B	0.43	6.98	0.31	1.01e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg04863758	chr4:1303710	MAEA	0.44	7.29	0.32	1.33e-12	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg02002194	chr4:3960332	NA	-0.42	-7.96	-0.35	1.38e-14	Mood instability;
LGG	trans	rs1032833	0.732	rs17363449	chr2:180016141	G/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg25883020	chr8:41504993	NKX6-3	0.32	7.11	0.31	4.54e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg06917634	chr15:78832804	PSMA4	-0.64	-9.7	-0.41	2.33e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs4714291	0.963	rs1743973	chr6:40094549	T/G	cg02267698	chr19:7991119	CTXN1	0.6	9.53	0.4	9.07e-20	Strep throat;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	15.74	0.59	5.08e-45	Platelet count;
LGG	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg06636001	chr8:8085503	FLJ10661	0.39	6.69	0.3	6.47e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7923837	0.650	rs10882098	chr10:94444793	C/T	cg27639046	chr2:171608303	NA	-0.36	-7.06	-0.31	6.17e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs1580019	0.523	rs13236410	chr7:32690663	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.07	25.72	0.77	3.05e-91	Cognitive ability;
LGG	cis	rs4363385	0.693	rs490553	chr1:153033277	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.75e-11	Psoriasis vulgaris;
LGG	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg23625390	chr15:77176239	SCAPER	0.48	9.27	0.4	7.23e-19	Blood metabolite levels;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg17178900	chr1:205818956	PM20D1	0.57	12.73	0.51	4.71e-32	Menarche (age at onset);
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg26554054	chr8:600488	NA	0.94	9.92	0.42	3.6e-21	IgG glycosylation;
LGG	cis	rs1003719	0.788	rs2835588	chr21:38462716	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs9399135	1.000	rs4896130	chr6:135355118	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.75	0.41	1.54e-20	Red blood cell count;
LGG	trans	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.96e-27	Corneal astigmatism;
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg11494091	chr17:61959527	GH2	0.49	7.78	0.34	4.77e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4774899	0.932	rs3794613	chr15:57539638	T/C	cg08128148	chr15:57256372	TCF12	-0.32	-7.53	-0.33	2.6e-13	Urinary tract infection frequency;
LGG	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg12751644	chr20:60527061	NA	-0.3	-6.73	-0.3	5.08e-11	Body mass index;
LGG	cis	rs7633770	0.841	rs6774048	chr3:46702202	C/G	cg11219411	chr3:46661640	NA	0.58	13.61	0.53	1.06e-35	Coronary artery disease;
LGG	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg08975724	chr8:8085496	FLJ10661	0.42	7.59	0.33	1.83e-13	Neuroticism;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.92	0.38	1.12e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.25	-0.32	1.79e-12	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05340844	chr15:90808742	NGRN	0.42	6.84	0.3	2.55e-11	Cognitive performance;
LGG	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-15.89	-0.59	1.07e-45	Chronic sinus infection;
LGG	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg13010199	chr12:38710504	ALG10B	0.74	15.24	0.58	8.37e-43	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18796520	chr12:4758272	NDUFA9	0.46	7.26	0.32	1.63e-12	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg16141378	chr3:129829833	LOC729375	0.33	6.96	0.31	1.18e-11	Triglycerides;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs975722	0.646	rs43035	chr7:117113624	A/C	cg10524701	chr7:117356490	CTTNBP2	0.43	9.47	0.4	1.43e-19	Coronary artery disease;
LGG	cis	rs3796352	1.000	rs114562844	chr3:52991584	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9291683	0.546	rs13129453	chr4:10044784	T/C	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs2652834	0.851	rs16946416	chr15:63356721	A/T	cg05507819	chr15:63340323	TPM1	-0.6	-8.08	-0.35	5.72e-15	HDL cholesterol;
LGG	cis	rs7572733	1.000	rs6738825	chr2:198896895	A/G	cg00792783	chr2:198669748	PLCL1	0.45	7.48	0.33	3.84e-13	Dermatomyositis;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs58235267	0.656	rs13410889	chr2:63087778	T/C	cg17519650	chr2:63277830	OTX1	0.63	11.21	0.46	5.82e-26	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs1882538	0.569	rs11562036	chr7:133076862	T/C	cg10665199	chr7:133106180	EXOC4	0.55	9.25	0.4	8.01e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11758351	0.500	rs113738935	chr6:26196567	T/A	cg02612650	chr6:26195910	NA	0.88	6.85	0.3	2.4e-11	Gout;Renal underexcretion gout;
LGG	cis	rs668210	0.793	rs502363	chr11:65775592	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	9.55	0.41	7.73e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7202877	0.610	rs1010631	chr16:75328590	C/G	cg03315344	chr16:75512273	CHST6	0.5	6.77	0.3	3.99e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg19774624	chr17:42201019	HDAC5	-0.96	-20.76	-0.69	3.87e-68	Total body bone mineral density;
LGG	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg14191688	chr11:70257035	CTTN	0.59	8.48	0.37	3.01e-16	Coronary artery disease;
LGG	cis	rs79146658	0.920	rs1032282	chr2:179758007	C/T	cg17765952	chr2:179737173	CCDC141	-0.56	-7.91	-0.35	1.85e-14	Diastolic blood pressure;
LGG	cis	rs7572733	0.534	rs1464209	chr2:198814396	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs564799	0.842	rs586094	chr3:159729548	T/G	cg04855961	chr3:159719849	NA	-0.27	-7.4	-0.33	6.41e-13	Systemic lupus erythematosus;
LGG	trans	rs9354308	0.764	rs9345716	chr6:66607782	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.65	-0.3	8.26e-11	Metabolite levels;
LGG	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14283194	chr7:91763737	CYP51A1	0.43	7.53	0.33	2.73e-13	Bipolar disorder;
LGG	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.65	-0.44	7.49e-24	Systemic lupus erythematosus;
LGG	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg22961513	chr11:14280813	SPON1	0.38	9.64	0.41	3.7799999999999997e-20	Mitochondrial DNA levels;
LGG	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.94	-0.31	1.36e-11	Blood metabolite levels;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg23978390	chr7:1156363	C7orf50	0.43	7.3	0.32	1.24e-12	Longevity;Endometriosis;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg13009111	chr11:71350975	NA	0.39	8.87	0.38	1.59e-17	Neuroticism;
LGG	cis	rs3735485	0.678	rs113572217	chr7:45098776	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs11169552	0.510	rs10459233	chr12:50973897	G/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.32	-0.32	1.08e-12	Colorectal cancer;
LGG	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg04117972	chr1:227635322	NA	0.55	9.07	0.39	3.39e-18	Major depressive disorder;
LGG	cis	rs758324	0.504	rs55764014	chr5:131170905	G/T	cg06307176	chr5:131281290	NA	0.53	8.87	0.38	1.58e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg03237606	chr10:63212265	TMEM26	0.46	8.49	0.37	2.73e-16	Night sleep phenotypes;
LGG	cis	rs7607369	0.648	rs7599984	chr2:219656713	T/G	cg01130898	chr2:219473002	PLCD4	0.41	6.73	0.3	5.01e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg18357526	chr6:26021779	HIST1H4A	0.67	10.8	0.45	2.05e-24	Urate levels;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg17202724	chr17:61916730	SMARCD2	0.55	12.72	0.51	5.6e-32	Prudent dietary pattern;
LGG	cis	rs2274273	0.905	rs2147961	chr14:55585381	T/C	cg04306507	chr14:55594613	LGALS3	0.65	18.77	0.66	7.05e-59	Protein biomarker;
LGG	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17859882	chr6:58287694	GUSBL2	0.43	6.95	0.31	1.23e-11	Cognitive performance;
LGG	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg23306229	chr2:178417860	TTC30B	0.64	8.02	0.35	8.52e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.9	0.31	1.72e-11	Glycated hemoglobin levels;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.77	-0.38	3.47e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg23029597	chr12:123009494	RSRC2	0.93	17.16	0.62	1.92e-51	Body mass index;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.03	0.84	8.44e-124	Prudent dietary pattern;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg15352829	chr14:105391018	PLD4	-0.46	-10.93	-0.45	6.86e-25	Rheumatoid arthritis;
LGG	cis	rs3736485	0.609	rs1456299	chr15:51982065	T/A	cg13474965	chr15:52030001	LYSMD2	0.4	6.71	0.3	5.8e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6429082	0.608	rs4659838	chr1:235565315	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.88	-0.38	1.5e-17	Adiposity;
LGG	cis	rs13040088	0.518	rs2427452	chr20:61577275	T/C	cg23096297	chr20:61557774	DIDO1	-0.64	-9.26	-0.4	7.59e-19	Menopause (age at onset);
LGG	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg24110177	chr3:50126178	RBM5	-0.47	-7.45	-0.33	4.63e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg26384229	chr12:38710491	ALG10B	0.74	14.76	0.57	1.14e-40	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04100724	chr12:92539208	BTG1	0.51	8.07	0.35	6.27e-15	Gut microbiome composition (summer);
LGG	trans	rs4714291	0.832	rs1524087	chr6:40057504	A/G	cg02267698	chr19:7991119	CTXN1	-0.61	-10.03	-0.42	1.49e-21	Strep throat;
LGG	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg04248312	chr19:17393744	ANKLE1	-0.65	-10.92	-0.45	7.42e-25	Systemic lupus erythematosus;
LGG	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg11161011	chr14:65562177	MAX	0.7	13.55	0.53	1.87e-35	Obesity-related traits;
LGG	cis	rs12220238	1.000	rs12357530	chr10:75928654	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.5e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg16141378	chr3:129829833	LOC729375	0.38	8.29	0.36	1.26e-15	Mood instability;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	trans	rs2840044	1.000	rs225259	chr17:33958168	A/G	cg19694781	chr19:47549865	TMEM160	-0.55	-9.07	-0.39	3.51e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs1408799	0.720	rs13288681	chr9:12721881	C/G	cg05274944	chr9:12693694	TYRP1	0.34	8.36	0.36	7.3e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs9972944	0.756	rs9899781	chr17:63769384	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.39	-0.36	5.77e-16	Total body bone mineral density;
LGG	cis	rs2795502	1.000	rs2744090	chr10:43339614	G/C	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs7572644	0.640	rs4555299	chr2:28071190	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.89	0.3	1.82e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.33	0.36	9.15e-16	Neuroticism;
LGG	cis	rs968451	0.865	rs2076125	chr22:39711351	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	12.02	0.49	3.84e-29	Primary biliary cholangitis;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05025164	chr4:1340916	KIAA1530	0.54	9.9	0.42	4.45e-21	Longevity;
LGG	cis	rs7927771	0.524	rs10838775	chr11:47856382	C/G	cg20307385	chr11:47447363	PSMC3	0.57	11.08	0.46	1.88e-25	Subjective well-being;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg05861140	chr6:150128134	PCMT1	-0.32	-7.19	-0.32	2.61e-12	Testicular germ cell tumor;
LGG	trans	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg18335740	chr13:41363409	SLC25A15	0.56	10.38	0.43	7.62e-23	Lewy body disease;
LGG	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.24	-20.34	-0.69	3.64e-66	Hemostatic factors and hematological phenotypes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg12496657	chr2:105488809	NA	0.41	7.08	0.31	5.27e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs8141529	0.748	rs5762882	chr22:29290680	C/A	cg15103426	chr22:29168792	CCDC117	0.59	8.96	0.38	7.86e-18	Lymphocyte counts;
LGG	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg02297831	chr4:17616191	MED28	0.52	9.36	0.4	3.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9916302	0.861	rs7503514	chr17:37669884	G/C	cg00129232	chr17:37814104	STARD3	-0.6	-11.37	-0.47	1.38e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs11105298	0.838	rs10858862	chr12:89842053	T/C	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg16077055	chr2:106428750	NCK2	0.31	8.22	0.36	1.99e-15	Addiction;
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.15e-21	Aortic root size;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg02725872	chr8:58115012	NA	-0.97	-12.73	-0.51	4.94e-32	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11407514	chr10:99094219	FRAT2	0.46	7.37	0.32	7.8e-13	Gut microbiome composition (summer);
LGG	cis	rs2651899	0.902	rs2742673	chr1:3080019	A/C	cg22674798	chr1:3096360	PRDM16	-0.31	-6.66	-0.3	7.68e-11	Migraine;
LGG	trans	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg22232500	chr2:134024266	NCKAP5	0.54	7.6	0.33	1.62e-13	Neuroticism;
LGG	cis	rs2229238	0.911	rs41313910	chr1:154514203	C/G	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg12654349	chr5:56205094	C5orf35	-0.52	-8.71	-0.38	5.22e-17	Coronary artery disease;
LGG	cis	rs9300255	0.543	rs520088	chr12:123522150	C/G	cg00376283	chr12:123451042	ABCB9	0.65	10.66	0.44	6.88e-24	Neutrophil percentage of white cells;
LGG	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	trans	rs9354308	0.764	rs1353877	chr6:66569619	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg02297831	chr4:17616191	MED28	0.47	8.31	0.36	1.06e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6754311	0.731	rs1470457	chr2:136581848	A/G	cg07169764	chr2:136633963	MCM6	0.82	14.34	0.55	7.74e-39	Mosquito bite size;
LGG	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg11342453	chr6:26196699	NA	0.49	6.82	0.3	2.83e-11	Gout;Renal underexcretion gout;
LGG	cis	rs853679	0.517	rs9393885	chr6:28050009	A/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs7580658	0.895	rs4662722	chr2:128102569	T/C	cg10021288	chr2:128175891	PROC	-0.63	-12.87	-0.51	1.27e-32	Protein C levels;
LGG	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.03e-37	Bladder cancer;
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg03517284	chr6:25882590	NA	-0.52	-9.94	-0.42	3.15e-21	Height;
LGG	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg05527609	chr1:210001259	C1orf107	0.59	9.57	0.41	6.51e-20	Orofacial clefts;
LGG	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg21775007	chr8:11205619	TDH	0.45	7.46	0.33	4.2e-13	Mood instability;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.04	-0.42	1.4e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg05552183	chr6:42928497	GNMT	0.31	7.38	0.32	7.22e-13	Blood protein levels;
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg03605463	chr16:89740564	NA	-0.4	-6.9	-0.31	1.7e-11	Vitiligo;
LGG	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg11839771	chr15:80205821	ST20	-0.39	-8.51	-0.37	2.45e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9596863	0.898	rs35646102	chr13:54364897	G/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.02	0.31	7.94e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs17253792	0.822	rs28831725	chr14:56087569	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs3087591	0.708	rs2189525	chr17:29668808	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.59	-12.18	-0.49	8.72e-30	Hip circumference;
LGG	cis	rs4900538	0.927	rs1190544	chr14:102903398	G/A	cg18135206	chr14:102964638	TECPR2	-0.82	-16.1	-0.6	1.18e-46	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10532262	chr3:172428426	NCEH1	-0.42	-7.08	-0.31	5.52e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs854765	0.552	rs11078407	chr17:17841083	T/C	cg05444541	chr17:17804740	TOM1L2	-0.79	-21.85	-0.71	3.08e-73	Total body bone mineral density;
LGG	cis	rs7226408	0.857	rs72887035	chr18:34474461	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs8056064	0.739	rs16958619	chr16:82816475	A/C	cg08271366	chr16:82816457	CDH13	0.46	8.17	0.35	3.02e-15	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg11789530	chr4:8429930	ACOX3	0.74	14.41	0.56	3.77e-39	Response to antineoplastic agents;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.12e-18	Fuchs's corneal dystrophy;
LGG	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	13.16	0.52	7.63e-34	Menopause (age at onset);
LGG	cis	rs963731	0.579	rs6544195	chr2:39288486	A/G	cg04010122	chr2:39346883	SOS1	-0.76	-7.42	-0.33	5.71e-13	Corticobasal degeneration;
LGG	cis	rs258892	0.947	rs62360681	chr5:72187013	T/G	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs787274	0.867	rs2798316	chr9:115462552	T/C	cg13803584	chr9:115635662	SNX30	0.48	6.71	0.3	5.59e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4731207	0.698	rs12536575	chr7:124510276	G/A	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs4891159	0.527	rs690593	chr18:74160408	C/G	cg24786174	chr18:74118243	ZNF516	0.64	15.44	0.58	1.16e-43	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02657836	chr5:155109126	NA	0.36	7.52	0.33	2.85e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7113850	0.541	rs7129839	chr11:24208606	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	9.96	0.42	2.71e-21	Bone fracture in osteoporosis;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg08491964	chr18:53255771	TCF4	0.42	6.83	0.3	2.72e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs56161922	0.818	rs4437879	chr1:207875977	G/A	cg09557387	chr1:207818395	CR1L	0.93	8.93	0.38	9.79e-18	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs9815354	1.000	rs9869282	chr3:41756064	A/G	cg03022575	chr3:42003672	ULK4	0.59	7.45	0.33	4.48e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12282928	0.959	rs1503192	chr11:48289355	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.31	-0.32	1.21e-12	Migraine - clinic-based;
LGG	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2640806	0.656	rs17781044	chr8:97338931	C/T	cg22138393	chr8:97340270	PTDSS1	-0.32	-8.18	-0.36	2.74e-15	Obesity-related traits;
LGG	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg26384229	chr12:38710491	ALG10B	1.07	28.94	0.8	6.99e-106	Heart rate;
LGG	cis	rs8013055	0.706	rs8003957	chr14:105971702	A/G	cg19700328	chr14:106028568	NA	-0.58	-9.66	-0.41	3.06e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg07870213	chr5:140052090	DND1	-0.65	-12.61	-0.51	1.49e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1497828	0.956	rs1007737	chr1:217547872	G/C	cg04411442	chr1:217543379	NA	0.47	8.01	0.35	9.43e-15	Dialysis-related mortality;
LGG	cis	rs1420338	0.933	rs731844	chr7:34150264	C/T	cg01275685	chr7:34179230	BMPER	-0.51	-9.4	-0.4	2.57e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs2050392	0.767	rs2183175	chr10:30699336	A/G	cg25182066	chr10:30743637	MAP3K8	0.6	12.37	0.5	1.49e-30	Inflammatory bowel disease;
LGG	cis	rs9324022	0.858	rs1004573	chr14:101178235	G/C	cg01194073	chr14:101175302	NA	0.44	7.02	0.31	8.08e-12	Plateletcrit;
LGG	trans	rs1459104	0.866	rs35456973	chr11:54838812	C/A	cg15704280	chr7:45808275	SEPT13	0.77	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs209489	0.892	rs9463891	chr6:53111497	G/A	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs6964587	0.967	rs10279210	chr7:91616891	G/A	cg17063962	chr7:91808500	NA	0.49	8.72	0.38	4.93e-17	Breast cancer;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg17202724	chr17:61916730	SMARCD2	-0.54	-12.9	-0.51	9.48e-33	Prudent dietary pattern;
LGG	cis	rs611744	0.870	rs596703	chr8:109160146	A/G	cg21045802	chr8:109455806	TTC35	-0.4	-7.16	-0.32	3.16e-12	Dupuytren's disease;
LGG	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg04986931	chr22:39850128	NA	0.34	7.85	0.34	2.9e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs10793308	chr11:78086005	C/T	cg02023728	chr11:77925099	USP35	0.43	7.66	0.34	1.06e-13	Testicular germ cell tumor;
LGG	cis	rs1816854	0.938	rs10506231	chr12:44206027	C/T	cg20956634	chr12:44200518	TWF1	0.44	6.7	0.3	5.91e-11	Inflammatory bowel disease;
LGG	cis	rs79839061	0.610	rs2279181	chr4:882643	A/G	cg07828340	chr4:882639	GAK	-0.91	-9.73	-0.41	1.77e-20	Intelligence (multi-trait analysis);
LGG	cis	rs239198	0.602	rs4840157	chr6:101326375	C/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.19	-0.32	2.68e-12	Menarche (age at onset);
LGG	cis	rs4430311	0.756	rs2953329	chr1:244025999	A/G	cg25706552	chr1:244017396	NA	0.61	15.63	0.59	1.64e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs975722	0.639	rs213936	chr7:117184516	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	9.63	0.41	4.11e-20	Coronary artery disease;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05025164	chr4:1340916	KIAA1530	-0.69	-12.91	-0.51	8.93e-33	Obesity-related traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18160880	chr20:57463903	GNAS	0.39	6.66	0.3	7.87e-11	Menarche (age at onset);
LGG	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.72	-0.34	7.23e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs17685	0.753	rs13240967	chr7:75658197	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.05	-24.97	-0.76	8.46e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs7017697	1.000	rs2410612	chr8:19681647	A/G	cg03894339	chr8:19674705	INTS10	0.54	8.8	0.38	2.68e-17	Breast cancer;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00689492	chr4:1303491	MAEA	-0.45	-7.63	-0.33	1.34e-13	Obesity-related traits;
LGG	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg07027305	chr7:2059796	MAD1L1	-0.35	-8.21	-0.36	2.19e-15	Neuroticism;
LGG	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg21427119	chr20:30132790	HM13	-0.45	-7.59	-0.33	1.8e-13	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs6429082	0.967	rs834143	chr1:235626406	C/T	cg26050004	chr1:235667680	B3GALNT2	0.51	8.53	0.37	2.11e-16	Adiposity;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.51	0.33	3.11e-13	Menopause (age at onset);
LGG	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg22961513	chr11:14280813	SPON1	-0.3	-6.7	-0.3	5.9e-11	Sense of smell;
LGG	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg18196295	chr10:418757	DIP2C	-0.68	-14.2	-0.55	2.91e-38	Psychosis in Alzheimer's disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg12484590	chr1:156475177	NA	0.38	6.69	0.3	6.64e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11644362	1.000	rs3843707	chr16:12996788	G/A	cg08528231	chr16:12997261	SHISA9	-0.37	-7.4	-0.33	6.27e-13	Positive affect;Subjective well-being;
LGG	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.9e-48	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.632	rs12336875	chr9:5138404	C/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.55	-0.61	1.2e-48	Pediatric autoimmune diseases;
LGG	cis	rs2011503	1.000	rs11671253	chr19:19604206	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs4789693	0.808	rs12935995	chr17:80394883	C/T	cg04308225	chr17:80449738	NA	0.54	7.67	0.34	1.05e-13	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs7928758	0.943	rs877456	chr11:134265315	T/C	cg22777979	chr11:134283252	B3GAT1	0.96	12.11	0.49	1.64e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg18129748	chr3:49941408	MST1R	-0.21	-6.85	-0.3	2.36e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg11062466	chr8:58055876	NA	0.54	8.87	0.38	1.56e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	8.34	0.36	8.71e-16	Colorectal cancer;
LGG	cis	rs8005172	0.663	rs7493001	chr14:88529064	A/G	cg02175263	chr14:88627849	NA	-0.3	-6.81	-0.3	3.07e-11	Parkinson's disease;
LGG	cis	rs28374715	0.681	rs8037574	chr15:41630770	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.17	-26.22	-0.77	1.46e-93	Ulcerative colitis;
LGG	cis	rs7582180	0.764	rs920269	chr2:100918363	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.71e-43	Intelligence (multi-trait analysis);
LGG	cis	rs1506636	1.000	rs666266	chr7:123417759	A/G	cg03229431	chr7:123269106	ASB15	0.73	17.88	0.64	9.97e-55	Plateletcrit;Platelet count;
LGG	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg06221963	chr1:154839813	KCNN3	-0.4	-7.79	-0.34	4.36e-14	Prostate cancer;
LGG	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.66	-0.34	1.07e-13	Myopia (pathological);
LGG	cis	rs67311347	1.000	rs2305522	chr3:40429358	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.53	-0.69	4.45e-67	Renal cell carcinoma;
LGG	cis	rs1003719	0.680	rs767998	chr21:38525652	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.55	-0.59	3.74e-44	Eye color traits;
LGG	cis	rs12200782	0.674	rs12207224	chr6:26519280	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.18	-0.36	2.74e-15	Small cell lung carcinoma;
LGG	cis	rs12681288	0.823	rs4735974	chr8:1000218	T/G	cg08648136	chr8:956695	NA	0.36	7.57	0.33	2.04e-13	Schizophrenia;
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	8.85	0.38	1.9e-17	Personality dimensions;
LGG	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.85	-0.3	2.34e-11	Total body bone mineral density;
LGG	cis	rs4731207	0.596	rs1481327	chr7:124628282	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22111723	chr13:21872664	NA	0.46	7.73	0.34	6.76e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg00830817	chr11:109293614	C11orf87	0.4	6.82	0.3	2.81e-11	Schizophrenia;
LGG	cis	rs7220401	0.521	rs11080105	chr17:27904711	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.52	9.15	0.39	1.8e-18	Coronary artery disease;
LGG	cis	rs283228	1.000	rs516735	chr6:101792268	T/C	cg27451362	chr6:101846650	GRIK2	0.54	8.98	0.39	6.62e-18	Coenzyme Q10 levels;
LGG	cis	rs1847505	0.609	rs1514541	chr13:61586096	C/G	cg25164009	chr13:61490935	NA	-0.74	-17.52	-0.63	4.31e-53	Polychlorinated biphenyl levels;
LGG	cis	rs6663390	0.831	rs11118880	chr1:208085583	T/A	cg03990033	chr1:208084030	CD34	0.57	7.87	0.34	2.54e-14	Facial morphology (factor 18);
LGG	cis	rs6547631	0.622	rs4832185	chr2:85928814	T/A	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.62e-22	Blood protein levels;
LGG	cis	rs7020830	0.931	rs3802422	chr9:37097172	G/A	cg14294708	chr9:37120828	ZCCHC7	1.16	33.66	0.84	1.61e-126	Schizophrenia;
LGG	cis	rs4713118	0.621	rs4713133	chr6:28034041	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.7	-0.3	6.1e-11	Parkinson's disease;
LGG	cis	rs6732160	0.588	rs10192654	chr2:73370882	A/T	cg01422370	chr2:73384389	NA	-0.57	-9.93	-0.42	3.47e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9309473	1.000	rs6546838	chr2:73679280	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.54	-0.33	2.52e-13	Metabolite levels;
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg13009111	chr11:71350975	NA	-0.31	-7.03	-0.31	7.48e-12	Systolic blood pressure;
LGG	cis	rs7584330	0.737	rs12465714	chr2:238365637	C/T	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	cis	rs7444	0.556	rs5754100	chr22:21916166	T/C	cg05046821	chr22:21984468	YDJC	-0.4	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	cis	rs2018055	0.526	rs6940327	chr6:117790700	A/T	cg14611402	chr6:117803162	DCBLD1	0.29	8.42	0.36	4.7e-16	Diastolic blood pressure;
LGG	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.23	0.46	4.92e-26	Response to antipsychotic treatment;
LGG	trans	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.2	0.43	3.49e-22	Mean corpuscular volume;
LGG	cis	rs7236492	0.872	rs79617804	chr18:77237142	G/A	cg15644404	chr18:77186268	NFATC1	-0.76	-8.78	-0.38	3.19e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2016266	0.929	rs7486393	chr12:53652885	C/T	cg04065151	chr12:53682969	ESPL1	-0.6	-10.41	-0.44	5.85e-23	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6860806	0.507	rs635619	chr5:131720265	G/A	cg07395648	chr5:131743802	NA	0.48	9.91	0.42	4.17e-21	Breast cancer;
LGG	cis	rs997295	0.520	rs4776971	chr15:68081097	C/A	cg08079166	chr15:68083412	MAP2K5	0.28	6.67	0.3	7.11e-11	Motion sickness;
LGG	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg08717414	chr16:71523259	ZNF19	-0.47	-7.16	-0.32	3.19e-12	Post bronchodilator FEV1;
LGG	cis	rs3206736	0.548	rs10265125	chr7:35061136	G/A	cg13400248	chr7:35225412	NA	0.55	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.83	0.38	2.13e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06470251	chr20:60548479	NA	0.42	7.33	0.32	1.01e-12	Body mass index;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	trans	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg07817883	chr1:32538562	TMEM39B	1.15	12.07	0.49	2.45e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4919694	1.000	rs4919694	chr10:104698978	T/C	cg04362960	chr10:104952993	NT5C2	1.06	15.0	0.57	1.03e-41	Arsenic metabolism;
LGG	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3806843	0.576	rs246007	chr5:140338748	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs713587	0.563	rs10865315	chr2:25100738	C/A	cg04586622	chr2:25135609	ADCY3	0.42	11.5	0.47	4.15e-27	Body mass index in non-asthmatics;
LGG	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg25173405	chr17:45401733	C17orf57	-0.73	-12.96	-0.52	5.28e-33	Glaucoma (primary open-angle);
LGG	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Body mass index;
LGG	cis	rs4804815	0.780	rs62125168	chr19:7840521	T/G	cg00371453	chr19:7854482	CLEC4GP1	0.71	10.69	0.44	5.68e-24	Neutrophil count;
LGG	cis	rs79349575	0.783	rs4793998	chr17:47019899	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.27	-0.32	1.55e-12	Blood metabolite levels;
LGG	cis	rs1003719	0.788	rs7277657	chr21:38469523	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs2013441	0.508	rs8081817	chr17:19975466	C/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.76e-14	Hepatitis;
LGG	cis	rs9815354	0.761	rs73083326	chr3:41927150	G/T	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8053891	0.906	rs8047643	chr16:71996498	A/G	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.66	-0.3	7.62e-11	Coronary artery disease;
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.57	-0.33	2.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11608355	0.508	rs12822899	chr12:109800978	A/G	cg19025524	chr12:109796872	NA	-0.47	-8.4	-0.36	5.67e-16	Neuroticism;
LGG	trans	rs73198271	1.000	rs11774744	chr8:8607764	A/G	cg16141378	chr3:129829833	LOC729375	0.37	6.84	0.3	2.52e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9549367	0.789	rs3764124	chr13:113897320	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.66	-0.37	8e-17	Platelet distribution width;
LGG	cis	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.23	-0.36	1.98e-15	Retinal vascular caliber;
LGG	cis	rs2594989	0.943	rs2244617	chr3:11503097	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.71e-13	Circulating chemerin levels;
LGG	cis	rs7267979	1.000	rs6107047	chr20:25442097	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.98	0.42	2.15e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg07460842	chr6:66804631	NA	0.95	17.53	0.63	3.99e-53	Exhaled nitric oxide output;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.8	-16.05	-0.6	2.13e-46	Obesity-related traits;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.94	-0.38	9.15e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg27129171	chr3:47204927	SETD2	0.78	15.04	0.57	6.33e-42	Colorectal cancer;
LGG	cis	rs6121246	0.609	rs6088997	chr20:30289824	A/G	cg13852791	chr20:30311386	BCL2L1	-0.92	-17.41	-0.63	1.44e-52	Mean corpuscular hemoglobin;
LGG	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.34	0.43	1.08e-22	Mean platelet volume;
LGG	cis	rs11785693	0.862	rs17350978	chr8:4983418	G/C	cg26367366	chr8:4980734	NA	1.01	15.49	0.58	6.81e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.03	0.52	2.89e-33	Lung cancer in ever smokers;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.09	0.31	5.19e-12	Longevity;
LGG	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.8	0.57	7.03e-41	Cognitive test performance;
LGG	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1784581	0.588	rs9295180	chr6:162420579	T/C	cg17173639	chr6:162384350	PARK2	0.64	13.4	0.53	7.82e-35	Itch intensity from mosquito bite;
LGG	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.23e-56	White matter hyperintensity burden;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06888550	chr17:43238612	HEXIM2	0.45	7.21	0.32	2.24e-12	Cognitive performance;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11645453	chr3:52864694	ITIH4	0.39	6.74	0.3	4.58e-11	Bipolar disorder;
LGG	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg13550731	chr2:172543902	DYNC1I2	1.06	27.59	0.79	8.66e-100	Schizophrenia;
LGG	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.77	-0.45	2.64e-24	Vitiligo;
LGG	cis	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg21775007	chr8:11205619	TDH	0.52	8.02	0.35	8.57e-15	Neuroticism;
LGG	cis	rs887829	0.531	rs4338954	chr2:234593931	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.14	-0.35	3.77e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-10.99	-0.45	4.01e-25	Total body bone mineral density;
LGG	cis	rs3849570	0.961	rs11915042	chr3:81834060	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.86	-0.34	2.67e-14	Waist circumference;Body mass index;
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg10587741	chr22:38071170	LGALS1	0.82	21.55	0.71	7.53e-72	Fat distribution (HIV);
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg11878867	chr6:150167359	LRP11	-0.54	-11.1	-0.46	1.5e-25	Lung cancer;
LGG	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.66	0.59	1.19e-44	Body mass index;
LGG	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22862193	chr5:86564070	RASA1	-0.45	-7.82	-0.34	3.62e-14	Brain structure;
LGG	cis	rs1465370	0.711	rs4731689	chr7:130009839	C/T	cg04743876	chr7:130013617	NA	0.31	6.84	0.3	2.45e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.35	0.43	9.9e-23	Motion sickness;
LGG	cis	rs3764563	1.000	rs4239612	chr19:15727442	A/G	cg20725493	chr19:15740067	CYP4F8	-0.67	-7.98	-0.35	1.17e-14	Inflammatory biomarkers;
LGG	cis	rs7552404	0.731	rs5745458	chr1:76345429	G/A	cg22875332	chr1:76189707	ACADM	-0.6	-8.93	-0.38	9.78e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg20387954	chr3:183756860	HTR3D	0.65	13.24	0.52	3.69e-34	Anterior chamber depth;
LGG	cis	rs1620921	0.505	rs4708892	chr6:161209101	T/C	cg01280913	chr6:161186852	NA	-0.51	-10.75	-0.45	3.35e-24	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7246760	0.748	rs73006398	chr19:9723447	A/G	cg16876255	chr19:9731953	ZNF561	0.88	7.92	0.35	1.82e-14	Pursuit maintenance gain;
LGG	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg16482183	chr6:26056742	HIST1H1C	0.6	9.77	0.41	1.29e-20	Iron status biomarkers;
LGG	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg20573242	chr4:122745356	CCNA2	0.55	10.26	0.43	2.18e-22	Type 2 diabetes;
LGG	cis	rs2018055	0.912	rs17079281	chr6:117803138	A/G	cg14611402	chr6:117803162	DCBLD1	-0.31	-9.11	-0.39	2.51e-18	Diastolic blood pressure;
LGG	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg09085632	chr11:111637200	PPP2R1B	0.96	18.48	0.65	1.62e-57	Primary sclerosing cholangitis;
LGG	cis	rs758324	0.797	rs644713	chr5:131339089	T/C	cg06307176	chr5:131281290	NA	0.49	7.18	0.32	2.71e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs344364	0.602	rs2745193	chr16:1853959	A/G	cg06886374	chr16:1844152	IGFALS	-0.47	-8.29	-0.36	1.2e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	13.18	0.52	6.73e-34	Monocyte count;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg18350739	chr11:68623251	NA	-0.86	-21.94	-0.71	1.11e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11875185	0.915	rs28416175	chr18:55616084	T/C	cg15513957	chr14:69354734	ACTN1	-0.75	-7.92	-0.35	1.77e-14	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.62e-13	Prudent dietary pattern;
LGG	cis	rs1595825	0.838	rs73058854	chr2:198885060	G/A	cg00982548	chr2:198649783	BOLL	-0.52	-6.9	-0.31	1.69e-11	Ulcerative colitis;
LGG	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-10.39	-0.43	7.45e-23	Morning vs. evening chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04912466	chr11:63742028	COX8A	0.47	7.68	0.34	9.44e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7949566	0.557	rs59400168	chr11:126280544	G/T	cg05055844	chr11:126275997	ST3GAL4	0.38	7.42	0.33	5.63e-13	Platelet distribution width;Mean platelet volume;
LGG	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15541040	chr2:3486749	NA	-0.47	-8.7	-0.37	6.01e-17	Neurofibrillary tangles;
LGG	cis	rs12791968	1.000	rs1552301	chr11:45002551	A/G	cg11846598	chr11:44996168	LOC221122	-0.66	-12.27	-0.5	3.58e-30	Inhibitory control;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.57	-0.53	1.54e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.83	0.42	8.05e-21	Longevity;
LGG	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg26396452	chr14:65542826	MAX	0.54	11.75	0.48	4.25e-28	Obesity-related traits;
LGG	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg18876405	chr7:65276391	NA	0.56	10.04	0.42	1.42e-21	Aortic root size;
LGG	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg03733263	chr8:22462867	KIAA1967	-1.09	-29.2	-0.81	4.67e-107	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7717393	1.000	rs7725121	chr5:155753983	A/T	cg01474424	chr5:155754231	SGCD	0.8	7.64	0.33	1.24e-13	Egg allergy;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg13206674	chr6:150067644	NUP43	0.45	8.4	0.36	5.48e-16	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs10743315	0.557	rs78468792	chr12:19351592	T/A	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.06e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05927802	chr8:110346885	ENY2;NUDCD1	0.5	8.54	0.37	1.91e-16	Gut microbiome composition (summer);
LGG	trans	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	7.65	0.33	1.19e-13	Mononucleosis;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg13939156	chr17:80058883	NA	-0.44	-8.57	-0.37	1.52e-16	Life satisfaction;
LGG	cis	rs4774899	0.869	rs2733171	chr15:57322998	G/T	cg08128148	chr15:57256372	TCF12	0.3	7.31	0.32	1.22e-12	Urinary tract infection frequency;
LGG	cis	rs4891159	0.790	rs1056714	chr18:74149526	A/G	cg24786174	chr18:74118243	ZNF516	-0.56	-13.15	-0.52	8.41e-34	Longevity;
LGG	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg27532318	chr7:32358331	NA	0.87	8.21	0.36	2.27e-15	Body mass index;
LGG	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg13010199	chr12:38710504	ALG10B	-0.63	-13.04	-0.52	2.52e-33	Morning vs. evening chronotype;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	9.67	0.41	2.76e-20	Tonsillectomy;
LGG	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg06360820	chr2:242988706	NA	-0.91	-11.62	-0.48	1.39e-27	Obesity-related traits;
LGG	cis	rs36051895	0.632	rs10121316	chr9:5147539	C/T	cg02405213	chr9:5042618	JAK2	0.75	14.49	0.56	1.73e-39	Pediatric autoimmune diseases;
LGG	cis	rs6840360	0.642	rs2709819	chr4:152383832	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg26384229	chr12:38710491	ALG10B	0.98	22.67	0.73	4.19e-77	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2985684	0.948	rs11623263	chr14:50083295	A/G	cg04989706	chr14:50066350	PPIL5	-0.54	-8.53	-0.37	2.13e-16	Carotid intima media thickness;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.45	0.44	4.17e-23	Prudent dietary pattern;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg02725872	chr8:58115012	NA	-0.89	-12.11	-0.49	1.56e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.71	12.91	0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs6840360	0.533	rs13145446	chr4:152729035	G/A	cg22705602	chr4:152727874	NA	0.31	7.71	0.34	7.73e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.62	0.37	1.04e-16	Lung cancer;
LGG	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg05425664	chr17:57184151	TRIM37	0.59	9.42	0.4	2.15e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-8.93	-0.38	1.01e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.4	0.33	6.65e-13	Joint mobility (Beighton score);
LGG	cis	rs10773046	0.740	rs11057382	chr12:124362889	C/T	cg18594669	chr12:124364423	DNAH10	0.34	6.71	0.3	5.81e-11	Osteoarthritis (hip);
LGG	cis	rs1318772	0.932	rs11747062	chr5:112901836	A/T	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	trans	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg23762105	chr12:34175262	ALG10	-0.33	-6.73	-0.3	5.12e-11	Morning vs. evening chronotype;
LGG	cis	rs1256531	0.661	rs7160754	chr14:65830705	T/C	cg15999311	chr14:65749247	NA	0.77	6.77	0.3	3.97e-11	Conduct disorder (symptom count);
LGG	cis	rs7546	0.504	rs2075637	chr16:4938280	T/C	cg08329684	chr16:4932620	PPL	-0.56	-12.68	-0.51	8.05e-32	Cancer;
LGG	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg26818257	chr2:241905806	NA	0.5	11.58	0.47	2.06e-27	Joint mobility (Beighton score);
LGG	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs1010254	0.510	rs72808347	chr5:151760491	G/C	cg12297329	chr5:152029980	NA	-0.51	-7.23	-0.32	1.99e-12	Optic nerve measurement (cup area);
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	7.98e-17	Lung cancer;
LGG	cis	rs17253792	0.822	rs78988988	chr14:56152404	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7647973	0.667	rs4241405	chr3:49642027	C/T	cg03060546	chr3:49711283	APEH	0.6	7.91	0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg19147804	chr7:1989927	MAD1L1	-0.61	-12.26	-0.5	4.07e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	0.901	rs35823062	chr7:65965821	A/G	cg12463550	chr7:65579703	CRCP	0.76	8.28	0.36	1.36e-15	Diabetic kidney disease;
LGG	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg21248554	chr2:27665150	KRTCAP3	0.27	7.28	0.32	1.44e-12	Total body bone mineral density;
LGG	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11764359	chr7:65958608	NA	0.56	9.57	0.41	6.62e-20	Aortic root size;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg02725872	chr8:58115012	NA	-0.52	-8.38	-0.36	6.2e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs2834485	1.000	rs2834484	chr21:35816941	G/T	cg07474852	chr4:123073612	NA	-0.65	-11.17	-0.46	8.41e-26	Cancer;
LGG	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.29	0.32	1.39e-12	Bipolar disorder;
LGG	cis	rs7312774	0.748	rs10492211	chr12:107298213	T/C	cg16260113	chr12:107380972	MTERFD3	0.65	6.83	0.3	2.74e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs7107174	0.892	rs2512548	chr11:77962116	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.64	-0.33	1.22e-13	Testicular germ cell tumor;
LGG	cis	rs1570884	0.539	rs2407696	chr13:50112525	G/A	cg11801959	chr13:50123613	RCBTB1	-0.39	-6.84	-0.3	2.55e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7635838	0.565	rs347592	chr3:11248656	T/C	cg00170343	chr3:11313890	ATG7	0.41	6.91	0.31	1.63e-11	HDL cholesterol;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg10505658	chr17:80084571	CCDC57	0.42	8.5	0.37	2.65e-16	Life satisfaction;
LGG	cis	rs2735413	0.918	rs1922612	chr16:78052983	G/C	cg04733911	chr16:78082701	NA	-0.67	-14.61	-0.56	4.93e-40	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg07460842	chr6:66804631	NA	0.57	9.62	0.41	4.31e-20	Metabolite levels;
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.78	0.48	3.36e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg18129748	chr3:49941408	MST1R	0.22	6.85	0.3	2.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3796352	0.881	rs34238610	chr3:53026480	A/T	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2249694	1.000	rs2515644	chr10:135353079	A/C	cg20169779	chr10:135381914	SYCE1	0.5	7.63	0.33	1.38e-13	Obesity-related traits;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	trans	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg18335740	chr13:41363409	SLC25A15	0.68	13.6	0.53	1.07e-35	Lewy body disease;
LGG	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.33	-0.32	1.05e-12	Myopia (pathological);
LGG	cis	rs28588043	1.000	rs11486182	chr1:170975587	G/A	cg03458344	chr1:170964477	C1orf129	-0.55	-7.48	-0.33	3.69e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg24253500	chr15:84953950	NA	-0.4	-7.49	-0.33	3.58e-13	P wave terminal force;
LGG	cis	rs8048589	0.604	rs11642033	chr16:12207990	A/G	cg02910054	chr16:12241554	SNX29	0.53	8.12	0.35	4.13e-15	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg23933602	chr10:16859644	RSU1	1.01	26.29	0.77	6.97e-94	Platelet distribution width;
LGG	cis	rs10504073	0.584	rs56078938	chr8:49940342	A/C	cg00325661	chr8:49890786	NA	0.8	15.7	0.59	7.65e-45	Blood metabolite ratios;
LGG	cis	rs9287719	0.967	rs6706542	chr2:10742491	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	trans	rs1941687	0.831	rs62091190	chr18:31387700	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-9.01	-0.39	5.31e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.45	-0.44	4.49e-23	Total body bone mineral density;
LGG	cis	rs7089973	0.604	rs10490909	chr10:116593532	C/T	cg08188268	chr10:116634841	FAM160B1	0.33	7.42	0.33	5.72e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11690935	0.959	rs3770452	chr2:172668682	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.49	-0.78	8.13e-95	Schizophrenia;
LGG	cis	rs2120243	0.508	rs12492874	chr3:157113227	C/A	cg24825693	chr3:157122686	VEPH1	-0.58	-13.53	-0.53	2.17e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7917772	0.508	rs2252147	chr10:104467774	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	9.39	0.4	2.7e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs1707322	1.000	rs12403666	chr1:46431621	G/A	cg03146154	chr1:46216737	IPP	0.54	10.22	0.43	2.93e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7927771	1.000	rs35902101	chr11:47795169	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	trans	rs3764796	0.748	rs2904699	chr8:17090798	A/G	cg23596620	chr12:113229465	RPH3A	-0.41	-6.69	-0.3	6.64e-11	Calcium levels;
LGG	cis	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.3	-0.32	1.31e-12	Myopia (pathological);
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.59	-10.68	-0.44	5.83e-24	Longevity;Endometriosis;
LGG	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.29	-0.32	1.37e-12	Body mass index;
LGG	cis	rs9815354	0.767	rs73077390	chr3:41860255	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7523273	0.606	rs1962149	chr1:207956559	G/A	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.85	-0.48	1.77e-28	Schizophrenia;
LGG	cis	rs150986675	1	rs150986675	chr11:102777303	T/C	cg14995062	chr11:102826570	MMP13	0.55	7.03	0.31	7.3e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg06374794	chr16:88002281	BANP	0.46	8.68	0.37	6.64e-17	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.29e-18	Motion sickness;
LGG	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.18	0.36	2.7e-15	Height;
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.46	0.4	1.53e-19	Bipolar disorder;
LGG	cis	rs2865126	0.523	rs2865119	chr18:10759935	A/G	cg21165219	chr18:10698044	FAM38B	-0.45	-7.3	-0.32	1.27e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg06212747	chr3:49208901	KLHDC8B	0.66	11.17	0.46	8.26e-26	Parkinson's disease;
LGG	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.63	-0.37	9.59e-17	Triglycerides;
LGG	cis	rs2108225	0.900	rs7805114	chr7:107450033	G/T	cg18560240	chr7:107437656	SLC26A3	0.55	9.89	0.42	4.58e-21	Ulcerative colitis;
LGG	cis	rs13421350	0.579	rs115142421	chr2:173382777	T/A	cg15021238	chr2:173305865	ITGA6	-0.75	-8.23	-0.36	1.87e-15	Diabetic kidney disease;
LGG	cis	rs7928758	0.767	rs746431	chr11:134267093	A/G	cg25213107	chr11:134282864	B3GAT1	0.8	11.12	0.46	1.23e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.59	-0.33	1.83e-13	Tonsillectomy;
LGG	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg12560992	chr17:57184187	TRIM37	0.8	13.54	0.53	1.98e-35	Intelligence (multi-trait analysis);
LGG	cis	rs8016982	0.963	rs2099108	chr14:81675420	C/G	cg01989461	chr14:81687754	GTF2A1	0.64	12.63	0.51	1.2e-31	Schizophrenia;
LGG	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-8.82	-0.38	2.26e-17	Parkinson's disease;
LGG	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.14	-0.31	3.63e-12	Schizophrenia;
LGG	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.54	-0.41	8.18e-20	Mean corpuscular volume;
LGG	cis	rs12579753	1.000	rs17749267	chr12:82178308	A/G	cg07988820	chr12:82153109	PPFIA2	0.76	10.87	0.45	1.11e-24	Resting heart rate;
LGG	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.45	-0.53	4.85e-35	Bladder cancer;
LGG	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.52	-0.37	2.34e-16	Myopia (pathological);
LGG	cis	rs4684776	1.000	rs4684776	chr3:11443223	T/C	cg24705426	chr3:11550659	ATG7	-0.4	-7.52	-0.33	2.87e-13	Small vessel stroke;
LGG	cis	rs7168592	1.000	rs35059326	chr15:101746312	G/A	cg24254196	chr15:101719523	CHSY1	-0.63	-6.88	-0.3	1.94e-11	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.85e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg07636037	chr3:49044803	WDR6	0.97	20.74	0.69	4.44e-68	Menarche (age at onset);
LGG	cis	rs1707322	1.000	rs11211219	chr1:46359478	G/C	cg03146154	chr1:46216737	IPP	0.54	10.37	0.43	8.54e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11608355	0.515	rs12833054	chr12:109890955	G/A	cg05360138	chr12:110035743	NA	0.84	11.63	0.48	1.36e-27	Neuroticism;
LGG	cis	rs11758351	0.500	rs16891404	chr6:26203970	G/A	cg11342453	chr6:26196699	NA	0.83	6.98	0.31	1.03e-11	Gout;Renal underexcretion gout;
LGG	cis	rs300703	0.719	rs400040	chr2:199422	G/T	cg21211680	chr2:198530	NA	1.3	22.08	0.72	2.4e-74	Blood protein levels;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg06925179	chr17:43578568	NA	0.43	10.0	0.42	1.84e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.49	-0.47	4.9e-27	Schizophrenia;
LGG	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg12751644	chr20:60527061	NA	-0.3	-7.17	-0.32	2.98e-12	Body mass index;
LGG	cis	rs4356975	0.563	rs6600886	chr4:69969735	G/A	cg27372994	chr4:70080453	UGT2B11	0.37	6.65	0.3	8.1e-11	Obesity-related traits;
LGG	cis	rs67478160	0.643	rs34813623	chr14:104263294	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs2735413	0.918	rs7190752	chr16:78077430	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs12476592	0.602	rs262509	chr2:63885708	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	cis	rs9796	0.689	rs692511	chr15:41446252	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.56	-0.41	6.96e-20	Menopause (age at onset);
LGG	cis	rs972578	0.765	rs4374465	chr22:43283262	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.7	-0.3	5.99e-11	Mean platelet volume;
LGG	cis	rs12410462	0.551	rs67216605	chr1:227901637	A/G	cg04117972	chr1:227635322	NA	0.44	7.94	0.35	1.5e-14	Major depressive disorder;
LGG	cis	rs2901460	0.509	rs12463815	chr2:62087165	C/T	cg02183531	chr2:62113199	CCT4	-0.45	-8.02	-0.35	8.94e-15	Mean corpuscular volume;
LGG	cis	rs981844	0.712	rs3925717	chr4:154750917	C/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs17604090	0.775	rs76480599	chr7:29689180	A/G	cg19413766	chr7:29689036	LOC646762	-0.58	-7.54	-0.33	2.51e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4950322	0.748	rs17356680	chr1:146826644	C/T	cg22381352	chr1:146742008	CHD1L	-0.49	-7.86	-0.34	2.77e-14	Protein quantitative trait loci;
LGG	trans	rs61931739	0.547	rs7966400	chr12:33703107	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.44	-0.37	4.21e-16	Morning vs. evening chronotype;
LGG	cis	rs3820068	0.705	rs16851731	chr1:15860240	A/G	cg05660106	chr1:15850417	CASP9	1.09	26.93	0.78	8.35e-97	Systolic blood pressure;
LGG	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg07882059	chr11:68924751	NA	0.41	7.33	0.32	1.02e-12	Blond vs. brown hair color;
LGG	cis	rs7940866	0.874	rs11222406	chr11:130814093	A/G	cg12179176	chr11:130786555	SNX19	0.75	14.38	0.56	4.78e-39	Schizophrenia;
LGG	cis	rs2066819	1.000	rs744051	chr12:56667298	C/T	cg26714650	chr12:56694279	CS	1.58	16.18	0.6	5.66e-47	Psoriasis vulgaris;
LGG	trans	rs12517041	1.000	rs1593966	chr5:23313785	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs1595825	0.891	rs17520121	chr2:198898718	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.36e-11	Ulcerative colitis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21325941	chr15:85923618	AKAP13	-0.5	-7.5	-0.33	3.38e-13	Systemic lupus erythematosus;
LGG	cis	rs733592	0.507	rs7299704	chr12:48444488	A/G	cg24011408	chr12:48396354	COL2A1	0.69	12.16	0.49	1.04e-29	Plateletcrit;
LGG	cis	rs963731	0.649	rs297140	chr2:39319121	A/G	cg04010122	chr2:39346883	SOS1	-0.91	-8.03	-0.35	8.34e-15	Corticobasal degeneration;
LGG	cis	rs745821	0.701	rs73959982	chr18:48130202	T/C	cg18923635	chr18:48083994	NA	0.47	8.27	0.36	1.43e-15	Diastolic blood pressure;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg08621203	chr6:150244597	RAET1G	0.53	9.82	0.42	8.65e-21	Lung cancer;
LGG	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Vitiligo;
LGG	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg18131467	chr2:239335373	ASB1	-1.0	-23.2	-0.73	1.4e-79	Multiple system atrophy;
LGG	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.81e-21	Platelet count;
LGG	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg01221209	chr5:554886	NA	-0.51	-7.6	-0.33	1.62e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs9839821	chr3:153796323	G/A	cg12800244	chr3:153838788	SGEF	0.82	8.93	0.38	9.95e-18	Coronary artery disease;
LGG	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.17	-0.46	8.42e-26	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.44	-0.53	5.09e-35	Personality dimensions;
LGG	trans	rs17685	0.753	rs12531559	chr7:75631697	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.04	-25.07	-0.76	3.04e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6554196	0.525	rs12504135	chr4:55505933	A/T	cg18836493	chr4:55524333	KIT	-0.44	-8.29	-0.36	1.2e-15	Monocyte count;
LGG	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg20821713	chr7:1055600	C7orf50	-0.51	-7.92	-0.35	1.73e-14	Bronchopulmonary dysplasia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg20349687	chr2:88927127	EIF2AK3	0.41	6.7	0.3	5.9e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.5	-9.02	-0.39	5.01e-18	Total body bone mineral density;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	cis	rs7267979	0.966	rs4815414	chr20:25361701	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg01236616	chr12:121019343	POP5	1.28	23.0	0.73	1.18e-78	Type 1 diabetes nephropathy;
LGG	cis	rs9951602	0.512	rs58352488	chr18:76651113	T/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	trans	rs61931739	0.534	rs1352207	chr12:34036862	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-9.9	-0.42	4.37e-21	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs4688689	chr3:50035542	C/T	cg24308560	chr3:49941425	MST1R	0.22	7.01	0.31	8.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.04	-0.35	7.69e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.43	0.47	8.09e-27	Coronary artery disease;
LGG	cis	rs17253792	0.822	rs13379343	chr14:56050205	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.62	-0.51	1.41e-31	Putamen volume;
LGG	cis	rs6831352	1.000	rs10017466	chr4:100055800	C/T	cg12011299	chr4:100065546	ADH4	0.44	9.27	0.4	7.01e-19	Alcohol dependence;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.82	0.45	1.7e-24	Personality dimensions;
LGG	trans	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.76	-0.38	3.82e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.927	rs4376768	chr1:248476088	A/G	cg00666640	chr1:248458726	OR2T12	-0.55	-8.87	-0.38	1.64e-17	Common traits (Other);
LGG	cis	rs12493885	0.725	rs73158447	chr3:153729792	A/G	cg12800244	chr3:153838788	SGEF	-0.8	-8.96	-0.38	8.18e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.07	-0.31	5.67e-12	HDL cholesterol;
LGG	cis	rs2652834	1.000	rs2652834	chr15:63396867	A/G	cg05507819	chr15:63340323	TPM1	0.57	7.68	0.34	9.67e-14	HDL cholesterol;
LGG	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs3916	0.955	rs35525135	chr12:121140064	T/C	cg21892295	chr12:121157589	UNC119B	-0.41	-7.21	-0.32	2.25e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs36051895	0.603	rs10123980	chr9:5130363	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-14.75	-0.57	1.25e-40	Pediatric autoimmune diseases;
LGG	cis	rs7084402	0.967	rs1427224	chr10:60290620	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	trans	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg23762105	chr12:34175262	ALG10	0.34	6.84	0.3	2.44e-11	Morning vs. evening chronotype;
LGG	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs12478296	0.901	rs7423119	chr2:243005488	T/A	cg18898632	chr2:242989856	NA	-0.76	-9.24	-0.39	8.64e-19	Obesity-related traits;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg11766577	chr21:47581405	C21orf56	-0.58	-10.3	-0.43	1.51e-22	Testicular germ cell tumor;
LGG	cis	rs7712401	0.584	rs28373879	chr5:122372402	G/C	cg19412675	chr5:122181750	SNX24	0.46	7.4	0.33	6.5e-13	Mean platelet volume;
LGG	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg08997352	chr12:9597637	DDX12	-0.77	-15.45	-0.58	9.75e-44	Breast size;
LGG	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg09165964	chr15:75287851	SCAMP5	-0.7	-8.24	-0.36	1.75e-15	Lung cancer;
LGG	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs67133203	0.851	rs12811684	chr12:51476484	A/G	cg14688905	chr12:51403056	SLC11A2	0.69	10.55	0.44	1.79e-23	Urinary tract infection frequency;
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg12395012	chr8:11607386	GATA4	0.37	6.96	0.31	1.16e-11	Neuroticism;
LGG	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs1506636	0.927	rs6959270	chr7:123310628	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11764359	chr7:65958608	NA	0.54	9.0	0.39	6.09e-18	Calcium levels;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.58	0.65	5.77e-58	Personality dimensions;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg18538332	chr22:24372958	LOC391322	-0.51	-8.47	-0.37	3.29e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg12560992	chr17:57184187	TRIM37	0.83	14.76	0.57	1.11e-40	Intelligence (multi-trait analysis);
LGG	cis	rs228769	0.562	rs228762	chr17:42138392	C/T	cg19774624	chr17:42201019	HDAC5	0.52	7.18	0.32	2.73e-12	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs8017423	0.791	rs7146250	chr14:90711703	A/G	cg04374321	chr14:90722782	PSMC1	0.87	18.45	0.65	2.2e-57	Mortality in heart failure;
LGG	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg13010199	chr12:38710504	ALG10B	0.76	16.2	0.6	4.58e-47	Heart rate;
LGG	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.49	8.89	0.38	1.36e-17	Nonalcoholic fatty liver disease;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.64	-0.56	3.7e-40	Prudent dietary pattern;
LGG	cis	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg08250081	chr4:10125330	NA	0.63	11.76	0.48	4.19e-28	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg05091796	chr16:4465799	CORO7	-0.99	-17.3	-0.63	4.34e-52	Schizophrenia;
LGG	cis	rs774359	0.830	rs774357	chr9:27559835	G/A	cg21249376	chr9:27528432	MOBKL2B	0.43	7.73	0.34	6.93e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs3813359	0.545	rs4897381	chr6:130554020	T/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg03060546	chr3:49711283	APEH	0.61	8.48	0.37	2.97e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg02002194	chr4:3960332	NA	-0.46	-8.86	-0.38	1.79e-17	Mood instability;
LGG	cis	rs2694528	0.623	rs7726421	chr5:60072477	A/G	cg11474532	chr5:59995715	DEPDC1B	0.61	6.88	0.3	1.96e-11	Parkinson's disease;
LGG	cis	rs209489	1.000	rs209516	chr6:53206600	C/T	cg15607103	chr6:53167650	ELOVL5	-0.54	-7.63	-0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg15596359	chr8:11213517	TDH	-0.4	-8.13	-0.35	3.84e-15	Retinal vascular caliber;
LGG	cis	rs11785400	1.000	rs4736365	chr8:143742197	A/G	cg10596483	chr8:143751796	JRK	0.58	9.62	0.41	4.15e-20	Schizophrenia;
LGG	cis	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg07152817	chr6:56299822	NA	0.54	7.16	0.32	3.16e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg14673194	chr17:80132900	CCDC57	0.42	7.3	0.32	1.27e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg03161606	chr19:29218774	NA	0.69	11.0	0.46	3.56e-25	Methadone dose in opioid dependence;
LGG	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg26513180	chr16:89883248	FANCA	-0.53	-9.36	-0.4	3.4e-19	Vitiligo;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.6	-10.11	-0.43	7.45e-22	Longevity;
LGG	cis	rs1577917	1.000	rs7747824	chr6:86647106	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.4	-0.47	1.09e-26	Response to antipsychotic treatment;
LGG	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs8133932	0.654	rs402039	chr21:47358809	A/G	cg11214348	chr21:47283868	PCBP3	-0.43	-7.51	-0.33	3.03e-13	Schizophrenia;
LGG	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.89	-0.38	1.36e-17	Mood instability;
LGG	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg02574844	chr11:5959923	NA	0.54	8.47	0.37	3.18e-16	DNA methylation (variation);
LGG	cis	rs6032067	0.929	rs876835	chr20:43827241	T/C	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	trans	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg27523141	chr10:43048294	ZNF37B	0.32	6.71	0.3	5.55e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	0.917	rs12202170	chr6:86590386	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.95	-0.42	2.93e-21	Response to antipsychotic treatment;
LGG	cis	rs17208368	0.628	rs2129367	chr16:55098707	A/C	cg11181171	chr16:55090946	NA	0.46	7.79	0.34	4.38e-14	Hypospadias;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs9916302	0.861	rs9903363	chr17:37499604	C/G	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg12623918	chr2:306882	NA	0.52	9.72	0.41	1.85e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.09	0.31	4.99e-12	Resting heart rate;
LGG	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg11040518	chr10:102331378	NA	-0.38	-6.85	-0.3	2.34e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11168187	0.800	rs2074532	chr12:48119562	G/A	cg12761788	chr12:48120090	P11	0.51	8.86	0.38	1.77e-17	Vertical cup-disc ratio;
LGG	cis	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg23624725	chr11:116147899	NA	0.6	6.97	0.31	1.07e-11	Airflow obstruction;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg23758822	chr17:41437982	NA	0.9	15.86	0.59	1.52e-45	Menopause (age at onset);
LGG	cis	rs7077256	0.564	rs35732435	chr10:65120962	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.95	-0.31	1.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.48e-23	Prudent dietary pattern;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg08499158	chr17:42289980	UBTF	-0.55	-10.44	-0.44	4.8e-23	Total body bone mineral density;
LGG	cis	rs283228	0.678	rs2852501	chr6:101842165	T/C	cg27451362	chr6:101846650	GRIK2	0.7	11.42	0.47	9.11e-27	Coenzyme Q10 levels;
LGG	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.33	-0.36	9.27e-16	Breast cancer;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6714710	0.603	rs35424768	chr2:98395653	A/C	cg26665480	chr2:98280029	ACTR1B	0.58	9.39	0.4	2.69e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs9308433	0.529	rs904321	chr1:214506550	G/C	cg06198575	chr1:214491504	SMYD2	0.49	7.4	0.33	6.66e-13	IgG glycosylation;
LGG	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg05082376	chr22:42548792	NA	-0.39	-7.86	-0.34	2.78e-14	Schizophrenia;
LGG	cis	rs1728785	0.818	rs11075684	chr16:68582365	C/T	cg02972257	chr16:68554789	NA	-0.55	-8.28	-0.36	1.38e-15	Ulcerative colitis;
LGG	cis	rs736801	0.729	rs1050152	chr5:131676320	C/T	cg07395648	chr5:131743802	NA	-0.55	-11.8	-0.48	2.84e-28	Breast cancer;Mosquito bite size;
LGG	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.19	-0.32	2.64e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7524258	0.903	rs4908608	chr1:7292772	T/C	cg07173049	chr1:7289937	CAMTA1	0.78	19.42	0.67	6.95e-62	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg11494091	chr17:61959527	GH2	0.52	8.21	0.36	2.29e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6547631	0.592	rs13408224	chr2:85923936	C/T	cg24620635	chr2:85921963	GNLY	0.49	9.91	0.42	4.03e-21	Blood protein levels;
LGG	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg12395012	chr8:11607386	GATA4	-0.41	-7.76	-0.34	5.46e-14	Mood instability;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs17453880	0.929	rs12522239	chr5:152054873	C/G	cg10931792	chr5:152022470	NA	0.39	8.54	0.37	1.92e-16	Subjective well-being;
LGG	cis	rs12431410	0.782	rs10138093	chr14:60170932	T/C	cg07950296	chr14:60194823	RTN1	-0.37	-7.19	-0.32	2.53e-12	Schizophrenia;
LGG	cis	rs4237845	0.780	rs3751331	chr12:58290278	G/A	cg02175503	chr12:58329896	NA	0.61	10.78	0.45	2.6e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4919044	0.808	rs2486687	chr10:94778283	T/C	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.07	-0.31	5.73e-12	Coronary artery disease;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.52	-0.44	2.41e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg19901956	chr11:77921274	USP35	-0.41	-6.74	-0.3	4.86e-11	Testicular germ cell tumor;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg14395634	chr11:65626208	CFL1	0.45	6.82	0.3	2.9e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs8179	0.627	rs17688839	chr7:92263350	A/T	cg15732164	chr7:92237376	CDK6	-0.57	-9.2	-0.39	1.21e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg11494091	chr17:61959527	GH2	0.51	8.11	0.35	4.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs2016266	0.896	rs3741663	chr12:53664015	G/A	cg04065151	chr12:53682969	ESPL1	-0.59	-10.12	-0.43	7.29e-22	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.3	-0.55	1.13e-38	Tonsillectomy;
LGG	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg18876405	chr7:65276391	NA	0.54	9.6	0.41	5.18e-20	Aortic root size;
LGG	cis	rs9682041	1.000	rs4955588	chr3:170072864	C/A	cg11886554	chr3:170076028	SKIL	0.83	10.76	0.45	2.9e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2066819	1.000	rs78149779	chr12:56694817	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00761968	chr13:53314142	LECT1	0.39	8.4	0.36	5.43e-16	Lewy body disease;
LGG	cis	rs7580658	0.545	rs13001179	chr2:127952193	A/C	cg10021288	chr2:128175891	PROC	-0.44	-8.53	-0.37	2.1e-16	Protein C levels;
LGG	cis	rs2247341	0.965	rs3752747	chr4:1737108	C/T	cg05026014	chr4:1749153	NA	-0.34	-9.46	-0.4	1.56e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7582720	1.000	rs72936834	chr2:203771260	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Vitiligo;
LGG	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg10158843	chr11:60776172	CD6	0.6	10.41	0.44	5.91e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6032067	0.929	rs6017512	chr20:43835038	G/A	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs17106184	0.536	rs12083078	chr1:51066950	A/T	cg07174182	chr1:51127561	FAF1	-0.36	-6.69	-0.3	6.61e-11	Type 2 diabetes;
LGG	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs76070545	0.551	rs55985336	chr8:104204139	C/T	cg03923813	chr8:104230441	BAALC	-1.17	-13.01	-0.52	3.4e-33	Alzheimer disease and age of onset;
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.72e-18	Aortic root size;
LGG	cis	rs9849248	0.585	rs115019733	chr3:88146963	T/G	cg14530983	chr3:88190749	ZNF654	0.55	7.77	0.34	5.01e-14	Menarche (age at onset);
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.74	-0.41	1.57e-20	Personality dimensions;
LGG	cis	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.3	-0.36	1.17e-15	Mean corpuscular hemoglobin;
LGG	cis	rs7737355	0.812	rs2042252	chr5:130980027	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.63	-0.37	9.7e-17	Life satisfaction;
LGG	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg17215666	chr7:56131930	SUMF2	0.46	7.54	0.33	2.53e-13	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg07120314	chr15:79043507	NA	-0.77	-19.43	-0.67	6.33e-62	Coronary artery disease or large artery stroke;
LGG	cis	rs123509	0.687	rs73075301	chr3:42832650	C/T	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.19	-0.55	3.29e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1355223	0.902	rs1453380	chr11:34703682	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.86	-0.3	2.26e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg11360546	chr7:1094263	C7orf50	0.39	6.88	0.3	1.93e-11	Longevity;Endometriosis;
LGG	cis	rs4901847	0.967	rs6573188	chr14:58549613	C/G	cg15908186	chr14:58618357	C14orf37	0.56	9.95	0.42	2.91e-21	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7551222	0.749	rs7532236	chr1:204561617	A/G	cg20240347	chr1:204465584	NA	0.46	9.02	0.39	4.85e-18	Schizophrenia;
LGG	trans	rs783540	0.521	rs1259176	chr15:83270898	G/A	cg16105309	chr15:79090380	ADAMTS7	0.43	7.13	0.31	3.93e-12	Schizophrenia;
LGG	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg00383909	chr3:49044727	WDR6	0.43	7.0	0.31	9.24e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg14829155	chr15:31115871	NA	0.48	8.36	0.36	7.28e-16	Huntington's disease progression;
LGG	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg07777115	chr5:623756	CEP72	-0.63	-8.2	-0.36	2.47e-15	Obesity-related traits;
LGG	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg12395012	chr8:11607386	GATA4	0.43	7.96	0.35	1.36e-14	Morning vs. evening chronotype;
LGG	trans	rs12310956	0.510	rs10844694	chr12:33865682	A/C	cg26384229	chr12:38710491	ALG10B	0.63	12.18	0.49	8.21e-30	Morning vs. evening chronotype;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14878842	chr13:113730426	MCF2L	0.38	6.91	0.31	1.65e-11	Electrocardiographic conduction measures;
LGG	cis	rs7607369	0.782	rs514799	chr2:219411203	A/G	cg01130898	chr2:219473002	PLCD4	-0.43	-7.31	-0.32	1.16e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg01028140	chr2:1542097	TPO	-0.45	-7.26	-0.32	1.66e-12	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg01620082	chr3:125678407	NA	-0.65	-7.16	-0.32	3.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12579753	0.709	rs34503239	chr12:82124199	G/T	cg07988820	chr12:82153109	PPFIA2	-0.79	-11.62	-0.48	1.5e-27	Resting heart rate;
LGG	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg06212747	chr3:49208901	KLHDC8B	0.51	7.99	0.35	1.07e-14	Menarche (age at onset);
LGG	cis	rs3771570	1.000	rs73002147	chr2:242302934	T/C	cg21155796	chr2:242212141	HDLBP	0.72	9.2	0.39	1.27e-18	Prostate cancer;
LGG	cis	rs9457247	0.905	rs377232	chr6:167409638	C/A	cg07741184	chr6:167504864	NA	0.34	7.39	0.32	7.03e-13	Crohn's disease;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg06640241	chr16:89574553	SPG7	0.68	11.54	0.47	2.89e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00166722	chr3:10149974	C3orf24	0.54	9.02	0.39	4.98e-18	Alzheimer's disease;
LGG	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg06453172	chr10:134556979	INPP5A	-0.48	-7.53	-0.33	2.63e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.74	-0.48	4.87e-28	Response to antipsychotic treatment;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.81	-0.51	2.22e-32	Vitiligo;
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.76	14.61	0.56	4.88e-40	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9943753	0.508	rs7958071	chr12:109836089	G/A	cg19025524	chr12:109796872	NA	-0.55	-11.69	-0.48	7.43e-28	HDL cholesterol;
LGG	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg05091796	chr16:4465799	CORO7	-0.84	-13.55	-0.53	1.86e-35	Schizophrenia;
LGG	cis	rs853679	0.542	rs9393892	chr6:28081394	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.79	0.3	3.37e-11	Depression;
LGG	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg00579200	chr11:133705235	NA	0.49	9.49	0.4	1.19e-19	Childhood ear infection;
LGG	cis	rs9457247	0.967	rs377753	chr6:167389496	A/T	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs73787773	0.644	rs78455089	chr5:111478870	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.61	-7.65	-0.33	1.2e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs12681288	0.862	rs2600487	chr8:1016903	C/T	cg15309053	chr8:964076	NA	0.38	7.53	0.33	2.77e-13	Schizophrenia;
LGG	cis	rs6728642	0.519	rs62152905	chr2:97572222	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.23	-0.36	1.89e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19748678	chr4:122722346	EXOSC9	-0.55	-10.12	-0.43	7.17e-22	Type 2 diabetes;
LGG	cis	rs9858542	0.537	rs115753735	chr3:49355005	T/C	cg03060546	chr3:49711283	APEH	-0.53	-7.18	-0.32	2.79e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.07	-0.35	6.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.75	13.83	0.54	1.16e-36	Obesity-related traits;
LGG	cis	rs4423214	0.559	rs10898203	chr11:71203436	C/T	cg10847948	chr11:71163743	NADSYN1	0.57	8.51	0.37	2.39e-16	Vitamin D levels;
LGG	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.53	0.44	2.08e-23	Aortic root size;
LGG	cis	rs16937	0.662	rs10900456	chr1:205145005	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.79	-0.34	4.51e-14	Schizophrenia;
LGG	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg06347083	chr6:39282316	KCNK17	0.44	12.65	0.51	1.02e-31	Type 2 diabetes;
LGG	cis	rs9462027	0.628	rs2814959	chr6:34705947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.92	-0.45	7.12e-25	Systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs114678295	chr4:119756281	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9863	0.861	rs12301673	chr12:124455818	C/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.35	-0.32	9.32e-13	White blood cell count;
LGG	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.4	0.4	2.48e-19	Colorectal cancer;
LGG	cis	rs2742417	1.000	rs2742385	chr3:45756270	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg12486710	chr1:178512616	C1orf220	0.51	10.65	0.44	7.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3762637	0.941	rs6788746	chr3:122106743	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-9.16	-0.39	1.75e-18	LDL cholesterol levels;
LGG	cis	rs504918	1.000	rs10934668	chr3:124076609	G/T	cg05766129	chr3:123988013	KALRN	-0.39	-7.18	-0.32	2.79e-12	Schizophrenia;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg06074448	chr4:187884817	NA	-0.58	-12.76	-0.51	3.64e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs600231	0.706	rs4244811	chr11:65320780	G/A	cg17120908	chr11:65337727	SSSCA1	0.61	10.98	0.45	4.36e-25	Bone mineral density;
LGG	cis	rs6977660	0.714	rs17141884	chr7:19790280	A/G	cg07541023	chr7:19748670	TWISTNB	-0.58	-8.27	-0.36	1.48e-15	Thyroid stimulating hormone;
LGG	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.84	-9.36	-0.4	3.53e-19	Diabetic retinopathy;
LGG	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg24189917	chr7:1970923	MAD1L1	-0.62	-9.08	-0.39	3.21e-18	Bipolar disorder;
LGG	cis	rs7432375	0.523	rs12486911	chr3:136558953	C/G	cg12473912	chr3:136751656	NA	0.41	6.78	0.3	3.7e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs35110281	0.667	rs4819287	chr21:45120147	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.99	0.42	2.13e-21	Mean corpuscular volume;
LGG	cis	rs67366981	1.000	rs57178676	chr14:77704595	A/C	cg22824376	chr14:77648248	TMEM63C	0.7	7.42	0.33	5.55e-13	Obsessive-compulsive symptoms;
LGG	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.79	-0.38	3.01e-17	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.19	0.6	4.9e-47	Lymphocyte counts;
LGG	trans	rs877282	0.898	rs10904547	chr10:766283	C/T	cg22713356	chr15:30763199	NA	0.52	7.6	0.33	1.71e-13	Uric acid levels;
LGG	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg11752832	chr7:134001865	SLC35B4	0.59	10.76	0.45	3e-24	Mean platelet volume;
LGG	cis	rs9911578	0.967	rs7502208	chr17:57165097	G/A	cg05425664	chr17:57184151	TRIM37	-0.71	-11.59	-0.47	1.95e-27	Intelligence (multi-trait analysis);
LGG	cis	rs74781061	0.932	rs6495121	chr15:75003508	G/T	cg02384859	chr15:74862662	ARID3B	-0.32	-6.7	-0.3	5.94e-11	Endometriosis;
LGG	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.69	-17.33	-0.63	3.19e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.46	7.47	0.33	4.05e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg19338460	chr6:170058176	WDR27	-0.62	-8.39	-0.36	5.99e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg27426351	chr10:43362370	NA	0.47	7.04	0.31	7.06e-12	Blood protein levels;
LGG	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg11040518	chr10:102331378	NA	-0.41	-7.27	-0.32	1.52e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2735413	0.881	rs11150036	chr16:78075687	C/G	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3087591	0.922	rs2905879	chr17:29545431	T/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.46	0.56	2.2e-39	Hip circumference;
LGG	cis	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg20283391	chr11:68216788	NA	-0.49	-7.99	-0.35	1.04e-14	Total body bone mineral density;
LGG	cis	rs3782089	0.793	rs34789990	chr11:65252477	G/T	cg21890820	chr11:65308645	LTBP3	0.58	6.66	0.3	7.76e-11	Height;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5.18e-17	Aortic root size;
LGG	cis	rs7666738	0.791	rs7665273	chr4:98997413	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.49e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.18	-0.32	2.78e-12	Retinal vascular caliber;
LGG	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg25319279	chr11:5960081	NA	-0.52	-8.37	-0.36	7.1e-16	DNA methylation (variation);
LGG	cis	rs1883415	0.750	rs2076316	chr6:24489741	A/C	cg20631270	chr6:24437470	GPLD1	0.43	6.96	0.31	1.17e-11	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg27131176	chr22:46450114	C22orf26;LOC150381	-0.45	-7.18	-0.32	2.77e-12	Coronary artery disease;
LGG	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg06766960	chr11:133703094	NA	-0.51	-10.18	-0.43	4.15e-22	Childhood ear infection;
LGG	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg22852734	chr6:133119734	C6orf192	1.18	14.81	0.57	6.93e-41	Type 2 diabetes nephropathy;
LGG	cis	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs1348850	0.958	rs4243390	chr2:178468008	G/A	cg27490568	chr2:178487706	NA	0.48	9.4	0.4	2.53e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs28595532	0.720	rs72670230	chr4:119312490	T/C	cg26518628	chr1:97050305	NA	-0.82	-7.06	-0.31	5.98e-12	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.53	0.84	6.16e-126	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.64	0.37	9.34e-17	Prudent dietary pattern;
LGG	cis	rs12701220	0.655	rs6955290	chr7:1151066	A/G	cg00990874	chr7:1149470	C7orf50	0.83	15.23	0.58	9.65e-43	Bronchopulmonary dysplasia;
LGG	cis	rs3849570	0.925	rs6799080	chr3:81905591	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-7.01	-0.31	8.73e-12	Waist circumference;Body mass index;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.76e-12	Lung cancer;
LGG	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-6.82	-0.3	2.78e-11	Huntington's disease progression;
LGG	cis	rs2013441	1.000	rs4924810	chr17:20071819	T/C	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg23649088	chr2:200775458	C2orf69	-0.55	-6.66	-0.3	7.86e-11	Schizophrenia;
LGG	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg05692746	chr2:100937584	LONRF2	-0.49	-7.5	-0.33	3.22e-13	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-13.98	-0.54	2.6e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg04990556	chr1:26633338	UBXN11	-0.69	-14.32	-0.55	8.8e-39	Obesity-related traits;
LGG	cis	rs941873	0.900	rs7092536	chr10:81131332	A/C	cg09469691	chr10:81107165	PPIF	0.58	10.04	0.42	1.32e-21	Height;
LGG	cis	rs7072216	0.763	rs6584200	chr10:100170037	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.17	-0.32	3.04e-12	Metabolite levels;
LGG	trans	rs9354308	0.727	rs9453466	chr6:66590654	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.01e-12	Diabetic retinopathy;
LGG	cis	rs3087591	0.659	rs7218930	chr17:29640204	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.34	0.5	1.88e-30	Hip circumference;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg23034840	chr1:205782522	SLC41A1	0.73	13.94	0.54	4.11e-37	Monocyte percentage of white cells;
LGG	cis	rs989128	0.614	rs8077587	chr17:48626575	C/T	cg20467136	chr17:48638190	CACNA1G	0.47	6.7	0.3	5.95e-11	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.31	-7.21	-0.32	2.35e-12	Obesity;
LGG	cis	rs7927592	0.830	rs7120635	chr11:68261293	A/G	cg16797656	chr11:68205561	LRP5	0.42	7.43	0.33	5.17e-13	Total body bone mineral density;
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs1387259	0.929	rs11168460	chr12:48597365	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.3	-0.32	1.23e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs6439153	0.524	rs395020	chr3:128744735	C/T	cg24176926	chr3:128744824	CCDC48	-0.35	-7.77	-0.34	5.18e-14	Pneumococcal bacteremia;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg13939156	chr17:80058883	NA	0.47	9.22	0.39	1.04e-18	Life satisfaction;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.79e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7385804	0.761	rs504141	chr7:100309125	G/A	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.41e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg11050988	chr7:1952600	MAD1L1	-0.36	-8.66	-0.37	7.85e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6964587	0.541	rs6947170	chr7:91451471	A/G	cg17063962	chr7:91808500	NA	0.4	7.19	0.32	2.6e-12	Breast cancer;
LGG	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg20240347	chr1:204465584	NA	-0.53	-10.59	-0.44	1.27e-23	Schizophrenia;
LGG	trans	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg27661571	chr11:113659931	NA	0.58	7.87	0.34	2.57e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6988985	0.594	rs12543598	chr8:143955318	T/G	cg10324643	chr8:143916377	GML	0.4	7.98	0.35	1.12e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11229555	0.645	rs7931394	chr11:58212617	T/A	cg15696309	chr11:58395628	NA	-0.95	-15.38	-0.58	2.06e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg07382826	chr16:28625726	SULT1A1	0.38	7.85	0.34	2.85e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg02836325	chr17:76403955	PGS1	-0.7	-14.25	-0.55	1.75e-38	HDL cholesterol levels;
LGG	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg18898632	chr2:242989856	NA	-0.7	-8.43	-0.36	4.56e-16	Obesity-related traits;
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg03517284	chr6:25882590	NA	-0.54	-10.6	-0.44	1.14e-23	Height;
LGG	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg00383909	chr3:49044727	WDR6	0.43	7.09	0.31	5.1e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18404041	chr3:52824283	ITIH1	0.48	9.2	0.39	1.24e-18	Electroencephalogram traits;
LGG	cis	rs123509	0.863	rs339662	chr3:42752093	T/C	cg12982090	chr3:42733453	KBTBD5	0.94	15.19	0.58	1.41e-42	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2120243	0.539	rs2047649	chr3:157085605	G/C	cg24825693	chr3:157122686	VEPH1	-0.5	-11.03	-0.46	2.85e-25	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.38	-0.4	2.91e-19	Diabetic kidney disease;
LGG	cis	rs738322	0.967	rs133024	chr22:38574066	C/T	cg03162506	chr22:38580953	NA	-0.38	-9.8	-0.41	9.78e-21	Cutaneous nevi;
LGG	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg16077055	chr2:106428750	NCK2	0.31	8.19	0.36	2.66e-15	Addiction;
LGG	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.03	0.42	1.52e-21	Motion sickness;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg20607798	chr8:58055168	NA	0.64	7.39	0.32	6.96e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg11738485	chr19:12877000	HOOK2	0.44	7.05	0.31	6.51e-12	Red blood cell traits;
LGG	cis	rs1270639	0.778	rs2530405	chr7:157446021	C/G	cg13357408	chr7:157437802	PTPRN2	0.65	10.51	0.44	2.66e-23	Colorectal cancer;
LGG	cis	rs7168592	1.000	rs4489986	chr15:101731838	A/G	cg24254196	chr15:101719523	CHSY1	-0.64	-7.16	-0.32	3.13e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg01221209	chr5:554886	NA	-0.48	-7.04	-0.31	6.94e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9357271	1.000	rs4714152	chr6:38343341	C/T	cg07362130	chr6:38359646	BTBD9	-0.44	-10.18	-0.43	4.24e-22	Restless legs syndrome;
LGG	cis	rs10905065	0.833	rs6602259	chr10:5844628	C/T	cg11519256	chr10:5708881	ASB13	0.42	7.3	0.32	1.29e-12	Menopause (age at onset);
LGG	cis	rs12765878	0.580	rs11191839	chr10:105634895	G/A	cg11005552	chr10:105648138	OBFC1	-0.72	-12.57	-0.5	2.24e-31	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs7945718	0.621	rs6485989	chr11:12695171	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.35	0.32	9.26e-13	Educational attainment (years of education);
LGG	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg20744362	chr22:50050164	C22orf34	0.42	7.31	0.32	1.15e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg10207240	chr12:122356781	WDR66	0.27	8.22	0.36	2.02e-15	Mean corpuscular volume;
LGG	cis	rs8064299	0.967	rs878906	chr17:72769334	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.69	13.38	0.53	9.56e-35	Monocyte count;
LGG	cis	rs344364	0.511	rs1657144	chr16:1963989	C/A	cg14074117	chr16:1909714	C16orf73	-0.5	-7.38	-0.32	7.55e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7224668	0.647	rs9892688	chr17:79252517	C/G	cg03823431	chr17:79229385	SLC38A10	0.36	7.59	0.33	1.82e-13	IgG glycosylation;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.51	-0.4	1.06e-19	Menopause (age at onset);
LGG	cis	rs9357271	1.000	rs9470868	chr6:38359077	A/G	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	cis	rs7107174	0.681	rs11237443	chr11:78005089	C/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.58	-0.33	1.9e-13	Testicular germ cell tumor;
LGG	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.42	-6.8	-0.3	3.19e-11	Coronary artery disease;
LGG	cis	rs4771122	0.697	rs1475220	chr13:28037448	G/C	cg01674679	chr13:27998804	GTF3A	0.55	7.4	0.33	6.3e-13	Body mass index;
LGG	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-17.47	-0.63	7.1e-53	Vitiligo;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg17328964	chr8:145687451	CYHR1	0.62	11.1	0.46	1.5e-25	Age at first birth;
LGG	trans	rs4714291	0.832	rs9471247	chr6:40105318	A/G	cg02267698	chr19:7991119	CTXN1	-0.61	-10.05	-0.42	1.21e-21	Strep throat;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg18050959	chr15:68126178	NA	-0.37	-7.07	-0.31	5.79e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg01494348	chr8:144660395	NAPRT1	0.9	6.92	0.31	1.54e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-7.97	-0.35	1.21e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg13385794	chr1:248469461	NA	0.45	8.0	0.35	1.02e-14	Common traits (Other);
LGG	cis	rs9359856	0.529	rs1328017	chr6:90297603	T/C	cg13799429	chr6:90582589	CASP8AP2	0.69	8.88	0.38	1.51e-17	Bipolar disorder;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg20110707	chr11:118481992	PHLDB1	0.48	9.46	0.4	1.59e-19	Cholesterol, total;
LGG	cis	rs3859192	0.577	rs2227333	chr17:38174167	C/G	cg17467752	chr17:38218738	THRA	-0.58	-9.71	-0.41	2.03e-20	White blood cell count;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05025164	chr4:1340916	KIAA1530	0.68	13.01	0.52	3.48e-33	Longevity;
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.23e-11	Educational attainment;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg20607798	chr8:58055168	NA	0.65	7.57	0.33	2.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.25	-0.43	2.37e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00684032	chr4:1343700	KIAA1530	0.54	11.22	0.46	5.19e-26	Obesity-related traits;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg27574168	chr18:54318782	WDR7	0.38	6.71	0.3	5.69e-11	Body mass index;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg19168338	chr16:4465731	CORO7	-0.74	-13.86	-0.54	8.59e-37	Schizophrenia;
LGG	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg16339924	chr4:17578868	LAP3	0.57	9.54	0.41	8.08e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.5	-0.4	1.1e-19	Life satisfaction;
LGG	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs524281	0.814	rs10896098	chr11:65968416	G/A	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg00531865	chr16:30841666	NA	0.54	10.2	0.43	3.6e-22	Dementia with Lewy bodies;
LGG	cis	rs9359856	0.636	rs1980878	chr6:90314749	A/C	cg13799429	chr6:90582589	CASP8AP2	0.6	7.9	0.34	2.1e-14	Bipolar disorder;
LGG	cis	rs9814567	0.752	rs4456908	chr3:134340353	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-10.89	-0.45	9.42e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.71	-0.3	5.52e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.5	-0.4	1.12e-19	Mean corpuscular volume;
LGG	cis	rs7100689	0.646	rs9804233	chr10:82134667	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.73	-0.34	6.77e-14	IgG glycosylation;
LGG	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg10523679	chr1:76189770	ACADM	-0.81	-14.63	-0.56	4.04e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4925386	0.840	rs6143036	chr20:60921721	C/A	cg24112000	chr20:60950667	NA	-0.39	-7.96	-0.35	1.38e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs283228	0.502	rs2852505	chr6:101843474	G/C	cg02011392	chr6:101847541	GRIK2	0.57	7.92	0.35	1.75e-14	Coenzyme Q10 levels;
LGG	cis	rs7503807	0.688	rs12942347	chr17:78587942	C/T	cg18469159	chr17:78755841	RPTOR	-0.38	-7.07	-0.31	5.57e-12	Obesity;
LGG	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg08603382	chr10:743973	NA	0.61	11.87	0.48	1.53e-28	Psychosis in Alzheimer's disease;
LGG	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.71	0.45	4.5e-24	Lung cancer in ever smokers;
LGG	cis	rs17209837	1.000	rs45593435	chr7:87088772	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs7717393	1.000	rs10079754	chr5:155747951	G/C	cg12904904	chr5:155754151	SGCD	0.86	8.02	0.35	8.67e-15	Egg allergy;
LGG	cis	rs7811528	0.656	rs7782028	chr7:2706478	T/C	cg11411865	chr7:2701802	TTYH3	0.46	6.74	0.3	4.69e-11	Schizophrenia;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	10.45	0.44	4.46e-23	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.29e-12	Bipolar disorder;
LGG	trans	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg26043149	chr18:55253948	FECH	-0.42	-6.89	-0.3	1.78e-11	Bone mineral density;
LGG	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg25174290	chr11:3078921	CARS	-0.46	-8.12	-0.35	4.33e-15	Calcium levels;
LGG	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg00717180	chr2:96193071	NA	0.42	7.42	0.33	5.8e-13	HDL cholesterol;
LGG	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg24375607	chr4:120327624	NA	0.44	7.41	0.33	6.18e-13	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs1584647	chr2:100001109	A/G	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg14784868	chr12:69753453	YEATS4	1.0	24.04	0.75	1.77e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9388451	0.839	rs9401845	chr6:126104118	A/G	cg05901451	chr6:126070800	HEY2	-0.82	-17.53	-0.63	4.07e-53	Brugada syndrome;
LGG	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg27490568	chr2:178487706	NA	0.78	14.56	0.56	8.62e-40	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17331151	0.512	rs9637477	chr3:52891426	G/C	cg04865290	chr3:52927548	TMEM110	0.39	7.1	0.31	4.84e-12	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg11441553	chr12:57614120	NXPH4	-0.66	-7.86	-0.34	2.7e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.754	rs4107728	chr4:120253910	G/A	cg24375607	chr4:120327624	NA	0.6	10.16	0.43	5.18e-22	Corneal astigmatism;
LGG	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.81	-0.38	2.61e-17	Mood instability;
LGG	cis	rs755249	0.567	rs16825939	chr1:39662508	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.26	0.32	1.68e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7113850	0.541	rs78737372	chr11:24233984	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	10.43	0.44	5.12e-23	Bone fracture in osteoporosis;
LGG	cis	rs11677416	1.000	rs1878318	chr2:113545185	A/G	cg27083787	chr2:113543245	IL1A	0.53	8.97	0.38	7.25e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7582720	1.000	rs72936323	chr2:204050474	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.48	0.4	1.36e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.8	0.38	2.76e-17	Hypertriglyceridemia;
LGG	cis	rs10267417	0.603	rs1159874	chr7:19916619	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	6.96	0.31	1.13e-11	Night sleep phenotypes;
LGG	trans	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg02002194	chr4:3960332	NA	0.47	7.29	0.32	1.39e-12	Myopia (pathological);
LGG	cis	rs8018808	0.522	rs8007669	chr14:77965748	G/C	cg20045696	chr14:77926864	AHSA1	0.48	7.13	0.31	3.96e-12	Myeloid white cell count;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg27189623	chr16:705930	WDR90	0.4	7.7	0.34	8.37e-14	Height;
LGG	cis	rs2916247	0.954	rs10109190	chr8:93171673	C/T	cg10183463	chr8:93005414	RUNX1T1	0.34	6.9	0.31	1.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg11789530	chr4:8429930	ACOX3	0.69	13.19	0.52	5.71e-34	Response to antineoplastic agents;
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg21171335	chr12:122356390	WDR66	0.28	8.07	0.35	6.27e-15	Mean platelet volume;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg08645402	chr16:4508243	NA	0.49	8.6	0.37	1.26e-16	Schizophrenia;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.04	-0.42	1.34e-21	Lung cancer;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg14926445	chr8:58193284	C8orf71	-0.76	-9.29	-0.4	5.82e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.559	rs1484994	chr20:30305975	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.15	0.66	1.23e-60	Mean corpuscular hemoglobin;
LGG	cis	rs4595586	0.679	rs35743713	chr12:39318539	C/G	cg26384229	chr12:38710491	ALG10B	0.53	9.89	0.42	4.57e-21	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-13.97	-0.54	2.94e-37	Alzheimer's disease;
LGG	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg03788504	chr6:150331562	NA	-0.53	-11.74	-0.48	4.69e-28	Alopecia areata;
LGG	cis	rs2120243	0.592	rs28638274	chr3:157124479	C/T	cg24825693	chr3:157122686	VEPH1	-0.48	-11.19	-0.46	7.09e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg06374794	chr16:88002281	BANP	0.47	8.57	0.37	1.59e-16	Menopause (age at onset);
LGG	cis	rs9814567	0.727	rs4245908	chr3:134349205	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.94	-0.45	6.09e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs12517041	0.935	rs28493622	chr5:23282147	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.03	-0.46	2.71e-25	Calcium levels;
LGG	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-10.08	-0.42	9.62e-22	Chronic sinus infection;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg02959939	chr21:47813025	PCNT	0.29	7.05	0.31	6.52e-12	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21887597	chr15:83419354	NA	0.55	8.75	0.38	4.1e-17	Gut microbiome composition (summer);
LGG	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg11062466	chr8:58055876	NA	0.52	8.48	0.37	3.13e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg05418105	chr22:50981406	NA	-0.62	-10.47	-0.44	3.55e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7619833	0.685	rs2034190	chr3:27292557	T/C	cg02860705	chr3:27208620	NA	0.39	7.56	0.33	2.24e-13	Breast cancer;
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg10505658	chr17:80084571	CCDC57	0.42	8.46	0.37	3.46e-16	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.14	0.39	2.03e-18	Lung cancer;
LGG	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs4148087	1.000	rs4148091	chr21:43635126	C/T	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg09021430	chr5:549028	NA	-0.52	-10.1	-0.43	7.97e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs7765175	0.631	rs9488152	chr6:113664302	A/G	cg26552650	chr6:113682475	NA	0.33	7.48	0.33	3.72e-13	Coronary artery calcification;
LGG	cis	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg05084668	chr3:125655381	ALG1L	-0.88	-11.17	-0.46	8.28e-26	Blood pressure (smoking interaction);
LGG	cis	rs4750440	0.585	rs10508470	chr10:14021822	G/A	cg27542038	chr10:14027202	FRMD4A	-0.77	-14.14	-0.55	5.36e-38	Adiponectin levels;
LGG	cis	rs10463554	0.857	rs158397	chr5:102412201	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs3818285	0.632	rs536343	chr10:111632879	T/C	cg00817464	chr10:111662876	XPNPEP1	0.49	10.26	0.43	2.1e-22	Superior crus of antihelix expression;
LGG	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg04935436	chr20:30431758	NA	0.4	7.01	0.31	8.65e-12	Mean corpuscular hemoglobin;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg01470637	chr2:183580950	DNAJC10	-0.5	-6.88	-0.3	2.01e-11	Educational attainment (years of education);
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg05368731	chr17:41323189	NBR1	0.84	15.91	0.59	8.54e-46	Menopause (age at onset);
LGG	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg16230307	chr14:35515116	FAM177A1	0.9	13.19	0.52	5.88e-34	Psoriasis;
LGG	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg02002194	chr4:3960332	NA	-0.46	-8.02	-0.35	8.84e-15	Triglycerides;
LGG	cis	rs4808199	1.000	rs60321073	chr19:19499598	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.6	0.33	1.7e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs4262150	0.810	rs56047721	chr5:152082865	A/T	cg12297329	chr5:152029980	NA	-0.76	-14.3	-0.55	1.15e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	1.000	rs12201571	chr6:86609750	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.43	-0.53	5.67e-35	Response to antipsychotic treatment;
LGG	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.69	0.34	9.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg12560992	chr17:57184187	TRIM37	-0.53	-8.68	-0.37	6.94e-17	Testicular germ cell tumor;
LGG	cis	rs7166081	1.000	rs12148134	chr15:67592098	G/C	cg05925327	chr15:68127851	NA	-0.33	-6.91	-0.31	1.64e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg12310025	chr6:25882481	NA	-0.45	-7.44	-0.33	4.96e-13	Iron status biomarkers;
LGG	cis	rs17683430	0.681	rs12157575	chr22:32543338	T/C	cg02631450	chr22:32366979	NA	0.69	8.13	0.35	4.06e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.61	0.33	1.51e-13	Schizophrenia;
LGG	cis	rs7914558	0.869	rs10883842	chr10:104941589	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.78	0.45	2.6e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6743376	0.532	rs2251872	chr2:113818632	G/A	cg05949173	chr2:113825882	IL1F10	0.48	9.06	0.39	3.7e-18	Inflammatory biomarkers;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg09303159	chr6:26284866	NA	0.34	7.88	0.34	2.32e-14	Educational attainment;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.94	-0.35	1.51e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1065852	0.526	rs9623490	chr22:42398266	G/C	cg15128208	chr22:42549153	NA	0.41	7.07	0.31	5.71e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs7267979	1.000	rs6050629	chr20:25430680	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	cis	rs8067545	0.750	rs4267380	chr17:19971564	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.56e-11	Schizophrenia;
LGG	cis	rs12210905	1.000	rs12192320	chr6:27090305	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg17462356	chr17:80056334	FASN	0.48	6.98	0.31	1.05e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21800906	chr11:32914818	QSER1	0.49	7.52	0.33	2.8e-13	Gut microbiome composition (summer);
LGG	cis	rs6066825	0.666	rs6019374	chr20:47303812	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.02	0.35	8.68e-15	Colorectal cancer;
LGG	trans	rs561341	1.000	rs2470267	chr17:30274132	G/A	cg20587970	chr11:113659929	NA	-1.3	-24.17	-0.75	4.24e-84	Hip circumference adjusted for BMI;
LGG	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg01200585	chr1:228362443	C1orf69	-0.45	-8.06	-0.35	6.38e-15	Diastolic blood pressure;
LGG	cis	rs7215564	0.908	rs34384177	chr17:78667040	A/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.16	-0.35	3.11e-15	Myopia (pathological);
LGG	cis	rs10155981	0.510	rs10255241	chr7:22593806	C/T	cg06110297	chr7:22589830	NA	-0.66	-6.65	-0.3	8.27e-11	Bilirubin levels;
LGG	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg14664628	chr15:75095509	CSK	0.46	8.65	0.37	8.73e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs7267979	0.586	rs1007707	chr20:25190598	A/G	cg06421707	chr20:25228305	PYGB	0.39	7.96	0.35	1.33e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg19468946	chr17:37922297	IKZF3	-0.37	-6.71	-0.3	5.58e-11	Self-reported allergy;
LGG	cis	rs76419734	0.510	rs2544417	chr4:106745405	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.63	-0.33	1.37e-13	Post bronchodilator FEV1;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-16.95	-0.62	1.72e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs78456975	0.941	rs13423300	chr2:1553809	C/A	cg01028140	chr2:1542097	TPO	-0.54	-8.36	-0.36	7.44e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg01324343	chr3:183735012	ABCC5	0.86	18.32	0.65	8.71e-57	Anterior chamber depth;
LGG	cis	rs113835537	0.529	rs3179961	chr11:66244454	A/G	cg24851651	chr11:66362959	CCS	0.43	7.85	0.34	2.91e-14	Airway imaging phenotypes;
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	8.92	0.38	1.05e-17	Lymphocyte counts;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.88	-0.34	2.38e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.87	-0.45	1.14e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.88	-0.38	1.54e-17	Mean corpuscular volume;
LGG	cis	rs867371	0.929	rs7176075	chr15:82471339	C/G	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	2.99e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.12e-84	Height;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg06925179	chr17:43578568	NA	-0.31	-8.17	-0.35	2.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs753955	0.567	rs11617286	chr13:24409348	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.43	-7.69	-0.34	8.96e-14	Lung cancer;
LGG	cis	rs4740619	0.870	rs7020983	chr9:15544062	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.61	-0.41	4.52e-20	Body mass index;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.93	-0.31	1.4e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.33	-0.4	4.54e-19	Sudden cardiac arrest;
LGG	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg18477163	chr1:228402036	OBSCN	0.25	6.67	0.3	7.17e-11	Diastolic blood pressure;
LGG	cis	rs7932354	0.528	rs11039097	chr11:47131881	C/T	cg03339077	chr11:47165057	C11orf49	-0.53	-10.08	-0.42	9.43e-22	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg06521331	chr12:34319734	NA	-0.65	-12.06	-0.49	2.61e-29	Morning vs. evening chronotype;
LGG	cis	rs1062177	1.000	rs62394155	chr5:151248069	G/A	cg00977110	chr5:151150581	G3BP1	0.51	7.98	0.35	1.17e-14	Preschool internalizing problems;
LGG	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg05791153	chr7:19748676	TWISTNB	0.55	7.93	0.35	1.7e-14	Rubella;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.28	0.6	1.88e-47	Lymphocyte counts;
LGG	cis	rs4819852	0.958	rs758374	chr22:19971552	T/C	cg07821417	chr22:19972146	ARVCF	0.59	12.61	0.51	1.46e-31	Pulse pressure;
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg09033563	chr22:24373618	LOC391322	0.48	6.65	0.3	8.36e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg12438819	chr7:158236134	PTPRN2	0.32	8.23	0.36	1.86e-15	Obesity-related traits;
LGG	cis	rs2285947	0.901	rs2285943	chr7:21582963	G/T	cg03697024	chr7:21583438	DNAH11	0.34	8.39	0.36	5.76e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs10791323	0.536	rs1944731	chr11:133726067	G/A	cg15485101	chr11:133734466	NA	0.62	10.78	0.45	2.5300000000000002e-24	Childhood ear infection;
LGG	cis	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.66	-0.37	8.05e-17	Mean corpuscular volume;
LGG	cis	rs4363385	0.740	rs4845518	chr1:153003903	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-8.43	-0.36	4.53e-16	Inflammatory skin disease;
LGG	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.96	0.54	3.11e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72781680	0.848	rs56218741	chr2:23977377	A/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.01	0.39	5.52e-18	Lymphocyte counts;
LGG	cis	rs6066825	0.568	rs6095245	chr20:47320770	G/C	cg18078177	chr20:47281410	PREX1	0.48	8.08	0.35	5.84e-15	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg13385521	chr17:29058706	SUZ12P	0.83	9.54	0.41	8.02e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11696845	1.000	rs1467472	chr20:43371551	G/A	cg25301532	chr20:43378953	KCNK15	0.36	7.79	0.34	4.53e-14	Obesity-related traits;
LGG	cis	rs4891159	0.790	rs690619	chr18:74108744	A/G	cg24786174	chr18:74118243	ZNF516	0.57	13.04	0.52	2.54e-33	Longevity;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg01601518	chr4:2404284	ZFYVE28	-0.49	-8.45	-0.37	3.71e-16	Cognitive function;
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.6	10.27	0.43	2.07e-22	Lymphocyte counts;
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.15e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1059312	0.932	rs11059916	chr12:129287609	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.0	-0.62	1.05e-50	Systemic lupus erythematosus;
LGG	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.56	8.48	0.37	2.95e-16	Height;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg16507663	chr6:150244633	RAET1G	-0.46	-7.3	-0.32	1.26e-12	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23162983	chr17:63119174	NA	0.41	7.1	0.31	4.6e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs78487399	0.808	rs6708735	chr2:43731354	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs7589342	0.929	rs7562054	chr2:106433513	G/C	cg16077055	chr2:106428750	NCK2	0.33	8.75	0.38	3.99e-17	Addiction;
LGG	cis	rs774359	0.797	rs868856	chr9:27489251	A/G	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.23	-0.36	1.94e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg20568497	chr10:133558893	NA	0.35	7.5	0.33	3.39e-13	Survival in rectal cancer;
LGG	cis	rs644148	0.836	rs2686774	chr19:44999827	T/C	cg15540054	chr19:45004280	ZNF180	-0.56	-10.72	-0.45	4.21e-24	Personality dimensions;
LGG	trans	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg18335740	chr13:41363409	SLC25A15	0.64	13.05	0.52	2.37e-33	Lewy body disease;
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg19847130	chr8:10466454	RP1L1	0.32	6.96	0.31	1.15e-11	Triglycerides;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14778311	chr13:93880842	GPC6	-0.41	-6.72	-0.3	5.42e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6743376	0.556	rs2472188	chr2:113820814	C/G	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.67	-0.3	7.25e-11	Total body bone mineral density;
LGG	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg19468946	chr17:37922297	IKZF3	-0.43	-7.74	-0.34	6.49e-14	Self-reported allergy;
LGG	cis	rs11874712	0.965	rs8085444	chr18:43652203	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.55	-11.92	-0.48	9.42e-29	Migraine - clinic-based;
LGG	cis	rs9807989	0.507	rs2287033	chr2:103011237	C/T	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.53	-0.4	9.07e-20	Asthma;
LGG	cis	rs10791097	0.667	rs1893019	chr11:130756664	C/G	cg12179176	chr11:130786555	SNX19	0.84	17.37	0.63	2.13e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7312933	0.898	rs10880221	chr12:42384589	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.87	0.3	2.05e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg12395012	chr8:11607386	GATA4	0.37	6.69	0.3	6.62e-11	Neuroticism;
LGG	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4936894	0.500	rs4935881	chr11:124178948	G/A	cg27160556	chr11:124181099	OR8D1	-0.46	-10.6	-0.44	1.18e-23	Aging (time to death);
LGG	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.11e-100	Height;
LGG	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.63	-0.37	9.9e-17	Total body bone mineral density;
LGG	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg02836325	chr17:76403955	PGS1	-0.79	-17.22	-0.62	9.89e-52	HDL cholesterol levels;
LGG	cis	rs1355223	0.902	rs7130325	chr11:34750959	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.07	-0.31	5.8e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4604732	0.536	rs78019731	chr1:247626430	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs883115	0.791	rs4654060	chr1:224817330	A/G	cg01808320	chr1:224927238	CNIH3	-0.44	-7.78	-0.34	4.9e-14	Cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11877228	chr18:12947957	SEH1L	-0.44	-8.09	-0.35	5.24e-15	Brain structure;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.56	-10.93	-0.45	6.74e-25	Prudent dietary pattern;
LGG	cis	rs4919044	0.808	rs2478238	chr10:94805531	A/G	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg01059449	chr18:44338099	ST8SIA5	0.36	7.87	0.34	2.58e-14	Personality dimensions;
LGG	cis	rs34638657	0.827	rs3829548	chr16:82206238	C/G	cg07918374	chr16:82182319	MPHOSPH6	-0.54	-8.81	-0.38	2.58e-17	Lung adenocarcinoma;
LGG	trans	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg06521331	chr12:34319734	NA	0.51	9.39	0.4	2.66e-19	Bladder cancer;
LGG	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg01324343	chr3:183735012	ABCC5	0.85	18.12	0.64	7.5e-56	Anterior chamber depth;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg09263875	chr16:632152	PIGQ	0.66	13.33	0.53	1.55e-34	Height;
LGG	cis	rs2862064	1.000	rs9313400	chr5:156433341	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.8	-0.45	2.05e-24	Platelet count;
LGG	cis	rs9880211	1.000	rs9826454	chr3:135953220	A/G	cg21827317	chr3:136751795	NA	-0.45	-6.7	-0.3	6.23e-11	Body mass index;Height;
LGG	trans	rs10853191	0.558	rs11080464	chr18:10851742	T/C	cg11727592	chr13:46916922	C13orf18	0.3	6.78	0.3	3.75e-11	Post bronchodilator FEV1 in COPD;
LGG	trans	rs2840044	1.000	rs8073935	chr17:33985849	C/T	cg19694781	chr19:47549865	TMEM160	-0.55	-9.15	-0.39	1.86e-18	Response to radiotherapy in cancer (late toxicity);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19387228	chr4:8442570	ACOX3	0.48	7.37	0.32	8.11e-13	Gut microbiome composition (summer);
LGG	cis	rs208520	1.000	rs72884033	chr6:66995747	T/C	cg07460842	chr6:66804631	NA	0.9	14.77	0.57	9.71e-41	Exhaled nitric oxide output;
LGG	cis	rs28655083	0.828	rs7190227	chr16:77119568	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.56	9.21	0.39	1.14e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.94	-0.35	1.59e-14	Schizophrenia;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.23	-0.39	9.78e-19	Menopause (age at onset);
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg24829409	chr8:58192753	C8orf71	-0.68	-9.34	-0.4	4.01e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs861020	0.916	rs669694	chr1:209950760	C/G	cg05527609	chr1:210001259	C1orf107	0.67	9.06	0.39	3.59e-18	Orofacial clefts;
LGG	cis	rs2795502	1.000	rs2744092	chr10:43339343	T/C	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs10504130	0.569	rs13265006	chr8:52790523	C/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.56e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs208520	0.690	rs207082	chr6:66773796	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.76	-0.64	3.53e-54	Exhaled nitric oxide output;
LGG	cis	rs11628318	0.614	rs7143783	chr14:103128751	A/G	cg23461800	chr14:103021989	NA	0.53	8.41	0.36	5.01e-16	Platelet count;
LGG	cis	rs1018836	0.663	rs2205152	chr8:91483618	C/T	cg16814680	chr8:91681699	NA	0.68	11.6	0.47	1.74e-27	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs7980799	1.000	rs7980799	chr12:33576990	A/C	cg13010199	chr12:38710504	ALG10B	-0.38	-6.8	-0.3	3.3e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9948	1.000	rs13419073	chr2:97507554	G/C	cg01990225	chr2:97406019	LMAN2L	-0.62	-6.8	-0.3	3.14e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg08200770	chr17:80723486	TBCD	-0.45	-8.07	-0.35	5.95e-15	Glycated hemoglobin levels;
LGG	cis	rs6964587	0.967	rs10248102	chr7:91699779	G/A	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	cis	rs7215564	0.730	rs35718970	chr17:78585662	T/C	cg16980736	chr17:78789706	RPTOR	-0.64	-8.35	-0.36	8.17e-16	Myopia (pathological);
LGG	cis	rs6424115	1.000	rs12116511	chr1:24162662	A/G	cg15997130	chr1:24165203	NA	-0.48	-13.09	-0.52	1.54e-33	Immature fraction of reticulocytes;
LGG	cis	rs709400	1.000	rs61995780	chr14:104120612	A/G	cg26031613	chr14:104095156	KLC1	1.15	27.63	0.79	5.21e-100	Body mass index;
LGG	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg06827562	chr3:125932279	NA	0.51	12.04	0.49	3.02e-29	Metabolite levels;
LGG	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg18681998	chr4:17616180	MED28	0.87	19.94	0.68	2.59e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg23202291	chr11:1979235	NA	0.53	10.92	0.45	7.42e-25	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg00198680	chr16:28758506	NA	0.29	7.31	0.32	1.2e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06634786	chr22:41940651	POLR3H	-0.79	-12.64	-0.51	1.11e-31	Vitiligo;
LGG	cis	rs7917772	0.582	rs7091252	chr10:104328859	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.66	-0.37	7.98e-17	Blood metabolite levels;
LGG	cis	rs11690935	0.959	rs67204065	chr2:172672624	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.02	-24.79	-0.76	6.11e-87	Schizophrenia;
LGG	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23802518	chr10:80827482	ZMIZ1;LOC283050	0.41	6.85	0.3	2.29e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62238980	0.614	rs79397654	chr22:32468027	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg16434002	chr17:42200994	HDAC5	0.45	7.93	0.35	1.68e-14	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	trans	rs7944735	0.508	rs79368019	chr11:47813820	A/C	cg15704280	chr7:45808275	SEPT13	0.63	6.91	0.31	1.66e-11	Intraocular pressure;
LGG	cis	rs6542838	0.704	rs13011428	chr2:99528305	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-7.01	-0.31	8.55e-12	Fear of minor pain;
LGG	cis	rs5753037	0.702	rs9614055	chr22:30187702	C/T	cg01021169	chr22:30184971	ASCC2	-0.36	-7.19	-0.32	2.7e-12	Type 1 diabetes;
LGG	cis	rs9463078	0.803	rs9463083	chr6:45272062	T/G	cg25276700	chr6:44698697	NA	-0.4	-8.4	-0.36	5.53e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg03929089	chr4:120376271	NA	0.74	8.6	0.37	1.23e-16	Axial length;
LGG	trans	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.87	-0.42	5.59e-21	Bladder cancer;
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg22509179	chr1:25234806	RUNX3	-0.66	-14.06	-0.55	1.2e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7084402	0.934	rs1579394	chr10:60294625	T/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.76e-12	Tonsillectomy;
LGG	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg04111992	chr7:158790115	NA	-0.35	-7.01	-0.31	8.29e-12	Facial morphology (factor 20);
LGG	cis	rs847649	1.000	rs11514917	chr7:102609221	A/C	cg18108683	chr7:102477205	FBXL13	-0.64	-14.17	-0.55	3.98e-38	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs6686643	0.762	rs9333432	chr1:165611159	A/G	cg19407955	chr1:165599744	MGST3	-0.62	-8.93	-0.38	1.03e-17	Total ventricular volume;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.41	-0.33	6.12e-13	Vitamin D levels;
LGG	trans	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.65e-14	Resting heart rate;
LGG	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg26597838	chr10:835615	NA	0.74	10.06	0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs4481887	0.741	rs11488135	chr1:248568961	G/A	cg15454534	chr1:248569605	OR2T1	0.39	6.82	0.3	2.8e-11	Common traits (Other);
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg07414643	chr4:187882934	NA	0.54	11.25	0.46	4.13e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs921968	0.608	rs658378	chr2:219483881	T/A	cg01130898	chr2:219473002	PLCD4	-0.4	-6.86	-0.3	2.27e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1941687	0.831	rs28402875	chr18:31351506	G/A	cg27147174	chr7:100797783	AP1S1	-0.53	-8.78	-0.38	3.07e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7717393	0.786	rs6866394	chr5:155797257	C/T	cg04435420	chr5:155754009	SGCD	-0.77	-9.77	-0.41	1.23e-20	Egg allergy;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.94	0.57	1.73e-41	Platelet count;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg04503457	chr17:41445688	NA	0.38	9.18	0.39	1.39e-18	Menopause (age at onset);
LGG	trans	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.04	-0.39	4.43e-18	Bladder cancer;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1691799	0.867	rs1168339	chr12:66759236	T/G	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	trans	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg06875740	chr19:51307921	C19orf48	-0.66	-8.28	-0.36	1.29e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2070488	1.000	rs13058903	chr3:38513365	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.86	-18.4	-0.65	3.94e-57	Electrocardiographic conduction measures;
LGG	cis	rs9916302	0.904	rs12600751	chr17:37553651	G/C	cg07936489	chr17:37558343	FBXL20	0.83	14.9	0.57	2.56e-41	Glomerular filtration rate (creatinine);
LGG	cis	rs5758511	0.689	rs5758691	chr22:42668504	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.43	0.33	5.2e-13	Birth weight;
LGG	cis	rs9911578	1.000	rs1971659	chr17:57004787	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg04469686	chr1:162760199	HSD17B7	-0.44	-7.12	-0.31	4.2e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	6.76	0.3	4.28e-11	Schizophrenia;
LGG	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg00262122	chr8:11665843	FDFT1	-0.42	-6.69	-0.3	6.49e-11	Monocyte count;
LGG	cis	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs7937890	0.535	rs2575857	chr11:14501296	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.78e-14	Mitochondrial DNA levels;
LGG	cis	rs42235	0.683	rs2282983	chr7:92279363	A/G	cg15732164	chr7:92237376	CDK6	-0.35	-6.91	-0.31	1.57e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14240646	chr10:27532245	ACBD5	-0.73	-10.4	-0.44	6.5e-23	Breast cancer;
LGG	trans	rs2270927	0.790	rs4566770	chr5:75576313	A/G	cg13563193	chr19:33072644	PDCD5	-0.66	-9.73	-0.41	1.7e-20	Mean corpuscular volume;
LGG	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-11.58	-0.47	2e-27	Vitiligo;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19671926	chr4:122722719	EXOSC9	0.53	8.15	0.35	3.34e-15	Type 2 diabetes;
LGG	cis	rs758324	0.812	rs116369002	chr5:131242055	G/A	cg06307176	chr5:131281290	NA	-0.53	-8.73	-0.38	4.52e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs858239	0.539	rs10279194	chr7:23191083	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.85	0.3	2.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs892961	1.000	rs1110638	chr17:75400690	T/C	cg05865280	chr17:75406074	SEPT9	0.42	9.92	0.42	3.65e-21	Airflow obstruction;
LGG	cis	rs6993813	0.678	rs6469792	chr8:120008371	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.84	0.34	3.04e-14	Bone mineral density (hip);
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.45	0.37	3.7e-16	Prudent dietary pattern;
LGG	cis	rs3770081	1.000	rs12617717	chr2:86342303	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.7	7.29	0.32	1.37e-12	Facial emotion recognition (sad faces);
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.32	0.32	1.1e-12	Prudent dietary pattern;
LGG	cis	rs4690686	0.769	rs7660827	chr4:177274542	T/C	cg17059388	chr4:177262070	NA	0.76	16.39	0.61	6.32e-48	Essential tremor;
LGG	cis	rs4731207	0.596	rs11981797	chr7:124579451	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg23306229	chr2:178417860	TTC30B	-0.73	-8.61	-0.37	1.12e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs1682825	0.932	rs13099026	chr3:10769631	C/T	cg23512531	chr3:10780469	NA	-0.59	-8.28	-0.36	1.28e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs6740322	0.895	rs10172375	chr2:43572047	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.61	-0.41	4.76e-20	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg07395648	chr5:131743802	NA	-0.56	-13.11	-0.52	1.26e-33	Blood metabolite levels;
LGG	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs17023223	0.537	rs61806983	chr1:119731524	G/C	cg05756136	chr1:119680316	WARS2	-0.42	-8.59	-0.37	1.37e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.88	0.34	2.32e-14	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.94	0.35	1.52e-14	Homoarginine levels;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	13.91	0.54	5.55e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg05368731	chr17:41323189	NBR1	-0.95	-18.67	-0.66	2.22e-58	Menopause (age at onset);
LGG	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11987759	chr7:65425863	GUSB	0.37	6.85	0.3	2.38e-11	Aortic root size;
LGG	cis	rs2153535	0.580	rs6597335	chr6:8527714	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.74	0.3	4.75e-11	Dupuytren's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04192862	chr10:28966472	BAMBI	0.4	7.12	0.31	4.17e-12	Obesity-related traits;
LGG	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg16680214	chr1:154839983	KCNN3	-0.48	-9.57	-0.41	6.63e-20	Prostate cancer;
LGG	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg13175981	chr1:150552382	MCL1	0.44	6.92	0.31	1.48e-11	Blood protein levels;
LGG	cis	rs503734	0.521	rs348881	chr3:100970920	A/C	cg27318481	chr3:100970896	IMPG2	-0.58	-13.23	-0.52	4.13e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7412746	0.634	rs3754212	chr1:150738200	A/G	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.31e-11	Melanoma;
LGG	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.67e-42	Heart rate;
LGG	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.34	-0.36	8.56e-16	Parkinson's disease;
LGG	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg22307297	chr20:60903441	LAMA5	0.44	8.42	0.36	4.74e-16	Colorectal cancer;
LGG	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	cg07928641	chr1:182991847	LAMC1	0.44	8.79	0.38	2.95e-17	Fuchs's corneal dystrophy;
LGG	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.36	-0.32	8.43e-13	Monocyte count;
LGG	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg22834771	chr12:69754056	YEATS4	0.48	8.56	0.37	1.68e-16	Cerebrospinal fluid biomarker levels;
LGG	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.22	-0.32	2.09e-12	HDL cholesterol;
LGG	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg10792982	chr14:105748885	BRF1	0.67	13.15	0.52	8.64e-34	Mean platelet volume;Platelet distribution width;
LGG	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs698813	0.573	rs6544750	chr2:44490780	T/C	cg00619915	chr2:44497795	NA	-0.61	-8.88	-0.38	1.47e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg03351412	chr1:154909251	PMVK	0.67	12.5	0.5	4.24e-31	Prostate cancer;
LGG	cis	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg26384229	chr12:38710491	ALG10B	0.9	19.74	0.68	2.29e-63	Bladder cancer;
LGG	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg00405596	chr8:11794950	NA	0.44	7.47	0.33	3.97e-13	Mood instability;
LGG	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	9.24	0.39	9.11e-19	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	7.61	0.33	1.6e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg16325326	chr1:53192061	ZYG11B	0.73	16.54	0.61	1.24e-48	Monocyte count;
LGG	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.09	-0.35	5.39e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2274273	0.686	rs66782529	chr14:55587867	C/T	cg04306507	chr14:55594613	LGALS3	0.51	12.05	0.49	2.74e-29	Protein biomarker;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg06916706	chr16:4465613	CORO7	0.75	13.24	0.52	3.52e-34	Schizophrenia;
LGG	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.44	0.4	1.84e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs11098499	0.754	rs12513083	chr4:120249612	A/T	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs2797160	1.000	rs6933302	chr6:126016951	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs3008870	1.000	rs1118393	chr1:67366668	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.71	0.73	2.94e-77	Lymphocyte percentage of white cells;
LGG	trans	rs9354308	0.738	rs1938115	chr6:66593165	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs7851660	0.935	rs4460498	chr9:100620412	T/C	cg13688889	chr9:100608707	NA	-0.69	-14.74	-0.57	1.35e-40	Strep throat;
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.92	0.45	7.18e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs55665837	1.000	rs2305305	chr11:14540942	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.71	-0.38	5.38e-17	Vitamin D levels;
LGG	cis	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg21775007	chr8:11205619	TDH	0.48	7.6	0.33	1.67e-13	Neuroticism;
LGG	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg07936489	chr17:37558343	FBXL20	-0.46	-6.82	-0.3	2.78e-11	Primary biliary cholangitis;
LGG	cis	rs7726354	0.793	rs73756771	chr5:56001002	C/G	cg27303933	chr5:56029418	NA	0.5	6.93	0.31	1.45e-11	Breast cancer (early onset);
LGG	cis	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.89	-0.38	1.34e-17	Mean corpuscular volume;
LGG	cis	rs283228	0.550	rs1385762	chr6:101811976	T/C	cg02011392	chr6:101847541	GRIK2	0.52	7.3	0.32	1.28e-12	Coenzyme Q10 levels;
LGG	cis	rs2404602	0.716	rs117129193	chr15:76656803	A/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.66	-0.3	7.75e-11	Blood metabolite levels;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.73	-0.38	4.66e-17	Longevity;Endometriosis;
LGG	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.98	0.31	1.04e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-8.99	-0.39	6.21e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12371263	chr12:132522852	EP400	0.35	6.69	0.3	6.35e-11	Menarche (age at onset);
LGG	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.58	-0.5	1.96e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07570687	chr10:102243282	WNT8B	0.41	7.49	0.33	3.59e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.87	-0.38	1.58e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs12517041	1.000	rs6879720	chr5:23312477	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs9473924	0.505	rs34793301	chr6:50859462	G/T	cg14470998	chr6:50812995	TFAP2B	0.7	8.17	0.35	3.03e-15	Body mass index;
LGG	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg07157834	chr1:205819609	PM20D1	0.4	6.85	0.3	2.38e-11	Parkinson's disease;
LGG	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.87	-0.42	5.44e-21	Body mass index;
LGG	cis	rs6489785	0.509	rs3213570	chr12:121222411	C/G	cg02419362	chr12:121203948	SPPL3	0.57	9.69	0.41	2.52e-20	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg05555928	chr11:63887634	MACROD1	0.42	7.78	0.34	4.68e-14	Platelet count;
LGG	cis	rs2075371	0.966	rs1646676	chr7:133999267	G/A	cg11752832	chr7:134001865	SLC35B4	0.61	11.05	0.46	2.26e-25	Mean platelet volume;
LGG	cis	rs1577917	1.000	rs68171315	chr6:86707400	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.14	-0.43	6.11e-22	Response to antipsychotic treatment;
LGG	cis	rs3820928	0.874	rs10194663	chr2:227875369	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.44	-0.33	4.81e-13	Pulmonary function;
LGG	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg09222892	chr1:25734099	RHCE	0.45	9.38	0.4	2.93e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.41	0.53	7.22e-35	Colorectal cancer;
LGG	cis	rs9457247	0.756	rs1811123	chr6:167403443	T/C	cg07741184	chr6:167504864	NA	0.31	6.73	0.3	4.96e-11	Crohn's disease;
LGG	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7953508	0.711	rs11611927	chr12:93977591	A/G	cg18151635	chr12:93972918	NA	-0.45	-8.13	-0.35	4.08e-15	Pubertal anthropometrics;
LGG	cis	rs9796	0.745	rs2947493	chr15:41375694	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.88	-0.42	4.99e-21	Menopause (age at onset);
LGG	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg19468946	chr17:37922297	IKZF3	0.38	6.97	0.31	1.07e-11	Self-reported allergy;
LGG	trans	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg02002194	chr4:3960332	NA	-0.55	-10.97	-0.45	4.8e-25	Neuroticism;
LGG	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.77	0.57	9.82e-41	Cognitive test performance;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	9.62	0.41	4.29e-20	Thyroid stimulating hormone;
LGG	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11890956	chr21:40555474	PSMG1	-0.99	-21.9	-0.71	1.78e-73	Cognitive function;
LGG	cis	rs9354308	0.868	rs4388276	chr6:66546565	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.85	-0.34	2.86e-14	Metabolite levels;
LGG	cis	rs61931739	0.500	rs35391785	chr12:34444478	C/T	cg06521331	chr12:34319734	NA	-0.57	-9.86	-0.42	6.19e-21	Morning vs. evening chronotype;
LGG	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg05914723	chr15:78953907	NA	-0.47	-6.65	-0.3	8.52e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7122257	0.507	rs869872	chr11:11162347	C/A	cg16931664	chr11:11169707	NA	-0.26	-7.54	-0.33	2.52e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	8.84	0.38	2.03e-17	Schizophrenia;
LGG	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-7.1	-0.31	4.74e-12	Vitiligo;
LGG	cis	rs6977660	0.714	rs10249477	chr7:19805388	T/A	cg05791153	chr7:19748676	TWISTNB	0.77	10.35	0.43	1.04e-22	Thyroid stimulating hormone;
LGG	cis	rs875971	0.862	rs11769079	chr7:65842128	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs2346160	0.867	rs2076005	chr6:167704944	A/C	cg20683250	chr6:167653907	NA	-0.42	-6.93	-0.31	1.39e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1670533	1.000	rs6837145	chr4:1071067	T/C	cg27284194	chr4:1044797	NA	0.54	9.94	0.42	3.08e-21	Recombination rate (females);
LGG	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg12856521	chr11:46389249	DGKZ	-0.41	-7.03	-0.31	7.39e-12	Leprosy;
LGG	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg02002194	chr4:3960332	NA	-0.42	-7.86	-0.34	2.7e-14	Mood instability;
LGG	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs2587949	0.571	rs2587916	chr3:4185379	T/C	cg16519197	chr3:4211558	NA	-0.34	-6.88	-0.3	1.95e-11	Periodontitis (DPAL);
LGG	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg08000102	chr2:233561755	GIGYF2	-0.65	-10.37	-0.43	8.47e-23	Schizophrenia;
LGG	cis	rs1978968	1.000	rs7285566	chr22:18445288	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-12.67	-0.51	8.5e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.86	-0.45	1.21e-24	Alzheimer's disease;
LGG	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-18.02	-0.64	2.04e-55	Morning vs. evening chronotype;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg20814179	chr4:940893	TMEM175	0.55	11.48	0.47	5.36e-27	Sjögren's syndrome;
LGG	cis	rs4076764	0.914	rs6689760	chr1:163358704	A/G	cg06092702	chr1:163392909	NA	0.42	7.44	0.33	4.86e-13	Motion sickness;
LGG	cis	rs6546550	0.901	rs7598283	chr2:70128717	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.04	-0.35	7.71e-15	Prevalent atrial fibrillation;
LGG	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs2737618	0.630	rs2821328	chr1:200082051	G/A	cg21825944	chr1:200113062	NR5A2	-0.59	-11.49	-0.47	4.61e-27	Uric acid levels;
LGG	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06803689	chr22:29949796	THOC5	0.59	6.85	0.3	2.4e-11	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs911555	0.723	rs4906320	chr14:103876925	T/C	cg24130564	chr14:104152367	KLC1	0.38	7.08	0.31	5.45e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.68	-0.34	9.44e-14	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06797661	chr2:48338981	NA	0.45	7.3	0.32	1.23e-12	Cognitive performance;
LGG	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg00319359	chr11:70116639	PPFIA1	0.74	8.25	0.36	1.7e-15	Coronary artery disease;
LGG	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg13385794	chr1:248469461	NA	-0.45	-7.39	-0.32	6.78e-13	Common traits (Other);
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.62e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg06360820	chr2:242988706	NA	-0.93	-11.35	-0.47	1.6e-26	Obesity-related traits;
LGG	cis	rs11690935	0.589	rs6729945	chr2:172864695	C/G	cg13550731	chr2:172543902	DYNC1I2	0.63	11.9	0.48	1.13e-28	Schizophrenia;
LGG	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg25986240	chr4:9926439	SLC2A9	0.49	10.62	0.44	9.88e-24	Bone mineral density;
LGG	trans	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg19894588	chr14:64061835	NA	-0.64	-10.24	-0.43	2.53e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3735485	0.843	rs6463256	chr7:45024876	A/G	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.49	-0.37	2.76e-16	Myopia (pathological);
LGG	trans	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg11430096	chr6:110968061	CDK19	0.65	6.84	0.3	2.49e-11	Prostate cancer;
LGG	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg20892847	chr12:58011875	NA	0.35	7.26	0.32	1.64e-12	Multiple sclerosis;
LGG	cis	rs2188554	0.502	rs35244428	chr7:117277926	G/A	cg10524701	chr7:117356490	CTTNBP2	0.46	7.87	0.34	2.47e-14	Esophageal adenocarcinoma;
LGG	cis	rs12701220	0.520	rs7803208	chr7:1162084	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-12.49	-0.5	4.73e-31	Bronchopulmonary dysplasia;
LGG	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg27446573	chr6:127587934	RNF146	0.74	13.42	0.53	6.68e-35	Breast cancer;
LGG	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg00571178	chr13:114841904	RASA3	-0.53	-9.86	-0.42	6.21e-21	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg08888203	chr3:10149979	C3orf24	0.55	9.33	0.4	4.36e-19	Alzheimer's disease;
LGG	cis	rs7011049	0.841	rs66726879	chr8:53866586	T/C	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs977987	0.815	rs11149821	chr16:75422817	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.26e-22	Dupuytren's disease;
LGG	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.64	0.51	1.14e-31	Motion sickness;
LGG	cis	rs6964587	0.597	rs975707	chr7:91874527	C/G	cg17063962	chr7:91808500	NA	0.51	9.72	0.41	1.86e-20	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07017636	chr1:165567312	NA	0.49	7.68	0.34	9.37e-14	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.09	-0.39	2.98e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg20607798	chr8:58055168	NA	0.72	8.12	0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg26818010	chr10:134567672	INPP5A	-0.63	-9.74	-0.41	1.61e-20	Migraine;
LGG	cis	rs4281086	0.587	rs56225449	chr8:10365181	C/T	cg01072821	chr8:10382165	T-SP1	-0.33	-6.81	-0.3	3.13e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	trans	rs4714291	0.963	rs1767672	chr6:40104107	G/T	cg02267698	chr19:7991119	CTXN1	0.59	9.46	0.4	1.58e-19	Strep throat;
LGG	cis	rs7523273	0.565	rs11118453	chr1:207887996	A/C	cg22525895	chr1:207977042	MIR29B2	0.45	8.66	0.37	7.91e-17	Schizophrenia;
LGG	cis	rs6504108	0.624	rs34949267	chr17:46212052	G/C	cg02219949	chr17:45927392	SP6	0.44	8.3	0.36	1.18e-15	Body mass index;
LGG	cis	rs3784262	0.565	rs2642632	chr15:58308254	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.77	-0.3	3.85e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14240646	chr10:27532245	ACBD5	0.73	10.09	0.42	9e-22	Breast cancer;
LGG	cis	rs1008375	1.000	rs4698200	chr4:17657051	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.6	0.44	1.15e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs714515	0.546	rs9425573	chr1:172330437	G/T	cg01573306	chr1:172330400	DNM3	-0.46	-10.44	-0.44	4.8e-23	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.63	-0.48	1.33e-27	Height;
LGG	cis	rs11122272	0.735	rs2247124	chr1:231493687	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.46	-0.47	6.04e-27	Hemoglobin concentration;
LGG	cis	rs4665809	1.000	rs6729080	chr2:26301282	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg07511668	chr11:68622177	NA	0.5	9.72	0.41	1.85e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.3	0.32	1.24e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4936891	0.577	rs12225469	chr11:123902719	G/A	cg22125253	chr11:123886957	OR10G4	-0.54	-9.08	-0.39	3.05e-18	Male fertility;
LGG	cis	rs6694672	0.764	rs10801594	chr1:197160308	G/C	cg13682187	chr1:196946512	CFHR5	0.49	6.99	0.31	9.77e-12	Asthma;
LGG	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.96	-0.35	1.32e-14	HDL cholesterol;
LGG	cis	rs9815354	0.812	rs73075250	chr3:42063734	A/G	cg03022575	chr3:42003672	ULK4	0.65	7.84	0.34	3.05e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7582720	1.000	rs72928609	chr2:203837573	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg03795903	chr2:30669940	LCLAT1	0.5	6.87	0.3	2.08e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6867032	0.917	rs10474733	chr5:2004160	A/G	cg26168224	chr5:2018326	NA	-1.14	-21.65	-0.71	2.49e-72	Gut microbiome composition (winter);
LGG	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg02487422	chr3:49467188	NICN1	-0.59	-10.88	-0.45	1.09e-24	Resting heart rate;
LGG	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.71	-0.41	2.03e-20	Retinal vascular caliber;
LGG	cis	rs9309473	1.000	rs11893881	chr2:73824373	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-8.07	-0.35	6.32e-15	Metabolite levels;
LGG	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21659725	chr3:3221576	CRBN	-0.61	-9.87	-0.42	5.54e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg16141378	chr3:129829833	LOC729375	0.43	10.52	0.44	2.41e-23	Mood instability;
LGG	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg19980929	chr12:42632907	YAF2	0.4	8.96	0.38	7.92e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.64	0.41	3.56e-20	Height;
LGG	trans	rs853679	0.567	rs16894091	chr6:28390137	A/T	cg06606381	chr12:133084897	FBRSL1	0.45	6.74	0.3	4.61e-11	Depression;
LGG	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg10523679	chr1:76189770	ACADM	0.81	14.74	0.57	1.4e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6546324	0.625	rs6546325	chr2:67861901	C/A	cg18237512	chr2:67827392	NA	-0.38	-6.65	-0.3	8.12e-11	Endometriosis;
LGG	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.41	6.71	0.3	5.74e-11	Eosinophil percentage of white cells;
LGG	cis	rs7000551	0.751	rs896379	chr8:22374200	C/T	cg12081754	chr8:22256438	SLC39A14	0.7	13.67	0.54	5.78e-36	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11169552	0.510	rs10783382	chr12:51054950	A/G	cg12884762	chr12:50931848	DIP2B	-0.41	-7.86	-0.34	2.63e-14	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg05313129	chr8:58192883	C8orf71	-0.79	-12.62	-0.51	1.42e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6500395	0.651	rs28432694	chr16:48666310	A/T	cg04672837	chr16:48644449	N4BP1	0.47	7.79	0.34	4.36e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4132509	1.000	rs10927078	chr1:243983830	C/T	cg21452805	chr1:244014465	NA	0.63	7.09	0.31	5.06e-12	RR interval (heart rate);
LGG	cis	rs988958	0.958	rs6730389	chr2:42279349	A/C	cg19376973	chr2:42229025	NA	-0.49	-8.07	-0.35	6.27e-15	Hypospadias;
LGG	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.5	-0.5	4.25e-31	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.32	2.59e-12	Menarche (age at onset);
LGG	cis	rs867371	1.000	rs1392976	chr15:82446175	A/G	cg00614314	chr15:82944287	LOC80154	-0.6	-10.14	-0.43	5.94e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	12.06	0.49	2.58e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg09640425	chr7:158790006	NA	-0.38	-7.06	-0.31	6.16e-12	Facial morphology (factor 20);
LGG	cis	rs1620921	0.594	rs9365219	chr6:161270070	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg12183467	chr14:104352244	NA	-0.4	-6.99	-0.31	9.63e-12	Bipolar disorder;
LGG	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg24998770	chr7:37888106	TXNDC3	0.53	8.56	0.37	1.72e-16	Alzheimer's disease (late onset);
LGG	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg26597838	chr10:835615	NA	0.64	9.37	0.4	3.16e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.64	16.22	0.6	3.38e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12079745	0.793	rs12074013	chr1:169133621	C/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.98	-7.07	-0.31	5.75e-12	QT interval;
LGG	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-10.88	-0.45	1.08e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9534288	0.762	rs3934247	chr13:46549137	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.09	-0.52	1.55e-33	Blood protein levels;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs433406	0.935	rs390741	chr11:131372976	A/G	cg27203895	chr11:131369037	NTM	-0.52	-11.32	-0.47	2.17e-26	Male fertility;
LGG	cis	rs3816183	0.647	rs6544560	chr2:42769610	A/G	cg14631114	chr2:43023945	NA	0.45	8.28	0.36	1.3e-15	Hypospadias;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.58	10.91	0.45	8.05e-25	Lymphocyte counts;
LGG	cis	rs7623687	0.681	rs34484573	chr3:49880399	G/A	cg19401529	chr3:49056140	DALRD3	0.74	7.01	0.31	8.6e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.73	-0.41	1.77e-20	Morning vs. evening chronotype;
LGG	cis	rs1971762	0.527	rs7300936	chr12:54030586	C/T	cg06632207	chr12:54070931	ATP5G2	0.23	7.23	0.32	2.01e-12	Height;
LGG	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg18850127	chr7:39170497	POU6F2	0.62	15.22	0.58	1.08e-42	IgG glycosylation;
LGG	cis	rs7598759	0.679	rs10202701	chr2:232328681	C/T	cg19187155	chr2:232395269	NMUR1	-0.41	-7.41	-0.33	6.24e-13	Noise-induced hearing loss;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg18000306	chr6:288505	NA	0.61	10.85	0.45	1.41e-24	Menopause (age at onset);
LGG	cis	rs9868809	0.881	rs2286652	chr3:48689192	G/A	cg00383909	chr3:49044727	WDR6	0.84	9.99	0.42	2.03e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2013441	0.613	rs12451841	chr17:20004875	G/A	cg13482628	chr17:19912719	NA	0.53	9.88	0.42	5.28e-21	Obesity-related traits;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg11494091	chr17:61959527	GH2	-1.04	-26.19	-0.77	2.09e-93	Prudent dietary pattern;
LGG	cis	rs258892	0.842	rs34956	chr5:72203696	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.11e-11	Small cell lung carcinoma;
LGG	cis	rs17125944	0.686	rs77625717	chr14:53336544	T/C	cg00686598	chr14:53173677	PSMC6	0.85	8.64	0.37	8.91e-17	Alzheimer's disease (late onset);
LGG	cis	rs11779988	0.598	rs13255037	chr8:17911046	A/G	cg18067069	chr8:17937731	ASAH1	-0.31	-7.51	-0.33	3.03e-13	Breast cancer;
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.55	0.41	7.28e-20	Bipolar disorder;
LGG	cis	rs704	0.790	rs9913833	chr17:26718592	C/T	cg10342447	chr17:26645325	TMEM97	-0.39	-7.02	-0.31	8.15e-12	Osteoprotegerin levels;
LGG	cis	rs17221829	0.733	rs7942295	chr11:89372341	T/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs9358372	0.752	rs4293992	chr6:20805983	C/G	cg13405222	chr6:20811065	CDKAL1	-0.53	-11.12	-0.46	1.26e-25	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg10523679	chr1:76189770	ACADM	0.82	15.75	0.59	4.76e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg19761014	chr17:28927070	LRRC37B2	0.67	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg02574844	chr11:5959923	NA	-0.53	-8.62	-0.37	1.1e-16	DNA methylation (variation);
LGG	cis	rs3820068	0.705	rs4646022	chr1:15839112	G/A	cg05660106	chr1:15850417	CASP9	1.1	26.89	0.78	1.27e-96	Systolic blood pressure;
LGG	cis	rs9783347	0.925	rs3802968	chr11:18343878	A/G	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs911263	0.515	rs12889206	chr14:68769182	A/G	cg18825221	chr14:68749962	RAD51L1	0.43	7.27	0.32	1.58e-12	Primary biliary cholangitis;
LGG	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.84	0.38	1.97e-17	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg14004847	chr7:1930337	MAD1L1	-0.57	-9.82	-0.42	8.21e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.830	rs13129479	chr4:98987860	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4750440	0.702	rs7918501	chr10:14029895	C/T	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.68	-0.54	5.16e-36	Adiponectin levels;
LGG	trans	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg07211511	chr3:129823064	LOC729375	-1.4	-21.66	-0.71	2.43e-72	Blood pressure (smoking interaction);
LGG	cis	rs4595586	0.545	rs7310463	chr12:39368927	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	trans	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.03	-0.31	7.53e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs977987	0.771	rs12929673	chr16:75470295	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.01	0.42	1.7e-21	Dupuytren's disease;
LGG	cis	rs1059312	0.500	rs12303338	chr12:129276641	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.59	10.92	0.45	7.3e-25	Systemic lupus erythematosus;
LGG	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.27e-12	Morning vs. evening chronotype;
LGG	trans	rs3960554	0.529	rs6465049	chr7:75874489	A/G	cg19862616	chr7:65841803	NCRNA00174	0.62	9.68	0.41	2.62e-20	Eotaxin levels;
LGG	cis	rs2820315	0.867	rs2644121	chr1:201881284	A/G	cg10061532	chr1:201886748	LMOD1	0.32	6.78	0.3	3.77e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs537930	0.925	rs877811	chr5:134346485	T/G	cg24576358	chr5:134350122	NA	0.46	9.35	0.4	3.64e-19	Height;
LGG	cis	rs2597513	0.860	rs9310427	chr3:13563124	C/G	cg24006715	chr3:13568212	NA	-0.52	-9.54	-0.41	8.41e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.94	-0.35	1.51e-14	Myeloid white cell count;
LGG	cis	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg00806245	chr18:76673096	NA	-0.73	-9.1	-0.39	2.78e-18	Obesity-related traits;
LGG	cis	rs12445022	0.571	rs4843625	chr16:87576996	G/C	cg08031982	chr16:87577539	NA	0.35	8.91	0.38	1.13e-17	Small vessel stroke;Systemic juvenile idiopathic arthritis;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.13	-0.39	2.05e-18	Menarche (age at onset);
LGG	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.26	-0.43	2.24e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7953508	0.711	rs11107117	chr12:93979419	T/C	cg18151635	chr12:93972918	NA	-0.49	-8.63	-0.37	9.74e-17	Pubertal anthropometrics;
LGG	cis	rs7928758	0.943	rs78975867	chr11:134264729	G/A	cg15243474	chr11:134282918	B3GAT1	1.26	16.27	0.6	2.11e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4538187	0.599	rs2919222	chr2:64293274	C/T	cg14150252	chr2:64069583	UGP2	-0.4	-9.09	-0.39	2.97e-18	Systolic blood pressure;
LGG	cis	rs1801251	0.778	rs709933	chr2:233733144	G/A	cg08000102	chr2:233561755	GIGYF2	-0.43	-7.09	-0.31	5.1e-12	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg02772935	chr3:125709198	NA	-0.54	-6.95	-0.31	1.25e-11	Blood pressure (smoking interaction);
LGG	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg02002194	chr4:3960332	NA	-0.51	-9.62	-0.41	4.45e-20	Retinal vascular caliber;
LGG	cis	rs7674212	0.570	rs6810571	chr4:104086787	G/T	cg16532752	chr4:104119610	CENPE	-0.41	-7.2	-0.32	2.49e-12	Type 2 diabetes;
LGG	cis	rs9557207	0.756	rs9557174	chr13:99827250	C/G	cg24509225	chr13:100037070	UBAC2	0.57	10.57	0.44	1.59e-23	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg06719900	chr11:109292894	C11orf87	0.44	8.12	0.35	4.38e-15	Schizophrenia;
LGG	cis	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg12463550	chr7:65579703	CRCP	0.75	8.13	0.35	3.93e-15	Diabetic kidney disease;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08787964	chr17:16797017	NA	0.36	7.43	0.33	5.44e-13	Electrocardiographic conduction measures;
LGG	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg08975724	chr8:8085496	FLJ10661	0.47	9.1	0.39	2.6e-18	Joint mobility (Beighton score);
LGG	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs17209837	0.607	rs45496691	chr7:87110795	C/A	cg25823085	chr7:87105416	ABCB4	0.3	7.38	0.32	7.51e-13	Gallbladder cancer;
LGG	cis	rs6456156	0.792	rs9366089	chr6:167512896	A/G	cg07741184	chr6:167504864	NA	0.41	9.26	0.4	7.93e-19	Primary biliary cholangitis;
LGG	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03878208	chr11:72483293	STARD10	0.53	6.71	0.3	5.53e-11	Type 2 diabetes;
LGG	cis	rs11711311	0.822	rs9850256	chr3:113408382	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.89	-0.34	2.24e-14	IgG glycosylation;
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg10469329	chr4:170947241	MFAP3L	-0.39	-6.86	-0.3	2.22e-11	Brain structure;
LGG	cis	rs11124272	0.857	rs11683744	chr2:31985308	C/T	cg02381751	chr2:32503542	YIPF4	-0.48	-6.67	-0.3	7.31e-11	Interleukin-18 levels;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg13397359	chr6:42928475	GNMT	0.58	16.31	0.6	1.34e-47	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.92e-12	Blood metabolite levels;
LGG	cis	rs2070433	0.706	rs2268524	chr21:47838700	C/T	cg02959939	chr21:47813025	PCNT	-0.38	-6.98	-0.31	1e-11	Lymphocyte counts;
LGG	cis	rs3741151	0.773	rs73548688	chr11:73279544	C/T	cg17517138	chr11:73019481	ARHGEF17	0.83	7.9	0.34	2.04e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs962888	0.627	rs8077267	chr17:43055718	C/T	cg16772514	chr17:43046872	C1QL1	-0.33	-6.72	-0.3	5.43e-11	White matter hyperintensity burden;
LGG	cis	rs2274273	0.686	rs2182207	chr14:55589803	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.91	0.48	1.05e-28	Protein biomarker;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg06138931	chr13:21896616	NA	0.39	7.92	0.35	1.8e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2120243	0.504	rs114107407	chr3:157062635	G/A	cg24825693	chr3:157122686	VEPH1	-0.38	-8.19	-0.36	2.66e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2862064	0.932	rs1553316	chr5:156479509	A/G	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.9	-0.45	8.88e-25	Platelet count;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg19223190	chr17:80058835	NA	0.44	8.38	0.36	6.5e-16	Life satisfaction;
LGG	trans	rs12505749	0.935	rs4260596	chr4:57368413	G/A	cg09583921	chr3:87101925	NA	0.69	6.82	0.3	2.92e-11	Airflow obstruction;
LGG	cis	rs2470578	0.792	rs2348003	chr3:17292100	T/C	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.4e-11	Schizophrenia;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg23758822	chr17:41437982	NA	0.85	14.67	0.56	2.63e-40	Menopause (age at onset);
LGG	cis	rs4974559	0.739	rs1250121	chr4:1263521	A/G	cg02980000	chr4:1222292	CTBP1	-0.84	-10.32	-0.43	1.27e-22	Systolic blood pressure;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22433210	chr17:43662623	NA	0.64	11.11	0.46	1.42e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.15	-0.35	3.43e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.51	-0.44	2.48e-23	Migraine;Coronary artery disease;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg16270222	chr17:41446396	NA	-0.3	-6.89	-0.31	1.78e-11	Menopause (age at onset);
LGG	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg13683864	chr3:40499215	RPL14	-1.15	-29.86	-0.81	5.25e-110	Renal cell carcinoma;
LGG	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg05194412	chr2:137003533	NA	0.37	8.07	0.35	6.29e-15	Colorectal cancer;
LGG	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg03538708	chr1:25844672	NA	-0.36	-6.74	-0.3	4.65e-11	Erythrocyte sedimentation rate;
LGG	trans	rs800082	0.668	rs9876975	chr3:144292255	G/A	cg24215973	chr2:240111563	HDAC4	-0.64	-12.66	-0.51	9.71e-32	Smoking behavior;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs7666738	0.830	rs4699589	chr4:98973889	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg15212455	chr7:39170539	POU6F2	0.37	8.17	0.36	2.95e-15	IgG glycosylation;
LGG	cis	rs61990749	0.597	rs2364584	chr14:78152286	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.31	-0.32	1.16e-12	Fibroblast growth factor basic levels;
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs7247513	0.964	rs12104149	chr19:12721088	A/G	cg01871581	chr19:12707946	ZNF490	-0.43	-8.7	-0.37	5.89e-17	Bipolar disorder;
LGG	cis	rs7582720	0.943	rs72936879	chr2:203792628	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.63	0.41	4.12e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg20607798	chr8:58055168	NA	0.78	7.58	0.33	1.91e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9354308	0.868	rs9453450	chr6:66545431	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg17734273	chr15:78292508	TBC1D2B	-0.36	-8.68	-0.37	6.58e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg00700412	chr12:58011837	NA	0.34	6.71	0.3	5.58e-11	Multiple sclerosis;
LGG	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg02187348	chr16:89574699	SPG7	0.65	10.86	0.45	1.26e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs523522	1.000	rs1563333	chr12:120934407	C/T	cg12219531	chr12:120966889	COQ5	0.62	10.32	0.43	1.31e-22	High light scatter reticulocyte count;
LGG	cis	rs11122272	0.735	rs11122281	chr1:231519842	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.34	-0.32	9.52e-13	Hemoglobin concentration;
LGG	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg27129171	chr3:47204927	SETD2	0.83	14.8	0.57	7.61e-41	Colorectal cancer;
LGG	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg26384229	chr12:38710491	ALG10B	1.0	23.84	0.74	1.56e-82	Heart rate;
LGG	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.43	0.4	2.06e-19	Bone mineral density;
LGG	cis	rs1707322	0.752	rs8179296	chr1:46143791	G/A	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs367943	0.901	rs171180	chr5:112817093	A/C	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.8	0.3	3.26e-11	Lung cancer;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg08621203	chr6:150244597	RAET1G	0.4	6.81	0.3	3.08e-11	Lung cancer;
LGG	cis	rs9341808	0.718	rs9448898	chr6:80845341	T/A	cg08355045	chr6:80787529	NA	0.41	7.97	0.35	1.29e-14	Sitting height ratio;
LGG	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg25457927	chr22:38595422	NA	-0.37	-8.66	-0.37	8.19e-17	Breast cancer;
LGG	cis	rs9457247	0.565	rs2239824	chr6:167511799	T/A	cg07741184	chr6:167504864	NA	0.45	10.09	0.42	8.72e-22	Crohn's disease;
LGG	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.16	0.39	1.73e-18	Motion sickness;
LGG	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg00012203	chr2:219082015	ARPC2	0.79	15.67	0.59	1.1e-44	Colorectal cancer;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg22907277	chr7:1156413	C7orf50	0.72	8.91	0.38	1.21e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg11645453	chr3:52864694	ITIH4	0.4	6.67	0.3	7.25e-11	Bipolar disorder;
LGG	cis	rs56775891	0.527	rs71367544	chr18:77574374	C/T	cg13263691	chr18:77568018	NA	0.55	7.19	0.32	2.63e-12	Schizophrenia;
LGG	cis	rs806215	0.568	rs806188	chr7:127268806	T/C	cg25922125	chr7:127225783	GCC1	0.53	7.77	0.34	5.18e-14	Type 2 diabetes;
LGG	cis	rs2273669	0.915	rs6935782	chr6:109289881	A/G	cg05315195	chr6:109294784	ARMC2	-0.53	-7.49	-0.33	3.51e-13	Prostate cancer;
LGG	cis	rs9560113	0.919	rs11069896	chr13:112178887	C/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs6714710	0.603	rs6738389	chr2:98386731	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	9.8	0.41	9.59e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs9460578	0.537	rs9465905	chr6:20822131	C/T	cg13405222	chr6:20811065	CDKAL1	0.76	17.35	0.63	2.69e-52	Breast cancer;
LGG	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.22	0.55	2.41e-38	Morning vs. evening chronotype;
LGG	cis	rs8049634	0.720	rs11864916	chr16:84228305	C/G	cg26466773	chr16:84211947	TAF1C	0.41	6.97	0.31	1.13e-11	Small cell lung carcinoma;
LGG	cis	rs1927790	0.727	rs34818702	chr13:96977512	A/G	cg02571835	chr13:96230311	CLDN10	-0.35	-6.99	-0.31	9.59e-12	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03637447	chr2:99061186	INPP4A	0.47	7.05	0.31	6.44e-12	Gut microbiome composition (summer);
LGG	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg21399703	chr1:247681439	NA	0.63	11.27	0.46	3.27e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg13010199	chr12:38710504	ALG10B	0.58	11.28	0.46	3.06e-26	Morning vs. evening chronotype;
LGG	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg26818257	chr2:241905806	NA	0.37	7.11	0.31	4.44e-12	Urinary metabolites;
LGG	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg08305652	chr11:111469057	NA	-0.44	-8.61	-0.37	1.18e-16	Primary sclerosing cholangitis;
LGG	cis	rs12786942	0.569	rs7948940	chr11:101311359	C/T	cg03942599	chr11:101341554	TRPC6	0.49	7.54	0.33	2.46e-13	Facial depth;
LGG	cis	rs9875589	0.957	rs6768050	chr3:13930490	A/G	cg19554555	chr3:13937349	NA	0.69	13.14	0.52	9.58e-34	Ovarian reserve;
LGG	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg02461776	chr11:598696	PHRF1	0.54	8.68	0.37	6.86e-17	Systemic lupus erythematosus;
LGG	cis	rs9815354	1.000	rs9856088	chr3:41860482	G/T	cg03022575	chr3:42003672	ULK4	0.66	8.49	0.37	2.93e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9912468	1.000	rs7210446	chr17:64307014	C/T	cg19474267	chr17:64306194	PRKCA	-0.97	-27.85	-0.79	5.62e-101	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs4268898	0.722	rs11680491	chr2:24416292	T/A	cg06627628	chr2:24431161	ITSN2	0.48	7.94	0.35	1.57e-14	Asthma;
LGG	cis	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg13443165	chr9:33130375	B4GALT1	-0.77	-15.15	-0.58	2.07e-42	IgG glycosylation;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.44	10.68	0.44	6.01e-24	Tonsillectomy;
LGG	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.08e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg15485101	chr11:133734466	NA	-0.64	-11.45	-0.47	6.76e-27	Childhood ear infection;
LGG	cis	rs2290159	0.800	rs9849807	chr3:12675026	A/G	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs5769707	0.967	rs5770585	chr22:50007874	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.49	0.33	3.44e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9326248	0.773	rs1060211	chr11:117039797	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	7.55	0.33	2.27e-13	Blood protein levels;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg03351412	chr1:154909251	PMVK	-0.67	-13.01	-0.52	3.47e-33	Prostate cancer;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs4917300	0.566	rs1388798	chr8:143100592	T/A	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.29e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs1059312	0.966	rs35907548	chr12:129282180	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.08	-0.62	4.35e-51	Systemic lupus erythematosus;
LGG	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg27624424	chr6:160112604	SOD2	0.67	9.26	0.4	7.84e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9463078	0.845	rs9369514	chr6:44797271	C/A	cg25276700	chr6:44698697	NA	-0.41	-8.65	-0.37	8.51e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00689492	chr4:1303491	MAEA	0.47	8.12	0.35	4.29e-15	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00149659	chr3:10157352	C3orf10	0.84	10.76	0.45	3.01e-24	Alzheimer's disease;
LGG	cis	rs737693	1.000	rs114176245	chr11:102719534	C/T	cg14995062	chr11:102826570	MMP13	0.54	6.93	0.31	1.39e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.05	-0.35	7.09e-15	Retinal vascular caliber;
LGG	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg06640241	chr16:89574553	SPG7	0.93	18.03	0.64	1.9e-55	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.35e-13	Lung cancer;
LGG	cis	rs35740288	0.770	rs11631660	chr15:86215412	G/T	cg04173714	chr15:86211321	AKAP13	-0.48	-8.81	-0.38	2.62e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg13628971	chr7:2884303	GNA12	0.52	10.59	0.44	1.35e-23	Height;
LGG	cis	rs1048238	0.506	rs7547314	chr1:16186722	G/A	cg21385522	chr1:16154831	NA	0.55	10.11	0.43	7.46e-22	Systolic blood pressure;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg19635926	chr16:89946313	TCF25	0.71	8.45	0.37	3.69e-16	Skin colour saturation;
LGG	cis	rs11166927	0.904	rs12547230	chr8:140818544	C/T	cg16909799	chr8:140841666	TRAPPC9	0.55	11.51	0.47	3.75e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg16576597	chr16:28551801	NUPR1	0.3	6.68	0.3	7.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg11342453	chr6:26196699	NA	0.49	6.84	0.3	2.58e-11	Gout;Renal underexcretion gout;
LGG	trans	rs6598955	0.671	rs17163868	chr1:26648381	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.7	12.03	0.49	3.35e-29	Obesity-related traits;
LGG	trans	rs11875185	0.510	rs79982510	chr18:55594364	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs3741151	0.773	rs73543000	chr11:73151774	T/C	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs12545912	0.908	rs6983762	chr8:9581400	C/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs17767392	0.958	rs17767446	chr14:71820963	G/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.16	0.39	1.65e-18	Mitral valve prolapse;
LGG	cis	rs17208368	0.628	rs12447137	chr16:55093833	A/G	cg11181171	chr16:55090946	NA	0.46	7.68	0.34	9.39e-14	Hypospadias;
LGG	trans	rs62344088	0.590	rs62329989	chr5:300141	A/G	cg00938859	chr5:1591904	SDHAP3	0.89	13.06	0.52	2.1e-33	Asthma (childhood onset);
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg26513180	chr16:89883248	FANCA	-0.45	-7.68	-0.34	9.53e-14	Vitiligo;
LGG	trans	rs1493916	0.777	rs1845385	chr18:31318336	T/C	cg04226714	chr8:49833948	SNAI2	-0.47	-8.4	-0.36	5.36e-16	Life satisfaction;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.44	0.33	5.06e-13	Tonsillectomy;
LGG	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg02297831	chr4:17616191	MED28	0.51	9.67	0.41	2.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.64	0.37	9.35e-17	Bipolar disorder;
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg08302650	chr8:145750040	LRRC24;LRRC14	0.33	7.21	0.32	2.36e-12	Age at first birth;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg23649088	chr2:200775458	C2orf69	0.54	9.15	0.39	1.76e-18	Osteoporosis;
LGG	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg15627072	chr1:2432621	PLCH2	0.33	7.34	0.32	9.65e-13	Ulcerative colitis;
LGG	trans	rs629535	0.814	rs488231	chr8:70064993	T/C	cg21567404	chr3:27674614	NA	0.4	6.74	0.3	4.86e-11	Dupuytren's disease;
LGG	cis	rs858239	0.601	rs764533	chr7:23153875	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.0	0.31	9.06e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7503807	0.967	rs12949279	chr17:78558411	T/C	cg06872548	chr17:78716983	RPTOR	0.46	10.78	0.45	2.49e-24	Obesity;
LGG	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg02297831	chr4:17616191	MED28	0.39	6.83	0.3	2.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12410462	0.585	rs2644143	chr1:227731157	T/C	cg21459583	chr1:227974177	NA	0.36	6.87	0.3	2.02e-11	Major depressive disorder;
LGG	cis	rs7927771	0.524	rs7123952	chr11:47852057	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.08	0.46	1.88e-25	Subjective well-being;
LGG	cis	rs172166	0.694	rs203892	chr6:28067196	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.13	-0.31	3.98e-12	Cardiac Troponin-T levels;
LGG	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg16482183	chr6:26056742	HIST1H1C	0.73	11.05	0.46	2.43e-25	Iron status biomarkers;
LGG	cis	rs2463822	1.000	rs2513747	chr11:62098735	T/C	cg06239285	chr11:62104954	ASRGL1	1.16	16.25	0.6	2.59e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26342734	chr17:7211307	EIF5A	0.6	6.71	0.3	5.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg18225595	chr11:63971243	STIP1	0.64	12.69	0.51	7.28e-32	Platelet count;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg05861140	chr6:150128134	PCMT1	-0.39	-8.68	-0.37	7.06e-17	Lung cancer;
LGG	trans	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.82	-0.3	2.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08879241	chr10:74927972	FAM149B1;ECD	0.51	7.86	0.34	2.63e-14	Hip circumference;
LGG	trans	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.99e-30	Corneal astigmatism;
LGG	cis	rs5756391	0.568	rs4821568	chr22:37316476	T/C	cg21209356	chr22:37319042	CSF2RB	0.42	9.55	0.41	7.4e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.08	-0.39	3.24e-18	Aortic root size;
LGG	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg09222892	chr1:25734099	RHCE	0.46	9.63	0.41	3.96e-20	Erythrocyte sedimentation rate;
LGG	cis	rs7508	0.512	rs2283109	chr8:17878572	T/C	cg18067069	chr8:17937731	ASAH1	-0.29	-6.66	-0.3	7.76e-11	Atrial fibrillation;
LGG	cis	rs936229	0.768	rs12442901	chr15:75083912	A/G	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.81	-0.41	9.36e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs9399135	0.967	rs59329760	chr6:135342437	G/A	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg00684032	chr4:1343700	KIAA1530	0.38	7.16	0.32	3.17e-12	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7833790	0.724	rs10958045	chr8:82722994	T/C	cg06027949	chr8:82754900	SNX16	-0.55	-8.7	-0.37	5.8e-17	Diastolic blood pressure;
LGG	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.07	-0.35	6.09e-15	Neuroticism;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg02733842	chr7:1102375	C7orf50	0.67	10.18	0.43	4.23e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10231759	0.583	rs4725948	chr7:150516404	T/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.21	0.36	2.22e-15	Height;
LGG	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.72	-0.38	4.98e-17	Alzheimer's disease (survival time);
LGG	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs8062405	1.000	rs28403629	chr16:28854769	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg01493522	chr13:37497338	NA	-0.52	-9.13	-0.39	2.09e-18	Coronary artery disease;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg12310025	chr6:25882481	NA	-1.03	-23.82	-0.74	1.96e-82	Urate levels;
LGG	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg25272121	chr1:152190972	HRNR	-0.4	-8.08	-0.35	5.6e-15	Inflammatory skin disease;
LGG	cis	rs7508	0.612	rs17636098	chr8:17918726	G/A	cg18067069	chr8:17937731	ASAH1	0.33	7.54	0.33	2.45e-13	Atrial fibrillation;
LGG	cis	rs4737010	0.578	rs4466386	chr8:41679853	A/G	cg17182837	chr8:41585554	ANK1	-0.53	-7.85	-0.34	2.97e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg03060546	chr3:49711283	APEH	-0.7	-11.73	-0.48	5.11e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.82	0.38	2.35e-17	Retinal vascular caliber;
LGG	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg12310025	chr6:25882481	NA	-0.66	-12.26	-0.5	4.06e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2658782	0.951	rs2608215	chr11:93148817	G/A	cg15737290	chr11:93063684	CCDC67	0.55	8.1	0.35	4.84e-15	Pulmonary function decline;
LGG	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.58	-0.33	1.93e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg03433033	chr1:76189801	ACADM	-0.46	-7.3	-0.32	1.24e-12	Daytime sleep phenotypes;
LGG	cis	rs7737355	1.000	rs12517604	chr5:130748500	T/C	cg06307176	chr5:131281290	NA	-0.54	-9.06	-0.39	3.66e-18	Life satisfaction;
LGG	cis	rs60843830	0.661	rs62116682	chr2:104618	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.32	0.4	4.75e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg11764359	chr7:65958608	NA	0.63	10.87	0.45	1.14e-24	Aortic root size;
LGG	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg00071950	chr4:10020882	SLC2A9	0.38	7.84	0.34	3.06e-14	Bone mineral density;
LGG	cis	rs7827545	1.000	rs4909910	chr8:135565201	T/C	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs1010254	0.559	rs72808328	chr5:151746310	G/A	cg12297329	chr5:152029980	NA	-0.46	-6.76	-0.3	4.2e-11	Optic nerve measurement (cup area);
LGG	cis	rs908922	0.605	rs3753448	chr1:152486407	A/C	cg09873164	chr1:152488093	CRCT1	0.64	15.72	0.59	6.26e-45	Hair morphology;
LGG	cis	rs7202877	0.706	rs247425	chr16:75460402	C/T	cg03315344	chr16:75512273	CHST6	-0.53	-7.05	-0.31	6.4e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs3735485	0.738	rs10280691	chr7:45089255	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg27147174	chr7:100797783	AP1S1	0.66	12.35	0.5	1.7e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg12927641	chr6:109611667	NA	0.37	7.04	0.31	7.06e-12	Reticulocyte fraction of red cells;
LGG	trans	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.27	0.43	1.97e-22	Morning vs. evening chronotype;
LGG	cis	rs7100689	0.646	rs10736348	chr10:82139244	C/A	cg01528321	chr10:82214614	TSPAN14	0.88	15.68	0.59	9.62e-45	Post bronchodilator FEV1;
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.57	0.41	6.28e-20	Bipolar disorder;
LGG	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg21775007	chr8:11205619	TDH	-0.43	-6.73	-0.3	5.11e-11	Neuroticism;
LGG	cis	rs4356203	0.905	rs651513	chr11:17199328	C/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.26	-0.32	1.67e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9902453	0.904	rs4598962	chr17:28293948	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	12.81	0.51	2.18e-32	Coffee consumption (cups per day);
LGG	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs6495122	0.501	rs6495151	chr15:75385990	A/G	cg17294928	chr15:75287854	SCAMP5	-0.54	-9.93	-0.42	3.35e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7512552	0.809	rs9436108	chr1:150360930	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7428	0.847	rs1969260	chr2:85568810	C/T	cg24342717	chr2:85555507	TGOLN2	-0.53	-8.32	-0.36	9.61e-16	Ear protrusion;
LGG	cis	rs10883723	0.810	rs7090276	chr10:104281239	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg02825527	chr7:2087843	MAD1L1	-0.38	-7.7	-0.34	8.12e-14	Neuroticism;
LGG	cis	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg24623649	chr8:11872141	NA	0.31	6.84	0.3	2.54e-11	Systemic lupus erythematosus;
LGG	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg13147721	chr7:65941812	NA	-0.82	-9.95	-0.42	2.86e-21	Diabetic kidney disease;
LGG	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg04731861	chr2:219085781	ARPC2	0.49	12.63	0.51	1.21e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg23594656	chr7:65796392	TPST1	0.4	8.81	0.38	2.6e-17	Aortic root size;
LGG	trans	rs28595532	0.545	rs17516582	chr4:119296763	C/G	cg26518628	chr1:97050305	NA	-0.87	-8.98	-0.39	6.62e-18	Cannabis dependence symptom count;
LGG	cis	rs490234	0.841	rs10114882	chr9:128303425	T/C	cg14078157	chr9:128172775	NA	-0.48	-9.12	-0.39	2.3e-18	Mean arterial pressure;
LGG	trans	rs853679	0.607	rs13203816	chr6:28079598	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.76	0.38	3.65e-17	Obesity-related traits;
LGG	cis	rs6495367	1.000	rs13380104	chr15:79378821	C/T	cg17916960	chr15:79447300	NA	0.5	9.01	0.39	5.58e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.75e-11	Psoriasis vulgaris;
LGG	cis	rs11074306	0.561	rs7172907	chr15:28062405	A/G	cg26402630	chr15:28053930	OCA2	0.36	7.21	0.32	2.3e-12	Uveal melanoma;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg24250549	chr1:154909240	PMVK	0.76	15.72	0.59	6.44e-45	Prostate cancer;
LGG	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.66	-0.3	7.67e-11	Systolic blood pressure;
LGG	cis	rs9581943	1.000	rs2297316	chr13:28490211	G/A	cg16302790	chr13:28498334	PDX1	0.54	9.07	0.39	3.53e-18	Pancreatic cancer;
LGG	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.59	-10.9	-0.45	8.66e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs61931739	0.635	rs10772122	chr12:33964674	A/C	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs6815814	0.731	rs11096956	chr4:38776180	G/T	cg06935464	chr4:38784597	TLR10	0.45	6.88	0.3	1.96e-11	Breast cancer;
LGG	cis	rs9443645	0.901	rs1567167	chr6:79553827	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.59	-0.37	1.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg15596359	chr8:11213517	TDH	-0.34	-6.93	-0.31	1.4e-11	Retinal vascular caliber;
LGG	cis	rs6988985	0.560	rs2078674	chr8:143928233	G/T	cg10324643	chr8:143916377	GML	0.45	9.25	0.39	8.41e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs3736594	1.000	rs3792252	chr2:27995931	A/G	cg27432699	chr2:27873401	GPN1	0.51	8.3	0.36	1.13e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.46e-15	Ulcerative colitis;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.69e-14	Height;
LGG	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.74	-0.34	6.25e-14	Total cholesterol levels;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.07	-0.35	5.98e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19080138	chr7:35734733	HERPUD2	0.42	6.91	0.31	1.6e-11	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06814637	chr1:36554277	ADPRHL2	0.53	7.96	0.35	1.32e-14	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-7.81	-0.34	3.75e-14	IgG glycosylation;
LGG	cis	rs4774899	0.966	rs12050751	chr15:57495060	A/G	cg08128148	chr15:57256372	TCF12	-0.3	-7.03	-0.31	7.58e-12	Urinary tract infection frequency;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg27102117	chr16:15229624	NA	0.58	11.02	0.46	3.21e-25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs67460515	0.892	rs16832082	chr3:161043571	A/G	cg04691961	chr3:161091175	C3orf57	-0.48	-9.79	-0.41	1.06e-20	Parkinson's disease;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.23	-0.43	2.75e-22	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg26174226	chr8:58114915	NA	-0.58	-7.89	-0.34	2.26e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs4417704	0.551	rs55978049	chr2:241890228	A/C	cg05025159	chr2:241905733	NA	0.49	10.12	0.43	6.75e-22	Joint mobility (Beighton score);
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.85	0.42	6.78e-21	Schizophrenia;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18404041	chr3:52824283	ITIH1	-0.5	-9.66	-0.41	3.21e-20	Bipolar disorder;
LGG	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg14664628	chr15:75095509	CSK	-0.55	-10.45	-0.44	4.22e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04936382	chr20:36662003	RPRD1B;KIAA0406	0.42	6.83	0.3	2.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7552404	0.960	rs12085123	chr1:76149749	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.22	0.43	3.09e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3092073	0.624	rs11906879	chr20:44591324	C/T	cg27529037	chr20:44575021	PCIF1	-0.4	-7.56	-0.33	2.25e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg13010199	chr12:38710504	ALG10B	0.68	14.19	0.55	3.2e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00864171	chr11:67383662	NA	-0.51	-8.17	-0.35	3.04e-15	Mean corpuscular volume;
LGG	cis	rs924607	1.000	rs12523022	chr5:598643	C/T	cg09021430	chr5:549028	NA	0.53	10.1	0.42	8.22e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg13010199	chr12:38710504	ALG10B	-0.58	-11.14	-0.46	1.07e-25	Morning vs. evening chronotype;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg02184643	chr11:10879647	ZBED5	-0.43	-6.79	-0.3	3.42e-11	Coronary artery disease;
LGG	cis	rs977987	0.806	rs11862684	chr16:75461746	T/G	cg03315344	chr16:75512273	CHST6	0.51	10.12	0.43	7.02e-22	Dupuytren's disease;
LGG	trans	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg19862616	chr7:65841803	NCRNA00174	0.73	7.64	0.33	1.27e-13	Mononucleosis;
LGG	cis	rs7712401	0.525	rs246312	chr5:122269455	G/A	cg19412675	chr5:122181750	SNX24	0.43	7.24	0.32	1.86e-12	Mean platelet volume;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg02002194	chr4:3960332	NA	0.43	7.81	0.34	3.82e-14	Neuroticism;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg19774624	chr17:42201019	HDAC5	0.65	11.34	0.47	1.8e-26	Total body bone mineral density;
LGG	trans	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg07817883	chr1:32538562	TMEM39B	-0.68	-9.31	-0.4	5.18e-19	Monocyte percentage of white cells;
LGG	cis	rs3731896	0.700	rs2271593	chr2:220168607	C/T	cg14987769	chr2:220197576	RESP18	0.47	6.85	0.3	2.37e-11	Educational attainment;
LGG	cis	rs9397585	0.824	rs1933261	chr6:153379454	T/G	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.43e-39	Body mass index;
LGG	cis	rs4959677	0.868	rs7747066	chr6:2490587	A/G	cg20147862	chr6:2634573	C6orf195	-0.4	-8.72	-0.38	5.15e-17	Orthostatic hypotension;
LGG	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg00383909	chr3:49044727	WDR6	0.43	7.06	0.31	6.24e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs283228	0.605	rs673464	chr6:101728256	A/G	cg27451362	chr6:101846650	GRIK2	0.91	13.31	0.53	1.84e-34	Coenzyme Q10 levels;
LGG	cis	rs774359	0.797	rs774355	chr9:27515794	G/T	cg21249376	chr9:27528432	MOBKL2B	0.43	8.9	0.38	1.23e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs778371	0.647	rs974321	chr2:233638351	G/A	cg08000102	chr2:233561755	GIGYF2	0.68	10.97	0.45	4.65e-25	Schizophrenia;
LGG	cis	rs4713118	0.513	rs149941	chr6:28001033	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-6.76	-0.3	4.24e-11	Parkinson's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16178878	chr10:88280863	WAPAL	0.42	7.11	0.31	4.42e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10178094	0.716	rs7424771	chr2:161276378	G/A	cg03641300	chr2:160917029	PLA2R1	-0.49	-8.59	-0.37	1.36e-16	White blood cell count;
LGG	cis	rs7215564	0.818	rs1126064	chr17:78610388	A/G	cg16980736	chr17:78789706	RPTOR	-0.66	-8.59	-0.37	1.3e-16	Myopia (pathological);
LGG	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-9.84	-0.42	7.29e-21	Hepatocellular carcinoma;
LGG	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg05555928	chr11:63887634	MACROD1	-0.63	-9.14	-0.39	1.99e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.96	-0.45	5.22e-25	IgG glycosylation;
LGG	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg02389323	chr16:88786976	FAM38A	1.11	12.71	0.51	5.69e-32	Plateletcrit;
LGG	cis	rs67311347	1.000	rs7642906	chr3:40492633	G/A	cg13683864	chr3:40499215	RPL14	1.03	23.03	0.73	9.25e-79	Renal cell carcinoma;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12362060	chr15:41575950	LOC729082	-0.46	-6.89	-0.3	1.78e-11	Systemic lupus erythematosus;
LGG	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg01528321	chr10:82214614	TSPAN14	0.65	11.64	0.48	1.16e-27	Post bronchodilator FEV1;
LGG	cis	rs8067545	0.750	rs9897653	chr17:19987924	G/A	cg13482628	chr17:19912719	NA	0.63	12.53	0.5	3.09e-31	Schizophrenia;
LGG	cis	rs4788570	0.584	rs8051968	chr16:71761978	C/A	cg06353428	chr16:71660113	MARVELD3	1.25	21.37	0.7	5.29e-71	Intelligence (multi-trait analysis);
LGG	cis	rs67478160	0.634	rs2295140	chr14:104216293	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.16	-0.32	3.25e-12	Schizophrenia;
LGG	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg05585630	chr7:157510462	PTPRN2	-0.67	-14.05	-0.55	1.34e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg02466173	chr16:30829666	NA	-0.46	-8.26	-0.36	1.52e-15	Dementia with Lewy bodies;
LGG	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.02	-0.35	8.99e-15	Obesity;
LGG	cis	rs7106204	1.000	rs4622259	chr11:24215789	A/G	ch.11.24196551F	chr11:24239977	NA	0.95	12.04	0.49	3.04e-29	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3540	0.618	rs11636089	chr15:91039527	C/T	cg22089800	chr15:90895588	ZNF774	0.68	12.51	0.5	3.77e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4262150	0.883	rs4958583	chr5:152223531	C/T	cg12297329	chr5:152029980	NA	-0.68	-12.61	-0.51	1.56e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs2652834	0.851	rs1007076	chr15:63413371	T/C	cg05507819	chr15:63340323	TPM1	0.5	7.03	0.31	7.55e-12	HDL cholesterol;
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00294572	chr6:26285232	NA	0.43	7.42	0.33	5.83e-13	Educational attainment;
LGG	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg13147721	chr7:65941812	NA	-0.79	-9.58	-0.41	5.9e-20	Diabetic kidney disease;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg04166393	chr7:2884313	GNA12	0.46	8.53	0.37	2.12e-16	Height;
LGG	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg27398817	chr8:82754497	SNX16	0.78	11.26	0.46	3.74e-26	Diastolic blood pressure;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	15.64	0.59	1.46e-44	Obesity-related traits;
LGG	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.27	-0.36	1.48e-15	Calcium levels;
LGG	cis	rs9916302	0.904	rs7216086	chr17:37709422	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.76	-0.59	4.1e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10911457	0.727	rs6424917	chr1:183892657	T/C	cg18131582	chr1:183912305	GLT25D2	0.27	6.77	0.3	3.83e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg04731861	chr2:219085781	ARPC2	0.29	7.01	0.31	8.65e-12	Ulcerative colitis;
LGG	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.5e-11	Alzheimer's disease (survival time);
LGG	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg12458913	chr13:53173898	NA	0.88	20.76	0.69	3.76e-68	Lewy body disease;
LGG	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg08200770	chr17:80723486	TBCD	-0.44	-8.18	-0.36	2.73e-15	Glycated hemoglobin levels;
LGG	cis	rs6964587	0.900	rs62467794	chr7:91850578	C/T	cg17063962	chr7:91808500	NA	0.53	9.43	0.4	1.97e-19	Breast cancer;
LGG	cis	rs6988985	0.589	rs6987382	chr8:143987191	G/A	cg10324643	chr8:143916377	GML	0.43	9.02	0.39	4.91e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2455799	0.613	rs7614204	chr3:15792748	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs826838	1.000	rs55828987	chr12:39056421	A/C	cg26384229	chr12:38710491	ALG10B	1.01	25.6	0.77	1.04e-90	Heart rate;
LGG	cis	rs7129556	0.737	rs56218634	chr11:77464834	A/G	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.36e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25564901	chr17:17140463	FLCN	0.39	6.89	0.3	1.8e-11	Obesity-related traits;
LGG	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg25319279	chr11:5960081	NA	-0.56	-8.42	-0.36	4.9e-16	DNA methylation (variation);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg21941374	chr3:120461451	GTF2E1;RABL3	0.42	7.25	0.32	1.8e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs6912958	0.781	rs9444512	chr6:88223397	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.58	-0.37	1.44e-16	Monocyte percentage of white cells;
LGG	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.82	0.3	2.86e-11	Electroencephalogram traits;
LGG	cis	rs4481887	1.000	rs10788782	chr1:248496132	C/A	cg00666640	chr1:248458726	OR2T12	0.62	9.99	0.42	2.08e-21	Common traits (Other);
LGG	cis	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg02972257	chr16:68554789	NA	-0.56	-8.48	-0.37	2.97e-16	Ulcerative colitis;
LGG	cis	rs7503807	0.515	rs12943155	chr17:78667125	A/G	cg18469159	chr17:78755841	RPTOR	-0.66	-11.41	-0.47	9.74e-27	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27576415	chr15:41709087	RTF1	0.51	8.03	0.35	8.11e-15	Gut microbiome composition (summer);
LGG	cis	rs9715521	0.775	rs12646141	chr4:59846130	G/C	cg11281224	chr4:60001000	NA	-0.51	-8.48	-0.37	2.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3784262	0.542	rs2899611	chr15:58327347	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.69	-0.3	6.5e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg00830817	chr11:109293614	C11orf87	0.42	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs826838	0.967	rs7299170	chr12:38789536	G/A	cg13010199	chr12:38710504	ALG10B	0.77	16.59	0.61	7.31e-49	Heart rate;
LGG	cis	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.39e-17	Mean corpuscular volume;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg18402987	chr7:1209562	NA	0.74	10.92	0.45	7.21e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg06925179	chr17:43578568	NA	0.43	10.16	0.43	4.86e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs362296	0.698	rs3095083	chr4:3263499	G/A	cg06533319	chr4:3265114	C4orf44	0.52	10.81	0.45	1.96e-24	Parental longevity (mother's age at death);
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg09699651	chr6:150184138	LRP11	0.46	6.83	0.3	2.69e-11	Lung cancer;
LGG	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03264133	chr6:25882463	NA	0.52	9.53	0.41	8.69e-20	Blood metabolite levels;
LGG	cis	rs909674	0.775	rs4821896	chr22:39833437	T/C	cg04986931	chr22:39850128	NA	0.4	9.03	0.39	4.63e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs61931739	0.635	rs4442626	chr12:33912530	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.41	0.36	5.06e-16	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	trans	rs7939886	0.623	rs77065109	chr11:55906843	G/A	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.04	0.55	1.54e-37	Bladder cancer;
LGG	cis	rs11250464	0.804	rs11250463	chr10:1406228	T/C	cg08668359	chr10:1443807	ADARB2	0.63	11.92	0.48	9.46e-29	Radiation response;
LGG	cis	rs4684776	0.800	rs11128555	chr3:11621461	G/C	cg24705426	chr3:11550659	ATG7	-0.41	-7.08	-0.31	5.35e-12	Small vessel stroke;
LGG	cis	rs4665809	1.000	rs6546744	chr2:26302161	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg13443165	chr9:33130375	B4GALT1	-0.76	-14.86	-0.57	4.23e-41	IgG glycosylation;
LGG	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg09021430	chr5:549028	NA	-0.72	-10.11	-0.43	7.65e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20295408	chr7:1910781	MAD1L1	-0.41	-7.03	-0.31	7.24e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-8.53	-0.37	2.02e-16	Lung cancer;
LGG	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-13.85	-0.54	1e-36	Menarche (age at onset);
LGG	cis	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg13647721	chr17:30228624	UTP6	-0.72	-9.21	-0.39	1.14e-18	Hip circumference adjusted for BMI;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.74	-0.3	4.83e-11	Longevity;Endometriosis;
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.77	-0.38	3.53e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8027181	0.617	rs6495017	chr15:73089625	T/A	cg02923145	chr15:73089643	NA	-0.49	-9.22	-0.39	1.09e-18	Triglyceride levels;
LGG	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg15596359	chr8:11213517	TDH	-0.34	-6.95	-0.31	1.22e-11	Retinal vascular caliber;
LGG	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg24692254	chr21:30365293	RNF160	0.58	8.79	0.38	3.01e-17	Cognitive test performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04527840	chr4:110736869	GAR1	0.46	6.99	0.31	9.44e-12	Gut microbiome composition (summer);
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.68	0.37	6.9e-17	Height;
LGG	cis	rs12615966	0.872	rs11898434	chr2:105376704	G/A	cg16465502	chr2:105461796	NA	0.86	10.45	0.44	4.36e-23	Pancreatic cancer;
LGG	cis	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-8.56	-0.37	1.66e-16	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06888550	chr17:43238612	HEXIM2	0.43	7.1	0.31	4.76e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs637571	0.510	rs10896052	chr11:65579600	C/A	cg26695010	chr11:65641043	EFEMP2	0.51	8.7	0.37	5.99e-17	Eosinophil percentage of white cells;
LGG	cis	rs4819852	0.958	rs12628032	chr22:19967980	C/T	cg07821417	chr22:19972146	ARVCF	0.58	12.33	0.5	2.07e-30	Pulse pressure;
LGG	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg01620082	chr3:125678407	NA	-0.66	-8.5	-0.37	2.67e-16	Lung cancer in ever smokers;
LGG	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6909430	0.901	rs17058348	chr6:98726503	A/T	cg12860156	chr6:98744658	NA	-0.45	-7.02	-0.31	7.83e-12	Quantitative traits;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg05165339	chr4:1420672	NA	-0.3	-7.85	-0.34	2.88e-14	Longevity;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg24250549	chr1:154909240	PMVK	0.75	15.06	0.57	5.44e-42	Prostate cancer;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg04025307	chr7:1156635	C7orf50	0.82	14.55	0.56	9.29e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg22044901	chr15:68126292	NA	-0.42	-7.71	-0.34	7.58e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7149337	0.805	rs3007164	chr14:51646935	A/G	cg23942311	chr14:51606299	NA	0.31	6.87	0.3	2.07e-11	Cancer;
LGG	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg00666640	chr1:248458726	OR2T12	0.51	8.74	0.38	4.28e-17	Common traits (Other);
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg21724239	chr8:58056113	NA	0.63	9.24	0.39	8.92e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs72960926	1.000	rs72958964	chr6:75124792	C/T	cg03266952	chr6:74778945	NA	-0.69	-6.84	-0.3	2.58e-11	Metabolite levels (MHPG);
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg20309703	chr11:118481025	PHLDB1	-0.56	-10.43	-0.44	5.19e-23	Cholesterol, total;
LGG	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg00343986	chr7:65444356	GUSB	0.5	8.83	0.38	2.17e-17	Aortic root size;
LGG	cis	rs4363385	0.747	rs3806219	chr1:152972522	C/T	cg13444842	chr1:152974279	SPRR3	0.44	9.1	0.39	2.67e-18	Inflammatory skin disease;
LGG	cis	rs2247341	0.965	rs2854913	chr4:1723137	A/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.99	-0.52	4.05e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6076065	0.630	rs2424559	chr20:23430519	A/G	cg11657817	chr20:23433608	CST11	0.46	9.31	0.4	5.34e-19	Facial morphology (factor 15, philtrum width);
LGG	cis	rs11203032	0.831	rs11203017	chr10:90948709	C/T	cg16672925	chr10:90967113	CH25H	0.77	11.08	0.46	1.8e-25	Heart failure;
LGG	cis	rs10791111	1	rs10791111	chr11:130856099	T/G	cg12179176	chr11:130786555	SNX19	0.7	13.04	0.52	2.58e-33	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg03162506	chr22:38580953	NA	0.27	6.78	0.3	3.79e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg22120825	chr2:201024476	NA	0.51	6.76	0.3	4.17e-11	Schizophrenia;
LGG	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg06028605	chr16:24865363	SLC5A11	0.5	8.47	0.37	3.32e-16	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12949688	1.000	rs12949688	chr17:55825701	C/T	cg12229367	chr17:55822335	NA	-0.43	-8.09	-0.35	5.27e-15	Schizophrenia;
LGG	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg15212455	chr7:39170539	POU6F2	0.5	11.82	0.48	2.35e-28	IgG glycosylation;
LGG	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.09	0.31	4.95e-12	Total cholesterol levels;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg27476859	chr7:2772710	GNA12	-0.4	-6.86	-0.3	2.26e-11	Height;
LGG	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg08344181	chr3:125677491	NA	-0.68	-7.98	-0.35	1.13e-14	Depression;
LGG	cis	rs28498503	0.867	rs1462627	chr18:76641125	T/C	cg00806245	chr18:76673096	NA	-0.58	-6.83	-0.3	2.68e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg24642844	chr7:1081250	C7orf50	-0.71	-9.02	-0.39	4.91e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.74	-0.38	4.31e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	3.93e-21	Colorectal cancer;
LGG	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg18511798	chr11:2018149	H19;MIR675	-0.56	-10.8	-0.45	2.2e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10819861	0.645	rs12686105	chr9:98852303	A/G	cg14508093	chr9:98862825	NA	0.3	7.17	0.32	2.95e-12	Electrocardiographic traits;
LGG	cis	rs4731207	0.698	rs3919896	chr7:124553007	A/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs727505	1.000	rs77718560	chr7:124514544	T/A	cg23710748	chr7:124431027	NA	-0.52	-9.81	-0.41	9.39e-21	Lewy body disease;
LGG	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg10556349	chr10:835070	NA	-0.3	-7.69	-0.34	9.06e-14	Survival in rectal cancer;
LGG	cis	rs2408955	0.501	rs8716	chr12:48539482	T/G	cg24011408	chr12:48396354	COL2A1	0.56	9.36	0.4	3.59e-19	Glycated hemoglobin levels;
LGG	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.83	0.34	3.31e-14	Height;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.01	-0.39	5.31e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg26248373	chr2:1572462	NA	-0.86	-14.99	-0.57	1.11e-41	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg08677398	chr8:58056175	NA	0.56	8.71	0.38	5.51e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.741	rs55909524	chr3:143794734	T/C	cg06585982	chr3:143692056	C3orf58	0.56	9.19	0.39	1.37e-18	Economic and political preferences (feminism/equality);
LGG	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.0	-0.31	9.04e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.94	-0.38	9.56e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18657643	chr3:195545456	NA	0.48	6.67	0.3	7.49e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05647005	chr8:56685498	TMEM68;TGS1	0.44	7.56	0.33	2.15e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12999616	0.817	rs7425883	chr2:98331521	C/G	cg26665480	chr2:98280029	ACTR1B	-0.56	-8.08	-0.35	5.48e-15	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.8	0.34	4.08e-14	Lung cancer;
LGG	trans	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.7	-0.34	8.4e-14	Mood instability;
LGG	cis	rs7188861	0.768	rs7184969	chr16:11397206	C/A	cg01510278	chr16:11456238	NA	0.31	7.28	0.32	1.47e-12	HDL cholesterol;
LGG	cis	rs1670533	1.000	rs10084890	chr4:1053934	C/G	cg27284194	chr4:1044797	NA	-0.55	-10.12	-0.43	7.13e-22	Recombination rate (females);
LGG	cis	rs4319547	0.662	rs35417323	chr12:123090572	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.43	-6.73	-0.3	4.9e-11	Body mass index;
LGG	cis	rs17169635	0.721	rs2198342	chr7:134561120	A/G	cg02516134	chr7:134575187	CALD1	-0.41	-8.34	-0.36	8.68e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.8e-22	Arsenic metabolism;
LGG	trans	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.27	0.4	7.23e-19	Resting heart rate;
LGG	cis	rs4253772	0.591	rs6008384	chr22:46655948	T/C	cg24881330	chr22:46731750	TRMU	0.71	8.85	0.38	1.81e-17	LDL cholesterol;Cholesterol, total;
LGG	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs990171	0.955	rs11465583	chr2:102982466	C/G	cg05295703	chr2:102895712	NA	-0.56	-9.67	-0.41	2.76e-20	Lymphocyte counts;
LGG	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg07423050	chr13:99094983	FARP1	-0.55	-10.66	-0.44	7.4e-24	Longevity;
LGG	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.88	-0.38	1.49e-17	Personality dimensions;
LGG	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.71	0.41	2.11e-20	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.3	-0.36	1.16e-15	Life satisfaction;
LGG	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg23845249	chr11:68861649	NA	0.44	7.9	0.34	2.09e-14	Blond vs. brown hair color;
LGG	cis	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg12940923	chr8:10282607	MSRA	0.29	6.82	0.3	2.89e-11	Neuroticism;
LGG	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs60180747	0.909	rs78136741	chr15:66728310	A/G	cg07575407	chr15:66541975	MEGF11	0.38	7.4	0.33	6.48e-13	Testicular germ cell tumor;
LGG	cis	rs3741151	1.000	rs74346863	chr11:73054772	C/T	cg17517138	chr11:73019481	ARHGEF17	1.03	10.4	0.44	6.61e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg09217309	chr6:150244204	RAET1G	0.41	7.51	0.33	3.13e-13	Testicular germ cell tumor;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg15948088	chr11:109293068	C11orf87	-0.46	-7.58	-0.33	1.84e-13	Schizophrenia;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	trans	rs8073060	0.586	rs8074800	chr17:33979148	A/G	cg19694781	chr19:47549865	TMEM160	1.15	18.31	0.65	9.48e-57	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs11920090	0.932	rs10513687	chr3:170725730	C/T	cg09710316	chr3:170744871	SLC2A2	0.61	8.6	0.37	1.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25525163	chr3:38178867	ACAA1;MYD88	0.46	7.59	0.33	1.76e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9358372	1.000	rs4395717	chr6:20826281	G/T	cg13405222	chr6:20811065	CDKAL1	-0.69	-15.2	-0.58	1.34e-42	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9863	0.828	rs12303671	chr12:124492610	T/G	cg13487667	chr12:124434373	CCDC92	-0.35	-7.0	-0.31	9.19e-12	White blood cell count;
LGG	trans	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg09699651	chr6:150184138	LRP11	0.54	9.62	0.41	4.33e-20	Lung cancer;
LGG	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.92e-12	Blood metabolite levels;
LGG	cis	rs6754311	0.638	rs2322659	chr2:136555659	A/G	cg07169764	chr2:136633963	MCM6	-0.77	-13.12	-0.52	1.18e-33	Mosquito bite size;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg12708336	chr17:41446283	NA	-0.31	-7.3	-0.32	1.29e-12	Menopause (age at onset);
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg22907277	chr7:1156413	C7orf50	0.86	15.25	0.58	7.39e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg27129171	chr3:47204927	SETD2	-0.83	-15.86	-0.59	1.42e-45	Colorectal cancer;
LGG	trans	rs3206736	0.548	rs329235	chr7:35056166	C/T	cg14337134	chr7:102920323	DPY19L2P2	-0.41	-7.2	-0.32	2.4e-12	Diastolic blood pressure;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20555477	chr9:86594889	HNRNPK;RMI1	-0.41	-6.8	-0.3	3.27e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg02733842	chr7:1102375	C7orf50	0.64	10.39	0.43	7.26e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg21775007	chr8:11205619	TDH	-0.42	-7.02	-0.31	7.94e-12	Mood instability;
LGG	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.59	-0.33	1.76e-13	Mood instability;
LGG	cis	rs2153535	0.580	rs9406162	chr6:8466196	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	trans	rs11671005	0.504	rs7257669	chr19:59064939	T/C	cg22037779	chr5:139682734	PFDN1	-0.43	-6.71	-0.3	5.74e-11	Mean platelet volume;
LGG	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg07606381	chr6:8435919	SLC35B3	-0.65	-11.49	-0.47	4.8400000000000004e-27	Motion sickness;
LGG	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg01221209	chr5:554886	NA	-0.46	-6.69	-0.3	6.31e-11	Obesity-related traits;
LGG	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg20368463	chr18:77673604	PQLC1	-0.67	-13.35	-0.53	1.26e-34	Schizophrenia;
LGG	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs4363385	0.747	rs4319267	chr1:152972699	T/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.35	-0.4	3.81e-19	Inflammatory skin disease;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08280861	chr8:58055591	NA	0.65	8.0	0.35	1.04e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg14191688	chr11:70257035	CTTN	0.59	8.53	0.37	2.02e-16	Coronary artery disease;
LGG	cis	rs1555322	0.505	rs639763	chr20:33861904	C/T	cg03689076	chr20:33865952	NA	0.66	8.49	0.37	2.77e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg07362569	chr17:61921086	SMARCD2	-0.48	-9.15	-0.39	1.88e-18	Prudent dietary pattern;
LGG	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg24642844	chr7:1081250	C7orf50	-0.63	-10.24	-0.43	2.61e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs1044826	0.619	rs6439856	chr3:139134868	A/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.93	-0.31	1.4e-11	Obesity-related traits;
LGG	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg24955955	chr5:415729	AHRR	0.81	10.82	0.45	1.75e-24	Fat distribution (HIV);
LGG	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg02527881	chr3:46936655	PTH1R	0.37	9.26	0.4	7.52e-19	Birth weight;
LGG	cis	rs727505	0.564	rs57841320	chr7:124847732	T/A	cg23710748	chr7:124431027	NA	-0.44	-8.31	-0.36	1.08e-15	Lewy body disease;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.69	12.42	0.5	9.13e-31	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-15.16	-0.58	1.99e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.555	rs8071831	chr17:57292950	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.45	7.17	0.32	2.96e-12	Cognitive test performance;
LGG	cis	rs6547631	0.622	rs1437742	chr2:85924899	T/A	cg24620635	chr2:85921963	GNLY	0.49	9.91	0.42	4.03e-21	Blood protein levels;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.3	0.46	2.54e-26	Tonsillectomy;
LGG	cis	rs9362426	0.639	rs9450674	chr6:88120920	G/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.46	-8.72	-0.38	5.14e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs4746818	0.892	rs2394505	chr10:70871598	A/G	cg11621586	chr10:70884670	VPS26A	-0.98	-16.65	-0.61	3.84e-49	Left atrial antero-posterior diameter;
LGG	cis	rs4363385	0.510	rs6664380	chr1:153030365	G/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.32	-0.4	4.82e-19	Inflammatory skin disease;
LGG	cis	rs13082711	0.911	rs13078798	chr3:27445971	A/G	cg02860705	chr3:27208620	NA	-0.72	-13.41	-0.53	7.03e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg04455712	chr21:45112962	RRP1B	0.55	10.1	0.42	8.19e-22	Mean corpuscular volume;
LGG	cis	rs72781680	0.898	rs72796171	chr2:23942667	G/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.13e-18	Lymphocyte counts;
LGG	cis	rs740474	0.569	rs4912762	chr5:140881691	A/G	cg00076195	chr5:140892677	NA	0.39	7.27	0.32	1.53e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg14092988	chr3:52407081	DNAH1	0.3	8.1	0.35	4.88e-15	Electroencephalogram traits;
LGG	cis	rs7166081	1.000	rs4776906	chr15:67520617	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs8056893	0.513	rs1968757	chr16:68346625	G/A	cg07273125	chr16:68295692	NA	0.46	10.42	0.44	5.64e-23	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs920590	0.837	rs4398935	chr8:19649487	T/C	cg03894339	chr8:19674705	INTS10	0.51	8.45	0.37	3.79e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08645402	chr16:4508243	NA	0.47	8.37	0.36	6.92e-16	Schizophrenia;
LGG	cis	rs6988985	0.728	rs4581033	chr8:143950698	A/C	cg10324643	chr8:143916377	GML	0.39	7.74	0.34	6.28e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	10.79	0.45	2.34e-24	Longevity;
LGG	cis	rs12410462	0.551	rs2819503	chr1:227712488	A/G	cg23173402	chr1:227635558	NA	0.38	7.15	0.32	3.46e-12	Major depressive disorder;
LGG	trans	rs1459104	0.925	rs35535067	chr11:54995548	G/T	cg15704280	chr7:45808275	SEPT13	0.72	7.14	0.31	3.7e-12	Body mass index;
LGG	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg15764593	chr10:829463	NA	-0.7	-10.62	-0.44	9.91e-24	Uric acid levels;
LGG	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg00405596	chr8:11794950	NA	-0.59	-10.3	-0.43	1.59e-22	Monocyte count;
LGG	cis	rs9815354	0.812	rs73071356	chr3:41829486	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.46	0.4	1.53e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg09173681	chr1:183549694	NCF2	-0.37	-8.33	-0.36	9.46e-16	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.21	0.68	1.43e-65	Alzheimer's disease;
LGG	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg02711726	chr17:80685570	FN3KRP	-0.57	-9.96	-0.42	2.72e-21	Glycated hemoglobin levels;
LGG	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2816316	1.000	rs2760527	chr1:192536758	G/A	cg02586212	chr1:192544902	RGS1	0.46	9.21	0.39	1.14e-18	Celiac disease;
LGG	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg24759859	chr6:86352639	SYNCRIP	0.44	7.41	0.33	5.85e-13	Smooth-surface caries;
LGG	cis	rs7264396	0.623	rs761827	chr20:34207897	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.09	0.31	4.96e-12	Total cholesterol levels;
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg22398616	chr13:53314203	LECT1	-0.48	-9.87	-0.42	5.65e-21	Lewy body disease;
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.78e-18	Skin colour saturation;
LGG	cis	rs9899728	0.520	rs12936866	chr17:73052050	A/G	cg27626185	chr17:73056755	KCTD2	-1.04	-12.26	-0.49	4.17e-30	Alzheimer's disease or small vessel stroke;
LGG	trans	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg25482853	chr8:67687455	SGK3	0.85	11.15	0.46	9.37e-26	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs896249	chr2:100089212	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs12681288	0.523	rs111782857	chr8:962486	T/C	cg15309053	chr8:964076	NA	0.43	9.21	0.39	1.14e-18	Schizophrenia;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.9	-0.34	2e-14	Personality dimensions;
LGG	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg17294928	chr15:75287854	SCAMP5	0.6	11.22	0.46	5.34e-26	Breast cancer;
LGG	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-12.76	-0.51	3.51e-32	HDL cholesterol;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg13206674	chr6:150067644	NUP43	0.66	14.99	0.57	1.08e-41	Lung cancer;
LGG	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.78	0.38	3.15e-17	Mood instability;
LGG	trans	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	cis	rs7586879	0.828	rs4077677	chr2:25122798	G/C	cg04586622	chr2:25135609	ADCY3	0.38	9.51	0.4	1.06e-19	Body mass index;
LGG	cis	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg01028140	chr2:1542097	TPO	-0.52	-9.39	-0.4	2.68e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg24209194	chr3:40518798	ZNF619	-0.43	-6.96	-0.31	1.16e-11	Renal cell carcinoma;
LGG	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg20891283	chr12:69753455	YEATS4	0.8	16.24	0.6	2.99e-47	Blood protein levels;
LGG	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg06115741	chr20:33292138	TP53INP2	0.59	9.81	0.41	9.26e-21	Coronary artery disease;
LGG	cis	rs910187	0.901	rs6124969	chr20:45816277	C/T	cg27589058	chr20:45804311	EYA2	-0.33	-7.88	-0.34	2.44e-14	Migraine;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22605179	chr22:29664171	EWSR1;RHBDD3	0.48	7.65	0.33	1.16e-13	Cognitive performance;
LGG	cis	rs9467711	0.591	rs3752417	chr6:26045905	G/C	cg21479132	chr6:26055353	NA	0.74	6.86	0.3	2.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg08048268	chr3:133502702	NA	-0.68	-12.98	-0.52	4.52e-33	Iron status biomarkers;
LGG	cis	rs11098499	0.913	rs35271032	chr4:120156659	C/T	cg09307838	chr4:120376055	NA	0.72	12.09	0.49	1.95e-29	Corneal astigmatism;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05665937	chr4:1216051	CTBP1	0.59	11.02	0.46	3.16e-25	Obesity-related traits;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.43	-7.75	-0.34	5.83e-14	Schizophrenia;
LGG	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg09904177	chr6:26538194	HMGN4	0.67	13.93	0.54	4.36e-37	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	1.000	rs12637751	chr3:134266124	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6964587	0.692	rs6953256	chr7:91575417	C/T	cg17063962	chr7:91808500	NA	-0.5	-9.39	-0.4	2.79e-19	Breast cancer;
LGG	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-14.75	-0.57	1.22e-40	Total body bone mineral density;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	trans	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.67	0.34	1.05e-13	Obesity-related traits;
LGG	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg02023728	chr11:77925099	USP35	-0.41	-7.31	-0.32	1.15e-12	Alzheimer's disease (survival time);
LGG	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg11707556	chr5:10655725	ANKRD33B	0.49	9.56	0.41	6.92e-20	Coronary artery disease;
LGG	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg06598544	chr20:61472147	COL9A3	-0.9	-9.84	-0.42	6.9299999999999992e-21	Obesity-related traits;
LGG	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg18854424	chr1:2615690	NA	0.36	7.17	0.32	2.89e-12	Ulcerative colitis;
LGG	cis	rs68170813	0.559	rs2107319	chr7:106863744	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-10.54	-0.44	1.93e-23	Coronary artery disease;
LGG	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.88	-0.3	1.98e-11	Blood metabolite levels;
LGG	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg03060546	chr3:49711283	APEH	0.75	13.51	0.53	2.56e-35	Resting heart rate;
LGG	cis	rs7084783	0.538	rs3781367	chr10:105337294	C/G	cg00126946	chr10:105363258	SH3PXD2A	0.49	8.37	0.36	7.1e-16	Fear of pain;
LGG	cis	rs2470578	0.792	rs2733493	chr3:17302355	T/C	cg20981856	chr3:17787350	NA	0.36	6.84	0.3	2.51e-11	Schizophrenia;
LGG	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs2067615	0.579	rs66716938	chr12:107196825	T/C	cg15890332	chr12:107067104	RFX4	0.4	11.69	0.48	7.89e-28	Heart rate;
LGG	cis	rs60695258	0.550	rs340641	chr4:87951393	C/T	cg01323104	chr4:87958903	AFF1	-0.24	-6.93	-0.31	1.43e-11	Hematocrit;
LGG	cis	rs9534338	0.520	rs7139813	chr13:46715612	G/A	cg11274337	chr13:46717068	LCP1	-0.36	-8.26	-0.36	1.54e-15	Blood protein levels;
LGG	cis	rs4740619	0.846	rs10121393	chr9:15690496	G/T	cg14451791	chr9:16040625	NA	0.34	8.78	0.38	3.13e-17	Body mass index;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg05163923	chr11:71159392	DHCR7	0.7	13.69	0.54	4.73e-36	Vitamin D levels;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg14338887	chr6:42928500	GNMT	0.27	8.91	0.38	1.17e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3742264	0.656	rs4942460	chr13:46550443	A/G	cg15192986	chr13:46630673	CPB2	-0.35	-6.81	-0.3	3.1e-11	Blood protein levels;
LGG	cis	rs7654585	0.645	rs6828416	chr4:25933273	C/T	cg10409131	chr4:25915609	C4orf52	0.57	9.65	0.41	3.32e-20	Obesity-related traits;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg22105103	chr4:187893119	NA	0.57	10.92	0.45	7.1e-25	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.38	0.56	4.8e-39	Morning vs. evening chronotype;
LGG	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-7.77	-0.34	5.16e-14	Schizophrenia;
LGG	trans	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg02002194	chr4:3960332	NA	0.45	7.15	0.32	3.43e-12	Cervical cancer;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg19635926	chr16:89946313	TCF25	0.73	7.35	0.32	9.19e-13	Skin colour saturation;
LGG	cis	rs735539	0.521	rs2818996	chr13:21428271	A/T	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14555127	chr7:35841578	SEPT7	-0.48	-6.93	-0.31	1.38e-11	Systemic lupus erythematosus;
LGG	cis	rs7927771	0.965	rs35184771	chr11:47475189	G/T	cg20307385	chr11:47447363	PSMC3	-0.52	-9.16	-0.39	1.72e-18	Subjective well-being;
LGG	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.28e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9308731	0.644	rs1837367	chr2:111874551	G/A	cg26001287	chr2:111877753	BCL2L11	-0.33	-6.69	-0.3	6.56e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2274273	0.837	rs11625968	chr14:55801004	G/C	cg04306507	chr14:55594613	LGALS3	0.64	17.85	0.64	1.33e-54	Protein biomarker;
LGG	cis	rs10210302	0.502	rs880116	chr2:234246264	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.42	6.95	0.31	1.24e-11	Crohn's disease;
LGG	cis	rs10876993	0.928	rs1689596	chr12:58053029	T/C	cg18357645	chr12:58087776	OS9	0.71	13.01	0.52	3.36e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg08461772	chr7:95026248	PON3	0.37	8.16	0.35	3.08e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg12011299	chr4:100065546	ADH4	0.42	8.5	0.37	2.68e-16	Alcohol dependence;
LGG	cis	rs651907	0.935	rs2929922	chr3:101587934	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.43	7.49	0.33	3.46e-13	Colorectal cancer;
LGG	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.26e-14	Cystic fibrosis severity;
LGG	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg25809561	chr17:30822961	MYO1D	0.39	9.25	0.39	8.36e-19	Schizophrenia;
LGG	cis	rs9463078	0.665	rs4714816	chr6:44715168	T/C	cg25276700	chr6:44698697	NA	0.44	9.17	0.39	1.6e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs367943	0.712	rs9326887	chr5:112728581	T/A	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.29e-23	Type 2 diabetes;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg18316613	chr7:23719636	C7orf46	0.38	8.82	0.38	2.36e-17	Schizophrenia;
LGG	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.86	-0.38	1.78e-17	Response to antipsychotic treatment;
LGG	cis	rs283228	0.569	rs572036	chr6:101784274	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.51	0.53	2.67e-35	Coenzyme Q10 levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02994645	chr8:30891371	WRN;PURG	0.42	6.9	0.31	1.7e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg08999081	chr20:33150536	PIGU	0.32	7.56	0.33	2.19e-13	Coronary artery disease;
LGG	cis	rs2075371	1.000	rs7486	chr7:133975183	A/G	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs4950322	0.580	rs4950308	chr1:146591674	C/T	cg22381352	chr1:146742008	CHD1L	-0.43	-7.29	-0.32	1.34e-12	Protein quantitative trait loci;
LGG	cis	rs8014204	0.816	rs10144023	chr14:75291531	T/C	cg06637938	chr14:75390232	RPS6KL1	0.64	11.84	0.48	1.96e-28	Caffeine consumption;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	5.99e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg06558623	chr16:89946397	TCF25	0.9	11.61	0.47	1.58e-27	Skin colour saturation;
LGG	cis	rs3540	0.533	rs2601197	chr15:90940059	C/A	cg22089800	chr15:90895588	ZNF774	0.69	12.77	0.51	3.2e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2688608	0.620	rs12253408	chr10:75495956	G/T	cg19442545	chr10:75533431	FUT11	-0.43	-7.0	-0.31	9.21e-12	Inflammatory bowel disease;
LGG	cis	rs7769051	1.000	rs9493454	chr6:133144629	G/T	cg07930552	chr6:133119739	C6orf192	-0.83	-12.29	-0.5	2.97e-30	Type 2 diabetes nephropathy;
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg13264159	chr8:625131	ERICH1	-0.78	-9.38	-0.4	3.03e-19	IgG glycosylation;
LGG	cis	rs1318772	1.000	rs26980	chr5:112770027	T/G	cg12552261	chr5:112820674	MCC	0.7	7.83	0.34	3.46e-14	F-cell distribution;
LGG	cis	rs9911578	0.900	rs4793593	chr17:56892699	C/G	cg05425664	chr17:57184151	TRIM37	0.64	10.13	0.43	6.3e-22	Intelligence (multi-trait analysis);
LGG	cis	rs981844	0.775	rs56101345	chr4:154764261	C/T	cg14289246	chr4:154710475	SFRP2	0.67	11.1	0.46	1.53e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10465746	0.780	rs7551787	chr1:84419297	A/G	cg10977910	chr1:84465055	TTLL7	0.56	10.57	0.44	1.54e-23	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20250874	chr13:47127354	LRCH1	0.52	7.95	0.35	1.43e-14	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	8.89	0.38	1.39e-17	Lung cancer in ever smokers;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg02158880	chr13:53174818	NA	0.46	9.48	0.4	1.32e-19	Lewy body disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25302936	chr8:67579596	VCPIP1	0.39	7.01	0.31	8.6e-12	Obesity-related traits;
LGG	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg10840412	chr1:235813424	GNG4	0.66	8.75	0.38	4e-17	Bipolar disorder;
LGG	cis	rs17221829	0.733	rs12283497	chr11:89357907	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-8.98	-0.39	6.82e-18	Anxiety in major depressive disorder;
LGG	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg20913747	chr6:44695427	NA	-0.61	-10.13	-0.43	6.46e-22	Total body bone mineral density;
LGG	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg25986240	chr4:9926439	SLC2A9	-0.37	-7.6	-0.33	1.62e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg15704280	chr7:45808275	SEPT13	0.72	9.92	0.42	3.69e-21	Axial length;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-8.92	-0.38	1.05e-17	Obesity-related traits;
LGG	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg09021430	chr5:549028	NA	-0.82	-12.79	-0.51	2.73e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg25866889	chr13:114914595	NA	-0.35	-7.11	-0.31	4.28e-12	Schizophrenia;
LGG	cis	rs10940138	0.501	rs6898808	chr5:67249637	T/G	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.04	-0.35	7.46e-15	Menarche (age at onset);
LGG	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg03929089	chr4:120376271	NA	-0.87	-17.65	-0.63	1.08e-53	Coronary artery disease;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg04287289	chr16:89883240	FANCA	0.74	7.22	0.32	2.13e-12	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs208520	0.507	rs7755710	chr6:66783355	G/A	cg07460842	chr6:66804631	NA	-1.13	-30.69	-0.82	1.12e-113	Exhaled nitric oxide output;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01245787	chr4:71859630	DCK	0.44	7.28	0.32	1.4e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs61884328	0.852	rs60088916	chr11:47115967	C/T	cg03339077	chr11:47165057	C11orf49	0.63	6.85	0.3	2.32e-11	Total body bone mineral density (age over 60);
LGG	cis	rs6693295	0.887	rs2787993	chr1:246231383	A/G	cg11798871	chr1:246315928	SMYD3	-0.41	-6.65	-0.3	8.12e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.81	-0.34	3.93e-14	Psoriasis;
LGG	cis	rs6541297	1.000	rs6665260	chr1:230279067	G/T	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.47	0.44	3.5e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1707322	0.963	rs11211202	chr1:46292382	C/T	cg03146154	chr1:46216737	IPP	0.54	10.23	0.43	2.68e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg27523141	chr10:43048294	ZNF37B	-0.36	-7.53	-0.33	2.74e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.05	-0.46	2.44e-25	Lung cancer;
LGG	cis	rs722599	0.639	rs12882676	chr14:75272433	A/G	cg06637938	chr14:75390232	RPS6KL1	0.55	8.93	0.38	9.73e-18	IgG glycosylation;
LGG	trans	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg16141378	chr3:129829833	LOC729375	0.3	6.73	0.3	4.98e-11	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05157318	chr1:29508594	SFRS4	0.44	6.66	0.3	7.99e-11	Gut microbiome composition (summer);
LGG	cis	rs1538970	0.924	rs1826691	chr1:45881262	A/G	cg05343316	chr1:45956843	TESK2	-0.73	-11.82	-0.48	2.29e-28	Platelet count;
LGG	trans	rs1814175	0.754	rs10219245	chr11:49645052	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-25.88	-0.77	5.15e-92	Height;
LGG	cis	rs3820928	0.775	rs10179756	chr2:227897076	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.35	-0.32	8.98e-13	Pulmonary function;
LGG	cis	rs61192259	1.000	rs6933758	chr6:38446371	G/A	cg07362130	chr6:38359646	BTBD9	0.3	7.07	0.31	5.67e-12	Restless legs syndrome;
LGG	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.37	-0.32	7.89e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.22	-0.32	2.18e-12	Iron status biomarkers;
LGG	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	8.33	0.36	9.34e-16	Gout;Renal underexcretion gout;
LGG	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg15309053	chr8:964076	NA	0.43	9.18	0.39	1.39e-18	Schizophrenia;
LGG	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11890956	chr21:40555474	PSMG1	1.15	26.86	0.78	1.8e-96	Cognitive function;
LGG	trans	rs7762018	0.607	rs6907814	chr6:170058206	G/A	cg06875740	chr19:51307921	C19orf48	-0.66	-6.83	-0.3	2.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6840360	0.571	rs2165789	chr4:152510130	A/T	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02071572	chr4:1403502	NA	0.39	6.72	0.3	5.29e-11	Longevity;
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg00864171	chr11:67383662	NA	0.54	9.32	0.4	4.76e-19	Mean corpuscular volume;
LGG	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.32	0.4	4.74e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg15997130	chr1:24165203	NA	0.49	13.54	0.53	2.03e-35	Immature fraction of reticulocytes;
LGG	cis	rs988958	0.958	rs11891490	chr2:42285915	A/G	cg19376973	chr2:42229025	NA	-0.43	-7.05	-0.31	6.4e-12	Hypospadias;
LGG	cis	rs7666738	0.830	rs6851253	chr4:99029980	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg00666640	chr1:248458726	OR2T12	0.6	9.79	0.41	1.06e-20	Common traits (Other);
LGG	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.3	0.43	1.49e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.76e-17	Lung cancer;
LGG	trans	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.92	-0.42	3.55e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg18335740	chr13:41363409	SLC25A15	0.55	9.72	0.41	1.88e-20	Lewy body disease;
LGG	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1971762	0.545	rs10747676	chr12:54049930	T/C	cg06632207	chr12:54070931	ATP5G2	0.24	7.43	0.33	5.29e-13	Height;
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg15971980	chr6:150254442	NA	0.45	8.61	0.37	1.12e-16	Lung cancer;
LGG	cis	rs36051895	0.622	rs12686652	chr9:5071942	C/G	cg02405213	chr9:5042618	JAK2	-0.82	-15.34	-0.58	3.03e-43	Pediatric autoimmune diseases;
LGG	cis	rs9682041	0.627	rs3772172	chr3:170077713	C/T	cg11886554	chr3:170076028	SKIL	-0.54	-6.94	-0.31	1.31e-11	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg25801113	chr15:45476975	SHF	0.89	20.48	0.69	7.7e-67	Uric acid levels;
LGG	cis	rs8044868	0.530	rs2288002	chr16:72057282	A/G	cg06353428	chr16:71660113	MARVELD3	0.42	7.05	0.31	6.52e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs1401999	0.934	rs1132776	chr3:183696402	A/G	cg01324343	chr3:183735012	ABCC5	0.85	18.05	0.64	1.59e-55	Anterior chamber depth;
LGG	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06558623	chr16:89946397	TCF25	0.96	12.34	0.5	1.93e-30	Skin colour saturation;
LGG	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg27661571	chr11:113659931	NA	-0.64	-9.14	-0.39	2.04e-18	Hip circumference adjusted for BMI;
LGG	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs1971762	0.527	rs2365343	chr12:54038149	C/T	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.81	-0.3	3.02e-11	Height;
LGG	cis	rs7474896	0.515	rs688608	chr10:38331624	G/A	cg25427524	chr10:38739819	LOC399744	0.5	7.14	0.31	3.73e-12	Obesity (extreme);
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg13607699	chr17:42295918	UBTF	0.57	9.38	0.4	3.08e-19	Total body bone mineral density;
LGG	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg25811766	chr13:21894605	NA	0.63	8.45	0.37	3.86e-16	White matter hyperintensity burden;
LGG	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-10.55	-0.44	1.9e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg21724239	chr8:58056113	NA	0.43	6.74	0.3	4.67e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6489882	0.867	rs7316586	chr12:113365828	C/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.39	-0.32	6.81e-13	Chronic lymphocytic leukemia;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7914558	1.000	rs7077291	chr10:104945751	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.69	0.44	5.42e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg06917634	chr15:78832804	PSMA4	-0.65	-12.1	-0.49	1.82e-29	Sudden cardiac arrest;
LGG	cis	rs4363385	1.000	rs4363385	chr1:152989321	A/G	cg13444842	chr1:152974279	SPRR3	-0.36	-7.17	-0.32	3.04e-12	Inflammatory skin disease;
LGG	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.25	-0.32	1.81e-12	Hemoglobin concentration;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg04287289	chr16:89883240	FANCA	0.73	7.81	0.34	3.95e-14	Skin colour saturation;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11775334	0.599	rs11774836	chr8:10062543	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.58	0.33	1.84e-13	Hypertension;
LGG	cis	rs67311347	0.544	rs35112505	chr3:40337075	A/G	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.84e-45	Renal cell carcinoma;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg18538332	chr22:24372958	LOC391322	-0.5	-8.24	-0.36	1.74e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg13013644	chr5:502571	SLC9A3	-0.35	-7.27	-0.32	1.51e-12	Cystic fibrosis severity;
LGG	cis	rs6964587	0.610	rs7788951	chr7:91468765	A/T	cg17063962	chr7:91808500	NA	0.4	7.22	0.32	2.08e-12	Breast cancer;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg15763984	chr4:1342303	KIAA1530	0.38	6.79	0.3	3.55e-11	Obesity-related traits;
LGG	cis	rs6882046	0.513	rs254780	chr5:88019747	G/C	cg22951263	chr5:87985283	NA	-0.57	-10.49	-0.44	3.17e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs12367572	0.620	rs2643151	chr12:45410808	A/G	cg03114573	chr12:45410052	DBX2	-0.69	-12.77	-0.51	3.2e-32	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.810	rs1056857	chr10:104240003	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.01	0.55	1.99e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs533581	0.708	rs2968475	chr16:88976663	C/G	cg16701003	chr16:89028210	CBFA2T3	0.63	10.48	0.44	3.25e-23	Social autistic-like traits;
LGG	cis	rs2268241	0.938	rs17879003	chr21:34778527	C/T	cg14850771	chr21:34775459	IFNGR2	0.75	9.1	0.39	2.63e-18	Obesity-related traits;
LGG	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg10847948	chr11:71163743	NADSYN1	-0.69	-13.65	-0.54	7.13e-36	Vitamin D levels;
LGG	cis	rs7717393	1.000	rs9313897	chr5:155791181	A/C	cg12904904	chr5:155754151	SGCD	0.83	8.36	0.36	7.2e-16	Egg allergy;
LGG	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-12.78	-0.51	3.11e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.06	0.35	6.67e-15	Diabetic kidney disease;
LGG	cis	rs12738007	0.967	rs7522989	chr1:29552958	C/A	cg01115565	chr1:29584222	PTPRU	-0.27	-7.27	-0.32	1.55e-12	Schizophrenia;
LGG	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg13271783	chr10:134563150	INPP5A	-0.5	-7.68	-0.34	9.75e-14	Migraine;
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg03665457	chr10:38645376	HSD17B7P2	0.43	6.89	0.3	1.88e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7727544	0.618	rs2631367	chr5:131705458	C/G	cg24060327	chr5:131705240	SLC22A5	0.43	7.38	0.32	7.5e-13	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg25072359	chr17:41440525	NA	0.5	9.9	0.42	4.37e-21	Menopause (age at onset);
LGG	cis	rs590121	0.876	rs649257	chr11:75279846	C/T	cg26104986	chr11:75275303	SERPINH1	-0.38	-8.68	-0.37	6.96e-17	Coronary artery disease;
LGG	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg04672837	chr16:48644449	N4BP1	-0.56	-9.22	-0.39	1.05e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1595825	0.945	rs73056890	chr2:198831260	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.78	-0.3	3.65e-11	Ulcerative colitis;
LGG	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg27087555	chr16:88793112	FAM38A	1.39	18.18	0.65	3.99e-56	Plateletcrit;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg15664640	chr17:80829946	TBCD	0.45	8.21	0.36	2.28e-15	Glycated hemoglobin levels;
LGG	cis	rs10504073	0.647	rs9643394	chr8:50014427	A/G	cg00325661	chr8:49890786	NA	0.7	13.75	0.54	2.65e-36	Blood metabolite ratios;
LGG	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26306683	chr17:18585705	ZNF286B	0.44	7.3	0.32	1.28e-12	Pancreatic cancer;
LGG	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg26384229	chr12:38710491	ALG10B	1.0	23.86	0.74	1.15e-82	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg26408565	chr15:76604113	ETFA	-0.38	-6.65	-0.3	8.37e-11	Blood metabolite levels;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.91	-0.59	8.66e-46	Longevity;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.22	0.36	2.09e-15	Lung cancer;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg08621203	chr6:150244597	RAET1G	0.48	9.02	0.39	4.96e-18	Testicular germ cell tumor;
LGG	cis	rs17092148	1.000	rs3787220	chr20:33337751	T/C	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg05096777	chr10:104283225	SUFU	0.32	7.1	0.31	4.67e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg26446133	chr18:72167187	CNDP2	-0.74	-17.44	-0.63	1.04e-52	Refractive error;
LGG	trans	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg20587970	chr11:113659929	NA	-0.9	-13.95	-0.54	3.58e-37	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.18	-0.32	2.77e-12	Menopause (age at onset);
LGG	cis	rs35771425	0.509	rs3120782	chr1:211419700	A/T	cg10512769	chr1:211675356	NA	-0.42	-7.65	-0.34	1.14e-13	Educational attainment (years of education);
LGG	cis	rs2011503	0.782	rs35545554	chr19:19715613	A/G	cg11584989	chr19:19387371	SF4	-0.65	-10.08	-0.42	9.96e-22	Bipolar disorder;
LGG	cis	rs1790761	0.967	rs1638556	chr11:67213518	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.83	-0.3	2.69e-11	Mean corpuscular volume;
LGG	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg08250081	chr4:10125330	NA	-0.34	-6.91	-0.31	1.57e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	cis	rs67311347	0.955	rs4974068	chr3:40376929	T/C	cg13683864	chr3:40499215	RPL14	-0.99	-20.21	-0.68	1.36e-65	Renal cell carcinoma;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg08645402	chr16:4508243	NA	0.5	9.11	0.39	2.47e-18	Schizophrenia;
LGG	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.99	0.49	4.76e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9894429	1.000	rs11652797	chr17:79574124	A/G	cg10661904	chr17:79619235	PDE6G	-0.41	-8.54	-0.37	1.9e-16	Eye color traits;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg22907277	chr7:1156413	C7orf50	0.42	7.23	0.32	2.08e-12	Longevity;Endometriosis;
LGG	cis	rs8058578	1.000	rs7187359	chr16:30703155	G/A	cg05768032	chr16:30646687	NA	0.42	7.07	0.31	5.75e-12	Multiple myeloma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11312613	chr22:46610390	PPARA	-0.41	-7.18	-0.32	2.83e-12	Cognitive performance;
LGG	cis	rs2370759	1.000	rs11599522	chr10:32568434	G/C	cg01819863	chr10:32635814	EPC1	1.08	15.07	0.57	4.89e-42	Sexual dysfunction (female);
LGG	trans	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg08344181	chr3:125677491	NA	-0.52	-6.65	-0.3	8.49e-11	Lung cancer in ever smokers;
LGG	cis	rs4660214	0.666	rs2256614	chr1:39824718	C/G	cg18385671	chr1:39797026	MACF1	0.47	9.85	0.42	6.68e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg24375607	chr4:120327624	NA	0.65	10.73	0.45	3.82e-24	Corneal astigmatism;
LGG	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg02297831	chr4:17616191	MED28	-0.48	-8.69	-0.37	6.19e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1957429	0.808	rs1951492	chr14:65346895	G/A	cg23373153	chr14:65346875	NA	1.14	15.34	0.58	3.03e-43	Pediatric areal bone mineral density (radius);
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg06968155	chr5:131705112	SLC22A5	-0.72	-8.41	-0.36	4.93e-16	Rheumatoid arthritis;
LGG	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12791968	1.000	rs1552300	chr11:45002594	G/A	cg11846598	chr11:44996168	LOC221122	-0.66	-12.27	-0.5	3.58e-30	Inhibitory control;
LGG	cis	rs17102423	0.755	rs4902358	chr14:65542477	A/G	cg16583315	chr14:65563665	MAX	-0.36	-7.09	-0.31	4.95e-12	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg18032289	chr17:61959525	GH2	-0.42	-6.95	-0.31	1.28e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.83	-0.45	1.69e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs2549003	1.000	rs2549009	chr5:131826765	T/C	cg21138405	chr5:131827807	IRF1	-0.39	-10.22	-0.43	3.11e-22	Asthma (sex interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27394046	chr20:21283521	XRN2	-0.46	-6.68	-0.3	6.86e-11	Systemic lupus erythematosus;
LGG	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg23202291	chr11:1979235	NA	0.4	7.61	0.33	1.56e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9486719	0.947	rs12194971	chr6:96911073	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.64	-0.44	8.09e-24	Migraine;Coronary artery disease;
LGG	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg04450456	chr4:17643702	FAM184B	0.33	7.39	0.32	7.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg14668632	chr7:2872130	GNA12	-0.34	-7.11	-0.31	4.43e-12	Height;
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.47	0.33	4.08e-13	Tonsillectomy;
LGG	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg27490568	chr2:178487706	NA	-0.81	-14.31	-0.55	1.02e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.05	-0.42	1.22e-21	Sudden cardiac arrest;
LGG	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg26818257	chr2:241905806	NA	0.49	11.17	0.46	8.21e-26	Joint mobility (Beighton score);
LGG	cis	rs751728	0.664	rs943474	chr6:33749834	G/C	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg02466173	chr16:30829666	NA	0.47	8.5	0.37	2.59e-16	Dementia with Lewy bodies;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg22444338	chr7:1054449	C7orf50	0.42	8.77	0.38	3.56e-17	Bronchopulmonary dysplasia;
LGG	cis	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg15596359	chr8:11213517	TDH	-0.35	-7.07	-0.31	5.9e-12	Retinal vascular caliber;
LGG	cis	rs2463822	0.583	rs72919477	chr11:62042403	G/C	cg06239285	chr11:62104954	ASRGL1	-1.02	-12.53	-0.5	3.27e-31	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg15320075	chr8:145703422	NA	-0.78	-15.26	-0.58	6.75e-43	Age at first birth;
LGG	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.09	0.49	1.94e-29	Rheumatoid arthritis;
LGG	cis	rs977987	0.843	rs4888415	chr16:75448921	C/T	cg03315344	chr16:75512273	CHST6	0.52	10.64	0.44	8.38e-24	Dupuytren's disease;
LGG	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg24623649	chr8:11872141	NA	0.32	7.48	0.33	3.88e-13	Monocyte count;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.66	0.37	7.72e-17	Platelet count;
LGG	cis	rs1023500	0.573	rs4822088	chr22:42470589	G/C	cg15557168	chr22:42548783	NA	-0.39	-8.5	-0.37	2.69e-16	Schizophrenia;
LGG	cis	rs2276314	1.000	rs9304154	chr18:33562227	C/T	cg19628046	chr18:33552617	C18orf21	0.55	7.88	0.34	2.36e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs12362504	0.532	rs7126063	chr11:9925602	G/C	cg07197493	chr11:9884649	SBF2	-0.34	-6.68	-0.3	7.02e-11	Survival in pancreatic cancer;
LGG	cis	rs35110281	0.626	rs10854486	chr21:45118280	G/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.93	-0.38	1.03e-17	Mean corpuscular volume;
LGG	cis	rs722599	0.683	rs10144845	chr14:75237770	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.76	0.38	3.57e-17	IgG glycosylation;
LGG	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg01448562	chr3:133502909	NA	-0.73	-13.55	-0.53	1.8e-35	Iron status biomarkers;
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.38e-16	Aortic root size;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg09699651	chr6:150184138	LRP11	0.49	7.99	0.35	1.1e-14	Lung cancer;
LGG	cis	rs988958	0.565	rs35411295	chr2:42236631	T/A	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs10979	0.597	rs9321927	chr6:143913295	A/G	cg25407410	chr6:143891975	LOC285740	0.53	7.94	0.35	1.51e-14	Hypospadias;
LGG	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg13147721	chr7:65941812	NA	0.82	10.09	0.42	8.89e-22	Gout;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21862992	chr11:68658383	NA	0.51	8.43	0.36	4.27e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7166081	1.000	rs12594229	chr15:67596084	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg11871910	chr12:69753446	YEATS4	0.84	15.8	0.59	2.71e-45	Response to diuretic therapy;
LGG	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg07747251	chr5:1868357	NA	0.41	7.36	0.32	8.37e-13	Cardiovascular disease risk factors;
LGG	cis	rs2599510	1.000	rs2599510	chr2:32826002	A/G	cg02381751	chr2:32503542	YIPF4	0.53	8.91	0.38	1.18e-17	Interleukin-18 levels;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg04529724	chr6:150244392	RAET1G	0.33	6.73	0.3	4.91e-11	Testicular germ cell tumor;
LGG	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg09307838	chr4:120376055	NA	0.7	11.35	0.47	1.69e-26	Corneal astigmatism;
LGG	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg06636001	chr8:8085503	FLJ10661	0.73	15.79	0.59	3.08e-45	Mood instability;
LGG	cis	rs17401966	0.838	rs946502	chr1:10309279	G/C	cg15208524	chr1:10270712	KIF1B	0.45	8.02	0.35	8.52e-15	Hepatocellular carcinoma;
LGG	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06481639	chr22:41940642	POLR3H	0.46	6.65	0.3	8.46e-11	Vitiligo;
LGG	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg13010199	chr12:38710504	ALG10B	0.63	12.68	0.51	7.62e-32	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg02725872	chr8:58115012	NA	-1.03	-13.55	-0.53	1.75e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs17253792	0.822	rs78826571	chr14:56048906	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.02	-0.49	3.91e-29	Putamen volume;
LGG	cis	rs1322639	0.614	rs4708414	chr6:169574144	C/G	cg03254818	chr6:169586852	NA	0.43	9.06	0.39	3.62e-18	Pulse pressure;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg13607699	chr17:42295918	UBTF	-0.43	-6.88	-0.3	2e-11	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02018176	chr4:1364513	KIAA1530	0.65	15.52	0.58	5e-44	Longevity;
LGG	cis	rs12580194	0.593	rs7488940	chr12:55802591	C/T	cg19537932	chr12:55886519	OR6C68	-0.58	-10.63	-0.44	9e-24	Cancer;
LGG	trans	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg25214090	chr10:38739885	LOC399744	0.68	12.14	0.49	1.26e-29	Corneal astigmatism;
LGG	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.37	0.4	3.25e-19	Bone mineral density;
LGG	cis	rs12915659	1	rs12915659	chr15:67655973	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.27	-0.32	1.58e-12	Total body bone mineral density;
LGG	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg00376283	chr12:123451042	ABCB9	0.64	9.91	0.42	4.01e-21	Neutrophil percentage of white cells;
LGG	cis	rs2273669	0.510	rs11757590	chr6:109370003	T/C	cg05315195	chr6:109294784	ARMC2	-0.61	-8.33	-0.36	9.13e-16	Prostate cancer;
LGG	cis	rs6032067	0.777	rs34233258	chr20:43788265	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs975722	0.614	rs213942	chr7:117172269	A/T	cg10524701	chr7:117356490	CTTNBP2	0.41	9.21	0.39	1.1e-18	Coronary artery disease;
LGG	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg23231163	chr10:75533350	FUT11	-0.4	-6.72	-0.3	5.36e-11	Inflammatory bowel disease;
LGG	cis	rs483069	0.933	rs487638	chr1:34422278	C/T	cg24941457	chr1:34420873	CSMD2	-0.42	-10.4	-0.44	6.5e-23	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs25645	0.823	rs12453334	chr17:38153473	C/T	cg17467752	chr17:38218738	THRA	-0.59	-9.72	-0.41	1.91e-20	Myeloid white cell count;
LGG	cis	rs2976388	1.000	rs2978982	chr8:143763490	T/C	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg13206674	chr6:150067644	NUP43	-0.39	-6.73	-0.3	5.15e-11	Lung cancer;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.36	-0.32	8.73e-13	Bipolar disorder;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	8.18	0.36	2.73e-15	Obesity-related traits;
LGG	cis	rs9522267	0.535	rs914036	chr13:112235542	G/A	cg12773197	chr13:112238673	NA	-0.36	-7.3	-0.32	1.28e-12	Hepatitis;
LGG	cis	rs1800469	1.000	rs1549933	chr19:41871142	A/G	cg09537434	chr19:41945824	ATP5SL	-0.47	-7.75	-0.34	5.72e-14	Colorectal cancer;
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg13009111	chr11:71350975	NA	-0.31	-6.83	-0.3	2.63e-11	Neuroticism;
LGG	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-12.77	-0.51	3.3e-32	Bladder cancer;
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg00405596	chr8:11794950	NA	-0.41	-6.83	-0.3	2.74e-11	Neuroticism;
LGG	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.55	0.47	2.81e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs755249	0.567	rs61783378	chr1:39777159	G/A	cg18385671	chr1:39797026	MACF1	0.43	7.28	0.32	1.48e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28595532	0.546	rs13102483	chr4:119246396	G/A	cg21605333	chr4:119757512	SEC24D	0.89	8.32	0.36	9.75e-16	Cannabis dependence symptom count;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.66	0.41	3.02e-20	Longevity;
LGG	cis	rs28595532	0.920	rs116094766	chr4:119729291	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs1814175	0.817	rs12290508	chr11:49621037	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.95	-0.73	2.04e-78	Height;
LGG	cis	rs721917	0.506	rs2254016	chr10:81658424	T/C	cg25562619	chr10:81652821	NA	-0.35	-8.04	-0.35	7.65e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs9560113	0.960	rs9560102	chr13:112173825	G/A	cg14154082	chr13:112174009	NA	0.41	9.13	0.39	2.08e-18	Menarche (age at onset);
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	13.77	0.54	2.04e-36	Platelet count;
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5015933	0.734	rs4838261	chr9:128149249	C/T	cg14078157	chr9:128172775	NA	-0.38	-7.01	-0.31	8.55e-12	Body mass index;
LGG	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg07460842	chr6:66804631	NA	0.95	17.19	0.62	1.4e-51	Exhaled nitric oxide levels;
LGG	cis	rs2836974	0.545	rs8128901	chr21:40710419	G/A	cg11644478	chr21:40555479	PSMG1	0.64	10.59	0.44	1.27e-23	Cognitive function;
LGG	trans	rs72991	0.595	rs10892742	chr11:121229932	G/A	cg27192990	chr6:129479024	LAMA2	-0.6	-9.51	-0.4	1.02e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg09845145	chr15:78292470	TBC1D2B	0.67	13.06	0.52	2.05e-33	Coronary artery disease or large artery stroke;
LGG	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.04	-0.31	6.98e-12	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.547	rs9505475	chr6:8542890	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.12	0.39	2.36e-18	Motion sickness;
LGG	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg26898376	chr11:64110657	CCDC88B	0.33	7.39	0.32	6.89e-13	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs782590	0.935	rs782568	chr2:55881538	T/C	cg18811423	chr2:55921094	PNPT1	0.9	21.12	0.7	7.9e-70	Metabolic syndrome;
LGG	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.76	0.3	4.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1577917	0.771	rs2842601	chr6:86330133	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.88	-0.48	1.37e-28	Response to antipsychotic treatment;
LGG	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.3	0.63	4.33e-52	Cognitive function;
LGG	cis	rs7737355	0.947	rs40989	chr5:130992284	T/G	cg06307176	chr5:131281290	NA	0.58	9.45	0.4	1.75e-19	Life satisfaction;
LGG	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg05333889	chr7:157238977	NA	-0.63	-13.01	-0.52	3.34e-33	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.69	0.37	6.19e-17	Neuroticism;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs483180	0.531	rs541503	chr1:120208297	A/G	cg19096424	chr1:120255104	PHGDH	-0.56	-10.02	-0.42	1.61e-21	Macular telangiectasia type 2;
LGG	cis	rs9863	0.861	rs9971695	chr12:124413491	G/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.01	-0.31	8.6e-12	White blood cell count;
LGG	cis	rs739401	0.572	rs410820	chr11:3080102	G/A	cg08508325	chr11:3079039	CARS	-0.61	-13.39	-0.53	8.56e-35	Longevity;
LGG	cis	rs2865126	0.818	rs2865128	chr18:10764029	A/G	cg21165219	chr18:10698044	FAM38B	-0.46	-7.44	-0.33	5.06e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg11161011	chr14:65562177	MAX	-0.63	-12.28	-0.5	3.27e-30	Obesity-related traits;
LGG	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg21427119	chr20:30132790	HM13	-0.49	-8.07	-0.35	6.07e-15	Mean corpuscular hemoglobin;
LGG	cis	rs2307022	0.586	rs11075673	chr16:68404425	G/A	cg07273125	chr16:68295692	NA	0.44	9.81	0.41	8.95e-21	Body mass index;
LGG	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg20913747	chr6:44695427	NA	-0.67	-11.99	-0.49	4.89e-29	Total body bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10620501	chr8:37620046	PROSC	-0.46	-6.76	-0.3	4.04e-11	Systemic lupus erythematosus;
LGG	cis	rs17504614	0.678	rs17504263	chr2:51061240	T/C	cg23851515	chr2:51057218	NRXN1	0.47	7.75	0.34	5.99e-14	Educational attainment (years of education);
LGG	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.22	-0.49	5.65e-30	Chronic sinus infection;
LGG	cis	rs12477438	0.501	rs4851206	chr2:100068069	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.88	-0.3	1.95e-11	Chronic sinus infection;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs12493885	0.725	rs61793489	chr3:153731156	T/C	cg17054900	chr3:154042577	DHX36	-0.72	-8.75	-0.38	3.92e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13421350	0.579	rs12622724	chr2:173324908	A/G	cg15021238	chr2:173305865	ITGA6	0.77	8.85	0.38	1.87e-17	Diabetic kidney disease;
LGG	cis	rs4356932	0.967	rs6532103	chr4:76953885	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.7	-0.3	6.24e-11	Blood protein levels;
LGG	cis	rs4936891	0.577	rs1453650	chr11:123921929	A/G	cg22125253	chr11:123886957	OR10G4	-0.52	-8.73	-0.38	4.74e-17	Male fertility;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg04025307	chr7:1156635	C7orf50	0.81	17.06	0.62	5.65e-51	Longevity;Endometriosis;
LGG	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg21399703	chr1:247681439	NA	0.66	12.04	0.49	3.05e-29	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.6	-0.37	1.24e-16	Height;
LGG	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.9e-22	Axial length;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.638	rs6960778	chr7:66071597	C/T	cg18876405	chr7:65276391	NA	-0.63	-11.76	-0.48	4.21e-28	Aortic root size;
LGG	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg11764359	chr7:65958608	NA	0.63	9.54	0.41	8.46e-20	Aortic root size;
LGG	cis	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs9815354	0.904	rs4621303	chr3:41839370	T/A	cg03022575	chr3:42003672	ULK4	0.65	8.38	0.36	6.21e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4789452	0.967	rs12451315	chr17:75372126	C/G	cg06761530	chr17:75373219	SEPT9	-0.38	-7.48	-0.33	3.89e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs11096990	0.600	rs6835337	chr4:39282809	T/A	cg24403649	chr4:39172243	NA	-0.4	-7.17	-0.32	3.03e-12	Cognitive function;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg25811766	chr13:21894605	NA	0.81	16.29	0.6	1.7e-47	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs36051895	0.632	rs2381213	chr9:5168871	A/G	cg02405213	chr9:5042618	JAK2	0.66	11.29	0.46	2.78e-26	Pediatric autoimmune diseases;
LGG	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.23	-0.46	4.84e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg18200150	chr17:30822561	MYO1D	-0.51	-9.85	-0.42	6.69e-21	Schizophrenia;
LGG	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg21918786	chr6:109611834	NA	-0.48	-8.94	-0.38	9.25e-18	Reticulocyte fraction of red cells;
LGG	cis	rs11971779	0.680	rs7785903	chr7:139122643	T/C	cg07862535	chr7:139043722	LUC7L2	0.45	7.42	0.33	5.84e-13	Diisocyanate-induced asthma;
LGG	cis	rs9815354	0.812	rs73073226	chr3:42005838	T/C	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4740619	0.619	rs4741559	chr9:16041982	G/A	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs8028182	0.636	rs7495610	chr15:75784441	T/C	cg20655648	chr15:75932815	IMP3	0.47	7.82	0.34	3.55e-14	Sudden cardiac arrest;
LGG	cis	rs727505	1.000	rs10246424	chr7:124494861	A/G	cg23710748	chr7:124431027	NA	-0.53	-10.0	-0.42	1.83e-21	Lewy body disease;
LGG	cis	rs4595586	0.545	rs925828	chr12:39364222	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg02023728	chr11:77925099	USP35	0.38	6.72	0.3	5.43e-11	Alzheimer's disease (survival time);
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.13	-0.35	4e-15	IgG glycosylation;
LGG	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.23	-0.32	1.97e-12	Retinal vascular caliber;
LGG	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.83	0.45	1.64e-24	Rheumatoid arthritis;
LGG	cis	rs6882076	0.961	rs4704827	chr5:156392089	T/C	cg12943317	chr5:156479607	HAVCR1	-0.64	-11.33	-0.47	1.89e-26	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg27432699	chr2:27873401	GPN1	0.7	14.12	0.55	6.41e-38	Oral cavity cancer;
LGG	cis	rs78456975	1.000	rs72778004	chr2:1571892	T/A	cg26248373	chr2:1572462	NA	-0.7	-9.01	-0.39	5.23e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05900347	chr2:105461392	NA	0.44	7.03	0.31	7.38e-12	Cognitive performance;
LGG	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14019695	chr9:139328340	INPP5E	0.43	7.71	0.34	7.83e-14	Monocyte percentage of white cells;
LGG	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.65	-0.37	8.43e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg25173405	chr17:45401733	C17orf57	-0.49	-8.06	-0.35	6.38e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4684776	0.867	rs1562616	chr3:11374151	C/T	cg24705426	chr3:11550659	ATG7	-0.45	-8.52	-0.37	2.28e-16	Small vessel stroke;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg02002194	chr4:3960332	NA	-0.43	-8.36	-0.36	7.2e-16	Mood instability;
LGG	cis	rs1007190	0.570	rs8064954	chr17:42867443	A/C	cg15406952	chr17:42872593	NA	-1.14	-14.06	-0.55	1.23e-37	DNA methylation (variation);
LGG	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.39	0.43	7.46e-23	Diabetic retinopathy;
LGG	cis	rs870825	0.616	rs6552810	chr4:185644143	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs8017423	0.967	rs61989980	chr14:90727635	C/T	cg04374321	chr14:90722782	PSMC1	0.9	18.94	0.66	1.2e-59	Mortality in heart failure;
LGG	cis	rs9397585	0.857	rs6913406	chr6:153386942	G/A	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.28e-38	Body mass index;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs2285947	0.838	rs976516	chr7:21581561	A/G	cg03697024	chr7:21583438	DNAH11	0.33	7.73	0.34	6.89e-14	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg07157834	chr1:205819609	PM20D1	0.71	16.17	0.6	5.7e-47	Menarche (age at onset);
LGG	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg21452805	chr1:244014465	NA	0.65	7.83	0.34	3.26e-14	RR interval (heart rate);
LGG	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg06618935	chr21:46677482	NA	-0.47	-9.3	-0.4	5.76e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.58	-0.33	1.87e-13	Neuroticism;
LGG	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.81	0.3	3.08e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg08250081	chr4:10125330	NA	-0.38	-7.18	-0.32	2.77e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg18898632	chr2:242989856	NA	-0.8	-9.95	-0.42	2.8e-21	Obesity-related traits;
LGG	cis	rs240764	0.817	rs239242	chr6:101092776	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	4.99e-14	Neuroticism;
LGG	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.37	-0.36	6.99e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.58	0.33	1.96e-13	Obesity-related traits;
LGG	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg10556349	chr10:835070	NA	-0.27	-6.7	-0.3	6.16e-11	Survival in rectal cancer;
LGG	cis	rs6500395	0.926	rs11643272	chr16:48639723	T/C	cg16662043	chr16:48846231	NA	0.37	7.29	0.32	1.39e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg08859206	chr1:53392774	SCP2	0.46	9.1	0.39	2.65e-18	Monocyte count;
LGG	cis	rs2742417	0.603	rs2064062	chr3:45761115	G/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.47	-0.4	1.39e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs78487399	0.808	rs7567535	chr2:43668261	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.72	-0.3	5.43e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg02002194	chr4:3960332	NA	-0.4	-7.06	-0.31	6.08e-12	Retinal vascular caliber;
LGG	cis	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg26695010	chr11:65641043	EFEMP2	-0.42	-6.67	-0.3	7.25e-11	Breast cancer;
LGG	cis	rs2180341	0.538	rs11556354	chr6:127664661	G/A	cg27446573	chr6:127587934	RNF146	0.67	12.09	0.49	1.9e-29	Breast cancer;
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.73	0.38	4.53e-17	Bipolar disorder;
LGG	cis	rs752010	0.806	rs4457567	chr1:42091407	C/T	cg16096631	chr1:42092165	HIVEP3	0.81	24.92	0.76	1.52e-87	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3740540	0.530	rs10794163	chr10:126291398	A/G	cg04949429	chr10:126290192	LHPP	0.6	11.5	0.47	4.35e-27	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg03733263	chr8:22462867	KIAA1967	1.04	27.12	0.78	1.11e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg14227996	chr4:17616232	MED28	-0.52	-6.74	-0.3	4.82e-11	Opioid sensitivity;
LGG	trans	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs6693295	0.625	rs6680215	chr1:246347153	G/A	cg11798871	chr1:246315928	SMYD3	-0.42	-7.36	-0.32	8.61e-13	Migraine - clinic-based;Migraine with aura;
LGG	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg06606381	chr12:133084897	FBRSL1	-1.27	-11.76	-0.48	4.24e-28	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.692	rs762810	chr14:65544367	C/A	cg26396452	chr14:65542826	MAX	0.41	8.14	0.35	3.69e-15	Obesity-related traits;
LGG	cis	rs877426	0.681	rs61973920	chr13:114836067	C/A	cg27119904	chr13:114814333	RASA3	0.35	7.23	0.32	2.01e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg13206674	chr6:150067644	NUP43	0.66	15.4	0.58	1.63e-43	Lung cancer;
LGG	cis	rs2901460	0.509	rs6721488	chr2:62071562	A/T	cg02183531	chr2:62113199	CCT4	-0.46	-8.09	-0.35	5.17e-15	Mean corpuscular volume;
LGG	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.86	0.45	1.24e-24	Bone mineral density;
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg14092988	chr3:52407081	DNAH1	0.31	8.33	0.36	9.35e-16	Bipolar disorder;
LGG	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg05775895	chr3:12838266	CAND2	0.56	9.48	0.4	1.31e-19	QRS complex (12-leadsum);
LGG	cis	rs9911578	1.000	rs8067571	chr17:56868856	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.55e-45	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs200996	chr6:27811828	G/A	cg06606381	chr12:133084897	FBRSL1	-0.98	-10.65	-0.44	7.73e-24	Depression;
LGG	cis	rs72772090	0.520	rs56325109	chr5:96112295	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10876993	0.928	rs1678530	chr12:58054076	A/C	cg18357645	chr12:58087776	OS9	0.69	12.35	0.5	1.79e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg12395012	chr8:11607386	GATA4	-0.39	-7.19	-0.32	2.66e-12	Monocyte count;
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08645402	chr16:4508243	NA	-0.51	-9.69	-0.41	2.52e-20	Schizophrenia;
LGG	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg21518248	chr2:162101506	NA	0.23	7.28	0.32	1.44e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs1801251	0.685	rs1515961	chr2:233623763	C/A	cg08000102	chr2:233561755	GIGYF2	0.56	9.64	0.41	3.63e-20	Coronary artery disease;
LGG	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg10523679	chr1:76189770	ACADM	0.77	14.61	0.56	4.92e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs5753618	0.583	rs5753632	chr22:31863097	C/T	cg02404636	chr22:31891804	SFI1	0.38	7.03	0.31	7.5e-12	Colorectal cancer;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.08	-0.35	5.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.12	0.57	3e-42	Platelet count;
LGG	cis	rs6912958	0.712	rs6454638	chr6:88329427	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	8.16	0.35	3.09e-15	Monocyte percentage of white cells;
LGG	cis	rs3789045	0.520	rs2010432	chr1:204462619	G/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.78	-0.38	3.28e-17	Educational attainment (college completion);
LGG	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs9309473	0.847	rs13538	chr2:73868328	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.22	-0.32	2.12e-12	Metabolite levels;
LGG	cis	rs8077889	0.917	rs58283314	chr17:41905963	T/G	cg26893861	chr17:41843967	DUSP3	0.9	15.49	0.58	6.74e-44	Triglycerides;
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg24575275	chr7:1094737	C7orf50	-0.44	-8.87	-0.38	1.6e-17	Longevity;Endometriosis;
LGG	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.25	-0.77	1.05e-93	Height;
LGG	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg02549819	chr16:58548995	SETD6	1.45	13.97	0.54	2.81e-37	Schizophrenia;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-7.35	-0.32	8.75e-13	Schizophrenia;
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg16301924	chr13:53314226	LECT1	-0.41	-8.21	-0.36	2.18e-15	Lewy body disease;
LGG	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	9.19	0.39	1.32e-18	Height;
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.47	0.4	1.49e-19	Life satisfaction;
LGG	cis	rs9611198	0.765	rs5757721	chr22:39947574	A/G	cg03390717	chr22:39966585	CACNA1I	0.34	7.07	0.31	5.6e-12	Schizophrenia;
LGG	cis	rs7949030	0.523	rs67308910	chr11:62377359	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.55	11.16	0.46	8.92e-26	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg04166393	chr7:2884313	GNA12	0.48	9.47	0.4	1.49e-19	Height;
LGG	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs6120849	0.754	rs6088686	chr20:33623437	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs7226408	0.857	rs72885278	chr18:34441154	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.97	-0.31	1.09e-11	Obesity-related traits;
LGG	cis	rs9457247	1.000	rs422780	chr6:167406209	A/G	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	trans	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg15556689	chr8:8085844	FLJ10661	0.4	6.83	0.3	2.72e-11	Retinal vascular caliber;
LGG	cis	rs7927771	0.524	rs7107922	chr11:47669289	C/A	cg20307385	chr11:47447363	PSMC3	0.56	10.88	0.45	1.04e-24	Subjective well-being;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	9.21	0.39	1.12e-18	Obesity-related traits;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg09699651	chr6:150184138	LRP11	0.53	9.23	0.39	9.61e-19	Lung cancer;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg23758822	chr17:41437982	NA	0.87	15.57	0.59	2.99e-44	Menopause (age at onset);
LGG	cis	rs6871536	1.000	rs7449456	chr5:131953427	C/T	cg04303330	chr5:131992430	IL13	0.3	7.18	0.32	2.75e-12	Asthma (childhood onset);
LGG	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg16096631	chr1:42092165	HIVEP3	-0.47	-10.13	-0.43	6.18e-22	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg06848047	chr4:90757629	SNCA	-0.41	-7.85	-0.34	2.97e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg14926445	chr8:58193284	C8orf71	-0.46	-7.2	-0.32	2.51e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	1.000	rs4660335	chr1:46474718	C/T	cg03146154	chr1:46216737	IPP	0.55	10.02	0.42	1.58e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6732160	0.774	rs1367291	chr2:73374865	A/T	cg01422370	chr2:73384389	NA	0.54	10.48	0.44	3.27e-23	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14871712	chr9:102861491	INVS;ERP44	0.46	6.75	0.3	4.49e-11	Gut microbiome composition (summer);
LGG	cis	rs2640806	0.505	rs6997446	chr8:97366458	G/A	cg22138393	chr8:97340270	PTDSS1	0.28	7.3	0.32	1.3e-12	Obesity-related traits;
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg18357526	chr6:26021779	HIST1H4A	0.57	9.75	0.41	1.52e-20	Height;
LGG	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg21238619	chr17:78079768	GAA	-0.35	-7.26	-0.32	1.64e-12	Yeast infection;
LGG	cis	rs17102423	0.594	rs1124751	chr14:65567601	C/A	cg11161011	chr14:65562177	MAX	-0.65	-12.46	-0.5	5.96e-31	Obesity-related traits;
LGG	cis	rs3820068	0.705	rs4646063	chr1:15829813	G/A	cg05660106	chr1:15850417	CASP9	1.1	25.0	0.76	6.49e-88	Systolic blood pressure;
LGG	cis	rs7503807	0.688	rs901062	chr17:78595674	C/T	cg18469159	chr17:78755841	RPTOR	-0.37	-6.91	-0.31	1.61e-11	Obesity;
LGG	cis	rs9513627	1.000	rs4466950	chr13:100166875	G/T	cg25919922	chr13:100150906	NA	0.74	7.93	0.35	1.62e-14	Obesity-related traits;
LGG	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg13397898	chr9:133768931	QRFP	-0.42	-8.39	-0.36	5.77e-16	Bilirubin levels;
LGG	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg06636001	chr8:8085503	FLJ10661	0.49	8.63	0.37	9.71e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs62238980	0.614	rs9609388	chr22:32334739	G/A	cg02631450	chr22:32366979	NA	0.77	7.32	0.32	1.11e-12	Childhood ear infection;
LGG	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg24623649	chr8:11872141	NA	-0.3	-7.04	-0.31	7.15e-12	Neuroticism;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.27	-0.36	1.42e-15	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6421948	chr6:8531020	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.67	0.51	8.22e-32	Motion sickness;
LGG	trans	rs17685	0.632	rs1859793	chr7:75821283	G/A	cg19862616	chr7:65841803	NCRNA00174	1.02	22.09	0.72	2.34e-74	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg21238619	chr17:78079768	GAA	-0.37	-7.56	-0.33	2.18e-13	Yeast infection;
LGG	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg08470875	chr2:26401718	FAM59B	-0.41	-8.07	-0.35	6.11e-15	Gut microbiome composition (summer);
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg20790798	chr5:1857306	NA	-0.44	-7.21	-0.32	2.23e-12	Cardiovascular disease risk factors;
LGG	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg18709589	chr6:96969512	KIAA0776	0.43	7.11	0.31	4.57e-12	Migraine;Coronary artery disease;
LGG	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.62	-0.67	7.91e-63	Height;
LGG	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg04727924	chr7:799746	HEATR2	-0.49	-7.83	-0.34	3.32e-14	Cerebrospinal P-tau181p levels;
LGG	trans	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg06521331	chr12:34319734	NA	0.5	9.24	0.39	8.91e-19	Bladder cancer;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.76	-0.3	4.2e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28374715	0.578	rs8036026	chr15:41630499	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.66	-0.84	1.68e-126	Ulcerative colitis;
LGG	cis	rs9783347	0.961	rs4150588	chr11:18360131	G/A	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.25	-0.32	1.74e-12	Pancreatic cancer;
LGG	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg01422370	chr2:73384389	NA	0.53	9.82	0.42	8.69e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10089	0.904	rs2228112	chr5:127469859	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.97	0.49	5.87e-29	Ileal carcinoids;
LGG	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg18876405	chr7:65276391	NA	0.56	10.16	0.43	4.86e-22	Aortic root size;
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg00149659	chr3:10157352	C3orf10	0.88	11.36	0.47	1.54e-26	Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.09	0.31	5.19e-12	Lung cancer;
LGG	cis	rs2108225	0.967	rs7785790	chr7:107449896	C/T	cg18560240	chr7:107437656	SLC26A3	0.54	9.61	0.41	4.7e-20	Ulcerative colitis;
LGG	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg00376283	chr12:123451042	ABCB9	0.65	10.67	0.44	6.51e-24	Neutrophil percentage of white cells;
LGG	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg12463550	chr7:65579703	CRCP	-0.52	-8.66	-0.37	7.76e-17	Aortic root size;
LGG	trans	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs3820068	0.705	rs41486146	chr1:15900517	A/G	cg05660106	chr1:15850417	CASP9	-1.13	-23.7	-0.74	6.48e-82	Systolic blood pressure;
LGG	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg10483660	chr13:112241077	NA	0.34	6.64	0.3	8.62e-11	Menarche (age at onset);
LGG	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.21e-35	Corneal astigmatism;
LGG	cis	rs2905347	0.895	rs2961282	chr7:22640389	C/G	cg23521230	chr7:22704884	NA	0.37	6.69	0.3	6.57e-11	Major depression and alcohol dependence;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.65	0.44	7.52e-24	Personality dimensions;
LGG	cis	rs8067545	0.512	rs34726000	chr17:19887821	G/T	cg13482628	chr17:19912719	NA	0.49	8.27	0.36	1.47e-15	Schizophrenia;
LGG	cis	rs698833	0.962	rs786406	chr2:44735953	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	-0.48	-7.23	-0.32	2.03e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg17237111	chr4:114682438	CAMK2D	0.37	6.87	0.3	2.12e-11	Corneal astigmatism;
LGG	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.87	0.34	2.57e-14	Neuroticism;
LGG	cis	rs7660520	0.557	rs76004373	chr4:183731011	C/G	cg09197432	chr4:183729176	NA	0.62	8.71	0.38	5.5e-17	Pediatric autoimmune diseases;
LGG	cis	rs9399137	0.507	rs4896129	chr6:135349845	C/T	cg22676075	chr6:135203613	NA	0.43	7.63	0.33	1.33e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg03806693	chr22:41940476	POLR3H	-0.53	-8.19	-0.36	2.49e-15	Neuroticism;
LGG	cis	rs9513627	1.000	rs3928270	chr13:100184268	A/G	cg25919922	chr13:100150906	NA	0.73	7.73	0.34	6.64e-14	Obesity-related traits;
LGG	cis	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg26384229	chr12:38710491	ALG10B	0.93	20.76	0.69	3.96e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12618769	0.597	rs72819996	chr2:99059983	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.56e-17	Bipolar disorder;
LGG	trans	rs4714291	0.698	rs9296321	chr6:40118352	C/T	cg02267698	chr19:7991119	CTXN1	-0.51	-8.63	-0.37	9.83e-17	Strep throat;
LGG	cis	rs7917772	0.582	rs7922780	chr10:104401203	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.04	-0.39	4.34e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10267417	0.603	rs4275126	chr7:19911030	A/G	cg05791153	chr7:19748676	TWISTNB	0.58	7.64	0.33	1.23e-13	Night sleep phenotypes;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	7.86	0.34	2.73e-14	Lung function (FEV1/FVC);
LGG	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg03929089	chr4:120376271	NA	0.68	10.68	0.44	6.18e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9880211	1.000	rs9818056	chr3:136210074	C/T	cg21827317	chr3:136751795	NA	-0.48	-7.18	-0.32	2.79e-12	Body mass index;Height;
LGG	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg02002194	chr4:3960332	NA	0.38	6.92	0.31	1.5e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs35883536	0.647	rs10875317	chr1:101045438	G/T	cg06223162	chr1:101003688	GPR88	-0.4	-9.7	-0.41	2.25e-20	Monocyte count;
LGG	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg13010199	chr12:38710504	ALG10B	0.47	9.28	0.4	6.42e-19	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs2734839	0.964	rs2734838	chr11:113286501	A/G	cg14159747	chr11:113255604	NA	0.28	7.35	0.32	8.76e-13	Information processing speed;
LGG	trans	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg11441553	chr12:57614120	NXPH4	-0.58	-7.2	-0.32	2.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs2273669	0.667	rs76094073	chr6:109288036	C/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.4	-0.36	5.66e-16	Prostate cancer;
LGG	cis	rs4561483	0.582	rs35063476	chr16:12044301	A/G	cg08843971	chr16:11963173	GSPT1	-0.57	-12.54	-0.5	3.01e-31	Testicular germ cell tumor;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.7	-0.3	5.99e-11	Lung cancer;
LGG	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg05084668	chr3:125655381	ALG1L	-0.57	-7.66	-0.34	1.12e-13	Blood pressure (smoking interaction);
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg08742575	chr21:47604166	C21orf56	-0.53	-8.94	-0.38	9.62e-18	Testicular germ cell tumor;
LGG	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.12	-0.39	2.25e-18	Mean corpuscular volume;
LGG	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg27661571	chr11:113659931	NA	-0.58	-8.02	-0.35	8.97e-15	Hip circumference adjusted for BMI;
LGG	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.55	0.33	2.29e-13	Schizophrenia;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg13395646	chr4:1353034	KIAA1530	0.47	7.96	0.35	1.3e-14	Obesity-related traits;
LGG	trans	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-8.43	-0.36	4.48e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.575	rs11604704	chr11:111764396	G/A	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14552260	chr9:36572685	MELK	0.49	7.62	0.33	1.48e-13	Gut microbiome composition (summer);
LGG	cis	rs9462027	0.628	rs9462006	chr6:34710327	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-11.01	-0.46	3.47e-25	Systemic lupus erythematosus;
LGG	cis	rs1620921	0.565	rs28544460	chr6:161271777	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7945705	0.967	rs1569408	chr11:8909732	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.16	0.32	3.24e-12	Hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06312776	chr11:67374151	NDUFV1	0.48	7.4	0.33	6.52e-13	Gut microbiome composition (summer);
LGG	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg01043669	chr3:72786069	NA	0.44	7.2	0.32	2.52e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg01221209	chr5:554886	NA	-0.45	-6.72	-0.3	5.38e-11	Obesity-related traits;
LGG	cis	rs9911578	1.000	rs8071916	chr17:56660279	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-9.62	-0.41	4.15e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.597	rs17505088	chr2:99149473	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.56	0.37	1.62e-16	Bipolar disorder;
LGG	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg22044901	chr15:68126292	NA	-0.38	-6.68	-0.3	6.69e-11	Restless legs syndrome;
LGG	cis	rs4862307	0.514	rs7696176	chr4:185014390	A/G	cg06737308	chr4:185021514	ENPP6	0.64	12.4	0.5	1.08e-30	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg01238044	chr22:24384105	GSTT1	-0.44	-7.38	-0.32	7.43e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1620921	0.967	rs783174	chr6:161171919	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.41	-0.33	5.89e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg02725872	chr8:58115012	NA	-0.83	-11.7	-0.48	6.73e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg25647823	chr17:719411	NXN	-0.39	-6.73	-0.3	5.03e-11	Alzheimer's disease (survival time);
LGG	cis	rs1595825	0.891	rs16825188	chr2:198741134	G/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.81	-0.3	3.08e-11	Ulcerative colitis;
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg04166393	chr7:2884313	GNA12	0.44	8.32	0.36	9.73e-16	Height;
LGG	trans	rs61931739	0.534	rs2636072	chr12:34062386	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.91	0.42	3.97e-21	Morning vs. evening chronotype;
LGG	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.22	0.32	2.18e-12	Diabetic retinopathy;
LGG	cis	rs12681366	0.663	rs2919666	chr8:95465287	T/C	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1371867	0.846	rs1788199	chr8:101292854	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.78	-0.38	3.26e-17	Atrioventricular conduction;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg17644776	chr2:200775616	C2orf69	-0.54	-7.28	-0.32	1.48e-12	Schizophrenia;
LGG	trans	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.68	12.04	0.49	3.13e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07923666	chr12:49932857	KCNH3	-0.51	-7.67	-0.34	1.04e-13	Resting heart rate;
LGG	cis	rs11191270	1.000	rs4919624	chr10:104021085	A/G	cg15320455	chr10:103880129	LDB1	0.47	6.68	0.3	6.94e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28785552	0.966	rs7247272	chr19:53236331	C/T	cg10871876	chr19:53194124	ZNF83	-0.81	-16.53	-0.61	1.43e-48	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs701145	1.000	rs355784	chr3:153986371	A/C	cg17054900	chr3:154042577	DHX36	0.99	12.39	0.5	1.24e-30	Coronary artery disease;
LGG	cis	rs1256531	0.661	rs61987770	chr14:66163780	G/A	cg15999311	chr14:65749247	NA	0.81	6.73	0.3	5e-11	Conduct disorder (symptom count);
LGG	cis	rs2845885	0.793	rs57779243	chr11:63882363	G/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.69	8.27	0.36	1.46e-15	Body mass index;
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg00864171	chr11:67383662	NA	0.54	9.34	0.4	4.12e-19	Mean corpuscular volume;
LGG	cis	rs7940866	0.774	rs10894292	chr11:130820757	C/T	cg12179176	chr11:130786555	SNX19	0.75	14.19	0.55	3.49e-38	Schizophrenia;
LGG	cis	rs12478296	0.901	rs73007142	chr2:243010852	T/C	cg18898632	chr2:242989856	NA	-0.87	-9.39	-0.4	2.75e-19	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.83	-0.48	2.09e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs2070488	0.662	rs7375040	chr3:38469116	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.65	11.52	0.47	3.67e-27	Electrocardiographic conduction measures;
LGG	cis	rs4950322	0.518	rs72692970	chr1:146804618	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	18.74	0.66	9.54e-59	Testicular germ cell tumor;
LGG	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg00294572	chr6:26285232	NA	0.4	6.91	0.31	1.66e-11	Educational attainment;
LGG	cis	rs6733011	0.508	rs12712041	chr2:99522059	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.93	-0.31	1.43e-11	Bipolar disorder;
LGG	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg02297831	chr4:17616191	MED28	-0.44	-8.17	-0.35	2.96e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.03	-0.31	7.23e-12	Red cell distribution width;
LGG	cis	rs7143963	0.945	rs8013266	chr14:103326780	T/C	cg23020514	chr14:103360112	TRAF3	0.48	9.6	0.41	5.05e-20	Body mass index;
LGG	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg11380483	chr2:127933992	NA	-0.38	-7.36	-0.32	8.62e-13	Self-rated health;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.96e-18	Cognitive test performance;
LGG	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg20488157	chr14:104394430	TDRD9	0.56	9.12	0.39	2.29e-18	Bipolar disorder;
LGG	cis	rs6800768	0.658	rs938080	chr3:24149658	C/G	cg10674438	chr3:24145617	LOC152024	-0.35	-7.16	-0.32	3.29e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08341821	chr5:81573780	RPS23	0.46	6.75	0.3	4.56e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.9	0.34	2e-14	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg14926445	chr8:58193284	C8orf71	-0.8	-9.73	-0.41	1.81e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg27661571	chr11:113659931	NA	0.56	6.92	0.31	1.5e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg24375607	chr4:120327624	NA	0.68	11.19	0.46	7.14e-26	Corneal astigmatism;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg04503457	chr17:41445688	NA	-0.37	-8.8	-0.38	2.76e-17	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.85	0.38	1.91e-17	Joint mobility (Beighton score);
LGG	cis	rs4639966	0.836	rs1893029	chr11:118610826	G/T	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.25	-0.36	1.69e-15	Systemic lupus erythematosus;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg12855166	chr17:30846586	MYO1D	0.38	6.8	0.3	3.19e-11	Schizophrenia;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg11141652	chr22:24348549	GSTTP1	-0.4	-6.86	-0.3	2.15e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs758324	0.898	rs11958749	chr5:131166014	T/C	cg06307176	chr5:131281290	NA	0.56	9.4	0.4	2.57e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg02753203	chr1:228287806	NA	-0.64	-11.74	-0.48	4.69e-28	Diastolic blood pressure;
LGG	trans	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	7.33e-43	Height;
LGG	cis	rs4696584	0.877	rs59686383	chr4:155400718	T/C	cg13738195	chr4:155413469	DCHS2	-0.36	-7.17	-0.32	2.95e-12	Folding of antihelix;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22322834	chr12:50135138	TMBIM6	-0.42	-6.96	-0.31	1.15e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs6840360	0.573	rs11099806	chr4:152269116	G/T	cg25486957	chr4:152246857	NA	-0.41	-7.24	-0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg13453750	chr1:205783389	SLC41A1	-0.37	-7.26	-0.32	1.63e-12	Menarche (age at onset);
LGG	trans	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.65	0.54	6.52e-36	Obesity-related traits;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs1497828	0.956	rs2815242	chr1:217552998	C/T	cg04411442	chr1:217543379	NA	0.47	7.91	0.34	1.96e-14	Dialysis-related mortality;
LGG	cis	rs5769707	0.681	rs739236	chr22:50041602	A/G	cg06623630	chr22:50017776	C22orf34	-0.5	-9.81	-0.41	9.08e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.32	0.32	1.13e-12	Alzheimer's disease;
LGG	trans	rs826838	0.933	rs980573	chr12:39127811	T/C	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs7172689	0.866	rs67571153	chr15:81575655	G/T	cg11808699	chr15:81528661	IL16	-0.5	-10.07	-0.42	1.06e-21	Inattentive symptoms;
LGG	cis	rs6547741	0.967	rs4665986	chr2:27755168	G/A	cg27432699	chr2:27873401	GPN1	0.7	14.14	0.55	5.67e-38	Oral cavity cancer;
LGG	cis	rs13421350	0.579	rs3762618	chr2:173305847	G/C	cg15021238	chr2:173305865	ITGA6	-0.82	-9.4	-0.4	2.52e-19	Diabetic kidney disease;
LGG	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.5	7.92	0.35	1.75e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2737618	0.674	rs2821332	chr1:200085714	A/T	cg21825944	chr1:200113062	NR5A2	-0.59	-11.56	-0.47	2.57e-27	Uric acid levels;
LGG	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22509189	chr2:225307070	NA	0.59	9.55	0.41	7.82e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg08847335	chr10:891726	LARP4B	-0.53	-9.0	-0.39	6.07e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg22535103	chr8:58192502	C8orf71	-1.05	-16.16	-0.6	6.34e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg22875332	chr1:76189707	ACADM	0.6	10.09	0.42	9.23e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12230010	chr10:72163718	EIF4EBP2	0.45	7.2	0.32	2.39e-12	Gut microbiome composition (summer);
LGG	trans	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg07817883	chr1:32538562	TMEM39B	1.13	11.76	0.48	4.21e-28	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6500395	0.788	rs12446280	chr16:48651171	G/T	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.44e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs4430311	0.723	rs4590656	chr1:244002773	C/T	cg25706552	chr1:244017396	NA	-0.66	-16.1	-0.6	1.21e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs929596	0.755	rs6742078	chr2:234672639	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.74	13.73	0.54	3.04e-36	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs5756813	0.754	rs4821706	chr22:38154690	A/G	cg19171272	chr22:38449367	NA	0.4	6.83	0.3	2.67e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6942756	1.000	rs66538149	chr7:128974061	G/A	cg02491457	chr7:128862824	NA	-0.74	-13.21	-0.52	4.9e-34	White matter hyperintensity burden;
LGG	cis	rs4006360	0.524	rs4986678	chr17:39225182	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-10.96	-0.45	5.29e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7572733	0.811	rs771013	chr2:198625237	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs4788570	0.566	rs72795867	chr16:71484465	A/G	cg06353428	chr16:71660113	MARVELD3	-1.0	-13.55	-0.53	1.9e-35	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.77	-0.34	5.03e-14	Initial pursuit acceleration;
LGG	cis	rs2479724	1.000	rs2254479	chr6:41831143	G/A	cg17623882	chr6:41773611	USP49	-0.46	-7.87	-0.34	2.61e-14	Menarche (age at onset);
LGG	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg24848339	chr3:12840334	CAND2	-0.38	-8.9	-0.38	1.26e-17	QRS complex (12-leadsum);
LGG	cis	rs7481584	0.624	rs412149	chr11:3069943	G/A	cg08508325	chr11:3079039	CARS	0.42	8.19	0.36	2.65e-15	Calcium levels;
LGG	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg26384229	chr12:38710491	ALG10B	0.84	16.28	0.6	1.93e-47	Morning vs. evening chronotype;
LGG	cis	rs7781557	1.000	rs10487281	chr7:102477581	G/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.48	-0.37	2.96e-16	Colorectal adenoma (advanced);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02663265	chr8:104513186	RIMS2	0.42	6.93	0.31	1.39e-11	Gut microbiome composition (summer);
LGG	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg04000281	chr11:63949212	NA	-0.42	-8.02	-0.35	8.66e-15	Platelet count;
LGG	cis	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg00262122	chr8:11665843	FDFT1	0.42	6.65	0.3	8.2e-11	Myopia (pathological);
LGG	cis	rs4268898	1.000	rs4268898	chr2:24490413	C/T	cg06627628	chr2:24431161	ITSN2	0.52	8.72	0.38	5.08e-17	Asthma;
LGG	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg10661904	chr17:79619235	PDE6G	0.42	8.61	0.37	1.14e-16	Eye color traits;
LGG	cis	rs67311347	0.955	rs11719205	chr3:40417258	G/A	cg13683864	chr3:40499215	RPL14	-0.99	-20.2	-0.68	1.57e-65	Renal cell carcinoma;
LGG	cis	rs4988958	0.565	rs3771154	chr2:103039360	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.66	12.31	0.5	2.48e-30	Obesity-related traits;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.42	-7.03	-0.31	7.59e-12	Longevity;Endometriosis;
LGG	cis	rs4959677	0.935	rs4320420	chr6:2496046	G/A	cg20147862	chr6:2634573	C6orf195	-0.39	-8.5	-0.37	2.56e-16	Orthostatic hypotension;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-11.04	-0.46	2.65e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg12310025	chr6:25882481	NA	-0.66	-12.32	-0.5	2.26e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg15971980	chr6:150254442	NA	0.45	8.47	0.37	3.25e-16	Lung cancer;
LGG	cis	rs12190007	0.512	rs2984464	chr6:169837242	T/C	cg15038512	chr6:170123185	PHF10	-0.45	-8.51	-0.37	2.41e-16	Obesity-related traits;
LGG	trans	rs7395662	0.929	rs34584314	chr11:48627686	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.08e-12	HDL cholesterol;
LGG	trans	rs2270927	1.000	rs2270927	chr5:75591710	C/G	cg13563193	chr19:33072644	PDCD5	0.78	10.38	0.43	7.87e-23	Mean corpuscular volume;
LGG	cis	rs11229555	0.609	rs34782543	chr11:58187398	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg07943548	chr15:86304357	KLHL25	-0.32	-6.66	-0.3	7.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.66	0.41	3.09e-20	Diabetic retinopathy;
LGG	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg15038512	chr6:170123185	PHF10	0.49	6.83	0.3	2.76e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7558370	1.000	rs11891569	chr2:3722104	C/A	cg17046650	chr2:3699563	NA	0.7	7.14	0.31	3.61e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10739663	0.520	rs3122935	chr9:128154203	A/G	cg14078157	chr9:128172775	NA	0.57	10.95	0.45	5.87e-25	Resting heart rate;
LGG	cis	rs3857536	0.813	rs9360189	chr6:66933424	A/C	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	cis	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg03929089	chr4:120376271	NA	0.69	7.56	0.33	2.17e-13	Intraocular pressure;
LGG	cis	rs10463554	0.892	rs1837256	chr5:102304556	A/G	cg23492399	chr5:102201601	PAM	-0.58	-8.69	-0.37	6.35e-17	Parkinson's disease;
LGG	cis	rs17428076	0.756	rs62181743	chr2:172552001	T/C	cg21435375	chr2:172878103	MAP1D	0.39	6.96	0.31	1.2e-11	Myopia;
LGG	cis	rs67311347	0.911	rs9863737	chr3:40439836	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-25.74	-0.77	2.28e-91	Renal cell carcinoma;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-7.36	-0.32	8.52e-13	Schizophrenia;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg20887711	chr4:1340912	KIAA1530	0.92	19.76	0.68	1.8e-63	Longevity;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg03188948	chr7:1209495	NA	0.42	7.31	0.32	1.16e-12	Longevity;Endometriosis;
LGG	cis	rs4380275	0.782	rs4468850	chr2:749467	G/T	cg14072418	chr2:740025	NA	-0.35	-6.85	-0.3	2.42e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs1568889	1.000	rs1568889	chr11:28009463	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	13.69	0.54	4.7e-36	Bipolar disorder;
LGG	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg25237894	chr2:233734115	C2orf82	0.52	9.83	0.42	7.7e-21	Coronary artery disease;
LGG	cis	rs7647973	0.925	rs4384984	chr3:49289878	T/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.35	0.36	7.83e-16	Menarche (age at onset);
LGG	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg04731861	chr2:219085781	ARPC2	0.49	12.45	0.5	6.91e-31	Colorectal cancer;
LGG	cis	rs10905065	0.965	rs10752110	chr10:5837038	T/C	cg11519256	chr10:5708881	ASB13	0.41	7.06	0.31	6.08e-12	Menopause (age at onset);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg17084299	chr6:3259239	PSMG4	0.45	6.7	0.3	5.91e-11	Hip circumference;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.93	-0.38	9.83e-18	Response to antipsychotic treatment;
LGG	cis	rs4144027	0.904	rs55696130	chr14:104341864	A/G	cg26031613	chr14:104095156	KLC1	0.44	7.02	0.31	7.94e-12	Blood metabolite levels;
LGG	cis	rs2050392	0.517	rs593400	chr10:30762088	A/G	cg25182066	chr10:30743637	MAP3K8	0.64	13.53	0.53	2.17e-35	Inflammatory bowel disease;
LGG	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg02002194	chr4:3960332	NA	0.44	7.72	0.34	7.13e-14	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg21605333	chr4:119757512	SEC24D	1.47	14.83	0.57	5.7e-41	Cannabis dependence symptom count;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.76e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs4262150	0.846	rs56313315	chr5:152307156	C/T	cg12297329	chr5:152029980	NA	-0.61	-11.05	-0.46	2.34e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.87	0.34	2.6e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.73	0.34	6.74e-14	Electroencephalogram traits;
LGG	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg15268244	chr15:77196840	NA	0.41	8.81	0.38	2.59e-17	Blood metabolite levels;
LGG	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.89	-0.38	1.39e-17	Height;
LGG	cis	rs4409675	0.576	rs7533918	chr1:28230667	G/A	cg23691781	chr1:28212827	C1orf38	0.41	11.13	0.46	1.13e-25	Corneal astigmatism;
LGG	cis	rs367943	0.672	rs1517207	chr5:112717245	G/A	cg12552261	chr5:112820674	MCC	0.57	10.42	0.44	5.35e-23	Type 2 diabetes;
LGG	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg00376283	chr12:123451042	ABCB9	-0.66	-11.4	-0.47	1.05e-26	Neutrophil percentage of white cells;
LGG	cis	rs68170813	0.559	rs4730232	chr7:106942382	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.55	-0.44	1.88e-23	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs3852123	chr4:98697586	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.04	0.31	6.78e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2274273	0.905	rs4652	chr14:55605036	A/C	cg04306507	chr14:55594613	LGALS3	0.65	18.35	0.65	6.65e-57	Protein biomarker;
LGG	cis	rs1595825	1.000	rs59441945	chr2:198879645	T/A	cg00982548	chr2:198649783	BOLL	-0.52	-7.28	-0.32	1.42e-12	Ulcerative colitis;
LGG	cis	rs9543976	1.000	rs4885324	chr13:76173747	G/A	cg01531495	chr13:76123901	UCHL3	0.63	7.59	0.33	1.81e-13	Diabetic retinopathy;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg16920238	chr17:80076378	CCDC57	-0.33	-7.28	-0.32	1.44e-12	Life satisfaction;
LGG	cis	rs1318772	1.000	rs67344014	chr5:112687127	A/C	cg12552261	chr5:112820674	MCC	0.69	8.2	0.36	2.41e-15	F-cell distribution;
LGG	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.7	-11.79	-0.48	3.01e-28	Mean platelet volume;
LGG	cis	rs9470366	0.637	rs730506	chr6:36645968	G/C	cg08179530	chr6:36648295	CDKN1A	0.55	7.52	0.33	2.89e-13	QRS duration;
LGG	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.84	-0.51	1.76e-32	Uric acid levels;
LGG	cis	rs4851254	0.584	rs35774174	chr2:100655130	T/A	cg17356467	chr2:100759845	AFF3	0.47	7.57	0.33	1.97e-13	Intelligence (multi-trait analysis);
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg09845145	chr15:78292470	TBC1D2B	-0.64	-12.66	-0.51	9.85e-32	Coronary artery disease or large artery stroke;
LGG	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg05973401	chr12:123451056	ABCB9	-0.45	-6.69	-0.3	6.31e-11	Neutrophil percentage of white cells;
LGG	cis	rs4742903	0.967	rs10820605	chr9:106881402	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.36	0.36	7.43e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4789294	0.806	rs3809691	chr17:74396421	G/C	cg27112972	chr17:74378252	NA	-0.26	-6.66	-0.3	7.55e-11	Lymphocyte percentage of white cells;
LGG	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg01657329	chr11:68192670	LRP5	-0.6	-10.88	-0.45	1.03e-24	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg11494091	chr17:61959527	GH2	0.51	8.34	0.36	8.31e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg20573242	chr4:122745356	CCNA2	0.54	10.11	0.43	7.9e-22	Type 2 diabetes;
LGG	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.1	-0.31	4.66e-12	HDL cholesterol;
LGG	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg11995313	chr8:8860691	ERI1	0.44	7.5	0.33	3.38e-13	Joint mobility (Beighton score);
LGG	cis	rs17039065	0.920	rs11932814	chr4:109461558	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.75	0.34	6.07e-14	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.72	0.54	3.61e-36	Bladder cancer;
LGG	cis	rs9814567	0.806	rs4955525	chr3:134317008	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.15	-0.46	9.57e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.27	-0.32	1.55e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9398803	0.698	rs853979	chr6:127057941	A/T	cg19875578	chr6:126661172	C6orf173	-0.49	-8.93	-0.38	9.94e-18	Male-pattern baldness;
LGG	trans	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg00938859	chr5:1591904	SDHAP3	0.82	7.32	0.32	1.1e-12	Asthma (childhood onset);
LGG	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.47	-0.4	1.43e-19	Mean corpuscular volume;
LGG	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg13256891	chr4:100009986	ADH5	0.51	8.73	0.38	4.83e-17	Alcohol dependence;
LGG	trans	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg04842962	chr6:43655489	MRPS18A	-1.12	-24.18	-0.75	4.08e-84	IgG glycosylation;
LGG	cis	rs4474465	1.000	rs11237509	chr11:78173439	C/A	cg02023728	chr11:77925099	USP35	0.4	7.15	0.32	3.31e-12	Alzheimer's disease (survival time);
LGG	cis	rs55940034	0.523	rs2149067	chr13:111062324	G/A	cg11096515	chr13:111062287	COL4A2	0.35	9.09	0.39	2.88e-18	Myocardial infarction;
LGG	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg18154014	chr19:37997991	ZNF793	-0.45	-7.85	-0.34	2.87e-14	Coronary artery calcification;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg01238044	chr22:24384105	GSTT1	-0.41	-7.04	-0.31	7.11e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4740619	0.688	rs10810484	chr9:15935338	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.1	-0.42	8.14e-22	Body mass index;
LGG	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.89	9.57	0.41	6.43e-20	Diabetic retinopathy;
LGG	cis	rs9867325	0.895	rs9879531	chr3:136638975	A/G	cg21827317	chr3:136751795	NA	-0.5	-7.3	-0.32	1.26e-12	Body mass index;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs981844	1.000	rs2606337	chr4:154656845	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	8.26e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg24848339	chr3:12840334	CAND2	0.37	8.29	0.36	1.2e-15	QRS complex (12-leadsum);
LGG	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg06640241	chr16:89574553	SPG7	0.67	11.48	0.47	5.14e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs7647973	0.626	rs35129566	chr3:49866584	T/G	cg03060546	chr3:49711283	APEH	-0.6	-8.45	-0.37	3.91e-16	Menarche (age at onset);
LGG	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11890956	chr21:40555474	PSMG1	1.2	29.59	0.81	8.01e-109	Cognitive function;
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.01	0.39	5.46e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3785574	1.000	rs2955245	chr17:61979845	T/C	cg06873352	chr17:61820015	STRADA	-0.46	-6.89	-0.3	1.83e-11	Height;
LGG	cis	rs9359856	0.564	rs72917989	chr6:90470385	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.87	-0.42	5.71e-21	Bipolar disorder;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg18279126	chr7:2041391	MAD1L1	0.33	6.92	0.31	1.49e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.98	0.42	2.17e-21	Height;
LGG	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg16414030	chr3:133502952	NA	-0.6	-10.34	-0.43	1.07e-22	Iron status biomarkers;
LGG	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27286337	chr10:134555280	INPP5A	0.87	13.62	0.53	9.48e-36	Migraine;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg03929089	chr4:120376271	NA	-0.98	-21.33	-0.7	8.39e-71	Coronary artery disease;
LGG	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.66	-0.37	7.98e-17	Blood metabolite levels;
LGG	cis	rs2562152	0.786	rs216594	chr16:103009	A/T	cg02949481	chr16:131562	MPG	0.56	8.31	0.36	1.06e-15	Glioblastoma;
LGG	cis	rs6500395	0.962	rs1477135	chr16:48726823	C/T	cg04672837	chr16:48644449	N4BP1	0.52	8.39	0.36	5.89e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09771049	chr17:66031798	KPNA2	-0.5	-7.26	-0.32	1.62e-12	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.47	-0.44	3.75e-23	Retinal vascular caliber;
LGG	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg06470251	chr20:60548479	NA	0.48	8.36	0.36	7.25e-16	Body mass index;
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg19524238	chr7:2802976	GNA12	0.37	8.64	0.37	9.38e-17	Height;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg27432699	chr2:27873401	GPN1	-0.52	-8.89	-0.38	1.38e-17	Total body bone mineral density;
LGG	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg10596483	chr8:143751796	JRK	0.53	8.3	0.36	1.14e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.5	0.33	3.24e-13	Morning vs. evening chronotype;
LGG	cis	rs7937612	1.000	rs10892582	chr11:120347715	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.89	-0.51	1.06e-32	Intraocular pressure;
LGG	cis	rs11039131	1.000	rs11039131	chr11:47232038	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-6.95	-0.31	1.24e-11	Schizophrenia;
LGG	cis	rs5756391	0.568	rs2075941	chr22:37318515	T/C	cg21209356	chr22:37319042	CSF2RB	0.42	9.64	0.41	3.76e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2244613	0.706	rs7200011	chr16:55794768	C/A	cg04521981	chr16:55850985	CES1	0.44	7.19	0.32	2.56e-12	Response to dabigatran etexilate treatment;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg11494091	chr17:61959527	GH2	0.51	8.08	0.35	5.51e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.61	-0.33	1.53e-13	Total body bone mineral density;
LGG	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg13009111	chr11:71350975	NA	-0.33	-7.23	-0.32	1.99e-12	Monocyte count;
LGG	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg13073564	chr4:8508604	NA	0.6	11.94	0.49	8.02e-29	Response to antineoplastic agents;
LGG	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17830980	chr10:43048298	ZNF37B	-0.58	-13.01	-0.52	3.4e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs4595586	0.545	rs12816776	chr12:39375817	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg26597838	chr10:835615	NA	0.55	7.1	0.31	4.87e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg13939156	chr17:80058883	NA	-0.46	-9.02	-0.39	5.15e-18	Life satisfaction;
LGG	trans	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.38	0.4	2.9e-19	Diabetic kidney disease;
LGG	cis	rs10743315	0.557	rs74974316	chr12:19344688	A/G	cg02471346	chr12:19282374	PLEKHA5	0.86	8.38	0.36	6.48e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg15145296	chr3:125709740	NA	-0.6	-7.82	-0.34	3.56e-14	Blood pressure (smoking interaction);
LGG	trans	rs8073060	0.660	rs58266733	chr17:34003812	A/T	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6748734	0.779	rs11680800	chr2:241793977	A/G	cg07537917	chr2:241836409	C2orf54	-0.39	-7.89	-0.34	2.25e-14	Urinary metabolites;
LGG	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	trans	rs9354308	0.764	rs9363473	chr6:66587713	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs11239187	0.523	rs11239168	chr10:45105272	G/A	cg03916630	chr10:45065415	NA	0.39	7.15	0.32	3.33e-12	Body mass index;
LGG	cis	rs3791406	0.500	rs11124180	chr2:240031909	C/G	cg14550559	chr2:240039617	HDAC4	-0.76	-11.48	-0.47	5.23e-27	Skin aging (microtopography measurement);
LGG	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.41	6.67	0.3	7.3e-11	Hip circumference adjusted for BMI;
LGG	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg01221209	chr5:554886	NA	-0.51	-7.58	-0.33	1.95e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs7572644	0.699	rs1506537	chr2:28181901	G/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.66	-0.3	7.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg25214090	chr10:38739885	LOC399744	0.7	12.36	0.5	1.66e-30	Corneal astigmatism;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg07747251	chr5:1868357	NA	0.47	9.44	0.4	1.8e-19	Cardiovascular disease risk factors;
LGG	trans	rs11098499	0.644	rs10009566	chr4:120558608	A/G	cg25214090	chr10:38739885	LOC399744	0.58	10.57	0.44	1.57e-23	Corneal astigmatism;
LGG	cis	rs9325144	0.555	rs6582607	chr12:38717678	T/C	cg13010199	chr12:38710504	ALG10B	-0.58	-11.03	-0.46	2.77e-25	Morning vs. evening chronotype;
LGG	cis	rs6784615	0.744	rs419604	chr3:52441606	A/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.88	0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.94e-11	Aortic root size;
LGG	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg02002194	chr4:3960332	NA	0.52	10.49	0.44	3.08e-23	Neuroticism;
LGG	cis	rs2273669	0.667	rs12195378	chr6:109284255	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.37	-0.36	7.01e-16	Prostate cancer;
LGG	cis	rs13314892	0.764	rs1897159	chr3:69870465	T/A	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.72	-0.48	5.88e-28	Life satisfaction;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg08742575	chr21:47604166	C21orf56	0.58	10.31	0.43	1.4e-22	Testicular germ cell tumor;
LGG	cis	rs7106204	0.748	rs7122986	chr11:24224634	G/A	ch.11.24196551F	chr11:24239977	NA	1.0	16.02	0.6	2.81e-46	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3859192	0.539	rs2302774	chr17:38183090	G/T	cg17467752	chr17:38218738	THRA	-0.62	-10.51	-0.44	2.54e-23	White blood cell count;
LGG	cis	rs6942756	0.688	rs2718089	chr7:128927022	G/T	cg02491457	chr7:128862824	NA	0.63	11.7	0.48	7.03e-28	White matter hyperintensity burden;
LGG	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg08847335	chr10:891726	LARP4B	-0.5	-8.98	-0.39	6.73e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs8067287	0.635	rs4343329	chr17:16840889	C/G	cg26910001	chr17:16838321	NA	0.41	8.41	0.36	4.94e-16	Diabetic kidney disease;
LGG	cis	rs62238980	0.614	rs79343805	chr22:32522040	A/C	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.66e-12	Bipolar disorder;
LGG	cis	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg00405596	chr8:11794950	NA	-0.63	-11.0	-0.46	3.82e-25	Monocyte count;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.5e-14	Bipolar disorder;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08280861	chr8:58055591	NA	0.62	7.75	0.34	5.99e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg02462569	chr6:150064036	NUP43	-0.42	-9.12	-0.39	2.24e-18	Lung cancer;
LGG	cis	rs4973397	0.765	rs10445830	chr2:232263973	C/T	cg06574960	chr2:232265084	B3GNT7	0.38	6.86	0.3	2.2e-11	Anti-saccade response;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg15627072	chr1:2432621	PLCH2	0.42	10.22	0.43	2.93e-22	Ulcerative colitis;
LGG	cis	rs526231	0.543	rs246909	chr5:102563677	A/G	cg23492399	chr5:102201601	PAM	-0.58	-8.34	-0.36	8.5e-16	Primary biliary cholangitis;
LGG	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg00405596	chr8:11794950	NA	-0.41	-6.78	-0.3	3.63e-11	Triglycerides;
LGG	cis	rs8077889	0.750	rs72836564	chr17:41935064	G/A	cg26893861	chr17:41843967	DUSP3	0.92	12.53	0.5	3.08e-31	Triglycerides;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.63	-0.37	9.79e-17	Menopause (age at onset);
LGG	cis	rs600550	0.588	rs61900468	chr11:60079555	C/T	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.85	-0.34	2.88e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.94	-0.35	1.51e-14	Myeloid white cell count;
LGG	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.2	-0.32	2.52e-12	Menarche (age at onset);
LGG	cis	rs36051895	0.664	rs3780370	chr9:5095167	A/C	cg02405213	chr9:5042618	JAK2	-0.81	-15.5	-0.58	6.23e-44	Pediatric autoimmune diseases;
LGG	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.89	-0.59	1.12e-45	Chronic sinus infection;
LGG	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg12081754	chr8:22256438	SLC39A14	1.18	28.59	0.8	2.51e-104	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs490234	0.812	rs626208	chr9:128428267	A/G	cg14078157	chr9:128172775	NA	0.38	6.65	0.3	8.48e-11	Mean arterial pressure;
LGG	cis	rs6860806	0.507	rs272882	chr5:131669161	G/T	cg07395648	chr5:131743802	NA	-0.48	-9.87	-0.42	5.39e-21	Breast cancer;
LGG	cis	rs1465370	0.720	rs2402995	chr7:130016595	C/T	cg04743876	chr7:130013617	NA	0.37	8.64	0.37	9.38e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs9354308	0.764	rs1938111	chr6:66567345	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs758324	0.773	rs11951407	chr5:131142661	T/C	cg06307176	chr5:131281290	NA	0.53	8.83	0.38	2.23e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg24375607	chr4:120327624	NA	0.52	8.77	0.38	3.47e-17	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12030002	chr3:61237226	FHIT	0.51	7.68	0.34	9.39e-14	Gut microbiome composition (summer);
LGG	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.39	0.4	2.64e-19	Rheumatoid arthritis;
LGG	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg02733842	chr7:1102375	C7orf50	-0.49	-7.86	-0.34	2.78e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12379764	chr21:47803548	PCNT	-0.42	-7.16	-0.32	3.28e-12	Testicular germ cell tumor;
LGG	cis	rs1620921	0.505	rs1344729	chr6:161204841	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4650994	0.593	rs12074085	chr1:178504163	G/A	cg19399532	chr1:178512495	C1orf220	-0.41	-7.84	-0.34	3.21e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2074193	0.569	rs215362	chr12:47740069	A/C	cg02516419	chr12:47771422	NA	0.53	7.81	0.34	3.92e-14	Migraine with aura;
LGG	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg03959625	chr15:84868606	LOC388152	0.57	9.07	0.39	3.34e-18	Schizophrenia;
LGG	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11890956	chr21:40555474	PSMG1	0.84	15.06	0.57	5.07e-42	Cognitive function;
LGG	cis	rs9399135	0.935	rs11759999	chr6:135370495	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.47	0.4	1.46e-19	Red blood cell count;
LGG	cis	rs2070488	1.000	rs2268757	chr3:38505853	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.86	18.44	0.65	2.43e-57	Electrocardiographic conduction measures;
LGG	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.17	0.32	2.98e-12	Red blood cell count;
LGG	cis	rs27434	0.583	rs34756	chr5:96152383	C/T	cg16492584	chr5:96139282	ERAP1	0.35	6.74	0.3	4.71e-11	Ankylosing spondylitis;
LGG	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.15	-0.32	3.3e-12	Sudden cardiac arrest;
LGG	cis	rs972578	0.791	rs4588289	chr22:43292632	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	3.03e-11	Mean platelet volume;
LGG	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-17.22	-0.62	1.06e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg18876405	chr7:65276391	NA	0.54	9.75	0.41	1.55e-20	Aortic root size;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05025164	chr4:1340916	KIAA1530	0.68	13.23	0.52	4.2e-34	Longevity;
LGG	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.37	-0.32	8.1e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.67	-0.41	2.83e-20	Carotid intima media thickness;
LGG	cis	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.16	-0.35	3.23e-15	Retinal vascular caliber;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	10.46	0.44	3.83e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg06766960	chr11:133703094	NA	-0.58	-11.31	-0.47	2.33e-26	Childhood ear infection;
LGG	cis	rs12220238	1.000	rs7897778	chr10:75916105	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	10.98	0.45	4.51e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg25214090	chr10:38739885	LOC399744	0.69	12.38	0.5	1.34e-30	Corneal astigmatism;
LGG	cis	rs13319406	0.546	rs6788289	chr3:189832810	G/A	cg03343083	chr3:189718843	LEPREL1	-0.5	-6.8	-0.3	3.17e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.23	0.36	1.94e-15	Obesity-related traits;
LGG	cis	rs9300255	0.568	rs3018098	chr12:123654812	T/C	cg00376283	chr12:123451042	ABCB9	0.63	9.93	0.42	3.33e-21	Neutrophil percentage of white cells;
LGG	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg24189917	chr7:1970923	MAD1L1	-0.57	-8.41	-0.36	5.25e-16	Bipolar disorder;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03324837	chr17:61044407	NA	0.4	6.77	0.3	3.86e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg05696931	chr1:227175867	NA	-0.4	-7.88	-0.34	2.4e-14	Myeloid white cell count;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.66	-12.08	-0.49	2.2e-29	Obesity-related traits;
LGG	cis	rs6558530	0.692	rs6558522	chr8:1702370	C/G	cg08198773	chr8:1697536	NA	-0.44	-7.7	-0.34	8.14e-14	Systolic blood pressure;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg05064044	chr6:292385	DUSP22	-0.48	-8.36	-0.36	7.67e-16	Menopause (age at onset);
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00631329	chr6:26305371	NA	-0.53	-9.85	-0.42	6.81e-21	Educational attainment;
LGG	cis	rs758324	0.812	rs2133706	chr5:131165216	T/G	cg06307176	chr5:131281290	NA	0.53	8.87	0.38	1.58e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6977660	0.714	rs10155949	chr7:19834747	T/C	cg05791153	chr7:19748676	TWISTNB	0.74	9.79	0.41	1.09e-20	Thyroid stimulating hormone;
LGG	cis	rs3771570	1.000	rs3771570	chr2:242382864	C/T	cg21155796	chr2:242212141	HDLBP	0.77	10.1	0.42	8.59e-22	Prostate cancer;
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg16590910	chr6:42928470	GNMT	0.45	13.3	0.53	2.06e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9902453	0.765	rs2628185	chr17:28070107	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.36	-0.56	5.86e-39	Coffee consumption (cups per day);
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg00405596	chr8:11794950	NA	-0.46	-7.62	-0.33	1.46e-13	Triglycerides;
LGG	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg15704280	chr7:45808275	SEPT13	0.73	8.63	0.37	9.79e-17	Axial length;
LGG	cis	rs72781680	0.846	rs72780108	chr2:23986780	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg18404041	chr3:52824283	ITIH1	0.61	11.87	0.48	1.42e-28	Bipolar disorder;
LGG	cis	rs1358748	0.522	rs2144656	chr1:67579386	A/G	cg02640540	chr1:67518911	SLC35D1	0.55	6.75	0.3	4.41e-11	Tuberculosis;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-14.89	-0.57	3e-41	Pancreatic cancer;
LGG	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4731207	0.596	rs1013754	chr7:124642047	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg07936489	chr17:37558343	FBXL20	-1.02	-15.27	-0.58	6.05e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs1018836	0.886	rs10112242	chr8:91642631	G/C	cg16814680	chr8:91681699	NA	-0.83	-15.89	-0.59	1.04e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs62400317	0.859	rs2038765	chr6:45076494	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.55e-22	Total body bone mineral density;
LGG	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg16486109	chr11:613632	IRF7	0.4	7.1	0.31	4.76e-12	Systemic lupus erythematosus;
LGG	cis	rs73198271	0.530	rs113160067	chr8:8654521	A/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg00700412	chr12:58011837	NA	0.38	7.41	0.33	6.07e-13	Multiple sclerosis;
LGG	trans	rs17685	0.712	rs56088021	chr7:75852480	C/T	cg19862616	chr7:65841803	NCRNA00174	1.04	22.94	0.73	2.27e-78	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.33	0.36	9.22e-16	Tonsillectomy;
LGG	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg05753993	chr18:77199432	NFATC1	0.36	6.78	0.3	3.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9916302	0.706	rs9646419	chr17:37597185	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.36	-0.58	2.56e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg01966878	chr4:90757139	SNCA	-0.33	-6.75	-0.3	4.39e-11	Dementia with Lewy bodies;
LGG	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4076764	0.515	rs4657268	chr1:163376507	A/T	cg24596788	chr1:163392923	NA	-0.55	-10.2	-0.43	3.58e-22	Motion sickness;
LGG	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	7.79	0.34	4.6e-14	Schizophrenia;
LGG	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs7215564	0.730	rs34405143	chr17:78585681	G/C	cg16980736	chr17:78789706	RPTOR	-0.66	-8.53	-0.37	2.15e-16	Myopia (pathological);
LGG	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg03342759	chr3:160939853	NMD3	-0.61	-10.3	-0.43	1.51e-22	Morning vs. evening chronotype;
LGG	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg10818794	chr15:86012489	AKAP13	-0.31	-6.74	-0.3	4.66e-11	Interstitial lung disease;
LGG	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.27	-0.32	1.59e-12	Coronary artery disease;
LGG	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.44	-0.33	4.9e-13	IgG glycosylation;
LGG	cis	rs11650494	0.710	rs76651802	chr17:47473785	A/G	cg08112188	chr17:47440006	ZNF652	1.12	12.48	0.5	5.14e-31	Prostate cancer;
LGG	cis	rs2273669	0.748	rs11759732	chr6:109370006	A/G	cg05315195	chr6:109294784	ARMC2	-0.46	-6.87	-0.3	2.03e-11	Prostate cancer;
LGG	cis	rs1348850	0.567	rs7605609	chr2:178534942	C/G	cg27490568	chr2:178487706	NA	0.5	9.88	0.42	4.97e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs477895	1.000	rs1047206	chr11:64089216	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.7	7.99	0.35	1.09e-14	Mean platelet volume;
LGG	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.5	-0.37	2.7e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.47	-0.37	3.33e-16	Bladder cancer;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg13397359	chr6:42928475	GNMT	0.58	15.95	0.6	6.06e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg00599393	chr8:22457479	C8orf58	-0.47	-8.7	-0.37	5.69e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.55	-0.33	2.32e-13	Body mass index;
LGG	cis	rs79349575	0.783	rs318095	chr17:46974734	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.18	0.36	2.76e-15	Type 2 diabetes;
LGG	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg00898013	chr13:113819073	PROZ	0.46	9.61	0.41	4.52e-20	Platelet distribution width;
LGG	trans	rs12517041	0.935	rs10062553	chr5:23294800	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg24308560	chr3:49941425	MST1R	0.23	7.18	0.32	2.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg19635926	chr16:89946313	TCF25	0.8	8.24	0.36	1.83e-15	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26236440	chr2:113341947	CHCHD5	0.45	7.27	0.32	1.53e-12	Cognitive performance;
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-19.94	-0.68	2.63e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg08677398	chr8:58056175	NA	0.56	12.31	0.5	2.6e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.37	0.32	7.87e-13	Menopause (age at onset);
LGG	trans	rs1728785	1.000	rs698728	chr16:68625253	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.16	0.43	5.12e-22	Ulcerative colitis;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg00495681	chr13:53174319	NA	0.6	11.37	0.47	1.36e-26	Lewy body disease;
LGG	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg20368463	chr18:77673604	PQLC1	0.58	7.56	0.33	2.12e-13	Opioid sensitivity;
LGG	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg03970086	chr16:88974840	CBFA2T3	0.41	7.52	0.33	2.89e-13	Social autistic-like traits;
LGG	cis	rs35740288	0.689	rs11630688	chr15:86253279	C/T	cg07943548	chr15:86304357	KLHL25	-0.36	-7.03	-0.31	7.47e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg19980929	chr12:42632907	YAF2	-0.34	-7.65	-0.33	1.21e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9815354	1.000	rs10865914	chr3:41919499	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.3	-0.36	1.13e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg00800038	chr16:89945340	TCF25	-0.62	-8.51	-0.37	2.4e-16	Skin colour saturation;
LGG	trans	rs2243480	1.000	rs68189316	chr7:65409169	C/G	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs3790455	0.965	rs3790457	chr1:156458840	C/T	cg14087168	chr1:156450669	MEF2D	0.47	7.73	0.34	6.72e-14	Migraine;
LGG	cis	rs4237845	0.804	rs11172372	chr12:58286273	T/C	cg02175503	chr12:58329896	NA	0.67	12.63	0.51	1.24e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.43	0.47	8.11e-27	Electroencephalogram traits;
LGG	cis	rs7945705	0.870	rs10840142	chr11:8906078	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.44	0.33	4.91e-13	Hemoglobin concentration;
LGG	cis	rs4262150	0.672	rs72806784	chr5:152351711	G/C	cg12297329	chr5:152029980	NA	-0.55	-8.63	-0.37	9.75e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs8002861	0.840	rs1819597	chr13:44429553	G/A	cg17145862	chr1:211918768	LPGAT1	0.94	23.15	0.73	2.52e-79	Leprosy;
LGG	cis	rs7113874	0.524	rs10769918	chr11:8609710	T/C	cg23764900	chr11:8616102	STK33	0.39	6.81	0.3	3.13e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.93	0.31	1.38e-11	Educational attainment;
LGG	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg15997130	chr1:24165203	NA	-0.5	-13.41	-0.53	7.19e-35	Immature fraction of reticulocytes;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg15971980	chr6:150254442	NA	0.44	8.79	0.38	2.89e-17	Testicular germ cell tumor;
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00166722	chr3:10149974	C3orf24	0.51	8.7	0.37	5.93e-17	Alzheimer's disease;
LGG	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	5.95e-19	Coronary artery disease;
LGG	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg23740940	chr11:68924746	NA	0.43	6.95	0.31	1.29e-11	Blond vs. brown hair color;
LGG	cis	rs3849046	0.846	rs2043273	chr5:137931091	C/T	cg10920316	chr5:137946599	NA	-0.47	-7.39	-0.32	6.84e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs34783982	0.510	rs12910277	chr15:89528773	C/T	cg09489435	chr15:89561491	NA	-0.38	-7.14	-0.31	3.71e-12	Squamous cell lung carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02467765	chr4:78978708	FRAS1	0.44	7.37	0.32	8.17e-13	Gut microbiome composition (summer);
LGG	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27297192	chr10:134578999	INPP5A	0.32	7.4	0.33	6.59e-13	Migraine;
LGG	trans	rs2389217	0.614	rs7309229	chr12:33592681	C/G	cg13010199	chr12:38710504	ALG10B	-0.37	-6.68	-0.3	6.93e-11	Morning vs. evening chronotype;
LGG	cis	rs9807989	0.507	rs10439410	chr2:102990788	A/C	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.59	-0.41	5.49e-20	Asthma;
LGG	cis	rs2916247	1.000	rs4477079	chr8:93059038	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.26	-0.36	1.51e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4430311	0.755	rs4658401	chr1:243803979	G/T	cg25706552	chr1:244017396	NA	-0.64	-15.75	-0.59	4.38e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs77741769	0.507	rs11065264	chr12:121218380	T/G	cg02419362	chr12:121203948	SPPL3	0.55	9.58	0.41	5.93e-20	Mean corpuscular volume;
LGG	cis	rs6429082	0.818	rs453315	chr1:235680585	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	10.33	0.43	1.24e-22	Adiposity;
LGG	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.84	-0.3	2.52e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg17971929	chr21:40555470	PSMG1	0.86	17.2	0.62	1.31e-51	Cognitive function;
LGG	cis	rs2067615	0.899	rs4964188	chr12:107100717	T/C	cg15890332	chr12:107067104	RFX4	0.31	8.62	0.37	1.08e-16	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13929566	chr6:152958173	SYNE1	0.46	6.77	0.3	3.95e-11	Gut microbiome composition (summer);
LGG	cis	rs3820068	0.603	rs67349836	chr1:15966176	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.78	0.61	1.08e-49	Systolic blood pressure;
LGG	cis	rs113835537	0.529	rs11227502	chr11:66274148	T/G	cg24851651	chr11:66362959	CCS	0.45	7.77	0.34	5.26e-14	Airway imaging phenotypes;
LGG	cis	rs4538187	0.906	rs11695421	chr2:63954237	T/C	cg14150252	chr2:64069583	UGP2	-0.46	-9.23	-0.39	9.63e-19	Systolic blood pressure;
LGG	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg16077055	chr2:106428750	NCK2	0.27	6.82	0.3	2.87e-11	Addiction;
LGG	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg11366901	chr6:160182831	ACAT2	0.91	12.69	0.51	7.02e-32	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4478137	0.501	rs6828820	chr4:164230540	C/T	cg06758707	chr4:164254230	NPY1R	-0.53	-7.98	-0.35	1.13e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.28e-13	HDL cholesterol;
LGG	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg24687543	chr11:63912206	MACROD1	0.46	6.65	0.3	8.09e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18876405	chr7:65276391	NA	0.6	10.92	0.45	7.42e-25	Aortic root size;
LGG	cis	rs4595586	0.545	rs12828866	chr12:39391925	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4356975	0.563	rs4588522	chr4:69973667	C/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.68	0.3	6.7e-11	Obesity-related traits;
LGG	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg18681998	chr4:17616180	MED28	0.85	18.03	0.64	2.03e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9902453	0.933	rs7221154	chr17:28505024	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-12.81	-0.51	2.27e-32	Coffee consumption (cups per day);
LGG	cis	rs6815814	0.898	rs115807384	chr4:38851585	A/C	cg06935464	chr4:38784597	TLR10	0.55	7.43	0.33	5.31e-13	Breast cancer;
LGG	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg01194073	chr14:101175302	NA	0.44	6.98	0.31	1.05e-11	Plateletcrit;
LGG	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg09696939	chr10:60272079	BICC1	0.36	7.03	0.31	7.5e-12	Refractive error;
LGG	cis	rs7309	0.622	rs4664395	chr2:161901301	T/C	cg22496339	chr2:162101262	NA	-0.38	-7.49	-0.33	3.41e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs372883	0.554	rs10154065	chr21:30749480	G/C	cg08807101	chr21:30365312	RNF160	0.58	9.66	0.41	3.05e-20	Pancreatic cancer;
LGG	cis	rs6500395	1.000	rs2354579	chr16:48601521	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg19729930	chr2:74357872	NA	0.51	10.19	0.43	3.75e-22	Gestational age at birth (maternal effect);
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg21798802	chr22:38057573	PDXP	-0.61	-14.16	-0.55	4.28e-38	Fat distribution (HIV);
LGG	cis	rs694739	0.964	rs2510066	chr11:64052447	C/T	cg22916017	chr11:64110731	CCDC88B	0.49	10.0	0.42	1.91e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13692869	chr1:169336982	NME7;BLZF1	0.52	7.88	0.34	2.39e-14	Gut microbiome composition (summer);
LGG	cis	rs911119	0.909	rs3761279	chr20:23620075	C/G	cg16589663	chr20:23618590	CST3	0.47	6.75	0.3	4.46e-11	Chronic kidney disease;
LGG	cis	rs3762637	1.000	rs9879508	chr3:122136480	A/G	cg24169773	chr3:122142474	KPNA1	-0.6	-10.07	-0.42	1.05e-21	LDL cholesterol levels;
LGG	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg02574844	chr11:5959923	NA	-0.56	-8.73	-0.38	4.67e-17	DNA methylation (variation);
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg11878867	chr6:150167359	LRP11	-0.34	-6.84	-0.3	2.56e-11	Lung cancer;
LGG	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg04833646	chr19:10679720	CDKN2D	1.14	19.26	0.67	4.01e-61	Red cell distribution width;
LGG	cis	rs61990749	0.597	rs176955	chr14:78181220	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.34	0.32	9.69e-13	Fibroblast growth factor basic levels;
LGG	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg05555928	chr11:63887634	MACROD1	-0.39	-7.09	-0.31	5.09e-12	Platelet count;
LGG	cis	rs2282978	0.557	rs191777	chr7:92250374	T/A	cg15732164	chr7:92237376	CDK6	-0.34	-7.06	-0.31	6.09e-12	Height;
LGG	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.42	-7.22	-0.32	2.2e-12	Total body bone mineral density;
LGG	cis	rs7010267	0.602	rs1485307	chr8:120007395	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.6	0.37	1.23e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs7717393	0.582	rs17556534	chr5:155809735	C/G	cg12904904	chr5:155754151	SGCD	0.77	7.53	0.33	2.71e-13	Egg allergy;
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg16141378	chr3:129829833	LOC729375	0.4	9.55	0.41	7.81e-20	Neuroticism;
LGG	cis	rs9467773	1.000	rs9461259	chr6:26504835	C/A	cg11502198	chr6:26597334	ABT1	0.54	9.35	0.4	3.64e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg24250549	chr1:154909240	PMVK	0.77	15.89	0.59	1.07e-45	Prostate cancer;
LGG	cis	rs1982963	0.950	rs61973203	chr14:52510567	A/G	cg05884192	chr14:52515736	NID2	0.34	7.4	0.33	6.47e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6696846	0.515	rs11240364	chr1:205105917	C/G	cg00889227	chr1:205173544	DSTYK	-0.3	-7.29	-0.32	1.36e-12	Red blood cell count;
LGG	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg16141378	chr3:129829833	LOC729375	0.36	8.16	0.35	3.18e-15	Triglycerides;
LGG	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.93	-0.31	1.38e-11	Colorectal cancer;
LGG	cis	rs35771425	0.600	rs6679980	chr1:211433672	C/T	cg10512769	chr1:211675356	NA	-0.6	-8.09	-0.35	5.45e-15	Educational attainment (years of education);
LGG	cis	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg19847130	chr8:10466454	RP1L1	0.32	6.7	0.3	6.16e-11	Neuroticism;
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.26	0.36	1.55e-15	Tonsillectomy;
LGG	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.02	0.64	2.26e-55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg15479754	chr10:1447082	ADARB2	-0.34	-7.01	-0.31	8.48e-12	Radiation response;
LGG	cis	rs9308731	0.842	rs56173510	chr2:111928436	G/T	cg19992207	chr2:111874495	ACOXL	-0.41	-7.56	-0.33	2.14e-13	Chronic lymphocytic leukemia;
LGG	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11890956	chr21:40555474	PSMG1	1.16	28.4	0.8	1.73e-103	Cognitive function;
LGG	cis	rs4356203	0.905	rs35933265	chr11:17115254	C/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.11e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg26769984	chr7:1090371	C7orf50	0.54	9.37	0.4	3.24e-19	Bronchopulmonary dysplasia;
LGG	cis	rs9783347	0.714	rs4150644	chr11:18370969	C/T	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.24	-0.49	4.83e-30	Pancreatic cancer;
LGG	cis	rs239198	0.578	rs11155708	chr6:101292189	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.21	0.32	2.36e-12	Menarche (age at onset);
LGG	cis	rs7572263	0.724	rs7579275	chr2:209053080	A/C	cg00164906	chr2:209055251	C2orf80	0.66	9.06	0.39	3.78e-18	Glioma;Non-glioblastoma glioma;
LGG	cis	rs59918340	0.764	rs4961258	chr8:142232878	A/G	cg03653399	chr8:142233436	SLC45A4	-0.42	-8.31	-0.36	1.06e-15	Immature fraction of reticulocytes;
LGG	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg15268244	chr15:77196840	NA	0.49	10.39	0.43	7.24e-23	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26451873	chr13:26829095	CDK8	0.44	7.18	0.32	2.87e-12	Cognitive performance;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07659893	chr17:61819838	STRADA	0.41	6.67	0.3	7.39e-11	Prudent dietary pattern;
LGG	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-8.53	-0.37	2.04e-16	Ulcerative colitis;
LGG	cis	rs3008870	1.000	rs7511948	chr1:67430427	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.6	0.74	2.01e-81	Lymphocyte percentage of white cells;
LGG	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg19628046	chr18:33552617	C18orf21	0.53	7.73	0.34	6.9e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9462027	0.606	rs2744941	chr6:34646917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.67e-24	Systemic lupus erythematosus;
LGG	cis	rs1620921	0.594	rs56238146	chr6:161264866	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2133450	0.679	rs7615261	chr3:7367637	G/A	cg19930620	chr3:7340148	GRM7	-0.37	-8.18	-0.36	2.68e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs8040855	0.579	rs4843029	chr15:85725395	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.32	6.73	0.3	5.03e-11	Bulimia nervosa;
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs6963495	0.818	rs6961233	chr7:105150469	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.85	0.34	2.86e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg04608330	chr12:45269318	NELL2	-0.65	-11.61	-0.47	1.57e-27	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs2274273	0.837	rs10141552	chr14:55746091	C/T	cg04306507	chr14:55594613	LGALS3	-0.62	-17.0	-0.62	1.02e-50	Protein biomarker;
LGG	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg24375607	chr4:120327624	NA	0.67	11.04	0.46	2.56e-25	Corneal astigmatism;
LGG	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.31	-0.36	1.03e-15	Systolic blood pressure;
LGG	trans	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.74	0.48	4.82e-28	Mean corpuscular volume;
LGG	cis	rs701145	0.537	rs1713819	chr3:153864474	A/G	cg12800244	chr3:153838788	SGEF	0.64	7.24	0.32	1.84e-12	Coronary artery disease;
LGG	cis	rs79146658	0.688	rs6433738	chr2:179710706	A/G	cg17765952	chr2:179737173	CCDC141	-0.61	-8.71	-0.38	5.24e-17	Diastolic blood pressure;
LGG	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg11642891	chr2:3452563	TTC15	-0.48	-9.6	-0.41	4.93e-20	Obesity-related traits;
LGG	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.52	-0.37	2.33e-16	Mean corpuscular volume;
LGG	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.9	-0.34	2.03e-14	Neuroticism;
LGG	cis	rs9549367	0.713	rs9577211	chr13:113830718	G/C	cg18105134	chr13:113819100	PROZ	-0.76	-16.55	-0.61	1.12e-48	Platelet distribution width;
LGG	cis	rs1595825	0.891	rs3851979	chr2:198707638	A/T	cg00982548	chr2:198649783	BOLL	0.5	6.7	0.3	6.08e-11	Ulcerative colitis;
LGG	cis	rs7264396	0.747	rs2425158	chr20:34419664	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	7.78	0.34	4.8e-14	Total cholesterol levels;
LGG	cis	rs1978968	0.871	rs5746498	chr22:18435794	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.46	8.95	0.38	8.8e-18	Presence of antiphospholipid antibodies;
LGG	cis	rs11711311	0.955	rs12630833	chr3:113390883	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.13	-0.31	3.84e-12	IgG glycosylation;
LGG	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg15596359	chr8:11213517	TDH	0.41	8.47	0.37	3.19e-16	Retinal vascular caliber;
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg16507663	chr6:150244633	RAET1G	-0.43	-6.97	-0.31	1.08e-11	Lung cancer;
LGG	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	cis	rs888194	0.589	rs874170	chr12:110004960	C/T	cg19025524	chr12:109796872	NA	-0.36	-7.11	-0.31	4.37e-12	Neuroticism;
LGG	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.24e-12	Iron status biomarkers;
LGG	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs924607	1.000	rs2455331	chr5:643593	T/C	cg07001201	chr5:642380	CEP72	-0.41	-6.8	-0.3	3.26e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs11920090	0.860	rs35297160	chr3:170738981	C/G	cg09710316	chr3:170744871	SLC2A2	0.58	7.94	0.35	1.52e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs889398	0.802	rs12921407	chr16:69860933	T/C	cg00738113	chr16:70207722	CLEC18C	0.24	6.73	0.3	5.11e-11	Body mass index;
LGG	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg19507638	chr5:93509721	C5orf36	-0.63	-9.0	-0.39	5.8e-18	Diabetic retinopathy;
LGG	cis	rs3820928	0.845	rs13384342	chr2:227805010	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.94	-0.35	1.52e-14	Pulmonary function;
LGG	cis	rs6831352	0.918	rs7669636	chr4:100059312	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.72	-0.41	1.97e-20	Alcohol dependence;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs6456156	0.565	rs12525345	chr6:167478875	T/C	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Primary biliary cholangitis;
LGG	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg13009111	chr11:71350975	NA	-0.3	-6.65	-0.3	8.09e-11	Neuroticism;
LGG	cis	rs3099143	1.000	rs3099142	chr15:77104909	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-10.11	-0.43	7.87e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs3806843	0.521	rs192231	chr5:140248539	C/T	cg19875535	chr5:140030758	IK	-0.37	-7.36	-0.32	8.6e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg06026331	chr20:60912101	LAMA5	0.41	7.39	0.32	7.09e-13	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg05280133	chr15:45670068	GATM;LOC145663	-0.42	-7.7	-0.34	8.05e-14	Homoarginine levels;
LGG	trans	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg27349345	chr7:35225932	NA	-0.52	-7.42	-0.33	5.67e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg12617538	chr9:69786570	NA	0.37	6.86	0.3	2.29e-11	Parkinson's disease (motor and cognition);
LGG	trans	rs941408	1.000	rs941407	chr19:2812153	A/G	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.27	-0.43	1.98e-22	Total cholesterol levels;
LGG	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg14983838	chr19:29218262	NA	0.71	11.77	0.48	3.71e-28	Methadone dose in opioid dependence;
LGG	cis	rs7572644	0.680	rs12623170	chr2:28020157	C/T	cg27432699	chr2:27873401	GPN1	0.48	6.85	0.3	2.31e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs28830936	1.000	rs11070343	chr15:41940146	T/A	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.74	-0.3	4.65e-11	Diastolic blood pressure;
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg02524346	chr8:600233	NA	1.36	12.88	0.51	1.12e-32	IgG glycosylation;
LGG	cis	rs704	0.790	rs708100	chr17:26688663	G/A	cg10342447	chr17:26645325	TMEM97	-0.38	-7.07	-0.31	5.63e-12	Osteoprotegerin levels;
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.44	0.33	5.08e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2066819	1.000	rs75265219	chr12:56640341	G/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg15269541	chr15:43626905	ADAL	-0.41	-7.07	-0.31	5.79e-12	Lung cancer in ever smokers;
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	9.1	0.39	2.74e-18	Lung function (FEV1/FVC);
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg07142201	chr11:109293216	C11orf87	0.53	9.12	0.39	2.27e-18	Schizophrenia;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.42	-0.33	5.58e-13	Neuroticism;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-6.93	-0.31	1.37e-11	Vitiligo;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.17	0.55	4.14e-38	Platelet count;
LGG	cis	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.89	-0.48	1.26e-28	Morning vs. evening chronotype;
LGG	cis	rs4679904	0.883	rs114457071	chr3:160311740	G/A	cg20378687	chr3:160281681	KPNA4	-0.35	-6.68	-0.3	6.75e-11	Primary biliary cholangitis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10185519	chr16:30621987	ZNF689	0.39	7.09	0.31	5.12e-12	Obesity-related traits;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11245990	chr11:68621969	NA	0.38	8.25	0.36	1.61e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg16339924	chr4:17578868	LAP3	0.6	10.42	0.44	5.75e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1018836	0.828	rs10091275	chr8:91559751	A/G	cg16814680	chr8:91681699	NA	-0.73	-13.2	-0.52	5.22e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs921968	0.541	rs6720403	chr2:219294258	A/C	cg01130898	chr2:219473002	PLCD4	0.43	7.39	0.32	6.81e-13	Mean corpuscular hemoglobin concentration;
LGG	trans	rs931812	0.895	rs4236763	chr8:101913022	G/A	cg20993868	chr7:22813445	NA	0.7	13.17	0.52	7.36e-34	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg22875332	chr1:76189707	ACADM	-0.57	-8.75	-0.38	4.13e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.06	-0.31	6.16e-12	Primary sclerosing cholangitis;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg03804240	chr11:118481350	PHLDB1	0.4	8.2	0.36	2.44e-15	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.38	0.47	1.25e-26	Obesity-related traits;
LGG	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg07777115	chr5:623756	CEP72	-0.57	-7.29	-0.32	1.31e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19524238	chr7:2802976	GNA12	0.38	8.97	0.38	7.68e-18	Height;
LGG	cis	rs3735485	0.843	rs3213658	chr7:45025720	G/C	cg03440944	chr7:45023329	C7orf40	0.57	9.77	0.41	1.24e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs12762955	0.507	rs7070724	chr10:1040138	C/T	cg18964960	chr10:1102726	WDR37	-0.43	-6.85	-0.3	2.33e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs7226408	0.857	rs72887063	chr18:34493121	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.97	-0.31	1.09e-11	Obesity-related traits;
LGG	cis	rs16854884	0.657	rs6783089	chr3:143738034	T/C	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg15763984	chr4:1342303	KIAA1530	0.39	7.06	0.31	6.1e-12	Obesity-related traits;
LGG	trans	rs2975734	0.709	rs4841298	chr8:10111637	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.59	-0.33	1.73e-13	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07939768	chr17:27621433	NUFIP2	0.4	6.75	0.3	4.55e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18402987	chr7:1209562	NA	0.42	7.48	0.33	3.8e-13	Longevity;Endometriosis;
LGG	cis	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg24375607	chr4:120327624	NA	0.54	9.18	0.39	1.49e-18	Educational attainment;
LGG	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg14227996	chr4:17616232	MED28	0.72	8.74	0.38	4.19e-17	Opioid sensitivity;
LGG	trans	rs2840044	1.000	rs225277	chr17:33973311	G/A	cg19694781	chr19:47549865	TMEM160	-0.55	-9.16	-0.39	1.69e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs3820928	0.874	rs13413235	chr2:227893863	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.46e-13	Pulmonary function;
LGG	cis	rs11209002	0.614	rs10732837	chr1:67573120	A/G	cg02640540	chr1:67518911	SLC35D1	0.42	7.19	0.32	2.63e-12	Crohn's disease;
LGG	trans	rs2018683	0.584	rs4722880	chr7:28999197	C/T	cg19402173	chr7:128379420	CALU	-0.73	-13.24	-0.52	3.6e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs763121	0.819	rs5750658	chr22:39060917	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.48	0.63	6.84e-53	Menopause (age at onset);
LGG	cis	rs1957429	0.520	rs72625642	chr14:65338884	G/T	cg23373153	chr14:65346875	NA	-1.04	-9.94	-0.42	3.2e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs2439831	0.867	rs2245715	chr15:43818052	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	9.91	0.42	3.93e-21	Lung cancer in ever smokers;
LGG	cis	rs4959677	0.586	rs3924452	chr6:2476910	C/G	cg23817096	chr6:1620687	NA	-0.31	-7.75	-0.34	5.75e-14	Orthostatic hypotension;
LGG	cis	rs888194	0.714	rs6606717	chr12:109873227	A/C	cg19025524	chr12:109796872	NA	-0.38	-7.52	-0.33	2.78e-13	Neuroticism;
LGG	cis	rs17023223	0.537	rs12083510	chr1:119746620	T/G	cg05756136	chr1:119680316	WARS2	-0.43	-8.43	-0.36	4.4e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs7000551	0.663	rs7827093	chr8:22334610	A/G	cg12081754	chr8:22256438	SLC39A14	0.63	11.87	0.48	1.52e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4820539	1.000	rs4822361	chr22:23482718	A/G	cg14186256	chr22:23484241	RTDR1	-0.99	-25.86	-0.77	6.82e-92	Bone mineral density;
LGG	cis	rs2204008	0.715	rs12815986	chr12:38343869	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.63	0.71	3.28e-72	Bladder cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19594360	chr1:151255303	ZNF687	0.47	6.94	0.31	1.34e-11	Hip circumference;
LGG	cis	rs9811920	0.809	rs902159	chr3:99747445	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	8.61	0.37	1.11e-16	Axial length;
LGG	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	trans	rs1997103	0.822	rs940878	chr7:55419663	A/G	cg20935933	chr6:143382018	AIG1	0.54	7.94	0.35	1.58e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg08930214	chr7:62859557	LOC100287834	0.45	7.62	0.33	1.4e-13	Obesity-related traits;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg25937216	chr8:58172855	NA	-0.55	-8.66	-0.37	7.63e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6732160	0.588	rs13394018	chr2:73372605	C/T	cg01422370	chr2:73384389	NA	0.56	9.68	0.41	2.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.635	rs3018758	chr11:89410463	A/G	cg02982614	chr11:89391479	FOLH1B	0.38	8.47	0.37	3.35e-16	Anxiety in major depressive disorder;
LGG	trans	rs7944735	0.567	rs7946766	chr11:48004369	C/T	cg03929089	chr4:120376271	NA	0.64	6.78	0.3	3.63e-11	Intraocular pressure;
LGG	cis	rs2463822	0.764	rs7125402	chr11:62097259	C/T	cg06239285	chr11:62104954	ASRGL1	1.16	16.25	0.6	2.59e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2302729	0.515	rs7136840	chr12:2768723	C/T	cg19945202	chr12:2788847	CACNA1C	-0.7	-11.86	-0.48	1.69e-28	Sleep quality;
LGG	cis	rs834603	0.575	rs1620852	chr7:47481786	A/T	cg09696706	chr7:47479511	TNS3	0.35	7.85	0.34	2.85e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs35306767	0.715	rs17221463	chr10:1038040	T/C	cg20503657	chr10:835505	NA	0.54	6.83	0.3	2.74e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs11645898	0.688	rs398580	chr16:72095453	A/G	cg14768367	chr16:72042858	DHODH	-0.99	-12.6	-0.51	1.68e-31	Blood protein levels;
LGG	cis	rs13191362	1.000	rs34637087	chr6:163004064	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	8.88	0.38	1.45e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs61931739	0.546	rs61927758	chr12:33712017	T/C	cg26384229	chr12:38710491	ALG10B	-0.48	-8.51	-0.37	2.39e-16	Morning vs. evening chronotype;
LGG	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs35740288	0.929	rs11630684	chr15:86306256	C/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.27	-0.32	1.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6445975	0.666	rs6773099	chr3:58403452	G/A	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg00830817	chr11:109293614	C11orf87	0.59	9.67	0.41	2.78e-20	Schizophrenia;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg05863683	chr7:1912471	MAD1L1	-0.44	-8.58	-0.37	1.49e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7226408	0.600	rs323308	chr18:34712267	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.11	-0.39	2.48e-18	Obesity-related traits;
LGG	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg16325326	chr1:53192061	ZYG11B	0.84	23.19	0.73	1.56e-79	Monocyte count;
LGG	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.02	-0.39	5.2e-18	Gut microbiome composition (summer);
LGG	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.61	0.44	1.13e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs4356932	1.000	rs4422436	chr4:76977784	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.72	-0.3	5.19e-11	Blood protein levels;
LGG	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg17545662	chr6:170176663	C6orf70	-0.63	-8.0	-0.35	9.73e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg05484376	chr2:27715224	FNDC4	0.45	9.61	0.41	4.79e-20	Total body bone mineral density;
LGG	cis	rs35771425	0.600	rs17267491	chr1:211463815	C/T	cg10512769	chr1:211675356	NA	-0.62	-8.35	-0.36	8.05e-16	Educational attainment (years of education);
LGG	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	cis	rs638893	0.578	rs582200	chr11:118668908	A/G	cg13782932	chr11:118662891	DDX6	-0.41	-6.83	-0.3	2.71e-11	Vitiligo;
LGG	cis	rs3858526	0.676	rs10838752	chr11:5887243	A/G	cg02574844	chr11:5959923	NA	-0.54	-8.53	-0.37	2.15e-16	DNA methylation (variation);
LGG	cis	rs11169552	0.510	rs7138604	chr12:50952797	T/C	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.68e-14	Colorectal cancer;
LGG	cis	rs6500395	1.000	rs12933948	chr16:48705825	C/G	cg16662043	chr16:48846231	NA	-0.37	-7.26	-0.32	1.7e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-17.06	-0.62	5.29e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.15	-0.49	1.13e-29	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18770186	chr8:141521259	CHRAC1	0.38	6.77	0.3	3.96e-11	Obesity-related traits;
LGG	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg08885076	chr2:99613938	TSGA10	-0.55	-9.99	-0.42	2.01e-21	Chronic sinus infection;
LGG	trans	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg16386425	chr10:429943	DIP2C	-0.47	-9.76	-0.41	1.37e-20	Psychosis in Alzheimer's disease;
LGG	trans	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg18335740	chr13:41363409	SLC25A15	0.6	11.86	0.48	1.57e-28	Lewy body disease;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.2e-28	Tonsillectomy;
LGG	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg10621924	chr7:39171070	POU6F2	0.42	8.43	0.36	4.37e-16	IgG glycosylation;
LGG	cis	rs7647973	1.000	rs9862534	chr3:49598064	A/G	cg07636037	chr3:49044803	WDR6	0.77	13.88	0.54	6.83e-37	Menarche (age at onset);
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.55	9.67	0.41	2.97e-20	Longevity;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.72	0.3	5.44e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	12.44	0.5	7.52e-31	Lung cancer in ever smokers;
LGG	cis	rs4684776	0.877	rs4684065	chr3:11376559	G/T	cg24705426	chr3:11550659	ATG7	0.46	8.63	0.37	9.85e-17	Small vessel stroke;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.51	8.68	0.37	6.86e-17	Renal function-related traits (BUN);
LGG	cis	rs6594713	0.577	rs6883547	chr5:112916853	A/G	cg12552261	chr5:112820674	MCC	-0.51	-7.06	-0.31	5.94e-12	Brain cytoarchitecture;
LGG	cis	rs3735485	0.738	rs56291124	chr7:45090477	A/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg26597838	chr10:835615	NA	0.95	12.69	0.51	6.9e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7220401	0.521	rs2278217	chr17:27904617	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	9.25	0.39	8.53e-19	Coronary artery disease;
LGG	cis	rs929354	1.000	rs1182378	chr7:157048322	T/C	cg17757837	chr7:157058334	UBE3C	-0.91	-20.11	-0.68	4.02e-65	Body mass index;
LGG	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-7.61	-0.33	1.55e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2070488	0.775	rs7374458	chr3:38531211	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.54	0.56	9.81e-40	Electrocardiographic conduction measures;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs6993813	0.805	rs4327884	chr8:120019593	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.97	0.38	7.25e-18	Bone mineral density (hip);
LGG	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.82	15.64	0.59	1.36e-44	Subjective well-being;
LGG	cis	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs62238980	0.614	rs76142630	chr22:32392177	A/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs61990749	0.597	rs2112136	chr14:78248952	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	6.94	0.31	1.29e-11	Fibroblast growth factor basic levels;
LGG	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg21775007	chr8:11205619	TDH	0.44	6.95	0.31	1.27e-11	Neuroticism;
LGG	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg24634471	chr8:143751801	JRK	0.53	8.45	0.37	3.77e-16	Schizophrenia;
LGG	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg06138931	chr13:21896616	NA	-0.43	-7.13	-0.31	3.81e-12	White matter hyperintensity burden;
LGG	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg08344181	chr3:125677491	NA	-0.65	-7.44	-0.33	4.81e-13	Depression;
LGG	cis	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.52e-32	Bladder cancer;
LGG	cis	rs8017423	0.647	rs4904674	chr14:90817412	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-12.76	-0.51	3.65e-32	Mortality in heart failure;
LGG	cis	rs11190604	1.000	rs2295776	chr10:102295629	G/T	cg07570687	chr10:102243282	WNT8B	0.44	7.42	0.33	5.83e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.48	-9.17	-0.39	1.6e-18	Obesity-related traits;
LGG	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg27489772	chr12:121021490	NA	0.56	7.28	0.32	1.45e-12	Type 1 diabetes nephropathy;
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg18681998	chr4:17616180	MED28	0.89	20.61	0.69	1.91e-67	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.83	-0.3	2.68e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg13736514	chr6:26305472	NA	0.36	7.23	0.32	1.97e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.74	-0.51	4.62e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17221829	0.965	rs10830361	chr11:89456273	C/A	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.58	-0.33	1.93e-13	Anxiety in major depressive disorder;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs2075371	1.000	rs2598285	chr7:133971153	A/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.33	0.58	3.28e-43	Mean platelet volume;
LGG	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.63	0.44	9.12e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9912468	0.899	rs72843895	chr17:64331156	T/G	cg19474267	chr17:64306194	PRKCA	0.94	24.0	0.74	2.77e-83	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg03647239	chr10:116582469	FAM160B1	-0.41	-6.96	-0.31	1.15e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs701145	0.537	rs1727952	chr3:153871565	C/T	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.52	-0.61	1.5e-48	Total body bone mineral density;
LGG	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.67	-11.95	-0.49	6.98e-29	Personality dimensions;
LGG	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.33e-12	Obesity-related traits;
LGG	cis	rs6840360	0.593	rs10016160	chr4:152693998	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.28	-0.43	1.86e-22	Intelligence (multi-trait analysis);
LGG	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg27336068	chr10:1336103	ADARB2	-0.4	-8.49	-0.37	2.78e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg22947322	chr17:47091978	IGF2BP1	-0.47	-8.23	-0.36	1.9e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg19160520	chr1:226927217	ITPKB	-0.38	-7.0	-0.31	9.11e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg06521331	chr12:34319734	NA	0.43	7.71	0.34	7.71e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg15320455	chr10:103880129	LDB1	0.68	9.22	0.39	1.02e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.522	rs2251366	chr14:55518156	A/G	cg04306507	chr14:55594613	LGALS3	0.43	10.76	0.45	2.96e-24	Protein biomarker;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg14926445	chr8:58193284	C8orf71	-0.87	-13.1	-0.52	1.44e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg25718383	chr7:130020096	CPA1	0.33	8.41	0.36	5.09e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.33	-0.32	1.03e-12	Hemoglobin concentration;
LGG	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg01403660	chr11:68851641	TPCN2	0.51	7.19	0.32	2.58e-12	Blond vs. brown hair color;
LGG	cis	rs763121	0.853	rs5757253	chr22:39104320	C/T	cg06022373	chr22:39101656	GTPBP1	0.92	19.22	0.67	5.62e-61	Menopause (age at onset);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21495022	chr2:203499796	FAM117B	-0.43	-7.28	-0.32	1.41e-12	Brain structure;
LGG	cis	rs6977660	0.714	rs4719586	chr7:19825548	T/C	cg05791153	chr7:19748676	TWISTNB	0.76	10.06	0.42	1.15e-21	Thyroid stimulating hormone;
LGG	cis	rs7412746	0.658	rs4970988	chr1:150950062	A/G	cg15448220	chr1:150897856	SETDB1	-0.38	-6.94	-0.31	1.34e-11	Melanoma;
LGG	cis	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg19847130	chr8:10466454	RP1L1	0.32	6.79	0.3	3.44e-11	Neuroticism;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-9.17	-0.39	1.61e-18	Personality dimensions;
LGG	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg20503657	chr10:835505	NA	0.53	6.94	0.31	1.32e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs2797160	1.000	rs4895798	chr6:126000162	A/G	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	cis	rs4665809	1.000	rs6546736	chr2:26293878	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.8	12.99	0.52	4.15e-33	Gut microbiome composition (summer);
LGG	cis	rs66561647	0.719	rs4733582	chr8:128947967	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	6.69	0.3	6.5500000000000006e-11	Hemoglobin concentration;
LGG	cis	rs4684776	0.867	rs1470613	chr3:11347525	G/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.55	-0.37	1.78e-16	Small vessel stroke;
LGG	cis	rs73198271	0.740	rs10100066	chr8:8650393	T/G	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1003719	0.788	rs4572679	chr21:38453227	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	trans	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-8.79	-0.38	3.05e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs986417	0.818	rs767603	chr14:61098683	T/C	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.32e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg08250081	chr4:10125330	NA	0.39	7.37	0.32	8.08e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.09	0.35	5.27e-15	Mood instability;
LGG	cis	rs2758596	1.000	rs2758617	chr1:156160693	A/G	cg25208724	chr1:156163844	SLC25A44	0.82	7.39	0.32	7.08e-13	Paclitaxel disposition in epithelial ovarian cancer;
LGG	trans	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	17.09	0.62	4.15e-51	Exhaled nitric oxide levels;
LGG	cis	rs611744	0.647	rs702808	chr8:109252554	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs6558174	0.965	rs6558172	chr8:22492052	C/T	cg03733263	chr8:22462867	KIAA1967	0.64	10.83	0.45	1.59e-24	Breast cancer;
LGG	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg24692254	chr21:30365293	RNF160	-0.86	-19.48	-0.67	3.46e-62	Dental caries;
LGG	cis	rs2470578	0.792	rs2596678	chr3:17320600	C/T	cg20981856	chr3:17787350	NA	-0.35	-6.76	-0.3	4.07e-11	Schizophrenia;
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.61	-0.37	1.18e-16	Personality dimensions;
LGG	cis	rs7551222	0.646	rs4951384	chr1:204452514	A/T	cg20240347	chr1:204465584	NA	-0.49	-9.08	-0.39	3.07e-18	Schizophrenia;
LGG	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg04000281	chr11:63949212	NA	0.42	7.9	0.34	2.02e-14	Platelet count;
LGG	cis	rs67460515	0.892	rs7647374	chr3:160975576	T/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.39e-20	Parkinson's disease;
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.67e-12	Height;
LGG	cis	rs2415984	0.579	rs1494097	chr14:46960552	T/C	cg14871534	chr14:47121158	RPL10L	0.58	10.27	0.43	1.97e-22	Number of children ever born;
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg04450456	chr4:17643702	FAM184B	0.34	7.38	0.32	7.32e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs35094601	0.559	rs72858190	chr2:139229106	A/G	cg25299176	chr17:1303341	YWHAE	-0.64	-8.21	-0.36	2.29e-15	Schizophrenia;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs4262150	0.810	rs4301224	chr5:152060244	A/G	cg12297329	chr5:152029980	NA	-0.79	-14.99	-0.57	1.09e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg11050988	chr7:1952600	MAD1L1	0.44	11.33	0.47	1.88e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05491587	chr18:77659695	KCNG2	-0.52	-6.87	-0.3	2.14e-11	Opioid sensitivity;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	7.27	0.32	1.53e-12	Longevity;
LGG	cis	rs67478160	0.619	rs12878682	chr14:104233627	G/C	cg26031613	chr14:104095156	KLC1	-0.46	-7.56	-0.33	2.18e-13	Schizophrenia;
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg18032289	chr17:61959525	GH2	-0.4	-6.82	-0.3	2.82e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.21	0.52	4.99e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4683346	0.623	rs565521	chr3:43048159	T/C	cg05453631	chr3:43117548	NA	0.36	7.14	0.31	3.74e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs939658	0.967	rs11629665	chr15:79457133	C/T	cg17916960	chr15:79447300	NA	0.62	11.96	0.49	6.36e-29	Refractive error;
LGG	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs8060686	0.641	rs11075665	chr16:68070774	C/T	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12618769	0.652	rs1139829	chr2:99225168	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.78	0.34	4.91e-14	Bipolar disorder;
LGG	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg08603382	chr10:743973	NA	-0.51	-8.63	-0.37	1.02e-16	Psychosis in Alzheimer's disease;
LGG	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg15596359	chr8:11213517	TDH	0.33	6.69	0.3	6.29e-11	Retinal vascular caliber;
LGG	cis	rs568617	0.533	rs679147	chr11:65644363	A/G	cg26695010	chr11:65641043	EFEMP2	0.56	9.22	0.39	1.07e-18	Crohn's disease;
LGG	cis	rs1816752	0.755	rs1981277	chr13:24983513	G/A	cg02811702	chr13:24901961	NA	0.4	7.34	0.32	9.63e-13	Obesity-related traits;
LGG	cis	rs9462027	0.628	rs2814969	chr6:34713399	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.73e-14	Personality dimensions;
LGG	cis	rs2070488	1.000	rs2070488	chr3:38442490	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.32	-0.63	3.73e-52	Electrocardiographic conduction measures;
LGG	cis	rs9880211	0.800	rs9873536	chr3:136474267	A/G	cg21827317	chr3:136751795	NA	-0.49	-6.95	-0.31	1.21e-11	Body mass index;Height;
LGG	trans	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg16011800	chr17:1958478	HIC1	-0.63	-9.34	-0.4	4.15e-19	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg06916706	chr16:4465613	CORO7	-0.97	-16.08	-0.6	1.53e-46	Schizophrenia;
LGG	cis	rs3796352	1.000	rs34933390	chr3:53006265	T/G	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg14926445	chr8:58193284	C8orf71	-0.73	-9.11	-0.39	2.46e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7119	0.717	rs12916973	chr15:77808099	C/T	cg10437265	chr15:77819839	NA	-0.24	-6.86	-0.3	2.22e-11	Type 2 diabetes;
LGG	cis	rs7829975	0.502	rs11785183	chr8:8565957	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.58	-0.33	1.86e-13	Mood instability;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg11494091	chr17:61959527	GH2	1.01	25.08	0.76	2.74e-88	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.08e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9796	0.621	rs2918462	chr15:41481254	A/G	cg18705301	chr15:41695430	NDUFAF1	0.58	9.95	0.42	2.96e-21	Menopause (age at onset);
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08280861	chr8:58055591	NA	0.6	7.76	0.34	5.43e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7615952	0.932	rs3811679	chr3:125648283	A/G	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	trans	rs6561151	0.645	rs61959960	chr13:44439265	T/G	cg12856521	chr11:46389249	DGKZ	0.91	14.36	0.56	5.99e-39	Crohn's disease;
LGG	cis	rs7226408	0.857	rs72885256	chr18:34430466	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg02002194	chr4:3960332	NA	0.38	7.13	0.31	3.83e-12	Triglycerides;
LGG	cis	rs2247341	0.965	rs11248074	chr4:1743754	C/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.8	-0.51	2.59e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9790314	0.637	rs778643	chr3:160706041	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-9.12	-0.39	2.24e-18	Morning vs. evening chronotype;
LGG	cis	rs8032158	1.000	rs7176225	chr15:56126857	G/A	cg02198044	chr15:56286336	NEDD4	-0.69	-11.82	-0.48	2.44e-28	Keloid;
LGG	cis	rs55788414	0.932	rs2873367	chr16:81184380	T/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs9457247	0.967	rs2149084	chr6:167370988	G/C	cg07741184	chr6:167504864	NA	-0.32	-7.09	-0.31	4.89e-12	Crohn's disease;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg08645402	chr16:4508243	NA	0.53	9.52	0.4	1e-19	Schizophrenia;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.94	-0.31	1.32e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	1.000	rs6481400	chr10:60268783	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.87	-0.64	1.1e-54	Refractive error;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg07701084	chr6:150067640	NUP43	0.63	11.87	0.48	1.43e-28	Lung cancer;
LGG	cis	rs11785400	1.000	rs7459630	chr8:143738585	A/C	cg24634471	chr8:143751801	JRK	0.54	8.62	0.37	1.04e-16	Schizophrenia;
LGG	trans	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6942756	1.000	rs2141075	chr7:128877305	C/T	cg02491457	chr7:128862824	NA	0.76	14.04	0.55	1.45e-37	White matter hyperintensity burden;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-15.1	-0.57	3.53e-42	Platelet count;
LGG	cis	rs9467773	0.620	rs2494701	chr6:26634432	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.69	0.34	8.69e-14	Neutrophil percentage of white cells;
LGG	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg05692746	chr2:100937584	LONRF2	0.52	8.88	0.38	1.45e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10876993	0.928	rs1678540	chr12:58065002	A/G	cg18357645	chr12:58087776	OS9	0.68	12.43	0.5	8.37e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs4926611	1.000	rs6699114	chr1:54108112	G/A	cg23596471	chr1:54105337	GLIS1	0.39	8.18	0.36	2.78e-15	Hand grip strength;
LGG	cis	rs763121	0.853	rs5757162	chr22:38993370	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	17.24	0.63	8.38e-52	Menopause (age at onset);
LGG	cis	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.81	-0.3	2.98e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10950821	0.843	rs73684578	chr7:20665782	T/A	cg22066521	chr7:20687223	ABCB5	-0.32	-6.75	-0.3	4.42e-11	Response to statin therapy;
LGG	cis	rs6456042	1.000	rs3127412	chr6:166535561	A/G	cg11088901	chr6:166572345	T	0.34	7.13	0.31	3.81e-12	Asthma;
LGG	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg06353428	chr16:71660113	MARVELD3	0.75	7.41	0.33	6.17e-13	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.52	0.61	1.59e-48	Smoking behavior;
LGG	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg02275930	chr1:2372054	NA	-0.85	-17.44	-0.63	9.6e-53	Non-obstructive azoospermia;
LGG	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg13385794	chr1:248469461	NA	0.46	7.82	0.34	3.55e-14	Common traits (Other);
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg21724239	chr8:58056113	NA	0.57	8.24	0.36	1.82e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg05335186	chr13:53173507	NA	0.6	13.37	0.53	1.03e-34	Lewy body disease;
LGG	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.04	-0.31	7.12e-12	Schizophrenia;
LGG	trans	rs9929218	0.954	rs9646284	chr16:68791306	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.55	-0.5	2.59e-31	Colorectal cancer;
LGG	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg17127132	chr2:85788382	GGCX	0.47	8.13	0.35	4.06e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7737355	0.773	rs3756290	chr5:130951750	A/G	cg06307176	chr5:131281290	NA	0.54	8.97	0.38	7.17e-18	Life satisfaction;
LGG	cis	rs972578	0.715	rs738537	chr22:43277922	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.21e-11	Mean platelet volume;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.79	-0.3	3.45e-11	Total body bone mineral density;
LGG	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg00745463	chr17:30367425	LRRC37B	-0.68	-9.76	-0.41	1.35e-20	Hip circumference adjusted for BMI;
LGG	cis	rs73086581	0.787	rs67724338	chr20:3869057	A/G	cg02187196	chr20:3869020	PANK2	0.93	13.04	0.52	2.61e-33	Response to antidepressants in depression;
LGG	cis	rs611744	0.870	rs650925	chr8:109196725	T/C	cg21045802	chr8:109455806	TTC35	0.4	7.15	0.32	3.5e-12	Dupuytren's disease;
LGG	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg23743428	chr13:21893420	NA	-0.4	-6.76	-0.3	4.08e-11	White matter hyperintensity burden;
LGG	cis	rs12135191	0.967	rs61835496	chr1:236462230	A/G	cg21399712	chr1:236511386	NA	-0.39	-7.47	-0.33	4.02e-13	Urate levels (BMI interaction);
LGG	cis	rs4363385	0.747	rs4568784	chr1:152972694	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.17	-0.39	1.55e-18	Inflammatory skin disease;
LGG	cis	rs35740288	0.857	rs11630274	chr15:86288387	C/T	cg07943548	chr15:86304357	KLHL25	-0.35	-6.83	-0.3	2.68e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00631329	chr6:26305371	NA	-0.5	-8.97	-0.38	7.36e-18	Educational attainment;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs56399783	0.901	rs73049341	chr7:2812255	G/C	cg19731401	chr7:2775893	GNA12	0.36	7.43	0.33	5.14e-13	Childhood ear infection;
LGG	trans	rs11875185	0.510	rs76877857	chr18:55593772	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6430585	0.591	rs12466487	chr2:136407078	C/T	cg07169764	chr2:136633963	MCM6	-1.11	-18.67	-0.66	2.12e-58	Corneal structure;
LGG	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.95	-0.38	8.88e-18	Lung cancer;
LGG	cis	rs758324	0.947	rs60847707	chr5:131252554	C/T	cg06307176	chr5:131281290	NA	-0.57	-9.47	-0.4	1.44e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg07120314	chr15:79043507	NA	-0.76	-18.99	-0.66	6.82e-60	Coronary artery disease or large artery stroke;
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.49	0.33	3.51e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11650494	0.516	rs13341862	chr17:47494203	A/G	cg08112188	chr17:47440006	ZNF652	-0.94	-10.72	-0.45	4.07e-24	Prostate cancer;
LGG	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.51	-10.75	-0.45	3.4e-24	Aortic root size;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg11050988	chr7:1952600	MAD1L1	0.33	8.0	0.35	1.03e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15687138	chr1:151138326	SCNM1;LYSMD1	0.43	6.77	0.3	3.89e-11	Cognitive performance;
LGG	cis	rs3087591	0.879	rs59015798	chr17:29580882	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.14	-0.55	5.67e-38	Hip circumference;
LGG	cis	rs6489882	0.966	rs6489879	chr12:113377822	G/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7727544	0.735	rs272875	chr5:131674888	T/C	cg07395648	chr5:131743802	NA	-0.55	-13.2	-0.52	5.5e-34	Blood metabolite levels;
LGG	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg12081754	chr8:22256438	SLC39A14	0.97	20.91	0.7	7.84e-69	Verbal declarative memory;
LGG	cis	rs13424612	0.965	rs34789127	chr2:240952002	C/T	cg01812947	chr2:240904978	NDUFA10	0.41	6.8	0.3	3.25e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg14993813	chr1:46806288	NSUN4	-0.55	-9.05	-0.39	4.02e-18	Menopause (age at onset);
LGG	cis	rs10743315	0.557	rs80051304	chr12:19286086	G/A	cg02471346	chr12:19282374	PLEKHA5	0.83	7.31	0.32	1.15e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12681287	0.605	rs2953509	chr8:87343194	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.05e-13	Caudate activity during reward;
LGG	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg02002194	chr4:3960332	NA	0.45	8.33	0.36	9.34e-16	Monocyte count;
LGG	cis	rs7129220	0.588	rs60257382	chr11:10122172	C/T	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05422897	chr2:113403145	SLC20A1	0.4	6.77	0.3	3.96e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-16.76	-0.61	1.28e-49	Vitiligo;
LGG	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg14675211	chr2:100938903	LONRF2	0.63	11.2	0.46	6.48e-26	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg00204512	chr16:28754710	NA	0.26	7.13	0.31	3.95e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.9	-0.38	1.22e-17	Retinal vascular caliber;
LGG	cis	rs526231	0.578	rs17154821	chr5:102241341	A/T	cg23492399	chr5:102201601	PAM	-0.6	-9.2	-0.39	1.19e-18	Primary biliary cholangitis;
LGG	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg11890956	chr21:40555474	PSMG1	1.19	29.85	0.81	5.65e-110	Cognitive function;
LGG	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg20387954	chr3:183756860	HTR3D	0.71	14.32	0.55	9.07e-39	Anterior chamber depth;
LGG	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg11764359	chr7:65958608	NA	-0.6	-9.82	-0.42	8.07e-21	Aortic root size;
LGG	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.89	-0.45	9.3e-25	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.613	rs61927728	chr12:33667690	T/C	cg13010199	chr12:38710504	ALG10B	-0.37	-6.65	-0.3	8.4e-11	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.933	rs7216494	chr17:28502651	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.72	0.51	5.16e-32	Coffee consumption (cups per day);
LGG	cis	rs4974559	0.947	rs7659916	chr4:1361013	C/T	cg02980000	chr4:1222292	CTBP1	0.65	8.05	0.35	6.81e-15	Systolic blood pressure;
LGG	cis	rs912057	1.000	rs912056	chr6:6736197	A/T	cg06612196	chr6:6737390	NA	0.43	8.57	0.37	1.57e-16	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg03961551	chr1:25251730	RUNX3	0.47	12.05	0.49	2.9e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg27336068	chr10:1336103	ADARB2	-0.4	-9.16	-0.39	1.71e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6723226	0.708	rs2754513	chr2:32782763	G/A	cg02381751	chr2:32503542	YIPF4	0.68	11.57	0.47	2.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4851266	0.832	rs10865037	chr2:100871361	T/C	cg21926883	chr2:100939477	LONRF2	-0.46	-8.12	-0.35	4.19e-15	Educational attainment;
LGG	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg22643751	chr7:855365	UNC84A	-0.46	-7.92	-0.35	1.74e-14	Cerebrospinal P-tau181p levels;
LGG	trans	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg25214090	chr10:38739885	LOC399744	0.4	7.32	0.32	1.09e-12	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02326858	chr1:151253959	ZNF687	0.49	7.46	0.33	4.25e-13	Gut microbiome composition (summer);
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg00516966	chr17:19651653	ALDH3A1	-0.55	-14.65	-0.56	3.34e-40	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	trans	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.65	-0.33	1.19e-13	Heart rate;
LGG	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.43	-0.33	5.42e-13	Testicular germ cell tumor;
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg24503407	chr1:205819492	PM20D1	-0.42	-8.6	-0.37	1.21e-16	Prostate-specific antigen levels;
LGG	cis	rs1008375	0.933	rs10939757	chr4:17694125	T/C	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.37e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg04733989	chr22:42467013	NAGA	0.57	10.14	0.43	5.72e-22	Schizophrenia;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.04	0.57	6.41e-42	Platelet count;
LGG	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg23461800	chr14:103021989	NA	-0.53	-8.32	-0.36	9.770000000000001e-16	Platelet count;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-6.98	-0.31	1.03e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7474896	0.537	rs2749586	chr10:38270214	G/C	cg25427524	chr10:38739819	LOC399744	0.52	7.72	0.34	7.08e-14	Obesity (extreme);
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg20978937	chr14:105399321	PLD4	0.49	11.16	0.46	8.67e-26	Rheumatoid arthritis;
LGG	cis	rs4853012	0.539	rs9789534	chr2:74362990	A/T	cg20891558	chr2:74357851	NA	0.41	7.75	0.34	6.08e-14	Gestational age at birth (maternal effect);
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.59	-0.33	1.75e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg05119469	chr22:50946460	LMF2;NCAPH2	0.39	6.72	0.3	5.34e-11	Eye color traits;
LGG	trans	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs709400	0.859	rs942863	chr14:104021268	C/T	cg26031613	chr14:104095156	KLC1	1.14	24.65	0.75	2.65e-86	Body mass index;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.18	-0.32	2.75e-12	Lung cancer;
LGG	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg03959625	chr15:84868606	LOC388152	0.56	8.69	0.37	6.32e-17	Schizophrenia;
LGG	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2470578	0.740	rs2733524	chr3:17322397	G/T	cg20981856	chr3:17787350	NA	0.35	6.69	0.3	6.59e-11	Schizophrenia;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.3	-0.32	1.24e-12	Electroencephalogram traits;
LGG	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg21385522	chr1:16154831	NA	0.66	10.89	0.45	9.63e-25	Dilated cardiomyopathy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26373942	chr12:108523463	WSCD2	0.33	6.66	0.3	7.73e-11	Obesity-related traits;
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg07685180	chr8:600429	NA	0.78	8.32	0.36	1.01e-15	IgG glycosylation;
LGG	cis	rs4665809	1.000	rs4665821	chr2:26309949	A/C	cg22920501	chr2:26401640	FAM59B	-0.39	-7.81	-0.34	3.94e-14	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg16339924	chr4:17578868	LAP3	-0.64	-10.98	-0.45	4.44e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	9.21	0.39	1.11e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7119	0.717	rs12904584	chr15:77815991	C/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.46	-0.33	4.24e-13	Morning vs. evening chronotype;
LGG	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg26695010	chr11:65641043	EFEMP2	-0.54	-8.92	-0.38	1.07e-17	Eosinophil percentage of white cells;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg00689492	chr4:1303491	MAEA	-0.47	-8.09	-0.35	5.41e-15	Obesity-related traits;
LGG	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7552404	0.924	rs67757078	chr1:76169456	G/A	cg03433033	chr1:76189801	ACADM	0.82	15.25	0.58	7.4e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00689492	chr4:1303491	MAEA	-0.47	-8.01	-0.35	9.71e-15	Obesity-related traits;
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.96	-0.31	1.17e-11	Bipolar disorder;
LGG	cis	rs1620921	0.563	rs2243944	chr6:161280766	C/G	cg01280913	chr6:161186852	NA	-0.37	-7.64	-0.33	1.23e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14173624	chr17:72199366	RPL38	0.48	7.44	0.33	4.99e-13	Gut microbiome composition (summer);
LGG	cis	rs3806843	1.000	rs3822346	chr5:140187322	C/T	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	trans	rs17685	0.736	rs4732594	chr7:75753273	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.28e-44	Platelet count;
LGG	cis	rs782590	0.902	rs7582278	chr2:55742924	C/G	cg18811423	chr2:55921094	PNPT1	0.87	19.74	0.68	2.19e-63	Metabolic syndrome;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg11062466	chr8:58055876	NA	0.47	7.34	0.32	9.63e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9715521	0.677	rs67500083	chr4:59862419	C/T	cg11281224	chr4:60001000	NA	-0.56	-9.88	-0.42	5.32e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg11764359	chr7:65958608	NA	-0.62	-10.76	-0.45	3.1e-24	Aortic root size;
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.27	0.36	1.4e-15	Platelet count;
LGG	cis	rs6430585	0.528	rs75667274	chr2:136682486	C/T	cg07169764	chr2:136633963	MCM6	1.22	21.1	0.7	9.38e-70	Corneal structure;
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg06481639	chr22:41940642	POLR3H	-0.64	-9.21	-0.39	1.1e-18	Vitiligo;
LGG	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.84	0.38	2.03e-17	Mood instability;
LGG	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg25237894	chr2:233734115	C2orf82	0.65	12.6	0.51	1.61e-31	Coronary artery disease;
LGG	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.69	-0.44	5.55e-24	Neuroticism;
LGG	cis	rs2270450	0.650	rs9381477	chr6:46707580	C/T	cg10156739	chr6:46714674	LOC100287718	-0.47	-10.53	-0.44	2.27e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	7.72	0.34	7.38e-14	Thyroid stimulating hormone;
LGG	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.56	0.37	1.7e-16	Fuchs's corneal dystrophy;
LGG	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.87	-0.48	1.53e-28	Depression;
LGG	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg08847533	chr14:75593920	NEK9	0.62	12.0	0.49	4.53e-29	Height;
LGG	cis	rs4948275	0.530	rs2139778	chr10:63134943	A/T	cg02023345	chr10:63212226	TMEM26	0.4	7.49	0.33	3.59e-13	Night sleep phenotypes;
LGG	cis	rs6963495	0.818	rs73190156	chr7:105153567	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs11792861	0.781	rs28361152	chr9:111727529	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.25	0.43	2.43e-22	Menarche (age at onset);
LGG	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08109568	chr15:31115862	NA	-0.53	-8.79	-0.38	3e-17	Huntington's disease progression;
LGG	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.91	-0.51	9.19e-33	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.48	0.33	3.86e-13	Menopause (age at onset);
LGG	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.72	-0.34	7.47e-14	Diastolic blood pressure;
LGG	cis	rs2117029	0.737	rs34436857	chr12:49439521	A/G	cg24176009	chr12:49580217	TUBA1A	0.48	8.54	0.37	1.95e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.58	-0.41	5.73e-20	Schizophrenia;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08219700	chr8:58056026	NA	0.44	7.01	0.31	8.49e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.85	-0.38	1.79e-17	Lymphocyte counts;
LGG	cis	rs709400	1.000	rs58133129	chr14:104104759	A/G	cg26031613	chr14:104095156	KLC1	1.15	27.69	0.79	2.81e-100	Body mass index;
LGG	cis	rs477692	0.569	rs10764887	chr10:131321719	A/T	cg05714579	chr10:131428358	MGMT	0.52	10.29	0.43	1.72e-22	Response to temozolomide;
LGG	cis	rs4660214	0.666	rs10493087	chr1:39717256	C/G	cg18385671	chr1:39797026	MACF1	-0.46	-9.56	-0.41	7.07e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2444217	0.872	rs2531977	chr16:4043701	C/G	cg09300795	chr16:4042428	ADCY9	0.62	11.69	0.48	8.02e-28	Body mass index;
LGG	cis	rs9557207	0.901	rs11618948	chr13:99891382	C/G	cg24509225	chr13:100037070	UBAC2	0.7	12.48	0.5	4.99e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs9596863	0.898	rs9563174	chr13:54335298	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	7.32	0.32	1.09e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg26384229	chr12:38710491	ALG10B	0.59	11.07	0.46	1.99e-25	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs9296092	0.538	rs3916674	chr6:33522975	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.97e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12681366	0.614	rs2919663	chr8:95470146	C/A	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs17152411	0.744	rs10901835	chr10:126589712	G/T	cg06432487	chr10:126623651	NA	0.4	6.66	0.3	8.02e-11	Height;
LGG	cis	rs4144743	1.000	rs66738981	chr17:45325538	T/A	cg18085866	chr17:45331354	ITGB3	-0.77	-9.28	-0.4	6.48e-19	Body mass index;
LGG	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg06374794	chr16:88002281	BANP	0.43	8.12	0.35	4.4e-15	Menopause (age at onset);
LGG	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.15	0.43	5.34e-22	Dupuytren's disease;
LGG	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg17294928	chr15:75287854	SCAMP5	0.68	12.63	0.51	1.25e-31	Breast cancer;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs903263	0.601	rs11163900	chr1:84557569	G/A	cg10977910	chr1:84465055	TTLL7	0.44	7.83	0.34	3.45e-14	Breast cancer (male);
LGG	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-8.42	-0.36	4.71e-16	Fibrinogen levels;
LGG	trans	rs9650657	0.665	rs1897207	chr8:10615235	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.88	-0.34	2.32e-14	Neuroticism;
LGG	cis	rs3736594	0.513	rs78170284	chr2:27835082	G/A	cg27432699	chr2:27873401	GPN1	0.57	8.52	0.37	2.19e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs60843830	1.000	rs55936726	chr2:258210	T/C	cg04617936	chr2:214353	NA	-0.39	-7.23	-0.32	2.03e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7582720	0.943	rs72926800	chr2:203829225	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.59	0.5	1.89e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.51	-0.63	5e-53	Chronic sinus infection;
LGG	cis	rs11858210	1	rs11858210	chr15:79078358	G/A	cg00540400	chr15:79124168	NA	-0.37	-7.08	-0.31	5.53e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.98	-0.38	7.07e-18	Body mass index;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.95e-42	Prudent dietary pattern;
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg14646974	chr10:38645378	HSD17B7P2	0.43	6.85	0.3	2.37e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8180040	0.903	rs12487736	chr3:47459679	C/T	cg27129171	chr3:47204927	SETD2	0.75	13.97	0.54	2.8e-37	Colorectal cancer;
LGG	cis	rs62025270	0.547	rs416916	chr15:86192416	G/A	cg25843651	chr15:86329602	KLHL25	0.55	9.28	0.4	6.3e-19	Idiopathic pulmonary fibrosis;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.57	0.41	6.29e-20	Total body bone mineral density;
LGG	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg15704280	chr7:45808275	SEPT13	0.86	13.57	0.53	1.54e-35	Coronary artery disease;
LGG	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	cis	rs782590	0.774	rs782629	chr2:55900283	C/T	cg18811423	chr2:55921094	PNPT1	-0.92	-21.75	-0.71	8.9e-73	Metabolic syndrome;
LGG	cis	rs8058578	1.000	rs67456513	chr16:30714828	A/T	cg02466173	chr16:30829666	NA	-0.53	-9.56	-0.41	7.14e-20	Multiple myeloma;
LGG	cis	rs9399135	0.967	rs2150681	chr6:135375232	A/G	cg24558204	chr6:135376177	HBS1L	-0.51	-9.31	-0.4	5.15e-19	Red blood cell count;
LGG	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg06453172	chr10:134556979	INPP5A	-0.45	-7.47	-0.33	4.08e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg07777115	chr5:623756	CEP72	-0.51	-6.78	-0.3	3.74e-11	Obesity-related traits;
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg19774624	chr17:42201019	HDAC5	-0.96	-20.38	-0.69	2.34e-66	Total body bone mineral density;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg11062466	chr8:58055876	NA	0.58	13.41	0.53	7.44e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.34	-0.36	8.42e-16	Educational attainment;
LGG	cis	rs7188861	0.724	rs1794019	chr16:11379775	T/C	cg01510278	chr16:11456238	NA	0.3	7.3	0.32	1.25e-12	HDL cholesterol;
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.61	0.37	1.11e-16	Bipolar disorder;
LGG	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.71e-12	Aortic root size;
LGG	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18876405	chr7:65276391	NA	0.49	8.82	0.38	2.41e-17	Aortic root size;
LGG	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg26513180	chr16:89883248	FANCA	-0.52	-9.02	-0.39	5.21e-18	Vitiligo;
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg22105103	chr4:187893119	NA	0.58	11.12	0.46	1.22e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	5.07e-34	Prudent dietary pattern;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg23782820	chr8:58130467	NA	0.49	7.74	0.34	6.22e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13394619	0.935	rs12468019	chr2:11725049	T/C	cg07314298	chr2:11723111	GREB1	-0.48	-9.93	-0.42	3.29e-21	Endometriosis;
LGG	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg08305652	chr11:111469057	NA	-0.43	-8.57	-0.37	1.54e-16	Primary sclerosing cholangitis;
LGG	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-11.47	-0.47	5.58e-27	Morning vs. evening chronotype;
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg21171335	chr12:122356390	WDR66	0.29	8.34	0.36	8.4e-16	Mean corpuscular volume;
LGG	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.71	0.45	4.8e-24	Lung cancer in ever smokers;
LGG	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg26850624	chr5:429559	AHRR	-0.38	-8.43	-0.36	4.44e-16	Cystic fibrosis severity;
LGG	cis	rs12643440	0.538	rs4698538	chr4:17150001	T/G	cg22650099	chr4:17144496	NA	-0.53	-9.05	-0.39	4.12e-18	Metabolite levels (Pyroglutamine);
LGG	cis	rs2041895	0.509	rs2072559	chr12:107307287	T/G	cg13944111	chr12:107296891	NA	0.27	7.09	0.31	5.19e-12	Glaucoma (low intraocular pressure);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08764805	chr12:95867684	METAP2	0.41	6.85	0.3	2.32e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4926611	1.000	rs6697692	chr1:54116416	A/G	cg23596471	chr1:54105337	GLIS1	0.41	8.52	0.37	2.2e-16	Hand grip strength;
LGG	cis	rs2153535	0.580	rs7747306	chr6:8453663	C/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-9.88	-0.42	5.12e-21	Motion sickness;
LGG	cis	rs13421350	0.579	rs74355465	chr2:173410168	G/A	cg15021238	chr2:173305865	ITGA6	-0.79	-8.46	-0.37	3.57e-16	Diabetic kidney disease;
LGG	cis	rs41005	1.000	rs13402078	chr2:8113107	C/T	cg03155496	chr2:8117019	LOC339788	-0.89	-20.08	-0.68	5.78e-65	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.82	0.51	2.04e-32	Obesity-related traits;
LGG	cis	rs11583043	1.000	rs7521424	chr1:101475901	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.32	0.36	9.87e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg16301924	chr13:53314226	LECT1	-0.41	-8.14	-0.35	3.73e-15	Lewy body disease;
LGG	cis	rs722599	0.748	rs2300599	chr14:75359441	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.05	-0.42	1.24e-21	IgG glycosylation;
LGG	cis	rs4148087	0.656	rs57137919	chr21:43639018	G/A	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.44e-20	Eating disorder in bipolar disorder;
LGG	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg08048268	chr3:133502702	NA	-0.51	-8.93	-0.38	9.8e-18	Iron status biomarkers;
LGG	cis	rs537930	0.925	rs565244	chr5:134349385	T/G	cg24576358	chr5:134350122	NA	0.49	10.32	0.43	1.33e-22	Height;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg03959625	chr15:84868606	LOC388152	0.54	8.13	0.35	3.87e-15	Schizophrenia;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg14668821	chr17:77704760	ENPP7	0.33	6.71	0.3	5.65e-11	Menopause (age at onset);
LGG	trans	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg25482853	chr8:67687455	SGK3	0.94	11.83	0.48	2.06e-28	Obesity-related traits;
LGG	cis	rs11168351	0.591	rs4258439	chr12:48468652	A/G	cg24011408	chr12:48396354	COL2A1	-0.69	-12.22	-0.49	5.77e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg26150922	chr2:100937072	LONRF2	-0.58	-11.06	-0.46	2.23e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.625	rs56232707	chr2:99032298	G/A	cg18455616	chr2:99124870	INPP4A	0.3	8.75	0.38	4.14e-17	Bipolar disorder;
LGG	cis	rs4731207	0.623	rs4506149	chr7:124626473	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.75	-0.3	4.55e-11	Cutaneous malignant melanoma;
LGG	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-8.88	-0.38	1.48e-17	Educational attainment;
LGG	cis	rs4262150	0.672	rs72806780	chr5:152349221	C/T	cg12297329	chr5:152029980	NA	-0.55	-8.56	-0.37	1.72e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	3.08e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs4474465	0.850	rs7942371	chr11:78219975	A/G	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.44	-0.47	7.45e-27	Type 2 diabetes;
LGG	cis	rs9462027	0.606	rs2814979	chr6:34578425	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.29	-0.43	1.69e-22	Systemic lupus erythematosus;
LGG	cis	rs561341	1.000	rs501957	chr17:30314504	C/T	cg13647721	chr17:30228624	UTP6	0.63	7.87	0.34	2.47e-14	Hip circumference adjusted for BMI;
LGG	cis	rs17767392	0.881	rs757850	chr14:72016006	C/G	cg02058870	chr14:72053146	SIPA1L1	-0.43	-8.98	-0.39	6.98e-18	Mitral valve prolapse;
LGG	cis	rs4330281	0.692	rs4908967	chr3:17774944	C/A	cg20981856	chr3:17787350	NA	-0.39	-7.21	-0.32	2.33e-12	Schizophrenia;
LGG	cis	rs13392177	0.647	rs10932761	chr2:219064391	T/A	cg04731861	chr2:219085781	ARPC2	0.5	12.59	0.5	1.88e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1580019	0.961	rs1868777	chr7:32494076	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.65	11.06	0.46	2.16e-25	Cognitive ability;
LGG	cis	rs1682825	0.615	rs5026889	chr3:10777448	C/G	cg25137700	chr3:10780651	NA	0.48	6.89	0.3	1.83e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.98	-0.42	2.28e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7020830	0.823	rs7019699	chr9:37125081	C/A	cg14294708	chr9:37120828	ZCCHC7	1.2	35.67	0.86	6.15e-135	Schizophrenia;
LGG	cis	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.12	-0.35	4.25e-15	Retinal vascular caliber;
LGG	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.03	-0.31	7.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.32	0.4	4.95e-19	Electroencephalogram traits;
LGG	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg04691961	chr3:161091175	C3orf57	-0.54	-12.61	-0.51	1.46e-31	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	11.01	0.46	3.41e-25	Obesity-related traits;
LGG	cis	rs11105298	0.786	rs10858897	chr12:89922032	C/A	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg25208724	chr1:156163844	SLC25A44	1.13	20.4	0.69	1.74e-66	Testicular germ cell tumor;
LGG	trans	rs3812049	0.784	rs7734927	chr5:127453735	T/A	cg16011800	chr17:1958478	HIC1	-0.65	-9.76	-0.41	1.39e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs3806843	0.706	rs2563302	chr5:140079051	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.75	-0.3	4.57e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7113850	0.541	rs75850541	chr11:24211467	C/G	ch.11.24196551F	chr11:24239977	NA	0.9	9.78	0.41	1.13e-20	Bone fracture in osteoporosis;
LGG	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg04691961	chr3:161091175	C3orf57	0.64	14.86	0.57	4.11e-41	Morning vs. evening chronotype;
LGG	cis	rs2012796	0.913	rs8010181	chr14:81820125	T/C	cg02996355	chr14:81879375	NA	0.44	7.11	0.31	4.41e-12	Night sleep phenotypes;
LGG	cis	rs42648	0.564	rs12154563	chr7:89828226	G/T	cg04070188	chr7:89809444	NA	-0.28	-6.69	-0.3	6.54e-11	Homocysteine levels;
LGG	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg06917634	chr15:78832804	PSMA4	-0.5	-7.78	-0.34	4.61e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs12210905	1.000	rs6902012	chr6:27243767	C/T	cg15325629	chr6:28072465	NA	-0.83	-6.82	-0.3	2.88e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	6.98	0.31	1.02e-11	Longevity;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg09217309	chr6:150244204	RAET1G	0.43	7.99	0.35	1.09e-14	Testicular germ cell tumor;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.5	0.56	1.58e-39	Tonsillectomy;
LGG	cis	rs4803468	0.967	rs4802116	chr19:41905540	C/T	cg14132834	chr19:41945861	ATP5SL	-0.48	-9.55	-0.41	7.44e-20	Height;
LGG	cis	rs295140	0.506	rs4673855	chr2:201136143	A/G	cg23649088	chr2:200775458	C2orf69	-0.44	-7.68	-0.34	9.61e-14	QT interval;
LGG	cis	rs6681460	0.625	rs2312154	chr1:67072976	C/T	cg20812318	chr1:67072952	SGIP1	0.32	7.59	0.33	1.77e-13	Presence of antiphospholipid antibodies;
LGG	cis	rs11758351	0.500	rs113738935	chr6:26196567	T/A	cg23601095	chr6:26197514	HIST1H3D	0.89	6.73	0.3	5.12e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg19077165	chr18:44547161	KATNAL2	0.53	9.47	0.4	1.43e-19	Personality dimensions;
LGG	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	9.96	0.42	2.61e-21	Rheumatoid arthritis;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg04703951	chr17:43578652	NA	0.39	7.94	0.35	1.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg11366901	chr6:160182831	ACAT2	0.88	14.37	0.56	5.4e-39	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7432375	1.000	rs6439649	chr3:136371691	G/T	cg21827317	chr3:136751795	NA	-0.48	-8.66	-0.37	7.69e-17	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21068152	chr12:120740453	SIRT4	0.53	7.92	0.35	1.81e-14	Gut microbiome composition (summer);
LGG	cis	rs72925845	0.577	rs691317	chr17:76429346	T/A	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs10883723	0.810	rs6584504	chr10:104253507	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg05941027	chr17:61774174	LIMD2	0.33	8.25	0.36	1.67e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08307612	chr20:62526785	DNAJC5	0.49	7.21	0.32	2.24e-12	Hip circumference;
LGG	cis	rs9487051	0.676	rs6925716	chr6:109597641	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.88	-0.34	2.31e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg21174375	chr14:64681225	SYNE2	-0.47	-9.07	-0.39	3.31e-18	Atrial fibrillation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01302669	chr3:49824110	IP6K1	0.42	7.12	0.31	4.11e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs13394619	1.000	rs4669752	chr2:11727988	G/C	cg07314298	chr2:11723111	GREB1	-0.49	-10.11	-0.43	7.82e-22	Endometriosis;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.29	0.36	1.2e-15	Schizophrenia;
LGG	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg25358565	chr5:93447407	FAM172A	1.26	15.32	0.58	3.96e-43	Diabetic retinopathy;
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	-1.09	-17.0	-0.62	1.06e-50	Platelet count;
LGG	cis	rs908922	0.924	rs6669608	chr1:152475233	A/G	cg20991723	chr1:152506922	NA	-0.58	-9.47	-0.4	1.47e-19	Hair morphology;
LGG	cis	rs9811920	0.770	rs4928237	chr3:99731330	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.78	-0.38	3.09e-17	Axial length;
LGG	cis	rs3857067	0.901	rs4693368	chr4:95046907	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.14	-0.35	3.63e-15	QT interval;
LGG	cis	rs78366141	0.649	rs17014616	chr4:89736565	A/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.77	6.79	0.3	3.45e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs894344	0.546	rs10481417	chr8:135551178	T/A	cg09855544	chr8:135498122	ZFAT	0.43	7.77	0.34	5.12e-14	Systolic blood pressure;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg04287289	chr16:89883240	FANCA	0.8	8.57	0.37	1.52e-16	Skin colour saturation;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs55823223	0.564	rs936396	chr17:73846829	C/G	cg08125733	chr17:73851984	WBP2	0.72	11.29	0.46	2.71e-26	Psoriasis;
LGG	cis	rs972578	0.715	rs5759054	chr22:43348178	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.11	-0.31	4.28e-12	Mean platelet volume;
LGG	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg07636037	chr3:49044803	WDR6	1.1	28.1	0.79	4.13e-102	Parkinson's disease;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.52	-0.44	2.44e-23	Triglycerides;
LGG	cis	rs7084402	0.935	rs10763556	chr10:60341398	A/G	cg07615347	chr10:60278583	BICC1	-0.61	-17.37	-0.63	2.2e-52	Refractive error;
LGG	cis	rs59197085	0.636	rs4728138	chr7:128468105	A/G	cg00734629	chr7:128471146	FLNC	0.34	6.95	0.31	1.25e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.6	0.33	1.67e-13	Triglycerides;
LGG	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4308124	0.708	rs6747657	chr2:112003163	C/T	cg04571233	chr2:111982156	NA	-0.62	-10.17	-0.43	4.7e-22	Vitiligo;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.49	-0.33	3.44e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg15596359	chr8:11213517	TDH	0.42	8.69	0.37	6.46e-17	Retinal vascular caliber;
LGG	cis	rs701145	0.585	rs1527800	chr3:153875075	A/G	cg17054900	chr3:154042577	DHX36	0.81	9.54	0.41	8.24e-20	Coronary artery disease;
LGG	cis	rs9815354	1.000	rs3890604	chr3:41760625	C/T	cg03022575	chr3:42003672	ULK4	0.59	7.59	0.33	1.76e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.14	-0.35	3.76e-15	Joint mobility (Beighton score);
LGG	cis	rs36051895	0.659	rs3780365	chr9:5068520	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-16.01	-0.6	3.05e-46	Pediatric autoimmune diseases;
LGG	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg07303275	chr16:75499416	TMEM170A	0.38	6.89	0.3	1.88e-11	Dupuytren's disease;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.9	0.59	9.87e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14893161	chr1:205819251	PM20D1	1.0	27.0	0.78	3.93e-97	Menarche (age at onset);
LGG	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	cis	rs2597513	0.719	rs2675228	chr3:13553380	C/T	cg24006715	chr3:13568212	NA	0.63	10.59	0.44	1.34e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs12200560	0.505	rs211178	chr6:97074094	T/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.71	0.34	8.02e-14	Coronary heart disease;
LGG	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg00204512	chr16:28754710	NA	0.26	7.33	0.32	1.01e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.24e-13	Schizophrenia;
LGG	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg07005078	chr4:17578674	LAP3	0.36	6.82	0.3	2.82e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg15440763	chr7:158190612	PTPRN2	0.49	10.18	0.43	4.37e-22	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.56	0.33	2.19e-13	Lung cancer;
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg13699009	chr12:122356056	WDR66	-0.43	-10.22	-0.43	3.14e-22	Mean corpuscular volume;
LGG	trans	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg18335740	chr13:41363409	SLC25A15	0.61	12.2	0.49	7.05e-30	Lewy body disease;
LGG	cis	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg20368463	chr18:77673604	PQLC1	0.5	7.66	0.34	1.06e-13	Opioid sensitivity;
LGG	cis	rs7523273	0.927	rs1891423	chr1:207931913	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.04	0.46	2.47e-25	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.17e-21	Diabetic kidney disease;
LGG	cis	rs6692729	0.897	rs7518926	chr1:227000011	C/G	cg08708961	chr1:227070630	PSEN2	-0.28	-7.13	-0.31	3.92e-12	Electrodermal activity;
LGG	cis	rs6450176	0.857	rs1541680	chr5:53304725	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.57e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs3126085	0.935	rs6666382	chr1:152217226	C/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.32	-0.36	1e-15	Atopic dermatitis;
LGG	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs2836974	0.931	rs13047663	chr21:40708818	C/T	cg11890956	chr21:40555474	PSMG1	1.11	23.38	0.74	2.06e-80	Cognitive function;
LGG	cis	rs7580658	0.929	rs4150496	chr2:128029503	C/T	cg10021288	chr2:128175891	PROC	-0.63	-13.11	-0.52	1.27e-33	Protein C levels;
LGG	cis	rs62432291	0.681	rs404461	chr6:159640709	T/C	cg14500486	chr6:159655392	FNDC1	0.63	7.03	0.31	7.49e-12	Joint mobility (Beighton score);
LGG	trans	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.74	-0.3	4.62e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4330281	0.647	rs6577616	chr3:17715524	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs4660214	0.724	rs3931300	chr1:39660847	A/G	cg18385671	chr1:39797026	MACF1	-0.47	-9.0	-0.39	5.86e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.05	0.39	3.97e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08564027	chr20:61660810	NA	1.03	25.77	0.77	1.75e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1707322	0.721	rs6665808	chr1:46162283	C/T	cg03146154	chr1:46216737	IPP	0.56	11.06	0.46	2.1e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg08888203	chr3:10149979	C3orf24	0.53	9.01	0.39	5.37e-18	Alzheimer's disease;
LGG	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg11752832	chr7:134001865	SLC35B4	0.6	11.0	0.46	3.67e-25	Mean platelet volume;
LGG	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	13.06	0.52	2.01e-33	Cognitive test performance;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09699651	chr6:150184138	LRP11	0.58	11.19	0.46	6.93e-26	Testicular germ cell tumor;
LGG	cis	rs1007190	0.764	rs8082522	chr17:42876340	G/C	cg15406952	chr17:42872593	NA	-1.21	-15.37	-0.58	2.28e-43	DNA methylation (variation);
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg13866156	chr1:1669148	SLC35E2	-0.63	-14.23	-0.55	2.15e-38	Body mass index;
LGG	cis	rs1018836	0.886	rs10283086	chr8:91616651	G/A	cg16814680	chr8:91681699	NA	-0.84	-16.12	-0.6	1.04e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26118713	chr7:148580496	EZH2	0.46	7.19	0.32	2.61e-12	Gut microbiome composition (summer);
LGG	trans	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg13565492	chr6:43139072	SRF	-0.75	-9.04	-0.39	4.29e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11166927	0.524	rs10092101	chr8:140830697	C/T	cg16909799	chr8:140841666	TRAPPC9	-0.61	-12.4	-0.5	1.07e-30	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg14092988	chr3:52407081	DNAH1	0.29	7.9	0.34	2.09e-14	Bipolar disorder;
LGG	cis	rs4780401	0.901	rs34774904	chr16:11817107	G/A	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.06	-0.31	6.15e-12	Rheumatoid arthritis;
LGG	cis	rs9557207	1.000	rs12877480	chr13:100002818	G/C	cg24509225	chr13:100037070	UBAC2	0.7	12.77	0.51	3.19e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7192750	0.538	rs4788582	chr16:71981806	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.71	0.45	4.59e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg16096631	chr1:42092165	HIVEP3	-0.59	-13.45	-0.53	4.91e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11245990	chr11:68621969	NA	0.43	9.08	0.39	3.07e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7296418	0.738	rs10846489	chr12:123743927	A/G	cg00376283	chr12:123451042	ABCB9	-0.64	-11.92	-0.48	9.24e-29	Platelet count;
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg22105103	chr4:187893119	NA	0.54	10.35	0.43	1.03e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7666738	0.830	rs6854594	chr4:99065312	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg08355456	chr11:67383691	NA	0.5	8.51	0.37	2.44e-16	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs564799	0.966	rs2647930	chr3:159736893	T/C	cg04855961	chr3:159719849	NA	-0.28	-7.53	-0.33	2.72e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.97	-0.31	1.12e-11	Lung cancer;
LGG	trans	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg18187862	chr3:45730750	SACM1L	-0.55	-8.61	-0.37	1.14e-16	Primary sclerosing cholangitis;
LGG	cis	rs7103648	1.000	rs12292911	chr11:47449072	C/T	cg20307385	chr11:47447363	PSMC3	0.98	23.62	0.74	1.52e-81	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.22	-0.43	3.11e-22	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05468351	chr5:21459598	LOC728411	0.45	7.43	0.33	5.36e-13	Cognitive performance;
LGG	cis	rs6732160	0.613	rs57208378	chr2:73389999	G/A	cg01422370	chr2:73384389	NA	0.58	10.21	0.43	3.41e-22	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg14088196	chr11:70211408	PPFIA1	0.96	13.11	0.52	1.35e-33	Coronary artery disease;
LGG	trans	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg14222797	chr10:16859974	RSU1	-0.6	-7.21	-0.32	2.24e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg08859206	chr1:53392774	SCP2	-0.35	-6.78	-0.3	3.69e-11	Monocyte count;
LGG	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.75e-23	Hip circumference adjusted for BMI;
LGG	cis	rs6594713	0.732	rs13174206	chr5:112728482	C/T	cg12552261	chr5:112820674	MCC	-0.52	-7.54	-0.33	2.44e-13	Brain cytoarchitecture;
LGG	cis	rs35306767	0.714	rs7072554	chr10:1090988	C/T	cg25019033	chr10:957182	NA	-0.45	-8.77	-0.38	3.39e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs7246760	0.867	rs2336090	chr19:9879584	A/G	cg02900749	chr2:68251473	NA	-1.04	-11.35	-0.47	1.63e-26	Pursuit maintenance gain;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13732083	chr21:47605072	C21orf56	0.5	8.47	0.37	3.38e-16	Testicular germ cell tumor;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.6	-10.14	-0.43	6.14e-22	Obesity-related traits;
LGG	trans	rs9914544	0.545	rs9898426	chr17:18794071	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg08999081	chr20:33150536	PIGU	-0.39	-9.86	-0.42	6.06e-21	Glomerular filtration rate (creatinine);
LGG	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.87	0.38	1.65e-17	Myopia (pathological);
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.77	0.41	1.3e-20	Triglycerides;
LGG	cis	rs10754283	0.935	rs10801756	chr1:90101832	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.22	-0.32	2.22e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.49	-0.33	3.62e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg04568710	chr12:38710424	ALG10B	0.36	7.71	0.34	7.7e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.85	11.35	0.47	1.7e-26	Mean platelet volume;
LGG	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.57	-0.33	2.07e-13	Psoriasis;
LGG	cis	rs9397585	0.857	rs1338066	chr6:153380462	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.35	0.47	1.59e-26	Bipolar disorder;
LGG	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg05444541	chr17:17804740	TOM1L2	-0.75	-18.17	-0.65	4.3e-56	Total body bone mineral density;
LGG	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	Neuroticism;
LGG	cis	rs11628318	0.570	rs2896450	chr14:103076595	T/C	cg01864069	chr14:103024347	NA	-0.68	-9.57	-0.41	6.59e-20	Platelet count;
LGG	cis	rs4538187	0.518	rs781516	chr2:64276576	A/G	cg19915305	chr2:64069682	UGP2	0.51	12.66	0.51	9.47e-32	Systolic blood pressure;
LGG	cis	rs3820068	0.603	rs7529759	chr1:15977877	A/G	cg05660106	chr1:15850417	CASP9	0.82	16.81	0.62	7.6e-50	Systolic blood pressure;
LGG	cis	rs1823874	0.581	rs12910401	chr15:100339897	T/C	cg16400843	chr15:100339927	C15orf51	0.42	6.96	0.31	1.2e-11	IgG glycosylation;
LGG	cis	rs9814567	1.000	rs7428326	chr3:134251184	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2562152	0.706	rs216598	chr16:108585	T/C	cg02949481	chr16:131562	MPG	0.57	8.4	0.36	5.35e-16	Glioblastoma;
LGG	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg02002194	chr4:3960332	NA	-0.45	-8.63	-0.37	1.03e-16	Mood instability;
LGG	cis	rs7945705	0.967	rs10769968	chr11:8907583	G/C	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.2	0.46	6.18e-26	Hemoglobin concentration;
LGG	cis	rs7020830	0.928	rs11544336	chr9:37089150	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	33.58	0.84	3.5e-126	Schizophrenia;
LGG	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.65	-0.33	1.15e-13	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.25	0.7	1.92e-70	Morning vs. evening chronotype;
LGG	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg24253500	chr15:84953950	NA	-0.56	-10.29	-0.43	1.65e-22	Schizophrenia;
LGG	cis	rs17221829	0.733	rs1873083	chr11:89396810	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-8.9	-0.38	1.24e-17	Anxiety in major depressive disorder;
LGG	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.28	-0.4	6.43e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72781680	0.716	rs2712065	chr2:23973603	C/T	cg08917208	chr2:24149416	ATAD2B	-0.64	-8.34	-0.36	8.43e-16	Lymphocyte counts;
LGG	cis	rs1801251	1.000	rs11676216	chr2:233706368	C/T	cg25237894	chr2:233734115	C2orf82	-0.66	-12.44	-0.5	7.84e-31	Coronary artery disease;
LGG	trans	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.26	0.5	4.09e-30	Type 2 diabetes;
LGG	cis	rs1665650	0.957	rs1638419	chr10:118493063	G/T	cg14919929	chr10:118506882	NA	0.5	8.78	0.38	3.16e-17	Colorectal cancer;
LGG	cis	rs367615	0.918	rs10055528	chr5:108861129	G/T	cg17395555	chr5:108820864	NA	0.66	9.35	0.4	3.66e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg03352830	chr11:487213	PTDSS2	0.87	11.35	0.47	1.63e-26	Body mass index;
LGG	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg26597838	chr10:835615	NA	0.74	10.03	0.42	1.44e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs10131894	0.611	rs175000	chr14:75436367	T/C	cg08847533	chr14:75593920	NEK9	-0.46	-8.48	-0.37	3.12e-16	Coronary artery disease;
LGG	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg01657329	chr11:68192670	LRP5	-0.5	-8.54	-0.37	1.99e-16	Total body bone mineral density;
LGG	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg15325629	chr6:28072465	NA	0.81	6.64	0.3	8.54e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1790761	0.505	rs7106423	chr11:67314144	A/G	cg09038676	chr11:67351608	GSTP1	0.35	6.94	0.31	1.35e-11	Mean corpuscular volume;
LGG	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.59	8.0	0.35	9.84e-15	Facial emotion recognition (sad faces);
LGG	cis	rs7215564	0.818	rs35929483	chr17:78635944	C/A	cg16980736	chr17:78789706	RPTOR	-0.71	-9.31	-0.4	5.22e-19	Myopia (pathological);
LGG	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg08717414	chr16:71523259	ZNF19	-1.02	-12.92	-0.51	8.04e-33	Post bronchodilator FEV1;
LGG	cis	rs240764	0.746	rs240156	chr6:101063149	C/G	cg09795085	chr6:101329169	ASCC3	0.46	7.56	0.33	2.19e-13	Neuroticism;
LGG	cis	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg21775007	chr8:11205619	TDH	-0.48	-7.39	-0.32	6.85e-13	Triglycerides;
LGG	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg16339924	chr4:17578868	LAP3	0.6	10.47	0.44	3.58e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.01e-85	Height;
LGG	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-7.93	-0.35	1.64e-14	Response to antipsychotic treatment;
LGG	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg15704280	chr7:45808275	SEPT13	0.7	7.23	0.32	2.02e-12	Intraocular pressure;
LGG	cis	rs9549367	0.713	rs3024769	chr13:113825601	A/C	cg00898013	chr13:113819073	PROZ	0.48	9.93	0.42	3.43e-21	Platelet distribution width;
LGG	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs28830936	1.000	rs2577960	chr15:42028354	C/A	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	0.33	6.74	0.3	4.76e-11	Diastolic blood pressure;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg13206674	chr6:150067644	NUP43	0.4	8.6	0.37	1.24e-16	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.61	-0.37	1.19e-16	Myopia (pathological);
LGG	cis	rs11966931	0.711	rs4945790	chr6:108109985	C/T	cg04749840	chr6:108095067	SCML4	-0.45	-9.03	-0.39	4.63e-18	Neutrophil percentage of white cells;
LGG	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.52	-0.37	2.27e-16	Menarche (age at onset);
LGG	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.0	0.31	8.81e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.17	0.58	1.75e-42	Alzheimer's disease;
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.84	0.57	4.92e-41	Platelet count;
LGG	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.47	-0.33	4.02e-13	Joint mobility (Beighton score);
LGG	cis	rs4959677	0.718	rs1680853	chr6:2500701	A/G	cg20147862	chr6:2634573	C6orf195	-0.37	-8.2	-0.36	2.39e-15	Orthostatic hypotension;
LGG	cis	rs1707322	0.638	rs9429095	chr1:46603348	A/C	cg03146154	chr1:46216737	IPP	-0.53	-9.18	-0.39	1.45e-18	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg18252515	chr7:66147081	NA	0.41	6.93	0.31	1.44e-11	Aortic root size;
LGG	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	14.76	0.57	1.13e-40	Smoking behavior;
LGG	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg16230307	chr14:35515116	FAM177A1	0.82	11.82	0.48	2.24e-28	Psoriasis;
LGG	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.22	-0.43	3.02e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.41	7.14	0.32	3.56e-12	HDL cholesterol;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs1497828	0.956	rs2646831	chr1:217544521	C/T	cg04411442	chr1:217543379	NA	0.48	8.18	0.36	2.82e-15	Dialysis-related mortality;
LGG	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	11.06	0.46	2.25e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17767392	0.918	rs34533948	chr14:71772727	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs988958	0.526	rs7604662	chr2:42243943	A/G	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Hypospadias;
LGG	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.28	0.43	1.77e-22	Height;
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.5	0.37	2.67e-16	Aortic root size;
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg17178900	chr1:205818956	PM20D1	-0.36	-7.36	-0.32	8.54e-13	Menarche (age at onset);
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg11301795	chr4:187892539	NA	-0.94	-25.27	-0.76	3.57e-89	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4789452	1.000	rs34596832	chr17:75373170	C/T	cg06761530	chr17:75373219	SEPT9	-0.38	-7.51	-0.33	3.08e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs926938	0.527	rs6680112	chr1:115548915	G/C	cg12756093	chr1:115239321	AMPD1	0.42	7.81	0.34	3.91e-14	Autism;
LGG	cis	rs1003719	0.680	rs2835619	chr21:38505380	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs10744422	1.000	rs10744434	chr12:123368419	T/A	cg25930673	chr12:123319894	HIP1R	-0.7	-9.24	-0.39	9.09e-19	Schizophrenia;
LGG	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg02269571	chr22:50332266	NA	0.53	8.27	0.36	1.43e-15	Schizophrenia;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.36	0.32	8.34e-13	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs36068983	chr7:65408991	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.83	-0.34	3.36e-14	Neuroticism;
LGG	cis	rs10463316	0.928	rs10060441	chr5:150750006	A/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.51	-0.44	2.63e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs2708240	0.504	rs851704	chr7:147538431	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.3	-7.06	-0.31	6.25e-12	QT interval (drug interaction);
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.56	0.37	1.7e-16	Prostate cancer;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	1.000	rs4955555	chr3:134286427	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7572733	0.534	rs1401091	chr2:198790423	T/G	cg00792783	chr2:198669748	PLCL1	-0.68	-11.05	-0.46	2.39e-25	Dermatomyositis;
LGG	cis	rs6565180	0.926	rs4788409	chr16:30393771	G/A	cg17640201	chr16:30407289	ZNF48	0.84	16.21	0.6	3.93e-47	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2688608	0.901	rs2459446	chr10:75601596	C/T	cg23231163	chr10:75533350	FUT11	0.41	7.08	0.31	5.48e-12	Inflammatory bowel disease;
LGG	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs9399135	0.935	rs4273704	chr6:135297520	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.53e-19	Red blood cell count;
LGG	cis	rs793571	0.669	rs28864995	chr15:58945671	T/G	cg05156742	chr15:59063176	FAM63B	0.49	7.86	0.34	2.75e-14	Schizophrenia;
LGG	cis	rs798766	1.000	rs1665364	chr4:1727206	A/G	cg05874882	chr4:1763078	NA	0.47	6.8	0.3	3.31e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs4974559	0.947	rs28649968	chr4:1362913	G/A	cg02980000	chr4:1222292	CTBP1	0.66	8.16	0.35	3.26e-15	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg18681998	chr4:17616180	MED28	0.89	20.5	0.69	6.2e-67	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-7.08	-0.31	5.51e-12	Vitiligo;
LGG	cis	rs10766496	1.000	rs4424652	chr11:18737095	C/T	cg02515468	chr11:18743222	IGSF22	-0.46	-7.78	-0.34	4.83e-14	Diabetic kidney disease;
LGG	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs4799461	0.580	rs1941953	chr18:35154890	A/G	cg27332583	chr18:35150602	NA	0.55	8.55	0.37	1.83e-16	Neuroticism;
LGG	cis	rs986417	1.000	rs1254296	chr14:60870389	T/C	cg27398547	chr14:60952738	C14orf39	-0.69	-6.88	-0.3	1.94e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg13010199	chr12:38710504	ALG10B	0.36	6.8	0.3	3.19e-11	Morning vs. evening chronotype;
LGG	trans	rs11875185	0.510	rs35899742	chr18:55634518	C/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg05444541	chr17:17804740	TOM1L2	-0.78	-21.62	-0.71	3.72e-72	Total body bone mineral density;
LGG	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg11502198	chr6:26597334	ABT1	0.7	12.1	0.49	1.87e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg09904177	chr6:26538194	HMGN4	0.77	16.91	0.62	2.6e-50	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg16678437	chr1:245133033	EFCAB2	0.43	6.74	0.3	4.71e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg12708336	chr17:41446283	NA	-0.31	-7.36	-0.32	8.74e-13	Menopause (age at onset);
LGG	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg12623918	chr2:306882	NA	0.52	9.75	0.41	1.48e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs17672112	0.834	rs614097	chr6:101344673	C/T	cg27451362	chr6:101846650	GRIK2	0.8	10.18	0.43	4.13e-22	Putamen volume;
LGG	cis	rs4740619	0.507	rs7866894	chr9:15809051	G/A	cg14451791	chr9:16040625	NA	0.31	7.68	0.34	9.36e-14	Body mass index;
LGG	cis	rs2018055	0.644	rs4632931	chr6:117798433	T/C	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs2597513	0.790	rs2675229	chr3:13551810	C/T	cg24006715	chr3:13568212	NA	-0.59	-9.89	-0.42	4.86e-21	Hip circumference adjusted for BMI;Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13662262	chr21:30364895	RNF160	0.46	6.99	0.31	9.69e-12	Gut microbiome composition (summer);
LGG	cis	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.22	-0.49	5.78e-30	Resting heart rate;
LGG	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg11843606	chr2:227700838	RHBDD1	-0.56	-10.35	-0.43	1.04e-22	Pulmonary function;
LGG	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg14500267	chr11:67383377	NA	-0.39	-7.2	-0.32	2.51e-12	Mean corpuscular volume;
LGG	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg04568710	chr12:38710424	ALG10B	0.38	8.26	0.36	1.6e-15	Heart rate;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg16639922	chr3:9975056	IL17RC;CRELD1	-0.38	-6.84	-0.3	2.58e-11	Iris color (L* coordinate);
LGG	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg09998033	chr7:158218633	PTPRN2	0.45	8.04	0.35	7.51e-15	Obesity-related traits;
LGG	cis	rs271738	0.674	rs94878	chr1:234678716	C/A	cg05133706	chr1:234667230	NA	-0.33	-7.57	-0.33	2.03e-13	Bipolar disorder;
LGG	cis	rs60180747	0.909	rs17200970	chr15:66731045	A/C	cg07575407	chr15:66541975	MEGF11	0.38	7.27	0.32	1.53e-12	Testicular germ cell tumor;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-8.46	-0.37	3.65e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.77	0.38	3.32e-17	Intelligence (multi-trait analysis);
LGG	trans	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg22232500	chr2:134024266	NCKAP5	0.55	7.91	0.35	1.89e-14	Bipolar disorder;
LGG	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg13770153	chr20:60521292	NA	-0.48	-7.71	-0.34	7.75e-14	Body mass index;
LGG	cis	rs7267979	0.932	rs433352	chr20:25467992	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-9.91	-0.42	3.93e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.93	0.31	1.41e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12464559	0.579	rs6740508	chr2:152613212	T/A	cg01189475	chr2:152685088	ARL5A	0.75	6.78	0.3	3.6e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.66	-0.54	6.39e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs4865875	1.000	rs6450252	chr5:54101890	G/T	cg22421804	chr5:54100067	NA	0.51	7.68	0.34	9.64e-14	Sense of smell;
LGG	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg14829155	chr15:31115871	NA	-0.56	-9.89	-0.42	4.76e-21	Huntington's disease progression;
LGG	cis	rs28830936	0.966	rs3743024	chr15:42118971	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.95	-0.52	6.23e-33	Diastolic blood pressure;
LGG	cis	rs9487094	0.885	rs59906308	chr6:109759552	G/A	cg16315928	chr6:109776240	MICAL1	0.56	9.35	0.4	3.67e-19	Height;
LGG	cis	rs7432375	1.000	rs10935186	chr3:136346206	T/C	cg21827317	chr3:136751795	NA	0.48	8.66	0.37	7.69e-17	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.57	9.36	0.4	3.59e-19	Longevity;
LGG	trans	rs9650657	0.801	rs4841437	chr8:10596795	T/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.87	-0.3	2.08e-11	Neuroticism;
LGG	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.39	0.36	6.08e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs11191205	0.686	rs11191092	chr10:103449251	T/C	cg15320455	chr10:103880129	LDB1	0.53	7.66	0.34	1.13e-13	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs7241530	0.610	rs12457297	chr18:75893680	G/A	cg14642773	chr18:75888474	NA	0.48	9.42	0.4	2.16e-19	Educational attainment (years of education);
LGG	cis	rs9310709	0.538	rs822770	chr3:23032988	T/C	cg00327796	chr3:23032191	NA	0.45	9.15	0.39	1.85e-18	Chronic kidney disease and serum creatinine levels;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-32.93	-0.84	2.25e-123	Prudent dietary pattern;
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg26850624	chr5:429559	AHRR	-0.37	-7.89	-0.34	2.18e-14	Cystic fibrosis severity;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.38	0.32	7.58e-13	Prudent dietary pattern;
LGG	cis	rs10089	1.000	rs4836366	chr5:127482494	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.82	0.48	2.33e-28	Ileal carcinoids;
LGG	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg18196295	chr10:418757	DIP2C	-0.56	-10.02	-0.42	1.62e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03517284	chr6:25882590	NA	-0.49	-9.37	-0.4	3.19e-19	Blood metabolite levels;
LGG	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg05234568	chr11:5960015	NA	-0.75	-12.47	-0.5	5.7e-31	DNA methylation (variation);
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14159672	chr1:205819179	PM20D1	-0.5	-9.28	-0.4	6.51e-19	Menarche (age at onset);
LGG	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.65	-0.33	1.21e-13	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.68	0.41	2.54e-20	Longevity;
LGG	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg21475434	chr5:93447410	FAM172A	0.72	6.68	0.3	6.73e-11	Diabetic retinopathy;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1707322	0.827	rs12125508	chr1:46246010	A/G	cg03146154	chr1:46216737	IPP	0.58	10.62	0.44	9.66e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.03	-21.34	-0.7	7.32e-71	Homoarginine levels;
LGG	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg19398112	chr19:14529923	DDX39	-0.38	-7.71	-0.34	7.88e-14	Iris color (L* coordinate);
LGG	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	12.99	0.52	4.27e-33	Lung cancer in ever smokers;
LGG	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg02002194	chr4:3960332	NA	-0.52	-10.12	-0.43	6.81e-22	Mood instability;
LGG	cis	rs2795502	1.000	rs1581702	chr10:43344246	G/A	cg27426351	chr10:43362370	NA	0.55	7.79	0.34	4.49e-14	Blood protein levels;
LGG	cis	rs3796352	1.000	rs11710707	chr3:52975916	A/G	cg12962167	chr3:53033115	SFMBT1	0.77	8.07	0.35	6.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg02487422	chr3:49467188	NICN1	0.57	10.42	0.44	5.39e-23	Resting heart rate;
LGG	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4262150	0.960	rs9324737	chr5:152279610	C/G	cg12297329	chr5:152029980	NA	0.6	11.44	0.47	7.5e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7737355	1.000	rs257389	chr5:130744263	A/C	cg06307176	chr5:131281290	NA	-0.51	-8.62	-0.37	1.11e-16	Life satisfaction;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-9.01	-0.39	5.62e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7296418	0.699	rs1109559	chr12:123757861	C/T	cg05973401	chr12:123451056	ABCB9	0.43	7.22	0.32	2.12e-12	Platelet count;
LGG	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg04450456	chr4:17643702	FAM184B	0.3	6.78	0.3	3.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs42648	1.000	rs42649	chr7:89977789	A/T	cg25739043	chr7:89950458	NA	-0.38	-8.0	-0.35	9.86e-15	Homocysteine levels;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg06028808	chr11:68637592	NA	0.69	11.86	0.48	1.56e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7772486	0.558	rs2142978	chr6:146012061	T/C	cg13319975	chr6:146136371	FBXO30	0.41	6.75	0.3	4.43e-11	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6787172	0.702	rs1193509	chr3:158030243	C/T	cg23275840	chr4:47708675	CORIN	-0.41	-8.74	-0.38	4.45e-17	Subjective well-being;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.84	0.38	2.04e-17	Lung cancer;
LGG	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs7928758	0.887	rs76956658	chr11:134272144	G/A	cg25213107	chr11:134282864	B3GAT1	1.22	15.03	0.57	6.95e-42	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7166081	1.000	rs877177	chr15:67505960	T/A	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.04	0.31	6.99e-12	Lung cancer;
LGG	cis	rs11877825	0.865	rs34956381	chr18:10571021	G/A	cg07277756	chr18:10589357	NA	0.56	10.1	0.43	7.97e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs28588043	0.877	rs72710580	chr1:170995732	G/A	cg03458344	chr1:170964477	C1orf129	-0.54	-7.25	-0.32	1.81e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs55883249	0.957	rs62119393	chr2:9718247	C/T	cg23886495	chr2:9695866	ADAM17	0.65	9.24	0.39	8.97e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs13177180	0.671	rs10043094	chr5:114919459	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-10.18	-0.43	4.24e-22	Conotruncal heart defects (inherited effects);
LGG	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg05082376	chr22:42548792	NA	0.37	7.81	0.34	3.82e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7527798	0.592	rs12563520	chr1:207844062	C/T	cg09232269	chr1:207846808	CR1L	-0.36	-6.79	-0.3	3.44e-11	Erythrocyte sedimentation rate;
LGG	cis	rs6831352	0.918	rs29001199	chr4:100053891	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.93	-0.38	1e-17	Alcohol dependence;
LGG	cis	rs4780401	0.933	rs11075010	chr16:11826013	C/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.36	-0.32	8.53e-13	Rheumatoid arthritis;
LGG	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg21972741	chr5:435613	AHRR	0.5	8.99	0.39	6.13e-18	Cystic fibrosis severity;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg06916706	chr16:4465613	CORO7	0.7	11.75	0.48	4.35e-28	Schizophrenia;
LGG	cis	rs7937612	0.965	rs4938806	chr11:120274353	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.51	-12.11	-0.49	1.59e-29	Intraocular pressure;
LGG	cis	rs6719977	0.543	rs4953631	chr2:42970990	G/T	cg14631114	chr2:43023945	NA	-0.44	-9.03	-0.39	4.67e-18	Hyperactive-impulsive symptoms;
LGG	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg12698349	chr2:225449008	CUL3	0.69	11.65	0.48	1.09e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs17106184	1.000	rs11205773	chr1:51284905	C/T	cg07174182	chr1:51127561	FAF1	-0.59	-8.75	-0.38	3.93e-17	Type 2 diabetes;
LGG	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.59	-11.42	-0.47	8.97e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs847577	0.609	rs11763970	chr7:97817321	A/G	cg13397024	chr7:97797637	LMTK2	-0.35	-6.68	-0.3	6.73e-11	Breast cancer;
LGG	cis	rs7647973	0.922	rs7620024	chr3:49451691	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.48	-7.36	-0.32	8.71e-13	Menarche (age at onset);
LGG	cis	rs16854884	0.586	rs13081286	chr3:143723757	A/T	cg06585982	chr3:143692056	C3orf58	0.66	11.93	0.48	8.42e-29	Economic and political preferences (feminism/equality);
LGG	cis	rs2562456	0.917	rs11085463	chr19:21751302	G/T	cg00806126	chr19:22604979	ZNF98	-0.64	-9.77	-0.41	1.3e-20	Pain;
LGG	cis	rs73001065	0.901	rs73002956	chr19:19578743	A/G	cg03709012	chr19:19516395	GATAD2A	0.91	7.87	0.34	2.56e-14	LDL cholesterol;
LGG	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg16434002	chr17:42200994	HDAC5	0.43	7.72	0.34	7.28e-14	Total body bone mineral density;
LGG	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg15522984	chr1:182991683	LAMC1	0.48	9.83	0.42	7.64e-21	Hypertriglyceridemia;
LGG	cis	rs12765878	1.000	rs11191849	chr10:105650880	T/A	cg11005552	chr10:105648138	OBFC1	1.03	27.18	0.78	5.76e-98	Coronary artery disease;
LGG	cis	rs7089973	0.872	rs17092542	chr10:116630289	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.53	0.33	2.68e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs914187	0.840	rs914186	chr21:42619657	A/G	cg21268422	chr21:42620091	BACE2	-0.65	-12.13	-0.49	1.29e-29	Body mass index;
LGG	cis	rs1693575	0.624	rs1693560	chr8:101680292	A/G	cg06874326	chr8:101662790	SNX31	-0.36	-7.21	-0.32	2.37e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4819388	0.751	rs7283760	chr21:45640629	G/A	cg01992765	chr21:45622493	NA	0.47	8.98	0.39	6.72e-18	Celiac disease;
LGG	cis	rs9972944	0.902	rs9972881	chr17:63771334	A/G	cg07283582	chr17:63770753	CCDC46	0.44	8.68	0.37	6.87e-17	Total body bone mineral density;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs8078723	0.714	rs3859187	chr17:38150613	C/A	cg17467752	chr17:38218738	THRA	-0.61	-11.15	-0.46	1e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs2018683	0.711	rs917213	chr7:28968204	A/G	cg19402173	chr7:128379420	CALU	-0.55	-9.38	-0.4	2.89e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	4.15e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9381040	0.655	rs2294696	chr6:41036988	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.37	7.11	0.31	4.56e-12	Alzheimer's disease (late onset);
LGG	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg03342759	chr3:160939853	NMD3	0.45	7.62	0.33	1.47e-13	Morning vs. evening chronotype;
LGG	cis	rs6500395	0.802	rs13330784	chr16:48661530	A/C	cg04672837	chr16:48644449	N4BP1	0.48	8.0	0.35	1.04e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2070488	0.965	rs7372849	chr3:38524328	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.82	0.64	1.85e-54	Electrocardiographic conduction measures;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.21	-0.39	1.16e-18	Menopause (age at onset);
LGG	cis	rs10227331	0.521	rs17667159	chr7:157296065	A/C	cg04156418	chr7:157293606	NA	0.55	10.75	0.45	3.29e-24	Inattentive symptoms;
LGG	cis	rs910187	1.000	rs910187	chr20:45841052	A/G	cg27589058	chr20:45804311	EYA2	0.3	7.36	0.32	8.66e-13	Migraine;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs15676	0.947	rs2293966	chr9:131591832	G/A	cg04621255	chr9:131581398	ENDOG	-0.41	-7.12	-0.31	4.21e-12	Blood metabolite levels;
LGG	cis	rs4702718	0.616	rs900535	chr5:10706152	C/T	cg14521931	chr5:10832172	NA	-0.43	-8.01	-0.35	9.44e-15	Obesity-related traits;
LGG	cis	rs6545977	0.531	rs2539982	chr2:63111004	G/A	cg17519650	chr2:63277830	OTX1	0.62	11.84	0.48	1.96e-28	Prostate cancer;
LGG	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg19761014	chr17:28927070	LRRC37B2	0.53	6.67	0.3	7.46e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg01620082	chr3:125678407	NA	-0.66	-7.41	-0.33	5.97e-13	Depression;
LGG	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.27	0.4	6.92e-19	Diabetic retinopathy;
LGG	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.66	-0.37	8.11e-17	Lung cancer;
LGG	cis	rs4006360	0.600	rs6503595	chr17:39257008	C/G	cg16985667	chr17:39306289	KRTAP4-5	-0.44	-9.78	-0.41	1.14e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg13802316	chr11:70253460	CTTN	-0.65	-8.97	-0.38	7.21e-18	Coronary artery disease;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.81	-0.3	2.98e-11	Menopause (age at onset);
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg11050988	chr7:1952600	MAD1L1	0.42	10.66	0.44	7.4e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg13047869	chr3:10149882	C3orf24	0.39	7.15	0.32	3.33e-12	Alzheimer's disease;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg19357499	chr8:144660631	NAPRT1	0.92	6.99	0.31	9.72e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs7949030	1.000	rs2956993	chr11:62406162	G/T	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-13.48	-0.53	3.65e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs62400317	0.859	rs4498350	chr6:45268438	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.26	-0.43	2.12e-22	Total body bone mineral density;
LGG	cis	rs10463554	1.000	rs6596529	chr5:102317042	C/T	cg23492399	chr5:102201601	PAM	-0.54	-8.28	-0.36	1.36e-15	Parkinson's disease;
LGG	cis	rs11229555	0.609	rs12289198	chr11:58175057	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg18681998	chr4:17616180	MED28	0.85	17.59	0.63	2.04e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.5	0.33	3.31e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6076065	0.823	rs743021	chr20:23401707	C/T	cg11657817	chr20:23433608	CST11	-0.35	-6.85	-0.3	2.35e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg11812906	chr14:75593930	NEK9	0.54	10.14	0.43	5.71e-22	Height;
LGG	trans	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg27661571	chr11:113659931	NA	-0.68	-9.34	-0.4	3.94e-19	Hip circumference adjusted for BMI;
LGG	trans	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg26043149	chr18:55253948	FECH	-0.4	-6.74	-0.3	4.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg05022225	chr19:49866942	DKKL1;TEAD2	0.42	7.26	0.32	1.68e-12	Multiple sclerosis;
LGG	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.22	-0.36	2.06e-15	Joint mobility (Beighton score);
LGG	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	3.09e-11	Corneal structure;
LGG	cis	rs11574514	1.000	rs8058835	chr16:67814865	C/T	cg09738193	chr16:67926317	PSKH1	-0.72	-6.89	-0.31	1.8e-11	Crohn's disease;
LGG	cis	rs9560113	0.550	rs1163632	chr13:112231530	T/C	cg14154082	chr13:112174009	NA	-0.37	-8.25	-0.36	1.69e-15	Menarche (age at onset);
LGG	cis	rs2286885	0.965	rs4836548	chr9:129255456	G/A	cg14319473	chr9:129242481	FAM125B	0.46	8.66	0.37	7.73e-17	Intraocular pressure;
LGG	cis	rs10489202	0.657	rs3767478	chr1:168069626	G/A	cg24449463	chr1:168025552	DCAF6	-0.58	-10.28	-0.43	1.77e-22	Schizophrenia;
LGG	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg04672837	chr16:48644449	N4BP1	0.54	8.89	0.38	1.32e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.24	0.36	1.79e-15	Menarche (age at onset);
LGG	cis	rs476633	0.691	rs11858115	chr15:41542591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.66	-0.44	6.95e-24	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.6e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg02269571	chr22:50332266	NA	-0.57	-8.92	-0.38	1.11e-17	Schizophrenia;
LGG	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg13072238	chr3:49761600	GMPPB	-0.53	-6.81	-0.3	2.98e-11	Menarche (age at onset);
LGG	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.74	-0.45	3.62e-24	Neuroticism;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg26513180	chr16:89883248	FANCA	0.71	8.02	0.35	9.04e-15	Skin colour saturation;
LGG	cis	rs7843479	1.000	rs2054711	chr8:21818060	A/G	cg17168535	chr8:21777572	XPO7	0.61	9.93	0.42	3.45e-21	Mean corpuscular volume;
LGG	cis	rs6901152	0.584	rs7748846	chr6:143564401	A/C	cg14646893	chr6:143592425	AIG1	-0.34	-7.24	-0.32	1.91e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15369054	chr17:80825471	TBCD	-0.39	-7.75	-0.34	5.89e-14	Breast cancer;
LGG	trans	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs832540	0.593	rs96844	chr5:56196604	G/A	cg12654349	chr5:56205094	C5orf35	-0.43	-7.42	-0.33	5.47e-13	Coronary artery disease;
LGG	trans	rs7824557	0.592	rs2572371	chr8:11223793	G/T	cg06636001	chr8:8085503	FLJ10661	0.42	7.59	0.33	1.8e-13	Retinal vascular caliber;
LGG	cis	rs9831754	0.526	rs6548551	chr3:78342292	C/T	cg06138941	chr3:78371609	NA	0.57	11.38	0.47	1.25e-26	Calcium levels;
LGG	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg11266682	chr4:10021025	SLC2A9	-0.47	-8.86	-0.38	1.7e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs16837677	1.000	rs74370674	chr1:156769595	G/C	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	trans	rs459571	0.959	rs410876	chr9:136893867	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.25	-0.49	4.27e-30	Platelet distribution width;
LGG	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg21459583	chr1:227974177	NA	0.55	7.64	0.33	1.29e-13	Major depressive disorder;
LGG	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.34e-13	Morning vs. evening chronotype;
LGG	cis	rs2075466	0.514	rs75804753	chr16:4943033	G/T	cg04440724	chr16:4920505	UBN1	-0.59	-8.25	-0.36	1.68e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12893668	0.703	rs729438	chr14:104092789	A/G	cg26031613	chr14:104095156	KLC1	0.6	9.18	0.39	1.46e-18	Reticulocyte count;
LGG	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.99	-0.35	1.06e-14	HDL cholesterol;
LGG	cis	rs2797369	0.570	rs2770336	chr6:101576247	A/T	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.86e-15	Renal function-related traits (eGRFcrea);
LGG	trans	rs7824557	0.619	rs7012218	chr8:11145676	T/A	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.12e-11	Retinal vascular caliber;
LGG	cis	rs9992101	0.669	rs10006043	chr4:77357747	C/T	cg17010112	chr4:77227123	STBD1	-0.35	-6.7	-0.3	5.92e-11	Creatinine levels;
LGG	cis	rs2120243	0.539	rs4640512	chr3:157120066	C/T	cg24825693	chr3:157122686	VEPH1	-0.58	-13.5	-0.53	2.85e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.42	7.01	0.31	8.73e-12	Personality dimensions;
LGG	cis	rs4727027	0.840	rs12670633	chr7:148796707	G/A	cg23583168	chr7:148888333	NA	-0.86	-16.26	-0.6	2.25e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6577655	0.501	rs7004326	chr8:135610915	G/T	cg17885191	chr8:135476712	NA	-0.44	-7.15	-0.32	3.4e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs2204008	0.658	rs11181310	chr12:38315963	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	8.04e-18	Bladder cancer;
LGG	cis	rs561341	0.609	rs739800	chr17:30190083	T/A	cg00745463	chr17:30367425	LRRC37B	0.53	7.09	0.31	5.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg22535103	chr8:58192502	C8orf71	-1.0	-13.57	-0.53	1.52e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.68	-0.41	2.54e-20	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.0	0.35	1e-14	HDL cholesterol;
LGG	cis	rs4262150	0.639	rs72806713	chr5:152342669	C/T	cg12297329	chr5:152029980	NA	-0.57	-9.21	-0.39	1.1e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7843479	1.000	rs11775444	chr8:21813018	A/G	cg17168535	chr8:21777572	XPO7	0.61	9.99	0.42	2e-21	Mean corpuscular volume;
LGG	cis	rs10046574	0.519	rs10250947	chr7:135211017	T/G	cg27474649	chr7:135195673	CNOT4	0.72	9.03	0.39	4.56e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg16482183	chr6:26056742	HIST1H1C	0.73	12.42	0.5	9.41e-31	Height;
LGG	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg02631450	chr22:32366979	NA	1.0	9.64	0.41	3.77e-20	Childhood ear infection;
LGG	cis	rs13082711	0.522	rs646577	chr3:27352225	A/G	cg02860705	chr3:27208620	NA	0.58	10.97	0.45	4.86e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.92	0.38	1.13e-17	Aortic root size;
LGG	cis	rs1109114	0.808	rs10035236	chr5:148627054	G/A	cg06539116	chr5:148597365	ABLIM3	-0.46	-10.99	-0.45	3.95e-25	Body mass index;
LGG	trans	rs11875185	0.510	rs78115000	chr18:55595657	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6540556	0.723	rs6702301	chr1:209923154	C/T	cg23920097	chr1:209922102	NA	-0.5	-8.97	-0.38	7.67e-18	Red blood cell count;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg03188948	chr7:1209495	NA	0.59	7.82	0.34	3.65e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.48	0.5	4.99e-31	Corneal astigmatism;
LGG	cis	rs2652834	0.851	rs7175185	chr15:63425337	A/G	cg05507819	chr15:63340323	TPM1	0.5	7.06	0.31	6.23e-12	HDL cholesterol;
LGG	cis	rs17767392	0.645	rs55737377	chr14:71671426	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.9	-0.31	1.7e-11	Mitral valve prolapse;
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	8.65	0.37	8.27e-17	Lung function (FEV1/FVC);
LGG	cis	rs7558370	0.541	rs13409287	chr2:3722494	A/G	cg17046650	chr2:3699563	NA	0.52	6.77	0.3	3.81e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg14092988	chr3:52407081	DNAH1	0.32	8.34	0.36	8.84e-16	Bipolar disorder;
LGG	cis	rs3791406	0.500	rs3791414	chr2:240032214	T/C	cg14550559	chr2:240039617	HDAC4	-0.76	-11.43	-0.47	8.29e-27	Skin aging (microtopography measurement);
LGG	cis	rs883565	0.568	rs4616582	chr3:39028854	G/T	cg01426195	chr3:39028469	NA	0.78	18.76	0.66	8.15e-59	Handedness;
LGG	trans	rs17685	0.753	rs10233282	chr7:75790081	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-8.61	-0.37	1.12e-16	Neuroticism;
LGG	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg18128536	chr17:47092178	IGF2BP1	0.5	9.7	0.41	2.17e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs67133203	0.768	rs7960381	chr12:51527113	C/T	cg14688905	chr12:51403056	SLC11A2	0.69	10.62	0.44	1.02e-23	Urinary tract infection frequency;
LGG	cis	rs74781061	1.000	rs6495117	chr15:74899500	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.06	-0.31	6.27e-12	Endometriosis;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.25	-0.36	1.69e-15	Height;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15778350	chr1:163291775	NUF2	0.45	7.56	0.33	2.23e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs765787	0.530	rs11854689	chr15:45516052	A/G	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg11252792	chr3:125932053	NA	0.79	17.42	0.63	1.28e-52	Metabolite levels;
LGG	cis	rs6868223	0.617	rs10045283	chr5:33648501	T/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.51	0.58	5.52e-44	Mortality in heart failure;
LGG	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg09264619	chr17:80180166	NA	0.37	7.4	0.33	6.61e-13	Life satisfaction;
LGG	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg08250081	chr4:10125330	NA	-0.51	-10.0	-0.42	1.93e-21	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg16141378	chr3:129829833	LOC729375	-0.32	-7.37	-0.32	7.79e-13	Systemic lupus erythematosus;
LGG	cis	rs1595825	0.891	rs73061068	chr2:198908439	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.8	-0.3	3.26e-11	Ulcerative colitis;
LGG	cis	rs3736594	0.513	rs6704596	chr2:27796927	A/G	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7215564	0.908	rs77750710	chr17:78717117	C/T	cg16980736	chr17:78789706	RPTOR	-0.64	-8.48	-0.37	2.96e-16	Myopia (pathological);
LGG	cis	rs4595586	0.525	rs12809307	chr12:39365927	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.72	-0.3	5.21e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg21535247	chr6:8435926	SLC35B3	0.61	10.46	0.44	4.04e-23	Motion sickness;
LGG	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.23e-17	Cognitive function;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg04008888	chr11:68622739	NA	-0.52	-11.34	-0.47	1.82e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg07465881	chr4:1713556	SLBP	-0.46	-7.23	-0.32	2.04e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs4262150	0.672	rs72806782	chr5:152349863	T/C	cg12297329	chr5:152029980	NA	-0.55	-8.56	-0.37	1.72e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.6	0.37	1.2e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7929679	0.521	rs10836307	chr11:34800228	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.41	6.93	0.31	1.39e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs12478296	0.901	rs7420176	chr2:243005277	G/A	cg06360820	chr2:242988706	NA	-0.93	-11.88	-0.48	1.38e-28	Obesity-related traits;
LGG	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-9.15	-0.39	1.82e-18	Common traits (Other);
LGG	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg21466736	chr12:48725269	NA	-0.39	-7.89	-0.34	2.21e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs12928939	0.517	rs12149325	chr16:71968147	G/C	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.42	-0.53	6.19e-35	Post bronchodilator FEV1;
LGG	cis	rs7267979	0.903	rs6107015	chr20:25216764	G/A	cg08601574	chr20:25228251	PYGB	0.33	6.75	0.3	4.56e-11	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs10109025	0.701	rs10101292	chr8:10856474	T/C	cg02002194	chr4:3960332	NA	0.39	6.71	0.3	5.8e-11	Joint mobility (Beighton score);
LGG	trans	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg21659725	chr3:3221576	CRBN	-0.75	-6.8	-0.3	3.3e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs9467711	1.000	rs9467708	chr6:26327956	T/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.18	-0.32	2.78e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg00684032	chr4:1343700	KIAA1530	-0.45	-8.79	-0.38	3.04e-17	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4936894	0.500	rs7112726	chr11:124168688	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.95	-0.45	5.5e-25	Aging (time to death);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09843086	chr7:131013189	MKLN1	0.41	6.92	0.31	1.53e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg00198680	chr16:28758506	NA	0.3	7.41	0.33	5.91e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg00149659	chr3:10157352	C3orf10	0.89	11.49	0.47	4.74e-27	Alzheimer's disease;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg03395511	chr6:291903	DUSP22	-0.66	-11.13	-0.46	1.16e-25	Menopause (age at onset);
LGG	trans	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.89	0.48	1.18e-28	Mean corpuscular volume;
LGG	trans	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg26043149	chr18:55253948	FECH	0.42	7.04	0.31	7.2e-12	Bone mineral density;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg13453750	chr1:205783389	SLC41A1	-0.48	-9.34	-0.4	3.96e-19	Menarche (age at onset);
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.3	0.55	1.14e-38	Tonsillectomy;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.51	0.58	5.39e-44	Platelet count;
LGG	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg01238044	chr22:24384105	GSTT1	-0.41	-6.96	-0.31	1.16e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	trans	rs1962073	0.507	rs7460226	chr8:10197718	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	6.84	0.3	2.48e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs67460515	0.563	rs11720263	chr3:160848293	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-8.35	-0.36	7.9e-16	Parkinson's disease;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04464219	chr8:98657199	MTDH	0.49	8.16	0.35	3.22e-15	Cognitive performance;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11292385	chr22:29138453	CHEK2;HSCB	0.39	6.99	0.31	9.8e-12	Bilirubin levels;
LGG	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg01191920	chr7:158217561	PTPRN2	-0.77	-17.13	-0.62	2.62e-51	Obesity-related traits;
LGG	cis	rs266717	0.816	rs266753	chr3:186509059	A/G	cg00373256	chr3:186519153	RFC4	-0.41	-8.45	-0.37	3.81e-16	Adiponectin levels;
LGG	cis	rs1659258	0.568	rs2579026	chr2:88601555	G/A	cg00685853	chr2:88648947	NA	-0.45	-6.73	-0.3	4.91e-11	Visceral fat;
LGG	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg16586182	chr3:47516702	SCAP	0.72	13.12	0.52	1.12e-33	Colorectal cancer;
LGG	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.71	0.45	4.42e-24	Mean platelet volume;
LGG	cis	rs1978968	1.000	rs5992926	chr22:18449876	A/G	cg03078520	chr22:18463400	MICAL3	-0.63	-12.67	-0.51	8.35e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.57	-0.33	2.11e-13	Life satisfaction;
LGG	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg21775007	chr8:11205619	TDH	-0.52	-8.48	-0.37	3.05e-16	Neuroticism;
LGG	cis	rs514406	0.861	rs4926577	chr1:53226788	C/A	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.06	-0.31	6e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs250677	0.687	rs36046	chr5:148441257	A/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.67e-12	Breast cancer;
LGG	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.3	0.32	1.26e-12	Migraine;
LGG	cis	rs2735413	0.881	rs4888727	chr16:78077038	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-12.73	-0.51	4.89e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg26354017	chr1:205819088	PM20D1	0.5	9.3	0.4	5.57e-19	Menarche (age at onset);
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg02733842	chr7:1102375	C7orf50	0.68	8.01	0.35	9.69e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg02891314	chr5:179741120	GFPT2	-0.63	-11.49	-0.47	4.62e-27	Height;
LGG	cis	rs12477438	0.501	rs769105	chr2:100077966	G/A	cg23527387	chr2:100056660	REV1	0.42	9.39	0.4	2.72e-19	Chronic sinus infection;
LGG	cis	rs10416265	0.528	rs3786932	chr19:33620488	T/A	cg27124370	chr19:33622961	WDR88	0.49	6.86	0.3	2.19e-11	Bone properties (heel);
LGG	cis	rs2635047	0.905	rs7504798	chr18:44610879	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	7.46	0.33	4.39e-13	Educational attainment;
LGG	cis	rs4687717	0.689	rs2306569	chr3:53274602	C/T	cg16894138	chr3:53270350	TKT	-0.44	-8.25	-0.36	1.65e-15	Blood metabolite levels;Blood metabolite ratios;
LGG	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.45	0.5	6.62e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.38	-0.32	7.22e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7408868	1.000	rs10407320	chr19:15275716	G/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs4642101	0.597	rs2305397	chr3:12857493	C/T	cg24848339	chr3:12840334	CAND2	0.42	9.44	0.4	1.81e-19	QRS complex (12-leadsum);
LGG	trans	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg21775007	chr8:11205619	TDH	0.46	7.41	0.33	5.85e-13	Mood instability;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.54	-0.41	8.34e-20	Primary sclerosing cholangitis;
LGG	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg01411142	chr8:19674711	INTS10	0.46	7.46	0.33	4.17e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2652834	0.950	rs2652815	chr15:63401345	T/C	cg05507819	chr15:63340323	TPM1	0.56	7.5	0.33	3.21e-13	HDL cholesterol;
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.03	-0.31	7.61e-12	Bipolar disorder;
LGG	cis	rs877282	1.000	rs11253370	chr10:773712	G/A	cg17470449	chr10:769945	NA	0.65	8.36	0.36	7.43e-16	Uric acid levels;
LGG	cis	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg22496380	chr5:211416	CCDC127	-1.14	-10.18	-0.43	4.38e-22	Breast cancer;
LGG	cis	rs17401966	0.894	rs12141201	chr1:10454714	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-10.51	-0.44	2.64e-23	Hepatocellular carcinoma;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.31	0.4	5.27e-19	Lung cancer;
LGG	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg20026190	chr17:76395443	PGS1	-0.54	-9.19	-0.39	1.33e-18	HDL cholesterol levels;
LGG	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.11	15.05	0.57	5.91e-42	Alzheimer's disease;
LGG	cis	rs300774	0.844	rs300728	chr2:131828	G/A	cg04617936	chr2:214353	NA	-0.48	-7.36	-0.32	8.26e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg16141378	chr3:129829833	LOC729375	-0.45	-10.94	-0.45	6.32e-25	Retinal vascular caliber;
LGG	trans	rs9929218	0.508	rs6499194	chr16:68744100	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	24.4	0.75	3.86e-85	Colorectal cancer;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg03575189	chr17:44344142	NA	0.47	6.96	0.31	1.19e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg05775895	chr3:12838266	CAND2	0.66	11.85	0.48	1.84e-28	QRS complex (12-leadsum);
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1697139	0.583	rs11960733	chr5:66538715	C/T	cg11553311	chr5:66541588	NA	0.46	10.39	0.43	7e-23	Breast cancer;
LGG	cis	rs13421350	0.579	rs6741759	chr2:173401123	T/C	cg15021238	chr2:173305865	ITGA6	-0.75	-8.23	-0.36	1.87e-15	Diabetic kidney disease;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.48	7.0	0.31	8.83e-12	Renal function-related traits (BUN);
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.83e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg07395648	chr5:131743802	NA	-0.5	-11.77	-0.48	3.7e-28	Blood metabolite levels;
LGG	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg19223190	chr17:80058835	NA	-0.49	-9.74	-0.41	1.66e-20	Life satisfaction;
LGG	cis	rs7727544	0.507	rs10051679	chr5:131570931	T/A	cg07395648	chr5:131743802	NA	-0.36	-7.26	-0.32	1.7e-12	Blood metabolite levels;
LGG	cis	rs9517320	1.000	rs7338549	chr13:99142745	C/T	cg07423050	chr13:99094983	FARP1	0.39	7.9	0.34	2.05e-14	Longevity;
LGG	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg00188032	chr5:96141721	ERAP1	0.55	7.18	0.32	2.83e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg27490568	chr2:178487706	NA	0.52	10.15	0.43	5.52e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2201728	0.967	rs12507573	chr4:100226324	A/C	cg07219303	chr4:100140905	ADH6	0.4	7.97	0.35	1.24e-14	Cardiac Troponin-T levels;
LGG	trans	rs8002861	0.619	rs1337203	chr13:44423621	T/G	cg12856521	chr11:46389249	DGKZ	0.51	9.26	0.4	7.39e-19	Leprosy;
LGG	cis	rs67133203	0.847	rs11833022	chr12:51465785	C/T	cg14688905	chr12:51403056	SLC11A2	0.7	10.65	0.44	7.71e-24	Urinary tract infection frequency;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg20309703	chr11:118481025	PHLDB1	0.57	11.13	0.46	1.19e-25	Cholesterol, total;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg03647317	chr4:187891568	NA	-0.41	-8.83	-0.38	2.09e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg16584676	chr17:46985605	UBE2Z	0.47	7.96	0.35	1.31e-14	Type 2 diabetes;
LGG	cis	rs7192750	0.586	rs2335712	chr16:71906597	A/G	cg06353428	chr16:71660113	MARVELD3	-0.66	-10.35	-0.43	9.76e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg08250081	chr4:10125330	NA	0.38	7.23	0.32	2e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.41	0.33	6.08e-13	Longevity;
LGG	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg14784868	chr12:69753453	YEATS4	0.68	10.65	0.44	7.64e-24	Response to diuretic therapy;
LGG	trans	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg05484376	chr2:27715224	FNDC4	0.47	10.2	0.43	3.65e-22	Total body bone mineral density;
LGG	cis	rs7945705	0.869	rs7925728	chr11:9013002	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.35	-7.19	-0.32	2.67e-12	Hemoglobin concentration;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.75	0.38	3.87e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg03188948	chr7:1209495	NA	0.68	9.66	0.41	3.23e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9649465	0.561	rs600420	chr7:123408050	G/A	cg03229431	chr7:123269106	ASB15	0.61	14.04	0.55	1.53e-37	Migraine;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.55	0.33	2.29e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9972944	0.756	rs7220733	chr17:63764890	A/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.3	-0.36	1.16e-15	Total body bone mineral density;
LGG	cis	rs36051895	0.587	rs7848872	chr9:5197027	T/A	cg02405213	chr9:5042618	JAK2	-0.76	-13.03	-0.52	2.78e-33	Pediatric autoimmune diseases;
LGG	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.19	-0.43	4.02e-22	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15312298	chr8:127570908	FAM84B	0.48	7.93	0.35	1.66e-14	Gut microbiome composition (summer);
LGG	cis	rs2236267	0.726	rs2208547	chr14:88604515	C/T	cg02175263	chr14:88627849	NA	0.32	7.33	0.32	1.03e-12	Food antigen IgG levels;
LGG	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg00717180	chr2:96193071	NA	-0.49	-9.24	-0.39	8.75e-19	HDL cholesterol;
LGG	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.28	-0.5	3.23e-30	Morning vs. evening chronotype;
LGG	cis	rs12681287	0.547	rs4961197	chr8:87512436	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg18681998	chr4:17616180	MED28	-0.86	-18.94	-0.66	1.23e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2236267	0.600	rs993688	chr14:88616722	A/T	cg18078958	chr14:88630771	NA	-0.32	-7.43	-0.33	5.33e-13	Food antigen IgG levels;
LGG	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.78	-0.3	3.74e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4774899	0.966	rs12904321	chr15:57507579	A/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.34	-0.32	9.79e-13	Urinary tract infection frequency;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.21	0.36	2.15e-15	Obesity-related traits;
LGG	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg08916839	chr5:415575	AHRR	0.96	14.06	0.55	1.25e-37	Fat distribution (HIV);
LGG	cis	rs6684428	0.901	rs11206681	chr1:56364528	T/C	cg11651538	chr1:56320950	NA	-0.75	-12.82	-0.51	2.15e-32	Airflow obstruction;
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg15432903	chr11:17409602	KCNJ11	0.8	17.25	0.63	7.16e-52	Type 2 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18299363	chr10:103816089	C10orf76	0.42	6.87	0.3	2.06e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11690935	0.879	rs13017585	chr2:172721808	C/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-25.51	-0.76	2.86e-90	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-7.37	-0.32	7.97e-13	Lung cancer;
LGG	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.2	-0.43	3.44e-22	Chronic sinus infection;
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.77	-0.34	5.07e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10927875	1.000	rs12138117	chr1:16305279	T/C	cg21385522	chr1:16154831	NA	-0.81	-14.94	-0.57	1.72e-41	Dilated cardiomyopathy;
LGG	cis	rs7843479	0.601	rs10101881	chr8:21830158	A/G	cg17168535	chr8:21777572	XPO7	0.75	14.3	0.55	1.09e-38	Mean corpuscular volume;
LGG	cis	rs4740619	0.682	rs1887664	chr9:16003597	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.32	-0.43	1.28e-22	Body mass index;
LGG	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.71e-22	Motion sickness;
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg08888203	chr3:10149979	C3orf24	0.54	9.03	0.39	4.52e-18	Alzheimer's disease;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg22963979	chr7:1858916	MAD1L1	0.39	7.42	0.33	5.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Calcium levels;
LGG	cis	rs7474896	0.583	rs10827817	chr10:37997974	A/G	cg00409905	chr10:38381863	ZNF37A	-0.46	-7.21	-0.32	2.27e-12	Obesity (extreme);
LGG	cis	rs7172677	1.000	rs11638746	chr15:75403108	A/C	cg14664628	chr15:75095509	CSK	0.54	8.28	0.36	1.3e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg16512390	chr1:228756714	NA	0.48	6.71	0.3	5.63e-11	Chronic lymphocytic leukemia;
LGG	cis	rs8114671	0.562	rs3818273	chr20:33509275	G/A	cg07148914	chr20:33460835	GGT7	0.53	8.88	0.38	1.44e-17	Height;
LGG	cis	rs6840360	0.558	rs2709821	chr4:152342190	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.11	0.31	4.39e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs9715521	1.000	rs9715521	chr4:59824487	G/A	cg11281224	chr4:60001000	NA	-0.44	-7.31	-0.32	1.16e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6032067	0.777	rs2868235	chr20:43794069	T/C	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs7617773	0.832	rs6775114	chr3:48182620	G/C	cg11946769	chr3:48343235	NME6	-0.5	-8.23	-0.36	1.98e-15	Coronary artery disease;
LGG	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg04568710	chr12:38710424	ALG10B	0.38	8.26	0.36	1.6e-15	Heart rate;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00620304	chr6:34231334	NA	-0.55	-6.78	-0.3	3.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	1.000	rs17376456	chr5:93557702	C/T	cg25358565	chr5:93447407	FAM172A	-1.36	-16.52	-0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs4330281	0.647	rs13096559	chr3:17694643	G/T	cg20981856	chr3:17787350	NA	-0.4	-7.54	-0.33	2.46e-13	Schizophrenia;
LGG	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.61	-0.37	1.11e-16	Retinal vascular caliber;
LGG	cis	rs67311347	0.911	rs9849224	chr3:40392562	T/C	cg13683864	chr3:40499215	RPL14	-0.98	-20.21	-0.68	1.38e-65	Renal cell carcinoma;
LGG	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg17050807	chr22:42548356	NA	-0.36	-6.76	-0.3	4.28e-11	Schizophrenia;
LGG	cis	rs2282032	0.527	rs8009799	chr14:90766365	A/G	cg14092571	chr14:90743983	NA	0.43	7.63	0.33	1.35e-13	Longevity;
LGG	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg06238570	chr21:40685208	BRWD1	-0.5	-8.3	-0.36	1.15e-15	Cognitive function;
LGG	cis	rs11098499	0.535	rs7671759	chr4:120248094	A/C	cg24375607	chr4:120327624	NA	0.57	9.22	0.39	1.01e-18	Corneal astigmatism;
LGG	cis	rs548181	0.611	rs2849225	chr11:125415936	A/G	cg03464685	chr11:125439445	EI24	1.47	21.85	0.71	3.04e-73	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs8114671	0.967	rs2065979	chr20:33767690	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.14	0.31	3.65e-12	Height;
LGG	cis	rs151997	0.649	rs152688	chr5:50211776	C/T	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg17230874	chr3:125932073	NA	0.54	11.09	0.46	1.62e-25	Metabolite levels;
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.26	-0.4	7.57e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg04703951	chr17:43578652	NA	0.37	7.51	0.33	3.07e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.61	-11.23	-0.46	4.82e-26	Lymphocyte counts;
LGG	cis	rs10979	1.000	rs9390107	chr6:143892721	A/T	cg25407410	chr6:143891975	LOC285740	-0.71	-12.23	-0.49	5.38e-30	Hypospadias;
LGG	cis	rs4474465	1.000	rs12277701	chr11:78140726	A/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.59	-0.37	1.37e-16	Alzheimer's disease (survival time);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19752602	chr5:153039227	GRIA1	-0.54	-6.66	-0.3	7.67e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3741151	0.686	rs17132115	chr11:73264656	C/T	cg17517138	chr11:73019481	ARHGEF17	0.67	7.01	0.31	8.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg24642844	chr7:1081250	C7orf50	-0.84	-14.03	-0.55	1.64e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs283228	0.535	rs413614	chr6:101720517	A/G	cg27451362	chr6:101846650	GRIK2	0.89	12.81	0.51	2.37e-32	Coenzyme Q10 levels;
LGG	cis	rs1562975	0.609	rs55707402	chr4:109418264	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	8.31	0.36	1.06e-15	Height;
LGG	cis	rs7551222	0.752	rs1380576	chr1:204488278	G/C	cg20240347	chr1:204465584	NA	-0.56	-11.3	-0.46	2.62e-26	Schizophrenia;
LGG	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg24375607	chr4:120327624	NA	-0.56	-9.33	-0.4	4.4e-19	Corneal astigmatism;
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg25811766	chr13:21894605	NA	0.7	9.46	0.4	1.61e-19	White matter hyperintensity burden;
LGG	cis	rs367943	0.698	rs11741887	chr5:112959315	T/C	cg12552261	chr5:112820674	MCC	0.52	9.02	0.39	4.86e-18	Type 2 diabetes;
LGG	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.34	-0.32	9.4e-13	Morning vs. evening chronotype;
LGG	cis	rs34734847	0.814	rs17847	chr12:121149475	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-7.41	-0.33	5.88e-13	Mean corpuscular volume;
LGG	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg13944838	chr5:179740914	GFPT2	-0.68	-11.93	-0.48	8.8e-29	Height;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg26897989	chr16:1907736	C16orf73	-0.84	-13.64	-0.54	7.7e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2133450	0.526	rs73020271	chr3:7346412	C/T	cg19930620	chr3:7340148	GRM7	-0.42	-9.23	-0.39	9.38e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg10621924	chr7:39171070	POU6F2	0.48	9.92	0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg15823100	chr22:32027580	PISD	-0.75	-8.52	-0.37	2.27e-16	Age-related hearing impairment;
LGG	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg00745463	chr17:30367425	LRRC37B	-0.47	-7.53	-0.33	2.73e-13	Hip circumference adjusted for BMI;
LGG	trans	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.88	-0.3	1.89e-11	Mood instability;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg24250549	chr1:154909240	PMVK	0.71	13.27	0.52	2.88e-34	Prostate cancer;
LGG	cis	rs12580194	1.000	rs7971451	chr12:55699950	G/A	cg19537932	chr12:55886519	OR6C68	-0.37	-6.68	-0.3	7.01e-11	Cancer;
LGG	trans	rs1997103	1.000	rs6945937	chr7:55407140	C/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9487051	0.738	rs171272	chr6:109530094	T/C	cg21918786	chr6:109611834	NA	-0.38	-6.9	-0.31	1.75e-11	Reticulocyte fraction of red cells;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg06719900	chr11:109292894	C11orf87	0.41	7.59	0.33	1.83e-13	Schizophrenia;
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03264133	chr6:25882463	NA	-0.73	-13.59	-0.53	1.22e-35	Intelligence (multi-trait analysis);
LGG	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg15103426	chr22:29168792	CCDC117	0.72	11.69	0.48	7.72e-28	Lymphocyte counts;
LGG	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Bone mineral density;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	8.01	0.35	9.25e-15	Prostate cancer;
LGG	cis	rs7769051	1.000	rs5006218	chr6:133126220	T/G	cg22852734	chr6:133119734	C6orf192	1.16	15.71	0.59	6.98e-45	Type 2 diabetes nephropathy;
LGG	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg15704280	chr7:45808275	SEPT13	-0.87	-16.09	-0.6	1.37e-46	Coronary artery disease;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.64	-0.37	9.12e-17	Skin colour saturation;
LGG	cis	rs193541	0.632	rs30063	chr5:122295693	G/A	cg19412675	chr5:122181750	SNX24	0.55	8.88	0.38	1.45e-17	Glucose homeostasis traits;
LGG	cis	rs4948275	0.550	rs7082786	chr10:63176990	C/A	cg02023345	chr10:63212226	TMEM26	0.42	7.87	0.34	2.55e-14	Night sleep phenotypes;
LGG	cis	rs10884984	0.739	rs1042606	chr10:112270675	A/C	cg18756771	chr10:112261994	DUSP5	-0.73	-13.81	-0.54	1.37e-36	Facial morphology (factor 22);
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg18446336	chr7:2847575	GNA12	0.31	7.32	0.32	1.08e-12	Height;
LGG	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.16	-0.32	3.29e-12	Total cholesterol levels;
LGG	cis	rs7215564	0.908	rs2316059	chr17:78663732	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs1878931	0.507	rs67218524	chr16:3403057	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-10.63	-0.44	8.96e-24	Body mass index (adult);
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg00908189	chr16:619842	PIGQ	0.85	15.64	0.59	1.38e-44	Height;
LGG	cis	rs7166081	1.000	rs34296414	chr15:67514409	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg25457927	chr22:38595422	NA	-0.44	-10.92	-0.45	7.37e-25	Cutaneous nevi;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.9	-0.34	2.02e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.0	-12.95	-0.52	5.91e-33	Lung cancer in ever smokers;
LGG	cis	rs4268898	0.931	rs2111882	chr2:24434424	A/G	cg06627628	chr2:24431161	ITSN2	0.55	9.3	0.4	5.74e-19	Asthma;
LGG	cis	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg15556689	chr8:8085844	FLJ10661	0.54	10.11	0.43	7.49e-22	Neuroticism;
LGG	cis	rs208520	0.609	rs208436	chr6:66897470	G/A	cg07460842	chr6:66804631	NA	-0.72	-12.63	-0.51	1.27e-31	Exhaled nitric oxide output;
LGG	cis	rs9902453	0.874	rs11653805	chr17:28378276	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.3e-74	Bladder cancer;
LGG	cis	rs7107174	1.000	rs11237468	chr11:78072833	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	8.01e-13	Testicular germ cell tumor;
LGG	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg21775007	chr8:11205619	TDH	0.44	7.26	0.32	1.63e-12	Systolic blood pressure;
LGG	cis	rs877282	0.891	rs34383514	chr10:800181	T/C	cg01169559	chr10:831247	NA	0.44	6.91	0.31	1.65e-11	Uric acid levels;
LGG	cis	rs564799	0.966	rs485499	chr3:159745863	C/T	cg04855961	chr3:159719849	NA	0.28	7.52	0.33	2.92e-13	Systemic lupus erythematosus;
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.2	-0.46	6.14e-26	Neuroticism;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.8	-0.3	3.17e-11	Lung cancer;
LGG	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg03653399	chr8:142233436	SLC45A4	-0.35	-7.18	-0.32	2.86e-12	Immature fraction of reticulocytes;
LGG	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.68	-0.44	6.17e-24	Aortic root size;
LGG	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-6.96	-0.31	1.18e-11	Huntington's disease progression;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg14773178	chr5:1868261	NA	0.39	8.57	0.37	1.58e-16	Cardiovascular disease risk factors;
LGG	cis	rs55962025	0.846	rs363064	chr4:3141410	C/T	cg06533319	chr4:3265114	C4orf44	0.38	6.73	0.3	5.02e-11	Parental longevity (mother's age at death);
LGG	cis	rs7927771	0.507	rs7119517	chr11:47675316	T/C	cg20307385	chr11:47447363	PSMC3	0.55	10.73	0.45	3.73e-24	Subjective well-being;
LGG	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg11812906	chr14:75593930	NEK9	0.46	8.12	0.35	4.33e-15	Height;
LGG	cis	rs643506	0.874	rs663511	chr11:111710034	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.92	0.31	1.54e-11	Breast cancer;
LGG	cis	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.92e-26	Corneal astigmatism;
LGG	cis	rs4595586	0.679	rs7312898	chr12:39346833	T/C	cg26384229	chr12:38710491	ALG10B	0.47	8.71	0.38	5.47e-17	Morning vs. evening chronotype;
LGG	cis	rs9341835	0.679	rs9344137	chr6:64156964	A/T	cg00787780	chr6:64151745	NA	0.42	7.51	0.33	3.11e-13	Schizophrenia;
LGG	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg00631329	chr6:26305371	NA	-0.46	-7.68	-0.34	9.57e-14	Educational attainment;
LGG	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg12473912	chr3:136751656	NA	0.45	7.8	0.34	4.23e-14	Neuroticism;
LGG	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2224391	0.628	rs2753233	chr6:5250982	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.35	-0.32	8.91e-13	Height;
LGG	cis	rs6540556	0.682	rs932335	chr1:209905734	G/C	cg23920097	chr1:209922102	NA	-0.42	-7.04	-0.31	6.79e-12	Red blood cell count;
LGG	cis	rs11585357	0.947	rs11584287	chr1:17607501	G/C	cg08277548	chr1:17600880	PADI3	-0.77	-8.93	-0.38	1.01e-17	Hair shape;
LGG	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg05308233	chr10:104796373	CNNM2	0.32	7.23	0.32	1.99e-12	Arsenic metabolism;
LGG	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg00129232	chr17:37814104	STARD3	-0.74	-15.86	-0.59	1.5e-45	Asthma;
LGG	cis	rs6684428	0.706	rs10888942	chr1:56335432	C/G	cg11651538	chr1:56320950	NA	-0.72	-13.03	-0.52	2.83e-33	Airflow obstruction;
LGG	cis	rs4740619	0.525	rs7032457	chr9:15826730	C/T	cg14451791	chr9:16040625	NA	-0.3	-7.26	-0.32	1.61e-12	Body mass index;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg06873352	chr17:61820015	STRADA	-0.59	-10.31	-0.43	1.39e-22	Prudent dietary pattern;
LGG	cis	rs4481887	0.741	rs11485458	chr1:248569050	A/G	cg15454534	chr1:248569605	OR2T1	0.38	6.78	0.3	3.67e-11	Common traits (Other);
LGG	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.65e-31	Motion sickness;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg08355456	chr11:67383691	NA	0.48	8.15	0.35	3.31e-15	Mean corpuscular volume;
LGG	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg23302884	chr18:44338147	ST8SIA5	0.35	6.74	0.3	4.65e-11	Educational attainment;
LGG	cis	rs9815354	1.000	rs7650227	chr3:41794937	T/G	cg03022575	chr3:42003672	ULK4	0.59	7.49	0.33	3.42e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2797369	0.943	rs2852492	chr6:101678241	G/T	cg27451362	chr6:101846650	GRIK2	0.71	9.64	0.41	3.74e-20	Renal function-related traits (eGRFcrea);
LGG	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.837	rs2924583	chr4:100044640	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.85	0.42	6.83e-21	Alcohol dependence;
LGG	cis	rs9549367	0.789	rs12866090	chr13:113869410	G/A	cg00898013	chr13:113819073	PROZ	-0.44	-8.63	-0.37	9.87e-17	Platelet distribution width;
LGG	cis	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.47e-14	Mononucleosis;
LGG	cis	rs244899	0.935	rs2445786	chr5:167930877	G/A	cg06604206	chr5:167912465	RARS	-0.53	-11.65	-0.48	1.08e-27	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	trans	rs1997103	0.906	rs4618644	chr7:55402037	T/G	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7568458	0.783	rs1561198	chr2:85809989	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-7.03	-0.31	7.41e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9547996	0.879	rs3934220	chr13:38206249	T/C	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.62e-11	Diastolic blood pressure;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg05863683	chr7:1912471	MAD1L1	-0.41	-8.15	-0.35	3.51e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	13.81	0.54	1.43e-36	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05323904	chr16:691677	FAM195A	0.45	6.83	0.3	2.7e-11	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.520	rs11677247	chr2:99756358	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs6964587	1.000	rs4644173	chr7:91759597	A/G	cg17063962	chr7:91808500	NA	0.51	9.27	0.4	7.16e-19	Breast cancer;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14952266	chr13:112191215	NA	-0.42	-7.56	-0.33	2.17e-13	Menarche (age at onset);
LGG	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg06917634	chr15:78832804	PSMA4	0.46	7.6	0.33	1.61e-13	Sudden cardiac arrest;
LGG	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.48	-0.37	3.01e-16	Aortic root size;
LGG	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg13482628	chr17:19912719	NA	0.54	10.26	0.43	2.16e-22	Schizophrenia;
LGG	trans	rs12439619	0.739	rs4778988	chr15:82540337	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.45	-8.89	-0.38	1.37e-17	Intelligence (multi-trait analysis);
LGG	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg24692254	chr21:30365293	RNF160	0.58	10.5	0.44	2.76e-23	Pancreatic cancer;
LGG	cis	rs35160687	0.644	rs4832276	chr2:86545018	A/G	cg10973622	chr2:86423274	IMMT	0.39	6.92	0.31	1.5e-11	Night sleep phenotypes;
LGG	cis	rs4722166	0.564	rs1800797	chr7:22766221	A/G	cg05265849	chr7:22767390	IL6	0.43	8.13	0.35	3.88e-15	Lung cancer;
LGG	cis	rs908922	0.676	rs11584191	chr1:152500428	A/T	cg03606772	chr1:152487856	CRCT1	-0.31	-7.28	-0.32	1.41e-12	Hair morphology;
LGG	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-15.71	-0.59	7.05e-45	Colorectal cancer;
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg19774624	chr17:42201019	HDAC5	-0.95	-20.68	-0.69	8.76e-68	Total body bone mineral density;
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7011049	0.778	rs113641746	chr8:53870078	T/G	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg18897632	chr2:5836231	SOX11	0.43	6.85	0.3	2.33e-11	Mitral valve prolapse;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg27129171	chr3:47204927	SETD2	0.87	16.78	0.61	1.07e-49	Colorectal cancer;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.84	-0.42	6.95e-21	Triglycerides;
LGG	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/A	cg00383909	chr3:49044727	WDR6	0.92	11.43	0.47	8.39e-27	Parkinson's disease;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.13	-0.43	6.24e-22	Lung cancer;
LGG	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg27426351	chr10:43362370	NA	0.54	7.68	0.34	9.4e-14	Blood protein levels;
LGG	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg02297831	chr4:17616191	MED28	0.48	8.8	0.38	2.81e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg00631329	chr6:26305371	NA	-0.46	-7.69	-0.34	9.14e-14	Educational attainment;
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg08888203	chr3:10149979	C3orf24	0.53	9.26	0.4	7.43e-19	Alzheimer's disease;
LGG	cis	rs1595825	0.891	rs35817167	chr2:198718928	A/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.69	-0.3	6.51e-11	Ulcerative colitis;
LGG	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg27624424	chr6:160112604	SOD2	0.69	10.36	0.43	9.41e-23	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10589950	chr19:36231534	TMEM149	0.4	7.15	0.32	3.47e-12	Gut microbiome composition (summer);
LGG	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg20608306	chr11:116969690	SIK3	0.42	13.44	0.53	5.08e-35	Blood protein levels;
LGG	cis	rs4356975	0.522	rs6600888	chr4:69969859	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.65	0.3	8.1e-11	Obesity-related traits;
LGG	cis	rs2029213	0.523	rs3773739	chr3:53268429	A/G	cg16894138	chr3:53270350	TKT	-0.49	-10.08	-0.42	9.76e-22	Heart rate;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg25452632	chr12:56754141	STAT2	0.43	7.02	0.31	7.77e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg18050959	chr15:68126178	NA	-0.38	-6.98	-0.31	1.05e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11699826	chr1:26438425	PDIK1L	0.45	7.23	0.32	2e-12	Cognitive performance;
LGG	trans	rs11098499	0.697	rs10020027	chr4:120381879	G/C	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.81	0.38	2.46e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4689642	0.507	rs4689655	chr4:7224033	C/T	cg21353189	chr4:7228343	SORCS2	-0.34	-7.15	-0.32	3.48e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg08508325	chr11:3079039	CARS	-0.6	-13.0	-0.52	3.82e-33	Longevity;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg13010199	chr12:38710504	ALG10B	-0.51	-9.35	-0.4	3.83e-19	Morning vs. evening chronotype;
LGG	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg24803719	chr17:45855879	NA	-0.26	-6.66	-0.3	7.73e-11	IgG glycosylation;
LGG	cis	rs3796352	0.892	rs11718388	chr3:53076415	G/A	cg12962167	chr3:53033115	SFMBT1	0.7	7.16	0.32	3.09e-12	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.38	-0.32	7.46e-13	HDL cholesterol;
LGG	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg07636037	chr3:49044803	WDR6	1.09	27.84	0.79	6.33e-101	Parkinson's disease;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2274273	0.686	rs66531545	chr14:55587460	T/C	cg04306507	chr14:55594613	LGALS3	0.51	11.91	0.48	1.05e-28	Protein biomarker;
LGG	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.78	-0.71	6.16e-73	Leprosy;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	11.47	0.47	5.52e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.18	-0.6	5.47e-47	Asthma;
LGG	cis	rs713587	0.624	rs1550110	chr2:25124563	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index in non-asthmatics;
LGG	cis	rs745821	0.879	rs58693787	chr18:48141710	A/G	cg18923635	chr18:48083994	NA	0.43	7.37	0.32	7.84e-13	Diastolic blood pressure;
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg13607699	chr17:42295918	UBTF	0.55	9.24	0.39	9.04e-19	Total body bone mineral density;
LGG	cis	rs2075371	0.611	rs62462979	chr7:134019379	G/T	cg11752832	chr7:134001865	SLC35B4	0.51	8.59	0.37	1.37e-16	Mean platelet volume;
LGG	trans	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg06521331	chr12:34319734	NA	-0.43	-7.49	-0.33	3.6e-13	Heart rate;
LGG	cis	rs1957429	0.808	rs763346	chr14:65330386	A/G	cg23373153	chr14:65346875	NA	-1.02	-13.25	-0.52	3.2e-34	Pediatric areal bone mineral density (radius);
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17554472	chr22:41940697	POLR3H	0.47	6.82	0.3	2.92e-11	Vitiligo;
LGG	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg08000102	chr2:233561755	GIGYF2	0.59	9.58	0.41	6.13e-20	Coronary artery disease;
LGG	cis	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg26384229	chr12:38710491	ALG10B	1.04	26.88	0.78	1.41e-96	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15008879	chr10:22292810	DNAJC1	0.48	7.64	0.33	1.26e-13	Gut microbiome composition (summer);
LGG	cis	rs1506636	1.000	rs615410	chr7:123437765	T/C	cg03229431	chr7:123269106	ASB15	0.71	16.86	0.62	4.48e-50	Plateletcrit;Platelet count;
LGG	cis	rs13082711	0.911	rs7640957	chr3:27514015	C/A	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.24e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.37	-0.32	8.14e-13	Bipolar disorder;
LGG	cis	rs11771526	0.892	rs62457539	chr7:32364604	G/A	cg13207630	chr7:32358064	NA	0.82	8.34	0.36	8.51e-16	Body mass index;
LGG	cis	rs2694528	0.764	rs112511311	chr5:59872002	G/A	cg11474532	chr5:59995715	DEPDC1B	0.92	8.82	0.38	2.43e-17	Parkinson's disease;
LGG	cis	rs2797369	0.766	rs55869926	chr6:101589339	G/T	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.52e-13	Personality dimensions;
LGG	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg11890956	chr21:40555474	PSMG1	-0.73	-12.5	-0.5	4.24e-31	Menarche (age at onset);
LGG	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.51e-38	IgG glycosylation;
LGG	cis	rs9916302	0.560	rs907094	chr17:37790371	G/A	cg00129232	chr17:37814104	STARD3	-0.78	-14.03	-0.55	1.62e-37	Glomerular filtration rate (creatinine);
LGG	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg15212455	chr7:39170539	POU6F2	0.4	8.52	0.37	2.33e-16	IgG glycosylation;
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09476347	chr16:613343	C16orf11	-0.37	-6.85	-0.3	2.35e-11	Height;
LGG	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg09238746	chr17:78121135	EIF4A3	0.5	8.62	0.37	1.04e-16	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.38	-0.32	7.51e-13	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs1371867	0.846	rs2047249	chr8:101234126	A/G	cg06636551	chr8:101224915	SPAG1	0.47	8.58	0.37	1.4e-16	Atrioventricular conduction;
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.82	0.42	8.47e-21	Neuroticism;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg22076118	chr2:100106147	REV1	-0.39	-6.67	-0.3	7.51e-11	Blood metabolite levels;
LGG	cis	rs11098499	0.874	rs12509054	chr4:120115075	A/C	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs17767392	0.915	rs7147434	chr14:71811526	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.16	-0.39	1.65e-18	Mitral valve prolapse;
LGG	cis	rs8048589	0.615	rs12924889	chr16:12241768	A/G	cg02910054	chr16:12241554	SNX29	0.64	9.55	0.41	7.4e-20	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	cis	rs4737010	0.501	rs3758128	chr8:41657366	G/A	cg08923054	chr8:41654455	ANK1	0.86	12.93	0.51	7.42e-33	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs2439831	0.702	rs2788	chr15:44064886	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.54e-24	Lung cancer in ever smokers;
LGG	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs2307022	0.586	rs1532211	chr16:68394307	G/A	cg07273125	chr16:68295692	NA	0.45	10.07	0.42	1.04e-21	Body mass index;
LGG	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg00504896	chr12:9437009	LOC642846	-0.61	-12.96	-0.52	5.53e-33	Breast size;
LGG	cis	rs11864453	0.647	rs3764311	chr16:72125617	C/G	cg01557791	chr16:72042693	DHODH	-0.45	-8.24	-0.36	1.79e-15	Fibrinogen levels;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.32	0.36	9.64e-16	Tonsillectomy;
LGG	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.38	0.43	7.63e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7404843	0.850	rs6498553	chr16:15539902	T/C	cg02716450	chr16:28638775	NA	-0.69	-7.25	-0.32	1.76e-12	Testicular germ cell tumor;
LGG	trans	rs6787172	0.622	rs12107103	chr3:158126282	C/T	cg23275840	chr4:47708675	CORIN	0.34	7.02	0.31	7.96e-12	Subjective well-being;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs6784615	0.744	rs13091360	chr3:52414273	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.89	0.34	2.2e-14	Waist-hip ratio;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.51	8.48	0.37	3.04e-16	Personality dimensions;
LGG	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg09998033	chr7:158218633	PTPRN2	-0.56	-10.41	-0.44	6.28e-23	Obesity-related traits;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg27490568	chr2:178487706	NA	0.51	10.17	0.43	4.42e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.58	-13.22	-0.52	4.52e-34	Multiple sclerosis;
LGG	cis	rs5742933	0.857	rs1233284	chr2:190689771	G/A	cg04003228	chr2:190539410	ANKAR	0.45	6.67	0.3	7.47e-11	Ferritin levels;
LGG	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	trans	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg05926928	chr17:57297772	GDPD1	-0.51	-7.6	-0.33	1.69e-13	Schizophrenia;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.45e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	trans	rs2562456	0.834	rs13346641	chr19:21592283	C/T	cg00806126	chr19:22604979	ZNF98	-0.54	-7.21	-0.32	2.34e-12	Pain;
LGG	cis	rs2050392	0.894	rs2480277	chr10:30703513	G/T	cg25182066	chr10:30743637	MAP3K8	0.52	10.86	0.45	1.3e-24	Inflammatory bowel disease;
LGG	cis	rs727505	1.000	rs66922607	chr7:124512555	T/A	cg23710748	chr7:124431027	NA	-0.52	-9.85	-0.42	6.65e-21	Lewy body disease;
LGG	cis	rs7843479	0.932	rs68023663	chr8:21794379	T/C	cg17168535	chr8:21777572	XPO7	0.61	10.02	0.42	1.66e-21	Mean corpuscular volume;
LGG	cis	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg07460842	chr6:66804631	NA	-0.98	-18.51	-0.65	1.21e-57	Exhaled nitric oxide output;
LGG	cis	rs36051895	0.559	rs12342390	chr9:5211297	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-11.57	-0.47	2.24e-27	Pediatric autoimmune diseases;
LGG	cis	rs10484885	0.878	rs17763820	chr6:90569634	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.83	-10.38	-0.43	7.73e-23	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs5753037	0.809	rs2074707	chr22:30210356	G/A	cg27665648	chr22:30112403	NA	0.29	6.82	0.3	2.9100000000000002e-11	Type 1 diabetes;
LGG	cis	rs4148087	0.725	rs28476477	chr21:43631874	T/C	cg08841829	chr21:43638893	ABCG1	-0.48	-7.99	-0.35	1.06e-14	Eating disorder in bipolar disorder;
LGG	cis	rs703842	0.739	rs701008	chr12:58117645	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.44	6.88	0.3	1.9e-11	Multiple sclerosis;
LGG	trans	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.48e-28	Corneal astigmatism;
LGG	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg03795903	chr2:30669940	LCLAT1	0.54	7.42	0.33	5.64e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs3008870	0.916	rs2025608	chr1:67422550	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.49	0.74	6.36e-81	Lymphocyte percentage of white cells;
LGG	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg15704280	chr7:45808275	SEPT13	-0.57	-9.56	-0.41	7.14e-20	HDL cholesterol;
LGG	cis	rs754466	0.651	rs11002322	chr10:79649653	G/T	cg17075019	chr10:79541650	NA	-0.94	-18.84	-0.66	3.53e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2131877	0.871	rs62290351	chr3:194856979	G/A	cg07250128	chr3:194833983	C3orf21	0.41	6.95	0.31	1.22e-11	Non-small cell lung cancer;
LGG	cis	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg09307838	chr4:120376055	NA	0.81	13.55	0.53	1.74e-35	Corneal astigmatism;
LGG	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg00745463	chr17:30367425	LRRC37B	-0.56	-7.76	-0.34	5.66e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2224391	0.590	rs2145372	chr6:5245070	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-7.7	-0.34	8.25e-14	Height;
LGG	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg12310025	chr6:25882481	NA	0.65	12.22	0.49	5.8e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.68	-0.34	9.26e-14	Schizophrenia;
LGG	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg00717180	chr2:96193071	NA	0.42	7.42	0.33	5.55e-13	HDL cholesterol;
LGG	cis	rs9325144	0.555	rs4882358	chr12:38726640	A/G	cg26384229	chr12:38710491	ALG10B	0.75	14.96	0.57	1.49e-41	Morning vs. evening chronotype;
LGG	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg06808227	chr14:105710500	BRF1	0.61	10.74	0.45	3.66e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg25174290	chr11:3078921	CARS	0.75	16.03	0.6	2.67e-46	Longevity;
LGG	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg13660082	chr14:53194042	PSMC6	-0.55	-7.82	-0.34	3.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs7717393	1.000	rs11950100	chr5:155755768	G/A	cg04435420	chr5:155754009	SGCD	1.13	13.01	0.52	3.5e-33	Egg allergy;
LGG	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	4.97e-87	Height;
LGG	trans	rs8073060	0.544	rs225268	chr17:33966224	A/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7580658	0.534	rs2089109	chr2:127951458	G/A	cg10021288	chr2:128175891	PROC	-0.44	-8.57	-0.37	1.5e-16	Protein C levels;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg08742575	chr21:47604166	C21orf56	0.54	8.63	0.37	9.86e-17	Testicular germ cell tumor;
LGG	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-8.18	-0.36	2.8e-15	Vitiligo;
LGG	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg04287289	chr16:89883240	FANCA	0.8	16.69	0.61	2.71e-49	Vitiligo;
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg05650719	chr12:132293520	NA	-0.35	-7.45	-0.33	4.55e-13	Migraine;
LGG	trans	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.84	0.38	2.01e-17	Morning vs. evening chronotype;
LGG	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg16208657	chr15:68119293	LBXCOR1	-0.37	-7.13	-0.31	3.76e-12	Obesity;
LGG	trans	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7633787	0.511	rs537660	chr3:23054508	A/G	cg00327796	chr3:23032191	NA	-0.4	-7.76	-0.34	5.52e-14	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	trans	rs800082	1.000	rs800084	chr3:144340494	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.52	0.37	2.34e-16	Smoking behavior;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg15208524	chr1:10270712	KIF1B	0.43	7.6	0.33	1.63e-13	Hepatocellular carcinoma;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01570182	chr17:44337453	NA	0.74	12.5	0.5	4.38e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18000306	chr6:288505	NA	0.6	10.66	0.44	7.22e-24	Menopause (age at onset);
LGG	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.15	-0.32	3.38e-12	Testicular germ cell tumor;
LGG	cis	rs10489202	0.608	rs7556350	chr1:168077797	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-9.99	-0.42	2.03e-21	Schizophrenia;
LGG	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.74	-0.3	4.71e-11	Parkinson's disease;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg10574377	chr1:18908098	NA	0.35	6.85	0.3	2.42e-11	Urate levels in lean individuals;
LGG	cis	rs4363385	0.791	rs3120744	chr1:153010330	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.5	-0.37	2.63e-16	Inflammatory skin disease;
LGG	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg03929089	chr4:120376271	NA	-0.91	-18.48	-0.65	1.65e-57	Coronary artery disease;
LGG	cis	rs7408868	0.831	rs7249115	chr19:15280765	A/G	cg14696996	chr19:15285081	NOTCH3	0.9	11.45	0.47	6.45e-27	Pulse pressure;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05665937	chr4:1216051	CTBP1	0.59	10.97	0.45	4.75e-25	Obesity-related traits;
LGG	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg09307838	chr4:120376055	NA	0.7	11.42	0.47	9.18e-27	Corneal astigmatism;
LGG	cis	rs7566780	0.725	rs4347841	chr2:16702165	C/T	cg09580478	chr2:16689509	NA	0.5	7.5	0.33	3.23e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg14092988	chr3:52407081	DNAH1	0.28	7.21	0.32	2.22e-12	Bipolar disorder;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg11878867	chr6:150167359	LRP11	-0.47	-8.12	-0.35	4.36e-15	Lung cancer;
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg18252515	chr7:66147081	NA	0.43	7.04	0.31	6.98e-12	Aortic root size;
LGG	cis	rs7192750	0.562	rs9302632	chr16:71943511	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs981844	0.778	rs55895613	chr4:154638121	G/T	cg14289246	chr4:154710475	SFRP2	0.67	10.69	0.44	5.5e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs7607369	0.714	rs4674338	chr2:219647487	A/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.24	-0.32	1.91e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg23978390	chr7:1156363	C7orf50	0.56	9.62	0.41	4.15e-20	Longevity;Endometriosis;
LGG	cis	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg21775007	chr8:11205619	TDH	-0.49	-7.73	-0.34	6.55e-14	Triglycerides;
LGG	cis	rs4330281	0.647	rs7630695	chr3:17726483	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs9912789	0.744	rs9893755	chr17:79187432	C/T	cg03823431	chr17:79229385	SLC38A10	-0.33	-7.37	-0.32	7.85e-13	Frontotemporal dementia;
LGG	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.9	0.45	8.89e-25	Morning vs. evening chronotype;
LGG	cis	rs8112449	0.822	rs11670504	chr19:10546771	C/T	cg21868191	chr19:10515988	NA	0.46	7.97	0.35	1.24e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg03959625	chr15:84868606	LOC388152	0.55	8.71	0.38	5.41e-17	Schizophrenia;
LGG	cis	rs7017914	0.967	rs1477944	chr8:71615600	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	trans	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg16141378	chr3:129829833	LOC729375	0.4	8.68	0.37	6.58e-17	Mood instability;
LGG	cis	rs6500637	0.591	rs2075466	chr16:4872970	G/C	cg04440724	chr16:4920505	UBN1	-0.66	-13.14	-0.52	1.01e-33	Cancer;
LGG	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.34	-20.68	-0.69	9.28e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7949566	0.647	rs4937127	chr11:126290510	C/T	cg05055844	chr11:126275997	ST3GAL4	-0.33	-6.85	-0.3	2.36e-11	Platelet distribution width;Mean platelet volume;
LGG	trans	rs783540	0.500	rs783541	chr15:83255061	T/C	cg16105309	chr15:79090380	ADAMTS7	0.51	8.33	0.36	8.91e-16	Schizophrenia;
LGG	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.69	0.44	5.45e-24	Body mass index;
LGG	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg25358565	chr5:93447407	FAM172A	1.37	16.82	0.62	6.79e-50	Diabetic retinopathy;
LGG	trans	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg02227867	chr8:22457446	C8orf58	0.42	8.01	0.35	9.47e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20419181	chr4:38063874	TBC1D1	-0.49	-7.23	-0.32	1.96e-12	Systemic lupus erythematosus;
LGG	cis	rs4780401	0.933	rs4439779	chr16:11826841	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.15	-0.32	3.31e-12	Rheumatoid arthritis;
LGG	cis	rs7914558	0.966	rs1591915	chr10:104646849	C/T	cg04362960	chr10:104952993	NT5C2	0.52	9.87	0.42	5.71e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.05	0.42	1.23e-21	Aortic root size;
LGG	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.24	0.49	4.87e-30	Lung cancer in ever smokers;
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.44	4.34e-23	Bipolar disorder;
LGG	cis	rs254781	0.505	rs190438	chr5:88026902	C/T	cg22951263	chr5:87985283	NA	-0.46	-7.23	-0.32	1.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg18867708	chr6:26865862	GUSBL1	0.46	7.7	0.34	8.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs6500395	1.000	rs36077931	chr16:48594221	A/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg03762349	chr15:79060523	ADAMTS7	0.37	8.11	0.35	4.42e-15	Sudden cardiac arrest;
LGG	cis	rs4006360	0.575	rs7501893	chr17:39311411	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.65	-14.7	-0.56	2.06e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs888194	0.677	rs10774696	chr12:109875753	C/T	cg19025524	chr12:109796872	NA	-0.47	-9.39	-0.4	2.71e-19	Neuroticism;
LGG	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg18089426	chr14:101175970	NA	0.68	11.33	0.47	1.9e-26	Plateletcrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26642667	chr7:127292389	SND1	0.46	7.13	0.31	3.84e-12	Gut microbiome composition (summer);
LGG	cis	rs9457247	0.967	rs1187532	chr6:167382020	G/A	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-10.03	-0.42	1.49e-21	IgG glycosylation;
LGG	cis	rs9783347	1.000	rs59150578	chr11:18340862	G/A	cg03595886	chr11:18357587	GTF2H1	-0.38	-7.77	-0.34	5.18e-14	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00149659	chr3:10157352	C3orf10	0.84	10.76	0.45	3.01e-24	Alzheimer's disease;
LGG	cis	rs6076065	0.723	rs2424532	chr20:23373877	G/A	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05000123	chr14:20937394	PNP	0.46	7.54	0.33	2.52e-13	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg18681998	chr4:17616180	MED28	0.84	18.72	0.66	1.24e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10284592	chr11:57434942	ZDHHC5	0.43	6.76	0.3	4.24e-11	Cognitive performance;
LGG	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.61	-0.33	1.51e-13	Joint mobility (Beighton score);
LGG	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg27129171	chr3:47204927	SETD2	0.86	16.89	0.62	3.28e-50	Colorectal cancer;
LGG	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg22980697	chr10:16874865	CUBN	0.39	7.41	0.33	5.88e-13	Platelet distribution width;
LGG	cis	rs10463554	0.963	rs257294	chr5:102467267	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.54	-0.33	2.48e-13	Parkinson's disease;
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.62	0.48	1.44e-27	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg06212747	chr3:49208901	KLHDC8B	0.44	7.09	0.31	4.99e-12	Resting heart rate;
LGG	cis	rs9783347	0.925	rs3825025	chr11:18343822	C/G	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.92	10.55	0.44	1.85e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9649465	0.967	rs10224062	chr7:123304609	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.6	-0.33	1.64e-13	Neuroticism;
LGG	cis	rs7077256	0.564	rs34205815	chr10:65289904	A/G	cg02276361	chr10:65351566	REEP3	-0.33	-6.66	-0.3	7.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs13205279	chr6:162945030	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.85	8.28	0.36	1.37e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4430311	0.721	rs4610997	chr1:243946917	T/A	cg25706552	chr1:244017396	NA	-0.64	-15.76	-0.59	4e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg04490037	chr7:50633773	DDC	0.33	7.17	0.32	2.93e-12	Systemic sclerosis;
LGG	cis	rs526231	0.578	rs17154825	chr5:102246069	T/C	cg23492399	chr5:102201601	PAM	-0.61	-9.33	-0.4	4.51e-19	Primary biliary cholangitis;
LGG	cis	rs17001868	0.568	rs9611316	chr22:40737027	A/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.97e-26	Bipolar disorder;
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg00830817	chr11:109293614	C11orf87	-0.44	-7.03	-0.31	7.66e-12	Schizophrenia;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.25	0.55	1.81e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg12437481	chr16:420112	MRPL28	-0.59	-9.26	-0.4	7.37e-19	Body mass index;
LGG	cis	rs2404602	0.610	rs28823285	chr15:77050395	T/C	cg15268244	chr15:77196840	NA	0.48	10.19	0.43	3.77e-22	Blood metabolite levels;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.63	0.56	4.11e-40	Platelet count;
LGG	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg25947184	chr8:1697459	NA	-0.41	-6.84	-0.3	2.56e-11	Systolic blood pressure;
LGG	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs35160687	0.862	rs13023154	chr2:86516984	A/G	cg10973622	chr2:86423274	IMMT	-0.45	-7.71	-0.34	7.98e-14	Night sleep phenotypes;
LGG	cis	rs919433	0.680	rs1116734	chr2:198365043	C/G	cg00792783	chr2:198669748	PLCL1	0.5	7.84	0.34	3.05e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg15971980	chr6:150254442	NA	0.46	8.39	0.36	6.13e-16	Lung cancer;
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.64	0.41	3.71e-20	Bipolar disorder;
LGG	cis	rs67478160	0.643	rs2024667	chr14:104211529	T/G	cg26031613	chr14:104095156	KLC1	-0.44	-7.28	-0.32	1.46e-12	Schizophrenia;
LGG	cis	rs526231	0.543	rs34801	chr5:102426513	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg16105309	chr15:79090380	ADAMTS7	0.39	6.79	0.3	3.37e-11	Schizophrenia;
LGG	cis	rs4820539	0.966	rs2267001	chr22:23456696	T/C	cg14186256	chr22:23484241	RTDR1	0.96	23.82	0.74	1.83e-82	Bone mineral density;
LGG	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg11266682	chr4:10021025	SLC2A9	0.38	6.65	0.3	8.37e-11	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg19847130	chr8:10466454	RP1L1	0.32	6.99	0.31	9.78e-12	Triglycerides;
LGG	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg14675211	chr2:100938903	LONRF2	0.67	12.08	0.49	2.06e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg15212455	chr7:39170539	POU6F2	0.37	8.2	0.36	2.44e-15	IgG glycosylation;
LGG	cis	rs3816183	1.000	rs3816184	chr2:43015757	A/G	cg14631114	chr2:43023945	NA	-0.49	-9.16	-0.39	1.62e-18	Hypospadias;
LGG	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	8.01e-13	Refractive error;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22726039	chr2:32390678	SLC30A6	0.39	6.67	0.3	7.45e-11	Body mass index;
LGG	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg22961513	chr11:14280813	SPON1	-0.29	-6.79	-0.3	3.51e-11	Mitochondrial DNA levels;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg24623649	chr8:11872141	NA	-0.3	-6.78	-0.3	3.57e-11	Neuroticism;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.63	-12.42	-0.5	9.02e-31	Obesity-related traits;
LGG	cis	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.15	-0.43	5.26e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.36	-7.15	-0.32	3.38e-12	Hemoglobin concentration;
LGG	cis	rs2985684	1.000	rs2985687	chr14:50100386	T/C	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs2073300	0.609	rs2281434	chr20:23378101	C/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg11342453	chr6:26196699	NA	0.49	6.84	0.3	2.58e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.25	-0.32	1.73e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg13880726	chr7:1868755	MAD1L1	0.41	7.23	0.32	2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2274273	0.805	rs10131926	chr14:55713246	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.37	0.63	2.05e-52	Protein biomarker;
LGG	cis	rs12580194	0.593	rs12581916	chr12:55764409	A/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.21	-0.43	3.35e-22	Cancer;
LGG	cis	rs7172677	0.768	rs72730583	chr15:75351630	T/C	cg10253484	chr15:75165896	SCAMP2	0.52	7.71	0.34	7.51e-14	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7635838	0.859	rs34621655	chr3:11530121	T/C	cg00170343	chr3:11313890	ATG7	0.4	6.7	0.3	6.22e-11	HDL cholesterol;
LGG	cis	rs6547741	0.844	rs9941696	chr2:27920064	C/T	cg27432699	chr2:27873401	GPN1	-0.76	-15.84	-0.59	1.79e-45	Oral cavity cancer;
LGG	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg03213289	chr20:61660250	NA	0.65	14.01	0.55	2.02e-37	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4262150	0.810	rs17454420	chr5:152014941	A/G	cg12297329	chr5:152029980	NA	0.81	16.15	0.6	7.73e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs3862030	0.694	rs12781742	chr10:104227469	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.14e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.94	0.38	9.02e-18	Lung cancer in ever smokers;
LGG	cis	rs611744	0.631	rs627392	chr8:109254677	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	cis	rs6460942	0.915	rs62447640	chr7:12488282	A/T	cg06484146	chr7:12443880	VWDE	-0.39	-6.82	-0.3	2.87e-11	Coronary artery disease;
LGG	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.93	0.57	1.95e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2120019	0.938	rs3850093	chr15:75318482	A/G	cg17294928	chr15:75287854	SCAMP5	0.95	17.49	0.63	6.03e-53	Blood trace element (Zn levels);
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08677398	chr8:58056175	NA	0.48	8.01	0.35	9.41e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg02487422	chr3:49467188	NICN1	0.58	10.73	0.45	3.81e-24	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg08344181	chr3:125677491	NA	-0.64	-7.23	-0.32	2.05e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72781680	1.000	rs72796326	chr2:24137047	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs2463822	0.925	rs2513075	chr11:62102408	C/T	cg06239285	chr11:62104954	ASRGL1	1.16	16.32	0.6	1.28e-47	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.63e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3789045	0.528	rs61817953	chr1:204462612	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.78	-0.38	3.28e-17	Educational attainment (college completion);
LGG	cis	rs9543976	0.623	rs6562915	chr13:76170886	G/T	cg12827798	chr13:76122768	UCHL3	-0.43	-6.69	-0.3	6.5500000000000006e-11	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20607318	chr19:36391512	NFKBID	0.42	6.75	0.3	4.49e-11	Gut microbiome composition (summer);
LGG	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg05044414	chr3:183734942	ABCC5	0.75	16.11	0.6	1.17e-46	Anterior chamber depth;
LGG	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg02389323	chr16:88786976	FAM38A	0.84	7.98	0.35	1.12e-14	Plateletcrit;
LGG	cis	rs6746896	0.683	rs6576983	chr2:97454650	T/G	cg01990225	chr2:97406019	LMAN2L	-0.4	-6.65	-0.3	8.45e-11	Bipolar disorder;
LGG	cis	rs68170813	0.559	rs12536491	chr7:106978024	T/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.3	-0.43	1.59e-22	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.66	-0.37	8.2e-17	Retinal vascular caliber;
LGG	cis	rs892085	0.681	rs7246673	chr19:10876841	T/G	cg17710535	chr19:10819994	QTRT1	0.51	9.09	0.39	2.96e-18	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs9325144	0.560	rs10876005	chr12:39126149	C/G	cg26384229	chr12:38710491	ALG10B	-0.72	-14.39	-0.56	4.68e-39	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.91	-9.94	-0.42	3.17e-21	Corneal curvature;
LGG	cis	rs11252926	0.501	rs2050971	chr10:525530	T/G	cg16386425	chr10:429943	DIP2C	0.36	7.2	0.32	2.53e-12	Psychosis in Alzheimer's disease;
LGG	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg22232500	chr2:134024266	NCKAP5	0.57	8.04	0.35	7.83e-15	Bipolar disorder;
LGG	cis	rs6500395	1.000	rs7197732	chr16:48575878	G/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7209395	0.700	rs17690171	chr17:64202857	C/T	cg19474267	chr17:64306194	PRKCA	-0.69	-10.43	-0.44	5.27e-23	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs2274273	0.624	rs68138420	chr14:55777967	G/T	cg04306507	chr14:55594613	LGALS3	0.53	12.43	0.5	7.87e-31	Protein biomarker;
LGG	cis	rs7264396	0.709	rs2425073	chr20:34293699	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.41	0.33	6.24e-13	Total cholesterol levels;
LGG	cis	rs11229555	0.645	rs17474373	chr11:58191243	G/A	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg00806245	chr18:76673096	NA	-0.68	-8.7	-0.37	6.01e-17	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg03060546	chr3:49711283	APEH	0.74	13.34	0.53	1.39e-34	Resting heart rate;
LGG	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs240764	0.644	rs4329121	chr6:101087507	G/C	cg09795085	chr6:101329169	ASCC3	0.41	6.82	0.3	2.77e-11	Neuroticism;
LGG	cis	rs3849046	0.846	rs154076	chr5:137863134	A/C	cg10920316	chr5:137946599	NA	-0.45	-7.29	-0.32	1.34e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg11247378	chr22:39784982	NA	-0.31	-8.77	-0.38	3.56e-17	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg00495681	chr13:53174319	NA	-0.51	-9.22	-0.39	1.05e-18	Lewy body disease;
LGG	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg17951613	chr5:131705445	SLC22A5	0.7	7.91	0.34	1.95e-14	Rheumatoid arthritis;
LGG	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg08250081	chr4:10125330	NA	0.67	12.24	0.49	5.09e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs3816183	0.958	rs4953665	chr2:43026041	A/T	cg14631114	chr2:43023945	NA	0.49	9.25	0.39	8.19e-19	Hypospadias;
LGG	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg11279151	chr3:101281821	RG9MTD1	0.67	11.21	0.46	5.97e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg03188948	chr7:1209495	NA	0.63	8.13	0.35	3.98e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.7	-0.41	2.33e-20	Lung cancer;
LGG	cis	rs911263	0.603	rs60593979	chr14:68773298	C/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.2	0.36	2.41e-15	Primary biliary cholangitis;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg21724239	chr8:58056113	NA	0.5	7.74	0.34	6.25e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3617	0.625	rs11922961	chr3:52868610	T/C	cg11645453	chr3:52864694	ITIH4	-0.43	-7.28	-0.32	1.46e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs28489187	0.706	rs1498375	chr1:85787323	T/A	cg16011679	chr1:85725395	C1orf52	0.36	6.72	0.3	5.35e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg23231163	chr10:75533350	FUT11	-0.42	-7.08	-0.31	5.3e-12	Inflammatory bowel disease;
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg11814155	chr7:99998594	ZCWPW1	0.53	8.09	0.35	5.15e-15	Platelet count;
LGG	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	8.18	0.36	2.78e-15	Retinal vascular caliber;
LGG	cis	rs61897795	0.628	rs174585	chr11:61611694	G/A	cg19610905	chr11:61596333	FADS2	-0.67	-9.6	-0.41	5.09e-20	Neutrophil count;Sum basophil neutrophil counts;
LGG	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg02002194	chr4:3960332	NA	-0.48	-9.54	-0.41	8.42e-20	Joint mobility (Beighton score);
LGG	cis	rs4629180	0.651	rs9653468	chr2:102108403	A/G	cg16435561	chr2:102091048	RFX8	0.46	8.48	0.37	3.14e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs6669008	1.000	rs1891969	chr1:114185855	C/A	cg26035817	chr1:114414802	PTPN22	0.51	10.92	0.45	7.33e-25	Bacteremia;
LGG	cis	rs12580194	0.593	rs11171431	chr12:55757609	G/T	cg19537932	chr12:55886519	OR6C68	-0.55	-10.12	-0.43	7e-22	Cancer;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg18032289	chr17:61959525	GH2	-0.41	-7.11	-0.31	4.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.05	0.66	3.71e-60	Platelet count;
LGG	cis	rs11169552	0.510	rs10783373	chr12:50966980	C/T	cg12884762	chr12:50931848	DIP2B	-0.4	-7.36	-0.32	8.64e-13	Colorectal cancer;
LGG	cis	rs2274273	0.588	rs58296156	chr14:55828327	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.24	0.49	4.85e-30	Protein biomarker;
LGG	cis	rs6540556	0.723	rs3766618	chr1:209895437	G/T	cg23920097	chr1:209922102	NA	-0.43	-6.8	-0.3	3.15e-11	Red blood cell count;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg27279351	chr12:120934652	DYNLL1	0.78	12.67	0.51	8.76e-32	High light scatter reticulocyte count;
LGG	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs5769765	0.908	rs138867	chr22:50207703	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.62	8.62	0.37	1.08e-16	Schizophrenia;
LGG	cis	rs2439831	0.681	rs484846	chr15:43600803	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	13.92	0.54	4.78e-37	Lung cancer in ever smokers;
LGG	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.5	-0.37	2.72e-16	Retinal vascular caliber;
LGG	cis	rs939658	0.805	rs6495374	chr15:79434031	C/T	cg17916960	chr15:79447300	NA	-0.67	-13.03	-0.52	2.68e-33	Refractive error;
LGG	cis	rs11225247	1.000	rs11225244	chr11:102278334	A/T	cg06323957	chr11:102217781	BIRC2	0.8	7.03	0.31	7.51e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg10778915	chr4:100576610	NA	0.35	6.72	0.3	5.45e-11	Metabolite levels (MHPG);
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg06719900	chr11:109292894	C11orf87	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	trans	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg14926445	chr8:58193284	C8orf71	-0.72	-8.53	-0.37	2.17e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.33	0.47	1.93e-26	Ovarian reserve;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.35	0.55	6.67e-39	Bladder cancer;
LGG	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg20336341	chr7:50628841	DDC	0.45	8.21	0.36	2.28e-15	Malaria;
LGG	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.29	-0.36	1.28e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01449415	chr16:3184811	ZNF213	0.4	6.7	0.3	6.14e-11	Bipolar disorder;
LGG	cis	rs4731207	0.565	rs4355714	chr7:124627521	T/G	cg05630886	chr7:124431682	NA	-0.29	-6.74	-0.3	4.71e-11	Cutaneous malignant melanoma;
LGG	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.94	-0.52	6.71e-33	Diastolic blood pressure;
LGG	trans	rs61931739	0.614	rs6488172	chr12:33745669	A/G	cg26384229	chr12:38710491	ALG10B	0.45	8.15	0.35	3.38e-15	Morning vs. evening chronotype;
LGG	cis	rs3780378	0.967	rs7852988	chr9:5010751	C/A	cg02405213	chr9:5042618	JAK2	-0.52	-9.31	-0.4	5.03e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.96	0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg18681998	chr4:17616180	MED28	0.8	16.63	0.61	5.19e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg25703541	chr22:24373054	LOC391322	-0.96	-19.66	-0.67	5.36e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9487094	0.670	rs12197838	chr6:109993291	G/A	cg01125227	chr6:109776195	MICAL1	0.43	7.56	0.33	2.18e-13	Height;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg11062466	chr8:58055876	NA	0.43	7.6	0.33	1.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.559	rs6060922	chr20:30333909	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs36071027	0.593	rs11745589	chr5:158428274	A/T	cg18496440	chr5:158532302	NA	0.4	6.72	0.3	5.34e-11	Carotid intima media thickness;
LGG	cis	rs12190007	0.547	rs3006182	chr6:169808323	C/T	cg15038512	chr6:170123185	PHF10	-0.44	-8.54	-0.37	2.01e-16	Obesity-related traits;
LGG	cis	rs61906588	0.595	rs490526	chr11:116353106	A/T	cg12564567	chr11:116371188	NA	-0.38	-7.03	-0.31	7.4e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs2028299	0.919	rs7174878	chr15:90434888	A/G	cg23731826	chr15:90371692	NA	0.34	7.59	0.33	1.79e-13	Type 2 diabetes;
LGG	cis	rs9287719	0.967	rs963831	chr2:10745184	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-9.67	-0.41	2.91e-20	Aortic root size;
LGG	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7651736	0.636	rs60985825	chr3:136755496	G/T	cg12473912	chr3:136751656	NA	-0.5	-8.54	-0.37	1.93e-16	Neuroticism;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.2e-19	Life satisfaction;
LGG	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg08600765	chr20:34638493	LOC647979	-0.75	-10.88	-0.45	1.01e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13082711	0.911	rs13086867	chr3:27529937	G/A	cg02860705	chr3:27208620	NA	0.72	12.71	0.51	5.96e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.1	-0.46	1.49e-25	Triglycerides;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11169552	0.510	rs4768899	chr12:51000666	T/A	cg12884762	chr12:50931848	DIP2B	-0.41	-7.72	-0.34	7.25e-14	Colorectal cancer;
LGG	cis	rs12410462	0.710	rs74140145	chr1:227423946	C/T	cg04117972	chr1:227635322	NA	0.46	7.74	0.34	6.49e-14	Major depressive disorder;
LGG	cis	rs28595532	1.000	rs73842212	chr4:119638122	A/G	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26617929	chr16:1858877	NA	-0.59	-8.46	-0.37	3.54e-16	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg11693508	chr17:37793320	STARD3	0.61	8.52	0.37	2.31e-16	Bipolar disorder;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.85	0.3	2.34e-11	Schizophrenia;
LGG	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.57	-8.99	-0.39	6.49e-18	Resting heart rate;
LGG	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg25143771	chr10:104629124	AS3MT	0.41	6.95	0.31	1.27e-11	Arsenic metabolism;
LGG	cis	rs6121246	0.697	rs6087716	chr20:30229040	C/T	cg21427119	chr20:30132790	HM13	-0.5	-8.26	-0.36	1.55e-15	Mean corpuscular hemoglobin;
LGG	trans	rs11039798	0.778	rs7944523	chr11:48911019	G/A	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.99	0.49	4.76e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.53	0.63	4e-53	Longevity;
LGG	cis	rs11971779	0.680	rs4728467	chr7:139120562	G/A	cg07862535	chr7:139043722	LUC7L2	0.49	7.81	0.34	3.82e-14	Diisocyanate-induced asthma;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07281370	chr11:121970768	MIR125B1;LOC399959	-0.3	-7.01	-0.31	8.22e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg14019146	chr3:50243930	SLC38A3	-0.35	-7.28	-0.32	1.43e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1034435	0.547	rs5768686	chr22:48899214	G/A	cg05992904	chr22:48892994	FAM19A5	-0.69	-11.91	-0.48	1e-28	Late-onset Alzheimer's disease;
LGG	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs4604732	0.631	rs35046441	chr1:247626812	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs13424612	1.000	rs13424612	chr2:240900121	C/T	cg01812947	chr2:240904978	NDUFA10	0.43	7.23	0.32	2e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg27279351	chr12:120934652	DYNLL1	0.81	13.07	0.52	1.93e-33	High light scatter reticulocyte count;
LGG	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg10189774	chr4:17578691	LAP3	0.38	6.84	0.3	2.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg20587970	chr11:113659929	NA	-1.31	-24.18	-0.75	3.93e-84	Hip circumference adjusted for BMI;
LGG	cis	rs3126085	0.935	rs74127901	chr1:152195579	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-7.92	-0.35	1.8e-14	Atopic dermatitis;
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.75	-0.34	6.05e-14	Total body bone mineral density;
LGG	cis	rs847577	0.646	rs10270222	chr7:97781799	C/T	cg13397024	chr7:97797637	LMTK2	0.42	7.34	0.32	9.99e-13	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13580471	chr1:104068704	RNPC3	0.57	8.64	0.37	9e-17	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg13385521	chr17:29058706	SUZ12P	0.91	10.55	0.44	1.89e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.59e-14	Skin colour saturation;
LGG	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg26897989	chr16:1907736	C16orf73	-0.51	-9.36	-0.4	3.55e-19	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs6489785	0.775	rs1732398	chr12:121357694	G/A	cg02419362	chr12:121203948	SPPL3	0.45	7.07	0.31	5.63e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-12.94	-0.52	6.86e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg21171335	chr12:122356390	WDR66	0.28	7.91	0.35	1.9e-14	Mean corpuscular volume;
LGG	cis	rs838147	0.733	rs12975781	chr19:49249698	A/G	cg13540341	chr19:49222985	MAMSTR	-0.42	-9.94	-0.42	3.16e-21	Dietary macronutrient intake;
LGG	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.51e-12	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.28e-13	Lung cancer;
LGG	cis	rs3820928	0.692	rs17416354	chr2:227770844	A/G	cg05526886	chr2:227700861	RHBDD1	-0.44	-7.73	-0.34	6.93e-14	Pulmonary function;
LGG	cis	rs75920871	0.925	rs11826651	chr11:116920693	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.52e-12	Subjective well-being;
LGG	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg11317459	chr13:21872234	NA	1.33	24.95	0.76	1.1e-87	White matter hyperintensity burden;
LGG	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg15704280	chr7:45808275	SEPT13	-0.98	-21.5	-0.71	1.27e-71	Height;
LGG	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg26384229	chr12:38710491	ALG10B	0.88	19.65	0.67	5.75e-63	Bladder cancer;
LGG	cis	rs763121	0.853	rs8140617	chr22:38970439	A/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-14.66	-0.56	3e-40	Menopause (age at onset);
LGG	trans	rs12517041	0.515	rs10064157	chr5:23277468	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-8.87	-0.38	1.63e-17	Calcium levels;
LGG	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg16141378	chr3:129829833	LOC729375	0.32	7.15	0.32	3.35e-12	Monocyte count;
LGG	cis	rs4740619	0.619	rs10738428	chr9:16046489	T/C	cg14451791	chr9:16040625	NA	-0.44	-11.5	-0.47	4.21e-27	Body mass index;
LGG	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg25767906	chr1:53392781	SCP2	-0.39	-7.77	-0.34	5.05e-14	Monocyte count;
LGG	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.23	0.58	9.69e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1372520	0.684	rs3113355	chr4:90745345	A/T	cg15133208	chr4:90757351	SNCA	-0.4	-8.21	-0.36	2.25e-15	Neuroticism;
LGG	cis	rs11644362	0.932	rs3848239	chr16:12996642	A/G	cg06890432	chr16:12997467	SHISA9	-0.33	-7.05	-0.31	6.41e-12	Positive affect;Subjective well-being;
LGG	cis	rs11096990	0.613	rs4974990	chr4:39193265	T/C	cg24403649	chr4:39172243	NA	0.42	7.51	0.33	3.03e-13	Cognitive function;
LGG	cis	rs787274	0.619	rs1475293	chr9:115619587	C/T	cg13803584	chr9:115635662	SNX30	0.56	7.88	0.34	2.33e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11758351	1.000	rs77961951	chr6:26186075	A/G	cg01420254	chr6:26195488	NA	0.87	10.72	0.45	4.4e-24	Gout;Renal underexcretion gout;
LGG	cis	rs12681287	0.640	rs13253515	chr8:87458596	T/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs9308433	0.529	rs4655332	chr1:214490756	G/A	cg06198575	chr1:214491504	SMYD2	0.51	7.81	0.34	3.99e-14	IgG glycosylation;
LGG	cis	rs4689388	0.609	rs1046319	chr4:6304286	C/T	cg00701064	chr4:6280414	WFS1	0.59	10.93	0.45	6.82e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12618769	0.597	rs72819987	chr2:99046253	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	1.95e-16	Bipolar disorder;
LGG	cis	rs240764	0.658	rs11155666	chr6:101234841	G/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.68	-0.34	9.4e-14	Neuroticism;
LGG	cis	rs6988985	0.728	rs4370512	chr8:143943157	A/G	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs7246760	0.867	rs55800282	chr19:9833530	A/G	cg02900749	chr2:68251473	NA	-1.01	-10.79	-0.45	2.29e-24	Pursuit maintenance gain;
LGG	cis	rs151997	1.000	rs152803	chr5:50212120	C/T	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.07e-24	Callous-unemotional behaviour;
LGG	cis	rs834603	0.575	rs1704970	chr7:47466512	C/T	cg09696706	chr7:47479511	TNS3	0.36	7.85	0.34	2.83e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9487051	0.837	rs2356817	chr6:109642675	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.97	-0.35	1.21e-14	Reticulocyte fraction of red cells;
LGG	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg04000281	chr11:63949212	NA	0.45	8.6	0.37	1.26e-16	Platelet count;
LGG	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg21475434	chr5:93447410	FAM172A	0.69	7.12	0.31	4.17e-12	Diabetic retinopathy;
LGG	cis	rs4774899	0.902	rs11854015	chr15:57282990	T/C	cg08128148	chr15:57256372	TCF12	-0.34	-8.25	-0.36	1.63e-15	Urinary tract infection frequency;
LGG	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.65	-11.68	-0.48	8.19e-28	Hemoglobin concentration;
LGG	cis	rs7582720	0.945	rs72932711	chr2:203639846	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.32	0.4	4.59e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4704187	0.640	rs7707246	chr5:74354875	G/T	cg03227963	chr5:74354835	NA	0.34	7.53	0.33	2.62e-13	Response to amphetamines;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	8.02e-17	Menopause (age at onset);
LGG	cis	rs2769264	0.505	rs4246526	chr1:151403916	G/T	cg18801370	chr1:151430492	POGZ	0.84	13.81	0.54	1.4e-36	Blood trace element (Cu levels);
LGG	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg01420254	chr6:26195488	NA	0.91	12.28	0.5	3.29e-30	Gout;Renal underexcretion gout;
LGG	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg17127132	chr2:85788382	GGCX	0.44	7.61	0.33	1.55e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8078723	0.668	rs4239225	chr17:38127112	G/A	cg17467752	chr17:38218738	THRA	0.59	10.68	0.44	5.81e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs9815354	0.638	rs56194645	chr3:41843593	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9506514	0.722	rs10400670	chr13:21253489	G/A	cg27499820	chr13:21296301	IL17D	-0.24	-6.88	-0.3	2.01e-11	Coronary artery calcification;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09984370	chr19:37178943	ZNF567	0.37	6.81	0.3	3.08e-11	Obesity-related traits;
LGG	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.76	-14.31	-0.55	1.06e-38	Platelet count;
LGG	cis	rs8170	0.603	rs3810204	chr19:17448660	T/C	cg04749549	chr19:17459798	NA	-0.41	-7.54	-0.33	2.56e-13	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg20476274	chr7:133979776	SLC35B4	0.71	13.53	0.53	2.13e-35	Mean platelet volume;
LGG	cis	rs1719271	0.520	rs36026376	chr15:65124874	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.5	-6.73	-0.3	4.89e-11	Platelet count;
LGG	cis	rs888194	0.690	rs9593	chr12:109994870	A/T	cg19025524	chr12:109796872	NA	-0.35	-6.95	-0.31	1.28e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg15971980	chr6:150254442	NA	0.43	8.08	0.35	5.77e-15	Lung cancer;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg25703541	chr22:24373054	LOC391322	-0.86	-16.33	-0.6	1.08e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg16339924	chr4:17578868	LAP3	0.5	8.45	0.37	3.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg15971980	chr6:150254442	NA	0.45	8.35	0.36	8.21e-16	Lung cancer;
LGG	cis	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg12292205	chr6:26970375	C6orf41	-0.62	-8.19	-0.36	2.61e-15	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02952686	chr15:99791546	LRRC28	-0.46	-6.75	-0.3	4.55e-11	Systemic lupus erythematosus;
LGG	cis	rs11230563	1.000	rs2074227	chr11:60776781	T/C	cg27098804	chr11:60776124	CD6	0.59	10.41	0.44	6.19e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2404602	0.692	rs2137307	chr15:77149020	T/A	cg23625390	chr15:77176239	SCAPER	0.48	9.38	0.4	2.86e-19	Blood metabolite levels;
LGG	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.23	-0.36	1.96e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.82	0.51	2.06e-32	Obesity-related traits;
LGG	cis	rs741702	0.892	rs1799918	chr19:13002400	G/C	cg06417478	chr19:12876846	HOOK2	-0.41	-6.81	-0.3	3.01e-11	Red blood cell traits;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2688608	0.933	rs2633307	chr10:75653881	G/A	cg10168709	chr10:75599394	CAMK2G	-0.34	-6.66	-0.3	7.97e-11	Inflammatory bowel disease;
LGG	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9611565	0.525	rs9611548	chr22:41704143	G/T	cg03806693	chr22:41940476	POLR3H	-0.75	-12.51	-0.5	3.73e-31	Vitiligo;
LGG	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg16070123	chr10:51489643	NA	-0.39	-7.17	-0.32	3.03e-12	Prostate-specific antigen levels;
LGG	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg01169559	chr10:831247	NA	0.52	9.17	0.39	1.55e-18	Uric acid levels;
LGG	cis	rs896854	0.846	rs7845219	chr8:95937502	T/C	cg16049864	chr8:95962084	TP53INP1	-0.39	-8.38	-0.36	6.18e-16	Type 2 diabetes;
LGG	cis	rs490234	0.841	rs2790035	chr9:128439923	C/T	cg14078157	chr9:128172775	NA	0.41	7.65	0.34	1.16e-13	Mean arterial pressure;
LGG	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg00579200	chr11:133705235	NA	-0.58	-11.16	-0.46	8.91e-26	Childhood ear infection;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg05793240	chr7:2802953	GNA12	0.32	7.41	0.33	5.98e-13	Height;
LGG	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.52	-0.47	3.56e-27	Response to antipsychotic treatment;
LGG	trans	rs6582630	0.537	rs7310749	chr12:38400472	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.97	-0.38	7.61e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.22	-0.43	3.1e-22	Diabetic kidney disease;
LGG	cis	rs908922	0.676	rs908927	chr1:152513338	C/G	cg03606772	chr1:152487856	CRCT1	0.31	7.35	0.32	9.19e-13	Hair morphology;
LGG	cis	rs9911578	1.000	rs9901114	chr17:56575208	G/A	cg05425664	chr17:57184151	TRIM37	0.6	9.58	0.41	5.86e-20	Intelligence (multi-trait analysis);
LGG	cis	rs780094	0.500	rs4665987	chr2:27755825	G/A	cg27432699	chr2:27873401	GPN1	0.45	6.75	0.3	4.58e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.12	-0.35	4.29e-15	Coronary artery disease;
LGG	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg26248373	chr2:1572462	NA	-0.89	-15.04	-0.57	6.36e-42	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg19901956	chr11:77921274	USP35	-0.41	-6.67	-0.3	7.12e-11	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg11814155	chr7:99998594	ZCWPW1	-0.59	-9.12	-0.39	2.39e-18	Platelet count;
LGG	trans	rs9467711	0.651	rs67554133	chr6:25866232	T/A	cg01620082	chr3:125678407	NA	-0.74	-6.86	-0.3	2.15e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11971779	0.648	rs9642121	chr7:139092621	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4926611	0.762	rs2948053	chr1:54062273	C/T	cg23596471	chr1:54105337	GLIS1	0.39	8.43	0.36	4.37e-16	Hand grip strength;
LGG	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg18681998	chr4:17616180	MED28	0.86	19.31	0.67	2.21e-61	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8067545	0.641	rs860335	chr17:19837679	A/G	cg13482628	chr17:19912719	NA	0.53	9.58	0.41	5.99e-20	Schizophrenia;
LGG	cis	rs3796619	1.000	rs11939380	chr4:1086871	C/T	cg27284194	chr4:1044797	NA	-0.56	-11.59	-0.47	1.89e-27	Recombination rate (males);
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg24607181	chr17:41446203	NA	-0.3	-6.94	-0.31	1.32e-11	Menopause (age at onset);
LGG	trans	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg07211511	chr3:129823064	LOC729375	-0.64	-8.78	-0.38	3.09e-17	Blood pressure (smoking interaction);
LGG	cis	rs9915657	0.870	rs918081	chr17:70127808	G/A	cg09344028	chr17:70110421	NA	0.48	10.43	0.44	5.24e-23	Thyroid hormone levels;
LGG	cis	rs7267979	0.816	rs390123	chr20:25480105	C/G	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.69e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10493773	1.000	rs12754358	chr1:86248431	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.58	-9.88	-0.42	5.08e-21	Urate levels in overweight individuals;
LGG	cis	rs9513627	1.000	rs7996624	chr13:100127541	G/T	cg15490075	chr13:100150979	NA	-0.66	-6.97	-0.31	1.07e-11	Obesity-related traits;
LGG	cis	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.17e-11	Bladder cancer;
LGG	cis	rs7098414	0.511	rs7916349	chr10:82152638	G/A	cg00277334	chr10:82204260	NA	-0.34	-7.51	-0.33	3.1400000000000003e-13	Post bronchodilator FEV1;
LGG	cis	rs17162190	0.698	rs4659443	chr1:26823631	C/T	cg23229016	chr1:26872525	RPS6KA1	0.25	6.77	0.3	3.92e-11	Mean corpuscular volume;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.74	0.41	1.61e-20	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg08400814	chr5:56204995	C5orf35	-0.49	-7.8	-0.34	4.04e-14	Initial pursuit acceleration;
LGG	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-10.07	-0.42	1.06e-21	Diastolic blood pressure;
LGG	cis	rs9916302	0.904	rs11867312	chr17:37597748	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs701145	0.585	rs62276842	chr3:153784048	A/T	cg12800244	chr3:153838788	SGEF	-0.84	-10.01	-0.42	1.76e-21	Coronary artery disease;
LGG	cis	rs6429082	0.791	rs61836205	chr1:235638753	C/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.02	0.42	1.6e-21	Adiposity;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.45	-0.33	4.75e-13	Bipolar disorder;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.92	-0.38	1.07e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs60180747	1.000	rs11631448	chr15:66757961	T/A	cg07575407	chr15:66541975	MEGF11	0.33	6.67	0.3	7.48e-11	Testicular germ cell tumor;
LGG	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg03433033	chr1:76189801	ACADM	-0.8	-13.61	-0.53	9.85e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	cg15522984	chr1:182991683	LAMC1	-0.39	-7.84	-0.34	3.21e-14	Colorectal cancer;
LGG	cis	rs4919694	0.808	rs80020194	chr10:105035954	A/G	cg04362960	chr10:104952993	NT5C2	1.03	12.54	0.5	3.06e-31	Arsenic metabolism;
LGG	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg15644404	chr18:77186268	NFATC1	-0.81	-10.11	-0.43	7.74e-22	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03983647	chr5:31194330	CDH6	0.45	7.02	0.31	7.89e-12	Gut microbiome composition (summer);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg15586420	chr15:90294517	MESP1	0.45	7.04	0.31	7e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.02	-13.22	-0.52	4.37e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg13444538	chr7:158905317	VIPR2	-0.39	-7.52	-0.33	2.94e-13	Facial morphology (factor 20);
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg06232512	chr2:240612347	NA	-0.36	-7.16	-0.32	3.1e-12	Migraine with aura;
LGG	cis	rs9972944	0.756	rs7212901	chr17:63766499	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.25	-0.36	1.64e-15	Total body bone mineral density;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.76	0.41	1.38e-20	Prudent dietary pattern;
LGG	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg15532942	chr18:77220712	NFATC1	0.52	7.44	0.33	4.82e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2820315	1.000	rs2820312	chr1:201869257	G/A	cg10061532	chr1:201886748	LMOD1	0.32	6.71	0.3	5.58e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.04	-0.49	2.98e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9487094	0.644	rs3757231	chr6:109704451	A/C	cg01125227	chr6:109776195	MICAL1	0.38	6.69	0.3	6.58e-11	Height;
LGG	cis	rs2013441	1.000	rs17759923	chr17:20022035	G/A	cg13482628	chr17:19912719	NA	0.51	9.47	0.4	1.48e-19	Obesity-related traits;
LGG	cis	rs68170813	0.599	rs12533516	chr7:106937135	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.63	-0.44	9.03e-24	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.31	0.32	1.15e-12	Menopause (age at onset);
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg04025307	chr7:1156635	C7orf50	0.67	8.53	0.37	2.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7107174	1.000	rs4944198	chr11:78032605	T/A	cg02023728	chr11:77925099	USP35	0.46	8.17	0.35	3.06e-15	Testicular germ cell tumor;
LGG	cis	rs593982	0.920	rs1108922	chr11:65423930	C/T	cg08755490	chr11:65554678	OVOL1	-0.64	-7.32	-0.32	1.09e-12	Atopic dermatitis;
LGG	cis	rs5758511	0.731	rs58302269	chr22:42351309	G/A	cg15128208	chr22:42549153	NA	0.57	8.92	0.38	1.07e-17	Birth weight;
LGG	cis	rs74781061	0.929	rs4261483	chr15:74813334	T/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09529537	chr5:78531947	JMY	0.5	7.8	0.34	4.06e-14	Gut microbiome composition (summer);
LGG	cis	rs4973397	0.686	rs10933370	chr2:232289960	C/A	cg18859089	chr2:232277014	NA	0.44	6.9	0.31	1.69e-11	Anti-saccade response;
LGG	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg12292205	chr6:26970375	C6orf41	-0.42	-7.44	-0.33	5.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg15038512	chr6:170123185	PHF10	0.52	6.86	0.3	2.21e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8180040	0.620	rs2278963	chr3:47054869	G/T	cg27129171	chr3:47204927	SETD2	-0.85	-15.3	-0.58	4.84e-43	Colorectal cancer;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg05659262	chr3:195539315	MUC4	0.54	8.06	0.35	6.67e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs727505	0.954	rs28728448	chr7:124532938	T/A	cg23710748	chr7:124431027	NA	-0.51	-9.63	-0.41	4.08e-20	Lewy body disease;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg04772025	chr11:68637568	NA	0.75	12.64	0.51	1.13e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9916302	0.560	rs3764353	chr17:37790781	T/C	cg00129232	chr17:37814104	STARD3	-0.78	-14.03	-0.55	1.62e-37	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	12.54	0.5	3.07e-31	Obesity-related traits;
LGG	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg07549998	chr6:150325970	RAET1K	-0.38	-7.25	-0.32	1.76e-12	Alopecia areata;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg07701084	chr6:150067640	NUP43	0.66	12.42	0.5	9.08e-31	Lung cancer;
LGG	cis	rs11785400	0.928	rs10100287	chr8:143734836	C/T	cg24634471	chr8:143751801	JRK	0.52	8.28	0.36	1.37e-15	Schizophrenia;
LGG	cis	rs2652834	0.851	rs12902237	chr15:63418188	C/T	cg05507819	chr15:63340323	TPM1	0.5	7.11	0.31	4.43e-12	HDL cholesterol;
LGG	cis	rs12586317	0.576	rs10146115	chr14:35631184	C/G	cg05294307	chr14:35346193	BAZ1A	-0.4	-7.61	-0.33	1.54e-13	Psoriasis;
LGG	cis	rs362272	0.545	rs3135145	chr4:3299504	T/C	cg06533319	chr4:3265114	C4orf44	-0.36	-7.09	-0.31	5.1e-12	Serum sulfate level;
LGG	cis	rs8064024	0.513	rs1049208	chr16:4934549	G/A	cg08329684	chr16:4932620	PPL	-0.57	-12.69	-0.51	6.97e-32	Cancer;
LGG	cis	rs9611565	0.573	rs9306355	chr22:42111896	A/T	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.89e-41	Vitiligo;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00689492	chr4:1303491	MAEA	0.47	8.06	0.35	6.38e-15	Obesity-related traits;
LGG	cis	rs73086581	0.945	rs6052222	chr20:3972793	G/A	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	cis	rs17162190	0.740	rs12046497	chr1:26847640	C/T	cg23229016	chr1:26872525	RPS6KA1	0.26	7.1	0.31	4.58e-12	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03537747	chr2:27886640	SLC4A1AP;SUPT7L	0.43	6.83	0.3	2.75e-11	Cognitive performance;
LGG	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs1978968	0.763	rs9605472	chr22:18463216	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-14.78	-0.57	8.7e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs6977660	1.000	rs714239	chr7:19803944	C/T	cg07541023	chr7:19748670	TWISTNB	0.47	7.3	0.32	1.26e-12	Thyroid stimulating hormone;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg16507663	chr6:150244633	RAET1G	0.5	10.12	0.43	6.74e-22	Testicular germ cell tumor;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.85	0.66	3.1e-59	Menopause (age at onset);
LGG	cis	rs3087591	0.708	rs2854311	chr17:29671327	C/T	cg24425628	chr17:29625626	OMG;NF1	0.6	12.56	0.5	2.44e-31	Hip circumference;
LGG	cis	rs4731207	0.536	rs13307657	chr7:124600864	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs11696845	0.899	rs2868198	chr20:43367935	C/T	cg25301532	chr20:43378953	KCNK15	0.37	8.14	0.35	3.67e-15	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.66	0.34	1.12e-13	Lung cancer;
LGG	cis	rs9487051	1.000	rs7748918	chr6:109613564	A/G	cg21918786	chr6:109611834	NA	-0.45	-8.36	-0.36	7.39e-16	Reticulocyte fraction of red cells;
LGG	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.43	-7.52	-0.33	2.83e-13	Schizophrenia;
LGG	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Vitiligo;
LGG	cis	rs939658	0.805	rs35832166	chr15:79417994	G/T	cg17916960	chr15:79447300	NA	-0.67	-13.34	-0.53	1.35e-34	Refractive error;
LGG	cis	rs7264396	0.690	rs2425157	chr20:34419083	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.07	0.31	5.81e-12	Total cholesterol levels;
LGG	cis	rs5769765	0.773	rs11090920	chr22:50320105	A/G	cg02269571	chr22:50332266	NA	-0.69	-10.33	-0.43	1.23e-22	Schizophrenia;
LGG	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.94	-0.31	1.35e-11	Monocyte count;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.6	0.63	1.92e-53	Longevity;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs6787172	0.651	rs4680437	chr3:158170122	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.55	-0.33	2.27e-13	Subjective well-being;
LGG	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-9.67	-0.41	2.98e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg16507663	chr6:150244633	RAET1G	0.47	8.75	0.38	3.99e-17	Lung cancer;
LGG	cis	rs10426930	0.639	rs1136405	chr19:5062814	T/C	cg15621731	chr19:5074616	KDM4B	0.3	7.4	0.33	6.36e-13	Monocyte percentage of white cells;
LGG	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7945718	0.967	rs11022490	chr11:12773526	C/G	cg25843174	chr11:12811716	TEAD1	-0.39	-7.97	-0.35	1.27e-14	Educational attainment (years of education);
LGG	cis	rs7084402	0.902	rs1593670	chr10:60300766	C/G	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.05e-56	Refractive error;
LGG	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg17031739	chr1:67600172	NA	-0.4	-8.1	-0.35	4.99e-15	Psoriasis;
LGG	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs1555895	0.680	rs11253448	chr10:841115	T/C	cg10556349	chr10:835070	NA	-0.32	-8.11	-0.35	4.64e-15	Survival in rectal cancer;
LGG	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg25809561	chr17:30822961	MYO1D	0.39	9.13	0.39	2.11e-18	Schizophrenia;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.39	-0.32	7.09e-13	Bipolar disorder;
LGG	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg01403660	chr11:68851641	TPCN2	0.48	6.74	0.3	4.69e-11	Blond vs. brown hair color;
LGG	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	7.9	0.34	2.1e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg18850127	chr7:39170497	POU6F2	0.6	14.6	0.56	5.64e-40	IgG glycosylation;
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg26150922	chr2:100937072	LONRF2	0.6	11.77	0.48	3.67e-28	Intelligence (multi-trait analysis);
LGG	cis	rs611744	0.583	rs1448148	chr8:109333074	T/A	cg21045802	chr8:109455806	TTC35	0.6	11.3	0.47	2.46e-26	Dupuytren's disease;
LGG	trans	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg02002194	chr4:3960332	NA	0.39	7.33	0.32	1.07e-12	Joint mobility (Beighton score);
LGG	cis	rs11771526	0.792	rs10249413	chr7:32304259	G/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg03264133	chr6:25882463	NA	-0.7	-13.3	-0.53	2.01e-34	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg18876405	chr7:65276391	NA	-0.53	-9.4	-0.4	2.58e-19	Aortic root size;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9457247	1.000	rs2013815	chr6:167373812	T/A	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg05692746	chr2:100937584	LONRF2	-0.57	-9.22	-0.39	1.07e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10979	1.000	rs12211659	chr6:143898348	G/T	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg02631450	chr22:32366979	NA	0.98	9.32	0.4	4.81e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7572733	0.840	rs770666	chr2:198611897	T/A	cg00792783	chr2:198669748	PLCL1	0.46	7.77	0.34	5.23e-14	Dermatomyositis;
LGG	cis	rs10173297	0.686	rs12621171	chr2:3710463	A/G	cg17046650	chr2:3699563	NA	-0.65	-9.05	-0.39	4.05e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg06271696	chr7:157225062	NA	-0.64	-14.8	-0.57	7.53e-41	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg16751781	chr15:78858589	CHRNA5	0.46	9.21	0.39	1.12e-18	Sudden cardiac arrest;
LGG	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg20891283	chr12:69753455	YEATS4	0.69	13.18	0.52	6.34e-34	Blood protein levels;
LGG	cis	rs11792861	0.962	rs3750454	chr9:111801325	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.6	-9.6	-0.41	5.04e-20	Menarche (age at onset);
LGG	cis	rs17270561	0.525	rs10484432	chr6:26008876	G/A	cg16482183	chr6:26056742	HIST1H1C	0.96	14.43	0.56	3.06e-39	Iron status biomarkers;
LGG	cis	rs12282928	0.917	rs9651621	chr11:48340048	G/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs7617773	0.780	rs11714176	chr3:48360862	C/T	cg11946769	chr3:48343235	NME6	0.71	11.94	0.49	7.5e-29	Coronary artery disease;
LGG	cis	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg21605333	chr4:119757512	SEC24D	1.28	12.4	0.5	1.12e-30	Cannabis dependence symptom count;
LGG	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.5	-0.5	4.11e-31	Cognitive function;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03647317	chr4:187891568	NA	-0.41	-8.73	-0.38	4.5e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg19442545	chr10:75533431	FUT11	-0.43	-7.07	-0.31	5.68e-12	Inflammatory bowel disease;
LGG	cis	rs9398803	0.796	rs1361107	chr6:126767511	A/C	cg19875578	chr6:126661172	C6orf173	0.57	10.3	0.43	1.5e-22	Male-pattern baldness;
LGG	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg04842962	chr6:43655489	MRPS18A	1.01	17.02	0.62	8.01e-51	IgG glycosylation;
LGG	cis	rs9487094	0.961	rs12193493	chr6:109692776	T/C	cg16315928	chr6:109776240	MICAL1	0.53	9.0	0.39	5.76e-18	Height;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg02725872	chr8:58115012	NA	-0.97	-12.94	-0.52	6.59e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.28	-0.53	2.59e-34	Vitamin D levels;
LGG	cis	rs2028299	0.920	rs8027198	chr15:90426689	A/G	cg23731826	chr15:90371692	NA	0.35	7.78	0.34	4.85e-14	Type 2 diabetes;
LGG	cis	rs7940866	0.678	rs61909201	chr11:130839547	C/T	cg12179176	chr11:130786555	SNX19	0.72	12.8	0.51	2.46e-32	Schizophrenia;
LGG	cis	rs711245	0.574	rs1179494	chr2:36809496	C/G	cg09467607	chr2:36825704	FEZ2	-0.47	-9.33	-0.4	4.29e-19	Height;
LGG	cis	rs6450176	1.000	rs6876198	chr5:53303595	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.72	-11.85	-0.48	1.8e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1847202	0.826	rs13063441	chr3:72952400	A/G	cg25664220	chr3:72788482	NA	-0.24	-7.03	-0.31	7.32e-12	Motion sickness;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs4722166	0.630	rs4722169	chr7:22785419	C/T	cg05265849	chr7:22767390	IL6	0.42	7.83	0.34	3.44e-14	Lung cancer;
LGG	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg23625390	chr15:77176239	SCAPER	0.42	8.0	0.35	1.02e-14	Blood metabolite levels;
LGG	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg18681998	chr4:17616180	MED28	0.86	19.69	0.68	3.72e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7615952	0.932	rs13314869	chr3:125644669	G/A	cg07211511	chr3:129823064	LOC729375	-1.34	-20.82	-0.7	1.98e-68	Blood pressure (smoking interaction);
LGG	trans	rs1478898	0.569	rs2264866	chr8:11388653	C/T	cg02002194	chr4:3960332	NA	0.45	7.28	0.32	1.48e-12	Morning vs. evening chronotype;
LGG	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg04979063	chr2:113191202	RGPD5;RGPD8	0.77	10.02	0.42	1.66e-21	Yeast infection;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg11905131	chr22:24372483	LOC391322	-0.45	-7.79	-0.34	4.38e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3087591	0.960	rs2905790	chr17:29476110	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.89	0.34	2.25e-14	Electroencephalogram traits;
LGG	cis	rs10193935	0.901	rs6727657	chr2:42632117	A/G	cg27598129	chr2:42591480	NA	-0.63	-9.53	-0.4	9.07e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6964587	0.904	rs6465339	chr7:91570790	T/A	cg17063962	chr7:91808500	NA	-0.5	-8.8	-0.38	2.79e-17	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06757925	chr1:70671216	LRRC40;SFRS11	0.46	6.98	0.31	1.06e-11	Gut microbiome composition (summer);
LGG	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07570687	chr10:102243282	WNT8B	0.4	7.08	0.31	5.44e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs752010	0.841	rs7519983	chr1:42083369	C/T	cg16096631	chr1:42092165	HIVEP3	0.72	19.61	0.67	8.54e-63	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.51	-0.47	4.06e-27	Personality dimensions;
LGG	cis	rs9902453	0.934	rs7223645	chr17:28491029	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.53	0.53	2.32e-35	Coffee consumption (cups per day);
LGG	cis	rs8078723	0.668	rs3907022	chr17:38134889	T/C	cg17467752	chr17:38218738	THRA	0.61	11.14	0.46	1.05e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs8072100	0.967	rs11079784	chr17:45702280	A/G	cg25173405	chr17:45401733	C17orf57	0.45	7.48	0.33	3.82e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg20488157	chr14:104394430	TDRD9	-0.57	-9.09	-0.39	2.91e-18	Bipolar disorder;
LGG	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14442939	chr10:27389572	ANKRD26	-0.74	-11.08	-0.46	1.78e-25	Breast cancer;
LGG	trans	rs617791	0.530	rs7934543	chr11:65752508	G/T	cg17712092	chr4:129076599	LARP1B	-0.58	-9.62	-0.41	4.27e-20	Breast cancer;
LGG	cis	rs7666738	0.830	rs17550735	chr4:99014076	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.19	0.36	2.49e-15	Schizophrenia;
LGG	cis	rs1065852	0.906	rs5751230	chr22:42553353	G/A	cg15128208	chr22:42549153	NA	0.75	11.77	0.48	3.73e-28	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs9341808	0.718	rs3812121	chr6:80968727	A/G	cg08355045	chr6:80787529	NA	0.39	7.51	0.33	3.13e-13	Sitting height ratio;
LGG	cis	rs4973397	0.643	rs2034413	chr2:232288149	C/T	cg18859089	chr2:232277014	NA	0.42	6.83	0.3	2.62e-11	Anti-saccade response;
LGG	cis	rs10489167	1.000	rs572777	chr1:41140301	G/A	cg11417323	chr1:41160271	NFYC	-0.52	-7.02	-0.31	7.95e-12	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs79976124	0.879	rs17432710	chr6:66621744	T/C	cg07460842	chr6:66804631	NA	0.74	12.28	0.5	3.39e-30	Type 2 diabetes;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg26666090	chr16:58549219	SETD6	1.15	10.19	0.43	3.94e-22	Schizophrenia;
LGG	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.31	-0.4	5.28e-19	Neuroticism;
LGG	cis	rs12912251	1.000	rs34356257	chr15:38989605	T/C	cg01338139	chr15:38987640	C15orf53	-0.55	-8.72	-0.38	4.98e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs10849893	0.557	rs10774593	chr12:121828763	T/C	cg01154721	chr12:121881891	KDM2B	-0.39	-6.73	-0.3	4.92e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4e-19	Life satisfaction;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg05368731	chr17:41323189	NBR1	0.93	18.1	0.64	9.11e-56	Menopause (age at onset);
LGG	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs6838801	0.857	rs17002148	chr4:77580240	A/G	cg17476223	chr4:77663285	SHROOM3	-0.38	-6.85	-0.3	2.39e-11	Cleft lip with or without cleft palate;
LGG	cis	rs9397585	0.857	rs9383644	chr6:153377227	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.25	-0.46	3.97e-26	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.861	rs505444	chr1:53251860	C/T	cg16325326	chr1:53192061	ZYG11B	0.78	18.71	0.66	1.33e-58	Monocyte count;
LGG	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg25457927	chr22:38595422	NA	-0.4	-9.63	-0.41	4.07e-20	Cutaneous nevi;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.12	-0.35	4.11e-15	IgG glycosylation;
LGG	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg25025879	chr12:53359317	NA	-0.49	-8.48	-0.37	2.98e-16	Cancer (pleiotropy);
LGG	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg26875233	chr11:93583750	C11orf90	-0.43	-8.35	-0.36	7.94e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.5	-0.33	3.24e-13	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21036854	chr14:77506705	NA	0.44	6.74	0.3	4.79e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.35	0.5	1.8e-30	Obesity-related traits;
LGG	cis	rs12282928	0.959	rs10769331	chr11:48249779	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-6.96	-0.31	1.2e-11	Migraine - clinic-based;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.698	rs3815221	chr7:124481245	G/A	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.48	-0.53	3.74e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.68	7.5	0.33	3.25e-13	Initial pursuit acceleration;
LGG	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg24585782	chr17:78113791	EIF4A3	-0.51	-8.47	-0.37	3.36e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9942416	0.660	rs67803720	chr5:74984408	A/T	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs10895140	0.756	rs2508250	chr11:101486583	T/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.28	-0.32	1.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg16586182	chr3:47516702	SCAP	-0.78	-15.62	-0.59	1.77e-44	Colorectal cancer;
LGG	trans	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.63	-0.44	9.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.2e-54	Cognitive function;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08677398	chr8:58056175	NA	0.46	7.24	0.32	1.82e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.28	-0.6	1.98e-47	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg05692746	chr2:100937584	LONRF2	-0.59	-9.49	-0.4	1.2e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.516	rs12490393	chr3:49196132	C/T	cg06212747	chr3:49208901	KLHDC8B	0.71	12.52	0.5	3.68e-31	Menarche (age at onset);
LGG	cis	rs9611565	0.918	rs4820438	chr22:41767135	C/T	cg03806693	chr22:41940476	POLR3H	-0.94	-16.17	-0.6	5.79e-47	Vitiligo;
LGG	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg13114125	chr14:105738426	BRF1	-0.84	-16.0	-0.6	3.64e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12738007	0.967	rs4654393	chr1:29534437	G/A	cg11747820	chr1:29584023	PTPRU	-0.35	-8.09	-0.35	5.35e-15	Schizophrenia;
LGG	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg01620082	chr3:125678407	NA	-0.78	-7.82	-0.34	3.65e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg04624458	chr1:1913527	KIAA1751	0.4	8.36	0.36	7.24e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs4731207	0.596	rs1026836	chr7:124683632	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg23758822	chr17:41437982	NA	0.88	15.39	0.58	1.8e-43	Menopause (age at onset);
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.04	0.55	1.45e-37	Obesity-related traits;
LGG	cis	rs3219090	0.861	rs1341334	chr1:226605024	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.33	0.5	2.01e-30	Melanoma;
LGG	cis	rs7572644	0.723	rs12473400	chr2:28024024	G/T	cg27432699	chr2:27873401	GPN1	0.47	6.88	0.3	1.95e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.2	0.39	1.24e-18	Blood metabolite levels;
LGG	cis	rs9296092	0.538	rs5000098	chr6:33519231	T/G	cg13560919	chr6:33536144	NA	-1.04	-21.71	-0.71	1.3e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs735539	1.000	rs6490606	chr13:21285096	C/G	cg04906043	chr13:21280425	IL17D	0.61	10.75	0.45	3.23e-24	Dental caries;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg02002194	chr4:3960332	NA	0.43	7.96	0.35	1.3e-14	Neuroticism;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg16270222	chr17:41446396	NA	-0.31	-7.29	-0.32	1.32e-12	Menopause (age at onset);
LGG	cis	rs6723226	0.638	rs6543657	chr2:32705085	T/C	cg02381751	chr2:32503542	YIPF4	0.6	10.25	0.43	2.4e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9783347	1.000	rs10832921	chr11:18380835	C/T	cg15585147	chr11:18324498	HPS5	0.42	8.86	0.38	1.72e-17	Pancreatic cancer;
LGG	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.88	-0.42	5.29e-21	Common traits (Other);
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs4917300	0.802	rs11167111	chr8:143097622	G/C	cg26003909	chr8:143102224	NA	-0.32	-6.91	-0.31	1.61e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg10950524	chr7:2139216	MAD1L1	0.32	6.86	0.3	2.17e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20887711	chr4:1340912	KIAA1530	-0.53	-9.86	-0.42	6.17e-21	Obesity-related traits;
LGG	cis	rs193541	0.632	rs7729834	chr5:122122159	A/G	cg19412675	chr5:122181750	SNX24	0.53	8.57	0.37	1.58e-16	Glucose homeostasis traits;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs8067545	0.750	rs11867585	chr17:19992607	A/G	cg13482628	chr17:19912719	NA	0.61	12.22	0.49	5.97e-30	Schizophrenia;
LGG	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	13.3	0.53	2.03e-34	Cognitive test performance;
LGG	cis	rs990171	0.955	rs3755268	chr2:103038527	C/G	cg05295703	chr2:102895712	NA	-0.55	-9.69	-0.41	2.53e-20	Lymphocyte counts;
LGG	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-10.99	-0.45	3.88e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10895140	0.627	rs10791516	chr11:101520048	C/G	cg23650423	chr11:101454676	TRPC6	-0.4	-6.77	-0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs9868809	1.000	rs9868809	chr3:48681053	C/T	cg00383909	chr3:49044727	WDR6	0.85	9.52	0.4	9.56e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7172689	0.862	rs72746155	chr15:81562699	A/C	cg11808699	chr15:81528661	IL16	-0.46	-9.27	-0.4	7.12e-19	Inattentive symptoms;
LGG	trans	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.95	0.35	1.43e-14	Obesity-related traits;
LGG	cis	rs7914558	0.966	rs11191471	chr10:104702050	T/A	cg04362960	chr10:104952993	NT5C2	0.53	10.04	0.42	1.33e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1506636	1.000	rs2896332	chr7:123297223	A/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.23	-0.65	2.27e-56	Plateletcrit;Platelet count;
LGG	cis	rs10267417	0.657	rs12668709	chr7:19858946	T/G	cg05791153	chr7:19748676	TWISTNB	0.62	7.89	0.34	2.16e-14	Night sleep phenotypes;
LGG	trans	rs7246760	1.000	rs7246760	chr19:9918229	G/A	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs3845702	0.736	rs72962575	chr2:180862133	C/G	cg01881094	chr2:180872142	CWC22	1.28	16.49	0.61	2.12e-48	Schizophrenia;
LGG	cis	rs7582720	1.000	rs72934740	chr2:203741362	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9964724	0.796	rs11082014	chr18:35197905	G/T	cg27332583	chr18:35150602	NA	0.37	7.83	0.34	3.27e-14	Educational attainment (years of education);
LGG	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg14460708	chr3:172428874	NCEH1	0.39	6.73	0.3	5.15e-11	Body mass index;
LGG	trans	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg03115019	chr17:80708279	FN3K	0.35	6.68	0.3	6.97e-11	Glycated hemoglobin levels;
LGG	cis	rs2439831	0.867	rs935901	chr15:43651256	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	10.64	0.44	8.67e-24	Lung cancer in ever smokers;
LGG	cis	rs12291225	0.679	rs34238445	chr11:14315915	C/T	cg22961513	chr11:14280813	SPON1	-0.3	-6.75	-0.3	4.34e-11	Sense of smell;
LGG	cis	rs11023332	1.000	rs11023332	chr11:14784110	G/C	cg18937875	chr11:14930189	NA	-0.47	-7.66	-0.34	1.11e-13	Adiponectin levels;Vitamin D levels;
LGG	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg13560919	chr6:33536144	NA	-0.42	-7.83	-0.34	3.26e-14	Crohn's disease;
LGG	cis	rs1109114	0.764	rs2963494	chr5:148596131	T/C	cg06539116	chr5:148597365	ABLIM3	-0.61	-16.19	-0.6	4.77e-47	Body mass index;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.97	-0.38	7.33e-18	Lung cancer;
LGG	cis	rs2180341	0.843	rs4895821	chr6:127572761	T/A	cg24812749	chr6:127587940	RNF146	0.94	15.77	0.59	3.71e-45	Breast cancer;
LGG	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17554472	chr22:41940697	POLR3H	-0.45	-6.84	-0.3	2.51e-11	Vitiligo;
LGG	cis	rs7119	0.689	rs12916833	chr15:77819778	G/A	cg10437265	chr15:77819839	NA	0.24	6.75	0.3	4.55e-11	Type 2 diabetes;
LGG	cis	rs910316	0.967	rs8013444	chr14:75661981	A/G	cg11812906	chr14:75593930	NEK9	-0.55	-10.08	-0.42	9.95e-22	Height;
LGG	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg06885757	chr1:42089581	HIVEP3	0.53	11.05	0.46	2.38e-25	Airway imaging phenotypes;
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.19	-0.32	2.62e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg18402987	chr7:1209562	NA	0.49	8.21	0.36	2.27e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9912468	0.966	rs9910577	chr17:64314548	T/C	cg19474267	chr17:64306194	PRKCA	-0.97	-28.04	-0.79	7.55e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1355223	0.573	rs1148930	chr11:34732225	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.16	0.32	3.29e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs67311347	1.000	rs6793596	chr3:40457795	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-25.69	-0.77	3.93e-91	Renal cell carcinoma;
LGG	cis	rs10936602	0.527	rs9882101	chr3:169548655	G/A	cg00832555	chr3:169529716	LRRC34	0.35	6.99	0.31	9.91e-12	Renal cell carcinoma;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg02462569	chr6:150064036	NUP43	-0.37	-7.92	-0.35	1.8e-14	Lung cancer;
LGG	cis	rs6594499	0.500	rs10491424	chr5:110453806	T/C	cg04022379	chr5:110408740	TSLP	0.42	7.44	0.33	5.07e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11644478	chr21:40555479	PSMG1	0.89	16.6	0.61	6.61e-49	Cognitive function;
LGG	trans	rs853679	0.713	rs200991	chr6:27815494	A/C	cg06606381	chr12:133084897	FBRSL1	0.63	7.87	0.34	2.57e-14	Depression;
LGG	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg02896835	chr1:92012615	NA	-0.46	-10.11	-0.43	7.49e-22	Breast cancer;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.3	0.4	5.61e-19	Electroencephalogram traits;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg02002194	chr4:3960332	NA	-0.42	-7.96	-0.35	1.33e-14	Morning vs. evening chronotype;
LGG	trans	rs57221529	0.654	rs11740553	chr5:672593	C/T	cg25482853	chr8:67687455	SGK3	0.99	11.94	0.49	7.95e-29	Lung disease severity in cystic fibrosis;
LGG	cis	rs11608355	0.515	rs11614551	chr12:109931630	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg04166393	chr7:2884313	GNA12	0.43	7.91	0.34	1.94e-14	Height;
LGG	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg01678292	chr8:41522873	ANK1	0.35	8.21	0.36	2.19e-15	Type 2 diabetes;
LGG	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg12219531	chr12:120966889	COQ5	0.62	10.31	0.43	1.41e-22	High light scatter reticulocyte count;
LGG	trans	rs6582630	0.502	rs11522899	chr12:38270637	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg13010199	chr12:38710504	ALG10B	0.75	15.47	0.58	8.42e-44	Heart rate;
LGG	cis	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg21775007	chr8:11205619	TDH	-0.5	-7.99	-0.35	1.12e-14	Triglycerides;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.71	-0.54	3.68e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg04824913	chr4:887549	GAK	0.44	6.83	0.3	2.76e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	11.52	0.47	3.66e-27	Bone mineral density;
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.37e-12	Height;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.22	0.36	2.04e-15	Schizophrenia;
LGG	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg06636001	chr8:8085503	FLJ10661	0.49	9.12	0.39	2.3e-18	Neuroticism;
LGG	cis	rs9487094	0.961	rs9487100	chr6:109750410	C/T	cg01125227	chr6:109776195	MICAL1	0.54	9.07	0.39	3.4e-18	Height;
LGG	cis	rs7619833	0.719	rs11914763	chr3:27319538	A/T	cg02860705	chr3:27208620	NA	0.39	7.5	0.33	3.37e-13	Breast cancer;
LGG	cis	rs2562456	0.917	rs2650793	chr19:21676115	C/G	cg00806126	chr19:22604979	ZNF98	0.6	8.95	0.38	8.97e-18	Pain;
LGG	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg04469686	chr1:162760199	HSD17B7	-0.48	-8.14	-0.35	3.78e-15	Breast cancer;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg01145232	chr6:150245071	RAET1G	0.32	6.75	0.3	4.35e-11	Testicular germ cell tumor;
LGG	cis	rs7394190	0.748	rs11000771	chr10:75524458	T/G	cg07699608	chr10:75541558	CHCHD1	0.55	7.3	0.32	1.28e-12	Incident atrial fibrillation;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-32.75	-0.84	1.25e-122	Prudent dietary pattern;
LGG	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg26384229	chr12:38710491	ALG10B	0.64	11.63	0.48	1.29e-27	Morning vs. evening chronotype;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.57	0.41	6.29e-20	Menopause (age at onset);
LGG	cis	rs910316	0.712	rs175037	chr14:75465038	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.14	-0.39	2.05e-18	Height;
LGG	cis	rs1983891	1.000	rs9381082	chr6:41542214	T/C	cg20194872	chr6:41519635	FOXP4	0.6	10.3	0.43	1.58e-22	Prostate cancer;
LGG	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg02023728	chr11:77925099	USP35	-0.4	-7.12	-0.31	4.13e-12	Alzheimer's disease (survival time);
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.0	0.31	8.87e-12	Prudent dietary pattern;
LGG	cis	rs12950390	1.000	rs8068453	chr17:45852354	A/G	cg06532163	chr17:45867833	NA	-0.44	-6.66	-0.3	7.76e-11	IgG glycosylation;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7408868	0.706	rs2238642	chr19:15282237	T/C	cg14696996	chr19:15285081	NOTCH3	0.9	11.45	0.47	6.65e-27	Pulse pressure;
LGG	trans	rs877282	0.945	rs71489301	chr10:770191	A/G	cg22713356	chr15:30763199	NA	0.56	8.44	0.37	4.15e-16	Uric acid levels;
LGG	cis	rs963731	0.649	rs10166801	chr2:39250771	C/T	cg04010122	chr2:39346883	SOS1	-0.86	-7.31	-0.32	1.2e-12	Corticobasal degeneration;
LGG	cis	rs7582720	1.000	rs72932731	chr2:203650410	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.3	0.4	5.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10237118	0.915	rs6943477	chr7:140223015	A/G	cg09787580	chr7:140227335	DENND2A	0.73	8.67	0.37	7.3e-17	Optic nerve measurement (cup area);
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-6.91	-0.31	1.64e-11	Lung cancer;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs9682444	chr3:48852639	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs7084402	0.967	rs1658452	chr10:60311114	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.56e-13	Refractive error;
LGG	trans	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-10.91	-0.45	8.18e-25	Brugada syndrome;
LGG	cis	rs2797369	0.656	rs648360	chr6:101362843	C/T	cg27451362	chr6:101846650	GRIK2	0.7	9.7	0.41	2.2e-20	Renal function-related traits (eGRFcrea);
LGG	cis	rs4262150	0.544	rs4958550	chr5:151889813	G/A	cg12297329	chr5:152029980	NA	-0.66	-11.73	-0.48	5.35e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg00960700	chr17:80709150	TBCD	0.47	9.07	0.39	3.35e-18	Glycated hemoglobin levels;
LGG	cis	rs4702718	0.574	rs2930050	chr5:10700127	G/A	cg18867653	chr5:10760375	DAP	0.29	7.21	0.32	2.26e-12	Obesity-related traits;
LGG	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs8017423	0.647	rs1958346	chr14:90824011	G/T	cg04374321	chr14:90722782	PSMC1	-0.64	-12.83	-0.51	1.91e-32	Mortality in heart failure;
LGG	cis	rs4788570	0.578	rs8062188	chr16:71729825	T/C	cg06353428	chr16:71660113	MARVELD3	1.28	20.38	0.69	2.25e-66	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07956936	chr16:72127419	TXNL4B;DHX38	0.39	6.85	0.3	2.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09699651	chr6:150184138	LRP11	0.55	10.57	0.44	1.51e-23	Testicular germ cell tumor;
LGG	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs2732480	0.538	rs2732462	chr12:48696384	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.31	-0.32	1.18e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	trans	rs1459104	1.000	rs12795435	chr11:55047287	C/T	cg15704280	chr7:45808275	SEPT13	0.69	6.8	0.3	3.29e-11	Body mass index;
LGG	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.16	0.6	6.61e-47	Anterior chamber depth;
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.93	-0.45	6.83e-25	Longevity;
LGG	cis	rs5758659	0.714	rs5758589	chr22:42518382	A/G	cg04733989	chr22:42467013	NAGA	-0.38	-6.81	-0.3	2.96e-11	Cognitive function;
LGG	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs9811920	0.809	rs1387647	chr3:99826942	T/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	8.73	0.38	4.5e-17	Axial length;
LGG	cis	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg07460842	chr6:66804631	NA	-0.95	-17.42	-0.63	1.25e-52	Exhaled nitric oxide output;
LGG	cis	rs12458462	0.851	rs62097746	chr18:77487508	G/A	cg11879182	chr18:77439856	CTDP1	0.79	14.67	0.56	2.64e-40	Monocyte count;
LGG	cis	rs2235642	0.821	rs8051895	chr16:1602811	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.52	0.4	9.48e-20	Coronary artery disease;
LGG	cis	rs8077889	0.645	rs1230393	chr17:41842592	A/G	cg26893861	chr17:41843967	DUSP3	-1.11	-26.19	-0.77	2.05e-93	Triglycerides;
LGG	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	9.82e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg14926445	chr8:58193284	C8orf71	-0.8	-10.32	-0.43	1.27e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	12.96	0.52	5.38e-33	Lymphocyte counts;
LGG	cis	rs9815354	0.680	rs17218936	chr3:42019392	C/T	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs800082	0.501	rs9878902	chr3:144220319	A/T	cg24215973	chr2:240111563	HDAC4	0.4	7.35	0.32	8.99e-13	Smoking behavior;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	cis	rs888194	0.677	rs10850139	chr12:109875934	A/C	cg19025524	chr12:109796872	NA	-0.47	-9.39	-0.4	2.71e-19	Neuroticism;
LGG	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg07936489	chr17:37558343	FBXL20	-0.5	-7.97	-0.35	1.26e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs9899728	0.539	rs12940199	chr17:73054759	C/T	cg27626185	chr17:73056755	KCTD2	-1.04	-12.33	-0.5	2.02e-30	Alzheimer's disease or small vessel stroke;
LGG	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg11707556	chr5:10655725	ANKRD33B	0.64	11.01	0.46	3.5e-25	Coronary artery disease;
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.07e-11	Total body bone mineral density;
LGG	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.42e-15	Triglycerides;
LGG	cis	rs308971	0.656	rs307578	chr3:12084158	A/G	cg02700894	chr3:12045449	SYN2	0.48	6.92	0.31	1.49e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg02297831	chr4:17616191	MED28	0.45	8.33	0.36	9.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	4.96e-18	Lung cancer;
LGG	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.72	0.41	1.98e-20	Neuroticism;
LGG	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg27087555	chr16:88793112	FAM38A	1.01	10.49	0.44	2.93e-23	Plateletcrit;
LGG	cis	rs4423214	0.550	rs4944885	chr11:71114075	C/T	cg05163923	chr11:71159392	DHCR7	0.51	9.33	0.4	4.32e-19	Vitamin D levels;
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	16.55	0.61	1.18e-48	Alzheimer's disease;
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.08	0.35	5.61e-15	Electroencephalogram traits;
LGG	cis	rs7084402	0.967	rs1658440	chr10:60323933	T/A	cg07615347	chr10:60278583	BICC1	0.64	18.19	0.65	3.44e-56	Refractive error;
LGG	cis	rs7444	0.941	rs5754295	chr22:21951740	C/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.61	-0.33	1.5700000000000001e-13	Systemic lupus erythematosus;
LGG	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.05	0.39	4.11e-18	Rheumatoid arthritis;
LGG	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg04117972	chr1:227635322	NA	0.57	9.4	0.4	2.62e-19	Major depressive disorder;
LGG	cis	rs12681288	0.676	rs62488537	chr8:1011962	A/C	cg15309053	chr8:964076	NA	0.43	8.47	0.37	3.17e-16	Schizophrenia;
LGG	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.02	-0.46	3.05e-25	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12323884	chr15:70392862	NA	-0.43	-6.94	-0.31	1.31e-11	Pancreatic cancer;
LGG	cis	rs11585357	0.895	rs877552	chr1:17631236	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-8.38	-0.36	6.57e-16	Hair shape;
LGG	cis	rs10904908	0.733	rs359298	chr10:17334176	C/T	cg01003015	chr10:17271136	VIM	0.52	8.6	0.37	1.23e-16	Total cholesterol levels;Cholesterol, total;
LGG	trans	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg06875740	chr19:51307921	C19orf48	-0.73	-6.87	-0.3	2.03e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs11190604	0.943	rs7085261	chr10:102209811	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg11789530	chr4:8429930	ACOX3	-0.68	-10.95	-0.45	5.66e-25	Response to antineoplastic agents;
LGG	cis	rs778371	0.723	rs737027	chr2:233641083	G/C	cg08000102	chr2:233561755	GIGYF2	0.73	12.46	0.5	6.38e-31	Schizophrenia;
LGG	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg20607798	chr8:58055168	NA	0.72	8.12	0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs372883	0.600	rs2832294	chr21:30739671	A/C	cg08807101	chr21:30365312	RNF160	0.61	10.21	0.43	3.18e-22	Pancreatic cancer;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg13010199	chr12:38710504	ALG10B	0.7	14.51	0.56	1.36e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs10904908	0.763	rs10795469	chr10:17334935	A/G	cg01003015	chr10:17271136	VIM	0.5	8.07	0.35	6.3e-15	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg12560992	chr17:57184187	TRIM37	0.85	15.0	0.57	9.82e-42	Intelligence (multi-trait analysis);
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg27363327	chr6:43211208	TTBK1	0.37	7.02	0.31	8.01e-12	Coronary artery disease;
LGG	cis	rs12618769	0.597	rs3754885	chr2:99121708	G/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg15733309	chr7:157513707	PTPRN2	0.62	14.74	0.57	1.35e-40	Bipolar disorder and schizophrenia;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18360149	chr9:130186444	ZNF79	0.39	6.76	0.3	4.26e-11	Body mass index;
LGG	cis	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg15148918	chr7:75625777	STYXL1	-0.66	-7.18	-0.32	2.74e-12	Mononucleosis;
LGG	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg24231037	chr15:68117551	LBXCOR1	0.32	7.82	0.34	3.55e-14	Restless legs syndrome;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg23762105	chr12:34175262	ALG10	0.34	6.82	0.3	2.93e-11	Morning vs. evening chronotype;
LGG	cis	rs6764363	0.654	rs432685	chr3:298171	A/G	cg02057681	chr3:285234	CHL1	-0.38	-6.88	-0.3	1.94e-11	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg15971980	chr6:150254442	NA	0.45	8.53	0.37	2.13e-16	Lung cancer;
LGG	cis	rs9942416	0.660	rs17649055	chr5:74984269	C/T	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.54e-11	Age-related disease endophenotypes;
LGG	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg16586182	chr3:47516702	SCAP	0.74	13.38	0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg18681998	chr4:17616180	MED28	0.77	15.11	0.57	3.27e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9650657	0.650	rs2898248	chr8:10636750	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.97	0.31	1.09e-11	Neuroticism;
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00761968	chr13:53314142	LECT1	-0.37	-7.96	-0.35	1.33e-14	Lewy body disease;
LGG	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg10661904	chr17:79619235	PDE6G	0.42	8.53	0.37	2.03e-16	Eye color traits;
LGG	cis	rs9297145	0.958	rs11975761	chr7:98766688	G/A	cg05967295	chr7:98741636	SMURF1	-0.98	-19.31	-0.67	2.21e-61	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg01028140	chr2:1542097	TPO	-0.43	-8.12	-0.35	4.33e-15	IgG glycosylation;
LGG	cis	rs8064024	0.508	rs2037912	chr16:4933939	G/C	cg08329684	chr16:4932620	PPL	-0.57	-12.79	-0.51	2.66e-32	Cancer;
LGG	cis	rs1062177	1.000	rs17804178	chr5:151197729	T/G	cg00977110	chr5:151150581	G3BP1	0.5	7.88	0.34	2.36e-14	Preschool internalizing problems;
LGG	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg15212455	chr7:39170539	POU6F2	0.4	8.51	0.37	2.39e-16	IgG glycosylation;
LGG	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.46	7.6	0.33	1.71e-13	Osteoporosis;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.93	0.35	1.64e-14	Renal function-related traits (BUN);
LGG	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.32	-0.7	8.92e-71	Monocyte count;
LGG	cis	rs9341808	0.754	rs1324121	chr6:80946077	A/G	cg08355045	chr6:80787529	NA	0.4	7.77	0.34	5.29e-14	Sitting height ratio;
LGG	cis	rs13132184	0.507	rs933821	chr4:38026389	C/T	cg24826020	chr4:38070998	TBC1D1	0.49	8.39	0.36	5.88e-16	Verbal declarative memory;
LGG	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.59e-22	Height;
LGG	cis	rs4774899	1.000	rs12906042	chr15:57479668	A/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.2	-0.32	2.43e-12	Urinary tract infection frequency;
LGG	cis	rs7843479	0.562	rs11774629	chr8:21859315	C/T	cg17168535	chr8:21777572	XPO7	0.79	15.66	0.59	1.11e-44	Mean corpuscular volume;
LGG	cis	rs7172689	1.000	rs11638444	chr15:81534820	A/G	cg11808699	chr15:81528661	IL16	-0.46	-8.69	-0.37	6.44e-17	Inattentive symptoms;
LGG	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.12	0.7	8.14e-70	Morning vs. evening chronotype;
LGG	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg22834771	chr12:69754056	YEATS4	-0.49	-8.61	-0.37	1.17e-16	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2798269	0.646	rs4770182	chr13:22179186	G/T	cg18095732	chr13:22033692	ZDHHC20	0.41	7.38	0.32	7.39e-13	PR segment;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.1	0.31	4.86e-12	Longevity;
LGG	trans	rs526821	0.595	rs517627	chr11:55356489	C/T	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg17133734	chr15:86042851	AKAP13	-0.29	-6.86	-0.3	2.26e-11	Coronary artery disease;
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg16590910	chr6:42928470	GNMT	0.41	11.75	0.48	4.6e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg18357526	chr6:26021779	HIST1H4A	0.6	10.54	0.44	2.0500000000000001e-23	Height;
LGG	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg04287289	chr16:89883240	FANCA	0.81	17.35	0.63	2.71e-52	Vitiligo;
LGG	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02886208	chr11:14281011	SPON1	0.52	11.45	0.47	6.99e-27	Mitochondrial DNA levels;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg23782820	chr8:58130467	NA	0.56	8.29	0.36	1.23e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.48	-0.33	3.82e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs4737010	0.591	rs13282514	chr8:41619713	A/G	cg17182837	chr8:41585554	ANK1	-0.48	-7.8	-0.34	4.25e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs1422110	0.616	rs6452689	chr5:85445059	A/T	cg01787110	chr1:109008453	NBPF6	0.69	12.13	0.49	1.32e-29	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs7267979	0.932	rs449703	chr20:25458559	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.1	0.42	8.35e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1997103	0.954	rs9649780	chr7:55411741	A/C	cg20935933	chr6:143382018	AIG1	0.55	8.54	0.37	1.9e-16	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.36	-0.36	7.2e-16	Triglycerides;
LGG	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22509189	chr2:225307070	NA	-0.59	-9.39	-0.4	2.83e-19	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-6.99	-0.31	9.4e-12	Longevity;Endometriosis;
LGG	cis	rs6942756	1.000	rs6974155	chr7:128914545	C/G	cg02491457	chr7:128862824	NA	-0.76	-13.95	-0.54	3.49e-37	White matter hyperintensity burden;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg05091796	chr16:4465799	CORO7	0.77	12.45	0.5	6.73e-31	Schizophrenia;
LGG	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs4474465	0.790	rs7106931	chr11:78229612	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.37	0.36	6.71e-16	Alzheimer's disease (survival time);
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs9715521	0.746	rs62301192	chr4:59843340	T/C	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4740619	0.905	rs4741517	chr9:15616281	G/A	cg14451791	chr9:16040625	NA	-0.38	-9.93	-0.42	3.28e-21	Body mass index;
LGG	cis	rs7914558	0.966	rs4917997	chr10:104945213	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.68	0.44	5.97e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03264133	chr6:25882463	NA	-0.57	-10.58	-0.44	1.48e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg11812906	chr14:75593930	NEK9	-0.41	-7.34	-0.32	9.9e-13	Coronary artery disease;
LGG	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg13770153	chr20:60521292	NA	-0.46	-7.43	-0.33	5.13e-13	Body mass index;
LGG	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg24699146	chr1:24152579	HMGCL	-0.26	-7.76	-0.34	5.33e-14	Immature fraction of reticulocytes;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.51	0.37	2.47e-16	Platelet count;
LGG	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg12856521	chr11:46389249	DGKZ	0.75	13.27	0.52	2.85e-34	Crohn's disease;
LGG	cis	rs9937943	0.667	rs12919002	chr16:74612377	A/G	cg01733217	chr16:74700730	RFWD3	0.67	9.41	0.4	2.29e-19	Neutrophil percentage of white cells;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg02158880	chr13:53174818	NA	-0.39	-7.59	-0.33	1.72e-13	Lewy body disease;
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07685180	chr8:600429	NA	1.04	10.66	0.44	6.84e-24	IgG glycosylation;
LGG	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg04287289	chr16:89883240	FANCA	-0.55	-10.0	-0.42	1.9e-21	Vitiligo;
LGG	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg25427524	chr10:38739819	LOC399744	-0.67	-13.64	-0.54	7.74e-36	Extrinsic epigenetic age acceleration;
LGG	cis	rs157093	1.000	rs157096	chr20:56255398	C/T	cg04055238	chr20:56251166	PMEPA1	0.45	8.11	0.35	4.47e-15	Verbal declarative memory;
LGG	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg01657329	chr11:68192670	LRP5	-0.5	-8.79	-0.38	2.93e-17	Total body bone mineral density;
LGG	cis	rs7444	0.941	rs9619386	chr22:21979938	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-6.65	-0.3	8.22e-11	Systemic lupus erythematosus;
LGG	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg17646820	chr3:66848679	NA	0.52	7.96	0.35	1.35e-14	Type 2 diabetes;
LGG	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Neuroticism;
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-6.9	-0.31	1.75e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.3	-0.4	5.79e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs6692729	0.933	rs2855560	chr1:227081028	A/C	cg08708961	chr1:227070630	PSEN2	0.31	7.89	0.34	2.15e-14	Electrodermal activity;
LGG	cis	rs68170813	0.559	rs12537730	chr7:106844281	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-11.0	-0.46	3.73e-25	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.63	0.69	1.48e-67	Gut microbiome composition (summer);
LGG	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.36	0.53	1.11e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg13010199	chr12:38710504	ALG10B	0.77	16.59	0.61	7.24e-49	Heart rate;
LGG	cis	rs9942416	0.660	rs41534344	chr5:74997832	T/C	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs240110	0.539	rs6919745	chr6:101338978	T/C	cg09795085	chr6:101329169	ASCC3	0.47	7.76	0.34	5.65e-14	Neuroticism;
LGG	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg26597838	chr10:835615	NA	0.74	10.15	0.43	5.62e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs11657217	1.000	rs11657217	chr17:77709339	C/G	cg06901238	chr17:77706717	ENPP7	0.44	8.61	0.37	1.19e-16	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs2018055	0.826	rs7756187	chr6:117776756	A/T	cg14611402	chr6:117803162	DCBLD1	0.29	7.93	0.35	1.66e-14	Diastolic blood pressure;
LGG	cis	rs2476847	1.000	rs2476847	chr6:549390	C/T	cg13471009	chr6:564609	EXOC2	0.34	7.4	0.33	6.52e-13	Inflammatory skin disease;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	17.18	0.62	1.55e-51	Platelet count;
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00761968	chr13:53314142	LECT1	-0.33	-7.02	-0.31	7.91e-12	Lewy body disease;
LGG	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg02855558	chr7:158107723	PTPRN2	0.42	7.6	0.33	1.7e-13	Calcium levels;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21862992	chr11:68658383	NA	0.51	8.41	0.36	5.04e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs941408	1.000	rs941408	chr19:2814181	C/T	cg06609049	chr19:2785107	THOP1	0.64	9.91	0.42	3.97e-21	Total cholesterol levels;
LGG	cis	rs477692	0.663	rs491929	chr10:131368111	G/A	cg05714579	chr10:131428358	MGMT	0.46	8.89	0.38	1.33e-17	Response to temozolomide;
LGG	trans	rs4650994	1.000	rs10798617	chr1:178515806	T/C	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4740619	0.619	rs12379466	chr9:16028394	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.56	-0.44	1.75e-23	Body mass index;
LGG	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg26513180	chr16:89883248	FANCA	-0.62	-11.24	-0.46	4.41e-26	Vitiligo;
LGG	cis	rs3820068	0.581	rs67806552	chr1:15927138	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.87	0.62	4.12e-50	Systolic blood pressure;
LGG	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-13.12	-0.52	1.18e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9916302	0.904	rs35285898	chr17:37555872	A/C	cg00129232	chr17:37814104	STARD3	0.6	11.29	0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs2635047	0.811	rs10502880	chr18:44770746	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.22	0.36	2.01e-15	Educational attainment;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.32	0.36	9.59e-16	Lung cancer;
LGG	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg02753203	chr1:228287806	NA	-0.65	-11.95	-0.49	7.16e-29	Diastolic blood pressure;
LGG	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs870825	0.929	rs72689265	chr4:185590982	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg20607798	chr8:58055168	NA	0.57	8.77	0.38	3.33e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2479724	0.846	rs2251084	chr6:41838119	T/C	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	cis	rs875971	0.660	rs801190	chr7:66033033	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.81	-0.45	1.97e-24	Aortic root size;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg05025164	chr4:1340916	KIAA1530	0.69	13.24	0.52	3.51e-34	Longevity;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.6	-0.59	2.23e-44	Rheumatoid arthritis;
LGG	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	7.35	0.32	8.81e-13	Retinal vascular caliber;
LGG	cis	rs4731207	0.596	rs1600739	chr7:124639606	A/G	cg05630886	chr7:124431682	NA	0.31	7.08	0.31	5.46e-12	Cutaneous malignant melanoma;
LGG	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg25358565	chr5:93447407	FAM172A	1.26	15.38	0.58	2.02e-43	Diabetic retinopathy;
LGG	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.44	-0.58	1.11e-43	Longevity;
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.71	0.34	7.86e-14	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg04287289	chr16:89883240	FANCA	0.88	8.74	0.38	4.37e-17	Skin colour saturation;
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg03517284	chr6:25882590	NA	-0.39	-6.97	-0.31	1.1e-11	Height;
LGG	cis	rs17067123	0.614	rs72712853	chr4:180066431	A/G	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg01765077	chr12:122356316	WDR66	0.29	7.78	0.34	4.69e-14	Mean corpuscular volume;
LGG	cis	rs7928758	1.000	rs28402124	chr11:134280521	T/C	cg25213107	chr11:134282864	B3GAT1	0.98	11.51	0.47	4.02e-27	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12477438	0.520	rs2053917	chr2:100070884	C/T	cg23527387	chr2:100056660	REV1	0.43	9.55	0.41	7.51e-20	Chronic sinus infection;
LGG	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.54	-8.81	-0.38	2.48e-17	Iron status biomarkers;
LGG	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.08	-0.35	5.86e-15	IgG glycosylation;
LGG	trans	rs3206736	0.514	rs1649236	chr7:35004134	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.3	0.32	1.28e-12	Diastolic blood pressure;
LGG	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg00631329	chr6:26305371	NA	-0.45	-7.61	-0.33	1.56e-13	Educational attainment;
LGG	cis	rs774359	0.797	rs774352	chr9:27516590	C/T	cg14173147	chr9:27528300	MOBKL2B	-0.41	-8.15	-0.35	3.35e-15	Amyotrophic lateral sclerosis;
LGG	trans	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.44	0.33	4.82e-13	Joint mobility (Beighton score);
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs6909430	0.803	rs34385501	chr6:98559572	C/T	cg12860156	chr6:98744658	NA	-0.44	-7.2	-0.32	2.47e-12	Quantitative traits;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg03804240	chr11:118481350	PHLDB1	-0.4	-7.8	-0.34	4.1e-14	Cholesterol, total;
LGG	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.38	-0.36	6.42e-16	Restless legs syndrome;
LGG	trans	rs6011368	0.654	rs1570521	chr20:62911019	G/T	cg13869341	chr1:15865	WASH5P	0.57	10.37	0.43	8.36e-23	Clozapine-induced cytotoxicity;
LGG	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg19784903	chr17:45786737	TBKBP1	0.34	7.13	0.31	3.78e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg22947322	chr17:47091978	IGF2BP1	-0.45	-8.04	-0.35	7.72e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs950027	0.595	rs2486288	chr15:45712339	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	11.78	0.48	3.52e-28	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg22681709	chr2:178499509	PDE11A	0.47	7.31	0.32	1.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9796	0.663	rs11853192	chr15:41368515	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.8	-0.41	9.67e-21	Menopause (age at onset);
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.59	-0.37	1.34e-16	Lung cancer;
LGG	cis	rs11225247	0.772	rs61895376	chr11:102227892	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.53	0.33	2.69e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg03605463	chr16:89740564	NA	0.61	11.01	0.46	3.37e-25	Vitiligo;
LGG	cis	rs79146658	0.688	rs6734390	chr2:179711748	T/C	cg17765952	chr2:179737173	CCDC141	0.6	8.56	0.37	1.64e-16	Diastolic blood pressure;
LGG	cis	rs7444	0.941	rs181362	chr22:21932068	C/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.75	-0.3	4.33e-11	Bipolar disorder;
LGG	cis	rs12410462	0.591	rs2132366	chr1:227787102	C/T	cg04117972	chr1:227635322	NA	0.47	8.59	0.37	1.34e-16	Major depressive disorder;
LGG	cis	rs7666738	0.830	rs6831588	chr4:98977356	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.29	-0.36	1.26e-15	Cognitive function;
LGG	cis	rs151349	0.564	rs4810150	chr20:57627369	G/T	cg23907860	chr20:57583709	CTSZ	-0.37	-6.7	-0.3	6.12e-11	Platelet distribution width;
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg05484376	chr2:27715224	FNDC4	0.46	9.97	0.42	2.44e-21	Total body bone mineral density;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02249930	chr10:70166207	RUFY2	0.37	6.85	0.3	2.29e-11	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.68	-0.48	8.46e-28	Response to antipsychotic treatment;
LGG	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg08717414	chr16:71523259	ZNF19	-0.48	-7.17	-0.32	2.91e-12	Post bronchodilator FEV1;
LGG	cis	rs3087591	0.959	rs9893872	chr17:29571195	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.75	-0.57	1.17e-40	Hip circumference;
LGG	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg26384229	chr12:38710491	ALG10B	0.78	16.89	0.62	3.22e-50	Bladder cancer;
LGG	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.35	0.32	9.27e-13	Refractive error;
LGG	cis	rs240764	0.555	rs4840150	chr6:101183774	T/C	cg09795085	chr6:101329169	ASCC3	0.48	8.32	0.36	9.68e-16	Neuroticism;
LGG	cis	rs2976388	1.000	rs2717562	chr8:143776668	T/C	cg06565975	chr8:143823917	SLURP1	-0.43	-10.88	-0.45	1.08e-24	Urinary tract infection frequency;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg16359550	chr11:109292809	C11orf87	0.42	8.06	0.35	6.36e-15	Schizophrenia;
LGG	cis	rs7523273	0.925	rs4844394	chr1:208000625	C/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.48	-0.47	5.13e-27	Schizophrenia;
LGG	cis	rs4946717	0.740	rs6941301	chr6:106472457	T/C	cg02270332	chr6:106475062	NA	0.38	7.9	0.34	2.12e-14	Inflammatory bowel disease;
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg02158880	chr13:53174818	NA	0.42	7.69	0.34	8.83e-14	Lewy body disease;
LGG	cis	rs9443645	0.901	rs7742034	chr6:79737106	A/G	cg18132916	chr6:79620363	NA	-0.3	-8.31	-0.36	1.04e-15	Intelligence (multi-trait analysis);
LGG	cis	rs8114671	0.967	rs1577924	chr20:33784288	C/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.32	-0.32	1.08e-12	Height;
LGG	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg23899408	chr19:12877188	HOOK2	0.48	7.75	0.34	5.82e-14	Red blood cell traits;
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.71	-0.3	5.81e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg02820901	chr13:113351484	ATP11A	0.58	7.01	0.31	8.67e-12	Glycated hemoglobin levels;
LGG	trans	rs6787172	0.622	rs2362965	chr3:158109379	A/T	cg23275840	chr4:47708675	CORIN	0.36	7.58	0.33	1.94e-13	Subjective well-being;
LGG	cis	rs1847202	0.859	rs4550778	chr3:72949198	G/A	cg25664220	chr3:72788482	NA	-0.26	-7.64	-0.33	1.28e-13	Motion sickness;
LGG	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7296418	0.961	rs12425850	chr12:123501972	T/C	cg00376283	chr12:123451042	ABCB9	0.66	12.34	0.5	1.88e-30	Platelet count;
LGG	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.9	-10.88	-0.45	1.1e-24	Lung cancer in ever smokers;
LGG	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.19	-0.43	3.98e-22	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg02297831	chr4:17616191	MED28	0.49	8.95	0.38	8.55e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg22681709	chr2:178499509	PDE11A	-0.38	-7.2	-0.32	2.48e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6546550	0.933	rs6546555	chr2:70135760	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	trans	rs8073060	0.963	rs11080354	chr17:33872407	A/G	cg19694781	chr19:47549865	TMEM160	-0.65	-10.42	-0.44	5.79e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg03806693	chr22:41940476	POLR3H	1.13	20.44	0.69	1.21e-66	Vitiligo;
LGG	cis	rs7851660	0.594	rs28703314	chr9:100660145	A/T	cg13688889	chr9:100608707	NA	-0.65	-13.02	-0.52	3.13e-33	Strep throat;
LGG	cis	rs7766436	0.767	rs6909752	chr6:22612629	G/A	cg13666174	chr6:22585274	NA	-0.37	-8.69	-0.37	6.42e-17	Coronary artery disease;
LGG	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs7918232	0.830	rs7911024	chr10:27433636	A/C	cg14442939	chr10:27389572	ANKRD26	0.72	11.05	0.46	2.26e-25	Breast cancer;
LGG	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06634786	chr22:41940651	POLR3H	0.7	11.21	0.46	5.81e-26	Vitiligo;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.47	-0.4	1.46e-19	Height;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg13206674	chr6:150067644	NUP43	0.66	13.64	0.54	7.81e-36	Lung cancer;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg11141652	chr22:24348549	GSTTP1	-0.46	-8.02	-0.35	8.93e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg11812906	chr14:75593930	NEK9	-0.51	-9.44	-0.4	1.85e-19	Height;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.11	0.6	1.17e-46	Lymphocyte counts;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg05025164	chr4:1340916	KIAA1530	-0.88	-17.44	-0.63	1.05e-52	Longevity;
LGG	cis	rs9868809	0.772	rs9877794	chr3:48718388	G/C	cg00383909	chr3:49044727	WDR6	0.8	9.99	0.42	2.14e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6466055	0.639	rs3823752	chr7:104624626	C/T	cg03782966	chr7:104585482	NA	0.31	6.73	0.3	4.92e-11	Schizophrenia;
LGG	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg05491587	chr18:77659695	KCNG2	0.4	7.22	0.32	2.16e-12	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16677955	chr1:32930380	ZBTB8B	0.44	7.35	0.32	9.28e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22433210	chr17:43662623	NA	-0.84	-13.91	-0.54	5.45e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9902453	0.874	rs4474741	chr17:28148117	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-14.16	-0.55	4.38e-38	Coffee consumption (cups per day);
LGG	cis	rs5769765	1.000	rs5770728	chr22:50259984	G/A	cg02269571	chr22:50332266	NA	0.64	10.09	0.42	9.13e-22	Schizophrenia;
LGG	cis	rs736801	0.521	rs2070729	chr5:131819921	G/T	cg21138405	chr5:131827807	IRF1	0.35	9.44	0.4	1.82e-19	Breast cancer;Mosquito bite size;
LGG	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.2	0.36	2.31e-15	Diabetic kidney disease;
LGG	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.87	0.54	7.83e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.37	-7.88	-0.34	2.3e-14	Personality dimensions;
LGG	cis	rs727505	0.607	rs17387389	chr7:124784751	T/C	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs10751667	0.643	rs11246344	chr11:933783	A/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.49	0.71	1.38e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs858239	0.600	rs10233039	chr7:23143113	G/A	cg23682824	chr7:23144976	KLHL7	0.45	7.75	0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg05887092	chr17:76393375	PGS1	0.71	15.35	0.58	2.89e-43	HDL cholesterol levels;
LGG	cis	rs2274273	0.840	rs11626751	chr14:55835227	T/C	cg04306507	chr14:55594613	LGALS3	0.61	16.92	0.62	2.44e-50	Protein biomarker;
LGG	cis	rs709400	0.663	rs7158822	chr14:103887868	C/T	cg26031613	chr14:104095156	KLC1	0.78	13.65	0.54	6.76e-36	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22223655	chr18:67872902	RTTN	-0.48	-7.03	-0.31	7.38e-12	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg04863758	chr4:1303710	MAEA	-0.43	-7.48	-0.33	3.78e-13	Obesity-related traits;
LGG	trans	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.52	9.75	0.41	1.5e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.21	-0.36	2.16e-15	Prudent dietary pattern;
LGG	cis	rs5769707	0.967	rs2071904	chr22:50034477	C/T	cg06623630	chr22:50017776	C22orf34	-0.36	-7.73	-0.34	6.65e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9457247	0.638	rs239933	chr6:167413230	A/G	cg07741184	chr6:167504864	NA	0.4	8.7	0.37	5.7e-17	Crohn's disease;
LGG	cis	rs524281	0.861	rs10791855	chr11:65963737	A/G	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg10560079	chr2:191398806	TMEM194B	-0.36	-8.19	-0.36	2.53e-15	Pulse pressure;
LGG	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.4	-0.33	6.44e-13	Morning vs. evening chronotype;
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg00405596	chr8:11794950	NA	-0.6	-10.49	-0.44	3.08e-23	Monocyte count;
LGG	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	12.55	0.5	2.72e-31	Lung cancer in ever smokers;
LGG	cis	rs3213961	0.529	rs6708	chr2:33789534	A/G	cg04131969	chr2:33951647	MYADML	0.52	8.46	0.37	3.51e-16	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs4740619	0.590	rs1359955	chr9:16040879	C/T	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs17209837	1.000	rs45607141	chr7:87087025	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02475777	chr4:1388615	CRIPAK	0.44	8.16	0.35	3.17e-15	Longevity;
LGG	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg11764359	chr7:65958608	NA	0.8	14.91	0.57	2.46e-41	Aortic root size;
LGG	trans	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg05059571	chr16:84539110	KIAA1609	-0.55	-10.46	-0.44	4.05e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10089	1.000	rs3816006	chr5:127450581	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs1008375	1.000	rs3815413	chr4:17654648	T/C	cg04450456	chr4:17643702	FAM184B	0.34	7.66	0.34	1.12e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg18187862	chr3:45730750	SACM1L	0.57	9.32	0.4	4.82e-19	Primary sclerosing cholangitis;
LGG	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs6840360	0.593	rs6857073	chr4:152689274	A/G	cg22705602	chr4:152727874	NA	0.36	8.82	0.38	2.41e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3770081	1.000	rs2164879	chr2:86261579	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.93	-0.31	1.38e-11	Facial emotion recognition (sad faces);
LGG	cis	rs3857747	0.931	rs34058459	chr7:40364145	A/G	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs1997103	1.000	rs9649781	chr7:55411809	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.44e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs258892	0.895	rs10036866	chr5:72068932	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.7	-0.3	5.98e-11	Small cell lung carcinoma;
LGG	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	5.09e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg21427119	chr20:30132790	HM13	-0.48	-8.02	-0.35	8.67e-15	Mean corpuscular hemoglobin;
LGG	cis	rs56159542	1	rs56159542	chr19:19682971	T/C	cg11584989	chr19:19387371	SF4	-0.64	-10.11	-0.43	7.8e-22	Attention deficit hyperactivity disorder symptom score;
LGG	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.77	0.38	3.49e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2235642	0.582	rs8051374	chr16:1566284	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.96	0.31	1.15e-11	Coronary artery disease;
LGG	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg15103426	chr22:29168792	CCDC117	0.72	11.49	0.47	4.83e-27	Lymphocyte counts;
LGG	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg10204951	chr7:910479	UNC84A	-0.55	-7.59	-0.33	1.82e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.13	0.31	3.86e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05204798	chr11:30607888	MPPED2	0.41	6.83	0.3	2.69e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.11	-0.31	4.4e-12	Personality dimensions;
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg13009111	chr11:71350975	NA	0.4	9.19	0.39	1.29e-18	Monocyte count;
LGG	cis	rs6964587	1.000	rs6979085	chr7:91673623	C/T	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.22e-16	Breast cancer;
LGG	cis	rs11971779	0.838	rs11764161	chr7:139115198	T/C	cg07862535	chr7:139043722	LUC7L2	0.63	9.92	0.42	3.6e-21	Diisocyanate-induced asthma;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.89e-13	Menopause (age at onset);
LGG	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg04568710	chr12:38710424	ALG10B	0.35	6.97	0.31	1.08e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg13010199	chr12:38710504	ALG10B	0.69	13.41	0.53	6.93e-35	Morning vs. evening chronotype;
LGG	cis	rs9463078	0.774	rs9369558	chr6:45274021	A/C	cg25276700	chr6:44698697	NA	-0.4	-8.45	-0.37	3.69e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg13147721	chr7:65941812	NA	-0.82	-10.09	-0.42	9.2e-22	Diabetic kidney disease;
LGG	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg16576597	chr16:28551801	NUPR1	0.43	10.21	0.43	3.38e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2040771	0.740	rs9617783	chr22:19260575	C/A	cg02655711	chr22:19163373	SLC25A1	0.46	8.1	0.35	5.05e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs7818345	0.967	rs4546679	chr8:19283335	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.75	0.3	4.36e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs1997103	0.871	rs1997100	chr7:55399656	C/G	cg20935933	chr6:143382018	AIG1	0.59	9.14	0.39	1.96e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs11877825	0.826	rs6505573	chr18:10579542	G/A	cg25239095	chr18:10589360	NA	0.46	8.38	0.36	6.19e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg13565492	chr6:43139072	SRF	-0.72	-8.94	-0.38	9.64e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4704187	0.687	rs2335136	chr5:74407994	T/C	cg03227963	chr5:74354835	NA	0.31	6.65	0.3	8.04e-11	Response to amphetamines;
LGG	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.33	0.32	1.02e-12	Retinal vascular caliber;
LGG	cis	rs11622475	1.000	rs7143682	chr14:104413455	C/T	cg12183467	chr14:104352244	NA	-0.43	-7.35	-0.32	9.1e-13	Bipolar disorder;
LGG	cis	rs6977660	1.000	rs5017193	chr7:19820103	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg12432903	chr7:1882776	MAD1L1	0.55	8.23	0.36	1.9e-15	Bipolar disorder;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg11062466	chr8:58055876	NA	0.47	8.15	0.35	3.53e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs600550	0.588	rs2304934	chr11:60102396	A/G	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.8	-0.34	4.09e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg08477640	chr19:41863820	B9D2	-0.45	-8.28	-0.36	1.29e-15	Migraine;Coronary artery disease;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24110177	chr3:50126178	RBM5	-0.56	-10.4	-0.44	6.64e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg18188782	chr20:61659543	NA	0.4	6.76	0.3	4.13e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2288073	1.000	rs2288073	chr2:24413298	C/T	cg06627628	chr2:24431161	ITSN2	0.64	10.43	0.44	4.92e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24395307	chr7:39990042	CDK13	0.41	6.8	0.3	3.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg21918786	chr6:109611834	NA	-0.48	-8.85	-0.38	1.89e-17	Reticulocyte fraction of red cells;
LGG	cis	rs6460942	0.915	rs17444044	chr7:12458736	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg24134504	chr18:76639479	NA	-0.47	-8.28	-0.36	1.34e-15	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg17202724	chr17:61916730	SMARCD2	0.62	15.12	0.57	3.01e-42	Prudent dietary pattern;
LGG	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.39	0.32	6.96e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4700695	0.764	rs152941	chr5:65241446	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg07636037	chr3:49044803	WDR6	1.1	27.05	0.78	2.33e-97	Parkinson's disease;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg04503457	chr17:41445688	NA	-0.4	-9.6	-0.41	5.08e-20	Menopause (age at onset);
LGG	cis	rs7914558	0.933	rs12763665	chr10:104653717	G/A	cg04362960	chr10:104952993	NT5C2	0.52	9.87	0.42	5.71e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10193935	0.901	rs6544529	chr2:42510652	A/T	cg27598129	chr2:42591480	NA	-0.64	-9.65	-0.41	3.48e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10929925	0.966	rs2693829	chr2:6159326	A/C	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.9	9.59	0.41	5.66e-20	Diabetic retinopathy;
LGG	cis	rs12367572	1.000	rs12367572	chr12:45290466	C/T	cg03114573	chr12:45410052	DBX2	0.51	8.68	0.37	6.7e-17	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19963728	chr2:44588792	PREPL;C2orf34	0.48	7.03	0.31	7.52e-12	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg23625390	chr15:77176239	SCAPER	0.39	7.33	0.32	1.03e-12	Blood metabolite levels;
LGG	cis	rs4737010	0.644	rs555466	chr8:41610346	G/A	cg17182837	chr8:41585554	ANK1	0.44	6.88	0.3	1.95e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.0	-0.39	6.02e-18	Mean corpuscular volume;
LGG	cis	rs6700896	0.522	rs59258332	chr1:66143591	C/G	cg04111102	chr1:66153794	NA	0.33	6.86	0.3	2.15e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg20991723	chr1:152506922	NA	-0.73	-14.96	-0.57	1.42e-41	Hair morphology;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.93	-0.42	3.34e-21	Lung cancer;
LGG	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg08085267	chr17:45401833	C17orf57	-0.59	-11.8	-0.48	2.86e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	8.16e-39	Hair morphology;
LGG	cis	rs9381107	0.505	rs13208500	chr6:9479707	T/C	cg14735645	chr6:9486422	NA	-0.53	-10.15	-0.43	5.23e-22	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9644630	0.841	rs7018210	chr8:19327643	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.34	6.71	0.3	5.65e-11	Oropharynx cancer;
LGG	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg04287289	chr16:89883240	FANCA	0.45	8.14	0.35	3.71e-15	Vitiligo;
LGG	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg17050807	chr22:42548356	NA	-0.35	-6.82	-0.3	2.92e-11	Cognitive function;
LGG	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg06598544	chr20:61472147	COL9A3	-0.9	-10.16	-0.43	4.97e-22	Obesity-related traits;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.08	-0.31	5.23e-12	Obesity-related traits;
LGG	cis	rs3806843	0.735	rs702394	chr5:140086786	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.75	-0.3	4.57e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg27490568	chr2:178487706	NA	0.49	9.9	0.42	4.46e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs965513	1.000	rs7020976	chr9:100547972	T/C	cg13688889	chr9:100608707	NA	-0.53	-9.71	-0.41	2.04e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.1	-0.35	5.06e-15	Calcium levels;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.82	0.3	2.79e-11	Lung cancer;
LGG	cis	rs944722	0.623	rs9913854	chr17:26062362	A/G	cg07704981	chr17:26127537	NOS2	-0.42	-7.21	-0.32	2.22e-12	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.21e-21	Prudent dietary pattern;
LGG	cis	rs60180747	0.544	rs11638535	chr15:66559261	A/C	cg07575407	chr15:66541975	MEGF11	0.64	13.72	0.54	3.37e-36	Testicular germ cell tumor;
LGG	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.37	-0.47	1.38e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.19	-0.32	2.56e-12	Life satisfaction;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg14191688	chr11:70257035	CTTN	0.57	7.84	0.34	3.22e-14	Coronary artery disease;
LGG	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23598886	chr18:12777645	NA	-0.68	-9.23	-0.39	9.37e-19	Inflammatory skin disease;
LGG	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.87	0.34	2.61e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2708377	0.929	rs73053785	chr12:11162411	T/C	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.63	-6.99	-0.31	9.81e-12	Bitter taste perception;
LGG	cis	rs11645898	0.810	rs72787085	chr16:72182564	C/T	cg14768367	chr16:72042858	DHODH	-0.82	-11.06	-0.46	2.14e-25	Blood protein levels;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg06028808	chr11:68637592	NA	0.73	12.56	0.5	2.52e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7572733	0.534	rs1435570	chr2:198731371	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2688608	0.725	rs2688623	chr10:75689615	C/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.06	-0.31	5.98e-12	Inflammatory bowel disease;
LGG	cis	rs975722	0.516	rs2023708	chr7:116981071	G/A	cg10524701	chr7:117356490	CTTNBP2	0.39	8.2	0.36	2.31e-15	Coronary artery disease;
LGG	cis	rs7512552	0.839	rs1103115	chr1:150332304	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7155454	0.815	rs11627485	chr14:65487694	T/C	cg11161011	chr14:65562177	MAX	-0.5	-8.2	-0.36	2.38e-15	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg19147804	chr7:1989927	MAD1L1	0.55	11.0	0.46	3.76e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9397585	0.857	rs4869778	chr6:153389837	G/A	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg26769984	chr7:1090371	C7orf50	0.54	9.37	0.4	3.24e-19	Bronchopulmonary dysplasia;
LGG	cis	rs7215564	0.908	rs8070102	chr17:78683982	C/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg09021430	chr5:549028	NA	-0.68	-9.27	-0.4	7.12e-19	Obesity-related traits;
LGG	trans	rs1814175	0.669	rs10839315	chr11:49654406	G/A	cg03929089	chr4:120376271	NA	-0.79	-14.86	-0.57	4.02e-41	Height;
LGG	cis	rs13082711	0.555	rs7627508	chr3:27252495	A/C	cg02860705	chr3:27208620	NA	0.92	18.16	0.64	4.91e-56	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.68e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.686	rs1148478	chr1:11174067	A/T	cg08854313	chr1:11322531	MTOR	0.71	14.38	0.56	5.12e-39	Body mass index;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg25632114	chr8:95732714	DPY19L4	0.44	6.72	0.3	5.42e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs959260	0.557	rs4788887	chr17:73323876	C/G	cg14668889	chr17:73230827	NUP85	-0.51	-8.62	-0.37	1.08e-16	Systemic lupus erythematosus;
LGG	cis	rs9912468	0.933	rs67675584	chr17:64324501	A/G	cg19474267	chr17:64306194	PRKCA	0.94	25.49	0.76	3.45e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	trans	rs8073060	0.586	rs2523114	chr17:34023762	G/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9487094	0.848	rs7372	chr6:109688114	A/G	cg16315928	chr6:109776240	MICAL1	0.53	9.0	0.39	5.76e-18	Height;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.11	-0.31	4.52e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg21095983	chr6:86352623	SYNCRIP	0.61	11.36	0.47	1.47e-26	Smooth-surface caries;
LGG	cis	rs6500395	0.962	rs9921737	chr16:48589873	G/T	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9487051	0.768	rs463916	chr6:109520538	A/G	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg07882059	chr11:68924751	NA	0.4	7.14	0.32	3.56e-12	Blond vs. brown hair color;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.83	0.42	7.92e-21	Height;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg07332563	chr6:291687	DUSP22	-0.6	-9.91	-0.42	4.13e-21	Menopause (age at onset);
LGG	cis	rs72700829	0.531	rs12070288	chr1:151009984	C/G	cg11822372	chr1:151115635	SEMA6C	-0.69	-7.17	-0.32	2.93e-12	Schizophrenia;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.17	0.46	8.27e-26	Bipolar disorder;
LGG	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg01631408	chr1:248437212	OR2T33	0.53	9.93	0.42	3.37e-21	Common traits (Other);
LGG	cis	rs79911532	0.551	rs41301427	chr7:75614557	G/A	cg15148918	chr7:75625777	STYXL1	-0.61	-6.76	-0.3	4.16e-11	Mononucleosis;
LGG	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg00012203	chr2:219082015	ARPC2	-0.75	-14.39	-0.56	4.47e-39	Colorectal cancer;
LGG	trans	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg25214090	chr10:38739885	LOC399744	0.65	11.55	0.47	2.85e-27	Corneal astigmatism;
LGG	cis	rs4750440	0.702	rs7917812	chr10:14030067	G/A	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.7	-0.54	4.26e-36	Adiponectin levels;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg11878867	chr6:150167359	LRP11	-0.53	-11.36	-0.47	1.49e-26	Lung cancer;
LGG	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.44e-11	Blood metabolite levels;
LGG	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05491587	chr18:77659695	KCNG2	-0.52	-7.02	-0.31	8.06e-12	Opioid sensitivity;
LGG	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.69	0.41	2.49e-20	Menopause (age at onset);
LGG	cis	rs1003719	0.667	rs73201942	chr21:38475164	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.72	13.15	0.52	8.77e-34	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02101719	chr7:148787553	ZNF786	0.45	7.02	0.31	8.13e-12	Gut microbiome composition (summer);
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.75	-0.38	4.13e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg26656751	chr17:43910226	CRHR1	0.48	8.85	0.38	1.81e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12956009	0.518	rs11663852	chr18:44887542	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.45	0.33	4.72e-13	Educational attainment (years of education);
LGG	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg26384229	chr12:38710491	ALG10B	0.63	12.27	0.5	3.53e-30	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.37	0.53	1.07e-34	Bladder cancer;
LGG	cis	rs2243480	1.000	rs1267820	chr7:66050295	C/G	cg18252515	chr7:66147081	NA	-1.42	-20.51	-0.69	5.3e-67	Diabetic kidney disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06689961	chr12:12870959	CDKN1B	0.41	6.75	0.3	4.37e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.56	0.33	2.26e-13	Neuroticism;
LGG	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg26150922	chr2:100937072	LONRF2	-0.49	-8.72	-0.38	5.03e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	7.1	0.31	4.59e-12	Platelet count;
LGG	cis	rs745821	0.701	rs17741814	chr18:48098624	C/A	cg18923635	chr18:48083994	NA	0.42	7.52	0.33	2.81e-13	Diastolic blood pressure;
LGG	cis	rs796364	0.760	rs55906940	chr2:201049386	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.24	-0.36	1.82e-15	Schizophrenia;
LGG	cis	rs883565	0.655	rs9837975	chr3:39064293	T/C	cg01426195	chr3:39028469	NA	-0.67	-15.05	-0.57	5.89e-42	Handedness;
LGG	trans	rs561341	1.000	rs498391	chr17:30328704	G/A	cg20587970	chr11:113659929	NA	-1.31	-23.38	-0.74	2.03e-80	Hip circumference adjusted for BMI;
LGG	cis	rs73086581	0.838	rs73088424	chr20:4001006	T/G	cg02187196	chr20:3869020	PANK2	0.71	9.89	0.42	4.87e-21	Response to antidepressants in depression;
LGG	cis	rs8141529	0.748	rs7287918	chr22:29281710	G/A	cg02153584	chr22:29168773	CCDC117	0.6	9.5	0.4	1.14e-19	Lymphocyte counts;
LGG	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg11494091	chr17:61959527	GH2	0.6	9.81	0.41	8.78e-21	Height;
LGG	cis	rs7017914	0.967	rs35207116	chr8:71708971	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs9400467	0.506	rs12191195	chr6:111712718	C/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.71	0.3	5.56e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg10621924	chr7:39171070	POU6F2	0.48	9.92	0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs16976116	1.000	rs16976116	chr15:55480467	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.39	0.32	6.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-17.17	-0.62	1.66e-51	Monocyte count;
LGG	trans	rs2727020	0.664	rs4929893	chr11:49196332	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.97	-0.31	1.09e-11	Coronary artery disease;
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg24250549	chr1:154909240	PMVK	0.66	11.68	0.48	8.37e-28	Prostate cancer;
LGG	trans	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg25042112	chr7:64838748	ZNF92	-0.47	-6.69	-0.3	6.64e-11	Pain;
LGG	cis	rs7512552	0.780	rs2794681	chr1:150321951	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg18446336	chr7:2847575	GNA12	-0.4	-10.73	-0.45	3.83e-24	Height;
LGG	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg14675211	chr2:100938903	LONRF2	0.64	11.61	0.47	1.58e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs7319311	0.965	rs9583488	chr13:111031352	G/A	cg06243866	chr13:111019493	COL4A2	0.51	8.85	0.38	1.94e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg21545522	chr1:205238299	TMCC2	0.37	7.07	0.31	5.62e-12	Red blood cell count;
LGG	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.53	0.47	3.18e-27	Mean platelet volume;
LGG	cis	rs7166081	1.000	rs2289262	chr15:67501033	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.39	-0.32	6.73e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg14416269	chr4:6271139	WFS1	0.5	9.33	0.4	4.5e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2072732	0.821	rs1005471	chr1:2952614	T/C	cg08733933	chr1:2954429	NA	-0.38	-8.28	-0.36	1.32e-15	Plateletcrit;
LGG	cis	rs679087	1.000	rs672107	chr12:29917266	T/A	cg14258853	chr12:29935411	TMTC1	-0.43	-8.61	-0.37	1.17e-16	Schizophrenia;
LGG	cis	rs1620921	0.653	rs7382456	chr6:161276583	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23953395	chr11:116658773	ZNF259	0.45	6.91	0.31	1.58e-11	Gut microbiome composition (summer);
LGG	trans	rs2797160	0.904	rs1612274	chr6:126014907	C/A	cg05039488	chr6:79577232	IRAK1BP1	0.42	6.95	0.31	1.22e-11	Endometrial cancer;
LGG	trans	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg25482853	chr8:67687455	SGK3	0.84	11.13	0.46	1.21e-25	Obesity-related traits;
LGG	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg00198680	chr16:28758506	NA	0.29	7.19	0.32	2.61e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04730665	chr2:236403704	AGAP1	0.43	7.17	0.32	2.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg18252515	chr7:66147081	NA	1.44	20.8	0.7	2.34e-68	Diabetic kidney disease;
LGG	cis	rs763121	0.849	rs12004	chr22:38877461	T/G	cg06022373	chr22:39101656	GTPBP1	0.86	17.06	0.62	5.42e-51	Menopause (age at onset);
LGG	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg15627072	chr1:2432621	PLCH2	-0.38	-8.38	-0.36	6.28e-16	Ulcerative colitis;
LGG	trans	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg05926928	chr17:57297772	GDPD1	-0.9	-13.51	-0.53	2.77e-35	Opioid sensitivity;
LGG	cis	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.32	-0.32	1.12e-12	Bipolar disorder;
LGG	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg01181863	chr3:195395398	SDHAP2	-0.68	-10.37	-0.43	8.55e-23	Pancreatic cancer;
LGG	cis	rs2439831	0.850	rs28858500	chr15:44156942	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.12	0.39	2.39e-18	Lung cancer in ever smokers;
LGG	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.29	0.36	1.23e-15	Iron status biomarkers;
LGG	cis	rs2742417	1.000	rs2742420	chr3:45732237	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2916247	0.908	rs10956823	chr8:93140909	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.39	-8.11	-0.35	4.51e-15	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-14.2	-0.55	3.04e-38	Schizophrenia;
LGG	cis	rs1691799	0.899	rs903590	chr12:66745777	C/G	cg16791601	chr12:66731901	HELB	-0.64	-14.85	-0.57	4.58e-41	White blood cell count (basophil);
LGG	cis	rs4561483	0.801	rs33631	chr16:11995387	G/C	cg08843971	chr16:11963173	GSPT1	-0.68	-18.63	-0.65	3.25e-58	Testicular germ cell tumor;
LGG	cis	rs7166081	1.000	rs8030620	chr15:67620665	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.68	-0.3	6.89e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg20608306	chr11:116969690	SIK3	-0.38	-10.3	-0.43	1.55e-22	Subjective well-being;
LGG	cis	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg21775007	chr8:11205619	TDH	-0.43	-6.74	-0.3	4.63e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.64	0.69	1.4e-67	Alzheimer's disease;
LGG	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs11690935	0.595	rs788171	chr2:172921832	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	14.35	0.55	6.55e-39	Schizophrenia;
LGG	cis	rs7928758	0.887	rs75373472	chr11:134264506	T/G	cg15243474	chr11:134282918	B3GAT1	1.26	16.21	0.6	4.11e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg23730037	chr7:158596552	ESYT2	-0.4	-6.79	-0.3	3.5e-11	Height;
LGG	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.54e-24	Aortic root size;
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg04703951	chr17:43578652	NA	0.4	8.04	0.35	7.66e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg01625945	chr7:157512322	PTPRN2	-0.46	-10.7	-0.45	4.99e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs10979	1.000	rs1416207	chr6:143889275	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs9972944	0.729	rs12939140	chr17:63777249	T/A	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs2798269	0.902	rs2476637	chr13:22112927	G/A	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.08	-0.31	5.32e-12	PR segment;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25072359	chr17:41440525	NA	0.53	10.21	0.43	3.31e-22	Menopause (age at onset);
LGG	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg18225595	chr11:63971243	STIP1	-0.62	-11.81	-0.48	2.47e-28	Platelet count;
LGG	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg03929089	chr4:120376271	NA	-0.79	-15.17	-0.58	1.81e-42	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02494117	chr9:130965474	DNM1;CIZ1	0.48	7.64	0.33	1.3e-13	Gut microbiome composition (summer);
LGG	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18252515	chr7:66147081	NA	-0.41	-6.87	-0.3	2.12e-11	Aortic root size;
LGG	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg06532163	chr17:45867833	NA	-0.38	-6.89	-0.3	1.88e-11	IgG glycosylation;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg16301924	chr13:53314226	LECT1	0.46	9.35	0.4	3.63e-19	Lewy body disease;
LGG	cis	rs7267979	0.966	rs2227890	chr20:25260931	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	2.96e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg14664628	chr15:75095509	CSK	-1.15	-26.79	-0.78	3.48e-96	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs209489	0.892	rs16883624	chr6:53112290	C/G	cg15607103	chr6:53167650	ELOVL5	0.58	7.16	0.32	3.23e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg04568710	chr12:38710424	ALG10B	-0.35	-7.55	-0.33	2.36e-13	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg07511668	chr11:68622177	NA	0.5	9.28	0.4	6.57e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg08677398	chr8:58056175	NA	0.54	8.22	0.36	2.01e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.47	-0.71	1.71e-71	Height;
LGG	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.05e-11	Aortic root size;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.79	-0.34	4.45e-14	Total body bone mineral density;
LGG	cis	rs12824058	0.831	rs4759658	chr12:130815872	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.04	0.52	2.62e-33	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12780845	0.540	rs10795451	chr10:17179195	T/C	cg01003015	chr10:17271136	VIM	-0.44	-7.51	-0.33	2.99e-13	Homocysteine levels;
LGG	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.2	-0.52	5.35e-34	Vitamin D levels;
LGG	trans	rs656319	0.513	rs34990153	chr8:9996389	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.55	0.33	2.37e-13	Myopia (pathological);
LGG	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.78	13.44	0.53	5.43e-35	Hip circumference adjusted for BMI;
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.05e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2180341	1.000	rs2326567	chr6:127606160	G/A	cg27446573	chr6:127587934	RNF146	1.12	22.1	0.72	2.09e-74	Breast cancer;
LGG	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg24450063	chr1:156163899	SLC25A44	1.25	31.98	0.83	2.58e-119	Testicular germ cell tumor;
LGG	trans	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg01620082	chr3:125678407	NA	-0.62	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs80282103	0.764	rs12244052	chr10:1103266	G/A	cg08668510	chr10:1095578	IDI1	0.75	7.54	0.33	2.44e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs216026	0.515	rs12813847	chr12:2736551	C/T	cg19945202	chr12:2788847	CACNA1C	0.69	7.81	0.34	3.9e-14	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.72	0.51	5.32e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18011946	chr5:65440816	SFRS12	0.47	7.07	0.31	5.63e-12	Gut microbiome composition (summer);
LGG	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg11812906	chr14:75593930	NEK9	-0.45	-8.28	-0.36	1.29e-15	Height;
LGG	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg23950597	chr19:37808831	NA	0.55	8.13	0.35	3.94e-15	Coronary artery calcification;
LGG	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg07615347	chr10:60278583	BICC1	0.62	17.55	0.63	3.23e-53	Refractive error;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg20913747	chr6:44695427	NA	-0.61	-10.47	-0.44	3.5e-23	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.74	-0.45	3.48e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg02254774	chr11:50257496	LOC441601	0.57	6.75	0.3	4.37e-11	Myopia (pathological);
LGG	cis	rs8141529	0.843	rs1065497	chr22:29279991	C/T	cg15103426	chr22:29168792	CCDC117	0.62	9.11	0.39	2.53e-18	Lymphocyte counts;
LGG	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg12193833	chr17:30244370	NA	-0.28	-7.07	-0.31	5.72e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8177179	0.967	rs4994581	chr3:133437563	T/C	cg16262614	chr3:133464971	TF	0.46	8.41	0.36	5.12e-16	Iron status biomarkers (transferrin levels);
LGG	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg26150922	chr2:100937072	LONRF2	-0.58	-10.89	-0.45	9.52e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg26513180	chr16:89883248	FANCA	0.88	8.56	0.37	1.66e-16	Skin colour saturation;
LGG	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg12386194	chr3:101231763	SENP7	0.45	7.85	0.34	2.96e-14	Colorectal cancer;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.82	-0.3	2.92e-11	Lung cancer;
LGG	cis	rs4740619	0.669	rs7872912	chr9:15761077	C/T	cg14451791	chr9:16040625	NA	0.35	8.9	0.38	1.3e-17	Body mass index;
LGG	cis	rs113835537	0.529	rs75683511	chr11:66275026	A/G	cg24851651	chr11:66362959	CCS	0.44	7.53	0.33	2.7e-13	Airway imaging phenotypes;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.76	-0.34	5.58e-14	Life satisfaction;
LGG	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.56	14.88	0.57	3.28e-41	Oropharynx cancer;
LGG	cis	rs7215564	0.730	rs7212125	chr17:78628863	C/T	cg16980736	chr17:78789706	RPTOR	0.6	8.41	0.36	5.22e-16	Myopia (pathological);
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg19168338	chr16:4465731	CORO7	-0.73	-13.17	-0.52	6.93e-34	Schizophrenia;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14893161	chr1:205819251	PM20D1	-0.73	-16.49	-0.61	2.26e-48	Monocyte percentage of white cells;
LGG	cis	rs10781543	0.748	rs68002978	chr9:139325641	C/T	cg14019695	chr9:139328340	INPP5E	0.45	7.93	0.35	1.61e-14	Monocyte percentage of white cells;
LGG	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg10778915	chr4:100576610	NA	0.36	7.13	0.31	3.88e-12	Metabolite levels (MHPG);
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg04234412	chr22:24373322	LOC391322	-0.73	-14.87	-0.57	3.79e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7619833	0.542	rs56073144	chr3:27538650	G/A	cg02860705	chr3:27208620	NA	0.39	7.75	0.34	5.73e-14	Breast cancer;
LGG	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.83	-0.42	7.87e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.688	rs12952285	chr17:78596158	C/G	cg06872548	chr17:78716983	RPTOR	-0.39	-8.56	-0.37	1.65e-16	Obesity;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17872999	chr7:104653783	MLL5;LOC100216545	0.39	6.8	0.3	3.3e-11	Bipolar disorder;
LGG	cis	rs908922	0.676	rs945788	chr1:152512762	A/G	cg20991723	chr1:152506922	NA	-0.68	-13.78	-0.54	1.88e-36	Hair morphology;
LGG	cis	rs4363385	0.720	rs883810	chr1:152941345	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-8.62	-0.37	1.08e-16	Inflammatory skin disease;
LGG	trans	rs2624839	0.704	rs12637671	chr3:50224562	G/A	cg21659725	chr3:3221576	CRBN	-0.5	-7.81	-0.34	3.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12464559	0.522	rs11676866	chr2:152628858	G/C	cg01189475	chr2:152685088	ARL5A	0.67	7.11	0.31	4.48e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.87	-0.45	1.15e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg05861140	chr6:150128134	PCMT1	-0.45	-10.42	-0.44	5.48e-23	Lung cancer;
LGG	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs7119	0.717	rs11630916	chr15:77821331	G/A	cg10437265	chr15:77819839	NA	0.25	6.95	0.31	1.23e-11	Type 2 diabetes;
LGG	cis	rs6988985	0.703	rs7016088	chr8:143950026	G/A	cg10324643	chr8:143916377	GML	0.39	7.69	0.34	8.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9921222	0.786	rs3848365	chr16:374617	C/T	cg07915516	chr16:377344	AXIN1	0.32	9.36	0.4	3.47e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7106204	0.609	rs35037636	chr11:24299533	C/G	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7607369	0.714	rs1344643	chr2:219584975	G/C	cg01130898	chr2:219473002	PLCD4	0.43	7.41	0.33	5.9e-13	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.94	-14.63	-0.56	4.14e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.08	-0.42	9.9700000000000009e-22	Lung cancer;
LGG	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.84	-0.3	2.5e-11	Schizophrenia;
LGG	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg27446573	chr6:127587934	RNF146	1.14	22.61	0.72	8.25e-77	Breast cancer;
LGG	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg15038512	chr6:170123185	PHF10	-0.55	-7.28	-0.32	1.43e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg02030672	chr11:45687055	CHST1	0.56	9.97	0.42	2.5e-21	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.18	-0.6	5.64e-47	Platelet count;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg11050988	chr7:1952600	MAD1L1	-0.38	-9.06	-0.39	3.7e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.16	-0.32	3.2e-12	Lung cancer;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.679	rs7955725	chr12:39322903	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.88	0.38	1.53e-17	Morning vs. evening chronotype;
LGG	cis	rs1620921	0.505	rs9458032	chr6:161210205	G/T	cg01280913	chr6:161186852	NA	-0.49	-10.04	-0.42	1.36e-21	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4481887	0.893	rs6587450	chr1:248480496	T/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.48	-0.61	2.41e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg07061783	chr6:25882402	NA	-0.42	-7.22	-0.32	2.15e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg17376030	chr22:41985996	PMM1	-0.58	-9.53	-0.41	8.75e-20	Vitiligo;
LGG	cis	rs7100689	0.646	rs6585967	chr10:82139791	A/G	cg01528321	chr10:82214614	TSPAN14	-0.89	-15.74	-0.59	4.98e-45	Post bronchodilator FEV1;
LGG	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg09307838	chr4:120376055	NA	-0.73	-12.22	-0.49	6.06e-30	Corneal astigmatism;
LGG	cis	rs514406	0.505	rs269290	chr1:53167027	A/T	cg16325326	chr1:53192061	ZYG11B	0.84	23.23	0.73	1.05e-79	Monocyte count;
LGG	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg11161011	chr14:65562177	MAX	-0.71	-13.52	-0.53	2.33e-35	Obesity-related traits;
LGG	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.17	0.6	5.99e-47	Hip circumference adjusted for BMI;
LGG	trans	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg26384229	chr12:38710491	ALG10B	0.96	21.05	0.7	1.68e-69	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs6874745	chr5:264527	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg10523679	chr1:76189770	ACADM	0.81	15.02	0.57	7.69e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs13202913	0.639	rs9397407	chr6:151748995	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	6.78	0.3	3.61e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.73	0.38	4.55e-17	Obesity-related traits;
LGG	trans	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.75	-13.57	-0.53	1.51e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.75e-26	Bipolar disorder;
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg01262667	chr19:19385393	TM6SF2	0.45	11.63	0.48	1.32e-27	Tonsillectomy;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00149659	chr3:10157352	C3orf10	0.84	10.83	0.45	1.61e-24	Alzheimer's disease;
LGG	cis	rs75059851	0.756	rs11223661	chr11:133851412	G/T	cg17703048	chr11:133852993	NA	-0.87	-15.46	-0.58	9.02e-44	Schizophrenia;
LGG	cis	rs2066819	0.892	rs77415512	chr12:56627300	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg04568710	chr12:38710424	ALG10B	0.34	6.87	0.3	2.08e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg09307838	chr4:120376055	NA	0.79	13.46	0.53	4.51e-35	Corneal astigmatism;
LGG	cis	rs4799461	0.821	rs55731231	chr18:35183274	C/G	cg27332583	chr18:35150602	NA	0.59	11.83	0.48	2.14e-28	Neuroticism;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	7.03	0.31	7.54e-12	Resting heart rate;
LGG	cis	rs35740288	0.617	rs17633749	chr15:86140791	G/A	cg04173714	chr15:86211321	AKAP13	0.46	8.94	0.38	9.4e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.24	0.32	1.92e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9894429	0.789	rs9747336	chr17:79584189	C/T	cg18240062	chr17:79603768	NPLOC4	0.82	15.45	0.58	1.02e-43	Eye color traits;
LGG	cis	rs4764487	0.735	rs2072372	chr12:6344600	C/A	cg08284733	chr12:6341482	CD9	0.38	10.09	0.42	8.79e-22	Mean platelet volume;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg06719900	chr11:109292894	C11orf87	0.44	8.61	0.37	1.15e-16	Schizophrenia;
LGG	cis	rs8016982	0.662	rs1864169	chr14:81670033	G/T	cg01989461	chr14:81687754	GTF2A1	0.57	8.92	0.38	1.06e-17	Schizophrenia;
LGG	cis	rs10849893	0.576	rs7134248	chr12:121897052	T/C	cg01154721	chr12:121881891	KDM2B	-0.4	-6.92	-0.31	1.54e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.36	0.53	1.16e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21963583	chr11:68658836	MRPL21	0.6	10.37	0.43	8.34e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg06138931	chr13:21896616	NA	0.39	7.89	0.34	2.2e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg24642439	chr20:33292090	TP53INP2	0.77	8.14	0.35	3.72e-15	Hip circumference adjusted for BMI;
LGG	cis	rs10940138	0.501	rs3953388	chr5:67248570	C/G	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.08	-0.35	5.54e-15	Menarche (age at onset);
LGG	cis	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg24375607	chr4:120327624	NA	0.61	10.16	0.43	4.94e-22	Corneal astigmatism;
LGG	cis	rs3824867	0.959	rs4237544	chr11:47454271	G/T	cg20307385	chr11:47447363	PSMC3	-0.49	-7.81	-0.34	3.98e-14	Mean corpuscular hemoglobin;
LGG	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.98	0.64	3.18e-55	Cognitive function;
LGG	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12667521	chr19:29218732	NA	0.62	9.48	0.4	1.36e-19	Methadone dose in opioid dependence;
LGG	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.29	-0.43	1.71e-22	Colorectal cancer;
LGG	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.7	0.41	2.31e-20	Diabetic retinopathy;
LGG	cis	rs2361718	0.527	rs11150847	chr17:78153130	G/A	cg09238746	chr17:78121135	EIF4A3	-0.42	-7.37	-0.32	8.03e-13	Yeast infection;
LGG	trans	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.11	0.62	3.22e-51	Exhaled nitric oxide levels;
LGG	cis	rs2070488	0.775	rs2268762	chr3:38516075	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.78	0.57	8.79e-41	Electrocardiographic conduction measures;
LGG	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-8.45	-0.37	3.77e-16	Blood protein levels;
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg03517284	chr6:25882590	NA	0.52	9.69	0.41	2.53e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.59	11.3	0.47	2.48e-26	Obesity-related traits;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.13	0.43	6.47e-22	Longevity;
LGG	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.46e-18	Corneal astigmatism;
LGG	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg00631329	chr6:26305371	NA	-0.47	-7.79	-0.34	4.46e-14	Mosquito bite size;
LGG	cis	rs3087591	0.879	rs4795591	chr17:29612410	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.52	-0.56	1.25e-39	Hip circumference;
LGG	cis	rs6732160	0.588	rs2043101	chr2:73374050	A/G	cg01422370	chr2:73384389	NA	0.57	9.94	0.42	3.05e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6963495	0.585	rs1728653	chr7:105191335	A/G	cg19920283	chr7:105172520	RINT1	0.48	6.92	0.31	1.55e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg04617936	chr2:214353	NA	-0.38	-7.22	-0.32	2.19e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.96	0.35	1.35e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2131877	0.645	rs903310	chr3:194875944	C/T	cg07250128	chr3:194833983	C3orf21	0.32	6.95	0.31	1.24e-11	Non-small cell lung cancer;
LGG	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg08528231	chr16:12997261	SHISA9	-0.34	-6.84	-0.3	2.56e-11	Positive affect;Subjective well-being;
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	trans	rs6787172	0.592	rs6414389	chr3:158108138	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs1497828	0.956	rs2646828	chr1:217542361	C/T	cg04411442	chr1:217543379	NA	0.48	8.18	0.36	2.68e-15	Dialysis-related mortality;
LGG	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg04287289	chr16:89883240	FANCA	-0.47	-8.31	-0.36	1.07e-15	Vitiligo;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.33	-6.78	-0.3	3.78e-11	Schizophrenia;
LGG	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg15627072	chr1:2432621	PLCH2	-0.37	-7.92	-0.35	1.83e-14	Ulcerative colitis;
LGG	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-10.55	-0.44	1.91e-23	Bipolar disorder;
LGG	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.41e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs8064029	0.655	rs77468976	chr16:4869250	G/A	cg04440724	chr16:4920505	UBN1	-0.64	-7.42	-0.33	5.71e-13	Cancer;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.58	11.27	0.46	3.26e-26	Obesity-related traits;
LGG	cis	rs7267979	0.789	rs4815429	chr20:25521611	T/C	cg06421707	chr20:25228305	PYGB	-0.42	-8.73	-0.38	4.54e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1062746	0.520	rs17770996	chr16:87330207	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-7.71	-0.34	7.9e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg02048412	chr16:4421654	VASN;CORO7	0.29	7.0	0.31	9.18e-12	Schizophrenia;
LGG	cis	rs528418	0.592	rs1832379	chr6:145674933	G/A	cg03642472	chr6:145670687	NA	0.55	7.07	0.31	5.74e-12	Methadone dose in opioid dependence;
LGG	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.99	0.31	9.73e-12	Parkinson's disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03284175	chr1:146643471	PRKAB2	0.39	6.68	0.3	7.01e-11	Body mass index;
LGG	cis	rs2415984	0.562	rs1494092	chr14:46970304	T/C	cg14871534	chr14:47121158	RPL10L	0.46	7.46	0.33	4.45e-13	Number of children ever born;
LGG	cis	rs17453880	0.926	rs6885111	chr5:152027557	T/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs988958	0.675	rs34863191	chr2:42217615	G/A	cg27428208	chr2:42229179	NA	0.54	9.27	0.4	7.11e-19	Hypospadias;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15646359	chr4:69048430	LOC100130017	0.41	7.77	0.34	5.01e-14	Menarche (age at onset);
LGG	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-11.71	-0.48	6.16e-28	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07659893	chr17:61819838	STRADA	0.47	7.67	0.34	1.04e-13	Prudent dietary pattern;
LGG	cis	rs2742417	0.603	rs2064063	chr3:45759924	T/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.42	-0.4	2.17e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs11885103	0.791	rs17042062	chr2:585129	C/T	cg21195176	chr2:593345	NA	0.39	7.41	0.33	6e-13	Heschl's gyrus morphology;
LGG	cis	rs7444	0.941	rs73166619	chr22:21930093	C/T	cg11654148	chr22:21984483	YDJC	-0.4	-7.8	-0.34	4.24e-14	Systemic lupus erythematosus;
LGG	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.68	8.95	0.38	8.81e-18	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg16284684	chr7:1164063	C7orf50	0.35	6.72	0.3	5.38e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.46	-0.37	3.42e-16	Lung cancer;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.53	0.33	2.61e-13	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs7444	0.941	rs738127	chr22:21968221	G/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.54	-0.33	2.53e-13	Systemic lupus erythematosus;
LGG	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07570687	chr10:102243282	WNT8B	0.43	7.35	0.32	9.21e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06012509	chr6:43027269	KLC4;MRPL2	0.52	8.41	0.36	5e-16	Cognitive performance;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.08e-11	Neuroticism;
LGG	trans	rs35110281	0.592	rs10211901	chr21:45122573	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.21	0.39	1.09e-18	Mean corpuscular volume;
LGG	cis	rs2046867	0.908	rs62251648	chr3:72806083	A/G	cg25664220	chr3:72788482	NA	-0.32	-8.81	-0.38	2.49e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9992101	0.645	rs17238882	chr4:77289800	G/A	cg17010112	chr4:77227123	STBD1	-0.46	-9.57	-0.41	6.29e-20	Creatinine levels;
LGG	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg03433033	chr1:76189801	ACADM	0.77	14.0	0.55	2.18e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	9.5	0.4	1.09e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8056893	0.885	rs4381598	chr16:68353664	G/A	cg07273125	chr16:68295692	NA	0.36	6.9	0.31	1.68e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.51	0.4	1.03e-19	Bipolar disorder;
LGG	cis	rs77633900	0.772	rs2944377	chr15:76699652	C/A	cg21673338	chr15:77095150	SCAPER	-0.63	-8.32	-0.36	9.76e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg24829409	chr8:58192753	C8orf71	-0.71	-9.37	-0.4	3.23e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs17030434	0.784	rs11099900	chr4:154669471	C/T	cg14289246	chr4:154710475	SFRP2	-0.59	-9.83	-0.42	7.46e-21	Electrocardiographic conduction measures;
LGG	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg01221209	chr5:554886	NA	0.51	7.58	0.33	1.95e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg18252515	chr7:66147081	NA	-1.38	-19.63	-0.67	7.29e-63	Diabetic kidney disease;
LGG	cis	rs6430585	0.527	rs62168830	chr2:136443900	A/T	cg07169764	chr2:136633963	MCM6	1.0	16.85	0.62	4.88e-50	Corneal structure;
LGG	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.95e-16	Primary sclerosing cholangitis;
LGG	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg03264133	chr6:25882463	NA	0.46	7.7	0.34	8.4e-14	Iron status biomarkers;
LGG	cis	rs1577917	0.958	rs2121594	chr6:86576854	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.79	-13.83	-0.54	1.15e-36	Response to antipsychotic treatment;
LGG	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg15212455	chr7:39170539	POU6F2	0.47	10.86	0.45	1.23e-24	IgG glycosylation;
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg14668632	chr7:2872130	GNA12	-0.36	-7.5	-0.33	3.36e-13	Height;
LGG	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs42648	0.748	rs10226014	chr7:89902533	C/T	cg25739043	chr7:89950458	NA	0.35	7.28	0.32	1.41e-12	Homocysteine levels;
LGG	cis	rs9788721	0.836	rs2009746	chr15:78754102	A/G	cg18825076	chr15:78729989	IREB2	-0.57	-9.38	-0.4	2.86e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-14.19	-0.55	3.3e-38	Schizophrenia;
LGG	cis	rs3816183	0.585	rs6544579	chr2:42856701	A/G	cg14631114	chr2:43023945	NA	0.33	6.65	0.3	8.18e-11	Hypospadias;
LGG	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.81	0.54	1.37e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3741151	1.000	rs79078097	chr11:73049771	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	9.83	0.42	8.06e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11711311	1.000	rs9828099	chr3:113518402	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.17	0.55	4.02e-38	IgG glycosylation;
LGG	cis	rs2172802	0.693	rs4860097	chr4:62482723	A/G	cg04118610	chr4:62707027	LPHN3	-0.51	-8.01	-0.35	9.2e-15	Partial epilepsies;
LGG	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg19468946	chr17:37922297	IKZF3	-0.38	-6.78	-0.3	3.64e-11	Self-reported allergy;
LGG	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.62	-0.33	1.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg02503808	chr4:7069936	GRPEL1	-0.98	-13.5	-0.53	3.02e-35	Monocyte percentage of white cells;
LGG	cis	rs8078723	1.000	rs59925331	chr17:38169273	C/G	cg17467752	chr17:38218738	THRA	0.74	13.92	0.54	4.81e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs62400317	0.859	rs4267941	chr6:45241302	A/C	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.76	-14.03	-0.55	1.56e-37	Longevity;Endometriosis;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg13397359	chr6:42928475	GNMT	0.58	16.31	0.6	1.39e-47	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4460629	0.521	rs4361977	chr1:155076079	C/T	cg13808842	chr1:155066096	NA	-0.32	-7.93	-0.35	1.71e-14	Serum magnesium levels;
LGG	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg04617936	chr2:214353	NA	-0.4	-7.31	-0.32	1.17e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg07777115	chr5:623756	CEP72	-0.51	-6.72	-0.3	5.48e-11	Obesity-related traits;
LGG	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg24375607	chr4:120327624	NA	0.62	10.06	0.42	1.13e-21	Corneal astigmatism;
LGG	cis	rs68170813	0.559	rs5002976	chr7:107050620	C/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.22	-0.43	3.14e-22	Coronary artery disease;
LGG	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-14.02	-0.55	1.81e-37	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg00800038	chr16:89945340	TCF25	-0.68	-8.04	-0.35	7.67e-15	Skin colour saturation;
LGG	cis	rs7267979	0.966	rs2263204	chr20:25377688	A/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg20637307	chr2:213403960	ERBB4	0.43	8.03	0.35	8.19e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs745821	0.701	rs11873632	chr18:48100407	C/T	cg18923635	chr18:48083994	NA	0.42	7.41	0.33	5.93e-13	Diastolic blood pressure;
LGG	cis	rs7814319	0.677	rs2319599	chr8:97305907	T/C	cg20787634	chr8:97240163	UQCRB	-0.62	-13.32	-0.53	1.7e-34	Lung function (FVC);
LGG	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	6.15e-38	Bladder cancer;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs7267979	0.565	rs13040726	chr20:25559881	T/G	cg06421707	chr20:25228305	PYGB	-0.36	-7.43	-0.33	5.37e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.15	-0.39	1.82e-18	Diabetic kidney disease;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg03188948	chr7:1209495	NA	0.45	8.22	0.36	2.11e-15	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27505538	chr15:81616786	STARD5	0.46	6.72	0.3	5.51e-11	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs4900538	0.855	rs12586378	chr14:102853150	T/C	cg18135206	chr14:102964638	TECPR2	-0.7	-12.72	-0.51	5.23e-32	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.31	-0.4	5.29e-19	Primary sclerosing cholangitis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22037798	chr1:231473786	C1orf124;EXOC8	0.39	6.88	0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs72949976	0.584	rs4673729	chr2:214023810	A/G	cg08319019	chr2:214017104	IKZF2	0.67	12.67	0.51	8.8e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg11062466	chr8:58055876	NA	0.58	9.08	0.39	3.2e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs2404602	0.669	rs17367297	chr15:77158026	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22336747	chr1:161087401	PFDN2;NIT1	0.47	6.89	0.3	1.84e-11	Gut microbiome composition (summer);
LGG	cis	rs7106204	0.748	rs7946633	chr11:24237411	C/T	ch.11.24196551F	chr11:24239977	NA	1.02	16.48	0.61	2.28e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	trans	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg21659725	chr3:3221576	CRBN	0.63	11.67	0.48	9.46e-28	Intelligence (multi-trait analysis);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06837242	chr1:19578761	MRTO4;KIAA0090	0.38	6.66	0.3	7.61e-11	Bilirubin levels;
LGG	cis	rs61931739	0.500	rs11053249	chr12:34518834	A/T	cg06521331	chr12:34319734	NA	-0.54	-9.33	-0.4	4.56e-19	Morning vs. evening chronotype;
LGG	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	trans	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg06521331	chr12:34319734	NA	0.43	7.76	0.34	5.38e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.24	-0.7	2.2e-70	Heart rate;
LGG	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.87	-0.51	1.24e-32	Response to antipsychotic treatment;
LGG	cis	rs7818345	0.512	rs4922028	chr8:19303771	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.41	-8.95	-0.38	8.69e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.17e-21	Diabetic kidney disease;
LGG	cis	rs4561483	0.603	rs17235629	chr16:11932421	C/T	cg08843971	chr16:11963173	GSPT1	-0.54	-13.02	-0.52	3.12e-33	Testicular germ cell tumor;
LGG	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg14952266	chr13:112191215	NA	0.52	10.96	0.45	5.21e-25	Hepatitis;
LGG	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg24838063	chr12:130822603	PIWIL1	-0.7	-13.01	-0.52	3.47e-33	Menopause (age at onset);
LGG	cis	rs2013441	0.508	rs4341795	chr17:19977228	C/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs283228	0.550	rs662360	chr6:101829555	T/C	cg27451362	chr6:101846650	GRIK2	0.98	14.58	0.56	7.1e-40	Coenzyme Q10 levels;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00149659	chr3:10157352	C3orf10	0.9	11.43	0.47	7.92e-27	Alzheimer's disease;
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg13009111	chr11:71350975	NA	0.36	8.41	0.36	5.25e-16	Monocyte count;
LGG	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.09	0.35	5.21e-15	Retinal vascular caliber;
LGG	cis	rs79349575	0.783	rs28409394	chr17:46998118	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg27532318	chr7:32358331	NA	0.74	7.49	0.33	3.45e-13	Body mass index;
LGG	cis	rs6908034	0.607	rs78402429	chr6:19811690	C/A	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg23985595	chr17:80112537	CCDC57	0.48	9.7	0.41	2.26e-20	Life satisfaction;
LGG	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg16850897	chr7:100343110	ZAN	-0.7	-10.34	-0.43	1.13e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62244186	0.659	rs9819766	chr3:44520980	G/C	cg02073558	chr3:44770973	ZNF501	0.67	12.48	0.5	5.15e-31	Depressive symptoms;
LGG	cis	rs9916302	0.904	rs57399933	chr17:37551189	A/G	cg00129232	chr17:37814104	STARD3	0.6	11.29	0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg18187862	chr3:45730750	SACM1L	-0.58	-9.51	-0.4	1.06e-19	Primary sclerosing cholangitis;
LGG	cis	rs2865126	0.743	rs10502403	chr18:10749140	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-7.48	-0.33	3.64e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs12580194	0.593	rs3935215	chr12:55792401	T/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.32	-0.43	1.3e-22	Cancer;
LGG	cis	rs7582720	0.945	rs72932759	chr2:203674288	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.48	0.4	1.31e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg08250081	chr4:10125330	NA	-0.38	-7.46	-0.33	4.2e-13	Bone mineral density;
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.51	-0.71	1.12e-71	Heart rate;
LGG	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg25706281	chr1:46860511	FAAH	-0.28	-6.8	-0.3	3.26e-11	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg21605333	chr4:119757512	SEC24D	1.47	14.51	0.56	1.43e-39	Cannabis dependence symptom count;
LGG	cis	rs4262150	0.883	rs72799148	chr5:152107108	A/G	cg12297329	chr5:152029980	NA	-0.7	-12.89	-0.51	1.08e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.43	-0.33	5.31e-13	Height;
LGG	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg04117972	chr1:227635322	NA	-0.56	-9.24	-0.39	8.86e-19	Major depressive disorder;
LGG	trans	rs1814175	0.616	rs10769644	chr11:49987676	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.95	-11.63	-0.48	1.35e-27	Lung cancer in ever smokers;
LGG	cis	rs988958	0.565	rs6756395	chr2:42236128	G/C	cg19376973	chr2:42229025	NA	0.63	9.32	0.4	4.95e-19	Hypospadias;
LGG	cis	rs12724450	0.793	rs35347210	chr1:150319977	C/T	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	trans	rs7944735	0.508	rs2869531	chr11:47797402	G/C	cg15704280	chr7:45808275	SEPT13	0.64	6.85	0.3	2.36e-11	Intraocular pressure;
LGG	cis	rs921968	0.643	rs4674320	chr2:219510768	A/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.2	-0.32	2.42e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg03929089	chr4:120376271	NA	-0.9	-17.92	-0.64	6.53e-55	Coronary artery disease;
LGG	cis	rs4771450	0.924	rs4772541	chr13:103971137	A/G	cg02987523	chr13:103978230	NA	-0.32	-6.89	-0.3	1.86e-11	Uric acid levels;
LGG	cis	rs7917772	0.503	rs7078435	chr10:104304766	T/C	cg05096777	chr10:104283225	SUFU	0.32	7.05	0.31	6.51e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3617	0.573	rs12638968	chr3:52919447	T/A	cg11645453	chr3:52864694	ITIH4	-0.45	-7.59	-0.33	1.84e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs968451	1.000	rs57078777	chr22:39697458	A/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	11.14	0.46	1.09e-25	Primary biliary cholangitis;
LGG	trans	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.29	-0.32	1.37e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs921968	0.643	rs3931102	chr2:219520405	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.95	-0.31	1.24e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg21775007	chr8:11205619	TDH	0.46	6.9	0.31	1.68e-11	Triglycerides;
LGG	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.42	-0.33	5.75e-13	Obesity;
LGG	cis	rs4664304	0.658	rs2667015	chr2:160868586	T/C	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.91	-0.34	1.92e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg18709589	chr6:96969512	KIAA0776	-0.47	-7.15	-0.32	3.41e-12	Migraine;Coronary artery disease;
LGG	cis	rs10779751	1.000	rs2076655	chr1:11289161	A/G	cg08854313	chr1:11322531	MTOR	-0.76	-17.45	-0.63	8.73e-53	Body mass index;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg11977488	chr1:1858286	NA	0.34	7.01	0.31	8.73e-12	Body mass index;
LGG	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg17201900	chr20:34330562	RBM39	0.52	7.03	0.31	7.34e-12	Total cholesterol levels;
LGG	cis	rs367943	0.698	rs6594746	chr5:112995895	A/C	cg12552261	chr5:112820674	MCC	-0.54	-9.61	-0.41	4.72e-20	Type 2 diabetes;
LGG	cis	rs9517302	0.615	rs4772081	chr13:99100262	T/C	cg24044564	chr13:99115944	STK24	0.49	6.75	0.3	4.32e-11	Obesity-related traits;
LGG	cis	rs2692947	0.702	rs2312955	chr2:96777168	T/G	cg22654517	chr2:96458247	NA	-0.38	-7.73	-0.34	6.57e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2421770	0.532	rs2901605	chr11:35340431	A/T	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.6	-0.33	1.7e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs7524258	0.868	rs4908448	chr1:7269283	A/G	cg07173049	chr1:7289937	CAMTA1	-0.62	-14.78	-0.57	8.95e-41	Tourette's syndrome or obsessive-compulsive disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18679886	chr7:107531975	DLD	0.62	9.82	0.42	8.23e-21	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg04287289	chr16:89883240	FANCA	0.84	7.81	0.34	3.81e-14	Skin colour saturation;
LGG	cis	rs2519796	0.509	rs635277	chr9:136822180	C/G	cg13751417	chr9:136814406	VAV2	-0.46	-8.3	-0.36	1.13e-15	Hematocrit;Hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10016350	chr1:100817860	CDC14A	0.47	7.07	0.31	5.66e-12	Gut microbiome composition (summer);
LGG	cis	rs7932354	0.528	rs1060573	chr11:47179829	A/G	cg03339077	chr11:47165057	C11orf49	-0.55	-10.48	-0.44	3.24e-23	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs947612	0.576	rs9342991	chr6:73683775	G/A	cg13494037	chr12:24737079	C12orf67	0.37	7.47	0.33	4.07e-13	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.99	-0.35	1.09e-14	Skin colour saturation;
LGG	cis	rs875971	0.862	rs7796162	chr7:65745758	T/C	cg18252515	chr7:66147081	NA	0.44	7.47	0.33	3.97e-13	Aortic root size;
LGG	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg20573242	chr4:122745356	CCNA2	0.49	9.06	0.39	3.76e-18	Type 2 diabetes;
LGG	cis	rs6909430	0.901	rs2505066	chr6:98597788	C/T	cg12860156	chr6:98744658	NA	-0.45	-7.54	-0.33	2.47e-13	Quantitative traits;
LGG	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg19847130	chr8:10466454	RP1L1	0.38	7.93	0.35	1.64e-14	Neuroticism;
LGG	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg11247378	chr22:39784982	NA	0.28	8.34	0.36	8.65e-16	IgG glycosylation;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.04	-0.49	3.19e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg11189052	chr15:85197271	WDR73	-0.56	-9.1	-0.39	2.71e-18	P wave terminal force;
LGG	cis	rs911263	0.603	rs2013413	chr14:68805451	C/G	cg18825221	chr14:68749962	RAD51L1	0.36	8.0	0.35	1.01e-14	Primary biliary cholangitis;
LGG	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg00431813	chr7:1051703	C7orf50	-0.38	-8.3	-0.36	1.16e-15	Longevity;Endometriosis;
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg02725872	chr8:58115012	NA	-0.84	-11.53	-0.47	3.33e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.08	0.49	2.15e-29	Lung cancer in ever smokers;
LGG	trans	rs7395662	0.700	rs11493668	chr11:48727582	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	trans	rs1728785	0.892	rs1617749	chr16:68580890	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	11.06	0.46	2.24e-25	Ulcerative colitis;
LGG	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg21972741	chr5:435613	AHRR	0.5	9.01	0.39	5.55e-18	Cystic fibrosis severity;
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg04727924	chr7:799746	HEATR2	-0.49	-7.17	-0.32	2.94e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs74781061	0.929	rs79600239	chr15:74774328	A/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.86	-0.3	2.18e-11	Endometriosis;
LGG	cis	rs6754311	0.597	rs2278544	chr2:136546110	A/G	cg07169764	chr2:136633963	MCM6	-0.85	-15.29	-0.58	5.27e-43	Mosquito bite size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13619528	chr22:24667492	CYTSA	0.43	7.14	0.31	3.54e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.12	0.35	4.17e-15	Myopia (pathological);
LGG	cis	rs1707322	1.000	rs11211237	chr1:46447329	G/C	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg01043669	chr3:72786069	NA	0.43	7.18	0.32	2.73e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.25e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7103648	1.000	rs10838709	chr11:47447346	C/T	cg20307385	chr11:47447363	PSMC3	0.98	24.33	0.75	7.74e-85	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg19635926	chr16:89946313	TCF25	0.72	7.09	0.31	5.12e-12	Skin colour saturation;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg19635926	chr16:89946313	TCF25	0.79	8.1	0.35	5.04e-15	Skin colour saturation;
LGG	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg11764359	chr7:65958608	NA	-0.55	-9.41	-0.4	2.25e-19	Aortic root size;
LGG	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg06481639	chr22:41940642	POLR3H	0.55	7.77	0.34	5.24e-14	Vitiligo;
LGG	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.25	0.32	1.8e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.71	-0.38	5.57e-17	Menopause (age at onset);
LGG	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-19.86	-0.68	6.27e-64	Body mass index;
LGG	cis	rs1550582	1.000	rs76091740	chr8:135514419	C/T	cg17885191	chr8:135476712	NA	0.67	10.48	0.44	3.23e-23	Educational attainment;
LGG	cis	rs72925845	0.577	rs691331	chr17:76429262	C/T	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs13314892	0.764	rs62251040	chr3:69869384	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.46	0.58	9.27e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs3540	0.513	rs2589974	chr15:90891566	C/T	cg22089800	chr15:90895588	ZNF774	-0.74	-13.88	-0.54	7.1e-37	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg04842962	chr6:43655489	MRPS18A	0.8	14.95	0.57	1.7e-41	IgG glycosylation;
LGG	cis	rs9487051	0.714	rs9487058	chr6:109631060	A/C	cg21918786	chr6:109611834	NA	-0.49	-9.11	-0.39	2.48e-18	Reticulocyte fraction of red cells;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg04503457	chr17:41445688	NA	-0.39	-9.02	-0.39	5.1e-18	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.92e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11718455	0.960	rs35666538	chr3:44004826	A/G	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.61e-11	Coronary artery disease;
LGG	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-12.16	-0.49	1.03e-29	Morning vs. evening chronotype;
LGG	trans	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07923666	chr12:49932857	KCNH3	-0.5	-7.67	-0.34	1.01e-13	Resting heart rate;
LGG	cis	rs2718058	0.630	rs2718051	chr7:37824790	G/A	cg15028436	chr7:37888078	TXNDC3	0.52	8.25	0.36	1.66e-15	Alzheimer's disease (late onset);
LGG	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg03517284	chr6:25882590	NA	-0.44	-7.19	-0.32	2.6e-12	Iron status biomarkers;
LGG	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg25486957	chr4:152246857	NA	-0.5	-8.3	-0.36	1.15e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4727027	0.680	rs6464941	chr7:148826352	A/G	cg23583168	chr7:148888333	NA	-0.7	-11.23	-0.46	4.6e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs701145	0.585	rs357473	chr3:153895147	C/T	cg12800244	chr3:153838788	SGEF	0.8	8.33	0.36	9.08e-16	Coronary artery disease;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg00761968	chr13:53314142	LECT1	-0.4	-8.33	-0.36	9.21e-16	Lewy body disease;
LGG	cis	rs1355223	0.902	rs12802323	chr11:34747739	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.09	-0.31	4.92e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6500602	0.584	rs11646063	chr16:4439209	A/G	cg05091796	chr16:4465799	CORO7	0.63	10.28	0.43	1.79e-22	Schizophrenia;
LGG	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.51	0.33	3.1e-13	Myopia (pathological);
LGG	cis	rs17030434	0.954	rs17030570	chr4:154755186	A/G	cg14289246	chr4:154710475	SFRP2	0.72	11.23	0.46	4.82e-26	Electrocardiographic conduction measures;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg16339924	chr4:17578868	LAP3	0.61	10.55	0.44	1.78e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.5	-8.0	-0.35	1.02e-14	Longevity;Endometriosis;
LGG	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg11789530	chr4:8429930	ACOX3	-0.65	-10.6	-0.44	1.16e-23	Response to antineoplastic agents;
LGG	cis	rs4683346	0.623	rs517650	chr3:43050414	G/A	cg05453631	chr3:43117548	NA	0.38	7.65	0.34	1.14e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg06475006	chr16:89985975	MC1R	-0.59	-6.95	-0.31	1.23e-11	Skin colour saturation;
LGG	cis	rs9318086	0.712	rs9318100	chr13:24442482	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.49	-9.42	-0.4	2.14e-19	Myopia (pathological);
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08645402	chr16:4508243	NA	0.5	9.63	0.41	3.9e-20	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	0.503	rs11719968	chr3:40241600	G/T	cg13683864	chr3:40499215	RPL14	-0.78	-14.63	-0.56	4.26e-40	Renal cell carcinoma;
LGG	cis	rs11098499	0.754	rs2036857	chr4:120249240	T/C	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs172166	0.694	rs203884	chr6:28077374	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.1	-0.31	4.74e-12	Cardiac Troponin-T levels;
LGG	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg15664640	chr17:80829946	TBCD	-0.49	-9.54	-0.41	8.41e-20	Breast cancer;
LGG	cis	rs736801	0.808	rs72797306	chr5:131800750	G/C	cg21138405	chr5:131827807	IRF1	-0.28	-6.78	-0.3	3.64e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.72	-0.38	5.19e-17	Lung cancer;
LGG	cis	rs3735485	0.738	rs80197482	chr7:45093468	T/C	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg25427524	chr10:38739819	LOC399744	0.66	13.47	0.53	3.8e-35	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg08344181	chr3:125677491	NA	-0.65	-7.4	-0.33	6.49e-13	Depression;
LGG	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg22232500	chr2:134024266	NCKAP5	0.67	9.26	0.4	7.82e-19	Bipolar disorder;
LGG	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg24955955	chr5:415729	AHRR	0.81	10.87	0.45	1.2e-24	Fat distribution (HIV);
LGG	cis	rs7100689	0.784	rs11202699	chr10:82131453	A/G	cg01528321	chr10:82214614	TSPAN14	0.93	16.52	0.61	1.61e-48	Post bronchodilator FEV1;
LGG	cis	rs9287719	0.967	rs4555318	chr2:10744295	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	4.16e-13	Prostate cancer;
LGG	cis	rs897984	0.645	rs58726213	chr16:31044683	A/G	cg00531865	chr16:30841666	NA	-0.51	-10.45	-0.44	4.35e-23	Dementia with Lewy bodies;
LGG	cis	rs2640806	0.525	rs34646355	chr8:97346990	T/A	cg22138393	chr8:97340270	PTDSS1	-0.28	-7.23	-0.32	2.06e-12	Obesity-related traits;
LGG	cis	rs7940866	0.834	rs10791108	chr11:130849354	T/A	cg12179176	chr11:130786555	SNX19	0.71	13.24	0.52	3.65e-34	Schizophrenia;
LGG	cis	rs9486719	1.000	rs11756315	chr6:97008678	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.67	0.44	6.33e-24	Migraine;Coronary artery disease;
LGG	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg12856521	chr11:46389249	DGKZ	0.44	7.63	0.33	1.39e-13	Leprosy;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg26338869	chr17:61819248	STRADA	0.59	9.96	0.42	2.6e-21	Prudent dietary pattern;
LGG	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg09165964	chr15:75287851	SCAMP5	0.51	9.31	0.4	5.14e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7084402	0.934	rs1649067	chr10:60305240	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg20891558	chr2:74357851	NA	0.49	9.56	0.41	6.82e-20	Gestational age at birth (maternal effect);
LGG	trans	rs2840044	1.000	rs9913003	chr17:33893904	C/A	cg19694781	chr19:47549865	TMEM160	0.52	8.62	0.37	1.06e-16	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.38	-0.36	6.34e-16	Diabetic kidney disease;
LGG	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs7949566	0.652	rs4937128	chr11:126292596	C/T	cg05055844	chr11:126275997	ST3GAL4	-0.34	-6.89	-0.31	1.81e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-11.95	-0.49	7.11e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2108225	0.714	rs929394	chr7:107437252	C/T	cg18560240	chr7:107437656	SLC26A3	-0.62	-10.86	-0.45	1.26e-24	Ulcerative colitis;
LGG	cis	rs2013441	1.000	rs2263175	chr17:20128029	C/G	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6.11e-11	Obesity-related traits;
LGG	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg19442545	chr10:75533431	FUT11	-0.43	-7.0	-0.31	8.89e-12	Inflammatory bowel disease;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg18402987	chr7:1209562	NA	0.65	9.01	0.39	5.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs66887589	0.870	rs2389875	chr4:120557014	G/T	cg09307838	chr4:120376055	NA	-0.43	-7.4	-0.33	6.54e-13	Diastolic blood pressure;
LGG	cis	rs6743226	0.548	rs886811	chr2:242397292	G/A	cg10021735	chr2:242295487	FARP2	0.39	7.01	0.31	8.26e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs8114671	0.562	rs959829	chr20:33346047	T/C	cg07148914	chr20:33460835	GGT7	-0.56	-9.3	-0.4	5.7e-19	Height;
LGG	cis	rs7808935	0.628	rs62451116	chr7:27938980	A/G	cg22168087	chr7:27702803	HIBADH	0.71	9.9	0.42	4.21e-21	Prostate cancer;
LGG	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg07636037	chr3:49044803	WDR6	-0.95	-20.65	-0.69	1.2e-67	Menarche (age at onset);
LGG	cis	rs11627756	0.915	rs12100848	chr14:103127449	T/C	cg12046867	chr14:103022105	NA	0.42	7.95	0.35	1.42e-14	Mean platelet volume;
LGG	cis	rs2120243	0.539	rs988588	chr3:157054016	C/G	cg24825693	chr3:157122686	VEPH1	-0.51	-11.26	-0.46	3.8e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	trans	rs78049276	0.562	rs55965782	chr4:148378442	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.87	-0.34	2.55e-14	Pulse pressure;
LGG	cis	rs6450176	0.951	rs255757	chr5:53309371	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.57	-0.47	2.31e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00262415	chr1:1242732	PUSL1;ACAP3	0.44	6.95	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	cis	rs17433780	0.504	rs4142706	chr1:89475230	A/C	cg09516651	chr1:89888402	LOC400759	0.53	11.15	0.46	9.55e-26	Carotid intima media thickness;
LGG	cis	rs6430585	0.583	rs12475516	chr2:136560761	C/G	cg07169764	chr2:136633963	MCM6	1.14	21.9	0.71	1.7e-73	Corneal structure;
LGG	cis	rs28595532	0.920	rs114575045	chr4:119739794	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.36	0.69	2.86e-66	Alzheimer's disease;
LGG	cis	rs9487051	0.676	rs13211313	chr6:109562074	G/C	cg21918786	chr6:109611834	NA	-0.37	-6.81	-0.3	3e-11	Reticulocyte fraction of red cells;
LGG	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg05194412	chr2:137003533	NA	0.37	8.07	0.35	6.29e-15	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg11494091	chr17:61959527	GH2	1.01	25.12	0.76	1.69e-88	Prudent dietary pattern;
LGG	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-12.01	-0.49	4.1e-29	Chronic sinus infection;
LGG	cis	rs34467563	0.872	rs35984709	chr8:97364103	C/T	cg22138393	chr8:97340270	PTDSS1	0.3	6.65	0.3	8.24e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.55e-23	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.71	0.3	5.55e-11	Renal cell carcinoma;
LGG	cis	rs72792276	1.000	rs13357283	chr5:127423114	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.12	0.31	4.25e-12	Red cell distribution width;
LGG	cis	rs1707322	0.752	rs7541962	chr1:46235117	G/A	cg03146154	chr1:46216737	IPP	0.57	10.26	0.43	2.08e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg24558204	chr6:135376177	HBS1L	0.52	8.92	0.38	1.13e-17	Red blood cell count;
LGG	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Vitiligo;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg02951883	chr7:2050386	MAD1L1	0.71	14.36	0.56	5.83e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs7584330	0.868	rs7569197	chr2:238383073	A/G	cg16989719	chr2:238392110	NA	-0.35	-7.14	-0.32	3.57e-12	Prostate cancer;
LGG	cis	rs11608355	0.515	rs4766609	chr12:109973297	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02071572	chr4:1403502	NA	0.42	7.15	0.32	3.3e-12	Longevity;
LGG	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.09	-0.49	1.9e-29	Bladder cancer;
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg03709012	chr19:19516395	GATAD2A	-0.82	-15.92	-0.59	8.19e-46	Tonsillectomy;
LGG	cis	rs2865126	0.743	rs2865120	chr18:10754921	A/G	cg21165219	chr18:10698044	FAM38B	-0.46	-7.41	-0.33	5.92e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs1863824	0.625	rs2018507	chr10:88163251	A/G	cg07322936	chr10:88137208	NA	0.52	8.76	0.38	3.78e-17	Schizophrenia;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg01145232	chr6:150245071	RAET1G	0.33	6.92	0.31	1.48e-11	Testicular germ cell tumor;
LGG	cis	rs1829883	1.000	rs1829883	chr5:98781103	C/T	cg08333243	chr5:99726346	NA	-0.39	-7.58	-0.33	1.88e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg04398451	chr17:18023971	MYO15A	-0.6	-11.97	-0.49	5.69e-29	Total body bone mineral density;
LGG	cis	rs2832191	0.679	rs2705659	chr21:30363908	G/C	cg24692254	chr21:30365293	RNF160	1.04	29.64	0.81	5.02e-109	Dental caries;
LGG	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.11e-84	Height;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs4538187	0.851	rs35960986	chr2:64221195	G/A	cg19915305	chr2:64069682	UGP2	-0.68	-15.34	-0.58	3e-43	Systolic blood pressure;
LGG	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs7619833	0.685	rs472146	chr3:27337379	T/C	cg02860705	chr3:27208620	NA	0.39	7.56	0.33	2.15e-13	Breast cancer;
LGG	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs7010267	0.668	rs4876876	chr8:119986235	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.39	9.98	0.42	2.34e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg23205692	chr1:25664452	TMEM50A	0.45	9.26	0.4	7.51e-19	Erythrocyte sedimentation rate;
LGG	cis	rs6963495	0.745	rs73192150	chr7:105211610	A/C	cg19920283	chr7:105172520	RINT1	0.64	8.24	0.36	1.78e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg15212455	chr7:39170539	POU6F2	0.49	11.52	0.47	3.57e-27	IgG glycosylation;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg16103275	chr6:290800	DUSP22	0.49	7.95	0.35	1.4e-14	Menopause (age at onset);
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg11062466	chr8:58055876	NA	0.6	9.53	0.41	8.76e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11105298	0.891	rs8181784	chr12:89828591	A/G	cg00757033	chr12:89920650	WDR51B	0.58	8.5	0.37	2.72e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6840360	0.571	rs28608620	chr4:152504791	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.23	-0.36	1.96e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4917300	0.606	rs1388797	chr8:143096908	G/C	cg26003909	chr8:143102224	NA	-0.34	-6.79	-0.3	3.48e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.71	0.38	5.39e-17	Schizophrenia;
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg17691542	chr6:26056736	HIST1H1C	0.4	6.83	0.3	2.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11792861	0.926	rs7870597	chr9:111871864	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.59e-21	Menopause (age at onset);
LGG	cis	rs6540556	0.769	rs6540552	chr1:209927710	C/T	cg05527609	chr1:210001259	C1orf107	0.49	6.75	0.3	4.47e-11	Red blood cell count;
LGG	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg15704280	chr7:45808275	SEPT13	0.74	9.92	0.42	3.71e-21	Axial length;
LGG	cis	rs7765175	0.573	rs6920652	chr6:113618048	G/A	cg26552650	chr6:113682475	NA	0.34	7.46	0.33	4.39e-13	Coronary artery calcification;
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.21	-0.32	2.33e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12701220	0.655	rs7778968	chr7:1144622	C/G	cg00990874	chr7:1149470	C7orf50	-0.83	-14.83	-0.57	5.51e-41	Bronchopulmonary dysplasia;
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg26384229	chr12:38710491	ALG10B	0.72	14.53	0.56	1.15e-39	Morning vs. evening chronotype;
LGG	cis	rs5769707	0.706	rs2071903	chr22:50034517	G/A	cg06623630	chr22:50017776	C22orf34	-0.5	-10.09	-0.42	8.87e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.29	-0.53	2.38e-34	Alzheimer's disease;
LGG	cis	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg26384229	chr12:38710491	ALG10B	0.94	20.95	0.7	4.66e-69	Bladder cancer;
LGG	cis	rs41271951	0.512	rs115968379	chr1:151050087	A/C	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.02	-0.31	7.83e-12	Blood protein levels;
LGG	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.4	0.33	6.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs3779273	1.000	rs3779273	chr7:77828940	G/A	cg05596911	chr5:118502651	DMXL1	0.44	9.31	0.4	5.01e-19	Body mass index;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15109221	chr6:15245772	JARID2	0.44	7.13	0.31	3.95e-12	Menarche (age at onset);
LGG	cis	rs4819388	0.915	rs6518352	chr21:45646698	A/G	cg01992765	chr21:45622493	NA	-0.44	-8.4	-0.36	5.6e-16	Celiac disease;
LGG	cis	rs3126085	0.935	rs11588174	chr1:152175970	C/T	cg26876637	chr1:152193138	HRNR	-0.55	-8.93	-0.38	1.02e-17	Atopic dermatitis;
LGG	cis	rs2708240	0.561	rs1723441	chr7:147549011	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.16	-0.32	3.15e-12	QT interval (drug interaction);
LGG	cis	rs11203032	1.000	rs11203033	chr10:90964731	C/G	cg16672925	chr10:90967113	CH25H	-0.82	-11.67	-0.48	8.97e-28	Heart failure;
LGG	cis	rs5015933	0.815	rs13294021	chr9:128068388	G/A	cg14078157	chr9:128172775	NA	-0.36	-6.79	-0.3	3.39e-11	Body mass index;
LGG	cis	rs7215564	0.908	rs2340772	chr17:78752017	C/A	cg16980736	chr17:78789706	RPTOR	0.58	7.65	0.33	1.18e-13	Myopia (pathological);
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.37e-12	Height;
LGG	cis	rs2797369	0.656	rs705618	chr6:101361792	T/A	cg27451362	chr6:101846650	GRIK2	0.77	10.52	0.44	2.28e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg14196790	chr5:131705035	SLC22A5	0.58	7.37	0.32	7.8e-13	Rheumatoid arthritis;
LGG	cis	rs1355223	0.902	rs34610590	chr11:34725440	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.7	-0.3	6.1e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs733592	0.507	rs3825403	chr12:48457159	G/A	cg24011408	chr12:48396354	COL2A1	-0.69	-12.19	-0.49	7.49e-30	Plateletcrit;
LGG	cis	rs7264396	0.508	rs6060739	chr20:34567592	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.55	-0.33	2.39e-13	Total cholesterol levels;
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg20916646	chr4:852691	GAK	0.51	8.88	0.38	1.52e-17	Sjögren's syndrome;
LGG	cis	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.61	-0.44	1.07e-23	Hip circumference adjusted for BMI;
LGG	cis	rs9916302	0.904	rs10491128	chr17:37551988	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.37	0.47	1.42e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg05863683	chr7:1912471	MAD1L1	0.38	7.55	0.33	2.28e-13	Schizophrenia;
LGG	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg13010199	chr12:38710504	ALG10B	0.45	8.0	0.35	9.88e-15	Morning vs. evening chronotype;
LGG	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg16208657	chr15:68119293	LBXCOR1	-0.34	-6.74	-0.3	4.72e-11	Obesity;
LGG	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.11	0.39	2.57e-18	Schizophrenia;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg08219700	chr8:58056026	NA	0.52	11.35	0.47	1.72e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.66	0.3	7.78e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4774899	0.752	rs2733332	chr15:57388349	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.97	-0.31	1.13e-11	Urinary tract infection frequency;
LGG	cis	rs7584330	0.695	rs6709497	chr2:238368925	C/T	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg11845111	chr2:191398756	TMEM194B	0.36	8.06	0.35	6.73e-15	Pulse pressure;
LGG	cis	rs875971	0.545	rs2420612	chr7:66001812	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.6	0.44	1.15e-23	Aortic root size;
LGG	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.54e-68	Diabetic kidney disease;
LGG	cis	rs34172651	0.917	rs200536	chr16:24749203	G/A	cg02428538	chr16:24856791	SLC5A11	0.48	8.1	0.35	4.98e-15	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs10861342	0.892	rs3829297	chr12:105592823	G/C	cg23923672	chr12:105501055	KIAA1033	0.8	7.27	0.32	1.54e-12	IgG glycosylation;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg13939156	chr17:80058883	NA	-0.46	-8.97	-0.38	7.18e-18	Life satisfaction;
LGG	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.78e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg02023728	chr11:77925099	USP35	0.45	7.75	0.34	6.01e-14	Testicular germ cell tumor;
LGG	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg03806693	chr22:41940476	POLR3H	-1.01	-17.34	-0.63	2.91e-52	Vitiligo;
LGG	cis	rs9674544	0.757	rs2289636	chr17:47120776	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.46	-8.76	-0.38	3.59e-17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs2303319	1.000	rs12463483	chr2:162252619	G/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17151990	chr8:58907242	FAM110B	0.59	6.73	0.3	5.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-13.9	-0.54	5.89e-37	Platelet count;
LGG	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs1018836	0.828	rs4735236	chr8:91583909	A/G	cg16814680	chr8:91681699	NA	-0.74	-13.24	-0.52	3.53e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg07460842	chr6:66804631	NA	0.57	9.55	0.41	7.54e-20	Metabolite levels;
LGG	cis	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg13443165	chr9:33130375	B4GALT1	-0.69	-11.45	-0.47	6.99e-27	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs6882076	1.000	rs4704727	chr5:156380067	T/G	cg12943317	chr5:156479607	HAVCR1	-0.69	-12.07	-0.49	2.27e-29	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	trans	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg13264159	chr8:625131	ERICH1	-1.05	-11.89	-0.48	1.28e-28	IgG glycosylation;
LGG	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs10463554	0.892	rs6871715	chr5:102266102	A/G	cg23492399	chr5:102201601	PAM	-0.53	-8.19	-0.36	2.66e-15	Parkinson's disease;
LGG	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg13010199	chr12:38710504	ALG10B	0.54	9.52	0.4	9.43e-20	Resting heart rate;
LGG	cis	rs2041895	0.509	rs1838445	chr12:107314585	T/A	cg13944111	chr12:107296891	NA	0.27	7.24	0.32	1.89e-12	Glaucoma (low intraocular pressure);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03627896	chr16:30934334	NCRNA00095	0.41	7.34	0.32	9.74e-13	Obesity-related traits;
LGG	cis	rs6982240	0.514	rs28588820	chr8:142285342	C/T	cg20799268	chr8:142275649	NA	-0.24	-6.73	-0.3	5.16e-11	Tonsillectomy;
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.47	-0.37	3.25e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg16141378	chr3:129829833	LOC729375	0.35	7.52	0.33	2.83e-13	Systemic lupus erythematosus;
LGG	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg16797656	chr11:68205561	LRP5	-0.47	-7.81	-0.34	3.8e-14	Bone mineral density (spine);
LGG	trans	rs637571	0.726	rs526631	chr11:65681965	T/G	cg17712092	chr4:129076599	LARP1B	-0.86	-18.73	-0.66	1.15e-58	Eosinophil percentage of white cells;
LGG	trans	rs66887589	0.616	rs11098497	chr4:120187068	C/T	cg25214090	chr10:38739885	LOC399744	0.46	8.4	0.36	5.49e-16	Diastolic blood pressure;
LGG	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22857025	chr5:266934	NA	-1.56	-25.57	-0.77	1.43e-90	Breast cancer;
LGG	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg03847636	chr4:7070632	GRPEL1	-0.49	-6.95	-0.31	1.28e-11	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.65	11.86	0.48	1.58e-28	Obesity-related traits;
LGG	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.48	0.4	1.38e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs503734	0.666	rs6441610	chr3:101225620	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs73416724	1.000	rs75320251	chr6:43395101	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.72e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg02023728	chr11:77925099	USP35	-0.38	-6.84	-0.3	2.58e-11	Alzheimer's disease (survival time);
LGG	cis	rs1044826	0.642	rs7652860	chr3:139205818	T/A	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs7113850	0.541	rs78048500	chr11:24217764	T/G	ch.11.24196551F	chr11:24239977	NA	0.91	10.24	0.43	2.56e-22	Bone fracture in osteoporosis;
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.42	0.4	2.2e-19	Height;
LGG	cis	rs6663390	0.831	rs3754172	chr1:208086878	G/T	cg00387621	chr1:208086895	NA	0.59	6.76	0.3	4.18e-11	Facial morphology (factor 18);
LGG	trans	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.31	0.5	2.51e-30	Corneal astigmatism;
LGG	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg11822372	chr1:151115635	SEMA6C	0.49	8.63	0.37	1e-16	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.08	0.39	3.16e-18	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs4237845	0.537	rs4237844	chr12:58267987	A/G	cg00677455	chr12:58241039	CTDSP2	-0.4	-7.3	-0.32	1.26e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9397585	0.857	rs9479490	chr6:153388414	A/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	9.37	0.4	3.13e-19	Triglycerides;
LGG	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs6693567	0.565	rs1260408	chr1:150307270	T/G	cg15654264	chr1:150340011	RPRD2	0.33	6.73	0.3	5.16e-11	Migraine;
LGG	cis	rs12195424	0.730	rs79512233	chr6:56300380	T/C	cg07152817	chr6:56299822	NA	-0.58	-7.12	-0.31	4.15e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs7119	0.717	rs12909645	chr15:77816819	A/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs72634501	0.568	rs6679564	chr1:39617080	A/G	cg18385671	chr1:39797026	MACF1	-0.45	-9.76	-0.41	1.39e-20	HDL cholesterol;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.56	-0.53	1.67e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26605046	chr4:2439731	NA	-0.37	-7.17	-0.32	2.99e-12	Cognitive function;
LGG	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg11822372	chr1:151115635	SEMA6C	0.47	8.44	0.37	3.98e-16	Childhood ear infection;
LGG	cis	rs6840360	1.000	rs10049991	chr4:152664163	A/T	cg22705602	chr4:152727874	NA	-0.27	-6.82	-0.3	2.79e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.645	rs28441045	chr11:50048971	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg09237302	chr4:906077	GAK	-0.46	-7.76	-0.34	5.33e-14	Type 2 diabetes;
LGG	cis	rs7166081	1.000	rs4776917	chr15:67600344	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.09	-0.31	4.91e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	10.25	0.43	2.26e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg08344181	chr3:125677491	NA	-0.85	-8.24	-0.36	1.84e-15	Depression;
LGG	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg24375607	chr4:120327624	NA	0.59	9.83	0.42	7.83e-21	Corneal astigmatism;
LGG	cis	rs11098499	0.754	rs714899	chr4:120243035	G/A	cg09307838	chr4:120376055	NA	0.73	12.56	0.5	2.4e-31	Corneal astigmatism;
LGG	cis	rs9397585	0.824	rs6934238	chr6:153378061	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg07382826	chr16:28625726	SULT1A1	0.42	8.88	0.38	1.51e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.1	0.35	5.06e-15	Colorectal cancer;
LGG	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.16	-0.32	3.24e-12	Testicular germ cell tumor;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-11.97	-0.49	5.94e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6901004	0.803	rs9400470	chr6:111478131	T/C	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.61	-0.33	1.52e-13	Blood metabolite levels;
LGG	cis	rs7929679	0.545	rs2421740	chr11:34796754	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.89	0.3	1.84e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg15948088	chr11:109293068	C11orf87	0.8	15.04	0.57	6.35e-42	Schizophrenia;
LGG	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg09873164	chr1:152488093	CRCT1	0.53	10.79	0.45	2.23e-24	Hair morphology;
LGG	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg18478394	chr8:109455254	TTC35	0.49	10.07	0.42	1.07e-21	Dupuytren's disease;
LGG	cis	rs12200560	0.505	rs211162	chr6:97067344	G/A	cg06623918	chr6:96969491	KIAA0776	0.46	7.78	0.34	4.93e-14	Coronary heart disease;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.6	7.14	0.31	3.67e-12	Schizophrenia;
LGG	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.65	-0.44	7.85e-24	Lung cancer in ever smokers;
LGG	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg04398451	chr17:18023971	MYO15A	-0.74	-15.46	-0.58	8.88e-44	Total body bone mineral density;
LGG	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.27	0.32	1.52e-12	Retinal vascular caliber;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg02127607	chr17:61920694	SMARCD2	0.46	8.37	0.36	6.95e-16	Prudent dietary pattern;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg06916706	chr16:4465613	CORO7	-0.71	-12.37	-0.5	1.43e-30	Schizophrenia;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg05692746	chr2:100937584	LONRF2	-0.61	-11.06	-0.46	2.08e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg05896524	chr21:47604654	C21orf56	0.59	10.6	0.44	1.15e-23	Testicular germ cell tumor;
LGG	cis	rs9487094	0.922	rs2275650	chr6:109668288	C/T	cg16315928	chr6:109776240	MICAL1	0.56	9.64	0.41	3.73e-20	Height;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs35306767	0.904	rs35667562	chr10:950630	G/A	cg26597838	chr10:835615	NA	0.96	12.76	0.51	3.63e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg17509989	chr5:176798049	RGS14	0.88	14.49	0.56	1.66e-39	Hemoglobin concentration;Hematocrit;
LGG	trans	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.93	-0.31	1.38e-11	Neuroticism;
LGG	cis	rs9649213	0.614	rs4729432	chr7:97947055	G/C	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.37	-0.36	6.96e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	trans	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.19	-0.36	2.51e-15	Monocyte count;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03647317	chr4:187891568	NA	-0.42	-8.91	-0.38	1.22e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11157436	0.560	rs2031071	chr14:22625480	G/T	cg00994629	chr14:22694547	NA	0.3	6.75	0.3	4.34e-11	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg08344181	chr3:125677491	NA	-0.87	-9.05	-0.39	3.99e-18	Depression;
LGG	cis	rs6540556	0.521	rs1337531	chr1:209911988	T/G	cg23920097	chr1:209922102	NA	-0.42	-7.65	-0.33	1.21e-13	Red blood cell count;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg15971980	chr6:150254442	NA	0.44	8.43	0.36	4.56e-16	Lung cancer;
LGG	trans	rs17685	0.753	rs9691174	chr7:75790405	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2769264	0.593	rs4971040	chr1:151366494	A/C	cg18801370	chr1:151430492	POGZ	0.82	13.23	0.52	4.11e-34	Blood trace element (Cu levels);
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16405210	chr4:1374714	KIAA1530	0.43	7.11	0.31	4.39e-12	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs17641971	0.708	rs4873303	chr8:49922675	G/A	cg00325661	chr8:49890786	NA	0.52	9.42	0.4	2.16e-19	Blood metabolite levels;
LGG	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg11584989	chr19:19387371	SF4	-0.76	-12.69	-0.51	7.09e-32	Bipolar disorder;
LGG	cis	rs4948496	1.000	rs4948496	chr10:63805617	T/C	cg16389209	chr10:63809121	ARID5B	0.36	6.99	0.31	9.73e-12	Systemic lupus erythematosus;
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.25	-0.32	1.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg16077055	chr2:106428750	NCK2	0.28	7.24	0.32	1.88e-12	Addiction;
LGG	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg05444541	chr17:17804740	TOM1L2	0.59	12.91	0.51	8.95e-33	Total body bone mineral density;
LGG	cis	rs6663390	0.510	rs73072979	chr1:208072057	G/A	cg03990033	chr1:208084030	CD34	0.63	8.08	0.35	5.61e-15	Facial morphology (factor 18);
LGG	cis	rs67460515	0.563	rs1599388	chr3:160846866	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.35	-0.36	7.9e-16	Parkinson's disease;
LGG	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg22916017	chr11:64110731	CCDC88B	0.49	9.7	0.41	2.32e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg13939156	chr17:80058883	NA	-0.46	-8.99	-0.39	6.46e-18	Life satisfaction;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs1348850	0.567	rs880899	chr2:178532416	A/G	cg27490568	chr2:178487706	NA	0.49	9.62	0.41	4.15e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21431338	chr20:61427688	C20orf20	0.47	7.73	0.34	6.79e-14	Gut microbiome composition (summer);
LGG	cis	rs4696584	0.877	rs10517594	chr4:155399442	C/G	cg13738195	chr4:155413469	DCHS2	0.37	7.1	0.31	4.66e-12	Folding of antihelix;
LGG	cis	rs561341	1.000	rs537166	chr17:30326827	C/T	cg00745463	chr17:30367425	LRRC37B	-0.69	-10.2	-0.43	3.57e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg07636037	chr3:49044803	WDR6	0.98	21.88	0.71	2.21e-73	Menarche (age at onset);
LGG	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg20477318	chr10:51623047	TIMM23	0.69	8.29	0.36	1.24e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs4776059	1.000	rs1863512	chr15:52959687	C/T	cg22715398	chr15:52968154	KIAA1370	-0.51	-8.51	-0.37	2.39e-16	Schizophrenia;
LGG	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg02574844	chr11:5959923	NA	0.61	9.46	0.4	1.5700000000000001e-19	DNA methylation (variation);
LGG	cis	rs79149102	0.579	rs12591994	chr15:75320306	A/G	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.55	-0.37	1.85e-16	Lung cancer;
LGG	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg25718383	chr7:130020096	CPA1	0.32	8.42	0.36	4.83e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg05335186	chr13:53173507	NA	-0.53	-11.19	-0.46	6.93e-26	Lewy body disease;
LGG	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg10204951	chr7:910479	UNC84A	-0.53	-7.1	-0.31	4.64e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.6	-0.37	1.24e-16	Alzheimer's disease (survival time);
LGG	cis	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg09307838	chr4:120376055	NA	0.72	12.16	0.49	1.06e-29	Corneal astigmatism;
LGG	trans	rs877282	0.947	rs12358875	chr10:757531	T/C	cg22713356	chr15:30763199	NA	0.48	7.24	0.32	1.93e-12	Uric acid levels;
LGG	cis	rs329674	0.556	rs1793681	chr11:133763230	A/C	cg06766960	chr11:133703094	NA	-0.57	-6.89	-0.3	1.86e-11	Bipolar disorder;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg21963583	chr11:68658836	MRPL21	0.58	10.1	0.43	8.08e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg26150922	chr2:100937072	LONRF2	0.56	9.84	0.42	7.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7100689	0.580	rs2168721	chr10:82208192	A/G	cg00277334	chr10:82204260	NA	-0.45	-9.61	-0.41	4.75e-20	Post bronchodilator FEV1;
LGG	cis	rs2976388	0.935	rs2978979	chr8:143757286	C/A	cg06565975	chr8:143823917	SLURP1	-0.42	-10.55	-0.44	1.79e-23	Urinary tract infection frequency;
LGG	cis	rs9942416	0.660	rs17563686	chr5:74984818	A/T	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs9427116	0.875	rs11264233	chr1:154625632	C/T	cg11650704	chr1:154556575	ADAR	-0.41	-8.05	-0.35	7.01e-15	Blood protein levels;
LGG	cis	rs16937	0.711	rs12142514	chr1:205122529	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.11e-13	Schizophrenia;
LGG	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.42	0.4	2.23e-19	Diabetic retinopathy;
LGG	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07570687	chr10:102243282	WNT8B	-0.43	-7.65	-0.33	1.2e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg26384229	chr12:38710491	ALG10B	-0.85	-19.34	-0.67	1.58e-61	Bladder cancer;
LGG	cis	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg24375607	chr4:120327624	NA	0.67	10.86	0.45	1.24e-24	Corneal astigmatism;
LGG	cis	rs3806843	0.576	rs246005	chr5:140339884	A/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6089584	0.566	rs6061964	chr20:60607536	G/A	cg06108461	chr20:60628389	TAF4	-0.72	-13.0	-0.52	3.55e-33	Body mass index;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg18402987	chr7:1209562	NA	0.66	9.19	0.39	1.3e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.88	0.34	2.35e-14	Lung cancer;
LGG	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-6.88	-0.3	1.96e-11	Neuroticism;
LGG	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.84	0.45	1.51e-24	Lung cancer in ever smokers;
LGG	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg23649088	chr2:200775458	C2orf69	0.61	8.12	0.35	4.26e-15	Schizophrenia;
LGG	cis	rs4268898	1.000	rs10165445	chr2:24441698	C/T	cg06627628	chr2:24431161	ITSN2	0.53	8.98	0.39	6.81e-18	Asthma;
LGG	cis	rs477692	1.000	rs558764	chr10:131426957	G/T	cg05714579	chr10:131428358	MGMT	-0.56	-11.87	-0.48	1.46e-28	Response to temozolomide;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg15537850	chr8:144661051	NAPRT1	1.01	7.66	0.34	1.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg13607699	chr17:42295918	UBTF	-0.67	-11.55	-0.47	2.75e-27	Total body bone mineral density;
LGG	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg13607699	chr17:42295918	UBTF	0.88	18.15	0.64	5.19e-56	Red cell distribution width;Reticulocyte count;
LGG	cis	rs6904897	0.563	rs4896117	chr6:135229400	T/C	cg22676075	chr6:135203613	NA	-0.59	-11.17	-0.46	7.96e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4731207	0.569	rs10252443	chr7:124578931	G/A	cg05630886	chr7:124431682	NA	-0.34	-7.59	-0.33	1.76e-13	Cutaneous malignant melanoma;
LGG	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs9486719	0.741	rs2499799	chr6:96851676	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.79	0.41	1.12e-20	Migraine;Coronary artery disease;
LGG	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg19455335	chr8:22457658	C8orf58	0.38	7.64	0.33	1.27e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.49	-0.4	1.18e-19	Neuroticism;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.81	-0.34	3.77e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg07414643	chr4:187882934	NA	0.53	10.51	0.44	2.56e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs7582720	1.000	rs72932772	chr2:203682304	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.54e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.75	-0.34	5.7e-14	Bladder cancer;
LGG	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg08305652	chr11:111469057	NA	-0.44	-8.92	-0.38	1.05e-17	Primary sclerosing cholangitis;
LGG	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg06637938	chr14:75390232	RPS6KL1	0.56	10.34	0.43	1.08e-22	Height;
LGG	trans	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs4356932	0.967	rs6532161	chr4:76978366	G/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	trans	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg10756647	chr7:56101905	PSPH	0.83	9.79	0.41	1.05e-20	Diabetic kidney disease;
LGG	cis	rs988958	0.565	rs10166263	chr2:42235265	C/T	cg27428208	chr2:42229179	NA	0.48	7.51	0.33	2.98e-13	Hypospadias;
LGG	cis	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg18252515	chr7:66147081	NA	-1.43	-20.76	-0.69	3.88e-68	Diabetic kidney disease;
LGG	cis	rs727505	1.000	rs28523990	chr7:124436139	C/T	cg23710748	chr7:124431027	NA	-0.56	-10.43	-0.44	5.03e-23	Lewy body disease;
LGG	cis	rs12618769	0.652	rs17033813	chr2:99196483	A/G	cg18455616	chr2:99124870	INPP4A	-0.26	-7.53	-0.33	2.68e-13	Bipolar disorder;
LGG	cis	rs941873	0.805	rs876678	chr10:81111036	G/T	cg09469691	chr10:81107165	PPIF	0.53	9.04	0.39	4.25e-18	Height;
LGG	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.77	-0.38	3.36e-17	Depression;
LGG	trans	rs1941687	0.800	rs12968906	chr18:31378307	G/A	cg27147174	chr7:100797783	AP1S1	-0.53	-8.85	-0.38	1.92e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-16.44	-0.61	3.66e-48	Body mass index;
LGG	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08045932	chr20:61659980	NA	0.6	13.22	0.52	4.29e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg24642439	chr20:33292090	TP53INP2	0.64	11.17	0.46	7.87e-26	Coronary artery disease;
LGG	trans	rs11875185	0.915	rs72937679	chr18:55617126	G/C	cg15513957	chr14:69354734	ACTN1	-0.73	-7.81	-0.34	3.81e-14	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg01472538	chr16:58549086	SETD6	0.98	8.73	0.38	4.54e-17	Schizophrenia;
LGG	cis	rs72772090	0.539	rs72775817	chr5:96190709	A/C	cg00188032	chr5:96141721	ERAP1	0.55	7.24	0.32	1.89e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25427524	chr10:38739819	LOC399744	0.69	14.1	0.55	8.16e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs7143963	1.000	rs4906269	chr14:103362017	A/C	cg23020514	chr14:103360112	TRAF3	0.48	9.71	0.41	2.06e-20	Body mass index;
LGG	cis	rs2018055	0.912	rs6914910	chr6:117806461	G/A	cg14611402	chr6:117803162	DCBLD1	0.3	8.42	0.36	4.89e-16	Diastolic blood pressure;
LGG	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26734620	chr12:56694298	CS	0.75	6.82	0.3	2.89e-11	Psoriasis vulgaris;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.22	-0.36	2.1e-15	Personality dimensions;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.85	0.59	1.69e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs59918340	0.738	rs3739235	chr8:142229145	A/G	cg03653399	chr8:142233436	SLC45A4	0.43	8.45	0.37	3.87e-16	Immature fraction of reticulocytes;
LGG	cis	rs12579753	0.667	rs7487640	chr12:82286681	A/G	cg07988820	chr12:82153109	PPFIA2	0.51	7.36	0.32	8.24e-13	Resting heart rate;
LGG	cis	rs8141529	0.764	rs5752809	chr22:29225500	G/A	cg15103426	chr22:29168792	CCDC117	0.73	11.79	0.48	3.17e-28	Lymphocyte counts;
LGG	cis	rs6764363	0.527	rs7648248	chr3:275692	A/G	cg02057681	chr3:285234	CHL1	-0.44	-7.75	-0.34	5.93e-14	Sudden cardiac arrest;
LGG	cis	rs17209837	1.000	rs12673662	chr7:87110351	C/G	cg00919237	chr7:87102261	ABCB4	0.7	11.16	0.46	8.63e-26	Gallbladder cancer;
LGG	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg05791153	chr7:19748676	TWISTNB	1.16	16.11	0.6	1.11e-46	Thyroid stimulating hormone;
LGG	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	23.57	0.74	2.71e-81	Chronic sinus infection;
LGG	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7634476	1	rs7634476	chr3:136398387	A/G	cg21827317	chr3:136751795	NA	-0.48	-8.66	-0.37	7.69e-17	Neuroticism;
LGG	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-7.06	-0.31	6.01e-12	Vitiligo;
LGG	trans	rs36715	1.000	rs36697	chr5:127549613	A/G	cg16011800	chr17:1958478	HIC1	-0.45	-6.71	-0.3	5.76e-11	Breast cancer;
LGG	cis	rs885389	1.000	rs867411	chr12:131621789	T/G	cg07124762	chr12:131619285	GPR133	-0.45	-8.49	-0.37	2.73e-16	RR interval (heart rate);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21569844	chr2:86564582	REEP1	0.45	6.67	0.3	7.54e-11	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.22	-0.32	2.1e-12	Coronary artery disease;
LGG	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg13482628	chr17:19912719	NA	-0.5	-9.32	-0.4	4.7e-19	Obesity-related traits;
LGG	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg04731861	chr2:219085781	ARPC2	-0.32	-7.43	-0.33	5.17e-13	Ulcerative colitis;
LGG	cis	rs2276314	1.000	rs2276314	chr18:33557466	C/T	cg05985134	chr18:33552581	C18orf21	-0.66	-10.38	-0.43	7.77e-23	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.75	0.34	5.88e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg08807101	chr21:30365312	RNF160	-0.58	-7.98	-0.35	1.16e-14	Cognitive test performance;
LGG	cis	rs2777491	1.000	rs316605	chr15:41771591	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-19.71	-0.68	2.97e-63	Ulcerative colitis;
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg23202291	chr11:1979235	NA	0.39	7.42	0.33	5.55e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg15704280	chr7:45808275	SEPT13	0.75	8.88	0.38	1.48e-17	Intraocular pressure;
LGG	cis	rs11676348	0.846	rs4674259	chr2:218991005	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-9.68	-0.41	2.58e-20	Ulcerative colitis;
LGG	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg08125733	chr17:73851984	WBP2	0.69	10.99	0.45	4.02e-25	Psoriasis;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg02018176	chr4:1364513	KIAA1530	-0.42	-9.52	-0.4	9.3e-20	Obesity-related traits;
LGG	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg13010199	chr12:38710504	ALG10B	0.53	10.0	0.42	1.89e-21	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg13010199	chr12:38710504	ALG10B	-0.63	-13.12	-0.52	1.15e-33	Bladder cancer;
LGG	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.0	-0.39	5.88e-18	Myopia (pathological);
LGG	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.94	-0.35	1.52e-14	Morning vs. evening chronotype;
LGG	cis	rs17209837	1.000	rs998671	chr7:87123275	C/T	cg00919237	chr7:87102261	ABCB4	-0.74	-11.62	-0.48	1.39e-27	Gallbladder cancer;
LGG	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14169450	chr9:139327907	INPP5E	-0.37	-6.72	-0.3	5.5e-11	Monocyte percentage of white cells;
LGG	cis	rs11628318	0.805	rs749543	chr14:103057250	C/A	cg01864069	chr14:103024347	NA	-0.63	-10.42	-0.44	5.68e-23	Platelet count;
LGG	trans	rs79911532	0.551	rs41301427	chr7:75614557	G/A	cg19862616	chr7:65841803	NCRNA00174	0.74	7.61	0.33	1.54e-13	Mononucleosis;
LGG	cis	rs2735413	0.957	rs2735414	chr16:78053658	C/A	cg04733911	chr16:78082701	NA	-0.71	-15.79	-0.59	3.05e-45	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs11585357	0.843	rs12095095	chr1:17625832	C/G	cg08277548	chr1:17600880	PADI3	-0.61	-7.14	-0.31	3.72e-12	Hair shape;
LGG	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg20608306	chr11:116969690	SIK3	0.38	10.37	0.43	8.86e-23	Subjective well-being;
LGG	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg12454169	chr2:30669597	LCLAT1	0.5	7.04	0.31	6.91e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs2482931	chr20:25334445	G/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.13	-0.43	6.65e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-10.51	-0.44	2.59e-23	Height;
LGG	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.34	-0.36	8.46e-16	Cognitive test performance;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg26441486	chr22:50317300	CRELD2	0.42	7.68	0.34	9.34e-14	Schizophrenia;
LGG	cis	rs11229555	0.645	rs36002376	chr11:58204809	C/G	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9816226	0.591	rs4234589	chr3:185818882	A/G	cg00760338	chr3:185826511	ETV5	-0.84	-10.48	-0.44	3.44e-23	Obesity;Body mass index;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.05	0.83	1.32e-119	Prudent dietary pattern;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.11	-0.31	4.33e-12	Menopause (age at onset);
LGG	trans	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.27e-14	Heart rate;
LGG	cis	rs10463554	0.963	rs12054848	chr5:102380440	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-11.05	-0.46	2.45e-25	Heart rate;
LGG	cis	rs11971779	0.680	rs6467848	chr7:139080205	T/A	cg07862535	chr7:139043722	LUC7L2	0.43	7.15	0.32	3.38e-12	Diisocyanate-induced asthma;
LGG	cis	rs2732480	0.577	rs2634678	chr12:48735538	C/G	cg24011408	chr12:48396354	COL2A1	0.5	7.92	0.35	1.78e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg11494091	chr17:61959527	GH2	-1.04	-26.18	-0.77	2.18e-93	Prudent dietary pattern;
LGG	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.83	-0.3	2.63e-11	Parkinson's disease;
LGG	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg14728415	chr7:32535168	LSM5;AVL9	0.46	7.35	0.32	8.8e-13	Cognitive ability;
LGG	trans	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.12	-0.31	4.27e-12	Testicular germ cell tumor;
LGG	cis	rs11096990	0.574	rs34070258	chr4:39189752	T/C	cg24403649	chr4:39172243	NA	0.42	7.51	0.33	3.03e-13	Cognitive function;
LGG	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	7.66	0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg03806693	chr22:41940476	POLR3H	0.99	16.75	0.61	1.45e-49	Vitiligo;
LGG	cis	rs36071027	0.554	rs9918118	chr5:158394846	C/T	cg00594129	chr5:158524270	EBF1	0.45	8.09	0.35	5.32e-15	Carotid intima media thickness;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	11.76	0.48	4.11e-28	Lymphocyte counts;
LGG	cis	rs36051895	0.659	rs12337134	chr9:5061578	G/A	cg02405213	chr9:5042618	JAK2	-0.82	-15.2	-0.58	1.24e-42	Pediatric autoimmune diseases;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	12.01	0.49	4.07e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.74	-0.66	9.65e-59	Monocyte count;
LGG	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg08610935	chr16:1836813	NUBP2	0.43	6.84	0.3	2.46e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg17294928	chr15:75287854	SCAMP5	0.92	16.28	0.6	1.83e-47	Blood trace element (Zn levels);
LGG	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.88	14.51	0.56	1.34e-39	Gut microbiome composition (summer);
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00761968	chr13:53314142	LECT1	-0.38	-7.96	-0.35	1.31e-14	Lewy body disease;
LGG	cis	rs3784262	1.000	rs1372368	chr15:58297363	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-7.96	-0.35	1.3e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.15	0.49	1.12e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg11317459	chr13:21872234	NA	-1.18	-19.41	-0.67	7.63e-62	White matter hyperintensity burden;
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg14689365	chr7:158441557	NCAPG2	0.62	10.36	0.43	9.4e-23	Height;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	6.89	0.31	1.8e-11	Schizophrenia;
LGG	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg03929089	chr4:120376271	NA	-1.02	-22.67	-0.73	4.25e-77	Height;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.18	-0.36	2.8e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9399135	0.967	rs9389254	chr6:135330709	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.06e-19	Red blood cell count;
LGG	trans	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg21659725	chr3:3221576	CRBN	0.45	7.35	0.32	9.26e-13	Menarche (age at onset);
LGG	cis	rs4538187	0.627	rs11694253	chr2:63948135	T/G	cg14150252	chr2:64069583	UGP2	-0.46	-7.55	-0.33	2.3e-13	Systolic blood pressure;
LGG	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg17691542	chr6:26056736	HIST1H1C	0.39	6.65	0.3	8.07e-11	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16219491	chr6:26197733	HIST1H3D	-0.53	-7.75	-0.34	5.69e-14	Systemic lupus erythematosus;
LGG	cis	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.13	0.35	3.91e-15	Obesity-related traits;
LGG	cis	rs10193935	0.786	rs13399052	chr2:42385151	G/A	cg27598129	chr2:42591480	NA	-0.6	-9.05	-0.39	4.13e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg24375607	chr4:120327624	NA	0.65	10.57	0.44	1.53e-23	Corneal astigmatism;
LGG	cis	rs7512552	0.839	rs1260386	chr1:150369622	G/T	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg20308403	chr7:2120281	MAD1L1	0.34	7.27	0.32	1.52e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.08e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7914558	0.966	rs10786724	chr10:104668942	A/G	cg04362960	chr10:104952993	NT5C2	0.53	10.02	0.42	1.58e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7241530	0.610	rs4799267	chr18:75896178	A/G	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.97	-0.31	1.08e-11	Uric acid levels;
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.6	-0.33	1.71e-13	Tonsillectomy;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.38	0.56	5.25e-39	Lung cancer;
LGG	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-15.05	-0.57	5.98e-42	Response to antipsychotic treatment;
LGG	cis	rs17092148	0.597	rs57495888	chr20:33092724	T/C	cg12302830	chr20:33297742	TP53INP2	0.41	6.85	0.3	2.42e-11	Neuroticism;
LGG	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg02254774	chr11:50257496	LOC441601	-0.58	-6.79	-0.3	3.5e-11	Myopia (pathological);
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.83	-0.42	7.6e-21	IgG glycosylation;
LGG	cis	rs854037	0.583	rs28548548	chr5:57073003	A/T	cg08523694	chr5:57076192	NA	0.51	7.12	0.31	4.03e-12	Birth weight;
LGG	cis	rs457717	0.730	rs460431	chr5:75946044	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.48	-0.33	3.78e-13	Total body bone mineral density;
LGG	cis	rs10214930	0.697	rs12700817	chr7:27591093	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.8	0.3	3.14e-11	Hypospadias;
LGG	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	10.15	0.43	5.61e-22	Chronic sinus infection;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.812	rs73069213	chr3:41940590	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7177699	0.557	rs12898293	chr15:79112568	C/A	cg00540400	chr15:79124168	NA	0.53	11.0	0.46	3.79e-25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.69	0.34	8.95e-14	Longevity;
LGG	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.41	-0.44	6.24e-23	Chronic sinus infection;
LGG	cis	rs7017914	0.967	rs12679261	chr8:71844649	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.89	-0.31	1.81e-11	Bone mineral density;
LGG	cis	rs9815354	1.000	rs9824731	chr3:41889698	G/T	cg03022575	chr3:42003672	ULK4	0.73	9.19	0.39	1.34e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg15437457	chr12:1100385	ERC1	-0.4	-6.81	-0.3	3.13e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7633770	0.735	rs11719679	chr3:46687684	A/G	cg11219411	chr3:46661640	NA	-0.54	-12.03	-0.49	3.38e-29	Coronary artery disease;
LGG	trans	rs12310956	0.527	rs10772117	chr12:33900096	C/T	cg26384229	chr12:38710491	ALG10B	0.66	12.63	0.51	1.2e-31	Morning vs. evening chronotype;
LGG	trans	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg06521331	chr12:34319734	NA	0.44	7.93	0.35	1.66e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72781680	0.898	rs72786276	chr2:24062566	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.66	0.41	3.23e-20	Lymphocyte counts;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg19635926	chr16:89946313	TCF25	0.71	8.45	0.37	3.69e-16	Skin colour saturation;
LGG	cis	rs6546550	0.901	rs6546553	chr2:70111711	C/A	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.93	-0.35	1.62e-14	Prevalent atrial fibrillation;
LGG	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg03733263	chr8:22462867	KIAA1967	1.13	33.35	0.84	3.35e-125	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg26513180	chr16:89883248	FANCA	0.88	8.51	0.37	2.5e-16	Skin colour saturation;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg14403583	chr14:105418241	AHNAK2	-0.76	-15.17	-0.58	1.65e-42	Rheumatoid arthritis;
LGG	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08045932	chr20:61659980	NA	0.6	13.11	0.52	1.27e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7666738	0.830	rs6852015	chr4:99054373	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.08e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9309711	0.813	rs11690865	chr2:3471950	C/T	cg10845886	chr2:3471009	TTC15	-0.74	-14.35	-0.55	6.53e-39	Neurofibrillary tangles;
LGG	cis	rs9341835	0.593	rs9449291	chr6:64162953	G/A	cg00787780	chr6:64151745	NA	0.41	7.22	0.32	2.15e-12	Schizophrenia;
LGG	cis	rs7917772	0.636	rs1475644	chr10:104491164	G/A	cg04362960	chr10:104952993	NT5C2	-0.48	-7.96	-0.35	1.37e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4740619	0.792	rs183928	chr9:15611506	C/A	cg14451791	chr9:16040625	NA	-0.34	-8.73	-0.38	4.6e-17	Body mass index;
LGG	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-12.23	-0.49	5.36e-30	Vitiligo;
LGG	cis	rs953387	1.000	rs1401687	chr2:136908062	G/C	cg05194412	chr2:137003533	NA	-0.32	-6.89	-0.31	1.79e-11	Arthritis (juvenile idiopathic);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.41	7.02	0.31	8.05e-12	Bipolar disorder;
LGG	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg03606772	chr1:152487856	CRCT1	0.3	7.18	0.32	2.88e-12	Hair morphology;
LGG	cis	rs7772486	0.875	rs1331639	chr6:146431869	A/G	cg23711669	chr6:146136114	FBXO30	-0.38	-6.77	-0.3	3.8e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9300255	0.512	rs2851436	chr12:123667354	G/T	cg00376283	chr12:123451042	ABCB9	0.64	9.93	0.42	3.35e-21	Neutrophil percentage of white cells;
LGG	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg24692254	chr21:30365293	RNF160	-1.03	-29.24	-0.81	3.05e-107	Dental caries;
LGG	cis	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg26384229	chr12:38710491	ALG10B	1.07	28.94	0.8	6.99e-106	Heart rate;
LGG	cis	rs3849570	0.695	rs6809528	chr3:81872048	A/C	cg07356753	chr3:81810745	GBE1	-0.42	-7.24	-0.32	1.84e-12	Waist circumference;Body mass index;
LGG	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs2304069	0.729	rs2066933	chr5:149433597	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.5	6.68	0.3	6.71e-11	HIV-1 control;
LGG	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg08048268	chr3:133502702	NA	-0.61	-11.38	-0.47	1.25e-26	Iron status biomarkers;
LGG	cis	rs1707322	1.000	rs10890381	chr1:46451771	T/G	cg03146154	chr1:46216737	IPP	0.52	9.58	0.41	5.72e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7551222	1.000	rs7551222	chr1:204599295	G/A	cg20240347	chr1:204465584	NA	-0.41	-7.49	-0.33	3.52e-13	Schizophrenia;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.04	0.57	6.41e-42	Platelet count;
LGG	cis	rs17683430	0.558	rs4488763	chr22:32380164	C/G	cg00543991	chr22:32367038	NA	0.49	6.7	0.3	6.24e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs3741151	0.686	rs7125598	chr11:73160589	C/T	cg17517138	chr11:73019481	ARHGEF17	-0.76	-8.23	-0.36	1.87e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs656319	0.513	rs6985941	chr8:9983179	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.88	-0.34	2.37e-14	Myopia (pathological);
LGG	trans	rs6076960	0.684	rs3909041	chr20:6249598	C/G	cg24759859	chr6:86352639	SYNCRIP	0.44	7.12	0.31	4.05e-12	Smooth-surface caries;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21047354	chr17:75954694	NA	0.45	6.74	0.3	4.79e-11	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.78	-0.3	3.71e-11	Bipolar disorder;
LGG	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg03477792	chr4:77819574	ANKRD56	0.51	8.95	0.38	8.44e-18	Emphysema distribution in smoking;
LGG	cis	rs4936894	0.500	rs4935873	chr11:124103523	G/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.48	-0.44	3.33e-23	Aging (time to death);
LGG	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.28	-0.32	1.42e-12	Systemic lupus erythematosus;
LGG	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	trans	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg19862616	chr7:65841803	NCRNA00174	0.74	7.68	0.34	9.68e-14	Mononucleosis;
LGG	trans	rs11875185	0.510	rs80298740	chr18:55609962	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.883	rs17489682	chr5:152312444	T/G	cg12297329	chr5:152029980	NA	-0.62	-11.35	-0.47	1.68e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4262150	0.883	rs72799202	chr5:152193105	A/C	cg12297329	chr5:152029980	NA	-0.68	-12.82	-0.51	2.03e-32	Bipolar disorder and schizophrenia;
LGG	trans	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.49	-0.33	3.6e-13	Joint mobility (Beighton score);
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg14500267	chr11:67383377	NA	0.46	8.67	0.37	7.29e-17	Mean corpuscular volume;
LGG	cis	rs75920871	0.623	rs625145	chr11:116727936	A/T	cg20608306	chr11:116969690	SIK3	-0.3	-7.6	-0.33	1.61e-13	Subjective well-being;
LGG	cis	rs2963155	0.518	rs56150733	chr5:142765099	T/C	cg17617527	chr5:142782415	NR3C1	1.0	12.72	0.51	5.37e-32	Breast cancer;
LGG	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.27	-42.87	-0.89	2.59e-163	Myeloid white cell count;
LGG	cis	rs7818345	1.000	rs4392915	chr8:19308938	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.66	0.3	7.74e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2386661	1.000	rs2386661	chr10:5670275	A/G	cg26603656	chr10:5671107	NA	0.34	7.19	0.32	2.64e-12	Breast cancer;
LGG	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg03961551	chr1:25251730	RUNX3	0.46	11.63	0.48	1.33e-27	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.3	-0.5	2.74e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg13010199	chr12:38710504	ALG10B	-0.42	-7.56	-0.33	2.22e-13	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg25019033	chr10:957182	NA	-0.53	-9.09	-0.39	2.86e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9976767	0.646	rs876497	chr21:43841905	G/A	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.05	-0.39	3.95e-18	Type 1 diabetes;
LGG	cis	rs17453880	0.853	rs60230149	chr5:151965041	G/A	cg12297329	chr5:152029980	NA	-0.86	-21.98	-0.71	7.27e-74	Subjective well-being;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg21165519	chr14:105310921	NA	0.41	6.87	0.3	2.06e-11	IgG glycosylation;
LGG	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.51	0.5	3.95e-31	Motion sickness;
LGG	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.34	0.32	9.7e-13	Schizophrenia;
LGG	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.67	7.52	0.33	2.87e-13	Initial pursuit acceleration;
LGG	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg02023728	chr11:77925099	USP35	0.46	8.15	0.35	3.53e-15	Testicular germ cell tumor;
LGG	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg12292205	chr6:26970375	C6orf41	-0.44	-7.8	-0.34	4.21e-14	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.17	-0.32	2.9e-12	Colorectal cancer;
LGG	cis	rs2270450	1.000	rs7739815	chr6:46624656	A/T	cg10156739	chr6:46714674	LOC100287718	-0.34	-8.03	-0.35	7.99e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	trans	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.59	-11.31	-0.47	2.25e-26	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg15268244	chr15:77196840	NA	0.32	7.04	0.31	7.07e-12	Blood metabolite levels;
LGG	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.78	-0.3	3.63e-11	Mood instability;
LGG	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg10057126	chr4:77819792	ANKRD56	0.35	6.84	0.3	2.49e-11	Emphysema distribution in smoking;
LGG	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg01557791	chr16:72042693	DHODH	-0.59	-9.07	-0.39	3.36e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9463078	0.790	rs1324531	chr6:45136224	T/C	cg25276700	chr6:44698697	NA	-0.39	-8.34	-0.36	8.44e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6547741	0.743	rs7564625	chr2:27862397	C/T	cg27432699	chr2:27873401	GPN1	-0.76	-15.96	-0.6	5.18e-46	Oral cavity cancer;
LGG	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg01620082	chr3:125678407	NA	-0.64	-7.06	-0.31	6.31e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7572733	0.742	rs3828317	chr2:198495431	G/C	cg00792783	chr2:198669748	PLCL1	0.4	6.71	0.3	5.54e-11	Dermatomyositis;
LGG	cis	rs1862618	0.671	rs2591964	chr5:56236900	T/G	cg08400814	chr5:56204995	C5orf35	0.4	7.25	0.32	1.78e-12	Initial pursuit acceleration;
LGG	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg24375607	chr4:120327624	NA	0.67	11.22	0.46	5.25e-26	Corneal astigmatism;
LGG	cis	rs4430311	0.688	rs4518884	chr1:243990833	C/T	cg25706552	chr1:244017396	NA	-0.65	-16.13	-0.6	8.98e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs2880765	0.835	rs4526974	chr15:86024284	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-7.52	-0.33	2.92e-13	Coronary artery disease;
LGG	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15557168	chr22:42548783	NA	-0.34	-7.68	-0.34	9.53e-14	Cognitive function;
LGG	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.21e-18	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.42	-6.83	-0.3	2.67e-11	Prudent dietary pattern;
LGG	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.38	-0.36	6.41e-16	Breast cancer;
LGG	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15664640	chr17:80829946	TBCD	-0.68	-10.1	-0.43	8.08e-22	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.27	-0.32	1.51e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg06925179	chr17:43578568	NA	-0.4	-9.62	-0.41	4.41e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg21699342	chr2:239360505	ASB1	-0.39	-7.47	-0.33	4.03e-13	Multiple system atrophy;
LGG	cis	rs7216064	1.000	rs12602655	chr17:65909442	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.69e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.43	-6.98	-0.31	1.03e-11	Longevity;Endometriosis;
LGG	cis	rs394563	0.534	rs388335	chr6:149791986	T/C	cg14343457	chr6:149716235	MAP3K7IP2	-0.39	-6.83	-0.3	2.68e-11	Dupuytren's disease;
LGG	cis	rs367615	0.704	rs7726991	chr5:108847434	C/T	cg17395555	chr5:108820864	NA	0.87	15.86	0.59	1.53e-45	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg18187862	chr3:45730750	SACM1L	-0.45	-7.61	-0.33	1.56e-13	Primary sclerosing cholangitis;
LGG	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs1577917	1.000	rs12661204	chr6:86678586	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.17	-0.43	4.64e-22	Response to antipsychotic treatment;
LGG	cis	rs427394	0.582	rs4701751	chr5:6704137	C/T	cg15145174	chr5:6755386	POLS	-0.4	-7.3	-0.32	1.3e-12	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg19223190	chr17:80058835	NA	0.44	8.56	0.37	1.65e-16	Life satisfaction;
LGG	cis	rs7267979	0.844	rs4815413	chr20:25359229	G/T	cg06421707	chr20:25228305	PYGB	-0.43	-9.11	-0.39	2.58e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg26384229	chr12:38710491	ALG10B	0.62	12.12	0.49	1.52e-29	Morning vs. evening chronotype;
LGG	cis	rs240764	0.781	rs239227	chr6:101107089	C/G	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs55665837	0.502	rs4757269	chr11:14836192	A/C	cg18937875	chr11:14930189	NA	-0.47	-7.6	-0.33	1.67e-13	Vitamin D levels;
LGG	cis	rs4417704	0.551	rs4675841	chr2:241876580	A/G	cg26818257	chr2:241905806	NA	0.47	10.47	0.44	3.51e-23	Joint mobility (Beighton score);
LGG	cis	rs7192750	0.586	rs4788584	chr16:71993386	A/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.74	0.45	3.7e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg11764359	chr7:65958608	NA	0.64	9.91	0.42	3.85e-21	Aortic root size;
LGG	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg05234568	chr11:5960015	NA	-0.57	-9.41	-0.4	2.39e-19	DNA methylation (variation);
LGG	cis	rs911263	0.560	rs12896939	chr14:68812662	T/C	cg18825221	chr14:68749962	RAD51L1	0.38	8.28	0.36	1.37e-15	Primary biliary cholangitis;
LGG	cis	rs963731	0.579	rs10190377	chr2:39250673	A/G	cg04010122	chr2:39346883	SOS1	-0.74	-7.59	-0.33	1.79e-13	Corticobasal degeneration;
LGG	cis	rs2303319	1.000	rs62194247	chr2:162113406	G/A	cg13806767	chr2:162164127	PSMD14	-0.65	-7.54	-0.33	2.43e-13	Cognitive function;
LGG	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg17145862	chr1:211918768	LPGAT1	0.8	17.33	0.63	3.26e-52	Leprosy;
LGG	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17219203	chr10:38645113	HSD17B7P2	0.45	7.36	0.32	8.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6500395	1.000	rs1420701	chr16:48730873	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.51e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2865126	0.779	rs7228152	chr18:10758384	C/T	cg21165219	chr18:10698044	FAM38B	-0.45	-7.27	-0.32	1.51e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg19676328	chr12:49525230	TUBA1B	-0.65	-10.14	-0.43	6.1e-22	Total cholesterol levels;
LGG	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.48	8.97	0.38	7.69e-18	Colorectal cancer;
LGG	trans	rs11039798	0.925	rs10769373	chr11:48531980	T/A	cg03929089	chr4:120376271	NA	0.73	8.42	0.36	4.71e-16	Axial length;
LGG	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg02574844	chr11:5959923	NA	-0.54	-8.74	-0.38	4.29e-17	DNA methylation (variation);
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	5.07e-34	Prudent dietary pattern;
LGG	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg23625390	chr15:77176239	SCAPER	0.5	9.93	0.42	3.52e-21	Blood metabolite levels;
LGG	cis	rs6684428	1.000	rs12141666	chr1:56370556	T/C	cg11651538	chr1:56320950	NA	-0.75	-12.82	-0.51	2.04e-32	Airflow obstruction;
LGG	trans	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg05926928	chr17:57297772	GDPD1	-0.84	-11.66	-0.48	1.04e-27	Opioid sensitivity;
LGG	trans	rs3942852	0.568	rs10769312	chr11:48094769	C/T	cg15704280	chr7:45808275	SEPT13	0.68	10.75	0.45	3.27e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg05084668	chr3:125655381	ALG1L	-0.66	-8.32	-0.36	9.9e-16	Blood pressure (smoking interaction);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg05165339	chr4:1420672	NA	-0.36	-9.16	-0.39	1.7e-18	Longevity;
LGG	cis	rs8072100	0.846	rs6503796	chr17:45765249	T/C	cg08085267	chr17:45401833	C17orf57	-0.5	-9.25	-0.39	8.37e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2274273	0.624	rs7151581	chr14:55788445	A/G	cg04306507	chr14:55594613	LGALS3	-0.54	-12.57	-0.5	2.26e-31	Protein biomarker;
LGG	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.28	-0.32	1.41e-12	Triglycerides;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10132348	chr4:6784379	KIAA0232	-0.43	-6.99	-0.31	9.85e-12	Pancreatic cancer;
LGG	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.64	-0.44	8.14e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg22535103	chr8:58192502	C8orf71	-0.47	-7.45	-0.33	4.48e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6429082	0.791	rs291394	chr1:235651682	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.1	0.42	8.3e-22	Adiposity;
LGG	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg03959625	chr15:84868606	LOC388152	0.58	9.12	0.39	2.34e-18	Schizophrenia;
LGG	cis	rs7301016	0.948	rs7303825	chr12:62921978	A/G	cg11441379	chr12:63026424	NA	0.66	8.74	0.38	4.31e-17	IgG glycosylation;
LGG	cis	rs7267979	0.966	rs2424715	chr20:25420077	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.38	0.43	8.06e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4474465	0.850	rs10793327	chr11:78256841	A/C	cg27205649	chr11:78285834	NARS2	0.52	8.82	0.38	2.36e-17	Alzheimer's disease (survival time);
LGG	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg24596788	chr1:163392923	NA	-0.68	-12.79	-0.51	2.7e-32	Motion sickness;
LGG	trans	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg05926928	chr17:57297772	GDPD1	0.48	7.5	0.33	3.18e-13	Schizophrenia;
LGG	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg22968622	chr17:43663579	NA	1.09	21.29	0.7	1.19e-70	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.34	0.36	8.79e-16	Monocyte count;
LGG	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.79	-0.34	4.5e-14	Type 2 diabetes;
LGG	cis	rs870825	0.549	rs10015956	chr4:185614705	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs4975616	0.869	rs465498	chr5:1325803	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.9	-18.74	-0.66	9.64e-59	Lung cancer;
LGG	cis	rs9878978	1.000	rs9834459	chr3:2484710	G/A	cg21928760	chr3:2462534	CNTN4	0.39	8.66	0.37	7.62e-17	Blood pressure (smoking interaction);
LGG	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.52	0.37	2.19e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12107626	chr17:39992626	KLHL10;NT5C3L	0.52	7.77	0.34	5.26e-14	Gut microbiome composition (summer);
LGG	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg17757837	chr7:157058334	UBE3C	-0.95	-22.04	-0.72	3.84e-74	Body mass index;
LGG	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg03929089	chr4:120376271	NA	0.86	17.37	0.63	2.14e-52	Coronary artery disease;
LGG	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg08344181	chr3:125677491	NA	-0.63	-7.92	-0.35	1.76e-14	Depression;
LGG	cis	rs892961	0.932	rs7216155	chr17:75405155	C/G	cg05865280	chr17:75406074	SEPT9	0.42	9.7	0.41	2.22e-20	Airflow obstruction;
LGG	trans	rs2235573	0.527	rs139884	chr22:38369976	A/G	cg19894588	chr14:64061835	NA	0.63	10.42	0.44	5.57e-23	Glioblastoma;Glioma;
LGG	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg22681709	chr2:178499509	PDE11A	-0.39	-7.47	-0.33	3.94e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2412208	0.727	rs7543531	chr1:7072726	A/G	cg20434152	chr1:7120926	CAMTA1	0.4	8.01	0.35	9.51e-15	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs7828089	0.819	rs4872488	chr8:22257012	G/A	cg13512537	chr8:22265999	SLC39A14	-0.37	-6.7	-0.3	5.95e-11	Verbal declarative memory;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg19635926	chr16:89946313	TCF25	0.81	8.33	0.36	8.92e-16	Skin colour saturation;
LGG	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg14784868	chr12:69753453	YEATS4	-1.01	-24.33	-0.75	7.5e-85	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4481887	0.508	rs4474292	chr1:248396646	G/A	cg00666640	chr1:248458726	OR2T12	0.46	6.96	0.31	1.17e-11	Common traits (Other);
LGG	cis	rs59918340	0.764	rs10101692	chr8:142230823	C/T	cg03653399	chr8:142233436	SLC45A4	0.43	8.35	0.36	8.13e-16	Immature fraction of reticulocytes;
LGG	cis	rs77972916	0.611	rs61552842	chr2:43584036	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-8.38	-0.36	6.59e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg15269541	chr15:43626905	ADAL	-0.45	-7.82	-0.34	3.68e-14	Lung cancer in ever smokers;
LGG	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	12.22	0.49	5.75e-30	Lung cancer in ever smokers;
LGG	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.51	-0.33	3.07e-13	Blood pressure (smoking interaction);
LGG	cis	rs7572733	0.773	rs7603839	chr2:198534708	C/T	cg00792783	chr2:198669748	PLCL1	0.41	6.82	0.3	2.88e-11	Dermatomyositis;
LGG	cis	rs7336332	0.628	rs9581854	chr13:28017782	C/T	cg01674679	chr13:27998804	GTF3A	-0.67	-8.75	-0.38	4.12e-17	Weight;
LGG	cis	rs2985684	0.740	rs2883438	chr14:50044392	T/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.72	-0.41	1.86e-20	Carotid intima media thickness;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	5.76e-37	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs10028505	chr4:98962310	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.84	0.79	6.33e-101	Parkinson's disease;
LGG	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg19676328	chr12:49525230	TUBA1B	-0.65	-10.49	-0.44	2.96e-23	Total cholesterol levels;
LGG	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	11.07	0.46	1.96e-25	Lung cancer in ever smokers;
LGG	cis	rs9914988	0.943	rs9891925	chr17:27104540	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg25482853	chr8:67687455	SGK3	1.03	12.57	0.5	2.12e-31	Lung disease severity in cystic fibrosis;
LGG	trans	rs6076960	0.652	rs3905171	chr20:6211177	T/C	cg21095983	chr6:86352623	SYNCRIP	0.55	10.34	0.43	1.06e-22	Smooth-surface caries;
LGG	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.97	0.52	5.17e-33	IgG glycosylation;
LGG	cis	rs2797160	1.000	rs1739352	chr6:126005310	T/C	cg05901451	chr6:126070800	HEY2	-0.44	-7.31	-0.32	1.18e-12	Endometrial cancer;
LGG	cis	rs7444	0.941	rs4820091	chr22:21940189	T/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.79	-0.34	4.35e-14	Systemic lupus erythematosus;
LGG	cis	rs4684776	1.000	rs1546230	chr3:11471770	G/A	cg24705426	chr3:11550659	ATG7	-0.44	-7.99	-0.35	1.05e-14	Small vessel stroke;
LGG	trans	rs61931739	0.649	rs864174	chr12:33729352	C/A	cg26384229	chr12:38710491	ALG10B	0.48	8.59	0.37	1.35e-16	Morning vs. evening chronotype;
LGG	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg12046867	chr14:103022105	NA	-0.81	-15.71	-0.59	6.71e-45	Platelet count;
LGG	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg25237894	chr2:233734115	C2orf82	0.66	12.71	0.51	6.05e-32	Coronary artery disease;
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.38e-12	Height;
LGG	cis	rs10773046	0.740	rs11057381	chr12:124357857	C/G	cg18594669	chr12:124364423	DNAH10	0.33	6.75	0.3	4.57e-11	Osteoarthritis (hip);
LGG	cis	rs9814567	1.000	rs6766818	chr3:134226159	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.08	-0.52	1.7e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs921968	0.541	rs562510	chr2:219443001	A/C	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12410462	0.681	rs6670816	chr1:227610592	G/T	cg23173402	chr1:227635558	NA	-0.68	-11.29	-0.46	2.9e-26	Major depressive disorder;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.87e-14	Lung cancer;
LGG	cis	rs911555	0.723	rs6575986	chr14:103886671	G/A	cg24130564	chr14:104152367	KLC1	-0.38	-7.16	-0.32	3.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9783347	1.000	rs4150610	chr11:18364140	A/G	cg15585147	chr11:18324498	HPS5	0.44	9.34	0.4	4.05e-19	Pancreatic cancer;
LGG	trans	rs7395662	0.927	rs4882141	chr11:48627525	C/T	cg00717180	chr2:96193071	NA	-0.39	-6.71	-0.3	5.75e-11	HDL cholesterol;
LGG	cis	rs9815354	0.767	rs73830585	chr3:42003698	T/A	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg08344181	chr3:125677491	NA	-0.68	-7.18	-0.32	2.85e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg08508325	chr11:3079039	CARS	-0.62	-13.91	-0.54	5.4e-37	Longevity;
LGG	cis	rs7215564	0.730	rs34806161	chr17:78573839	T/C	cg16980736	chr17:78789706	RPTOR	-0.68	-8.48	-0.37	3.1e-16	Myopia (pathological);
LGG	cis	rs7202877	0.706	rs467780	chr16:75437138	A/G	cg03315344	chr16:75512273	CHST6	-0.52	-7.26	-0.32	1.65e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs10754283	0.934	rs10754284	chr1:90113702	A/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9487094	0.626	rs12204548	chr6:110036707	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.65	0.33	1.19e-13	Height;
LGG	cis	rs4888262	0.526	rs8062959	chr16:74627628	T/C	cg01733217	chr16:74700730	RFWD3	0.89	18.21	0.65	2.89e-56	Testicular germ cell tumor;
LGG	cis	rs7552167	0.789	rs6424162	chr1:24512576	T/C	cg17246694	chr1:24480847	IL28RA	0.51	6.65	0.3	8.04e-11	Psoriasis vulgaris;
LGG	cis	rs58649573	0.509	rs4836956	chr9:126788836	C/T	cg14112217	chr9:126806003	NA	0.39	7.68	0.34	9.86e-14	Post-traumatic stress disorder;
LGG	trans	rs4427176	0.507	rs11785927	chr8:9587740	G/A	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Mosquito bite size;
LGG	cis	rs4740619	0.811	rs7035863	chr9:15683175	G/C	cg14451791	chr9:16040625	NA	-0.33	-8.25	-0.36	1.68e-15	Body mass index;
LGG	cis	rs36051895	0.632	rs62541959	chr9:5175687	G/C	cg02405213	chr9:5042618	JAK2	-0.74	-13.48	-0.53	3.49e-35	Pediatric autoimmune diseases;
LGG	cis	rs4363385	0.553	rs1415972	chr1:152953552	A/G	cg13444842	chr1:152974279	SPRR3	0.51	10.4	0.44	6.46e-23	Inflammatory skin disease;
LGG	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg11366901	chr6:160182831	ACAT2	1.05	16.2	0.6	4.33e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7412746	0.611	rs7556661	chr1:150892009	C/T	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.28	0.32	1.48e-12	Obesity-related traits;
LGG	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg02151108	chr14:50098012	C14orf104	-0.49	-10.61	-0.44	1.12e-23	Carotid intima media thickness;
LGG	cis	rs4771450	0.962	rs4587823	chr13:103970461	C/T	cg02987523	chr13:103978230	NA	-0.32	-6.88	-0.3	1.95e-11	Uric acid levels;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg18279126	chr7:2041391	MAD1L1	-0.32	-6.71	-0.3	5.71e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.49	0.56	1.62e-39	Colorectal cancer;
LGG	cis	rs7166081	1.000	rs9806377	chr15:67612062	A/G	cg05925327	chr15:68127851	NA	-0.33	-7.06	-0.31	6.3e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2243480	1.000	rs57057549	chr7:65405738	A/G	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	17.84	0.64	1.47e-54	Personality dimensions;
LGG	trans	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg25482853	chr8:67687455	SGK3	0.68	9.75	0.41	1.44e-20	Obesity-related traits;
LGG	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08704250	chr15:31115839	NA	-0.43	-7.87	-0.34	2.61e-14	Huntington's disease progression;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09695652	chr3:139108473	COPB2	0.45	7.28	0.32	1.48e-12	Cognitive performance;
LGG	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg03342759	chr3:160939853	NMD3	-0.65	-10.75	-0.45	3.22e-24	Parkinson's disease;
LGG	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg27144592	chr16:783916	NARFL	0.8	14.15	0.55	5e-38	Height;
LGG	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg07061783	chr6:25882402	NA	-0.63	-10.48	-0.44	3.3e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg10122326	chr6:28072925	NA	0.97	7.37	0.32	7.88e-13	Hip circumference adjusted for BMI;
LGG	cis	rs972578	0.791	rs2092209	chr22:43318648	G/C	cg01576275	chr22:43409880	NA	-0.22	-6.72	-0.3	5.38e-11	Mean platelet volume;
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.54	-0.41	8.12e-20	Lewy body disease;
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11645453	chr3:52864694	ITIH4	0.41	6.89	0.31	1.77e-11	Bipolar disorder;
LGG	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.05	0.31	6.38e-12	Hip circumference adjusted for BMI;
LGG	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.14	0.7	6.5e-70	Chronic sinus infection;
LGG	cis	rs6032067	0.929	rs6032049	chr20:43825556	C/T	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25346576	chr17:28443852	CCDC55;MIR423	0.49	8.01	0.35	9.68e-15	Cognitive performance;
LGG	trans	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg21775007	chr8:11205619	TDH	0.62	10.18	0.43	4.21e-22	Retinal vascular caliber;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg01059449	chr18:44338099	ST8SIA5	-0.37	-7.94	-0.35	1.53e-14	Personality dimensions;
LGG	cis	rs72945132	0.882	rs2276001	chr11:70181560	T/C	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.55e-15	Coronary artery disease;
LGG	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg25566285	chr7:158114605	PTPRN2	0.7	11.69	0.48	7.9e-28	Response to amphetamines;
LGG	cis	rs34734847	0.806	rs696340	chr12:121173653	A/T	cg21892295	chr12:121157589	UNC119B	-0.4	-7.54	-0.33	2.45e-13	Mean corpuscular volume;
LGG	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg13271783	chr10:134563150	INPP5A	-0.54	-7.87	-0.34	2.56e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4363385	0.719	rs6587714	chr1:152933023	T/C	cg13444842	chr1:152974279	SPRR3	-0.41	-7.78	-0.34	4.85e-14	Inflammatory skin disease;
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.36	-0.36	7.37e-16	Dementia with Lewy bodies;
LGG	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg16141378	chr3:129829833	LOC729375	-0.45	-11.07	-0.46	1.98e-25	Mood instability;
LGG	cis	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg12826209	chr6:26865740	GUSBL1	0.77	8.18	0.36	2.86e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10979	0.557	rs9390116	chr6:143907577	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-8.07	-0.35	6.26e-15	Hypospadias;
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03517284	chr6:25882590	NA	-0.52	-9.95	-0.42	2.93e-21	Blood metabolite levels;
LGG	cis	rs28595532	0.623	rs71608363	chr4:119227259	T/C	cg21605333	chr4:119757512	SEC24D	0.88	9.48	0.4	1.28e-19	Cannabis dependence symptom count;
LGG	trans	rs7937682	0.562	rs955744	chr11:111374334	C/T	cg18187862	chr3:45730750	SACM1L	-0.43	-7.32	-0.32	1.08e-12	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.12	0.55	6.55e-38	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg04025307	chr7:1156635	C7orf50	0.66	8.64	0.37	9.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg03805757	chr16:71968109	PKD1L3	-0.47	-8.68	-0.37	6.55e-17	Post bronchodilator FEV1;
LGG	cis	rs6963495	0.592	rs114793754	chr7:105152162	G/C	cg19920283	chr7:105172520	RINT1	0.6	7.91	0.34	1.95e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs769267	0.501	rs2965187	chr19:19522970	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.43	9.75	0.41	1.46e-20	Tonsillectomy;
LGG	trans	rs11671005	0.610	rs4756	chr19:59074653	T/C	cg22037779	chr5:139682734	PFDN1	-0.44	-6.86	-0.3	2.21e-11	Mean platelet volume;
LGG	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg15665833	chr6:26285013	NA	0.35	6.65	0.3	8.49e-11	Educational attainment;
LGG	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg12463550	chr7:65579703	CRCP	-0.75	-8.0	-0.35	1.04e-14	Diabetic kidney disease;
LGG	cis	rs2067615	0.524	rs1882543	chr12:107067160	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-11.65	-0.48	1.08e-27	Heart rate;
LGG	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.61	-0.51	1.5e-31	Bipolar disorder;
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.81	-0.3	2.96e-11	Testicular germ cell tumor;
LGG	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg25566285	chr7:158114605	PTPRN2	-0.95	-24.69	-0.75	1.7e-86	Calcium levels;
LGG	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg04490037	chr7:50633773	DDC	0.31	6.87	0.3	2.13e-11	Systemic sclerosis;
LGG	cis	rs7223966	1.000	rs9893348	chr17:61676534	G/T	cg05941027	chr17:61774174	LIMD2	0.33	8.07	0.35	5.97e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs701145	0.585	rs1727887	chr3:153839465	G/T	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs151234	0.548	rs17639997	chr16:28600282	G/T	cg01378222	chr16:28622494	SULT1A1	-0.71	-6.82	-0.3	2.9e-11	Platelet distribution width;
LGG	cis	rs3735485	0.800	rs1859489	chr7:45027808	G/A	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.23	-0.36	1.99e-15	Calcium levels;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6594713	0.717	rs2972689	chr5:112945966	C/T	cg12552261	chr5:112820674	MCC	0.53	7.02	0.31	7.92e-12	Brain cytoarchitecture;
LGG	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26076054	chr5:421317	AHRR	-0.44	-6.89	-0.3	1.85e-11	Cystic fibrosis severity;
LGG	trans	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg14227996	chr4:17616232	MED28	0.68	8.27	0.36	1.46e-15	Opioid sensitivity;
LGG	cis	rs2304069	0.954	rs9324638	chr5:149400718	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.85	-12.4	-0.5	1.07e-30	HIV-1 control;
LGG	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg06640241	chr16:89574553	SPG7	0.76	13.16	0.52	7.84e-34	Multiple myeloma (IgH translocation);
LGG	cis	rs2120019	0.938	rs2304903	chr15:75315778	A/G	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.39	-0.65	4.32e-57	Blood trace element (Zn levels);
LGG	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.2	-0.77	1.87e-93	Renal cell carcinoma;
LGG	cis	rs12049351	0.774	rs767303	chr1:229698931	A/C	cg13547644	chr1:229569608	ACTA1	0.29	6.74	0.3	4.65e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11890956	chr21:40555474	PSMG1	-0.99	-21.49	-0.71	1.51e-71	Cognitive function;
LGG	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg16751781	chr15:78858589	CHRNA5	0.45	8.85	0.38	1.85e-17	Sudden cardiac arrest;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.63	-11.04	-0.46	2.67e-25	Obesity-related traits;
LGG	cis	rs537930	0.925	rs72800392	chr5:134356061	C/T	cg24576358	chr5:134350122	NA	0.43	8.61	0.37	1.15e-16	Height;
LGG	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg20573242	chr4:122745356	CCNA2	0.54	10.17	0.43	4.54e-22	Type 2 diabetes;
LGG	cis	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.15	-0.46	9.72e-26	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.61	0.41	4.66e-20	Schizophrenia;
LGG	cis	rs568617	0.953	rs645900	chr11:65648135	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.05	-0.31	6.71e-12	Crohn's disease;
LGG	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg08885076	chr2:99613938	TSGA10	0.59	12.05	0.49	2.85e-29	Chronic sinus infection;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs5769707	0.681	rs2071902	chr22:50034538	G/C	cg06623630	chr22:50017776	C22orf34	-0.5	-10.23	-0.43	2.71e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.36	-0.4	3.61e-19	Post bronchodilator FEV1;
LGG	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06108461	chr20:60628389	TAF4	-1.03	-20.3	-0.69	5.16e-66	Body mass index;
LGG	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg09448879	chr15:79043637	NA	-0.43	-8.47	-0.37	3.25e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs3087591	1.000	rs2905870	chr17:29521833	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.36	0.56	5.86e-39	Hip circumference;
LGG	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.9	-0.42	4.22e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05165339	chr4:1420672	NA	-0.27	-6.97	-0.31	1.13e-11	Obesity-related traits;
LGG	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	trans	rs2018683	0.707	rs4722877	chr7:28972906	A/G	cg19402173	chr7:128379420	CALU	-0.54	-9.37	-0.4	3.31e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs72634258	0.945	rs7539255	chr1:8133352	T/C	cg00042356	chr1:8021962	PARK7	0.82	10.06	0.42	1.11e-21	Inflammatory bowel disease;
LGG	cis	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg07274523	chr3:49395745	GPX1	0.57	9.68	0.41	2.65e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7107174	1.000	rs11237456	chr11:78040780	C/G	cg02023728	chr11:77925099	USP35	0.46	8.2	0.36	2.39e-15	Testicular germ cell tumor;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg05335186	chr13:53173507	NA	0.57	12.52	0.5	3.44e-31	Lewy body disease;
LGG	cis	rs9309473	0.950	rs13408433	chr2:73883072	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.26	-0.32	1.64e-12	Metabolite levels;
LGG	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.81	-0.34	3.93e-14	Psoriasis;
LGG	cis	rs7444	0.941	rs2283790	chr22:21956653	C/T	cg15846791	chr22:21984385	YDJC	0.46	6.98	0.31	1.01e-11	Systemic lupus erythematosus;
LGG	cis	rs7666738	0.830	rs880472	chr4:98922595	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.7	0.34	8.6e-14	Menopause (age at onset);
LGG	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.44	-7.97	-0.35	1.21e-14	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7924176	0.580	rs7912162	chr10:75921763	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.87	-0.3	2.09e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs300703	0.542	rs189762	chr2:180079	A/T	cg24565620	chr2:194026	NA	0.67	10.52	0.44	2.41e-23	Blood protein levels;
LGG	cis	rs1371867	0.846	rs1660332	chr8:101309490	A/G	cg06636551	chr8:101224915	SPAG1	0.46	8.52	0.37	2.33e-16	Atrioventricular conduction;
LGG	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg08344181	chr3:125677491	NA	-0.52	-7.12	-0.31	4.22e-12	Depression;
LGG	cis	rs950169	0.545	rs4354897	chr15:84644971	T/C	cg24253500	chr15:84953950	NA	0.44	7.02	0.31	7.93e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg05973401	chr12:123451056	ABCB9	0.46	7.76	0.34	5.49e-14	Platelet count;
LGG	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg17830980	chr10:43048298	ZNF37B	0.44	9.84	0.42	7.09e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs9811920	0.609	rs17174947	chr3:99598884	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg05096777	chr10:104283225	SUFU	0.31	6.82	0.3	2.8e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4262150	0.810	rs4958562	chr5:151964590	C/T	cg12297329	chr5:152029980	NA	-0.8	-15.3	-0.58	4.69e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs67366981	0.925	rs8007762	chr14:77708465	A/C	cg22824376	chr14:77648248	TMEM63C	0.71	7.66	0.34	1.13e-13	Obsessive-compulsive symptoms;
LGG	cis	rs9788682	0.747	rs6495308	chr15:78907656	A/G	cg07120314	chr15:79043507	NA	0.37	6.79	0.3	3.55e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12220238	0.915	rs10824197	chr10:76282793	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.15	0.35	3.46e-15	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs503734	0.562	rs7636475	chr3:101198604	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg23594656	chr7:65796392	TPST1	0.3	6.69	0.3	6.57e-11	Aortic root size;
LGG	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg08305652	chr11:111469057	NA	0.45	9.18	0.39	1.39e-18	Primary sclerosing cholangitis;
LGG	trans	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.01	0.46	3.26e-25	Corneal astigmatism;
LGG	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.11	-0.31	4.46e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg19774624	chr17:42201019	HDAC5	0.66	11.64	0.48	1.25e-27	Total body bone mineral density;
LGG	cis	rs17384381	0.859	rs12130591	chr1:85904985	C/T	cg16011679	chr1:85725395	C1orf52	0.57	9.66	0.41	3.1e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg13013644	chr5:502571	SLC9A3	-0.35	-6.84	-0.3	2.53e-11	Cystic fibrosis severity;
LGG	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg06618935	chr21:46677482	NA	-0.37	-6.69	-0.3	6.41e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs10506458	1.000	rs17763435	chr12:63416511	A/G	cg22491629	chr6:157744540	C6orf35	0.9	12.77	0.51	3.2e-32	Hemostatic factors and hematological phenotypes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23587005	chr12:9600941	DDX12	0.44	7.03	0.31	7.6e-12	Cognitive performance;
LGG	cis	rs9948	0.881	rs1317911	chr2:97488698	T/G	cg01990225	chr2:97406019	LMAN2L	-0.69	-7.73	-0.34	6.52e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg17757837	chr7:157058334	UBE3C	0.77	15.74	0.59	5.25e-45	Body mass index;
LGG	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg12395012	chr8:11607386	GATA4	0.37	6.67	0.3	7.26e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12863373	chr8:27695096	PBK	0.45	6.84	0.3	2.45e-11	Gut microbiome composition (summer);
LGG	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg26597838	chr10:835615	NA	0.74	10.03	0.42	1.53e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg02403541	chr12:121454288	C12orf43	-0.54	-8.84	-0.38	2.03e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs17221829	0.645	rs11018705	chr11:89382700	T/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg06925179	chr17:43578568	NA	0.42	9.71	0.41	2.11e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg19673125	chr6:150240577	RAET1G	0.34	8.48	0.37	2.98e-16	Testicular germ cell tumor;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg14789911	chr21:47582049	C21orf56	0.45	7.35	0.32	8.98e-13	Testicular germ cell tumor;
LGG	cis	rs2694528	0.925	rs162243	chr5:60297500	A/G	cg11474532	chr5:59995715	DEPDC1B	-0.73	-7.75	-0.34	6.02e-14	Parkinson's disease;
LGG	cis	rs10751667	0.643	rs7396767	chr11:938808	G/A	cg22143635	chr11:980567	AP2A2	0.42	7.74	0.34	6.41e-14	Alzheimer's disease (late onset);
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.8	0.38	2.68e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9547692	0.938	rs9547689	chr13:37451861	G/A	cg01493522	chr13:37497338	NA	-0.52	-8.61	-0.37	1.13e-16	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25294185	chr11:65487814	RNASEH2C	0.43	8.01	0.35	9.2e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.53	-0.44	2.19e-23	Total body bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18882576	chr2:191184621	HIBCH	-0.48	-7.07	-0.31	5.82e-12	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1712517	0.525	rs11191667	chr10:105128898	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.46e-15	Migraine;
LGG	cis	rs35164067	1.000	rs11879191	chr19:10512911	G/A	cg21868191	chr19:10515988	NA	-0.49	-7.32	-0.32	1.09e-12	Inflammatory bowel disease;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg13880726	chr7:1868755	MAD1L1	0.45	7.77	0.34	5.17e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg26769984	chr7:1090371	C7orf50	0.46	7.22	0.32	2.13e-12	Bronchopulmonary dysplasia;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.62	0.37	1.03e-16	Personality dimensions;
LGG	cis	rs7172689	1.000	rs66862541	chr15:81543921	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.71	-0.45	4.53e-24	Inattentive symptoms;
LGG	cis	rs6694270	0.913	rs3935030	chr1:19116956	C/T	cg19637330	chr1:19110922	NA	-0.45	-7.04	-0.31	6.79e-12	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs9926296	0.632	rs4785717	chr16:89801133	A/G	cg04287289	chr16:89883240	FANCA	0.54	9.84	0.42	7.13e-21	Vitiligo;
LGG	cis	rs2820315	1.000	rs2820310	chr1:201838107	G/A	cg10061532	chr1:201886748	LMOD1	0.33	6.8	0.3	3.17e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg16262614	chr3:133464971	TF	0.48	8.81	0.38	2.49e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg09021430	chr5:549028	NA	-0.8	-12.59	-0.5	1.84e-31	Obesity-related traits;
LGG	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg16070123	chr10:51489643	NA	-0.49	-8.5	-0.37	2.63e-16	Prostate-specific antigen levels;
LGG	cis	rs17604090	0.938	rs850029	chr7:29678087	A/G	cg19413766	chr7:29689036	LOC646762	-0.59	-7.36	-0.32	8.56e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.42	-0.58	1.3e-43	Chronic sinus infection;
LGG	cis	rs988958	0.675	rs7583681	chr2:42225701	G/A	cg27252766	chr2:42229092	NA	0.56	8.62	0.37	1.08e-16	Hypospadias;
LGG	cis	rs911555	0.617	rs7156036	chr14:103908142	A/G	cg24130564	chr14:104152367	KLC1	0.37	7.04	0.31	7.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.09	0.52	1.52e-33	Colorectal cancer;
LGG	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg17971929	chr21:40555470	PSMG1	-0.49	-8.09	-0.35	5.2e-15	Menarche (age at onset);
LGG	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg16339924	chr4:17578868	LAP3	-0.52	-8.51	-0.37	2.35e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9902453	0.808	rs62068617	chr17:28144728	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.88	0.54	6.98e-37	Coffee consumption (cups per day);
LGG	cis	rs16937	0.711	rs10900471	chr1:205173134	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	cis	rs28655083	1.000	rs11864710	chr16:77075284	A/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.45	-7.1	-0.31	4.57e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2708240	0.666	rs2708270	chr7:147594647	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-8.54	-0.37	1.98e-16	QT interval (drug interaction);
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg04287289	chr16:89883240	FANCA	0.78	7.7	0.34	8.58e-14	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg11859384	chr17:80120422	CCDC57	-0.48	-8.13	-0.35	4.02e-15	Life satisfaction;
LGG	cis	rs782590	0.934	rs62165184	chr2:55788253	G/C	cg18811423	chr2:55921094	PNPT1	0.88	20.14	0.68	3.14e-65	Metabolic syndrome;
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.52	0.33	2.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4561483	0.767	rs33633	chr16:11994857	A/C	cg08843971	chr16:11963173	GSPT1	-0.68	-18.42	-0.65	2.89e-57	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg01765077	chr12:122356316	WDR66	0.28	7.45	0.33	4.51e-13	Mean corpuscular volume;
LGG	cis	rs9487094	0.961	rs6911838	chr6:109799923	C/T	cg16315928	chr6:109776240	MICAL1	0.48	7.87	0.34	2.54e-14	Height;
LGG	cis	rs6909430	1.000	rs1466612	chr6:98684466	A/T	cg12860156	chr6:98744658	NA	0.42	7.48	0.33	3.67e-13	Quantitative traits;
LGG	cis	rs11191205	0.954	rs11191191	chr10:103800979	G/A	cg00857846	chr10:103824917	HPS6	0.73	9.18	0.39	1.44e-18	Intelligence (multi-trait analysis);
LGG	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg22232500	chr2:134024266	NCKAP5	-0.62	-8.75	-0.38	3.87e-17	Bipolar disorder;
LGG	cis	rs9976767	0.792	rs2839508	chr21:43845294	A/G	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.78	-0.41	1.21e-20	Type 1 diabetes;
LGG	cis	rs754466	0.580	rs1866437	chr10:79526766	A/G	cg17075019	chr10:79541650	NA	-0.99	-21.71	-0.71	1.33e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7010267	0.902	rs7006553	chr8:119970779	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.39	0.43	7.37e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs17767392	0.628	rs61989247	chr14:71720349	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.33	-7.42	-0.33	5.53e-13	Mitral valve prolapse;
LGG	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg11266682	chr4:10021025	SLC2A9	0.53	10.62	0.44	9.97e-24	Bone mineral density;
LGG	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg25319279	chr11:5960081	NA	-0.57	-8.77	-0.38	3.49e-17	DNA methylation (variation);
LGG	cis	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg12501888	chr15:85177176	SCAND2	-0.56	-9.09	-0.39	2.86e-18	P wave terminal force;
LGG	cis	rs67133203	0.904	rs12830073	chr12:51419381	G/A	cg14688905	chr12:51403056	SLC11A2	0.8	12.41	0.5	1.01e-30	Urinary tract infection frequency;
LGG	cis	rs2594989	0.831	rs2443703	chr3:11564191	C/T	cg01796438	chr3:11312864	ATG7	0.56	7.94	0.35	1.57e-14	Circulating chemerin levels;
LGG	cis	rs17453880	0.963	rs6869968	chr5:151945837	A/G	cg10931792	chr5:152022470	NA	0.37	7.81	0.34	3.77e-14	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07197864	chr1:32110446	PEF1	0.45	6.78	0.3	3.75e-11	Gut microbiome composition (summer);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25695166	chr10:15131005	ACBD7	-0.44	-6.68	-0.3	7e-11	Systemic lupus erythematosus;
LGG	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg09361094	chr10:834503	NA	-0.28	-7.35	-0.32	9.18e-13	Survival in rectal cancer;
LGG	cis	rs6032067	0.777	rs80323300	chr20:43785287	T/C	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.53	-0.44	2.17e-23	Type 2 diabetes;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg02462569	chr6:150064036	NUP43	-0.42	-8.95	-0.38	8.55e-18	Lung cancer;
LGG	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg02536541	chr18:77568900	NA	-0.56	-9.32	-0.4	4.62e-19	Schizophrenia;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg16103275	chr6:290800	DUSP22	0.49	7.99	0.35	1.11e-14	Menopause (age at onset);
LGG	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg14416269	chr4:6271139	WFS1	0.52	9.4	0.4	2.47e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9362426	1.000	rs406900	chr6:88085447	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	9.96	0.42	2.59e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	trans	rs61931739	0.635	rs10743837	chr12:33982162	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.5	0.37	2.65e-16	Morning vs. evening chronotype;
LGG	trans	rs2018683	0.509	rs221192	chr7:29014909	C/T	cg19402173	chr7:128379420	CALU	0.51	7.52	0.33	2.92e-13	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.68e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1059312	0.808	rs4760533	chr12:129297651	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.34	-8.59	-0.37	1.31e-16	Systemic lupus erythematosus;
LGG	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg08600765	chr20:34638493	LOC647979	-0.6	-7.62	-0.33	1.46e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-7.25	-0.32	1.73e-12	Total body bone mineral density;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg13545763	chr17:47755325	SPOP	0.39	6.85	0.3	2.4e-11	Coronary artery disease;
LGG	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9354308	0.764	rs9294659	chr6:66579131	A/C	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.06e-11	Metabolite levels;
LGG	cis	rs2286885	0.965	rs4837092	chr9:129250251	T/C	cg14319473	chr9:129242481	FAM125B	0.45	8.38	0.36	6.63e-16	Intraocular pressure;
LGG	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-9.0	-0.39	6.05e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7727544	0.570	rs7701237	chr5:131534381	C/T	cg07395648	chr5:131743802	NA	-0.4	-8.68	-0.37	6.71e-17	Blood metabolite levels;
LGG	cis	rs8016982	0.698	rs12590764	chr14:81704417	G/A	cg01989461	chr14:81687754	GTF2A1	0.75	17.69	0.64	6.96e-54	Schizophrenia;
LGG	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg06766960	chr11:133703094	NA	-0.56	-10.91	-0.45	7.87e-25	Childhood ear infection;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg23782820	chr8:58130467	NA	0.44	6.99	0.31	9.41e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs773506	1.000	rs773509	chr9:93958422	C/T	cg14446406	chr9:93919335	NA	0.46	8.21	0.36	2.28e-15	Type 2 diabetes nephropathy;
LGG	cis	rs1358748	0.522	rs4655676	chr1:67580054	C/T	cg02640540	chr1:67518911	SLC35D1	0.55	6.75	0.3	4.41e-11	Tuberculosis;
LGG	cis	rs9902453	0.817	rs2628170	chr17:28056612	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.48	-0.53	3.6e-35	Coffee consumption (cups per day);
LGG	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.54	8.12	0.35	4.23e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05926928	chr17:57297772	GDPD1	0.58	9.46	0.4	1.52e-19	Schizophrenia;
LGG	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.63	0.61	4.79e-49	Anterior chamber depth;
LGG	cis	rs6141769	0.569	rs6057618	chr20:31264083	A/G	cg13636640	chr20:31349939	DNMT3B	-0.47	-6.97	-0.31	1.09e-11	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11084020	chr7:27779567	TAX1BP1	0.44	7.08	0.31	5.23e-12	Cognitive performance;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg11878867	chr6:150167359	LRP11	-0.39	-7.98	-0.35	1.14e-14	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.1.3132707F	chr1:160211343	DCAF8	0.36	6.67	0.3	7.2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg20368463	chr18:77673604	PQLC1	0.6	7.86	0.34	2.8e-14	Opioid sensitivity;
LGG	cis	rs6121246	0.559	rs6058468	chr20:30406448	C/A	cg13852791	chr20:30311386	BCL2L1	0.98	19.49	0.67	3.15e-62	Mean corpuscular hemoglobin;
LGG	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg10792982	chr14:105748885	BRF1	0.59	12.05	0.49	2.96e-29	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4330281	0.631	rs6795189	chr3:17711724	T/A	cg20981856	chr3:17787350	NA	-0.41	-7.68	-0.34	9.65e-14	Schizophrenia;
LGG	cis	rs897984	0.568	rs4889653	chr16:30895713	C/T	cg02466173	chr16:30829666	NA	0.52	8.83	0.38	2.15e-17	Dementia with Lewy bodies;
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg21171335	chr12:122356390	WDR66	0.27	7.51	0.33	3.09e-13	Mean corpuscular volume;
LGG	cis	rs9486719	0.843	rs2499793	chr6:96846402	A/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg02524346	chr8:600233	NA	-1.2	-10.38	-0.43	7.61e-23	IgG glycosylation;
LGG	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1790761	0.806	rs35787427	chr11:67255877	C/T	cg14500267	chr11:67383377	NA	-0.41	-7.36	-0.32	8.45e-13	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.32	0.4	4.79e-19	Alzheimer's disease;
LGG	trans	rs9467603	0.925	rs13199775	chr6:25828782	A/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.65	-0.3	8.17e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.89	-0.48	1.26e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg12708336	chr17:41446283	NA	-0.33	-8.1	-0.35	4.85e-15	Menopause (age at onset);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs7503807	0.664	rs9913181	chr17:78573872	A/C	cg06872548	chr17:78716983	RPTOR	0.42	9.19	0.39	1.32e-18	Obesity;
LGG	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7812879	0.602	rs2736355	chr8:11369777	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.16	-0.32	3.13e-12	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg12070911	chr6:150209640	RAET1E	0.3	7.26	0.32	1.6e-12	Lung cancer;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg11245990	chr11:68621969	NA	0.45	9.15	0.39	1.87e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.43	-7.75	-0.34	5.86e-14	Rheumatoid arthritis;
LGG	cis	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg06521331	chr12:34319734	NA	-0.6	-10.93	-0.45	6.87e-25	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs4654899	0.865	rs6700459	chr1:21279396	T/C	cg05370193	chr1:21551575	ECE1	0.31	7.09	0.31	5.12e-12	Superior frontal gyrus grey matter volume;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7939886	0.920	rs7115395	chr11:55877116	G/A	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.48e-11	Myopia (pathological);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18856501	chr10:126781591	CTBP2	0.37	6.66	0.3	7.77e-11	Body fat percentage;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg23782820	chr8:58130467	NA	0.54	7.38	0.32	7.48e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg00204512	chr16:28754710	NA	0.25	6.79	0.3	3.47e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs240764	0.817	rs239249	chr6:101087081	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	4.99e-14	Neuroticism;
LGG	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg22987457	chr7:157211561	NA	0.36	6.65	0.3	8.5e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.65	0.56	3.23e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2115630	0.905	rs1975277	chr15:85329558	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.77	-0.3	3.79e-11	P wave terminal force;
LGG	cis	rs9660992	0.762	rs1172130	chr1:205244953	G/A	cg21545522	chr1:205238299	TMCC2	0.43	7.89	0.34	2.27e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg16325326	chr1:53192061	ZYG11B	0.86	23.03	0.73	8.94e-79	Monocyte count;
LGG	cis	rs9790314	0.715	rs980976	chr3:160771668	T/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.85	-0.42	6.35e-21	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.62	0.37	1.08e-16	Personality dimensions;
LGG	cis	rs17331151	0.573	rs2276818	chr3:52864635	A/G	cg04865290	chr3:52927548	TMEM110	-0.4	-7.01	-0.31	8.47e-12	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs9929218	0.817	rs3114402	chr16:68719607	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-17.3	-0.63	4.3e-52	Colorectal cancer;
LGG	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg23161317	chr6:28129485	ZNF389	-0.33	-6.72	-0.3	5.2e-11	Depression;
LGG	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg00717180	chr2:96193071	NA	0.4	7.0	0.31	9.09e-12	HDL cholesterol;
LGG	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.42	-0.33	5.52e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg24006582	chr15:45444508	DUOX1	-0.66	-12.65	-0.51	1.01e-31	Uric acid levels;
LGG	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs4918072	0.917	rs17573075	chr10:105649940	C/G	cg11005552	chr10:105648138	OBFC1	0.69	11.74	0.48	4.94e-28	Coronary artery disease;
LGG	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.11	-0.35	4.51e-15	Retinal vascular caliber;
LGG	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg17217059	chr4:152329364	FAM160A1	0.22	6.82	0.3	2.77e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.64	-0.41	3.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4474465	0.688	rs4367973	chr11:78284545	C/A	cg27205649	chr11:78285834	NARS2	0.6	11.05	0.46	2.45e-25	Alzheimer's disease (survival time);
LGG	cis	rs12042938	0.600	rs823165	chr1:231769446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.62	10.86	0.45	1.26e-24	Neuranatomic and neurocognitive phenotypes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg17490921	chr11:116658887	ZNF259	0.4	7.02	0.31	7.85e-12	Body mass index;
LGG	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs74417235	0.673	rs6873342	chr5:154051835	A/G	cg08754654	chr5:154026448	NA	-0.56	-11.24	-0.46	4.23e-26	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg08645402	chr16:4508243	NA	0.44	7.3	0.32	1.25e-12	Schizophrenia;
LGG	cis	rs7507204	0.723	rs12979645	chr19:3414688	A/T	cg08380311	chr19:3435252	NFIC	0.83	12.03	0.49	3.53e-29	Height;
LGG	cis	rs9783347	1.000	rs4353250	chr11:18323517	T/C	cg15585147	chr11:18324498	HPS5	0.43	9.12	0.39	2.39e-18	Pancreatic cancer;
LGG	cis	rs600231	0.708	rs2957268	chr11:65245816	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.07	-0.39	3.33e-18	Bone mineral density;
LGG	cis	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg20368463	chr18:77673604	PQLC1	0.57	7.49	0.33	3.55e-13	Opioid sensitivity;
LGG	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.67	0.34	1.06e-13	Neutrophil percentage of white cells;
LGG	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	trans	rs10506458	0.915	rs56321182	chr12:63392023	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.75	-0.69	4.13e-68	Hemostatic factors and hematological phenotypes;
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.42	-0.33	5.58e-13	Neuroticism;
LGG	cis	rs56283067	0.578	rs10948233	chr6:45364096	A/T	cg20913747	chr6:44695427	NA	0.54	8.11	0.35	4.55e-15	Total body bone mineral density;
LGG	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs7552404	1.000	rs4646961	chr1:76217169	G/A	cg03433033	chr1:76189801	ACADM	0.77	13.25	0.52	3.27e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7927771	0.864	rs2868459	chr11:47454972	C/G	cg20307385	chr11:47447363	PSMC3	-0.58	-10.63	-0.44	9.23e-24	Subjective well-being;
LGG	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	18.74	0.66	1.01e-58	Platelet count;
LGG	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	cis	rs9658691	0.607	rs34891735	chr10:90779212	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-9.05	-0.39	4.13e-18	Mosquito bite size;
LGG	cis	rs870825	0.616	rs7659201	chr4:185632013	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs7766436	0.767	rs62391062	chr6:22598736	G/A	cg13666174	chr6:22585274	NA	-0.34	-8.0	-0.35	1.03e-14	Coronary artery disease;
LGG	cis	rs11229555	0.645	rs7929868	chr11:58209418	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2404602	0.735	rs2468130	chr15:76796496	T/C	cg23625390	chr15:77176239	SCAPER	-0.61	-12.08	-0.49	2.18e-29	Blood metabolite levels;
LGG	cis	rs9788721	1.000	rs931794	chr15:78826180	G/A	cg18825076	chr15:78729989	IREB2	0.49	7.94	0.35	1.5e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg08305652	chr11:111469057	NA	-0.46	-9.15	-0.39	1.81e-18	Primary sclerosing cholangitis;
LGG	cis	rs4356932	1.000	rs6826163	chr4:76973445	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg10223061	chr2:219282414	VIL1	0.31	6.89	0.3	1.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2439831	0.681	rs28594657	chr15:43588888	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	11.72	0.48	6.03e-28	Lung cancer in ever smokers;
LGG	cis	rs2075371	1.000	rs447266	chr7:133989543	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	14.16	0.55	4.32e-38	Mean platelet volume;
LGG	cis	rs6088580	0.524	rs6087612	chr20:33230822	T/G	cg08999081	chr20:33150536	PIGU	-0.3	-7.21	-0.32	2.35e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs1577917	0.958	rs1447160	chr6:86546123	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.01	-0.39	5.46e-18	Response to antipsychotic treatment;
LGG	trans	rs11098499	0.909	rs7681978	chr4:120383775	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.36	0.5	1.63e-30	Corneal astigmatism;
LGG	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg08975724	chr8:8085496	FLJ10661	0.42	7.64	0.33	1.29e-13	Retinal vascular caliber;
LGG	trans	rs12579753	0.917	rs11115032	chr12:82205073	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg03795903	chr2:30669940	LCLAT1	0.6	8.02	0.35	8.82e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg25237894	chr2:233734115	C2orf82	-0.56	-11.11	-0.46	1.38e-25	Coronary artery disease;
LGG	cis	rs12153243	0.686	rs17342813	chr5:142909383	T/C	cg13907255	chr5:142895549	NA	-0.5	-8.74	-0.38	4.43e-17	Migraine;
LGG	trans	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.38	-0.4	3.05e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.62	0.53	8.82e-36	Bladder cancer;
LGG	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.92	0.38	1.07e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7598759	0.679	rs6437019	chr2:232327707	T/C	cg19187155	chr2:232395269	NMUR1	0.42	7.59	0.33	1.82e-13	Noise-induced hearing loss;
LGG	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg16434002	chr17:42200994	HDAC5	0.42	8.08	0.35	5.72e-15	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs714031	0.934	rs5757764	chr22:40067818	C/T	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.5	-0.56	1.51e-39	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.45	-0.33	4.62e-13	Lung cancer;
LGG	cis	rs804292	0.800	rs8191542	chr8:11629809	C/G	cg12395012	chr8:11607386	GATA4	0.54	7.64	0.33	1.27e-13	Alcohol dependence;Nicotine use;
LGG	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg21972741	chr5:435613	AHRR	0.42	7.41	0.33	6.01e-13	Cystic fibrosis severity;
LGG	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.86	0.42	6.24e-21	Hypertriglyceridemia;
LGG	cis	rs7666738	0.606	rs10006414	chr4:99101401	T/C	cg05340658	chr4:99064831	C4orf37	0.42	6.73	0.3	4.91e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7589342	0.669	rs11895604	chr2:106536134	G/A	cg14210321	chr2:106509881	NCK2	-0.48	-8.36	-0.36	7.57e-16	Addiction;
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg19635926	chr16:89946313	TCF25	0.76	7.33	0.32	1.01e-12	Skin colour saturation;
LGG	cis	rs4243830	0.850	rs4908558	chr1:6584101	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-12.32	-0.5	2.3e-30	Body mass index;
LGG	cis	rs7017914	0.902	rs11991273	chr8:71645860	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.52	0.53	2.39e-35	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02501334	chr17:66508232	PRKAR1A	0.42	6.7	0.3	6.11e-11	Cognitive performance;
LGG	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg13207630	chr7:32358064	NA	0.78	7.68	0.34	9.79e-14	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04985396	chr1:72749735	NEGR1	0.49	7.9	0.34	2.02e-14	Cognitive performance;
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg03709012	chr19:19516395	GATAD2A	0.86	17.49	0.63	6.2e-53	Tonsillectomy;
LGG	cis	rs9399135	0.967	rs1041481	chr6:135335063	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.46	0.4	1.62e-19	Red blood cell count;
LGG	cis	rs7582720	1.000	rs72936309	chr2:204040296	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.47	0.4	1.48e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg03806693	chr22:41940476	POLR3H	0.89	14.9	0.57	2.66e-41	Vitiligo;
LGG	trans	rs12310956	0.532	rs1852226	chr12:33962940	G/A	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.41	2.16e-20	Morning vs. evening chronotype;
LGG	cis	rs701145	0.537	rs1713831	chr3:153836299	T/C	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs9875589	0.794	rs2117039	chr3:13963330	T/C	cg19554555	chr3:13937349	NA	0.71	13.75	0.54	2.54e-36	Ovarian reserve;
LGG	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg13010199	chr12:38710504	ALG10B	-0.56	-10.65	-0.44	7.99e-24	Morning vs. evening chronotype;
LGG	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg05082376	chr22:42548792	NA	-0.38	-8.04	-0.35	7.52e-15	Schizophrenia;
LGG	cis	rs3008870	0.583	rs3008861	chr1:67396222	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.01	17.73	0.64	4.77e-54	Lymphocyte percentage of white cells;
LGG	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg26677194	chr12:130822605	PIWIL1	-0.52	-9.36	-0.4	3.52e-19	Menopause (age at onset);
LGG	trans	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg18335740	chr13:41363409	SLC25A15	0.85	20.3	0.69	5.24e-66	Lewy body disease;
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.24	-0.36	1.78e-15	Total body bone mineral density;
LGG	cis	rs7166081	1.000	rs11071940	chr15:67499477	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.05	-0.31	6.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1493916	0.837	rs2123333	chr18:31410730	G/A	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg12857652	chr6:64289969	PTP4A1	-0.37	-6.82	-0.3	2.85e-11	Asthma;
LGG	cis	rs3735485	0.800	rs1294963	chr7:45068784	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.4	0.4	2.62e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg08125733	chr17:73851984	WBP2	0.42	7.04	0.31	7.07e-12	White matter hyperintensity burden;
LGG	trans	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.44	0.4	1.83e-19	Diabetic kidney disease;
LGG	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs2798269	0.966	rs2798268	chr13:22131690	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.96	-0.31	1.16e-11	PR segment;
LGG	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-10.06	-0.42	1.13e-21	HDL cholesterol;
LGG	trans	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg06521331	chr12:34319734	NA	0.46	8.1	0.35	5.04e-15	Bladder cancer;
LGG	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg26513180	chr16:89883248	FANCA	0.53	9.48	0.4	1.37e-19	Vitiligo;
LGG	cis	rs4704187	0.687	rs6888707	chr5:74442920	A/G	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs3820068	0.562	rs10927841	chr1:16045261	T/C	cg05660106	chr1:15850417	CASP9	0.74	13.59	0.53	1.25e-35	Systolic blood pressure;
LGG	cis	rs12210905	1.000	rs67310631	chr6:27233243	T/A	cg15325629	chr6:28072465	NA	0.7	6.86	0.3	2.24e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9463078	0.605	rs13216116	chr6:44936681	C/T	cg25276700	chr6:44698697	NA	0.33	6.91	0.31	1.65e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7584330	0.868	rs13408361	chr2:238382899	A/G	cg16989719	chr2:238392110	NA	-0.32	-6.67	-0.3	7.14e-11	Prostate cancer;
LGG	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg11247378	chr22:39784982	NA	-0.32	-9.27	-0.4	7.16e-19	Intelligence (multi-trait analysis);
LGG	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg10935138	chr17:73851978	WBP2	0.51	7.34	0.32	9.71e-13	Psoriasis;
LGG	trans	rs1997103	0.954	rs2030807	chr7:55378485	A/G	cg20935933	chr6:143382018	AIG1	0.57	8.65	0.37	8.73e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6594713	0.679	rs71577448	chr5:112768874	C/T	cg12552261	chr5:112820674	MCC	0.65	8.22	0.36	2.06e-15	Brain cytoarchitecture;
LGG	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.81	-0.38	2.52e-17	Morning vs. evening chronotype;
LGG	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg10253484	chr15:75165896	SCAMP2	0.55	8.04	0.35	7.39e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg02462569	chr6:150064036	NUP43	-0.45	-9.17	-0.39	1.53e-18	Lung cancer;
LGG	cis	rs6708331	1.000	rs35734267	chr2:70281190	C/T	cg01613454	chr2:70366299	NA	0.51	8.84	0.38	2.07e-17	Obesity-related traits;
LGG	cis	rs526231	0.543	rs183752	chr5:102507812	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.39	-0.36	5.72e-16	Primary biliary cholangitis;
LGG	cis	rs721399	0.513	rs35354956	chr8:18241319	T/C	cg18736775	chr8:18248649	NAT2	-0.77	-11.9	-0.48	1.12e-28	Blood metabolite levels;
LGG	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00292662	chr22:38071168	LGALS1	0.7	13.3	0.53	2.13e-34	Fat distribution (HIV);
LGG	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.37	0.43	8.18e-23	Lung cancer in ever smokers;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.95	-0.38	8.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg20003494	chr4:90757398	SNCA	-0.38	-7.45	-0.33	4.57e-13	Dementia with Lewy bodies;
LGG	cis	rs2860975	0.620	rs7898759	chr10:96800354	T/C	cg09036531	chr10:96991505	NA	-0.47	-8.23	-0.36	1.93e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.85	-0.54	9.69e-37	Tonsillectomy;
LGG	cis	rs6840360	0.571	rs7664663	chr4:152508014	G/C	cg25486957	chr4:152246857	NA	-0.51	-8.37	-0.36	6.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg08925882	chr11:67350491	GSTP1	-0.35	-6.88	-0.3	1.91e-11	Mean corpuscular volume;
LGG	cis	rs1801251	1.000	rs1446311	chr2:233705071	G/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.17	-0.39	1.52e-18	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.45	0.37	3.75e-16	Obesity-related traits;
LGG	cis	rs977987	0.843	rs62062564	chr16:75442622	G/A	cg03315344	chr16:75512273	CHST6	0.52	10.42	0.44	5.6e-23	Dupuytren's disease;
LGG	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg05623727	chr3:50126028	RBM5	-0.34	-6.66	-0.3	7.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs926392	0.799	rs742274	chr20:37680944	T/C	cg16355469	chr20:37678765	NA	0.48	7.98	0.35	1.19e-14	Dialysis-related mortality;
LGG	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg10818794	chr15:86012489	AKAP13	-0.39	-8.24	-0.36	1.84e-15	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg11494091	chr17:61959527	GH2	0.51	8.11	0.35	4.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2204008	0.837	rs10876019	chr12:37985477	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg12165864	chr7:66369176	NA	-0.44	-7.38	-0.32	7.27e-13	Corneal structure;
LGG	cis	rs42648	0.869	rs12374728	chr7:89941884	T/C	cg25739043	chr7:89950458	NA	-0.44	-9.35	-0.4	3.73e-19	Homocysteine levels;
LGG	cis	rs74781061	0.929	rs11072492	chr15:74824123	T/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs11920090	0.722	rs66888782	chr3:170673971	C/T	cg09710316	chr3:170744871	SLC2A2	0.63	8.17	0.35	3.04e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.89	0.54	6.56e-37	Obesity-related traits;
LGG	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg25706552	chr1:244017396	NA	0.52	8.5	0.37	2.59e-16	RR interval (heart rate);
LGG	cis	rs35160687	1.000	rs35160687	chr2:86472114	C/T	cg10973622	chr2:86423274	IMMT	0.41	6.99	0.31	9.34e-12	Night sleep phenotypes;
LGG	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.54e-21	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg23166289	chr1:210001082	C1orf107	-0.35	-6.79	-0.3	3.35e-11	Orofacial clefts;
LGG	cis	rs2204008	0.807	rs4123933	chr12:37973539	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.07e-37	Bladder cancer;
LGG	cis	rs11971779	0.616	rs1133068	chr7:139053143	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.32	0.53	1.72e-34	IgG glycosylation;
LGG	cis	rs7100689	0.646	rs7077712	chr10:82134894	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.7e-20	Intelligence (multi-trait analysis);
LGG	cis	rs919433	0.679	rs10931788	chr2:198531084	A/G	cg00792783	chr2:198669748	PLCL1	0.55	9.06	0.39	3.71e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg03342759	chr3:160939853	NMD3	-0.64	-11.0	-0.46	3.6e-25	Morning vs. evening chronotype;
LGG	cis	rs9487094	0.670	rs10782163	chr6:109854243	C/A	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.51	-0.47	3.82e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs10904887	0.846	rs1885396	chr10:17243351	C/T	cg01003015	chr10:17271136	VIM	-0.41	-6.85	-0.3	2.37e-11	Telomere length;
LGG	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.97	-0.35	1.27e-14	Obesity;
LGG	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg26513180	chr16:89883248	FANCA	0.6	10.63	0.44	9.56e-24	Vitiligo;
LGG	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg13010199	chr12:38710504	ALG10B	0.7	13.71	0.54	3.94e-36	Morning vs. evening chronotype;
LGG	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.24	0.36	1.76e-15	Height;
LGG	cis	rs9463078	0.527	rs2040032	chr6:44743009	C/T	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.79e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg17757837	chr7:157058334	UBE3C	-0.9	-20.86	-0.7	1.23e-68	Body mass index;
LGG	cis	rs11690935	0.802	rs34636594	chr2:172911094	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.08	-0.72	2.47e-74	Schizophrenia;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg17525428	chr19:51197463	SHANK1	-0.35	-6.72	-0.3	5.35e-11	Iris color (L* coordinate);
LGG	cis	rs975722	0.638	rs10231905	chr7:117329970	G/A	cg10524701	chr7:117356490	CTTNBP2	0.5	10.18	0.43	4.37e-22	Coronary artery disease;
LGG	cis	rs58616815	0.857	rs1341825	chr10:92160834	A/G	cg17905462	chr10:92153495	NA	-0.26	-6.77	-0.3	4.03e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6141769	0.542	rs6087976	chr20:31316287	G/A	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs7336332	0.600	rs9579083	chr13:28017270	G/C	cg01674679	chr13:27998804	GTF3A	-0.67	-8.75	-0.38	4.12e-17	Weight;
LGG	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.56	-9.36	-0.4	3.45e-19	Prudent dietary pattern;
LGG	cis	rs2050392	0.861	rs1042058	chr10:30728101	T/C	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.97	-0.45	4.66e-25	Inflammatory bowel disease;
LGG	trans	rs17685	0.784	rs1613890	chr7:75735037	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.97	0.77	2.03e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35740288	0.770	rs4843085	chr15:86158499	A/G	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs7503807	0.515	rs12450876	chr17:78682630	A/G	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg07570687	chr10:102243282	WNT8B	0.42	7.13	0.31	4e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg20368463	chr18:77673604	PQLC1	0.43	7.52	0.33	2.96e-13	Schizophrenia;
LGG	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-9.61	-0.41	4.8e-20	Menarche (age at onset);
LGG	cis	rs6121246	0.559	rs6087779	chr20:30370566	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs17253792	0.822	rs78386830	chr14:56069224	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg02972257	chr16:68554789	NA	0.44	6.82	0.3	2.77e-11	Colorectal cancer;
LGG	trans	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs977987	0.806	rs4888404	chr16:75428097	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg05941027	chr17:61774174	LIMD2	0.36	8.62	0.37	1.04e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg21782813	chr7:2030301	MAD1L1	0.51	12.29	0.5	2.95e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg14952266	chr13:112191215	NA	0.51	10.78	0.45	2.49e-24	Hepatitis;
LGG	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg15162869	chr22:32027605	PISD	-0.69	-7.25	-0.32	1.73e-12	Age-related hearing impairment;
LGG	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs7241530	0.662	rs6506734	chr18:75888374	A/G	cg14642773	chr18:75888474	NA	0.47	9.89	0.42	4.75e-21	Educational attainment (years of education);
LGG	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.8	-0.34	4.03e-14	Huntington's disease progression;
LGG	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	7.23	0.32	1.96e-12	Platelet count;
LGG	cis	rs9291683	0.632	rs13137074	chr4:10042842	C/T	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	trans	rs9944715	0.954	rs4890317	chr18:43770510	A/G	cg01718231	chr17:29326311	RNF135	-0.43	-6.74	-0.3	4.59e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg23029597	chr12:123009494	RSRC2	-0.92	-18.09	-0.64	1.07e-55	Body mass index;
LGG	trans	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.58	-0.33	1.87e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7084402	0.555	rs7069916	chr10:60271824	A/G	cg07615347	chr10:60278583	BICC1	0.54	13.27	0.52	2.8e-34	Refractive error;
LGG	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.6	-0.33	1.71e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10479542	0.503	rs12719865	chr5:178993566	C/T	cg09060608	chr5:178986726	RUFY1	0.42	6.7	0.3	5.97e-11	Lung cancer;
LGG	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg20573242	chr4:122745356	CCNA2	0.44	8.12	0.35	4.38e-15	Type 2 diabetes;
LGG	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.33	0.4	4.53e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg21972741	chr5:435613	AHRR	0.51	9.11	0.39	2.55e-18	Cystic fibrosis severity;
LGG	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.95	-0.35	1.48e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6784615	0.744	rs1011064	chr3:52504503	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs6598955	0.671	rs12129482	chr1:26623641	C/T	cg04990556	chr1:26633338	UBXN11	0.58	8.22	0.36	2.09e-15	Obesity-related traits;
LGG	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg13010199	chr12:38710504	ALG10B	0.55	10.93	0.45	6.85e-25	Heart rate;
LGG	cis	rs963731	0.737	rs10194374	chr2:39244914	G/A	cg04010122	chr2:39346883	SOS1	-0.85	-7.58	-0.33	1.94e-13	Corticobasal degeneration;
LGG	cis	rs35740288	0.770	rs11631449	chr15:86148653	T/C	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg01967586	chr1:228894546	NA	0.38	7.54	0.33	2.43e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.27	0.32	1.53e-12	Total cholesterol levels;
LGG	cis	rs9388451	0.505	rs9372828	chr6:126175185	A/T	cg05901451	chr6:126070800	HEY2	-0.58	-10.15	-0.43	5.5e-22	Brugada syndrome;
LGG	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg13047869	chr3:10149882	C3orf24	0.49	7.69	0.34	9.19e-14	Alzheimer's disease;
LGG	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	11.59	0.47	1.83e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1355223	0.506	rs7131272	chr11:34869548	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.5	8.23	0.36	1.92e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.7	0.3	6.15e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs3789045	1.000	rs3747631	chr1:204587569	G/C	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.62	-0.37	1.03e-16	Educational attainment (college completion);
LGG	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.5	0.37	2.62e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg00495681	chr13:53174319	NA	1.0	22.95	0.73	2.18e-78	Lewy body disease;
LGG	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg03929089	chr4:120376271	NA	0.69	7.56	0.33	2.13e-13	Intraocular pressure;
LGG	cis	rs4774899	0.752	rs2733188	chr15:57370507	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.76	-0.3	4.08e-11	Urinary tract infection frequency;
LGG	cis	rs8072100	0.713	rs9807106	chr17:45457102	G/T	cg25173405	chr17:45401733	C17orf57	-0.55	-9.25	-0.4	8.09e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs7523273	0.853	rs7537216	chr1:208006429	A/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.46	-0.47	6.28e-27	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg00933542	chr6:150070202	PCMT1	0.37	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.44	0.61	3.58e-48	Diabetic retinopathy;
LGG	cis	rs2247341	0.965	rs2236787	chr4:1718883	A/T	cg07465881	chr4:1713556	SLBP	-0.47	-7.5	-0.33	3.25e-13	Hip circumference adjusted for BMI;Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21194448	chr13:88323940	SLITRK5	-0.4	-6.69	-0.3	6.37e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	18.91	0.66	1.57e-59	Platelet count;
LGG	cis	rs9300255	0.507	rs1615350	chr12:123650335	C/T	cg05973401	chr12:123451056	ABCB9	0.51	8.18	0.36	2.79e-15	Neutrophil percentage of white cells;
LGG	cis	rs8180040	0.620	rs1811652	chr3:47208698	C/G	cg27129171	chr3:47204927	SETD2	-0.82	-14.92	-0.57	2.3e-41	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19074970	chr2:228189846	NA	0.48	7.32	0.32	1.12e-12	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg13770153	chr20:60521292	NA	-0.49	-8.04	-0.35	7.49e-15	Body mass index;
LGG	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.7	0.41	2.21e-20	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-11.09	-0.46	1.61e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1790761	0.967	rs7131041	chr11:67230184	A/T	cg00290607	chr11:67383545	NA	-0.48	-8.5	-0.37	2.59e-16	Mean corpuscular volume;
LGG	cis	rs12134245	0.874	rs34842487	chr1:92021611	C/T	cg25838465	chr1:92012736	NA	-0.41	-7.48	-0.33	3.65e-13	Breast cancer;
LGG	cis	rs4917300	0.606	rs4917225	chr8:143116169	T/C	cg06573787	chr8:143070187	NA	0.6	9.92	0.42	3.81e-21	Amyotrophic lateral sclerosis;
LGG	trans	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg02800362	chr5:177631904	HNRNPAB	1.0	12.41	0.5	1e-30	Obesity-related traits;
LGG	cis	rs11214589	0.747	rs11214577	chr11:113204266	A/G	cg14373873	chr11:113211441	TTC12	-0.53	-11.75	-0.48	4.47e-28	Neuroticism;
LGG	cis	rs9796	0.870	rs12905926	chr15:41283408	G/A	cg18705301	chr15:41695430	NDUFAF1	0.48	8.19	0.36	2.5e-15	Menopause (age at onset);
LGG	cis	rs75920871	0.588	rs6589580	chr11:116819873	G/A	cg20608306	chr11:116969690	SIK3	-0.41	-10.55	-0.44	1.87e-23	Subjective well-being;
LGG	cis	rs265548	0.510	rs28415068	chr19:17910582	T/A	cg04517722	chr19:17905589	B3GNT3	0.39	6.72	0.3	5.5e-11	Tumor biomarkers;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03456512	chr7:107531689	DLD	0.39	6.97	0.31	1.06e-11	Obesity-related traits;
LGG	cis	rs9837602	0.529	rs793495	chr3:99507934	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	8.63	0.37	1.01e-16	Breast cancer;
LGG	cis	rs4273100	0.526	rs2074280	chr17:18917915	A/G	cg18093559	chr17:18951025	GRAP	-0.51	-7.0	-0.31	8.8e-12	Schizophrenia;
LGG	cis	rs2832191	0.692	rs8134627	chr21:30349069	C/T	cg08807101	chr21:30365312	RNF160	-0.9	-19.0	-0.66	5.97e-60	Dental caries;
LGG	cis	rs12908161	1.000	rs34900908	chr15:85257599	G/A	cg24253500	chr15:84953950	NA	0.42	7.02	0.31	7.99e-12	Schizophrenia;
LGG	cis	rs922692	0.744	rs11072806	chr15:79079074	G/A	cg00540400	chr15:79124168	NA	-0.38	-7.27	-0.32	1.52e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7106204	0.764	rs4508205	chr11:24218850	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	11.25	0.46	3.99e-26	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	25.09	0.76	2.42e-88	IgG glycosylation;
LGG	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	cis	rs889122	0.513	rs6511235	chr19:10012666	C/T	cg00846166	chr19:10022875	OLFM2	0.32	7.16	0.32	3.27e-12	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg13047869	chr3:10149882	C3orf24	0.53	8.91	0.38	1.17e-17	Alzheimer's disease;
LGG	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg21775007	chr8:11205619	TDH	-0.49	-8.0	-0.35	9.78e-15	Neuroticism;
LGG	cis	rs2737618	0.651	rs2816975	chr1:200081159	A/G	cg21825944	chr1:200113062	NR5A2	-0.55	-10.65	-0.44	7.6e-24	Uric acid levels;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09699651	chr6:150184138	LRP11	0.57	10.76	0.45	2.92e-24	Testicular germ cell tumor;
LGG	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.28	0.4	6.43e-19	Height;
LGG	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg15268244	chr15:77196840	NA	0.48	10.19	0.43	3.84e-22	Blood metabolite levels;
LGG	cis	rs4430311	0.723	rs10927044	chr1:243767493	A/G	cg25706552	chr1:244017396	NA	0.63	15.28	0.58	5.45e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg03254818	chr6:169586852	NA	-0.44	-9.12	-0.39	2.39e-18	Pulse pressure;
LGG	cis	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.71	-0.3	5.59e-11	Neuroticism;
LGG	cis	rs12477438	0.501	rs6737560	chr2:100095219	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.68	-0.3	6.72e-11	Chronic sinus infection;
LGG	cis	rs911263	0.961	rs2104047	chr14:68754417	T/C	cg18825221	chr14:68749962	RAD51L1	0.53	11.37	0.47	1.33e-26	Primary biliary cholangitis;
LGG	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-8.06	-0.35	6.74e-15	Morning vs. evening chronotype;
LGG	cis	rs12681366	0.734	rs4735288	chr8:95366544	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.68	0.3	6.98e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4363385	0.693	rs4845331	chr1:152982623	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs4595586	0.679	rs1878228	chr12:39355595	T/C	cg13010199	chr12:38710504	ALG10B	0.36	6.82	0.3	2.9e-11	Morning vs. evening chronotype;
LGG	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.09	-0.35	5.43e-15	IgG glycosylation;
LGG	cis	rs4650994	1.000	rs17276527	chr1:178520680	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.18e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg11473876	chr11:109292803	C11orf87	0.48	9.45	0.4	1.64e-19	Schizophrenia;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7112043	1.000	rs7112043	chr11:34789386	A/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.5e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.32	-0.32	1.13e-12	Total body bone mineral density;
LGG	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572733	0.534	rs700684	chr2:198713099	C/T	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.76	0.38	3.57e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg00376283	chr12:123451042	ABCB9	0.65	11.7	0.48	7.05e-28	Platelet count;
LGG	cis	rs1555133	0.651	rs2295762	chr20:31025535	A/G	cg00028034	chr20:30779307	TSPYL3	0.33	6.7	0.3	6.13e-11	Monocyte count;
LGG	trans	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg01620082	chr3:125678407	NA	-0.67	-7.12	-0.31	4.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg19628046	chr18:33552617	C18orf21	0.53	7.74	0.34	6.13e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs754423	0.515	rs2144983	chr14:52548843	C/T	cg12071775	chr14:52591786	NA	0.41	6.97	0.31	1.09e-11	Craniofacial microsomia;
LGG	cis	rs977987	0.902	rs34539062	chr16:75493279	C/A	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.09e-28	Dupuytren's disease;
LGG	cis	rs1461503	0.966	rs10790545	chr11:122838350	G/C	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs17102423	0.826	rs10873180	chr14:65604361	A/G	cg16583315	chr14:65563665	MAX	0.35	6.86	0.3	2.21e-11	Obesity-related traits;
LGG	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg06634786	chr22:41940651	POLR3H	0.73	12.24	0.49	4.65e-30	Vitiligo;
LGG	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.19	-0.39	1.28e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.52	9.03	0.39	4.54e-18	Prudent dietary pattern;
LGG	cis	rs8028182	0.549	rs4886696	chr15:75664570	A/T	cg20655648	chr15:75932815	IMP3	-0.45	-7.51	-0.33	3.17e-13	Sudden cardiac arrest;
LGG	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg16395133	chr6:150326394	RAET1K	0.27	6.84	0.3	2.47e-11	Alopecia areata;
LGG	cis	rs877282	0.891	rs12767062	chr10:797961	C/T	cg17470449	chr10:769945	NA	0.62	7.72	0.34	7.03e-14	Uric acid levels;
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg24101359	chr6:42928495	GNMT	0.57	16.9	0.62	3.08e-50	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.68	-0.41	2.55e-20	Coronary artery disease;
LGG	trans	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg23933602	chr10:16859644	RSU1	0.99	25.56	0.77	1.59e-90	Platelet distribution width;
LGG	cis	rs2486288	0.656	rs11854365	chr15:45558083	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.1	-0.43	8.07e-22	Glomerular filtration rate;
LGG	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg00198680	chr16:28758506	NA	0.28	6.89	0.31	1.79e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9457247	1.000	rs397713	chr6:167386714	G/A	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg27427491	chr17:78079615	GAA	-0.3	-7.7	-0.34	8.42e-14	Yeast infection;
LGG	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.82	0.3	2.93e-11	Aortic root size;
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.69	12.45	0.5	6.82e-31	Lymphocyte counts;
LGG	cis	rs472402	0.580	rs10076470	chr5:6632875	G/A	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.05	-0.31	6.37e-12	Response to amphetamines;
LGG	cis	rs757081	0.648	rs10766382	chr11:17274441	A/T	cg15432903	chr11:17409602	KCNJ11	-0.43	-7.95	-0.35	1.44e-14	Systolic blood pressure;
LGG	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg04568710	chr12:38710424	ALG10B	0.4	8.67	0.37	7.55e-17	Morning vs. evening chronotype;
LGG	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg10523679	chr1:76189770	ACADM	-0.85	-14.59	-0.56	6.3e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg11366901	chr6:160182831	ACAT2	1.04	16.83	0.62	6.43e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg08200770	chr17:80723486	TBCD	-0.46	-8.23	-0.36	1.91e-15	Glycated hemoglobin levels;
LGG	cis	rs4742903	0.967	rs7023085	chr9:106904265	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.29	0.36	1.21e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs963731	0.649	rs9679498	chr2:39218458	G/C	cg04010122	chr2:39346883	SOS1	-0.78	-6.73	-0.3	4.95e-11	Corticobasal degeneration;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg19223190	chr17:80058835	NA	0.44	8.44	0.37	4.09e-16	Life satisfaction;
LGG	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg07936489	chr17:37558343	FBXL20	0.84	15.6	0.59	2.08e-44	Glomerular filtration rate (creatinine);
LGG	trans	rs7939886	0.920	rs11227428	chr11:55941972	C/G	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg03476357	chr21:30257390	N6AMT1	0.48	7.97	0.35	1.28e-14	Cognitive test performance;
LGG	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg24675658	chr1:53192096	ZYG11B	-0.5	-9.76	-0.41	1.43e-20	Monocyte count;
LGG	cis	rs9972944	0.756	rs4594282	chr17:63762930	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.3	-0.36	1.13e-15	Total body bone mineral density;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg26513180	chr16:89883248	FANCA	0.93	9.89	0.42	4.79e-21	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01219670	chr7:76054755	ZP3	0.4	7.16	0.32	3.22e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg09307838	chr4:120376055	NA	0.81	13.57	0.53	1.56e-35	Corneal astigmatism;
LGG	cis	rs4356203	0.870	rs10766381	chr11:17257045	A/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.23	-0.32	2.01e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg08085267	chr17:45401833	C17orf57	-0.55	-10.01	-0.42	1.82e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg15028436	chr7:37888078	TXNDC3	-0.57	-8.94	-0.38	9.18e-18	Alzheimer's disease (late onset);
LGG	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.6	-0.37	1.23e-16	Plateletcrit;
LGG	cis	rs6540556	0.521	rs9430015	chr1:209911734	G/A	cg23920097	chr1:209922102	NA	-0.43	-7.87	-0.34	2.61e-14	Red blood cell count;
LGG	cis	rs17401966	1.000	rs12118323	chr1:10469641	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-9.21	-0.39	1.1e-18	Hepatocellular carcinoma;
LGG	trans	rs61931739	0.649	rs815049	chr12:33726757	G/C	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.97	0.35	1.24e-14	Colorectal cancer;
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.77	12.9	0.51	9.86e-33	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg17294928	chr15:75287854	SCAMP5	-0.79	-11.16	-0.46	9.33e-26	Blood trace element (Zn levels);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02273166	chr14:105487914	CDCA4	0.5	7.41	0.33	5.96e-13	Gut microbiome composition (summer);
LGG	cis	rs9486719	1.000	rs13208422	chr6:96892119	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs62244186	0.520	rs9311361	chr3:44796132	T/G	cg02073558	chr3:44770973	ZNF501	0.86	19.25	0.67	4.28e-61	Depressive symptoms;
LGG	cis	rs6998277	0.830	rs7017839	chr8:103610769	G/C	cg10187029	chr8:103597600	NA	1.02	19.46	0.67	4.44e-62	Migraine;
LGG	cis	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg26384229	chr12:38710491	ALG10B	1.01	25.84	0.77	8e-92	Heart rate;
LGG	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg13939156	chr17:80058883	NA	-0.41	-7.21	-0.32	2.35e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.0	0.6	3.35e-46	Obesity-related traits;
LGG	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg26818010	chr10:134567672	INPP5A	-0.62	-9.7	-0.41	2.29e-20	Migraine;
LGG	cis	rs35306767	0.622	rs66462130	chr10:1022108	C/T	cg20503657	chr10:835505	NA	0.62	8.01	0.35	9.54e-15	Eosinophil percentage of granulocytes;
LGG	cis	rs459571	0.959	rs408307	chr9:136892523	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.56	-10.51	-0.44	2.61e-23	Platelet distribution width;
LGG	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.42	-0.4	2.21e-19	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12961656	chr3:193853443	HES1	0.47	7.14	0.31	3.54e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg20290983	chr6:43655470	MRPS18A	0.82	15.92	0.59	7.87e-46	IgG glycosylation;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg10295955	chr4:187884368	NA	-1.13	-30.5	-0.82	7.81e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1670533	0.932	rs13108207	chr4:1054218	C/T	cg27284194	chr4:1044797	NA	0.54	9.77	0.41	1.31e-20	Recombination rate (females);
LGG	cis	rs7553864	0.636	rs7543740	chr1:87609026	C/T	cg17420885	chr1:87600446	LOC339524	-0.36	-6.83	-0.3	2.65e-11	Smoking behavior;
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.21	-0.32	2.36e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.65	-0.37	8.66e-17	IgG glycosylation;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg04267008	chr7:1944627	MAD1L1	-0.5	-8.21	-0.36	2.28e-15	Schizophrenia;
LGG	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg02023728	chr11:77925099	USP35	0.46	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.99	-0.31	9.4e-12	Neuroticism;
LGG	cis	rs283228	0.958	rs2518178	chr6:101832390	A/C	cg27451362	chr6:101846650	GRIK2	0.54	9.03	0.39	4.74e-18	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs17445774	1.000	rs17445774	chr2:200859249	A/G	cg17644776	chr2:200775616	C2orf69	-0.6	-9.41	-0.4	2.39e-19	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg07701084	chr6:150067640	NUP43	-0.71	-13.83	-0.54	1.2e-36	Lung cancer;
LGG	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-9.23	-0.39	9.95e-19	Morning vs. evening chronotype;
LGG	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg24631222	chr15:78858424	CHRNA5	-0.43	-6.86	-0.3	2.18e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg24503407	chr1:205819492	PM20D1	-0.54	-9.08	-0.39	3.06e-18	Parkinson's disease;
LGG	cis	rs75920871	1.000	rs7130531	chr11:116863833	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.27	-0.32	1.59e-12	Coronary artery disease;
LGG	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.53	-0.5	3.12e-31	Cognitive function;
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.19e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs4789693	0.679	rs7213057	chr17:80378939	T/C	cg04308225	chr17:80449738	NA	0.49	7.57	0.33	1.99e-13	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.51	0.33	3.17e-13	Schizophrenia;
LGG	trans	rs66887589	0.560	rs9684327	chr4:120365441	A/G	cg25214090	chr10:38739885	LOC399744	0.38	6.93	0.31	1.46e-11	Diastolic blood pressure;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg16318349	chr1:154917307	PBXIP1	-0.3	-7.55	-0.33	2.32e-13	Prostate cancer;
LGG	cis	rs1506636	1.000	rs2402669	chr7:123297460	C/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.27	-0.65	1.44e-56	Plateletcrit;Platelet count;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs9677476	0.909	rs13408391	chr2:232124127	G/T	cg23338755	chr2:231921595	PSMD1	0.47	7.18	0.32	2.88e-12	Food antigen IgG levels;
LGG	cis	rs921968	0.643	rs864990	chr2:219494037	G/A	cg01130898	chr2:219473002	PLCD4	-0.41	-7.06	-0.31	6.32e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.58	-0.33	1.85e-13	Joint mobility (Beighton score);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06098346	chr12:48499667	PFKM;SENP1	-0.44	-7.4	-0.33	6.35e-13	Menarche (age at onset);
LGG	cis	rs8064029	0.892	rs3859159	chr16:4898744	A/G	cg04440724	chr16:4920505	UBN1	-0.61	-7.33	-0.32	1.03e-12	Cancer;
LGG	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg15557168	chr22:42548783	NA	-0.45	-9.58	-0.41	5.82e-20	Schizophrenia;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg26354017	chr1:205819088	PM20D1	-0.52	-8.85	-0.38	1.81e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs524281	0.861	rs10896090	chr11:65945186	A/G	cg16950941	chr11:66035639	RAB1B	-0.49	-6.95	-0.31	1.23e-11	Electroencephalogram traits;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.01	-0.35	9.47e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.6	-7.16	-0.32	3.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs270601	0.770	rs932019	chr5:131599370	T/C	cg07395648	chr5:131743802	NA	-0.37	-7.41	-0.33	6.04e-13	Acylcarnitine levels;
LGG	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs4742903	0.904	rs1605448	chr9:106976405	T/G	cg14250997	chr9:106856677	SMC2	0.39	8.17	0.36	2.91e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg06115741	chr20:33292138	TP53INP2	-0.56	-9.24	-0.39	8.92e-19	Coronary artery disease;
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg01494348	chr8:144660395	NAPRT1	0.9	6.92	0.31	1.54e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg01579765	chr21:45077557	HSF2BP	-0.32	-6.99	-0.31	9.48e-12	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg14926445	chr8:58193284	C8orf71	-0.87	-11.51	-0.47	4.01e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs11971779	0.680	rs11760420	chr7:139114768	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg22906224	chr7:99728672	NA	-0.57	-9.42	-0.4	2.09e-19	Coronary artery disease;
LGG	cis	rs11690935	0.655	rs12997093	chr2:172564438	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	14.74	0.57	1.39e-40	Schizophrenia;
LGG	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.3	-0.36	1.14e-15	Parkinson's disease;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	cis	rs75920871	0.588	rs4620758	chr11:116945718	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.42	-0.36	4.66e-16	Subjective well-being;
LGG	cis	rs8141529	0.509	rs12628211	chr22:29239250	T/C	cg15103426	chr22:29168792	CCDC117	0.68	10.02	0.42	1.58e-21	Lymphocyte counts;
LGG	cis	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg24375607	chr4:120327624	NA	0.57	9.47	0.4	1.39e-19	Corneal astigmatism;
LGG	trans	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg19676328	chr12:49525230	TUBA1B	-0.59	-8.69	-0.37	6.4e-17	Total cholesterol levels;
LGG	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg00666640	chr1:248458726	OR2T12	0.52	8.95	0.38	8.32e-18	Common traits (Other);
LGG	cis	rs911555	0.511	rs2296483	chr14:104029792	G/A	cg24130564	chr14:104152367	KLC1	-0.7	-16.05	-0.6	2.08e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg13147721	chr7:65941812	NA	-0.79	-9.55	-0.41	7.33e-20	Diabetic kidney disease;
LGG	cis	rs72848980	0.512	rs11191749	chr10:105378840	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.8	13.04	0.52	2.53e-33	White matter hyperintensity burden;
LGG	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg24642439	chr20:33292090	TP53INP2	-0.59	-9.99	-0.42	1.99e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs564799	0.966	rs564976	chr3:159729059	G/A	cg04855961	chr3:159719849	NA	-0.29	-7.71	-0.34	7.66e-14	Systemic lupus erythematosus;
LGG	cis	rs4740619	0.525	rs7468344	chr9:15814752	T/C	cg14451791	chr9:16040625	NA	0.32	8.01	0.35	9.48e-15	Body mass index;
LGG	cis	rs981844	0.775	rs62323976	chr4:154739032	A/G	cg14289246	chr4:154710475	SFRP2	0.67	11.03	0.46	2.89e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-23.53	-0.74	4.21e-81	Height;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs8038465	0.615	rs6495076	chr15:73982965	G/A	cg15420318	chr15:73925796	NPTN	0.4	6.94	0.31	1.36e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg19455335	chr8:22457658	C8orf58	-0.37	-7.51	-0.33	3.17e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3806843	0.520	rs265312	chr5:140296272	T/G	cg19875535	chr5:140030758	IK	0.38	7.53	0.33	2.69e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.08e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2599510	0.811	rs2583713	chr2:32822729	A/G	cg02381751	chr2:32503542	YIPF4	0.49	7.89	0.34	2.15e-14	Interleukin-18 levels;
LGG	cis	rs6942756	0.806	rs7794622	chr7:128996268	T/C	cg02491457	chr7:128862824	NA	-0.62	-11.34	-0.47	1.74e-26	White matter hyperintensity burden;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.72	0.34	7.26e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg27286337	chr10:134555280	INPP5A	0.84	13.5	0.53	3.09e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg02018176	chr4:1364513	KIAA1530	-0.48	-11.14	-0.46	1.05e-25	Obesity-related traits;
LGG	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs6712932	1.000	rs28521663	chr2:105846716	T/C	cg27422857	chr2:105853526	NA	-0.38	-7.08	-0.31	5.24e-12	Type 2 diabetes;
LGG	cis	rs7267979	0.868	rs6138553	chr20:25239233	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.51	0.44	2.63e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.5e-33	Chronic sinus infection;
LGG	cis	rs35771425	1.000	rs12739630	chr1:211591687	G/A	cg10512769	chr1:211675356	NA	-0.74	-11.97	-0.49	5.93e-29	Educational attainment (years of education);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08351019	chr7:90893462	FZD1	0.46	7.75	0.34	5.74e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs4731207	0.698	rs10236403	chr7:124539542	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.54	-0.33	2.59e-13	Cutaneous malignant melanoma;
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg27532560	chr4:187881888	NA	-0.58	-12.69	-0.51	7.2e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg00149659	chr3:10157352	C3orf10	0.89	11.49	0.47	4.74e-27	Alzheimer's disease;
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg03264133	chr6:25882463	NA	-0.43	-7.53	-0.33	2.67e-13	Height;
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.67	-0.34	1.01e-13	Dementia with Lewy bodies;
LGG	trans	rs3198697	1.000	rs3198697	chr16:15129940	C/T	cg04146151	chr16:2155961	PKD1	-0.53	-10.21	-0.43	3.22e-22	Triglycerides;
LGG	cis	rs13040088	1.000	rs10854167	chr20:61533039	G/C	cg23096297	chr20:61557774	DIDO1	0.88	12.44	0.5	7.24e-31	Menopause (age at onset);
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg05863683	chr7:1912471	MAD1L1	-0.38	-7.24	-0.32	1.94e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg02403541	chr12:121454288	C12orf43	0.53	8.63	0.37	1e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs59197085	0.636	rs62479609	chr7:128443492	C/G	cg00734629	chr7:128471146	FLNC	0.33	6.71	0.3	5.8e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs514406	0.727	rs61768342	chr1:53217028	G/A	cg24675658	chr1:53192096	ZYG11B	0.51	10.48	0.44	3.44e-23	Monocyte count;
LGG	cis	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg08250081	chr4:10125330	NA	0.35	6.83	0.3	2.65e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	cis	rs894344	0.650	rs11166592	chr8:135577008	A/C	cg09855544	chr8:135498122	ZFAT	0.42	7.63	0.33	1.31e-13	Systolic blood pressure;
LGG	cis	rs6429082	1.000	rs2055127	chr1:235598973	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.5	-8.38	-0.36	6.46e-16	Adiposity;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21963583	chr11:68658836	MRPL21	0.6	10.28	0.43	1.83e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs6456156	0.792	rs4710183	chr6:167514083	A/G	cg07741184	chr6:167504864	NA	-0.38	-8.4	-0.36	5.68e-16	Primary biliary cholangitis;
LGG	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg18681998	chr4:17616180	MED28	0.81	16.38	0.61	6.61e-48	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11644478	chr21:40555479	PSMG1	-0.53	-8.63	-0.37	9.73e-17	Menarche (age at onset);
LGG	cis	rs10193935	0.901	rs10171643	chr2:42532912	C/T	cg27598129	chr2:42591480	NA	-0.66	-9.66	-0.41	3.08e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.45	-9.04	-0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg21775007	chr8:11205619	TDH	0.51	8.31	0.36	1.03e-15	Retinal vascular caliber;
LGG	cis	rs10766496	1.000	rs4993024	chr11:18736877	A/G	cg02515468	chr11:18743222	IGSF22	-0.46	-7.74	-0.34	6.14e-14	Diabetic kidney disease;
LGG	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	8.76	0.38	3.6e-17	Bipolar disorder;
LGG	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg13385794	chr1:248469461	NA	0.49	8.16	0.35	3.17e-15	Common traits (Other);
LGG	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg08704250	chr15:31115839	NA	-0.43	-7.97	-0.35	1.23e-14	Huntington's disease progression;
LGG	cis	rs6540556	1.000	rs6540556	chr1:209936631	G/A	cg23920097	chr1:209922102	NA	-0.45	-7.94	-0.35	1.53e-14	Red blood cell count;
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.19	-0.36	2.65e-15	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04073608	chr11:65268100	MALAT1	0.46	7.79	0.34	4.46e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg15268244	chr15:77196840	NA	-0.41	-8.22	-0.36	2.12e-15	Blood metabolite levels;
LGG	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg24812749	chr6:127587940	RNF146	0.53	8.75	0.38	3.95e-17	Breast cancer;
LGG	cis	rs9831754	0.906	rs4680929	chr3:78387591	T/A	cg06138941	chr3:78371609	NA	-0.9	-18.78	-0.66	6.52e-59	Calcium levels;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	10.99	0.46	3.84e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.86	-0.38	1.71e-17	Mean corpuscular volume;
LGG	cis	rs4727027	0.835	rs11767810	chr7:148774433	T/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.83	0.3	2.61e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02667081	chr16:71880439	ATXN1L	0.44	7.03	0.31	7.42e-12	Gut microbiome composition (summer);
LGG	cis	rs11874712	1.000	rs11082509	chr18:43655010	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.75	-0.45	3.34e-24	Migraine - clinic-based;
LGG	cis	rs17125944	0.615	rs12586707	chr14:53298277	A/G	cg00686598	chr14:53173677	PSMC6	-0.74	-7.87	-0.34	2.45e-14	Alzheimer's disease (late onset);
LGG	cis	rs911186	0.786	rs3800307	chr6:27185792	A/T	cg12292205	chr6:26970375	C6orf41	-0.62	-9.1	-0.39	2.7e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6426558	0.502	rs2813965	chr1:227445733	A/G	cg10327440	chr1:227177885	CDC42BPA	0.62	10.18	0.43	4.11e-22	Neutrophil percentage of white cells;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.91	-0.78	1.01e-96	Primary sclerosing cholangitis;
LGG	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	12.88	0.51	1.15e-32	Hip circumference adjusted for BMI;
LGG	cis	rs10214930	0.697	rs10447552	chr7:27683298	A/G	cg22168087	chr7:27702803	HIBADH	-0.45	-6.74	-0.3	4.79e-11	Hypospadias;
LGG	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg00504896	chr12:9437009	LOC642846	-0.44	-8.07	-0.35	6.21e-15	Breast size;
LGG	cis	rs1595825	0.891	rs16824376	chr2:198684342	C/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.75	-0.3	4.3e-11	Ulcerative colitis;
LGG	cis	rs9318086	0.648	rs4067969	chr13:24469120	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.26	0.4	7.37e-19	Myopia (pathological);
LGG	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg24634471	chr8:143751801	JRK	0.54	8.62	0.37	1.04e-16	Schizophrenia;
LGG	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg09021430	chr5:549028	NA	-0.69	-9.85	-0.42	6.69e-21	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.51	0.37	2.45e-16	Electroencephalogram traits;
LGG	cis	rs5758511	0.773	rs12167978	chr22:42346475	G/A	cg15128208	chr22:42549153	NA	0.55	8.87	0.38	1.57e-17	Birth weight;
LGG	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg12667521	chr19:29218732	NA	0.63	9.9	0.42	4.37e-21	Methadone dose in opioid dependence;
LGG	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg16141378	chr3:129829833	LOC729375	-0.33	-7.38	-0.32	7.42e-13	Monocyte count;
LGG	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg02836325	chr17:76403955	PGS1	-0.7	-14.12	-0.55	6.54e-38	HDL cholesterol levels;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.56	0.37	1.7e-16	Prostate cancer;
LGG	cis	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg22857025	chr5:266934	NA	-1.52	-25.08	-0.76	2.78e-88	Breast cancer;
LGG	cis	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.39	-0.43	7.12e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	15.28	0.58	5.9e-43	Mean platelet volume;
LGG	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg13010199	chr12:38710504	ALG10B	0.74	15.25	0.58	7.84e-43	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.58	-0.33	1.86e-13	Initial pursuit acceleration;
LGG	cis	rs870825	0.655	rs35397385	chr4:185639095	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	22.77	0.73	1.54e-77	Blood protein levels;
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg21226059	chr5:178986404	RUFY1	0.49	8.89	0.38	1.4e-17	Lung cancer;
LGG	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg15268244	chr15:77196840	NA	0.44	9.73	0.41	1.69e-20	Blood metabolite levels;
LGG	cis	rs6504108	0.624	rs2021811	chr17:46237782	A/G	cg02219949	chr17:45927392	SP6	0.44	8.18	0.36	2.82e-15	Body mass index;
LGG	cis	rs72634258	0.836	rs9658012	chr1:7989022	C/T	cg00042356	chr1:8021962	PARK7	0.83	10.38	0.43	7.88e-23	Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08795170	chr5:108746307	PJA2	0.44	7.08	0.31	5.37e-12	Cognitive performance;
LGG	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.49	0.37	2.81e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10851411	0.697	rs113979838	chr15:42792353	T/C	cg21293051	chr15:42870591	STARD9	0.5	6.97	0.31	1.09e-11	Glucose homeostasis traits;
LGG	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.87	-0.38	1.66e-17	Mean corpuscular volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12484590	chr1:156475177	NA	0.45	8.06	0.35	6.79e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.09	-0.31	4.96e-12	Bipolar disorder;
LGG	cis	rs5769765	0.773	rs9616206	chr22:50310847	G/T	cg02269571	chr22:50332266	NA	-0.72	-10.9	-0.45	9.11e-25	Schizophrenia;
LGG	cis	rs2415984	0.600	rs61993299	chr14:46944880	A/C	cg14871534	chr14:47121158	RPL10L	-0.58	-10.26	-0.43	2.14e-22	Number of children ever born;
LGG	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg00405596	chr8:11794950	NA	-0.41	-6.7	-0.3	6.25e-11	Neuroticism;
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	7.88	0.34	2.37e-14	Monocyte count;
LGG	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs10465746	0.725	rs2024591	chr1:84329235	C/T	cg10977910	chr1:84465055	TTLL7	0.58	10.55	0.44	1.91e-23	Obesity-related traits;
LGG	cis	rs10463554	0.927	rs257317	chr5:102422585	T/C	cg23492399	chr5:102201601	PAM	-0.5	-7.43	-0.33	5.31e-13	Parkinson's disease;
LGG	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9790314	0.905	rs7632797	chr3:161002694	C/T	cg04691961	chr3:161091175	C3orf57	0.61	14.06	0.55	1.25e-37	Morning vs. evening chronotype;
LGG	cis	rs714031	0.934	rs2235341	chr22:40068679	T/G	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.42	-0.56	3.5e-39	Schizophrenia;
LGG	cis	rs12210905	1.000	rs7756481	chr6:27115069	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.88	-0.34	2.41e-14	Hip circumference adjusted for BMI;
LGG	cis	rs11150038	0.826	rs12927722	chr16:78080285	T/C	cg04733911	chr16:78082701	NA	-0.68	-10.18	-0.43	4.28e-22	Colorectal or endometrial cancer;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg02462569	chr6:150064036	NUP43	-0.35	-7.51	-0.33	2.98e-13	Lung cancer;
LGG	cis	rs17453880	0.929	rs10071370	chr5:152048813	T/G	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	cis	rs2120243	0.874	rs7616177	chr3:157153208	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	7.09	0.31	5.06e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs6956675	1.000	rs10231112	chr7:62601257	A/G	cg01314568	chr7:57830625	NA	-0.52	-8.15	-0.35	3.31e-15	Obesity-related traits;
LGG	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-9.07	-0.39	3.36e-18	Parkinson's disease;
LGG	cis	rs933688	1.000	rs1035476	chr5:90745976	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs7134594	0.677	rs1866066	chr12:109858264	A/T	cg19025524	chr12:109796872	NA	-0.48	-9.81	-0.41	8.95e-21	HDL cholesterol;
LGG	cis	rs4132509	1.000	rs6675851	chr1:243787494	G/A	cg25706552	chr1:244017396	NA	0.52	8.19	0.36	2.57e-15	RR interval (heart rate);
LGG	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg03929089	chr4:120376271	NA	-0.69	-10.83	-0.45	1.6e-24	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.72	-0.41	1.85e-20	Bladder cancer;
LGG	trans	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg17763188	chr8:6692148	XKR5	0.42	7.06	0.31	6.18e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg04025307	chr7:1156635	C7orf50	0.79	11.04	0.46	2.51e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs72949976	0.606	rs2178756	chr2:214031423	A/G	cg08319019	chr2:214017104	IKZF2	0.65	12.14	0.49	1.24e-29	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.87	0.3	2.06e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6976053	0.518	rs314357	chr7:100410069	A/G	cg03098644	chr7:100410630	EPHB4	-0.57	-11.06	-0.46	2.11e-25	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.66	0.34	1.12e-13	Longevity;
LGG	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.8	-0.34	4.1e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7940866	0.845	rs10894294	chr11:130830748	G/T	cg12179176	chr11:130786555	SNX19	0.72	13.89	0.54	6.49e-37	Schizophrenia;
LGG	cis	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.28	-0.36	1.35e-15	Retinal vascular caliber;
LGG	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg17376030	chr22:41985996	PMM1	0.54	8.69	0.37	6.45e-17	Vitiligo;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg24503407	chr1:205819492	PM20D1	0.84	20.35	0.69	3.19e-66	Menarche (age at onset);
LGG	cis	rs9354308	0.764	rs1938073	chr6:66583387	C/G	cg07460842	chr6:66804631	NA	0.4	6.69	0.3	6.65e-11	Metabolite levels;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.16	0.32	3.1e-12	Skin colour saturation;
LGG	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.8	0.3	3.17e-11	Bone mineral density;
LGG	cis	rs2111398	0.645	rs7309370	chr12:13053001	A/C	cg03534847	chr12:13053055	GPRC5A	0.46	9.75	0.41	1.48e-20	Cutaneous malignant melanoma;
LGG	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg24110177	chr3:50126178	RBM5	-0.59	-10.79	-0.45	2.37e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg01494348	chr8:144660395	NAPRT1	0.93	7.34	0.32	9.71e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs7084402	0.935	rs10740731	chr10:60348886	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.28	0.63	5.15e-52	Refractive error;
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg01943577	chr7:158741284	NA	-0.45	-7.92	-0.35	1.73e-14	Height;
LGG	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.03	23.69	0.74	7.15e-82	Cognitive ability;
LGG	cis	rs9912468	0.933	rs67700546	chr17:64301081	C/T	cg19474267	chr17:64306194	PRKCA	0.94	24.86	0.76	2.69e-87	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.76	0.38	3.62e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg20607798	chr8:58055168	NA	0.55	6.72	0.3	5.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs78487399	0.808	rs72865297	chr2:43743248	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-6.66	-0.3	7.8e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.88	-0.38	1.47e-17	Morning vs. evening chronotype;
LGG	cis	rs2084898	0.943	rs2077784	chr11:120024874	G/A	cg13907859	chr11:120009124	TRIM29	0.91	12.33	0.5	2.04e-30	Stroke (pediatric);
LGG	cis	rs2303319	1.000	rs12463535	chr2:162252899	C/G	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs13095912	0.752	rs9758141	chr3:185315085	A/T	cg11274856	chr3:185301563	NA	0.49	7.92	0.35	1.74e-14	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21613324	chr5:175875188	FAF2	0.54	8.34	0.36	8.67e-16	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.7	0.41	2.3e-20	Schizophrenia;
LGG	cis	rs7927771	0.524	rs3816605	chr11:47857253	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	1.9e-25	Subjective well-being;
LGG	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.66e-18	Alzheimer's disease;
LGG	cis	rs12282928	0.879	rs713324	chr11:48285064	T/C	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20110780	chr8:109261090	EIF3E	0.45	7.33	0.32	1.01e-12	Cognitive performance;
LGG	cis	rs62400317	0.859	rs6927213	chr6:45206283	A/G	cg20913747	chr6:44695427	NA	0.52	7.89	0.34	2.12e-14	Total body bone mineral density;
LGG	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.55	-0.5	2.55e-31	Chronic sinus infection;
LGG	cis	rs10979	1.000	rs12203151	chr6:143884856	C/T	cg25407410	chr6:143891975	LOC285740	-0.71	-12.28	-0.5	3.38e-30	Hypospadias;
LGG	cis	rs738321	0.756	rs11570745	chr22:38513493	C/T	cg25457927	chr22:38595422	NA	-0.36	-8.34	-0.36	8.29e-16	Breast cancer;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.45	0.33	4.58e-13	Obesity-related traits;
LGG	cis	rs7100689	0.784	rs10749578	chr10:82139115	A/G	cg01528321	chr10:82214614	TSPAN14	-0.97	-17.8	-0.64	2.18e-54	Post bronchodilator FEV1;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18621852	chr3:10150065	C3orf24	0.39	6.65	0.3	8.36e-11	Alzheimer's disease;
LGG	cis	rs11190604	1.000	rs17113137	chr10:102241998	G/C	cg07570687	chr10:102243282	WNT8B	0.46	7.99	0.35	1.09e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.42	-0.33	5.79e-13	Life satisfaction;
LGG	cis	rs73416724	1.000	rs113163694	chr6:43283410	C/T	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06614563	chr5:89770451	MBLAC2;POLR3G	0.46	6.82	0.3	2.83e-11	Gut microbiome composition (summer);
LGG	cis	rs526231	0.543	rs34809	chr5:102430117	C/A	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs12493885	0.697	rs55955923	chr3:153660054	G/A	cg17054900	chr3:154042577	DHX36	-0.69	-8.34	-0.36	8.52e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1555133	0.543	rs13043838	chr20:30984802	A/C	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Monocyte count;
LGG	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg04450456	chr4:17643702	FAM184B	0.33	7.47	0.33	4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg19980929	chr12:42632907	YAF2	0.34	7.63	0.33	1.31e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg17127132	chr2:85788382	GGCX	-0.47	-8.13	-0.35	3.86e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg10402321	chr1:26617780	UBXN11	-0.36	-6.87	-0.3	2.03e-11	Obesity-related traits;
LGG	cis	rs2731664	0.792	rs335435	chr5:176867943	A/G	cg23176889	chr5:176863531	GRK6	-0.64	-12.34	-0.5	1.88e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg24375607	chr4:120327624	NA	0.53	9.15	0.39	1.82e-18	Corneal astigmatism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10324419	chr4:175205038	FBXO8;KIAA1712	0.44	7.75	0.34	6.05e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg12856521	chr11:46389249	DGKZ	0.51	9.23	0.39	9.61e-19	Leprosy;
LGG	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg07395648	chr5:131743802	NA	-0.53	-11.16	-0.46	8.9e-26	Breast cancer;Mosquito bite size;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg24846343	chr22:24311635	DDTL	0.61	12.26	0.5	4e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13102973	0.932	rs28801464	chr4:135876630	A/G	cg14419869	chr4:135874104	NA	-0.57	-10.9	-0.45	8.6e-25	Subjective well-being;
LGG	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg11342453	chr6:26196699	NA	0.49	6.84	0.3	2.58e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7129556	0.520	rs12290511	chr11:77266663	T/G	cg12586386	chr11:77299805	AQP11	0.38	6.73	0.3	5.05e-11	Weight loss (gastric bypass surgery);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg03318654	chr2:87034200	CD8A	-0.34	-6.73	-0.3	5.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg07414643	chr4:187882934	NA	0.56	11.59	0.47	1.91e-27	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9929218	0.954	rs17715762	chr16:68828250	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-11.84	-0.48	1.99e-28	Colorectal cancer;
LGG	cis	rs7216064	1.000	rs2128792	chr17:65857177	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg25237894	chr2:233734115	C2orf82	-0.56	-10.73	-0.45	3.97e-24	Coronary artery disease;
LGG	trans	rs747782	0.585	rs1604655	chr11:48274778	G/A	cg03929089	chr4:120376271	NA	0.69	8.13	0.35	3.82e-15	Intraocular pressure;
LGG	cis	rs9948	0.786	rs62156227	chr2:97417942	C/A	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	5.09e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs968567	0.539	rs174555	chr11:61579760	T/C	cg19610905	chr11:61596333	FADS2	-0.77	-13.11	-0.52	1.29e-33	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs1894633	0.574	rs56340136	chr1:172326143	A/T	cg01573306	chr1:172330400	DNM3	-0.41	-7.16	-0.32	3.1e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21774377	chr6:34760070	UHRF1BP1	0.51	7.94	0.35	1.53e-14	Gut microbiome composition (summer);
LGG	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.6	0.53	1.14e-35	Mean platelet volume;Platelet distribution width;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg02985366	chr16:32360428	NA	-0.45	-7.0	-0.31	9.33e-12	Menopause (age at onset);
LGG	cis	rs72949976	0.584	rs12467619	chr2:214022933	T/C	cg08319019	chr2:214017104	IKZF2	0.67	12.86	0.51	1.36e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25976786	chr12:53662079	ESPL1	-0.41	-6.82	-0.3	2.81e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7587476	0.765	rs2121284	chr2:215656260	T/C	cg04530015	chr2:215796436	ABCA12	0.46	8.33	0.36	9.19e-16	Neuroblastoma;
LGG	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg16339924	chr4:17578868	LAP3	-0.62	-9.74	-0.41	1.64e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg15208524	chr1:10270712	KIF1B	0.41	7.21	0.32	2.33e-12	Hepatocellular carcinoma;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg26155939	chr18:44337853	ST8SIA5	0.36	6.75	0.3	4.55e-11	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04902049	chr1:36622448	MAP7D1	0.51	8.06	0.35	6.57e-15	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01148728	chr11:117198424	CEP164	0.5	8.63	0.37	1.01e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg11235426	chr6:292522	DUSP22	-0.6	-10.15	-0.43	5.66e-22	Menopause (age at onset);
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.14	0.55	5.61e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10819861	0.620	rs10819834	chr9:98857473	C/G	cg14508093	chr9:98862825	NA	0.31	7.17	0.32	2.96e-12	Electrocardiographic traits;
LGG	cis	rs4150161	0.656	rs77958073	chr16:84223622	T/G	cg10106505	chr16:84220380	TAF1C	-0.85	-7.01	-0.31	8.21e-12	Systolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs7394190	0.748	rs11000773	chr10:75534115	G/T	cg07699608	chr10:75541558	CHCHD1	0.55	7.33	0.32	1.03e-12	Incident atrial fibrillation;
LGG	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg16586182	chr3:47516702	SCAP	0.74	13.53	0.53	2.15e-35	Colorectal cancer;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.52	0.37	2.21e-16	Obesity-related traits;
LGG	cis	rs9487051	0.872	rs1111866	chr6:109610846	A/C	cg12927641	chr6:109611667	NA	0.38	7.27	0.32	1.51e-12	Reticulocyte fraction of red cells;
LGG	cis	rs3816183	0.585	rs4953562	chr2:42912035	T/C	cg14631114	chr2:43023945	NA	0.34	6.83	0.3	2.6e-11	Hypospadias;
LGG	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	9.54	0.41	8.02e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12549902	1.000	rs12549902	chr8:41509259	C/T	cg21772509	chr8:41503840	NKX6-3	0.87	19.57	0.67	1.37e-62	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23030894	chr19:37701637	ZNF585B	0.43	6.81	0.3	2.95e-11	Cognitive performance;
LGG	cis	rs10937275	0.623	rs34421968	chr3:186645080	T/C	cg13419791	chr3:186648285	ST6GAL1	0.78	8.05	0.35	7.17e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg16447950	chr5:562315	NA	-0.47	-7.89	-0.34	2.18e-14	Obesity-related traits;
LGG	cis	rs6831352	0.918	rs17218602	chr4:100061073	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.6	-0.37	1.26e-16	Alcohol dependence;
LGG	cis	rs141670911	1	rs141670911	chr6:26581258	A/T	cg11502198	chr6:26597334	ABT1	-0.9	-7.66	-0.34	1.06e-13	Small cell lung carcinoma;
LGG	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg08999081	chr20:33150536	PIGU	0.37	9.26	0.4	7.41e-19	Coronary artery disease;
LGG	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.51	-0.33	3.03e-13	Psoriasis;
LGG	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg20336341	chr7:50628841	DDC	0.37	7.03	0.31	7.44e-12	Malaria;
LGG	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05665937	chr4:1216051	CTBP1	-0.42	-7.45	-0.33	4.75e-13	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.84	0.42	6.85e-21	Prudent dietary pattern;
LGG	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg16141378	chr3:129829833	LOC729375	0.33	7.07	0.31	5.74e-12	Neuroticism;
LGG	cis	rs67460515	0.563	rs6441362	chr3:160877613	G/A	cg03342759	chr3:160939853	NMD3	-0.69	-11.53	-0.47	3.21e-27	Parkinson's disease;
LGG	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.29	-0.36	1.22e-15	Retinal vascular caliber;
LGG	cis	rs6141769	0.542	rs9421	chr20:31291161	C/T	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.72	-0.3	5.23e-11	Subjective well-being;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg05368731	chr17:41323189	NBR1	0.94	18.74	0.66	9.51e-59	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg16339924	chr4:17578868	LAP3	0.61	10.71	0.45	4.41e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg05052969	chr1:214156842	NA	0.44	8.62	0.37	1.1e-16	Schizophrenia;
LGG	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.25	-0.49	4.57e-30	Depression;
LGG	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg24006582	chr15:45444508	DUOX1	-0.71	-13.64	-0.54	7.67e-36	Uric acid levels;
LGG	cis	rs6444746	1.000	rs4687454	chr3:193491392	C/G	cg22553634	chr3:193489233	NA	0.69	8.31	0.36	1.06e-15	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg23758822	chr17:41437982	NA	0.86	14.74	0.57	1.37e-40	Menopause (age at onset);
LGG	cis	rs4650994	0.505	rs2811291	chr1:178574217	C/T	cg19399532	chr1:178512495	C1orf220	-0.53	-10.81	-0.45	1.93e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs5758659	0.652	rs133340	chr22:42417687	A/T	cg15557168	chr22:42548783	NA	0.34	7.78	0.34	4.9e-14	Cognitive function;
LGG	cis	rs17453880	0.929	rs4618416	chr5:152028995	G/A	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs3762637	0.941	rs9873842	chr3:122135331	A/T	cg24169773	chr3:122142474	KPNA1	-0.6	-10.07	-0.42	1.05e-21	LDL cholesterol levels;
LGG	cis	rs6840360	0.967	rs10049728	chr4:152672121	C/G	cg22705602	chr4:152727874	NA	-0.26	-6.66	-0.3	7.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg12310025	chr6:25882481	NA	-0.53	-10.15	-0.43	5.56e-22	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15655316	chr13:20356642	PSPC1	0.42	6.77	0.3	3.85e-11	Cognitive performance;
LGG	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.41	7.03	0.31	7.49e-12	Vitiligo;
LGG	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg23649088	chr2:200775458	C2orf69	-0.59	-7.62	-0.33	1.49e-13	Schizophrenia;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg13468214	chr4:1046988	NA	-0.36	-8.24	-0.36	1.77e-15	Recombination rate (males);
LGG	cis	rs7095944	0.614	rs10901818	chr10:126449428	G/A	cg08799069	chr10:126477246	METTL10	-0.5	-11.51	-0.47	3.9e-27	Asthma;
LGG	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg03254818	chr6:169586852	NA	-0.61	-10.9	-0.45	9.08e-25	Pulse pressure;
LGG	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg15208524	chr1:10270712	KIF1B	0.45	8.05	0.35	6.81e-15	Hepatocellular carcinoma;
LGG	trans	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.46	-0.37	3.65e-16	Triglycerides;
LGG	cis	rs11191205	0.644	rs10883664	chr10:103368208	C/T	cg15320455	chr10:103880129	LDB1	0.47	6.73	0.3	5.09e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12258864	chr10:104004885	GBF1	0.5	7.46	0.33	4.35e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg05372495	chr19:1063624	ABCA7	-0.56	-9.06	-0.39	3.82e-18	Alzheimer's disease (late onset);
LGG	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.44	0.53	5.36e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg23302884	chr18:44338147	ST8SIA5	-0.4	-8.0	-0.35	1.02e-14	Personality dimensions;
LGG	cis	rs2195525	0.572	rs3814759	chr11:119217580	C/T	cg01451205	chr11:119252210	USP2	0.41	6.76	0.3	4.07e-11	Urate levels;
LGG	trans	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg16141378	chr3:129829833	LOC729375	0.35	7.67	0.34	9.94e-14	Neuroticism;
LGG	cis	rs8114671	0.562	rs6058137	chr20:33475074	G/A	cg07148914	chr20:33460835	GGT7	0.57	9.44	0.4	1.87e-19	Height;
LGG	trans	rs7944735	0.817	rs6485784	chr11:47832260	C/T	cg03929089	chr4:120376271	NA	0.56	7.03	0.31	7.22e-12	Intraocular pressure;
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs9815354	1.000	rs7631057	chr3:41817951	C/T	cg03022575	chr3:42003672	ULK4	0.62	7.88	0.34	2.36e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg08305652	chr11:111469057	NA	-0.44	-9.01	-0.39	5.23e-18	Primary sclerosing cholangitis;
LGG	cis	rs2404602	0.647	rs116090606	chr15:77075209	A/G	cg23625390	chr15:77176239	SCAPER	-0.73	-14.67	-0.56	2.63e-40	Blood metabolite levels;
LGG	cis	rs3816183	0.531	rs6544612	chr2:43122766	G/A	cg14631114	chr2:43023945	NA	0.43	7.46	0.33	4.19e-13	Hypospadias;
LGG	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs10875746	0.669	rs11168487	chr12:48640709	G/A	cg24011408	chr12:48396354	COL2A1	-0.59	-7.56	-0.33	2.24e-13	Longevity (90 years and older);
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.8e-17	Lung cancer;
LGG	cis	rs7940866	0.801	rs10894288	chr11:130808679	T/C	cg12179176	chr11:130786555	SNX19	0.77	14.93	0.57	2.03e-41	Schizophrenia;
LGG	cis	rs17604090	0.793	rs66956566	chr7:29688702	A/G	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21582582	chr3:182698605	DCUN1D1	0.51	9.52	0.4	9.54e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs7662389	chr4:99019892	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.56e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3750082	0.505	rs7807550	chr7:32984472	C/T	cg08946731	chr7:32981826	RP9P	0.49	7.17	0.32	3.08e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs1348850	0.567	rs1405714	chr2:178538584	A/G	cg22681709	chr2:178499509	PDE11A	0.47	8.68	0.37	6.6e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg23306229	chr2:178417860	TTC30B	0.55	7.21	0.32	2.25e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9527	0.590	rs7087040	chr10:104799668	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.21	-0.32	2.29e-12	Arsenic metabolism;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg21045802	chr8:109455806	TTC35	0.53	9.96	0.42	2.54e-21	Dupuytren's disease;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg26345216	chr11:117747030	FXYD6	-0.38	-6.74	-0.3	4.81e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4774899	0.966	rs12904501	chr15:57507617	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.34	-0.32	9.79e-13	Urinary tract infection frequency;
LGG	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg06636001	chr8:8085503	FLJ10661	0.56	10.22	0.43	3.1e-22	Retinal vascular caliber;
LGG	trans	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg02030672	chr11:45687055	CHST1	0.58	10.45	0.44	4.28e-23	Obesity-related traits;
LGG	cis	rs2718058	0.519	rs2722242	chr7:37873610	A/G	cg24998770	chr7:37888106	TXNDC3	-0.61	-10.7	-0.45	5.16e-24	Alzheimer's disease (late onset);
LGG	cis	rs4919044	0.808	rs835277	chr10:94809677	T/C	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg23782820	chr8:58130467	NA	0.44	7.0	0.31	9.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-8.23	-0.36	1.93e-15	Blood protein levels;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00292662	chr22:38071168	LGALS1	0.88	23.64	0.74	1.33e-81	Fat distribution (HIV);
LGG	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	8.47	0.37	3.36e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs10193935	0.901	rs59890734	chr2:42595662	G/A	cg27598129	chr2:42591480	NA	-0.67	-9.8	-0.41	9.93e-21	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.43	-0.71	2.8e-71	Height;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03517284	chr6:25882590	NA	0.51	9.58	0.41	6.15e-20	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg06917634	chr15:78832804	PSMA4	0.82	17.09	0.62	3.96e-51	Sudden cardiac arrest;
LGG	cis	rs357618	1.000	rs357623	chr5:150848500	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs7584262	0.736	rs10174871	chr2:42263018	G/A	cg27428208	chr2:42229179	NA	0.5	7.58	0.33	1.87e-13	Bone mineral density;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg15112475	chr7:1198522	ZFAND2A	-0.41	-7.56	-0.33	2.22e-13	Longevity;Endometriosis;
LGG	cis	rs3087591	1.000	rs6505234	chr17:29688299	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.69	-0.56	2.26e-40	Hip circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00767560	chr19:19887256	LOC284440	0.45	7.42	0.33	5.71e-13	Gut microbiome composition (summer);
LGG	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.54	-0.37	2.01e-16	Neuroticism;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg01765077	chr12:122356316	WDR66	0.28	7.42	0.33	5.49e-13	Mean corpuscular volume;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	0.31	8.21	0.36	2.15e-15	IgG glycosylation;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.14	-0.52	9.5e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	1.000	rs9784993	chr7:91672403	G/A	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.97e-16	Breast cancer;
LGG	cis	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg08250081	chr4:10125330	NA	0.67	12.31	0.5	2.61e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9875589	0.957	rs1108341	chr3:13937328	T/A	cg19554555	chr3:13937349	NA	0.72	13.61	0.53	9.64e-36	Ovarian reserve;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13126279	chr21:47581558	C21orf56	-0.56	-9.98	-0.42	2.23e-21	Testicular germ cell tumor;
LGG	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.45	-0.33	4.59e-13	Systemic lupus erythematosus;
LGG	cis	rs2292096	0.929	rs6667419	chr1:200756197	G/C	cg07580975	chr1:200843333	NA	0.49	7.83	0.34	3.27e-14	Epilepsy;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg11494091	chr17:61959527	GH2	0.99	24.14	0.75	6.1e-84	Prudent dietary pattern;
LGG	cis	rs11001765	0.530	rs11001756	chr10:78133348	C/T	cg16072382	chr10:78096093	C10orf11	0.5	6.79	0.3	3.55e-11	Chin dimples;
LGG	cis	rs11122272	0.735	rs2486727	chr1:231539245	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.5e-13	Hemoglobin concentration;
LGG	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg04016957	chr4:1044486	NA	0.35	6.79	0.3	3.43e-11	Recombination rate (males);
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg11494091	chr17:61959527	GH2	0.51	8.25	0.36	1.69e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg01472538	chr16:58549086	SETD6	0.98	8.69	0.37	6.49e-17	Schizophrenia;
LGG	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg12046867	chr14:103022105	NA	-0.75	-12.39	-0.5	1.21e-30	Platelet count;
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs13177180	0.705	rs13153908	chr5:114937416	T/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-10.13	-0.43	6.64e-22	Conotruncal heart defects (inherited effects);
LGG	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.51	0.33	3.03e-13	Joint mobility (Beighton score);
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.15e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4936891	1.000	rs7119122	chr11:123917281	A/C	cg22125253	chr11:123886957	OR10G4	0.54	10.32	0.43	1.29e-22	Male fertility;
LGG	cis	rs11203032	0.831	rs10509567	chr10:90945756	G/A	cg16672925	chr10:90967113	CH25H	0.76	11.29	0.46	2.93e-26	Heart failure;
LGG	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg07549590	chr16:15018862	NA	-0.58	-9.92	-0.42	3.74e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg26897989	chr16:1907736	C16orf73	-0.86	-14.0	-0.55	2.17e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7143963	0.580	rs9671376	chr14:103370163	C/T	cg23020514	chr14:103360112	TRAF3	0.36	7.42	0.33	5.74e-13	Body mass index;
LGG	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	6.2e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1109114	0.844	rs2304610	chr5:148627597	C/A	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.22	-0.46	5.05e-26	Body mass index;
LGG	cis	rs1707322	1.000	rs6693336	chr1:46354595	C/T	cg03146154	chr1:46216737	IPP	0.54	10.29	0.43	1.67e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01297674	chr2:122406765	CLASP1	0.57	8.75	0.38	3.88e-17	Gut microbiome composition (summer);
LGG	cis	rs11096990	0.892	rs28639548	chr4:39187150	G/C	cg24403649	chr4:39172243	NA	-0.46	-7.55	-0.33	2.41e-13	Cognitive function;
LGG	cis	rs2066819	1.000	rs2291361	chr12:56717805	G/A	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs1568889	1.000	rs66857704	chr11:28212346	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	14.27	0.55	1.51e-38	Bipolar disorder;
LGG	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg04978709	chr7:75101039	POM121C	-0.4	-8.26	-0.36	1.58e-15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4803455	0.565	rs2241713	chr19:41869468	C/G	cg09537434	chr19:41945824	ATP5SL	0.59	11.66	0.48	9.68e-28	Migraine;Coronary artery disease;
LGG	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg24623649	chr8:11872141	NA	0.29	6.8	0.3	3.25e-11	Neuroticism;
LGG	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg17644776	chr2:200775616	C2orf69	-0.48	-7.99	-0.35	1.11e-14	Asthma (bronchodilator response);
LGG	cis	rs7937682	0.562	rs12275761	chr11:111367083	T/A	cg09085632	chr11:111637200	PPP2R1B	0.73	13.36	0.53	1.18e-34	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05665937	chr4:1216051	CTBP1	-0.41	-7.2	-0.32	2.47e-12	Obesity-related traits;
LGG	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.72	-0.34	7e-14	Mean corpuscular volume;
LGG	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs7580658	0.857	rs2896980	chr2:128139959	T/C	cg10021288	chr2:128175891	PROC	-0.63	-12.89	-0.51	1.01e-32	Protein C levels;
LGG	cis	rs4664304	0.903	rs72957578	chr2:160754133	G/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.33	-0.32	1.06e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2273669	0.915	rs4992382	chr6:109292826	T/A	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-13.17	-0.52	7.27e-34	Personality dimensions;
LGG	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg11871910	chr12:69753446	YEATS4	-1.02	-27.6	-0.79	7.2e-100	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg15890332	chr12:107067104	RFX4	0.31	8.22	0.36	2.01e-15	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.15	-20.12	-0.68	3.63e-65	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00166722	chr3:10149974	C3orf24	0.5	8.57	0.37	1.55e-16	Alzheimer's disease;
LGG	cis	rs870825	0.616	rs7700216	chr4:185648510	G/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.98	-0.31	1.01e-11	Neuroticism;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.65	-0.48	1.07e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.88	-0.48	1.3e-28	Morning vs. evening chronotype;
LGG	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg14835575	chr10:16859367	RSU1	0.33	6.68	0.3	7.07e-11	Platelet distribution width;
LGG	trans	rs2018683	0.677	rs12540529	chr7:28969384	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.22	-0.39	1.03e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs950169	0.922	rs12910334	chr15:84958318	G/A	cg03959625	chr15:84868606	LOC388152	0.55	8.59	0.37	1.34e-16	Schizophrenia;
LGG	cis	rs10426930	0.607	rs877287	chr19:5041989	G/A	cg15621731	chr19:5074616	KDM4B	-0.31	-7.7	-0.34	8.12e-14	Monocyte percentage of white cells;
LGG	cis	rs559928	0.502	rs11231787	chr11:64179813	T/C	cg05555928	chr11:63887634	MACROD1	-0.59	-9.88	-0.42	5.14e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg25237894	chr2:233734115	C2orf82	0.64	11.86	0.48	1.68e-28	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg00666640	chr1:248458726	OR2T12	0.62	9.97	0.42	2.44e-21	Common traits (Other);
LGG	cis	rs9911578	0.967	rs2567892	chr17:56668929	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.85	0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg16339924	chr4:17578868	LAP3	0.58	10.1	0.43	7.94e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg08222618	chr4:941054	TMEM175	0.77	16.16	0.6	6.84e-47	Sjögren's syndrome;
LGG	cis	rs8133932	0.654	rs407651	chr21:47350587	C/T	cg11214348	chr21:47283868	PCBP3	-0.45	-7.95	-0.35	1.45e-14	Schizophrenia;
LGG	cis	rs2153904	0.793	rs12118655	chr1:205663478	A/G	cg24503407	chr1:205819492	PM20D1	-0.5	-6.66	-0.3	8.02e-11	Prostate-specific antigen levels;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.52	0.4	1e-19	Bipolar disorder;
LGG	trans	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-11.72	-0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.77	0.34	5.15e-14	Prudent dietary pattern;
LGG	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg02002194	chr4:3960332	NA	-0.52	-9.65	-0.41	3.41e-20	Retinal vascular caliber;
LGG	cis	rs6982240	0.514	rs1865247	chr8:142274654	A/T	cg20799268	chr8:142275649	NA	-0.25	-6.93	-0.31	1.38e-11	Tonsillectomy;
LGG	cis	rs2718058	0.540	rs2722331	chr7:37816055	G/T	cg24998770	chr7:37888106	TXNDC3	0.4	6.78	0.3	3.79e-11	Alzheimer's disease (late onset);
LGG	cis	rs4642101	0.640	rs7629354	chr3:12827746	T/G	cg24848339	chr3:12840334	CAND2	0.43	9.8	0.41	9.69e-21	QRS complex (12-leadsum);
LGG	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg11764359	chr7:65958608	NA	-0.79	-14.76	-0.57	1.1e-40	Aortic root size;
LGG	cis	rs9326248	0.581	rs10502222	chr11:116833730	C/T	cg20608306	chr11:116969690	SIK3	0.42	13.45	0.53	5.05e-35	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05577945	chr13:78271874	SLAIN1	0.48	7.35	0.32	9.29e-13	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs17253792	0.822	rs17683656	chr14:56053361	C/T	cg01858014	chr14:56050164	KTN1	0.9	12.16	0.49	1.06e-29	Putamen volume;
LGG	cis	rs3741798	1.000	rs17303178	chr12:12485351	G/A	cg08615371	chr12:12503544	MANSC1	0.6	6.82	0.3	2.93e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17401966	1.000	rs4845934	chr1:10468946	G/A	cg19773385	chr1:10388646	KIF1B	-0.44	-8.47	-0.37	3.16e-16	Hepatocellular carcinoma;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg18926786	chr6:150244388	RAET1G	0.32	6.88	0.3	1.95e-11	Testicular germ cell tumor;
LGG	trans	rs9354308	0.764	rs9342515	chr6:66591303	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs7267979	1.000	rs4815406	chr20:25341316	C/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.44e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02621020	chr8:145159250	SHARPIN;MAF1	0.48	7.02	0.31	8.01e-12	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.93	0.31	1.41e-11	Mood instability;
LGG	cis	rs9473924	0.542	rs36093098	chr6:50833931	G/A	cg14470998	chr6:50812995	TFAP2B	0.7	8.33	0.36	9.25e-16	Body mass index;
LGG	cis	rs67133203	0.904	rs7965566	chr12:51331164	A/G	cg14688905	chr12:51403056	SLC11A2	0.7	10.67	0.44	6.41e-24	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.3	-0.32	1.24e-12	Mood instability;
LGG	trans	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg05059571	chr16:84539110	KIAA1609	-0.61	-11.64	-0.48	1.23e-27	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs2840044	1.000	rs17637907	chr17:33891386	A/G	cg19694781	chr19:47549865	TMEM160	0.54	8.97	0.38	7.68e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg20476274	chr7:133979776	SLC35B4	-0.7	-12.5	-0.5	4.28e-31	Mean platelet volume;
LGG	cis	rs4731207	0.596	rs6466989	chr7:124690963	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.52	-0.33	2.85e-13	Cutaneous malignant melanoma;
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg22044901	chr15:68126292	NA	0.42	7.88	0.34	2.37e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg11062466	chr8:58055876	NA	0.52	9.03	0.39	4.74e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-10.73	-0.45	3.95e-24	Total body bone mineral density;
LGG	cis	rs7106204	0.748	rs28552633	chr11:24207518	A/C	ch.11.24196551F	chr11:24239977	NA	1.0	15.7	0.59	7.31e-45	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6993813	0.653	rs4355805	chr8:120016374	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.89	0.34	2.17e-14	Bone mineral density (hip);
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05665937	chr4:1216051	CTBP1	0.47	8.4	0.36	5.44e-16	Obesity-related traits;
LGG	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg24130564	chr14:104152367	KLC1	-0.39	-7.09	-0.31	5.09e-12	Reticulocyte count;
LGG	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg15485101	chr11:133734466	NA	0.46	7.91	0.34	1.98e-14	Childhood ear infection;
LGG	cis	rs7267979	1.000	rs2387880	chr20:25377787	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg06872548	chr17:78716983	RPTOR	0.45	11.11	0.46	1.33e-25	Obesity;
LGG	cis	rs9303280	0.901	rs12936231	chr17:38029120	C/G	cg00129232	chr17:37814104	STARD3	-0.48	-9.1	-0.39	2.65e-18	Self-reported allergy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20570410	chr6:46097530	ENPP4	0.4	7.01	0.31	8.42e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7707921	0.522	rs4703537	chr5:81480371	C/T	cg15871215	chr5:81402204	ATG10	0.31	7.0	0.31	9.19e-12	Breast cancer;
LGG	cis	rs62400317	0.859	rs62438864	chr6:45041787	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.55e-22	Total body bone mineral density;
LGG	trans	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg06521331	chr12:34319734	NA	-0.45	-7.68	-0.34	9.74e-14	Heart rate;
LGG	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.39	-0.43	7.26e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg03060546	chr3:49711283	APEH	0.6	8.43	0.36	4.47e-16	Menarche (age at onset);
LGG	cis	rs1882538	0.503	rs13240997	chr7:133135373	C/A	cg10665199	chr7:133106180	EXOC4	0.58	9.39	0.4	2.67e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1018836	0.537	rs13251501	chr8:91458796	G/A	cg16814680	chr8:91681699	NA	-0.6	-9.63	-0.41	3.83e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg20587970	chr11:113659929	NA	-1.41	-24.72	-0.75	1.28e-86	Hip circumference adjusted for BMI;
LGG	cis	rs10189230	0.967	rs11692482	chr2:222352405	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.19	-0.32	2.68e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15322783	chr19:37407152	ZNF829;ZNF568	0.46	7.04	0.31	6.96e-12	Gut microbiome composition (summer);
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.67	-0.34	1.04e-13	Testicular germ cell tumor;
LGG	cis	rs721399	0.542	rs10085931	chr8:18245449	A/G	cg18736775	chr8:18248649	NAT2	-0.74	-11.84	-0.48	1.98e-28	Blood metabolite levels;
LGG	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg03806693	chr22:41940476	POLR3H	1.07	19.01	0.66	5.58e-60	Vitiligo;
LGG	cis	rs28374715	0.681	rs28728213	chr15:41653602	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.19	-26.37	-0.77	2.87e-94	Ulcerative colitis;
LGG	cis	rs6918586	0.658	rs198829	chr6:26118893	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.79	-0.41	1.1e-20	Schizophrenia;
LGG	cis	rs10227331	1.000	rs10255520	chr7:157292087	C/T	cg06076350	chr7:157294107	NA	0.35	6.67	0.3	7.49e-11	Inattentive symptoms;
LGG	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg19773385	chr1:10388646	KIF1B	0.47	9.73	0.41	1.79e-20	Hepatocellular carcinoma;
LGG	cis	rs701145	0.640	rs184825	chr3:153931342	C/G	cg17054900	chr3:154042577	DHX36	-0.82	-9.17	-0.39	1.58e-18	Coronary artery disease;
LGG	cis	rs35146811	0.660	rs6465760	chr7:99591418	A/G	cg22906224	chr7:99728672	NA	-0.52	-8.51	-0.37	2.36e-16	Coronary artery disease;
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg12395012	chr8:11607386	GATA4	0.37	7.01	0.31	8.46e-12	Neuroticism;
LGG	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Colorectal cancer;
LGG	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg23029597	chr12:123009494	RSRC2	0.8	7.17	0.32	2.96e-12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LGG	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg23840854	chr1:161414152	NA	-0.71	-8.69	-0.37	6.4e-17	Rheumatoid arthritis;
LGG	cis	rs988958	0.565	rs6753186	chr2:42235998	C/T	cg19376973	chr2:42229025	NA	0.63	9.27	0.4	7.36e-19	Hypospadias;
LGG	cis	rs72781680	0.768	rs56339558	chr2:24125234	G/A	cg08917208	chr2:24149416	ATAD2B	0.66	8.62	0.37	1.05e-16	Lymphocyte counts;
LGG	cis	rs4262150	0.883	rs72799189	chr5:152186600	T/C	cg12297329	chr5:152029980	NA	-0.7	-13.15	-0.52	8.67e-34	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-18.02	-0.64	2.04e-55	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg23758822	chr17:41437982	NA	-0.83	-14.88	-0.57	3.38e-41	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10974632	chr14:51562381	TRIM9	0.47	7.51	0.33	3.02e-13	Cognitive performance;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.28	-0.32	1.43e-12	Life satisfaction;
LGG	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg03929089	chr4:120376271	NA	-0.56	-9.72	-0.41	1.97e-20	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg02725872	chr8:58115012	NA	-0.84	-12.04	-0.49	3.01e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs2901460	0.509	rs11677509	chr2:62045191	T/G	cg02183531	chr2:62113199	CCT4	-0.44	-7.34	-0.32	9.84e-13	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25072359	chr17:41440525	NA	0.5	9.76	0.41	1.39e-20	Menopause (age at onset);
LGG	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg24375607	chr4:120327624	NA	0.59	9.94	0.42	3.11e-21	Corneal astigmatism;
LGG	cis	rs1816854	0.938	rs3764004	chr12:44201451	T/C	cg20956634	chr12:44200518	TWF1	0.44	6.65	0.3	8.09e-11	Inflammatory bowel disease;
LGG	cis	rs34599045	1.000	rs34599045	chr1:152886874	G/C	cg07796016	chr1:152779584	LCE1C	-0.74	-7.76	-0.34	5.31e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7737355	0.853	rs593767	chr5:131043660	T/G	cg06307176	chr5:131281290	NA	0.56	9.23	0.39	9.71e-19	Life satisfaction;
LGG	cis	rs4727027	0.835	rs6959224	chr7:148784495	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	7.01	0.31	8.47e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9783347	1.000	rs4150575	chr11:18356466	C/T	cg15585147	chr11:18324498	HPS5	0.43	9.07	0.39	3.4e-18	Pancreatic cancer;
LGG	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	7.03	0.31	7.33e-12	Renal function-related traits (BUN);
LGG	cis	rs7552404	0.690	rs11161620	chr1:76255228	A/G	cg10523679	chr1:76189770	ACADM	-0.75	-12.15	-0.49	1.17e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg18032289	chr17:61959525	GH2	-0.41	-7.1	-0.31	4.69e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01570182	chr17:44337453	NA	0.51	9.32	0.4	4.74e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs9354308	0.727	rs9342517	chr6:66603293	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	9.06	0.39	3.58e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.15	0.62	2.2e-51	Chronic sinus infection;
LGG	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	8.4	0.36	5.4e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs73001065	0.901	rs739846	chr19:19419071	G/A	cg03709012	chr19:19516395	GATAD2A	0.86	7.82	0.34	3.61e-14	LDL cholesterol;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg05793240	chr7:2802953	GNA12	-0.33	-7.93	-0.35	1.7e-14	Height;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg21724239	chr8:58056113	NA	0.44	6.92	0.31	1.51e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2373794	0.583	rs390579	chr2:40380254	A/G	cg17740179	chr2:40377776	SLC8A1	0.79	9.98	0.42	2.21e-21	Asthma;
LGG	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg17644776	chr2:200775616	C2orf69	0.59	6.76	0.3	4.2e-11	Schizophrenia;
LGG	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg04727924	chr7:799746	HEATR2	0.46	7.23	0.32	1.98e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25130800	chr15:85143846	ZSCAN2	0.54	8.19	0.36	2.59e-15	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	9.18	0.39	1.49e-18	Lung cancer in ever smokers;
LGG	cis	rs36051895	0.587	rs16922785	chr9:5200409	C/G	cg02405213	chr9:5042618	JAK2	-0.73	-12.2	-0.49	7.21e-30	Pediatric autoimmune diseases;
LGG	cis	rs6598955	0.671	rs12145403	chr1:26597189	C/T	cg04990556	chr1:26633338	UBXN11	0.55	7.6	0.33	1.68e-13	Obesity-related traits;
LGG	cis	rs2880765	0.805	rs11858817	chr15:86031260	C/T	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	trans	rs9929218	0.954	rs34097984	chr16:68824148	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.39	-0.36	5.88e-16	Tonsillectomy;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg15971980	chr6:150254442	NA	0.43	8.23	0.36	1.87e-15	Lung cancer;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs7432375	0.901	rs7648531	chr3:136462223	T/A	cg21827317	chr3:136751795	NA	-0.46	-8.24	-0.36	1.74e-15	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.12e-19	Bone mineral density;
LGG	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.31	0.32	1.21e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	7.26e-15	Obesity-related traits;
LGG	cis	rs870825	0.616	rs61539306	chr4:185650276	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01724336	chr1:111992067	WDR77;ATP5F1	0.46	7.29	0.32	1.31e-12	Cognitive performance;
LGG	cis	rs4731207	0.596	rs922711	chr7:124604304	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.4e-11	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00922073	chr13:111364588	ING1	0.43	6.84	0.3	2.48e-11	Cognitive performance;
LGG	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.67	-12.12	-0.49	1.46e-29	Hip circumference adjusted for BMI;
LGG	cis	rs6547741	0.844	rs55826602	chr2:27863452	A/G	cg22903471	chr2:27725779	GCKR	-0.37	-8.27	-0.36	1.47e-15	Oral cavity cancer;
LGG	cis	rs1816752	0.740	rs6490924	chr13:25007052	G/A	cg02811702	chr13:24901961	NA	-0.39	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs3820928	0.967	rs720501	chr2:227778445	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.65	-0.34	1.14e-13	Pulmonary function;
LGG	cis	rs11748327	0.919	rs59799921	chr5:4047315	C/A	cg01025095	chr5:4101132	NA	-0.58	-9.31	-0.4	4.97e-19	Myocardial infarction;
LGG	cis	rs16912285	0.688	rs7128427	chr11:24338598	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	12.78	0.51	2.92e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.2	-0.52	5.47e-34	Gut microbiome composition (summer);
LGG	trans	rs12517041	1.000	rs10941982	chr5:23298902	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	cis	rs9326248	0.861	rs4938343	chr11:117003528	G/C	cg20608306	chr11:116969690	SIK3	0.31	6.91	0.31	1.59e-11	Blood protein levels;
LGG	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg17330251	chr7:94953956	PON1	-0.43	-8.38	-0.36	6.28e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs782590	0.902	rs4672052	chr2:55732018	A/C	cg18811423	chr2:55921094	PNPT1	0.86	19.02	0.66	4.93e-60	Metabolic syndrome;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02071572	chr4:1403502	NA	0.39	6.7	0.3	6.26e-11	Longevity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13662262	chr21:30364895	RNF160	0.41	6.92	0.31	1.49e-11	Cognitive performance;
LGG	cis	rs3820928	0.904	rs10188570	chr2:227792540	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.49	-0.33	3.54e-13	Pulmonary function;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg12193833	chr17:30244370	NA	0.29	6.92	0.31	1.48e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4740619	0.711	rs12216921	chr9:15994502	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.5	-0.44	2.8e-23	Body mass index;
LGG	trans	rs9354308	0.764	rs4273669	chr6:66583060	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.11	-0.31	4.57e-12	Metabolite levels;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.59	0.37	1.34e-16	Lung cancer;
LGG	cis	rs9810089	0.814	rs73226190	chr3:136213310	T/C	cg21827317	chr3:136751795	NA	0.45	7.95	0.35	1.41e-14	Gestational age at birth (child effect);
LGG	cis	rs6496667	0.558	rs10459677	chr15:91042399	A/C	cg22089800	chr15:90895588	ZNF774	-0.51	-8.36	-0.36	7.37e-16	Rheumatoid arthritis;
LGG	cis	rs4132509	0.793	rs10927047	chr1:243803677	A/T	cg21452805	chr1:244014465	NA	0.78	7.76	0.34	5.44e-14	RR interval (heart rate);
LGG	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg06606381	chr12:133084897	FBRSL1	0.69	8.23	0.36	1.88e-15	Depression;
LGG	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg12386194	chr3:101231763	SENP7	-0.43	-7.57	-0.33	1.99e-13	Colorectal cancer;
LGG	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.76	-0.41	1.41e-20	Retinal vascular caliber;
LGG	trans	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	8.45	0.37	3.74e-16	Retinal vascular caliber;
LGG	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Educational attainment;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.94	0.35	1.59e-14	Lung cancer;
LGG	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg02428538	chr16:24856791	SLC5A11	-0.67	-10.27	-0.43	1.99e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11920090	0.932	rs61791107	chr3:170729552	C/A	cg09710316	chr3:170744871	SLC2A2	0.61	8.6	0.37	1.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.27	-0.43	1.93e-22	Longevity;Endometriosis;
LGG	trans	rs55986470	0.817	rs66895963	chr2:239403902	A/T	cg01134436	chr17:81009848	B3GNTL1	0.65	7.3	0.32	1.29e-12	Chronotype;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.5	-0.53	2.84e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg13902645	chr11:5959945	NA	-0.67	-10.84	-0.45	1.49e-24	DNA methylation (variation);
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.58	0.5	2.1e-31	Total body bone mineral density;
LGG	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg15704280	chr7:45808275	SEPT13	0.69	8.33	0.36	9.55e-16	Body mass index;
LGG	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-7.61	-0.33	1.52e-13	Menarche (age at onset);
LGG	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg23625390	chr15:77176239	SCAPER	-0.7	-13.64	-0.54	7.42e-36	Blood metabolite levels;
LGG	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.58	-0.33	1.85e-13	Triglycerides;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg12070911	chr6:150209640	RAET1E	0.28	6.87	0.3	2.03e-11	Lung cancer;
LGG	cis	rs2692947	0.832	rs2692954	chr2:96683378	T/G	cg22654517	chr2:96458247	NA	0.37	7.36	0.32	8.45e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7589342	0.894	rs6736932	chr2:106444854	A/G	cg14210321	chr2:106509881	NCK2	-0.52	-8.97	-0.38	7.2e-18	Addiction;
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg02772935	chr3:125709198	NA	-0.55	-7.05	-0.31	6.33e-12	Blood pressure (smoking interaction);
LGG	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg14101638	chr12:121416612	HNF1A	-0.44	-9.4	-0.4	2.51e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg06374794	chr16:88002281	BANP	0.44	8.09	0.35	5.13e-15	Menopause (age at onset);
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.79	-0.41	1.08e-20	IgG glycosylation;
LGG	cis	rs7412746	0.658	rs72704685	chr1:150897687	C/G	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs1754541	1.000	rs1754541	chr1:101625883	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-6.76	-0.3	4.17e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg27129171	chr3:47204927	SETD2	-0.48	-7.86	-0.34	2.79e-14	Birth weight;
LGG	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs283228	0.617	rs480221	chr6:101748182	C/A	cg27451362	chr6:101846650	GRIK2	0.86	13.52	0.53	2.35e-35	Coenzyme Q10 levels;
LGG	cis	rs9462027	0.628	rs2814945	chr6:34647978	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.67e-24	Systemic lupus erythematosus;
LGG	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.14	0.49	1.24e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg13271783	chr10:134563150	INPP5A	-0.49	-7.72	-0.34	7.49e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.32	-0.32	1.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4731207	0.698	rs7778544	chr7:124527481	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.93	0.45	6.52e-25	Neuroticism;
LGG	trans	rs853679	0.567	rs2232427	chr6:28359709	T/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.72	-0.3	5.22e-11	Depression;
LGG	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg11764359	chr7:65958608	NA	0.81	15.1	0.57	3.44e-42	Aortic root size;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg18402987	chr7:1209562	NA	0.7	9.53	0.41	8.77e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1497828	0.956	rs2859771	chr1:217539502	G/C	cg04411442	chr1:217543379	NA	-0.48	-8.24	-0.36	1.85e-15	Dialysis-related mortality;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.57	-0.53	1.53e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg13282195	chr8:144660772	NAPRT1	0.89	7.35	0.32	9.23e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg15145296	chr3:125709740	NA	-0.62	-8.02	-0.35	8.78e-15	Blood pressure (smoking interaction);
LGG	cis	rs2050392	0.799	rs303429	chr10:30708441	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.84	-0.45	1.5e-24	Inflammatory bowel disease;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.18	-0.32	2.88e-12	Schizophrenia;
LGG	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg04064380	chr11:117688259	NA	-0.52	-7.48	-0.33	3.78e-13	Myopia;
LGG	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg00405596	chr8:11794950	NA	-0.42	-7.17	-0.32	3.04e-12	Neuroticism;
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.65	-0.3	8.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.86	-0.42	5.85e-21	Lung cancer;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg11245990	chr11:68621969	NA	0.42	8.94	0.38	9.62e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg15556689	chr8:8085844	FLJ10661	0.4	6.69	0.3	6.4e-11	Triglycerides;
LGG	cis	rs986417	1.000	rs4901995	chr14:61090629	C/G	cg27398547	chr14:60952738	C14orf39	0.72	6.78	0.3	3.58e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs34421088	0.532	rs2736385	chr8:11148613	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.73	-0.3	5.13e-11	Neuroticism;
LGG	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.14	0.49	1.26e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.55	9.24	0.39	9.17e-19	Blood protein levels;
LGG	cis	rs113835537	0.529	rs2298806	chr11:66282095	G/A	cg24851651	chr11:66362959	CCS	0.44	7.58	0.33	1.89e-13	Airway imaging phenotypes;
LGG	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	trans	rs9354308	0.764	rs4710545	chr6:66584855	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.15	-0.32	3.47e-12	Metabolite levels;
LGG	cis	rs4820539	0.933	rs2267004	chr22:23459863	G/A	cg21100191	chr22:23484243	RTDR1	0.95	20.99	0.7	3.1e-69	Bone mineral density;
LGG	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg07636037	chr3:49044803	WDR6	0.6	10.46	0.44	3.81e-23	Resting heart rate;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00290607	chr11:67383545	NA	0.64	11.57	0.47	2.3e-27	Mean corpuscular volume;
LGG	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.65e-16	Aortic root size;
LGG	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg26384229	chr12:38710491	ALG10B	0.93	21.24	0.7	2.22e-70	Bladder cancer;
LGG	trans	rs4698048	0.545	rs6811287	chr4:10180823	C/T	cg26043149	chr18:55253948	FECH	-0.41	-7.02	-0.31	7.98e-12	Skin aging (microtopography measurement);
LGG	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg10935138	chr17:73851978	WBP2	0.52	7.76	0.34	5.61e-14	Psoriasis;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08040740	chr19:11925285	ZNF440	0.38	6.7	0.3	6.05e-11	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg16339924	chr4:17578868	LAP3	-0.62	-11.05	-0.46	2.36e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.89	0.3	1.87e-11	Schizophrenia;
LGG	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg08198773	chr8:1697536	NA	-0.42	-7.27	-0.32	1.55e-12	Systolic blood pressure;
LGG	cis	rs2712184	0.875	rs2541382	chr2:217680034	C/A	cg05032264	chr2:217675019	NA	-0.45	-9.72	-0.41	1.9e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs7923609	0.729	rs7902616	chr10:65336373	G/A	cg02276361	chr10:65351566	REEP3	-0.31	-6.92	-0.31	1.49e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1348850	0.915	rs10930798	chr2:178446141	G/A	cg27490568	chr2:178487706	NA	0.45	8.7	0.37	6.05e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03054491	chr12:101674203	UTP20	0.47	7.05	0.31	6.62e-12	Gut microbiome composition (summer);
LGG	cis	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg04455712	chr21:45112962	RRP1B	0.53	9.97	0.42	2.42e-21	Mean corpuscular volume;
LGG	trans	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs975739	0.695	rs9544662	chr13:78553723	G/A	cg07847733	chr13:78271382	SLAIN1	0.43	7.55	0.33	2.31e-13	Hair color;
LGG	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg18252515	chr7:66147081	NA	1.42	20.1	0.68	4.43e-65	Diabetic kidney disease;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.45	0.33	4.57e-13	Tonsillectomy;
LGG	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg04362960	chr10:104952993	NT5C2	0.56	10.12	0.43	7.22e-22	Arsenic metabolism;
LGG	cis	rs4936891	0.520	rs61908590	chr11:123869811	A/C	cg22125253	chr11:123886957	OR10G4	-0.46	-7.8	-0.34	4.2e-14	Male fertility;
LGG	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg10326726	chr10:51549505	MSMB	-0.61	-12.35	-0.5	1.69e-30	Prostate-specific antigen levels;
LGG	cis	rs12612619	0.579	rs6722906	chr2:27080035	C/A	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.94	-0.31	1.3e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.18	-0.55	3.57e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg18551225	chr6:44695536	NA	-0.63	-10.15	-0.43	5.43e-22	Total body bone mineral density;
LGG	cis	rs10896135	0.526	rs1987169	chr11:66448044	A/G	cg01599099	chr11:66649832	PC	-0.4	-7.35	-0.32	8.79e-13	Bipolar disorder;
LGG	cis	rs7633770	0.786	rs1402148	chr3:46678295	C/T	cg11219411	chr3:46661640	NA	0.58	13.93	0.54	4.25e-37	Coronary artery disease;
LGG	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg11366901	chr6:160182831	ACAT2	1.01	15.39	0.58	1.9e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6878727	1.000	rs6878727	chr5:123736406	A/G	cg01806427	chr5:123737813	NA	0.32	6.78	0.3	3.72e-11	Breast cancer;
LGG	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.99	-0.31	9.65e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.68	-0.37	6.59e-17	Plateletcrit;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.65	-0.3	8.15e-11	Retinal vascular caliber;
LGG	cis	rs3806843	0.750	rs2563285	chr5:140126137	T/C	cg19875535	chr5:140030758	IK	-0.53	-11.11	-0.46	1.37e-25	Depressive symptoms (multi-trait analysis);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg13519464	chr19:9938554	UBL5	0.43	7.12	0.31	4.18e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg22643751	chr7:855365	UNC84A	0.36	6.95	0.31	1.21e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs4631830	0.863	rs2611508	chr10:51518047	T/A	cg10326726	chr10:51549505	MSMB	-0.67	-13.84	-0.54	1.07e-36	Prostate-specific antigen levels;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08280861	chr8:58055591	NA	0.64	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs317689	0.690	rs7969559	chr12:69655167	A/G	cg11871910	chr12:69753446	YEATS4	0.43	6.79	0.3	3.53e-11	Response to diuretic therapy;
LGG	cis	rs11098499	0.909	rs7681214	chr4:120385320	C/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-7.09	-0.31	5.08e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg03647239	chr10:116582469	FAM160B1	0.4	6.99	0.31	9.42e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9467773	0.804	rs2073526	chr6:26374658	C/T	cg09904177	chr6:26538194	HMGN4	-0.49	-9.24	-0.39	9.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12493885	0.818	rs73158489	chr3:153757862	C/T	cg17054900	chr3:154042577	DHX36	-0.65	-8.5	-0.37	2.7e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7264396	0.623	rs11698601	chr20:34205035	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.12	0.31	4.27e-12	Total cholesterol levels;
LGG	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg14675211	chr2:100938903	LONRF2	0.53	8.85	0.38	1.84e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.15	-0.43	5.29e-22	Bipolar disorder;
LGG	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.87	-0.38	1.62e-17	Bone mineral density;
LGG	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg18200150	chr17:30822561	MYO1D	-0.74	-15.5	-0.58	5.8e-44	Schizophrenia;
LGG	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg27205649	chr11:78285834	NARS2	0.52	8.84	0.38	2e-17	Alzheimer's disease (survival time);
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-10.12	-0.43	7.03e-22	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18535011	chr5:31194448	CDH6	0.54	8.98	0.39	6.91e-18	Gut microbiome composition (summer);
LGG	cis	rs11203032	0.831	rs4933496	chr10:90952338	T/C	cg16672925	chr10:90967113	CH25H	0.79	11.31	0.47	2.33e-26	Heart failure;
LGG	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg26924012	chr15:45694286	SPATA5L1	1.04	22.5	0.72	2.81e-76	Homoarginine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03483426	chr7:134671876	AGBL3	0.47	7.02	0.31	8e-12	Gut microbiome composition (summer);
LGG	cis	rs72945132	0.882	rs55758686	chr11:70172204	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	8.1	0.35	4.78e-15	Coronary artery disease;
LGG	trans	rs2270927	0.510	rs2937740	chr5:75623625	C/G	cg13563193	chr19:33072644	PDCD5	0.73	8.0	0.35	9.88e-15	Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg03517284	chr6:25882590	NA	-0.43	-7.07	-0.31	5.71e-12	Iron status biomarkers;
LGG	cis	rs2119480	0.793	rs7317796	chr13:111313674	C/T	cg16216153	chr13:111290848	CARKD	0.34	6.66	0.3	8e-11	Diastolic blood pressure;
LGG	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.76e-21	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg11430096	chr6:110968061	CDK19	0.68	7.1	0.31	4.76e-12	Prostate cancer;
LGG	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg11812906	chr14:75593930	NEK9	0.5	9.23	0.39	9.62e-19	Height;
LGG	cis	rs2249625	0.545	rs9791273	chr6:72891016	G/T	cg27608224	chr6:72922399	RIMS1	-0.34	-7.46	-0.33	4.42e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.38	7.25	0.32	1.82e-12	Schizophrenia;
LGG	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg18129748	chr3:49941408	MST1R	0.22	6.84	0.3	2.55e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24308560	chr3:49941425	MST1R	0.22	6.73	0.3	4.94e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.564	rs8006489	chr14:103121232	G/A	cg12046867	chr14:103022105	NA	0.41	7.75	0.34	5.69e-14	Platelet count;
LGG	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.68	0.63	7.8e-54	Cognitive function;
LGG	cis	rs9938149	0.677	rs12919641	chr16:88312600	G/C	cg05435882	chr16:88311214	NA	-0.4	-6.9	-0.31	1.73e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg25072359	chr17:41440525	NA	0.53	9.97	0.42	2.52e-21	Menopause (age at onset);
LGG	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs12431204	0.866	rs9576389	chr13:38435027	G/A	cg23307680	chr13:38443104	TRPC4	0.4	6.94	0.31	1.34e-11	Schizophrenia;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg14668632	chr7:2872130	GNA12	-0.38	-7.77	-0.34	5.24e-14	Height;
LGG	cis	rs11711311	0.712	rs6764048	chr3:113332859	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.39	6.81	0.3	3.11e-11	IgG glycosylation;
LGG	cis	rs67311347	0.521	rs2887963	chr3:40243466	C/T	cg13683864	chr3:40499215	RPL14	0.71	13.58	0.53	1.39e-35	Renal cell carcinoma;
LGG	cis	rs35740288	0.822	rs56322219	chr15:86276340	A/T	cg04173714	chr15:86211321	AKAP13	0.42	7.2	0.32	2.53e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg04450456	chr4:17643702	FAM184B	0.34	7.55	0.33	2.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6693567	0.565	rs698914	chr1:150298750	A/G	cg15654264	chr1:150340011	RPRD2	0.33	6.74	0.3	4.75e-11	Migraine;
LGG	cis	rs28595532	1.000	rs11098451	chr4:119717673	C/T	cg11846333	chr4:119757529	SEC24D	0.67	6.7	0.3	5.89e-11	Cannabis dependence symptom count;
LGG	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14019695	chr9:139328340	INPP5E	0.4	7.27	0.32	1.52e-12	Monocyte percentage of white cells;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.16	-0.32	3.24e-12	Monocyte count;
LGG	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg00666640	chr1:248458726	OR2T12	0.55	9.12	0.39	2.39e-18	Common traits (Other);
LGG	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg21798802	chr22:38057573	PDXP	0.39	8.51	0.37	2.38e-16	Fat distribution (HIV);
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg16405210	chr4:1374714	KIAA1530	-0.62	-11.32	-0.47	2.12e-26	Longevity;
LGG	cis	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.08e-25	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.97e-41	Skin colour saturation;
LGG	cis	rs9815354	1.000	rs6599178	chr3:41842129	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.2	0.36	2.39e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	cis	rs2985684	1.000	rs1957977	chr14:50090603	A/G	cg04989706	chr14:50066350	PPIL5	-0.52	-8.2	-0.36	2.31e-15	Carotid intima media thickness;
LGG	cis	rs7851660	0.844	rs12342417	chr9:100639065	G/A	cg13688889	chr9:100608707	NA	-0.59	-11.65	-0.48	1.14e-27	Strep throat;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.07	-0.39	3.33e-18	Primary sclerosing cholangitis;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg18402987	chr7:1209562	NA	0.43	8.11	0.35	4.56e-15	Longevity;Endometriosis;
LGG	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10922622	chr9:108210153	FSD1L	0.36	6.65	0.3	8.3e-11	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs10895140	0.624	rs10895153	chr11:101498066	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.03e-11	Menarche (age at onset);
LGG	trans	rs17780086	0.527	rs72827711	chr17:30537920	T/A	cg20587970	chr11:113659929	NA	-1.37	-16.98	-0.62	1.26e-50	Height;
LGG	cis	rs2802728	0.881	rs13374290	chr1:243571001	A/T	cg05593162	chr1:243577377	SDCCAG8	0.49	6.87	0.3	2.03e-11	Toenail selenium levels;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.08	-0.31	5.34e-12	Menopause (age at onset);
LGG	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	cis	rs10904908	0.733	rs359288	chr10:17330180	A/G	cg01003015	chr10:17271136	VIM	-0.45	-7.3	-0.32	1.23e-12	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs9362426	1.000	rs9362426	chr6:88089874	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.51	9.82	0.42	8.44e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg14893161	chr1:205819251	PM20D1	0.74	16.59	0.61	7.54e-49	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg07659893	chr17:61819838	STRADA	0.47	7.68	0.34	9.78e-14	Prudent dietary pattern;
LGG	cis	rs9815354	0.812	rs55916959	chr3:41849130	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	cis	rs9357271	0.955	rs6903767	chr6:38374812	A/G	cg07362130	chr6:38359646	BTBD9	-0.47	-10.74	-0.45	3.58e-24	Restless legs syndrome;
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg02002194	chr4:3960332	NA	0.47	9.15	0.39	1.87e-18	Systolic blood pressure;
LGG	cis	rs13217239	0.646	rs4403259	chr6:26997617	C/T	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.62e-11	Schizophrenia;
LGG	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9378357	0.850	rs9391986	chr6:3290583	A/G	cg08754725	chr6:3293098	SLC22A23	0.73	7.69	0.34	8.92e-14	Obesity-related traits;
LGG	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	13.62	0.53	9.31e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg12463550	chr7:65579703	CRCP	0.51	8.5	0.37	2.55e-16	Aortic root size;
LGG	cis	rs10463554	0.892	rs158252	chr5:102406250	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg13114125	chr14:105738426	BRF1	-0.84	-16.77	-0.61	1.11e-49	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7172689	0.908	rs67157897	chr15:81562537	T/C	cg11808699	chr15:81528661	IL16	-0.45	-9.15	-0.39	1.88e-18	Inattentive symptoms;
LGG	cis	rs10089	0.953	rs6875982	chr5:127529197	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.45	0.47	6.5e-27	Ileal carcinoids;
LGG	cis	rs7927771	0.542	rs11039336	chr11:47706141	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-10.99	-0.45	3.98e-25	Subjective well-being;
LGG	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg06766960	chr11:133703094	NA	0.54	10.6	0.44	1.21e-23	Childhood ear infection;
LGG	cis	rs4665809	0.590	rs7586047	chr2:26447335	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.0	-0.7	2.82e-69	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.09	-0.31	5.2e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8017423	0.615	rs12586761	chr14:90820897	A/G	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.4	-0.4	2.54e-19	Common traits (Other);
LGG	cis	rs1957429	0.520	rs72625647	chr14:65344106	T/C	cg23373153	chr14:65346875	NA	-0.96	-9.58	-0.41	6.12e-20	Pediatric areal bone mineral density (radius);
LGG	cis	rs921968	0.541	rs6717433	chr2:219375711	G/C	cg01130898	chr2:219473002	PLCD4	0.46	7.87	0.34	2.55e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs8049634	0.913	rs4150115	chr16:84220332	G/T	cg26466773	chr16:84211947	TAF1C	-0.46	-7.55	-0.33	2.31e-13	Small cell lung carcinoma;
LGG	trans	rs56804039	1.000	rs11777086	chr8:8384479	G/T	cg02002194	chr4:3960332	NA	0.44	6.94	0.31	1.29e-11	Cervical cancer;
LGG	cis	rs7635838	0.785	rs904475	chr3:11535417	G/A	cg00170343	chr3:11313890	ATG7	0.4	6.66	0.3	7.86e-11	HDL cholesterol;
LGG	cis	rs6772849	0.930	rs9873888	chr3:128360987	G/A	cg08795948	chr3:128337044	NA	0.66	11.3	0.47	2.47e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs75059851	0.756	rs11223652	chr11:133841207	A/G	cg17703048	chr11:133852993	NA	-0.87	-15.95	-0.6	5.94e-46	Schizophrenia;
LGG	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg20026190	chr17:76395443	PGS1	0.56	9.95	0.42	2.95e-21	HDL cholesterol levels;
LGG	cis	rs4538187	0.760	rs35697586	chr2:64181216	A/T	cg14150252	chr2:64069583	UGP2	-0.49	-8.02	-0.35	8.67e-15	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg00933542	chr6:150070202	PCMT1	0.4	7.32	0.32	1.08e-12	Lung cancer;
LGG	cis	rs7765175	0.698	rs3851198	chr6:113666648	G/A	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.42e-13	Coronary artery calcification;
LGG	cis	rs350251	0.899	rs350277	chr16:12232547	C/T	cg02910054	chr16:12241554	SNX29	0.48	8.96	0.38	7.73e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.58	-0.33	1.85e-13	Other erythrocyte phenotypes;
LGG	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg02002194	chr4:3960332	NA	0.54	10.65	0.44	7.99e-24	Systolic blood pressure;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.13	-0.31	3.77e-12	Life satisfaction;
LGG	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg16586182	chr3:47516702	SCAP	0.72	13.33	0.53	1.49e-34	Colorectal cancer;
LGG	cis	rs13082711	0.863	rs77135084	chr3:27423549	A/C	cg02860705	chr3:27208620	NA	0.77	14.2	0.55	2.88e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25072359	chr17:41440525	NA	0.51	10.15	0.43	5.33e-22	Menopause (age at onset);
LGG	cis	rs2154319	0.887	rs2024860	chr1:41562243	C/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.0	-0.39	5.91e-18	Height;
LGG	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg25809561	chr17:30822961	MYO1D	0.38	8.96	0.38	8.02e-18	Schizophrenia;
LGG	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg07936489	chr17:37558343	FBXL20	1.05	18.83	0.66	3.96e-59	Glomerular filtration rate (creatinine);
LGG	trans	rs1823913	0.614	rs1947457	chr2:192163696	C/T	cg27541374	chr17:58042493	RNFT1	0.58	6.81	0.3	2.95e-11	Obesity-related traits;
LGG	cis	rs3741151	1.000	rs75912489	chr11:73073846	G/A	cg17517138	chr11:73019481	ARHGEF17	1.03	10.37	0.43	8.17e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg06494592	chr3:125709126	NA	-0.54	-6.84	-0.3	2.54e-11	Blood pressure (smoking interaction);
LGG	cis	rs5015933	0.902	rs2291858	chr9:128128782	A/G	cg14078157	chr9:128172775	NA	-0.34	-6.67	-0.3	7.42e-11	Body mass index;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.23	-0.43	2.74e-22	Lymphocyte counts;
LGG	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg08121117	chr13:112575735	NA	-0.38	-8.24	-0.36	1.84e-15	Axial length;
LGG	cis	rs139320	1	rs139320	chr22:39501196	T/C	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.81	-0.3	3.09e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23434654	chr5:121648409	SNCAIP	0.49	8.28	0.36	1.32e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs9397585	0.857	rs3904837	chr6:153382225	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg11814155	chr7:99998594	ZCWPW1	0.54	8.13	0.35	4.03e-15	Platelet count;
LGG	cis	rs2479106	0.892	rs7849665	chr9:126697865	C/T	cg16191174	chr9:126692580	DENND1A	0.47	7.13	0.31	3.79e-12	Polycystic ovary syndrome;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg04166393	chr7:2884313	GNA12	0.45	8.45	0.37	3.67e-16	Height;
LGG	cis	rs10779751	0.734	rs2791649	chr1:11132561	A/G	cg08854313	chr1:11322531	MTOR	0.75	16.74	0.61	1.52e-49	Body mass index;
LGG	cis	rs6669919	0.647	rs4951753	chr1:211671794	C/T	cg10512769	chr1:211675356	NA	-0.57	-11.74	-0.48	4.7e-28	Intelligence (multi-trait analysis);
LGG	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg09904177	chr6:26538194	HMGN4	0.42	7.55	0.33	2.28e-13	Schizophrenia;
LGG	cis	rs6503863	1	rs6503863	chr17:56517034	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.41	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs36093844	0.800	rs17817326	chr11:85595213	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.07	-0.31	5.61e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg07615347	chr10:60278583	BICC1	0.63	18.01	0.64	2.4e-55	Refractive error;
LGG	cis	rs2730245	0.510	rs2788474	chr7:158649005	T/C	cg23730037	chr7:158596552	ESYT2	-0.42	-7.28	-0.32	1.4e-12	Height;
LGG	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg27286337	chr10:134555280	INPP5A	0.9	13.3	0.53	1.98e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3824867	0.804	rs12419342	chr11:47468545	C/T	cg20307385	chr11:47447363	PSMC3	0.48	7.68	0.34	9.62e-14	Mean corpuscular hemoglobin;
LGG	cis	rs801193	0.569	rs2659893	chr7:66199993	G/A	cg11764359	chr7:65958608	NA	0.71	12.91	0.51	8.77e-33	Aortic root size;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08800530	chr5:175788722	KIAA1191	0.42	7.16	0.32	3.19e-12	Bipolar disorder;
LGG	cis	rs546131	0.928	rs558967	chr11:34827168	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	11.13	0.46	1.2e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs1355223	0.507	rs11032903	chr11:34876176	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.34	-0.36	8.35e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.39	-0.32	6.86e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9287719	0.967	rs7582775	chr2:10738449	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.87	0.34	2.49e-14	Birth weight;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.66	-0.41	3.12e-20	Platelet count;
LGG	cis	rs1256531	0.661	rs17102910	chr14:66214842	A/T	cg15999311	chr14:65749247	NA	0.76	6.87	0.3	2.05e-11	Conduct disorder (symptom count);
LGG	cis	rs1878931	0.582	rs4785933	chr16:3419741	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.71	11.36	0.47	1.48e-26	Body mass index (adult);
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00933542	chr6:150070202	PCMT1	0.4	7.16	0.32	3.25e-12	Lung cancer;
LGG	cis	rs9381040	0.610	rs2268196	chr6:41021950	C/G	cg04346459	chr6:41068666	NFYA;LOC221442	0.38	6.73	0.3	4.96e-11	Alzheimer's disease (late onset);
LGG	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg14675211	chr2:100938903	LONRF2	0.49	7.45	0.33	4.51e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.634	rs4911151	chr20:32932273	T/C	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.36	-0.36	7.47e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs6062302	0.522	rs4809312	chr20:62234240	C/T	cg16989086	chr20:62203971	PRIC285	0.47	6.95	0.31	1.22e-11	Glioblastoma;
LGG	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg14228332	chr4:119757509	SEC24D	0.97	9.22	0.39	1.04e-18	Cannabis dependence symptom count;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg24250549	chr1:154909240	PMVK	0.75	15.35	0.58	2.64e-43	Prostate cancer;
LGG	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg27279351	chr12:120934652	DYNLL1	0.81	13.01	0.52	3.25e-33	High light scatter reticulocyte count;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg21058520	chr6:100914733	NA	0.39	6.84	0.3	2.57e-11	Neuroticism;
LGG	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg22601191	chr20:60968625	CABLES2	0.5	9.32	0.4	4.79e-19	Colorectal cancer;
LGG	cis	rs10463316	0.894	rs7707964	chr5:150765475	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.11	-0.43	7.5e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.38	0.53	9.05e-35	Lung cancer;
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg04861929	chr11:109293070	C11orf87	0.55	10.09	0.42	9.03e-22	Schizophrenia;
LGG	cis	rs10504130	0.569	rs34004633	chr8:52676839	G/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9393777	0.513	rs13194053	chr6:27143883	T/C	cg12292205	chr6:26970375	C6orf41	-0.65	-8.62	-0.37	1.04e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg15268244	chr15:77196840	NA	-0.33	-7.4	-0.33	6.47e-13	Blood metabolite levels;
LGG	cis	rs11264213	0.901	rs72661628	chr1:36406547	A/G	cg27506609	chr1:36549197	TEKT2	0.77	7.77	0.34	4.96e-14	Schizophrenia;
LGG	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.44	-0.53	5.34e-35	Personality dimensions;
LGG	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg20503657	chr10:835505	NA	0.64	9.46	0.4	1.51e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs5756391	0.568	rs4821569	chr22:37316873	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.58	0.41	5.87e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23451424	chr7:82073339	CACNA2D1	0.45	7.03	0.31	7.54e-12	Gut microbiome composition (summer);
LGG	cis	rs1375194	0.606	rs935625	chr2:33811516	C/G	cg04131969	chr2:33951647	MYADML	-0.57	-10.14	-0.43	5.98e-22	Response to antidepressants in depression;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs367943	0.608	rs4705563	chr5:112979539	T/C	cg12552261	chr5:112820674	MCC	0.51	8.89	0.38	1.4e-17	Type 2 diabetes;
LGG	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.46	0.4	1.61e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7408868	0.908	rs4809028	chr19:15273231	A/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg08470875	chr2:26401718	FAM59B	-0.42	-8.22	-0.36	2.1e-15	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs116862462	chr22:32470463	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.43	7.44	0.33	4.97e-13	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.78	-0.3	3.71e-11	Bipolar disorder;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.13	0.6	8.94e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs883565	0.502	rs7427462	chr3:38963275	G/A	cg01426195	chr3:39028469	NA	0.6	12.72	0.51	5.13e-32	Handedness;
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg26354017	chr1:205819088	PM20D1	0.59	11.39	0.47	1.1e-26	Menarche (age at onset);
LGG	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg14092571	chr14:90743983	NA	-0.71	-14.95	-0.57	1.56e-41	Gut microbiota (bacterial taxa);
LGG	cis	rs13314892	0.764	rs55890624	chr3:69858976	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.61	0.33	1.56e-13	Schizophrenia;
LGG	cis	rs17776563	0.593	rs8023916	chr15:89150528	T/C	cg05013243	chr15:89149849	MIR1179	-0.33	-6.86	-0.3	2.16e-11	Thyroid hormone levels;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg04863758	chr4:1303710	MAEA	0.44	7.75	0.34	5.75e-14	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg20607798	chr8:58055168	NA	0.64	7.12	0.31	4.17e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.13	-0.31	3.9e-12	Educational attainment (years of education);
LGG	cis	rs832540	0.966	rs252925	chr5:56203773	G/A	cg14703610	chr5:56206110	C5orf35	0.45	7.71	0.34	7.8e-14	Coronary artery disease;
LGG	cis	rs1728785	1.000	rs12918865	chr16:68566546	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg21453758	chr17:80185943	SLC16A3	0.33	6.91	0.31	1.56e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.77e-13	HDL cholesterol;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg07414643	chr4:187882934	NA	0.57	12.12	0.49	1.55e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.69	-9.5	-0.4	1.14e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg27476859	chr7:2772710	GNA12	0.52	10.16	0.43	4.96e-22	Height;
LGG	cis	rs7798500	0.590	rs67183972	chr7:106922379	C/T	cg20898273	chr7:107300718	SLC26A4;LOC286002	-0.89	-9.47	-0.4	1.49e-19	Adverse response to lamotrigine and phenytoin;
LGG	cis	rs9513627	1.000	rs4584676	chr13:100160560	A/G	cg15490075	chr13:100150979	NA	0.62	6.73	0.3	4.98e-11	Obesity-related traits;
LGG	cis	rs2012796	0.665	rs72703728	chr14:81834523	G/A	cg02996355	chr14:81879375	NA	0.61	10.14	0.43	5.7e-22	Night sleep phenotypes;
LGG	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg02403541	chr12:121454288	C12orf43	0.5	7.92	0.35	1.78e-14	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9487094	0.778	rs11757877	chr6:109681882	T/C	cg01125227	chr6:109776195	MICAL1	0.49	8.22	0.36	2.05e-15	Height;
LGG	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs9644630	0.804	rs11783263	chr8:19371674	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.5	-11.55	-0.47	2.68e-27	Oropharynx cancer;
LGG	cis	rs2734839	0.964	rs1107162	chr11:113289037	A/G	cg14159747	chr11:113255604	NA	-0.26	-6.9	-0.31	1.71e-11	Information processing speed;
LGG	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg12386194	chr3:101231763	SENP7	0.45	8.01	0.35	9.16e-15	Colorectal cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01148728	chr11:117198424	CEP164	0.41	7.14	0.31	3.73e-12	Bipolar disorder;
LGG	cis	rs9400467	0.506	rs4639374	chr6:111458270	A/G	cg15721981	chr6:111408429	SLC16A10	0.56	6.84	0.3	2.48e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4919087	1.000	rs4919090	chr10:99088419	C/G	cg25902810	chr10:99078978	FRAT1	-0.5	-9.07	-0.39	3.41e-18	Monocyte count;
LGG	cis	rs7215564	0.908	rs2873059	chr17:78663874	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg02466173	chr16:30829666	NA	-0.53	-9.3	-0.4	5.45e-19	Multiple myeloma;
LGG	cis	rs4242434	0.927	rs720746	chr8:22471399	T/C	cg00599393	chr8:22457479	C8orf58	-0.47	-8.66	-0.37	7.67e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.06	0.42	1.18e-21	Height;
LGG	cis	rs12586317	0.547	rs2383693	chr14:35500205	A/C	cg05294307	chr14:35346193	BAZ1A	-0.56	-7.76	-0.34	5.36e-14	Psoriasis;
LGG	cis	rs1816752	1.000	rs9511272	chr13:25020633	A/G	cg02811702	chr13:24901961	NA	0.41	7.62	0.33	1.45e-13	Obesity-related traits;
LGG	cis	rs4566357	0.930	rs13398295	chr2:227926873	A/G	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.06	-0.31	6.07e-12	Coronary artery disease;
LGG	cis	rs953387	1.000	rs10179271	chr2:136910834	T/C	cg05194412	chr2:137003533	NA	-0.32	-6.86	-0.3	2.18e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.45e-17	Schizophrenia;
LGG	cis	rs4665809	1.000	rs2384321	chr2:26290054	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.9	-0.54	5.94e-37	Gut microbiome composition (summer);
LGG	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg02403541	chr12:121454288	C12orf43	0.63	9.98	0.42	2.24e-21	N-glycan levels;
LGG	cis	rs17125944	0.686	rs77650471	chr14:53364307	C/T	cg00686598	chr14:53173677	PSMC6	0.81	8.17	0.36	2.88e-15	Alzheimer's disease (late onset);
LGG	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.24	-0.36	1.84e-15	Retinal vascular caliber;
LGG	cis	rs9992101	1.000	rs9992101	chr4:77360431	A/G	cg17010112	chr4:77227123	STBD1	0.38	7.32	0.32	1.1e-12	Creatinine levels;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg05603938	chr12:6960421	USP5;CDCA3	0.44	6.8	0.3	3.26e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg08648136	chr8:956695	NA	0.42	8.94	0.38	9.17e-18	Schizophrenia;
LGG	cis	rs1978968	1.000	rs7286607	chr22:18444657	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs62064224	0.554	rs9901737	chr17:30681354	C/G	cg18200150	chr17:30822561	MYO1D	0.48	9.19	0.39	1.31e-18	Schizophrenia;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05025164	chr4:1340916	KIAA1530	0.65	12.23	0.49	5.4e-30	Longevity;
LGG	cis	rs8064024	0.680	rs3747613	chr16:4908504	C/G	cg08329684	chr16:4932620	PPL	-0.49	-11.06	-0.46	2.14e-25	Cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26597500	chr13:73356092	PIBF1;DIS3	0.39	6.67	0.3	7.25e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7072216	0.727	rs10748728	chr10:100171198	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.16	-0.32	3.11e-12	Metabolite levels;
LGG	cis	rs10779751	0.734	rs1148485	chr1:11148759	G/A	cg08854313	chr1:11322531	MTOR	0.73	14.89	0.57	2.87e-41	Body mass index;
LGG	cis	rs8114671	0.839	rs2104084	chr20:33649217	G/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs17102423	0.723	rs8181938	chr14:65555712	A/G	cg11161011	chr14:65562177	MAX	-0.77	-15.54	-0.59	3.87e-44	Obesity-related traits;
LGG	trans	rs7980799	0.635	rs10743816	chr12:33475559	T/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.82	-0.3	2.85e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08908148	chr7:39606013	C7orf36	0.48	7.79	0.34	4.55e-14	Cognitive performance;
LGG	trans	rs7937682	0.602	rs503905	chr11:111390762	G/C	cg18187862	chr3:45730750	SACM1L	0.47	7.92	0.35	1.76e-14	Primary sclerosing cholangitis;
LGG	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg21665744	chr7:39171113	POU6F2	0.41	8.54	0.37	1.95e-16	IgG glycosylation;
LGG	cis	rs77633900	0.772	rs284901	chr15:76747761	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-8.39	-0.36	5.81e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.09e-13	Tonsillectomy;
LGG	cis	rs12579753	0.574	rs7488890	chr12:82293300	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.32	-0.32	1.13e-12	Resting heart rate;
LGG	cis	rs17767392	0.881	rs2190240	chr14:72024889	T/C	cg02058870	chr14:72053146	SIPA1L1	-0.46	-9.67	-0.41	2.85e-20	Mitral valve prolapse;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23522508	chr19:11287505	KANK2	0.45	7.84	0.34	3.17e-14	Pancreatic cancer;
LGG	cis	rs3784262	0.669	rs12915989	chr15:58315736	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.99	-0.31	9.93e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs9657904	0.774	rs4894953	chr3:105520184	T/C	cg14088669	chr1:158435396	OR10K1	0.41	7.69	0.34	9.21e-14	Multiple sclerosis;
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg11766577	chr21:47581405	C21orf56	-0.48	-8.5	-0.37	2.58e-16	Testicular germ cell tumor;
LGG	cis	rs7512552	0.839	rs486275	chr1:150282784	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-9.02	-0.39	4.92e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9473924	0.542	rs2857501	chr6:50797286	A/G	cg14470998	chr6:50812995	TFAP2B	0.69	8.28	0.36	1.33e-15	Body mass index;
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg04287289	chr16:89883240	FANCA	0.9	8.76	0.38	3.83e-17	Skin colour saturation;
LGG	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.9	-0.31	1.75e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13082711	0.911	rs3755652	chr3:27472936	A/G	cg02860705	chr3:27208620	NA	-0.69	-12.57	-0.5	2.18e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2072499	0.833	rs2842870	chr1:156200671	T/C	cg24450063	chr1:156163899	SLC25A44	1.04	22.12	0.72	1.58e-74	Testicular germ cell tumor;
LGG	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.91	0.35	1.92e-14	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.55e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg08305652	chr11:111469057	NA	-0.44	-9.01	-0.39	5.23e-18	Primary sclerosing cholangitis;
LGG	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg14664628	chr15:75095509	CSK	-0.47	-8.45	-0.37	3.72e-16	Caffeine consumption;
LGG	cis	rs2617583	0.679	rs2652511	chr5:1446389	A/G	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.0	-0.31	9.14e-12	Breast cancer;
LGG	cis	rs9325144	0.555	rs28738714	chr12:38706912	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-8.83	-0.38	2.18e-17	Morning vs. evening chronotype;
LGG	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs6868223	0.617	rs10059623	chr5:33647440	G/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	cis	rs1355223	0.867	rs7925421	chr11:34681677	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.84	-0.3	2.49e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2115630	1.000	rs55646601	chr15:85323568	G/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.91	-0.31	1.65e-11	P wave terminal force;
LGG	cis	rs3743102	0.591	rs76037357	chr15:83399490	A/G	cg00614314	chr15:82944287	LOC80154	-0.73	-7.5	-0.33	3.39e-13	Colorectal adenoma (advanced);
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg07005078	chr4:17578674	LAP3	0.38	7.01	0.31	8.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8064024	0.679	rs2072595	chr16:4897153	A/G	cg04440724	chr16:4920505	UBN1	-0.56	-12.43	-0.5	8.51e-31	Cancer;
LGG	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-18.72	-0.66	1.3e-58	Chronic sinus infection;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15128208	chr22:42549153	NA	-0.43	-8.53	-0.37	2.1e-16	Cognitive function;
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg05084668	chr3:125655381	ALG1L	-0.57	-7.61	-0.33	1.55e-13	Blood pressure (smoking interaction);
LGG	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18876405	chr7:65276391	NA	0.49	8.8	0.38	2.83e-17	Aortic root size;
LGG	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg03511173	chr18:77590860	NA	0.62	7.79	0.34	4.41e-14	Opioid sensitivity;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg14159672	chr1:205819179	PM20D1	0.73	15.43	0.58	1.25e-43	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.52	0.61	1.63e-48	Obesity-related traits;
LGG	cis	rs7633770	0.805	rs11710264	chr3:46661579	T/C	cg11219411	chr3:46661640	NA	0.63	15.68	0.59	9.04e-45	Coronary artery disease;
LGG	cis	rs3204270	1.000	rs3204270	chr17:79682051	C/T	cg18367735	chr17:79674897	NA	0.64	7.22	0.32	2.11e-12	Dental caries;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg00761968	chr13:53314142	LECT1	-0.34	-7.23	-0.32	1.98e-12	Lewy body disease;
LGG	cis	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg04990556	chr1:26633338	UBXN11	0.63	8.28	0.36	1.34e-15	Obesity-related traits;
LGG	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.24e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02931753	chr4:154074737	TRIM2	0.47	8.13	0.35	4.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg05084668	chr3:125655381	ALG1L	-1.12	-12.89	-0.51	1.09e-32	Blood pressure (smoking interaction);
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg11360546	chr7:1094263	C7orf50	-0.41	-7.33	-0.32	1.03e-12	Longevity;Endometriosis;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.61	0.37	1.19e-16	Personality dimensions;
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.91	0.42	3.91e-21	Height;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg04529724	chr6:150244392	RAET1G	0.33	6.65	0.3	8.12e-11	Testicular germ cell tumor;
LGG	cis	rs1018836	0.892	rs10105142	chr8:91547420	C/T	cg16814680	chr8:91681699	NA	-0.69	-12.13	-0.49	1.34e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg05925327	chr15:68127851	NA	-0.42	-8.69	-0.37	6.27e-17	Restless legs syndrome;
LGG	cis	rs62064224	0.578	rs2109158	chr17:30695964	T/C	cg18200150	chr17:30822561	MYO1D	0.47	8.9	0.38	1.32e-17	Schizophrenia;
LGG	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.0	-0.46	3.73e-25	Bipolar disorder;
LGG	cis	rs11112613	0.713	rs11112587	chr12:105941285	G/A	cg03607813	chr12:105948248	NA	0.6	10.32	0.43	1.27e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg24829409	chr8:58192753	C8orf71	-0.84	-13.36	-0.53	1.14e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs7923609	0.934	rs10761756	chr10:65172328	C/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.67e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg05165339	chr4:1420672	NA	-0.29	-7.75	-0.34	5.75e-14	Longevity;
LGG	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-8.01	-0.35	9.7e-15	Neuroticism;
LGG	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	cis	rs4363385	0.530	rs11205181	chr1:153045728	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.26	-0.4	7.84e-19	Inflammatory skin disease;
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg11764359	chr7:65958608	NA	0.74	13.2	0.52	5.36e-34	Aortic root size;
LGG	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg11693508	chr17:37793320	STARD3	0.73	10.51	0.44	2.53e-23	Bipolar disorder;
LGG	cis	rs7586879	0.521	rs1865689	chr2:25108197	C/T	cg04586622	chr2:25135609	ADCY3	-0.44	-11.76	-0.48	3.92e-28	Body mass index;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.63	-0.44	9.16e-24	IgG glycosylation;
LGG	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.42	0.4	2.21e-19	Diabetic retinopathy;
LGG	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.91	0.34	1.96e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11690935	0.879	rs908671	chr2:172690265	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-25.58	-0.77	1.24e-90	Schizophrenia;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7914558	1.000	rs67908413	chr10:104764989	T/C	cg04362960	chr10:104952993	NT5C2	0.53	10.2	0.43	3.52e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg13660082	chr14:53194042	PSMC6	-0.55	-7.54	-0.33	2.5e-13	Alzheimer's disease (late onset);
LGG	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4356203	0.870	rs214901	chr11:17227728	A/G	cg15432903	chr11:17409602	KCNJ11	0.41	7.56	0.33	2.16e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.54	-11.26	-0.46	3.6e-26	Ovarian reserve;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg14926445	chr8:58193284	C8orf71	-0.85	-10.38	-0.43	8.11e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.56	9.9	0.42	4.19e-21	Longevity;
LGG	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg04568710	chr12:38710424	ALG10B	0.34	6.89	0.3	1.84e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.32e-17	Diabetic kidney disease;
LGG	cis	rs7599312	1.000	rs7599312	chr2:213413231	C/T	cg16329650	chr2:213403929	ERBB4	0.61	10.06	0.42	1.11e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg07936489	chr17:37558343	FBXL20	-0.42	-6.76	-0.3	4.06e-11	Asthma;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16436509	chr12:120875898	COX6A1	-0.46	-6.66	-0.3	7.62e-11	Systemic lupus erythematosus;
LGG	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg12633918	chr20:23549525	CST9L	-0.36	-7.15	-0.32	3.32e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs68170813	0.641	rs12539895	chr7:107091849	C/A	cg02696742	chr7:106810147	HBP1	-0.73	-9.94	-0.42	3.25e-21	Coronary artery disease;
LGG	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg16070123	chr10:51489643	NA	-0.4	-7.23	-0.32	1.99e-12	Prostate-specific antigen levels;
LGG	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11644478	chr21:40555479	PSMG1	0.65	10.84	0.45	1.47e-24	Cognitive function;
LGG	cis	rs17039065	1.000	rs75264077	chr4:109393185	T/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.17e-11	Gut microbiome composition (summer);
LGG	cis	rs13421350	0.579	rs79160711	chr2:173302006	A/G	cg15021238	chr2:173305865	ITGA6	-0.83	-9.31	-0.4	5.27e-19	Diabetic kidney disease;
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-7.4	-0.33	6.68e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9863	0.861	rs11057394	chr12:124407676	T/C	cg13487667	chr12:124434373	CCDC92	-0.35	-7.03	-0.31	7.39e-12	White blood cell count;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.75e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.967	rs826879	chr12:39088999	A/C	cg26384229	chr12:38710491	ALG10B	-0.89	-21.06	-0.7	1.48e-69	Heart rate;
LGG	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg25019033	chr10:957182	NA	-0.46	-8.84	-0.38	2.04e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs8064024	0.620	rs9923349	chr16:4905124	A/G	cg04440724	chr16:4920505	UBN1	-0.57	-12.45	-0.5	6.77e-31	Cancer;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.84e-19	Testicular germ cell tumor;
LGG	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs4748857	0.853	rs6482261	chr10:23584488	T/C	cg18853376	chr10:23633759	C10orf67	0.37	6.99	0.31	9.87e-12	Systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.12e-25	Homoarginine levels;
LGG	cis	rs6998277	0.830	rs12543008	chr8:103603747	C/T	cg10187029	chr8:103597600	NA	1.02	19.7	0.68	3.54e-63	Migraine;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg04204079	chr8:58130323	NA	0.38	7.19	0.32	2.65e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.67	0.3	7.15e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs6466055	0.720	rs2030776	chr7:105008458	C/G	cg04380332	chr7:105027541	SRPK2	-0.38	-7.15	-0.32	3.39e-12	Schizophrenia;
LGG	cis	rs2197308	0.606	rs12314897	chr12:38392293	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.11e-19	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg14541582	chr5:601475	NA	-0.69	-10.64	-0.44	8.45e-24	Lung disease severity in cystic fibrosis;
LGG	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg25373794	chr1:162760220	HSD17B7	0.41	7.0	0.31	8.94e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9397585	0.637	rs6916910	chr6:153399737	G/T	cg17707550	chr6:153380415	RGS17	-0.45	-9.9	-0.42	4.43e-21	Body mass index;
LGG	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg14829155	chr15:31115871	NA	-0.58	-10.13	-0.43	6.47e-22	Huntington's disease progression;
LGG	cis	rs1670533	0.818	rs643484	chr4:1085826	A/G	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg10513866	chr5:139070639	NA	-0.37	-7.02	-0.31	7.77e-12	Schizophrenia;
LGG	cis	rs240764	0.817	rs240146	chr6:101078718	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg11317459	chr13:21872234	NA	-1.22	-20.63	-0.69	1.57e-67	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17848828	chr15:83875649	HDGFRP3	0.44	6.66	0.3	7.74e-11	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.43	0.4	1.99e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.25	0.83	1.76e-120	Chronic sinus infection;
LGG	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg17294928	chr15:75287854	SCAMP5	0.56	10.24	0.43	2.47e-22	Breast cancer;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	7.98	0.35	1.18e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7647973	0.667	rs11721148	chr3:49646669	G/A	cg13072238	chr3:49761600	GMPPB	-0.55	-7.2	-0.32	2.52e-12	Menarche (age at onset);
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9807989	0.507	rs6758936	chr2:102991369	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.45	-0.4	1.75e-19	Asthma;
LGG	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.4	0.5	1.06e-30	Lung cancer in ever smokers;
LGG	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg11502198	chr6:26597334	ABT1	0.73	13.34	0.53	1.46e-34	Intelligence (multi-trait analysis);
LGG	cis	rs2018055	0.871	rs2104064	chr6:117793798	A/G	cg14611402	chr6:117803162	DCBLD1	0.32	9.02	0.39	4.86e-18	Diastolic blood pressure;
LGG	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.41	-0.33	5.94e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1620921	0.625	rs12173853	chr6:161266428	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.01e-12	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg06521331	chr12:34319734	NA	-0.54	-10.01	-0.42	1.79e-21	Bladder cancer;
LGG	cis	rs6912958	0.516	rs242278	chr6:88047059	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.04	0.52	2.47e-33	Monocyte percentage of white cells;
LGG	cis	rs2404602	0.669	rs1875884	chr15:76638161	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.28	0.4	6.36e-19	Blood metabolite levels;
LGG	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.66	0.48	1.05e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6430585	0.583	rs3769012	chr2:136556480	C/T	cg07169764	chr2:136633963	MCM6	1.29	24.45	0.75	2.09e-85	Corneal structure;
LGG	cis	rs12478296	0.685	rs6705935	chr2:242995110	C/T	cg18898632	chr2:242989856	NA	-0.69	-7.96	-0.35	1.37e-14	Obesity-related traits;
LGG	cis	rs861020	0.630	rs685248	chr1:210008367	C/G	cg23166289	chr1:210001082	C1orf107	0.32	6.72	0.3	5.29e-11	Orofacial clefts;
LGG	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg12373951	chr3:133503437	NA	0.44	7.89	0.34	2.17e-14	Iron status biomarkers;
LGG	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg07606381	chr6:8435919	SLC35B3	-0.68	-12.56	-0.5	2.37e-31	Motion sickness;
LGG	cis	rs3739821	0.793	rs7023663	chr9:130714930	T/C	cg21181453	chr9:130700954	DPM2	0.33	7.59	0.33	1.79e-13	Glaucoma (primary angle closure);
LGG	trans	rs4924935	0.509	rs8074020	chr17:18801380	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.86	-0.34	2.63e-14	Pancreatic cancer;
LGG	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.12e-12	Bipolar disorder;
LGG	cis	rs3219090	1.000	rs2793377	chr1:226600639	T/C	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg27661571	chr11:113659931	NA	0.58	7.87	0.34	2.57e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3789045	0.774	rs12041243	chr1:204490470	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.7	-0.37	5.94e-17	Educational attainment (college completion);
LGG	cis	rs9682041	0.627	rs11924474	chr3:170091333	T/G	cg11886554	chr3:170076028	SKIL	0.54	7.21	0.32	2.28e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg13647721	chr17:30228624	UTP6	0.78	11.18	0.46	7.31e-26	Hip circumference adjusted for BMI;
LGG	cis	rs988958	0.675	rs67312072	chr2:42230670	T/C	cg27252766	chr2:42229092	NA	0.54	8.45	0.37	3.91e-16	Hypospadias;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg08297393	chr2:100937505	LONRF2	-0.47	-7.39	-0.32	6.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11167764	1.000	rs13354528	chr5:141476769	C/T	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.71	-0.3	5.7e-11	Crohn's disease;
LGG	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-1.1	-27.31	-0.79	1.56e-98	Cognitive ability;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.16	-0.32	3.2e-12	Lung cancer;
LGG	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg09238746	chr17:78121135	EIF4A3	-0.96	-16.48	-0.61	2.38e-48	Yeast infection;
LGG	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.37	-0.56	5.34e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.71e-12	Blood metabolite levels;
LGG	cis	rs2905347	0.560	rs2961293	chr7:22684084	G/A	cg23521230	chr7:22704884	NA	0.39	7.16	0.32	3.28e-12	Major depression and alcohol dependence;
LGG	cis	rs10895140	0.681	rs7924692	chr11:101519094	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.8	-0.3	3.15e-11	Menarche (age at onset);
LGG	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	cis	rs2236918	0.932	rs1635517	chr1:242012033	A/G	cg17736920	chr1:242011382	EXO1	-0.55	-10.04	-0.42	1.38e-21	Menopause (age at onset);
LGG	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.54	-0.63	3.44e-53	Morning vs. evening chronotype;
LGG	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg09998033	chr7:158218633	PTPRN2	-0.56	-10.29	-0.43	1.67e-22	Obesity-related traits;
LGG	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg03128945	chr5:622914	CEP72	-0.44	-7.24	-0.32	1.89e-12	Obesity-related traits;
LGG	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg11707556	chr5:10655725	ANKRD33B	0.57	9.81	0.41	9.4499999999999992e-21	Coronary artery disease;
LGG	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Colorectal cancer;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg24846343	chr22:24311635	DDTL	0.56	10.36	0.43	9.54e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg27476859	chr7:2772710	GNA12	0.53	10.35	0.43	1.01e-22	Height;
LGG	cis	rs11969893	0.649	rs9390699	chr6:101306502	C/G	cg12253828	chr6:101329408	ASCC3	0.82	7.71	0.34	7.84e-14	Economic and political preferences (immigration/crime);
LGG	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.65	-0.3	8.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9811920	0.603	rs2638948	chr3:99501539	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.46	-7.86	-0.34	2.63e-14	Axial length;
LGG	cis	rs6868223	0.617	rs10065974	chr5:33643308	A/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.67	0.59	9.99e-45	Mortality in heart failure;
LGG	cis	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	6.91	0.31	1.57e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7129556	0.701	rs4945220	chr11:77528161	C/G	cg12586386	chr11:77299805	AQP11	-0.45	-7.4	-0.33	6.52e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.29	0.32	1.39e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11225247	0.881	rs12277594	chr11:102257415	A/C	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg03606772	chr1:152487856	CRCT1	-0.3	-7.06	-0.31	6.05e-12	Hair morphology;
LGG	trans	rs2562456	0.754	rs62109227	chr19:21536930	G/A	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs607541	1.000	rs675413	chr15:45936745	C/T	cg26924012	chr15:45694286	SPATA5L1	0.51	7.05	0.31	6.53e-12	Obesity-related traits;
LGG	trans	rs17685	0.753	rs6953665	chr7:75769049	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.39e-17	Mean corpuscular volume;
LGG	cis	rs17767392	0.813	rs12878989	chr14:71856184	G/A	cg02058870	chr14:72053146	SIPA1L1	0.39	8.19	0.36	2.53e-15	Mitral valve prolapse;
LGG	cis	rs7226408	0.857	rs72887029	chr18:34471969	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg22643751	chr7:855365	UNC84A	0.39	6.66	0.3	7.98e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg25174290	chr11:3078921	CARS	0.75	15.98	0.6	4.28e-46	Longevity;
LGG	cis	rs62045849	0.557	rs4782444	chr16:89183973	A/G	cg08015503	chr16:89190385	ACSF3	-0.63	-7.53	-0.33	2.63e-13	Red blood cell count;
LGG	cis	rs9549367	0.789	rs35569628	chr13:113872712	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-13.7	-0.54	4.36e-36	Platelet distribution width;
LGG	cis	rs919433	0.889	rs12693816	chr2:198208420	T/A	cg00792783	chr2:198669748	PLCL1	-0.45	-6.93	-0.31	1.39e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2046867	0.862	rs62251645	chr3:72805733	T/C	cg25664220	chr3:72788482	NA	-0.32	-8.85	-0.38	1.83e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3126085	0.877	rs1969019	chr1:152211502	A/C	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg03162506	chr22:38580953	NA	0.36	8.6	0.37	1.27e-16	Breast cancer;
LGG	cis	rs13102973	0.899	rs4546304	chr4:135902382	G/A	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.81e-15	Subjective well-being;
LGG	cis	rs2797369	0.598	rs705624	chr6:101456163	C/T	cg27451362	chr6:101846650	GRIK2	0.6	9.15	0.39	1.83e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.05	0.39	4.08e-18	Diabetic retinopathy;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	6.99	0.31	9.85e-12	Schizophrenia;
LGG	cis	rs11229555	0.645	rs11229489	chr11:58244917	A/G	cg15696309	chr11:58395628	NA	-0.97	-15.79	-0.59	3e-45	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg22875332	chr1:76189707	ACADM	0.53	8.22	0.36	2.01e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19853194	chr18:9913725	VAPA	0.46	7.25	0.32	1.81e-12	Gut microbiome composition (summer);
LGG	trans	rs1941687	0.764	rs4799357	chr18:31366442	T/C	cg27147174	chr7:100797783	AP1S1	-0.55	-9.17	-0.39	1.51e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15557168	chr22:42548783	NA	0.35	7.81	0.34	3.79e-14	Cognitive function;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs4787491	0.729	rs4788212	chr16:30034469	G/T	cg06326092	chr16:30034487	C16orf92	-0.42	-8.48	-0.37	2.96e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg24955955	chr5:415729	AHRR	0.81	10.82	0.45	1.71e-24	Fat distribution (HIV);
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg07117364	chr1:16154769	NA	-0.48	-8.97	-0.38	7.54e-18	Dilated cardiomyopathy;
LGG	cis	rs4927850	1.000	rs7625570	chr3:195747398	A/G	cg02975922	chr3:195473998	MUC4	-0.54	-8.84	-0.38	1.97e-17	Pancreatic cancer;
LGG	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg20476274	chr7:133979776	SLC35B4	0.76	15.24	0.58	8.88e-43	Mean platelet volume;
LGG	cis	rs7107174	1.000	rs7127187	chr11:77995188	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.46	-0.33	4.36e-13	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.99	0.39	6.17e-18	Motion sickness;
LGG	cis	rs9354308	0.764	rs4273669	chr6:66583060	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.37e-12	Metabolite levels;
LGG	cis	rs1010254	0.559	rs72808322	chr5:151742736	G/A	cg12297329	chr5:152029980	NA	-0.46	-6.76	-0.3	4.2e-11	Optic nerve measurement (cup area);
LGG	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg08824895	chr13:115047677	UPF3A	0.4	6.9	0.31	1.7e-11	Schizophrenia;
LGG	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg26384229	chr12:38710491	ALG10B	0.89	20.82	0.7	2.04e-68	Heart rate;
LGG	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg19554555	chr3:13937349	NA	-0.54	-9.34	-0.4	4.16e-19	Ovarian reserve;
LGG	cis	rs13102973	0.600	rs13122485	chr4:135834437	G/A	cg14419869	chr4:135874104	NA	0.51	9.46	0.4	1.54e-19	Subjective well-being;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs7512552	0.966	rs2147324	chr1:150255587	T/C	cg15654264	chr1:150340011	RPRD2	-0.4	-8.06	-0.35	6.67e-15	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.12	0.35	4.14e-15	Prostate cancer;
LGG	cis	rs17767392	1.000	rs34524083	chr14:71858372	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.94	-0.38	9.54e-18	Mitral valve prolapse;
LGG	cis	rs459482	1.000	rs464783	chr21:42796480	A/G	cg14166395	chr21:42792516	MX1	-0.44	-7.41	-0.33	6.03e-13	IgG glycosylation;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04008888	chr11:68622739	NA	-0.57	-11.82	-0.48	2.28e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9329221	0.662	rs9650650	chr8:10247976	C/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.72	0.3	5.24e-11	Neuroticism;
LGG	cis	rs3750082	0.817	rs4723221	chr7:32954207	C/T	cg08946731	chr7:32981826	RP9P	-0.4	-6.67	-0.3	7.28e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24075738	chr3:50605156	C3orf18	-0.43	-6.8	-0.3	3.27e-11	Pancreatic cancer;
LGG	cis	rs12618769	0.597	rs3769729	chr2:99102810	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg22771759	chr13:24902376	NA	0.42	7.06	0.31	6.05e-12	Obesity-related traits;
LGG	cis	rs870825	0.616	rs2141258	chr4:185609576	A/C	cg04058563	chr4:185651563	MLF1IP	-1.0	-20.92	-0.7	6.6e-69	Blood protein levels;
LGG	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg06640241	chr16:89574553	SPG7	0.68	11.54	0.47	2.89e-27	Multiple myeloma (IgH translocation);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04966789	chr14:35591779	PPP2R3C;KIAA0391	0.43	7.15	0.32	3.33e-12	Cognitive performance;
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.24	-0.46	4.28e-26	Intelligence (multi-trait analysis);
LGG	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.64	0.44	8.64e-24	Calcium levels;
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg19774624	chr17:42201019	HDAC5	0.94	19.96	0.68	2.13e-64	Total body bone mineral density;
LGG	cis	rs17539620	0.624	rs62432736	chr6:154834401	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	7.68	0.34	9.75e-14	Lipoprotein (a) levels;
LGG	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.48e-22	Total body bone mineral density;
LGG	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11771526	0.892	rs62457504	chr7:32336097	G/A	cg13207630	chr7:32358064	NA	0.8	7.85	0.34	2.83e-14	Body mass index;
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg11247378	chr22:39784982	NA	-0.32	-9.09	-0.39	2.89e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.93	0.38	1.03e-17	Platelet count;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.65	0.41	3.26e-20	Schizophrenia;
LGG	cis	rs10193935	0.901	rs10201586	chr2:42622594	C/G	cg27598129	chr2:42591480	NA	-0.64	-9.62	-0.41	4.28e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs41005	0.967	rs6752776	chr2:8104594	A/G	cg03155496	chr2:8117019	LOC339788	0.81	17.51	0.63	4.67e-53	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg06562184	chr8:19319451	CSGALNACT1	0.35	6.72	0.3	5.31e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg06634786	chr22:41940651	POLR3H	-0.62	-10.15	-0.43	5.39e-22	Vitiligo;
LGG	cis	rs2066819	1.000	rs79436528	chr12:56686997	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs2236293	0.789	rs10758323	chr9:35786449	A/G	cg12876594	chr9:35791798	NPR2	0.43	8.24	0.36	1.74e-15	Blood protein levels;
LGG	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg09855544	chr8:135498122	ZFAT	0.45	7.52	0.33	2.78e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg18551225	chr6:44695536	NA	-0.55	-8.02	-0.35	8.89e-15	Total body bone mineral density;
LGG	cis	rs6714710	0.603	rs1470483	chr2:98393894	C/T	cg26665480	chr2:98280029	ACTR1B	0.63	10.28	0.43	1.81e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg06026331	chr20:60912101	LAMA5	0.37	6.92	0.31	1.53e-11	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.75	-0.41	1.52e-20	Life satisfaction;
LGG	cis	rs2832191	1.000	rs2832191	chr21:30489300	A/C	cg08807101	chr21:30365312	RNF160	-0.81	-15.86	-0.59	1.46e-45	Dental caries;
LGG	cis	rs2251381	0.778	rs2471947	chr21:30534219	G/T	cg08807101	chr21:30365312	RNF160	0.76	13.76	0.54	2.38e-36	Selective IgA deficiency;
LGG	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21659725	chr3:3221576	CRBN	0.57	9.86	0.42	6.1e-21	Body mass index;
LGG	cis	rs6558530	0.692	rs6558521	chr8:1700818	C/T	cg25947184	chr8:1697459	NA	-0.45	-7.64	-0.33	1.26e-13	Systolic blood pressure;
LGG	cis	rs17253792	0.915	rs28375514	chr14:56179941	G/A	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs4865875	0.892	rs10053168	chr5:54097821	T/G	cg22421804	chr5:54100067	NA	0.5	7.39	0.32	6.9e-13	Sense of smell;
LGG	trans	rs11098499	0.863	rs1383532	chr4:120434404	A/T	cg25214090	chr10:38739885	LOC399744	-0.65	-11.41	-0.47	9.89e-27	Corneal astigmatism;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.16	0.43	4.92e-22	Tonsillectomy;
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.35e-12	Bipolar disorder;
LGG	cis	rs9487094	0.961	rs9487068	chr6:109671845	G/C	cg01125227	chr6:109776195	MICAL1	0.5	8.53	0.37	2.1e-16	Height;
LGG	cis	rs2274273	0.638	rs67416413	chr14:55702263	A/G	cg04306507	chr14:55594613	LGALS3	0.51	11.78	0.48	3.51e-28	Protein biomarker;
LGG	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg07636037	chr3:49044803	WDR6	0.59	10.38	0.43	7.52e-23	Resting heart rate;
LGG	cis	rs10782582	0.593	rs11163967	chr1:76154185	T/C	cg10523679	chr1:76189770	ACADM	-0.43	-6.97	-0.31	1.12e-11	Daytime sleep phenotypes;
LGG	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg14019146	chr3:50243930	SLC38A3	-0.55	-11.57	-0.47	2.33e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.48	-0.37	3.06e-16	Eye color traits;
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.25	-0.32	1.72e-12	Neuroticism;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9409565	0.855	rs9409720	chr9:97074179	A/G	cg05679027	chr9:99775184	HIATL2	0.5	8.4	0.36	5.59e-16	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9549260	0.755	rs7338669	chr13:41200091	C/T	cg21288729	chr13:41239152	FOXO1	-0.33	-6.71	-0.3	5.74e-11	Red blood cell count;
LGG	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg18154014	chr19:37997991	ZNF793	-0.42	-7.53	-0.33	2.64e-13	Coronary artery calcification;
LGG	cis	rs9303280	0.901	rs9901146	chr17:38043343	G/A	cg19468946	chr17:37922297	IKZF3	-0.37	-6.73	-0.3	4.96e-11	Self-reported allergy;
LGG	cis	rs9300255	0.569	rs1790115	chr12:123620270	C/G	cg00376283	chr12:123451042	ABCB9	0.64	10.51	0.44	2.5e-23	Neutrophil percentage of white cells;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.67	11.88	0.48	1.32e-28	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs1869897	chr4:98730997	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500395	1.000	rs9939103	chr16:48592376	G/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4979906	1.000	rs11002246	chr10:79446777	T/A	cg07817648	chr10:79422355	NA	-0.5	-7.97	-0.35	1.29e-14	Mortality in heart failure;
LGG	cis	rs3742264	0.656	rs9534280	chr13:46585051	T/C	cg15192986	chr13:46630673	CPB2	-0.36	-6.97	-0.31	1.07e-11	Blood protein levels;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg19774624	chr17:42201019	HDAC5	-0.83	-16.27	-0.6	2.11e-47	Total body bone mineral density;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04273556	chr9:35096672	PIGO	0.45	7.62	0.33	1.47e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.67	-0.37	7.45e-17	Menopause (age at onset);
LGG	cis	rs897080	0.552	rs1067326	chr2:44628605	T/A	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs12410462	0.636	rs7413796	chr1:227741423	A/G	cg23173402	chr1:227635558	NA	0.4	7.46	0.33	4.17e-13	Major depressive disorder;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2108225	0.872	rs2051955	chr7:107441154	C/T	cg18560240	chr7:107437656	SLC26A3	-0.55	-9.75	-0.41	1.45e-20	Ulcerative colitis;
LGG	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.85	0.54	9.42e-37	Bladder cancer;
LGG	cis	rs7166081	1.000	rs4776905	chr15:67500330	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg27476859	chr7:2772710	GNA12	0.46	8.68	0.37	6.77e-17	Height;
LGG	cis	rs4478037	0.749	rs6550204	chr3:33107645	C/T	cg19404215	chr3:33155277	CRTAP	-0.67	-8.56	-0.37	1.69e-16	Major depressive disorder;
LGG	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg17971929	chr21:40555470	PSMG1	-0.52	-8.7	-0.37	5.8e-17	Menarche (age at onset);
LGG	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs10089	0.953	rs4836358	chr5:127376869	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.44	0.47	7.49e-27	Ileal carcinoids;
LGG	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.71	0.3	5.8e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg03528353	chr17:61819722	STRADA	0.43	7.3	0.32	1.28e-12	Prudent dietary pattern;
LGG	cis	rs4319547	0.774	rs7295105	chr12:123124225	G/A	cg23029597	chr12:123009494	RSRC2	-0.84	-15.89	-0.59	1.11e-45	Body mass index;
LGG	cis	rs3806843	0.801	rs801170	chr5:140115343	C/T	cg19875535	chr5:140030758	IK	-0.55	-11.15	-0.46	9.54e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs17030434	0.834	rs11734251	chr4:154732218	C/T	cg14289246	chr4:154710475	SFRP2	-0.61	-9.99	-0.42	1.98e-21	Electrocardiographic conduction measures;
LGG	cis	rs690037	0.673	rs690573	chr3:16376440	G/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.52	-8.79	-0.38	2.94e-17	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LGG	cis	rs2797160	1.000	rs1630556	chr6:126013155	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.45	0.33	4.62e-13	Endometrial cancer;
LGG	cis	rs7247513	1.000	rs2042947	chr19:12693103	A/G	cg01871581	chr19:12707946	ZNF490	-0.45	-9.24	-0.39	8.79e-19	Bipolar disorder;
LGG	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs919433	0.963	rs4850429	chr2:198178409	A/G	cg00792783	chr2:198669748	PLCL1	0.44	6.92	0.31	1.51e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg09699651	chr6:150184138	LRP11	0.53	9.39	0.4	2.75e-19	Lung cancer;
LGG	cis	rs9649465	0.561	rs2429620	chr7:123430012	A/G	cg03229431	chr7:123269106	ASB15	0.6	13.67	0.54	5.73e-36	Migraine;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.63	0.33	1.31e-13	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7113850	0.541	rs7107667	chr11:24224091	T/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.23	0.43	2.88e-22	Bone fracture in osteoporosis;
LGG	cis	rs7106204	1.000	rs7106204	chr11:24236096	C/T	ch.11.24196551F	chr11:24239977	NA	-0.92	-11.84	-0.48	1.88e-28	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg08250081	chr4:10125330	NA	-0.36	-6.94	-0.31	1.32e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28655083	0.529	rs1485794	chr16:77101977	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.96	0.31	1.19e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg08916839	chr5:415575	AHRR	1.0	14.23	0.55	2.25e-38	Fat distribution (HIV);
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	ch.2.195648145F	chr2:195939902	NA	0.4	6.97	0.31	1.09e-11	Migraine with aura;
LGG	trans	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.67	-0.34	1.02e-13	Retinal vascular caliber;
LGG	cis	rs45544231	0.569	rs7186498	chr16:52539740	C/T	cg09051775	chr16:52580266	TOX3	-0.42	-6.88	-0.3	1.92e-11	Restless legs syndrome;
LGG	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg18404041	chr3:52824283	ITIH1	-0.39	-7.29	-0.32	1.33e-12	Electroencephalogram traits;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs240764	0.658	rs10457849	chr6:101245591	A/G	cg09795085	chr6:101329169	ASCC3	0.47	7.79	0.34	4.5e-14	Neuroticism;
LGG	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg05044414	chr3:183734942	ABCC5	0.76	16.74	0.61	1.61e-49	Anterior chamber depth;
LGG	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.08e-19	Common traits (Other);
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg15948088	chr11:109293068	C11orf87	0.49	8.32	0.36	1.02e-15	Schizophrenia;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67133203	0.904	rs11169636	chr12:51358580	A/T	cg14688905	chr12:51403056	SLC11A2	0.68	10.13	0.43	6.43e-22	Urinary tract infection frequency;
LGG	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.99	0.39	6.1e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3805663	1.000	rs39882	chr5:134371870	G/T	cg24576358	chr5:134350122	NA	0.35	7.43	0.33	5.37e-13	Testicular germ cell tumor;
LGG	cis	rs745821	0.879	rs11082833	chr18:48140734	C/T	cg18923635	chr18:48083994	NA	0.43	7.45	0.33	4.72e-13	Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.78	-0.3	3.71e-11	Lung cancer;
LGG	cis	rs7010267	0.744	rs2062377	chr8:120007420	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.38	9.89	0.42	4.61e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs2652834	0.851	rs4551986	chr15:63424400	T/G	cg05507819	chr15:63340323	TPM1	0.51	7.17	0.32	2.89e-12	HDL cholesterol;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	trans	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.79e-39	Exhaled nitric oxide output;
LGG	cis	rs6868223	0.964	rs4380665	chr5:33636326	T/G	cg10594543	chr5:33649717	ADAMTS12	0.56	12.52	0.5	3.41e-31	Mortality in heart failure;
LGG	cis	rs514406	0.825	rs6695819	chr1:53223366	T/C	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs34602589	0.535	rs7346579	chr20:43844722	A/G	cg10761708	chr20:43804764	PI3	0.75	11.63	0.48	1.31e-27	Parental longevity (mother's age at death);
LGG	cis	rs735860	0.687	rs2294852	chr6:53157214	C/G	cg10236188	chr6:53219634	NA	-0.41	-8.03	-0.35	8.12e-15	Glaucoma;
LGG	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg05793240	chr7:2802953	GNA12	0.36	8.22	0.36	2.07e-15	Height;
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg19147804	chr7:1989927	MAD1L1	-0.41	-7.76	-0.34	5.66e-14	Schizophrenia;
LGG	cis	rs7267979	0.932	rs928121	chr20:25534818	A/G	cg06421707	chr20:25228305	PYGB	0.46	9.59	0.41	5.64e-20	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108043	0.605	rs62306514	chr4:87976338	C/T	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.58e-12	Red blood cell count;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg18379455	chr17:41446167	NA	-0.31	-7.44	-0.33	4.94e-13	Menopause (age at onset);
LGG	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-10.13	-0.43	6.47e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11864453	0.647	rs7194397	chr16:72128299	C/T	cg01557791	chr16:72042693	DHODH	-0.46	-8.37	-0.36	6.92e-16	Fibrinogen levels;
LGG	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg27489772	chr12:121021490	NA	-0.55	-7.42	-0.33	5.69e-13	Type 1 diabetes nephropathy;
LGG	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg21775007	chr8:11205619	TDH	-0.5	-8.21	-0.36	2.19e-15	Neuroticism;
LGG	cis	rs10193935	0.748	rs11124879	chr2:42697576	C/A	cg27598129	chr2:42591480	NA	0.67	9.79	0.41	1.12e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg08885076	chr2:99613938	TSGA10	-0.51	-10.71	-0.45	4.58e-24	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9581943	0.967	rs9554197	chr13:28476978	C/T	cg16302790	chr13:28498334	PDX1	0.5	8.48	0.37	3.01e-16	Pancreatic cancer;
LGG	cis	rs17534004	0.764	rs17599975	chr13:31472977	C/T	cg00367615	chr13:31480979	C13orf33	0.35	7.02	0.31	7.87e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg24607181	chr17:41446203	NA	-0.29	-6.72	-0.3	5.23e-11	Menopause (age at onset);
LGG	cis	rs990171	0.913	rs1403554	chr2:103083453	G/A	cg05295703	chr2:102895712	NA	-0.51	-9.0	-0.39	6.06e-18	Lymphocyte counts;
LGG	trans	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg17712092	chr4:129076599	LARP1B	-0.58	-9.62	-0.41	4.27e-20	Breast cancer;
LGG	cis	rs3741151	0.686	rs7938391	chr11:73221957	A/G	cg17517138	chr11:73019481	ARHGEF17	0.68	7.1	0.31	4.58e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7106204	0.514	rs2099889	chr11:24255971	A/G	ch.11.24196551F	chr11:24239977	NA	0.97	14.73	0.56	1.5e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs13177180	0.523	rs256984	chr5:114906471	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.29	-0.32	1.33e-12	Conotruncal heart defects (inherited effects);
LGG	trans	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.22	-0.39	1.04e-18	Bladder cancer;
LGG	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.05	0.35	7.17e-15	Iron status biomarkers;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg09033563	chr22:24373618	LOC391322	-0.52	-8.84	-0.38	2.01e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12220238	1.000	rs10762582	chr10:75968316	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2191566	0.960	rs2270196	chr19:44506623	A/G	cg20607764	chr19:44506953	ZNF230	0.43	7.53	0.33	2.76e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg03351412	chr1:154909251	PMVK	-0.64	-12.07	-0.49	2.39e-29	Prostate cancer;
LGG	cis	rs1847505	0.609	rs75746063	chr13:61483475	T/C	cg25164009	chr13:61490935	NA	0.6	9.26	0.4	7.55e-19	Polychlorinated biphenyl levels;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg05064044	chr6:292385	DUSP22	-0.43	-7.41	-0.33	5.95e-13	Menopause (age at onset);
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg21963583	chr11:68658836	MRPL21	0.57	9.67	0.41	2.87e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg17050807	chr22:42548356	NA	-0.34	-6.72	-0.3	5.31e-11	Cognitive function;
LGG	cis	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg04455712	chr21:45112962	RRP1B	0.51	9.59	0.41	5.26e-20	Mean corpuscular volume;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg08769966	chr15:92937735	ST8SIA2	0.39	6.69	0.3	6.49e-11	Coronary artery disease;
LGG	cis	rs9596863	0.821	rs4884722	chr13:54429821	C/A	ch.13.53330881F	chr13:54432880	NA	-0.5	-6.99	-0.31	9.74e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.53	-0.4	8.63e-20	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg11707556	chr5:10655725	ANKRD33B	0.5	9.79	0.41	1.1e-20	Coronary artery disease;
LGG	cis	rs3735485	0.638	rs10236356	chr7:45138465	C/T	cg03440944	chr7:45023329	C7orf40	-0.45	-7.94	-0.35	1.57e-14	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg06873352	chr17:61820015	STRADA	0.48	7.51	0.33	3.07e-13	Height;
LGG	cis	rs11605924	0.935	rs6485645	chr11:45862353	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.49	-8.13	-0.35	3.96e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg02187348	chr16:89574699	SPG7	0.59	9.59	0.41	5.37e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs7020830	0.898	rs2047010	chr9:37077947	A/G	cg14294708	chr9:37120828	ZCCHC7	1.15	31.29	0.82	2.73e-116	Schizophrenia;
LGG	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg24558204	chr6:135376177	HBS1L	-0.59	-10.07	-0.42	1.05e-21	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs1459104	1.000	rs35992551	chr11:55340631	C/T	cg15704280	chr7:45808275	SEPT13	0.66	6.69	0.3	6.33e-11	Body mass index;
LGG	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg10432423	chr10:51371707	LOC728407;PARG	0.54	6.76	0.3	4.16e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs9398803	0.687	rs9388507	chr6:126970895	G/T	cg19875578	chr6:126661172	C6orf173	0.51	9.36	0.4	3.39e-19	Male-pattern baldness;
LGG	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7666738	0.830	rs7689495	chr4:98920152	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.77e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2479106	0.553	rs3739827	chr9:126690157	A/G	cg16191174	chr9:126692580	DENND1A	-0.52	-7.16	-0.32	3.15e-12	Polycystic ovary syndrome;
LGG	cis	rs8014204	0.604	rs11625594	chr14:75389833	G/A	cg06637938	chr14:75390232	RPS6KL1	1.08	26.67	0.78	1.32e-95	Caffeine consumption;
LGG	cis	rs12368653	0.840	rs3816896	chr12:58195773	C/T	cg02175503	chr12:58329896	NA	-0.51	-8.72	-0.38	4.88e-17	Multiple sclerosis;
LGG	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg20503657	chr10:835505	NA	0.77	11.03	0.46	2.74e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg26119090	chr2:26468346	HADHA;HADHB	0.88	13.24	0.52	3.73e-34	Gut microbiome composition (summer);
LGG	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg16141378	chr3:129829833	LOC729375	0.33	6.79	0.3	3.38e-11	Neuroticism;
LGG	cis	rs67133203	0.904	rs17125137	chr12:51365006	A/T	cg14688905	chr12:51403056	SLC11A2	0.79	12.17	0.49	9.48e-30	Urinary tract infection frequency;
LGG	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg12560992	chr17:57184187	TRIM37	0.92	16.37	0.61	7.45e-48	Intelligence (multi-trait analysis);
LGG	cis	rs10048158	0.709	rs8178845	chr17:64217978	C/A	cg19474267	chr17:64306194	PRKCA	-0.65	-13.11	-0.52	1.26e-33	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs892961	0.899	rs35217221	chr17:75412385	G/A	cg05865280	chr17:75406074	SEPT9	0.43	10.04	0.42	1.35e-21	Airflow obstruction;
LGG	cis	rs12971120	0.891	rs12968731	chr18:72169708	G/T	cg25817165	chr18:72167213	CNDP2	-0.66	-13.5	-0.53	2.98e-35	Refractive error;
LGG	cis	rs9361491	0.580	rs13204088	chr6:79757438	A/C	cg18132916	chr6:79620363	NA	-0.26	-6.88	-0.3	1.94e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.28	-0.36	1.29e-15	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16608053	chr17:79633742	C17orf90;CCDC137	0.47	7.33	0.32	1.05e-12	Gut microbiome composition (summer);
LGG	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.44e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4330281	0.715	rs11128850	chr3:17764748	A/G	cg20981856	chr3:17787350	NA	-0.38	-6.87	-0.3	2.06e-11	Schizophrenia;
LGG	cis	rs10489202	1.000	rs7523437	chr1:168029365	A/G	cg24449463	chr1:168025552	DCAF6	-0.63	-10.2	-0.43	3.57e-22	Schizophrenia;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg19168338	chr16:4465731	CORO7	-0.88	-17.12	-0.62	2.85e-51	Schizophrenia;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg04709771	chr16:646395	RAB40C	0.37	6.92	0.31	1.48e-11	Height;
LGG	cis	rs981844	1.000	rs2606327	chr4:154653629	C/T	cg14289246	chr4:154710475	SFRP2	0.68	10.98	0.45	4.4e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg15971980	chr6:150254442	NA	0.43	7.95	0.35	1.46e-14	Lung cancer;
LGG	cis	rs9783347	1.000	rs10734259	chr11:18314865	A/G	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.07	-0.31	5.93e-12	Pancreatic cancer;
LGG	trans	rs6787172	0.677	rs1193514	chr3:158024929	G/T	cg23275840	chr4:47708675	CORIN	0.41	8.89	0.38	1.33e-17	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05573182	chr20:39318437	MAFB	0.55	8.57	0.37	1.55e-16	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02795624	chr11:118992260	HINFP	0.45	7.4	0.33	6.47e-13	Cognitive performance;
LGG	cis	rs11626933	1.000	rs11621007	chr14:90743967	G/A	cg14092571	chr14:90743983	NA	-0.82	-16.76	-0.61	1.28e-49	Gut microbiota (bacterial taxa);
LGG	cis	rs4713675	0.565	rs4711340	chr6:33681131	C/T	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.63e-11	Plateletcrit;
LGG	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg14456004	chr13:21872349	NA	-1.15	-17.93	-0.64	5.35e-55	White matter hyperintensity burden;
LGG	trans	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-11.42	-0.47	9.12e-27	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7818345	0.874	rs56298301	chr8:19305937	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.41	6.95	0.31	1.25e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6840360	1.000	rs4696111	chr4:152671405	T/C	cg22705602	chr4:152727874	NA	-0.27	-6.78	-0.3	3.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg18099408	chr3:52552593	STAB1	0.36	7.35	0.32	9.01e-13	Electroencephalogram traits;
LGG	cis	rs2229238	0.911	rs73023331	chr1:154508210	G/A	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.13e-11	Coronary heart disease;
LGG	cis	rs1497828	0.912	rs2810764	chr1:217573645	T/C	cg04411442	chr1:217543379	NA	0.45	7.38	0.32	7.26e-13	Dialysis-related mortality;
LGG	cis	rs6547741	0.563	rs10196039	chr2:27971195	C/T	cg22903471	chr2:27725779	GCKR	-0.37	-8.08	-0.35	5.76e-15	Oral cavity cancer;
LGG	cis	rs4243971	0.516	rs62208761	chr20:30862874	T/G	cg00028034	chr20:30779307	TSPYL3	0.34	6.99	0.31	9.37e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.45	-0.4	1.66e-19	Aortic root size;
LGG	cis	rs7923452	0.507	rs103441	chr10:30778184	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-12.35	-0.5	1.67e-30	Itch intensity from mosquito bite;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00795915	chr5:70751728	BDP1	0.41	6.89	0.3	1.78e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2084898	1.000	rs569044	chr11:119999191	A/G	cg13907859	chr11:120009124	TRIM29	-0.94	-12.29	-0.5	2.92e-30	Stroke (pediatric);
LGG	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs1997103	0.765	rs55686950	chr7:55396552	A/C	cg20935933	chr6:143382018	AIG1	0.59	9.1	0.39	2.74e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17376030	chr22:41985996	PMM1	0.47	7.57	0.33	2.01e-13	Vitiligo;
LGG	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs7572733	0.515	rs35730302	chr2:198818626	A/T	cg00792783	chr2:198669748	PLCL1	-0.68	-11.1	-0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs17767392	0.788	rs7492426	chr14:71699139	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.15	-0.32	3.33e-12	Mitral valve prolapse;
LGG	cis	rs988958	0.530	rs12712818	chr2:42236321	C/T	cg19376973	chr2:42229025	NA	0.63	9.32	0.4	4.95e-19	Hypospadias;
LGG	cis	rs2075371	0.673	rs35290398	chr7:134011773	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	9.94	0.42	3.23e-21	Mean platelet volume;
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg10802521	chr3:52805072	NEK4	-0.4	-6.89	-0.3	1.83e-11	Bipolar disorder;
LGG	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg02297831	chr4:17616191	MED28	0.43	7.97	0.35	1.26e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7762018	0.760	rs28660085	chr6:170101996	C/G	cg15038512	chr6:170123185	PHF10	0.55	9.39	0.4	2.75e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg24565620	chr2:194026	NA	0.67	10.59	0.44	1.31e-23	Blood protein levels;
LGG	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-11.35	-0.47	1.62e-26	Chronic sinus infection;
LGG	cis	rs12476592	0.571	rs4671505	chr2:63644303	G/T	cg17519650	chr2:63277830	OTX1	-0.46	-7.11	-0.31	4.37e-12	Childhood ear infection;
LGG	cis	rs314370	0.951	rs17884589	chr7:100493711	G/A	cg10426581	chr7:100472382	SRRT	0.53	7.28	0.32	1.45e-12	Resting heart rate;
LGG	cis	rs986417	0.818	rs1950315	chr14:61000031	A/C	cg27398547	chr14:60952738	C14orf39	0.7	6.71	0.3	5.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.15	-0.35	3.35e-15	Total body bone mineral density;
LGG	cis	rs12681287	0.547	rs6998303	chr8:87510185	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg26874229	chr2:105853672	NA	-0.34	-7.29	-0.32	1.33e-12	Type 2 diabetes;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.31	-0.5	2.48e-30	Alzheimer's disease;
LGG	trans	rs853679	0.607	rs28360499	chr6:27945396	G/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	cis	rs4650994	0.593	rs10753180	chr1:178520653	A/G	cg19399532	chr1:178512495	C1orf220	-0.39	-7.44	-0.33	4.99e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg19131313	chr8:1704013	NA	-0.31	-6.89	-0.31	1.81e-11	Systolic blood pressure;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07856758	chr19:37861652	ZNF527	-0.42	-7.13	-0.31	3.97e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1670533	0.769	rs6814833	chr4:1057679	A/C	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg11062466	chr8:58055876	NA	0.5	8.1	0.35	4.86e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg12070911	chr6:150209640	RAET1E	0.29	7.15	0.32	3.5e-12	Lung cancer;
LGG	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.38	0.32	7.2e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4818225	0.784	rs4818226	chr21:42633065	C/T	cg21268422	chr21:42620091	BACE2	-0.44	-7.49	-0.33	3.64e-13	Educational attainment;
LGG	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg02574844	chr11:5959923	NA	-0.58	-9.19	-0.39	1.32e-18	DNA methylation (variation);
LGG	cis	rs11645898	0.748	rs11641424	chr16:72066879	C/T	cg14768367	chr16:72042858	DHODH	-0.89	-11.81	-0.48	2.5e-28	Blood protein levels;
LGG	cis	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg10587741	chr22:38071170	LGALS1	-0.36	-6.94	-0.31	1.33e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.86	0.42	6.21e-21	Coronary artery disease;
LGG	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	8.63	0.37	9.66e-17	Mean corpuscular hemoglobin;
LGG	trans	rs11134654	1.000	rs12515575	chr5:170238724	A/G	cg20034712	chr19:52675470	ZNF836	-0.46	-7.47	-0.33	4.1e-13	Smooth-surface caries;
LGG	cis	rs981844	0.890	rs62325115	chr4:154694847	A/G	cg14289246	chr4:154710475	SFRP2	0.74	12.01	0.49	4.14e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.06e-15	Life satisfaction;
LGG	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg27119904	chr13:114814333	RASA3	0.34	7.09	0.31	4.91e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg00376283	chr12:123451042	ABCB9	0.6	9.3	0.4	5.4e-19	Neutrophil percentage of white cells;
LGG	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg25986240	chr4:9926439	SLC2A9	0.37	7.62	0.33	1.49e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4973397	0.810	rs12993290	chr2:232279687	G/A	cg11378575	chr2:232265004	B3GNT7	0.56	9.57	0.41	6.24e-20	Anti-saccade response;
LGG	cis	rs703842	0.616	rs7489290	chr12:58228588	C/G	cg02175503	chr12:58329896	NA	0.48	7.74	0.34	6.18e-14	Multiple sclerosis;
LGG	cis	rs7927592	0.763	rs10896340	chr11:68312645	A/G	cg01657329	chr11:68192670	LRP5	0.57	10.8	0.45	2.19e-24	Total body bone mineral density;
LGG	cis	rs6032067	0.714	rs4359712	chr20:43884861	A/G	cg10761708	chr20:43804764	PI3	0.54	8.23	0.36	1.92e-15	Blood protein levels;
LGG	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs10927875	0.632	rs4661667	chr1:16162731	C/T	cg21385522	chr1:16154831	NA	-1.03	-25.76	-0.77	1.97e-91	Dilated cardiomyopathy;
LGG	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg02825527	chr7:2087843	MAD1L1	-0.4	-7.65	-0.33	1.2e-13	Neuroticism;
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18099408	chr3:52552593	STAB1	-0.37	-7.19	-0.32	2.68e-12	Bipolar disorder;
LGG	cis	rs12618769	0.597	rs4851133	chr2:99050519	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs239198	0.521	rs13198473	chr6:101337779	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.97	0.31	1.12e-11	Menarche (age at onset);
LGG	cis	rs10991814	0.920	rs7856555	chr9:94001263	A/G	cg14446406	chr9:93919335	NA	-0.73	-8.14	-0.35	3.56e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs7737355	0.947	rs31583	chr5:130992432	T/C	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	2.92e-19	Life satisfaction;
LGG	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg25664220	chr3:72788482	NA	-0.34	-9.03	-0.39	4.71e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12519773	0.555	rs2578490	chr5:92389236	C/T	cg18783429	chr5:92414398	NA	0.31	7.61	0.33	1.54e-13	Migraine;
LGG	cis	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg24110177	chr3:50126178	RBM5	0.61	11.08	0.46	1.85e-25	Body mass index;
LGG	trans	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg11430096	chr6:110968061	CDK19	0.66	6.95	0.31	1.28e-11	Prostate cancer;
LGG	cis	rs11748327	0.959	rs2005071	chr5:4041959	A/G	cg01025095	chr5:4101132	NA	-0.58	-9.32	-0.4	4.71e-19	Myocardial infarction;
LGG	cis	rs3820068	0.554	rs60233444	chr1:15921330	A/C	cg05660106	chr1:15850417	CASP9	0.86	17.53	0.63	4.02e-53	Systolic blood pressure;
LGG	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg01028140	chr2:1542097	TPO	-0.55	-8.65	-0.37	8.56e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg10523679	chr1:76189770	ACADM	-0.71	-11.12	-0.46	1.29e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg18187862	chr3:45730750	SACM1L	0.66	10.96	0.45	5.15e-25	Primary sclerosing cholangitis;
LGG	cis	rs2718058	0.606	rs2722273	chr7:37808298	T/C	cg15028436	chr7:37888078	TXNDC3	0.52	8.15	0.35	3.33e-15	Alzheimer's disease (late onset);
LGG	cis	rs72781680	0.821	rs72781644	chr2:24209348	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	8.67	0.37	7.44e-17	Lymphocyte counts;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.68	-0.41	2.56e-20	Lung cancer;
LGG	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg00071950	chr4:10020882	SLC2A9	0.43	9.02	0.39	4.87e-18	Bone mineral density;
LGG	cis	rs7927771	0.524	rs10838784	chr11:47882341	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.04	0.46	2.49e-25	Subjective well-being;
LGG	trans	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg19894588	chr14:64061835	NA	0.51	8.61	0.37	1.19e-16	Glioblastoma;Glioma;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.6	-0.33	1.69e-13	Depression;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.56	0.47	2.53e-27	Bipolar disorder;
LGG	cis	rs963731	0.649	rs78905728	chr2:39339241	G/T	cg04010122	chr2:39346883	SOS1	0.93	8.24	0.36	1.83e-15	Corticobasal degeneration;
LGG	cis	rs6867032	1.000	rs10462750	chr5:2012963	A/G	cg26168224	chr5:2018326	NA	1.25	27.58	0.79	8.79e-100	Gut microbiome composition (winter);
LGG	cis	rs6868223	0.583	rs4129123	chr5:33646283	T/C	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	trans	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg13565492	chr6:43139072	SRF	-0.76	-9.11	-0.39	2.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	trans	rs12517041	1.000	rs1428630	chr5:23321186	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.18	-0.46	7.64e-26	Calcium levels;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg18350739	chr11:68623251	NA	0.86	22.29	0.72	2.48e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9354308	0.764	rs4710555	chr6:66614561	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18975462	chr8:119123269	EXT1	0.41	6.79	0.3	3.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg15674680	chr20:60982522	CABLES2	0.52	7.23	0.32	1.95e-12	Colorectal cancer;
LGG	cis	rs3540	0.576	rs1974519	chr15:91036460	A/G	cg22089800	chr15:90895588	ZNF774	0.68	12.44	0.5	7.19e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2413583	0.527	rs12485061	chr22:39732665	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	10.87	0.45	1.17e-24	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs365132	1.000	rs1700490	chr5:176402401	G/A	cg16309518	chr5:176445507	NA	-0.55	-12.35	-0.5	1.77e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg20607798	chr8:58055168	NA	0.68	7.85	0.34	2.93e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.44	0.53	5.49e-35	Lung cancer;
LGG	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.88	-0.51	1.16e-32	Morning vs. evening chronotype;
LGG	cis	rs6993813	0.872	rs6469795	chr8:120016469	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.83	0.3	2.64e-11	Bone mineral density (hip);
LGG	cis	rs7666738	0.830	rs13110498	chr4:98959150	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg11859384	chr17:80120422	CCDC57	0.39	6.78	0.3	3.74e-11	Life satisfaction;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg21926883	chr2:100939477	LONRF2	0.5	8.76	0.38	3.58e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.32	-0.5	2.38e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg16339924	chr4:17578868	LAP3	0.59	10.29	0.43	1.67e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg08773314	chr2:239334832	ASB1	0.42	8.06	0.35	6.59e-15	Multiple system atrophy;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.2	0.36	2.37e-15	Retinal vascular caliber;
LGG	cis	rs709400	0.627	rs55859054	chr14:103953666	T/A	cg26031613	chr14:104095156	KLC1	0.76	13.23	0.52	4.19e-34	Body mass index;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10335543	chr14:102829157	TECPR2;CINP	0.6	6.7	0.3	6.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg12081754	chr8:22256438	SLC39A14	1.16	25.07	0.76	2.82e-88	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1909881	1.000	rs3104903	chr8:96509113	C/T	cg04203453	chr8:96504381	NA	-1.08	-18.65	-0.65	2.72e-58	Obesity-related traits;
LGG	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.56	-0.37	1.74e-16	Triglycerides;
LGG	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-9.15	-0.39	1.76e-18	Height;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.66	-0.41	3.12e-20	Platelet count;
LGG	cis	rs9354308	0.738	rs9453472	chr6:66599064	A/T	cg07460842	chr6:66804631	NA	-0.4	-6.86	-0.3	2.26e-11	Metabolite levels;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg15971980	chr6:150254442	NA	0.43	8.0	0.35	1.01e-14	Lung cancer;
LGG	cis	rs8179	0.645	rs2282979	chr7:92264993	T/C	cg15732164	chr7:92237376	CDK6	-0.47	-9.05	-0.39	3.87e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg11693508	chr17:37793320	STARD3	0.55	7.98	0.35	1.15e-14	Bipolar disorder;
LGG	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg24558204	chr6:135376177	HBS1L	0.62	10.75	0.45	3.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6942756	1.000	rs11769045	chr7:128895335	A/G	cg02491457	chr7:128862824	NA	-0.77	-14.08	-0.55	1.02e-37	White matter hyperintensity burden;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg05623727	chr3:50126028	RBM5	0.41	8.88	0.38	1.45e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.850	rs16950562	chr15:44036364	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.57	0.44	1.51e-23	Lung cancer in ever smokers;
LGG	cis	rs4666002	0.871	rs10208529	chr2:27786188	A/T	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	4.88e-11	Phospholipid levels (plasma);
LGG	cis	rs3087591	0.960	rs757384	chr17:29596135	C/T	cg24425628	chr17:29625626	OMG;NF1	0.71	14.66	0.56	2.9e-40	Hip circumference;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	trans	rs2727020	0.521	rs10839299	chr11:49573981	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.29	-0.53	2.24e-34	Coronary artery disease;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-14.45	-0.56	2.48e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	-0.8	-15.42	-0.58	1.29e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4430311	0.600	rs61833201	chr1:243783763	A/G	cg25706552	chr1:244017396	NA	-0.63	-15.22	-0.58	1.02e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9443189	0.762	rs2647417	chr6:76435943	A/G	cg01950844	chr6:76311363	SENP6	-0.58	-7.89	-0.34	2.22e-14	Prostate cancer;
LGG	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg26513180	chr16:89883248	FANCA	0.63	11.35	0.47	1.61e-26	Vitiligo;
LGG	trans	rs6089829	0.962	rs4809455	chr20:61660781	G/C	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.04e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg03352830	chr11:487213	PTDSS2	-0.61	-8.8	-0.38	2.68e-17	Body mass index;
LGG	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg24253500	chr15:84953950	NA	0.55	9.33	0.4	4.48e-19	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09742170	chr7:25021208	OSBPL3	0.43	7.3	0.32	1.22e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs701145	0.878	rs355774	chr3:154036196	A/G	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg17809284	chr5:56205270	C5orf35	0.51	9.59	0.41	5.6e-20	Initial pursuit acceleration;
LGG	cis	rs7582720	1.000	rs72932781	chr2:203697278	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-14.37	-0.56	5.57e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg17951613	chr5:131705445	SLC22A5	0.69	7.78	0.34	4.61e-14	Rheumatoid arthritis;
LGG	cis	rs4731207	0.698	rs10233589	chr7:124468599	G/A	cg05630886	chr7:124431682	NA	0.34	7.98	0.35	1.12e-14	Cutaneous malignant melanoma;
LGG	cis	rs8067287	0.708	rs1004439	chr17:16841924	A/G	cg26910001	chr17:16838321	NA	-0.5	-9.53	-0.4	8.9e-20	Diabetic kidney disease;
LGG	cis	rs7849585	0.830	rs11103390	chr9:139120828	A/G	cg14094347	chr9:139131620	QSOX2	-0.48	-9.31	-0.4	4.96e-19	Height;
LGG	cis	rs10744422	1.000	rs7959441	chr12:123363825	C/T	cg25930673	chr12:123319894	HIP1R	-0.7	-9.24	-0.39	9.09e-19	Schizophrenia;
LGG	cis	rs137603	0.644	rs137620	chr22:39709776	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.72	-13.75	-0.54	2.6e-36	Primary biliary cholangitis;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.79	-0.54	1.76e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.755	rs10888754	chr1:53228751	C/G	cg16325326	chr1:53192061	ZYG11B	-0.73	-17.62	-0.63	1.46e-53	Monocyte count;
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.58	-0.33	1.86e-13	Height;
LGG	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg18129748	chr3:49941408	MST1R	0.22	7.18	0.32	2.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg06916706	chr16:4465613	CORO7	-1.07	-20.49	-0.69	6.92e-67	Schizophrenia;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04772025	chr11:68637568	NA	0.77	13.78	0.54	1.94e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg25173405	chr17:45401733	C17orf57	0.49	8.53	0.37	2.12e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.27e-23	Aortic root size;
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg06558623	chr16:89946397	TCF25	1.1	11.79	0.48	3e-28	Skin colour saturation;
LGG	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.38	0.32	7.42e-13	Birth weight;
LGG	cis	rs6598955	0.543	rs60433268	chr1:26548055	A/C	cg04990556	chr1:26633338	UBXN11	0.71	10.37	0.43	8.72e-23	Obesity-related traits;
LGG	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	cis	rs939658	0.683	rs1434459	chr15:79465210	T/C	cg17916960	chr15:79447300	NA	-0.52	-9.92	-0.42	3.84e-21	Refractive error;
LGG	cis	rs9300255	0.602	rs1106241	chr12:123627016	T/C	cg05973401	chr12:123451056	ABCB9	0.49	7.53	0.33	2.71e-13	Neutrophil percentage of white cells;
LGG	cis	rs9783347	1.000	rs4150673	chr11:18383449	A/C	cg15585147	chr11:18324498	HPS5	0.41	8.67	0.37	7.08e-17	Pancreatic cancer;
LGG	cis	rs7666738	0.830	rs4699591	chr4:98974171	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.51	0.69	5.75e-67	Alzheimer's disease;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg26174226	chr8:58114915	NA	-0.53	-7.15	-0.32	3.37e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12724450	0.793	rs12747619	chr1:150387143	A/C	cg03818307	chr1:150480534	ECM1	0.51	7.17	0.32	3.08e-12	Blood protein levels;
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg03351412	chr1:154909251	PMVK	0.67	12.86	0.51	1.43e-32	Prostate cancer;
LGG	cis	rs7107174	0.901	rs2450138	chr11:77924870	C/T	cg02023728	chr11:77925099	USP35	0.46	8.08	0.35	5.88e-15	Testicular germ cell tumor;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-6.93	-0.31	1.4e-11	Schizophrenia;
LGG	cis	rs17504614	0.648	rs17504635	chr2:51080824	A/G	cg08066024	chr2:51057548	NRXN1	-0.52	-6.81	-0.3	3.1e-11	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22081084	chr1:89990230	LRRC8B	0.52	8.15	0.35	3.39e-15	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	17.26	0.63	6.53e-52	Personality dimensions;
LGG	cis	rs963731	0.649	rs297130	chr2:39299314	C/T	cg04010122	chr2:39346883	SOS1	0.7	6.65	0.3	8.47e-11	Corticobasal degeneration;
LGG	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg05044414	chr3:183734942	ABCC5	0.77	16.96	0.62	1.53e-50	Anterior chamber depth;
LGG	cis	rs2276314	1.000	rs9956938	chr18:33567061	A/G	cg19628046	chr18:33552617	C18orf21	0.53	7.64	0.33	1.22e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2276314	1.000	rs62101367	chr18:33550884	C/T	cg05985134	chr18:33552581	C18orf21	0.65	10.29	0.43	1.74e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg24631222	chr15:78858424	CHRNA5	0.46	6.95	0.31	1.25e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2898857	0.524	rs2119931	chr17:47429834	A/G	cg08112188	chr17:47440006	ZNF652	-0.42	-6.82	-0.3	2.87e-11	Cancer;
LGG	trans	rs877282	0.891	rs11599917	chr10:762288	G/A	cg22713356	chr15:30763199	NA	0.5	7.43	0.33	5.15e-13	Uric acid levels;
LGG	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg21775007	chr8:11205619	TDH	0.44	7.09	0.31	5.18e-12	Mood instability;
LGG	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs947474	0.540	rs744254	chr10:6392848	A/G	cg19837174	chr10:6389707	NA	-0.47	-7.6	-0.33	1.71e-13	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs9815354	0.723	rs6763508	chr3:41750989	T/C	cg03022575	chr3:42003672	ULK4	0.56	7.03	0.31	7.4e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1007190	0.764	rs8070598	chr17:42876865	T/C	cg15406952	chr17:42872593	NA	-1.21	-15.37	-0.58	2.28e-43	DNA methylation (variation);
LGG	cis	rs757978	0.810	rs2055569	chr2:242401439	C/G	cg10173475	chr2:242152697	ANO7	-0.56	-7.27	-0.32	1.57e-12	Chronic lymphocytic leukemia;
LGG	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg12864912	chr4:6988209	TBC1D14	-0.47	-8.95	-0.38	8.79e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs2235642	0.551	rs1966171	chr16:1562804	G/A	cg04525384	chr16:1557733	TELO2	0.45	7.76	0.34	5.32e-14	Coronary artery disease;
LGG	cis	rs11626933	1.000	rs59905513	chr14:90749638	T/C	cg04374321	chr14:90722782	PSMC1	0.42	6.65	0.3	8.35e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07570687	chr10:102243282	WNT8B	0.43	7.18	0.32	2.75e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9625935	0.518	rs9614086	chr22:30259608	A/C	cg01021169	chr22:30184971	ASCC2	0.36	7.08	0.31	5.41e-12	Tonsillectomy;
LGG	trans	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg26043149	chr18:55253948	FECH	-0.47	-8.04	-0.35	7.63e-15	Bone mineral density;
LGG	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.81	0.3	3.07e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7599312	0.534	rs10182996	chr2:213404834	T/C	cg20637307	chr2:213403960	ERBB4	0.75	16.9	0.62	3.06e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11645898	0.935	rs17603936	chr16:72169002	C/A	cg14768367	chr16:72042858	DHODH	-0.82	-11.03	-0.46	2.81e-25	Blood protein levels;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg00149659	chr3:10157352	C3orf10	0.86	10.98	0.45	4.49e-25	Alzheimer's disease;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.64	-0.48	1.16e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4808199	0.895	rs2285628	chr19:19467996	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.65	0.3	8.35e-11	Nonalcoholic fatty liver disease;
LGG	cis	rs4262150	0.810	rs17565470	chr5:152063844	A/G	cg12297329	chr5:152029980	NA	-0.78	-14.84	-0.57	5.14e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg04034577	chr2:241836375	C2orf54	-0.5	-10.26	-0.43	2.17e-22	Urinary metabolites;
LGG	cis	rs7149337	0.836	rs12588488	chr14:51660217	C/A	cg23942311	chr14:51606299	NA	0.32	7.11	0.31	4.39e-12	Cancer;
LGG	cis	rs11711311	1.000	rs2566963	chr3:113531849	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.45	8.0	0.35	1.02e-14	IgG glycosylation;
LGG	cis	rs17767392	1.000	rs35621718	chr14:71780758	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.34e-18	Mitral valve prolapse;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.05	0.55	1.3e-37	Obesity-related traits;
LGG	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-7.86	-0.34	2.74e-14	Vitiligo;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.99	-0.31	9.36e-12	Lung cancer;
LGG	cis	rs7267979	1.000	rs6050564	chr20:25344231	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs116095464	1.000	rs10054850	chr5:335827	C/G	cg22857025	chr5:266934	NA	-1.36	-11.37	-0.47	1.33e-26	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25755107	chr3:49757239	AMIGO3;RNF123	0.46	6.9	0.31	1.73e-11	Gut microbiome composition (summer);
LGG	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg02023728	chr11:77925099	USP35	0.44	7.81	0.34	3.92e-14	Testicular germ cell tumor;
LGG	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg03929089	chr4:120376271	NA	-0.45	-7.19	-0.32	2.61e-12	HDL cholesterol;
LGG	cis	rs7769051	0.615	rs12209144	chr6:133191064	A/T	cg22852734	chr6:133119734	C6orf192	0.98	11.58	0.47	2.12e-27	Type 2 diabetes nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09852007	chr3:134092862	AMOTL2	0.46	7.08	0.31	5.4e-12	Gut microbiome composition (summer);
LGG	cis	rs75059851	0.756	rs7122746	chr11:133838808	A/G	cg17703048	chr11:133852993	NA	-0.88	-16.31	-0.6	1.35e-47	Schizophrenia;
LGG	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.11	-0.43	7.9e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg15627072	chr1:2432621	PLCH2	0.36	7.99	0.35	1.12e-14	Ulcerative colitis;
LGG	cis	rs4748857	0.947	rs4748856	chr10:23599342	C/T	cg18853376	chr10:23633759	C10orf67	-0.39	-7.32	-0.32	1.13e-12	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-6.67	-0.3	7.51e-11	Bipolar disorder;
LGG	cis	rs2072732	0.861	rs72630906	chr1:2961023	C/A	cg08733933	chr1:2954429	NA	-0.46	-8.7	-0.37	5.88e-17	Plateletcrit;
LGG	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg02353165	chr6:42928485	GNMT	0.31	7.51	0.33	3.05e-13	Blood protein levels;
LGG	cis	rs7928758	0.832	rs75190711	chr11:134269772	G/C	cg22777979	chr11:134283252	B3GAT1	0.94	12.23	0.49	5.25e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg08648136	chr8:956695	NA	0.37	7.98	0.35	1.18e-14	Schizophrenia;
LGG	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg16141378	chr3:129829833	LOC729375	-0.46	-11.21	-0.46	5.7e-26	Systolic blood pressure;
LGG	cis	rs6840360	0.582	rs2724553	chr4:152321881	T/C	cg17217059	chr4:152329364	FAM160A1	0.22	7.16	0.32	3.21e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.967	rs9637172	chr21:47685787	T/C	cg13126279	chr21:47581558	C21orf56	-0.49	-8.3	-0.36	1.15e-15	Testicular germ cell tumor;
LGG	cis	rs77372450	0.636	rs60855017	chr5:157012717	G/A	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.34	-0.32	9.62e-13	Life satisfaction;
LGG	cis	rs11190604	0.697	rs4559619	chr10:102199884	C/T	cg07080220	chr10:102295463	HIF1AN	-0.59	-10.3	-0.43	1.49e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.56	-10.07	-0.42	1.08e-21	Lung cancer;
LGG	cis	rs7129556	0.561	rs621456	chr11:77553030	C/T	cg12586386	chr11:77299805	AQP11	0.43	7.34	0.32	9.95e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs283228	0.535	rs2852504	chr6:101842891	G/A	cg02011392	chr6:101847541	GRIK2	0.52	7.36	0.32	8.34e-13	Coenzyme Q10 levels;
LGG	cis	rs1144	0.537	rs2470942	chr7:104583772	G/A	cg03782966	chr7:104585482	NA	0.35	7.98	0.35	1.18e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs17818399	0.926	rs13033177	chr2:46831062	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-10.63	-0.44	8.97e-24	Height;
LGG	trans	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg14227996	chr4:17616232	MED28	-0.5	-6.79	-0.3	3.38e-11	Opioid sensitivity;
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg16270222	chr17:41446396	NA	-0.3	-6.84	-0.3	2.58e-11	Menopause (age at onset);
LGG	trans	rs10506458	0.915	rs12426308	chr12:63405778	C/T	cg22491629	chr6:157744540	C6orf35	-0.94	-12.91	-0.51	8.46e-33	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg22349387	chr12:9600060	DDX12	-0.28	-6.97	-0.31	1.13e-11	Breast size;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg14500267	chr11:67383377	NA	0.45	8.5	0.37	2.56e-16	Mean corpuscular volume;
LGG	cis	rs62238980	0.614	rs33954397	chr22:32506143	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10556830	chr5:68462986	CCNB1	0.45	7.26	0.32	1.63e-12	Gut microbiome composition (summer);
LGG	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15369054	chr17:80825471	TBCD	0.5	6.82	0.3	2.95e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg26031613	chr14:104095156	KLC1	-0.48	-6.67	-0.3	7.12e-11	Coronary artery disease;
LGG	cis	rs7267979	0.773	rs6132821	chr20:25226192	A/G	cg06421707	chr20:25228305	PYGB	0.53	12.16	0.49	1.05e-29	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg09303159	chr6:26284866	NA	0.34	7.23	0.32	1.99e-12	Educational attainment;
LGG	trans	rs7819412	0.654	rs6987059	chr8:11071057	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.74	-0.3	4.81e-11	Triglycerides;
LGG	cis	rs208520	0.690	rs12202805	chr6:66703903	A/G	cg07460842	chr6:66804631	NA	-0.96	-17.81	-0.64	2.08e-54	Exhaled nitric oxide output;
LGG	cis	rs11190604	0.767	rs10883489	chr10:102194532	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.64e-21	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10933002	chr11:78780983	ODZ4	0.36	6.81	0.3	3.02e-11	Electrocardiographic conduction measures;
LGG	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg24253500	chr15:84953950	NA	-0.39	-7.31	-0.32	1.2e-12	P wave terminal force;
LGG	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg27411982	chr8:10470053	RP1L1	0.43	7.53	0.33	2.75e-13	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22191803	chr12:122499348	BCL7A	0.36	6.77	0.3	4e-11	Gut microbiome composition (summer);
LGG	cis	rs4711350	0.723	rs684119	chr6:33662667	C/T	cg06471254	chr6:33690276	IP6K3	0.55	7.73	0.34	6.57e-14	Schizophrenia;
LGG	cis	rs4262150	0.774	rs6872796	chr5:151951125	A/C	cg12297329	chr5:152029980	NA	-0.78	-15.32	-0.58	3.87e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg03078520	chr22:18463400	MICAL3	0.41	8.17	0.35	3.01e-15	Presence of antiphospholipid antibodies;
LGG	cis	rs2692947	0.770	rs4527246	chr2:96560303	T/C	cg22654517	chr2:96458247	NA	0.37	7.89	0.34	2.24e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9944715	0.954	rs8084309	chr18:43751993	T/C	cg26436583	chr18:43649176	PSTPIP2	0.39	7.15	0.32	3.3e-12	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7742824	0.646	rs6925508	chr6:44105442	T/A	cg04074908	chr6:44101190	TMEM63B	0.54	11.21	0.46	5.61e-26	Major depressive disorder;
LGG	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg26396452	chr14:65542826	MAX	0.43	8.35	0.36	8.19e-16	Obesity-related traits;
LGG	cis	rs4604732	0.527	rs79329288	chr1:247626513	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2587949	0.615	rs2686720	chr3:4215480	G/A	cg16519197	chr3:4211558	NA	-0.32	-6.65	-0.3	8.23e-11	Periodontitis (DPAL);
LGG	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs240764	0.658	rs9322181	chr6:101221630	C/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.14e-11	Neuroticism;
LGG	cis	rs9828933	0.938	rs7617036	chr3:64002995	G/A	cg17941049	chr3:63904683	ATXN7	0.62	7.8	0.34	4.13e-14	Type 2 diabetes;
LGG	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-8.55	-0.37	1.75e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs9914988	0.943	rs9902953	chr17:27139834	C/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs3741151	0.686	rs7944346	chr11:73244230	C/T	cg17517138	chr11:73019481	ARHGEF17	0.69	7.29	0.32	1.35e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	trans	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg20587970	chr11:113659929	NA	0.92	12.79	0.51	2.79e-32	Hip circumference adjusted for BMI;
LGG	cis	rs7928758	0.887	rs55751035	chr11:134265723	C/T	cg22777979	chr11:134283252	B3GAT1	1.01	12.73	0.51	4.8e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg22963979	chr7:1858916	MAD1L1	-0.57	-11.13	-0.46	1.12e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg22704520	chr2:200820451	C2orf60;C2orf47	0.41	6.84	0.3	2.53e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg15704280	chr7:45808275	SEPT13	-0.85	-16.79	-0.62	9.77e-50	Height;
LGG	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs727505	0.954	rs59283092	chr7:124678282	T/C	cg23710748	chr7:124431027	NA	-0.5	-9.16	-0.39	1.69e-18	Lewy body disease;
LGG	cis	rs7091068	0.522	rs10748612	chr10:95494458	G/A	cg20715218	chr10:95462985	C10orf4	0.69	11.28	0.46	3.11e-26	Urinary tract infection frequency;
LGG	cis	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg20368463	chr18:77673604	PQLC1	-0.47	-8.34	-0.36	8.55e-16	Schizophrenia;
LGG	cis	rs1345301	0.518	rs1558624	chr2:102862233	A/G	cg05295703	chr2:102895712	NA	0.48	9.54	0.41	8.22e-20	Waist circumference;
LGG	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.25	0.49	4.6e-30	Intelligence (multi-trait analysis);
LGG	cis	rs72827839	0.846	rs72823601	chr17:46135208	C/T	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg05941027	chr17:61774174	LIMD2	0.36	9.25	0.4	8.04e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg07661805	chr8:143867942	LY6D	-0.3	-8.18	-0.36	2.77e-15	Urinary tract infection frequency;
LGG	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.23	-0.32	1.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-16.92	-0.62	2.37e-50	Personality dimensions;
LGG	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg08048268	chr3:133502702	NA	-0.58	-9.81	-0.41	9.15e-21	Iron status biomarkers;
LGG	cis	rs7786808	0.649	rs1377374	chr7:158215647	G/T	cg09998033	chr7:158218633	PTPRN2	0.47	8.77	0.38	3.32e-17	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.13	-0.46	1.19e-25	Hemoglobin concentration;
LGG	cis	rs9547996	1.000	rs9547997	chr13:38222943	G/A	cg17979426	chr13:38220150	TRPC4	-0.45	-8.72	-0.38	4.94e-17	Diastolic blood pressure;
LGG	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg22467129	chr15:76604101	ETFA	0.41	6.84	0.3	2.51e-11	Blood metabolite levels;
LGG	cis	rs3820068	0.581	rs72645874	chr1:15926238	C/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs12618769	0.652	rs72821965	chr2:99188783	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.6	0.33	1.69e-13	Bipolar disorder;
LGG	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.45	-8.02	-0.35	8.81e-15	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.94	0.38	9.33e-18	Aortic root size;
LGG	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.43	6.88	0.3	2.01e-11	Carotid intima media thickness;
LGG	cis	rs12362504	0.504	rs1546541	chr11:9900438	T/C	cg07197493	chr11:9884649	SBF2	-0.35	-6.8	-0.3	3.18e-11	Survival in pancreatic cancer;
LGG	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs2267681	0.583	rs764746	chr7:139530089	G/A	cg14116596	chr7:139528673	TBXAS1	0.32	7.1	0.31	4.78e-12	Cervical cancer;
LGG	cis	rs7122539	0.646	rs10896135	chr11:66551002	G/C	cg01599099	chr11:66649832	PC	0.48	9.8	0.41	1.03e-20	HIV-1 susceptibility;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.74e-13	Life satisfaction;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.29	-0.6	1.8e-47	Calcium levels;
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.28e-15	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24357447	chr15:99091802	NA	0.42	6.85	0.3	2.42e-11	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.97	-0.31	1.11e-11	Neuroticism;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg26656751	chr17:43910226	CRHR1	0.48	8.99	0.39	6.5e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4731207	0.565	rs2402760	chr7:124595920	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.98	-0.62	1.32e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg21775007	chr8:11205619	TDH	0.45	7.35	0.32	9.26e-13	Mood instability;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg08409687	chr2:201936025	NDUFB3;FAM126B	-0.44	-7.19	-0.32	2.56e-12	Coronary artery disease;
LGG	trans	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.2	-0.32	2.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs11237460	chr11:78056274	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.47	-0.33	3.92e-13	Testicular germ cell tumor;
LGG	cis	rs6089584	0.606	rs6089599	chr20:60576992	A/G	cg06470251	chr20:60548479	NA	-0.41	-7.35	-0.32	9.33e-13	Body mass index;
LGG	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.71	0.59	6.71e-45	HDL cholesterol levels;
LGG	cis	rs317689	0.690	rs618470	chr12:69672060	A/G	cg20891283	chr12:69753455	YEATS4	0.45	6.75	0.3	4.52e-11	Response to diuretic therapy;
LGG	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg26850624	chr5:429559	AHRR	-0.38	-8.43	-0.36	4.44e-16	Cystic fibrosis severity;
LGG	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.52e-22	Total body bone mineral density;
LGG	cis	rs4742903	0.935	rs10991182	chr9:106983578	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.31	0.36	1.05e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1318772	0.932	rs26982	chr5:112771342	G/A	cg12552261	chr5:112820674	MCC	0.7	7.89	0.34	2.21e-14	F-cell distribution;
LGG	cis	rs10937275	0.623	rs35166820	chr3:186646140	C/T	cg24050613	chr3:186648279	ST6GAL1	0.87	8.84	0.38	2.09e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2048656	0.605	rs11989726	chr8:9648687	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.68	0.3	6.88e-11	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg06640241	chr16:89574553	SPG7	-0.71	-12.53	-0.5	3.3e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg13010199	chr12:38710504	ALG10B	0.67	13.3	0.53	2.12e-34	Bladder cancer;
LGG	cis	rs2354432	0.607	rs11587707	chr1:146707186	T/C	cg25205988	chr1:146714368	CHD1L	-1.43	-13.69	-0.54	4.62e-36	Mitochondrial DNA levels;
LGG	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	8.14e-23	Blood metabolite levels;
LGG	cis	rs11920090	0.656	rs58035261	chr3:170629770	G/A	cg09710316	chr3:170744871	SLC2A2	0.65	7.34	0.32	9.54e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07648498	chr16:89883185	FANCA	0.4	6.87	0.3	2.14e-11	Vitiligo;
LGG	cis	rs10193935	0.901	rs6544536	chr2:42522042	G/A	cg27598129	chr2:42591480	NA	-0.57	-8.54	-0.37	1.95e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg03806693	chr22:41940476	POLR3H	-0.81	-13.81	-0.54	1.38e-36	Vitiligo;
LGG	cis	rs2243480	0.908	rs2460431	chr7:65622846	A/G	cg12463550	chr7:65579703	CRCP	-0.79	-8.53	-0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03274991	chr11:120207803	ARHGEF12	0.42	7.11	0.31	4.5e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg03795903	chr2:30669940	LCLAT1	0.61	8.05	0.35	6.86e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg24642844	chr7:1081250	C7orf50	-0.47	-8.78	-0.38	3.08e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7192750	0.586	rs6499551	chr16:71943107	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs42648	0.518	rs12535435	chr7:89830817	G/A	cg04070188	chr7:89809444	NA	-0.28	-6.69	-0.3	6.57e-11	Homocysteine levels;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg05368731	chr17:41323189	NBR1	0.94	18.74	0.66	1.01e-58	Menopause (age at onset);
LGG	cis	rs42648	0.564	rs17867585	chr7:89819174	C/T	cg04070188	chr7:89809444	NA	-0.28	-6.78	-0.3	3.67e-11	Homocysteine levels;
LGG	cis	rs7546	0.505	rs760118	chr16:4940994	A/G	cg04440724	chr16:4920505	UBN1	0.57	12.27	0.5	3.85e-30	Cancer;
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg03709012	chr19:19516395	GATAD2A	-0.83	-16.06	-0.6	1.86e-46	Tonsillectomy;
LGG	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg00717180	chr2:96193071	NA	0.41	7.38	0.32	7.28e-13	HDL cholesterol;
LGG	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg13010199	chr12:38710504	ALG10B	0.65	13.33	0.53	1.55e-34	Bladder cancer;
LGG	cis	rs67133203	0.612	rs34498074	chr12:51546090	C/T	cg14688905	chr12:51403056	SLC11A2	0.68	10.39	0.43	7.01e-23	Urinary tract infection frequency;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.05	-0.31	6.39e-12	Lung cancer;
LGG	cis	rs283228	0.535	rs2852509	chr6:101844515	A/G	cg27451362	chr6:101846650	GRIK2	0.9	14.0	0.55	2.27e-37	Coenzyme Q10 levels;
LGG	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	10.02	0.42	1.61e-21	Hypertriglyceridemia;
LGG	trans	rs9650657	0.836	rs891556	chr8:10623633	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs774359	0.789	rs2764326	chr9:27535342	T/C	cg14173147	chr9:27528300	MOBKL2B	0.46	8.69	0.37	6.23e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg13010199	chr12:38710504	ALG10B	0.59	11.16	0.46	8.73e-26	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.08	0.57	4.48e-42	Lung cancer;
LGG	cis	rs2243480	1.000	rs1039664	chr7:65449716	T/G	cg12463550	chr7:65579703	CRCP	0.73	8.14	0.35	3.58e-15	Diabetic kidney disease;
LGG	cis	rs2033732	1.000	rs1465809	chr8:85080457	G/A	cg05716166	chr8:85095498	RALYL	0.51	7.92	0.35	1.76e-14	Body mass index;
LGG	cis	rs1707322	0.752	rs61784798	chr1:46173481	C/T	cg03146154	chr1:46216737	IPP	0.56	10.61	0.44	1.13e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4302748	0.862	rs73335288	chr7:36185070	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg19077165	chr18:44547161	KATNAL2	0.54	9.7	0.41	2.3e-20	Personality dimensions;
LGG	cis	rs2018055	0.912	rs35599105	chr6:117803749	C/A	cg14611402	chr6:117803162	DCBLD1	0.31	8.58	0.37	1.48e-16	Diastolic blood pressure;
LGG	cis	rs7572644	0.629	rs28662360	chr2:28208920	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.67	-0.3	7.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs11771526	0.901	rs11764193	chr7:32272200	C/T	cg13207630	chr7:32358064	NA	0.61	6.8	0.3	3.16e-11	Body mass index;
LGG	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg07636037	chr3:49044803	WDR6	0.56	7.49	0.33	3.43e-13	Menarche (age at onset);
LGG	cis	rs7660883	1.000	rs3775220	chr4:88014753	C/T	cg21988461	chr4:88008667	AFF1	0.34	9.54	0.41	8.07e-20	HDL cholesterol levels;
LGG	cis	rs7551222	0.662	rs4951399	chr1:204533255	G/A	cg20240347	chr1:204465584	NA	-0.54	-10.7	-0.45	5.04e-24	Schizophrenia;
LGG	trans	rs61931739	0.500	rs11053269	chr12:34545307	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.76e-11	Educational attainment;
LGG	cis	rs4812048	0.503	rs41314904	chr20:57564489	G/A	cg23907860	chr20:57583709	CTSZ	0.48	7.0	0.31	9.11e-12	Mean platelet volume;
LGG	cis	rs7756236	0.521	rs9462209	chr6:36628042	T/G	cg08179530	chr6:36648295	CDKN1A	0.42	6.69	0.3	6.59e-11	QRS duration;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg13395646	chr4:1353034	KIAA1530	0.52	9.05	0.39	3.85e-18	Obesity-related traits;
LGG	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.89	0.3	1.86e-11	Mood instability;
LGG	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg13010199	chr12:38710504	ALG10B	0.7	14.46	0.56	2.33e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.41	-0.47	9.39e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg02071572	chr4:1403502	NA	0.38	7.03	0.31	7.68e-12	Longevity;
LGG	cis	rs6764363	0.527	rs12496555	chr3:278154	A/G	cg02057681	chr3:285234	CHL1	-0.43	-7.63	-0.33	1.32e-13	Sudden cardiac arrest;
LGG	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.61	-0.33	1.53e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg15971980	chr6:150254442	NA	-0.43	-6.84	-0.3	2.47e-11	Lung cancer;
LGG	cis	rs12410462	1.000	rs12410243	chr1:227669474	A/G	cg04117972	chr1:227635322	NA	0.72	11.63	0.48	1.31e-27	Major depressive disorder;
LGG	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17219203	chr10:38645113	HSD17B7P2	0.42	6.97	0.31	1.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6714710	0.603	rs6746768	chr2:98466647	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.47	0.4	1.4e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs11890338	chr2:99767868	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs17539620	0.624	rs111484697	chr6:154838903	A/G	cg17771515	chr6:154831774	CNKSR3	0.64	7.82	0.34	3.62e-14	Lipoprotein (a) levels;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.71e-33	Prudent dietary pattern;
LGG	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg20587970	chr11:113659929	NA	-1.29	-23.79	-0.74	2.55e-82	Hip circumference adjusted for BMI;
LGG	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.34	0.53	1.3600000000000001e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg19774624	chr17:42201019	HDAC5	-0.5	-8.36	-0.36	7.21e-16	Red cell distribution width;Reticulocyte count;
LGG	cis	rs888194	0.738	rs2241213	chr12:109938857	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.16	-0.32	3.25e-12	Neuroticism;
LGG	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg24692254	chr21:30365293	RNF160	0.97	24.98	0.76	7.68e-88	Dental caries;
LGG	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg11812906	chr14:75593930	NEK9	0.55	10.35	0.43	9.88e-23	Height;
LGG	trans	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg25214090	chr10:38739885	LOC399744	0.64	11.58	0.47	2.06e-27	Corneal astigmatism;
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.54	-0.41	8.26e-20	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg07142201	chr11:109293216	C11orf87	0.54	9.66	0.41	3.17e-20	Schizophrenia;
LGG	cis	rs7017914	0.934	rs1993862	chr8:71579362	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.89	-0.31	1.81e-11	Bone mineral density;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-13.08	-0.52	1.65e-33	Personality dimensions;
LGG	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.75	0.38	3.96e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg27129171	chr3:47204927	SETD2	-0.83	-15.61	-0.59	1.95e-44	Colorectal cancer;
LGG	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg21427119	chr20:30132790	HM13	-0.58	-8.97	-0.38	7.18e-18	Mean corpuscular hemoglobin;
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg03808351	chr9:123631620	PHF19	0.29	7.21	0.32	2.37e-12	Birth weight;
LGG	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg20848291	chr7:100343083	ZAN	-0.66	-9.48	-0.4	1.31e-19	Other erythrocyte phenotypes;
LGG	cis	rs9790314	1.000	rs9870059	chr3:161017240	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.74	-0.57	1.41e-40	Morning vs. evening chronotype;
LGG	cis	rs12200782	1.000	rs12205909	chr6:26630999	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.16	-0.35	3.25e-15	Small cell lung carcinoma;
LGG	cis	rs7586879	0.828	rs10195271	chr2:25108650	A/C	cg04586622	chr2:25135609	ADCY3	-0.35	-8.58	-0.37	1.48e-16	Body mass index;
LGG	cis	rs9972944	0.756	rs4791133	chr17:63769118	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg04450456	chr4:17643702	FAM184B	-0.34	-7.26	-0.32	1.62e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg11812906	chr14:75593930	NEK9	-0.52	-9.74	-0.41	1.58e-20	Height;
LGG	cis	rs16866061	0.962	rs72972361	chr2:225341550	G/A	cg12698349	chr2:225449008	CUL3	0.92	19.16	0.67	1.09e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.88	0.57	3.22e-41	Morning vs. evening chronotype;
LGG	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.88	0.34	2.36e-14	Alcohol dependence;
LGG	trans	rs12579753	1.000	rs66646148	chr12:82248520	T/G	cg07923666	chr12:49932857	KCNH3	-0.5	-7.52	-0.33	2.84e-13	Resting heart rate;
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.76	0.38	3.6e-17	Height;
LGG	cis	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg06521331	chr12:34319734	NA	0.41	6.92	0.31	1.49e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.17	0.65	4.14e-56	Refractive error;
LGG	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg24112000	chr20:60950667	NA	0.37	8.59	0.37	1.36e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg18335740	chr13:41363409	SLC25A15	0.61	12.0	0.49	4.3e-29	Lewy body disease;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg19673125	chr6:150240577	RAET1G	0.35	8.75	0.38	3.86e-17	Testicular germ cell tumor;
LGG	cis	rs684232	0.835	rs1833459	chr17:562244	C/T	cg15660573	chr17:549704	VPS53	-0.51	-9.46	-0.4	1.6e-19	Prostate cancer;
LGG	cis	rs7619833	0.719	rs580057	chr3:27345103	G/A	cg02860705	chr3:27208620	NA	0.39	7.48	0.33	3.82e-13	Breast cancer;
LGG	cis	rs9527	0.637	rs11191424	chr10:104625886	G/A	cg04362960	chr10:104952993	NT5C2	0.53	9.45	0.4	1.72e-19	Arsenic metabolism;
LGG	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.02	-0.39	5.12e-18	Primary sclerosing cholangitis;
LGG	cis	rs1318772	1.000	rs72797916	chr5:112690587	C/T	cg12552261	chr5:112820674	MCC	0.72	8.38	0.36	6.21e-16	F-cell distribution;
LGG	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg27165867	chr14:105738592	BRF1	-0.47	-8.0	-0.35	9.99e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.63	0.51	1.29e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg10523679	chr1:76189770	ACADM	0.82	15.93	0.6	7.14e-46	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7681440	0.715	rs17016251	chr4:90742639	G/C	cg26578617	chr4:90757533	SNCA	-0.34	-6.88	-0.3	1.95e-11	Dementia with Lewy bodies;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg04632378	chr13:21900426	NA	0.41	8.45	0.37	3.86e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.69	-0.3	6.3e-11	Cervical cancer;
LGG	cis	rs9649213	0.586	rs55648546	chr7:97960800	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.48	-8.31	-0.36	1.06e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.48e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.93e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-8.4	-0.36	5.54e-16	Depression;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs6878727	0.850	rs2408163	chr5:123707016	C/T	cg01806427	chr5:123737813	NA	0.33	7.09	0.31	5.11e-12	Breast cancer;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.74e-13	Life satisfaction;
LGG	cis	rs9443645	0.869	rs1567168	chr6:79536455	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.62	-0.37	1.04e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg02018176	chr4:1364513	KIAA1530	-0.42	-9.69	-0.41	2.48e-20	Obesity-related traits;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08219700	chr8:58056026	NA	0.46	6.8	0.3	3.18e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg22903471	chr2:27725779	GCKR	-0.57	-13.03	-0.52	2.91e-33	Total body bone mineral density;
LGG	cis	rs9896850	0.513	rs10445407	chr17:79261809	A/C	cg25342872	chr17:79175132	AZI1	0.45	7.51	0.33	3.12e-13	Frontotemporal dementia;
LGG	cis	rs10463316	0.832	rs246486	chr5:150727880	C/T	cg03212797	chr5:150827313	SLC36A1	0.57	9.86	0.42	6.03e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs4774899	1.000	rs12906873	chr15:57295310	A/G	cg08128148	chr15:57256372	TCF12	-0.33	-8.04	-0.35	7.6e-15	Urinary tract infection frequency;
LGG	cis	rs9814567	0.712	rs9838889	chr3:134332311	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-10.97	-0.45	4.88e-25	Prostate cancer;
LGG	cis	rs7927771	0.524	rs1563820	chr11:47833398	A/T	cg20307385	chr11:47447363	PSMC3	-0.55	-10.84	-0.45	1.55e-24	Subjective well-being;
LGG	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.53	-0.56	1.12e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02179239	chr10:23002514	PIP4K2A	0.43	6.81	0.3	3.02e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.75e-37	Morning vs. evening chronotype;
LGG	cis	rs9463078	0.715	rs9395049	chr6:44792718	C/T	cg25276700	chr6:44698697	NA	0.37	7.74	0.34	6.38e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs7633770	0.786	rs1520489	chr3:46677519	A/G	cg11219411	chr3:46661640	NA	-0.58	-14.14	-0.55	5.45e-38	Coronary artery disease;
LGG	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg01448562	chr3:133502909	NA	0.42	7.13	0.31	3.8e-12	Iron status biomarkers (transferrin levels);
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	11.15	0.46	9.65e-26	Obesity-related traits;
LGG	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.2	0.32	2.5e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs735396	0.770	rs1169300	chr12:121431225	G/A	cg14101638	chr12:121416612	HNF1A	0.4	7.92	0.35	1.78e-14	N-glycan levels;
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg14893161	chr1:205819251	PM20D1	-0.58	-11.13	-0.46	1.15e-25	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.55	0.65	7.97e-58	Personality dimensions;
LGG	cis	rs11785400	1.000	rs3735999	chr8:143746069	T/C	cg24634471	chr8:143751801	JRK	0.53	8.37	0.36	6.74e-16	Schizophrenia;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.92	-0.38	1.06e-17	Lymphocyte counts;
LGG	trans	rs7819412	0.502	rs4840548	chr8:10992883	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.43	-0.33	5.14e-13	Triglycerides;
LGG	cis	rs16976116	0.901	rs3759861	chr15:55473192	C/T	cg11288833	chr15:55489084	RSL24D1	0.55	7.59	0.33	1.72e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9443645	0.527	rs10943608	chr6:79674929	T/C	cg18132916	chr6:79620363	NA	-0.28	-7.39	-0.32	6.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11719291	0.504	rs34571182	chr3:49209057	T/A	cg00383909	chr3:49044727	WDR6	0.99	12.55	0.5	2.68e-31	Cognitive function;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.04	0.57	6.41e-42	Platelet count;
LGG	cis	rs55871839	0.708	rs4738735	chr8:59816985	T/C	cg07426533	chr8:59803705	TOX	-0.57	-12.71	-0.51	5.61e-32	Pneumonia;
LGG	trans	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg26384229	chr12:38710491	ALG10B	0.63	12.33	0.5	2.02e-30	Morning vs. evening chronotype;
LGG	cis	rs870825	0.616	rs6825561	chr4:185615532	A/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg12486710	chr1:178512616	C1orf220	0.5	10.56	0.44	1.67e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg12708336	chr17:41446283	NA	-0.33	-8.05	-0.35	7.1e-15	Menopause (age at onset);
LGG	cis	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg19399532	chr1:178512495	C1orf220	0.54	10.88	0.45	1.03e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4820539	1.000	rs5759598	chr22:23480962	T/G	cg21100191	chr22:23484243	RTDR1	0.97	21.78	0.71	6.66e-73	Bone mineral density;
LGG	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg00364696	chr7:1142433	C7orf50	-0.38	-7.01	-0.31	8.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9290877	0.580	rs1568668	chr3:188467286	G/A	cg17392043	chr3:188495102	LPP	-0.45	-7.93	-0.35	1.65e-14	IgE levels;
LGG	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg19847130	chr8:10466454	RP1L1	-0.37	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg08188268	chr10:116634841	FAM160B1	0.32	7.05	0.31	6.58e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg10840412	chr1:235813424	GNG4	0.56	7.38	0.32	7.39e-13	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	trans	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg03929089	chr4:120376271	NA	0.71	6.95	0.31	1.24e-11	Intraocular pressure;
LGG	cis	rs7301826	0.967	rs4759792	chr12:131296631	G/A	cg11011512	chr12:131303247	STX2	0.34	7.32	0.32	1.08e-12	Plasma plasminogen activator levels;
LGG	cis	rs4851266	0.901	rs4851271	chr2:100833058	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.08	-0.35	5.87e-15	Educational attainment;
LGG	trans	rs62103177	0.608	rs613847	chr18:77845644	A/G	cg05926928	chr17:57297772	GDPD1	-0.93	-11.95	-0.49	7.44e-29	Opioid sensitivity;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg04691961	chr3:161091175	C3orf57	0.43	9.05	0.39	4.1e-18	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.66	-0.51	9.72e-32	Developmental language disorder (linguistic errors);
LGG	trans	rs9354308	0.764	rs9345709	chr6:66587678	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs6784615	1.000	rs6784615	chr3:52506426	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.63	7.23	0.32	2.03e-12	Waist-hip ratio;
LGG	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.42	7.85	0.34	2.91e-14	Platelet count;
LGG	cis	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg12486710	chr1:178512616	C1orf220	-0.38	-7.79	-0.34	4.57e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg22903471	chr2:27725779	GCKR	-0.59	-13.48	-0.53	3.62e-35	Total body bone mineral density;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg17096665	chr2:20101961	TTC32	-0.3	-6.81	-0.3	2.96e-11	Migraine with aura;
LGG	cis	rs9914544	0.628	rs4630608	chr17:18678548	C/T	cg26378065	chr17:18585709	ZNF286B	0.44	8.3	0.36	1.18e-15	Educational attainment (years of education);
LGG	trans	rs61931739	0.500	rs11513287	chr12:34584351	G/A	cg26384229	chr12:38710491	ALG10B	0.96	20.65	0.69	1.18e-67	Morning vs. evening chronotype;
LGG	cis	rs4423214	0.559	rs10898228	chr11:71228358	A/T	cg05163923	chr11:71159392	DHCR7	-0.55	-8.06	-0.35	6.66e-15	Vitamin D levels;
LGG	cis	rs1691799	0.899	rs1168321	chr12:66744517	C/G	cg16791601	chr12:66731901	HELB	0.66	15.65	0.59	1.23e-44	White blood cell count (basophil);
LGG	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.63	-10.87	-0.45	1.17e-24	Coronary artery disease;
LGG	cis	rs7646881	1.000	rs73015654	chr3:158451654	G/A	cg19483011	chr3:158453295	NA	-0.66	-9.89	-0.42	4.83e-21	Tetralogy of Fallot;
LGG	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.89	9.42	0.4	2.15e-19	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg26116260	chr4:7069785	GRPEL1	-0.74	-6.89	-0.3	1.84e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs12549902	0.800	rs7825494	chr8:41507350	C/T	cg21772509	chr8:41503840	NKX6-3	0.8	16.84	0.62	5.58e-50	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.37	0.5	1.49e-30	Obesity-related traits;
LGG	cis	rs988958	0.527	rs1440099	chr2:42291037	T/C	cg27428208	chr2:42229179	NA	0.38	7.72	0.34	7.49e-14	Hypospadias;
LGG	cis	rs4748857	0.947	rs9888000	chr10:23606391	A/G	cg18853376	chr10:23633759	C10orf67	0.36	6.89	0.31	1.8e-11	Systemic lupus erythematosus;
LGG	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg04398451	chr17:18023971	MYO15A	-0.84	-18.75	-0.66	9.03e-59	Total body bone mineral density;
LGG	cis	rs1976403	0.659	rs10799699	chr1:21820961	C/T	cg20417195	chr1:21767127	NBPF3	0.41	7.55	0.33	2.37e-13	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg27467005	chr19:17622279	PGLS	0.46	7.91	0.35	1.97e-14	Bipolar disorder;
LGG	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	trans	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg16141378	chr3:129829833	LOC729375	0.34	7.9	0.34	2.03e-14	Myopia;Myopia (pathological);
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg27144592	chr16:783916	NARFL	0.42	7.06	0.31	6e-12	Height;
LGG	cis	rs2241941	0.840	rs72927519	chr11:20628407	C/G	cg09136245	chr11:20631761	SLC6A5	-0.46	-8.35	-0.36	7.89e-16	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	7.32e-32	Coronary artery disease;
LGG	trans	rs7395662	1.000	rs4882111	chr11:48558447	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs2762353	0.526	rs6456693	chr6:25710087	C/G	cg03264133	chr6:25882463	NA	0.37	6.71	0.3	5.85e-11	Blood metabolite levels;
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.03	0.46	2.84e-25	Lymphocyte counts;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg14668632	chr7:2872130	GNA12	-0.33	-7.03	-0.31	7.59e-12	Height;
LGG	cis	rs751728	0.687	rs943479	chr6:33752013	A/G	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	trans	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs6800768	0.550	rs4858548	chr3:23887898	G/A	cg10674438	chr3:24145617	LOC152024	0.4	6.88	0.3	1.94e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.66	-0.44	6.92e-24	Longevity;Endometriosis;
LGG	cis	rs7619833	0.592	rs7615829	chr3:27252196	C/G	cg02860705	chr3:27208620	NA	0.42	8.19	0.36	2.51e-15	Breast cancer;
LGG	cis	rs1451375	0.755	rs3829897	chr7:50629764	G/T	cg00647317	chr7:50633725	DDC	-0.37	-8.61	-0.37	1.2e-16	Malaria;
LGG	cis	rs11168854	0.719	rs11168902	chr12:49568266	C/T	cg24176009	chr12:49580217	TUBA1A	0.61	11.6	0.47	1.77e-27	Body mass index;
LGG	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.39e-12	HDL cholesterol;
LGG	cis	rs6977660	0.714	rs6943204	chr7:19818671	A/G	cg05791153	chr7:19748676	TWISTNB	0.73	10.12	0.43	6.75e-22	Thyroid stimulating hormone;
LGG	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg23815491	chr16:72088622	HP	0.5	11.25	0.46	4.14e-26	Fibrinogen levels;
LGG	cis	rs473651	0.935	rs472357	chr2:239355454	A/G	cg21699342	chr2:239360505	ASB1	-0.39	-7.58	-0.33	1.95e-13	Multiple system atrophy;
LGG	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg26697477	chr16:1836234	NUBP2	-0.44	-6.95	-0.31	1.23e-11	Insulin-like growth factors;
LGG	trans	rs6981523	0.500	rs4412337	chr8:11072020	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.93	0.35	1.69e-14	Neuroticism;
LGG	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg16141378	chr3:129829833	LOC729375	0.31	7.2	0.32	2.53e-12	Triglycerides;
LGG	cis	rs34845616	0.813	rs36086419	chr11:133761715	G/C	cg06067394	chr11:133789110	IGSF9B	0.46	7.9	0.34	2.08e-14	Hand grip strength;
LGG	cis	rs9487094	0.517	rs3778474	chr6:109695985	G/A	cg01125227	chr6:109776195	MICAL1	0.45	8.04	0.35	7.51e-15	Height;
LGG	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg08085267	chr17:45401833	C17orf57	-0.72	-13.4	-0.53	7.5e-35	Coronary artery disease;
LGG	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg03929089	chr4:120376271	NA	-0.95	-19.94	-0.68	2.55e-64	Height;
LGG	trans	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg18335740	chr13:41363409	SLC25A15	0.56	10.42	0.44	5.7e-23	Lewy body disease;
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.36	0.36	7.46e-16	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1427198	chr10:60274970	T/G	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.71e-12	Refractive error;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg18538332	chr22:24372958	LOC391322	-0.46	-7.64	-0.33	1.23e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.29	0.4	6.26e-19	Alzheimer's disease;
LGG	cis	rs7646881	0.767	rs73015629	chr3:158433840	C/A	cg19483011	chr3:158453295	NA	-0.58	-7.81	-0.34	3.86e-14	Tetralogy of Fallot;
LGG	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs9911578	1.000	rs9892795	chr17:57023054	G/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg25817165	chr18:72167213	CNDP2	-0.43	-9.28	-0.4	6.34e-19	Mononucleosis;
LGG	cis	rs9644630	0.804	rs11783263	chr8:19371674	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.53	13.76	0.54	2.38e-36	Oropharynx cancer;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg07308232	chr7:1071921	C7orf50	-0.57	-10.5	-0.44	2.72e-23	Longevity;Endometriosis;
LGG	cis	rs523522	0.962	rs1050187	chr12:120902111	A/G	cg27279351	chr12:120934652	DYNLL1	-0.79	-12.93	-0.52	7.17e-33	High light scatter reticulocyte count;
LGG	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg12395012	chr8:11607386	GATA4	-0.38	-6.95	-0.31	1.23e-11	Mood instability;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg05304366	chr15:40226905	EIF2AK4	-0.39	-7.91	-0.34	1.93e-14	Response to haloperidol in psychosis;
LGG	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.84	17.23	0.62	9.6e-52	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.05	-0.31	6.72e-12	Triglycerides;
LGG	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg27029518	chr18:72166324	CNDP2	-0.29	-7.02	-0.31	8.02e-12	Refractive error;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg07701084	chr6:150067640	NUP43	0.67	12.47	0.5	5.63e-31	Lung cancer;
LGG	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.93	-0.31	1.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8017423	0.935	rs10147186	chr14:90779879	G/C	cg04374321	chr14:90722782	PSMC1	0.84	17.09	0.62	4.11e-51	Mortality in heart failure;
LGG	cis	rs2916247	1.000	rs35604666	chr8:93037953	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.39	-0.36	6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.591	rs230642	chr21:44915533	A/C	cg04455712	chr21:45112962	RRP1B	-0.45	-8.43	-0.36	4.43e-16	Mean corpuscular volume;
LGG	cis	rs7209395	0.959	rs9914932	chr17:64144283	A/T	cg19474267	chr17:64306194	PRKCA	0.51	7.99	0.35	1.1e-14	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg16434002	chr17:42200994	HDAC5	0.45	8.17	0.35	3.03e-15	Total body bone mineral density;
LGG	cis	rs12042938	0.600	rs4658880	chr1:231764621	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.64	10.9	0.45	8.75e-25	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	trans	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	6.73	0.3	5.04e-11	Aortic root size;
LGG	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg05692746	chr2:100937584	LONRF2	-0.65	-11.92	-0.48	9.64e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg08916839	chr5:415575	AHRR	1.0	14.14	0.55	5.26e-38	Fat distribution (HIV);
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg11494091	chr17:61959527	GH2	1.01	24.56	0.75	6.87e-86	Prudent dietary pattern;
LGG	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg12395012	chr8:11607386	GATA4	0.39	6.91	0.31	1.57e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg22862003	chr21:42797588	MX1	0.33	8.27	0.36	1.42e-15	IgG glycosylation;
LGG	cis	rs6912958	0.559	rs451465	chr6:88043372	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-12.79	-0.51	2.67e-32	Monocyte percentage of white cells;
LGG	cis	rs367943	1.000	rs348958	chr5:112821137	G/A	cg12552261	chr5:112820674	MCC	-0.75	-14.29	-0.55	1.21e-38	Type 2 diabetes;
LGG	cis	rs2735413	0.918	rs4888725	chr16:78076761	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs2153535	0.541	rs9328477	chr6:8519109	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.26	-0.5	4.1e-30	Resting heart rate;
LGG	cis	rs459193	0.957	rs392794	chr5:55808342	C/T	cg26646659	chr5:55776364	NA	0.3	6.78	0.3	3.65e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7924005	0.891	rs11593335	chr10:6160702	A/T	cg17191567	chr10:6178319	NA	-0.41	-6.88	-0.3	1.96e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1728785	1.000	rs1170434	chr16:68606590	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg02158880	chr13:53174818	NA	0.65	15.01	0.57	8.73e-42	Lewy body disease;
LGG	cis	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg06521331	chr12:34319734	NA	-0.59	-10.36	-0.43	9.12e-23	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg01657329	chr11:68192670	LRP5	0.56	10.62	0.44	9.83e-24	Total body bone mineral density;
LGG	cis	rs12144309	0.554	rs2476602	chr1:114396955	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.34	6.9	0.31	1.69e-11	Coronary artery disease;
LGG	cis	rs10276381	0.579	rs11520706	chr7:28202748	C/T	cg23620719	chr7:28220237	JAZF1	-0.78	-7.9	-0.34	2.02e-14	Crohn's disease;
LGG	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.74	0.38	4.45e-17	Morning vs. evening chronotype;
LGG	cis	rs17539620	0.565	rs61383594	chr6:154841632	A/T	cg17771515	chr6:154831774	CNKSR3	0.62	7.53	0.33	2.69e-13	Lipoprotein (a) levels;
LGG	cis	rs17208368	0.883	rs4784467	chr16:55080084	C/T	cg09947736	chr16:55091198	NA	0.8	12.73	0.51	4.73e-32	Hypospadias;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.92	0.38	1.12e-17	Lung cancer;
LGG	cis	rs11718455	0.960	rs35277738	chr3:44006732	T/C	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.61e-11	Coronary artery disease;
LGG	trans	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-6.92	-0.31	1.51e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg18129748	chr3:49941408	MST1R	0.22	6.93	0.31	1.4e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.31	-0.4	5.05e-19	Systolic blood pressure;
LGG	cis	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg07460842	chr6:66804631	NA	-1.13	-30.96	-0.82	7.58e-115	Exhaled nitric oxide output;
LGG	cis	rs12586317	0.513	rs17102962	chr14:35478782	A/T	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs7385804	0.761	rs1734908	chr7:100313768	G/T	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.93e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08109568	chr15:31115862	NA	-0.53	-9.35	-0.4	3.84e-19	Huntington's disease progression;
LGG	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg07636037	chr3:49044803	WDR6	0.92	17.05	0.62	5.86e-51	Menarche (age at onset);
LGG	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg24690094	chr11:67383802	NA	-0.39	-6.85	-0.3	2.41e-11	Mean corpuscular volume;
LGG	cis	rs1957429	0.614	rs75819890	chr14:65370321	T/G	cg23373153	chr14:65346875	NA	-0.94	-9.15	-0.39	1.8e-18	Pediatric areal bone mineral density (radius);
LGG	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-11.91	-0.48	1.06e-28	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.72	-0.56	1.61e-40	IgG glycosylation;
LGG	trans	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	cis	rs8072100	0.935	rs8070759	chr17:45638760	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.89	0.34	2.13e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.99	-0.35	1.12e-14	Heart rate;
LGG	cis	rs6912958	0.525	rs59322	chr6:88020521	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	12.84	0.51	1.76e-32	Monocyte percentage of white cells;
LGG	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg16339924	chr4:17578868	LAP3	0.6	10.45	0.44	4.42e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9358372	0.964	rs12213956	chr6:20817357	A/T	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.42	-0.58	1.31e-43	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4538187	0.853	rs2439183	chr2:64287632	C/T	cg19915305	chr2:64069682	UGP2	-0.69	-14.76	-0.57	1.07e-40	Systolic blood pressure;
LGG	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg26035817	chr1:114414802	PTPN22	0.51	10.75	0.45	3.4e-24	Bacteremia;
LGG	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg26446133	chr18:72167187	CNDP2	-0.48	-10.44	-0.44	4.54e-23	Mononucleosis;
LGG	cis	rs2133450	0.724	rs1858060	chr3:7361224	C/T	cg19930620	chr3:7340148	GRM7	-0.37	-7.88	-0.34	2.4e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs3617	0.573	rs13072537	chr3:52896032	C/A	cg11645453	chr3:52864694	ITIH4	0.43	7.24	0.32	1.83e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs7765175	0.698	rs9488157	chr6:113665595	T/A	cg26552650	chr6:113682475	NA	0.33	7.49	0.33	3.5e-13	Coronary artery calcification;
LGG	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg20573242	chr4:122745356	CCNA2	0.42	7.6	0.33	1.68e-13	Type 2 diabetes;
LGG	cis	rs738322	0.553	rs28718653	chr22:38570698	C/A	cg03162506	chr22:38580953	NA	0.41	10.18	0.43	4.24e-22	Cutaneous nevi;
LGG	cis	rs1595825	0.891	rs73056859	chr2:198801720	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.96	-0.31	1.19e-11	Ulcerative colitis;
LGG	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg03342759	chr3:160939853	NMD3	-0.44	-7.27	-0.32	1.51e-12	Morning vs. evening chronotype;
LGG	cis	rs6942756	1.000	rs67520056	chr7:128982075	A/G	cg02491457	chr7:128862824	NA	-0.74	-13.43	-0.53	5.94e-35	White matter hyperintensity burden;
LGG	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg03806693	chr22:41940476	POLR3H	1.07	17.9	0.64	7.93e-55	Vitiligo;
LGG	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.8	0.34	4.29e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg16876255	chr19:9731953	ZNF561	0.79	7.29	0.32	1.31e-12	Pursuit maintenance gain;
LGG	cis	rs12431410	0.550	rs12588565	chr14:60215095	G/C	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.66e-11	Schizophrenia;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg14912033	chr15:79043428	NA	-0.37	-9.2	-0.39	1.2e-18	Coronary artery disease or large artery stroke;
LGG	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg11502198	chr6:26597334	ABT1	0.55	9.49	0.4	1.27e-19	Intelligence (multi-trait analysis);
LGG	trans	rs629535	0.783	rs510632	chr8:70034570	A/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs11719291	0.833	rs11709246	chr3:48859498	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	Cognitive function;
LGG	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg10911889	chr6:126070802	HEY2	0.45	7.8	0.34	4.22e-14	Brugada syndrome;
LGG	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg24130564	chr14:104152367	KLC1	0.69	15.06	0.57	5.5e-42	Intelligence (multi-trait analysis);
LGG	cis	rs4664308	1.000	rs16844715	chr2:160915106	A/G	cg03641300	chr2:160917029	PLA2R1	0.85	17.71	0.64	5.61e-54	Idiopathic membranous nephropathy;
LGG	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.3	0.36	1.15e-15	Retinal vascular caliber;
LGG	cis	rs703842	0.963	rs2291617	chr12:58166403	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	7.76	0.34	5.47e-14	Multiple sclerosis;
LGG	cis	rs72634258	0.786	rs7524424	chr1:8173369	A/G	cg00042356	chr1:8021962	PARK7	0.54	7.58	0.33	1.85e-13	Inflammatory bowel disease;
LGG	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg18404041	chr3:52824283	ITIH1	-0.45	-7.92	-0.35	1.74e-14	Bipolar disorder;
LGG	cis	rs4474465	0.833	rs10793320	chr11:78217460	G/A	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.52e-15	Alzheimer's disease (survival time);
LGG	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02187348	chr16:89574699	SPG7	0.65	11.21	0.46	5.88e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg23302884	chr18:44338147	ST8SIA5	0.43	8.76	0.38	3.72e-17	Personality dimensions;
LGG	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg15704280	chr7:45808275	SEPT13	-0.57	-9.52	-0.4	9.27e-20	HDL cholesterol;
LGG	cis	rs1465370	0.720	rs7811463	chr7:130017488	G/A	cg04743876	chr7:130013617	NA	0.38	8.71	0.38	5.34e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23335946	chr1:185125966	C1orf25;C1orf26	0.49	7.72	0.34	7.03e-14	Gut microbiome composition (summer);
LGG	cis	rs8014204	0.804	rs34956813	chr14:75254167	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.09	-0.31	5.01e-12	Caffeine consumption;
LGG	trans	rs800082	1.000	rs1405599	chr3:144328759	T/C	cg24215973	chr2:240111563	HDAC4	-0.51	-8.91	-0.38	1.17e-17	Smoking behavior;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01129155	chr16:33817129	NA	0.39	6.74	0.3	4.67e-11	Menarche (age at onset);
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.29	-0.75	1.15e-84	Height;
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg04287289	chr16:89883240	FANCA	-0.82	-17.63	-0.63	1.29e-53	Vitiligo;
LGG	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.64	-0.33	1.23e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs35160687	0.623	rs13005014	chr2:86487216	T/C	cg10973622	chr2:86423274	IMMT	-0.41	-7.23	-0.32	2.04e-12	Night sleep phenotypes;
LGG	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg12654349	chr5:56205094	C5orf35	-0.63	-9.81	-0.41	9.25e-21	Initial pursuit acceleration;
LGG	trans	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg23762105	chr12:34175262	ALG10	-0.34	-6.83	-0.3	2.74e-11	Morning vs. evening chronotype;
LGG	cis	rs28374715	0.681	rs7168307	chr15:41620534	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.21	-27.56	-0.79	1.09e-99	Ulcerative colitis;
LGG	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg08847533	chr14:75593920	NEK9	0.62	11.89	0.48	1.25e-28	Height;
LGG	cis	rs17767392	0.560	rs1008517	chr14:72041434	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.3	-0.4	5.72e-19	Mitral valve prolapse;
LGG	cis	rs3820928	0.874	rs4675134	chr2:227843489	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.87	-0.34	2.58e-14	Pulmonary function;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg12708336	chr17:41446283	NA	-0.31	-7.12	-0.31	4.22e-12	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg23758822	chr17:41437982	NA	0.89	15.65	0.59	1.23e-44	Menopause (age at onset);
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg20887711	chr4:1340912	KIAA1530	0.73	15.59	0.59	2.37e-44	Longevity;
LGG	cis	rs59918340	0.764	rs3824234	chr8:142229370	T/C	cg03653399	chr8:142233436	SLC45A4	0.43	8.45	0.37	3.87e-16	Immature fraction of reticulocytes;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg02462569	chr6:150064036	NUP43	-0.44	-8.57	-0.37	1.54e-16	Lung cancer;
LGG	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.73	-0.3	5.08e-11	Crohn's disease;
LGG	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06634786	chr22:41940651	POLR3H	0.78	12.23	0.49	5.46e-30	Vitiligo;
LGG	trans	rs1493916	0.805	rs1452648	chr18:31411003	G/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg23958373	chr8:599963	NA	1.12	10.37	0.43	8.77e-23	IgG glycosylation;
LGG	cis	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	7.24e-21	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.917	rs13196576	chr6:86534066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.18	-0.49	8.18e-30	Response to antipsychotic treatment;
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.21e-15	Bipolar disorder;
LGG	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.38	0.4	3.04e-19	Rheumatoid arthritis;
LGG	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg25427524	chr10:38739819	LOC399744	-0.37	-6.77	-0.3	3.85e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg05868516	chr6:26286170	HIST1H4H	0.46	7.98	0.35	1.17e-14	Educational attainment;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg21782813	chr7:2030301	MAD1L1	0.41	9.68	0.41	2.68e-20	Schizophrenia;
LGG	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.87	-0.3	2.11e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg03342759	chr3:160939853	NMD3	-0.66	-11.77	-0.48	3.6e-28	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.36e-33	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16674475	chr2:241987968	SNED1	0.4	7.88	0.34	2.4e-14	Electrocardiographic conduction measures;
LGG	trans	rs877282	0.891	rs10904557	chr10:797490	C/T	cg22713356	chr15:30763199	NA	-0.55	-8.55	-0.37	1.81e-16	Uric acid levels;
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg08499158	chr17:42289980	UBTF	0.57	10.53	0.44	2.11e-23	Total body bone mineral density;
LGG	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg07796016	chr1:152779584	LCE1C	-0.48	-7.66	-0.34	1.13e-13	Inflammatory skin disease;
LGG	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.48e-14	Bone mineral density;
LGG	trans	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.66	-9.41	-0.4	2.37e-19	Ulcerative colitis;
LGG	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg17971929	chr21:40555470	PSMG1	-0.72	-13.42	-0.53	6.22e-35	Cognitive function;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg16507663	chr6:150244633	RAET1G	0.44	8.27	0.36	1.41e-15	Lung cancer;
LGG	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg23029597	chr12:123009494	RSRC2	-0.93	-17.35	-0.63	2.65e-52	Body mass index;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00933542	chr6:150070202	PCMT1	0.38	6.86	0.3	2.25e-11	Lung cancer;
LGG	cis	rs17767392	0.958	rs55883127	chr14:71980236	G/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.24	0.39	8.7e-19	Mitral valve prolapse;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg04450456	chr4:17643702	FAM184B	0.32	6.84	0.3	2.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2832191	0.740	rs2832168	chr21:30463695	G/A	cg24692254	chr21:30365293	RNF160	1.04	29.39	0.81	6.57e-108	Dental caries;
LGG	cis	rs7666738	0.962	rs17027204	chr4:98997049	G/A	cg05340658	chr4:99064831	C4orf37	0.42	6.74	0.3	4.71e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10864302	0.525	rs4908626	chr1:7422216	G/T	cg08923594	chr1:7462176	CAMTA1	0.59	7.47	0.33	3.96e-13	Photic sneeze reflex;
LGG	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg19913688	chr11:428466	ANO9	-0.68	-8.65	-0.37	8.43e-17	Body mass index;
LGG	cis	rs3764563	1.000	rs1022413	chr19:15741984	G/A	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.36	-0.36	7.5e-16	Inflammatory biomarkers;
LGG	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.95	-0.35	1.4e-14	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.69	-0.41	2.36e-20	Diabetic retinopathy;
LGG	cis	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg21775007	chr8:11205619	TDH	-0.43	-6.78	-0.3	3.62e-11	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12016809	chr21:47604291	C21orf56	0.54	9.67	0.41	2.85e-20	Testicular germ cell tumor;
LGG	cis	rs9815354	0.859	rs9822288	chr3:41954588	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.72e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611519	0.579	rs8136274	chr22:41415311	T/C	cg03806693	chr22:41940476	POLR3H	-0.46	-7.63	-0.33	1.36e-13	Neuroticism;
LGG	cis	rs2415984	0.579	rs2123129	chr14:46960920	G/T	cg14871534	chr14:47121158	RPL10L	-0.58	-10.09	-0.42	9.08e-22	Number of children ever born;
LGG	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg13010199	chr12:38710504	ALG10B	0.77	16.45	0.61	3.35e-48	Heart rate;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.82	0.48	2.28e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17221829	0.703	rs10047486	chr11:89405190	A/G	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.63	-0.37	1.02e-16	Anxiety in major depressive disorder;
LGG	cis	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg06521331	chr12:34319734	NA	-0.63	-11.16	-0.46	8.78e-26	Morning vs. evening chronotype;
LGG	cis	rs2991971	0.934	rs11211129	chr1:45983080	C/T	cg24296786	chr1:45957014	TESK2	0.4	7.19	0.32	2.54e-12	High light scatter reticulocyte count;
LGG	cis	rs6665290	0.935	rs12409755	chr1:227196949	A/T	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs926938	0.618	rs904292	chr1:115358421	C/T	cg12756093	chr1:115239321	AMPD1	0.46	8.58	0.37	1.48e-16	Autism;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg16141378	chr3:129829833	LOC729375	0.41	9.61	0.41	4.62e-20	Systolic blood pressure;
LGG	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-12.67	-0.51	8.66e-32	Parkinson's disease;
LGG	cis	rs7617480	0.648	rs6766238	chr3:48801929	G/A	cg07636037	chr3:49044803	WDR6	0.91	16.74	0.61	1.53e-49	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg26513180	chr16:89883248	FANCA	-0.49	-8.48	-0.37	3.04e-16	Vitiligo;
LGG	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg01620082	chr3:125678407	NA	-0.91	-9.04	-0.39	4.34e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg01657329	chr11:68192670	LRP5	0.48	8.29	0.36	1.26e-15	Total body bone mineral density;
LGG	cis	rs876084	0.505	rs4409431	chr8:121104019	C/G	cg06265175	chr8:121136014	COL14A1	0.47	9.63	0.41	4.01e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg12070911	chr6:150209640	RAET1E	0.28	7.13	0.31	3.76e-12	Testicular germ cell tumor;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.31	-0.43	1.45e-22	Obesity-related traits;
LGG	cis	rs55843245	1	rs55843245	chr8:13437876	C/A	cg03566418	chr8:13424080	C8orf48	0.63	9.93	0.42	3.34e-21	Small cell lung carcinoma;
LGG	cis	rs7020830	0.898	rs308523	chr9:37338785	C/T	cg14294708	chr9:37120828	ZCCHC7	1.12	28.66	0.8	1.22e-104	Schizophrenia;
LGG	cis	rs12971120	0.504	rs11665154	chr18:72147006	A/C	cg26446133	chr18:72167187	CNDP2	-0.51	-11.42	-0.47	9.16e-27	Refractive error;
LGG	cis	rs13421350	0.579	rs10207654	chr2:173307756	A/G	cg15021238	chr2:173305865	ITGA6	-0.83	-9.76	-0.41	1.36e-20	Diabetic kidney disease;
LGG	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-10.03	-0.42	1.5e-21	Glomerular filtration rate (creatinine);
LGG	trans	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.25	-0.32	1.74e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg11764359	chr7:65958608	NA	-0.76	-14.22	-0.55	2.43e-38	Aortic root size;
LGG	cis	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg00745463	chr17:30367425	LRRC37B	-0.48	-7.07	-0.31	5.91e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.32	0.67	2.12e-61	Platelet count;
LGG	cis	rs9398803	0.865	rs9375441	chr6:126778600	G/A	cg19875578	chr6:126661172	C6orf173	0.57	10.41	0.44	5.91e-23	Male-pattern baldness;
LGG	cis	rs9916302	0.861	rs2338801	chr17:37490780	G/T	cg07936489	chr17:37558343	FBXL20	0.85	15.96	0.6	5.06e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg19524238	chr7:2802976	GNA12	0.4	9.19	0.39	1.29e-18	Height;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg19168338	chr16:4465731	CORO7	-0.93	-18.91	-0.66	1.61e-59	Schizophrenia;
LGG	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.91e-11	Alzheimer's disease (survival time);
LGG	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.58	0.33	1.85e-13	Hepatocellular carcinoma;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.58	-0.37	1.39e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	1.000	rs12471809	chr2:26307140	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.09	-0.52	1.6e-33	Gut microbiome composition (summer);
LGG	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg02002194	chr4:3960332	NA	0.41	7.45	0.33	4.67e-13	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.13	-0.31	3.89e-12	Life satisfaction;
LGG	cis	rs10463554	0.927	rs158245	chr5:102409505	G/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs2224391	0.534	rs2753228	chr6:5246623	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.2	-0.32	2.53e-12	Height;
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8049040	0.644	rs16973000	chr16:71493165	T/C	cg06353428	chr16:71660113	MARVELD3	-0.5	-7.55	-0.33	2.38e-13	Blood protein levels;
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17554472	chr22:41940697	POLR3H	-0.49	-6.81	-0.3	3.06e-11	Vitiligo;
LGG	trans	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.6	0.53	1.14e-35	Obesity-related traits;
LGG	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg21665744	chr7:39171113	POU6F2	0.43	8.84	0.38	1.98e-17	IgG glycosylation;
LGG	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg13010199	chr12:38710504	ALG10B	0.48	8.52	0.37	2.2e-16	Resting heart rate;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.64	11.75	0.48	4.45e-28	Personality dimensions;
LGG	cis	rs2154319	0.790	rs2363096	chr1:41514949	A/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.02	-0.39	5.03e-18	Height;
LGG	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.5	-0.4	1.11e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg21132104	chr15:45694354	SPATA5L1	-0.72	-11.11	-0.46	1.4e-25	Homoarginine levels;
LGG	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.49e-11	Blood metabolite levels;
LGG	cis	rs10504229	0.516	rs4361758	chr8:57990401	C/T	cg22535103	chr8:58192502	C8orf71	-0.47	-7.44	-0.33	5.01e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg21775007	chr8:11205619	TDH	0.49	8.23	0.36	1.89e-15	Mood instability;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.25	-0.43	2.37e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs1978968	1.000	rs1076544	chr22:18446565	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.79	-0.41	1.12e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4268898	0.560	rs78711174	chr2:24496531	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-12.33	-0.5	2.01e-30	Asthma;
LGG	cis	rs4242434	0.854	rs3064	chr8:22451688	C/G	cg03733263	chr8:22462867	KIAA1967	-1.04	-26.27	-0.77	8.79e-94	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.63	-11.13	-0.46	1.12e-25	Renal function-related traits (BUN);
LGG	cis	rs240764	0.853	rs2062635	chr6:101002659	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.91	-0.31	1.61e-11	Neuroticism;
LGG	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg26396452	chr14:65542826	MAX	0.44	8.88	0.38	1.49e-17	Obesity-related traits;
LGG	cis	rs7191700	0.511	rs8043625	chr16:11361895	C/G	cg00044050	chr16:11439710	C16orf75	-0.56	-9.39	-0.4	2.72e-19	Multiple sclerosis;
LGG	cis	rs4363385	0.818	rs4845522	chr1:153011099	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs6546550	0.901	rs6721891	chr2:70146121	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.99	-0.35	1.08e-14	Prevalent atrial fibrillation;
LGG	trans	rs4650994	1.000	rs4650999	chr1:178532188	A/C	cg05059571	chr16:84539110	KIAA1609	0.41	7.59	0.33	1.77e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg04986931	chr22:39850128	NA	0.41	9.02	0.39	5e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs4423214	1.000	rs12422045	chr11:71154820	C/T	cg05163923	chr11:71159392	DHCR7	0.71	14.1	0.55	8.01e-38	Vitamin D levels;
LGG	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-11.82	-0.48	2.41e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7580658	0.864	rs3088374	chr2:128062048	T/C	cg10021288	chr2:128175891	PROC	-0.55	-11.36	-0.47	1.52e-26	Protein C levels;
LGG	cis	rs2708240	1.000	rs2710105	chr7:147574236	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg16141378	chr3:129829833	LOC729375	-0.41	-9.68	-0.41	2.67e-20	Mood instability;
LGG	cis	rs864537	0.646	rs2995091	chr1:167434277	T/C	cg09179987	chr1:167433047	CD247	0.44	9.95	0.42	2.92e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.8	-0.34	4.1e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs55871839	0.559	rs4738736	chr8:59836001	C/T	cg07426533	chr8:59803705	TOX	0.6	12.5	0.5	4.38e-31	Pneumonia;
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg05793240	chr7:2802953	GNA12	0.29	7.26	0.32	1.63e-12	Height;
LGG	cis	rs4423214	0.840	rs1790344	chr11:71176897	A/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg24829409	chr8:58192753	C8orf71	-0.66	-8.5	-0.37	2.6e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg12800244	chr3:153838788	SGEF	0.74	7.87	0.34	2.58e-14	Coronary artery disease;
LGG	trans	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg01620082	chr3:125678407	NA	-0.67	-8.38	-0.36	6.24e-16	Lung cancer in ever smokers;
LGG	cis	rs11225247	0.772	rs35623064	chr11:102237391	T/C	cg06323957	chr11:102217781	BIRC2	0.78	7.39	0.32	6.77e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg00631329	chr6:26305371	NA	-0.55	-9.83	-0.42	8.03e-21	Educational attainment;
LGG	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg23740940	chr11:68924746	NA	0.43	6.95	0.31	1.29e-11	Blond vs. brown hair color;
LGG	cis	rs3857747	0.827	rs7803105	chr7:40477360	G/A	cg00420559	chr7:40367873	C7orf10	0.38	7.86	0.34	2.74e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg00647317	chr7:50633725	DDC	0.37	8.93	0.38	1.01e-17	Body mass index;
LGG	cis	rs7241530	0.662	rs71362787	chr18:75907482	G/A	cg14642773	chr18:75888474	NA	0.46	8.96	0.38	8.24e-18	Educational attainment (years of education);
LGG	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg16141378	chr3:129829833	LOC729375	0.31	6.9	0.31	1.73e-11	Myopia (pathological);
LGG	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg27165867	chr14:105738592	BRF1	-0.44	-7.42	-0.33	5.75e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1318772	1.000	rs72788641	chr5:112621327	T/G	cg12552261	chr5:112820674	MCC	0.71	8.18	0.36	2.86e-15	F-cell distribution;
LGG	cis	rs15676	0.812	rs10819447	chr9:131576416	T/G	cg04621255	chr9:131581398	ENDOG	-0.38	-6.77	-0.3	4.03e-11	Blood metabolite levels;
LGG	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.86	16.84	0.62	5.44e-50	Smoking behavior;
LGG	cis	rs679087	1.000	rs679087	chr12:29917265	C/A	cg14258853	chr12:29935411	TMTC1	-0.43	-8.61	-0.37	1.17e-16	Schizophrenia;
LGG	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.76	0.38	3.61e-17	Systolic blood pressure;
LGG	cis	rs4356932	0.935	rs4380549	chr4:76979082	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg17294928	chr15:75287854	SCAMP5	-0.54	-9.92	-0.42	3.64e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2629540	0.889	rs4962402	chr10:126459114	T/G	cg08799069	chr10:126477246	METTL10	-0.68	-14.5	-0.56	1.53e-39	Cocaine dependence;
LGG	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg09021430	chr5:549028	NA	-0.69	-9.64	-0.41	3.71e-20	Obesity-related traits;
LGG	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg17294928	chr15:75287854	SCAMP5	-0.42	-6.76	-0.3	4.15e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs10937275	1.000	rs35461422	chr3:186649678	A/G	cg24050613	chr3:186648279	ST6GAL1	0.86	8.87	0.38	1.6e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.76	0.68	1.75e-63	Platelet count;
LGG	cis	rs8062405	0.558	rs231976	chr16:28545587	C/G	cg00198680	chr16:28758506	NA	0.28	7.19	0.32	2.67e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	6.85	0.3	2.4e-11	Myopia (pathological);
LGG	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg23583168	chr7:148888333	NA	-0.67	-10.6	-0.44	1.24e-23	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs834603	0.575	rs2665775	chr7:47465387	C/T	cg23694490	chr7:47445681	TNS3	-0.42	-12.12	-0.49	1.47e-29	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs11976180	1.000	rs2951369	chr7:143752638	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.88	-0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs17125944	0.656	rs74825460	chr14:53390015	C/T	cg00686598	chr14:53173677	PSMC6	0.78	7.55	0.33	2.39e-13	Alzheimer's disease (late onset);
LGG	cis	rs77633900	0.614	rs1905694	chr15:76951772	T/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.82	-0.42	8.72e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg22105103	chr4:187893119	NA	0.57	10.72	0.45	4.29e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs68170813	0.559	rs80341862	chr7:106934731	C/G	cg02696742	chr7:106810147	HBP1	-0.72	-10.36	-0.43	9.36e-23	Coronary artery disease;
LGG	trans	rs17685	0.623	rs7782808	chr7:75768645	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-7.31	-0.32	1.19e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2479106	0.791	rs12237685	chr9:126689557	T/C	cg16191174	chr9:126692580	DENND1A	0.54	8.05	0.35	6.89e-15	Polycystic ovary syndrome;
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.48	0.37	3.03e-16	Aortic root size;
LGG	cis	rs3096299	0.596	rs889573	chr16:89437560	C/T	cg08822215	chr16:89438651	ANKRD11	-0.47	-8.97	-0.38	7.13e-18	Multiple myeloma (IgH translocation);
LGG	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg27205649	chr11:78285834	NARS2	0.5	8.53	0.37	2.04e-16	Alzheimer's disease (survival time);
LGG	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg24060327	chr5:131705240	SLC22A5	0.49	8.52	0.37	2.22e-16	Blood metabolite levels;
LGG	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg16797656	chr11:68205561	LRP5	-0.45	-7.55	-0.33	2.32e-13	Bone mineral density (spine);
LGG	cis	rs7084402	0.967	rs1649035	chr10:60332701	A/T	cg07615347	chr10:60278583	BICC1	0.61	16.99	0.62	1.1e-50	Refractive error;
LGG	cis	rs7122539	0.646	rs9633985	chr11:66520608	A/T	cg01599099	chr11:66649832	PC	0.41	8.18	0.36	2.78e-15	HIV-1 susceptibility;
LGG	cis	rs3857067	0.806	rs1585651	chr4:95058755	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.6	-0.33	1.69e-13	QT interval;
LGG	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-9.74	-0.41	1.61e-20	Body mass index;
LGG	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.94	0.45	6.01e-25	Parkinson's disease;
LGG	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg03342759	chr3:160939853	NMD3	0.45	7.5	0.33	3.2e-13	Morning vs. evening chronotype;
LGG	trans	rs9467711	1.000	rs6939978	chr6:26328462	G/C	cg06606381	chr12:133084897	FBRSL1	-0.65	-7.18	-0.32	2.78e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg07777115	chr5:623756	CEP72	-0.51	-6.78	-0.3	3.74e-11	Obesity-related traits;
LGG	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg05082376	chr22:42548792	NA	0.37	7.74	0.34	6.19e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg24607181	chr17:41446203	NA	-0.29	-6.91	-0.31	1.58e-11	Menopause (age at onset);
LGG	cis	rs2282300	0.696	rs12578061	chr11:30249365	T/A	cg25418670	chr11:30344373	C11orf46	-0.57	-7.92	-0.35	1.8e-14	Morning vs. evening chronotype;
LGG	cis	rs11696845	0.966	rs1467474	chr20:43372005	A/G	cg25301532	chr20:43378953	KCNK15	0.36	7.85	0.34	2.88e-14	Obesity-related traits;
LGG	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg06627557	chr7:32535165	LSM5;AVL9	-0.91	-16.9	-0.62	2.99e-50	Cognitive ability;
LGG	cis	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg12395012	chr8:11607386	GATA4	0.39	6.76	0.3	4.29e-11	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23436918	chr7:16685595	BZW2;ANKMY2	0.5	7.77	0.34	5.27e-14	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg14675211	chr2:100938903	LONRF2	0.68	12.31	0.5	2.61e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.590	rs6467839	chr7:139062790	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.03	0.31	7.6e-12	Diisocyanate-induced asthma;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22470056	chr3:49947811	MON1A	0.49	8.3	0.36	1.13e-15	Electrocardiographic conduction measures;
LGG	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg23205692	chr1:25664452	TMEM50A	0.45	9.22	0.39	1.04e-18	Erythrocyte sedimentation rate;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg26578617	chr4:90757533	SNCA	-0.44	-8.72	-0.38	4.97e-17	Dementia with Lewy bodies;
LGG	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg11584989	chr19:19387371	SF4	0.73	12.62	0.51	1.44e-31	Bipolar disorder;
LGG	cis	rs2361710	0.704	rs12937349	chr17:78120320	G/C	cg06718696	chr17:78121285	EIF4A3	0.44	6.92	0.31	1.56e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg18128536	chr17:47092178	IGF2BP1	-0.47	-8.95	-0.38	8.55e-18	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg13565492	chr6:43139072	SRF	-0.91	-15.7	-0.59	7.81e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg10189774	chr4:17578691	LAP3	0.38	6.73	0.3	4.93e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9926296	0.605	rs8046243	chr16:89852133	A/G	cg07440826	chr16:89882328	FANCA	-0.26	-6.86	-0.3	2.18e-11	Vitiligo;
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.93	0.38	9.97e-18	Renal function-related traits (BUN);
LGG	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.96	-0.31	1.17e-11	HDL cholesterol;
LGG	cis	rs1109114	1.000	rs34180939	chr5:148618964	G/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.27	-0.58	6.01e-43	Body mass index;
LGG	cis	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.31e-20	Smoking initiation;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg19168338	chr16:4465731	CORO7	-0.74	-13.85	-0.54	9.92e-37	Schizophrenia;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs2050392	1.000	rs2265186	chr10:30691743	C/T	cg25182066	chr10:30743637	MAP3K8	0.49	9.87	0.42	5.64e-21	Inflammatory bowel disease;
LGG	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	3.97e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9944715	0.954	rs7245091	chr18:43743081	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.42	-8.01	-0.35	9.14e-15	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2067615	0.579	rs1922438	chr12:107085171	C/G	cg15890332	chr12:107067104	RFX4	0.41	12.06	0.49	2.56e-29	Heart rate;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg11168104	chr5:1857477	NA	-0.4	-7.1	-0.31	4.59e-12	Cardiovascular disease risk factors;
LGG	cis	rs9815354	1.000	rs1716676	chr3:41903208	T/C	cg03022575	chr3:42003672	ULK4	0.65	8.4	0.36	5.68e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4727027	0.704	rs10952805	chr7:148907849	G/A	cg23583168	chr7:148888333	NA	-0.91	-18.3	-0.65	1.11e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.5	-0.61	2.03e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7572733	0.534	rs58374969	chr2:198764363	C/T	cg00792783	chr2:198669748	PLCL1	0.68	10.87	0.45	1.1e-24	Dermatomyositis;
LGG	cis	rs13082711	0.522	rs480646	chr3:27327143	C/T	cg02860705	chr3:27208620	NA	0.6	11.34	0.47	1.85e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg05555928	chr11:63887634	MACROD1	-0.78	-10.75	-0.45	3.15e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.71	0.41	2.09e-20	Prudent dietary pattern;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg06968155	chr5:131705112	SLC22A5	0.72	8.3	0.36	1.18e-15	Rheumatoid arthritis;
LGG	cis	rs4561483	0.603	rs7202065	chr16:11951045	C/T	cg08843971	chr16:11963173	GSPT1	0.55	13.21	0.52	4.93e-34	Testicular germ cell tumor;
LGG	cis	rs1395	0.744	rs62130709	chr2:27505782	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-7.04	-0.31	6.76e-12	Blood metabolite levels;
LGG	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.59	0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg24692254	chr21:30365293	RNF160	1.01	26.99	0.78	4.42e-97	Dental caries;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg20453264	chr5:131705742	SLC22A5	0.65	8.15	0.35	3.33e-15	Rheumatoid arthritis;
LGG	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.4	0.4	2.48e-19	Diabetic retinopathy;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg00933542	chr6:150070202	PCMT1	0.39	6.99	0.31	9.58e-12	Lung cancer;
LGG	cis	rs3857067	0.967	rs1355240	chr4:95019353	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.49	-0.33	3.53e-13	QT interval;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg09699651	chr6:150184138	LRP11	0.52	9.39	0.4	2.64e-19	Lung cancer;
LGG	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg22676075	chr6:135203613	NA	0.42	7.3	0.32	1.25e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.56	-0.47	2.45e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1978968	0.763	rs5992136	chr22:18453103	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.98	-0.52	4.6e-33	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-13.92	-0.54	4.61e-37	Coronary artery disease;
LGG	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg18551225	chr6:44695536	NA	-0.54	-8.08	-0.35	5.74e-15	Total body bone mineral density;
LGG	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg12193833	chr17:30244370	NA	0.28	6.99	0.31	9.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg04568710	chr12:38710424	ALG10B	-0.41	-9.2	-0.39	1.22e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg10053473	chr17:62856997	LRRC37A3	0.89	13.93	0.54	4.54e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs933688	0.941	rs11948056	chr5:90680468	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.7	0.64	6.14e-54	Smoking behavior;
LGG	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.87e-14	Cystic fibrosis severity;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg26783146	chr16:4423632	VASN;CORO7	-0.34	-6.84	-0.3	2.46e-11	Schizophrenia;
LGG	cis	rs36051895	0.623	rs11506293	chr9:5257430	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-11.9	-0.48	1.16e-28	Pediatric autoimmune diseases;
LGG	cis	rs7166081	1.000	rs4238407	chr15:67633784	G/A	cg05925327	chr15:68127851	NA	-0.33	-6.97	-0.31	1.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.04	0.31	7.15e-12	Neuroticism;
LGG	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.92	0.48	9.67e-29	Lymphocyte counts;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg13628971	chr7:2884303	GNA12	0.47	9.28	0.4	6.6e-19	Height;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.39	7.79	0.34	4.52e-14	Schizophrenia;
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18099408	chr3:52552593	STAB1	-0.35	-6.97	-0.31	1.1e-11	Bipolar disorder;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.26	-0.36	1.59e-15	Tonsillectomy;
LGG	cis	rs17767392	0.670	rs4902928	chr14:71732652	G/C	cg02058870	chr14:72053146	SIPA1L1	0.36	7.65	0.34	1.16e-13	Mitral valve prolapse;
LGG	trans	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08862035	chr2:2617432	NA	0.42	6.94	0.31	1.33e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1008375	1.000	rs7688682	chr4:17693794	A/G	cg27347728	chr4:17578864	LAP3	-0.37	-6.66	-0.3	7.75e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs701145	0.585	rs896013	chr3:153863873	A/G	cg17054900	chr3:154042577	DHX36	0.75	9.07	0.39	3.31e-18	Coronary artery disease;
LGG	cis	rs7306456	0.623	rs10902513	chr12:132693487	A/G	cg23693797	chr12:132685342	GALNT9	-0.34	-6.98	-0.31	1.01e-11	Anti-saccade response;
LGG	cis	rs6547741	1.000	rs13026621	chr2:27807624	G/A	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs4742903	0.935	rs17237053	chr9:106946359	C/T	cg14250997	chr9:106856677	SMC2	-0.39	-8.01	-0.35	9.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg02002194	chr4:3960332	NA	-0.49	-9.62	-0.41	4.15e-20	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25550279	chr7:53254983	NA	0.38	6.68	0.3	7.05e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	13.91	0.54	5.48e-37	Obesity-related traits;
LGG	cis	rs9658691	0.646	rs2862834	chr10:90741374	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.93	10.01	0.42	1.77e-21	Mosquito bite size;
LGG	cis	rs2117029	1.000	rs11168827	chr12:49419677	C/G	cg24176009	chr12:49580217	TUBA1A	-0.45	-8.33	-0.36	8.91e-16	Intelligence (multi-trait analysis);
LGG	cis	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs11711311	0.955	rs7617313	chr3:113391740	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.13	-0.31	3.84e-12	IgG glycosylation;
LGG	cis	rs1784581	0.631	rs3016544	chr6:162393065	T/C	cg17173639	chr6:162384350	PARK2	-0.76	-17.22	-0.62	1.02e-51	Itch intensity from mosquito bite;
LGG	cis	rs9815354	0.812	rs704964	chr3:42053899	G/A	cg03022575	chr3:42003672	ULK4	-0.6	-7.48	-0.33	3.84e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs13191362	0.507	rs1954810	chr6:163061749	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-8.33	-0.36	9.39e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg25319279	chr11:5960081	NA	-0.56	-8.68	-0.37	7e-17	DNA methylation (variation);
LGG	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.67	-0.44	6.76e-24	Mood instability;
LGG	cis	rs9611519	0.603	rs9607764	chr22:41411804	G/C	cg03806693	chr22:41940476	POLR3H	-0.45	-7.46	-0.33	4.19e-13	Neuroticism;
LGG	cis	rs4774899	0.932	rs3095821	chr15:57575916	G/A	cg08128148	chr15:57256372	TCF12	0.31	7.24	0.32	1.93e-12	Urinary tract infection frequency;
LGG	cis	rs4253772	0.637	rs3087501	chr22:46647909	A/G	cg24881330	chr22:46731750	TRMU	0.68	8.08	0.35	5.65e-15	LDL cholesterol;Cholesterol, total;
LGG	cis	rs988958	0.920	rs2053396	chr2:42296508	C/T	cg19376973	chr2:42229025	NA	0.41	6.73	0.3	4.93e-11	Hypospadias;
LGG	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8032158	0.963	rs28778631	chr15:56255589	T/C	cg02198044	chr15:56286336	NEDD4	-0.74	-12.87	-0.51	1.25e-32	Keloid;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.26	0.46	3.77e-26	Height;
LGG	cis	rs11168618	0.743	rs12815151	chr12:48874836	A/C	cg24011408	chr12:48396354	COL2A1	0.49	8.04	0.35	7.5e-15	Adiponectin levels;
LGG	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg15627072	chr1:2432621	PLCH2	0.36	7.76	0.34	5.35e-14	Ulcerative colitis;
LGG	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg04995300	chr3:66848608	NA	-0.55	-8.09	-0.35	5.18e-15	Type 2 diabetes;
LGG	cis	rs9463078	0.691	rs9381373	chr6:45175908	T/C	cg25276700	chr6:44698697	NA	-0.33	-6.75	-0.3	4.34e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9303401	0.614	rs3803753	chr17:56540110	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.36	0.56	5.99e-39	Cognitive test performance;
LGG	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.07	-0.35	6.26e-15	Neuroticism;
LGG	cis	rs774359	0.789	rs2492815	chr9:27490296	T/C	cg21249376	chr9:27528432	MOBKL2B	0.46	8.52	0.37	2.22e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.74	-0.34	6.42e-14	Neuroticism;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.59	-9.13	-0.39	2.08e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg09527670	chr19:5059110	KDM4B	-0.23	-6.85	-0.3	2.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.94	-0.31	1.33e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.52	0.33	2.84e-13	Cystic fibrosis severity;
LGG	cis	rs10489202	1.000	rs34774552	chr1:168032245	G/A	cg24449463	chr1:168025552	DCAF6	-0.63	-10.2	-0.43	3.65e-22	Schizophrenia;
LGG	trans	rs2834485	1.000	rs5010906	chr21:35818590	G/C	cg07474852	chr4:123073612	NA	0.65	11.02	0.46	3.01e-25	Cancer;
LGG	cis	rs11748327	0.580	rs10064638	chr5:4007094	T/G	cg01025095	chr5:4101132	NA	-0.42	-6.75	-0.3	4.54e-11	Myocardial infarction;
LGG	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.71	-0.48	6.66e-28	Coronary artery disease;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg22433210	chr17:43662623	NA	0.64	11.04	0.46	2.63e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.54	-0.33	2.59e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs367615	0.660	rs10477972	chr5:108831951	C/A	cg17395555	chr5:108820864	NA	0.87	15.8	0.59	2.71e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg23649088	chr2:200775458	C2orf69	0.4	6.96	0.31	1.15e-11	QT interval;
LGG	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg27489772	chr12:121021490	NA	-0.55	-7.48	-0.33	3.7e-13	Type 1 diabetes nephropathy;
LGG	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs244899	0.967	rs184957	chr5:167919623	T/A	cg06604206	chr5:167912465	RARS	-0.53	-11.66	-0.48	9.64e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs6499165	0.560	rs9934232	chr16:68345675	C/G	cg07273125	chr16:68295692	NA	0.46	10.42	0.44	5.64e-23	Metabolic traits;
LGG	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg17644776	chr2:200775616	C2orf69	0.6	8.38	0.36	6.17e-16	Schizophrenia;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg12419862	chr22:24373484	LOC391322	-0.87	-17.76	-0.64	3.52e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg23649088	chr2:200775458	C2orf69	-0.39	-6.73	-0.3	5.04e-11	QT interval;
LGG	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg02251663	chr11:14281053	SPON1	-0.3	-7.16	-0.32	3.27e-12	Mitochondrial DNA levels;
LGG	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg06640241	chr16:89574553	SPG7	0.85	15.89	0.59	1.08e-45	Multiple myeloma (IgH translocation);
LGG	cis	rs4629710	0.562	rs3798252	chr6:131583758	A/T	cg12606694	chr6:131520996	AKAP7	0.5	8.32	0.36	1.02e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs7851660	0.967	rs7847126	chr9:100600635	A/C	cg13688889	chr9:100608707	NA	-0.68	-14.48	-0.56	1.82e-39	Strep throat;
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9309473	0.583	rs6546822	chr2:73575098	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-8.02	-0.35	8.81e-15	Metabolite levels;
LGG	cis	rs2108225	0.837	rs6959729	chr7:107446180	A/C	cg18560240	chr7:107437656	SLC26A3	-0.55	-9.92	-0.42	3.66e-21	Ulcerative colitis;
LGG	cis	rs1784581	0.851	rs1784591	chr6:162388893	C/G	cg17173639	chr6:162384350	PARK2	-0.88	-23.1	-0.73	4.31e-79	Itch intensity from mosquito bite;
LGG	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.9	0.31	1.67e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg17376030	chr22:41985996	PMM1	0.51	8.22	0.36	2.07e-15	Vitiligo;
LGG	cis	rs2274273	0.870	rs17741542	chr14:55805861	A/G	cg04306507	chr14:55594613	LGALS3	-0.61	-17.07	-0.62	4.95e-51	Protein biomarker;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg02725872	chr8:58115012	NA	-1.07	-14.75	-0.57	1.17e-40	Developmental language disorder (linguistic errors);
LGG	trans	rs6787172	0.811	rs827102	chr3:157940116	A/G	cg23275840	chr4:47708675	CORIN	0.34	7.16	0.32	3.14e-12	Subjective well-being;
LGG	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg20476274	chr7:133979776	SLC35B4	0.66	11.86	0.48	1.69e-28	Mean platelet volume;
LGG	cis	rs6032067	0.586	rs62208373	chr20:43764426	G/A	cg10761708	chr20:43804764	PI3	0.74	11.01	0.46	3.31e-25	Blood protein levels;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs1355223	0.506	rs7130678	chr11:34869181	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.53	-8.52	-0.37	2.32e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9462027	0.630	rs9469871	chr6:34745007	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg16583315	chr14:65563665	MAX	-0.41	-8.33	-0.36	9.52e-16	Obesity-related traits;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9868809	0.881	rs34368826	chr3:48670827	G/T	cg00383909	chr3:49044727	WDR6	0.83	9.59	0.41	5.61e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.3	-0.32	1.28e-12	Retinal vascular caliber;
LGG	cis	rs7143963	0.636	rs8003422	chr14:103321603	G/A	cg23020514	chr14:103360112	TRAF3	0.4	8.41	0.36	5.13e-16	Body mass index;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.45	-0.56	2.41e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs9790314	0.586	rs35713426	chr3:161131271	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-11.13	-0.46	1.21e-25	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg02158880	chr13:53174818	NA	0.47	9.58	0.41	5.88e-20	Lewy body disease;
LGG	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.75e-28	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.8	-0.34	4.05e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12134245	0.747	rs17501512	chr1:92012481	C/G	cg25838465	chr1:92012736	NA	0.56	10.73	0.45	3.75e-24	Breast cancer;
LGG	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.3	-0.43	1.56e-22	Triglycerides;
LGG	cis	rs7208859	0.614	rs7216394	chr17:28825756	T/C	cg01831904	chr17:28903510	LRRC37B2	0.66	8.28	0.36	1.31e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06634786	chr22:41940651	POLR3H	0.71	11.41	0.47	9.33e-27	Vitiligo;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.99	0.31	9.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs963731	0.649	rs2123881	chr2:39247742	G/A	cg04010122	chr2:39346883	SOS1	-0.81	-7.08	-0.31	5.37e-12	Corticobasal degeneration;
LGG	cis	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg07460842	chr6:66804631	NA	0.93	17.02	0.62	8.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.4	0.33	6.63e-13	Refractive error;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.36e-18	Lung cancer;
LGG	cis	rs9403521	0.673	rs3934959	chr6:143979710	A/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-10.47	-0.44	3.54e-23	Obesity-related traits;
LGG	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-10.44	-0.44	4.55e-23	Body mass index;
LGG	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg19455335	chr8:22457658	C8orf58	-0.43	-9.02	-0.39	5.15e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1459104	0.714	rs1851614	chr11:54836269	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.53	0.33	2.62e-13	Body mass index;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.54	-14.55	-0.56	8.76e-40	Tonsillectomy;
LGG	cis	rs17331151	0.505	rs71299610	chr3:52641703	T/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.5	6.66	0.3	7.6e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg05775895	chr3:12838266	CAND2	0.81	16.27	0.6	2.2e-47	QRS complex (12-leadsum);
LGG	cis	rs7998202	0.667	rs282574	chr13:113361310	C/T	cg17218041	chr13:113365319	ATP11A	-0.41	-6.82	-0.3	2.85e-11	Glycated hemoglobin levels;
LGG	cis	rs7572733	0.555	rs35563720	chr2:198923075	A/G	cg00792783	chr2:198669748	PLCL1	0.61	9.72	0.41	1.9e-20	Dermatomyositis;
LGG	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg13798912	chr7:905769	UNC84A	0.58	7.33	0.32	1.01e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.84	-0.3	2.55e-11	Lung cancer;
LGG	cis	rs10048158	0.585	rs6504405	chr17:64246471	T/G	cg19474267	chr17:64306194	PRKCA	-0.65	-13.46	-0.53	4.26e-35	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs7226408	0.857	rs72887016	chr18:34464090	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1658422	chr10:60331758	G/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.33	-0.32	1.02e-12	Refractive error;
LGG	cis	rs7089973	0.604	rs7915943	chr10:116618077	G/A	cg08188268	chr10:116634841	FAM160B1	0.33	7.18	0.32	2.81e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6088580	0.634	rs6142164	chr20:33006597	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.2	-0.39	1.19e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs2708977	0.966	rs2708978	chr2:97202243	A/C	cg01950434	chr2:97203154	ARID5A	-0.59	-9.4	-0.4	2.47e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs17685	0.725	rs7807647	chr7:75628669	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.03	-24.57	-0.75	6.28e-86	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg11766577	chr21:47581405	C21orf56	-0.58	-10.63	-0.44	8.94e-24	Testicular germ cell tumor;
LGG	trans	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg13565492	chr6:43139072	SRF	-0.7	-8.81	-0.38	2.45e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-10.37	-0.43	8.23e-23	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs9866695	chr3:50069452	G/T	cg05623727	chr3:50126028	RBM5	-0.32	-6.92	-0.31	1.47e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	trans	rs1821002	1	rs1821002	chr8:10640065	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.46	-0.33	4.44e-13	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg23782820	chr8:58130467	NA	0.44	6.81	0.3	3.13e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2267681	0.544	rs1990354	chr7:139523858	A/G	cg14116596	chr7:139528673	TBXAS1	0.33	7.22	0.32	2.16e-12	Cervical cancer;
LGG	trans	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.36	6.87	0.3	2.08e-11	Platelet count;
LGG	cis	rs9287719	0.837	rs4331474	chr2:10755583	G/A	cg02196655	chr2:10830764	NOL10	-0.41	-6.89	-0.31	1.81e-11	Prostate cancer;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.57	-0.33	2.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs912057	1.000	rs1294410	chr6:6738752	C/T	cg06612196	chr6:6737390	NA	-0.44	-8.95	-0.38	8.48e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	trans	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-9.44	-0.4	1.87e-19	Brugada syndrome;
LGG	cis	rs7084402	0.905	rs1649031	chr10:60279742	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	trans	rs11976180	1.000	rs2961115	chr7:143753371	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.88	-0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg12654349	chr5:56205094	C5orf35	-0.63	-9.98	-0.42	2.23e-21	Initial pursuit acceleration;
LGG	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg17211192	chr8:82754475	SNX16	0.78	12.07	0.49	2.27e-29	Diastolic blood pressure;
LGG	cis	rs6568686	0.786	rs6927920	chr6:111820382	A/T	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg00277334	chr10:82204260	NA	-0.53	-12.62	-0.51	1.4e-31	Post bronchodilator FEV1;
LGG	cis	rs977987	0.742	rs34624768	chr16:75331572	G/A	cg03315344	chr16:75512273	CHST6	0.48	9.73	0.41	1.81e-20	Dupuytren's disease;
LGG	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg17788362	chr6:86352627	SYNCRIP	0.55	9.78	0.41	1.17e-20	Smooth-surface caries;
LGG	trans	rs6956675	0.958	rs7779974	chr7:62576724	T/C	cg01314568	chr7:57830625	NA	-0.51	-8.05	-0.35	7.23e-15	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11644478	chr21:40555479	PSMG1	-0.59	-9.87	-0.42	5.78e-21	Menarche (age at onset);
LGG	cis	rs11690935	0.550	rs62183784	chr2:172866696	A/G	cg13550731	chr2:172543902	DYNC1I2	0.63	12.0	0.49	4.59e-29	Schizophrenia;
LGG	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg08847533	chr14:75593920	NEK9	0.63	12.24	0.49	4.87e-30	Height;
LGG	cis	rs3206736	0.530	rs329553	chr7:35105062	G/A	cg13400248	chr7:35225412	NA	0.4	7.2	0.32	2.5e-12	Diastolic blood pressure;
LGG	cis	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg04455712	chr21:45112962	RRP1B	0.5	9.57	0.41	6.35e-20	Mean corpuscular volume;
LGG	cis	rs12282928	0.921	rs7933408	chr11:48246824	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.09	-0.31	4.94e-12	Migraine - clinic-based;
LGG	cis	rs7727544	0.557	rs2897096	chr5:131486284	A/G	cg07395648	chr5:131743802	NA	-0.4	-8.68	-0.37	6.63e-17	Blood metabolite levels;
LGG	cis	rs55986470	0.763	rs6713788	chr2:239456932	T/A	cg18131467	chr2:239335373	ASB1	-0.57	-6.98	-0.31	1.05e-11	Chronotype;
LGG	cis	rs2404602	0.598	rs71405204	chr15:76635305	C/G	cg15268244	chr15:77196840	NA	0.43	8.47	0.37	3.23e-16	Blood metabolite levels;
LGG	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11764359	chr7:65958608	NA	0.57	9.57	0.41	6.19e-20	Aortic root size;
LGG	cis	rs972578	0.905	rs60752002	chr22:43371628	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14298792	chr15:30685198	CHRFAM7A	0.53	8.02	0.35	8.83e-15	Huntington's disease progression;
LGG	cis	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg06374794	chr16:88002281	BANP	0.45	8.27	0.36	1.43e-15	Menopause (age at onset);
LGG	cis	rs11239187	0.548	rs11599242	chr10:45063456	T/G	cg03916630	chr10:45065415	NA	0.37	8.81	0.38	2.62e-17	Body mass index;
LGG	cis	rs62238980	0.614	rs79173736	chr22:32379966	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg13565492	chr6:43139072	SRF	-0.69	-8.53	-0.37	2.15e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8077889	0.672	rs1230400	chr17:41845451	G/A	cg26893861	chr17:41843967	DUSP3	-1.08	-25.41	-0.76	8.14e-90	Triglycerides;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg08677398	chr8:58056175	NA	0.44	7.36	0.32	8.55e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.632	rs56153788	chr15:86170992	G/A	cg25843651	chr15:86329602	KLHL25	0.56	8.36	0.36	7.55e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs6964587	1.000	rs2106171	chr7:91750450	A/G	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.48e-18	Breast cancer;
LGG	trans	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg16141378	chr3:129829833	LOC729375	0.43	10.09	0.42	9.07e-22	Mood instability;
LGG	trans	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg00711542	chr16:29343894	RUNDC2C	0.41	6.87	0.3	2.12e-11	Menopause (age at onset);
LGG	cis	rs35160687	0.644	rs4832271	chr2:86505327	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-7.22	-0.32	2.1e-12	Night sleep phenotypes;
LGG	cis	rs3812049	0.784	rs1560637	chr5:127448066	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.1	0.42	8.36e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4538187	1.000	rs6731508	chr2:64094506	G/C	cg19915305	chr2:64069682	UGP2	0.68	14.71	0.56	1.85e-40	Systolic blood pressure;
LGG	trans	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.47	10.11	0.43	7.35e-22	Schizophrenia;
LGG	cis	rs4380275	1.000	rs4450634	chr2:773257	G/A	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.23	-0.32	2.08e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg08999081	chr20:33150536	PIGU	0.39	9.68	0.41	2.66e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg00908189	chr16:619842	PIGQ	0.84	15.6	0.59	2.12e-44	Height;
LGG	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg15704280	chr7:45808275	SEPT13	0.87	9.18	0.39	1.4e-18	Myopia (pathological);
LGG	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg06532163	chr17:45867833	NA	0.55	9.3	0.4	5.63e-19	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.22	-32.94	-0.84	2.03e-123	Chronic sinus infection;
LGG	cis	rs12681366	0.663	rs2921389	chr8:95466366	G/A	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs79976124	0.797	rs74995761	chr6:66640216	G/A	cg07460842	chr6:66804631	NA	0.73	12.6	0.51	1.65e-31	Type 2 diabetes;
LGG	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg02023728	chr11:77925099	USP35	-0.38	-6.78	-0.3	3.69e-11	Alzheimer's disease (survival time);
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25172604	chr17:41446521	NA	-0.31	-7.23	-0.32	2.03e-12	Menopause (age at onset);
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7615952	0.605	rs11708269	chr3:125332150	C/T	cg07211511	chr3:129823064	LOC729375	-0.57	-6.71	-0.3	5.81e-11	Blood pressure (smoking interaction);
LGG	cis	rs3740540	0.530	rs10751598	chr10:126290951	A/G	cg04949429	chr10:126290192	LHPP	-0.6	-11.49	-0.47	4.76e-27	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7917772	0.503	rs6584510	chr10:104299868	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg13047869	chr3:10149882	C3orf24	0.44	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	14.95	0.57	1.54e-41	Tonsillectomy;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.838	rs12488245	chr3:99835254	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.47	8.19	0.36	2.48e-15	Axial length;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6076065	0.963	rs2424543	chr20:23389955	G/T	cg12633918	chr20:23549525	CST9L	-0.33	-6.82	-0.3	2.79e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg06618935	chr21:46677482	NA	0.42	7.73	0.34	6.92e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs7917772	0.510	rs2001389	chr10:104375258	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.63	0.48	1.37e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9443189	0.813	rs2748956	chr6:76465003	G/C	cg01950844	chr6:76311363	SENP6	-0.52	-6.79	-0.3	3.45e-11	Prostate cancer;
LGG	cis	rs3925075	1.000	rs9673404	chr16:31347592	A/T	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27297192	chr10:134578999	INPP5A	0.33	7.14	0.31	3.63e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17767392	0.781	rs34388001	chr14:71883500	A/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.26	0.36	1.5e-15	Mitral valve prolapse;
LGG	cis	rs9902453	0.868	rs7212162	chr17:28321328	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.79	0.54	1.67e-36	Coffee consumption (cups per day);
LGG	cis	rs2274273	0.934	rs10139337	chr14:55742113	C/T	cg04306507	chr14:55594613	LGALS3	0.62	16.94	0.62	2.02e-50	Protein biomarker;
LGG	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg01579765	chr21:45077557	HSF2BP	0.41	9.4	0.4	2.58e-19	Mean corpuscular volume;
LGG	cis	rs870825	0.655	rs10033035	chr4:185630880	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.95	-0.38	8.84e-18	Lung cancer;
LGG	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.32	0.4	4.74e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.32	3.07e-12	Lung cancer;
LGG	cis	rs13102973	0.965	rs4597893	chr4:135863043	C/T	cg14419869	chr4:135874104	NA	-0.57	-10.97	-0.45	4.84e-25	Subjective well-being;
LGG	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg27572855	chr1:25598939	RHD	-0.49	-11.05	-0.46	2.44e-25	Erythrocyte sedimentation rate;
LGG	cis	rs703842	0.642	rs73123375	chr12:58063664	C/T	cg18357645	chr12:58087776	OS9	-0.56	-8.19	-0.36	2.55e-15	Multiple sclerosis;
LGG	cis	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg27411982	chr8:10470053	RP1L1	0.4	6.79	0.3	3.5e-11	Neuroticism;
LGG	cis	rs4363385	0.747	rs4845507	chr1:152968414	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.02	-0.39	4.84e-18	Inflammatory skin disease;
LGG	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg12927641	chr6:109611667	NA	-0.37	-7.11	-0.31	4.46e-12	Reticulocyte fraction of red cells;
LGG	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg24848339	chr3:12840334	CAND2	0.36	7.85	0.34	2.89e-14	QRS complex (12-leadsum);
LGG	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg07606381	chr6:8435919	SLC35B3	-0.67	-11.98	-0.49	5.59e-29	Motion sickness;
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs11877825	0.813	rs34276557	chr18:10571005	A/G	cg25239095	chr18:10589360	NA	0.49	9.06	0.39	3.54e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg15823100	chr22:32027580	PISD	-0.81	-8.97	-0.38	7.63e-18	Age-related hearing impairment;
LGG	cis	rs3845702	0.736	rs6433818	chr2:180810264	A/T	cg01881094	chr2:180872142	CWC22	-1.26	-16.35	-0.6	9.59e-48	Schizophrenia;
LGG	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg02002194	chr4:3960332	NA	-0.42	-7.86	-0.34	2.69e-14	Neuroticism;
LGG	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg05887092	chr17:76393375	PGS1	0.79	18.86	0.66	2.75e-59	HDL cholesterol levels;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.39	0.61	6.31e-48	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.89	0.34	2.28e-14	Life satisfaction;
LGG	cis	rs35538253	0.522	rs10492823	chr16:72018860	G/C	cg08717414	chr16:71523259	ZNF19	-0.75	-8.37	-0.36	6.85e-16	Post bronchodilator FEV1;
LGG	cis	rs2712184	0.967	rs7587010	chr2:217674989	G/T	cg05032264	chr2:217675019	NA	-0.54	-12.56	-0.5	2.49e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg02018176	chr4:1364513	KIAA1530	0.35	7.41	0.33	5.93e-13	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg06618935	chr21:46677482	NA	-0.49	-9.52	-0.4	1e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg21775007	chr8:11205619	TDH	-0.52	-8.48	-0.37	3.05e-16	Neuroticism;
LGG	cis	rs4788570	0.655	rs1392484	chr16:71822101	T/A	cg06353428	chr16:71660113	MARVELD3	1.27	20.46	0.69	9.34e-67	Intelligence (multi-trait analysis);
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27189623	chr16:705930	WDR90	0.4	7.69	0.34	8.72e-14	Height;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg05091796	chr16:4465799	CORO7	-0.76	-12.63	-0.51	1.28e-31	Schizophrenia;
LGG	trans	rs7944735	0.508	rs17791016	chr11:47727590	A/C	cg15704280	chr7:45808275	SEPT13	0.63	6.85	0.3	2.31e-11	Intraocular pressure;
LGG	cis	rs4959677	0.901	rs6920875	chr6:2478975	C/T	cg20147862	chr6:2634573	C6orf195	-0.35	-6.85	-0.3	2.42e-11	Orthostatic hypotension;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18918831	chr3:195489782	MUC4	0.6	8.58	0.37	1.43e-16	Lung disease severity in cystic fibrosis;
LGG	trans	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg09836344	chr4:1243392	C4orf42;CTBP1	0.54	7.61	0.33	1.55e-13	Mosquito bite size;
LGG	cis	rs4561483	0.831	rs33648	chr16:11979622	G/A	cg08843971	chr16:11963173	GSPT1	-0.64	-15.35	-0.58	2.75e-43	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.61	-0.37	1.15e-16	Menopause (age at onset);
LGG	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	9.98	0.42	2.29e-21	Body mass index;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg07382826	chr16:28625726	SULT1A1	0.41	8.9	0.38	1.26e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.68	-0.75	1.83e-86	Height;
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.64	-0.37	9.34e-17	Alzheimer's disease (survival time);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg24054938	chr1:153651301	NPR1	-0.39	-6.8	-0.3	3.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4696584	0.941	rs6536012	chr4:155398445	C/G	cg04517429	chr4:155413618	DCHS2	0.31	7.22	0.32	2.12e-12	Folding of antihelix;
LGG	cis	rs3096299	0.967	rs2911253	chr16:89488587	T/G	cg08392591	chr16:89556376	ANKRD11	0.46	7.18	0.32	2.77e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.49	0.56	1.62e-39	Colorectal cancer;
LGG	cis	rs5758659	0.623	rs133328	chr22:42408079	T/C	cg15557168	chr22:42548783	NA	-0.34	-7.59	-0.33	1.76e-13	Cognitive function;
LGG	cis	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg06521331	chr12:34319734	NA	-0.4	-6.9	-0.31	1.77e-11	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.02	-0.31	7.85e-12	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.36	-0.32	8.45e-13	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg18032289	chr17:61959525	GH2	0.42	7.24	0.32	1.86e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs929354	0.713	rs6459733	chr7:156930550	G/C	cg05182265	chr7:156933206	UBE3C	-0.35	-7.11	-0.31	4.48e-12	Body mass index;
LGG	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg09307838	chr4:120376055	NA	0.72	12.45	0.5	6.7e-31	Corneal astigmatism;
LGG	cis	rs28595532	0.841	rs114363775	chr4:119765587	G/A	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg03396347	chr1:1875803	NA	-0.49	-9.61	-0.41	4.77e-20	Body mass index;
LGG	cis	rs727505	1.000	rs7790856	chr7:124459852	C/T	cg23710748	chr7:124431027	NA	-0.48	-9.16	-0.39	1.72e-18	Lewy body disease;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.65	0.37	8.76e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10089	1.000	rs10057122	chr5:127512063	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.35	0.47	1.61e-26	Ileal carcinoids;
LGG	cis	rs3750082	0.852	rs7786669	chr7:32898338	A/G	cg08946731	chr7:32981826	RP9P	0.4	6.68	0.3	6.68e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.2	0.32	2.41e-12	Mood instability;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg06074448	chr4:187884817	NA	-0.58	-12.77	-0.51	3.47e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7572644	0.723	rs3935148	chr2:28020966	T/A	cg27432699	chr2:27873401	GPN1	0.48	6.76	0.3	4.04e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2282802	0.685	rs7737543	chr5:139646026	A/G	cg26211634	chr5:139558579	C5orf32	0.35	7.67	0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg24623649	chr8:11872141	NA	0.29	6.97	0.31	1.1e-11	Systolic blood pressure;
LGG	cis	rs7572263	0.959	rs10804167	chr2:209049840	C/T	cg00164906	chr2:209055251	C2orf80	-0.51	-8.59	-0.37	1.31e-16	Glioma;Non-glioblastoma glioma;
LGG	cis	rs1577917	0.958	rs11756615	chr6:86679835	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.55	-0.53	1.85e-35	Response to antipsychotic treatment;
LGG	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg20503657	chr10:835505	NA	0.75	10.31	0.43	1.46e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs907683	0.635	rs11691617	chr2:220295167	C/T	cg15015639	chr2:220282977	DES	0.34	9.93	0.42	3.29e-21	Resting heart rate;
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.65	-0.41	3.41e-20	Aortic root size;
LGG	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg25358565	chr5:93447407	FAM172A	-0.7	-10.08	-0.42	1.01e-21	Diabetic retinopathy;
LGG	cis	rs3733585	0.699	rs6823361	chr4:9963127	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.61e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg17788362	chr6:86352627	SYNCRIP	0.51	8.69	0.37	6.28e-17	Smooth-surface caries;
LGG	cis	rs2562456	0.754	rs11666213	chr19:21605645	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.52	-0.33	2.91e-13	Pain;
LGG	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg26811252	chr16:29126840	RRN3P2	0.7	11.03	0.46	2.79e-25	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.63	0.33	1.32e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.97	0.35	1.25e-14	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg05313129	chr8:58192883	C8orf71	-0.76	-9.96	-0.42	2.72e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg08048268	chr3:133502702	NA	-0.46	-7.94	-0.35	1.54e-14	Iron status biomarkers;
LGG	cis	rs1335587	0.550	rs7319319	chr13:102079361	T/C	cg13538571	chr13:102108074	ITGBL1	0.36	6.74	0.3	4.83e-11	Obesity-related traits;
LGG	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.9	-0.34	1.99e-14	Blood metabolite levels;
LGG	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg21452805	chr1:244014465	NA	0.56	6.68	0.3	6.95e-11	RR interval (heart rate);
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01585723	chr16:33734837	NA	0.45	7.9	0.34	2.05e-14	Menopause (age at onset);
LGG	cis	rs17428076	0.837	rs72889848	chr2:172527238	T/C	cg21435375	chr2:172878103	MAP1D	0.37	7.99	0.35	1.04e-14	Myopia;
LGG	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg11901034	chr3:128598214	ACAD9	-0.44	-6.7	-0.3	6.18e-11	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.17	0.32	3.08e-12	Myopia (pathological);
LGG	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.06	0.35	6.78e-15	Neuroticism;
LGG	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.35	0.36	7.85e-16	Response to antipsychotic treatment;
LGG	cis	rs6450176	1.000	rs3776717	chr5:53298762	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.66	-0.44	7.3e-24	IgG glycosylation;
LGG	cis	rs11792861	0.816	rs2275637	chr9:111696043	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.21	0.43	3.19e-22	Menarche (age at onset);
LGG	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.29	-0.4	6.23e-19	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg13939156	chr17:80058883	NA	0.47	9.15	0.39	1.81e-18	Life satisfaction;
LGG	trans	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs2798269	0.867	rs60181111	chr13:22097453	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.07	-0.31	5.83e-12	PR segment;
LGG	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg13010199	chr12:38710504	ALG10B	-0.58	-11.04	-0.46	2.59e-25	Morning vs. evening chronotype;
LGG	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg02959939	chr21:47813025	PCNT	-0.31	-6.93	-0.31	1.44e-11	Lymphocyte counts;
LGG	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.61	-0.33	1.53e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7106204	0.544	rs16912364	chr11:24291549	A/G	ch.11.24196551F	chr11:24239977	NA	0.89	10.02	0.42	1.58e-21	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg08888203	chr3:10149979	C3orf24	0.36	7.07	0.31	5.72e-12	Alzheimer's disease;
LGG	cis	rs7646881	0.812	rs73017540	chr3:158460788	T/A	cg19483011	chr3:158453295	NA	-0.62	-8.34	-0.36	8.53e-16	Tetralogy of Fallot;
LGG	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21659725	chr3:3221576	CRBN	-0.91	-20.26	-0.69	8.57e-66	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00294572	chr6:26285232	NA	0.42	7.72	0.34	7.01e-14	Educational attainment;
LGG	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.42	-0.33	5.49e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12431410	0.550	rs2147831	chr14:60218343	C/T	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.66e-11	Schizophrenia;
LGG	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.81	-0.38	2.5e-17	Initial pursuit acceleration;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.36	6.99	0.31	9.56e-12	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07445963	chr5:140856469	PCDHGA4;PCDHGA12;PCDHGA11;PCDHGA9;PCDHGA1;PCDHGB1;PCDHGB6;PCDHGC3;PCDHGB3;PCDHGB7;PCDHGA6;PCDHGA8;PCDHGA10;PCDHGA5;PCDHGB4;PCDHGA3;PCDHGA2;PCDHGA7;PCDHGB2;PCDHGB5	0.46	7.6	0.33	1.69e-13	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.68	-0.34	9.47e-14	Personality dimensions;
LGG	trans	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg25214090	chr10:38739885	LOC399744	0.57	10.39	0.43	7.24e-23	Corneal astigmatism;
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg18963800	chr10:38644991	HSD17B7P2	0.45	7.23	0.32	1.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg02158880	chr13:53174818	NA	0.77	17.44	0.63	9.66e-53	Lewy body disease;
LGG	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.09	-0.39	2.85e-18	Retinal vascular caliber;
LGG	cis	rs7945718	0.967	rs11826129	chr11:12768883	G/A	cg25843174	chr11:12811716	TEAD1	0.41	8.32	0.36	9.62e-16	Educational attainment (years of education);
LGG	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg26695010	chr11:65641043	EFEMP2	0.46	7.19	0.32	2.68e-12	Breast cancer;
LGG	cis	rs3771570	0.681	rs12151655	chr2:242281438	T/A	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg00012203	chr2:219082015	ARPC2	-0.49	-8.64	-0.37	9.44e-17	Ulcerative colitis;
LGG	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg16105309	chr15:79090380	ADAMTS7	0.39	6.96	0.31	1.18e-11	Schizophrenia;
LGG	cis	rs4901847	0.562	rs11628678	chr14:58611623	A/C	cg15908186	chr14:58618357	C14orf37	0.68	12.59	0.51	1.83e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.86	-0.3	2.16e-11	Triglycerides;
LGG	cis	rs66573146	0.572	rs66611116	chr4:6953270	A/G	cg00086871	chr4:6988644	TBC1D14	0.84	8.33	0.36	9.23e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs11098499	0.754	rs28643450	chr4:120245242	G/A	cg24375607	chr4:120327624	NA	0.59	9.99	0.42	2.14e-21	Corneal astigmatism;
LGG	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg06640241	chr16:89574553	SPG7	0.93	17.8	0.64	2.29e-54	Multiple myeloma (IgH translocation);
LGG	cis	rs7077256	0.564	rs12762639	chr10:65112853	G/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.95	-0.31	1.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg13147721	chr7:65941812	NA	-0.8	-9.73	-0.41	1.73e-20	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.24e-12	Menopause (age at onset);
LGG	cis	rs778371	0.871	rs2675954	chr2:233750627	C/G	cg25237894	chr2:233734115	C2orf82	-0.44	-7.45	-0.33	4.56e-13	Schizophrenia;
LGG	cis	rs4950322	0.570	rs80270233	chr1:146734978	C/G	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs6964587	1.000	rs12540055	chr7:91707921	A/G	cg17063962	chr7:91808500	NA	0.46	8.22	0.36	2.01e-15	Breast cancer;
LGG	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg13147721	chr7:65941812	NA	-0.83	-9.92	-0.42	3.55e-21	Diabetic kidney disease;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg11905131	chr22:24372483	LOC391322	-0.46	-7.96	-0.35	1.34e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03517284	chr6:25882590	NA	-0.53	-10.14	-0.43	6.08e-22	Height;
LGG	cis	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg14019146	chr3:50243930	SLC38A3	-0.42	-8.72	-0.38	5.1e-17	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.78	-0.78	3.86e-96	Height;
LGG	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	trans	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.15	-0.32	3.36e-12	Triglycerides;
LGG	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.11e-21	Hypertriglyceridemia;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg13732083	chr21:47605072	C21orf56	0.47	7.98	0.35	1.16e-14	Testicular germ cell tumor;
LGG	cis	rs13108043	0.605	rs13140610	chr4:87876826	A/G	cg11209507	chr4:87813803	C4orf36	0.61	8.07	0.35	5.99e-15	Red blood cell count;
LGG	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg13072238	chr3:49761600	GMPPB	0.55	7.5	0.33	3.31e-13	Menarche (age at onset);
LGG	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg19628046	chr18:33552617	C18orf21	0.55	7.95	0.35	1.47e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs882300	0.967	rs2322864	chr2:136963072	C/T	cg07169764	chr2:136633963	MCM6	0.45	7.33	0.32	1.04e-12	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs3806843	1.000	rs2337985	chr5:140157861	T/C	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10089	1.000	rs73337363	chr5:127483597	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.82	0.48	2.33e-28	Ileal carcinoids;
LGG	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-10.08	-0.42	9.43e-22	Height;
LGG	cis	rs10463554	0.963	rs62364876	chr5:102394158	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.83	-0.34	3.42e-14	Parkinson's disease;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg05484376	chr2:27715224	FNDC4	0.45	9.57	0.41	6.29e-20	Total body bone mineral density;
LGG	trans	rs3758785	0.512	rs11020758	chr11:94110284	C/A	cg14656441	chr1:39500070	NDUFS5	-0.29	-6.72	-0.3	5.46e-11	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18252515	chr7:66147081	NA	0.44	7.33	0.32	1.04e-12	Aortic root size;
LGG	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg26752888	chr8:11627280	NEIL2	0.48	6.66	0.3	7.66e-11	Myopia (pathological);
LGG	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg08250081	chr4:10125330	NA	-0.37	-7.06	-0.31	6.2e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg12692727	chr7:1102344	C7orf50	0.49	6.82	0.3	2.79e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06037631	chr2:74942369	NA	0.4	6.9	0.31	1.72e-11	Bipolar disorder;
LGG	cis	rs9964724	0.559	rs72893182	chr18:35167218	G/A	cg27332583	chr18:35150602	NA	0.61	12.07	0.49	2.33e-29	Educational attainment (years of education);
LGG	cis	rs3206736	0.548	rs6971363	chr7:34953681	A/G	cg13400248	chr7:35225412	NA	0.51	8.82	0.38	2.41e-17	Diastolic blood pressure;
LGG	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs11587400	0.572	rs2268699	chr1:115227896	G/T	cg12756093	chr1:115239321	AMPD1	0.46	8.39	0.36	6.14e-16	Autism;
LGG	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg14541582	chr5:601475	NA	-0.68	-10.64	-0.44	8.67e-24	Obesity-related traits;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg20887711	chr4:1340912	KIAA1530	0.49	9.17	0.39	1.55e-18	Obesity-related traits;
LGG	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg13482628	chr17:19912719	NA	0.54	10.18	0.43	4.38e-22	Schizophrenia;
LGG	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.82e-13	Refractive error;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg02158880	chr13:53174818	NA	0.39	7.24	0.32	1.88e-12	Lewy body disease;
LGG	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg08603382	chr10:743973	NA	-0.6	-11.08	-0.46	1.77e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs68170813	0.523	rs79607134	chr7:107033619	A/T	cg02696742	chr7:106810147	HBP1	-0.7	-9.85	-0.42	6.8e-21	Coronary artery disease;
LGG	cis	rs6693295	0.536	rs12132151	chr1:246229264	C/T	cg11798871	chr1:246315928	SMYD3	-0.62	-8.34	-0.36	8.28e-16	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs653465	0.739	rs7641830	chr3:27208003	G/A	cg02860705	chr3:27208620	NA	0.42	8.1	0.35	5.08e-15	Breast cancer (early onset);
LGG	cis	rs1385374	0.858	rs11059928	chr12:129296103	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg17971929	chr21:40555470	PSMG1	-0.55	-9.78	-0.41	1.17e-20	Cognitive function;
LGG	cis	rs4925386	1.000	rs2151512	chr20:60913495	T/C	cg24112000	chr20:60950667	NA	0.36	8.14	0.35	3.63e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs8133932	0.736	rs2839030	chr21:47292007	A/C	cg13695288	chr21:47294981	PCBP3	-0.36	-7.17	-0.32	2.93e-12	Schizophrenia;
LGG	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	11.24	0.46	4.41e-26	Response to antipsychotic treatment;
LGG	cis	rs1348850	1.000	rs1348850	chr2:178418575	A/G	cg27490568	chr2:178487706	NA	0.49	9.66	0.41	3.01e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-19.22	-0.67	5.84e-61	Cognitive function;
LGG	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07080220	chr10:102295463	HIF1AN	0.64	11.03	0.46	2.85e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg21724239	chr8:58056113	NA	0.62	9.17	0.39	1.61e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg15971980	chr6:150254442	NA	0.45	8.93	0.38	1.01e-17	Testicular germ cell tumor;
LGG	cis	rs7444	0.941	rs140489	chr22:21921294	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-7.14	-0.31	3.66e-12	Systemic lupus erythematosus;
LGG	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.8e-14	Personality dimensions;
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg11764359	chr7:65958608	NA	-0.69	-11.93	-0.48	8.5e-29	Aortic root size;
LGG	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg20503657	chr10:835505	NA	0.62	9.33	0.4	4.54e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs8038465	0.622	rs62004587	chr15:73859016	A/C	cg15420318	chr15:73925796	NPTN	0.49	8.3	0.36	1.14e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7236492	0.688	rs35455644	chr18:77184282	A/G	cg15644404	chr18:77186268	NFATC1	-0.79	-9.5	-0.4	1.15e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg22852734	chr6:133119734	C6orf192	1.3	10.2	0.43	3.55e-22	Type 2 diabetes nephropathy;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg13628971	chr7:2884303	GNA12	0.49	9.62	0.41	4.21e-20	Height;
LGG	cis	rs2235642	0.653	rs7197288	chr16:1654753	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.23	0.39	9.37e-19	Coronary artery disease;
LGG	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs7590368	0.640	rs56260452	chr2:10954843	C/G	cg15705551	chr2:10952987	PDIA6	0.58	7.56	0.33	2.26e-13	Educational attainment (years of education);
LGG	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.77	-0.34	5.24e-14	Myopia (pathological);
LGG	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11890956	chr21:40555474	PSMG1	1.16	29.12	0.8	1.07e-106	Cognitive function;
LGG	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg08807101	chr21:30365312	RNF160	-0.61	-9.81	-0.41	9.27e-21	Cognitive test performance;
LGG	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.22	0.58	1.08e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.17	0.46	7.94e-26	Homoarginine levels;
LGG	cis	rs651907	0.535	rs13094911	chr3:101519021	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs55871839	0.684	rs4738729	chr8:59808617	T/C	cg07426533	chr8:59803705	TOX	-0.56	-12.61	-0.51	1.48e-31	Pneumonia;
LGG	cis	rs7586879	0.639	rs6713978	chr2:25120851	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.86	0.51	1.4e-32	Body mass index;
LGG	cis	rs10193935	0.901	rs10189710	chr2:42573102	C/G	cg27598129	chr2:42591480	NA	-0.65	-9.72	-0.41	1.95e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg18898632	chr2:242989856	NA	-0.8	-9.85	-0.42	6.51e-21	Obesity-related traits;
LGG	cis	rs4919044	0.866	rs11187247	chr10:94794319	G/T	cg05127821	chr10:94822908	CYP26C1	-0.48	-8.05	-0.35	7e-15	Coronary artery disease;
LGG	cis	rs7928758	0.887	rs79256507	chr11:134263728	C/A	cg22777979	chr11:134283252	B3GAT1	1.03	12.26	0.5	4.04e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25072359	chr17:41440525	NA	0.53	10.18	0.43	4.36e-22	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs9467773	0.583	rs2498380	chr6:26643996	C/G	cg09904177	chr6:26538194	HMGN4	-0.67	-14.06	-0.55	1.19e-37	Intelligence (multi-trait analysis);
LGG	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg11657817	chr20:23433608	CST11	0.37	6.68	0.3	6.7e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg21130718	chr4:1044621	NA	0.38	7.38	0.32	7.18e-13	Recombination rate (males);
LGG	trans	rs1997103	1.000	rs9642580	chr7:55400359	G/A	cg20935933	chr6:143382018	AIG1	0.59	9.19	0.39	1.38e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	8.15	0.35	3.37e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9308433	0.529	rs4655246	chr1:214502898	G/C	cg06198575	chr1:214491504	SMYD2	0.5	7.54	0.33	2.43e-13	IgG glycosylation;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.59	11.67	0.48	9.42e-28	Obesity-related traits;
LGG	cis	rs2276314	0.857	rs6507157	chr18:33631703	A/C	cg05985134	chr18:33552581	C18orf21	0.63	9.88	0.42	5.3e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.69	0.34	9.14e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg22398616	chr13:53314203	LECT1	-0.48	-9.89	-0.42	4.78e-21	Lewy body disease;
LGG	trans	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27022615	chr11:70049105	FADD	0.64	10.27	0.43	2.06e-22	Gut microbiome composition (summer);
LGG	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs6956675	0.915	rs4717497	chr7:62645096	A/G	cg08930214	chr7:62859557	LOC100287834	0.46	7.74	0.34	6.4e-14	Obesity-related traits;
LGG	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg22875332	chr1:76189707	ACADM	0.61	10.55	0.44	1.88e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg12046867	chr14:103022105	NA	0.74	11.91	0.48	1.01e-28	Platelet count;
LGG	cis	rs2153535	0.601	rs718504	chr6:8527512	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.01	0.42	1.68e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13102973	1.000	rs4569802	chr4:135905371	A/C	cg14419869	chr4:135874104	NA	0.55	10.15	0.43	5.66e-22	Subjective well-being;
LGG	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.27	-0.43	2.03e-22	Total body bone mineral density;
LGG	cis	rs7177699	0.534	rs7403708	chr15:79123885	T/C	cg00540400	chr15:79124168	NA	-0.54	-11.43	-0.47	7.77e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2797160	1.000	rs1739362	chr6:126020703	A/T	cg05901451	chr6:126070800	HEY2	0.46	7.75	0.34	5.68e-14	Endometrial cancer;
LGG	cis	rs2708240	0.666	rs2710121	chr7:147608448	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.86	-0.34	2.65e-14	QT interval (drug interaction);
LGG	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg17218041	chr13:113365319	ATP11A	-0.48	-7.93	-0.35	1.64e-14	Glycated hemoglobin levels;
LGG	cis	rs4788570	0.616	rs11075901	chr16:71790812	A/C	cg06353428	chr16:71660113	MARVELD3	1.25	19.53	0.67	2.14e-62	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs7192380	0.928	rs12933210	chr16:69742048	A/T	cg00738113	chr16:70207722	CLEC18C	0.28	8.02	0.35	8.65e-15	Sjögren's syndrome;
LGG	trans	rs9354308	0.764	rs12661106	chr6:66594110	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.85	-0.3	2.41e-11	Metabolite levels;
LGG	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.91e-11	Aortic root size;
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.24	0.46	4.45e-26	Bipolar disorder;
LGG	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg18171855	chr10:2543474	NA	0.4	7.98	0.35	1.16e-14	Age-related hearing impairment;
LGG	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg06219351	chr7:158114137	PTPRN2	-0.82	-14.18	-0.55	3.61e-38	Response to amphetamines;
LGG	cis	rs6988985	0.560	rs3753122	chr8:143926927	G/T	cg10324643	chr8:143916377	GML	0.43	9.02	0.39	5.12e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14106298	chr2:70475633	TIA1	-0.47	-6.88	-0.3	1.95e-11	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg20308403	chr7:2120281	MAD1L1	0.36	7.73	0.34	6.76e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg19455335	chr8:22457658	C8orf58	-0.45	-9.0	-0.39	5.7e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.42	0.44	5.53e-23	Ulcerative colitis;
LGG	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.04	0.35	7.44e-15	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg08888203	chr3:10149979	C3orf24	0.56	9.47	0.4	1.43e-19	Alzheimer's disease;
LGG	cis	rs11227306	0.934	rs2303384	chr11:65640204	C/T	cg26695010	chr11:65641043	EFEMP2	0.5	8.41	0.36	5.31e-16	DNA methylation (variation);
LGG	cis	rs939658	1.000	rs8027411	chr15:79461029	G/T	cg17916960	chr15:79447300	NA	0.64	12.39	0.5	1.17e-30	Refractive error;
LGG	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg03342759	chr3:160939853	NMD3	-0.45	-7.72	-0.34	7.09e-14	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.52	-0.44	2.4e-23	Prostate cancer;
LGG	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg04691961	chr3:161091175	C3orf57	-0.54	-12.43	-0.5	8.35e-31	Morning vs. evening chronotype;
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg17734273	chr15:78292508	TBC1D2B	-0.32	-7.34	-0.32	9.59e-13	Coronary artery disease or large artery stroke;
LGG	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg15664640	chr17:80829946	TBCD	-0.8	-15.85	-0.59	1.63e-45	Breast cancer;
LGG	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg02820901	chr13:113351484	ATP11A	0.62	7.35	0.32	9.1e-13	Glycated hemoglobin levels;
LGG	cis	rs433406	0.967	rs380593	chr11:131372548	A/G	cg27203895	chr11:131369037	NTM	0.58	12.44	0.5	7.3e-31	Male fertility;
LGG	trans	rs3812049	0.693	rs9327468	chr5:127441861	C/A	cg16011800	chr17:1958478	HIC1	-0.67	-10.03	-0.42	1.5e-21	Lymphocyte counts;Red cell distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27309920	chr12:6798957	ZNF384	0.51	8.32	0.36	9.96e-16	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14225546	chr19:8386349	NDUFA7;RPS28	0.48	7.32	0.32	1.1e-12	Gut microbiome composition (summer);
LGG	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg04989706	chr14:50066350	PPIL5	-0.6	-9.69	-0.41	2.48e-20	Carotid intima media thickness;
LGG	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg00376283	chr12:123451042	ABCB9	0.64	10.32	0.43	1.35e-22	Neutrophil percentage of white cells;
LGG	cis	rs12618769	0.597	rs17505326	chr2:99156807	T/A	cg18455616	chr2:99124870	INPP4A	0.27	7.66	0.34	1.06e-13	Bipolar disorder;
LGG	cis	rs6466055	0.720	rs1204056	chr7:104957761	G/A	cg04380332	chr7:105027541	SRPK2	0.39	7.25	0.32	1.75e-12	Schizophrenia;
LGG	cis	rs9314323	0.964	rs3808579	chr8:26250682	C/T	cg11498726	chr8:26250323	BNIP3L	-0.55	-11.58	-0.47	2.12e-27	Red cell distribution width;
LGG	trans	rs7746199	0.736	rs56405707	chr6:27640246	G/A	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9513627	0.915	rs9582298	chr13:100118707	T/C	cg15490075	chr13:100150979	NA	-0.68	-7.07	-0.31	5.58e-12	Obesity-related traits;
LGG	cis	rs3617	0.625	rs2336558	chr3:52886240	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-7.54	-0.33	2.48e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg02721184	chr3:9834899	ARPC4;TADA3	-0.4	-6.79	-0.3	3.51e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.35	-0.43	1.03e-22	Lymphocyte counts;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg25703541	chr22:24373054	LOC391322	-0.86	-16.2	-0.6	4.33e-47	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8016982	0.962	rs8007841	chr14:81647878	C/T	cg01989461	chr14:81687754	GTF2A1	-0.6	-10.79	-0.45	2.23e-24	Schizophrenia;
LGG	cis	rs2247341	1.000	rs2247341	chr4:1701317	C/T	cg08446824	chr4:1720184	TMEM129	-0.65	-12.35	-0.5	1.73e-30	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4731207	0.596	rs1021080	chr7:124633805	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs9354308	0.764	rs9445606	chr6:66570361	A/C	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.92e-13	Restless legs syndrome;
LGG	cis	rs2734839	0.929	rs11608185	chr11:113294976	T/C	cg14159747	chr11:113255604	NA	0.27	7.06	0.31	6.24e-12	Information processing speed;
LGG	trans	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg21659725	chr3:3221576	CRBN	0.56	7.53	0.33	2.64e-13	Menarche (age at onset);
LGG	cis	rs9463078	0.804	rs9472418	chr6:44968072	C/G	cg25276700	chr6:44698697	NA	-0.37	-7.65	-0.33	1.19e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2797369	0.599	rs2813654	chr6:101585995	G/A	cg27451362	chr6:101846650	GRIK2	0.82	11.27	0.46	3.38e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs8078723	0.510	rs3859189	chr17:38137033	A/G	cg17467752	chr17:38218738	THRA	-0.54	-9.36	-0.4	3.51e-19	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg25019033	chr10:957182	NA	0.59	12.64	0.51	1.18e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs9906944	0.933	rs4794018	chr17:47093398	T/C	cg09029085	chr17:47094198	IGF2BP1	0.32	8.77	0.38	3.34e-17	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs4566357	0.576	rs3769644	chr2:227917240	C/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.06	-0.39	3.56e-18	Coronary artery disease;
LGG	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg21138405	chr5:131827807	IRF1	-0.29	-6.97	-0.31	1.1e-11	Breast cancer;Mosquito bite size;
LGG	trans	rs11098499	0.863	rs10018280	chr4:120478139	T/G	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.88e-27	Corneal astigmatism;
LGG	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-15.28	-0.58	5.85e-43	Colorectal cancer;
LGG	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.38	0.32	7.43e-13	Prudent dietary pattern;
LGG	cis	rs2455799	0.634	rs6771390	chr3:15906637	C/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.76	-0.34	5.49e-14	Mean platelet volume;
LGG	cis	rs17428076	0.673	rs6737876	chr2:172926676	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.65	0.41	3.4e-20	Myopia;
LGG	cis	rs1010254	0.510	rs10515658	chr5:151758452	C/T	cg12297329	chr5:152029980	NA	-0.51	-7.23	-0.32	1.99e-12	Optic nerve measurement (cup area);
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg00800038	chr16:89945340	TCF25	-0.71	-9.35	-0.4	3.72e-19	Skin colour saturation;
LGG	cis	rs9733	0.744	rs2089081	chr1:150800117	T/C	cg13175981	chr1:150552382	MCL1	0.54	8.81	0.38	2.55e-17	Tonsillectomy;
LGG	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-13.36	-0.53	1.13e-34	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3816183	0.597	rs4953569	chr2:42918300	T/C	cg14631114	chr2:43023945	NA	0.37	7.16	0.32	3.09e-12	Hypospadias;
LGG	cis	rs56404409	0.911	rs56328670	chr11:123330641	A/T	cg04681489	chr11:123325084	NA	-0.46	-8.05	-0.35	7.1e-15	Ulcerative colitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17255878	chr17:4699455	PSMB6	0.42	6.74	0.3	4.82e-11	Cognitive performance;
LGG	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.17	-0.43	4.5e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.69	0.34	8.87e-14	Retinal vascular caliber;
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg17734273	chr15:78292508	TBC1D2B	-0.39	-9.52	-0.4	9.41e-20	Coronary artery disease or large artery stroke;
LGG	cis	rs9486715	0.867	rs1855533	chr6:97050265	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.38	-0.61	7e-48	Headache;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg16316162	chr8:144660157	NAPRT1	-0.59	-7.72	-0.34	7.44e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7100689	0.577	rs9421464	chr10:82043426	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.35	0.55	7.03e-39	Post bronchodilator FEV1;
LGG	cis	rs4330281	0.669	rs8179983	chr3:17764309	C/T	cg20981856	chr3:17787350	NA	-0.39	-7.3	-0.32	1.3e-12	Schizophrenia;
LGG	cis	rs13177180	0.842	rs13356084	chr5:114879967	C/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.38	-8.36	-0.36	7.35e-16	Conotruncal heart defects (inherited effects);
LGG	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs10493773	0.775	rs12739713	chr1:86150378	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.62	-12.26	-0.5	4.02e-30	Urate levels in overweight individuals;
LGG	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg11987759	chr7:65425863	GUSB	0.4	7.79	0.34	4.49e-14	Calcium levels;
LGG	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg18252515	chr7:66147081	NA	-0.41	-7.03	-0.31	7.31e-12	Aortic root size;
LGG	cis	rs4851254	0.618	rs7596359	chr2:100665274	T/G	cg17356467	chr2:100759845	AFF3	0.43	7.1	0.31	4.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs981844	0.712	rs1037646	chr4:154738015	C/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	trans	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.71	0.64	5.77e-54	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg05313129	chr8:58192883	C8orf71	-0.63	-8.47	-0.37	3.37e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg26818010	chr10:134567672	INPP5A	0.41	6.9	0.31	1.7e-11	Migraine;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.15e-12	Lung cancer;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs504918	0.783	rs17289013	chr3:124120040	C/T	cg05766129	chr3:123988013	KALRN	-0.44	-7.97	-0.35	1.21e-14	Schizophrenia;
LGG	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg07636037	chr3:49044803	WDR6	0.61	10.57	0.44	1.51e-23	Resting heart rate;
LGG	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg00376283	chr12:123451042	ABCB9	-0.61	-9.31	-0.4	5.02e-19	Lymphocyte percentage of white cells;
LGG	cis	rs11885103	0.504	rs6736712	chr2:527882	C/G	cg21195176	chr2:593345	NA	0.37	6.75	0.3	4.49e-11	Heschl's gyrus morphology;
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14893161	chr1:205819251	PM20D1	-0.48	-7.74	-0.34	6.19e-14	Parkinson's disease;
LGG	cis	rs2274273	0.905	rs2075601	chr14:55609234	C/T	cg04306507	chr14:55594613	LGALS3	0.65	18.42	0.65	2.94e-57	Protein biomarker;
LGG	cis	rs2455799	0.573	rs2455831	chr3:15751583	T/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.66	-0.34	1.13e-13	Mean platelet volume;
LGG	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg21435375	chr2:172878103	MAP1D	-0.32	-7.08	-0.31	5.4e-12	Schizophrenia;
LGG	cis	rs9462027	0.527	rs6939600	chr6:34822176	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-10.98	-0.45	4.51e-25	Systemic lupus erythematosus;
LGG	trans	rs1459104	1.000	rs67831168	chr11:55235603	C/A	cg15704280	chr7:45808275	SEPT13	0.69	6.69	0.3	6.3e-11	Body mass index;
LGG	cis	rs2274273	0.713	rs56725788	chr14:55540101	A/G	cg04306507	chr14:55594613	LGALS3	0.44	10.93	0.45	6.95e-25	Protein biomarker;
LGG	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	12.67	0.51	8.23e-32	Mean corpuscular hemoglobin;
LGG	cis	rs2731664	0.792	rs335420	chr5:176898619	C/T	cg23176889	chr5:176863531	GRK6	0.62	12.31	0.5	2.65e-30	Intelligence (multi-trait analysis);
LGG	trans	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg19676328	chr12:49525230	TUBA1B	-0.6	-8.82	-0.38	2.38e-17	Total cholesterol levels;
LGG	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg00024416	chr22:24240387	NA	0.45	6.8	0.3	3.28e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs77633900	0.772	rs284905	chr15:76743345	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.94e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12016809	chr21:47604291	C21orf56	-0.49	-8.57	-0.37	1.52e-16	Testicular germ cell tumor;
LGG	cis	rs889312	0.500	rs185219	chr5:56136492	A/G	cg14703610	chr5:56206110	C5orf35	0.4	6.96	0.31	1.16e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs2033732	0.706	rs10102194	chr8:85075662	T/G	cg05716166	chr8:85095498	RALYL	0.46	7.32	0.32	1.1e-12	Body mass index;
LGG	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg15596359	chr8:11213517	TDH	-0.41	-8.31	-0.36	1.09e-15	Retinal vascular caliber;
LGG	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.16e-31	Motion sickness;
LGG	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10779751	1.000	rs7525957	chr1:11318236	C/T	cg08854313	chr1:11322531	MTOR	0.74	16.3	0.6	1.63e-47	Body mass index;
LGG	cis	rs4430311	0.723	rs2125233	chr1:243748629	C/T	cg25706552	chr1:244017396	NA	-0.64	-15.53	-0.59	4.44e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.29	0.4	6.12e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.33	-0.4	4.44e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs13190036	0.901	rs28684504	chr5:176727438	T/C	cg06733329	chr5:176740039	MXD3	-0.47	-6.71	-0.3	5.8e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg01448562	chr3:133502909	NA	-0.73	-13.65	-0.54	6.92e-36	Iron status biomarkers;
LGG	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg11887960	chr12:57824829	NA	0.59	6.96	0.31	1.18e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs6723226	0.521	rs1991626	chr2:32602450	G/A	cg02381751	chr2:32503542	YIPF4	-0.55	-8.98	-0.38	7.1e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9951602	0.573	rs8098953	chr18:76648734	A/G	cg24134504	chr18:76639479	NA	-0.47	-8.23	-0.36	1.94e-15	Obesity-related traits;
LGG	trans	rs10802346	0.545	rs10924545	chr1:246364592	C/T	cg22732515	chr19:44031385	ETHE1	-0.54	-9.53	-0.4	8.63e-20	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg05044414	chr3:183734942	ABCC5	0.81	17.34	0.63	2.9e-52	Anterior chamber depth;
LGG	cis	rs11583043	1.000	rs6675353	chr1:101459625	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.46	8.18	0.36	2.69e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs77372450	0.636	rs7718217	chr5:156998684	C/T	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	trans	rs7395662	0.927	rs2135690	chr11:48733601	A/G	cg00717180	chr2:96193071	NA	0.41	7.28	0.32	1.49e-12	HDL cholesterol;
LGG	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg05425664	chr17:57184151	TRIM37	0.74	11.35	0.47	1.71e-26	Intelligence (multi-trait analysis);
LGG	trans	rs73198271	0.603	rs546606	chr8:8595843	A/G	cg16141378	chr3:129829833	LOC729375	0.35	6.92	0.31	1.52e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1472147	0.503	rs62479604	chr7:128433964	T/C	cg00734629	chr7:128471146	FLNC	0.32	6.81	0.3	2.96e-11	Calcium levels;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.34	-0.4	4.01e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7216064	1.000	rs62084240	chr17:65859233	C/A	cg12091567	chr17:66097778	LOC651250	-0.64	-9.38	-0.4	2.9e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg21775007	chr8:11205619	TDH	-0.42	-6.75	-0.3	4.51e-11	Neuroticism;
LGG	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.29	0.58	5.25e-43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9467773	0.523	rs2498399	chr6:26706544	T/C	cg09904177	chr6:26538194	HMGN4	0.62	11.94	0.49	7.99e-29	Intelligence (multi-trait analysis);
LGG	trans	rs3206736	0.548	rs328895	chr7:35016387	G/C	cg14337134	chr7:102920323	DPY19L2P2	0.4	6.98	0.31	1.01e-11	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.55e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg18876405	chr7:65276391	NA	0.64	11.92	0.48	8.96e-29	Aortic root size;
LGG	cis	rs2862064	0.932	rs1809941	chr5:156482459	G/T	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.62	-0.44	9.7e-24	Platelet count;
LGG	cis	rs5769707	0.616	rs135869	chr22:50008366	T/C	cg06623630	chr22:50017776	C22orf34	-0.48	-9.75	-0.41	1.47e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs11071200	0.550	rs12438177	chr15:55951432	A/G	cg17396834	chr15:56014697	PRTG	-0.33	-6.95	-0.31	1.21e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	8.15	0.35	3.46e-15	Schizophrenia;
LGG	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg09596252	chr17:78655493	RPTOR	0.44	7.99	0.35	1.05e-14	Obesity;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.81	-12.78	-0.51	2.9e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs755249	0.529	rs4660732	chr1:39863215	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.5	0.33	3.32e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-15.95	-0.6	5.91e-46	Intelligence (multi-trait analysis);
LGG	cis	rs4888262	0.545	rs8050624	chr16:74686690	A/G	cg01733217	chr16:74700730	RFWD3	-0.93	-19.86	-0.68	5.87e-64	Testicular germ cell tumor;
LGG	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg08975724	chr8:8085496	FLJ10661	0.45	9.0	0.39	5.68e-18	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19015582	chr11:75946767	NA	-0.43	-7.1	-0.31	4.6e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg20026190	chr17:76395443	PGS1	0.57	10.06	0.42	1.2e-21	HDL cholesterol levels;
LGG	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06634786	chr22:41940651	POLR3H	0.67	11.21	0.46	5.65e-26	Vitiligo;
LGG	cis	rs8056893	0.543	rs1111573	chr16:68378669	G/T	cg07273125	chr16:68295692	NA	0.39	8.49	0.37	2.82e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs988958	0.675	rs12712816	chr2:42224048	G/C	cg27252766	chr2:42229092	NA	0.56	8.76	0.38	3.67e-17	Hypospadias;
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg08888203	chr3:10149979	C3orf24	0.55	7.91	0.35	1.89e-14	Alzheimer's disease;
LGG	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	trans	rs8073060	0.586	rs7221203	chr17:34015532	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7582720	1.000	rs6738618	chr2:203749439	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs12682352	0.535	rs12677550	chr8:8644322	A/G	cg02002194	chr4:3960332	NA	0.39	7.08	0.31	5.25e-12	Neuroticism;
LGG	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg15665833	chr6:26285013	NA	0.36	6.94	0.31	1.34e-11	Educational attainment;
LGG	cis	rs12367572	0.663	rs4561266	chr12:45415763	C/T	cg03114573	chr12:45410052	DBX2	-0.7	-12.97	-0.52	4.86e-33	Gut microbiome composition (summer);
LGG	cis	rs7646881	0.812	rs7635704	chr3:158459720	T/C	cg19483011	chr3:158453295	NA	-0.56	-7.68	-0.34	9.45e-14	Tetralogy of Fallot;
LGG	cis	rs774359	0.750	rs2453565	chr9:27551040	C/T	cg14173147	chr9:27528300	MOBKL2B	0.45	7.83	0.34	3.31e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs7208859	0.623	rs79607958	chr17:28934548	T/G	cg13385521	chr17:29058706	SUZ12P	0.9	10.18	0.43	4.36e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23092844	chr2:169103738	STK39	-0.43	-6.82	-0.3	2.93e-11	Pancreatic cancer;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.68	-0.34	9.41e-14	Longevity;
LGG	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.31	0.55	9.79e-39	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24334809	chr2:178483498	TTC30A	0.42	7.21	0.32	2.33e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg24829409	chr8:58192753	C8orf71	-0.89	-13.51	-0.53	2.58e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2732480	0.537	rs1061986	chr12:48736439	T/C	cg24011408	chr12:48396354	COL2A1	0.5	7.94	0.35	1.54e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg11644478	chr21:40555479	PSMG1	0.92	18.0	0.64	2.59e-55	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06819375	chr16:278788	LUC7L	0.45	6.67	0.3	7.38e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs4704846	1.000	rs1432872	chr5:156543396	C/A	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.37	0.67	1.24e-61	Personality dimensions;
LGG	cis	rs9457247	0.534	rs933243	chr6:167403873	A/C	cg18261144	chr6:167370276	RNASET2	0.38	7.67	0.34	1.05e-13	Crohn's disease;
LGG	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.27e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.6	-0.51	1.74e-31	Alzheimer's disease;
LGG	cis	rs9487094	0.601	rs4945831	chr6:109761437	A/G	cg16315928	chr6:109776240	MICAL1	0.39	6.69	0.3	6.57e-11	Height;
LGG	cis	rs926392	0.640	rs2867899	chr20:37694622	C/A	cg16355469	chr20:37678765	NA	0.55	8.76	0.38	3.83e-17	Dialysis-related mortality;
LGG	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.98	0.39	6.99e-18	Eosinophil percentage of white cells;
LGG	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg05484508	chr16:89589025	SPG7	0.41	6.8	0.3	3.24e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.84	-0.3	2.5e-11	Schizophrenia;
LGG	cis	rs7106204	0.748	rs6484024	chr11:24210079	T/C	ch.11.24196551F	chr11:24239977	NA	1.04	16.47	0.61	2.78e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg26378065	chr17:18585709	ZNF286B	0.51	9.6	0.41	4.92e-20	Educational attainment (years of education);
LGG	cis	rs6028335	0.867	rs73621987	chr20:37700816	C/T	cg16355469	chr20:37678765	NA	0.54	6.92	0.31	1.47e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs12681287	0.640	rs12550142	chr8:87471861	C/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg20290983	chr6:43655470	MRPS18A	0.85	12.5	0.5	4.35e-31	IgG glycosylation;
LGG	trans	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.99	-0.35	1.05e-14	Neuroticism;
LGG	cis	rs981844	0.712	rs1456397	chr4:154744554	C/G	cg14289246	chr4:154710475	SFRP2	0.58	10.06	0.42	1.13e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg06808227	chr14:105710500	BRF1	-0.63	-10.94	-0.45	6.06e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg23601095	chr6:26197514	HIST1H3D	0.72	9.25	0.39	8.42e-19	Gout;Renal underexcretion gout;
LGG	cis	rs8060686	0.565	rs75286242	chr16:68145798	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.7	-0.3	6.03e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.87	0.45	1.17e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg08989290	chr16:615782	NHLRC4	0.34	7.02	0.31	7.72e-12	Height;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg05091796	chr16:4465799	CORO7	-1.03	-18.95	-0.66	1.06e-59	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15853329	chr3:48481696	CCDC51;CCDC72	0.46	6.89	0.3	1.77e-11	Gut microbiome composition (summer);
LGG	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg26441486	chr22:50317300	CRELD2	0.43	7.79	0.34	4.46e-14	Schizophrenia;
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	cis	rs2562456	0.793	rs7259708	chr19:21750648	T/C	cg00806126	chr19:22604979	ZNF98	-0.64	-9.43	-0.4	1.96e-19	Pain;
LGG	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-7.15	-0.32	3.3e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs12924604	1	rs12924604	chr16:74601486	G/A	cg01733217	chr16:74700730	RFWD3	0.5	6.68	0.3	6.95e-11	Monocyte percentage of white cells;
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg05793240	chr7:2802953	GNA12	0.32	7.9	0.34	2.01e-14	Height;
LGG	cis	rs9472414	0.771	rs2139863	chr6:44796139	A/G	cg20913747	chr6:44695427	NA	0.45	6.7	0.3	5.89e-11	Height;
LGG	cis	rs1008375	0.902	rs7654332	chr4:17691778	A/T	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.26e-27	Corneal astigmatism;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.25	-6.94	-0.31	1.36e-11	IgG glycosylation;
LGG	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22857025	chr5:266934	NA	-1.28	-12.31	-0.5	2.43e-30	Asthma (childhood onset);
LGG	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg18876405	chr7:65276391	NA	0.54	9.67	0.41	2.94e-20	Aortic root size;
LGG	cis	rs12738007	0.870	rs1908088	chr1:29572966	G/C	cg11747820	chr1:29584023	PTPRU	-0.35	-8.04	-0.35	7.57e-15	Schizophrenia;
LGG	cis	rs12410462	0.579	rs116423559	chr1:227575014	A/G	cg23173402	chr1:227635558	NA	0.56	8.83	0.38	2.24e-17	Major depressive disorder;
LGG	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.37	-7.65	-0.34	1.16e-13	Neuroticism;
LGG	cis	rs11971779	0.680	rs1133067	chr7:139053069	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09223439	chr15:65282374	SPG21	0.43	7.23	0.32	2.01e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-9.88	-0.42	5.08e-21	Mean corpuscular volume;
LGG	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg03795903	chr2:30669940	LCLAT1	0.53	7.27	0.32	1.49e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg26554054	chr8:600488	NA	0.94	9.87	0.42	5.75e-21	IgG glycosylation;
LGG	cis	rs11229555	0.645	rs12283414	chr11:58176920	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2795502	0.938	rs3121281	chr10:43400753	A/G	cg20628663	chr10:43360327	NA	0.37	7.36	0.32	8.62e-13	Blood protein levels;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs9911578	0.839	rs1871751	chr17:57190368	A/G	cg05425664	chr17:57184151	TRIM37	-0.66	-10.86	-0.45	1.29e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs7666738	0.830	rs28818180	chr4:98953625	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs4268898	1.000	rs6707781	chr2:24441883	T/G	cg06627628	chr2:24431161	ITSN2	0.53	8.98	0.39	6.81e-18	Asthma;
LGG	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.91	-0.48	1.04e-28	Height;
LGG	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	13.03	0.52	2.84e-33	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg21926883	chr2:100939477	LONRF2	-0.68	-15.97	-0.6	4.56e-46	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.716	rs62134741	chr2:46782189	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.72	-12.22	-0.49	5.71e-30	Height;
LGG	cis	rs11838776	0.586	rs750598	chr13:111028978	C/T	cg06243866	chr13:111019493	COL4A2	-0.71	-13.79	-0.54	1.7e-36	Coronary artery disease;
LGG	cis	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg05084668	chr3:125655381	ALG1L	-1.17	-13.65	-0.54	6.86e-36	Blood pressure (smoking interaction);
LGG	cis	rs2635047	0.901	rs2684837	chr18:44749884	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.59	0.33	1.76e-13	Educational attainment;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg00294572	chr6:26285232	NA	0.42	7.55	0.33	2.41e-13	Educational attainment;
LGG	cis	rs6430585	0.583	rs11886852	chr2:136589379	G/A	cg07169764	chr2:136633963	MCM6	1.23	24.12	0.75	7.75e-84	Corneal structure;
LGG	cis	rs787274	1.000	rs7030795	chr9:115558962	G/A	cg13803584	chr9:115635662	SNX30	-0.59	-7.48	-0.33	3.75e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6541297	0.938	rs7551742	chr1:230290118	A/G	cg20703242	chr1:230279135	GALNT2	0.37	7.5	0.33	3.38e-13	Coronary artery disease;
LGG	cis	rs12643440	0.503	rs34795372	chr4:17142116	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs9611565	0.512	rs5751153	chr22:42156561	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	trans	rs6787172	0.651	rs6800887	chr3:158163628	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.45	-0.33	4.69e-13	Subjective well-being;
LGG	cis	rs7095944	0.585	rs11245357	chr10:126452042	A/G	cg08799069	chr10:126477246	METTL10	-0.49	-11.43	-0.47	8.38e-27	Asthma;
LGG	cis	rs17767392	0.958	rs61989373	chr14:71935156	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.12e-23	Intelligence (multi-trait analysis);
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg21775007	chr8:11205619	TDH	0.56	9.38	0.4	2.86e-19	Neuroticism;
LGG	cis	rs7267979	0.966	rs3827014	chr20:25371559	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.59	0.33	1.75e-13	Educational attainment;
LGG	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-10.06	-0.42	1.18e-21	IgG glycosylation;
LGG	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.01e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6138458	1.000	rs2387361	chr20:24899905	C/T	cg26195577	chr20:24973756	C20orf3	-1.22	-25.52	-0.76	2.39e-90	Blood protein levels;
LGG	cis	rs7129556	0.775	rs72945592	chr11:77360496	A/T	cg12586386	chr11:77299805	AQP11	0.45	7.4	0.33	6.61e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01437395	chr2:110962594	NPHP1	0.47	7.05	0.31	6.46e-12	Gut microbiome composition (summer);
LGG	cis	rs7267979	0.565	rs958075	chr20:25595123	C/T	cg06421707	chr20:25228305	PYGB	-0.36	-7.42	-0.33	5.63e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.3	-0.53	1.99e-34	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9914544	0.564	rs11868500	chr17:18770254	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.25e-13	Educational attainment (years of education);
LGG	trans	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg18187862	chr3:45730750	SACM1L	0.58	9.54	0.41	8.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg06271696	chr7:157225062	NA	-0.55	-11.73	-0.48	5.26e-28	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.9	0.34	2.02e-14	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03264133	chr6:25882463	NA	-0.51	-9.58	-0.41	5.91e-20	Height;
LGG	cis	rs6882046	0.513	rs34316	chr5:88015545	A/C	cg22951263	chr5:87985283	NA	-0.57	-10.34	-0.43	1.08e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7394190	0.748	rs2306327	chr10:75573778	A/T	cg07699608	chr10:75541558	CHCHD1	0.58	7.59	0.33	1.77e-13	Incident atrial fibrillation;
LGG	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg16070123	chr10:51489643	NA	0.41	7.48	0.33	3.64e-13	Prostate-specific antigen levels;
LGG	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.41	0.33	5.98e-13	Triglycerides;
LGG	cis	rs2013441	0.606	rs12942179	chr17:19999781	G/A	cg13482628	chr17:19912719	NA	0.52	9.79	0.41	1.05e-20	Obesity-related traits;
LGG	cis	rs4478858	0.684	rs11579845	chr1:31736248	A/G	cg19084893	chr1:31688959	NA	0.31	6.83	0.3	2.64e-11	Alcohol dependence;
LGG	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg12046867	chr14:103022105	NA	-0.8	-14.8	-0.57	7.62e-41	Platelet count;
LGG	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.49	-0.53	3.26e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs1806153	0.611	rs1806179	chr11:31841860	T/C	cg11990419	chr11:31841155	NA	0.33	7.67	0.34	1.05e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.7	-0.3	6.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9443645	0.836	rs9352676	chr6:79629999	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.64	-0.37	9.47e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.58	-0.41	5.83e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg02725872	chr8:58115012	NA	-0.86	-12.41	-0.5	9.62e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11627756	0.801	rs4906237	chr14:103077649	T/G	cg01864069	chr14:103024347	NA	-0.41	-6.72	-0.3	5.46e-11	Mean platelet volume;
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg23422044	chr7:1970798	MAD1L1	-0.66	-11.28	-0.46	3.06e-26	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs2404602	0.647	rs2404600	chr15:77173557	C/T	cg23625390	chr15:77176239	SCAPER	-0.74	-14.66	-0.56	3.01e-40	Blood metabolite levels;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.56	0.37	1.69e-16	Schizophrenia;
LGG	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs7572644	0.699	rs1458396	chr2:28136351	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.7	-0.3	6.1e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs1459104	1.000	rs12797013	chr11:55318288	T/G	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.82e-11	Body mass index;
LGG	trans	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg26043149	chr18:55253948	FECH	0.95	16.56	0.61	1.02e-48	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06143012	chr17:34258076	RDM1	-0.46	-7.29	-0.32	1.32e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg15704280	chr7:45808275	SEPT13	0.83	14.87	0.57	3.54e-41	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs8074047	chr17:20176703	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.33	-0.4	4.5e-19	Obesity-related traits;
LGG	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.41	-0.78	2.02e-94	Schizophrenia;
LGG	cis	rs701145	0.585	rs7612886	chr3:153821176	T/A	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.81	0.3	3.1e-11	Carotid intima media thickness;
LGG	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg17644776	chr2:200775616	C2orf69	-0.67	-8.47	-0.37	3.28e-16	Schizophrenia;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs3960554	0.808	rs79864016	chr7:75655838	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	12.26	0.5	4.05e-30	Eotaxin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06613840	chr3:49395574	GPX1	0.38	7.05	0.31	6.69e-12	Gut microbiome composition (summer);
LGG	cis	rs4838594	0.537	rs2377354	chr10:49696844	A/C	cg17291251	chr10:49678358	ARHGAP22	-0.4	-7.84	-0.34	3.11e-14	Daytime sleep phenotypes;
LGG	cis	rs4909189	1.000	rs62493649	chr7:158135556	C/G	cg06219351	chr7:158114137	PTPRN2	-0.82	-14.18	-0.55	3.61e-38	Response to amphetamines;
LGG	cis	rs1018836	0.700	rs12678527	chr8:91527411	T/C	cg16814680	chr8:91681699	NA	-0.75	-12.7	-0.51	6.2e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952809	0.532	rs6461361	chr7:2432167	A/G	cg23289794	chr7:2394357	EIF3B	-0.81	-10.27	-0.43	2.06e-22	Multiple sclerosis;
LGG	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg06636001	chr8:8085503	FLJ10661	0.6	11.76	0.48	4.01e-28	Retinal vascular caliber;
LGG	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.97	-0.52	4.72e-33	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs2820315	0.763	rs4950743	chr1:201887457	C/T	cg10061532	chr1:201886748	LMOD1	-0.35	-7.24	-0.32	1.86e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg15997130	chr1:24165203	NA	0.47	12.71	0.51	5.74e-32	Immature fraction of reticulocytes;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.53	0.37	2.11e-16	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11653107	chr12:6832969	COPS7A	0.45	6.82	0.3	2.81e-11	Gut microbiome composition (summer);
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg03647317	chr4:187891568	NA	0.36	7.36	0.32	8.7e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg26354017	chr1:205819088	PM20D1	0.87	20.81	0.7	2.23e-68	Menarche (age at onset);
LGG	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs4330281	0.605	rs6787756	chr3:17453223	T/C	cg20981856	chr3:17787350	NA	0.35	6.66	0.3	7.64e-11	Schizophrenia;
LGG	cis	rs9354308	0.738	rs1353876	chr6:66569534	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.4	-0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg03351412	chr1:154909251	PMVK	-0.65	-12.61	-0.51	1.54e-31	Prostate cancer;
LGG	cis	rs4764487	0.760	rs4764488	chr12:6332910	A/G	cg08284733	chr12:6341482	CD9	0.38	10.21	0.43	3.33e-22	Mean platelet volume;
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg18357526	chr6:26021779	HIST1H4A	0.58	9.87	0.42	5.75e-21	Height;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg07234876	chr8:600039	NA	1.17	11.6	0.47	1.78e-27	IgG glycosylation;
LGG	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-18.98	-0.66	7.81e-60	Monocyte count;
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.82	-0.38	2.42e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg00319359	chr11:70116639	PPFIA1	0.76	8.3	0.36	1.15e-15	Coronary artery disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg17751867	chr5:32173610	GOLPH3	-0.42	-6.93	-0.31	1.39e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg02975922	chr3:195473998	MUC4	-0.45	-7.31	-0.32	1.19e-12	Pancreatic cancer;
LGG	cis	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg06521331	chr12:34319734	NA	0.42	7.58	0.33	1.92e-13	Morning vs. evening chronotype;
LGG	cis	rs350251	0.934	rs350210	chr16:12212689	T/G	cg02910054	chr16:12241554	SNX29	0.44	8.13	0.35	4.1e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2404618	0.624	rs7012381	chr8:1475357	C/T	cg13402656	chr8:1511478	DLGAP2	-0.73	-13.5	-0.53	3.1e-35	Lung cancer;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg15971980	chr6:150254442	NA	0.44	8.18	0.36	2.85e-15	Lung cancer;
LGG	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg14092988	chr3:52407081	DNAH1	0.26	7.08	0.31	5.37e-12	Electroencephalogram traits;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.86	0.34	2.8e-14	Lung cancer;
LGG	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-8.47	-0.37	3.22e-16	Ulcerative colitis;
LGG	cis	rs1109114	0.833	rs6897262	chr5:148642706	T/C	cg06539116	chr5:148597365	ABLIM3	-0.47	-10.45	-0.44	4.49e-23	Body mass index;
LGG	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs12911832	1.000	rs4774310	chr15:58985164	T/G	cg05156742	chr15:59063176	FAM63B	0.57	9.09	0.39	2.81e-18	Schizophrenia;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg18099408	chr3:52552593	STAB1	-0.37	-7.18	-0.32	2.82e-12	Bipolar disorder;
LGG	cis	rs4684776	1.000	rs35578145	chr3:11440089	G/C	cg24705426	chr3:11550659	ATG7	-0.42	-7.52	-0.33	2.93e-13	Small vessel stroke;
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.67	-0.34	1.02e-13	Neuroticism;
LGG	cis	rs877282	0.891	rs11599917	chr10:762288	G/A	cg17470449	chr10:769945	NA	0.55	6.72	0.3	5.47e-11	Uric acid levels;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.9	0.31	1.67e-11	Schizophrenia;
LGG	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg00204512	chr16:28754710	NA	0.26	7.24	0.32	1.87e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16405210	chr4:1374714	KIAA1530	0.66	11.8	0.48	2.7e-28	Obesity-related traits;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.0500000000000001e-23	Lymphocyte counts;
LGG	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg13736514	chr6:26305472	NA	-0.48	-9.39	-0.4	2.67e-19	Educational attainment;
LGG	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Autism spectrum disorder or schizophrenia;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.99	-0.45	4.13e-25	Neuroticism;
LGG	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.41	0.4	2.28e-19	Bone mineral density;
LGG	cis	rs2494938	0.730	rs6915503	chr6:40523269	T/G	cg14084896	chr6:40530702	LRFN2	-0.3	-6.66	-0.3	7.56e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs13148324	chr4:98833616	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.72	0.34	7.28e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7580658	0.857	rs11890187	chr2:128083738	T/C	cg10021288	chr2:128175891	PROC	-0.62	-12.78	-0.51	3.09e-32	Protein C levels;
LGG	cis	rs4604732	0.631	rs10925043	chr1:247627001	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs3942852	0.774	rs10838813	chr11:48186969	C/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.18	-0.43	4.27e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg09998033	chr7:158218633	PTPRN2	-0.47	-8.25	-0.36	1.66e-15	Obesity-related traits;
LGG	cis	rs62025270	0.848	rs62025269	chr15:86300090	C/T	cg25843651	chr15:86329602	KLHL25	0.65	10.65	0.44	7.75e-24	Idiopathic pulmonary fibrosis;
LGG	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg03517284	chr6:25882590	NA	-0.67	-12.49	-0.5	4.82e-31	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.600	rs4628176	chr7:23142566	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.42	0.33	5.55e-13	Cerebrospinal fluid biomarker levels;
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.97	-0.42	2.5e-21	Neuroticism;
LGG	cis	rs10940138	0.501	rs6878860	chr5:67244515	A/G	ch.5.1281357F	chr5:67228439	NA	-0.44	-8.14	-0.35	3.64e-15	Menarche (age at onset);
LGG	cis	rs4460629	0.742	rs11264314	chr1:155078423	C/G	cg13808842	chr1:155066096	NA	-0.29	-7.06	-0.31	6.18e-12	Serum magnesium levels;
LGG	cis	rs778371	0.676	rs4973563	chr2:233716421	C/T	cg08000102	chr2:233561755	GIGYF2	-0.67	-10.76	-0.45	2.88e-24	Schizophrenia;
LGG	trans	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg18187862	chr3:45730750	SACM1L	-0.53	-8.32	-0.36	9.71e-16	Primary sclerosing cholangitis;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg13010199	chr12:38710504	ALG10B	0.76	16.27	0.6	2.16e-47	Heart rate;
LGG	cis	rs11676348	0.772	rs11676275	chr2:218944808	G/A	cg04731861	chr2:219085781	ARPC2	0.29	6.85	0.3	2.29e-11	Ulcerative colitis;
LGG	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg15556689	chr8:8085844	FLJ10661	0.54	10.34	0.43	1.11e-22	Neuroticism;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19524238	chr7:2802976	GNA12	0.33	8.27	0.36	1.47e-15	Height;
LGG	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-12.89	-0.51	1.07e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs9354308	0.764	rs9283823	chr6:66596378	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg08085267	chr17:45401833	C17orf57	-0.5	-9.2	-0.39	1.2e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg05368731	chr17:41323189	NBR1	0.94	18.44	0.65	2.45e-57	Menopause (age at onset);
LGG	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06470251	chr20:60548479	NA	0.43	7.7	0.34	8.33e-14	Body mass index;
LGG	cis	rs9303401	0.614	rs35308719	chr17:57163501	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.94	0.52	6.37e-33	Cognitive test performance;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.59	8.79	0.38	2.95e-17	Renal function-related traits (BUN);
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.74	-0.3	4.77e-11	Total body bone mineral density;
LGG	cis	rs7666738	0.753	rs1527520	chr4:98929164	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2731664	0.721	rs2450333	chr5:176899546	G/A	cg23176889	chr5:176863531	GRK6	-0.62	-12.2	-0.49	6.97e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.65	0.37	8.63e-17	Colorectal cancer;
LGG	cis	rs1816752	0.777	rs6490915	chr13:24987862	G/C	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12960782	chr5:59996455	DEPDC1B	-0.52	-7.82	-0.34	3.57e-14	Systemic lupus erythematosus;
LGG	cis	rs3213545	0.700	rs2260399	chr12:121469653	C/T	cg02403541	chr12:121454288	C12orf43	0.53	9.19	0.39	1.31e-18	Subjective well-being;Cardiovascular disease risk factors;
LGG	cis	rs11877825	0.865	rs8098008	chr18:10569443	C/T	cg07277756	chr18:10589357	NA	0.59	10.8	0.45	2.2e-24	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.47	-0.4	1.4e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.43	-6.78	-0.3	3.62e-11	Menarche (age at onset);
LGG	cis	rs11252926	0.770	rs2124585	chr10:680428	G/A	cg16386425	chr10:429943	DIP2C	-0.37	-7.23	-0.32	2.01e-12	Psychosis in Alzheimer's disease;
LGG	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg00717180	chr2:96193071	NA	-0.47	-8.59	-0.37	1.32e-16	HDL cholesterol;
LGG	cis	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg05623727	chr3:50126028	RBM5	0.39	8.51	0.37	2.35e-16	Body mass index;
LGG	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg21775007	chr8:11205619	TDH	-0.54	-9.12	-0.39	2.35e-18	Neuroticism;
LGG	cis	rs9815354	1.000	rs28733681	chr3:41863444	C/A	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg09264619	chr17:80180166	NA	0.37	7.36	0.32	8.42e-13	Life satisfaction;
LGG	cis	rs10791323	0.571	rs4937839	chr11:133734177	T/C	cg00579200	chr11:133705235	NA	-0.53	-10.05	-0.42	1.27e-21	Childhood ear infection;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg26384229	chr12:38710491	ALG10B	1.07	28.86	0.8	1.49e-105	Heart rate;
LGG	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.22	0.39	1.06e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg02574844	chr11:5959923	NA	-0.57	-9.46	-0.4	1.51e-19	DNA methylation (variation);
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.38	-7.7	-0.34	8.43e-14	Longevity;Endometriosis;
LGG	cis	rs2273669	0.667	rs12198182	chr6:109318704	T/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs7017914	0.967	rs34409123	chr8:71662116	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.51e-11	Bone mineral density;
LGG	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg23601095	chr6:26197514	HIST1H3D	-0.7	-8.55	-0.37	1.84e-16	Gout;Renal underexcretion gout;
LGG	cis	rs10743315	0.778	rs965861	chr12:19360719	A/G	cg02471346	chr12:19282374	PLEKHA5	-0.55	-7.83	-0.34	3.26e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg16339924	chr4:17578868	LAP3	0.66	11.28	0.46	3e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs240764	0.687	rs239209	chr6:101140977	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.81	0.34	3.89e-14	Neuroticism;
LGG	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg26248373	chr2:1572462	NA	-0.88	-15.18	-0.58	1.58e-42	IgG glycosylation;
LGG	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg13010199	chr12:38710504	ALG10B	0.59	11.68	0.48	8.66e-28	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg14926445	chr8:58193284	C8orf71	-0.79	-9.67	-0.41	2.87e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-7.38	-0.32	7.37e-13	Schizophrenia;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16405210	chr4:1374714	KIAA1530	0.52	8.62	0.37	1.05e-16	Obesity-related traits;
LGG	cis	rs1005224	0.889	rs2059382	chr14:76158916	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.7	-0.3	6e-11	Large artery stroke;
LGG	cis	rs12928939	0.815	rs12446005	chr16:71655035	G/A	cg08717414	chr16:71523259	ZNF19	-0.49	-7.37	-0.32	7.95e-13	Post bronchodilator FEV1;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.45e-22	Menopause (age at onset);
LGG	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs4604732	0.631	rs12039596	chr1:247624766	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs13421350	0.579	rs116532339	chr2:173321791	T/G	cg15021238	chr2:173305865	ITGA6	-0.81	-9.27	-0.4	7.19e-19	Diabetic kidney disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06719391	chr11:2554330	KCNQ1	0.45	7.26	0.32	1.61e-12	Cognitive performance;
LGG	trans	rs7939886	0.623	rs77065109	chr11:55906843	G/A	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg15733309	chr7:157513707	PTPRN2	0.62	14.7	0.56	1.94e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs7166081	0.950	rs12917612	chr15:67491274	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.95	-0.31	1.23e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2712184	0.868	rs1548946	chr2:217665368	C/T	cg05032264	chr2:217675019	NA	-0.54	-12.64	-0.51	1.14e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs7914558	1.000	rs7911789	chr10:104756374	T/C	cg04362960	chr10:104952993	NT5C2	0.53	10.2	0.43	3.6e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2408955	0.522	rs11168408	chr12:48498327	G/A	cg24011408	chr12:48396354	COL2A1	-0.59	-9.84	-0.42	7.13e-21	Glycated hemoglobin levels;
LGG	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg17971929	chr21:40555470	PSMG1	0.86	17.03	0.62	7.9e-51	Cognitive function;
LGG	cis	rs1045714	0.779	rs3735113	chr7:2651563	G/A	cg20813462	chr7:2646259	IQCE	0.52	6.68	0.3	6.78e-11	Urate levels in lean individuals;
LGG	cis	rs1408799	0.704	rs1326788	chr9:12759781	C/T	cg05274944	chr9:12693694	TYRP1	0.36	8.36	0.36	7.39e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	11.31	0.47	2.43e-26	Lung cancer in ever smokers;
LGG	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg05535760	chr7:792225	HEATR2	0.79	12.8	0.51	2.39e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs459193	1.000	rs464605	chr5:55807370	C/T	cg26646659	chr5:55776364	NA	0.3	6.78	0.3	3.65e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg02574844	chr11:5959923	NA	-0.55	-8.57	-0.37	1.51e-16	DNA methylation (variation);
LGG	cis	rs11690935	0.851	rs10930502	chr2:172890588	A/G	cg21435375	chr2:172878103	MAP1D	-0.33	-7.72	-0.34	7.38e-14	Schizophrenia;
LGG	cis	rs3126085	0.935	rs72696997	chr1:152257099	A/C	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.83	-0.3	2.65e-11	Bipolar disorder;
LGG	cis	rs4262150	0.883	rs72804758	chr5:152259430	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16611736	chr16:25123254	LCMT1	0.43	7.3	0.32	1.22e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg09858108	chr8:58055024	NA	0.49	7.73	0.34	6.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.76	14.8	0.57	7.37e-41	Personality dimensions;
LGG	cis	rs138665726	1	rs138665726	chr22:21917859	A/C	cg22858872	chr22:21984481	YDJC	-0.37	-6.72	-0.3	5.38e-11	Mean corpuscular volume;Red cell distribution width;
LGG	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg24846343	chr22:24311635	DDTL	-0.46	-6.96	-0.31	1.14e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.64	-0.48	1.18e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs34929064	0.718	rs35345753	chr7:22740513	C/G	cg18045685	chr7:22629474	NA	0.55	7.46	0.33	4.39e-13	Major depression and alcohol dependence;
LGG	cis	rs56146971	0.763	rs11160005	chr14:91872587	G/C	cg14409461	chr14:91925021	SMEK1	-0.43	-7.14	-0.31	3.72e-12	Alzheimer disease and age of onset;
LGG	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.93	-0.31	1.4e-11	Sudden cardiac arrest;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.46	-0.4	1.54e-19	Personality dimensions;
LGG	cis	rs11252926	0.674	rs11598550	chr10:504778	A/C	cg18196295	chr10:418757	DIP2C	-0.58	-11.32	-0.47	2.2e-26	Psychosis in Alzheimer's disease;
LGG	cis	rs10850519	0.751	rs11067631	chr12:115945021	T/C	cg18639984	chr12:115943877	NA	-0.41	-8.94	-0.38	9.05e-18	Diastolic blood pressure;
LGG	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg20821713	chr7:1055600	C7orf50	-0.46	-6.66	-0.3	7.64e-11	Bronchopulmonary dysplasia;
LGG	cis	rs6456156	0.742	rs6456157	chr6:167527818	C/A	cg07741184	chr6:167504864	NA	-0.31	-7.05	-0.31	6.35e-12	Primary biliary cholangitis;
LGG	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg12661370	chr5:149340060	SLC26A2	-0.51	-6.76	-0.3	4.2e-11	HIV-1 control;
LGG	cis	rs9633740	1.000	rs7896832	chr10:82257570	T/C	cg01528321	chr10:82214614	TSPAN14	1.05	16.49	0.61	2.2e-48	Post bronchodilator FEV1;
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26076054	chr5:421317	AHRR	-0.53	-8.7	-0.37	5.67e-17	Cystic fibrosis severity;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs12643440	0.538	rs2041444	chr4:17138005	A/C	cg22650099	chr4:17144496	NA	-0.51	-8.68	-0.37	6.69e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	cis	rs7928758	0.562	rs1561613	chr11:134294571	A/T	cg25213107	chr11:134282864	B3GAT1	-0.89	-10.04	-0.42	1.36e-21	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.06	-0.52	2.09e-33	Schizophrenia;
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs10186029	0.539	rs4672676	chr2:214001948	C/T	cg08319019	chr2:214017104	IKZF2	0.4	7.12	0.31	4.12e-12	Systemic sclerosis;
LGG	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.39	-6.94	-0.31	1.32e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg25517755	chr10:38738941	LOC399744	-0.35	-6.69	-0.3	6.39e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg17971929	chr21:40555470	PSMG1	0.86	16.61	0.61	5.91e-49	Cognitive function;
LGG	cis	rs9486719	1.000	rs2971608	chr6:97039757	T/C	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.78	-0.34	4.68e-14	Migraine;Coronary artery disease;
LGG	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.3	0.75	1.09e-84	Chronic sinus infection;
LGG	trans	rs11250098	0.583	rs36030755	chr8:10816771	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.85	-0.3	2.35e-11	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg00071950	chr4:10020882	SLC2A9	0.4	8.47	0.37	3.29e-16	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14599714	chr12:31226825	DDX11	0.46	6.77	0.3	3.91e-11	Gut microbiome composition (summer);
LGG	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	7.18	0.32	2.8e-12	Platelet count;
LGG	cis	rs7394190	0.748	rs60212594	chr10:75414344	G/C	cg07699608	chr10:75541558	CHCHD1	0.58	7.94	0.35	1.56e-14	Incident atrial fibrillation;
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg18681998	chr4:17616180	MED28	0.86	18.7	0.66	1.47e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg08085267	chr17:45401833	C17orf57	-0.63	-13.05	-0.52	2.23e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7143963	0.666	rs57613851	chr14:103319835	C/T	cg23020514	chr14:103360112	TRAF3	0.4	8.59	0.37	1.29e-16	Body mass index;
LGG	cis	rs35160687	0.623	rs1863060	chr2:86511456	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.76	0.3	4.18e-11	Night sleep phenotypes;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.12	0.35	4.22e-15	Longevity;
LGG	cis	rs7765175	0.598	rs2130850	chr6:113649375	C/T	cg26552650	chr6:113682475	NA	0.33	7.47	0.33	4.16e-13	Coronary artery calcification;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10104683	chr2:20424989	SDC1	0.46	6.89	0.3	1.86e-11	Gut microbiome composition (summer);
LGG	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.86	0.34	2.78e-14	Cannabis dependence symptom count;
LGG	cis	rs1577917	1.000	rs12200330	chr6:86656653	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.94	-0.42	3.03e-21	Response to antipsychotic treatment;
LGG	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.19	0.32	2.57e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.87	-0.42	5.45e-21	Morning vs. evening chronotype;
LGG	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg05887092	chr17:76393375	PGS1	0.8	18.81	0.66	4.81e-59	HDL cholesterol levels;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.99	-0.42	2.12e-21	Tonsillectomy;
LGG	cis	rs8062405	1.000	rs4788095	chr16:28831359	T/C	cg00198680	chr16:28758506	NA	0.29	7.14	0.31	3.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg18335740	chr13:41363409	SLC25A15	0.55	10.11	0.43	7.85e-22	Lewy body disease;
LGG	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs7737355	0.947	rs7720339	chr5:130837134	T/C	cg06307176	chr5:131281290	NA	0.55	9.26	0.4	7.9e-19	Life satisfaction;
LGG	cis	rs9674544	0.792	rs8076012	chr17:47101989	G/A	cg22947322	chr17:47091978	IGF2BP1	-0.42	-7.3	-0.32	1.26e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs1941687	0.563	rs1565784	chr18:31358491	G/T	cg04226714	chr8:49833948	SNAI2	0.48	8.56	0.37	1.68e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18952654	chr15:41408642	INO80	0.51	7.51	0.33	3.15e-13	Gut microbiome composition (summer);
LGG	cis	rs2011503	1.000	rs77616520	chr19:19652776	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg05153347	chr5:171434267	FBXW11	0.4	6.74	0.3	4.65e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs4731207	0.596	rs6466965	chr7:124579726	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs17401966	0.800	rs2039778	chr1:10354601	A/G	cg19773385	chr1:10388646	KIF1B	-0.46	-9.94	-0.42	3.05e-21	Hepatocellular carcinoma;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13126279	chr21:47581558	C21orf56	-0.49	-8.74	-0.38	4.34e-17	Testicular germ cell tumor;
LGG	cis	rs9296092	0.500	rs9469504	chr6:33527243	G/A	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg00713939	chr8:144660590	NAPRT1	0.9	7.09	0.31	5.19e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs2730245	0.527	rs842702	chr7:158696814	C/T	cg18245976	chr7:158708271	WDR60	-0.58	-7.64	-0.33	1.23e-13	Height;
LGG	cis	rs7134594	0.677	rs9668180	chr12:109860597	T/G	cg19025524	chr12:109796872	NA	-0.47	-9.59	-0.41	5.5e-20	HDL cholesterol;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg07308232	chr7:1071921	C7orf50	-0.67	-13.42	-0.53	6.59e-35	Longevity;Endometriosis;
LGG	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.88	-0.54	7.31e-37	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	8.42	0.36	4.84e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9324022	0.929	rs12888043	chr14:101170436	A/G	cg18089426	chr14:101175970	NA	-0.71	-11.52	-0.47	3.72e-27	Plateletcrit;
LGG	cis	rs139371	0.516	rs139284	chr22:39495670	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.28	-7.09	-0.31	5.19e-12	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg26597838	chr10:835615	NA	0.95	12.7	0.51	6.55e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06634786	chr22:41940651	POLR3H	0.78	12.86	0.51	1.41e-32	Vitiligo;
LGG	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg16096631	chr1:42092165	HIVEP3	-0.74	-20.5	-0.69	6.41e-67	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1957429	0.901	rs8008745	chr14:65351593	C/G	cg23373153	chr14:65346875	NA	1.15	16.05	0.6	2.03e-46	Pediatric areal bone mineral density (radius);
LGG	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg09307838	chr4:120376055	NA	0.67	11.74	0.48	4.67e-28	Corneal astigmatism;
LGG	cis	rs7463659	0.904	rs7826572	chr8:135433805	G/T	cg17885191	chr8:135476712	NA	-0.42	-7.29	-0.32	1.34e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs926938	0.527	rs360670	chr1:115482386	G/A	cg12756093	chr1:115239321	AMPD1	0.43	8.02	0.35	8.63e-15	Autism;
LGG	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg01620082	chr3:125678407	NA	-1.03	-10.04	-0.42	1.37e-21	Depression;
LGG	trans	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.12	0.49	1.46e-29	Corneal astigmatism;
LGG	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22857025	chr5:266934	NA	-1.44	-25.53	-0.76	2.16e-90	Breast cancer;
LGG	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg09085632	chr11:111637200	PPP2R1B	0.88	16.83	0.62	6.15e-50	Primary sclerosing cholangitis;
LGG	cis	rs3816183	1.000	rs893729	chr2:43015224	A/G	cg27299406	chr2:43020013	HAAO	-0.27	-6.79	-0.3	3.44e-11	Hypospadias;
LGG	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg20608306	chr11:116969690	SIK3	0.42	13.29	0.53	2.2e-34	Blood protein levels;
LGG	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	13.68	0.54	5.06e-36	Type 2 diabetes;
LGG	cis	rs9487094	0.961	rs3757234	chr6:109706290	A/G	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.15e-18	Height;
LGG	trans	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.43	0.65	2.76e-57	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22857025	chr5:266934	NA	-1.52	-26.77	-0.78	4.31e-96	Breast cancer;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg05091796	chr16:4465799	CORO7	-0.77	-13.05	-0.52	2.28e-33	Schizophrenia;
LGG	cis	rs944722	0.651	rs4293436	chr17:26064942	G/A	cg07704981	chr17:26127537	NOS2	-0.41	-7.16	-0.32	3.14e-12	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs7766436	0.648	rs7757111	chr6:22591154	C/A	cg13666174	chr6:22585274	NA	-0.4	-9.85	-0.42	6.52e-21	Coronary artery disease;
LGG	cis	rs4776059	1.000	rs11070909	chr15:52931601	A/G	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.74	-0.34	6.14e-14	Schizophrenia;
LGG	cis	rs9399135	0.773	rs949895	chr6:135405359	C/T	cg24558204	chr6:135376177	HBS1L	0.39	6.67	0.3	7.44e-11	Red blood cell count;
LGG	cis	rs1018836	0.923	rs6986001	chr8:91650205	T/C	cg16814680	chr8:91681699	NA	-0.85	-16.42	-0.61	4.53e-48	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.11	-0.31	4.46e-12	Height;
LGG	cis	rs367943	0.712	rs6594709	chr5:112700714	T/C	cg12552261	chr5:112820674	MCC	0.57	10.5	0.44	2.74e-23	Type 2 diabetes;
LGG	cis	rs7241530	0.610	rs7226819	chr18:75892508	C/T	cg14642773	chr18:75888474	NA	0.46	8.92	0.38	1.12e-17	Educational attainment (years of education);
LGG	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-16.19	-0.6	4.94e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9911578	1.000	rs2611782	chr17:56717956	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19617932	chr12:1703704	FBXL14	0.62	6.88	0.3	1.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg27411982	chr8:10470053	RP1L1	0.42	7.0	0.31	9.21e-12	Morning vs. evening chronotype;
LGG	cis	rs7619833	0.685	rs1899998	chr3:27307155	C/T	cg02860705	chr3:27208620	NA	0.4	7.58	0.33	1.85e-13	Breast cancer;
LGG	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg00666640	chr1:248458726	OR2T12	0.54	8.83	0.38	2.18e-17	Common traits (Other);
LGG	cis	rs9547692	1.000	rs604279	chr13:37471254	G/C	cg02985381	chr13:37494744	SMAD9	0.67	11.95	0.49	7.06e-29	Coronary artery disease;
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg27400746	chr16:89904261	SPIRE2	-0.87	-14.57	-0.56	7.69e-40	Skin colour saturation;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg22535103	chr8:58192502	C8orf71	-0.7	-9.16	-0.39	1.74e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6430585	1.000	rs73958618	chr2:136500475	A/G	cg07169764	chr2:136633963	MCM6	0.99	18.7	0.66	1.47e-58	Corneal structure;
LGG	trans	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg13565492	chr6:43139072	SRF	-0.87	-14.12	-0.55	6.83e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg06970220	chr1:156163860	SLC25A44	0.44	6.64	0.3	8.61e-11	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.4e-31	Motion sickness;
LGG	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg13256891	chr4:100009986	ADH5	-0.64	-12.41	-0.5	1.04e-30	Alcohol dependence;
LGG	cis	rs8016982	0.674	rs28890880	chr14:81708031	A/G	cg01989461	chr14:81687754	GTF2A1	0.77	17.68	0.63	7.64e-54	Schizophrenia;
LGG	cis	rs4917300	0.606	rs2029621	chr8:143111165	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.77	-0.3	3.84e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10227331	0.617	rs55977076	chr7:157301739	A/G	cg04156418	chr7:157293606	NA	0.54	11.14	0.46	1.08e-25	Inattentive symptoms;
LGG	cis	rs4849845	0.653	rs34874174	chr2:121011980	A/C	cg15425061	chr2:121036351	RALB	0.38	7.0	0.31	8.94e-12	Mean platelet volume;
LGG	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.8	-0.34	4.1e-14	Blood metabolite levels;
LGG	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.19e-16	Aortic root size;
LGG	trans	rs9329221	0.576	rs1986972	chr8:10268805	C/T	cg02002194	chr4:3960332	NA	-0.39	-7.0	-0.31	9.27e-12	Neuroticism;
LGG	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg08847335	chr10:891726	LARP4B	-0.37	-7.0	-0.31	9.18e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg19628046	chr18:33552617	C18orf21	0.55	7.92	0.35	1.84e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs714515	0.868	rs2001128	chr1:172361179	G/C	cg01573306	chr1:172330400	DNM3	0.34	7.34	0.32	9.5e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg14092988	chr3:52407081	DNAH1	0.29	7.86	0.34	2.69e-14	Bipolar disorder;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13012494	chr21:47604986	C21orf56	0.5	8.37	0.36	6.85e-16	Testicular germ cell tumor;
LGG	cis	rs17739794	0.517	rs10106028	chr8:783286	C/A	cg01971667	chr8:817044	NA	-0.35	-6.91	-0.31	1.56e-11	Clozapine-induced cytotoxicity;
LGG	cis	rs4713118	0.621	rs9295755	chr6:28033174	C/T	cg18032046	chr6:28092343	ZSCAN16	0.52	6.79	0.3	3.37e-11	Parkinson's disease;
LGG	cis	rs9880211	1.000	rs9809988	chr3:136522221	C/G	cg21827317	chr3:136751795	NA	-0.5	-7.35	-0.32	8.78e-13	Body mass index;Height;
LGG	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4077515	0.806	rs3812564	chr9:139271190	A/G	cg21253087	chr9:139290292	SNAPC4	0.36	7.47	0.33	4.13e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.42e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.8	-0.45	2.19e-24	Total body bone mineral density;
LGG	cis	rs4849845	0.637	rs62168279	chr2:121026771	T/C	cg15425061	chr2:121036351	RALB	0.37	6.81	0.3	3.07e-11	Mean platelet volume;
LGG	trans	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg06521331	chr12:34319734	NA	0.45	8.04	0.35	7.38e-15	Bladder cancer;
LGG	cis	rs2455601	0.744	rs7938995	chr11:8975675	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.57	-9.9	-0.42	4.31e-21	Schizophrenia;
LGG	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.3e-11	Aortic root size;
LGG	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg08975724	chr8:8085496	FLJ10661	0.53	10.49	0.44	3.05e-23	Mood instability;
LGG	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg08807101	chr21:30365312	RNF160	-0.68	-11.67	-0.48	8.89e-28	Cognitive test performance;
LGG	cis	rs10464366	0.544	rs4355688	chr7:39158402	C/T	cg20302533	chr7:39170763	POU6F2	0.58	15.02	0.57	7.67e-42	IgG glycosylation;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs919433	0.617	rs4850436	chr2:198541398	C/T	cg00792783	chr2:198669748	PLCL1	-0.62	-9.96	-0.42	2.72e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg08302650	chr8:145750040	LRRC24;LRRC14	0.35	7.46	0.33	4.33e-13	Age at first birth;
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg06558623	chr16:89946397	TCF25	1.24	13.52	0.53	2.52e-35	Skin colour saturation;
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13126279	chr21:47581558	C21orf56	0.45	7.41	0.33	6.18e-13	Testicular germ cell tumor;
LGG	cis	rs6815814	0.731	rs66735315	chr4:38774180	G/T	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs10465746	0.935	rs4907189	chr1:84374982	G/T	cg10977910	chr1:84465055	TTLL7	0.51	9.45	0.4	1.72e-19	Obesity-related traits;
LGG	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06470251	chr20:60548479	NA	0.49	8.25	0.36	1.66e-15	Body mass index;
LGG	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg02153584	chr22:29168773	CCDC117	0.69	11.77	0.48	3.86e-28	Lymphocyte counts;
LGG	cis	rs6894268	0.793	rs7379689	chr5:178992378	A/C	cg22014891	chr5:179071901	C5orf60	-0.37	-7.17	-0.32	2.93e-12	Eating disorders;
LGG	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg15485101	chr11:133734466	NA	0.57	10.18	0.43	4.35e-22	Childhood ear infection;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.51	0.33	3.12e-13	Renal function-related traits (BUN);
LGG	cis	rs6121246	0.520	rs6060425	chr20:30224355	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	10.2	0.43	3.71e-22	Mean corpuscular hemoglobin;
LGG	cis	rs9815354	0.556	rs55953604	chr3:42004428	A/G	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.35	0.53	1.33e-34	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.64	-12.66	-0.51	9.23e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4253772	0.530	rs9615955	chr22:46743931	A/G	cg00784671	chr22:46762841	CELSR1	-0.63	-6.95	-0.31	1.22e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg02297831	chr4:17616191	MED28	-0.45	-8.19	-0.36	2.51e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.13	-0.46	1.19e-25	Hemoglobin concentration;
LGG	cis	rs61884328	0.733	rs79044335	chr11:47200402	G/C	cg03339077	chr11:47165057	C11orf49	0.62	6.72	0.3	5.37e-11	Total body bone mineral density (age over 60);
LGG	cis	rs9815354	1.000	rs9842261	chr3:41822708	A/G	cg03022575	chr3:42003672	ULK4	-0.55	-7.14	-0.32	3.55e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg24112000	chr20:60950667	NA	-0.39	-7.84	-0.34	3.11e-14	Colorectal cancer;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg13206674	chr6:150067644	NUP43	0.65	14.53	0.56	1.15e-39	Lung cancer;
LGG	cis	rs300703	0.515	rs300693	chr2:181748	C/A	cg21211680	chr2:198530	NA	-1.17	-19.83	-0.68	8.28e-64	Blood protein levels;
LGG	cis	rs981844	0.712	rs4525952	chr4:154746606	G/T	cg14289246	chr4:154710475	SFRP2	0.57	9.44	0.4	1.84e-19	Response to statins (LDL cholesterol change);
LGG	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.42	-0.4	2.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.22	0.43	3.08e-22	Schizophrenia;
LGG	cis	rs7412746	0.658	rs11204723	chr1:150731618	T/C	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.31e-11	Melanoma;
LGG	cis	rs7617773	0.817	rs11720622	chr3:48246679	G/A	cg11946769	chr3:48343235	NME6	0.57	9.51	0.4	1e-19	Coronary artery disease;
LGG	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.2	-0.46	6.37e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg13206674	chr6:150067644	NUP43	0.59	12.65	0.51	1.02e-31	Lung cancer;
LGG	cis	rs6684428	1.000	rs12070494	chr1:56348904	C/T	cg11651538	chr1:56320950	NA	-0.66	-11.66	-0.48	9.89e-28	Airflow obstruction;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg19524238	chr7:2802976	GNA12	0.37	8.38	0.36	6.26e-16	Height;
LGG	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg15103426	chr22:29168792	CCDC117	0.62	8.64	0.37	8.93e-17	Lymphocyte counts;
LGG	cis	rs3784262	0.565	rs4646606	chr15:58287526	A/G	cg12031962	chr15:58353849	ALDH1A2	0.32	6.76	0.3	4.04e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9886651	0.935	rs28660151	chr8:128803578	A/T	cg24514600	chr8:128805414	PVT1	-0.55	-12.59	-0.51	1.74e-31	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg00579200	chr11:133705235	NA	-0.58	-11.17	-0.46	8.31e-26	Childhood ear infection;
LGG	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg13009111	chr11:71350975	NA	0.36	7.78	0.34	4.67e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.32	0.32	1.09e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs367615	0.552	rs3828603	chr5:108712068	G/C	cg17395555	chr5:108820864	NA	-0.71	-11.56	-0.47	2.54e-27	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg03314080	chr2:178129903	NFE2L2	0.48	6.97	0.31	1.11e-11	Breast cancer;
LGG	cis	rs12049351	0.774	rs767301	chr1:229699015	T/C	cg13547644	chr1:229569608	ACTA1	0.29	6.74	0.3	4.6e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	10.98	0.45	4.46e-25	Height;
LGG	trans	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg07211511	chr3:129823064	LOC729375	-1.29	-15.88	-0.59	1.23e-45	Blood pressure (smoking interaction);
LGG	cis	rs7577696	0.626	rs3769603	chr2:32360887	G/T	cg02381751	chr2:32503542	YIPF4	-0.41	-6.67	-0.3	7.31e-11	Inflammatory biomarkers;
LGG	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg27366882	chr3:133540807	NA	-0.48	-10.12	-0.43	6.95e-22	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs7444	0.882	rs5754217	chr22:21939675	G/T	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg10503236	chr1:231470652	EXOC8	0.38	7.33	0.32	1.05e-12	Hemoglobin concentration;
LGG	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.03	-21.33	-0.7	8.13e-71	Homoarginine levels;
LGG	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg19680485	chr15:31195859	MTMR15	0.54	9.38	0.4	2.89e-19	Huntington's disease progression;
LGG	cis	rs6598955	0.585	rs12138111	chr1:26590432	G/A	cg04990556	chr1:26633338	UBXN11	0.6	8.01	0.35	9.53e-15	Obesity-related traits;
LGG	cis	rs17767392	0.958	rs1981588	chr14:72039689	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.81	-0.41	9.44e-21	Mitral valve prolapse;
LGG	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg03060546	chr3:49711283	APEH	0.56	8.64	0.37	9.26e-17	Resting heart rate;
LGG	cis	rs16937	0.711	rs11240385	chr1:205173101	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs3931020	0.688	rs405445	chr1:75221150	C/T	cg00121533	chr1:75199117	CRYZ;TYW3	-0.43	-6.93	-0.31	1.44e-11	Resistin levels;
LGG	cis	rs7246865	0.813	rs13346655	chr19:17176757	C/G	cg19418318	chr19:17219073	MYO9B	0.29	7.63	0.33	1.37e-13	Reticulocyte fraction of red cells;
LGG	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.75	-0.3	4.57e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25161386	chr17:27621177	NUFIP2	0.48	8.07	0.35	6.03e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg27400746	chr16:89904261	SPIRE2	-1.14	-17.01	-0.62	9.12e-51	Skin colour saturation;
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	trans	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.35	0.53	1.25e-34	Breast cancer;
LGG	cis	rs17221829	0.673	rs4491227	chr11:89403759	G/A	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.63	-0.37	1.02e-16	Anxiety in major depressive disorder;
LGG	cis	rs9291683	0.704	rs11726271	chr4:10098192	G/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.07	-0.35	6.26e-15	Bone mineral density;
LGG	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg27532318	chr7:32358331	NA	0.65	6.87	0.3	2.11e-11	Body mass index;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.95	-16.05	-0.6	2.1e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs72634258	0.945	rs2050198	chr1:8111839	T/G	cg00042356	chr1:8021962	PARK7	0.84	10.96	0.45	5.41e-25	Inflammatory bowel disease;
LGG	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg20368463	chr18:77673604	PQLC1	-0.49	-8.99	-0.39	6.45e-18	Schizophrenia;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1003719	0.788	rs4816560	chr21:38487561	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.35	0.63	2.63e-52	Eye color traits;
LGG	cis	rs1497828	0.956	rs2646861	chr1:217521978	G/A	cg04411442	chr1:217543379	NA	-0.5	-8.37	-0.36	6.72e-16	Dialysis-related mortality;
LGG	cis	rs7649275	1.000	rs1020821	chr3:53749880	A/G	cg21503701	chr3:53781065	CACNA1D	-0.49	-7.2	-0.32	2.41e-12	Trans fatty acid levels;
LGG	cis	rs9595066	1.000	rs7981575	chr13:44710947	C/T	cg04068111	chr13:44716778	NA	-0.52	-7.49	-0.33	3.51e-13	Schizophrenia;
LGG	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg16447950	chr5:562315	NA	-0.47	-7.77	-0.34	5.23e-14	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg00938859	chr5:1591904	SDHAP3	0.93	13.76	0.54	2.39e-36	Breast cancer;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg00864171	chr11:67383662	NA	0.51	8.6	0.37	1.29e-16	Mean corpuscular volume;
LGG	trans	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg02800362	chr5:177631904	HNRNPAB	0.7	8.96	0.38	8.17e-18	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.82e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12450255	chr15:34659304	LPCAT4	0.49	7.57	0.33	2.08e-13	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.22	-0.36	1.99e-15	Retinal vascular caliber;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.8	0.34	4.08e-14	Lung cancer;
LGG	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs6456156	0.742	rs1331299	chr6:167533467	A/G	cg07741184	chr6:167504864	NA	0.3	6.69	0.3	6.28e-11	Primary biliary cholangitis;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg00262122	chr8:11665843	FDFT1	0.41	6.73	0.3	5.11e-11	Neuroticism;
LGG	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg11040518	chr10:102331378	NA	-0.36	-6.73	-0.3	5.12e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs1728785	0.818	rs1645984	chr16:68628850	T/C	cg02972257	chr16:68554789	NA	-0.54	-7.96	-0.35	1.33e-14	Ulcerative colitis;
LGG	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg27165867	chr14:105738592	BRF1	-0.45	-7.16	-0.32	3.18e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg24375607	chr4:120327624	NA	0.65	10.71	0.45	4.79e-24	Corneal astigmatism;
LGG	trans	rs6601327	0.585	rs11249934	chr8:9510830	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.87	-0.34	2.49e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs800082	0.690	rs2575191	chr3:144279228	G/A	cg24215973	chr2:240111563	HDAC4	0.61	11.74	0.48	4.98e-28	Smoking behavior;
LGG	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg17595323	chr11:93583763	C11orf90	-0.44	-7.94	-0.35	1.5e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg00631329	chr6:26305371	NA	-0.44	-7.06	-0.31	6.16e-12	Educational attainment;
LGG	cis	rs4774899	0.752	rs2951899	chr15:57381851	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.81	-0.3	2.96e-11	Urinary tract infection frequency;
LGG	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg27411982	chr8:10470053	RP1L1	0.39	6.73	0.3	4.98e-11	Retinal vascular caliber;
LGG	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg26818010	chr10:134567672	INPP5A	-0.63	-9.77	-0.41	1.25e-20	Migraine;
LGG	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.72	-0.38	5.19e-17	Neuroticism;
LGG	cis	rs1408799	0.772	rs10756406	chr9:12748587	A/G	cg05274944	chr9:12693694	TYRP1	-0.37	-8.62	-0.37	1.09e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs4743820	0.651	rs10739912	chr9:93929115	A/G	cg14446406	chr9:93919335	NA	0.9	15.21	0.58	1.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.45	0.5	6.62e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg13385794	chr1:248469461	NA	0.45	7.72	0.34	7.12e-14	Common traits (Other);
LGG	cis	rs9815354	0.812	rs73081361	chr3:41912535	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.94	-0.35	1.53e-14	Bladder cancer;
LGG	cis	rs9815354	1.000	rs9815354	chr3:41912651	G/A	cg03022575	chr3:42003672	ULK4	0.73	9.17	0.39	1.56e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.48	0.37	3.08e-16	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg25358565	chr5:93447407	FAM172A	1.27	15.43	0.58	1.18e-43	Diabetic retinopathy;
LGG	cis	rs10489202	0.686	rs6427113	chr1:167845787	C/T	cg24449463	chr1:168025552	DCAF6	0.5	6.79	0.3	3.39e-11	Schizophrenia;
LGG	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.84	0.48	1.9e-28	Rheumatoid arthritis;
LGG	trans	rs3779273	0.722	rs4730115	chr7:77833976	A/G	cg05596911	chr5:118502651	DMXL1	-0.49	-10.72	-0.45	4.31e-24	Body mass index;
LGG	cis	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg21775007	chr8:11205619	TDH	-0.47	-7.46	-0.33	4.22e-13	Neuroticism;
LGG	cis	rs5750830	0.649	rs4821893	chr22:39797779	G/A	cg11247378	chr22:39784982	NA	-0.32	-9.17	-0.39	1.52e-18	Intelligence (multi-trait analysis);
LGG	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs546131	0.642	rs579926	chr11:34853155	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.29	0.32	1.31e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6977660	0.619	rs12530799	chr7:19782793	G/A	cg05791153	chr7:19748676	TWISTNB	0.65	9.35	0.4	3.82e-19	Thyroid stimulating hormone;
LGG	cis	rs7769051	1.000	rs12203977	chr6:133122760	A/G	cg07930552	chr6:133119739	C6orf192	0.85	11.81	0.48	2.5e-28	Type 2 diabetes nephropathy;
LGG	cis	rs10744422	0.920	rs3896871	chr12:123333610	G/T	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	4.96e-19	Schizophrenia;
LGG	trans	rs11875185	0.915	rs1893469	chr18:55625499	A/C	cg15513957	chr14:69354734	ACTN1	-0.68	-7.76	-0.34	5.5e-14	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-9.71	-0.41	1.99e-20	Schizophrenia;
LGG	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg06640241	chr16:89574553	SPG7	0.86	15.21	0.58	1.17e-42	Multiple myeloma (IgH translocation);
LGG	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg26384229	chr12:38710491	ALG10B	0.81	16.23	0.6	3.31e-47	Morning vs. evening chronotype;
LGG	trans	rs1973993	0.691	rs6658131	chr1:96889314	C/T	cg10631902	chr5:14652156	NA	0.64	15.58	0.59	2.64e-44	Weight;
LGG	cis	rs9905704	0.647	rs11652713	chr17:57079742	C/T	cg05425664	chr17:57184151	TRIM37	-0.44	-7.11	-0.31	4.3e-12	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg21475434	chr5:93447410	FAM172A	0.69	7.13	0.31	3.99e-12	Diabetic retinopathy;
LGG	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.53	0.33	2.64e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs3820928	1.000	rs4675115	chr2:227769123	C/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.03	-0.31	7.29e-12	Pulmonary function;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.71	-0.41	1.99e-20	Personality dimensions;
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.55	0.37	1.87e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1682825	0.789	rs2600069	chr3:10758284	G/T	cg23512531	chr3:10780469	NA	-0.59	-7.58	-0.33	1.89e-13	Economic and political preferences (feminism/equality);
LGG	cis	rs1348850	0.914	rs1975544	chr2:178465423	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-7.72	-0.34	7.16e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.61	-0.51	1.45e-31	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-13.27	-0.53	2.65e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs782590	0.967	rs4290693	chr2:55799991	C/G	cg18811423	chr2:55921094	PNPT1	0.87	19.75	0.68	2.02e-63	Metabolic syndrome;
LGG	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.94	0.42	3.04e-21	Neuroticism;
LGG	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg14673194	chr17:80132900	CCDC57	-0.42	-7.29	-0.32	1.31e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg27432699	chr2:27873401	GPN1	0.67	13.42	0.53	6.71e-35	Oral cavity cancer;
LGG	cis	rs524281	0.861	rs10750778	chr11:65948648	T/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.65	-0.3	8.3e-11	Electroencephalogram traits;
LGG	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg06026331	chr20:60912101	LAMA5	-0.47	-8.91	-0.38	1.18e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7568458	0.837	rs12714145	chr2:85787341	C/T	cg23752985	chr2:85803571	VAMP8	0.45	8.8	0.38	2.65e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.77	-0.3	3.96e-11	Mood instability;
LGG	cis	rs7927771	1.000	rs7105282	chr11:47805614	C/A	cg20307385	chr11:47447363	PSMC3	-0.48	-8.49	-0.37	2.73e-16	Subjective well-being;
LGG	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg15627072	chr1:2432621	PLCH2	-0.38	-8.34	-0.36	8.46e-16	Ulcerative colitis;
LGG	cis	rs2470578	0.792	rs283906	chr3:17337410	C/A	cg20981856	chr3:17787350	NA	0.35	6.74	0.3	4.86e-11	Schizophrenia;
LGG	cis	rs6460942	0.841	rs6968277	chr7:12443795	C/A	cg06484146	chr7:12443880	VWDE	-0.38	-7.16	-0.32	3.29e-12	Coronary artery disease;
LGG	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg17031739	chr1:67600172	NA	-0.42	-8.61	-0.37	1.12e-16	Psoriasis;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.7	0.56	1.99e-40	Platelet count;
LGG	trans	rs4714291	0.832	rs6917417	chr6:40104628	T/C	cg02267698	chr19:7991119	CTXN1	-0.61	-10.03	-0.42	1.54e-21	Strep throat;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg14926445	chr8:58193284	C8orf71	-0.7	-9.42	-0.4	2.22e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.920	rs10751291	chr11:78217687	T/C	cg27205649	chr11:78285834	NARS2	0.47	8.12	0.35	4.37e-15	Alzheimer's disease (survival time);
LGG	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg06634786	chr22:41940651	POLR3H	0.76	12.2	0.49	6.91e-30	Vitiligo;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg15383120	chr6:291909	DUSP22	-0.41	-7.01	-0.31	8.69e-12	Menopause (age at onset);
LGG	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg14598338	chr9:96623480	NA	-0.54	-9.64	-0.41	3.7799999999999997e-20	DNA methylation (variation);
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.21	-0.32	2.26e-12	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs4815412	chr20:25350325	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.42	0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7666738	0.830	rs6532719	chr4:99043691	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.88	0.34	2.35e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.36	0.32	8.18e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	cg15522984	chr1:182991683	LAMC1	0.47	9.4	0.4	2.43e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2404602	0.735	rs1607017	chr15:76726465	G/T	cg23625390	chr15:77176239	SCAPER	-0.64	-12.78	-0.51	3.11e-32	Blood metabolite levels;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20887711	chr4:1340912	KIAA1530	0.93	20.49	0.69	6.89e-67	Longevity;
LGG	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.65	0.37	8.84e-17	Bipolar disorder;
LGG	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg13802316	chr11:70253460	CTTN	-0.59	-7.63	-0.33	1.35e-13	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11718455	1.000	rs1524885	chr3:44031847	G/A	cg21419209	chr3:44054225	NA	-0.43	-7.02	-0.31	7.94e-12	Coronary artery disease;
LGG	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg04607235	chr12:12878440	APOLD1	-1.0	-20.43	-0.69	1.27e-66	Lymphocyte counts;
LGG	cis	rs742614	0.533	rs2103804	chr20:32425403	A/G	cg06304546	chr20:32448765	NA	0.7	13.93	0.54	4.47e-37	Stearic acid (18:0) levels;
LGG	cis	rs2013441	0.508	rs35156798	chr17:19967935	A/G	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19524238	chr7:2802976	GNA12	0.39	8.8	0.38	2.64e-17	Height;
LGG	cis	rs9487094	0.778	rs6914498	chr6:109934408	G/A	cg16315928	chr6:109776240	MICAL1	0.54	9.06	0.39	3.76e-18	Height;
LGG	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Myopia (pathological);
LGG	cis	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.68	-0.3	6.71e-11	Parkinson's disease;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.44	-0.47	7.14e-27	Obesity-related traits;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.78	0.41	1.19e-20	Schizophrenia;
LGG	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.72	-0.48	5.83e-28	Intelligence (multi-trait analysis);
LGG	cis	rs36093844	0.752	rs17817254	chr11:85564826	A/C	cg16165120	chr11:85566439	CCDC83	-0.44	-7.02	-0.31	8.05e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06950479	chr16:240114	LUC7L	0.35	6.74	0.3	4.79e-11	Body fat percentage;
LGG	cis	rs2749592	0.611	rs2505199	chr10:38392457	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-13.85	-0.54	9.49e-37	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs79911532	0.515	rs111356249	chr7:75716527	A/G	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.55	0.59	3.5e-44	Lymphocyte percentage of white cells;
LGG	cis	rs896543	0.702	rs12692190	chr2:237496190	C/T	cg25295825	chr2:237489920	CXCR7	0.87	13.66	0.54	6.23e-36	Alcohol dependence (age at onset);
LGG	cis	rs9674544	0.556	rs1390154	chr17:47071483	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.39	-7.1	-0.31	4.83e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg11266682	chr4:10021025	SLC2A9	0.53	10.6	0.44	1.16e-23	Bone mineral density;
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg04287289	chr16:89883240	FANCA	0.77	7.68	0.34	9.72e-14	Skin colour saturation;
LGG	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19233923	chr11:63753598	OTUB1	0.41	7.38	0.32	7.22e-13	Obesity-related traits;
LGG	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg06598544	chr20:61472147	COL9A3	-0.9	-9.84	-0.42	6.9299999999999992e-21	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg14926445	chr8:58193284	C8orf71	-0.68	-9.0	-0.39	6.01e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4689642	1.000	rs10010473	chr4:7224309	A/G	cg21353189	chr4:7228343	SORCS2	0.32	7.88	0.34	2.34e-14	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2860975	0.967	rs7902572	chr10:96772717	C/A	cg09036531	chr10:96991505	NA	-0.48	-8.78	-0.38	3.18e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.48e-17	Bipolar disorder;
LGG	cis	rs1008375	0.618	rs13129002	chr4:17567513	A/G	cg02297831	chr4:17616191	MED28	0.44	7.59	0.33	1.79e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs42648	0.869	rs1015402	chr7:89913269	C/T	cg25739043	chr7:89950458	NA	-0.43	-9.17	-0.39	1.6e-18	Homocysteine levels;
LGG	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg24631222	chr15:78858424	CHRNA5	0.46	7.03	0.31	7.46e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4700695	0.841	rs27132	chr5:65288791	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.34	0.32	9.79e-13	Facial morphology (factor 19);
LGG	cis	rs55665837	1.000	rs10766182	chr11:14499536	A/G	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.84e-17	Vitamin D levels;
LGG	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg26031613	chr14:104095156	KLC1	-0.63	-10.11	-0.43	7.4e-22	Reticulocyte count;
LGG	cis	rs537930	0.560	rs10072362	chr5:134342720	C/A	cg24576358	chr5:134350122	NA	-0.44	-9.87	-0.42	5.64e-21	Height;
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg05896524	chr21:47604654	C21orf56	-0.65	-10.97	-0.45	4.58e-25	Testicular germ cell tumor;
LGG	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg04672837	chr16:48644449	N4BP1	0.51	8.39	0.36	5.84e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg03605463	chr16:89740564	NA	0.61	11.18	0.46	7.79e-26	Vitiligo;
LGG	trans	rs4942242	0.663	rs9590779	chr13:44234886	A/G	cg19169023	chr15:41853346	TYRO3	0.44	8.86	0.38	1.76e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.76	0.3	4.2e-11	Bone mineral density;
LGG	cis	rs3916	0.955	rs35599677	chr12:121141458	G/A	cg21892295	chr12:121157589	UNC119B	-0.41	-7.02	-0.31	7.75e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.35	0.32	8.81e-13	Height;
LGG	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg13802316	chr11:70253460	CTTN	-0.6	-7.63	-0.33	1.31e-13	Coronary artery disease;
LGG	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg17971929	chr21:40555470	PSMG1	-0.53	-8.97	-0.38	7.64e-18	Menarche (age at onset);
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.65e-12	Bipolar disorder;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	9.55	0.41	7.81e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06634786	chr22:41940651	POLR3H	-0.65	-10.91	-0.45	7.83e-25	Vitiligo;
LGG	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg16797656	chr11:68205561	LRP5	0.57	10.59	0.44	1.3e-23	Total body bone mineral density;
LGG	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg20821713	chr7:1055600	C7orf50	-0.41	-7.93	-0.35	1.7e-14	Longevity;Endometriosis;
LGG	trans	rs7939886	0.920	rs77344682	chr11:55999358	A/G	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg03929089	chr4:120376271	NA	-0.42	-6.75	-0.3	4.32e-11	HDL cholesterol;
LGG	cis	rs1568889	1.000	rs7933332	chr11:28036392	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	15.38	0.58	1.96e-43	Bipolar disorder;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.83	0.38	2.16e-17	Lung cancer;
LGG	cis	rs10751667	0.643	rs6597970	chr11:928669	C/A	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.3	-0.5	2.7e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Schizophrenia;
LGG	cis	rs4538187	0.865	rs35474183	chr2:63982523	C/T	cg19915305	chr2:64069682	UGP2	-0.63	-13.95	-0.54	3.57e-37	Systolic blood pressure;
LGG	cis	rs526231	0.511	rs10434793	chr5:102389815	A/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.58	-0.33	1.88e-13	Menopause (age at onset);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg19010396	chr19:19431384	KIAA0892;SF4	0.43	7.21	0.32	2.23e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7712401	0.502	rs30066	chr5:122293702	A/G	cg19412675	chr5:122181750	SNX24	0.55	8.88	0.38	1.45e-17	Mean platelet volume;
LGG	trans	rs6825911	0.767	rs10004154	chr4:111380759	G/A	cg10580549	chr19:53101634	ZNF137	0.46	7.16	0.32	3.16e-12	Blood pressure;
LGG	cis	rs8064024	0.870	rs930854	chr16:4864101	A/G	cg08329684	chr16:4932620	PPL	0.41	9.06	0.39	3.61e-18	Cancer;
LGG	cis	rs11792861	0.816	rs2304779	chr9:111670513	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.64	-10.38	-0.43	7.86e-23	Menarche (age at onset);
LGG	cis	rs7617773	0.817	rs11709691	chr3:48303669	A/G	cg11946769	chr3:48343235	NME6	0.69	11.44	0.47	7.37e-27	Coronary artery disease;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg22535103	chr8:58192502	C8orf71	-0.82	-11.69	-0.48	7.84e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs13382275	0.908	rs13429476	chr2:964442	A/G	cg10902693	chr2:875509	NA	0.43	7.21	0.32	2.22e-12	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs758324	0.812	rs2088718	chr5:131179189	C/T	cg06307176	chr5:131281290	NA	0.53	8.85	0.38	1.85e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4650994	0.571	rs6676507	chr1:178508743	C/G	cg19399532	chr1:178512495	C1orf220	-0.41	-8.0	-0.35	9.94e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg07541023	chr7:19748670	TWISTNB	0.6	8.61	0.37	1.14e-16	Thyroid stimulating hormone;
LGG	cis	rs1018836	0.923	rs4735230	chr8:91574184	G/C	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	5.12e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg15704280	chr7:45808275	SEPT13	0.88	12.46	0.5	6.14e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.26	-0.43	2.25e-22	Total body bone mineral density;
LGG	cis	rs7524258	0.903	rs763197	chr1:7289959	A/G	cg07173049	chr1:7289937	CAMTA1	0.77	18.51	0.65	1.2e-57	Tourette's syndrome or obsessive-compulsive disorder;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.68	-0.41	2.63e-20	Triglycerides;
LGG	cis	rs35160687	0.644	rs4832272	chr2:86516211	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.91	0.31	1.66e-11	Night sleep phenotypes;
LGG	cis	rs4262150	0.774	rs72799164	chr5:152132148	C/G	cg12297329	chr5:152029980	NA	-0.7	-12.78	-0.51	3.08e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs208520	0.661	rs207079	chr6:66770462	C/T	cg07460842	chr6:66804631	NA	-0.95	-17.48	-0.63	6.8e-53	Exhaled nitric oxide output;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.69	-0.3	6.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6598955	0.671	rs12141563	chr1:26589636	A/G	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.45e-15	Obesity-related traits;
LGG	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg02269571	chr22:50332266	NA	0.64	10.11	0.43	7.52e-22	Schizophrenia;
LGG	cis	rs3870371	0.868	rs11774882	chr8:122702067	T/C	cg15679747	chr8:122755315	NA	-0.35	-6.73	-0.3	4.93e-11	Periodontal disease-related phenotypes;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg04025307	chr7:1156635	C7orf50	0.53	9.9	0.42	4.34e-21	Longevity;Endometriosis;
LGG	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg13647721	chr17:30228624	UTP6	0.62	7.5	0.33	3.29e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2290159	0.800	rs2290162	chr3:12647457	A/G	cg23032965	chr3:12705835	RAF1	0.67	9.78	0.41	1.21e-20	Cholesterol, total;
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.54	-0.37	1.93e-16	Neuroticism;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04507121	chr2:172778341	HAT1	0.36	7.05	0.31	6.49e-12	Menarche (age at onset);
LGG	cis	rs509477	0.718	rs273342	chr18:32604956	G/A	cg23791764	chr18:32556832	MAPRE2	0.44	7.45	0.33	4.61e-13	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.06	-0.31	6.3e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs62244186	0.659	rs12489887	chr3:44547124	A/T	cg02073558	chr3:44770973	ZNF501	0.66	12.03	0.49	3.42e-29	Depressive symptoms;
LGG	cis	rs977987	0.872	rs7206665	chr16:75475287	A/C	cg03315344	chr16:75512273	CHST6	0.52	10.46	0.44	3.86e-23	Dupuytren's disease;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg22907277	chr7:1156413	C7orf50	0.83	14.93	0.57	1.9e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	cis	rs11098499	0.690	rs34818745	chr4:120257055	T/C	cg24375607	chr4:120327624	NA	0.68	10.99	0.45	3.95e-25	Corneal astigmatism;
LGG	trans	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg16141378	chr3:129829833	LOC729375	0.41	9.91	0.42	3.96e-21	Systolic blood pressure;
LGG	trans	rs6011368	0.678	rs6090105	chr20:62911343	G/T	cg13869341	chr1:15865	WASH5P	0.56	9.98	0.42	2.18e-21	Clozapine-induced cytotoxicity;
LGG	cis	rs757081	0.667	rs7108067	chr11:17200220	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.92	-0.38	1.09e-17	Systolic blood pressure;
LGG	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg03929089	chr4:120376271	NA	-0.53	-9.01	-0.39	5.52e-18	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg05313129	chr8:58192883	C8orf71	-0.65	-8.39	-0.36	6.1e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs919433	0.926	rs787996	chr2:198216805	A/G	cg00792783	chr2:198669748	PLCL1	0.44	6.96	0.31	1.15e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.4	0.44	6.64e-23	Ulcerative colitis;
LGG	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg16141378	chr3:129829833	LOC729375	0.36	7.66	0.34	1.12e-13	Triglycerides;
LGG	cis	rs4077515	0.874	rs4498662	chr9:139290251	C/G	cg21253087	chr9:139290292	SNAPC4	0.37	7.7	0.34	8.53e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2404602	0.552	rs11630185	chr15:76959783	A/T	cg23625390	chr15:77176239	SCAPER	-0.74	-13.26	-0.52	3.13e-34	Blood metabolite levels;
LGG	cis	rs28595532	0.920	rs114165587	chr4:119779525	C/T	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs6684428	0.706	rs11206673	chr1:56326340	C/T	cg11651538	chr1:56320950	NA	0.68	12.23	0.49	5.22e-30	Airflow obstruction;
LGG	cis	rs698813	0.674	rs7590224	chr2:44501209	T/G	cg00619915	chr2:44497795	NA	-0.62	-8.77	-0.38	3.52e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs11976180	1.000	rs2951364	chr7:143754483	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.88	-0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	7.99	0.35	1.1e-14	Osteoporosis;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg13206674	chr6:150067644	NUP43	0.62	13.58	0.53	1.35e-35	Lung cancer;
LGG	cis	rs9457247	0.602	rs17615336	chr6:167506734	A/G	cg07741184	chr6:167504864	NA	0.46	10.28	0.43	1.86e-22	Crohn's disease;
LGG	cis	rs6088590	0.735	rs2273684	chr20:33529766	G/T	cg08999081	chr20:33150536	PIGU	-0.31	-7.6	-0.33	1.71e-13	Coronary artery disease;
LGG	cis	rs8058578	1.000	rs8058578	chr16:30726248	C/T	cg05768032	chr16:30646687	NA	0.41	6.86	0.3	2.23e-11	Multiple myeloma;
LGG	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg24110177	chr3:50126178	RBM5	0.56	10.37	0.43	8.41e-23	Intelligence (multi-trait analysis);
LGG	cis	rs17208368	0.723	rs4784468	chr16:55090245	C/A	cg11181171	chr16:55090946	NA	0.48	7.15	0.32	3.32e-12	Hypospadias;
LGG	cis	rs7192380	0.767	rs8061725	chr16:69581077	G/A	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.41	-0.36	4.99e-16	Sjögren's syndrome;
LGG	cis	rs6956675	0.874	rs10266439	chr7:62647022	G/T	cg08930214	chr7:62859557	LOC100287834	0.44	7.48	0.33	3.65e-13	Obesity-related traits;
LGG	cis	rs561341	1.000	rs555629	chr17:30294136	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.63	-0.44	9.3e-24	Hip circumference adjusted for BMI;
LGG	cis	rs5742933	0.762	rs12992061	chr2:190600752	G/A	cg04003228	chr2:190539410	ANKAR	-0.5	-7.27	-0.32	1.52e-12	Ferritin levels;
LGG	cis	rs9815354	0.951	rs9868066	chr3:41794161	T/A	cg03022575	chr3:42003672	ULK4	0.59	7.56	0.33	2.13e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2798269	0.690	rs1148976	chr13:22040557	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.52	-9.0	-0.39	5.92e-18	PR segment;
LGG	cis	rs9815354	1.000	rs4408846	chr3:41753679	A/G	cg03022575	chr3:42003672	ULK4	0.63	7.78	0.34	4.85e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7635838	0.619	rs347616	chr3:11277927	G/A	cg00170343	chr3:11313890	ATG7	0.56	9.26	0.4	7.74e-19	HDL cholesterol;
LGG	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg11764359	chr7:65958608	NA	-0.8	-14.86	-0.57	4.04e-41	Aortic root size;
LGG	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.74	-0.45	3.47e-24	Retinal vascular caliber;
LGG	trans	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.48e-28	Corneal astigmatism;
LGG	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg00409905	chr10:38381863	ZNF37A	0.53	10.46	0.44	3.83e-23	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg20673091	chr1:2541236	MMEL1	0.78	19.04	0.66	3.89e-60	Ulcerative colitis;
LGG	cis	rs477692	0.905	rs544217	chr10:131420584	A/G	cg05714579	chr10:131428358	MGMT	0.66	13.74	0.54	2.87e-36	Response to temozolomide;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg24846343	chr22:24311635	DDTL	0.54	10.31	0.43	1.46e-22	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg13385794	chr1:248469461	NA	0.49	8.48	0.37	3.13e-16	Common traits (Other);
LGG	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg17809284	chr5:56205270	C5orf35	-0.54	-9.98	-0.42	2.24e-21	Initial pursuit acceleration;
LGG	cis	rs17253792	0.730	rs77079997	chr14:56155250	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.33	-0.5	2.08e-30	Putamen volume;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.59	-0.37	1.32e-16	Lung cancer;
LGG	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg26656751	chr17:43910226	CRHR1	0.35	7.11	0.31	4.37e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg25801113	chr15:45476975	SHF	0.87	20.0	0.68	1.34e-64	Uric acid levels;
LGG	cis	rs6540556	0.859	rs11119340	chr1:209940560	A/T	cg23920097	chr1:209922102	NA	0.47	7.59	0.33	1.8e-13	Red blood cell count;
LGG	cis	rs2694528	0.858	rs2270822	chr5:60459040	C/T	cg11474532	chr5:59995715	DEPDC1B	0.67	7.33	0.32	1.03e-12	Parkinson's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05668205	chr19:16738998	MED26	0.5	7.45	0.33	4.54e-13	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg26396452	chr14:65542826	MAX	0.51	11.2	0.46	6.47e-26	Obesity-related traits;
LGG	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14154082	chr13:112174009	NA	0.43	9.31	0.4	4.99e-19	Menarche (age at onset);
LGG	cis	rs1957429	0.803	rs10873177	chr14:65318228	G/C	cg23373153	chr14:65346875	NA	1.02	12.84	0.51	1.78e-32	Pediatric areal bone mineral density (radius);
LGG	cis	rs988958	0.565	rs13417438	chr2:42237876	A/G	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg18709589	chr6:96969512	KIAA0776	0.42	8.32	0.36	9.81e-16	Headache;
LGG	trans	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg27661571	chr11:113659931	NA	-0.57	-7.75	-0.34	5.93e-14	Hip circumference adjusted for BMI;
LGG	trans	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7586879	0.828	rs13012304	chr2:25122246	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.54	0.41	8.03e-20	Body mass index;
LGG	cis	rs701145	0.640	rs1657621	chr3:153929795	T/C	cg17054900	chr3:154042577	DHX36	0.86	9.5	0.4	1.18e-19	Coronary artery disease;
LGG	cis	rs6764363	0.527	rs62228321	chr3:279372	A/C	cg02057681	chr3:285234	CHL1	-0.43	-7.71	-0.34	7.59e-14	Sudden cardiac arrest;
LGG	cis	rs11096990	0.892	rs11729098	chr4:39233977	G/A	cg24403649	chr4:39172243	NA	-0.45	-7.22	-0.32	2.09e-12	Cognitive function;
LGG	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs360798	0.532	rs12713468	chr2:62983213	G/A	cg17519650	chr2:63277830	OTX1	-0.47	-7.49	-0.33	3.47e-13	Coronary artery disease;
LGG	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00292662	chr22:38071168	LGALS1	0.65	14.88	0.57	3.15e-41	Fat distribution (HIV);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.37e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08280861	chr8:58055591	NA	-0.63	-7.8	-0.34	4.08e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg13033054	chr21:33948561	TCP10L	0.52	8.81	0.38	2.61e-17	Gut microbiome composition (summer and winter);
LGG	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24607948	chr9:100459097	XPA	0.53	8.09	0.35	5.17e-15	Gut microbiome composition (summer);
LGG	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg06212747	chr3:49208901	KLHDC8B	0.67	11.56	0.47	2.55e-27	Parkinson's disease;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.54	-0.44	2.04e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg08621203	chr6:150244597	RAET1G	0.42	7.12	0.31	4.06e-12	Lung cancer;
LGG	cis	rs7551222	0.646	rs2926536	chr1:204456983	T/G	cg20240347	chr1:204465584	NA	0.45	7.87	0.34	2.48e-14	Schizophrenia;
LGG	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.36	-0.32	8.68e-13	Iron status biomarkers;
LGG	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7949030	0.523	rs67308910	chr11:62377359	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.55	11.81	0.48	2.65e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg22771759	chr13:24902376	NA	0.44	7.48	0.33	3.82e-13	Obesity-related traits;
LGG	cis	rs67311347	0.544	rs13062243	chr3:40336789	G/A	cg13683864	chr3:40499215	RPL14	-0.8	-15.84	-0.59	1.84e-45	Renal cell carcinoma;
LGG	trans	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg16141378	chr3:129829833	LOC729375	-0.44	-10.3	-0.43	1.57e-22	Mood instability;
LGG	trans	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.66	0.48	9.65e-28	Corneal astigmatism;
LGG	cis	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.24	-0.36	1.76e-15	Mean corpuscular volume;
LGG	cis	rs752010	0.749	rs12141084	chr1:42117737	C/T	cg06885757	chr1:42089581	HIVEP3	0.43	9.0	0.39	5.73e-18	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg13012494	chr21:47604986	C21orf56	0.41	6.72	0.3	5.48e-11	Testicular germ cell tumor;
LGG	trans	rs9393777	0.622	rs13191326	chr6:27031029	A/G	cg06606381	chr12:133084897	FBRSL1	-0.93	-9.92	-0.42	3.74e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8192917	0.614	rs8021523	chr14:25065944	A/G	cg01932691	chr14:25045625	CTSG	-0.39	-6.94	-0.31	1.35e-11	Vitiligo;
LGG	cis	rs546131	0.642	rs537873	chr11:34835121	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.44	6.95	0.31	1.27e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg22857025	chr5:266934	NA	-1.48	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.15	-0.35	3.4e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg20302533	chr7:39170763	POU6F2	0.59	14.99	0.57	1.09e-41	IgG glycosylation;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg20978937	chr14:105399321	PLD4	0.49	10.9	0.45	9.16e-25	Rheumatoid arthritis;
LGG	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.61	-0.47	1.6e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs1873147	0.569	rs59418037	chr15:63310871	A/G	cg12160578	chr15:63334699	TPM1	0.57	7.89	0.34	2.19e-14	Orofacial clefts;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.06	-0.31	6.1e-12	Testicular germ cell tumor;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg08888203	chr3:10149979	C3orf24	0.53	8.71	0.38	5.45e-17	Alzheimer's disease;
LGG	cis	rs7408868	1.000	rs757475	chr19:15273749	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14082963	chr4:89444434	PIGY	0.47	7.87	0.34	2.46e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7122539	0.506	rs10791896	chr11:66689240	G/T	cg24851651	chr11:66362959	CCS	0.36	7.02	0.31	7.81e-12	HIV-1 susceptibility;
LGG	trans	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg25482853	chr8:67687455	SGK3	0.86	11.22	0.46	5.18e-26	Ulcerative colitis;
LGG	cis	rs4780401	0.609	rs55934118	chr16:11820003	G/C	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.94	-0.52	6.37e-33	Rheumatoid arthritis;
LGG	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs877282	0.583	rs11253428	chr10:823233	C/T	cg15764593	chr10:829463	NA	-0.69	-9.72	-0.41	1.94e-20	Uric acid levels;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.1	-0.31	4.73e-12	Bipolar disorder;
LGG	cis	rs12220238	0.822	rs7919517	chr10:76111355	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.95	0.38	8.34e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	7.98	0.35	1.18e-14	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1107366	0.722	rs1992855	chr3:125909669	C/T	cg17230874	chr3:125932073	NA	-0.58	-11.68	-0.48	8.2e-28	Metabolite levels;
LGG	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg13010199	chr12:38710504	ALG10B	0.7	14.37	0.56	5.56e-39	Bladder cancer;
LGG	cis	rs9815354	0.812	rs17280952	chr3:41810834	T/C	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11785693	0.862	rs11774099	chr8:4988218	C/T	cg26367366	chr8:4980734	NA	0.93	14.96	0.57	1.4e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.47	0.53	4.06e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17453880	0.853	rs60230149	chr5:151965041	G/A	cg10931792	chr5:152022470	NA	0.38	8.29	0.36	1.25e-15	Subjective well-being;
LGG	cis	rs1030877	0.515	rs2576742	chr2:105898822	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.65	10.34	0.43	1.08e-22	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.75	-0.64	3.78e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs71718386	1	rs71718386	chr13:41224287	CTATA/C	cg21288729	chr13:41239152	FOXO1	0.33	6.72	0.3	5.34e-11	Eosinophil counts;
LGG	cis	rs9487051	0.703	rs351755	chr6:109538073	G/A	cg21918786	chr6:109611834	NA	0.42	7.73	0.34	6.8e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7712401	0.562	rs401729	chr5:122264285	G/T	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	7.14	0.31	3.75e-12	Prudent dietary pattern;
LGG	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.04	0.49	3.08e-29	Height;
LGG	cis	rs6466055	0.666	rs4730081	chr7:105006850	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.04	-0.31	7.07e-12	Schizophrenia;
LGG	cis	rs701145	0.537	rs377565	chr3:153921953	A/G	cg17054900	chr3:154042577	DHX36	0.83	9.53	0.41	8.64e-20	Coronary artery disease;
LGG	cis	rs365132	0.875	rs353479	chr5:176372593	C/T	cg16309518	chr5:176445507	NA	-0.43	-8.55	-0.37	1.81e-16	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.81	12.66	0.51	9.36e-32	Cognitive test performance;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg05555928	chr11:63887634	MACROD1	-0.67	-9.23	-0.39	9.63e-19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7945705	0.840	rs10840136	chr11:8885024	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-9.11	-0.39	2.4e-18	Hemoglobin concentration;
LGG	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg15432903	chr11:17409602	KCNJ11	0.8	16.05	0.6	2.01e-46	Type 2 diabetes;
LGG	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.2	0.39	1.18e-18	Aortic root size;
LGG	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg23752985	chr2:85803571	VAMP8	0.39	7.61	0.33	1.54e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	6.83	0.3	2.71e-11	Schizophrenia;
LGG	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Urinary tract infection frequency;
LGG	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg13852791	chr20:30311386	BCL2L1	0.7	10.27	0.43	1.96e-22	Mean corpuscular hemoglobin;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20560182	chr5:140700478	TAF7	0.38	6.69	0.3	6.5e-11	Obesity-related traits;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07157834	chr1:205819609	PM20D1	0.82	19.87	0.68	5.36e-64	Menarche (age at onset);
LGG	cis	rs6539288	0.677	rs10778515	chr12:107332481	A/G	cg26297688	chr12:107349093	C12orf23	-0.38	-7.1	-0.31	4.78e-12	Total body bone mineral density;
LGG	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg17294928	chr15:75287854	SCAMP5	-0.68	-7.62	-0.33	1.42e-13	Lung cancer;
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg13264159	chr8:625131	ERICH1	-0.76	-8.64	-0.37	9.53e-17	IgG glycosylation;
LGG	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.6	-0.33	1.64e-13	Retinal vascular caliber;
LGG	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs9296092	0.538	rs76589475	chr6:33519517	G/C	cg13560919	chr6:33536144	NA	-1.04	-21.71	-0.71	1.3e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9790314	0.747	rs7619011	chr3:160855676	A/G	cg04691961	chr3:161091175	C3orf57	-0.51	-11.15	-0.46	1.02e-25	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.803	rs1984246	chr9:15898553	A/C	cg14451791	chr9:16040625	NA	0.39	9.99	0.42	2.07e-21	Body mass index;
LGG	cis	rs2075466	0.514	rs112861583	chr16:4907125	T/C	cg04440724	chr16:4920505	UBN1	-0.62	-9.06	-0.39	3.62e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg25174290	chr11:3078921	CARS	-0.51	-9.28	-0.4	6.58e-19	Calcium levels;
LGG	cis	rs8141529	0.509	rs5762863	chr22:29253335	A/C	cg02153584	chr22:29168773	CCDC117	0.61	9.27	0.4	6.98e-19	Lymphocyte counts;
LGG	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg10792982	chr14:105748885	BRF1	0.68	13.66	0.54	6.48e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7247513	0.797	rs3815914	chr19:12760664	T/C	cg01871581	chr19:12707946	ZNF490	-0.36	-7.17	-0.32	3.07e-12	Bipolar disorder;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7106204	0.748	rs4382909	chr11:24236618	C/T	ch.11.24196551F	chr11:24239977	NA	1.01	16.38	0.61	6.64e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9790314	0.586	rs11710086	chr3:161125858	A/T	cg03342759	chr3:160939853	NMD3	-0.64	-11.2	-0.46	6.4e-26	Morning vs. evening chronotype;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg00145757	chr11:118478637	PHLDB1	-0.45	-8.09	-0.35	5.15e-15	Glioma;
LGG	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg13256891	chr4:100009986	ADH5	0.54	9.69	0.41	2.41e-20	Alcohol dependence;
LGG	cis	rs3733585	0.699	rs6449171	chr4:9965998	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.77	0.34	5.18e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8114671	0.562	rs2223881	chr20:33506463	A/C	cg07148914	chr20:33460835	GGT7	0.57	9.48	0.4	1.29e-19	Height;
LGG	cis	rs7527798	0.544	rs11118354	chr1:207856868	A/G	cg09232269	chr1:207846808	CR1L	-0.38	-7.27	-0.32	1.58e-12	Erythrocyte sedimentation rate;
LGG	trans	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg25214090	chr10:38739885	LOC399744	0.67	11.84	0.48	1.99e-28	Corneal astigmatism;
LGG	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-6.85	-0.3	2.32e-11	Body mass index;
LGG	cis	rs2204008	0.715	rs11514282	chr12:38169056	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.54	2.54e-37	Bladder cancer;
LGG	cis	rs975722	0.638	rs213967	chr7:117229837	G/T	cg10524701	chr7:117356490	CTTNBP2	0.47	10.44	0.44	4.61e-23	Coronary artery disease;
LGG	cis	rs4846580	0.660	rs1933447	chr1:219895501	A/C	cg08034750	chr1:219919793	NA	0.42	7.49	0.33	3.44e-13	Total body bone mineral density;
LGG	cis	rs9790314	0.613	rs6799160	chr3:160634889	A/G	cg04691961	chr3:161091175	C3orf57	0.43	9.01	0.39	5.4e-18	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.76	-0.48	3.92e-28	Response to antipsychotic treatment;
LGG	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg03162506	chr22:38580953	NA	0.39	9.81	0.41	9.4e-21	Cutaneous nevi;
LGG	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg00717180	chr2:96193071	NA	-0.46	-8.39	-0.36	5.96e-16	HDL cholesterol;
LGG	cis	rs62400317	0.859	rs10456122	chr6:45163057	C/G	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.46e-22	Total body bone mineral density;
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg08297393	chr2:100937505	LONRF2	0.55	10.43	0.44	5.09e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4909189	0.915	rs11773551	chr7:158136146	C/T	cg15736062	chr7:158136485	PTPRN2	-0.52	-9.1	-0.39	2.77e-18	Response to amphetamines;
LGG	cis	rs1620921	0.505	rs11756055	chr6:161210622	C/T	cg01280913	chr6:161186852	NA	-0.49	-9.91	-0.42	4.13e-21	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs8002861	0.935	rs7319725	chr13:44445421	T/C	cg17145862	chr1:211918768	LPGAT1	0.99	25.94	0.77	2.99e-92	Leprosy;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs10504073	0.647	rs10435574	chr8:49996028	G/A	cg00325661	chr8:49890786	NA	0.75	14.4	0.56	4.31e-39	Blood metabolite ratios;
LGG	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg03788504	chr6:150331562	NA	-0.59	-13.16	-0.52	8.14e-34	Alopecia areata;
LGG	cis	rs4950322	0.515	rs76327075	chr1:146717973	C/T	cg22381352	chr1:146742008	CHD1L	-0.47	-7.85	-0.34	2.95e-14	Protein quantitative trait loci;
LGG	trans	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg24247370	chr13:99142703	STK24	-0.37	-7.11	-0.31	4.49e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9814567	1.000	rs6787371	chr3:134254991	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.51	-0.53	2.75e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg21926883	chr2:100939477	LONRF2	-0.68	-15.93	-0.6	7.08e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2463822	0.507	rs72919442	chr11:62028707	A/G	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.22	-0.49	5.64e-30	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-11.25	-0.46	4.12e-26	Prostate cancer;
LGG	trans	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg05926928	chr17:57297772	GDPD1	-0.44	-6.99	-0.31	9.45e-12	Schizophrenia;
LGG	cis	rs6540556	0.906	rs17015169	chr1:209936914	C/T	cg23920097	chr1:209922102	NA	-0.44	-7.7	-0.34	8.59e-14	Red blood cell count;
LGG	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg12419862	chr22:24373484	LOC391322	0.81	12.96	0.52	5.33e-33	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11644478	chr21:40555479	PSMG1	0.92	18.02	0.64	2.23e-55	Cognitive function;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg26668828	chr6:292823	DUSP22	-0.69	-12.19	-0.49	7.74e-30	Menopause (age at onset);
LGG	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	7.26	0.32	1.6e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11039798	0.588	rs6485891	chr11:48612024	T/A	cg03929089	chr4:120376271	NA	0.72	9.71	0.41	2.15e-20	Axial length;
LGG	cis	rs11249608	0.548	rs6875622	chr5:178451397	C/T	cg21905437	chr5:178450457	ZNF879	0.46	6.7	0.3	5.97e-11	Pubertal anthropometrics;
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg07959490	chr17:80112427	CCDC57	0.46	9.23	0.39	9.37e-19	Life satisfaction;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg17178900	chr1:205818956	PM20D1	0.58	12.96	0.52	5.46e-33	Menarche (age at onset);
LGG	cis	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg13010199	chr12:38710504	ALG10B	0.78	16.78	0.61	1.04e-49	Heart rate;
LGG	cis	rs11098499	0.730	rs78971550	chr4:120281041	C/T	cg24375607	chr4:120327624	NA	0.58	9.63	0.41	3.81e-20	Corneal astigmatism;
LGG	cis	rs243505	0.691	rs243484	chr7:148448655	G/T	cg18940274	chr7:148469757	CUL1	0.36	6.79	0.3	3.42e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs60180747	1.000	rs11636809	chr15:66729927	T/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	10.97	0.45	4.88e-25	Testicular germ cell tumor;
LGG	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg10513866	chr5:139070639	NA	0.42	8.05	0.35	7.04e-15	Schizophrenia;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.84e-13	Menopause (age at onset);
LGG	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg01181863	chr3:195395398	SDHAP2	0.48	7.38	0.32	7.3e-13	Mean corpuscular volume;
LGG	cis	rs742614	0.576	rs2747537	chr20:32405217	A/G	cg06304546	chr20:32448765	NA	-0.67	-13.13	-0.52	1.08e-33	Stearic acid (18:0) levels;
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.47	-0.44	3.73e-23	Intelligence (multi-trait analysis);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07316298	chr16:32823289	NA	0.4	7.09	0.31	5.14e-12	Menarche (age at onset);
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.53	-0.44	2.19e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12543725	0.601	rs7018178	chr8:142239210	C/T	cg23750338	chr8:142222470	SLC45A4	-0.35	-6.95	-0.31	1.23e-11	Birth weight;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27483261	chr19:17326064	USE1	0.46	7.13	0.31	3.76e-12	Gut microbiome composition (summer);
LGG	cis	rs12478296	1.000	rs56102931	chr2:243039936	A/G	cg18898632	chr2:242989856	NA	-0.8	-9.92	-0.42	3.55e-21	Obesity-related traits;
LGG	cis	rs2227564	0.700	rs2675677	chr10:75648249	C/A	cg00564723	chr10:75632066	CAMK2G	-0.44	-8.98	-0.39	6.75e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg10760299	chr15:45669010	GATM	0.4	7.73	0.34	6.54e-14	Homoarginine levels;
LGG	cis	rs6998277	1.000	rs34217554	chr8:103646352	T/C	cg10187029	chr8:103597600	NA	0.79	11.51	0.47	3.96e-27	Migraine;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs12474201	0.832	rs6738426	chr2:46986416	A/G	cg06386533	chr2:46925753	SOCS5	0.78	14.34	0.55	7.72e-39	Height;
LGG	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg21918786	chr6:109611834	NA	-0.47	-8.66	-0.37	8.14e-17	Reticulocyte fraction of red cells;
LGG	cis	rs17401966	0.931	rs10864448	chr1:10277497	A/T	cg19773385	chr1:10388646	KIF1B	-0.51	-10.55	-0.44	1.84e-23	Hepatocellular carcinoma;
LGG	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.68	-7.65	-0.33	1.2e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9906944	0.707	rs9912906	chr17:47104432	A/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.95	-0.31	1.28e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg22920501	chr2:26401640	FAM59B	-0.4	-7.89	-0.34	2.27e-14	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07620849	chr5:57879049	RAB3C	0.42	7.13	0.31	3.97e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.84	0.34	3.23e-14	Height;
LGG	cis	rs78487399	0.808	rs6732766	chr2:43712785	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.65	-7.03	-0.31	7.41e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs477692	0.597	rs574831	chr10:131379190	C/T	cg05714579	chr10:131428358	MGMT	-0.54	-10.75	-0.45	3.28e-24	Response to temozolomide;
LGG	cis	rs2797160	1.000	rs983543	chr6:126005767	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.31	-0.32	1.18e-12	Endometrial cancer;
LGG	cis	rs7106204	0.748	rs12273426	chr11:24212058	T/C	ch.11.24196551F	chr11:24239977	NA	1.03	16.03	0.6	2.6e-46	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7264396	0.561	rs6060750	chr20:34596371	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.41	-0.33	6e-13	Total cholesterol levels;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg14092988	chr3:52407081	DNAH1	0.26	7.06	0.31	6.03e-12	Hemoglobin concentration;
LGG	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	Neuroticism;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg01147727	chr14:105363015	KIAA0284	-0.46	-7.24	-0.32	1.84e-12	IgG glycosylation;
LGG	cis	rs1023500	0.596	rs133350	chr22:42429049	A/G	cg15557168	chr22:42548783	NA	-0.42	-8.64	-0.37	9.05e-17	Schizophrenia;
LGG	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg12560992	chr17:57184187	TRIM37	0.47	7.05	0.31	6.34e-12	Cognitive test performance;
LGG	cis	rs9783347	0.857	rs4150561	chr11:18354877	T/C	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs6547631	0.628	rs2886768	chr2:85927555	A/C	cg24620635	chr2:85921963	GNLY	0.5	10.09	0.42	8.97e-22	Blood protein levels;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.84e-21	Lung cancer;
LGG	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg03060546	chr3:49711283	APEH	0.52	8.66	0.37	7.9e-17	Parkinson's disease;
LGG	cis	rs6723226	0.764	rs176403	chr2:32637864	C/A	cg02381751	chr2:32503542	YIPF4	-0.77	-13.18	-0.52	6.51e-34	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg27523141	chr10:43048294	ZNF37B	0.4	7.85	0.34	2.97e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs4430311	0.723	rs12735854	chr1:243748184	G/C	cg25706552	chr1:244017396	NA	-0.64	-15.5	-0.58	6.06e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.88	0.3	1.93e-11	Schizophrenia;
LGG	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg16230307	chr14:35515116	FAM177A1	0.91	12.94	0.52	6.86e-33	Psoriasis;
LGG	cis	rs193541	0.632	rs430069	chr5:122263351	G/A	cg19412675	chr5:122181750	SNX24	0.55	8.72	0.38	5.04e-17	Glucose homeostasis traits;
LGG	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg12310025	chr6:25882481	NA	0.5	9.11	0.39	2.45e-18	Blood metabolite levels;
LGG	trans	rs2749592	0.531	rs10764134	chr10:37856660	T/C	cg17830980	chr10:43048298	ZNF37B	0.39	8.77	0.38	3.36e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg13385794	chr1:248469461	NA	0.48	8.1	0.35	4.8e-15	Common traits (Other);
LGG	cis	rs727505	1.000	rs10233385	chr7:124498707	C/G	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	12.29	0.5	3.14e-30	Lung cancer in ever smokers;
LGG	cis	rs4262150	0.883	rs72799186	chr5:152182121	G/T	cg12297329	chr5:152029980	NA	-0.7	-13.13	-0.52	1.04e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	cis	rs877282	0.947	rs7923867	chr10:768094	G/A	cg17470449	chr10:769945	NA	0.61	7.62	0.33	1.46e-13	Uric acid levels;
LGG	cis	rs6424115	0.965	rs2502979	chr1:24149315	C/A	cg24699146	chr1:24152579	HMGCL	0.26	7.77	0.34	5.25e-14	Immature fraction of reticulocytes;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg06873352	chr17:61820015	STRADA	0.73	13.57	0.53	1.43e-35	Prudent dietary pattern;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.7	-12.87	-0.51	1.29e-32	Obesity-related traits;
LGG	trans	rs3960554	0.867	rs76408713	chr7:75829540	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	11.58	0.47	2.07e-27	Eotaxin levels;
LGG	cis	rs42648	0.869	rs6948139	chr7:89937781	T/A	cg25739043	chr7:89950458	NA	-0.44	-9.27	-0.4	6.89e-19	Homocysteine levels;
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg19635926	chr16:89946313	TCF25	0.74	7.31	0.32	1.19e-12	Skin colour saturation;
LGG	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg08601574	chr20:25228251	PYGB	0.38	7.92	0.35	1.73e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4865875	1.000	rs4610422	chr5:54107893	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-11.32	-0.47	2.12e-26	Longevity;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03517284	chr6:25882590	NA	0.51	9.68	0.41	2.62e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg10523679	chr1:76189770	ACADM	0.71	9.98	0.42	2.18e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7760949	0.889	rs9396272	chr6:13938080	C/T	cg27413430	chr6:13925136	RNF182	-0.47	-7.13	-0.31	3.86e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4771122	0.728	rs1475221	chr13:28037566	C/T	cg01674679	chr13:27998804	GTF3A	0.57	7.56	0.33	2.23e-13	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18036763	chr22:45404910	PHF21B	-0.46	-6.67	-0.3	7.52e-11	Systemic lupus erythematosus;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.73e-15	Electroencephalogram traits;
LGG	cis	rs13314892	0.843	rs4855323	chr3:69807905	G/T	cg17445875	chr3:69859618	MITF	-0.34	-7.0	-0.31	9.31e-12	QRS complex (12-leadsum);
LGG	cis	rs283228	0.958	rs1338156	chr6:101817863	G/A	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs1707322	1.000	rs7547189	chr1:46319514	C/A	cg03146154	chr1:46216737	IPP	0.54	10.52	0.44	2.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.85	-0.78	1.84e-96	Height;
LGG	trans	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19894588	chr14:64061835	NA	0.5	8.48	0.37	2.97e-16	Glioblastoma;Glioma;
LGG	cis	rs6840360	0.554	rs10222838	chr4:152690099	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs501957	chr17:30314504	C/T	cg20587970	chr11:113659929	NA	-1.32	-22.98	-0.73	1.52e-78	Hip circumference adjusted for BMI;
LGG	cis	rs988958	0.675	rs1866668	chr2:42222004	C/T	cg27428208	chr2:42229179	NA	0.55	9.41	0.4	2.34e-19	Hypospadias;
LGG	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg21100191	chr22:23484243	RTDR1	0.98	22.41	0.72	7.45e-76	Bone mineral density;
LGG	cis	rs9814567	0.896	rs10935123	chr3:134345327	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.3	-0.5	2.7e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs727505	1.000	rs10241173	chr7:124453258	A/G	cg23710748	chr7:124431027	NA	-0.51	-9.64	-0.41	3.59e-20	Lewy body disease;
LGG	cis	rs13191362	1.000	rs34931503	chr6:163003876	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9393777	0.920	rs13212562	chr6:27300310	A/G	cg06606381	chr12:133084897	FBRSL1	-0.88	-9.19	-0.39	1.33e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.894	rs12798346	chr11:47583121	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.73	-0.38	4.72e-17	Subjective well-being;
LGG	cis	rs3820068	0.705	rs11584209	chr1:15885041	G/T	cg05660106	chr1:15850417	CASP9	1.17	25.19	0.76	7.94e-89	Systolic blood pressure;
LGG	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg23029597	chr12:123009494	RSRC2	-0.93	-17.24	-0.63	8.29e-52	Body mass index;
LGG	cis	rs12210905	0.688	rs12194842	chr6:27367978	A/C	cg15325629	chr6:28072465	NA	0.91	6.78	0.3	3.76e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg25703541	chr22:24373054	LOC391322	-0.77	-13.23	-0.52	4.03e-34	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2439831	0.867	rs3213990	chr15:43670226	C/A	cg15269541	chr15:43626905	ADAL	-0.44	-7.54	-0.33	2.53e-13	Lung cancer in ever smokers;
LGG	cis	rs9463078	0.715	rs1891411	chr6:44760903	G/C	cg25276700	chr6:44698697	NA	0.43	9.13	0.39	2.1e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg06238570	chr21:40685208	BRWD1	-0.51	-8.3	-0.36	1.15e-15	Cognitive function;
LGG	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-8.18	-0.36	2.82e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18876405	chr7:65276391	NA	0.55	9.88	0.42	5.09e-21	Aortic root size;
LGG	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg17127132	chr2:85788382	GGCX	0.47	8.13	0.35	3.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.8	0.38	2.74e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2242116	0.796	rs7645278	chr3:46974100	A/C	cg02527881	chr3:46936655	PTH1R	-0.33	-7.84	-0.34	3.19e-14	Birth weight;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.49	-0.4	1.25e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	7.03e-19	Diabetic kidney disease;
LGG	cis	rs1062177	1.000	rs2964578	chr5:151147198	T/A	cg00977110	chr5:151150581	G3BP1	0.49	7.91	0.34	1.96e-14	Preschool internalizing problems;
LGG	cis	rs6499255	1.000	rs1139178	chr16:69781468	T/C	cg00738113	chr16:70207722	CLEC18C	-0.3	-6.7	-0.3	6.17e-11	IgE levels;
LGG	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.61	-0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24153754	chr5:149901187	NDST1	0.39	7.09	0.31	5.15e-12	Electrocardiographic conduction measures;
LGG	cis	rs10463316	0.779	rs6871318	chr5:150801545	G/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.21	-0.43	3.41e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg03161606	chr19:29218774	NA	0.76	11.69	0.48	7.96e-28	Methadone dose in opioid dependence;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.29	-0.46	2.84e-26	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.28e-19	Obesity-related traits;
LGG	cis	rs6500395	0.963	rs4785248	chr16:48687947	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg14019146	chr3:50243930	SLC38A3	0.43	9.24	0.39	9.3e-19	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg07167872	chr1:205819463	PM20D1	0.38	7.02	0.31	7.88e-12	Menarche (age at onset);
LGG	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.39	-0.32	7.01e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7289126	0.966	rs2267380	chr22:38631768	T/C	cg25457927	chr22:38595422	NA	-0.32	-7.88	-0.34	2.43e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.37	0.47	1.39e-26	Ovarian reserve;
LGG	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-9.7	-0.41	2.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs5742933	0.779	rs7595020	chr2:190643676	G/A	cg04003228	chr2:190539410	ANKAR	-0.48	-7.0	-0.31	8.87e-12	Ferritin levels;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02071572	chr4:1403502	NA	0.38	7.08	0.31	5.46e-12	Longevity;
LGG	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg24375607	chr4:120327624	NA	0.6	9.77	0.41	1.23e-20	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg05313129	chr8:58192883	C8orf71	-0.76	-10.12	-0.43	7.03e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.54	-0.41	8.13e-20	Lung cancer;
LGG	cis	rs7659604	0.539	rs11098645	chr4:122729251	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	13.64	0.54	7.91e-36	Type 2 diabetes;
LGG	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg12310025	chr6:25882481	NA	-0.63	-11.73	-0.48	5.11e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10540	0.584	rs6598021	chr11:438939	G/C	cg19913688	chr11:428466	ANO9	0.7	10.86	0.45	1.28e-24	Body mass index;
LGG	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg13256891	chr4:100009986	ADH5	0.59	11.58	0.47	2.01e-27	HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg25174290	chr11:3078921	CARS	0.75	16.14	0.6	8.13e-47	Longevity;
LGG	cis	rs4330281	0.669	rs9757339	chr3:17569829	T/C	cg20981856	chr3:17787350	NA	0.38	7.09	0.31	4.93e-12	Schizophrenia;
LGG	cis	rs9644630	1.000	rs6988743	chr8:19369583	C/A	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.34	-0.47	1.75e-26	Oropharynx cancer;
LGG	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.49	-0.56	1.64e-39	Leprosy;
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11191205	0.686	rs75299772	chr10:103418987	G/A	cg15320455	chr10:103880129	LDB1	0.53	7.76	0.34	5.62e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11872342	chr8:125985352	ZNF572	0.44	7.16	0.32	3.12e-12	Gut microbiome composition (summer);
LGG	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg20673091	chr1:2541236	MMEL1	0.77	20.08	0.68	5.45e-65	Ulcerative colitis;
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg06848047	chr4:90757629	SNCA	0.4	7.63	0.33	1.38e-13	Dementia with Lewy bodies;
LGG	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg15704280	chr7:45808275	SEPT13	0.94	19.45	0.67	4.99e-62	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.59	0.37	1.33e-16	Lung cancer;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg13770153	chr20:60521292	NA	-0.51	-8.21	-0.36	2.29e-15	Body mass index;
LGG	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19717773	chr7:2847554	GNA12	-0.38	-8.62	-0.37	1.05e-16	Height;
LGG	cis	rs1190596	0.525	rs6575897	chr14:102647125	G/A	cg23904247	chr14:102554826	HSP90AA1	0.24	6.84	0.3	2.56e-11	Behavioural disinhibition (generation interaction);
LGG	trans	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.31	-0.32	1.16e-12	Neuroticism;
LGG	cis	rs10028187	0.646	rs9997743	chr4:154406794	A/G	cg24020152	chr4:154419554	KIAA0922	0.43	10.09	0.42	9.16e-22	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06028048	chr5:175815674	HIGD2A;NOP16	0.45	6.9	0.31	1.71e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg00149659	chr3:10157352	C3orf10	0.77	9.35	0.4	3.84e-19	Alzheimer's disease;
LGG	cis	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.52	0.37	2.31e-16	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.12	-0.43	7.22e-22	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.65	-0.41	3.3e-20	Retinal vascular caliber;
LGG	cis	rs8044868	0.521	rs7203821	chr16:72101165	T/C	cg23815491	chr16:72088622	HP	0.4	8.38	0.36	6.37e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs11088226	1.000	rs11701091	chr21:33920244	T/A	cg09050820	chr6:167586206	TCP10L2	0.66	9.54	0.41	7.94e-20	Gastritis;
LGG	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg13385794	chr1:248469461	NA	0.46	7.75	0.34	6.05e-14	Common traits (Other);
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg24250549	chr1:154909240	PMVK	0.76	15.52	0.58	5.01e-44	Prostate cancer;
LGG	cis	rs9398803	0.636	rs1262542	chr6:127032008	T/A	cg19875578	chr6:126661172	C6orf173	-0.53	-9.67	-0.41	2.89e-20	Male-pattern baldness;
LGG	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg07150166	chr2:30669952	LCLAT1	0.61	8.56	0.37	1.68e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg23422044	chr7:1970798	MAD1L1	-0.76	-12.38	-0.5	1.33e-30	Bipolar disorder;
LGG	trans	rs2055729	0.677	rs491364	chr8:9758230	G/A	cg06636001	chr8:8085503	FLJ10661	0.46	6.85	0.3	2.34e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.62	0.37	1.08e-16	Platelet count;
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg13047869	chr3:10149882	C3orf24	0.49	8.12	0.35	4.14e-15	Alzheimer's disease;
LGG	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg05729581	chr11:3078854	CARS	0.41	6.71	0.3	5.84e-11	Calcium levels;
LGG	cis	rs950169	1.000	rs950169	chr15:84706461	C/T	cg03959625	chr15:84868606	LOC388152	0.55	8.59	0.37	1.34e-16	Schizophrenia;
LGG	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg18225595	chr11:63971243	STIP1	-0.52	-10.48	-0.44	3.38e-23	Platelet count;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg25554036	chr4:6271136	WFS1	0.57	10.01	0.42	1.77e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9814567	1.000	rs1814336	chr3:134200823	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.79	-0.51	2.84e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7654585	1.000	rs7654585	chr4:25942751	A/G	cg10409131	chr4:25915609	C4orf52	0.51	8.57	0.37	1.52e-16	Obesity-related traits;
LGG	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.56	0.47	2.48e-27	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.5e-14	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.06	-0.42	1.14e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9912468	0.555	rs3744317	chr17:64216644	G/A	cg19474267	chr17:64306194	PRKCA	-0.74	-15.47	-0.58	8.06e-44	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg05863683	chr7:1912471	MAD1L1	0.44	8.52	0.37	2.33e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.87	-0.34	2.56e-14	IgG glycosylation;
LGG	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.88	0.3	1.9e-11	Resting heart rate;
LGG	cis	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg00806126	chr19:22604979	ZNF98	0.64	9.42	0.4	2.15e-19	Pain;
LGG	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.09e-16	Platelet distribution width;
LGG	cis	rs1975974	1.000	rs1985717	chr17:21731807	T/A	cg18423549	chr17:21743878	NA	-0.46	-6.67	-0.3	7.36e-11	Psoriasis;
LGG	cis	rs950027	0.620	rs872192	chr15:45614502	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	11.46	0.47	5.89e-27	Response to fenofibrate (adiponectin levels);
LGG	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg21775007	chr8:11205619	TDH	-0.5	-8.13	-0.35	4.01e-15	Neuroticism;
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.25	0.32	1.71e-12	Height;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg02524346	chr8:600233	NA	1.17	11.68	0.48	8.12e-28	IgG glycosylation;
LGG	cis	rs854765	0.583	rs4925125	chr17:17794444	T/C	cg04398451	chr17:18023971	MYO15A	0.6	11.95	0.49	7.44e-29	Total body bone mineral density;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	9.98e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	7.49	0.33	3.42e-13	Personality dimensions;
LGG	cis	rs735539	1.000	rs9506537	chr13:21280410	T/C	cg04906043	chr13:21280425	IL17D	0.61	10.5	0.44	2.87e-23	Dental caries;
LGG	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.31e-16	Retinal vascular caliber;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs9397585	0.857	rs2152964	chr6:153381725	T/A	cg17707550	chr6:153380415	RGS17	0.62	14.39	0.56	4.54e-39	Body mass index;
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.17	-0.32	2.98e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-15.09	-0.57	3.97e-42	Platelet count;
LGG	cis	rs3812049	0.737	rs1993878	chr5:127476971	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.14	0.43	6.14e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs13424612	0.930	rs12478169	chr2:240951603	C/T	cg01812947	chr2:240904978	NDUFA10	0.41	6.91	0.31	1.62e-11	Odorant perception (isobutyraldehyde);
LGG	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg10891888	chr12:46765615	SLC38A2	-0.4	-6.66	-0.3	7.69e-11	Myopia (pathological);
LGG	cis	rs9916302	0.560	rs3764353	chr17:37790781	T/C	cg07936489	chr17:37558343	FBXL20	-0.75	-11.6	-0.47	1.69e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg25706552	chr1:244017396	NA	0.52	8.34	0.36	8.79e-16	RR interval (heart rate);
LGG	cis	rs867371	0.502	rs3759800	chr15:82532963	A/C	cg00614314	chr15:82944287	LOC80154	-0.44	-7.43	-0.33	5.29e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.79e-15	HDL cholesterol;
LGG	cis	rs9815354	0.672	rs12107296	chr3:41892503	C/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16346588	chr10:242978	ZMYND11	0.4	6.87	0.3	2.05e-11	Psychosis in Alzheimer's disease;
LGG	trans	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.27	-0.7	1.56e-70	Blood pressure (smoking interaction);
LGG	cis	rs2652822	0.662	rs34367270	chr15:63410912	G/A	cg02713581	chr15:63449717	RPS27L	0.42	7.08	0.31	5.48e-12	Metabolic traits;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg24623649	chr8:11872141	NA	-0.3	-6.81	-0.3	3.11e-11	Neuroticism;
LGG	cis	rs72781680	1.000	rs12616985	chr2:24165511	A/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg20887711	chr4:1340912	KIAA1530	0.49	9.13	0.39	2.14e-18	Obesity-related traits;
LGG	cis	rs4926611	0.931	rs4927019	chr1:54085048	C/T	cg23596471	chr1:54105337	GLIS1	0.41	8.18	0.36	2.81e-15	Hand grip strength;
LGG	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-12.19	-0.49	7.84e-30	Monocyte count;
LGG	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	7.89	0.34	2.21e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4926611	0.798	rs12140369	chr1:54047882	A/T	cg23596471	chr1:54105337	GLIS1	0.38	7.89	0.34	2.18e-14	Hand grip strength;
LGG	cis	rs8180040	0.934	rs4858811	chr3:47480524	G/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.67e-44	Colorectal cancer;
LGG	cis	rs11920090	0.932	rs12495622	chr3:170684878	A/G	cg09710316	chr3:170744871	SLC2A2	0.58	8.33	0.36	9.28e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	8.2	0.36	2.45e-15	Personality dimensions;
LGG	cis	rs7928758	0.943	rs877456	chr11:134265315	T/C	cg15243474	chr11:134282918	B3GAT1	1.19	15.37	0.58	2.23e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs853679	0.546	rs36092177	chr6:28357807	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs9534288	0.699	rs4280137	chr13:46664008	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-13.83	-0.54	1.17e-36	Blood protein levels;
LGG	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg12011299	chr4:100065546	ADH4	0.42	8.33	0.36	9.27e-16	Alcohol dependence;
LGG	cis	rs67311347	1.000	rs951560	chr3:40463471	A/G	cg13683864	chr3:40499215	RPL14	-0.98	-20.45	-0.69	1.04e-66	Renal cell carcinoma;
LGG	cis	rs6547631	0.592	rs13408224	chr2:85923936	C/T	cg19805943	chr2:85933069	NA	0.32	6.73	0.3	5.17e-11	Blood protein levels;
LGG	cis	rs6032067	0.777	rs13042694	chr20:43799368	G/A	cg10761708	chr20:43804764	PI3	0.75	11.75	0.48	4.39e-28	Blood protein levels;
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg05555928	chr11:63887634	MACROD1	-0.77	-10.35	-0.43	9.67e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3784262	1.000	rs12907038	chr15:58244032	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.14	-0.35	3.67e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07659893	chr17:61819838	STRADA	0.48	7.91	0.34	1.98e-14	Prudent dietary pattern;
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.44	0.4	1.87e-19	Bipolar disorder;
LGG	cis	rs61332075	0.518	rs6749508	chr2:239456243	C/T	cg18131467	chr2:239335373	ASB1	-0.63	-7.52	-0.33	2.92e-13	Lung function (FEV1/FVC);
LGG	cis	rs227833	1.000	rs227832	chr6:44681257	T/C	cg20913747	chr6:44695427	NA	0.46	7.79	0.34	4.36e-14	Monobrow;
LGG	cis	rs2439831	0.702	rs9989313	chr15:44152817	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.49	0.4	1.26e-19	Lung cancer in ever smokers;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg26043149	chr18:55253948	FECH	0.42	6.96	0.31	1.16e-11	Bone mineral density;
LGG	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg24642844	chr7:1081250	C7orf50	-0.76	-9.87	-0.42	5.77e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs938554	0.829	rs5028843	chr4:9940806	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	6.96	0.31	1.19e-11	Blood metabolite levels;
LGG	cis	rs2688419	0.545	rs6550719	chr3:23072185	C/G	cg00327796	chr3:23032191	NA	-0.35	-6.86	-0.3	2.22e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.31	5.36e-12	Lung cancer;
LGG	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.06	11.47	0.47	5.36e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2249694	0.509	rs9419072	chr10:135310445	G/A	cg20169779	chr10:135381914	SYCE1	0.61	8.37	0.36	7.02e-16	Obesity-related traits;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg26752003	chr8:145688521	CYHR1	0.52	10.39	0.43	7.02e-23	Age at first birth;
LGG	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg17054900	chr3:154042577	DHX36	0.5	7.53	0.33	2.72e-13	Coronary artery disease;
LGG	trans	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg25214090	chr10:38739885	LOC399744	0.62	10.76	0.45	3.1e-24	Corneal astigmatism;
LGG	cis	rs11018874	0.709	rs11018854	chr11:89835191	A/G	cg21153622	chr11:89784906	NA	-0.62	-6.81	-0.3	3.04e-11	White blood cell types;
LGG	cis	rs17376456	1.000	rs34756085	chr5:93556294	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg26516362	chr5:178986906	RUFY1	-0.44	-7.66	-0.34	1.11e-13	Lung cancer;
LGG	cis	rs4665809	0.877	rs34536218	chr2:26287376	T/A	cg22920501	chr2:26401640	FAM59B	0.41	7.58	0.33	1.95e-13	Gut microbiome composition (summer);
LGG	trans	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg21775007	chr8:11205619	TDH	0.46	7.3	0.32	1.27e-12	Morning vs. evening chronotype;
LGG	cis	rs1062753	0.527	rs6519296	chr22:42348602	G/C	cg15128208	chr22:42549153	NA	0.39	7.07	0.31	5.64e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7103648	0.669	rs7131262	chr11:47836302	T/A	cg20307385	chr11:47447363	PSMC3	0.81	16.08	0.6	1.49e-46	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs62460802	1	rs62460802	chr7:83052869	G/A	cg14519356	chr7:83097669	SEMA3E	0.27	7.56	0.33	2.13e-13	Lobe attachment (rater scored);
LGG	cis	rs7106204	0.686	rs12790317	chr11:24254405	T/C	ch.11.24196551F	chr11:24239977	NA	0.88	10.53	0.44	2.23e-23	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-8.61	-0.37	1.12e-16	Schizophrenia;
LGG	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg06481639	chr22:41940642	POLR3H	0.54	7.86	0.34	2.7e-14	Vitiligo;
LGG	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg23625390	chr15:77176239	SCAPER	-0.74	-14.61	-0.56	4.96e-40	Blood metabolite levels;
LGG	cis	rs935334	1.000	rs2121071	chr14:76665477	C/T	cg14073839	chr14:76668648	C14orf118	-0.42	-7.01	-0.31	8.63e-12	Blood pressure;
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.17	0.62	1.69e-51	Alzheimer's disease;
LGG	trans	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.27	0.5	3.79e-30	Type 2 diabetes;
LGG	cis	rs12477438	0.684	rs6756880	chr2:99676991	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg26031613	chr14:104095156	KLC1	-0.61	-9.75	-0.41	1.54e-20	Reticulocyte count;
LGG	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01055543	chr2:27994702	MRPL33	0.46	7.35	0.32	9.24e-13	Gut microbiome composition (summer);
LGG	cis	rs273218	0.573	rs11742692	chr5:53343576	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.94	-14.07	-0.55	1.07e-37	Migraine;
LGG	cis	rs4268898	0.722	rs12185638	chr2:24382030	C/G	cg06627628	chr2:24431161	ITSN2	0.48	7.78	0.34	4.67e-14	Asthma;
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.37	-0.5	1.48e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg12458913	chr13:53173898	NA	0.67	13.3	0.53	2.14e-34	Lewy body disease;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg08621203	chr6:150244597	RAET1G	0.43	7.28	0.32	1.41e-12	Lung cancer;
LGG	trans	rs2204008	0.575	rs10444564	chr12:38043782	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.88e-18	Bladder cancer;
LGG	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.18e-19	Chronic lymphocytic leukemia;
LGG	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.62	-0.48	1.41e-27	Hemoglobin concentration;
LGG	cis	rs3796352	1.000	rs34244302	chr3:53102236	C/G	cg12962167	chr3:53033115	SFMBT1	0.77	8.06	0.35	6.65e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg15627072	chr1:2432621	PLCH2	-0.38	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs585510	1	rs585510	chr12:121000133	A/G	cg12219531	chr12:120966889	COQ5	0.66	11.07	0.46	1.95e-25	Reticulocyte fraction of red cells;
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.49	0.33	3.44e-13	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.54	-0.41	8.4e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs11191205	0.644	rs10883665	chr10:103374233	G/A	cg15320455	chr10:103880129	LDB1	0.48	7.02	0.31	7.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.77	0.34	5.16e-14	Neuroticism;
LGG	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg11871910	chr12:69753446	YEATS4	0.42	6.68	0.3	7.06e-11	Response to diuretic therapy;
LGG	cis	rs6504108	0.624	rs954226	chr17:46304812	T/A	cg02219949	chr17:45927392	SP6	0.43	7.92	0.35	1.82e-14	Body mass index;
LGG	cis	rs9815354	1.000	rs1717014	chr3:41917395	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg13206674	chr6:150067644	NUP43	0.65	14.39	0.56	4.57e-39	Lung cancer;
LGG	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg07382826	chr16:28625726	SULT1A1	0.38	7.85	0.34	2.85e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	11.78	0.48	3.52e-28	Lymphocyte counts;
LGG	cis	rs9916302	0.904	rs7208274	chr17:37513796	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg13271783	chr10:134563150	INPP5A	-0.53	-8.37	-0.36	6.97e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9796	0.870	rs11855248	chr15:41276158	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.2	-0.36	2.32e-15	Menopause (age at onset);
LGG	trans	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg05059571	chr16:84539110	KIAA1609	-0.45	-8.26	-0.36	1.57e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs210138	1.000	rs210138	chr6:33542538	C/T	cg04201373	chr6:33551533	GGNBP1	-0.35	-6.9	-0.31	1.68e-11	Testicular germ cell tumor;
LGG	cis	rs763121	0.853	rs6001185	chr22:39052155	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.06	-0.42	1.19e-21	Lung cancer;
LGG	cis	rs7712401	0.601	rs173480	chr5:122254131	C/A	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs6964587	0.869	rs2013334	chr7:91549657	G/A	cg17063962	chr7:91808500	NA	-0.44	-7.9	-0.34	2.08e-14	Breast cancer;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg14159672	chr1:205819179	PM20D1	0.9	21.55	0.71	7.16e-72	Menarche (age at onset);
LGG	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg03727229	chr11:118479170	PHLDB1	0.48	8.42	0.36	4.73e-16	Systemic lupus erythematosus;
LGG	cis	rs990171	0.955	rs4070554	chr2:103074493	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.93	-0.38	1.04e-17	Lymphocyte counts;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg15921436	chr17:44337874	NA	0.57	12.18	0.49	8.54e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg01988459	chr11:68622903	NA	-0.64	-12.36	-0.5	1.55e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.606	rs7663216	chr4:99088385	A/C	cg05340658	chr4:99064831	C4orf37	0.42	6.84	0.3	2.49e-11	Colonoscopy-negative controls vs population controls;
LGG	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg17145862	chr1:211918768	LPGAT1	0.77	16.28	0.6	2e-47	Leprosy;
LGG	cis	rs9398803	0.673	rs1262556	chr6:127054435	G/C	cg19875578	chr6:126661172	C6orf173	-0.51	-9.25	-0.4	8.13e-19	Male-pattern baldness;
LGG	cis	rs9677476	0.909	rs60240472	chr2:232131217	A/G	cg23338755	chr2:231921595	PSMD1	0.47	6.96	0.31	1.15e-11	Food antigen IgG levels;
LGG	cis	rs2230307	0.536	rs506044	chr1:100611931	A/G	cg24955406	chr1:100503596	HIAT1	-0.58	-7.97	-0.35	1.22e-14	Carotid intima media thickness;
LGG	cis	rs7582720	1.000	rs75869289	chr2:203806724	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10189230	0.967	rs13012331	chr2:222350600	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg15596359	chr8:11213517	TDH	-0.34	-6.87	-0.3	2.14e-11	Retinal vascular caliber;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg11965913	chr1:205819406	PM20D1	0.51	8.06	0.35	6.79e-15	Prostate-specific antigen levels;
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07243736	chr16:783730	NARFL	0.39	6.75	0.3	4.5e-11	Height;
LGG	cis	rs896854	0.654	rs1453377	chr8:95969947	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.93	-0.38	1e-17	Type 2 diabetes;
LGG	cis	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg22857025	chr5:266934	NA	-1.53	-25.04	-0.76	3.96e-88	Breast cancer;
LGG	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg11890956	chr21:40555474	PSMG1	-0.97	-20.36	-0.69	2.91e-66	Cognitive function;
LGG	cis	rs7166081	1.000	rs11071942	chr15:67516948	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4919087	0.590	rs1253400	chr10:99049566	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-6.95	-0.31	1.27e-11	Monocyte count;
LGG	cis	rs4474465	0.679	rs4945288	chr11:78244823	C/A	cg02023728	chr11:77925099	USP35	-0.41	-7.31	-0.32	1.16e-12	Alzheimer's disease (survival time);
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.12	-0.31	4.02e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg26695010	chr11:65641043	EFEMP2	0.51	8.7	0.37	5.82e-17	Eosinophil percentage of white cells;
LGG	cis	rs6800768	0.636	rs11927256	chr3:24091463	T/C	cg10674438	chr3:24145617	LOC152024	-0.33	-6.74	-0.3	4.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg11789530	chr4:8429930	ACOX3	-0.89	-17.84	-0.64	1.4e-54	Response to antineoplastic agents;
LGG	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg26267310	chr19:49340593	PLEKHA4;HSD17B14	0.56	7.8	0.34	4.03e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.82	0.45	1.84e-24	Systolic blood pressure;
LGG	cis	rs3849046	0.817	rs4835689	chr5:137915767	T/A	cg10920316	chr5:137946599	NA	0.43	6.86	0.3	2.2e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg09461388	chr22:46763229	CELSR1	-0.67	-7.06	-0.31	6e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22857025	chr5:266934	NA	1.5	27.07	0.78	1.96e-97	Breast cancer;
LGG	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg00990874	chr7:1149470	C7orf50	-0.84	-15.33	-0.58	3.51e-43	Bronchopulmonary dysplasia;
LGG	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg00204512	chr16:28754710	NA	0.25	7.15	0.32	3.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg18963800	chr10:38644991	HSD17B7P2	-0.41	-6.9	-0.31	1.75e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg01631408	chr1:248437212	OR2T33	-0.39	-7.06	-0.31	6.05e-12	Common traits (Other);
LGG	cis	rs9547996	0.879	rs17197908	chr13:38175744	G/T	cg13634560	chr13:38173852	POSTN	-0.35	-6.84	-0.3	2.53e-11	Diastolic blood pressure;
LGG	cis	rs778371	1.000	rs778370	chr2:233743363	C/T	cg08000102	chr2:233561755	GIGYF2	-0.66	-10.49	-0.44	3.07e-23	Schizophrenia;
LGG	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg07636037	chr3:49044803	WDR6	1.02	23.22	0.73	1.12e-79	Parkinson's disease;
LGG	cis	rs240764	0.658	rs4840155	chr6:101253942	G/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	cis	rs911263	0.603	rs12892777	chr14:68778913	T/G	cg18825221	chr14:68749962	RAD51L1	0.36	7.9	0.34	2.07e-14	Primary biliary cholangitis;
LGG	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg17230874	chr3:125932073	NA	0.68	12.78	0.51	3.09e-32	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg07520158	chr7:32535189	LSM5;AVL9	0.58	9.67	0.41	2.98e-20	Cognitive ability;
LGG	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg05484508	chr16:89589025	SPG7	0.47	7.13	0.31	3.95e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg00405596	chr8:11794950	NA	-0.6	-10.58	-0.44	1.39e-23	Monocyte count;
LGG	cis	rs243505	0.624	rs6975291	chr7:148548393	C/G	cg18940274	chr7:148469757	CUL1	-0.35	-6.7	-0.3	5.9e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9828933	0.752	rs12633353	chr3:63970280	T/C	cg17941049	chr3:63904683	ATXN7	0.69	7.08	0.31	5.48e-12	Type 2 diabetes;
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg20913747	chr6:44695427	NA	-0.65	-11.16	-0.46	8.74e-26	Total body bone mineral density;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10289190	chr9:37422575	GRHPR	0.41	6.84	0.3	2.59e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs853679	0.713	rs200991	chr6:27815494	A/C	cg01620082	chr3:125678407	NA	0.51	6.83	0.3	2.73e-11	Depression;
LGG	cis	rs13088318	0.504	rs55759062	chr3:101202152	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.39	-7.39	-0.32	7.08e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.01e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs3923380	0.607	rs17002080	chr4:77464524	A/G	cg07933720	chr4:77468187	SHROOM3	-0.33	-7.15	-0.32	3.49e-12	Craniofacial microsomia;
LGG	cis	rs7236492	0.572	rs7237333	chr18:77178511	G/A	cg05753993	chr18:77199432	NFATC1	0.41	6.75	0.3	4.47e-11	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg19894588	chr14:64061835	NA	0.63	10.28	0.43	1.82e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg25019033	chr10:957182	NA	-0.54	-9.04	-0.39	4.17e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg26043149	chr18:55253948	FECH	0.46	7.97	0.35	1.22e-14	Bone mineral density;
LGG	cis	rs651907	0.557	rs11917682	chr3:101355427	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.04	0.35	7.77e-15	Colorectal cancer;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs12200782	1.000	rs3927423	chr6:26393487	C/T	cg11502198	chr6:26597334	ABT1	-0.84	-6.94	-0.31	1.31e-11	Small cell lung carcinoma;
LGG	cis	rs10791323	0.559	rs10750548	chr11:133729469	A/G	cg00579200	chr11:133705235	NA	-0.59	-11.28	-0.46	3.01e-26	Childhood ear infection;
LGG	cis	rs6076065	0.802	rs2424527	chr20:23357329	A/C	cg11657817	chr20:23433608	CST11	0.39	8.0	0.35	1.03e-14	Facial morphology (factor 15, philtrum width);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03630683	chr3:4534997	ITPR1	0.46	7.16	0.32	3.16e-12	Gut microbiome composition (summer);
LGG	trans	rs3960554	0.808	rs78587454	chr7:75688672	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.22	0.49	5.75e-30	Eotaxin levels;
LGG	cis	rs10421328	1.000	rs10421328	chr19:19776814	C/T	cg11584989	chr19:19387371	SF4	0.44	6.72	0.3	5.29e-11	Parental longevity (combined parental age at death);
LGG	cis	rs921968	0.541	rs526897	chr2:219433597	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.82	-0.3	2.9e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg12929805	chr1:2399054	NA	-0.51	-10.44	-0.44	4.58e-23	Non-obstructive azoospermia;
LGG	cis	rs4363385	0.643	rs11576457	chr1:152918556	C/T	cg13444842	chr1:152974279	SPRR3	0.42	7.93	0.35	1.71e-14	Inflammatory skin disease;
LGG	cis	rs883115	0.748	rs969027	chr1:224766762	C/T	cg01808320	chr1:224927238	CNIH3	-0.42	-7.74	-0.34	6.14e-14	Cancer;
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg18538332	chr22:24372958	LOC391322	-0.48	-7.99	-0.35	1.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3806843	1.000	rs1548699	chr5:140164918	T/C	cg19875535	chr5:140030758	IK	0.51	10.67	0.44	6.5e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs8012	0.517	rs1060218	chr19:13008607	G/T	cg06417478	chr19:12876846	HOOK2	-0.4	-6.66	-0.3	7.87e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs7917772	0.636	rs4919676	chr10:104524352	C/T	cg04362960	chr10:104952993	NT5C2	0.48	7.99	0.35	1.05e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg08048268	chr3:133502702	NA	0.68	12.69	0.51	6.83e-32	Iron status biomarkers;
LGG	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg02711726	chr17:80685570	FN3KRP	0.39	7.76	0.34	5.32e-14	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16600119	chr3:129033604	NA	0.51	7.9	0.34	2.09e-14	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02018176	chr4:1364513	KIAA1530	0.47	11.64	0.48	1.22e-27	Longevity;
LGG	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg23057051	chr16:89984268	MC1R	-0.36	-6.76	-0.3	4.22e-11	Vitiligo;
LGG	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg08975724	chr8:8085496	FLJ10661	0.39	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs2370759	1.000	rs79487858	chr10:32616405	T/C	cg01819863	chr10:32635814	EPC1	1.11	15.46	0.58	9.12e-44	Sexual dysfunction (female);
LGG	cis	rs6977660	1.000	rs10240227	chr7:19823188	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	8.96	0.38	8e-18	Thyroid stimulating hormone;
LGG	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.96	0.54	3.28e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00873037	chr8:11626984	NEIL2	0.47	6.8	0.3	3.19e-11	Gut microbiome composition (summer);
LGG	trans	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg20587970	chr11:113659929	NA	1.06	15.99	0.6	3.68e-46	Hip circumference adjusted for BMI;
LGG	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg16662043	chr16:48846231	NA	0.38	7.38	0.32	7.39e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.57	-0.37	1.56e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs919433	0.713	rs2045245	chr2:198485341	A/C	cg00792783	chr2:198669748	PLCL1	0.51	8.1	0.35	5.03e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs55788414	1.000	rs28395434	chr16:81182222	G/A	cg06400318	chr16:81190750	PKD1L2	-0.92	-11.0	-0.46	3.83e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs1729951	0.546	rs835634	chr3:136676303	C/T	cg12473912	chr3:136751656	NA	0.43	7.65	0.33	1.22e-13	Neuroticism;
LGG	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.15	-0.35	3.49e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-10.55	-0.44	1.85e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4538187	0.760	rs35697586	chr2:64181216	A/T	cg19915305	chr2:64069682	UGP2	-0.65	-11.5	-0.47	4.24e-27	Systolic blood pressure;
LGG	cis	rs9341808	0.754	rs6918172	chr6:81019242	A/G	cg08355045	chr6:80787529	NA	0.39	7.7	0.34	8.47e-14	Sitting height ratio;
LGG	cis	rs3126085	0.515	rs1923503	chr1:152360820	G/A	cg26876637	chr1:152193138	HRNR	-0.43	-6.67	-0.3	7.24e-11	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08286599	chr2:191208694	INPP1	0.53	8.19	0.36	2.52e-15	Gut microbiome composition (summer);
LGG	cis	rs1348850	0.914	rs2364854	chr2:178378452	T/A	cg27490568	chr2:178487706	NA	0.47	9.36	0.4	3.54e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg16339924	chr4:17578868	LAP3	0.64	11.03	0.46	2.85e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg13271783	chr10:134563150	INPP5A	-0.59	-8.67	-0.37	7.24e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.57	-9.41	-0.4	2.28e-19	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs4851266	1.000	rs11691409	chr2:100826165	T/A	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg24764310	chr7:157512201	PTPRN2	-0.47	-10.19	-0.43	3.79e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.84	-0.51	1.68e-32	Uric acid levels;
LGG	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg08250081	chr4:10125330	NA	-0.38	-7.34	-0.32	9.57e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6495122	0.501	rs12101482	chr15:75344784	A/T	cg17294928	chr15:75287854	SCAMP5	-0.56	-10.44	-0.44	4.74e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03264133	chr6:25882463	NA	-0.63	-11.57	-0.47	2.34e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs896854	0.653	rs13266313	chr8:95975302	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg20608306	chr11:116969690	SIK3	0.41	13.15	0.52	8.97e-34	Blood protein levels;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg19635926	chr16:89946313	TCF25	0.73	7.06	0.31	6.15e-12	Skin colour saturation;
LGG	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.89	-0.3	1.89e-11	Bipolar disorder;
LGG	trans	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-7.64	-0.33	1.28e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg17830980	chr10:43048298	ZNF37B	-0.38	-8.18	-0.36	2.81e-15	Extrinsic epigenetic age acceleration;
LGG	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg24812749	chr6:127587940	RNF146	0.69	11.43	0.47	8.19e-27	Breast cancer;
LGG	cis	rs755249	0.501	rs2484133	chr1:39653994	T/C	cg18385671	chr1:39797026	MACF1	0.49	9.59	0.41	5.69e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg12395012	chr8:11607386	GATA4	-0.39	-7.17	-0.32	2.91e-12	Monocyte count;
LGG	cis	rs397969	0.646	rs850622	chr17:19837536	C/T	cg13482628	chr17:19912719	NA	0.49	8.12	0.35	4.21e-15	Platelet count;
LGG	cis	rs6546550	0.900	rs897122	chr2:70140271	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs7523273	0.565	rs2796232	chr1:207900368	T/A	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.69	-0.37	6.53e-17	Schizophrenia;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.23	-0.32	1.95e-12	Refractive error;
LGG	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg13334819	chr7:99746414	C7orf59	-0.45	-6.99	-0.31	9.71e-12	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	7.33e-21	Common traits (Other);
LGG	trans	rs853679	0.607	rs35345226	chr6:28091580	A/G	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg05484376	chr2:27715224	FNDC4	0.47	10.15	0.43	5.56e-22	Total body bone mineral density;
LGG	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.27	-0.32	1.55e-12	Lung cancer in ever smokers;
LGG	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.63	-0.44	9.3e-24	Hip circumference adjusted for BMI;
LGG	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg07541023	chr7:19748670	TWISTNB	0.61	8.47	0.37	3.17e-16	Thyroid stimulating hormone;
LGG	cis	rs96067	0.652	rs274132	chr1:36581978	C/T	cg27506609	chr1:36549197	TEKT2	0.51	6.67	0.3	7.34e-11	Corneal structure;
LGG	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.8	0.34	4.04e-14	Retinal vascular caliber;
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg20790798	chr5:1857306	NA	-0.43	-7.0	-0.31	8.77e-12	Cardiovascular disease risk factors;
LGG	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg10792982	chr14:105748885	BRF1	0.66	12.89	0.51	1.06e-32	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	24.3	0.75	1.07e-84	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg05444541	chr17:17804740	TOM1L2	-0.57	-11.89	-0.48	1.28e-28	Total body bone mineral density;
LGG	cis	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg21775007	chr8:11205619	TDH	-0.78	-13.64	-0.54	7.32e-36	Retinal vascular caliber;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.67e-25	Aortic root size;
LGG	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg13010199	chr12:38710504	ALG10B	0.44	8.27	0.36	1.43e-15	Morning vs. evening chronotype;
LGG	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg21644426	chr2:191273491	MFSD6	-0.56	-9.42	-0.4	2.15e-19	Pulse pressure;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg08208917	chr15:42565872	GANC;TMEM87A	0.4	6.89	0.3	1.86e-11	Body mass index;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9649465	0.967	rs13225110	chr7:123340849	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.85	-0.38	1.87e-17	Migraine;
LGG	cis	rs6977940	0.818	rs73033460	chr7:2900662	C/T	cg19731401	chr7:2775893	GNA12	0.37	7.11	0.31	4.44e-12	White matter integrity;
LGG	trans	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.7	10.94	0.45	6.38e-25	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg02127607	chr17:61920694	SMARCD2	-0.44	-7.87	-0.34	2.58e-14	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs2489048	chr10:102348497	G/T	cg07570687	chr10:102243282	WNT8B	0.42	7.11	0.31	4.47e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg18335740	chr13:41363409	SLC25A15	0.5	8.76	0.38	3.81e-17	Lewy body disease;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg22907277	chr7:1156413	C7orf50	0.85	15.05	0.57	5.82e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7914558	1.000	rs10786733	chr10:104794947	G/A	cg04362960	chr10:104952993	NT5C2	0.55	10.52	0.44	2.42e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs722599	0.748	rs17102884	chr14:75374899	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-9.95	-0.42	2.95e-21	IgG glycosylation;
LGG	cis	rs10170846	0.731	rs10180632	chr2:223526384	G/A	cg25565276	chr2:223520875	FARSB	0.64	11.26	0.46	3.69e-26	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs6754311	0.509	rs12616520	chr2:136516748	A/T	cg07169764	chr2:136633963	MCM6	-0.84	-15.15	-0.58	2.05e-42	Mosquito bite size;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.76	-0.38	3.77e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1620921	0.505	rs4708882	chr6:161203182	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg08989290	chr16:615782	NHLRC4	0.33	6.7	0.3	6.19e-11	Height;
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.95	-0.35	1.42e-14	Neuroticism;
LGG	cis	rs11039131	0.629	rs67871383	chr11:47335838	T/C	cg20307385	chr11:47447363	PSMC3	-0.45	-7.72	-0.34	7.28e-14	Schizophrenia;
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19723775	chr5:179050963	HNRNPH1	0.45	7.44	0.33	5e-13	Lung cancer;
LGG	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg16268157	chr7:99778414	STAG3	-0.5	-8.43	-0.36	4.26e-16	Lung function (FEV1/FVC);
LGG	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg11764359	chr7:65958608	NA	-0.63	-10.87	-0.45	1.14e-24	Aortic root size;
LGG	cis	rs7216064	0.953	rs75231441	chr17:65885485	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7172677	1.000	rs4886658	chr15:75414536	A/C	cg14664628	chr15:75095509	CSK	-0.48	-7.27	-0.32	1.51e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1949733	0.656	rs2688224	chr4:8404700	C/G	cg11789530	chr4:8429930	ACOX3	0.74	14.71	0.56	1.79e-40	Response to antineoplastic agents;
LGG	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg06138931	chr13:21896616	NA	0.54	8.72	0.38	4.93e-17	White matter hyperintensity burden;
LGG	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg06271696	chr7:157225062	NA	-0.54	-11.54	-0.47	3.02e-27	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07923666	chr12:49932857	KCNH3	-0.5	-7.79	-0.34	4.3e-14	Resting heart rate;
LGG	trans	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs7172689	1.000	rs8028334	chr15:81548981	A/G	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg11764359	chr7:65958608	NA	0.63	10.77	0.45	2.75e-24	Aortic root size;
LGG	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg19761014	chr17:28927070	LRRC37B2	0.7	8.85	0.38	1.89e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs877282	0.583	rs12358255	chr10:828626	C/T	cg01169559	chr10:831247	NA	0.52	9.09	0.39	2.91e-18	Uric acid levels;
LGG	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg08344181	chr3:125677491	NA	-0.81	-7.62	-0.33	1.46e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs17331151	0.573	rs77223362	chr3:52865125	G/A	cg04865290	chr3:52927548	TMEM110	-0.42	-7.16	-0.32	3.28e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6938	0.618	rs12912839	chr15:75221245	C/T	cg09165964	chr15:75287851	SCAMP5	0.68	12.85	0.51	1.57e-32	Breast cancer;
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg11764359	chr7:65958608	NA	0.73	13.15	0.52	8.61e-34	Aortic root size;
LGG	cis	rs11168187	0.943	rs12812460	chr12:48098562	G/A	cg12761788	chr12:48120090	P11	0.49	7.74	0.34	6.09e-14	Vertical cup-disc ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12838843	chr3:141205758	RASA2	0.44	6.67	0.3	7.3e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.71	-0.45	4.77e-24	Lung cancer;
LGG	cis	rs9790314	0.875	rs459515	chr3:161092351	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-15.89	-0.59	1.1e-45	Morning vs. evening chronotype;
LGG	cis	rs526231	0.511	rs17155009	chr5:102374144	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.43	-0.36	4.43e-16	Primary biliary cholangitis;
LGG	cis	rs2153535	0.580	rs9406143	chr6:8444583	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16632433	chr5:180649677	TRIM41	0.41	6.96	0.31	1.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2370759	0.891	rs11592754	chr10:32619572	A/C	cg01819863	chr10:32635814	EPC1	1.07	13.0	0.52	3.53e-33	Sexual dysfunction (female);
LGG	cis	rs889312	0.500	rs865570	chr5:56161975	C/T	cg14703610	chr5:56206110	C5orf35	0.42	7.44	0.33	4.9e-13	Breast cancer;Breast cancer (early onset);
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg11352418	chr22:48886654	FAM19A5	0.38	6.66	0.3	7.77e-11	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03459952	chr17:58754990	BCAS3	0.45	6.75	0.3	4.45e-11	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg26384229	chr12:38710491	ALG10B	0.64	12.19	0.49	7.96e-30	Morning vs. evening chronotype;
LGG	trans	rs11782517	1.000	rs11782517	chr8:10113507	T/C	cg16141378	chr3:129829833	LOC729375	-0.38	-7.07	-0.31	5.81e-12	Nose size;
LGG	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs477895	1.000	rs2276014	chr11:64081445	G/A	cg22916017	chr11:64110731	CCDC88B	-0.52	-7.08	-0.31	5.48e-12	Mean platelet volume;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg10360139	chr7:1886902	MAD1L1	-0.4	-7.06	-0.31	5.98e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg01403660	chr11:68851641	TPCN2	0.46	6.98	0.31	1.01e-11	Blond vs. brown hair color;
LGG	cis	rs3206736	0.578	rs6462595	chr7:35224327	C/T	cg13400248	chr7:35225412	NA	0.39	7.06	0.31	6.24e-12	Diastolic blood pressure;
LGG	cis	rs9393813	0.626	rs9357038	chr6:27334573	G/A	cg18711553	chr6:27366782	ZNF391	0.51	9.83	0.42	7.54e-21	Bipolar disorder;
LGG	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg04132146	chr6:87862158	NA	-0.38	-6.77	-0.3	3.87e-11	Monocyte percentage of white cells;
LGG	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.2	-0.46	6.3e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg04287289	chr16:89883240	FANCA	0.89	8.67	0.37	7.41e-17	Skin colour saturation;
LGG	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg26913058	chr16:419975	MRPL28	-0.48	-7.53	-0.33	2.66e-13	Body mass index;
LGG	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-10.1	-0.43	8.06e-22	Hepatocellular carcinoma;
LGG	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg02403541	chr12:121454288	C12orf43	0.63	9.98	0.42	2.24e-21	N-glycan levels;
LGG	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg17054900	chr3:154042577	DHX36	0.49	7.39	0.32	7.06e-13	Coronary artery disease;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.93	-0.31	1.42e-11	Lung cancer;
LGG	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg00343986	chr7:65444356	GUSB	-0.48	-8.29	-0.36	1.25e-15	Aortic root size;
LGG	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg11266682	chr4:10021025	SLC2A9	0.55	11.2	0.46	6.34e-26	Bone mineral density;
LGG	cis	rs7216064	0.953	rs11871285	chr17:65840809	G/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.82	-0.38	2.32e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs12220238	1.000	rs11000894	chr10:75906598	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.1	0.46	1.58e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7849585	0.792	rs11103398	chr9:139134474	T/C	cg14094347	chr9:139131620	QSOX2	-0.5	-9.56	-0.41	6.73e-20	Height;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.67	-0.37	7.54e-17	Personality dimensions;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg14004847	chr7:1930337	MAD1L1	0.52	8.69	0.37	6.23e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg13009111	chr11:71350975	NA	-0.33	-7.16	-0.32	3.26e-12	Monocyte count;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg06347212	chr1:228270676	ARF1	0.46	6.82	0.3	2.82e-11	Hip circumference;
LGG	cis	rs72781680	1.000	rs72796388	chr2:24171509	A/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs2273669	0.667	rs12198088	chr6:109338433	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05025164	chr4:1340916	KIAA1530	0.89	17.73	0.64	4.7e-54	Longevity;
LGG	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg13009111	chr11:71350975	NA	-0.32	-7.11	-0.31	4.48e-12	Monocyte count;
LGG	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg03284175	chr1:146643471	PRKAB2	-0.48	-7.44	-0.33	4.86e-13	Coronary artery disease;
LGG	cis	rs6665290	0.669	rs3768424	chr1:227177444	A/G	cg05696931	chr1:227175867	NA	-0.42	-8.49	-0.37	2.88e-16	Myeloid white cell count;
LGG	cis	rs35160687	0.623	rs35408390	chr2:86471782	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.39	7.25	0.32	1.72e-12	Night sleep phenotypes;
LGG	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg14675211	chr2:100938903	LONRF2	0.64	11.61	0.47	1.58e-27	Intelligence (multi-trait analysis);
LGG	cis	rs12453935	0.627	rs12602103	chr17:59913158	G/T	cg14757157	chr17:59911755	BRIP1	0.31	6.98	0.31	1.02e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.59	0.37	1.36e-16	Bipolar disorder;
LGG	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg06022373	chr22:39101656	GTPBP1	0.9	18.41	0.65	3.49e-57	Menopause (age at onset);
LGG	cis	rs7267979	0.966	rs2261785	chr20:25262403	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.05	0.42	1.26e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.47e-13	Lung cancer;
LGG	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg20503657	chr10:835505	NA	0.62	9.32	0.4	4.78e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-9.8	-0.41	1.01e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg10587741	chr22:38071170	LGALS1	0.83	22.14	0.72	1.32e-74	Fat distribution (HIV);
LGG	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.52e-22	Diabetic kidney disease;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg05313129	chr8:58192883	C8orf71	-0.68	-8.74	-0.38	4.4e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs77956314	0.515	rs10850733	chr12:117380961	G/A	cg02017074	chr12:117425053	FBXW8	0.57	7.86	0.34	2.62e-14	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs7020830	0.898	rs7038219	chr9:37182892	C/A	cg14294708	chr9:37120828	ZCCHC7	1.15	30.78	0.82	4.56e-114	Schizophrenia;
LGG	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg23594656	chr7:65796392	TPST1	0.38	8.27	0.36	1.41e-15	Aortic root size;
LGG	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg02002194	chr4:3960332	NA	-0.37	-7.15	-0.32	3.46e-12	Neuroticism;
LGG	cis	rs7927997	0.783	rs61893460	chr11:76291154	G/A	cg17647271	chr11:76299819	NA	-0.41	-7.27	-0.32	1.52e-12	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg10523679	chr1:76189770	ACADM	0.82	15.73	0.59	5.9e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg17178900	chr1:205818956	PM20D1	0.66	15.42	0.58	1.35e-43	Menarche (age at onset);
LGG	cis	rs9467773	1.000	rs2393670	chr6:26535541	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2018055	0.618	rs13217856	chr6:117797945	T/C	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs7296418	0.599	rs2277343	chr12:123794450	A/T	cg00376283	chr12:123451042	ABCB9	0.62	11.51	0.47	3.84e-27	Platelet count;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.42	-8.42	-0.36	4.91e-16	Prostate cancer;
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.03	-0.35	8.01e-15	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27507545	chr10:103880405	LDB1	0.5	7.78	0.34	4.93e-14	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg07511668	chr11:68622177	NA	-0.5	-9.45	-0.4	1.63e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg01236616	chr12:121019343	POP5	1.26	22.2	0.72	6.81e-75	Type 1 diabetes nephropathy;
LGG	cis	rs9341808	0.650	rs6909546	chr6:80869923	C/G	cg08355045	chr6:80787529	NA	0.41	7.99	0.35	1.05e-14	Sitting height ratio;
LGG	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.86	-0.34	2.72e-14	Joint mobility (Beighton score);
LGG	trans	rs8073060	0.671	rs9894813	chr17:33873848	C/T	cg19694781	chr19:47549865	TMEM160	0.78	11.73	0.48	5.18e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12828867	chr5:61708427	IPO11	0.44	6.72	0.3	5.5e-11	Gut microbiome composition (summer);
LGG	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg15208524	chr1:10270712	KIF1B	0.46	7.64	0.33	1.22e-13	Hepatocellular carcinoma;
LGG	cis	rs13102973	0.932	rs7656273	chr4:135852678	G/A	cg14419869	chr4:135874104	NA	0.57	10.77	0.45	2.79e-24	Subjective well-being;
LGG	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07659893	chr17:61819838	STRADA	0.5	8.35	0.36	8e-16	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg07701084	chr6:150067640	NUP43	0.69	13.33	0.53	1.57e-34	Lung cancer;
LGG	cis	rs7166081	0.951	rs34590589	chr15:67514190	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4319547	0.956	rs10773302	chr12:123043145	G/T	cg23029597	chr12:123009494	RSRC2	-0.92	-18.08	-0.64	1.15e-55	Body mass index;
LGG	cis	rs7647973	1.000	rs62261249	chr3:49594060	T/C	cg06212747	chr3:49208901	KLHDC8B	-0.54	-8.31	-0.36	1.11e-15	Menarche (age at onset);
LGG	cis	rs3820928	1.000	rs59904960	chr2:227761269	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.46	-0.33	4.45e-13	Pulmonary function;
LGG	cis	rs9880211	0.660	rs9289514	chr3:136493203	C/T	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	13.57	0.53	1.49e-35	Hip circumference adjusted for BMI;
LGG	trans	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg05059571	chr16:84539110	KIAA1609	-0.42	-7.78	-0.34	4.83e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg21605333	chr4:119757512	SEC24D	1.48	14.89	0.57	2.87e-41	Cannabis dependence symptom count;
LGG	cis	rs2758596	0.850	rs2842879	chr1:156163695	G/T	cg24450063	chr1:156163899	SLC25A44	0.92	8.6	0.37	1.23e-16	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.23	-0.46	4.79e-26	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-10.66	-0.44	7.33e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2665103	0.610	rs1972460	chr15:82530630	A/G	cg00614314	chr15:82944287	LOC80154	0.46	7.67	0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg02855558	chr7:158107723	PTPRN2	-0.37	-6.74	-0.3	4.87e-11	Calcium levels;
LGG	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg12573674	chr2:1569213	NA	-0.65	-10.04	-0.42	1.38e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8064024	0.901	rs930855	chr16:4864179	A/G	cg08329684	chr16:4932620	PPL	0.42	9.2	0.39	1.21e-18	Cancer;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25427524	chr10:38739819	LOC399744	-0.67	-12.48	-0.5	5.23e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs7666738	0.830	rs17486413	chr4:99060544	G/T	cg05340658	chr4:99064831	C4orf37	0.48	7.77	0.34	5.07e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10779751	1.000	rs7524202	chr1:11297762	T/C	cg08854313	chr1:11322531	MTOR	0.74	16.13	0.6	9.28e-47	Body mass index;
LGG	cis	rs6764363	0.506	rs13091018	chr3:277659	A/G	cg02057681	chr3:285234	CHL1	-0.41	-7.39	-0.32	7.15e-13	Sudden cardiac arrest;
LGG	cis	rs1577917	0.916	rs12661611	chr6:86553835	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.6	-0.44	1.16e-23	Response to antipsychotic treatment;
LGG	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs9472414	0.680	rs9463039	chr6:44752124	C/T	cg20913747	chr6:44695427	NA	0.47	7.25	0.32	1.81e-12	Height;
LGG	cis	rs4330281	0.669	rs9681232	chr3:17760883	A/G	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.31e-13	Schizophrenia;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg26668828	chr6:292823	DUSP22	-0.68	-11.76	-0.48	4e-28	Menopause (age at onset);
LGG	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg04842962	chr6:43655489	MRPS18A	1.12	24.45	0.75	2.26e-85	IgG glycosylation;
LGG	cis	rs16837677	1.000	rs6701637	chr1:156767253	C/T	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs1670533	1.000	rs6857085	chr4:1095920	C/A	cg27284194	chr4:1044797	NA	-0.54	-9.64	-0.41	3.62e-20	Recombination rate (females);
LGG	cis	rs7402982	0.647	rs34038360	chr15:99201573	A/C	cg03437748	chr15:99193247	IGF1R	0.82	14.41	0.56	3.61e-39	Birth weight;
LGG	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.38	6.8	0.3	3.28e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2243480	1.000	rs1723270	chr7:65469830	T/G	cg12463550	chr7:65579703	CRCP	0.74	8.03	0.35	8.13e-15	Diabetic kidney disease;
LGG	cis	rs9324022	0.929	rs59488041	chr14:101180041	T/A	cg18089426	chr14:101175970	NA	0.68	11.26	0.46	3.83e-26	Plateletcrit;
LGG	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg09238746	chr17:78121135	EIF4A3	0.89	15.62	0.59	1.68e-44	Yeast infection;
LGG	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs5015933	0.902	rs10819047	chr9:128127412	A/G	cg14078157	chr9:128172775	NA	-0.35	-6.72	-0.3	5.47e-11	Body mass index;
LGG	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.23	-0.32	1.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.13e-35	Corneal astigmatism;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.68	0.41	2.71e-20	Bipolar disorder;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-8.52	-0.37	2.32e-16	Lymphocyte counts;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01840575	chr2:38977957	SFRS7	0.41	6.84	0.3	2.54e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg08677398	chr8:58056175	NA	0.44	6.96	0.31	1.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs3849046	0.817	rs11953219	chr5:137928170	T/C	cg10920316	chr5:137946599	NA	0.42	6.81	0.3	3.13e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg15501526	chr10:2543763	NA	0.7	14.85	0.57	4.41e-41	Age-related hearing impairment;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg03528353	chr17:61819722	STRADA	0.46	7.76	0.34	5.36e-14	Prudent dietary pattern;
LGG	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.64	-9.22	-0.39	1.05e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1568889	1.000	rs61236373	chr11:28212720	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.78	0.57	8.74e-41	Bipolar disorder;
LGG	trans	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg18187862	chr3:45730750	SACM1L	0.65	10.82	0.45	1.8e-24	Primary sclerosing cholangitis;
LGG	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg11502198	chr6:26597334	ABT1	-0.7	-12.78	-0.51	3.1e-32	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.737	rs91144	chr14:75449517	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.3	-0.4	5.67e-19	Height;
LGG	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.94	0.31	1.34e-11	Retinal vascular caliber;
LGG	cis	rs5758511	0.680	rs1001586	chr22:42670293	G/T	cg15128208	chr22:42549153	NA	0.75	11.78	0.48	3.41e-28	Birth weight;
LGG	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg16384552	chr7:74938386	SPDYE8P	0.51	9.02	0.39	5.2e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg25019033	chr10:957182	NA	-0.6	-11.44	-0.47	7.5e-27	Eosinophil percentage of granulocytes;
LGG	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Vitiligo;
LGG	cis	rs7666738	0.791	rs4699329	chr4:99056212	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.85	0.54	9.79e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs6787172	0.702	rs1983469	chr3:158032271	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.67	0.37	7.13e-17	Subjective well-being;
LGG	cis	rs2067615	0.579	rs7964605	chr12:107205413	C/T	cg15890332	chr12:107067104	RFX4	-0.4	-11.68	-0.48	8.7300000000000009e-28	Heart rate;
LGG	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27297192	chr10:134578999	INPP5A	0.31	6.73	0.3	4.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs367943	0.712	rs4331889	chr5:112679795	C/T	cg12552261	chr5:112820674	MCC	0.54	9.78	0.41	1.2e-20	Type 2 diabetes;
LGG	cis	rs4720575	1.000	rs4720575	chr7:47086805	A/G	cg00036614	chr7:47093842	NA	-0.51	-10.2	-0.43	3.58e-22	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs2985684	1.000	rs56098064	chr14:50105849	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-8.58	-0.37	1.47e-16	Carotid intima media thickness;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg22535103	chr8:58192502	C8orf71	-1.03	-16.37	-0.61	7.35e-48	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg26384229	chr12:38710491	ALG10B	-0.84	-19.57	-0.67	1.34e-62	Heart rate;
LGG	cis	rs2273669	1.000	rs2273669	chr6:109285189	A/G	cg05315195	chr6:109294784	ARMC2	-0.52	-7.3	-0.32	1.23e-12	Prostate cancer;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs3742264	0.615	rs7333544	chr13:46517714	A/G	cg15192986	chr13:46630673	CPB2	-0.35	-6.88	-0.3	2e-11	Blood protein levels;
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00166722	chr3:10149974	C3orf24	0.51	8.59	0.37	1.32e-16	Alzheimer's disease;
LGG	cis	rs936229	1.000	rs936229	chr15:75132319	A/G	cg10253484	chr15:75165896	SCAMP2	-0.69	-10.68	-0.44	5.98e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg16950941	chr11:66035639	RAB1B	0.56	10.49	0.44	2.95e-23	Gout;
LGG	cis	rs1395	0.744	rs11679220	chr2:27476378	G/A	cg23587288	chr2:27483067	SLC30A3	-0.33	-7.41	-0.33	5.97e-13	Blood metabolite levels;
LGG	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg12698349	chr2:225449008	CUL3	1.04	26.99	0.78	4.5e-97	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs698813	0.789	rs2592195	chr2:44607707	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.87	-0.3	2.1e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg00491522	chr10:135256596	NA	0.51	8.13	0.35	3.99e-15	Systemic lupus erythematosus;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26477793	chr10:104262085	ACTR1A	0.4	6.71	0.3	5.58e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1707322	0.964	rs12067716	chr1:46434428	T/A	cg03146154	chr1:46216737	IPP	0.53	9.89	0.42	4.57e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg08847335	chr10:891726	LARP4B	-0.55	-9.28	-0.4	6.37e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs12615966	1.000	rs55805894	chr2:105380420	A/T	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	cis	rs1941023	0.503	rs11230288	chr11:60128968	G/A	cg08716584	chr11:60157161	MS4A7	-0.41	-8.2	-0.36	2.4e-15	Congenital heart disease (maternal effect);
LGG	cis	rs79839061	0.520	rs11730111	chr4:942833	C/T	cg07828340	chr4:882639	GAK	0.9	9.6	0.41	5.02e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2708240	0.689	rs2710114	chr7:147598021	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.35	-8.61	-0.37	1.15e-16	QT interval (drug interaction);
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs12493885	0.585	rs696869	chr3:153630341	A/C	cg17054900	chr3:154042577	DHX36	-0.57	-7.15	-0.32	3.51e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9790314	0.746	rs898680	chr3:160772853	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-10.03	-0.42	1.42e-21	Morning vs. evening chronotype;
LGG	cis	rs9341808	0.935	rs9448894	chr6:80837253	G/T	cg08355045	chr6:80787529	NA	0.38	7.64	0.33	1.24e-13	Sitting height ratio;
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg15017067	chr4:17643749	FAM184B	0.29	6.72	0.3	5.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg13010199	chr12:38710504	ALG10B	0.56	11.09	0.46	1.65e-25	Bladder cancer;
LGG	cis	rs2274273	0.934	rs17740741	chr14:55762712	G/C	cg04306507	chr14:55594613	LGALS3	0.61	16.8	0.62	8.54e-50	Protein biomarker;
LGG	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg18478394	chr8:109455254	TTC35	0.43	8.63	0.37	1.02e-16	Dupuytren's disease;
LGG	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.24	-0.55	1.95e-38	Heart rate;
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg22903471	chr2:27725779	GCKR	-0.55	-12.35	-0.5	1.69e-30	Total body bone mineral density;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg00607725	chr16:70380558	DDX19A	-0.4	-6.8	-0.3	3.28e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs2153535	0.967	rs10484750	chr6:8378609	A/G	cg07606381	chr6:8435919	SLC35B3	-0.39	-6.76	-0.3	4.08e-11	Motion sickness;
LGG	trans	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03264133	chr6:25882463	NA	0.7	13.48	0.53	3.61e-35	Blood metabolite levels;
LGG	cis	rs1801251	1.000	rs11679079	chr2:233612656	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	6.91e-32	Coronary artery disease;
LGG	cis	rs9875589	0.509	rs1488379	chr3:14014719	A/G	cg19554555	chr3:13937349	NA	-0.55	-9.85	-0.42	6.49e-21	Ovarian reserve;
LGG	cis	rs7236492	0.688	rs73494217	chr18:77186200	G/A	cg05753993	chr18:77199432	NFATC1	0.39	7.27	0.32	1.51e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12643440	0.538	rs4698536	chr4:17142175	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.41	0.65	3.21e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg21911579	chr5:131705225	SLC22A5	0.67	7.55	0.33	2.4e-13	Rheumatoid arthritis;
LGG	cis	rs74417235	0.639	rs2396994	chr5:154052750	A/T	cg08754654	chr5:154026448	NA	-0.52	-10.67	-0.44	6.68e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg14541582	chr5:601475	NA	-0.69	-10.87	-0.45	1.18e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.61	0.33	1.56e-13	Birth weight;
LGG	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg21926883	chr2:100939477	LONRF2	-0.48	-9.33	-0.4	4.24e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg07636037	chr3:49044803	WDR6	1.05	23.9	0.74	7.76e-83	Parkinson's disease;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs885389	0.920	rs1880842	chr12:131621997	A/G	cg07124762	chr12:131619285	GPR133	-0.38	-6.73	-0.3	5e-11	RR interval (heart rate);
LGG	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19942237	chr7:29603211	PRR15	-0.28	-6.73	-0.3	5.17e-11	Facial emotion recognition (angry faces);
LGG	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs9513627	1.000	rs4285989	chr13:100132342	A/G	cg25919922	chr13:100150906	NA	0.77	8.03	0.35	7.96e-15	Obesity-related traits;
LGG	cis	rs7100689	0.784	rs10749562	chr10:82108253	G/T	cg01528321	chr10:82214614	TSPAN14	0.87	15.5	0.58	5.74e-44	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.52	0.37	2.33e-16	Lung cancer;
LGG	cis	rs17221829	0.536	rs7943784	chr11:89377310	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs4926611	0.931	rs1526909	chr1:54084347	G/C	cg23596471	chr1:54105337	GLIS1	0.41	8.18	0.36	2.81e-15	Hand grip strength;
LGG	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.42	-0.33	5.64e-13	Neuroticism;
LGG	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg23649088	chr2:200775458	C2orf69	-0.62	-11.03	-0.46	2.72e-25	Osteoporosis;
LGG	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg08499158	chr17:42289980	UBTF	-0.39	-7.24	-0.32	1.88e-12	Total body bone mineral density;
LGG	cis	rs1847202	0.859	rs13068268	chr3:72938132	G/A	cg25664220	chr3:72788482	NA	-0.25	-7.32	-0.32	1.12e-12	Motion sickness;
LGG	cis	rs10489525	1.000	rs10489525	chr1:115263685	A/G	cg12756093	chr1:115239321	AMPD1	0.48	7.63	0.33	1.33e-13	Autism;
LGG	trans	rs9914544	0.545	rs8066636	chr17:18761109	G/A	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.57	-0.33	2.01e-13	Educational attainment (years of education);
LGG	cis	rs2404602	0.647	rs11072607	chr15:76908529	C/T	cg23625390	chr15:77176239	SCAPER	-0.7	-13.92	-0.54	4.63e-37	Blood metabolite levels;
LGG	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.77	0.45	2.73e-24	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg00631329	chr6:26305371	NA	-0.53	-9.98	-0.42	2.3e-21	Educational attainment;
LGG	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg16141378	chr3:129829833	LOC729375	0.38	8.39	0.36	5.8e-16	Morning vs. evening chronotype;
LGG	cis	rs1784581	0.894	rs1784594	chr6:162382734	A/G	cg17173639	chr6:162384350	PARK2	-0.87	-22.4	-0.72	8.2e-76	Itch intensity from mosquito bite;
LGG	trans	rs61931739	0.635	rs1486883	chr12:33908740	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.12	0.46	1.24e-25	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg03959625	chr15:84868606	LOC388152	0.5	7.5	0.33	3.39e-13	Schizophrenia;
LGG	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg22676075	chr6:135203613	NA	0.59	11.31	0.47	2.3e-26	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs4774899	0.934	rs11858783	chr15:57472751	C/A	cg08128148	chr15:57256372	TCF12	-0.32	-7.55	-0.33	2.4e-13	Urinary tract infection frequency;
LGG	cis	rs7020830	0.825	rs13297152	chr9:37075623	C/T	cg14294708	chr9:37120828	ZCCHC7	1.15	30.88	0.82	1.73e-114	Schizophrenia;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg03188948	chr7:1209495	NA	0.56	7.39	0.32	6.89e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg07274523	chr3:49395745	GPX1	0.57	9.52	0.4	9.66e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs71403859	0.502	rs17345863	chr16:71523261	C/T	cg08717414	chr16:71523259	ZNF19	-1.38	-18.59	-0.65	4.83e-58	Post bronchodilator FEV1;
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19717773	chr7:2847554	GNA12	-0.31	-6.67	-0.3	7.25e-11	Height;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg13206674	chr6:150067644	NUP43	0.41	8.78	0.38	3.16e-17	Lung cancer;
LGG	cis	rs933688	1.000	rs1035477	chr5:90743325	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.71	0.56	1.81e-40	Cognitive test performance;
LGG	cis	rs11920090	0.860	rs7643425	chr3:170737395	A/G	cg09710316	chr3:170744871	SLC2A2	0.62	8.49	0.37	2.73e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04549115	chr6:116892534	RWDD1	0.42	7.0	0.31	8.83e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.57	0.47	2.28e-27	Corneal astigmatism;
LGG	cis	rs870825	0.616	rs4623060	chr4:185642943	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.16	0.72	1.03e-74	Blood protein levels;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.68e-12	Lung cancer;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs6800768	0.633	rs7623348	chr3:24130263	C/A	cg10674438	chr3:24145617	LOC152024	-0.51	-9.13	-0.39	2.06e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg06138931	chr13:21896616	NA	-0.42	-6.88	-0.3	1.89e-11	White matter hyperintensity burden;
LGG	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.52e-12	HDL cholesterol;
LGG	cis	rs68170813	0.559	rs12535258	chr7:106971050	T/C	cg02696742	chr7:106810147	HBP1	-0.7	-9.94	-0.42	3.16e-21	Coronary artery disease;
LGG	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.31	0.32	1.19e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7113850	0.541	rs7927067	chr11:24232604	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.45	0.44	4.3e-23	Bone fracture in osteoporosis;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg02353165	chr6:42928485	GNMT	0.4	11.64	0.48	1.2100000000000001e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg04568710	chr12:38710424	ALG10B	-0.43	-9.45	-0.4	1.72e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7649275	1.000	rs1020820	chr3:53762569	G/A	cg21503701	chr3:53781065	CACNA1D	-0.47	-6.95	-0.31	1.29e-11	Trans fatty acid levels;
LGG	cis	rs7215564	0.908	rs35918698	chr17:78683533	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg05091796	chr16:4465799	CORO7	-0.76	-13.13	-0.52	1.04e-33	Schizophrenia;
LGG	cis	rs1881797	0.527	rs79724455	chr1:247646957	T/C	cg18198730	chr1:247681584	NA	0.62	6.67	0.3	7.52e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.28e-14	Dementia with Lewy bodies;
LGG	cis	rs524281	0.861	rs11607393	chr11:65875149	C/A	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg23484912	chr5:273055	PDCD6	0.45	9.14	0.39	1.99e-18	Pancreatic cancer;
LGG	cis	rs2439831	0.850	rs12442297	chr15:44168470	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.69	0.44	5.49e-24	Lung cancer in ever smokers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02043083	chr6:150070997	PCMT1	0.47	7.45	0.33	4.52e-13	Cognitive performance;
LGG	cis	rs8180040	0.764	rs13084117	chr3:47183239	C/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.5	0.37	2.69e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg20570797	chr2:1712800	PXDN	-0.46	-7.79	-0.34	4.53e-14	Response to antipsychotic treatment;
LGG	cis	rs1046896	0.503	rs12947062	chr17:80686370	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.4	-6.77	-0.3	3.86e-11	Glycated hemoglobin levels;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.33	0.32	1.06e-12	Schizophrenia;
LGG	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.47	-0.4	1.39e-19	Common traits (Other);
LGG	cis	rs3540	0.554	rs12443252	chr15:91064690	C/T	cg22089800	chr15:90895588	ZNF774	-0.67	-12.1	-0.49	1.85e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs372883	0.580	rs2254038	chr21:30745722	C/T	cg08807101	chr21:30365312	RNF160	0.54	8.71	0.38	5.3e-17	Pancreatic cancer;
LGG	trans	rs6787172	0.622	rs6773939	chr3:158069706	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.38	-0.32	7.47e-13	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23074401	chr11:108535840	DDX10	0.53	8.21	0.36	2.19e-15	Gut microbiome composition (summer);
LGG	cis	rs6594713	0.921	rs7731231	chr5:112717546	C/A	cg12552261	chr5:112820674	MCC	0.51	7.27	0.32	1.51e-12	Brain cytoarchitecture;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.17	-0.39	1.58e-18	Life satisfaction;
LGG	cis	rs3126085	0.935	rs4511113	chr1:152222192	G/A	cg26876637	chr1:152193138	HRNR	0.55	8.98	0.39	6.85e-18	Atopic dermatitis;
LGG	cis	rs7219021	0.926	rs68169424	chr17:46851676	T/C	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.69	-0.3	6.32e-11	Schizophrenia or bipolar disorder;
LGG	trans	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg18187862	chr3:45730750	SACM1L	-0.42	-6.84	-0.3	2.47e-11	Primary sclerosing cholangitis;
LGG	cis	rs9325144	0.560	rs7314632	chr12:38636979	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.11	-0.62	3.25e-51	Morning vs. evening chronotype;
LGG	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06689961	chr12:12870959	CDKN1B	0.43	7.35	0.32	8.91e-13	Lung adenocarcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17979863	chr2:231852034	NA	0.39	6.74	0.3	4.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg12573674	chr2:1569213	NA	-0.66	-10.45	-0.44	4.23e-23	IgG glycosylation;
LGG	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.79	0.34	4.39e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs59918340	0.728	rs10112337	chr8:142233573	A/G	cg03653399	chr8:142233436	SLC45A4	-0.42	-8.27	-0.36	1.42e-15	Immature fraction of reticulocytes;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.670	rs2024853	chr6:109819954	T/A	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	trans	rs7395662	0.963	rs12418254	chr11:48988262	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.91	-0.31	1.58e-11	HDL cholesterol;
LGG	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg08508325	chr11:3079039	CARS	-0.57	-11.65	-0.48	1.12e-27	Longevity;
LGG	cis	rs7133214	0.771	rs34341933	chr12:27927383	A/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.8	-0.3	3.19e-11	Gut microbiota (functional units);
LGG	cis	rs75920871	0.528	rs7930264	chr11:116870766	G/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.31	-0.43	1.44e-22	Subjective well-being;
LGG	cis	rs4901847	0.716	rs10144556	chr14:58560475	T/C	cg15908186	chr14:58618357	C14orf37	0.41	7.23	0.32	1.95e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg09818912	chr17:20140352	CYTSB	0.3	6.78	0.3	3.58e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13191172	chr4:186064250	SLC25A4	0.51	8.05	0.35	7.19e-15	Gut microbiome composition (summer);
LGG	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg11247378	chr22:39784982	NA	-0.33	-8.64	-0.37	9.21e-17	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg02725872	chr8:58115012	NA	-0.84	-16.12	-0.6	1.05e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs774359	0.830	rs2453555	chr9:27563868	G/A	cg14173147	chr9:27528300	MOBKL2B	0.43	7.86	0.34	2.77e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07659893	chr17:61819838	STRADA	0.47	7.88	0.34	2.42e-14	Prudent dietary pattern;
LGG	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg02527881	chr3:46936655	PTH1R	0.33	7.92	0.35	1.72e-14	Birth weight;
LGG	cis	rs754466	0.510	rs10824579	chr10:79590685	C/T	cg17075019	chr10:79541650	NA	-0.83	-17.23	-0.63	9.37e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg20578329	chr17:80767326	TBCD	-0.46	-7.9	-0.34	2.06e-14	Breast cancer;
LGG	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg26396452	chr14:65542826	MAX	0.38	7.44	0.33	4.99e-13	Obesity-related traits;
LGG	cis	rs12701220	0.572	rs7792825	chr7:1006573	T/C	cg00990874	chr7:1149470	C7orf50	-0.44	-6.7	-0.3	6.18e-11	Bronchopulmonary dysplasia;
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.03	-0.31	7.69e-12	Neuroticism;
LGG	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg10845886	chr2:3471009	TTC15	-0.48	-9.72	-0.41	1.9e-20	Neurofibrillary tangles;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	1.01e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7179456	0.557	rs446126	chr15:59113102	A/G	cg05156742	chr15:59063176	FAM63B	0.65	12.06	0.49	2.5e-29	Asperger disorder;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg04703951	chr17:43578652	NA	-0.37	-7.51	-0.33	2.97e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	13.29	0.53	2.28e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.38	-0.32	7.19e-13	Uric acid levels;
LGG	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.69	0.45	5.25e-24	Lung cancer in ever smokers;
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg16339924	chr4:17578868	LAP3	0.64	11.21	0.46	5.5e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7301826	0.627	rs7978987	chr12:131281494	G/A	cg11011512	chr12:131303247	STX2	-0.4	-8.45	-0.37	3.75e-16	Plasma plasminogen activator levels;
LGG	cis	rs7711186	0.881	rs721142	chr5:178019208	C/A	cg17371294	chr5:178012716	COL23A1	-0.67	-6.79	-0.3	3.4e-11	Urate levels in obese individuals;
LGG	cis	rs9916302	0.904	rs10432031	chr17:37397852	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-15.24	-0.58	8.59e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.44	7.76	0.34	5.57e-14	Menarche (age at onset);
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.71	9.88	0.42	4.93e-21	Lung function (FEV1/FVC);
LGG	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg02487422	chr3:49467188	NICN1	0.58	10.66	0.44	7.2e-24	Resting heart rate;
LGG	cis	rs4774899	0.869	rs2962993	chr15:57344066	A/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.44	-0.33	4.85e-13	Urinary tract infection frequency;
LGG	cis	rs7666738	0.830	rs4699593	chr4:98980628	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg05044414	chr3:183734942	ABCC5	0.76	16.73	0.61	1.76e-49	Anterior chamber depth;
LGG	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.14	-0.35	3.77e-15	Coronary artery disease;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.15	0.32	3.34e-12	Lung cancer;
LGG	cis	rs62064224	0.702	rs735555	chr17:30817450	A/G	cg09324608	chr17:30823087	MYO1D	-0.33	-7.72	-0.34	7.29e-14	Schizophrenia;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg04166393	chr7:2884313	GNA12	0.43	8.06	0.35	6.4e-15	Height;
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg18099408	chr3:52552593	STAB1	-0.37	-7.18	-0.32	2.81e-12	Bipolar disorder;
LGG	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg00426182	chr6:28072559	NA	0.93	6.96	0.31	1.21e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs7226408	0.857	rs72887014	chr18:34463771	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg26174226	chr8:58114915	NA	-0.49	-7.2	-0.32	2.49e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9677476	0.863	rs2006780	chr2:232066704	T/G	cg14237567	chr2:232057245	NA	-0.32	-6.66	-0.3	7.58e-11	Food antigen IgG levels;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg09303159	chr6:26284866	NA	0.35	7.82	0.34	3.54e-14	Educational attainment;
LGG	trans	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.37	0.4	3.23e-19	Mean corpuscular volume;
LGG	cis	rs3735485	0.722	rs3801407	chr7:45143503	G/A	cg03440944	chr7:45023329	C7orf40	-0.55	-8.98	-0.39	6.84e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs10276381	0.579	rs73072539	chr7:28146255	C/G	cg23620719	chr7:28220237	JAZF1	0.71	7.64	0.33	1.29e-13	Crohn's disease;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13421350	0.579	rs16860419	chr2:173317826	G/C	cg15021238	chr2:173305865	ITGA6	-0.84	-9.64	-0.41	3.54e-20	Diabetic kidney disease;
LGG	cis	rs3126085	0.935	rs4845750	chr1:152201217	A/G	cg26876637	chr1:152193138	HRNR	0.57	7.85	0.34	2.91e-14	Atopic dermatitis;
LGG	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.15e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1862618	0.853	rs11739344	chr5:56111087	A/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	cis	rs1256061	0.654	rs1256040	chr14:64738394	G/A	cg23250157	chr14:64679961	SYNE2	0.38	7.06	0.31	6.29e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs8067287	0.634	rs17793572	chr17:16843992	A/G	cg26910001	chr17:16838321	NA	0.41	8.04	0.35	7.72e-15	Diabetic kidney disease;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.12	-0.31	4.13e-12	Personality dimensions;
LGG	trans	rs8073060	0.592	rs225306	chr17:33920036	A/C	cg19694781	chr19:47549865	TMEM160	0.72	11.67	0.48	9.4e-28	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs4740619	0.689	rs10756724	chr9:15951855	A/T	cg14451791	chr9:16040625	NA	-0.41	-10.26	-0.43	2.15e-22	Body mass index;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg19182353	chr11:118479428	PHLDB1	-0.55	-11.02	-0.46	3.06e-25	Cholesterol, total;
LGG	cis	rs526231	0.543	rs34804	chr5:102428239	G/A	cg23492399	chr5:102201601	PAM	-0.64	-9.32	-0.4	4.7e-19	Primary biliary cholangitis;
LGG	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg12560992	chr17:57184187	TRIM37	0.53	8.57	0.37	1.58e-16	Testicular germ cell tumor;
LGG	cis	rs77741769	0.571	rs35905305	chr12:121328082	T/G	cg02419362	chr12:121203948	SPPL3	0.53	9.27	0.4	7.26e-19	Mean corpuscular volume;
LGG	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg27661571	chr11:113659931	NA	0.47	6.77	0.3	3.97e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg08280861	chr8:58055591	NA	0.63	7.76	0.34	5.38e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg27129171	chr3:47204927	SETD2	-0.78	-15.27	-0.58	6.07e-43	Colorectal cancer;
LGG	cis	rs4819052	0.851	rs9979545	chr21:46679805	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.88	0.38	1.51e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg11693508	chr17:37793320	STARD3	0.6	8.3	0.36	1.13e-15	Bipolar disorder;
LGG	cis	rs17767392	0.958	rs61989367	chr14:71907295	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.95	-0.38	8.43e-18	Mitral valve prolapse;
LGG	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.19	0.43	3.82e-22	Iron status biomarkers;
LGG	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg12288994	chr5:1860383	NA	0.7	11.41	0.47	9.62e-27	Cardiovascular disease risk factors;
LGG	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg18876405	chr7:65276391	NA	-0.64	-11.53	-0.47	3.3e-27	Aortic root size;
LGG	cis	rs988958	0.675	rs7576689	chr2:42218358	C/T	cg27428208	chr2:42229179	NA	0.56	9.57	0.41	6.7e-20	Hypospadias;
LGG	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00495681	chr13:53174319	NA	-0.69	-13.37	-0.53	1.06e-34	Lewy body disease;
LGG	cis	rs2224391	0.784	rs59548069	chr6:5276595	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.56	-0.33	2.14e-13	Height;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg26174226	chr8:58114915	NA	-0.53	-7.42	-0.33	5.83e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	8.15	0.35	3.48e-15	Bipolar disorder;
LGG	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.36	-0.36	7.6e-16	Triglycerides;
LGG	cis	rs7192380	1.000	rs11075726	chr16:69584523	A/G	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.43	-0.33	5.33e-13	Sjögren's syndrome;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.9	-0.57	2.68e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg05484376	chr2:27715224	FNDC4	0.44	9.48	0.4	1.38e-19	Total body bone mineral density;
LGG	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.17	0.55	4.02e-38	IgG glycosylation;
LGG	cis	rs7615952	0.546	rs11717632	chr3:125321130	G/C	cg21696256	chr3:125484277	NA	-0.44	-6.69	-0.3	6.27e-11	Blood pressure (smoking interaction);
LGG	trans	rs7939886	0.841	rs11227809	chr11:56070386	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg24189917	chr7:1970923	MAD1L1	0.58	8.66	0.37	7.7e-17	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs7100689	0.784	rs1972370	chr10:82127180	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	16.77	0.61	1.15e-49	Post bronchodilator FEV1;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg01988459	chr11:68622903	NA	0.64	12.94	0.52	6.88e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs12765878	1.000	rs4918068	chr10:105644736	T/G	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs7226408	0.576	rs2034213	chr18:34504970	G/C	cg15022739	chr18:34823045	BRUNOL4	0.41	8.72	0.38	4.93e-17	Obesity-related traits;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.08	-0.31	5.27e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs912330	0.825	rs7317938	chr13:99234361	C/T	cg07423050	chr13:99094983	FARP1	-0.48	-9.51	-0.4	1.03e-19	Alzheimer's disease;
LGG	cis	rs1550582	0.662	rs4909628	chr8:135502380	A/T	cg17885191	chr8:135476712	NA	-0.94	-16.41	-0.61	4.98e-48	Educational attainment;
LGG	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs12681287	0.640	rs13251006	chr8:87469105	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg12373951	chr3:133503437	NA	-0.44	-7.97	-0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11764359	chr7:65958608	NA	0.57	9.58	0.41	6.15e-20	Calcium levels;
LGG	cis	rs1882538	0.538	rs7803848	chr7:133108547	C/T	cg10665199	chr7:133106180	EXOC4	0.59	10.28	0.43	1.86e-22	Intelligence (multi-trait analysis);
LGG	cis	rs614226	1.000	rs7174	chr12:121017171	A/G	cg21053147	chr12:120880522	NA	-0.55	-8.24	-0.36	1.82e-15	Type 1 diabetes nephropathy;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.22	0.32	2.1e-12	Lung cancer;
LGG	cis	rs66569888	0.754	rs6719028	chr2:106895212	T/C	cg16099169	chr2:106886729	NA	0.33	7.3	0.32	1.23e-12	Facial morphology (factor 23);
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-10.42	-0.44	5.42e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg20991723	chr1:152506922	NA	-0.61	-10.48	-0.44	3.44e-23	Hair morphology;
LGG	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg17219203	chr10:38645113	HSD17B7P2	0.45	7.37	0.32	7.8e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg07725658	chr4:71705655	GRSF1	-0.38	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.72	0.34	7.11e-14	Coronary artery disease;
LGG	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg03929089	chr4:120376271	NA	0.68	7.06	0.31	6.06e-12	Axial length;
LGG	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-7.14	-0.31	3.67e-12	Reticulocyte count;
LGG	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg08400814	chr5:56204995	C5orf35	-0.41	-7.39	-0.32	6.83e-13	Initial pursuit acceleration;
LGG	cis	rs9911578	0.967	rs11656413	chr17:57082013	A/C	cg12560992	chr17:57184187	TRIM37	-0.91	-16.2	-0.6	4.36e-47	Intelligence (multi-trait analysis);
LGG	cis	rs6693295	0.625	rs12144675	chr1:246349981	G/A	cg11798871	chr1:246315928	SMYD3	-0.41	-6.73	-0.3	5.18e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg06640241	chr16:89574553	SPG7	0.72	12.63	0.51	1.21e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg17294928	chr15:75287854	SCAMP5	0.57	10.24	0.43	2.46e-22	Breast cancer;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg15971980	chr6:150254442	NA	0.43	8.13	0.35	4.07e-15	Lung cancer;
LGG	cis	rs2710642	0.962	rs1828398	chr2:63034870	A/G	cg17519650	chr2:63277830	OTX1	-0.48	-7.96	-0.35	1.38e-14	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs13095912	0.785	rs6444076	chr3:185321405	T/C	cg11274856	chr3:185301563	NA	0.49	7.92	0.35	1.74e-14	Systolic blood pressure;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.46	0.83	2.37e-121	Prudent dietary pattern;
LGG	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg25019033	chr10:957182	NA	-0.6	-10.83	-0.45	1.67e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs9397585	0.857	rs7773325	chr6:153375839	T/A	cg17707550	chr6:153380415	RGS17	0.62	14.5	0.56	1.45e-39	Body mass index;
LGG	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg26396452	chr14:65542826	MAX	0.44	8.93	0.38	9.76e-18	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs34599045	0.522	rs28924725	chr1:152974920	T/A	cg07796016	chr1:152779584	LCE1C	-0.88	-7.41	-0.33	5.96e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg11693508	chr17:37793320	STARD3	0.73	10.76	0.45	3.1e-24	Bipolar disorder;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg24848339	chr3:12840334	CAND2	0.43	9.91	0.42	3.85e-21	QRS complex (12-leadsum);
LGG	cis	rs13260300	0.597	rs10957729	chr8:75505981	C/G	cg22993706	chr8:75542856	NA	-0.36	-7.15	-0.32	3.38e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg17127132	chr2:85788382	GGCX	0.44	7.72	0.34	7.02e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00689492	chr4:1303491	MAEA	0.51	8.95	0.38	8.74e-18	Obesity-related traits;
LGG	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-6.89	-0.3	1.82e-11	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16266895	chr12:101674004	UTP20	0.55	8.91	0.38	1.22e-17	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg19812747	chr11:111475976	SIK2	0.44	8.7	0.37	5.7e-17	Primary sclerosing cholangitis;
LGG	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.71e-13	Refractive error;
LGG	cis	rs2133450	0.745	rs34225103	chr3:7370729	C/T	cg19930620	chr3:7340148	GRM7	-0.37	-7.82	-0.34	3.69e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2279817	0.863	rs2354291	chr1:18027554	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.67	-11.89	-0.48	1.18e-28	Neuroticism;
LGG	cis	rs12282928	0.876	rs4980428	chr11:48296661	G/T	cg26585981	chr11:48327164	OR4S1	-0.45	-7.17	-0.32	3e-12	Migraine - clinic-based;
LGG	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-8.02	-0.35	8.76e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.8e-22	Neutrophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24720361	chr12:57882021	MARS	0.39	6.68	0.3	6.73e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4689388	0.926	rs4343789	chr4:6285228	C/G	cg14416269	chr4:6271139	WFS1	0.52	9.68	0.41	2.59e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11676855	1.000	rs11889801	chr2:235902470	T/C	cg14917874	chr2:235941519	SH3BP4	0.54	9.62	0.41	4.32e-20	Dialysis-related mortality;
LGG	cis	rs2354432	0.556	rs11239965	chr1:146753907	C/A	cg25205988	chr1:146714368	CHD1L	-1.47	-14.82	-0.57	5.75e-41	Mitochondrial DNA levels;
LGG	cis	rs2710642	0.821	rs56373728	chr2:63095792	G/A	cg17519650	chr2:63277830	OTX1	0.5	8.24	0.36	1.79e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-1.09	-26.38	-0.77	2.64e-94	Cognitive ability;
LGG	cis	rs7927771	0.929	rs12787646	chr11:47669665	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.68	-0.37	6.65e-17	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02872623	chr3:185304179	SENP2	0.43	6.78	0.3	3.61e-11	Cognitive performance;
LGG	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg00938859	chr5:1591904	SDHAP3	0.89	12.49	0.5	4.5e-31	Breast cancer;
LGG	cis	rs4750440	0.614	rs898718	chr10:14027235	C/T	cg27542038	chr10:14027202	FRMD4A	-0.8	-15.87	-0.59	1.27e-45	Adiponectin levels;
LGG	trans	rs747782	0.528	rs16905753	chr11:48285906	C/T	cg15704280	chr7:45808275	SEPT13	0.73	8.63	0.37	1.01e-16	Intraocular pressure;
LGG	cis	rs2013441	0.866	rs12947950	chr17:20045176	C/T	cg13482628	chr17:19912719	NA	0.4	6.92	0.31	1.53e-11	Obesity-related traits;
LGG	cis	rs7084783	0.519	rs4917395	chr10:105351382	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.48	8.47	0.37	3.21e-16	Fear of pain;
LGG	cis	rs11676348	0.741	rs12694425	chr2:218942313	A/G	cg00012203	chr2:219082015	ARPC2	0.48	8.35	0.36	7.83e-16	Ulcerative colitis;
LGG	cis	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg08112188	chr17:47440006	ZNF652	1.33	15.76	0.59	4.07e-45	Prostate cancer;
LGG	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs10751667	0.666	rs7394958	chr11:965944	C/G	cg22143635	chr11:980567	AP2A2	0.44	8.22	0.36	2.12e-15	Alzheimer's disease (late onset);
LGG	cis	rs12360000	0.522	rs11250865	chr10:1913841	T/C	cg26364871	chr10:1889757	NA	-0.52	-9.98	-0.42	2.32e-21	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.34	-0.32	1e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.19	0.36	2.49e-15	Retinal vascular caliber;
LGG	cis	rs17021463	0.555	rs7664979	chr4:95325397	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-6.78	-0.3	3.68e-11	Testicular germ cell tumor;
LGG	cis	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05901451	chr6:126070800	HEY2	0.59	10.61	0.44	1.11e-23	Endometrial cancer;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.88	-0.3	1.94e-11	Lung cancer;
LGG	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.48	-0.33	3.66e-13	Neuroticism;
LGG	cis	rs4936894	0.500	rs10893205	chr11:124172565	A/G	cg27160556	chr11:124181099	OR8D1	0.45	10.54	0.44	1.92e-23	Aging (time to death);
LGG	cis	rs6977940	0.512	rs6461600	chr7:2816537	C/T	cg19731401	chr7:2775893	GNA12	0.34	7.09	0.31	4.9e-12	White matter integrity;
LGG	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg25817165	chr18:72167213	CNDP2	-0.67	-13.91	-0.54	5.4e-37	Refractive error;
LGG	trans	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg27661571	chr11:113659931	NA	-0.65	-7.35	-0.32	8.8e-13	Hip circumference adjusted for BMI;
LGG	cis	rs17776563	0.593	rs8023681	chr15:89148093	A/G	cg05013243	chr15:89149849	MIR1179	-0.33	-6.84	-0.3	2.51e-11	Thyroid hormone levels;
LGG	cis	rs6028335	0.825	rs66581112	chr20:37722740	A/T	cg16355469	chr20:37678765	NA	0.53	6.88	0.3	1.97e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs4704846	0.614	rs6555827	chr5:156492438	C/T	cg12943317	chr5:156479607	HAVCR1	0.59	8.02	0.35	8.61e-15	Blood protein levels;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg05863683	chr7:1912471	MAD1L1	-0.39	-7.62	-0.33	1.43e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4268898	0.662	rs72793208	chr2:24510284	C/T	cg06627628	chr2:24431161	ITSN2	-0.76	-12.42	-0.5	8.66e-31	Asthma;
LGG	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg15208524	chr1:10270712	KIF1B	0.45	8.04	0.35	7.47e-15	Hepatocellular carcinoma;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg04008888	chr11:68622739	NA	0.49	10.55	0.44	1.89e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg13453750	chr1:205783389	SLC41A1	-0.4	-7.75	-0.34	5.8e-14	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.35	0.36	7.96e-16	Life satisfaction;
LGG	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg20578329	chr17:80767326	TBCD	-0.79	-11.64	-0.48	1.24e-27	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg01988459	chr11:68622903	NA	-0.63	-12.78	-0.51	2.97e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg01448562	chr3:133502909	NA	0.74	13.73	0.54	3e-36	Iron status biomarkers;
LGG	cis	rs877282	0.898	rs12357995	chr10:765739	T/C	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.05e-11	Uric acid levels;
LGG	cis	rs11969893	0.850	rs9404058	chr6:101323078	T/C	cg12253828	chr6:101329408	ASCC3	1.22	10.41	0.44	5.83e-23	Economic and political preferences (immigration/crime);
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg06916706	chr16:4465613	CORO7	-1.15	-24.01	-0.74	2.41e-83	Schizophrenia;
LGG	cis	rs11264213	0.901	rs72661625	chr1:36401003	T/C	cg27506609	chr1:36549197	TEKT2	0.77	7.64	0.33	1.3e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19782243	chr11:125133120	PKNOX2	0.47	8.15	0.35	3.47e-15	Gut microbiome composition (summer);
LGG	cis	rs12447804	0.906	rs12447579	chr16:58075085	G/A	cg03859792	chr16:58121049	NA	0.47	7.08	0.31	5.46e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg08648136	chr8:956695	NA	0.44	9.34	0.4	4.1e-19	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08795170	chr5:108746307	PJA2	0.43	7.15	0.32	3.36e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9807989	0.524	rs4851576	chr2:103028895	C/T	cg03938978	chr2:103052716	IL18RAP	0.4	9.27	0.4	7.2e-19	Asthma;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19723775	chr5:179050963	HNRNPH1	0.44	7.23	0.32	2.02e-12	Lung cancer;
LGG	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.75	0.54	2.61e-36	Cognitive test performance;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.29	0.36	1.2e-15	Lung cancer;
LGG	cis	rs7851660	0.809	rs3808893	chr9:100663745	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs7546	0.504	rs2075636	chr16:4938321	A/T	cg08329684	chr16:4932620	PPL	-0.56	-12.68	-0.51	8.05e-32	Cancer;
LGG	cis	rs1577917	0.958	rs12191340	chr6:86521400	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.96	-0.38	7.97e-18	Response to antipsychotic treatment;
LGG	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg15704280	chr7:45808275	SEPT13	-1.0	-21.44	-0.71	2.6e-71	Coronary artery disease;
LGG	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg16586182	chr3:47516702	SCAP	0.74	13.29	0.53	2.23e-34	Colorectal cancer;
LGG	cis	rs9549367	0.662	rs3818334	chr13:113825174	C/G	cg00898013	chr13:113819073	PROZ	-0.5	-9.94	-0.42	3.09e-21	Platelet distribution width;
LGG	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.19	-0.46	7.01e-26	Mean platelet volume;
LGG	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg02711726	chr17:80685570	FN3KRP	-0.38	-7.39	-0.32	6.82e-13	Breast cancer;
LGG	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg16797656	chr11:68205561	LRP5	0.51	10.05	0.42	1.29e-21	Total body bone mineral density;
LGG	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	8.36	0.36	7.44e-16	Neuroticism;
LGG	cis	rs7582720	1.000	rs72926802	chr2:203830228	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.33	0.36	9.12e-16	Schizophrenia;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.01	-0.31	8.3e-12	IgG glycosylation;
LGG	cis	rs4430311	0.723	rs4658588	chr1:243846271	A/G	cg25706552	chr1:244017396	NA	-0.64	-15.24	-0.58	8.52e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.71	0.3	5.87e-11	Cognitive function;
LGG	cis	rs975739	0.684	rs7985821	chr13:78599459	G/A	cg07847733	chr13:78271382	SLAIN1	0.45	7.79	0.34	4.3e-14	Hair color;
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg02158880	chr13:53174818	NA	0.4	7.86	0.34	2.76e-14	Lewy body disease;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg02002194	chr4:3960332	NA	0.44	8.16	0.35	3.3e-15	Triglycerides;
LGG	cis	rs7928758	0.943	rs78975867	chr11:134264729	G/A	cg25213107	chr11:134282864	B3GAT1	1.26	14.95	0.57	1.61e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2404602	0.647	rs11633869	chr15:77133322	G/T	cg15268244	chr15:77196840	NA	-0.48	-10.35	-0.43	9.99e-23	Blood metabolite levels;
LGG	cis	rs6963495	0.818	rs115609508	chr7:105163716	C/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.66	0.34	1.08e-13	Homoarginine levels;
LGG	cis	rs3784262	0.757	rs74655564	chr15:58325512	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.4	-8.38	-0.36	6.55e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4474465	0.850	rs10793326	chr11:78255422	A/C	cg27205649	chr11:78285834	NARS2	0.5	8.54	0.37	2.01e-16	Alzheimer's disease (survival time);
LGG	cis	rs7932354	0.710	rs2306032	chr11:46897253	G/C	cg03339077	chr11:47165057	C11orf49	-0.45	-8.11	-0.35	4.58e-15	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs8072100	0.713	rs2136750	chr17:45456100	A/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.26	-0.4	7.42e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4774830	0.744	rs1912401	chr15:56161609	A/G	cg05129572	chr15:56138634	NEDD4	0.85	7.92	0.35	1.8e-14	Delta-5 desaturase activity;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.22e-26	Personality dimensions;
LGG	cis	rs2463822	0.514	rs10750972	chr11:62053687	A/G	cg06239285	chr11:62104954	ASRGL1	0.73	9.87	0.42	5.7e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg03929089	chr4:120376271	NA	0.9	17.92	0.64	6.53e-55	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.01	-0.39	5.46e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg26384229	chr12:38710491	ALG10B	0.72	14.27	0.55	1.47e-38	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00006032	chr14:66974439	GPHN	0.41	7.15	0.32	3.49e-12	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18305333	chr11:62439274	C11orf83;C11orf48	0.45	6.68	0.3	7.03e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.4	0.4	2.47e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg07511668	chr11:68622177	NA	0.49	9.27	0.4	7.03e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs758324	0.947	rs253943	chr5:131320730	C/T	cg06307176	chr5:131281290	NA	0.57	9.03	0.39	4.57e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12295403	0.691	rs11607934	chr11:18689168	C/T	cg09201001	chr11:18656081	SPTY2D1	0.39	6.69	0.3	6.27e-11	Ovarian reserve;
LGG	cis	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.605	rs12938099	chr17:37612910	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.62	-0.37	1.11e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg24112000	chr20:60950667	NA	-0.36	-8.28	-0.36	1.34e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.632	rs74025655	chr15:86217550	C/A	cg25843651	chr15:86329602	KLHL25	0.55	8.34	0.36	8.33e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs2204008	0.774	rs11520273	chr12:38354075	A/T	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Bladder cancer;
LGG	cis	rs2201728	1.000	rs12510722	chr4:100147101	A/G	cg07219303	chr4:100140905	ADH6	-0.42	-8.35	-0.36	8.24e-16	Cardiac Troponin-T levels;
LGG	cis	rs6840360	0.571	rs11726892	chr4:152555106	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg03788504	chr6:150331562	NA	-0.61	-13.98	-0.54	2.72e-37	Alopecia areata;
LGG	cis	rs4891159	0.548	rs2554830	chr18:74127702	A/G	cg24786174	chr18:74118243	ZNF516	0.68	17.43	0.63	1.14e-52	Longevity;
LGG	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg20813462	chr7:2646259	IQCE	0.55	7.07	0.31	5.66e-12	Urate levels in lean individuals;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	7.66	0.34	1.1e-13	Renal function-related traits (BUN);
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00166722	chr3:10149974	C3orf24	0.58	7.97	0.35	1.24e-14	Alzheimer's disease;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg05926928	chr17:57297772	GDPD1	-0.84	-11.66	-0.48	1.04e-27	Opioid sensitivity;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg19223190	chr17:80058835	NA	0.44	8.44	0.37	4.01e-16	Life satisfaction;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg08677398	chr8:58056175	NA	0.45	7.44	0.33	4.85e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs77633900	0.772	rs16968196	chr15:76682238	C/T	cg21673338	chr15:77095150	SCAPER	-0.64	-8.39	-0.36	5.81e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4683346	0.525	rs6806706	chr3:43066308	C/A	cg05453631	chr3:43117548	NA	-0.36	-7.23	-0.32	2.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1707322	0.752	rs4660880	chr1:46111040	C/T	cg03146154	chr1:46216737	IPP	0.56	11.0	0.46	3.59e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs735396	0.694	rs2264750	chr12:121450165	C/T	cg14101638	chr12:121416612	HNF1A	0.4	8.08	0.35	5.73e-15	N-glycan levels;
LGG	cis	rs2439831	0.717	rs2447198	chr15:43895118	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.68	0.41	2.71e-20	Lung cancer in ever smokers;
LGG	cis	rs9287719	0.967	rs2010073	chr2:10736478	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	10.0	0.42	1.96e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg08888203	chr3:10149979	C3orf24	0.55	9.29	0.4	6.26e-19	Alzheimer's disease;
LGG	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg19524238	chr7:2802976	GNA12	0.41	9.42	0.4	2.17e-19	Height;
LGG	cis	rs8133932	0.701	rs7280054	chr21:47301246	T/G	cg11214348	chr21:47283868	PCBP3	0.44	7.99	0.35	1.07e-14	Schizophrenia;
LGG	cis	rs477692	0.870	rs512655	chr10:131424547	T/A	cg05714579	chr10:131428358	MGMT	0.65	13.69	0.54	4.48e-36	Response to temozolomide;
LGG	cis	rs1799949	0.965	rs8071278	chr17:41193910	A/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	4.9e-17	Menopause (age at onset);
LGG	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg19418458	chr7:158789849	NA	-0.52	-10.92	-0.45	7.11e-25	Facial morphology (factor 20);
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg15242686	chr22:24348715	GSTTP1	0.56	10.59	0.44	1.32e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.26	0.36	1.5e-15	Coronary artery disease;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.27	-0.36	1.44e-15	Total body bone mineral density;
LGG	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg21399703	chr1:247681439	NA	0.63	11.27	0.46	3.27e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.64	-0.41	3.59e-20	Height;
LGG	cis	rs9880211	1.000	rs9823373	chr3:136167027	T/C	cg21827317	chr3:136751795	NA	-0.48	-7.21	-0.32	2.25e-12	Body mass index;Height;
LGG	cis	rs950027	0.620	rs2461700	chr15:45640627	T/C	cg26924012	chr15:45694286	SPATA5L1	0.69	12.49	0.5	4.9e-31	Response to fenofibrate (adiponectin levels);
LGG	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg26001287	chr2:111877753	BCL2L11	-0.36	-7.23	-0.32	2.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs8112449	1.000	rs17697965	chr19:10519410	A/C	cg21868191	chr19:10515988	NA	0.46	8.08	0.35	5.86e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.95	-0.52	6.19e-33	Vitiligo;
LGG	cis	rs4808199	0.842	rs11085259	chr19:19445856	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.32	0.32	1.1e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13012494	chr21:47604986	C21orf56	-0.63	-10.46	-0.44	4.03e-23	Testicular germ cell tumor;
LGG	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.54	-0.37	1.92e-16	Morning vs. evening chronotype;
LGG	cis	rs2797369	0.656	rs1928067	chr6:101589657	A/G	cg27451362	chr6:101846650	GRIK2	0.84	11.45	0.47	6.56e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg03188948	chr7:1209495	NA	0.42	7.09	0.31	5.17e-12	Longevity;Endometriosis;
LGG	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14829155	chr15:31115871	NA	-0.6	-9.72	-0.41	1.92e-20	Huntington's disease progression;
LGG	cis	rs1577917	0.958	rs11754330	chr6:86455070	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.67	-0.44	6.57e-24	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg05313129	chr8:58192883	C8orf71	-0.67	-8.75	-0.38	4.06e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.75	-0.3	4.55e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg08085267	chr17:45401833	C17orf57	-0.58	-11.34	-0.47	1.81e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7394190	0.748	rs79936644	chr10:75545117	C/T	cg07699608	chr10:75541558	CHCHD1	0.55	7.37	0.32	7.9e-13	Incident atrial fibrillation;
LGG	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.44	-0.33	4.93e-13	Body mass index;
LGG	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg12386194	chr3:101231763	SENP7	0.74	12.87	0.51	1.23e-32	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-8.79	-0.38	3.01e-17	Chronic sinus infection;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg08200770	chr17:80723486	TBCD	-0.43	-7.88	-0.34	2.35e-14	Glycated hemoglobin levels;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7586673	0.930	rs2884364	chr2:161977647	G/A	cg22496339	chr2:162101262	NA	-0.34	-6.72	-0.3	5.44e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.34	-0.32	9.92e-13	Mood instability;
LGG	cis	rs9443189	0.570	rs775072	chr6:76377998	G/A	cg01950844	chr6:76311363	SENP6	-0.76	-10.07	-0.42	1.07e-21	Prostate cancer;
LGG	cis	rs7927592	0.913	rs6591346	chr11:68384618	T/A	cg20283391	chr11:68216788	NA	-0.5	-8.15	-0.35	3.44e-15	Total body bone mineral density;
LGG	cis	rs990171	1.000	rs1420106	chr2:103035044	C/T	cg05295703	chr2:102895712	NA	0.56	9.79	0.41	1.06e-20	Lymphocyte counts;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11393614	chr10:88282152	WAPAL	-0.47	-6.81	-0.3	3.1e-11	Systemic lupus erythematosus;
LGG	cis	rs7107174	0.901	rs866901	chr11:77926309	C/T	cg19901956	chr11:77921274	USP35	-0.41	-6.67	-0.3	7.3e-11	Testicular germ cell tumor;
LGG	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.11	-0.31	4.45e-12	Systolic blood pressure;
LGG	cis	rs11064837	0.523	rs7960723	chr12:120099521	G/A	cg25937854	chr12:120150414	CIT	-0.68	-11.25	-0.46	4.18e-26	Schizophrenia;
LGG	cis	rs2267681	0.583	rs10256282	chr7:139528444	C/T	cg14116596	chr7:139528673	TBXAS1	0.32	7.1	0.31	4.83e-12	Cervical cancer;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.52	0.4	9.29e-20	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.65	-0.41	3.42e-20	Lung cancer;
LGG	cis	rs10540	0.908	rs35608427	chr11:498976	T/C	cg19913688	chr11:428466	ANO9	-0.65	-8.42	-0.36	4.59e-16	Body mass index;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs4818225	0.818	rs2837999	chr21:42630531	A/G	cg21268422	chr21:42620091	BACE2	0.46	7.87	0.34	2.46e-14	Educational attainment;
LGG	cis	rs758324	0.738	rs648304	chr5:131286708	T/C	cg06307176	chr5:131281290	NA	-0.56	-9.19	-0.39	1.32e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs16933812	0.510	rs7868685	chr9:36989837	G/T	cg13738729	chr9:36989127	PAX5	-0.41	-9.25	-0.39	8.49e-19	Obesity-related traits;
LGG	cis	rs6076065	0.963	rs999072	chr20:23347553	C/T	cg11657817	chr20:23433608	CST11	0.35	6.92	0.31	1.48e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg13264159	chr8:625131	ERICH1	-1.01	-10.86	-0.45	1.28e-24	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg04503457	chr17:41445688	NA	-0.4	-9.27	-0.4	7.23e-19	Menopause (age at onset);
LGG	cis	rs4660214	0.666	rs61783383	chr1:39807018	T/C	cg18385671	chr1:39797026	MACF1	-0.47	-9.79	-0.41	1.08e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	7.17	0.32	2.91e-12	Multiple sclerosis;
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg15145296	chr3:125709740	NA	0.61	7.92	0.35	1.72e-14	Blood pressure (smoking interaction);
LGG	cis	rs4662945	0.525	rs4662951	chr2:130256272	C/T	cg05962382	chr2:130345044	NA	-0.44	-7.7	-0.34	8.08e-14	Response to cytidine analogues (gemcitabine);
LGG	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg20814179	chr4:940893	TMEM175	0.46	8.23	0.36	1.94e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs6540556	0.834	rs6700223	chr1:209935031	G/A	cg23920097	chr1:209922102	NA	-0.42	-7.7	-0.34	8.22e-14	Red blood cell count;
LGG	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg02002194	chr4:3960332	NA	0.39	7.03	0.31	7.24e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.75	-0.3	4.41e-11	Systolic blood pressure;
LGG	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg00290607	chr11:67383545	NA	-0.5	-8.99	-0.39	6.5e-18	Mean corpuscular volume;
LGG	cis	rs17818399	0.633	rs2242033	chr2:46842410	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.48	-8.54	-0.37	1.97e-16	Height;
LGG	cis	rs9788682	0.706	rs2568493	chr15:78740233	G/A	cg06917634	chr15:78832804	PSMA4	0.53	8.12	0.35	4.16e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6582630	0.502	rs2204008	chr12:38439203	C/T	cg26384229	chr12:38710491	ALG10B	0.9	20.2	0.68	1.56e-65	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01570182	chr17:44337453	NA	0.68	11.21	0.46	5.63e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs727505	0.821	rs73225498	chr7:124704197	C/T	cg23710748	chr7:124431027	NA	-0.48	-8.74	-0.38	4.43e-17	Lewy body disease;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.77	0.38	3.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6546537	0.571	rs4852274	chr2:69780637	G/A	cg10773587	chr2:69614142	GFPT1	-0.46	-8.15	-0.35	3.42e-15	Serum thyroid-stimulating hormone levels;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-14.76	-0.57	1.16e-40	Colorectal cancer;
LGG	cis	rs638893	0.947	rs12808822	chr11:118702269	C/T	cg22253036	chr11:118662786	DDX6	0.41	6.91	0.31	1.59e-11	Vitiligo;
LGG	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg06138931	chr13:21896616	NA	-0.48	-7.86	-0.34	2.68e-14	White matter hyperintensity burden;
LGG	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg24130564	chr14:104152367	KLC1	0.37	6.88	0.3	1.93e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.23	0.32	2.01e-12	Educational attainment;
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg23594656	chr7:65796392	TPST1	-0.4	-8.94	-0.38	9.18e-18	Aortic root size;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg20607798	chr8:58055168	NA	0.65	7.17	0.32	2.99e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg19223190	chr17:80058835	NA	0.44	8.45	0.37	3.85e-16	Life satisfaction;
LGG	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg03114573	chr12:45410052	DBX2	0.67	12.14	0.49	1.24e-29	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.4	0.56	4.01e-39	Lung cancer;
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.58	-0.41	5.91e-20	Triglycerides;
LGG	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg01448562	chr3:133502909	NA	-0.52	-8.7	-0.37	5.9e-17	Iron status biomarkers;
LGG	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg01631408	chr1:248437212	OR2T33	-0.39	-7.29	-0.32	1.35e-12	Common traits (Other);
LGG	cis	rs4704846	0.950	rs919746	chr5:156531316	C/T	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.32	-0.32	1.12e-12	Blood protein levels;
LGG	cis	rs2916247	0.955	rs2920462	chr8:92985508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.41	8.56	0.37	1.72e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10940138	0.774	rs16897196	chr5:67228478	G/C	ch.5.1281357F	chr5:67228439	NA	0.76	13.66	0.54	6.51e-36	Menarche (age at onset);
LGG	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg02466173	chr16:30829666	NA	-0.52	-9.26	-0.4	7.8e-19	Multiple myeloma;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs10267417	0.603	rs17142124	chr7:19903631	C/G	cg05791153	chr7:19748676	TWISTNB	0.56	7.32	0.32	1.1e-12	Night sleep phenotypes;
LGG	cis	rs10504073	0.647	rs12156111	chr8:50017328	G/C	cg00325661	chr8:49890786	NA	0.7	13.44	0.53	5.15e-35	Blood metabolite ratios;
LGG	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg07636037	chr3:49044803	WDR6	0.91	15.28	0.58	5.85e-43	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg18795169	chr1:18902165	NA	-1.05	-34.22	-0.85	7.14e-129	Urate levels in lean individuals;
LGG	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs701145	0.938	rs701138	chr3:154063609	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.36	0.5	1.63e-30	Coronary artery disease;
LGG	trans	rs853679	1.000	rs853676	chr6:28299687	C/T	cg01620082	chr3:125678407	NA	-0.59	-7.49	-0.33	3.42e-13	Depression;
LGG	cis	rs2028299	0.879	rs3803534	chr15:90441870	A/G	cg23731826	chr15:90371692	NA	0.37	8.11	0.35	4.61e-15	Type 2 diabetes;
LGG	cis	rs7584330	0.910	rs880932	chr2:238396963	A/G	cg16989719	chr2:238392110	NA	-0.32	-6.92	-0.31	1.49e-11	Prostate cancer;
LGG	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg21699342	chr2:239360505	ASB1	0.39	7.51	0.33	3.17e-13	Multiple system atrophy;
LGG	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.22	0.32	2.1e-12	Retinal vascular caliber;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg11965913	chr1:205819406	PM20D1	0.83	18.3	0.65	1.15e-56	Menarche (age at onset);
LGG	cis	rs3764563	0.932	rs617436	chr19:15693151	T/C	cg20725493	chr19:15740067	CYP4F8	0.57	6.74	0.3	4.69e-11	Inflammatory biomarkers;
LGG	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg12432903	chr7:1882776	MAD1L1	0.52	8.04	0.35	7.72e-15	Bipolar disorder;
LGG	cis	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg20368463	chr18:77673604	PQLC1	0.7	13.53	0.53	2.31e-35	Schizophrenia;
LGG	trans	rs1814175	0.645	rs866427	chr11:49923853	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs11252926	0.801	rs12358553	chr10:558014	C/T	cg16386425	chr10:429943	DIP2C	0.39	7.35	0.32	9.25e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs4774830	0.590	rs4774837	chr15:56255774	G/T	cg05129572	chr15:56138634	NEDD4	0.87	7.99	0.35	1.11e-14	Delta-5 desaturase activity;
LGG	trans	rs6076960	0.744	rs6053961	chr20:6176793	A/G	cg21095983	chr6:86352623	SYNCRIP	0.49	8.76	0.38	3.78e-17	Smooth-surface caries;
LGG	cis	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg07636037	chr3:49044803	WDR6	0.57	7.63	0.33	1.35e-13	Menarche (age at onset);
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg08645402	chr16:4508243	NA	0.54	9.79	0.41	1.08e-20	Schizophrenia;
LGG	cis	rs7523050	0.643	rs34801874	chr1:109404382	C/T	cg08274380	chr1:109419600	GPSM2	0.99	12.11	0.49	1.58e-29	Fat distribution (HIV);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10132588	chr2:163695190	KCNH7	0.39	6.82	0.3	2.89e-11	Menarche (age at onset);
LGG	cis	rs8114671	0.562	rs2378292	chr20:33485178	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	6.95	0.31	1.26e-11	Height;
LGG	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-10.47	-0.44	3.59e-23	Height;
LGG	cis	rs4478037	0.822	rs9827863	chr3:33118951	C/T	cg19404215	chr3:33155277	CRTAP	-0.8	-9.43	-0.4	2.06e-19	Major depressive disorder;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg15971980	chr6:150254442	NA	0.45	8.5	0.37	2.72e-16	Lung cancer;
LGG	cis	rs7000551	0.675	rs2469758	chr8:22363032	C/T	cg12081754	chr8:22256438	SLC39A14	0.63	11.83	0.48	2.17e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2133450	0.662	rs9873905	chr3:7299331	A/G	cg19930620	chr3:7340148	GRM7	0.33	7.01	0.31	8.5e-12	Early response to risperidone in schizophrenia;
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg05335186	chr13:53173507	NA	0.89	23.63	0.74	1.37e-81	Lewy body disease;
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.23	0.39	9.57e-19	Aortic root size;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.94	0.38	9.44e-18	Renal function-related traits (BUN);
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.3e-13	Lung cancer;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05165339	chr4:1420672	NA	0.31	8.05	0.35	7.18e-15	Obesity-related traits;
LGG	cis	rs68170813	0.559	rs76843318	chr7:106863173	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.79	-0.45	2.22e-24	Coronary artery disease;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	16.23	0.6	3.22e-47	Tonsillectomy;
LGG	trans	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.86	-0.34	2.68e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.49	-0.33	3.52e-13	Lung cancer;
LGG	cis	rs7209395	0.959	rs9889344	chr17:64179827	G/A	cg19474267	chr17:64306194	PRKCA	0.52	8.23	0.36	1.95e-15	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs317689	0.788	rs317679	chr12:69693172	A/C	cg11871910	chr12:69753446	YEATS4	0.47	7.51	0.33	2.97e-13	Response to diuretic therapy;
LGG	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.28	-0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs6032067	0.632	rs35361894	chr20:43794403	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.69	0.54	4.8e-36	Morning vs. evening chronotype;
LGG	trans	rs7615952	0.932	rs6438948	chr3:125650045	A/T	cg07211511	chr3:129823064	LOC729375	1.28	19.64	0.67	6.5e-63	Blood pressure (smoking interaction);
LGG	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg02527881	chr3:46936655	PTH1R	0.33	7.92	0.35	1.72e-14	Birth weight;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.6	-0.47	1.71e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7769051	0.522	rs7759524	chr6:133109574	A/G	cg07930552	chr6:133119739	C6orf192	1.15	10.6	0.44	1.22e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7309	0.935	rs6432674	chr2:162025322	G/T	cg22496339	chr2:162101262	NA	-0.53	-11.63	-0.48	1.33e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs7336332	0.598	rs1885988	chr13:28010262	C/T	cg01674679	chr13:27998804	GTF3A	0.63	8.22	0.36	2.1e-15	Weight;
LGG	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg22484793	chr3:52261325	TLR9	0.3	6.94	0.31	1.3e-11	Bipolar disorder;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg11473876	chr11:109292803	C11orf87	-0.46	-9.31	-0.4	5.28e-19	Schizophrenia;
LGG	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg01625945	chr7:157512322	PTPRN2	-0.48	-11.24	-0.46	4.29e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4363385	0.588	rs12082627	chr1:153023650	G/A	cg13444842	chr1:152974279	SPRR3	-0.48	-9.77	-0.41	1.24e-20	Inflammatory skin disease;
LGG	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg16339924	chr4:17578868	LAP3	0.59	10.3	0.43	1.48e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg05425664	chr17:57184151	TRIM37	-0.44	-7.22	-0.32	2.14e-12	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg27661571	chr11:113659931	NA	-0.59	-8.38	-0.36	6.23e-16	Hip circumference adjusted for BMI;
LGG	trans	rs6825911	0.638	rs7696406	chr4:111373078	A/C	cg10580549	chr19:53101634	ZNF137	0.55	6.99	0.31	9.67e-12	Blood pressure;
LGG	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.1	14.66	0.56	2.98e-40	Alzheimer's disease;
LGG	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg08999081	chr20:33150536	PIGU	-0.35	-8.45	-0.37	3.72e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-12.39	-0.5	1.25e-30	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg01620082	chr3:125678407	NA	-0.83	-9.45	-0.4	1.74e-19	Depression;
LGG	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.5e-13	Hemoglobin concentration;
LGG	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.18e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3206736	0.548	rs57315957	chr7:35062819	A/G	cg13400248	chr7:35225412	NA	0.55	9.59	0.41	5.63e-20	Diastolic blood pressure;
LGG	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.66	0.41	2.98e-20	Retinal vascular caliber;
LGG	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.39	-0.32	7e-13	Blood metabolite levels;
LGG	cis	rs2013441	0.965	rs7207611	chr17:20204516	C/T	cg13482628	chr17:19912719	NA	0.51	9.37	0.4	3.21e-19	Obesity-related traits;
LGG	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg18854424	chr1:2615690	NA	-0.35	-7.45	-0.33	4.48e-13	Ulcerative colitis;
LGG	cis	rs1801251	1.000	rs283477	chr2:233649427	A/G	cg08000102	chr2:233561755	GIGYF2	0.6	9.84	0.42	6.87e-21	Coronary artery disease;
LGG	trans	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.72	-12.43	-0.5	8.57e-31	Type 2 diabetes;
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg05368731	chr17:41323189	NBR1	0.96	18.85	0.66	3.1e-59	Menopause (age at onset);
LGG	cis	rs7100689	0.622	rs10749595	chr10:82172975	C/T	cg01528321	chr10:82214614	TSPAN14	1.02	19.75	0.68	1.95e-63	Post bronchodilator FEV1;
LGG	cis	rs4566357	1.000	rs4296417	chr2:227921941	G/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs11168618	0.904	rs7137866	chr12:48922802	T/C	cg24011408	chr12:48396354	COL2A1	0.46	7.44	0.33	4.78e-13	Adiponectin levels;
LGG	trans	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg06521331	chr12:34319734	NA	0.43	7.68	0.34	9.68e-14	Heart rate;
LGG	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg09873164	chr1:152488093	CRCT1	0.56	11.17	0.46	8.52e-26	Hair morphology;
LGG	cis	rs11608355	0.521	rs4766469	chr12:109836890	C/G	cg19025524	chr12:109796872	NA	0.58	12.64	0.51	1.14e-31	Neuroticism;
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00166722	chr3:10149974	C3orf24	0.42	7.44	0.33	5.03e-13	Alzheimer's disease;
LGG	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg05163923	chr11:71159392	DHCR7	0.71	13.91	0.54	5.52e-37	Vitamin D levels;
LGG	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg00129232	chr17:37814104	STARD3	-0.56	-8.42	-0.36	4.6e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs12579753	0.869	rs12366920	chr12:82223015	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg01028140	chr2:1542097	TPO	-0.43	-8.14	-0.35	3.67e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7580658	0.929	rs4150477	chr2:128032546	A/G	cg10021288	chr2:128175891	PROC	0.63	13.02	0.52	2.99e-33	Protein C levels;
LGG	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg20476274	chr7:133979776	SLC35B4	0.74	14.15	0.55	5.05e-38	Mean platelet volume;
LGG	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg11871910	chr12:69753446	YEATS4	-0.77	-12.92	-0.51	8e-33	Response to diuretic therapy;
LGG	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg06219351	chr7:158114137	PTPRN2	-0.74	-14.22	-0.55	2.41e-38	Calcium levels;
LGG	cis	rs6089584	0.627	rs13045575	chr20:60565596	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-11.16	-0.46	8.86e-26	Body mass index;
LGG	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg26150922	chr2:100937072	LONRF2	-0.55	-9.64	-0.41	3.61e-20	Intelligence (multi-trait analysis);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg10038085	chr1:165797905	UCK2	-0.44	-6.79	-0.3	3.37e-11	Coronary artery disease;
LGG	cis	rs2494938	1.000	rs1618714	chr6:40532551	G/C	cg14084896	chr6:40530702	LRFN2	-0.3	-7.06	-0.31	6.15e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg23231163	chr10:75533350	FUT11	-0.44	-7.31	-0.32	1.22e-12	Inflammatory bowel disease;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg17911788	chr17:44343683	NA	0.62	9.62	0.41	4.3e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.37	0.5	1.4e-30	Colorectal cancer;
LGG	cis	rs6976053	0.935	rs12669120	chr7:100476110	T/C	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.84e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7568458	0.811	rs10175792	chr2:85761654	A/G	cg17127132	chr2:85788382	GGCX	0.47	8.13	0.35	3.98e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs16854884	0.683	rs10935505	chr3:143777966	T/C	cg06585982	chr3:143692056	C3orf58	0.55	9.39	0.4	2.73e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03352830	chr11:487213	PTDSS2	0.87	10.91	0.45	7.93e-25	Body mass index;
LGG	cis	rs55788414	1.000	rs67345347	chr16:81185125	G/C	cg06400318	chr16:81190750	PKD1L2	-0.92	-10.96	-0.45	5.4e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Body mass index;
LGG	cis	rs2224391	0.656	rs68061889	chr6:5292817	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-7.07	-0.31	5.71e-12	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05930166	chr1:222884917	AIDA;C1orf58	0.48	7.96	0.35	1.35e-14	Cognitive performance;
LGG	cis	rs7166081	1.000	rs17526859	chr15:67611066	A/C	cg24231037	chr15:68117551	LBXCOR1	0.31	6.95	0.31	1.28e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7202877	0.706	rs40217	chr16:75480066	C/A	cg03315344	chr16:75512273	CHST6	-0.51	-6.74	-0.3	4.64e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg12070911	chr6:150209640	RAET1E	0.31	7.51	0.33	3.03e-13	Lung cancer;
LGG	cis	rs17039065	1.000	rs34038779	chr4:109377817	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.01	0.31	8.24e-12	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg02227867	chr8:22457446	C8orf58	-0.43	-7.76	-0.34	5.61e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.34	-0.32	9.37e-13	Menopause (age at onset);
LGG	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg06634786	chr22:41940651	POLR3H	-0.72	-11.54	-0.47	2.88e-27	Vitiligo;
LGG	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg05444541	chr17:17804740	TOM1L2	0.62	14.5	0.56	1.53e-39	Total body bone mineral density;
LGG	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg14088196	chr11:70211408	PPFIA1	0.91	12.67	0.51	8.94e-32	Coronary artery disease;
LGG	cis	rs4538187	1.000	rs6732746	chr2:64089748	C/A	cg14150252	chr2:64069583	UGP2	0.5	10.1	0.42	8.26e-22	Systolic blood pressure;
LGG	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.4	-0.33	6.4e-13	Bladder cancer;
LGG	cis	rs2635047	0.638	rs1434529	chr18:44730142	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.95	0.31	1.27e-11	Educational attainment;
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.65e-12	Bipolar disorder;
LGG	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg16339924	chr4:17578868	LAP3	0.68	11.55	0.47	2.82e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs77633900	0.772	rs75253262	chr15:76657124	G/A	cg21673338	chr15:77095150	SCAPER	-0.61	-7.92	-0.35	1.84e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2012796	0.743	rs12435764	chr14:81836866	A/C	cg02996355	chr14:81879375	NA	0.57	9.53	0.4	9.13e-20	Night sleep phenotypes;
LGG	trans	rs208520	0.837	rs208498	chr6:66931560	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.21	-0.58	1.14e-42	Exhaled nitric oxide output;
LGG	cis	rs10819861	0.645	rs4743537	chr9:98862861	C/A	cg14508093	chr9:98862825	NA	0.29	6.8	0.3	3.34e-11	Electrocardiographic traits;
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg10207240	chr12:122356781	WDR66	0.26	7.76	0.34	5.29e-14	Mean corpuscular volume;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg04287289	chr16:89883240	FANCA	0.53	9.82	0.42	8.25e-21	Vitiligo;
LGG	cis	rs2282300	0.739	rs1222221	chr11:30342738	A/G	cg06241208	chr11:30344200	C11orf46	-0.5	-6.69	-0.3	6.53e-11	Morning vs. evening chronotype;
LGG	cis	rs1693575	0.624	rs1693551	chr8:101675584	C/T	cg06874326	chr8:101662790	SNX31	0.36	7.23	0.32	2.06e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs698813	0.763	rs1067335	chr2:44625958	T/C	cg00619915	chr2:44497795	NA	-0.49	-6.84	-0.3	2.5e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.17e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs3812831	0.695	rs6560936	chr13:114945972	C/T	cg22348356	chr13:114891224	RASA3	-0.4	-7.76	-0.34	5.44e-14	Schizophrenia;
LGG	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg10847948	chr11:71163743	NADSYN1	-0.66	-12.99	-0.52	4.07e-33	Vitamin D levels;
LGG	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg02466173	chr16:30829666	NA	-0.63	-12.61	-0.51	1.53e-31	Dementia with Lewy bodies;
LGG	trans	rs4650994	0.525	rs4650997	chr1:178530744	T/A	cg05059571	chr16:84539110	KIAA1609	-0.57	-10.89	-0.45	9.44e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-9.05	-0.39	4e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg07930552	chr6:133119739	C6orf192	0.87	11.5	0.47	4.41e-27	Type 2 diabetes nephropathy;
LGG	cis	rs2455799	0.593	rs2062823	chr3:15732256	G/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.96	-0.35	1.37e-14	Mean platelet volume;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg04234412	chr22:24373322	LOC391322	-0.8	-16.38	-0.61	6.83e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	8.41	0.36	5.04e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs11168187	0.843	rs2074531	chr12:48119832	G/T	cg12761788	chr12:48120090	P11	0.52	8.9	0.38	1.25e-17	Vertical cup-disc ratio;
LGG	cis	rs75920871	1.000	rs7950213	chr11:116868654	C/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs1754541	1.000	rs612083	chr1:101625042	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.37	-6.73	-0.3	4.95e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg19773385	chr1:10388646	KIF1B	-0.5	-11.0	-0.46	3.74e-25	Hepatocellular carcinoma;
LGG	cis	rs9557207	0.901	rs9517620	chr13:99788979	G/A	cg24509225	chr13:100037070	UBAC2	-0.63	-11.19	-0.46	6.73e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	9.4	0.4	2.52e-19	Iron status biomarkers;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg08601574	chr20:25228251	PYGB	0.37	7.48	0.33	3.69e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg02023728	chr11:77925099	USP35	0.43	7.35	0.32	8.77e-13	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06766450	chr1:16766999	NECAP2	0.48	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.0	-0.42	1.9e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs3857536	0.740	rs9342532	chr6:66886297	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.25	-0.36	1.63e-15	Blood trace element (Cu levels);
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg08355456	chr11:67383691	NA	0.48	8.23	0.36	1.89e-15	Mean corpuscular volume;
LGG	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg08704250	chr15:31115839	NA	0.5	9.41	0.4	2.38e-19	Huntington's disease progression;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg10295955	chr4:187884368	NA	-1.14	-29.64	-0.81	4.84e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg07274523	chr3:49395745	GPX1	0.57	9.66	0.41	3.08e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2117029	0.587	rs7958572	chr12:49509441	C/G	cg24176009	chr12:49580217	TUBA1A	0.6	11.73	0.48	5.36e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs79387448	0.638	rs74731686	chr2:103043981	G/A	cg20060108	chr2:102954350	IL1RL1	-0.45	-6.77	-0.3	3.87e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg27286337	chr10:134555280	INPP5A	0.84	13.7	0.54	4.33e-36	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11096990	0.855	rs2711988	chr4:39152748	C/T	cg24403649	chr4:39172243	NA	-0.48	-7.66	-0.34	1.1e-13	Cognitive function;
LGG	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg15268244	chr15:77196840	NA	0.49	10.35	0.43	1.02e-22	Blood metabolite levels;
LGG	cis	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-8.47	-0.37	3.34e-16	Systolic blood pressure;
LGG	trans	rs11039798	0.920	rs11039940	chr11:48716316	C/T	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg25457927	chr22:38595422	NA	-0.31	-7.65	-0.33	1.19e-13	Mammographic density (dense area);Percent mammographic density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14463748	chr2:96971527	SNRNP200	0.45	7.06	0.31	5.94e-12	Gut microbiome composition (summer);
LGG	cis	rs1568889	1.000	rs12797689	chr11:28076042	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	13.93	0.54	4.38e-37	Bipolar disorder;
LGG	cis	rs977987	0.843	rs11641801	chr16:75455448	A/C	cg03315344	chr16:75512273	CHST6	0.51	10.23	0.43	2.69e-22	Dupuytren's disease;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.92	-0.35	1.75e-14	IgG glycosylation;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg02158880	chr13:53174818	NA	0.41	8.2	0.36	2.34e-15	Lewy body disease;
LGG	cis	rs975722	0.638	rs213965	chr7:117229537	A/T	cg10524701	chr7:117356490	CTTNBP2	-0.45	-9.72	-0.41	1.95e-20	Coronary artery disease;
LGG	cis	rs7580658	0.676	rs58475809	chr2:128002650	A/G	cg10021288	chr2:128175891	PROC	-0.6	-12.13	-0.49	1.34e-29	Protein C levels;
LGG	cis	rs1003719	0.762	rs4399800	chr21:38489478	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.33	0.63	3.07e-52	Eye color traits;
LGG	cis	rs4774899	0.752	rs2439918	chr15:57344647	T/G	cg08128148	chr15:57256372	TCF12	-0.28	-6.95	-0.31	1.25e-11	Urinary tract infection frequency;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg11245990	chr11:68621969	NA	0.42	9.0	0.39	5.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.39	0.32	6.88e-13	Obesity-related traits;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.57	-0.5	2.31e-31	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19906760	chr14:78227687	SNW1;C14orf178	0.46	6.77	0.3	3.86e-11	Gut microbiome composition (summer);
LGG	cis	rs17209837	0.607	rs4148820	chr7:87080482	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.63	-0.59	1.64e-44	Gallbladder cancer;
LGG	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-11.28	-0.46	3.11e-26	Height;
LGG	cis	rs10781543	0.845	rs35763810	chr9:139323799	A/G	cg14019695	chr9:139328340	INPP5E	0.43	7.74	0.34	6.14e-14	Monocyte percentage of white cells;
LGG	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.74	0.38	4.18e-17	Systolic blood pressure;
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.68	0.63	7.57e-54	Platelet count;
LGG	trans	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg05926928	chr17:57297772	GDPD1	0.62	10.79	0.45	2.39e-24	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs2120243	0.653	rs3816527	chr3:157155314	C/A	cg01018701	chr3:157155998	VEPH1;PTX3	0.35	7.48	0.33	3.79e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg14926445	chr8:58193284	C8orf71	-0.68	-8.98	-0.39	6.75e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7558370	0.737	rs112914737	chr2:3713431	G/A	cg14882966	chr2:3699353	NA	0.81	7.22	0.32	2.15e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg22491629	chr6:157744540	C6orf35	-0.96	-13.75	-0.54	2.6e-36	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1401999	1.000	rs7620350	chr3:183710053	A/T	cg20387954	chr3:183756860	HTR3D	0.66	13.4	0.53	7.88e-35	Anterior chamber depth;
LGG	cis	rs1318772	1.000	rs13182359	chr5:112721135	A/G	cg12552261	chr5:112820674	MCC	0.69	7.98	0.35	1.2e-14	F-cell distribution;
LGG	cis	rs4409675	0.576	rs6662916	chr1:28219873	G/T	cg23691781	chr1:28212827	C1orf38	0.43	11.63	0.48	1.28e-27	Corneal astigmatism;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.69	0.3	6.3e-11	Schizophrenia;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg21724239	chr8:58056113	NA	0.61	8.84	0.38	1.95e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg18850127	chr7:39170497	POU6F2	0.6	14.6	0.56	5.64e-40	IgG glycosylation;
LGG	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.57	-0.33	1.99e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4700695	0.719	rs27087	chr5:65453050	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs763121	0.853	rs3788545	chr22:39065172	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	17.54	0.63	3.38e-53	Menopause (age at onset);
LGG	cis	rs8180040	0.620	rs9844122	chr3:47108330	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-13.25	-0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs3780378	0.840	rs10119004	chr9:5071049	C/T	cg02405213	chr9:5042618	JAK2	-0.42	-7.33	-0.32	1e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg00689492	chr4:1303491	MAEA	0.47	8.0	0.35	1.02e-14	Obesity-related traits;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg19635926	chr16:89946313	TCF25	0.8	8.29	0.36	1.27e-15	Skin colour saturation;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg07362569	chr17:61921086	SMARCD2	-0.45	-8.64	-0.37	8.86e-17	Prudent dietary pattern;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.68	0.3	6.77e-11	Schizophrenia;
LGG	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg01411142	chr8:19674711	INTS10	0.48	7.35	0.32	8.81e-13	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg02002194	chr4:3960332	NA	0.38	6.86	0.3	2.15e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.26	-0.43	2.22e-22	Neuroticism;
LGG	cis	rs968451	1.000	rs62228376	chr22:39701097	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	11.14	0.46	1.09e-25	Primary biliary cholangitis;
LGG	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg04851639	chr8:1020857	NA	-0.43	-9.03	-0.39	4.51e-18	Schizophrenia;
LGG	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg17215666	chr7:56131930	SUMF2	0.47	7.76	0.34	5.6e-14	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg01879757	chr17:41196368	BRCA1	-0.39	-8.0	-0.35	1.01e-14	Menopause (age at onset);
LGG	cis	rs3762637	0.941	rs79493664	chr3:122109546	T/A	cg24169773	chr3:122142474	KPNA1	-0.58	-9.38	-0.4	2.97e-19	LDL cholesterol levels;
LGG	cis	rs9964724	0.559	rs7243428	chr18:35156177	C/T	cg27332583	chr18:35150602	NA	-0.64	-12.52	-0.5	3.69e-31	Educational attainment (years of education);
LGG	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs7524258	0.868	rs4908451	chr1:7299618	C/G	cg07173049	chr1:7289937	CAMTA1	-0.83	-18.21	-0.65	2.81e-56	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg03433033	chr1:76189801	ACADM	0.72	12.65	0.51	1.09e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs870825	0.929	rs1405940	chr4:185591481	A/G	cg04058563	chr4:185651563	MLF1IP	1.06	20.1	0.68	4.55e-65	Blood protein levels;
LGG	trans	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg18335740	chr13:41363409	SLC25A15	0.88	20.61	0.69	1.85e-67	Lewy body disease;
LGG	trans	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.05	-0.35	7.29e-15	Blood trace element (Cu levels);
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs6694672	1.000	rs10754214	chr1:197059892	A/G	cg13682187	chr1:196946512	CFHR5	0.49	6.92	0.31	1.54e-11	Asthma;
LGG	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg17376030	chr22:41985996	PMM1	-0.56	-9.01	-0.39	5.47e-18	Vitiligo;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	8.06	0.35	6.74e-15	Tonsillectomy;
LGG	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.31	-0.32	1.19e-12	Systolic blood pressure;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.19	-0.58	1.38e-42	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg17376030	chr22:41985996	PMM1	0.66	10.51	0.44	2.56e-23	Vitiligo;
LGG	cis	rs4975616	0.804	rs457130	chr5:1336178	A/T	cg06550200	chr5:1325588	CLPTM1L	-0.62	-10.97	-0.45	4.58e-25	Lung cancer;
LGG	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.11	0.39	2.57e-18	Schizophrenia;
LGG	cis	rs7552167	0.852	rs10794647	chr1:24509133	C/T	cg17246694	chr1:24480847	IL28RA	0.52	6.72	0.3	5.49e-11	Psoriasis vulgaris;
LGG	trans	rs9929218	1.000	rs9929218	chr16:68820946	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.92	-0.48	9.65e-29	Colorectal cancer;
LGG	cis	rs4917300	0.605	rs11786676	chr8:143124513	G/A	cg06573787	chr8:143070187	NA	0.39	6.66	0.3	7.84e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10861342	1.000	rs1345095	chr12:105471577	C/T	cg23923672	chr12:105501055	KIAA1033	0.82	7.23	0.32	2.02e-12	IgG glycosylation;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.56	-9.65	-0.41	3.3e-20	Renal function-related traits (BUN);
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg04166393	chr7:2884313	GNA12	0.48	8.79	0.38	3.02e-17	Height;
LGG	cis	rs6840360	0.638	rs2406974	chr4:152601841	G/A	cg22705602	chr4:152727874	NA	-0.38	-9.32	-0.4	4.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.620	rs9358927	chr6:26330492	T/G	cg13736514	chr6:26305472	NA	-0.47	-9.15	-0.39	1.85e-18	Educational attainment;
LGG	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	Neuroticism;
LGG	cis	rs9879311	0.966	rs6442165	chr3:10415108	A/C	cg21387009	chr3:10280255	IRAK2	-0.37	-7.0	-0.31	9.18e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs62238980	0.614	rs74399071	chr22:32455990	G/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs1997103	0.954	rs9649854	chr7:55410213	G/A	cg20935933	chr6:143382018	AIG1	0.55	8.7	0.37	5.91e-17	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21659725	chr3:3221576	CRBN	0.92	20.58	0.69	2.72e-67	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs4363385	0.747	rs1129655	chr1:152958267	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.25	-0.4	8.17e-19	Inflammatory skin disease;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg26174226	chr8:58114915	NA	-0.47	-7.17	-0.32	3.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4702718	0.616	rs267973	chr5:10726281	A/G	cg14521931	chr5:10832172	NA	-0.43	-8.03	-0.35	8.15e-15	Obesity-related traits;
LGG	cis	rs7568458	0.684	rs7593969	chr2:85809670	A/G	cg17127132	chr2:85788382	GGCX	-0.51	-8.13	-0.35	3.97e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg27205649	chr11:78285834	NARS2	0.5	8.39	0.36	6e-16	Alzheimer's disease (survival time);
LGG	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg00024416	chr22:24240387	NA	0.44	6.73	0.3	4.93e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	16.92	0.62	2.47e-50	Smoking behavior;
LGG	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2735413	0.564	rs11859770	chr16:78126734	A/G	cg04733911	chr16:78082701	NA	0.57	7.97	0.35	1.25e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg15971980	chr6:150254442	NA	0.46	8.57	0.37	1.52e-16	Lung cancer;
LGG	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs1008375	0.966	rs4698636	chr4:17632834	T/C	cg15017067	chr4:17643749	FAM184B	0.31	7.07	0.31	5.67e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg07661805	chr8:143867942	LY6D	-0.27	-7.34	-0.32	9.95e-13	Urinary tract infection frequency;
LGG	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.4	-6.92	-0.31	1.53e-11	Coronary artery disease;
LGG	cis	rs11098499	0.754	rs1511017	chr4:120250805	G/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs11225247	0.772	rs10219215	chr11:102238237	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.49	0.33	3.58e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg02151108	chr14:50098012	C14orf104	-0.48	-10.33	-0.43	1.17e-22	Carotid intima media thickness;
LGG	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg00142150	chr22:38071001	LGALS1	0.67	12.78	0.51	3.16e-32	Fat distribution (HIV);
LGG	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg15325629	chr6:28072465	NA	0.83	6.76	0.3	4.07e-11	Hip circumference adjusted for BMI;
LGG	cis	rs701145	0.643	rs357488	chr3:153885006	A/G	cg12800244	chr3:153838788	SGEF	0.8	8.4	0.36	5.43e-16	Coronary artery disease;
LGG	cis	rs9549367	0.789	rs12584981	chr13:113881185	T/C	cg00898013	chr13:113819073	PROZ	-0.44	-8.58	-0.37	1.42e-16	Platelet distribution width;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.56	0.37	1.63e-16	Schizophrenia;
LGG	cis	rs6732160	0.845	rs72807999	chr2:73391695	T/C	cg01422370	chr2:73384389	NA	0.55	10.97	0.45	4.93e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12496230	1.000	rs17782285	chr3:66833592	A/G	cg04995300	chr3:66848608	NA	0.52	7.63	0.33	1.35e-13	Type 2 diabetes;
LGG	cis	rs1920116	0.778	rs2421830	chr3:169554129	G/A	cg00832555	chr3:169529716	LRRC34	0.38	6.66	0.3	7.9e-11	Glioma (high-grade);
LGG	cis	rs832540	0.966	rs33321	chr5:56206073	G/T	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.85e-11	Coronary artery disease;
LGG	cis	rs6540556	0.608	rs4314885	chr1:209902704	G/A	cg23920097	chr1:209922102	NA	-0.4	-7.41	-0.33	6.15e-13	Red blood cell count;
LGG	trans	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.48	0.33	3.86e-13	Joint mobility (Beighton score);
LGG	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.14	0.32	3.57e-12	Homoarginine levels;
LGG	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-11.44	-0.47	7.52e-27	Parkinson's disease;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	9.29e-19	Menopause (age at onset);
LGG	cis	rs9815354	0.812	rs73071328	chr3:41810055	A/C	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2153535	0.580	rs2184585	chr6:8474168	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs113835537	0.597	rs7116921	chr11:66303854	T/C	cg24851651	chr11:66362959	CCS	0.46	7.99	0.35	1.06e-14	Airway imaging phenotypes;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg23306229	chr2:178417860	TTC30B	0.63	8.01	0.35	9.37e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg03060546	chr3:49711283	APEH	-0.64	-10.6	-0.44	1.17e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2289700	0.518	rs77362013	chr15:79167260	T/C	cg05786009	chr15:79152474	NA	-0.47	-7.28	-0.32	1.43e-12	Bipolar disorder;
LGG	cis	rs2075371	0.644	rs1643041	chr7:134012211	C/T	cg20476274	chr7:133979776	SLC35B4	0.56	10.15	0.43	5.26e-22	Mean platelet volume;
LGG	cis	rs11969893	0.737	rs1856131	chr6:101407104	C/G	cg12253828	chr6:101329408	ASCC3	1.12	9.68	0.41	2.62e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg05044414	chr3:183734942	ABCC5	0.76	16.16	0.6	6.61e-47	Anterior chamber depth;
LGG	cis	rs3806843	0.900	rs2563254	chr5:140142701	T/C	cg19875535	chr5:140030758	IK	-0.52	-10.78	-0.45	2.51e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7762018	0.505	rs79843499	chr6:170068420	A/G	cg19338460	chr6:170058176	WDR27	-0.85	-10.08	-0.42	9.81e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs61931739	0.658	rs708142	chr12:33719872	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs17221829	0.965	rs11018745	chr11:89443808	A/C	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.59	-0.33	1.75e-13	Anxiety in major depressive disorder;
LGG	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg10587741	chr22:38071170	LGALS1	0.6	13.93	0.54	4.33e-37	Fat distribution (HIV);
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs42648	0.564	rs6956980	chr7:89803634	T/C	cg04070188	chr7:89809444	NA	-0.27	-6.66	-0.3	7.93e-11	Homocysteine levels;
LGG	cis	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg12395012	chr8:11607386	GATA4	0.41	7.39	0.32	7.05e-13	Monocyte count;
LGG	cis	rs9354308	0.764	rs4710549	chr6:66612262	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg25019033	chr10:957182	NA	-0.54	-9.96	-0.42	2.69e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg09845145	chr15:78292470	TBC1D2B	0.69	13.79	0.54	1.69e-36	Coronary artery disease or large artery stroke;
LGG	trans	rs1864585	0.616	rs117478948	chr8:10664824	A/C	cg26278703	chr11:58910052	FAM111A	0.52	6.81	0.3	3.11e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs9581857	0.547	rs78273785	chr13:28052884	T/C	cg01674679	chr13:27998804	GTF3A	-0.63	-7.31	-0.32	1.16e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg07332563	chr6:291687	DUSP22	-0.44	-7.51	-0.33	2.97e-13	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15128208	chr22:42549153	NA	-0.46	-9.03	-0.39	4.78e-18	Cognitive function;
LGG	cis	rs1555133	0.694	rs2295763	chr20:31025231	T/C	cg00028034	chr20:30779307	TSPYL3	0.33	6.75	0.3	4.52e-11	Monocyte count;
LGG	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs3820068	0.603	rs6660234	chr1:15962590	T/C	cg05660106	chr1:15850417	CASP9	0.85	17.21	0.62	1.17e-51	Systolic blood pressure;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg24690094	chr11:67383802	NA	0.5	9.1	0.39	2.62e-18	Mean corpuscular volume;
LGG	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10504130	0.569	rs9650180	chr8:52824866	C/T	cg24946253	chr8:52722146	PXDNL	-0.45	-6.65	-0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.06	-0.35	6.49e-15	Schizophrenia;
LGG	trans	rs17639063	0.571	rs17696120	chr3:62551030	C/T	cg16261619	chr7:50132977	ZPBP	0.55	6.67	0.3	7.28e-11	QT interval (sulfonylurea treatment interaction);
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.09	-0.31	5.11e-12	Total body bone mineral density;
LGG	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg03517284	chr6:25882590	NA	0.66	12.87	0.51	1.33e-32	Blood metabolite levels;
LGG	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg08885076	chr2:99613938	TSGA10	-0.45	-8.32	-0.36	9.6e-16	Chronic sinus infection;
LGG	cis	rs4268898	0.662	rs17733015	chr2:24509370	A/G	cg06627628	chr2:24431161	ITSN2	-0.76	-12.42	-0.5	8.66e-31	Asthma;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg06917634	chr15:78832804	PSMA4	-0.83	-17.56	-0.63	2.76e-53	Sudden cardiac arrest;
LGG	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	7.65e-13	Schizophrenia;
LGG	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.51	-0.44	2.66e-23	Hip circumference adjusted for BMI;
LGG	cis	rs496547	0.520	rs11216963	chr11:118580814	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.9	0.31	1.68e-11	Hip minimal joint space width;
LGG	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg16070123	chr10:51489643	NA	-0.4	-7.18	-0.32	2.81e-12	Prostate-specific antigen levels;
LGG	cis	rs7927592	0.513	rs901823	chr11:68205578	T/C	cg01657329	chr11:68192670	LRP5	-0.59	-10.75	-0.45	3.18e-24	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21295104	chr22:29168639	CCDC117	0.5	7.37	0.32	7.96e-13	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.953	rs7631914	chr3:41813557	T/C	cg03022575	chr3:42003672	ULK4	0.62	7.96	0.35	1.35e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg24110177	chr3:50126178	RBM5	0.39	6.75	0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4660214	0.666	rs1180383	chr1:39846267	C/T	cg18385671	chr1:39797026	MACF1	0.47	10.17	0.43	4.45e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.16	0.39	1.68e-18	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs17767392	0.881	rs34993988	chr14:71923692	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.09	-0.39	2.84e-18	Mitral valve prolapse;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg19223190	chr17:80058835	NA	-0.45	-8.83	-0.38	2.2e-17	Life satisfaction;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg02725872	chr8:58115012	NA	-0.94	-12.97	-0.52	4.82e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	4.95e-12	Prudent dietary pattern;
LGG	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.35	-0.5	1.73e-30	Alzheimer's disease;
LGG	cis	rs12765878	0.580	rs11191840	chr10:105634896	A/T	cg11005552	chr10:105648138	OBFC1	-0.71	-12.36	-0.5	1.65e-30	Coronary artery disease;
LGG	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.2	-0.36	2.4e-15	Educational attainment;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg02048412	chr16:4421654	VASN;CORO7	0.28	6.8	0.3	3.32e-11	Schizophrenia;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7793919	0.726	rs10232008	chr7:4783206	T/G	cg09789173	chr7:4769017	FOXK1	0.78	17.37	0.63	2.07e-52	Mosquito bite size;
LGG	cis	rs826838	1.000	rs826838	chr12:39106731	C/T	cg26384229	chr12:38710491	ALG10B	-0.88	-20.84	-0.7	1.54e-68	Heart rate;
LGG	cis	rs9807841	0.617	rs2229383	chr19:10794630	G/T	cg17710535	chr19:10819994	QTRT1	0.51	8.21	0.36	2.19e-15	Inflammatory skin disease;
LGG	cis	rs4595586	0.679	rs1356264	chr12:39393754	A/T	cg26384229	chr12:38710491	ALG10B	0.46	8.38	0.36	6.59e-16	Morning vs. evening chronotype;
LGG	cis	rs2050392	0.762	rs306587	chr10:30722908	G/C	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.85	-0.45	1.32e-24	Inflammatory bowel disease;
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg08250081	chr4:10125330	NA	0.38	7.32	0.32	1.1e-12	Bone mineral density;
LGG	cis	rs3816183	1.000	rs920391	chr2:43019347	C/G	cg27299406	chr2:43020013	HAAO	-0.29	-6.95	-0.31	1.28e-11	Hypospadias;
LGG	cis	rs9811920	0.609	rs793462	chr3:99616461	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs7408868	1.000	rs6512018	chr19:15282138	T/C	cg14696996	chr19:15285081	NOTCH3	1.08	12.89	0.51	1.04e-32	Pulse pressure;
LGG	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	1.99e-82	Dental caries;
LGG	cis	rs2486288	0.656	rs8039352	chr15:45551790	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.36	-0.43	9.64e-23	Glomerular filtration rate;
LGG	cis	rs4330281	0.740	rs4349529	chr3:17792118	A/G	cg20981856	chr3:17787350	NA	-0.38	-6.95	-0.31	1.22e-11	Schizophrenia;
LGG	trans	rs877282	1.000	rs10904552	chr10:774326	A/G	cg22713356	chr15:30763199	NA	0.56	8.74	0.38	4.38e-17	Uric acid levels;
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.55	-11.12	-0.46	1.29e-25	Personality dimensions;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg12728061	chr1:2383438	NA	-0.46	-11.52	-0.47	3.49e-27	Non-obstructive azoospermia;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.7	-0.34	8.33e-14	Life satisfaction;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg02725872	chr8:58115012	NA	0.94	13.13	0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4936894	0.500	rs10893156	chr11:124054741	T/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.92	-0.45	7.42e-25	Aging (time to death);
LGG	cis	rs75920871	0.925	rs4936359	chr11:116893724	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.98e-12	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15574263	chr11:911693	CHID1	0.5	8.28	0.36	1.3e-15	Cognitive performance;
LGG	cis	rs911555	0.755	rs55742283	chr14:103942965	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.19	0.32	2.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.61	-8.43	-0.36	4.53e-16	Lung function (FEV1/FVC);
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg15558759	chr11:118478939	PHLDB1	0.38	6.65	0.3	8.22e-11	Cholesterol, total;
LGG	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.91	-0.38	1.22e-17	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22857025	chr5:266934	NA	-1.51	-26.49	-0.78	8.66e-95	Breast cancer;
LGG	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg21459583	chr1:227974177	NA	0.43	6.99	0.31	9.36e-12	Major depressive disorder;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16405210	chr4:1374714	KIAA1530	-0.54	-9.64	-0.41	3.62e-20	Longevity;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.86	-0.34	2.76e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10229583	0.527	rs6979634	chr7:127323965	A/C	cg25855768	chr7:127472121	SND1	0.38	6.65	0.3	8.13e-11	Type 2 diabetes;
LGG	cis	rs1595825	0.945	rs73058813	chr2:198858268	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.87	-0.3	2.1e-11	Ulcerative colitis;
LGG	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23598886	chr18:12777645	NA	0.75	10.42	0.44	5.73e-23	Inflammatory skin disease;
LGG	cis	rs4664308	0.967	rs7563607	chr2:160910215	C/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs877282	1.000	rs12763443	chr10:771941	G/A	cg17470449	chr10:769945	NA	0.64	8.09	0.35	5.42e-15	Uric acid levels;
LGG	cis	rs4728302	0.583	rs1424583	chr7:133159583	T/G	cg10665199	chr7:133106180	EXOC4	0.6	10.28	0.43	1.86e-22	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg23461800	chr14:103021989	NA	0.48	7.83	0.34	3.33e-14	Platelet count;
LGG	cis	rs6460942	0.915	rs62448593	chr7:12436845	G/C	cg06484146	chr7:12443880	VWDE	-0.41	-7.13	-0.31	3.77e-12	Coronary artery disease;
LGG	cis	rs7904368	0.806	rs7087360	chr10:16872337	C/A	cg14835575	chr10:16859367	RSU1	0.79	14.63	0.56	4.16e-40	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs986417	1.000	rs996285	chr14:60869837	T/G	cg27398547	chr14:60952738	C14orf39	-0.69	-6.89	-0.31	1.8e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.71	0.61	2.16e-49	Smoking behavior;
LGG	cis	rs7851660	0.805	rs4255258	chr9:100647545	A/G	cg13688889	chr9:100608707	NA	-0.63	-12.54	-0.5	3.07e-31	Strep throat;
LGG	cis	rs9916302	0.706	rs57933226	chr17:37412829	C/T	cg07936489	chr17:37558343	FBXL20	-1.0	-15.96	-0.6	5.42e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs853679	0.517	rs1947863	chr6:28099344	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs11587400	0.572	rs2268697	chr1:115227493	A/G	cg12756093	chr1:115239321	AMPD1	0.43	7.99	0.35	1.08e-14	Autism;
LGG	cis	rs17401966	0.838	rs4846209	chr1:10322054	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-10.62	-0.44	9.84e-24	Hepatocellular carcinoma;
LGG	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg12386194	chr3:101231763	SENP7	0.42	7.37	0.32	7.68e-13	Colorectal cancer;
LGG	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.0	-0.31	8.89e-12	Triglycerides;
LGG	cis	rs6735179	0.600	rs57620327	chr2:1778208	G/T	cg10160682	chr2:1713001	PXDN	-0.44	-7.34	-0.32	9.46e-13	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg08621203	chr6:150244597	RAET1G	0.48	8.39	0.36	5.88e-16	Lung cancer;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.46	0.4	1.54e-19	Schizophrenia;
LGG	cis	rs6840360	0.582	rs57585665	chr4:152327017	G/C	cg17217059	chr4:152329364	FAM160A1	0.2	6.88	0.3	1.96e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg21659725	chr3:3221576	CRBN	-0.64	-11.59	-0.47	1.85e-27	Intelligence (multi-trait analysis);
LGG	cis	rs504918	0.627	rs13093450	chr3:124061442	A/C	cg05766129	chr3:123988013	KALRN	-0.45	-8.07	-0.35	6.22e-15	Schizophrenia;
LGG	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.06	-0.31	6.08e-12	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg02297831	chr4:17616191	MED28	0.49	8.81	0.38	2.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg24110177	chr3:50126178	RBM5	-0.41	-7.06	-0.31	6.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg07005078	chr4:17578674	LAP3	0.37	6.88	0.3	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09155575	chr17:38084037	ORMDL3	0.51	8.81	0.38	2.62e-17	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg16141378	chr3:129829833	LOC729375	0.38	8.18	0.36	2.77e-15	Retinal vascular caliber;
LGG	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.78	-0.3	3.7e-11	Myopia (pathological);
LGG	cis	rs1395	0.744	rs57881048	chr2:27474165	T/C	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	cis	rs10936602	0.539	rs28688695	chr3:169554781	A/G	cg08193579	chr3:169529701	LRRC34	0.39	7.77	0.34	5.25e-14	Renal cell carcinoma;
LGG	cis	rs755249	0.510	rs599892	chr1:39922884	C/G	cg18385671	chr1:39797026	MACF1	0.49	9.41	0.4	2.36e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.13	0.35	4.08e-15	Personality dimensions;
LGG	cis	rs17221829	0.899	rs10830356	chr11:89443939	C/A	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.59	-0.33	1.75e-13	Anxiety in major depressive disorder;
LGG	cis	rs8180040	0.966	rs12486969	chr3:47429003	G/C	cg16586182	chr3:47516702	SCAP	0.78	15.62	0.59	1.83e-44	Colorectal cancer;
LGG	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg04455712	chr21:45112962	RRP1B	0.54	10.48	0.44	3.46e-23	Mean corpuscular volume;
LGG	cis	rs1719271	0.614	rs2899704	chr15:65130631	G/C	cg11671771	chr15:65133392	PLEKHO2	-0.51	-6.84	-0.3	2.57e-11	Platelet count;
LGG	cis	rs13132184	0.507	rs68066615	chr4:38094791	G/A	cg24826020	chr4:38070998	TBC1D1	0.47	7.9	0.34	2.07e-14	Verbal declarative memory;
LGG	cis	rs11608355	0.545	rs34737994	chr12:109901621	C/T	cg05360138	chr12:110035743	NA	0.85	12.24	0.49	4.97e-30	Neuroticism;
LGG	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.5	0.44	2.78e-23	Calcium levels;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg14338887	chr6:42928500	GNMT	0.23	7.44	0.33	4.9e-13	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6445975	1.000	rs6445975	chr3:58370177	G/T	cg24175188	chr3:58374923	PXK	-0.52	-9.52	-0.4	9.93e-20	Systemic lupus erythematosus;
LGG	cis	rs9321453	1.000	rs6937846	chr6:134775632	A/G	cg08754004	chr6:134775465	NA	-0.45	-6.71	-0.3	5.69e-11	Urate levels;
LGG	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg06238570	chr21:40685208	BRWD1	-0.52	-8.47	-0.37	3.35e-16	Cognitive function;
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg08888203	chr3:10149979	C3orf24	0.56	9.43	0.4	2.04e-19	Alzheimer's disease;
LGG	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg05163923	chr11:71159392	DHCR7	-0.63	-10.9	-0.45	8.53e-25	Vitamin D levels;
LGG	cis	rs896854	0.625	rs4735335	chr8:95973327	G/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.73e-17	Type 2 diabetes;
LGG	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg06360820	chr2:242988706	NA	-0.88	-11.54	-0.47	3.12e-27	Obesity-related traits;
LGG	cis	rs988958	0.565	rs35733689	chr2:42236778	G/C	cg27428208	chr2:42229179	NA	0.51	7.64	0.33	1.27e-13	Hypospadias;
LGG	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg10483660	chr13:112241077	NA	0.38	8.1	0.35	5.1e-15	Hepatitis;
LGG	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg26384229	chr12:38710491	ALG10B	-0.72	-13.69	-0.54	4.72e-36	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg03929089	chr4:120376271	NA	0.45	7.3	0.32	1.29e-12	HDL cholesterol;
LGG	cis	rs10193935	0.901	rs10202848	chr2:42515661	A/G	cg27598129	chr2:42591480	NA	-0.63	-9.45	-0.4	1.69e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg05313129	chr8:58192883	C8orf71	-0.81	-12.48	-0.5	4.99e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg08742575	chr21:47604166	C21orf56	0.56	9.95	0.42	2.79e-21	Testicular germ cell tumor;
LGG	cis	rs4906332	1.000	rs35126287	chr14:103959432	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-7.61	-0.33	1.6e-13	Coronary artery disease;
LGG	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg07061783	chr6:25882402	NA	-0.39	-6.77	-0.3	4.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg09021430	chr5:549028	NA	-0.69	-9.63	-0.41	4.05e-20	Obesity-related traits;
LGG	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.96	-0.35	1.38e-14	Morning vs. evening chronotype;
LGG	cis	rs67311347	0.544	rs7644643	chr3:40350209	C/T	cg13683864	chr3:40499215	RPL14	0.81	16.05	0.6	2.07e-46	Renal cell carcinoma;
LGG	cis	rs3750965	0.734	rs11604251	chr11:68820429	A/G	cg23121140	chr11:68816938	TPCN2	-0.38	-7.56	-0.33	2.25e-13	Hair color;
LGG	cis	rs2898279	0.933	rs28639872	chr8:11297387	T/C	cg26274995	chr8:11302983	FAM167A	0.5	10.09	0.42	9.05e-22	Small cell lung carcinoma;
LGG	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg23649088	chr2:200775458	C2orf69	-0.65	-9.32	-0.4	4.68e-19	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg25358565	chr5:93447407	FAM172A	1.37	17.04	0.62	7.07e-51	Diabetic retinopathy;
LGG	cis	rs7615952	0.736	rs13063122	chr3:125643860	G/A	cg05084668	chr3:125655381	ALG1L	-0.89	-11.15	-0.46	9.36e-26	Blood pressure (smoking interaction);
LGG	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs72781680	1.000	rs11125372	chr2:24257582	A/T	cg08917208	chr2:24149416	ATAD2B	-0.79	-8.65	-0.37	8.8e-17	Lymphocyte counts;
LGG	trans	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg01324343	chr3:183735012	ABCC5	0.85	18.04	0.64	1.66e-55	Anterior chamber depth;
LGG	cis	rs12282928	0.876	rs7937826	chr11:48299348	T/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	cis	rs735860	0.726	rs209510	chr6:53202035	T/C	cg10236188	chr6:53219634	NA	0.35	6.85	0.3	2.36e-11	Glaucoma;
LGG	cis	rs3106136	0.527	rs10030586	chr4:95150805	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.93	-0.45	6.86e-25	Capecitabine sensitivity;
LGG	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg25554036	chr4:6271136	WFS1	0.62	11.5	0.47	4.43e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.94	-0.31	1.36e-11	Schizophrenia;
LGG	cis	rs988958	0.567	rs6718777	chr2:42246498	G/A	cg27252766	chr2:42229092	NA	0.5	7.79	0.34	4.39e-14	Hypospadias;
LGG	cis	rs2288073	0.801	rs10176347	chr2:24367994	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-8.54	-0.37	2.02e-16	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg08280861	chr8:58055591	NA	0.65	7.93	0.35	1.68e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg04025307	chr7:1156635	C7orf50	0.64	12.13	0.49	1.36e-29	Longevity;Endometriosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04380669	chr17:49230692	NME1;NME1-NME2	0.41	6.83	0.3	2.65e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg13395646	chr4:1353034	KIAA1530	-0.54	-9.57	-0.41	6.58e-20	Obesity-related traits;
LGG	cis	rs7582720	1.000	rs72934505	chr2:203916487	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.29	0.4	5.99e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2760061	0.819	rs708115	chr1:228198046	C/T	cg18477163	chr1:228402036	OBSCN	0.25	6.67	0.3	7.44e-11	Diastolic blood pressure;
LGG	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg26384229	chr12:38710491	ALG10B	-0.78	-15.64	-0.59	1.49e-44	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05819205	chr22:36425231	RBM9	0.47	6.83	0.3	2.7e-11	Gut microbiome composition (summer);
LGG	cis	rs10791097	0.568	rs4411284	chr11:130738568	A/C	cg09137382	chr11:130731461	NA	0.35	6.8	0.3	3.19e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg08109568	chr15:31115862	NA	-0.6	-9.97	-0.42	2.38e-21	Huntington's disease progression;
LGG	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.63	7.25	0.32	1.82e-12	Bitter taste perception;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.19e-14	Lung cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06361531	chr16:68057779	DUS2L;DDX28	-0.46	-6.75	-0.3	4.46e-11	Systemic lupus erythematosus;
LGG	cis	rs8067545	0.586	rs2526459	chr17:20090042	G/T	cg09818912	chr17:20140352	CYTSB	0.33	7.63	0.33	1.35e-13	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.97	0.6	4.92e-46	Lung cancer;
LGG	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg15596359	chr8:11213517	TDH	-0.34	-6.95	-0.31	1.27e-11	Retinal vascular caliber;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.8e-16	Tonsillectomy;
LGG	cis	rs10929925	1.000	rs2609197	chr2:6155823	C/T	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	7.99e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3762318	0.806	rs10127763	chr1:67651733	C/T	cg17031739	chr1:67600172	NA	-0.56	-7.07	-0.31	5.69e-12	Leprosy;
LGG	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg18225595	chr11:63971243	STIP1	-0.38	-7.17	-0.32	2.9e-12	Platelet count;
LGG	cis	rs752010	1.000	rs6664724	chr1:42093821	G/A	cg06885757	chr1:42089581	HIVEP3	0.57	12.96	0.52	5.58e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg24060327	chr5:131705240	SLC22A5	0.6	6.64	0.3	8.58e-11	Rheumatoid arthritis;
LGG	cis	rs7091068	0.616	rs7901507	chr10:95505424	C/G	cg20715218	chr10:95462985	C10orf4	0.65	9.44	0.4	1.79e-19	Urinary tract infection frequency;
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	7.33e-43	Height;
LGG	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg00701064	chr4:6280414	WFS1	0.75	17.41	0.63	1.31e-52	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.23e-13	Schizophrenia;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg05272556	chr6:34360624	NUDT3	-0.53	-6.83	-0.3	2.65e-11	Educational attainment (years of education);
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg20607798	chr8:58055168	NA	0.66	7.52	0.33	2.82e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg26384229	chr12:38710491	ALG10B	-0.79	-16.48	-0.61	2.28e-48	Morning vs. evening chronotype;
LGG	cis	rs13191362	1.000	rs34619021	chr6:163029767	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	7.91	0.34	1.93e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg22643751	chr7:855365	UNC84A	-0.42	-7.29	-0.32	1.36e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs754466	0.651	rs11815015	chr10:79625482	C/T	cg17075019	chr10:79541650	NA	-0.95	-20.43	-0.69	1.25e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.14e-27	Height;
LGG	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs2213920	0.619	rs4979528	chr9:118194902	G/A	cg13918206	chr9:118159781	DEC1	0.63	8.91	0.38	1.2e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg12070911	chr6:150209640	RAET1E	0.32	7.64	0.33	1.25e-13	Lung cancer;
LGG	cis	rs4243971	0.516	rs6141721	chr20:31028127	A/G	cg00028034	chr20:30779307	TSPYL3	-0.32	-6.68	-0.3	7e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs734999	0.545	rs6684865	chr1:2546229	A/G	cg15627072	chr1:2432621	PLCH2	-0.33	-6.79	-0.3	3.41e-11	Ulcerative colitis;
LGG	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg01864069	chr14:103024347	NA	-0.65	-9.48	-0.4	1.3e-19	Platelet count;
LGG	cis	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg06521331	chr12:34319734	NA	-0.4	-7.24	-0.32	1.91e-12	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.21	0.39	1.16e-18	Life satisfaction;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.3	0.55	1.07e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.29	-0.36	1.25e-15	Glycated hemoglobin levels;
LGG	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg06453172	chr10:134556979	INPP5A	-0.48	-7.49	-0.33	3.62e-13	Migraine;
LGG	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg24642439	chr20:33292090	TP53INP2	0.82	15.36	0.58	2.58e-43	Coronary artery disease;
LGG	cis	rs7166081	1.000	rs16950804	chr15:67554479	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1044826	0.642	rs6784684	chr3:139177634	T/C	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-8.03	-0.35	8.01e-15	Psoriasis;
LGG	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.37	-0.4	3.27e-19	Joint mobility (Beighton score);
LGG	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	trans	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.66	0.41	3.18e-20	Mean corpuscular volume;
LGG	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg19628046	chr18:33552617	C18orf21	0.53	7.61	0.33	1.52e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16866257	chr17:61905183	FTSJ3;PSMC5	0.46	7.22	0.32	2.13e-12	Gut microbiome composition (summer);
LGG	cis	rs6546550	0.901	rs13028508	chr2:70118427	A/T	cg02498382	chr2:70120550	SNRNP27	0.42	7.84	0.34	3.15e-14	Prevalent atrial fibrillation;
LGG	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.38	-0.43	7.83e-23	Response to antipsychotic treatment;
LGG	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg16141378	chr3:129829833	LOC729375	-0.53	-13.63	-0.54	8.25e-36	Mood instability;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.79	-0.41	1.08e-20	IgG glycosylation;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.9	0.38	1.29e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg16920238	chr17:80076378	CCDC57	-0.33	-7.49	-0.33	3.49e-13	Life satisfaction;
LGG	cis	rs2916247	0.954	rs11782927	chr8:93045726	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.76	0.45	2.98e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg10792982	chr14:105748885	BRF1	0.54	10.64	0.44	8.79e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg25427524	chr10:38739819	LOC399744	0.61	10.47	0.44	3.73e-23	Extrinsic epigenetic age acceleration;
LGG	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-7.02	-0.31	8.2e-12	Triglycerides;
LGG	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg01017244	chr2:74357527	NA	0.46	8.04	0.35	7.53e-15	Gestational age at birth (maternal effect);
LGG	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.54e-81	Hip circumference adjusted for BMI;
LGG	trans	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.07	-0.35	6.14e-15	Joint mobility (Beighton score);
LGG	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg26513180	chr16:89883248	FANCA	0.65	12.32	0.5	2.23e-30	Vitiligo;
LGG	cis	rs774359	0.789	rs2453552	chr9:27527512	A/C	cg14173147	chr9:27528300	MOBKL2B	0.44	8.65	0.37	8.77e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs17767392	0.788	rs57723945	chr14:71699182	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.15	-0.32	3.33e-12	Mitral valve prolapse;
LGG	cis	rs9902453	0.845	rs116840018	chr17:28232049	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.73	0.54	3.15e-36	Coffee consumption (cups per day);
LGG	cis	rs11690935	0.959	rs7604918	chr2:172588094	G/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg08925882	chr11:67350491	GSTP1	-0.34	-6.69	-0.3	6.5e-11	Mean corpuscular volume;
LGG	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg02931644	chr1:25747376	RHCE	0.42	9.27	0.4	6.96e-19	Erythrocyte sedimentation rate;
LGG	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg04731861	chr2:219085781	ARPC2	0.35	7.96	0.35	1.38e-14	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08483876	chr8:145910754	NA	0.44	7.32	0.32	1.09e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.0	-0.39	5.68e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg12708336	chr17:41446283	NA	-0.32	-7.25	-0.32	1.77e-12	Menopause (age at onset);
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg15971980	chr6:150254442	NA	0.44	8.05	0.35	7.18e-15	Lung cancer;
LGG	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg08847533	chr14:75593920	NEK9	0.6	11.74	0.48	4.81e-28	Height;
LGG	cis	rs1008375	0.931	rs3775926	chr4:17599837	G/A	cg18681998	chr4:17616180	MED28	0.8	17.04	0.62	6.81e-51	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg24607181	chr17:41446203	NA	-0.3	-7.13	-0.31	3.91e-12	Menopause (age at onset);
LGG	trans	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg05059571	chr16:84539110	KIAA1609	-0.56	-11.0	-0.46	3.83e-25	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs67340775	0.541	rs169287	chr6:27854760	C/A	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.45	-0.37	3.68e-16	Lung cancer in ever smokers;
LGG	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg06022373	chr22:39101656	GTPBP1	-0.89	-18.08	-0.64	1.16e-55	Menopause (age at onset);
LGG	cis	rs171408	0.895	rs164968	chr3:8619185	A/G	cg03557445	chr3:8615444	LOH3CR2A	-0.49	-8.73	-0.38	4.57e-17	Mitral valve prolapse;
LGG	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg02487422	chr3:49467188	NICN1	0.57	10.52	0.44	2.32e-23	Resting heart rate;
LGG	cis	rs4851266	0.898	rs12053126	chr2:100864646	A/T	cg21926883	chr2:100939477	LONRF2	-0.46	-8.29	-0.36	1.2e-15	Educational attainment;
LGG	cis	rs11168618	0.715	rs35367885	chr12:48919660	G/A	cg24011408	chr12:48396354	COL2A1	0.46	7.45	0.33	4.66e-13	Adiponectin levels;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.96	0.38	7.74e-18	Longevity;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg22535103	chr8:58192502	C8orf71	-0.97	-15.68	-0.59	9.24e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs3816183	0.585	rs7594977	chr2:42860598	G/A	cg14631114	chr2:43023945	NA	0.35	6.92	0.31	1.49e-11	Hypospadias;
LGG	cis	rs1014246	0.826	rs1900508	chr10:118470750	C/T	cg14919929	chr10:118506882	NA	-0.62	-12.39	-0.5	1.25e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	10.03	0.42	1.51e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg19223190	chr17:80058835	NA	-0.44	-8.5	-0.37	2.68e-16	Life satisfaction;
LGG	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg05082376	chr22:42548792	NA	-0.3	-6.69	-0.3	6.65e-11	Cognitive function;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.45	8.31	0.36	1.1e-15	Schizophrenia;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11245990	chr11:68621969	NA	0.4	8.48	0.37	3.12e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg26695010	chr11:65641043	EFEMP2	-0.49	-7.7	-0.34	8.3e-14	DNA methylation (variation);
LGG	cis	rs2540226	0.515	rs2540248	chr2:39909117	G/T	cg02886589	chr2:39892450	TMEM178	0.31	8.44	0.37	4e-16	Personality dimensions;
LGG	cis	rs4731207	0.623	rs1481342	chr7:124651479	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg26384229	chr12:38710491	ALG10B	0.94	22.22	0.72	5.52e-75	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24464101	chr4:38690487	KLF3	-0.58	-6.94	-0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.32	0.55	8.85e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-7.5	-0.33	3.18e-13	Breast cancer;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09217309	chr6:150244204	RAET1G	0.44	8.21	0.36	2.14e-15	Lung cancer;
LGG	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg03605463	chr16:89740564	NA	-0.41	-6.78	-0.3	3.58e-11	Vitiligo;
LGG	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.26	-0.43	2.24e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg07541023	chr7:19748670	TWISTNB	0.5	6.73	0.3	5.12e-11	Night sleep phenotypes;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg08645402	chr16:4508243	NA	0.49	8.9	0.38	1.25e-17	Schizophrenia;
LGG	cis	rs16912285	0.786	rs76326641	chr11:24253072	G/A	ch.11.24196551F	chr11:24239977	NA	0.84	9.49	0.4	1.22e-19	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.67	0.48	9.53e-28	Mean corpuscular volume;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg06112835	chr11:68658793	MRPL21	0.63	10.14	0.43	5.74e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7927592	0.673	rs2510392	chr11:68394457	C/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.55	-0.44	1.89e-23	Total body bone mineral density;
LGG	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg13770153	chr20:60521292	NA	-0.49	-7.92	-0.35	1.82e-14	Body mass index;
LGG	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.97	0.38	7.44e-18	Mood instability;
LGG	cis	rs5758659	1.000	rs5758659	chr22:42622003	C/T	cg15557168	chr22:42548783	NA	-0.4	-8.86	-0.38	1.78e-17	Cognitive function;
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg08888203	chr3:10149979	C3orf24	-0.56	-8.11	-0.35	4.52e-15	Alzheimer's disease;
LGG	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs1062746	0.771	rs12447487	chr16:87377036	C/T	cg02258303	chr16:87377426	FBXO31	0.61	11.9	0.48	1.12e-28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs9976767	0.608	rs3746923	chr21:43826344	C/T	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.23	-0.52	4.13e-34	Type 1 diabetes;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg23131131	chr22:24373011	LOC391322	-0.5	-8.41	-0.36	5.29e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10802521	chr3:52805072	NEK4	-0.39	-7.06	-0.31	6.17e-12	Cognitive function;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.85	0.48	1.86e-28	Obesity-related traits;
LGG	cis	rs526231	0.511	rs73179850	chr5:102348577	T/A	cg23492399	chr5:102201601	PAM	-0.56	-8.28	-0.36	1.29e-15	Primary biliary cholangitis;
LGG	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.42	-0.33	5.63e-13	Neuroticism;
LGG	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.66	0.44	7.21e-24	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg06766960	chr11:133703094	NA	-0.58	-11.5	-0.47	4.1e-27	Childhood ear infection;
LGG	cis	rs62344088	0.590	rs62329989	chr5:300141	A/G	cg22496380	chr5:211416	CCDC127	-1.16	-15.73	-0.59	5.9e-45	Asthma (childhood onset);
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg23782820	chr8:58130467	NA	0.57	8.25	0.36	1.64e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs259282	0.524	rs1559180	chr19:33127443	C/T	cg02997394	chr19:33096574	ANKRD27	-0.37	-7.14	-0.32	3.56e-12	Schizophrenia;
LGG	cis	rs10489202	0.913	rs380753	chr1:168035273	G/T	cg24449463	chr1:168025552	DCAF6	-0.62	-10.31	-0.43	1.41e-22	Schizophrenia;
LGG	cis	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.6	-0.44	1.22e-23	Hip circumference adjusted for BMI;
LGG	cis	rs56283067	0.887	rs12202698	chr6:44784724	G/T	cg18551225	chr6:44695536	NA	-0.68	-10.77	-0.45	2.76e-24	Total body bone mineral density;
LGG	cis	rs11650494	0.908	rs8076023	chr17:47399633	C/G	cg08112188	chr17:47440006	ZNF652	1.28	15.3	0.58	4.78e-43	Prostate cancer;
LGG	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg15674680	chr20:60982522	CABLES2	0.48	6.69	0.3	6.56e-11	Colorectal cancer;
LGG	cis	rs12681366	0.663	rs2919662	chr8:95470272	C/A	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs10267417	0.603	rs1557774	chr7:19908777	A/G	cg05791153	chr7:19748676	TWISTNB	0.61	7.93	0.35	1.61e-14	Night sleep phenotypes;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg23129478	chr18:44337922	ST8SIA5	-0.36	-6.99	-0.31	9.64e-12	Personality dimensions;
LGG	cis	rs9902453	0.808	rs4595850	chr17:28206326	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.4	0.53	7.48e-35	Coffee consumption (cups per day);
LGG	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.56	9.81	0.41	9.25e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg26248373	chr2:1572462	NA	-0.88	-15.35	-0.58	2.81e-43	IgG glycosylation;
LGG	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg02725872	chr8:58115012	NA	-1.0	-11.12	-0.46	1.23e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg00647317	chr7:50633725	DDC	0.47	12.0	0.49	4.53e-29	Systemic sclerosis;
LGG	cis	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.92	-0.31	1.53e-11	Morning vs. evening chronotype;
LGG	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg01631408	chr1:248437212	OR2T33	0.49	8.92	0.38	1.06e-17	Common traits (Other);
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.65	-0.37	8.53e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17039065	0.920	rs72891053	chr4:109460871	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.67	0.34	1.03e-13	Gut microbiome composition (summer);
LGG	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg10483660	chr13:112241077	NA	-0.36	-7.78	-0.34	4.63e-14	Hepatitis;
LGG	cis	rs10447419	1.000	rs10447441	chr6:130549752	T/A	cg23281432	chr6:130554730	NA	0.39	6.72	0.3	5.27e-11	PR interval;
LGG	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg08807101	chr21:30365312	RNF160	-0.61	-10.45	-0.44	4.32e-23	Dental caries;
LGG	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.16	0.35	3.23e-15	Retinal vascular caliber;
LGG	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.64	0.37	9.38e-17	Resting heart rate;
LGG	cis	rs4330281	0.692	rs11719266	chr3:17781576	A/G	cg20981856	chr3:17787350	NA	-0.42	-7.73	-0.34	6.53e-14	Schizophrenia;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg16920238	chr17:80076378	CCDC57	0.36	8.18	0.36	2.71e-15	Life satisfaction;
LGG	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.59	-0.61	7.81e-49	Height;
LGG	cis	rs8141529	0.732	rs5762815	chr22:29205076	A/G	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.62e-28	Lymphocyte counts;
LGG	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg13444842	chr1:152974279	SPRR3	-0.39	-7.41	-0.33	6.12e-13	Inflammatory skin disease;
LGG	cis	rs6723226	0.842	rs2754522	chr2:32801257	C/G	cg02381751	chr2:32503542	YIPF4	0.72	12.06	0.49	2.63e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1949733	1.000	rs6837429	chr4:8502374	A/G	cg11789530	chr4:8429930	ACOX3	0.88	17.48	0.63	6.44e-53	Response to antineoplastic agents;
LGG	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08564027	chr20:61660810	NA	1.02	24.88	0.76	2.13e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg18681998	chr4:17616180	MED28	0.88	18.8	0.66	5.5099999999999996e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg09873164	chr1:152488093	CRCT1	0.61	14.69	0.56	2.32e-40	Hair morphology;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg20887711	chr4:1340912	KIAA1530	0.7	14.55	0.56	8.83e-40	Longevity;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg14004847	chr7:1930337	MAD1L1	-0.43	-7.28	-0.32	1.49e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11608355	0.515	rs7955932	chr12:109941303	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs4906332	1.000	rs4900574	chr14:103879024	G/A	cg26031613	chr14:104095156	KLC1	0.5	7.62	0.33	1.47e-13	Coronary artery disease;
LGG	cis	rs72949976	0.864	rs10176806	chr2:214022596	T/G	cg08319019	chr2:214017104	IKZF2	-0.64	-11.18	-0.46	7.19e-26	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg25482853	chr8:67687455	SGK3	1.0	12.85	0.51	1.52e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg13010199	chr12:38710504	ALG10B	0.77	16.31	0.6	1.38e-47	Heart rate;
LGG	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg21045802	chr8:109455806	TTC35	0.49	8.96	0.38	7.98e-18	Dupuytren's disease;
LGG	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs9972944	0.631	rs6504345	chr17:63757052	T/G	cg07283582	chr17:63770753	CCDC46	-0.34	-6.7	-0.3	6.09e-11	Total body bone mineral density;
LGG	cis	rs9649465	0.967	rs10269196	chr7:123321073	G/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.84	-0.38	2.01e-17	Migraine;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.4	-0.44	6.66e-23	Lung cancer;
LGG	cis	rs12282928	0.959	rs1827502	chr11:48265966	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.15	-0.32	3.34e-12	Migraine - clinic-based;
LGG	cis	rs28595532	0.764	rs56071514	chr4:119761833	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2742417	1.000	rs2673037	chr3:45749094	A/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg26513180	chr16:89883248	FANCA	-0.64	-7.07	-0.31	5.8e-12	Skin colour saturation;
LGG	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg22437258	chr11:111473054	SIK2	0.52	8.82	0.38	2.42e-17	Primary sclerosing cholangitis;
LGG	cis	rs36071027	0.615	rs56176059	chr5:158414823	T/C	cg00594129	chr5:158524270	EBF1	0.45	8.05	0.35	7.04e-15	Carotid intima media thickness;
LGG	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg10483660	chr13:112241077	NA	0.34	6.77	0.3	3.87e-11	Menarche (age at onset);
LGG	cis	rs981844	0.725	rs872453	chr4:154727131	T/C	cg14289246	chr4:154710475	SFRP2	0.65	10.9	0.45	9.04e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.46	0.33	4.4e-13	Height;
LGG	cis	rs7572733	0.534	rs770662	chr2:198729283	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.53e-25	Dermatomyositis;
LGG	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg05096777	chr10:104283225	SUFU	0.32	6.95	0.31	1.22e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7181230	0.885	rs17723133	chr15:40365418	A/G	cg22705835	chr10:65332833	REEP3	0.59	9.66	0.41	3.22e-20	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.46	8.72	0.38	5.13e-17	Obesity-related traits;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.18	-0.52	6.86e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg12432903	chr7:1882776	MAD1L1	0.48	7.15	0.32	3.48e-12	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg08851530	chr6:28072375	NA	0.86	6.79	0.3	3.49e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2285947	1.000	rs2285950	chr7:21584432	C/T	cg23045935	chr7:21583304	DNAH11	-0.43	-9.32	-0.4	4.63e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.45e-14	HDL cholesterol;
LGG	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.07	-0.49	2.33e-29	Height;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.79	0.41	1.06e-20	Longevity;
LGG	trans	rs2797160	0.651	rs6569437	chr6:126034540	T/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	7.89	0.34	2.12e-14	Endometrial cancer;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs1707322	0.721	rs10890344	chr1:46166090	C/T	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs208520	0.526	rs9351542	chr6:66788571	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-31.9	-0.83	6.05e-119	Exhaled nitric oxide output;
LGG	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg25039879	chr17:56429692	SUPT4H1	0.63	8.99	0.39	6.31e-18	Cognitive test performance;
LGG	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg21926883	chr2:100939477	LONRF2	-0.49	-9.54	-0.41	8.21e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg22676075	chr6:135203613	NA	0.36	6.69	0.3	6.62e-11	Red blood cell count;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.22	-0.32	2.08e-12	Lung cancer;
LGG	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-11.93	-0.48	8.8e-29	Chronic sinus infection;
LGG	cis	rs171408	0.947	rs355131	chr3:8612282	G/C	cg03557445	chr3:8615444	LOH3CR2A	-0.51	-9.02	-0.39	4.94e-18	Mitral valve prolapse;
LGG	cis	rs17125944	0.686	rs7158555	chr14:53362006	G/A	cg00686598	chr14:53173677	PSMC6	-0.62	-6.7	-0.3	5.99e-11	Alzheimer's disease (late onset);
LGG	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg26874164	chr19:58962979	ZNF324B	0.38	7.47	0.33	3.96e-13	Uric acid clearance;
LGG	cis	rs73001065	0.591	rs57962361	chr19:19425025	C/T	cg03709012	chr19:19516395	GATAD2A	0.89	9.8	0.41	9.68e-21	LDL cholesterol;
LGG	cis	rs1065852	0.526	rs9623489	chr22:42397026	A/G	cg15128208	chr22:42549153	NA	0.41	7.13	0.31	3.96e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.31e-16	Total body bone mineral density;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.37	2.51e-16	Prostate cancer;
LGG	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.67e-12	Neuroticism;
LGG	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg22852734	chr6:133119734	C6orf192	1.17	16.03	0.6	2.5e-46	Type 2 diabetes nephropathy;
LGG	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.05	0.39	4.04e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-13.68	-0.54	5.09e-36	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg00800038	chr16:89945340	TCF25	-0.7	-8.24	-0.36	1.82e-15	Skin colour saturation;
LGG	cis	rs2635047	0.615	rs2571007	chr18:44645610	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.99	0.31	9.93e-12	Educational attainment;
LGG	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg14196790	chr5:131705035	SLC22A5	-0.6	-7.85	-0.34	3e-14	Rheumatoid arthritis;
LGG	cis	rs10078	0.848	rs890985	chr5:479746	C/G	cg24955955	chr5:415729	AHRR	0.45	6.65	0.3	8.08e-11	Fat distribution (HIV);
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.91	0.59	8.41e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.62e-22	Height;
LGG	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg05623727	chr3:50126028	RBM5	-0.41	-8.65	-0.37	8.83e-17	Menarche (age at onset);
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg12070911	chr6:150209640	RAET1E	0.28	6.68	0.3	6.87e-11	Lung cancer;
LGG	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.51	0.63	4.55e-53	Cognitive function;
LGG	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.94	-0.35	1.54e-14	Initial pursuit acceleration;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg04703951	chr17:43578652	NA	0.39	7.93	0.35	1.7e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.66	0.3	7.64e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12580194	0.556	rs61249728	chr12:55728922	A/G	cg19537932	chr12:55886519	OR6C68	-0.53	-9.45	-0.4	1.75e-19	Cancer;
LGG	cis	rs17641971	0.965	rs341815	chr8:49978424	A/C	cg00325661	chr8:49890786	NA	0.46	7.56	0.33	2.2e-13	Blood metabolite levels;
LGG	cis	rs12946454	0.668	rs4792867	chr17:43249444	C/T	cg10701640	chr17:43249399	NA	0.39	7.22	0.32	2.16e-12	Systolic blood pressure;
LGG	cis	rs2282300	0.739	rs2225909	chr11:30329744	T/C	cg06241208	chr11:30344200	C11orf46	0.51	6.68	0.3	7.01e-11	Morning vs. evening chronotype;
LGG	cis	rs7255436	1.000	rs7255436	chr19:8433196	C/A	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.78	-0.3	3.72e-11	HDL cholesterol;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	9.35	0.4	3.62e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	12.32	0.5	2.22e-30	Lung cancer in ever smokers;
LGG	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg27523141	chr10:43048294	ZNF37B	0.36	7.55	0.33	2.27e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg00204512	chr16:28754710	NA	0.25	7.15	0.32	3.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg21045802	chr8:109455806	TTC35	0.53	10.09	0.42	8.98e-22	Dupuytren's disease;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg06654118	chr4:1303317	MAEA	0.46	8.15	0.35	3.47e-15	Obesity-related traits;
LGG	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg02487422	chr3:49467188	NICN1	0.56	10.24	0.43	2.46e-22	Resting heart rate;
LGG	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.16	0.35	3.23e-15	Mood instability;
LGG	cis	rs7917772	0.582	rs6584512	chr10:104329685	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4430311	0.723	rs7549780	chr1:243712455	A/C	cg25706552	chr1:244017396	NA	-0.64	-15.24	-0.58	8.56e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg03929089	chr4:120376271	NA	-0.7	-9.53	-0.4	8.61e-20	Axial length;
LGG	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg23625390	chr15:77176239	SCAPER	-0.68	-12.87	-0.51	1.31e-32	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.38	0.32	7.43e-13	Prudent dietary pattern;
LGG	cis	rs6815814	0.898	rs17582830	chr4:38867427	A/G	cg06935464	chr4:38784597	TLR10	0.58	8.07	0.35	6.15e-15	Breast cancer;
LGG	cis	rs13065560	0.515	rs2103150	chr3:39056026	T/C	cg01426195	chr3:39028469	NA	-0.43	-8.57	-0.37	1.52e-16	Interleukin-18 levels;
LGG	cis	rs2180341	1.000	rs6569477	chr6:127589302	T/A	cg24812749	chr6:127587940	RNF146	0.96	15.84	0.59	1.82e-45	Breast cancer;
LGG	cis	rs4653767	1.000	rs4653767	chr1:226916078	T/C	cg00279406	chr1:226924739	ITPKB	0.26	6.68	0.3	6.82e-11	Parkinson's disease;
LGG	cis	rs1620921	0.783	rs1782618	chr6:161230368	A/G	cg01280913	chr6:161186852	NA	-0.33	-6.84	-0.3	2.48e-11	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs2736337	0.532	rs6998387	chr8:11293458	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.02	-0.31	7.88e-12	Rheumatoid arthritis;
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg16301924	chr13:53314226	LECT1	-0.45	-9.04	-0.39	4.31e-18	Lewy body disease;
LGG	cis	rs4330281	0.647	rs57309958	chr3:17732035	T/G	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg26031613	chr14:104095156	KLC1	0.73	12.48	0.5	5.37e-31	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12410154	chr3:57261551	APPL1	-0.51	-7.56	-0.33	2.17e-13	Systemic lupus erythematosus;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.11	17.68	0.63	7.57e-54	Platelet count;
LGG	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.9e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs6429082	0.608	rs4469707	chr1:235570634	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.93	-0.38	1.04e-17	Adiposity;
LGG	cis	rs9381040	0.610	rs6940462	chr6:41020223	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.76	-0.3	4.21e-11	Alzheimer's disease (late onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16142952	chr22:24129598	SMARCB1	0.44	7.15	0.32	3.44e-12	Cognitive performance;
LGG	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg23933602	chr10:16859644	RSU1	-1.02	-26.78	-0.78	4.13e-96	Platelet distribution width;
LGG	cis	rs4038782	0.503	rs7201526	chr16:4907082	C/A	cg08329684	chr16:4932620	PPL	0.47	7.23	0.32	2.03e-12	Cancer;
LGG	cis	rs2067615	0.579	rs4964486	chr12:107140790	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.19	0.49	7.94e-30	Heart rate;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22633769	chr20:60982531	CABLES2	-0.52	-8.24	-0.36	1.82e-15	Colorectal cancer;
LGG	trans	rs7916697	0.626	rs3858145	chr10:70011838	A/G	cg04882175	chr6:131122610	NA	-0.43	-6.65	-0.3	8.44e-11	Optic disc area;
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs892961	0.932	rs11657725	chr17:75405501	G/C	cg05865280	chr17:75406074	SEPT9	0.42	9.61	0.41	4.6e-20	Airflow obstruction;
LGG	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14373873	chr11:113211441	TTC12	0.56	12.49	0.5	4.51e-31	Neuroticism;
LGG	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	10.19	0.43	3.75e-22	Lung cancer in ever smokers;
LGG	cis	rs1018836	0.651	rs2339175	chr8:91565805	A/T	cg16814680	chr8:91681699	NA	-0.8	-14.33	-0.55	8.48e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4631830	0.812	rs11593361	chr10:51539156	A/G	cg16070123	chr10:51489643	NA	-0.4	-7.33	-0.32	1.01e-12	Prostate-specific antigen levels;
LGG	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg13385521	chr17:29058706	SUZ12P	0.81	9.66	0.41	3.09e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg10596483	chr8:143751796	JRK	0.53	8.26	0.36	1.58e-15	Schizophrenia;
LGG	cis	rs4718428	0.662	rs34577323	chr7:66310041	G/C	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	2.96e-11	Corneal structure;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	trans	rs3779273	0.776	rs1829989	chr7:77830751	A/C	cg05596911	chr5:118502651	DMXL1	-0.52	-11.85	-0.48	1.81e-28	Body mass index;
LGG	cis	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg07460842	chr6:66804631	NA	0.74	12.72	0.51	5.13e-32	Type 2 diabetes;
LGG	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg07936489	chr17:37558343	FBXL20	0.85	15.99	0.6	3.77e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg02002194	chr4:3960332	NA	0.48	9.09	0.39	2.82e-18	Mood instability;
LGG	cis	rs4262150	0.660	rs72806710	chr5:152339648	A/G	cg12297329	chr5:152029980	NA	-0.69	-11.54	-0.47	2.96e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs9368481	0.672	rs3931463	chr6:26939797	G/A	cg18867708	chr6:26865862	GUSBL1	0.45	7.43	0.33	5.45e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs701145	0.585	rs2596629	chr3:153931142	A/C	cg17054900	chr3:154042577	DHX36	0.91	10.03	0.42	1.43e-21	Coronary artery disease;
LGG	cis	rs9287719	0.967	rs4470306	chr2:10743998	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg03264133	chr6:25882463	NA	-0.4	-6.98	-0.31	1.05e-11	Height;
LGG	cis	rs12220238	1.000	rs11000930	chr10:75982982	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.8	-10.51	-0.44	2.62e-23	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg07308232	chr7:1071921	C7orf50	-0.5	-9.19	-0.39	1.32e-18	Longevity;Endometriosis;
LGG	cis	rs171408	0.895	rs355140	chr3:8621732	C/G	cg03557445	chr3:8615444	LOH3CR2A	-0.46	-8.19	-0.36	2.51e-15	Mitral valve prolapse;
LGG	cis	rs10492096	1.000	rs10849462	chr12:6575992	C/T	cg13857086	chr12:6580257	VAMP1	0.64	9.23	0.39	9.33e-19	Hip geometry;
LGG	cis	rs7666738	0.830	rs880470	chr4:98922522	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.06e-21	Bipolar disorder;
LGG	cis	rs1007190	0.764	rs4793153	chr17:42873792	T/C	cg15406952	chr17:42872593	NA	-1.21	-15.37	-0.58	2.28e-43	DNA methylation (variation);
LGG	cis	rs28595532	0.920	rs114938162	chr4:119756407	T/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7091068	0.518	rs4144097	chr10:95432480	A/C	cg20715218	chr10:95462985	C10orf4	0.65	11.73	0.48	5.42e-28	Urinary tract infection frequency;
LGG	cis	rs1953600	0.818	rs2152546	chr10:81906384	G/T	cg04850286	chr10:81895943	PLAC9	-0.46	-10.62	-0.44	1e-23	Sarcoidosis;
LGG	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg21926883	chr2:100939477	LONRF2	-0.68	-16.23	-0.6	3.27e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg27624424	chr6:160112604	SOD2	0.65	9.36	0.4	3.58e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.11	0.7	8.73e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg14789911	chr21:47582049	C21orf56	-0.41	-6.9	-0.31	1.73e-11	Testicular germ cell tumor;
LGG	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.83	-0.42	7.83e-21	Triglycerides;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.16	-0.49	1.06e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06028808	chr11:68637592	NA	0.72	12.42	0.5	9.05e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6663390	0.831	rs2267894	chr1:208085735	G/A	cg00387621	chr1:208086895	NA	0.63	6.98	0.31	1.04e-11	Facial morphology (factor 18);
LGG	cis	rs240110	0.525	rs6917195	chr6:101277926	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.98	0.31	1.01e-11	Neuroticism;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg19847130	chr8:10466454	RP1L1	0.32	7.17	0.32	3.08e-12	Systolic blood pressure;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg18279126	chr7:2041391	MAD1L1	0.32	6.65	0.3	8.46e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9287719	0.967	rs4405729	chr2:10755779	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg04617936	chr2:214353	NA	-0.38	-7.22	-0.32	2.19e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs7241530	0.636	rs35648462	chr18:75911987	G/A	cg14642773	chr18:75888474	NA	0.44	8.44	0.37	4.13e-16	Educational attainment (years of education);
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg11584989	chr19:19387371	SF4	0.4	7.28	0.32	1.43e-12	Tonsillectomy;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.76	0.54	2.35e-36	Obesity-related traits;
LGG	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg18252515	chr7:66147081	NA	-1.34	-19.01	-0.66	5.65e-60	Diabetic kidney disease;
LGG	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.41e-20	Heart rate;
LGG	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg05692746	chr2:100937584	LONRF2	-0.6	-9.75	-0.41	1.44e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg01221209	chr5:554886	NA	-0.47	-6.78	-0.3	3.72e-11	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.72	-0.3	5.26e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs778371	0.915	rs938569	chr2:233759695	C/G	cg08000102	chr2:233561755	GIGYF2	0.64	9.49	0.4	1.27e-19	Schizophrenia;
LGG	cis	rs7899547	1.000	rs7899547	chr10:54536839	T/G	cg27418851	chr10:54531653	MBL2	0.31	6.7	0.3	5.94e-11	Blood protein levels;
LGG	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.08	0.35	5.66e-15	Colorectal cancer;
LGG	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg08109568	chr15:31115862	NA	0.54	9.53	0.4	9.07e-20	Huntington's disease progression;
LGG	cis	rs9790314	0.543	rs1349352	chr3:161118486	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-11.33	-0.47	2.02e-26	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.905	rs10756697	chr9:15728517	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.27	-0.43	1.98e-22	Body mass index;
LGG	cis	rs12476592	0.602	rs9789351	chr2:63740614	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.92	-0.31	1.55e-11	Childhood ear infection;
LGG	cis	rs12765878	1.000	rs4918067	chr10:105644636	A/C	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg18857889	chr7:23719661	C7orf46	0.36	7.37	0.32	7.75e-13	Schizophrenia;
LGG	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	cg07928641	chr1:182991847	LAMC1	0.46	9.17	0.39	1.52e-18	Colorectal cancer;
LGG	cis	rs6714710	0.535	rs3192177	chr2:98354511	G/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.26	0.4	7.41e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.67	-0.3	7.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg04705435	chr11:17411270	KCNJ11	0.42	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.1	-0.52	1.38e-33	Alzheimer's disease;
LGG	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs6784615	0.744	rs10865972	chr3:52491447	G/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.59	-7.16	-0.32	3.16e-12	Waist-hip ratio;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs7959452	0.640	rs4761233	chr12:69722880	T/C	cg20891283	chr12:69753455	YEATS4	0.76	14.82	0.57	6.07e-41	Blood protein levels;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.21	0.32	2.34e-12	Lung cancer;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-8.92	-0.38	1.09e-17	Lung cancer;
LGG	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg27432699	chr2:27873401	GPN1	-0.7	-14.26	-0.55	1.72e-38	Oral cavity cancer;
LGG	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2732480	0.500	rs7297824	chr12:48598650	T/C	cg21466736	chr12:48725269	NA	-0.36	-7.3	-0.32	1.23e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06481639	chr22:41940642	POLR3H	0.49	6.94	0.31	1.33e-11	Vitiligo;
LGG	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg01081584	chr15:40268610	EIF2AK4	0.97	10.18	0.43	4.14e-22	Corneal curvature;
LGG	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	trans	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg06875740	chr19:51307921	C19orf48	-0.64	-8.04	-0.35	7.45e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3862030	0.720	rs11595149	chr10:104235978	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.53	-10.05	-0.42	1.21e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs13403149	0.656	rs12988342	chr2:2849451	A/C	cg02105481	chr2:2853515	NA	-0.32	-6.87	-0.3	2.03e-11	Smoking initiation;
LGG	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg12386194	chr3:101231763	SENP7	-0.44	-7.84	-0.34	3.11e-14	Colorectal cancer;
LGG	cis	rs12493885	0.585	rs696869	chr3:153630341	A/C	cg12800244	chr3:153838788	SGEF	-0.65	-7.63	-0.33	1.34e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2274273	0.624	rs72717738	chr14:55842761	C/G	cg04306507	chr14:55594613	LGALS3	0.52	12.33	0.5	2.2e-30	Protein biomarker;
LGG	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg10760299	chr15:45669010	GATM	0.41	8.05	0.35	7.26e-15	Homoarginine levels;
LGG	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg06889755	chr6:150326021	RAET1K	-0.4	-8.26	-0.36	1.54e-15	Alopecia areata;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg06654118	chr4:1303317	MAEA	0.4	6.89	0.31	1.8e-11	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.71	-0.34	7.73e-14	Sudden cardiac arrest;
LGG	cis	rs9815354	0.951	rs6781529	chr3:41751333	C/T	cg03022575	chr3:42003672	ULK4	0.58	7.26	0.32	1.65e-12	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs35146811	0.735	rs1138417	chr7:99807146	C/G	cg13334819	chr7:99746414	C7orf59	0.46	7.31	0.32	1.19e-12	Coronary artery disease;
LGG	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg02227867	chr8:22457446	C8orf58	-0.46	-8.95	-0.38	8.87e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs643506	0.874	rs648544	chr11:111666128	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.89	0.3	1.85e-11	Breast cancer;
LGG	cis	rs9790314	0.663	rs9811594	chr3:160745935	A/G	cg03342759	chr3:160939853	NMD3	-0.44	-7.47	-0.33	4.16e-13	Morning vs. evening chronotype;
LGG	cis	rs2371030	0.965	rs2216403	chr2:211573391	G/T	cg18417063	chr2:211583084	NA	-0.64	-12.47	-0.5	5.52e-31	Non-small cell lung cancer;
LGG	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg02002194	chr4:3960332	NA	0.4	7.18	0.32	2.75e-12	Neuroticism;
LGG	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg13482628	chr17:19912719	NA	-0.53	-10.06	-0.42	1.13e-21	Schizophrenia;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.97	0.38	7.66e-18	Alzheimer's disease;
LGG	cis	rs727505	0.789	rs9641761	chr7:124735205	A/T	cg23710748	chr7:124431027	NA	-0.49	-9.23	-0.39	9.67e-19	Lewy body disease;
LGG	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg09640425	chr7:158790006	NA	0.38	7.25	0.32	1.8e-12	Facial morphology (factor 20);
LGG	cis	rs13191362	1.000	rs35583420	chr6:163214327	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.94	9.59	0.41	5.41e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2675662	0.525	rs12264025	chr10:75494450	A/G	cg23231163	chr10:75533350	FUT11	-0.4	-6.67	-0.3	7.46e-11	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs7737355	0.812	rs2108870	chr5:131088486	C/T	cg06307176	chr5:131281290	NA	0.52	8.6	0.37	1.26e-16	Life satisfaction;
LGG	trans	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg06521331	chr12:34319734	NA	0.44	7.84	0.34	3.21e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7119038	0.509	rs10892260	chr11:118583525	A/C	cg19182353	chr11:118479428	PHLDB1	0.37	6.74	0.3	4.75e-11	Sjögren's syndrome;
LGG	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg02931644	chr1:25747376	RHCE	-0.42	-9.08	-0.39	3.06e-18	Erythrocyte sedimentation rate;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg02725872	chr8:58115012	NA	-0.78	-10.66	-0.44	7.37e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg16006296	chr10:38738647	LOC399744	0.35	6.85	0.3	2.35e-11	Diastolic blood pressure;
LGG	cis	rs4959677	0.725	rs1772976	chr6:2503335	C/T	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.55e-15	Orthostatic hypotension;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.97	0.52	5.17e-33	Morning vs. evening chronotype;
LGG	cis	rs875971	0.522	rs4502988	chr7:65297746	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Aortic root size;
LGG	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.57	-0.33	2.01e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs28785552	0.577	rs12463163	chr19:53212821	A/C	cg10871876	chr19:53194124	ZNF83	0.52	9.83	0.42	7.74e-21	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs9948	0.786	rs62152765	chr2:97440420	G/A	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg07148914	chr20:33460835	GGT7	0.42	6.72	0.3	5.32e-11	Height;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs28830936	0.966	rs890505	chr15:42129158	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.72	-0.51	5.2e-32	Diastolic blood pressure;
LGG	cis	rs17767392	1.000	rs7156460	chr14:71855334	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.67e-18	Mitral valve prolapse;
LGG	cis	rs6500395	0.926	rs8057777	chr16:48565643	T/C	cg16662043	chr16:48846231	NA	0.37	7.17	0.32	2.98e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6714710	0.580	rs11692470	chr2:98520564	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	9.95	0.42	2.82e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-13.03	-0.52	2.8e-33	Total body bone mineral density;
LGG	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.49	12.63	0.51	1.22e-31	Oropharynx cancer;
LGG	cis	rs7666738	0.830	rs35752787	chr4:98935202	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.29	-0.36	1.27e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2188561	0.697	rs2237679	chr7:107334026	C/T	cg16793755	chr7:107334138	SLC26A4	0.43	7.58	0.33	1.97e-13	Alcohol consumption;
LGG	trans	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg16141378	chr3:129829833	LOC729375	0.32	7.54	0.33	2.51e-13	Joint mobility (Beighton score);
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg04772025	chr11:68637568	NA	0.73	12.43	0.5	7.88e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17539620	0.628	rs11541340	chr6:154831572	C/G	cg17771515	chr6:154831774	CNKSR3	0.67	8.83	0.38	2.18e-17	Lipoprotein (a) levels;
LGG	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg25811766	chr13:21894605	NA	-0.56	-7.4	-0.33	6.2800000000000005e-13	White matter hyperintensity burden;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg07701084	chr6:150067640	NUP43	0.68	12.55	0.5	2.77e-31	Lung cancer;
LGG	cis	rs68170813	0.605	rs4730227	chr7:106904031	G/C	cg02696742	chr7:106810147	HBP1	-0.72	-10.41	-0.44	5.91e-23	Coronary artery disease;
LGG	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg02574844	chr11:5959923	NA	-0.59	-9.93	-0.42	3.42e-21	DNA methylation (variation);
LGG	cis	rs11239187	0.530	rs10160186	chr10:45061621	C/T	cg03916630	chr10:45065415	NA	0.36	8.89	0.38	1.41e-17	Body mass index;
LGG	cis	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs1538970	0.781	rs713358	chr1:45988267	C/G	cg05343316	chr1:45956843	TESK2	0.77	13.21	0.52	4.73e-34	Platelet count;
LGG	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.92	-0.42	3.72e-21	Lung cancer;
LGG	cis	rs7512552	0.839	rs1498308	chr1:150295131	G/T	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs6921919	0.887	rs16894116	chr6:28414967	G/T	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.25	-0.32	1.8e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28830936	1.000	rs12441300	chr15:42102845	A/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-6.67	-0.3	7.13e-11	Diastolic blood pressure;
LGG	cis	rs6142618	0.562	rs6142616	chr20:30714428	A/G	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs62400317	0.762	rs12208605	chr6:44963735	A/C	cg18551225	chr6:44695536	NA	0.67	11.11	0.46	1.41e-25	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17430625	chr19:18304286	MPV17L2	0.44	6.76	0.3	4.26e-11	Gut microbiome composition (summer);
LGG	cis	rs4639966	0.758	rs11217013	chr11:118624919	G/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.85	-0.3	2.38e-11	Systemic lupus erythematosus;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-9.99	-0.42	2.07e-21	Prostate cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19857457	chr18:47018947	RPL17;SNORD58A;SNORD58B	0.43	7.25	0.32	1.72e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10979	1.000	rs9376762	chr6:143887248	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.42	-0.5	9.07e-31	Hypospadias;
LGG	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.63	-0.37	9.98e-17	Life satisfaction;
LGG	cis	rs9397585	0.637	rs674882	chr6:153407553	T/C	cg17707550	chr6:153380415	RGS17	-0.44	-9.81	-0.41	9.07e-21	Body mass index;
LGG	cis	rs2229238	0.911	rs4639752	chr1:154508974	T/A	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.13e-11	Coronary heart disease;
LGG	cis	rs36051895	0.632	rs57698263	chr9:5143262	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-15.74	-0.59	5.28e-45	Pediatric autoimmune diseases;
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg13607699	chr17:42295918	UBTF	-0.76	-13.55	-0.53	1.82e-35	Total body bone mineral density;
LGG	cis	rs8013055	0.846	rs12717698	chr14:105979015	G/A	cg19700328	chr14:106028568	NA	-0.6	-9.95	-0.42	3e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	trans	rs7939886	0.920	rs76934983	chr11:55993334	A/C	cg15704280	chr7:45808275	SEPT13	0.84	7.67	0.34	1.02e-13	Myopia (pathological);
LGG	cis	rs757110	0.745	rs2074311	chr11:17421860	A/G	cg22710661	chr11:17411071	KCNJ11	0.38	6.69	0.3	6.35e-11	Type 2 diabetes;
LGG	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.57	-0.37	1.57e-16	Calcium levels;
LGG	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg11247378	chr22:39784982	NA	-0.31	-9.19	-0.39	1.31e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs258892	0.895	rs34672	chr5:72165389	G/A	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg23758822	chr17:41437982	NA	0.89	15.13	0.58	2.49e-42	Menopause (age at onset);
LGG	cis	rs3857747	0.895	rs11764628	chr7:40364425	T/A	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs6541297	0.793	rs6692319	chr1:230284375	C/T	cg05784532	chr1:230284198	GALNT2	0.52	9.25	0.39	8.48e-19	Coronary artery disease;
LGG	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06481639	chr22:41940642	POLR3H	-0.57	-8.42	-0.36	4.63e-16	Vitiligo;
LGG	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg24812749	chr6:127587940	RNF146	0.53	8.72	0.38	4.91e-17	Breast cancer;
LGG	cis	rs6997458	0.742	rs7841178	chr8:86337919	A/C	cg02393479	chr8:86352350	CA3	0.3	6.76	0.3	4.1e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7647973	0.588	rs4855848	chr3:49653457	C/T	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs4731207	0.564	rs10234592	chr7:124611656	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18876405	chr7:65276391	NA	-0.53	-9.46	-0.4	1.5700000000000001e-19	Aortic root size;
LGG	cis	rs34929064	0.881	rs2067074	chr7:22720943	G/C	cg18045685	chr7:22629474	NA	-0.51	-9.13	-0.39	2.08e-18	Major depression and alcohol dependence;
LGG	trans	rs1814175	0.645	rs1851869	chr11:49960552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.61	0.33	1.6e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.1	-0.42	8.45e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs763121	0.962	rs5757130	chr22:38937794	G/A	cg06022373	chr22:39101656	GTPBP1	0.79	15.59	0.59	2.32e-44	Menopause (age at onset);
LGG	cis	rs72781680	1.000	rs11553491	chr2:24225901	G/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.03	0.39	4.65e-18	Lymphocyte counts;
LGG	cis	rs8133932	0.654	rs7410105	chr21:47332181	A/G	cg11214348	chr21:47283868	PCBP3	0.46	7.94	0.35	1.54e-14	Schizophrenia;
LGG	trans	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg07211511	chr3:129823064	LOC729375	-1.4	-22.43	-0.72	5.98e-76	Blood pressure (smoking interaction);
LGG	cis	rs12731740	1.000	rs6701735	chr1:208030923	C/T	cg22525895	chr1:207977042	MIR29B2	-0.62	-6.83	-0.3	2.73e-11	Biomedical quantitative traits;
LGG	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.17	-0.49	9.64e-30	Hemoglobin concentration;
LGG	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg11890956	chr21:40555474	PSMG1	-0.94	-18.89	-0.66	2.02e-59	Cognitive function;
LGG	cis	rs9547692	1.000	rs11619849	chr13:37468238	A/G	cg02985381	chr13:37494744	SMAD9	0.69	12.2	0.49	6.75e-30	Coronary artery disease;
LGG	cis	rs1881509	0.660	rs7102167	chr11:1438103	T/C	cg07067744	chr11:1421172	BRSK2	0.34	6.73	0.3	4.95e-11	Heroin dependence;
LGG	cis	rs13082711	0.689	rs34641383	chr3:27320210	G/A	cg02860705	chr3:27208620	NA	1.08	20.57	0.69	3.04e-67	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs8073060	0.586	rs188959	chr17:34021307	C/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs10463554	0.963	rs26821	chr5:102520400	A/C	cg23492399	chr5:102201601	PAM	-0.5	-7.55	-0.33	2.33e-13	Parkinson's disease;
LGG	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg24209194	chr3:40518798	ZNF619	0.44	6.86	0.3	2.18e-11	Renal cell carcinoma;
LGG	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg11887960	chr12:57824829	NA	0.59	7.29	0.32	1.34e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg14541582	chr5:601475	NA	-0.71	-11.21	-0.46	5.75e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs56399783	0.614	rs116929101	chr7:2760325	G/A	cg19731401	chr7:2775893	GNA12	0.37	7.35	0.32	9.2e-13	Childhood ear infection;
LGG	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.18	0.36	2.78e-15	Diabetic kidney disease;
LGG	cis	rs2280630	1.000	rs2280630	chr3:39195964	C/T	cg01426195	chr3:39028469	NA	-0.46	-8.67	-0.37	7.31e-17	Verbal declarative memory;
LGG	cis	rs968451	0.526	rs5757617	chr22:39722714	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.91	18.06	0.64	1.41e-55	Primary biliary cholangitis;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	trans	rs6598955	0.671	rs7551557	chr1:26596614	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.35	-0.5	1.82e-30	Obesity-related traits;
LGG	cis	rs2976388	0.609	rs2585145	chr8:143799457	G/A	cg06565975	chr8:143823917	SLURP1	0.36	9.17	0.39	1.58e-18	Urinary tract infection frequency;
LGG	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.88	0.34	2.38e-14	Smoking initiation;
LGG	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.26	-0.46	3.53e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17039065	0.920	rs7671977	chr4:109435999	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.74	0.34	6.43e-14	Gut microbiome composition (summer);
LGG	cis	rs74781061	0.860	rs8033841	chr15:74763881	A/T	cg02384859	chr15:74862662	ARID3B	-0.34	-6.97	-0.31	1.1e-11	Endometriosis;
LGG	cis	rs2247341	0.965	rs11248073	chr4:1737502	C/T	cg07465881	chr4:1713556	SLBP	-0.44	-6.94	-0.31	1.34e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.27	-0.4	7.23e-19	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.68	-0.48	8.48e-28	Vitiligo;
LGG	cis	rs9815354	0.680	rs78402272	chr3:42028425	G/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg08764805	chr12:95867684	METAP2	0.63	6.69	0.3	6.61e-11	Kashin-Beck disease;
LGG	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.43e-20	Aortic root size;
LGG	trans	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg25214090	chr10:38739885	LOC399744	0.65	11.4	0.47	1.02e-26	Corneal astigmatism;
LGG	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-14.08	-0.55	9.94e-38	Colorectal cancer;
LGG	cis	rs1185460	1.000	rs1185460	chr11:118943433	C/T	cg23280166	chr11:118938394	VPS11	-0.56	-9.96	-0.42	2.59e-21	Coronary artery disease;
LGG	cis	rs7241530	0.662	rs924889	chr18:75900770	A/G	cg14642773	chr18:75888474	NA	0.47	9.21	0.39	1.15e-18	Educational attainment (years of education);
LGG	cis	rs11895698	1	rs11895698	chr2:239338495	C/T	cg18131467	chr2:239335373	ASB1	-0.7	-8.22	-0.36	2.11e-15	Chronotype;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg23758822	chr17:41437982	NA	0.88	15.39	0.58	1.8e-43	Menopause (age at onset);
LGG	cis	rs11785400	0.793	rs7017851	chr8:143722038	G/T	cg10596483	chr8:143751796	JRK	0.5	7.78	0.34	4.72e-14	Schizophrenia;
LGG	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07362569	chr17:61921086	SMARCD2	0.48	9.32	0.4	4.86e-19	Prudent dietary pattern;
LGG	cis	rs4820539	1.000	rs4822362	chr22:23482744	C/A	cg14186256	chr22:23484241	RTDR1	0.99	25.84	0.77	8.63e-92	Bone mineral density;
LGG	cis	rs9487051	0.872	rs1111863	chr6:109611206	C/T	cg21918786	chr6:109611834	NA	0.5	9.24	0.39	9.16e-19	Reticulocyte fraction of red cells;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.24e-13	Educational attainment;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13732083	chr21:47605072	C21orf56	0.53	8.44	0.36	4.25e-16	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03351460	chr19:19007311	GDF1;LASS1	0.41	6.68	0.3	7.04e-11	Gut microbiome composition (summer);
LGG	cis	rs35771425	0.529	rs7532911	chr1:211380444	G/T	cg10512769	chr1:211675356	NA	-0.63	-8.02	-0.35	8.9e-15	Educational attainment (years of education);
LGG	cis	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg07460842	chr6:66804631	NA	-0.47	-7.95	-0.35	1.46e-14	Blood trace element (Cu levels);
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-13.24	-0.52	3.8e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4253772	0.591	rs9615934	chr22:46682310	C/G	cg09461388	chr22:46763229	CELSR1	-0.65	-6.74	-0.3	4.78e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg10664184	chr19:17420304	DDA1	0.53	8.16	0.35	3.28e-15	Systemic lupus erythematosus;
LGG	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs9527	1.000	rs4919690	chr10:104616500	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-9.32	-0.4	4.66e-19	Arsenic metabolism;
LGG	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.67	-0.3	7.52e-11	Parkinson's disease;
LGG	cis	rs61931739	0.620	rs61927734	chr12:33691977	A/T	cg06521331	chr12:34319734	NA	0.39	6.77	0.3	3.92e-11	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg11211951	chr8:145729740	GPT	0.38	8.17	0.35	3.06e-15	Age at first birth;
LGG	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg12751644	chr20:60527061	NA	-0.31	-7.22	-0.32	2.19e-12	Body mass index;
LGG	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg10523679	chr1:76189770	ACADM	0.82	14.58	0.56	6.77e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35160687	0.644	rs1863056	chr2:86491245	C/T	cg10973622	chr2:86423274	IMMT	-0.41	-7.2	-0.32	2.43e-12	Night sleep phenotypes;
LGG	cis	rs2613964	0.504	rs3995917	chr3:112852614	A/G	cg16248390	chr3:112854924	NA	-0.5	-10.6	-0.44	1.21e-23	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.08	-0.31	5.23e-12	Obesity-related traits;
LGG	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7226408	0.600	rs323325	chr18:34721029	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.11	-0.39	2.48e-18	Obesity-related traits;
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06481639	chr22:41940642	POLR3H	-0.65	-9.12	-0.39	2.29e-18	Vitiligo;
LGG	cis	rs3749237	0.964	rs34522271	chr3:49808517	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.77	0.3	4e-11	Resting heart rate;
LGG	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg24088639	chr11:34937564	PDHX;APIP	0.38	7.03	0.31	7.66e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs881375	0.678	rs7031752	chr9:123663482	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.04	0.52	2.63e-33	Rheumatoid arthritis;
LGG	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs62037369	chr16:28883841	C/T	cg16576597	chr16:28551801	NUPR1	0.31	7.02	0.31	7.72e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg22105103	chr4:187893119	NA	0.57	11.21	0.46	5.96e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1524927	0.566	rs12704876	chr7:96366342	C/T	cg03808172	chr7:96339361	SHFM1	0.45	8.02	0.35	8.88e-15	Total body bone mineral density;
LGG	cis	rs1538970	0.884	rs1771551	chr1:45883643	C/G	cg05343316	chr1:45956843	TESK2	0.68	11.19	0.46	6.72e-26	Platelet count;
LGG	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.97	0.57	1.32e-41	Cognitive test performance;
LGG	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.78	-0.3	3.68e-11	Blood metabolite levels;
LGG	cis	rs13065560	0.593	rs9818630	chr3:38930307	T/G	cg01426195	chr3:39028469	NA	-0.5	-10.27	-0.43	2.06e-22	Interleukin-18 levels;
LGG	cis	rs8072100	0.790	rs3760371	chr17:45695914	T/C	cg08085267	chr17:45401833	C17orf57	0.52	9.67	0.41	2.95e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.91	-0.34	1.95e-14	Colorectal cancer;
LGG	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg10847948	chr11:71163743	NADSYN1	-0.66	-12.99	-0.52	4.02e-33	Vitamin D levels;
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg07870213	chr5:140052090	DND1	0.69	13.37	0.53	1.05e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.69	-0.3	6.4e-11	Aortic root size;
LGG	cis	rs41271951	0.512	rs12058128	chr1:151106113	C/T	cg11822372	chr1:151115635	SEMA6C	-0.67	-6.99	-0.31	9.43e-12	Blood protein levels;
LGG	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg08807101	chr21:30365312	RNF160	0.92	19.39	0.67	9.2e-62	Dental caries;
LGG	cis	rs910187	0.564	rs6124949	chr20:45764370	C/T	cg27589058	chr20:45804311	EYA2	-0.29	-6.93	-0.31	1.46e-11	Migraine;
LGG	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.66	-0.34	1.11e-13	Menarche (age at onset);
LGG	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07080220	chr10:102295463	HIF1AN	-0.59	-10.26	-0.43	2.09e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg03264133	chr6:25882463	NA	-0.51	-9.43	-0.4	2.06e-19	Height;
LGG	cis	rs714031	1.000	rs714031	chr22:40070234	C/T	cg21377881	chr22:40064566	CACNA1I	0.6	14.3	0.55	1.08e-38	Schizophrenia;
LGG	cis	rs9596863	1.000	rs9568943	chr13:54423065	G/T	ch.13.53330881F	chr13:54432880	NA	0.5	6.77	0.3	3.94e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.5e-11	Myopia (pathological);
LGG	trans	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg07211511	chr3:129823064	LOC729375	-0.64	-8.8	-0.38	2.67e-17	Blood pressure (smoking interaction);
LGG	cis	rs500492	0.508	rs449566	chr16:1074581	C/T	cg08273874	chr16:1060765	NA	-0.57	-8.16	-0.35	3.11e-15	Polycystic ovary syndrome;
LGG	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.06	0.42	1.15e-21	Cognitive ability;
LGG	cis	rs7937890	0.559	rs2597188	chr11:14516906	G/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs3762637	1.000	rs28434553	chr3:122229515	C/A	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.58e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.89	-0.38	1.42e-17	Life satisfaction;
LGG	cis	rs12210905	0.925	rs858989	chr6:27179373	T/A	cg23155468	chr6:27110703	HIST1H2BK	0.53	6.7	0.3	6.07e-11	Hip circumference adjusted for BMI;
LGG	cis	rs523522	0.962	rs7136951	chr12:120941927	C/T	cg12219531	chr12:120966889	COQ5	0.63	10.36	0.43	9.27e-23	High light scatter reticulocyte count;
LGG	cis	rs10193935	0.901	rs6720837	chr2:42463173	A/T	cg27598129	chr2:42591480	NA	-0.59	-9.02	-0.39	5.11e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72827839	0.846	rs76950846	chr17:46102153	G/A	cg02219949	chr17:45927392	SP6	0.53	8.07	0.35	6.16e-15	Ease of getting up in the morning;
LGG	cis	rs57221529	0.654	rs72707041	chr5:677152	G/A	cg09021430	chr5:549028	NA	-0.7	-9.02	-0.39	5.06e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.16	0.39	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg03929089	chr4:120376271	NA	-0.46	-7.76	-0.34	5.57e-14	HDL cholesterol;
LGG	cis	rs2479106	0.892	rs2768819	chr9:126593370	A/G	cg16191174	chr9:126692580	DENND1A	0.45	6.7	0.3	6.03e-11	Polycystic ovary syndrome;
LGG	trans	rs3749237	0.929	rs62260715	chr3:49829326	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	8.91	0.38	1.2e-17	Resting heart rate;
LGG	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.72	0.41	1.83e-20	Lung cancer in ever smokers;
LGG	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03264133	chr6:25882463	NA	-0.56	-10.41	-0.44	5.98e-23	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.89	-0.42	4.66e-21	Common traits (Other);
LGG	cis	rs754466	0.580	rs2289309	chr10:79571108	C/T	cg17075019	chr10:79541650	NA	-0.98	-22.15	-0.72	1.13e-74	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg03101763	chr11:65319844	LTBP3	-0.66	-6.77	-0.3	3.86e-11	Height;
LGG	cis	rs721917	0.506	rs1923538	chr10:81695032	G/A	cg25562619	chr10:81652821	NA	-0.34	-7.67	-0.34	1.01e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg21775007	chr8:11205619	TDH	-0.51	-7.72	-0.34	6.99e-14	Triglycerides;
LGG	cis	rs11605924	0.967	rs7121611	chr11:45864142	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-8.11	-0.35	4.5e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg12501888	chr15:85177176	SCAND2	-0.52	-8.62	-0.37	1.03e-16	P wave terminal force;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04691540	chr1:179198414	ABL2	0.43	6.82	0.3	2.89e-11	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	trans	rs2562456	0.793	rs62109212	chr19:21526518	T/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	11.82	0.48	2.25e-28	Obesity-related traits;
LGG	cis	rs9964724	1.000	rs9964724	chr18:35159124	C/T	cg27332583	chr18:35150602	NA	-0.48	-9.83	-0.42	7.91e-21	Educational attainment (years of education);
LGG	cis	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.56	-0.33	2.16e-13	DNA methylation (variation);
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.5	8.79	0.38	2.9e-17	Longevity;
LGG	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.63	-0.37	9.81e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.38	-0.32	7.55e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.8	0.3	3.15e-11	Alzheimer's disease;
LGG	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.75	0.45	3.32e-24	Diabetic retinopathy;
LGG	cis	rs17253792	0.555	rs17683626	chr14:56041112	G/T	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.9	-13.83	-0.54	1.16e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4740619	0.619	rs1359956	chr9:16044097	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.47	-0.47	5.37e-27	Body mass index;
LGG	cis	rs11608355	0.545	rs12822974	chr12:109909154	G/T	cg05360138	chr12:110035743	NA	0.84	12.02	0.49	3.87e-29	Neuroticism;
LGG	cis	rs62344088	0.590	rs58563514	chr5:177837	C/T	cg22496380	chr5:211416	CCDC127	-0.86	-6.71	-0.3	5.78e-11	Asthma (childhood onset);
LGG	cis	rs2427308	0.643	rs477859	chr20:60937597	A/G	cg06026331	chr20:60912101	LAMA5	-0.72	-12.93	-0.52	7.08e-33	Colorectal cancer;
LGG	cis	rs6089584	0.927	rs1886007	chr20:60581049	G/A	cg12751644	chr20:60527061	NA	-0.29	-6.86	-0.3	2.15e-11	Body mass index;
LGG	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg13009111	chr11:71350975	NA	0.35	7.72	0.34	7.43e-14	Myopia (pathological);
LGG	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.8	-0.38	2.7e-17	Self-reported allergy;
LGG	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg00504896	chr12:9437009	LOC642846	-0.44	-8.07	-0.35	6.21e-15	Breast size;
LGG	cis	rs3857067	0.806	rs2865343	chr4:95103005	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.97	-0.35	1.24e-14	QT interval;
LGG	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg14835575	chr10:16859367	RSU1	0.79	14.59	0.56	5.92e-40	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs295140	1.000	rs4516413	chr2:201163920	T/C	cg25099087	chr2:201172481	SPATS2L	0.27	6.74	0.3	4.66e-11	QT interval;
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg06558623	chr16:89946397	TCF25	1.04	13.58	0.53	1.42e-35	Skin colour saturation;
LGG	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.55e-17	Aortic root size;
LGG	cis	rs9902453	0.817	rs1038089	chr17:28178724	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs11758351	0.660	rs16891446	chr6:26226996	A/C	cg01420254	chr6:26195488	NA	0.83	10.71	0.45	4.74e-24	Gout;Renal underexcretion gout;
LGG	cis	rs4363385	0.818	rs12195	chr1:153004983	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.28	-0.36	1.29e-15	Inflammatory skin disease;
LGG	cis	rs6692729	1.000	rs6692729	chr1:227018919	C/T	cg08708961	chr1:227070630	PSEN2	-0.28	-7.23	-0.32	2.03e-12	Electrodermal activity;
LGG	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg13334819	chr7:99746414	C7orf59	-0.43	-6.73	-0.3	5.17e-11	Coronary artery disease;
LGG	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg18854424	chr1:2615690	NA	0.36	7.58	0.33	1.96e-13	Ulcerative colitis;
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.8	-0.3	3.28e-11	Total body bone mineral density;
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.88	-0.3	2e-11	Bipolar disorder;
LGG	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.3100000000000004e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg26174226	chr8:58114915	NA	-0.58	-7.77	-0.34	5.17e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.46	0.44	3.81e-23	Resting heart rate;
LGG	cis	rs7412746	0.658	rs12068264	chr1:150727329	C/T	cg15448220	chr1:150897856	SETDB1	0.39	7.3	0.32	1.29e-12	Melanoma;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.12	-0.39	2.37e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.05	0.31	6.71e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg00204512	chr16:28754710	NA	0.25	6.87	0.3	2.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8141529	0.529	rs5762774	chr22:29149796	G/A	cg02153584	chr22:29168773	CCDC117	0.59	6.65	0.3	8.3e-11	Lymphocyte counts;
LGG	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg11764359	chr7:65958608	NA	0.62	9.28	0.4	6.3e-19	Aortic root size;
LGG	cis	rs9911578	1.000	rs2643119	chr17:56827760	G/T	cg12560992	chr17:57184187	TRIM37	0.89	15.73	0.59	5.41e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11673344	0.932	rs76350084	chr19:37678819	A/C	cg27390819	chr19:37464633	NA	-0.38	-6.68	-0.3	6.93e-11	Obesity-related traits;
LGG	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg13482628	chr17:19912719	NA	0.58	11.58	0.47	2.11e-27	Schizophrenia;
LGG	cis	rs9354308	0.738	rs1392147	chr6:66613145	A/C	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.4e-11	Metabolite levels;
LGG	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.19	0.36	2.57e-15	Mean platelet volume;
LGG	cis	rs12476592	0.543	rs10170988	chr2:63650582	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.87	-0.3	2.02e-11	Childhood ear infection;
LGG	cis	rs2247341	0.965	rs798761	chr4:1731126	G/A	cg08446824	chr4:1720184	TMEM129	-0.69	-13.04	-0.52	2.47e-33	Hip circumference adjusted for BMI;Height;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg11492041	chr2:139259481	SPOPL	-0.4	-6.94	-0.31	1.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg19635926	chr16:89946313	TCF25	0.8	8.29	0.36	1.27e-15	Skin colour saturation;
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.1	0.46	1.48e-25	Alzheimer's disease;
LGG	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.32	0.32	1.1e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2153535	0.601	rs9505474	chr6:8539794	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.37e-31	Motion sickness;
LGG	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg14541582	chr5:601475	NA	-0.69	-10.98	-0.45	4.26e-25	Obesity-related traits;
LGG	cis	rs2976388	0.566	rs4736301	chr8:143829499	T/G	cg06565975	chr8:143823917	SLURP1	-0.54	-13.97	-0.54	2.88e-37	Urinary tract infection frequency;
LGG	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.19	0.52	5.95e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.17	-0.32	3.07e-12	Lung cancer;
LGG	cis	rs9902453	0.845	rs7221516	chr17:28232506	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.33	0.55	8.31e-39	Coffee consumption (cups per day);
LGG	cis	rs757278	0.591	rs17549557	chr7:117303243	G/T	cg10524701	chr7:117356490	CTTNBP2	0.42	7.5	0.33	3.35e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12949141	chr5:134259545	PCBD2	-0.36	-6.81	-0.3	3.04e-11	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20141549	chr3:51534298	VPRBP	0.48	8.13	0.35	4.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7617773	0.780	rs4392440	chr3:48343920	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-8.68	-0.37	6.96e-17	Morning vs. evening chronotype;
LGG	cis	rs3806933	0.522	rs17553936	chr5:110454681	A/G	cg04022379	chr5:110408740	TSLP	0.47	7.99	0.35	1.11e-14	Eosinophilic esophagitis;
LGG	cis	rs4664308	0.870	rs1870104	chr2:161032285	A/G	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.96	-0.6	5.09e-46	Idiopathic membranous nephropathy;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg08888203	chr3:10149979	C3orf24	0.56	9.57	0.41	6.42e-20	Alzheimer's disease;
LGG	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg01346077	chr3:125931526	NA	0.54	13.87	0.54	8.02e-37	Metabolite levels;
LGG	trans	rs7939886	0.844	rs10501350	chr11:56058690	G/A	cg03929089	chr4:120376271	NA	0.73	6.81	0.3	3.06e-11	Myopia (pathological);
LGG	cis	rs433406	0.733	rs425803	chr11:131372475	A/G	cg27203895	chr11:131369037	NTM	0.79	18.44	0.65	2.33e-57	Male fertility;
LGG	cis	rs8078723	0.714	rs2241244	chr17:38153554	G/C	cg17467752	chr17:38218738	THRA	-0.61	-11.08	-0.46	1.88e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs12701220	0.602	rs9638882	chr7:1023617	C/A	cg26769984	chr7:1090371	C7orf50	0.58	10.05	0.42	1.21e-21	Bronchopulmonary dysplasia;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.74	-0.34	6.41e-14	Menopause (age at onset);
LGG	cis	rs1881396	0.531	rs76586169	chr2:27897835	G/A	cg27432699	chr2:27873401	GPN1	0.58	7.5	0.33	3.28e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs7191439	0.626	rs8059794	chr16:88787388	C/T	cg27087555	chr16:88793112	FAM38A	-1.36	-19.78	-0.68	1.4e-63	Plateletcrit;
LGG	cis	rs1577917	0.917	rs12665464	chr6:86574133	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.09	-0.39	2.88e-18	Response to antipsychotic treatment;
LGG	cis	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg21775007	chr8:11205619	TDH	-0.47	-7.39	-0.32	7.12e-13	Morning vs. evening chronotype;
LGG	cis	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg06521331	chr12:34319734	NA	-0.61	-11.36	-0.47	1.47e-26	Morning vs. evening chronotype;
LGG	cis	rs283228	0.617	rs2518319	chr6:101799259	A/G	cg27451362	chr6:101846650	GRIK2	-0.86	-12.72	-0.51	5.25e-32	Coenzyme Q10 levels;
LGG	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19717773	chr7:2847554	GNA12	-0.36	-8.14	-0.35	3.7e-15	Height;
LGG	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.17	0.52	7.05e-34	Lung cancer in ever smokers;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.6e-22	Menopause (age at onset);
LGG	cis	rs7129556	0.690	rs947841	chr11:77592909	C/T	cg12586386	chr11:77299805	AQP11	0.42	6.81	0.3	3.04e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs4253772	0.637	rs9627402	chr22:46702586	C/T	cg24881330	chr22:46731750	TRMU	0.71	7.09	0.31	5.02e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.61	0.44	1.11e-23	Testicular germ cell tumor;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg25866889	chr13:114914595	NA	-0.35	-6.94	-0.31	1.35e-11	Schizophrenia;
LGG	cis	rs7648466	0.915	rs1491961	chr3:46250348	T/C	cg12441928	chr3:46249985	CCR1	-0.57	-10.01	-0.42	1.74e-21	Eotaxin levels;
LGG	cis	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg06521331	chr12:34319734	NA	-0.41	-6.95	-0.31	1.23e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg06212747	chr3:49208901	KLHDC8B	0.47	7.08	0.31	5.45e-12	Menarche (age at onset);
LGG	cis	rs7618501	0.602	rs2071207	chr3:50159844	T/C	cg18129748	chr3:49941408	MST1R	-0.22	-6.93	-0.31	1.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg01420254	chr6:26195488	NA	0.89	11.78	0.48	3.48e-28	Gout;Renal underexcretion gout;
LGG	cis	rs1670533	1.000	rs6850784	chr4:1059809	G/A	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.53e-21	Recombination rate (females);
LGG	cis	rs7666738	0.830	rs2167892	chr4:99048503	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.78	-10.18	-0.43	4.3e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17092148	1.000	rs62211612	chr20:33386156	C/T	cg12302830	chr20:33297742	TP53INP2	0.46	7.75	0.34	5.97e-14	Neuroticism;
LGG	cis	rs3087591	1.000	rs2905877	chr17:29543269	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.68	-14.16	-0.55	4.5e-38	Hip circumference;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14996935	chr7:91875850	KRIT1;ANKIB1	0.39	6.81	0.3	3.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Vitiligo;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg27400746	chr16:89904261	SPIRE2	-0.94	-14.9	-0.57	2.8e-41	Skin colour saturation;
LGG	cis	rs9790314	0.690	rs6799130	chr3:160847801	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg17376030	chr22:41985996	PMM1	0.51	8.22	0.36	2.07e-15	Vitiligo;
LGG	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg12395012	chr8:11607386	GATA4	-0.4	-7.08	-0.31	5.49e-12	Retinal vascular caliber;
LGG	cis	rs919433	0.783	rs788011	chr2:198230771	A/G	cg00792783	chr2:198669748	PLCL1	0.46	7.33	0.32	1e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06347996	chr1:98386915	DPYD	0.43	6.82	0.3	2.84e-11	Cognitive performance;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08133824	chr7:99698538	MCM7;AP4M1	-0.42	-6.94	-0.31	1.34e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10463316	0.894	rs7719630	chr5:150760961	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs3126085	0.935	rs12407553	chr1:152297517	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.1	-0.35	4.76e-15	Atopic dermatitis;
LGG	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.97	-0.45	4.8e-25	Heart rate;
LGG	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg12561776	chr17:30844705	MYO1D	-0.27	-6.78	-0.3	3.64e-11	Schizophrenia;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg02988316	chr9:504774	KANK1	-0.38	-6.76	-0.3	4.19e-11	Blood metabolite levels;
LGG	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.82	0.54	1.24e-36	Bladder cancer;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg05775895	chr3:12838266	CAND2	0.62	11.08	0.46	1.75e-25	QRS complex (12-leadsum);
LGG	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg26031613	chr14:104095156	KLC1	-0.63	-9.98	-0.42	2.28e-21	Reticulocyte count;
LGG	cis	rs62238980	0.614	rs117628874	chr22:32452970	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs11074306	0.508	rs12438618	chr15:28045534	A/G	cg26402630	chr15:28053930	OCA2	0.34	6.69	0.3	6.56e-11	Uveal melanoma;
LGG	cis	rs7666738	0.962	rs2865986	chr4:99067907	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.1	0.31	4.63e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg12419862	chr22:24373484	LOC391322	-0.97	-20.95	-0.7	4.78e-69	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg16006296	chr10:38738647	LOC399744	0.34	6.72	0.3	5.4e-11	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16406212	chr2:24163862	UBXN2A	0.57	8.54	0.37	1.96e-16	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg04731861	chr2:219085781	ARPC2	-0.49	-12.37	-0.5	1.43e-30	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23639257	chr17:73663270	RECQL5;SAP30BP	0.45	7.61	0.33	1.56e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg08477640	chr19:41863820	B9D2	-0.4	-7.41	-0.33	6.2e-13	Colorectal cancer;
LGG	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg02487422	chr3:49467188	NICN1	0.58	10.75	0.45	3.16e-24	Resting heart rate;
LGG	cis	rs4959677	0.935	rs2325965	chr6:2493314	A/T	cg23817096	chr6:1620687	NA	-0.32	-7.5	-0.33	3.34e-13	Orthostatic hypotension;
LGG	cis	rs6547631	0.622	rs1866141	chr2:85925386	T/C	cg24620635	chr2:85921963	GNLY	0.49	9.91	0.42	4.03e-21	Blood protein levels;
LGG	cis	rs7926971	0.631	rs7938009	chr11:12660882	C/T	cg25843174	chr11:12811716	TEAD1	0.31	6.78	0.3	3.7e-11	Height;
LGG	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.04	0.35	7.47e-15	Mood instability;
LGG	cis	rs17776563	0.614	rs12324850	chr15:89132175	C/G	cg05013243	chr15:89149849	MIR1179	-0.34	-6.98	-0.31	1.05e-11	Thyroid hormone levels;
LGG	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-8.16	-0.35	3.12e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg19223190	chr17:80058835	NA	0.44	8.55	0.37	1.82e-16	Life satisfaction;
LGG	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg08344181	chr3:125677491	NA	-0.64	-7.59	-0.33	1.81e-13	Depression;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg12070911	chr6:150209640	RAET1E	0.33	7.9	0.34	1.99e-14	Lung cancer;
LGG	cis	rs870825	0.929	rs2310102	chr4:185595141	C/G	cg04058563	chr4:185651563	MLF1IP	-0.98	-19.23	-0.67	5.51e-61	Blood protein levels;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg08888203	chr3:10149979	C3orf24	0.53	9.18	0.39	1.45e-18	Alzheimer's disease;
LGG	trans	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-10.07	-0.42	1.07e-21	Corneal astigmatism;
LGG	cis	rs4474465	0.920	rs10899527	chr11:78207394	A/G	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs7843479	0.562	rs4872191	chr8:21824547	A/G	cg17168535	chr8:21777572	XPO7	0.82	16.16	0.6	6.73e-47	Mean corpuscular volume;
LGG	cis	rs4409675	0.597	rs1467464	chr1:28211650	T/C	cg23691781	chr1:28212827	C1orf38	0.41	11.12	0.46	1.31e-25	Corneal astigmatism;
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs12579753	0.917	rs7138533	chr12:82187885	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.86	-0.34	2.7e-14	Resting heart rate;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-7.73	-0.34	6.9e-14	Longevity;Endometriosis;
LGG	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg11644478	chr21:40555479	PSMG1	-0.72	-12.78	-0.51	3.13e-32	Cognitive function;
LGG	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs778371	0.723	rs12999865	chr2:233627250	T/C	cg08000102	chr2:233561755	GIGYF2	0.72	12.25	0.49	4.6e-30	Schizophrenia;
LGG	cis	rs6840360	0.593	rs4696286	chr4:152606547	G/A	cg22705602	chr4:152727874	NA	-0.37	-8.98	-0.39	6.91e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg23649088	chr2:200775458	C2orf69	0.79	16.04	0.6	2.25e-46	Osteoporosis;
LGG	cis	rs12476592	0.602	rs262477	chr2:63870959	A/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.84	-0.3	2.55e-11	Childhood ear infection;
LGG	cis	rs1790761	0.967	rs1638588	chr11:67199706	C/A	cg00864171	chr11:67383662	NA	-0.42	-7.01	-0.31	8.36e-12	Mean corpuscular volume;
LGG	cis	rs4481887	0.538	rs4916117	chr1:248387187	G/C	cg00666640	chr1:248458726	OR2T12	0.49	7.32	0.32	1.11e-12	Common traits (Other);
LGG	cis	rs7584262	0.740	rs13401256	chr2:42245188	G/A	cg19376973	chr2:42229025	NA	0.64	9.48	0.4	1.29e-19	Bone mineral density;
LGG	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg22437258	chr11:111473054	SIK2	-0.58	-9.74	-0.41	1.66e-20	Primary sclerosing cholangitis;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg12091567	chr17:66097778	LOC651250	-0.77	-12.83	-0.51	1.87e-32	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4774899	0.752	rs2951904	chr15:57364814	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.81	-0.3	3.12e-11	Urinary tract infection frequency;
LGG	trans	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.67	-0.34	1.01e-13	Educational attainment (years of education);
LGG	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.11	0.46	1.43e-25	Response to antipsychotic treatment;
LGG	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg16070123	chr10:51489643	NA	-0.4	-7.23	-0.32	1.98e-12	Prostate-specific antigen levels;
LGG	cis	rs9457247	0.765	rs6904946	chr6:167433948	C/T	cg07741184	chr6:167504864	NA	-0.41	-9.31	-0.4	5.32e-19	Crohn's disease;
LGG	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg26039829	chr8:22132926	PIWIL2	0.54	12.52	0.5	3.49e-31	Hypertriglyceridemia;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg08000102	chr2:233561755	GIGYF2	0.59	9.74	0.41	1.64e-20	Coronary artery disease;
LGG	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg14835575	chr10:16859367	RSU1	-0.34	-6.74	-0.3	4.65e-11	Platelet distribution width;
LGG	trans	rs9951602	0.920	rs3859334	chr18:76684193	G/A	cg02800362	chr5:177631904	HNRNPAB	0.77	9.5	0.4	1.14e-19	Obesity-related traits;
LGG	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg08250081	chr4:10125330	NA	0.36	6.98	0.31	1.05e-11	Bone mineral density;
LGG	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg00599393	chr8:22457479	C8orf58	0.39	6.9	0.31	1.77e-11	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg12373951	chr3:133503437	NA	0.4	7.03	0.31	7.56e-12	Iron status biomarkers;
LGG	cis	rs858239	0.601	rs929507	chr7:23166664	G/C	cg23682824	chr7:23144976	KLHL7	0.42	7.04	0.31	6.95e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14240646	chr10:27532245	ACBD5	0.79	11.61	0.47	1.52e-27	Breast cancer;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.97	-0.45	4.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-10.79	-0.45	2.36e-24	Vitamin D levels;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.4	0.36	5.44e-16	Aortic root size;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg11062466	chr8:58055876	NA	0.59	9.26	0.4	7.68e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg27476859	chr7:2772710	GNA12	0.53	10.23	0.43	2.89e-22	Height;
LGG	cis	rs7095944	0.584	rs4962693	chr10:126424835	C/T	cg08799069	chr10:126477246	METTL10	-0.43	-9.45	-0.4	1.63e-19	Asthma;
LGG	cis	rs7582720	1.000	rs72936304	chr2:204036357	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.47	0.4	1.48e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs71017072	1	rs71017072	chr7:19794295	G/GA	cg07541023	chr7:19748670	TWISTNB	0.45	6.74	0.3	4.69e-11	Rubella;
LGG	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg18252515	chr7:66147081	NA	-1.42	-20.51	-0.69	5.3e-67	Diabetic kidney disease;
LGG	cis	rs3784262	0.669	rs17820990	chr15:58349568	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.93	-0.31	1.44e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs80282103	0.764	rs12268949	chr10:1104257	A/G	cg08668510	chr10:1095578	IDI1	0.75	7.54	0.33	2.44e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.37	0.32	8.14e-13	Resting heart rate;
LGG	cis	rs2361710	0.611	rs12051781	chr17:78074468	A/G	cg06718696	chr17:78121285	EIF4A3	0.56	8.99	0.39	6.43e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg05313129	chr8:58192883	C8orf71	-0.84	-12.5	-0.5	4.31e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs926938	0.584	rs1299780	chr1:115366014	G/A	cg12756093	chr1:115239321	AMPD1	0.46	8.55	0.37	1.79e-16	Autism;
LGG	cis	rs2729354	1.000	rs2511983	chr11:57346874	A/G	cg24343310	chr11:57249947	NA	0.36	6.74	0.3	4.58e-11	Blood protein levels;
LGG	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg18200150	chr17:30822561	MYO1D	0.48	9.16	0.39	1.74e-18	Schizophrenia;
LGG	cis	rs7828089	1.000	rs7837964	chr8:22264417	G/C	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.74	-0.3	4.86e-11	Verbal declarative memory;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg04166393	chr7:2884313	GNA12	0.48	9.28	0.4	6.47e-19	Height;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.63	0.41	3.97e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	11.55	0.47	2.77e-27	Mean platelet volume;
LGG	cis	rs10979	0.546	rs9496686	chr6:143908735	G/C	cg25407410	chr6:143891975	LOC285740	-0.56	-8.23	-0.36	1.97e-15	Hypospadias;
LGG	cis	rs6740322	0.748	rs6727631	chr2:43470408	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-11.14	-0.46	1.09e-25	Coronary artery disease;
LGG	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.25	-0.39	8.41e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1620921	0.624	rs13203412	chr6:161275871	G/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg11166453	chr1:247681781	NA	0.63	9.92	0.42	3.79e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.45	-0.37	3.83e-16	Height;
LGG	cis	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.22	-0.32	2.12e-12	Triglycerides;
LGG	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.46	-0.33	4.17e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6909430	0.665	rs2502946	chr6:98622734	G/C	cg12860156	chr6:98744658	NA	-0.37	-6.71	-0.3	5.81e-11	Quantitative traits;
LGG	cis	rs9356171	0.572	rs62435477	chr6:164328670	C/T	cg25752492	chr6:164341247	NA	-0.46	-9.07	-0.39	3.3e-18	Diisocyanate-induced asthma;
LGG	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	25.16	0.76	1.14e-88	Height;
LGG	cis	rs12478296	0.901	rs7603560	chr2:243043256	C/T	cg06360820	chr2:242988706	NA	-0.96	-11.88	-0.48	1.32e-28	Obesity-related traits;
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.02	-0.31	7.85e-12	Neuroticism;
LGG	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.34	0.32	9.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.15	-0.35	3.32e-15	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg27490568	chr2:178487706	NA	0.69	12.94	0.52	6.46e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg09222892	chr1:25734099	RHCE	-0.49	-10.44	-0.44	4.49e-23	Erythrocyte sedimentation rate;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg11878867	chr6:150167359	LRP11	-0.38	-7.98	-0.35	1.17e-14	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07303308	chr7:128695042	LOC286016;TNPO3	0.4	6.7	0.3	5.96e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	-0.54	-9.8	-0.41	9.53e-21	Menarche (age at onset);
LGG	cis	rs4764124	0.646	rs11610238	chr12:14975721	C/T	cg19759883	chr12:14956454	WBP11;C12orf60	0.58	11.14	0.46	1.08e-25	Pubertal anthropometrics;
LGG	cis	rs6723226	0.806	rs6543658	chr2:32718849	G/A	cg02381751	chr2:32503542	YIPF4	0.74	12.61	0.51	1.59e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6032067	0.925	rs13042522	chr20:43829290	G/A	cg10761708	chr20:43804764	PI3	0.76	11.41	0.47	9.87e-27	Blood protein levels;
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg00383909	chr3:49044727	WDR6	0.45	7.3	0.32	1.26e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7980799	0.717	rs7315242	chr12:33493764	G/A	cg26384229	chr12:38710491	ALG10B	-0.4	-6.7	-0.3	6.04e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.58	0.33	1.95e-13	Renal function-related traits (BUN);
LGG	cis	rs7408868	1.000	rs10416389	chr19:15278674	G/C	cg14696996	chr19:15285081	NOTCH3	1.1	13.17	0.52	7.11e-34	Pulse pressure;
LGG	cis	rs10791323	0.720	rs2851117	chr11:133705905	A/G	cg15485101	chr11:133734466	NA	-0.49	-8.88	-0.38	1.53e-17	Childhood ear infection;
LGG	cis	rs59918340	0.764	rs4961339	chr8:142231504	A/G	cg23750338	chr8:142222470	SLC45A4	0.6	12.35	0.5	1.67e-30	Immature fraction of reticulocytes;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11229555	0.645	rs11229457	chr11:58207203	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11874712	0.965	rs12954944	chr18:43664115	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg10636054	chr15:40330586	SRP14	0.63	6.98	0.31	1.04e-11	Response to haloperidol in psychosis;
LGG	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg01236616	chr12:121019343	POP5	1.29	23.46	0.74	8.77e-81	Type 1 diabetes nephropathy;
LGG	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05491587	chr18:77659695	KCNG2	-0.53	-7.08	-0.31	5.26e-12	Opioid sensitivity;
LGG	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22590775	chr19:49891494	CCDC155	0.42	7.65	0.33	1.18e-13	Multiple sclerosis;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.17	0.39	1.58e-18	Obesity-related traits;
LGG	cis	rs61931739	0.649	rs1068864	chr12:33733119	A/C	cg06521331	chr12:34319734	NA	-0.4	-7.02	-0.31	7.97e-12	Morning vs. evening chronotype;
LGG	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg21972741	chr5:435613	AHRR	0.5	8.92	0.38	1.13e-17	Cystic fibrosis severity;
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.48	0.37	3.03e-16	Aortic root size;
LGG	cis	rs6747952	0.899	rs12731	chr2:239087912	G/A	cg17459225	chr2:239074497	NA	0.44	7.94	0.35	1.5e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10949834	0.878	rs2269083	chr7:73519661	G/A	cg07137043	chr7:73588983	EIF4H	-0.64	-7.26	-0.32	1.64e-12	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs7020830	0.931	rs6476613	chr9:37084340	A/G	cg14294708	chr9:37120828	ZCCHC7	1.12	30.41	0.82	1.95e-112	Schizophrenia;
LGG	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.34e-13	HDL cholesterol;
LGG	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg08859206	chr1:53392774	SCP2	-0.44	-9.04	-0.39	4.33e-18	Monocyte count;
LGG	cis	rs36051895	0.632	rs12343038	chr9:5178579	A/G	cg02405213	chr9:5042618	JAK2	0.78	15.29	0.58	4.87e-43	Pediatric autoimmune diseases;
LGG	cis	rs2302729	0.929	rs10744567	chr12:2780816	A/G	cg19945202	chr12:2788847	CACNA1C	-0.84	-12.47	-0.5	5.71e-31	Sleep quality;
LGG	cis	rs3735485	0.800	rs1866579	chr7:45085863	A/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6815814	0.904	rs2101521	chr4:38811551	C/T	cg06935464	chr4:38784597	TLR10	0.46	7.37	0.32	7.85e-13	Breast cancer;
LGG	cis	rs4144743	0.528	rs16941802	chr17:45355353	C/G	cg18085866	chr17:45331354	ITGB3	0.76	7.64	0.33	1.25e-13	Body mass index;
LGG	cis	rs6032067	0.929	rs17424356	chr20:43804190	A/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.55e-28	Blood protein levels;
LGG	trans	rs11039798	1.000	rs7102865	chr11:48458361	A/C	cg15704280	chr7:45808275	SEPT13	0.78	8.95	0.38	8.34e-18	Axial length;
LGG	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.4	-6.92	-0.31	1.53e-11	Coronary artery disease;
LGG	cis	rs9640161	0.742	rs2108851	chr7:150019634	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.55	-0.59	3.73e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1978968	0.830	rs11089210	chr22:18445692	A/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.44	-0.5	7.62e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.79	-0.34	4.5e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6750795	0.507	rs1667320	chr2:232418314	G/T	cg19187155	chr2:232395269	NMUR1	0.5	9.22	0.39	1.07e-18	Height;
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg21171335	chr12:122356390	WDR66	-0.28	-8.03	-0.35	8.13e-15	Mean corpuscular volume;
LGG	cis	rs4919044	0.756	rs835257	chr10:94779801	T/A	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.08	-0.31	5.48e-12	Coronary artery disease;
LGG	cis	rs6800768	0.633	rs6807599	chr3:24145588	A/C	cg10674438	chr3:24145617	LOC152024	-0.52	-9.37	-0.4	3.29e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg26384229	chr12:38710491	ALG10B	0.81	16.01	0.6	3.25e-46	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.68	0.3	6.79e-11	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg07701084	chr6:150067640	NUP43	0.64	12.06	0.49	2.53e-29	Lung cancer;
LGG	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg20283391	chr11:68216788	NA	-0.49	-8.07	-0.35	5.94e-15	Total body bone mineral density;
LGG	trans	rs6598955	0.671	rs12354062	chr1:26608761	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.32	-0.5	2.21e-30	Obesity-related traits;
LGG	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg02390115	chr1:21767211	NBPF3	0.58	11.17	0.46	8.09e-26	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg07389463	chr12:132296394	NA	-0.61	-14.15	-0.55	4.99e-38	Migraine;
LGG	cis	rs240764	0.559	rs9404049	chr6:101237129	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg02002194	chr4:3960332	NA	0.47	8.84	0.38	2.09e-17	Neuroticism;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg10935494	chr17:80760059	TBCD	-0.39	-6.65	-0.3	8.48e-11	Glycated hemoglobin levels;
LGG	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg16301924	chr13:53314226	LECT1	-0.55	-11.88	-0.48	1.41e-28	Lewy body disease;
LGG	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02743256	chr7:2109353	MAD1L1	-0.39	-7.02	-0.31	8.16e-12	Neuroticism;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs9487094	1.000	rs10872032	chr6:109676776	C/T	cg01125227	chr6:109776195	MICAL1	0.45	7.69	0.34	9.13e-14	Height;
LGG	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg24375607	chr4:120327624	NA	-0.56	-9.36	-0.4	3.38e-19	Corneal astigmatism;
LGG	cis	rs4642101	0.793	rs13320486	chr3:12822069	C/A	cg05775895	chr3:12838266	CAND2	0.65	11.77	0.48	3.69e-28	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00933542	chr6:150070202	PCMT1	-0.39	-7.09	-0.31	5.07e-12	Lung cancer;
LGG	trans	rs11098499	0.863	rs11736416	chr4:120431661	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.71e-27	Corneal astigmatism;
LGG	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-14.38	-0.56	5.04e-39	Presence of antiphospholipid antibodies;
LGG	trans	rs12517041	0.873	rs6886748	chr5:23307271	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.8	-11.92	-0.48	9.6e-29	Calcium levels;
LGG	cis	rs4330281	0.836	rs4908941	chr3:17821483	G/A	cg20981856	chr3:17787350	NA	-0.36	-6.65	-0.3	8.29e-11	Schizophrenia;
LGG	cis	rs1534166	0.602	rs3817524	chr3:133526403	C/T	cg27366882	chr3:133540807	NA	-0.5	-10.44	-0.44	4.63e-23	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07677032	chr17:61819896	STRADA	0.69	12.77	0.51	3.23e-32	Prudent dietary pattern;
LGG	cis	rs758324	0.947	rs6596039	chr5:131198652	C/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-11.9	-0.48	1.15e-28	Alzheimer's disease;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01516881	chr6:292596	DUSP22	-0.54	-9.39	-0.4	2.66e-19	Menopause (age at onset);
LGG	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg27490568	chr2:178487706	NA	-0.47	-9.35	-0.4	3.75e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg24812749	chr6:127587940	RNF146	0.71	11.38	0.47	1.23e-26	Breast cancer;
LGG	cis	rs7552404	0.924	rs1694419	chr1:76219801	C/T	cg22875332	chr1:76189707	ACADM	0.52	9.04	0.39	4.25e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg03264133	chr6:25882463	NA	-0.49	-7.89	-0.34	2.24e-14	Iron status biomarkers;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg13880726	chr7:1868755	MAD1L1	0.39	7.02	0.31	8.04e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06929872	chr15:65322164	MTFMT	0.4	6.69	0.3	6.33e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7147624	0.938	rs10467734	chr14:65913947	C/T	cg03016385	chr14:66212404	NA	-0.76	-9.94	-0.42	3.12e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg22482690	chr17:47019901	SNF8	0.34	6.67	0.3	7.3e-11	Type 2 diabetes;
LGG	cis	rs981844	1.000	rs55702511	chr4:154665978	A/C	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.22e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg09537434	chr19:41945824	ATP5SL	0.89	22.73	0.73	2.17e-77	Height;
LGG	trans	rs2048656	0.507	rs7813718	chr8:9676094	G/T	cg16141378	chr3:129829833	LOC729375	0.33	7.01	0.31	8.73e-12	Schizophrenia;
LGG	cis	rs2694528	0.920	rs2120954	chr5:60219480	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.73	-7.68	-0.34	9.46e-14	Parkinson's disease;
LGG	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg12698349	chr2:225449008	CUL3	1.04	28.01	0.79	1.01e-101	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg05082376	chr22:42548792	NA	0.38	8.06	0.35	6.74e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg25482853	chr8:67687455	SGK3	0.94	11.8	0.48	2.82e-28	Obesity-related traits;
LGG	cis	rs283228	1.000	rs1832410	chr6:101826202	G/T	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg03517284	chr6:25882590	NA	-0.4	-7.08	-0.31	5.35e-12	Height;
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs1372520	0.684	rs2619368	chr4:90729747	T/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.92	0.51	8.17e-33	Obesity-related traits;
LGG	cis	rs55788414	0.932	rs59201365	chr16:81185681	C/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.17	-0.43	4.75e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg00409905	chr10:38381863	ZNF37A	0.47	8.16	0.35	3.23e-15	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-24.01	-0.74	2.46e-83	Lymphocyte percentage of white cells;
LGG	trans	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.8	-0.3	3.17e-11	Retinal vascular caliber;
LGG	cis	rs2455799	0.613	rs10510443	chr3:15829127	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-8.11	-0.35	4.54e-15	Mean platelet volume;
LGG	cis	rs7208859	0.623	rs73271872	chr17:29152228	C/G	cg13385521	chr17:29058706	SUZ12P	0.84	9.65	0.41	3.48e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-6.94	-0.31	1.33e-11	Schizophrenia;
LGG	cis	rs6840360	0.582	rs2709812	chr4:152335749	C/T	cg25486957	chr4:152246857	NA	0.38	6.84	0.3	2.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg21948465	chr5:131705150	SLC22A5	0.65	7.32	0.32	1.13e-12	Rheumatoid arthritis;
LGG	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02788857	chr8:22132959	PIWIL2	0.51	11.88	0.48	1.32e-28	Hypertriglyceridemia;
LGG	cis	rs7089973	0.872	rs7075888	chr10:116627117	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.6e-12	Bipolar disorder;
LGG	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg15454534	chr1:248569605	OR2T1	0.38	6.82	0.3	2.9e-11	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08367703	chr9:139304491	SDCCAG3;PMPCA	0.49	7.43	0.33	5.33e-13	Gut microbiome composition (summer);
LGG	cis	rs9487051	0.734	rs56214745	chr6:109536748	G/T	cg21918786	chr6:109611834	NA	-0.37	-6.67	-0.3	7.3e-11	Reticulocyte fraction of red cells;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24334809	chr2:178483498	TTC30A	0.38	6.97	0.31	1.08e-11	Obesity-related traits;
LGG	cis	rs12586317	0.557	rs10137757	chr14:35653853	A/G	cg05294307	chr14:35346193	BAZ1A	-0.38	-6.98	-0.31	1.05e-11	Psoriasis;
LGG	cis	rs11634851	1.000	rs4630510	chr15:81032822	C/T	cg03950166	chr15:80988613	FAM108C1	-0.36	-6.68	-0.3	6.96e-11	Systolic blood pressure;
LGG	cis	rs3816183	0.716	rs4952943	chr2:43082062	G/A	cg14631114	chr2:43023945	NA	0.45	8.1	0.35	4.75e-15	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01013600	chr19:49141177	DBP;SEC1	0.43	7.27	0.32	1.55e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.66	-0.34	1.13e-13	Resting heart rate;
LGG	cis	rs72781680	0.716	rs6731314	chr2:24048338	C/T	cg08917208	chr2:24149416	ATAD2B	-0.64	-8.28	-0.36	1.37e-15	Lymphocyte counts;
LGG	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-15.22	-0.58	1.04e-42	Platelet count;
LGG	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg10189774	chr4:17578691	LAP3	0.4	7.01	0.31	8.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27286337	chr10:134555280	INPP5A	0.87	12.85	0.51	1.55e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg13010199	chr12:38710504	ALG10B	0.55	10.08	0.42	9.85e-22	Morning vs. evening chronotype;
LGG	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg15556689	chr8:8085844	FLJ10661	0.48	9.0	0.39	5.65e-18	Mood instability;
LGG	cis	rs9329289	0.510	rs11251283	chr10:2555784	C/G	cg15501526	chr10:2543763	NA	0.48	8.84	0.38	2.07e-17	Age-related hearing impairment;
LGG	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg20891283	chr12:69753455	YEATS4	0.85	15.2	0.58	1.32e-42	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2153535	0.623	rs2327055	chr6:8443145	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	7.2e-22	Motion sickness;
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg07120314	chr15:79043507	NA	-0.73	-17.46	-0.63	8.33e-53	Coronary artery disease or large artery stroke;
LGG	cis	rs4356932	1.000	rs6825045	chr4:76957558	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg16301924	chr13:53314226	LECT1	-0.42	-7.55	-0.33	2.4e-13	Lewy body disease;
LGG	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.01	0.42	1.81e-21	Height;
LGG	trans	rs800082	0.698	rs1178943	chr3:144391772	T/G	cg24215973	chr2:240111563	HDAC4	-0.74	-13.54	-0.53	2.04e-35	Smoking behavior;
LGG	cis	rs943466	0.955	rs2894342	chr6:33774394	C/A	cg07519485	chr6:33762594	MLN	0.53	10.7	0.45	5.16e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.73	-9.44	-0.4	1.89e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg21747090	chr2:27597821	SNX17	0.38	6.85	0.3	2.38e-11	Total body bone mineral density;
LGG	cis	rs10779751	0.770	rs6701524	chr1:11198502	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-14.49	-0.56	1.68e-39	Body mass index;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.66	0.3	7.6e-11	Schizophrenia;
LGG	cis	rs7851660	0.874	rs7868534	chr9:100632606	G/A	cg13688889	chr9:100608707	NA	-0.59	-11.65	-0.48	1.14e-27	Strep throat;
LGG	cis	rs11690935	0.632	rs17581284	chr2:172659376	C/T	cg13550731	chr2:172543902	DYNC1I2	0.7	14.02	0.55	1.87e-37	Schizophrenia;
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg26138144	chr22:38071188	LGALS1	0.91	24.31	0.75	1.03e-84	Fat distribution (HIV);
LGG	cis	rs55665837	0.559	rs11023210	chr11:14422762	A/G	cg19336497	chr11:14380999	RRAS2	0.53	10.94	0.45	5.95e-25	Vitamin D levels;
LGG	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg03433033	chr1:76189801	ACADM	-0.79	-12.57	-0.5	2.26e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg03806693	chr22:41940476	POLR3H	-1.13	-20.49	-0.69	7.13e-67	Vitiligo;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg11764359	chr7:65958608	NA	-0.73	-13.02	-0.52	3.13e-33	Aortic root size;
LGG	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg15103426	chr22:29168792	CCDC117	0.6	8.04	0.35	7.51e-15	Lymphocyte counts;
LGG	cis	rs7215564	0.908	rs35584560	chr17:78668256	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.16	-0.35	3.11e-15	Myopia (pathological);
LGG	cis	rs9964724	0.826	rs11082013	chr18:35186448	G/T	cg27332583	chr18:35150602	NA	-0.42	-9.11	-0.39	2.56e-18	Educational attainment (years of education);
LGG	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg19524238	chr7:2802976	GNA12	0.34	8.12	0.35	4.11e-15	Height;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs2073499	0.935	rs2526393	chr3:50189173	C/G	cg03645007	chr3:50255295	SLC38A3	-0.61	-7.08	-0.31	5.53e-12	Schizophrenia;
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.67e-16	Rheumatoid arthritis;
LGG	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Calcium levels;
LGG	cis	rs9300255	0.722	rs67624109	chr12:123824635	C/T	cg05973401	chr12:123451056	ABCB9	-0.46	-6.66	-0.3	7.67e-11	Neutrophil percentage of white cells;
LGG	trans	rs208520	1.000	rs208537	chr6:66963544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg15596359	chr8:11213517	TDH	-0.41	-8.57	-0.37	1.59e-16	Retinal vascular caliber;
LGG	cis	rs17169635	0.579	rs1563047	chr7:134573443	C/G	cg02516134	chr7:134575187	CALD1	0.35	7.59	0.33	1.76e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs77741769	0.571	rs10849807	chr12:121314056	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.13	0.39	2.1e-18	Mean corpuscular volume;
LGG	cis	rs7216064	1.000	rs4271626	chr17:65930133	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-9.0	-0.39	6e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11785693	0.862	rs13281354	chr8:4987756	G/T	cg26367366	chr8:4980734	NA	0.99	15.82	0.59	2.26e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg10950524	chr7:2139216	MAD1L1	0.3	6.72	0.3	5.3e-11	Schizophrenia;
LGG	cis	rs6963495	0.818	rs73192144	chr7:105203535	C/T	cg19920283	chr7:105172520	RINT1	0.66	8.55	0.37	1.75e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg05165339	chr4:1420672	NA	-0.33	-8.35	-0.36	7.98e-16	Longevity;
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg22072935	chr14:105399595	NA	-0.5	-9.51	-0.4	1.05e-19	Rheumatoid arthritis;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs72772090	0.634	rs17402639	chr5:96107005	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-9.25	-0.4	8.14e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg10756647	chr7:56101905	PSPH	-0.81	-9.43	-0.4	1.98e-19	Diabetic kidney disease;
LGG	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.23	-0.46	4.76e-26	Blood metabolite levels;
LGG	cis	rs2439831	0.850	rs28595038	chr15:44044859	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.64	0.44	8.58e-24	Lung cancer in ever smokers;
LGG	cis	rs7129556	0.911	rs10899394	chr11:77324261	A/G	cg12586386	chr11:77299805	AQP11	0.49	8.16	0.35	3.24e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.44	-0.47	7.1e-27	Response to antipsychotic treatment;
LGG	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-7.28	-0.32	1.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.7e-28	Lymphocyte counts;
LGG	trans	rs9987353	0.840	rs329994	chr8:9123233	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.9	0.31	1.7e-11	Recombination measurement;
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg04287289	chr16:89883240	FANCA	0.84	7.81	0.34	3.81e-14	Skin colour saturation;
LGG	cis	rs6577655	0.547	rs7841171	chr8:135591699	G/A	cg17885191	chr8:135476712	NA	0.58	8.56	0.37	1.67e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg13607699	chr17:42295918	UBTF	-0.45	-7.17	-0.32	3e-12	Total body bone mineral density;
LGG	cis	rs4684776	0.800	rs2077507	chr3:11618468	C/T	cg24705426	chr3:11550659	ATG7	0.39	6.84	0.3	2.49e-11	Small vessel stroke;
LGG	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg12654349	chr5:56205094	C5orf35	-0.58	-10.03	-0.42	1.43e-21	Initial pursuit acceleration;
LGG	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg00129232	chr17:37814104	STARD3	0.43	8.07	0.35	6.02e-15	Self-reported allergy;
LGG	cis	rs2251381	0.523	rs2832306	chr21:30754468	C/T	cg08807101	chr21:30365312	RNF160	-0.44	-6.97	-0.31	1.12e-11	Selective IgA deficiency;
LGG	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25517755	chr10:38738941	LOC399744	-0.35	-6.7	-0.3	6.09e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.48	-0.44	3.27e-23	Body mass index;
LGG	cis	rs4319547	0.656	rs6488951	chr12:122873928	A/G	cg23029597	chr12:123009494	RSRC2	-0.93	-17.27	-0.63	5.92e-52	Body mass index;
LGG	cis	rs13314892	0.764	rs62251029	chr3:69864732	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	trans	rs73198271	0.737	rs565203	chr8:8632957	T/C	cg16141378	chr3:129829833	LOC729375	0.34	6.91	0.31	1.58e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6582630	0.519	rs4002440	chr12:38485012	A/G	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1375194	0.606	rs2044644	chr2:33817559	A/G	cg04131969	chr2:33951647	MYADML	-0.58	-10.31	-0.43	1.44e-22	Response to antidepressants in depression;
LGG	cis	rs7267979	0.844	rs6076343	chr20:25376663	C/T	cg06421707	chr20:25228305	PYGB	-0.43	-9.0	-0.39	5.84e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	9.07	0.39	3.33e-18	Mood instability;
LGG	cis	rs6784615	0.744	rs9850471	chr3:52492475	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.66	0.34	1.07e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10185519	chr16:30621987	ZNF689	0.47	8.07	0.35	6.16e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs2131877	0.830	rs62285219	chr3:194871480	A/T	cg07250128	chr3:194833983	C3orf21	0.41	7.6	0.33	1.67e-13	Non-small cell lung cancer;
LGG	cis	rs62238980	0.522	rs62238977	chr22:32573224	G/C	cg00543991	chr22:32367038	NA	0.73	8.56	0.37	1.68e-16	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01044731	chr13:24554006	NA	0.48	7.93	0.35	1.6e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7580658	1.000	rs7580658	chr2:128159261	G/A	cg10021288	chr2:128175891	PROC	-0.67	-13.78	-0.54	1.91e-36	Protein C levels;
LGG	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs2304069	0.545	rs7728248	chr5:149394965	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.11	0.35	4.45e-15	HIV-1 control;
LGG	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg26695010	chr11:65641043	EFEMP2	0.51	8.6	0.37	1.28e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7927771	0.542	rs10769300	chr11:47865560	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg24812749	chr6:127587940	RNF146	0.7	11.51	0.47	3.87e-27	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24581572	chr1:205197876	TMCC2	0.47	7.51	0.33	3.16e-13	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg05941027	chr17:61774174	LIMD2	0.34	8.67	0.37	7.35e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.33	0.32	1e-12	Homoarginine levels;
LGG	cis	rs9398803	0.865	rs9398805	chr6:126726295	C/T	cg19875578	chr6:126661172	C6orf173	0.57	10.54	0.44	1.98e-23	Male-pattern baldness;
LGG	cis	rs6547631	0.622	rs10210321	chr2:85928128	A/C	cg24620635	chr2:85921963	GNLY	0.5	10.07	0.42	1.09e-21	Blood protein levels;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12282928	0.959	rs1393788	chr11:48279416	A/G	cg26585981	chr11:48327164	OR4S1	0.44	7.12	0.31	4.13e-12	Migraine - clinic-based;
LGG	cis	rs7503807	0.515	rs12452916	chr17:78664655	C/T	cg06872548	chr17:78716983	RPTOR	0.37	6.93	0.31	1.38e-11	Obesity;
LGG	cis	rs9457247	0.663	rs9295384	chr6:167448113	T/A	cg07741184	chr6:167504864	NA	0.39	8.67	0.37	7.37e-17	Crohn's disease;
LGG	cis	rs12286929	0.668	rs17304149	chr11:115049180	C/T	cg04055981	chr11:115044050	NA	0.38	7.07	0.31	5.65e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4595586	1.000	rs1523118	chr12:39229699	C/T	cg26384229	chr12:38710491	ALG10B	-0.42	-7.34	-0.32	9.36e-13	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg02018176	chr4:1364513	KIAA1530	0.44	9.74	0.41	1.63e-20	Obesity-related traits;
LGG	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.4	-0.33	6.55e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12643440	0.538	rs4280726	chr4:17139547	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.64	-0.37	9.15e-17	Metabolite levels (Pyroglutamine);
LGG	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.75	-0.41	1.46e-20	Urinary tract infection frequency;
LGG	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg22437258	chr11:111473054	SIK2	0.57	9.73	0.41	1.72e-20	Primary sclerosing cholangitis;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg16590910	chr6:42928470	GNMT	0.48	14.1	0.55	8.48e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7226408	0.600	rs8087932	chr18:34424991	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.2	-0.36	2.33e-15	Obesity-related traits;
LGG	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.16e-19	Bone mineral density;
LGG	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg06028605	chr16:24865363	SLC5A11	-0.45	-7.4	-0.33	6.66e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.8	-0.38	2.78e-17	Lung cancer;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.78	-15.61	-0.59	1.86e-44	Longevity;Endometriosis;
LGG	cis	rs2712184	0.687	rs62180470	chr2:217645451	A/G	cg05032264	chr2:217675019	NA	0.41	9.1	0.39	2.68e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	18.69	0.66	1.75e-58	Personality dimensions;
LGG	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6732160	0.549	rs6744529	chr2:73480869	A/G	cg01422370	chr2:73384389	NA	0.47	8.97	0.38	7.44e-18	Intelligence (multi-trait analysis);
LGG	cis	rs1021993	0.597	rs79455200	chr1:209507767	G/A	cg24446417	chr1:209558027	NA	-0.69	-10.09	-0.42	8.85e-22	Gut microbiome composition (winter);
LGG	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg09163369	chr1:210001066	C1orf107	0.39	6.93	0.31	1.38e-11	Orofacial clefts;
LGG	cis	rs711245	0.545	rs848617	chr2:36811298	G/C	cg01206211	chr2:36825736	FEZ2	0.42	8.05	0.35	6.89e-15	Height;
LGG	cis	rs4595586	0.545	rs4254106	chr12:39389342	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.37	0.32	7.85e-13	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg22920501	chr2:26401640	FAM59B	0.44	8.68	0.37	6.69e-17	Gut microbiome composition (summer);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25791773	chr11:129910324	NA	0.37	6.74	0.3	4.6e-11	Electrocardiographic conduction measures;
LGG	cis	rs9457247	1.000	rs422562	chr6:167406318	A/G	cg07741184	chr6:167504864	NA	0.31	6.82	0.3	2.86e-11	Crohn's disease;
LGG	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.62	-0.37	1.09e-16	Eosinophil percentage of white cells;
LGG	cis	rs2274273	0.673	rs2209808	chr14:55807695	A/T	cg04306507	chr14:55594613	LGALS3	0.61	16.81	0.62	7.32e-50	Protein biomarker;
LGG	cis	rs7681440	0.746	rs6812192	chr4:90817848	A/G	cg14346243	chr4:90757452	SNCA	-0.37	-7.42	-0.33	5.56e-13	Dementia with Lewy bodies;
LGG	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.08	-0.31	5.45e-12	Refractive error;
LGG	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.03	0.42	1.46e-21	Dupuytren's disease;
LGG	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8141529	0.529	rs2236141	chr22:29137870	C/T	cg15103426	chr22:29168792	CCDC117	0.63	6.68	0.3	7.02e-11	Lymphocyte counts;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg25703541	chr22:24373054	LOC391322	-0.89	-18.18	-0.65	3.76e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg18538332	chr22:24372958	LOC391322	-0.47	-8.08	-0.35	5.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg11878867	chr6:150167359	LRP11	-0.39	-8.04	-0.35	7.54e-15	Testicular germ cell tumor;
LGG	cis	rs721399	0.553	rs13262341	chr8:18243097	A/G	cg18736775	chr8:18248649	NAT2	-0.77	-12.2	-0.49	6.74e-30	Blood metabolite levels;
LGG	cis	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg05062323	chr7:22590069	NA	-0.75	-9.76	-0.41	1.42e-20	Bilirubin levels;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.54	0.37	1.96e-16	Aortic root size;
LGG	cis	rs17641971	0.599	rs2385230	chr8:50015755	A/G	cg00325661	chr8:49890786	NA	0.55	10.48	0.44	3.22e-23	Blood metabolite levels;
LGG	cis	rs67311347	1.000	rs12633431	chr3:40505740	C/T	cg13683864	chr3:40499215	RPL14	1.15	28.92	0.8	8.46e-106	Renal cell carcinoma;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg13880726	chr7:1868755	MAD1L1	-0.52	-9.31	-0.4	5e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9290877	0.667	rs6774775	chr3:188455874	A/G	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg20040747	chr15:74715105	SEMA7A	-0.5	-8.95	-0.38	8.87e-18	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LGG	trans	rs1493916	0.967	rs9953765	chr18:31399464	A/G	cg04226714	chr8:49833948	SNAI2	-0.48	-8.45	-0.37	3.84e-16	Life satisfaction;
LGG	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg25237894	chr2:233734115	C2orf82	0.62	11.63	0.48	1.33e-27	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05468351	chr5:21459598	LOC728411	0.46	8.0	0.35	9.98e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs16866061	0.926	rs1523919	chr2:225403615	G/A	cg12698349	chr2:225449008	CUL3	0.89	17.97	0.64	3.49e-55	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs35771425	0.750	rs61848984	chr1:211550620	A/G	cg10512769	chr1:211675356	NA	-0.67	-9.3	-0.4	5.45e-19	Educational attainment (years of education);
LGG	cis	rs2153535	0.580	rs1577472	chr6:8486215	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs12286929	0.644	rs7942036	chr11:115078356	G/C	cg04055981	chr11:115044050	NA	0.37	6.95	0.31	1.26e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	12.81	0.51	2.34e-32	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.56e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg08645402	chr16:4508243	NA	0.5	8.65	0.37	8.37e-17	Schizophrenia;
LGG	cis	rs1125355	0.656	rs72937298	chr2:159636048	T/C	cg02251393	chr2:159651559	DAPL1	0.43	8.91	0.38	1.13e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs368123	0.961	rs2313207	chr6:160731480	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs2444240	0.967	rs470645	chr11:120007889	G/T	cg16005559	chr11:120040616	NA	-0.32	-7.23	-0.32	1.95e-12	Corneal curvature;
LGG	trans	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.54	-0.37	1.94e-16	Triglycerides;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg05025164	chr4:1340916	KIAA1530	0.44	7.51	0.33	3.07e-13	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg23782820	chr8:58130467	NA	0.44	7.0	0.31	9.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6430585	0.583	rs4988163	chr2:136628121	G/T	cg07169764	chr2:136633963	MCM6	1.25	23.55	0.74	3.46e-81	Corneal structure;
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.69	-0.37	6.19e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.6	0.37	1.2e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg25801113	chr15:45476975	SHF	0.88	20.14	0.68	2.84e-65	Uric acid levels;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg15383120	chr6:291909	DUSP22	-0.53	-8.81	-0.38	2.53e-17	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16208491	chr6:4021748	PRPF4B	0.52	8.15	0.35	3.53e-15	Gut microbiome composition (summer);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05654289	chr17:66201647	NA	-0.43	-6.65	-0.3	8.49e-11	Pancreatic cancer;
LGG	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.96	0.35	1.36e-14	Height;
LGG	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg14668821	chr17:77704760	ENPP7	0.43	8.38	0.36	6.29e-16	Menopause (age at onset);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg13129662	chr17:48227708	PPP1R9B	0.39	6.68	0.3	6.82e-11	Body mass index;
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg16141378	chr3:129829833	LOC729375	0.43	10.08	0.42	1.01e-21	Neuroticism;
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg17911788	chr17:44343683	NA	0.63	9.39	0.4	2.77e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.92	-0.38	1.06e-17	Lymphocyte counts;
LGG	cis	rs4727027	0.704	rs12704071	chr7:148904795	C/T	cg23583168	chr7:148888333	NA	-0.92	-18.87	-0.66	2.38e-59	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.24	-0.32	1.89e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1838472	0.607	rs11929003	chr3:123979321	A/G	cg05766129	chr3:123988013	KALRN	0.4	7.38	0.32	7.3e-13	Schizophrenia;
LGG	cis	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08380311	chr19:3435252	NFIC	0.82	12.93	0.51	7.47e-33	Height;
LGG	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22857025	chr5:266934	NA	-1.31	-13.53	-0.53	2.29e-35	Breast cancer;
LGG	trans	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg10756647	chr7:56101905	PSPH	0.81	9.37	0.4	3.2e-19	Diabetic kidney disease;
LGG	cis	rs8048589	0.615	rs34147612	chr16:12233188	G/A	cg02910054	chr16:12241554	SNX29	0.64	9.45	0.4	1.69e-19	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs9815354	0.812	rs10510729	chr3:41831998	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs867371	0.820	rs7164362	chr15:82486742	C/G	cg00614314	chr15:82944287	LOC80154	0.48	7.62	0.33	1.44e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs4820066	chr22:32409269	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs60843830	1.000	rs62114501	chr2:231741	C/T	cg04617936	chr2:214353	NA	-0.39	-7.1	-0.31	4.65e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs35176054	0.730	rs12779135	chr10:105519364	A/G	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-7.04	-0.31	7.11e-12	Atrial fibrillation;
LGG	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg01028140	chr2:1542097	TPO	-0.54	-8.62	-0.37	1.05e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs7178375	0.941	rs4779796	chr15:31208050	C/T	cg04373760	chr16:53404718	NA	0.53	8.09	0.35	5.45e-15	Hypertriglyceridemia;
LGG	cis	rs2594989	0.733	rs6779007	chr3:11583254	C/T	cg01796438	chr3:11312864	ATG7	0.45	6.69	0.3	6.36e-11	Circulating chemerin levels;
LGG	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06634786	chr22:41940651	POLR3H	0.78	12.78	0.51	2.99e-32	Vitiligo;
LGG	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg24375607	chr4:120327624	NA	0.6	9.8	0.41	1.02e-20	Corneal astigmatism;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.23	0.39	9.71e-19	Schizophrenia;
LGG	cis	rs11169552	0.510	rs10783381	chr12:51016450	G/A	cg12884762	chr12:50931848	DIP2B	-0.41	-7.66	-0.34	1.09e-13	Colorectal cancer;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg20887711	chr4:1340912	KIAA1530	0.93	20.56	0.69	3.36e-67	Longevity;
LGG	cis	rs4973397	0.765	rs13030174	chr2:232271284	A/C	cg11378575	chr2:232265004	B3GNT7	0.58	10.35	0.43	9.75e-23	Anti-saccade response;
LGG	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs526231	0.543	rs246916	chr5:102557515	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.22	-0.36	2.13e-15	Primary biliary cholangitis;
LGG	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg01620082	chr3:125678407	NA	-0.63	-6.94	-0.31	1.36e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.63e-12	Bipolar disorder;
LGG	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg02711726	chr17:80685570	FN3KRP	0.66	13.64	0.54	7.87e-36	Glycated hemoglobin levels;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg21788624	chr2:20251350	LAPTM4A	-0.36	-6.98	-0.31	1.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg20368463	chr18:77673604	PQLC1	0.43	7.5	0.33	3.19e-13	Schizophrenia;
LGG	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.34	-0.32	9.36e-13	Restless legs syndrome;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs986417	0.748	rs10147346	chr14:61083334	G/C	cg27398547	chr14:60952738	C14orf39	0.69	7.11	0.31	4.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6504108	0.624	rs3897986	chr17:46261539	A/G	cg02219949	chr17:45927392	SP6	-0.44	-8.12	-0.35	4.21e-15	Body mass index;
LGG	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-13.23	-0.52	3.89e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs2304069	0.507	rs4705407	chr5:149404983	G/T	cg12661370	chr5:149340060	SLC26A2	0.55	9.56	0.41	7.18e-20	HIV-1 control;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	9.63	0.41	3.83e-20	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg00166722	chr3:10149974	C3orf24	-0.51	-8.54	-0.37	1.97e-16	Alzheimer's disease;
LGG	cis	rs9457247	1.000	rs365189	chr6:167384545	G/A	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg17809284	chr5:56205270	C5orf35	-0.49	-8.09	-0.35	5.16e-15	Initial pursuit acceleration;
LGG	cis	rs1371867	0.839	rs1788186	chr8:101335686	T/C	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs7215564	0.908	rs34914062	chr17:78655909	C/T	cg16980736	chr17:78789706	RPTOR	-0.72	-9.39	-0.4	2.65e-19	Myopia (pathological);
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg23000464	chr19:633785	POLRMT	-0.4	-6.75	-0.3	4.58e-11	Hematological and biochemical traits;
LGG	cis	rs73086581	1.000	rs17215340	chr20:3970173	C/G	cg02187196	chr20:3869020	PANK2	-0.81	-10.97	-0.45	4.7e-25	Response to antidepressants in depression;
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.06	-0.31	6.12e-12	Prostate cancer;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg01098959	chr19:46284187	DMPK	0.41	7.49	0.33	3.63e-13	Coronary artery disease;
LGG	cis	rs35771425	0.600	rs17188937	chr1:211475333	A/C	cg10512769	chr1:211675356	NA	-0.63	-8.4	-0.36	5.49e-16	Educational attainment (years of education);
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.1	0.49	1.7e-29	Lung cancer;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.61	-0.44	1.1e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg17911788	chr17:44343683	NA	-0.59	-9.14	-0.39	1.94e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs920590	0.549	rs11204077	chr8:19653739	C/G	cg03894339	chr8:19674705	INTS10	0.43	7.39	0.32	6.77e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg07460842	chr6:66804631	NA	-0.97	-18.14	-0.64	6.14e-56	Exhaled nitric oxide output;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg26513180	chr16:89883248	FANCA	0.81	8.82	0.38	2.38e-17	Skin colour saturation;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.01	0.42	1.69e-21	Longevity;
LGG	cis	rs3096299	0.702	rs2086825	chr16:89471542	C/T	cg08822215	chr16:89438651	ANKRD11	-0.35	-6.96	-0.31	1.19e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs12493885	0.818	rs61791545	chr3:153768888	G/A	cg12800244	chr3:153838788	SGEF	-0.82	-9.02	-0.39	4.83e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg17202724	chr17:61916730	SMARCD2	-0.41	-8.25	-0.36	1.66e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg13009111	chr11:71350975	NA	0.32	7.04	0.31	6.92e-12	Systolic blood pressure;
LGG	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg25730555	chr22:47059586	GRAMD4	0.39	6.65	0.3	8.38e-11	Urate levels in obese individuals;
LGG	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg21427119	chr20:30132790	HM13	-0.43	-7.01	-0.31	8.26e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4700695	0.640	rs27083	chr5:65435865	C/T	cg21114390	chr5:65439923	SFRS12	-0.72	-10.49	-0.44	3.15e-23	Facial morphology (factor 19);
LGG	cis	rs778371	0.649	rs13021823	chr2:233686862	A/G	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.08	-0.46	1.79e-25	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg23782820	chr8:58130467	NA	0.43	6.76	0.3	4.18e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.918	rs34725136	chr14:71760422	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.09	-0.39	2.89e-18	Mitral valve prolapse;
LGG	cis	rs7572733	0.905	rs6735214	chr2:198760507	C/T	cg00792783	chr2:198669748	PLCL1	0.5	8.42	0.36	4.89e-16	Dermatomyositis;
LGG	cis	rs877282	0.891	rs11253406	chr10:796297	G/A	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs6426558	0.537	rs488104	chr1:227300277	G/A	cg10327440	chr1:227177885	CDC42BPA	0.61	10.26	0.43	2.07e-22	Neutrophil percentage of white cells;
LGG	cis	rs7336332	0.569	rs57724994	chr13:28010389	T/C	cg01674679	chr13:27998804	GTF3A	-0.58	-7.96	-0.35	1.32e-14	Weight;
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg02002194	chr4:3960332	NA	0.54	10.45	0.44	4.42e-23	Triglycerides;
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs804292	0.803	rs8191598	chr8:11635616	A/G	cg26752888	chr8:11627280	NEIL2	1.07	17.02	0.62	8.52e-51	Alcohol dependence;Nicotine use;
LGG	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg13010199	chr12:38710504	ALG10B	0.47	8.53	0.37	2.08e-16	Morning vs. evening chronotype;
LGG	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg10845886	chr2:3471009	TTC15	-0.5	-9.89	-0.42	4.9e-21	Neurofibrillary tangles;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg00364696	chr7:1142433	C7orf50	-0.38	-7.41	-0.33	6e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg04568710	chr12:38710424	ALG10B	0.34	6.82	0.3	2.81e-11	Bladder cancer;
LGG	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg20637307	chr2:213403960	ERBB4	-0.45	-8.79	-0.38	3.03e-17	QT interval (ambient particulate matter interaction);
LGG	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs950027	0.620	rs1153860	chr15:45636584	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.67	-12.11	-0.49	1.65e-29	Response to fenofibrate (adiponectin levels);
LGG	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7959452	0.649	rs4761239	chr12:69776886	T/A	cg11871910	chr12:69753446	YEATS4	0.91	21.63	0.71	3.27e-72	Blood protein levels;
LGG	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg12623918	chr2:306882	NA	-0.56	-10.68	-0.44	6.01e-24	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs778371	0.630	rs13007579	chr2:233725364	G/A	cg08000102	chr2:233561755	GIGYF2	-0.66	-10.69	-0.44	5.67e-24	Schizophrenia;
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg09359103	chr1:154839909	KCNN3	-0.5	-10.24	-0.43	2.47e-22	Prostate cancer;
LGG	cis	rs3008870	0.755	rs4655660	chr1:67402953	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.76e-44	Lymphocyte percentage of white cells;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.39	-0.47	1.18e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	0.904	rs73079327	chr3:41864697	A/T	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.63e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6912958	0.781	rs2268993	chr6:88184111	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.47	-0.37	3.4e-16	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10150615	chr22:24372951	LOC391322	0.47	6.95	0.31	1.25e-11	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-13.35	-0.53	1.28e-34	Colorectal cancer;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg22535103	chr8:58192502	C8orf71	-0.77	-9.86	-0.42	5.82e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.688	rs62025297	chr15:86316939	G/C	cg25843651	chr15:86329602	KLHL25	0.63	10.15	0.43	5.53e-22	Idiopathic pulmonary fibrosis;
LGG	cis	rs11190604	1.000	rs9420782	chr10:102235015	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.82	0.34	3.54e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3768617	0.811	rs10911205	chr1:183009277	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.77	0.3	3.93e-11	Fuchs's corneal dystrophy;
LGG	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.37	-0.32	7.88e-13	Cognitive ability;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21044577	chr13:111364847	ING1	0.61	7.01	0.31	8.74e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg25993851	chr11:46722334	ARHGAP1;ZNF408	0.41	7.02	0.31	7.97e-12	Body mass index;
LGG	cis	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05901451	chr6:126070800	HEY2	-0.62	-11.17	-0.46	8.34e-26	Endometrial cancer;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00761968	chr13:53314142	LECT1	-0.42	-9.15	-0.39	1.76e-18	Lewy body disease;
LGG	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg24112000	chr20:60950667	NA	-0.35	-8.32	-0.36	9.68e-16	Colorectal cancer;
LGG	cis	rs4262150	0.960	rs7713322	chr5:152278906	T/C	cg12297329	chr5:152029980	NA	0.6	11.59	0.47	1.93e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4851254	0.626	rs115581542	chr2:100717725	T/A	cg17356467	chr2:100759845	AFF3	0.45	7.34	0.32	9.73e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.926	rs3889821	chr4:6282596	C/T	cg25554036	chr4:6271136	WFS1	0.65	12.57	0.5	2.21e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg02733842	chr7:1102375	C7orf50	-0.45	-6.83	-0.3	2.76e-11	Bronchopulmonary dysplasia;
LGG	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg06885757	chr1:42089581	HIVEP3	-0.6	-14.1	-0.55	8.1e-38	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3820928	1.000	rs4675116	chr2:227769607	A/C	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.24	-0.32	1.91e-12	Pulmonary function;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs7696715	chr4:98938486	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.35	-0.36	7.85e-16	Neuroticism;
LGG	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg21211680	chr2:198530	NA	1.28	15.96	0.6	5.23e-46	Blood protein levels;
LGG	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg21435375	chr2:172878103	MAP1D	-0.3	-6.73	-0.3	4.89e-11	Schizophrenia;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg22535103	chr8:58192502	C8orf71	-0.87	-11.15	-0.46	9.99e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26125787	chr4:164415830	C4orf43	-0.39	-6.7	-0.3	6.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg10505658	chr17:80084571	CCDC57	0.34	6.85	0.3	2.43e-11	Life satisfaction;
LGG	cis	rs7326068	0.610	rs2314720	chr13:21313373	G/A	cg04906043	chr13:21280425	IL17D	-0.49	-7.86	-0.34	2.65e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg26174226	chr8:58114915	NA	-0.53	-7.33	-0.32	1.06e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs35123781	1.000	rs600848	chr5:139057270	T/C	cg21230503	chr5:139085173	NA	0.31	7.41	0.33	5.92e-13	Schizophrenia;
LGG	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg08824895	chr13:115047677	UPF3A	0.4	6.89	0.3	1.88e-11	Schizophrenia;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg01988459	chr11:68622903	NA	-0.55	-10.99	-0.45	3.91e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.25e-13	Educational attainment;
LGG	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg23625390	chr15:77176239	SCAPER	-0.68	-12.11	-0.49	1.67e-29	Blood metabolite levels;
LGG	cis	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.61	-10.04	-0.42	1.37e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs6977660	1.000	rs6955510	chr7:19821333	G/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg00031303	chr3:195681400	NA	0.6	9.13	0.39	2.09e-18	Pancreatic cancer;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.07e-11	Menopause (age at onset);
LGG	cis	rs73081554	0.505	rs7626442	chr3:58338712	A/G	cg24175188	chr3:58374923	PXK	0.55	8.87	0.38	1.56e-17	Rheumatoid arthritis;
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.88	-0.3	1.93e-11	Mood instability;
LGG	cis	rs2070433	0.752	rs11700468	chr21:47776391	C/T	cg02959939	chr21:47813025	PCNT	-0.36	-6.75	-0.3	4.56e-11	Lymphocyte counts;
LGG	cis	rs79349575	0.756	rs2291726	chr17:47039254	T/C	cg16584676	chr17:46985605	UBE2Z	-0.45	-7.82	-0.34	3.69e-14	Type 2 diabetes;
LGG	cis	rs142958719	1	rs142958719	chr5:131232959	G/A	cg06307176	chr5:131281290	NA	-0.58	-9.55	-0.41	7.8e-20	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg03034668	chr16:1723424	CRAMP1L	-0.41	-6.65	-0.3	8.26e-11	Coronary artery disease;
LGG	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Iron status biomarkers;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.16	0.55	4.63e-38	Obesity-related traits;
LGG	cis	rs9796	0.835	rs2927062	chr15:41302687	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.35	-0.36	7.92e-16	Menopause (age at onset);
LGG	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg05234568	chr11:5960015	NA	-0.63	-10.12	-0.43	6.81e-22	DNA methylation (variation);
LGG	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10193935	0.901	rs2088281	chr2:42672731	A/G	cg27598129	chr2:42591480	NA	0.67	9.94	0.42	3.01e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9296092	0.538	rs56205713	chr6:33517510	A/G	cg13560919	chr6:33536144	NA	-1.05	-21.67	-0.71	2.07e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.91	-0.31	1.59e-11	Total body bone mineral density;
LGG	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg14541582	chr5:601475	NA	-0.68	-10.23	-0.43	2.9e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-13.13	-0.52	1.05e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03647317	chr4:187891568	NA	-0.42	-8.91	-0.38	1.13e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7100689	0.556	rs3120976	chr10:82025682	C/A	cg01528321	chr10:82214614	TSPAN14	0.79	13.44	0.53	5.34e-35	Post bronchodilator FEV1;
LGG	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg07120314	chr15:79043507	NA	0.58	9.14	0.39	1.92e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.75	0.51	4.17e-32	Obesity-related traits;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg08742575	chr21:47604166	C21orf56	0.51	8.73	0.38	4.73e-17	Testicular germ cell tumor;
LGG	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	9.09	0.39	2.94e-18	Height;
LGG	cis	rs2797160	1.000	rs6934435	chr6:126017481	T/G	cg05901451	chr6:126070800	HEY2	0.45	7.53	0.33	2.73e-13	Endometrial cancer;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.27	0.32	1.55e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs11877825	0.826	rs3748426	chr18:10581732	G/A	cg25239095	chr18:10589360	NA	0.47	8.49	0.37	2.76e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06108461	chr20:60628389	TAF4	-1.05	-21.05	-0.7	1.74e-69	Body mass index;
LGG	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg03433033	chr1:76189801	ACADM	0.78	12.57	0.5	2.23e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.78e-18	Skin colour saturation;
LGG	cis	rs1806153	0.673	rs60171845	chr11:31835468	A/C	cg11990419	chr11:31841155	NA	0.36	8.18	0.36	2.82e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.82	-0.51	2.08e-32	Chronic sinus infection;
LGG	cis	rs806215	0.526	rs806174	chr7:127291072	C/A	cg25922125	chr7:127225783	GCC1	0.52	7.64	0.33	1.28e-13	Type 2 diabetes;
LGG	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg08461772	chr7:95026248	PON3	0.38	8.25	0.36	1.64e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.1	31.26	0.82	3.75e-116	Birth weight;
LGG	cis	rs4380275	1.000	rs4380275	chr2:773278	C/T	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs2084898	0.550	rs470941	chr11:119999755	C/T	cg24611264	chr11:120008944	TRIM29	0.37	8.67	0.37	7.29e-17	Stroke (pediatric);
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14159672	chr1:205819179	PM20D1	-0.75	-16.12	-0.6	1.01e-46	Menarche (age at onset);
LGG	trans	rs6787172	0.702	rs1852285	chr3:157992277	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.87	0.38	1.55e-17	Subjective well-being;
LGG	cis	rs2180341	1.000	rs6904520	chr6:127629802	T/C	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg00700412	chr12:58011837	NA	0.39	7.71	0.34	7.61e-14	Multiple sclerosis;
LGG	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.6	0.37	1.22e-16	Fuchs's corneal dystrophy;
LGG	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.34	0.47	1.82e-26	Ovarian reserve;
LGG	cis	rs12493885	0.725	rs57740056	chr3:153744530	A/C	cg12800244	chr3:153838788	SGEF	-0.75	-9.17	-0.39	1.59e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg11766577	chr21:47581405	C21orf56	-0.49	-8.56	-0.37	1.74e-16	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02083259	chr16:57220135	RSPRY1;FAM192A	0.51	8.32	0.36	1.01e-15	Cognitive performance;
LGG	cis	rs1595825	0.945	rs1850634	chr2:198827896	T/C	cg00982548	chr2:198649783	BOLL	-0.5	-6.78	-0.3	3.65e-11	Ulcerative colitis;
LGG	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg05535760	chr7:792225	HEATR2	-0.81	-11.57	-0.47	2.32e-27	Cerebrospinal P-tau181p levels;
LGG	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.44	0.37	4.25e-16	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.689	rs10810508	chr9:15955566	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.97	-0.42	2.44e-21	Body mass index;
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg08621203	chr6:150244597	RAET1G	-0.47	-6.87	-0.3	2.12e-11	Lung cancer;
LGG	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg03351412	chr1:154909251	PMVK	0.66	12.82	0.51	1.99e-32	Prostate cancer;
LGG	cis	rs732765	1.000	rs59159639	chr14:75351106	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.48	-6.7	-0.3	6.19e-11	Non-small cell lung cancer;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg24829409	chr8:58192753	C8orf71	-0.88	-12.9	-0.51	9.59e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs6011368	0.765	rs6062682	chr20:62891820	C/T	cg13869341	chr1:15865	WASH5P	0.54	9.79	0.41	1.07e-20	Clozapine-induced cytotoxicity;
LGG	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg16434002	chr17:42200994	HDAC5	0.45	8.02	0.35	8.76e-15	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs258892	0.947	rs9885319	chr5:72179404	T/G	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs6061231	0.834	rs2427311	chr20:60970123	A/G	cg06026331	chr20:60912101	LAMA5	0.41	7.27	0.32	1.58e-12	Colorectal cancer;
LGG	cis	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	7.83	0.34	3.35e-14	Bone mineral density;
LGG	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	cis	rs7236492	0.748	rs8092987	chr18:77208141	C/T	cg15644404	chr18:77186268	NFATC1	-0.82	-10.04	-0.42	1.39e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg06916706	chr16:4465613	CORO7	-0.89	-15.85	-0.59	1.72e-45	Schizophrenia;
LGG	cis	rs17376456	1.000	rs13181660	chr5:93533658	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.51	-0.4	1.08e-19	Diabetic retinopathy;
LGG	cis	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg17545662	chr6:170176663	C6orf70	0.66	8.86	0.38	1.71e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg02023728	chr11:77925099	USP35	0.43	7.37	0.32	7.76e-13	Testicular germ cell tumor;
LGG	trans	rs3960554	0.800	rs80002395	chr7:75814902	C/T	cg19862616	chr7:65841803	NCRNA00174	0.83	11.52	0.47	3.62e-27	Eotaxin levels;
LGG	cis	rs4713118	0.586	rs9468290	chr6:28087674	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs11971779	0.680	rs3924296	chr7:139041927	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg06685724	chr7:23720386	C7orf46	-0.46	-10.85	-0.45	1.36e-24	Schizophrenia;
LGG	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	5.14e-19	Coronary artery disease;
LGG	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.12	0.31	4.25e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.3	-0.36	1.12e-15	Longevity;Endometriosis;
LGG	trans	rs1994135	0.715	rs10844625	chr12:33693006	C/T	cg26384229	chr12:38710491	ALG10B	0.7	13.02	0.52	3.14e-33	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14079893	chr12:108908917	FICD	0.46	6.69	0.3	6.31e-11	Gut microbiome composition (summer);
LGG	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg01221209	chr5:554886	NA	-0.46	-6.75	-0.3	4.49e-11	Obesity-related traits;
LGG	cis	rs853679	0.517	rs9348797	chr6:28137533	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg03894339	chr8:19674705	INTS10	-0.63	-10.37	-0.43	8.44e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8135665	0.600	rs3026685	chr22:38462680	C/T	cg19171272	chr22:38449367	NA	-0.44	-7.67	-0.34	1.04e-13	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs9658691	0.607	rs12416581	chr10:90780440	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.7	-9.05	-0.39	4.09e-18	Mosquito bite size;
LGG	cis	rs4936891	0.504	rs11219389	chr11:123852381	C/T	cg22125253	chr11:123886957	OR10G4	-0.46	-8.2	-0.36	2.32e-15	Male fertility;
LGG	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11650494	0.516	rs9900373	chr17:47512945	C/G	cg08112188	chr17:47440006	ZNF652	0.95	10.45	0.44	4.27e-23	Prostate cancer;
LGG	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg19824325	chr16:58548873	SETD6	1.23	11.2	0.46	6.13e-26	Schizophrenia;
LGG	cis	rs10769945	0.605	rs656757	chr11:1966106	G/A	cg06197492	chr11:2016605	H19	0.44	8.76	0.38	3.76e-17	DNA methylation (variation);
LGG	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg11789530	chr4:8429930	ACOX3	0.73	14.53	0.56	1.16e-39	Response to antineoplastic agents;
LGG	cis	rs3806843	0.576	rs246024	chr5:140333952	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.23	0.49	5.14e-30	Hip circumference adjusted for BMI;
LGG	cis	rs2120019	1.000	rs7173833	chr15:75369618	C/T	cg09165964	chr15:75287851	SCAMP5	-0.93	-18.13	-0.64	7.03e-56	Blood trace element (Zn levels);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12973936	chr19:45755125	MARK4	-0.36	-6.68	-0.3	6.81e-11	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.86	13.22	0.52	4.68e-34	Alzheimer's disease;
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg04503457	chr17:41445688	NA	-0.35	-8.18	-0.36	2.81e-15	Menopause (age at onset);
LGG	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.74	0.3	4.7e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg03162506	chr22:38580953	NA	-0.42	-11.02	-0.46	3.12e-25	Cutaneous nevi;
LGG	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg09137382	chr11:130731461	NA	0.36	7.03	0.31	7.61e-12	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg21171335	chr12:122356390	WDR66	0.28	7.89	0.34	2.16e-14	Mean corpuscular volume;
LGG	cis	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.97	0.31	1.12e-11	Neuroticism;
LGG	trans	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg22153745	chr1:153894579	GATAD2B	-0.67	-10.6	-0.44	1.22e-23	Total cholesterol levels;
LGG	cis	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-7.83	-0.34	3.29e-14	Neuroticism;
LGG	cis	rs7226408	0.857	rs7233017	chr18:34529710	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg02725872	chr8:58115012	NA	1.05	14.56	0.56	8.55e-40	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs1353872	chr6:66610076	A/G	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs11249608	0.548	rs17078988	chr5:178459283	A/G	cg21905437	chr5:178450457	ZNF879	0.47	6.66	0.3	8e-11	Pubertal anthropometrics;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	trans	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg26043149	chr18:55253948	FECH	0.4	6.66	0.3	7.96e-11	Bone mineral density;
LGG	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg00031303	chr3:195681400	NA	0.55	8.82	0.38	2.3e-17	Pancreatic cancer;
LGG	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg03264133	chr6:25882463	NA	0.55	10.12	0.43	7.28e-22	Blood metabolite levels;
LGG	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.13	-0.43	6.37e-22	Colorectal cancer;
LGG	cis	rs6087771	0.504	rs6087786	chr20:30451844	C/T	cg13852791	chr20:30311386	BCL2L1	0.58	8.97	0.38	7.61e-18	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.66	0.3	7.6e-11	Cognitive function;
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg21782813	chr7:2030301	MAD1L1	0.35	8.16	0.35	3.26e-15	Schizophrenia;
LGG	cis	rs2229238	0.823	rs61275241	chr1:154504887	T/G	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.11e-11	Coronary heart disease;
LGG	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg02389323	chr16:88786976	FAM38A	0.93	12.1	0.49	1.71e-29	Plateletcrit;
LGG	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.3	0.36	1.17e-15	Colorectal cancer;
LGG	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg02811702	chr13:24901961	NA	0.43	8.1	0.35	4.92e-15	Obesity-related traits;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27443310	chr7:90225778	NA	0.44	6.74	0.3	4.85e-11	Hip circumference;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.590	rs11191513	chr10:104772984	T/G	cg05308233	chr10:104796373	CNNM2	-0.32	-6.98	-0.31	1.01e-11	Arsenic metabolism;
LGG	cis	rs2066819	1.000	rs2695789	chr12:56694261	C/A	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.75e-11	Psoriasis vulgaris;
LGG	cis	rs2270450	0.731	rs13196132	chr6:46655603	C/T	cg10156739	chr6:46714674	LOC100287718	-0.34	-8.21	-0.36	2.15e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs644799	0.526	rs506180	chr11:95623109	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	12.69	0.51	7.18e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9287719	0.967	rs6721739	chr2:10751246	G/T	cg02196655	chr2:10830764	NOL10	0.43	7.36	0.32	8.27e-13	Prostate cancer;
LGG	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg20476274	chr7:133979776	SLC35B4	0.67	11.92	0.48	9.52e-29	Mean platelet volume;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.52	10.1	0.42	8.32e-22	Longevity;
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg02772935	chr3:125709198	NA	-0.54	-6.95	-0.31	1.25e-11	Blood pressure (smoking interaction);
LGG	cis	rs28655083	0.529	rs4550465	chr16:77104785	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.51	0.33	3.12e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06028808	chr11:68637592	NA	0.72	12.34	0.5	2e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg24692254	chr21:30365293	RNF160	-0.87	-19.84	-0.68	7.95e-64	Dental caries;
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg24690094	chr11:67383802	NA	-0.56	-9.3	-0.4	5.65e-19	Mean corpuscular volume;
LGG	cis	rs67478160	0.643	rs4906369	chr14:104242458	T/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.47	-0.33	3.97e-13	Schizophrenia;
LGG	cis	rs6545977	0.527	rs2710647	chr2:63213970	T/C	cg17519650	chr2:63277830	OTX1	0.69	13.42	0.53	6.17e-35	Prostate cancer;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.1	-0.42	8.09e-22	Platelet count;
LGG	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg03342759	chr3:160939853	NMD3	-0.77	-13.7	-0.54	4.37e-36	Parkinson's disease;
LGG	cis	rs708547	0.671	rs1718863	chr4:57887586	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg19318889	chr4:1322082	MAEA	0.48	8.19	0.36	2.6e-15	Longevity;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg16141378	chr3:129829833	LOC729375	0.42	9.83	0.42	7.91e-21	Triglycerides;
LGG	cis	rs11920090	0.800	rs6766331	chr3:170755713	C/A	cg09710316	chr3:170744871	SLC2A2	0.64	8.44	0.37	3.96e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs228437	1.000	rs4896083	chr6:134932535	G/A	cg24504307	chr6:134963096	NA	0.41	7.63	0.33	1.32e-13	Melanoma;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg24829409	chr8:58192753	C8orf71	-0.83	-12.75	-0.51	4.12e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg10224037	chr5:178157518	ZNF354A	0.73	11.26	0.46	3.59e-26	Neutrophil percentage of white cells;
LGG	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg03162506	chr22:38580953	NA	0.39	9.97	0.42	2.35e-21	Cutaneous nevi;
LGG	cis	rs950169	0.920	rs17300048	chr15:84749477	C/T	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg11905131	chr22:24372483	LOC391322	-0.4	-6.89	-0.3	1.83e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6121246	0.529	rs6060134	chr20:30176794	A/G	cg13852791	chr20:30311386	BCL2L1	0.63	8.49	0.37	2.93e-16	Mean corpuscular hemoglobin;
LGG	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg23422044	chr7:1970798	MAD1L1	-0.45	-8.36	-0.36	7.34e-16	Neuroticism;
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.26	-0.4	7.92e-19	Life satisfaction;
LGG	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg27490568	chr2:178487706	NA	0.46	9.24	0.39	8.67e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10927875	0.526	rs2179615	chr1:16282426	G/A	cg21385522	chr1:16154831	NA	-0.93	-14.94	-0.57	1.81e-41	Dilated cardiomyopathy;
LGG	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.08	-0.49	2.11e-29	Bladder cancer;
LGG	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.54e-11	Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg21535247	chr6:8435926	SLC35B3	-0.58	-9.82	-0.42	8.32e-21	Motion sickness;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.67	-0.37	7.19e-17	Personality dimensions;
LGG	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg18551225	chr6:44695536	NA	-0.67	-11.96	-0.49	6.3e-29	Total body bone mineral density;
LGG	cis	rs2652834	0.851	rs2729813	chr15:63412154	A/G	cg05507819	chr15:63340323	TPM1	0.5	7.07	0.31	5.79e-12	HDL cholesterol;
LGG	cis	rs3735485	0.738	rs11552377	chr7:45104131	C/T	cg03440944	chr7:45023329	C7orf40	-0.54	-9.52	-0.4	9.62e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg01765077	chr12:122356316	WDR66	0.28	7.6	0.33	1.67e-13	Mean corpuscular volume;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.85	-0.42	6.32e-21	Prostate cancer;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.03	-0.49	3.27e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg02725872	chr8:58115012	NA	-0.76	-11.33	-0.47	1.96e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7586879	0.639	rs6722022	chr2:25098859	A/G	cg04586622	chr2:25135609	ADCY3	0.45	12.05	0.49	2.74e-29	Body mass index;
LGG	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg22705602	chr4:152727874	NA	-0.33	-7.88	-0.34	2.43e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1015291	0.708	rs1492126	chr12:20007501	C/A	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.93	0.35	1.68e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs2562456	0.833	rs56179986	chr19:21520684	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.65	-0.33	1.2e-13	Pain;
LGG	cis	rs4700695	0.614	rs394828	chr5:65209552	C/T	cg21114390	chr5:65439923	SFRS12	0.6	6.71	0.3	5.67e-11	Facial morphology (factor 19);
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg16405210	chr4:1374714	KIAA1530	-0.53	-9.16	-0.39	1.65e-18	Obesity-related traits;
LGG	cis	rs283228	0.798	rs694008	chr6:101769945	T/A	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg09699651	chr6:150184138	LRP11	0.51	8.78	0.38	3.1e-17	Lung cancer;
LGG	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg12463550	chr7:65579703	CRCP	0.49	8.23	0.36	1.87e-15	Aortic root size;
LGG	cis	rs17604090	0.878	rs4000281	chr7:29726287	A/G	cg19413766	chr7:29689036	LOC646762	-0.55	-6.68	-0.3	6.74e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.85	-0.38	1.85e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg08250081	chr4:10125330	NA	0.41	8.14	0.35	3.81e-15	Bone mineral density;
LGG	cis	rs7412746	0.658	rs10888397	chr1:150886752	A/G	cg15448220	chr1:150897856	SETDB1	-0.4	-7.32	-0.32	1.07e-12	Melanoma;
LGG	cis	rs1978968	0.717	rs13057517	chr22:18402669	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.62	-0.41	4.35e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs782590	0.967	rs2627759	chr2:55853341	T/C	cg18811423	chr2:55921094	PNPT1	0.89	20.8	0.7	2.39e-68	Metabolic syndrome;
LGG	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.7	-0.41	2.2e-20	Retinal vascular caliber;
LGG	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg07636037	chr3:49044803	WDR6	1.1	28.03	0.79	8.03e-102	Parkinson's disease;
LGG	cis	rs13191362	1.000	rs13199223	chr6:163001083	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg05165339	chr4:1420672	NA	-0.27	-6.97	-0.31	1.12e-11	Obesity-related traits;
LGG	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.16	-0.35	3.25e-15	Small cell lung carcinoma;
LGG	cis	rs8133932	0.654	rs2776402	chr21:47360761	T/C	cg11214348	chr21:47283868	PCBP3	-0.4	-7.08	-0.31	5.39e-12	Schizophrenia;
LGG	cis	rs9914988	0.943	rs34693224	chr17:27079555	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg07549590	chr16:15018862	NA	-0.52	-8.97	-0.38	7.27e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg02975922	chr3:195473998	MUC4	0.53	8.79	0.38	2.97e-17	Pancreatic cancer;
LGG	cis	rs7133214	0.601	rs11049134	chr12:27923398	G/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.99	-0.31	9.53e-12	Gut microbiota (functional units);
LGG	cis	rs61931739	0.620	rs815052	chr12:33727270	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.85	-0.3	2.38e-11	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg14541582	chr5:601475	NA	-0.68	-10.65	-0.44	7.82e-24	Obesity-related traits;
LGG	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.12	0.31	4.02e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs75059851	1.000	rs73036065	chr11:133830067	G/T	cg20042908	chr11:133852938	NA	-0.72	-12.89	-0.51	1.05e-32	Schizophrenia;
LGG	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg18854424	chr1:2615690	NA	0.36	7.65	0.33	1.19e-13	Ulcerative colitis;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.51	-0.44	2.68e-23	Platelet count;
LGG	cis	rs60180747	0.865	rs11639073	chr15:66600097	C/A	cg07575407	chr15:66541975	MEGF11	0.4	7.74	0.34	6.19e-14	Testicular germ cell tumor;
LGG	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	trans	rs75804782	0.572	rs111233411	chr2:239289041	T/G	cg01134436	chr17:81009848	B3GNTL1	0.79	6.84	0.3	2.54e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6815814	0.950	rs11722788	chr4:38810738	C/G	cg06935464	chr4:38784597	TLR10	0.6	8.09	0.35	5.1e-15	Breast cancer;
LGG	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.64	14.49	0.56	1.68e-39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg26513180	chr16:89883248	FANCA	0.93	19.99	0.68	1.52e-64	Vitiligo;
LGG	cis	rs1519814	0.740	rs4348544	chr8:121044090	T/C	cg22335954	chr8:121166405	COL14A1	-0.49	-9.55	-0.41	7.32e-20	Breast cancer;
LGG	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg15128208	chr22:42549153	NA	0.48	9.64	0.41	3.64e-20	Cognitive function;
LGG	cis	rs7582720	0.836	rs72938315	chr2:204121063	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.39	0.4	2.69e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.35	-0.55	7.05e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.48	-0.47	5.2e-27	Personality dimensions;
LGG	cis	rs4268898	0.662	rs72795832	chr2:24441855	C/A	cg06627628	chr2:24431161	ITSN2	-0.78	-12.88	-0.51	1.22e-32	Asthma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03324837	chr17:61044407	NA	0.47	8.09	0.35	5.25e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg00717180	chr2:96193071	NA	-0.42	-7.38	-0.32	7.47e-13	HDL cholesterol;
LGG	cis	rs963731	0.579	rs1454219	chr2:39276957	C/T	cg04010122	chr2:39346883	SOS1	-0.73	-7.67	-0.34	1.01e-13	Corticobasal degeneration;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg22907277	chr7:1156413	C7orf50	0.81	11.61	0.47	1.55e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.54e-81	Hip circumference adjusted for BMI;
LGG	trans	rs17685	0.712	rs10271413	chr7:75754858	G/A	cg19862616	chr7:65841803	NCRNA00174	1.08	25.92	0.77	3.61e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.4	0.36	5.64e-16	Tonsillectomy;
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg01966878	chr4:90757139	SNCA	-0.34	-7.09	-0.31	4.9e-12	Dementia with Lewy bodies;
LGG	cis	rs11718455	1.000	rs34347753	chr3:44058053	G/A	cg21419209	chr3:44054225	NA	-0.45	-7.09	-0.31	5.01e-12	Coronary artery disease;
LGG	cis	rs72781680	0.533	rs34668726	chr2:23895901	C/G	cg08917208	chr2:24149416	ATAD2B	0.68	7.57	0.33	2.02e-13	Lymphocyte counts;
LGG	cis	rs883565	0.696	rs7620304	chr3:39079623	T/A	cg01426195	chr3:39028469	NA	-0.71	-16.0	-0.6	3.44e-46	Handedness;
LGG	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg14673194	chr17:80132900	CCDC57	-0.43	-7.6	-0.33	1.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11169552	0.510	rs34867510	chr12:50974541	G/C	cg12884762	chr12:50931848	DIP2B	-0.4	-7.32	-0.32	1.08e-12	Colorectal cancer;
LGG	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	18.54	0.65	8.42e-58	Smoking behavior;
LGG	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.59	-11.13	-0.46	1.18e-25	HDL cholesterol;
LGG	trans	rs9747201	0.926	rs7222764	chr17:80062698	G/A	cg07393940	chr7:158741817	NA	-0.6	-11.0	-0.46	3.67e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10875595	0.836	rs12187725	chr5:140662912	A/G	cg24830062	chr5:140700576	TAF7	-0.54	-6.79	-0.3	3.47e-11	Pulmonary function decline;
LGG	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg20368463	chr18:77673604	PQLC1	0.6	7.96	0.35	1.32e-14	Opioid sensitivity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17872999	chr7:104653783	MLL5;LOC100216545	0.41	6.77	0.3	3.91e-11	Cognitive performance;
LGG	cis	rs9486719	1.000	rs11153018	chr6:96956137	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.65	-0.44	7.68e-24	Migraine;Coronary artery disease;
LGG	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	8.02	0.35	8.96e-15	Restless legs syndrome;
LGG	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg17757837	chr7:157058334	UBE3C	0.77	15.78	0.59	3.52e-45	Body mass index;
LGG	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.24e-15	Monocyte count;
LGG	cis	rs1322639	0.614	rs7768154	chr6:169565470	A/G	cg04662567	chr6:169592167	NA	-0.79	-11.46	-0.47	5.96e-27	Pulse pressure;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg02002194	chr4:3960332	NA	0.48	9.28	0.4	6.65e-19	Joint mobility (Beighton score);
LGG	cis	rs7975161	0.638	rs10861170	chr12:104615957	A/G	cg25273343	chr12:104657179	TXNRD1	-0.58	-9.48	-0.4	1.28e-19	Toenail selenium levels;
LGG	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg24110177	chr3:50126178	RBM5	-0.61	-11.14	-0.46	1.08e-25	Body mass index;
LGG	cis	rs4959677	0.934	rs11242779	chr6:2507901	T/C	cg23817096	chr6:1620687	NA	-0.32	-7.49	-0.33	3.55e-13	Orthostatic hypotension;
LGG	cis	rs651907	0.935	rs2926538	chr3:101587585	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.38	7.37	0.32	7.89e-13	Colorectal cancer;
LGG	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg24699146	chr1:24152579	HMGCL	0.27	8.06	0.35	6.38e-15	Immature fraction of reticulocytes;
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg19508488	chr2:152266495	RIF1	0.57	10.42	0.44	5.43e-23	Lung cancer;
LGG	cis	rs1682825	0.858	rs9854094	chr3:10757162	A/G	cg23512531	chr3:10780469	NA	-0.57	-7.54	-0.33	2.54e-13	Economic and political preferences (feminism/equality);
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg03036210	chr16:89904091	SPIRE2	-0.58	-7.78	-0.34	4.73e-14	Skin colour saturation;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.92	-0.35	1.75e-14	Neuroticism;
LGG	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg05444541	chr17:17804740	TOM1L2	-0.75	-18.17	-0.65	4.3e-56	Total body bone mineral density;
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg05335186	chr13:53173507	NA	-0.56	-12.37	-0.5	1.5e-30	Lewy body disease;
LGG	cis	rs7503807	0.688	rs7503186	chr17:78590472	G/C	cg06872548	chr17:78716983	RPTOR	0.4	8.8	0.38	2.68e-17	Obesity;
LGG	cis	rs7927771	0.524	rs10838732	chr11:47607940	C/G	cg20307385	chr11:47447363	PSMC3	0.57	11.32	0.47	2.19e-26	Subjective well-being;
LGG	cis	rs1003719	0.788	rs9977314	chr21:38471963	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.82	16.63	0.61	4.81e-49	Eye color traits;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.77	0.34	5.03e-14	Longevity;
LGG	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.41	6.78	0.3	3.72e-11	Birth weight;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.1.2890615F	chr1:150313655	PRPF3	-0.58	-8.75	-0.38	3.91e-17	Systemic lupus erythematosus;
LGG	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14373873	chr11:113211441	TTC12	0.41	8.5	0.37	2.64e-16	Neuroticism;
LGG	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.18	-0.32	2.79e-12	Calcium levels;
LGG	cis	rs2204008	0.687	rs11181339	chr12:38322271	G/T	cg04568710	chr12:38710424	ALG10B	0.33	7.05	0.31	6.47e-12	Bladder cancer;
LGG	cis	rs6088580	0.634	rs62212172	chr20:32987705	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-9.71	-0.41	2.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs763121	0.925	rs1056661	chr22:39080245	A/G	cg06022373	chr22:39101656	GTPBP1	0.83	17.16	0.62	1.99e-51	Menopause (age at onset);
LGG	trans	rs7819412	0.703	rs2409713	chr8:11009797	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.37	-0.32	7.92e-13	Triglycerides;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg20607798	chr8:58055168	NA	0.69	7.8	0.34	4.28e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.752	rs12150047	chr17:37601755	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.42	-0.36	4.6e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg02951883	chr7:2050386	MAD1L1	0.44	7.06	0.31	6.18e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16330517	chr18:43913699	RNF165	0.43	6.65	0.3	8.15e-11	Gut microbiome composition (summer);
LGG	cis	rs12246027	0.505	rs10903832	chr10:320954	A/G	cg11001780	chr10:623056	DIP2C	-0.52	-6.95	-0.31	1.24e-11	Blood metabolite levels;
LGG	cis	rs1357245	0.503	rs9816609	chr3:27100459	A/G	cg02860705	chr3:27208620	NA	0.37	7.33	0.32	1.04e-12	Breast cancer;
LGG	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs6708331	1.000	rs6708331	chr2:70368923	C/T	cg01613454	chr2:70366299	NA	0.52	9.33	0.4	4.37e-19	Obesity-related traits;
LGG	trans	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg20587970	chr11:113659929	NA	-1.4	-24.87	-0.76	2.48e-87	Hip circumference adjusted for BMI;
LGG	cis	rs734999	0.566	rs6664969	chr1:2534978	G/A	cg20673091	chr1:2541236	MMEL1	0.77	17.88	0.64	9.58e-55	Ulcerative colitis;
LGG	cis	rs7100689	0.646	rs1290317	chr10:82062531	C/A	cg01528321	chr10:82214614	TSPAN14	0.81	14.5	0.56	1.55e-39	Post bronchodilator FEV1;
LGG	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg20673091	chr1:2541236	MMEL1	-0.77	-17.91	-0.64	6.73e-55	Ulcerative colitis;
LGG	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg08704250	chr15:31115839	NA	0.48	8.64	0.37	8.87e-17	Huntington's disease progression;
LGG	cis	rs7666738	1.000	rs35066600	chr4:98991066	C/A	cg05340658	chr4:99064831	C4orf37	0.43	6.76	0.3	4.15e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.78	-0.3	3.62e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg18240062	chr17:79603768	NPLOC4	0.62	10.41	0.44	6.07e-23	Eye color traits;
LGG	cis	rs526231	0.543	rs3776863	chr5:102327869	G/C	cg23492399	chr5:102201601	PAM	-0.59	-9.16	-0.39	1.68e-18	Primary biliary cholangitis;
LGG	cis	rs4409675	0.576	rs2749110	chr1:28235010	T/C	cg23691781	chr1:28212827	C1orf38	0.42	10.9	0.45	8.74e-25	Corneal astigmatism;
LGG	cis	rs7241530	0.610	rs34622862	chr18:75896444	A/T	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg27171569	chr16:83987465	OSGIN1	-0.55	-9.89	-0.42	4.63e-21	Pursuit maintenance gain;
LGG	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg17927777	chr20:33865990	NA	0.74	10.87	0.45	1.11e-24	Attention deficit hyperactivity disorder;
LGG	trans	rs11782517	0.803	rs12549696	chr8:10107022	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-6.77	-0.3	3.86e-11	Nose size;
LGG	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg05182265	chr7:156933206	UBE3C	-0.37	-7.45	-0.33	4.63e-13	Body mass index;
LGG	cis	rs638893	0.578	rs582200	chr11:118668908	A/G	cg22253036	chr11:118662786	DDX6	-0.51	-7.17	-0.32	3e-12	Vitiligo;
LGG	cis	rs12681287	0.577	rs11992955	chr8:87530485	A/G	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg07395648	chr5:131743802	NA	0.42	9.4	0.4	2.44e-19	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.54	0.33	2.56e-13	Lung cancer;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg02725872	chr8:58115012	NA	-0.94	-14.08	-0.55	1e-37	Developmental language disorder (linguistic errors);
LGG	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.34	-0.32	9.84e-13	Alzheimer's disease (late onset);
LGG	cis	rs17253792	0.822	rs75016910	chr14:56050466	C/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.02	-0.49	3.91e-29	Putamen volume;
LGG	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg09307838	chr4:120376055	NA	0.8	13.14	0.52	9.94e-34	Corneal astigmatism;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg22105103	chr4:187893119	NA	-0.51	-9.35	-0.4	3.72e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7503807	0.967	rs12940622	chr17:78615571	G/A	cg06872548	chr17:78716983	RPTOR	0.45	11.09	0.46	1.61e-25	Obesity;
LGG	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.34	-0.36	8.46e-16	Cognitive test performance;
LGG	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.61	-0.41	4.84e-20	Aortic root size;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.83e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.04	0.52	2.64e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg27490568	chr2:178487706	NA	-0.7	-13.17	-0.52	7.39e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1499614	1.000	rs2707828	chr7:66171377	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs3790455	0.965	rs2282286	chr1:156452870	G/A	cg14087168	chr1:156450669	MEF2D	0.47	7.73	0.34	6.61e-14	Migraine;
LGG	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg04000281	chr11:63949212	NA	-0.36	-6.96	-0.31	1.19e-11	Platelet count;
LGG	cis	rs8077889	0.917	rs6503479	chr17:41917003	A/G	cg26893861	chr17:41843967	DUSP3	0.9	15.76	0.59	4.13e-45	Triglycerides;
LGG	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg02733842	chr7:1102375	C7orf50	-0.44	-6.78	-0.3	3.56e-11	Bronchopulmonary dysplasia;
LGG	cis	rs1707322	1.000	rs34444543	chr1:46358862	G/A	cg03146154	chr1:46216737	IPP	0.54	10.28	0.43	1.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9534288	0.797	rs9526127	chr13:46571744	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.53	-8.45	-0.37	3.77e-16	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-8.94	-0.38	9.15e-18	Menopause (age at onset);
LGG	cis	rs4740619	0.901	rs2136355	chr9:15718989	G/A	cg14451791	chr9:16040625	NA	-0.38	-9.93	-0.42	3.46e-21	Body mass index;
LGG	cis	rs2070488	0.965	rs2126534	chr3:38445165	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.5	0.63	5.11e-53	Electrocardiographic conduction measures;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.74	0.54	2.72e-36	Obesity-related traits;
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22433210	chr17:43662623	NA	-0.61	-10.66	-0.44	7.24e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16346588	chr10:242978	ZMYND11	-0.4	-6.88	-0.3	1.91e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-12.76	-0.51	3.56e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs7129556	0.775	rs72945598	chr11:77367738	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.36	0.32	8.21e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs2243480	1.000	rs58062456	chr7:65394852	G/T	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00495681	chr13:53174319	NA	0.57	10.52	0.44	2.36e-23	Lewy body disease;
LGG	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg16141378	chr3:129829833	LOC729375	0.43	9.88	0.42	5.07e-21	Mood instability;
LGG	cis	rs1580019	0.885	rs3801331	chr7:32497039	A/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.85	-16.01	-0.6	3.13e-46	Cognitive ability;
LGG	cis	rs3857536	0.704	rs4710570	chr6:66890244	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs3748682	0.861	rs72661832	chr1:38260733	C/T	cg12658694	chr1:38397304	INPP5B	0.38	7.01	0.31	8.25e-12	Hypothyroidism;
LGG	cis	rs950776	0.593	rs621849	chr15:78872861	G/A	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.97	-0.42	2.54e-21	Sudden cardiac arrest;
LGG	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg14541582	chr5:601475	NA	-0.68	-10.59	-0.44	1.29e-23	Obesity-related traits;
LGG	cis	rs2635047	0.577	rs1025563	chr18:44740003	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.75	0.3	4.4e-11	Educational attainment;
LGG	cis	rs3931020	0.548	rs969435	chr1:75273866	A/G	cg26855724	chr1:75198818	TYW3;CRYZ	-0.47	-7.96	-0.35	1.33e-14	Resistin levels;
LGG	trans	rs7980799	0.967	rs7971226	chr12:33586881	C/T	cg26384229	chr12:38710491	ALG10B	0.51	8.99	0.39	6.54e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13588572	chr11:65769523	EIF1AD;BANF1	0.37	6.77	0.3	3.9e-11	Obesity-related traits;
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg02297831	chr4:17616191	MED28	0.48	8.83	0.38	2.15e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6445975	1.000	rs4681681	chr3:58332912	C/T	cg24175188	chr3:58374923	PXK	0.53	9.85	0.42	6.6e-21	Systemic lupus erythematosus;
LGG	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg02574844	chr11:5959923	NA	-0.61	-9.37	-0.4	3.09e-19	DNA methylation (variation);
LGG	cis	rs17106184	1.000	rs17106184	chr1:50909985	A/G	cg07174182	chr1:51127561	FAF1	-0.57	-8.76	-0.38	3.59e-17	Type 2 diabetes;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg00490583	chr16:1843685	IGFALS	-0.41	-6.98	-0.31	9.98e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.54	0.37	2e-16	Alzheimer's disease;
LGG	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg05535760	chr7:792225	HEATR2	0.77	12.25	0.49	4.54e-30	Cerebrospinal P-tau181p levels;
LGG	trans	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.89	-0.38	1.39e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.43	0.36	4.52e-16	Bipolar disorder;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.21	0.39	1.14e-18	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18188768	chr5:158689930	UBLCP1	0.42	6.68	0.3	6.85e-11	Cognitive performance;
LGG	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.2e-13	Testicular germ cell tumor;
LGG	trans	rs853679	0.567	rs13209596	chr6:28396190	C/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.66	-0.3	7.89e-11	Depression;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.37	-0.36	6.68e-16	Tonsillectomy;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg08742575	chr21:47604166	C21orf56	-0.58	-10.58	-0.44	1.45e-23	Testicular germ cell tumor;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg15384640	chr17:6557720	NA	0.34	6.91	0.31	1.61e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7662987	0.517	rs2602865	chr4:100034841	T/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg08344181	chr3:125677491	NA	-0.61	-7.12	-0.31	4.19e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg11905131	chr22:24372483	LOC391322	-0.46	-7.95	-0.35	1.48e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7188861	0.681	rs12935137	chr16:11422015	T/C	cg01510278	chr16:11456238	NA	0.29	6.82	0.3	2.78e-11	HDL cholesterol;
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg13939156	chr17:80058883	NA	-0.45	-8.69	-0.37	6.11e-17	Life satisfaction;
LGG	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12432903	chr7:1882776	MAD1L1	0.55	8.87	0.38	1.64e-17	Bipolar disorder;
LGG	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.38e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1335587	0.518	rs9513904	chr13:102107582	G/A	cg13538571	chr13:102108074	ITGBL1	0.48	8.96	0.38	8.1e-18	Obesity-related traits;
LGG	cis	rs62025270	0.632	rs16943251	chr15:86235235	T/G	cg25843651	chr15:86329602	KLHL25	0.58	8.78	0.38	3.21e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs2286885	0.965	rs4837091	chr9:129244928	A/G	cg14319473	chr9:129242481	FAM125B	0.45	8.42	0.36	4.6e-16	Intraocular pressure;
LGG	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg24229701	chr12:130821962	PIWIL1	0.47	8.14	0.35	3.74e-15	Menopause (age at onset);
LGG	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg00149659	chr3:10157352	C3orf10	0.59	8.54	0.37	1.88e-16	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03160445	chr3:100120349	LNP1;TOMM70A	0.43	6.66	0.3	7.74e-11	Gut microbiome composition (summer);
LGG	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08109568	chr15:31115862	NA	-0.51	-8.36	-0.36	7.37e-16	Huntington's disease progression;
LGG	cis	rs7572644	0.699	rs7577437	chr2:28168415	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs4363385	0.747	rs6668696	chr1:152964910	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.85	-0.38	1.79e-17	Inflammatory skin disease;
LGG	cis	rs4731207	0.698	rs34600520	chr7:124490938	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs4690686	0.534	rs11133147	chr4:177281718	A/G	cg17059388	chr4:177262070	NA	0.58	11.81	0.48	2.67e-28	Essential tremor;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg12929805	chr1:2399054	NA	-0.52	-10.2	-0.43	3.49e-22	Non-obstructive azoospermia;
LGG	cis	rs2798269	1.000	rs4770170	chr13:22092961	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.03	-0.31	7.68e-12	PR segment;
LGG	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg11764359	chr7:65958608	NA	0.8	14.86	0.57	4e-41	Aortic root size;
LGG	trans	rs7246760	1.000	rs73014068	chr19:9922783	T/C	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	cis	rs9923856	0.652	rs62026379	chr16:11241806	G/A	cg16765268	chr16:11229200	CLEC16A	0.38	6.66	0.3	7.68e-11	Atopic dermatitis;Adult asthma;
LGG	cis	rs9357271	0.956	rs4714157	chr6:38366385	T/C	cg07362130	chr6:38359646	BTBD9	-0.43	-9.8	-0.41	1.02e-20	Restless legs syndrome;
LGG	cis	rs17209837	1.000	rs2072383	chr7:87081349	A/G	cg00919237	chr7:87102261	ABCB4	-0.68	-11.04	-0.46	2.59e-25	Gallbladder cancer;
LGG	trans	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg02002194	chr4:3960332	NA	0.42	7.93	0.35	1.69e-14	Neuroticism;
LGG	cis	rs9944715	0.906	rs7241527	chr18:43736932	G/A	cg26436583	chr18:43649176	PSTPIP2	0.43	8.14	0.35	3.76e-15	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.2	-0.49	6.95e-30	Intelligence (multi-trait analysis);
LGG	cis	rs977987	0.806	rs4887823	chr16:75433074	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg13147721	chr7:65941812	NA	0.84	10.18	0.43	4.21e-22	Diabetic kidney disease;
LGG	cis	rs1552244	0.554	rs2272122	chr3:10047975	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.28	0.5	3.47e-30	Alzheimer's disease;
LGG	cis	rs36051895	0.623	rs2146041	chr9:5262911	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-13.63	-0.54	8.14e-36	Pediatric autoimmune diseases;
LGG	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg15103426	chr22:29168792	CCDC117	0.67	8.55	0.37	1.75e-16	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg03264133	chr6:25882463	NA	-0.41	-7.24	-0.32	1.91e-12	Height;
LGG	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.1	0.31	4.84e-12	Educational attainment;
LGG	cis	rs1670533	1.000	rs28562028	chr4:1055115	G/A	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	-0.7	-7.67	-0.34	1.04e-13	Initial pursuit acceleration;
LGG	cis	rs34172651	0.917	rs200539	chr16:24735178	T/C	cg02428538	chr16:24856791	SLC5A11	0.49	8.24	0.36	1.85e-15	Intelligence (multi-trait analysis);
LGG	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg21547979	chr19:49141364	SEC1;DBP;CA11	-0.44	-7.81	-0.34	3.78e-14	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs3858526	0.883	rs11039584	chr11:5935251	C/G	cg02574844	chr11:5959923	NA	-0.53	-8.57	-0.37	1.61e-16	DNA methylation (variation);
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg02725872	chr8:58115012	NA	-0.93	-12.98	-0.52	4.62e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg00262122	chr8:11665843	FDFT1	0.48	7.75	0.34	5.84e-14	Morning vs. evening chronotype;
LGG	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg17376030	chr22:41985996	PMM1	0.44	7.09	0.31	4.96e-12	Vitiligo;
LGG	cis	rs9815354	1.000	rs13087719	chr3:41951576	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.26	-0.36	1.58e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs758324	0.588	rs687429	chr5:131328523	A/C	cg06307176	chr5:131281290	NA	0.45	6.77	0.3	3.86e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs9783347	0.961	rs4150653	chr11:18374782	G/A	cg15585147	chr11:18324498	HPS5	0.42	8.98	0.39	6.69e-18	Pancreatic cancer;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg12458913	chr13:53173898	NA	0.75	15.52	0.59	4.7e-44	Lewy body disease;
LGG	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.05	-0.35	6.94e-15	IgG glycosylation;
LGG	trans	rs629535	0.814	rs72654071	chr8:70079484	A/G	cg21567404	chr3:27674614	NA	-0.4	-6.7	-0.3	6.22e-11	Dupuytren's disease;
LGG	cis	rs151997	0.962	rs56170692	chr5:50247928	G/A	cg06027927	chr5:50259733	NA	0.64	10.49	0.44	3.1e-23	Callous-unemotional behaviour;
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00149659	chr3:10157352	C3orf10	0.83	10.68	0.44	5.84e-24	Alzheimer's disease;
LGG	cis	rs745080	0.519	rs10144579	chr14:52918397	A/G	cg23333723	chr14:53022898	GPR137C	-0.42	-8.6	-0.37	1.23e-16	Orofacial clefts;
LGG	cis	rs7107174	1.000	rs7939352	chr11:78003151	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.15	-0.32	3.51e-12	Testicular germ cell tumor;
LGG	cis	rs17169635	0.836	rs3800735	chr7:134536969	A/G	cg02516134	chr7:134575187	CALD1	-0.37	-8.13	-0.35	3.98e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg10857441	chr5:6722123	POLS	-0.28	-6.89	-0.3	1.84e-11	Menopause (age at onset);
LGG	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg11266682	chr4:10021025	SLC2A9	0.48	9.46	0.4	1.53e-19	Bone mineral density;
LGG	cis	rs2229238	0.866	rs112231452	chr1:154504900	G/A	cg10237817	chr1:154519846	TDRD10	0.34	6.65	0.3	8.49e-11	Coronary heart disease;
LGG	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg00405596	chr8:11794950	NA	-0.46	-7.66	-0.34	1.07e-13	Triglycerides;
LGG	cis	rs9398803	0.687	rs3905044	chr6:126972883	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.7	0.41	2.27e-20	Male-pattern baldness;
LGG	cis	rs473651	0.935	rs508483	chr2:239339709	T/C	cg08773314	chr2:239334832	ASB1	0.42	8.04	0.35	7.53e-15	Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07145255	chr5:59995354	DEPDC1B	0.51	8.46	0.37	3.61e-16	Gut microbiome composition (summer);
LGG	cis	rs7301016	1.000	rs10877855	chr12:62870510	C/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg15269541	chr15:43626905	ADAL	-0.42	-7.09	-0.31	4.95e-12	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.06e-19	Obesity-related traits;
LGG	cis	rs362296	0.511	rs2051558	chr4:3324886	G/A	cg06533319	chr4:3265114	C4orf44	-0.41	-8.63	-0.37	9.85e-17	Parental longevity (mother's age at death);
LGG	cis	rs12681366	0.659	rs2046666	chr8:95388148	G/A	cg13257157	chr8:95487014	RAD54B	-0.36	-6.65	-0.3	8.47e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7000551	0.778	rs2469760	chr8:22365945	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	12.63	0.51	1.31e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2354432	0.607	rs7523812	chr1:146673489	A/G	cg25205988	chr1:146714368	CHD1L	-1.07	-9.3	-0.4	5.75e-19	Mitochondrial DNA levels;
LGG	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg03264133	chr6:25882463	NA	-0.43	-6.99	-0.31	9.69e-12	Iron status biomarkers;
LGG	trans	rs4427176	0.507	rs11989409	chr8:9581766	C/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs2033732	0.643	rs9643459	chr8:85058753	A/G	cg05716166	chr8:85095498	RALYL	0.42	6.76	0.3	4.1e-11	Body mass index;
LGG	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg16701003	chr16:89028210	CBFA2T3	0.55	8.48	0.37	3.12e-16	Social autistic-like traits;
LGG	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.47	7.27	0.32	1.53e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6500395	0.962	rs3743780	chr16:48647480	A/G	cg16662043	chr16:48846231	NA	0.38	7.41	0.33	5.96e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6840360	0.593	rs1429559	chr4:152681952	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.15	-0.43	5.66e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.28e-19	Life satisfaction;
LGG	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.92	-0.38	1.08e-17	Systolic blood pressure;
LGG	cis	rs62400317	0.859	rs10948221	chr6:45236707	T/G	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs9462027	0.606	rs6906129	chr6:34801160	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.48	-0.47	5.27e-27	Systemic lupus erythematosus;
LGG	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.7	-0.41	2.24e-20	Life satisfaction;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg16507663	chr6:150244633	RAET1G	0.47	8.9	0.38	1.29e-17	Lung cancer;
LGG	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.74e-21	Diabetic retinopathy;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg11814155	chr7:99998594	ZCWPW1	0.59	9.2	0.39	1.2e-18	Platelet count;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.37e-16	Lung cancer;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	20.25	0.69	9.63e-66	Platelet count;
LGG	cis	rs9814567	0.964	rs4974480	chr3:134178562	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.69	-12.45	-0.5	6.57e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg26150922	chr2:100937072	LONRF2	-0.49	-8.78	-0.38	3.06e-17	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg21475434	chr5:93447410	FAM172A	0.7	7.18	0.32	2.73e-12	Diabetic retinopathy;
LGG	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.01	0.55	1.99e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4268898	0.571	rs1986478	chr2:24468545	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-12.56	-0.5	2.54e-31	Asthma;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg14092988	chr3:52407081	DNAH1	-0.3	-7.96	-0.35	1.34e-14	Bipolar disorder;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17833341	chr1:154947313	SHC1;CKS1B	0.38	6.9	0.31	1.75e-11	Obesity-related traits;
LGG	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs12362504	0.532	rs12365540	chr11:9917109	T/C	cg07197493	chr11:9884649	SBF2	-0.34	-6.65	-0.3	8.42e-11	Survival in pancreatic cancer;
LGG	cis	rs2235642	1.000	rs2235642	chr16:1584866	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	9.16	0.39	1.66e-18	Coronary artery disease;
LGG	cis	rs9868809	0.772	rs9812200	chr3:48695667	A/G	cg00383909	chr3:49044727	WDR6	-0.78	-9.36	-0.4	3.4e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg21724239	chr8:58056113	NA	0.79	18.89	0.66	1.91e-59	Developmental language disorder (linguistic errors);
LGG	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg27211696	chr2:191398769	TMEM194B	0.4	9.14	0.39	1.94e-18	Pulse pressure;
LGG	cis	rs4740619	0.544	rs1341738	chr9:15808249	A/G	cg14451791	chr9:16040625	NA	0.31	7.63	0.33	1.35e-13	Body mass index;
LGG	cis	rs526231	0.511	rs2288389	chr5:102353808	C/G	cg23492399	chr5:102201601	PAM	-0.56	-8.38	-0.36	6.52e-16	Primary biliary cholangitis;
LGG	cis	rs9926296	0.643	rs2159114	chr16:89831841	A/G	cg04287289	chr16:89883240	FANCA	0.5	8.79	0.38	2.96e-17	Vitiligo;
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs6598955	0.671	rs17257169	chr1:26570009	C/T	cg04990556	chr1:26633338	UBXN11	0.63	7.64	0.33	1.25e-13	Obesity-related traits;
LGG	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10779751	1.000	rs12032364	chr1:11286872	G/T	cg08854313	chr1:11322531	MTOR	0.74	16.22	0.6	3.72e-47	Body mass index;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg16405210	chr4:1374714	KIAA1530	-0.62	-11.22	-0.46	5.1e-26	Longevity;
LGG	cis	rs2236918	0.710	rs1776159	chr1:242018583	C/G	cg17736920	chr1:242011382	EXO1	0.39	7.15	0.32	3.41e-12	Menopause (age at onset);
LGG	cis	rs12200560	0.505	rs1988040	chr6:97076271	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	9.96	0.42	2.67e-21	Iron status biomarkers;
LGG	cis	rs9309473	0.950	rs10169213	chr2:73787234	G/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.51e-14	Metabolite levels;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg12708336	chr17:41446283	NA	0.32	7.6	0.33	1.61e-13	Menopause (age at onset);
LGG	cis	rs8072100	0.935	rs78737171	chr17:45668760	A/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7843479	0.601	rs11780532	chr8:21838670	T/A	cg17168535	chr8:21777572	XPO7	0.8	15.72	0.59	6.33e-45	Mean corpuscular volume;
LGG	cis	rs1595825	1.000	rs1304164	chr2:198877234	C/A	cg00982548	chr2:198649783	BOLL	-0.51	-7.18	-0.32	2.72e-12	Ulcerative colitis;
LGG	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-14.0	-0.55	2.29e-37	Platelet distribution width;
LGG	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs9815354	0.953	rs1716694	chr3:41986399	G/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.43	-0.36	4.46e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg01472538	chr16:58549086	SETD6	0.98	8.78	0.38	3.23e-17	Schizophrenia;
LGG	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg19773385	chr1:10388646	KIF1B	-0.45	-9.77	-0.41	1.26e-20	Hepatocellular carcinoma;
LGG	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18252515	chr7:66147081	NA	-0.4	-6.67	-0.3	7.38e-11	Aortic root size;
LGG	cis	rs4740619	0.819	rs276449	chr9:15574785	G/C	cg14451791	chr9:16040625	NA	-0.34	-8.6	-0.37	1.22e-16	Body mass index;
LGG	trans	rs35110281	0.782	rs1454651	chr21:45012476	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.18	0.43	4.09e-22	Mean corpuscular volume;
LGG	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg01448562	chr3:133502909	NA	-0.73	-13.46	-0.53	4.46e-35	Iron status biomarkers;
LGG	cis	rs9487094	0.813	rs12528566	chr6:109738148	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.75	0.38	3.88e-17	Height;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.25	0.63	7.5e-52	Obesity-related traits;
LGG	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg00092383	chr7:157075207	NA	-0.38	-6.66	-0.3	7.66e-11	Body mass index;
LGG	cis	rs1003719	0.715	rs2835659	chr21:38567902	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.3	-0.58	4.74e-43	Eye color traits;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05665937	chr4:1216051	CTBP1	0.54	9.93	0.42	3.38e-21	Obesity-related traits;
LGG	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.83	0.54	1.18e-36	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.34e-19	Intelligence (multi-trait analysis);
LGG	cis	rs68170813	0.559	rs75932578	chr7:106844694	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.47	-0.44	3.61e-23	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11511713	chr14:92587796	CPSF2;NDUFB1	0.42	6.67	0.3	7.21e-11	Cognitive performance;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.68	11.87	0.48	1.44e-28	Obesity-related traits;
LGG	cis	rs9487094	0.670	rs3899233	chr6:109976994	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.74	0.34	6.26e-14	Height;
LGG	cis	rs9611519	1.000	rs3818003	chr22:41609690	C/T	cg03806693	chr22:41940476	POLR3H	-0.5	-8.09	-0.35	5.16e-15	Neuroticism;
LGG	cis	rs7766436	0.848	rs11759474	chr6:22580980	G/T	cg13666174	chr6:22585274	NA	-0.48	-10.58	-0.44	1.36e-23	Coronary artery disease;
LGG	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg16141378	chr3:129829833	LOC729375	0.39	9.22	0.39	1.02e-18	Joint mobility (Beighton score);
LGG	trans	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg23484912	chr5:273055	PDCD6	-0.38	-7.43	-0.33	5.33e-13	Mean corpuscular volume;
LGG	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg14664628	chr15:75095509	CSK	-0.54	-10.15	-0.43	5.42e-22	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs4417704	0.551	rs10169544	chr2:241899356	A/C	cg05025159	chr2:241905733	NA	0.52	10.72	0.45	4.35e-24	Joint mobility (Beighton score);
LGG	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg07777115	chr5:623756	CEP72	-0.44	-6.66	-0.3	7.7e-11	Obesity-related traits;
LGG	cis	rs8044868	0.586	rs7199261	chr16:72082788	A/G	cg23815491	chr16:72088622	HP	0.36	7.61	0.33	1.56e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg18709589	chr6:96969512	KIAA0776	0.42	8.17	0.36	2.93e-15	Headache;
LGG	cis	rs4466137	0.868	rs1975801	chr5:83022127	A/G	cg16102102	chr5:83017553	HAPLN1	-0.59	-10.87	-0.45	1.12e-24	Prostate cancer;
LGG	cis	rs9310709	0.518	rs506284	chr3:23048922	A/T	cg00327796	chr3:23032191	NA	-0.41	-7.89	-0.34	2.23e-14	Chronic kidney disease and serum creatinine levels;
LGG	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14373873	chr11:113211441	TTC12	0.42	8.62	0.37	1.09e-16	Neuroticism;
LGG	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.94	0.54	3.87e-37	Cognitive test performance;
LGG	cis	rs785830	0.749	rs578216	chr9:250935	G/C	cg14500300	chr9:211689	NA	0.3	7.58	0.33	1.96e-13	Platelet distribution width;
LGG	cis	rs17767392	0.874	rs34649709	chr14:71762296	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs701145	0.537	rs1358403	chr3:153862757	C/T	cg12800244	chr3:153838788	SGEF	0.8	8.71	0.38	5.32e-17	Coronary artery disease;
LGG	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.38	0.58	2.07e-43	Hair morphology;
LGG	trans	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg11693508	chr17:37793320	STARD3	0.53	7.7	0.34	8.17e-14	Bipolar disorder;
LGG	cis	rs11877825	0.826	rs3748426	chr18:10581732	G/A	cg07277756	chr18:10589357	NA	0.57	10.19	0.43	4.05e-22	Gut microbiota (bacterial taxa);
LGG	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.28	-0.75	1.41e-84	Height;
LGG	cis	rs61931739	0.591	rs4931764	chr12:33979423	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.15	-0.32	3.31e-12	Morning vs. evening chronotype;
LGG	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg07936489	chr17:37558343	FBXL20	1.07	19.52	0.67	2.25e-62	Glomerular filtration rate (creatinine);
LGG	cis	rs4740619	0.619	rs2026661	chr9:16045125	C/G	cg14451791	chr9:16040625	NA	0.43	11.3	0.46	2.59e-26	Body mass index;
LGG	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-8.67	-0.37	7.09e-17	Total body bone mineral density;
LGG	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.94	0.31	1.36e-11	Bipolar disorder;
LGG	cis	rs3762637	0.941	rs74467988	chr3:122083140	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-9.07	-0.39	3.42e-18	LDL cholesterol levels;
LGG	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg20744362	chr22:50050164	C22orf34	0.37	7.05	0.31	6.72e-12	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01044731	chr13:24554006	NA	0.4	6.68	0.3	6.97e-11	Body mass index;
LGG	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg17201900	chr20:34330562	RBM39	0.53	7.09	0.31	4.96e-12	Total cholesterol levels;
LGG	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg12046867	chr14:103022105	NA	-0.76	-13.08	-0.52	1.68e-33	Platelet count;
LGG	cis	rs283228	0.502	rs2852500	chr6:101841721	C/A	cg02011392	chr6:101847541	GRIK2	0.5	7.06	0.31	6.2e-12	Coenzyme Q10 levels;
LGG	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-8.42	-0.36	4.64e-16	Asthma;
LGG	cis	rs8028182	0.636	rs11636199	chr15:75825337	A/G	cg20655648	chr15:75932815	IMP3	0.44	7.32	0.32	1.11e-12	Sudden cardiac arrest;
LGG	cis	rs752010	0.714	rs7513753	chr1:42079232	A/G	cg16096631	chr1:42092165	HIVEP3	0.73	20.8	0.7	2.44e-68	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6964587	0.605	rs6956022	chr7:91553199	A/G	cg17063962	chr7:91808500	NA	-0.47	-8.76	-0.38	3.66e-17	Breast cancer;
LGG	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.4e-11	Blood metabolite levels;
LGG	cis	rs1044826	0.642	rs6439860	chr3:139175797	A/G	cg15131784	chr3:139108705	COPB2	0.42	6.85	0.3	2.39e-11	Obesity-related traits;
LGG	cis	rs1505368	0.563	rs1394798	chr2:213230641	G/A	cg16329650	chr2:213403929	ERBB4	0.42	7.48	0.33	3.81e-13	Symmetrical dimethylarginine levels;
LGG	cis	rs7084402	0.967	rs2170779	chr10:60277249	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05165339	chr4:1420672	NA	-0.36	-9.02	-0.39	4.84e-18	Longevity;
LGG	cis	rs4538187	0.901	rs67765474	chr2:64168437	C/T	cg14150252	chr2:64069583	UGP2	-0.49	-9.7	-0.41	2.2e-20	Systolic blood pressure;
LGG	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06634786	chr22:41940651	POLR3H	-0.61	-10.22	-0.43	2.99e-22	Vitiligo;
LGG	cis	rs6696846	0.740	rs17344537	chr1:205091427	T/G	cg21545522	chr1:205238299	TMCC2	0.37	7.18	0.32	2.79e-12	Red blood cell count;
LGG	cis	rs2295359	0.724	rs10489630	chr1:67662622	G/T	cg12940439	chr1:67600707	NA	-0.34	-6.95	-0.31	1.24e-11	Psoriasis;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.91	-0.31	1.58e-11	Lung cancer;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.3	0.43	1.49e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1577917	0.883	rs13212415	chr6:86608083	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.73	-0.34	6.8e-14	Response to antipsychotic treatment;
LGG	cis	rs10504130	0.569	rs16916966	chr8:52843329	C/A	cg22653915	chr8:52722023	PXDNL	-0.52	-8.86	-0.38	1.72e-17	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7192750	0.586	rs12444829	chr16:71959727	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.77	0.45	2.77e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-8.47	-0.37	3.39e-16	Height;
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9399137	0.507	rs11753673	chr6:135316476	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.75	0.45	3.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9880211	1.000	rs13071220	chr3:136314119	T/C	cg21827317	chr3:136751795	NA	-0.49	-7.29	-0.32	1.32e-12	Body mass index;Height;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22481606	chr17:56429567	SUPT4H1	0.38	7.01	0.31	8.66e-12	Body mass index;
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Electroencephalogram traits;
LGG	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg05555928	chr11:63887634	MACROD1	-0.63	-9.05	-0.39	3.95e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7444	0.941	rs5749502	chr22:21945096	T/A	cg15846791	chr22:21984385	YDJC	-0.47	-7.09	-0.31	5.06e-12	Systemic lupus erythematosus;
LGG	cis	rs3747547	0.792	rs72726052	chr9:38056290	C/T	cg13774184	chr9:37916125	SHB	-0.65	-6.65	-0.3	8.28e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.56	-0.33	2.21e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7937682	0.632	rs10789850	chr11:111750829	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs5750830	0.594	rs6001587	chr22:39819008	T/C	cg11247378	chr22:39784982	NA	-0.32	-9.02	-0.39	4.83e-18	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg18876405	chr7:65276391	NA	0.63	11.24	0.46	4.26e-26	Aortic root size;
LGG	cis	rs8044868	0.586	rs2070937	chr16:72089740	A/G	cg23815491	chr16:72088622	HP	0.38	7.88	0.34	2.31e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2180341	1.000	rs6569480	chr6:127621748	A/G	cg24812749	chr6:127587940	RNF146	0.96	16.21	0.6	4.05e-47	Breast cancer;
LGG	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg12310025	chr6:25882481	NA	-0.44	-6.96	-0.31	1.16e-11	Iron status biomarkers;
LGG	cis	rs4363385	0.818	rs451939	chr1:153006877	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	trans	rs9951602	0.512	rs61021837	chr18:76648210	A/C	cg02800362	chr5:177631904	HNRNPAB	0.77	13.48	0.53	3.57e-35	Obesity-related traits;
LGG	cis	rs7619833	0.719	rs628802	chr3:27341789	A/G	cg02860705	chr3:27208620	NA	0.39	7.55	0.33	2.39e-13	Breast cancer;
LGG	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg08704250	chr15:31115839	NA	-0.48	-8.64	-0.37	8.95e-17	Huntington's disease progression;
LGG	cis	rs584438	0.780	rs11657212	chr17:38591673	T/C	cg09358481	chr17:38600305	IGFBP4	-0.43	-8.21	-0.36	2.21e-15	Height;
LGG	cis	rs12210905	1.000	rs9368494	chr6:27237301	C/T	cg15325629	chr6:28072465	NA	0.7	6.88	0.3	1.98e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4845570	1.000	rs11585294	chr1:151769887	A/C	cg07092448	chr1:151763213	TDRKH	-1.18	-18.04	-0.64	1.75e-55	Coronary artery disease;
LGG	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.23	-0.43	2.8e-22	Glycated hemoglobin levels;
LGG	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.05	-0.31	6.57e-12	Joint mobility (Beighton score);
LGG	cis	rs6743226	0.901	rs7599888	chr2:242248033	C/G	cg10021735	chr2:242295487	FARP2	-0.53	-9.79	-0.41	1.09e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7917772	0.619	rs2801050	chr10:104509393	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.54	8.47	0.37	3.35e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1493916	0.905	rs7239283	chr18:31395397	G/A	cg27147174	chr7:100797783	AP1S1	-0.7	-13.44	-0.53	5.45e-35	Life satisfaction;
LGG	cis	rs2455601	0.608	rs11042104	chr11:8890924	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.47	9.29	0.4	6.05e-19	Schizophrenia;
LGG	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg09085632	chr11:111637200	PPP2R1B	1.06	21.69	0.71	1.72e-72	Primary sclerosing cholangitis;
LGG	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14442939	chr10:27389572	ANKRD26	0.75	11.33	0.47	1.92e-26	Breast cancer;
LGG	trans	rs6787172	0.565	rs9816143	chr3:158094125	A/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.61	10.61	0.44	1.06e-23	Chronic sinus infection;
LGG	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.31	-0.32	1.19e-12	Uric acid levels;
LGG	cis	rs9790314	0.690	rs1599389	chr3:160836006	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-10.9	-0.45	8.56e-25	Morning vs. evening chronotype;
LGG	cis	rs2734839	0.964	rs12363125	chr11:113285916	C/T	cg14159747	chr11:113255604	NA	0.28	7.44	0.33	4.87e-13	Information processing speed;
LGG	cis	rs950027	0.620	rs1617984	chr15:45622662	A/G	cg26924012	chr15:45694286	SPATA5L1	0.67	11.88	0.48	1.31e-28	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg17764715	chr19:33622953	WDR88	0.49	8.8	0.38	2.69e-17	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs4788570	0.584	rs4788548	chr16:71655361	A/G	cg06353428	chr16:71660113	MARVELD3	1.21	20.39	0.69	2.08e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.89	0.48	1.27e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17376456	0.825	rs35496867	chr5:93220400	T/C	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03226425	chr6:170151538	C6orf70;TCTE3	0.46	7.14	0.31	3.57e-12	Gut microbiome composition (summer);
LGG	cis	rs6882046	0.513	rs628158	chr5:88041781	G/A	cg22951263	chr5:87985283	NA	-0.56	-10.38	-0.43	7.88e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.81	0.38	2.63e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9581857	0.685	rs78595793	chr13:28031881	C/T	cg01674679	chr13:27998804	GTF3A	-0.66	-7.53	-0.33	2.62e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs1728785	1.000	rs12918861	chr16:68566508	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs909674	0.818	rs5757678	chr22:39843409	A/G	cg11247378	chr22:39784982	NA	0.3	8.28	0.36	1.35e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.47	0.4	1.49e-19	Longevity;
LGG	trans	rs9944715	0.954	rs8098751	chr18:43850587	G/A	cg01718231	chr17:29326311	RNF135	-0.42	-6.67	-0.3	7.41e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7918232	1.000	rs7918232	chr10:27369162	A/G	cg14240646	chr10:27532245	ACBD5	-0.77	-11.25	-0.46	3.89e-26	Breast cancer;
LGG	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15532942	chr18:77220712	NFATC1	0.47	7.67	0.34	1.03e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.36	-0.43	9.08e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg18898632	chr2:242989856	NA	-0.75	-9.53	-0.4	9.21e-20	Obesity-related traits;
LGG	cis	rs8030485	0.716	rs12899109	chr15:79410970	T/C	cg17916960	chr15:79447300	NA	0.47	8.68	0.37	6.79e-17	Left ventricle wall thickness;
LGG	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg16141378	chr3:129829833	LOC729375	-0.48	-12.4	-0.5	1.12e-30	Mood instability;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.33e-20	Life satisfaction;
LGG	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg18188782	chr20:61659543	NA	0.39	6.65	0.3	8.05e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7914558	1.000	rs2275271	chr10:104814162	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.69	0.44	5.43e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg22044901	chr15:68126292	NA	0.4	6.73	0.3	5.12e-11	Restless legs syndrome;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg11062466	chr8:58055876	NA	0.61	9.68	0.41	2.58e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg05368731	chr17:41323189	NBR1	0.79	14.01	0.55	1.91e-37	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs1426666	chr4:99030887	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg03645007	chr3:50255295	SLC38A3	0.65	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs1018697	1.000	rs7909612	chr10:104561456	G/A	cg04362960	chr10:104952993	NT5C2	0.49	8.97	0.38	7.62e-18	Colorectal adenoma (advanced);
LGG	cis	rs7084402	0.935	rs12263522	chr10:60343527	C/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.52	-0.33	2.79e-13	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24995352	chr10:13203403	MCM10	0.43	6.78	0.3	3.62e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06634786	chr22:41940651	POLR3H	0.75	12.38	0.5	1.35e-30	Vitiligo;
LGG	cis	rs9902453	0.817	rs4794861	chr17:28183174	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.62	0.53	9.36e-36	Coffee consumption (cups per day);
LGG	cis	rs2033732	0.826	rs2196618	chr8:85089437	A/G	cg05716166	chr8:85095498	RALYL	0.56	9.13	0.39	2.09e-18	Body mass index;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg23782820	chr8:58130467	NA	0.56	8.2	0.36	2.33e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg11878867	chr6:150167359	LRP11	-0.41	-7.44	-0.33	4.87e-13	Lung cancer;
LGG	cis	rs4243830	0.649	rs11579888	chr1:6609896	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-12.26	-0.5	4.05e-30	Body mass index;
LGG	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9886651	0.935	rs4404878	chr8:128798394	T/C	cg24514600	chr8:128805414	PVT1	-0.55	-12.61	-0.51	1.46e-31	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.71	0.3	5.67e-11	Bladder cancer;
LGG	trans	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.37	-0.32	8.08e-13	Educational attainment (years of education);
LGG	cis	rs2798269	0.966	rs12584577	chr13:22120666	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.77	-0.3	4e-11	PR segment;
LGG	cis	rs9796	0.870	rs12910027	chr15:41283817	A/T	cg18705301	chr15:41695430	NDUFAF1	0.48	8.19	0.36	2.5e-15	Menopause (age at onset);
LGG	cis	rs7639513	0.545	rs13061104	chr3:12717321	G/T	cg23032965	chr3:12705835	RAF1	0.73	11.49	0.47	4.72e-27	Itch intensity from mosquito bite;
LGG	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.13	0.52	1.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs908922	0.887	rs7535188	chr1:152475899	G/A	cg09873164	chr1:152488093	CRCT1	0.55	11.49	0.47	4.74e-27	Hair morphology;
LGG	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.5	0.33	3.25e-13	Total cholesterol levels;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg19539972	chr4:7069911	GRPEL1	0.69	10.14	0.43	5.84e-22	Monocyte percentage of white cells;
LGG	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	cis	rs2274273	0.662	rs67958555	chr14:55670866	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.87	0.48	1.51e-28	Protein biomarker;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.52e-21	Lymphocyte counts;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.56	9.72	0.41	1.84e-20	Obesity-related traits;
LGG	cis	rs1142	0.504	rs2470945	chr7:104585760	C/A	cg03782966	chr7:104585482	NA	0.35	7.99	0.35	1.1e-14	Advanced age-related macular degeneration;
LGG	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg21014159	chr11:117668035	DSCAML1	0.48	7.33	0.32	1.07e-12	Myopia;
LGG	cis	rs2976388	0.625	rs2257840	chr8:143809193	C/T	cg06565975	chr8:143823917	SLURP1	0.37	9.42	0.4	2.11e-19	Urinary tract infection frequency;
LGG	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg19628046	chr18:33552617	C18orf21	0.53	7.71	0.34	7.62e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2224391	0.656	rs17140118	chr6:5291334	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-7.14	-0.31	3.71e-12	Height;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.45	0.37	3.75e-16	Obesity-related traits;
LGG	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg17108064	chr15:78857060	CHRNA5	-0.36	-6.98	-0.31	1.05e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs3126085	1.000	rs3126085	chr1:152300817	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.89	-0.34	2.24e-14	Atopic dermatitis;
LGG	cis	rs2859741	0.967	rs822854	chr1:37485788	A/G	cg09363841	chr1:37513479	NA	-0.65	-15.57	-0.59	2.91e-44	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.72	-0.41	1.85e-20	Platelet count;
LGG	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21659725	chr3:3221576	CRBN	-0.62	-9.86	-0.42	6.04e-21	Educational attainment;
LGG	cis	rs9515201	0.781	rs2391825	chr13:111035483	G/A	cg06243866	chr13:111019493	COL4A2	-0.58	-9.46	-0.4	1.51e-19	White matter hyperintensity burden;
LGG	cis	rs701145	0.585	rs1470662	chr3:153870997	T/G	cg12800244	chr3:153838788	SGEF	0.78	8.53	0.37	2.11e-16	Coronary artery disease;
LGG	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg19729930	chr2:74357872	NA	0.55	11.19	0.46	6.95e-26	Gestational age at birth (maternal effect);
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06850241	chr22:41845214	NA	-0.47	-7.13	-0.31	3.91e-12	Vitiligo;
LGG	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.82	0.34	3.69e-14	HDL cholesterol;
LGG	cis	rs2229238	0.868	rs73023348	chr1:154513418	G/A	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs12431410	0.514	rs7155725	chr14:60235901	C/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.21	-0.32	2.35e-12	Schizophrenia;
LGG	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg18446336	chr7:2847575	GNA12	-0.31	-8.02	-0.35	8.6e-15	Height;
LGG	cis	rs77633900	0.772	rs2469224	chr15:76651327	T/G	cg21673338	chr15:77095150	SCAPER	-0.62	-8.11	-0.35	4.67e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg03264133	chr6:25882463	NA	0.71	13.69	0.54	4.41e-36	Blood metabolite levels;
LGG	cis	rs977987	0.836	rs35209155	chr16:75470496	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.01	0.42	1.7e-21	Dupuytren's disease;
LGG	cis	rs4988958	0.584	rs12712149	chr2:103045193	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.58	0.41	5.74e-20	Asthma (childhood onset);
LGG	cis	rs12282928	0.959	rs1566737	chr11:48238302	A/C	cg26585981	chr11:48327164	OR4S1	0.45	7.2	0.32	2.44e-12	Migraine - clinic-based;
LGG	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg10760299	chr15:45669010	GATM	0.4	8.0	0.35	9.82e-15	Homoarginine levels;
LGG	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg03959625	chr15:84868606	LOC388152	0.47	7.06	0.31	6.03e-12	Schizophrenia;
LGG	cis	rs34311866	0.748	rs10029038	chr4:899352	T/C	cg07828340	chr4:882639	GAK	0.93	9.69	0.41	2.38e-20	Parkinson's disease;
LGG	cis	rs7267979	0.933	rs2258728	chr20:25276343	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.41	0.44	6.12e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11574758	chr20:21107113	PLK1S1	0.46	7.36	0.32	8.58e-13	Gut microbiome composition (summer);
LGG	cis	rs4363385	0.588	rs6660878	chr1:153027068	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-9.75	-0.41	1.53e-20	Inflammatory skin disease;
LGG	cis	rs7799006	0.862	rs3757439	chr7:2272122	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-7.6	-0.33	1.63e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg07541023	chr7:19748670	TWISTNB	1.09	20.5	0.69	6.35e-67	Night sleep phenotypes;
LGG	cis	rs9394438	0.593	rs10947679	chr6:37543524	C/G	cg00985040	chr6:37553208	NA	0.37	8.35	0.36	8.14e-16	IgG glycosylation;
LGG	cis	rs6138458	0.546	rs6050118	chr20:24891895	C/T	cg26195577	chr20:24973756	C20orf3	-1.0	-12.44	-0.5	7.71e-31	Blood protein levels;
LGG	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.81	-0.3	3.1e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7191439	0.584	rs11076698	chr16:88752693	T/G	cg02389323	chr16:88786976	FAM38A	0.89	8.66	0.37	7.98e-17	Plateletcrit;
LGG	cis	rs4589502	1.000	rs16950284	chr15:67154184	A/G	cg09911534	chr15:67153556	NA	0.57	7.03	0.31	7.42e-12	Lung cancer (smoking interaction);
LGG	cis	rs10743315	0.732	rs7309614	chr12:19453358	T/C	cg02471346	chr12:19282374	PLEKHA5	0.6	6.85	0.3	2.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9287719	0.967	rs3814388	chr2:10702099	A/T	cg02196655	chr2:10830764	NOL10	-0.42	-7.14	-0.32	3.57e-12	Prostate cancer;
LGG	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.13	0.46	1.16e-25	Response to antipsychotic treatment;
LGG	cis	rs7786877	0.723	rs6969697	chr7:100209604	G/A	cg16850897	chr7:100343110	ZAN	-0.56	-7.56	-0.33	2.15e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg26597838	chr10:835615	NA	0.75	10.44	0.44	4.51e-23	Eosinophil percentage of granulocytes;
LGG	trans	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.76	-0.34	5.3e-14	Heart rate;
LGG	cis	rs853679	0.517	rs34716816	chr6:28046169	C/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg06640241	chr16:89574553	SPG7	0.91	17.18	0.62	1.52e-51	Multiple myeloma (IgH translocation);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02048674	chr19:49991517	RPL13AP5;RPL13A	-0.39	-6.7	-0.3	6.14e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg25019033	chr10:957182	NA	-0.61	-11.03	-0.46	2.74e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg13047869	chr3:10149882	C3orf24	0.47	7.69	0.34	9.22e-14	Alzheimer's disease;
LGG	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-8.61	-0.37	1.12e-16	Schizophrenia;
LGG	trans	rs11039798	0.623	rs635632	chr11:48399532	T/C	cg03929089	chr4:120376271	NA	-0.7	-9.53	-0.4	8.61e-20	Axial length;
LGG	cis	rs2171564	0.557	rs9831780	chr3:112442083	G/A	cg06685282	chr3:112453648	NA	0.61	11.34	0.47	1.78e-26	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs3106136	0.967	rs72665658	chr4:95144761	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.98	-0.35	1.17e-14	Capecitabine sensitivity;
LGG	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-12.89	-0.51	1.04e-32	Response to antipsychotic treatment;
LGG	cis	rs7529073	0.545	rs1431985	chr1:214148246	C/T	cg24083324	chr1:214162604	PROX1	-0.45	-8.02	-0.35	8.67e-15	Schizophrenia;
LGG	cis	rs990171	1.000	rs6543141	chr2:103076351	G/A	cg05295703	chr2:102895712	NA	-0.51	-8.92	-0.38	1.1e-17	Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11162385	chr20:25604740	NANP	0.47	8.28	0.36	1.36e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs972578	0.791	rs5759015	chr22:43291529	C/A	cg01576275	chr22:43409880	NA	-0.23	-7.04	-0.31	7.16e-12	Mean platelet volume;
LGG	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg18105134	chr13:113819100	PROZ	0.71	14.83	0.57	5.36e-41	Platelet distribution width;
LGG	cis	rs11785400	0.793	rs7000765	chr8:143722457	G/A	cg10596483	chr8:143751796	JRK	0.5	7.67	0.34	1.01e-13	Schizophrenia;
LGG	cis	rs9790314	0.639	rs6769642	chr3:160763469	C/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.13	-0.35	4.02e-15	Morning vs. evening chronotype;
LGG	cis	rs4731207	0.698	rs11978656	chr7:124449965	C/T	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg12591125	chr7:1885375	MAD1L1	0.49	7.14	0.31	3.68e-12	Bipolar disorder;
LGG	cis	rs11955398	0.716	rs2061250	chr5:59917678	C/A	cg02684056	chr5:59996105	DEPDC1B	0.4	6.66	0.3	7.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9549260	0.755	rs9549255	chr13:41235213	C/T	cg21288729	chr13:41239152	FOXO1	0.33	6.71	0.3	5.84e-11	Red blood cell count;
LGG	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-9.31	-0.4	5.07e-19	Diabetic retinopathy;
LGG	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg02002194	chr4:3960332	NA	-0.48	-8.95	-0.38	8.81e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs903263	0.601	rs12746741	chr1:84539576	C/T	cg10977910	chr1:84465055	TTLL7	-0.4	-6.85	-0.3	2.4e-11	Breast cancer (male);
LGG	cis	rs9303401	0.615	rs7502342	chr17:56922629	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.14	0.58	2.27e-42	Cognitive test performance;
LGG	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	12.03	0.49	3.52e-29	Mean corpuscular hemoglobin;
LGG	cis	rs12618769	0.597	rs3769740	chr2:99069208	A/G	cg18455616	chr2:99124870	INPP4A	-0.28	-8.4	-0.36	5.7e-16	Bipolar disorder;
LGG	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07570687	chr10:102243282	WNT8B	0.4	7.1	0.31	4.79e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18404041	chr3:52824283	ITIH1	0.53	10.13	0.43	6.22e-22	Bipolar disorder;
LGG	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg24006582	chr15:45444508	DUOX1	0.66	12.28	0.5	3.34e-30	Uric acid levels;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg10505658	chr17:80084571	CCDC57	0.4	8.23	0.36	1.9e-15	Life satisfaction;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-8.88	-0.38	1.48e-17	Yeast infection;
LGG	cis	rs2289328	0.943	rs3803360	chr15:40662669	C/T	cg13931752	chr15:40660718	DISP2	0.36	7.49	0.33	3.49e-13	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12667521	chr19:29218732	NA	0.62	9.48	0.4	1.36e-19	Methadone dose in opioid dependence;
LGG	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.91	-0.31	1.61e-11	Caffeine consumption;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09093137	chr7:105028539	SRPK2	0.46	7.08	0.31	5.36e-12	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg01673284	chr16:4527211	HMOX2	0.37	7.32	0.32	1.07e-12	Schizophrenia;
LGG	cis	rs6964587	1.000	rs6967256	chr7:91643219	G/A	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.44	-0.5	7.84e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs62045849	0.557	rs3743982	chr16:89181139	T/G	cg08015503	chr16:89190385	ACSF3	-0.63	-7.27	-0.32	1.57e-12	Red blood cell count;
LGG	cis	rs6840360	0.642	rs2709831	chr4:152379651	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4380275	0.782	rs60367761	chr2:766414	C/T	cg02758766	chr2:740531	NA	-0.39	-6.8	-0.3	3.29e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08280392	chr2:228028601	COL4A3;COL4A4	0.47	7.15	0.32	3.32e-12	Gut microbiome composition (summer);
LGG	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg10483660	chr13:112241077	NA	0.35	6.91	0.31	1.56e-11	Menarche (age at onset);
LGG	cis	rs4690686	0.836	rs10027831	chr4:177256699	T/C	cg17059388	chr4:177262070	NA	0.74	15.9	0.59	9.43e-46	Essential tremor;
LGG	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg00405596	chr8:11794950	NA	0.66	11.64	0.48	1.18e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg08305652	chr11:111469057	NA	0.41	8.09	0.35	5.23e-15	Primary sclerosing cholangitis;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs9682041	0.808	rs9880558	chr3:170067771	A/G	cg11886554	chr3:170076028	SKIL	-0.68	-8.72	-0.38	4.94e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs12369635	1.000	rs11060121	chr12:129564206	C/T	cg01909103	chr12:129572610	TMEM132D	-0.76	-7.57	-0.33	2e-13	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14442939	chr10:27389572	ANKRD26	-0.73	-11.03	-0.46	2.77e-25	Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26618210	chr15:41576042	LOC729082	0.44	7.02	0.31	7.96e-12	Cognitive performance;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg04503457	chr17:41445688	NA	0.38	9.36	0.4	3.53e-19	Menopause (age at onset);
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.19	-0.32	2.67e-12	Bipolar disorder;
LGG	cis	rs7814319	0.838	rs10955067	chr8:97230982	C/T	cg20787634	chr8:97240163	UQCRB	-0.7	-15.52	-0.58	5.09e-44	Lung function (FVC);
LGG	cis	rs4330281	0.904	rs11128858	chr3:17827985	A/G	cg20981856	chr3:17787350	NA	-0.37	-6.87	-0.3	2.09e-11	Schizophrenia;
LGG	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg17644776	chr2:200775616	C2orf69	0.53	8.55	0.37	1.83e-16	Osteoporosis;
LGG	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg03929089	chr4:120376271	NA	-0.42	-6.66	-0.3	7.85e-11	Height;
LGG	cis	rs6908034	0.607	rs73378506	chr6:19819987	T/C	cg02682789	chr6:19804855	NA	0.72	8.15	0.35	3.45e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13897145	chr3:113557582	GRAMD1C	-0.41	-6.9	-0.31	1.7e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs736408	0.632	rs2240919	chr3:52831701	C/G	cg14092988	chr3:52407081	DNAH1	0.35	8.88	0.38	1.46e-17	Bipolar disorder;
LGG	cis	rs7247513	0.759	rs73002392	chr19:12768391	G/A	cg01871581	chr19:12707946	ZNF490	-0.39	-7.62	-0.33	1.4e-13	Bipolar disorder;
LGG	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg26597838	chr10:835615	NA	0.77	10.86	0.45	1.22e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs10751667	0.666	rs10794354	chr11:954615	A/T	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.67e-15	Alzheimer's disease (late onset);
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.64	0.67	6.31e-63	Platelet count;
LGG	trans	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg06606381	chr12:133084897	FBRSL1	-0.64	-8.24	-0.36	1.72e-15	Depression;
LGG	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.36e-36	Cognitive function;
LGG	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg13271783	chr10:134563150	INPP5A	-0.5	-7.57	-0.33	2.09e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs2048656	0.524	rs7840706	chr8:9535056	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.19	0.32	2.63e-12	Schizophrenia;
LGG	cis	rs2153535	0.584	rs62395678	chr6:8371689	C/T	cg23788917	chr6:8435910	SLC35B3	-0.45	-7.39	-0.32	6.71e-13	Motion sickness;
LGG	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs2599510	0.934	rs2710634	chr2:32808804	T/C	cg02381751	chr2:32503542	YIPF4	0.52	8.77	0.38	3.53e-17	Interleukin-18 levels;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg18379455	chr17:41446167	NA	-0.31	-7.07	-0.31	5.56e-12	Menopause (age at onset);
LGG	cis	rs60180747	0.544	rs11637318	chr15:66558655	C/G	cg07575407	chr15:66541975	MEGF11	0.64	13.72	0.54	3.37e-36	Testicular germ cell tumor;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg15145296	chr3:125709740	NA	-0.62	-8.14	-0.35	3.66e-15	Blood pressure (smoking interaction);
LGG	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27286337	chr10:134555280	INPP5A	0.83	13.32	0.53	1.7e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.77	-0.3	4.01e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7582720	1.000	rs114527590	chr2:203787405	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1707322	0.716	rs10890342	chr1:46157087	C/T	cg03146154	chr1:46216737	IPP	0.56	10.61	0.44	1.13e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04064611	chr7:72298987	SBDSP;TYW1B	0.4	7.09	0.31	5.04e-12	Bilirubin levels;
LGG	cis	rs6429082	0.608	rs903348	chr1:235571343	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.93	-0.38	9.71e-18	Adiposity;
LGG	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg17691542	chr6:26056736	HIST1H1C	-0.61	-10.15	-0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs10895140	0.665	rs4492785	chr11:101515319	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg13736514	chr6:26305472	NA	0.48	10.09	0.42	9.24e-22	Educational attainment;
LGG	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg15664640	chr17:80829946	TBCD	0.49	9.58	0.41	6.06e-20	Breast cancer;
LGG	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg09467607	chr2:36825704	FEZ2	0.48	9.01	0.39	5.48e-18	Height;
LGG	cis	rs45544231	0.510	rs3112581	chr16:52571533	A/G	cg09051775	chr16:52580266	TOX3	-0.43	-7.18	-0.32	2.78e-12	Restless legs syndrome;
LGG	cis	rs7166081	1.000	rs8031627	chr15:67484119	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.83	-0.3	2.6e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	15.76	0.59	4.13e-45	Headache;
LGG	cis	rs2470578	0.792	rs283919	chr3:17328070	G/C	cg20981856	chr3:17787350	NA	0.35	6.75	0.3	4.43e-11	Schizophrenia;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00810752	chr4:113277063	ALPK1	0.4	8.06	0.35	6.33e-15	Electrocardiographic conduction measures;
LGG	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg08600765	chr20:34638493	LOC647979	-0.63	-7.81	-0.34	3.88e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg08885076	chr2:99613938	TSGA10	-0.56	-10.01	-0.42	1.77e-21	Chronic sinus infection;
LGG	cis	rs17767392	1.000	rs17178045	chr14:71756358	A/G	cg02058870	chr14:72053146	SIPA1L1	0.47	9.51	0.4	1.05e-19	Mitral valve prolapse;
LGG	trans	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg05059571	chr16:84539110	KIAA1609	0.41	7.52	0.33	2.86e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4604732	0.588	rs7549495	chr1:247627806	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.14	0.39	1.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2797369	0.882	rs2764271	chr6:101651617	A/T	cg27451362	chr6:101846650	GRIK2	-0.81	-10.72	-0.45	4.27e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs370915	0.890	rs28610515	chr4:187835260	A/T	cg19519643	chr4:187840862	NA	-0.5	-9.16	-0.39	1.73e-18	Gout;
LGG	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg00938859	chr5:1591904	SDHAP3	0.89	13.16	0.52	7.66e-34	Breast cancer;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs870825	0.581	rs28602720	chr4:185630598	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.25	0.72	4.16e-75	Blood protein levels;
LGG	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs877282	1.000	rs71491304	chr10:772982	C/T	cg22713356	chr15:30763199	NA	0.56	8.63	0.37	1.02e-16	Uric acid levels;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs2307022	0.586	rs7188235	chr16:68393930	C/T	cg07273125	chr16:68295692	NA	0.45	10.07	0.42	1.04e-21	Body mass index;
LGG	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg22875332	chr1:76189707	ACADM	0.6	9.53	0.41	8.54e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg20026190	chr17:76395443	PGS1	0.44	7.49	0.33	3.54e-13	HDL cholesterol levels;
LGG	cis	rs7208859	0.524	rs8069400	chr17:29075967	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.33	-0.43	1.18e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.52	0.33	2.89e-13	Triglycerides;
LGG	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg06026331	chr20:60912101	LAMA5	0.47	8.38	0.36	6.5e-16	Colorectal cancer;
LGG	cis	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.73	-0.3	5.07e-11	Mean platelet volume;
LGG	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg00745463	chr17:30367425	LRRC37B	-0.66	-9.85	-0.42	6.46e-21	Hip circumference adjusted for BMI;
LGG	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs11690935	0.788	rs6715929	chr2:172877507	A/G	cg21435375	chr2:172878103	MAP1D	-0.36	-8.68	-0.37	6.83e-17	Schizophrenia;
LGG	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg03959625	chr15:84868606	LOC388152	0.47	7.08	0.31	5.34e-12	Schizophrenia;
LGG	cis	rs11792861	0.816	rs744980	chr9:111690388	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.34	0.43	1.12e-22	Menarche (age at onset);
LGG	trans	rs1814175	0.615	rs4545557	chr11:50027329	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs6743226	0.934	rs6704615	chr2:242228733	A/G	cg10021735	chr2:242295487	FARP2	-0.5	-9.28	-0.4	6.62e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	6.87	0.3	2.03e-11	Schizophrenia;
LGG	trans	rs1941687	0.797	rs9963397	chr18:31395015	A/T	cg27147174	chr7:100797783	AP1S1	-0.52	-8.63	-0.37	1.03e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg21017887	chr14:105400489	NA	0.4	7.91	0.35	1.89e-14	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg13010199	chr12:38710504	ALG10B	0.7	14.76	0.57	1.06e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9902453	0.934	rs4343336	chr17:28488236	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.53	0.53	2.32e-35	Coffee consumption (cups per day);
LGG	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg16325326	chr1:53192061	ZYG11B	-0.62	-12.69	-0.51	7.25e-32	Monocyte count;
LGG	cis	rs3126085	0.877	rs3126045	chr1:152256794	A/G	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02475777	chr4:1388615	CRIPAK	0.38	6.98	0.31	1.05e-11	Longevity;
LGG	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.4	-0.4	2.55e-19	Body mass index;
LGG	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg12463550	chr7:65579703	CRCP	0.49	8.27	0.36	1.45e-15	Aortic root size;
LGG	cis	rs240764	0.658	rs4571568	chr6:101223955	T/A	cg09795085	chr6:101329169	ASCC3	-0.46	-7.64	-0.33	1.24e-13	Neuroticism;
LGG	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg25237894	chr2:233734115	C2orf82	-0.49	-8.97	-0.38	7.48e-18	Schizophrenia;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-15.09	-0.57	3.97e-42	Platelet count;
LGG	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg21475434	chr5:93447410	FAM172A	0.69	7.13	0.31	3.9e-12	Diabetic retinopathy;
LGG	cis	rs4538187	1.000	rs35002211	chr2:64152855	A/G	cg14150252	chr2:64069583	UGP2	-0.5	-9.67	-0.41	2.83e-20	Systolic blood pressure;
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg04703951	chr17:43578652	NA	0.4	8.08	0.35	5.74e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2470578	0.792	rs2596639	chr3:17287135	G/A	cg20981856	chr3:17787350	NA	0.35	6.73	0.3	5e-11	Schizophrenia;
LGG	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg20019365	chr2:219134978	PNKD;AAMP	0.68	11.7	0.48	7.09e-28	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LGG	trans	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-12.82	-0.51	2.15e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg27087555	chr16:88793112	FAM38A	-1.5	-19.13	-0.66	1.54e-60	Plateletcrit;
LGG	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg16339924	chr4:17578868	LAP3	0.65	10.76	0.45	2.95e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs990171	0.865	rs6717915	chr2:103079619	A/C	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.57	-0.41	6.66e-20	Height;
LGG	cis	rs1801251	1.000	rs1446308	chr2:233639309	T/C	cg25237894	chr2:233734115	C2orf82	0.65	12.6	0.51	1.67e-31	Coronary artery disease;
LGG	cis	rs4363385	0.510	rs7532166	chr1:153046851	C/G	cg13444842	chr1:152974279	SPRR3	-0.46	-9.22	-0.39	1.07e-18	Inflammatory skin disease;
LGG	cis	rs3087591	0.960	rs4435317	chr17:29436512	G/C	cg24425628	chr17:29625626	OMG;NF1	0.71	14.28	0.55	1.4e-38	Hip circumference;
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg00713939	chr8:144660590	NAPRT1	0.86	6.76	0.3	4.07e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg12458913	chr13:53173898	NA	0.46	7.95	0.35	1.43e-14	Lewy body disease;
LGG	cis	rs1670533	1.000	rs62879260	chr4:1050850	T/C	cg27284194	chr4:1044797	NA	0.55	9.84	0.42	6.95e-21	Recombination rate (females);
LGG	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg00631329	chr6:26305371	NA	-0.45	-7.68	-0.34	9.41e-14	Educational attainment;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.95	0.31	1.21e-11	Lung cancer;
LGG	cis	rs2933343	0.700	rs883602	chr3:128653952	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.66	0.3	7.92e-11	IgG glycosylation;
LGG	cis	rs977987	0.737	rs8046697	chr16:75442144	T/C	cg03315344	chr16:75512273	CHST6	0.53	10.63	0.44	9.49e-24	Dupuytren's disease;
LGG	cis	rs17767392	0.846	rs56180634	chr14:71989933	C/T	cg02058870	chr14:72053146	SIPA1L1	0.41	8.55	0.37	1.86e-16	Mitral valve prolapse;
LGG	cis	rs9487051	0.735	rs459956	chr6:109524760	A/G	cg21918786	chr6:109611834	NA	-0.39	-7.03	-0.31	7.38e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg06623918	chr6:96969491	KIAA0776	0.74	11.63	0.48	1.32e-27	Migraine;Coronary artery disease;
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	trans	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs1143633	0.566	rs12987491	chr2:113691499	G/A	cg06771106	chr2:113671356	IL1F7	0.37	7.15	0.32	3.51e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6598955	0.670	rs10794525	chr1:26537193	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.36	7.49	0.33	3.47e-13	Obesity-related traits;
LGG	trans	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg26043149	chr18:55253948	FECH	-0.4	-6.68	-0.3	7e-11	Bone mineral density;
LGG	cis	rs7940866	0.834	rs10894298	chr11:130840571	C/A	cg12179176	chr11:130786555	SNX19	0.73	13.51	0.53	2.8e-35	Schizophrenia;
LGG	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg21775007	chr8:11205619	TDH	-0.52	-8.39	-0.36	5.92e-16	Triglycerides;
LGG	cis	rs4716602	0.596	rs10265482	chr7:156160655	C/G	cg16983916	chr7:156159713	NA	-0.49	-9.49	-0.4	1.25e-19	Anti-saccade response;
LGG	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	6.67	0.3	7.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.6	-0.33	1.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10227331	0.632	rs10215531	chr7:157301180	A/G	cg04156418	chr7:157293606	NA	0.56	11.45	0.47	6.94e-27	Inattentive symptoms;
LGG	cis	rs10927875	0.619	rs7537101	chr1:16150384	T/C	cg21385522	chr1:16154831	NA	-0.75	-15.48	-0.58	6.99e-44	Dilated cardiomyopathy;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00166722	chr3:10149974	C3orf24	0.54	8.94	0.38	9.13e-18	Alzheimer's disease;
LGG	cis	rs8060686	0.545	rs12598630	chr16:68258852	T/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg01673284	chr16:4527211	HMOX2	0.37	7.29	0.32	1.32e-12	Schizophrenia;
LGG	cis	rs4356932	1.000	rs4417995	chr4:76945999	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs6988985	0.563	rs4523233	chr8:143941389	T/C	cg10324643	chr8:143916377	GML	0.39	7.6	0.33	1.71e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10064886	chr14:58764945	FLJ31306;ARID4A	0.45	7.46	0.33	4.43e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	13.25	0.52	3.37e-34	Hip circumference adjusted for BMI;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10831504	chr12:69005104	RAP1B	0.44	7.07	0.31	5.75e-12	Cognitive performance;
LGG	cis	rs11690935	0.632	rs1607254	chr2:172626552	A/G	cg13550731	chr2:172543902	DYNC1I2	0.71	14.44	0.56	2.75e-39	Schizophrenia;
LGG	cis	rs2273669	0.667	rs12214121	chr6:109322554	A/G	cg05315195	chr6:109294784	ARMC2	0.63	8.53	0.37	2.11e-16	Prostate cancer;
LGG	cis	rs7843479	1.000	rs13276082	chr8:21823184	A/G	cg17168535	chr8:21777572	XPO7	0.6	9.82	0.42	8.2e-21	Mean corpuscular volume;
LGG	cis	rs10911232	0.560	rs10911221	chr1:183046737	G/C	cg07245641	chr1:182991651	LAMC1	0.41	9.25	0.39	8.52e-19	Hypertriglyceridemia;
LGG	cis	rs8060686	0.698	rs8044558	chr16:68210165	T/C	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.23	-0.32	1.97e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.67	-12.39	-0.5	1.19e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.82	0.34	3.66e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2201728	0.538	rs1229966	chr4:100213433	A/G	cg07219303	chr4:100140905	ADH6	0.38	7.23	0.32	2.02e-12	Cardiac Troponin-T levels;
LGG	cis	rs883565	0.569	rs784515	chr3:39163848	C/T	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg19680485	chr15:31195859	MTMR15	0.45	7.37	0.32	7.76e-13	Huntington's disease progression;
LGG	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg22643751	chr7:855365	UNC84A	-0.49	-11.83	-0.48	2.06e-28	Perceived unattractiveness to mosquitoes;
LGG	cis	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.17.1008464R	chr17:37630567	CDK12	-0.48	-7.35	-0.32	8.96e-13	Systemic lupus erythematosus;
LGG	cis	rs3820068	0.705	rs4646075	chr1:15827461	T/C	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs216026	0.515	rs11062286	chr12:2735215	G/A	cg19945202	chr12:2788847	CACNA1C	0.84	6.69	0.3	6.52e-11	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs6743226	0.870	rs4675966	chr2:242244342	T/C	cg10021735	chr2:242295487	FARP2	0.52	9.53	0.41	8.8e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg20887711	chr4:1340912	KIAA1530	0.47	8.18	0.36	2.73e-15	Obesity-related traits;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs28595532	0.641	rs72670213	chr4:119281608	G/T	cg21605333	chr4:119757512	SEC24D	0.82	7.55	0.33	2.26e-13	Cannabis dependence symptom count;
LGG	cis	rs6964587	0.934	rs2961019	chr7:91572749	T/G	cg17063962	chr7:91808500	NA	-0.49	-8.46	-0.37	3.45e-16	Breast cancer;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9987353	0.519	rs13276350	chr8:9063157	T/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.75	-0.3	4.38e-11	Recombination measurement;
LGG	cis	rs9462027	0.628	rs1998702	chr6:34741917	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.23	-0.46	4.95e-26	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	trans	rs1814175	0.765	rs1722003	chr11:49895896	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.42	-0.5	8.98e-31	Height;
LGG	cis	rs2404618	0.624	rs4457358	chr8:1477213	C/A	cg13402656	chr8:1511478	DLGAP2	-0.75	-13.99	-0.55	2.48e-37	Lung cancer;
LGG	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg06636001	chr8:8085503	FLJ10661	0.64	12.65	0.51	1.01e-31	Mood instability;
LGG	cis	rs477895	0.713	rs882146	chr11:63976699	G/A	cg04317338	chr11:64019027	PLCB3	0.67	8.25	0.36	1.66e-15	Mean platelet volume;
LGG	cis	rs7766436	0.885	rs765782	chr6:22592216	A/G	cg13666174	chr6:22585274	NA	-0.51	-12.0	-0.49	4.41e-29	Coronary artery disease;
LGG	cis	rs3806843	0.933	rs2879087	chr5:140188575	G/C	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs611744	0.967	rs608115	chr8:109231948	T/A	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.04e-11	Dupuytren's disease;
LGG	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg08648136	chr8:956695	NA	0.38	7.89	0.34	2.22e-14	Schizophrenia;
LGG	cis	rs3824867	0.881	rs4752829	chr11:47396654	G/A	cg20307385	chr11:47447363	PSMC3	-0.45	-7.04	-0.31	7.09e-12	Mean corpuscular hemoglobin;
LGG	cis	rs11885103	0.791	rs10197290	chr2:584872	A/G	cg21195176	chr2:593345	NA	0.39	7.41	0.33	6e-13	Heschl's gyrus morphology;
LGG	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg27129171	chr3:47204927	SETD2	-0.79	-14.11	-0.55	7.48e-38	Colorectal cancer;
LGG	cis	rs2742417	0.624	rs2742394	chr3:45757591	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.27	-0.4	7.09e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs611744	1.000	rs611744	chr8:109228008	A/G	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.04e-11	Dupuytren's disease;
LGG	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs1018836	0.828	rs2105968	chr8:91591825	A/G	cg16814680	chr8:91681699	NA	-0.76	-13.94	-0.54	4.07e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg11494091	chr17:61959527	GH2	-0.98	-23.14	-0.73	2.84e-79	Prudent dietary pattern;
LGG	cis	rs9308731	0.644	rs4849403	chr2:111874037	T/C	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.06	-0.31	5.98e-12	Chronic lymphocytic leukemia;
LGG	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.46	-0.44	3.91e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg07424592	chr7:64974309	NA	0.73	7.02	0.31	7.99e-12	Diabetic kidney disease;
LGG	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.42	-9.33	-0.4	4.3e-19	Multiple sclerosis;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.59	0.37	1.39e-16	Obesity-related traits;
LGG	cis	rs4740619	0.755	rs7860528	chr9:15795532	A/G	cg14451791	chr9:16040625	NA	0.31	7.77	0.34	4.98e-14	Body mass index;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg27476859	chr7:2772710	GNA12	0.43	7.33	0.32	1.03e-12	Height;
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.52e-27	Personality dimensions;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg05861140	chr6:150128134	PCMT1	-0.38	-8.38	-0.36	6.48e-16	Lung cancer;
LGG	cis	rs524281	0.692	rs2452681	chr11:65814842	G/A	cg16950941	chr11:66035639	RAB1B	0.44	7.05	0.31	6.63e-12	Electroencephalogram traits;
LGG	cis	rs62064224	0.614	rs4794921	chr17:30742310	C/T	cg18200150	chr17:30822561	MYO1D	0.49	9.33	0.4	4.51e-19	Schizophrenia;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg00290607	chr11:67383545	NA	-0.52	-9.26	-0.4	7.43e-19	Mean corpuscular volume;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg11473876	chr11:109292803	C11orf87	0.48	9.44	0.4	1.88e-19	Schizophrenia;
LGG	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.83	0.38	2.13e-17	Motion sickness;
LGG	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg09754948	chr16:28834200	ATXN2L	0.43	6.82	0.3	2.81e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg02972257	chr16:68554789	NA	0.62	9.08	0.39	3.15e-18	Plateletcrit;
LGG	cis	rs12738007	0.840	rs1565714	chr1:29574363	C/T	cg01115565	chr1:29584222	PTPRU	-0.34	-9.0	-0.39	5.81e-18	Schizophrenia;
LGG	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.08	0.57	4.41e-42	Cognitive test performance;
LGG	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24308560	chr3:49941425	MST1R	0.23	7.23	0.32	2.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2070488	0.775	rs6599207	chr3:38554901	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.31	-0.55	1.01e-38	Electrocardiographic conduction measures;
LGG	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg09818912	chr17:20140352	CYTSB	-0.31	-7.31	-0.32	1.16e-12	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21224049	chr4:668623	ATP5I	0.49	7.52	0.33	2.84e-13	Gut microbiome composition (summer);
LGG	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg07636037	chr3:49044803	WDR6	0.46	6.79	0.3	3.34e-11	Resting heart rate;
LGG	cis	rs7106204	0.609	rs75559464	chr11:24285585	C/T	ch.11.24196551F	chr11:24239977	NA	0.84	8.75	0.38	3.95e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3008870	0.583	rs11208985	chr1:67464666	G/A	cg11518657	chr1:67396239	MIER1	-0.49	-7.42	-0.33	5.51e-13	Lymphocyte percentage of white cells;
LGG	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.64	-0.51	1.15e-31	Bladder cancer;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg16141378	chr3:129829833	LOC729375	0.41	9.44	0.4	1.79e-19	Neuroticism;
LGG	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.52	-0.4	9.5e-20	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7818345	0.663	rs11786904	chr8:19327267	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.43	-0.4	2.05e-19	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg15268244	chr15:77196840	NA	0.48	10.17	0.43	4.51e-22	Blood metabolite levels;
LGG	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg10950924	chr17:47092072	IGF2BP1	0.51	10.19	0.43	3.79e-22	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs1927702	0.681	rs10756732	chr9:16009634	C/T	cg14451791	chr9:16040625	NA	0.28	6.87	0.3	2.11e-11	Body mass index;
LGG	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg00686598	chr14:53173677	PSMC6	1.4	15.42	0.58	1.33e-43	Alzheimer's disease (late onset);
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	cis	rs1519814	0.624	rs2176749	chr8:121032434	T/C	cg22335954	chr8:121166405	COL14A1	-0.48	-8.77	-0.38	3.52e-17	Breast cancer;
LGG	cis	rs1348850	0.554	rs1374438	chr2:178376684	A/G	cg27490568	chr2:178487706	NA	0.81	14.32	0.55	8.75e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2802728	1.000	rs4658395	chr1:243529105	A/G	cg05593162	chr1:243577377	SDCCAG8	0.5	6.91	0.31	1.57e-11	Toenail selenium levels;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg16301924	chr13:53314226	LECT1	-0.54	-11.57	-0.47	2.21e-27	Lewy body disease;
LGG	cis	rs7192380	1.000	rs2161630	chr16:69606461	C/T	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.5	-0.33	3.24e-13	Sjögren's syndrome;
LGG	cis	rs7584262	0.740	rs13401256	chr2:42245188	G/A	cg27428208	chr2:42229179	NA	0.47	7.49	0.33	3.54e-13	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17851730	chr1:19229128	ALDH4A1	0.5	7.69	0.34	9.02e-14	Gut microbiome composition (summer);
LGG	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.17	-0.36	2.87e-15	Total body bone mineral density;
LGG	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11634705	chr7:873449	UNC84A	0.45	8.16	0.35	3.22e-15	Subjective well-being;
LGG	cis	rs593982	0.920	rs521678	chr11:65485727	T/G	cg08755490	chr11:65554678	OVOL1	0.7	8.61	0.37	1.12e-16	Atopic dermatitis;
LGG	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.69	-13.53	-0.53	2.27e-35	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6500637	0.931	rs79338890	chr16:4905127	T/G	cg04440724	chr16:4920505	UBN1	-0.72	-16.38	-0.61	6.81e-48	Cancer;
LGG	cis	rs1577917	0.740	rs9344542	chr6:86393905	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	12.3	0.5	2.74e-30	Response to antipsychotic treatment;
LGG	cis	rs1983891	0.955	rs2025645	chr6:41519654	A/G	cg20194872	chr6:41519635	FOXP4	0.61	10.55	0.44	1.89e-23	Prostate cancer;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg02951883	chr7:2050386	MAD1L1	0.74	15.27	0.58	5.97e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs6594713	0.837	rs6887914	chr5:112711486	C/T	cg12552261	chr5:112820674	MCC	0.5	6.68	0.3	6.73e-11	Brain cytoarchitecture;
LGG	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg20891283	chr12:69753455	YEATS4	0.79	12.88	0.51	1.18e-32	Response to diuretic therapy;
LGG	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.61	0.37	1.18e-16	Educational attainment;
LGG	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg23601416	chr22:19950040	COMT	-0.47	-11.72	-0.48	6.03e-28	Blood metabolite levels;
LGG	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg10144569	chr3:42726640	KBTBD5	0.5	7.42	0.33	5.6e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.76	16.64	0.61	4.45e-49	Obesity-related traits;
LGG	trans	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.11e-13	Cognitive test performance;
LGG	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg15704280	chr7:45808275	SEPT13	0.78	9.04	0.39	4.28e-18	Axial length;
LGG	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg13271783	chr10:134563150	INPP5A	-0.55	-8.27	-0.36	1.39e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3742264	0.656	rs4941538	chr13:46586609	C/T	cg15192986	chr13:46630673	CPB2	-0.36	-6.97	-0.31	1.07e-11	Blood protein levels;
LGG	cis	rs17826219	0.706	rs9905827	chr17:29192168	C/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Body mass index;
LGG	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.93	0.52	7.23e-33	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.669	rs846800	chr6:101270498	C/G	cg09795085	chr6:101329169	ASCC3	0.46	7.55	0.33	2.4e-13	Neuroticism;
LGG	cis	rs975739	0.630	rs7332993	chr13:78517991	T/A	cg07847733	chr13:78271382	SLAIN1	0.4	6.93	0.31	1.46e-11	Hair color;
LGG	cis	rs9427116	0.702	rs9427109	chr1:154609009	A/G	cg11650704	chr1:154556575	ADAR	-0.44	-8.45	-0.37	3.84e-16	Blood protein levels;
LGG	cis	rs7074356	0.523	rs7087728	chr10:82033470	G/A	cg27171509	chr10:82033454	MAT1A	-0.41	-8.2	-0.36	2.34e-15	Borderline personality disorder;
LGG	cis	rs7122257	0.542	rs7120813	chr11:11151077	G/A	cg16931664	chr11:11169707	NA	-0.26	-7.59	-0.33	1.82e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg24060327	chr5:131705240	SLC22A5	0.45	6.83	0.3	2.68e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	9.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	12.54	0.5	3.07e-31	Obesity-related traits;
LGG	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.92	-0.42	3.79e-21	Triglycerides;
LGG	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.45	-7.1	-0.31	4.73e-12	Bipolar disorder;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26617929	chr16:1858877	NA	-0.61	-8.7	-0.37	5.94e-17	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04273556	chr9:35096672	PIGO	0.42	7.23	0.32	2e-12	Bipolar disorder;
LGG	cis	rs4862750	0.914	rs7658351	chr4:187875680	G/T	cg27532560	chr4:187881888	NA	-0.6	-13.27	-0.53	2.64e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6500395	1.000	rs12599744	chr16:48716729	G/A	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.56	-0.37	1.66e-16	Obesity-related traits;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.71	-0.54	3.65e-36	Tonsillectomy;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg09264619	chr17:80180166	NA	0.34	6.89	0.31	1.79e-11	Life satisfaction;
LGG	cis	rs7192750	0.586	rs8051038	chr16:71870700	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.28e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs8016982	0.662	rs9806020	chr14:81668555	A/C	cg01989461	chr14:81687754	GTF2A1	0.53	8.23	0.36	1.94e-15	Schizophrenia;
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs4481887	0.741	rs11488133	chr1:248548380	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-6.99	-0.31	9.84e-12	Common traits (Other);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23106865	chr7:142374345	NA	0.34	6.68	0.3	6.97e-11	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg26174226	chr8:58114915	NA	0.59	8.56	0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg10483660	chr13:112241077	NA	-0.35	-7.69	-0.34	8.78e-14	Hepatitis;
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg13264159	chr8:625131	ERICH1	-0.99	-11.18	-0.46	7.37e-26	IgG glycosylation;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg03351412	chr1:154909251	PMVK	0.67	12.98	0.52	4.41e-33	Prostate cancer;
LGG	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg08975724	chr8:8085496	FLJ10661	-0.35	-6.83	-0.3	2.66e-11	Joint mobility (Beighton score);
LGG	trans	rs7819412	0.617	rs10087081	chr8:10974917	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.01	-0.35	9.53e-15	Triglycerides;
LGG	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg05555928	chr11:63887634	MACROD1	0.58	11.23	0.46	5e-26	Platelet count;
LGG	cis	rs2439831	0.850	rs12441861	chr15:44060883	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.8	8.62	0.37	1.06e-16	Lung cancer in ever smokers;
LGG	cis	rs7255436	0.965	rs11666233	chr19:8452045	G/T	cg10811474	chr19:8428787	ANGPTL4	-0.37	-6.67	-0.3	7.32e-11	HDL cholesterol;
LGG	cis	rs62244186	0.566	rs55901755	chr3:44834707	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	7.91	0.35	1.9e-14	Depressive symptoms;
LGG	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg13560919	chr6:33536144	NA	0.42	7.85	0.34	2.9e-14	Crohn's disease;
LGG	cis	rs4319547	0.688	rs10847415	chr12:123144293	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-9.11	-0.39	2.5e-18	Body mass index;
LGG	cis	rs943466	0.666	rs11755421	chr6:33715323	G/A	cg07519485	chr6:33762594	MLN	0.49	8.46	0.37	3.53e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg09537434	chr19:41945824	ATP5SL	-0.86	-21.64	-0.71	2.95e-72	Height;
LGG	cis	rs9916302	0.555	rs12940193	chr17:37652178	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.86	-0.59	1.49e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg23461800	chr14:103021989	NA	0.47	7.06	0.31	6.3e-12	Platelet count;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg11584989	chr19:19387371	SF4	-0.39	-6.98	-0.31	1.05e-11	Tonsillectomy;
LGG	cis	rs6909430	0.901	rs2502932	chr6:98554881	A/G	cg12860156	chr6:98744658	NA	-0.43	-7.17	-0.32	3.08e-12	Quantitative traits;
LGG	cis	rs17270561	0.609	rs1892246	chr6:25764408	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.14e-11	Iron status biomarkers;
LGG	trans	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.23	-0.36	1.91e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg17330251	chr7:94953956	PON1	0.4	7.84	0.34	3.11e-14	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs9354308	0.764	rs9294661	chr6:66595971	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08564027	chr20:61660810	NA	1.0	21.85	0.71	3.02e-73	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4262150	0.883	rs17488630	chr5:152244165	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.09	-0.49	1.96e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg04691961	chr3:161091175	C3orf57	-0.63	-14.81	-0.57	6.37e-41	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.89	-0.45	9.97e-25	Hemoglobin concentration;
LGG	cis	rs4911259	0.552	rs6058926	chr20:31465450	T/C	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.67	-0.48	8.79e-28	Inflammatory bowel disease;
LGG	cis	rs2070488	1.000	rs6772046	chr3:38479660	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.67	0.63	8.75e-54	Electrocardiographic conduction measures;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.36	-0.36	7.24e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs6601327	0.606	rs4841203	chr8:9582730	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.1	0.35	5.07e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.36	-7.86	-0.34	2.79e-14	Restless legs syndrome;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08811588	chr7:100473311	SRRT	-0.48	-6.93	-0.31	1.42e-11	Systemic lupus erythematosus;
LGG	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg16262614	chr3:133464971	TF	0.47	8.76	0.38	3.81e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.31	6.66e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9397585	0.598	rs11155893	chr6:153404237	C/A	cg17707550	chr6:153380415	RGS17	-0.47	-10.36	-0.43	9.25e-23	Body mass index;
LGG	cis	rs59918340	0.728	rs59172574	chr8:142231945	C/G	cg23750338	chr8:142222470	SLC45A4	0.59	12.3	0.5	2.81e-30	Immature fraction of reticulocytes;
LGG	cis	rs4262150	0.883	rs72802893	chr5:152256185	A/G	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg25600027	chr14:23388339	RBM23	-0.45	-7.34	-0.32	1e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs80282103	0.571	rs10047269	chr10:1103058	G/A	cg08668510	chr10:1095578	IDI1	0.76	7.72	0.34	6.99e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs1620921	0.625	rs2489958	chr6:161261109	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs9811920	0.638	rs796977	chr3:99549723	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-8.7	-0.37	5.83e-17	Axial length;
LGG	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg18252515	chr7:66147081	NA	1.25	17.01	0.62	8.93e-51	Diabetic kidney disease;
LGG	cis	rs62238980	0.614	rs80217052	chr22:32413767	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.59	-0.33	1.72e-13	Prostate cancer;
LGG	cis	rs62400317	0.793	rs6924185	chr6:45017228	C/A	cg18551225	chr6:44695536	NA	-0.63	-10.21	-0.43	3.18e-22	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.87	-0.34	2.48e-14	Obesity-related traits;
LGG	cis	rs11971779	0.715	rs10954646	chr7:139061069	C/G	cg07862535	chr7:139043722	LUC7L2	-0.43	-7.31	-0.32	1.15e-12	Diisocyanate-induced asthma;
LGG	cis	rs11711311	1.000	rs9854504	chr3:113532381	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.0	-0.35	1.02e-14	IgG glycosylation;
LGG	cis	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg12826209	chr6:26865740	GUSBL1	-0.75	-7.95	-0.35	1.45e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4356975	0.563	rs5013211	chr4:69972777	G/A	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs9796	0.689	rs11855797	chr15:41434679	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.79	-0.41	1.1e-20	Menopause (age at onset);
LGG	cis	rs7586879	0.789	rs13382979	chr2:25131736	G/A	cg04586622	chr2:25135609	ADCY3	0.39	9.54	0.41	8.22e-20	Body mass index;
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.14	-0.43	6.1e-22	Total body bone mineral density;
LGG	cis	rs4740619	0.669	rs62571268	chr9:15759446	G/C	cg14451791	chr9:16040625	NA	0.35	8.9	0.38	1.3e-17	Body mass index;
LGG	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs9807989	0.524	rs6759479	chr2:103040047	A/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs422249	0.819	rs174608	chr11:61627484	A/G	cg19610905	chr11:61596333	FADS2	-0.54	-7.82	-0.34	3.58e-14	Trans fatty acid levels;
LGG	trans	rs1814175	0.817	rs7932683	chr11:49983640	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.46	-0.5	5.94e-31	Height;
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg11878867	chr6:150167359	LRP11	0.48	8.16	0.35	3.15e-15	Lung cancer;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07362569	chr17:61921086	SMARCD2	0.48	9.32	0.4	4.82e-19	Prudent dietary pattern;
LGG	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	10.56	0.44	1.64e-23	Lung cancer in ever smokers;
LGG	cis	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	trans	rs7613875	0.620	rs17657688	chr3:50033228	C/T	cg21659725	chr3:3221576	CRBN	-0.53	-9.31	-0.4	5.17e-19	Body mass index;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.82	-0.3	2.85e-11	Menopause (age at onset);
LGG	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg20503657	chr10:835505	NA	0.95	13.02	0.52	3.16e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs988958	0.566	rs7599890	chr2:42247958	A/G	cg19376973	chr2:42229025	NA	0.63	9.83	0.42	7.49e-21	Hypospadias;
LGG	cis	rs12144309	0.554	rs1217375	chr1:114346904	G/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.35	6.92	0.31	1.54e-11	Coronary artery disease;
LGG	trans	rs9929218	0.529	rs8059194	chr16:68749663	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	25.04	0.76	4.09e-88	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg13385521	chr17:29058706	SUZ12P	0.81	9.61	0.41	4.62e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6540556	0.608	rs2064148	chr1:209909385	C/T	cg23920097	chr1:209922102	NA	0.41	7.47	0.33	3.91e-13	Red blood cell count;
LGG	cis	rs6920372	0.692	rs11153216	chr6:110070022	G/A	cg01125227	chr6:109776195	MICAL1	0.43	7.53	0.33	2.69e-13	Height;
LGG	cis	rs10237118	0.915	rs6980049	chr7:140228727	T/A	cg09787580	chr7:140227335	DENND2A	0.7	9.09	0.39	2.83e-18	Optic nerve measurement (cup area);
LGG	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg14088196	chr11:70211408	PPFIA1	0.92	12.98	0.52	4.42e-33	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg14228332	chr4:119757509	SEC24D	0.99	10.14	0.43	6.09e-22	Cannabis dependence symptom count;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg04025307	chr7:1156635	C7orf50	0.77	16.13	0.6	8.7e-47	Longevity;Endometriosis;
LGG	cis	rs774359	0.789	rs2492815	chr9:27490296	T/C	cg14173147	chr9:27528300	MOBKL2B	0.46	8.68	0.37	6.96e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs9905704	0.647	rs11659035	chr17:56966052	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-6.78	-0.3	3.59e-11	Testicular germ cell tumor;
LGG	cis	rs27434	0.529	rs34757	chr5:96152588	T/C	cg16492584	chr5:96139282	ERAP1	-0.34	-6.76	-0.3	4.22e-11	Ankylosing spondylitis;
LGG	cis	rs2050392	1.000	rs2489864	chr10:30693744	C/G	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.56	-0.44	1.74e-23	Inflammatory bowel disease;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg04234412	chr22:24373322	LOC391322	-0.73	-14.66	-0.56	2.96e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1693575	0.624	rs2978102	chr8:101679411	A/G	cg06874326	chr8:101662790	SNX31	-0.37	-7.3	-0.32	1.24e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg13259177	chr13:114761607	RASA3	-0.78	-10.98	-0.45	4.44e-25	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05926928	chr17:57297772	GDPD1	1.36	21.78	0.71	6.66e-73	Opioid sensitivity;
LGG	cis	rs7071206	0.947	rs1356090	chr10:79395312	T/C	cg07817648	chr10:79422355	NA	-0.76	-13.91	-0.54	5.42e-37	Bone mineral density;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs9318086	0.687	rs9507182	chr13:24442365	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.57	0.41	6.55e-20	Myopia (pathological);
LGG	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.41	0.44	6.18e-23	Diabetic retinopathy;
LGG	cis	rs4838594	0.537	rs3896665	chr10:49689413	A/G	cg17291251	chr10:49678358	ARHGAP22	0.41	7.91	0.35	1.88e-14	Daytime sleep phenotypes;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg26174226	chr8:58114915	NA	-0.5	-7.43	-0.33	5.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs883115	0.810	rs7516323	chr1:224785960	C/G	cg01808320	chr1:224927238	CNIH3	-0.41	-7.51	-0.33	3.07e-13	Cancer;
LGG	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg03735888	chr19:58951602	ZNF132	0.41	8.23	0.36	1.94e-15	Uric acid clearance;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9323205	0.954	rs7150336	chr14:51584596	A/T	cg23942311	chr14:51606299	NA	-0.38	-6.74	-0.3	4.72e-11	Cancer;
LGG	cis	rs1691799	0.836	rs1184552	chr12:66756215	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.5	-0.58	5.76e-44	White blood cell count (basophil);
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.01	-0.6	3.01e-46	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12972275	chr4:122722461	EXOSC9	0.44	7.32	0.32	1.1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7572644	0.699	rs4233719	chr2:28079344	C/A	cg27432699	chr2:27873401	GPN1	0.46	6.98	0.31	1.04e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg24110177	chr3:50126178	RBM5	0.4	6.83	0.3	2.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg05368731	chr17:41323189	NBR1	0.94	18.68	0.66	1.98e-58	Menopause (age at onset);
LGG	cis	rs7727544	0.735	rs274568	chr5:131713578	C/T	cg07395648	chr5:131743802	NA	0.56	13.27	0.53	2.68e-34	Blood metabolite levels;
LGG	cis	rs7614311	0.689	rs2276863	chr3:63849043	C/A	cg22134162	chr3:63841271	THOC7	-0.45	-7.88	-0.34	2.43e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs11690935	0.549	rs2129475	chr2:172916772	A/G	cg13550731	chr2:172543902	DYNC1I2	0.68	13.28	0.53	2.43e-34	Schizophrenia;
LGG	cis	rs7849585	0.898	rs67827752	chr9:139137204	G/A	cg14094347	chr9:139131620	QSOX2	0.47	10.06	0.42	1.18e-21	Height;
LGG	cis	rs3849046	0.619	rs181919	chr5:137882612	A/G	cg10920316	chr5:137946599	NA	0.45	7.38	0.32	7.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg23782820	chr8:58130467	NA	0.56	8.33	0.36	9.09e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.818	rs441229	chr1:153015059	A/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.87	-0.38	1.58e-17	Inflammatory skin disease;
LGG	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.66	-0.3	7.81e-11	Aortic root size;
LGG	cis	rs1707322	1.000	rs785480	chr1:46492164	C/G	cg03146154	chr1:46216737	IPP	0.54	10.06	0.42	1.16e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg16797656	chr11:68205561	LRP5	0.52	10.0	0.42	1.96e-21	Total body bone mineral density;
LGG	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg12893428	chr3:195717962	SDHAP1	0.48	10.0	0.42	1.96e-21	Pancreatic cancer;
LGG	cis	rs7727544	0.684	rs611084	chr5:131709739	A/C	cg07395648	chr5:131743802	NA	0.56	13.07	0.52	1.81e-33	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.6	-0.37	1.26e-16	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03270376	chr2:219536588	RNF25;STK36	0.43	6.96	0.31	1.14e-11	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs883565	0.569	rs784514	chr3:39164622	A/G	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg14784868	chr12:69753453	YEATS4	0.69	10.87	0.45	1.11e-24	Response to diuretic therapy;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.51	-0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2033908	0.620	rs1440271	chr11:12852068	A/G	cg25843174	chr11:12811716	TEAD1	-0.35	-7.3	-0.32	1.22e-12	Sitting height ratio;
LGG	cis	rs2617583	0.967	rs2550946	chr5:1450513	A/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-7.36	-0.32	8.68e-13	Breast cancer;
LGG	cis	rs34929064	1.000	rs12700385	chr7:22732038	C/T	cg18045685	chr7:22629474	NA	0.55	8.74	0.38	4.29e-17	Major depression and alcohol dependence;
LGG	cis	rs2274273	0.712	rs17832311	chr14:55534466	A/G	cg04306507	chr14:55594613	LGALS3	0.44	10.9	0.45	8.85e-25	Protein biomarker;
LGG	cis	rs7020830	0.931	rs7027473	chr9:37132462	A/G	cg14294708	chr9:37120828	ZCCHC7	1.2	35.67	0.86	6.15e-135	Schizophrenia;
LGG	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-17.01	-0.62	9.29e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg03709012	chr19:19516395	GATAD2A	-0.58	-9.8	-0.41	9.94e-21	Tonsillectomy;
LGG	cis	rs7503807	0.688	rs901061	chr17:78595328	G/C	cg06872548	chr17:78716983	RPTOR	0.39	8.56	0.37	1.65e-16	Obesity;
LGG	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg09165964	chr15:75287851	SCAMP5	0.59	11.04	0.46	2.59e-25	Breast cancer;
LGG	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg25809561	chr17:30822961	MYO1D	0.39	9.49	0.4	1.18e-19	Schizophrenia;
LGG	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	5.22e-27	Bone mineral density;
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.85	-17.87	-0.64	1.04e-54	Age at first birth;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09133386	chr6:20404188	E2F3	0.49	7.67	0.34	1.06e-13	Gut microbiome composition (summer);
LGG	cis	rs3126085	0.935	rs2291770	chr1:152179792	G/C	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	trans	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs6960043	0.743	rs1002061	chr7:15039499	A/T	cg19272540	chr7:15055459	NA	-0.31	-6.93	-0.31	1.44e-11	Type 2 diabetes;
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg08355456	chr11:67383691	NA	-0.42	-6.98	-0.31	1.03e-11	Mean corpuscular volume;
LGG	cis	rs28595532	0.702	rs72670256	chr4:119391043	G/A	cg21605333	chr4:119757512	SEC24D	0.99	10.05	0.42	1.22e-21	Cannabis dependence symptom count;
LGG	cis	rs11203032	0.831	rs4078488	chr10:90966546	C/T	cg16672925	chr10:90967113	CH25H	0.84	11.48	0.47	5.18e-27	Heart failure;
LGG	cis	rs68170813	0.559	rs74898466	chr7:107053998	C/A	cg02696742	chr7:106810147	HBP1	-0.69	-9.65	-0.41	3.43e-20	Coronary artery disease;
LGG	cis	rs2040771	0.770	rs9605962	chr22:19233615	C/T	cg02655711	chr22:19163373	SLC25A1	0.46	8.08	0.35	5.6e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	0.39	10.2	0.43	3.49e-22	IgG glycosylation;
LGG	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg15557168	chr22:42548783	NA	-0.4	-8.64	-0.37	9.24e-17	Schizophrenia;
LGG	cis	rs9815354	0.627	rs80120812	chr3:42021760	C/T	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2346177	0.580	rs1530628	chr2:46670941	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-13.42	-0.53	6.44e-35	HDL cholesterol;
LGG	cis	rs7582720	0.725	rs72934725	chr2:203725983	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg23029597	chr12:123009494	RSRC2	0.92	18.56	0.65	7.08e-58	Body mass index;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.03	0.42	1.47e-21	Rheumatoid arthritis;
LGG	cis	rs17453880	0.929	rs4487479	chr5:152008600	C/G	cg12297329	chr5:152029980	NA	-0.86	-21.95	-0.71	1.06e-73	Subjective well-being;
LGG	trans	rs6575793	0.512	rs1888581	chr14:101042715	A/C	cg22806444	chr17:72968764	C17orf28	0.49	8.07	0.35	5.89e-15	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg11494091	chr17:61959527	GH2	0.51	8.27	0.36	1.4e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg24623649	chr8:11872141	NA	0.3	6.96	0.31	1.19e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.85	0.38	1.93e-17	Neuroticism;
LGG	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs7011049	1.000	rs72640865	chr8:53842471	C/T	cg26025543	chr8:53854495	NA	0.75	9.96	0.42	2.66e-21	Systolic blood pressure;
LGG	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.92	-0.31	1.52e-11	Joint mobility (Beighton score);
LGG	cis	rs1451375	0.785	rs6593010	chr7:50629888	A/G	cg20336341	chr7:50628841	DDC	0.38	7.29	0.32	1.4e-12	Malaria;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg23034840	chr1:205782522	SLC41A1	0.56	9.09	0.39	2.82e-18	Menarche (age at onset);
LGG	cis	rs3784262	0.904	rs4646620	chr15:58258241	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.29	-0.36	1.25e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4742903	0.904	rs12380062	chr9:106941903	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4950322	0.518	rs4950305	chr1:146589293	C/A	cg22381352	chr1:146742008	CHD1L	-0.41	-7.1	-0.31	4.59e-12	Protein quantitative trait loci;
LGG	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg03806693	chr22:41940476	POLR3H	0.9	14.9	0.57	2.59e-41	Vitiligo;
LGG	cis	rs6901004	0.935	rs1150078	chr6:111560301	C/T	cg15721981	chr6:111408429	SLC16A10	0.42	7.54	0.33	2.45e-13	Blood metabolite levels;
LGG	trans	rs11039798	0.841	rs11039760	chr11:48479009	C/T	cg15704280	chr7:45808275	SEPT13	0.75	7.92	0.35	1.76e-14	Axial length;
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg18479299	chr3:125709523	NA	-0.6	-7.73	-0.34	6.6e-14	Blood pressure (smoking interaction);
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg07747251	chr5:1868357	NA	0.47	9.44	0.4	1.8e-19	Cardiovascular disease risk factors;
LGG	cis	rs2213920	0.568	rs6478166	chr9:118213548	T/C	cg13918206	chr9:118159781	DEC1	0.61	8.65	0.37	8.63e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg08621203	chr6:150244597	RAET1G	0.41	6.92	0.31	1.51e-11	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07077115	chr13:28024429	MTIF3	0.48	7.5	0.33	3.37e-13	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.61	-0.44	1.12e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg03469862	chr11:68924853	NA	0.45	6.83	0.3	2.76e-11	Blond vs. brown hair color;
LGG	cis	rs45544231	0.569	rs1362550	chr16:52582816	C/G	cg09051775	chr16:52580266	TOX3	-0.46	-7.92	-0.35	1.83e-14	Restless legs syndrome;
LGG	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-7.04	-0.31	6.77e-12	Inflammatory bowel disease;
LGG	cis	rs17401966	0.867	rs7546364	chr1:10418815	G/A	cg15208524	chr1:10270712	KIF1B	0.42	7.22	0.32	2.12e-12	Hepatocellular carcinoma;
LGG	cis	rs8072100	0.967	rs7221548	chr17:45582952	T/C	cg19784903	chr17:45786737	TBKBP1	0.36	8.0	0.35	1.02e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1577917	0.876	rs12201992	chr6:86618219	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.15	-0.52	8.96e-34	Response to antipsychotic treatment;
LGG	cis	rs7312933	1.000	rs11181328	chr12:42504679	T/G	cg19980929	chr12:42632907	YAF2	0.34	7.65	0.34	1.16e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg18225595	chr11:63971243	STIP1	0.62	11.96	0.49	6.68e-29	Platelet count;
LGG	cis	rs17253792	0.822	rs79747476	chr14:56160485	C/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.06	-0.49	2.49e-29	Putamen volume;
LGG	trans	rs75804782	0.630	rs75921156	chr2:239279633	C/T	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.37e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg13628971	chr7:2884303	GNA12	0.37	7.67	0.34	1.03e-13	Height;
LGG	cis	rs4129767	0.647	rs1976703	chr17:76401328	C/T	cg20026190	chr17:76395443	PGS1	0.42	7.27	0.32	1.55e-12	HDL cholesterol;
LGG	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg06138931	chr13:21896616	NA	-0.45	-7.34	-0.32	9.35e-13	White matter hyperintensity burden;
LGG	cis	rs12618769	0.597	rs17031139	chr2:99036530	A/G	cg18455616	chr2:99124870	INPP4A	-0.29	-8.55	-0.37	1.87e-16	Bipolar disorder;
LGG	trans	rs853679	0.666	rs200956	chr6:27839746	A/G	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.06	-0.31	6.23e-12	Depression;
LGG	cis	rs858239	0.730	rs858289	chr7:23248158	C/T	cg23682824	chr7:23144976	KLHL7	0.4	6.85	0.3	2.29e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6740322	0.895	rs6738717	chr2:43573670	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-9.87	-0.42	5.74e-21	Coronary artery disease;
LGG	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg12591125	chr7:1885375	MAD1L1	-0.44	-7.1	-0.31	4.79e-12	Bipolar disorder;
LGG	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg02002194	chr4:3960332	NA	0.41	7.49	0.33	3.41e-13	Morning vs. evening chronotype;
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg03517284	chr6:25882590	NA	-0.41	-7.34	-0.32	9.36e-13	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05484393	chr3:170587694	RPL22L1	0.43	6.98	0.31	1.05e-11	Cognitive performance;
LGG	cis	rs7444	0.941	rs140491	chr22:21922364	T/C	cg22858872	chr22:21984481	YDJC	-0.36	-6.72	-0.3	5.51e-11	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-12.05	-0.49	2.72e-29	Vitiligo;
LGG	trans	rs877282	0.947	rs957642	chr10:773966	C/T	cg22713356	chr15:30763199	NA	0.56	8.62	0.37	1.09e-16	Uric acid levels;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.603	rs4994101	chr7:19939660	C/G	cg05791153	chr7:19748676	TWISTNB	0.53	6.86	0.3	2.19e-11	Night sleep phenotypes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18715511	chr12:1058965	RAD52	0.45	7.17	0.32	2.89e-12	Cognitive performance;
LGG	trans	rs6787172	0.622	rs55964653	chr3:158093666	G/A	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	cis	rs12476592	0.602	rs1446564	chr2:63731682	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.65	-0.33	1.2e-13	Height;
LGG	cis	rs12210905	1.000	rs12196889	chr6:27156095	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.46	-0.33	4.21e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2777491	0.574	rs2730056	chr15:41735785	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.66	-0.84	1.63e-126	Ulcerative colitis;
LGG	cis	rs8064299	0.655	rs895691	chr17:72766300	G/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.49	8.71	0.38	5.38e-17	Monocyte count;
LGG	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-8.11	-0.35	4.69e-15	Self-reported allergy;
LGG	cis	rs2421770	0.532	rs2273688	chr11:35338743	C/T	cg10331829	chr11:35343789	SLC1A2	0.34	7.68	0.34	9.62e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	7.74	0.34	6.13e-14	Lung function (FEV1/FVC);
LGG	cis	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg05084668	chr3:125655381	ALG1L	-0.91	-11.1	-0.46	1.47e-25	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.27	-0.4	6.87e-19	Life satisfaction;
LGG	cis	rs4356203	0.905	rs7946010	chr11:17176057	G/A	cg15432903	chr11:17409602	KCNJ11	0.39	7.29	0.32	1.33e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.09e-12	Life satisfaction;
LGG	cis	rs17453880	0.929	rs10056328	chr5:152024369	C/G	cg10931792	chr5:152022470	NA	-0.4	-8.74	-0.38	4.34e-17	Subjective well-being;
LGG	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Neuroticism;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg08200770	chr17:80723486	TBCD	-0.43	-8.6	-0.37	1.28e-16	Glycated hemoglobin levels;
LGG	cis	rs4631830	0.900	rs10763534	chr10:51534920	C/T	cg10326726	chr10:51549505	MSMB	-0.69	-14.31	-0.55	1.02e-38	Prostate-specific antigen levels;
LGG	cis	rs7267979	0.932	rs417110	chr20:25458297	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.1	0.42	8.35e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs7932354	0.528	rs2018527	chr11:47175809	A/G	cg03339077	chr11:47165057	C11orf49	0.55	10.58	0.44	1.4e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg27165867	chr14:105738592	BRF1	0.44	7.27	0.32	1.56e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.5	0.4	1.15e-19	Diabetic retinopathy;
LGG	cis	rs9814567	0.752	rs6779294	chr3:134329821	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.6	-0.44	1.2e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg06219351	chr7:158114137	PTPRN2	-0.74	-14.53	-0.56	1.14e-39	Calcium levels;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg21724239	chr8:58056113	NA	0.56	8.44	0.37	4.08e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1475911	0.947	rs67055914	chr21:43510427	T/C	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.44	-8.01	-0.35	9.06e-15	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	10.04	0.42	1.33e-21	Bipolar disorder;
LGG	cis	rs1010254	0.510	rs72808338	chr5:151755461	C/T	cg12297329	chr5:152029980	NA	-0.48	-6.82	-0.3	2.83e-11	Optic nerve measurement (cup area);
LGG	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg17809284	chr5:56205270	C5orf35	0.68	10.84	0.45	1.47e-24	Initial pursuit acceleration;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.62	-10.26	-0.43	2.1e-22	Urate levels;
LGG	cis	rs758324	0.755	rs2221674	chr5:131242218	T/A	cg06307176	chr5:131281290	NA	-0.53	-8.73	-0.38	4.52e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs922107	0.967	rs6428555	chr1:90010388	A/C	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.55	-0.33	2.37e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs7666738	0.753	rs13122897	chr4:98936185	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9964724	0.507	rs80035064	chr18:35146366	T/A	cg27332583	chr18:35150602	NA	0.64	12.51	0.5	4.06e-31	Educational attainment (years of education);
LGG	cis	rs1568889	0.838	rs11030185	chr11:28041904	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.44	0.67	5.82e-62	Bipolar disorder;
LGG	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19748678	chr4:122722346	EXOSC9	-0.43	-7.6	-0.33	1.7e-13	Type 2 diabetes;
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg04553112	chr3:125709451	NA	-0.53	-6.65	-0.3	8.15e-11	Blood pressure (smoking interaction);
LGG	cis	rs6500395	0.588	rs3826176	chr16:48589062	A/G	cg04672837	chr16:48644449	N4BP1	0.5	8.5	0.37	2.62e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6028335	0.808	rs68006880	chr20:37720421	C/T	cg16355469	chr20:37678765	NA	0.55	7.06	0.31	6.08e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg19729930	chr2:74357872	NA	0.54	11.55	0.47	2.67e-27	Gestational age at birth (maternal effect);
LGG	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg07636037	chr3:49044803	WDR6	0.77	13.6	0.53	1.13e-35	Menarche (age at onset);
LGG	cis	rs643506	0.817	rs658373	chr11:111682991	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.89	0.31	1.81e-11	Breast cancer;
LGG	cis	rs858239	0.600	rs4321896	chr7:23128056	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.36	0.32	8.28e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg10281770	chr17:80606947	WDR45L	0.59	10.65	0.44	7.66e-24	Breast cancer;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg00424166	chr6:150045504	NUP43	0.34	7.03	0.31	7.48e-12	Lung cancer;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg11235426	chr6:292522	DUSP22	-0.44	-7.44	-0.33	4.96e-13	Menopause (age at onset);
LGG	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.6	-0.47	1.81e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-11.02	-0.46	3.14e-25	Coronary artery disease;
LGG	trans	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg21775007	chr8:11205619	TDH	0.45	7.53	0.33	2.73e-13	Mood instability;
LGG	cis	rs2180341	0.960	rs7745944	chr6:127709574	A/G	cg27446573	chr6:127587934	RNF146	1.13	22.27	0.72	3.21e-75	Breast cancer;
LGG	cis	rs1021993	0.545	rs74155473	chr1:209545863	A/G	cg24446417	chr1:209558027	NA	-0.74	-10.97	-0.45	4.81e-25	Gut microbiome composition (winter);
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg14123153	chr12:6602654	NCAPD2;MRPL51	-0.43	-6.9	-0.31	1.66e-11	Height;
LGG	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg00717180	chr2:96193071	NA	0.42	7.44	0.33	4.97e-13	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.98	0.45	4.32e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03810516	chr4:655893	PDE6B	0.37	6.73	0.3	5.15e-11	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27460715	chr7:73668680	RFC2	0.49	7.25	0.32	1.79e-12	Gut microbiome composition (summer);
LGG	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.15e-12	HDL cholesterol;
LGG	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg20587970	chr11:113659929	NA	-1.07	-16.46	-0.61	3.01e-48	Hip circumference adjusted for BMI;
LGG	cis	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg09307838	chr4:120376055	NA	0.48	7.87	0.34	2.58e-14	Diastolic blood pressure;
LGG	cis	rs12477438	0.520	rs13035311	chr2:99717322	C/G	cg08885076	chr2:99613938	TSGA10	0.43	9.25	0.39	8.23e-19	Chronic sinus infection;
LGG	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.43	-8.02	-0.35	8.61e-15	Chronic sinus infection;
LGG	cis	rs17767392	0.846	rs12884929	chr14:71788946	C/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.0	0.35	1.02e-14	Mitral valve prolapse;
LGG	cis	rs5769765	0.954	rs1569954	chr22:50244071	C/T	cg02269571	chr22:50332266	NA	0.62	9.97	0.42	2.53e-21	Schizophrenia;
LGG	cis	rs7666738	0.830	rs62318472	chr4:98926030	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg12856521	chr11:46389249	DGKZ	0.9	14.78	0.57	9.34e-41	Crohn's disease;
LGG	cis	rs6912958	0.500	rs4706287	chr6:87806496	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-9.89	-0.42	4.58e-21	Monocyte percentage of white cells;
LGG	cis	rs11785693	0.817	rs62491199	chr8:4997878	G/A	cg26367366	chr8:4980734	NA	1.02	15.11	0.57	3.12e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs965469	0.553	rs6051767	chr20:3324521	C/T	cg25506879	chr20:3388711	C20orf194	-0.46	-7.53	-0.33	2.66e-13	IFN-related cytopenia;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg22398616	chr13:53314203	LECT1	-0.45	-9.3	-0.4	5.62e-19	Lewy body disease;
LGG	trans	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg26174226	chr8:58114915	NA	-0.57	-7.77	-0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.56	-0.59	3.2e-44	Skin colour saturation;
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.45	-0.33	4.64e-13	Neuroticism;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg00761968	chr13:53314142	LECT1	-0.37	-7.98	-0.35	1.18e-14	Lewy body disease;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.77	-0.34	5.05e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6489882	0.867	rs7306205	chr12:113366899	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.41	-0.33	5.98e-13	Chronic lymphocytic leukemia;
LGG	cis	rs754423	0.515	rs10150755	chr14:52545019	T/C	cg12071775	chr14:52591786	NA	-0.43	-7.11	-0.31	4.55e-12	Craniofacial microsomia;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-9.31	-0.4	5.12e-19	Schizophrenia;
LGG	cis	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs7216064	0.953	rs2086744	chr17:65849275	C/G	cg12091567	chr17:66097778	LOC651250	-0.59	-8.69	-0.37	6.45e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.06	-0.35	6.72e-15	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg11494091	chr17:61959527	GH2	0.5	7.91	0.34	1.93e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	1.000	rs9977571	chr21:43624157	G/A	cg08841829	chr21:43638893	ABCG1	-0.59	-7.95	-0.35	1.47e-14	Eating disorder in bipolar disorder;
LGG	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.02	-0.46	3.08e-25	Migraine;Coronary artery disease;
LGG	cis	rs6988985	0.678	rs28710914	chr8:144003290	A/G	cg10324643	chr8:143916377	GML	0.48	10.18	0.43	4.11e-22	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03837627	chr17:28443756	CCDC55;MIR423	0.46	7.51	0.33	3.17e-13	Cognitive performance;
LGG	cis	rs7523273	0.526	rs3849274	chr1:208021557	T/A	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.97	-0.49	5.93e-29	Schizophrenia;
LGG	cis	rs1665650	0.834	rs4752003	chr10:118472715	T/C	cg14919929	chr10:118506882	NA	-0.45	-7.22	-0.32	2.14e-12	Colorectal cancer;
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg15394860	chr11:2017084	H19	0.63	13.87	0.54	7.66e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs42648	0.935	rs42635	chr7:89966198	T/A	cg25739043	chr7:89950458	NA	-0.43	-9.02	-0.39	4.9e-18	Homocysteine levels;
LGG	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg26597838	chr10:835615	NA	0.64	8.72	0.38	5.08e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg18279126	chr7:2041391	MAD1L1	-0.32	-6.69	-0.3	6.53e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs473651	0.935	rs559579	chr2:239339501	G/C	cg18131467	chr2:239335373	ASB1	0.88	15.69	0.59	8.54e-45	Multiple system atrophy;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg08888203	chr3:10149979	C3orf24	0.53	8.96	0.38	7.82e-18	Alzheimer's disease;
LGG	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.21	0.32	2.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs9399135	0.967	rs1590975	chr6:135352088	C/T	cg24558204	chr6:135376177	HBS1L	0.51	9.43	0.4	1.93e-19	Red blood cell count;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg15942142	chr2:201374895	KCTD18	-0.4	-7.27	-0.32	1.56e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg05425664	chr17:57184151	TRIM37	-0.43	-6.92	-0.31	1.56e-11	Testicular germ cell tumor;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.21	0.46	5.62e-26	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	trans	rs11098499	0.575	rs907205	chr4:120238664	G/C	cg25214090	chr10:38739885	LOC399744	0.61	10.98	0.45	4.23e-25	Corneal astigmatism;
LGG	cis	rs2439831	0.717	rs9806227	chr15:43680115	C/T	cg15269541	chr15:43626905	ADAL	-0.45	-7.72	-0.34	7.09e-14	Lung cancer in ever smokers;
LGG	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.52	0.44	2.44e-23	Aortic root size;
LGG	cis	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	8.44	0.37	4.04e-16	Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.03e-11	Aortic root size;
LGG	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg22980697	chr10:16874865	CUBN	0.61	9.94	0.42	3.12e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9947295	0.649	rs11872939	chr18:11782521	G/A	cg14735704	chr18:11749182	GNAL	0.48	7.35	0.32	8.78e-13	QT interval (drug interaction);
LGG	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.41	6.85	0.3	2.36e-11	Cognitive test performance;
LGG	cis	rs727505	0.954	rs66691367	chr7:124654217	G/T	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18252515	chr7:66147081	NA	-0.4	-6.8	-0.3	3.32e-11	Aortic root size;
LGG	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.59	-0.79	8.3e-100	Height;
LGG	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg01864069	chr14:103024347	NA	0.45	8.11	0.35	4.55e-15	Platelet count;
LGG	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.44	-0.44	4.75e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg10661904	chr17:79619235	PDE6G	0.41	8.28	0.36	1.31e-15	Eye color traits;
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg03575189	chr17:44344142	NA	0.48	7.09	0.31	4.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1801251	1.000	rs12987513	chr2:233622066	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.11	0.39	2.41e-18	Coronary artery disease;
LGG	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.21e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.14	-0.43	6.07e-22	Total body bone mineral density;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.79	-0.3	3.54e-11	Neuroticism;
LGG	cis	rs12999616	0.817	rs35321033	chr2:98327812	T/C	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.35	3.7e-15	Colorectal cancer;
LGG	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.62	-0.51	1.42e-31	Cognitive function;
LGG	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg16414030	chr3:133502952	NA	-0.59	-10.23	-0.43	2.82e-22	Iron status biomarkers;
LGG	trans	rs12517041	1.000	rs1560177	chr5:23322987	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.77	-0.48	3.61e-28	Calcium levels;
LGG	cis	rs2692947	0.644	rs772175	chr2:96944553	G/A	cg22654517	chr2:96458247	NA	0.36	7.41	0.33	5.94e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.76	-0.34	5.36e-14	Morning vs. evening chronotype;
LGG	cis	rs1707322	1.000	rs4660336	chr1:46487976	T/C	cg03146154	chr1:46216737	IPP	-0.52	-9.93	-0.42	3.33e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4846580	0.622	rs10863480	chr1:219877373	G/A	cg08034750	chr1:219919793	NA	0.41	7.33	0.32	1.01e-12	Total body bone mineral density;
LGG	cis	rs4262150	0.544	rs17451810	chr5:151901848	C/G	cg12297329	chr5:152029980	NA	-0.64	-11.76	-0.48	4.13e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2635047	0.615	rs2137287	chr18:44751856	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.91	0.31	1.64e-11	Educational attainment;
LGG	cis	rs4144743	0.641	rs67696888	chr17:45355116	A/G	cg18085866	chr17:45331354	ITGB3	-0.69	-7.83	-0.34	3.29e-14	Body mass index;
LGG	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-8.23	-0.36	1.88e-15	Vitiligo;
LGG	cis	rs6665290	0.868	rs2183836	chr1:227199404	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.26	-38.73	-0.87	2.61e-147	Myeloid white cell count;
LGG	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg08250081	chr4:10125330	NA	0.39	7.53	0.33	2.69e-13	Bone mineral density;
LGG	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg20302533	chr7:39170763	POU6F2	0.49	11.99	0.49	5.11e-29	IgG glycosylation;
LGG	trans	rs7246760	0.748	rs61604825	chr19:9726998	C/A	cg02900749	chr2:68251473	NA	-0.93	-9.12	-0.39	2.33e-18	Pursuit maintenance gain;
LGG	cis	rs7173743	0.525	rs7166501	chr15:79133739	C/T	cg00540400	chr15:79124168	NA	0.36	6.96	0.31	1.17e-11	Coronary artery disease;
LGG	cis	rs975722	0.531	rs739798	chr7:117378356	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	8.96	0.38	8.11e-18	Coronary artery disease;
LGG	cis	rs7587476	0.822	rs6726763	chr2:215681580	T/G	cg04004882	chr2:215674386	BARD1	0.54	7.8	0.34	4.02e-14	Neuroblastoma;
LGG	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg20308403	chr7:2120281	MAD1L1	-0.36	-7.42	-0.33	5.68e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500395	0.962	rs9938126	chr16:48572121	A/T	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3540	0.533	rs11633692	chr15:91056043	G/A	cg18942110	chr15:91072797	CRTC3	-0.29	-6.66	-0.3	8e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2153535	0.580	rs9406171	chr6:8515362	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.69	0.34	8.81e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs498079	0.544	rs509904	chr6:133517082	A/T	cg14017655	chr6:133562193	EYA4	-0.4	-7.26	-0.32	1.61e-12	Total body bone mineral density;
LGG	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg26384229	chr12:38710491	ALG10B	-0.71	-13.56	-0.53	1.6e-35	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg11050988	chr7:1952600	MAD1L1	-0.34	-8.13	-0.35	3.87e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.83	0.7	1.83e-68	Calcium levels;
LGG	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg00376283	chr12:123451042	ABCB9	0.59	9.05	0.39	4.05e-18	Neutrophil percentage of white cells;
LGG	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg06640241	chr16:89574553	SPG7	-0.84	-15.54	-0.59	3.91e-44	Multiple myeloma (IgH translocation);
LGG	cis	rs7666738	0.800	rs28427190	chr4:98989106	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.66	-0.41	3.06e-20	Pancreatic cancer;
LGG	cis	rs72781680	0.898	rs12619525	chr2:23999565	G/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg03665457	chr10:38645376	HSD17B7P2	0.45	7.03	0.31	7.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs774359	0.789	rs774349	chr9:27521908	T/A	cg14173147	chr9:27528300	MOBKL2B	0.46	8.8	0.38	2.83e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs858239	0.698	rs858295	chr7:23245569	A/G	cg23682824	chr7:23144976	KLHL7	0.4	6.85	0.3	2.33e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13437525	chr12:51318487	METTL7A	0.38	7.01	0.31	8.25e-12	Menarche (age at onset);
LGG	cis	rs28830936	0.535	rs28657602	chr15:41869162	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.38	-7.82	-0.34	3.63e-14	Diastolic blood pressure;
LGG	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg14092988	chr3:52407081	DNAH1	0.26	6.93	0.31	1.45e-11	Electroencephalogram traits;
LGG	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	8.3	0.36	1.13e-15	Bone mineral density;
LGG	cis	rs6815814	0.950	rs5743795	chr4:38832495	C/T	cg06935464	chr4:38784597	TLR10	0.58	7.92	0.35	1.78e-14	Breast cancer;
LGG	cis	rs13088318	0.595	rs34255148	chr3:101230678	G/T	cg27318481	chr3:100970896	IMPG2	0.35	7.13	0.31	3.84e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11150038	1.000	rs3909028	chr16:78067744	C/G	cg04733911	chr16:78082701	NA	-0.69	-9.1	-0.39	2.64e-18	Colorectal or endometrial cancer;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13126279	chr21:47581558	C21orf56	0.53	9.55	0.41	7.31e-20	Testicular germ cell tumor;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.56	-0.53	1.69e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12493885	0.769	rs11718319	chr3:153776944	G/A	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg00938859	chr5:1591904	SDHAP3	0.9	12.45	0.5	6.71e-31	Breast cancer;
LGG	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.47	0.33	3.95e-13	Cystic fibrosis severity;
LGG	trans	rs3779273	0.965	rs1852006	chr7:77829768	G/A	cg05596911	chr5:118502651	DMXL1	0.4	7.86	0.34	2.75e-14	Body mass index;
LGG	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03837627	chr17:28443756	CCDC55;MIR423	0.39	7.01	0.31	8.44e-12	Obesity-related traits;
LGG	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg21427119	chr20:30132790	HM13	-0.58	-8.99	-0.39	6.44e-18	Mean corpuscular hemoglobin;
LGG	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg12288994	chr5:1860383	NA	0.72	11.78	0.48	3.37e-28	Cardiovascular disease risk factors;
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.81	-0.38	2.55e-17	Systolic blood pressure;
LGG	cis	rs9329289	0.550	rs11251294	chr10:2562328	C/T	cg15501526	chr10:2543763	NA	-0.48	-7.9	-0.34	2.06e-14	Age-related hearing impairment;
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg00825309	chr19:58991885	ZNF446	0.55	11.35	0.47	1.63e-26	Uric acid clearance;
LGG	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg03342759	chr3:160939853	NMD3	-0.58	-9.92	-0.42	3.59e-21	Morning vs. evening chronotype;
LGG	cis	rs7914558	0.966	rs3758543	chr10:104944744	C/G	cg04362960	chr10:104952993	NT5C2	0.56	10.68	0.44	5.97e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs56235845	0.694	rs11949401	chr5:176765989	A/G	cg17509989	chr5:176798049	RGS14	0.66	10.99	0.45	3.93e-25	Hemoglobin concentration;Hematocrit;
LGG	trans	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg06521331	chr12:34319734	NA	0.44	7.99	0.35	1.1e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2117029	0.782	rs7969091	chr12:49464449	A/G	cg24176009	chr12:49580217	TUBA1A	0.43	7.75	0.34	6e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2953174	0.938	rs2975758	chr2:241530750	G/A	cg07929629	chr2:241523174	NA	0.56	6.77	0.3	4.02e-11	Bipolar disorder;
LGG	cis	rs116095464	0.558	rs7708182	chr5:234788	C/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.86	-0.64	1.12e-54	Breast cancer;
LGG	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12101261	0.580	rs3783950	chr14:81448282	C/G	cg06600135	chr14:81408086	NA	-0.37	-7.07	-0.31	5.68e-12	Graves' disease;
LGG	cis	rs7412746	0.611	rs4970984	chr1:150887377	T/C	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Melanoma;
LGG	trans	rs1814175	0.817	rs1818890	chr11:49856882	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.14	-0.49	1.27e-29	Height;
LGG	cis	rs9815354	0.812	rs73071343	chr3:41826877	G/C	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14169450	chr9:139327907	INPP5E	0.4	7.37	0.32	7.71e-13	Monocyte percentage of white cells;
LGG	cis	rs7649275	0.882	rs2016271	chr3:53781737	A/G	cg21503701	chr3:53781065	CACNA1D	-0.42	-6.88	-0.3	1.91e-11	Trans fatty acid levels;
LGG	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg12615879	chr12:58013172	SLC26A10	0.33	7.3	0.32	1.3e-12	Multiple sclerosis;
LGG	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg16141378	chr3:129829833	LOC729375	0.4	8.76	0.38	3.74e-17	Myopia (pathological);
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.16	0.6	6.63e-47	Lymphocyte counts;
LGG	cis	rs28374715	0.662	rs113913466	chr15:41483100	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.01	-18.03	-0.64	1.93e-55	Ulcerative colitis;
LGG	cis	rs7226408	0.749	rs17567737	chr18:34499369	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.99	-0.31	9.37e-12	Obesity-related traits;
LGG	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	5.9e-15	Neuroticism;
LGG	cis	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg03476357	chr21:30257390	N6AMT1	-0.54	-8.18	-0.36	2.68e-15	Cognitive test performance;
LGG	cis	rs2201728	0.667	rs36083197	chr4:100185537	A/G	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.95	-0.38	8.78e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01060165	chr19:50321417	MED25	0.41	6.87	0.3	2.03e-11	Cognitive performance;
LGG	cis	rs8072100	0.967	rs62076549	chr17:45579555	T/G	cg08085267	chr17:45401833	C17orf57	0.58	11.67	0.48	9.28e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4684776	0.676	rs2067472	chr3:11299190	G/C	cg24705426	chr3:11550659	ATG7	-0.4	-7.22	-0.32	2.09e-12	Small vessel stroke;
LGG	cis	rs8180040	0.726	rs11130110	chr3:47000606	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-14.15	-0.55	5.19e-38	Colorectal cancer;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg01262667	chr19:19385393	TM6SF2	0.43	11.08	0.46	1.76e-25	Tonsillectomy;
LGG	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22509189	chr2:225307070	NA	-0.6	-9.76	-0.41	1.36e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs8005677	0.828	rs4981451	chr14:23410281	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-7.15	-0.32	3.34e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs2204008	0.837	rs11495548	chr12:38076756	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.18	0.72	8.8400000000000005e-75	Bladder cancer;
LGG	cis	rs4819052	1.000	rs4818769	chr21:46667451	C/T	cg06618935	chr21:46677482	NA	-0.53	-9.39	-0.4	2.67e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.63	-0.33	1.39e-13	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	cis	rs3816183	0.531	rs4953675	chr2:43121284	T/G	cg14631114	chr2:43023945	NA	0.43	7.39	0.32	6.89e-13	Hypospadias;
LGG	cis	rs73086581	1.000	rs17214949	chr20:3940952	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	9.01	0.39	5.57e-18	Mood instability;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg10500218	chr1:181058063	IER5	0.39	7.04	0.31	7.16e-12	Corneal astigmatism;
LGG	trans	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.42	-0.33	5.55e-13	Educational attainment (years of education);
LGG	cis	rs10847980	0.590	rs79798267	chr12:123321819	A/T	cg25930673	chr12:123319894	HIP1R	1.17	9.76	0.41	1.41e-20	Adiponectin levels;
LGG	cis	rs9912468	0.933	rs8081834	chr17:64331037	C/T	cg19474267	chr17:64306194	PRKCA	0.95	25.25	0.76	4.32e-89	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.23	0.46	4.87e-26	Obesity-related traits;
LGG	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.42	-0.33	5.66e-13	Morning vs. evening chronotype;
LGG	trans	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg18187862	chr3:45730750	SACM1L	0.65	10.85	0.45	1.39e-24	Primary sclerosing cholangitis;
LGG	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg12654349	chr5:56205094	C5orf35	0.67	10.57	0.44	1.55e-23	Initial pursuit acceleration;
LGG	cis	rs10937275	0.590	rs116050195	chr3:186672937	G/A	cg16751732	chr3:186648392	ST6GAL1	0.64	6.69	0.3	6.53e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg17211192	chr8:82754475	SNX16	-0.8	-12.48	-0.5	5.39e-31	Diastolic blood pressure;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.84	0.34	3.1e-14	Schizophrenia;
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg18479299	chr3:125709523	NA	-0.6	-7.72	-0.34	7.34e-14	Blood pressure (smoking interaction);
LGG	cis	rs3206736	0.548	rs1637673	chr7:34997850	A/G	cg13400248	chr7:35225412	NA	0.53	9.42	0.4	2.2e-19	Diastolic blood pressure;
LGG	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg09873164	chr1:152488093	CRCT1	0.65	16.06	0.6	1.82e-46	Hair morphology;
LGG	cis	rs12153243	0.686	rs6580291	chr5:142942129	A/G	cg13907255	chr5:142895549	NA	-0.46	-8.06	-0.35	6.59e-15	Migraine;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21617494	chr15:57618479	NA	0.51	7.67	0.34	1e-13	Gut microbiome composition (summer);
LGG	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.48	-0.44	3.4e-23	Migraine;Coronary artery disease;
LGG	cis	rs7011192	0.793	rs13269921	chr8:10520913	A/G	cg17329886	chr8:10513629	RP1L1	0.59	7.59	0.33	1.82e-13	Suicide;
LGG	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg00599393	chr8:22457479	C8orf58	-0.47	-8.31	-0.36	1.05e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.74	-0.34	6.27e-14	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.28	-0.32	1.47e-12	Lung cancer;
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg19847130	chr8:10466454	RP1L1	0.32	7.0	0.31	9.18e-12	Retinal vascular caliber;
LGG	cis	rs36051895	0.664	rs12340866	chr9:5094185	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.53	-0.56	1.16e-39	Pediatric autoimmune diseases;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg25703541	chr22:24373054	LOC391322	0.86	16.77	0.61	1.21e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg08742575	chr21:47604166	C21orf56	0.5	8.63	0.37	9.72e-17	Testicular germ cell tumor;
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs9649465	0.967	rs6944031	chr7:123299304	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.99	-0.39	6.53e-18	Migraine;
LGG	cis	rs193541	0.632	rs1903260	chr5:122135188	T/C	cg19412675	chr5:122181750	SNX24	0.53	8.57	0.37	1.58e-16	Glucose homeostasis traits;
LGG	cis	rs4665809	1.000	rs11126375	chr2:26344787	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs4936891	0.601	rs7929503	chr11:123916160	A/G	cg22125253	chr11:123886957	OR10G4	0.68	13.29	0.53	2.34e-34	Male fertility;
LGG	cis	rs6768930	0.509	rs55645723	chr3:57750240	G/A	cg01571842	chr3:57934672	NA	0.3	6.65	0.3	8.22e-11	Obesity-related traits;
LGG	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg01043669	chr3:72786069	NA	0.42	6.94	0.31	1.33e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3096299	0.933	rs2965938	chr16:89491336	C/T	cg06640241	chr16:89574553	SPG7	0.71	12.17	0.49	9.63e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg24060327	chr5:131705240	SLC22A5	0.6	6.64	0.3	8.58e-11	Rheumatoid arthritis;
LGG	trans	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.85	-0.3	2.37e-11	Joint mobility (Beighton score);
LGG	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-8.75	-0.38	3.89e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg06481639	chr22:41940642	POLR3H	-0.44	-6.76	-0.3	4.23e-11	Vitiligo;
LGG	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg17376030	chr22:41985996	PMM1	0.56	9.02	0.39	5.11e-18	Vitiligo;
LGG	cis	rs7119	0.717	rs12902925	chr15:77819141	T/C	cg10437265	chr15:77819839	NA	0.24	6.83	0.3	2.62e-11	Type 2 diabetes;
LGG	cis	rs1336900	0.637	rs35967040	chr1:150555588	A/C	cg17724175	chr1:150552817	MCL1	-0.36	-6.68	-0.3	7.07e-11	Blood protein levels;
LGG	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg19729930	chr2:74357872	NA	0.51	10.3	0.43	1.53e-22	Gestational age at birth (maternal effect);
LGG	cis	rs4481887	0.927	rs4279879	chr1:248486475	A/G	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	cis	rs7027203	0.964	rs7854075	chr9:96571211	G/A	cg14598338	chr9:96623480	NA	0.5	8.66	0.37	7.78e-17	DNA methylation (variation);
LGG	trans	rs61931739	0.500	rs7311284	chr12:34478477	C/G	cg26384229	chr12:38710491	ALG10B	0.96	21.25	0.7	1.9e-70	Morning vs. evening chronotype;
LGG	cis	rs742614	0.533	rs6059499	chr20:32447920	C/T	cg06304546	chr20:32448765	NA	0.71	14.07	0.55	1.12e-37	Stearic acid (18:0) levels;
LGG	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07080220	chr10:102295463	HIF1AN	0.73	12.11	0.49	1.62e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs490234	0.783	rs10119855	chr9:128271123	A/T	cg14078157	chr9:128172775	NA	-0.48	-9.14	-0.39	1.91e-18	Mean arterial pressure;
LGG	cis	rs509477	0.718	rs273348	chr18:32601632	A/C	cg23791764	chr18:32556832	MAPRE2	0.44	7.3	0.32	1.28e-12	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs4901847	0.716	rs12435980	chr14:58552535	C/T	cg15908186	chr14:58618357	C14orf37	0.41	7.1	0.31	4.75e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.76	-0.51	3.8e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs644799	1.000	rs563653	chr11:95561488	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1719271	0.831	rs1684037	chr15:65171577	A/C	cg11671771	chr15:65133392	PLEKHO2	-0.53	-7.42	-0.33	5.57e-13	Platelet count;
LGG	trans	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg18335740	chr13:41363409	SLC25A15	-0.65	-12.92	-0.51	7.8e-33	Lewy body disease;
LGG	trans	rs5756813	0.661	rs11703407	chr22:38200124	C/T	cg19894588	chr14:64061835	NA	-0.64	-9.98	-0.42	2.22e-21	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7226408	0.901	rs17652953	chr18:34761705	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.01	-0.31	8.49e-12	Obesity-related traits;
LGG	cis	rs981844	1.000	rs2251639	chr4:154656410	T/C	cg14289246	chr4:154710475	SFRP2	0.68	11.14	0.46	1.1e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg22907277	chr7:1156413	C7orf50	0.62	11.32	0.47	2.19e-26	Longevity;Endometriosis;
LGG	cis	rs6960043	0.875	rs10249299	chr7:15054391	C/T	cg19272540	chr7:15055459	NA	0.34	7.72	0.34	7.23e-14	Type 2 diabetes;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg13647721	chr17:30228624	UTP6	0.67	9.19	0.39	1.33e-18	Hip circumference adjusted for BMI;
LGG	cis	rs12210905	1.000	rs12208534	chr6:27066759	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7444	0.941	rs5998599	chr22:21941981	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.64	-0.33	1.28e-13	Systemic lupus erythematosus;
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.39	-7.28	-0.32	1.49e-12	Chronic sinus infection;
LGG	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.75	0.3	4.35e-11	Cognitive function;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05228735	chr16:30621825	ZNF689	0.43	6.85	0.3	2.43e-11	Cognitive performance;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11245990	chr11:68621969	NA	0.42	9.0	0.39	5.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg20283391	chr11:68216788	NA	-0.49	-8.05	-0.35	7.03e-15	Total body bone mineral density;
LGG	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.83	-0.3	2.76e-11	Iron status biomarkers;
LGG	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	8.12	0.35	4.24e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.52	-0.71	1.05e-71	Height;
LGG	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.85	-0.34	2.87e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.14e-36	Corneal astigmatism;
LGG	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg02002194	chr4:3960332	NA	0.42	7.15	0.32	3.36e-12	Neuroticism;
LGG	cis	rs6963495	0.818	rs73192115	chr7:105169605	T/A	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs9878978	0.963	rs62233814	chr3:2481778	A/G	cg21928760	chr3:2462534	CNTN4	0.41	9.0	0.39	5.76e-18	Blood pressure (smoking interaction);
LGG	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg06889755	chr6:150326021	RAET1K	-0.4	-8.28	-0.36	1.33e-15	Alopecia areata;
LGG	cis	rs2594989	0.733	rs2616539	chr3:11580371	C/A	cg01796438	chr3:11312864	ATG7	-0.45	-6.72	-0.3	5.24e-11	Circulating chemerin levels;
LGG	cis	rs2594989	0.943	rs4684070	chr3:11437551	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.21	-0.32	2.31e-12	Circulating chemerin levels;
LGG	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.49	-0.37	2.74e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00864171	chr11:67383662	NA	0.55	9.57	0.41	6.54e-20	Mean corpuscular volume;
LGG	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.48e-11	Myopia (pathological);
LGG	cis	rs977987	0.645	rs10871311	chr16:75450912	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.24e-21	Dupuytren's disease;
LGG	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.33	0.47	2.01e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.97	0.35	1.22e-14	Bipolar disorder;
LGG	trans	rs62103177	0.608	rs551643	chr18:77838970	C/G	cg05926928	chr17:57297772	GDPD1	-0.93	-11.95	-0.49	7.44e-29	Opioid sensitivity;
LGG	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.51e-19	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04329977	chr3:61546343	PTPRG	0.49	7.55	0.33	2.37e-13	Gut microbiome composition (summer);
LGG	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg17054900	chr3:154042577	DHX36	-0.48	-7.47	-0.33	4.16e-13	Coronary artery disease;
LGG	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg16850897	chr7:100343110	ZAN	-0.63	-9.17	-0.39	1.5e-18	Other erythrocyte phenotypes;
LGG	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg11764359	chr7:65958608	NA	-0.63	-10.85	-0.45	1.39e-24	Aortic root size;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.67e-12	Lung cancer;
LGG	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	15.84	0.59	1.88e-45	Total body bone mineral density;
LGG	trans	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs208520	0.690	rs7739253	chr6:66861052	A/G	cg07460842	chr6:66804631	NA	-0.97	-18.12	-0.64	7.59e-56	Exhaled nitric oxide output;
LGG	cis	rs11758351	0.929	rs75475698	chr6:26190609	C/G	cg06951627	chr6:26196580	NA	0.53	8.06	0.35	6.43e-15	Gout;Renal underexcretion gout;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.49e-17	Bipolar disorder;
LGG	trans	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-13.07	-0.52	1.84e-33	Obesity-related traits;
LGG	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg06618935	chr21:46677482	NA	0.43	8.47	0.37	3.24e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9487094	0.961	rs1546980	chr6:109773946	T/C	cg16315928	chr6:109776240	MICAL1	0.56	9.37	0.4	3.16e-19	Height;
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg17691542	chr6:26056736	HIST1H1C	0.46	8.17	0.35	3.07e-15	Height;
LGG	cis	rs2274273	0.682	rs8008134	chr14:55507520	T/C	cg04306507	chr14:55594613	LGALS3	0.43	10.77	0.45	2.63e-24	Protein biomarker;
LGG	cis	rs12477438	0.765	rs12470471	chr2:99689141	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	0.87	15.16	0.58	1.84e-42	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg08645402	chr16:4508243	NA	0.49	8.85	0.38	1.86e-17	Schizophrenia;
LGG	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11225247	0.649	rs11605087	chr11:102225219	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.5	0.33	3.3e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs12220238	0.722	rs6480748	chr10:76421529	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.52	6.71	0.3	5.78e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs11875185	1.000	rs67711672	chr18:55638182	C/G	cg15513957	chr14:69354734	ACTN1	-0.76	-8.14	-0.35	3.62e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7666738	0.830	rs17483521	chr4:98974058	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.02e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12496230	0.953	rs13096599	chr3:66848809	T/C	cg17646820	chr3:66848679	NA	0.52	8.01	0.35	9.71e-15	Type 2 diabetes;
LGG	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg13010199	chr12:38710504	ALG10B	0.65	13.53	0.53	2.12e-35	Bladder cancer;
LGG	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg15269541	chr15:43626905	ADAL	-0.43	-6.75	-0.3	4.56e-11	Lung cancer in ever smokers;
LGG	cis	rs2658782	1.000	rs2608216	chr11:93149172	G/A	cg15737290	chr11:93063684	CCDC67	0.58	8.54	0.37	1.89e-16	Pulmonary function decline;
LGG	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg20573242	chr4:122745356	CCNA2	0.42	7.75	0.34	6e-14	Type 2 diabetes;
LGG	cis	rs11874712	0.899	rs11872954	chr18:43686450	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.53	-11.46	-0.47	5.97e-27	Migraine - clinic-based;
LGG	cis	rs881375	1.000	rs6478484	chr9:123652380	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.45	0.4	1.7e-19	Rheumatoid arthritis;
LGG	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg08085267	chr17:45401833	C17orf57	0.58	11.56	0.47	2.46e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs972578	0.740	rs5758972	chr22:43232973	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.79	-0.3	3.54e-11	Mean platelet volume;
LGG	cis	rs1620921	0.653	rs62435284	chr6:161268570	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs8032158	0.702	rs1042477	chr15:56121886	C/A	cg02198044	chr15:56286336	NEDD4	-0.53	-9.02	-0.39	5.15e-18	Keloid;
LGG	cis	rs9325144	0.647	rs61930266	chr12:38922048	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-10.7	-0.45	4.98e-24	Morning vs. evening chronotype;
LGG	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg05753993	chr18:77199432	NFATC1	0.36	6.78	0.3	3.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.54e-14	Bipolar disorder;
LGG	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg03929089	chr4:120376271	NA	0.86	17.2	0.62	1.3e-51	Height;
LGG	cis	rs9333075	0.507	rs1954180	chr10:15743711	A/C	cg14364212	chr10:15760690	ITGA8	-0.44	-9.7	-0.41	2.23e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2028299	0.920	rs1866476	chr15:90428543	T/C	cg23731826	chr15:90371692	NA	0.34	7.76	0.34	5.31e-14	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg07701084	chr6:150067640	NUP43	0.68	12.36	0.5	1.54e-30	Lung cancer;
LGG	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg06346307	chr22:19949965	COMT	0.45	12.1	0.49	1.86e-29	Blood metabolite levels;
LGG	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg04719120	chr6:96025338	MANEA	0.57	7.98	0.35	1.19e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.85	-0.3	2.42e-11	Bipolar disorder;
LGG	cis	rs4417704	0.526	rs4130554	chr2:241881642	G/A	cg05025159	chr2:241905733	NA	0.49	9.56	0.41	7.19e-20	Joint mobility (Beighton score);
LGG	cis	rs9658691	0.607	rs9658788	chr10:90776486	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-9.09	-0.39	2.83e-18	Mosquito bite size;
LGG	cis	rs17253792	0.822	rs77033617	chr14:56129746	T/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg24375607	chr4:120327624	NA	0.68	11.11	0.46	1.44e-25	Corneal astigmatism;
LGG	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg05082376	chr22:42548792	NA	-0.36	-7.63	-0.33	1.35e-13	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs870825	0.616	rs28375770	chr4:185647395	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs4740619	0.967	rs9886779	chr9:15637447	T/A	cg14451791	chr9:16040625	NA	-0.4	-9.94	-0.42	3.11e-21	Body mass index;
LGG	cis	rs4660214	0.724	rs10888683	chr1:39623669	A/T	cg18385671	chr1:39797026	MACF1	0.44	9.62	0.41	4.47e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg11984989	chr7:158649758	WDR60	1.04	23.7	0.74	6.62e-82	Height;
LGG	trans	rs7944735	0.628	rs4752879	chr11:47897772	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.77	0.34	5.24e-14	Intraocular pressure;
LGG	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg14664628	chr15:75095509	CSK	-0.54	-10.39	-0.43	7.12e-23	Breast cancer;
LGG	cis	rs8133932	0.861	rs79965202	chr21:47078774	T/A	cg11214348	chr21:47283868	PCBP3	-0.43	-7.04	-0.31	6.8e-12	Schizophrenia;
LGG	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	trans	rs11039798	0.582	rs1483119	chr11:48382334	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-9.95	-0.42	2.86e-21	Axial length;
LGG	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.71	0.54	3.92e-36	Cognitive test performance;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.81	0.59	2.43e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs12517041	1.000	rs10520889	chr5:23280920	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.17e-25	Calcium levels;
LGG	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.93	-0.35	1.65e-14	Mood instability;
LGG	cis	rs11971779	0.680	rs7792752	chr7:139066196	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.76	-0.34	5.32e-14	Systolic blood pressure;
LGG	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	13.3	0.53	2.09e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs61897795	0.657	rs174590	chr11:61616977	G/C	cg19610905	chr11:61596333	FADS2	-0.65	-9.41	-0.4	2.26e-19	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg08499158	chr17:42289980	UBTF	-0.38	-7.08	-0.31	5.45e-12	Red cell distribution width;Reticulocyte count;
LGG	cis	rs6141769	0.542	rs6057627	chr20:31306728	C/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.8	-0.3	3.32e-11	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00949670	chr12:120967105	COQ5	0.48	7.74	0.34	6.51e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg14668632	chr7:2872130	GNA12	-0.33	-6.94	-0.31	1.3e-11	Height;
LGG	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg00277334	chr10:82204260	NA	-0.35	-7.68	-0.34	9.63e-14	Post bronchodilator FEV1;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg22329336	chr7:1950478	MAD1L1	0.38	6.66	0.3	7.91e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg18898632	chr2:242989856	NA	-0.8	-9.89	-0.42	4.69e-21	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.44	-0.4	1.87e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12360000	0.577	rs10430757	chr10:1906265	C/T	cg26364871	chr10:1889757	NA	-0.49	-9.1	-0.39	2.63e-18	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg11494091	chr17:61959527	GH2	-0.5	-8.11	-0.35	4.49e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg16141378	chr3:129829833	LOC729375	0.39	8.75	0.38	3.86e-17	Neuroticism;
LGG	cis	rs9911578	0.967	rs12938821	chr17:56959422	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.97	-0.42	2.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.76	0.3	4.1e-11	Bone mineral density;
LGG	cis	rs1620921	0.563	rs28670241	chr6:161268736	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.86e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg07870213	chr5:140052090	DND1	0.84	15.81	0.59	2.54e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg00106254	chr7:1943704	MAD1L1	0.45	7.88	0.34	2.32e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs929596	0.564	rs2741024	chr2:234517745	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.28	-0.4	6.64e-19	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg08847533	chr14:75593920	NEK9	0.56	9.25	0.4	8.08e-19	Height;
LGG	cis	rs910316	0.763	rs175042	chr14:75470833	A/T	cg11812906	chr14:75593930	NEK9	-0.45	-8.16	-0.35	3.29e-15	Height;
LGG	cis	rs7646881	0.812	rs75267618	chr3:158443816	T/C	cg19483011	chr3:158453295	NA	-0.59	-7.94	-0.35	1.5e-14	Tetralogy of Fallot;
LGG	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	10.92	0.45	7.19e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg02254774	chr11:50257496	LOC441601	0.57	6.76	0.3	4.15e-11	Myopia (pathological);
LGG	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg18198730	chr1:247681584	NA	0.72	12.79	0.51	2.76e-32	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1318772	1.000	rs67894881	chr5:112613778	C/G	cg12552261	chr5:112820674	MCC	0.71	8.18	0.36	2.86e-15	F-cell distribution;
LGG	cis	rs1497828	0.912	rs1497832	chr1:217527626	A/G	cg04411442	chr1:217543379	NA	-0.48	-8.09	-0.35	5.36e-15	Dialysis-related mortality;
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg08888203	chr3:10149979	C3orf24	-0.55	-9.01	-0.39	5.24e-18	Alzheimer's disease;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.51	0.33	3.15e-13	Schizophrenia;
LGG	cis	rs9389248	0.690	rs1028314	chr6:135255710	A/C	cg24558204	chr6:135376177	HBS1L	-0.56	-9.48	-0.4	1.29e-19	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs3820928	0.874	rs10169717	chr2:227796911	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs72781680	1.000	rs72798417	chr2:24188656	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.83	0.51	1.85e-32	Morning vs. evening chronotype;
LGG	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg01620082	chr3:125678407	NA	-0.61	-7.51	-0.33	3.03e-13	Depression;
LGG	cis	rs4742903	0.875	rs10991192	chr9:107008496	C/T	cg14250997	chr9:106856677	SMC2	0.35	7.25	0.32	1.77e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04041942	chr8:28747613	INTS9;HMBOX1	0.41	7.04	0.31	7.05e-12	Bipolar disorder;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.87	0.38	1.65e-17	Schizophrenia;
LGG	cis	rs367943	0.933	rs451453	chr5:112808970	G/C	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	cis	rs9398803	0.723	rs853968	chr6:127071753	C/T	cg19875578	chr6:126661172	C6orf173	-0.51	-9.29	-0.4	6e-19	Male-pattern baldness;
LGG	cis	rs7192750	0.517	rs152827	chr16:72126753	C/G	cg06353428	chr16:71660113	MARVELD3	0.79	7.18	0.32	2.72e-12	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7617773	0.743	rs13071960	chr3:48367537	A/G	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg17644776	chr2:200775616	C2orf69	-0.7	-12.66	-0.51	9.56e-32	Osteoporosis;
LGG	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg05729581	chr11:3078854	CARS	-0.46	-8.21	-0.36	2.23e-15	Longevity;
LGG	cis	rs283228	0.535	rs2852502	chr6:101842178	C/A	cg02011392	chr6:101847541	GRIK2	0.53	7.52	0.33	2.92e-13	Coenzyme Q10 levels;
LGG	cis	rs11711311	0.955	rs9860642	chr3:113419211	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.11	0.55	7.36e-38	IgG glycosylation;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg26668828	chr6:292823	DUSP22	-0.48	-8.39	-0.36	5.95e-16	Menopause (age at onset);
LGG	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.66	0.41	3.06e-20	Lung cancer in ever smokers;
LGG	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.26e-32	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg05793240	chr7:2802953	GNA12	0.33	7.67	0.34	1.04e-13	Height;
LGG	cis	rs9420907	0.901	rs1265164	chr10:105674854	A/G	cg11005552	chr10:105648138	OBFC1	0.71	9.11	0.39	2.43e-18	Telomere length;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.33	0.43	1.21e-22	Diabetic retinopathy;
LGG	cis	rs13418717	0.793	rs4663053	chr2:127638990	A/G	cg25501666	chr2:127640322	NA	-1.19	-9.5	-0.4	1.16e-19	Heart failure;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02018176	chr4:1364513	KIAA1530	0.51	12.45	0.5	6.56e-31	Longevity;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg10189774	chr4:17578691	LAP3	0.38	6.73	0.3	5.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1816752	0.774	rs55888616	chr13:25016092	C/T	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs1595825	0.735	rs113834557	chr2:198611624	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-6.77	-0.3	3.93e-11	Ulcerative colitis;
LGG	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg13660082	chr14:53194042	PSMC6	-0.58	-8.01	-0.35	9.52e-15	Alzheimer's disease (late onset);
LGG	cis	rs9943753	0.525	rs6606708	chr12:109833146	T/C	cg19025524	chr12:109796872	NA	-0.54	-11.71	-0.48	6.3e-28	HDL cholesterol;
LGG	cis	rs7580658	0.895	rs7589451	chr2:128128775	T/C	cg10021288	chr2:128175891	PROC	-0.63	-12.92	-0.51	7.61e-33	Protein C levels;
LGG	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7617773	0.780	rs79089926	chr3:48348564	A/C	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.58e-45	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.72	-0.64	5.43e-54	Breast cancer;
LGG	cis	rs8064024	0.538	rs11076854	chr16:4929269	A/G	cg08329684	chr16:4932620	PPL	-0.57	-12.94	-0.52	6.5e-33	Cancer;
LGG	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg03806693	chr22:41940476	POLR3H	-0.76	-12.75	-0.51	3.91e-32	Vitiligo;
LGG	cis	rs7666738	0.830	rs34916200	chr4:98851593	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg05025164	chr4:1340916	KIAA1530	0.57	10.06	0.42	1.13e-21	Obesity-related traits;
LGG	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.43	0.36	4.5e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs9929218	1.000	rs12446575	chr16:68791644	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.88	-0.54	7.17e-37	Colorectal cancer;
LGG	cis	rs1881396	0.588	rs1881394	chr2:27949052	G/A	cg27432699	chr2:27873401	GPN1	0.58	7.55	0.33	2.3e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs2072732	0.950	rs1109251	chr1:2973576	G/A	cg08733933	chr1:2954429	NA	-0.44	-8.24	-0.36	1.77e-15	Plateletcrit;
LGG	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg06636001	chr8:8085503	FLJ10661	0.39	7.09	0.31	5.07e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs67133203	0.768	rs12829630	chr12:51537309	A/G	cg14688905	chr12:51403056	SLC11A2	0.71	10.69	0.44	5.47e-24	Urinary tract infection frequency;
LGG	cis	rs7570	1.000	rs7570	chr11:66610645	G/C	cg01599099	chr11:66649832	PC	0.47	9.52	0.4	9.83e-20	Breast cancer;
LGG	cis	rs6500395	0.962	rs9936883	chr16:48676443	G/A	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9915657	0.660	rs1558748	chr17:70066502	T/C	cg09344028	chr17:70110421	NA	0.55	11.55	0.47	2.76e-27	Thyroid hormone levels;
LGG	cis	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg24623649	chr8:11872141	NA	0.32	7.68	0.34	9.71e-14	Neuroticism;
LGG	cis	rs988958	0.600	rs10205005	chr2:42248713	A/G	cg27428208	chr2:42229179	NA	0.56	9.25	0.39	8.27e-19	Hypospadias;
LGG	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg22771759	chr13:24902376	NA	0.42	7.18	0.32	2.85e-12	Obesity-related traits;
LGG	cis	rs7737355	1.000	rs2158428	chr5:130751481	T/A	cg06307176	chr5:131281290	NA	-0.54	-9.11	-0.39	2.51e-18	Life satisfaction;
LGG	trans	rs7923837	0.663	rs7903302	chr10:94429511	T/C	cg27639046	chr2:171608303	NA	-0.39	-7.9	-0.34	2.04e-14	Body mass index;Multiple sclerosis;
LGG	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg21995147	chr19:1064017	ABCA7	-0.47	-7.35	-0.32	8.96e-13	Alzheimer's disease (late onset);
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg18567174	chr15:68126065	LBXCOR1	0.38	7.72	0.34	7.22e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs5769707	0.706	rs763128	chr22:50018045	G/A	cg06623630	chr22:50017776	C22orf34	-0.5	-10.28	-0.43	1.86e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2050392	0.965	rs2265371	chr10:30690840	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.64	-0.44	8.74e-24	Inflammatory bowel disease;
LGG	cis	rs889312	0.500	rs33328	chr5:56143419	T/C	cg14703610	chr5:56206110	C5orf35	0.4	6.97	0.31	1.11e-11	Breast cancer;Breast cancer (early onset);
LGG	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.27	0.36	1.39e-15	Neuroticism;
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg06558623	chr16:89946397	TCF25	1.09	11.4	0.47	1.04e-26	Skin colour saturation;
LGG	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg23517279	chr6:96025343	MANEA	0.52	6.69	0.3	6.62e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs977987	0.806	rs11641587	chr16:75464419	G/T	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs9611565	0.649	rs139540	chr22:42178040	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-10.84	-0.45	1.45e-24	Vitiligo;
LGG	cis	rs4671458	1.000	rs115634863	chr2:63328774	C/T	cg17519650	chr2:63277830	OTX1	-0.63	-7.08	-0.31	5.24e-12	Subjective well-being;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.77	-0.38	3.41e-17	Life satisfaction;
LGG	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.8	0.41	1e-20	Height;
LGG	cis	rs13191362	0.935	rs34268859	chr6:162934731	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.72	0.3	5.31e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.8	-0.45	2.18e-24	Vitiligo;
LGG	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-11.59	-0.47	1.94e-27	Morning vs. evening chronotype;
LGG	cis	rs733592	1.000	rs733592	chr12:48429776	C/T	cg24011408	chr12:48396354	COL2A1	-0.68	-11.66	-0.48	9.71e-28	Plateletcrit;
LGG	cis	rs62025270	0.688	rs62022939	chr15:86250882	C/G	cg25843651	chr15:86329602	KLHL25	0.58	8.84	0.38	1.94e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.63	0.37	9.86e-17	Alzheimer's disease (survival time);
LGG	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg05555928	chr11:63887634	MACROD1	-0.58	-9.69	-0.41	2.34e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg09060608	chr5:178986726	RUFY1	0.5	8.93	0.38	1.02e-17	Lung cancer;
LGG	cis	rs62238980	0.614	rs73391051	chr22:32475878	G/C	cg00543991	chr22:32367038	NA	0.78	8.52	0.37	2.3e-16	Childhood ear infection;
LGG	cis	rs9341808	0.905	rs3805903	chr6:80975829	T/C	cg08355045	chr6:80787529	NA	0.34	6.86	0.3	2.17e-11	Sitting height ratio;
LGG	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.05	-0.35	6.93e-15	Mood instability;
LGG	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg10483660	chr13:112241077	NA	-0.36	-7.87	-0.34	2.52e-14	Hepatitis;
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg04703951	chr17:43578652	NA	-0.37	-7.46	-0.33	4.24e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9815354	0.767	rs61283393	chr3:41854135	T/G	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs877282	0.898	rs2004478	chr10:770709	C/A	cg17470449	chr10:769945	NA	0.65	8.25	0.36	1.72e-15	Uric acid levels;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg21782813	chr7:2030301	MAD1L1	0.42	9.83	0.42	7.68e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs1270639	0.778	rs2906930	chr7:157446453	T/C	cg13357408	chr7:157437802	PTPRN2	0.65	10.57	0.44	1.58e-23	Colorectal cancer;
LGG	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg23594656	chr7:65796392	TPST1	-0.41	-8.72	-0.38	4.88e-17	Aortic root size;
LGG	cis	rs62238980	0.614	rs117338064	chr22:32447147	A/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg12310025	chr6:25882481	NA	-0.7	-13.36	-0.53	1.17e-34	Intelligence (multi-trait analysis);
LGG	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.64	-0.41	3.55e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg11871910	chr12:69753446	YEATS4	0.8	13.67	0.54	5.9e-36	Response to diuretic therapy;
LGG	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.23	-0.32	2.04e-12	Arsenic metabolism;
LGG	cis	rs6088590	1.000	rs910870	chr20:33292893	T/C	cg24642439	chr20:33292090	TP53INP2	0.81	14.9	0.57	2.71e-41	Coronary artery disease;
LGG	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.08	0.52	1.69e-33	Coronary artery disease;
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg21775007	chr8:11205619	TDH	-0.45	-7.5	-0.33	3.34e-13	Neuroticism;
LGG	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg01966878	chr4:90757139	SNCA	-0.34	-6.93	-0.31	1.39e-11	Dementia with Lewy bodies;
LGG	cis	rs2652822	0.967	rs1472631	chr15:63423739	A/G	cg02713581	chr15:63449717	RPS27L	0.48	8.18	0.36	2.72e-15	Metabolic traits;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.74	-0.3	4.74e-11	Lung cancer;
LGG	cis	rs7928758	0.623	rs10894808	chr11:134256805	C/T	cg25213107	chr11:134282864	B3GAT1	1.07	11.65	0.48	1.15e-27	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg03162506	chr22:38580953	NA	0.4	10.27	0.43	1.94e-22	Cutaneous nevi;
LGG	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg09307838	chr4:120376055	NA	-0.78	-13.14	-0.52	9.79e-34	Corneal astigmatism;
LGG	cis	rs9486719	1.000	rs9373978	chr6:97056255	T/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-7.25	-0.32	1.71e-12	Migraine;Coronary artery disease;
LGG	cis	rs17818399	0.890	rs34752561	chr2:46850150	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-10.43	-0.44	5.04e-23	Height;
LGG	cis	rs4838594	1.000	rs4838594	chr10:49669142	C/T	cg17291251	chr10:49678358	ARHGAP22	0.49	9.38	0.4	3e-19	Daytime sleep phenotypes;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.09	-0.35	5.33e-15	Skin colour saturation;
LGG	trans	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.45e-14	Obesity-related traits;
LGG	trans	rs28595532	0.623	rs10016452	chr4:119277490	A/G	cg26518628	chr1:97050305	NA	-0.85	-8.7	-0.37	5.78e-17	Cannabis dependence symptom count;
LGG	cis	rs472402	0.540	rs10062086	chr5:6633042	C/T	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.07	-0.31	5.91e-12	Response to amphetamines;
LGG	cis	rs1040	0.873	rs10280	chr6:169617430	T/C	cg04662567	chr6:169592167	NA	-0.4	-7.34	-0.32	9.88e-13	Joint mobility (Beighton score);
LGG	cis	rs2018055	0.644	rs7746536	chr6:117799572	A/C	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.89	0.48	1.26e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs798766	1.000	rs1665366	chr4:1728381	A/G	cg00006948	chr4:1768889	NA	0.5	6.84	0.3	2.59e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.7	-0.3	6.01e-11	Personality dimensions;
LGG	cis	rs2071403	0.933	rs10183390	chr2:1404885	T/C	cg06500727	chr2:1417164	TPO	-0.5	-9.53	-0.41	8.61e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs56176327	0.583	rs7613603	chr3:49812866	C/T	cg13072238	chr3:49761600	GMPPB	0.55	7.44	0.33	4.79e-13	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.729	rs34647977	chr11:49195543	G/A	cg00717180	chr2:96193071	NA	-0.39	-7.07	-0.31	5.84e-12	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg08470875	chr2:26401718	FAM59B	-0.36	-6.74	-0.3	4.66e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.83	0.54	1.18e-36	Prudent dietary pattern;
LGG	cis	rs362272	0.502	rs2798298	chr4:3036602	G/A	cg13731523	chr4:3047190	NA	-0.43	-9.75	-0.41	1.44e-20	Serum sulfate level;
LGG	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.71	-0.38	5.58e-17	Lung cancer;
LGG	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg10326726	chr10:51549505	MSMB	-0.68	-14.06	-0.55	1.19e-37	Prostate-specific antigen levels;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg17178900	chr1:205818956	PM20D1	-0.35	-6.86	-0.3	2.25e-11	Menarche (age at onset);
LGG	cis	rs7666738	0.830	rs4699597	chr4:99019031	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.8e-26	Electroencephalogram traits;
LGG	cis	rs620875	1.000	rs642870	chr11:126856769	T/C	cg06504925	chr11:126872760	NA	-0.54	-7.57	-0.33	1.98e-13	Response to antipsychotic treatment;
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.49	0.67	3.32e-62	Platelet count;
LGG	trans	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg02002194	chr4:3960332	NA	0.38	7.02	0.31	8.2e-12	Joint mobility (Beighton score);
LGG	cis	rs7077256	0.564	rs12780983	chr10:65161786	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.89	-0.3	1.88e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg02725872	chr8:58115012	NA	-0.76	-10.72	-0.45	4.25e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	0.688	rs12193557	chr6:27435944	T/C	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg21775007	chr8:11205619	TDH	0.62	10.17	0.43	4.56e-22	Retinal vascular caliber;
LGG	cis	rs1152591	0.792	rs1152595	chr14:64674981	T/C	cg23250157	chr14:64679961	SYNE2	0.4	7.24	0.32	1.93e-12	Atrial fibrillation;
LGG	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg19774624	chr17:42201019	HDAC5	0.65	11.41	0.47	9.92e-27	Total body bone mineral density;
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	8.79	0.38	2.99e-17	Retinal vascular caliber;
LGG	cis	rs988958	0.675	rs35297530	chr2:42224825	G/C	cg27252766	chr2:42229092	NA	0.56	8.76	0.38	3.77e-17	Hypospadias;
LGG	cis	rs6489882	0.902	rs10774679	chr12:113374748	A/G	cg25319449	chr12:113376135	OAS3	0.38	7.17	0.32	3.04e-12	Chronic lymphocytic leukemia;
LGG	cis	rs3849570	0.961	rs13340130	chr3:81790970	A/T	cg07356753	chr3:81810745	GBE1	-0.48	-7.94	-0.35	1.59e-14	Waist circumference;Body mass index;
LGG	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg11707556	chr5:10655725	ANKRD33B	0.49	7.19	0.32	2.63e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13740771	chr20:3026904	MRPS26	0.49	7.47	0.33	4.12e-13	Gut microbiome composition (summer);
LGG	cis	rs4330281	0.647	rs4908992	chr3:17693974	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.54	-0.33	2.46e-13	Schizophrenia;
LGG	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.75	13.25	0.52	3.44e-34	Response to antipsychotic treatment;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.59	-9.62	-0.41	4.45e-20	Longevity;
LGG	cis	rs4919694	1.000	rs17727391	chr10:104836101	C/A	cg04362960	chr10:104952993	NT5C2	1.06	15.51	0.58	5.26e-44	Arsenic metabolism;
LGG	trans	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg20587970	chr11:113659929	NA	0.94	13.01	0.52	3.41e-33	Hip circumference adjusted for BMI;
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.27	7.41	0.33	6.1e-13	IgG glycosylation;
LGG	cis	rs240764	0.621	rs6570930	chr6:101181258	C/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs3796352	1.000	rs13078971	chr3:53103645	G/C	cg12962167	chr3:53033115	SFMBT1	0.78	8.16	0.35	3.17e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg20503657	chr10:835505	NA	0.95	13.02	0.52	3.16e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs4363385	0.818	rs6587719	chr1:152993409	G/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.73	-0.38	4.66e-17	Inflammatory skin disease;
LGG	cis	rs7927997	0.783	rs11236797	chr11:76299649	C/A	cg17647271	chr11:76299819	NA	-0.41	-7.3	-0.32	1.26e-12	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs4689388	0.889	rs13128674	chr4:6294517	C/T	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg15704280	chr7:45808275	SEPT13	-1.02	-23.2	-0.73	1.42e-79	Coronary artery disease;
LGG	cis	rs2599510	0.783	rs62136349	chr2:32827504	G/A	cg02381751	chr2:32503542	YIPF4	0.51	8.42	0.36	4.76e-16	Interleukin-18 levels;
LGG	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg06951627	chr6:26196580	NA	0.51	7.86	0.34	2.71e-14	Gout;Renal underexcretion gout;
LGG	cis	rs6032067	0.538	rs13041506	chr20:43739655	G/A	cg10761708	chr20:43804764	PI3	0.68	9.99	0.42	2.12e-21	Blood protein levels;
LGG	trans	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg02002194	chr4:3960332	NA	0.41	7.79	0.34	4.37e-14	Systolic blood pressure;
LGG	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg08250081	chr4:10125330	NA	0.38	7.33	0.32	1.02e-12	Bone mineral density;
LGG	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg13482628	chr17:19912719	NA	0.52	9.55	0.41	7.5599999999999994e-20	Schizophrenia;
LGG	trans	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg06521331	chr12:34319734	NA	0.51	9.32	0.4	4.94e-19	Bladder cancer;
LGG	cis	rs11209002	0.876	rs7517744	chr1:67570879	T/C	cg02640540	chr1:67518911	SLC35D1	0.45	6.85	0.3	2.39e-11	Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04223366	chr3:66024364	MAGI1	0.44	7.04	0.31	7.2e-12	Cognitive performance;
LGG	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg10189774	chr4:17578691	LAP3	0.41	7.22	0.32	2.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.22	-0.36	2.04e-15	Ulcerative colitis;
LGG	cis	rs3213545	0.700	rs2260445	chr12:121468863	C/A	cg02403541	chr12:121454288	C12orf43	0.53	9.12	0.39	2.29e-18	Subjective well-being;Cardiovascular disease risk factors;
LGG	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg17467752	chr17:38218738	THRA	-0.45	-7.23	-0.32	2.06e-12	Self-reported allergy;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg06654118	chr4:1303317	MAEA	-0.43	-7.28	-0.32	1.44e-12	Obesity-related traits;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.23	0.36	1.86e-15	Schizophrenia;
LGG	cis	rs67311347	0.713	rs73073505	chr3:40310693	C/T	cg13683864	chr3:40499215	RPL14	-0.9	-17.93	-0.64	5.46e-55	Renal cell carcinoma;
LGG	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg16662043	chr16:48846231	NA	0.38	7.41	0.33	5.96e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4595586	0.545	rs7952765	chr12:39375325	C/G	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs1456208	chr4:98678563	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.25e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7945705	0.837	rs10769981	chr11:9024460	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.35	6.89	0.3	1.85e-11	Hemoglobin concentration;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg07701084	chr6:150067640	NUP43	0.67	12.67	0.51	8.26e-32	Lung cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17427856	chr6:90539462	CASP8AP2	0.42	6.71	0.3	5.73e-11	Menarche (age at onset);
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg14926445	chr8:58193284	C8orf71	-0.9	-11.19	-0.46	7.02e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.93	-0.31	1.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg11859384	chr17:80120422	CCDC57	0.46	8.02	0.35	8.55e-15	Life satisfaction;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25172604	chr17:41446521	NA	-0.3	-6.77	-0.3	3.96e-11	Menopause (age at onset);
LGG	cis	rs1200821	0.535	rs1208783	chr10:37767467	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-8.12	-0.35	4.11e-15	Hemostatic factors and hematological phenotypes;
LGG	cis	rs10193935	0.892	rs7574609	chr2:42388468	C/A	cg27598129	chr2:42591480	NA	-0.61	-9.11	-0.39	2.59e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02773019	chr3:135684688	PPP2R3A	0.48	7.61	0.33	1.5700000000000001e-13	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg01879757	chr17:41196368	BRCA1	-0.46	-9.12	-0.39	2.29e-18	Menopause (age at onset);
LGG	cis	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg06521331	chr12:34319734	NA	-0.44	-8.04	-0.35	7.84e-15	Morning vs. evening chronotype;
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22968622	chr17:43663579	NA	-1.01	-18.82	-0.66	4.37e-59	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17376456	0.825	rs10038828	chr5:93124056	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.82	0.45	1.8e-24	Diabetic retinopathy;
LGG	cis	rs2070488	0.736	rs2070988	chr3:38437835	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.71	13.13	0.52	1.09e-33	Electrocardiographic conduction measures;
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.87	11.59	0.47	1.85e-27	Alzheimer's disease;
LGG	cis	rs60843830	1.000	rs60843830	chr2:286756	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	13.91	0.54	5.54e-37	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs17253792	0.822	rs2296181	chr14:56107051	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.78e-31	Putamen volume;
LGG	cis	rs7011049	1.000	rs72640852	chr8:53838084	G/A	cg26025543	chr8:53854495	NA	0.75	9.93	0.42	3.32e-21	Systolic blood pressure;
LGG	cis	rs4789452	1.000	rs11659109	chr17:75375859	C/T	cg06761530	chr17:75373219	SEPT9	-0.37	-7.27	-0.32	1.51e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg14789911	chr21:47582049	C21orf56	-0.45	-7.53	-0.33	2.65e-13	Testicular germ cell tumor;
LGG	cis	rs7766436	0.767	rs11754964	chr6:22604737	G/T	cg13666174	chr6:22585274	NA	-0.36	-8.41	-0.36	5.23e-16	Coronary artery disease;
LGG	cis	rs9467773	1.000	rs1321480	chr6:26532742	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.37	0.4	3.1400000000000002e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14829155	chr15:31115871	NA	-0.67	-11.31	-0.47	2.45e-26	Huntington's disease progression;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg13395646	chr4:1353034	KIAA1530	-0.61	-10.45	-0.44	4.33e-23	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs1591437	chr6:86525305	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-14.21	-0.55	2.78e-38	Response to antipsychotic treatment;
LGG	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg06115741	chr20:33292138	TP53INP2	0.55	8.49	0.37	2.91e-16	Coronary artery disease;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg16301924	chr13:53314226	LECT1	-0.38	-7.5	-0.33	3.33e-13	Lewy body disease;
LGG	cis	rs60871478	0.636	rs56393680	chr7:885696	A/G	cg22643751	chr7:855365	UNC84A	-0.43	-7.34	-0.32	9.62e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg04287289	chr16:89883240	FANCA	0.76	7.62	0.33	1.41e-13	Skin colour saturation;
LGG	cis	rs3857747	0.765	rs9718577	chr7:40365512	G/T	cg00420559	chr7:40367873	C7orf10	-0.41	-8.27	-0.36	1.47e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs754466	0.651	rs10824584	chr10:79625947	G/A	cg17075019	chr10:79541650	NA	-0.95	-20.43	-0.69	1.25e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4737010	0.644	rs518718	chr8:41611375	T/C	cg17182837	chr8:41585554	ANK1	0.45	7.02	0.31	7.76e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs757081	0.608	rs214938	chr11:17188516	C/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.92	-0.38	1.09e-17	Systolic blood pressure;
LGG	cis	rs7598759	0.527	rs4973417	chr2:232349636	G/T	cg19187155	chr2:232395269	NMUR1	0.53	9.75	0.41	1.51e-20	Noise-induced hearing loss;
LGG	cis	rs2652834	0.808	rs4775614	chr15:63351687	A/G	cg05507819	chr15:63340323	TPM1	0.6	8.08	0.35	5.72e-15	HDL cholesterol;
LGG	cis	rs4561483	0.583	rs11075032	chr16:12004450	C/T	cg08843971	chr16:11963173	GSPT1	0.59	14.76	0.57	1.16e-40	Testicular germ cell tumor;
LGG	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.31	-0.55	1.02e-38	Hair morphology;
LGG	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg09448879	chr15:79043637	NA	-0.43	-8.47	-0.37	3.25e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg01324343	chr3:183735012	ABCC5	0.82	17.42	0.63	1.22e-52	Anterior chamber depth;
LGG	cis	rs986417	0.901	rs1956558	chr14:60975956	T/C	cg27398547	chr14:60952738	C14orf39	0.73	7.03	0.31	7.36e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg01528321	chr10:82214614	TSPAN14	0.65	11.5	0.47	4.13e-27	Post bronchodilator FEV1;
LGG	trans	rs3780486	0.846	rs7873903	chr9:33142728	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	24.9	0.76	1.77e-87	IgG glycosylation;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg04008888	chr11:68622739	NA	-0.55	-11.84	-0.48	1.87e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg25664220	chr3:72788482	NA	-0.33	-9.23	-0.39	9.69e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg04287289	chr16:89883240	FANCA	0.56	10.1	0.42	8.15e-22	Vitiligo;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs894344	0.650	rs10111965	chr8:135590960	C/T	cg09855544	chr8:135498122	ZFAT	-0.42	-7.62	-0.33	1.48e-13	Systolic blood pressure;
LGG	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg13482628	chr17:19912719	NA	0.54	10.26	0.43	2.16e-22	Schizophrenia;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2282032	0.527	rs2282033	chr14:90769635	G/T	cg04374321	chr14:90722782	PSMC1	-0.47	-7.87	-0.34	2.51e-14	Longevity;
LGG	cis	rs858239	0.600	rs7785842	chr7:23141706	T/A	cg23682824	chr7:23144976	KLHL7	0.45	7.75	0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.68	0.3	6.91e-11	Schizophrenia;
LGG	cis	rs9534288	0.830	rs1409435	chr13:46631660	G/A	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg17747265	chr1:1875780	NA	-0.57	-11.35	-0.47	1.66e-26	Body mass index;
LGG	cis	rs9880211	0.821	rs9832813	chr3:136065565	A/G	cg12473912	chr3:136751656	NA	-0.5	-8.07	-0.35	6.29e-15	Body mass index;Height;
LGG	cis	rs2070488	0.965	rs7642472	chr3:38525567	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.22	0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs1707322	1.000	rs7547284	chr1:46319565	C/G	cg03146154	chr1:46216737	IPP	0.54	10.52	0.44	2.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7474896	0.559	rs1735641	chr10:38184852	C/A	cg25427524	chr10:38739819	LOC399744	0.51	7.45	0.33	4.7e-13	Obesity (extreme);
LGG	cis	rs8060686	0.641	rs8047119	chr16:68047345	G/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.15	0.35	3.35e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs17534004	1.000	rs35858501	chr13:31472120	C/T	cg00367615	chr13:31480979	C13orf33	0.36	7.22	0.32	2.12e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-11.11	-0.46	1.38e-25	Response to antipsychotic treatment;
LGG	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg21775007	chr8:11205619	TDH	0.42	6.74	0.3	4.61e-11	Morning vs. evening chronotype;
LGG	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg26874164	chr19:58962979	ZNF324B	0.38	7.53	0.33	2.7e-13	Uric acid clearance;
LGG	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	cg07928641	chr1:182991847	LAMC1	-0.46	-9.25	-0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg00290607	chr11:67383545	NA	0.62	11.71	0.48	6.51e-28	Mean corpuscular volume;
LGG	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg26384229	chr12:38710491	ALG10B	0.76	15.58	0.59	2.55e-44	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.89	-0.38	1.37e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.77	-0.3	3.96e-11	Electroencephalogram traits;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg22398616	chr13:53314203	LECT1	0.44	8.94	0.38	9.49e-18	Lewy body disease;
LGG	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg00129232	chr17:37814104	STARD3	-0.49	-9.43	-0.4	2.01e-19	Self-reported allergy;
LGG	cis	rs9457247	0.534	rs9356551	chr6:167400345	T/C	cg18261144	chr6:167370276	RNASET2	-0.38	-7.85	-0.34	2.88e-14	Crohn's disease;
LGG	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg15704280	chr7:45808275	SEPT13	-0.58	-9.87	-0.42	5.6e-21	HDL cholesterol;
LGG	cis	rs2769264	0.602	rs11204777	chr1:151072049	G/A	cg03258749	chr1:151040405	MLLT11	-0.54	-8.41	-0.36	5.15e-16	Blood trace element (Cu levels);
LGG	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.7	-0.37	5.88e-17	Platelet distribution width;
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.02	-0.31	7.95e-12	Prostate cancer;
LGG	cis	rs7715806	0.500	rs17563610	chr5:74981322	A/T	cg19683494	chr5:74908142	NA	0.52	6.89	0.31	1.78e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2188561	0.697	rs3735607	chr7:107384278	C/T	cg16793755	chr7:107334138	SLC26A4	0.41	7.17	0.32	2.94e-12	Alcohol consumption;
LGG	trans	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg05059571	chr16:84539110	KIAA1609	0.54	10.07	0.42	1.09e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11771526	0.901	rs11767773	chr7:32272342	T/G	cg13207630	chr7:32358064	NA	0.61	6.8	0.3	3.23e-11	Body mass index;
LGG	cis	rs2377585	0.706	rs73053851	chr12:8839377	C/G	cg03761649	chr12:8850719	RIMKLB	0.49	7.78	0.34	4.65e-14	Reticulocyte fraction of red cells;
LGG	cis	rs10463316	0.894	rs7709994	chr5:150753597	A/T	cg03212797	chr5:150827313	SLC36A1	-0.61	-10.66	-0.44	7.1e-24	Metabolite levels (Pyroglutamine);
LGG	trans	rs12439619	0.846	rs62012059	chr15:82544010	A/C	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.67	-0.3	7.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4948275	0.773	rs2787696	chr10:63293207	A/G	cg03237606	chr10:63212265	TMEM26	-0.39	-7.01	-0.31	8.41e-12	Night sleep phenotypes;
LGG	cis	rs3806843	1.000	rs1030164	chr5:140185272	A/G	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.71	-13.23	-0.52	3.94e-34	Longevity;Endometriosis;
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg12395012	chr8:11607386	GATA4	0.38	6.79	0.3	3.5e-11	Triglycerides;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg08645402	chr16:4508243	NA	0.5	9.55	0.41	7.49e-20	Schizophrenia;
LGG	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg22232500	chr2:134024266	NCKAP5	-0.55	-8.0	-0.35	9.87e-15	Bipolar disorder;
LGG	cis	rs9596863	0.948	rs9568907	chr13:54335565	C/G	ch.13.53330881F	chr13:54432880	NA	0.54	7.32	0.32	1.09e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg25600027	chr14:23388339	RBM23	-0.44	-7.31	-0.32	1.19e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs8180040	0.934	rs12630641	chr3:47534836	G/T	cg27129171	chr3:47204927	SETD2	0.79	15.13	0.58	2.6e-42	Colorectal cancer;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg11965913	chr1:205819406	PM20D1	-0.37	-6.98	-0.31	1.02e-11	Prostate-specific antigen levels;
LGG	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg21211680	chr2:198530	NA	-1.17	-16.01	-0.6	3.02e-46	Blood protein levels;
LGG	cis	rs4950322	0.518	rs61838938	chr1:146577525	G/A	cg22381352	chr1:146742008	CHD1L	-0.42	-7.24	-0.32	1.82e-12	Protein quantitative trait loci;
LGG	cis	rs8067545	0.532	rs3862151	chr17:19957289	A/G	cg13482628	chr17:19912719	NA	0.53	8.8	0.38	2.78e-17	Schizophrenia;
LGG	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg07936489	chr17:37558343	FBXL20	-0.83	-15.33	-0.58	3.28e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs2594989	0.721	rs9860504	chr3:11573615	G/T	cg01796438	chr3:11312864	ATG7	0.53	7.17	0.32	2.98e-12	Circulating chemerin levels;
LGG	cis	rs17767392	0.670	rs11845249	chr14:71723237	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.9	-0.34	2.06e-14	Mitral valve prolapse;
LGG	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg02002194	chr4:3960332	NA	0.45	8.28	0.36	1.37e-15	Neuroticism;
LGG	cis	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg08835221	chr22:38071607	LGALS1	0.27	7.52	0.33	2.81e-13	Fat distribution (HIV);
LGG	cis	rs9308433	0.505	rs958304	chr1:214474241	C/T	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.1e-14	IgG glycosylation;
LGG	cis	rs3106136	0.546	rs4693003	chr4:95145469	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.94	-0.45	6.4e-25	Capecitabine sensitivity;
LGG	trans	rs4714291	0.963	rs847743	chr6:40087154	C/G	cg02267698	chr19:7991119	CTXN1	0.6	9.36	0.4	3.36e-19	Strep throat;
LGG	trans	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg07393940	chr7:158741817	NA	-0.6	-10.9	-0.45	8.51e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs514406	0.861	rs72637996	chr1:53249618	A/T	cg16325326	chr1:53192061	ZYG11B	-0.72	-17.12	-0.62	3e-51	Monocyte count;
LGG	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg18876405	chr7:65276391	NA	0.68	12.96	0.52	5.64e-33	Aortic root size;
LGG	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-8.9	-0.38	1.25e-17	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14073117	chr9:4792649	RCL1	0.45	7.52	0.33	2.78e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs8014204	0.836	rs7154256	chr14:75252587	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.04	-0.31	6.84e-12	Caffeine consumption;
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg09461388	chr22:46763229	CELSR1	-0.59	-6.66	-0.3	7.81e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg22676075	chr6:135203613	NA	-0.44	-7.37	-0.32	8.08e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9814567	1.000	rs4974484	chr3:134219019	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.98	-0.52	4.69e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.21e-13	Personality dimensions;
LGG	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-6.96	-0.31	1.18e-11	Huntington's disease progression;
LGG	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.46	-0.47	5.89e-27	Schizophrenia;
LGG	cis	rs9300255	0.602	rs1716160	chr12:123700225	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs67460515	0.563	rs11922959	chr3:160828871	A/G	cg04691961	chr3:161091175	C3orf57	-0.44	-8.33	-0.36	9.38e-16	Parkinson's disease;
LGG	cis	rs963731	0.649	rs366840	chr2:39315651	A/C	cg04010122	chr2:39346883	SOS1	-0.78	-8.1	-0.35	4.82e-15	Corticobasal degeneration;
LGG	cis	rs7215564	0.908	rs2873060	chr17:78663497	A/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.23	-0.36	1.96e-15	Myopia (pathological);
LGG	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg21095983	chr6:86352623	SYNCRIP	0.55	9.82	0.42	8.58e-21	Smooth-surface caries;
LGG	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg13010199	chr12:38710504	ALG10B	0.76	16.28	0.6	1.88e-47	Heart rate;
LGG	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-19.87	-0.68	5.59e-64	Blood trace element (Zn levels);
LGG	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-22.01	-0.72	5.23e-74	Leprosy;
LGG	cis	rs9810089	0.814	rs10804640	chr3:136165695	G/A	cg21827317	chr3:136751795	NA	0.47	8.43	0.36	4.29e-16	Gestational age at birth (child effect);
LGG	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg10596483	chr8:143751796	JRK	0.59	9.69	0.41	2.51e-20	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11877577	chr6:133135687	RPS12;SNORD101	-0.46	-7.77	-0.34	5.19e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg02725872	chr8:58115012	NA	0.87	12.61	0.51	1.49e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06689961	chr12:12870959	CDKN1B	0.45	7.19	0.32	2.62e-12	Cognitive performance;
LGG	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs929596	0.501	rs4530361	chr2:234590041	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.4	-0.36	5.53e-16	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.88	-0.42	5.23e-21	Aortic root size;
LGG	cis	rs6831352	0.819	rs2851274	chr4:100025866	G/C	cg12011299	chr4:100065546	ADH4	0.42	8.63	0.37	9.84e-17	Alcohol dependence;
LGG	cis	rs7683537	0.501	rs2171838	chr4:185667404	A/G	cg04058563	chr4:185651563	MLF1IP	-0.73	-12.87	-0.51	1.25e-32	Systemic lupus erythematosus;
LGG	cis	rs2816062	0.775	rs2816046	chr1:18893708	A/G	cg18795169	chr1:18902165	NA	-1.03	-30.14	-0.81	3.14e-111	Urate levels in lean individuals;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg03188948	chr7:1209495	NA	0.69	9.68	0.41	2.61e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg22903471	chr2:27725779	GCKR	-0.36	-7.98	-0.35	1.19e-14	Oral cavity cancer;
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg16359550	chr11:109292809	C11orf87	0.7	14.5	0.56	1.45e-39	Schizophrenia;
LGG	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg18681998	chr4:17616180	MED28	0.89	19.74	0.68	2.3e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg13206674	chr6:150067644	NUP43	0.66	14.9	0.57	2.57e-41	Lung cancer;
LGG	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg26150922	chr2:100937072	LONRF2	0.51	9.17	0.39	1.51e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	9.89	0.42	4.89e-21	Neuroticism;
LGG	cis	rs7666738	0.830	rs3911282	chr4:99037602	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg08027265	chr7:2291960	NA	0.48	8.5	0.37	2.59e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.37	-0.32	7.88e-13	Morning vs. evening chronotype;
LGG	cis	rs2180341	0.960	rs7753913	chr6:127671296	A/G	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	cis	rs7666738	0.791	rs62318641	chr4:98816964	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.79	0.34	4.56e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10492096	0.947	rs11559082	chr12:6602367	C/T	cg13857086	chr12:6580257	VAMP1	0.51	7.35	0.32	9.3e-13	Hip geometry;
LGG	cis	rs6748734	0.779	rs11680800	chr2:241793977	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-10.1	-0.42	8.5e-22	Urinary metabolites;
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg18446336	chr7:2847575	GNA12	-0.29	-7.34	-0.32	9.43e-13	Height;
LGG	cis	rs2188554	0.675	rs39325	chr7:116970290	C/G	cg10524701	chr7:117356490	CTTNBP2	0.36	7.02	0.31	8.04e-12	Esophageal adenocarcinoma;
LGG	cis	rs8005677	0.962	rs11157931	chr14:23403193	A/C	cg25600027	chr14:23388339	RBM23	-0.43	-7.1	-0.31	4.82e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs61990749	0.544	rs2544567	chr14:78181739	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.34	0.32	9.85e-13	Fibroblast growth factor basic levels;
LGG	cis	rs3784262	0.631	rs4646566	chr15:58348173	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.8	-0.3	3.18e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.94	-0.35	1.52e-14	Retinal vascular caliber;
LGG	cis	rs7222240	1.000	rs16939858	chr17:43183420	C/T	cg24806326	chr17:43207588	PLCD3	0.47	8.06	0.35	6.54e-15	Craniofacial microsomia;
LGG	cis	rs5769765	0.908	rs138889	chr22:50226673	T/C	cg26441486	chr22:50317300	CRELD2	0.4	7.45	0.33	4.74e-13	Schizophrenia;
LGG	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg08305652	chr11:111469057	NA	0.35	6.93	0.31	1.43e-11	Primary sclerosing cholangitis;
LGG	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.46	2.55e-26	Total body bone mineral density;
LGG	cis	rs2415984	0.622	rs1955262	chr14:46940639	A/G	cg14871534	chr14:47121158	RPL10L	-0.59	-10.38	-0.43	7.76e-23	Number of children ever born;
LGG	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-10.8	-0.45	2.19e-24	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg26578617	chr4:90757533	SNCA	-0.4	-8.07	-0.35	6.05e-15	Dementia with Lewy bodies;
LGG	cis	rs60871478	0.787	rs4720928	chr7:808002	T/C	cg05535760	chr7:792225	HEATR2	0.79	12.68	0.51	7.97e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25072359	chr17:41440525	NA	0.54	10.23	0.43	2.85e-22	Menopause (age at onset);
LGG	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	11.91	0.48	1.05e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs721399	0.583	rs4646267	chr8:18247913	A/G	cg18736775	chr8:18248649	NAT2	-0.8	-12.19	-0.49	7.92e-30	Blood metabolite levels;
LGG	trans	rs6582630	0.502	rs11182760	chr12:38606273	A/T	cg06521331	chr12:34319734	NA	-0.5	-8.61	-0.37	1.13e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg04287289	chr16:89883240	FANCA	0.84	7.81	0.34	3.81e-14	Skin colour saturation;
LGG	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg13939156	chr17:80058883	NA	0.41	7.31	0.32	1.21e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4731207	0.569	rs75791754	chr7:124464917	C/T	cg05630886	chr7:124431682	NA	0.32	7.56	0.33	2.16e-13	Cutaneous malignant melanoma;
LGG	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg26769984	chr7:1090371	C7orf50	0.5	8.16	0.35	3.12e-15	Bronchopulmonary dysplasia;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.26	0.46	3.56e-26	Bone mineral density;
LGG	cis	rs6784615	1.000	rs34181173	chr3:52360647	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.74	0.34	6.47e-14	Waist-hip ratio;
LGG	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	9.75	0.41	1.53e-20	Coronary artery disease;
LGG	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg07274523	chr3:49395745	GPX1	0.56	9.37	0.4	3.29e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs12517041	0.873	rs10039144	chr5:23272483	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.62	-8.96	-0.38	7.93e-18	Calcium levels;
LGG	cis	rs2594989	0.616	rs6442254	chr3:11474491	T/C	cg01796438	chr3:11312864	ATG7	-0.52	-7.2	-0.32	2.4e-12	Circulating chemerin levels;
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.68	-0.54	5.22e-36	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.09	-0.39	2.89e-18	Obesity-related traits;
LGG	trans	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg25214090	chr10:38739885	LOC399744	0.68	12.02	0.49	3.86e-29	Corneal astigmatism;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg16507663	chr6:150244633	RAET1G	0.42	8.01	0.35	9.11e-15	Lung cancer;
LGG	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg18551225	chr6:44695536	NA	-0.61	-10.06	-0.42	1.18e-21	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19738812	chr7:99102438	ZKSCAN5	0.47	7.72	0.34	7.35e-14	Cognitive performance;
LGG	cis	rs7792596	0.861	rs57900160	chr7:93986265	C/G	cg20814616	chr7:94014465	NA	-0.39	-7.75	-0.34	5.73e-14	Intelligence;
LGG	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs6977660	0.714	rs28371050	chr7:19816882	C/T	cg05791153	chr7:19748676	TWISTNB	0.75	10.47	0.44	3.59e-23	Thyroid stimulating hormone;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg05165339	chr4:1420672	NA	-0.26	-6.91	-0.31	1.6e-11	Longevity;
LGG	cis	rs6032067	0.641	rs34313230	chr20:43755858	C/G	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs1800795	0.652	rs7802307	chr7:22766433	T/A	cg05265849	chr7:22767390	IL6	0.41	7.88	0.34	2.34e-14	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LGG	cis	rs2587949	0.615	rs1087728	chr3:4202778	A/G	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.76e-11	Periodontitis (DPAL);
LGG	trans	rs62458065	0.640	rs6950077	chr7:32502895	A/G	cg00845942	chr12:64062724	DPY19L2	0.51	6.74	0.3	4.6e-11	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs8077889	0.719	rs57227660	chr17:41858984	T/C	cg26893861	chr17:41843967	DUSP3	1.05	23.95	0.74	4.86e-83	Triglycerides;
LGG	cis	rs7020830	0.823	rs13285624	chr9:37129496	T/G	cg14294708	chr9:37120828	ZCCHC7	1.2	32.21	0.83	2.62e-120	Schizophrenia;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg11245990	chr11:68621969	NA	0.4	8.59	0.37	1.33e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg19774624	chr17:42201019	HDAC5	-0.96	-20.83	-0.7	1.76e-68	Total body bone mineral density;
LGG	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.0	-0.31	8.77e-12	Vitiligo;
LGG	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg26248373	chr2:1572462	NA	-0.89	-14.25	-0.55	1.77e-38	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs11771526	1.000	rs11771526	chr7:32342618	A/G	cg27532318	chr7:32358331	NA	0.84	7.98	0.35	1.18e-14	Body mass index;
LGG	cis	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg21775007	chr8:11205619	TDH	-0.75	-12.79	-0.51	2.72e-32	Retinal vascular caliber;
LGG	cis	rs367943	0.712	rs6896650	chr5:112681048	T/C	cg12552261	chr5:112820674	MCC	0.54	9.77	0.41	1.28e-20	Type 2 diabetes;
LGG	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg04727924	chr7:799746	HEATR2	-0.49	-7.2	-0.32	2.53e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs41005	0.967	rs41002	chr2:8113921	C/T	cg03155496	chr2:8117019	LOC339788	0.94	22.95	0.73	2.24e-78	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs16976116	0.901	rs1050931	chr15:55497691	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	3.92e-34	Bladder cancer;
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg02353165	chr6:42928485	GNMT	0.55	17.59	0.63	2.07e-53	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.54e-12	Hemoglobin concentration;
LGG	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg10664184	chr19:17420304	DDA1	0.55	8.49	0.37	2.86e-16	Systemic lupus erythematosus;
LGG	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg12623918	chr2:306882	NA	0.51	9.5	0.4	1.17e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7766436	0.885	rs6935379	chr6:22581462	A/G	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg16586182	chr3:47516702	SCAP	0.73	13.24	0.52	3.59e-34	Colorectal cancer;
LGG	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.19	0.32	2.59e-12	Educational attainment;
LGG	cis	rs7226408	0.842	rs62083201	chr18:34347836	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.79	-0.3	3.46e-11	Obesity-related traits;
LGG	cis	rs17092148	1.000	rs7271289	chr20:33397303	C/T	cg12302830	chr20:33297742	TP53INP2	0.46	7.75	0.34	5.97e-14	Neuroticism;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg20309703	chr11:118481025	PHLDB1	0.52	9.49	0.4	1.19e-19	Cholesterol, total;
LGG	cis	rs8135665	0.600	rs3948	chr22:38456680	G/A	cg19171272	chr22:38449367	NA	-0.44	-7.73	-0.34	6.76e-14	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs7945705	0.692	rs2742470	chr11:9004002	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.32	-0.47	2.2e-26	Hemoglobin concentration;
LGG	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg27398817	chr8:82754497	SNX16	-0.71	-10.07	-0.42	1.06e-21	Diastolic blood pressure;
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg22753661	chr15:79092743	ADAMTS7	0.41	6.7	0.3	6.2e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs7589342	0.839	rs11895235	chr2:106432355	C/G	cg14210321	chr2:106509881	NCK2	-0.49	-8.39	-0.36	6e-16	Addiction;
LGG	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg02227867	chr8:22457446	C8orf58	-0.41	-7.94	-0.35	1.51e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs17767392	0.958	rs3825719	chr14:72053097	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.32	-0.36	9.69e-16	Mitral valve prolapse;
LGG	trans	rs7246760	1.000	rs10425775	chr19:9912917	G/A	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg15971980	chr6:150254442	NA	0.45	8.53	0.37	2.17e-16	Lung cancer;
LGG	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.58	0.33	1.88e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4819388	1.000	rs4819388	chr21:45647421	T/C	cg01992765	chr21:45622493	NA	-0.44	-8.29	-0.36	1.24e-15	Celiac disease;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg17470184	chr11:118478236	PHLDB1	0.4	6.88	0.3	1.94e-11	Cholesterol, total;
LGG	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs9926296	0.528	rs4785721	chr16:89839997	G/A	cg07648498	chr16:89883185	FANCA	0.41	6.92	0.31	1.52e-11	Vitiligo;
LGG	cis	rs9398803	0.687	rs9491653	chr6:126943630	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs4363385	0.818	rs10888525	chr1:153000215	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.77	-0.38	3.52e-17	Inflammatory skin disease;
LGG	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg07636037	chr3:49044803	WDR6	1.1	27.91	0.79	2.84e-101	Parkinson's disease;
LGG	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg11441379	chr12:63026424	NA	0.69	9.66	0.41	3.04e-20	IgG glycosylation;
LGG	cis	rs2074193	0.627	rs215343	chr12:47733012	T/C	cg02516419	chr12:47771422	NA	-0.63	-8.47	-0.37	3.22e-16	Migraine with aura;
LGG	trans	rs208520	0.690	rs1100981	chr6:66852052	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.75	-0.64	3.93e-54	Exhaled nitric oxide output;
LGG	cis	rs4713675	0.565	rs2281829	chr6:33675642	A/G	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.79e-11	Plateletcrit;
LGG	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg17230874	chr3:125932073	NA	0.59	11.76	0.48	4.02e-28	Metabolite levels;
LGG	cis	rs4843747	0.671	rs8062855	chr16:88106941	T/C	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	cis	rs62380364	0.566	rs1705565	chr5:88048457	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg00666640	chr1:248458726	OR2T12	-0.59	-9.21	-0.39	1.17e-18	Common traits (Other);
LGG	cis	rs909674	0.818	rs5750833	chr22:39843091	C/A	cg11247378	chr22:39784982	NA	-0.3	-8.38	-0.36	6.33e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg20040747	chr15:74715105	SEMA7A	0.44	9.53	0.4	9.06e-20	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs12476592	0.602	rs10176522	chr2:63722433	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.91	-0.31	1.58e-11	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg17202724	chr17:61916730	SMARCD2	0.62	15.02	0.57	7.92e-42	Prudent dietary pattern;
LGG	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg15704280	chr7:45808275	SEPT13	0.84	8.77	0.38	3.42e-17	Myopia (pathological);
LGG	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg09238746	chr17:78121135	EIF4A3	0.53	9.56	0.41	7.11e-20	Yeast infection;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.9e-12	Life satisfaction;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg00495681	chr13:53174319	NA	0.94	21.64	0.71	2.94e-72	Lewy body disease;
LGG	cis	rs9640161	0.659	rs7788316	chr7:150013995	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.7	-14.35	-0.55	6.81e-39	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg03175030	chr11:2018143	H19;MIR675	-0.43	-8.0	-0.35	9.85e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1566085	0.674	rs73713412	chr8:142658347	T/G	cg26331504	chr8:142652174	NA	-0.29	-6.72	-0.3	5.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.27	0.46	3.37e-26	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03664139	chr6:101329504	ASCC3	0.49	7.9	0.34	2.04e-14	Gut microbiome composition (summer);
LGG	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg22771759	chr13:24902376	NA	0.41	6.78	0.3	3.57e-11	Obesity-related traits;
LGG	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg27490568	chr2:178487706	NA	-0.81	-14.28	-0.55	1.4e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.62	0.33	1.46e-13	Electroencephalogram traits;
LGG	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg09307838	chr4:120376055	NA	0.72	12.45	0.5	6.76e-31	Corneal astigmatism;
LGG	cis	rs9902453	0.967	rs4429345	chr17:28458105	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.66	-0.54	6.48e-36	Coffee consumption (cups per day);
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-7.31	-0.32	1.18e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg06611532	chr13:114900021	NA	0.3	7.66	0.34	1.12e-13	Schizophrenia;
LGG	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.23	0.49	5.45e-30	Rheumatoid arthritis;
LGG	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07570687	chr10:102243282	WNT8B	0.45	7.82	0.34	3.62e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg04691961	chr3:161091175	C3orf57	-0.46	-9.59	-0.41	5.69e-20	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.920	rs116246794	chr4:119732491	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg07120314	chr15:79043507	NA	0.57	9.05	0.39	3.98e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg19761014	chr17:28927070	LRRC37B2	0.53	6.67	0.3	7.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs240764	0.604	rs705583	chr6:101261408	C/A	cg09795085	chr6:101329169	ASCC3	0.46	7.74	0.34	6.26e-14	Neuroticism;
LGG	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg16141378	chr3:129829833	LOC729375	0.4	8.8	0.38	2.63e-17	Retinal vascular caliber;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg22907277	chr7:1156413	C7orf50	0.62	11.65	0.48	1.15e-27	Longevity;Endometriosis;
LGG	cis	rs3806843	0.868	rs2563281	chr5:140131219	T/A	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4851266	1.000	rs893246	chr2:100814917	T/C	cg21926883	chr2:100939477	LONRF2	-0.43	-7.73	-0.34	6.82e-14	Educational attainment;
LGG	cis	rs2640806	0.645	rs3735987	chr8:97332661	A/G	cg22138393	chr8:97340270	PTDSS1	0.32	8.31	0.36	1.09e-15	Obesity-related traits;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02461391	chr16:80838265	CDYL2	-0.4	-6.73	-0.3	4.89e-11	Brain structure;
LGG	cis	rs4474465	1.000	rs7943673	chr11:78172986	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs847649	0.731	rs1829957	chr7:102687010	T/A	cg18108683	chr7:102477205	FBXL13	0.54	10.92	0.45	7.29e-25	Morning vs. evening chronotype;
LGG	cis	rs910316	0.789	rs12894419	chr14:75471802	C/T	cg08847533	chr14:75593920	NEK9	0.55	10.18	0.43	4.4e-22	Height;
LGG	cis	rs10267417	0.603	rs10215844	chr7:19909227	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	7.49	0.33	3.55e-13	Night sleep phenotypes;
LGG	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.93e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg07936489	chr17:37558343	FBXL20	0.99	15.36	0.58	2.5e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg13013644	chr5:502571	SLC9A3	0.32	6.92	0.31	1.55e-11	Cystic fibrosis severity;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg10802521	chr3:52805072	NEK4	0.4	6.81	0.3	2.98e-11	Bipolar disorder;
LGG	cis	rs9557207	0.538	rs1536657	chr13:99805420	T/C	cg24509225	chr13:100037070	UBAC2	-0.37	-7.35	-0.32	8.98e-13	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7742824	0.843	rs7743249	chr6:44072863	G/A	cg04074908	chr6:44101190	TMEM63B	0.59	12.08	0.49	2.24e-29	Major depressive disorder;
LGG	trans	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg21659725	chr3:3221576	CRBN	-0.54	-9.36	-0.4	3.52e-19	Body mass index;
LGG	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.75	-0.41	1.53e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs1408799	0.711	rs10960723	chr9:12622878	C/A	cg05274944	chr9:12693694	TYRP1	0.32	7.47	0.33	4.01e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg18252515	chr7:66147081	NA	-0.76	-12.05	-0.49	2.93e-29	Corneal structure;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg11235426	chr6:292522	DUSP22	-0.45	-7.77	-0.34	4.98e-14	Menopause (age at onset);
LGG	cis	rs12545109	0.800	rs1348082	chr8:57415016	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs12369635	1.000	rs12369635	chr12:129561356	C/T	cg01909103	chr12:129572610	TMEM132D	-0.71	-7.08	-0.31	5.52e-12	Schizophrenia (inflammation and infection response interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22141315	chr7:6523968	KDELR2	0.39	6.77	0.3	3.98e-11	Bipolar disorder;
LGG	cis	rs10791323	0.628	rs4937838	chr11:133733406	T/C	cg00579200	chr11:133705235	NA	-0.52	-9.85	-0.42	6.5e-21	Childhood ear infection;
LGG	cis	rs9831754	0.654	rs9837024	chr3:78451637	C/T	cg06138941	chr3:78371609	NA	0.8	15.38	0.58	2.14e-43	Calcium levels;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	5.12e-12	Prudent dietary pattern;
LGG	cis	rs2832077	0.943	rs11702320	chr21:30195251	A/T	cg08807101	chr21:30365312	RNF160	-0.58	-7.98	-0.35	1.16e-14	Cognitive test performance;
LGG	cis	rs8056893	0.531	rs4783616	chr16:68343224	G/A	cg07273125	chr16:68295692	NA	0.46	10.24	0.43	2.48e-22	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	1.02e-16	Lung cancer;
LGG	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg07606381	chr6:8435919	SLC35B3	-0.58	-10.18	-0.43	4.12e-22	Motion sickness;
LGG	cis	rs17665859	0.925	rs13258819	chr8:479636	G/A	cg17960703	chr8:356704	FBXO25	0.84	7.81	0.34	3.87e-14	Bilirubin levels;
LGG	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg12395012	chr8:11607386	GATA4	0.42	7.34	0.32	9.7e-13	Myopia (pathological);
LGG	cis	rs62244186	0.566	rs3762636	chr3:44854563	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	7.9	0.34	2.04e-14	Depressive symptoms;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.5	9.64	0.41	3.53e-20	Prudent dietary pattern;
LGG	cis	rs7646881	0.812	rs73017541	chr3:158460796	T/G	cg19483011	chr3:158453295	NA	-0.62	-8.34	-0.36	8.53e-16	Tetralogy of Fallot;
LGG	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-6.69	-0.3	6.61e-11	Huntington's disease progression;
LGG	cis	rs7814319	0.901	rs13253635	chr8:97240847	A/G	cg20787634	chr8:97240163	UQCRB	-0.78	-18.24	-0.65	2.08e-56	Lung function (FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06187921	chr16:86597575	NA	0.48	7.03	0.31	7.55e-12	Gut microbiome composition (summer);
LGG	trans	rs800082	1.000	rs1405597	chr3:144314276	A/C	cg24215973	chr2:240111563	HDAC4	-0.48	-8.48	-0.37	3.03e-16	Smoking behavior;
LGG	cis	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.36	-0.32	8.45e-13	Triglycerides;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.71	0.3	5.56e-11	Lung cancer;
LGG	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.15	-0.49	1.12e-29	Morning vs. evening chronotype;
LGG	cis	rs12195424	0.558	rs77156915	chr6:56299661	T/C	cg07152817	chr6:56299822	NA	-0.98	-10.57	-0.44	1.54e-23	Cerebrospinal fluid clusterin levels;
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12016809	chr21:47604291	C21orf56	-0.59	-9.91	-0.42	3.93e-21	Testicular germ cell tumor;
LGG	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg23625390	chr15:77176239	SCAPER	0.49	9.61	0.41	4.73e-20	Blood metabolite levels;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg04166393	chr7:2884313	GNA12	-0.45	-8.89	-0.38	1.42e-17	Height;
LGG	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg03929089	chr4:120376271	NA	-0.64	-8.93	-0.38	9.91e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs533581	0.866	rs488251	chr16:88972554	G/A	cg08484992	chr16:88977278	CBFA2T3	0.33	7.16	0.32	3.12e-12	Social autistic-like traits;
LGG	cis	rs7766436	0.767	rs6909574	chr6:22606773	A/G	cg13666174	chr6:22585274	NA	-0.36	-8.68	-0.37	7.03e-17	Coronary artery disease;
LGG	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg27129171	chr3:47204927	SETD2	-0.79	-15.22	-0.58	1.01e-42	Colorectal cancer;
LGG	cis	rs425535	0.757	rs4694653	chr4:74797752	G/A	cg01447579	chr4:74847100	PF4	0.54	6.92	0.31	1.55e-11	Blood protein levels;
LGG	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.31e-13	HDL cholesterol;
LGG	cis	rs7827545	0.545	rs1867062	chr8:135559079	G/A	cg17885191	chr8:135476712	NA	0.6	8.87	0.38	1.56e-17	Hypertension (SNP x SNP interaction);
LGG	trans	rs9354308	0.834	rs9354307	chr6:66552953	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-8.47	-0.37	3.23e-16	Metabolite levels;
LGG	cis	rs9534288	0.762	rs4941539	chr13:46597067	A/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.89	9.99	0.42	2.02e-21	Diabetic retinopathy;
LGG	cis	rs963731	0.579	rs12620003	chr2:39345862	C/T	cg04010122	chr2:39346883	SOS1	0.77	7.93	0.35	1.68e-14	Corticobasal degeneration;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	9.07	0.39	3.38e-18	Longevity;
LGG	cis	rs9649465	1.000	rs2299983	chr7:123356642	C/G	cg03229431	chr7:123269106	ASB15	-0.41	-9.04	-0.39	4.45e-18	Migraine;
LGG	cis	rs7666738	0.715	rs3857216	chr4:99032129	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg24803719	chr17:45855879	NA	0.3	8.31	0.36	1.05e-15	IgG glycosylation;
LGG	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs9815354	0.761	rs17280777	chr3:41806167	C/T	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6988985	0.703	rs4736309	chr8:143947580	A/G	cg10324643	chr8:143916377	GML	0.38	7.5	0.33	3.37e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg10122326	chr6:28072925	NA	0.88	6.78	0.3	3.61e-11	Parkinson's disease;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.69	-0.51	6.91e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg03929089	chr4:120376271	NA	0.71	9.88	0.42	5.02e-21	Axial length;
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.69e-12	Bipolar disorder;
LGG	cis	rs9814567	0.929	rs1863911	chr3:134205231	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	3.91e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg20308403	chr7:2120281	MAD1L1	-0.33	-6.93	-0.31	1.46e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7614311	0.731	rs3733121	chr3:63850660	C/G	cg22134162	chr3:63841271	THOC7	-0.45	-7.86	-0.34	2.64e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg01557791	chr16:72042693	DHODH	-0.6	-9.26	-0.4	7.41e-19	Blood protein levels;
LGG	cis	rs4774830	0.590	rs62045212	chr15:56251312	A/T	cg05129572	chr15:56138634	NEDD4	0.87	7.99	0.35	1.05e-14	Delta-5 desaturase activity;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.33	-0.32	1.05e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	1.000	rs9990351	chr3:134239191	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.95	0.52	5.93e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7084783	0.500	rs9521	chr10:105358458	C/G	cg00126946	chr10:105363258	SH3PXD2A	-0.48	-8.61	-0.37	1.18e-16	Fear of pain;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.62e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6500395	0.735	rs74017013	chr16:48664120	G/A	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06522063	chr2:190306158	WDR75	-0.48	-7.07	-0.31	5.85e-12	Systemic lupus erythematosus;
LGG	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg12179176	chr11:130786555	SNX19	0.78	14.72	0.56	1.64e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2354432	0.505	rs7551766	chr1:146858964	A/G	cg25205988	chr1:146714368	CHD1L	-1.23	-11.73	-0.48	5.32e-28	Mitochondrial DNA levels;
LGG	cis	rs36051895	0.695	rs12352214	chr9:5018041	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-15.83	-0.59	2.11e-45	Pediatric autoimmune diseases;
LGG	cis	rs1014246	0.807	rs12784789	chr10:118473593	A/T	cg14919929	chr10:118506882	NA	0.58	11.14	0.46	1.08e-25	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg05791153	chr7:19748676	TWISTNB	0.58	8.82	0.38	2.43e-17	Thyroid stimulating hormone;
LGG	cis	rs9354308	0.764	rs9351530	chr6:66589648	G/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg24375607	chr4:120327624	NA	0.68	11.03	0.46	2.74e-25	Corneal astigmatism;
LGG	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg14019146	chr3:50243930	SLC38A3	-0.55	-11.59	-0.47	1.91e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg05313129	chr8:58192883	C8orf71	-0.63	-8.47	-0.37	3.37e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-10.4	-0.44	6.6e-23	Bronchopulmonary dysplasia;
LGG	cis	rs6489882	0.902	rs4767040	chr12:113374017	C/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.52	-0.33	2.88e-13	Chronic lymphocytic leukemia;
LGG	cis	rs73193808	0.614	rs11088112	chr21:30566236	T/A	cg03476357	chr21:30257390	N6AMT1	0.41	6.85	0.3	2.38e-11	Coronary artery disease;
LGG	cis	rs36051895	0.664	rs2274649	chr9:5090934	A/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.66	-0.56	3.02e-40	Pediatric autoimmune diseases;
LGG	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg24558204	chr6:135376177	HBS1L	0.62	10.79	0.45	2.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03606328	chr1:62902271	USP1	0.4	7.21	0.32	2.31e-12	Gut microbiome composition (summer);
LGG	cis	rs2304069	0.954	rs216127	chr5:149428890	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.59	7.73	0.34	6.63e-14	HIV-1 control;
LGG	cis	rs752010	0.714	rs6658500	chr1:42088344	A/G	cg06885757	chr1:42089581	HIVEP3	-0.62	-14.22	-0.55	2.36e-38	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg24607181	chr17:41446203	NA	-0.29	-6.79	-0.3	3.54e-11	Menopause (age at onset);
LGG	cis	rs10992471	0.756	rs11792342	chr9:95143668	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.15	-0.32	3.43e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs3206736	0.606	rs6953221	chr7:35216404	A/C	cg13400248	chr7:35225412	NA	0.44	7.93	0.35	1.64e-14	Diastolic blood pressure;
LGG	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.28e-29	Hip circumference adjusted for BMI;
LGG	cis	rs45544231	0.569	rs9923558	chr16:52548183	A/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.75	-0.3	4.32e-11	Restless legs syndrome;
LGG	cis	rs3857067	0.806	rs7654919	chr4:95136164	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.48	-0.37	3.07e-16	QT interval;
LGG	cis	rs9460578	0.537	rs9465897	chr6:20806662	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.67	0.63	9.26e-54	Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22141315	chr7:6523968	KDELR2	0.42	6.82	0.3	2.94e-11	Cognitive performance;
LGG	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.11	12.49	0.5	4.53e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg26655873	chr3:72818019	SHQ1	0.37	7.13	0.31	3.85e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg01620082	chr3:125678407	NA	-0.66	-8.18	-0.36	2.69e-15	Lung cancer in ever smokers;
LGG	cis	rs1983891	0.826	rs9381075	chr6:41515224	G/A	cg20194872	chr6:41519635	FOXP4	0.51	8.05	0.35	7.04e-15	Prostate cancer;
LGG	cis	rs7408868	0.611	rs11669982	chr19:15292366	C/T	cg14696996	chr19:15285081	NOTCH3	0.77	10.49	0.44	3.07e-23	Pulse pressure;
LGG	cis	rs9397585	0.588	rs9371676	chr6:153445965	C/A	cg12989544	chr6:153429875	RGS17	0.31	7.11	0.31	4.32e-12	Body mass index;
LGG	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg25019033	chr10:957182	NA	-0.59	-12.0	-0.49	4.41e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs116095464	1.000	rs55671190	chr5:287422	G/A	cg00938859	chr5:1591904	SDHAP3	0.75	7.5	0.33	3.36e-13	Breast cancer;
LGG	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg24596788	chr1:163392923	NA	-0.68	-12.84	-0.51	1.63e-32	Motion sickness;
LGG	cis	rs909674	0.818	rs7364148	chr22:39842165	T/C	cg04986931	chr22:39850128	NA	0.4	8.77	0.38	3.41e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7582180	0.629	rs11678148	chr2:100966950	A/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.58e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.964	rs1324084	chr6:25915134	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Bladder cancer;
LGG	cis	rs11718455	1.000	rs34585866	chr3:44058411	G/A	cg21419209	chr3:44054225	NA	-0.44	-7.03	-0.31	7.61e-12	Coronary artery disease;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg13671590	chr9:125056607	MRRF	-0.41	-6.81	-0.3	2.99e-11	Apolipoprotein A-IV levels;
LGG	cis	rs4716602	0.674	rs10244637	chr7:156157853	G/A	cg16983916	chr7:156159713	NA	-0.48	-9.28	-0.4	6.78e-19	Anti-saccade response;
LGG	cis	rs12615966	0.932	rs17020857	chr2:105401306	A/G	cg16465502	chr2:105461796	NA	-0.85	-10.24	-0.43	2.6e-22	Pancreatic cancer;
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg13939156	chr17:80058883	NA	0.49	9.76	0.41	1.39e-20	Life satisfaction;
LGG	cis	rs9356171	0.572	rs2322175	chr6:164328086	G/C	cg25752492	chr6:164341247	NA	-0.46	-9.14	-0.39	1.95e-18	Diisocyanate-induced asthma;
LGG	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg08508325	chr11:3079039	CARS	-0.6	-13.12	-0.52	1.12e-33	Longevity;
LGG	cis	rs11098499	0.954	rs10008392	chr4:120318839	G/A	cg09307838	chr4:120376055	NA	0.8	13.09	0.52	1.51e-33	Corneal astigmatism;
LGG	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg27490568	chr2:178487706	NA	0.81	14.28	0.55	1.42e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.17	-0.62	1.68e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.89	-0.34	2.23e-14	Monocyte count;
LGG	cis	rs6460942	0.915	rs6945067	chr7:12444731	A/C	cg06484146	chr7:12443880	VWDE	-0.42	-7.45	-0.33	4.69e-13	Coronary artery disease;
LGG	cis	rs3818285	0.556	rs944966	chr10:111658334	C/G	cg00817464	chr10:111662876	XPNPEP1	-0.57	-10.43	-0.44	4.94e-23	Superior crus of antihelix expression;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg01988459	chr11:68622903	NA	-0.62	-12.58	-0.5	2e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg22903471	chr2:27725779	GCKR	0.38	8.53	0.37	2.16e-16	Oral cavity cancer;
LGG	trans	rs10506458	1.000	rs1495013	chr12:63428188	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.33	-21.16	-0.7	5.27e-70	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2764208	0.576	rs6932930	chr6:34677103	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.46	8.28	0.36	1.3e-15	Systemic lupus erythematosus;
LGG	cis	rs9911578	0.967	rs405684	chr17:56777148	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg15726326	chr17:19651983	ALDH3A1	-0.82	-18.46	-0.65	1.91e-57	Response to paliperidone in schizophrenia (CGI-S score);
LGG	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.74	-0.3	4.8e-11	Pediatric bone mineral density (spine);
LGG	cis	rs701145	0.585	rs12493885	chr3:153839866	G/C	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.78e-19	Coronary artery disease;
LGG	cis	rs1784581	0.588	rs1784606	chr6:162405992	A/T	cg17173639	chr6:162384350	PARK2	-0.6	-12.33	-0.5	2.06e-30	Itch intensity from mosquito bite;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg21548813	chr6:291882	DUSP22	-0.55	-9.74	-0.41	1.67e-20	Menopause (age at onset);
LGG	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.61	10.81	0.45	1.91e-24	Menarche (age at onset);
LGG	cis	rs13421350	0.579	rs116108611	chr2:173331076	G/A	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs6772849	0.930	rs12630379	chr3:128370204	G/C	cg08795948	chr3:128337044	NA	0.67	11.4	0.47	1.03e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg16482183	chr6:26056742	HIST1H1C	0.73	12.4	0.5	1.1e-30	Height;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs6594713	0.851	rs13171482	chr5:112701966	G/A	cg12552261	chr5:112820674	MCC	0.47	6.78	0.3	3.59e-11	Brain cytoarchitecture;
LGG	cis	rs151349	0.714	rs6123845	chr20:57607668	C/T	cg23907860	chr20:57583709	CTSZ	-0.36	-6.84	-0.3	2.51e-11	Platelet distribution width;
LGG	trans	rs6787172	0.840	rs1656374	chr3:158283060	C/T	cg23275840	chr4:47708675	CORIN	-0.34	-7.18	-0.32	2.75e-12	Subjective well-being;
LGG	cis	rs9834373	0.769	rs9856198	chr3:78496305	A/G	cg06138941	chr3:78371609	NA	-0.51	-9.18	-0.39	1.47e-18	Protein quantitative trait loci;
LGG	cis	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg02972257	chr16:68554789	NA	0.62	9.04	0.39	4.4e-18	Ulcerative colitis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17047993	chr17:49197695	SPAG9	0.59	6.71	0.3	5.73e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11696845	0.776	rs6073538	chr20:43379264	A/C	cg25301532	chr20:43378953	KCNK15	0.49	12.13	0.49	1.29e-29	Obesity-related traits;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg14092988	chr3:52407081	DNAH1	0.29	7.89	0.34	2.22e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6912958	0.684	rs6931069	chr6:88367082	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.46	-0.37	3.42e-16	Monocyte percentage of white cells;
LGG	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg01620082	chr3:125678407	NA	-0.77	-9.0	-0.39	6.08e-18	Depression;
LGG	cis	rs11676348	0.808	rs4674267	chr2:219046437	C/T	cg00012203	chr2:219082015	ARPC2	-0.52	-9.08	-0.39	3.1e-18	Ulcerative colitis;
LGG	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.85	0.45	1.34e-24	Lung cancer in ever smokers;
LGG	cis	rs2594989	0.943	rs2606733	chr3:11412319	C/T	cg01796438	chr3:11312864	ATG7	-0.55	-7.23	-0.32	2.02e-12	Circulating chemerin levels;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.22	-0.36	2.07e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs172166	0.694	rs1225716	chr6:28113746	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.21	-0.32	2.27e-12	Cardiac Troponin-T levels;
LGG	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg26384229	chr12:38710491	ALG10B	-0.58	-11.16	-0.46	8.61e-26	Morning vs. evening chronotype;
LGG	cis	rs2562456	0.876	rs62110163	chr19:21728822	G/A	cg00806126	chr19:22604979	ZNF98	-0.64	-9.56	-0.41	7.05e-20	Pain;
LGG	cis	rs939658	0.728	rs8031638	chr15:79422726	C/T	cg17916960	chr15:79447300	NA	-0.62	-11.77	-0.48	3.86e-28	Refractive error;
LGG	cis	rs4917300	0.657	rs6996685	chr8:143071894	C/A	cg06573787	chr8:143070187	NA	0.76	15.98	0.6	4.29e-46	Amyotrophic lateral sclerosis;
LGG	cis	rs6430585	0.583	rs60253740	chr2:136571852	G/T	cg07169764	chr2:136633963	MCM6	1.3	26.4	0.78	2.13e-94	Corneal structure;
LGG	cis	rs209489	0.786	rs80062634	chr6:53167352	G/C	cg15607103	chr6:53167650	ELOVL5	0.72	9.01	0.39	5.41e-18	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs1463132	0.553	rs55941845	chr16:10215936	C/A	cg08466385	chr6:18368294	NA	0.32	6.78	0.3	3.79e-11	HIV-1 control;
LGG	cis	rs2013441	1.000	rs3850781	chr17:20181939	T/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg05527609	chr1:210001259	C1orf107	-0.5	-6.89	-0.31	1.81e-11	Red blood cell count;
LGG	cis	rs7315438	0.512	rs7958945	chr12:115947901	A/G	cg18639984	chr12:115943877	NA	-0.41	-8.96	-0.38	8.01e-18	Colorectal cancer;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.86	0.66	2.81e-59	Menopause (age at onset);
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg15674680	chr20:60982522	CABLES2	0.51	7.9	0.34	2.09e-14	Colorectal cancer;
LGG	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.43e-17	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07879319	chr3:57678116	FAM116A	0.46	6.7	0.3	6e-11	Gut microbiome composition (summer);
LGG	cis	rs972578	0.740	rs7287792	chr22:43394489	T/C	cg01576275	chr22:43409880	NA	-0.24	-7.44	-0.33	5.01e-13	Mean platelet volume;
LGG	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs4926611	0.795	rs12563871	chr1:54071610	A/G	cg23596471	chr1:54105337	GLIS1	0.38	7.64	0.33	1.29e-13	Hand grip strength;
LGG	trans	rs6076960	0.650	rs6516126	chr20:6165322	C/A	cg21095983	chr6:86352623	SYNCRIP	0.54	9.74	0.41	1.67e-20	Smooth-surface caries;
LGG	cis	rs3784262	1.000	rs10851630	chr15:58242148	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.26	-0.36	1.59e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	13.09	0.52	1.5e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg19913688	chr11:428466	ANO9	0.68	10.62	0.44	9.89e-24	Body mass index;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11229555	1.000	rs2298608	chr11:58404467	A/G	cg15696309	chr11:58395628	NA	0.97	17.16	0.62	1.92e-51	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg18105134	chr13:113819100	PROZ	-0.71	-14.04	-0.55	1.45e-37	Platelet distribution width;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.59	-0.37	1.34e-16	Lung cancer;
LGG	cis	rs17039065	0.920	rs1595196	chr4:109470485	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs1957429	0.901	rs60979440	chr14:65390231	A/G	cg23373153	chr14:65346875	NA	-1.0	-12.91	-0.51	8.85e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.01	-0.49	3.95e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg18032289	chr17:61959525	GH2	-0.41	-7.09	-0.31	5.03e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.74	-0.38	4.47e-17	Lung cancer;
LGG	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg18681998	chr4:17616180	MED28	-0.74	-15.06	-0.57	5.33e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.09	-24.13	-0.75	6.58e-84	Primary sclerosing cholangitis;
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.62	-0.44	9.85e-24	Prostate cancer;
LGG	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.21e-14	Restless legs syndrome;
LGG	cis	rs35740288	0.571	rs11629608	chr15:86330124	C/G	cg04173714	chr15:86211321	AKAP13	0.44	7.27	0.32	1.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg00908189	chr16:619842	PIGQ	0.53	7.74	0.34	6.36e-14	Height;
LGG	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg26384229	chr12:38710491	ALG10B	0.71	14.49	0.56	1.61e-39	Heart rate;
LGG	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg22643751	chr7:855365	UNC84A	-0.43	-7.56	-0.33	2.22e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.3	0.43	1.59e-22	Obesity-related traits;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.79	-0.38	3.02e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.9	0.31	1.71e-11	Bone mineral density;
LGG	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	5e-24	Aortic root size;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08295258	chr5:102455984	GIN1	0.4	6.83	0.3	2.66e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg05623727	chr3:50126028	RBM5	0.35	7.56	0.33	2.12e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.86	0.34	2.81e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4474465	1.000	rs10793319	chr11:78217237	G/A	cg27205649	chr11:78285834	NARS2	0.48	8.35	0.36	8.25e-16	Alzheimer's disease (survival time);
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.19	0.36	2.52e-15	Schizophrenia;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg11301795	chr4:187892539	NA	-0.95	-26.83	-0.78	2.46e-96	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs113835537	0.529	rs2276406	chr11:66283257	C/T	cg24851651	chr11:66362959	CCS	0.44	7.58	0.33	1.89e-13	Airway imaging phenotypes;
LGG	cis	rs2637030	0.586	rs1552649	chr5:52870476	A/T	cg06476337	chr5:52856530	NDUFS4	0.44	6.76	0.3	4.09e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7561149	0.580	rs36051007	chr2:179545859	C/T	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.41	7.08	0.31	5.28e-12	QT interval;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs6714710	0.603	rs55776387	chr2:98405034	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	9.98	0.42	2.29e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg24006582	chr15:45444508	DUOX1	-0.66	-12.65	-0.51	1.01e-31	Uric acid levels;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg21782813	chr7:2030301	MAD1L1	0.41	9.52	0.4	1e-19	Schizophrenia;
LGG	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	13.87	0.54	7.94e-37	Lung cancer in ever smokers;
LGG	cis	rs7444	0.941	rs59391722	chr22:21920817	G/C	cg11654148	chr22:21984483	YDJC	-0.41	-7.8	-0.34	4.25e-14	Systemic lupus erythematosus;
LGG	trans	rs17685	0.753	rs1806885	chr7:75785612	T/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.82	0.77	9.73e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs12410462	0.581	rs77837509	chr1:227559873	C/T	cg04117972	chr1:227635322	NA	0.72	11.07	0.46	1.94e-25	Major depressive disorder;
LGG	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg25664220	chr3:72788482	NA	-0.27	-7.89	-0.34	2.26e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg02030672	chr11:45687055	CHST1	-0.49	-8.82	-0.38	2.31e-17	Obesity-related traits;
LGG	trans	rs75804782	0.630	rs55762325	chr2:239250723	A/G	cg01134436	chr17:81009848	B3GNTL1	0.81	7.11	0.31	4.48e-12	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs9487094	0.645	rs34292461	chr6:109673480	C/T	cg16315928	chr6:109776240	MICAL1	0.47	7.28	0.32	1.41e-12	Height;
LGG	cis	rs11574514	1.000	rs9928374	chr16:67811930	A/G	cg01866162	chr16:67596514	CTCF	-0.96	-6.83	-0.3	2.71e-11	Crohn's disease;
LGG	cis	rs2273669	0.667	rs75671532	chr6:109341298	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs5753037	0.809	rs740041	chr22:30200099	A/G	cg27665648	chr22:30112403	NA	0.3	6.85	0.3	2.33e-11	Type 1 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08017156	chr16:21611107	METTL9	0.49	7.49	0.33	3.46e-13	Gut microbiome composition (summer);
LGG	cis	rs41271473	0.687	rs10916364	chr1:228884405	A/G	cg16512390	chr1:228756714	NA	-0.43	-6.9	-0.31	1.75e-11	Chronic lymphocytic leukemia;
LGG	trans	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.14	-0.31	3.73e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.53	-0.44	2.1e-23	Lung cancer;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg05863683	chr7:1912471	MAD1L1	0.4	7.83	0.34	3.28e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg14581129	chr12:53358946	NA	-0.33	-7.22	-0.32	2.19e-12	Cancer (pleiotropy);
LGG	cis	rs11628318	0.515	rs7152144	chr14:103126101	C/T	cg12046867	chr14:103022105	NA	0.46	8.99	0.39	6.23e-18	Platelet count;
LGG	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.49e-15	Common traits (Other);
LGG	cis	rs3796352	1.000	rs2336541	chr3:52974630	G/C	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs11885103	0.791	rs2724902	chr2:588777	T/C	cg21195176	chr2:593345	NA	0.4	7.67	0.34	1.04e-13	Heschl's gyrus morphology;
LGG	trans	rs7246760	1.000	rs2081066	chr19:9928044	C/T	cg02900749	chr2:68251473	NA	-1.01	-11.33	-0.47	2e-26	Pursuit maintenance gain;
LGG	cis	rs62244186	0.566	rs2135531	chr3:44881158	C/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.42	7.31	0.32	1.17e-12	Depressive symptoms;
LGG	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg02574844	chr11:5959923	NA	-0.53	-8.45	-0.37	3.73e-16	DNA methylation (variation);
LGG	cis	rs7555523	0.887	rs12691499	chr1:165687665	A/C	cg24409356	chr1:165738333	TMCO1	0.71	8.7	0.37	5.79e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg20673091	chr1:2541236	MMEL1	0.75	18.27	0.65	1.45e-56	Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.39	0.5	1.15e-30	Prudent dietary pattern;
LGG	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18956558	chr12:56615815	RNF41	0.42	6.73	0.3	4.98e-11	Cognitive performance;
LGG	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg13445358	chr12:53661749	ESPL1	-0.41	-7.69	-0.34	8.66e-14	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg16127683	chr15:40268777	EIF2AK4	-0.88	-9.8	-0.41	9.51e-21	Corneal curvature;
LGG	cis	rs9902453	0.935	rs9909093	chr17:28271207	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.22	0.55	2.4e-38	Coffee consumption (cups per day);
LGG	cis	rs7267979	1.000	rs2259926	chr20:25281733	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9341808	0.754	rs6916405	chr6:81024188	C/T	cg08355045	chr6:80787529	NA	0.39	7.7	0.34	8.47e-14	Sitting height ratio;
LGG	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-1.05	-23.39	-0.74	1.79e-80	Height;
LGG	cis	rs4423214	0.650	rs7940244	chr11:71221574	C/T	cg10847948	chr11:71163743	NADSYN1	0.56	9.64	0.41	3.7799999999999997e-20	Vitamin D levels;
LGG	cis	rs10791097	0.547	rs10791101	chr11:130739133	C/T	cg12179176	chr11:130786555	SNX19	0.87	17.77	0.64	3.04e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.65e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.65	-0.44	7.45e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg06481639	chr22:41940642	POLR3H	-0.55	-8.15	-0.35	3.38e-15	Vitiligo;
LGG	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg13699009	chr12:122356056	WDR66	-0.43	-10.23	-0.43	2.69e-22	Mean corpuscular volume;
LGG	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.61	-0.44	1.06e-23	Vitiligo;
LGG	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg02487422	chr3:49467188	NICN1	0.57	10.48	0.44	3.33e-23	Resting heart rate;
LGG	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.53	0.33	2.69e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13784889	chr4:89513377	HERC3	0.46	7.0	0.31	9.24e-12	Gut microbiome composition (summer);
LGG	cis	rs11971779	0.680	rs10261557	chr7:139099037	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4819052	0.807	rs7283915	chr21:46671288	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.52	-0.4	1e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.83	-0.34	3.35e-14	Response to antipsychotic treatment;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.23	-0.32	1.98e-12	Menopause (age at onset);
LGG	trans	rs8073060	0.586	rs7213804	chr17:34010931	T/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.74	0.66	9.51e-59	Menopause (age at onset);
LGG	cis	rs12230513	1.000	rs77755732	chr12:55924293	C/T	cg19537932	chr12:55886519	OR6C68	-0.45	-7.13	-0.31	3.91e-12	Contrast sensitivity;
LGG	cis	rs367615	0.552	rs2963023	chr5:108730070	C/T	cg17395555	chr5:108820864	NA	-0.71	-11.56	-0.47	2.54e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg03665457	chr10:38645376	HSD17B7P2	-0.45	-7.15	-0.32	3.5e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg15971980	chr6:150254442	NA	0.44	8.3	0.36	1.16e-15	Lung cancer;
LGG	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.33	0.32	1.05e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6838801	0.823	rs13139112	chr4:77584089	G/A	cg17476223	chr4:77663285	SHROOM3	0.38	6.84	0.3	2.54e-11	Cleft lip with or without cleft palate;
LGG	cis	rs12310956	0.510	rs4931743	chr12:33867588	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.88	-0.3	1.91e-11	Morning vs. evening chronotype;
LGG	cis	rs9596837	0.514	rs36044722	chr13:54266959	G/T	ch.13.53330881F	chr13:54432880	NA	0.42	6.69	0.3	6.49e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.58	0.61	8.64e-49	Personality dimensions;
LGG	cis	rs17767392	0.881	rs7142343	chr14:72023489	T/C	cg13720639	chr14:72061746	SIPA1L1	0.4	8.77	0.38	3.35e-17	Mitral valve prolapse;
LGG	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.87	0.59	1.36e-45	Morning vs. evening chronotype;
LGG	cis	rs9457247	0.663	rs2282861	chr6:167440128	C/T	cg07741184	chr6:167504864	NA	0.4	8.87	0.38	1.55e-17	Crohn's disease;
LGG	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg08344181	chr3:125677491	NA	-0.87	-9.05	-0.39	3.99e-18	Depression;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08875180	chr17:21454528	C17orf51	0.38	6.84	0.3	2.56e-11	Bipolar disorder;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg10253484	chr15:75165896	SCAMP2	0.5	7.08	0.31	5.4e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg00376283	chr12:123451042	ABCB9	0.67	11.6	0.47	1.77e-27	Neutrophil percentage of white cells;
LGG	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.16	-0.43	4.97e-22	Joint mobility (Beighton score);
LGG	cis	rs2013441	1.000	rs2013576	chr17:20167692	G/C	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg21775007	chr8:11205619	TDH	0.43	6.84	0.3	2.59e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg11062466	chr8:58055876	NA	0.48	8.39	0.36	5.93e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.27	-0.32	1.54e-12	Uric acid levels;
LGG	cis	rs67478160	0.643	rs7147171	chr14:104264857	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	6.81	0.3	3.08e-11	Schizophrenia;
LGG	cis	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg21775007	chr8:11205619	TDH	0.51	7.98	0.35	1.15e-14	Neuroticism;
LGG	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg00101154	chr16:420108	MRPL28	0.63	10.81	0.45	1.96e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg00012203	chr2:219082015	ARPC2	-0.67	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg01620082	chr3:125678407	NA	-0.75	-7.56	-0.33	2.24e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7937682	0.632	rs10891294	chr11:111699224	C/T	cg22437258	chr11:111473054	SIK2	-0.42	-6.91	-0.31	1.59e-11	Primary sclerosing cholangitis;
LGG	cis	rs28489187	0.706	rs233115	chr1:85786977	G/A	cg16011679	chr1:85725395	C1orf52	0.35	6.72	0.3	5.44e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs6867032	0.958	rs4975798	chr5:2015580	G/A	cg26168224	chr5:2018326	NA	1.28	30.94	0.82	9.35e-115	Gut microbiome composition (winter);
LGG	cis	rs34891900	0.507	rs738133	chr22:18205557	C/T	cg19898043	chr22:18121309	BCL2L13	0.56	9.17	0.39	1.5e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	cis	rs6868223	0.927	rs6868084	chr5:33636670	C/G	cg10594543	chr5:33649717	ADAMTS12	0.57	12.66	0.51	9.22e-32	Mortality in heart failure;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.75e-25	Prostate cancer;
LGG	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg12310025	chr6:25882481	NA	0.71	14.19	0.55	3.26e-38	Blood metabolite levels;
LGG	cis	rs4819388	0.693	rs4818889	chr21:45645308	A/G	cg01992765	chr21:45622493	NA	-0.45	-8.68	-0.37	7e-17	Celiac disease;
LGG	cis	rs66887589	0.934	rs7672519	chr4:120544112	C/T	cg09307838	chr4:120376055	NA	-0.48	-8.41	-0.36	5.27e-16	Diastolic blood pressure;
LGG	cis	rs377457	0.821	rs755464	chr16:85738795	T/A	cg08768472	chr16:85689701	KIAA0182	0.4	7.5	0.33	3.26e-13	Type 2 diabetes;
LGG	cis	rs2041895	0.509	rs10861674	chr12:107304037	A/G	cg13944111	chr12:107296891	NA	0.26	6.8	0.3	3.16e-11	Glaucoma (low intraocular pressure);
LGG	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.25	0.36	1.63e-15	Bipolar disorder;
LGG	cis	rs28595532	0.844	rs115411027	chr4:119490685	T/C	cg14228332	chr4:119757509	SEC24D	0.95	9.45	0.4	1.63e-19	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.31	6.66	0.3	7.94e-11	Schizophrenia;
LGG	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg00319359	chr11:70116639	PPFIA1	0.7	7.14	0.32	3.56e-12	Coronary artery disease;
LGG	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg16384552	chr7:74938386	SPDYE8P	-0.51	-8.92	-0.38	1.06e-17	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg27239842	chr4:2403781	ZFYVE28	-0.45	-7.47	-0.33	3.92e-13	Cognitive function;
LGG	trans	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg02002194	chr4:3960332	NA	0.38	6.7	0.3	5.98e-11	Triglycerides;
LGG	trans	rs6561151	0.957	rs1932990	chr13:44460242	C/T	cg17145862	chr1:211918768	LPGAT1	0.71	12.88	0.51	1.16e-32	Crohn's disease;
LGG	cis	rs4917300	0.606	rs7015050	chr8:143100960	T/A	cg26003909	chr8:143102224	NA	-0.34	-6.72	-0.3	5.43e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg23531748	chr20:60969906	CABLES2	0.4	6.96	0.31	1.2e-11	Colorectal cancer;
LGG	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.87	-18.53	-0.65	9.53e-58	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg07132326	chr6:150258058	NA	0.39	8.44	0.37	4.04e-16	Testicular germ cell tumor;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.12e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1015291	0.708	rs2731614	chr12:19999688	T/C	cg25401612	chr12:20009446	NA	-0.34	-7.26	-0.32	1.63e-12	Diastolic blood pressure;
LGG	cis	rs1018697	0.966	rs10748831	chr10:104558743	T/C	cg04362960	chr10:104952993	NT5C2	0.5	9.14	0.39	1.95e-18	Colorectal adenoma (advanced);
LGG	cis	rs9814567	1.000	rs6439487	chr3:134260860	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4363385	0.818	rs3820141	chr1:153004778	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	trans	rs3779273	0.776	rs1969441	chr7:77835255	G/T	cg05596911	chr5:118502651	DMXL1	-0.52	-12.1	-0.49	1.81e-29	Body mass index;
LGG	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22857025	chr5:266934	NA	-1.48	-25.41	-0.76	7.76e-90	Breast cancer;
LGG	cis	rs2073300	0.609	rs6137914	chr20:23358364	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.05	0.39	3.97e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.8	8.37	0.36	6.99e-16	Initial pursuit acceleration;
LGG	trans	rs7944735	0.508	rs77685652	chr11:47778777	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.89	0.3	1.81e-11	Intraocular pressure;
LGG	trans	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.53	-0.33	2.61e-13	Educational attainment (years of education);
LGG	trans	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg07211511	chr3:129823064	LOC729375	-0.65	-8.96	-0.38	8.1e-18	Blood pressure (smoking interaction);
LGG	cis	rs721048	1.000	rs2710646	chr2:63134879	C/A	cg17519650	chr2:63277830	OTX1	0.55	6.95	0.31	1.24e-11	Prostate cancer;
LGG	cis	rs68170813	0.559	rs6971774	chr7:106834139	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.69	-0.44	5.53e-24	Coronary artery disease;
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg15971980	chr6:150254442	NA	0.44	8.28	0.36	1.38e-15	Lung cancer;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg21724239	chr8:58056113	NA	0.45	6.66	0.3	7.59e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10715820	chr1:17235063	NA	-0.57	-6.83	-0.3	2.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.579	rs2373497	chr2:39288098	C/T	cg04010122	chr2:39346883	SOS1	-0.71	-7.87	-0.34	2.52e-14	Corticobasal degeneration;
LGG	cis	rs7712401	0.645	rs154497	chr5:122221420	T/C	cg19412675	chr5:122181750	SNX24	0.42	6.97	0.31	1.13e-11	Mean platelet volume;
LGG	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.44	-7.95	-0.35	1.42e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.31	-0.5	2.43e-30	Morning vs. evening chronotype;
LGG	cis	rs4731207	0.596	rs7792654	chr7:124653637	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg26666090	chr16:58549219	SETD6	1.13	10.05	0.42	1.3e-21	Schizophrenia;
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg14346243	chr4:90757452	SNCA	0.37	7.57	0.33	2.03e-13	Dementia with Lewy bodies;
LGG	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg06637938	chr14:75390232	RPS6KL1	0.57	10.49	0.44	3.18e-23	Height;
LGG	cis	rs4973397	0.765	rs13025087	chr2:232264914	A/C	cg11378575	chr2:232265004	B3GNT7	-0.57	-10.37	-0.43	8.84e-23	Anti-saccade response;
LGG	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg08700190	chr5:6636046	SRD5A1	-0.36	-7.76	-0.34	5.41e-14	Response to amphetamines;
LGG	cis	rs4918072	0.834	rs35521930	chr10:105713796	T/C	cg11005552	chr10:105648138	OBFC1	0.42	7.31	0.32	1.17e-12	Coronary artery disease;
LGG	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg08048268	chr3:133502702	NA	0.38	6.83	0.3	2.7e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs2229238	0.911	rs3811449	chr1:154517504	G/A	cg10237817	chr1:154519846	TDRD10	0.35	7.03	0.31	7.21e-12	Coronary heart disease;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg19077165	chr18:44547161	KATNAL2	-0.59	-11.06	-0.46	2.14e-25	Personality dimensions;
LGG	cis	rs7267979	0.604	rs242130	chr20:25594020	C/A	cg06421707	chr20:25228305	PYGB	-0.33	-6.96	-0.31	1.15e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg03563238	chr19:33554763	RHPN2	0.44	9.62	0.41	4.39e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg23649088	chr2:200775458	C2orf69	0.6	7.97	0.35	1.28e-14	Schizophrenia;
LGG	cis	rs5758659	0.935	rs134879	chr22:42664201	A/C	cg15557168	chr22:42548783	NA	-0.38	-8.55	-0.37	1.76e-16	Cognitive function;
LGG	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18256790	chr17:8532950	MYH10	0.41	7.0	0.31	9.22e-12	Bilirubin levels;
LGG	trans	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg12045294	chr17:78518616	RPTOR	-0.47	-7.17	-0.32	2.93e-12	Glycated hemoglobin levels;
LGG	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg03030879	chr14:75389066	RPS6KL1	0.38	7.01	0.31	8.66e-12	Caffeine consumption;
LGG	cis	rs2153535	0.580	rs7341201	chr6:8470270	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg04398451	chr17:18023971	MYO15A	-0.74	-15.55	-0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.27	-0.32	1.57e-12	Body mass index;
LGG	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg02002194	chr4:3960332	NA	0.44	8.15	0.35	3.46e-15	Triglycerides;
LGG	cis	rs4363385	0.510	rs55959888	chr1:152913490	A/G	cg13444842	chr1:152974279	SPRR3	-0.47	-9.37	-0.4	3.3e-19	Inflammatory skin disease;
LGG	trans	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg18187862	chr3:45730750	SACM1L	0.55	9.09	0.39	2.99e-18	Primary sclerosing cholangitis;
LGG	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg12573674	chr2:1569213	NA	-0.65	-10.22	-0.43	3.02e-22	IgG glycosylation;
LGG	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.58	0.37	1.48e-16	Triglycerides;
LGG	cis	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	8.25	0.36	1.69e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.33	0.53	1.55e-34	Colorectal cancer;
LGG	cis	rs12618769	0.597	rs3754881	chr2:99132093	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs7267979	1.000	rs6037095	chr20:25335687	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.86e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg02002194	chr4:3960332	NA	-0.46	-8.95	-0.38	8.81e-18	Systolic blood pressure;
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.09	18.1	0.64	9.36e-56	Alzheimer's disease;
LGG	cis	rs7616330	0.895	rs7615404	chr3:71045288	T/C	cg23830205	chr3:71127516	FOXP1	0.43	6.97	0.31	1.11e-11	QT interval;
LGG	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs67133203	0.898	rs12828349	chr12:51459675	A/G	cg14688905	chr12:51403056	SLC11A2	0.7	10.59	0.44	1.34e-23	Urinary tract infection frequency;
LGG	cis	rs774359	0.789	rs2492821	chr9:27503506	T/A	cg14173147	chr9:27528300	MOBKL2B	0.47	9.0	0.39	5.75e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs1555322	0.530	rs2425053	chr20:33881820	A/G	cg03689076	chr20:33865952	NA	0.56	7.8	0.34	4.1e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs637571	0.522	rs538954	chr11:65756808	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.09	0.39	3.02e-18	Eosinophil percentage of white cells;
LGG	cis	rs2276314	0.857	rs28396546	chr18:33639024	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.83	0.42	7.58e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4808199	1.000	rs17288409	chr19:19504167	T/C	cg03709012	chr19:19516395	GATAD2A	1.07	17.45	0.63	9.24e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs7143963	1.000	rs12588538	chr14:103360000	A/G	cg23020514	chr14:103360112	TRAF3	0.52	9.64	0.41	3.65e-20	Body mass index;
LGG	trans	rs7824557	0.638	rs4413734	chr8:11212778	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.52	0.33	2.86e-13	Retinal vascular caliber;
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00166722	chr3:10149974	C3orf24	0.49	8.42	0.36	4.67e-16	Alzheimer's disease;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.6	10.69	0.45	5.33e-24	Lymphocyte counts;
LGG	cis	rs11605275	1.000	rs11604681	chr11:20031042	G/A	cg14835545	chr11:20032148	NAV2	-0.96	-10.87	-0.45	1.19e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-9.61	-0.41	4.67e-20	Height;
LGG	cis	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg13010199	chr12:38710504	ALG10B	0.59	12.26	0.5	4.01e-30	Bladder cancer;
LGG	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg13147721	chr7:65941812	NA	-0.84	-10.16	-0.43	4.94e-22	Diabetic kidney disease;
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg02772935	chr3:125709198	NA	-0.55	-7.08	-0.31	5.39e-12	Blood pressure (smoking interaction);
LGG	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.64e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg26174226	chr8:58114915	NA	-0.48	-6.65	-0.3	8.28e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	0.793	rs55940445	chr3:134306064	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.89	0.51	1.03e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8028182	0.636	rs4886715	chr15:75831449	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.54	0.33	2.54e-13	Sudden cardiac arrest;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.17	-0.35	3.07e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg18000306	chr6:288505	NA	0.48	8.84	0.38	2e-17	Menopause (age at onset);
LGG	cis	rs7928758	0.887	rs11820880	chr11:134268453	T/C	cg22777979	chr11:134283252	B3GAT1	0.95	11.93	0.48	8.9e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg03929089	chr4:120376271	NA	-0.45	-7.19	-0.32	2.61e-12	HDL cholesterol;
LGG	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg09359103	chr1:154839909	KCNN3	-0.38	-7.38	-0.32	7.19e-13	Prostate cancer;
LGG	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg16586182	chr3:47516702	SCAP	0.77	15.07	0.57	4.7e-42	Colorectal cancer;
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.16	-0.43	5.16e-22	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg11062466	chr8:58055876	NA	0.41	7.21	0.32	2.35e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.63	0.33	1.35e-13	Longevity;
LGG	cis	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	8.57	0.37	1.53e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3806843	0.576	rs405192	chr5:140324710	T/G	cg19875535	chr5:140030758	IK	0.37	7.45	0.33	4.57e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.07	-0.57	5e-42	Platelet count;
LGG	trans	rs12478296	0.515	rs13412492	chr2:243000583	T/G	cg01596870	chr19:55963115	NA	-0.51	-7.8	-0.34	4.13e-14	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg24623649	chr8:11872141	NA	-0.3	-6.69	-0.3	6.59e-11	Triglycerides;
LGG	cis	rs854037	0.698	rs35435527	chr5:57068202	A/G	cg08523694	chr5:57076192	NA	0.5	7.09	0.31	4.95e-12	Birth weight;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg04267008	chr7:1944627	MAD1L1	0.55	9.27	0.4	7.25e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.908	rs62251640	chr3:72801605	T/C	cg25664220	chr3:72788482	NA	-0.32	-8.8	-0.38	2.73e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg11266682	chr4:10021025	SLC2A9	0.52	10.18	0.43	4.11e-22	Bone mineral density;
LGG	cis	rs853679	0.517	rs9380049	chr6:28048535	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg05064044	chr6:292385	DUSP22	-0.67	-11.39	-0.47	1.13e-26	Menopause (age at onset);
LGG	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg14101638	chr12:121416612	HNF1A	0.35	7.22	0.32	2.17e-12	N-glycan levels;
LGG	cis	rs908922	0.676	rs6658925	chr1:152482801	C/T	cg20991723	chr1:152506922	NA	0.7	14.12	0.55	6.49e-38	Hair morphology;
LGG	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg08847533	chr14:75593920	NEK9	-0.6	-11.69	-0.48	7.6e-28	Height;
LGG	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg02746640	chr7:145689965	NA	0.37	6.94	0.31	1.34e-11	Hematocrit;Hemoglobin concentration;Red blood cell count;
LGG	cis	rs35306767	0.623	rs36051896	chr10:1155747	T/C	cg25019033	chr10:957182	NA	-0.48	-8.41	-0.36	5.09e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11764359	chr7:65958608	NA	-0.48	-8.04	-0.35	7.79e-15	Calcium levels;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19723459	chr12:113658936	IQCD;TPCN1	0.4	6.98	0.31	1.06e-11	Bilirubin levels;
LGG	cis	rs3768617	0.811	rs12043805	chr1:183008150	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.77	0.3	3.93e-11	Fuchs's corneal dystrophy;
LGG	cis	rs2808510	0.521	rs4427435	chr1:200421466	A/G	cg10889502	chr1:200398670	NA	-0.32	-7.39	-0.32	6.71e-13	Myopia;
LGG	cis	rs66561647	0.597	rs34390452	chr8:128940141	G/A	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	6.73	0.3	4.91e-11	Hemoglobin concentration;
LGG	trans	rs9657904	0.951	rs9846534	chr3:105581750	T/C	cg14088669	chr1:158435396	OR10K1	-0.39	-6.76	-0.3	4.27e-11	Multiple sclerosis;
LGG	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg19761014	chr17:28927070	LRRC37B2	0.58	6.73	0.3	5.08e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1465370	0.711	rs4731689	chr7:130009839	C/T	cg25718383	chr7:130020096	CPA1	0.3	7.57	0.33	2.08e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.58	0.44	1.44e-23	Aortic root size;
LGG	trans	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg06521331	chr12:34319734	NA	0.46	8.11	0.35	4.63e-15	Bladder cancer;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.43	-0.4	1.93e-19	Lewy body disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07608671	chr7:75115567	POM121C	0.38	6.95	0.31	1.25e-11	Menarche (age at onset);
LGG	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-9.6	-0.41	5.13e-20	Schizophrenia;
LGG	cis	rs1555322	0.872	rs2425046	chr20:33871661	A/G	cg03689076	chr20:33865952	NA	0.65	6.82	0.3	2.92e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg27661571	chr11:113659931	NA	-0.68	-9.31	-0.4	5.24e-19	Hip circumference adjusted for BMI;
LGG	cis	rs9660992	0.674	rs72745219	chr1:205262271	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.74	0.3	4.58e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs12410462	0.551	rs12085546	chr1:227886463	C/T	cg04117972	chr1:227635322	NA	0.45	8.22	0.36	2.05e-15	Major depressive disorder;
LGG	cis	rs2885056	0.830	rs7259124	chr19:10671664	T/C	cg08312369	chr19:10679775	CDKN2D	-0.5	-6.76	-0.3	4.12e-11	Red cell distribution width;
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg16339924	chr4:17578868	LAP3	0.6	10.33	0.43	1.19e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg26818010	chr10:134567672	INPP5A	-0.71	-10.92	-0.45	7.73e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs208520	1.000	rs72882100	chr6:66981495	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.9	-0.48	1.08e-28	Height;
LGG	cis	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg07460842	chr6:66804631	NA	0.9	14.82	0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs4732038	0.510	rs12673683	chr7:134275850	T/C	cg06906464	chr7:134288099	NA	-0.66	-17.16	-0.62	1.94e-51	Longevity;
LGG	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg02503808	chr4:7069936	GRPEL1	-0.97	-13.62	-0.53	9.01e-36	Monocyte percentage of white cells;
LGG	cis	rs55883249	1.000	rs17362902	chr2:9768564	C/T	cg23886495	chr2:9695866	ADAM17	-0.64	-8.96	-0.38	7.93e-18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs12517041	1.000	rs10473633	chr5:23310565	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	cis	rs1728785	1.000	rs6499181	chr16:68593002	A/T	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs72634501	0.540	rs16826036	chr1:39757799	G/C	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	HDL cholesterol;
LGG	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.0	0.42	1.89e-21	Height;
LGG	cis	rs10911363	0.659	rs2275676	chr1:183430822	C/G	cg09173681	chr1:183549694	NCF2	-0.37	-8.33	-0.36	9.44e-16	Systemic lupus erythematosus;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.43	-7.11	-0.31	4.48e-12	Longevity;Endometriosis;
LGG	cis	rs8067545	0.611	rs2703800	chr17:20086562	C/T	cg13482628	chr17:19912719	NA	0.54	10.18	0.43	4.28e-22	Schizophrenia;
LGG	cis	rs1008375	0.544	rs56227066	chr4:17565713	G/A	cg10189774	chr4:17578691	LAP3	0.41	7.09	0.31	4.95e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg11812906	chr14:75593930	NEK9	-0.55	-10.19	-0.43	3.84e-22	Height;
LGG	cis	rs7712401	0.601	rs246282	chr5:122225605	G/T	cg19412675	chr5:122181750	SNX24	0.42	6.97	0.31	1.13e-11	Mean platelet volume;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs919433	0.647	rs2045242	chr2:198507649	G/A	cg00792783	chr2:198669748	PLCL1	0.56	9.16	0.39	1.72e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg14791747	chr16:20752902	THUMPD1	0.52	7.74	0.34	6.46e-14	Cognitive test performance;
LGG	cis	rs1538970	0.816	rs11211124	chr1:45962409	T/C	cg05343316	chr1:45956843	TESK2	0.75	13.0	0.52	3.73e-33	Platelet count;
LGG	cis	rs9636252	0.887	rs6744935	chr2:9267071	C/G	cg20341998	chr2:9276514	NA	0.37	7.09	0.31	5.14e-12	IgG glycosylation;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg23302884	chr18:44338147	ST8SIA5	0.36	6.97	0.31	1.12e-11	Personality dimensions;
LGG	cis	rs10791097	0.702	rs11222346	chr11:130715343	T/C	cg12179176	chr11:130786555	SNX19	-0.67	-11.95	-0.49	6.99e-29	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6692209	1	rs6692209	chr1:152506444	C/T	cg20991723	chr1:152506922	NA	-0.72	-14.85	-0.57	4.57e-41	Plantar warts;
LGG	cis	rs11758351	0.660	rs11753131	chr6:26219384	G/A	cg23601095	chr6:26197514	HIST1H3D	0.71	9.0	0.39	6.01e-18	Gout;Renal underexcretion gout;
LGG	cis	rs4774899	0.902	rs12912210	chr15:57471823	A/G	cg08128148	chr15:57256372	TCF12	-0.33	-7.98	-0.35	1.18e-14	Urinary tract infection frequency;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	1.01e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg24112000	chr20:60950667	NA	-0.36	-7.99	-0.35	1.11e-14	Colorectal cancer;
LGG	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg05044414	chr3:183734942	ABCC5	-0.68	-12.77	-0.51	3.37e-32	Anterior chamber depth;
LGG	cis	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.19e-26	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.735	rs11072598	chr15:76764788	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-12.94	-0.52	6.58e-33	Blood metabolite levels;
LGG	cis	rs2413583	0.591	rs76449672	chr22:39696482	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	7.82	0.34	3.52e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.72	-0.38	4.85e-17	Bladder cancer;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg04287289	chr16:89883240	FANCA	0.85	8.07	0.35	5.93e-15	Skin colour saturation;
LGG	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg25039879	chr17:56429692	SUPT4H1	0.77	11.27	0.46	3.23e-26	Cognitive test performance;
LGG	cis	rs11676348	0.774	rs57545959	chr2:219047718	A/G	cg00012203	chr2:219082015	ARPC2	0.5	8.7	0.37	6.06e-17	Ulcerative colitis;
LGG	cis	rs457717	0.730	rs1697844	chr5:75929833	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.65	0.3	8.47e-11	Hearing impairment;
LGG	cis	rs4535700	0.501	rs57251705	chr7:55981083	A/G	cg17215666	chr7:56131930	SUMF2	-0.44	-6.81	-0.3	3.06e-11	Macular telangiectasia type 2;
LGG	cis	rs3784262	0.967	rs4646612	chr15:58265077	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.12	-0.35	4.26e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10751667	0.560	rs7924794	chr11:962745	A/T	cg22143635	chr11:980567	AP2A2	0.44	8.13	0.35	3.87e-15	Alzheimer's disease (late onset);
LGG	cis	rs67133203	0.904	rs12812727	chr12:51332347	G/A	cg14688905	chr12:51403056	SLC11A2	0.7	10.47	0.44	3.75e-23	Urinary tract infection frequency;
LGG	cis	rs6032067	0.632	rs62208389	chr20:43794783	A/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg09845145	chr15:78292470	TBC1D2B	0.61	9.61	0.41	4.69e-20	Coronary artery disease or large artery stroke;
LGG	cis	rs79057730	0.684	rs6955004	chr7:790792	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.77	8.21	0.36	2.19e-15	Initial pursuit acceleration;
LGG	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.54	-0.37	2.02e-16	Neuroticism;
LGG	cis	rs752010	0.806	rs4641303	chr1:42091310	A/G	cg16096631	chr1:42092165	HIVEP3	0.81	24.92	0.76	1.52e-87	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs12580194	0.593	rs12581060	chr12:55797484	A/C	cg19537932	chr12:55886519	OR6C68	-0.58	-10.51	-0.44	2.68e-23	Cancer;
LGG	cis	rs4700695	0.719	rs40176	chr5:65464965	C/T	cg21114390	chr5:65439923	SFRS12	-0.72	-10.57	-0.44	1.61e-23	Facial morphology (factor 19);
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18000306	chr6:288505	NA	0.49	9.0	0.39	5.83e-18	Menopause (age at onset);
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg00717180	chr2:96193071	NA	0.4	7.13	0.31	3.83e-12	Coronary artery disease;
LGG	cis	rs4262150	0.810	rs17453775	chr5:151976244	C/T	cg12297329	chr5:152029980	NA	-0.81	-15.84	-0.59	1.83e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs526231	0.543	rs26523	chr5:102456254	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.34	-0.36	8.82e-16	Primary biliary cholangitis;
LGG	cis	rs6964587	1.000	rs7797369	chr7:91570615	C/A	cg17063962	chr7:91808500	NA	-0.48	-8.59	-0.37	1.34e-16	Breast cancer;
LGG	cis	rs988958	0.636	rs7581391	chr2:42219967	G/C	cg27428208	chr2:42229179	NA	0.52	9.2	0.39	1.21e-18	Hypospadias;
LGG	cis	rs12956009	0.518	rs3889651	chr18:44865012	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.46	0.33	4.27e-13	Educational attainment (years of education);
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	7.42	0.33	5.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg26818010	chr10:134567672	INPP5A	0.73	11.49	0.47	4.72e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs12339094	0.860	rs961391	chr9:90408587	G/T	cg24436365	chr6:63940138	NA	0.41	6.67	0.3	7.2e-11	Smoking quantity;
LGG	cis	rs300774	1.000	rs167282	chr2:117174	A/G	cg04617936	chr2:214353	NA	-0.48	-7.18	-0.32	2.82e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg05333889	chr7:157238977	NA	-0.52	-10.0	-0.42	1.89e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg02002194	chr4:3960332	NA	-0.42	-7.77	-0.34	5.02e-14	Mood instability;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.78	-0.3	3.7e-11	Menopause (age at onset);
LGG	cis	rs6772849	0.830	rs4857917	chr3:128376178	C/T	cg08795948	chr3:128337044	NA	0.67	11.26	0.46	3.76e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4953318	0.894	rs10495928	chr2:46353166	A/G	cg12428440	chr2:46370979	PRKCE	0.42	8.01	0.35	9.65e-15	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.24e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8114671	0.562	rs6088621	chr20:33418740	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.95	0.38	8.49e-18	Height;
LGG	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg00864171	chr11:67383662	NA	-0.43	-7.14	-0.31	3.65e-12	Mean corpuscular volume;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.64e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.84	-0.45	1.47e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1847505	0.957	rs6562145	chr13:61525919	G/A	cg25164009	chr13:61490935	NA	-0.61	-9.77	-0.41	1.22e-20	Polychlorinated biphenyl levels;
LGG	cis	rs7777484	0.500	rs2533885	chr7:2835655	C/T	cg27476859	chr7:2772710	GNA12	0.67	13.67	0.54	5.67e-36	Height;
LGG	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg20477318	chr10:51623047	TIMM23	-0.71	-8.69	-0.37	6.3e-17	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs7945718	0.905	rs7935997	chr11:12728651	A/G	cg25843174	chr11:12811716	TEAD1	0.41	8.32	0.36	9.62e-16	Educational attainment (years of education);
LGG	cis	rs2153535	0.580	rs1115078	chr6:8449638	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.99	0.39	6.17e-18	Motion sickness;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08747777	chr16:65156158	CDH11	-0.43	-6.92	-0.31	1.5e-11	Pancreatic cancer;
LGG	cis	rs2012796	0.957	rs8011477	chr14:81815587	C/T	cg02996355	chr14:81879375	NA	0.45	7.26	0.32	1.65e-12	Night sleep phenotypes;
LGG	cis	rs6977955	1.000	rs740122	chr7:28166442	G/A	cg23620719	chr7:28220237	JAZF1	0.47	7.36	0.32	8.39e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg04166393	chr7:2884313	GNA12	0.47	9.37	0.4	3.1e-19	Height;
LGG	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg09307838	chr4:120376055	NA	0.7	11.33	0.47	1.9e-26	Corneal astigmatism;
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg13452994	chr2:3699195	NA	0.63	6.88	0.3	1.95e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-20.98	-0.7	3.62e-69	Body mass index;
LGG	cis	rs12220238	0.915	rs11000988	chr10:76073723	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.88	0.38	1.44e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs972578	0.791	rs9611951	chr22:43274772	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.87	-0.3	2.06e-11	Mean platelet volume;
LGG	cis	rs283228	0.617	rs504406	chr6:101739040	A/G	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs870825	0.860	rs10015194	chr4:185598925	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	20.72	0.69	5.75e-68	Blood protein levels;
LGG	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.33	-0.7	8.24e-71	Gut microbiome composition (summer);
LGG	cis	rs9303401	0.659	rs12946397	chr17:56769979	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.35	0.32	9.03e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07701084	chr6:150067640	NUP43	0.42	7.75	0.34	5.84e-14	Testicular germ cell tumor;
LGG	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg18876405	chr7:65276391	NA	-0.63	-11.79	-0.48	3.21e-28	Aortic root size;
LGG	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.99	-0.52	4.18e-33	Schizophrenia;
LGG	cis	rs7851660	0.967	rs7851552	chr9:100610652	C/A	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.58e-40	Strep throat;
LGG	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg08400814	chr5:56204995	C5orf35	0.53	8.14	0.35	3.65e-15	Initial pursuit acceleration;
LGG	trans	rs61931739	0.534	rs11053131	chr12:34282109	A/G	cg26384229	chr12:38710491	ALG10B	0.71	14.58	0.56	6.53e-40	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs12712817	chr2:42236230	A/G	cg19376973	chr2:42229025	NA	0.63	9.32	0.4	4.95e-19	Hypospadias;
LGG	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.61e-23	Aortic root size;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs1978968	0.912	rs5992932	chr22:18456254	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-14.66	-0.56	3.13e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs10924309	0.882	rs10924305	chr1:245856763	A/G	cg00036263	chr1:245852353	KIF26B	0.46	6.78	0.3	3.59e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.68	0.37	6.61e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs3206736	0.548	rs73110557	chr7:35068057	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.22	0.32	2.15e-12	Diastolic blood pressure;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.0	-0.49	4.31e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg11645453	chr3:52864694	ITIH4	0.45	7.19	0.32	2.69e-12	Bipolar disorder;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.71	-0.38	5.32e-17	Personality dimensions;
LGG	cis	rs12765878	0.627	rs1265166	chr10:105671248	C/A	cg11005552	chr10:105648138	OBFC1	-0.73	-12.87	-0.51	1.24e-32	Coronary artery disease;
LGG	cis	rs283228	0.550	rs549135	chr6:101833972	G/T	cg27451362	chr6:101846650	GRIK2	0.98	14.66	0.56	3.08e-40	Coenzyme Q10 levels;
LGG	cis	rs2694528	0.858	rs7712364	chr5:60418506	A/T	cg11474532	chr5:59995715	DEPDC1B	0.68	7.29	0.32	1.35e-12	Parkinson's disease;
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.99	-12.96	-0.52	5.52e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6669919	0.553	rs7527603	chr1:211668090	G/A	cg10512769	chr1:211675356	NA	-0.93	-23.52	-0.74	4.6e-81	Intelligence (multi-trait analysis);
LGG	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg04824913	chr4:887549	GAK	0.81	16.08	0.6	1.55e-46	Systemic sclerosis;
LGG	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.85	17.72	0.64	5.39e-54	Personality dimensions;
LGG	cis	rs11098499	0.863	rs1010739	chr4:120463471	C/T	cg09307838	chr4:120376055	NA	0.76	12.06	0.49	2.48e-29	Corneal astigmatism;
LGG	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg27147174	chr7:100797783	AP1S1	-0.65	-12.02	-0.49	3.58e-29	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg02002194	chr4:3960332	NA	0.43	7.58	0.33	1.96e-13	Neuroticism;
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.36e-13	Life satisfaction;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.17	0.36	2.91e-15	Schizophrenia;
LGG	trans	rs9650657	0.707	rs4593498	chr8:10655470	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.35	-0.32	9.31e-13	Neuroticism;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.43	-0.47	7.74e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg10760299	chr15:45669010	GATM	-0.37	-6.94	-0.31	1.35e-11	Homoarginine levels;
LGG	cis	rs3796352	1.000	rs34943350	chr3:53012888	C/T	cg12962167	chr3:53033115	SFMBT1	0.8	8.32	0.36	9.8e-16	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7937612	1.000	rs4938805	chr11:120274211	C/T	cg24566217	chr11:120254723	ARHGEF12	0.52	12.58	0.5	2.07e-31	Intraocular pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18451256	chr2:128284158	IWS1	0.43	7.03	0.31	7.47e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.62	0.63	1.43e-53	Cognitive function;
LGG	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg27398817	chr8:82754497	SNX16	-0.8	-11.64	-0.48	1.2100000000000001e-27	Diastolic blood pressure;
LGG	cis	rs3812565	0.506	rs8413	chr9:139323311	T/C	cg14019695	chr9:139328340	INPP5E	0.44	8.04	0.35	7.69e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2797160	1.000	rs6927161	chr6:126015954	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg26338869	chr17:61819248	STRADA	-0.56	-9.21	-0.39	1.15e-18	Prudent dietary pattern;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg22283653	chr8:49824208	NA	0.64	12.11	0.49	1.6e-29	Sudden cardiac arrest;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02334926	chr5:63802741	RGS7BP	0.36	6.65	0.3	8.16e-11	Bipolar disorder;
LGG	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03517284	chr6:25882590	NA	-0.49	-9.32	-0.4	4.79e-19	Blood metabolite levels;
LGG	cis	rs7236492	0.688	rs77069608	chr18:77186319	C/T	cg05753993	chr18:77199432	NFATC1	0.39	7.27	0.32	1.51e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4330281	0.702	rs10433561	chr3:17803996	T/G	cg20981856	chr3:17787350	NA	-0.38	-6.95	-0.31	1.28e-11	Schizophrenia;
LGG	cis	rs490234	0.966	rs509753	chr9:128303518	G/A	cg14078157	chr9:128172775	NA	0.39	7.29	0.32	1.35e-12	Mean arterial pressure;
LGG	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg27411982	chr8:10470053	RP1L1	0.43	7.44	0.33	5.02e-13	Mood instability;
LGG	trans	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.76	-0.34	5.3e-14	Heart rate;
LGG	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg15309053	chr8:964076	NA	0.42	9.02	0.39	5e-18	Schizophrenia;
LGG	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	7.7	0.34	8.4e-14	Schizophrenia;
LGG	cis	rs1816752	0.633	rs9578729	chr13:24999244	T/A	cg02811702	chr13:24901961	NA	0.39	7.24	0.32	1.94e-12	Obesity-related traits;
LGG	cis	rs7106204	0.514	rs10834307	chr11:24272516	G/A	ch.11.24196551F	chr11:24239977	NA	-0.91	-13.91	-0.54	5.25e-37	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6754311	0.773	rs1435576	chr2:136641882	A/T	cg07169764	chr2:136633963	MCM6	0.76	13.01	0.52	3.33e-33	Mosquito bite size;
LGG	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs7084402	0.905	rs7914888	chr10:60308558	T/C	cg09696939	chr10:60272079	BICC1	0.36	7.03	0.31	7.46e-12	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05241470	chr15:45815405	SLC30A4;C15orf21	0.42	6.66	0.3	7.69e-11	Gut microbiome composition (summer);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23435730	chr3:127770634	SEC61A1	0.39	6.67	0.3	7.34e-11	Menarche (age at onset);
LGG	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.82	0.34	3.64e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	cis	rs9398803	0.965	rs9388489	chr6:126698719	C/T	cg19875578	chr6:126661172	C6orf173	-0.57	-10.33	-0.43	1.17e-22	Male-pattern baldness;
LGG	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg17376030	chr22:41985996	PMM1	-0.41	-6.68	-0.3	7.01e-11	Vitiligo;
LGG	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg18129748	chr3:49941408	MST1R	0.22	7.18	0.32	2.86e-12	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg09048205	chr5:1608656	LOC728613	0.46	8.0	0.35	1.02e-14	Breast cancer;
LGG	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.37	0.36	6.92e-16	Retinal vascular caliber;
LGG	cis	rs13420028	0.606	rs4263162	chr2:133195387	C/G	cg02570563	chr2:133174168	GPR39	0.4	6.78	0.3	3.77e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs10463316	0.894	rs6579860	chr5:150752338	G/A	cg03212797	chr5:150827313	SLC36A1	-0.61	-10.66	-0.44	7.1e-24	Metabolite levels (Pyroglutamine);
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg19635926	chr16:89946313	TCF25	0.81	9.09	0.39	3.03e-18	Skin colour saturation;
LGG	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg24565620	chr2:194026	NA	-0.67	-9.06	-0.39	3.6e-18	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01636747	chr16:28957148	NA	0.4	6.68	0.3	6.81e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.42	-8.34	-0.36	8.57e-16	Obesity-related traits;
LGG	cis	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg21775007	chr8:11205619	TDH	-0.76	-13.16	-0.52	8.01e-34	Retinal vascular caliber;
LGG	cis	rs2652834	1.000	rs2729784	chr15:63402735	T/C	cg05507819	chr15:63340323	TPM1	0.61	8.32	0.36	1.03e-15	HDL cholesterol;
LGG	trans	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg04492858	chr10:133558786	NA	0.42	8.87	0.38	1.62e-17	Survival in rectal cancer;
LGG	cis	rs7236492	0.688	rs76247824	chr18:77186287	G/A	cg15644404	chr18:77186268	NFATC1	-0.8	-9.78	-0.41	1.17e-20	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.94e-30	Corneal astigmatism;
LGG	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2742417	1.000	rs1609554	chr3:45735192	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg03606772	chr1:152487856	CRCT1	0.31	7.26	0.32	1.69e-12	Hair morphology;
LGG	cis	rs4650994	0.816	rs2093770	chr1:178604633	C/A	cg19399532	chr1:178512495	C1orf220	-0.38	-7.21	-0.32	2.22e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs6964587	0.967	rs7781221	chr7:91664645	A/G	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.77e-16	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06190759	chr16:71757240	NA	0.51	7.55	0.33	2.29e-13	Gut microbiome composition (summer);
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26617929	chr16:1858877	NA	-0.62	-8.69	-0.37	6.34e-17	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04853151	chr1:54519244	C1orf83;TMEM59	-0.42	-7.01	-0.31	8.4e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs77972916	0.536	rs59362315	chr2:43594931	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.81	-0.34	3.84e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.21	-0.32	2.24e-12	Calcium levels;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs73198271	0.515	rs17629935	chr8:8619381	A/T	cg01851573	chr8:8652454	MFHAS1	0.52	7.07	0.31	5.77e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.08	-0.31	5.47e-12	Total cholesterol levels;
LGG	cis	rs28374715	0.532	rs11854632	chr15:41682094	A/G	cg18705301	chr15:41695430	NDUFAF1	1.34	35.12	0.85	1.24e-132	Ulcerative colitis;
LGG	cis	rs741702	0.928	rs2974750	chr19:13044544	C/A	cg23899408	chr19:12877188	HOOK2	0.5	7.98	0.35	1.12e-14	Red blood cell traits;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg16359550	chr11:109292809	C11orf87	0.39	7.83	0.34	3.4e-14	Schizophrenia;
LGG	cis	rs4774899	0.966	rs935326	chr15:57567244	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg14541582	chr5:601475	NA	-0.71	-11.05	-0.46	2.29e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs713587	0.935	rs11676272	chr2:25141538	A/G	cg04586622	chr2:25135609	ADCY3	0.45	12.26	0.49	4.15e-30	Body mass index in non-asthmatics;
LGG	trans	rs6598955	0.627	rs7550127	chr1:26592871	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.63	-0.51	1.28e-31	Obesity-related traits;
LGG	cis	rs1707322	0.650	rs4553239	chr1:46150486	C/A	cg03146154	chr1:46216737	IPP	0.56	10.67	0.44	6.32e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg14227996	chr4:17616232	MED28	0.72	8.83	0.38	2.25e-17	Opioid sensitivity;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg07511668	chr11:68622177	NA	0.51	9.37	0.4	3.18e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs2008242	0.683	rs11725344	chr4:5219883	G/A	cg26099876	chr8:141644609	EIF2C2	-0.42	-7.46	-0.33	4.46e-13	Electrocardiographic conduction measures;
LGG	cis	rs7737355	0.947	rs12656936	chr5:130788642	A/C	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.9e-19	Life satisfaction;
LGG	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg02023345	chr10:63212226	TMEM26	0.43	7.95	0.35	1.43e-14	Night sleep phenotypes;
LGG	cis	rs10462794	0.713	rs896134	chr5:4511542	T/C	cg18482690	chr5:4511582	NA	0.42	7.59	0.33	1.72e-13	DNA methylation (variation);
LGG	trans	rs9309473	0.519	rs12991161	chr2:73871371	G/A	cg23020402	chr6:24666573	ACOT13;TTRAP	-0.43	-6.67	-0.3	7.28e-11	Metabolite levels;
LGG	cis	rs539514	0.690	rs528783	chr13:76319460	T/C	cg04757411	chr13:76259545	LMO7	-0.27	-7.05	-0.31	6.69e-12	Type 1 diabetes;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02475777	chr4:1388615	CRIPAK	0.61	10.67	0.44	6.24e-24	Longevity;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22168489	chr12:122356033	WDR66	0.42	9.84	0.42	7.33e-21	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26082856	chr14:23503928	PSMB5	0.44	6.98	0.31	9.99e-12	Cognitive performance;
LGG	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg00204512	chr16:28754710	NA	0.26	7.16	0.32	3.13e-12	Tonsillectomy;Mean corpuscular volume;
LGG	cis	rs4731207	0.533	rs1481340	chr7:124582051	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.67	-0.3	7.19e-11	Cutaneous malignant melanoma;
LGG	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.2	0.43	3.56e-22	Retinal vascular caliber;
LGG	cis	rs3741151	0.773	rs57673166	chr11:73232557	T/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.87	0.34	2.57e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg22105103	chr4:187893119	NA	0.59	11.25	0.46	3.98e-26	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19656070	chr17:3571978	TMEM93;TAX1BP3	0.48	8.01	0.35	9.32e-15	Cognitive performance;
LGG	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg10664184	chr19:17420304	DDA1	0.56	8.7	0.37	5.76e-17	Systemic lupus erythematosus;
LGG	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg05234568	chr11:5960015	NA	-0.67	-11.63	-0.48	1.37e-27	DNA methylation (variation);
LGG	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.03	0.31	7.57e-12	Neuroticism;
LGG	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg25706552	chr1:244017396	NA	-0.49	-8.07	-0.35	6.27e-15	RR interval (heart rate);
LGG	cis	rs9473924	0.505	rs55653665	chr6:50812984	T/C	cg14470998	chr6:50812995	TFAP2B	0.7	8.37	0.36	6.91e-16	Body mass index;
LGG	cis	rs7166081	1.000	rs12443279	chr15:67561355	C/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.75	-0.3	4.5e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg18854424	chr1:2615690	NA	-0.35	-7.12	-0.31	4.23e-12	Ulcerative colitis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03017104	chr17:8089904	NA	-0.52	-7.76	-0.34	5.61e-14	Systemic lupus erythematosus;
LGG	cis	rs4911259	0.552	rs13042651	chr20:31467423	C/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.92	-0.48	9.59e-29	Inflammatory bowel disease;
LGG	cis	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs4268898	0.662	rs2891382	chr2:24511491	C/G	cg06627628	chr2:24431161	ITSN2	-0.76	-12.32	-0.5	2.33e-30	Asthma;
LGG	cis	rs2455601	1.000	rs11042108	chr11:8906021	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-9.92	-0.42	3.75e-21	Schizophrenia;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs988958	0.755	rs10201161	chr2:42291087	G/C	cg19376973	chr2:42229025	NA	0.45	6.8	0.3	3.26e-11	Hypospadias;
LGG	cis	rs1639906	0.895	rs34255795	chr7:2207416	A/G	cg20308403	chr7:2120281	MAD1L1	-0.37	-7.56	-0.33	2.25e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs283228	1.000	rs2787581	chr6:101816456	A/G	cg27451362	chr6:101846650	GRIK2	0.54	9.04	0.39	4.2e-18	Coenzyme Q10 levels;
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg04450456	chr4:17643702	FAM184B	0.32	6.92	0.31	1.48e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9472414	0.566	rs72664272	chr6:44737467	A/C	cg20913747	chr6:44695427	NA	0.48	7.47	0.33	4.09e-13	Height;
LGG	cis	rs644799	0.509	rs580181	chr11:95643040	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	12.32	0.5	2.22e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs561341	1.000	rs8070262	chr17:30262467	A/G	cg00745463	chr17:30367425	LRRC37B	-0.59	-8.49	-0.37	2.89e-16	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.71	-0.3	5.74e-11	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg19635926	chr16:89946313	TCF25	0.73	7.16	0.32	3.1e-12	Skin colour saturation;
LGG	cis	rs4650994	0.816	rs2811303	chr1:178595646	G/T	cg19399532	chr1:178512495	C1orf220	-0.37	-6.99	-0.31	9.7e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg05425664	chr17:57184151	TRIM37	-0.71	-11.57	-0.47	2.28e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.846	rs13083229	chr3:161008125	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.19	-0.49	7.79e-30	Morning vs. evening chronotype;
LGG	cis	rs3815700	1.000	rs8109768	chr19:33095463	A/G	cg02997394	chr19:33096574	ANKRD27	0.88	12.91	0.51	8.82e-33	Eosinophilic esophagitis;
LGG	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.52	0.37	2.21e-16	Retinal vascular caliber;
LGG	cis	rs2842992	1.000	rs2842992	chr6:160071159	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.54	0.47	3e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.35	0.4	3.9e-19	Alzheimer's disease;
LGG	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg13647721	chr17:30228624	UTP6	0.64	7.99	0.35	1.07e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3741404	0.825	rs2515241	chr11:63975331	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	7.28	0.32	1.43e-12	Platelet count;
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg05863683	chr7:1912471	MAD1L1	0.46	8.95	0.38	8.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg15736062	chr7:158136485	PTPRN2	-0.39	-7.49	-0.33	3.6e-13	Calcium levels;
LGG	cis	rs4740619	0.648	rs752489	chr9:16032679	G/C	cg14451791	chr9:16040625	NA	-0.43	-11.27	-0.46	3.37e-26	Body mass index;
LGG	cis	rs1707322	1.000	rs4660334	chr1:46462126	A/C	cg03146154	chr1:46216737	IPP	0.53	9.7	0.41	2.16e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4595586	0.545	rs12809206	chr12:39388748	A/C	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.71	-0.48	6.64e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg05556477	chr5:131705319	SLC22A5	0.86	10.27	0.43	1.92e-22	Rheumatoid arthritis;
LGG	cis	rs17776563	0.573	rs59546113	chr15:89142705	G/A	cg05013243	chr15:89149849	MIR1179	-0.34	-7.07	-0.31	5.84e-12	Thyroid hormone levels;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg18350739	chr11:68623251	NA	-0.89	-22.53	-0.72	1.95e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6692729	0.933	rs1794038	chr1:227073712	T/G	cg08708961	chr1:227070630	PSEN2	0.31	7.8	0.34	4.11e-14	Electrodermal activity;
LGG	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg27478167	chr7:817139	HEATR2	-0.43	-6.71	-0.3	5.77e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7027203	0.828	rs3996239	chr9:96611290	T/A	cg13679303	chr9:96623674	NA	-0.38	-6.82	-0.3	2.9100000000000002e-11	DNA methylation (variation);
LGG	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	9.29e-26	Colorectal cancer;
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg24690094	chr11:67383802	NA	0.51	9.23	0.39	9.54e-19	Mean corpuscular volume;
LGG	cis	rs6772849	0.965	rs4286447	chr3:128310589	G/T	cg08795948	chr3:128337044	NA	0.53	8.74	0.38	4.31e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg27129171	chr3:47204927	SETD2	0.82	15.19	0.58	1.38e-42	Colorectal cancer;
LGG	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs10838798	0.584	rs17198859	chr11:48140354	C/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.78	-0.3	3.73e-11	Height;
LGG	cis	rs2303319	1.000	rs12471336	chr2:162265189	A/C	cg13806767	chr2:162164127	PSMD14	0.69	8.15	0.35	3.5e-15	Cognitive function;
LGG	cis	rs7927771	0.524	rs61895760	chr11:47794538	G/C	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg05560165	chr5:133450315	TCF7	-0.4	-6.73	-0.3	5e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs11758351	0.715	rs75390741	chr6:26209784	A/T	cg01420254	chr6:26195488	NA	0.85	11.09	0.46	1.71e-25	Gout;Renal underexcretion gout;
LGG	cis	rs988958	0.958	rs6730389	chr2:42279349	A/C	cg27252766	chr2:42229092	NA	-0.47	-7.58	-0.33	1.88e-13	Hypospadias;
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-8.03	-0.35	8.12e-15	Skin colour saturation;
LGG	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg00599393	chr8:22457479	C8orf58	-0.45	-8.07	-0.35	5.97e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12580194	0.593	rs79104523	chr12:55749220	T/C	cg19537932	chr12:55886519	OR6C68	-0.54	-9.71	-0.41	2e-20	Cancer;
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.62	-0.41	4.24e-20	Aortic root size;
LGG	cis	rs2594989	0.943	rs2454493	chr3:11506458	A/G	cg01796438	chr3:11312864	ATG7	-0.52	-7.09	-0.31	5.16e-12	Circulating chemerin levels;
LGG	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg06197492	chr11:2016605	H19	0.41	8.77	0.38	3.55e-17	DNA methylation (variation);
LGG	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.94	-0.31	1.37e-11	Monocyte count;
LGG	cis	rs9916302	0.706	rs4287601	chr17:37513852	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.92e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4595586	0.525	rs1878227	chr12:39355719	A/T	cg26384229	chr12:38710491	ALG10B	0.67	12.1	0.49	1.75e-29	Morning vs. evening chronotype;
LGG	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.78	0.41	1.18e-20	Neuroticism;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg21862992	chr11:68658383	NA	0.49	7.93	0.35	1.63e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16405210	chr4:1374714	KIAA1530	-0.49	-8.4	-0.36	5.32e-16	Obesity-related traits;
LGG	cis	rs6547631	0.622	rs10203826	chr2:85926190	A/C	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs12079745	0.623	rs2982468	chr1:169090971	A/T	cg09363564	chr1:169337483	NME7;BLZF1	-0.93	-7.05	-0.31	6.33e-12	QT interval;
LGG	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.02	25.18	0.76	9.49e-89	Chronic sinus infection;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg19049616	chr17:58042270	RNFT1	0.46	6.94	0.31	1.31e-11	Emphysema imaging phenotypes;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg20120463	chr17:44301886	NA	-0.47	-7.2	-0.32	2.42e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg02725872	chr8:58115012	NA	-0.84	-12.02	-0.49	3.74e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.501	rs2070865	chr21:40715519	C/T	cg11890956	chr21:40555474	PSMG1	-0.65	-10.91	-0.45	8.16e-25	Menarche (age at onset);
LGG	cis	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.95	0.42	2.78e-21	Mean corpuscular volume;
LGG	cis	rs3806843	1.000	rs9686540	chr5:140174622	G/A	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.31e-16	Restless legs syndrome;
LGG	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg27053975	chr1:166958233	MAEL	-0.48	-6.68	-0.3	7.05e-11	Obesity-related traits;
LGG	cis	rs2731664	0.792	rs335452	chr5:176879671	C/T	cg23176889	chr5:176863531	GRK6	-0.66	-13.08	-0.52	1.69e-33	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg03264133	chr6:25882463	NA	-0.49	-7.9	-0.34	2.05e-14	Iron status biomarkers;
LGG	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.88	0.38	1.43e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2404602	0.647	rs12910820	chr15:77022825	T/C	cg23625390	chr15:77176239	SCAPER	-0.71	-13.91	-0.54	5.16e-37	Blood metabolite levels;
LGG	cis	rs7923609	0.905	rs10740129	chr10:65250808	G/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.64	-0.3	8.55e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	10.32	0.43	1.32e-22	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs13354585	chr5:242263	G/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.37	-0.36	7.08e-16	Breast cancer;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-11.0	-0.46	3.79e-25	Prostate cancer;
LGG	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg12402800	chr5:56204917	C5orf35	0.43	6.74	0.3	4.61e-11	Initial pursuit acceleration;
LGG	cis	rs2153535	0.580	rs1577468	chr6:8444266	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.95	0.38	8.92e-18	Motion sickness;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.622	rs11182004	chr12:38441254	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.36	-0.4	3.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs67311347	0.956	rs12633446	chr3:40505661	G/A	cg13683864	chr3:40499215	RPL14	1.03	23.01	0.73	1.11e-78	Renal cell carcinoma;
LGG	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg09904177	chr6:26538194	HMGN4	0.77	17.02	0.62	8.32e-51	Intelligence (multi-trait analysis);
LGG	cis	rs3742264	0.656	rs4460970	chr13:46540293	A/T	cg15192986	chr13:46630673	CPB2	-0.36	-6.86	-0.3	2.15e-11	Blood protein levels;
LGG	cis	rs2072153	0.715	rs34367165	chr17:47330796	G/A	cg08112188	chr17:47440006	ZNF652	0.43	6.72	0.3	5.3e-11	Height;
LGG	cis	rs4948102	0.961	rs7776550	chr7:56092391	T/C	cg17215666	chr7:56131930	SUMF2	0.43	6.89	0.31	1.79e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-9.77	-0.41	1.22e-20	Educational attainment (years of education);
LGG	cis	rs6466055	0.501	rs6965384	chr7:104603112	A/G	cg03782966	chr7:104585482	NA	0.32	6.86	0.3	2.2e-11	Schizophrenia;
LGG	cis	rs4788570	0.615	rs11075894	chr16:71690030	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	21.94	0.71	1.16e-73	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg09699651	chr6:150184138	LRP11	0.49	8.62	0.37	1.05e-16	Lung cancer;
LGG	cis	rs11834862	0.770	rs10444603	chr12:132694910	C/G	cg16245054	chr12:132698494	GALNT9	-0.44	-6.87	-0.3	2.12e-11	Anti-saccade response;
LGG	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg18850127	chr7:39170497	POU6F2	0.65	16.33	0.6	1.11e-47	IgG glycosylation;
LGG	cis	rs300703	0.639	rs397719	chr2:204870	T/G	cg24565620	chr2:194026	NA	-0.67	-10.56	-0.44	1.67e-23	Blood protein levels;
LGG	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs9329289	0.510	rs1155447	chr10:2553240	C/T	cg15501526	chr10:2543763	NA	0.47	8.81	0.38	2.58e-17	Age-related hearing impairment;
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg23743428	chr13:21893420	NA	-0.41	-6.76	-0.3	4.19e-11	White matter hyperintensity burden;
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26617929	chr16:1858877	NA	-0.63	-8.83	-0.38	2.09e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11190604	1.000	rs3750719	chr10:102248950	C/G	cg07080220	chr10:102295463	HIF1AN	0.65	11.21	0.46	5.8e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg09303159	chr6:26284866	NA	0.34	7.5	0.33	3.18e-13	Educational attainment;
LGG	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg18245976	chr7:158708271	WDR60	-0.56	-9.73	-0.41	1.75e-20	Height;
LGG	cis	rs7598759	0.712	rs6727510	chr2:232332016	T/C	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.49e-14	Noise-induced hearing loss;
LGG	cis	rs7226408	0.857	rs72887024	chr18:34468482	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.52	0.4	1e-19	Height;
LGG	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg12395012	chr8:11607386	GATA4	0.4	7.32	0.32	1.07e-12	Monocyte count;
LGG	cis	rs36051895	0.593	rs12340303	chr9:5176147	C/T	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.66	0.34	1.13e-13	Lung cancer;
LGG	cis	rs427394	1.000	rs274672	chr5:6744176	G/A	cg15145174	chr5:6755386	POLS	-0.38	-7.17	-0.32	3.03e-12	Menopause (age at onset);
LGG	cis	rs303806	1	rs303806	chr12:52166503	A/G	cg07929700	chr12:52204284	NA	-0.57	-7.72	-0.34	7.44e-14	Morning vs. evening chronotype;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg12288994	chr5:1860383	NA	0.77	15.42	0.58	1.41e-43	Cardiovascular disease risk factors;
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.58	-0.47	2.08e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.741	rs1557969	chr7:124405738	A/G	cg05630886	chr7:124431682	NA	0.32	7.52	0.33	2.93e-13	Cutaneous malignant melanoma;
LGG	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.23	0.36	1.97e-15	Triglycerides;
LGG	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.7	-0.34	8.37e-14	Colorectal cancer;
LGG	cis	rs12200782	0.685	rs9467734	chr6:26379694	T/G	cg27193005	chr6:26382695	BTN2A2	-0.49	-7.0	-0.31	9.31e-12	Small cell lung carcinoma;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg15948088	chr11:109293068	C11orf87	0.51	9.0	0.39	5.81e-18	Schizophrenia;
LGG	cis	rs11628318	0.660	rs12887323	chr14:103083322	T/C	cg23461800	chr14:103021989	NA	-0.53	-8.32	-0.36	9.770000000000001e-16	Platelet count;
LGG	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg02466173	chr16:30829666	NA	-0.57	-10.2	-0.43	3.73e-22	Multiple myeloma;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg03452623	chr4:187889614	NA	-1.04	-29.58	-0.81	9.52e-109	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7615952	0.932	rs13325495	chr3:125637416	T/G	cg07211511	chr3:129823064	LOC729375	-1.42	-21.25	-0.7	2e-70	Blood pressure (smoking interaction);
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.16	-0.35	3.09e-15	Neuroticism;
LGG	cis	rs911555	0.723	rs2273701	chr14:103923225	G/T	cg24130564	chr14:104152367	KLC1	0.37	6.95	0.31	1.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.697	rs6060446	chr20:30231637	T/C	cg21427119	chr20:30132790	HM13	-0.5	-8.26	-0.36	1.55e-15	Mean corpuscular hemoglobin;
LGG	cis	rs11608355	0.545	rs1073780	chr12:109895143	T/C	cg05360138	chr12:110035743	NA	0.86	11.93	0.48	8.71e-29	Neuroticism;
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg10207240	chr12:122356781	WDR66	0.28	8.21	0.36	2.18e-15	Mean corpuscular volume;
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19524238	chr7:2802976	GNA12	0.32	7.86	0.34	2.77e-14	Height;
LGG	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg02397686	chr17:73851076	WBP2	0.6	7.49	0.33	3.6e-13	Psoriasis;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.59	-10.28	-0.43	1.87e-22	Obesity-related traits;
LGG	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	23.72	0.74	5.3e-82	Chronic sinus infection;
LGG	cis	rs6844506	1.000	rs6844506	chr4:185217148	C/T	cg12654155	chr4:185238627	NA	-0.39	-6.73	-0.3	5e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs897080	0.516	rs1067393	chr2:44638832	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.71	-0.3	5.85e-11	Height;
LGG	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg13647721	chr17:30228624	UTP6	0.6	7.79	0.34	4.41e-14	Hip circumference adjusted for BMI;
LGG	cis	rs11622475	1.000	rs11622475	chr14:104509076	C/T	cg20488157	chr14:104394430	TDRD9	0.52	8.17	0.35	3.06e-15	Bipolar disorder;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.88	-0.34	2.34e-14	IgG glycosylation;
LGG	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.0	-0.31	9.33e-12	Iron status biomarkers;
LGG	cis	rs4750440	0.706	rs1599414	chr10:14019519	G/A	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.84	-0.51	1.71e-32	Adiponectin levels;
LGG	cis	rs6840360	0.593	rs1366907	chr4:152682749	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.15	-0.43	5.66e-22	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.5	-12.38	-0.5	1.34e-30	Tonsillectomy;
LGG	cis	rs4642101	0.597	rs12638595	chr3:12819281	T/C	cg24848339	chr3:12840334	CAND2	0.46	11.07	0.46	2.04e-25	QRS complex (12-leadsum);
LGG	cis	rs7267979	0.932	rs4280527	chr20:25544014	A/G	cg06421707	chr20:25228305	PYGB	0.47	9.88	0.42	5e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7241530	0.662	rs6506753	chr18:75904851	G/A	cg14642773	chr18:75888474	NA	0.47	9.23	0.39	9.43e-19	Educational attainment (years of education);
LGG	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg03606772	chr1:152487856	CRCT1	-0.3	-7.11	-0.31	4.43e-12	Hair morphology;
LGG	cis	rs7712401	0.601	rs246287	chr5:122245426	A/T	cg19412675	chr5:122181750	SNX24	0.43	7.23	0.32	2.01e-12	Mean platelet volume;
LGG	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.2	-0.39	1.26e-18	Schizophrenia;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06112835	chr11:68658793	MRPL21	0.6	9.89	0.42	4.7e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4363385	0.747	rs2339496	chr1:152970719	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.81e-18	Inflammatory skin disease;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg06565975	chr8:143823917	SLURP1	-0.29	-7.11	-0.31	4.49e-12	Urinary tract infection frequency;
LGG	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg12310025	chr6:25882481	NA	-0.46	-7.52	-0.33	2.79e-13	Iron status biomarkers;
LGG	cis	rs7618915	0.547	rs4687548	chr3:52666650	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg24189917	chr7:1970923	MAD1L1	-0.46	-6.91	-0.31	1.58e-11	Bipolar disorder;
LGG	cis	rs1355223	0.872	rs7116409	chr11:34751007	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.92	-0.31	1.48e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1497828	1.000	rs2810766	chr1:217565056	G/A	cg04411442	chr1:217543379	NA	0.46	7.92	0.35	1.81e-14	Dialysis-related mortality;
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.62	0.37	1.06e-16	Bipolar disorder;
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00495681	chr13:53174319	NA	-0.5	-8.95	-0.38	8.87e-18	Lewy body disease;
LGG	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.25	-0.43	2.39e-22	Chronic sinus infection;
LGG	cis	rs7927771	0.832	rs1542321	chr11:47379615	G/A	cg20307385	chr11:47447363	PSMC3	0.55	9.98	0.42	2.15e-21	Subjective well-being;
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs2235642	0.582	rs2235637	chr16:1567694	G/A	cg04525384	chr16:1557733	TELO2	0.48	8.46	0.37	3.55e-16	Coronary artery disease;
LGG	cis	rs12549902	0.933	rs17659428	chr8:41513809	T/C	cg21772509	chr8:41503840	NKX6-3	0.86	18.96	0.66	9.65e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg04851639	chr8:1020857	NA	0.43	9.34	0.4	4.17e-19	Schizophrenia;
LGG	cis	rs10901296	0.660	rs2855198	chr9:133764606	T/C	cg13397898	chr9:133768931	QRFP	0.43	8.43	0.36	4.38e-16	Bilirubin levels;
LGG	cis	rs711244	0.772	rs11124554	chr2:37149498	T/C	cg14987922	chr2:37194071	STRN	0.42	6.82	0.3	2.9100000000000002e-11	Mean platelet volume;
LGG	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.07e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg00101154	chr16:420108	MRPL28	0.45	7.52	0.33	2.88e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg09426994	chr11:118478258	PHLDB1	0.43	7.84	0.34	3.19e-14	Cholesterol, total;
LGG	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.2e-14	Hip circumference adjusted for BMI;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg18225595	chr11:63971243	STIP1	0.56	7.58	0.33	1.85e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs72827839	0.802	rs72825584	chr17:46293089	G/A	cg02219949	chr17:45927392	SP6	0.52	7.74	0.34	6.08e-14	Ease of getting up in the morning;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02018176	chr4:1364513	KIAA1530	-0.65	-16.16	-0.6	6.85e-47	Longevity;
LGG	cis	rs4851254	0.961	rs11680586	chr2:100746207	G/T	cg17356467	chr2:100759845	AFF3	0.4	6.95	0.31	1.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.3	0.36	1.12e-15	Diabetic kidney disease;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04772025	chr11:68637568	NA	0.75	13.17	0.52	7.42e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6908034	0.660	rs76322282	chr6:19801660	G/A	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs11690935	0.610	rs3770458	chr2:172651287	C/T	cg13550731	chr2:172543902	DYNC1I2	0.69	14.02	0.55	1.87e-37	Schizophrenia;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg03188948	chr7:1209495	NA	0.64	8.45	0.37	3.72e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17270561	0.636	rs9393656	chr6:25722059	A/C	cg03517284	chr6:25882590	NA	-0.43	-6.99	-0.31	9.78e-12	Iron status biomarkers;
LGG	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg22875332	chr1:76189707	ACADM	0.62	10.73	0.45	3.88e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11249608	0.548	rs17078991	chr5:178459426	A/C	cg21905437	chr5:178450457	ZNF879	0.46	6.65	0.3	8.26e-11	Pubertal anthropometrics;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.14	-0.35	3.72e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg17734273	chr15:78292508	TBC1D2B	-0.34	-8.25	-0.36	1.67e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs137603	0.644	rs94852	chr22:39712334	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.72	-13.85	-0.54	9.55e-37	Primary biliary cholangitis;
LGG	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.85	-0.34	2.89e-14	Iron status biomarkers;
LGG	cis	rs7552404	1.000	rs7524467	chr1:76194054	C/G	cg22875332	chr1:76189707	ACADM	0.62	10.54	0.44	2.04e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg19635926	chr16:89946313	TCF25	0.81	9.16	0.39	1.62e-18	Skin colour saturation;
LGG	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg00757033	chr12:89920650	WDR51B	-0.64	-9.38	-0.4	2.86e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg10523679	chr1:76189770	ACADM	0.74	12.3	0.5	2.9e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg00701064	chr4:6280414	WFS1	0.67	13.22	0.52	4.41e-34	Cisplatin-induced ototoxicity;
LGG	cis	rs9815354	0.680	rs73075219	chr3:42038429	A/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs240764	0.658	rs4840147	chr6:101182323	T/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg04450456	chr4:17643702	FAM184B	0.33	7.23	0.32	1.99e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs826838	0.868	rs864324	chr12:39122853	A/G	cg13010199	chr12:38710504	ALG10B	0.63	13.2	0.52	5.67e-34	Heart rate;
LGG	cis	rs7927592	0.913	rs67005337	chr11:68307758	A/C	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg12458913	chr13:53173898	NA	0.61	11.61	0.47	1.55e-27	Lewy body disease;
LGG	cis	rs4665809	1.000	rs4665309	chr2:26335502	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.01	-0.35	9.49e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02672962	chr16:3665541	NA	0.38	6.84	0.3	2.54e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg14926445	chr8:58193284	C8orf71	-0.71	-9.23	-0.39	9.4e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg05484376	chr2:27715224	FNDC4	0.46	9.97	0.42	2.38e-21	Total body bone mineral density;
LGG	cis	rs526231	0.575	rs62362524	chr5:102314227	G/T	cg23492399	chr5:102201601	PAM	-0.62	-9.34	-0.4	4.14e-19	Primary biliary cholangitis;
LGG	cis	rs7712401	0.546	rs30021	chr5:122285894	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs9354308	0.746	rs9360157	chr6:66555811	T/G	cg07460842	chr6:66804631	NA	-0.45	-7.59	-0.33	1.76e-13	Metabolite levels;
LGG	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg03929089	chr4:120376271	NA	-0.7	-9.53	-0.4	8.61e-20	Axial length;
LGG	cis	rs9942416	0.517	rs116509898	chr5:74994361	C/T	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg06618935	chr21:46677482	NA	-0.37	-7.11	-0.31	4.38e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9513627	1.000	rs7338335	chr13:100125296	G/C	cg25919922	chr13:100150906	NA	-0.71	-7.27	-0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg12432903	chr7:1882776	MAD1L1	-0.56	-8.86	-0.38	1.68e-17	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25368113	chr19:33462881	C19orf40;CCDC123	0.38	7.53	0.33	2.63e-13	Gut microbiome composition (summer);
LGG	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.73	0.3	4.88e-11	Depression;
LGG	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg02836325	chr17:76403955	PGS1	-0.71	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg02002194	chr4:3960332	NA	0.44	8.28	0.36	1.36e-15	Neuroticism;
LGG	cis	rs773506	1.000	rs773513	chr9:93980843	G/A	cg14446406	chr9:93919335	NA	0.47	8.51	0.37	2.51e-16	Type 2 diabetes nephropathy;
LGG	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg27205649	chr11:78285834	NARS2	-0.44	-7.28	-0.32	1.41e-12	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs7911264	0.967	rs2488087	chr10:94446041	G/A	cg25093409	chr10:94429542	NA	-0.57	-11.78	-0.48	3.28e-28	Inflammatory bowel disease;
LGG	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15128208	chr22:42549153	NA	-0.37	-7.31	-0.32	1.16e-12	Cognitive function;
LGG	cis	rs12580194	0.593	rs7959124	chr12:55726957	A/G	cg19537932	chr12:55886519	OR6C68	-0.56	-9.89	-0.42	4.75e-21	Cancer;
LGG	cis	rs2354432	0.607	rs9661159	chr1:146757923	G/A	cg25205988	chr1:146714368	CHD1L	-1.47	-14.82	-0.57	5.75e-41	Mitochondrial DNA levels;
LGG	cis	rs881375	0.934	rs2159778	chr9:123678129	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.69	0.41	2.38e-20	Rheumatoid arthritis;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	8.18	0.36	2.76e-15	Longevity;
LGG	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.14	0.43	5.72e-22	Height;
LGG	cis	rs7523273	1.000	rs7541230	chr1:207957555	T/C	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.64	-0.48	1.2e-27	Schizophrenia;
LGG	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.46	-0.33	4.44e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs67311347	0.713	rs9861194	chr3:40309225	C/T	cg13683864	chr3:40499215	RPL14	-0.79	-15.47	-0.58	7.99e-44	Renal cell carcinoma;
LGG	cis	rs3790455	0.965	rs12131289	chr1:156446450	C/T	cg14087168	chr1:156450669	MEF2D	0.48	7.84	0.34	3.05e-14	Migraine;
LGG	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg02002194	chr4:3960332	NA	-0.52	-9.73	-0.41	1.8e-20	Retinal vascular caliber;
LGG	cis	rs283228	0.617	rs471631	chr6:101745809	C/A	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs60180747	0.909	rs56913458	chr15:66702345	C/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.59	10.0	0.42	1.91e-21	Testicular germ cell tumor;
LGG	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg02711726	chr17:80685570	FN3KRP	-0.38	-7.39	-0.32	6.82e-13	Breast cancer;
LGG	cis	rs7737355	0.947	rs31254	chr5:130829404	C/T	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	6.78e-18	Life satisfaction;
LGG	cis	rs1538970	0.816	rs11211123	chr1:45957609	G/A	cg05343316	chr1:45956843	TESK2	0.75	13.25	0.52	3.44e-34	Platelet count;
LGG	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.71	-0.38	5.46e-17	Neuroticism;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg14926445	chr8:58193284	C8orf71	-0.73	-9.11	-0.39	2.46e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.765	rs132920	chr22:41810170	T/C	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs2455799	0.593	rs2470544	chr3:15727234	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.85	-0.34	2.83e-14	Mean platelet volume;
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.6	-0.59	2.23e-44	Rheumatoid arthritis;
LGG	cis	rs17301259	0.624	rs10952930	chr7:88430455	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-6.88	-0.3	1.9e-11	Heschl's gyrus morphology;
LGG	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.88	-13.61	-0.53	1e-35	HIV-1 control;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-14.89	-0.57	3e-41	Pancreatic cancer;
LGG	cis	rs7940866	0.834	rs1594821	chr11:130835883	C/T	cg12179176	chr11:130786555	SNX19	0.7	12.74	0.51	4.49e-32	Schizophrenia;
LGG	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg27446573	chr6:127587934	RNF146	-0.9	-17.12	-0.62	2.79e-51	Breast cancer;
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.79	-0.41	1.09e-20	Retinal vascular caliber;
LGG	cis	rs1707322	0.682	rs10890335	chr1:46100394	G/C	cg03146154	chr1:46216737	IPP	0.57	10.89	0.45	9.75e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.83	0.48	2.2e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg06521331	chr12:34319734	NA	-0.63	-11.39	-0.47	1.2e-26	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.86	-15.4	-0.58	1.69e-43	Response to antipsychotic treatment;
LGG	cis	rs7572644	0.582	rs7570730	chr2:28022675	G/A	cg27432699	chr2:27873401	GPN1	0.47	6.79	0.3	3.52e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg22618164	chr12:122356400	WDR66	-0.32	-9.38	-0.4	3.05e-19	Mean corpuscular volume;
LGG	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.43	0.33	5.16e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8017423	0.630	rs4904678	chr14:90821670	T/C	cg04374321	chr14:90722782	PSMC1	-0.65	-12.84	-0.51	1.64e-32	Mortality in heart failure;
LGG	cis	rs2172802	0.693	rs7660566	chr4:62481231	G/T	cg04118610	chr4:62707027	LPHN3	0.63	11.24	0.46	4.44e-26	Partial epilepsies;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.57	-0.33	2.05e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21862992	chr11:68658383	NA	-0.5	-8.53	-0.37	2.11e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg23782820	chr8:58130467	NA	0.58	8.63	0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11106794	chr5:134241538	PCBD2	0.36	6.91	0.31	1.63e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs988958	0.526	rs12712822	chr2:42238995	C/G	cg27252766	chr2:42229092	NA	0.51	7.01	0.31	8.53e-12	Hypospadias;
LGG	cis	rs9398803	0.713	rs4621656	chr6:126896168	G/C	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.97e-20	Male-pattern baldness;
LGG	trans	rs9354308	0.764	rs9345697	chr6:66572280	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-7.03	-0.31	7.63e-12	Metabolite levels;
LGG	cis	rs2071403	0.509	rs11675342	chr2:1407628	C/T	cg06500727	chr2:1417164	TPO	-0.6	-12.19	-0.49	7.75e-30	Thyroid peroxidase antibody positivity;
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg14668632	chr7:2872130	GNA12	-0.37	-7.6	-0.33	1.7e-13	Height;
LGG	cis	rs2180341	0.566	rs982306	chr6:127777039	T/C	cg27446573	chr6:127587934	RNF146	0.81	14.23	0.55	2.32e-38	Breast cancer;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg00990874	chr7:1149470	C7orf50	-0.7	-11.15	-0.46	9.42e-26	Bronchopulmonary dysplasia;
LGG	cis	rs6982240	0.569	rs6992278	chr8:142279383	C/G	cg20799268	chr8:142275649	NA	-0.25	-7.1	-0.31	4.84e-12	Tonsillectomy;
LGG	cis	rs67133203	0.768	rs17296192	chr12:51524459	A/T	cg14688905	chr12:51403056	SLC11A2	0.72	10.91	0.45	8.06e-25	Urinary tract infection frequency;
LGG	cis	rs3087591	1.000	rs2905795	chr17:29547601	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	14.43	0.56	2.91e-39	Hip circumference;
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg24231037	chr15:68117551	LBXCOR1	0.37	8.94	0.38	9.31e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg00934597	chr7:893267	UNC84A	-0.49	-7.78	-0.34	4.74e-14	Perceived unattractiveness to mosquitoes;
LGG	cis	rs3806843	0.735	rs778597	chr5:140040665	A/G	cg16577123	chr5:140027231	NDUFA2;IK	0.43	6.83	0.3	2.76e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.39e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg03264133	chr6:25882463	NA	0.43	7.63	0.33	1.33e-13	Height;
LGG	cis	rs6032067	0.777	rs35476703	chr20:43802875	C/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs758324	0.853	rs6865911	chr5:131204659	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	3.01e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6460942	0.915	rs62448600	chr7:12454944	T/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs4330281	0.669	rs12634674	chr3:17704685	T/G	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.53e-13	Schizophrenia;
LGG	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs754466	1.000	rs754466	chr10:79680434	A/T	cg17075019	chr10:79541650	NA	-0.83	-14.3	-0.55	1.15e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg00711542	chr16:29343894	RUNDC2C	0.42	6.87	0.3	2.04e-11	Menopause (age at onset);
LGG	cis	rs6546550	0.933	rs57278310	chr2:70093647	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.15	-0.35	3.32e-15	Prevalent atrial fibrillation;
LGG	cis	rs17641971	0.619	rs6983929	chr8:49984896	T/C	cg00325661	chr8:49890786	NA	0.57	10.89	0.45	9.93e-25	Blood metabolite levels;
LGG	cis	rs7582720	1.000	rs72936838	chr2:203772984	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12908161	0.853	rs12912342	chr15:85248216	T/C	cg03959625	chr15:84868606	LOC388152	0.46	7.01	0.31	8.38e-12	Schizophrenia;
LGG	cis	rs9399137	0.507	rs12664898	chr6:135288663	T/C	cg22676075	chr6:135203613	NA	0.45	7.67	0.34	1.02e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14940636	chr12:56498092	PA2G4	0.4	6.68	0.3	7.08e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg14088196	chr11:70211408	PPFIA1	0.95	13.37	0.53	1.07e-34	Coronary artery disease;
LGG	cis	rs7555523	0.779	rs6662839	chr1:165722646	T/G	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg16414030	chr3:133502952	NA	-0.66	-11.56	-0.47	2.45e-27	Iron status biomarkers;
LGG	cis	rs12282928	1.000	rs6485817	chr11:48250764	T/A	cg26585981	chr11:48327164	OR4S1	-0.43	-6.97	-0.31	1.07e-11	Migraine - clinic-based;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg12070911	chr6:150209640	RAET1E	0.32	7.61	0.33	1.52e-13	Lung cancer;
LGG	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg15704280	chr7:45808275	SEPT13	-1.0	-21.96	-0.71	9.16e-74	Height;
LGG	cis	rs700651	0.821	rs4850812	chr2:198743655	G/T	cg00792783	chr2:198669748	PLCL1	-0.68	-11.04	-0.46	2.5e-25	Intracranial aneurysm;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.54	-0.33	2.48e-13	Prudent dietary pattern;
LGG	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.35	-0.32	8.87e-13	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14103574	chr5:162932455	MAT2B	0.59	10.08	0.42	9.83e-22	Gut microbiome composition (summer);
LGG	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-10.78	-0.45	2.46e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.42	-0.58	1.3e-43	Chronic sinus infection;
LGG	cis	rs9463078	0.683	rs227847	chr6:44695493	A/G	cg25276700	chr6:44698697	NA	0.43	8.95	0.38	8.7e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.62	-10.14	-0.43	5.78e-22	Mean corpuscular volume;
LGG	cis	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg27411982	chr8:10470053	RP1L1	-0.39	-6.73	-0.3	5.06e-11	Neuroticism;
LGG	cis	rs9399137	0.507	rs12663447	chr6:135317026	A/C	cg24558204	chr6:135376177	HBS1L	0.62	10.75	0.45	3.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1465370	0.711	rs10265824	chr7:130005092	G/T	cg25718383	chr7:130020096	CPA1	0.29	7.19	0.32	2.6e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs919433	0.680	rs3792159	chr2:198403697	A/G	cg00792783	chr2:198669748	PLCL1	-0.52	-7.98	-0.35	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.61	0.37	1.14e-16	Lung cancer;
LGG	cis	rs2635047	0.615	rs2137288	chr18:44752041	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.42	6.74	0.3	4.71e-11	Educational attainment;
LGG	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg03929089	chr4:120376271	NA	-0.91	-18.49	-0.65	1.42e-57	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg17691542	chr6:26056736	HIST1H1C	0.94	13.84	0.54	1.07e-36	Iron status biomarkers;
LGG	trans	rs6426551	1.000	rs6426551	chr1:226542049	A/G	cg27539482	chr13:111589090	NA	-0.51	-7.59	-0.33	1.84e-13	Coronary artery disease;
LGG	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08704250	chr15:31115839	NA	0.41	6.84	0.3	2.58e-11	Huntington's disease progression;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.4	6.84	0.3	2.51e-11	Prudent dietary pattern;
LGG	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.4e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs994014	0.572	rs7662021	chr4:82290806	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.8	-0.3	3.19e-11	Height;
LGG	cis	rs11966931	1.000	rs7755216	chr6:108147875	G/T	cg04749840	chr6:108095067	SCML4	0.41	6.96	0.31	1.14e-11	Neutrophil percentage of white cells;
LGG	cis	rs981844	0.683	rs1563462	chr4:154755051	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.7	-0.41	2.18e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg09165964	chr15:75287851	SCAMP5	-0.85	-12.61	-0.51	1.55e-31	Blood trace element (Zn levels);
LGG	trans	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg21775007	chr8:11205619	TDH	-0.46	-7.29	-0.32	1.34e-12	Joint mobility (Beighton score);
LGG	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.63e-22	Schizophrenia;
LGG	cis	rs1421811	0.509	rs7733428	chr5:32689850	G/A	cg16267343	chr5:32710456	NPR3	0.56	7.6	0.33	1.61e-13	Blood pressure;
LGG	trans	rs9409565	0.826	rs4744338	chr9:97158965	C/T	cg05679027	chr9:99775184	HIATL2	0.47	7.66	0.34	1.11e-13	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg04450456	chr4:17643702	FAM184B	0.32	7.08	0.31	5.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg02353165	chr6:42928485	GNMT	0.48	14.44	0.56	2.88e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg18200150	chr17:30822561	MYO1D	0.51	9.69	0.41	2.39e-20	Schizophrenia;
LGG	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs9768139	0.935	rs7809076	chr7:158118438	C/T	cg25566285	chr7:158114605	PTPRN2	-0.96	-25.11	-0.76	1.95e-88	Calcium levels;
LGG	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.43e-26	Corneal astigmatism;
LGG	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg13207630	chr7:32358064	NA	0.81	7.5	0.33	3.29e-13	Body mass index;
LGG	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg11502198	chr6:26597334	ABT1	-0.48	-8.38	-0.36	6.25e-16	Intelligence (multi-trait analysis);
LGG	cis	rs42648	0.935	rs7793743	chr7:90031619	G/A	cg25739043	chr7:89950458	NA	0.37	7.88	0.34	2.35e-14	Homocysteine levels;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg13880726	chr7:1868755	MAD1L1	0.41	7.23	0.32	2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg26655873	chr3:72818019	SHQ1	-0.37	-7.51	-0.33	2.97e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9443645	0.901	rs9448584	chr6:79572799	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.65e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06634786	chr22:41940651	POLR3H	-0.72	-11.58	-0.47	2e-27	Vitiligo;
LGG	trans	rs7246760	0.748	rs113505247	chr19:9725671	C/T	cg02900749	chr2:68251473	NA	-0.93	-9.12	-0.39	2.33e-18	Pursuit maintenance gain;
LGG	cis	rs35110281	0.627	rs11701746	chr21:44975137	C/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.54	-0.33	2.47e-13	Mean corpuscular volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17773020	chr10:104178670	PSD;FBXL15	-0.41	-6.81	-0.3	3.11e-11	Pancreatic cancer;
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg19223190	chr17:80058835	NA	0.44	8.61	0.37	1.12e-16	Life satisfaction;
LGG	trans	rs75804782	0.625	rs72984524	chr2:239468692	G/T	cg01134436	chr17:81009848	B3GNTL1	0.75	7.92	0.35	1.73e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7444	0.941	rs4821130	chr22:21980894	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.77	-0.3	3.81e-11	Systemic lupus erythematosus;
LGG	cis	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.1	-0.46	1.49e-25	Resting heart rate;
LGG	cis	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg08508325	chr11:3079039	CARS	0.39	7.28	0.32	1.46e-12	Calcium levels;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.45	0.58	1.05e-43	Lung cancer;
LGG	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.89	-9.59	-0.41	5.5e-20	Corneal curvature;
LGG	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg13147721	chr7:65941812	NA	0.84	10.19	0.43	4.03e-22	Diabetic kidney disease;
LGG	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg13009111	chr11:71350975	NA	-0.33	-7.32	-0.32	1.13e-12	Monocyte count;
LGG	cis	rs2133450	0.712	rs17697853	chr3:7366195	A/G	cg19930620	chr3:7340148	GRM7	0.38	8.32	0.36	9.63e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg24375607	chr4:120327624	NA	-0.52	-8.86	-0.38	1.71e-17	Corneal astigmatism;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.32	0.32	1.1e-12	Menopause (age at onset);
LGG	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.92	-12.05	-0.49	2.91e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs36051895	0.658	rs72699568	chr9:5007138	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.23	-0.58	9.55e-43	Pediatric autoimmune diseases;
LGG	cis	rs2905347	0.737	rs2905349	chr7:22629285	A/G	cg18045685	chr7:22629474	NA	0.91	22.28	0.72	3.04e-75	Major depression and alcohol dependence;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.52	0.4	9.5e-20	Renal function-related traits (BUN);
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg16662043	chr16:48846231	NA	0.36	7.04	0.31	7.18e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19894588	chr14:64061835	NA	-0.63	-10.57	-0.44	1.5e-23	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg24375607	chr4:120327624	NA	0.59	9.69	0.41	2.46e-20	Corneal astigmatism;
LGG	cis	rs6489882	0.867	rs1859332	chr12:113371114	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7191439	0.858	rs6500489	chr16:88772046	T/C	cg27087555	chr16:88793112	FAM38A	-1.38	-16.03	-0.6	2.49e-46	Plateletcrit;
LGG	trans	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg20587970	chr11:113659929	NA	0.93	12.95	0.52	5.99e-33	Hip circumference adjusted for BMI;
LGG	cis	rs9309473	0.950	rs10189885	chr2:73877055	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.24	-0.32	1.93e-12	Metabolite levels;
LGG	cis	rs1790761	0.967	rs7110021	chr11:67253564	T/C	cg00864171	chr11:67383662	NA	-0.44	-7.12	-0.31	4.24e-12	Mean corpuscular volume;
LGG	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.29	0.36	1.21e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs7843479	0.601	rs11781959	chr8:21841863	C/G	cg17168535	chr8:21777572	XPO7	0.82	16.2	0.6	4.31e-47	Mean corpuscular volume;
LGG	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.88	0.42	5.09e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.57	0.37	1.5e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11234017	chr17:42767172	CCDC43	0.45	6.85	0.3	2.42e-11	Gut microbiome composition (summer);
LGG	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg11040518	chr10:102331378	NA	-0.36	-6.87	-0.3	2.1e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg08807101	chr21:30365312	RNF160	0.92	19.29	0.67	2.66e-61	Dental caries;
LGG	cis	rs72781680	0.752	rs7578606	chr2:23902360	T/C	cg08917208	chr2:24149416	ATAD2B	0.85	8.89	0.38	1.4e-17	Lymphocyte counts;
LGG	trans	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg02002194	chr4:3960332	NA	-0.45	-8.74	-0.38	4.4e-17	Mood instability;
LGG	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg03162506	chr22:38580953	NA	-0.43	-11.23	-0.46	4.91e-26	Cutaneous nevi;
LGG	cis	rs1318772	1.000	rs164252	chr5:112791801	T/A	cg12552261	chr5:112820674	MCC	-0.69	-8.1	-0.35	5.02e-15	F-cell distribution;
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.94	-0.35	1.53e-14	Bladder cancer;
LGG	cis	rs2882926	0.764	rs16929282	chr8:63522266	G/T	cg20602954	chr8:63776762	NKAIN3	0.5	6.89	0.3	1.86e-11	Periodontitis (PAL4Q3);
LGG	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.85	-0.78	1.84e-96	Height;
LGG	cis	rs4925386	0.840	rs6143034	chr20:60920545	T/C	cg06026331	chr20:60912101	LAMA5	0.7	12.77	0.51	3.41e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1691799	0.899	rs1168295	chr12:66734151	G/C	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs12134040	0.646	rs61835532	chr1:236511729	T/G	cg21399712	chr1:236511386	NA	-0.42	-8.31	-0.36	1.1e-15	Urate levels (BMI interaction);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21452447	chr2:1880131	MYT1L	-0.58	-7.28	-0.32	1.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs35771425	0.564	rs17267484	chr1:211417709	G/C	cg10512769	chr1:211675356	NA	-0.62	-8.23	-0.36	1.9e-15	Educational attainment (years of education);
LGG	cis	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.43e-59	Diabetic kidney disease;
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.73	-0.34	6.81e-14	Skin colour saturation;
LGG	cis	rs2415984	0.579	rs2642103	chr14:46963280	C/T	cg14871534	chr14:47121158	RPL10L	0.58	10.26	0.43	2.2e-22	Number of children ever born;
LGG	cis	rs6840360	0.582	rs59714108	chr4:152325939	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	6.88	0.3	1.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.61	-0.63	1.6e-53	Breast cancer;
LGG	cis	rs703842	0.616	rs4760171	chr12:58225904	A/G	cg02175503	chr12:58329896	NA	0.49	7.95	0.35	1.46e-14	Multiple sclerosis;
LGG	cis	rs9818758	0.556	rs116432667	chr3:48947589	C/T	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2549003	1.000	rs2549005	chr5:131827191	C/T	cg21138405	chr5:131827807	IRF1	0.37	8.78	0.38	3.08e-17	Asthma (sex interaction);
LGG	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.53	10.38	0.43	7.71e-23	Longevity;
LGG	cis	rs6565180	1.000	rs12930787	chr16:30381303	C/G	cg17640201	chr16:30407289	ZNF48	-0.85	-16.64	-0.61	4.41e-49	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg10253484	chr15:75165896	SCAMP2	0.4	6.81	0.3	3.11e-11	Breast cancer;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.22	0.32	2.12e-12	Lung cancer;
LGG	cis	rs55788414	0.932	rs12103403	chr16:81185904	C/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.17	-0.43	4.75e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs10506458	0.834	rs17738403	chr12:63389200	A/G	cg22491629	chr6:157744540	C6orf35	-0.97	-13.36	-0.53	1.2e-34	Hemostatic factors and hematological phenotypes;
LGG	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.28	-0.43	1.88e-22	Mood instability;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.86	0.59	1.43e-45	Longevity;
LGG	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs1707322	0.717	rs28752166	chr1:46213309	G/A	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7267979	0.753	rs404148	chr20:25447931	A/G	cg06421707	chr20:25228305	PYGB	0.37	7.76	0.34	5.41e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.3	-0.36	1.17e-15	Retinal vascular caliber;
LGG	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;
LGG	trans	rs17685	0.753	rs55812043	chr7:75747241	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.91	0.77	4e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.44	0.4	1.83e-19	Longevity;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg13009111	chr11:71350975	NA	-0.33	-6.92	-0.31	1.53e-11	Neuroticism;
LGG	cis	rs11785400	1.000	rs10108059	chr8:143750028	G/T	cg24634471	chr8:143751801	JRK	-0.53	-8.43	-0.36	4.49e-16	Schizophrenia;
LGG	cis	rs1577917	1.000	rs13196930	chr6:86652245	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.96	-0.54	3.18e-37	Response to antipsychotic treatment;
LGG	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg06889755	chr6:150326021	RAET1K	-0.38	-7.72	-0.34	7.08e-14	Alopecia areata;
LGG	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Bladder cancer;
LGG	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.3	0.43	1.58e-22	Diabetic retinopathy;
LGG	cis	rs12580194	0.593	rs11832308	chr12:55755506	C/A	cg19537932	chr12:55886519	OR6C68	-0.55	-10.12	-0.43	7e-22	Cancer;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06028808	chr11:68637592	NA	-0.68	-11.92	-0.48	9.51e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg05234568	chr11:5960015	NA	0.48	8.73	0.38	4.83e-17	DNA methylation (variation);
LGG	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg06885757	chr1:42089581	HIVEP3	0.56	12.86	0.51	1.46e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9527	0.590	rs11191553	chr10:104851396	G/T	cg04362960	chr10:104952993	NT5C2	0.57	10.81	0.45	1.96e-24	Arsenic metabolism;
LGG	cis	rs1371867	0.846	rs1660347	chr8:101314980	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs10267417	0.535	rs4275125	chr7:19911004	A/G	cg05791153	chr7:19748676	TWISTNB	0.58	7.7	0.34	8.05e-14	Night sleep phenotypes;
LGG	cis	rs6694672	0.850	rs1412632	chr1:197036868	G/A	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg00495681	chr13:53174319	NA	0.56	10.4	0.44	6.44e-23	Lewy body disease;
LGG	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg11161011	chr14:65562177	MAX	-0.55	-10.17	-0.43	4.46e-22	Obesity-related traits;
LGG	cis	rs4950322	0.580	rs17359629	chr1:146593119	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.7	-0.34	8.44e-14	Protein quantitative trait loci;
LGG	cis	rs55883249	0.957	rs62119432	chr2:9753939	C/T	cg23886495	chr2:9695866	ADAM17	0.68	9.84	0.42	7e-21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.6	0.33	1.61e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9644630	1.000	rs9644628	chr8:19369134	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.59	16.45	0.61	3.13e-48	Oropharynx cancer;
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg18446336	chr7:2847575	GNA12	-0.29	-6.86	-0.3	2.19e-11	Height;
LGG	cis	rs1570884	0.539	rs7999363	chr13:50111368	A/G	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.71	-0.3	5.65e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg23649088	chr2:200775458	C2orf69	0.44	7.72	0.34	7.05e-14	Asthma (bronchodilator response);
LGG	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg04731861	chr2:219085781	ARPC2	0.29	6.77	0.3	3.82e-11	Ulcerative colitis;
LGG	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.28	0.43	1.82e-22	Colorectal cancer;
LGG	cis	rs7119	0.689	rs12907630	chr15:77812906	G/T	cg10437265	chr15:77819839	NA	0.26	7.26	0.32	1.7e-12	Type 2 diabetes;
LGG	cis	rs60843830	0.596	rs17041320	chr2:112051	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.51	8.68	0.37	6.89e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg13047869	chr3:10149882	C3orf24	0.47	7.92	0.35	1.74e-14	Alzheimer's disease;
LGG	cis	rs919433	0.617	rs10931793	chr2:198577585	G/A	cg00792783	chr2:198669748	PLCL1	-0.62	-9.95	-0.42	2.86e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.72	-0.45	4.07e-24	Morning vs. evening chronotype;
LGG	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.64	-9.21	-0.39	1.16e-18	Homoarginine levels;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg13206674	chr6:150067644	NUP43	0.65	14.44	0.56	2.68e-39	Lung cancer;
LGG	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.35	-0.32	9.14e-13	Refractive error;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg15537850	chr8:144661051	NAPRT1	0.94	7.41	0.33	6.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg08847533	chr14:75593920	NEK9	-0.53	-9.86	-0.42	5.95e-21	Height;
LGG	cis	rs3099143	1.000	rs3099137	chr15:77123626	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-10.64	-0.44	8.64e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs6840360	0.901	rs1946999	chr4:152455339	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.21	0.32	2.23e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg03929089	chr4:120376271	NA	-1.02	-23.07	-0.73	5.74e-79	Height;
LGG	cis	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.74	-0.3	4.69e-11	Neuroticism;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs6558530	0.666	rs4242539	chr8:1694236	A/G	cg08198773	chr8:1697536	NA	0.43	7.47	0.33	3.91e-13	Systolic blood pressure;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg19168338	chr16:4465731	CORO7	-0.73	-13.5	-0.53	2.93e-35	Schizophrenia;
LGG	cis	rs12579753	0.692	rs11115064	chr12:82278683	G/A	cg07988820	chr12:82153109	PPFIA2	-0.54	-7.78	-0.34	4.64e-14	Resting heart rate;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02994863	chr1:64059297	PGM1	0.42	7.06	0.31	6.01e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg26513180	chr16:89883248	FANCA	0.93	19.53	0.67	2.21e-62	Vitiligo;
LGG	cis	rs13314892	0.764	rs4579020	chr3:69878028	A/C	cg17445875	chr3:69859618	MITF	-0.4	-7.76	-0.34	5.29e-14	QRS complex (12-leadsum);
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg20290983	chr6:43655470	MRPS18A	0.99	17.57	0.63	2.65e-53	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg13047869	chr3:10149882	C3orf24	0.48	7.91	0.35	1.87e-14	Alzheimer's disease;
LGG	cis	rs6558530	0.666	rs11136422	chr8:1695909	T/C	cg25947184	chr8:1697459	NA	0.46	8.05	0.35	7.08e-15	Systolic blood pressure;
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg23758822	chr17:41437982	NA	0.87	15.47	0.58	7.84e-44	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24147849	chr3:100053372	NIT2	0.48	8.01	0.35	9.13e-15	Cognitive performance;
LGG	cis	rs3762637	1.000	rs9842736	chr3:122161101	C/T	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.73	-0.3	5.07e-11	Mean platelet volume;
LGG	cis	rs262150	0.851	rs2527224	chr7:158769198	G/A	cg19418458	chr7:158789849	NA	-0.45	-9.1	-0.39	2.79e-18	Facial morphology (factor 20);
LGG	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.91	0.42	3.93e-21	Morning vs. evening chronotype;
LGG	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	10.81	0.45	1.99e-24	Height;
LGG	cis	rs4302748	0.774	rs58840739	chr7:36181940	C/T	cg24442661	chr7:36192818	EEPD1	0.56	7.47	0.33	4.16e-13	Platelet count;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg13397359	chr6:42928475	GNMT	0.58	15.95	0.6	6.11e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1395	0.744	rs11126929	chr2:27472027	C/T	cg23587288	chr2:27483067	SLC30A3	0.36	8.19	0.36	2.52e-15	Blood metabolite levels;
LGG	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg00405596	chr8:11794950	NA	-0.42	-6.88	-0.3	1.99e-11	Neuroticism;
LGG	cis	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg13010199	chr12:38710504	ALG10B	0.55	10.93	0.45	7.05e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg21475434	chr5:93447410	FAM172A	0.65	6.77	0.3	4.01e-11	Diabetic retinopathy;
LGG	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg15454534	chr1:248569605	OR2T1	0.38	6.83	0.3	2.68e-11	Common traits (Other);
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg04025307	chr7:1156635	C7orf50	0.77	10.05	0.42	1.26e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6066825	0.606	rs4810830	chr20:47219740	T/C	cg18078177	chr20:47281410	PREX1	0.47	7.88	0.34	2.3e-14	Colorectal cancer;
LGG	cis	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg09021430	chr5:549028	NA	-0.69	-9.62	-0.41	4.28e-20	Obesity-related traits;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02018176	chr4:1364513	KIAA1530	-0.47	-11.09	-0.46	1.66e-25	Obesity-related traits;
LGG	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.79	0.34	4.35e-14	Joint mobility (Beighton score);
LGG	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.67	-0.34	1.05e-13	HDL cholesterol;
LGG	cis	rs9902453	0.904	rs55866125	chr17:28312993	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.81	0.54	1.45e-36	Coffee consumption (cups per day);
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	cis	rs4356932	1.000	rs6829896	chr4:76970739	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.05e-11	Blood protein levels;
LGG	cis	rs6748734	1.000	rs4675860	chr2:241840417	A/G	cg26818257	chr2:241905806	NA	0.37	6.94	0.31	1.36e-11	Urinary metabolites;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg13395646	chr4:1353034	KIAA1530	0.47	7.96	0.35	1.3e-14	Obesity-related traits;
LGG	cis	rs6542838	0.702	rs4851177	chr2:99535188	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.1	-0.31	4.74e-12	Fear of minor pain;
LGG	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg24881330	chr22:46731750	TRMU	0.73	7.19	0.32	2.62e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.35	-7.44	-0.33	4.94e-13	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.28e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs11885103	0.791	rs6712649	chr2:584523	C/T	cg21195176	chr2:593345	NA	0.39	7.37	0.32	7.85e-13	Heschl's gyrus morphology;
LGG	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg16751781	chr15:78858589	CHRNA5	0.43	8.17	0.36	2.91e-15	Sudden cardiac arrest;
LGG	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg18681998	chr4:17616180	MED28	-0.8	-16.58	-0.61	8.39e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.22	0.32	2.21e-12	Triglycerides;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11722228	0.522	rs73212808	chr4:10055439	G/C	cg26043149	chr18:55253948	FECH	0.91	15.92	0.59	7.56e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg12193833	chr17:30244370	NA	0.28	7.0	0.31	8.83e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg06618935	chr21:46677482	NA	-0.48	-9.45	-0.4	1.76e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-9.99	-0.42	2.09e-21	Chronic sinus infection;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2404602	0.716	rs56216512	chr15:76686936	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.51	0.4	1.04e-19	Blood metabolite levels;
LGG	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg08079166	chr15:68083412	MAP2K5	-0.35	-7.94	-0.35	1.6e-14	Restless legs syndrome;
LGG	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg04662567	chr6:169592167	NA	-0.79	-11.46	-0.47	5.96e-27	Pulse pressure;
LGG	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg17145862	chr1:211918768	LPGAT1	-0.72	-14.98	-0.57	1.19e-41	Leprosy;
LGG	cis	rs6429082	0.755	rs291384	chr1:235644300	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	10.15	0.43	5.4e-22	Adiposity;
LGG	cis	rs2251381	0.640	rs2183568	chr21:30484782	A/T	cg24692254	chr21:30365293	RNF160	-0.89	-18.67	-0.66	2.13e-58	Selective IgA deficiency;
LGG	cis	rs6445975	0.578	rs6782218	chr3:58408765	T/C	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07820310	chr20:44035078	DBNDD2;SYS1-DBNDD2	-0.36	-6.78	-0.3	3.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-6.65	-0.3	8.16e-11	Lung cancer;
LGG	cis	rs6901004	0.803	rs1022092	chr6:111427286	G/A	cg15721981	chr6:111408429	SLC16A10	-0.45	-7.9	-0.34	2.1e-14	Blood metabolite levels;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg20670292	chr2:131099506	IMP4;CCDC115	0.41	7.21	0.32	2.33e-12	Bilirubin levels;
LGG	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08109568	chr15:31115862	NA	-0.6	-10.05	-0.42	1.27e-21	Huntington's disease progression;
LGG	cis	rs7312933	0.703	rs2406567	chr12:42551479	G/C	cg19980929	chr12:42632907	YAF2	0.37	8.23	0.36	1.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg04731861	chr2:219085781	ARPC2	-0.52	-13.1	-0.52	1.42e-33	Colorectal cancer;
LGG	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg04450456	chr4:17643702	FAM184B	0.34	7.55	0.33	2.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6088580	0.634	rs6142159	chr20:32993035	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-9.84	-0.42	7.36e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg15921436	chr17:44337874	NA	-0.54	-11.28	-0.46	3.08e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9682041	0.867	rs6444925	chr3:170123358	G/T	cg11886554	chr3:170076028	SKIL	1.05	11.6	0.47	1.73e-27	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg06112835	chr11:68658793	MRPL21	0.56	9.4	0.4	2.62e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg04025307	chr7:1156635	C7orf50	0.68	8.61	0.37	1.19e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg10207240	chr12:122356781	WDR66	0.28	8.26	0.36	1.58e-15	Mean corpuscular volume;
LGG	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg04727924	chr7:799746	HEATR2	-0.48	-7.68	-0.34	9.34e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs3087591	0.708	rs7505	chr17:29644852	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg09163369	chr1:210001066	C1orf107	0.39	7.03	0.31	7.34e-12	Orofacial clefts;
LGG	cis	rs17655565	1.000	rs60696802	chr12:52693176	C/T	cg02645295	chr12:52705424	NA	-0.57	-7.66	-0.34	1.07e-13	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.85	-15.1	-0.57	3.68e-42	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg08400814	chr5:56204995	C5orf35	-0.55	-8.51	-0.37	2.41e-16	Initial pursuit acceleration;
LGG	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg12386194	chr3:101231763	SENP7	0.45	7.8	0.34	4.14e-14	Colorectal cancer;
LGG	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg20573242	chr4:122745356	CCNA2	0.52	9.52	0.4	9.4e-20	Type 2 diabetes;
LGG	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-10.94	-0.45	6.05e-25	Schizophrenia;
LGG	cis	rs7781557	1.000	rs7790451	chr7:102465988	G/A	cg18108683	chr7:102477205	FBXL13	-0.55	-8.9	-0.38	1.29e-17	Colorectal adenoma (advanced);
LGG	cis	rs68170813	0.641	rs1978085	chr7:107095216	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-9.93	-0.42	3.46e-21	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg25072359	chr17:41440525	NA	0.52	9.84	0.42	7.36e-21	Menopause (age at onset);
LGG	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.71	0.38	5.26e-17	Height;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg07167872	chr1:205819463	PM20D1	0.69	14.63	0.56	4.28e-40	Menarche (age at onset);
LGG	cis	rs3820068	0.581	rs1122386	chr1:15946877	C/T	cg05660106	chr1:15850417	CASP9	0.84	16.78	0.61	1.04e-49	Systolic blood pressure;
LGG	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg23202291	chr11:1979235	NA	0.44	8.82	0.38	2.39e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9486719	1.000	rs12205728	chr6:96891838	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.21	0.36	2.29e-15	Mood instability;
LGG	cis	rs1971762	0.527	rs6580950	chr12:53926656	T/A	cg06632207	chr12:54070931	ATP5G2	0.21	6.69	0.3	6.47e-11	Height;
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg16434002	chr17:42200994	HDAC5	-0.56	-10.38	-0.43	7.59e-23	Total body bone mineral density;
LGG	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg26384229	chr12:38710491	ALG10B	0.95	20.58	0.69	2.67e-67	Bladder cancer;
LGG	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg00198680	chr16:28758506	NA	0.29	7.31	0.32	1.2e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4243971	0.516	rs4911088	chr20:30861791	T/G	cg00028034	chr20:30779307	TSPYL3	0.34	6.97	0.31	1.12e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.38	-0.36	6.33e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.724	rs6968693	chr7:124549976	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg25566285	chr7:158114605	PTPRN2	0.89	19.31	0.67	2.13e-61	Calcium levels;
LGG	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg10792982	chr14:105748885	BRF1	0.66	13.15	0.52	8.5e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7623687	0.786	rs34290943	chr3:49161660	T/C	cg19401529	chr3:49056140	DALRD3	0.72	7.44	0.33	4.8e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs2688608	0.592	rs11000759	chr10:75493726	G/A	cg19442545	chr10:75533431	FUT11	-0.44	-7.22	-0.32	2.16e-12	Inflammatory bowel disease;
LGG	cis	rs2562456	0.652	rs4809145	chr19:21780709	A/C	cg00806126	chr19:22604979	ZNF98	-0.67	-9.06	-0.39	3.58e-18	Pain;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.36	-0.43	9.13e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg26384229	chr12:38710491	ALG10B	-0.66	-12.91	-0.51	9.05e-33	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg14952266	chr13:112191215	NA	0.5	10.66	0.44	7.1e-24	Hepatitis;
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.66	-0.54	6.05e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs9929218	1.000	rs8056538	chr16:68802282	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.13	-0.52	1.02e-33	Colorectal cancer;
LGG	cis	rs8072100	0.869	rs4439799	chr17:45781599	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-13.05	-0.52	2.27e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs972578	0.691	rs5759057	chr22:43354130	T/C	cg01576275	chr22:43409880	NA	-0.25	-7.4	-0.33	6.29e-13	Mean platelet volume;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.78	-0.41	1.15e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg11707556	chr5:10655725	ANKRD33B	0.49	9.56	0.41	6.92e-20	Coronary artery disease;
LGG	cis	rs1982963	1.000	rs3742536	chr14:52507429	C/T	cg05884192	chr14:52515736	NID2	0.34	7.6	0.33	1.67e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9467711	0.591	rs13201821	chr6:26057781	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	7.33	0.32	1e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg02002194	chr4:3960332	NA	-0.39	-7.13	-0.31	3.93e-12	Retinal vascular caliber;
LGG	cis	rs4132509	0.793	rs7522883	chr1:243803022	C/T	cg21452805	chr1:244014465	NA	0.87	8.48	0.37	3.16e-16	RR interval (heart rate);
LGG	cis	rs2307022	0.586	rs3785123	chr16:68386581	C/T	cg07273125	chr16:68295692	NA	0.44	9.88	0.42	4.96e-21	Body mass index;
LGG	cis	rs7020830	0.894	rs28766572	chr9:37093872	G/T	cg14294708	chr9:37120828	ZCCHC7	1.12	30.19	0.81	1.79e-111	Schizophrenia;
LGG	trans	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.68	-0.41	2.65e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.42	0.33	5.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7666738	0.830	rs3852122	chr4:98697400	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.72	0.34	7.05e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.72	0.3	5.35e-11	Parkinson's disease;
LGG	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg00383909	chr3:49044727	WDR6	0.44	7.25	0.32	1.74e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs16854884	0.837	rs6804060	chr3:143804040	C/T	cg06585982	chr3:143692056	C3orf58	0.57	9.23	0.39	9.69e-19	Economic and political preferences (feminism/equality);
LGG	trans	rs7746199	0.736	rs34543938	chr6:27624640	A/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11096990	0.855	rs2566176	chr4:39155993	A/G	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg01043669	chr3:72786069	NA	0.41	6.86	0.3	2.21e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg07537917	chr2:241836409	C2orf54	0.4	7.73	0.34	6.94e-14	Urinary metabolites;
LGG	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.46	-6.86	-0.3	2.17e-11	Menarche (age at onset);
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06558623	chr16:89946397	TCF25	1.17	14.9	0.57	2.77e-41	Skin colour saturation;
LGG	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.0	-0.42	1.92e-21	Menarche (age at onset);
LGG	cis	rs7267979	0.844	rs6107027	chr20:25288632	A/G	cg06421707	chr20:25228305	PYGB	0.43	8.88	0.38	1.43e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg09690326	chr7:23720549	C7orf46	0.45	10.29	0.43	1.73e-22	Schizophrenia;
LGG	cis	rs4936894	0.500	rs11219533	chr11:124119298	T/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.22	-0.43	2.9e-22	Aging (time to death);
LGG	cis	rs3206736	0.541	rs6964650	chr7:34964947	C/T	cg13400248	chr7:35225412	NA	0.51	8.79	0.38	2.93e-17	Diastolic blood pressure;
LGG	cis	rs758324	0.812	rs667419	chr5:131282064	A/G	cg06307176	chr5:131281290	NA	0.53	8.73	0.38	4.68e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	cis	rs10193935	0.901	rs62142639	chr2:42600019	C/G	cg27598129	chr2:42591480	NA	-0.64	-9.66	-0.41	3.05e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs933688	0.938	rs10942634	chr5:90658392	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.41	0.61	5.05e-48	Smoking behavior;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06872176	chr1:68697386	GPR177	0.45	7.47	0.33	4.16e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3742264	0.656	rs9526126	chr13:46565202	G/A	cg15192986	chr13:46630673	CPB2	-0.36	-6.95	-0.31	1.23e-11	Blood protein levels;
LGG	cis	rs9640161	0.750	rs3735173	chr7:150020526	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.73	-15.22	-0.58	1.06e-42	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.75	-0.34	5.77e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs16854884	0.586	rs7642551	chr3:143732167	C/T	cg06585982	chr3:143692056	C3orf58	0.67	12.15	0.49	1.11e-29	Economic and political preferences (feminism/equality);
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	cis	rs17253792	0.822	rs76192881	chr14:56034654	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs9964724	0.929	rs7242923	chr18:35159833	A/G	cg27332583	chr18:35150602	NA	-0.48	-10.34	-0.43	1.11e-22	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18879991	chr6:27861393	HIST1H2AM;HIST1H2BO	0.44	6.88	0.3	1.97e-11	Gut microbiome composition (summer);
LGG	cis	rs1580019	0.922	rs34545272	chr7:32460630	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.84	15.47	0.58	8.01e-44	Cognitive ability;
LGG	cis	rs17767392	0.957	rs35692397	chr14:71756683	A/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.22e-18	Mitral valve prolapse;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.81	-0.34	3.84e-14	Lung cancer;
LGG	cis	rs12425451	0.552	rs10848765	chr12:3141495	C/T	cg05389053	chr12:3131226	TEAD4	0.66	11.72	0.48	5.86e-28	Narcolepsy with cataplexy;
LGG	cis	rs806321	0.510	rs1262867	chr13:50891047	A/C	cg10393508	chr13:50950265	NA	-0.34	-8.69	-0.37	6.31e-17	Multiple sclerosis;
LGG	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg04842962	chr6:43655489	MRPS18A	1.13	24.68	0.75	1.79e-86	IgG glycosylation;
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg06634786	chr22:41940651	POLR3H	-0.83	-13.23	-0.52	3.94e-34	Vitiligo;
LGG	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg00976097	chr5:421733	AHRR	-0.41	-6.84	-0.3	2.56e-11	Cystic fibrosis severity;
LGG	cis	rs283228	0.550	rs662360	chr6:101829555	T/C	cg02011392	chr6:101847541	GRIK2	0.5	6.85	0.3	2.38e-11	Coenzyme Q10 levels;
LGG	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.76	0.3	4.2e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg12395012	chr8:11607386	GATA4	-0.44	-7.89	-0.34	2.18e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg09537434	chr19:41945824	ATP5SL	-0.87	-23.01	-0.73	1.17e-78	Height;
LGG	cis	rs7649275	1.000	rs2169144	chr3:53750170	C/T	cg21503701	chr3:53781065	CACNA1D	-0.5	-7.42	-0.33	5.68e-13	Trans fatty acid levels;
LGG	cis	rs9487094	0.961	rs12209691	chr6:109786432	C/T	cg16315928	chr6:109776240	MICAL1	0.57	9.44	0.4	1.89e-19	Height;
LGG	cis	rs6866344	0.661	rs72812606	chr5:178129094	A/T	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-13.98	-0.54	2.78e-37	Morning vs. evening chronotype;
LGG	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs894344	0.812	rs894360	chr8:135601194	T/C	cg17885191	chr8:135476712	NA	0.41	6.92	0.31	1.56e-11	Systolic blood pressure;
LGG	cis	rs4689388	0.890	rs6446481	chr4:6295583	C/A	cg00701064	chr4:6280414	WFS1	0.74	16.5	0.61	1.86e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	9.85	0.42	6.66e-21	Bipolar disorder;
LGG	cis	rs9308731	0.644	rs3789065	chr2:111915022	C/G	cg19992207	chr2:111874495	ACOXL	-0.38	-7.02	-0.31	7.76e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2241941	0.840	rs10500882	chr11:20629837	A/G	cg18855426	chr11:20631935	SLC6A5	0.44	7.47	0.33	4.06e-13	Obesity-related traits;
LGG	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg07382826	chr16:28625726	SULT1A1	-0.35	-7.31	-0.32	1.2e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg26396452	chr14:65542826	MAX	0.48	10.09	0.42	9.35e-22	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg21132104	chr15:45694354	SPATA5L1	0.68	9.94	0.42	3.14e-21	Homoarginine levels;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg15556689	chr8:8085844	FLJ10661	0.49	8.92	0.38	1.06e-17	Neuroticism;
LGG	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg26513180	chr16:89883248	FANCA	-0.53	-9.27	-0.4	7.36e-19	Vitiligo;
LGG	cis	rs6429082	0.521	rs291390	chr1:235649678	T/C	cg26050004	chr1:235667680	B3GALNT2	0.84	16.98	0.62	1.22e-50	Adiposity;
LGG	cis	rs295140	1.000	rs7599609	chr2:201177653	G/A	cg25099087	chr2:201172481	SPATS2L	0.28	6.9	0.31	1.77e-11	QT interval;
LGG	cis	rs7011049	0.778	rs11785654	chr8:53873364	A/G	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-8.34	-0.36	8.42e-16	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.21	-0.43	3.37e-22	Total body bone mineral density;
LGG	cis	rs12928939	0.954	rs34998650	chr16:71829329	T/C	cg03805757	chr16:71968109	PKD1L3	-0.54	-10.33	-0.43	1.15e-22	Post bronchodilator FEV1;
LGG	cis	rs12898370	0.641	rs11632999	chr15:77436995	T/G	cg17802220	chr15:77601643	NA	-0.52	-9.86	-0.42	6.14e-21	Risky sexual behaviors (alcohol dependence interaction);
LGG	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	cg07928641	chr1:182991847	LAMC1	0.43	8.21	0.36	2.26e-15	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.78	-0.3	3.75e-11	Lung cancer;
LGG	cis	rs806321	0.534	rs1319883	chr13:50887164	C/T	cg10393508	chr13:50950265	NA	-0.32	-8.25	-0.36	1.68e-15	Multiple sclerosis;
LGG	cis	rs668210	0.793	rs507672	chr11:65767153	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-9.57	-0.41	6.43e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg09264619	chr17:80180166	NA	-0.52	-9.87	-0.42	5.64e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.84	0.3	2.45e-11	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg20503657	chr10:835505	NA	0.74	10.24	0.43	2.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg22705602	chr4:152727874	NA	-0.33	-8.02	-0.35	8.48e-15	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs6504169	chr17:61709145	A/G	cg05941027	chr17:61774174	LIMD2	0.38	9.7	0.41	2.33e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg23029597	chr12:123009494	RSRC2	0.94	17.29	0.63	4.71e-52	Body mass index;
LGG	cis	rs61931739	0.517	rs1486882	chr12:34025896	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs4237845	0.537	rs1599931	chr12:58258850	A/G	cg02175503	chr12:58329896	NA	0.56	9.17	0.39	1.55e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	7.5e-24	Lung cancer;
LGG	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg24642439	chr20:33292090	TP53INP2	0.82	14.45	0.56	2.54e-39	Coronary artery disease;
LGG	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg03806693	chr22:41940476	POLR3H	-1.14	-21.83	-0.71	3.77e-73	Vitiligo;
LGG	cis	rs453301	0.631	rs7843789	chr8:8800561	G/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.69	-0.3	6.31e-11	Joint mobility (Beighton score);
LGG	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20916646	chr4:852691	GAK	0.56	9.83	0.42	7.91e-21	Sjögren's syndrome;
LGG	cis	rs2413583	0.591	rs75378967	chr22:39735210	T/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.56	0.33	2.15e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4077515	0.935	rs3088081	chr9:139270149	A/G	cg21253087	chr9:139290292	SNAPC4	0.36	7.51	0.33	3.03e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17253792	0.822	rs17253730	chr14:56157911	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg20637307	chr2:213403960	ERBB4	-0.46	-8.95	-0.38	8.6e-18	QT interval (ambient particulate matter interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22555392	chr3:50649683	CISH	-0.44	-6.93	-0.31	1.42e-11	Pancreatic cancer;
LGG	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg05360138	chr12:110035743	NA	0.41	6.7	0.3	6.04e-11	Neuroticism;
LGG	cis	rs975722	0.700	rs177284	chr7:117311978	T/C	cg10524701	chr7:117356490	CTTNBP2	0.43	8.75	0.38	3.88e-17	Coronary artery disease;
LGG	cis	rs55788414	0.932	rs12103303	chr16:81181497	A/G	cg06400318	chr16:81190750	PKD1L2	-0.79	-9.75	-0.41	1.48e-20	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19478983	chr7:120590592	ING3	0.44	7.11	0.31	4.29e-12	Cognitive performance;
LGG	cis	rs10883723	0.847	rs3808934	chr10:104264280	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6032067	0.537	rs6032033	chr20:43795081	G/C	cg10761708	chr20:43804764	PI3	0.59	9.06	0.39	3.81e-18	Blood protein levels;
LGG	cis	rs8056893	0.550	rs9788810	chr16:68329997	G/A	cg07273125	chr16:68295692	NA	0.46	10.37	0.43	8.87e-23	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs11625487	1.000	rs11625487	chr14:77961609	G/C	cg20045696	chr14:77926864	AHSA1	0.58	7.53	0.33	2.61e-13	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg03733263	chr8:22462867	KIAA1967	0.98	23.54	0.74	3.59e-81	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg15558759	chr11:118478939	PHLDB1	0.38	6.7	0.3	6.18e-11	Cholesterol, total;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg23758822	chr17:41437982	NA	0.89	15.65	0.59	1.23e-44	Menopause (age at onset);
LGG	cis	rs8179	1.000	rs4272	chr7:92236829	C/T	cg15732164	chr7:92237376	CDK6	0.69	12.83	0.51	1.88e-32	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs3008870	0.883	rs2755249	chr1:67493662	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	23.1	0.73	4.39e-79	Lymphocyte percentage of white cells;
LGG	cis	rs10832963	0.847	rs4237722	chr11:18639363	T/C	cg20219074	chr11:18656078	SPTY2D1	0.77	13.9	0.54	5.97e-37	Breast cancer;
LGG	cis	rs7296418	0.961	rs7957096	chr12:123544878	A/G	cg00376283	chr12:123451042	ABCB9	0.68	12.85	0.51	1.6e-32	Platelet count;
LGG	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.86	-0.48	1.59e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7106204	0.590	rs7115417	chr11:24247696	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	15.39	0.58	1.75e-43	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg10587741	chr22:38071170	LGALS1	0.61	14.18	0.55	3.79e-38	Fat distribution (HIV);
LGG	cis	rs1650123	0.645	rs703616	chr12:104020232	T/C	cg23227824	chr12:103980017	STAB2	0.36	8.28	0.36	1.37e-15	IgG glycosylation;
LGG	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg06642177	chr6:134496341	SGK1	0.4	6.76	0.3	4.07e-11	Lung adenocarcinoma;
LGG	cis	rs6840360	0.571	rs4696271	chr4:152509118	G/A	cg25486957	chr4:152246857	NA	-0.51	-8.37	-0.36	6.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg21724239	chr8:58056113	NA	0.43	6.8	0.3	3.33e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg18188782	chr20:61659543	NA	0.39	6.7	0.3	5.98e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6735179	0.601	rs114382205	chr2:1747539	G/A	cg10160682	chr2:1713001	PXDN	-0.55	-9.56	-0.41	7.02e-20	Response to antipsychotic treatment;
LGG	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg14191688	chr11:70257035	CTTN	0.51	7.47	0.33	4.01e-13	Coronary artery disease;
LGG	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg03929089	chr4:120376271	NA	-0.79	-13.27	-0.52	2.67e-34	Coronary artery disease;
LGG	cis	rs2594989	0.887	rs2454513	chr3:11549596	C/T	cg01796438	chr3:11312864	ATG7	-0.53	-7.17	-0.32	2.97e-12	Circulating chemerin levels;
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg01059449	chr18:44338099	ST8SIA5	0.31	6.83	0.3	2.67e-11	Personality dimensions;
LGG	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25517755	chr10:38738941	LOC399744	-0.38	-6.87	-0.3	2.03e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10189230	0.967	rs12613015	chr2:222356119	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.85e-32	Urate levels in lean individuals;
LGG	cis	rs13132184	0.507	rs13129650	chr4:38025101	A/G	cg24826020	chr4:38070998	TBC1D1	0.5	8.39	0.36	6.12e-16	Verbal declarative memory;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg24846343	chr22:24311635	DDTL	0.6	11.72	0.48	5.59e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg22232500	chr2:134024266	NCKAP5	0.61	8.61	0.37	1.2e-16	Bipolar disorder;
LGG	cis	rs537930	0.734	rs12520136	chr5:134371333	C/A	cg24576358	chr5:134350122	NA	0.38	7.27	0.32	1.59e-12	Height;
LGG	cis	rs1023500	0.573	rs2413666	chr22:42459622	C/T	cg15557168	chr22:42548783	NA	-0.39	-8.11	-0.35	4.42e-15	Schizophrenia;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.49	-0.47	4.83e-27	Personality dimensions;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	4.15e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs977987	0.806	rs12051136	chr16:75435731	G/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.47e-11	Dupuytren's disease;
LGG	cis	rs1983891	0.874	rs3747744	chr6:41516351	A/G	cg20194872	chr6:41519635	FOXP4	0.6	10.47	0.44	3.75e-23	Prostate cancer;
LGG	cis	rs3617	0.625	rs11715347	chr3:52883070	C/T	cg11645453	chr3:52864694	ITIH4	-0.44	-7.35	-0.32	9e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg17175376	chr5:145562478	LARS	0.46	6.73	0.3	5.05e-11	Breast cancer;
LGG	trans	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.1e-18	Bladder cancer;
LGG	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg26597838	chr10:835615	NA	0.54	6.87	0.3	2.1e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.53e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	1.000	rs1138273	chr3:134261437	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.96	-0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3820928	0.874	rs2177594	chr2:227836239	C/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.85	-0.34	3.02e-14	Pulmonary function;
LGG	cis	rs600231	0.665	rs2105608	chr11:65228618	T/A	cg17120908	chr11:65337727	SSSCA1	-0.48	-8.47	-0.37	3.23e-16	Bone mineral density;
LGG	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg10223061	chr2:219282414	VIL1	0.37	7.99	0.35	1.1e-14	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs6977660	0.714	rs10229108	chr7:19824253	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.45	0.37	3.87e-16	Thyroid stimulating hormone;
LGG	cis	rs9814567	1.000	rs7637227	chr3:134244155	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.13	-0.52	1.03e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg24803719	chr17:45855879	NA	-0.29	-8.54	-0.37	1.89e-16	IgG glycosylation;
LGG	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg03060546	chr3:49711283	APEH	-0.63	-10.34	-0.43	1.14e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg20848291	chr7:100343083	ZAN	-0.69	-10.22	-0.43	2.9e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.57	-0.33	1.98e-13	Schizophrenia;
LGG	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg22232500	chr2:134024266	NCKAP5	0.56	7.96	0.35	1.31e-14	Bipolar disorder;
LGG	cis	rs774359	0.789	rs2484316	chr9:27527173	T/C	cg14173147	chr9:27528300	MOBKL2B	0.44	8.64	0.37	9.09e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg06494592	chr3:125709126	NA	-0.52	-6.67	-0.3	7.35e-11	Blood pressure (smoking interaction);
LGG	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg06637938	chr14:75390232	RPS6KL1	0.58	10.73	0.45	3.85e-24	Height;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg26656751	chr17:43910226	CRHR1	0.48	8.9	0.38	1.31e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12580194	0.957	rs12579451	chr12:55694116	C/T	cg19537932	chr12:55886519	OR6C68	-0.41	-6.94	-0.31	1.35e-11	Cancer;
LGG	trans	rs7762018	0.607	rs75010113	chr6:170057441	C/T	cg06875740	chr19:51307921	C19orf48	-0.67	-6.92	-0.31	1.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg05896524	chr21:47604654	C21orf56	0.59	10.63	0.44	9.28e-24	Testicular germ cell tumor;
LGG	cis	rs6546550	0.935	rs4241261	chr2:70063660	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.99	-0.35	1.04e-14	Prevalent atrial fibrillation;
LGG	cis	rs963731	0.579	rs6544184	chr2:39188915	A/G	cg04010122	chr2:39346883	SOS1	-0.8	-7.04	-0.31	7.15e-12	Corticobasal degeneration;
LGG	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.45	7.35	0.32	8.88e-13	Hip circumference adjusted for BMI;
LGG	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.86	-0.34	2.67e-14	Schizophrenia;
LGG	cis	rs988958	0.917	rs13401037	chr2:42282632	A/T	cg19376973	chr2:42229025	NA	0.45	7.41	0.33	6.14e-13	Hypospadias;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.02	-0.49	3.75e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs9399137	0.507	rs6569986	chr6:135311641	T/C	cg22676075	chr6:135203613	NA	0.43	7.32	0.32	1.09e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs3213961	0.744	rs6746691	chr2:33814331	C/G	cg04131969	chr2:33951647	MYADML	0.5	7.28	0.32	1.49e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	trans	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg27523141	chr10:43048294	ZNF37B	-0.38	-7.92	-0.35	1.77e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1595825	0.891	rs73054817	chr2:198623751	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.65	-0.3	8.53e-11	Ulcerative colitis;
LGG	cis	rs8061903	0.710	rs1835084	chr16:9416690	C/T	cg03762483	chr16:10274847	GRIN2A	0.39	7.08	0.31	5.3e-12	HIV-1 viral setpoint;
LGG	cis	rs7590368	0.961	rs12474895	chr2:10957848	A/C	cg15705551	chr2:10952987	PDIA6	0.63	9.26	0.4	7.37e-19	Educational attainment (years of education);
LGG	cis	rs8017423	0.967	rs7155315	chr14:90700787	G/A	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.81e-57	Mortality in heart failure;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-14.21	-0.55	2.68e-38	Tonsillectomy;
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.85	0.48	1.79e-28	Tonsillectomy;
LGG	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.82	-0.42	8.3e-21	Response to antipsychotic treatment;
LGG	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	cis	rs6700896	0.500	rs12025906	chr1:66101384	A/G	cg04111102	chr1:66153794	NA	0.36	7.07	0.31	5.85e-12	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg21862992	chr11:68658383	NA	0.5	7.98	0.35	1.15e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11887277	0.900	rs13418647	chr2:27074493	G/A	cg12045002	chr2:27069975	DPYSL5	-0.34	-7.22	-0.32	2.18e-12	Obesity-related traits;
LGG	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg21775007	chr8:11205619	TDH	-0.47	-7.66	-0.34	1.1e-13	Triglycerides;
LGG	cis	rs17253792	0.822	rs9972178	chr14:56073480	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.67	-0.51	8.86e-32	Putamen volume;
LGG	cis	rs6540556	0.859	rs12131636	chr1:209942435	G/C	cg23920097	chr1:209922102	NA	-0.5	-7.9	-0.34	2.09e-14	Red blood cell count;
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg13607699	chr17:42295918	UBTF	-0.62	-10.33	-0.43	1.2e-22	Total body bone mineral density;
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg19635926	chr16:89946313	TCF25	0.8	8.29	0.36	1.27e-15	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg20607798	chr8:58055168	NA	0.68	7.7	0.34	8.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg23758822	chr17:41437982	NA	0.87	15.43	0.58	1.24e-43	Menopause (age at onset);
LGG	cis	rs2354432	1.000	rs2120003	chr1:146690635	A/G	cg25205988	chr1:146714368	CHD1L	0.71	6.76	0.3	4.12e-11	Mitochondrial DNA levels;
LGG	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg16414030	chr3:133502952	NA	-0.49	-7.98	-0.35	1.18e-14	Iron status biomarkers;
LGG	cis	rs9649465	0.967	rs13239184	chr7:123314618	G/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.18	0.72	8.17e-75	Bladder cancer;
LGG	trans	rs7395662	0.857	rs3902433	chr11:48733324	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.24	-0.32	1.83e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.78	-0.48	3.38e-28	Height;
LGG	cis	rs6424115	0.830	rs2503002	chr1:24196957	C/G	cg15997130	chr1:24165203	NA	0.47	12.96	0.52	5.51e-33	Immature fraction of reticulocytes;
LGG	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg08048268	chr3:133502702	NA	0.57	10.87	0.45	1.15e-24	Iron status biomarkers;
LGG	cis	rs3771570	1.000	rs62186400	chr2:242226700	A/G	cg21155796	chr2:242212141	HDLBP	0.74	9.78	0.41	1.21e-20	Prostate cancer;
LGG	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.59	9.47	0.4	1.47e-19	Height;
LGG	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.71	0.3	5.68e-11	Morning vs. evening chronotype;
LGG	cis	rs7428	0.924	rs908304	chr2:85573049	G/A	cg24342717	chr2:85555507	TGOLN2	-0.53	-8.24	-0.36	1.77e-15	Ear protrusion;
LGG	cis	rs2735413	0.563	rs11646833	chr16:78057379	G/C	cg04733911	chr16:78082701	NA	0.59	7.8	0.34	4.06e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg07701084	chr6:150067640	NUP43	0.69	13.19	0.52	5.7e-34	Lung cancer;
LGG	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg25019033	chr10:957182	NA	-0.51	-9.42	-0.4	2.11e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	15.17	0.58	1.69e-42	Platelet count;
LGG	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs16973500	0.711	rs2878491	chr16:71981218	T/G	cg09427745	chr16:71932006	KIAA0174	-0.5	-7.32	-0.32	1.12e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg17644776	chr2:200775616	C2orf69	0.71	12.69	0.51	7.02e-32	Osteoporosis;
LGG	cis	rs10883723	0.773	rs11191313	chr10:104278618	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	12.61	0.51	1.54e-31	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg02002194	chr4:3960332	NA	-0.41	-7.73	-0.34	6.6e-14	Neuroticism;
LGG	cis	rs7572733	0.840	rs13029495	chr2:198582601	C/A	cg00792783	chr2:198669748	PLCL1	-0.45	-7.67	-0.34	1.04e-13	Dermatomyositis;
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg00830817	chr11:109293614	C11orf87	0.58	9.42	0.4	2.14e-19	Schizophrenia;
LGG	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg13010199	chr12:38710504	ALG10B	0.53	10.54	0.44	1.95e-23	Morning vs. evening chronotype;
LGG	cis	rs12479064	0.724	rs10496336	chr2:99996165	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-10.9	-0.45	8.55e-25	Chronic sinus infection;
LGG	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06481639	chr22:41940642	POLR3H	-0.54	-8.05	-0.35	6.97e-15	Vitiligo;
LGG	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg08355456	chr11:67383691	NA	0.49	8.36	0.36	7.61e-16	Mean corpuscular volume;
LGG	cis	rs911555	0.755	rs8010247	chr14:103933556	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.18	0.32	2.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4774899	0.872	rs11855648	chr15:57394050	A/G	cg08128148	chr15:57256372	TCF12	0.29	6.97	0.31	1.07e-11	Urinary tract infection frequency;
LGG	cis	rs3735485	0.800	rs10235041	chr7:45086913	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-7.19	-0.32	2.56e-12	Height;
LGG	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg18137308	chr11:63775436	MACROD1	0.29	6.9	0.31	1.74e-11	Pulse pressure;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg06916706	chr16:4465613	CORO7	0.7	11.52	0.47	3.51e-27	Schizophrenia;
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg24687543	chr11:63912206	MACROD1	0.6	8.21	0.36	2.15e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12745769	chr19:21579993	ZNF493	0.42	7.04	0.31	7.11e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11292385	chr22:29138453	CHEK2;HSCB	0.47	8.14	0.35	3.7e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.69	-0.3	6.64e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs763121	0.853	rs5757166	chr22:38995385	G/T	cg06022373	chr22:39101656	GTPBP1	0.88	17.86	0.64	1.24e-54	Menopause (age at onset);
LGG	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs9297145	0.565	rs56132062	chr7:98778198	C/T	cg05967295	chr7:98741636	SMURF1	-0.65	-11.54	-0.47	2.97e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	trans	rs7939886	0.920	rs11227849	chr11:56081413	A/T	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs988958	0.526	rs2374382	chr2:42255080	A/G	cg19376973	chr2:42229025	NA	-0.56	-8.38	-0.36	6.52e-16	Hypospadias;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg07747251	chr5:1868357	NA	0.46	9.31	0.4	5.04e-19	Cardiovascular disease risk factors;
LGG	cis	rs4417704	0.551	rs11688859	chr2:241904001	G/C	cg05025159	chr2:241905733	NA	0.53	10.73	0.45	3.88e-24	Joint mobility (Beighton score);
LGG	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg02269571	chr22:50332266	NA	0.63	9.98	0.42	2.27e-21	Schizophrenia;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	trans	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-11.04	-0.46	2.53e-25	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.56	-11.08	-0.46	1.83e-25	Prudent dietary pattern;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	19.12	0.66	1.78e-60	Alzheimer's disease;
LGG	cis	rs4742903	0.904	rs10123189	chr9:107000640	A/G	cg14250997	chr9:106856677	SMC2	0.37	7.6	0.33	1.61e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	9.91	0.42	4.12e-21	Response to antipsychotic treatment;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg22875332	chr1:76189707	ACADM	0.58	10.29	0.43	1.65e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.45	0.53	4.78e-35	Morning vs. evening chronotype;
LGG	cis	rs4780401	0.609	rs12927966	chr16:11814562	C/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.86	-0.51	1.39e-32	Rheumatoid arthritis;
LGG	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg25566285	chr7:158114605	PTPRN2	-0.97	-25.27	-0.76	3.33e-89	Calcium levels;
LGG	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg02002194	chr4:3960332	NA	0.45	8.06	0.35	6.42e-15	Retinal vascular caliber;
LGG	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg02428538	chr16:24856791	SLC5A11	-0.48	-8.17	-0.35	3.01e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg13013644	chr5:502571	SLC9A3	-0.35	-6.82	-0.3	2.9100000000000002e-11	Cystic fibrosis severity;
LGG	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs36051895	0.632	rs10815171	chr9:5172567	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-15.72	-0.59	6.33e-45	Pediatric autoimmune diseases;
LGG	trans	rs4427176	0.507	rs7016561	chr8:9580493	C/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.88	0.3	1.95e-11	Schizophrenia;
LGG	cis	rs2249694	0.620	rs2070673	chr10:135340567	A/T	cg20169779	chr10:135381914	SYCE1	0.57	7.9	0.34	1.99e-14	Obesity-related traits;
LGG	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg24375607	chr4:120327624	NA	0.64	10.64	0.44	8.53e-24	Corneal astigmatism;
LGG	cis	rs2832077	0.505	rs9305386	chr21:30386751	A/G	cg03476357	chr21:30257390	N6AMT1	0.85	10.69	0.44	5.65e-24	Cognitive test performance;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.21	-0.32	2.22e-12	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.62	0.37	1.11e-16	Mood instability;
LGG	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg21132104	chr15:45694354	SPATA5L1	0.74	11.2	0.46	6.35e-26	Homoarginine levels;
LGG	cis	rs988958	0.565	rs56407905	chr2:42236607	G/A	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.34	-0.32	9.91e-13	Lung cancer;
LGG	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg00012203	chr2:219082015	ARPC2	-0.48	-8.51	-0.37	2.5e-16	Ulcerative colitis;
LGG	cis	rs738321	0.757	rs6001020	chr22:38538246	C/G	cg03162506	chr22:38580953	NA	0.39	9.65	0.41	3.27e-20	Breast cancer;
LGG	cis	rs9487094	0.961	rs11153174	chr6:109674055	C/T	cg16315928	chr6:109776240	MICAL1	0.55	9.3	0.4	5.65e-19	Height;
LGG	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg12193833	chr17:30244370	NA	-0.29	-7.32	-0.32	1.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg11878867	chr6:150167359	LRP11	-0.35	-7.27	-0.32	1.58e-12	Testicular germ cell tumor;
LGG	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.27	0.5	3.71e-30	Hip circumference adjusted for BMI;
LGG	cis	rs6840360	0.607	rs2724547	chr4:152365576	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg26769984	chr7:1090371	C7orf50	0.44	7.17	0.32	3.08e-12	Bronchopulmonary dysplasia;
LGG	cis	rs1256531	0.661	rs61987809	chr14:66214220	C/T	cg15999311	chr14:65749247	NA	0.77	6.72	0.3	5.2e-11	Conduct disorder (symptom count);
LGG	cis	rs1506636	1.000	rs10225428	chr7:123357646	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs4820539	1.000	rs13054985	chr22:23458577	G/A	cg14186256	chr22:23484241	RTDR1	0.97	24.54	0.75	8.11e-86	Bone mineral density;
LGG	cis	rs9942416	0.592	rs10462521	chr5:74985867	T/C	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg13010199	chr12:38710504	ALG10B	0.76	16.31	0.6	1.43e-47	Heart rate;
LGG	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg19508488	chr2:152266495	RIF1	0.51	9.01	0.39	5.44e-18	Squamous cell lung carcinoma;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg14092988	chr3:52407081	DNAH1	0.32	8.28	0.36	1.33e-15	Bipolar disorder;
LGG	cis	rs7851660	0.874	rs1955144	chr9:100634589	A/G	cg13688889	chr9:100608707	NA	-0.58	-11.55	-0.47	2.63e-27	Strep throat;
LGG	cis	rs9358372	0.502	rs9368232	chr6:20771863	C/T	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs62400317	0.859	rs62438877	chr6:45089064	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.5	-0.44	2.85e-23	Total body bone mineral density;
LGG	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21659725	chr3:3221576	CRBN	0.92	20.59	0.69	2.48e-67	Intelligence (multi-trait analysis);
LGG	cis	rs2180341	1.000	rs2038378	chr6:127590400	C/T	cg24812749	chr6:127587940	RNF146	0.96	15.81	0.59	2.43e-45	Breast cancer;
LGG	cis	rs1249910	0.695	rs9876497	chr3:112396247	C/T	cg02954903	chr3:112359935	CCDC80	0.41	7.23	0.32	1.98e-12	Diabetic kidney disease;
LGG	cis	rs7129556	0.701	rs4322421	chr11:77459394	C/T	cg12586386	chr11:77299805	AQP11	0.45	7.39	0.32	6.71e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs7828089	0.875	rs6998575	chr8:22254499	C/T	cg12081754	chr8:22256438	SLC39A14	0.77	15.52	0.58	5.01e-44	Verbal declarative memory;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21824902	chr1:27560832	WDTC1	0.43	7.36	0.32	8.27e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2629540	0.766	rs10794177	chr10:126407409	G/C	cg08799069	chr10:126477246	METTL10	0.65	13.04	0.52	2.52e-33	Cocaine dependence;
LGG	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs11583043	0.918	rs11581062	chr1:101407519	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.4	-7.17	-0.32	2.91e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg00631329	chr6:26305371	NA	0.44	7.57	0.33	1.98e-13	Educational attainment;
LGG	trans	rs853679	0.760	rs9368563	chr6:28208558	A/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.92	-0.35	1.8e-14	Depression;
LGG	cis	rs12493885	0.818	rs61791544	chr3:153767504	T/A	cg17054900	chr3:154042577	DHX36	-0.62	-7.91	-0.34	1.96e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4704187	0.687	rs6453111	chr5:74379926	C/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg15704280	chr7:45808275	SEPT13	-0.87	-13.15	-0.52	9.1e-34	Coronary artery disease;
LGG	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.18	-0.43	4.36e-22	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.681	rs4131980	chr1:227572123	A/G	cg04117972	chr1:227635322	NA	0.72	11.2	0.46	6.29e-26	Major depressive disorder;
LGG	cis	rs4566357	1.000	rs12612535	chr2:227926998	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.02	-0.31	7.84e-12	Coronary artery disease;
LGG	cis	rs4253772	0.591	rs6520010	chr22:46721223	G/A	cg24881330	chr22:46731750	TRMU	0.84	10.21	0.43	3.4e-22	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11955398	0.716	rs3857236	chr5:59909529	G/A	cg02684056	chr5:59996105	DEPDC1B	0.4	6.66	0.3	7.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg12751644	chr20:60527061	NA	-0.29	-6.64	-0.3	8.62e-11	Body mass index;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg17911788	chr17:44343683	NA	0.62	9.53	0.4	9.16e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs939658	0.935	rs954292	chr15:79449237	C/T	cg17916960	chr15:79447300	NA	0.64	12.57	0.5	2.22e-31	Refractive error;
LGG	cis	rs7241530	0.636	rs56067080	chr18:75912794	T/A	cg14642773	chr18:75888474	NA	0.42	7.98	0.35	1.13e-14	Educational attainment (years of education);
LGG	cis	rs2188561	0.697	rs3735606	chr7:107384309	C/G	cg16793755	chr7:107334138	SLC26A4	0.37	6.75	0.3	4.55e-11	Alcohol consumption;
LGG	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg09021430	chr5:549028	NA	-0.83	-12.9	-0.51	1e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.84e-12	Lung cancer;
LGG	cis	rs10463554	1.000	rs6879788	chr5:102314057	T/C	cg23492399	chr5:102201601	PAM	-0.54	-8.34	-0.36	8.67e-16	Parkinson's disease;
LGG	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	trans	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.54	0.53	2.05e-35	Obesity-related traits;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg04450456	chr4:17643702	FAM184B	0.31	6.72	0.3	5.38e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9303280	0.901	rs8067378	chr17:38051348	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-8.89	-0.38	1.35e-17	Self-reported allergy;
LGG	cis	rs2635047	0.935	rs2576031	chr18:44658146	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	7.74	0.34	6.34e-14	Educational attainment;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04008888	chr11:68622739	NA	-0.55	-11.73	-0.48	5.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.79	0.54	1.82e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11096990	0.613	rs6840578	chr4:39208616	A/G	cg24403649	chr4:39172243	NA	0.42	7.53	0.33	2.71e-13	Cognitive function;
LGG	trans	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg02030672	chr11:45687055	CHST1	0.48	8.34	0.36	8.64e-16	Obesity-related traits;
LGG	cis	rs9354308	0.868	rs9363458	chr6:66552798	T/C	cg07460842	chr6:66804631	NA	-0.45	-7.69	-0.34	8.61e-14	Metabolite levels;
LGG	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg13736514	chr6:26305472	NA	-0.41	-8.43	-0.36	4.43e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9393692	0.557	rs61324092	chr6:26297392	G/A	cg00631329	chr6:26305371	NA	-0.47	-7.95	-0.35	1.4e-14	Educational attainment;
LGG	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg08461772	chr7:95026248	PON3	0.37	8.16	0.35	3.08e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11890956	chr21:40555474	PSMG1	-1.0	-21.55	-0.71	7.23e-72	Cognitive function;
LGG	cis	rs9381107	1.000	rs11759603	chr6:9443977	T/C	cg14735645	chr6:9486422	NA	-0.42	-7.21	-0.32	2.32e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02071572	chr4:1403502	NA	0.42	7.19	0.32	2.56e-12	Longevity;
LGG	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg20302533	chr7:39170763	POU6F2	0.55	13.25	0.52	3.42e-34	IgG glycosylation;
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg04617936	chr2:214353	NA	-0.4	-7.44	-0.33	5.02e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg07308232	chr7:1071921	C7orf50	-0.54	-9.82	-0.42	8.21e-21	Longevity;Endometriosis;
LGG	cis	rs55728055	0.661	rs9619215	chr22:32042732	A/G	cg01338084	chr22:32026380	PISD	1.34	12.17	0.49	9.66e-30	Age-related hearing impairment;
LGG	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.04e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9788682	0.747	rs12101809	chr15:78779801	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-7.98	-0.35	1.14e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg19399532	chr1:178512495	C1orf220	0.56	11.54	0.47	2.97e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg08250081	chr4:10125330	NA	0.36	7.05	0.31	6.39e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg12432903	chr7:1882776	MAD1L1	0.45	6.99	0.31	9.86e-12	Bipolar disorder;
LGG	trans	rs57046232	0.552	rs932828	chr20:6340080	G/A	cg21095983	chr6:86352623	SYNCRIP	0.42	7.02	0.31	7.76e-12	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00603498	chr17:5322775	RPAIN;NUP88	0.45	7.37	0.32	7.79e-13	Cognitive performance;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.36	-0.36	7.44e-16	Joint mobility (Beighton score);
LGG	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg07541023	chr7:19748670	TWISTNB	0.84	11.09	0.46	1.66e-25	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg02297831	chr4:17616191	MED28	0.52	9.36	0.4	3.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs738321	0.757	rs2284062	chr22:38544221	A/G	cg25457927	chr22:38595422	NA	-0.4	-9.49	-0.4	1.2e-19	Breast cancer;
LGG	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.61	-0.33	1.56e-13	Testicular germ cell tumor;
LGG	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg00277334	chr10:82204260	NA	-0.35	-7.32	-0.32	1.11e-12	Post bronchodilator FEV1;
LGG	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg24812749	chr6:127587940	RNF146	0.97	16.06	0.6	1.86e-46	Breast cancer;
LGG	cis	rs7617773	0.925	rs34513961	chr3:48173653	T/C	cg11946769	chr3:48343235	NME6	0.64	9.95	0.42	2.89e-21	Coronary artery disease;
LGG	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg03929089	chr4:120376271	NA	-1.01	-22.64	-0.72	6.08e-77	Height;
LGG	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg04691961	chr3:161091175	C3orf57	-0.64	-14.94	-0.57	1.85e-41	Morning vs. evening chronotype;
LGG	cis	rs564799	0.871	rs1874886	chr3:159729655	G/A	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs75920871	0.858	rs7950501	chr11:116963965	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.53	-0.33	2.6e-13	Other erythrocyte phenotypes;
LGG	cis	rs17209837	1.000	rs17149641	chr7:87086090	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.8	-0.51	2.45e-32	Gallbladder cancer;
LGG	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.83	-0.3	2.75e-11	Neuroticism;
LGG	cis	rs7511006	0.893	rs2038049	chr22:50654888	G/C	cg16473166	chr22:50639996	SELO	0.65	11.5	0.47	4.45e-27	Obesity-related traits;
LGG	cis	rs1577917	0.959	rs12201739	chr6:86720739	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-10.07	-0.42	1.07e-21	Response to antipsychotic treatment;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18239851	chr1:70671762	SFRS11;LRRC40	-0.43	-7.1	-0.31	4.73e-12	Body fat percentage;
LGG	cis	rs599083	0.530	rs689179	chr11:68179166	A/G	cg01657329	chr11:68192670	LRP5	0.62	10.28	0.43	1.9e-22	Bone mineral density (spine);
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.43	-0.5	7.96e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.554	rs7856773	chr9:5204705	T/C	cg02405213	chr9:5042618	JAK2	-0.73	-13.28	-0.53	2.59e-34	Pediatric autoimmune diseases;
LGG	cis	rs2456568	0.771	rs2102333	chr11:93634749	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg18350739	chr11:68623251	NA	-0.87	-22.45	-0.72	4.75e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3790455	1.000	rs2274317	chr1:156446903	T/C	cg14087168	chr1:156450669	MEF2D	0.48	7.84	0.34	3.05e-14	Migraine;
LGG	cis	rs941408	0.515	rs7253128	chr19:2776982	C/T	cg06609049	chr19:2785107	THOP1	0.96	16.57	0.61	9.75e-49	Total cholesterol levels;
LGG	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg11995313	chr8:8860691	ERI1	0.44	7.65	0.34	1.17e-13	Joint mobility (Beighton score);
LGG	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg14829155	chr15:31115871	NA	-0.57	-9.28	-0.4	6.79e-19	Huntington's disease progression;
LGG	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg03213289	chr20:61660250	NA	0.58	10.39	0.43	7.36e-23	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs953387	1.000	rs4954567	chr2:136901587	G/T	cg07169764	chr2:136633963	MCM6	0.54	8.99	0.39	6.24e-18	Arthritis (juvenile idiopathic);
LGG	cis	rs701145	0.938	rs355773	chr3:154036657	A/G	cg17054900	chr3:154042577	DHX36	-0.95	-12.19	-0.49	8.09e-30	Coronary artery disease;
LGG	cis	rs7192380	1.000	rs7192380	chr16:69704342	T/C	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.76	-0.34	5.64e-14	Sjögren's syndrome;
LGG	trans	rs72991	0.793	rs10892740	chr11:121225136	C/T	cg27192990	chr6:129479024	LAMA2	-0.43	-7.23	-0.32	1.99e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2737618	0.651	rs2249156	chr1:200083541	A/G	cg21825944	chr1:200113062	NR5A2	0.59	11.67	0.48	9.44e-28	Uric acid levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02182114	chr7:139876578	LOC100134229;JHDM1D	0.45	7.61	0.33	1.5700000000000001e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.68	-0.37	6.65e-17	Bladder cancer;
LGG	cis	rs10463554	0.927	rs34825	chr5:102439318	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.86	-0.3	2.15e-11	Aortic root size;
LGG	cis	rs2470578	0.792	rs2470347	chr3:17313703	T/A	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg06808227	chr14:105710500	BRF1	0.62	11.44	0.47	7.67e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs698833	0.741	rs2340808	chr2:44511861	T/C	cg00619915	chr2:44497795	NA	-0.48	-7.08	-0.31	5.42e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs208520	0.837	rs208509	chr6:66941706	A/G	cg07460842	chr6:66804631	NA	-0.9	-15.55	-0.59	3.63e-44	Exhaled nitric oxide output;
LGG	trans	rs78049276	0.736	rs73855814	chr4:148397751	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.58	-0.33	1.86e-13	Pulse pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08684830	chr9:80851119	CEP78	0.4	6.7	0.3	5.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.99	-0.42	2.03e-21	Joint mobility (Beighton score);
LGG	cis	rs17227506	0.543	rs966908	chr8:13403934	G/A	cg03566418	chr8:13424080	C8orf48	-0.62	-9.53	-0.41	8.73e-20	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs11229555	1.000	rs11229543	chr11:58370698	G/A	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.14	0.31	3.65e-12	Electroencephalogram traits;
LGG	cis	rs16973500	1.000	rs16973500	chr16:71965196	C/T	cg09427745	chr16:71932006	KIAA0174	-0.48	-7.04	-0.31	6.86e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg27532560	chr4:187881888	NA	-0.58	-12.44	-0.5	7.6e-31	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg11965913	chr1:205819406	PM20D1	0.47	7.39	0.32	6.96e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs6977660	0.714	rs10486365	chr7:19801364	A/G	cg05791153	chr7:19748676	TWISTNB	0.71	9.91	0.42	4.09e-21	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1994135	0.654	rs1384591	chr12:33734170	T/C	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.1e-16	Resting heart rate;
LGG	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg08997352	chr12:9597637	DDX12	-0.68	-13.27	-0.52	2.68e-34	Breast size;
LGG	cis	rs17401966	0.867	rs10492973	chr1:10398985	T/C	cg19773385	chr1:10388646	KIF1B	-0.45	-9.63	-0.41	3.92e-20	Hepatocellular carcinoma;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.16	-0.35	3.26e-15	Schizophrenia;
LGG	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg18105134	chr13:113819100	PROZ	-0.66	-13.28	-0.53	2.62e-34	Platelet distribution width;
LGG	cis	rs4268898	0.610	rs34216622	chr2:24463445	G/C	cg06627628	chr2:24431161	ITSN2	-0.78	-12.59	-0.5	1.86e-31	Asthma;
LGG	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-12.85	-0.51	1.52e-32	Monocyte count;
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.11	-0.31	4.32e-12	Monocyte percentage of white cells;
LGG	cis	rs1256531	0.661	rs61987981	chr14:66031638	T/G	cg15999311	chr14:65749247	NA	0.79	6.71	0.3	5.84e-11	Conduct disorder (symptom count);
LGG	cis	rs1519814	0.956	rs6995843	chr8:121159867	C/T	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg22072935	chr14:105399595	NA	0.52	10.11	0.43	7.66e-22	Rheumatoid arthritis;
LGG	cis	rs1799810	0.739	rs13030284	chr2:128158719	G/A	cg10021288	chr2:128175891	PROC	-0.37	-6.81	-0.3	3.09e-11	Self-rated health;
LGG	cis	rs6665290	0.904	rs11586604	chr1:227183865	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg16507663	chr6:150244633	RAET1G	0.46	8.56	0.37	1.62e-16	Lung cancer;
LGG	trans	rs7395662	1.000	rs12420372	chr11:48497603	A/C	cg15704280	chr7:45808275	SEPT13	0.48	7.7	0.34	8.13e-14	HDL cholesterol;
LGG	cis	rs6500602	0.592	rs8051780	chr16:4434374	G/A	cg06916706	chr16:4465613	CORO7	-0.89	-14.87	-0.57	3.47e-41	Schizophrenia;
LGG	trans	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg14791747	chr16:20752902	THUMPD1	0.51	7.53	0.33	2.6e-13	Cognitive test performance;
LGG	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg04034577	chr2:241836375	C2orf54	-0.53	-11.1	-0.46	1.51e-25	Urinary metabolites;
LGG	trans	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.11e-13	Cognitive test performance;
LGG	trans	rs656319	0.559	rs17689007	chr8:9974824	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.58	0.33	1.88e-13	Myopia (pathological);
LGG	cis	rs1669338	0.588	rs73005226	chr3:3195369	A/G	cg16797762	chr3:3221439	CRBN	-0.94	-12.56	-0.5	2.34e-31	White matter integrity;
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg14668632	chr7:2872130	GNA12	-0.33	-7.03	-0.31	7.21e-12	Height;
LGG	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg00908189	chr16:619842	PIGQ	0.52	7.59	0.33	1.76e-13	Height;
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg04287289	chr16:89883240	FANCA	0.84	7.87	0.34	2.5e-14	Skin colour saturation;
LGG	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg04691961	chr3:161091175	C3orf57	-0.42	-8.56	-0.37	1.66e-16	Parkinson's disease;
LGG	cis	rs9815354	0.951	rs1716674	chr3:41902972	G/C	cg03022575	chr3:42003672	ULK4	0.65	8.4	0.36	5.68e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.7	-0.34	8.29e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9309473	0.718	rs6546829	chr2:73613789	C/G	cg20560298	chr2:73613845	ALMS1	-0.52	-9.33	-0.4	4.26e-19	Metabolite levels;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.23	0.49	5.13e-30	Prudent dietary pattern;
LGG	cis	rs7143963	0.636	rs58638472	chr14:103303311	A/T	cg23020514	chr14:103360112	TRAF3	0.41	8.56	0.37	1.72e-16	Body mass index;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg11494091	chr17:61959527	GH2	1.0	24.73	0.75	1.06e-86	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21790971	chr4:54244117	FIP1L1	0.54	8.51	0.37	2.44e-16	Gut microbiome composition (summer);
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg21548813	chr6:291882	DUSP22	-0.75	-13.42	-0.53	6.16e-35	Menopause (age at onset);
LGG	cis	rs36715	1.000	rs40527	chr5:127550252	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.45	7.09	0.31	4.91e-12	Breast cancer;
LGG	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg07274523	chr3:49395745	GPX1	0.58	9.7	0.41	2.17e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08991232	chr8:70746365	SLCO5A1	0.43	6.86	0.3	2.25e-11	Gut microbiome composition (summer);
LGG	cis	rs941408	0.515	rs759066	chr19:2775337	G/T	cg06609049	chr19:2785107	THOP1	1.01	15.19	0.58	1.42e-42	Total cholesterol levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03762505	chr1:171750926	METTL13	0.4	6.68	0.3	6.74e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs3942852	0.955	rs6485809	chr11:48112468	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-8.52	-0.37	2.24e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.09	0.42	8.95e-22	Mean corpuscular volume;
LGG	cis	rs10214930	0.697	rs1404276	chr7:27590847	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.78	0.3	3.68e-11	Hypospadias;
LGG	cis	rs11159840	0.573	rs7146550	chr14:88599886	G/A	cg18078958	chr14:88630771	NA	-0.29	-6.85	-0.3	2.43e-11	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs4704187	0.687	rs4389672	chr5:74368642	G/T	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs4538187	0.802	rs35480874	chr2:64221458	T/C	cg02541582	chr2:64069798	UGP2	-0.61	-14.37	-0.56	5.48e-39	Systolic blood pressure;
LGG	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.82e-21	HDL cholesterol;
LGG	trans	rs9914544	0.524	rs7209853	chr17:18798600	G/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs6489785	0.737	rs497273	chr12:121204682	C/G	cg02419362	chr12:121203948	SPPL3	0.44	6.93	0.31	1.37e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs611744	0.647	rs13280487	chr8:109270263	G/C	cg18478394	chr8:109455254	TTC35	0.42	8.43	0.36	4.35e-16	Dupuytren's disease;
LGG	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.04	0.31	6.78e-12	Aortic root size;
LGG	cis	rs4696584	0.761	rs1388080	chr4:155405425	C/G	cg13738195	chr4:155413469	DCHS2	0.39	8.23	0.36	1.89e-15	Folding of antihelix;
LGG	cis	rs6445975	0.575	rs7614726	chr3:58243289	C/T	cg24175188	chr3:58374923	PXK	0.39	7.22	0.32	2.1e-12	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs77972916	0.609	rs72790903	chr2:43561985	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.96	-0.31	1.18e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9972944	0.651	rs7221371	chr17:63765174	C/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs9326248	0.581	rs11216242	chr11:116901549	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.85	0.45	1.39e-24	Blood protein levels;
LGG	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg03646474	chr1:174992368	MRPS14	0.42	6.83	0.3	2.75e-11	Schizophrenia;
LGG	cis	rs7742824	1.000	rs2096199	chr6:44096014	G/A	cg04074908	chr6:44101190	TMEM63B	0.69	13.21	0.52	5e-34	Major depressive disorder;
LGG	cis	rs10193935	1.000	rs13386385	chr2:42436928	G/T	cg27598129	chr2:42591480	NA	-0.63	-9.46	-0.4	1.54e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04305870	chr14:75725648	NA	0.46	6.7	0.3	6.01e-11	Gut microbiome composition (summer);
LGG	cis	rs77372450	0.636	rs73814834	chr5:157024459	A/G	cg25387487	chr5:157003181	ADAM19	-0.56	-7.1	-0.31	4.76e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.93	-0.48	8.59e-29	Parkinson's disease;
LGG	cis	rs6594713	0.531	rs13362189	chr5:112940706	A/G	cg12552261	chr5:112820674	MCC	0.6	8.39	0.36	5.74e-16	Brain cytoarchitecture;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg22398616	chr13:53314203	LECT1	-0.41	-8.26	-0.36	1.49e-15	Lewy body disease;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg00290607	chr11:67383545	NA	-0.5	-8.81	-0.38	2.47e-17	Mean corpuscular volume;
LGG	cis	rs7589342	0.831	rs6731173	chr2:106522928	A/G	cg16077055	chr2:106428750	NCK2	0.26	6.81	0.3	3e-11	Addiction;
LGG	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg08085267	chr17:45401833	C17orf57	-0.53	-10.41	-0.44	6.12e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	9.05	0.39	3.99e-18	Bipolar disorder;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.66	13.44	0.53	5.14e-35	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-13.2	-0.52	5.68e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.18	-0.39	1.49e-18	Menopause (age at onset);
LGG	trans	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.66	0.34	1.07e-13	Mood instability;
LGG	cis	rs892961	0.932	rs67719929	chr17:75412605	G/A	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs3816183	0.756	rs6544603	chr2:43061646	C/G	cg14631114	chr2:43023945	NA	0.43	7.88	0.34	2.35e-14	Hypospadias;
LGG	cis	rs12282928	0.959	rs11039633	chr11:48297665	A/C	cg26585981	chr11:48327164	OR4S1	0.46	7.35	0.32	8.94e-13	Migraine - clinic-based;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10436540	chr17:4047319	ZZEF1;CYB5D2	0.47	6.89	0.3	1.85e-11	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.12e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08219700	chr8:58056026	NA	0.47	7.08	0.31	5.33e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.37e-17	Life satisfaction;
LGG	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg04149295	chr10:70884716	VPS26A	0.49	7.44	0.33	4.84e-13	Left atrial antero-posterior diameter;
LGG	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.69e-16	Aortic root size;
LGG	trans	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg27661571	chr11:113659931	NA	-0.73	-9.62	-0.41	4.26e-20	Hip circumference adjusted for BMI;
LGG	trans	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg05163923	chr11:71159392	DHCR7	-0.56	-8.19	-0.36	2.6e-15	Vitamin D levels;
LGG	trans	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg15736062	chr7:158136485	PTPRN2	0.46	8.61	0.37	1.17e-16	Calcium levels;
LGG	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg18198730	chr1:247681584	NA	-0.75	-12.7	-0.51	6.68e-32	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs5758511	0.514	rs5758626	chr22:42572363	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.61	0.33	1.54e-13	Birth weight;
LGG	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.77	-0.34	5.11e-14	Retinal vascular caliber;
LGG	trans	rs1547374	0.737	rs178741	chr21:43779408	G/A	cg09521743	chr10:75415752	SYNPO2L	0.34	7.31	0.32	1.19e-12	Pancreatic cancer;
LGG	cis	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	cis	rs9910055	0.571	rs10208	chr17:42300278	C/T	cg13607699	chr17:42295918	UBTF	0.98	20.98	0.7	3.64e-69	Total body bone mineral density;
LGG	cis	rs10267417	0.556	rs6977047	chr7:19960417	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.74	0.3	4.79e-11	Night sleep phenotypes;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg05941027	chr17:61774174	LIMD2	0.35	8.9	0.38	1.25e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs16854884	0.657	rs7610378	chr3:143711298	G/A	cg06585982	chr3:143692056	C3orf58	0.64	11.11	0.46	1.45e-25	Economic and political preferences (feminism/equality);
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.56	0.69	3.31e-67	Alzheimer's disease;
LGG	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg16482183	chr6:26056742	HIST1H1C	0.95	13.9	0.54	5.8e-37	Iron status biomarkers;
LGG	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	19.38	0.67	1.02e-61	Gut microbiome composition (summer);
LGG	cis	rs503341	0.756	rs626333	chr11:63591861	C/T	cg04362095	chr11:63592001	C11orf84	-0.55	-10.86	-0.45	1.25e-24	Pulse pressure;
LGG	cis	rs4417704	0.551	rs10933524	chr2:241879795	A/G	cg05025159	chr2:241905733	NA	0.45	9.28	0.4	6.51e-19	Joint mobility (Beighton score);
LGG	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.53e-11	Blood metabolite levels;
LGG	cis	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg12826209	chr6:26865740	GUSBL1	0.59	7.35	0.32	9.08e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.585	rs12712854	chr2:42861393	C/G	cg14631114	chr2:43023945	NA	-0.34	-6.72	-0.3	5.32e-11	Hypospadias;
LGG	cis	rs7312933	1.000	rs7312933	chr12:42503467	C/T	cg19980929	chr12:42632907	YAF2	-0.35	-7.6	-0.33	1.64e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.67	0.34	1.03e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02475777	chr4:1388615	CRIPAK	0.61	10.69	0.45	5.25e-24	Longevity;
LGG	trans	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg02753203	chr1:228287806	NA	-0.64	-11.74	-0.48	4.84e-28	Diastolic blood pressure;
LGG	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg04568710	chr12:38710424	ALG10B	-0.41	-9.04	-0.39	4.21e-18	Bladder cancer;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg11766577	chr21:47581405	C21orf56	-0.43	-7.54	-0.33	2.49e-13	Testicular germ cell tumor;
LGG	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg18200150	chr17:30822561	MYO1D	0.87	21.97	0.71	8.28e-74	Schizophrenia;
LGG	cis	rs9463078	0.774	rs4510673	chr6:45350107	A/G	cg25276700	chr6:44698697	NA	0.39	8.22	0.36	1.99e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg06917634	chr15:78832804	PSMA4	0.83	17.53	0.63	3.77e-53	Sudden cardiac arrest;
LGG	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs16854884	0.586	rs7634145	chr3:143754150	G/A	cg06585982	chr3:143692056	C3orf58	0.68	12.34	0.5	1.84e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg04455712	chr21:45112962	RRP1B	0.51	9.6	0.41	5.25e-20	Mean corpuscular volume;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg11905131	chr22:24372483	LOC391322	-0.44	-7.65	-0.33	1.18e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.79	-0.34	4.39e-14	HDL cholesterol;
LGG	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.41	-0.36	5.17e-16	Primary sclerosing cholangitis;
LGG	cis	rs7133214	0.824	rs61915423	chr12:27937471	C/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.74	-0.3	4.82e-11	Gut microbiota (functional units);
LGG	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg26318627	chr11:63887540	MACROD1	-0.48	-6.86	-0.3	2.23e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs1620921	0.564	rs12196838	chr6:161272765	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.04e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg02297831	chr4:17616191	MED28	-0.48	-8.65	-0.37	8.29e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.84e-13	Menopause (age at onset);
LGG	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg05163923	chr11:71159392	DHCR7	-0.54	-7.98	-0.35	1.17e-14	Vitamin D levels;
LGG	cis	rs16866061	1.000	rs11688397	chr2:225393173	C/T	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04063615	chr12:132293388	NA	-0.35	-7.02	-0.31	7.97e-12	Migraine;
LGG	cis	rs1408799	0.745	rs2209271	chr9:12745643	G/A	cg05274944	chr9:12693694	TYRP1	0.33	7.85	0.34	2.95e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.15	-0.64	5.26e-56	Refractive error;
LGG	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.48	0.61	2.49e-48	Hip circumference adjusted for BMI;
LGG	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00142150	chr22:38071001	LGALS1	0.67	12.85	0.51	1.5e-32	Fat distribution (HIV);
LGG	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg11764359	chr7:65958608	NA	-0.58	-9.8	-0.41	1e-20	Aortic root size;
LGG	cis	rs4969178	0.965	rs12451791	chr17:76397343	G/A	cg02836325	chr17:76403955	PGS1	-0.71	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	cis	rs6964587	1.000	rs733957	chr7:91707197	C/T	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.13e-16	Breast cancer;
LGG	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.47e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9849248	0.671	rs9851777	chr3:88267467	T/C	cg14530983	chr3:88190749	ZNF654	-0.5	-7.14	-0.31	3.68e-12	Menarche (age at onset);
LGG	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.56e-19	Diabetic retinopathy;
LGG	cis	rs13102973	0.863	rs13103492	chr4:135907685	A/C	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.83e-15	Subjective well-being;
LGG	cis	rs9649465	0.561	rs603060	chr7:123427568	A/G	cg03229431	chr7:123269106	ASB15	-0.61	-14.22	-0.55	2.52e-38	Migraine;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.7	-0.45	5.11e-24	Personality dimensions;
LGG	trans	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg13565492	chr6:43139072	SRF	-0.69	-8.53	-0.37	2.05e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.08e-12	Electroencephalogram traits;
LGG	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg02002194	chr4:3960332	NA	0.45	8.11	0.35	4.69e-15	Retinal vascular caliber;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00149659	chr3:10157352	C3orf10	0.88	11.5	0.47	4.41e-27	Alzheimer's disease;
LGG	cis	rs2742417	0.603	rs2742449	chr3:45764544	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.28	-0.4	6.47e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.23e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4141404	0.851	rs8135417	chr22:31559255	G/A	cg22777020	chr22:31556080	RNF185	-0.43	-6.72	-0.3	5.27e-11	Paclitaxel-induced neuropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08165151	chr6:88411075	NCRNA00120;AKIRIN2	0.49	7.68	0.34	9.28e-14	Gut microbiome composition (summer);
LGG	cis	rs7666738	0.830	rs6825211	chr4:98807698	A/T	cg05340658	chr4:99064831	C4orf37	0.47	7.74	0.34	6.35e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	9.46	0.4	1.54e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1620921	0.594	rs11753819	chr6:161264775	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6708331	0.517	rs7599072	chr2:70360006	C/T	cg01613454	chr2:70366299	NA	0.56	11.26	0.46	3.69e-26	Obesity-related traits;
LGG	cis	rs8014204	0.550	rs2302832	chr14:75137664	T/C	cg06637938	chr14:75390232	RPS6KL1	0.69	12.98	0.52	4.29e-33	Caffeine consumption;
LGG	trans	rs9354308	0.764	rs9445606	chr6:66570361	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs7215564	0.908	rs7501659	chr17:78662061	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.36	-0.36	7.45e-16	Myopia (pathological);
LGG	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg20503657	chr10:835505	NA	0.64	9.52	0.4	9.85e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7717393	0.786	rs17053484	chr5:155794624	A/G	cg12904904	chr5:155754151	SGCD	0.64	7.45	0.33	4.53e-13	Egg allergy;
LGG	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg05163923	chr11:71159392	DHCR7	-0.71	-13.89	-0.54	6.49e-37	Vitamin D levels;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-13.27	-0.52	2.75e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4330281	0.678	rs4566568	chr3:17798924	A/G	cg20981856	chr3:17787350	NA	-0.39	-7.16	-0.32	3.13e-12	Schizophrenia;
LGG	cis	rs7911264	0.739	rs6583830	chr10:94398118	A/G	cg25093409	chr10:94429542	NA	0.49	9.51	0.4	1.06e-19	Inflammatory bowel disease;
LGG	cis	rs360798	0.553	rs11682530	chr2:63073194	C/T	cg17519650	chr2:63277830	OTX1	-0.49	-8.18	-0.36	2.83e-15	Coronary artery disease;
LGG	cis	rs12291225	0.585	rs4517475	chr11:14386145	A/G	cg19336497	chr11:14380999	RRAS2	-0.63	-13.44	-0.53	5.57e-35	Sense of smell;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.82	-0.34	3.56e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg04450456	chr4:17643702	FAM184B	0.31	6.74	0.3	4.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17767392	0.514	rs72726654	chr14:71664422	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.91	-0.31	1.59e-11	Mitral valve prolapse;
LGG	cis	rs568617	0.716	rs111953392	chr11:65595697	G/A	cg26695010	chr11:65641043	EFEMP2	-0.54	-6.82	-0.3	2.83e-11	Crohn's disease;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01585723	chr16:33734837	NA	0.46	7.98	0.35	1.18e-14	Menopause (age at onset);
LGG	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg27189623	chr16:705930	WDR90	0.37	7.29	0.32	1.39e-12	Height;
LGG	cis	rs654950	0.806	rs1535505	chr1:42026152	A/G	cg16096631	chr1:42092165	HIVEP3	0.44	9.1	0.39	2.72e-18	Airway imaging phenotypes;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.59	-0.37	1.34e-16	Lung cancer;
LGG	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg12386194	chr3:101231763	SENP7	0.46	8.12	0.35	4.14e-15	Colorectal cancer;
LGG	cis	rs7267979	0.934	rs4815423	chr20:25387521	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.75e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg16301924	chr13:53314226	LECT1	-0.41	-7.74	-0.34	6.36e-14	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09000830	chr1:94883752	ABCD3	0.39	6.87	0.3	2.06e-11	Cognitive performance;
LGG	cis	rs62238980	0.614	rs118130048	chr22:32413324	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs10193935	0.901	rs10200000	chr2:42442212	A/G	cg27598129	chr2:42591480	NA	-0.6	-9.35	-0.4	3.7e-19	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg13010199	chr12:38710504	ALG10B	0.52	9.91	0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs17039065	0.920	rs72891081	chr4:109471687	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.26	0.32	1.69e-12	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.34	-0.36	8.63e-16	Breast cancer;
LGG	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg13271783	chr10:134563150	INPP5A	-0.52	-7.78	-0.34	4.66e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6840360	0.554	rs58751443	chr4:152709905	A/G	cg22705602	chr4:152727874	NA	-0.39	-10.07	-0.42	1.02e-21	Intelligence (multi-trait analysis);
LGG	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg01620082	chr3:125678407	NA	-0.61	-9.18	-0.39	1.41e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg26513180	chr16:89883248	FANCA	0.69	7.74	0.34	6.44e-14	Skin colour saturation;
LGG	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg24189917	chr7:1970923	MAD1L1	0.5	8.07	0.35	6.1e-15	Bipolar disorder;
LGG	cis	rs9487094	0.670	rs1998811	chr6:109812138	A/G	cg01125227	chr6:109776195	MICAL1	0.41	7.26	0.32	1.7e-12	Height;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg27517502	chr10:1248770	ADARB2	0.36	7.04	0.31	7.02e-12	Electrocardiographic conduction measures;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.1	-0.31	4.57e-12	Lung cancer;
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg18402987	chr7:1209562	NA	0.64	8.95	0.38	8.76e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.86	-0.54	8.79e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg13010199	chr12:38710504	ALG10B	0.48	8.54	0.37	1.94e-16	Morning vs. evening chronotype;
LGG	trans	rs2008242	0.593	rs1447282	chr4:5228238	G/A	cg26099876	chr8:141644609	EIF2C2	-0.47	-8.46	-0.37	3.56e-16	Electrocardiographic conduction measures;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg21724239	chr8:58056113	NA	0.62	9.33	0.4	4.36e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1497828	0.956	rs2815250	chr1:217573979	C/T	cg04411442	chr1:217543379	NA	-0.45	-7.83	-0.34	3.27e-14	Dialysis-related mortality;
LGG	cis	rs12477438	0.520	rs11123766	chr2:99780915	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	trans	rs10802346	0.545	rs4607841	chr1:246373295	T/C	cg22732515	chr19:44031385	ETHE1	0.55	9.31	0.4	5.04e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs11966931	1.000	rs17589005	chr6:108140282	A/G	cg04749840	chr6:108095067	SCML4	-0.4	-6.9	-0.31	1.68e-11	Neutrophil percentage of white cells;
LGG	cis	rs4926611	0.698	rs12072004	chr1:54060991	C/A	cg23596471	chr1:54105337	GLIS1	-0.4	-8.26	-0.36	1.55e-15	Hand grip strength;
LGG	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg02002194	chr4:3960332	NA	-0.51	-10.27	-0.43	2.01e-22	Mood instability;
LGG	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.36	0.63	2.36e-52	Chronic sinus infection;
LGG	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.52e-13	Personality dimensions;
LGG	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22022881	chr2:105853494	NA	-0.36	-7.48	-0.33	3.77e-13	Type 2 diabetes;
LGG	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg17809284	chr5:56205270	C5orf35	0.55	10.2	0.43	3.64e-22	Initial pursuit acceleration;
LGG	cis	rs9393692	0.557	rs9358924	chr6:26322473	G/A	cg00631329	chr6:26305371	NA	-0.44	-7.06	-0.31	6.16e-12	Educational attainment;
LGG	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15644404	chr18:77186268	NFATC1	-0.82	-9.02	-0.39	5.09e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.94	-0.38	9.24e-18	Life satisfaction;
LGG	cis	rs12431410	0.548	rs35879984	chr14:60244215	T/C	cg07950296	chr14:60194823	RTN1	-0.38	-7.38	-0.32	7.21e-13	Schizophrenia;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.53	0.37	2.14e-16	Personality dimensions;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg08297393	chr2:100937505	LONRF2	-0.52	-9.54	-0.41	8.14e-20	Intelligence (multi-trait analysis);
LGG	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg02002194	chr4:3960332	NA	-0.47	-8.64	-0.37	9.02e-17	Joint mobility (Beighton score);
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg14074117	chr16:1909714	C16orf73	0.48	6.92	0.31	1.51e-11	Insulin-like growth factors;
LGG	trans	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg07817883	chr1:32538562	TMEM39B	-0.71	-9.54	-0.41	8.5e-20	Monocyte percentage of white cells;
LGG	cis	rs7523273	0.597	rs66532523	chr1:207983745	A/C	cg22525895	chr1:207977042	MIR29B2	-0.45	-6.81	-0.3	3.13e-11	Schizophrenia;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.56	0.37	1.64e-16	Platelet count;
LGG	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg10523679	chr1:76189770	ACADM	0.82	15.75	0.59	4.76e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	9.74	0.41	1.68e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2290402	0.536	rs4690204	chr4:881195	C/T	cg09237302	chr4:906077	GAK	-0.46	-7.84	-0.34	3.21e-14	Type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg23166955	chr16:30077191	ALDOA	0.46	7.78	0.34	4.65e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	11.12	0.46	1.26e-25	Schizophrenia;
LGG	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg13385521	chr17:29058706	SUZ12P	0.91	10.55	0.44	1.86e-23	Body mass index;
LGG	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.68	-0.37	6.82e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg27661571	chr11:113659931	NA	-0.62	-8.96	-0.38	7.83e-18	Hip circumference adjusted for BMI;
LGG	cis	rs4076764	0.914	rs12123378	chr1:163377846	C/T	cg24596788	chr1:163392923	NA	-0.72	-13.64	-0.54	7.9e-36	Motion sickness;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.783	rs11079844	chr17:47028334	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	trans	rs747782	0.646	rs61914719	chr11:48059091	C/T	cg15704280	chr7:45808275	SEPT13	0.71	7.2	0.32	2.52e-12	Intraocular pressure;
LGG	cis	rs11098499	0.779	rs28495013	chr4:120375831	A/C	cg09307838	chr4:120376055	NA	0.81	13.62	0.53	9.39e-36	Corneal astigmatism;
LGG	cis	rs2880765	0.835	rs730372	chr15:86038193	G/T	cg13263323	chr15:86062960	AKAP13	0.35	7.24	0.32	1.89e-12	Coronary artery disease;
LGG	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs9486719	1.000	rs2499807	chr6:96864053	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg27239842	chr4:2403781	ZFYVE28	-0.46	-7.69	-0.34	9.12e-14	Cognitive function;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7773004	0.601	rs13210340	chr6:26326314	G/A	cg13736514	chr6:26305472	NA	-0.48	-9.26	-0.4	7.69e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg06470251	chr20:60548479	NA	0.52	8.38	0.36	6.41e-16	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19625377	chr1:11322792	MTOR	0.44	6.94	0.31	1.31e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.54	0.69	4.18e-67	Alzheimer's disease;
LGG	cis	rs77972916	0.611	rs6709988	chr2:43601317	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-8.82	-0.38	2.43e-17	Granulocyte percentage of myeloid white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12661088	chr5:43120934	ZNF131	0.43	6.93	0.31	1.41e-11	Gut microbiome composition (summer);
LGG	cis	rs7751419	0.651	rs7758693	chr6:39104371	C/T	cg08089693	chr6:39098871	NA	-0.43	-7.66	-0.34	1.11e-13	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs7937682	0.855	rs521947	chr11:111492616	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg02475777	chr4:1388615	CRIPAK	0.4	7.26	0.32	1.66e-12	Longevity;
LGG	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06108461	chr20:60628389	TAF4	-0.81	-15.06	-0.57	5.26e-42	Body mass index;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg26724248	chr22:46645903	C22orf40	0.4	6.71	0.3	5.86e-11	Corneal astigmatism;
LGG	cis	rs1784581	0.588	rs1789986	chr6:162409978	C/T	cg17173639	chr6:162384350	PARK2	-0.64	-13.62	-0.53	9.03e-36	Itch intensity from mosquito bite;
LGG	cis	rs62244186	0.659	rs9835270	chr3:44553722	G/A	cg02073558	chr3:44770973	ZNF501	0.66	11.8	0.48	2.88e-28	Depressive symptoms;
LGG	cis	rs17253792	0.822	rs79024594	chr14:56092997	T/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg10818794	chr15:86012489	AKAP13	-0.37	-7.63	-0.33	1.32e-13	Coronary artery disease;
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs9355610	0.892	rs2247314	chr6:167370230	T/C	cg18261144	chr6:167370276	RNASET2	-0.38	-7.72	-0.34	7e-14	Graves' disease;
LGG	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg20573242	chr4:122745356	CCNA2	0.53	9.84	0.42	6.99e-21	Type 2 diabetes;
LGG	cis	rs13177180	0.600	rs256995	chr5:114913364	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.41	-9.23	-0.39	9.87e-19	Conotruncal heart defects (inherited effects);
LGG	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg24450063	chr1:156163899	SLC25A44	1.16	26.86	0.78	1.78e-96	Testicular germ cell tumor;
LGG	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg08400814	chr5:56204995	C5orf35	-0.45	-7.28	-0.32	1.49e-12	Initial pursuit acceleration;
LGG	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg06481639	chr22:41940642	POLR3H	-0.46	-6.8	-0.3	3.17e-11	Vitiligo;
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.48	-0.37	3.14e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4478037	0.749	rs9311003	chr3:33131070	A/G	cg19404215	chr3:33155277	CRTAP	-0.72	-9.28	-0.4	6.64e-19	Major depressive disorder;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg02462569	chr6:150064036	NUP43	-0.45	-9.3	-0.4	5.66e-19	Lung cancer;
LGG	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg07440826	chr16:89882328	FANCA	-0.26	-7.05	-0.31	6.51e-12	Vitiligo;
LGG	cis	rs727505	1.000	rs67939974	chr7:124554364	C/T	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	cis	rs6772849	1.000	rs2734037	chr3:128308884	C/T	cg08795948	chr3:128337044	NA	0.53	8.74	0.38	4.31e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.71	0.51	6.03e-32	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.73	-0.54	3.09e-36	Alzheimer's disease;
LGG	cis	rs36093844	0.752	rs56202113	chr11:85553558	G/A	cg16165120	chr11:85566439	CCDC83	-0.46	-7.4	-0.33	6.47e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg12011299	chr4:100065546	ADH4	0.44	9.11	0.39	2.56e-18	Alcohol dependence;
LGG	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg02153584	chr22:29168773	CCDC117	0.6	7.37	0.32	7.94e-13	Hematocrit;Hemoglobin concentration;
LGG	trans	rs1941687	0.563	rs1586987	chr18:31338661	A/G	cg27147174	chr7:100797783	AP1S1	-0.67	-12.75	-0.51	4.08e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9462027	0.628	rs6924898	chr6:34811199	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.32	-0.47	2.13e-26	Systemic lupus erythematosus;
LGG	cis	rs2000999	0.573	rs34139543	chr16:72158477	C/T	cg04254540	chr16:71951199	KIAA0174	-0.61	-6.82	-0.3	2.79e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs3845702	0.736	rs6733426	chr2:180830958	A/G	cg01881094	chr2:180872142	CWC22	-1.25	-16.82	-0.62	7.03e-50	Schizophrenia;
LGG	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg04672837	chr16:48644449	N4BP1	0.55	9.04	0.39	4.4e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3770081	1.000	rs59947468	chr2:86289436	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.21	0.32	2.37e-12	Facial emotion recognition (sad faces);
LGG	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg27490568	chr2:178487706	NA	0.53	10.23	0.43	2.7e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg04166393	chr7:2884313	GNA12	0.46	8.45	0.37	3.8e-16	Height;
LGG	cis	rs11785693	0.862	rs11783719	chr8:4991311	G/T	cg26367366	chr8:4980734	NA	1.02	16.01	0.6	2.99e-46	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs4974559	0.739	rs10012819	chr4:1324758	G/C	cg02980000	chr4:1222292	CTBP1	0.81	9.16	0.39	1.73e-18	Systolic blood pressure;
LGG	cis	rs11676348	0.935	rs13007992	chr2:218964051	G/T	cg00012203	chr2:219082015	ARPC2	-0.5	-8.85	-0.38	1.84e-17	Ulcerative colitis;
LGG	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg02574844	chr11:5959923	NA	-0.61	-10.95	-0.45	5.92e-25	DNA methylation (variation);
LGG	cis	rs1577917	0.771	rs2842607	chr6:86345039	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.25	-0.63	7.73e-52	Response to antipsychotic treatment;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06951363	chr1:241683161	FH	-0.41	-6.86	-0.3	2.28e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06112835	chr11:68658793	MRPL21	0.6	10.16	0.43	4.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg13147721	chr7:65941812	NA	-0.82	-9.8	-0.41	1.01e-20	Diabetic kidney disease;
LGG	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11190604	1.000	rs10883509	chr10:102296461	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	12.07	0.49	2.25e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1707322	1.000	rs946527	chr1:46485970	C/T	cg03146154	chr1:46216737	IPP	0.52	10.25	0.43	2.41e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4595586	0.525	rs7313120	chr12:39388027	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg09699651	chr6:150184138	LRP11	-0.49	-8.62	-0.37	1.06e-16	Lung cancer;
LGG	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg03877680	chr5:178157825	ZNF354A	0.77	12.3	0.5	2.81e-30	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs2692947	0.655	rs2315668	chr2:96429562	T/C	cg22654517	chr2:96458247	NA	0.38	7.4	0.33	6.46e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10089	0.953	rs72794400	chr5:127516028	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.74	0.48	4.93e-28	Ileal carcinoids;
LGG	cis	rs8103278	1.000	rs9807819	chr19:46239598	C/T	cg11657440	chr19:46296263	DMWD	-0.6	-11.66	-0.48	1e-27	Coronary artery disease;
LGG	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	trans	rs11165623	0.564	rs6673207	chr1:96999259	C/G	cg10631902	chr5:14652156	NA	-0.46	-9.57	-0.41	6.57e-20	Hip circumference;Waist circumference;
LGG	cis	rs2688419	0.565	rs1817581	chr3:23078375	T/A	cg00327796	chr3:23032191	NA	-0.36	-6.96	-0.31	1.19e-11	Type 2 diabetes;
LGG	cis	rs35740288	0.752	rs11635956	chr15:86279928	G/A	cg07943548	chr15:86304357	KLHL25	-0.36	-6.96	-0.31	1.17e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4740619	0.544	rs9407645	chr9:15813149	G/A	cg14451791	chr9:16040625	NA	0.31	7.61	0.33	1.52e-13	Body mass index;
LGG	cis	rs2302729	0.545	rs3794291	chr12:2769665	C/T	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.51	-0.5	3.91e-31	Sleep quality;
LGG	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.71	0.51	5.76e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg16434002	chr17:42200994	HDAC5	-0.52	-9.51	-0.4	1.01e-19	Total body bone mineral density;
LGG	cis	rs9863	0.896	rs2130382	chr12:124484643	C/G	cg13487667	chr12:124434373	CCDC92	-0.37	-7.38	-0.32	7.43e-13	White blood cell count;
LGG	cis	rs6693567	0.565	rs834225	chr1:150300727	T/C	cg15654264	chr1:150340011	RPRD2	0.33	6.73	0.3	5.16e-11	Migraine;
LGG	cis	rs894344	0.650	rs11166598	chr8:135581352	T/C	cg09855544	chr8:135498122	ZFAT	0.42	7.58	0.33	1.92e-13	Systolic blood pressure;
LGG	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg24189917	chr7:1970923	MAD1L1	-0.51	-7.83	-0.34	3.31e-14	Bipolar disorder;
LGG	cis	rs523522	0.962	rs4767902	chr12:120910004	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.9	0.51	9.98e-33	High light scatter reticulocyte count;
LGG	cis	rs10979	1.000	rs9285500	chr6:143897614	G/C	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.69	-0.34	8.86e-14	Testicular germ cell tumor;
LGG	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg21453758	chr17:80185943	SLC16A3	0.35	7.48	0.33	3.69e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2456568	0.803	rs10765641	chr11:93640312	T/C	cg26875233	chr11:93583750	C11orf90	-0.34	-6.74	-0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	cis	rs1707322	1.000	rs7531911	chr1:46330423	A/G	cg03146154	chr1:46216737	IPP	0.55	10.49	0.44	3.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg24675658	chr1:53192096	ZYG11B	0.49	9.8	0.41	9.69e-21	Monocyte count;
LGG	cis	rs11608355	0.506	rs11066471	chr12:109828039	T/C	cg19025524	chr12:109796872	NA	-0.45	-8.34	-0.36	8.55e-16	Neuroticism;
LGG	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg02733842	chr7:1102375	C7orf50	-0.48	-7.8	-0.34	4.01e-14	Bronchopulmonary dysplasia;
LGG	cis	rs4423214	1.000	rs4423214	chr11:71173254	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.06	-0.52	2.09e-33	Vitamin D levels;
LGG	cis	rs912057	0.632	rs1294432	chr6:6745027	C/T	cg06612196	chr6:6737390	NA	0.5	10.76	0.45	3.03e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7737355	0.504	rs31256	chr5:130828749	T/C	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	6.73e-18	Life satisfaction;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg11766577	chr21:47581405	C21orf56	0.49	8.14	0.35	3.72e-15	Testicular germ cell tumor;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.46	-0.4	1.61e-19	Obesity-related traits;
LGG	cis	rs6142618	0.562	rs2235900	chr20:30719578	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.88	0.34	2.38e-14	Inflammatory bowel disease;
LGG	cis	rs3820928	0.845	rs7570869	chr2:227878818	A/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.8	-0.34	4.01e-14	Pulmonary function;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-12.87	-0.51	1.26e-32	Menarche (age at onset);
LGG	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21659725	chr3:3221576	CRBN	0.55	9.68	0.41	2.68e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17253792	0.822	rs10142757	chr14:56074211	C/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg23758822	chr17:41437982	NA	0.85	14.6	0.56	5.35e-40	Menopause (age at onset);
LGG	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg06886374	chr16:1844152	IGFALS	0.44	7.78	0.34	4.63e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg10935138	chr17:73851978	WBP2	0.54	7.98	0.35	1.17e-14	Psoriasis;
LGG	cis	rs2694528	0.858	rs158697	chr5:60330165	A/G	cg11474532	chr5:59995715	DEPDC1B	-0.68	-7.28	-0.32	1.43e-12	Parkinson's disease;
LGG	cis	rs12545109	0.800	rs2610052	chr8:57411316	C/A	cg19413350	chr8:57351067	NA	-0.43	-6.93	-0.31	1.44e-11	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg03929089	chr4:120376271	NA	0.44	7.0	0.31	9.26e-12	HDL cholesterol;
LGG	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg25019033	chr10:957182	NA	0.34	7.08	0.31	5.44e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12517041	1.000	rs7737479	chr5:23288235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.75	-10.31	-0.43	1.42e-22	Calcium levels;
LGG	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08045932	chr20:61659980	NA	0.6	13.0	0.52	3.8e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg12046867	chr14:103022105	NA	0.46	8.98	0.38	7.11e-18	Platelet count;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.93	0.31	1.45e-11	Lung cancer;
LGG	cis	rs2486288	0.656	rs11632778	chr15:45551056	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg02574844	chr11:5959923	NA	-0.59	-9.31	-0.4	5.04e-19	DNA methylation (variation);
LGG	cis	rs13095912	0.743	rs13076556	chr3:185339575	A/G	cg11274856	chr3:185301563	NA	0.49	7.9	0.34	2.03e-14	Systolic blood pressure;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17099445	chr17:77078091	ENGASE	0.37	6.67	0.3	7.29e-11	Electrocardiographic conduction measures;
LGG	cis	rs5742933	0.817	rs3816196	chr2:190640475	A/G	cg10453823	chr2:190539512	ANKAR	-0.46	-6.7	-0.3	6.14e-11	Ferritin levels;
LGG	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.82e-18	Common traits (Other);
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.89e-12	Life satisfaction;
LGG	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.58	-0.44	1.41e-23	Bladder cancer;
LGG	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-9.41	-0.4	2.32e-19	HDL cholesterol;
LGG	cis	rs7188861	0.768	rs60409583	chr16:11392098	C/T	cg01510278	chr16:11456238	NA	0.31	7.39	0.32	6.72e-13	HDL cholesterol;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs9297145	0.678	rs62473048	chr7:98775511	T/C	cg05967295	chr7:98741636	SMURF1	0.92	15.06	0.57	5.52e-42	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg05313129	chr8:58192883	C8orf71	-0.72	-10.06	-0.42	1.15e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs990171	0.955	rs10197881	chr2:103091715	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.95	-0.38	8.35e-18	Lymphocyte counts;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg02461776	chr11:598696	PHRF1	0.41	6.87	0.3	2.05e-11	Systemic lupus erythematosus;
LGG	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.65	-11.66	-0.48	1.05e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg15522984	chr1:182991683	LAMC1	-0.49	-10.11	-0.43	7.56e-22	Colorectal cancer;
LGG	cis	rs1497828	0.956	rs1021620	chr1:217564392	A/C	cg04411442	chr1:217543379	NA	0.46	7.85	0.34	2.85e-14	Dialysis-related mortality;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.78	-0.41	1.17e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs3813359	0.545	rs17058576	chr6:130555976	A/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.27e-14	Huntington's disease progression;
LGG	cis	rs12220238	0.915	rs10824074	chr10:75876457	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.76	0.48	3.91e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg01579765	chr21:45077557	HSF2BP	0.39	8.6	0.37	1.28e-16	Mean corpuscular volume;
LGG	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.69	0.41	2.49e-20	Menopause (age at onset);
LGG	cis	rs2046867	0.862	rs6778168	chr3:72840206	T/A	cg25664220	chr3:72788482	NA	-0.33	-9.42	-0.4	2.17e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs8062405	0.755	rs4787455	chr16:28589455	G/A	cg16576597	chr16:28551801	NUPR1	0.43	10.14	0.43	5.88e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg05163923	chr11:71159392	DHCR7	-0.59	-8.61	-0.37	1.14e-16	Vitamin D levels;
LGG	cis	rs4330281	0.669	rs6784025	chr3:17701058	A/T	cg20981856	chr3:17787350	NA	-0.39	-7.19	-0.32	2.61e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg12070911	chr6:150209640	RAET1E	0.32	7.65	0.34	1.16e-13	Lung cancer;
LGG	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg24812749	chr6:127587940	RNF146	0.64	10.92	0.45	7.4e-25	Breast cancer;
LGG	cis	rs9362426	0.639	rs5009694	chr6:88131868	A/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.46	-8.77	-0.38	3.4e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.59	0.33	1.74e-13	Lung cancer;
LGG	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	11.94	0.49	7.5e-29	Total body bone mineral density;
LGG	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.03	0.39	4.76e-18	Fuchs's corneal dystrophy;
LGG	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.08	-0.39	3.06e-18	Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18113417	chr1:54665836	CYB5RL;MRPL37	0.47	7.4	0.33	6.56e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07659893	chr17:61819838	STRADA	0.47	7.93	0.35	1.69e-14	Prudent dietary pattern;
LGG	cis	rs7927771	0.524	rs10838777	chr11:47860954	A/C	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09955859	chr1:40626914	RLF	0.43	6.9	0.31	1.71e-11	Gut microbiome composition (summer);
LGG	cis	rs4740619	0.819	rs276454	chr9:15585047	C/T	cg14451791	chr9:16040625	NA	-0.35	-8.87	-0.38	1.55e-17	Body mass index;
LGG	cis	rs4423214	1.000	rs7928249	chr11:71161063	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.0	-0.52	3.89e-33	Vitamin D levels;
LGG	cis	rs7666738	0.830	rs13149346	chr4:99009933	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg03517284	chr6:25882590	NA	-0.44	-7.19	-0.32	2.69e-12	Iron status biomarkers;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg04450456	chr4:17643702	FAM184B	-0.32	-7.15	-0.32	3.48e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg12438819	chr7:158236134	PTPRN2	-0.33	-8.85	-0.38	1.83e-17	Obesity-related traits;
LGG	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg24375607	chr4:120327624	NA	0.68	11.11	0.46	1.44e-25	Corneal astigmatism;
LGG	cis	rs1843834	0.505	rs7585047	chr2:225373897	C/T	cg22509189	chr2:225307070	NA	-0.6	-9.79	-0.41	1.1e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.3	-0.32	1.26e-12	Uric acid levels;
LGG	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.57	0.5	2.23e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2290405	0.532	rs11248050	chr4:854409	T/C	cg04824913	chr4:887549	GAK	0.81	17.25	0.63	7.31e-52	Systemic sclerosis;
LGG	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg10580341	chr11:889148	CHID1	-0.38	-6.96	-0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg20368463	chr18:77673604	PQLC1	0.43	7.5	0.33	3.19e-13	Schizophrenia;
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18876405	chr7:65276391	NA	0.54	9.73	0.41	1.8e-20	Aortic root size;
LGG	cis	rs11098499	0.754	rs11732087	chr4:120239831	A/G	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg13010199	chr12:38710504	ALG10B	0.76	16.1	0.6	1.29e-46	Heart rate;
LGG	cis	rs965513	0.901	rs7045465	chr9:100534823	A/T	cg13688889	chr9:100608707	NA	-0.47	-8.82	-0.38	2.34e-17	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs3109167	0.524	rs2713182	chr7:83097221	T/A	cg14519356	chr7:83097669	SEMA3E	-0.27	-7.84	-0.34	3.08e-14	Blood protein levels;
LGG	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg11764359	chr7:65958608	NA	0.78	14.59	0.56	6.22e-40	Aortic root size;
LGG	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg09060608	chr5:178986726	RUFY1	-0.47	-8.43	-0.36	4.52e-16	Lung cancer;
LGG	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg10760299	chr15:45669010	GATM	-0.34	-6.66	-0.3	7.74e-11	Homoarginine levels;
LGG	trans	rs10838798	0.563	rs2870080	chr11:48144224	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.8	-0.3	3.32e-11	Height;
LGG	cis	rs911263	0.581	rs61985135	chr14:68769195	C/T	cg18825221	chr14:68749962	RAD51L1	0.38	8.38	0.36	6.42e-16	Primary biliary cholangitis;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg11494091	chr17:61959527	GH2	0.52	8.15	0.35	3.38e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg15269541	chr15:43626905	ADAL	-0.44	-7.62	-0.33	1.43e-13	Lung cancer in ever smokers;
LGG	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg22681709	chr2:178499509	PDE11A	-0.49	-7.57	-0.33	2.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg02886208	chr11:14281011	SPON1	-0.36	-7.03	-0.31	7.33e-12	Sense of smell;
LGG	cis	rs3892630	0.878	rs1061686	chr19:33204544	C/T	cg22980127	chr19:33182716	NUDT19	-0.9	-12.56	-0.5	2.32e-31	Red blood cell traits;
LGG	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg13147721	chr7:65941812	NA	0.83	10.12	0.43	6.81e-22	Diabetic kidney disease;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg15971980	chr6:150254442	NA	0.46	8.71	0.38	5.51e-17	Lung cancer;
LGG	cis	rs11583043	0.708	rs36023027	chr1:101575205	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	8.25	0.36	1.64e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.59	-0.33	1.72e-13	Prostate cancer;
LGG	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg00405596	chr8:11794950	NA	0.43	6.8	0.3	3.21e-11	Neuroticism;
LGG	cis	rs2239815	0.515	rs5752810	chr22:29225523	G/A	cg02153584	chr22:29168773	CCDC117	0.6	7.37	0.32	7.94e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs72949976	0.678	rs7573232	chr2:214040425	C/T	cg08319019	chr2:214017104	IKZF2	-0.5	-7.8	-0.34	4.29e-14	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs12439619	0.508	rs17354842	chr15:82469600	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.39	7.76	0.34	5.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.35	-0.36	8.07e-16	Life satisfaction;
LGG	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17662034	chr8:74207518	RDH10	0.41	6.72	0.3	5.3e-11	Cognitive performance;
LGG	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg11846333	chr4:119757529	SEC24D	0.84	7.55	0.33	2.34e-13	Cannabis dependence symptom count;
LGG	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.42	-0.33	5.61e-13	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg13385794	chr1:248469461	NA	0.5	8.34	0.36	8.83e-16	Common traits (Other);
LGG	cis	rs4808199	0.649	rs34755166	chr19:19665581	G/A	cg03709012	chr19:19516395	GATAD2A	0.91	10.73	0.45	3.82e-24	Nonalcoholic fatty liver disease;
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	13.32	0.53	1.63e-34	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.28	0.43	1.77e-22	Mean corpuscular volume;
LGG	cis	rs7252981	0.632	rs8113682	chr19:19743730	T/G	cg11584989	chr19:19387371	SF4	-0.49	-8.31	-0.36	1.1e-15	Perceived unattractiveness to mosquitoes;
LGG	cis	rs8031584	0.918	rs61997138	chr15:31270776	C/T	cg08109568	chr15:31115862	NA	-0.53	-9.45	-0.4	1.63e-19	Huntington's disease progression;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.31	0.4	5.01e-19	Lung cancer;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg08621203	chr6:150244597	RAET1G	0.45	6.68	0.3	6.91e-11	Lung cancer;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg05091796	chr16:4465799	CORO7	-0.61	-10.07	-0.42	1.03e-21	Schizophrenia;
LGG	cis	rs4253772	0.530	rs28528366	chr22:46680696	G/A	cg00784671	chr22:46762841	CELSR1	-0.65	-7.41	-0.33	5.89e-13	LDL cholesterol;Cholesterol, total;
LGG	trans	rs2164273	0.565	rs2736387	chr8:11157371	A/C	cg02002194	chr4:3960332	NA	-0.39	-7.09	-0.31	5.1e-12	Extraversion;
LGG	cis	rs4917300	0.606	rs4917277	chr8:143095525	C/G	cg26003909	chr8:143102224	NA	0.34	6.77	0.3	4.03e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg16590910	chr6:42928470	GNMT	0.45	13.17	0.52	7.59e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10870270	0.956	rs6557	chr10:133781449	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.53	-0.5	3.1e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11239187	0.888	rs7086189	chr10:45109199	A/T	cg03916630	chr10:45065415	NA	0.35	7.64	0.33	1.26e-13	Body mass index;
LGG	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg20290983	chr6:43655470	MRPS18A	1.11	24.8	0.76	5.44e-87	IgG glycosylation;
LGG	cis	rs77372450	0.636	rs11746670	chr5:157027705	C/T	cg25387487	chr5:157003181	ADAM19	-0.55	-7.02	-0.31	8.01e-12	Bipolar disorder (body mass index interaction);
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.73	-0.34	6.83e-14	Neuroticism;
LGG	cis	rs9341808	0.718	rs9343971	chr6:80882056	C/T	cg08355045	chr6:80787529	NA	0.41	7.8	0.34	4.28e-14	Sitting height ratio;
LGG	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg02820901	chr13:113351484	ATP11A	-0.58	-6.87	-0.3	2.07e-11	Glycated hemoglobin levels;
LGG	cis	rs1577917	0.958	rs2197648	chr6:86543887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.95	-0.38	8.8e-18	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07659893	chr17:61819838	STRADA	0.5	8.08	0.35	5.73e-15	Prudent dietary pattern;
LGG	cis	rs10819861	0.621	rs4743536	chr9:98857986	T/C	cg14508093	chr9:98862825	NA	0.3	7.16	0.32	3.09e-12	Electrocardiographic traits;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12282928	0.918	rs1503174	chr11:48246336	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.59e-12	Migraine - clinic-based;
LGG	cis	rs7917772	0.582	rs7907417	chr10:104370662	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.59	-0.47	1.82e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17125944	0.686	rs7149638	chr14:53346931	T/C	cg00686598	chr14:53173677	PSMC6	-0.67	-7.23	-0.32	2.05e-12	Alzheimer's disease (late onset);
LGG	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg16339924	chr4:17578868	LAP3	0.63	10.83	0.45	1.6e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg11764359	chr7:65958608	NA	-0.63	-9.75	-0.41	1.44e-20	Aortic root size;
LGG	trans	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	cis	rs7927771	0.832	rs10838699	chr11:47386073	T/C	cg20307385	chr11:47447363	PSMC3	0.57	10.43	0.44	5.25e-23	Subjective well-being;
LGG	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg23933602	chr10:16859644	RSU1	0.67	10.15	0.43	5.67e-22	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.13	-0.58	2.64e-42	Colorectal cancer;
LGG	cis	rs7106204	0.534	rs16925305	chr11:24308924	A/G	ch.11.24196551F	chr11:24239977	NA	0.83	8.26	0.36	1.55e-15	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg13385794	chr1:248469461	NA	0.46	7.79	0.34	4.5e-14	Common traits (Other);
LGG	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.54	0.47	3.08e-27	Hemoglobin concentration;
LGG	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	12.77	0.51	3.33e-32	Response to antipsychotic treatment;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.59	-0.44	1.29e-23	Longevity;Endometriosis;
LGG	trans	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs5758659	0.652	rs5758537	chr22:42397042	G/T	cg15128208	chr22:42549153	NA	-0.38	-7.55	-0.33	2.4e-13	Cognitive function;
LGG	cis	rs139371	0.713	rs139309	chr22:39499006	C/G	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.75	-0.3	4.34e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs3845702	0.736	rs56401468	chr2:180857757	C/T	cg01881094	chr2:180872142	CWC22	1.28	16.49	0.61	2.2e-48	Schizophrenia;
LGG	cis	rs7166081	1.000	rs1444935	chr15:67635420	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.85	-0.3	2.43e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.94	0.38	9.45e-18	Bipolar disorder;
LGG	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg20578329	chr17:80767326	TBCD	-0.46	-7.95	-0.35	1.42e-14	Breast cancer;
LGG	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.24e-13	Schizophrenia;
LGG	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg12310025	chr6:25882481	NA	-0.67	-12.71	-0.51	5.98e-32	Intelligence (multi-trait analysis);
LGG	cis	rs11792861	0.926	rs72607174	chr9:111899132	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.03	0.39	4.71e-18	Menarche (age at onset);
LGG	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.18	-0.36	2.79e-15	Retinal vascular caliber;
LGG	cis	rs7208859	0.673	rs73265633	chr17:29236306	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11039798	1.000	rs11039798	chr11:48540223	G/A	cg03929089	chr4:120376271	NA	0.73	7.78	0.34	4.81e-14	Axial length;
LGG	cis	rs28719689	0.892	rs28415621	chr8:1270475	C/T	cg22761795	chr8:1265118	NA	0.81	9.02	0.39	4.85e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg09448879	chr15:79043637	NA	0.46	10.57	0.44	1.59e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg16680214	chr1:154839983	KCNN3	-0.5	-9.75	-0.41	1.45e-20	Prostate cancer;
LGG	cis	rs9814567	0.964	rs10935113	chr3:134173091	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.66	-11.38	-0.47	1.31e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.01	0.39	5.47e-18	Aortic root size;
LGG	cis	rs881375	0.967	rs10739579	chr9:123694788	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.73	0.48	5.18e-28	Rheumatoid arthritis;
LGG	cis	rs4774830	0.744	rs117596592	chr15:56188307	T/G	cg05129572	chr15:56138634	NEDD4	0.87	7.87	0.34	2.51e-14	Delta-5 desaturase activity;
LGG	cis	rs6032067	0.850	rs4566421	chr20:43783761	G/T	cg10761708	chr20:43804764	PI3	0.73	10.76	0.45	3.1e-24	Blood protein levels;
LGG	cis	rs3126085	0.935	rs12730241	chr1:152274016	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.87	-0.34	2.56e-14	Atopic dermatitis;
LGG	cis	rs9287719	0.967	rs6759714	chr2:10747207	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.37e-17	Self-reported allergy;
LGG	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg21775007	chr8:11205619	TDH	-0.43	-7.09	-0.31	5.14e-12	Mood instability;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.12	0.39	2.32e-18	Life satisfaction;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg19223190	chr17:80058835	NA	0.43	8.29	0.36	1.28e-15	Life satisfaction;
LGG	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg27053975	chr1:166958233	MAEL	-0.49	-6.66	-0.3	7.67e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08613513	chr1:52870060	ORC1L;PRPF38A	0.44	7.06	0.31	5.97e-12	Cognitive performance;
LGG	cis	rs4460629	0.650	rs11264319	chr1:155083942	T/C	cg13808842	chr1:155066096	NA	-0.29	-7.05	-0.31	6.39e-12	Serum magnesium levels;
LGG	cis	rs1401999	1.000	rs7632670	chr3:183713877	A/G	cg05044414	chr3:183734942	ABCC5	0.77	17.04	0.62	6.62e-51	Anterior chamber depth;
LGG	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	trans	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.17	0.49	9.18e-30	Type 2 diabetes;
LGG	cis	rs9788721	1.000	rs8034191	chr15:78806023	A/G	cg18825076	chr15:78729989	IREB2	-0.43	-6.83	-0.3	2.65e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.28	-0.58	5.87e-43	Chronic sinus infection;
LGG	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg24690094	chr11:67383802	NA	-0.4	-6.94	-0.31	1.32e-11	Mean corpuscular volume;
LGG	cis	rs537930	0.580	rs658621	chr5:134356158	T/C	cg24576358	chr5:134350122	NA	0.4	8.75	0.38	4.15e-17	Height;
LGG	cis	rs7241530	0.610	rs12455840	chr18:75893593	T/G	cg14642773	chr18:75888474	NA	0.48	9.13	0.39	2.11e-18	Educational attainment (years of education);
LGG	cis	rs7017914	0.967	rs34042354	chr8:71730961	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.77	-0.3	3.85e-11	Bone mineral density;
LGG	trans	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg26043149	chr18:55253948	FECH	0.95	16.3	0.6	1.53e-47	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02184643	chr11:10879647	ZBED5	0.41	7.04	0.31	7.01e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.97	-0.49	5.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07677032	chr17:61819896	STRADA	0.65	12.02	0.49	3.84e-29	Prudent dietary pattern;
LGG	cis	rs6445975	0.531	rs6804460	chr3:58365857	T/G	cg24175188	chr3:58374923	PXK	-0.54	-8.83	-0.38	2.11e-17	Systemic lupus erythematosus;
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg02524346	chr8:600233	NA	1.14	11.37	0.47	1.33e-26	IgG glycosylation;
LGG	cis	rs7666738	0.830	rs10028692	chr4:98962585	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-17.2	-0.62	1.31e-51	Personality dimensions;
LGG	cis	rs753955	0.554	rs2031587	chr13:24417335	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.41	7.38	0.32	7.41e-13	Lung cancer;
LGG	cis	rs17572109	0.666	rs11696005	chr2:219229641	T/C	cg04731861	chr2:219085781	ARPC2	0.33	6.81	0.3	3.03e-11	Platelet count;Platelet distribution width;Mean platelet volume;
LGG	trans	rs2840044	1.000	rs7212704	chr17:33898897	C/T	cg19694781	chr19:47549865	TMEM160	0.53	8.83	0.38	2.24e-17	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs1395	0.634	rs72817542	chr2:27526681	C/G	cg22903471	chr2:27725779	GCKR	-0.44	-7.37	-0.32	7.91e-13	Blood metabolite levels;
LGG	cis	rs1124376	0.935	rs12490215	chr3:20156185	A/G	cg05072819	chr3:20081367	KAT2B	0.6	8.11	0.35	4.51e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.88	-0.38	1.44e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9341835	0.740	rs10755410	chr6:64150689	G/A	cg00787780	chr6:64151745	NA	0.41	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg14541582	chr5:601475	NA	-0.49	-8.75	-0.38	3.98e-17	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs453301	0.686	rs6748	chr8:8890802	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.9	0.34	2.03e-14	Joint mobility (Beighton score);
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg08975724	chr8:8085496	FLJ10661	0.49	9.6	0.41	4.98e-20	Neuroticism;
LGG	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg06028605	chr16:24865363	SLC5A11	-0.45	-8.2	-0.36	2.37e-15	Intelligence (multi-trait analysis);
LGG	cis	rs700590	0.515	rs62380364	chr5:88107337	C/A	cg22951263	chr5:87985283	NA	-0.42	-7.49	-0.33	3.59e-13	Educational attainment (years of education);
LGG	cis	rs68170813	0.559	rs7800443	chr7:106910723	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.52	-0.44	2.38e-23	Coronary artery disease;
LGG	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-12.43	-0.5	8.6e-31	Menarche (age at onset);
LGG	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.27	-0.32	1.5e-12	Colorectal cancer;
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.78	15.29	0.58	4.91e-43	Personality dimensions;
LGG	cis	rs3780378	0.633	rs10758677	chr9:5188078	A/G	cg02405213	chr9:5042618	JAK2	-0.47	-8.25	-0.36	1.62e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs34891900	0.507	rs9605364	chr22:18127437	G/A	cg19898043	chr22:18121309	BCL2L13	0.57	9.19	0.39	1.34e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.21	-0.39	1.15e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs9354308	0.764	rs2351715	chr6:66585879	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg07414643	chr4:187882934	NA	0.54	11.31	0.47	2.28e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg25718383	chr7:130020096	CPA1	0.33	8.46	0.37	3.45e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg14926445	chr8:58193284	C8orf71	-0.91	-12.66	-0.51	9.74e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.673	rs7376505	chr4:9952744	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs172166	0.694	rs1150666	chr6:28123928	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.23	-0.32	2.02e-12	Cardiac Troponin-T levels;
LGG	cis	rs11583043	0.708	rs1335745	chr1:101546439	T/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	7.96	0.35	1.35e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2832191	0.636	rs8131283	chr21:30516796	A/G	cg24692254	chr21:30365293	RNF160	-0.73	-14.26	-0.55	1.61e-38	Dental caries;
LGG	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs644799	0.562	rs515546	chr11:95588756	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.61	10.59	0.44	1.29e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs774359	0.744	rs12115670	chr9:27486172	C/G	cg22262168	chr9:27528999	MOBKL2B	0.45	6.73	0.3	4.92e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg25319279	chr11:5960081	NA	0.46	7.52	0.33	2.88e-13	DNA methylation (variation);
LGG	trans	rs12517041	1.000	rs16899396	chr5:23304911	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs11628318	1.000	rs11628318	chr14:103040087	T/A	cg23461800	chr14:103021989	NA	-0.5	-9.2	-0.39	1.24e-18	Platelet count;
LGG	trans	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.82	0.48	2.31e-28	Mean corpuscular volume;
LGG	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg21211680	chr2:198530	NA	1.23	17.04	0.62	6.94e-51	Blood protein levels;
LGG	cis	rs35740288	0.929	rs11556865	chr15:86303180	C/G	cg07943548	chr15:86304357	KLHL25	-0.37	-7.44	-0.33	5.03e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1620921	0.524	rs12194271	chr6:161195895	A/G	cg01280913	chr6:161186852	NA	-0.51	-10.52	-0.44	2.44e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2120019	1.000	rs35577967	chr15:75354621	G/A	cg17294928	chr15:75287854	SCAMP5	-0.95	-16.95	-0.62	1.78e-50	Blood trace element (Zn levels);
LGG	cis	rs806215	0.526	rs3757780	chr7:127435520	T/G	cg25922125	chr7:127225783	GCC1	-0.48	-7.05	-0.31	6.74e-12	Type 2 diabetes;
LGG	cis	rs590121	0.876	rs650241	chr11:75277757	C/G	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.54	-0.37	1.93e-16	Coronary artery disease;
LGG	trans	rs6787172	0.622	rs9827781	chr3:158050196	T/C	cg23275840	chr4:47708675	CORIN	-0.36	-7.42	-0.33	5.75e-13	Subjective well-being;
LGG	cis	rs2153535	0.580	rs9406170	chr6:8514153	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg03433033	chr1:76189801	ACADM	0.77	12.5	0.5	4.17e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.87	0.3	2.07e-11	Resting heart rate;
LGG	cis	rs6541297	1.000	rs4846838	chr1:230281618	G/A	cg20703242	chr1:230279135	GALNT2	0.4	7.58	0.33	1.96e-13	Coronary artery disease;
LGG	cis	rs3806843	0.576	rs155358	chr5:140297032	A/T	cg19875535	chr5:140030758	IK	0.39	7.6	0.33	1.61e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg02297831	chr4:17616191	MED28	0.5	9.64	0.41	3.52e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9341808	0.558	rs2490234	chr6:80816966	G/C	cg08355045	chr6:80787529	NA	0.34	6.68	0.3	6.85e-11	Sitting height ratio;
LGG	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg16797656	chr11:68205561	LRP5	0.51	10.05	0.42	1.29e-21	Total body bone mineral density;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg07840538	chr7:99097998	ZNF394	0.38	6.71	0.3	5.54e-11	Body mass index;
LGG	cis	rs9393777	0.623	rs7756567	chr6:26481642	T/G	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs3790455	0.560	rs1171551	chr1:156472214	C/T	cg14087168	chr1:156450669	MEF2D	0.66	9.65	0.41	3.3e-20	Migraine;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27026509	chr1:36348944	EIF2C1	-0.41	-6.77	-0.3	3.86e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6462411	0.818	rs6978060	chr7:3919195	C/T	cg18022346	chr7:3920534	SDK1	-0.37	-7.2	-0.32	2.52e-12	Quantitative traits;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.58	-0.33	1.85e-13	IgG glycosylation;
LGG	cis	rs4929949	0.839	rs11041997	chr11:8602016	G/A	cg23764900	chr11:8616102	STK33	0.39	6.88	0.3	1.99e-11	Body mass index;
LGG	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.72	-13.96	-0.54	3.39e-37	Primary biliary cholangitis;
LGG	cis	rs1348850	0.958	rs1405713	chr2:178461560	G/C	cg27490568	chr2:178487706	NA	0.47	9.24	0.39	9.26e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.33	-0.32	1.02e-12	Lung cancer;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.97	0.42	2.54e-21	Tonsillectomy;
LGG	cis	rs9341808	0.655	rs9350846	chr6:80865481	T/A	cg08355045	chr6:80787529	NA	0.42	8.02	0.35	8.98e-15	Sitting height ratio;
LGG	cis	rs4363385	0.747	rs1015995	chr1:152976114	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.7	-9.69	-0.41	2.53e-20	Lung function (FEV1/FVC);
LGG	cis	rs7707921	0.522	rs12374541	chr5:81491408	A/G	cg15871215	chr5:81402204	ATG10	0.31	6.93	0.31	1.4e-11	Breast cancer;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg20387954	chr3:183756860	HTR3D	-0.42	-7.82	-0.34	3.57e-14	Anterior chamber depth;
LGG	cis	rs988958	0.675	rs11894053	chr2:42229545	C/T	cg27252766	chr2:42229092	NA	-0.54	-8.37	-0.36	6.76e-16	Hypospadias;
LGG	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.05	-0.31	6.34e-12	Iron status biomarkers;
LGG	cis	rs9783347	0.961	rs4150588	chr11:18360131	G/A	cg15585147	chr11:18324498	HPS5	0.43	9.18	0.39	1.43e-18	Pancreatic cancer;
LGG	cis	rs7503807	0.837	rs9915667	chr17:78754340	A/G	cg09596252	chr17:78655493	RPTOR	-0.43	-7.61	-0.33	1.53e-13	Obesity;
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.54	-0.33	2.49e-13	Morning vs. evening chronotype;
LGG	cis	rs10979	1.000	rs9484769	chr6:143896719	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.58	-0.5	2.1e-31	Hypospadias;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg05863683	chr7:1912471	MAD1L1	0.39	7.39	0.32	7.03e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg16103275	chr6:290800	DUSP22	0.49	7.95	0.35	1.44e-14	Menopause (age at onset);
LGG	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg18876405	chr7:65276391	NA	-0.68	-13.09	-0.52	1.63e-33	Calcium levels;
LGG	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg26874229	chr2:105853672	NA	-0.32	-6.99	-0.31	9.63e-12	Type 2 diabetes;
LGG	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.33	0.7	8.12e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg00080972	chr5:178986291	RUFY1	0.47	7.33	0.32	1.02e-12	Lung cancer;
LGG	cis	rs774359	0.797	rs774354	chr9:27515967	A/G	cg14173147	chr9:27528300	MOBKL2B	0.43	9.06	0.39	3.64e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.59e-22	Height;
LGG	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg00343986	chr7:65444356	GUSB	0.39	6.65	0.3	8.42e-11	Aortic root size;
LGG	cis	rs721399	0.539	rs7460653	chr8:18266983	G/C	cg18736775	chr8:18248649	NAT2	-0.76	-11.7	-0.48	7.03e-28	Blood metabolite levels;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	cis	rs9487094	0.644	rs910730	chr6:109768295	G/A	cg01125227	chr6:109776195	MICAL1	0.4	6.97	0.31	1.12e-11	Height;
LGG	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg14541582	chr5:601475	NA	-0.69	-10.74	-0.45	3.64e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs4076764	0.958	rs6688997	chr1:163411562	G/A	cg06092702	chr1:163392909	NA	-0.46	-8.14	-0.35	3.67e-15	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02717437	chr18:14132207	ZNF519	0.44	7.06	0.31	5.94e-12	Cognitive performance;
LGG	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg00031303	chr3:195681400	NA	0.52	8.26	0.36	1.58e-15	Pancreatic cancer;
LGG	cis	rs1978968	0.827	rs5992134	chr22:18433994	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-9.58	-0.41	5.75e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.44	-0.37	3.95e-16	Tonsillectomy;
LGG	cis	rs7691216	0.514	rs7694080	chr4:86134264	C/T	cg21153358	chr4:86049133	NA	-0.34	-8.2	-0.36	2.35e-15	IgG glycosylation;
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg14092988	chr3:52407081	DNAH1	0.32	8.39	0.36	5.94e-16	Bipolar disorder;
LGG	cis	rs4742903	0.875	rs7037174	chr9:106924871	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.27	0.36	1.48e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs10267417	0.603	rs9654952	chr7:19945201	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	6.82	0.3	2.9100000000000002e-11	Night sleep phenotypes;
LGG	cis	rs498079	0.544	rs509904	chr6:133517082	A/T	cg06181518	chr6:133562196	EYA4	-0.41	-7.25	-0.32	1.75e-12	Total body bone mineral density;
LGG	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.46e-32	Uric acid levels;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg10950524	chr7:2139216	MAD1L1	0.31	6.71	0.3	5.54e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs56235845	0.694	rs4532376	chr5:176774403	G/A	cg17509989	chr5:176798049	RGS14	0.65	10.74	0.45	3.41e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs9309473	1.000	rs13431267	chr2:73782200	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.69	-0.34	9.02e-14	Metabolite levels;
LGG	cis	rs6867032	0.958	rs9312970	chr5:2002415	C/A	cg26168224	chr5:2018326	NA	-1.13	-21.02	-0.7	2.17e-69	Gut microbiome composition (winter);
LGG	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs4936894	0.500	rs4331103	chr11:124146921	T/C	cg27160556	chr11:124181099	OR8D1	-0.48	-11.12	-0.46	1.26e-25	Aging (time to death);
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg00800038	chr16:89945340	TCF25	-0.58	-8.19	-0.36	2.54e-15	Interleukin-17 levels;
LGG	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg23188684	chr11:67383651	NA	-0.41	-6.75	-0.3	4.49e-11	Mean corpuscular volume;
LGG	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9905704	0.647	rs12943705	chr17:57097047	T/C	cg05425664	chr17:57184151	TRIM37	0.45	7.17	0.32	2.98e-12	Testicular germ cell tumor;
LGG	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	7.35	0.32	9.18e-13	Height;
LGG	cis	rs9324022	0.860	rs72698720	chr14:101178715	C/G	cg01194073	chr14:101175302	NA	0.44	7.02	0.31	8.08e-12	Plateletcrit;
LGG	cis	rs9487094	0.626	rs3799845	chr6:110027717	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.77	0.34	4.95e-14	Height;
LGG	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.06	-0.42	1.14e-21	Type 2 diabetes;
LGG	cis	rs36051895	0.623	rs12720	chr9:5231712	T/A	cg02405213	chr9:5042618	JAK2	-0.79	-13.84	-0.54	1.07e-36	Pediatric autoimmune diseases;
LGG	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg17691542	chr6:26056736	HIST1H1C	0.61	9.98	0.42	2.22e-21	Iron status biomarkers;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.79	-0.45	2.32e-24	Neuroticism;
LGG	cis	rs12580194	0.593	rs60774348	chr12:55757717	A/G	cg19537932	chr12:55886519	OR6C68	-0.57	-10.46	-0.44	3.93e-23	Cancer;
LGG	cis	rs367943	0.666	rs10041899	chr5:112724742	A/T	cg12552261	chr5:112820674	MCC	0.57	10.28	0.43	1.89e-22	Type 2 diabetes;
LGG	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.97	0.82	6.69e-115	Cognitive function;
LGG	cis	rs6430585	0.528	rs309159	chr2:136684940	C/T	cg07169764	chr2:136633963	MCM6	1.19	21.57	0.71	6.14e-72	Corneal structure;
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14159672	chr1:205819179	PM20D1	0.52	9.75	0.41	1.55e-20	Menarche (age at onset);
LGG	cis	rs4006360	0.547	rs9892487	chr17:39252969	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.18	-0.46	7.29e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg09165964	chr15:75287851	SCAMP5	-0.52	-7.04	-0.31	7.07e-12	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LGG	cis	rs12282928	0.959	rs11039637	chr11:48306980	C/T	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.8e-12	Migraine - clinic-based;
LGG	cis	rs4938330	0.608	rs2239011	chr11:117088994	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.63	-0.33	1.39e-13	Blood protein levels;
LGG	cis	rs10465746	1.000	rs10465746	chr1:84387632	T/G	cg10977910	chr1:84465055	TTLL7	0.52	9.43	0.4	1.92e-19	Obesity-related traits;
LGG	cis	rs679087	0.659	rs302318	chr12:29921667	T/C	cg14258853	chr12:29935411	TMTC1	-0.37	-7.85	-0.34	2.95e-14	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17157630	chr2:74648928	WDR54	0.44	6.66	0.3	7.64e-11	Gut microbiome composition (summer);
LGG	cis	rs12980942	0.872	rs2304230	chr19:41774064	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.5	7.08	0.31	5.33e-12	Coronary artery disease;
LGG	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg02975922	chr3:195473998	MUC4	0.46	7.33	0.32	1e-12	Mean corpuscular volume;
LGG	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.21	-0.36	2.19e-15	Schizophrenia;
LGG	cis	rs28595532	0.844	rs115202072	chr4:119732458	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs1497828	1.000	rs2646846	chr1:217564117	G/A	cg04411442	chr1:217543379	NA	0.46	7.83	0.34	3.32e-14	Dialysis-related mortality;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.45	-0.4	1.75e-19	Personality dimensions;
LGG	cis	rs10924309	0.640	rs6700599	chr1:245854047	G/T	cg00036263	chr1:245852353	KIF26B	-0.44	-6.9	-0.31	1.74e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg03575189	chr17:44344142	NA	0.46	6.75	0.3	4.5e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg26655873	chr3:72818019	SHQ1	0.35	7.07	0.31	5.79e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.93	0.35	1.6e-14	Colorectal cancer;
LGG	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg10224037	chr5:178157518	ZNF354A	0.73	11.37	0.47	1.4e-26	Neutrophil percentage of white cells;
LGG	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg26850624	chr5:429559	AHRR	-0.37	-8.13	-0.35	3.94e-15	Cystic fibrosis severity;
LGG	cis	rs6963495	0.818	rs73190149	chr7:105152793	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7928758	0.943	rs79416046	chr11:134270003	C/T	cg25213107	chr11:134282864	B3GAT1	1.14	13.8	0.54	1.51e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	trans	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.76	-0.34	5.41e-14	Resting heart rate;
LGG	cis	rs9549367	0.789	rs12584813	chr13:113895443	C/G	cg18105134	chr13:113819100	PROZ	-0.66	-13.6	-0.53	1.11e-35	Platelet distribution width;
LGG	cis	rs3820928	1.000	rs9288617	chr2:227762815	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.36	-0.32	8.54e-13	Pulmonary function;
LGG	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg00149659	chr3:10157352	C3orf10	0.57	8.2	0.36	2.45e-15	Alzheimer's disease;
LGG	trans	rs5756813	0.661	rs2246503	chr22:38204540	C/A	cg19894588	chr14:64061835	NA	-0.64	-10.21	-0.43	3.18e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7216064	0.953	rs1599859	chr17:65837193	C/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.89	-0.38	1.35e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.03	-0.31	7.33e-12	Bipolar disorder;
LGG	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.96	0.31	1.16e-11	Parkinson's disease;
LGG	cis	rs7666738	0.830	rs6811940	chr4:98777898	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.74	0.34	6.45e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4742903	0.967	rs2122577	chr9:106866703	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.25	0.36	1.66e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg17545662	chr6:170176663	C6orf70	0.68	8.52	0.37	2.34e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.85	0.3	2.36e-11	Carotid intima media thickness;
LGG	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.13	0.35	3.9e-15	Retinal vascular caliber;
LGG	cis	rs7917772	0.503	rs11191328	chr10:104305185	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	7.84e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs11229555	0.874	rs11605297	chr11:58296806	G/A	cg15696309	chr11:58395628	NA	-0.99	-17.58	-0.63	2.27e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9462027	0.883	rs6941110	chr6:34791334	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.37	-0.47	1.43e-26	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg15556689	chr8:8085844	FLJ10661	-0.56	-10.31	-0.43	1.45e-22	Triglycerides;
LGG	cis	rs4430311	0.759	rs12691548	chr1:243820128	A/G	cg25706552	chr1:244017396	NA	-0.63	-14.97	-0.57	1.27e-41	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg22920501	chr2:26401640	FAM59B	0.41	7.73	0.34	6.98e-14	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.37	-0.43	8.31e-23	Initial pursuit acceleration;
LGG	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg15145296	chr3:125709740	NA	-0.6	-7.69	-0.34	9.17e-14	Blood pressure (smoking interaction);
LGG	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg08498830	chr11:832797	CD151	-0.45	-7.28	-0.32	1.41e-12	Mean platelet volume;
LGG	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg05444541	chr17:17804740	TOM1L2	-0.75	-18.17	-0.65	4.3e-56	Total body bone mineral density;
LGG	cis	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.78	-0.57	8.83e-41	IgG glycosylation;
LGG	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg26811252	chr16:29126840	RRN3P2	0.63	9.87	0.42	5.57e-21	Menopause (age at onset);
LGG	cis	rs55794721	0.509	rs12027135	chr1:25775733	A/T	cg02931644	chr1:25747376	RHCE	0.42	9.27	0.4	7.31e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs1003719	0.591	rs2835618	chr21:38503126	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.7	-12.77	-0.51	3.19e-32	Eye color traits;
LGG	cis	rs9640161	0.659	rs77354576	chr7:150013300	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.69	-14.44	-0.56	2.82e-39	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1109114	0.844	rs12659695	chr5:148641093	A/G	cg06539116	chr5:148597365	ABLIM3	0.48	11.52	0.47	3.55e-27	Body mass index;
LGG	cis	rs2797369	0.656	rs72946427	chr6:101353332	A/G	cg27451362	chr6:101846650	GRIK2	0.77	10.67	0.44	6.72e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs2455601	0.671	rs10840135	chr11:8879794	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.77	-0.41	1.31e-20	Schizophrenia;
LGG	cis	rs6499255	1.000	rs7189424	chr16:69782746	G/A	cg00738113	chr16:70207722	CLEC18C	-0.3	-6.67	-0.3	7.23e-11	IgE levels;
LGG	cis	rs4917300	0.606	rs4917292	chr8:143115553	T/C	cg26003909	chr8:143102224	NA	-0.35	-6.81	-0.3	3.01e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.27	0.67	3.4e-61	Platelet count;
LGG	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg06634786	chr22:41940651	POLR3H	-0.79	-12.73	-0.51	4.91e-32	Vitiligo;
LGG	cis	rs7508	0.694	rs7830490	chr8:17922414	A/G	cg18067069	chr8:17937731	ASAH1	-0.39	-9.09	-0.39	2.88e-18	Atrial fibrillation;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.4	-7.81	-0.34	3.87e-14	Schizophrenia;
LGG	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg02297831	chr4:17616191	MED28	0.51	9.7	0.41	2.18e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1707322	0.682	rs10890334	chr1:46100378	A/T	cg03146154	chr1:46216737	IPP	0.57	10.89	0.45	9.75e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg24829409	chr8:58192753	C8orf71	-0.86	-13.6	-0.53	1.1e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg11693508	chr17:37793320	STARD3	0.63	9.4	0.4	2.54e-19	Bipolar disorder;
LGG	cis	rs933688	1.000	rs60513756	chr5:90727692	A/C	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.84	0.62	5.42e-50	Smoking behavior;
LGG	cis	rs2540226	0.655	rs2716681	chr2:39932862	G/A	cg02886589	chr2:39892450	TMEM178	0.26	6.94	0.31	1.37e-11	Personality dimensions;
LGG	cis	rs4727027	0.866	rs2373437	chr7:148779032	T/C	cg23583168	chr7:148888333	NA	-0.83	-15.75	-0.59	4.63e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9921192	0.967	rs251737	chr16:4318305	C/T	cg00021532	chr16:4324280	TFAP4	0.48	12.56	0.5	2.39e-31	Prostate-specific antigen levels;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	9.22	0.39	1.04e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg20608306	chr11:116969690	SIK3	0.42	13.44	0.53	5.08e-35	Blood protein levels;
LGG	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg17927777	chr20:33865990	NA	0.67	10.04	0.42	1.39e-21	Attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs975739	0.872	rs1146927	chr13:78365944	A/G	cg07847733	chr13:78271382	SLAIN1	0.38	6.9	0.31	1.72e-11	Hair color;
LGG	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.46	0.47	6.37e-27	Schizophrenia;
LGG	cis	rs713587	0.646	rs2384061	chr2:25135620	C/T	cg04586622	chr2:25135609	ADCY3	0.45	12.23	0.49	5.56e-30	Body mass index in non-asthmatics;
LGG	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.74	-0.38	4.38e-17	Bone mineral density;
LGG	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg12560992	chr17:57184187	TRIM37	-0.87	-15.27	-0.58	6.37e-43	Intelligence (multi-trait analysis);
LGG	trans	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.44	-0.33	4.85e-13	Educational attainment (years of education);
LGG	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.26	0.43	2.07e-22	Iron status biomarkers;
LGG	trans	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.79	-0.3	3.38e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs45544231	0.544	rs7193453	chr16:52565150	C/T	cg09051775	chr16:52580266	TOX3	-0.42	-7.24	-0.32	1.85e-12	Restless legs syndrome;
LGG	cis	rs941873	0.772	rs7920127	chr10:81122914	T/C	cg09469691	chr10:81107165	PPIF	0.56	9.64	0.41	3.75e-20	Height;
LGG	cis	rs3126085	0.935	rs2152862	chr1:152259742	T/C	cg26876637	chr1:152193138	HRNR	-0.54	-8.79	-0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs17604090	0.793	rs17150665	chr7:29688860	T/G	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg26384229	chr12:38710491	ALG10B	0.71	14.49	0.56	1.61e-39	Heart rate;
LGG	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg00531865	chr16:30841666	NA	-0.62	-13.31	-0.53	1.93e-34	Multiple myeloma;
LGG	cis	rs2273669	0.667	rs12210444	chr6:109305743	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs600231	0.508	rs11227201	chr11:65242548	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.65	-0.37	8.55e-17	Bone mineral density;
LGG	cis	rs7219021	0.674	rs4793990	chr17:46960760	G/A	cg16584676	chr17:46985605	UBE2Z	0.42	6.95	0.31	1.25e-11	Schizophrenia or bipolar disorder;
LGG	trans	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.18e-13	Heart rate;
LGG	trans	rs72991	0.639	rs10750187	chr11:121230225	A/G	cg27192990	chr6:129479024	LAMA2	-0.59	-9.35	-0.4	3.81e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg18110333	chr6:292329	DUSP22	-0.69	-11.77	-0.48	3.63e-28	Menopause (age at onset);
LGG	cis	rs12210905	0.925	rs17345718	chr6:26964258	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg02725872	chr8:58115012	NA	-0.87	-11.78	-0.48	3.23e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03576123	chr11:487126	PTDSS2	-1.31	-17.33	-0.63	3.17e-52	Body mass index;
LGG	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	10.22	0.43	3.1e-22	Retinal vascular caliber;
LGG	cis	rs7998202	0.667	rs282584	chr13:113349819	C/T	cg02820901	chr13:113351484	ATP11A	-0.59	-7.27	-0.32	1.57e-12	Glycated hemoglobin levels;
LGG	cis	rs7932354	0.528	rs6485739	chr11:47145072	G/A	cg03339077	chr11:47165057	C11orf49	-0.54	-10.21	-0.43	3.2e-22	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.79	12.56	0.5	2.49e-31	Alzheimer's disease;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.5	-7.9	-0.34	2.12e-14	Tonsillectomy;
LGG	cis	rs9457247	0.534	rs7750593	chr6:167387359	C/G	cg18261144	chr6:167370276	RNASET2	-0.38	-7.62	-0.33	1.43e-13	Crohn's disease;
LGG	cis	rs72781680	0.898	rs55846516	chr2:24158003	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg07959490	chr17:80112427	CCDC57	0.46	9.1	0.39	2.75e-18	Life satisfaction;
LGG	cis	rs10751667	0.666	rs6597962	chr11:976351	C/T	cg22143635	chr11:980567	AP2A2	0.44	8.13	0.35	4.09e-15	Alzheimer's disease (late onset);
LGG	cis	rs80282103	0.867	rs80254477	chr10:1077387	T/G	cg08668510	chr10:1095578	IDI1	0.76	7.78	0.34	4.75e-14	Glomerular filtration rate (creatinine);
LGG	trans	rs79976124	0.837	rs12194087	chr6:66644399	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.37	0.5	1.38e-30	Type 2 diabetes;
LGG	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg16850897	chr7:100343110	ZAN	-0.55	-7.51	-0.33	3.09e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg09998033	chr7:158218633	PTPRN2	0.46	8.43	0.36	4.5e-16	Obesity-related traits;
LGG	cis	rs4740619	0.740	rs2185663	chr9:15782760	A/T	cg14451791	chr9:16040625	NA	0.34	8.78	0.38	3.25e-17	Body mass index;
LGG	cis	rs870825	0.860	rs72703519	chr4:185602707	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	cis	rs6489882	0.867	rs10850098	chr12:113362058	C/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.26	-0.32	1.66e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.43	-7.53	-0.33	2.68e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg21798802	chr22:38057573	PDXP	0.61	14.09	0.55	9.33e-38	Fat distribution (HIV);
LGG	cis	rs13421350	0.579	rs79416408	chr2:173303800	C/T	cg15021238	chr2:173305865	ITGA6	-0.82	-9.3	-0.4	5.37e-19	Diabetic kidney disease;
LGG	cis	rs9733	0.715	rs12402006	chr1:150869829	G/A	cg13175981	chr1:150552382	MCL1	0.51	8.18	0.36	2.78e-15	Tonsillectomy;
LGG	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg19748678	chr4:122722346	EXOSC9	0.59	11.47	0.47	5.79e-27	Type 2 diabetes;
LGG	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.27	-0.32	1.53e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10155981	0.510	rs4719704	chr7:22588827	T/G	cg06110297	chr7:22589830	NA	-0.69	-6.84	-0.3	2.46e-11	Bilirubin levels;
LGG	cis	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg12826209	chr6:26865740	GUSBL1	0.78	6.68	0.3	6.88e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4629710	0.592	rs9492868	chr6:131542238	A/C	cg12606694	chr6:131520996	AKAP7	0.51	8.32	0.36	9.7e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs3741151	0.686	rs60860405	chr11:73248673	A/C	cg17517138	chr11:73019481	ARHGEF17	0.67	7.02	0.31	7.83e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg00666640	chr1:248458726	OR2T12	0.6	9.73	0.41	1.71e-20	Common traits (Other);
LGG	cis	rs2276314	0.802	rs9963714	chr18:33592056	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.86	0.34	2.74e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs17253792	0.822	rs10483643	chr14:56089931	G/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg15596359	chr8:11213517	TDH	0.41	8.4	0.36	5.52e-16	Retinal vascular caliber;
LGG	cis	rs9354308	0.868	rs7743811	chr6:66540028	C/T	cg07460842	chr6:66804631	NA	-0.48	-7.24	-0.32	1.87e-12	Metabolite levels;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22433210	chr17:43662623	NA	0.91	15.15	0.58	2.03e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.64e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.76	-0.41	1.41e-20	Platelet count;
LGG	cis	rs870825	0.616	rs28416641	chr4:185617999	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19462523	chr3:181429908	SOX2;SOX2OT	-0.51	-7.36	-0.32	8.22e-13	Systemic lupus erythematosus;
LGG	cis	rs12618769	0.597	rs12617721	chr2:99083892	G/T	cg18455616	chr2:99124870	INPP4A	-0.29	-8.51	-0.37	2.41e-16	Bipolar disorder;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg03100196	chr7:143077761	ZYX	-0.47	-6.65	-0.3	8.28e-11	Beard thickness;
LGG	cis	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg06521331	chr12:34319734	NA	-0.41	-7.29	-0.32	1.31e-12	Morning vs. evening chronotype;
LGG	cis	rs9397585	0.857	rs9384075	chr6:153387390	A/T	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs7089973	0.584	rs4752322	chr10:116613258	A/C	cg03647239	chr10:116582469	FAM160B1	0.43	7.64	0.33	1.27e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg12658694	chr1:38397304	INPP5B	0.44	9.18	0.39	1.47e-18	Coronary artery disease;
LGG	cis	rs35740288	0.651	rs34257708	chr15:86184267	G/A	cg04173714	chr15:86211321	AKAP13	0.47	7.17	0.32	3.04e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4684776	1.000	rs34267990	chr3:11439490	G/A	cg24705426	chr3:11550659	ATG7	-0.41	-7.52	-0.33	2.84e-13	Small vessel stroke;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.28	-0.32	1.43e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Colorectal cancer;
LGG	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.74e-21	Diabetic retinopathy;
LGG	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.32	0.72	1.9e-75	Homoarginine levels;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg15971980	chr6:150254442	NA	0.44	8.42	0.36	4.67e-16	Lung cancer;
LGG	cis	rs62238980	0.614	rs78907591	chr22:32459673	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.76	-0.34	5.62e-14	IgG glycosylation;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.16	-0.35	3.22e-15	Schizophrenia;
LGG	cis	rs5742933	0.744	rs13002216	chr2:190611084	T/C	cg04003228	chr2:190539410	ANKAR	-0.48	-7.12	-0.31	4.22e-12	Ferritin levels;
LGG	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.01	0.83	1.98e-119	Chronic sinus infection;
LGG	cis	rs1873147	0.569	rs58819603	chr15:63310866	T/A	cg12160578	chr15:63334699	TPM1	0.57	7.89	0.34	2.19e-14	Orofacial clefts;
LGG	cis	rs1927702	0.593	rs2185665	chr9:15828641	C/G	cg14451791	chr9:16040625	NA	0.31	7.73	0.34	6.95e-14	Body mass index;
LGG	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.39	-0.32	7.01e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12579753	0.719	rs12369450	chr12:82266940	A/G	cg07988820	chr12:82153109	PPFIA2	-0.56	-8.22	-0.36	2.05e-15	Resting heart rate;
LGG	cis	rs7617773	0.539	rs6779517	chr3:48384388	C/T	cg11946769	chr3:48343235	NME6	0.48	8.11	0.35	4.56e-15	Coronary artery disease;
LGG	cis	rs858239	0.509	rs6975524	chr7:23186452	T/C	cg23682824	chr7:23144976	KLHL7	0.41	6.77	0.3	3.92e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4950322	0.571	rs4373796	chr1:146788460	C/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs4538187	0.906	rs11695421	chr2:63954237	T/C	cg02541582	chr2:64069798	UGP2	-0.55	-12.69	-0.51	7.32e-32	Systolic blood pressure;
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	7.92	0.35	1.8e-14	Tonsillectomy;
LGG	cis	rs2204008	0.694	rs11179394	chr12:38210389	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.82	-0.34	3.6e-14	Bladder cancer;
LGG	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14829155	chr15:31115871	NA	-0.67	-11.23	-0.46	4.93e-26	Huntington's disease progression;
LGG	cis	rs35740288	0.787	rs2291047	chr15:86225805	A/G	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.28e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg10253484	chr15:75165896	SCAMP2	0.44	7.07	0.31	5.93e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.93	0.38	1.03e-17	Common traits (Other);
LGG	cis	rs7336332	0.598	rs12018313	chr13:28012266	C/A	cg01674679	chr13:27998804	GTF3A	-0.65	-8.4	-0.36	5.33e-16	Weight;
LGG	cis	rs1538970	0.816	rs3790583	chr1:45956828	C/G	cg05343316	chr1:45956843	TESK2	0.75	13.25	0.52	3.44e-34	Platelet count;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18500714	chr14:100706288	YY1	0.41	6.96	0.31	1.19e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg20916646	chr4:852691	GAK	0.62	10.39	0.43	7.2e-23	Sjögren's syndrome;
LGG	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.15	0.39	1.83e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg25486957	chr4:152246857	NA	-0.49	-8.18	-0.36	2.82e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7166081	1.000	rs58074225	chr15:67545892	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.18	-0.32	2.72e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9972944	0.702	rs6416946	chr17:63763967	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.44	-0.37	4.1e-16	Total body bone mineral density;
LGG	cis	rs12497850	0.931	rs6791542	chr3:48787219	A/G	cg07636037	chr3:49044803	WDR6	1.06	25.66	0.77	5.38e-91	Parkinson's disease;
LGG	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg03929089	chr4:120376271	NA	0.72	8.37	0.36	7e-16	Axial length;
LGG	cis	rs1878931	0.520	rs2015640	chr16:3465018	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.76	-11.8	-0.48	2.93e-28	Body mass index (adult);
LGG	cis	rs599083	0.829	rs314751	chr11:68179560	C/T	cg16797656	chr11:68205561	LRP5	-0.52	-9.52	-0.4	9.66e-20	Bone mineral density (spine);
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.63	-0.41	3.95e-20	Lung cancer;
LGG	cis	rs875971	0.545	rs316324	chr7:65610614	A/G	cg11764359	chr7:65958608	NA	-0.64	-9.82	-0.42	8.38e-21	Aortic root size;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06679752	chr13:50367340	KPNA3	0.51	7.57	0.33	2.08e-13	Gut microbiome composition (summer);
LGG	cis	rs2732480	0.577	rs2634681	chr12:48733084	C/T	cg24011408	chr12:48396354	COL2A1	-0.47	-7.59	-0.33	1.74e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs12042938	0.902	rs1094658	chr1:231773397	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	10.92	0.45	7.4e-25	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs11018904	0.906	rs35286339	chr11:89965679	A/G	cg16176437	chr11:89678848	NA	0.41	6.94	0.31	1.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.44	0.44	4.76e-23	Cognitive test performance;
LGG	trans	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg27661571	chr11:113659931	NA	-0.57	-7.75	-0.34	5.93e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs4700695	0.719	rs27588	chr5:65459360	C/A	cg21114390	chr5:65439923	SFRS12	-0.72	-10.46	-0.44	3.84e-23	Facial morphology (factor 19);
LGG	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	10.1	0.42	8.51e-22	Height;
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg14403583	chr14:105418241	AHNAK2	-0.76	-15.38	-0.58	2.1e-43	Rheumatoid arthritis;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg19077165	chr18:44547161	KATNAL2	0.59	11.0	0.46	3.75e-25	Personality dimensions;
LGG	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.75	-13.84	-0.54	1.05e-36	Blood protein levels;
LGG	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg05941027	chr17:61774174	LIMD2	-0.28	-6.67	-0.3	7.25e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg12386194	chr3:101231763	SENP7	0.41	7.6	0.33	1.69e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7939886	0.920	rs77561310	chr11:56062586	G/A	cg15704280	chr7:45808275	SEPT13	0.81	7.25	0.32	1.82e-12	Myopia (pathological);
LGG	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg17545662	chr6:170176663	C6orf70	0.7	8.95	0.38	8.96e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.49	-0.47	4.9e-27	Schizophrenia;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03264133	chr6:25882463	NA	-0.95	-20.11	-0.68	4.07e-65	Urate levels;
LGG	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg01631408	chr1:248437212	OR2T33	-0.55	-9.97	-0.42	2.39e-21	Common traits (Other);
LGG	cis	rs7444	0.941	rs2298429	chr22:21983260	A/G	cg15846791	chr22:21984385	YDJC	-0.44	-6.73	-0.3	4.92e-11	Systemic lupus erythematosus;
LGG	cis	rs12431410	0.550	rs2350137	chr14:60197269	A/G	cg07950296	chr14:60194823	RTN1	0.4	7.74	0.34	6.36e-14	Schizophrenia;
LGG	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg07061783	chr6:25882402	NA	0.45	7.86	0.34	2.72e-14	Blood metabolite levels;
LGG	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg21055462	chr7:100276975	NA	0.38	8.74	0.38	4.47e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7149337	1.000	rs4261445	chr14:51723540	G/A	cg23942311	chr14:51606299	NA	0.33	7.46	0.33	4.35e-13	Cancer;
LGG	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg13147721	chr7:65941812	NA	0.79	9.72	0.41	1.92e-20	Diabetic kidney disease;
LGG	cis	rs7107174	1.000	rs4492844	chr11:78026516	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg08400814	chr5:56204995	C5orf35	-0.41	-7.39	-0.32	6.83e-13	Initial pursuit acceleration;
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg11764359	chr7:65958608	NA	-0.73	-12.87	-0.51	1.29e-32	Aortic root size;
LGG	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg05793240	chr7:2802953	GNA12	0.28	6.72	0.3	5.37e-11	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16344026	chr5:149109979	PPARGC1B	-0.42	-7.05	-0.31	6.38e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.79	-0.41	1.04e-20	Personality dimensions;
LGG	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg15269541	chr15:43626905	ADAL	-0.44	-7.62	-0.33	1.45e-13	Lung cancer in ever smokers;
LGG	cis	rs4819052	0.724	rs9753987	chr21:46661389	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg04568710	chr12:38710424	ALG10B	0.38	8.23	0.36	1.99e-15	Bladder cancer;
LGG	cis	rs9357271	0.955	rs58424668	chr6:38339506	A/T	cg07362130	chr6:38359646	BTBD9	-0.45	-9.4	-0.4	2.45e-19	Restless legs syndrome;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.31	7.04e-12	Bipolar disorder;
LGG	cis	rs7949566	0.652	rs4935968	chr11:126290950	C/T	cg05055844	chr11:126275997	ST3GAL4	0.34	6.8	0.3	3.33e-11	Platelet distribution width;Mean platelet volume;
LGG	trans	rs35110281	0.805	rs2838330	chr21:45023876	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.48	0.44	3.32e-23	Mean corpuscular volume;
LGG	cis	rs2282300	0.739	rs1765133	chr11:30339400	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-6.69	-0.3	6.5500000000000006e-11	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.41	-0.44	6.31e-23	Neuroticism;
LGG	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17767392	0.846	rs34281405	chr14:71780587	G/A	cg02058870	chr14:72053146	SIPA1L1	0.4	8.34	0.36	8.28e-16	Mitral valve prolapse;
LGG	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg00012203	chr2:219082015	ARPC2	-0.68	-12.13	-0.49	1.35e-29	Colorectal cancer;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.05	-0.35	7.26e-15	Total body bone mineral density;
LGG	cis	rs7129556	0.737	rs72949616	chr11:77464370	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.36e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg26412358	chr1:26503933	CNKSR1	0.27	6.98	0.31	1.06e-11	Height;
LGG	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg22920501	chr2:26401640	FAM59B	0.45	9.22	0.39	1.04e-18	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg08305652	chr11:111469057	NA	0.36	7.37	0.32	8.08e-13	Primary sclerosing cholangitis;
LGG	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg11317459	chr13:21872234	NA	1.39	27.17	0.78	6.87e-98	White matter hyperintensity burden;
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.56	0.37	1.64e-16	Neuroticism;
LGG	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg17644776	chr2:200775616	C2orf69	-0.68	-9.13	-0.39	2.13e-18	Schizophrenia;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg02985366	chr16:32360428	NA	-0.45	-7.01	-0.31	8.75e-12	Menopause (age at onset);
LGG	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg26384229	chr12:38710491	ALG10B	0.89	19.95	0.68	2.4e-64	Bladder cancer;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg18876405	chr7:65276391	NA	0.54	9.61	0.41	4.75e-20	Aortic root size;
LGG	cis	rs7765175	0.698	rs7762238	chr6:113682472	G/T	cg26552650	chr6:113682475	NA	0.34	7.36	0.32	8.25e-13	Coronary artery calcification;
LGG	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg04691961	chr3:161091175	C3orf57	-0.64	-14.75	-0.57	1.25e-40	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.87e-35	Skin colour saturation;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18402987	chr7:1209562	NA	0.41	7.49	0.33	3.63e-13	Longevity;Endometriosis;
LGG	cis	rs950027	0.620	rs1049518	chr15:45653367	G/A	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg11764359	chr7:65958608	NA	0.73	13.08	0.52	1.71e-33	Aortic root size;
LGG	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.49	0.37	2.82e-16	Dupuytren's disease;
LGG	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg03517284	chr6:25882590	NA	-0.43	-7.07	-0.31	5.71e-12	Iron status biomarkers;
LGG	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.54	-9.66	-0.41	3.09e-20	Lymphocyte percentage of white cells;
LGG	cis	rs9287719	0.967	rs4453662	chr2:10739128	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.96e-13	Prostate cancer;
LGG	cis	rs11018904	0.768	rs56160356	chr11:89987280	G/C	cg16176437	chr11:89678848	NA	0.48	7.09	0.31	5.1e-12	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg23422044	chr7:1970798	MAD1L1	-0.76	-12.7	-0.51	6.5e-32	Bipolar disorder;
LGG	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg17971929	chr21:40555470	PSMG1	-0.72	-13.51	-0.53	2.81e-35	Cognitive function;
LGG	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.99	-0.31	9.47e-12	Uric acid levels;
LGG	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08045932	chr20:61659980	NA	0.59	12.77	0.51	3.24e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-9.46	-0.4	1.5700000000000001e-19	Personality dimensions;
LGG	cis	rs9880211	0.898	rs9866840	chr3:136029258	G/C	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.31	1.81e-11	Body mass index;Height;
LGG	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg08807101	chr21:30365312	RNF160	0.92	19.48	0.67	3.44e-62	Dental caries;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.56	-0.44	1.7e-23	IgG glycosylation;
LGG	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	7.55	0.33	2.34e-13	Initial pursuit acceleration;
LGG	cis	rs7565124	1.000	rs67305930	chr2:20258070	G/C	cg24657347	chr2:20261756	NA	-0.76	-15.04	-0.57	6.27e-42	Major depressive disorder;
LGG	trans	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.36	0.43	9.51e-23	Ulcerative colitis;
LGG	cis	rs7172677	0.961	rs12102035	chr15:75418871	A/G	cg14664628	chr15:75095509	CSK	-0.45	-6.88	-0.3	2.01e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	18.73	0.66	1.06e-58	Smoking behavior;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.49	-0.37	2.76e-16	Personality dimensions;
LGG	cis	rs2236267	0.661	rs2245688	chr14:88595873	G/A	cg02175263	chr14:88627849	NA	0.31	7.03	0.31	7.4e-12	Food antigen IgG levels;
LGG	cis	rs2985684	0.895	rs3007033	chr14:50103816	T/C	cg02151108	chr14:50098012	C14orf104	-0.48	-10.24	-0.43	2.49e-22	Carotid intima media thickness;
LGG	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.31e-14	Coronary artery disease;
LGG	cis	rs7267979	1.000	rs2257432	chr20:25271086	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.73e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs283228	0.617	rs668267	chr6:101745031	T/C	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg24692254	chr21:30365293	RNF160	-0.85	-19.3	-0.67	2.51e-61	Dental caries;
LGG	cis	rs4851254	0.660	rs9784000	chr2:100697201	G/C	cg17356467	chr2:100759845	AFF3	0.45	7.36	0.32	8.53e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	7.87	0.34	2.6e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg08400814	chr5:56204995	C5orf35	-0.42	-6.8	-0.3	3.2e-11	Initial pursuit acceleration;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.31	0.43	1.47e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2544527	0.563	rs6728667	chr2:15904705	G/A	cg26669897	chr2:15909070	NA	0.37	9.29	0.4	6.21e-19	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs763121	0.889	rs6001209	chr22:39121252	C/T	cg06022373	chr22:39101656	GTPBP1	-0.8	-16.24	-0.6	2.84e-47	Menopause (age at onset);
LGG	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg20283391	chr11:68216788	NA	-0.49	-8.12	-0.35	4.18e-15	Total body bone mineral density;
LGG	cis	rs16837677	1.000	rs9330272	chr1:156747189	A/G	cg14991358	chr1:156767203	PRCC	-0.72	-7.48	-0.33	3.87e-13	Sjögren's syndrome;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg22398616	chr13:53314203	LECT1	0.49	10.23	0.43	2.86e-22	Lewy body disease;
LGG	cis	rs9815354	0.904	rs9852991	chr3:41875455	C/A	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs644799	0.511	rs12791736	chr11:95475399	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	8.99	0.39	6.13e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9354308	0.727	rs4710551	chr6:66612467	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs7191439	0.589	rs11076699	chr16:88756812	A/C	cg02389323	chr16:88786976	FAM38A	-0.69	-7.18	-0.32	2.73e-12	Plateletcrit;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg22105103	chr4:187893119	NA	-0.57	-10.8	-0.45	2.13e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11785693	0.862	rs7007542	chr8:4996718	G/A	cg26367366	chr8:4980734	NA	1.03	15.6	0.59	2.18e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs4595586	0.545	rs12827197	chr12:39404362	C/T	cg26384229	chr12:38710491	ALG10B	0.61	11.13	0.46	1.13e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.52	-0.37	2.31e-16	Obesity-related traits;
LGG	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg09998033	chr7:158218633	PTPRN2	-0.5	-9.29	-0.4	6.2800000000000005e-19	Obesity-related traits;
LGG	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.83	0.7	1.83e-68	Calcium levels;
LGG	cis	rs9513627	0.573	rs12431100	chr13:100184918	C/G	cg15490075	chr13:100150979	NA	-0.57	-7.58	-0.33	1.87e-13	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9457247	0.544	rs6920858	chr6:167464630	G/A	cg07741184	chr6:167504864	NA	0.44	10.07	0.42	1.03e-21	Crohn's disease;
LGG	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg13385521	chr17:29058706	SUZ12P	0.79	8.81	0.38	2.46e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11711311	1.000	rs9865965	chr3:113450495	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.44e-13	IgG glycosylation;
LGG	cis	rs6496667	0.509	rs2657948	chr15:90948617	G/A	cg22089800	chr15:90895588	ZNF774	0.5	8.19	0.36	2.52e-15	Rheumatoid arthritis;
LGG	cis	rs4356932	0.967	rs28642977	chr4:76972731	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.07e-11	Blood protein levels;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.47	0.33	4e-13	Menopause (age at onset);
LGG	cis	rs4740619	0.935	rs10962070	chr9:15566017	C/T	cg14451791	chr9:16040625	NA	-0.38	-9.68	-0.41	2.55e-20	Body mass index;
LGG	cis	rs1965732	0.522	rs34086816	chr2:3718985	A/G	cg20493526	chr2:3714936	ALLC	0.45	9.79	0.41	1.09e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9287719	0.967	rs7570118	chr2:10718007	G/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.4	-0.33	6.39e-13	Prostate cancer;
LGG	cis	rs10870270	0.956	rs10781555	chr10:133745720	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-13.23	-0.52	3.89e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7737355	0.947	rs6895586	chr5:130588008	C/A	cg06307176	chr5:131281290	NA	0.5	8.34	0.36	8.69e-16	Life satisfaction;
LGG	trans	rs2055729	0.677	rs1962430	chr8:9759620	G/T	cg06636001	chr8:8085503	FLJ10661	0.46	6.97	0.31	1.1e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4740619	0.935	rs10756679	chr9:15623644	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.11	-0.43	7.5e-22	Body mass index;
LGG	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9942416	0.660	rs61173369	chr5:74997995	A/G	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-9.07	-0.39	3.5e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg01238044	chr22:24384105	GSTT1	-0.41	-6.91	-0.31	1.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12786942	0.569	rs11224766	chr11:101312430	T/A	cg03942599	chr11:101341554	TRPC6	0.49	7.32	0.32	1.13e-12	Facial depth;
LGG	cis	rs5769765	0.646	rs9627789	chr22:50300562	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-11.96	-0.49	6.54e-29	Schizophrenia;
LGG	cis	rs7020830	0.898	rs506981	chr9:37351348	A/T	cg14294708	chr9:37120828	ZCCHC7	-1.12	-29.67	-0.81	3.87e-109	Schizophrenia;
LGG	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.82	-0.3	2.9100000000000002e-11	Retinal vascular caliber;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.73	-0.38	4.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-6.96	-0.31	1.13e-11	Personality dimensions;
LGG	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs8064024	0.783	rs2341986	chr16:4819496	A/G	cg04440724	chr16:4920505	UBN1	-0.45	-9.34	-0.4	4.12e-19	Cancer;
LGG	trans	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg08344181	chr3:125677491	NA	-0.58	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg23978390	chr7:1156363	C7orf50	0.47	8.09	0.35	5.23e-15	Longevity;Endometriosis;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs67311347	0.956	rs11714871	chr3:40428938	T/G	cg13683864	chr3:40499215	RPL14	-0.97	-19.96	-0.68	2.08e-64	Renal cell carcinoma;
LGG	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.82	-0.38	2.29e-17	Post bronchodilator FEV1;
LGG	cis	rs774359	0.753	rs7036117	chr9:27507836	C/T	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.49	-0.37	2.78e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.49	0.53	3.15e-35	IgG glycosylation;
LGG	cis	rs8017423	0.935	rs2236403	chr14:90736325	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-17.58	-0.63	2.27e-53	Mortality in heart failure;
LGG	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	8.31	0.36	1.06e-15	Neuroticism;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.39	6.9	0.31	1.72e-11	Schizophrenia;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.57	-0.53	1.47e-35	Alzheimer's disease;
LGG	cis	rs6062302	0.522	rs13043255	chr20:62218916	C/G	cg16989086	chr20:62203971	PRIC285	0.49	7.26	0.32	1.62e-12	Glioblastoma;
LGG	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg04166393	chr7:2884313	GNA12	0.45	8.41	0.36	5.03e-16	Height;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.74	0.3	4.65e-11	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20670292	chr2:131099506	IMP4;CCDC115	0.45	7.4	0.33	6.58e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6456156	0.586	rs10946209	chr6:167480991	G/A	cg07741184	chr6:167504864	NA	0.4	9.19	0.39	1.38e-18	Primary biliary cholangitis;
LGG	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs6061231	0.631	rs2427310	chr20:60969929	C/G	cg23531748	chr20:60969906	CABLES2	0.46	8.42	0.36	4.61e-16	Colorectal cancer;
LGG	cis	rs12220238	1.000	rs10824128	chr10:76007903	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.85	12.01	0.49	3.96e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07167872	chr1:205819463	PM20D1	0.57	11.55	0.47	2.72e-27	Menarche (age at onset);
LGG	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.54	0.41	8.39e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8180040	0.620	rs11707736	chr3:47069504	G/T	cg16586182	chr3:47516702	SCAP	0.73	13.33	0.53	1.53e-34	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.86e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.77	-0.34	5.01e-14	Parkinson's disease;
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg13047869	chr3:10149882	C3orf24	0.56	7.67	0.34	9.89e-14	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.37e-12	Lung cancer;
LGG	cis	rs34929064	0.671	rs34743674	chr7:22742812	C/T	cg18045685	chr7:22629474	NA	0.51	6.96	0.31	1.21e-11	Major depression and alcohol dependence;
LGG	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs57927100	0.800	rs3760143	chr17:75316497	C/T	cg18271897	chr17:75316784	SEPT9	0.44	10.58	0.44	1.42e-23	Systolic blood pressure;
LGG	cis	rs7011049	1.000	rs78200075	chr8:53845907	G/A	cg26025543	chr8:53854495	NA	0.75	9.92	0.42	3.73e-21	Systolic blood pressure;
LGG	cis	rs9397585	0.637	rs11155892	chr6:153404161	T/C	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs892961	0.932	rs7207891	chr17:75413922	G/C	cg05865280	chr17:75406074	SEPT9	0.42	9.84	0.42	7.3e-21	Airflow obstruction;
LGG	cis	rs7119038	0.509	rs11216961	chr11:118580338	C/G	cg19182353	chr11:118479428	PHLDB1	0.38	6.9	0.31	1.68e-11	Sjögren's syndrome;
LGG	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.4	-0.33	6.52e-13	Type 2 diabetes;
LGG	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.55	0.5	2.67e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-9.87	-0.42	5.6e-21	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05329982	chr11:62359210	TUT1	0.53	8.74	0.38	4.32e-17	Gut microbiome composition (summer);
LGG	cis	rs735396	0.595	rs1169279	chr12:121455873	C/T	cg02403541	chr12:121454288	C12orf43	0.75	12.96	0.52	5.41e-33	N-glycan levels;
LGG	cis	rs911263	0.603	rs12878858	chr14:68786797	G/A	cg18825221	chr14:68749962	RAD51L1	0.35	7.69	0.34	9.12e-14	Primary biliary cholangitis;
LGG	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	18.72	0.66	1.23e-58	Testicular germ cell tumor;
LGG	cis	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.56	-0.47	2.45e-27	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7666738	0.753	rs1830230	chr4:99026186	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.45	0.37	3.78e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg22875332	chr1:76189707	ACADM	0.62	11.0	0.46	3.75e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs227833	1.000	rs227833	chr6:44681840	G/C	cg20913747	chr6:44695427	NA	0.46	7.76	0.34	5.63e-14	Monobrow;
LGG	cis	rs72945132	0.598	rs61887433	chr11:70240997	A/G	cg00319359	chr11:70116639	PPFIA1	0.64	6.94	0.31	1.34e-11	Coronary artery disease;
LGG	cis	rs4604732	0.527	rs60444724	chr1:247623164	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.15	0.39	1.79e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg04851639	chr8:1020857	NA	-0.33	-6.82	-0.3	2.87e-11	Schizophrenia;
LGG	cis	rs17221829	0.703	rs4237550	chr11:89360585	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs1620921	0.625	rs10945702	chr6:161267174	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9384488	0.524	rs7755448	chr6:157028615	T/C	cg08839808	chr6:156983304	NA	-0.43	-6.95	-0.31	1.25e-11	Alzheimer's disease biomarkers;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06558623	chr16:89946397	TCF25	1.05	13.82	0.54	1.35e-36	Skin colour saturation;
LGG	trans	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg13010199	chr12:38710504	ALG10B	0.52	9.95	0.42	2.82e-21	Morning vs. evening chronotype;
LGG	cis	rs6784615	0.744	rs6414568	chr3:52501292	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg14004847	chr7:1930337	MAD1L1	-0.58	-9.92	-0.42	3.57e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg21775007	chr8:11205619	TDH	-0.8	-13.85	-0.54	9.41e-37	Retinal vascular caliber;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg19147804	chr7:1989927	MAD1L1	-0.59	-12.01	-0.49	3.92e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9359856	0.636	rs6454767	chr6:90317335	G/A	cg13799429	chr6:90582589	CASP8AP2	0.61	7.99	0.35	1.11e-14	Bipolar disorder;
LGG	cis	rs9660992	0.547	rs748012	chr1:205216573	C/T	cg00857998	chr1:205179979	DSTYK	0.5	7.8	0.34	4.1e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg13010199	chr12:38710504	ALG10B	0.58	10.96	0.45	5.06e-25	Morning vs. evening chronotype;
LGG	cis	rs41271473	0.950	rs72750042	chr1:228854138	T/C	cg00850481	chr1:228891306	NA	-0.48	-8.25	-0.36	1.7e-15	Chronic lymphocytic leukemia;
LGG	cis	rs3820068	0.603	rs998032	chr1:15989918	T/C	cg05660106	chr1:15850417	CASP9	0.81	16.16	0.6	6.92e-47	Systolic blood pressure;
LGG	cis	rs73086581	1.000	rs73086544	chr20:3950928	C/A	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.89e-14	Common traits (Other);
LGG	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg10760299	chr15:45669010	GATM	0.4	7.81	0.34	3.88e-14	Homoarginine levels;
LGG	cis	rs172166	0.652	rs476167	chr6:28065888	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.13	-0.31	3.98e-12	Cardiac Troponin-T levels;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04008888	chr11:68622739	NA	-0.54	-11.76	-0.48	4.1e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1497828	0.956	rs2810779	chr1:217542866	G/A	cg04411442	chr1:217543379	NA	0.48	8.24	0.36	1.85e-15	Dialysis-related mortality;
LGG	cis	rs9522267	1.000	rs9522266	chr13:112195456	C/T	cg14952266	chr13:112191215	NA	0.37	6.92	0.31	1.49e-11	Hepatitis;
LGG	trans	rs11039571	0.588	rs10734564	chr11:48160429	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-8.34	-0.36	8.37e-16	D-dimer levels;
LGG	cis	rs709400	0.628	rs1951392	chr14:103853367	T/G	cg26031613	chr14:104095156	KLC1	0.8	13.65	0.54	6.71e-36	Body mass index;
LGG	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9916302	0.904	rs588193	chr17:37440439	A/C	cg07936489	chr17:37558343	FBXL20	0.85	16.01	0.6	3.12e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg26043149	chr18:55253948	FECH	1.0	18.57	0.65	5.95e-58	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	8.21	0.36	2.17e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg08847533	chr14:75593920	NEK9	0.55	10.12	0.43	7.24e-22	Height;
LGG	cis	rs2294693	0.945	rs9349175	chr6:40982401	T/C	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.91	-0.31	1.61e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.2	0.6	4.33e-47	Hip circumference adjusted for BMI;
LGG	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg00277334	chr10:82204260	NA	-0.44	-9.42	-0.4	2.16e-19	Post bronchodilator FEV1;
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg13397359	chr6:42928475	GNMT	0.58	16.31	0.6	1.34e-47	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.93	-0.42	3.53e-21	Educational attainment;
LGG	cis	rs7394190	0.748	rs3843939	chr10:75578948	T/C	cg07699608	chr10:75541558	CHCHD1	0.53	7.02	0.31	8.1e-12	Incident atrial fibrillation;
LGG	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg20573242	chr4:122745356	CCNA2	0.55	10.14	0.43	5.69e-22	Type 2 diabetes;
LGG	cis	rs7647973	0.677	rs11130211	chr3:49645209	C/T	cg03060546	chr3:49711283	APEH	0.6	7.9	0.34	2.11e-14	Menarche (age at onset);
LGG	cis	rs60843830	0.661	rs7561648	chr2:105171	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.31	0.4	5.21e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2404602	0.679	rs12899871	chr15:76757347	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.16	-0.32	3.23e-12	Blood metabolite levels;
LGG	cis	rs2797369	0.656	rs817233	chr6:101441212	T/C	cg27451362	chr6:101846650	GRIK2	0.78	10.46	0.44	4.12e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26306683	chr17:18585705	ZNF286B	0.44	8.15	0.35	3.5e-15	Educational attainment (years of education);
LGG	cis	rs8044868	0.530	rs2287998	chr16:72059269	C/T	cg23815491	chr16:72088622	HP	-0.34	-7.16	-0.32	3.26e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs6601327	0.665	rs12546411	chr8:9655916	T/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.96	-0.31	1.17e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.02	-0.52	3.18e-33	Vitamin D levels;
LGG	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg12310025	chr6:25882481	NA	-0.52	-10.04	-0.42	1.37e-21	Blood metabolite levels;
LGG	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg02931644	chr1:25747376	RHCE	-0.45	-9.9	-0.42	4.32e-21	Plateletcrit;Mean corpuscular volume;
LGG	trans	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.66	-0.63	9.65e-54	Exhaled nitric oxide output;
LGG	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg14703610	chr5:56206110	C5orf35	0.41	7.07	0.31	5.75e-12	Breast cancer;Breast cancer (early onset);
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg16405210	chr4:1374714	KIAA1530	-0.84	-15.18	-0.58	1.52e-42	Longevity;
LGG	cis	rs4538187	0.707	rs67308158	chr2:64129453	G/A	cg19915305	chr2:64069682	UGP2	-0.66	-13.19	-0.52	6.09e-34	Systolic blood pressure;
LGG	cis	rs6087990	0.806	rs4911258	chr20:31369479	G/A	cg13636640	chr20:31349939	DNMT3B	0.96	20.28	0.69	6.96e-66	Ulcerative colitis;
LGG	cis	rs9649465	1.000	rs10238422	chr7:123353708	G/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.99	-0.39	6.21e-18	Migraine;
LGG	cis	rs9527	0.590	rs7901197	chr10:104840433	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.2	-0.32	2.39e-12	Arsenic metabolism;
LGG	cis	rs75059851	1.000	rs3758927	chr11:133829644	C/G	cg20042908	chr11:133852938	NA	0.66	11.88	0.48	1.33e-28	Schizophrenia;
LGG	cis	rs9308731	1.000	rs2015454	chr2:111872148	A/G	cg26001287	chr2:111877753	BCL2L11	-0.38	-7.59	-0.33	1.78e-13	Chronic lymphocytic leukemia;
LGG	cis	rs897080	0.515	rs1067345	chr2:44618897	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	4.01e-11	Height;
LGG	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.64	-0.51	1.09e-31	Uric acid levels;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07167872	chr1:205819463	PM20D1	0.48	9.84	0.42	7.17e-21	Monocyte percentage of white cells;
LGG	trans	rs7246760	0.867	rs12462694	chr19:9778032	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.57	-0.44	1.55e-23	Pursuit maintenance gain;
LGG	trans	rs643955	0.637	rs4841271	chr8:9870137	T/A	cg16141378	chr3:129829833	LOC729375	0.31	6.81	0.3	2.99e-11	Systemic lupus erythematosus;
LGG	cis	rs939658	0.967	rs7171067	chr15:79452727	G/T	cg17916960	chr15:79447300	NA	0.64	12.41	0.5	9.61e-31	Refractive error;
LGG	cis	rs72901758	0.662	rs56326958	chr17:76250439	C/G	cg26068271	chr17:76253126	NA	0.54	10.87	0.45	1.1e-24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7814319	0.838	rs6989983	chr8:97229679	A/G	cg20787634	chr8:97240163	UQCRB	-0.7	-15.26	-0.58	6.91e-43	Lung function (FVC);
LGG	cis	rs2710642	0.888	rs2539985	chr2:63134507	T/A	cg17519650	chr2:63277830	OTX1	0.49	8.05	0.35	6.83e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs523522	0.962	rs4766966	chr12:120942911	G/C	cg27279351	chr12:120934652	DYNLL1	0.78	12.67	0.51	8.76e-32	High light scatter reticulocyte count;
LGG	cis	rs6964587	1.000	rs28410528	chr7:91647390	A/G	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.91e-22	Motion sickness;
LGG	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg03733263	chr8:22462867	KIAA1967	1.12	28.8	0.8	2.97e-105	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg07870213	chr5:140052090	DND1	-0.86	-15.62	-0.59	1.7e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs208520	0.955	rs12204033	chr6:67001525	T/C	cg07460842	chr6:66804631	NA	0.83	13.45	0.53	4.6e-35	Exhaled nitric oxide output;
LGG	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.49	-0.47	4.9e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg21926883	chr2:100939477	LONRF2	-0.65	-15.16	-0.58	1.99e-42	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg20503657	chr10:835505	NA	0.72	10.22	0.43	3.13e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6087990	0.865	rs6058859	chr20:31335157	A/G	cg13636640	chr20:31349939	DNMT3B	0.9	18.85	0.66	3.17e-59	Ulcerative colitis;
LGG	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg03806693	chr22:41940476	POLR3H	-0.55	-9.35	-0.4	3.67e-19	Alzheimer's disease biomarkers;
LGG	cis	rs1957429	0.901	rs1951491	chr14:65346950	G/A	cg23373153	chr14:65346875	NA	1.14	15.34	0.58	3.03e-43	Pediatric areal bone mineral density (radius);
LGG	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg17054900	chr3:154042577	DHX36	0.46	7.12	0.31	4.17e-12	Coronary artery disease;
LGG	cis	rs10779751	0.666	rs77270747	chr1:11214584	A/C	cg08854313	chr1:11322531	MTOR	-0.72	-15.41	-0.58	1.44e-43	Body mass index;
LGG	cis	rs963731	0.579	rs1043793	chr2:39209047	A/G	cg04010122	chr2:39346883	SOS1	-0.67	-6.77	-0.3	4.02e-11	Corticobasal degeneration;
LGG	cis	rs13418410	0.539	rs1545399	chr2:33843801	A/G	cg04131969	chr2:33951647	MYADML	-0.69	-12.48	-0.5	5e-31	Non-response to antidepressants and depression;
LGG	cis	rs7949030	0.591	rs35156678	chr11:62369881	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.72	17.98	0.64	3.41e-55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	8.74	0.38	4.38e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs36051895	0.623	rs6476952	chr9:5236924	T/C	cg02405213	chr9:5042618	JAK2	-0.73	-12.56	-0.5	2.44e-31	Pediatric autoimmune diseases;
LGG	trans	rs1814175	0.817	rs1851860	chr11:49861310	A/C	cg03929089	chr4:120376271	NA	-1.03	-24.5	-0.75	1.34e-85	Height;
LGG	cis	rs919433	0.854	rs787994	chr2:198223121	T/C	cg00792783	chr2:198669748	PLCL1	0.45	7.15	0.32	3.49e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs8058578	0.832	rs35969813	chr16:30714417	T/C	cg02466173	chr16:30829666	NA	-0.54	-9.48	-0.4	1.35e-19	Multiple myeloma;
LGG	cis	rs9788721	0.835	rs17487223	chr15:78923987	A/G	cg17108064	chr15:78857060	CHRNA5	0.35	6.83	0.3	2.61e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.6	-0.41	5.03e-20	Aortic root size;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.51	-0.37	2.36e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs79839061	0.610	rs9994159	chr4:891150	C/T	cg07828340	chr4:882639	GAK	0.94	9.98	0.42	2.19e-21	Intelligence (multi-trait analysis);
LGG	cis	rs139371	0.742	rs139324	chr22:39501823	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.93	-0.31	1.43e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs300703	0.719	rs446488	chr2:195365	T/C	cg24565620	chr2:194026	NA	-0.7	-10.83	-0.45	1.59e-24	Blood protein levels;
LGG	cis	rs68170813	0.559	rs60255281	chr7:106963913	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-10.26	-0.43	2.21e-22	Coronary artery disease;
LGG	cis	rs9611519	0.929	rs73174660	chr22:41437304	T/C	cg06634786	chr22:41940651	POLR3H	-0.42	-6.74	-0.3	4.77e-11	Neuroticism;
LGG	cis	rs6964587	1.000	rs6952389	chr7:91657994	A/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs9815354	0.680	rs73073263	chr3:42018666	C/A	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg13482628	chr17:19912719	NA	0.63	12.38	0.5	1.29e-30	Schizophrenia;
LGG	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.71	-0.34	7.89e-14	Diastolic blood pressure;
LGG	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg11764359	chr7:65958608	NA	0.62	9.58	0.41	5.79e-20	Aortic root size;
LGG	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.9	-0.31	1.71e-11	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg13009111	chr11:71350975	NA	-0.31	-6.75	-0.3	4.47e-11	Triglycerides;
LGG	cis	rs6815814	0.950	rs5743566	chr4:38805942	G/C	cg06935464	chr4:38784597	TLR10	0.6	8.24	0.36	1.76e-15	Breast cancer;
LGG	trans	rs4427176	0.507	rs13269437	chr8:9579290	A/T	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs8049634	0.913	rs2098738	chr16:84222593	A/C	cg26466773	chr16:84211947	TAF1C	0.45	6.88	0.3	2.01e-11	Small cell lung carcinoma;
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg16301924	chr13:53314226	LECT1	-0.41	-7.69	-0.34	9.04e-14	Lewy body disease;
LGG	cis	rs992157	0.835	rs2271543	chr2:219142491	C/T	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.34e-26	Colorectal cancer;
LGG	cis	rs9362426	0.524	rs61731441	chr6:88125542	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	-0.94	-14.47	-0.56	2.06e-39	Depressive episodes in bipolar disorder;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg11062466	chr8:58055876	NA	0.6	9.53	0.41	8.76e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs300703	0.935	rs417829	chr2:206851	A/G	cg21211680	chr2:198530	NA	1.18	15.97	0.6	4.85e-46	Blood protein levels;
LGG	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg04990556	chr1:26633338	UBXN11	-0.68	-13.85	-0.54	9.43e-37	Obesity-related traits;
LGG	cis	rs7944584	0.632	rs749067	chr11:47318157	T/C	cg20307385	chr11:47447363	PSMC3	0.63	12.24	0.49	4.92e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg02574844	chr11:5959923	NA	-0.57	-9.76	-0.41	1.41e-20	DNA methylation (variation);
LGG	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg10792982	chr14:105748885	BRF1	0.68	13.66	0.54	6.48e-36	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg18187862	chr3:45730750	SACM1L	0.54	8.53	0.37	2.04e-16	Primary sclerosing cholangitis;
LGG	cis	rs11744848	0.775	rs72751331	chr5:57125178	G/T	cg08523694	chr5:57076192	NA	0.52	7.03	0.31	7.53e-12	Longitudinal change in brain amyloid plaque burden;
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10053473	chr17:62856997	LRRC37A3	0.82	14.78	0.57	9.44e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.52	-0.37	2.23e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6743376	0.532	rs2515395	chr2:113818702	G/C	cg05949173	chr2:113825882	IL1F10	0.48	9.07	0.39	3.42e-18	Inflammatory biomarkers;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13231117	chr2:96193797	NA	-0.58	-6.94	-0.31	1.36e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg18451016	chr1:38461880	NA	0.57	13.08	0.52	1.74e-33	Coronary artery disease;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.19	0.43	3.83e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7647973	0.592	rs55754265	chr3:49687486	C/T	cg03060546	chr3:49711283	APEH	-0.64	-7.62	-0.33	1.46e-13	Menarche (age at onset);
LGG	cis	rs1865760	0.623	rs12216125	chr6:25997458	C/T	cg16482183	chr6:26056742	HIST1H1C	0.71	12.21	0.49	6.44e-30	Height;
LGG	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg26655873	chr3:72818019	SHQ1	0.35	6.88	0.3	1.93e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2708240	0.515	rs2708269	chr7:147595615	T/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.28	-7.13	-0.31	3.94e-12	QT interval (drug interaction);
LGG	cis	rs3106136	0.967	rs3106135	chr4:95138308	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.98	-0.35	1.17e-14	Capecitabine sensitivity;
LGG	cis	rs2071403	0.509	rs11678852	chr2:1408101	A/T	cg06500727	chr2:1417164	TPO	-0.6	-12.14	-0.49	1.23e-29	Thyroid peroxidase antibody positivity;
LGG	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	6.77	0.3	4e-11	Body mass index;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg17734273	chr15:78292508	TBC1D2B	-0.38	-9.49	-0.4	1.19e-19	Coronary artery disease or large artery stroke;
LGG	cis	rs6997458	0.902	rs2453868	chr8:86302696	C/T	cg02393479	chr8:86352350	CA3	-0.31	-6.77	-0.3	3.82e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg04553112	chr3:125709451	NA	-0.54	-6.88	-0.3	1.92e-11	Blood pressure (smoking interaction);
LGG	cis	rs11583043	0.874	rs11578366	chr1:101396852	T/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	7.08	0.31	5.53e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6546550	0.869	rs6712827	chr2:70156540	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-8.0	-0.35	9.95e-15	Prevalent atrial fibrillation;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg19500098	chr13:21900506	NA	0.47	10.0	0.42	1.87e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg26384229	chr12:38710491	ALG10B	0.86	19.23	0.67	5.43e-61	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6942756	0.955	rs68187585	chr7:129002211	T/C	cg02491457	chr7:128862824	NA	-0.73	-12.8	-0.51	2.55e-32	White matter hyperintensity burden;
LGG	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.67	-0.34	1.03e-13	Obesity-related traits;
LGG	cis	rs6977955	0.627	rs1513275	chr7:28259233	C/T	cg23620719	chr7:28220237	JAZF1	-0.47	-7.54	-0.33	2.52e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9296092	0.538	rs9461875	chr6:33516644	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.7	-0.69	7.11e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.747	rs73283043	chr20:34383863	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.39	-0.32	6.73e-13	Total cholesterol levels;
LGG	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg13010199	chr12:38710504	ALG10B	0.68	14.03	0.55	1.66e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6708331	0.941	rs12989257	chr2:70368598	T/C	cg01613454	chr2:70366299	NA	0.52	9.27	0.4	7.07e-19	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg16330517	chr18:43913699	RNF165	-0.39	-6.66	-0.3	7.81e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg07461501	chr17:79650226	HGS;ARL16	0.53	9.79	0.41	1.11e-20	Monocyte percentage of white cells;
LGG	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.62e-15	Obesity-related traits;
LGG	cis	rs2777491	0.957	rs7181911	chr15:41674060	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.87	-0.68	5.72e-64	Ulcerative colitis;
LGG	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg21435375	chr2:172878103	MAP1D	0.3	6.8	0.3	3.24e-11	Schizophrenia;
LGG	cis	rs4478858	0.684	rs4949372	chr1:31738857	G/A	cg19084893	chr1:31688959	NA	0.31	6.69	0.3	6.65e-11	Alcohol dependence;
LGG	cis	rs11229555	0.645	rs11229443	chr11:58197188	G/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.667	rs10053762	chr5:152276650	A/C	cg12297329	chr5:152029980	NA	0.61	11.94	0.49	7.89e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg13628971	chr7:2884303	GNA12	0.55	11.46	0.47	6.3e-27	Height;
LGG	cis	rs1978968	0.731	rs9605463	chr22:18459889	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.85	-0.57	4.35e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg07701084	chr6:150067640	NUP43	-0.45	-6.85	-0.3	2.33e-11	Lung cancer;
LGG	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.3	-0.36	1.19e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.42	-0.36	4.82e-16	Life satisfaction;
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg04025675	chr15:45671028	LOC145663;GATM	-0.34	-6.74	-0.3	4.71e-11	Homoarginine levels;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16449840	chr12:54718606	COPZ1	-0.42	-6.69	-0.3	6.65e-11	Body fat percentage;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg16920238	chr17:80076378	CCDC57	0.32	7.36	0.32	8.34e-13	Life satisfaction;
LGG	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg07636037	chr3:49044803	WDR6	1.12	29.06	0.8	1.98e-106	Parkinson's disease;
LGG	cis	rs36051895	0.587	rs7035915	chr9:5238253	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-14.24	-0.55	2.09e-38	Pediatric autoimmune diseases;
LGG	cis	rs62400317	0.762	rs10484625	chr6:44823449	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.26	-0.46	3.74e-26	Total body bone mineral density;
LGG	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs11122272	0.766	rs1435166	chr1:231502310	T/C	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.43e-13	Hemoglobin concentration;
LGG	cis	rs9357271	1.000	rs4711538	chr6:38337281	C/T	cg07362130	chr6:38359646	BTBD9	-0.47	-10.63	-0.44	8.98e-24	Restless legs syndrome;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16232504	chr1:99127707	SNX7	-0.47	-6.89	-0.3	1.88e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.571	rs4840512	chr8:10596825	T/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.66	-0.3	7.61e-11	Neuroticism;
LGG	cis	rs988958	0.565	rs7576782	chr2:42218378	C/A	cg27252766	chr2:42229092	NA	0.58	8.19	0.36	2.54e-15	Hypospadias;
LGG	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg11621586	chr10:70884670	VPS26A	1.19	23.03	0.73	8.55e-79	Left atrial antero-posterior diameter;
LGG	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6547741	1.000	rs1528404	chr2:27846603	C/T	cg22903471	chr2:27725779	GCKR	-0.38	-8.63	-0.37	1.02e-16	Oral cavity cancer;
LGG	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg14416269	chr4:6271139	WFS1	0.45	7.22	0.32	2.13e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4727443	0.866	rs6963345	chr7:99618606	G/A	cg12813108	chr7:99719912	CNPY4	-0.58	-11.31	-0.47	2.39e-26	Interstitial lung disease;
LGG	cis	rs4851266	1.000	rs12619178	chr2:100838157	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs477692	0.905	rs485579	chr10:131425492	T/G	cg05714579	chr10:131428358	MGMT	0.66	14.06	0.55	1.24e-37	Response to temozolomide;
LGG	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg24812749	chr6:127587940	RNF146	-0.95	-15.52	-0.59	4.81e-44	Breast cancer;
LGG	cis	rs10492096	1.000	rs11064210	chr12:6576721	C/T	cg13857086	chr12:6580257	VAMP1	0.64	9.28	0.4	6.59e-19	Hip geometry;
LGG	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.71	-10.62	-0.44	1e-23	Homoarginine levels;
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	cis	rs17665859	0.844	rs76478160	chr8:446900	G/C	cg17960703	chr8:356704	FBXO25	0.95	8.26	0.36	1.56e-15	Bilirubin levels;
LGG	cis	rs4911259	0.552	rs62208880	chr20:31463284	T/C	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.81	-0.48	2.53e-28	Inflammatory bowel disease;
LGG	cis	rs3816183	0.626	rs6732008	chr2:42815066	A/G	cg14631114	chr2:43023945	NA	0.33	6.66	0.3	8.02e-11	Hypospadias;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg04503457	chr17:41445688	NA	-0.37	-8.47	-0.37	3.17e-16	Menopause (age at onset);
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.35	-0.36	8e-16	Personality dimensions;
LGG	cis	rs523522	0.962	rs10849759	chr12:120994488	T/A	cg12219531	chr12:120966889	COQ5	0.66	11.13	0.46	1.2e-25	High light scatter reticulocyte count;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg11878867	chr6:150167359	LRP11	-0.53	-10.99	-0.46	3.84e-25	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06975592	chr1:165796857	UCK2	0.51	7.78	0.34	4.84e-14	Gut microbiome composition (summer);
LGG	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.65	-0.3	8.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg13647721	chr17:30228624	UTP6	0.77	11.11	0.46	1.44e-25	Hip circumference adjusted for BMI;
LGG	cis	rs225245	0.782	rs225293	chr17:33925906	A/G	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.04	0.57	6.59e-42	Lung cancer;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs28551159	1	rs28551159	chr6:26376368	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Urinary tract infection frequency;
LGG	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg13010199	chr12:38710504	ALG10B	-0.49	-9.21	-0.39	1.11e-18	Morning vs. evening chronotype;
LGG	cis	rs11711311	1.000	rs9830978	chr3:113455940	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.54e-13	IgG glycosylation;
LGG	cis	rs2040771	0.745	rs362148	chr22:19262852	T/C	cg02655711	chr22:19163373	SLC25A1	0.46	8.08	0.35	5.57e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.83	0.34	3.35e-14	Rheumatoid arthritis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09306365	chr3:61547944	PTPRG	0.39	6.88	0.3	1.92e-11	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.67	-12.34	-0.5	1.83e-30	Obesity-related traits;
LGG	cis	rs2011503	1.000	rs75453386	chr19:19637781	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.91	0.38	1.22e-17	Aortic root size;
LGG	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg06028605	chr16:24865363	SLC5A11	0.51	8.55	0.37	1.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.545	rs1547529	chr7:65723846	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.27	0.43	1.91e-22	Aortic root size;
LGG	cis	rs9397585	0.857	rs6935771	chr6:153378204	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg16141378	chr3:129829833	LOC729375	-0.37	-8.2	-0.36	2.38e-15	Neuroticism;
LGG	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.6	-0.51	1.6e-31	Vitiligo;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25517755	chr10:38738941	LOC399744	0.37	6.67	0.3	7.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg21138405	chr5:131827807	IRF1	0.38	10.22	0.43	2.9e-22	Asthma (sex interaction);
LGG	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg08085267	chr17:45401833	C17orf57	0.59	11.75	0.48	4.53e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg14298792	chr15:30685198	CHRFAM7A	0.53	7.99	0.35	1.09e-14	Huntington's disease progression;
LGG	cis	rs17445240	0.515	rs9308790	chr2:3705712	C/T	cg14882966	chr2:3699353	NA	0.59	8.11	0.35	4.48e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	8.25	0.36	1.7e-15	Colorectal cancer;
LGG	cis	rs2075371	1.000	rs2598291	chr7:133988313	C/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.9	0.59	9.48e-46	Mean platelet volume;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.55	0.37	1.83e-16	Personality dimensions;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg10950524	chr7:2139216	MAD1L1	0.32	6.87	0.3	2.04e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs16976116	0.901	rs28541469	chr15:55500788	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-10.42	-0.44	5.48e-23	Lung cancer;
LGG	trans	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg13565492	chr6:43139072	SRF	-0.78	-10.43	-0.44	5.32e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs738322	0.600	rs6001035	chr22:38562425	A/G	cg25457927	chr22:38595422	NA	-0.42	-10.5	-0.44	2.83e-23	Cutaneous nevi;
LGG	cis	rs9814567	0.806	rs4245903	chr3:134317074	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.74	-0.45	3.51e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.49	0.56	1.59e-39	Cognitive test performance;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg19077165	chr18:44547161	KATNAL2	0.53	9.64	0.41	3.74e-20	Personality dimensions;
LGG	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg22467129	chr15:76604101	ETFA	-0.42	-6.96	-0.31	1.19e-11	Blood metabolite levels;
LGG	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg01221209	chr5:554886	NA	-0.48	-7.21	-0.32	2.35e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg25427524	chr10:38739819	LOC399744	-0.64	-13.0	-0.52	3.63e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs7208859	0.725	rs9910051	chr17:29161202	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.23	-0.39	1e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572733	0.935	rs10189897	chr2:198813410	C/T	cg00792783	chr2:198669748	PLCL1	-0.49	-8.25	-0.36	1.66e-15	Dermatomyositis;
LGG	cis	rs8049634	0.732	rs13332770	chr16:84232749	C/T	cg26466773	chr16:84211947	TAF1C	0.42	7.02	0.31	8.02e-12	Small cell lung carcinoma;
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs7940866	0.903	rs7940465	chr11:130861339	C/T	cg12179176	chr11:130786555	SNX19	0.71	13.09	0.52	1.59e-33	Schizophrenia;
LGG	trans	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs34929064	0.958	rs35263987	chr7:22727848	T/A	cg18045685	chr7:22629474	NA	0.56	8.78	0.38	3.22e-17	Major depression and alcohol dependence;
LGG	cis	rs7106204	0.688	rs4462347	chr11:24218865	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	11.1	0.46	1.54e-25	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.83	-0.38	2.15e-17	Response to antipsychotic treatment;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.95	-0.38	8.8e-18	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg16339924	chr4:17578868	LAP3	0.57	9.93	0.42	3.27e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	11.7	0.48	7.25e-28	Mood instability;
LGG	cis	rs7432375	0.610	rs56163507	chr3:136516056	C/T	cg21827317	chr3:136751795	NA	0.44	7.98	0.35	1.18e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg26384229	chr12:38710491	ALG10B	0.72	14.53	0.56	1.15e-39	Morning vs. evening chronotype;
LGG	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg03929089	chr4:120376271	NA	0.82	8.62	0.37	1.05e-16	Myopia (pathological);
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.08	-0.35	5.51e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-10.27	-0.43	1.99e-22	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.54	0.37	1.97e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg11494091	chr17:61959527	GH2	0.97	22.52	0.72	2.17e-76	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22624255	chr19:19779476	ZNF101	0.48	7.69	0.34	8.91e-14	Cognitive performance;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg04287289	chr16:89883240	FANCA	0.56	10.5	0.44	2.78e-23	Vitiligo;
LGG	trans	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.0	-0.42	1.93e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7236492	0.935	rs77865749	chr18:77216756	G/A	cg15532942	chr18:77220712	NFATC1	0.45	7.21	0.32	2.37e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.61	-0.41	4.77e-20	Eosinophil percentage of white cells;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs9818758	0.607	rs67831908	chr3:49313513	T/G	cg00383909	chr3:49044727	WDR6	0.99	12.39	0.5	1.24e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.02	11.75	0.48	4.41e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg26354017	chr1:205819088	PM20D1	0.89	22.19	0.72	7.36e-75	Menarche (age at onset);
LGG	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg24623649	chr8:11872141	NA	0.3	6.92	0.31	1.5e-11	Myopia (pathological);
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg01346077	chr3:125931526	NA	0.54	13.98	0.54	2.6e-37	Metabolite levels;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg08742575	chr21:47604166	C21orf56	0.4	7.01	0.31	8.73e-12	Testicular germ cell tumor;
LGG	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs745080	0.519	rs7154166	chr14:52979950	A/T	cg23333723	chr14:53022898	GPR137C	0.39	7.79	0.34	4.39e-14	Orofacial clefts;
LGG	cis	rs4629710	0.534	rs6916881	chr6:131565153	C/T	cg12606694	chr6:131520996	AKAP7	0.5	8.2	0.36	2.45e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.23e-15	Obesity-related traits;
LGG	cis	rs4901847	0.868	rs7161692	chr14:58545107	C/G	cg15908186	chr14:58618357	C14orf37	0.5	8.69	0.37	6.26e-17	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04455180	chr1:227506639	CDC42BPA	0.44	7.47	0.33	4.01e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7945718	0.650	rs4316494	chr11:12664541	C/T	cg25843174	chr11:12811716	TEAD1	-0.32	-6.99	-0.31	9.63e-12	Educational attainment (years of education);
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg13628971	chr7:2884303	GNA12	0.55	11.71	0.48	6.67e-28	Height;
LGG	cis	rs12478296	1.000	rs56323081	chr2:243040807	A/G	cg18898632	chr2:242989856	NA	-0.87	-10.48	-0.44	3.2e-23	Obesity-related traits;
LGG	cis	rs4851254	0.618	rs35840153	chr2:100669829	A/G	cg17356467	chr2:100759845	AFF3	0.44	7.3	0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg00953403	chr17:74099816	EXOC7	0.41	6.81	0.3	2.98e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs12201899	chr6:45298204	C/A	cg20913747	chr6:44695427	NA	-0.61	-10.47	-0.44	3.5e-23	Total body bone mineral density;
LGG	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg21724239	chr8:58056113	NA	0.42	6.69	0.3	6.33e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg20336341	chr7:50628841	DDC	-0.51	-9.47	-0.4	1.47e-19	Malaria;
LGG	cis	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg26116260	chr4:7069785	GRPEL1	0.49	8.48	0.37	3e-16	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs9636252	0.887	rs13412481	chr2:9267412	A/T	cg20341998	chr2:9276514	NA	0.37	7.16	0.32	3.13e-12	IgG glycosylation;
LGG	cis	rs7727544	0.604	rs2069803	chr5:131400433	T/C	cg07395648	chr5:131743802	NA	-0.4	-8.23	-0.36	1.93e-15	Blood metabolite levels;
LGG	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.45	-0.4	1.67e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs68170813	0.641	rs34084719	chr7:107095227	A/G	cg02696742	chr7:106810147	HBP1	-0.71	-9.92	-0.42	3.69e-21	Coronary artery disease;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.07e-20	Lung cancer;
LGG	cis	rs734999	1.000	rs10797432	chr1:2501338	C/T	cg15627072	chr1:2432621	PLCH2	0.43	10.49	0.44	3.1e-23	Ulcerative colitis;
LGG	cis	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg26384229	chr12:38710491	ALG10B	-0.69	-13.33	-0.53	1.59e-34	Bladder cancer;
LGG	cis	rs6963495	0.818	rs6977748	chr7:105167462	T/G	cg19920283	chr7:105172520	RINT1	0.61	7.89	0.34	2.24e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg26384229	chr12:38710491	ALG10B	-0.47	-8.73	-0.38	4.8e-17	Morning vs. evening chronotype;
LGG	cis	rs1010254	0.559	rs55693068	chr5:151750439	T/A	cg12297329	chr5:152029980	NA	-0.5	-7.16	-0.32	3.09e-12	Optic nerve measurement (cup area);
LGG	cis	rs4642101	0.824	rs9825233	chr3:12843368	A/G	cg05775895	chr3:12838266	CAND2	-0.69	-12.82	-0.51	2.01e-32	QRS complex (12-leadsum);
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.83	0.45	1.63e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs6908034	0.607	rs73376650	chr6:19805506	T/G	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6456042	0.965	rs3099294	chr6:166530992	T/C	cg11088901	chr6:166572345	T	-0.35	-7.18	-0.32	2.73e-12	Asthma;
LGG	cis	rs11229555	0.645	rs11229429	chr11:58180872	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08280861	chr8:58055591	NA	0.61	7.76	0.34	5.54e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg06470251	chr20:60548479	NA	0.48	7.9	0.34	2.1e-14	Body mass index;
LGG	cis	rs7100689	0.524	rs7902460	chr10:82199263	T/A	cg01528321	chr10:82214614	TSPAN14	0.76	13.72	0.54	3.61e-36	Post bronchodilator FEV1;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04011206	chr18:74204120	NA	0.37	6.7	0.3	5.91e-11	Obesity-related traits;
LGG	cis	rs1816752	0.905	rs11839006	chr13:25010031	T/C	cg02811702	chr13:24901961	NA	0.41	7.84	0.34	3.12e-14	Obesity-related traits;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12016809	chr21:47604291	C21orf56	0.49	8.2	0.36	2.3e-15	Testicular germ cell tumor;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg15674680	chr20:60982522	CABLES2	0.5	7.82	0.34	3.6e-14	Colorectal cancer;
LGG	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.12	-0.49	1.53e-29	Height;
LGG	cis	rs10781543	0.967	rs7851507	chr9:139328722	G/T	cg14019695	chr9:139328340	INPP5E	0.43	7.51	0.33	2.99e-13	Monocyte percentage of white cells;
LGG	cis	rs8068544	0.818	rs78333491	chr17:40163138	A/G	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.45	-0.56	2.5e-39	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	trans	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.73	-0.51	4.81e-32	Obesity-related traits;
LGG	cis	rs4474465	0.688	rs7940507	chr11:78284453	T/C	cg27205649	chr11:78285834	NARS2	0.61	11.36	0.47	1.45e-26	Alzheimer's disease (survival time);
LGG	cis	rs9393692	0.557	rs62394768	chr6:26326033	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.44	-0.4	1.78e-19	Educational attainment;
LGG	cis	rs7617773	0.743	rs11716371	chr3:48362750	C/T	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	14.8	0.57	7.14e-41	Age at first birth;
LGG	cis	rs4566357	0.615	rs10174591	chr2:227913140	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.05	-0.39	3.88e-18	Coronary artery disease;
LGG	trans	rs11875185	0.510	rs113057265	chr18:55620853	A/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.91e-14	Rheumatoid arthritis;
LGG	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.8	0.54	1.55e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1707322	0.685	rs28617418	chr1:46189526	T/A	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg19673125	chr6:150240577	RAET1G	0.36	8.92	0.38	1.07e-17	Testicular germ cell tumor;
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg07243736	chr16:783730	NARFL	0.42	7.18	0.32	2.74e-12	Height;
LGG	trans	rs6601327	0.600	rs4841219	chr8:9654185	A/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.91	-0.31	1.61e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11096990	0.634	rs17431358	chr4:39277296	T/C	cg24403649	chr4:39172243	NA	-0.39	-6.95	-0.31	1.21e-11	Cognitive function;
LGG	cis	rs2180341	0.532	rs6933893	chr6:127707250	A/G	cg24812749	chr6:127587940	RNF146	0.64	10.81	0.45	1.86e-24	Breast cancer;
LGG	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg15704280	chr7:45808275	SEPT13	-0.59	-10.15	-0.43	5.67e-22	HDL cholesterol;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.99	-0.49	4.77e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg02002194	chr4:3960332	NA	-0.51	-10.3	-0.43	1.48e-22	Mood instability;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.33	-0.36	9.05e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.690	rs207102	chr6:66795671	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs3087591	0.708	rs10445402	chr17:29661340	G/T	cg24425628	chr17:29625626	OMG;NF1	0.6	12.34	0.5	1.99e-30	Hip circumference;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16027622	chr11:93517359	MED17	-0.37	-6.69	-0.3	6.53e-11	Brain structure;
LGG	cis	rs7828089	0.582	rs7825938	chr8:22266866	G/A	cg12081754	chr8:22256438	SLC39A14	0.98	20.68	0.69	9.21e-68	Verbal declarative memory;
LGG	cis	rs35110281	0.667	rs7282122	chr21:45082365	G/A	cg04455712	chr21:45112962	RRP1B	0.55	10.39	0.43	7.15e-23	Mean corpuscular volume;
LGG	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg03847636	chr4:7070632	GRPEL1	0.53	6.79	0.3	3.45e-11	Monocyte percentage of white cells;
LGG	cis	rs1008375	1.000	rs10032326	chr4:17630717	A/T	cg04450456	chr4:17643702	FAM184B	0.33	7.23	0.32	2.03e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13243377	chr8:17103891	CNOT7;VPS37A	0.48	7.37	0.32	7.9e-13	Gut microbiome composition (summer);
LGG	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg04731861	chr2:219085781	ARPC2	0.29	6.82	0.3	2.87e-11	Ulcerative colitis;
LGG	cis	rs9807841	0.544	rs10417412	chr19:10766798	A/C	cg17710535	chr19:10819994	QTRT1	0.44	6.78	0.3	3.73e-11	Inflammatory skin disease;
LGG	cis	rs9341835	0.772	rs9341841	chr6:64135010	G/A	cg00787780	chr6:64151745	NA	0.42	7.67	0.34	1.02e-13	Schizophrenia;
LGG	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg17927777	chr20:33865990	NA	0.75	10.72	0.45	4.37e-24	Attention deficit hyperactivity disorder;
LGG	cis	rs9649465	1.000	rs10270877	chr7:123327860	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs1784581	0.674	rs1789996	chr6:162391895	T/C	cg17173639	chr6:162384350	PARK2	-0.76	-17.2	-0.62	1.2e-51	Itch intensity from mosquito bite;
LGG	cis	rs9815354	0.812	rs73073230	chr3:42008263	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.28	0.4	6.36e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6693567	0.545	rs5011187	chr1:150422761	T/C	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg02462569	chr6:150064036	NUP43	-0.37	-7.69	-0.34	8.86e-14	Lung cancer;
LGG	cis	rs12142240	0.698	rs6697123	chr1:46811310	A/C	cg25706281	chr1:46860511	FAAH	-0.29	-7.02	-0.31	7.82e-12	Menopause (age at onset);
LGG	cis	rs584438	0.837	rs10852940	chr17:38590706	G/C	cg09358481	chr17:38600305	IGFBP4	-0.45	-8.6	-0.37	1.21e-16	Height;
LGG	cis	rs1023500	0.551	rs133379	chr22:42468535	A/G	cg15557168	chr22:42548783	NA	-0.42	-8.81	-0.38	2.52e-17	Schizophrenia;
LGG	cis	rs9807989	0.524	rs2110662	chr2:103020139	A/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg22857025	chr5:266934	NA	-1.39	-12.9	-0.51	9.55e-33	Breast cancer;
LGG	cis	rs62238980	0.614	rs117581209	chr22:32420212	T/C	cg00543991	chr22:32367038	NA	0.78	8.58	0.37	1.46e-16	Childhood ear infection;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg20308403	chr7:2120281	MAD1L1	0.34	7.36	0.32	8.68e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg25358565	chr5:93447407	FAM172A	1.26	15.36	0.58	2.4e-43	Diabetic retinopathy;
LGG	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-7.04	-0.31	7.16e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs881375	0.967	rs10733648	chr9:123700779	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.84	0.38	2.08e-17	Rheumatoid arthritis;
LGG	cis	rs2230307	0.572	rs17122001	chr1:100628311	A/T	cg24955406	chr1:100503596	HIAT1	0.59	7.83	0.34	3.37e-14	Carotid intima media thickness;
LGG	cis	rs9964724	1.000	rs1941954	chr18:35159596	A/C	cg27332583	chr18:35150602	NA	-0.49	-10.39	-0.43	7.28e-23	Educational attainment (years of education);
LGG	cis	rs2439831	0.850	rs28504496	chr15:44016883	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	10.24	0.43	2.56e-22	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg06481639	chr22:41940642	POLR3H	0.57	8.59	0.37	1.37e-16	Vitiligo;
LGG	cis	rs9902453	0.967	rs61240589	chr17:28449035	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.86e-34	Coffee consumption (cups per day);
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.45	0.61	3.22e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.36	-0.32	8.74e-13	Life satisfaction;
LGG	cis	rs787274	1.000	rs787298	chr9:115542206	C/T	cg13803584	chr9:115635662	SNX30	-0.55	-7.72	-0.34	7.01e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.49	0.53	3.21e-35	Obesity-related traits;
LGG	cis	rs227833	0.560	rs227817	chr6:44674765	T/C	cg18551225	chr6:44695536	NA	-0.49	-6.9	-0.31	1.67e-11	Monobrow;
LGG	cis	rs2247341	0.894	rs2592831	chr4:1711404	T/C	cg08629884	chr4:1719983	TMEM129	-0.56	-10.67	-0.44	6.58e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-12.87	-0.51	1.31e-32	Morning vs. evening chronotype;
LGG	cis	rs1209950	0.866	rs1734588	chr21:40180889	A/G	cg01359822	chr21:40176597	ETS2	0.36	8.01	0.35	9.68e-15	Non-small cell lung cancer (survival);
LGG	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.57e-15	Coronary artery disease;
LGG	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	9.25	0.39	8.41e-19	Type 2 diabetes;
LGG	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg18105134	chr13:113819100	PROZ	0.65	13.42	0.53	6.42e-35	Platelet distribution width;
LGG	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg13393036	chr8:95962371	TP53INP1	-0.27	-7.16	-0.32	3.12e-12	Type 2 diabetes;
LGG	trans	rs6787172	0.622	rs7426603	chr3:158107097	A/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs709400	0.663	rs62007681	chr14:103884651	G/A	cg26031613	chr14:104095156	KLC1	0.78	13.44	0.53	5.38e-35	Body mass index;
LGG	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.35	-0.32	9.01e-13	Joint mobility (Beighton score);
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg04503457	chr17:41445688	NA	-0.38	-8.7	-0.37	5.8e-17	Menopause (age at onset);
LGG	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg16070123	chr10:51489643	NA	-0.4	-7.46	-0.33	4.44e-13	Prostate-specific antigen levels;
LGG	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg03929089	chr4:120376271	NA	-0.53	-8.98	-0.39	6.86e-18	HDL cholesterol;
LGG	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg24375607	chr4:120327624	NA	0.68	11.0	0.46	3.68e-25	Corneal astigmatism;
LGG	cis	rs9513627	1.000	rs7996624	chr13:100127541	G/T	cg25919922	chr13:100150906	NA	-0.73	-7.54	-0.33	2.53e-13	Obesity-related traits;
LGG	cis	rs80282103	0.618	rs74117848	chr10:1160974	T/G	cg08668510	chr10:1095578	IDI1	0.78	7.51	0.33	3.1400000000000003e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs67311347	0.824	rs59922539	chr3:40337110	G/A	cg13683864	chr3:40499215	RPL14	-0.87	-17.14	-0.62	2.29e-51	Renal cell carcinoma;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg16282339	chr11:47927019	NA	0.36	7.21	0.32	2.3e-12	Electrocardiographic conduction measures;
LGG	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg19338460	chr6:170058176	WDR27	-0.69	-8.4	-0.36	5.56e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg14541582	chr5:601475	NA	-0.57	-9.16	-0.39	1.71e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs9443189	0.570	rs504323	chr6:76294965	A/G	cg01950844	chr6:76311363	SENP6	-0.71	-8.95	-0.38	8.73e-18	Prostate cancer;
LGG	cis	rs981844	0.826	rs4585278	chr4:154684145	A/G	cg14289246	chr4:154710475	SFRP2	0.67	11.4	0.47	1.04e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs6840360	0.571	rs12647566	chr4:152482525	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.33	-0.36	8.9e-16	Intelligence (multi-trait analysis);
LGG	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.52	-0.33	2.92e-13	Subjective well-being;
LGG	cis	rs7474896	0.515	rs2738203	chr10:38277596	G/A	cg00409905	chr10:38381863	ZNF37A	0.47	6.73	0.3	4.95e-11	Obesity (extreme);
LGG	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg01244601	chr4:120671846	NA	-0.36	-6.93	-0.31	1.42e-11	Corneal astigmatism;
LGG	cis	rs2273669	0.667	rs12206606	chr6:109353519	C/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22857025	chr5:266934	NA	-1.53	-26.16	-0.77	2.64e-93	Breast cancer;
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg06197492	chr11:2016605	H19	0.51	10.13	0.43	6.63e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs283228	0.798	rs507292	chr6:101772447	A/G	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs1010254	0.510	rs1363419	chr5:151696411	A/G	cg12297329	chr5:152029980	NA	-0.47	-6.82	-0.3	2.8e-11	Optic nerve measurement (cup area);
LGG	cis	rs61935443	0.720	rs10859783	chr12:95285339	A/G	cg21533806	chr12:95267307	NA	0.51	6.8	0.3	3.24e-11	Schizophrenia;
LGG	cis	rs867371	0.929	rs7173852	chr15:82461853	A/G	cg00614314	chr15:82944287	LOC80154	0.58	9.85	0.42	6.4e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.11	0.52	1.33e-33	Obesity-related traits;
LGG	cis	rs12928939	0.723	rs28667298	chr16:71855134	T/G	cg03805757	chr16:71968109	PKD1L3	-0.6	-11.41	-0.47	9.55e-27	Post bronchodilator FEV1;
LGG	cis	rs2880765	0.835	rs11074276	chr15:86030363	C/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	cis	rs11252926	0.528	rs11252090	chr10:436547	C/T	cg16386425	chr10:429943	DIP2C	0.45	9.19	0.39	1.3e-18	Psychosis in Alzheimer's disease;
LGG	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.38e-15	Myopia (pathological);
LGG	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.72	-9.07	-0.39	3.51e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg11317459	chr13:21872234	NA	-1.18	-19.42	-0.67	6.9e-62	White matter hyperintensity burden;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg15394860	chr11:2017084	H19	0.63	13.87	0.54	7.66e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	ch.1.194281253F	chr1:196014630	NA	-0.41	-6.77	-0.3	3.96e-11	Pancreatic cancer;
LGG	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.58	-0.37	1.44e-16	Triglycerides;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.22e-26	Personality dimensions;
LGG	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg20892847	chr12:58011875	NA	0.4	8.64	0.37	9.05e-17	Multiple sclerosis;
LGG	trans	rs35110281	0.837	rs2838341	chr21:45076443	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.16	0.43	4.9e-22	Mean corpuscular volume;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-9.78	-0.41	1.15e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.79	0.3	3.45e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17453880	0.643	rs7701534	chr5:151952520	T/G	cg10931792	chr5:152022470	NA	0.38	8.22	0.36	2.09e-15	Subjective well-being;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg16339924	chr4:17578868	LAP3	0.62	10.9	0.45	9.04e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg11764359	chr7:65958608	NA	0.75	13.4	0.53	7.98e-35	Aortic root size;
LGG	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.67	-0.34	1.04e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.71	-0.3	5.68e-11	Neuroticism;
LGG	cis	rs3857536	0.741	rs9363558	chr6:66937260	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg23758822	chr17:41437982	NA	0.9	15.87	0.59	1.4e-45	Menopause (age at onset);
LGG	cis	rs889312	0.500	rs702688	chr5:56190986	A/G	cg14703610	chr5:56206110	C5orf35	0.43	7.35	0.32	9.11e-13	Breast cancer;Breast cancer (early onset);
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.32	-0.5	2.23e-30	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2613964	0.504	rs2399465	chr3:112847992	A/G	cg16248390	chr3:112854924	NA	0.51	10.73	0.45	3.82e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs34929064	0.536	rs2961279	chr7:22638154	T/C	cg23521230	chr7:22704884	NA	0.44	7.91	0.34	1.97e-14	Major depression and alcohol dependence;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg04267008	chr7:1944627	MAD1L1	-0.5	-8.31	-0.36	1.06e-15	Schizophrenia;
LGG	cis	rs9506514	0.722	rs11147813	chr13:21258558	T/C	cg27499820	chr13:21296301	IL17D	-0.24	-7.0	-0.31	8.86e-12	Coronary artery calcification;
LGG	cis	rs9443645	0.901	rs4415132	chr6:79554107	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4965869	0.866	rs2412014	chr15:101974398	A/G	cg12371147	chr15:101978424	PCSK6	-0.4	-7.3	-0.32	1.29e-12	Platelet-derived growth factor BB levels;
LGG	trans	rs75804782	0.521	rs72993056	chr2:239404671	G/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.73	0.38	4.54e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg19812747	chr11:111475976	SIK2	0.48	9.51	0.4	1.01e-19	Primary sclerosing cholangitis;
LGG	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.52	-0.37	2.28e-16	Alzheimer's disease (survival time);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17417191	chr1:218458683	RRP15	0.49	7.93	0.35	1.68e-14	Cognitive performance;
LGG	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.44	7.74	0.34	6.21e-14	Alzheimer's disease (late onset);
LGG	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.06	19.42	0.67	6.65e-62	Gut microbiome composition (summer);
LGG	cis	rs11074306	0.561	rs7163137	chr15:28065601	A/C	cg26402630	chr15:28053930	OCA2	0.36	7.24	0.32	1.83e-12	Uveal melanoma;
LGG	cis	rs7301826	0.603	rs7975825	chr12:131288444	C/T	cg11011512	chr12:131303247	STX2	0.36	7.76	0.34	5.32e-14	Plasma plasminogen activator levels;
LGG	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg08704250	chr15:31115839	NA	-0.42	-7.79	-0.34	4.36e-14	Huntington's disease progression;
LGG	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.48	-0.4	1.34e-19	Retinal vascular caliber;
LGG	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs6503525	0.591	rs8080734	chr17:38103285	G/A	cg17467752	chr17:38218738	THRA	0.47	7.88	0.34	2.43e-14	Asthma;
LGG	cis	rs295140	0.546	rs295119	chr2:201117944	C/T	cg23649088	chr2:200775458	C2orf69	0.46	7.93	0.35	1.6e-14	QT interval;
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.23	0.32	2.04e-12	Height;
LGG	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg03517284	chr6:25882590	NA	-0.42	-6.84	-0.3	2.55e-11	Iron status biomarkers;
LGG	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.16	0.55	4.57e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3091242	0.933	rs61775174	chr1:25787313	G/A	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.04	-0.39	4.27e-18	Erythrocyte sedimentation rate;
LGG	cis	rs9783347	0.961	rs2061163	chr11:18322924	A/C	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.06	-0.31	6e-12	Pancreatic cancer;
LGG	cis	rs2712184	0.756	rs715049	chr2:217657102	C/T	cg05032264	chr2:217675019	NA	-0.43	-9.45	-0.4	1.68e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg20040747	chr15:74715105	SEMA7A	0.36	6.71	0.3	5.6e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.15	-0.35	3.39e-15	Total body bone mineral density;
LGG	trans	rs1814175	0.529	rs10839396	chr11:49852406	G/T	cg11707556	chr5:10655725	ANKRD33B	0.65	12.16	0.49	1.02e-29	Height;
LGG	cis	rs7385804	0.727	rs221790	chr7:100278282	G/C	cg16850897	chr7:100343110	ZAN	0.44	7.0	0.31	8.86e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg26174226	chr8:58114915	NA	0.6	8.48	0.37	3.03e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-13.02	-0.52	3.06e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs853679	0.517	rs11552219	chr6:28126834	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs1358748	0.522	rs2092911	chr1:67574319	T/G	cg02640540	chr1:67518911	SLC35D1	0.55	6.69	0.3	6.43e-11	Tuberculosis;
LGG	cis	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.58e-15	Retinal vascular caliber;
LGG	cis	rs9399135	0.660	rs4646868	chr6:135271946	A/G	cg22676075	chr6:135203613	NA	0.41	7.36	0.32	8.72e-13	Red blood cell count;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.52e-13	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.05	0.31	6.4e-12	Lung cancer;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07659893	chr17:61819838	STRADA	-0.44	-7.23	-0.32	1.96e-12	Prudent dietary pattern;
LGG	cis	rs4743820	0.620	rs10991784	chr9:93917094	T/C	cg14446406	chr9:93919335	NA	-0.9	-15.15	-0.58	2.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9487051	0.768	rs2483913	chr6:109521042	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs926938	0.520	rs6663115	chr1:115272254	G/A	cg12756093	chr1:115239321	AMPD1	-0.53	-9.08	-0.39	3.12e-18	Autism;
LGG	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg22496380	chr5:211416	CCDC127	-1.34	-18.55	-0.65	7.6e-58	Breast cancer;
LGG	cis	rs6450176	0.633	rs391448	chr5:53332323	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.58	-0.47	1.99e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	cis	rs11098499	0.955	rs1511018	chr4:120161580	G/T	cg24375607	chr4:120327624	NA	0.62	10.35	0.43	1e-22	Corneal astigmatism;
LGG	cis	rs17453880	0.853	rs6885419	chr5:152027678	T/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs6743376	0.556	rs2515397	chr2:113819258	T/C	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.18e-18	Inflammatory biomarkers;
LGG	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg17219203	chr10:38645113	HSD17B7P2	0.4	6.7	0.3	6.09e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9815354	0.951	rs1716679	chr3:41905339	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg24232236	chr22:38142998	TRIOBP	0.38	7.38	0.32	7.23e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg12070911	chr6:150209640	RAET1E	0.28	7.24	0.32	1.94e-12	Testicular germ cell tumor;
LGG	cis	rs752092	0.894	rs8036083	chr15:101767822	T/G	cg25114630	chr15:101792522	CHSY1	0.55	9.29	0.4	6.25e-19	Corneal structure;
LGG	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg13770153	chr20:60521292	NA	0.6	9.19	0.39	1.31e-18	Body mass index;
LGG	cis	rs4604732	0.536	rs12037221	chr1:247631212	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.22	0.39	1.05e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg07930552	chr6:133119739	C6orf192	0.88	11.66	0.48	1.03e-27	Type 2 diabetes nephropathy;
LGG	cis	rs67460515	0.892	rs35310734	chr3:160943209	T/G	cg03342759	chr3:160939853	NMD3	-0.76	-13.65	-0.54	6.59e-36	Parkinson's disease;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg01059449	chr18:44338099	ST8SIA5	0.39	8.58	0.37	1.49e-16	Personality dimensions;
LGG	trans	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg02002194	chr4:3960332	NA	0.38	6.98	0.31	1e-11	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg25358565	chr5:93447407	FAM172A	1.3	15.75	0.59	4.41e-45	Diabetic retinopathy;
LGG	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg00666640	chr1:248458726	OR2T12	-0.57	-8.81	-0.38	2.53e-17	Common traits (Other);
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg24829409	chr8:58192753	C8orf71	-0.77	-10.37	-0.43	8.28e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs41278232	1.000	rs73153168	chr20:62677563	A/G	cg03065311	chr20:62601662	ZNF512B	0.62	8.98	0.39	6.89e-18	Tonsillectomy;
LGG	cis	rs9649465	0.934	rs718781	chr7:123313573	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs5769707	0.568	rs2011097	chr22:50018069	A/G	cg06623630	chr22:50017776	C22orf34	-0.51	-10.43	-0.44	4.95e-23	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25509782	chr9:108210743	FSD1L	0.42	7.12	0.31	4.09e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1697139	0.583	rs1428474	chr5:66544015	C/A	cg11553311	chr5:66541588	NA	0.46	10.15	0.43	5.32e-22	Breast cancer;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg04267008	chr7:1944627	MAD1L1	-0.78	-13.99	-0.55	2.44e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg13147721	chr7:65941812	NA	-0.78	-9.53	-0.4	8.95e-20	Diabetic kidney disease;
LGG	cis	rs8028182	0.636	rs4886699	chr15:75692303	A/C	cg20655648	chr15:75932815	IMP3	0.46	7.87	0.34	2.57e-14	Sudden cardiac arrest;
LGG	cis	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.84	0.57	5.04e-41	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg08888203	chr3:10149979	C3orf24	0.57	9.58	0.41	5.91e-20	Alzheimer's disease;
LGG	cis	rs988958	0.526	rs7592119	chr2:42243667	T/A	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Hypospadias;
LGG	cis	rs4919044	0.808	rs835275	chr10:94796683	T/C	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg25703541	chr22:24373054	LOC391322	-0.97	-19.67	-0.67	4.62e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs367943	0.712	rs9326884	chr5:112697520	C/A	cg12552261	chr5:112820674	MCC	0.58	10.43	0.44	5.16e-23	Type 2 diabetes;
LGG	cis	rs6964587	1.000	rs13224513	chr7:91601465	G/A	cg17063962	chr7:91808500	NA	0.48	8.63	0.37	1.01e-16	Breast cancer;
LGG	cis	rs7444	0.825	rs2256609	chr22:21925017	A/G	cg11654148	chr22:21984483	YDJC	-0.41	-7.8	-0.34	4.25e-14	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.57	-0.44	1.55e-23	Bladder cancer;
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg02002194	chr4:3960332	NA	0.48	9.26	0.4	7.53e-19	Joint mobility (Beighton score);
LGG	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs2249625	0.545	rs2496487	chr6:72875226	G/C	cg27608224	chr6:72922399	RIMS1	0.32	7.22	0.32	2.11e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs3816183	0.547	rs12712841	chr2:42741424	G/C	cg14631114	chr2:43023945	NA	0.43	7.97	0.35	1.28e-14	Hypospadias;
LGG	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	8.03e-13	Uric acid levels;
LGG	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg00777063	chr17:45855553	NA	-0.32	-6.78	-0.3	3.76e-11	IgG glycosylation;
LGG	cis	rs7918232	0.698	rs6482586	chr10:27297829	A/C	cg14442939	chr10:27389572	ANKRD26	0.54	8.47	0.37	3.23e-16	Breast cancer;
LGG	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg21775007	chr8:11205619	TDH	0.61	10.02	0.42	1.64e-21	Retinal vascular caliber;
LGG	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg08773314	chr2:239334832	ASB1	0.41	7.9	0.34	2.08e-14	Multiple system atrophy;
LGG	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.47	0.5	5.42e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs41271951	0.558	rs79671334	chr1:151115887	C/G	cg11822372	chr1:151115635	SEMA6C	-0.77	-7.14	-0.31	3.64e-12	Blood protein levels;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7166081	1.000	rs877177	chr15:67505960	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.86	-0.3	2.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg21911579	chr5:131705225	SLC22A5	0.67	7.55	0.33	2.4e-13	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.15e-21	Lung cancer;
LGG	cis	rs1107366	0.722	rs9851577	chr3:125908310	C/T	cg06827562	chr3:125932279	NA	0.58	13.63	0.54	8.05e-36	Metabolite levels;
LGG	cis	rs7104764	0.507	rs6598054	chr11:254010	C/T	cg00562011	chr11:252351	PSMD13	0.45	6.65	0.3	8.12e-11	Menarche (age at onset);
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00689492	chr4:1303491	MAEA	0.47	8.09	0.35	5.16e-15	Obesity-related traits;
LGG	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg07549998	chr6:150325970	RAET1K	-0.36	-6.88	-0.3	1.96e-11	Alopecia areata;
LGG	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.85e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9463078	0.838	rs2396373	chr6:44983134	G/A	cg25276700	chr6:44698697	NA	-0.34	-7.15	-0.32	3.37e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs62400317	0.762	rs12214794	chr6:44931465	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.22	-0.46	5.08e-26	Total body bone mineral density;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg11028950	chr20:50808697	ZFP64	-0.46	-6.79	-0.3	3.41e-11	Educational attainment (years of education);
LGG	cis	rs806215	0.547	rs11772303	chr7:127398962	G/T	cg25922125	chr7:127225783	GCC1	-0.49	-7.14	-0.31	3.75e-12	Type 2 diabetes;
LGG	cis	rs490234	0.702	rs12553882	chr9:128195044	G/A	cg14078157	chr9:128172775	NA	-0.53	-9.86	-0.42	6.11e-21	Mean arterial pressure;
LGG	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg16096631	chr1:42092165	HIVEP3	0.8	24.64	0.75	2.86e-86	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-10.56	-0.44	1.74e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06924873	chr2:172943770	MAP1D	0.31	6.91	0.31	1.59e-11	Menarche (age at onset);
LGG	cis	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg26384229	chr12:38710491	ALG10B	1.06	28.23	0.8	1.09e-102	Heart rate;
LGG	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.27e-22	Height;
LGG	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg06718696	chr17:78121285	EIF4A3	0.45	7.02	0.31	8e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg27432699	chr2:27873401	GPN1	0.66	13.14	0.52	9.76e-34	Oral cavity cancer;
LGG	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg06219351	chr7:158114137	PTPRN2	-0.83	-14.32	-0.55	9.03e-39	Response to amphetamines;
LGG	cis	rs778371	0.522	rs6704768	chr2:233592501	C/T	cg08000102	chr2:233561755	GIGYF2	0.61	10.62	0.44	9.87e-24	Schizophrenia;
LGG	trans	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg09872104	chr7:134855509	C7orf49	-0.72	-6.69	-0.3	6.47e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg11430096	chr6:110968061	CDK19	0.65	6.65	0.3	8.04e-11	Prostate cancer;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg22968622	chr17:43663579	NA	1.08	20.74	0.69	4.76e-68	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23829577	chr6:160183769	ACAT2	0.42	6.86	0.3	2.27e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg00292662	chr22:38071168	LGALS1	0.88	23.73	0.74	5.06e-82	Fat distribution (HIV);
LGG	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg24607181	chr17:41446203	NA	-0.29	-6.76	-0.3	4.22e-11	Menopause (age at onset);
LGG	cis	rs734999	0.588	rs2985859	chr1:2532416	T/C	cg18854424	chr1:2615690	NA	-0.35	-7.14	-0.31	3.73e-12	Ulcerative colitis;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	cis	rs6032067	0.561	rs6032104	chr20:43932412	G/A	cg10761708	chr20:43804764	PI3	0.56	8.61	0.37	1.15e-16	Blood protein levels;
LGG	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg07936489	chr17:37558343	FBXL20	-0.99	-15.47	-0.58	8.25e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg02073558	chr3:44770973	ZNF501	-0.86	-19.07	-0.66	3.08e-60	Depressive symptoms;
LGG	cis	rs2067615	0.524	rs10778500	chr12:107074410	T/A	cg15890332	chr12:107067104	RFX4	0.44	12.8	0.51	2.39e-32	Heart rate;
LGG	cis	rs7084402	0.935	rs4948523	chr10:60339098	A/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.18	-0.32	2.73e-12	Refractive error;
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	6.99	0.31	9.78e-12	Schizophrenia;
LGG	cis	rs9920506	0.536	rs1316971	chr15:78930510	A/G	cg07120314	chr15:79043507	NA	-0.49	-8.83	-0.38	2.21e-17	Post bronchodilator FEV1;
LGG	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg03929089	chr4:120376271	NA	-0.67	-9.78	-0.41	1.12e-20	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.41	-0.33	6.16e-13	Uric acid levels;
LGG	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-9.69	-0.41	2.37e-20	Schizophrenia;
LGG	cis	rs9457247	0.967	rs430145	chr6:167410369	C/T	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs9296249	0.514	rs57137936	chr6:38410783	T/A	cg07362130	chr6:38359646	BTBD9	-0.34	-7.67	-0.34	1.03e-13	Restless legs syndrome;
LGG	cis	rs600231	0.708	rs2957269	chr11:65243007	C/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.07	-0.39	3.33e-18	Bone mineral density;
LGG	cis	rs36071027	0.577	rs11740411	chr5:158396215	C/T	cg04248271	chr5:158524404	EBF1	0.41	7.24	0.32	1.89e-12	Carotid intima media thickness;
LGG	cis	rs4481887	0.861	rs6676061	chr1:248443887	G/C	cg13385794	chr1:248469461	NA	0.47	7.75	0.34	5.72e-14	Common traits (Other);
LGG	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg03929089	chr4:120376271	NA	-0.67	-9.24	-0.39	8.79e-19	Axial length;
LGG	cis	rs6598955	0.671	rs17257176	chr1:26578233	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	cis	rs4538187	0.865	rs11686956	chr2:63938708	T/G	cg19915305	chr2:64069682	UGP2	-0.62	-13.75	-0.54	2.45e-36	Systolic blood pressure;
LGG	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.14	0.72	1.26e-74	Bladder cancer;
LGG	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg08344181	chr3:125677491	NA	-0.67	-7.56	-0.33	2.12e-13	Depression;
LGG	cis	rs9600832	0.597	rs9544444	chr13:36066578	G/A	cg20704442	chr13:36052768	MIR548F5;NBEA	0.41	11.96	0.49	6.36e-29	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	trans	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg16141378	chr3:129829833	LOC729375	0.34	7.68	0.34	9.32e-14	Mood instability;
LGG	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-9.57	-0.41	6.64e-20	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05300158	chr4:140477727	SETD7	-0.56	-8.23	-0.36	1.9e-15	Systemic lupus erythematosus;
LGG	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg25427524	chr10:38739819	LOC399744	-0.37	-6.68	-0.3	6.71e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg03909863	chr11:638404	DRD4	-0.41	-6.86	-0.3	2.24e-11	Systemic lupus erythematosus;
LGG	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg17691542	chr6:26056736	HIST1H1C	0.45	7.64	0.33	1.27e-13	Blood metabolite levels;
LGG	trans	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg02900749	chr2:68251473	NA	-1.07	-11.46	-0.47	6.15e-27	Pursuit maintenance gain;
LGG	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg22348356	chr13:114891224	RASA3	0.39	7.51	0.33	3e-13	Schizophrenia;
LGG	cis	rs10463316	0.784	rs906678	chr5:150779040	T/C	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.76	-0.41	1.32e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs2180341	0.782	rs6924274	chr6:127721556	T/A	cg27446573	chr6:127587934	RNF146	0.89	17.21	0.62	1.14e-51	Breast cancer;
LGG	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.18	-0.32	2.86e-12	Obesity;
LGG	cis	rs300703	1.000	rs300703	chr2:239416	C/T	cg21211680	chr2:198530	NA	1.25	14.94	0.57	1.86e-41	Blood protein levels;
LGG	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.68	-0.3	6.72e-11	Iron status biomarkers;
LGG	trans	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.52e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4746818	1.000	rs906217	chr10:70954661	T/C	cg11621586	chr10:70884670	VPS26A	1.14	16.23	0.6	3.37e-47	Left atrial antero-posterior diameter;
LGG	cis	rs4742903	0.935	rs10122352	chr9:106993511	T/C	cg14250997	chr9:106856677	SMC2	0.38	7.76	0.34	5.37e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.65	0.34	1.16e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.31	-0.4	5.23e-19	Mood instability;
LGG	cis	rs2342371	0.756	rs4916492	chr3:196106306	G/A	cg15048948	chr3:196158458	UBXN7	0.62	10.44	0.44	4.7e-23	Fat distribution (HIV);
LGG	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg06374794	chr16:88002281	BANP	0.43	7.78	0.34	4.92e-14	Menopause (age at onset);
LGG	cis	rs600231	0.542	rs11227199	chr11:65238121	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.71	-0.38	5.56e-17	Bone mineral density;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg00495681	chr13:53174319	NA	0.56	10.34	0.43	1.07e-22	Lewy body disease;
LGG	cis	rs67478160	0.595	rs12879501	chr14:104272634	G/T	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	cis	rs6933660	0.800	rs6931104	chr6:151786177	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.85	0.42	6.62e-21	Menarche (age at onset);
LGG	cis	rs12477438	0.501	rs6542881	chr2:100089871	A/C	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg26384229	chr12:38710491	ALG10B	0.64	12.38	0.5	1.28e-30	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21582582	chr3:182698605	DCUN1D1	0.43	7.46	0.33	4.19e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg07636037	chr3:49044803	WDR6	1.09	27.65	0.79	4.44e-100	Parkinson's disease;
LGG	cis	rs701145	0.585	rs357466	chr3:153902868	A/G	cg17054900	chr3:154042577	DHX36	0.88	10.21	0.43	3.42e-22	Coronary artery disease;
LGG	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg22875332	chr1:76189707	ACADM	0.59	8.86	0.38	1.72e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7312933	1.000	rs12372623	chr12:42531666	G/A	cg19980929	chr12:42632907	YAF2	0.34	7.56	0.33	2.16e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4805272	0.512	rs4805278	chr19:29336664	C/T	cg04546413	chr19:29218101	NA	0.66	8.93	0.38	1.01e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9911578	1.000	rs304270	chr17:56802141	A/G	cg12560992	chr17:57184187	TRIM37	-0.88	-15.88	-0.59	1.25e-45	Intelligence (multi-trait analysis);
LGG	cis	rs365132	0.517	rs7706790	chr5:176359136	C/T	cg16309518	chr5:176445507	NA	-0.51	-10.1	-0.43	8e-22	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.78	-0.3	3.79e-11	Parkinson's disease;
LGG	cis	rs7584262	0.535	rs114695310	chr2:42238625	C/T	cg27428208	chr2:42229179	NA	0.53	7.56	0.33	2.13e-13	Bone mineral density;
LGG	cis	rs9487051	0.735	rs1260594	chr6:109519891	A/C	cg21918786	chr6:109611834	NA	-0.41	-7.57	-0.33	2.06e-13	Reticulocyte fraction of red cells;
LGG	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg15557168	chr22:42548783	NA	-0.42	-8.67	-0.37	7.15e-17	Schizophrenia;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg02951883	chr7:2050386	MAD1L1	-0.76	-15.85	-0.59	1.65e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.42	7.09	0.31	4.88e-12	Longevity;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.14e-12	Menopause (age at onset);
LGG	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.22	-0.32	2.14e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs4950322	0.634	rs4950415	chr1:146822702	G/C	cg22381352	chr1:146742008	CHD1L	-0.46	-7.46	-0.33	4.28e-13	Protein quantitative trait loci;
LGG	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.59	-0.44	1.24e-23	Total cholesterol levels;
LGG	cis	rs9357271	1.000	rs2294739	chr6:38336289	T/G	cg07362130	chr6:38359646	BTBD9	-0.49	-10.98	-0.45	4.36e-25	Restless legs syndrome;
LGG	cis	rs6908034	0.607	rs79842087	chr6:19821316	G/A	cg02682789	chr6:19804855	NA	0.9	8.41	0.36	4.95e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.08	-0.35	5.67e-15	Myopia (pathological);
LGG	cis	rs9487051	0.708	rs378447	chr6:109526823	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.47e-11	Reticulocyte fraction of red cells;
LGG	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.41	0.4	2.38e-19	Rheumatoid arthritis;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.36	-0.53	1.19e-34	Personality dimensions;
LGG	trans	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-12.03	-0.49	3.48e-29	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs11971779	0.680	rs7799598	chr7:139051833	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs738321	0.756	rs12169611	chr22:38513735	T/C	cg25457927	chr22:38595422	NA	-0.36	-8.34	-0.36	8.29e-16	Breast cancer;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg00800038	chr16:89945340	TCF25	-0.7	-7.99	-0.35	1.06e-14	Skin colour saturation;
LGG	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg08305652	chr11:111469057	NA	0.43	8.62	0.37	1.04e-16	Primary sclerosing cholangitis;
LGG	cis	rs882632	0.702	rs34360803	chr2:29291931	G/A	cg23429306	chr2:29287725	C2orf71	0.39	7.85	0.34	2.93e-14	Major depressive disorder;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg14088196	chr11:70211408	PPFIA1	0.96	13.11	0.52	1.35e-33	Coronary artery disease;
LGG	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.91	-0.31	1.63e-11	Caffeine consumption;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.53	9.13	0.39	2.08e-18	Obesity-related traits;
LGG	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg01864069	chr14:103024347	NA	-0.68	-9.87	-0.42	5.39e-21	Platelet count;
LGG	cis	rs4975709	0.686	rs2307118	chr5:1881916	A/C	cg07747251	chr5:1868357	NA	0.41	7.0	0.31	9.08e-12	Cardiovascular disease risk factors;
LGG	cis	rs1371867	0.810	rs1618528	chr8:101259134	T/C	cg06636551	chr8:101224915	SPAG1	0.48	8.78	0.38	3.2e-17	Atrioventricular conduction;
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.23e-11	Educational attainment;
LGG	cis	rs9443645	0.901	rs10943605	chr6:79655477	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.64	-0.37	9.14e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-6.77	-0.3	3.86e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6704644	0.932	rs4047189	chr2:234442949	G/T	cg27060346	chr2:234359958	DGKD	-0.59	-7.21	-0.32	2.23e-12	Bilirubin levels;
LGG	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg23335576	chr14:104009727	NA	0.43	7.29	0.32	1.36e-12	Reticulocyte count;
LGG	cis	rs9814567	0.502	rs12634127	chr3:134256159	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.49	-8.58	-0.37	1.4e-16	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4889911	0.544	rs1285271	chr17:77834197	C/T	cg07923794	chr17:77834237	NA	0.88	13.53	0.53	2.22e-35	Electroencephalogram traits;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg15921436	chr17:44337874	NA	0.59	12.79	0.51	2.67e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7027203	1.000	rs7854820	chr9:96526027	A/G	cg14598338	chr9:96623480	NA	0.49	8.57	0.37	1.6e-16	DNA methylation (variation);
LGG	cis	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg08975724	chr8:8085496	FLJ10661	0.36	6.71	0.3	5.74e-11	Neuroticism;
LGG	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg03351412	chr1:154909251	PMVK	-0.48	-8.34	-0.36	8.69e-16	Prostate cancer;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7106204	0.590	rs7114724	chr11:24239976	A/G	ch.11.24196551F	chr11:24239977	NA	0.99	16.25	0.6	2.68e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs7193541	0.965	rs7184423	chr16:74709737	C/A	cg01733217	chr16:74700730	RFWD3	0.9	20.1	0.68	4.85e-65	Multiple myeloma;
LGG	cis	rs7937612	0.931	rs10892562	chr11:120221618	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.51	-0.5	3.92e-31	Intraocular pressure;
LGG	trans	rs17685	0.712	rs1637049	chr7:75729975	C/G	cg19862616	chr7:65841803	NCRNA00174	1.06	25.69	0.77	4.06e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg26384229	chr12:38710491	ALG10B	1.06	28.86	0.8	1.48e-105	Heart rate;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.43	7.85	0.34	3.02e-14	Longevity;
LGG	cis	rs9309473	1.000	rs10189574	chr2:73698518	C/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.46	-0.33	4.27e-13	Metabolite levels;
LGG	cis	rs7215564	0.818	rs4075782	chr17:78556325	A/G	cg16980736	chr17:78789706	RPTOR	0.66	8.3	0.36	1.12e-15	Myopia (pathological);
LGG	cis	rs7168592	1.000	rs35086434	chr15:101743925	A/C	cg24254196	chr15:101719523	CHSY1	-0.64	-7.16	-0.32	3.11e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg04851639	chr8:1020857	NA	-0.33	-6.9	-0.31	1.72e-11	Schizophrenia;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg02725872	chr8:58115012	NA	-0.78	-10.69	-0.44	5.41e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs7909791	0.743	rs11191832	chr10:105619362	T/C	cg11005552	chr10:105648138	OBFC1	0.64	9.61	0.41	4.59e-20	White matter hyperintensity burden;
LGG	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg11871910	chr12:69753446	YEATS4	0.66	12.33	0.5	2.12e-30	Response to diuretic therapy;
LGG	cis	rs2688419	0.527	rs1355740	chr3:23070957	C/T	cg00327796	chr3:23032191	NA	0.36	6.95	0.31	1.22e-11	Type 2 diabetes;
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25072359	chr17:41440525	NA	0.52	10.14	0.43	5.8e-22	Menopause (age at onset);
LGG	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg02227867	chr8:22457446	C8orf58	0.44	8.19	0.36	2.62e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7662987	0.517	rs2602872	chr4:100038996	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.62	0.41	4.46e-20	Smoking initiation;
LGG	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg00383909	chr3:49044727	WDR6	0.98	12.54	0.5	2.8e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg18187862	chr3:45730750	SACM1L	-0.68	-11.02	-0.46	3.09e-25	Primary sclerosing cholangitis;
LGG	cis	rs17818399	0.781	rs4952837	chr2:46865734	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-9.11	-0.39	2.44e-18	Height;
LGG	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.29	0.5	3.1e-30	Mean corpuscular hemoglobin;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg09739081	chr7:23719861	C7orf46	-0.37	-8.06	-0.35	6.58e-15	Schizophrenia;
LGG	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.37	6.69	0.3	6.47e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs988958	0.675	rs35657711	chr2:42216386	T/C	cg19376973	chr2:42229025	NA	0.62	9.48	0.4	1.31e-19	Hypospadias;
LGG	cis	rs17401966	0.894	rs12722830	chr1:10395134	A/G	cg15208524	chr1:10270712	KIF1B	0.42	7.3	0.32	1.27e-12	Hepatocellular carcinoma;
LGG	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.59	0.5	1.84e-31	Prudent dietary pattern;
LGG	cis	rs7100689	0.646	rs9804236	chr10:82135100	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.07	0.35	6.04e-15	Rheumatoid arthritis;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.68	-12.74	-0.51	4.45e-32	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg14829360	chr17:73884958	NA	-0.52	-9.99	-0.42	2.02e-21	White matter hyperintensity burden;
LGG	cis	rs60180747	0.544	rs11635253	chr15:66569207	C/T	cg07575407	chr15:66541975	MEGF11	0.63	13.57	0.53	1.55e-35	Testicular germ cell tumor;
LGG	cis	rs1971762	0.527	rs7972401	chr12:53940046	T/C	cg06632207	chr12:54070931	ATP5G2	0.21	6.76	0.3	4.2e-11	Height;
LGG	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.03	0.7	2.01e-69	Chronic sinus infection;
LGG	cis	rs3096299	0.503	rs4785677	chr16:89555101	A/G	cg06640241	chr16:89574553	SPG7	0.84	15.13	0.58	2.56e-42	Multiple myeloma (IgH translocation);
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg00689492	chr4:1303491	MAEA	-0.44	-7.41	-0.33	6.09e-13	Obesity-related traits;
LGG	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg10911889	chr6:126070802	HEY2	-0.45	-7.62	-0.33	1.4e-13	Brugada syndrome;
LGG	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.69	-0.37	6.25e-17	Retinal vascular caliber;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg18402987	chr7:1209562	NA	0.5	7.46	0.33	4.18e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg00490583	chr16:1843685	IGFALS	-0.42	-7.07	-0.31	5.65e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs7980799	0.682	rs1580396	chr12:33615841	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-11.8	-0.48	2.7e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2933343	1.000	rs1680795	chr3:128620388	T/C	cg25356066	chr3:128598488	ACAD9	0.46	6.72	0.3	5.47e-11	IgG glycosylation;
LGG	cis	rs1018836	0.923	rs12545279	chr8:91636373	C/G	cg16814680	chr8:91681699	NA	-0.82	-15.03	-0.57	6.96e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.86	-0.42	5.92e-21	Response to antipsychotic treatment;
LGG	cis	rs7590368	0.673	rs55648622	chr2:10932765	C/T	cg15705551	chr2:10952987	PDIA6	0.58	7.51	0.33	3.12e-13	Educational attainment (years of education);
LGG	cis	rs7107174	1.000	rs2510050	chr11:77982564	A/G	cg02023728	chr11:77925099	USP35	0.44	7.64	0.33	1.28e-13	Testicular germ cell tumor;
LGG	cis	rs4820539	0.932	rs3788349	chr22:23467950	A/G	cg14186256	chr22:23484241	RTDR1	1.0	25.39	0.76	1.01e-89	Bone mineral density;
LGG	cis	rs2797369	0.883	rs2518322	chr6:101690178	A/G	cg27451362	chr6:101846650	GRIK2	0.74	10.06	0.42	1.14e-21	Renal function-related traits (eGRFcrea);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19245361	chr17:61699734	MAP3K3	0.45	7.43	0.33	5.29e-13	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.839	rs9450333	chr6:86519755	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.81	-0.34	3.78e-14	Response to antipsychotic treatment;
LGG	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg09324608	chr17:30823087	MYO1D	0.31	7.34	0.32	9.54e-13	Schizophrenia;
LGG	cis	rs7924176	0.564	rs10762588	chr10:75985845	G/A	cg19889307	chr10:75911429	ADK;AP3M1	-0.42	-7.03	-0.31	7.44e-12	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg13877915	chr19:58951672	ZNF132	0.99	26.75	0.78	5.26e-96	Uric acid clearance;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.12	0.31	4.07e-12	Prudent dietary pattern;
LGG	cis	rs537930	0.560	rs658556	chr5:134356115	G/A	cg24576358	chr5:134350122	NA	0.41	8.79	0.38	2.85e-17	Height;
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg16507663	chr6:150244633	RAET1G	0.44	7.18	0.32	2.78e-12	Lung cancer;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg24642844	chr7:1081250	C7orf50	-0.48	-8.96	-0.38	8.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4356932	1.000	rs11097219	chr4:76980163	G/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg23758822	chr17:41437982	NA	0.83	14.7	0.56	1.94e-40	Menopause (age at onset);
LGG	cis	rs72781680	0.898	rs2339851	chr2:23938883	G/A	cg08917208	chr2:24149416	ATAD2B	0.87	9.33	0.4	4.4e-19	Lymphocyte counts;
LGG	cis	rs11112613	0.713	rs11112590	chr12:105951376	C/G	cg03607813	chr12:105948248	NA	-0.59	-10.38	-0.43	7.83e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg24692254	chr21:30365293	RNF160	-0.67	-12.31	-0.5	2.46e-30	Cognitive test performance;
LGG	cis	rs58688157	0.705	rs12272434	chr11:615011	A/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.46	-0.4	1.58e-19	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	6.83e-37	Prudent dietary pattern;
LGG	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg16482183	chr6:26056742	HIST1H1C	0.5	7.91	0.34	1.96e-14	Iron status biomarkers;
LGG	cis	rs6764363	0.654	rs408685	chr3:297928	G/A	cg02057681	chr3:285234	CHL1	0.38	6.9	0.31	1.69e-11	Sudden cardiac arrest;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02342362	chr19:12792713	DHPS	0.4	6.84	0.3	2.55e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2832191	0.755	rs2832192	chr21:30491173	G/T	cg24692254	chr21:30365293	RNF160	-0.93	-22.9	-0.73	3.69e-78	Dental caries;
LGG	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg04691961	chr3:161091175	C3orf57	0.43	9.19	0.39	1.29e-18	Morning vs. evening chronotype;
LGG	cis	rs7660883	1.000	rs3775217	chr4:88019467	A/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.25	-0.39	8.25e-19	HDL cholesterol levels;
LGG	cis	rs3740540	0.530	rs2362507	chr10:126290820	A/G	cg04949429	chr10:126290192	LHPP	0.6	11.49	0.47	4.53e-27	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg22105103	chr4:187893119	NA	-0.57	-10.9	-0.45	8.48e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg16507663	chr6:150244633	RAET1G	-0.47	-8.85	-0.38	1.86e-17	Lung cancer;
LGG	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg25486957	chr4:152246857	NA	-0.52	-8.67	-0.37	7.36e-17	Intelligence (multi-trait analysis);
LGG	cis	rs8114671	0.933	rs6087683	chr20:33774444	C/T	cg07148914	chr20:33460835	GGT7	0.42	6.81	0.3	3.13e-11	Height;
LGG	cis	rs6489785	0.775	rs2649998	chr12:121354489	T/C	cg02419362	chr12:121203948	SPPL3	0.46	7.14	0.31	3.73e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1978968	0.654	rs13056749	chr22:18402924	G/A	cg03078520	chr22:18463400	MICAL3	-0.51	-9.91	-0.42	3.92e-21	Presence of antiphospholipid antibodies;
LGG	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg25063058	chr15:52860530	ARPP19	0.56	7.86	0.34	2.73e-14	Schizophrenia;
LGG	cis	rs849898	1	rs849898	chr1:228153917	A/G	cg01200585	chr1:228362443	C1orf69	-0.45	-7.63	-0.33	1.33e-13	Parkinson's disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02249930	chr10:70166207	RUFY2	-0.41	-6.99	-0.31	9.75e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.81	-0.38	2.53e-17	Bladder cancer;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg05091796	chr16:4465799	CORO7	-0.65	-10.81	-0.45	1.96e-24	Schizophrenia;
LGG	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg08085267	chr17:45401833	C17orf57	0.59	11.72	0.48	5.68e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs283228	0.550	rs668048	chr6:101827363	G/A	cg02011392	chr6:101847541	GRIK2	0.52	6.93	0.31	1.38e-11	Coenzyme Q10 levels;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.33	-0.36	8.99e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg05552183	chr6:42928497	GNMT	0.48	14.73	0.56	1.54e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg16070123	chr10:51489643	NA	-0.39	-7.14	-0.31	3.67e-12	Prostate-specific antigen levels;
LGG	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg18567174	chr15:68126065	LBXCOR1	-0.39	-6.98	-0.31	1e-11	Restless legs syndrome;
LGG	cis	rs12410462	0.551	rs2012432	chr1:227866157	T/G	cg04117972	chr1:227635322	NA	0.44	8.11	0.35	4.54e-15	Major depressive disorder;
LGG	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.07	0.42	1.03e-21	Asthma (sex interaction);
LGG	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg23815491	chr16:72088622	HP	0.39	8.26	0.36	1.54e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12952179	chr4:111866981	NA	0.45	7.78	0.34	4.74e-14	Menarche (age at onset);
LGG	cis	rs2742417	0.603	rs2742455	chr3:45767116	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.65e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.09	0.52	1.58e-33	Lung cancer;
LGG	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs1707322	0.656	rs3014210	chr1:46066608	A/G	cg03146154	chr1:46216737	IPP	-0.56	-10.23	-0.43	2.85e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.03	0.52	2.71e-33	Colorectal cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06826115	chr15:67835137	MAP2K5	-0.38	-6.9	-0.31	1.74e-11	Brain structure;
LGG	cis	rs9814567	1.000	rs1534025	chr3:134313304	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.09	0.52	1.53e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3771570	0.818	rs73008126	chr2:242443157	A/C	cg21155796	chr2:242212141	HDLBP	0.71	8.83	0.38	2.17e-17	Prostate cancer;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	2.98e-15	Testicular germ cell tumor;
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09118169	chr16:1833616	NUBP2;SPSB3	0.41	6.84	0.3	2.54e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg27189623	chr16:705930	WDR90	0.39	7.36	0.32	8.53e-13	Height;
LGG	cis	rs2033732	0.706	rs6473527	chr8:85070610	C/T	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs4731207	0.596	rs13240512	chr7:124571890	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg01059449	chr18:44338099	ST8SIA5	-0.36	-7.64	-0.33	1.28e-13	Personality dimensions;
LGG	cis	rs9487094	0.922	rs971434	chr6:109977308	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.76	0.38	3.62e-17	Height;
LGG	cis	rs2180341	0.924	rs9285459	chr6:127631113	T/C	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	cis	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg05623727	chr3:50126028	RBM5	0.39	8.4	0.36	5.67e-16	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs896249	chr2:100089212	G/A	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15815607	chr20:30135144	HM13;PSIMCT-1	-0.39	-6.98	-0.31	1.03e-11	Lung adenocarcinoma;
LGG	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.91e-101	Cognitive ability;
LGG	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg01620082	chr3:125678407	NA	0.8	9.11	0.39	2.48e-18	Depression;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.38	-0.4	2.89e-19	Obesity-related traits;
LGG	cis	rs10911232	0.524	rs10737238	chr1:183025303	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.85e-20	Hypertriglyceridemia;
LGG	cis	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg00383909	chr3:49044727	WDR6	1.12	12.37	0.5	1.49e-30	Cognitive function;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg21724239	chr8:58056113	NA	0.44	6.84	0.3	2.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	1.000	rs6807015	chr3:41754514	T/C	cg03022575	chr3:42003672	ULK4	0.62	7.64	0.33	1.3e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg26384229	chr12:38710491	ALG10B	0.94	21.29	0.7	1.2e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg26354017	chr1:205819088	PM20D1	-0.54	-8.71	-0.38	5.29e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg23625390	chr15:77176239	SCAPER	-0.69	-13.47	-0.53	3.9e-35	Blood metabolite levels;
LGG	cis	rs6728642	0.519	rs62152906	chr2:97572270	T/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.09	-0.35	5.26e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.74	0.48	4.96e-28	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg02297831	chr4:17616191	MED28	0.51	9.31	0.4	4.96e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500637	0.631	rs12921187	chr16:4943019	T/G	cg08329684	chr16:4932620	PPL	-0.57	-12.73	-0.51	4.72e-32	Cancer;
LGG	cis	rs4936891	0.666	rs7947913	chr11:123918456	C/T	cg22125253	chr11:123886957	OR10G4	-0.43	-7.42	-0.33	5.58e-13	Male fertility;
LGG	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.42	6.94	0.31	1.33e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.42	0.4	2.09e-19	Colorectal cancer;
LGG	cis	rs6586163	1.000	rs1926195	chr10:90753758	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.91	-0.31	1.58e-11	Chronic lymphocytic leukemia;
LGG	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Myopia (pathological);
LGG	cis	rs7166081	1.000	rs11071940	chr15:67499477	A/C	cg05925327	chr15:68127851	NA	-0.32	-6.72	-0.3	5.28e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs8114671	0.904	rs6060197	chr20:33654315	C/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9381107	1.000	rs11754173	chr6:9455664	T/G	cg14735645	chr6:9486422	NA	-0.43	-7.25	-0.32	1.72e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7927592	0.871	rs12360903	chr11:68236314	C/A	cg01657329	chr11:68192670	LRP5	-0.47	-7.88	-0.34	2.34e-14	Total body bone mineral density;
LGG	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg09264619	chr17:80180166	NA	-0.52	-9.98	-0.42	2.33e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg21775007	chr8:11205619	TDH	0.44	6.86	0.3	2.2e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs77633900	0.772	rs157778	chr15:76759444	G/C	cg21673338	chr15:77095150	SCAPER	-0.64	-8.47	-0.37	3.33e-16	Non-glioblastoma glioma;Glioma;
LGG	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg03929089	chr4:120376271	NA	0.71	9.81	0.41	8.94e-21	Axial length;
LGG	cis	rs4731207	0.596	rs28817916	chr7:124588550	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg24687543	chr11:63912206	MACROD1	0.6	8.34	0.36	8.39e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.45	8.55	0.37	1.74e-16	Obesity-related traits;
LGG	cis	rs7945705	0.783	rs11042125	chr11:8938049	A/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-11.67	-0.48	8.96e-28	Hemoglobin concentration;
LGG	cis	rs4566357	0.615	rs10184991	chr2:227916533	G/A	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.06	-0.39	3.56e-18	Coronary artery disease;
LGG	cis	rs950169	0.922	rs11631096	chr15:85100929	G/C	cg03959625	chr15:84868606	LOC388152	0.58	9.36	0.4	3.51e-19	Schizophrenia;
LGG	trans	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg25214090	chr10:38739885	LOC399744	0.65	11.51	0.47	3.8e-27	Corneal astigmatism;
LGG	cis	rs35740288	0.770	rs11634177	chr15:86148390	A/G	cg07943548	chr15:86304357	KLHL25	0.34	6.81	0.3	3.13e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19524238	chr7:2802976	GNA12	0.4	9.44	0.4	1.87e-19	Height;
LGG	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg24130564	chr14:104152367	KLC1	-0.4	-7.5	-0.33	3.26e-13	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17408923	chr2:109335769	RANBP2	0.49	7.8	0.34	4.03e-14	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs13106338	chr4:17676871	G/T	cg16339924	chr4:17578868	LAP3	-0.62	-10.96	-0.45	5.18e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17767392	0.788	rs7155259	chr14:71698090	C/T	cg02058870	chr14:72053146	SIPA1L1	0.36	6.83	0.3	2.6e-11	Mitral valve prolapse;
LGG	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7649275	1.000	rs2612034	chr3:53760051	T/C	cg21503701	chr3:53781065	CACNA1D	-0.48	-6.84	-0.3	2.49e-11	Trans fatty acid levels;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.94e-13	Menopause (age at onset);
LGG	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg00049323	chr5:472564	LOC25845	0.38	8.55	0.37	1.81e-16	Cystic fibrosis severity;
LGG	cis	rs4720575	1.000	rs4507670	chr7:47097526	C/T	cg00036614	chr7:47093842	NA	-0.51	-10.24	-0.43	2.63e-22	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg11161011	chr14:65562177	MAX	-0.77	-14.96	-0.57	1.53e-41	Obesity-related traits;
LGG	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg14979609	chr8:8086686	FLJ10661	-0.36	-9.31	-0.4	5.24e-19	Schizophrenia;
LGG	cis	rs6831352	0.918	rs7694646	chr4:100059732	T/A	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs7512552	0.809	rs1694363	chr1:150368677	T/G	cg15654264	chr1:150340011	RPRD2	0.45	8.75	0.38	4.06e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg12525768	chr7:29689996	LOC646762	-0.55	-7.84	-0.34	3.11e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs8133932	0.736	rs11089025	chr21:47281579	C/A	cg11214348	chr21:47283868	PCBP3	0.43	7.73	0.34	6.76e-14	Schizophrenia;
LGG	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg27661571	chr11:113659931	NA	0.58	7.87	0.34	2.57e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2084898	1.000	rs12420591	chr11:120061195	A/G	cg13907859	chr11:120009124	TRIM29	0.76	10.35	0.43	1.03e-22	Stroke (pediatric);
LGG	cis	rs4356932	1.000	rs4309862	chr4:76945981	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg15556689	chr8:8085844	FLJ10661	0.58	10.81	0.45	1.89e-24	Neuroticism;
LGG	trans	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg21659725	chr3:3221576	CRBN	-0.5	-7.81	-0.34	3.85e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg18245976	chr7:158708271	WDR60	-0.56	-9.96	-0.42	2.74e-21	Height;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg20003494	chr4:90757398	SNCA	-0.39	-7.8	-0.34	4.01e-14	Dementia with Lewy bodies;
LGG	cis	rs7267979	1.000	rs448396	chr20:25440269	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg22307029	chr19:49891270	CCDC155	0.51	9.74	0.41	1.67e-20	Multiple sclerosis;
LGG	cis	rs1519814	0.696	rs2875927	chr8:121036841	G/A	cg22335954	chr8:121166405	COL14A1	-0.48	-8.82	-0.38	2.43e-17	Breast cancer;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.11	-0.35	4.58e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7017914	0.934	rs7830550	chr8:71570431	C/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.44e-11	Bone mineral density;
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg05623727	chr3:50126028	RBM5	0.38	8.41	0.36	5.03e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04850017	chr11:63683019	RCOR2	0.34	8.6	0.37	1.22e-16	Schizophrenia;
LGG	trans	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.38	0.4	2.9e-19	Diabetic kidney disease;
LGG	cis	rs9460578	0.537	rs9460562	chr6:20824829	A/G	cg13405222	chr6:20811065	CDKAL1	0.76	17.21	0.62	1.18e-51	Breast cancer;
LGG	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg00745463	chr17:30367425	LRRC37B	-0.66	-9.61	-0.41	4.81e-20	Hip circumference adjusted for BMI;
LGG	trans	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg06521331	chr12:34319734	NA	0.41	6.9	0.31	1.75e-11	Morning vs. evening chronotype;
LGG	cis	rs806215	1.000	rs806215	chr7:127237312	T/C	cg25922125	chr7:127225783	GCC1	-0.76	-10.36	-0.43	9.56e-23	Type 2 diabetes;
LGG	cis	rs4846580	0.660	rs10863482	chr1:219878129	C/G	cg08034750	chr1:219919793	NA	0.4	7.01	0.31	8.22e-12	Total body bone mineral density;
LGG	cis	rs6076065	0.609	rs3746736	chr20:23424613	T/C	cg12633918	chr20:23549525	CST9L	-0.33	-6.68	-0.3	6.86e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01458961	chr4:102269425	PPP3CA	0.41	6.73	0.3	4.97e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg06968155	chr5:131705112	SLC22A5	0.73	8.5	0.37	2.71e-16	Rheumatoid arthritis;
LGG	cis	rs4253772	0.550	rs9615951	chr22:46728056	C/A	cg00784671	chr22:46762841	CELSR1	-0.56	-7.12	-0.31	4.03e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs62400317	0.826	rs62400290	chr6:45209788	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.24	-0.43	2.48e-22	Total body bone mineral density;
LGG	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg20493526	chr2:3714936	ALLC	0.46	10.31	0.43	1.46e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2404602	0.716	rs2404737	chr15:76872217	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.98e-18	Blood metabolite levels;
LGG	cis	rs17122278	1.000	rs9736327	chr11:118447580	T/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.14e-11	Total cholesterol levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04367680	chr8:74005697	C8orf84	0.39	6.72	0.3	5.35e-11	Menarche (age at onset);
LGG	cis	rs2274273	0.905	rs10134800	chr14:55635209	A/G	cg04306507	chr14:55594613	LGALS3	0.65	17.95	0.64	4.29e-55	Protein biomarker;
LGG	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs11764590	0.694	rs4721359	chr7:2104951	A/G	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.44	-0.37	4.03e-16	Neuroticism;
LGG	cis	rs7843479	0.601	rs878873	chr8:21834581	T/C	cg17168535	chr8:21777572	XPO7	0.83	16.25	0.6	2.51e-47	Mean corpuscular volume;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg26783146	chr16:4423632	VASN;CORO7	-0.42	-7.93	-0.35	1.64e-14	Schizophrenia;
LGG	cis	rs950027	0.549	rs2899375	chr15:45598335	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.78	-0.41	1.19e-20	Response to fenofibrate (adiponectin levels);
LGG	cis	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.64	-0.51	1.14e-31	Resting heart rate;
LGG	cis	rs4742903	1.000	rs3780535	chr9:106894211	A/C	cg14250997	chr9:106856677	SMC2	0.39	8.4	0.36	5.68e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg26384229	chr12:38710491	ALG10B	0.93	20.93	0.7	6.32e-69	Bladder cancer;
LGG	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg24375607	chr4:120327624	NA	0.66	10.71	0.45	4.62e-24	Corneal astigmatism;
LGG	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg04731861	chr2:219085781	ARPC2	-0.38	-9.08	-0.39	3.17e-18	Colorectal cancer;
LGG	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg27205649	chr11:78285834	NARS2	0.43	7.22	0.32	2.2e-12	Testicular germ cell tumor;
LGG	cis	rs28595532	0.623	rs34284204	chr4:119227672	C/T	cg21605333	chr4:119757512	SEC24D	0.89	9.53	0.4	9.12e-20	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg07791516	chr6:150247246	NA	0.32	6.78	0.3	3.73e-11	Lung cancer;
LGG	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg06634786	chr22:41940651	POLR3H	-0.77	-12.2	-0.49	7.03e-30	Vitiligo;
LGG	cis	rs79349575	0.651	rs4378658	chr17:46993370	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11084020	chr7:27779567	TAX1BP1	0.46	7.81	0.34	3.82e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs994014	0.508	rs6853731	chr4:82288844	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.8	-0.3	3.17e-11	Height;
LGG	cis	rs137603	0.901	rs137612	chr22:39698010	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.45	-7.54	-0.33	2.55e-13	Primary biliary cholangitis;
LGG	cis	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.79	0.34	4.36e-14	Mood instability;
LGG	cis	rs7568458	0.709	rs1446669	chr2:85762209	T/C	cg17127132	chr2:85788382	GGCX	0.5	8.18	0.36	2.85e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6834538	0.965	rs2101391	chr4:113531599	A/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.29	0.36	1.21e-15	Free thyroxine concentration;
LGG	cis	rs10214930	0.560	rs1015750	chr7:27593219	G/A	cg22168087	chr7:27702803	HIBADH	0.46	6.8	0.3	3.14e-11	Hypospadias;
LGG	cis	rs7428	0.527	rs4459734	chr2:85547429	G/T	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.74	-0.54	2.91e-36	Ear protrusion;
LGG	trans	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.87	0.42	5.72e-21	Diabetic kidney disease;
LGG	cis	rs9596837	0.514	rs7989655	chr13:54207295	G/A	ch.13.53330881F	chr13:54432880	NA	0.43	6.94	0.31	1.35e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17270843	chr10:99079074	FRAT1	0.49	6.7	0.3	5.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.839	rs12216103	chr6:86571128	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	1e-15	Response to antipsychotic treatment;
LGG	trans	rs9929218	0.906	rs9932679	chr16:68751904	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.88	-15.86	-0.59	1.47e-45	Colorectal cancer;
LGG	cis	rs60180747	0.544	rs11633568	chr15:66564406	T/C	cg07575407	chr15:66541975	MEGF11	0.64	13.83	0.54	1.19e-36	Testicular germ cell tumor;
LGG	cis	rs4664308	0.935	rs17216980	chr2:160960932	G/A	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.23	-0.63	8.96e-52	Idiopathic membranous nephropathy;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.0	-0.52	3.76e-33	Aortic root size;
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg16680214	chr1:154839983	KCNN3	-0.45	-8.51	-0.37	2.5e-16	Prostate cancer;
LGG	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg21395723	chr22:39101663	GTPBP1	0.38	6.69	0.3	6.36e-11	Menopause (age at onset);
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	9.28	0.4	6.39e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2668423	1.000	rs2668423	chr19:1370526	T/G	cg02639931	chr19:1387894	NDUFS7	-0.82	-13.7	-0.54	4.01e-36	Nonalcoholic fatty liver disease;
LGG	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03264133	chr6:25882463	NA	0.54	9.89	0.42	4.54e-21	Blood metabolite levels;
LGG	trans	rs9929218	1.000	rs17772363	chr16:68788909	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-14.0	-0.55	2.14e-37	Colorectal cancer;
LGG	trans	rs17685	0.753	rs1637045	chr7:75703895	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.77	0.77	1.68e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg08470875	chr2:26401718	FAM59B	0.42	8.1	0.35	4.78e-15	Gut microbiome composition (summer);
LGG	cis	rs12478296	0.681	rs56357900	chr2:243033966	A/C	cg06360820	chr2:242988706	NA	-0.91	-11.8	-0.48	2.78e-28	Obesity-related traits;
LGG	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg16141378	chr3:129829833	LOC729375	0.38	9.1	0.39	2.7e-18	Joint mobility (Beighton score);
LGG	cis	rs1555895	0.576	rs748112	chr10:862889	C/T	cg09361094	chr10:834503	NA	-0.29	-7.78	-0.34	4.89e-14	Survival in rectal cancer;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.85	-0.3	2.35e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg15269541	chr15:43626905	ADAL	-0.46	-7.17	-0.32	3.08e-12	Lung cancer in ever smokers;
LGG	cis	rs6938	0.618	rs12901190	chr15:75231452	T/C	cg17294928	chr15:75287854	SCAMP5	0.71	13.11	0.52	1.27e-33	Breast cancer;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg02002194	chr4:3960332	NA	0.42	7.86	0.34	2.66e-14	Triglycerides;
LGG	cis	rs9905704	0.624	rs11652761	chr17:56986095	C/T	cg05425664	chr17:57184151	TRIM37	-0.43	-6.77	-0.3	3.93e-11	Testicular germ cell tumor;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg11301795	chr4:187892539	NA	0.94	23.83	0.74	1.68e-82	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg03647317	chr4:187891568	NA	-0.41	-8.73	-0.38	4.58e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg08499158	chr17:42289980	UBTF	0.4	7.66	0.34	1.08e-13	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs8012	0.517	rs17706531	chr19:13015530	A/G	cg04657146	chr19:12876947	HOOK2	-0.45	-7.36	-0.32	8.4e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs4776059	1.000	rs4776066	chr15:52930499	T/C	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.78	-0.34	4.76e-14	Schizophrenia;
LGG	cis	rs637571	0.544	rs12361552	chr11:65701204	G/A	cg26695010	chr11:65641043	EFEMP2	0.58	9.95	0.42	2.85e-21	Eosinophil percentage of white cells;
LGG	cis	rs35146811	0.660	rs3779045	chr7:99779259	T/C	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs4727443	0.653	rs6465759	chr7:99587980	T/C	cg12813108	chr7:99719912	CNPY4	0.41	7.85	0.34	2.87e-14	Interstitial lung disease;
LGG	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	7.41	0.33	6.07e-13	Educational attainment;
LGG	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.38	-9.01	-0.39	5.59e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.49	-8.23	-0.36	1.89e-15	Uric acid levels;
LGG	cis	rs2071403	0.966	rs11686524	chr2:1412244	T/G	cg06500727	chr2:1417164	TPO	-0.51	-9.64	-0.41	3.51e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.57	-8.75	-0.38	4.1e-17	Body mass index;
LGG	cis	rs870825	0.929	rs72689254	chr4:185589941	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	19.07	0.66	2.88e-60	Blood protein levels;
LGG	cis	rs7017914	0.967	rs6472538	chr8:71586971	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04921814	chr1:145575587	PIAS3	0.46	7.76	0.34	5.65e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs8060686	0.641	rs12598256	chr16:68084021	G/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.17e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg18681998	chr4:17616180	MED28	-0.74	-14.38	-0.56	4.94e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2467099	0.735	rs55793071	chr17:73909948	C/T	cg23806715	chr17:73775811	H3F3B	0.5	7.42	0.33	5.63e-13	Systolic blood pressure;
LGG	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg00745463	chr17:30367425	LRRC37B	-0.54	-7.56	-0.33	2.23e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg08807101	chr21:30365312	RNF160	0.92	19.48	0.67	3.75e-62	Dental caries;
LGG	cis	rs4356203	0.519	rs214097	chr11:17291499	G/T	cg15432903	chr11:17409602	KCNJ11	-0.37	-6.95	-0.31	1.27e-11	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.2	0.6	4.43e-47	Lymphocyte counts;
LGG	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-15.67	-0.59	1.03e-44	Headache;
LGG	cis	rs12210905	1.000	rs1062834	chr6:27222539	A/G	cg15325629	chr6:28072465	NA	0.81	6.64	0.3	8.54e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4132509	1.000	rs320320	chr1:243835186	A/G	cg21452805	chr1:244014465	NA	0.61	7.43	0.33	5.33e-13	RR interval (heart rate);
LGG	cis	rs10751667	0.666	rs6597960	chr11:977036	C/T	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs4936894	0.500	rs10790665	chr11:124175973	C/T	cg27160556	chr11:124181099	OR8D1	-0.47	-10.81	-0.45	1.97e-24	Aging (time to death);
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	6.98	0.31	1.06e-11	Menopause (age at onset);
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg24250549	chr1:154909240	PMVK	0.74	14.97	0.57	1.34e-41	Prostate cancer;
LGG	cis	rs17001868	0.614	rs5995849	chr22:40777072	C/G	cg07138101	chr22:40742427	ADSL	-0.62	-8.17	-0.35	2.96e-15	Mammographic density (dense area);
LGG	cis	rs11150038	1.000	rs2735403	chr16:78062190	T/C	cg04733911	chr16:78082701	NA	-0.66	-8.38	-0.36	6.17e-16	Colorectal or endometrial cancer;
LGG	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg09197432	chr4:183729176	NA	0.59	7.82	0.34	3.72e-14	Pediatric autoimmune diseases;
LGG	cis	rs875971	0.666	rs13242072	chr7:65765988	A/G	cg11764359	chr7:65958608	NA	-0.63	-10.51	-0.44	2.52e-23	Aortic root size;
LGG	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg00908189	chr16:619842	PIGQ	0.51	7.54	0.33	2.43e-13	Height;
LGG	cis	rs1538970	0.816	rs868351	chr1:46009818	G/T	cg05343316	chr1:45956843	TESK2	0.76	12.47	0.5	5.84e-31	Platelet count;
LGG	cis	rs73086581	1.000	rs17215529	chr20:3975402	A/G	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg00531865	chr16:30841666	NA	-0.48	-10.14	-0.43	5.93e-22	Dementia with Lewy bodies;
LGG	cis	rs7666738	0.606	rs6852813	chr4:99084671	G/A	cg05340658	chr4:99064831	C4orf37	0.43	6.95	0.31	1.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.38	-0.36	6.51e-16	Eosinophil percentage of white cells;
LGG	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg23985595	chr17:80112537	CCDC57	-0.4	-7.89	-0.34	2.24e-14	Life satisfaction;
LGG	cis	rs881375	0.715	rs10818482	chr9:123648085	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-12.13	-0.49	1.4e-29	Rheumatoid arthritis;
LGG	cis	rs7737355	0.947	rs17167760	chr5:130782699	A/G	cg06307176	chr5:131281290	NA	-0.53	-8.85	-0.38	1.83e-17	Life satisfaction;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	cis	rs2797160	0.967	rs1777182	chr6:126013614	T/A	cg05901451	chr6:126070800	HEY2	0.44	7.32	0.32	1.1e-12	Endometrial cancer;
LGG	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.18e-14	Restless legs syndrome;
LGG	cis	rs9393692	0.645	rs9467703	chr6:26318903	A/G	cg16885296	chr6:26284938	NA	0.36	7.4	0.33	6.45e-13	Educational attainment;
LGG	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg08344181	chr3:125677491	NA	-0.69	-7.3	-0.32	1.28e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs2758596	0.850	rs2495270	chr1:156181530	A/G	cg24450063	chr1:156163899	SLC25A44	0.88	7.97	0.35	1.26e-14	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs6450176	0.953	rs3776724	chr5:53292270	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.0	-0.46	3.53e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg07936489	chr17:37558343	FBXL20	1.06	18.67	0.66	2e-58	Glomerular filtration rate (creatinine);
LGG	cis	rs11711311	0.784	rs13081931	chr3:113349928	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.61	-0.33	1.58e-13	IgG glycosylation;
LGG	cis	rs2243480	1.000	rs6959002	chr7:65650496	A/G	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	trans	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg02002194	chr4:3960332	NA	0.39	7.15	0.32	3.36e-12	Neuroticism;
LGG	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg15269541	chr15:43626905	ADAL	-0.44	-7.64	-0.33	1.22e-13	Lung cancer in ever smokers;
LGG	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg02153584	chr22:29168773	CCDC117	0.7	11.89	0.48	1.27e-28	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.61	-0.61	6.26e-49	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg11266682	chr4:10021025	SLC2A9	0.51	9.92	0.42	3.84e-21	Bone mineral density;
LGG	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg02023728	chr11:77925099	USP35	0.45	7.82	0.34	3.51e-14	Testicular germ cell tumor;
LGG	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg04568710	chr12:38710424	ALG10B	-0.39	-8.33	-0.36	9.48e-16	Morning vs. evening chronotype;
LGG	cis	rs1062746	0.527	rs35143469	chr16:87335483	T/C	cg02258303	chr16:87377426	FBXO31	-0.41	-7.51	-0.33	3.07e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs4423214	1.000	rs2852853	chr11:71150217	C/T	cg10847948	chr11:71163743	NADSYN1	-0.66	-13.06	-0.52	2.08e-33	Vitamin D levels;
LGG	cis	rs3780378	1.000	rs1328918	chr9:5107394	A/G	cg02405213	chr9:5042618	JAK2	-0.5	-8.73	-0.38	4.76e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4356975	0.563	rs6600897	chr4:69987249	A/C	cg27372994	chr4:70080453	UGT2B11	0.37	6.82	0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs6942756	1.000	rs4440569	chr7:128923907	T/A	cg02491457	chr7:128862824	NA	-0.76	-13.68	-0.54	5.3e-36	White matter hyperintensity burden;
LGG	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.17	0.32	2.92e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.622	rs9635380	chr15:77103479	A/G	cg23625390	chr15:77176239	SCAPER	-0.68	-12.75	-0.51	4.16e-32	Blood metabolite levels;
LGG	trans	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.16	-0.32	3.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg08807101	chr21:30365312	RNF160	0.61	10.19	0.43	4.04e-22	Pancreatic cancer;
LGG	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.63	0.44	9.1e-24	Morning vs. evening chronotype;
LGG	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg21211680	chr2:198530	NA	1.24	17.03	0.62	7.36e-51	Blood protein levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03390183	chr3:36779043	DCLK3	0.4	7.0	0.31	9.2e-12	Pancreatic cancer;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs9522267	0.737	rs9522289	chr13:112232110	G/A	cg10483660	chr13:112241077	NA	-0.38	-8.14	-0.35	3.56e-15	Hepatitis;
LGG	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3809863	0.602	rs11650072	chr17:45393665	A/G	cg08085267	chr17:45401833	C17orf57	-0.73	-14.52	-0.56	1.26e-39	Glaucoma (primary open-angle);
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	7.79	0.34	4.59e-14	Longevity;
LGG	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	trans	rs7395662	1.000	rs7479134	chr11:48625409	A/C	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	cis	rs990171	1.000	rs11677107	chr2:103057087	C/A	cg05295703	chr2:102895712	NA	-0.52	-9.2	-0.39	1.19e-18	Lymphocyte counts;
LGG	cis	rs2373794	0.961	rs10221571	chr2:40377749	G/C	cg17740179	chr2:40377776	SLC8A1	0.98	21.06	0.7	1.49e-69	Asthma;
LGG	cis	rs2916247	1.000	rs894754	chr8:93012369	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20317180	chr19:56111252	FIZ1;ZNF524	0.42	7.37	0.32	7.89e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs1816752	0.935	rs4770676	chr13:25003883	A/G	cg02811702	chr13:24901961	NA	0.44	8.24	0.36	1.77e-15	Obesity-related traits;
LGG	cis	rs7973719	0.773	rs6486911	chr12:7356494	G/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.08	-0.35	5.51e-15	IgG glycosylation;
LGG	cis	rs55788414	0.932	rs12103301	chr16:81181423	A/C	cg06400318	chr16:81190750	PKD1L2	-0.79	-9.57	-0.41	6.44e-20	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.83	0.64	1.63e-54	Chronic sinus infection;
LGG	trans	rs1032833	0.732	rs80339028	chr2:180119936	A/G	cg23654767	chr2:101192981	PDCL3	0.66	7.81	0.34	3.79e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02018176	chr4:1364513	KIAA1530	0.65	16.07	0.6	1.67e-46	Longevity;
LGG	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg11742103	chr11:62369870	EML3;MTA2	0.56	12.28	0.5	3.27e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.92	-0.35	1.83e-14	Diabetic retinopathy;
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.26	0.46	3.73e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg04911050	chr16:677664	RAB40C	0.34	6.68	0.3	6.91e-11	Height;
LGG	cis	rs3820068	0.705	rs4645983	chr1:15850603	G/A	cg05660106	chr1:15850417	CASP9	1.11	27.19	0.78	5.18e-98	Systolic blood pressure;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.66	-0.34	1.12e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02635494	chr6:4018361	NA	0.52	7.76	0.34	5.46e-14	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6429082	0.689	rs4659923	chr1:235709519	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-8.39	-0.36	5.83e-16	Adiposity;
LGG	cis	rs9815354	0.638	rs73075241	chr3:42058045	C/T	cg03022575	chr3:42003672	ULK4	0.73	8.12	0.35	4.39e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg11279151	chr3:101281821	RG9MTD1	0.66	11.33	0.47	1.93e-26	Colonoscopy-negative controls vs population controls;
LGG	trans	rs8073060	0.586	rs6505485	chr17:33996102	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-16.98	-0.62	1.23e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.26	-0.36	1.55e-15	Dementia with Lewy bodies;
LGG	cis	rs6964587	0.967	rs2040499	chr7:91809657	C/G	cg17063962	chr7:91808500	NA	-0.51	-9.51	-0.4	1.08e-19	Breast cancer;
LGG	cis	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg02487422	chr3:49467188	NICN1	0.44	6.92	0.31	1.49e-11	Resting heart rate;
LGG	cis	rs7084783	0.532	rs3781344	chr10:105419287	G/T	cg00126946	chr10:105363258	SH3PXD2A	-0.39	-7.32	-0.32	1.08e-12	Fear of pain;
LGG	cis	rs7666738	0.830	rs2865990	chr4:99067399	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4819052	0.851	rs2236446	chr21:46678985	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.22	0.49	6.04e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg19748678	chr4:122722346	EXOSC9	0.51	9.68	0.41	2.6e-20	Type 2 diabetes;
LGG	cis	rs953387	1.000	rs10179271	chr2:136910834	T/C	cg07169764	chr2:136633963	MCM6	0.54	8.99	0.39	6.49e-18	Arthritis (juvenile idiopathic);
LGG	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg13010199	chr12:38710504	ALG10B	-0.52	-10.11	-0.43	7.89e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.29	0.4	6.2800000000000005e-19	Lung cancer in ever smokers;
LGG	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg25457927	chr22:38595422	NA	-0.42	-10.19	-0.43	3.93e-22	Cutaneous nevi;
LGG	cis	rs11718455	0.960	rs13060222	chr3:44005046	A/T	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.61e-11	Coronary artery disease;
LGG	cis	rs4727027	0.704	rs2888600	chr7:148908562	C/T	cg23583168	chr7:148888333	NA	-0.91	-18.3	-0.65	1.11e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27297192	chr10:134578999	INPP5A	0.33	7.32	0.32	1.12e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9527	0.545	rs10218853	chr10:104796787	A/C	cg05308233	chr10:104796373	CNNM2	-0.32	-7.09	-0.31	5.11e-12	Arsenic metabolism;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg18050959	chr15:68126178	NA	-0.38	-7.14	-0.31	3.67e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-12.72	-0.51	5.59e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs35883536	0.967	rs1577509	chr1:101089253	C/T	cg06223162	chr1:101003688	GPR88	0.29	6.86	0.3	2.21e-11	Monocyte count;
LGG	cis	rs11971779	0.793	rs4728464	chr7:139017670	C/T	cg07862535	chr7:139043722	LUC7L2	-0.5	-8.04	-0.35	7.63e-15	Diisocyanate-induced asthma;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg11062466	chr8:58055876	NA	0.53	8.66	0.37	7.83e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6868223	0.585	rs4519928	chr5:33641058	T/C	cg10594543	chr5:33649717	ADAMTS12	0.66	15.57	0.59	2.78e-44	Mortality in heart failure;
LGG	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg11995313	chr8:8860691	ERI1	-0.4	-6.7	-0.3	6.01e-11	Joint mobility (Beighton score);
LGG	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.41	-8.4	-0.36	5.52e-16	Oropharynx cancer;
LGG	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	trans	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	17.13	0.62	2.74e-51	Alzheimer's disease;
LGG	cis	rs4974559	0.501	rs1250096	chr4:1238836	G/C	cg02980000	chr4:1222292	CTBP1	-0.96	-11.66	-0.48	1.04e-27	Systolic blood pressure;
LGG	trans	rs7980799	0.649	rs12819439	chr12:33684509	A/C	cg26384229	chr12:38710491	ALG10B	0.67	12.24	0.49	4.64e-30	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9287719	0.967	rs2884233	chr2:10745303	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg00149659	chr3:10157352	C3orf10	-0.56	-8.2	-0.36	2.46e-15	Alzheimer's disease;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg18350739	chr11:68623251	NA	0.79	19.2	0.67	7e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs870825	1.000	rs870821	chr4:185587377	T/C	cg04058563	chr4:185651563	MLF1IP	0.98	18.48	0.65	1.56e-57	Blood protein levels;
LGG	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg08109568	chr15:31115862	NA	-0.53	-9.47	-0.4	1.46e-19	Huntington's disease progression;
LGG	cis	rs2599510	0.811	rs176410	chr2:32643437	C/G	cg02381751	chr2:32503542	YIPF4	-0.5	-8.16	-0.35	3.24e-15	Interleukin-18 levels;
LGG	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg00745463	chr17:30367425	LRRC37B	-0.77	-10.96	-0.45	5.01e-25	Hip circumference adjusted for BMI;
LGG	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg11161011	chr14:65562177	MAX	-0.73	-14.61	-0.56	4.87e-40	Obesity-related traits;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg26354017	chr1:205819088	PM20D1	0.87	20.8	0.7	2.39e-68	Menarche (age at onset);
LGG	cis	rs9462027	0.583	rs2814947	chr6:34653268	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.25e-24	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg13047869	chr3:10149882	C3orf24	0.6	8.58	0.37	1.43e-16	Alzheimer's disease;
LGG	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg06636001	chr8:8085503	FLJ10661	0.53	10.24	0.43	2.54e-22	Parkinson's disease;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg26174226	chr8:58114915	NA	-0.59	-7.92	-0.35	1.74e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22601191	chr20:60968625	CABLES2	0.56	9.72	0.41	1.9e-20	Colorectal cancer;
LGG	cis	rs4642101	0.597	rs9839768	chr3:12821403	C/T	cg24848339	chr3:12840334	CAND2	0.45	10.84	0.45	1.47e-24	QRS complex (12-leadsum);
LGG	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg17757837	chr7:157058334	UBE3C	-0.91	-20.54	-0.69	3.87e-67	Body mass index;
LGG	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg25885449	chr18:77638415	KCNG2	-0.43	-9.22	-0.39	1.07e-18	Schizophrenia;
LGG	cis	rs2470578	0.792	rs2733481	chr3:17320397	G/A	cg20981856	chr3:17787350	NA	0.36	6.97	0.31	1.11e-11	Schizophrenia;
LGG	cis	rs7100689	0.646	rs2994390	chr10:82074395	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	15.01	0.57	8.49e-42	Post bronchodilator FEV1;
LGG	cis	rs3008870	1.000	rs2985817	chr1:67398607	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.99	0.73	1.39e-78	Lymphocyte percentage of white cells;
LGG	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	1.99e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs62238980	0.614	rs4821023	chr22:32414413	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg07786668	chr16:73092391	ZFHX3	-0.47	-7.22	-0.32	2.12e-12	Coronary artery disease;
LGG	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	15.07	0.57	4.85e-42	Total body bone mineral density;
LGG	cis	rs2797160	0.935	rs6940748	chr6:125994080	C/T	cg05901451	chr6:126070800	HEY2	-0.41	-6.96	-0.31	1.16e-11	Endometrial cancer;
LGG	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg27129171	chr3:47204927	SETD2	0.81	14.62	0.56	4.71e-40	Colorectal cancer;
LGG	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs888194	0.690	rs7953014	chr12:109998097	A/G	cg19025524	chr12:109796872	NA	-0.35	-6.95	-0.31	1.28e-11	Neuroticism;
LGG	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg16434002	chr17:42200994	HDAC5	0.43	7.72	0.34	7.28e-14	Total body bone mineral density;
LGG	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg19913688	chr11:428466	ANO9	-0.7	-8.9	-0.38	1.27e-17	Body mass index;
LGG	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.38e-19	Aortic root size;
LGG	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.66	-0.48	1.02e-27	Body mass index;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07701084	chr6:150067640	NUP43	0.43	7.91	0.35	1.92e-14	Testicular germ cell tumor;
LGG	cis	rs74377301	1	rs74377301	chr7:123232495	C/T	cg03229431	chr7:123269106	ASB15	-0.56	-12.64	-0.51	1.09e-31	Left ventricular obstructive tract defect (inherited effect);
LGG	trans	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.9	0.45	9.08e-25	Ulcerative colitis;
LGG	cis	rs603424	0.551	rs525190	chr10:102087038	C/T	cg10365880	chr10:102089681	PKD2L1	-0.5	-7.58	-0.33	1.86e-13	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LGG	cis	rs2072499	0.898	rs2736609	chr1:156202640	C/T	cg25208724	chr1:156163844	SLC25A44	1.07	22.24	0.72	4.28e-75	Testicular germ cell tumor;
LGG	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg25173405	chr17:45401733	C17orf57	0.48	8.34	0.36	8.35e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11583043	1.000	rs11583043	chr1:101466054	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.39	0.36	5.81e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.15	0.55	5.1e-38	Tonsillectomy;
LGG	cis	rs6831352	0.734	rs3100630	chr4:100031715	T/A	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg02002194	chr4:3960332	NA	0.43	7.64	0.33	1.26e-13	Retinal vascular caliber;
LGG	trans	rs6921919	0.945	rs7765989	chr6:28400295	T/C	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.25	-0.32	1.8e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.62e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4787491	0.729	rs4788213	chr16:30034524	T/C	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.45	7.66	0.34	1.07e-13	Longevity;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4077515	0.577	rs10870165	chr9:139316601	C/T	cg14019695	chr9:139328340	INPP5E	0.39	7.22	0.32	2.11e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg27478167	chr7:817139	HEATR2	-0.44	-7.08	-0.31	5.38e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03264133	chr6:25882463	NA	0.54	10.22	0.43	3.04e-22	Blood metabolite levels;
LGG	cis	rs11074306	0.561	rs4778185	chr15:28065341	A/T	cg26402630	chr15:28053930	OCA2	-0.38	-7.61	-0.33	1.58e-13	Uveal melanoma;
LGG	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.97	-0.31	1.08e-11	Neuroticism;
LGG	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg12395012	chr8:11607386	GATA4	0.38	6.79	0.3	3.44e-11	Mood instability;
LGG	trans	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg07817883	chr1:32538562	TMEM39B	-0.68	-9.51	-0.4	1.01e-19	Monocyte percentage of white cells;
LGG	cis	rs7973719	0.966	rs7310539	chr12:7329996	C/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.0	-0.35	1.01e-14	IgG glycosylation;
LGG	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg12463550	chr7:65579703	CRCP	0.46	7.62	0.33	1.42e-13	Aortic root size;
LGG	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg25019033	chr10:957182	NA	-0.54	-9.18	-0.39	1.42e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05901451	chr6:126070800	HEY2	-0.68	-12.92	-0.51	8.22e-33	Brugada syndrome;
LGG	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg00745463	chr17:30367425	LRRC37B	-0.55	-7.53	-0.33	2.75e-13	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.65	11.98	0.49	5.27e-29	Obesity-related traits;
LGG	cis	rs62025270	0.747	rs12324721	chr15:86310972	C/T	cg25843651	chr15:86329602	KLHL25	0.68	11.26	0.46	3.63e-26	Idiopathic pulmonary fibrosis;
LGG	trans	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.5	-0.47	4.29e-27	Mean corpuscular volume;
LGG	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg24397884	chr7:158709396	WDR60	0.86	9.49	0.4	1.2e-19	Hippocampal volume;
LGG	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg09754948	chr16:28834200	ATXN2L	0.49	7.89	0.34	2.21e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs975722	0.543	rs6960356	chr7:117010356	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	8.57	0.37	1.57e-16	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04920270	chr11:112832249	NCAM1	0.43	6.78	0.3	3.78e-11	Gut microbiome composition (summer);
LGG	cis	rs4629710	0.592	rs10484763	chr6:131549060	T/C	cg12606694	chr6:131520996	AKAP7	0.51	8.42	0.36	4.82e-16	Multiple myeloma (IgH translocation);
LGG	trans	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg14664628	chr15:75095509	CSK	-0.54	-10.44	-0.44	4.67e-23	Breast cancer;
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg00864171	chr11:67383662	NA	0.52	8.4	0.36	5.4e-16	Mean corpuscular volume;
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.58	-11.59	-0.47	1.89e-27	Obesity-related traits;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.57	-0.41	6.32e-20	Blood metabolite levels;
LGG	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg15704280	chr7:45808275	SEPT13	0.74	7.9	0.34	2.05e-14	Axial length;
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.89	-0.45	9.26e-25	Bipolar disorder;
LGG	cis	rs28588043	0.712	rs61816865	chr1:170995356	A/G	cg03458344	chr1:170964477	C1orf129	-0.53	-7.3	-0.32	1.3e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.66	-0.3	7.89e-11	Menarche (age at onset);
LGG	cis	rs4788570	0.578	rs4788553	chr16:71780277	T/G	cg06353428	chr16:71660113	MARVELD3	1.26	21.54	0.71	8.15e-72	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.09	0.87	8.65e-145	Chronic sinus infection;
LGG	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11711311	1.000	rs7645473	chr3:113516187	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.94	-0.35	1.54e-14	IgG glycosylation;
LGG	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg04990556	chr1:26633338	UBXN11	-0.69	-14.08	-0.55	9.7e-38	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs4819044	chr21:46660118	G/A	cg06618935	chr21:46677482	NA	-0.49	-9.42	-0.4	2.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6071166	0.523	rs6015719	chr20:37341510	G/T	cg10737118	chr20:37354790	SLC32A1	-0.42	-7.62	-0.33	1.49e-13	circulating leptin levels adjusted for BMI;circulating leptin levels;
LGG	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg05784532	chr1:230284198	GALNT2	0.52	9.23	0.39	9.66e-19	Coronary artery disease;
LGG	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	cg07245641	chr1:182991651	LAMC1	0.39	8.65	0.37	8.82e-17	Colorectal cancer;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19524238	chr7:2802976	GNA12	0.38	8.73	0.38	4.5e-17	Height;
LGG	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg00129232	chr17:37814104	STARD3	-0.44	-8.16	-0.35	3.19e-15	Eosinophil percentage of white cells;
LGG	cis	rs10197940	0.510	rs7602715	chr2:152421937	A/G	cg19508488	chr2:152266495	RIF1	0.52	8.43	0.36	4.41e-16	Lung cancer;
LGG	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg07936489	chr17:37558343	FBXL20	-0.53	-8.81	-0.38	2.45e-17	Asthma;
LGG	cis	rs73086581	1.000	rs34640283	chr20:3989576	T/A	cg02187196	chr20:3869020	PANK2	0.81	11.39	0.47	1.18e-26	Response to antidepressants in depression;
LGG	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/GT	cg05169160	chr2:178484487	TTC30A	-0.58	-7.61	-0.33	1.5e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6764363	0.504	rs13072223	chr3:279586	G/C	cg02057681	chr3:285234	CHL1	-0.43	-7.73	-0.34	6.67e-14	Sudden cardiac arrest;
LGG	cis	rs42648	0.777	rs4728878	chr7:89924232	T/G	cg25739043	chr7:89950458	NA	-0.44	-9.26	-0.4	7.69e-19	Homocysteine levels;
LGG	cis	rs6504108	0.602	rs2938483	chr17:46318004	C/T	cg02219949	chr17:45927392	SP6	0.42	7.76	0.34	5.53e-14	Body mass index;
LGG	cis	rs2012796	1.000	rs7153469	chr14:81820979	T/G	cg02996355	chr14:81879375	NA	0.52	8.24	0.36	1.74e-15	Night sleep phenotypes;
LGG	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg18328702	chr4:46992926	GABRA4	-0.32	-6.86	-0.3	2.18e-11	Alzheimer's disease (survival time);
LGG	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg17330251	chr7:94953956	PON1	-0.43	-8.3	-0.36	1.16e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7937612	0.931	rs12806740	chr11:120203628	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.5	-11.7	-0.48	6.84e-28	Intraocular pressure;
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	-0.58	-8.79	-0.38	2.91e-17	Platelet count;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg19143629	chr17:61920732	SMARCD2	0.41	6.97	0.31	1.12e-11	Prudent dietary pattern;
LGG	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg22232500	chr2:134024266	NCKAP5	0.63	8.87	0.38	1.64e-17	Bipolar disorder;
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg05484376	chr2:27715224	FNDC4	0.46	10.11	0.43	7.88e-22	Total body bone mineral density;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg23758822	chr17:41437982	NA	0.87	15.39	0.58	1.93e-43	Menopause (age at onset);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21879029	chr17:78935175	RPTOR	0.4	7.19	0.32	2.64e-12	Electrocardiographic conduction measures;
LGG	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg03929089	chr4:120376271	NA	0.69	9.75	0.41	1.55e-20	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg11707556	chr5:10655725	ANKRD33B	0.49	9.54	0.41	8.02e-20	Coronary artery disease;
LGG	cis	rs6028335	0.674	rs3752301	chr20:37654024	T/G	cg16355469	chr20:37678765	NA	0.58	7.94	0.35	1.51e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs4481887	1.000	rs4409693	chr1:248479061	C/T	cg13385794	chr1:248469461	NA	0.49	8.17	0.35	3.06e-15	Common traits (Other);
LGG	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg25427524	chr10:38739819	LOC399744	-0.69	-13.86	-0.54	8.83e-37	Extrinsic epigenetic age acceleration;
LGG	cis	rs36051895	0.603	rs11795305	chr9:5179920	G/C	cg02405213	chr9:5042618	JAK2	-0.74	-13.41	-0.53	7.4e-35	Pediatric autoimmune diseases;
LGG	trans	rs877282	0.945	rs71491303	chr10:772884	G/T	cg22713356	chr15:30763199	NA	0.56	8.63	0.37	1.02e-16	Uric acid levels;
LGG	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg08344181	chr3:125677491	NA	-0.64	-7.72	-0.34	7.36e-14	Breast cancer;
LGG	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.29	-0.32	1.36e-12	Life satisfaction;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	trans	rs783540	1.000	rs7496954	chr15:83345536	T/G	cg16105309	chr15:79090380	ADAMTS7	-0.41	-7.12	-0.31	4.21e-12	Schizophrenia;
LGG	cis	rs2282802	0.711	rs1864970	chr5:139633042	T/C	cg26211634	chr5:139558579	C5orf32	0.35	7.5	0.33	3.27e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.02	-0.42	1.62e-21	Alzheimer's disease;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07677032	chr17:61819896	STRADA	0.67	12.23	0.49	5.38e-30	Prudent dietary pattern;
LGG	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.77	0.38	3.31e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.09	0.35	5.17e-15	Prostate cancer;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21438664	chr14:21738093	HNRNPC	0.4	6.66	0.3	7.65e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2290159	0.800	rs60953453	chr3:12654921	C/A	cg23032965	chr3:12705835	RAF1	0.66	9.64	0.41	3.61e-20	Cholesterol, total;
LGG	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg16576597	chr16:28551801	NUPR1	0.31	7.05	0.31	6.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7149337	0.869	rs10137481	chr14:51694614	C/T	cg23942311	chr14:51606299	NA	0.33	7.27	0.32	1.54e-12	Cancer;
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg16339924	chr4:17578868	LAP3	0.64	11.23	0.46	4.98e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg05925327	chr15:68127851	NA	-0.43	-8.69	-0.37	6.37e-17	Restless legs syndrome;
LGG	cis	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.71	-0.3	5.59e-11	Neuroticism;
LGG	cis	rs9443645	0.901	rs9343856	chr6:79678211	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.76e-16	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg03188948	chr7:1209495	NA	0.42	7.27	0.32	1.52e-12	Longevity;Endometriosis;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.67	12.2	0.49	6.81e-30	Lymphocyte counts;
LGG	cis	rs503425	0.688	rs2510902	chr11:118700218	G/A	cg19182353	chr11:118479428	PHLDB1	-0.49	-7.19	-0.32	2.59e-12	Systemic lupus erythematosus;
LGG	cis	rs36051895	0.622	rs12335546	chr9:5072182	C/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.88	-0.59	1.17e-45	Pediatric autoimmune diseases;
LGG	cis	rs17854409	1.000	rs16983290	chr20:61478894	A/G	cg06598544	chr20:61472147	COL9A3	0.92	10.38	0.43	8e-23	Obesity-related traits;
LGG	cis	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.56	-0.33	2.12e-13	Retinal vascular caliber;
LGG	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg09238746	chr17:78121135	EIF4A3	-0.54	-9.83	-0.42	8.05e-21	Yeast infection;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg11473876	chr11:109292803	C11orf87	0.48	9.39	0.4	2.78e-19	Schizophrenia;
LGG	cis	rs10504130	0.666	rs7813414	chr8:52860205	C/T	cg22653915	chr8:52722023	PXDNL	-0.47	-7.84	-0.34	3.21e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg17085576	chr10:5658249	NA	-0.42	-7.91	-0.34	1.96e-14	Breast cancer;
LGG	trans	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg18187862	chr3:45730750	SACM1L	0.42	6.81	0.3	3.03e-11	Primary sclerosing cholangitis;
LGG	trans	rs877282	0.945	rs11253397	chr10:789774	A/G	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.7	0.71	1.46e-72	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Myopia (pathological);
LGG	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg13647721	chr17:30228624	UTP6	-0.73	-9.34	-0.4	4.21e-19	Hip circumference adjusted for BMI;
LGG	cis	rs4746818	1.000	rs7916991	chr10:70895373	C/A	cg11621586	chr10:70884670	VPS26A	1.16	17.12	0.62	2.8e-51	Left atrial antero-posterior diameter;
LGG	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg23461800	chr14:103021989	NA	0.53	9.65	0.41	3.36e-20	Platelet count;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg07414643	chr4:187882934	NA	0.57	11.77	0.48	3.6e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs250677	0.687	rs3095947	chr5:148436728	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.22	-0.32	2.1e-12	Breast cancer;
LGG	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg21475434	chr5:93447410	FAM172A	0.71	7.24	0.32	1.9e-12	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18247126	chr11:121163951	SC5DL	0.41	6.77	0.3	3.86e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1847505	0.957	rs1394311	chr13:61523310	C/T	cg25164009	chr13:61490935	NA	-0.61	-9.75	-0.41	1.51e-20	Polychlorinated biphenyl levels;
LGG	cis	rs1847202	0.563	rs13095184	chr3:72951008	A/G	cg25664220	chr3:72788482	NA	-0.25	-7.32	-0.32	1.13e-12	Motion sickness;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.97	0.38	7.38e-18	Platelet count;
LGG	cis	rs7100689	0.556	rs946893	chr10:82023524	A/G	cg01528321	chr10:82214614	TSPAN14	0.78	13.28	0.53	2.6e-34	Post bronchodilator FEV1;
LGG	cis	rs9534288	0.797	rs6561281	chr13:46596601	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg08975724	chr8:8085496	FLJ10661	0.37	6.88	0.3	1.91e-11	Neuroticism;
LGG	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg13852791	chr20:30311386	BCL2L1	0.79	12.71	0.51	5.8e-32	Mean corpuscular hemoglobin;
LGG	trans	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg21659725	chr3:3221576	CRBN	-0.5	-7.8	-0.34	4.07e-14	Intelligence (multi-trait analysis);
LGG	cis	rs968451	0.789	rs1569498	chr22:39714704	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.86	14.39	0.56	4.62e-39	Primary biliary cholangitis;
LGG	cis	rs12447804	0.953	rs3743563	chr16:58079165	G/A	cg03859792	chr16:58121049	NA	0.47	7.13	0.31	3.84e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs735539	0.517	rs9552241	chr13:21127569	C/G	cg04906043	chr13:21280425	IL17D	0.47	7.85	0.34	2.93e-14	Dental caries;
LGG	cis	rs3740540	0.507	rs942015	chr10:126289932	G/T	cg04949429	chr10:126290192	LHPP	0.62	11.97	0.49	5.81e-29	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg21972741	chr5:435613	AHRR	0.5	8.98	0.39	6.94e-18	Cystic fibrosis severity;
LGG	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg20308403	chr7:2120281	MAD1L1	0.32	6.82	0.3	2.87e-11	Schizophrenia;
LGG	cis	rs9462027	0.628	rs6937132	chr6:34799221	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs7565124	0.954	rs7568484	chr2:20255251	A/G	cg24657347	chr2:20261756	NA	-0.73	-13.84	-0.54	1.11e-36	Major depressive disorder;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg13206674	chr6:150067644	NUP43	0.62	13.94	0.54	3.84e-37	Lung cancer;
LGG	trans	rs8073060	0.586	rs225286	chr17:33930458	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.42	-0.63	1.22e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1577917	1.000	rs1995688	chr6:86632319	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.87	-0.51	1.24e-32	Response to antipsychotic treatment;
LGG	cis	rs4919087	0.748	rs1687369	chr10:98976923	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.29	-0.32	1.35e-12	Monocyte count;
LGG	cis	rs10479542	0.544	rs10056863	chr5:179005100	G/A	cg14851468	chr5:179071604	C5orf60	0.48	8.2	0.36	2.37e-15	Lung cancer;
LGG	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg13010199	chr12:38710504	ALG10B	0.47	8.89	0.38	1.33e-17	Morning vs. evening chronotype;
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.39	-7.59	-0.33	1.76e-13	Obesity;
LGG	cis	rs7084402	0.967	rs1658483	chr10:60288933	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.34	0.32	9.7e-13	Height;
LGG	trans	rs9929218	1.000	rs35069703	chr16:68789445	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.73	-0.54	3.03e-36	Colorectal cancer;
LGG	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.4	0.4	2.51e-19	Retinal vascular caliber;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.81	15.86	0.59	1.43e-45	Lymphocyte counts;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.28	-0.36	1.37e-15	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg18379455	chr17:41446167	NA	-0.32	-7.29	-0.32	1.31e-12	Menopause (age at onset);
LGG	cis	rs9534288	0.912	rs3736944	chr13:46619316	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-16.0	-0.6	3.59e-46	Blood protein levels;
LGG	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg12432903	chr7:1882776	MAD1L1	0.48	7.15	0.32	3.48e-12	Bipolar disorder;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg08024992	chr7:2133441	MAD1L1	0.36	6.71	0.3	5.71e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs68170813	0.559	rs4730229	chr7:106925353	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.54	-0.44	2e-23	Coronary artery disease;
LGG	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21659725	chr3:3221576	CRBN	0.92	20.42	0.69	1.48e-66	Intelligence (multi-trait analysis);
LGG	cis	rs2797369	0.609	rs11155780	chr6:101398997	C/T	cg27451362	chr6:101846650	GRIK2	0.76	10.52	0.44	2.33e-23	Renal function-related traits (eGRFcrea);
LGG	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18252515	chr7:66147081	NA	-0.43	-7.3	-0.32	1.3e-12	Aortic root size;
LGG	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg13072238	chr3:49761600	GMPPB	0.52	6.85	0.3	2.41e-11	Menarche (age at onset);
LGG	cis	rs4631830	0.900	rs10763546	chr10:51536399	C/G	cg16070123	chr10:51489643	NA	-0.38	-7.03	-0.31	7.31e-12	Prostate-specific antigen levels;
LGG	trans	rs7829975	0.511	rs2976902	chr8:8341105	T/G	cg16141378	chr3:129829833	LOC729375	-0.43	-10.49	-0.44	2.96e-23	Mood instability;
LGG	trans	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.77	0.41	1.22e-20	Mean corpuscular volume;
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg12310025	chr6:25882481	NA	-0.42	-7.48	-0.33	3.83e-13	Height;
LGG	cis	rs8180040	0.932	rs11712445	chr3:47434552	T/C	cg27129171	chr3:47204927	SETD2	0.77	15.01	0.57	8.98e-42	Colorectal cancer;
LGG	cis	rs6500395	0.962	rs9921741	chr16:48589896	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.21	0.36	2.16e-15	Aortic root size;
LGG	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.9	-0.34	2.08e-14	Total cholesterol levels;
LGG	trans	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg22153745	chr1:153894579	GATAD2B	-0.58	-8.52	-0.37	2.34e-16	Total cholesterol levels;
LGG	cis	rs757978	0.733	rs11684403	chr2:242414874	C/T	cg10173475	chr2:242152697	ANO7	-0.53	-6.83	-0.3	2.7e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7107174	1.000	rs2373009	chr11:77945815	T/A	cg02023728	chr11:77925099	USP35	0.46	7.87	0.34	2.6e-14	Testicular germ cell tumor;
LGG	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.34e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg04160749	chr8:58172571	NA	-0.51	-7.99	-0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	8.98	0.38	7.11e-18	Personality dimensions;
LGG	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg03342759	chr3:160939853	NMD3	0.49	8.19	0.36	2.6e-15	Kawasaki disease;
LGG	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg03342759	chr3:160939853	NMD3	-0.72	-11.45	-0.47	6.44e-27	Parkinson's disease;
LGG	cis	rs9814567	0.727	rs7430034	chr3:134342127	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.91	-0.45	8.38e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.13	0.35	3.84e-15	Electroencephalogram traits;
LGG	cis	rs1003719	0.680	rs8130069	chr21:38552116	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.14	-0.58	2.41e-42	Eye color traits;
LGG	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.94	0.31	1.32e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.46	-7.63	-0.33	1.4e-13	Renal function-related traits (BUN);
LGG	cis	rs9354308	0.764	rs9294663	chr6:66596040	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.66	0.37	7.69e-17	Schizophrenia;
LGG	trans	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.29	0.63	4.95e-52	Exhaled nitric oxide levels;
LGG	cis	rs6462411	1.000	rs6968444	chr7:3911987	C/T	cg18022346	chr7:3920534	SDK1	-0.35	-6.84	-0.3	2.45e-11	Quantitative traits;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg06637938	chr14:75390232	RPS6KL1	0.76	15.17	0.58	1.71e-42	Caffeine consumption;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg01238044	chr22:24384105	GSTT1	-0.41	-7.0	-0.31	9.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6963495	0.818	rs1721500	chr7:105219233	T/G	cg19920283	chr7:105172520	RINT1	0.65	8.68	0.37	6.69e-17	Bipolar disorder (body mass index interaction);
LGG	cis	rs867371	1.000	rs1846911	chr15:82468650	G/A	cg00614314	chr15:82944287	LOC80154	0.59	9.83	0.42	7.52e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs701145	0.585	rs447429	chr3:153909946	T/C	cg17054900	chr3:154042577	DHX36	0.91	10.28	0.43	1.78e-22	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg12708336	chr17:41446283	NA	-0.3	-6.85	-0.3	2.38e-11	Menopause (age at onset);
LGG	cis	rs11074306	0.561	rs28653482	chr15:28067619	T/C	cg26402630	chr15:28053930	OCA2	0.36	7.33	0.32	1.04e-12	Uveal melanoma;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg19168338	chr16:4465731	CORO7	0.78	14.86	0.57	3.89e-41	Schizophrenia;
LGG	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.832	rs56030824	chr11:47397353	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.36	-0.43	8.89e-23	Subjective well-being;
LGG	trans	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg24247370	chr13:99142703	STK24	-0.41	-7.52	-0.33	2.84e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10893109	0.517	rs2315029	chr11:123773527	C/T	cg12387464	chr11:123775935	OR8D4	0.39	8.29	0.36	1.21e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2737618	0.551	rs2816992	chr1:200069216	C/T	cg21825944	chr1:200113062	NR5A2	0.47	8.87	0.38	1.64e-17	Uric acid levels;
LGG	trans	rs11671005	0.504	rs3794963	chr19:59071051	C/G	cg22037779	chr5:139682734	PFDN1	0.42	6.91	0.31	1.61e-11	Mean platelet volume;
LGG	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg18709589	chr6:96969512	KIAA0776	-0.38	-7.12	-0.31	4.23e-12	Headache;
LGG	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg02428538	chr16:24856791	SLC5A11	-0.71	-10.85	-0.45	1.32e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12756686	chr19:29218302	NA	0.7	11.37	0.47	1.35e-26	Methadone dose in opioid dependence;
LGG	cis	rs225245	0.782	rs161183	chr17:33919475	G/C	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg05639522	chr1:247681581	NA	0.64	10.37	0.43	8.37e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs154659	0.887	rs154660	chr16:89667637	C/G	cg01710450	chr16:89662404	CPNE7	-0.65	-11.94	-0.49	7.75e-29	Tanning;
LGG	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg26384229	chr12:38710491	ALG10B	0.86	16.78	0.61	1.07e-49	Heart rate;
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2154319	0.887	rs6669542	chr1:41525770	T/G	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.84	-0.38	2.03e-17	Height;
LGG	cis	rs7666738	0.830	rs7691864	chr4:98971376	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs758324	0.947	rs11948962	chr5:131113830	C/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.98	0.35	1.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.812	rs26010	chr5:131013815	G/A	cg06307176	chr5:131281290	NA	0.53	8.8	0.38	2.71e-17	Life satisfaction;
LGG	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs75920871	0.545	rs7939934	chr11:116861268	A/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.92	-0.45	7.39e-25	Subjective well-being;
LGG	trans	rs11088226	0.681	rs2833911	chr21:33949629	C/T	cg09050820	chr6:167586206	TCP10L2	-0.93	-13.65	-0.54	6.67e-36	Gastritis;
LGG	cis	rs28735056	0.904	rs72980087	chr18:77632194	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-8.79	-0.38	2.9e-17	Schizophrenia;
LGG	cis	rs2652834	1.000	rs2729788	chr15:63400378	G/C	cg05507819	chr15:63340323	TPM1	0.59	7.92	0.35	1.77e-14	HDL cholesterol;
LGG	cis	rs6912958	0.712	rs2814712	chr6:88396322	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.49	8.53	0.37	2.07e-16	Monocyte percentage of white cells;
LGG	cis	rs9358372	0.964	rs9465902	chr6:20814416	G/A	cg13405222	chr6:20811065	CDKAL1	-0.71	-15.61	-0.59	1.98e-44	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2180341	0.538	rs4577822	chr6:127712911	T/G	cg27446573	chr6:127587934	RNF146	0.67	12.04	0.49	3.1e-29	Breast cancer;
LGG	cis	rs2011503	0.941	rs10403273	chr19:19372968	C/G	cg11584989	chr19:19387371	SF4	0.73	12.11	0.49	1.62e-29	Bipolar disorder;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg09264619	chr17:80180166	NA	-0.36	-7.04	-0.31	7e-12	Life satisfaction;
LGG	cis	rs2188561	0.697	rs7787927	chr7:107404360	C/A	cg16793755	chr7:107334138	SLC26A4	0.37	6.77	0.3	3.93e-11	Alcohol consumption;
LGG	cis	rs2404602	0.583	rs3759853	chr15:76587777	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.76	-0.3	4.07e-11	Blood metabolite levels;
LGG	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg14228332	chr4:119757509	SEC24D	0.97	9.38	0.4	3.08e-19	Cannabis dependence symptom count;
LGG	cis	rs2762049	0.524	rs806344	chr13:50857421	A/G	cg10393508	chr13:50950265	NA	-0.3	-7.54	-0.33	2.57e-13	Aortic root size;
LGG	cis	rs7208859	0.673	rs999797	chr17:29159329	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.77	0.3	3.84e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23214285	chr7:16685646	BZW2;ANKMY2	0.42	6.65	0.3	8.09e-11	Cognitive performance;
LGG	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg06640241	chr16:89574553	SPG7	0.7	11.74	0.48	4.75e-28	Multiple myeloma (IgH translocation);
LGG	cis	rs9362426	0.579	rs9362428	chr6:88107415	A/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.44	8.5	0.37	2.64e-16	Depressive episodes in bipolar disorder;
LGG	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.02	-0.52	3.11e-33	Schizophrenia;
LGG	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.2e-14	Prudent dietary pattern;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg13264159	chr8:625131	ERICH1	-0.99	-11.28	-0.46	3.13e-26	IgG glycosylation;
LGG	cis	rs7647973	0.626	rs1078341	chr3:49685592	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.56	-0.33	2.22e-13	Menarche (age at onset);
LGG	cis	rs9596863	0.898	rs9568905	chr13:54330289	G/A	ch.13.53330881F	chr13:54432880	NA	0.54	7.31	0.32	1.16e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.74	-0.34	6.44e-14	Neuroticism;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.85	-0.3	2.37e-11	Blood metabolite levels;
LGG	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02825527	chr7:2087843	MAD1L1	-0.55	-9.29	-0.4	6.18e-19	Neuroticism;
LGG	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg18188782	chr20:61659543	NA	0.4	6.78	0.3	3.66e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06826431	chr17:46125498	NFE2L1	0.42	6.75	0.3	4.33e-11	Cognitive performance;
LGG	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs6993813	0.872	rs7813486	chr8:120032525	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs9309473	0.950	rs6546849	chr2:73831037	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.3e-14	Metabolite levels;
LGG	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg27129171	chr3:47204927	SETD2	-0.82	-14.92	-0.57	2.3e-41	Colorectal cancer;
LGG	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-10.9	-0.45	8.54e-25	Presence of antiphospholipid antibodies;
LGG	cis	rs1975974	0.511	rs113941161	chr17:21741346	T/C	cg18423549	chr17:21743878	NA	-0.53	-8.02	-0.35	9.04e-15	Psoriasis;
LGG	cis	rs8180040	0.739	rs4683320	chr3:47152992	C/T	cg27129171	chr3:47204927	SETD2	0.85	16.51	0.61	1.67e-48	Colorectal cancer;
LGG	cis	rs490234	0.932	rs506874	chr9:128319066	G/A	cg14078157	chr9:128172775	NA	0.39	7.33	0.32	1.01e-12	Mean arterial pressure;
LGG	cis	rs2114646	0.731	rs12473978	chr2:170632252	A/G	cg17598339	chr2:170624727	NA	0.36	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	cis	rs1124376	0.882	rs6791385	chr3:20136439	A/C	cg05072819	chr3:20081367	KAT2B	0.6	8.09	0.35	5.29e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.34	0.4	4.17e-19	Sudden cardiac arrest;
LGG	trans	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg06606381	chr12:133084897	FBRSL1	-0.56	-6.99	-0.31	9.49e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	0.647	rs2414529	chr15:58317094	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.93	-0.31	1.45e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.42	6.86	0.3	2.28e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg22348356	chr13:114891224	RASA3	0.4	7.63	0.33	1.36e-13	Schizophrenia;
LGG	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg26769984	chr7:1090371	C7orf50	0.43	7.7	0.34	8.19e-14	Bronchopulmonary dysplasia;
LGG	cis	rs910316	0.967	rs4903292	chr14:75656245	A/G	cg08847533	chr14:75593920	NEK9	0.58	11.0	0.46	3.73e-25	Height;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	8.93	0.38	9.99e-18	Intelligence (multi-trait analysis);
LGG	cis	rs17092148	1.000	rs6060017	chr20:33313042	G/T	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.73	-0.34	6.82e-14	Neuroticism;
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg24642844	chr7:1081250	C7orf50	-0.77	-9.79	-0.41	1.06e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7927771	0.524	rs10742820	chr11:47781057	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-10.93	-0.45	6.72e-25	Subjective well-being;
LGG	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg25566285	chr7:158114605	PTPRN2	0.88	19.34	0.67	1.69e-61	Calcium levels;
LGG	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06470251	chr20:60548479	NA	0.49	8.01	0.35	9.67e-15	Body mass index;
LGG	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg00579200	chr11:133705235	NA	-0.59	-11.25	-0.46	3.93e-26	Childhood ear infection;
LGG	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18252515	chr7:66147081	NA	0.41	7.03	0.31	7.52e-12	Aortic root size;
LGG	trans	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg01620082	chr3:125678407	NA	-0.61	-7.38	-0.32	7.64e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.15	-25.79	-0.77	1.38e-91	Primary sclerosing cholangitis;
LGG	cis	rs8067545	0.611	rs2526482	chr17:20119133	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.11	-0.35	4.5e-15	HDL cholesterol;
LGG	cis	rs79149102	0.579	rs8034149	chr15:75311842	G/C	cg17294928	chr15:75287854	SCAMP5	-0.82	-8.85	-0.38	1.89e-17	Lung cancer;
LGG	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg25173405	chr17:45401733	C17orf57	-0.49	-8.29	-0.36	1.2e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17554472	chr22:41940697	POLR3H	0.45	6.95	0.31	1.21e-11	Vitiligo;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.47e-27	Personality dimensions;
LGG	cis	rs701145	0.938	rs701133	chr3:154070312	A/G	cg17054900	chr3:154042577	DHX36	0.98	12.3	0.5	2.69e-30	Coronary artery disease;
LGG	cis	rs283228	0.959	rs1485833	chr6:101807507	C/T	cg27451362	chr6:101846650	GRIK2	0.53	8.96	0.38	7.83e-18	Coenzyme Q10 levels;
LGG	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	trans	rs747782	0.537	rs10838835	chr11:48246457	C/T	cg15704280	chr7:45808275	SEPT13	-0.67	-7.95	-0.35	1.42e-14	Intraocular pressure;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.53	0.37	2.09e-16	Personality dimensions;
LGG	cis	rs709400	0.663	rs11624367	chr14:103892818	T/A	cg26031613	chr14:104095156	KLC1	0.79	13.6	0.53	1.07e-35	Body mass index;
LGG	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.56	8.47	0.37	3.18e-16	Height;
LGG	cis	rs12580194	1.000	rs4491341	chr12:55697838	G/A	cg19537932	chr12:55886519	OR6C68	-0.37	-6.73	-0.3	5.18e-11	Cancer;
LGG	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.57	-9.88	-0.42	5.16e-21	Hemoglobin concentration;
LGG	cis	rs9462027	0.539	rs9469883	chr6:34758627	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.9	-0.38	1.25e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7614311	0.636	rs73117057	chr3:63915689	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.71	-0.34	8.02e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.57	0.44	1.56e-23	Iron status biomarkers;
LGG	cis	rs9398803	0.865	rs9375446	chr6:126835015	G/A	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs1577917	1.000	rs12154056	chr6:86634094	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	trans	rs3780486	0.757	rs10813949	chr9:33123464	G/A	cg04842962	chr6:43655489	MRPS18A	1.13	24.68	0.75	1.79e-86	IgG glycosylation;
LGG	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs36051895	0.695	rs1327494	chr9:4999303	A/G	cg02405213	chr9:5042618	JAK2	-0.79	-14.4	-0.56	3.92e-39	Pediatric autoimmune diseases;
LGG	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg02705964	chr17:66097276	LOC651250	-0.47	-8.24	-0.36	1.84e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7537052	0.646	rs6680302	chr1:36653540	C/T	cg24686825	chr1:36642396	MAP7D1	-0.62	-14.95	-0.57	1.59e-41	Schizophrenia;
LGG	cis	rs7737355	0.947	rs28720007	chr5:131077709	C/T	cg06307176	chr5:131281290	NA	0.56	9.27	0.4	6.99e-19	Life satisfaction;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.33e-13	Educational attainment;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.44	4.34e-23	Bipolar disorder;
LGG	trans	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg10756647	chr7:56101905	PSPH	0.83	9.95	0.42	2.87e-21	Diabetic kidney disease;
LGG	cis	rs2991971	0.967	rs2275276	chr1:45973928	C/T	cg24296786	chr1:45957014	TESK2	0.39	7.09	0.31	5.1e-12	High light scatter reticulocyte count;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26687661	chr11:121526609	NA	0.41	6.74	0.3	4.77e-11	Menarche (age at onset);
LGG	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.97	-0.74	3.67e-83	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18124201	chr20:46414952	SULF2	-0.44	-7.23	-0.32	2.02e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs847577	0.609	rs6465657	chr7:97816327	C/T	cg13397024	chr7:97797637	LMTK2	-0.36	-6.8	-0.3	3.26e-11	Breast cancer;
LGG	cis	rs96067	0.805	rs4653162	chr1:36613704	G/T	cg24686825	chr1:36642396	MAP7D1	0.41	7.71	0.34	7.73e-14	Corneal structure;
LGG	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg12046867	chr14:103022105	NA	-0.79	-15.63	-0.59	1.54e-44	Platelet count;
LGG	cis	rs883565	0.542	rs6802490	chr3:39033907	T/A	cg01426195	chr3:39028469	NA	-0.72	-16.2	-0.6	4.42e-47	Handedness;
LGG	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.38	0.32	7.3e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2916247	0.954	rs4506267	chr8:93079246	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.49	-0.33	3.59e-13	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.623	rs7859286	chr9:5260940	G/T	cg02405213	chr9:5042618	JAK2	-0.75	-13.39	-0.53	8.38e-35	Pediatric autoimmune diseases;
LGG	cis	rs2285947	0.935	rs10258022	chr7:21583667	A/G	cg04471919	chr7:21584483	DNAH11	0.49	13.74	0.54	2.82e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg21385522	chr1:16154831	NA	-0.97	-15.15	-0.58	2.04e-42	Dilated cardiomyopathy;
LGG	cis	rs6912958	0.712	rs9444525	chr6:88324142	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.89	-0.38	1.39e-17	Monocyte percentage of white cells;
LGG	cis	rs13421350	0.579	rs16860634	chr2:173368358	T/G	cg15021238	chr2:173305865	ITGA6	-0.79	-8.48	-0.37	3.07e-16	Diabetic kidney disease;
LGG	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg07636037	chr3:49044803	WDR6	0.6	10.29	0.43	1.7e-22	Resting heart rate;
LGG	cis	rs858239	0.601	rs764534	chr7:23153935	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.33	0.32	1e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg25486957	chr4:152246857	NA	-0.38	-6.89	-0.3	1.83e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.87	16.07	0.6	1.66e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg02725872	chr8:58115012	NA	1.05	15.31	0.58	4.24e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg06636001	chr8:8085503	FLJ10661	0.59	11.66	0.48	9.73e-28	Mood instability;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg17202724	chr17:61916730	SMARCD2	0.63	15.53	0.59	4.38e-44	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg00684032	chr4:1343700	KIAA1530	0.48	9.37	0.4	3.13e-19	Obesity-related traits;
LGG	cis	rs6754311	0.731	rs12988076	chr2:136569848	C/A	cg07169764	chr2:136633963	MCM6	-0.75	-12.78	-0.51	2.99e-32	Mosquito bite size;
LGG	cis	rs9916302	0.904	rs8065879	chr17:37515978	G/A	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.73	0.41	1.71e-20	Neuroticism;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg11494091	chr17:61959527	GH2	0.51	8.34	0.36	8.31e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs4700695	0.614	rs1864042	chr5:65206722	G/A	cg21114390	chr5:65439923	SFRS12	0.61	6.84	0.3	2.49e-11	Facial morphology (factor 19);
LGG	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2e-19	Diabetic retinopathy;
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00292662	chr22:38071168	LGALS1	0.89	23.89	0.74	9.2e-83	Fat distribution (HIV);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04025590	chr1:26560450	CCDC21	-0.41	-6.71	-0.3	5.87e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9457247	1.000	rs398278	chr6:167388169	A/G	cg07741184	chr6:167504864	NA	0.31	6.84	0.3	2.53e-11	Crohn's disease;
LGG	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.36	-0.32	8.47e-13	Iron status biomarkers;
LGG	trans	rs459571	0.959	rs2810491	chr9:136923331	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	0.68	11.65	0.48	1.15e-27	Platelet distribution width;
LGG	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg27446573	chr6:127587934	RNF146	0.93	17.24	0.63	8.41e-52	Breast cancer;
LGG	cis	rs7508	0.640	rs373983	chr8:17911905	C/T	cg18067069	chr8:17937731	ASAH1	-0.32	-7.46	-0.33	4.37e-13	Atrial fibrillation;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.1	0.31	4.69e-12	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07677032	chr17:61819896	STRADA	0.68	12.62	0.51	1.37e-31	Prudent dietary pattern;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.1	-0.42	8.37e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9944715	1.000	rs9952654	chr18:43849568	T/G	cg26436583	chr18:43649176	PSTPIP2	-0.36	-6.75	-0.3	4.57e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7737355	0.947	rs2108871	chr5:131089044	A/C	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	3.01e-19	Life satisfaction;
LGG	cis	rs11585357	0.895	rs72646798	chr1:17614422	C/T	cg08277548	chr1:17600880	PADI3	-0.74	-8.17	-0.35	3.05e-15	Hair shape;
LGG	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg07636037	chr3:49044803	WDR6	0.92	15.92	0.59	8.34e-46	Menarche (age at onset);
LGG	cis	rs1639906	0.965	rs1637742	chr7:2236432	G/A	cg20308403	chr7:2120281	MAD1L1	0.35	7.87	0.34	2.5e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.72e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg22875332	chr1:76189707	ACADM	0.6	9.69	0.41	2.42e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.01	-0.35	9.63e-15	Longevity;Endometriosis;
LGG	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg11494091	chr17:61959527	GH2	0.6	10.07	0.42	1.06e-21	Height;
LGG	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.16e-25	Aortic root size;
LGG	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	7.58	0.33	1.85e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6121246	0.560	rs6088854	chr20:30225357	G/A	cg13852791	chr20:30311386	BCL2L1	0.75	10.51	0.44	2.53e-23	Mean corpuscular hemoglobin;
LGG	trans	rs1814175	0.702	rs4881644	chr11:49786367	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.91	-0.78	1.05e-96	Height;
LGG	trans	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg18335740	chr13:41363409	SLC25A15	0.54	9.82	0.42	8.73e-21	Lewy body disease;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.75	0.34	5.81e-14	Longevity;
LGG	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg26297688	chr12:107349093	C12orf23	-0.38	-7.15	-0.32	3.47e-12	Total body bone mineral density;
LGG	cis	rs9948	0.655	rs6576981	chr2:97394406	G/C	cg01990225	chr2:97406019	LMAN2L	-0.77	-8.2	-0.36	2.46e-15	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2239547	0.657	rs2071040	chr3:52864860	A/G	cg11645453	chr3:52864694	ITIH4	0.72	11.07	0.46	1.97e-25	Schizophrenia;
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.48e-13	Alzheimer's disease;
LGG	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg17108064	chr15:78857060	CHRNA5	-0.47	-10.07	-0.42	1.06e-21	Sudden cardiac arrest;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.65	-0.33	1.2e-13	Tonsillectomy;
LGG	cis	rs3740909	1.000	rs75511608	chr11:125884374	A/G	cg24940576	chr11:125904314	CDON	-0.48	-7.53	-0.33	2.63e-13	Blood protein levels;
LGG	cis	rs4538187	0.585	rs34765999	chr2:64252793	G/A	cg19915305	chr2:64069682	UGP2	-0.65	-14.59	-0.56	5.86e-40	Systolic blood pressure;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-15.84	-0.59	1.74e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.6	0.41	4.87e-20	Height;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.38	7.87	0.34	2.62e-14	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02072896	chr1:3331137	PRDM16	0.42	6.9	0.31	1.77e-11	Pancreatic cancer;
LGG	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22496380	chr5:211416	CCDC127	-1.29	-11.62	-0.48	1.39e-27	Breast cancer;
LGG	trans	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg19694781	chr19:47549865	TMEM160	-0.41	-7.09	-0.31	4.89e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs847649	0.599	rs13232194	chr7:102742554	T/A	cg18108683	chr7:102477205	FBXL13	0.54	11.29	0.46	2.75e-26	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg01059449	chr18:44338099	ST8SIA5	0.31	6.73	0.3	4.9e-11	Personality dimensions;
LGG	cis	rs193541	0.632	rs39821	chr5:122295472	T/C	cg19412675	chr5:122181750	SNX24	0.55	8.72	0.38	5.04e-17	Glucose homeostasis traits;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05025164	chr4:1340916	KIAA1530	-0.87	-17.19	-0.62	1.47e-51	Longevity;
LGG	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg15557168	chr22:42548783	NA	-0.4	-8.57	-0.37	1.57e-16	Schizophrenia;
LGG	cis	rs9815354	1.000	rs9873207	chr3:41884750	C/T	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4742903	0.904	rs966390	chr9:106944031	A/G	cg14250997	chr9:106856677	SMC2	0.38	7.8	0.34	4.1e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs3733418	0.697	rs13111010	chr4:165956741	C/T	cg10852876	chr4:165953100	TRIM60	-0.44	-6.65	-0.3	8.15e-11	Obesity-related traits;
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg21926883	chr2:100939477	LONRF2	-0.66	-14.89	-0.57	2.85e-41	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.74	-0.3	4.69e-11	Sudden cardiac arrest;
LGG	cis	rs981844	0.775	rs62323975	chr4:154737617	A/G	cg14289246	chr4:154710475	SFRP2	0.67	11.03	0.46	2.89e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg03929089	chr4:120376271	NA	0.72	7.61	0.33	1.6e-13	Axial length;
LGG	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs17401966	0.624	rs6696978	chr1:10209557	C/T	cg19773385	chr1:10388646	KIF1B	0.35	6.67	0.3	7.25e-11	Hepatocellular carcinoma;
LGG	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.21e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs806795	0.513	rs10946808	chr6:26233387	A/G	cg13736514	chr6:26305472	NA	-0.39	-7.02	-0.31	7.7e-12	Mosquito bite size;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg11473876	chr11:109292803	C11orf87	0.48	9.1	0.39	2.66e-18	Schizophrenia;
LGG	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg00717180	chr2:96193071	NA	0.45	8.39	0.36	5.92e-16	HDL cholesterol;
LGG	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg02931644	chr1:25747376	RHCE	-0.42	-9.22	-0.39	1.03e-18	Erythrocyte sedimentation rate;
LGG	cis	rs7551222	0.680	rs2125855	chr1:204546947	T/C	cg20240347	chr1:204465584	NA	-0.46	-8.1	-0.35	4.81e-15	Schizophrenia;
LGG	cis	rs11866815	0.557	rs58919448	chr16:387587	C/T	cg07915516	chr16:377344	AXIN1	-0.48	-10.97	-0.45	4.71e-25	Body mass index;
LGG	cis	rs11150038	0.623	rs11860895	chr16:78072142	G/A	cg04733911	chr16:78082701	NA	-0.67	-9.58	-0.41	5.95e-20	Colorectal or endometrial cancer;
LGG	cis	rs9790314	0.663	rs4679924	chr3:160661862	T/C	cg04691961	chr3:161091175	C3orf57	0.44	9.25	0.39	8.6e-19	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.71	0.38	5.22e-17	Bipolar disorder;
LGG	cis	rs7909791	0.543	rs11191842	chr10:105639808	C/T	cg11005552	chr10:105648138	OBFC1	0.64	9.31	0.4	5.08e-19	White matter hyperintensity burden;
LGG	trans	rs1422110	0.774	rs1017200	chr5:85506455	G/A	cg01787110	chr1:109008453	NBPF6	0.63	10.11	0.43	7.68e-22	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs11866815	0.739	rs35050910	chr16:394483	T/G	cg00101154	chr16:420108	MRPL28	-0.46	-6.67	-0.3	7.49e-11	Body mass index;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.64	-0.41	3.65e-20	Triglycerides;
LGG	trans	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.46	-0.33	4.19e-13	Educational attainment (years of education);
LGG	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.89	-0.48	1.26e-28	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg27205649	chr11:78285834	NARS2	-0.42	-6.78	-0.3	3.56e-11	Testicular germ cell tumor;
LGG	cis	rs12586317	0.653	rs4981287	chr14:35828198	G/A	cg16230307	chr14:35515116	FAM177A1	0.53	7.83	0.34	3.31e-14	Psoriasis;
LGG	cis	rs9815354	1.000	rs28755797	chr3:41774446	C/T	cg03022575	chr3:42003672	ULK4	0.66	8.28	0.36	1.3e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg14675211	chr2:100938903	LONRF2	0.47	7.14	0.32	3.53e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9506514	0.509	rs9509279	chr13:21133719	C/G	cg27499820	chr13:21296301	IL17D	-0.26	-7.52	-0.33	2.89e-13	Coronary artery calcification;
LGG	cis	rs981844	1.000	rs62325083	chr4:154661775	T/C	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.73	-0.45	4e-24	Alzheimer's disease;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg05335186	chr13:53173507	NA	0.51	10.76	0.45	2.92e-24	Lewy body disease;
LGG	cis	rs2933343	0.661	rs2630259	chr3:128606322	C/T	cg11901034	chr3:128598214	ACAD9	-0.44	-6.68	-0.3	6.8e-11	IgG glycosylation;
LGG	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs8072100	0.967	rs4580230	chr17:45738861	G/A	cg19784903	chr17:45786737	TBKBP1	-0.32	-7.07	-0.31	5.73e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg11764359	chr7:65958608	NA	0.79	14.79	0.57	8.03e-41	Aortic root size;
LGG	cis	rs8018808	0.935	rs17824034	chr14:77878683	A/G	cg20045696	chr14:77926864	AHSA1	0.42	7.05	0.31	6.47e-12	Myeloid white cell count;
LGG	cis	rs6066825	0.627	rs6019349	chr20:47275245	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.21	0.36	2.2e-15	Colorectal cancer;
LGG	cis	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-8.85	-0.38	1.84e-17	Schizophrenia;
LGG	cis	rs1707322	1.000	rs9793167	chr1:46446800	G/A	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg13013644	chr5:502571	SLC9A3	-0.35	-7.3	-0.32	1.25e-12	Cystic fibrosis severity;
LGG	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg08000102	chr2:233561755	GIGYF2	0.61	9.89	0.42	4.6e-21	Coronary artery disease;
LGG	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg27165867	chr14:105738592	BRF1	-0.47	-7.6	-0.33	1.61e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7267979	0.789	rs9927	chr20:25277244	A/G	cg06421707	chr20:25228305	PYGB	0.44	9.31	0.4	5.16e-19	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.23	-0.32	1.98e-12	Morning vs. evening chronotype;
LGG	trans	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg07393940	chr7:158741817	NA	0.57	10.57	0.44	1.53e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs56283067	0.816	rs9472367	chr6:44774597	C/T	cg18551225	chr6:44695536	NA	-0.68	-10.1	-0.43	8e-22	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs6982240	0.514	rs10088801	chr8:142275801	T/C	cg20799268	chr8:142275649	NA	-0.25	-6.96	-0.31	1.17e-11	Tonsillectomy;
LGG	cis	rs7011049	1.000	rs7011049	chr8:53834012	C/A	cg26025543	chr8:53854495	NA	0.73	9.7	0.41	2.25e-20	Systolic blood pressure;
LGG	cis	rs13082711	0.911	rs11718991	chr3:27452944	A/G	cg02860705	chr3:27208620	NA	0.74	13.3	0.53	2.14e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.73e-15	Electroencephalogram traits;
LGG	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg18245976	chr7:158708271	WDR60	-0.58	-7.66	-0.34	1.09e-13	Height;
LGG	cis	rs7394190	0.748	rs78790589	chr10:75539598	G/A	cg07699608	chr10:75541558	CHCHD1	0.55	7.39	0.32	6.75e-13	Incident atrial fibrillation;
LGG	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg14039246	chr1:53365446	ECHDC2	0.35	6.75	0.3	4.4e-11	Monocyte count;
LGG	cis	rs4132509	1.000	rs6659180	chr1:243995348	C/T	cg25706552	chr1:244017396	NA	0.54	8.79	0.38	2.95e-17	RR interval (heart rate);
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.93	-0.54	4.4e-37	Alzheimer's disease;
LGG	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg23188684	chr11:67383651	NA	-0.41	-6.78	-0.3	3.65e-11	Mean corpuscular volume;
LGG	trans	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg06521331	chr12:34319734	NA	0.44	7.83	0.34	3.25e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg17023122	chr1:144479586	NA	0.34	7.24	0.32	1.94e-12	Hip geometry;
LGG	cis	rs11574514	0.744	rs7200210	chr16:67981896	A/G	cg09738193	chr16:67926317	PSKH1	-0.75	-6.84	-0.3	2.53e-11	Crohn's disease;
LGG	cis	rs8067545	0.717	rs34401389	chr17:19989436	A/T	cg13482628	chr17:19912719	NA	0.62	12.41	0.5	1e-30	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3739821	0.841	rs943392	chr9:130725441	A/G	cg21181453	chr9:130700954	DPM2	-0.34	-7.76	-0.34	5.32e-14	Glaucoma (primary angle closure);
LGG	cis	rs2075371	0.965	rs2544216	chr7:133987902	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	cis	rs1797081	1.000	rs780634	chr10:16864327	T/G	cg14835575	chr10:16859367	RSU1	0.36	7.08	0.31	5.54e-12	Platelet distribution width;
LGG	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	10.59	0.44	1.26e-23	Menopause (age at onset);
LGG	cis	rs9300255	0.770	rs28683528	chr12:123845351	C/T	cg00376283	chr12:123451042	ABCB9	-0.56	-8.63	-0.37	9.59e-17	Neutrophil percentage of white cells;
LGG	cis	rs1707322	0.691	rs11211174	chr1:46220816	C/G	cg03146154	chr1:46216737	IPP	0.57	11.05	0.46	2.31e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs77372450	0.636	rs6877434	chr5:157028947	A/C	cg25387487	chr5:157003181	ADAM19	0.55	7.02	0.31	8.01e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs9463078	0.739	rs1293457	chr6:44758098	T/C	cg25276700	chr6:44698697	NA	0.43	9.12	0.39	2.23e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2734839	0.964	rs7122246	chr11:113304457	G/A	cg14159747	chr11:113255604	NA	0.27	7.2	0.32	2.47e-12	Information processing speed;
LGG	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg03060546	chr3:49711283	APEH	0.74	13.19	0.52	6.13e-34	Resting heart rate;
LGG	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg24375607	chr4:120327624	NA	0.59	9.87	0.42	5.35e-21	Corneal astigmatism;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg02725872	chr8:58115012	NA	-0.94	-12.31	-0.5	2.54e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9393813	0.605	rs12529458	chr6:27361681	A/G	cg18711553	chr6:27366782	ZNF391	-0.49	-9.63	-0.41	3.85e-20	Bipolar disorder;
LGG	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg18135555	chr8:22132992	PIWIL2	-0.41	-10.96	-0.45	5.22e-25	Hypertriglyceridemia;
LGG	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg03653399	chr8:142233436	SLC45A4	0.44	8.72	0.38	5.04e-17	Immature fraction of reticulocytes;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18110333	chr6:292329	DUSP22	-0.69	-11.83	-0.48	2.2e-28	Menopause (age at onset);
LGG	cis	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-8.8	-0.38	2.71e-17	Morning vs. evening chronotype;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	8.08	0.35	5.62e-15	Renal function-related traits (BUN);
LGG	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg05555928	chr11:63887634	MACROD1	0.57	8.53	0.37	2.17e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg21095983	chr6:86352623	SYNCRIP	0.58	10.93	0.45	6.49e-25	Smooth-surface caries;
LGG	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.36	0.81	9.16e-108	Chronic sinus infection;
LGG	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg27398817	chr8:82754497	SNX16	-0.73	-11.31	-0.47	2.28e-26	Diastolic blood pressure;
LGG	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg01528321	chr10:82214614	TSPAN14	0.66	11.84	0.48	1.97e-28	Post bronchodilator FEV1;
LGG	trans	rs73198271	0.740	rs3827807	chr8:8679385	G/A	cg16141378	chr3:129829833	LOC729375	0.34	6.73	0.3	5e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6088590	0.901	rs6087631	chr20:33403509	T/C	cg06115741	chr20:33292138	TP53INP2	0.59	9.82	0.42	8.14e-21	Coronary artery disease;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.43	-0.36	4.52e-16	Lung cancer;
LGG	cis	rs2267681	0.508	rs10277705	chr7:139519293	C/G	cg14116596	chr7:139528673	TBXAS1	0.32	6.99	0.31	9.65e-12	Cervical cancer;
LGG	cis	rs875971	0.545	rs6460298	chr7:65907770	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.39	0.43	7.47e-23	Aortic root size;
LGG	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg19183879	chr15:85880815	NA	-0.49	-9.22	-0.39	1.07e-18	Coronary artery disease;
LGG	cis	rs6032067	0.683	rs13042431	chr20:43781253	A/G	cg10761708	chr20:43804764	PI3	0.59	9.04	0.39	4.19e-18	Blood protein levels;
LGG	cis	rs12887734	0.546	rs12886637	chr14:104222892	A/G	cg24130564	chr14:104152367	KLC1	0.37	6.74	0.3	4.84e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1784581	0.802	rs2156747	chr6:162430000	C/G	cg17173639	chr6:162384350	PARK2	-0.76	-18.06	-0.64	1.44e-55	Itch intensity from mosquito bite;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.07	-0.42	1.06e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.615	rs4909209	chr7:158194329	C/T	cg12438819	chr7:158236134	PTPRN2	0.32	8.11	0.35	4.73e-15	Obesity-related traits;
LGG	cis	rs34467563	0.656	rs991618	chr8:97404034	A/G	cg22138393	chr8:97340270	PTDSS1	0.28	6.78	0.3	3.78e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg03929089	chr4:120376271	NA	-0.95	-20.14	-0.68	3.12e-65	Coronary artery disease;
LGG	cis	rs2285947	0.967	rs2285948	chr7:21584229	T/C	cg23045935	chr7:21583304	DNAH11	0.43	9.33	0.4	4.36e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg25703541	chr22:24373054	LOC391322	-0.9	-18.43	-0.65	2.79e-57	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6693295	0.877	rs10924523	chr1:246319900	G/T	cg11798871	chr1:246315928	SMYD3	-0.46	-6.79	-0.3	3.36e-11	Migraine - clinic-based;Migraine with aura;
LGG	trans	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg12751644	chr20:60527061	NA	-0.31	-7.17	-0.32	2.95e-12	Body mass index;
LGG	cis	rs75920871	0.702	rs7946869	chr11:116963312	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-7.62	-0.33	1.44e-13	Subjective well-being;
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.59	0.63	2.06e-53	Alzheimer's disease;
LGG	cis	rs10267417	0.603	rs10263094	chr7:19872801	C/T	cg05791153	chr7:19748676	TWISTNB	0.64	8.16	0.35	3.09e-15	Night sleep phenotypes;
LGG	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg20818283	chr2:191399100	TMEM194B	0.31	7.44	0.33	4.81e-13	Pulse pressure;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.93	-0.38	1.01e-17	Lymphocyte counts;
LGG	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg20573242	chr4:122745356	CCNA2	0.53	9.6	0.41	5.18e-20	Type 2 diabetes;
LGG	cis	rs73081554	0.505	rs2063644	chr3:58330942	A/T	cg24175188	chr3:58374923	PXK	0.53	8.48	0.37	3.01e-16	Rheumatoid arthritis;
LGG	cis	rs7267979	0.932	rs431579	chr20:25470056	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.1	0.43	8.06e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg00531865	chr16:30841666	NA	0.54	11.19	0.46	6.83e-26	Dementia with Lewy bodies;
LGG	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg11502198	chr6:26597334	ABT1	-0.87	-7.63	-0.33	1.38e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7586879	0.616	rs12713422	chr2:25134497	A/C	cg04586622	chr2:25135609	ADCY3	0.47	12.88	0.51	1.12e-32	Body mass index;
LGG	cis	rs2735413	0.563	rs56214776	chr16:78045789	G/A	cg04733911	chr16:78082701	NA	0.56	7.36	0.32	8.29e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06634786	chr22:41940651	POLR3H	-0.78	-12.37	-0.5	1.49e-30	Vitiligo;
LGG	trans	rs853679	0.607	rs72846794	chr6:28137499	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.39	-7.97	-0.35	1.27e-14	Schizophrenia;
LGG	cis	rs9557207	0.756	rs4630393	chr13:100016972	T/C	cg24509225	chr13:100037070	UBAC2	0.63	11.61	0.47	1.65e-27	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs283228	0.602	rs2787574	chr6:101844119	C/T	cg27451362	chr6:101846650	GRIK2	0.59	9.75	0.41	1.54e-20	Coenzyme Q10 levels;
LGG	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg25801113	chr15:45476975	SHF	-0.87	-18.72	-0.66	1.24e-58	Uric acid levels;
LGG	cis	rs12482904	0.708	rs74278191	chr21:43820888	G/T	cg23042151	chr21:43824109	UBASH3A	-0.55	-10.55	-0.44	1.9e-23	Vitiligo;
LGG	cis	rs4704187	0.687	rs10942729	chr5:74364300	C/T	cg03227963	chr5:74354835	NA	0.32	6.8	0.3	3.2e-11	Response to amphetamines;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.6	-0.33	1.72e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg22408430	chr11:63883266	MACROD1;FLRT1	-0.4	-6.95	-0.31	1.21e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.47	-0.33	3.93e-13	Personality dimensions;
LGG	cis	rs7769051	1.000	rs9493444	chr6:133125320	C/G	cg22852734	chr6:133119734	C6orf192	1.17	16.03	0.6	2.5e-46	Type 2 diabetes nephropathy;
LGG	cis	rs981844	0.775	rs17371336	chr4:154749525	A/G	cg14289246	chr4:154710475	SFRP2	0.67	10.92	0.45	7.11e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg06238570	chr21:40685208	BRWD1	-0.53	-8.65	-0.37	8.51e-17	Cognitive function;
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg02002194	chr4:3960332	NA	0.42	7.92	0.35	1.84e-14	Triglycerides;
LGG	cis	rs2167364	0.623	rs10229387	chr7:50621473	G/A	cg00647317	chr7:50633725	DDC	0.3	6.67	0.3	7.42e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	5.14e-20	Hypertriglyceridemia;
LGG	trans	rs12579753	0.871	rs10862364	chr12:82201280	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.99	0.57	1.04e-41	Cannabis dependence symptom count;
LGG	cis	rs7666738	0.830	rs1834647	chr4:98882915	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.8	0.34	4.2e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs990171	1.000	rs4851584	chr2:103060313	A/G	cg05295703	chr2:102895712	NA	-0.53	-9.36	-0.4	3.6e-19	Lymphocyte counts;
LGG	cis	rs9308433	0.529	rs4655244	chr1:214497580	A/G	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.13e-14	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg00933542	chr6:150070202	PCMT1	0.37	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs11711311	0.955	rs9813630	chr3:113377361	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.59	0.53	1.25e-35	IgG glycosylation;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg01765077	chr12:122356316	WDR66	0.28	7.73	0.34	6.67e-14	Mean corpuscular volume;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg19147804	chr7:1989927	MAD1L1	-0.63	-12.61	-0.51	1.58e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9633740	1.000	rs7900536	chr10:82253701	G/T	cg01528321	chr10:82214614	TSPAN14	1.03	16.26	0.6	2.26e-47	Post bronchodilator FEV1;
LGG	cis	rs9303401	1.000	rs1390006	chr17:56890663	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.61	-10.41	-0.44	5.93e-23	Cognitive test performance;
LGG	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg07395648	chr5:131743802	NA	-0.56	-13.31	-0.53	1.94e-34	Blood metabolite levels;
LGG	cis	rs13190036	0.901	rs55741473	chr5:176574219	A/G	cg06733329	chr5:176740039	MXD3	0.49	6.81	0.3	3e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs6977955	1.000	rs2893312	chr7:28170403	C/T	cg23620719	chr7:28220237	JAZF1	-0.44	-6.94	-0.31	1.32e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	cis	rs7975161	0.565	rs4545635	chr12:104636844	A/C	cg25273343	chr12:104657179	TXNRD1	-0.72	-7.24	-0.32	1.88e-12	Toenail selenium levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04833430	chr12:56101579	ITGA7	-0.46	-7.26	-0.32	1.63e-12	Pancreatic cancer;
LGG	cis	rs13065560	0.659	rs6599266	chr3:38926912	C/G	cg01426195	chr3:39028469	NA	-0.46	-9.35	-0.4	3.65e-19	Interleukin-18 levels;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.94	0.38	9.33e-18	Lung cancer;
LGG	cis	rs1707322	1.000	rs1588663	chr1:46548825	G/A	cg03146154	chr1:46216737	IPP	-0.53	-9.66	-0.41	3.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg01673284	chr16:4527211	HMOX2	0.33	6.83	0.3	2.62e-11	Schizophrenia;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg11878867	chr6:150167359	LRP11	-0.54	-11.1	-0.46	1.5e-25	Lung cancer;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.65	0.48	1.08e-27	Obesity-related traits;
LGG	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.75	0.45	3.14e-24	Body mass index;
LGG	cis	rs7552404	1.000	rs7552404	chr1:76135946	A/G	cg03433033	chr1:76189801	ACADM	0.8	13.93	0.54	4.45e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12230513	0.732	rs60450959	chr12:55861373	A/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.99	-0.45	3.97e-25	Contrast sensitivity;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.79	-0.3	3.53e-11	Longevity;Endometriosis;
LGG	cis	rs11112613	0.713	rs11112586	chr12:105939816	C/T	cg03607813	chr12:105948248	NA	0.56	9.46	0.4	1.5700000000000001e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs11785693	0.862	rs6994150	chr8:4996630	T/G	cg26367366	chr8:4980734	NA	1.02	15.72	0.59	6.32e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs1595825	0.945	rs7426250	chr2:198837358	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.69	-0.3	6.46e-11	Ulcerative colitis;
LGG	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg08468577	chr11:2973342	NAP1L4	-0.39	-8.02	-0.35	8.73e-15	Calcium levels;
LGG	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.28	-0.32	1.41e-12	Neuroticism;
LGG	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg11644478	chr21:40555479	PSMG1	0.87	16.16	0.6	6.59e-47	Cognitive function;
LGG	cis	rs12618769	0.652	rs3820941	chr2:99233781	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.74	0.34	6.36e-14	Bipolar disorder;
LGG	cis	rs593982	0.920	rs72922791	chr11:65567395	G/A	cg08755490	chr11:65554678	OVOL1	-0.7	-9.85	-0.42	6.69e-21	Atopic dermatitis;
LGG	cis	rs77106637	0.722	rs11605691	chr11:72419514	C/T	cg03713592	chr11:72463424	ARAP1	0.44	7.45	0.33	4.61e-13	Type 2 diabetes;
LGG	cis	rs9324022	0.722	rs72698707	chr14:101156585	G/A	cg18089426	chr14:101175970	NA	0.65	7.16	0.32	3.13e-12	Plateletcrit;
LGG	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg04450456	chr4:17643702	FAM184B	0.34	7.59	0.33	1.8e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg11965913	chr1:205819406	PM20D1	0.49	7.88	0.34	2.34e-14	Prostate-specific antigen levels;
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg08888203	chr3:10149979	C3orf24	0.56	7.95	0.35	1.44e-14	Alzheimer's disease;
LGG	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.27	-0.4	7.12e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs9788682	0.747	rs12910984	chr15:78891627	G/A	cg06917634	chr15:78832804	PSMA4	0.49	7.64	0.33	1.28e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg19901956	chr11:77921274	USP35	-0.41	-6.66	-0.3	7.95e-11	Testicular germ cell tumor;
LGG	cis	rs483180	0.512	rs1163251	chr1:120209755	T/C	cg19096424	chr1:120255104	PHGDH	-0.6	-10.8	-0.45	2.05e-24	Macular telangiectasia type 2;
LGG	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg25922239	chr6:33757077	LEMD2	0.42	7.24	0.32	1.87e-12	Crohn's disease;
LGG	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs9300255	0.543	rs655293	chr12:123528405	G/A	cg00376283	chr12:123451042	ABCB9	0.65	10.32	0.43	1.26e-22	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.77	0.41	1.3e-20	Prudent dietary pattern;
LGG	cis	rs7241530	0.662	rs35857611	chr18:75901744	C/G	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs1697139	0.935	rs1623654	chr5:66512819	A/T	cg11553311	chr5:66541588	NA	0.42	9.3	0.4	5.76e-19	Breast cancer;
LGG	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.88	-0.3	1.9e-11	Mood instability;
LGG	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.47	0.5	5.54e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8044868	0.530	rs9932951	chr16:72075341	A/G	cg23815491	chr16:72088622	HP	0.37	7.92	0.35	1.73e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.34	0.47	1.85e-26	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.42	6.89	0.3	1.83e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3820068	0.705	rs2145396	chr1:15875184	A/G	cg05660106	chr1:15850417	CASP9	1.17	25.42	0.76	7.38e-90	Systolic blood pressure;
LGG	cis	rs8179	0.700	rs42043	chr7:92247333	A/G	cg15732164	chr7:92237376	CDK6	-0.55	-10.11	-0.43	7.9e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.69e-22	DNA methylation (variation);
LGG	cis	rs4740619	0.711	rs4590533	chr9:15989766	C/G	cg14451791	chr9:16040625	NA	-0.41	-10.61	-0.44	1.1e-23	Body mass index;
LGG	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07080220	chr10:102295463	HIF1AN	0.7	12.09	0.49	1.88e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2820315	1.000	rs903678	chr1:201809918	G/A	cg10061532	chr1:201886748	LMOD1	0.33	6.85	0.3	2.42e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-12.93	-0.52	7.05e-33	Personality dimensions;
LGG	cis	rs2270875	0.778	rs16904547	chr8:132924684	C/T	cg24184792	chr8:132919238	EFR3A	-0.43	-6.83	-0.3	2.71e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.61e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7408868	1.000	rs10418305	chr19:15278808	C/G	cg14696996	chr19:15285081	NOTCH3	1.1	13.17	0.52	7.11e-34	Pulse pressure;
LGG	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg20913747	chr6:44695427	NA	-0.68	-11.47	-0.47	5.7e-27	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07685180	chr8:600429	NA	-0.78	-7.41	-0.33	5.92e-13	IgG glycosylation;
LGG	cis	rs896854	0.540	rs2011567	chr8:95971920	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.87	-0.38	1.58e-17	Type 2 diabetes;
LGG	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.7	0.61	2.4e-49	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.09e-13	Lung cancer;
LGG	cis	rs4740619	0.590	rs10756735	chr9:16027606	T/G	cg14451791	chr9:16040625	NA	-0.43	-11.38	-0.47	1.29e-26	Body mass index;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-8.94	-0.38	9.15e-18	Menopause (age at onset);
LGG	cis	rs60180747	0.909	rs76549445	chr15:66826898	T/C	cg07575407	chr15:66541975	MEGF11	0.37	6.86	0.3	2.24e-11	Testicular germ cell tumor;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg07120314	chr15:79043507	NA	0.64	12.97	0.52	4.95e-33	Coronary artery disease or large artery stroke;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.63	10.56	0.44	1.64e-23	Longevity;
LGG	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg07835443	chr16:89734986	C16orf55	0.4	7.06	0.31	6.01e-12	Hemoglobin concentration;
LGG	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg12438819	chr7:158236134	PTPRN2	0.34	8.68	0.37	6.91e-17	Obesity-related traits;
LGG	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg27661571	chr11:113659931	NA	-0.71	-7.8	-0.34	4.01e-14	Height;
LGG	cis	rs6748734	0.548	rs4441463	chr2:241872597	A/G	cg26818257	chr2:241905806	NA	0.5	10.84	0.45	1.46e-24	Urinary metabolites;
LGG	cis	rs55788414	0.932	rs9929253	chr16:81181641	C/T	cg06400318	chr16:81190750	PKD1L2	-0.81	-10.26	-0.43	2.1e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs9650657	0.707	rs10098699	chr8:10676756	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.46	-0.33	4.43e-13	Neuroticism;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.53	-9.57	-0.41	6.43e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4417704	0.551	rs12620108	chr2:241874076	G/A	cg14055004	chr2:241860995	NA	-0.28	-7.41	-0.33	6.06e-13	Joint mobility (Beighton score);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg07920855	chr1:185286635	IVNS1ABP	0.35	6.72	0.3	5.47e-11	Corneal astigmatism;
LGG	cis	rs10857712	0.754	rs7921041	chr10:135229239	G/C	cg00491522	chr10:135256596	NA	0.48	7.71	0.34	7.77e-14	Systemic lupus erythematosus;
LGG	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.56	-0.69	3.2e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2013441	0.896	rs1812934	chr17:20030960	A/T	cg13482628	chr17:19912719	NA	-0.51	-9.31	-0.4	5.02e-19	Obesity-related traits;
LGG	cis	rs1976403	0.659	rs10799700	chr1:21820968	G/C	cg02390115	chr1:21767211	NBPF3	0.58	11.16	0.46	9.15e-26	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg12432903	chr7:1882776	MAD1L1	-0.46	-7.24	-0.32	1.9e-12	Bipolar disorder;
LGG	cis	rs28475163	1.000	rs28475163	chr11:327143	G/A	cg03071500	chr11:325964	NA	-0.42	-7.02	-0.31	7.91e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.13	-0.39	2.19e-18	Lewy body disease;
LGG	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg15596359	chr8:11213517	TDH	-0.4	-8.23	-0.36	1.85e-15	Retinal vascular caliber;
LGG	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.51	-0.47	3.92e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.850	rs28476182	chr15:44139643	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.75	0.38	4.14e-17	Lung cancer in ever smokers;
LGG	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.46	-0.37	3.65e-16	Urinary tract infection frequency;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08645402	chr16:4508243	NA	-0.52	-9.88	-0.42	5.31e-21	Schizophrenia;
LGG	trans	rs3206736	0.548	rs329234	chr7:35055880	A/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.18	0.32	2.85e-12	Diastolic blood pressure;
LGG	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg00666640	chr1:248458726	OR2T12	-0.54	-8.66	-0.37	8.02e-17	Common traits (Other);
LGG	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg16850897	chr7:100343110	ZAN	-0.57	-8.18	-0.36	2.81e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7666738	0.716	rs114187620	chr4:98819534	T/A	cg05340658	chr4:99064831	C4orf37	0.48	7.81	0.34	3.83e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9399135	0.933	rs28384512	chr6:135376232	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.45e-19	Red blood cell count;
LGG	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg26384229	chr12:38710491	ALG10B	-0.98	-22.16	-0.72	1.06e-74	Bladder cancer;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg00684032	chr4:1343700	KIAA1530	-0.5	-9.77	-0.41	1.25e-20	Obesity-related traits;
LGG	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-8.43	-0.36	4.49e-16	Thyroid stimulating hormone;
LGG	cis	rs11096990	0.819	rs4974991	chr4:39194767	T/A	cg24403649	chr4:39172243	NA	-0.48	-7.89	-0.34	2.23e-14	Cognitive function;
LGG	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	17.42	0.63	1.22e-52	Smoking behavior;
LGG	cis	rs55665837	0.961	rs12576926	chr11:14480292	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.81	-0.38	2.44e-17	Vitamin D levels;
LGG	cis	rs2777491	1.000	rs7177641	chr15:41743426	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.44	-0.67	5.33e-62	Ulcerative colitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02470625	chr7:39453784	POU6F2	0.42	6.73	0.3	5.17e-11	Cognitive performance;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs4824093	0.610	rs12106611	chr22:50242686	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.8	-6.95	-0.31	1.25e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs10276381	0.901	rs73300638	chr7:28187344	A/C	cg23620719	chr7:28220237	JAZF1	0.81	9.67	0.41	2.96e-20	Crohn's disease;
LGG	cis	rs7660520	0.524	rs12643521	chr4:183728242	C/G	cg09197432	chr4:183729176	NA	0.58	7.6	0.33	1.62e-13	Pediatric autoimmune diseases;
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg15394860	chr11:2017084	H19	0.62	13.28	0.53	2.6e-34	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg26384229	chr12:38710491	ALG10B	-0.93	-20.0	-0.68	1.33e-64	Morning vs. evening chronotype;
LGG	cis	rs6500637	0.860	rs11644917	chr16:4940387	G/A	cg08329684	chr16:4932620	PPL	-0.53	-11.28	-0.46	3.13e-26	Cancer;
LGG	trans	rs61931739	0.620	rs708141	chr12:33719664	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg00204512	chr16:28754710	NA	0.25	7.15	0.32	3.45e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9359856	0.510	rs4053618	chr6:90459454	G/A	cg13799429	chr6:90582589	CASP8AP2	0.86	13.3	0.53	2.12e-34	Bipolar disorder;
LGG	cis	rs6960043	0.818	rs10267273	chr7:15053589	A/G	cg19272540	chr7:15055459	NA	-0.34	-7.54	-0.33	2.49e-13	Type 2 diabetes;
LGG	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg03929089	chr4:120376271	NA	0.84	8.71	0.38	5.6e-17	Myopia (pathological);
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg18402987	chr7:1209562	NA	0.65	9.01	0.39	5.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.5	7.27	0.32	1.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2204008	0.567	rs2703685	chr12:38081423	G/C	cg13010199	chr12:38710504	ALG10B	0.56	10.81	0.45	2.01e-24	Bladder cancer;
LGG	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg15704280	chr7:45808275	SEPT13	0.89	12.56	0.5	2.48e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg06026331	chr20:60912101	LAMA5	0.36	6.78	0.3	3.76e-11	Colorectal cancer;
LGG	cis	rs2120243	0.539	rs2124497	chr3:157120259	T/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg02018176	chr4:1364513	KIAA1530	0.39	8.62	0.37	1.09e-16	Obesity-related traits;
LGG	cis	rs7683537	0.692	rs12509936	chr4:185662203	G/A	cg04058563	chr4:185651563	MLF1IP	0.98	16.3	0.6	1.5e-47	Systemic lupus erythematosus;
LGG	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg08305652	chr11:111469057	NA	0.43	8.37	0.36	7.08e-16	Primary sclerosing cholangitis;
LGG	cis	rs4740619	0.904	rs7049101	chr9:15640042	T/A	cg14451791	chr9:16040625	NA	-0.39	-9.87	-0.42	5.45e-21	Body mass index;
LGG	cis	rs2652834	0.808	rs6494393	chr15:63426435	A/C	cg05507819	chr15:63340323	TPM1	0.5	7.06	0.31	6.23e-12	HDL cholesterol;
LGG	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg25208724	chr1:156163844	SLC25A44	1.12	20.09	0.68	5.08e-65	Testicular germ cell tumor;
LGG	cis	rs1712517	0.525	rs11191642	chr10:105055912	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.48e-15	Migraine;
LGG	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.93	-0.38	9.72e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.38	7.37	0.32	7.9e-13	Longevity;
LGG	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg07308232	chr7:1071921	C7orf50	0.61	11.67	0.48	9.48e-28	Longevity;Endometriosis;
LGG	cis	rs2439831	0.850	rs7169988	chr15:44060435	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.0	0.39	5.71e-18	Lung cancer in ever smokers;
LGG	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg19468946	chr17:37922297	IKZF3	-0.43	-7.75	-0.34	5.88e-14	Self-reported allergy;
LGG	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12582317	chr17:55822272	NA	0.69	20.11	0.68	4.27e-65	Schizophrenia;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	trans	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg16141378	chr3:129829833	LOC729375	0.38	8.43	0.36	4.41e-16	Morning vs. evening chronotype;
LGG	cis	rs11771526	0.901	rs10271047	chr7:32289660	A/C	cg27532318	chr7:32358331	NA	-0.63	-6.72	-0.3	5.35e-11	Body mass index;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.75	-0.34	5.96e-14	Life satisfaction;
LGG	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg03264133	chr6:25882463	NA	0.56	10.48	0.44	3.48e-23	Blood metabolite levels;
LGG	trans	rs7939886	0.920	rs11227670	chr11:56026737	A/C	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.89	0.48	1.26e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.56	0.33	2.11e-13	Neuroticism;
LGG	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg06917763	chr7:130033247	NA	0.34	7.42	0.33	5.76e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.82	0.48	2.31e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17539620	0.628	rs62432729	chr6:154830044	T/C	cg17771515	chr6:154831774	CNKSR3	0.67	8.65	0.37	8.72e-17	Lipoprotein (a) levels;
LGG	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-8.02	-0.35	8.76e-15	Calcium levels;
LGG	cis	rs13191362	0.872	rs35672319	chr6:163245464	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.75	0.34	5.96e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02547025	chr2:30454275	LBH	-0.4	-6.79	-0.3	3.45e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7666738	0.830	rs13101352	chr4:98957544	C/T	cg05340658	chr4:99064831	C4orf37	0.49	8.02	0.35	8.48e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4595586	0.525	rs6580891	chr12:39370127	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs7765175	0.698	rs3851197	chr6:113666000	C/T	cg26552650	chr6:113682475	NA	0.33	7.48	0.33	3.7e-13	Coronary artery calcification;
LGG	cis	rs7944584	0.632	rs7116451	chr11:47322327	G/A	cg20307385	chr11:47447363	PSMC3	0.63	12.38	0.5	1.37e-30	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6840360	0.615	rs3828546	chr4:152679816	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.18	-0.43	4.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg08400814	chr5:56204995	C5orf35	0.41	7.27	0.32	1.52e-12	Initial pursuit acceleration;
LGG	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg21775007	chr8:11205619	TDH	0.78	13.74	0.54	2.94e-36	Retinal vascular caliber;
LGG	trans	rs34421088	0.585	rs1390950	chr8:11595829	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.78	-0.3	3.74e-11	Neuroticism;
LGG	trans	rs7178375	1.000	rs1474381	chr15:31214991	T/C	cg04373760	chr16:53404718	NA	0.56	8.49	0.37	2.83e-16	Hypertriglyceridemia;
LGG	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg23335576	chr14:104009727	NA	0.42	7.12	0.31	4.27e-12	Reticulocyte count;
LGG	cis	rs7762018	0.607	rs79897010	chr6:170042874	C/G	cg19338460	chr6:170058176	WDR27	-0.88	-9.39	-0.4	2.73e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs861020	0.630	rs616544	chr1:210007368	T/C	cg23166289	chr1:210001082	C1orf107	0.32	6.72	0.3	5.29e-11	Orofacial clefts;
LGG	cis	rs9807841	0.858	rs10410775	chr19:10856273	T/C	cg17710535	chr19:10819994	QTRT1	0.46	7.42	0.33	5.7e-13	Inflammatory skin disease;
LGG	cis	rs10895140	0.718	rs11523959	chr11:101440682	T/C	cg23650423	chr11:101454676	TRPC6	0.43	6.69	0.3	6.5500000000000006e-11	Menarche (age at onset);
LGG	cis	rs73787773	0.867	rs17651424	chr5:111488600	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.21	-0.36	2.24e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07575867	chr3:58223146	ABHD6	-0.4	-7.15	-0.32	3.37e-12	Brain structure;
LGG	cis	rs2635047	0.601	rs2684842	chr18:44725289	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.45	-7.43	-0.33	5.11e-13	Educational attainment;
LGG	cis	rs7385804	0.761	rs507392	chr7:100319936	G/A	cg20848291	chr7:100343083	ZAN	0.44	7.12	0.31	4.09e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg04132851	chr1:85155548	SSX2IP	0.48	7.81	0.34	3.96e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.56	0.37	1.66e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.51	0.53	2.59e-35	Lung cancer;
LGG	cis	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.64	10.23	0.43	2.84e-22	Lymphocyte counts;Red cell distribution width;
LGG	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg13009111	chr11:71350975	NA	0.35	7.48	0.33	3.82e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2371030	1.000	rs1019392	chr2:211593082	A/C	cg18417063	chr2:211583084	NA	-0.64	-12.32	-0.5	2.23e-30	Non-small cell lung cancer;
LGG	cis	rs9790314	0.905	rs7633186	chr3:161003124	A/G	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs11264213	0.901	rs12031138	chr1:36407806	C/T	cg27506609	chr1:36549197	TEKT2	-0.73	-8.91	-0.38	1.18e-17	Schizophrenia;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.76	-0.3	4.25e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2742417	0.603	rs7631818	chr3:45775931	A/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.38	-0.4	3.04e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs62025270	0.688	rs17575870	chr15:86257157	C/T	cg25843651	chr15:86329602	KLHL25	0.57	8.74	0.38	4.45e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs17818399	0.888	rs2346419	chr2:46845069	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.53	-9.28	-0.4	6.38e-19	Height;
LGG	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.28	-0.69	6.73e-66	Diabetic kidney disease;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg04772025	chr11:68637568	NA	0.7	12.35	0.5	1.67e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg24189917	chr7:1970923	MAD1L1	-0.59	-8.66	-0.37	8.04e-17	Bipolar disorder;
LGG	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg03929089	chr4:120376271	NA	0.73	8.4	0.36	5.36e-16	Axial length;
LGG	cis	rs9486719	1.000	rs12190508	chr6:96898269	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs75229567	0.618	rs11495622	chr12:70161286	G/A	cg10114359	chr12:70132523	RAB3IP	1.21	10.48	0.44	3.23e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs25645	0.800	rs11078935	chr17:38192137	T/G	cg17467752	chr17:38218738	THRA	-0.7	-12.33	-0.5	2.12e-30	Myeloid white cell count;
LGG	cis	rs1497828	1.000	rs2810769	chr1:217563585	A/T	cg04411442	chr1:217543379	NA	-0.44	-7.55	-0.33	2.33e-13	Dialysis-related mortality;
LGG	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg07061783	chr6:25882402	NA	-0.42	-7.22	-0.32	2.21e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.652	rs9903269	chr17:37742383	A/T	cg00129232	chr17:37814104	STARD3	-0.66	-10.14	-0.43	5.92e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs929354	0.742	rs10251112	chr7:156963524	A/G	cg17757837	chr7:157058334	UBE3C	0.75	15.07	0.57	4.85e-42	Body mass index;
LGG	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg00343986	chr7:65444356	GUSB	0.39	6.68	0.3	7.02e-11	Aortic root size;
LGG	cis	rs36051895	0.632	rs10118930	chr9:5148278	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-15.23	-0.58	9.17e-43	Pediatric autoimmune diseases;
LGG	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.86	0.45	1.28e-24	Blood protein levels;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs1372356	0.725	rs2896074	chr14:88555444	G/C	cg18078958	chr14:88630771	NA	0.3	7.17	0.32	3.02e-12	Food antigen IgG levels;
LGG	cis	rs6669919	0.933	rs10863899	chr1:211666218	A/G	cg10512769	chr1:211675356	NA	-0.7	-15.49	-0.58	6.6e-44	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.2	0.32	2.43e-12	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg18402987	chr7:1209562	NA	0.67	9.28	0.4	6.54e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.67	-0.63	8.49e-54	Exhaled nitric oxide output;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg02574844	chr11:5959923	NA	-0.56	-8.83	-0.38	2.19e-17	DNA methylation (variation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13661211	chr19:1237453	C19orf26	0.49	7.24	0.32	1.9e-12	Gut microbiome composition (summer);
LGG	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg08499158	chr17:42289980	UBTF	-0.4	-7.24	-0.32	1.86e-12	Total body bone mineral density;
LGG	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.62	-0.33	1.43e-13	Neuroticism;
LGG	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.82	-0.38	2.41e-17	Retinal vascular caliber;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg11473876	chr11:109292803	C11orf87	0.62	12.21	0.49	6.48e-30	Schizophrenia;
LGG	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.56	-10.61	-0.44	1.1e-23	Aortic root size;
LGG	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.24	0.36	1.79e-15	Mood instability;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.76	-0.34	5.58e-14	Life satisfaction;
LGG	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs250677	0.652	rs36042	chr5:148439782	G/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.84	-0.3	2.58e-11	Breast cancer;
LGG	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg02002194	chr4:3960332	NA	-0.41	-7.59	-0.33	1.8e-13	Neuroticism;
LGG	cis	rs62045849	0.557	rs6500533	chr16:89190065	G/A	cg08015503	chr16:89190385	ACSF3	-0.65	-7.61	-0.33	1.5e-13	Red blood cell count;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.96	-0.57	1.51e-41	Platelet count;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7572644	0.699	rs12466717	chr2:28096792	A/G	cg27432699	chr2:27873401	GPN1	-0.46	-6.95	-0.31	1.28e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs867371	0.656	rs2665103	chr15:82432715	A/G	cg00614314	chr15:82944287	LOC80154	-0.47	-7.8	-0.34	4.01e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs62064224	0.902	rs35830939	chr17:30627564	A/C	cg25809561	chr17:30822961	MYO1D	0.36	8.41	0.36	5.03e-16	Schizophrenia;
LGG	cis	rs9715521	0.868	rs6856620	chr4:59820960	A/G	cg11281224	chr4:60001000	NA	-0.43	-7.15	-0.32	3.36e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6912958	0.678	rs9450733	chr6:88250081	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.59	-0.37	1.36e-16	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg12623918	chr2:306882	NA	0.52	9.75	0.41	1.5e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg22232500	chr2:134024266	NCKAP5	0.54	7.62	0.33	1.49e-13	Bipolar disorder;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg19635926	chr16:89946313	TCF25	0.7	6.72	0.3	5.39e-11	Skin colour saturation;
LGG	cis	rs3617	0.573	rs4687682	chr3:52916939	T/C	cg11645453	chr3:52864694	ITIH4	-0.47	-7.86	-0.34	2.73e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg13798912	chr7:905769	UNC84A	-0.58	-6.79	-0.3	3.43e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04496899	chr1:70820341	HHLA3;ANKRD13C	0.48	8.26	0.36	1.54e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10979	1.000	rs9390112	chr6:143896147	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.45	-0.5	6.9e-31	Hypospadias;
LGG	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg04287289	chr16:89883240	FANCA	0.78	16.14	0.6	8.43e-47	Vitiligo;
LGG	cis	rs9611565	0.568	rs5758441	chr22:42132888	C/A	cg06634786	chr22:41940651	POLR3H	0.66	10.76	0.45	3.03e-24	Vitiligo;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4750440	0.671	rs10796149	chr10:14025859	C/T	cg27542038	chr10:14027202	FRMD4A	-0.71	-13.92	-0.54	4.61e-37	Adiponectin levels;
LGG	trans	rs877282	1.000	rs7100358	chr10:773681	G/A	cg22713356	chr15:30763199	NA	0.55	8.58	0.37	1.42e-16	Uric acid levels;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.97e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.91	-0.31	1.64e-11	Monocyte count;
LGG	cis	rs7635838	0.751	rs9850938	chr3:11587471	T/G	cg00170343	chr3:11313890	ATG7	-0.41	-6.66	-0.3	7.73e-11	HDL cholesterol;
LGG	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg07936489	chr17:37558343	FBXL20	0.85	16.12	0.6	1e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs1003719	0.646	rs2835672	chr21:38581234	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.83	-0.57	5.4e-41	Eye color traits;
LGG	cis	rs11225247	0.764	rs79028911	chr11:102262449	T/C	cg06323957	chr11:102217781	BIRC2	0.81	7.06	0.31	6.23e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs6444746	0.800	rs59220700	chr3:193486984	G/A	cg22553634	chr3:193489233	NA	0.82	8.75	0.38	3.99e-17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	9.79	0.41	1.08e-20	Height;
LGG	cis	rs17092148	0.616	rs1122174	chr20:33110846	T/C	cg12302830	chr20:33297742	TP53INP2	-0.41	-6.81	-0.3	2.95e-11	Neuroticism;
LGG	cis	rs243505	0.737	rs243513	chr7:148429806	G/A	cg18940274	chr7:148469757	CUL1	0.38	7.14	0.31	3.64e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg22358067	chr17:16797159	NA	-0.51	-6.92	-0.31	1.47e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3796352	1.000	rs71301808	chr3:53085577	C/G	cg12962167	chr3:53033115	SFMBT1	0.75	7.51	0.33	3.05e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.83	0.42	7.44e-21	Schizophrenia;
LGG	cis	rs7143963	0.636	rs7146581	chr14:103301072	C/T	cg23020514	chr14:103360112	TRAF3	0.41	8.59	0.37	1.3e-16	Body mass index;
LGG	cis	rs4631830	0.720	rs12412140	chr10:51503977	T/C	cg16070123	chr10:51489643	NA	0.41	7.53	0.33	2.63e-13	Prostate-specific antigen levels;
LGG	cis	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg06609049	chr19:2785107	THOP1	0.61	9.65	0.41	3.46e-20	Total cholesterol levels;
LGG	cis	rs7927771	0.524	rs7118747	chr11:47889545	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-10.72	-0.45	4.17e-24	Subjective well-being;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg11039808	chr5:77591002	AP3B1	-0.44	-6.72	-0.3	5.48e-11	Coronary artery disease;
LGG	cis	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg21775007	chr8:11205619	TDH	-0.77	-13.41	-0.53	7.33e-35	Retinal vascular caliber;
LGG	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg22044901	chr15:68126292	NA	-0.44	-7.16	-0.32	3.12e-12	Restless legs syndrome;
LGG	cis	rs1008375	1.000	rs917665	chr4:17668504	A/C	cg16339924	chr4:17578868	LAP3	-0.57	-9.9	-0.42	4.43e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.48	7.2	0.32	2.44e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg10792982	chr14:105748885	BRF1	0.55	10.73	0.45	3.96e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9583531	0.891	rs61969076	chr13:111391568	C/T	cg24331049	chr13:111365604	ING1	-0.88	-12.24	-0.49	4.88e-30	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08269037	chr1:11751616	MAD2L2;C1orf187	0.52	7.91	0.35	1.86e-14	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.49	-0.5	4.55e-31	Alzheimer's disease;
LGG	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs6908034	0.556	rs113071446	chr6:19810835	A/C	cg02682789	chr6:19804855	NA	0.92	8.65	0.37	8.82e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2880765	0.566	rs12911430	chr15:86011264	A/T	cg13263323	chr15:86062960	AKAP13	-0.35	-6.98	-0.31	1.03e-11	Coronary artery disease;
LGG	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08704250	chr15:31115839	NA	-0.48	-8.64	-0.37	8.95e-17	Huntington's disease progression;
LGG	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg21775007	chr8:11205619	TDH	-0.52	-8.36	-0.36	7.6e-16	Triglycerides;
LGG	cis	rs2243480	1.000	rs778729	chr7:65824419	T/C	cg12463550	chr7:65579703	CRCP	0.78	8.51	0.37	2.43e-16	Diabetic kidney disease;
LGG	cis	rs2991971	0.967	rs2356551	chr1:46009318	C/T	cg24296786	chr1:45957014	TESK2	0.39	6.93	0.31	1.46e-11	High light scatter reticulocyte count;
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.39	-0.43	7.4e-23	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10620530	chr9:139922595	C9orf139;ABCA2	0.48	7.29	0.32	1.36e-12	Gut microbiome composition (summer);
LGG	cis	rs972578	0.818	rs9611954	chr22:43283989	C/T	cg01576275	chr22:43409880	NA	-0.23	-7.14	-0.31	3.68e-12	Mean platelet volume;
LGG	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg08885076	chr2:99613938	TSGA10	-0.55	-9.79	-0.41	1.06e-20	Chronic sinus infection;
LGG	cis	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg02972257	chr16:68554789	NA	-0.56	-8.28	-0.36	1.31e-15	Ulcerative colitis;
LGG	cis	rs6589964	0.818	rs7117802	chr11:122876125	A/G	cg27398637	chr11:122830231	C11orf63	0.43	7.83	0.34	3.37e-14	Menarche (age at onset);
LGG	cis	rs7553864	0.667	rs6576866	chr1:87601471	T/C	cg17420885	chr1:87600446	LOC339524	-0.36	-6.84	-0.3	2.48e-11	Smoking behavior;
LGG	cis	rs11785400	0.793	rs4336593	chr8:143739647	A/C	cg24634471	chr8:143751801	JRK	-0.49	-7.54	-0.33	2.47e-13	Schizophrenia;
LGG	cis	rs17401966	0.838	rs1013952	chr1:10319247	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-10.57	-0.44	1.49e-23	Hepatocellular carcinoma;
LGG	cis	rs2072732	0.904	rs56069604	chr1:2971452	T/C	cg08733933	chr1:2954429	NA	-0.46	-8.49	-0.37	2.74e-16	Plateletcrit;
LGG	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg15268244	chr15:77196840	NA	0.35	7.7	0.34	8.55e-14	Blood metabolite levels;
LGG	trans	rs9354308	0.738	rs1353876	chr6:66569534	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs8060686	0.641	rs12445533	chr16:68082527	A/G	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.17e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6121246	0.954	rs6060978	chr20:30416893	G/A	cg04935436	chr20:30431758	NA	0.42	7.19	0.32	2.63e-12	Mean corpuscular hemoglobin;
LGG	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs6445975	0.666	rs13077234	chr3:58436705	G/A	cg24175188	chr3:58374923	PXK	-0.55	-8.7	-0.37	5.75e-17	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg04267008	chr7:1944627	MAD1L1	-0.75	-13.57	-0.53	1.48e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.73	-0.3	5.07e-11	Mean platelet volume;
LGG	cis	rs17286411	0.750	rs4788561	chr16:71878255	G/A	cg06353428	chr16:71660113	MARVELD3	0.42	7.42	0.33	5.58e-13	Blood protein levels;
LGG	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg08847533	chr14:75593920	NEK9	-0.52	-9.66	-0.41	3.16e-20	Height;
LGG	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.63e-14	Cystic fibrosis severity;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.21	-0.36	2.17e-15	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg15971980	chr6:150254442	NA	0.44	8.13	0.35	3.84e-15	Lung cancer;
LGG	cis	rs9398803	0.706	rs9388502	chr6:126909389	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.92e-19	Male-pattern baldness;
LGG	cis	rs7584330	0.868	rs13386290	chr2:238393136	G/C	cg16989719	chr2:238392110	NA	-0.38	-8.06	-0.35	6.72e-15	Prostate cancer;
LGG	cis	rs7188861	0.768	rs441349	chr16:11371759	C/T	cg01510278	chr16:11456238	NA	0.3	7.33	0.32	1.03e-12	HDL cholesterol;
LGG	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg06108461	chr20:60628389	TAF4	-0.84	-13.92	-0.54	4.63e-37	Body mass index;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.82	-0.59	2.34e-45	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.61	-0.41	4.58e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg26578617	chr4:90757533	SNCA	0.37	7.19	0.32	2.67e-12	Dementia with Lewy bodies;
LGG	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg17145862	chr1:211918768	LPGAT1	-0.87	-19.96	-0.68	2.03e-64	Leprosy;
LGG	cis	rs12476592	0.571	rs262510	chr2:63886712	A/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs8067287	0.696	rs62065422	chr17:16828570	G/A	cg26910001	chr17:16838321	NA	-0.47	-8.76	-0.38	3.79e-17	Diabetic kidney disease;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.62	0.37	1.06e-16	Obesity-related traits;
LGG	cis	rs55665837	0.523	rs10832301	chr11:14788964	G/A	cg18937875	chr11:14930189	NA	-0.47	-7.69	-0.34	9e-14	Vitamin D levels;
LGG	trans	rs6787172	0.622	rs7632059	chr3:158133307	T/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.45	-0.33	4.72e-13	Subjective well-being;
LGG	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12654349	chr5:56205094	C5orf35	-0.82	-12.44	-0.5	7.41e-31	Initial pursuit acceleration;
LGG	cis	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.8	-0.34	4.2e-14	Blood trace element (Cu levels);
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.13e-12	Bipolar disorder;
LGG	cis	rs2916247	0.954	rs2920940	chr8:93180965	T/C	cg10183463	chr8:93005414	RUNX1T1	0.35	7.05	0.31	6.56e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.46e-18	Educational attainment;
LGG	cis	rs911555	0.655	rs10141157	chr14:104018105	T/C	cg24130564	chr14:104152367	KLC1	-0.48	-9.6	-0.41	5.16e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg10253484	chr15:75165896	SCAMP2	-0.4	-6.72	-0.3	5.39e-11	Breast cancer;
LGG	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.51	-0.33	2.99e-13	Mean corpuscular volume;
LGG	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.59	-0.51	1.75e-31	Chronic sinus infection;
LGG	cis	rs7945705	0.791	rs7944560	chr11:8817276	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.34	6.64	0.3	8.56e-11	Hemoglobin concentration;
LGG	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg27476859	chr7:2772710	GNA12	0.49	9.12	0.39	2.29e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.76	-0.3	4.1e-11	Bipolar disorder;
LGG	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg26513180	chr16:89883248	FANCA	0.64	11.94	0.49	7.87e-29	Vitiligo;
LGG	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.74	-13.31	-0.53	1.9e-34	Chronic sinus infection;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg07022442	chr13:21864356	NA	-0.39	-6.84	-0.3	2.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg21132104	chr15:45694354	SPATA5L1	0.72	10.58	0.44	1.41e-23	Homoarginine levels;
LGG	cis	rs9815354	0.761	rs794896	chr3:42031902	C/T	cg03022575	chr3:42003672	ULK4	-0.6	-7.41	-0.33	5.95e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23924007	chr4:140099401	NA	0.54	9.24	0.39	8.98e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg16512390	chr1:228756714	NA	0.48	6.87	0.3	2.06e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	20.33	0.69	4.07e-66	Platelet count;
LGG	cis	rs5769707	0.967	rs763126	chr22:49988574	G/T	cg20744362	chr22:50050164	C22orf34	-0.37	-7.17	-0.32	2.95e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg02153584	chr22:29168773	CCDC117	0.6	7.37	0.32	7.94e-13	Hematocrit;Hemoglobin concentration;
LGG	cis	rs2075371	0.897	rs12667905	chr7:134000812	A/C	cg20476274	chr7:133979776	SLC35B4	0.75	14.17	0.55	3.92e-38	Mean platelet volume;
LGG	cis	rs9399137	0.507	rs4896118	chr6:135276065	A/G	cg24558204	chr6:135376177	HBS1L	-0.58	-9.5	-0.4	1.17e-19	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg00717180	chr2:96193071	NA	-0.4	-7.0	-0.31	8.94e-12	HDL cholesterol;
LGG	cis	rs6800768	0.663	rs7428009	chr3:24094151	A/C	cg10674438	chr3:24145617	LOC152024	-0.49	-8.77	-0.38	3.44e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.61e-22	Height;
LGG	cis	rs3206736	0.548	rs328901	chr7:35020451	C/T	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.19e-19	Diastolic blood pressure;
LGG	cis	rs12360000	0.864	rs9919410	chr10:1902486	A/G	cg26364871	chr10:1889757	NA	0.71	14.03	0.55	1.69e-37	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs4820318	1	rs4820318	chr22:38570313	G/A	cg03162506	chr22:38580953	NA	0.41	10.51	0.44	2.51e-23	Breast cancer;
LGG	cis	rs7264396	0.635	rs2064724	chr20:34522520	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.25	0.32	1.72e-12	Total cholesterol levels;
LGG	cis	rs7149337	0.869	rs7159770	chr14:51691835	G/A	cg23942311	chr14:51606299	NA	0.32	7.16	0.32	3.2e-12	Cancer;
LGG	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.76	0.51	3.7e-32	Vitiligo;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.27	0.55	1.47e-38	Platelet count;
LGG	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg03733263	chr8:22462867	KIAA1967	1.12	32.73	0.84	1.6e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6665290	0.935	rs6693535	chr1:227197685	G/A	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	8.91	0.38	1.18e-17	Retinal vascular caliber;
LGG	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.39	-0.32	7.12e-13	Testicular germ cell tumor;
LGG	cis	rs644799	0.710	rs1852535	chr11:95501241	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.37	0.58	2.24e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.11	-0.35	4.47e-15	Breast cancer;
LGG	cis	rs216026	0.689	rs4765701	chr12:2770891	C/T	cg19945202	chr12:2788847	CACNA1C	0.6	8.92	0.38	1.09e-17	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs10484885	0.878	rs17506550	chr6:90508896	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.82	-10.55	-0.44	1.84e-23	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs854765	0.647	rs4349203	chr17:17989425	T/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	12.6	0.51	1.65e-31	Total body bone mineral density;
LGG	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg13147721	chr7:65941812	NA	0.75	9.18	0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg22168489	chr12:122356033	WDR66	0.42	9.75	0.41	1.5e-20	Mean corpuscular volume;
LGG	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg06417478	chr19:12876846	HOOK2	0.41	6.92	0.31	1.51e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs7089973	0.872	rs11818115	chr10:116634891	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07323055	chr20:3140559	FASTKD5;UBOX5	0.42	6.73	0.3	5.02e-11	Cognitive performance;
LGG	cis	rs1595825	0.891	rs7585709	chr2:198883682	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.56e-11	Ulcerative colitis;
LGG	cis	rs999943	0.810	rs62407648	chr6:33622436	C/G	cg14003231	chr6:33640908	ITPR3	0.65	14.93	0.57	1.89e-41	Obesity (extreme);
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg03395511	chr6:291903	DUSP22	-0.48	-8.26	-0.36	1.49e-15	Menopause (age at onset);
LGG	cis	rs3733585	0.699	rs1122142	chr4:9947548	G/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.05e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9815354	0.812	rs794897	chr3:42031865	T/C	cg03022575	chr3:42003672	ULK4	-0.6	-7.41	-0.33	5.95e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.93	-0.31	1.45e-11	Joint mobility (Beighton score);
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg22105103	chr4:187893119	NA	0.58	11.13	0.46	1.19e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg22509179	chr1:25234806	RUNX3	-0.64	-13.99	-0.55	2.48e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs2247341	0.965	rs11730727	chr4:1738313	T/C	cg08629884	chr4:1719983	TMEM129	-0.56	-10.73	-0.45	3.73e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg06115741	chr20:33292138	TP53INP2	0.57	8.96	0.38	8.12e-18	Coronary artery disease;
LGG	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-16.76	-0.61	1.28e-49	Vitiligo;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg22535103	chr8:58192502	C8orf71	-0.95	-13.33	-0.53	1.5e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs653465	0.679	rs12488954	chr3:27145162	G/A	cg02860705	chr3:27208620	NA	-0.4	-7.69	-0.34	8.82e-14	Breast cancer (early onset);
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs3733585	0.566	rs35955619	chr4:9918986	T/A	cg25986240	chr4:9926439	SLC2A9	0.4	8.23	0.36	1.93e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7107174	0.681	rs10751288	chr11:78072658	A/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs1966248	0.656	rs6569906	chr6:134132333	T/A	cg25632230	chr6:134101081	NA	-0.33	-6.99	-0.31	9.41e-12	Coronary artery disease;
LGG	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg20913747	chr6:44695427	NA	-0.67	-11.92	-0.48	9.29e-29	Total body bone mineral density;
LGG	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg09307838	chr4:120376055	NA	0.68	11.8	0.48	2.73e-28	Corneal astigmatism;
LGG	cis	rs10426930	0.752	rs10401934	chr19:5038715	C/T	cg15621731	chr19:5074616	KDM4B	-0.33	-7.87	-0.34	2.46e-14	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg19168338	chr16:4465731	CORO7	0.72	13.21	0.52	4.93e-34	Schizophrenia;
LGG	cis	rs11191205	0.645	rs12255642	chr10:103456726	A/G	cg15320455	chr10:103880129	LDB1	0.53	7.64	0.33	1.3e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	9.6	0.41	5.06e-20	Neuroticism;
LGG	cis	rs10193935	0.582	rs13394853	chr2:42630900	T/C	cg27598129	chr2:42591480	NA	-0.64	-9.79	-0.41	1.04e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17208368	0.628	rs16954198	chr16:55093518	T/C	cg11181171	chr16:55090946	NA	0.46	7.59	0.33	1.77e-13	Hypospadias;
LGG	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.64	-9.23	-0.39	9.46e-19	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04071446	chr10:115933849	C10orf118	0.45	6.93	0.31	1.4e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22914507	chr8:27308068	PTK2B	0.4	6.68	0.3	6.67e-11	Gut microbiome composition (summer);
LGG	cis	rs6426558	0.537	rs4351610	chr1:227325245	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.63	-10.47	-0.44	3.71e-23	Neutrophil percentage of white cells;
LGG	cis	rs7107174	1.000	rs114142124	chr11:78047537	T/C	cg02023728	chr11:77925099	USP35	0.47	8.02	0.35	8.46e-15	Testicular germ cell tumor;
LGG	cis	rs1790761	0.967	rs869736	chr11:67205462	C/A	cg00864171	chr11:67383662	NA	-0.42	-6.86	-0.3	2.2e-11	Mean corpuscular volume;
LGG	cis	rs2658782	0.906	rs2658791	chr11:93198983	T/C	cg15737290	chr11:93063684	CCDC67	0.54	7.79	0.34	4.31e-14	Pulmonary function decline;
LGG	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg03929089	chr4:120376271	NA	-0.44	-7.04	-0.31	6.89e-12	HDL cholesterol;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	4.08e-20	Schizophrenia;
LGG	cis	rs4665809	0.590	rs10197494	chr2:26445550	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05694744	chr17:8191820	RANGRF;SLC25A35	0.54	8.18	0.36	2.83e-15	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02475777	chr4:1388615	CRIPAK	0.46	8.61	0.37	1.17e-16	Longevity;
LGG	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs6860806	0.507	rs270608	chr5:131648406	C/T	cg07395648	chr5:131743802	NA	-0.5	-10.22	-0.43	3.02e-22	Breast cancer;
LGG	cis	rs17401966	0.838	rs11579365	chr1:10470846	G/T	cg19773385	chr1:10388646	KIF1B	-0.43	-8.47	-0.37	3.36e-16	Hepatocellular carcinoma;
LGG	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.43	0.53	5.73e-35	Bladder cancer;
LGG	cis	rs2290402	0.505	rs17165087	chr4:845841	C/T	cg09237302	chr4:906077	GAK	-0.44	-7.43	-0.33	5.35e-13	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04144589	chr14:64932036	AKAP5	0.48	7.32	0.32	1.12e-12	Gut microbiome composition (summer);
LGG	cis	rs9914544	0.628	rs9908821	chr17:18679404	A/G	cg26378065	chr17:18585709	ZNF286B	0.43	8.25	0.36	1.65e-15	Educational attainment (years of education);
LGG	cis	rs10751667	0.621	rs10794351	chr11:946228	C/T	cg22143635	chr11:980567	AP2A2	0.43	7.95	0.35	1.44e-14	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.870	rs6573009	chr14:55682324	A/C	cg04306507	chr14:55594613	LGALS3	0.63	17.36	0.63	2.31e-52	Protein biomarker;
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.35e-12	Bipolar disorder;
LGG	cis	rs5756813	0.782	rs3171656	chr22:38172213	G/A	cg24232236	chr22:38142998	TRIOBP	0.39	7.39	0.32	6.97e-13	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.09	-0.6	1.37e-46	Height;
LGG	cis	rs7712401	0.601	rs30054	chr5:122301999	A/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.37	0.43	8.68e-23	Personality dimensions;
LGG	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.79	0.38	3.05e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10262624	1.000	rs10257777	chr7:23910981	T/C	cg09690326	chr7:23720549	C7orf46	-0.32	-6.65	-0.3	8.1e-11	Schizophrenia;
LGG	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg02811702	chr13:24901961	NA	0.4	7.43	0.33	5.18e-13	Obesity-related traits;
LGG	cis	rs7927771	1.000	rs9909	chr11:47799775	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs11693319	1.000	rs1016799	chr2:179749332	C/T	cg17765952	chr2:179737173	CCDC141	0.59	9.49	0.4	1.23e-19	Blood pressure measurement (cold pressor test);
LGG	cis	rs36051895	0.560	rs1575281	chr9:5219131	T/C	cg02405213	chr9:5042618	JAK2	-0.7	-13.06	-0.52	2.11e-33	Pediatric autoimmune diseases;
LGG	cis	rs2235649	0.833	rs7190337	chr16:1850469	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.21e-11	Blood metabolite levels;
LGG	cis	rs1883415	0.534	rs2817205	chr6:24477134	G/A	cg20631270	chr6:24437470	GPLD1	0.49	8.47	0.37	3.26e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7577696	0.597	rs13006495	chr2:32355490	C/T	cg02381751	chr2:32503542	YIPF4	-0.46	-6.74	-0.3	4.84e-11	Inflammatory biomarkers;
LGG	cis	rs12210905	0.925	rs12190201	chr6:27001458	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6960043	0.714	rs4719430	chr7:15047280	C/G	cg19272540	chr7:15055459	NA	-0.36	-8.16	-0.35	3.17e-15	Type 2 diabetes;
LGG	cis	rs876084	0.524	rs4633103	chr8:121116156	A/G	cg06265175	chr8:121136014	COL14A1	-0.45	-8.98	-0.39	6.59e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7829975	0.902	rs777707	chr8:8584344	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	8.7	0.37	6e-17	Mood instability;
LGG	trans	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg10523679	chr1:76189770	ACADM	0.77	14.76	0.57	1.13e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg13206674	chr6:150067644	NUP43	0.66	14.71	0.56	1.79e-40	Lung cancer;
LGG	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg26655873	chr3:72818019	SHQ1	0.36	7.05	0.31	6.48e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2963155	0.518	rs10482614	chr5:142782402	C/T	cg17617527	chr5:142782415	NR3C1	0.97	12.95	0.52	6.09e-33	Breast cancer;
LGG	cis	rs13394619	0.840	rs11674605	chr2:11722575	A/G	cg07314298	chr2:11723111	GREB1	-0.46	-9.5	-0.4	1.13e-19	Endometriosis;
LGG	cis	rs10927875	0.632	rs4481843	chr1:16128205	G/A	cg21385522	chr1:16154831	NA	-1.04	-25.65	-0.77	6.13e-91	Dilated cardiomyopathy;
LGG	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg19507638	chr5:93509721	C5orf36	-0.69	-9.8	-0.41	9.76e-21	Diabetic retinopathy;
LGG	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs939658	0.805	rs11634903	chr15:79436192	C/T	cg17916960	chr15:79447300	NA	0.67	13.12	0.52	1.21e-33	Refractive error;
LGG	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.92	0.51	7.99e-33	Intelligence (multi-trait analysis);
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg07343612	chr16:622815	PIGQ	-0.76	-15.86	-0.59	1.51e-45	Height;
LGG	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg16060761	chr17:80687452	NA	0.43	7.47	0.33	3.94e-13	Glycated hemoglobin levels;
LGG	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	cis	rs7264396	0.635	rs6060685	chr20:34512023	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.27	-0.32	1.58e-12	Total cholesterol levels;
LGG	cis	rs367615	1.000	rs58931051	chr5:108907732	A/G	cg17395555	chr5:108820864	NA	0.63	8.78	0.38	3.28e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs3796352	1.000	rs13058817	chr3:53024139	C/T	cg12962167	chr3:53033115	SFMBT1	0.8	8.35	0.36	7.91e-16	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs11676348	0.712	rs11687434	chr2:218945143	A/G	cg04731861	chr2:219085781	ARPC2	0.29	6.91	0.31	1.65e-11	Ulcerative colitis;
LGG	cis	rs2665103	0.632	rs3902959	chr15:82544927	C/T	cg00614314	chr15:82944287	LOC80154	0.47	7.9	0.34	2.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.41e-16	Life satisfaction;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.42	-0.36	4.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs7395662	0.853	rs4882054	chr11:48399899	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.81	-0.34	3.95e-14	HDL cholesterol;
LGG	cis	rs919433	0.680	rs2565160	chr2:198286474	A/G	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg01673284	chr16:4527211	HMOX2	0.36	7.17	0.32	3.03e-12	Schizophrenia;
LGG	cis	rs9834373	1.000	rs9834373	chr3:78498997	G/T	cg06138941	chr3:78371609	NA	-0.51	-8.63	-0.37	1.01e-16	Protein quantitative trait loci;
LGG	cis	rs735396	1.000	rs2259852	chr12:121434833	G/A	cg14101638	chr12:121416612	HNF1A	0.35	7.48	0.33	3.65e-13	N-glycan levels;
LGG	cis	rs4144743	0.759	rs16941731	chr17:45317022	C/T	cg18085866	chr17:45331354	ITGB3	0.72	7.49	0.33	3.53e-13	Body mass index;
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg05556477	chr5:131705319	SLC22A5	0.77	9.16	0.39	1.7e-18	Rheumatoid arthritis;
LGG	cis	rs16866061	1.000	rs72974205	chr2:225408468	C/T	cg12698349	chr2:225449008	CUL3	0.93	19.26	0.67	3.86e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20349687	chr2:88927127	EIF2AK3	0.42	7.1	0.31	4.83e-12	Bipolar disorder;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.69	0.34	9.07e-14	Renal function-related traits (BUN);
LGG	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.78	0.69	3.01e-68	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21487637	chr19:46195684	QPCTL;SNRPD2	-0.46	-6.68	-0.3	6.76e-11	Systemic lupus erythematosus;
LGG	cis	rs7226408	0.901	rs72885252	chr18:34429398	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4409675	0.576	rs7535816	chr1:28234054	A/G	cg23691781	chr1:28212827	C1orf38	0.4	10.5	0.44	2.71e-23	Corneal astigmatism;
LGG	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.92	-0.31	1.47e-11	Monocyte count;
LGG	cis	rs7937612	0.895	rs4936517	chr11:120228286	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.5	-11.87	-0.48	1.42e-28	Intraocular pressure;
LGG	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg12927641	chr6:109611667	NA	-0.38	-7.18	-0.32	2.77e-12	Reticulocyte fraction of red cells;
LGG	cis	rs4363385	0.867	rs310103	chr1:153042554	C/A	cg07796016	chr1:152779584	LCE1C	-0.42	-7.09	-0.31	4.98e-12	Inflammatory skin disease;
LGG	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg02631450	chr22:32366979	NA	1.01	9.71	0.41	2.06e-20	Childhood ear infection;
LGG	cis	rs1015291	0.599	rs2694980	chr12:20010909	A/G	cg25401612	chr12:20009446	NA	-0.35	-7.43	-0.33	5.39e-13	Diastolic blood pressure;
LGG	cis	rs1577917	1.000	rs12190604	chr6:86716215	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.16	-0.43	4.8e-22	Response to antipsychotic treatment;
LGG	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15644404	chr18:77186268	NFATC1	-0.81	-9.86	-0.42	6.19e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28588043	1.000	rs55988822	chr1:170966658	G/A	cg03458344	chr1:170964477	C1orf129	-0.52	-7.61	-0.33	1.5700000000000001e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs10489202	0.954	rs11586522	chr1:168091031	G/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.08	-0.42	9.8e-22	Schizophrenia;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg18000306	chr6:288505	NA	0.43	7.8	0.34	4.26e-14	Menopause (age at onset);
LGG	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg20307385	chr11:47447363	PSMC3	0.43	7.0	0.31	8.93e-12	Migraine - clinic-based;
LGG	cis	rs6462411	0.759	rs6954370	chr7:3918178	A/G	cg18022346	chr7:3920534	SDK1	-0.37	-7.22	-0.32	2.2e-12	Quantitative traits;
LGG	cis	rs6089584	0.706	rs6089625	chr20:60620622	T/C	cg06108461	chr20:60628389	TAF4	-1.01	-20.18	-0.68	1.97e-65	Body mass index;
LGG	trans	rs3960554	0.569	rs4728618	chr7:75865059	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	10.16	0.43	4.96e-22	Eotaxin levels;
LGG	cis	rs6977660	0.619	rs71526305	chr7:19785374	G/C	cg05791153	chr7:19748676	TWISTNB	0.63	9.04	0.39	4.38e-18	Thyroid stimulating hormone;
LGG	cis	rs7017697	0.569	rs10092840	chr8:19672040	G/T	cg03894339	chr8:19674705	INTS10	-0.43	-7.28	-0.32	1.44e-12	Breast cancer;
LGG	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg17985854	chr11:65770987	BANF1;EIF1AD	-0.45	-7.85	-0.34	2.89e-14	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.64	-0.51	1.15e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7586879	0.616	rs6726199	chr2:25126328	G/C	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	trans	rs4714291	0.962	rs847744	chr6:40085245	T/C	cg02267698	chr19:7991119	CTXN1	0.55	8.43	0.36	4.3e-16	Strep throat;
LGG	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg17376030	chr22:41985996	PMM1	0.66	10.27	0.43	1.94e-22	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg18188782	chr20:61659543	NA	0.4	6.78	0.3	3.66e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg04851639	chr8:1020857	NA	-0.33	-6.82	-0.3	2.87e-11	Schizophrenia;
LGG	cis	rs4731207	0.596	rs7791399	chr7:124577972	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6424115	1.000	rs4237	chr1:24114129	C/T	cg24699146	chr1:24152579	HMGCL	0.25	7.7	0.34	8.07e-14	Immature fraction of reticulocytes;
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg16507663	chr6:150244633	RAET1G	-0.45	-7.1	-0.31	4.66e-12	Lung cancer;
LGG	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg27171569	chr16:83987465	OSGIN1	0.55	9.7	0.41	2.3e-20	Pursuit maintenance gain;
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg08355456	chr11:67383691	NA	-0.51	-7.78	-0.34	4.7e-14	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.49	0.37	2.81e-16	Lung cancer;
LGG	cis	rs2953174	0.786	rs2953177	chr2:241516616	A/G	cg07929629	chr2:241523174	NA	0.56	7.68	0.34	9.29e-14	Bipolar disorder;
LGG	trans	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.87	-16.77	-0.61	1.19e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg14191688	chr11:70257035	CTTN	0.59	8.53	0.37	2.02e-16	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg11757124	chr7:157526947	PTPRN2	-0.78	-13.89	-0.54	6.29e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg27121462	chr16:89883253	FANCA	0.62	11.5	0.47	4.44e-27	Vitiligo;
LGG	cis	rs7659604	0.840	rs6821305	chr4:122713863	A/C	cg20573242	chr4:122745356	CCNA2	0.5	9.5	0.4	1.14e-19	Type 2 diabetes;
LGG	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg19680485	chr15:31195859	MTMR15	-0.46	-7.49	-0.33	3.55e-13	Huntington's disease progression;
LGG	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg00426182	chr6:28072559	NA	0.98	8.43	0.36	4.43e-16	Parkinson's disease;
LGG	cis	rs11122272	0.735	rs2749717	chr1:231489353	G/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.05	-0.31	6.5e-12	Hemoglobin concentration;
LGG	cis	rs6456042	0.965	rs6920259	chr6:166534490	A/G	cg11088901	chr6:166572345	T	-0.35	-7.34	-0.32	9.43e-13	Asthma;
LGG	trans	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg22358067	chr17:16797159	NA	-0.51	-7.19	-0.32	2.65e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7765175	0.698	rs9320441	chr6:113668814	A/G	cg26552650	chr6:113682475	NA	0.33	7.47	0.33	4.05e-13	Coronary artery calcification;
LGG	trans	rs1422110	0.513	rs987280	chr5:85448604	C/T	cg01787110	chr1:109008453	NBPF6	-0.54	-9.44	-0.4	1.87e-19	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	trans	rs877282	0.786	rs11253392	chr10:788768	G/A	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg11766577	chr21:47581405	C21orf56	0.46	7.68	0.34	9.53e-14	Testicular germ cell tumor;
LGG	cis	rs357618	1.000	rs441652	chr5:150847505	T/C	cg03212797	chr5:150827313	SLC36A1	-0.44	-7.21	-0.32	2.35e-12	Basophil percentage of white cells;
LGG	cis	rs10426930	0.607	rs2613755	chr19:5059941	A/G	cg15621731	chr19:5074616	KDM4B	0.31	7.66	0.34	1.11e-13	Monocyte percentage of white cells;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18252515	chr7:66147081	NA	0.44	7.47	0.33	3.97e-13	Aortic root size;
LGG	trans	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg24247370	chr13:99142703	STK24	0.36	6.7	0.3	6.25e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10751667	0.666	rs7396059	chr11:970490	C/A	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg10523679	chr1:76189770	ACADM	-0.84	-15.25	-0.58	7.68e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg24634471	chr8:143751801	JRK	0.53	8.51	0.37	2.51e-16	Schizophrenia;
LGG	cis	rs10489167	1.000	rs944940	chr1:41205276	A/G	cg11417323	chr1:41160271	NFYC	0.42	6.83	0.3	2.61e-11	Depressive and manic episodes in bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19983627	chr4:108852959	CYP2U1	-0.58	-9.02	-0.39	5.04e-18	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.63	0.61	4.9e-49	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs9379210	chr6:8461928	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.52	0.5	3.46e-31	Motion sickness;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.83	-0.51	1.96e-32	Bipolar disorder and schizophrenia;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg27570249	chr15:65688530	IGDCC4	0.27	6.77	0.3	3.93e-11	Parkinson's disease (motor and cognition);
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13012494	chr21:47604986	C21orf56	0.58	10.36	0.43	9.17e-23	Testicular germ cell tumor;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.09	0.46	1.63e-25	Personality dimensions;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7634476	1	rs7634476	chr3:136398387	A/G	cg12473912	chr3:136751656	NA	-0.4	-6.85	-0.3	2.36e-11	Neuroticism;
LGG	cis	rs708547	0.957	rs2458552	chr4:57773442	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.56	8.65	0.37	8.73e-17	Response to bleomycin (chromatid breaks);
LGG	cis	rs10979	0.571	rs7764231	chr6:143919151	C/G	cg25407410	chr6:143891975	LOC285740	-0.49	-7.17	-0.32	3.05e-12	Hypospadias;
LGG	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.49	-0.33	3.51e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg12310025	chr6:25882481	NA	-0.67	-12.43	-0.5	8.54e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.18	0.46	7.25e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg22903471	chr2:27725779	GCKR	-0.59	-13.57	-0.53	1.49e-35	Total body bone mineral density;
LGG	cis	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2117029	0.554	rs35884657	chr12:49531100	C/T	cg24176009	chr12:49580217	TUBA1A	0.6	11.41	0.47	9.64e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-9.14	-0.39	1.95e-18	Common traits (Other);
LGG	cis	rs7737355	0.812	rs10041712	chr5:130765670	C/G	cg06307176	chr5:131281290	NA	-0.52	-8.82	-0.38	2.28e-17	Life satisfaction;
LGG	cis	rs2880765	0.546	rs11639291	chr15:86064130	G/A	cg10818794	chr15:86012489	AKAP13	-0.4	-8.12	-0.35	4.25e-15	Coronary artery disease;
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg00157179	chr1:2383687	NA	-0.69	-15.66	-0.59	1.16e-44	Schizophrenia;
LGG	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.34	-6.89	-0.3	1.87e-11	Hemoglobin concentration;
LGG	cis	rs11098499	0.779	rs7356491	chr4:120381974	C/T	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs6088590	0.542	rs6059956	chr20:33220070	A/G	cg08999081	chr20:33150536	PIGU	0.43	11.08	0.46	1.85e-25	Coronary artery disease;
LGG	cis	rs11920090	0.789	rs6785233	chr3:170756985	A/C	cg09710316	chr3:170744871	SLC2A2	0.7	8.69	0.37	6.48e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs807669	0.934	rs762523	chr22:19180589	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	16.03	0.6	2.61e-46	Metabolite levels;
LGG	cis	rs9547996	0.879	rs9547985	chr13:38203181	G/A	cg17979426	chr13:38220150	TRPC4	-0.36	-6.88	-0.3	1.94e-11	Diastolic blood pressure;
LGG	cis	rs3087591	0.592	rs2342054	chr17:29724708	G/A	cg24425628	chr17:29625626	OMG;NF1	0.58	11.96	0.49	6.51e-29	Hip circumference;
LGG	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg12454169	chr2:30669597	LCLAT1	-0.52	-7.46	-0.33	4.25e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs561341	0.883	rs886224	chr17:30229902	T/C	cg27661571	chr11:113659931	NA	-0.58	-7.85	-0.34	2.87e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12478296	1.000	rs6717667	chr2:242997530	C/T	cg18898632	chr2:242989856	NA	-0.79	-9.41	-0.4	2.39e-19	Obesity-related traits;
LGG	cis	rs4944092	0.855	rs596339	chr11:75916507	T/C	cg04588336	chr11:75916460	WNT11	-0.41	-9.66	-0.41	3.02e-20	PR interval;
LGG	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg08048268	chr3:133502702	NA	-0.6	-11.17	-0.46	8.5e-26	Iron status biomarkers;
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.82	-16.14	-0.6	8.48e-47	Age at first birth;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg23958373	chr8:599963	NA	1.2	11.97	0.49	5.92e-29	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.65	0.59	1.27e-44	Platelet count;
LGG	cis	rs12142240	0.698	rs72677587	chr1:46813982	G/A	cg25706281	chr1:46860511	FAAH	-0.28	-6.8	-0.3	3.3e-11	Menopause (age at onset);
LGG	cis	rs8062405	1.000	rs12443881	chr16:28841777	C/T	cg07382826	chr16:28625726	SULT1A1	0.37	7.72	0.34	7.1e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.99	-0.42	2.05e-21	Morning vs. evening chronotype;
LGG	cis	rs10934753	0.632	rs4350878	chr3:125914214	C/G	cg01346077	chr3:125931526	NA	0.46	10.41	0.44	6.02e-23	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg15268244	chr15:77196840	NA	0.49	10.39	0.43	7.34e-23	Blood metabolite levels;
LGG	trans	rs11989744	0.843	rs10481331	chr8:23559257	T/C	cg03492747	chr16:86543808	FOXF1	0.55	8.29	0.36	1.22e-15	Waist-hip ratio;
LGG	cis	rs4665809	1.000	rs6546726	chr2:26275116	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.5700000000000001e-13	Gut microbiome composition (summer);
LGG	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.63	0.44	8.95e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	9.1	0.39	2.76e-18	Obesity-related traits;
LGG	cis	rs6840360	0.571	rs11729136	chr4:152529227	C/A	cg25486957	chr4:152246857	NA	-0.51	-8.37	-0.36	6.81e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06584030	chr17:63119265	NA	0.44	7.66	0.34	1.13e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs231513	0.954	rs231514	chr17:41964516	C/T	cg26893861	chr17:41843967	DUSP3	-0.58	-6.89	-0.3	1.88e-11	Cognitive function;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg19147804	chr7:1989927	MAD1L1	-0.6	-11.96	-0.49	6.28e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg08885076	chr2:99613938	TSGA10	0.42	8.81	0.38	2.49e-17	Chronic sinus infection;
LGG	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.06	0.42	1.14e-21	Diabetic retinopathy;
LGG	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg20913747	chr6:44695427	NA	-0.61	-10.4	-0.44	6.85e-23	Total body bone mineral density;
LGG	cis	rs16854884	0.586	rs4527375	chr3:143735515	A/T	cg06585982	chr3:143692056	C3orf58	-0.67	-12.07	-0.49	2.26e-29	Economic and political preferences (feminism/equality);
LGG	cis	rs854765	0.927	rs12943914	chr17:17980671	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.55	10.5	0.44	2.69e-23	Total body bone mineral density;
LGG	cis	rs12579753	0.872	rs7956132	chr12:82178709	A/G	cg07988820	chr12:82153109	PPFIA2	-0.66	-9.54	-0.41	8.2e-20	Resting heart rate;
LGG	trans	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01802975	chr1:67519155	SLC35D1	0.51	7.67	0.34	1.03e-13	Gut microbiome composition (summer);
LGG	cis	rs7589342	0.899	rs11885225	chr2:106486548	T/C	cg14210321	chr2:106509881	NCK2	-0.57	-10.0	-0.42	1.92e-21	Addiction;
LGG	cis	rs854037	0.698	rs67065498	chr5:57064351	G/A	cg08523694	chr5:57076192	NA	0.49	6.88	0.3	1.94e-11	Birth weight;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg03351412	chr1:154909251	PMVK	0.59	9.95	0.42	2.85e-21	Prostate cancer;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.96	17.55	0.63	3.27e-53	Alzheimer's disease;
LGG	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg13147721	chr7:65941812	NA	-0.45	-6.9	-0.31	1.74e-11	Corneal structure;
LGG	cis	rs7646881	1.000	rs61558956	chr3:158452655	T/A	cg19483011	chr3:158453295	NA	-0.64	-9.61	-0.41	4.74e-20	Tetralogy of Fallot;
LGG	cis	rs283228	1.000	rs1832411	chr6:101827805	G/T	cg27451362	chr6:101846650	GRIK2	-0.54	-9.09	-0.39	2.9e-18	Coenzyme Q10 levels;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg16434002	chr17:42200994	HDAC5	-0.5	-9.59	-0.41	5.44e-20	Total body bone mineral density;
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg19147804	chr7:1989927	MAD1L1	-0.59	-12.09	-0.49	1.94e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.56	0.33	2.24e-13	Retinal vascular caliber;
LGG	cis	rs36051895	0.589	rs10122037	chr9:5192874	A/G	cg02405213	chr9:5042618	JAK2	0.77	14.48	0.56	1.88e-39	Pediatric autoimmune diseases;
LGG	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg17554472	chr22:41940697	POLR3H	-0.46	-7.01	-0.31	8.69e-12	Vitiligo;
LGG	trans	rs208520	0.690	rs9345764	chr6:66820597	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.99	-18.4	-0.65	3.97e-57	Exhaled nitric oxide output;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10410142	chr4:158141542	GRIA2	0.6	6.75	0.3	4.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs5758511	0.633	rs5751258	chr22:42663871	C/G	cg15128208	chr22:42549153	NA	0.75	11.98	0.49	5.47e-29	Birth weight;
LGG	cis	rs113835537	0.529	rs11227503	chr11:66275242	G/C	cg24851651	chr11:66362959	CCS	0.45	7.76	0.34	5.46e-14	Airway imaging phenotypes;
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg23730037	chr7:158596552	ESYT2	-0.41	-7.12	-0.31	4.23e-12	Height;
LGG	cis	rs9863	0.931	rs4930721	chr12:124417889	C/T	cg13487667	chr12:124434373	CCDC92	-0.38	-7.26	-0.32	1.64e-12	White blood cell count;
LGG	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	10.39	0.43	6.97e-23	Height;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.44	-9.47	-0.4	1.48e-19	Schizophrenia;
LGG	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg13010199	chr12:38710504	ALG10B	0.58	11.28	0.46	3.06e-26	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1552244	0.706	rs279545	chr3:9972493	A/G	cg00149659	chr3:10157352	C3orf10	0.54	7.9	0.34	2.04e-14	Alzheimer's disease;
LGG	cis	rs12618769	0.597	rs4851140	chr2:99079339	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg22437258	chr11:111473054	SIK2	-0.57	-9.52	-0.4	9.32e-20	Primary sclerosing cholangitis;
LGG	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg16141378	chr3:129829833	LOC729375	-0.4	-8.91	-0.38	1.16e-17	Retinal vascular caliber;
LGG	trans	rs1997103	1.000	rs6957984	chr7:55397331	G/A	cg20935933	chr6:143382018	AIG1	0.59	9.12	0.39	2.29e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9457247	0.967	rs2769346	chr6:167370999	A/G	cg07741184	chr6:167504864	NA	-0.32	-7.09	-0.31	4.89e-12	Crohn's disease;
LGG	cis	rs9952991	0.941	rs2542151	chr18:12779947	G/T	cg23544223	chr18:12777786	NA	0.61	9.21	0.39	1.17e-18	Inflammatory skin disease;
LGG	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg14835575	chr10:16859367	RSU1	0.77	14.07	0.55	1.11e-37	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs12579753	0.879	rs11115010	chr12:82165895	G/T	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.59	-0.5	1.85e-31	Resting heart rate;
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.28	-0.32	1.48e-12	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg02592271	chr2:27665507	KRTCAP3	0.28	7.25	0.32	1.74e-12	Total body bone mineral density;
LGG	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg08222618	chr4:941054	TMEM175	-0.46	-9.6	-0.41	4.87e-20	Systemic sclerosis;
LGG	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg22947322	chr17:47091978	IGF2BP1	-0.44	-7.61	-0.33	1.51e-13	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs55665837	0.559	rs11023209	chr11:14422600	T/C	cg19336497	chr11:14380999	RRAS2	-0.53	-10.82	-0.45	1.74e-24	Vitamin D levels;
LGG	cis	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-10.81	-0.45	1.92e-24	Resting heart rate;
LGG	cis	rs7953508	0.506	rs12425869	chr12:93961353	A/G	cg18151635	chr12:93972918	NA	-0.56	-10.66	-0.44	7.24e-24	Pubertal anthropometrics;
LGG	cis	rs7712401	0.601	rs246268	chr5:122256342	C/T	cg19412675	chr5:122181750	SNX24	0.42	6.93	0.31	1.42e-11	Mean platelet volume;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.21	-0.32	2.25e-12	Lung cancer;
LGG	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg19761014	chr17:28927070	LRRC37B2	0.67	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg06558623	chr16:89946397	TCF25	0.96	12.48	0.5	5.38e-31	Skin colour saturation;
LGG	cis	rs12410462	1.000	rs12410462	chr1:227667790	A/G	cg04117972	chr1:227635322	NA	-0.74	-11.89	-0.48	1.27e-28	Major depressive disorder;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.34	-0.5	1.88e-30	Lymphocyte counts;
LGG	cis	rs4917300	0.606	rs902822	chr8:143105435	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.88	-0.3	1.9e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs4665809	1.000	rs1550381	chr2:26266946	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.88	-0.34	2.36e-14	Gut microbiome composition (summer);
LGG	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.62e-17	Cognitive function;
LGG	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg06618935	chr21:46677482	NA	-0.45	-8.72	-0.38	4.91e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1978968	0.731	rs9605468	chr22:18461180	T/C	cg03078520	chr22:18463400	MICAL3	-0.68	-14.66	-0.56	3.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs9790314	0.846	rs1478568	chr3:161014276	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-13.56	-0.53	1.61e-35	Morning vs. evening chronotype;
LGG	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg20578329	chr17:80767326	TBCD	0.39	6.86	0.3	2.28e-11	Breast cancer;
LGG	cis	rs7119	0.717	rs12898281	chr15:77786903	C/T	cg05673287	chr15:77411982	SGK269	0.44	9.6	0.41	5.02e-20	Type 2 diabetes;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.94	-0.42	3.17e-21	Bipolar disorder;
LGG	cis	rs7928758	0.945	rs11223787	chr11:134277978	G/A	cg25213107	chr11:134282864	B3GAT1	0.92	11.99	0.49	4.73e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg07005078	chr4:17578674	LAP3	0.38	6.89	0.31	1.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.56	-0.44	1.64e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1965732	1.000	rs1965732	chr2:3709108	A/G	cg15327641	chr2:3715039	ALLC	0.32	6.81	0.3	3.13e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg12011299	chr4:100065546	ADH4	0.42	8.12	0.35	4.25e-15	Alcohol dependence;
LGG	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.13	-0.31	3.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg19507638	chr5:93509721	C5orf36	-0.73	-10.06	-0.42	1.17e-21	Diabetic retinopathy;
LGG	cis	rs17534004	1.000	rs17505772	chr13:31456002	G/C	cg00367615	chr13:31480979	C13orf33	0.36	7.23	0.32	2.07e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2075371	0.863	rs34231360	chr7:133944988	A/C	cg20476274	chr7:133979776	SLC35B4	0.72	13.76	0.54	2.24e-36	Mean platelet volume;
LGG	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg00908189	chr16:619842	PIGQ	0.82	15.43	0.58	1.22e-43	Height;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	2.97e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg11494091	chr17:61959527	GH2	0.56	9.18	0.39	1.49e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg23762105	chr12:34175262	ALG10	-0.35	-7.03	-0.31	7.37e-12	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1538970	0.924	rs11211111	chr1:45908782	C/T	cg05343316	chr1:45956843	TESK2	0.72	11.83	0.48	2.23e-28	Platelet count;
LGG	trans	rs7618501	1.000	rs7372730	chr3:49790682	C/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.75	-0.41	1.52e-20	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.82	-0.76	4.07e-87	Height;
LGG	cis	rs17854409	1.000	rs66634465	chr20:61482306	C/T	cg05147244	chr20:61493195	TCFL5	0.76	7.43	0.33	5.29e-13	Obesity-related traits;
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg01765077	chr12:122356316	WDR66	-0.28	-7.61	-0.33	1.53e-13	Mean corpuscular volume;
LGG	cis	rs10089	0.953	rs758180	chr5:127354423	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	10.56	0.44	1.68e-23	Ileal carcinoids;
LGG	cis	rs6964587	0.967	rs10953065	chr7:91808915	A/G	cg17063962	chr7:91808500	NA	-0.52	-9.22	-0.39	1.02e-18	Breast cancer;
LGG	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg22920501	chr2:26401640	FAM59B	0.45	9.35	0.4	3.76e-19	Gut microbiome composition (summer);
LGG	trans	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.84	-0.42	7.04e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10876993	0.855	rs1689585	chr12:58080140	A/G	cg18357645	chr12:58087776	OS9	-0.7	-13.03	-0.52	2.86e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg08048268	chr3:133502702	NA	-0.6	-11.12	-0.46	1.22e-25	Iron status biomarkers;
LGG	cis	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.58e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	0.920	rs2905881	chr17:29547862	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	cis	rs11676855	1.000	rs11889801	chr2:235902470	T/C	cg06431347	chr2:235935754	SH3BP4	-0.43	-9.43	-0.4	2.04e-19	Dialysis-related mortality;
LGG	cis	rs11587400	0.634	rs4839385	chr1:115121461	A/G	cg12756093	chr1:115239321	AMPD1	0.38	6.79	0.3	3.34e-11	Autism;
LGG	cis	rs7717393	1.000	rs72798928	chr5:155790471	G/A	cg12904904	chr5:155754151	SGCD	0.84	8.39	0.36	6.09e-16	Egg allergy;
LGG	cis	rs2071403	0.901	rs56283137	chr2:1405809	C/A	cg06500727	chr2:1417164	TPO	-0.53	-10.13	-0.43	6.45e-22	Thyroid peroxidase antibody positivity;
LGG	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg08470875	chr2:26401718	FAM59B	-0.35	-6.65	-0.3	8.39e-11	Gut microbiome composition (summer);
LGG	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg08079166	chr15:68083412	MAP2K5	0.34	7.65	0.34	1.17e-13	Restless legs syndrome;
LGG	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.58	-0.69	2.53e-67	Intelligence (multi-trait analysis);
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg18479299	chr3:125709523	NA	-0.6	-7.8	-0.34	4.13e-14	Blood pressure (smoking interaction);
LGG	cis	rs11771526	0.901	rs62457502	chr7:32330797	C/T	cg27532318	chr7:32358331	NA	0.73	7.41	0.33	6.07e-13	Body mass index;
LGG	cis	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg21775007	chr8:11205619	TDH	0.81	14.18	0.55	3.62e-38	Retinal vascular caliber;
LGG	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg03806693	chr22:41940476	POLR3H	1.05	19.61	0.67	8.86e-63	Cannabis dependence symptom count;
LGG	cis	rs3847687	1.000	rs34853396	chr12:131519265	G/T	cg06093039	chr12:131527216	GPR133	0.28	7.01	0.31	8.34e-12	Longevity;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs1372520	0.748	rs990085	chr4:90754771	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.11	-0.35	4.47e-15	Neuroticism;
LGG	cis	rs11676348	0.710	rs11894169	chr2:219046846	T/C	cg00012203	chr2:219082015	ARPC2	0.53	9.11	0.39	2.56e-18	Ulcerative colitis;
LGG	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.6	0.37	1.24e-16	Fuchs's corneal dystrophy;
LGG	cis	rs8141529	0.664	rs5762861	chr22:29250505	T/G	cg15103426	chr22:29168792	CCDC117	0.63	8.66	0.37	7.97e-17	Lymphocyte counts;
LGG	cis	rs4481887	0.927	rs4427440	chr1:248480337	T/A	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.79	-0.41	1.05e-20	Primary sclerosing cholangitis;
LGG	cis	rs4740619	0.967	rs4741523	chr9:15634244	T/A	cg14451791	chr9:16040625	NA	-0.41	-10.52	-0.44	2.44e-23	Body mass index;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07003055	chr20:3776921	CDC25B	0.43	7.76	0.34	5.42e-14	Obesity-related traits;
LGG	cis	rs58688157	0.660	rs7117022	chr11:583787	T/C	cg03909863	chr11:638404	DRD4	-0.42	-6.84	-0.3	2.54e-11	Systemic lupus erythematosus;
LGG	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11890956	chr21:40555474	PSMG1	-0.69	-11.64	-0.48	1.16e-27	Menarche (age at onset);
LGG	cis	rs17689437	0.581	rs1170435	chr16:68607398	C/A	cg02972257	chr16:68554789	NA	-0.44	-7.25	-0.32	1.82e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.68	0.3	6.77e-11	Schizophrenia;
LGG	cis	rs11628318	0.614	rs1190342	chr14:103100382	C/T	cg12046867	chr14:103022105	NA	-0.75	-12.35	-0.5	1.8e-30	Platelet count;
LGG	cis	rs77633900	0.614	rs2469244	chr15:76884127	G/A	cg21673338	chr15:77095150	SCAPER	-0.65	-10.07	-0.42	1.08e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg08250081	chr4:10125330	NA	-0.38	-7.23	-0.32	2.04e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.46	-7.73	-0.34	6.72e-14	Uric acid levels;
LGG	cis	rs7551222	0.752	rs12125533	chr1:204529302	A/C	cg20240347	chr1:204465584	NA	-0.55	-11.1	-0.46	1.47e-25	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06128509	chr10:91461539	KIF20B	0.45	7.29	0.32	1.33e-12	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg16339924	chr4:17578868	LAP3	0.5	8.38	0.36	6.62e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg21775007	chr8:11205619	TDH	0.44	7.25	0.32	1.81e-12	Mood instability;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg03517284	chr6:25882590	NA	-0.88	-18.3	-0.65	1.06e-56	Urate levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25670839	chr19:52531956	ZNF614	0.59	9.44	0.4	1.88e-19	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg12751644	chr20:60527061	NA	-0.31	-7.27	-0.32	1.5e-12	Body mass index;
LGG	cis	rs559928	0.576	rs750832	chr11:64163302	C/T	cg05555928	chr11:63887634	MACROD1	0.59	10.01	0.42	1.78e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs5750830	0.649	rs5750811	chr22:39793066	G/T	cg04986931	chr22:39850128	NA	-0.34	-7.66	-0.34	1.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.95	-10.19	-0.43	3.91e-22	Corneal curvature;
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	8.07e-43	Height;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg04025307	chr7:1156635	C7orf50	0.55	10.06	0.42	1.14e-21	Longevity;Endometriosis;
LGG	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7980799	0.682	rs7311794	chr12:33635630	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.24	-0.36	1.76e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2072732	0.861	rs34408665	chr1:2950067	A/G	cg22517653	chr1:2918612	NA	-0.44	-6.95	-0.31	1.24e-11	Plateletcrit;
LGG	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg13256891	chr4:100009986	ADH5	0.51	8.72	0.38	5.1e-17	Alcohol dependence;
LGG	trans	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg26043149	chr18:55253948	FECH	0.41	6.73	0.3	5.12e-11	Bone mineral density;
LGG	cis	rs7267979	0.933	rs1130694	chr20:25276297	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.2	0.43	3.62e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9354308	0.868	rs2351729	chr6:66537291	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-8.28	-0.36	1.35e-15	Metabolite levels;
LGG	cis	rs9314323	0.767	rs10866848	chr8:26208209	G/C	cg11498726	chr8:26250323	BNIP3L	-0.54	-11.17	-0.46	8.14e-26	Red cell distribution width;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg12091567	chr17:66097778	LOC651250	0.79	13.08	0.52	1.68e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.48	0.4	1.32e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-7.72	-0.34	7.12e-14	Tonsillectomy;
LGG	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03264133	chr6:25882463	NA	-0.69	-12.64	-0.51	1.11e-31	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.967	rs2010678	chr14:75567178	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.68	0.44	6.22e-24	Height;
LGG	cis	rs7552404	0.731	rs5745491	chr1:76350159	T/G	cg10523679	chr1:76189770	ACADM	-0.72	-11.07	-0.46	1.92e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6764363	0.733	rs186704	chr3:295418	T/C	cg02057681	chr3:285234	CHL1	0.37	6.97	0.31	1.12e-11	Sudden cardiac arrest;
LGG	cis	rs9381040	0.655	rs9381031	chr6:41044957	A/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.66	-0.3	7.75e-11	Alzheimer's disease (late onset);
LGG	cis	rs10895140	0.756	rs4633432	chr11:101514325	A/G	cg04553838	chr11:101454733	TRPC6	0.42	6.73	0.3	5.18e-11	Menarche (age at onset);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21231776	chr2:47136690	MCFD2	0.41	7.13	0.31	3.84e-12	Electrocardiographic conduction measures;
LGG	cis	rs11676855	0.893	rs6721399	chr2:235936607	A/G	cg14917874	chr2:235941519	SH3BP4	0.53	9.84	0.42	6.92e-21	Dialysis-related mortality;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12188830	chr3:57741926	SLMAP	-0.47	-6.97	-0.31	1.11e-11	Systemic lupus erythematosus;
LGG	cis	rs9399137	0.507	rs11758774	chr6:135383789	T/G	cg24558204	chr6:135376177	HBS1L	0.61	10.41	0.44	6.06e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg07211511	chr3:129823064	LOC729375	-1.3	-16.0	-0.6	3.37e-46	Blood pressure (smoking interaction);
LGG	cis	rs262150	0.704	rs2730236	chr7:158765543	C/T	cg19418458	chr7:158789849	NA	-0.46	-9.08	-0.39	3.1e-18	Facial morphology (factor 20);
LGG	trans	rs1814175	0.817	rs28544182	chr11:50049577	G/T	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	5.37e-87	Height;
LGG	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg19680485	chr15:31195859	MTMR15	-0.45	-7.39	-0.32	6.82e-13	Huntington's disease progression;
LGG	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg03733263	chr8:22462867	KIAA1967	1.05	26.56	0.78	4.2e-95	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg25174290	chr11:3078921	CARS	-0.5	-8.98	-0.39	7.04e-18	Calcium levels;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg09596252	chr17:78655493	RPTOR	0.45	7.93	0.35	1.62e-14	Obesity;
LGG	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.31	0.36	1.07e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11758351	0.866	rs2069019	chr6:26205604	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.21	0.39	1.11e-18	Gout;Renal underexcretion gout;
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg05941027	chr17:61774174	LIMD2	0.35	8.85	0.38	1.92e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2836950	0.565	rs8131132	chr21:40538256	T/C	cg11890956	chr21:40555474	PSMG1	-0.72	-12.44	-0.5	7.8e-31	Menarche (age at onset);
LGG	cis	rs7226408	0.625	rs117502709	chr18:34455344	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.42	-8.82	-0.38	2.37e-17	Obesity-related traits;
LGG	cis	rs807669	0.525	rs738904	chr22:19167385	C/A	cg02655711	chr22:19163373	SLC25A1	0.52	9.31	0.4	5.33e-19	Metabolite levels;
LGG	cis	rs6840360	0.607	rs2724565	chr4:152350305	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	7.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1015291	0.708	rs941237	chr12:20004790	A/T	cg25401612	chr12:20009446	NA	-0.34	-7.26	-0.32	1.67e-12	Diastolic blood pressure;
LGG	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg23815491	chr16:72088622	HP	0.5	10.81	0.45	1.87e-24	Fibrinogen levels;
LGG	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.22	-0.46	5.14e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.47	0.33	4.17e-13	Height;
LGG	cis	rs835154	0.845	rs835156	chr5:14875813	C/A	cg18064842	chr5:14874549	NA	-0.48	-11.19	-0.46	7.16e-26	Blood metabolite levels;
LGG	cis	rs7301016	0.817	rs7302456	chr12:62997643	G/T	cg11441379	chr12:63026424	NA	0.66	9.16	0.39	1.65e-18	IgG glycosylation;
LGG	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs2916247	1.000	rs10092162	chr8:93062830	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.29	-0.36	1.27e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1595825	0.636	rs111540926	chr2:198885578	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.82	-0.3	2.77e-11	Ulcerative colitis;
LGG	cis	rs1355223	0.867	rs11821793	chr11:34681462	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.8	-0.3	3.2e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02760553	chr17:73975121	ACOX1;C17orf106	0.44	6.77	0.3	3.83e-11	Gut microbiome composition (summer);
LGG	cis	rs7580658	0.521	rs35577992	chr2:127941324	C/T	cg10021288	chr2:128175891	PROC	-0.42	-7.96	-0.35	1.39e-14	Protein C levels;
LGG	cis	rs755249	0.501	rs621807	chr1:39842443	G/A	cg18385671	chr1:39797026	MACF1	0.49	9.98	0.42	2.22e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7226408	0.857	rs8084381	chr18:34597522	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.33	0.36	9.1e-16	Joint mobility (Beighton score);
LGG	cis	rs2455799	0.573	rs2255248	chr3:15754849	A/G	cg16303742	chr3:15540471	COLQ	0.41	8.18	0.36	2.68e-15	Mean platelet volume;
LGG	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg08468577	chr11:2973342	NAP1L4	-0.38	-7.69	-0.34	8.69e-14	Calcium levels;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	8.89	0.38	1.4e-17	Lung function (FEV1/FVC);
LGG	cis	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg06521331	chr12:34319734	NA	-0.63	-12.05	-0.49	2.9e-29	Morning vs. evening chronotype;
LGG	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg00806245	chr18:76673096	NA	0.69	9.31	0.4	5.08e-19	Obesity-related traits;
LGG	cis	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg12395012	chr8:11607386	GATA4	-0.62	-12.44	-0.5	7.42e-31	Myopia (pathological);
LGG	cis	rs7666738	0.830	rs6831219	chr4:98993576	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg21926883	chr2:100939477	LONRF2	-0.54	-10.34	-0.43	1.06e-22	Intelligence (multi-trait analysis);
LGG	trans	rs4427176	0.507	rs11783635	chr8:9587803	T/C	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Mosquito bite size;
LGG	cis	rs7091068	0.671	rs1223296	chr10:95404621	T/C	cg20715218	chr10:95462985	C10orf4	-0.59	-9.35	-0.4	3.64e-19	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03313751	chr19:41857626	TGFB1	0.46	7.26	0.32	1.63e-12	Gut microbiome composition (summer);
LGG	cis	rs4478858	0.709	rs7514640	chr1:31752316	G/A	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.54e-11	Alcohol dependence;
LGG	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg11987759	chr7:65425863	GUSB	-0.4	-7.82	-0.34	3.52e-14	Aortic root size;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.67e-14	Life satisfaction;
LGG	cis	rs5756391	0.546	rs9607391	chr22:37314770	A/T	cg21209356	chr22:37319042	CSF2RB	-0.39	-8.81	-0.38	2.52e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg12654349	chr5:56205094	C5orf35	-0.42	-7.46	-0.33	4.17e-13	Coronary artery disease;
LGG	cis	rs3820928	0.804	rs4144327	chr2:227790262	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.74	-0.34	6.4e-14	Pulmonary function;
LGG	cis	rs2479724	0.875	rs2253961	chr6:41827011	A/G	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	trans	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.67	-0.34	1.03e-13	Joint mobility (Beighton score);
LGG	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.12	-0.31	4.05e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg14893161	chr1:205819251	PM20D1	0.79	17.57	0.63	2.67e-53	Menarche (age at onset);
LGG	cis	rs7412746	0.634	rs4451553	chr1:150937329	C/T	cg15448220	chr1:150897856	SETDB1	0.41	7.43	0.33	5.31e-13	Melanoma;
LGG	cis	rs13191362	1.000	rs35593345	chr6:163174981	G/C	cg21926612	chr6:163149169	PACRG;PARK2	1.16	12.28	0.5	3.43e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg08219700	chr8:58056026	NA	0.52	11.35	0.47	1.72e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.542	rs10831418	chr11:95468828	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	13.72	0.54	3.38e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg11878867	chr6:150167359	LRP11	-0.54	-11.04	-0.46	2.62e-25	Lung cancer;
LGG	cis	rs9790314	0.638	rs62280303	chr3:160647891	G/A	cg03342759	chr3:160939853	NMD3	0.45	7.54	0.33	2.44e-13	Morning vs. evening chronotype;
LGG	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg03060546	chr3:49711283	APEH	-0.52	-6.95	-0.31	1.24e-11	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg11473876	chr11:109292803	C11orf87	0.46	9.31	0.4	5.01e-19	Schizophrenia;
LGG	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03517284	chr6:25882590	NA	0.45	8.02	0.35	8.56e-15	Height;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.06	0.35	6.7e-15	Schizophrenia;
LGG	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.92	0.38	1.12e-17	Motion sickness;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.17	-0.49	9.6e-30	Cognitive function;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.67e-11	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.74	-0.34	6.15e-14	Skin colour saturation;
LGG	trans	rs75804782	0.630	rs13024052	chr2:239308456	T/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.22e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs963731	0.522	rs6755527	chr2:39187190	T/C	cg04010122	chr2:39346883	SOS1	-0.81	-6.99	-0.31	9.61e-12	Corticobasal degeneration;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.74	0.3	4.69e-11	Schizophrenia;
LGG	cis	rs7928758	0.943	rs79416046	chr11:134270003	C/T	cg22777979	chr11:134283252	B3GAT1	0.96	12.5	0.5	4.26e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10754283	0.934	rs7529653	chr1:90111851	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs755249	0.567	rs72637906	chr1:39708302	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.2	0.32	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg00292662	chr22:38071168	LGALS1	0.35	6.98	0.31	1.05e-11	Glioblastoma;Glioma;
LGG	cis	rs7572263	0.724	rs12986551	chr2:209052303	T/C	cg00164906	chr2:209055251	C2orf80	0.72	9.65	0.41	3.45e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.63	0.33	1.32e-13	Homoarginine levels;
LGG	cis	rs477895	0.713	rs12787852	chr11:63954648	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.51	0.47	4.06e-27	Mean platelet volume;
LGG	trans	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg24710671	chr21:45754203	C21orf2	-0.35	-6.85	-0.3	2.33e-11	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	trans	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg21775007	chr8:11205619	TDH	-0.44	-6.89	-0.3	1.8e-11	Joint mobility (Beighton score);
LGG	cis	rs6831352	0.918	rs28987088	chr4:100059139	T/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs7551222	0.752	rs35270244	chr1:204548416	A/C	cg20240347	chr1:204465584	NA	-0.54	-10.71	-0.45	4.49e-24	Schizophrenia;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg08645402	chr16:4508243	NA	-0.45	-7.66	-0.34	1.1e-13	Schizophrenia;
LGG	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg07537917	chr2:241836409	C2orf54	-0.42	-8.01	-0.35	9.49e-15	Urinary metabolites;
LGG	cis	rs8179	0.700	rs42041	chr7:92246744	C/G	cg15732164	chr7:92237376	CDK6	-0.51	-9.33	-0.4	4.35e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7717393	1.000	rs72798937	chr5:155796766	T/C	cg01474424	chr5:155754231	SGCD	0.72	6.96	0.31	1.19e-11	Egg allergy;
LGG	trans	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.1	0.31	4.81e-12	Retinal vascular caliber;
LGG	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg08250081	chr4:10125330	NA	-0.46	-8.66	-0.37	7.62e-17	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg07117364	chr1:16154769	NA	-0.49	-9.41	-0.4	2.27e-19	Dilated cardiomyopathy;
LGG	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg19445457	chr11:5799446	OR52N5	-0.42	-7.01	-0.31	8.71e-12	DNA methylation (variation);
LGG	cis	rs240764	0.658	rs4839792	chr6:101253788	A/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg23758822	chr17:41437982	NA	0.84	15.2	0.58	1.3e-42	Menopause (age at onset);
LGG	trans	rs17685	0.743	rs10277259	chr7:75802674	A/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg27532318	chr7:32358331	NA	0.67	6.96	0.31	1.13e-11	Body mass index;
LGG	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg11965913	chr1:205819406	PM20D1	-0.41	-6.82	-0.3	2.85e-11	Menarche (age at onset);
LGG	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.43e-20	Aortic root size;
LGG	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg13902645	chr11:5959945	NA	-0.7	-11.02	-0.46	3.02e-25	DNA methylation (variation);
LGG	cis	rs910187	0.641	rs6066232	chr20:45818905	C/T	cg27589058	chr20:45804311	EYA2	-0.36	-9.26	-0.4	7.87e-19	Migraine;
LGG	cis	rs2721811	0.738	rs2521755	chr7:24749223	T/C	cg06301139	chr7:24798175	DFNA5	-0.41	-7.66	-0.34	1.07e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10193935	0.901	rs2374429	chr2:42677888	A/G	cg27598129	chr2:42591480	NA	-0.66	-9.86	-0.42	6.07e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs236352	0.576	rs3778016	chr6:36842192	C/T	cg03410223	chr6:36853544	C6orf89	0.44	8.44	0.37	4.1e-16	Heart rate;
LGG	cis	rs8179	0.645	rs42046	chr7:92252203	C/G	cg15732164	chr7:92237376	CDK6	-0.52	-9.78	-0.41	1.19e-20	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg10950524	chr7:2139216	MAD1L1	0.32	6.97	0.31	1.13e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs62344088	0.590	rs2115276	chr5:169829	C/G	cg22857025	chr5:266934	NA	-1.09	-8.14	-0.35	3.72e-15	Asthma (childhood onset);
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg15105011	chr4:940614	TMEM175	0.41	7.92	0.35	1.79e-14	Sjögren's syndrome;
LGG	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs11168351	0.889	rs12817104	chr12:48382573	G/C	cg24011408	chr12:48396354	COL2A1	0.57	9.36	0.4	3.46e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10781543	0.845	rs36066734	chr9:139340351	A/G	cg14019695	chr9:139328340	INPP5E	0.42	7.43	0.33	5.3e-13	Monocyte percentage of white cells;
LGG	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg14593290	chr7:50529359	DDC	0.6	10.81	0.45	1.96e-24	Malaria;
LGG	cis	rs709400	0.965	rs861534	chr14:104168701	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-8.1	-0.35	5.08e-15	Body mass index;
LGG	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12893428	chr3:195717962	SDHAP1	0.5	10.3	0.43	1.54e-22	Pancreatic cancer;
LGG	cis	rs6733011	0.508	rs4850889	chr2:99521385	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.93	-0.31	1.43e-11	Bipolar disorder;
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03517284	chr6:25882590	NA	-0.5	-9.34	-0.4	4.05e-19	Height;
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.38e-12	Aortic root size;
LGG	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg14675211	chr2:100938903	LONRF2	0.65	11.28	0.46	3e-26	Intelligence (multi-trait analysis);
LGG	cis	rs727505	0.954	rs66871687	chr7:124670475	A/G	cg23710748	chr7:124431027	NA	-0.51	-9.41	-0.4	2.41e-19	Lewy body disease;
LGG	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg01244601	chr4:120671846	NA	-0.35	-6.67	-0.3	7.49e-11	Corneal astigmatism;
LGG	cis	rs10193935	0.901	rs72798529	chr2:42537471	C/T	cg27598129	chr2:42591480	NA	-0.65	-9.71	-0.41	2e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2130392	1.000	rs4862406	chr4:185629339	G/A	cg04058563	chr4:185651563	MLF1IP	-0.45	-9.53	-0.4	9.14e-20	Kawasaki disease;
LGG	cis	rs1568889	1.000	rs11602768	chr11:28351786	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	13.83	0.54	1.19e-36	Bipolar disorder;
LGG	trans	rs73191547	1.000	rs73191547	chr8:10033425	A/T	cg16141378	chr3:129829833	LOC729375	-0.31	-6.71	-0.3	5.58e-11	Schizophrenia;
LGG	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg11247378	chr22:39784982	NA	-0.32	-9.02	-0.39	5.08e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg14004847	chr7:1930337	MAD1L1	0.58	10.4	0.44	6.38e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg12395012	chr8:11607386	GATA4	0.37	6.69	0.3	6.27e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg01879757	chr17:41196368	BRCA1	-0.46	-9.16	-0.39	1.63e-18	Menopause (age at onset);
LGG	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg03213289	chr20:61660250	NA	0.65	14.32	0.55	8.93e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg11965913	chr1:205819406	PM20D1	0.52	8.11	0.35	4.47e-15	Parkinson's disease;
LGG	cis	rs17253792	0.822	rs10147688	chr14:56054642	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	trans	rs61931739	0.534	rs11053014	chr12:34103519	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg12373951	chr3:133503437	NA	0.39	6.93	0.31	1.44e-11	Iron status biomarkers;
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs1945213	0.694	rs7106894	chr11:55877315	T/C	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1670533	0.615	rs59985183	chr4:1087171	G/T	cg27284194	chr4:1044797	NA	0.56	10.31	0.43	1.37e-22	Recombination rate (females);
LGG	cis	rs10754283	0.967	rs4658302	chr1:90103336	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.35	-0.32	9.3e-13	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg02002194	chr4:3960332	NA	0.44	7.99	0.35	1.05e-14	Retinal vascular caliber;
LGG	cis	rs6500395	0.775	rs11640119	chr16:48662840	C/T	cg04672837	chr16:48644449	N4BP1	0.5	8.39	0.36	5.89e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg07234876	chr8:600039	NA	-1.13	-11.64	-0.48	1.19e-27	IgG glycosylation;
LGG	cis	rs6546550	0.904	rs3771537	chr2:70038792	A/C	cg02498382	chr2:70120550	SNRNP27	-0.38	-7.24	-0.32	1.91e-12	Prevalent atrial fibrillation;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	7.0	0.31	8.8e-12	Height;
LGG	cis	rs7551222	0.714	rs4951404	chr1:204541342	G/C	cg20240347	chr1:204465584	NA	-0.46	-8.12	-0.35	4.36e-15	Schizophrenia;
LGG	trans	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.06	0.62	5.34e-51	Exhaled nitric oxide levels;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.56	-0.53	1.69e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs3087591	0.922	rs2905799	chr17:29536901	G/A	cg24425628	chr17:29625626	OMG;NF1	0.68	14.25	0.55	1.74e-38	Hip circumference;
LGG	cis	rs7089973	0.604	rs3758603	chr10:116605368	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.3	-0.47	2.49e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11239187	0.586	rs10900076	chr10:45073411	C/G	cg03916630	chr10:45065415	NA	0.35	8.66	0.37	7.75e-17	Body mass index;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg05313129	chr8:58192883	C8orf71	-0.65	-9.31	-0.4	5.36e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.666	rs3778478	chr6:109791630	G/A	cg01125227	chr6:109776195	MICAL1	0.39	6.7	0.3	6e-11	Height;
LGG	cis	rs2760061	0.598	rs658238	chr1:228121291	A/G	cg02753203	chr1:228287806	NA	-0.63	-11.76	-0.48	4.24e-28	Diastolic blood pressure;
LGG	cis	rs6430585	0.583	rs76097170	chr2:136593498	C/T	cg07169764	chr2:136633963	MCM6	1.27	25.71	0.77	3.22e-91	Corneal structure;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-8.37	-0.36	7.04e-16	Lung cancer;
LGG	cis	rs9303401	0.659	rs34426768	chr17:56683385	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.84e-40	Cognitive test performance;
LGG	cis	rs1003719	0.699	rs1015549	chr21:38448880	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.6e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg09137382	chr11:130731461	NA	0.35	6.71	0.3	5.57e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg14675211	chr2:100938903	LONRF2	0.69	12.48	0.5	5.33e-31	Intelligence (multi-trait analysis);
LGG	cis	rs3813359	0.545	rs17058558	chr6:130553659	C/T	cg23281432	chr6:130554730	NA	0.49	6.85	0.3	2.42e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11245990	chr11:68621969	NA	0.43	9.09	0.39	2.99e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg13009111	chr11:71350975	NA	0.3	6.75	0.3	4.42e-11	Mood instability;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	7.72	0.34	7.41e-14	Schizophrenia;
LGG	cis	rs2839186	0.605	rs2839173	chr21:47676711	G/A	cg12379764	chr21:47803548	PCNT	-0.44	-7.25	-0.32	1.8e-12	Testicular germ cell tumor;
LGG	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs6993813	0.814	rs4617188	chr8:120024764	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.95e-11	Bone mineral density (hip);
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs4743820	0.651	rs10991797	chr9:93930671	A/G	cg14446406	chr9:93919335	NA	0.84	14.25	0.55	1.91e-38	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg09165964	chr15:75287851	SCAMP5	-0.66	-7.58	-0.33	1.88e-13	Lung cancer;
LGG	cis	rs66887589	0.934	rs4834792	chr4:120555696	T/A	cg09307838	chr4:120376055	NA	-0.48	-8.31	-0.36	1.05e-15	Diastolic blood pressure;
LGG	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.07	-0.35	6.11e-15	Neuroticism;
LGG	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.51	-8.24	-0.36	1.72e-15	Blood metabolite levels;
LGG	cis	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs17221829	0.617	rs1844194	chr11:89389367	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs7945705	0.774	rs6486060	chr11:9024630	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.48	9.93	0.42	3.34e-21	Hemoglobin concentration;
LGG	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg06618935	chr21:46677482	NA	-0.34	-6.68	-0.3	6.71e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg05707623	chr12:122985044	ZCCHC8	0.66	10.28	0.43	1.8e-22	Body mass index;
LGG	trans	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs9381107	0.932	rs9394529	chr6:9436737	G/A	cg14735645	chr6:9486422	NA	-0.42	-7.12	-0.31	4.06e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9487051	0.799	rs351725	chr6:109547939	G/A	cg21918786	chr6:109611834	NA	-0.39	-7.05	-0.31	6.7e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.63	-0.54	7.98e-36	Response to antipsychotic treatment;
LGG	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg07615347	chr10:60278583	BICC1	0.63	18.29	0.65	1.25e-56	Refractive error;
LGG	cis	rs787274	0.867	rs786978	chr9:115460239	A/G	cg13803584	chr9:115635662	SNX30	-0.51	-7.32	-0.32	1.13e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs12505749	1.000	rs17756240	chr4:57355192	G/C	cg09583921	chr3:87101925	NA	0.69	6.81	0.3	3.11e-11	Airflow obstruction;
LGG	cis	rs2742417	1.000	rs2742417	chr3:45731451	C/T	cg04837898	chr3:45731254	SACM1L	-0.39	-7.89	-0.34	2.23e-14	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9557207	0.951	rs9585037	chr13:100000840	A/T	cg24509225	chr13:100037070	UBAC2	-0.66	-12.15	-0.49	1.16e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs367943	0.608	rs2914170	chr5:112982616	C/T	cg12552261	chr5:112820674	MCC	-0.51	-8.97	-0.38	7.48e-18	Type 2 diabetes;
LGG	cis	rs12458462	0.892	rs3786228	chr18:77464170	C/T	cg11879182	chr18:77439856	CTDP1	-0.81	-15.2	-0.58	1.34e-42	Monocyte count;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	16.94	0.62	2e-50	Tonsillectomy;
LGG	trans	rs2574985	0.702	rs2983350	chr10:52287848	T/C	cg18558237	chr10:81444220	LOC650623	0.43	6.92	0.31	1.52e-11	Subjective well-being;
LGG	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg05973401	chr12:123451056	ABCB9	0.49	7.52	0.33	2.79e-13	Neutrophil percentage of white cells;
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.75	-12.54	-0.5	3.06e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs977987	0.806	rs4888391	chr16:75400746	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.52e-11	Dupuytren's disease;
LGG	cis	rs910316	0.967	rs35446981	chr14:75637351	A/T	cg11812906	chr14:75593930	NEK9	-0.51	-9.31	-0.4	5.14e-19	Height;
LGG	cis	rs755249	0.567	rs16826069	chr1:39797055	A/G	cg18385671	chr1:39797026	MACF1	0.43	7.28	0.32	1.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg26578617	chr4:90757533	SNCA	0.44	9.05	0.39	4.08e-18	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.42	-7.25	-0.32	1.74e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4595586	0.545	rs12812750	chr12:39363258	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.51	0.44	2.55e-23	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.84	10.48	0.44	3.37e-23	Lung cancer in ever smokers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01130127	chr19:51228821	CLEC11A	0.42	6.79	0.3	3.45e-11	Cognitive performance;
LGG	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg15557168	chr22:42548783	NA	-0.34	-7.44	-0.33	5.02e-13	Cognitive function;
LGG	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg08847533	chr14:75593920	NEK9	0.63	12.06	0.49	2.7e-29	Height;
LGG	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg00409905	chr10:38381863	ZNF37A	0.53	10.51	0.44	2.59e-23	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1670533	1.000	rs6812586	chr4:1069851	A/G	cg27284194	chr4:1044797	NA	0.54	9.87	0.42	5.39e-21	Recombination rate (females);
LGG	cis	rs1505368	1.000	rs1505368	chr2:213297253	G/A	cg16329650	chr2:213403929	ERBB4	0.45	7.64	0.33	1.22e-13	Symmetrical dimethylarginine levels;
LGG	cis	rs2033732	0.706	rs4598249	chr8:85073702	C/T	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.96	-0.42	2.73e-21	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18382590	chr9:131219195	ODF2	0.46	7.03	0.31	7.69e-12	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.58	-0.44	1.41e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs9976767	0.637	rs2277799	chr21:43824123	G/C	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.24	-0.52	3.58e-34	Type 1 diabetes;
LGG	cis	rs2645694	0.626	rs2703121	chr4:77822328	C/G	cg18351406	chr4:77819688	ANKRD56	0.47	8.04	0.35	7.31e-15	Emphysema distribution in smoking;
LGG	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.69	-0.48	7.69e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg25039879	chr17:56429692	SUPT4H1	0.76	10.98	0.45	4.24e-25	Cognitive test performance;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.0	-0.31	9.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg14983838	chr19:29218262	NA	0.71	11.43	0.47	8.31e-27	Methadone dose in opioid dependence;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2297440	0.530	rs34533955	chr20:62233020	A/C	cg16989086	chr20:62203971	PRIC285	0.48	6.97	0.31	1.07e-11	Glioma;Non-glioblastoma glioma;Glioblastoma;
LGG	cis	rs896854	0.654	rs10429443	chr8:95971164	A/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.81	-0.38	2.44e-17	Type 2 diabetes;
LGG	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7312933	0.558	rs11181501	chr12:42822671	G/A	cg19980929	chr12:42632907	YAF2	0.34	7.64	0.33	1.23e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9487094	0.670	rs12192268	chr6:110011458	T/C	cg01125227	chr6:109776195	MICAL1	0.43	7.61	0.33	1.51e-13	Height;
LGG	trans	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg09048205	chr5:1608656	LOC728613	-0.52	-8.45	-0.37	3.82e-16	Breast cancer;
LGG	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.11	0.46	1.42e-25	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	8.65e-26	Alzheimer's disease;
LGG	cis	rs7084402	0.934	rs1658455	chr10:60306089	G/C	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg11859384	chr17:80120422	CCDC57	0.43	7.44	0.33	5.1e-13	Life satisfaction;
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg27121462	chr16:89883253	FANCA	-0.62	-11.49	-0.47	4.52e-27	Vitiligo;
LGG	cis	rs9462027	0.628	rs9469917	chr6:34831369	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.19	-0.46	6.67e-26	Systemic lupus erythematosus;
LGG	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg08610935	chr16:1836813	NUBP2	0.42	6.67	0.3	7.54e-11	Insulin-like growth factors;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.28	0.6	1.99e-47	Lymphocyte counts;
LGG	cis	rs1034435	0.755	rs5767172	chr22:48892314	A/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.98	-0.62	1.28e-50	Late-onset Alzheimer's disease;
LGG	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg21775007	chr8:11205619	TDH	-0.5	-8.1	-0.35	4.97e-15	Triglycerides;
LGG	cis	rs774359	0.789	rs2477520	chr9:27509870	G/A	cg14173147	chr9:27528300	MOBKL2B	0.45	8.64	0.37	9.06e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg15394860	chr11:2017084	H19	0.59	12.57	0.5	2.11e-31	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg02002194	chr4:3960332	NA	-0.4	-7.23	-0.32	1.98e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7188861	0.768	rs423674	chr16:11373405	G/T	cg01510278	chr16:11456238	NA	0.29	7.13	0.31	3.8e-12	HDL cholesterol;
LGG	cis	rs8079658	1.000	rs62065085	chr17:63822828	G/C	cg18091269	chr17:63822838	CCDC46	-0.4	-6.78	-0.3	3.65e-11	Post bronchodilator FEV1;
LGG	cis	rs782590	0.643	rs13009906	chr2:55739434	A/G	cg18811423	chr2:55921094	PNPT1	-0.68	-12.07	-0.49	2.39e-29	Metabolic syndrome;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg27219399	chr15:67835830	MAP2K5	0.31	6.95	0.31	1.28e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9403521	1.000	rs6907410	chr6:143995142	A/G	cg18240653	chr6:144019428	PHACTR2	-0.63	-9.9	-0.42	4.41e-21	Obesity-related traits;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.14	-0.49	1.19e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7582720	1.000	rs72926779	chr2:203805929	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg21972741	chr5:435613	AHRR	0.49	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs17604090	0.793	rs17136535	chr7:29689158	C/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs5758511	0.514	rs5758622	chr22:42563933	C/T	cg15128208	chr22:42549153	NA	0.76	11.44	0.47	7.51e-27	Birth weight;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.65	0.3	8.34e-11	Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19473369	chr15:99190447	NA	0.42	7.04	0.31	7.04e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg10661904	chr17:79619235	PDE6G	-0.41	-8.31	-0.36	1.07e-15	Eye color traits;
LGG	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.54	0.5	2.9e-31	Alzheimer's disease;
LGG	cis	rs2408955	0.522	rs3997	chr12:48481587	T/C	cg24011408	chr12:48396354	COL2A1	-0.6	-9.92	-0.42	3.76e-21	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg21435375	chr2:172878103	MAP1D	0.3	6.85	0.3	2.35e-11	Schizophrenia;
LGG	cis	rs992157	0.764	rs10932774	chr2:219191569	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.56	9.31	0.4	5.31e-19	Colorectal cancer;
LGG	cis	rs440932	1.000	rs378974	chr8:9026639	C/T	cg06636001	chr8:8085503	FLJ10661	0.46	7.73	0.34	6.92e-14	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg11189052	chr15:85197271	WDR73	-0.5	-7.95	-0.35	1.49e-14	P wave terminal force;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07968927	chr13:115080364	ZNF828	-0.39	-6.67	-0.3	7.17e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs4538187	0.826	rs1440002	chr2:64147834	G/A	cg14150252	chr2:64069583	UGP2	-0.41	-8.46	-0.37	3.6e-16	Systolic blood pressure;
LGG	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg25319279	chr11:5960081	NA	-0.57	-8.8	-0.38	2.7e-17	DNA methylation (variation);
LGG	cis	rs12681288	0.550	rs7000482	chr8:958380	T/C	cg08648136	chr8:956695	NA	0.46	10.07	0.42	1.08e-21	Schizophrenia;
LGG	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg13010199	chr12:38710504	ALG10B	0.7	14.68	0.56	2.54e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg18273817	chr1:8936178	ENO1	-0.36	-6.75	-0.3	4.44e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7923837	0.928	rs10882105	chr10:94474111	C/T	cg25093409	chr10:94429542	NA	0.38	6.93	0.31	1.43e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs66716358	0.710	rs10838256	chr11:44321199	T/C	cg16977035	chr11:44330474	ALX4	-0.37	-9.76	-0.41	1.34e-20	Monobrow;
LGG	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg19773385	chr1:10388646	KIF1B	-0.48	-9.76	-0.41	1.36e-20	Hepatocellular carcinoma;
LGG	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs4262150	0.883	rs12186623	chr5:152214254	T/C	cg12297329	chr5:152029980	NA	-0.68	-12.61	-0.51	1.56e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs13314892	0.770	rs56099248	chr3:69857773	C/T	cg17445875	chr3:69859618	MITF	-0.38	-7.11	-0.31	4.49e-12	QRS complex (12-leadsum);
LGG	trans	rs11875185	0.510	rs17754634	chr18:55609307	C/T	cg15513957	chr14:69354734	ACTN1	-0.9	-8.81	-0.38	2.51e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg26384229	chr12:38710491	ALG10B	0.99	23.25	0.73	8.9e-80	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7590368	0.673	rs56140102	chr2:10943256	T/C	cg15705551	chr2:10952987	PDIA6	0.57	7.41	0.33	6e-13	Educational attainment (years of education);
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.33	0.55	7.9e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12493885	0.818	rs73158491	chr3:153764112	T/C	cg17054900	chr3:154042577	DHX36	-0.76	-8.99	-0.39	6.26e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs708547	0.874	rs1614251	chr4:57891386	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.26	0.43	2.11e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs10463554	1.000	rs3776864	chr5:102327868	A/C	cg23492399	chr5:102201601	PAM	-0.55	-8.55	-0.37	1.8e-16	Parkinson's disease;
LGG	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	trans	rs4843747	0.518	rs4072777	chr16:88107030	G/A	cg00711542	chr16:29343894	RUNDC2C	0.4	6.75	0.3	4.45e-11	Menopause (age at onset);
LGG	cis	rs12791968	1.000	rs11038240	chr11:45002878	A/G	cg11846598	chr11:44996168	LOC221122	0.67	12.57	0.5	2.31e-31	Inhibitory control;
LGG	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg26031613	chr14:104095156	KLC1	1.19	29.32	0.81	1.35e-107	Body mass index;
LGG	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.5	-0.37	2.53e-16	Height;
LGG	cis	rs1062746	0.527	rs12934628	chr16:87335161	A/G	cg02258303	chr16:87377426	FBXO31	-0.42	-7.78	-0.34	4.76e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.33e-11	Lung cancer;
LGG	cis	rs920590	0.704	rs6586867	chr8:19653050	A/G	cg03894339	chr8:19674705	INTS10	0.43	7.37	0.32	8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg23533926	chr12:111358616	MYL2	-0.41	-6.7	-0.3	6.03e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg11984989	chr7:158649758	WDR60	0.95	20.87	0.7	1.09e-68	Height;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.58	-0.33	1.88e-13	Skin colour saturation;
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.38	-0.32	7.57e-13	Tonsillectomy;
LGG	cis	rs2075371	0.932	rs2241332	chr7:133969439	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.41	0.44	5.99e-23	Mean platelet volume;
LGG	cis	rs3796352	1.000	rs35849389	chr3:53005235	A/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.63	0.33	1.32e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs3741151	0.892	rs2027761	chr11:73036179	C/T	cg17517138	chr11:73019481	ARHGEF17	0.94	9.91	0.42	4.11e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1048238	0.846	rs945422	chr1:16345619	T/C	cg22431228	chr1:16359049	CLCNKA	-0.52	-9.23	-0.39	1e-18	Systolic blood pressure;
LGG	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04533881	chr14:50583218	C14orf138	0.44	7.41	0.33	6.14e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.65	0.44	7.48e-24	Personality dimensions;
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	12.95	0.52	6.09e-33	Tonsillectomy;
LGG	cis	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg23422044	chr7:1970798	MAD1L1	0.59	10.57	0.44	1.54e-23	Bipolar disorder;
LGG	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.82	0.54	1.35e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4740619	0.935	rs1509310	chr9:15733836	G/A	cg14451791	chr9:16040625	NA	-0.38	-9.86	-0.42	6.01e-21	Body mass index;
LGG	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg06627628	chr2:24431161	ITSN2	-0.67	-10.62	-0.44	1.02e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.18	-0.32	2.72e-12	Bipolar disorder;
LGG	cis	rs12200560	0.505	rs4240555	chr6:97076274	T/C	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg00933542	chr6:150070202	PCMT1	0.38	6.9	0.31	1.75e-11	Lung cancer;
LGG	cis	rs1005224	0.895	rs11624114	chr14:76131800	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-6.96	-0.31	1.19e-11	Large artery stroke;
LGG	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Vitiligo;
LGG	cis	rs3206736	0.548	rs329229	chr7:35054029	T/C	cg13400248	chr7:35225412	NA	0.55	9.4	0.4	2.51e-19	Diastolic blood pressure;
LGG	cis	rs6735179	1.000	rs6735179	chr2:1777150	A/G	cg10160682	chr2:1713001	PXDN	-0.43	-7.24	-0.32	1.86e-12	Response to antipsychotic treatment;
LGG	cis	rs1031391	0.716	rs10772416	chr12:11170087	T/A	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	0.72	11.32	0.47	2.18e-26	Bitter taste perception;
LGG	cis	rs7572733	0.901	rs700689	chr2:198726649	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.59e-16	Dermatomyositis;
LGG	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.69	-0.41	2.36e-20	Diabetic retinopathy;
LGG	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg16405210	chr4:1374714	KIAA1530	0.48	8.12	0.35	4.36e-15	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs7582720	0.945	rs72932723	chr2:203647646	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.35	0.4	3.9e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4330281	0.967	rs2033379	chr3:17851238	A/G	cg20981856	chr3:17787350	NA	-0.36	-6.65	-0.3	8.4e-11	Schizophrenia;
LGG	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg16208657	chr15:68119293	LBXCOR1	0.35	7.08	0.31	5.53e-12	Motion sickness;
LGG	cis	rs28595532	1.000	rs56000725	chr4:119637675	G/A	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg18876405	chr7:65276391	NA	-0.67	-12.78	-0.51	2.99e-32	Corneal structure;
LGG	cis	rs2133450	0.712	rs1546235	chr3:7366864	T/A	cg19930620	chr3:7340148	GRM7	-0.37	-7.99	-0.35	1.1e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.67	-0.3	7.17e-11	Mean platelet volume;
LGG	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg06453172	chr10:134556979	INPP5A	-0.55	-8.19	-0.36	2.54e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg05425664	chr17:57184151	TRIM37	-0.71	-11.65	-0.48	1.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.505	rs12214254	chr6:161195932	C/A	cg01280913	chr6:161186852	NA	-0.51	-10.52	-0.44	2.44e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-12.18	-0.49	8.69e-30	Parkinson's disease;
LGG	trans	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg25482853	chr8:67687455	SGK3	1.03	13.32	0.53	1.62e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs503734	0.666	rs56075912	chr3:101135719	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs7975161	0.882	rs4406890	chr12:104638773	A/C	cg25273343	chr12:104657179	TXNRD1	-0.72	-9.69	-0.41	2.37e-20	Toenail selenium levels;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs56042726	chr4:119751777	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18538332	chr22:24372958	LOC391322	0.44	7.19	0.32	2.63e-12	Cognitive performance;
LGG	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg16414030	chr3:133502952	NA	0.6	10.48	0.44	3.22e-23	Iron status biomarkers;
LGG	cis	rs7077164	1.000	rs1227776	chr10:71580893	G/A	cg20696214	chr10:71583771	COL13A1	-0.4	-7.76	-0.34	5.42e-14	Non-alcoholic fatty liver disease histology (lobular);
LGG	trans	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.27	0.5	3.79e-30	Type 2 diabetes;
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-9.79	-0.41	1.05e-20	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2072499	0.966	rs887953	chr1:156191149	T/C	cg24450063	chr1:156163899	SLC25A44	1.17	25.96	0.77	2.37e-92	Testicular germ cell tumor;
LGG	trans	rs1814175	0.645	rs847635	chr11:49923323	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07132326	chr6:150258058	NA	0.38	8.08	0.35	5.59e-15	Testicular germ cell tumor;
LGG	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.38	-0.43	7.53e-23	Triglycerides;
LGG	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg14500267	chr11:67383377	NA	-0.41	-7.49	-0.33	3.45e-13	Mean corpuscular volume;
LGG	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg18351406	chr4:77819688	ANKRD56	0.46	7.99	0.35	1.05e-14	Emphysema distribution in smoking;
LGG	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg01043669	chr3:72786069	NA	0.39	6.85	0.3	2.4e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg07541023	chr7:19748670	TWISTNB	0.46	7.26	0.32	1.66e-12	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08219700	chr8:58056026	NA	0.56	12.39	0.5	1.17e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17539620	0.534	rs6557363	chr6:154827813	A/G	cg17771515	chr6:154831774	CNKSR3	0.57	8.04	0.35	7.32e-15	Lipoprotein (a) levels;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.42	0.4	2.07e-19	Renal function-related traits (BUN);
LGG	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg03060546	chr3:49711283	APEH	-0.54	-7.13	-0.31	3.83e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7084402	0.967	rs1658481	chr10:60289339	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.37	-0.32	7.68e-13	Refractive error;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg15269541	chr15:43626905	ADAL	-0.43	-6.83	-0.3	2.65e-11	Lung cancer in ever smokers;
LGG	cis	rs6815814	0.861	rs6531663	chr4:38792340	T/C	cg06935464	chr4:38784597	TLR10	0.54	8.73	0.38	4.74e-17	Breast cancer;
LGG	cis	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg12395012	chr8:11607386	GATA4	0.42	7.62	0.33	1.42e-13	Monocyte count;
LGG	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg17150306	chr7:855575	UNC84A	-0.34	-7.0	-0.31	9.11e-12	Perceived unattractiveness to mosquitoes;
LGG	cis	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs2213920	0.679	rs6415820	chr9:118231832	A/C	cg13918206	chr9:118159781	DEC1	0.54	7.31	0.32	1.18e-12	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs35306767	0.579	rs7091502	chr10:1154979	C/T	cg25019033	chr10:957182	NA	-0.48	-8.23	-0.36	1.97e-15	Eosinophil percentage of granulocytes;
LGG	trans	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.69e-12	Retinal vascular caliber;
LGG	cis	rs963731	0.579	rs963730	chr2:39216773	T/C	cg04010122	chr2:39346883	SOS1	-0.66	-6.88	-0.3	2e-11	Corticobasal degeneration;
LGG	trans	rs7404843	0.704	rs112251447	chr16:15521872	G/A	cg02716450	chr16:28638775	NA	0.72	7.32	0.32	1.13e-12	Testicular germ cell tumor;
LGG	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg00857998	chr1:205179979	DSTYK	0.56	8.98	0.38	7.09e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.35e-16	Life satisfaction;
LGG	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg11247378	chr22:39784982	NA	-0.29	-8.34	-0.36	8.79e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.24e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2479106	0.892	rs2109921	chr9:126701651	G/A	cg16191174	chr9:126692580	DENND1A	0.48	7.22	0.32	2.19e-12	Polycystic ovary syndrome;
LGG	cis	rs17001868	0.568	rs6001894	chr22:40779197	T/C	cg07138101	chr22:40742427	ADSL	0.7	9.16	0.39	1.7e-18	Mammographic density (dense area);
LGG	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.26	0.4	7.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17453880	0.929	rs4537047	chr5:151953565	A/G	cg12297329	chr5:152029980	NA	-0.86	-21.92	-0.71	1.35e-73	Subjective well-being;
LGG	cis	rs1010254	0.510	rs72806389	chr5:151704933	T/C	cg12297329	chr5:152029980	NA	-0.48	-6.96	-0.31	1.14e-11	Optic nerve measurement (cup area);
LGG	cis	rs5758659	1.000	rs5758660	chr22:42623718	C/A	cg15557168	chr22:42548783	NA	-0.4	-8.86	-0.38	1.76e-17	Cognitive function;
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05197191	chr6:15246420	JARID2	0.38	6.68	0.3	7.03e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg18252515	chr7:66147081	NA	-1.4	-19.23	-0.67	5.22e-61	Diabetic kidney disease;
LGG	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg02227867	chr8:22457446	C8orf58	-0.41	-7.24	-0.32	1.82e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg16141378	chr3:129829833	LOC729375	0.39	8.86	0.38	1.78e-17	Triglycerides;
LGG	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg03162506	chr22:38580953	NA	0.31	7.36	0.32	8.71e-13	Cutaneous nevi;
LGG	cis	rs7580658	0.680	rs2069931	chr2:128185569	C/T	cg10021288	chr2:128175891	PROC	-0.69	-14.42	-0.56	3.22e-39	Protein C levels;
LGG	cis	rs9300255	0.602	rs1790126	chr12:123683563	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Neutrophil percentage of white cells;
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs6558174	0.863	rs17746902	chr8:22491980	A/C	cg03733263	chr8:22462867	KIAA1967	-0.62	-10.83	-0.45	1.62e-24	Breast cancer;
LGG	cis	rs7586879	0.828	rs7597157	chr2:25089166	C/T	cg04586622	chr2:25135609	ADCY3	0.35	8.49	0.37	2.83e-16	Body mass index;
LGG	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg11812906	chr14:75593930	NEK9	-0.45	-8.15	-0.35	3.38e-15	Height;
LGG	cis	rs6918586	0.658	rs198803	chr6:26135052	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.64	-0.41	3.56e-20	Schizophrenia;
LGG	cis	rs7193541	0.550	rs76881401	chr16:74634309	G/A	cg01733217	chr16:74700730	RFWD3	0.73	12.28	0.5	3.44e-30	Multiple myeloma;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg15704280	chr7:45808275	SEPT13	-0.68	-8.49	-0.37	2.8e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.26	0.32	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-15.53	-0.59	4.42e-44	Colorectal cancer;
LGG	trans	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.81	0.3	3.12e-11	Retinal vascular caliber;
LGG	cis	rs10791097	0.694	rs3190331	chr11:130748131	C/T	cg09137382	chr11:130731461	NA	-0.36	-6.91	-0.31	1.64e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.4	-0.4	2.53e-19	Aortic root size;
LGG	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg25358565	chr5:93447407	FAM172A	-0.64	-9.33	-0.4	4.44e-19	Diabetic retinopathy;
LGG	cis	rs9581857	0.556	rs1885991	chr13:28040470	G/A	cg01674679	chr13:27998804	GTF3A	-0.59	-8.08	-0.35	5.52e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg17971929	chr21:40555470	PSMG1	0.86	16.39	0.61	5.99e-48	Cognitive function;
LGG	cis	rs1801251	1.000	rs991873	chr2:233711046	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.03	-0.39	4.83e-18	Coronary artery disease;
LGG	cis	rs2371030	0.833	rs2371027	chr2:211566074	T/C	cg18417063	chr2:211583084	NA	-0.57	-10.65	-0.44	7.91e-24	Non-small cell lung cancer;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.43	0.44	5.08e-23	Prudent dietary pattern;
LGG	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg27411982	chr8:10470053	RP1L1	-0.39	-6.68	-0.3	6.86e-11	Mood instability;
LGG	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.82	-10.0	-0.42	1.88e-21	Schizophrenia;
LGG	cis	rs4936894	0.500	rs10790667	chr11:124179450	A/G	cg27160556	chr11:124181099	OR8D1	-0.46	-10.58	-0.44	1.43e-23	Aging (time to death);
LGG	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg19748678	chr4:122722346	EXOSC9	0.65	13.32	0.53	1.75e-34	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs55689507	chr17:37404436	G/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.62	-0.59	1.74e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs7614311	0.636	rs67944903	chr3:63871195	A/T	cg22134162	chr3:63841271	THOC7	-0.4	-7.6	-0.33	1.63e-13	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.47	0.56	2.11e-39	Lung cancer;
LGG	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg11878867	chr6:150167359	LRP11	-0.49	-9.99	-0.42	2.04e-21	Lung cancer;
LGG	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg17788362	chr6:86352627	SYNCRIP	0.54	9.46	0.4	1.52e-19	Smooth-surface caries;
LGG	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg07537917	chr2:241836409	C2orf54	-0.4	-7.73	-0.34	6.71e-14	Urinary metabolites;
LGG	cis	rs9400467	0.506	rs75819068	chr6:111722487	A/C	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.71	0.3	5.56e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs3857536	0.730	rs2214126	chr6:66969162	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.06	-0.31	5.94e-12	Blood trace element (Cu levels);
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg13395646	chr4:1353034	KIAA1530	-0.43	-7.44	-0.33	5.04e-13	Longevity;
LGG	cis	rs668210	0.643	rs549334	chr11:65774659	C/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.74	9.91	0.42	4.04e-21	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2120019	1.000	rs12898259	chr15:75369780	G/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.59	-0.67	1.16e-62	Blood trace element (Zn levels);
LGG	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg02985541	chr2:219472218	PLCD4	0.28	6.69	0.3	6.5500000000000006e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3784262	0.654	rs4646568	chr15:58344290	A/G	cg12031962	chr15:58353849	ALDH1A2	0.37	7.58	0.33	1.95e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11018874	0.597	rs10765243	chr11:89855118	C/G	cg14505434	chr11:89522851	NA	0.65	9.27	0.4	7.14e-19	White blood cell types;
LGG	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.16	-0.43	5.07e-22	Glycated hemoglobin levels;
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg16606324	chr3:10149918	C3orf24	0.54	7.19	0.32	2.62e-12	Alzheimer's disease;
LGG	cis	rs2040771	0.711	rs361639	chr22:19268024	A/G	cg02655711	chr22:19163373	SLC25A1	0.46	8.02	0.35	8.82e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs6732160	0.525	rs2303907	chr2:73470497	T/C	cg01422370	chr2:73384389	NA	0.48	9.04	0.39	4.45e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs1010254	0.510	rs72806402	chr5:151712525	C/A	cg12297329	chr5:152029980	NA	-0.5	-7.2	-0.32	2.37e-12	Optic nerve measurement (cup area);
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.88	-0.34	2.42e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2455799	0.613	rs2470549	chr3:15737698	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.8	-0.34	4e-14	Mean platelet volume;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.0	0.68	1.29e-64	Alzheimer's disease;
LGG	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg23205692	chr1:25664452	TMEM50A	0.48	10.08	0.42	9.88e-22	Erythrocyte sedimentation rate;
LGG	cis	rs4740619	0.689	rs10738419	chr9:15956824	C/G	cg14451791	chr9:16040625	NA	-0.37	-9.41	-0.4	2.38e-19	Body mass index;
LGG	cis	rs4919694	1.000	rs77318450	chr10:104733098	A/G	cg04362960	chr10:104952993	NT5C2	1.03	13.23	0.52	3.9e-34	Arsenic metabolism;
LGG	cis	rs12369179	0.737	rs116896792	chr12:122948907	T/C	cg18578876	chr12:123200353	GPR109B	-1.13	-10.41	-0.44	5.88e-23	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LGG	cis	rs2898857	0.504	rs35822701	chr17:47422317	C/T	cg08112188	chr17:47440006	ZNF652	-0.41	-6.71	-0.3	5.54e-11	Cancer;
LGG	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.04	-0.39	4.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9926296	0.581	rs12598477	chr16:89902482	T/C	cg23057051	chr16:89984268	MC1R	-0.37	-7.25	-0.32	1.72e-12	Vitiligo;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg13480157	chr3:169780315	GPR160	-0.48	-6.69	-0.3	6.48e-11	QT interval;
LGG	cis	rs7586879	0.789	rs36029941	chr2:25127801	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01668174	chr2:106810661	UXS1	0.47	6.88	0.3	1.98e-11	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.671	rs17163751	chr1:26568698	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.17e-15	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg20215148	chr11:69357396	NA	0.35	7.09	0.31	5.15e-12	Electrocardiographic conduction measures;
LGG	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg13902645	chr11:5959945	NA	0.66	11.15	0.46	9.48e-26	DNA methylation (variation);
LGG	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7444	0.882	rs5754217	chr22:21939675	G/T	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.84	-0.3	2.57e-11	Personality dimensions;
LGG	cis	rs3617	0.539	rs12629687	chr3:52950659	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-7.6	-0.33	1.65e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs12643440	0.538	rs10489117	chr4:17145568	G/T	cg22650099	chr4:17144496	NA	-0.51	-8.76	-0.38	3.65e-17	Metabolite levels (Pyroglutamine);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01142353	chr4:1675595	FAM53A	0.33	6.75	0.3	4.35e-11	Electrocardiographic conduction measures;
LGG	cis	rs2188561	0.638	rs28690459	chr7:107380703	C/A	cg16793755	chr7:107334138	SLC26A4	0.41	7.32	0.32	1.07e-12	Alcohol consumption;
LGG	cis	rs3771570	1.000	rs62193204	chr2:242315443	A/G	cg21155796	chr2:242212141	HDLBP	0.74	9.75	0.41	1.46e-20	Prostate cancer;
LGG	cis	rs9486715	0.867	rs9486444	chr6:96963619	A/G	cg18709589	chr6:96969512	KIAA0776	0.41	8.2	0.36	2.3e-15	Headache;
LGG	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg21427119	chr20:30132790	HM13	-0.58	-9.0	-0.39	5.68e-18	Mean corpuscular hemoglobin;
LGG	cis	rs787274	1.000	rs813101	chr9:115532907	C/G	cg13803584	chr9:115635662	SNX30	-0.55	-7.76	-0.34	5.51e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg04287289	chr16:89883240	FANCA	0.6	6.8	0.3	3.24e-11	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs2562152	0.706	rs216596	chr16:105320	A/G	cg02949481	chr16:131562	MPG	0.56	8.29	0.36	1.28e-15	Glioblastoma;
LGG	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg18681998	chr4:17616180	MED28	0.78	15.67	0.59	1.01e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	10.41	0.44	5.94e-23	Erythrocyte sedimentation rate;
LGG	trans	rs656319	0.605	rs17747335	chr8:10003186	A/T	cg12395012	chr8:11607386	GATA4	0.4	7.18	0.32	2.75e-12	Myopia (pathological);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs10927875	0.631	rs28579893	chr1:16347534	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-7.39	-0.32	6.92e-13	Dilated cardiomyopathy;
LGG	cis	rs7584330	0.955	rs7581882	chr2:238390745	T/C	cg16989719	chr2:238392110	NA	-0.35	-7.64	-0.33	1.28e-13	Prostate cancer;
LGG	cis	rs760805	1.000	rs4648884	chr1:25261386	C/T	cg03961551	chr1:25251730	RUNX3	-0.45	-11.67	-0.48	9.53e-28	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg13232821	chr7:50628718	DDC	-0.39	-7.9	-0.34	2.11e-14	Malaria;
LGG	cis	rs4481887	0.927	rs7534188	chr1:248434303	C/T	cg01631408	chr1:248437212	OR2T33	0.5	8.81	0.38	2.52e-17	Common traits (Other);
LGG	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg15017067	chr4:17643749	FAM184B	-0.3	-6.83	-0.3	2.62e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg12560992	chr17:57184187	TRIM37	0.53	8.57	0.37	1.58e-16	Testicular germ cell tumor;
LGG	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg00666640	chr1:248458726	OR2T12	0.54	8.75	0.38	3.92e-17	Common traits (Other);
LGG	cis	rs2735413	0.914	rs11150035	chr16:78066449	G/C	cg04733911	chr16:78082701	NA	-0.76	-17.33	-0.63	3.05e-52	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6429082	0.713	rs867363	chr1:235579727	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	cis	rs2077654	0.556	rs4148624	chr11:17444024	A/G	cg25308976	chr11:17434268	ABCC8	0.54	7.02	0.31	7.82e-12	Gout;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06780358	chr11:48003065	PTPRJ	0.5	7.31	0.32	1.21e-12	Gut microbiome composition (summer);
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.07	0.46	1.96e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504130	0.569	rs16916966	chr8:52843329	C/A	cg24946253	chr8:52722146	PXDNL	-0.51	-8.08	-0.35	5.59e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11252926	0.510	rs4881371	chr10:554514	G/A	cg08603382	chr10:743973	NA	0.38	7.08	0.31	5.47e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs9443645	0.901	rs1027813	chr6:79552118	G/T	cg18132916	chr6:79620363	NA	0.31	8.71	0.38	5.34e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.28	-0.36	1.32e-15	Lymphocyte counts;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg03188948	chr7:1209495	NA	0.65	8.54	0.37	1.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.52	0.47	3.49e-27	Mean platelet volume;
LGG	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.74	-0.45	3.55e-24	Hemoglobin concentration;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs7940866	0.838	rs12790299	chr11:130803634	A/G	cg12179176	chr11:130786555	SNX19	0.77	14.78	0.57	8.9e-41	Schizophrenia;
LGG	trans	rs9818758	0.607	rs11706189	chr3:49210833	C/A	cg21659725	chr3:3221576	CRBN	-0.65	-7.04	-0.31	7.19e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.83	-0.38	2.15e-17	Lung cancer;
LGG	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.62	-0.41	4.37e-20	Aortic root size;
LGG	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg23625390	chr15:77176239	SCAPER	-0.61	-12.13	-0.49	1.37e-29	Blood metabolite levels;
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg19223190	chr17:80058835	NA	0.47	8.74	0.38	4.41e-17	Life satisfaction;
LGG	cis	rs8095374	1.000	rs8089153	chr18:43769305	A/G	cg26436583	chr18:43649176	PSTPIP2	0.39	8.4	0.36	5.46e-16	Clinical laboratory measurements;
LGG	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.37e-14	Height;
LGG	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg02733842	chr7:1102375	C7orf50	-0.44	-7.29	-0.32	1.38e-12	Bronchopulmonary dysplasia;
LGG	cis	rs9902453	0.904	rs11080115	chr17:28408070	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.68	-0.54	5.25e-36	Coffee consumption (cups per day);
LGG	cis	rs722599	0.683	rs8011071	chr14:75286705	T/C	cg06637938	chr14:75390232	RPS6KL1	0.55	9.02	0.39	5.09e-18	IgG glycosylation;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.9	-0.45	9.06e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.53e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2658782	0.547	rs3133454	chr11:93059019	A/C	cg15737290	chr11:93063684	CCDC67	0.67	11.12	0.46	1.23e-25	Pulmonary function decline;
LGG	cis	rs72960926	1.000	rs16884733	chr6:75064563	A/G	cg03266952	chr6:74778945	NA	-0.69	-6.92	-0.31	1.54e-11	Metabolite levels (MHPG);
LGG	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg25664220	chr3:72788482	NA	-0.29	-8.55	-0.37	1.86e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg04287289	chr16:89883240	FANCA	0.77	8.42	0.36	4.58e-16	Skin colour saturation;
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.46e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg05082376	chr22:42548792	NA	0.37	7.73	0.34	6.9e-14	Schizophrenia;
LGG	cis	rs763121	0.853	rs5757211	chr22:39051705	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.68	0.63	7.87e-54	Menopause (age at onset);
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg24642844	chr7:1081250	C7orf50	-0.84	-14.03	-0.55	1.64e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.79	-0.41	1.04e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.34	-0.36	8.38e-16	Aortic root size;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg03528353	chr17:61819722	STRADA	-0.44	-7.48	-0.33	3.86e-13	Prudent dietary pattern;
LGG	cis	rs896854	0.812	rs2340586	chr8:95969261	G/A	cg13393036	chr8:95962371	TP53INP1	-0.25	-6.85	-0.3	2.31e-11	Type 2 diabetes;
LGG	cis	rs3791556	0.853	rs56122162	chr2:240131281	T/C	cg21996813	chr2:240149575	HDAC4	-0.58	-7.1	-0.31	4.75e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs75804782	0.641	rs72987327	chr2:239359833	T/G	cg18131467	chr2:239335373	ASB1	-0.67	-6.74	-0.3	4.78e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg18351406	chr4:77819688	ANKRD56	-0.45	-8.0	-0.35	9.82e-15	Emphysema distribution in smoking;
LGG	cis	rs6963495	0.818	rs73190155	chr7:105153535	T/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg12813108	chr7:99719912	CNPY4	-0.63	-10.18	-0.43	4.28e-22	Lung function (FEV1/FVC);
LGG	cis	rs196889	0.611	rs1059111	chr8:24810088	T/A	cg25352397	chr8:24800883	NA	0.48	7.0	0.31	8.79e-12	Seasonality;
LGG	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-17.45	-0.63	8.79e-53	Vitiligo;
LGG	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg06238570	chr21:40685208	BRWD1	0.43	6.73	0.3	5.15e-11	Cognitive function;
LGG	cis	rs990171	0.770	rs6543116	chr2:102927726	A/G	cg05295703	chr2:102895712	NA	-0.64	-11.74	-0.48	4.91e-28	Lymphocyte counts;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg23758822	chr17:41437982	NA	0.87	15.55	0.59	3.72e-44	Menopause (age at onset);
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg24503407	chr1:205819492	PM20D1	0.82	19.74	0.68	2.15e-63	Menarche (age at onset);
LGG	cis	rs77106637	0.858	rs117819392	chr11:72514503	C/T	cg03713592	chr11:72463424	ARAP1	0.39	7.3	0.32	1.3e-12	Type 2 diabetes;
LGG	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg13939156	chr17:80058883	NA	0.41	7.31	0.32	1.21e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg19455335	chr8:22457658	C8orf58	-0.39	-8.05	-0.35	7.14e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9581857	0.579	rs77187836	chr13:27998646	C/A	cg01674679	chr13:27998804	GTF3A	-0.76	-8.86	-0.38	1.76e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs240764	0.658	rs3811078	chr6:101247503	T/C	cg21058520	chr6:100914733	NA	0.38	6.68	0.3	6.68e-11	Neuroticism;
LGG	cis	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg07460842	chr6:66804631	NA	-0.97	-17.78	-0.64	2.73e-54	Exhaled nitric oxide output;
LGG	cis	rs8060686	0.545	rs7199878	chr16:68186301	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs853679	0.546	rs2232429	chr6:28359632	T/G	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-9.18	-0.39	1.45e-18	Diabetic retinopathy;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg19147804	chr7:1989927	MAD1L1	-0.64	-12.85	-0.51	1.54e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg02811702	chr13:24901961	NA	0.42	7.93	0.35	1.71e-14	Obesity-related traits;
LGG	cis	rs7444	0.882	rs5998644	chr22:21953288	T/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.99	-0.35	1.06e-14	Systemic lupus erythematosus;
LGG	cis	rs990171	1.000	rs2110735	chr2:103050925	A/G	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs9534288	0.577	rs7999168	chr13:46680264	A/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.09	-0.55	9.06e-38	Blood protein levels;
LGG	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.49e-24	Aortic root size;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.55	-0.37	1.77e-16	Mood instability;
LGG	cis	rs3806843	0.735	rs809635	chr5:140081791	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.82	-0.48	2.26e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.56	10.21	0.43	3.34e-22	Longevity;
LGG	trans	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg06521331	chr12:34319734	NA	-0.43	-7.63	-0.33	1.36e-13	Morning vs. evening chronotype;
LGG	cis	rs12431410	1.000	rs12431410	chr14:60166022	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.15	0.32	3.34e-12	Schizophrenia;
LGG	cis	rs13191362	1.000	rs73035023	chr6:163000927	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.76	8.39	0.36	5.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg19468946	chr17:37922297	IKZF3	-0.44	-7.77	-0.34	5.24e-14	Self-reported allergy;
LGG	trans	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg11441553	chr12:57614120	NXPH4	-0.6	-7.47	-0.33	4.15e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.44	9.07	0.39	3.36e-18	Schizophrenia;
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.961	rs11153177	chr6:109737428	A/G	cg16315928	chr6:109776240	MICAL1	0.55	9.33	0.4	4.33e-19	Height;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs7552404	0.731	rs11161836	chr1:76354333	C/T	cg10523679	chr1:76189770	ACADM	0.74	11.03	0.46	2.88e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18652941	chr11:35160892	CD44	0.5	7.57	0.33	2.09e-13	Gut microbiome composition (summer);
LGG	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22496380	chr5:211416	CCDC127	1.15	16.19	0.6	4.65e-47	Breast cancer;
LGG	cis	rs868036	0.681	rs4776981	chr15:68109474	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.04	-0.35	7.62e-15	Restless legs syndrome;
LGG	cis	rs9403521	1.000	rs12528456	chr6:144003706	A/G	cg18240653	chr6:144019428	PHACTR2	-0.65	-10.14	-0.43	5.85e-22	Obesity-related traits;
LGG	cis	rs7617773	0.779	rs1045482	chr3:48312229	A/G	cg11946769	chr3:48343235	NME6	0.59	9.85	0.42	6.67e-21	Coronary artery disease;
LGG	cis	rs6694672	1.000	rs857021	chr1:197007479	A/G	cg13682187	chr1:196946512	CFHR5	0.51	6.9	0.31	1.76e-11	Asthma;
LGG	cis	rs7267979	1.000	rs6050555	chr20:25328543	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.12	-0.43	7.26e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg02733842	chr7:1102375	C7orf50	-0.49	-7.96	-0.35	1.32e-14	Bronchopulmonary dysplasia;
LGG	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.8	-0.34	4.22e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs4740619	0.846	rs11792937	chr9:15638678	A/T	cg14451791	chr9:16040625	NA	0.35	8.81	0.38	2.49e-17	Body mass index;
LGG	cis	rs11700980	0.551	rs57066619	chr21:30118948	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.69	-0.3	6.66e-11	QRS complex (12-leadsum);
LGG	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-9.57	-0.41	6.27e-20	Erythrocyte sedimentation rate;
LGG	cis	rs274567	0.599	rs11242110	chr5:131743777	A/C	cg07395648	chr5:131743802	NA	0.72	19.19	0.67	8.44e-61	Blood metabolite levels;
LGG	cis	rs9463078	0.874	rs2093903	chr6:45177482	A/C	cg25276700	chr6:44698697	NA	-0.39	-8.05	-0.35	6.98e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.31	0.36	1.03e-15	Lung cancer;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg13880726	chr7:1868755	MAD1L1	0.4	7.18	0.32	2.73e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg11473876	chr11:109292803	C11orf87	0.48	9.43	0.4	2.06e-19	Schizophrenia;
LGG	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg11040518	chr10:102331378	NA	-0.4	-7.07	-0.31	5.64e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg11812906	chr14:75593930	NEK9	0.53	9.96	0.42	2.64e-21	Height;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg05335186	chr13:53173507	NA	0.44	9.02	0.39	5.14e-18	Lewy body disease;
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs981844	0.775	rs17371545	chr4:154763980	A/G	cg14289246	chr4:154710475	SFRP2	-0.68	-11.4	-0.47	1.04e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16405210	chr4:1374714	KIAA1530	-0.61	-10.99	-0.45	4.05e-25	Longevity;
LGG	cis	rs340874	0.703	rs340835	chr1:214163675	C/T	cg00795024	chr1:214157026	NA	-0.28	-7.62	-0.33	1.4e-13	Type 2 diabetes;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;Fasting blood glucose;
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.91	-0.42	3.89e-21	Systolic blood pressure;
LGG	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	cis	rs13102973	0.931	rs13128765	chr4:135888141	A/G	cg14419869	chr4:135874104	NA	0.56	10.67	0.44	6.68e-24	Subjective well-being;
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg04287289	chr16:89883240	FANCA	0.61	6.93	0.31	1.43e-11	Skin colour saturation;
LGG	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg15596359	chr8:11213517	TDH	-0.4	-8.18	-0.36	2.71e-15	Retinal vascular caliber;
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg23958373	chr8:599963	NA	1.0	10.15	0.43	5.27e-22	IgG glycosylation;
LGG	trans	rs9929218	0.911	rs4783686	chr16:68834156	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.41	-0.5	1e-30	Colorectal cancer;
LGG	cis	rs774359	0.744	rs700782	chr9:27526047	C/T	cg14173147	chr9:27528300	MOBKL2B	0.44	8.48	0.37	2.95e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs1707322	0.752	rs7529699	chr1:46134634	C/T	cg03146154	chr1:46216737	IPP	0.55	10.71	0.45	4.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.02e-30	Corneal astigmatism;
LGG	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg19680485	chr15:31195859	MTMR15	-0.46	-7.49	-0.33	3.55e-13	Huntington's disease progression;
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg16606324	chr3:10149918	C3orf24	0.59	6.73	0.3	4.88e-11	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg26174226	chr8:58114915	NA	-0.6	-8.24	-0.36	1.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs8077889	0.871	rs16940243	chr17:41900003	C/G	cg26893861	chr17:41843967	DUSP3	0.9	15.76	0.59	4.08e-45	Triglycerides;
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg11878867	chr6:150167359	LRP11	-0.49	-10.39	-0.43	7.14e-23	Lung cancer;
LGG	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg02503808	chr4:7069936	GRPEL1	0.42	6.97	0.31	1.08e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg04911050	chr16:677664	RAB40C	0.34	6.86	0.3	2.22e-11	Height;
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg18032289	chr17:61959525	GH2	-0.42	-7.06	-0.31	5.97e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg11166453	chr1:247681781	NA	-0.64	-10.25	-0.43	2.37e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17767392	0.670	rs59697713	chr14:71729257	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.12	-0.35	4.32e-15	Mitral valve prolapse;
LGG	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg01017244	chr2:74357527	NA	0.49	9.23	0.39	9.47e-19	Gestational age at birth (maternal effect);
LGG	cis	rs2018055	0.827	rs13218378	chr6:117791110	T/C	cg14611402	chr6:117803162	DCBLD1	0.32	8.95	0.38	8.81e-18	Diastolic blood pressure;
LGG	cis	rs10991814	0.920	rs61021072	chr9:94038021	T/C	cg14446406	chr9:93919335	NA	-0.72	-8.12	-0.35	4.4e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.53	-0.41	8.71e-20	Menopause (age at onset);
LGG	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg09085632	chr11:111637200	PPP2R1B	1.04	22.11	0.72	1.75e-74	Primary sclerosing cholangitis;
LGG	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg01448562	chr3:133502909	NA	-0.8	-15.5	-0.58	6.15e-44	Iron status biomarkers;
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.84	0.38	2.06e-17	Platelet count;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs1620921	0.505	rs1965092	chr6:161204889	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg20587970	chr11:113659929	NA	-0.75	-11.9	-0.48	1.11e-28	Hip circumference adjusted for BMI;
LGG	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg07777115	chr5:623756	CEP72	-0.54	-6.89	-0.31	1.78e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12756686	chr19:29218302	NA	0.71	11.52	0.47	3.52e-27	Methadone dose in opioid dependence;
LGG	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.95	-0.31	1.27e-11	Caffeine consumption;
LGG	cis	rs8062405	0.754	rs62034323	chr16:28536473	C/T	cg16576597	chr16:28551801	NUPR1	0.37	8.61	0.37	1.14e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs921968	0.541	rs3845835	chr2:219342284	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1318772	1.000	rs34361144	chr5:112734005	C/T	cg12552261	chr5:112820674	MCC	0.7	7.99	0.35	1.11e-14	F-cell distribution;
LGG	trans	rs458649	0.947	rs457961	chr5:4277869	A/G	cg19819135	chr1:70710422	SFRS11	0.43	6.79	0.3	3.47e-11	Endometriosis;
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg07061783	chr6:25882402	NA	-0.61	-10.66	-0.44	7.39e-24	Urate levels;
LGG	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.66	14.92	0.57	2.14e-41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10979	0.965	rs9376759	chr6:143886959	G/A	cg25407410	chr6:143891975	LOC285740	-0.69	-11.87	-0.48	1.52e-28	Hypospadias;
LGG	cis	rs9473924	0.542	rs9473954	chr6:50928547	G/A	cg14470998	chr6:50812995	TFAP2B	0.65	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg14893161	chr1:205819251	PM20D1	-0.43	-7.11	-0.31	4.47e-12	Menarche (age at onset);
LGG	cis	rs12493885	0.818	rs55681005	chr3:153759257	G/T	cg12800244	chr3:153838788	SGEF	-0.82	-8.95	-0.38	8.88e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg26150922	chr2:100937072	LONRF2	-0.49	-8.83	-0.38	2.25e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.33	0.4	4.38e-19	Alzheimer's disease;
LGG	cis	rs9583531	0.600	rs3809344	chr13:111358705	G/A	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	cis	rs701145	0.878	rs355760	chr3:154009933	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs4319547	0.656	rs1553179	chr12:122831073	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.98	-0.42	2.19e-21	Body mass index;
LGG	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg03433033	chr1:76189801	ACADM	-0.44	-6.96	-0.31	1.2e-11	Daytime sleep phenotypes;
LGG	cis	rs6032067	0.641	rs35882692	chr20:43763968	T/C	cg10761708	chr20:43804764	PI3	0.72	10.51	0.44	2.5e-23	Blood protein levels;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.34	-0.63	2.8e-52	Skin colour saturation;
LGG	cis	rs7769051	0.711	rs7770081	chr6:133089569	G/T	cg22852734	chr6:133119734	C6orf192	1.18	15.04	0.57	6.21e-42	Type 2 diabetes nephropathy;
LGG	cis	rs78487399	0.808	rs1388387	chr2:43736969	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9534288	0.797	rs2896951	chr13:46581185	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg16077055	chr2:106428750	NCK2	0.28	7.36	0.32	8.62e-13	Addiction;
LGG	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg22437258	chr11:111473054	SIK2	0.57	10.08	0.42	9.78e-22	Primary sclerosing cholangitis;
LGG	cis	rs9831754	0.856	rs9824624	chr3:78407182	G/A	cg06138941	chr3:78371609	NA	-0.87	-17.6	-0.63	1.87e-53	Calcium levels;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg04369109	chr6:150039330	LATS1	-0.44	-7.32	-0.32	1.13e-12	Lung cancer;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg13206674	chr6:150067644	NUP43	0.62	13.94	0.54	3.84e-37	Lung cancer;
LGG	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg07274523	chr3:49395745	GPX1	0.55	8.95	0.38	8.44e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs75920871	0.660	rs4938330	chr11:116928514	C/G	cg20608306	chr11:116969690	SIK3	-0.35	-9.06	-0.39	3.54e-18	Subjective well-being;
LGG	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg01043669	chr3:72786069	NA	0.41	6.86	0.3	2.21e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22164238	chr1:110162488	AMPD2	0.4	6.72	0.3	5.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.13e-25	High light scatter reticulocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01114951	chr1:117664707	TRIM45	0.46	7.37	0.32	8.1e-13	Cognitive performance;
LGG	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg02891314	chr5:179741120	GFPT2	-0.61	-10.74	-0.45	3.45e-24	Height;
LGG	cis	rs7618501	0.665	rs7621352	chr3:50070763	A/C	cg18129748	chr3:49941408	MST1R	-0.21	-6.73	-0.3	5.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10463316	0.894	rs6864722	chr5:150752942	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.24	-0.43	2.51e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg19507638	chr5:93509721	C5orf36	-0.39	-6.82	-0.3	2.87e-11	Diabetic retinopathy;
LGG	cis	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19171272	chr22:38449367	NA	-0.48	-8.74	-0.38	4.46e-17	Glioblastoma;Glioma;
LGG	cis	rs11992162	0.591	rs35657308	chr8:11804402	G/A	cg12395012	chr8:11607386	GATA4	0.42	7.49	0.33	3.54e-13	Monocyte count;
LGG	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg10157359	chr2:10953004	PDIA6	-0.47	-7.06	-0.31	5.99e-12	Cardiac Troponin-T levels;
LGG	cis	rs7851660	0.967	rs4743134	chr9:100598568	C/A	cg13688889	chr9:100608707	NA	-0.69	-14.56	-0.56	8.14e-40	Strep throat;
LGG	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7781557	0.640	rs17135913	chr7:102538515	A/G	cg18108683	chr7:102477205	FBXL13	-0.55	-8.22	-0.36	2.07e-15	Colorectal adenoma (advanced);
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg11584989	chr19:19387371	SF4	-0.39	-6.98	-0.31	1.05e-11	Tonsillectomy;
LGG	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg22509179	chr1:25234806	RUNX3	0.65	13.58	0.53	1.33e-35	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9915657	0.933	rs4793272	chr17:70139257	A/T	cg09344028	chr17:70110421	NA	0.49	11.11	0.46	1.44e-25	Thyroid hormone levels;
LGG	cis	rs990171	1.000	rs2058623	chr2:102986170	C/T	cg05295703	chr2:102895712	NA	-0.56	-9.84	-0.42	7.4e-21	Lymphocyte counts;
LGG	cis	rs17641971	0.645	rs341805	chr8:50034658	T/G	cg00325661	chr8:49890786	NA	0.56	10.5	0.44	2.71e-23	Blood metabolite levels;
LGG	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.04	-0.35	7.69e-15	HDL cholesterol;
LGG	cis	rs1401999	0.724	rs1016752	chr3:183665062	C/G	cg20387954	chr3:183756860	HTR3D	-0.77	-15.06	-0.57	5.57e-42	Anterior chamber depth;
LGG	trans	rs6582630	0.593	rs7299329	chr12:38447943	G/C	cg06521331	chr12:34319734	NA	-0.5	-8.91	-0.38	1.17e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2274273	0.901	rs68046603	chr14:55762803	T/A	cg04306507	chr14:55594613	LGALS3	0.61	16.8	0.62	8.54e-50	Protein biomarker;
LGG	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg12698349	chr2:225449008	CUL3	0.69	11.65	0.48	1.07e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs16976116	0.901	rs1061823	chr15:55496043	T/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.24	0.32	1.93e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs975739	0.550	rs1831451	chr13:78624341	C/T	cg07847733	chr13:78271382	SLAIN1	0.4	7.07	0.31	5.69e-12	Hair color;
LGG	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12667521	chr19:29218732	NA	0.57	7.34	0.32	9.81e-13	Methadone dose in opioid dependence;
LGG	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.82	-0.34	3.49e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	Schizophrenia;
LGG	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg14092988	chr3:52407081	DNAH1	0.3	7.89	0.34	2.2e-14	Electroencephalogram traits;
LGG	trans	rs61931739	0.533	rs4270002	chr12:34313126	G/T	cg26384229	chr12:38710491	ALG10B	0.65	12.49	0.5	4.66e-31	Morning vs. evening chronotype;
LGG	trans	rs643955	0.609	rs13259465	chr8:9982953	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.8	-0.34	4.05e-14	Systemic lupus erythematosus;
LGG	cis	rs765787	0.530	rs11634794	chr15:45534492	A/C	cg24006582	chr15:45444508	DUOX1	-0.71	-13.65	-0.54	6.87e-36	Uric acid levels;
LGG	cis	rs1165472	0.588	rs7540786	chr1:56119747	G/T	cg11523071	chr1:56160889	NA	0.35	7.86	0.34	2.65e-14	Paclitaxel-induced neuropathy;
LGG	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00834779	chr19:12036415	ZNF700	0.47	7.04	0.31	7.12e-12	Gut microbiome composition (summer);
LGG	cis	rs11190604	1.000	rs7071271	chr10:102264824	G/A	cg11040518	chr10:102331378	NA	-0.36	-6.73	-0.3	5.12e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs240764	0.507	rs17794439	chr6:101177456	G/A	cg09795085	chr6:101329169	ASCC3	0.45	7.44	0.33	5.03e-13	Neuroticism;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.84	-0.45	1.53e-24	Retinal vascular caliber;
LGG	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg23894439	chr1:183413866	NA	-0.48	-8.96	-0.38	7.92e-18	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg21782813	chr7:2030301	MAD1L1	-0.47	-11.5	-0.47	4.25e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs1982963	0.950	rs2645738	chr14:52513202	G/A	cg05884192	chr14:52515736	NID2	-0.34	-7.59	-0.33	1.73e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg09165964	chr15:75287851	SCAMP5	-0.73	-7.9	-0.34	2e-14	Lung cancer;
LGG	cis	rs8014204	0.743	rs35809608	chr14:75254762	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.09	-0.31	5.01e-12	Caffeine consumption;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg09699651	chr6:150184138	LRP11	0.47	8.36	0.36	7.26e-16	Lung cancer;
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs4819052	0.766	rs4819035	chr21:46645715	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.59	9.05	0.39	3.91e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4409675	0.576	rs11247705	chr1:28212272	G/A	cg23691781	chr1:28212827	C1orf38	0.39	10.5	0.44	2.89e-23	Corneal astigmatism;
LGG	cis	rs11608355	0.846	rs12581637	chr12:109855429	G/A	cg19025524	chr12:109796872	NA	-0.4	-6.65	-0.3	8.32e-11	Neuroticism;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.33	0.55	7.9e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg18252515	chr7:66147081	NA	0.43	7.19	0.32	2.54e-12	Aortic root size;
LGG	cis	rs883565	0.684	rs811971	chr3:39168283	C/T	cg01426195	chr3:39028469	NA	-0.65	-12.21	-0.49	6.54e-30	Handedness;
LGG	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg04362960	chr10:104952993	NT5C2	0.55	10.32	0.43	1.3e-22	Arsenic metabolism;
LGG	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.04	0.49	3e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7255045	0.752	rs2418568	chr19:12987881	A/G	cg07955356	chr19:12992479	DNASE2	0.41	6.94	0.31	1.34e-11	Mean corpuscular volume;
LGG	cis	rs10883723	0.962	rs1056741	chr10:104236640	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.88	0.51	1.13e-32	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1577917	0.958	rs16876530	chr6:86595641	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.5	-8.5	-0.37	2.65e-16	Response to antipsychotic treatment;
LGG	cis	rs881375	0.967	rs1860824	chr9:123659339	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.14	0.39	1.97e-18	Rheumatoid arthritis;
LGG	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.42	-0.4	2.16e-19	Educational attainment;
LGG	cis	rs2916247	1.000	rs28550757	chr8:93047087	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.44	-0.37	4.1e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6669919	0.510	rs4951758	chr1:211690631	A/G	cg10512769	chr1:211675356	NA	-0.51	-10.34	-0.43	1.11e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2235649	0.843	rs9932890	chr16:1847868	G/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	0.41	7.04	0.31	6.9e-12	Blood metabolite levels;
LGG	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs7312933	0.932	rs10880220	chr12:42383046	A/G	cg19980929	chr12:42632907	YAF2	0.34	7.5	0.33	3.2e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9381107	1.000	rs9349190	chr6:9462881	T/A	cg14735645	chr6:9486422	NA	-0.47	-7.64	-0.33	1.28e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7216064	1.000	rs4569324	chr17:65872750	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11650494	0.710	rs61427980	chr17:47473580	A/G	cg08112188	chr17:47440006	ZNF652	1.13	12.68	0.51	8.06e-32	Prostate cancer;
LGG	cis	rs11235843	0.565	rs1723840	chr11:73473885	T/A	cg18195628	chr11:73498948	MRPL48	0.54	7.55	0.33	2.38e-13	Hand grip strength;
LGG	cis	rs763121	0.853	rs3788544	chr22:39064966	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	6.64	0.3	8.58e-11	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg11342453	chr6:26196699	NA	0.5	6.97	0.31	1.08e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg12560992	chr17:57184187	TRIM37	0.87	15.13	0.58	2.69e-42	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.517	rs4104182	chr12:34081343	G/A	cg06521331	chr12:34319734	NA	-0.61	-10.95	-0.45	5.69e-25	Morning vs. evening chronotype;
LGG	cis	rs5769765	0.955	rs9616367	chr22:50303515	A/C	cg26441486	chr22:50317300	CRELD2	0.43	7.55	0.33	2.39e-13	Schizophrenia;
LGG	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.35	-0.32	8.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4076764	1.000	rs7540279	chr1:163429970	A/T	cg06092702	chr1:163392909	NA	-0.47	-8.44	-0.37	4.17e-16	Motion sickness;
LGG	cis	rs921968	0.541	rs496674	chr2:219432569	G/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.28	-0.32	1.41e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs12517041	0.935	rs16892409	chr5:23324350	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.18	-0.46	7.64e-26	Calcium levels;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg15971980	chr6:150254442	NA	0.43	8.05	0.35	7.19e-15	Lung cancer;
LGG	trans	rs526821	0.595	rs624478	chr11:55340778	C/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.33e-11	Pediatric bone mineral density (spine);
LGG	cis	rs1707322	0.752	rs11211169	chr1:46166709	A/G	cg03146154	chr1:46216737	IPP	0.56	10.61	0.44	1.13e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7582720	0.945	rs72932716	chr2:203642244	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.32	0.4	4.59e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.87e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg18351406	chr4:77819688	ANKRD56	0.45	7.91	0.34	1.94e-14	Emphysema distribution in smoking;
LGG	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg14784868	chr12:69753453	YEATS4	0.69	11.11	0.46	1.39e-25	Response to diuretic therapy;
LGG	cis	rs73001065	0.636	rs73002960	chr19:19582992	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	10.75	0.45	3.38e-24	LDL cholesterol;
LGG	trans	rs9657904	0.865	rs11711088	chr3:105588069	G/A	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.39e-14	Multiple sclerosis;
LGG	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg18129748	chr3:49941408	MST1R	0.22	7.16	0.32	3.21e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg03036210	chr16:89904091	SPIRE2	0.65	8.0	0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs8014204	0.806	rs11159104	chr14:75293374	A/G	cg06637938	chr14:75390232	RPS6KL1	0.78	15.52	0.59	4.84e-44	Caffeine consumption;
LGG	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg18850127	chr7:39170497	POU6F2	0.51	11.6	0.47	1.68e-27	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg16507663	chr6:150244633	RAET1G	0.45	8.61	0.37	1.11e-16	Lung cancer;
LGG	cis	rs3735485	0.678	rs2289373	chr7:45139919	A/C	cg03440944	chr7:45023329	C7orf40	-0.55	-9.08	-0.39	3.09e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08125972	chr19:36705377	ZNF565;ZNF146	0.41	6.87	0.3	2.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7084402	0.967	rs12242287	chr10:60278340	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.15	-0.64	5.62e-56	Refractive error;
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg07157834	chr1:205819609	PM20D1	0.42	7.1	0.31	4.77e-12	Parkinson's disease;
LGG	cis	rs1371867	0.817	rs7846076	chr8:101327629	A/G	cg06636551	chr8:101224915	SPAG1	-0.47	-8.71	-0.38	5.43e-17	Atrioventricular conduction;
LGG	cis	rs3820068	0.705	rs1800616	chr1:15832229	G/A	cg05660106	chr1:15850417	CASP9	1.1	27.08	0.78	1.66e-97	Systolic blood pressure;
LGG	cis	rs4917300	0.606	rs13250335	chr8:143096061	G/C	cg06573787	chr8:143070187	NA	0.59	9.85	0.42	6.32e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs2535633	0.631	rs11915851	chr3:53096047	C/T	cg11645453	chr3:52864694	ITIH4	0.48	7.88	0.34	2.42e-14	Body mass index;
LGG	cis	rs7296418	0.961	rs1790094	chr12:123586688	T/C	cg00376283	chr12:123451042	ABCB9	0.66	12.07	0.49	2.34e-29	Platelet count;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.95	-0.38	8.93e-18	Personality dimensions;
LGG	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs4689642	0.709	rs13115404	chr4:7226101	T/G	cg21353189	chr4:7228343	SORCS2	0.39	9.02	0.39	5e-18	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg08888203	chr3:10149979	C3orf24	0.35	6.71	0.3	5.83e-11	Alzheimer's disease;
LGG	cis	rs9815354	0.951	rs1617271	chr3:41914000	G/T	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4926611	1.000	rs12045240	chr1:54103375	A/G	cg23596471	chr1:54105337	GLIS1	0.4	8.34	0.36	8.41e-16	Hand grip strength;
LGG	cis	rs6725041	0.541	rs11686852	chr2:213151472	G/A	cg20637307	chr2:213403960	ERBB4	-0.37	-6.93	-0.31	1.41e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs7923609	0.936	rs10761779	chr10:65274927	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.84e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4356975	0.563	rs12642938	chr4:69976217	T/C	cg27372994	chr4:70080453	UGT2B11	0.37	6.68	0.3	6.67e-11	Obesity-related traits;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg07511668	chr11:68622177	NA	-0.47	-9.13	-0.39	2.07e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg05925327	chr15:68127851	NA	-0.38	-7.95	-0.35	1.42e-14	Restless legs syndrome;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg06916706	chr16:4465613	CORO7	-0.9	-16.18	-0.6	5.34e-47	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24399406	chr17:33895357	NA	0.48	7.81	0.34	3.87e-14	Cognitive performance;
LGG	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg03433033	chr1:76189801	ACADM	0.61	8.93	0.38	9.96e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9649465	0.806	rs6971297	chr7:123293342	A/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.18e-17	Migraine;
LGG	cis	rs7289126	0.966	rs2267378	chr22:38630956	G/A	cg03162506	chr22:38580953	NA	0.27	6.76	0.3	4.08e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs1010254	0.510	rs56245652	chr5:151762153	A/G	cg08593883	chr5:151785301	NMUR2	-0.45	-6.93	-0.31	1.42e-11	Optic nerve measurement (cup area);
LGG	cis	rs3857747	0.931	rs4723951	chr7:40363735	C/T	cg00420559	chr7:40367873	C7orf10	-0.41	-8.36	-0.36	7.68e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2386661	0.784	rs2386652	chr10:5676326	G/A	cg26603656	chr10:5671107	NA	0.4	7.82	0.34	3.51e-14	Breast cancer;
LGG	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-11.27	-0.46	3.5e-26	Vitiligo;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7584262	0.737	rs7591932	chr2:42243550	T/G	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Bone mineral density;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.63	0.44	8.81e-24	Personality dimensions;
LGG	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.09	-0.46	1.64e-25	Coronary artery disease;
LGG	cis	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.66	-0.34	1.11e-13	Morning vs. evening chronotype;
LGG	cis	rs13102973	0.864	rs7442176	chr4:135899575	C/A	cg14419869	chr4:135874104	NA	-0.45	-8.18	-0.36	2.69e-15	Subjective well-being;
LGG	cis	rs9810089	0.749	rs664088	chr3:136036986	T/C	cg12473912	chr3:136751656	NA	0.41	6.9	0.31	1.75e-11	Gestational age at birth (child effect);
LGG	trans	rs11039798	0.588	rs7483361	chr11:48593786	G/A	cg15704280	chr7:45808275	SEPT13	0.73	10.05	0.42	1.26e-21	Axial length;
LGG	cis	rs2227564	0.729	rs2633298	chr10:75666339	C/G	cg00564723	chr10:75632066	CAMK2G	-0.42	-8.85	-0.38	1.85e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg17201900	chr20:34330562	RBM39	0.5	6.75	0.3	4.44e-11	Total cholesterol levels;
LGG	cis	rs4478858	0.698	rs6655946	chr1:31805728	G/A	cg19084893	chr1:31688959	NA	0.32	6.67	0.3	7.21e-11	Alcohol dependence;
LGG	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg16339924	chr4:17578868	LAP3	0.65	11.08	0.46	1.78e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-7.71	-0.34	7.59e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6993813	0.843	rs78317345	chr8:120046243	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.94e-11	Bone mineral density (hip);
LGG	cis	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg19338460	chr6:170058176	WDR27	-0.75	-9.72	-0.41	1.93e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs12517041	1.000	rs4701360	chr5:23292240	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg27286337	chr10:134555280	INPP5A	0.89	13.01	0.52	3.28e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs74781061	0.932	rs7178568	chr15:74851416	G/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.29	-0.32	1.33e-12	Endometriosis;
LGG	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs79349575	0.594	rs62078375	chr17:47034974	A/G	cg16584676	chr17:46985605	UBE2Z	0.5	8.46	0.37	3.52e-16	Type 2 diabetes;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	trans	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg18187862	chr3:45730750	SACM1L	0.43	7.01	0.31	8.21e-12	Primary sclerosing cholangitis;
LGG	cis	rs4481887	1.000	rs7553333	chr1:248493956	C/G	cg00666640	chr1:248458726	OR2T12	0.61	9.76	0.41	1.4e-20	Common traits (Other);
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg12016809	chr21:47604291	C21orf56	0.59	10.58	0.44	1.44e-23	Testicular germ cell tumor;
LGG	cis	rs67311347	1.000	rs2371186	chr3:40488713	G/C	cg24209194	chr3:40518798	ZNF619	0.44	6.87	0.3	2.07e-11	Renal cell carcinoma;
LGG	cis	rs8014204	0.901	rs4899536	chr14:75316614	A/G	cg03030879	chr14:75389066	RPS6KL1	0.37	6.72	0.3	5.23e-11	Caffeine consumption;
LGG	cis	rs3742264	0.603	rs9534257	chr13:46517366	T/G	cg15192986	chr13:46630673	CPB2	-0.35	-6.88	-0.3	2e-11	Blood protein levels;
LGG	cis	rs7945071	0.948	rs4754453	chr11:110306727	G/T	cg04157658	chr11:110243994	NA	0.29	6.77	0.3	4.03e-11	Cognitive function;
LGG	cis	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg13647721	chr17:30228624	UTP6	0.64	8.27	0.36	1.46e-15	Hip circumference adjusted for BMI;
LGG	cis	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg20368463	chr18:77673604	PQLC1	0.59	7.83	0.34	3.43e-14	Opioid sensitivity;
LGG	cis	rs1298908	0.639	rs2993763	chr10:82033594	G/A	cg01528321	chr10:82214614	TSPAN14	0.45	7.75	0.34	5.72e-14	Diabetic kidney disease;
LGG	cis	rs9463078	0.691	rs10948229	chr6:45306371	A/G	cg25276700	chr6:44698697	NA	0.32	6.78	0.3	3.6e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs12681287	0.547	rs60982560	chr8:87515046	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.59	-0.33	1.82e-13	Caudate activity during reward;
LGG	cis	rs67311347	0.910	rs7617361	chr3:40373259	G/T	cg13683864	chr3:40499215	RPL14	-0.97	-19.87	-0.68	5.3e-64	Renal cell carcinoma;
LGG	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg00142150	chr22:38071001	LGALS1	0.67	10.55	0.44	1.91e-23	Fat distribution (HIV);
LGG	cis	rs17286411	0.787	rs1834036	chr16:71972060	G/A	cg06353428	chr16:71660113	MARVELD3	0.42	7.36	0.32	8.54e-13	Blood protein levels;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.64	11.58	0.47	2.11e-27	Obesity-related traits;
LGG	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Gut microbiome composition (summer);
LGG	cis	rs8067545	0.611	rs2526477	chr17:20131193	A/G	cg13482628	chr17:19912719	NA	-0.52	-9.94	-0.42	3.13e-21	Schizophrenia;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.29	-0.6	1.8e-47	Calcium levels;
LGG	cis	rs300774	1.000	rs300774	chr2:112496	G/T	cg04617936	chr2:214353	NA	0.48	7.11	0.31	4.36e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.21	0.78	4.32e-98	Height;
LGG	cis	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.1e-17	Mean corpuscular volume;
LGG	cis	rs1107366	0.722	rs9862438	chr3:125910381	C/T	cg06827562	chr3:125932279	NA	0.58	13.83	0.54	1.21e-36	Metabolite levels;
LGG	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.05	0.39	4.13e-18	Blood metabolite levels;
LGG	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Bladder cancer;
LGG	cis	rs600231	0.708	rs602838	chr11:65253247	T/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.13	-0.39	2.19e-18	Bone mineral density;
LGG	trans	rs28595532	0.641	rs72670213	chr4:119281608	G/T	cg26518628	chr1:97050305	NA	-0.8	-6.8	-0.3	3.15e-11	Cannabis dependence symptom count;
LGG	cis	rs7113850	0.541	rs7944769	chr11:24224823	G/C	ch.11.24196551F	chr11:24239977	NA	0.89	10.13	0.43	6.61e-22	Bone fracture in osteoporosis;
LGG	cis	rs7928758	0.887	rs78642342	chr11:134269120	G/A	cg25213107	chr11:134282864	B3GAT1	1.23	14.63	0.56	4.06e-40	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2180341	0.960	rs7751865	chr6:127683040	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.73	0.59	5.72e-45	Breast cancer;
LGG	cis	rs12474201	0.928	rs12999586	chr2:46938736	C/T	cg06386533	chr2:46925753	SOCS5	0.79	14.54	0.56	1.04e-39	Height;
LGG	cis	rs1413885	0.549	rs4593866	chr1:65850968	G/C	cg14976592	chr1:65886160	LEPROT;LEPR	0.39	6.74	0.3	4.6e-11	Anticoagulant levels;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs270601	0.770	rs61352298	chr5:131600589	G/C	cg07395648	chr5:131743802	NA	-0.36	-7.37	-0.32	7.76e-13	Acylcarnitine levels;
LGG	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg16141378	chr3:129829833	LOC729375	-0.4	-9.08	-0.39	3.26e-18	Retinal vascular caliber;
LGG	trans	rs1459104	0.641	rs4454742	chr11:54840592	A/T	cg15704280	chr7:45808275	SEPT13	0.78	7.68	0.34	9.65e-14	Body mass index;
LGG	cis	rs1552244	0.554	rs55847233	chr3:9991101	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.74	-0.45	3.43e-24	Alzheimer's disease;
LGG	trans	rs3808502	0.501	rs7012219	chr8:11145679	T/A	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.12e-11	Neuroticism;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.75	0.34	5.79e-14	Height;
LGG	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg06453172	chr10:134556979	INPP5A	-0.56	-8.16	-0.35	3.27e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs8002861	0.664	rs9525873	chr13:44482204	T/C	cg12856521	chr11:46389249	DGKZ	0.51	8.73	0.38	4.75e-17	Leprosy;
LGG	cis	rs11866815	0.649	rs12597122	chr16:377644	C/G	cg07915516	chr16:377344	AXIN1	-0.52	-11.44	-0.47	7.34e-27	Body mass index;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	7.9	0.34	2e-14	Lung function (FEV1/FVC);
LGG	cis	rs34311866	0.808	rs748483	chr4:952409	A/G	cg07828340	chr4:882639	GAK	0.92	9.66	0.41	3.15e-20	Parkinson's disease;
LGG	cis	rs9658691	0.607	rs9658766	chr10:90771612	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-8.98	-0.39	6.75e-18	Mosquito bite size;
LGG	cis	rs11122272	0.735	rs2491412	chr1:231535880	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.71	-0.45	4.67e-24	Hemoglobin concentration;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-17.36	-0.63	2.44e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg12463550	chr7:65579703	CRCP	0.79	8.53	0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	trans	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.17	-0.32	2.9e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg12165864	chr7:66369176	NA	-0.58	-9.41	-0.4	2.28e-19	Corneal structure;
LGG	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs10744422	1.000	rs3817094	chr12:123332032	T/C	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	4.96e-19	Schizophrenia;
LGG	cis	rs11158026	0.757	rs7159933	chr14:55441641	C/A	cg04306507	chr14:55594613	LGALS3	0.31	7.18	0.32	2.75e-12	Parkinson's disease;
LGG	cis	rs4731207	0.596	rs7794959	chr7:124649139	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs2470578	0.792	rs283917	chr3:17328509	A/G	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.42e-11	Schizophrenia;
LGG	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.32	0.32	1.12e-12	Electroencephalogram traits;
LGG	cis	rs7412746	0.658	rs6656535	chr1:150940357	G/T	cg15448220	chr1:150897856	SETDB1	0.4	7.38	0.32	7.22e-13	Melanoma;
LGG	cis	rs2229238	0.911	rs12405637	chr1:154501285	C/T	cg10237817	chr1:154519846	TDRD10	0.34	6.86	0.3	2.25e-11	Coronary heart disease;
LGG	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.79	-0.3	3.54e-11	Coronary artery disease;
LGG	cis	rs1707322	0.963	rs1768815	chr1:46528603	G/A	cg03146154	chr1:46216737	IPP	-0.53	-9.71	-0.41	2.15e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg21564728	chr17:62398573	NA	-0.46	-6.72	-0.3	5.24e-11	Beard thickness;
LGG	cis	rs4605213	0.605	rs41524846	chr17:49252238	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	0.43	7.24	0.32	1.88e-12	Height;
LGG	cis	rs6963495	0.818	rs56165465	chr7:105180384	C/T	cg19920283	chr7:105172520	RINT1	0.62	8.31	0.36	1.09e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg27476859	chr7:2772710	GNA12	0.4	6.89	0.3	1.83e-11	Height;
LGG	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg08733933	chr1:2954429	NA	-0.4	-8.72	-0.38	4.92e-17	Plateletcrit;
LGG	cis	rs4356932	1.000	rs6852075	chr4:76952280	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.74	-0.3	4.68e-11	Blood protein levels;
LGG	trans	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-11.13	-0.46	1.2e-25	Morning vs. evening chronotype;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg14773178	chr5:1868261	NA	0.36	7.77	0.34	5.08e-14	Cardiovascular disease risk factors;
LGG	cis	rs7172689	0.908	rs4076201	chr15:81572303	C/T	cg11808699	chr15:81528661	IL16	0.48	9.89	0.42	4.55e-21	Inattentive symptoms;
LGG	trans	rs453301	0.506	rs686189	chr8:8623637	A/G	cg16141378	chr3:129829833	LOC729375	0.32	7.44	0.33	5.03e-13	Joint mobility (Beighton score);
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.18	-0.39	1.44e-18	Lewy body disease;
LGG	cis	rs9976767	0.608	rs11909987	chr21:43822402	C/A	cg23042151	chr21:43824109	UBASH3A	-0.62	-13.08	-0.52	1.74e-33	Type 1 diabetes;
LGG	cis	rs7106204	0.534	rs79475764	chr11:24278384	C/A	ch.11.24196551F	chr11:24239977	NA	0.84	8.63	0.37	1.03e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.71	0.41	2.12e-20	Hypertriglyceridemia;
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.72	0.45	4.16e-24	Total body bone mineral density;
LGG	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.09	-0.39	2.88e-18	Coronary artery disease;
LGG	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg14541582	chr5:601475	NA	-0.71	-11.08	-0.46	1.8e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs11191270	0.554	rs11191253	chr10:104066507	A/T	cg15320455	chr10:103880129	LDB1	0.66	8.59	0.37	1.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4006360	0.646	rs8080447	chr17:39301276	T/A	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.14	-0.43	5.76e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9788721	0.836	rs72738718	chr15:78735438	G/C	cg18825076	chr15:78729989	IREB2	-0.57	-9.43	-0.4	1.99e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.93	-11.93	-0.49	8.26e-29	Lung cancer in ever smokers;
LGG	cis	rs7715811	1.000	rs6554814	chr5:13774231	T/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.95	-0.42	2.94e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs4330281	0.669	rs9681893	chr3:17757024	T/A	cg20981856	chr3:17787350	NA	-0.39	-7.4	-0.33	6.53e-13	Schizophrenia;
LGG	cis	rs10876993	0.826	rs1678534	chr12:58057435	A/C	cg18357645	chr12:58087776	OS9	0.68	12.37	0.5	1.47e-30	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs7939886	0.920	rs7940563	chr11:55875133	C/T	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.38e-15	Myopia (pathological);
LGG	cis	rs7359276	1	rs7359276	chr15:78892661	C/T	cg06917634	chr15:78832804	PSMA4	0.53	8.5	0.37	2.59e-16	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg16141378	chr3:129829833	LOC729375	-0.45	-11.01	-0.46	3.23e-25	Mood instability;
LGG	cis	rs4671458	0.626	rs12476015	chr2:63807694	A/G	cg17519650	chr2:63277830	OTX1	-0.53	-7.3	-0.32	1.25e-12	Subjective well-being;
LGG	cis	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg16473166	chr22:50639996	SELO	0.64	10.01	0.42	1.81e-21	Late-onset Alzheimer's disease;
LGG	cis	rs1465370	0.711	rs11767377	chr7:130004758	A/G	cg25718383	chr7:130020096	CPA1	0.3	7.27	0.32	1.51e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs17854409	0.803	rs3210314	chr20:61472117	C/A	cg05147244	chr20:61493195	TCFL5	0.78	7.45	0.33	4.73e-13	Obesity-related traits;
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.23	-0.52	4.24e-34	Personality dimensions;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9341808	0.690	rs6930534	chr6:80896050	C/T	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21552701	chr13:111090453	COL4A2	0.36	7.39	0.32	7.09e-13	Body fat percentage;
LGG	cis	rs67133203	0.904	rs15897	chr12:51374923	A/G	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.57e-30	Urinary tract infection frequency;
LGG	cis	rs4538187	1.000	rs4233930	chr2:64077305	C/G	cg19915305	chr2:64069682	UGP2	0.64	14.56	0.56	8.22e-40	Systolic blood pressure;
LGG	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.46	-10.96	-0.45	5.05e-25	Oropharynx cancer;
LGG	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg01028140	chr2:1542097	TPO	-0.55	-8.54	-0.37	1.99e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7301016	0.846	rs12369751	chr12:63031133	G/C	cg11441379	chr12:63026424	NA	0.69	9.6	0.41	5.24e-20	IgG glycosylation;
LGG	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg09696939	chr10:60272079	BICC1	0.36	6.88	0.3	1.97e-11	Refractive error;
LGG	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.38	0.61	6.45e-48	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	trans	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg12045294	chr17:78518616	RPTOR	-0.48	-7.38	-0.32	7.63e-13	Glycated hemoglobin levels;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg19168338	chr16:4465731	CORO7	-0.73	-13.37	-0.53	1.07e-34	Schizophrenia;
LGG	cis	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg07460842	chr6:66804631	NA	-1.15	-31.84	-0.83	1.05e-118	Exhaled nitric oxide output;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs193541	0.632	rs6595413	chr5:122156949	G/A	cg19412675	chr5:122181750	SNX24	0.53	8.51	0.37	2.36e-16	Glucose homeostasis traits;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg04772025	chr11:68637568	NA	0.76	13.11	0.52	1.27e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg05091796	chr16:4465799	CORO7	-0.6	-9.76	-0.41	1.34e-20	Schizophrenia;
LGG	cis	rs4474465	0.920	rs9804428	chr11:78158948	G/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.57	-0.37	1.53e-16	Alzheimer's disease (survival time);
LGG	trans	rs629535	0.748	rs689410	chr8:70037558	G/A	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.89	0.3	1.87e-11	Vitiligo;
LGG	cis	rs9902453	0.904	rs8071742	chr17:28361669	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.57	-0.37	1.53e-16	Alzheimer's disease (survival time);
LGG	cis	rs16854884	0.582	rs34402874	chr3:143643249	T/A	cg06585982	chr3:143692056	C3orf58	0.62	10.58	0.44	1.42e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs714515	0.867	rs7534393	chr1:172318031	T/C	cg01573306	chr1:172330400	DNM3	-0.34	-7.69	-0.34	9.22e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.33	-0.32	1.02e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4812048	0.793	rs6070693	chr20:57589516	C/T	cg23907860	chr20:57583709	CTSZ	0.47	6.68	0.3	6.71e-11	Mean platelet volume;
LGG	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs7474896	0.515	rs624359	chr10:38299132	T/C	cg00409905	chr10:38381863	ZNF37A	0.47	7.02	0.31	7.88e-12	Obesity (extreme);
LGG	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg08847533	chr14:75593920	NEK9	-0.57	-10.59	-0.44	1.27e-23	Height;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg00166722	chr3:10149974	C3orf24	0.53	8.92	0.38	1.13e-17	Alzheimer's disease;
LGG	trans	rs6076960	0.684	rs3909086	chr20:6251639	A/G	cg21095983	chr6:86352623	SYNCRIP	0.58	10.55	0.44	1.77e-23	Smooth-surface caries;
LGG	cis	rs3796352	1.000	rs35507120	chr3:53053924	C/T	cg12962167	chr3:53033115	SFMBT1	0.79	8.03	0.35	8.29e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2273669	0.667	rs1407241	chr6:109328432	G/A	cg05315195	chr6:109294784	ARMC2	-0.63	-8.15	-0.35	3.38e-15	Prostate cancer;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.54	0.53	1.95e-35	Lung cancer;
LGG	trans	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg25214090	chr10:38739885	LOC399744	-0.63	-11.2	-0.46	6.24e-26	Corneal astigmatism;
LGG	trans	rs8002861	0.665	rs2065926	chr13:44422371	A/G	cg12856521	chr11:46389249	DGKZ	-0.5	-9.15	-0.39	1.83e-18	Leprosy;
LGG	cis	rs8114671	0.562	rs6087642	chr20:33468306	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.15	0.32	3.49e-12	Height;
LGG	cis	rs35306767	0.903	rs34847097	chr10:902252	A/T	cg20503657	chr10:835505	NA	0.75	10.23	0.43	2.85e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs112591243	0.570	rs2839340	chr21:47989804	C/T	cg10657630	chr21:48055338	PRMT2	0.84	7.38	0.32	7.48e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg26818257	chr2:241905806	NA	0.52	11.71	0.48	6.28e-28	Joint mobility (Beighton score);
LGG	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg26811252	chr16:29126840	RRN3P2	-0.71	-11.61	-0.47	1.66e-27	Menopause (age at onset);
LGG	cis	rs2455799	0.573	rs2455834	chr3:15753641	A/G	cg16303742	chr3:15540471	COLQ	-0.41	-8.03	-0.35	8.35e-15	Mean platelet volume;
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	10.03	0.42	1.46e-21	Myopia (pathological);
LGG	cis	rs9394152	0.845	rs9380367	chr6:33474975	G/A	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.75e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs783540	0.867	rs7167880	chr15:83294436	G/A	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.81	-0.3	3.12e-11	Schizophrenia;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00689492	chr4:1303491	MAEA	0.46	7.91	0.34	1.96e-14	Obesity-related traits;
LGG	cis	rs11645898	0.745	rs55824906	chr16:72064905	A/G	cg14768367	chr16:72042858	DHODH	-0.89	-11.84	-0.48	1.91e-28	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14211646	chr1:26758996	DHDDS	0.4	6.81	0.3	3.01e-11	Cognitive performance;
LGG	cis	rs3087591	1.000	rs2905800	chr17:29531980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	14.37	0.56	5.69e-39	Hip circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24151548	chr19:1285794	EFNA2	0.5	7.32	0.32	1.12e-12	Gut microbiome composition (summer);
LGG	cis	rs9581857	0.615	rs79553479	chr13:28007862	G/A	cg01674679	chr13:27998804	GTF3A	-0.69	-7.88	-0.34	2.35e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs2243480	0.522	rs12698511	chr7:65474919	G/T	cg10756647	chr7:56101905	PSPH	0.75	7.16	0.32	3.18e-12	Diabetic kidney disease;
LGG	cis	rs4242434	0.672	rs11785031	chr8:22486612	A/G	cg03733263	chr8:22462867	KIAA1967	0.97	23.29	0.73	5.59e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9359856	0.662	rs1179904	chr6:90322573	A/G	cg13799429	chr6:90582589	CASP8AP2	0.6	9.09	0.39	2.82e-18	Bipolar disorder;
LGG	cis	rs2073300	1.000	rs12625160	chr20:23442008	T/C	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg25173405	chr17:45401733	C17orf57	-0.64	-10.94	-0.45	5.98e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg13010199	chr12:38710504	ALG10B	0.64	12.87	0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs9393777	0.623	rs9358947	chr6:26479000	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs61237505	1	rs61237505	chr14:92245983	G/C	cg25729068	chr14:92303235	TC2N	-0.54	-6.66	-0.3	7.99e-11	Mean platelet volume;
LGG	cis	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg26384229	chr12:38710491	ALG10B	1.07	28.64	0.8	1.44e-104	Heart rate;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11368578	chr7:150754936	CDK5	-0.52	-7.63	-0.33	1.37e-13	Systemic lupus erythematosus;
LGG	cis	rs7937612	0.501	rs3809059	chr11:120206163	A/T	cg24566217	chr11:120254723	ARHGEF12	-0.35	-7.73	-0.34	6.79e-14	Intraocular pressure;
LGG	cis	rs733592	0.524	rs10875727	chr12:48426143	T/C	cg24011408	chr12:48396354	COL2A1	-0.69	-12.24	-0.49	4.94e-30	Plateletcrit;
LGG	trans	rs4942242	0.663	rs7985489	chr13:44206148	T/C	cg19169023	chr15:41853346	TYRO3	0.44	8.82	0.38	2.31e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg27053975	chr1:166958233	MAEL	-0.49	-7.05	-0.31	6.7e-12	Obesity-related traits;
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.44	0.47	7.26e-27	Bipolar disorder;
LGG	cis	rs4006360	0.543	rs937403	chr17:39296016	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.59	-12.7	-0.51	6.51e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs62400317	0.859	rs12205379	chr6:45215074	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.2	-0.43	3.57e-22	Total body bone mineral density;
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs6558530	0.666	rs7005699	chr8:1700620	A/T	cg25947184	chr8:1697459	NA	0.47	8.11	0.35	4.66e-15	Systolic blood pressure;
LGG	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg12667521	chr19:29218732	NA	0.57	7.3	0.32	1.3e-12	Methadone dose in opioid dependence;
LGG	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg16141378	chr3:129829833	LOC729375	0.4	9.55	0.41	7.57e-20	Mood instability;
LGG	cis	rs12670798	0.547	rs6461584	chr7:21616888	T/C	cg04471919	chr7:21584483	DNAH11	0.3	7.01	0.31	8.4e-12	Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs367943	0.665	rs13180704	chr5:112969261	A/T	cg12552261	chr5:112820674	MCC	-0.54	-9.39	-0.4	2.83e-19	Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03520983	chr3:61547287	PTPRG	0.43	6.73	0.3	4.96e-11	Cognitive performance;
LGG	cis	rs10193935	0.901	rs6733464	chr2:42563597	A/G	cg27598129	chr2:42591480	NA	-0.65	-9.82	-0.42	8.72e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs986417	0.748	rs10150234	chr14:61031284	C/G	cg27398547	chr14:60952738	C14orf39	-0.64	-6.7	-0.3	6.2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg25427524	chr10:38739819	LOC399744	0.52	7.81	0.34	3.73e-14	Obesity (extreme);
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg15537850	chr8:144661051	NAPRT1	1.01	7.66	0.34	1.13e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg11502198	chr6:26597334	ABT1	0.53	9.3	0.4	5.8e-19	Intelligence (multi-trait analysis);
LGG	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg20913747	chr6:44695427	NA	-0.51	-7.57	-0.33	2e-13	Total body bone mineral density;
LGG	trans	rs9844985	0.630	rs6766837	chr3:116893069	C/G	cg02629157	chr9:138670609	KCNT1	-0.34	-6.71	-0.3	5.6e-11	Major depression and alcohol dependence;
LGG	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-9.42	-0.4	2.14e-19	Blood metabolite levels;
LGG	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg23324259	chr8:82754387	SNX16	0.44	7.06	0.31	6.03e-12	Diastolic blood pressure;
LGG	trans	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	trans	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg18187862	chr3:45730750	SACM1L	0.57	9.51	0.4	1.07e-19	Primary sclerosing cholangitis;
LGG	cis	rs10771431	0.817	rs17202253	chr12:9361850	A/G	cg08997352	chr12:9597637	DDX12	-0.77	-15.33	-0.58	3.5e-43	Breast size;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs36093844	0.800	rs11826218	chr11:85568522	T/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.18	-0.32	2.76e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	14.54	0.56	1.02e-39	Menarche (age at onset);
LGG	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg13683864	chr3:40499215	RPL14	-1.09	-23.78	-0.74	2.79e-82	Renal cell carcinoma;
LGG	cis	rs2242663	0.798	rs1945302	chr11:66337498	C/T	cg01599099	chr11:66649832	PC	0.41	8.21	0.36	2.25e-15	Bipolar disorder;
LGG	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.42	-0.33	5.61e-13	Hemoglobin concentration;
LGG	cis	rs3733585	0.673	rs6850143	chr4:9958924	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs1008375	0.966	rs6832387	chr4:17697546	G/T	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.580	rs1577471	chr6:8485905	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs55823223	0.564	rs58363746	chr17:73850819	C/T	cg14829360	chr17:73884958	NA	-0.77	-14.2	-0.55	2.91e-38	Psoriasis;
LGG	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg04731861	chr2:219085781	ARPC2	-0.44	-10.88	-0.45	1.06e-24	Colorectal cancer;
LGG	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.65	0.3	8.2e-11	Morning vs. evening chronotype;
LGG	cis	rs708547	0.836	rs1612191	chr4:57724320	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.49	-7.6	-0.33	1.67e-13	Response to bleomycin (chromatid breaks);
LGG	cis	rs12431410	0.584	rs17096617	chr14:60243750	C/T	cg07950296	chr14:60194823	RTN1	-0.39	-7.62	-0.33	1.49e-13	Schizophrenia;
LGG	cis	rs2688608	0.592	rs3849967	chr10:75483366	C/T	cg23231163	chr10:75533350	FUT11	-0.4	-6.72	-0.3	5.36e-11	Inflammatory bowel disease;
LGG	cis	rs6817170	0.692	rs11099882	chr4:154371971	T/C	cg24020152	chr4:154419554	KIAA0922	0.32	6.69	0.3	6.46e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs75920871	1.000	rs11823013	chr11:116839535	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	7.78e-12	Subjective well-being;
LGG	cis	rs7077256	0.564	rs17740722	chr10:65138599	T/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.26	-0.55	1.72e-38	Alzheimer's disease;
LGG	cis	rs9487051	0.872	rs1320612	chr6:109611990	C/A	cg12927641	chr6:109611667	NA	-0.38	-7.29	-0.32	1.39e-12	Reticulocyte fraction of red cells;
LGG	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg07882059	chr11:68924751	NA	0.43	7.46	0.33	4.19e-13	Blond vs. brown hair color;
LGG	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg11040518	chr10:102331378	NA	-0.37	-6.75	-0.3	4.35e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3768617	0.510	rs10797835	chr1:183072908	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.03	0.39	4.76e-18	Fuchs's corneal dystrophy;
LGG	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs735539	0.645	rs9552250	chr13:21175217	C/G	cg04906043	chr13:21280425	IL17D	-0.5	-8.19	-0.36	2.65e-15	Dental caries;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.34	-0.63	2.8e-52	Skin colour saturation;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.88	-0.45	1.05e-24	Neuroticism;
LGG	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg24623649	chr8:11872141	NA	0.3	6.85	0.3	2.34e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9397585	0.819	rs1415891	chr6:153372684	C/A	cg17707550	chr6:153380415	RGS17	0.62	14.69	0.56	2.25e-40	Body mass index;
LGG	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg02023728	chr11:77925099	USP35	0.47	8.34	0.36	8.62e-16	Testicular germ cell tumor;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.36	0.32	8.57e-13	Prudent dietary pattern;
LGG	cis	rs2860975	0.936	rs1934973	chr10:96783601	A/C	cg09036531	chr10:96991505	NA	-0.47	-8.54	-0.37	1.89e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2404602	0.692	rs7169663	chr15:77192843	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09525994	chr12:48512905	PFKM	0.4	7.34	0.32	9.7e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs889398	0.683	rs8047682	chr16:69913446	G/A	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.8	-0.3	3.26e-11	Body mass index;
LGG	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.48	-0.4	1.34e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg04607235	chr12:12878440	APOLD1	-0.53	-7.71	-0.34	7.76e-14	Systemic lupus erythematosus;
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg27189623	chr16:705930	WDR90	0.4	7.62	0.33	1.44e-13	Height;
LGG	cis	rs4604732	0.631	rs12080860	chr1:247623053	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.15	0.39	1.77e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs1062177	0.724	rs2964590	chr5:151118146	C/G	cg00977110	chr5:151150581	G3BP1	-0.47	-7.46	-0.33	4.27e-13	Preschool internalizing problems;
LGG	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg21775007	chr8:11205619	TDH	-0.56	-9.04	-0.39	4.37e-18	Retinal vascular caliber;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	0.43	10.9	0.45	8.87e-25	IgG glycosylation;
LGG	cis	rs711245	1.000	rs848602	chr2:36778372	G/A	cg09467607	chr2:36825704	FEZ2	0.45	8.8	0.38	2.73e-17	Height;
LGG	cis	rs2386661	0.826	rs1132293	chr10:5681038	C/T	cg26603656	chr10:5671107	NA	0.38	7.52	0.33	2.92e-13	Breast cancer;
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg00031303	chr3:195681400	NA	-0.45	-6.94	-0.31	1.33e-11	Mean corpuscular volume;
LGG	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.88	0.38	1.52e-17	Alzheimer's disease;
LGG	cis	rs11628318	0.515	rs12884619	chr14:103095724	C/A	cg12046867	chr14:103022105	NA	-0.42	-7.74	-0.34	6.23e-14	Platelet count;
LGG	cis	rs3862435	0.572	rs9796504	chr15:90927939	C/T	cg22089800	chr15:90895588	ZNF774	0.59	7.35	0.32	9.09e-13	Response to exercise (triglyceride level interaction);
LGG	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg26446133	chr18:72167187	CNDP2	-0.7	-14.25	-0.55	1.84e-38	Refractive error;
LGG	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.83	0.34	3.47e-14	Colorectal cancer;
LGG	cis	rs6142618	0.562	rs3787371	chr20:30791178	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.0	0.35	1.03e-14	Inflammatory bowel disease;
LGG	cis	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg22857025	chr5:266934	NA	1.45	25.28	0.76	3.11e-89	Breast cancer;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg24687543	chr11:63912206	MACROD1	0.63	8.84	0.38	2.07e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs17685	0.697	rs28689051	chr7:75763624	G/A	cg19862616	chr7:65841803	NCRNA00174	1.05	24.63	0.75	3.26e-86	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs367943	0.712	rs10053654	chr5:112724314	G/C	cg12552261	chr5:112820674	MCC	0.58	10.45	0.44	4.15e-23	Type 2 diabetes;
LGG	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg03605463	chr16:89740564	NA	0.4	6.87	0.3	2.02e-11	Vitiligo;
LGG	cis	rs209489	0.892	rs113031669	chr6:53113145	G/A	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-24.7	-0.75	1.45e-86	Prudent dietary pattern;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs254781	0.505	rs664366	chr5:88055761	A/G	cg22951263	chr5:87985283	NA	-0.45	-7.08	-0.31	5.44e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg14541582	chr5:601475	NA	-0.71	-11.1	-0.46	1.54e-25	Lung disease severity in cystic fibrosis;
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.99	-0.31	9.7e-12	Triglycerides;
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03517284	chr6:25882590	NA	-0.38	-6.83	-0.3	2.68e-11	Height;
LGG	cis	rs7567389	0.889	rs1504136	chr2:127977118	T/C	cg10021288	chr2:128175891	PROC	-0.38	-6.94	-0.31	1.33e-11	Self-rated health;
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.12e-15	Bipolar disorder;
LGG	trans	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.26	-0.32	1.6e-12	Triglycerides;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.74	-0.34	6.27e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6787391	0.897	rs9866934	chr3:4746624	T/C	cg11584376	chr3:4789075	ITPR1	-0.34	-7.01	-0.31	8.52e-12	Breast cancer;
LGG	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg20913747	chr6:44695427	NA	0.6	10.19	0.43	3.87e-22	Total body bone mineral density;
LGG	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg14675211	chr2:100938903	LONRF2	0.56	9.3	0.4	5.37e-19	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.616	rs6810635	chr4:185616859	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg07777115	chr5:623756	CEP72	-0.64	-8.24	-0.36	1.78e-15	Obesity-related traits;
LGG	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs783540	0.934	rs803747	chr15:83258096	A/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.29	0.32	1.38e-12	Schizophrenia;
LGG	cis	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.35	0.32	8.75e-13	Joint mobility (Beighton score);
LGG	cis	rs6435862	0.500	rs6756902	chr2:215672827	C/T	cg04530015	chr2:215796436	ABCA12	0.49	9.86	0.42	6.16e-21	Neuroblastoma (high-risk);
LGG	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.71	0.41	2.15e-20	Mean corpuscular volume;
LGG	cis	rs3741798	1.000	rs61922026	chr12:12486428	C/G	cg08615371	chr12:12503544	MANSC1	0.6	6.87	0.3	2.06e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9815354	0.812	rs60927633	chr3:41844010	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg03517284	chr6:25882590	NA	-0.41	-6.79	-0.3	3.5e-11	Iron status biomarkers;
LGG	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg10167378	chr1:228756711	NA	-0.56	-7.91	-0.35	1.88e-14	Chronic lymphocytic leukemia;
LGG	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.04	-0.35	7.57e-15	Joint mobility (Beighton score);
LGG	cis	rs6674970	0.933	rs11204772	chr1:151056305	C/T	cg03258749	chr1:151040405	MLLT11	-0.44	-7.86	-0.34	2.78e-14	Childhood ear infection;
LGG	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.2	0.52	5.18e-34	Monocyte percentage of white cells;
LGG	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs9560113	0.509	rs4771758	chr13:112201573	C/G	cg14154082	chr13:112174009	NA	0.35	7.65	0.33	1.21e-13	Menarche (age at onset);
LGG	cis	rs6963495	0.818	rs73190184	chr7:105163736	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs11098499	0.954	rs6846442	chr4:120326323	G/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs7667	1.000	rs10753558	chr1:19697915	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.42	-7.41	-0.33	5.98e-13	Crohn's disease and psoriasis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00585733	chr7:69064884	AUTS2	0.45	7.36	0.32	8.41e-13	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg13047869	chr3:10149882	C3orf24	-0.56	-9.32	-0.4	4.84e-19	Alzheimer's disease;
LGG	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg13385521	chr17:29058706	SUZ12P	-0.8	-9.54	-0.41	8.18e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	21.05	0.7	1.6e-69	Alzheimer's disease;
LGG	cis	rs1707322	1.000	rs4524994	chr1:46370263	A/G	cg03146154	chr1:46216737	IPP	0.54	10.27	0.43	1.94e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1535500	1.000	rs1535500	chr6:39284050	G/T	cg13075951	chr6:39282393	KCNK17	0.26	6.76	0.3	4.2e-11	Type 2 diabetes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg17662034	chr8:74207518	RDH10	-0.42	-7.23	-0.32	2.03e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg20336341	chr7:50628841	DDC	0.42	7.39	0.32	7.14e-13	Malaria;
LGG	cis	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.65	-0.63	1.04e-53	Breast cancer;
LGG	cis	rs2117029	0.586	rs2114846	chr12:49548276	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.74	0.51	4.51e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg23302884	chr18:44338147	ST8SIA5	0.45	8.95	0.38	8.93e-18	Personality dimensions;
LGG	cis	rs4423214	0.959	rs12794668	chr11:71168715	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.01	-0.52	3.38e-33	Vitamin D levels;
LGG	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.66	-0.48	1.02e-27	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4740619	0.901	rs7024640	chr9:15705955	C/T	cg14451791	chr9:16040625	NA	-0.36	-8.94	-0.38	9.03e-18	Body mass index;
LGG	cis	rs2463822	1.000	rs951677	chr11:62107249	G/C	cg06239285	chr11:62104954	ASRGL1	1.13	15.48	0.58	7.49e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2637030	0.559	rs256105	chr5:53013889	T/C	cg06476337	chr5:52856530	NDUFS4	0.43	6.81	0.3	3.11e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs3768617	0.510	rs3768622	chr1:183090011	G/A	cg07928641	chr1:182991847	LAMC1	0.45	8.78	0.38	3.06e-17	Fuchs's corneal dystrophy;
LGG	trans	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg13565492	chr6:43139072	SRF	-0.73	-9.25	-0.39	8.18e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.53e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2732480	0.500	rs2450991	chr12:48651621	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.33	-0.32	1.06e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9393692	0.645	rs4145910	chr6:26313305	T/C	cg16885296	chr6:26284938	NA	0.35	7.25	0.32	1.72e-12	Educational attainment;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs2013441	0.830	rs2526469	chr17:20162748	C/T	cg13482628	chr17:19912719	NA	-0.42	-7.18	-0.32	2.85e-12	Obesity-related traits;
LGG	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg08851530	chr6:28072375	NA	0.84	6.68	0.3	6.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6977660	1.000	rs2107403	chr7:19819025	G/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.79	0.38	2.88e-17	Thyroid stimulating hormone;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11310629	chr13:45991975	SLC25A30	0.56	8.77	0.38	3.36e-17	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23247000	chr7:138794512	ZC3HAV1	0.49	8.14	0.35	3.68e-15	Cognitive performance;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.22	-0.46	5.34e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-6.77	-0.3	3.9e-11	Diastolic blood pressure;
LGG	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	7.15e-21	Common traits (Other);
LGG	cis	rs2274273	0.615	rs67008693	chr14:55702693	T/C	cg04306507	chr14:55594613	LGALS3	0.51	11.78	0.48	3.51e-28	Protein biomarker;
LGG	trans	rs970548	0.643	rs12765320	chr10:45930805	A/G	cg20477318	chr10:51623047	TIMM23	0.52	6.7	0.3	5.94e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg00666640	chr1:248458726	OR2T12	0.6	9.72	0.41	1.8899999999999998e-20	Common traits (Other);
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	6.93	0.31	1.4e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12949688	0.626	rs11869345	chr17:55839200	T/A	cg12582317	chr17:55822272	NA	0.51	11.73	0.48	5.24e-28	Schizophrenia;
LGG	cis	rs12431410	0.584	rs1952032	chr14:60242735	A/C	cg07950296	chr14:60194823	RTN1	-0.38	-7.33	-0.32	1.01e-12	Schizophrenia;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg12419862	chr22:24373484	LOC391322	-0.88	-17.16	-0.62	1.92e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6728642	1.000	rs113934577	chr2:97888047	G/A	cg26665480	chr2:98280029	ACTR1B	-0.69	-6.71	-0.3	5.58e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs6860806	1.000	rs6860806	chr5:131640536	C/T	cg16647868	chr5:131706066	SLC22A5	-0.37	-7.05	-0.31	6.4e-12	Breast cancer;
LGG	cis	rs7726354	0.793	rs73756773	chr5:56002851	T/A	cg27303933	chr5:56029418	NA	0.48	6.77	0.3	3.83e-11	Breast cancer (early onset);
LGG	cis	rs2280630	0.529	rs1274957	chr3:39185077	G/A	cg01426195	chr3:39028469	NA	0.69	14.8	0.57	7.09e-41	Verbal declarative memory;
LGG	cis	rs12597458	0.752	rs8051239	chr16:72036257	T/A	cg01557791	chr16:72042693	DHODH	0.7	14.04	0.55	1.48e-37	Prostate cancer;
LGG	cis	rs7177699	0.557	rs12898292	chr15:79112603	A/G	cg00540400	chr15:79124168	NA	0.54	11.49	0.47	4.88e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg19143629	chr17:61920732	SMARCD2	-0.42	-7.18	-0.32	2.81e-12	Prudent dietary pattern;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs5758659	0.652	rs1063392	chr22:42454950	C/T	cg15557168	chr22:42548783	NA	0.34	7.81	0.34	4e-14	Cognitive function;
LGG	cis	rs9849248	0.627	rs73146099	chr3:88132331	A/G	cg14530983	chr3:88190749	ZNF654	0.57	7.86	0.34	2.67e-14	Menarche (age at onset);
LGG	cis	rs6500395	0.588	rs2047601	chr16:48578101	C/T	cg04672837	chr16:48644449	N4BP1	-0.5	-8.68	-0.37	6.82e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4819052	0.819	rs8134084	chr21:46693295	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	2.05e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.6	-9.97	-0.42	2.35e-21	Height;
LGG	cis	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs4639966	0.797	rs68097885	chr11:118596444	G/A	cg20110707	chr11:118481992	PHLDB1	-0.44	-6.78	-0.3	3.7e-11	Systemic lupus erythematosus;
LGG	cis	rs4731207	0.698	rs6942933	chr7:124444522	C/T	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs9486715	0.809	rs9486467	chr6:96971803	C/T	cg18709589	chr6:96969512	KIAA0776	0.44	8.86	0.38	1.69e-17	Headache;
LGG	cis	rs721399	0.752	rs1495741	chr8:18272881	G/A	cg18736775	chr8:18248649	NAT2	0.49	8.33	0.36	9.37e-16	Blood metabolite levels;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs3820068	0.581	rs58425551	chr1:15922518	A/G	cg05660106	chr1:15850417	CASP9	0.86	17.7	0.64	6.49e-54	Systolic blood pressure;
LGG	trans	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.67	0.41	2.78e-20	Mean corpuscular volume;
LGG	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg08219700	chr8:58056026	NA	0.52	11.35	0.47	1.72e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs3960554	0.867	rs79359354	chr7:75702597	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	12.73	0.51	4.75e-32	Eotaxin levels;
LGG	cis	rs2274273	1.000	rs67098772	chr14:55595242	G/A	cg04306507	chr14:55594613	LGALS3	0.61	16.99	0.62	1.11e-50	Protein biomarker;
LGG	cis	rs12780845	0.540	rs3780961	chr10:17195132	G/A	cg01003015	chr10:17271136	VIM	-0.45	-7.67	-0.34	1.06e-13	Homocysteine levels;
LGG	cis	rs11098499	0.731	rs10015579	chr4:120271802	T/C	cg09307838	chr4:120376055	NA	0.66	11.26	0.46	3.71e-26	Corneal astigmatism;
LGG	cis	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.62	0.41	4.28e-20	Mean corpuscular volume;
LGG	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.65	-0.3	8.42e-11	Lung cancer;
LGG	cis	rs7178909	0.872	rs10852124	chr15:90430464	C/T	cg19708238	chr15:90437601	AP3S2	0.4	6.84	0.3	2.56e-11	Common traits (Other);
LGG	cis	rs41342147	0.529	rs6718952	chr2:242219350	C/G	cg10173475	chr2:242152697	ANO7	-0.58	-8.94	-0.38	9.58e-18	Vitiligo;
LGG	cis	rs7751419	0.651	rs67034191	chr6:39094811	G/A	cg08089693	chr6:39098871	NA	-0.43	-7.74	-0.34	6.35e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs10927875	0.722	rs6696912	chr1:16338474	T/C	cg22431228	chr1:16359049	CLCNKA	-0.44	-7.17	-0.32	3.05e-12	Dilated cardiomyopathy;
LGG	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.57	0.33	2.05e-13	Mood instability;
LGG	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg03929089	chr4:120376271	NA	-0.51	-8.47	-0.37	3.32e-16	Height;
LGG	cis	rs1451375	0.698	rs11238226	chr7:50645827	A/G	cg00647317	chr7:50633725	DDC	-0.33	-7.49	-0.33	3.47e-13	Malaria;
LGG	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg04240660	chr16:89714849	CHMP1A	0.41	7.34	0.32	9.36e-13	Hemoglobin concentration;
LGG	cis	rs7765175	0.598	rs7742701	chr6:113660772	C/T	cg26552650	chr6:113682475	NA	-0.34	-7.59	-0.33	1.74e-13	Coronary artery calcification;
LGG	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg26384229	chr12:38710491	ALG10B	-0.84	-19.72	-0.68	2.61e-63	Heart rate;
LGG	cis	rs3540	0.920	rs7182658	chr15:91019248	A/T	cg22089800	chr15:90895588	ZNF774	0.52	8.16	0.35	3.14e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4148883	0.629	rs2602899	chr4:100010128	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.39	0.36	5.8e-16	Alcohol dependence;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.87	-0.34	2.5e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2213920	0.679	rs7047851	chr9:118220718	A/G	cg13918206	chr9:118159781	DEC1	-0.63	-8.99	-0.39	6.47e-18	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs741702	0.928	rs2974750	chr19:13044544	C/A	cg11738485	chr19:12877000	HOOK2	0.45	7.16	0.32	3.2e-12	Red blood cell traits;
LGG	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs6089584	0.816	rs6061410	chr20:60625329	A/G	cg06470251	chr20:60548479	NA	0.5	8.2	0.36	2.36e-15	Body mass index;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19717773	chr7:2847554	GNA12	0.34	7.09	0.31	5.12e-12	Height;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.712	rs258332	chr16:89727683	G/A	cg04287289	chr16:89883240	FANCA	-0.44	-7.87	-0.34	2.61e-14	Vitiligo;
LGG	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.65	0.56	3.23e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1577917	0.958	rs36053156	chr6:86575509	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.57	-0.56	7.58e-40	Response to antipsychotic treatment;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs977987	0.778	rs2865528	chr16:75455942	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.43	0.44	5.06e-23	Dupuytren's disease;
LGG	cis	rs9463078	0.753	rs1980265	chr6:44928868	C/A	cg25276700	chr6:44698697	NA	-0.39	-8.16	-0.35	3.23e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg22484793	chr3:52261325	TLR9	0.31	7.17	0.32	3.05e-12	Bipolar disorder;
LGG	cis	rs4144743	0.941	rs7211563	chr17:45324061	T/C	cg18085866	chr17:45331354	ITGB3	-0.77	-9.76	-0.41	1.36e-20	Body mass index;
LGG	cis	rs9398803	0.830	rs1415671	chr6:126759587	T/G	cg19875578	chr6:126661172	C6orf173	0.58	10.49	0.44	2.99e-23	Male-pattern baldness;
LGG	cis	rs7928758	0.943	rs11823810	chr11:134270070	A/G	cg25213107	chr11:134282864	B3GAT1	1.08	13.42	0.53	6.73e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs240764	0.548	rs12206838	chr6:101180128	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4716602	0.596	rs10458244	chr7:156164285	C/T	cg16983916	chr7:156159713	NA	-0.5	-9.64	-0.41	3.8e-20	Anti-saccade response;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg21226059	chr5:178986404	RUFY1	-0.49	-8.94	-0.38	8.99e-18	Lung cancer;
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg06521331	chr12:34319734	NA	-0.54	-10.14	-0.43	6.03e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9814567	0.722	rs13083717	chr3:134348796	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	11.26	0.46	3.83e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.07	0.35	6.25e-15	Colorectal cancer;
LGG	cis	rs975722	1.000	rs975722	chr7:117332914	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.48	-10.95	-0.45	5.68e-25	Coronary artery disease;
LGG	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg19507638	chr5:93509721	C5orf36	-0.66	-9.18	-0.39	1.45e-18	Diabetic retinopathy;
LGG	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.1	0.42	8.55e-22	Dupuytren's disease;
LGG	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.66e-12	Hemoglobin concentration;
LGG	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg13877915	chr19:58951672	ZNF132	0.59	8.24	0.36	1.85e-15	Mean platelet volume;
LGG	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.75e-11	Psoriasis vulgaris;
LGG	cis	rs11864453	0.713	rs12708927	chr16:72126165	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-9.38	-0.4	2.93e-19	Fibrinogen levels;
LGG	cis	rs3806843	1.000	rs2098058	chr5:140157427	A/C	cg19875535	chr5:140030758	IK	-0.52	-10.81	-0.45	1.87e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg04861929	chr11:109293070	C11orf87	0.55	9.92	0.42	3.62e-21	Schizophrenia;
LGG	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg09165964	chr15:75287851	SCAMP5	-1.07	-23.13	-0.73	3.02e-79	Blood trace element (Zn levels);
LGG	trans	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg06521331	chr12:34319734	NA	0.44	7.9	0.34	2.11e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7264396	0.676	rs1341603	chr20:34556216	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.81	0.3	3.09e-11	Total cholesterol levels;
LGG	cis	rs988958	0.565	rs6737944	chr2:42226621	G/A	cg27428208	chr2:42229179	NA	0.52	7.77	0.34	5.28e-14	Hypospadias;
LGG	cis	rs11966931	0.948	rs17528372	chr6:108093657	A/G	cg04749840	chr6:108095067	SCML4	0.42	7.18	0.32	2.77e-12	Neutrophil percentage of white cells;
LGG	cis	rs2439831	0.850	rs8042868	chr15:43939642	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.6	0.41	5.22e-20	Lung cancer in ever smokers;
LGG	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.86	-0.34	2.74e-14	Retinal vascular caliber;
LGG	cis	rs11190604	1.000	rs4919472	chr10:102315864	T/A	cg07080220	chr10:102295463	HIF1AN	0.72	11.93	0.48	8.31e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg16662043	chr16:48846231	NA	-0.36	-7.13	-0.31	3.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3820928	0.904	rs2396432	chr2:227765891	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.29	-0.32	1.36e-12	Pulmonary function;
LGG	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg22643751	chr7:855365	UNC84A	0.36	6.98	0.31	1.03e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.72	-0.45	4.14e-24	Systemic lupus erythematosus;
LGG	cis	rs12188164	0.812	rs9313065	chr5:423426	T/C	cg00049323	chr5:472564	LOC25845	-0.33	-6.82	-0.3	2.88e-11	Cystic fibrosis severity;
LGG	cis	rs2153535	0.580	rs2184584	chr6:8468407	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs208520	1.000	rs208527	chr6:66957209	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs986417	0.786	rs1254273	chr14:60843581	C/A	cg27398547	chr14:60952738	C14orf39	-0.7	-6.82	-0.3	2.87e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg27297192	chr10:134578999	INPP5A	0.32	7.23	0.32	1.97e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9326248	0.569	rs10047459	chr11:116721826	C/T	cg20608306	chr11:116969690	SIK3	0.33	7.17	0.32	3.01e-12	Blood protein levels;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg24690094	chr11:67383802	NA	0.5	9.1	0.39	2.62e-18	Mean corpuscular volume;
LGG	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg11887960	chr12:57824829	NA	0.56	6.91	0.31	1.61e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27116842	chr5:66300503	MAST4	0.49	7.13	0.31	3.91e-12	Gut microbiome composition (summer);
LGG	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	13.54	0.53	2e-35	Type 2 diabetes;
LGG	cis	rs8010715	0.520	rs12435994	chr14:24589461	A/C	cg06429887	chr14:24600500	FITM1	0.35	7.15	0.32	3.38e-12	IgG glycosylation;
LGG	cis	rs1401999	0.690	rs3805112	chr3:183645662	C/T	cg20387954	chr3:183756860	HTR3D	0.47	9.01	0.39	5.22e-18	Anterior chamber depth;
LGG	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg24675658	chr1:53192096	ZYG11B	-0.6	-13.23	-0.52	4.07e-34	Monocyte count;
LGG	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.45	0.5	6.78e-31	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.58	10.17	0.43	4.55e-22	Obesity-related traits;
LGG	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg25358565	chr5:93447407	FAM172A	-0.83	-11.48	-0.47	4.99e-27	Diabetic retinopathy;
LGG	cis	rs8056893	0.523	rs4783618	chr16:68356419	A/G	cg07273125	chr16:68295692	NA	0.39	8.41	0.36	5.01e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg21724239	chr8:58056113	NA	0.43	6.76	0.3	4.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg13282195	chr8:144660772	NAPRT1	0.94	7.45	0.33	4.57e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg24623649	chr8:11872141	NA	0.29	6.74	0.3	4.7e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg05585630	chr7:157510462	PTPRN2	-0.63	-11.23	-0.46	4.66e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg02023728	chr11:77925099	USP35	0.4	6.82	0.3	2.9100000000000002e-11	Alzheimer's disease (survival time);
LGG	cis	rs910316	0.874	rs61980828	chr14:75630378	G/A	cg11812906	chr14:75593930	NEK9	-0.52	-9.54	-0.41	8.5e-20	Height;
LGG	trans	rs2270927	0.510	rs31244	chr5:75594743	G/A	cg13563193	chr19:33072644	PDCD5	0.86	10.17	0.43	4.63e-22	Mean corpuscular volume;
LGG	cis	rs266717	0.816	rs266759	chr3:186508312	C/T	cg00373256	chr3:186519153	RFC4	-0.41	-8.31	-0.36	1.04e-15	Adiponectin levels;
LGG	cis	rs758324	0.738	rs399714	chr5:131318788	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.5	-0.37	2.65e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg24189917	chr7:1970923	MAD1L1	-0.52	-7.5	-0.33	3.25e-13	Bipolar disorder;
LGG	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg03929089	chr4:120376271	NA	-0.62	-8.02	-0.35	8.58e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11700980	0.551	rs12481736	chr21:30113657	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg12379764	chr21:47803548	PCNT	0.69	12.1	0.49	1.76e-29	Lymphocyte counts;
LGG	trans	rs1032833	0.732	rs2008215	chr2:180040127	C/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg21926883	chr2:100939477	LONRF2	-0.6	-12.6	-0.51	1.59e-31	Intelligence (multi-trait analysis);
LGG	cis	rs881375	0.678	rs7037195	chr9:123684000	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.84	0.42	7.42e-21	Rheumatoid arthritis;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.35	-0.43	1.03e-22	Tonsillectomy;
LGG	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.63	0.63	1.41e-53	Cognitive function;
LGG	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.25	-0.49	4.24e-30	Colorectal cancer;
LGG	trans	rs78456975	0.527	rs72776299	chr2:1570300	G/C	cg26093954	chr3:50375239	RASSF1	0.51	6.97	0.31	1.09e-11	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6784615	0.744	rs1541495	chr3:52492707	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.62	-7.33	-0.32	1.04e-12	Waist-hip ratio;
LGG	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.68	0.44	6.1e-24	Diabetic retinopathy;
LGG	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg15704280	chr7:45808275	SEPT13	0.48	7.92	0.35	1.73e-14	HDL cholesterol;
LGG	cis	rs45544231	0.535	rs8046979	chr16:52555742	A/G	cg09051775	chr16:52580266	TOX3	-0.41	-6.75	-0.3	4.47e-11	Restless legs syndrome;
LGG	cis	rs889398	0.651	rs1566455	chr16:69900164	G/T	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.87	-0.3	2.04e-11	Body mass index;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.84	0.3	2.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg21665744	chr7:39171113	POU6F2	0.39	7.95	0.35	1.39e-14	IgG glycosylation;
LGG	cis	rs754466	0.724	rs11002318	chr10:79633807	G/A	cg17075019	chr10:79541650	NA	-0.95	-20.24	-0.69	9.89e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg06521331	chr12:34319734	NA	-0.59	-11.02	-0.46	3.03e-25	Morning vs. evening chronotype;
LGG	cis	rs7474896	0.526	rs1208716	chr10:38089273	T/A	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.48	-0.33	3.8e-13	Obesity (extreme);
LGG	trans	rs2190422	0.678	rs1990168	chr7:103079685	G/A	cg21537297	chr8:144298583	GPIHBP1	-0.4	-6.65	-0.3	8.25e-11	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.721	rs11211151	chr1:46112752	T/C	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	4.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg15352829	chr14:105391018	PLD4	-0.47	-11.4	-0.47	1.07e-26	Rheumatoid arthritis;
LGG	trans	rs1997103	1.000	rs10252413	chr7:55396740	C/G	cg20935933	chr6:143382018	AIG1	0.59	9.14	0.39	1.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4959677	0.901	rs2185659	chr6:2486398	C/T	cg23817096	chr6:1620687	NA	-0.32	-7.74	-0.34	6.31e-14	Orthostatic hypotension;
LGG	cis	rs6496932	0.802	rs12439958	chr15:85853730	T/C	cg19183879	chr15:85880815	NA	0.42	6.71	0.3	5.7e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg06719900	chr11:109292894	C11orf87	-0.42	-7.45	-0.33	4.75e-13	Schizophrenia;
LGG	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.77	-8.79	-0.38	2.97e-17	Diabetic retinopathy;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg20453264	chr5:131705742	SLC22A5	-0.56	-7.25	-0.32	1.81e-12	Rheumatoid arthritis;
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg04025307	chr7:1156635	C7orf50	0.58	10.83	0.45	1.62e-24	Longevity;Endometriosis;
LGG	cis	rs2797160	1.000	rs6910933	chr6:126017155	C/G	cg05901451	chr6:126070800	HEY2	0.45	7.59	0.33	1.72e-13	Endometrial cancer;
LGG	cis	rs240764	0.725	rs239193	chr6:101131848	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.7	0.3	6.24e-11	Neuroticism;
LGG	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.42e-22	Iron status biomarkers;
LGG	cis	rs9715521	0.718	rs62301190	chr4:59842351	A/G	cg11281224	chr4:60001000	NA	-0.51	-8.48	-0.37	2.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-12.37	-0.5	1.41e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00684032	chr4:1343700	KIAA1530	0.43	8.34	0.36	8.31e-16	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs2327060	chr6:8447111	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg13271783	chr10:134563150	INPP5A	-0.47	-7.22	-0.32	2.17e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7582180	0.764	rs11689439	chr2:100925399	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg02002194	chr4:3960332	NA	0.42	7.65	0.33	1.16e-13	Neuroticism;
LGG	cis	rs6993813	1.000	rs6993813	chr8:120052238	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.29	7.46	0.33	4.19e-13	Bone mineral density (hip);
LGG	cis	rs734999	0.588	rs4648562	chr1:2535613	C/A	cg15627072	chr1:2432621	PLCH2	0.36	7.84	0.34	3.12e-14	Ulcerative colitis;
LGG	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.47	-0.74	8.28e-81	Primary sclerosing cholangitis;
LGG	cis	rs7953508	0.506	rs930316	chr12:93967035	A/G	cg18151635	chr12:93972918	NA	-0.56	-10.53	-0.44	2.1e-23	Pubertal anthropometrics;
LGG	cis	rs9611565	0.921	rs4822021	chr22:41726053	G/A	cg06634786	chr22:41940651	POLR3H	-0.68	-11.24	-0.46	4.48e-26	Vitiligo;
LGG	cis	rs9583531	0.527	rs2391866	chr13:111363294	A/T	cg15841412	chr13:111365552	ING1	0.45	7.1	0.31	4.59e-12	Coronary artery disease;
LGG	cis	rs1461503	0.934	rs7115651	chr11:122831882	C/T	cg27398637	chr11:122830231	C11orf63	-0.7	-14.49	-0.56	1.69e-39	Menarche (age at onset);
LGG	trans	rs11098499	0.955	rs35916640	chr4:120155852	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.05	0.46	2.29e-25	Corneal astigmatism;
LGG	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg27490568	chr2:178487706	NA	0.51	10.06	0.42	1.17e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14893161	chr1:205819251	PM20D1	0.55	9.99	0.42	2.15e-21	Prostate cancer;
LGG	cis	rs12200782	0.649	rs9467742	chr6:26386363	A/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg05941027	chr17:61774174	LIMD2	0.37	9.64	0.41	3.75e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg11494091	chr17:61959527	GH2	0.51	8.16	0.35	3.17e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg08822215	chr16:89438651	ANKRD11	0.35	6.79	0.3	3.5e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs9487051	0.735	rs1761608	chr6:109517706	G/A	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.69e-13	Reticulocyte fraction of red cells;
LGG	cis	rs1801251	1.000	rs2044449	chr2:233718808	G/A	cg25237894	chr2:233734115	C2orf82	-0.66	-12.61	-0.51	1.53e-31	Coronary artery disease;
LGG	cis	rs4740619	0.811	rs954664	chr9:15695882	A/T	cg14451791	chr9:16040625	NA	0.33	8.32	0.36	1.03e-15	Body mass index;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.54	8.89	0.38	1.37e-17	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs193541	0.586	rs11241662	chr5:122181975	A/G	cg19412675	chr5:122181750	SNX24	-0.54	-8.65	-0.37	8.55e-17	Glucose homeostasis traits;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.84	-0.54	1.06e-36	Tonsillectomy;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.34	-0.5	1.98e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.76	0.38	3.57e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg11890956	chr21:40555474	PSMG1	-0.99	-21.49	-0.71	1.51e-71	Cognitive function;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.33	-0.36	9.35e-16	Neuroticism;
LGG	cis	rs6694672	1.000	rs1412631	chr1:197037237	C/T	cg13682187	chr1:196946512	CFHR5	-0.47	-6.85	-0.3	2.32e-11	Asthma;
LGG	cis	rs1862618	0.573	rs1550821	chr5:56242323	C/T	cg08400814	chr5:56204995	C5orf35	0.52	8.06	0.35	6.58e-15	Initial pursuit acceleration;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	9.04	0.39	4.33e-18	Obesity-related traits;
LGG	cis	rs7444	0.941	rs5749485	chr22:21938224	A/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	cis	rs11700980	0.591	rs2832046	chr21:30116806	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.06	-0.31	6.14e-12	Blood metabolite levels;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg25358565	chr5:93447407	FAM172A	1.31	15.98	0.6	4.4e-46	Diabetic retinopathy;
LGG	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg21427119	chr20:30132790	HM13	-0.5	-8.18	-0.36	2.74e-15	Mean corpuscular hemoglobin;
LGG	cis	rs10871290	0.881	rs3863439	chr16:74470644	T/C	cg01733217	chr16:74700730	RFWD3	-0.75	-14.53	-0.56	1.09e-39	Breast cancer;
LGG	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	cg07928641	chr1:182991847	LAMC1	-0.46	-9.28	-0.4	6.41e-19	Colorectal cancer;
LGG	cis	rs920590	0.876	rs3907478	chr8:19657753	G/T	cg03894339	chr8:19674705	INTS10	0.55	9.01	0.39	5.46e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.36	-0.32	8.28e-13	Bipolar disorder;
LGG	cis	rs17453880	0.890	rs4958563	chr5:151981337	A/G	cg10931792	chr5:152022470	NA	0.38	8.3	0.36	1.11e-15	Subjective well-being;
LGG	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.45	0.67	4.73e-62	Smoking behavior;
LGG	trans	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21659725	chr3:3221576	CRBN	0.62	10.4	0.44	6.32e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.0	-0.46	3.79e-25	Type 2 diabetes;
LGG	cis	rs4561483	0.801	rs154148	chr16:11956478	T/C	cg08843971	chr16:11963173	GSPT1	-0.66	-17.31	-0.63	3.82e-52	Testicular germ cell tumor;
LGG	cis	rs7944584	0.551	rs12224672	chr11:47500400	C/T	cg20307385	chr11:47447363	PSMC3	0.85	17.13	0.62	2.58e-51	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs17253792	0.545	rs35536987	chr14:56024021	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.73e-13	Menopause (age at onset);
LGG	cis	rs4423214	0.840	rs1790343	chr11:71177207	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.36	-0.32	8.26e-13	Testicular germ cell tumor;
LGG	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg25986240	chr4:9926439	SLC2A9	0.33	6.82	0.3	2.85e-11	Bone mineral density;
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.06e-12	Aortic root size;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg05091796	chr16:4465799	CORO7	-0.82	-13.74	-0.54	2.96e-36	Schizophrenia;
LGG	cis	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg19171272	chr22:38449367	NA	0.56	10.94	0.45	6.32e-25	Glioblastoma;Glioma;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.594	rs1985785	chr17:46967788	T/C	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.07e-14	Type 2 diabetes;
LGG	cis	rs7737355	0.812	rs10062078	chr5:130764102	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.79	-0.38	2.89e-17	Life satisfaction;
LGG	cis	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg21775007	chr8:11205619	TDH	-0.83	-14.62	-0.56	4.53e-40	Retinal vascular caliber;
LGG	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.16	0.58	1.9e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg14668632	chr7:2872130	GNA12	-0.37	-7.6	-0.33	1.7e-13	Height;
LGG	cis	rs13266463	0.830	rs7014552	chr8:143410423	A/G	cg16886403	chr8:143471632	TSNARE1	0.49	7.92	0.35	1.79e-14	Schizophrenia;
LGG	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg23306229	chr2:178417860	TTC30B	0.72	8.71	0.38	5.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs75059851	0.756	rs11223650	chr11:133840647	A/G	cg20042908	chr11:133852938	NA	-0.76	-14.24	-0.55	2.09e-38	Schizophrenia;
LGG	cis	rs239198	0.577	rs34716527	chr6:101284416	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.09	0.31	5.09e-12	Menarche (age at onset);
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg23978390	chr7:1156363	C7orf50	0.45	6.77	0.3	4.02e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs638893	1.000	rs649338	chr11:118705654	A/G	cg22253036	chr11:118662786	DDX6	0.41	6.94	0.31	1.35e-11	Vitiligo;
LGG	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg23335576	chr14:104009727	NA	0.42	7.12	0.31	4.27e-12	Reticulocyte count;
LGG	cis	rs7264396	0.635	rs6060673	chr20:34482396	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.5	-7.27	-0.32	1.52e-12	Total cholesterol levels;
LGG	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg19774624	chr17:42201019	HDAC5	-0.95	-20.65	-0.69	1.17e-67	Total body bone mineral density;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg06074448	chr4:187884817	NA	-0.59	-12.86	-0.51	1.36e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.55	0.59	3.66e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs992157	0.835	rs2292551	chr2:219143229	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.25	-0.49	4.24e-30	Colorectal cancer;
LGG	trans	rs6582630	0.576	rs4882375	chr12:38371939	G/T	cg06521331	chr12:34319734	NA	0.46	8.25	0.36	1.6e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.75	-0.54	2.59e-36	Bladder cancer;
LGG	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg18154014	chr19:37997991	ZNF793	0.46	7.85	0.34	2.9e-14	Coronary artery calcification;
LGG	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg16586182	chr3:47516702	SCAP	-0.79	-15.44	-0.58	1.09e-43	Colorectal cancer;
LGG	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg07148914	chr20:33460835	GGT7	0.43	6.88	0.3	1.94e-11	Height;
LGG	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.79	-0.38	2.93e-17	Alzheimer's disease (survival time);
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg09699651	chr6:150184138	LRP11	0.54	9.55	0.41	7.49e-20	Lung cancer;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg18446336	chr7:2847575	GNA12	-0.28	-6.64	-0.3	8.59e-11	Height;
LGG	cis	rs1878931	0.582	rs27238	chr16:3441223	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-11.51	-0.47	4.08e-27	Body mass index (adult);
LGG	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg02023728	chr11:77925099	USP35	-0.39	-6.8	-0.3	3.28e-11	Alzheimer's disease (survival time);
LGG	cis	rs7412746	0.634	rs12562939	chr1:150951452	A/C	cg15448220	chr1:150897856	SETDB1	0.39	7.08	0.31	5.53e-12	Melanoma;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.48	-0.37	2.94e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.66	0.41	3.12e-20	Total body bone mineral density;
LGG	cis	rs9880211	1.000	rs28641809	chr3:136290489	G/A	cg21827317	chr3:136751795	NA	-0.49	-7.3	-0.32	1.24e-12	Body mass index;Height;
LGG	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg08700190	chr5:6636046	SRD5A1	-0.32	-6.69	-0.3	6.43e-11	Response to amphetamines;
LGG	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg06917634	chr15:78832804	PSMA4	-0.69	-12.74	-0.51	4.52e-32	Sudden cardiac arrest;
LGG	cis	rs9467773	1.000	rs6932156	chr6:26571506	T/G	cg09904177	chr6:26538194	HMGN4	0.77	16.91	0.62	2.6e-50	Intelligence (multi-trait analysis);
LGG	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg27053975	chr1:166958233	MAEL	-0.49	-7.02	-0.31	7.98e-12	Obesity-related traits;
LGG	trans	rs61931739	0.513	rs10844698	chr12:33890158	C/T	cg13010199	chr12:38710504	ALG10B	0.47	9.01	0.39	5.27e-18	Morning vs. evening chronotype;
LGG	cis	rs7765175	0.698	rs1565528	chr6:113669875	A/G	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.41e-13	Coronary artery calcification;
LGG	cis	rs977987	1.000	rs62060550	chr16:75502252	C/T	cg07303275	chr16:75499416	TMEM170A	0.41	7.32	0.32	1.1e-12	Dupuytren's disease;
LGG	cis	rs10193935	0.901	rs12615383	chr2:42610551	A/G	cg27598129	chr2:42591480	NA	0.68	10.02	0.42	1.55e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.33	-0.36	9.25e-16	Personality dimensions;
LGG	cis	rs701145	0.537	rs446144	chr3:153922154	T/C	cg12800244	chr3:153838788	SGEF	0.82	8.4	0.36	5.65e-16	Coronary artery disease;
LGG	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.04e-21	Aortic root size;
LGG	cis	rs9400467	0.537	rs17663278	chr6:111504881	A/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.11	0.31	4.29e-12	Blood metabolite levels;Amino acid levels;
LGG	trans	rs7615952	0.551	rs6438945	chr3:125634473	G/A	cg07211511	chr3:129823064	LOC729375	-1.39	-21.25	-0.7	1.96e-70	Blood pressure (smoking interaction);
LGG	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg17509989	chr5:176798049	RGS14	0.81	13.07	0.52	1.95e-33	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22618164	chr12:122356400	WDR66	0.3	8.59	0.37	1.31e-16	Mean corpuscular volume;
LGG	cis	rs7215564	0.908	rs4969246	chr17:78740579	G/A	cg06153925	chr17:78755379	RPTOR	-0.4	-7.1	-0.31	4.72e-12	Myopia (pathological);
LGG	cis	rs10466868	0.580	rs11061492	chr12:131863336	G/C	cg23061396	chr12:131862608	NA	0.52	6.86	0.3	2.25e-11	Protein quantitative trait loci;
LGG	cis	rs7586673	0.893	rs889925	chr2:161971597	T/C	cg22496339	chr2:162101262	NA	-0.34	-6.72	-0.3	5.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.64	-0.37	9.46e-17	Lung cancer;
LGG	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.79e-21	Diabetic retinopathy;
LGG	cis	rs7843479	0.965	rs3816786	chr8:21860425	A/T	cg17168535	chr8:21777572	XPO7	0.59	9.5	0.4	1.1e-19	Mean corpuscular volume;
LGG	cis	rs2013441	0.866	rs7207817	chr17:20221328	A/G	cg13482628	chr17:19912719	NA	-0.41	-7.0	-0.31	8.94e-12	Obesity-related traits;
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.28e-23	Intelligence (multi-trait analysis);
LGG	cis	rs12042938	0.507	rs1765777	chr1:231731742	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-14.94	-0.57	1.81e-41	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg03733263	chr8:22462867	KIAA1967	1.13	33.38	0.84	2.55e-125	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-15.88	-0.59	1.15e-45	Mean platelet volume;Platelet distribution width;
LGG	trans	rs6598955	0.671	rs59143843	chr1:26641595	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.6	-0.51	1.66e-31	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg04842962	chr6:43655489	MRPS18A	1.11	24.73	0.75	1.05e-86	IgG glycosylation;
LGG	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.34	-0.36	8.82e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs55883249	1.000	rs62119423	chr2:9726601	C/T	cg23886495	chr2:9695866	ADAM17	0.65	9.37	0.4	3.28e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg09461388	chr22:46763229	CELSR1	-0.67	-7.4	-0.33	6.47e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs11874712	0.527	rs7359800	chr18:43649187	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.66	-16.01	-0.6	3.09e-46	Migraine - clinic-based;
LGG	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg25457927	chr22:38595422	NA	-0.43	-10.84	-0.45	1.46e-24	Cutaneous nevi;
LGG	trans	rs11039798	0.588	rs3924476	chr11:48581733	T/C	cg03929089	chr4:120376271	NA	0.71	9.85	0.42	6.78e-21	Axial length;
LGG	cis	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg03060546	chr3:49711283	APEH	-0.6	-8.11	-0.35	4.45e-15	Menarche (age at onset);
LGG	cis	rs2573652	0.722	rs12904962	chr15:100544113	A/G	cg14911520	chr15:100542628	ADAMTS17	0.29	7.21	0.32	2.29e-12	Height;
LGG	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs3812049	0.826	rs34576922	chr5:127364103	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.62	-10.17	-0.43	4.59e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs36051895	0.658	rs10974910	chr9:5010091	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-14.23	-0.55	2.3e-38	Pediatric autoimmune diseases;
LGG	cis	rs1497828	1.000	rs2810770	chr1:217563574	A/G	cg04411442	chr1:217543379	NA	-0.45	-7.72	-0.34	7.41e-14	Dialysis-related mortality;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09229947	chr4:153701185	ARFIP1;TIGD4	-0.46	-6.94	-0.31	1.3e-11	Pancreatic cancer;
LGG	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg02269571	chr22:50332266	NA	-0.63	-9.55	-0.41	7.54e-20	Schizophrenia;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg05368731	chr17:41323189	NBR1	0.86	16.22	0.6	3.45e-47	Menopause (age at onset);
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg15971980	chr6:150254442	NA	0.44	8.23	0.36	1.91e-15	Lung cancer;
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	17.46	0.63	8.32e-53	Tonsillectomy;
LGG	cis	rs7917772	0.546	rs10883743	chr10:104338389	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7577696	0.568	rs7574000	chr2:32342888	A/C	cg02381751	chr2:32503542	YIPF4	-0.45	-6.7	-0.3	5.88e-11	Inflammatory biomarkers;
LGG	cis	rs4750440	0.523	rs4565801	chr10:14032358	G/A	cg27542038	chr10:14027202	FRMD4A	-0.73	-14.3	-0.55	1.08e-38	Adiponectin levels;
LGG	cis	rs73416724	1.000	rs75782458	chr6:43340810	G/A	cg26312998	chr6:43337775	ZNF318	0.61	8.57	0.37	1.59e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.31	0.43	1.43e-22	Height;
LGG	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg25358565	chr5:93447407	FAM172A	-0.84	-11.72	-0.48	5.64e-28	Diabetic retinopathy;
LGG	cis	rs4740619	0.619	rs1410455	chr9:16042277	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.47	-0.47	5.58e-27	Body mass index;
LGG	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg01631408	chr1:248437212	OR2T33	-0.39	-7.12	-0.31	4.26e-12	Common traits (Other);
LGG	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.5	7.23	0.32	2.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg01507046	chr17:48637818	CACNA1G	0.44	6.84	0.3	2.58e-11	Emphysema imaging phenotypes;
LGG	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.09	-0.49	2.05e-29	Chronic sinus infection;
LGG	cis	rs6809651	0.524	rs1356292	chr3:185824903	C/T	cg00760338	chr3:185826511	ETV5	0.93	15.47	0.58	8.21e-44	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg26513180	chr16:89883248	FANCA	0.93	20.06	0.68	6.86e-65	Vitiligo;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg20309703	chr11:118481025	PHLDB1	-0.45	-8.33	-0.36	9.05e-16	Glioma;
LGG	cis	rs4538187	0.804	rs36123537	chr2:64217490	G/A	cg02541582	chr2:64069798	UGP2	-0.6	-13.87	-0.54	7.63e-37	Systolic blood pressure;
LGG	cis	rs4363385	0.553	rs28924721	chr1:152974254	C/T	cg13444842	chr1:152974279	SPRR3	-0.49	-9.75	-0.41	1.46e-20	Inflammatory skin disease;
LGG	trans	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.91	-0.31	1.58e-11	Heart rate;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg08847533	chr14:75593920	NEK9	-0.6	-11.37	-0.47	1.34e-26	Height;
LGG	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg25358565	chr5:93447407	FAM172A	1.35	16.44	0.61	3.48e-48	Diabetic retinopathy;
LGG	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg16395133	chr6:150326394	RAET1K	0.28	7.16	0.32	3.25e-12	Alopecia areata;
LGG	cis	rs6547741	1.000	rs6547734	chr2:27830990	G/T	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs4732038	0.510	rs11976004	chr7:134272392	C/A	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs9487094	0.614	rs13191444	chr6:110084064	A/G	cg01125227	chr6:109776195	MICAL1	0.51	8.35	0.36	8.25e-16	Height;
LGG	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.24	-0.32	1.83e-12	Neuroticism;
LGG	cis	rs6740322	0.644	rs11690918	chr2:43474112	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-10.74	-0.45	3.46e-24	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg07959490	chr17:80112427	CCDC57	-0.49	-9.65	-0.41	3.47e-20	Life satisfaction;
LGG	cis	rs7927771	0.524	rs10838769	chr11:47825333	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-10.84	-0.45	1.55e-24	Subjective well-being;
LGG	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.75	0.48	4.44e-28	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs783540	0.934	rs4779053	chr15:83371598	T/C	cg16105309	chr15:79090380	ADAMTS7	-0.44	-7.6	-0.33	1.68e-13	Schizophrenia;
LGG	cis	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg27411982	chr8:10470053	RP1L1	-0.47	-8.07	-0.35	6.3e-15	Triglycerides;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg18538332	chr22:24372958	LOC391322	-0.52	-8.54	-0.37	1.91e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs990171	1.000	rs2270297	chr2:102992675	T/C	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.33e-21	Lymphocyte counts;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg03821543	chr20:57463925	GNAS	-0.37	-6.65	-0.3	8.36e-11	Migraine with aura;
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg03709012	chr19:19516395	GATAD2A	-0.85	-17.01	-0.62	9.71e-51	Tonsillectomy;
LGG	cis	rs72949976	0.934	rs10197392	chr2:214038178	G/A	cg08319019	chr2:214017104	IKZF2	-0.6	-10.11	-0.43	7.6e-22	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs8114671	0.628	rs6060130	chr20:33549319	C/T	cg07148914	chr20:33460835	GGT7	0.54	9.0	0.39	6.04e-18	Height;
LGG	cis	rs11585357	0.671	rs2501776	chr1:17619279	C/T	cg08277548	chr1:17600880	PADI3	0.52	7.04	0.31	6.79e-12	Hair shape;
LGG	cis	rs11191270	1.000	rs4919626	chr10:104079818	T/C	cg15320455	chr10:103880129	LDB1	0.5	7.05	0.31	6.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg03474202	chr17:45855739	NA	-0.27	-7.96	-0.35	1.36e-14	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.48	0.33	3.86e-13	Menopause (age at onset);
LGG	trans	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs3796619	0.961	rs11732520	chr4:1074009	C/T	cg27284194	chr4:1044797	NA	0.56	11.37	0.47	1.4e-26	Recombination rate (males);
LGG	cis	rs2013441	1.000	rs2703792	chr17:20166950	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg08280861	chr8:58055591	NA	0.51	6.8	0.3	3.16e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.69	0.37	6.09e-17	Joint mobility (Beighton score);
LGG	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg26384229	chr12:38710491	ALG10B	0.69	13.31	0.53	1.91e-34	Bladder cancer;
LGG	cis	rs2688608	0.623	rs2633317	chr10:75690268	A/G	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.25	-0.32	1.79e-12	Inflammatory bowel disease;
LGG	cis	rs2067615	0.560	rs4964485	chr12:107121952	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.0	0.49	4.55e-29	Heart rate;
LGG	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg06197492	chr11:2016605	H19	0.5	10.42	0.44	5.55e-23	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg17376030	chr22:41985996	PMM1	-0.41	-7.52	-0.33	2.95e-13	Alzheimer's disease biomarkers;
LGG	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg08824895	chr13:115047677	UPF3A	0.41	6.87	0.3	2.08e-11	Schizophrenia;
LGG	cis	rs526231	0.543	rs62362521	chr5:102306061	G/A	cg23492399	chr5:102201601	PAM	-0.62	-9.34	-0.4	4.14e-19	Primary biliary cholangitis;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg04267008	chr7:1944627	MAD1L1	-0.56	-9.46	-0.4	1.51e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.83e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.567	rs6088796	chr20:30213229	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	8.89	0.38	1.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs6579956	0.537	rs7719628	chr5:152070715	C/G	cg12297329	chr5:152029980	NA	0.42	7.01	0.31	8.57e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs9287719	0.935	rs10803723	chr2:10722877	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg10818794	chr15:86012489	AKAP13	-0.39	-8.25	-0.36	1.64e-15	Coronary artery disease;
LGG	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.48	-0.33	3.81e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7336332	0.598	rs74183666	chr13:28007765	A/T	cg01674679	chr13:27998804	GTF3A	-0.67	-8.58	-0.37	1.5e-16	Weight;
LGG	cis	rs7412746	0.658	rs3768015	chr1:150812954	C/T	cg15448220	chr1:150897856	SETDB1	0.39	7.18	0.32	2.82e-12	Melanoma;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs977987	0.843	rs6564259	chr16:75447393	T/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs2354432	0.607	rs7545467	chr1:146746248	A/G	cg25205988	chr1:146714368	CHD1L	-1.47	-15.07	-0.57	4.59e-42	Mitochondrial DNA levels;
LGG	cis	rs977987	0.806	rs6564252	chr16:75388940	C/T	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg08645402	chr16:4508243	NA	0.51	9.75	0.41	1.52e-20	Schizophrenia;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-7.89	-0.34	2.2e-14	Skin colour saturation;
LGG	cis	rs763121	0.925	rs9835	chr22:39130971	A/G	cg06022373	chr22:39101656	GTPBP1	0.79	15.82	0.59	2.15e-45	Menopause (age at onset);
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg18350739	chr11:68623251	NA	-0.87	-22.71	-0.73	2.85e-77	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg00684032	chr4:1343700	KIAA1530	-0.47	-9.12	-0.39	2.3e-18	Obesity-related traits;
LGG	cis	rs9359856	0.623	rs1179907	chr6:90324849	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.27	-0.43	2.04e-22	Bipolar disorder;
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg11764359	chr7:65958608	NA	0.74	13.25	0.52	3.26e-34	Aortic root size;
LGG	cis	rs9790314	0.747	rs9848239	chr3:160823488	A/C	cg04691961	chr3:161091175	C3orf57	-0.54	-11.81	-0.48	2.63e-28	Morning vs. evening chronotype;
LGG	cis	rs6714710	0.603	rs11691494	chr2:98419726	T/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs6601327	0.613	rs33994795	chr8:9473429	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.52	0.33	2.83e-13	Multiple myeloma (hyperdiploidy);
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg18000306	chr6:288505	NA	-0.61	-10.96	-0.45	5.44e-25	Menopause (age at onset);
LGG	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12667521	chr19:29218732	NA	0.63	9.53	0.4	8.8e-20	Methadone dose in opioid dependence;
LGG	cis	rs2249625	0.564	rs2496496	chr6:72884053	A/G	cg27608224	chr6:72922399	RIMS1	0.32	7.23	0.32	2.05e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs7226408	0.857	rs72890545	chr18:34603292	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.07	-0.31	5.63e-12	Educational attainment;
LGG	cis	rs412658	0.812	rs17554725	chr19:22317759	A/G	cg25360861	chr19:22235199	ZNF257	-0.39	-6.65	-0.3	8.17e-11	Telomere length;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg20821713	chr7:1055600	C7orf50	-0.52	-7.76	-0.34	5.44e-14	Bronchopulmonary dysplasia;
LGG	cis	rs9472414	0.510	rs3997503	chr6:44708416	G/A	cg20913747	chr6:44695427	NA	0.46	7.61	0.33	1.59e-13	Height;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.25	-0.43	2.35e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg23231163	chr10:75533350	FUT11	-0.42	-7.11	-0.31	4.38e-12	Inflammatory bowel disease;
LGG	cis	rs34599045	0.522	rs71626737	chr1:152901930	A/G	cg07796016	chr1:152779584	LCE1C	-0.81	-7.51	-0.33	3.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10089	1.000	rs4836367	chr5:127482592	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.82	0.48	2.33e-28	Ileal carcinoids;
LGG	cis	rs6815814	0.950	rs73236618	chr4:38794041	T/C	cg06935464	chr4:38784597	TLR10	0.61	8.15	0.35	3.44e-15	Breast cancer;
LGG	cis	rs7781557	1.000	rs7781557	chr7:102481891	A/G	cg18108683	chr7:102477205	FBXL13	0.54	8.44	0.37	4.02e-16	Colorectal adenoma (advanced);
LGG	cis	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg19338460	chr6:170058176	WDR27	-0.58	-8.08	-0.35	5.77e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg00405596	chr8:11794950	NA	0.42	7.08	0.31	5.45e-12	Mood instability;
LGG	cis	rs10791097	0.694	rs4936123	chr11:130740967	G/A	cg12179176	chr11:130786555	SNX19	0.87	18.91	0.66	1.71e-59	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs735539	0.609	rs7332034	chr13:21214943	T/C	cg04906043	chr13:21280425	IL17D	-0.53	-8.68	-0.37	6.68e-17	Dental caries;
LGG	cis	rs5750830	0.597	rs4821889	chr22:39777254	T/C	cg04986931	chr22:39850128	NA	0.32	7.25	0.32	1.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg03213289	chr20:61660250	NA	0.65	13.96	0.54	3.26e-37	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs78545713	0.649	rs74928264	chr6:26224343	C/G	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs4639966	0.756	rs61219050	chr11:118648624	C/A	cg20110707	chr11:118481992	PHLDB1	-0.42	-6.81	-0.3	3e-11	Systemic lupus erythematosus;
LGG	cis	rs4731207	0.596	rs1481330	chr7:124631363	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg06873352	chr17:61820015	STRADA	-0.74	-13.81	-0.54	1.39e-36	Prudent dietary pattern;
LGG	cis	rs7555523	0.830	rs1547725	chr1:165670958	T/C	cg24409356	chr1:165738333	TMCO1	0.61	6.98	0.31	1e-11	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs3857067	0.806	rs72665627	chr4:95111824	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.49e-11	Coronary artery disease;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg02985366	chr16:32360428	NA	-0.45	-6.96	-0.31	1.2e-11	Menopause (age at onset);
LGG	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs656319	0.647	rs13264668	chr8:9884877	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.12	0.31	4.08e-12	Myopia (pathological);
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11792861	0.781	rs72607159	chr9:111764270	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.94	0.42	3.11e-21	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg23625390	chr15:77176239	SCAPER	-0.73	-12.92	-0.51	8.07e-33	Blood metabolite levels;
LGG	cis	rs7666738	0.830	rs17558151	chr4:99048699	T/C	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs66716358	0.744	rs11037943	chr11:44317445	A/G	cg16977035	chr11:44330474	ALX4	0.37	9.5	0.4	1.11e-19	Monobrow;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.13	-0.31	3.95e-12	Total cholesterol levels;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg22044901	chr15:68126292	NA	-0.4	-6.8	-0.3	3.25e-11	Restless legs syndrome;
LGG	cis	rs7582720	1.000	rs72926783	chr2:203815740	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.92	-11.98	-0.49	5.46e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9790314	0.812	rs2004862	chr3:161135638	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-8.95	-0.38	8.48e-18	Morning vs. evening chronotype;
LGG	cis	rs2865126	0.868	rs8092939	chr18:10765730	A/G	cg21165219	chr18:10698044	FAM38B	-0.47	-7.25	-0.32	1.79e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg15921436	chr17:44337874	NA	0.45	10.57	0.44	1.59e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg05082376	chr22:42548792	NA	-0.35	-7.56	-0.33	2.21e-13	Schizophrenia;
LGG	cis	rs4740619	0.740	rs1539172	chr9:15784631	A/G	cg14451791	chr9:16040625	NA	0.32	8.05	0.35	6.88e-15	Body mass index;
LGG	cis	rs514406	0.505	rs440871	chr1:53173052	C/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-13.53	-0.53	2.12e-35	Monocyte count;
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg03264133	chr6:25882463	NA	-0.54	-10.22	-0.43	3.04e-22	Blood metabolite levels;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.82	0.7	2.01e-68	Platelet count;
LGG	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.81	-0.45	1.99e-24	Aortic root size;
LGG	cis	rs344364	0.602	rs2745193	chr16:1853959	A/G	cg26897989	chr16:1907736	C16orf73	0.51	9.35	0.4	3.67e-19	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg05036130	chr6:150231994	NA	0.35	6.88	0.3	1.99e-11	Testicular germ cell tumor;
LGG	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	7.55	0.33	2.28e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg11901034	chr3:128598214	ACAD9	-0.44	-6.7	-0.3	6.18e-11	IgG glycosylation;
LGG	cis	rs9463078	0.605	rs9472411	chr6:44943183	T/C	cg25276700	chr6:44698697	NA	0.34	7.04	0.31	6.79e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2371030	1.000	rs10167685	chr2:211568055	A/T	cg18417063	chr2:211583084	NA	-0.63	-12.13	-0.49	1.32e-29	Non-small cell lung cancer;
LGG	cis	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg06521331	chr12:34319734	NA	-0.61	-11.55	-0.47	2.71e-27	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	28.98	0.8	4.36e-106	Chronic sinus infection;
LGG	cis	rs10791323	0.628	rs10750543	chr11:133718467	G/A	cg15485101	chr11:133734466	NA	0.61	10.72	0.45	4.28e-24	Childhood ear infection;
LGG	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.87	-0.45	1.17e-24	Hemoglobin concentration;
LGG	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg24331049	chr13:111365604	ING1	-0.88	-15.35	-0.58	2.8e-43	Coronary artery disease;
LGG	cis	rs834603	0.575	rs1704968	chr7:47468231	T/C	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs3784262	0.967	rs11630835	chr15:58269462	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.26	-0.36	1.57e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19738812	chr7:99102438	ZKSCAN5	-0.46	-6.82	-0.3	2.94e-11	Systemic lupus erythematosus;
LGG	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg10224037	chr5:178157518	ZNF354A	0.77	12.68	0.51	7.54e-32	Neutrophil percentage of white cells;
LGG	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.16	0.35	3.27e-15	Iron status biomarkers;
LGG	cis	rs4704846	0.614	rs6420075	chr5:156486120	C/G	cg12943317	chr5:156479607	HAVCR1	0.6	8.14	0.35	3.72e-15	Blood protein levels;
LGG	cis	rs6951245	0.572	rs74791540	chr7:1061913	C/A	cg18402987	chr7:1209562	NA	0.63	6.96	0.31	1.16e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg24112000	chr20:60950667	NA	-0.4	-8.21	-0.36	2.24e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs17209837	1.000	rs66510518	chr7:87111875	C/G	cg00919237	chr7:87102261	ABCB4	-0.73	-11.93	-0.49	8.19e-29	Gallbladder cancer;
LGG	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.44	-0.33	5.1e-13	Iron status biomarkers;
LGG	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.48	-0.72	3.37e-76	Height;
LGG	cis	rs7134594	0.714	rs7313056	chr12:109871458	T/C	cg19025524	chr12:109796872	NA	-0.44	-8.95	-0.38	8.49e-18	HDL cholesterol;
LGG	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.07	-0.31	5.8e-12	Common traits (Other);
LGG	cis	rs2712184	0.875	rs7586692	chr2:217674703	G/T	cg05032264	chr2:217675019	NA	-0.44	-9.56	-0.41	6.93e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15997484	chr3:62859461	CADPS	0.48	7.35	0.32	9.27e-13	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7395662	0.963	rs4882109	chr11:48557685	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	trans	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg26043149	chr18:55253948	FECH	0.43	7.22	0.32	2.12e-12	Bone mineral density;
LGG	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.43	-0.44	5.26e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10876993	0.928	rs2640636	chr12:58077544	A/G	cg18357645	chr12:58087776	OS9	0.71	13.07	0.52	1.9e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs1506636	1.000	rs12333705	chr7:123356062	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs6784615	0.744	rs4687541	chr3:52495365	G/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12517452	chr5:52084045	ITGA1;PELO	0.46	7.75	0.34	6e-14	Cognitive performance;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg04503457	chr17:41445688	NA	-0.39	-9.14	-0.39	2.03e-18	Menopause (age at onset);
LGG	cis	rs35740288	0.505	rs338500	chr15:86184118	G/A	cg04173714	chr15:86211321	AKAP13	0.4	8.17	0.35	3.06e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg08807101	chr21:30365312	RNF160	-0.75	-13.63	-0.54	8.23e-36	Selective IgA deficiency;
LGG	cis	rs77633900	0.614	rs2930681	chr15:76995150	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-10.03	-0.42	1.42e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg00761968	chr13:53314142	LECT1	-0.36	-7.62	-0.33	1.49e-13	Lewy body disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16219491	chr6:26197733	HIST1H3D	0.44	7.28	0.32	1.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.62e-12	Cognitive ability;
LGG	cis	rs62400317	0.859	rs62436780	chr6:45128261	A/T	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	cis	rs11190604	1.000	rs7099965	chr10:102301165	A/G	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg02002194	chr4:3960332	NA	-0.52	-9.78	-0.41	1.15e-20	Retinal vascular caliber;
LGG	cis	rs7587476	0.784	rs34112702	chr2:215696002	A/G	cg04004882	chr2:215674386	BARD1	0.57	8.23	0.36	1.88e-15	Neuroblastoma;
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg13010199	chr12:38710504	ALG10B	0.41	7.49	0.33	3.42e-13	Morning vs. evening chronotype;
LGG	cis	rs10888329	0.741	rs6587438	chr1:248355881	G/C	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Autism spectrum disorder;
LGG	cis	rs4356932	1.000	rs11097223	chr4:76987496	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.78	-0.3	3.76e-11	Blood protein levels;
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg16141378	chr3:129829833	LOC729375	-0.49	-12.32	-0.5	2.27e-30	Neuroticism;
LGG	cis	rs6430585	0.583	rs6728946	chr2:136635343	C/G	cg07169764	chr2:136633963	MCM6	1.3	27.3	0.79	1.7e-98	Corneal structure;
LGG	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.06	-0.31	6.01e-12	Height;
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.47	-7.2	-0.32	2.46e-12	Tonsillectomy;
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01341218	chr17:43662625	NA	-0.65	-11.77	-0.48	3.61e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2070433	0.800	rs11700596	chr21:47874054	G/C	cg12379764	chr21:47803548	PCNT	0.67	9.53	0.41	8.77e-20	Lymphocyte counts;
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg04287289	chr16:89883240	FANCA	0.81	17.33	0.63	3.18e-52	Vitiligo;
LGG	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	trans	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg16141378	chr3:129829833	LOC729375	-0.32	-7.28	-0.32	1.49e-12	Joint mobility (Beighton score);
LGG	cis	rs4727027	0.870	rs62507512	chr7:148799338	C/T	cg23583168	chr7:148888333	NA	-0.86	-16.4	-0.61	5.54e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7666738	0.830	rs9884501	chr4:98893721	A/C	cg05340658	chr4:99064831	C4orf37	0.48	7.81	0.34	3.73e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs1568889	0.838	rs6484347	chr11:28040969	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.85	-18.85	-0.66	3.12e-59	Bipolar disorder;
LGG	cis	rs1847505	0.663	rs7995967	chr13:61588849	C/T	cg25164009	chr13:61490935	NA	-0.64	-11.4	-0.47	1.05e-26	Polychlorinated biphenyl levels;
LGG	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	11.77	0.48	3.56e-28	Breast cancer;
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.12	0.46	1.29e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs939317	0.635	rs865809	chr3:183997735	C/T	cg09405238	chr3:183994500	ECE2	-0.56	-10.56	-0.44	1.75e-23	Menarche (age at onset);
LGG	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.61	0.56	5.13e-40	Cognitive test performance;
LGG	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.43e-26	Corneal astigmatism;
LGG	cis	rs283228	0.798	rs517802	chr6:101776456	A/G	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs34638952	0.577	rs7217365	chr17:27434490	G/A	cg13672501	chr17:27410685	MYO18A	-0.41	-7.34	-0.32	9.6e-13	Sitting height ratio;
LGG	cis	rs9560113	0.573	rs9560134	chr13:112244011	C/T	cg10483660	chr13:112241077	NA	0.44	9.12	0.39	2.26e-18	Menarche (age at onset);
LGG	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg03036210	chr16:89904091	SPIRE2	-0.64	-7.79	-0.34	4.53e-14	Skin colour saturation;
LGG	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.61	-0.41	4.52e-20	Height;
LGG	cis	rs2832191	0.716	rs9983051	chr21:30371890	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.28	0.81	2.06e-107	Dental caries;
LGG	cis	rs12618769	0.597	rs72821920	chr2:99111591	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20887711	chr4:1340912	KIAA1530	-0.59	-11.16	-0.46	9.07e-26	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.78	-0.3	3.62e-11	Aortic root size;
LGG	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.55	-0.37	1.82e-16	Triglycerides;
LGG	cis	rs1691799	0.899	rs1168351	chr12:66752505	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.5	-0.58	5.84e-44	White blood cell count (basophil);
LGG	cis	rs898097	0.841	rs8180	chr17:80901036	C/G	cg20578329	chr17:80767326	TBCD	0.41	7.08	0.31	5.51e-12	Breast cancer;
LGG	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.55	9.39	0.4	2.79e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs5769765	0.837	rs7284417	chr22:50314346	A/G	cg02269571	chr22:50332266	NA	-0.62	-9.66	-0.41	3.17e-20	Schizophrenia;
LGG	cis	rs9512730	0.517	rs9512717	chr13:28053400	C/T	cg04070771	chr13:27998621	GTF3A	-0.49	-7.3	-0.32	1.23e-12	Schizophrenia;
LGG	cis	rs727505	0.954	rs66526112	chr7:124504074	C/A	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7172677	0.768	rs34180494	chr15:75370012	A/C	cg14664628	chr15:75095509	CSK	0.59	9.42	0.4	2.1e-19	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg01422370	chr2:73384389	NA	0.53	9.82	0.42	8.69e-21	Intelligence (multi-trait analysis);
LGG	cis	rs60843830	0.661	rs62116681	chr2:104197	A/T	cg12623918	chr2:306882	NA	0.38	7.13	0.31	3.76e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg17971929	chr21:40555470	PSMG1	0.87	17.32	0.63	3.49e-52	Cognitive function;
LGG	cis	rs9790314	0.540	rs35462273	chr3:160991877	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-13.39	-0.53	8.77e-35	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.03	-0.49	3.26e-29	Response to antipsychotic treatment;
LGG	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.44	0.4	1.89e-19	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs7666738	0.822	rs13110418	chr4:99046963	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg07777115	chr5:623756	CEP72	-0.51	-6.72	-0.3	5.48e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs3008870	0.755	rs10789219	chr1:67417742	A/C	cg02640540	chr1:67518911	SLC35D1	0.39	7.39	0.32	6.86e-13	Lymphocyte percentage of white cells;
LGG	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg21055462	chr7:100276975	NA	0.46	9.88	0.42	5.3e-21	Other erythrocyte phenotypes;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg05091796	chr16:4465799	CORO7	-0.75	-12.83	-0.51	1.8e-32	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09572029	chr13:28194706	POLR1D;LNX2	-0.44	-6.7	-0.3	6.07e-11	Pancreatic cancer;
LGG	cis	rs2876643	0.530	rs4711012	chr6:22472549	C/T	cg13666174	chr6:22585274	NA	0.33	6.92	0.31	1.55e-11	Coronary artery disease;
LGG	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg07148914	chr20:33460835	GGT7	0.57	9.48	0.4	1.29e-19	Height;
LGG	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg02536541	chr18:77568900	NA	-0.59	-9.71	-0.41	2.02e-20	Schizophrenia;
LGG	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	trans	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg26043149	chr18:55253948	FECH	-0.47	-8.04	-0.35	7.63e-15	Bone mineral density;
LGG	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg13271783	chr10:134563150	INPP5A	-0.51	-7.84	-0.34	3.1e-14	Migraine;
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg17734273	chr15:78292508	TBC1D2B	0.36	8.94	0.38	9.32e-18	Coronary artery disease or large artery stroke;
LGG	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg18165381	chr3:44552316	NA	-0.39	-6.81	-0.3	2.99e-11	Depressive symptoms;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.33	-0.32	1.06e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9914544	1.000	rs9914544	chr17:18787828	A/C	cg26378065	chr17:18585709	ZNF286B	0.51	9.54	0.41	8.22e-20	Educational attainment (years of education);
LGG	cis	rs2050392	0.789	rs303438	chr10:30733493	C/T	cg25182066	chr10:30743637	MAP3K8	0.53	10.96	0.45	5.33e-25	Inflammatory bowel disease;
LGG	cis	rs58649573	0.509	rs10760308	chr9:126788294	G/A	cg14112217	chr9:126806003	NA	0.4	8.0	0.35	9.9e-15	Post-traumatic stress disorder;
LGG	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg12373951	chr3:133503437	NA	0.39	6.87	0.3	2.14e-11	Iron status biomarkers;
LGG	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg17054900	chr3:154042577	DHX36	0.48	7.39	0.32	7.03e-13	Coronary artery disease;
LGG	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.76	-0.34	5.41e-14	Calcium levels;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg04160749	chr8:58172571	NA	-0.49	-7.67	-0.34	1.05e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg09441152	chr18:77712293	PQLC1	-0.46	-8.14	-0.35	3.66e-15	Schizophrenia;
LGG	cis	rs75920871	0.528	rs2513094	chr11:116806412	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.47	-6.92	-0.31	1.54e-11	Subjective well-being;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18481087	chr3:160474064	PPM1L	0.43	7.21	0.32	2.27e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg10840412	chr1:235813424	GNG4	0.65	8.68	0.37	6.6e-17	Bipolar disorder;
LGG	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.97	-0.35	1.26e-14	Obesity;
LGG	cis	rs4622507	0.618	rs35138864	chr16:55070413	G/T	cg09947736	chr16:55091198	NA	0.77	11.65	0.48	1.12e-27	Social communication problems;
LGG	cis	rs11645898	0.935	rs28419077	chr16:72196776	A/G	cg14768367	chr16:72042858	DHODH	-0.74	-10.22	-0.43	3.09e-22	Blood protein levels;
LGG	trans	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg15704280	chr7:45808275	SEPT13	-1.0	-21.96	-0.71	9.16e-74	Height;
LGG	cis	rs12318506	1.000	rs12318506	chr12:75718423	G/T	cg04728562	chr12:75699417	CAPS2	-0.95	-9.48	-0.4	1.35e-19	Coronary artery calcification;
LGG	cis	rs12681366	0.683	rs2470739	chr8:95401922	G/A	cg13257157	chr8:95487014	RAD54B	-0.36	-6.69	-0.3	6.29e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg13010199	chr12:38710504	ALG10B	0.46	8.85	0.38	1.91e-17	Morning vs. evening chronotype;
LGG	cis	rs3767633	0.925	rs4579731	chr1:161766859	G/A	cg09175582	chr1:161736000	ATF6	0.66	8.28	0.36	1.34e-15	IgG glycosylation;
LGG	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.55	-0.44	1.85e-23	Lung cancer;Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg11050988	chr7:1952600	MAD1L1	0.43	10.58	0.44	1.44e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg19168338	chr16:4465731	CORO7	-0.9	-18.25	-0.65	1.82e-56	Schizophrenia;
LGG	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	17.68	0.63	7.89e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8133932	0.654	rs375971	chr21:47338854	C/G	cg11214348	chr21:47283868	PCBP3	-0.45	-8.07	-0.35	6.26e-15	Schizophrenia;
LGG	cis	rs4671458	1.000	rs4671461	chr2:63406800	T/C	cg17519650	chr2:63277830	OTX1	-0.65	-8.06	-0.35	6.49e-15	Subjective well-being;
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7301826	0.651	rs4759517	chr12:131283698	G/A	cg11011512	chr12:131303247	STX2	0.41	8.69	0.37	6.46e-17	Plasma plasminogen activator levels;
LGG	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg10760299	chr15:45669010	GATM	0.35	6.65	0.3	8.3e-11	Homoarginine levels;
LGG	cis	rs12360000	0.800	rs7096499	chr10:1918528	A/G	cg26364871	chr10:1889757	NA	0.68	12.81	0.51	2.21e-32	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs854037	0.595	rs34962616	chr5:57153542	T/C	cg08523694	chr5:57076192	NA	0.53	7.05	0.31	6.74e-12	Birth weight;
LGG	trans	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg17830980	chr10:43048298	ZNF37B	-0.45	-9.82	-0.42	8.17e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg18538332	chr22:24372958	LOC391322	-0.44	-7.23	-0.32	1.98e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg11168104	chr5:1857477	NA	-0.41	-7.22	-0.32	2.11e-12	Cardiovascular disease risk factors;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs9815354	0.638	rs17218866	chr3:42017634	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg05941027	chr17:61774174	LIMD2	0.38	9.59	0.41	5.69e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs4906332	0.834	rs12882130	chr14:103878774	C/G	cg26031613	chr14:104095156	KLC1	-0.46	-6.94	-0.31	1.37e-11	Coronary artery disease;
LGG	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg07271561	chr3:50359363	HYAL2	-0.32	-6.73	-0.3	5.13e-11	Schizophrenia;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg11645453	chr3:52864694	ITIH4	0.4	6.75	0.3	4.42e-11	Bipolar disorder;
LGG	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs9522267	0.737	rs9515455	chr13:112239671	A/G	cg14952266	chr13:112191215	NA	-0.43	-8.19	-0.36	2.62e-15	Hepatitis;
LGG	cis	rs9916302	0.706	rs3744349	chr17:37414842	C/T	cg07936489	chr17:37558343	FBXL20	-0.99	-15.27	-0.58	6.26e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11644478	chr21:40555479	PSMG1	0.83	14.65	0.56	3.31e-40	Cognitive function;
LGG	cis	rs15676	0.947	rs6478854	chr9:131588888	G/C	cg04621255	chr9:131581398	ENDOG	0.42	7.51	0.33	2.99e-13	Blood metabolite levels;
LGG	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.76	-0.51	3.8e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs36051895	0.623	rs6476955	chr9:5256533	C/G	cg02405213	chr9:5042618	JAK2	-0.71	-12.07	-0.49	2.36e-29	Pediatric autoimmune diseases;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg24607181	chr17:41446203	NA	-0.29	-6.91	-0.31	1.57e-11	Menopause (age at onset);
LGG	cis	rs3741151	0.881	rs7951174	chr11:73093135	G/C	cg17517138	chr11:73019481	ARHGEF17	0.91	8.82	0.38	2.27e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs61931739	0.564	rs7304271	chr12:33757011	G/T	cg26384229	chr12:38710491	ALG10B	0.47	8.38	0.36	6.63e-16	Morning vs. evening chronotype;
LGG	cis	rs12042938	0.837	rs1417584	chr1:231819050	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.45	-7.68	-0.34	9.83e-14	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs9952991	0.941	rs60735058	chr18:12795470	T/A	cg23544223	chr18:12777786	NA	-0.55	-7.83	-0.34	3.28e-14	Inflammatory skin disease;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg25019033	chr10:957182	NA	-0.57	-10.57	-0.44	1.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg05335186	chr13:53173507	NA	0.48	10.16	0.43	4.91e-22	Lewy body disease;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg13206674	chr6:150067644	NUP43	0.61	13.52	0.53	2.36e-35	Lung cancer;
LGG	cis	rs72772090	0.539	rs11747896	chr5:96113397	A/G	cg17330273	chr5:96107758	CAST;ERAP1	0.59	9.25	0.4	8.12e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12195424	0.730	rs6915066	chr6:56301453	T/G	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg21132104	chr15:45694354	SPATA5L1	0.69	10.15	0.43	5.42e-22	Homoarginine levels;
LGG	cis	rs6429082	0.818	rs61836206	chr1:235638754	C/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.02	0.42	1.6e-21	Adiposity;
LGG	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs9462027	0.628	rs7742652	chr6:34667075	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.96	0.45	5.39e-25	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.653	rs4786488	chr16:4442527	C/T	cg19168338	chr16:4465731	CORO7	-0.71	-12.17	-0.49	8.98e-30	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.13e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg00129232	chr17:37814104	STARD3	0.62	11.56	0.47	2.4200000000000002e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs62400317	0.731	rs12208523	chr6:45058828	C/T	cg20913747	chr6:44695427	NA	-0.53	-7.82	-0.34	3.54e-14	Total body bone mineral density;
LGG	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg26384229	chr12:38710491	ALG10B	0.72	14.53	0.56	1.15e-39	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.569	rs7702348	chr5:93065683	A/G	cg25358565	chr5:93447407	FAM172A	-0.76	-10.43	-0.44	5.19e-23	Diabetic retinopathy;
LGG	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.32	0.4	4.65e-19	Lung cancer in ever smokers;
LGG	cis	rs56283067	0.773	rs56115627	chr6:44683049	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.88	-0.48	1.37e-28	Total body bone mineral density;
LGG	cis	rs10895140	0.756	rs4754778	chr11:101436073	G/T	cg04553838	chr11:101454733	TRPC6	-0.43	-6.71	-0.3	5.63e-11	Menarche (age at onset);
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg13047869	chr3:10149882	C3orf24	0.47	7.89	0.34	2.2e-14	Alzheimer's disease;
LGG	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg05084668	chr3:125655381	ALG1L	-0.56	-7.52	-0.33	2.86e-13	Blood pressure (smoking interaction);
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.69	-0.37	6.07e-17	Menopause (age at onset);
LGG	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.59	-0.44	1.35e-23	Alzheimer's disease;
LGG	cis	rs4474465	1.000	rs10899533	chr11:78208480	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.45	0.37	3.71e-16	Alzheimer's disease (survival time);
LGG	cis	rs17125944	0.505	rs28568967	chr14:53223060	A/G	cg00686598	chr14:53173677	PSMC6	1.34	14.88	0.57	3.38e-41	Alzheimer's disease (late onset);
LGG	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg03929089	chr4:120376271	NA	-1.01	-21.64	-0.71	2.81e-72	Height;
LGG	cis	rs10229583	0.527	rs10249616	chr7:127399500	A/G	cg25855768	chr7:127472121	SND1	-0.44	-7.35	-0.32	9.23e-13	Type 2 diabetes;
LGG	cis	rs74781061	0.929	rs8028430	chr15:74845745	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.23	-0.32	2.06e-12	Endometriosis;
LGG	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg03517284	chr6:25882590	NA	-0.59	-11.26	-0.46	3.78e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6489882	0.902	rs1981557	chr12:113372866	G/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs10791097	0.720	rs4936121	chr11:130733878	A/G	cg09137382	chr11:130731461	NA	0.36	6.96	0.31	1.19e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs477895	1.000	rs11600990	chr11:64082807	C/T	cg22916017	chr11:64110731	CCDC88B	-0.52	-7.08	-0.31	5.48e-12	Mean platelet volume;
LGG	cis	rs7241530	0.595	rs12954372	chr18:75900263	C/A	cg14642773	chr18:75888474	NA	0.47	9.12	0.39	2.29e-18	Educational attainment (years of education);
LGG	cis	rs4950322	0.515	rs11239954	chr1:146717699	C/T	cg22381352	chr1:146742008	CHD1L	-0.47	-7.87	-0.34	2.55e-14	Protein quantitative trait loci;
LGG	trans	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.39	-7.9	-0.34	1.99e-14	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg02127607	chr17:61920694	SMARCD2	-0.48	-8.63	-0.37	9.77e-17	Prudent dietary pattern;
LGG	cis	rs12464559	0.649	rs9287998	chr2:152621356	C/T	cg01189475	chr2:152685088	ARL5A	0.74	6.73	0.3	4.97e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.92	0.48	8.96e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9359856	0.623	rs7742602	chr6:90327385	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.32	-0.43	1.3e-22	Bipolar disorder;
LGG	cis	rs7765175	0.598	rs2801436	chr6:113654001	A/G	cg26552650	chr6:113682475	NA	0.33	7.39	0.32	6.87e-13	Coronary artery calcification;
LGG	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg24397884	chr7:158709396	WDR60	0.85	16.99	0.62	1.15e-50	Height;
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.16e-16	Aortic root size;
LGG	cis	rs2836950	0.501	rs35994303	chr21:40686020	C/T	cg11644478	chr21:40555479	PSMG1	-0.58	-9.65	-0.41	3.24e-20	Menarche (age at onset);
LGG	cis	rs4006360	0.525	rs3907875	chr17:39268353	A/G	cg16985667	chr17:39306289	KRTAP4-5	0.39	8.13	0.35	3.94e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.09	0.35	5.11e-15	Iron status biomarkers;
LGG	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.86	0.45	1.23e-24	Aortic root size;
LGG	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.85	0.34	2.82e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12464483	0.524	rs1901906	chr2:30884576	A/G	cg03795903	chr2:30669940	LCLAT1	-0.52	-7.29	-0.32	1.35e-12	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg12751644	chr20:60527061	NA	0.31	6.73	0.3	4.95e-11	Body mass index;
LGG	cis	rs528418	0.592	rs7772490	chr6:145670484	T/G	cg03642472	chr6:145670687	NA	0.55	7.13	0.31	3.98e-12	Methadone dose in opioid dependence;
LGG	cis	rs1109114	0.816	rs2963499	chr5:148599681	A/T	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.64	-0.59	1.39e-44	Body mass index;
LGG	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg16325326	chr1:53192061	ZYG11B	-0.62	-12.64	-0.51	1.14e-31	Monocyte count;
LGG	trans	rs11039798	0.688	rs8188953	chr11:48749201	A/T	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg22437258	chr11:111473054	SIK2	0.57	9.82	0.42	8.47e-21	Primary sclerosing cholangitis;
LGG	cis	rs4474742	1	rs4474742	chr17:28065578	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-14.15	-0.55	4.98e-38	Monocyte count;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg07791516	chr6:150247246	NA	0.32	7.1	0.31	4.65e-12	Testicular germ cell tumor;
LGG	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg06481639	chr22:41940642	POLR3H	-0.61	-8.78	-0.38	3.29e-17	Vitiligo;
LGG	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg16141378	chr3:129829833	LOC729375	-0.48	-11.88	-0.48	1.32e-28	Systolic blood pressure;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg22433210	chr17:43662623	NA	0.91	14.57	0.56	7.39e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.7e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7589342	0.839	rs10192144	chr2:106439854	A/G	cg14210321	chr2:106509881	NCK2	-0.5	-8.52	-0.37	2.26e-16	Addiction;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11989744	0.597	rs11135768	chr8:23573278	A/G	cg03492747	chr16:86543808	FOXF1	0.55	9.69	0.41	2.45e-20	Waist-hip ratio;
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg00908189	chr16:619842	PIGQ	0.88	16.8	0.62	8.83e-50	Height;
LGG	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg06917634	chr15:78832804	PSMA4	0.83	17.61	0.63	1.66e-53	Sudden cardiac arrest;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg00830817	chr11:109293614	C11orf87	0.42	6.79	0.3	3.54e-11	Schizophrenia;
LGG	trans	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.9	-0.31	1.74e-11	Retinal vascular caliber;
LGG	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg03060546	chr3:49711283	APEH	-0.61	-8.4	-0.36	5.54e-16	Menarche (age at onset);
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg17340268	chr14:105411764	AHNAK2	-0.39	-7.27	-0.32	1.51e-12	Rheumatoid arthritis;
LGG	cis	rs4604732	0.527	rs7546805	chr1:247627259	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.11	0.39	2.5e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13445763	chr1:62902662	USP1	-0.41	-6.82	-0.3	2.9e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg26384229	chr12:38710491	ALG10B	0.81	16.06	0.6	1.82e-46	Morning vs. evening chronotype;
LGG	cis	rs2273669	0.588	rs114414265	chr6:109306489	C/A	cg05315195	chr6:109294784	ARMC2	-0.65	-8.5	-0.37	2.63e-16	Prostate cancer;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.08	-0.31	5.42e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9948	0.655	rs62156210	chr2:97393736	A/T	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9660992	0.789	rs1768584	chr1:205240145	A/G	cg21545522	chr1:205238299	TMCC2	0.45	8.39	0.36	5.85e-16	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg03929089	chr4:120376271	NA	0.81	11.17	0.46	7.87e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs634534	0.561	rs655744	chr11:65776585	G/T	cg26695010	chr11:65641043	EFEMP2	0.53	9.1	0.39	2.73e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs9397585	0.667	rs9479509	chr6:153427265	G/A	cg12989544	chr6:153429875	RGS17	0.33	7.27	0.32	1.58e-12	Body mass index;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs10791097	0.694	rs4937583	chr11:130741606	A/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6840360	0.615	rs9884167	chr4:152470799	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.73	-0.34	6.82e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12681287	0.640	rs13280468	chr8:87338452	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.53	-0.33	2.61e-13	Caudate activity during reward;
LGG	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg13647721	chr17:30228624	UTP6	0.63	7.83	0.34	3.34e-14	Hip circumference adjusted for BMI;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg22044901	chr15:68126292	NA	0.41	7.29	0.32	1.37e-12	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08664652	chr17:28804287	GOSR1	0.45	7.29	0.32	1.39e-12	Gut microbiome composition (summer);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02893490	chr16:68014110	DPEP3	0.43	7.31	0.32	1.16e-12	Pancreatic cancer;
LGG	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	12.14	0.49	1.25e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg08297393	chr2:100937505	LONRF2	-0.56	-10.5	-0.44	2.93e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.18	-20.63	-0.69	1.45e-67	Platelet count;
LGG	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg05425664	chr17:57184151	TRIM37	0.62	9.38	0.4	2.93e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg24812749	chr6:127587940	RNF146	0.96	15.89	0.59	1.09e-45	Breast cancer;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.9	-0.45	9.02e-25	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.09e-13	Lung cancer;
LGG	cis	rs72960926	1.000	rs16884854	chr6:75107223	C/T	cg03266952	chr6:74778945	NA	-0.7	-6.85	-0.3	2.43e-11	Metabolite levels (MHPG);
LGG	cis	rs1568889	0.838	rs11030230	chr11:28174631	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.41e-61	Bipolar disorder;
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg02725872	chr8:58115012	NA	-0.84	-12.11	-0.49	1.61e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.51	-0.44	2.6e-23	Total cholesterol levels;
LGG	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg26897989	chr16:1907736	C16orf73	0.67	10.25	0.43	2.34e-22	Insulin-like growth factors;
LGG	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg03098644	chr7:100410630	EPHB4	0.48	7.09	0.31	5.03e-12	Other erythrocyte phenotypes;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.41	-0.36	4.97e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2802728	0.881	rs58417768	chr1:243558394	T/C	cg05593162	chr1:243577377	SDCCAG8	0.49	6.89	0.3	1.82e-11	Toenail selenium levels;
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.26e-12	Bipolar disorder;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.45	7.23	0.32	2.06e-12	Lymphocyte counts;
LGG	cis	rs6121246	0.559	rs6060962	chr20:30397847	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs2030401	0.603	rs1727301	chr12:123664514	G/A	cg06742321	chr12:123595122	PITPNM2	0.44	7.86	0.34	2.67e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg23788917	chr6:8435910	SLC35B3	-0.46	-8.0	-0.35	9.83e-15	Motion sickness;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18807843	chr3:53857876	CHDH	0.4	6.66	0.3	7.59e-11	Pancreatic cancer;
LGG	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg21385522	chr1:16154831	NA	0.56	10.15	0.43	5.49e-22	Systolic blood pressure;
LGG	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg21775007	chr8:11205619	TDH	-0.82	-14.26	-0.55	1.6e-38	Retinal vascular caliber;
LGG	cis	rs908922	0.676	rs6587681	chr1:152512135	C/T	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.08	0.31	5.36e-12	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg04025307	chr7:1156635	C7orf50	0.66	8.5	0.37	2.58e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg06606381	chr12:133084897	FBRSL1	-0.96	-10.73	-0.45	3.84e-24	Breast cancer;
LGG	cis	rs7071206	0.853	rs66786803	chr10:79429941	A/G	cg07817648	chr10:79422355	NA	-0.63	-12.01	-0.49	4.04e-29	Bone mineral density;
LGG	cis	rs34929064	0.750	rs2961299	chr7:22708170	A/G	cg18045685	chr7:22629474	NA	0.66	11.87	0.48	1.48e-28	Major depression and alcohol dependence;
LGG	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg05925327	chr15:68127851	NA	0.37	8.59	0.37	1.3e-16	Restless legs syndrome;
LGG	cis	rs9733	0.688	rs12725667	chr1:150766070	A/T	cg13175981	chr1:150552382	MCL1	0.54	8.73	0.38	4.55e-17	Tonsillectomy;
LGG	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.5	0.37	2.69e-16	Mood instability;
LGG	cis	rs7998202	0.667	rs188166	chr13:113355498	T/C	cg17218041	chr13:113365319	ATP11A	-0.47	-7.74	-0.34	6.49e-14	Glycated hemoglobin levels;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.7e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg21475434	chr5:93447410	FAM172A	0.65	6.77	0.3	4.01e-11	Diabetic retinopathy;
LGG	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg02524346	chr8:600233	NA	1.13	11.34	0.47	1.72e-26	IgG glycosylation;
LGG	cis	rs911263	0.603	rs2064911	chr14:68807298	T/C	cg18825221	chr14:68749962	RAD51L1	0.37	8.21	0.36	2.18e-15	Primary biliary cholangitis;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.68	-0.34	9.76e-14	Life satisfaction;
LGG	cis	rs861020	0.630	rs592694	chr1:210009533	G/T	cg05527609	chr1:210001259	C1orf107	0.59	9.56	0.41	6.94e-20	Orofacial clefts;
LGG	cis	rs12282928	1.000	rs7481393	chr11:48302735	C/T	cg26585981	chr11:48327164	OR4S1	-0.45	-7.25	-0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg25486957	chr4:152246857	NA	-0.52	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23805780	chr6:130342187	L3MBTL3	0.41	6.86	0.3	2.19e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-9.62	-0.41	4.14e-20	Mean corpuscular volume;
LGG	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg04000281	chr11:63949212	NA	-0.45	-8.33	-0.36	9.36e-16	Platelet count;
LGG	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.25	0.43	2.44e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4302748	0.862	rs11973172	chr7:36183435	A/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs8064024	0.783	rs2341986	chr16:4819496	A/G	cg08329684	chr16:4932620	PPL	0.39	8.13	0.35	4.06e-15	Cancer;
LGG	cis	rs4356203	0.905	rs10832743	chr11:17216480	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.05	-0.31	6.49e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs4974559	0.947	rs28437782	chr4:1355062	A/G	cg02980000	chr4:1222292	CTBP1	0.66	7.94	0.35	1.57e-14	Systolic blood pressure;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07791516	chr6:150247246	NA	0.32	7.01	0.31	8.54e-12	Testicular germ cell tumor;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	11.83	0.48	2.08e-28	Lymphocyte counts;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg09742170	chr7:25021208	OSBPL3	-0.43	-6.81	-0.3	3e-11	Sitting height ratio;
LGG	cis	rs12765878	1.000	rs35223321	chr10:105646395	C/T	cg11005552	chr10:105648138	OBFC1	1.04	26.77	0.78	4.57e-96	Coronary artery disease;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.03	-0.35	8.31e-15	Skin colour saturation;
LGG	cis	rs17039065	0.920	rs79622192	chr4:109419632	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs590121	0.876	rs604021	chr11:75276769	G/C	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.58	-0.37	1.49e-16	Coronary artery disease;
LGG	cis	rs4731207	0.596	rs6466987	chr7:124677731	C/A	cg05630886	chr7:124431682	NA	-0.31	-7.11	-0.31	4.45e-12	Cutaneous malignant melanoma;
LGG	cis	rs7267979	1.000	rs2500432	chr20:25290512	A/C	cg06421707	chr20:25228305	PYGB	0.46	9.81	0.41	9.03e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.28	-0.32	1.41e-12	Personality dimensions;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.65	-0.37	8.64e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2033732	0.706	rs6473525	chr8:85070206	A/G	cg05716166	chr8:85095498	RALYL	0.44	7.17	0.32	3.07e-12	Body mass index;
LGG	cis	rs11122272	0.766	rs2808608	chr1:231543175	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.6	-0.47	1.8e-27	Hemoglobin concentration;
LGG	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.33	-0.32	1.04e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7582720	1.000	rs72928620	chr2:203840973	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.8	0.41	9.72e-21	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.57	0.44	1.51e-23	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.87	0.3	2.08e-11	Schizophrenia;
LGG	trans	rs3942852	0.594	rs10769311	chr11:48094009	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-11.0	-0.46	3.53e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg15145296	chr3:125709740	NA	-0.62	-8.1	-0.35	5.06e-15	Blood pressure (smoking interaction);
LGG	cis	rs9547996	0.837	rs1924298	chr13:38183502	A/G	cg13634560	chr13:38173852	POSTN	-0.34	-6.75	-0.3	4.4e-11	Diastolic blood pressure;
LGG	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.99	0.42	1.99e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg00898013	chr13:113819073	PROZ	0.41	8.27	0.36	1.47e-15	Platelet distribution width;
LGG	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg26769984	chr7:1090371	C7orf50	0.43	7.64	0.33	1.25e-13	Bronchopulmonary dysplasia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19759923	chr12:105630205	APPL2	0.44	7.72	0.34	7.2e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs17381785	0.773	rs13119988	chr4:14921247	A/G	cg12377275	chr4:15005593	CPEB2	0.41	6.87	0.3	2.06e-11	Urate levels in overweight individuals;
LGG	cis	rs2242663	0.529	rs1785640	chr11:66223158	C/T	cg01599099	chr11:66649832	PC	0.34	6.94	0.31	1.32e-11	Bipolar disorder;
LGG	cis	rs734999	0.588	rs6689711	chr1:2531467	T/C	cg18854424	chr1:2615690	NA	-0.35	-7.18	-0.32	2.79e-12	Ulcerative colitis;
LGG	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg04317338	chr11:64019027	PLCB3	0.59	6.66	0.3	7.8e-11	Mean platelet volume;
LGG	cis	rs7959452	0.503	rs7300266	chr12:69654187	A/G	cg14784868	chr12:69753453	YEATS4	0.66	12.54	0.5	2.83e-31	Blood protein levels;
LGG	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg24308560	chr3:49941425	MST1R	0.22	6.87	0.3	2.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg12463550	chr7:65579703	CRCP	0.73	8.33	0.36	9.56e-16	Diabetic kidney disease;
LGG	cis	rs367943	0.698	rs2115206	chr5:112999058	A/T	cg12552261	chr5:112820674	MCC	0.55	9.8	0.41	1.01e-20	Type 2 diabetes;
LGG	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-11.04	-0.46	2.6e-25	Heart rate;
LGG	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.86	0.3	2.2e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg07549998	chr6:150325970	RAET1K	-0.38	-7.25	-0.32	1.82e-12	Alopecia areata;
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg00166722	chr3:10149974	C3orf24	0.59	8.12	0.35	4.24e-15	Alzheimer's disease;
LGG	cis	rs2932538	0.922	rs7551933	chr1:113086706	C/T	cg22162597	chr1:113214053	CAPZA1	-0.6	-11.8	-0.48	2.93e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs8051149	0.652	rs9926829	chr16:87883089	A/G	cg01412419	chr16:87856264	NA	-0.51	-9.33	-0.4	4.34e-19	Blood metabolite levels;
LGG	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg19507638	chr5:93509721	C5orf36	-0.66	-9.22	-0.39	1.08e-18	Diabetic retinopathy;
LGG	cis	rs300774	0.858	rs300736	chr2:168466	C/G	cg04617936	chr2:214353	NA	-0.46	-6.98	-0.31	1.06e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg26597838	chr10:835615	NA	0.74	10.06	0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg21775007	chr8:11205619	TDH	0.43	6.91	0.31	1.61e-11	Joint mobility (Beighton score);
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.42e-50	Skin colour saturation;
LGG	cis	rs1909881	1.000	rs16917769	chr8:96504268	A/G	cg04203453	chr8:96504381	NA	-1.09	-18.48	-0.65	1.56e-57	Obesity-related traits;
LGG	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03713592	chr11:72463424	ARAP1	0.39	7.29	0.32	1.33e-12	Type 2 diabetes;
LGG	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05901451	chr6:126070800	HEY2	-0.79	-16.51	-0.61	1.73e-48	Brugada syndrome;
LGG	trans	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg25214090	chr10:38739885	LOC399744	-0.6	-10.94	-0.45	6.17e-25	Corneal astigmatism;
LGG	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-14.68	-0.56	2.52e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs12682352	0.602	rs635594	chr8:8613387	C/T	cg06636001	chr8:8085503	FLJ10661	-0.37	-6.67	-0.3	7.2e-11	Neuroticism;
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg16434002	chr17:42200994	HDAC5	0.56	10.28	0.43	1.89e-22	Total body bone mineral density;
LGG	cis	rs35160687	0.901	rs6714362	chr2:86476588	A/G	cg10973622	chr2:86423274	IMMT	-0.4	-6.92	-0.31	1.48e-11	Night sleep phenotypes;
LGG	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6462411	1.000	rs6956479	chr7:3915077	C/G	cg18022346	chr7:3920534	SDK1	-0.34	-6.65	-0.3	8.39e-11	Quantitative traits;
LGG	trans	rs1032833	0.732	rs61179885	chr2:180033590	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06108461	chr20:60628389	TAF4	-1.02	-20.44	-0.69	1.22e-66	Body mass index;
LGG	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg12011299	chr4:100065546	ADH4	0.41	8.96	0.38	8.19e-18	Alcohol dependence;
LGG	cis	rs758324	0.704	rs31480	chr5:131396332	C/T	cg06307176	chr5:131281290	NA	-0.45	-7.3	-0.32	1.27e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.16	0.49	1.04e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg25986240	chr4:9926439	SLC2A9	0.34	6.92	0.31	1.53e-11	Bone mineral density;
LGG	cis	rs1953600	0.870	rs1049550	chr10:81926702	G/A	cg04850286	chr10:81895943	PLAC9	-0.44	-9.78	-0.41	1.18e-20	Sarcoidosis;
LGG	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.18	-0.32	2.81e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7769051	1.000	rs9493446	chr6:133125643	C/T	cg22852734	chr6:133119734	C6orf192	1.16	15.75	0.59	4.47e-45	Type 2 diabetes nephropathy;
LGG	cis	rs6784615	0.590	rs13076508	chr3:52407805	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.67	7.45	0.33	4.7e-13	Waist-hip ratio;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg21724239	chr8:58056113	NA	0.63	9.35	0.4	3.88e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg03188948	chr7:1209495	NA	0.43	7.44	0.33	4.94e-13	Longevity;Endometriosis;
LGG	cis	rs17253792	0.822	rs17832371	chr14:56162302	C/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.05	-0.49	2.88e-29	Putamen volume;
LGG	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-7.5	-0.33	3.32e-13	Educational attainment;
LGG	cis	rs9443189	0.530	rs614065	chr6:76315633	G/A	cg01950844	chr6:76311363	SENP6	0.77	10.13	0.43	6.29e-22	Prostate cancer;
LGG	cis	rs72827839	0.516	rs72833458	chr17:45938051	A/G	cg23391107	chr17:45924227	SP6	0.57	9.26	0.4	7.9e-19	Ease of getting up in the morning;
LGG	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.38	0.7	4.71e-71	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.02	-0.31	8.17e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	0.613	rs2121718	chr3:160603511	C/T	cg04691961	chr3:161091175	C3orf57	0.42	8.95	0.38	8.75e-18	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg11494091	chr17:61959527	GH2	-0.99	-24.36	-0.75	5.97e-85	Prudent dietary pattern;
LGG	cis	rs8054556	0.633	rs12928610	chr16:30016022	C/T	cg06326092	chr16:30034487	C16orf92	0.35	6.91	0.31	1.6e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12410462	0.582	rs2872251	chr1:227647723	G/A	cg04117972	chr1:227635322	NA	0.73	11.76	0.48	4.02e-28	Major depressive disorder;
LGG	cis	rs1978968	0.763	rs9605479	chr22:18464611	T/C	cg03078520	chr22:18463400	MICAL3	-0.67	-14.2	-0.55	3.07e-38	Presence of antiphospholipid antibodies;
LGG	cis	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg09085632	chr11:111637200	PPP2R1B	0.69	12.64	0.51	1.1e-31	Primary sclerosing cholangitis;
LGG	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.86	-13.87	-0.54	8.09e-37	Gut microbiome composition (summer);
LGG	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg12560992	chr17:57184187	TRIM37	-0.82	-13.36	-0.53	1.21e-34	Intelligence (multi-trait analysis);
LGG	trans	rs2018683	0.621	rs10261556	chr7:28976636	G/T	cg19402173	chr7:128379420	CALU	-0.59	-10.23	-0.43	2.74e-22	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg19442545	chr10:75533431	FUT11	-0.46	-7.66	-0.34	1.08e-13	Inflammatory bowel disease;
LGG	cis	rs10940138	0.720	rs2372188	chr5:67233704	T/C	ch.5.1281357F	chr5:67228439	NA	0.75	13.27	0.52	2.86e-34	Menarche (age at onset);
LGG	cis	rs9682041	0.627	rs11917188	chr3:170088607	C/T	cg11886554	chr3:170076028	SKIL	0.57	7.45	0.33	4.65e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.05	0.35	7.14e-15	Homoarginine levels;
LGG	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg03806693	chr22:41940476	POLR3H	1.02	17.79	0.64	2.41e-54	Vitiligo;
LGG	cis	rs7119	0.651	rs12909292	chr15:77837982	G/T	cg10437265	chr15:77819839	NA	0.25	6.67	0.3	7.52e-11	Type 2 diabetes;
LGG	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.7	-14.09	-0.55	9.31e-38	Multiple sclerosis;
LGG	cis	rs6909430	0.901	rs2388335	chr6:98589992	T/G	cg12860156	chr6:98744658	NA	-0.45	-7.59	-0.33	1.82e-13	Quantitative traits;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg10207240	chr12:122356781	WDR66	0.26	7.77	0.34	5.07e-14	Mean corpuscular volume;
LGG	trans	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.15	0.43	5.65e-22	Schizophrenia;
LGG	cis	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg21775007	chr8:11205619	TDH	0.44	7.08	0.31	5.44e-12	Morning vs. evening chronotype;
LGG	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg00092383	chr7:157075207	NA	0.39	6.74	0.3	4.6e-11	Body mass index;
LGG	cis	rs5769707	0.933	rs2157444	chr22:49994292	A/G	cg06623630	chr22:50017776	C22orf34	-0.34	-7.16	-0.32	3.21e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7326068	0.610	rs2818985	chr13:21314209	G/T	cg04906043	chr13:21280425	IL17D	-0.49	-7.86	-0.34	2.65e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs9951602	0.512	rs12607938	chr18:76651887	A/C	cg24134504	chr18:76639479	NA	-0.47	-8.46	-0.37	3.66e-16	Obesity-related traits;
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.65	0.44	7.59e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs854765	0.619	rs4561528	chr17:17979099	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	14.21	0.55	2.74e-38	Total body bone mineral density;
LGG	cis	rs10779751	1.000	rs12124983	chr1:11286178	C/T	cg08854313	chr1:11322531	MTOR	-0.8	-18.27	-0.65	1.46e-56	Body mass index;
LGG	cis	rs3733585	0.631	rs3822236	chr4:10119961	T/G	cg25986240	chr4:9926439	SLC2A9	0.39	7.88	0.34	2.42e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05090725	chr11:107799287	RAB39	0.49	7.68	0.34	9.74e-14	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.572	rs79396168	chr7:1048928	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.99	-12.83	-0.51	1.81e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg00713939	chr8:144660590	NAPRT1	0.89	6.98	0.31	1.06e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-7.83	-0.34	3.41e-14	Inflammatory skin disease;
LGG	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg05985134	chr18:33552581	C18orf21	0.65	10.25	0.43	2.32e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg26799656	chr16:88458669	NA	-0.68	-6.81	-0.3	3.03e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs7555523	0.887	rs4657477	chr1:165736175	C/T	cg24409356	chr1:165738333	TMCO1	0.75	9.03	0.39	4.54e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg15242686	chr22:24348715	GSTTP1	0.42	7.61	0.33	1.54e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10048158	0.564	rs8178844	chr17:64218459	G/A	cg19474267	chr17:64306194	PRKCA	-0.6	-12.02	-0.49	3.81e-29	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg09307838	chr4:120376055	NA	0.81	13.52	0.53	2.53e-35	Corneal astigmatism;
LGG	cis	rs75920871	1.000	rs75858236	chr11:116872263	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg16141378	chr3:129829833	LOC729375	0.33	7.23	0.32	1.96e-12	Monocyte count;
LGG	cis	rs367615	0.879	rs2201015	chr5:108947450	C/T	cg17395555	chr5:108820864	NA	0.62	8.86	0.38	1.74e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1577917	1.000	rs12216203	chr6:86675301	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.78	-0.41	1.12e-20	Response to antipsychotic treatment;
LGG	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.59	-0.37	1.37e-16	Lung cancer;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05665937	chr4:1216051	CTBP1	0.44	8.04	0.35	7.39e-15	Obesity-related traits;
LGG	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.98	-0.39	6.96e-18	Mean corpuscular volume;
LGG	cis	rs3808502	0.527	rs56177149	chr8:11247298	G/A	cg21775007	chr8:11205619	TDH	0.64	10.38	0.43	8.0700000000000006e-23	Neuroticism;
LGG	cis	rs11122272	0.735	rs2790883	chr1:231532726	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-11.16	-0.46	8.66e-26	Hemoglobin concentration;
LGG	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.31	0.6	1.33e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2444240	0.935	rs470373	chr11:120026271	C/T	cg16005559	chr11:120040616	NA	-0.32	-6.97	-0.31	1.07e-11	Corneal curvature;
LGG	cis	rs6546537	1.000	rs3899666	chr2:69867871	A/G	cg10773587	chr2:69614142	GFPT1	0.43	7.15	0.32	3.3e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12826209	chr6:26865740	GUSBL1	0.57	7.1	0.31	4.72e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg06475006	chr16:89985975	MC1R	-0.55	-6.74	-0.3	4.86e-11	Skin colour saturation;
LGG	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs1200821	0.535	rs1208789	chr10:37722472	A/G	cg00409905	chr10:38381863	ZNF37A	-0.43	-7.8	-0.34	4.01e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg24829409	chr8:58192753	C8orf71	-0.67	-9.26	-0.4	7.86e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg15105969	chr2:36825350	FEZ2	0.51	7.95	0.35	1.41e-14	Height;
LGG	cis	rs73001065	0.792	rs17216525	chr19:19662220	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	6.67	0.3	7.18e-11	LDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08215925	chr3:71633214	FOXP1	0.45	7.27	0.32	1.58e-12	Cognitive performance;
LGG	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg24011408	chr12:48396354	COL2A1	-0.49	-7.78	-0.34	4.9e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg04911050	chr16:677664	RAB40C	0.33	6.71	0.3	5.67e-11	Height;
LGG	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-8.24	-0.36	1.84e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg07274523	chr3:49395745	GPX1	0.58	9.83	0.42	7.69e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.38e-11	Menopause (age at onset);
LGG	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.87	-0.38	1.57e-17	Bone mineral density;
LGG	cis	rs13033859	0.655	rs10171965	chr2:199144	G/A	cg04617936	chr2:214353	NA	-0.38	-6.78	-0.3	3.66e-11	Mitochondrial DNA levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27172057	chr12:64616385	C12orf66	0.51	7.63	0.33	1.3e-13	Gut microbiome composition (summer);
LGG	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.47e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9533623	1	rs9533623	chr13:44380753	C/T	cg17145862	chr1:211918768	LPGAT1	-0.49	-8.82	-0.38	2.4e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6740322	0.901	rs2163228	chr2:43549246	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-8.85	-0.38	1.91e-17	Coronary artery disease;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	trans	rs4714291	1.000	rs9369156	chr6:39993725	T/C	cg02267698	chr19:7991119	CTXN1	0.51	7.69	0.34	8.8e-14	Strep throat;
LGG	trans	rs6787172	0.693	rs7652909	chr3:157874208	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.66	0.37	7.85e-17	Subjective well-being;
LGG	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11971779	0.616	rs10269683	chr7:139100868	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.02	0.31	7.73e-12	Diisocyanate-induced asthma;
LGG	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg05973401	chr12:123451056	ABCB9	0.51	8.14	0.35	3.68e-15	Neutrophil percentage of white cells;
LGG	cis	rs1021993	0.545	rs1006317	chr1:209552636	G/T	cg24446417	chr1:209558027	NA	-0.75	-11.23	-0.46	4.97e-26	Gut microbiome composition (winter);
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.58	-0.44	1.4e-23	Triglycerides;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg06521331	chr12:34319734	NA	-0.6	-11.08	-0.46	1.85e-25	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.82e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs72827839	0.740	rs72823509	chr17:46044589	G/A	cg23391107	chr17:45924227	SP6	0.49	6.74	0.3	4.59e-11	Ease of getting up in the morning;
LGG	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg11707556	chr5:10655725	ANKRD33B	0.38	6.78	0.3	3.79e-11	Coronary artery disease;
LGG	cis	rs709400	0.663	rs62007687	chr14:103903763	G/T	cg26031613	chr14:104095156	KLC1	0.79	13.67	0.54	5.52e-36	Body mass index;
LGG	cis	rs745821	0.701	rs2338830	chr18:48106412	A/T	cg18923635	chr18:48083994	NA	-0.39	-7.19	-0.32	2.59e-12	Diastolic blood pressure;
LGG	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg00495681	chr13:53174319	NA	0.8	17.21	0.62	1.14e-51	Lewy body disease;
LGG	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg25885449	chr18:77638415	KCNG2	0.35	6.72	0.3	5.3e-11	Schizophrenia;
LGG	trans	rs7701967	0.697	rs11948761	chr5:130370970	A/T	cg07395648	chr5:131743802	NA	0.4	7.67	0.34	9.98e-14	Mosquito bite size;Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
LGG	cis	rs975210	0.656	rs16954106	chr15:70357918	C/T	cg01666796	chr15:70364327	TLE3	-0.55	-6.88	-0.3	1.94e-11	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg01043669	chr3:72786069	NA	0.41	6.92	0.31	1.52e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9309473	0.607	rs6740173	chr2:73602266	C/G	cg20560298	chr2:73613845	ALMS1	-0.47	-8.71	-0.38	5.45e-17	Metabolite levels;
LGG	cis	rs782590	0.556	rs782579	chr2:55917604	A/G	cg18811423	chr2:55921094	PNPT1	0.85	17.52	0.63	4.47e-53	Metabolic syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08748207	chr12:46777589	NA	0.46	7.07	0.31	5.85e-12	Gut microbiome composition (summer);
LGG	cis	rs950169	0.614	rs12911536	chr15:84673030	G/T	cg24253500	chr15:84953950	NA	0.46	7.47	0.33	4.09e-13	Schizophrenia;
LGG	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.54	-12.44	-0.5	7.28e-31	Diastolic blood pressure;
LGG	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg15736062	chr7:158136485	PTPRN2	0.36	7.13	0.31	3.82e-12	Calcium levels;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	0.688	rs10793336	chr11:78281867	A/G	cg27205649	chr11:78285834	NARS2	0.6	11.36	0.47	1.48e-26	Alzheimer's disease (survival time);
LGG	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg19628046	chr18:33552617	C18orf21	0.52	7.6	0.33	1.66e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg13206674	chr6:150067644	NUP43	0.61	13.6	0.53	1.07e-35	Lung cancer;
LGG	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg08499158	chr17:42289980	UBTF	0.38	7.26	0.32	1.6e-12	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg25319279	chr11:5960081	NA	-0.54	-8.45	-0.37	3.83e-16	DNA methylation (variation);
LGG	cis	rs72945132	0.882	rs7116191	chr11:70159781	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg12463550	chr7:65579703	CRCP	0.67	8.16	0.35	3.17e-15	Diabetic kidney disease;
LGG	cis	rs1620921	0.603	rs1084659	chr6:161163777	A/G	cg01280913	chr6:161186852	NA	-0.44	-8.99	-0.39	6.3e-18	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4900538	0.963	rs1885708	chr14:102960164	A/G	cg18135206	chr14:102964638	TECPR2	0.84	16.39	0.61	5.94e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg00339695	chr16:24857497	SLC5A11	0.4	6.95	0.31	1.24e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.72	0.38	4.95e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs16854884	0.837	rs4362712	chr3:143801076	G/A	cg06585982	chr3:143692056	C3orf58	0.57	9.48	0.4	1.29e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs8018808	0.935	rs760257	chr14:77935145	G/A	cg20045696	chr14:77926864	AHSA1	0.39	6.65	0.3	8.39e-11	Myeloid white cell count;
LGG	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg13852791	chr20:30311386	BCL2L1	0.68	9.06	0.39	3.55e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg11266682	chr4:10021025	SLC2A9	0.51	9.94	0.42	3.03e-21	Bone mineral density;
LGG	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.44	-0.37	3.99e-16	Total body bone mineral density;
LGG	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg12373951	chr3:133503437	NA	0.43	7.73	0.34	6.64e-14	Iron status biomarkers;
LGG	cis	rs4409675	0.576	rs12070659	chr1:28227175	G/A	cg23691781	chr1:28212827	C1orf38	0.4	10.59	0.44	1.27e-23	Corneal astigmatism;
LGG	cis	rs4363385	0.747	rs1933383	chr1:152963468	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.1	-0.39	2.64e-18	Inflammatory skin disease;
LGG	cis	rs34311866	0.656	rs11731377	chr4:971266	T/G	cg07828340	chr4:882639	GAK	0.69	7.87	0.34	2.51e-14	Parkinson's disease;
LGG	cis	rs981844	0.712	rs11099914	chr4:154743519	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-10.05	-0.42	1.28e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	10.43	0.44	5.17e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg10483660	chr13:112241077	NA	0.35	6.95	0.31	1.24e-11	Menarche (age at onset);
LGG	cis	rs11690935	1.000	rs3795999	chr2:172544483	A/G	cg21435375	chr2:172878103	MAP1D	0.31	6.84	0.3	2.46e-11	Schizophrenia;
LGG	cis	rs6495122	0.662	rs12898997	chr15:75090349	C/T	cg10253484	chr15:75165896	SCAMP2	-0.5	-8.04	-0.35	7.65e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01025762	chr7:107531363	DLD	0.47	7.27	0.32	1.53e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9863	0.931	rs11831913	chr12:124446898	T/C	cg13487667	chr12:124434373	CCDC92	-0.39	-7.55	-0.33	2.38e-13	White blood cell count;
LGG	cis	rs1401999	0.628	rs1520195	chr3:183736882	G/A	cg01324343	chr3:183735012	ABCC5	0.76	14.49	0.56	1.67e-39	Anterior chamber depth;
LGG	cis	rs4363385	0.574	rs4845505	chr1:152960943	T/A	cg13444842	chr1:152974279	SPRR3	-0.49	-10.04	-0.42	1.35e-21	Inflammatory skin disease;
LGG	cis	rs1348850	0.645	rs13431091	chr2:178434615	A/G	cg23306229	chr2:178417860	TTC30B	0.75	9.65	0.41	3.31e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8064024	0.649	rs9934930	chr16:4902038	A/G	cg04440724	chr16:4920505	UBN1	-0.56	-12.38	-0.5	1.35e-30	Cancer;
LGG	cis	rs611744	0.934	rs609102	chr8:109227406	A/G	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.03e-11	Dupuytren's disease;
LGG	cis	rs9964724	0.533	rs72893199	chr18:35182708	T/C	cg27332583	chr18:35150602	NA	0.59	11.83	0.48	2.15e-28	Educational attainment (years of education);
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg05863683	chr7:1912471	MAD1L1	0.44	8.77	0.38	3.45e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs754423	0.662	rs3825594	chr14:52507206	G/A	cg05884192	chr14:52515736	NID2	0.33	6.97	0.31	1.07e-11	Craniofacial microsomia;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.38	-0.36	6.5e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg16141378	chr3:129829833	LOC729375	0.41	9.61	0.41	4.48e-20	Neuroticism;
LGG	cis	rs708547	0.874	rs73242624	chr4:57847420	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.68	10.26	0.43	2.11e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs2439831	0.850	rs28413704	chr15:44148427	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.72	0.45	4.27e-24	Lung cancer in ever smokers;
LGG	cis	rs2180341	0.842	rs6569476	chr6:127553539	G/A	cg27446573	chr6:127587934	RNF146	1.06	18.93	0.66	1.26e-59	Breast cancer;
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg27532560	chr4:187881888	NA	0.49	9.97	0.42	2.4e-21	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg01620082	chr3:125678407	NA	-1.08	-10.61	-0.44	1.07e-23	Depression;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.34e-12	Lung cancer;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg09845145	chr15:78292470	TBC1D2B	0.66	13.0	0.52	3.88e-33	Coronary artery disease or large artery stroke;
LGG	cis	rs2916247	0.954	rs4623481	chr8:93079345	T/G	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.41	-0.33	6.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg23625390	chr15:77176239	SCAPER	0.49	9.65	0.41	3.33e-20	Blood metabolite levels;
LGG	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.89	0.3	1.88e-11	Hemoglobin concentration;
LGG	cis	rs6735179	0.607	rs10188708	chr2:1746032	G/C	cg08534653	chr2:1747700	PXDN	0.46	6.79	0.3	3.49e-11	Response to antipsychotic treatment;
LGG	cis	rs2658782	0.951	rs117384439	chr11:93111478	T/G	cg15737290	chr11:93063684	CCDC67	-0.55	-8.13	-0.35	4.07e-15	Pulmonary function decline;
LGG	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg17108064	chr15:78857060	CHRNA5	-0.46	-10.02	-0.42	1.61e-21	Sudden cardiac arrest;
LGG	trans	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg06521331	chr12:34319734	NA	-0.5	-8.54	-0.37	1.98e-16	Heart rate;
LGG	cis	rs71636213	0.527	rs12654489	chr5:79663875	A/G	cg12576332	chr5:79646847	LOC441089	-0.5	-7.72	-0.34	7.21e-14	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9354308	0.738	rs2211637	chr6:66596941	T/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.15e-11	Metabolite levels;
LGG	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.75	-15.05	-0.57	6.12e-42	Total body bone mineral density;
LGG	cis	rs4727027	0.704	rs7784122	chr7:148904624	A/G	cg23583168	chr7:148888333	NA	0.93	19.49	0.67	3.34e-62	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs8017423	0.647	rs4904673	chr14:90817338	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-12.76	-0.51	3.65e-32	Mortality in heart failure;
LGG	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg12183467	chr14:104352244	NA	-0.43	-7.3	-0.32	1.27e-12	Bipolar disorder;
LGG	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.43	0.33	5.16e-13	Morning vs. evening chronotype;
LGG	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.4e-11	Obesity-related traits;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg27471124	chr11:109292789	C11orf87	0.51	9.9	0.42	4.45e-21	Schizophrenia;
LGG	cis	rs858239	0.570	rs10235467	chr7:23148808	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.29	0.32	1.35e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.44	0.72	4.93e-76	Breast cancer;
LGG	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg13010199	chr12:38710504	ALG10B	0.4	7.2	0.32	2.44e-12	Morning vs. evening chronotype;
LGG	trans	rs12310956	0.532	rs1525903	chr12:33964163	T/C	cg13010199	chr12:38710504	ALG10B	0.52	9.97	0.42	2.54e-21	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg19635926	chr16:89946313	TCF25	0.81	9.19	0.39	1.35e-18	Skin colour saturation;
LGG	cis	rs892961	1.000	rs2164449	chr17:75401190	G/A	cg05865280	chr17:75406074	SEPT9	0.42	10.01	0.42	1.73e-21	Airflow obstruction;
LGG	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.27	0.63	5.94e-52	Chronic sinus infection;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06148375	chr16:12070864	RUNDC2A	-0.46	-7.14	-0.31	3.68e-12	Pancreatic cancer;
LGG	cis	rs7998202	0.667	rs282583	chr13:113349642	G/T	cg17218041	chr13:113365319	ATP11A	-0.47	-7.95	-0.35	1.44e-14	Glycated hemoglobin levels;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.12	-0.31	4.22e-12	Menopause (age at onset);
LGG	trans	rs4714291	0.894	rs2253393	chr6:39953821	G/A	cg02267698	chr19:7991119	CTXN1	0.54	8.17	0.35	2.91e-15	Strep throat;
LGG	trans	rs1814175	0.817	rs80244685	chr11:49763292	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.03	-0.6	2.66e-46	Height;
LGG	cis	rs2033732	0.673	rs920226	chr8:85054989	A/T	cg05716166	chr8:85095498	RALYL	0.43	6.86	0.3	2.24e-11	Body mass index;
LGG	cis	rs6541297	1.000	rs6686054	chr1:230282853	C/T	cg20703242	chr1:230279135	GALNT2	0.37	7.65	0.33	1.2e-13	Coronary artery disease;
LGG	cis	rs4073582	0.964	rs801742	chr11:65914766	C/A	cg16950941	chr11:66035639	RAB1B	0.41	6.9	0.31	1.73e-11	Gout;
LGG	cis	rs2213920	0.516	rs2188042	chr9:118159740	C/T	cg13918206	chr9:118159781	DEC1	-0.78	-10.55	-0.44	1.77e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs3087591	1.000	rs984125	chr17:29547254	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.68	0.56	2.38e-40	Hip circumference;
LGG	cis	rs1957429	0.901	rs1957435	chr14:65349697	G/A	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs6466055	0.720	rs12334245	chr7:104995627	T/C	cg04380332	chr7:105027541	SRPK2	-0.39	-7.27	-0.32	1.57e-12	Schizophrenia;
LGG	cis	rs12762955	0.528	rs10903358	chr10:1102386	G/A	cg25019033	chr10:957182	NA	-0.54	-9.69	-0.41	2.5e-20	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs208520	0.674	rs207103	chr6:66795568	G/T	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs2635047	0.935	rs2461247	chr18:44698537	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.23	0.39	9.45e-19	Educational attainment;
LGG	cis	rs7143963	0.945	rs12589771	chr14:103284276	A/G	cg23020514	chr14:103360112	TRAF3	0.51	9.47	0.4	1.4e-19	Body mass index;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg16103275	chr6:290800	DUSP22	0.49	7.95	0.35	1.4e-14	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16160182	chr1:2574031	NA	0.37	6.78	0.3	3.79e-11	Obesity-related traits;
LGG	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg22437258	chr11:111473054	SIK2	-0.42	-6.92	-0.31	1.46e-11	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18909525	chr9:132403873	ASB6	0.51	7.64	0.33	1.22e-13	Gut microbiome composition (summer);
LGG	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg02574844	chr11:5959923	NA	-0.56	-9.43	-0.4	1.99e-19	DNA methylation (variation);
LGG	cis	rs6754311	0.773	rs4988183	chr2:136622046	T/C	cg07169764	chr2:136633963	MCM6	0.82	14.53	0.56	1.15e-39	Mosquito bite size;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	8.0	0.35	1.03e-14	Personality dimensions;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg18350739	chr11:68623251	NA	-0.89	-22.13	-0.72	1.52e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1570884	0.539	rs7982964	chr13:50111762	G/A	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.71	-0.3	5.65e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs41271473	0.898	rs17352535	chr1:228822284	C/G	cg16512390	chr1:228756714	NA	0.5	6.69	0.3	6.31e-11	Chronic lymphocytic leukemia;
LGG	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6547631	0.527	rs55665393	chr2:85927727	T/C	cg19805943	chr2:85933069	NA	0.32	6.76	0.3	4.13e-11	Blood protein levels;
LGG	cis	rs2072499	0.966	rs2842882	chr1:156165342	T/G	cg25208724	chr1:156163844	SLC25A44	1.26	31.72	0.83	3.75e-118	Testicular germ cell tumor;
LGG	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg10483660	chr13:112241077	NA	0.36	6.96	0.31	1.13e-11	Menarche (age at onset);
LGG	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg24642439	chr20:33292090	TP53INP2	0.61	10.65	0.44	7.47e-24	Coronary artery disease;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg05793240	chr7:2802953	GNA12	0.29	7.03	0.31	7.66e-12	Height;
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg16578609	chr1:2399051	NA	-0.36	-9.18	-0.39	1.41e-18	Schizophrenia;
LGG	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.32e-28	Gout;Renal underexcretion gout;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg21724239	chr8:58056113	NA	0.6	9.25	0.39	8.47e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs17401966	0.838	rs4333852	chr1:10387704	A/T	cg19773385	chr1:10388646	KIF1B	0.46	9.86	0.42	5.99e-21	Hepatocellular carcinoma;
LGG	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg08999081	chr20:33150536	PIGU	0.33	7.96	0.35	1.3e-14	Coronary artery disease;
LGG	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg11266682	chr4:10021025	SLC2A9	0.42	8.19	0.36	2.59e-15	Bone mineral density;
LGG	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.42	6.94	0.31	1.31e-11	Carotid intima media thickness;
LGG	cis	rs10752881	1.000	rs10797812	chr1:182984597	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.62	-0.37	1.06e-16	Colorectal cancer;
LGG	trans	rs7181230	0.885	rs28444847	chr15:40356604	C/T	cg22705835	chr10:65332833	REEP3	-0.62	-10.28	-0.43	1.88e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs7666738	0.716	rs2865982	chr4:99031661	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6977955	1.000	rs6977955	chr7:28156887	A/G	cg23620719	chr7:28220237	JAZF1	-0.44	-6.89	-0.3	1.88e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs6568686	0.735	rs7762054	chr6:111870742	C/T	cg21044968	chr6:111895086	TRAF3IP2	0.4	6.72	0.3	5.2e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	12.36	0.5	1.53e-30	Lung cancer in ever smokers;
LGG	cis	rs7027203	0.828	rs10821229	chr9:96595136	A/C	cg14598338	chr9:96623480	NA	-0.54	-9.74	-0.41	1.62e-20	DNA methylation (variation);
LGG	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg20026190	chr17:76395443	PGS1	0.45	7.59	0.33	1.8e-13	HDL cholesterol;
LGG	cis	rs2075371	0.897	rs10488428	chr7:133997560	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.76	0.45	2.87e-24	Mean platelet volume;
LGG	cis	rs765787	0.530	rs12442533	chr15:45529631	G/C	cg24006582	chr15:45444508	DUOX1	0.67	12.25	0.49	4.47e-30	Uric acid levels;
LGG	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg02463440	chr8:22132932	PIWIL2	0.49	10.92	0.45	7.19e-25	Hypertriglyceridemia;
LGG	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg00149659	chr3:10157352	C3orf10	0.56	8.03	0.35	8.22e-15	Alzheimer's disease;
LGG	cis	rs638893	1.000	rs73005500	chr11:118697375	T/C	cg22253036	chr11:118662786	DDX6	-0.42	-6.82	-0.3	2.87e-11	Vitiligo;
LGG	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg12395012	chr8:11607386	GATA4	-0.41	-7.43	-0.33	5.45e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg05973401	chr12:123451056	ABCB9	0.5	7.23	0.32	1.98e-12	Neutrophil percentage of white cells;
LGG	cis	rs975739	0.872	rs1144384	chr13:78363063	C/T	cg07847733	chr13:78271382	SLAIN1	0.38	6.91	0.31	1.58e-11	Hair color;
LGG	cis	rs17539620	0.624	rs62432746	chr6:154838986	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	7.63	0.33	1.4e-13	Lipoprotein (a) levels;
LGG	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07697662	chr16:30934684	NCRNA00095;FBXL19	0.48	6.88	0.3	1.97e-11	Hip circumference;
LGG	cis	rs75804782	0.641	rs3769124	chr2:239349362	G/A	cg18131467	chr2:239335373	ASB1	-0.66	-6.66	-0.3	7.58e-11	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12517452	chr5:52084045	ITGA1;PELO	0.42	7.29	0.32	1.36e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg15704280	chr7:45808275	SEPT13	0.48	7.83	0.34	3.33e-14	HDL cholesterol;
LGG	trans	rs7980799	0.654	rs1482987	chr12:33614283	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-11.96	-0.49	6.7200000000000006e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6840360	0.642	rs1596290	chr4:152410540	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.0	0.31	8.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7103648	0.966	rs1534576	chr11:47419663	A/C	cg20307385	chr11:47447363	PSMC3	-0.95	-23.42	-0.74	1.33e-80	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs929354	0.713	rs3802129	chr7:156965297	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs490234	0.932	rs473426	chr9:128406988	G/C	cg14078157	chr9:128172775	NA	0.36	6.71	0.3	5.65e-11	Mean arterial pressure;
LGG	cis	rs6540556	0.859	rs1007693	chr1:209931799	C/T	cg23920097	chr1:209922102	NA	-0.46	-8.22	-0.36	2.1e-15	Red blood cell count;
LGG	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08045932	chr20:61659980	NA	0.6	13.22	0.52	4.47e-34	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7939886	0.920	rs76702940	chr11:55999305	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg13397359	chr6:42928475	GNMT	0.64	18.88	0.66	2.21e-59	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7166081	1.000	rs12595736	chr15:67582602	T/A	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4671458	0.656	rs72821631	chr2:63700164	G/A	cg17519650	chr2:63277830	OTX1	-0.51	-6.83	-0.3	2.74e-11	Subjective well-being;
LGG	cis	rs3857536	0.730	rs6927862	chr6:66971450	A/C	cg07460842	chr6:66804631	NA	-0.43	-7.16	-0.32	3.24e-12	Blood trace element (Cu levels);
LGG	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.07	-0.35	6.21e-15	Mood instability;
LGG	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-8.47	-0.37	3.35e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6740322	0.748	rs6755601	chr2:43483044	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.66	-10.36	-0.43	9.56e-23	Coronary artery disease;
LGG	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg14983838	chr19:29218262	NA	0.7	11.37	0.47	1.35e-26	Methadone dose in opioid dependence;
LGG	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg25019033	chr10:957182	NA	-0.55	-9.91	-0.42	4e-21	Eosinophil percentage of granulocytes;
LGG	trans	rs629535	0.814	rs56326813	chr8:70107736	T/A	cg21567404	chr3:27674614	NA	-0.4	-6.78	-0.3	3.73e-11	Dupuytren's disease;
LGG	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06481639	chr22:41940642	POLR3H	0.58	8.44	0.37	4e-16	Vitiligo;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg25072359	chr17:41440525	NA	0.51	9.46	0.4	1.59e-19	Menopause (age at onset);
LGG	cis	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg09307838	chr4:120376055	NA	-0.67	-11.39	-0.47	1.14e-26	Corneal astigmatism;
LGG	trans	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9807841	0.592	rs6511707	chr19:10767790	C/T	cg17710535	chr19:10819994	QTRT1	0.47	7.48	0.33	3.72e-13	Inflammatory skin disease;
LGG	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg21775007	chr8:11205619	TDH	0.41	6.66	0.3	7.59e-11	Monocyte count;
LGG	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg18196295	chr10:418757	DIP2C	-0.57	-10.91	-0.45	7.97e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg20302533	chr7:39170763	POU6F2	-0.57	-14.63	-0.56	4.16e-40	IgG glycosylation;
LGG	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg09873164	chr1:152488093	CRCT1	0.63	15.37	0.58	2.15e-43	Hair morphology;
LGG	cis	rs4906332	1.000	rs17617307	chr14:103904965	C/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.8e-14	Coronary artery disease;
LGG	cis	rs504918	1.000	rs504918	chr3:124083170	A/G	cg05766129	chr3:123988013	KALRN	-0.38	-6.95	-0.31	1.24e-11	Schizophrenia;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00149659	chr3:10157352	C3orf10	0.84	10.88	0.45	1.07e-24	Alzheimer's disease;
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg02711726	chr17:80685570	FN3KRP	-0.59	-10.97	-0.45	4.64e-25	Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27561949	chr6:88411006	NCRNA00120;AKIRIN2	0.51	7.59	0.33	1.77e-13	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.14	-0.6	8.21e-47	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.569	rs697438	chr6:101731054	G/A	cg27451362	chr6:101846650	GRIK2	0.89	13.22	0.52	4.3e-34	Coenzyme Q10 levels;
LGG	cis	rs599083	0.530	rs640569	chr11:68184820	A/G	cg01657329	chr11:68192670	LRP5	0.62	10.28	0.43	1.86e-22	Bone mineral density (spine);
LGG	cis	rs7681440	0.904	rs17192189	chr4:90774928	A/C	cg20003494	chr4:90757398	SNCA	0.39	7.61	0.33	1.53e-13	Dementia with Lewy bodies;
LGG	cis	rs62400317	0.826	rs12213735	chr6:45152848	C/T	cg18551225	chr6:44695536	NA	0.62	10.26	0.43	2.14e-22	Total body bone mineral density;
LGG	trans	rs330048	0.545	rs11781008	chr8:9153239	G/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.62	-0.33	1.42e-13	Systemic lupus erythematosus;
LGG	cis	rs9309473	0.579	rs1852644	chr2:73597718	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-8.32	-0.36	9.83e-16	Metabolite levels;
LGG	trans	rs9650657	0.623	rs10091636	chr8:10602966	A/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.3	-0.32	1.25e-12	Neuroticism;
LGG	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.82	-0.3	2.9100000000000002e-11	Blood metabolite levels;
LGG	cis	rs910316	0.967	rs2024653	chr14:75595154	G/A	cg08847533	chr14:75593920	NEK9	0.62	11.88	0.48	1.4e-28	Height;
LGG	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.51	7.28	0.32	1.47e-12	Birth weight;
LGG	cis	rs9397585	0.626	rs6932847	chr6:153448307	G/A	cg17707550	chr6:153380415	RGS17	0.45	9.99	0.42	2.06e-21	Body mass index;
LGG	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg17644776	chr2:200775616	C2orf69	-0.61	-7.13	-0.31	3.87e-12	Schizophrenia;
LGG	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg04568710	chr12:38710424	ALG10B	-0.41	-8.65	-0.37	8.78e-17	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.42	-0.53	6.18e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg04080417	chr5:1859792	NA	-0.52	-8.31	-0.36	1.07e-15	Cardiovascular disease risk factors;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.1	0.39	2.79e-18	Obesity-related traits;
LGG	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg07930552	chr6:133119739	C6orf192	1.14	10.16	0.43	5.16e-22	Type 2 diabetes nephropathy;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.56	-0.41	7.04e-20	Lung cancer;
LGG	cis	rs9457247	0.534	rs2345568	chr6:167381804	A/G	cg18261144	chr6:167370276	RNASET2	-0.37	-7.45	-0.33	4.55e-13	Crohn's disease;
LGG	cis	rs12681287	0.609	rs13279850	chr8:87477800	C/T	cg27223183	chr8:87520930	FAM82B	-0.49	-7.49	-0.33	3.5e-13	Caudate activity during reward;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.84	0.34	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs283228	0.833	rs283201	chr6:101727746	G/C	cg27451362	chr6:101846650	GRIK2	0.55	8.69	0.37	6.23e-17	Coenzyme Q10 levels;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg13628971	chr7:2884303	GNA12	0.51	10.33	0.43	1.24e-22	Height;
LGG	cis	rs7917772	0.565	rs1043450	chr10:104434209	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.62	0.48	1.44e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4732038	0.874	rs56242442	chr7:134242523	G/A	cg06906464	chr7:134288099	NA	-0.51	-12.72	-0.51	5.24e-32	Longevity;
LGG	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.22	-0.36	2.03e-15	Glycated hemoglobin levels;
LGG	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03264133	chr6:25882463	NA	-0.53	-9.99	-0.42	2.04e-21	Blood metabolite levels;
LGG	cis	rs7599312	0.534	rs6735626	chr2:213403972	G/A	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	6.2e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6800768	1.000	rs6800768	chr3:24113252	T/C	cg10674438	chr3:24145617	LOC152024	-0.38	-7.32	-0.32	1.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582720	0.511	rs116219813	chr2:204081675	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.36	0.4	3.59e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.79	0.3	3.49e-11	Cognitive function;
LGG	cis	rs35160687	0.623	rs4832263	chr2:86485157	G/T	cg10973622	chr2:86423274	IMMT	-0.41	-7.24	-0.32	1.93e-12	Night sleep phenotypes;
LGG	cis	rs4730250	0.655	rs4727671	chr7:106876045	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.94	-0.45	6.39e-25	Osteoarthritis;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	cis	rs9640161	0.711	rs3800781	chr7:150027324	T/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.79	-16.75	-0.61	1.42e-49	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs4697263	0.580	rs7657801	chr4:22044236	C/T	cg27131176	chr22:46450114	C22orf26;LOC150381	0.45	6.94	0.31	1.37e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7666738	0.791	rs60028147	chr4:99046618	G/A	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21659725	chr3:3221576	CRBN	0.6	10.63	0.44	9.04e-24	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg16586182	chr3:47516702	SCAP	0.76	14.75	0.57	1.23e-40	Colorectal cancer;
LGG	cis	rs7666738	0.830	rs7662948	chr4:99020132	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.61	10.39	0.43	7.23e-23	Obesity-related traits;
LGG	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg26597838	chr10:835615	NA	0.64	9.56	0.41	6.87e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs3087591	0.919	rs2952993	chr17:29539998	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg03929089	chr4:120376271	NA	0.75	7.86	0.34	2.79e-14	Axial length;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-21.72	-0.71	1.22e-72	Vitiligo;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg12310025	chr6:25882481	NA	-0.44	-7.93	-0.35	1.63e-14	Height;
LGG	cis	rs3213545	0.700	rs10849829	chr12:121470256	A/G	cg02403541	chr12:121454288	C12orf43	-0.52	-9.06	-0.39	3.7e-18	Subjective well-being;Cardiovascular disease risk factors;
LGG	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.38e-12	Blood metabolite levels;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg26174226	chr8:58114915	NA	-0.53	-7.64	-0.33	1.25e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2070433	1.000	rs2070433	chr21:47961386	G/A	cg12379764	chr21:47803548	PCNT	0.58	8.22	0.36	2.05e-15	Lymphocyte counts;
LGG	cis	rs9547996	0.796	rs9547968	chr13:38166068	C/G	cg13634560	chr13:38173852	POSTN	-0.35	-6.99	-0.31	9.58e-12	Diastolic blood pressure;
LGG	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15128208	chr22:42549153	NA	-0.43	-8.55	-0.37	1.84e-16	Cognitive function;
LGG	cis	rs4948496	0.840	rs56140430	chr10:63806563	C/A	cg07520810	chr10:63809149	ARID5B	0.36	6.86	0.3	2.19e-11	Systemic lupus erythematosus;
LGG	cis	rs1707322	0.717	rs12023439	chr1:46104636	C/T	cg03146154	chr1:46216737	IPP	0.58	11.02	0.46	3.02e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	8.8	0.38	2.79e-17	Lung function (FEV1/FVC);
LGG	cis	rs6976053	0.791	rs314377	chr7:100458049	A/G	cg03098644	chr7:100410630	EPHB4	-0.43	-7.8	-0.34	4.11e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9287719	0.967	rs6719701	chr2:10748283	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.0	-24.5	-0.75	1.23e-85	Prudent dietary pattern;
LGG	cis	rs1153858	0.887	rs7171163	chr15:45636395	A/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.5e-77	Homoarginine levels;
LGG	cis	rs4820539	1.000	rs916583	chr22:23469267	C/T	cg21100191	chr22:23484243	RTDR1	1.0	22.68	0.73	3.94e-77	Bone mineral density;
LGG	cis	rs7173389	1.000	rs7172038	chr15:73667255	T/G	cg01796676	chr15:73680284	NA	0.51	8.66	0.37	8.18e-17	Resting heart rate;
LGG	cis	rs12478296	1.000	rs56292923	chr2:243039986	C/T	cg06360820	chr2:242988706	NA	-0.91	-11.53	-0.47	3.23e-27	Obesity-related traits;
LGG	cis	rs4737010	0.501	rs12548116	chr8:41645074	A/G	cg17182837	chr8:41585554	ANK1	-0.56	-8.06	-0.35	6.42e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1003719	0.715	rs2835667	chr21:38579914	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.83	-0.57	5.4e-41	Eye color traits;
LGG	cis	rs4742903	0.904	rs1507510	chr9:106985153	T/A	cg14250997	chr9:106856677	SMC2	0.4	8.24	0.36	1.76e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs12458462	0.859	rs2242177	chr18:77477379	G/A	cg11879182	chr18:77439856	CTDP1	0.79	14.93	0.57	1.96e-41	Monocyte count;
LGG	trans	rs2727020	0.521	rs7946190	chr11:49521964	T/A	cg15704280	chr7:45808275	SEPT13	0.87	13.67	0.54	5.55e-36	Coronary artery disease;
LGG	cis	rs151997	1.000	rs373030	chr5:50215836	G/A	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs701145	0.938	rs355770	chr3:154040273	G/A	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	cis	rs10791323	0.511	rs4937837	chr11:133731134	T/C	cg06766960	chr11:133703094	NA	-0.58	-11.48	-0.47	5.18e-27	Childhood ear infection;
LGG	cis	rs2901656	0.677	rs1063412	chr1:172410967	G/A	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	7.12	0.31	4.26e-12	Red cell distribution width;Platelet distribution width;
LGG	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.68e-26	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg12432903	chr7:1882776	MAD1L1	0.52	8.08	0.35	5.53e-15	Bipolar disorder;
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10802521	chr3:52805072	NEK4	-0.44	-7.53	-0.33	2.7e-13	Bipolar disorder;
LGG	trans	rs7395662	0.591	rs4882012	chr11:48560597	T/A	cg21153622	chr11:89784906	NA	-0.39	-6.7	-0.3	6.02e-11	HDL cholesterol;
LGG	cis	rs10895140	0.756	rs2508725	chr11:101486608	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	trans	rs36715	0.909	rs152906	chr5:127551840	T/C	cg16011800	chr17:1958478	HIC1	-0.46	-6.89	-0.3	1.85e-11	Breast cancer;
LGG	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg17691542	chr6:26056736	HIST1H1C	0.55	9.84	0.42	7.24e-21	Height;
LGG	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs367943	0.712	rs10042223	chr5:112712832	C/T	cg12552261	chr5:112820674	MCC	0.57	10.42	0.44	5.35e-23	Type 2 diabetes;
LGG	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs965469	0.545	rs6051845	chr20:3402792	A/G	cg25506879	chr20:3388711	C20orf194	-0.46	-7.21	-0.32	2.33e-12	IFN-related cytopenia;
LGG	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg11693508	chr17:37793320	STARD3	0.68	9.94	0.42	3.06e-21	Bipolar disorder;
LGG	cis	rs4731207	0.698	rs7793441	chr7:124536238	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs2072732	1.000	rs72630911	chr1:2974064	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.24	-0.36	1.77e-15	Plateletcrit;
LGG	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg06453172	chr10:134556979	INPP5A	-0.55	-8.34	-0.36	8.43e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11877825	0.826	rs4121955	chr18:10569879	C/A	cg25239095	chr18:10589360	NA	0.49	9.28	0.4	6.36e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs3771570	0.892	rs55751610	chr2:242346057	C/T	cg21155796	chr2:242212141	HDLBP	0.75	9.71	0.41	2.03e-20	Prostate cancer;
LGG	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg15557168	chr22:42548783	NA	-0.46	-10.11	-0.43	7.64e-22	Schizophrenia;
LGG	cis	rs9790314	0.638	rs6441339	chr3:160619683	T/G	cg04691961	chr3:161091175	C3orf57	0.41	8.74	0.38	4.44e-17	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs2280630	0.898	rs1828679	chr3:39195507	C/T	cg23654821	chr3:39188656	CSRNP1	0.27	6.96	0.31	1.17e-11	Verbal declarative memory;
LGG	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	8.84	0.38	2.08e-17	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg26396452	chr14:65542826	MAX	0.43	8.29	0.36	1.21e-15	Obesity-related traits;
LGG	cis	rs752010	0.806	rs1109255	chr1:42091708	C/T	cg06885757	chr1:42089581	HIVEP3	0.54	12.1	0.49	1.86e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg19761014	chr17:28927070	LRRC37B2	0.61	7.23	0.32	1.95e-12	Body mass index;
LGG	cis	rs9788682	0.655	rs578776	chr15:78888400	G/A	cg06917634	chr15:78832804	PSMA4	-0.48	-7.77	-0.34	5.25e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg25173464	chr15:68126554	NA	-0.34	-7.21	-0.32	2.27e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs7512552	0.780	rs1260411	chr1:150382088	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.32	0.4	4.66e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	trans	rs9354308	0.714	rs9453467	chr6:66592836	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	cis	rs853679	0.517	rs9380056	chr6:28104476	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs6831352	0.918	rs13127582	chr4:100058194	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.41	-0.4	2.26e-19	Sudden cardiac arrest;
LGG	trans	rs783540	0.967	rs34186444	chr15:83287500	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.67	-0.3	7.24e-11	Schizophrenia;
LGG	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.26	0.46	3.6e-26	Bone mineral density;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg08499158	chr17:42289980	UBTF	0.58	11.1	0.46	1.53e-25	Total body bone mineral density;
LGG	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg09624528	chr10:1369823	ADARB2	-0.39	-6.69	-0.3	6.27e-11	Radiation response;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg22963979	chr7:1858916	MAD1L1	-0.53	-10.26	-0.43	2.22e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.82	-0.3	2.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7940866	0.774	rs2162059	chr11:130831224	C/T	cg12179176	chr11:130786555	SNX19	0.74	14.15	0.55	5.19e-38	Schizophrenia;
LGG	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.84	-0.45	1.5e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs763121	0.962	rs6001159	chr22:38966487	A/G	cg06022373	chr22:39101656	GTPBP1	0.81	16.25	0.6	2.58e-47	Menopause (age at onset);
LGG	cis	rs4148087	0.860	rs9980310	chr21:43607858	C/T	cg08841829	chr21:43638893	ABCG1	-0.54	-7.23	-0.32	2.03e-12	Eating disorder in bipolar disorder;
LGG	trans	rs6787172	0.755	rs9877909	chr3:158144264	C/T	cg23275840	chr4:47708675	CORIN	-0.39	-8.23	-0.36	1.88e-15	Subjective well-being;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg04863758	chr4:1303710	MAEA	0.45	7.65	0.33	1.2e-13	Obesity-related traits;
LGG	cis	rs208520	0.661	rs851466	chr6:66840476	A/G	cg07460842	chr6:66804631	NA	-0.97	-18.2	-0.65	3.3e-56	Exhaled nitric oxide output;
LGG	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.19	-0.36	2.6e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8072100	0.905	rs9901869	chr17:45575206	G/A	cg25173405	chr17:45401733	C17orf57	-0.5	-8.79	-0.38	3.04e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg23441090	chr1:2126425	C1orf86;LOC100128003	-0.37	-7.47	-0.33	4.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs62064224	0.714	rs11653974	chr17:30635002	T/C	cg18200150	chr17:30822561	MYO1D	0.51	9.83	0.42	7.59e-21	Schizophrenia;
LGG	trans	rs17685	0.523	rs10246583	chr7:75746667	C/A	cg19862616	chr7:65841803	NCRNA00174	1.08	25.91	0.77	4e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg24247370	chr13:99142703	STK24	-0.36	-6.65	-0.3	8.09e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	0.935	rs11772264	chr7:66176387	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.74	-0.3	4.78e-11	Aortic root size;
LGG	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.31e-13	HDL cholesterol;
LGG	cis	rs2797369	0.511	rs601360	chr6:101337765	C/A	cg27451362	chr6:101846650	GRIK2	0.68	9.12	0.39	2.25e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs1322639	0.614	rs9689800	chr6:169572945	T/A	cg04662567	chr6:169592167	NA	0.66	13.17	0.52	7.52e-34	Pulse pressure;
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.78	0.48	3.47e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11098499	0.866	rs9991221	chr4:120292107	G/C	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	trans	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg07142201	chr11:109293216	C11orf87	0.54	9.73	0.41	1.81e-20	Schizophrenia;
LGG	cis	rs4743820	0.590	rs10991785	chr9:93917111	C/T	cg14446406	chr9:93919335	NA	-0.9	-15.15	-0.58	2.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs8067545	0.586	rs8080649	chr17:20069677	G/C	cg09818912	chr17:20140352	CYTSB	-0.32	-7.57	-0.33	2e-13	Schizophrenia;
LGG	cis	rs6426558	0.537	rs648877	chr1:227283614	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	10.2	0.43	3.61e-22	Neutrophil percentage of white cells;
LGG	cis	rs4704846	1.000	rs415392	chr5:156546990	C/T	cg12943317	chr5:156479607	HAVCR1	-0.52	-7.0	-0.31	9.05e-12	Blood protein levels;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg06074448	chr4:187884817	NA	-0.59	-12.95	-0.52	6.24e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6032067	0.929	rs35880287	chr20:43821001	G/A	cg10761708	chr20:43804764	PI3	0.75	11.49	0.47	4.67e-27	Blood protein levels;
LGG	cis	rs8072100	0.817	rs6505049	chr17:45675781	G/A	cg25173405	chr17:45401733	C17orf57	0.48	8.07	0.35	5.93e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.66	0.41	2.99e-20	Alcohol dependence;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg11494091	chr17:61959527	GH2	0.98	24.13	0.75	6.91e-84	Prudent dietary pattern;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-10.33	-0.43	1.15e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg10483660	chr13:112241077	NA	-0.43	-8.85	-0.38	1.87e-17	Menarche (age at onset);
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg08461457	chr11:2027003	NA	-0.42	-8.11	-0.35	4.59e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7188861	0.768	rs1690500	chr16:11389986	C/T	cg01510278	chr16:11456238	NA	0.31	7.39	0.32	6.72e-13	HDL cholesterol;
LGG	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg14993813	chr1:46806288	NSUN4	-0.55	-9.08	-0.39	3.11e-18	Menopause (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18124201	chr20:46414952	SULF2	-0.48	-6.91	-0.31	1.66e-11	Systemic lupus erythematosus;
LGG	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.47	0.5	5.5e-31	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs754466	0.606	rs11002308	chr10:79594796	A/T	cg17075019	chr10:79541650	NA	-0.96	-20.47	-0.69	8.96e-67	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08677398	chr8:58056175	NA	0.5	7.91	0.34	1.97e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.22	0.32	2.19e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2380220	0.640	rs9320386	chr6:95994955	T/C	cg04719120	chr6:96025338	MANEA	0.49	6.66	0.3	7.89e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg12395012	chr8:11607386	GATA4	0.39	6.87	0.3	2.09e-11	Retinal vascular caliber;
LGG	cis	rs17767392	0.813	rs34991781	chr14:71921576	G/A	cg02058870	chr14:72053146	SIPA1L1	0.39	8.14	0.35	3.76e-15	Mitral valve prolapse;
LGG	trans	rs7944735	0.508	rs2138767	chr11:47629793	T/C	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.24e-11	Intraocular pressure;
LGG	cis	rs9972944	0.756	rs11870607	chr17:63773122	A/G	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.95	-0.31	1.26e-11	Colorectal cancer;
LGG	cis	rs6032067	0.673	rs13039345	chr20:43895932	G/C	cg10761708	chr20:43804764	PI3	0.59	8.89	0.38	1.4e-17	Blood protein levels;
LGG	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg12288994	chr5:1860383	NA	0.73	12.21	0.49	6.17e-30	Cardiovascular disease risk factors;
LGG	cis	rs807029	0.577	rs3740490	chr10:102756743	G/C	cg04662943	chr10:102668895	NA	0.48	6.98	0.31	1.02e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs16937	0.503	rs76939335	chr1:205178610	T/C	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.53e-13	Schizophrenia;
LGG	cis	rs6964587	0.934	rs7811328	chr7:91720931	A/T	cg17063962	chr7:91808500	NA	0.47	8.33	0.36	9.11e-16	Breast cancer;
LGG	cis	rs1669338	0.588	rs62228620	chr3:3184913	C/T	cg16797762	chr3:3221439	CRBN	-0.95	-12.74	-0.51	4.33e-32	White matter integrity;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg20255370	chr15:40268687	EIF2AK4	-0.8	-10.14	-0.43	5.74e-22	Response to haloperidol in psychosis;
LGG	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg00129232	chr17:37814104	STARD3	0.58	8.48	0.37	2.95e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg08297393	chr2:100937505	LONRF2	-0.47	-8.45	-0.37	3.78e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg06848047	chr4:90757629	SNCA	-0.38	-7.36	-0.32	8.55e-13	Dementia with Lewy bodies;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20887711	chr4:1340912	KIAA1530	0.9	19.9	0.68	4.07e-64	Longevity;
LGG	cis	rs11203032	0.831	rs11203009	chr10:90927163	G/A	cg16672925	chr10:90967113	CH25H	0.77	10.97	0.45	4.63e-25	Heart failure;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-8.36	-0.36	7.47e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7568458	0.811	rs3755014	chr2:85764006	C/T	cg02493740	chr2:85810744	VAMP5	-0.4	-7.26	-0.32	1.6e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4561483	0.801	rs33643	chr16:11986149	A/G	cg08843971	chr16:11963173	GSPT1	-0.67	-17.89	-0.64	8.38e-55	Testicular germ cell tumor;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg20607798	chr8:58055168	NA	0.62	7.27	0.32	1.56e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7737355	0.947	rs11744232	chr5:130911732	A/G	cg06307176	chr5:131281290	NA	0.53	8.75	0.38	3.9e-17	Life satisfaction;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg03575189	chr17:44344142	NA	0.49	7.2	0.32	2.38e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1595825	1.000	rs73058821	chr2:198864597	A/G	cg00982548	chr2:198649783	BOLL	-0.49	-6.76	-0.3	4.1e-11	Ulcerative colitis;
LGG	cis	rs210138	1.000	rs210144	chr6:33547430	G/A	cg04201373	chr6:33551533	GGNBP1	0.35	6.76	0.3	4.14e-11	Testicular germ cell tumor;
LGG	cis	rs758324	0.898	rs11956351	chr5:131137224	G/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg07777115	chr5:623756	CEP72	-0.52	-7.01	-0.31	8.47e-12	Obesity-related traits;
LGG	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.72e-13	Aortic root size;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg08888203	chr3:10149979	C3orf24	0.57	9.73	0.41	1.73e-20	Alzheimer's disease;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg26076054	chr5:421317	AHRR	0.43	7.79	0.34	4.56e-14	Cystic fibrosis severity;
LGG	cis	rs10791097	0.967	rs4366492	chr11:130717256	T/C	cg12179176	chr11:130786555	SNX19	0.75	14.43	0.56	3.02e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.89	-0.31	1.8e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3749237	0.595	rs17595772	chr3:49409704	G/A	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.02e-23	Resting heart rate;
LGG	cis	rs6988985	0.728	rs7388251	chr8:143969208	T/C	cg10324643	chr8:143916377	GML	0.4	8.0	0.35	1.03e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg22907277	chr7:1156413	C7orf50	0.62	11.54	0.47	2.88e-27	Longevity;Endometriosis;
LGG	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg23740940	chr11:68924746	NA	0.43	6.93	0.31	1.44e-11	Blond vs. brown hair color;
LGG	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg19761014	chr17:28927070	LRRC37B2	0.64	7.62	0.33	1.49e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	1.000	rs4557682	chr8:143738182	T/C	cg24634471	chr8:143751801	JRK	0.54	8.62	0.37	1.04e-16	Schizophrenia;
LGG	cis	rs4330281	0.653	rs11128852	chr3:17776334	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.16	-0.32	3.25e-12	Schizophrenia;
LGG	cis	rs651907	0.588	rs797866	chr3:101658031	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	7.45	0.33	4.72e-13	Colorectal cancer;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg07414643	chr4:187882934	NA	0.54	11.25	0.46	4.13e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg13010199	chr12:38710504	ALG10B	0.55	11.05	0.46	2.3e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.19	-0.32	2.63e-12	Prostate cancer;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.42	-7.6	-0.33	1.64e-13	Schizophrenia;
LGG	cis	rs9790314	0.613	rs13086250	chr3:160631965	G/A	cg04691961	chr3:161091175	C3orf57	0.41	8.63	0.37	9.85e-17	Morning vs. evening chronotype;
LGG	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1555895	0.576	rs2274376	chr10:850157	A/G	cg10556349	chr10:835070	NA	-0.3	-7.61	-0.33	1.6e-13	Survival in rectal cancer;
LGG	cis	rs8048589	0.604	rs11646584	chr16:12207975	G/A	cg02910054	chr16:12241554	SNX29	0.54	8.35	0.36	7.93e-16	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg21665744	chr7:39171113	POU6F2	0.43	8.87	0.38	1.57e-17	IgG glycosylation;
LGG	cis	rs2404602	0.716	rs1125932	chr15:76820540	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	2e-18	Blood metabolite levels;
LGG	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.04e-23	Resting heart rate;
LGG	cis	rs2011503	1.000	rs75667002	chr19:19592232	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs9902453	0.753	rs7226121	chr17:28208125	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.57	0.53	1.48e-35	Coffee consumption (cups per day);
LGG	cis	rs7027203	1.000	rs7864114	chr9:96551954	A/G	cg14598338	chr9:96623480	NA	0.5	8.72	0.38	5.04e-17	DNA methylation (variation);
LGG	cis	rs7651039	0.619	rs7640807	chr3:15685137	A/G	cg16303742	chr3:15540471	COLQ	0.57	11.7	0.48	6.78e-28	Coronary heart disease;
LGG	cis	rs4727443	0.899	rs6954978	chr7:99582212	A/G	cg12813108	chr7:99719912	CNPY4	-0.46	-8.74	-0.38	4.43e-17	Interstitial lung disease;
LGG	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg21132104	chr15:45694354	SPATA5L1	0.71	10.46	0.44	4.08e-23	Homoarginine levels;
LGG	cis	rs240764	0.817	rs11155596	chr6:101152631	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-7.68	-0.34	9.26e-14	Neuroticism;
LGG	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg14835575	chr10:16859367	RSU1	0.79	14.53	0.56	1.13e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs10504073	0.647	rs62507252	chr8:50028795	C/G	cg00325661	chr8:49890786	NA	0.75	14.31	0.55	9.7e-39	Blood metabolite ratios;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.08	-0.52	1.66e-33	Alzheimer's disease;
LGG	cis	rs7666738	0.830	rs17484966	chr4:99014432	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg12486710	chr1:178512616	C1orf220	0.4	8.13	0.35	3.93e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9463078	0.547	rs4714822	chr6:44742290	T/C	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.79e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs79349575	0.811	rs80032154	chr17:47014992	C/A	cg16584676	chr17:46985605	UBE2Z	0.49	8.25	0.36	1.69e-15	Type 2 diabetes;
LGG	cis	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-12.44	-0.5	7.66e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg07395648	chr5:131743802	NA	0.52	11.51	0.47	4.05e-27	Blood metabolite levels;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg04772025	chr11:68637568	NA	0.74	13.11	0.52	1.29e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06527865	chr1:234746497	IRF2BP2	0.38	6.72	0.3	5.51e-11	Obesity-related traits;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9326248	0.768	rs4936366	chr11:117026885	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.78	0.34	4.88e-14	Blood protein levels;
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg18681998	chr4:17616180	MED28	0.84	18.72	0.66	1.24e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg12395012	chr8:11607386	GATA4	-0.38	-7.16	-0.32	3.2e-12	Mood instability;
LGG	cis	rs7924176	0.601	rs7093532	chr10:75938040	T/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.93	-0.31	1.41e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs9815354	0.857	rs12108064	chr3:42016217	C/T	cg03022575	chr3:42003672	ULK4	0.68	8.06	0.35	6.76e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7264396	0.635	rs2024854	chr20:34511189	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.26	0.32	1.65e-12	Total cholesterol levels;
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg01472538	chr16:58549086	SETD6	0.98	8.78	0.38	3.23e-17	Schizophrenia;
LGG	cis	rs67311347	1.000	rs73076046	chr3:40447724	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-25.95	-0.77	2.66e-92	Renal cell carcinoma;
LGG	cis	rs6424115	0.737	rs10917430	chr1:24170458	C/T	cg15997130	chr1:24165203	NA	-0.43	-10.36	-0.43	9.19e-23	Immature fraction of reticulocytes;
LGG	cis	rs9358372	0.521	rs9356756	chr6:20844151	C/T	cg13405222	chr6:20811065	CDKAL1	-0.36	-6.88	-0.3	1.93e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11264213	0.901	rs811114	chr1:36345758	G/A	cg27506609	chr1:36549197	TEKT2	0.65	7.73	0.34	6.87e-14	Schizophrenia;
LGG	cis	rs6547631	0.670	rs4832181	chr2:85916005	A/G	cg24620635	chr2:85921963	GNLY	0.42	7.78	0.34	4.77e-14	Blood protein levels;
LGG	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg16662043	chr16:48846231	NA	0.34	6.66	0.3	7.97e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.71e-11	Depression;
LGG	cis	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.87	-0.45	1.1e-24	Resting heart rate;
LGG	cis	rs17818399	0.547	rs12997164	chr2:46758746	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.65	-10.77	-0.45	2.8e-24	Height;
LGG	cis	rs6714710	0.603	rs34974566	chr2:98552299	C/G	cg26665480	chr2:98280029	ACTR1B	0.61	9.83	0.42	7.56e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg02002194	chr4:3960332	NA	-0.39	-7.37	-0.32	8.11e-13	Neuroticism;
LGG	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg07570687	chr10:102243282	WNT8B	0.41	6.68	0.3	6.86e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	8.73	0.38	4.68e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg05775895	chr3:12838266	CAND2	0.78	15.32	0.58	3.67e-43	QRS complex (12-leadsum);
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg22903471	chr2:27725779	GCKR	-0.57	-12.86	-0.51	1.4e-32	Menopause (age at onset);
LGG	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs9388451	0.513	rs1268069	chr6:126039994	A/C	cg05901451	chr6:126070800	HEY2	-0.66	-11.88	-0.48	1.36e-28	Brugada syndrome;
LGG	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg14416269	chr4:6271139	WFS1	0.52	9.43	0.4	1.96e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	-0.45	-7.45	-0.33	4.51e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs57994353	0.861	rs34936112	chr9:139327062	G/A	cg14169450	chr9:139327907	INPP5E	0.4	6.85	0.3	2.31e-11	Eosinophil counts;Cutaneous squamous cell carcinoma;
LGG	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg13010199	chr12:38710504	ALG10B	-0.7	-14.22	-0.55	2.46e-38	Heart rate;
LGG	cis	rs4900538	0.928	rs1190551	chr14:102911508	A/G	cg18135206	chr14:102964638	TECPR2	-0.82	-16.3	-0.6	1.6e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg02269571	chr22:50332266	NA	0.63	10.05	0.42	1.26e-21	Schizophrenia;
LGG	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg24585782	chr17:78113791	EIF4A3	-0.48	-8.05	-0.35	7.27e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	trans	rs73198271	0.960	rs73198286	chr8:8612022	C/T	cg16141378	chr3:129829833	LOC729375	0.38	6.89	0.3	1.85e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3733585	0.638	rs7377625	chr4:9953099	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.88e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs16973500	0.711	rs2878491	chr16:71981218	T/G	cg00732059	chr16:71740210	PHLPP2	-0.6	-9.84	-0.42	6.9e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg00800038	chr16:89945340	TCF25	-0.59	-7.88	-0.34	2.39e-14	Skin colour saturation;
LGG	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg17108064	chr15:78857060	CHRNA5	0.4	8.02	0.35	8.99e-15	Sudden cardiac arrest;
LGG	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	8.09e-12	Refractive error;
LGG	cis	rs7998202	0.667	rs282576	chr13:113358864	A/G	cg17218041	chr13:113365319	ATP11A	-0.44	-7.32	-0.32	1.07e-12	Glycated hemoglobin levels;
LGG	cis	rs7107174	0.688	rs2063725	chr11:78133452	T/G	cg02023728	chr11:77925099	USP35	0.43	7.7	0.34	8.18e-14	Testicular germ cell tumor;
LGG	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg10950524	chr7:2139216	MAD1L1	0.34	7.32	0.32	1.11e-12	Schizophrenia;
LGG	cis	rs67133203	0.904	rs34514224	chr12:51335969	T/G	cg14688905	chr12:51403056	SLC11A2	0.73	10.83	0.45	1.65e-24	Urinary tract infection frequency;
LGG	trans	rs10880689	1	rs10880689	chr12:37930102	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.15e-20	Resting heart rate;
LGG	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg16797656	chr11:68205561	LRP5	0.55	10.27	0.43	1.91e-22	Total body bone mineral density;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg05754148	chr16:3507555	NAT15	-0.48	-6.91	-0.31	1.61e-11	Beard thickness;
LGG	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg13010199	chr12:38710504	ALG10B	0.73	14.87	0.57	3.59e-41	Bladder cancer;
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.56	0.37	1.68e-16	Bipolar disorder;
LGG	cis	rs7336332	0.574	rs9512699	chr13:28029896	G/A	cg01674679	chr13:27998804	GTF3A	0.64	8.36	0.36	7.23e-16	Weight;
LGG	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg26384229	chr12:38710491	ALG10B	0.68	12.18	0.49	8.31e-30	Morning vs. evening chronotype;
LGG	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs4604732	0.642	rs6426252	chr1:247639887	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	8.33	0.36	9.2e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.37	-0.56	5.34e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs701145	0.585	rs1713810	chr3:153876826	C/T	cg17054900	chr3:154042577	DHX36	-0.71	-8.93	-0.38	9.83e-18	Coronary artery disease;
LGG	cis	rs1707322	0.721	rs11211149	chr1:46112218	T/C	cg03146154	chr1:46216737	IPP	0.56	10.79	0.45	2.32e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg13607699	chr17:42295918	UBTF	-0.64	-10.95	-0.45	5.69e-25	Total body bone mineral density;
LGG	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22455342	chr2:225449267	CUL3	0.86	15.2	0.58	1.29e-42	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04853151	chr1:54519244	C1orf83;TMEM59	0.42	6.81	0.3	3.04e-11	Cognitive performance;
LGG	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg26597838	chr10:835615	NA	0.95	13.07	0.52	1.94e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs10936602	0.520	rs9290375	chr3:169566090	A/G	cg08193579	chr3:169529701	LRRC34	0.39	7.8	0.34	4.02e-14	Renal cell carcinoma;
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg06221963	chr1:154839813	KCNN3	-0.51	-10.46	-0.44	3.94e-23	Prostate cancer;
LGG	cis	rs7659604	0.502	rs4075066	chr4:122684283	T/C	cg19748678	chr4:122722346	EXOSC9	-0.42	-7.51	-0.33	3.1e-13	Type 2 diabetes;
LGG	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	1.000	rs11601205	chr11:34768479	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.42	-0.33	5.69e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg14673194	chr17:80132900	CCDC57	-0.45	-8.27	-0.36	1.48e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg19862616	chr7:65841803	NCRNA00174	0.74	7.68	0.34	9.68e-14	Mononucleosis;
LGG	trans	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs459571	0.959	rs460888	chr9:136913123	C/G	cg13789015	chr9:136890014	NCRNA00094	0.58	10.93	0.45	6.55e-25	Platelet distribution width;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26188571	chr5:179050811	HNRNPH1	0.44	7.13	0.31	3.98e-12	Cognitive performance;
LGG	cis	rs9318086	0.648	rs78881146	chr13:24468704	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.33	0.4	4.52e-19	Myopia (pathological);
LGG	cis	rs1670533	1.000	rs7673898	chr4:1056569	C/A	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs4919694	1.000	rs12258551	chr10:104767892	C/G	cg04362960	chr10:104952993	NT5C2	1.06	14.74	0.57	1.33e-40	Arsenic metabolism;
LGG	cis	rs9951602	0.512	rs7240758	chr18:76650677	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.23	-0.36	1.94e-15	Obesity-related traits;
LGG	cis	rs2742417	1.000	rs1877934	chr3:45753295	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs8077889	0.719	rs4793033	chr17:41879627	C/T	cg26893861	chr17:41843967	DUSP3	1.02	22.45	0.72	4.67e-76	Triglycerides;
LGG	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7296418	0.738	rs1568428	chr12:123738876	A/G	cg05973401	chr12:123451056	ABCB9	-0.42	-7.24	-0.32	1.88e-12	Platelet count;
LGG	cis	rs4363385	0.747	rs3964619	chr1:152972811	A/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.35	-0.4	3.81e-19	Inflammatory skin disease;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg08888203	chr3:10149979	C3orf24	0.55	7.91	0.35	1.89e-14	Alzheimer's disease;
LGG	cis	rs4731207	0.596	rs6967887	chr7:124609490	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs397969	0.596	rs12453720	chr17:19895202	A/G	cg13482628	chr17:19912719	NA	-0.47	-7.27	-0.32	1.53e-12	Platelet count;
LGG	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg24130564	chr14:104152367	KLC1	-0.7	-15.6	-0.59	2.21e-44	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs7246760	0.867	rs61580479	chr19:9782940	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg05639522	chr1:247681581	NA	0.63	7.23	0.32	1.96e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.74	0.34	6.37e-14	Testicular germ cell tumor;
LGG	cis	rs208520	1.000	rs208529	chr6:66957549	T/C	cg07460842	chr6:66804631	NA	-0.89	-14.62	-0.56	4.71e-40	Exhaled nitric oxide output;
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.18	-0.43	4.09e-22	Intelligence (multi-trait analysis);
LGG	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs853679	0.517	rs9393891	chr6:28079160	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs9875589	0.509	rs7653289	chr3:13986333	C/T	cg19554555	chr3:13937349	NA	-0.54	-9.73	-0.41	1.73e-20	Ovarian reserve;
LGG	cis	rs858239	0.601	rs73272048	chr7:23152653	C/G	cg23682824	chr7:23144976	KLHL7	0.44	7.42	0.33	5.51e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9894429	0.789	rs7213849	chr17:79567610	C/T	cg18240062	chr17:79603768	NPLOC4	-0.81	-15.39	-0.58	1.79e-43	Eye color traits;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg11245990	chr11:68621969	NA	0.39	8.37	0.36	7.13e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg26850624	chr5:429559	AHRR	-0.38	-8.36	-0.36	7.32e-16	Cystic fibrosis severity;
LGG	cis	rs4788815	0.532	rs59709630	chr16:71978608	G/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.82e-23	Metabolite levels;
LGG	cis	rs2115536	1.000	rs11637477	chr15:80193295	C/T	cg11839771	chr15:80205821	ST20	-0.34	-7.22	-0.32	2.11e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg02487422	chr3:49467188	NICN1	-0.39	-6.86	-0.3	2.16e-11	Menarche (age at onset);
LGG	cis	rs10046574	0.516	rs7802453	chr7:135200638	T/C	cg27474649	chr7:135195673	CNOT4	0.75	9.02	0.39	5.07e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg25809561	chr17:30822961	MYO1D	0.41	9.89	0.42	4.8e-21	Schizophrenia;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg08621203	chr6:150244597	RAET1G	0.46	8.08	0.35	5.64e-15	Lung cancer;
LGG	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.67	0.34	9.96e-14	Neuroticism;
LGG	cis	rs7172689	0.908	rs11637363	chr15:81567973	A/C	cg11808699	chr15:81528661	IL16	-0.44	-9.24	-0.39	8.84e-19	Inattentive symptoms;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-13.56	-0.53	1.66e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg15704280	chr7:45808275	SEPT13	0.84	8.83	0.38	2.18e-17	Myopia (pathological);
LGG	cis	rs6121246	0.559	rs6058462	chr20:30367674	C/T	cg13852791	chr20:30311386	BCL2L1	0.93	17.83	0.64	1.57e-54	Mean corpuscular hemoglobin;
LGG	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg00850481	chr1:228891306	NA	-0.49	-8.37	-0.36	6.7e-16	Chronic lymphocytic leukemia;
LGG	cis	rs9472414	0.510	rs609643	chr6:44705303	A/G	cg20913747	chr6:44695427	NA	-0.46	-7.61	-0.33	1.59e-13	Height;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.85	-0.38	1.93e-17	Schizophrenia;
LGG	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.3e-11	Aortic root size;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs9815354	0.680	rs79211428	chr3:41921810	C/T	cg03022575	chr3:42003672	ULK4	0.79	9.17	0.39	1.59e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg11038491	chr20:34638489	LOC647979	-0.6	-7.67	-0.34	9.98e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2251260	0.735	rs810087	chr14:62021879	A/G	cg23386212	chr14:62041363	NA	0.62	8.98	0.39	7.04e-18	Yeast infection;
LGG	cis	rs12477438	0.520	rs6717723	chr2:99756930	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs965469	0.532	rs6115865	chr20:3359303	A/G	cg25506879	chr20:3388711	C20orf194	0.43	7.21	0.32	2.26e-12	IFN-related cytopenia;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.52	-0.33	2.94e-13	Menopause (age at onset);
LGG	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.97	-0.42	2.42e-21	Rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs7489270	chr12:34432062	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.51	0.53	2.75e-35	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07659893	chr17:61819838	STRADA	0.48	8.12	0.35	4.19e-15	Prudent dietary pattern;
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.89	-0.3	1.84e-11	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.16e-17	Menopause (age at onset);
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Electroencephalogram traits;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.13	-0.43	6.5e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.92	0.35	1.84e-14	Iron status biomarkers;
LGG	cis	rs2077654	0.556	rs4756888	chr11:17442658	T/C	cg25308976	chr11:17434268	ABCC8	0.58	7.54	0.33	2.43e-13	Gout;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg00495681	chr13:53174319	NA	0.54	9.13	0.39	2.17e-18	Lewy body disease;
LGG	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg04398451	chr17:18023971	MYO15A	-0.73	-15.19	-0.58	1.48e-42	Total body bone mineral density;
LGG	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg26384229	chr12:38710491	ALG10B	0.96	21.22	0.7	2.62e-70	Morning vs. evening chronotype;
LGG	cis	rs300703	0.542	rs443419	chr2:189800	C/T	cg24565620	chr2:194026	NA	0.66	10.41	0.44	6.23e-23	Blood protein levels;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.45	0.33	4.5e-13	Lung cancer;
LGG	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg14088196	chr11:70211408	PPFIA1	0.96	13.05	0.52	2.33e-33	Coronary artery disease;
LGG	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24110177	chr3:50126178	RBM5	-0.55	-10.01	-0.42	1.78e-21	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.21	-0.43	3.17e-22	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg06558623	chr16:89946397	TCF25	1.12	12.22	0.49	6.01e-30	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.21	-0.43	3.23e-22	Lung cancer;
LGG	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.52	8.75	0.38	3.89e-17	Response to antipsychotic treatment;
LGG	trans	rs1728785	1.000	rs1645928	chr16:68590610	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.82	0.45	1.83e-24	Ulcerative colitis;
LGG	cis	rs2712184	0.652	rs13000985	chr2:217644361	T/G	cg05032264	chr2:217675019	NA	0.42	9.08	0.39	3.24e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs897080	0.515	rs1085450	chr2:44650698	A/T	cg00619915	chr2:44497795	NA	-0.49	-6.82	-0.3	2.78e-11	Height;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs763121	0.853	rs1043441	chr22:39130964	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	17.73	0.64	4.5e-54	Menopause (age at onset);
LGG	cis	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.5	-0.53	3.01e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.82	-0.3	2.9e-11	Lung cancer;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.27	0.36	1.42e-15	Lung cancer;
LGG	cis	rs10256972	1.000	rs10256972	chr7:1039003	G/T	cg16145915	chr7:1198662	ZFAND2A	0.47	8.02	0.35	8.44e-15	Longevity;Endometriosis;
LGG	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg13877915	chr19:58951672	ZNF132	1.01	26.86	0.78	1.64e-96	Uric acid clearance;
LGG	cis	rs2797369	0.656	rs705619	chr6:101363967	A/G	cg27451362	chr6:101846650	GRIK2	0.7	9.7	0.41	2.2e-20	Renal function-related traits (eGRFcrea);
LGG	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4919087	0.748	rs701813	chr10:98975632	C/T	cg25902810	chr10:99078978	FRAT1	-0.42	-7.38	-0.32	7.32e-13	Monocyte count;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.53	-0.33	2.64e-13	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs313802	chr7:65516373	A/G	cg12463550	chr7:65579703	CRCP	0.75	7.94	0.35	1.53e-14	Diabetic kidney disease;
LGG	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-15.79	-0.59	3.03e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1003719	0.788	rs4817845	chr21:38447132	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg26174226	chr8:58114915	NA	0.52	7.29	0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.564	rs1011721	chr7:124605159	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg00830817	chr11:109293614	C11orf87	0.42	6.88	0.3	1.9e-11	Schizophrenia;
LGG	cis	rs7264396	0.635	rs7263302	chr20:34545858	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.46e-12	Total cholesterol levels;
LGG	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg27490568	chr2:178487706	NA	0.52	10.07	0.42	1.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.52	-0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs78487399	0.808	rs6757251	chr2:43734847	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.75	-0.3	4.5e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs7166081	1.000	rs16953610	chr15:67501592	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12049351	0.665	rs7545592	chr1:229592660	A/G	cg13547644	chr1:229569608	ACTA1	0.35	7.6	0.33	1.66e-13	Circulating myeloperoxidase levels (plasma);
LGG	trans	rs961253	0.501	rs6054145	chr20:6335730	T/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.96	0.31	1.17e-11	Colorectal cancer;
LGG	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg13264159	chr8:625131	ERICH1	-1.05	-12.4	-0.5	1.1e-30	IgG glycosylation;
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg27189623	chr16:705930	WDR90	0.4	7.63	0.33	1.39e-13	Height;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg07930552	chr6:133119739	C6orf192	1.12	9.71	0.41	2.15e-20	Type 2 diabetes nephropathy;
LGG	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg20848291	chr7:100343083	ZAN	-0.6	-8.2	-0.36	2.32e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg11050988	chr7:1952600	MAD1L1	0.34	8.27	0.36	1.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2303319	1.000	rs62188133	chr2:162253435	T/C	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	trans	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-13.07	-0.52	1.84e-33	Obesity-related traits;
LGG	cis	rs4604732	0.631	rs10925044	chr1:247627071	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.58	-9.82	-0.42	8.38e-21	Menarche (age at onset);
LGG	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	9.06	0.39	3.59e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg24634471	chr8:143751801	JRK	0.49	7.43	0.33	5.12e-13	Schizophrenia;
LGG	trans	rs11039798	1.000	rs7942284	chr11:48520424	A/G	cg15704280	chr7:45808275	SEPT13	-0.74	-8.59	-0.37	1.33e-16	Axial length;
LGG	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg13010199	chr12:38710504	ALG10B	0.58	11.11	0.46	1.42e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.16	0.35	3.15e-15	Obesity-related traits;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg16606324	chr3:10149918	C3orf24	0.54	7.01	0.31	8.34e-12	Alzheimer's disease;
LGG	cis	rs3762637	1.000	rs9968189	chr3:122175136	G/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg21830797	chr15:40226279	EIF2AK4	0.6	8.35	0.36	8e-16	Response to haloperidol in psychosis;
LGG	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg16127683	chr15:40268777	EIF2AK4	0.92	9.88	0.42	5.01e-21	Corneal curvature;
LGG	cis	rs2287838	0.740	rs12974239	chr19:10004340	C/T	cg00846166	chr19:10022875	OLFM2	0.34	7.63	0.33	1.35e-13	Sleep duration;
LGG	cis	rs2070488	1.000	rs1002675	chr3:38445226	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	17.12	0.62	2.93e-51	Electrocardiographic conduction measures;
LGG	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2692947	0.770	rs72492163	chr2:96417816	G/A	cg22654517	chr2:96458247	NA	0.38	7.51	0.33	3.02e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6554196	0.644	rs7655709	chr4:55499386	C/G	cg18836493	chr4:55524333	KIT	-0.41	-7.71	-0.34	7.95e-14	Monocyte count;
LGG	cis	rs6565180	0.962	rs6565182	chr16:30374381	C/T	cg17640201	chr16:30407289	ZNF48	-0.86	-16.57	-0.61	8.98e-49	Tonsillectomy;
LGG	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg12463550	chr7:65579703	CRCP	-0.47	-7.8	-0.34	4.04e-14	Aortic root size;
LGG	cis	rs4595586	0.545	rs1319791	chr12:39372486	G/T	cg13010199	chr12:38710504	ALG10B	0.46	8.09	0.35	5.45e-15	Morning vs. evening chronotype;
LGG	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.93	-0.31	1.4e-11	Type 2 diabetes;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg03804240	chr11:118481350	PHLDB1	0.41	8.5	0.37	2.62e-16	Cholesterol, total;
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-20.42	-0.69	1.41e-66	Vitiligo;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08280861	chr8:58055591	NA	0.54	6.91	0.31	1.63e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.48e-13	Obesity-related traits;
LGG	cis	rs4660214	0.666	rs12025847	chr1:39766649	G/A	cg18385671	chr1:39797026	MACF1	-0.46	-9.57	-0.41	6.39e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-6.94	-0.31	1.35e-11	Common traits (Other);
LGG	cis	rs17767392	0.918	rs35822724	chr14:71776934	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.08	-0.39	3.23e-18	Mitral valve prolapse;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg01879757	chr17:41196368	BRCA1	-0.4	-8.16	-0.35	3.13e-15	Menopause (age at onset);
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg27471124	chr11:109292789	C11orf87	-0.83	-18.26	-0.65	1.76e-56	Schizophrenia;
LGG	cis	rs9790314	0.846	rs7636941	chr3:160993928	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.663	rs9860360	chr3:160747963	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.38	-0.4	2.93e-19	Morning vs. evening chronotype;
LGG	cis	rs4919694	1.000	rs4917986	chr10:104630181	T/C	cg04362960	chr10:104952993	NT5C2	1.11	15.35	0.58	2.81e-43	Arsenic metabolism;
LGG	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10424846	chr17:33894970	NA	-0.42	-6.68	-0.3	6.98e-11	Pancreatic cancer;
LGG	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg08824895	chr13:115047677	UPF3A	0.43	7.29	0.32	1.32e-12	Schizophrenia;
LGG	cis	rs7107174	0.892	rs1017907	chr11:77959124	A/T	cg02023728	chr11:77925099	USP35	0.43	7.65	0.33	1.19e-13	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	trans	rs3780486	0.522	rs7029897	chr9:33124042	T/C	cg04842962	chr6:43655489	MRPS18A	0.82	15.66	0.59	1.19e-44	IgG glycosylation;
LGG	trans	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg19894588	chr14:64061835	NA	0.43	6.88	0.3	1.95e-11	Glioblastoma;Glioma;
LGG	cis	rs6503525	0.701	rs28618095	chr17:38109075	T/C	cg17467752	chr17:38218738	THRA	0.45	6.94	0.31	1.35e-11	Asthma;
LGG	cis	rs9397585	0.676	rs12209140	chr6:153399195	G/A	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs11777747	1.000	rs11777747	chr8:142466821	C/T	cg15142913	chr8:142440250	PTP4A3	-0.46	-6.95	-0.31	1.28e-11	Coronary artery calcification;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27555529	chr19:13617518	CACNA1A	0.46	7.28	0.32	1.45e-12	Gut microbiome composition (summer);
LGG	cis	rs6500395	1.000	rs9930365	chr16:48682154	A/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg17691542	chr6:26056736	HIST1H1C	0.76	12.88	0.51	1.21e-32	Height;
LGG	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg18252515	chr7:66147081	NA	1.43	20.48	0.69	7.66e-67	Diabetic kidney disease;
LGG	cis	rs8064024	0.564	rs7214	chr16:4932560	T/G	cg04440724	chr16:4920505	UBN1	-0.55	-11.48	-0.47	5.11e-27	Cancer;
LGG	cis	rs620875	1.000	rs646236	chr11:126851452	A/G	cg06504925	chr11:126872760	NA	0.51	7.38	0.32	7.42e-13	Response to antipsychotic treatment;
LGG	cis	rs12497850	0.765	rs12487580	chr3:49182932	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.48	-7.21	-0.32	2.29e-12	Parkinson's disease;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg18379455	chr17:41446167	NA	-0.31	-7.15	-0.32	3.38e-12	Menopause (age at onset);
LGG	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.81e-14	Common traits (Other);
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg09845145	chr15:78292470	TBC1D2B	0.57	10.43	0.44	5.31e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs16957091	1.000	rs3742987	chr15:43016547	T/C	cg07484255	chr15:43025164	CDAN1	-0.5	-7.25	-0.32	1.76e-12	MGMT methylation in smokers;
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.43e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg20573242	chr4:122745356	CCNA2	-0.42	-7.31	-0.32	1.14e-12	Type 2 diabetes;
LGG	trans	rs3942852	0.868	rs7118232	chr11:48106274	T/C	cg15704280	chr7:45808275	SEPT13	-0.65	-8.15	-0.35	3.31e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7737355	0.898	rs1016068	chr5:131100246	T/C	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Life satisfaction;
LGG	cis	rs4006360	0.547	rs9901868	chr17:39232963	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-10.06	-0.42	1.18e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs79349575	0.777	rs28517720	chr17:46976756	C/G	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.88e-11	Type 2 diabetes;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg02018176	chr4:1364513	KIAA1530	0.44	10.58	0.44	1.44e-23	Longevity;
LGG	cis	rs7202877	0.706	rs4887813	chr16:75312494	A/G	cg03315344	chr16:75512273	CHST6	0.5	6.7	0.3	6.08e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.66	0.34	1.1e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg24687543	chr11:63912206	MACROD1	0.61	8.6	0.37	1.2e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg05868516	chr6:26286170	HIST1H4H	0.45	7.67	0.34	9.93e-14	Educational attainment;
LGG	trans	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg26384229	chr12:38710491	ALG10B	0.73	14.58	0.56	6.62e-40	Morning vs. evening chronotype;
LGG	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg00976097	chr5:421733	AHRR	-0.4	-6.66	-0.3	7.7e-11	Cystic fibrosis severity;
LGG	cis	rs933688	1.000	rs10058025	chr5:90689052	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.83	-0.38	2.16e-17	Life satisfaction;
LGG	trans	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs62025270	0.547	rs1026722	chr15:86119399	C/T	cg25843651	chr15:86329602	KLHL25	-0.55	-9.03	-0.39	4.75e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs6977660	1.000	rs10249989	chr7:19822296	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	cis	rs3818285	0.504	rs1973972	chr10:111651133	A/T	cg00817464	chr10:111662876	XPNPEP1	0.55	10.19	0.43	3.94e-22	Superior crus of antihelix expression;
LGG	cis	rs988958	0.565	rs34818443	chr2:42233809	C/T	cg27252766	chr2:42229092	NA	0.52	7.34	0.32	9.46e-13	Hypospadias;
LGG	cis	rs4363385	0.719	rs6664411	chr1:152932857	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-7.56	-0.33	2.14e-13	Inflammatory skin disease;
LGG	cis	rs2073300	0.609	rs77908916	chr20:23405626	C/G	cg12062639	chr20:23401060	NAPB	0.92	8.77	0.38	3.34e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs924043	0.636	rs12525300	chr6:170395759	C/T	cg00389036	chr6:170409598	NA	0.54	6.89	0.31	1.81e-11	Type 1 diabetes;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14893161	chr1:205819251	PM20D1	0.88	20.41	0.69	1.63e-66	Menarche (age at onset);
LGG	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.83	-0.42	7.56e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.74	-0.59	5.02e-45	Height;
LGG	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg04978709	chr7:75101039	POM121C	0.41	8.32	0.36	9.74e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.64	-0.48	1.18e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12210905	0.688	rs12212632	chr6:27472416	T/C	cg10122326	chr6:28072925	NA	0.93	7.1	0.31	4.69e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04530015	chr2:215796436	ABCA12	0.45	8.27	0.36	1.42e-15	Neuroblastoma;
LGG	cis	rs2470578	0.766	rs283911	chr3:17331704	C/T	cg20981856	chr3:17787350	NA	0.36	6.87	0.3	2.13e-11	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04730665	chr2:236403704	AGAP1	0.38	6.91	0.31	1.66e-11	Obesity-related traits;
LGG	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg01631408	chr1:248437212	OR2T33	-0.39	-7.23	-0.32	2.04e-12	Common traits (Other);
LGG	cis	rs3106136	0.967	rs4693377	chr4:95157256	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.12	-0.35	4.32e-15	Capecitabine sensitivity;
LGG	cis	rs4764487	0.735	rs1990384	chr12:6342921	G/T	cg08284733	chr12:6341482	CD9	0.36	9.74	0.41	1.62e-20	Mean platelet volume;
LGG	cis	rs12410462	0.551	rs6693348	chr1:227719467	C/G	cg21459583	chr1:227974177	NA	-0.36	-6.75	-0.3	4.57e-11	Major depressive disorder;
LGG	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg02023728	chr11:77925099	USP35	0.44	7.73	0.34	6.66e-14	Testicular germ cell tumor;
LGG	cis	rs6735179	0.641	rs10164792	chr2:1753375	G/A	cg08534653	chr2:1747700	PXDN	0.46	6.93	0.31	1.44e-11	Response to antipsychotic treatment;
LGG	cis	rs2133450	0.679	rs1396405	chr3:7365432	A/G	cg19930620	chr3:7340148	GRM7	-0.38	-8.32	-0.36	9.770000000000001e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg07549998	chr6:150325970	RAET1K	-0.37	-6.96	-0.31	1.14e-11	Alopecia areata;
LGG	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg25427524	chr10:38739819	LOC399744	0.7	14.25	0.55	1.91e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.33e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.32	0.47	2.22e-26	Bipolar disorder;
LGG	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg18357526	chr6:26021779	HIST1H4A	0.59	10.35	0.43	1.01e-22	Blood metabolite levels;
LGG	cis	rs12477438	0.520	rs7558062	chr2:99992784	A/G	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	trans	rs1493916	0.967	rs1389532	chr18:31392323	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-13.25	-0.52	3.43e-34	Life satisfaction;
LGG	cis	rs342442	0.780	rs6840470	chr4:88082526	T/C	cg21988461	chr4:88008667	AFF1	0.26	6.84	0.3	2.46e-11	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.97	-0.38	7.6e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg06280965	chr2:217410850	NA	-0.43	-6.99	-0.31	9.84e-12	Apolipoprotein A-IV levels;
LGG	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg23057051	chr16:89984268	MC1R	-0.37	-6.89	-0.3	1.86e-11	Hemoglobin concentration;
LGG	cis	rs75920871	0.702	rs11216162	chr11:116728277	A/G	cg20608306	chr11:116969690	SIK3	0.31	7.31	0.32	1.18e-12	Subjective well-being;
LGG	cis	rs459571	0.916	rs109536	chr9:136889987	G/C	cg13789015	chr9:136890014	NCRNA00094	0.58	10.82	0.45	1.78e-24	Platelet distribution width;
LGG	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.73	-0.41	1.81e-20	Alcohol dependence;
LGG	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg12310025	chr6:25882481	NA	0.41	6.76	0.3	4.09e-11	Iron status biomarkers;
LGG	cis	rs11874712	0.965	rs11661945	chr18:43672194	T/A	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.77	-0.48	3.7e-28	Migraine - clinic-based;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg19168338	chr16:4465731	CORO7	-0.73	-13.49	-0.53	3.36e-35	Schizophrenia;
LGG	cis	rs11734570	0.581	rs55958238	chr4:38604331	A/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	8.46	0.37	3.56e-16	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs709400	0.663	rs11623869	chr14:103883633	G/T	cg26031613	chr14:104095156	KLC1	0.77	13.39	0.53	8.58e-35	Body mass index;
LGG	cis	rs17125944	0.686	rs7143400	chr14:53324891	A/C	cg00686598	chr14:53173677	PSMC6	-0.76	-8.11	-0.35	4.66e-15	Alzheimer's disease (late onset);
LGG	cis	rs4750440	0.706	rs61837399	chr10:14016047	G/A	cg00551146	chr10:14014579	FRMD4A	0.28	6.92	0.31	1.56e-11	Adiponectin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07990511	chr6:36853609	C6orf89	0.42	6.89	0.3	1.81e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg22907277	chr7:1156413	C7orf50	0.55	7.42	0.33	5.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg03788504	chr6:150331562	NA	-0.53	-11.65	-0.48	1.12e-27	Alopecia areata;
LGG	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-11.29	-0.46	2.77e-26	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg12310025	chr6:25882481	NA	0.53	10.06	0.42	1.14e-21	Blood metabolite levels;
LGG	cis	rs2549003	0.934	rs2549006	chr5:131827065	A/G	cg21138405	chr5:131827807	IRF1	-0.39	-10.28	-0.43	1.89e-22	Asthma (sex interaction);
LGG	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg24623649	chr8:11872141	NA	0.31	7.09	0.31	4.94e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.1	-0.35	5.06e-15	Calcium levels;
LGG	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg00784671	chr22:46762841	CELSR1	-0.56	-7.31	-0.32	1.18e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9467773	1.000	rs10946835	chr6:26533757	C/T	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg03433033	chr1:76189801	ACADM	0.82	14.16	0.55	4.63e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg09699651	chr6:150184138	LRP11	-0.5	-8.93	-0.38	1.02e-17	Lung cancer;
LGG	cis	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg04455712	chr21:45112962	RRP1B	0.53	9.83	0.42	7.88e-21	Mean corpuscular volume;
LGG	cis	rs11711311	1.000	rs1073040	chr3:113522123	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	13.16	0.52	7.94e-34	IgG glycosylation;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23456826	chr14:24912049	SDR39U1	-0.47	-6.77	-0.3	3.83e-11	Systemic lupus erythematosus;
LGG	cis	rs868036	1.000	rs1026731	chr15:68095018	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.47	-0.4	1.48e-19	Neuroticism;
LGG	trans	rs8002861	0.905	rs12873099	chr13:44396247	G/A	cg12856521	chr11:46389249	DGKZ	-0.42	-6.97	-0.31	1.09e-11	Leprosy;
LGG	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.61e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg26384229	chr12:38710491	ALG10B	0.99	23.25	0.73	8.9e-80	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.19	0.32	2.62e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4262150	0.883	rs72799201	chr5:152191995	C/T	cg12297329	chr5:152029980	NA	-0.68	-12.82	-0.51	2.03e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg24250549	chr1:154909240	PMVK	-0.72	-14.23	-0.55	2.21e-38	Prostate cancer;
LGG	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg27490568	chr2:178487706	NA	0.45	8.72	0.38	5.11e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg01420254	chr6:26195488	NA	0.83	10.71	0.45	4.74e-24	Gout;Renal underexcretion gout;
LGG	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs826838	0.616	rs7966266	chr12:38626138	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.28e-20	Heart rate;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6918586	1.000	rs198811	chr6:26128446	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	8.12	0.35	4.31e-15	Schizophrenia;
LGG	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.74	0.51	4.35e-32	Alzheimer's disease;
LGG	cis	rs4319547	0.910	rs6416298	chr12:123002143	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-9.68	-0.41	2.63e-20	Body mass index;
LGG	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.86	-0.38	1.67e-17	Morning vs. evening chronotype;
LGG	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg23029597	chr12:123009494	RSRC2	-0.94	-17.2	-0.62	1.24e-51	Body mass index;
LGG	cis	rs4774899	0.932	rs11857507	chr15:57532479	T/C	cg08128148	chr15:57256372	TCF12	-0.32	-7.34	-0.32	9.55e-13	Urinary tract infection frequency;
LGG	cis	rs9644630	1.000	rs9644631	chr8:19370830	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.57	16.32	0.6	1.3e-47	Oropharynx cancer;
LGG	cis	rs3857067	0.806	rs6817795	chr4:95127716	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.44	-8.18	-0.36	2.8e-15	QT interval;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.74	-0.3	4.6e-11	Longevity;Endometriosis;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg05925327	chr15:68127851	NA	0.34	7.12	0.31	4.11e-12	Obesity;
LGG	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg20818283	chr2:191399100	TMEM194B	0.3	7.15	0.32	3.43e-12	Pulse pressure;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg24642844	chr7:1081250	C7orf50	-0.83	-13.93	-0.54	4.19e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6540556	0.769	rs627670	chr1:209929299	G/A	cg23920097	chr1:209922102	NA	0.5	8.89	0.38	1.35e-17	Red blood cell count;
LGG	cis	rs965513	0.965	rs10759944	chr9:100556972	A/G	cg13688889	chr9:100608707	NA	-0.54	-9.85	-0.42	6.79e-21	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg05973401	chr12:123451056	ABCB9	0.45	7.64	0.33	1.23e-13	Platelet count;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.92	-0.51	8.1e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg23649088	chr2:200775458	C2orf69	-0.62	-8.36	-0.36	7.23e-16	Schizophrenia;
LGG	cis	rs10089	0.953	rs1985268	chr5:127375931	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.44	0.47	7.49e-27	Ileal carcinoids;
LGG	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg16586182	chr3:47516702	SCAP	-0.77	-15.5	-0.58	5.86e-44	Colorectal cancer;
LGG	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.6	9.04	0.39	4.14e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7084402	0.905	rs1896244	chr10:60276182	A/G	cg09696939	chr10:60272079	BICC1	0.36	7.05	0.31	6.63e-12	Refractive error;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.88e-12	Tonsillectomy;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10035607	chr16:30366449	CD2BP2	0.43	7.31	0.32	1.18e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg03235661	chr20:60525775	NA	-0.32	-7.43	-0.33	5.32e-13	Obesity-related traits;
LGG	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.35	-0.36	8.15e-16	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19568834	chr20:34252926	CPNE1;RBM12	0.38	6.68	0.3	6.81e-11	Bilirubin levels;
LGG	cis	rs12949688	0.870	rs9906591	chr17:55816832	T/C	cg12229367	chr17:55822335	NA	0.45	8.63	0.37	1e-16	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13554071	chr9:131710473	NUP188;DOLK	0.43	6.81	0.3	3.1e-11	Gut microbiome composition (summer);
LGG	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg20387954	chr3:183756860	HTR3D	0.57	10.77	0.45	2.83e-24	Anterior chamber depth;
LGG	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.4	-0.33	6.52e-13	Fear of minor pain;
LGG	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.06	-0.49	2.48e-29	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.94	0.45	6e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6429082	0.818	rs291340	chr1:235674379	C/T	cg26050004	chr1:235667680	B3GALNT2	0.62	10.26	0.43	2.19e-22	Adiposity;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.45	-0.33	4.74e-13	Menopause (age at onset);
LGG	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg02733842	chr7:1102375	C7orf50	0.63	9.56	0.41	7e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9849248	0.627	rs7431968	chr3:88202045	G/A	cg14530983	chr3:88190749	ZNF654	-0.58	-7.91	-0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.61	0.33	1.54e-13	Homoarginine levels;
LGG	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg14882966	chr2:3699353	NA	0.89	9.23	0.39	9.46e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg02297831	chr4:17616191	MED28	0.43	7.69	0.34	9.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg12292205	chr6:26970375	C6orf41	-0.75	-15.01	-0.57	8.45e-42	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4851254	1.000	rs4851254	chr2:100762937	C/G	cg17356467	chr2:100759845	AFF3	0.41	7.08	0.31	5.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3617	0.625	rs7620690	chr3:52891707	A/G	cg11645453	chr3:52864694	ITIH4	-0.45	-7.52	-0.33	2.87e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6582630	0.513	rs1596446	chr12:38282160	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-13.38	-0.53	9.1e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs11874712	1.000	rs9962458	chr18:43678625	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.64	-0.48	1.25e-27	Migraine - clinic-based;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg24846343	chr22:24311635	DDTL	0.56	10.84	0.45	1.43e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.33	-0.36	9.21e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs9379945	1	rs9379945	chr6:26907831	T/C	cg01620082	chr3:125678407	NA	-0.61	-7.3	-0.32	1.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9796	0.516	rs28473405	chr15:41293170	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.61	-0.44	1.06e-23	Menopause (age at onset);
LGG	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs7216064	1.000	rs8082512	chr17:65837059	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs6011368	0.642	rs6062362	chr20:62911229	A/G	cg13869341	chr1:15865	WASH5P	0.57	10.19	0.43	3.78e-22	Clozapine-induced cytotoxicity;
LGG	cis	rs2075371	0.863	rs1421479	chr7:133949345	T/G	cg20476274	chr7:133979776	SLC35B4	0.73	13.83	0.54	1.16e-36	Mean platelet volume;
LGG	cis	rs4950322	0.570	rs17160051	chr1:146727388	G/T	cg22381352	chr1:146742008	CHD1L	-0.49	-8.07	-0.35	5.95e-15	Protein quantitative trait loci;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.48	8.36	0.36	7.38e-16	Longevity;
LGG	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg13073564	chr4:8508604	NA	-0.52	-10.62	-0.44	1.01e-23	Response to antineoplastic agents;
LGG	cis	rs6918586	0.658	rs198821	chr6:26123629	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.52	-0.4	9.33e-20	Schizophrenia;
LGG	cis	rs1003719	0.737	rs9974374	chr21:38479885	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.82	16.63	0.61	4.81e-49	Eye color traits;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.72	0.3	5.48e-11	Schizophrenia;
LGG	cis	rs9522267	0.737	rs12429582	chr13:112226657	A/G	cg10483660	chr13:112241077	NA	-0.38	-8.03	-0.35	7.95e-15	Hepatitis;
LGG	cis	rs7647973	1.000	rs13096474	chr3:49443081	C/T	cg07636037	chr3:49044803	WDR6	-0.75	-13.36	-0.53	1.13e-34	Menarche (age at onset);
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg05484376	chr2:27715224	FNDC4	0.47	10.18	0.43	4.08e-22	Total body bone mineral density;
LGG	cis	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.54	-0.63	3.54e-53	Breast cancer;
LGG	cis	rs701145	0.585	rs1727880	chr3:153835972	G/A	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg03929089	chr4:120376271	NA	-0.97	-20.45	-0.69	1.09e-66	Coronary artery disease;
LGG	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	2.94e-31	Motion sickness;
LGG	cis	rs11203032	1.000	rs11203030	chr10:90964286	A/G	cg16672925	chr10:90967113	CH25H	0.83	11.76	0.48	4.12e-28	Heart failure;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25072359	chr17:41440525	NA	0.53	9.88	0.42	5.25e-21	Menopause (age at onset);
LGG	cis	rs12618769	0.597	rs3769719	chr2:99124404	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.95	-0.42	2.99e-21	Bipolar disorder;
LGG	cis	rs7113850	0.541	rs7101719	chr11:24234947	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	10.5	0.44	2.89e-23	Bone fracture in osteoporosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02983885	chr19:42772892	NA	0.42	6.99	0.31	9.88e-12	Gut microbiome composition (summer);
LGG	cis	rs9522267	0.737	rs7330902	chr13:112227599	C/T	cg10483660	chr13:112241077	NA	-0.38	-8.09	-0.35	5.45e-15	Hepatitis;
LGG	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.18	-0.39	1.43e-18	Neuroticism;
LGG	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg02002194	chr4:3960332	NA	0.42	7.77	0.34	5.03e-14	Neuroticism;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08045932	chr20:61659980	NA	0.6	13.1	0.52	1.39e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg16230307	chr14:35515116	FAM177A1	0.39	6.82	0.3	2.94e-11	Psoriasis;
LGG	cis	rs9435341	0.896	rs1730850	chr1:107597988	C/T	cg09367891	chr1:107599246	PRMT6	-0.61	-10.66	-0.44	7.41e-24	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs11190604	1.000	rs3793772	chr10:102222825	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.87	0.45	1.18e-24	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.22	0.32	2.19e-12	Longevity;
LGG	cis	rs9796	0.558	rs4445868	chr15:41531991	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.35	-0.43	9.95e-23	Menopause (age at onset);
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.85	-0.3	2.34e-11	Total body bone mineral density;
LGG	cis	rs3087591	0.683	rs2854306	chr17:29648146	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg25008857	chr14:105974488	NA	0.58	10.26	0.43	2.24e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.72	0.34	7.28e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12049351	0.612	rs4925491	chr1:229608289	T/C	cg13547644	chr1:229569608	ACTA1	0.32	7.14	0.31	3.64e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs9325144	0.881	rs56344858	chr12:39180935	A/G	cg13010199	chr12:38710504	ALG10B	-0.5	-8.98	-0.39	6.6e-18	Morning vs. evening chronotype;
LGG	cis	rs1978968	0.912	rs5992933	chr22:18457043	G/T	cg03078520	chr22:18463400	MICAL3	-0.7	-14.81	-0.57	6.59e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs4423214	1.000	rs2282620	chr11:71183477	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.02	-0.52	3.18e-33	Vitamin D levels;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg15595755	chr5:1867978	NA	0.53	10.56	0.44	1.65e-23	Cardiovascular disease risk factors;
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg00495681	chr13:53174319	NA	1.01	23.18	0.73	1.7e-79	Lewy body disease;
LGG	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-7.83	-0.34	3.47e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs67311347	1.000	rs11129876	chr3:40401636	C/T	cg13683864	chr3:40499215	RPL14	0.98	20.2	0.68	1.59e-65	Renal cell carcinoma;
LGG	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	cis	rs2075371	1.000	rs2075371	chr7:133984127	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.26	0.58	6.89e-43	Mean platelet volume;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-8.48	-0.37	3.16e-16	Prudent dietary pattern;
LGG	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-12.25	-0.49	4.29e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6429082	0.715	rs2131923	chr1:235580821	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.94	-0.42	3.15e-21	Adiposity;
LGG	cis	rs7772486	0.754	rs9386133	chr6:146141213	A/G	cg23711669	chr6:146136114	FBXO30	0.4	6.76	0.3	4.06e-11	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.52	-0.33	2.89e-13	Neuroticism;
LGG	cis	rs4774899	0.869	rs12900874	chr15:57358997	T/A	cg08128148	chr15:57256372	TCF12	-0.3	-7.24	-0.32	1.89e-12	Urinary tract infection frequency;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.56	0.59	3.29e-44	Platelet count;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg13206674	chr6:150067644	NUP43	0.44	7.73	0.34	6.96e-14	Lung cancer;
LGG	cis	rs36093844	0.752	rs80323143	chr11:85546096	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs713587	0.563	rs2033655	chr2:25101092	C/T	cg04586622	chr2:25135609	ADCY3	0.43	11.63	0.48	1.33e-27	Body mass index in non-asthmatics;
LGG	cis	rs12493885	0.818	rs11928425	chr3:153773565	G/T	cg17054900	chr3:154042577	DHX36	-0.61	-7.82	-0.34	3.48e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	6.18e-19	Life satisfaction;
LGG	trans	rs9784649	1.000	rs1493479	chr5:24987768	A/G	cg11038491	chr20:34638489	LOC647979	-0.58	-7.53	-0.33	2.66e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3842397	1	rs3842397	chr18:43845880	CTT/C	cg26436583	chr18:43649176	PSTPIP2	-0.37	-8.08	-0.35	5.64e-15	Red cell distribution width;Mean platelet volume;
LGG	cis	rs992157	0.866	rs2292554	chr2:219146868	T/C	cg04731861	chr2:219085781	ARPC2	0.45	11.06	0.46	2.11e-25	Colorectal cancer;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	8.75	0.38	4.08e-17	Platelet count;
LGG	cis	rs28530618	0.558	rs6058794	chr20:31253277	C/G	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.75	-0.3	4.48e-11	Birth weight;
LGG	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg08847533	chr14:75593920	NEK9	-0.45	-8.24	-0.36	1.77e-15	Coronary artery disease;
LGG	cis	rs4689388	0.890	rs4688989	chr4:6290594	T/C	cg00701064	chr4:6280414	WFS1	0.73	16.1	0.6	1.25e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs600231	0.598	rs2508712	chr11:65232261	C/G	cg17120908	chr11:65337727	SSSCA1	-0.5	-9.01	-0.39	5.47e-18	Bone mineral density;
LGG	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.86	-0.3	2.21e-11	Neuroticism;
LGG	cis	rs2075371	1.000	rs1421486	chr7:133985196	T/C	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg08280861	chr8:58055591	NA	0.63	7.77	0.34	5.04e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs57244997	1.000	rs73026573	chr6:162405119	C/T	cg17173639	chr6:162384350	PARK2	-0.68	-8.31	-0.36	1.03e-15	Mosquito bite size;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.52	-0.5	3.38e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg04772025	chr11:68637568	NA	0.77	13.81	0.54	1.36e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg18252515	chr7:66147081	NA	-1.4	-20.12	-0.68	3.71e-65	Gout;
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg11644478	chr21:40555479	PSMG1	0.65	10.86	0.45	1.26e-24	Cognitive function;
LGG	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg01244601	chr4:120671846	NA	-0.39	-7.49	-0.33	3.52e-13	Corneal astigmatism;
LGG	cis	rs6728642	0.519	rs72811651	chr2:97572229	G/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.23	-0.36	1.89e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg18479299	chr3:125709523	NA	-0.58	-7.4	-0.33	6.44e-13	Blood pressure (smoking interaction);
LGG	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg04617936	chr2:214353	NA	-0.4	-7.34	-0.32	9.77e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.85	0.48	1.7e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3850699	0.683	rs67646802	chr10:104303748	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.46	-7.89	-0.34	2.25e-14	Prostate cancer;
LGG	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg23815491	chr16:72088622	HP	0.51	11.56	0.47	2.46e-27	Fibrinogen levels;
LGG	cis	rs1915146	1.000	rs1915146	chr10:126846214	A/G	cg03862225	chr10:126850454	CTBP2	0.24	6.73	0.3	5e-11	Menarche (age at onset);
LGG	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg03060546	chr3:49711283	APEH	-0.62	-10.3	-0.43	1.57e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2239547	0.523	rs6803486	chr3:53098209	T/A	cg11645453	chr3:52864694	ITIH4	0.65	10.43	0.44	5.27e-23	Schizophrenia;
LGG	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs13242809	1.000	rs13242809	chr7:22746564	T/A	cg18045685	chr7:22629474	NA	0.43	7.14	0.31	3.73e-12	Lymphocyte counts;
LGG	cis	rs1018836	0.923	rs13255452	chr8:91582988	A/G	cg16814680	chr8:91681699	NA	-0.83	-15.12	-0.57	2.96e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg17971929	chr21:40555470	PSMG1	-0.53	-8.95	-0.38	8.55e-18	Menarche (age at onset);
LGG	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg24209194	chr3:40518798	ZNF619	0.44	6.77	0.3	3.94e-11	Renal cell carcinoma;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg23166955	chr16:30077191	ALDOA	0.39	6.73	0.3	5.14e-11	Body mass index;
LGG	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg23173402	chr1:227635558	NA	0.48	8.32	0.36	1.01e-15	Major depressive disorder;
LGG	cis	rs7975161	1.000	rs7960443	chr12:104645363	G/A	cg25273343	chr12:104657179	TXNRD1	-0.75	-10.62	-0.44	1.01e-23	Toenail selenium levels;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg06925179	chr17:43578568	NA	0.43	10.0	0.42	1.84e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg16339924	chr4:17578868	LAP3	0.63	10.82	0.45	1.82e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13126279	chr21:47581558	C21orf56	-0.55	-9.88	-0.42	5.32e-21	Testicular germ cell tumor;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.14	-0.31	3.67e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	0.655	rs2758849	chr6:86344296	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.43	-7.71	-0.34	7.8500000000000006e-14	Response to antipsychotic treatment;
LGG	cis	rs2302729	0.515	rs1894980	chr12:2767183	G/C	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.37	-0.5	1.41e-30	Sleep quality;
LGG	trans	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg06521331	chr12:34319734	NA	0.44	7.83	0.34	3.44e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6580649	0.941	rs7971668	chr12:48469696	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs35740288	0.770	rs4843081	chr15:86153044	T/C	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs62244186	0.545	rs9284880	chr3:44759389	C/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.76	0.34	5.61e-14	Depressive symptoms;
LGG	cis	rs1728785	0.818	rs1814299	chr16:68581332	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg26695010	chr11:65641043	EFEMP2	-0.53	-8.99	-0.39	6.23e-18	Eosinophil percentage of white cells;
LGG	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg08885076	chr2:99613938	TSGA10	0.39	8.37	0.36	6.9e-16	Chronic sinus infection;
LGG	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg18721089	chr20:30220636	NA	-0.51	-7.57	-0.33	2e-13	Mean corpuscular hemoglobin;
LGG	cis	rs2274273	0.967	rs17832359	chr14:55615941	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	5.05e-51	Protein biomarker;
LGG	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.33	6.7e-13	Schizophrenia;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg19673125	chr6:150240577	RAET1G	0.3	6.71	0.3	5.81e-11	Lung cancer;
LGG	cis	rs7633770	0.749	rs6442011	chr3:46685722	C/T	cg11219411	chr3:46661640	NA	0.59	14.06	0.55	1.21e-37	Coronary artery disease;
LGG	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.66	0.3	7.92e-11	Depression;
LGG	cis	rs12519773	0.501	rs4449514	chr5:92521022	T/C	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	cis	rs1018234	0.503	rs316172	chr6:160758116	G/C	cg04181478	chr6:161122748	PLG	-0.37	-6.71	-0.3	5.64e-11	Lipoprotein (a) levels;
LGG	trans	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg23484912	chr5:273055	PDCD6	-0.39	-7.67	-0.34	1e-13	Mean corpuscular volume;
LGG	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	1.87e-29	Colorectal cancer;
LGG	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2836974	0.644	rs2410123	chr21:40700093	C/T	cg06238570	chr21:40685208	BRWD1	-0.5	-8.27	-0.36	1.48e-15	Cognitive function;
LGG	cis	rs4481887	0.604	rs4642918	chr1:248411057	A/C	cg01631408	chr1:248437212	OR2T33	0.41	6.68	0.3	6.86e-11	Common traits (Other);
LGG	cis	rs7000551	0.689	rs10110254	chr8:22309551	G/T	cg12081754	chr8:22256438	SLC39A14	0.69	13.48	0.53	3.64e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17092148	1.000	rs60789653	chr20:33447162	G/A	cg12302830	chr20:33297742	TP53INP2	0.46	7.57	0.33	1.99e-13	Neuroticism;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.46	0.37	3.42e-16	Obesity-related traits;
LGG	cis	rs7512552	0.803	rs9436125	chr1:150487961	C/G	cg15654264	chr1:150340011	RPRD2	0.44	9.02	0.39	5.07e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4988958	0.565	rs12712146	chr2:103008714	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg18876405	chr7:65276391	NA	-0.64	-11.92	-0.48	8.96e-29	Aortic root size;
LGG	cis	rs11628318	0.853	rs8003309	chr14:103050143	C/G	cg01864069	chr14:103024347	NA	-0.75	-11.98	-0.49	5.23e-29	Platelet count;
LGG	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg08975724	chr8:8085496	FLJ10661	0.37	6.96	0.31	1.15e-11	Retinal vascular caliber;
LGG	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg13147721	chr7:65941812	NA	-0.82	-9.79	-0.41	1.09e-20	Diabetic kidney disease;
LGG	cis	rs7084402	0.967	rs12569559	chr10:60312711	T/G	cg09696939	chr10:60272079	BICC1	0.36	7.05	0.31	6.53e-12	Refractive error;
LGG	cis	rs35079168	0.735	rs3118540	chr9:137307106	C/T	cg00753924	chr9:137298813	RXRA	-0.48	-8.77	-0.38	3.45e-17	Intelligence;
LGG	cis	rs8064029	0.892	rs62036114	chr16:4880827	C/A	cg04440724	chr16:4920505	UBN1	-0.64	-7.53	-0.33	2.72e-13	Cancer;
LGG	cis	rs9549367	0.713	rs3024745	chr13:113821598	A/G	cg18105134	chr13:113819100	PROZ	-0.78	-16.03	-0.6	2.46e-46	Platelet distribution width;
LGG	cis	rs9534288	0.671	rs4942465	chr13:46562687	C/T	cg15192986	chr13:46630673	CPB2	-0.56	-12.15	-0.49	1.09e-29	Blood protein levels;
LGG	trans	rs17685	0.753	rs2108274	chr7:75781636	C/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.68	0.77	4.25e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg26043149	chr18:55253948	FECH	-0.4	-6.66	-0.3	7.96e-11	Bone mineral density;
LGG	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg00405596	chr8:11794950	NA	0.65	11.51	0.47	3.9e-27	Myopia (pathological);
LGG	cis	rs262150	0.503	rs11769917	chr7:158817498	C/T	cg19418458	chr7:158789849	NA	-0.53	-10.96	-0.45	5e-25	Facial morphology (factor 20);
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.77	-0.38	3.4e-17	Cognitive function;
LGG	cis	rs7107174	1.000	rs7117238	chr11:78040259	G/A	cg02023728	chr11:77925099	USP35	0.45	8.05	0.35	6.97e-15	Testicular germ cell tumor;
LGG	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg02811702	chr13:24901961	NA	0.4	7.45	0.33	4.54e-13	Obesity-related traits;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.79	-0.3	3.38e-11	Lung cancer;
LGG	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs7044106	0.762	rs13291660	chr9:123392748	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.6	0.61	6.95e-49	Hip circumference adjusted for BMI;
LGG	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs1109114	0.738	rs2289283	chr5:148621805	C/T	cg06539116	chr5:148597365	ABLIM3	0.52	12.5	0.5	4.27e-31	Body mass index;
LGG	cis	rs6032067	0.516	rs991049	chr20:43898139	C/T	cg10761708	chr20:43804764	PI3	-0.47	-7.52	-0.33	2.96e-13	Blood protein levels;
LGG	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg10596483	chr8:143751796	JRK	0.53	8.36	0.36	7.2e-16	Schizophrenia;
LGG	cis	rs283228	1.000	rs979172	chr6:101829246	A/G	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg05044414	chr3:183734942	ABCC5	0.56	11.45	0.47	6.92e-27	Anterior chamber depth;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1318772	0.800	rs13160021	chr5:112935515	C/G	cg12552261	chr5:112820674	MCC	0.68	7.12	0.31	4.09e-12	F-cell distribution;
LGG	trans	rs9467603	1.000	rs9467603	chr6:25803712	A/G	cg01620082	chr3:125678407	NA	-0.69	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04772025	chr11:68637568	NA	0.77	13.8	0.54	1.59e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6032067	0.929	rs62208428	chr20:43827578	A/C	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg00495681	chr13:53174319	NA	0.58	10.33	0.43	1.2e-22	Lewy body disease;
LGG	trans	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg07393940	chr7:158741817	NA	-0.57	-10.56	-0.44	1.65e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.56	-0.33	2.11e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs12928939	0.911	rs77823468	chr16:71828616	C/T	cg03805757	chr16:71968109	PKD1L3	-0.54	-10.33	-0.43	1.15e-22	Post bronchodilator FEV1;
LGG	cis	rs28735056	0.967	rs623546	chr18:77595228	C/T	cg25885449	chr18:77638415	KCNG2	0.34	6.75	0.3	4.42e-11	Schizophrenia;
LGG	cis	rs12347191	0.500	rs925485	chr9:100619561	G/C	cg13688889	chr9:100608707	NA	-0.82	-16.07	-0.6	1.65e-46	Orofacial clefts;
LGG	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg16339924	chr4:17578868	LAP3	0.61	10.53	0.44	2.27e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8072100	1.000	rs7210738	chr17:45757598	G/A	cg08085267	chr17:45401833	C17orf57	0.62	12.79	0.51	2.66e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg00543991	chr22:32367038	NA	-0.78	-8.44	-0.37	4.03e-16	Childhood ear infection;
LGG	cis	rs2486288	0.656	rs2413774	chr15:45549423	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs1909881	0.935	rs11787394	chr8:96505818	T/A	cg04203453	chr8:96504381	NA	-1.09	-18.65	-0.65	2.63e-58	Obesity-related traits;
LGG	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-9.35	-0.4	3.72e-19	Neuroticism;
LGG	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg23845249	chr11:68861649	NA	0.45	8.03	0.35	7.98e-15	Blond vs. brown hair color;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg08305652	chr11:111469057	NA	0.44	8.35	0.36	7.99e-16	Primary sclerosing cholangitis;
LGG	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.24	-0.32	1.9e-12	Self-reported allergy;
LGG	trans	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-9.79	-0.41	1.1e-20	Brugada syndrome;
LGG	cis	rs4665809	1.000	rs6750681	chr2:26329677	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.54e-33	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1920116	0.778	rs9831336	chr3:169558373	C/G	cg08193579	chr3:169529701	LRRC34	-0.41	-7.14	-0.32	3.55e-12	Glioma (high-grade);
LGG	cis	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.29	0.36	1.26e-15	Red cell distribution width;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.42	-0.53	6.52e-35	Alzheimer's disease;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.2	-0.52	5.46e-34	Alzheimer's disease;
LGG	cis	rs4936894	0.500	rs10790655	chr11:124109822	T/C	cg27160556	chr11:124181099	OR8D1	-0.48	-11.09	-0.46	1.61e-25	Aging (time to death);
LGG	cis	rs3771570	1.000	rs56383420	chr2:242219281	A/G	cg21155796	chr2:242212141	HDLBP	0.76	9.95	0.42	2.98e-21	Prostate cancer;
LGG	cis	rs600231	0.571	rs10896000	chr11:65218018	A/G	cg17120908	chr11:65337727	SSSCA1	-0.48	-8.5	-0.37	2.6e-16	Bone mineral density;
LGG	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg15704280	chr7:45808275	SEPT13	0.77	8.98	0.39	6.83e-18	Axial length;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06733736	chr16:3661771	BTBD12	0.43	6.94	0.31	1.36e-11	Cognitive performance;
LGG	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg26384229	chr12:38710491	ALG10B	1.01	25.28	0.76	3.14e-89	Heart rate;
LGG	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg01221209	chr5:554886	NA	-0.51	-7.58	-0.33	1.95e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg15017067	chr4:17643749	FAM184B	0.32	7.45	0.33	4.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6087990	0.735	rs2424913	chr20:31374259	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	16.11	0.6	1.1e-46	Ulcerative colitis;
LGG	cis	rs9303280	0.901	rs2313430	chr17:37929816	T/C	cg00129232	chr17:37814104	STARD3	0.46	8.7	0.37	5.99e-17	Self-reported allergy;
LGG	cis	rs8141529	0.529	rs35017742	chr22:29216585	C/T	cg15103426	chr22:29168792	CCDC117	0.67	7.04	0.31	6.78e-12	Lymphocyte counts;
LGG	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg19554555	chr3:13937349	NA	0.74	14.04	0.55	1.49e-37	Ovarian reserve;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg21724239	chr8:58056113	NA	0.42	6.66	0.3	7.74e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg19143629	chr17:61920732	SMARCD2	0.41	7.12	0.31	4.08e-12	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02621907	chr5:93954419	ANKRD32;C5orf36	0.45	7.09	0.31	5.09e-12	Gut microbiome composition (summer);
LGG	trans	rs73191547	0.690	rs7011281	chr8:10036035	C/T	cg06636001	chr8:8085503	FLJ10661	-0.37	-6.83	-0.3	2.6e-11	Schizophrenia;
LGG	cis	rs12893668	0.572	rs12590968	chr14:104136633	G/C	cg26031613	chr14:104095156	KLC1	-0.66	-10.67	-0.44	6.52e-24	Reticulocyte count;
LGG	cis	rs78487399	0.808	rs75934770	chr2:43659694	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.02e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg03929089	chr4:120376271	NA	0.69	8.13	0.35	3.82e-15	Axial length;
LGG	cis	rs7558370	0.737	rs77200948	chr2:3710169	C/T	cg16123090	chr2:3699210	NA	0.79	7.63	0.33	1.34e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3540	0.960	rs1505936	chr15:91010776	T/C	cg22089800	chr15:90895588	ZNF774	0.51	8.02	0.35	8.86e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05482956	chr11:16635016	NA	0.5	7.99	0.35	1.11e-14	Gut microbiome composition (summer);
LGG	cis	rs2463822	1.000	rs2246920	chr11:62104937	T/G	cg06239285	chr11:62104954	ASRGL1	1.13	15.88	0.59	1.25e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg14196790	chr5:131705035	SLC22A5	0.59	7.48	0.33	3.79e-13	Rheumatoid arthritis;
LGG	cis	rs701145	0.640	rs357497	chr3:153943068	C/A	cg12800244	chr3:153838788	SGEF	0.84	8.35	0.36	8.02e-16	Coronary artery disease;
LGG	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg16482183	chr6:26056742	HIST1H1C	0.54	9.69	0.41	2.5e-20	Height;
LGG	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-9.79	-0.41	1.08e-20	Aortic root size;
LGG	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	trans	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg16325326	chr1:53192061	ZYG11B	-0.88	-23.16	-0.73	2.12e-79	Monocyte count;
LGG	trans	rs10802346	0.545	rs1770003	chr1:246408356	A/G	cg13514129	chr1:39547527	MACF1	0.68	12.62	0.51	1.35e-31	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03452623	chr4:187889614	NA	-0.92	-22.98	-0.73	1.53e-78	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg18357526	chr6:26021779	HIST1H4A	0.43	7.03	0.31	7.54e-12	Height;
LGG	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg22906224	chr7:99728672	NA	-0.48	-7.8	-0.34	4.23e-14	Coronary artery disease;
LGG	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.25	-0.32	1.8e-12	Inflammatory bowel disease;
LGG	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg01244601	chr4:120671846	NA	-0.35	-6.67	-0.3	7.23e-11	Corneal astigmatism;
LGG	cis	rs75804782	0.522	rs7561954	chr2:239318280	G/A	cg18131467	chr2:239335373	ASB1	-0.59	-7.76	-0.34	5.39e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg21132104	chr15:45694354	SPATA5L1	0.66	9.45	0.4	1.75e-19	Homoarginine levels;
LGG	cis	rs1847202	1.000	rs11918615	chr3:72942407	T/C	cg25664220	chr3:72788482	NA	-0.24	-7.46	-0.33	4.32e-13	Motion sickness;
LGG	cis	rs2415984	0.622	rs2817568	chr14:46940986	C/G	cg14871534	chr14:47121158	RPL10L	0.57	9.98	0.42	2.24e-21	Number of children ever born;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.8	0.3	3.27e-11	Schizophrenia;
LGG	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.67	0.44	6.43e-24	Lung cancer in ever smokers;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg18357526	chr6:26021779	HIST1H4A	0.46	7.46	0.33	4.24e-13	Height;
LGG	trans	rs208520	0.690	rs864314	chr6:66814830	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-31.95	-0.83	3.47e-119	Exhaled nitric oxide output;
LGG	cis	rs4595586	0.525	rs17467376	chr12:39377551	T/G	cg26384229	chr12:38710491	ALG10B	0.65	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs9487051	0.872	rs9487032	chr6:109605323	G/T	cg12927641	chr6:109611667	NA	-0.37	-7.16	-0.32	3.17e-12	Reticulocyte fraction of red cells;
LGG	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg02527881	chr3:46936655	PTH1R	-0.35	-8.49	-0.37	2.76e-16	Birth weight;
LGG	cis	rs6546550	0.901	rs12232914	chr2:70117176	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.82	-0.34	3.62e-14	Prevalent atrial fibrillation;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg22535103	chr8:58192502	C8orf71	-0.58	-9.78	-0.41	1.14e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.31e-18	Lung cancer;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs3219090	0.927	rs747657	chr1:226550924	G/C	cg17127702	chr1:226594323	PARP1	-0.37	-11.66	-0.48	9.73e-28	Melanoma;
LGG	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	9.73	0.41	1.72e-20	Schizophrenia;
LGG	cis	rs17227506	0.591	rs13262009	chr8:13405867	A/G	cg03566418	chr8:13424080	C8orf48	0.55	8.05	0.35	6.99e-15	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg02002194	chr4:3960332	NA	-0.47	-8.95	-0.38	8.88e-18	Joint mobility (Beighton score);
LGG	cis	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-8.79	-0.38	2.9e-17	Schizophrenia;
LGG	cis	rs7552404	0.765	rs1251078	chr1:76189488	C/G	cg03433033	chr1:76189801	ACADM	-0.82	-16.68	-0.61	2.99e-49	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg06353428	chr16:71660113	MARVELD3	0.41	6.86	0.3	2.27e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs968451	1.000	rs11703434	chr22:39698915	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	11.0	0.46	3.83e-25	Primary biliary cholangitis;
LGG	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	19.44	0.67	5.44e-62	Platelet count;
LGG	cis	rs6831256	0.899	rs36205397	chr4:3470604	A/G	cg00887848	chr4:3482507	DOK7	-0.44	-8.7	-0.37	5.8e-17	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.68	0.3	6.71e-11	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18721605	chr18:44676421	HDHD2	0.43	6.93	0.31	1.44e-11	Cognitive performance;
LGG	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg11693508	chr17:37793320	STARD3	0.74	10.89	0.45	9.26e-25	Bipolar disorder;
LGG	cis	rs757081	0.667	rs17560341	chr11:17107163	C/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.86	-0.38	1.73e-17	Systolic blood pressure;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg06074448	chr4:187884817	NA	-0.59	-13.05	-0.52	2.23e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3750450	0.718	rs10733569	chr9:111936732	G/A	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.04	-0.31	7.16e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg27446573	chr6:127587934	RNF146	1.12	22.04	0.72	3.91e-74	Breast cancer;
LGG	cis	rs7666738	0.830	rs13149404	chr4:99070236	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4654899	0.865	rs12130664	chr1:21332812	G/T	cg05370193	chr1:21551575	ECE1	0.29	6.68	0.3	7.05e-11	Superior frontal gyrus grey matter volume;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.13	-0.43	6.46e-22	Longevity;Endometriosis;
LGG	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.45	-6.9	-0.31	1.71e-11	Parkinson's disease;
LGG	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg23231163	chr10:75533350	FUT11	-0.41	-7.11	-0.31	4.28e-12	Inflammatory bowel disease;
LGG	cis	rs4409675	0.576	rs2749119	chr1:28236248	G/A	cg23691781	chr1:28212827	C1orf38	0.43	11.14	0.46	1.09e-25	Corneal astigmatism;
LGG	cis	rs13088645	0.541	rs9842113	chr3:134192338	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-8.0	-0.35	1.04e-14	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs3849046	0.817	rs13160755	chr5:137885631	A/G	cg10920316	chr5:137946599	NA	0.43	6.86	0.3	2.19e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg11247378	chr22:39784982	NA	-0.31	-8.99	-0.39	6.49e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs6969981	chr7:91689461	G/C	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.82e-16	Breast cancer;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.28	-0.43	1.77e-22	Obesity-related traits;
LGG	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg03060546	chr3:49711283	APEH	0.58	8.89	0.38	1.33e-17	Resting heart rate;
LGG	trans	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs7586879	0.964	rs13412941	chr2:25102709	C/T	cg04586622	chr2:25135609	ADCY3	0.35	8.54	0.37	1.89e-16	Body mass index;
LGG	cis	rs7647973	0.516	rs4536858	chr3:49193081	A/G	cg06212747	chr3:49208901	KLHDC8B	0.71	12.52	0.5	3.68e-31	Menarche (age at onset);
LGG	cis	rs240764	0.658	rs9386257	chr6:101252069	A/T	cg09795085	chr6:101329169	ASCC3	0.47	8.07	0.35	6.14e-15	Neuroticism;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00631329	chr6:26305371	NA	-0.53	-9.5	-0.4	1.14e-19	Educational attainment;
LGG	cis	rs9611519	0.929	rs4820423	chr22:41430338	A/T	cg03806693	chr22:41940476	POLR3H	-0.53	-8.0	-0.35	9.92e-15	Neuroticism;
LGG	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg24011408	chr12:48396354	COL2A1	-0.46	-7.05	-0.31	6.43e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs9929218	1.000	rs12921546	chr16:68780069	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-14.09	-0.55	9.17e-38	Colorectal cancer;
LGG	cis	rs13031619	0.950	rs7589966	chr2:3696636	A/G	cg01268866	chr2:3683757	COLEC11	-0.38	-7.01	-0.31	8.23e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4330281	0.647	rs6789697	chr3:17700708	A/G	cg20981856	chr3:17787350	NA	0.41	7.81	0.34	3.98e-14	Schizophrenia;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg00960700	chr17:80709150	TBCD	0.41	7.14	0.32	3.56e-12	Glycated hemoglobin levels;
LGG	cis	rs758324	0.797	rs246998	chr5:131348878	A/G	cg06307176	chr5:131281290	NA	0.48	7.0	0.31	9.19e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15057717	chr19:53837180	ZNF845	0.41	6.7	0.3	6.25e-11	Cognitive performance;
LGG	cis	rs7927997	0.783	rs11236791	chr11:76295598	G/A	cg17647271	chr11:76299819	NA	-0.4	-7.04	-0.31	6.82e-12	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs7582720	0.832	rs115194657	chr2:203829284	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs116095464	0.558	rs9687898	chr5:253952	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs36051895	0.626	rs10815149	chr9:5063701	T/C	cg02405213	chr9:5042618	JAK2	-0.81	-16.17	-0.6	6.22e-47	Pediatric autoimmune diseases;
LGG	cis	rs13314892	0.764	rs59487570	chr3:69860905	T/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs888194	0.690	rs3782894	chr12:110026024	G/T	cg19025524	chr12:109796872	NA	-0.34	-6.87	-0.3	2.13e-11	Neuroticism;
LGG	cis	rs853679	0.517	rs35512245	chr6:28079953	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs1577917	1.000	rs4706254	chr6:86602813	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.55	-0.37	1.82e-16	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg05665937	chr4:1216051	CTBP1	0.61	11.06	0.46	2.18e-25	Obesity-related traits;
LGG	cis	rs72781680	0.559	rs72796103	chr2:23900382	G/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.89	0.38	1.4e-17	Lymphocyte counts;
LGG	cis	rs67311347	1.000	rs2305521	chr3:40429183	A/G	cg13683864	chr3:40499215	RPL14	-0.97	-19.96	-0.68	2.08e-64	Renal cell carcinoma;
LGG	cis	rs738322	0.775	rs13056506	chr22:38580917	G/T	cg25457927	chr22:38595422	NA	0.49	12.44	0.5	7.82e-31	Cutaneous nevi;
LGG	cis	rs5995756	0.666	rs5750857	chr22:40000221	A/C	cg21377881	chr22:40064566	CACNA1I	0.35	7.21	0.32	2.24e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4665809	1.000	rs4665308	chr2:26330514	C/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.7	-12.8	-0.51	2.4e-32	Longevity;Endometriosis;
LGG	cis	rs9916302	0.847	rs7218670	chr17:37500424	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg24130564	chr14:104152367	KLC1	-0.77	-17.21	-0.62	1.19e-51	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.79	0.54	1.75e-36	Colorectal cancer;
LGG	cis	rs7590720	0.531	rs6435932	chr2:216906030	T/C	cg12620499	chr2:216877984	MREG	0.53	9.44	0.4	1.76e-19	Alcohol dependence;
LGG	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg20821713	chr7:1055600	C7orf50	-0.41	-6.66	-0.3	7.98e-11	Bronchopulmonary dysplasia;
LGG	cis	rs9938149	0.736	rs28716598	chr16:88324563	C/G	cg05435882	chr16:88311214	NA	-0.4	-6.79	-0.3	3.55e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs6963495	0.818	rs73192120	chr7:105171156	C/T	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	10.18	0.43	4.09e-22	Multiple sclerosis;
LGG	cis	rs4720575	1.000	rs1859522	chr7:47096901	G/A	cg00036614	chr7:47093842	NA	-0.5	-9.97	-0.42	2.51e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs1975974	0.935	rs11870387	chr17:21730236	G/C	cg18423549	chr17:21743878	NA	-0.47	-6.75	-0.3	4.49e-11	Psoriasis;
LGG	cis	rs11159840	0.609	rs7141583	chr14:88621760	T/C	cg18078958	chr14:88630771	NA	-0.3	-7.09	-0.31	5.02e-12	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg12756686	chr19:29218302	NA	0.77	10.92	0.45	7.68e-25	Methadone dose in opioid dependence;
LGG	cis	rs9443645	0.803	rs1547731	chr6:79776104	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.35	-0.36	7.95e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.677	rs13203636	chr6:110062288	G/C	cg01125227	chr6:109776195	MICAL1	0.48	7.42	0.33	5.79e-13	Height;
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	trans	rs12517041	0.938	rs1428616	chr5:23260829	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.8	-0.38	2.8e-17	Calcium levels;
LGG	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg23825213	chr18:77623475	KCNG2	-0.39	-7.04	-0.31	7.15e-12	Schizophrenia;
LGG	cis	rs826838	0.967	rs1719853	chr12:39128515	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.28	-0.55	1.32e-38	Heart rate;
LGG	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.43	-0.33	5.28e-13	Neuroticism;
LGG	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg05527609	chr1:210001259	C1orf107	0.71	10.92	0.45	7.23e-25	Orofacial clefts;
LGG	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.19	-0.43	3.77e-22	Total cholesterol levels;
LGG	cis	rs3747547	0.710	rs2091415	chr9:37951176	T/C	cg13774184	chr9:37916125	SHB	-0.72	-8.04	-0.35	7.67e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg13206674	chr6:150067644	NUP43	0.66	14.77	0.57	9.84e-41	Lung cancer;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.24	-0.58	8.34e-43	Prudent dietary pattern;
LGG	trans	rs877282	0.947	rs7923867	chr10:768094	G/A	cg22713356	chr15:30763199	NA	0.54	8.19	0.36	2.54e-15	Uric acid levels;
LGG	cis	rs9462027	0.628	rs1125341	chr6:34786305	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg17202724	chr17:61916730	SMARCD2	-0.6	-14.48	-0.56	1.81e-39	Prudent dietary pattern;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg13047869	chr3:10149882	C3orf24	0.53	8.76	0.38	3.65e-17	Alzheimer's disease;
LGG	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03576123	chr11:487126	PTDSS2	-1.27	-16.74	-0.61	1.65e-49	Body mass index;
LGG	trans	rs61931739	0.578	rs7133659	chr12:33619751	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-8.22	-0.36	2e-15	Morning vs. evening chronotype;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg01341218	chr17:43662625	NA	-0.65	-11.77	-0.48	3.61e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7582720	0.943	rs72932559	chr2:203847382	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.62	0.41	4.21e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03773681	chr2:63815918	MDH1;C2orf86	0.52	8.9	0.38	1.25e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg12438819	chr7:158236134	PTPRN2	0.34	8.71	0.38	5.23e-17	Obesity-related traits;
LGG	cis	rs643506	0.874	rs609007	chr11:111719593	A/G	cg09085632	chr11:111637200	PPP2R1B	-0.42	-6.76	-0.3	4.04e-11	Breast cancer;
LGG	cis	rs17321999	0.516	rs72787734	chr2:30500839	G/A	cg05247661	chr2:30472410	LBH	0.63	7.74	0.34	6.22e-14	Systemic lupus erythematosus;
LGG	cis	rs8044868	0.530	rs2287999	chr16:72059149	A/G	cg23815491	chr16:72088622	HP	0.34	7.16	0.32	3.17e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs4716602	0.898	rs4717047	chr7:156160671	T/C	cg16983916	chr7:156159713	NA	-0.38	-6.72	-0.3	5.22e-11	Anti-saccade response;
LGG	cis	rs7546	0.504	rs2075636	chr16:4938321	A/T	cg04440724	chr16:4920505	UBN1	0.56	12.18	0.49	8.51e-30	Cancer;
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg05941027	chr17:61774174	LIMD2	0.37	9.44	0.4	1.79e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg00666640	chr1:248458726	OR2T12	0.62	10.0	0.42	1.85e-21	Common traits (Other);
LGG	cis	rs193541	0.632	rs2910135	chr5:122229790	C/T	cg19412675	chr5:122181750	SNX24	0.55	8.85	0.38	1.81e-17	Glucose homeostasis traits;
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.34	0.36	8.64e-16	Tonsillectomy;
LGG	cis	rs713587	0.967	rs713586	chr2:25158008	A/G	cg04586622	chr2:25135609	ADCY3	0.44	11.7	0.48	7.2e-28	Body mass index in non-asthmatics;
LGG	cis	rs6708331	0.517	rs9989876	chr2:70342710	T/A	cg01613454	chr2:70366299	NA	0.52	10.48	0.44	3.23e-23	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg03060546	chr3:49711283	APEH	-0.64	-10.49	-0.44	3.11e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10463316	0.817	rs6879238	chr5:150820574	G/C	cg03212797	chr5:150827313	SLC36A1	-0.57	-10.14	-0.43	5.98e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs11190604	1.000	rs11190613	chr10:102313997	C/T	cg07570687	chr10:102243282	WNT8B	-0.4	-6.73	-0.3	4.96e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17221829	0.733	rs11018715	chr11:89394462	A/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.16e-18	Anxiety in major depressive disorder;
LGG	cis	rs11771526	1.000	rs17351142	chr7:32339843	T/G	cg27532318	chr7:32358331	NA	0.85	8.0	0.35	1.01e-14	Body mass index;
LGG	cis	rs7937682	0.921	rs34584980	chr11:111441537	G/A	cg19812747	chr11:111475976	SIK2	0.47	9.16	0.39	1.66e-18	Primary sclerosing cholangitis;
LGG	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.57	0.53	1.51e-35	Height;
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg13047869	chr3:10149882	C3orf24	0.48	7.87	0.34	2.6e-14	Alzheimer's disease;
LGG	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg09021430	chr5:549028	NA	-0.74	-10.57	-0.44	1.58e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs10876993	0.890	rs812304	chr12:58074853	A/C	cg18357645	chr12:58087776	OS9	0.68	12.33	0.5	2.16e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs1020064	0.945	rs1030878	chr2:105910598	T/G	cg02079111	chr2:105885981	TGFBRAP1	0.64	9.93	0.42	3.48e-21	AIDS;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-17.07	-0.62	4.9e-51	Skin colour saturation;
LGG	cis	rs8028182	0.636	rs4886707	chr15:75755467	C/T	cg20655648	chr15:75932815	IMP3	0.46	7.91	0.35	1.85e-14	Sudden cardiac arrest;
LGG	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg06027949	chr8:82754900	SNX16	-0.49	-6.98	-0.31	1.04e-11	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg25703541	chr22:24373054	LOC391322	-0.94	-18.84	-0.66	3.44e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg21926883	chr2:100939477	LONRF2	-0.49	-9.47	-0.4	1.42e-19	Intelligence (multi-trait analysis);
LGG	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23526055	chr8:74884794	TCEB1	0.46	7.38	0.32	7.47e-13	Cognitive performance;
LGG	cis	rs9479482	1.000	rs11155697	chr6:150357423	C/T	cg07549998	chr6:150325970	RAET1K	-0.38	-7.26	-0.32	1.66e-12	Alopecia areata;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs75229567	0.618	rs11177848	chr12:70180892	A/G	cg10114359	chr12:70132523	RAB3IP	1.39	11.21	0.46	5.69e-26	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs12618769	0.597	rs11901568	chr2:99128621	C/T	cg18455616	chr2:99124870	INPP4A	-0.29	-8.66	-0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.72e-44	Colorectal cancer;
LGG	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg13385794	chr1:248469461	NA	0.43	7.49	0.33	3.47e-13	Common traits (Other);
LGG	cis	rs3096299	0.802	rs3102336	chr16:89442006	C/T	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.44	-0.33	4.93e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.73	-0.48	5.52e-28	Schizophrenia;
LGG	cis	rs10911251	0.546	rs1062044	chr1:183112412	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.67	0.37	7.22e-17	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11150038	0.702	rs2204895	chr16:78102777	G/T	cg04733911	chr16:78082701	NA	0.59	8.19	0.36	2.6e-15	Colorectal or endometrial cancer;
LGG	cis	rs62025270	0.688	rs17577869	chr15:86314373	C/A	cg25843651	chr15:86329602	KLHL25	0.65	10.74	0.45	3.68e-24	Idiopathic pulmonary fibrosis;
LGG	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg09307838	chr4:120376055	NA	0.78	13.38	0.53	9.7e-35	Corneal astigmatism;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21862992	chr11:68658383	NA	0.51	8.41	0.36	5.18e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs62025270	0.806	rs7173923	chr15:86292471	A/T	cg25843651	chr15:86329602	KLHL25	0.61	9.94	0.42	3.17e-21	Idiopathic pulmonary fibrosis;
LGG	trans	rs12517041	1.000	rs4701362	chr5:23300849	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.09	-0.46	1.61e-25	Calcium levels;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.56e-18	Menopause (age at onset);
LGG	cis	rs4740619	0.689	rs10810501	chr9:15951954	G/C	cg14451791	chr9:16040625	NA	-0.4	-10.18	-0.43	4.07e-22	Body mass index;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.29	-0.55	1.2e-38	Alzheimer's disease;
LGG	cis	rs16976116	0.901	rs7172108	chr15:55501551	C/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg09699651	chr6:150184138	LRP11	-0.57	-11.03	-0.46	2.85e-25	Testicular germ cell tumor;
LGG	cis	rs7465272	1.000	rs35476574	chr8:143683784	C/A	cg10104451	chr8:143696006	ARC	-0.75	-11.04	-0.46	2.5e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4664308	1.000	rs17831191	chr2:160911332	T/C	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg13206674	chr6:150067644	NUP43	0.66	14.97	0.57	1.29e-41	Lung cancer;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg01988459	chr11:68622903	NA	0.58	11.67	0.48	9.44e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07234876	chr8:600039	NA	-1.37	-11.56	-0.47	2.48e-27	IgG glycosylation;
LGG	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-11.33	-0.47	2.02e-26	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg14541582	chr5:601475	NA	-0.66	-10.32	-0.43	1.27e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs16976116	0.851	rs28699327	chr15:55500335	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg11494091	chr17:61959527	GH2	0.51	8.34	0.36	8.31e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg10167378	chr1:228756711	NA	0.56	7.98	0.35	1.2e-14	Chronic lymphocytic leukemia;
LGG	trans	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.89	-0.42	4.67e-21	Bladder cancer;
LGG	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21659725	chr3:3221576	CRBN	0.61	10.86	0.45	1.23e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2201728	1.000	rs2201728	chr4:100163873	G/A	cg07219303	chr4:100140905	ADH6	-0.42	-8.4	-0.36	5.45e-16	Cardiac Troponin-T levels;
LGG	cis	rs4144743	0.759	rs16969966	chr17:45318452	G/T	cg18085866	chr17:45331354	ITGB3	-0.7	-7.48	-0.33	3.72e-13	Body mass index;
LGG	cis	rs4731207	0.698	rs4319000	chr7:124528055	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.7	-0.34	8.03e-14	Cutaneous malignant melanoma;
LGG	cis	rs10463554	0.892	rs10463988	chr5:102249299	T/C	cg23492399	chr5:102201601	PAM	-0.56	-8.63	-0.37	1.03e-16	Parkinson's disease;
LGG	cis	rs742614	0.533	rs13041078	chr20:32435497	G/T	cg06304546	chr20:32448765	NA	-0.71	-14.21	-0.55	2.82e-38	Stearic acid (18:0) levels;
LGG	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg11995313	chr8:8860691	ERI1	0.46	7.86	0.34	2.79e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg07701084	chr6:150067640	NUP43	-0.66	-12.38	-0.5	1.34e-30	Lung cancer;
LGG	cis	rs6963495	0.818	rs73192122	chr7:105171471	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.79	0.34	4.59e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg01028140	chr2:1542097	TPO	-0.46	-8.57	-0.37	1.53e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg19717773	chr7:2847554	GNA12	-0.37	-8.58	-0.37	1.43e-16	Height;
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg10207240	chr12:122356781	WDR66	0.24	7.32	0.32	1.07e-12	Mean corpuscular volume;
LGG	cis	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg27411982	chr8:10470053	RP1L1	-0.47	-8.14	-0.35	3.66e-15	Triglycerides;
LGG	cis	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg15038512	chr6:170123185	PHF10	0.51	6.67	0.3	7.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg19635926	chr16:89946313	TCF25	0.72	7.11	0.31	4.48e-12	Skin colour saturation;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.38e-16	Aortic root size;
LGG	cis	rs921968	0.643	rs2178019	chr2:219316303	G/A	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.57	-0.33	2.02e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg25703541	chr22:24373054	LOC391322	-0.77	-13.18	-0.52	6.46e-34	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg00543991	chr22:32367038	NA	0.77	8.65	0.37	8.29e-17	Childhood ear infection;
LGG	cis	rs3540	0.960	rs60825716	chr15:90958053	G/A	cg22089800	chr15:90895588	ZNF774	0.51	7.86	0.34	2.69e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg04234412	chr22:24373322	LOC391322	0.65	10.31	0.43	1.41e-22	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs7241530	0.717	rs9949518	chr18:75889092	C/A	cg14642773	chr18:75888474	NA	0.47	9.69	0.41	2.43e-20	Educational attainment (years of education);
LGG	cis	rs8067287	0.762	rs11649835	chr17:16823541	C/G	cg26910001	chr17:16838321	NA	-0.47	-8.84	-0.38	1.99e-17	Diabetic kidney disease;
LGG	cis	rs4950322	0.570	rs72691033	chr1:146732921	C/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg12982090	chr3:42733453	KBTBD5	0.95	15.95	0.6	5.57e-46	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00631329	chr6:26305371	NA	0.55	10.07	0.42	1.02e-21	Educational attainment;
LGG	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg00745463	chr17:30367425	LRRC37B	-0.6	-8.84	-0.38	1.98e-17	Hip circumference adjusted for BMI;
LGG	cis	rs7444	0.882	rs9621715	chr22:21942007	G/A	cg15846791	chr22:21984385	YDJC	-0.47	-7.12	-0.31	4.05e-12	Systemic lupus erythematosus;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg06848047	chr4:90757629	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs2172802	0.693	rs10025823	chr4:62487743	T/C	cg04118610	chr4:62707027	LPHN3	-0.5	-7.93	-0.35	1.68e-14	Partial epilepsies;
LGG	cis	rs9487051	0.676	rs9386774	chr6:109561646	C/T	cg21918786	chr6:109611834	NA	-0.37	-6.82	-0.3	2.9e-11	Reticulocyte fraction of red cells;
LGG	cis	rs752010	0.631	rs7515066	chr1:42076915	A/G	cg06885757	chr1:42089581	HIVEP3	-0.83	-20.56	-0.69	3.18e-67	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs17122278	0.613	rs572126	chr11:118359161	C/T	cg27286069	chr11:118481882	PHLDB1	0.46	6.82	0.3	2.78e-11	Total cholesterol levels;
LGG	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg26818010	chr10:134567672	INPP5A	-0.73	-11.03	-0.46	2.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4819052	0.851	rs2838865	chr21:46712299	C/T	cg06618935	chr21:46677482	NA	-0.47	-9.21	-0.39	1.17e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2640806	0.645	rs7824518	chr8:97330751	A/C	cg22138393	chr8:97340270	PTDSS1	0.31	8.16	0.35	3.09e-15	Obesity-related traits;
LGG	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg25039879	chr17:56429692	SUPT4H1	0.58	7.62	0.33	1.42e-13	Cognitive test performance;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg21659725	chr3:3221576	CRBN	-0.91	-20.26	-0.69	8.57e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg09998033	chr7:158218633	PTPRN2	-0.51	-9.07	-0.39	3.4e-18	Obesity-related traits;
LGG	cis	rs28655083	1.000	rs1875582	chr16:77063147	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.48	7.55	0.33	2.39e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	8.0	0.35	1e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2346177	0.875	rs1447565	chr2:46643682	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-10.63	-0.44	9.44e-24	HDL cholesterol;
LGG	cis	rs10937275	1.000	rs35102841	chr3:186649683	A/G	cg26193484	chr3:186648175	ST6GAL1	0.89	9.21	0.39	1.15e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.04	0.35	7.84e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg14675211	chr2:100938903	LONRF2	0.63	10.95	0.45	5.5e-25	Intelligence (multi-trait analysis);
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs10979	0.964	rs9496683	chr6:143898845	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.04	-0.49	3.05e-29	Hypospadias;
LGG	cis	rs13082711	0.522	rs543882	chr3:27331854	T/C	cg02860705	chr3:27208620	NA	0.63	11.83	0.48	2.1e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs7737355	0.773	rs11242069	chr5:130598318	A/C	cg06307176	chr5:131281290	NA	-0.47	-7.85	-0.34	2.94e-14	Life satisfaction;
LGG	cis	rs11785400	1.000	rs4518642	chr8:143737396	T/C	cg10596483	chr8:143751796	JRK	0.58	9.51	0.4	1.03e-19	Schizophrenia;
LGG	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg24675658	chr1:53192096	ZYG11B	0.66	13.77	0.54	2.04e-36	Monocyte count;
LGG	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg03929089	chr4:120376271	NA	-1.0	-22.22	-0.72	5.74e-75	Height;
LGG	cis	rs2084898	0.891	rs477361	chr11:120000873	T/G	cg13907859	chr11:120009124	TRIM29	-0.88	-12.57	-0.5	2.23e-31	Stroke (pediatric);
LGG	cis	rs4253772	0.591	rs6008362	chr22:46652737	G/A	cg24881330	chr22:46731750	TRMU	0.7	8.76	0.38	3.75e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs36051895	0.664	rs62543877	chr9:5093465	C/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.09	-0.57	3.86e-42	Pediatric autoimmune diseases;
LGG	trans	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg26043149	chr18:55253948	FECH	-0.5	-8.1	-0.35	5.05e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg09307838	chr4:120376055	NA	0.71	11.78	0.48	3.39e-28	Corneal astigmatism;
LGG	cis	rs3206736	0.548	rs328942	chr7:35051815	G/A	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.63e-19	Diastolic blood pressure;
LGG	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg25019033	chr10:957182	NA	-0.55	-10.12	-0.43	7.21e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs2302729	0.578	rs10774052	chr12:2772171	C/T	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.52	-0.5	3.67e-31	Sleep quality;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg05313129	chr8:58192883	C8orf71	-0.79	-12.25	-0.49	4.26e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	trans	rs2018683	0.624	rs1006521	chr7:28996220	G/A	cg19402173	chr7:128379420	CALU	-0.72	-12.95	-0.52	6.06e-33	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2120243	0.539	rs6441127	chr3:157095507	T/C	cg24825693	chr3:157122686	VEPH1	-0.57	-12.94	-0.52	6.44e-33	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7301826	0.651	rs7968675	chr12:131303377	C/T	cg11011512	chr12:131303247	STX2	0.41	8.81	0.38	2.51e-17	Plasma plasminogen activator levels;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg06925179	chr17:43578568	NA	0.31	8.21	0.36	2.2e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs60180747	0.909	rs41277720	chr15:66773975	G/A	cg07575407	chr15:66541975	MEGF11	0.38	7.15	0.32	3.4e-12	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg02725872	chr8:58115012	NA	-0.76	-10.85	-0.45	1.37e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2172802	0.629	rs62304005	chr4:62494219	C/T	cg04118610	chr4:62707027	LPHN3	0.62	11.06	0.46	2.11e-25	Partial epilepsies;
LGG	cis	rs721399	0.924	rs1115784	chr8:18255410	C/T	cg18736775	chr8:18248649	NAT2	0.49	8.54	0.37	1.9e-16	Blood metabolite levels;
LGG	cis	rs77972916	0.536	rs11694173	chr2:43590899	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.55	7.62	0.33	1.48e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	cis	rs4727443	0.899	rs886453	chr7:99588225	G/A	cg12813108	chr7:99719912	CNPY4	-0.47	-8.87	-0.38	1.59e-17	Interstitial lung disease;
LGG	cis	rs10155981	0.510	rs4719705	chr7:22592707	C/T	cg05062323	chr7:22590069	NA	-0.86	-10.86	-0.45	1.27e-24	Bilirubin levels;
LGG	cis	rs4684776	1.000	rs11712059	chr3:11448670	C/T	cg24705426	chr3:11550659	ATG7	-0.43	-7.6	-0.33	1.68e-13	Small vessel stroke;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg04287289	chr16:89883240	FANCA	0.74	7.23	0.32	1.99e-12	Skin colour saturation;
LGG	cis	rs8032158	0.963	rs11071231	chr15:56159118	A/C	cg02198044	chr15:56286336	NEDD4	-0.68	-11.78	-0.48	3.27e-28	Keloid;
LGG	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs709400	0.663	rs72708893	chr14:103929535	G/A	cg26031613	chr14:104095156	KLC1	0.8	13.85	0.54	9.57e-37	Body mass index;
LGG	cis	rs3206736	0.548	rs328939	chr7:35050227	C/T	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.12e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-9.35	-0.4	3.61e-19	Personality dimensions;
LGG	cis	rs9486719	0.857	rs9285393	chr6:97020917	C/A	cg18709589	chr6:96969512	KIAA0776	-0.44	-7.13	-0.31	3.96e-12	Migraine;Coronary artery disease;
LGG	cis	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	11.76	0.48	4.08e-28	Mood instability;
LGG	cis	rs2836974	0.563	rs997147	chr21:40695325	A/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.39	-0.36	5.91e-16	Cognitive function;
LGG	cis	rs11792861	0.926	rs72607169	chr9:111832471	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.56e-19	Menarche (age at onset);
LGG	trans	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg17712092	chr4:129076599	LARP1B	0.73	13.37	0.53	1.03e-34	Eosinophil percentage of white cells;
LGG	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2e-19	Diabetic retinopathy;
LGG	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg06766960	chr11:133703094	NA	-0.58	-11.39	-0.47	1.13e-26	Childhood ear infection;
LGG	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	trans	rs6076960	0.652	rs6085441	chr20:6211383	A/G	cg24759859	chr6:86352639	SYNCRIP	0.44	7.46	0.33	4.39e-13	Smooth-surface caries;
LGG	cis	rs994014	0.572	rs6535244	chr4:82290018	G/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.67	-0.3	7.18e-11	Height;
LGG	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-21.82	-0.71	3.92e-73	Vitiligo;
LGG	cis	rs262150	1.000	rs262150	chr7:158777934	G/A	cg19418458	chr7:158789849	NA	-0.48	-9.5	-0.4	1.18e-19	Facial morphology (factor 20);
LGG	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.51	0.4	1.01e-19	Schizophrenia;
LGG	cis	rs68170813	0.559	rs2395881	chr7:107074323	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19671926	chr4:122722719	EXOSC9	0.46	7.12	0.31	4.2e-12	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs2797160	1.000	rs2747719	chr6:126009214	C/T	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg00166722	chr3:10149974	C3orf24	-0.51	-8.85	-0.38	1.89e-17	Alzheimer's disease;
LGG	cis	rs4132509	0.744	rs12124113	chr1:243904366	A/G	cg25706552	chr1:244017396	NA	0.51	7.17	0.32	2.97e-12	RR interval (heart rate);
LGG	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg05234568	chr11:5960015	NA	-0.64	-10.93	-0.45	6.79e-25	DNA methylation (variation);
LGG	cis	rs12474201	0.928	rs1109380	chr2:46924490	G/T	cg06386533	chr2:46925753	SOCS5	0.78	14.64	0.56	3.75e-40	Height;
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs400736	0.930	rs225100	chr1:8066914	C/T	cg25007680	chr1:8021821	PARK7	-0.44	-8.16	-0.35	3.25e-15	Response to antidepressants and depression;
LGG	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg08807101	chr21:30365312	RNF160	-0.84	-17.07	-0.62	4.91e-51	Dental caries;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg04267008	chr7:1944627	MAD1L1	0.55	9.3	0.4	5.62e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9547996	0.917	rs7321585	chr13:38263176	G/C	cg17979426	chr13:38220150	TRPC4	-0.42	-8.14	-0.35	3.65e-15	Diastolic blood pressure;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg11050988	chr7:1952600	MAD1L1	0.3	7.26	0.32	1.65e-12	Schizophrenia;
LGG	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.01	-0.39	5.46e-18	Response to antipsychotic treatment;
LGG	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg06917634	chr15:78832804	PSMA4	-0.65	-12.1	-0.49	1.82e-29	Sudden cardiac arrest;
LGG	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg18245976	chr7:158708271	WDR60	0.62	8.41	0.36	5.07e-16	Height;
LGG	cis	rs7481584	1.000	rs12786344	chr11:3021392	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.32	-0.36	1.02e-15	Calcium levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13276752	chr17:57970287	TUBD1;RPS6KB1	-0.48	-6.88	-0.3	1.96e-11	Systemic lupus erythematosus;
LGG	cis	rs10911363	0.509	rs10911339	chr1:183442097	C/T	cg09173681	chr1:183549694	NCF2	0.38	8.53	0.37	2.07e-16	Systemic lupus erythematosus;
LGG	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.67	-0.37	7.25e-17	Initial pursuit acceleration;
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.76	-0.3	4.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg18129748	chr3:49941408	MST1R	0.22	6.89	0.31	1.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.962	rs1039341	chr16:48574869	C/T	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs526231	0.543	rs34787	chr5:102458903	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs8067287	0.762	rs11650981	chr17:16824038	A/G	cg26910001	chr17:16838321	NA	-0.48	-8.91	-0.38	1.19e-17	Diabetic kidney disease;
LGG	cis	rs2798269	0.690	rs2185884	chr13:22148433	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.43	-7.57	-0.33	2.02e-13	PR segment;
LGG	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg27661571	chr11:113659931	NA	-0.57	-8.28	-0.36	1.37e-15	Hip circumference adjusted for BMI;
LGG	cis	rs4704187	0.687	rs6858969	chr5:74379281	T/C	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	cis	rs751728	1.000	rs11752297	chr6:33735154	G/C	cg25922239	chr6:33757077	LEMD2	0.68	11.69	0.48	7.44e-28	Crohn's disease;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg09359103	chr1:154839909	KCNN3	-0.54	-11.21	-0.46	5.63e-26	Prostate cancer;
LGG	cis	rs13424612	0.930	rs6748327	chr2:240902511	G/A	cg01812947	chr2:240904978	NDUFA10	0.43	7.23	0.32	2.02e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs11018874	0.709	rs10765241	chr11:89849316	T/C	cg14505434	chr11:89522851	NA	0.67	8.45	0.37	3.7e-16	White blood cell types;
LGG	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg20573242	chr4:122745356	CCNA2	0.41	7.43	0.33	5.22e-13	Type 2 diabetes;
LGG	cis	rs6032067	0.714	rs6513969	chr20:43878475	A/G	cg10761708	chr20:43804764	PI3	0.58	9.01	0.39	5.5e-18	Blood protein levels;
LGG	cis	rs9486719	1.000	rs12205655	chr6:96891733	T/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg18393722	chr15:85113863	UBE2QP1	-0.43	-6.87	-0.3	2.05e-11	Schizophrenia;
LGG	cis	rs7945705	0.967	rs10840148	chr11:8923528	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.2	0.32	2.42e-12	Hemoglobin concentration;
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7226408	0.600	rs322639	chr18:34591719	C/T	cg15022739	chr18:34823045	BRUNOL4	0.43	9.31	0.4	5.15e-19	Obesity-related traits;
LGG	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg03788504	chr6:150331562	NA	-0.6	-13.75	-0.54	2.56e-36	Alopecia areata;
LGG	trans	rs9693857	0.520	rs13267391	chr8:9356714	C/T	cg21775007	chr8:11205619	TDH	0.46	6.7	0.3	5.89e-11	Systolic blood pressure;
LGG	cis	rs17776563	0.593	rs7162568	chr15:89151850	G/T	cg05013243	chr15:89149849	MIR1179	-0.33	-6.73	-0.3	5.03e-11	Thyroid hormone levels;
LGG	cis	rs7617480	0.648	rs7653408	chr3:48972351	A/C	cg07636037	chr3:49044803	WDR6	0.91	16.8	0.62	8.81e-50	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4819052	0.851	rs2838864	chr21:46711474	A/T	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.55	-9.13	-0.39	2.07e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg18876405	chr7:65276391	NA	0.62	11.37	0.47	1.43e-26	Aortic root size;
LGG	cis	rs9640161	0.789	rs1464751	chr7:150021282	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.76	-16.03	-0.6	2.45e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7647973	0.961	rs7626076	chr3:49298139	G/A	cg06212747	chr3:49208901	KLHDC8B	0.52	8.08	0.35	5.67e-15	Menarche (age at onset);
LGG	cis	rs283228	1.000	rs2787562	chr6:101778420	C/G	cg27451362	chr6:101846650	GRIK2	0.53	8.86	0.38	1.77e-17	Coenzyme Q10 levels;
LGG	cis	rs4740619	0.933	rs10738405	chr9:15704787	T/C	cg14451791	chr9:16040625	NA	-0.36	-9.25	-0.39	8.47e-19	Body mass index;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs3780378	0.875	rs4587378	chr9:5002011	C/T	cg02405213	chr9:5042618	JAK2	-0.44	-7.21	-0.32	2.33e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg15596359	chr8:11213517	TDH	0.36	7.22	0.32	2.17e-12	Neuroticism;
LGG	cis	rs8038465	0.622	rs17185294	chr15:73858415	C/T	cg15420318	chr15:73925796	NPTN	-0.51	-8.81	-0.38	2.6e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.46	-0.33	4.36e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg11764359	chr7:65958608	NA	0.63	9.71	0.41	2.06e-20	Aortic root size;
LGG	cis	rs79349575	0.783	rs4794003	chr17:47029904	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs7666738	0.791	rs1527516	chr4:98967937	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs225245	1.000	rs225245	chr17:33946107	A/G	cg19694781	chr19:47549865	TMEM160	-0.44	-7.49	-0.33	3.52e-13	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.56	0.37	1.68e-16	Obesity-related traits;
LGG	cis	rs11785693	0.862	rs62491196	chr8:4995690	C/T	cg26367366	chr8:4980734	NA	1.02	15.46	0.58	8.82e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18789337	chr6:114180353	MARCKS	0.45	6.99	0.31	9.47e-12	Gut microbiome composition (summer);
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg19006130	chr11:118478252	PHLDB1	-0.44	-7.77	-0.34	5.01e-14	Glioma;
LGG	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg03060546	chr3:49711283	APEH	-0.53	-7.07	-0.31	5.83e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11785693	0.862	rs62491168	chr8:4982290	A/T	cg26367366	chr8:4980734	NA	1.01	15.49	0.58	6.81e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg18479299	chr3:125709523	NA	-0.58	-7.39	-0.32	6.93e-13	Blood pressure (smoking interaction);
LGG	cis	rs10949834	1.000	rs3757587	chr7:73481028	C/T	cg07137043	chr7:73588983	EIF4H	-0.67	-7.38	-0.32	7.49e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg04455712	chr21:45112962	RRP1B	0.53	9.96	0.42	2.66e-21	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg16606324	chr3:10149918	C3orf24	0.58	7.76	0.34	5.44e-14	Alzheimer's disease;
LGG	cis	rs9886651	0.806	rs13280865	chr8:128781333	A/G	cg24514600	chr8:128805414	PVT1	-0.54	-11.9	-0.48	1.16e-28	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12519773	0.502	rs4613686	chr5:92498497	A/G	cg18783429	chr5:92414398	NA	0.32	7.89	0.34	2.22e-14	Migraine;
LGG	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.38	-0.32	7.47e-13	Alzheimer's disease (late onset);
LGG	cis	rs9443645	0.901	rs6937465	chr6:79570345	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.3e-17	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.965	rs4854762	chr3:133499063	A/G	cg12373951	chr3:133503437	NA	-0.38	-6.87	-0.3	2.04e-11	Iron status biomarkers;
LGG	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	7.96	0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg02725872	chr8:58115012	NA	-0.84	-12.15	-0.49	1.15e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs67133203	0.851	rs970098	chr12:51479404	G/C	cg14688905	chr12:51403056	SLC11A2	0.71	10.74	0.45	3.59e-24	Urinary tract infection frequency;
LGG	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg04000281	chr11:63949212	NA	-0.44	-8.3	-0.36	1.17e-15	Platelet count;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.38	0.36	6.39e-16	Platelet count;
LGG	cis	rs9300255	0.544	rs1727309	chr12:123658258	A/G	cg05973401	chr12:123451056	ABCB9	0.49	6.72	0.3	5.32e-11	Neutrophil percentage of white cells;
LGG	cis	rs472402	0.580	rs10060745	chr5:6658003	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.42	-6.71	-0.3	5.57e-11	Response to amphetamines;
LGG	cis	rs2439831	1.000	rs2467739	chr15:43740196	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.37	0.43	8.52e-23	Lung cancer in ever smokers;
LGG	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg05973401	chr12:123451056	ABCB9	0.5	8.03	0.35	8.03e-15	Neutrophil percentage of white cells;
LGG	trans	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg06521331	chr12:34319734	NA	-0.38	-6.77	-0.3	3.89e-11	Heart rate;
LGG	cis	rs741702	0.928	rs2974750	chr19:13044544	C/A	cg04657146	chr19:12876947	HOOK2	0.45	7.38	0.32	7.38e-13	Red blood cell traits;
LGG	cis	rs7551222	0.749	rs2887429	chr1:204565012	G/T	cg20240347	chr1:204465584	NA	-0.47	-9.17	-0.39	1.6e-18	Schizophrenia;
LGG	cis	rs9948	0.786	rs62156233	chr2:97434061	C/G	cg01990225	chr2:97406019	LMAN2L	-0.66	-7.41	-0.33	6.02e-13	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.3	-0.32	1.24e-12	HDL cholesterol;
LGG	cis	rs3087591	0.960	rs4559963	chr17:29438558	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.57	0.56	7.31e-40	Hip circumference;
LGG	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.41	0.33	5.94e-13	Joint mobility (Beighton score);
LGG	cis	rs1978968	0.707	rs13058527	chr22:18412929	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.56	-0.41	7.05e-20	Presence of antiphospholipid antibodies;
LGG	trans	rs11098499	0.865	rs4507344	chr4:120307485	C/A	cg25214090	chr10:38739885	LOC399744	0.7	12.49	0.5	4.81e-31	Corneal astigmatism;
LGG	cis	rs4704187	0.506	rs3935470	chr5:74352180	A/G	cg03227963	chr5:74354835	NA	0.32	7.22	0.32	2.13e-12	Response to amphetamines;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs9359856	0.636	rs9294440	chr6:90308666	C/G	cg13799429	chr6:90582589	CASP8AP2	0.6	7.99	0.35	1.12e-14	Bipolar disorder;
LGG	cis	rs1109114	0.816	rs2400826	chr5:148615479	A/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.63	-0.59	1.61e-44	Body mass index;
LGG	cis	rs4731207	0.596	rs7810654	chr7:124645089	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.8	-0.3	3.17e-11	Cutaneous malignant melanoma;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg04025307	chr7:1156635	C7orf50	0.54	10.0	0.42	1.94e-21	Longevity;Endometriosis;
LGG	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg08400814	chr5:56204995	C5orf35	-0.49	-7.8	-0.34	4.04e-14	Initial pursuit acceleration;
LGG	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg10760299	chr15:45669010	GATM	0.41	7.98	0.35	1.15e-14	Homoarginine levels;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.58	0.33	1.96e-13	Longevity;
LGG	trans	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg02002194	chr4:3960332	NA	0.41	7.2	0.32	2.44e-12	Mood instability;
LGG	cis	rs6784615	0.744	rs1035003	chr3:52504133	G/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs5762813	0.561	rs13058031	chr22:29273966	G/A	cg15103426	chr22:29168792	CCDC117	0.64	6.7	0.3	6.21e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.91	-0.35	1.9e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.4	-0.36	5.54e-16	Schizophrenia;
LGG	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-9.26	-0.4	7.76e-19	Lymphocyte counts;
LGG	cis	rs4696584	0.816	rs72731016	chr4:155410731	G/C	cg04517429	chr4:155413618	DCHS2	-0.33	-7.47	-0.33	4e-13	Folding of antihelix;
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg07234876	chr8:600039	NA	1.31	12.01	0.49	4.22e-29	IgG glycosylation;
LGG	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs1997103	1.000	rs2009441	chr7:55405989	A/G	cg20935933	chr6:143382018	AIG1	0.56	8.74	0.38	4.24e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4700695	0.719	rs27085	chr5:65435063	C/T	cg21114390	chr5:65439923	SFRS12	0.71	10.46	0.44	4.02e-23	Facial morphology (factor 19);
LGG	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg20307385	chr11:47447363	PSMC3	0.44	7.06	0.31	6.14e-12	Migraine - clinic-based;
LGG	trans	rs10838798	0.584	rs1566732	chr11:48151494	A/C	cg15704280	chr7:45808275	SEPT13	0.43	6.75	0.3	4.57e-11	Height;
LGG	cis	rs283228	0.550	rs541637	chr6:101783232	T/C	cg27451362	chr6:101846650	GRIK2	0.99	15.09	0.57	4.03e-42	Coenzyme Q10 levels;
LGG	cis	rs6032067	0.929	rs17424578	chr20:43806321	A/G	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs9462027	0.628	rs2764207	chr6:34712998	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.2	-0.46	6.53e-26	Systemic lupus erythematosus;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14928532	chr9:133454630	LOC100272217;FUBP3	0.44	7.1	0.31	4.65e-12	Cognitive performance;
LGG	cis	rs10267417	0.603	rs10242620	chr7:19897885	G/T	cg05791153	chr7:19748676	TWISTNB	0.6	7.73	0.34	6.64e-14	Night sleep phenotypes;
LGG	cis	rs416603	0.967	rs11640138	chr16:11362729	A/G	cg00044050	chr16:11439710	C16orf75	0.55	9.2	0.39	1.21e-18	Type 1 diabetes;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg08999081	chr20:33150536	PIGU	0.34	8.44	0.37	4.05e-16	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg13699009	chr12:122356056	WDR66	0.58	15.73	0.59	5.88e-45	Mean corpuscular volume;
LGG	cis	rs7481584	0.624	rs2106229	chr11:3041195	G/A	cg25174290	chr11:3078921	CARS	-0.51	-9.14	-0.39	2.01e-18	Calcium levels;
LGG	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg14088196	chr11:70211408	PPFIA1	0.95	12.93	0.51	7.59e-33	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.78	-0.34	4.85e-14	Skin colour saturation;
LGG	cis	rs1707322	0.964	rs1707339	chr1:46513179	A/G	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	8.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg11062466	chr8:58055876	NA	0.43	7.6	0.33	1.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6694672	1.000	rs6703400	chr1:197078400	C/T	cg13682187	chr1:196946512	CFHR5	-0.51	-7.2	-0.32	2.52e-12	Asthma;
LGG	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1978968	1.000	rs5992928	chr22:18451438	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-12.71	-0.51	6.04e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs7814319	0.833	rs13249716	chr8:97228412	G/T	cg20787634	chr8:97240163	UQCRB	-0.72	-15.62	-0.59	1.83e-44	Lung function (FVC);
LGG	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.47	0.58	8.36e-44	Coronary artery disease;
LGG	trans	rs57046232	0.552	rs6133307	chr20:6333298	C/T	cg21095983	chr6:86352623	SYNCRIP	0.42	6.99	0.31	9.85e-12	Colorectal cancer;
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg26656751	chr17:43910226	CRHR1	-0.43	-7.82	-0.34	3.68e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg01270228	chr10:1369114	ADARB2	0.55	9.55	0.41	7.6e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs2839186	0.587	rs35679325	chr21:47640980	A/G	cg12379764	chr21:47803548	PCNT	0.47	7.89	0.34	2.21e-14	Testicular germ cell tumor;
LGG	cis	rs2816062	0.786	rs2745320	chr1:18893592	G/A	cg18795169	chr1:18902165	NA	-1.06	-34.07	-0.85	3.16e-128	Urate levels in lean individuals;
LGG	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg09021430	chr5:549028	NA	-0.68	-9.57	-0.41	6.3e-20	Obesity-related traits;
LGG	cis	rs6993813	0.872	rs1905784	chr8:120014623	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.84	0.3	2.57e-11	Bone mineral density (hip);
LGG	cis	rs34783982	0.510	rs12901851	chr15:89530367	T/G	cg09489435	chr15:89561491	NA	-0.38	-7.23	-0.32	2.08e-12	Squamous cell lung carcinoma;
LGG	cis	rs61990749	0.597	rs1477260	chr14:78256818	G/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	7.11	0.31	4.57e-12	Fibroblast growth factor basic levels;
LGG	cis	rs11997175	0.549	rs4349945	chr8:33654323	T/C	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg12856521	chr11:46389249	DGKZ	0.41	7.04	0.31	7.04e-12	Leprosy;
LGG	cis	rs9398803	0.678	rs1844593	chr6:126897827	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.4	0.4	2.48e-19	Male-pattern baldness;
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg05793240	chr7:2802953	GNA12	0.3	7.53	0.33	2.68e-13	Height;
LGG	cis	rs4845570	1.000	rs3790514	chr1:151744168	T/C	cg07092448	chr1:151763213	TDRKH	-1.1	-18.22	-0.65	2.57e-56	Coronary artery disease;
LGG	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg16751781	chr15:78858589	CHRNA5	0.45	8.91	0.38	1.2e-17	Sudden cardiac arrest;
LGG	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.35	-0.4	3.64e-19	Response to antipsychotic treatment;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg07538946	chr5:131705188	SLC22A5	0.66	7.73	0.34	6.62e-14	Rheumatoid arthritis;
LGG	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg19168338	chr16:4465731	CORO7	-1.17	-27.39	-0.79	6.79e-99	Schizophrenia;
LGG	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg08999081	chr20:33150536	PIGU	-0.3	-6.88	-0.3	1.98e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg07157834	chr1:205819609	PM20D1	-0.42	-8.28	-0.36	1.36e-15	Menarche (age at onset);
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg11645453	chr3:52864694	ITIH4	0.4	6.66	0.3	7.74e-11	Bipolar disorder;
LGG	cis	rs6430585	0.702	rs2015532	chr2:136555525	G/T	cg07169764	chr2:136633963	MCM6	-1.26	-24.1	-0.75	9.44e-84	Corneal structure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13196826	chr10:98945664	SLIT1	0.43	6.91	0.31	1.66e-11	Cognitive performance;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12315590	chr3:128997497	C3orf37	0.36	6.68	0.3	6.91e-11	Cognitive performance;
LGG	cis	rs3824867	1.000	rs3824867	chr11:47468569	A/G	cg20307385	chr11:47447363	PSMC3	0.5	8.0	0.35	1.01e-14	Mean corpuscular hemoglobin;
LGG	trans	rs6601327	0.540	rs12542912	chr8:9585196	C/T	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6594499	0.872	rs7702774	chr5:110460851	G/T	cg04022379	chr5:110408740	TSLP	0.41	7.52	0.33	2.77e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6430585	0.536	rs3213892	chr2:136552517	G/A	cg07169764	chr2:136633963	MCM6	1.27	24.24	0.75	1.99e-84	Corneal structure;
LGG	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg17892150	chr10:133769511	PPP2R2D	0.67	13.61	0.53	1.02e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg10505658	chr17:80084571	CCDC57	0.41	8.18	0.36	2.69e-15	Life satisfaction;
LGG	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15128208	chr22:42549153	NA	-0.39	-7.69	-0.34	8.97e-14	Cognitive function;
LGG	cis	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg05491587	chr18:77659695	KCNG2	-0.53	-7.08	-0.31	5.26e-12	Opioid sensitivity;
LGG	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.66	0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs11150038	1.000	rs11150038	chr16:78076559	A/G	cg04733911	chr16:78082701	NA	-0.79	-8.06	-0.35	6.57e-15	Colorectal or endometrial cancer;
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.39e-12	Aortic root size;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.43	-7.75	-0.34	5.82e-14	Schizophrenia;
LGG	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg13207630	chr7:32358064	NA	0.81	7.5	0.33	3.29e-13	Body mass index;
LGG	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.47	-0.4	1.48e-19	Body mass index;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10053473	chr17:62856997	LRRC37A3	0.89	14.02	0.55	1.81e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13395090	1.000	rs11687349	chr2:3717496	A/C	cg15327641	chr2:3715039	ALLC	0.36	8.08	0.35	5.81e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4771450	0.962	rs4772540	chr13:103970941	G/T	cg02987523	chr13:103978230	NA	-0.32	-6.85	-0.3	2.33e-11	Uric acid levels;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.22	-0.32	2.19e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.31	0.43	1.42e-22	Prudent dietary pattern;
LGG	cis	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg16876255	chr19:9731953	ZNF561	0.76	7.13	0.31	3.92e-12	Pursuit maintenance gain;
LGG	cis	rs11153147	0.649	rs11153145	chr6:109300799	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.52	-0.37	2.21e-16	Mean corpuscular volume;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.67	-0.34	9.92e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg15105969	chr2:36825350	FEZ2	-0.55	-8.96	-0.38	8.12e-18	Height;
LGG	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-15.82	-0.59	2.28e-45	Platelet count;
LGG	trans	rs3780486	0.846	rs3780487	chr9:33139237	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	25.26	0.76	4.01e-89	IgG glycosylation;
LGG	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg12163867	chr12:51592794	POU6F1	-0.45	-9.82	-0.42	8.08e-21	Cisplatin-induced ototoxicity;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg09033563	chr22:24373618	LOC391322	-0.47	-7.8	-0.34	4.18e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg20887711	chr4:1340912	KIAA1530	0.59	11.65	0.48	1.07e-27	Longevity;
LGG	cis	rs1153858	1.000	rs7402650	chr15:45701895	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	1.01e-25	Homoarginine levels;
LGG	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg18196295	chr10:418757	DIP2C	0.53	10.08	0.42	1.01e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08280861	chr8:58055591	NA	0.59	7.62	0.33	1.45e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2764208	0.599	rs9368828	chr6:34661449	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.54	10.99	0.45	3.95e-25	Systemic lupus erythematosus;
LGG	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	cis	rs8078723	0.510	rs11655264	chr17:38138995	G/C	cg17467752	chr17:38218738	THRA	-0.55	-9.64	-0.41	3.7799999999999997e-20	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.93e-21	Aortic root size;
LGG	trans	rs7395662	1.000	rs8189391	chr11:48859789	A/G	cg15704280	chr7:45808275	SEPT13	0.54	8.77	0.38	3.37e-17	HDL cholesterol;
LGG	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	cg07928641	chr1:182991847	LAMC1	0.44	8.78	0.38	3.26e-17	Fuchs's corneal dystrophy;
LGG	cis	rs2644899	0.750	rs2607414	chr19:41267129	C/T	cg24958765	chr19:41283667	RAB4B	0.49	7.64	0.33	1.24e-13	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg02023728	chr11:77925099	USP35	0.44	7.77	0.34	5.21e-14	Testicular germ cell tumor;
LGG	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg22072935	chr14:105399595	NA	-0.48	-9.18	-0.39	1.49e-18	Rheumatoid arthritis;
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.44	4.43e-23	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-12.82	-0.51	1.97e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs11239187	0.586	rs12243864	chr10:45081159	C/T	cg03916630	chr10:45065415	NA	0.36	8.86	0.38	1.75e-17	Body mass index;
LGG	trans	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.46	0.33	4.44e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg06421707	chr20:25228305	PYGB	0.54	11.8	0.48	2.91e-28	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9911578	0.933	rs2632508	chr17:56533235	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-9.81	-0.41	8.85e-21	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.23	-0.32	2.03e-12	Neuroticism;
LGG	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg02153584	chr22:29168773	CCDC117	0.58	8.01	0.35	9.3e-15	Lymphocyte counts;
LGG	cis	rs2735413	0.564	rs78898310	chr16:78115510	T/C	cg04733911	chr16:78082701	NA	0.58	8.02	0.35	8.61e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg17294928	chr15:75287854	SCAMP5	-0.83	-8.93	-0.38	9.72e-18	Lung cancer;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg00364696	chr7:1142433	C7orf50	-0.38	-7.21	-0.32	2.34e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.76	-15.26	-0.58	7.05e-43	Total body bone mineral density;
LGG	cis	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.87	0.38	1.55e-17	Mood instability;
LGG	cis	rs4302748	0.862	rs61003864	chr7:36189798	T/C	cg24442661	chr7:36192818	EEPD1	0.58	7.47	0.33	4.15e-13	Platelet count;
LGG	cis	rs7474896	0.559	rs1208779	chr10:38077729	A/C	cg25427524	chr10:38739819	LOC399744	-0.51	-7.43	-0.33	5.4e-13	Obesity (extreme);
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg02002194	chr4:3960332	NA	0.45	8.26	0.36	1.6e-15	Triglycerides;
LGG	cis	rs12580194	0.593	rs67934812	chr12:55785591	T/G	cg19537932	chr12:55886519	OR6C68	-0.56	-10.24	-0.43	2.52e-22	Cancer;
LGG	cis	rs755249	0.567	rs4660636	chr1:39770227	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs4474465	1.000	rs7934678	chr11:78192968	G/A	cg02023728	chr11:77925099	USP35	0.39	7.06	0.31	6.18e-12	Alzheimer's disease (survival time);
LGG	cis	rs896543	0.702	rs12692188	chr2:237495929	A/G	cg25295825	chr2:237489920	CXCR7	0.89	13.77	0.54	2.06e-36	Alcohol dependence (age at onset);
LGG	cis	rs8077059	0.959	rs8074377	chr17:55810287	T/G	cg12582317	chr17:55822272	NA	0.39	6.73	0.3	5.09e-11	Sex hormone-binding globulin levels;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg03188948	chr7:1209495	NA	0.64	8.28	0.36	1.3e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg20120463	chr17:44301886	NA	0.45	7.05	0.31	6.6e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.68	-0.34	9.66e-14	Height;
LGG	trans	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.46	7.96	0.35	1.33e-14	Mean corpuscular volume;
LGG	cis	rs6840360	0.593	rs7654294	chr4:152690975	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg11266682	chr4:10021025	SLC2A9	0.49	9.23	0.39	9.96e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.72	17.98	0.64	3.12e-55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12618769	0.597	rs1587835	chr2:99041269	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.69	0.37	6.44e-17	Bipolar disorder;
LGG	cis	rs4481887	0.504	rs6587432	chr1:248355130	C/T	cg00666640	chr1:248458726	OR2T12	0.45	6.66	0.3	7.94e-11	Common traits (Other);
LGG	trans	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg25214090	chr10:38739885	LOC399744	-0.56	-10.06	-0.42	1.14e-21	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.87	0.3	2.07e-11	Lung cancer;
LGG	cis	rs2018055	0.618	rs13205753	chr6:117791585	A/G	cg14611402	chr6:117803162	DCBLD1	0.3	8.78	0.38	3.2e-17	Diastolic blood pressure;
LGG	cis	rs7000551	0.653	rs4872504	chr8:22326717	A/G	cg12081754	chr8:22256438	SLC39A14	0.69	13.35	0.53	1.26e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.97	-0.38	7.17e-18	Vitiligo;
LGG	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg01244601	chr4:120671846	NA	-0.39	-7.58	-0.33	1.89e-13	Corneal astigmatism;
LGG	cis	rs2693698	0.620	rs11160504	chr14:99683246	T/C	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.71e-28	Schizophrenia;
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg26656751	chr17:43910226	CRHR1	-0.4	-7.45	-0.33	4.46e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04529582	chr20:30697510	TM9SF4	0.4	7.25	0.32	1.76e-12	Obesity-related traits;
LGG	cis	rs11025559	0.643	rs11025570	chr11:20481109	T/A	cg19653624	chr11:20408972	PRMT3	-0.47	-7.0	-0.31	9.18e-12	Pursuit maintenance gain;
LGG	cis	rs7444	0.941	rs4821124	chr22:21979289	T/C	cg15846791	chr22:21984385	YDJC	-0.47	-6.9	-0.31	1.68e-11	Systemic lupus erythematosus;
LGG	cis	rs921968	0.541	rs17572485	chr2:219296545	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.37	0.32	7.72e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2371030	0.659	rs7586579	chr2:211569839	A/T	cg18417063	chr2:211583084	NA	0.53	8.32	0.36	1.03e-15	Non-small cell lung cancer;
LGG	cis	rs11785693	0.862	rs6994323	chr8:4996786	T/A	cg26367366	chr8:4980734	NA	1.03	15.6	0.59	2.18e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs11585357	0.947	rs11585118	chr1:17605774	C/A	cg08277548	chr1:17600880	PADI3	-0.78	-9.1	-0.39	2.76e-18	Hair shape;
LGG	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg02297831	chr4:17616191	MED28	0.49	9.31	0.4	5.01e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg12419862	chr22:24373484	LOC391322	-0.77	-13.51	-0.53	2.81e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.38	-0.43	7.64e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs11605924	0.934	rs7945689	chr11:45879006	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.5	-8.35	-0.36	7.7e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.56e-21	Prudent dietary pattern;
LGG	cis	rs9522267	1.000	rs9522267	chr13:112196367	C/T	cg14952266	chr13:112191215	NA	0.38	7.12	0.31	4.14e-12	Hepatitis;
LGG	cis	rs208520	0.874	rs208469	chr6:66915891	T/C	cg07460842	chr6:66804631	NA	-0.92	-16.06	-0.6	1.84e-46	Exhaled nitric oxide output;
LGG	cis	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.79	-0.3	3.55e-11	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg16301924	chr13:53314226	LECT1	-0.48	-9.96	-0.42	2.6e-21	Lewy body disease;
LGG	trans	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg25214090	chr10:38739885	LOC399744	0.68	11.98	0.49	5.31e-29	Corneal astigmatism;
LGG	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg03806693	chr22:41940476	POLR3H	-1.16	-21.39	-0.71	4.07e-71	Vitiligo;
LGG	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg27147174	chr7:100797783	AP1S1	-0.7	-12.93	-0.52	7.35e-33	Life satisfaction;
LGG	cis	rs2602381	0.599	rs6707947	chr2:234597915	T/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.38	-6.72	-0.3	5.47e-11	Attention deficit hyperactivity disorder;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg06232512	chr2:240612347	NA	0.38	6.98	0.31	1.02e-11	Body fat percentage;
LGG	cis	rs28374715	0.617	rs16971735	chr15:41563970	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.81	-14.12	-0.55	6.71e-38	Ulcerative colitis;
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg22535103	chr8:58192502	C8orf71	-0.74	-9.3	-0.4	5.47e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-6.98	-0.31	1.03e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2905347	0.895	rs2961281	chr7:22640292	T/G	cg18045685	chr7:22629474	NA	-0.73	-15.85	-0.59	1.63e-45	Major depression and alcohol dependence;
LGG	cis	rs11605275	1.000	rs74809393	chr11:20031520	C/A	cg14835545	chr11:20032148	NAV2	-0.97	-11.41	-0.47	9.88e-27	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6665290	0.839	rs6699400	chr1:227190497	A/G	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg07549998	chr6:150325970	RAET1K	-0.39	-7.5	-0.33	3.37e-13	Alopecia areata;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs1538970	0.816	rs12029322	chr1:45970446	C/T	cg05343316	chr1:45956843	TESK2	0.75	13.0	0.52	3.73e-33	Platelet count;
LGG	cis	rs28785552	0.589	rs7257371	chr19:53243910	A/G	cg10871876	chr19:53194124	ZNF83	0.75	14.5	0.56	1.52e-39	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs112591243	0.685	rs4819263	chr21:47950866	G/A	cg10657630	chr21:48055338	PRMT2	0.88	7.38	0.32	7.4e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs2070488	1.000	rs7433707	chr3:38443180	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.38	0.63	1.83e-52	Electrocardiographic conduction measures;
LGG	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.12	-0.31	4.13e-12	Personality dimensions;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg19168338	chr16:4465731	CORO7	-0.88	-16.78	-0.61	1.06e-49	Schizophrenia;
LGG	cis	rs10991814	1.000	rs77233736	chr9:93994201	T/G	cg14446406	chr9:93919335	NA	-0.78	-8.78	-0.38	3.29e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg26354017	chr1:205819088	PM20D1	0.59	11.59	0.47	1.84e-27	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.71	-0.38	5.39e-17	Menopause (age at onset);
LGG	cis	rs6430585	0.528	rs614193	chr2:136653925	A/T	cg07169764	chr2:136633963	MCM6	1.17	20.58	0.69	2.66e-67	Corneal structure;
LGG	cis	rs4481887	0.741	rs11488135	chr1:248568961	G/A	cg13385794	chr1:248469461	NA	0.43	7.33	0.32	1.06e-12	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00143700	chr13:49107116	RCBTB2	0.44	7.68	0.34	9.24e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs7122539	0.607	rs7103627	chr11:66648083	A/G	cg01599099	chr11:66649832	PC	0.47	9.35	0.4	3.63e-19	HIV-1 susceptibility;
LGG	cis	rs611744	0.647	rs864166	chr8:109249300	C/G	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg14835575	chr10:16859367	RSU1	0.43	7.9	0.34	1.99e-14	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs3617	0.625	rs6769789	chr3:52874446	C/T	cg11645453	chr3:52864694	ITIH4	-0.44	-7.43	-0.33	5.23e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.565	rs13030999	chr2:42237410	T/C	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs17227506	0.679	rs67768235	chr8:13443286	T/C	cg03566418	chr8:13424080	C8orf48	0.63	10.0	0.42	1.97e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4774899	0.932	rs2290938	chr15:57524857	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.17e-12	Urinary tract infection frequency;
LGG	cis	rs564799	0.966	rs547875	chr3:159732300	G/C	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs9354308	0.678	rs2000383	chr6:66597419	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.9e-11	Metabolite levels;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg11494091	chr17:61959527	GH2	1.02	25.59	0.77	1.15e-90	Prudent dietary pattern;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.79	-0.48	2.98e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.23	-0.46	4.95e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg20608306	chr11:116969690	SIK3	0.35	9.09	0.39	2.84e-18	Blood protein levels;
LGG	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg22852734	chr6:133119734	C6orf192	0.98	10.08	0.42	9.53e-22	Type 2 diabetes nephropathy;
LGG	cis	rs11605924	1.000	rs1401419	chr11:45879739	T/C	ch.11.939596F	chr11:45881766	CRY2	-0.5	-8.35	-0.36	7.7e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11245990	chr11:68621969	NA	-0.43	-9.0	-0.39	5.95e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08645402	chr16:4508243	NA	0.49	8.86	0.38	1.72e-17	Schizophrenia;
LGG	cis	rs2865126	0.818	rs2865130	chr18:10763813	C/A	cg21165219	chr18:10698044	FAM38B	-0.44	-7.22	-0.32	2.18e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs2273669	0.667	rs75942063	chr6:109352545	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg12395012	chr8:11607386	GATA4	-0.42	-7.47	-0.33	4.06e-13	Monocyte count;
LGG	cis	rs875971	0.964	rs6945019	chr7:65922458	C/G	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.2e-42	Aortic root size;
LGG	cis	rs7614311	0.681	rs6809100	chr3:63901180	A/G	cg22134162	chr3:63841271	THOC7	-0.46	-8.12	-0.35	4.14e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs11229555	0.874	rs11229512	chr11:58286105	T/C	cg15696309	chr11:58395628	NA	-0.99	-17.37	-0.63	2.12e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs75059851	0.756	rs73036081	chr11:133840156	C/T	cg17703048	chr11:133852993	NA	-0.87	-16.03	-0.6	2.6e-46	Schizophrenia;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg17470184	chr11:118478236	PHLDB1	0.42	7.65	0.34	1.14e-13	Cholesterol, total;
LGG	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg13647721	chr17:30228624	UTP6	0.79	12.54	0.5	2.82e-31	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg11494091	chr17:61959527	GH2	1.0	22.42	0.72	6.31e-76	Prudent dietary pattern;
LGG	cis	rs7646881	0.812	rs61387735	chr3:158456161	G/A	cg19483011	chr3:158453295	NA	-0.6	-8.02	-0.35	8.79e-15	Tetralogy of Fallot;
LGG	cis	rs2243480	1.000	rs464895	chr7:65527106	A/G	cg12463550	chr7:65579703	CRCP	0.79	8.23	0.36	1.94e-15	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.82	0.34	3.7e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7617773	0.817	rs11928691	chr3:48286765	C/T	cg11946769	chr3:48343235	NME6	0.62	10.35	0.43	1.03e-22	Coronary artery disease;
LGG	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.69	-0.3	6.31e-11	Joint mobility (Beighton score);
LGG	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.47	0.53	4.02e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs258892	0.895	rs34252662	chr5:72054308	G/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04268390	chr16:56485608	OGFOD1;NUDT21	0.39	6.69	0.3	6.6e-11	Bilirubin levels;
LGG	cis	rs7267979	1.000	rs11100	chr20:25281184	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs6828577	0.560	rs114938210	chr4:119457257	A/T	cg26518628	chr1:97050305	NA	-0.54	-8.69	-0.37	6.08e-17	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.36	6.77	0.3	4.02e-11	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.41	0.36	4.98e-16	Lung cancer;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07157834	chr1:205819609	PM20D1	0.72	16.54	0.61	1.32e-48	Menarche (age at onset);
LGG	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.59e-25	Aortic root size;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs295140	0.546	rs295137	chr2:201150040	C/T	cg23649088	chr2:200775458	C2orf69	0.4	6.81	0.3	3.02e-11	QT interval;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.61	0.33	1.55e-13	Schizophrenia;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.22e-11	Menopause (age at onset);
LGG	cis	rs367943	0.698	rs2115207	chr5:112998285	C/T	cg12552261	chr5:112820674	MCC	0.56	9.97	0.42	2.5e-21	Type 2 diabetes;
LGG	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg16586182	chr3:47516702	SCAP	-0.78	-15.62	-0.59	1.77e-44	Colorectal cancer;
LGG	cis	rs28374715	0.662	rs11852419	chr15:41456374	A/T	cg18705301	chr15:41695430	NDUFAF1	0.94	16.33	0.6	1.08e-47	Ulcerative colitis;
LGG	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg02725872	chr8:58115012	NA	-0.74	-10.31	-0.43	1.4e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs17221829	0.733	rs1844199	chr11:89376368	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg06558623	chr16:89946397	TCF25	1.17	13.36	0.53	1.14e-34	Skin colour saturation;
LGG	cis	rs2320614	0.679	rs10857352	chr4:164101482	A/G	cg15586945	chr4:164088095	NAF1	-0.49	-8.58	-0.37	1.49e-16	Lung adenocarcinoma;
LGG	cis	rs72781680	1.000	rs75046532	chr2:24167267	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	trans	rs11875185	0.588	rs79574385	chr18:55640407	A/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs459571	0.920	rs460154	chr9:136909309	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	10.3	0.43	1.5e-22	Platelet distribution width;
LGG	cis	rs7444	0.825	rs131664	chr22:21920403	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg16414030	chr3:133502952	NA	-0.51	-8.25	-0.36	1.62e-15	Iron status biomarkers;
LGG	cis	rs7267979	1.000	rs761025	chr20:25426968	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.14	0.43	6.11e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs71403859	0.803	rs17282500	chr16:71633653	C/A	cg08717414	chr16:71523259	ZNF19	-1.13	-14.5	-0.56	1.53e-39	Post bronchodilator FEV1;
LGG	cis	rs7937612	0.543	rs10790379	chr11:120221652	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.37	-8.47	-0.37	3.22e-16	Intraocular pressure;
LGG	cis	rs490234	0.783	rs13284243	chr9:128381785	A/G	cg14078157	chr9:128172775	NA	-0.48	-8.91	-0.38	1.18e-17	Mean arterial pressure;
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.68	0.41	2.59e-20	Monocyte count;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg15394860	chr11:2017084	H19	0.63	13.85	0.54	9.25e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg07882059	chr11:68924751	NA	0.41	7.36	0.32	8.69e-13	Blond vs. brown hair color;
LGG	cis	rs929354	0.772	rs2051876	chr7:157009037	A/G	cg17757837	chr7:157058334	UBE3C	-0.76	-15.23	-0.58	9.29e-43	Body mass index;
LGG	cis	rs2046867	0.862	rs7648954	chr3:72838756	C/A	cg26655873	chr3:72818019	SHQ1	0.37	7.49	0.33	3.56e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg21724239	chr8:58056113	NA	0.42	6.65	0.3	8.03e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs888194	0.738	rs1075467	chr12:109986935	C/T	cg19025524	chr12:109796872	NA	-0.36	-7.11	-0.31	4.36e-12	Neuroticism;
LGG	cis	rs9487094	0.744	rs13192476	chr6:109725154	G/A	cg01125227	chr6:109776195	MICAL1	0.53	9.0	0.39	6.03e-18	Height;
LGG	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg06191203	chr2:152266755	RIF1	-0.41	-7.21	-0.32	2.35e-12	Squamous cell lung carcinoma;
LGG	cis	rs6963495	0.818	rs73192141	chr7:105201129	T/G	cg19920283	chr7:105172520	RINT1	0.64	8.22	0.36	2.13e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs34467563	0.804	rs6994544	chr8:97368972	T/C	cg22138393	chr8:97340270	PTDSS1	0.3	6.65	0.3	8.39e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs4595586	0.525	rs35089392	chr12:39414547	T/G	cg26384229	chr12:38710491	ALG10B	0.69	12.69	0.51	7.25e-32	Morning vs. evening chronotype;
LGG	cis	rs56161922	1.000	rs74692669	chr1:207818120	G/C	cg09557387	chr1:207818395	CR1L	1.0	9.54	0.41	8.03e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg27165867	chr14:105738592	BRF1	-0.45	-7.4	-0.33	6.55e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs138249	1.000	rs138244	chr22:50565367	C/T	cg07310406	chr22:50524374	MLC1	0.45	9.05	0.39	3.92e-18	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs2415984	0.600	rs2084823	chr14:46966454	C/G	cg14871534	chr14:47121158	RPL10L	0.58	10.22	0.43	2.98e-22	Number of children ever born;
LGG	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg23933602	chr10:16859644	RSU1	0.65	9.63	0.41	3.9e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg24829409	chr8:58192753	C8orf71	-0.84	-13.15	-0.52	8.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs919433	0.889	rs788001	chr2:198213720	C/T	cg00792783	chr2:198669748	PLCL1	0.44	6.99	0.31	9.71e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg09307838	chr4:120376055	NA	0.79	13.29	0.53	2.17e-34	Corneal astigmatism;
LGG	cis	rs56161922	0.908	rs55952744	chr1:207860158	C/G	cg09557387	chr1:207818395	CR1L	0.94	9.47	0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg24623649	chr8:11872141	NA	-0.29	-6.96	-0.31	1.2e-11	Systolic blood pressure;
LGG	cis	rs8028182	0.636	rs11637586	chr15:75791112	G/C	cg20655648	chr15:75932815	IMP3	0.47	7.79	0.34	4.31e-14	Sudden cardiac arrest;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg24829409	chr8:58192753	C8orf71	-0.83	-12.75	-0.51	4.12e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.66	-0.3	7.7e-11	Neuroticism;
LGG	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg00717180	chr2:96193071	NA	0.41	7.28	0.32	1.47e-12	HDL cholesterol;
LGG	cis	rs7747724	0.692	rs7772390	chr6:20769995	C/G	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Bladder cancer;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg10580341	chr11:889148	CHID1	-0.38	-6.98	-0.31	1.04e-11	Mean platelet volume;
LGG	cis	rs6772849	0.804	rs4857920	chr3:128407623	C/T	cg08795948	chr3:128337044	NA	0.63	9.89	0.42	4.65e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs300774	1.000	rs300781	chr2:110385	G/A	cg04617936	chr2:214353	NA	-0.49	-7.25	-0.32	1.8e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg05234568	chr11:5960015	NA	0.66	11.53	0.47	3.3e-27	DNA methylation (variation);
LGG	cis	rs9326248	0.581	rs7120963	chr11:116830261	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-10.49	-0.44	3.09e-23	Blood protein levels;
LGG	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg25809561	chr17:30822961	MYO1D	0.37	8.79	0.38	2.86e-17	Schizophrenia;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg15971980	chr6:150254442	NA	0.46	8.54	0.37	1.92e-16	Lung cancer;
LGG	trans	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg22232500	chr2:134024266	NCKAP5	0.62	8.43	0.36	4.51e-16	Bipolar disorder;
LGG	cis	rs8133932	0.654	rs420386	chr21:47364816	G/A	cg11214348	chr21:47283868	PCBP3	-0.42	-7.39	-0.32	7.15e-13	Schizophrenia;
LGG	cis	rs62400317	0.859	rs11964844	chr6:45258823	T/A	cg18551225	chr6:44695536	NA	-0.62	-10.27	-0.43	2.03e-22	Total body bone mineral density;
LGG	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	9.57	0.41	6.25e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs736801	0.808	rs6866614	chr5:131787137	A/G	cg21138405	chr5:131827807	IRF1	0.29	6.93	0.31	1.45e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs61931739	0.534	rs2625897	chr12:34064295	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.99	-0.49	4.97e-29	Morning vs. evening chronotype;
LGG	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg16077055	chr2:106428750	NCK2	0.32	8.27	0.36	1.43e-15	Addiction;
LGG	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg08885076	chr2:99613938	TSGA10	-0.33	-6.92	-0.31	1.52e-11	Fear of minor pain;
LGG	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.99	0.39	6.1e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg00198680	chr16:28758506	NA	0.28	6.93	0.31	1.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg10760299	chr15:45669010	GATM	0.4	7.47	0.33	4.09e-13	Homoarginine levels;
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.04	0.35	7.44e-15	Personality dimensions;
LGG	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.93	0.71	1.21e-73	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs7781557	0.938	rs73192015	chr7:102511732	C/T	cg18108683	chr7:102477205	FBXL13	-0.49	-7.75	-0.34	5.8e-14	Colorectal adenoma (advanced);
LGG	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg00405596	chr8:11794950	NA	0.64	11.37	0.47	1.43e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg13010199	chr12:38710504	ALG10B	0.57	11.06	0.46	2.17e-25	Morning vs. evening chronotype;
LGG	cis	rs3206736	0.664	rs3909150	chr7:35117736	T/A	cg13400248	chr7:35225412	NA	0.39	7.19	0.32	2.61e-12	Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25072359	chr17:41440525	NA	0.53	9.97	0.42	2.38e-21	Menopause (age at onset);
LGG	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg25143771	chr10:104629124	AS3MT	0.4	6.73	0.3	5.05e-11	Arsenic metabolism;
LGG	cis	rs7633857	0.537	rs9813700	chr3:160683279	G/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.66	-0.37	7.89e-17	Educational attainment (years of education);
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg13206674	chr6:150067644	NUP43	0.67	15.58	0.59	2.62e-44	Lung cancer;
LGG	cis	rs13053817	0.904	rs13053624	chr22:29838203	A/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.66	-0.3	7.93e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg26116260	chr4:7069785	GRPEL1	-0.86	-8.87	-0.38	1.61e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg04287289	chr16:89883240	FANCA	0.53	9.62	0.41	4.17e-20	Vitiligo;
LGG	cis	rs283228	0.583	rs697441	chr6:101735466	G/A	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	12.76	0.51	3.51e-32	Tonsillectomy;
LGG	cis	rs72781680	0.821	rs113014365	chr2:24159903	C/T	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.68e-17	Lymphocyte counts;
LGG	trans	rs568617	0.533	rs679147	chr11:65644363	A/G	cg17712092	chr4:129076599	LARP1B	-0.49	-8.02	-0.35	8.46e-15	Crohn's disease;
LGG	trans	rs783540	1.000	rs783540	chr15:83254708	C/T	cg18393722	chr15:85113863	UBE2QP1	0.4	6.68	0.3	6.85e-11	Schizophrenia;
LGG	cis	rs35740288	0.706	rs2614664	chr15:86298716	G/A	cg04173714	chr15:86211321	AKAP13	0.41	7.75	0.34	5.9e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg24917645	chr20:3801318	C20orf29	-0.39	-6.67	-0.3	7.47e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs2540226	0.539	rs6707177	chr2:39918915	A/G	cg18968196	chr2:39892502	TMEM178	0.3	8.29	0.36	1.23e-15	Personality dimensions;
LGG	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg17809284	chr5:56205270	C5orf35	-0.67	-10.79	-0.45	2.39e-24	Type 2 diabetes;
LGG	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs13064447	0.870	rs7631468	chr3:12754997	A/G	cg23032965	chr3:12705835	RAF1	0.51	7.68	0.34	9.68e-14	Major depression and alcohol dependence;
LGG	cis	rs774359	0.789	rs9969707	chr9:27491104	A/G	cg14173147	chr9:27528300	MOBKL2B	0.49	8.96	0.38	8.16e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.42e-22	Iron status biomarkers;
LGG	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.1	-0.43	8.04e-22	Morning vs. evening chronotype;
LGG	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg01028140	chr2:1542097	TPO	-0.55	-8.28	-0.36	1.35e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6752107	1.000	rs13391356	chr2:234170369	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	8.0	0.35	1.04e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7546668	1.000	rs10803394	chr1:15909480	G/C	cg21858823	chr1:15850916	CASP9	0.37	6.86	0.3	2.21e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs701145	0.878	rs355753	chr3:153968846	T/C	cg17054900	chr3:154042577	DHX36	0.97	11.98	0.49	5.54e-29	Coronary artery disease;
LGG	cis	rs4959677	0.901	rs10458143	chr6:2479086	C/A	cg20147862	chr6:2634573	C6orf195	-0.41	-8.88	-0.38	1.47e-17	Orthostatic hypotension;
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg12708336	chr17:41446283	NA	-0.29	-6.74	-0.3	4.63e-11	Menopause (age at onset);
LGG	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg01631408	chr1:248437212	OR2T33	0.38	6.95	0.31	1.23e-11	Common traits (Other);
LGG	cis	rs7020830	0.830	rs13296413	chr9:37258105	C/T	cg14294708	chr9:37120828	ZCCHC7	1.14	31.56	0.83	1.81e-117	Schizophrenia;
LGG	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	12.72	0.51	5.29e-32	Cognitive test performance;
LGG	cis	rs950169	0.810	rs62029594	chr15:84955252	T/C	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	trans	rs6601327	0.573	rs13278824	chr8:9646119	T/A	cg16141378	chr3:129829833	LOC729375	-0.34	-8.06	-0.35	6.41e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.93	-0.31	1.38e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2018055	0.700	rs13205723	chr6:117798847	A/G	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg00343986	chr7:65444356	GUSB	0.42	7.22	0.32	2.12e-12	Aortic root size;
LGG	cis	rs367943	0.901	rs463167	chr5:112799369	C/A	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	cis	rs910316	1.000	rs175492	chr14:75545220	A/C	cg06637938	chr14:75390232	RPS6KL1	0.6	11.44	0.47	7.5e-27	Height;
LGG	cis	rs7638909	0.512	rs6793245	chr3:38599037	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.47	7.93	0.35	1.67e-14	Electrocardiographic conduction measures;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg13628971	chr7:2884303	GNA12	0.34	7.03	0.31	7.44e-12	Height;
LGG	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.62	0.44	9.9899999999999993e-24	Arsenic metabolism;
LGG	cis	rs760805	1.000	rs61774728	chr1:25258867	G/C	cg03961551	chr1:25251730	RUNX3	0.47	12.11	0.49	1.69e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3862030	0.503	rs6584506	chr10:104254428	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs9397585	0.626	rs6932847	chr6:153448307	G/A	cg12989544	chr6:153429875	RGS17	0.31	7.11	0.31	4.32e-12	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09857708	chr16:66586376	CKLF	0.45	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	cis	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg03511173	chr18:77590860	NA	0.43	7.22	0.32	2.2e-12	Schizophrenia;
LGG	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.46	0.37	3.53e-16	Neuroticism;
LGG	cis	rs2273669	0.915	rs6908104	chr6:109293973	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.29	-0.32	1.35e-12	Prostate cancer;
LGG	cis	rs1620921	0.774	rs783156	chr6:161231177	T/C	cg01280913	chr6:161186852	NA	-0.34	-7.08	-0.31	5.5e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2820315	1.000	rs8024	chr1:201845575	C/A	cg10061532	chr1:201886748	LMOD1	0.33	6.88	0.3	1.91e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs921968	0.678	rs2230115	chr2:219509618	C/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.2	-0.32	2.42e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg14259594	chr22:18958660	DGCR5	-0.56	-9.67	-0.41	2.89e-20	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg12458913	chr13:53173898	NA	0.63	12.33	0.5	2.11e-30	Lewy body disease;
LGG	cis	rs4356932	0.967	rs6816898	chr4:76969057	C/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.67	-0.3	7.33e-11	Blood protein levels;
LGG	cis	rs12915845	0.545	rs12911061	chr15:89066635	T/A	cg05013243	chr15:89149849	MIR1179	0.35	7.22	0.32	2.19e-12	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-9.83	-0.42	7.95e-21	Lung cancer;
LGG	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.79	0.3	3.52e-11	Monocyte count;
LGG	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg08999081	chr20:33150536	PIGU	0.3	6.74	0.3	4.75e-11	Coronary artery disease;
LGG	cis	rs1843834	0.858	rs12105685	chr2:225513164	A/G	cg22455342	chr2:225449267	CUL3	0.62	10.44	0.44	4.88e-23	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6840360	0.642	rs11726254	chr4:152438850	G/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.41	0.33	6.07e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.71	0.48	6.12e-28	Mood instability;
LGG	cis	rs2066819	1.000	rs111885088	chr12:56657216	A/C	cg26714650	chr12:56694279	CS	-1.58	-16.22	-0.6	3.61e-47	Psoriasis vulgaris;
LGG	trans	rs7746199	0.736	rs13212318	chr6:27688841	A/C	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs8032158	0.963	rs56333939	chr15:56124535	T/C	cg02198044	chr15:56286336	NEDD4	-0.68	-11.84	-0.48	1.96e-28	Keloid;
LGG	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg07061783	chr6:25882402	NA	0.38	6.74	0.3	4.59e-11	Blood metabolite levels;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg23939001	chr4:940644	TMEM175	0.67	14.71	0.56	1.75e-40	Sjögren's syndrome;
LGG	cis	rs6088580	0.619	rs1205335	chr20:32927507	C/T	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.42	-0.36	4.7e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg21226059	chr5:178986404	RUFY1	0.51	9.27	0.4	7.07e-19	Lung cancer;
LGG	cis	rs1878931	0.507	rs4429296	chr16:3408277	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-10.6	-0.44	1.24e-23	Body mass index (adult);
LGG	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.84	0.54	1.03e-36	Colorectal cancer;
LGG	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06481639	chr22:41940642	POLR3H	-0.54	-7.88	-0.34	2.32e-14	Vitiligo;
LGG	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.3	-7.75	-0.34	5.83e-14	IgG glycosylation;
LGG	cis	rs8028182	0.636	rs4462560	chr15:75647964	G/C	cg20655648	chr15:75932815	IMP3	-0.46	-7.57	-0.33	2.08e-13	Sudden cardiac arrest;
LGG	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.1	-0.35	5.09e-15	Aortic root size;
LGG	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg16141378	chr3:129829833	LOC729375	0.37	7.92	0.35	1.77e-14	Retinal vascular caliber;
LGG	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-9.94	-0.42	3.25e-21	Diabetic retinopathy;
LGG	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg04025307	chr7:1156635	C7orf50	0.46	8.18	0.36	2.79e-15	Longevity;Endometriosis;
LGG	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.95	0.31	1.25e-11	Resting heart rate;
LGG	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs7264396	0.790	rs6060518	chr20:34217309	A/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.4e-12	Total cholesterol levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14778311	chr13:93880842	GPC6	0.38	6.76	0.3	4.15e-11	Obesity-related traits;
LGG	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg17644776	chr2:200775616	C2orf69	-0.6	-7.01	-0.31	8.46e-12	Schizophrenia;
LGG	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg15145174	chr5:6755386	POLS	-0.4	-7.62	-0.33	1.44e-13	Menopause (age at onset);
LGG	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg10167378	chr1:228756711	NA	-0.51	-8.67	-0.37	7.27e-17	Chronic lymphocytic leukemia;
LGG	cis	rs4808199	0.947	rs2163804	chr19:19575965	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.66	0.34	1.13e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.45	-8.53	-0.37	2.02e-16	Personality dimensions;
LGG	trans	rs75804782	0.625	rs13382619	chr2:239467636	G/A	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25264554	chr3:142166789	XRN1	-0.4	-6.76	-0.3	4.14e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg06138931	chr13:21896616	NA	0.46	10.09	0.42	8.98e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg20607798	chr8:58055168	NA	0.69	7.75	0.34	5.79e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs757278	0.513	rs10276533	chr7:117241859	T/C	cg10524701	chr7:117356490	CTTNBP2	0.43	7.39	0.32	6.88e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.61e-81	Hip circumference adjusted for BMI;
LGG	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.66	-0.3	7.99e-11	HDL cholesterol;
LGG	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.67	-0.48	8.85e-28	Mean platelet volume;
LGG	cis	rs295140	0.605	rs10931893	chr2:201114652	A/G	cg17644776	chr2:200775616	C2orf69	-0.47	-7.84	-0.34	3.07e-14	QT interval;
LGG	cis	rs76419734	0.510	rs3943980	chr4:106676766	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.54	-7.28	-0.32	1.42e-12	Post bronchodilator FEV1;
LGG	trans	rs9650657	0.631	rs1124010	chr8:10595502	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.44	-0.33	5.04e-13	Neuroticism;
LGG	cis	rs7715806	0.500	rs72633983	chr5:75002845	C/T	cg19683494	chr5:74908142	NA	0.5	6.65	0.3	8.04e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6754459	0.694	rs4404281	chr2:3706055	C/T	cg20493526	chr2:3714936	ALLC	0.34	6.88	0.3	2e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2635047	0.811	rs9965170	chr18:44788274	C/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-6.99	-0.31	9.51e-12	Educational attainment;
LGG	cis	rs523522	0.962	rs509445	chr12:121017243	A/C	cg27279351	chr12:120934652	DYNLL1	0.8	13.06	0.52	2.11e-33	High light scatter reticulocyte count;
LGG	cis	rs11608355	0.618	rs11066368	chr12:109790342	C/T	cg19025524	chr12:109796872	NA	-0.61	-13.55	-0.53	1.8e-35	Neuroticism;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19524238	chr7:2802976	GNA12	-0.4	-9.05	-0.39	3.93e-18	Height;
LGG	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.53	-8.84	-0.38	1.94e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg02640540	chr1:67518911	SLC35D1	0.39	6.7	0.3	6e-11	Lymphocyte percentage of white cells;
LGG	cis	rs709400	0.659	rs7160366	chr14:103944137	C/T	cg26031613	chr14:104095156	KLC1	0.77	13.52	0.53	2.46e-35	Body mass index;
LGG	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg16339924	chr4:17578868	LAP3	0.58	10.1	0.43	7.94e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.12	-0.31	4.09e-12	Neuroticism;
LGG	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg23690444	chr14:81902736	NA	0.65	10.18	0.43	4.19e-22	Prudent dietary pattern;
LGG	cis	rs1010254	0.559	rs72808307	chr5:151728607	G/A	cg12297329	chr5:152029980	NA	-0.47	-6.79	-0.3	3.36e-11	Optic nerve measurement (cup area);
LGG	cis	rs2734839	0.537	rs1554929	chr11:113278764	C/T	cg14159747	chr11:113255604	NA	0.29	8.08	0.35	5.64e-15	Information processing speed;
LGG	cis	rs7166081	1.000	rs3743349	chr15:67652097	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.23	-0.32	2.02e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1018836	0.564	rs7821994	chr8:91700916	C/T	cg16814680	chr8:91681699	NA	-1.12	-28.48	-0.8	7.79e-104	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9560113	0.959	rs9555802	chr13:112179504	T/C	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.41	0.33	5.94e-13	Menopause (age at onset);
LGG	cis	rs17039065	0.920	rs6858617	chr4:109467008	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.11	0.31	4.5e-12	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.817	rs28594987	chr11:50045181	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	4.97e-87	Height;
LGG	trans	rs11976180	1.000	rs2961128	chr7:143763483	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.66	-0.37	8.2e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg07382826	chr16:28625726	SULT1A1	0.41	8.85	0.38	1.79e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	cis	rs2236293	1.000	rs2236293	chr9:35841783	G/A	cg12876594	chr9:35791798	NPR2	0.39	7.3	0.32	1.31e-12	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08733086	chr1:154947035	CKS1B;SHC1	0.42	6.79	0.3	3.46e-11	Cognitive performance;
LGG	trans	rs6787172	0.702	rs827096	chr3:157996457	A/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs514024	0.672	rs578997	chr9:130489189	C/T	cg13643465	chr9:130375613	STXBP1	0.59	11.3	0.46	2.65e-26	Eating disorders (purging via substances);
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.71	0.38	5.22e-17	Bipolar disorder;
LGG	cis	rs7226408	0.576	rs9304169	chr18:34557421	A/T	cg15022739	chr18:34823045	BRUNOL4	0.42	9.1	0.39	2.67e-18	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05745317	chr6:27441043	ZNF184	0.41	6.83	0.3	2.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg02297831	chr4:17616191	MED28	0.52	9.34	0.4	4.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg17376030	chr22:41985996	PMM1	0.68	10.74	0.45	3.41e-24	Vitiligo;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08677398	chr8:58056175	NA	0.57	9.14	0.39	1.95e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	6.2e-11	Height;
LGG	cis	rs4006360	0.646	rs6503602	chr17:39301175	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.05	-0.46	2.26e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs12949688	0.627	rs4793572	chr17:55834387	A/G	cg12582317	chr17:55822272	NA	0.46	10.61	0.44	1.06e-23	Schizophrenia;
LGG	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-11.41	-0.47	9.46e-27	Neuroticism;
LGG	cis	rs35123781	0.696	rs904612	chr5:139070952	G/A	cg21230503	chr5:139085173	NA	0.36	8.43	0.36	4.45e-16	Schizophrenia;
LGG	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs9460578	0.673	rs10946415	chr6:20881386	C/T	cg13405222	chr6:20811065	CDKAL1	0.67	11.9	0.48	1.13e-28	Breast cancer;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.32	-0.4	4.76e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs11064837	0.523	rs1978107	chr12:120101714	C/T	cg25937854	chr12:120150414	CIT	-0.67	-11.09	-0.46	1.67e-25	Schizophrenia;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.76	-0.3	4.05e-11	Menopause (age at onset);
LGG	cis	rs4604732	0.631	rs12036460	chr1:247626928	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11890956	chr21:40555474	PSMG1	0.98	14.55	0.56	9.47e-40	Cognitive function;
LGG	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg27297192	chr10:134578999	INPP5A	0.32	7.48	0.33	3.8e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2072732	0.768	rs12045368	chr1:2960192	A/G	cg08733933	chr1:2954429	NA	-0.47	-8.92	-0.38	1.07e-17	Plateletcrit;
LGG	cis	rs11920090	0.932	rs1996220	chr3:170722448	A/G	cg09710316	chr3:170744871	SLC2A2	0.61	8.61	0.37	1.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6546550	0.935	rs13017134	chr2:70090579	C/G	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.99	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	trans	rs1728785	1.000	rs1728773	chr16:68563644	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs6430585	0.583	rs4988201	chr2:136618507	A/G	cg07169764	chr2:136633963	MCM6	1.3	26.9	0.78	1.11e-96	Corneal structure;
LGG	cis	rs4959677	0.586	rs9501846	chr6:2477056	A/C	cg23817096	chr6:1620687	NA	-0.32	-7.64	-0.33	1.26e-13	Orthostatic hypotension;
LGG	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.9e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.720	rs1984197	chr1:152962915	C/G	cg13444842	chr1:152974279	SPRR3	-0.43	-9.0	-0.39	5.96e-18	Inflammatory skin disease;
LGG	cis	rs10791097	0.967	rs10750450	chr11:130719061	G/T	cg12179176	chr11:130786555	SNX19	0.75	14.29	0.55	1.24e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.73	0.3	5.18e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10832963	0.924	rs10832950	chr11:18635815	A/G	cg09201001	chr11:18656081	SPTY2D1	0.99	21.23	0.7	2.26e-70	Breast cancer;
LGG	cis	rs17767392	0.958	rs2332641	chr14:72044728	T/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.2	0.36	2.31e-15	Mitral valve prolapse;
LGG	cis	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.82	-0.3	2.9e-11	Joint mobility (Beighton score);
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg13939156	chr17:80058883	NA	0.47	9.22	0.39	1.08e-18	Life satisfaction;
LGG	cis	rs4481887	0.893	rs4297335	chr1:248473421	C/T	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs875971	0.545	rs801212	chr7:66015630	C/G	cg11764359	chr7:65958608	NA	-0.63	-9.81	-0.41	8.89e-21	Aortic root size;
LGG	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg05793240	chr7:2802953	GNA12	0.33	7.97	0.35	1.28e-14	Height;
LGG	cis	rs6912958	0.547	rs451089	chr6:88041859	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.09	0.52	1.53e-33	Monocyte percentage of white cells;
LGG	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg06636001	chr8:8085503	FLJ10661	0.58	11.06	0.46	2.21e-25	Mood instability;
LGG	cis	rs17767392	0.628	rs61989247	chr14:71720349	T/C	cg02058870	chr14:72053146	SIPA1L1	0.35	7.37	0.32	7.95e-13	Mitral valve prolapse;
LGG	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg21775007	chr8:11205619	TDH	-0.46	-7.45	-0.33	4.54e-13	Mood instability;
LGG	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg12458913	chr13:53173898	NA	0.88	20.7	0.69	7.21e-68	Lewy body disease;
LGG	cis	rs875971	0.660	rs3764903	chr7:66098482	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.75	-0.45	3.26e-24	Aortic root size;
LGG	cis	rs4919087	1.000	rs10786327	chr10:99071408	C/T	cg25902810	chr10:99078978	FRAT1	0.52	9.78	0.41	1.16e-20	Monocyte count;
LGG	cis	rs1670533	1.000	rs604597	chr4:1094151	G/A	cg27284194	chr4:1044797	NA	-0.54	-9.66	-0.41	3.19e-20	Recombination rate (females);
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs17767392	0.813	rs66645707	chr14:71985931	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.98	-0.39	7.01e-18	Mitral valve prolapse;
LGG	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg01411142	chr8:19674711	INTS10	0.48	7.45	0.33	4.72e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg12070911	chr6:150209640	RAET1E	0.28	6.99	0.31	9.65e-12	Lung cancer;
LGG	cis	rs28595532	0.920	rs116795224	chr4:119734570	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs2072732	0.861	rs12046233	chr1:2960608	A/G	cg08733933	chr1:2954429	NA	-0.46	-8.98	-0.38	7.08e-18	Plateletcrit;
LGG	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg00717180	chr2:96193071	NA	-0.49	-9.25	-0.39	8.52e-19	HDL cholesterol;
LGG	cis	rs911263	0.563	rs12883719	chr14:68810217	G/T	cg18825221	chr14:68749962	RAD51L1	0.37	8.19	0.36	2.59e-15	Primary biliary cholangitis;
LGG	trans	rs6601327	0.641	rs7014663	chr8:9587275	G/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.82	-0.34	3.65e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg12288994	chr5:1860383	NA	0.79	16.05	0.6	2.17e-46	Cardiovascular disease risk factors;
LGG	trans	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg22232500	chr2:134024266	NCKAP5	0.49	7.36	0.32	8.25e-13	Bipolar disorder;
LGG	cis	rs853679	0.517	rs9393896	chr6:28127703	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.7	-0.34	8.23e-14	Depression;
LGG	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.32	0.58	3.85e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg26818010	chr10:134567672	INPP5A	-0.69	-10.37	-0.43	8.28e-23	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9952991	0.527	rs2847259	chr18:12775821	A/C	cg23598886	chr18:12777645	NA	0.41	6.91	0.31	1.59e-11	Inflammatory skin disease;
LGG	trans	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg18335740	chr13:41363409	SLC25A15	0.84	19.97	0.68	1.93e-64	Lewy body disease;
LGG	cis	rs7727544	0.716	rs11955347	chr5:131567924	G/A	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.43	-0.33	5.17e-13	Blood metabolite levels;
LGG	cis	rs4740619	0.661	rs10810482	chr9:15931395	C/A	cg14451791	chr9:16040625	NA	-0.41	-10.22	-0.43	3.09e-22	Body mass index;
LGG	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg03103770	chr19:1753464	ONECUT3	-0.4	-6.84	-0.3	2.49e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg13010199	chr12:38710504	ALG10B	0.64	13.37	0.53	1.06e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11190604	1.000	rs10883513	chr10:102316964	A/G	cg07080220	chr10:102295463	HIF1AN	0.61	9.07	0.39	3.32e-18	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7255436	0.965	rs11668346	chr19:8450854	A/T	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.74	-0.3	4.8e-11	HDL cholesterol;
LGG	cis	rs4696584	0.877	rs10517594	chr4:155399442	C/G	cg04517429	chr4:155413618	DCHS2	0.32	6.96	0.31	1.16e-11	Folding of antihelix;
LGG	cis	rs1109114	0.816	rs2918266	chr5:148609728	C/T	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.58	-0.59	2.66e-44	Body mass index;
LGG	cis	rs113835537	0.597	rs4576	chr11:66331000	A/G	cg24851651	chr11:66362959	CCS	0.48	8.44	0.37	4.05e-16	Airway imaging phenotypes;
LGG	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg18876405	chr7:65276391	NA	0.55	9.85	0.42	6.77e-21	Aortic root size;
LGG	cis	rs4804815	1.000	rs4804815	chr19:7842669	C/G	cg00371453	chr19:7854482	CLEC4GP1	0.76	11.68	0.48	8.19e-28	Neutrophil count;
LGG	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	11.01	0.46	3.3e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs745821	0.598	rs73959977	chr18:48116645	T/A	cg18923635	chr18:48083994	NA	0.41	7.77	0.34	4.95e-14	Diastolic blood pressure;
LGG	cis	rs2708240	1.000	rs7806512	chr7:147574555	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	3.08e-11	QT interval (drug interaction);
LGG	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg03929089	chr4:120376271	NA	-0.5	-8.42	-0.36	4.91e-16	Height;
LGG	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.79	0.3	3.38e-11	Homoarginine levels;
LGG	cis	rs789852	0.681	rs789855	chr3:194329272	G/T	cg18000598	chr3:194342907	TMEM44	-0.76	-7.67	-0.34	9.92e-14	QT interval;
LGG	cis	rs3741151	1.000	rs79794992	chr11:73049352	A/G	cg17517138	chr11:73019481	ARHGEF17	1.07	10.72	0.45	4.34e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4862307	0.836	rs4507404	chr4:185003767	C/T	cg06737308	chr4:185021514	ENPP6	-0.39	-6.82	-0.3	2.8e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7017914	0.967	rs17760497	chr8:71617045	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs977987	0.843	rs4887820	chr16:75397287	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs861020	0.630	rs628445	chr1:210004953	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.42e-20	Orofacial clefts;
LGG	cis	rs4774899	0.966	rs12906566	chr15:57514874	A/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.1	-0.31	4.71e-12	Urinary tract infection frequency;
LGG	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg11038491	chr20:34638489	LOC647979	-0.59	-7.52	-0.33	2.93e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.62	-0.48	1.44e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.57	0.33	2.09e-13	Lung cancer;
LGG	cis	rs739401	0.572	rs7111857	chr11:3068106	A/G	cg08508325	chr11:3079039	CARS	0.6	13.24	0.52	3.72e-34	Longevity;
LGG	cis	rs4713118	0.513	rs149950	chr6:28033039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.9	-0.31	1.69e-11	Parkinson's disease;
LGG	cis	rs116095464	0.558	rs62346508	chr5:203668	T/C	cg22496380	chr5:211416	CCDC127	-1.35	-18.68	-0.66	1.84e-58	Breast cancer;
LGG	cis	rs300703	0.719	rs437853	chr2:196973	C/T	cg21211680	chr2:198530	NA	-1.28	-22.72	-0.73	2.51e-77	Blood protein levels;
LGG	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg18854424	chr1:2615690	NA	-0.36	-7.26	-0.32	1.66e-12	Ulcerative colitis;
LGG	cis	rs78456975	0.506	rs13402886	chr2:1575348	G/A	cg26248373	chr2:1572462	NA	-0.85	-14.85	-0.57	4.62e-41	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg07440826	chr16:89882328	FANCA	-0.26	-6.84	-0.3	2.5e-11	Vitiligo;
LGG	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg04226714	chr8:49833948	SNAI2	-0.46	-8.09	-0.35	5.15e-15	Life satisfaction;
LGG	cis	rs5762813	0.562	rs13053879	chr22:29259102	T/A	cg15103426	chr22:29168792	CCDC117	0.67	7.01	0.31	8.49e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg15948088	chr11:109293068	C11orf87	0.51	8.93	0.38	1e-17	Schizophrenia;
LGG	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.63	0.41	3.9e-20	Hypertriglyceridemia;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg04287289	chr16:89883240	FANCA	0.9	8.75	0.38	4.1e-17	Skin colour saturation;
LGG	cis	rs2952156	0.920	rs1018246	chr17:37835240	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.83e-16	Asthma;
LGG	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg05585630	chr7:157510462	PTPRN2	-0.66	-13.93	-0.54	4.45e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	13.04	0.52	2.5e-33	Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.76	0.3	4.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs727505	0.954	rs7789055	chr7:124677543	G/T	cg23710748	chr7:124431027	NA	-0.5	-9.17	-0.39	1.55e-18	Lewy body disease;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg03709012	chr19:19516395	GATAD2A	0.81	15.78	0.59	3.44e-45	Tonsillectomy;
LGG	cis	rs1983891	0.706	rs9381084	chr6:41570350	C/T	cg20194872	chr6:41519635	FOXP4	0.48	8.44	0.37	4.1e-16	Prostate cancer;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.7	-0.34	8.15e-14	Total body bone mineral density;
LGG	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg24955955	chr5:415729	AHRR	0.82	10.84	0.45	1.46e-24	Fat distribution (HIV);
LGG	cis	rs7949566	0.557	rs4937126	chr11:126281897	C/T	cg05055844	chr11:126275997	ST3GAL4	0.38	7.68	0.34	9.7e-14	Platelet distribution width;Mean platelet volume;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23077509	chr3:142166793	XRN1	0.41	6.65	0.3	8.5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1355223	0.583	rs2915177	chr11:34880266	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.47	-0.33	4.13e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	12.53	0.5	3.12e-31	Lung cancer in ever smokers;
LGG	cis	rs9902453	0.845	rs7222842	chr17:28246943	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.58	0.53	1.41e-35	Coffee consumption (cups per day);
LGG	cis	rs6684428	1.000	rs55693755	chr1:56369906	T/A	cg11651538	chr1:56320950	NA	-0.74	-12.67	-0.51	8.85e-32	Airflow obstruction;
LGG	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg24375607	chr4:120327624	NA	0.68	11.19	0.46	7.14e-26	Corneal astigmatism;
LGG	cis	rs12681366	0.683	rs1379246	chr8:95373301	G/A	cg13257157	chr8:95487014	RAD54B	-0.37	-6.66	-0.3	7.89e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs735396	1.000	rs1169310	chr12:121439433	G/A	cg14101638	chr12:121416612	HNF1A	0.35	7.46	0.33	4.27e-13	N-glycan levels;
LGG	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.52	-0.33	2.93e-13	Myopia (pathological);
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg08742575	chr21:47604166	C21orf56	0.55	9.1	0.39	2.74e-18	Testicular germ cell tumor;
LGG	cis	rs986417	0.688	rs6573321	chr14:61101710	A/G	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.32e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04080417	chr5:1859792	NA	-0.54	-8.97	-0.38	7.37e-18	Cardiovascular disease risk factors;
LGG	cis	rs9815354	1.000	rs13325965	chr3:41914942	G/T	cg03022575	chr3:42003672	ULK4	0.71	8.92	0.38	1.07e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg07777115	chr5:623756	CEP72	-0.63	-8.25	-0.36	1.69e-15	Obesity-related traits;
LGG	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	8.29	0.36	1.25e-15	Colorectal cancer;
LGG	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg06827562	chr3:125932279	NA	0.58	13.53	0.53	2.28e-35	Metabolite levels;
LGG	cis	rs9487094	0.689	rs9487066	chr6:109668910	G/A	cg16315928	chr6:109776240	MICAL1	0.45	7.87	0.34	2.53e-14	Height;
LGG	cis	rs12540874	0.931	rs4245555	chr7:50661409	A/G	cg04490037	chr7:50633773	DDC	0.36	7.95	0.35	1.43e-14	Systemic sclerosis;
LGG	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg22834771	chr12:69754056	YEATS4	-0.51	-8.81	-0.38	2.46e-17	Cerebrospinal fluid biomarker levels;
LGG	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg21775007	chr8:11205619	TDH	0.45	7.12	0.31	4.27e-12	Acne (severe);
LGG	cis	rs7113874	0.569	rs11041995	chr11:8598233	A/G	cg23764900	chr11:8616102	STK33	-0.38	-6.68	-0.3	6.93e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs806794	1.000	rs806794	chr6:26200677	A/G	cg13736514	chr6:26305472	NA	-0.36	-6.86	-0.3	2.2e-11	Waist circumference;Hip circumference adjusted for BMI;Waist circumference adjusted for body mass index;Hip circumference;Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs9487094	0.626	rs4947016	chr6:110062098	A/T	cg01125227	chr6:109776195	MICAL1	0.42	7.36	0.32	8.2e-13	Height;
LGG	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg03098644	chr7:100410630	EPHB4	-0.42	-7.25	-0.32	1.79e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7394579	1	rs7394579	chr11:61581450	A/G	cg19610905	chr11:61596333	FADS2	-0.74	-11.64	-0.48	1.2100000000000001e-27	Red cell distribution width;Mean platelet volume;
LGG	trans	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg06521331	chr12:34319734	NA	-0.51	-8.95	-0.38	8.92e-18	Bladder cancer;
LGG	cis	rs2050392	0.624	rs303436	chr10:30731893	G/T	cg25182066	chr10:30743637	MAP3K8	-0.6	-12.59	-0.51	1.81e-31	Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg15971980	chr6:150254442	NA	0.46	8.56	0.37	1.67e-16	Lung cancer;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	trans	rs877282	0.945	rs11253388	chr10:787852	A/G	cg22713356	chr15:30763199	NA	0.57	8.64	0.37	8.93e-17	Uric acid levels;
LGG	trans	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.36	0.36	7.56e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg22903471	chr2:27725779	GCKR	-0.52	-11.44	-0.47	7.42e-27	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs12220238	0.915	rs11001003	chr10:76099944	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.95	0.38	8.34e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg00599393	chr8:22457479	C8orf58	-0.43	-8.04	-0.35	7.64e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs910187	0.605	rs8184673	chr20:45806262	C/T	cg27589058	chr20:45804311	EYA2	-0.37	-9.78	-0.41	1.21e-20	Migraine;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg04217658	chr3:142720292	SR140	-0.39	-6.66	-0.3	7.74e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg06766960	chr11:133703094	NA	-0.58	-11.43	-0.47	7.76e-27	Childhood ear infection;
LGG	cis	rs9875589	0.509	rs12330714	chr3:14040342	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.49	10.21	0.43	3.19e-22	Ovarian reserve;
LGG	cis	rs6732160	0.613	rs6546804	chr2:73385919	G/A	cg01422370	chr2:73384389	NA	0.57	9.9	0.42	4.37e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg02353165	chr6:42928485	GNMT	0.51	15.59	0.59	2.44e-44	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2070488	0.636	rs2284817	chr3:38510388	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	12.03	0.49	3.55e-29	Electrocardiographic conduction measures;
LGG	trans	rs79911532	0.515	rs115332207	chr7:75635405	G/A	cg19862616	chr7:65841803	NCRNA00174	0.76	7.8	0.34	4.04e-14	Mononucleosis;
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.26	0.69	7.94e-66	Alzheimer's disease;
LGG	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.95	-0.38	8.59e-18	Kawasaki disease;
LGG	cis	rs3820068	0.603	rs6696286	chr1:15968770	C/T	cg05660106	chr1:15850417	CASP9	0.81	16.58	0.61	8.04e-49	Systolic blood pressure;
LGG	cis	rs3768617	0.510	rs3768620	chr1:183092237	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.88	0.38	1.48e-17	Renal function-related traits (BUN);
LGG	trans	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg11441553	chr12:57614120	NXPH4	-0.63	-7.53	-0.33	2.73e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.62	0.37	1.04e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4478037	1.000	rs57477065	chr3:33162532	A/C	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	trans	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.9	-0.38	1.31e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs283228	0.550	rs555909	chr6:101770304	A/G	cg02011392	chr6:101847541	GRIK2	0.53	7.32	0.32	1.07e-12	Coenzyme Q10 levels;
LGG	cis	rs854765	0.647	rs854769	chr17:18019011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.7	-13.55	-0.53	1.77e-35	Total body bone mineral density;
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg21948465	chr5:131705150	SLC22A5	0.65	7.31	0.32	1.2e-12	Rheumatoid arthritis;
LGG	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.45	0.63	9.21e-53	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg00319359	chr11:70116639	PPFIA1	0.73	7.82	0.34	3.66e-14	Coronary artery disease;
LGG	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg15145296	chr3:125709740	NA	-0.59	-7.71	-0.34	7.57e-14	Blood pressure (smoking interaction);
LGG	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.87	-0.45	1.13e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.57	0.59	3.05e-44	Lung cancer;
LGG	cis	rs2070488	1.000	rs13072809	chr3:38468171	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	17.76	0.64	3.29e-54	Electrocardiographic conduction measures;
LGG	cis	rs283228	0.839	rs1843487	chr6:101838272	A/G	cg27451362	chr6:101846650	GRIK2	0.55	9.34	0.4	3.94e-19	Coenzyme Q10 levels;
LGG	cis	rs9875589	0.509	rs4685061	chr3:14043823	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.89	0.42	4.8e-21	Ovarian reserve;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02731540	chr11:31391568	DCDC1;DNAJC24	0.39	6.83	0.3	2.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9868809	0.881	rs13324142	chr3:48669447	C/T	cg00383909	chr3:49044727	WDR6	0.78	8.79	0.38	3.02e-17	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg23188684	chr11:67383651	NA	0.53	8.98	0.39	6.85e-18	Mean corpuscular volume;
LGG	cis	rs151997	0.925	rs27624	chr5:50167662	C/T	cg06027927	chr5:50259733	NA	0.68	11.08	0.46	1.75e-25	Callous-unemotional behaviour;
LGG	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.79	-0.45	2.32e-24	Height;
LGG	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg02002194	chr4:3960332	NA	-0.43	-7.92	-0.35	1.73e-14	Neuroticism;
LGG	cis	rs9389248	0.690	rs6569982	chr6:135256495	C/G	cg22676075	chr6:135203613	NA	0.46	8.23	0.36	1.96e-15	High light scatter reticulocyte percentage of red cells;
LGG	trans	rs13128441	0.598	rs1374623	chr4:5151792	G/C	cg26099876	chr8:141644609	EIF2C2	-0.54	-8.51	-0.37	2.47e-16	Celiac disease;
LGG	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg24623649	chr8:11872141	NA	0.3	7.19	0.32	2.63e-12	Monocyte count;
LGG	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg08807101	chr21:30365312	RNF160	-0.45	-7.47	-0.33	4.07e-13	Pancreatic cancer;
LGG	cis	rs2120243	0.791	rs7615621	chr3:157152600	A/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	7.05	0.31	6.64e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg04132472	chr17:19861366	AKAP10	0.26	7.16	0.32	3.27e-12	Schizophrenia;
LGG	cis	rs9479482	0.686	rs2184452	chr6:150384827	T/C	cg03788504	chr6:150331562	NA	-0.47	-10.03	-0.42	1.54e-21	Alopecia areata;
LGG	cis	rs7647973	1.000	rs62259933	chr3:49469703	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.5	-7.82	-0.34	3.6e-14	Menarche (age at onset);
LGG	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.73	-0.38	4.69e-17	Retinal vascular caliber;
LGG	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15644404	chr18:77186268	NFATC1	-0.82	-8.81	-0.38	2.49e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.04	0.55	1.45e-37	Obesity-related traits;
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg13699009	chr12:122356056	WDR66	0.56	14.88	0.57	3.33e-41	Mean corpuscular volume;
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-6.71	-0.3	5.71e-11	Vitiligo;
LGG	cis	rs11683229	1.000	rs11683229	chr2:63596836	A/G	cg02541582	chr2:64069798	UGP2	-0.45	-6.67	-0.3	7.36e-11	Protein quantitative trait loci;
LGG	cis	rs1003719	0.715	rs6517405	chr21:38560334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.14	-0.58	2.41e-42	Eye color traits;
LGG	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg10523679	chr1:76189770	ACADM	0.81	15.25	0.58	7.69e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg15017067	chr4:17643749	FAM184B	0.32	7.45	0.33	4.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg19399532	chr1:178512495	C1orf220	0.54	10.89	0.45	9.86e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs939658	0.683	rs8038464	chr15:79463036	A/T	cg17916960	chr15:79447300	NA	-0.54	-10.21	-0.43	3.23e-22	Refractive error;
LGG	cis	rs9733	0.621	rs6669122	chr1:150591732	A/G	cg13175981	chr1:150552382	MCL1	0.59	10.18	0.43	4.25e-22	Tonsillectomy;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.47	0.65	1.81e-57	Platelet count;
LGG	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg01244601	chr4:120671846	NA	0.37	7.03	0.31	7.55e-12	Corneal astigmatism;
LGG	cis	rs7635838	0.684	rs2606750	chr3:11372151	T/C	cg00170343	chr3:11313890	ATG7	0.5	8.75	0.38	4.08e-17	HDL cholesterol;
LGG	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg14346243	chr4:90757452	SNCA	-0.33	-6.67	-0.3	7.16e-11	Dementia with Lewy bodies;
LGG	cis	rs847577	0.677	rs4729403	chr7:97707841	G/C	cg13397024	chr7:97797637	LMTK2	0.41	7.29	0.32	1.39e-12	Breast cancer;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg04166393	chr7:2884313	GNA12	0.43	8.1	0.35	4.85e-15	Height;
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg18252515	chr7:66147081	NA	-0.4	-6.76	-0.3	4.18e-11	Aortic root size;
LGG	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg13072238	chr3:49761600	GMPPB	-0.55	-7.5	-0.33	3.31e-13	Menarche (age at onset);
LGG	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.05	0.39	4.1e-18	Eosinophil percentage of white cells;
LGG	cis	rs7633770	0.805	rs12330414	chr3:46662428	T/C	cg11219411	chr3:46661640	NA	0.64	15.88	0.59	1.25e-45	Coronary artery disease;
LGG	cis	rs11153147	0.730	rs2798646	chr6:109310596	C/A	cg05315195	chr6:109294784	ARMC2	0.64	8.02	0.35	8.58e-15	Mean corpuscular volume;
LGG	cis	rs4851254	0.920	rs11123808	chr2:100750750	A/C	cg17356467	chr2:100759845	AFF3	0.4	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2050392	0.517	rs302423	chr10:30772513	A/G	cg25182066	chr10:30743637	MAP3K8	-0.64	-12.84	-0.51	1.74e-32	Inflammatory bowel disease;
LGG	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg03806693	chr22:41940476	POLR3H	1.08	19.37	0.67	1.18e-61	Vitiligo;
LGG	cis	rs9462027	1.000	rs9689160	chr6:34749849	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-8.43	-0.36	4.36e-16	Systemic lupus erythematosus;
LGG	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg09754948	chr16:28834200	ATXN2L	0.45	6.78	0.3	3.76e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg27411982	chr8:10470053	RP1L1	-0.47	-8.03	-0.35	8.22e-15	Neuroticism;
LGG	cis	rs7605378	1.000	rs2577852	chr2:200687248	C/T	cg23649088	chr2:200775458	C2orf69	0.53	8.96	0.38	7.69e-18	Osteoporosis;
LGG	cis	rs36051895	0.664	rs7857081	chr9:5096728	G/A	cg02405213	chr9:5042618	JAK2	-0.84	-16.39	-0.61	5.89e-48	Pediatric autoimmune diseases;
LGG	cis	rs11920090	0.722	rs58649226	chr3:170671389	C/T	cg09710316	chr3:170744871	SLC2A2	0.66	7.69	0.34	8.73e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg23594656	chr7:65796392	TPST1	-0.36	-8.11	-0.35	4.71e-15	Aortic root size;
LGG	cis	rs7192750	0.586	rs7204708	chr16:71986946	C/T	cg06353428	chr16:71660113	MARVELD3	-0.69	-10.98	-0.45	4.54e-25	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs981844	0.712	rs6855082	chr4:154754039	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01442958	chr1:222817780	MIA3	0.52	8.37	0.36	6.91e-16	Gut microbiome composition (summer);
LGG	cis	rs2502399	0.898	rs774577	chr6:113509406	A/G	cg20413948	chr6:113544930	NA	0.3	6.95	0.31	1.22e-11	Plasma clusterin levels;
LGG	cis	rs7914558	1.000	rs4917994	chr10:104811699	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.69	0.44	5.43e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg11494091	chr17:61959527	GH2	0.5	7.96	0.35	1.36e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17641971	0.862	rs341829	chr8:50005758	T/C	cg00325661	chr8:49890786	NA	-0.47	-8.05	-0.35	7.15e-15	Blood metabolite levels;
LGG	cis	rs68170813	0.559	rs77727587	chr7:106815754	C/G	cg02696742	chr7:106810147	HBP1	-0.77	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	cis	rs739401	0.611	rs2071104	chr11:3036933	G/T	cg05729581	chr11:3078854	CARS	-0.54	-9.53	-0.41	8.54e-20	Longevity;
LGG	cis	rs2742540	0.524	rs2653562	chr11:8918160	A/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.56	-12.33	-0.5	2.04e-30	Hematocrit;
LGG	cis	rs7267979	1.000	rs2387884	chr20:25379069	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4713118	0.516	rs7739216	chr6:28079946	G/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs3735485	0.738	rs1195	chr7:45099450	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-8.67	-0.37	7.12e-17	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs16944613	0.636	rs6416552	chr15:91132111	T/C	cg26821196	chr15:91095069	CRTC3	0.55	8.44	0.37	4.05e-16	Colorectal cancer;
LGG	cis	rs6684428	1.000	rs10888948	chr1:56382722	G/A	cg11651538	chr1:56320950	NA	-0.76	-13.27	-0.52	2.87e-34	Airflow obstruction;
LGG	cis	rs6142618	0.562	rs4911546	chr20:30718333	A/G	cg00028034	chr20:30779307	TSPYL3	0.36	7.88	0.34	2.38e-14	Inflammatory bowel disease;
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg23302884	chr18:44338147	ST8SIA5	0.38	7.7	0.34	8.46e-14	Personality dimensions;
LGG	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg17644776	chr2:200775616	C2orf69	-0.57	-7.04	-0.31	7.14e-12	Schizophrenia;
LGG	cis	rs6752107	0.935	rs10929322	chr2:234149702	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.4	-7.03	-0.31	7.57e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg01069141	chr11:67398826	TBX10;NUDT8	-0.41	-8.16	-0.35	3.17e-15	Mean corpuscular volume;
LGG	cis	rs2274273	0.870	rs61210954	chr14:55765402	T/C	cg04306507	chr14:55594613	LGALS3	0.64	18.18	0.65	4.12e-56	Protein biomarker;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02018176	chr4:1364513	KIAA1530	0.65	16.04	0.6	2.25e-46	Longevity;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03506944	chr4:154074021	TRIM2	0.39	6.89	0.3	1.81e-11	Obesity-related traits;
LGG	cis	rs210138	1.000	rs210137	chr6:33542478	C/T	cg04201373	chr6:33551533	GGNBP1	0.35	6.89	0.3	1.85e-11	Testicular germ cell tumor;
LGG	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg00129232	chr17:37814104	STARD3	-0.66	-10.14	-0.43	5.92e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.02	-0.31	7.89e-12	Triglycerides;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.14	-0.35	3.62e-15	Personality dimensions;
LGG	cis	rs17125944	0.505	rs74620173	chr14:53194068	G/T	cg13660082	chr14:53194042	PSMC6	-0.58	-8.16	-0.35	3.12e-15	Alzheimer's disease (late onset);
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-7.01	-0.31	8.69e-12	Longevity;Endometriosis;
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg01262667	chr19:19385393	TM6SF2	-0.47	-11.77	-0.48	3.78e-28	Tonsillectomy;
LGG	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg02023728	chr11:77925099	USP35	0.4	7.09	0.31	5.16e-12	Alzheimer's disease (survival time);
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-7.67	-0.34	1.04e-13	Bipolar disorder;
LGG	cis	rs9291683	0.588	rs3796842	chr4:9995851	A/T	cg25986240	chr4:9926439	SLC2A9	-0.45	-9.52	-0.4	9.75e-20	Bone mineral density;
LGG	cis	rs6740322	0.895	rs10196095	chr2:43571885	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.59	-8.54	-0.37	1.98e-16	Coronary artery disease;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg02462569	chr6:150064036	NUP43	-0.37	-7.77	-0.34	5.22e-14	Lung cancer;
LGG	cis	rs35740288	0.770	rs56092539	chr15:86182512	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.04e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.44	-0.33	4.83e-13	Skin colour saturation;
LGG	cis	rs6500395	0.735	rs16946340	chr16:48667717	G/A	cg04672837	chr16:48644449	N4BP1	0.48	8.04	0.35	7.32e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	24.31	0.75	1.01e-84	Height;
LGG	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.72	0.38	5.18e-17	Coronary artery disease;
LGG	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.68	13.0	0.52	3.71e-33	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.4	-0.33	6.65e-13	Life satisfaction;
LGG	cis	rs6669919	0.553	rs12733443	chr1:211667751	C/T	cg10512769	chr1:211675356	NA	-0.93	-23.57	-0.74	2.75e-81	Intelligence (multi-trait analysis);
LGG	cis	rs6976053	0.846	rs4729616	chr7:100462565	G/T	cg03098644	chr7:100410630	EPHB4	-0.43	-7.74	-0.34	6.4e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.47	-7.66	-0.34	1.1e-13	Tonsillectomy;
LGG	cis	rs921968	0.643	rs4674319	chr2:219510320	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.32	-0.32	1.11e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs72925845	0.519	rs72907435	chr17:76425923	A/C	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg27490568	chr2:178487706	NA	0.86	15.24	0.58	8.88e-43	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6860806	0.507	rs270614	chr5:131640813	G/A	cg07395648	chr5:131743802	NA	-0.49	-9.9	-0.42	4.53e-21	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00871530	chr2:153573966	ARL6IP6;PRPF40A	0.48	6.9	0.31	1.73e-11	Gut microbiome composition (summer);
LGG	trans	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg23762105	chr12:34175262	ALG10	-0.34	-6.88	-0.3	1.97e-11	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg00579200	chr11:133705235	NA	-0.51	-9.78	-0.41	1.12e-20	Childhood ear infection;
LGG	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg25566285	chr7:158114605	PTPRN2	-0.96	-24.78	-0.76	6.73e-87	Calcium levels;
LGG	cis	rs4242434	0.854	rs13258100	chr8:22451116	A/T	cg19455335	chr8:22457658	C8orf58	-0.46	-9.12	-0.39	2.29e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.68e-123	Prudent dietary pattern;
LGG	cis	rs1784581	0.588	rs9295178	chr6:162419226	T/A	cg17173639	chr6:162384350	PARK2	0.64	13.4	0.53	7.82e-35	Itch intensity from mosquito bite;
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg14039246	chr1:53365446	ECHDC2	0.34	6.84	0.3	2.45e-11	Monocyte count;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg18032289	chr17:61959525	GH2	-0.4	-6.73	-0.3	5.09e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg05692746	chr2:100937584	LONRF2	-0.62	-11.24	-0.46	4.28e-26	Intelligence (multi-trait analysis);
LGG	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.18e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4774830	0.744	rs77377502	chr15:56307889	A/G	cg24530489	chr15:56299380	NA	-0.84	-7.52	-0.33	2.85e-13	Delta-5 desaturase activity;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg05165339	chr4:1420672	NA	-0.35	-8.63	-0.37	9.72e-17	Longevity;
LGG	cis	rs35123781	1.000	rs34510678	chr5:139064835	C/T	cg21230503	chr5:139085173	NA	0.32	7.59	0.33	1.75e-13	Schizophrenia;
LGG	cis	rs11150038	1.000	rs4888722	chr16:78063578	C/T	cg04733911	chr16:78082701	NA	-0.66	-8.98	-0.39	6.66e-18	Colorectal or endometrial cancer;
LGG	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	cis	rs8056893	0.550	rs1127773	chr16:68332747	G/A	cg07273125	chr16:68295692	NA	0.44	9.94	0.42	3.04e-21	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs9880211	1.000	rs17200216	chr3:136067232	C/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.84e-11	Body mass index;Height;
LGG	trans	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg13010199	chr12:38710504	ALG10B	0.51	9.87	0.42	5.56e-21	Morning vs. evening chronotype;
LGG	cis	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg08930214	chr7:62859557	LOC100287834	0.45	7.62	0.33	1.41e-13	Obesity-related traits;
LGG	cis	rs9788682	0.747	rs2568490	chr15:78738370	T/C	cg06917634	chr15:78832804	PSMA4	0.53	8.12	0.35	4.16e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.74	10.98	0.45	4.19e-25	Schizophrenia;
LGG	cis	rs7444	0.941	rs181359	chr22:21928641	C/T	cg05046821	chr22:21984468	YDJC	-0.38	-6.96	-0.31	1.14e-11	Systemic lupus erythematosus;
LGG	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg25457927	chr22:38595422	NA	-0.4	-10.09	-0.42	9.25e-22	Cutaneous nevi;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg03188948	chr7:1209495	NA	0.48	7.75	0.34	5.9e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2905347	0.656	rs2051723	chr7:22665843	C/G	cg23521230	chr7:22704884	NA	0.53	9.81	0.41	9.47e-21	Major depression and alcohol dependence;
LGG	cis	rs3806843	0.576	rs550475	chr5:140273528	G/C	cg19875535	chr5:140030758	IK	0.37	7.26	0.32	1.65e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7000551	0.646	rs2979302	chr8:22359156	G/A	cg12081754	chr8:22256438	SLC39A14	0.68	13.11	0.52	1.23e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs72827839	0.740	rs72823594	chr17:46124276	C/T	cg02219949	chr17:45927392	SP6	0.54	8.01	0.35	9.72e-15	Ease of getting up in the morning;
LGG	cis	rs2797369	0.600	rs12189857	chr6:101303798	T/C	cg27451362	chr6:101846650	GRIK2	0.68	9.16	0.39	1.64e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg00864171	chr11:67383662	NA	-0.42	-6.74	-0.3	4.6e-11	Mean corpuscular volume;
LGG	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.22e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4865875	1.000	rs4336310	chr5:54098461	C/T	cg22421804	chr5:54100067	NA	0.51	7.41	0.33	6.17e-13	Sense of smell;
LGG	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg04455712	chr21:45112962	RRP1B	0.54	10.09	0.42	9.13e-22	Mean corpuscular volume;
LGG	cis	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg00383909	chr3:49044727	WDR6	1.03	11.33	0.47	1.94e-26	Cognitive function;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg06916706	chr16:4465613	CORO7	-0.91	-17.25	-0.63	7.61e-52	Schizophrenia;
LGG	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg02487422	chr3:49467188	NICN1	0.41	6.93	0.31	1.4e-11	Parkinson's disease;
LGG	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg02297831	chr4:17616191	MED28	0.44	8.24	0.36	1.77e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	trans	rs2204008	0.628	rs10876106	chr12:37990767	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs988958	0.565	rs12712817	chr2:42236230	A/G	cg27252766	chr2:42229092	NA	0.52	7.47	0.33	4.16e-13	Hypospadias;
LGG	cis	rs10463554	0.927	rs34796	chr5:102424429	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-15.26	-0.58	6.65e-43	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.647	rs7181506	chr15:76935677	G/T	cg15268244	chr15:77196840	NA	-0.46	-9.82	-0.42	8.2e-21	Blood metabolite levels;
LGG	cis	rs4700695	0.614	rs153388	chr5:65422308	G/T	cg21114390	chr5:65439923	SFRS12	-0.68	-6.92	-0.31	1.56e-11	Facial morphology (factor 19);
LGG	cis	rs55633855	0.516	rs72970452	chr11:88143843	A/G	cg08522340	chr11:88068493	CTSC	-0.39	-6.95	-0.31	1.26e-11	Body mass index;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02949340	chr10:102820489	KAZALD1	0.39	6.85	0.3	2.4e-11	Bilirubin levels;
LGG	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-7.18	-0.32	2.77e-12	Height;
LGG	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14119616	chr11:17099403	RPS13	0.41	6.87	0.3	2.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs701145	0.585	rs357480	chr3:153891182	A/G	cg17054900	chr3:154042577	DHX36	0.86	10.1	0.42	8.46e-22	Coronary artery disease;
LGG	cis	rs539514	0.690	rs4885345	chr13:76318453	C/T	cg04757411	chr13:76259545	LMO7	0.27	7.13	0.31	3.89e-12	Type 1 diabetes;
LGG	trans	rs9944715	0.911	rs9945783	chr18:43782260	T/C	cg01718231	chr17:29326311	RNF135	-0.41	-6.65	-0.3	8.44e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	7.83	0.34	3.42e-14	Total cholesterol levels;
LGG	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.49	-0.44	2.94e-23	Systemic lupus erythematosus;
LGG	cis	rs11096990	0.613	rs7690414	chr4:39212289	G/C	cg24403649	chr4:39172243	NA	0.42	7.53	0.33	2.71e-13	Cognitive function;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg02985366	chr16:32360428	NA	-0.46	-7.12	-0.31	4.11e-12	Menopause (age at onset);
LGG	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg00647317	chr7:50633725	DDC	0.46	11.33	0.47	1.94e-26	Systemic sclerosis;
LGG	cis	rs1568889	1.000	rs10767693	chr11:28093926	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.87	19.55	0.67	1.67e-62	Bipolar disorder;
LGG	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.38	-0.36	6.45e-16	Retinal vascular caliber;
LGG	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs7084402	0.935	rs717453	chr10:60268398	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.82	-0.64	1.86e-54	Refractive error;
LGG	cis	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.61	-0.33	1.51e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06665941	chr21:34602869	IFNAR2	0.55	8.92	0.38	1.07e-17	Gut microbiome composition (summer);
LGG	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg20913747	chr6:44695427	NA	0.71	12.31	0.5	2.57e-30	Total body bone mineral density;
LGG	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg06885757	chr1:42089581	HIVEP3	0.5	11.17	0.46	8.05e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.09	-0.46	1.61e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg03929089	chr4:120376271	NA	0.86	13.63	0.54	7.98e-36	Coronary artery disease;
LGG	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.54	8.9	0.38	1.23e-17	Vitiligo;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg26554054	chr8:600488	NA	0.94	9.87	0.42	5.75e-21	IgG glycosylation;
LGG	cis	rs9814567	0.574	rs1366067	chr3:134168830	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.51	-9.0	-0.39	5.8e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg20573242	chr4:122745356	CCNA2	0.55	10.14	0.43	5.69e-22	Type 2 diabetes;
LGG	cis	rs73591976	0.540	rs55757502	chr16:68228427	C/T	cg27539214	chr16:67997921	SLC12A4	-0.51	-7.74	-0.34	6.3e-14	HDL cholesterol;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs9309473	1.000	rs7594511	chr2:73681639	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.27e-14	Metabolite levels;
LGG	cis	rs3820928	0.810	rs10175929	chr2:227858609	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.51	-0.33	3.09e-13	Pulmonary function;
LGG	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg21798802	chr22:38057573	PDXP	0.45	8.57	0.37	1.57e-16	Fat distribution (HIV);
LGG	cis	rs2033732	0.706	rs4268126	chr8:85065958	T/G	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg02640540	chr1:67518911	SLC35D1	0.37	7.01	0.31	8.56e-12	Lymphocyte percentage of white cells;
LGG	cis	rs9783347	1.000	rs4150655	chr11:18375164	A/T	cg15585147	chr11:18324498	HPS5	-0.42	-8.84	-0.38	2.01e-17	Pancreatic cancer;
LGG	trans	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.51	-0.4	1.05e-19	Primary sclerosing cholangitis;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg11859384	chr17:80120422	CCDC57	0.4	6.92	0.31	1.53e-11	Life satisfaction;
LGG	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg00578828	chr5:131826934	IRF1	-0.42	-7.49	-0.33	3.61e-13	Asthma (sex interaction);
LGG	cis	rs7236492	0.872	rs74949301	chr18:77229409	C/G	cg15644404	chr18:77186268	NFATC1	-0.84	-10.16	-0.43	5.04e-22	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2916247	0.954	rs4458918	chr8:93076553	C/T	cg10183463	chr8:93005414	RUNX1T1	0.37	7.53	0.33	2.69e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.27	-0.36	1.48e-15	Total body bone mineral density;
LGG	cis	rs4380275	0.965	rs12621177	chr2:757786	C/T	cg14072418	chr2:740025	NA	-0.39	-7.25	-0.32	1.81e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7766436	0.727	rs2066339	chr6:22610612	T/C	cg13666174	chr6:22585274	NA	-0.36	-8.51	-0.37	2.37e-16	Coronary artery disease;
LGG	cis	rs2486288	0.656	rs2413772	chr15:45549862	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.81	-0.41	9.05e-21	Glomerular filtration rate;
LGG	cis	rs6489882	0.966	rs7980275	chr12:113380529	T/A	cg25319449	chr12:113376135	OAS3	-0.39	-7.21	-0.32	2.35e-12	Chronic lymphocytic leukemia;
LGG	cis	rs3857536	0.566	rs208463	chr6:66913962	T/A	cg07460842	chr6:66804631	NA	-0.68	-11.61	-0.47	1.64e-27	Blood trace element (Cu levels);
LGG	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg16586182	chr3:47516702	SCAP	-0.8	-15.68	-0.59	9.81e-45	Colorectal cancer;
LGG	cis	rs7503807	0.688	rs12600403	chr17:78602477	A/T	cg06872548	chr17:78716983	RPTOR	0.39	8.58	0.37	1.46e-16	Obesity;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg08297393	chr2:100937505	LONRF2	-0.56	-10.63	-0.44	9.04e-24	Intelligence (multi-trait analysis);
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22168489	chr12:122356033	WDR66	0.42	9.86	0.42	5.97e-21	Mean platelet volume;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg05896524	chr21:47604654	C21orf56	0.57	9.88	0.42	5.12e-21	Testicular germ cell tumor;
LGG	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg05925327	chr15:68127851	NA	0.38	8.93	0.38	1.02e-17	Restless legs syndrome;
LGG	trans	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg08344181	chr3:125677491	NA	-0.61	-6.91	-0.31	1.59e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.58	9.48	0.4	1.32e-19	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg05791153	chr7:19748676	TWISTNB	0.74	10.44	0.44	4.88e-23	Thyroid stimulating hormone;
LGG	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg16414030	chr3:133502952	NA	-0.59	-10.12	-0.43	7.11e-22	Iron status biomarkers;
LGG	cis	rs6908034	0.607	rs73376651	chr6:19805559	C/G	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs62400317	0.859	rs10948205	chr6:45124585	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	trans	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.25	0.49	4.25e-30	Corneal astigmatism;
LGG	cis	rs4740619	0.901	rs10810402	chr9:15586534	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.26	-0.43	2.16e-22	Body mass index;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.12	0.35	4.17e-15	Lung cancer;
LGG	cis	rs116095464	0.558	rs9654453	chr5:299621	T/C	cg22496380	chr5:211416	CCDC127	-1.35	-18.55	-0.65	7.63e-58	Breast cancer;
LGG	cis	rs9557207	0.950	rs7998034	chr13:100018975	C/T	cg24509225	chr13:100037070	UBAC2	0.73	13.04	0.52	2.61e-33	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs7939886	0.920	rs11227842	chr11:56079526	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.73	-14.28	-0.55	1.32e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg14703610	chr5:56206110	C5orf35	0.46	8.05	0.35	7e-15	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27199523	chr6:139094722	CCDC28A	0.48	7.42	0.33	5.47e-13	Gut microbiome composition (summer);
LGG	cis	rs11971779	0.688	rs8137	chr7:139104461	A/C	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.04	-0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.85	-0.42	6.54e-21	Lung cancer;
LGG	cis	rs28588043	0.877	rs61816860	chr1:170979240	G/A	cg03458344	chr1:170964477	C1orf129	-0.55	-7.48	-0.33	3.75e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg09699651	chr6:150184138	LRP11	0.51	8.96	0.38	8.06e-18	Lung cancer;
LGG	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.18	0.43	4.28e-22	Neuroticism;
LGG	cis	rs258892	0.947	rs250517	chr5:72200626	G/C	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs7674212	0.512	rs2720462	chr4:104056210	T/G	cg16532752	chr4:104119610	CENPE	-0.4	-7.12	-0.31	4.01e-12	Type 2 diabetes;
LGG	cis	rs9916302	0.851	rs11870631	chr17:37645129	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg14416269	chr4:6271139	WFS1	0.51	9.4	0.4	2.47e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg07148914	chr20:33460835	GGT7	0.52	8.66	0.37	7.9e-17	Height;
LGG	cis	rs4363385	0.510	rs6689066	chr1:153045154	T/C	cg13444842	chr1:152974279	SPRR3	-0.46	-9.22	-0.39	1.07e-18	Inflammatory skin disease;
LGG	trans	rs11165623	0.564	rs7525803	chr1:97000791	T/C	cg10631902	chr5:14652156	NA	-0.45	-9.38	-0.4	2.86e-19	Hip circumference;Waist circumference;
LGG	cis	rs7727544	0.606	rs10058074	chr5:131686146	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.87	-0.3	2.1e-11	Blood metabolite levels;
LGG	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg03433033	chr1:76189801	ACADM	-0.61	-9.17	-0.39	1.55e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg15971980	chr6:150254442	NA	0.45	8.56	0.37	1.7e-16	Lung cancer;
LGG	cis	rs2180341	1.000	rs7453272	chr6:127633959	C/T	cg24812749	chr6:127587940	RNF146	-0.91	-14.41	-0.56	3.89e-39	Breast cancer;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.82	-0.3	2.82e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs41342147	0.660	rs78522331	chr2:242250890	G/A	cg10173475	chr2:242152697	ANO7	-0.59	-8.94	-0.38	9.18e-18	Vitiligo;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02215898	chr6:24721656	NA	0.48	7.69	0.34	8.8e-14	Cognitive performance;
LGG	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg16141378	chr3:129829833	LOC729375	0.36	7.73	0.34	6.92e-14	Triglycerides;
LGG	cis	rs9309473	0.583	rs6705203	chr2:73574600	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-8.71	-0.38	5.48e-17	Metabolite levels;
LGG	cis	rs9393777	0.623	rs34313099	chr6:26489607	C/T	cg12826209	chr6:26865740	GUSBL1	0.85	11.91	0.48	9.94e-29	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-18.02	-0.64	2.04e-55	Morning vs. evening chronotype;
LGG	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9807989	0.507	rs6745614	chr2:102991213	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.67	0.41	2.88e-20	Asthma;
LGG	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg00579200	chr11:133705235	NA	-0.58	-10.98	-0.45	4.47e-25	Childhood ear infection;
LGG	cis	rs9815354	1.000	rs1717020	chr3:41981490	A/C	cg03022575	chr3:42003672	ULK4	0.65	8.43	0.36	4.46e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12155623	0.603	rs2203065	chr8:49881987	A/G	cg22283653	chr8:49824208	NA	-0.58	-10.76	-0.45	2.94e-24	Sudden cardiac arrest;
LGG	cis	rs2860975	1.000	rs2860974	chr10:96779866	A/G	cg09036531	chr10:96991505	NA	-0.42	-7.32	-0.32	1.13e-12	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg18187862	chr3:45730750	SACM1L	-0.55	-8.61	-0.37	1.14e-16	Primary sclerosing cholangitis;
LGG	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs10779751	0.734	rs2791650	chr1:11132541	G/C	cg08854313	chr1:11322531	MTOR	0.75	16.74	0.61	1.52e-49	Body mass index;
LGG	trans	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.52e-25	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26460378	chr19:36545594	WDR62;THAP8	0.42	6.8	0.3	3.18e-11	Cognitive performance;
LGG	cis	rs9357271	0.910	rs9380745	chr6:38373228	C/G	cg07362130	chr6:38359646	BTBD9	0.43	9.23	0.39	9.52e-19	Restless legs syndrome;
LGG	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg05163923	chr11:71159392	DHCR7	0.72	14.01	0.55	1.99e-37	Vitamin D levels;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.85	0.3	2.29e-11	Longevity;
LGG	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.66	0.34	1.13e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs6963495	0.818	rs17343556	chr7:105151272	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.82	0.34	3.6e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7590368	1.000	rs7590368	chr2:10961474	T/C	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs2540226	0.655	rs2716681	chr2:39932862	G/A	cg18968196	chr2:39892502	TMEM178	0.28	7.42	0.33	5.76e-13	Personality dimensions;
LGG	cis	rs2274273	0.684	rs2340921	chr14:55563705	A/G	cg04306507	chr14:55594613	LGALS3	0.49	12.4	0.5	1.09e-30	Protein biomarker;
LGG	cis	rs12190007	0.508	rs6605537	chr6:169730781	G/A	cg16388071	chr6:169726476	NA	0.56	11.69	0.48	7.55e-28	Obesity-related traits;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.7	-0.3	6.2e-11	Triglycerides;
LGG	cis	rs6598955	0.671	rs13374173	chr1:26602256	T/G	cg04990556	chr1:26633338	UBXN11	0.61	8.24	0.36	1.81e-15	Obesity-related traits;
LGG	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg13902645	chr11:5959945	NA	-0.66	-10.74	-0.45	3.57e-24	DNA methylation (variation);
LGG	cis	rs929354	0.742	rs6956046	chr7:156962874	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.35	0.58	2.82e-43	Body mass index;
LGG	cis	rs1007190	0.881	rs12941832	chr17:42987482	G/T	cg15406952	chr17:42872593	NA	1.1	14.01	0.55	1.94e-37	DNA methylation (variation);
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.34	-0.43	1.14e-22	Triglycerides;
LGG	cis	rs2455799	0.613	rs7633542	chr3:15816326	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-8.01	-0.35	9.1e-15	Mean platelet volume;
LGG	cis	rs12476592	0.602	rs262479	chr2:63872479	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.93	-0.31	1.41e-11	Childhood ear infection;
LGG	cis	rs74781061	0.932	rs12437519	chr15:74854450	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.29	-0.32	1.33e-12	Endometriosis;
LGG	cis	rs9487094	0.922	rs12208933	chr6:109903786	C/T	cg01125227	chr6:109776195	MICAL1	0.52	8.93	0.38	9.96e-18	Height;
LGG	cis	rs283228	0.798	rs475079	chr6:101755534	A/G	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs6866344	0.570	rs1132336	chr5:178140090	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	14.08	0.55	1.04e-37	Neutrophil percentage of white cells;
LGG	trans	rs2736345	0.755	rs2736338	chr8:11341883	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.66	0.3	7.99e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	trans	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg13010199	chr12:38710504	ALG10B	0.48	8.61	0.37	1.16e-16	Resting heart rate;
LGG	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg21545522	chr1:205238299	TMCC2	0.38	7.26	0.32	1.67e-12	Red blood cell count;
LGG	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg17960426	chr8:142067321	NA	-0.37	-7.23	-0.32	2.03e-12	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.79	-0.3	3.4e-11	Mood instability;
LGG	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.31	-0.32	1.19e-12	Cognitive ability (multi-trait analysis);
LGG	trans	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-12.28	-0.5	3.23e-30	Morning vs. evening chronotype;
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg13628971	chr7:2884303	GNA12	0.37	7.62	0.33	1.42e-13	Height;
LGG	cis	rs730775	0.505	rs324137	chr6:44273546	G/T	cg21130236	chr6:44246755	TMEM151B	0.35	7.61	0.33	1.58e-13	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs367943	0.665	rs10061922	chr5:112969775	G/T	cg12552261	chr5:112820674	MCC	0.51	8.77	0.38	3.48e-17	Type 2 diabetes;
LGG	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.54e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6500395	1.000	rs11649236	chr16:48632478	C/T	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.58e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg00426182	chr6:28072559	NA	0.92	6.93	0.31	1.4e-11	Hip circumference adjusted for BMI;
LGG	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.1	-0.46	1.5e-25	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08981181	chr6:43395557	NA	0.38	6.72	0.3	5.25e-11	Obesity-related traits;
LGG	cis	rs9290065	0.519	rs6441346	chr3:160709229	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-8.97	-0.38	7.25e-18	Kawasaki disease;
LGG	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg01657329	chr11:68192670	LRP5	0.5	8.75	0.38	3.94e-17	Total body bone mineral density;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg21948465	chr5:131705150	SLC22A5	-0.61	-7.0	-0.31	9.25e-12	Rheumatoid arthritis;
LGG	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14154082	chr13:112174009	NA	0.41	9.05	0.39	3.97e-18	Menarche (age at onset);
LGG	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg12091567	chr17:66097778	LOC651250	0.77	12.52	0.5	3.49e-31	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2249694	0.922	rs4306261	chr10:135410989	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-7.88	-0.34	2.37e-14	Obesity-related traits;
LGG	cis	rs6540556	0.769	rs909710	chr1:209930694	A/G	cg05527609	chr1:210001259	C1orf107	0.53	7.01	0.31	8.67e-12	Red blood cell count;
LGG	cis	rs6546550	0.900	rs2054047	chr2:70117421	A/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.14	-0.35	3.65e-15	Prevalent atrial fibrillation;
LGG	cis	rs4718428	1.000	rs4718421	chr7:66350300	C/T	cg18252515	chr7:66147081	NA	-0.58	-9.27	-0.4	7.16e-19	Corneal structure;
LGG	cis	rs12142240	0.731	rs12385693	chr1:46818921	A/C	cg25706281	chr1:46860511	FAAH	-0.31	-6.75	-0.3	4.46e-11	Menopause (age at onset);
LGG	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.02	0.31	8.06e-12	Monocyte count;
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.9	0.57	2.65e-41	Platelet count;
LGG	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	8.25	0.36	1.61e-15	Personality dimensions;
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg23422044	chr7:1970798	MAD1L1	-0.67	-11.33	-0.47	1.93e-26	Bipolar disorder;
LGG	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg21926883	chr2:100939477	LONRF2	-0.62	-13.61	-0.53	1.04e-35	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.19	-0.32	2.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.72	-0.3	5.51e-11	Personality dimensions;
LGG	trans	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg26518628	chr1:97050305	NA	-0.83	-6.82	-0.3	2.85e-11	Cannabis dependence symptom count;
LGG	cis	rs926938	0.505	rs2878573	chr1:115521602	A/G	cg12756093	chr1:115239321	AMPD1	0.41	7.83	0.34	3.47e-14	Autism;
LGG	cis	rs11645898	0.872	rs34832584	chr16:72162966	G/T	cg14768367	chr16:72042858	DHODH	-0.84	-11.29	-0.46	2.8e-26	Blood protein levels;
LGG	cis	rs3857067	0.806	rs12507575	chr4:95114920	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs9303401	0.659	rs714959	chr17:56628601	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.69	0.56	2.33e-40	Cognitive test performance;
LGG	cis	rs4731207	0.596	rs2402756	chr7:124579782	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9894429	0.646	rs9902264	chr17:79613828	G/A	cg10661904	chr17:79619235	PDE6G	-0.5	-10.31	-0.43	1.37e-22	Eye color traits;
LGG	cis	rs2640806	0.645	rs13255914	chr8:97329366	C/A	cg22138393	chr8:97340270	PTDSS1	0.33	8.44	0.37	4.12e-16	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11831286	chr5:66300433	MAST4	0.49	7.15	0.32	3.46e-12	Gut microbiome composition (summer);
LGG	cis	rs3106136	0.967	rs11722476	chr4:95170839	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.09	-0.35	5.1e-15	Capecitabine sensitivity;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.65	-0.33	1.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.657	rs28833898	chr7:19861022	G/A	cg05791153	chr7:19748676	TWISTNB	0.61	7.86	0.34	2.79e-14	Night sleep phenotypes;
LGG	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs2439831	0.850	rs28590651	chr15:44113016	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.77	8.5	0.37	2.6e-16	Lung cancer in ever smokers;
LGG	cis	rs12493885	0.725	rs11718315	chr3:153724197	A/G	cg12800244	chr3:153838788	SGEF	-0.73	-9.06	-0.39	3.77e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2635047	0.682	rs1980055	chr18:44792636	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.54	0.33	2.46e-13	Educational attainment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06045579	chr16:87425660	FBXO31;MAP1LC3B	-0.38	-6.99	-0.31	9.78e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8048589	0.948	rs35318501	chr16:12182531	A/C	cg02910054	chr16:12241554	SNX29	0.44	6.94	0.31	1.34e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg00424166	chr6:150045504	NUP43	-0.37	-7.46	-0.33	4.33e-13	Lung cancer;
LGG	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg07061783	chr6:25882402	NA	-0.39	-7.05	-0.31	6.43e-12	Blood metabolite levels;
LGG	cis	rs4262150	0.883	rs4958579	chr5:152184970	G/C	cg12297329	chr5:152029980	NA	-0.7	-13.3	-0.53	2.15e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs62064224	0.703	rs4287613	chr17:30827688	C/T	cg09324608	chr17:30823087	MYO1D	0.34	8.03	0.35	8.01e-15	Schizophrenia;
LGG	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg14191688	chr11:70257035	CTTN	0.55	8.05	0.35	7.11e-15	Coronary artery disease;
LGG	cis	rs9381040	0.655	rs9381032	chr6:41044986	A/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.19	-0.32	2.59e-12	Alzheimer's disease (late onset);
LGG	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25373794	chr1:162760220	HSD17B7	0.44	7.03	0.31	7.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1843834	0.721	rs4674939	chr2:225613552	G/A	cg22455342	chr2:225449267	CUL3	0.46	7.81	0.34	3.98e-14	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs12210905	1.000	rs9379970	chr6:27255231	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7572644	0.699	rs7595986	chr2:28085311	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-6.94	-0.31	1.33e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg11764359	chr7:65958608	NA	0.74	13.25	0.52	3.26e-34	Aortic root size;
LGG	cis	rs6912958	0.781	rs4334949	chr6:88290150	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18934136	chr17:55927456	MRPS23	0.44	6.71	0.3	5.66e-11	Gut microbiome composition (summer);
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg08508337	chr8:144660607	NAPRT1	0.87	7.22	0.32	2.14e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs7226408	0.901	rs1503359	chr18:34742415	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs6489785	0.775	rs1696361	chr12:121363823	T/C	cg02419362	chr12:121203948	SPPL3	0.44	6.96	0.31	1.17e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02951883	chr7:2050386	MAD1L1	0.45	7.36	0.32	8.62e-13	Neuroticism;
LGG	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg16583315	chr14:65563665	MAX	-0.37	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs6547741	0.788	rs7595739	chr2:27874563	G/T	cg27432699	chr2:27873401	GPN1	-0.74	-15.28	-0.58	5.58e-43	Oral cavity cancer;
LGG	cis	rs12477438	0.765	rs62154861	chr2:99590235	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-18.5	-0.65	1.27e-57	Chronic sinus infection;
LGG	cis	rs60733400	0.817	rs4648657	chr1:2560735	A/G	cg18854424	chr1:2615690	NA	-0.35	-7.33	-0.32	1.05e-12	Multiple sclerosis;
LGG	cis	rs26868	0.746	rs27381	chr16:2239402	C/T	cg02248941	chr16:2239361	CASKIN1	0.5	10.05	0.42	1.26e-21	Height;
LGG	cis	rs6594499	0.564	rs12518884	chr5:110452223	A/G	cg04022379	chr5:110408740	TSLP	0.43	7.53	0.33	2.7e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06634786	chr22:41940651	POLR3H	-0.7	-11.71	-0.48	6.23e-28	Vitiligo;
LGG	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-8.58	-0.37	1.48e-16	Oral cavity cancer;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.32	-0.36	1.01e-15	Bipolar disorder;
LGG	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg27661571	chr11:113659931	NA	-0.66	-9.53	-0.4	8.7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg03847636	chr4:7070632	GRPEL1	-0.54	-7.33	-0.32	1.05e-12	Monocyte percentage of white cells;
LGG	cis	rs1620921	0.840	rs783177	chr6:161169815	C/T	cg01280913	chr6:161186852	NA	-0.35	-7.2	-0.32	2.48e-12	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs9329221	0.585	rs12550717	chr8:10266706	G/A	cg02002194	chr4:3960332	NA	-0.38	-6.65	-0.3	8.45e-11	Neuroticism;
LGG	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.88	-0.34	2.44e-14	HDL cholesterol;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07454558	chr2:159826472	TANC1	0.41	6.75	0.3	4.44e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9354308	0.764	rs2154330	chr6:66567872	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	trans	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.17e-13	Cognitive test performance;
LGG	cis	rs4925386	0.959	rs4925385	chr20:60920624	A/G	cg24112000	chr20:60950667	NA	0.36	8.31	0.36	1.1e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.34	-0.36	8.54e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1707322	0.752	rs12024590	chr1:46127496	A/C	cg03146154	chr1:46216737	IPP	0.55	10.76	0.45	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4132509	1.000	rs2168812	chr1:243777066	G/A	cg25706552	chr1:244017396	NA	0.51	8.23	0.36	1.86e-15	RR interval (heart rate);
LGG	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg10792982	chr14:105748885	BRF1	0.55	10.73	0.45	3.96e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg24642439	chr20:33292090	TP53INP2	0.64	11.3	0.46	2.59e-26	Coronary artery disease;
LGG	cis	rs4845570	0.920	rs10788809	chr1:151760792	A/G	cg07092448	chr1:151763213	TDRKH	1.13	17.86	0.64	1.16e-54	Coronary artery disease;
LGG	cis	rs7927771	0.864	rs755553	chr11:47432303	G/A	cg20307385	chr11:47447363	PSMC3	0.57	10.59	0.44	1.28e-23	Subjective well-being;
LGG	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg18876405	chr7:65276391	NA	-0.64	-11.92	-0.48	8.96e-29	Aortic root size;
LGG	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg22947322	chr17:47091978	IGF2BP1	-0.45	-7.86	-0.34	2.75e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs7236492	0.748	rs11660128	chr18:77227950	G/T	cg15644404	chr18:77186268	NFATC1	-0.83	-10.08	-0.42	9.53e-22	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9583531	0.689	rs2165418	chr13:111379365	G/T	cg15841412	chr13:111365552	ING1	-0.44	-6.67	-0.3	7.26e-11	Coronary artery disease;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	9.03	0.39	4.64e-18	Schizophrenia;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7072216	0.806	rs9804285	chr10:100169472	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.28	-0.32	1.45e-12	Metabolite levels;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.01e-23	Lymphocyte counts;
LGG	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.25e-12	Morning vs. evening chronotype;
LGG	cis	rs7929679	0.521	rs10768094	chr11:34792189	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs11225247	1.000	rs11607908	chr11:102307399	A/G	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs975722	0.516	rs2188555	chr7:117057233	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	8.44	0.37	4.16e-16	Coronary artery disease;
LGG	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg08847335	chr10:891726	LARP4B	-0.37	-7.04	-0.31	7.19e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg21665744	chr7:39171113	POU6F2	0.43	8.88	0.38	1.45e-17	IgG glycosylation;
LGG	cis	rs9733	0.818	rs11204695	chr1:150657011	T/G	cg13175981	chr1:150552382	MCL1	0.54	9.15	0.39	1.83e-18	Tonsillectomy;
LGG	cis	rs870825	0.616	rs28673855	chr4:185627416	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs1577917	0.958	rs1337843	chr6:86675545	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	6.77	0.3	3.94e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2267681	0.603	rs194152	chr7:139539936	C/G	cg14116596	chr7:139528673	TBXAS1	-0.33	-7.34	-0.32	9.64e-13	Cervical cancer;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	trans	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.96	-0.35	1.35e-14	Neuroticism;
LGG	trans	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg02002194	chr4:3960332	NA	0.46	8.76	0.38	3.6e-17	Mood instability;
LGG	cis	rs72925845	0.577	rs691342	chr17:76429162	C/G	cg03830375	chr17:76426088	DNAH17	0.5	7.13	0.31	3.9e-12	Triglycerides;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs2239815	0.515	rs12170231	chr22:29237824	C/T	cg15103426	chr22:29168792	CCDC117	0.66	7.65	0.34	1.17e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg15704280	chr7:45808275	SEPT13	-1.08	-27.07	-0.78	1.91e-97	Height;
LGG	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg23029597	chr12:123009494	RSRC2	0.94	17.39	0.63	1.65e-52	Body mass index;
LGG	cis	rs12497850	0.931	rs4974082	chr3:48999323	G/A	cg07636037	chr3:49044803	WDR6	1.07	26.45	0.78	1.31e-94	Parkinson's disease;
LGG	cis	rs2652834	1.000	rs2652838	chr15:63396088	A/G	cg05507819	chr15:63340323	TPM1	0.57	7.75	0.34	6.06e-14	HDL cholesterol;
LGG	cis	rs17221829	0.673	rs11018700	chr11:89382066	A/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.1	-0.39	2.61e-18	Anxiety in major depressive disorder;
LGG	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.56	-0.53	1.73e-35	Coronary artery disease;
LGG	cis	rs4242434	0.597	rs11985023	chr8:22531463	C/T	cg02227867	chr8:22457446	C8orf58	0.39	7.28	0.32	1.49e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3733585	0.699	rs6852441	chr4:9973744	C/T	cg25986240	chr4:9926439	SLC2A9	0.37	7.57	0.33	2.02e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg02825527	chr7:2087843	MAD1L1	-0.39	-7.19	-0.32	2.7e-12	Bipolar disorder;
LGG	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs4538187	0.760	rs116503511	chr2:64155736	T/C	cg14150252	chr2:64069583	UGP2	-0.47	-8.57	-0.37	1.56e-16	Systolic blood pressure;
LGG	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg08923054	chr8:41654455	ANK1	0.84	14.42	0.56	3.43e-39	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg11878867	chr6:150167359	LRP11	-0.5	-10.42	-0.44	5.53e-23	Lung cancer;
LGG	cis	rs877282	0.945	rs10904555	chr10:787740	C/A	cg17470449	chr10:769945	NA	0.61	7.58	0.33	1.87e-13	Uric acid levels;
LGG	cis	rs9790314	1.000	rs336593	chr3:161076431	T/C	cg04691961	chr3:161091175	C3orf57	-0.66	-15.99	-0.6	3.88e-46	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg07959490	chr17:80112427	CCDC57	0.38	7.38	0.32	7.34e-13	Life satisfaction;
LGG	cis	rs2629751	0.512	rs2723845	chr12:104446721	T/C	cg14987745	chr12:104360022	TDG	-0.56	-7.7	-0.34	8.27e-14	Hepatitis C induced liver fibrosis;
LGG	trans	rs61931739	0.635	rs10743836	chr12:33961680	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.41	0.36	4.95e-16	Morning vs. evening chronotype;
LGG	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg06827562	chr3:125932279	NA	0.71	17.26	0.63	6.97e-52	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg01191920	chr7:158217561	PTPRN2	-0.62	-13.12	-0.52	1.21e-33	Obesity-related traits;
LGG	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11890956	chr21:40555474	PSMG1	1.19	30.87	0.82	1.94e-114	Cognitive function;
LGG	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg02002194	chr4:3960332	NA	0.42	7.43	0.33	5.26e-13	Triglycerides;
LGG	cis	rs4262150	0.726	rs6876723	chr5:151929344	C/T	cg12297329	chr5:152029980	NA	-0.72	-13.85	-0.54	9.67e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs2455799	0.634	rs11128765	chr3:15903331	G/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.19e-14	Mean platelet volume;
LGG	cis	rs7107174	1.000	rs2450123	chr11:77952771	T/C	cg19901956	chr11:77921274	USP35	-0.41	-6.67	-0.3	7.16e-11	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01570182	chr17:44337453	NA	0.71	11.91	0.48	9.89e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg27446573	chr6:127587934	RNF146	0.89	16.58	0.61	8.28e-49	Breast cancer;
LGG	cis	rs11122272	0.735	rs2491416	chr1:231547335	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	11.03	0.46	2.79e-25	Hemoglobin concentration;
LGG	cis	rs10416265	0.503	rs1981818	chr19:33615122	C/T	cg17764715	chr19:33622953	WDR88	-0.6	-11.8	-0.48	2.83e-28	Bone properties (heel);
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg19774624	chr17:42201019	HDAC5	-0.82	-16.21	-0.6	4.09e-47	Total body bone mineral density;
LGG	trans	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.18e-13	Heart rate;
LGG	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.68e-19	Diabetic retinopathy;
LGG	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg14228332	chr4:119757509	SEC24D	0.97	9.22	0.39	1.04e-18	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06850241	chr22:41845214	NA	0.46	7.19	0.32	2.57e-12	Vitiligo;
LGG	cis	rs10461617	0.531	rs2662033	chr5:56213410	T/G	cg08400814	chr5:56204995	C5orf35	-0.49	-7.63	-0.33	1.37e-13	Type 2 diabetes;
LGG	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg17749961	chr2:30669863	LCLAT1	0.71	10.11	0.43	7.63e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4604732	0.578	rs12038656	chr1:247623816	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.97	0.38	7.6e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12458462	0.851	rs60298379	chr18:77488422	C/T	cg11879182	chr18:77439856	CTDP1	0.79	14.67	0.56	2.64e-40	Monocyte count;
LGG	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.08	0.35	5.6e-15	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03264133	chr6:25882463	NA	-0.52	-9.24	-0.39	8.65e-19	Blood metabolite levels;
LGG	cis	rs6952809	0.532	rs7803015	chr7:2432143	G/A	cg23289794	chr7:2394357	EIF3B	-0.75	-9.68	-0.41	2.59e-20	Multiple sclerosis;
LGG	cis	rs9303280	0.806	rs13380815	chr17:38027583	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-7.76	-0.34	5.38e-14	Self-reported allergy;
LGG	cis	rs4622507	0.618	rs1466603	chr16:55064926	A/G	cg09947736	chr16:55091198	NA	0.77	11.29	0.46	2.77e-26	Social communication problems;
LGG	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.13	0.35	3.95e-15	Colorectal cancer;
LGG	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04098458	chr2:149402448	EPC2	-0.38	-7.15	-0.32	3.31e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3784262	0.669	rs2414530	chr15:58356362	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.78	-0.3	3.6e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.94	-0.42	3.08e-21	Bipolar disorder;
LGG	cis	rs8014204	0.541	rs35591392	chr14:75157713	G/T	cg06637938	chr14:75390232	RPS6KL1	0.68	12.65	0.51	1.04e-31	Caffeine consumption;
LGG	cis	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg13147721	chr7:65941812	NA	-0.77	-8.97	-0.38	7.45e-18	Diabetic kidney disease;
LGG	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs2455826	0.958	rs2470541	chr3:15655343	A/C	cg16303742	chr3:15540471	COLQ	0.4	7.02	0.31	8.06e-12	Inflammatory skin disease;
LGG	cis	rs6918586	0.658	rs198825	chr6:26122502	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.53	-0.4	8.91e-20	Schizophrenia;
LGG	cis	rs10791097	0.694	rs7125622	chr11:130743388	T/C	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs11971779	0.752	rs4732371	chr7:139077317	T/A	cg07862535	chr7:139043722	LUC7L2	0.51	8.21	0.36	2.27e-15	Diisocyanate-induced asthma;
LGG	cis	rs7927771	0.832	rs10838704	chr11:47424717	T/C	cg20307385	chr11:47447363	PSMC3	-0.57	-10.31	-0.43	1.43e-22	Subjective well-being;
LGG	cis	rs2273669	0.667	rs12196143	chr6:109302372	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg05887092	chr17:76393375	PGS1	0.72	15.83	0.59	2.04e-45	HDL cholesterol levels;
LGG	cis	rs1348850	0.645	rs4893963	chr2:178430747	A/G	cg22681709	chr2:178499509	PDE11A	0.47	7.72	0.34	7.33e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs834603	0.575	rs834597	chr7:47464488	A/T	cg09696706	chr7:47479511	TNS3	0.35	7.76	0.34	5.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs752010	0.530	rs10789401	chr1:42081111	A/G	cg16096631	chr1:42092165	HIVEP3	0.62	14.03	0.55	1.69e-37	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06738889	chr1:150208936	ANP32E	0.51	8.05	0.35	7.14e-15	Gut microbiome composition (summer);
LGG	cis	rs57502260	0.573	rs12291008	chr11:68389072	T/C	cg16797656	chr11:68205561	LRP5	0.47	7.67	0.34	9.97e-14	Total body bone mineral density (age 45-60);
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg05786053	chr1:118473064	GDAP2;WDR3	0.45	6.7	0.3	6e-11	Pancreatic cancer;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs600231	0.665	rs2846861	chr11:65222305	A/G	cg17120908	chr11:65337727	SSSCA1	-0.49	-8.76	-0.38	3.82e-17	Bone mineral density;
LGG	cis	rs7666738	0.723	rs35327100	chr4:98977788	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8114671	0.562	rs8116657	chr20:33476474	C/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.03	0.31	7.62e-12	Height;
LGG	cis	rs6735179	0.688	rs2382563	chr2:1763599	T/C	cg20570797	chr2:1712800	PXDN	-0.48	-8.67	-0.37	7.53e-17	Response to antipsychotic treatment;
LGG	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.21	-0.36	2.25e-15	Parkinson's disease;
LGG	cis	rs6735179	0.729	rs2382560	chr2:1762828	A/G	cg08534653	chr2:1747700	PXDN	0.43	6.77	0.3	3.97e-11	Response to antipsychotic treatment;
LGG	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.6	-0.33	1.67e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs16976116	0.901	rs1061821	chr15:55496111	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.66	0.37	7.7e-17	Bipolar disorder;
LGG	cis	rs2249694	0.960	rs9630033	chr10:135418505	G/T	cg20169779	chr10:135381914	SYCE1	-0.51	-7.85	-0.34	2.84e-14	Obesity-related traits;
LGG	cis	rs4746059	0.714	rs11599210	chr10:72457250	A/G	cg18968090	chr10:72432461	ADAMTS14	0.44	7.38	0.32	7.51e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2038227	1	rs2038227	chr16:539140	C/A	cg27494100	chr16:537705	RAB11FIP3	0.5	8.89	0.38	1.33e-17	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs644799	0.504	rs523049	chr11:95594831	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	10.15	0.43	5.67e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4750440	0.585	rs7072791	chr10:14028195	A/C	cg00551146	chr10:14014579	FRMD4A	0.32	7.43	0.33	5.12e-13	Adiponectin levels;
LGG	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg07382826	chr16:28625726	SULT1A1	0.42	9.03	0.39	4.64e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg16103275	chr6:290800	DUSP22	0.49	8.03	0.35	8.25e-15	Menopause (age at onset);
LGG	cis	rs42648	0.790	rs42637	chr7:89969831	A/G	cg25739043	chr7:89950458	NA	-0.35	-7.07	-0.31	5.89e-12	Homocysteine levels;
LGG	cis	rs4538187	1.000	rs6731508	chr2:64094506	G/C	cg14150252	chr2:64069583	UGP2	0.5	9.52	0.4	9.7e-20	Systolic blood pressure;
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	cis	rs28595532	0.764	rs55913633	chr4:119747444	C/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg11247378	chr22:39784982	NA	-0.31	-8.98	-0.39	6.94e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg06271696	chr7:157225062	NA	-0.64	-14.36	-0.56	6.24e-39	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg09307838	chr4:120376055	NA	-0.47	-8.16	-0.35	3.19e-15	Diastolic blood pressure;
LGG	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg11657817	chr20:23433608	CST11	0.37	6.68	0.3	6.7e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.57	10.63	0.44	8.92e-24	Personality dimensions;
LGG	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.95	0.31	1.27e-11	Educational attainment;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.66	-0.3	7.64e-11	Personality dimensions;
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.35	-0.43	1.02e-22	Bipolar disorder;
LGG	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg00578828	chr5:131826934	IRF1	-0.41	-7.09	-0.31	5.03e-12	Asthma (sex interaction);
LGG	cis	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	Neuroticism;
LGG	trans	rs75804782	0.521	rs72993033	chr2:239382882	A/G	cg01134436	chr17:81009848	B3GNTL1	0.83	8.76	0.38	3.7e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2117029	0.619	rs10747562	chr12:49505184	C/T	cg24176009	chr12:49580217	TUBA1A	0.6	11.52	0.47	3.67e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs2840044	0.711	rs225301	chr17:33922411	T/A	cg19694781	chr19:47549865	TMEM160	-0.76	-12.06	-0.49	2.47e-29	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg01765077	chr12:122356316	WDR66	0.29	7.91	0.35	1.91e-14	Mean corpuscular volume;
LGG	cis	rs6500395	0.775	rs28481630	chr16:48663664	G/C	cg16662043	chr16:48846231	NA	0.33	6.64	0.3	8.54e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs473651	0.935	rs520765	chr2:239354712	C/T	cg08773314	chr2:239334832	ASB1	0.43	8.14	0.35	3.58e-15	Multiple system atrophy;
LGG	cis	rs9815354	0.812	rs77047799	chr3:41958895	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.46	0.4	1.55e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09922871	chr2:71559595	ZNF638	0.43	6.93	0.31	1.38e-11	Cognitive performance;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg18681998	chr4:17616180	MED28	-0.88	-20.26	-0.69	8.18e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs2114646	0.731	rs10930379	chr2:170644549	C/T	cg17598339	chr2:170624727	NA	0.35	6.71	0.3	5.68e-11	Obesity-related traits;
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg14500267	chr11:67383377	NA	-0.4	-7.06	-0.31	6.21e-12	Mean corpuscular volume;
LGG	cis	rs7216064	0.636	rs62084696	chr17:66038181	C/G	cg12091567	chr17:66097778	LOC651250	0.79	13.15	0.52	8.69e-34	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg22535103	chr8:58192502	C8orf71	-0.8	-10.74	-0.45	3.56e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.76	15.11	0.57	3.17e-42	Obesity-related traits;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.52e-17	Prudent dietary pattern;
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg14137381	chr5:502291	SLC9A3	-0.33	-6.79	-0.3	3.56e-11	Cystic fibrosis severity;
LGG	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg11764359	chr7:65958608	NA	0.69	12.16	0.49	1.04e-29	Aortic root size;
LGG	cis	rs4595586	0.679	rs5017082	chr12:39314564	A/C	cg13010199	chr12:38710504	ALG10B	-0.36	-6.79	-0.3	3.45e-11	Morning vs. evening chronotype;
LGG	cis	rs4356203	0.870	rs10832746	chr11:17249953	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg22771759	chr13:24902376	NA	0.42	7.18	0.32	2.72e-12	Obesity-related traits;
LGG	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg27490568	chr2:178487706	NA	0.49	9.72	0.41	1.93e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8058578	0.945	rs885107	chr16:30672719	T/C	cg00531865	chr16:30841666	NA	-0.54	-10.92	-0.45	7.46e-25	Multiple myeloma;
LGG	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	11.71	0.48	6.16e-28	Mood instability;
LGG	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg20913747	chr6:44695427	NA	0.66	10.98	0.45	4.45e-25	Total body bone mineral density;
LGG	cis	rs7503807	0.515	rs12948040	chr17:78678434	A/G	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg11871910	chr12:69753446	YEATS4	1.06	28.69	0.8	9.09e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11098499	0.909	rs10020034	chr4:120294331	A/G	cg24375607	chr4:120327624	NA	0.65	10.61	0.44	1.07e-23	Corneal astigmatism;
LGG	cis	rs3790455	0.804	rs1109751	chr1:156439000	C/T	cg14087168	chr1:156450669	MEF2D	0.6	9.6	0.41	5.18e-20	Migraine;
LGG	cis	rs1008375	0.933	rs7689101	chr4:17694034	G/A	cg16339924	chr4:17578868	LAP3	0.51	8.51	0.37	2.36e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6831352	0.879	rs34360292	chr4:100051303	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs3806843	0.548	rs246058	chr5:140325134	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.59	8.92	0.38	1.07e-17	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg12458913	chr13:53173898	NA	0.93	23.04	0.73	8.15e-79	Lewy body disease;
LGG	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.92	0.54	4.74e-37	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg19717773	chr7:2847554	GNA12	-0.31	-6.68	-0.3	7.06e-11	Height;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs703842	1.000	rs10783848	chr12:58196528	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg26384229	chr12:38710491	ALG10B	-0.65	-12.73	-0.51	4.84e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg12661370	chr5:149340060	SLC26A2	0.51	8.5	0.37	2.55e-16	HIV-1 control;
LGG	cis	rs9487094	0.567	rs11964864	chr6:110094626	C/T	cg01125227	chr6:109776195	MICAL1	0.47	7.69	0.34	8.93e-14	Height;
LGG	trans	rs3206736	0.548	rs2108690	chr7:35082809	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.19	0.32	2.54e-12	Diastolic blood pressure;
LGG	cis	rs6500395	0.888	rs8057165	chr16:48563467	A/C	cg04672837	chr16:48644449	N4BP1	0.55	8.84	0.38	1.99e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9513627	0.920	rs7334943	chr13:100121287	C/G	cg25919922	chr13:100150906	NA	0.69	7.12	0.31	4.19e-12	Obesity-related traits;
LGG	cis	rs3764563	1.000	rs2031062	chr19:15717573	T/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.9	-0.34	2.12e-14	Inflammatory biomarkers;
LGG	trans	rs9650657	0.737	rs4551304	chr8:10665069	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.11	-0.31	4.35e-12	Neuroticism;
LGG	cis	rs1775715	0.707	rs2808081	chr10:32162342	C/T	cg14930904	chr10:32216787	ARHGAP12	-0.35	-6.83	-0.3	2.7e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs975739	0.933	rs1759974	chr13:78383998	G/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs10492096	0.947	rs10849484	chr12:6637941	C/T	cg13857086	chr12:6580257	VAMP1	0.51	7.27	0.32	1.5e-12	Hip geometry;
LGG	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg15268244	chr15:77196840	NA	-0.34	-7.52	-0.33	2.78e-13	Blood metabolite levels;
LGG	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg16325326	chr1:53192061	ZYG11B	0.63	13.68	0.54	5.02e-36	Monocyte count;
LGG	cis	rs1008375	1.000	rs7659718	chr4:17638020	A/C	cg18681998	chr4:17616180	MED28	0.88	20.18	0.68	1.93e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4918072	0.793	rs7912975	chr10:105705190	T/C	cg11005552	chr10:105648138	OBFC1	0.45	7.36	0.32	8.61e-13	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.68	-0.3	7.01e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs283228	0.502	rs2787573	chr6:101847505	C/A	cg27451362	chr6:101846650	GRIK2	1.02	14.83	0.57	5.44e-41	Coenzyme Q10 levels;
LGG	cis	rs2451279	0.565	rs509457	chr6:159503362	T/C	cg01046905	chr6:159515345	NA	0.33	7.07	0.31	5.61e-12	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs7635838	0.596	rs347599	chr3:11258191	C/T	cg00170343	chr3:11313890	ATG7	-0.43	-7.45	-0.33	4.69e-13	HDL cholesterol;
LGG	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg06636001	chr8:8085503	FLJ10661	0.54	9.79	0.41	1.04e-20	Retinal vascular caliber;
LGG	cis	rs6988985	0.703	rs7005638	chr8:143950214	T/C	cg10324643	chr8:143916377	GML	0.39	7.69	0.34	8.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg19455335	chr8:22457658	C8orf58	-0.43	-8.82	-0.38	2.27e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg10621924	chr7:39171070	POU6F2	-0.47	-9.92	-0.42	3.65e-21	IgG glycosylation;
LGG	cis	rs1008375	0.900	rs10019460	chr4:17686337	T/C	cg18681998	chr4:17616180	MED28	-0.82	-17.05	-0.62	5.8e-51	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg00495681	chr13:53174319	NA	0.49	8.96	0.38	8.27e-18	Lewy body disease;
LGG	cis	rs6696846	0.691	rs11240370	chr1:205118336	T/G	cg00857998	chr1:205179979	DSTYK	0.55	8.96	0.38	8.13e-18	Red blood cell count;
LGG	cis	rs4689388	0.890	rs4689397	chr4:6299387	G/A	cg00701064	chr4:6280414	WFS1	0.77	17.7	0.64	6.12e-54	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.82	-0.48	2.38e-28	Mean platelet volume;
LGG	cis	rs10262624	0.901	rs6966655	chr7:23906629	G/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.86	-0.3	2.27e-11	Schizophrenia;
LGG	cis	rs9527	0.590	rs7067663	chr10:104883650	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.25	0.43	2.43e-22	Arsenic metabolism;
LGG	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	cg07245641	chr1:182991651	LAMC1	0.4	8.94	0.38	9.17e-18	Colorectal cancer;
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg21545522	chr1:205238299	TMCC2	0.36	6.96	0.31	1.14e-11	Red blood cell count;
LGG	cis	rs3768617	0.966	rs6669796	chr1:183082825	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.75	0.3	4.38e-11	Fuchs's corneal dystrophy;
LGG	cis	rs2692947	0.770	rs2315421	chr2:96497516	G/C	cg22654517	chr2:96458247	NA	0.37	7.95	0.35	1.45e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.57	-0.33	2.02e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2415984	0.622	rs1761029	chr14:46934764	T/C	cg14871534	chr14:47121158	RPL10L	0.58	10.19	0.43	3.77e-22	Number of children ever born;
LGG	cis	rs12431410	0.584	rs10143626	chr14:60245982	C/T	cg07950296	chr14:60194823	RTN1	-0.39	-7.24	-0.32	1.86e-12	Schizophrenia;
LGG	cis	rs12580194	0.593	rs58254871	chr12:55750281	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.36	-0.43	9.59e-23	Total body bone mineral density;
LGG	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg03929089	chr4:120376271	NA	0.72	8.4	0.36	5.54e-16	Axial length;
LGG	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.46	-0.47	6.27e-27	Type 2 diabetes;
LGG	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.65	-0.71	2.64e-72	Height;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg13012494	chr21:47604986	C21orf56	0.42	7.06	0.31	5.95e-12	Testicular germ cell tumor;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg08795170	chr5:108746307	PJA2	-0.44	-6.78	-0.3	3.61e-11	Coronary artery disease;
LGG	cis	rs1555322	0.872	rs6579227	chr20:33879206	C/T	cg03689076	chr20:33865952	NA	0.65	6.82	0.3	2.78e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs3750965	0.920	rs896978	chr11:68828929	G/A	cg23121140	chr11:68816938	TPCN2	0.37	7.09	0.31	5.11e-12	Hair color;
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.84	0.48	1.96e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9929218	0.581	rs7203337	chr16:68774800	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.9	19.74	0.68	2.22e-63	Colorectal cancer;
LGG	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.42e-31	Motion sickness;
LGG	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.88	-0.34	2.35e-14	Total body bone mineral density;
LGG	cis	rs7584330	0.868	rs2325839	chr2:238386286	T/C	cg16989719	chr2:238392110	NA	-0.38	-7.96	-0.35	1.3e-14	Prostate cancer;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	9.18	0.39	1.43e-18	Longevity;Endometriosis;
LGG	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg25801113	chr15:45476975	SHF	0.87	19.87	0.68	5.2e-64	Uric acid levels;
LGG	cis	rs7236492	0.688	rs76247824	chr18:77186287	G/A	cg05753993	chr18:77199432	NFATC1	0.39	7.27	0.32	1.51e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9906944	0.624	rs2411759	chr17:47071074	C/T	cg09029085	chr17:47094198	IGF2BP1	0.26	6.95	0.31	1.27e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.47	-8.02	-0.35	8.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg11764359	chr7:65958608	NA	0.63	10.89	0.45	9.29e-25	Aortic root size;
LGG	trans	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg26384229	chr12:38710491	ALG10B	0.76	13.97	0.54	2.81e-37	Resting heart rate;
LGG	cis	rs6840360	0.607	rs6815320	chr4:152432500	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.32	0.32	1.08e-12	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	6.96	0.31	1.18e-11	Tonsillectomy;
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02625641	chr15:59041175	ADAM10	-0.4	-6.72	-0.3	5.39e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9584850	1.000	rs9584850	chr13:99101426	G/C	cg20487152	chr13:99095054	FARP1	0.37	6.73	0.3	4.99e-11	Neuroticism;
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.39	-0.32	7.12e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.52	0.33	2.91e-13	Schizophrenia;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg26818010	chr10:134567672	INPP5A	-0.55	-8.61	-0.37	1.17e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs79839061	0.611	rs2279183	chr4:882404	T/C	cg07828340	chr4:882639	GAK	0.62	7.74	0.34	6.1e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3820068	0.581	rs6429762	chr1:15945595	A/C	cg05660106	chr1:15850417	CASP9	0.87	18.22	0.65	2.43e-56	Systolic blood pressure;
LGG	cis	rs7814319	0.700	rs35290014	chr8:97263930	T/C	cg20787634	chr8:97240163	UQCRB	-0.67	-13.74	-0.54	2.9e-36	Lung function (FVC);
LGG	cis	rs35740288	0.822	rs2241268	chr15:86278309	G/A	cg07943548	chr15:86304357	KLHL25	-0.36	-7.0	-0.31	9.02e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7756236	0.521	rs6907793	chr6:36625206	A/G	cg08179530	chr6:36648295	CDKN1A	0.41	6.69	0.3	6.56e-11	QRS duration;
LGG	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg16339924	chr4:17578868	LAP3	0.5	8.37	0.36	6.72e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg27624424	chr6:160112604	SOD2	0.65	9.61	0.41	4.79e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11122272	0.735	rs2572249	chr1:231514829	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.87	-0.45	1.17e-24	Hemoglobin concentration;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg04503457	chr17:41445688	NA	-0.39	-8.97	-0.38	7.68e-18	Menopause (age at onset);
LGG	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg01620082	chr3:125678407	NA	-0.76	-7.47	-0.33	4.09e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg19784903	chr17:45786737	TBKBP1	-0.33	-7.2	-0.32	2.38e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7580658	0.857	rs17015199	chr2:128094053	A/G	cg10021288	chr2:128175891	PROC	-0.63	-12.88	-0.51	1.13e-32	Protein C levels;
LGG	cis	rs1167827	0.680	rs1167796	chr7:75173180	C/T	cg09988129	chr7:74988866	PMS2L2;STAG3L1	-0.48	-8.48	-0.37	3.02e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.15e-25	Homoarginine levels;
LGG	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg16141378	chr3:129829833	LOC729375	0.32	6.74	0.3	4.82e-11	Triglycerides;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.59	10.53	0.44	2.25e-23	Lymphocyte counts;
LGG	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg06873352	chr17:61820015	STRADA	0.73	13.56	0.53	1.67e-35	Prudent dietary pattern;
LGG	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	6.95	0.31	1.28e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12282928	1.000	rs10160559	chr11:48280684	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.21	-0.32	2.3e-12	Migraine - clinic-based;
LGG	cis	rs3771570	1.000	rs17386555	chr2:242371825	G/A	cg21155796	chr2:242212141	HDLBP	0.73	9.78	0.41	1.17e-20	Prostate cancer;
LGG	cis	rs9462027	0.628	rs2764198	chr6:34706128	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.92	-0.45	7.12e-25	Systemic lupus erythematosus;
LGG	cis	rs7089973	0.604	rs7920216	chr10:116611794	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.49	0.33	3.47e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23426587	chr9:21335126	KLHL9	0.43	6.79	0.3	3.55e-11	Gut microbiome composition (summer);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18703066	chr2:105363536	NA	0.4	6.8	0.3	3.2e-11	Pancreatic cancer;
LGG	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs4363385	0.747	rs10494285	chr1:152982285	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs10189230	0.967	rs13026378	chr2:222352712	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg19168338	chr16:4465731	CORO7	0.72	13.43	0.53	5.71e-35	Schizophrenia;
LGG	cis	rs209489	0.892	rs9474466	chr6:53111517	A/G	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs992157	0.560	rs4674275	chr2:219097738	G/A	cg04731861	chr2:219085781	ARPC2	0.52	13.46	0.53	4.17e-35	Colorectal cancer;
LGG	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14442939	chr10:27389572	ANKRD26	0.71	9.0	0.39	5.73e-18	Breast cancer;
LGG	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg05973401	chr12:123451056	ABCB9	0.52	7.71	0.34	7.53e-14	Neutrophil percentage of white cells;
LGG	cis	rs4653767	1.000	rs10916030	chr1:226919908	C/T	cg00279406	chr1:226924739	ITPKB	0.26	6.67	0.3	7.19e-11	Parkinson's disease;
LGG	trans	rs9951602	0.920	rs28639710	chr18:76679847	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	9.31	0.4	4.98e-19	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	9.87e-17	Lung cancer;
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg03891598	chr16:83986782	OSGIN1	0.64	12.16	0.49	9.77e-30	Pursuit maintenance gain;
LGG	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.76	-0.41	1.4e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg23782820	chr8:58130467	NA	0.51	7.83	0.34	3.43e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.545	rs7307303	chr12:39368976	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg22920501	chr2:26401640	FAM59B	0.45	9.35	0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs11648796	0.757	rs6600231	chr16:766485	A/G	cg00908189	chr16:619842	PIGQ	-0.48	-7.18	-0.32	2.79e-12	Height;
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20814179	chr4:940893	TMEM175	0.46	8.25	0.36	1.67e-15	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg21775007	chr8:11205619	TDH	-0.49	-7.64	-0.33	1.23e-13	Neuroticism;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg00701064	chr4:6280414	WFS1	0.75	17.22	0.62	1.01e-51	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2742417	0.603	rs2742457	chr3:45767487	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.42	-0.4	2.11e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4065321	0.522	rs11078930	chr17:38141955	C/T	cg17467752	chr17:38218738	THRA	-0.59	-9.79	-0.41	1.04e-20	White blood cell count (basophil);White blood cell count;
LGG	cis	rs11203032	0.831	rs7902290	chr10:90931602	T/C	cg16672925	chr10:90967113	CH25H	0.53	8.17	0.36	2.88e-15	Heart failure;
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg14500267	chr11:67383377	NA	-0.39	-7.13	-0.31	3.96e-12	Mean corpuscular volume;
LGG	cis	rs72960926	1.000	rs72969274	chr6:75089862	G/A	cg03266952	chr6:74778945	NA	-0.7	-6.9	-0.31	1.71e-11	Metabolite levels (MHPG);
LGG	cis	rs12362504	0.504	rs7131516	chr11:9893919	T/C	cg07197493	chr11:9884649	SBF2	-0.36	-6.75	-0.3	4.43e-11	Survival in pancreatic cancer;
LGG	cis	rs2470578	0.792	rs2348001	chr3:17251577	T/G	cg20981856	chr3:17787350	NA	0.35	6.64	0.3	8.57e-11	Schizophrenia;
LGG	cis	rs758324	0.812	rs2159243	chr5:131133900	G/A	cg06307176	chr5:131281290	NA	0.53	8.83	0.38	2.1e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00166722	chr3:10149974	C3orf24	0.54	8.86	0.38	1.71e-17	Alzheimer's disease;
LGG	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg25287198	chr4:183728479	NA	0.45	7.87	0.34	2.59e-14	Pediatric autoimmune diseases;
LGG	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.22e-19	Chronic lymphocytic leukemia;
LGG	cis	rs3126085	0.935	rs4845426	chr1:152195359	A/G	cg26876637	chr1:152193138	HRNR	0.56	9.19	0.39	1.3e-18	Atopic dermatitis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg15208247	chr1:244857838	PPPDE1	-0.61	-7.2	-0.32	2.46e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2270927	0.510	rs246814	chr5:75599208	C/T	cg13563193	chr19:33072644	PDCD5	0.86	10.17	0.43	4.63e-22	Mean corpuscular volume;
LGG	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.88	0.34	2.38e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.53e-13	Body mass index;
LGG	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg20026190	chr17:76395443	PGS1	0.56	10.0	0.42	1.84e-21	HDL cholesterol levels;
LGG	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg15541040	chr2:3486749	NA	-0.44	-7.99	-0.35	1.08e-14	Neurofibrillary tangles;
LGG	cis	rs1107366	0.722	rs1992855	chr3:125909669	C/T	cg06827562	chr3:125932279	NA	-0.58	-13.53	-0.53	2.15e-35	Metabolite levels;
LGG	cis	rs11098499	0.863	rs6833334	chr4:120504227	C/T	cg24375607	chr4:120327624	NA	0.68	11.21	0.46	5.75e-26	Corneal astigmatism;
LGG	cis	rs4622507	0.728	rs34585830	chr16:55054891	G/T	cg09947736	chr16:55091198	NA	0.68	12.09	0.49	1.92e-29	Social communication problems;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg16507663	chr6:150244633	RAET1G	0.43	7.94	0.35	1.57e-14	Lung cancer;
LGG	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg25114630	chr15:101792522	CHSY1	0.57	9.7	0.41	2.22e-20	Corneal structure;
LGG	cis	rs59918340	0.728	rs10875467	chr8:142233396	A/C	cg03653399	chr8:142233436	SLC45A4	-0.42	-8.18	-0.36	2.73e-15	Immature fraction of reticulocytes;
LGG	cis	rs6504108	0.624	rs7220922	chr17:46224908	A/G	cg02219949	chr17:45927392	SP6	0.44	8.3	0.36	1.18e-15	Body mass index;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.7	-0.41	2.24e-20	Lung cancer;
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg02976405	chr7:40174270	C7orf10;C7orf11	-0.37	-6.99	-0.31	9.83e-12	Select biomarker traits;
LGG	cis	rs12478296	1.000	rs6739247	chr2:243039189	C/A	cg06360820	chr2:242988706	NA	-0.88	-11.31	-0.47	2.32e-26	Obesity-related traits;
LGG	cis	rs6430585	0.527	rs961360	chr2:136393658	A/G	cg07169764	chr2:136633963	MCM6	1.0	16.45	0.61	3.4e-48	Corneal structure;
LGG	cis	rs10875746	0.624	rs10875777	chr12:48622071	T/C	cg24011408	chr12:48396354	COL2A1	-0.56	-7.42	-0.33	5.51e-13	Longevity (90 years and older);
LGG	trans	rs7937682	0.889	rs558736	chr11:111500760	C/G	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg26174226	chr8:58114915	NA	-0.6	-8.63	-0.37	9.85e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.54	0.63	3.32e-53	Smoking behavior;
LGG	cis	rs911119	1.000	rs5030707	chr20:23618656	C/G	cg16589663	chr20:23618590	CST3	0.48	6.75	0.3	4.41e-11	Chronic kidney disease;
LGG	cis	rs8053891	0.805	rs12149869	chr16:71995946	T/C	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.77	-0.3	3.98e-11	Coronary artery disease;
LGG	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg19784903	chr17:45786737	TBKBP1	0.33	7.32	0.32	1.09e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10220309	0.501	rs74064457	chr14:80660670	G/A	cg08183125	chr14:80678293	DIO2	-0.47	-7.48	-0.33	3.64e-13	Lung function (FEV1);
LGG	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg06623630	chr22:50017776	C22orf34	-0.36	-7.59	-0.33	1.82e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg01673284	chr16:4527211	HMOX2	0.34	6.71	0.3	5.68e-11	Schizophrenia;
LGG	trans	rs36715	1.000	rs36702	chr5:127552723	A/T	cg16011800	chr17:1958478	HIC1	-0.46	-6.95	-0.31	1.23e-11	Breast cancer;
LGG	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg26031613	chr14:104095156	KLC1	-0.56	-8.83	-0.38	2.11e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2658782	0.826	rs1975820	chr11:93081815	G/A	cg15737290	chr11:93063684	CCDC67	0.56	8.24	0.36	1.81e-15	Pulmonary function decline;
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.24	0.69	1.06e-65	Alzheimer's disease;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg23758822	chr17:41437982	NA	0.82	14.78	0.57	9.28e-41	Menopause (age at onset);
LGG	cis	rs17331151	0.541	rs4687676	chr3:52890418	C/T	cg04865290	chr3:52927548	TMEM110	0.39	6.84	0.3	2.48e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs68149176	0.772	rs997762	chr16:87879562	C/A	cg00025439	chr16:87856450	NA	-0.43	-6.65	-0.3	8.29e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg07274523	chr3:49395745	GPX1	0.57	9.58	0.41	5.82e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs870825	1.000	rs870825	chr4:185588045	A/G	cg04058563	chr4:185651563	MLF1IP	0.93	16.98	0.62	1.24e-50	Blood protein levels;
LGG	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg26695010	chr11:65641043	EFEMP2	-0.54	-9.45	-0.4	1.68e-19	Eosinophil percentage of white cells;
LGG	cis	rs62400317	0.859	rs10948213	chr6:45158515	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.59e-22	Height;
LGG	trans	rs9393777	0.513	rs9379895	chr6:26592707	A/G	cg06606381	chr12:133084897	FBRSL1	-0.51	-6.65	-0.3	8.41e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg15557168	chr22:42548783	NA	-0.4	-8.54	-0.37	1.95e-16	Schizophrenia;
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg15105011	chr4:940614	TMEM175	0.42	8.07	0.35	6.14e-15	Sjögren's syndrome;
LGG	cis	rs4665809	1.000	rs12475854	chr2:26267375	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.09	-0.52	1.62e-33	Gut microbiome composition (summer);
LGG	cis	rs4356932	0.967	rs6532159	chr4:76978124	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.67	-0.3	7.16e-11	Blood protein levels;
LGG	cis	rs1519814	1.000	rs12678023	chr8:121123494	G/A	cg22335954	chr8:121166405	COL14A1	-0.53	-10.9	-0.45	8.5e-25	Breast cancer;
LGG	cis	rs7586879	0.964	rs4077679	chr2:25122852	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.92	0.42	3.81e-21	Body mass index;
LGG	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs75920871	0.588	rs7101763	chr11:116941985	G/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.5	-0.44	2.87e-23	Subjective well-being;
LGG	cis	rs1577917	1.000	rs2816821	chr6:86657084	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg18129748	chr3:49941408	MST1R	0.23	7.2	0.32	2.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07570687	chr10:102243282	WNT8B	-0.43	-6.97	-0.31	1.11e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4006360	0.575	rs7503162	chr17:39233899	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.45e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs796364	0.715	rs77089299	chr2:201116853	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-7.06	-0.31	6.01e-12	Schizophrenia;
LGG	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.76	-13.8	-0.54	1.56e-36	Chronic sinus infection;
LGG	cis	rs2905347	0.757	rs1006509	chr7:22698466	C/T	cg23521230	chr7:22704884	NA	-0.4	-7.36	-0.32	8.67e-13	Major depression and alcohol dependence;
LGG	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	cg07245641	chr1:182991651	LAMC1	0.39	8.99	0.39	6.35e-18	Colorectal cancer;
LGG	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg09462578	chr12:12878428	APOLD1	-0.59	-8.16	-0.35	3.26e-15	Systemic lupus erythematosus;
LGG	cis	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg08112188	chr17:47440006	ZNF652	1.34	15.81	0.59	2.35e-45	Prostate cancer;
LGG	cis	rs3816183	0.716	rs4528815	chr2:43077037	G/T	cg14631114	chr2:43023945	NA	0.45	8.07	0.35	6.25e-15	Hypospadias;
LGG	cis	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg14019146	chr3:50243930	SLC38A3	0.38	8.01	0.35	9.68e-15	Menarche (age at onset);
LGG	trans	rs2736345	0.788	rs2618444	chr8:11338370	A/C	cg02002194	chr4:3960332	NA	-0.42	-6.76	-0.3	4.04e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg09264619	chr17:80180166	NA	-0.41	-7.94	-0.35	1.53e-14	Life satisfaction;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.37	-0.36	6.91e-16	Aortic root size;
LGG	cis	rs2191566	0.691	rs8104605	chr19:44589016	C/T	cg20607764	chr19:44506953	ZNF230	0.42	7.47	0.33	3.96e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.77	-0.41	1.25e-20	Lung cancer;
LGG	cis	rs472402	0.580	rs11134173	chr5:6659696	C/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-6.93	-0.31	1.4e-11	Response to amphetamines;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17376288	chr3:190993197	UTS2D	0.31	6.99	0.31	9.95e-12	Menarche (age at onset);
LGG	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	24.97	0.76	8.44e-88	IgG glycosylation;
LGG	cis	rs10191773	0.589	rs72831639	chr2:112949291	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.52	-7.08	-0.31	5.44e-12	Yeast infection;
LGG	cis	rs3845702	0.736	rs6433816	chr2:180809317	G/C	cg01881094	chr2:180872142	CWC22	-1.26	-16.35	-0.6	9.59e-48	Schizophrenia;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.48e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23550757	chr12:120755296	NA	0.49	7.22	0.32	2.22e-12	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs34172651	0.917	rs8043962	chr16:24781372	A/G	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.53	-0.33	2.73e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6424115	0.546	rs35993651	chr1:24180613	C/G	cg24699146	chr1:24152579	HMGCL	-0.27	-8.02	-0.35	8.87e-15	Immature fraction of reticulocytes;
LGG	cis	rs26868	0.712	rs26832	chr16:2238337	A/G	cg02248941	chr16:2239361	CASKIN1	0.5	10.13	0.43	6.22e-22	Height;
LGG	cis	rs17818399	0.815	rs62136873	chr2:46861237	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.71	0.3	5.86e-11	Height;
LGG	cis	rs8016982	0.662	rs2288498	chr14:81660710	T/C	cg01989461	chr14:81687754	GTF2A1	0.58	9.1	0.39	2.76e-18	Schizophrenia;
LGG	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.47	-0.44	3.57e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs227833	0.837	rs679769	chr6:44674860	C/T	cg18551225	chr6:44695536	NA	0.43	7.13	0.31	3.76e-12	Monobrow;
LGG	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg09998033	chr7:158218633	PTPRN2	-0.56	-10.2	-0.43	3.56e-22	Obesity-related traits;
LGG	cis	rs523522	0.962	rs11065154	chr12:120971417	T/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg23461800	chr14:103021989	NA	-0.58	-10.59	-0.44	1.3e-23	Platelet count;
LGG	cis	rs7412746	0.634	rs7521592	chr1:150821691	A/C	cg15448220	chr1:150897856	SETDB1	0.39	7.16	0.32	3.09e-12	Melanoma;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg07142201	chr11:109293216	C11orf87	0.5	9.24	0.39	8.96e-19	Schizophrenia;
LGG	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	cg07928641	chr1:182991847	LAMC1	0.44	8.77	0.38	3.54e-17	Colorectal cancer;
LGG	cis	rs4689388	0.791	rs1046317	chr4:6304242	T/C	cg14416269	chr4:6271139	WFS1	0.44	7.58	0.33	1.87e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs73198271	0.515	rs75660006	chr8:8619594	C/T	cg01851573	chr8:8652454	MFHAS1	0.5	6.71	0.3	5.7e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg15558759	chr11:118478939	PHLDB1	0.5	8.92	0.38	1.08e-17	Systemic lupus erythematosus;
LGG	cis	rs9902453	0.619	rs2255489	chr17:28084974	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.9	-0.54	6.12e-37	Coffee consumption (cups per day);
LGG	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg08564027	chr20:61660810	NA	1.02	25.33	0.76	1.88e-89	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg26200347	chr10:15254612	FAM171A1	-0.62	-6.66	-0.3	7.9e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.31	-0.47	2.41e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	7.54	0.33	2.55e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11690935	0.550	rs4280427	chr2:172813218	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.91	0.48	9.98e-29	Schizophrenia;
LGG	cis	rs4740619	0.905	rs10756678	chr9:15615932	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.55	-0.44	1.86e-23	Body mass index;
LGG	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	7.93e-13	Platelet count;
LGG	cis	rs745080	0.519	rs10140899	chr14:53008807	T/C	cg23333723	chr14:53022898	GPR137C	-0.4	-7.97	-0.35	1.21e-14	Orofacial clefts;
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9783347	1.000	rs7947378	chr11:18381327	T/C	cg03595886	chr11:18357587	GTF2H1	-0.34	-6.98	-0.31	1.03e-11	Pancreatic cancer;
LGG	cis	rs9914988	0.887	rs12948575	chr17:27130520	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs9398803	0.865	rs7738135	chr6:126829981	G/A	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs644799	1.000	rs1944074	chr11:95511445	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.91	0.35	1.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.29	0.36	1.24e-15	Aortic root size;
LGG	cis	rs2270450	1.000	rs2270450	chr6:46644875	C/T	cg10156739	chr6:46714674	LOC100287718	-0.35	-8.25	-0.36	1.65e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01813165	chr2:202646406	ALS2	0.48	7.56	0.33	2.19e-13	Gut microbiome composition (summer);
LGG	cis	rs13082711	0.522	rs537674	chr3:27361901	G/T	cg02860705	chr3:27208620	NA	0.58	10.96	0.45	5.4e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg06046430	chr4:77819534	ANKRD56	0.56	11.36	0.47	1.49e-26	Emphysema distribution in smoking;
LGG	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.71	-0.34	7.56e-14	Triglycerides;
LGG	cis	rs7847628	0.587	rs12684934	chr9:123593159	C/T	cg03808351	chr9:123631620	PHF19	0.29	7.27	0.32	1.5e-12	Birth weight;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg01238044	chr22:24384105	GSTT1	-0.52	-9.01	-0.39	5.45e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs651907	0.613	rs1707618	chr3:101631207	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.85	0.34	2.85e-14	Colorectal cancer;
LGG	cis	rs611744	0.608	rs1448152	chr8:109278249	C/T	cg18478394	chr8:109455254	TTC35	0.44	8.79	0.38	2.97e-17	Dupuytren's disease;
LGG	cis	rs36051895	0.623	rs7023639	chr9:5244058	A/C	cg02405213	chr9:5042618	JAK2	-0.74	-13.1	-0.52	1.43e-33	Pediatric autoimmune diseases;
LGG	trans	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.42	-0.4	2.17e-19	Bladder cancer;
LGG	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg21545522	chr1:205238299	TMCC2	0.41	7.78	0.34	4.92e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs4979906	1.000	rs12264636	chr10:79448539	C/G	cg07817648	chr10:79422355	NA	0.49	7.8	0.34	4.12e-14	Mortality in heart failure;
LGG	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg06153925	chr17:78755379	RPTOR	-0.42	-7.3	-0.32	1.26e-12	Myopia (pathological);
LGG	cis	rs11690935	0.851	rs7573003	chr2:172741415	T/A	cg21435375	chr2:172878103	MAP1D	-0.34	-7.55	-0.33	2.29e-13	Schizophrenia;
LGG	cis	rs10865541	0.869	rs4971499	chr2:3438749	C/G	cg11642891	chr2:3452563	TTC15	-0.39	-7.39	-0.32	7.1e-13	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21675115	chr13:78493564	EDNRB	0.45	7.74	0.34	6.45e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2976388	0.609	rs2717601	chr8:143807924	T/C	cg06565975	chr8:143823917	SLURP1	0.36	9.27	0.4	7.22e-19	Urinary tract infection frequency;
LGG	cis	rs4299518	0.516	rs12490293	chr3:45788127	T/C	cg04837898	chr3:45731254	SACM1L	0.45	8.8	0.38	2.83e-17	Hirschsprung disease;
LGG	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2865126	0.818	rs12605455	chr18:10757261	A/G	cg21165219	chr18:10698044	FAM38B	-0.45	-7.28	-0.32	1.45e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs2916247	0.954	rs1443558	chr8:92986385	G/A	cg10183463	chr8:93005414	RUNX1T1	0.39	8.2	0.36	2.35e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.41e-17	Self-reported allergy;
LGG	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.3e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg13073564	chr4:8508604	NA	-0.53	-10.89	-0.45	9.67e-25	Response to antineoplastic agents;
LGG	cis	rs2070997	0.618	rs3780282	chr9:133743654	G/A	cg13397898	chr9:133768931	QRFP	0.36	8.37	0.36	6.87e-16	Response to amphetamines;
LGG	cis	rs3126085	0.734	rs3120653	chr1:152284854	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.59	-0.37	1.37e-16	Atopic dermatitis;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.18	-0.36	2.74e-15	Small cell lung carcinoma;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg17192681	chr2:10953115	PDIA6	-0.41	-6.94	-0.31	1.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12908161	0.960	rs62019463	chr15:85288087	G/A	cg24253500	chr15:84953950	NA	0.42	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs7666738	0.830	rs4440224	chr4:99044924	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72781680	1.000	rs72796339	chr2:24143063	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg21926883	chr2:100939477	LONRF2	-0.51	-9.72	-0.41	1.87e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-13.84	-0.54	1.05e-36	Bladder cancer;
LGG	cis	rs3106136	0.527	rs2883	chr4:95158610	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.05	-0.46	2.36e-25	Capecitabine sensitivity;
LGG	cis	rs3816183	0.585	rs6742450	chr2:42859860	G/A	cg14631114	chr2:43023945	NA	0.35	6.94	0.31	1.32e-11	Hypospadias;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-13.66	-0.54	6.29e-36	Platelet count;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg01059449	chr18:44338099	ST8SIA5	0.37	7.95	0.35	1.42e-14	Personality dimensions;
LGG	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	trans	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.5	0.37	2.7e-16	Mood instability;
LGG	cis	rs611744	0.647	rs676654	chr8:109242303	A/G	cg18478394	chr8:109455254	TTC35	0.43	8.62	0.37	1.05e-16	Dupuytren's disease;
LGG	cis	rs6087990	0.735	rs4911260	chr20:31376490	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	16.75	0.61	1.35e-49	Ulcerative colitis;
LGG	cis	rs7264396	0.616	rs6060744	chr20:34581555	T/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-7.14	-0.31	3.66e-12	Total cholesterol levels;
LGG	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg11161011	chr14:65562177	MAX	-0.66	-12.23	-0.49	5.33e-30	Obesity-related traits;
LGG	cis	rs17023223	0.537	rs10802075	chr1:119627227	C/T	cg05756136	chr1:119680316	WARS2	-0.41	-8.19	-0.36	2.57e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs250677	0.652	rs1422582	chr5:148436925	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-6.8	-0.3	3.32e-11	Breast cancer;
LGG	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs7071206	0.947	rs716255	chr10:79419679	A/T	cg07817648	chr10:79422355	NA	-0.74	-13.98	-0.54	2.68e-37	Bone mineral density;
LGG	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg13852791	chr20:30311386	BCL2L1	0.64	8.67	0.37	7.12e-17	Mean corpuscular hemoglobin;
LGG	cis	rs703842	1.000	rs2072052	chr12:58146719	A/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.93	0.35	1.68e-14	Multiple sclerosis;
LGG	cis	rs7215564	0.818	rs901063	chr17:78595696	A/T	cg16980736	chr17:78789706	RPTOR	0.69	8.72	0.38	4.92e-17	Myopia (pathological);
LGG	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.13	-0.31	3.86e-12	Monocyte count;
LGG	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.13	-0.6	9.41e-47	Total body bone mineral density;
LGG	cis	rs2066819	1.000	rs59811639	chr12:56695954	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs4740619	0.509	rs78873905	chr9:15633070	T/G	cg14451791	chr9:16040625	NA	-0.41	-10.41	-0.44	5.98e-23	Body mass index;
LGG	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11644478	chr21:40555479	PSMG1	0.6	9.86	0.42	5.89e-21	Menarche (age at onset);
LGG	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg04117972	chr1:227635322	NA	0.55	8.79	0.38	3.04e-17	Major depressive disorder;
LGG	cis	rs922692	0.744	rs12903203	chr15:79084933	T/C	cg00540400	chr15:79124168	NA	-0.39	-7.62	-0.33	1.47e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs17102884	0.600	rs9671386	chr14:75151047	G/A	cg06637938	chr14:75390232	RPS6KL1	0.48	7.14	0.31	3.64e-12	Neuroticism;
LGG	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg21605333	chr4:119757512	SEC24D	1.51	14.93	0.57	1.94e-41	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg15971980	chr6:150254442	NA	0.44	8.44	0.37	4.04e-16	Lung cancer;
LGG	cis	rs1978968	1.000	rs1978968	chr22:18448113	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.6	11.65	0.48	1.09e-27	Presence of antiphospholipid antibodies;
LGG	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg11839771	chr15:80205821	ST20	-0.37	-7.88	-0.34	2.4e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9462027	0.628	rs6906759	chr6:34742990	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg26449787	chr6:133562087	EYA4	0.34	6.76	0.3	4.16e-11	Total body bone mineral density;
LGG	cis	rs7617773	0.743	rs71323397	chr3:48374874	A/G	cg11946769	chr3:48343235	NME6	0.7	11.6	0.47	1.66e-27	Coronary artery disease;
LGG	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg13271783	chr10:134563150	INPP5A	-0.58	-8.53	-0.37	2.18e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12464483	0.591	rs4952170	chr2:30885429	G/A	cg17749961	chr2:30669863	LCLAT1	0.79	10.56	0.44	1.72e-23	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs4356932	1.000	rs4543147	chr4:76976661	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.82	-0.3	2.89e-11	Blood protein levels;
LGG	cis	rs42648	0.792	rs4236517	chr7:89963465	A/T	cg25739043	chr7:89950458	NA	-0.34	-7.05	-0.31	6.52e-12	Homocysteine levels;
LGG	cis	rs1577917	0.958	rs2324840	chr6:86557620	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	trans	rs2624839	0.704	rs14321	chr3:50226151	T/C	cg21659725	chr3:3221576	CRBN	-0.5	-7.8	-0.34	4.06e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg07075026	chr17:47091521	IGF2BP1	-0.38	-6.92	-0.31	1.48e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs9463078	0.764	rs6458415	chr6:44881592	G/C	cg25276700	chr6:44698697	NA	-0.4	-8.53	-0.37	2.05e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg09307838	chr4:120376055	NA	0.82	13.53	0.53	2.31e-35	Corneal astigmatism;
LGG	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg03733263	chr8:22462867	KIAA1967	1.04	27.0	0.78	4.03e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs55633855	0.516	rs56000409	chr11:88142709	T/A	cg08522340	chr11:88068493	CTSC	-0.4	-7.09	-0.31	4.88e-12	Body mass index;
LGG	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg15309053	chr8:964076	NA	0.34	6.86	0.3	2.19e-11	Schizophrenia;
LGG	cis	rs4302748	0.862	rs11974209	chr7:36184479	A/G	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs11627756	0.915	rs11850368	chr14:103131770	G/C	cg12046867	chr14:103022105	NA	0.46	8.47	0.37	3.21e-16	Mean platelet volume;
LGG	cis	rs6032067	0.777	rs13044826	chr20:43801865	C/T	cg10761708	chr20:43804764	PI3	0.71	11.13	0.46	1.18e-25	Blood protein levels;
LGG	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg05692746	chr2:100937584	LONRF2	-0.56	-9.67	-0.41	2.92e-20	Intelligence (multi-trait analysis);
LGG	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg27147174	chr7:100797783	AP1S1	-0.68	-12.69	-0.51	7.21e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6540556	0.954	rs7548219	chr1:209936466	A/G	cg23920097	chr1:209922102	NA	-0.45	-7.95	-0.35	1.48e-14	Red blood cell count;
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg15105011	chr4:940614	TMEM175	0.4	7.67	0.34	9.92e-14	Sjögren's syndrome;
LGG	cis	rs11700980	0.636	rs115245768	chr21:30256118	T/G	cg24692254	chr21:30365293	RNF160	-0.61	-7.4	-0.33	6.53e-13	QRS complex (12-leadsum);
LGG	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg07382826	chr16:28625726	SULT1A1	-0.42	-8.85	-0.38	1.8e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg18344811	chr7:822633	HEATR2	-0.34	-6.65	-0.3	8.12e-11	Migraine with aura;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.67e-12	Menopause (age at onset);
LGG	cis	rs7674212	0.541	rs2623064	chr4:104030792	C/A	cg16532752	chr4:104119610	CENPE	-0.4	-6.92	-0.31	1.48e-11	Type 2 diabetes;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07274776	chr2:203241322	BMPR2	0.39	6.71	0.3	5.8e-11	Bipolar disorder;
LGG	cis	rs34172651	0.606	rs7194189	chr16:24703484	G/T	cg02428538	chr16:24856791	SLC5A11	0.58	9.37	0.4	3.29e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-12.4	-0.5	1.12e-30	Mood instability;
LGG	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg22875332	chr1:76189707	ACADM	0.57	8.65	0.37	8.69e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg16096631	chr1:42092165	HIVEP3	0.76	23.79	0.74	2.5e-82	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs11785693	0.862	rs11786595	chr8:5001621	T/G	cg26367366	chr8:4980734	NA	1.0	14.92	0.57	2.29e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg25427524	chr10:38739819	LOC399744	0.62	12.31	0.5	2.54e-30	Extrinsic epigenetic age acceleration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00838250	chr3:186287958	TBCCD1;DNAJB11	-0.49	-7.61	-0.33	1.5e-13	Systemic lupus erythematosus;
LGG	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg21452805	chr1:244014465	NA	0.61	6.81	0.3	2.98e-11	RR interval (heart rate);
LGG	cis	rs6456156	0.565	rs12529959	chr6:167469292	T/C	cg07741184	chr6:167504864	NA	0.4	9.16	0.39	1.68e-18	Primary biliary cholangitis;
LGG	cis	rs4474465	0.850	rs4590904	chr11:78263847	C/T	cg27205649	chr11:78285834	NARS2	0.5	8.56	0.37	1.64e-16	Alzheimer's disease (survival time);
LGG	cis	rs9660992	0.649	rs72745216	chr1:205261016	G/A	cg21545522	chr1:205238299	TMCC2	0.47	8.44	0.37	4.2e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	12.04	0.49	2.99e-29	Response to antipsychotic treatment;
LGG	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.32	-0.43	1.35e-22	Menarche (age at onset);
LGG	cis	rs72945132	0.882	rs66989619	chr11:70202127	G/C	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg12310025	chr6:25882481	NA	-0.94	-20.4	-0.69	1.84e-66	Urate levels;
LGG	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg19025524	chr12:109796872	NA	-0.41	-8.14	-0.35	3.67e-15	Neuroticism;
LGG	cis	rs11628318	0.614	rs7155804	chr14:103114945	A/G	cg23461800	chr14:103021989	NA	0.52	8.25	0.36	1.65e-15	Platelet count;
LGG	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg02002194	chr4:3960332	NA	0.39	6.9	0.31	1.73e-11	Triglycerides;
LGG	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg11890956	chr21:40555474	PSMG1	-1.0	-21.47	-0.71	1.74e-71	Cognitive function;
LGG	cis	rs7100689	0.556	rs6585971	chr10:82145057	G/C	cg01528321	chr10:82214614	TSPAN14	0.88	15.59	0.59	2.42e-44	Post bronchodilator FEV1;
LGG	trans	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg22705835	chr10:65332833	REEP3	-0.5	-9.39	-0.4	2.63e-19	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg00933542	chr6:150070202	PCMT1	0.4	7.25	0.32	1.75e-12	Lung cancer;
LGG	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.9	0.57	2.79e-41	Cognitive test performance;
LGG	trans	rs12517041	1.000	rs6890216	chr5:23299559	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg05623727	chr3:50126028	RBM5	-0.37	-7.72	-0.34	7.26e-14	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03853987	chr2:101034279	CHST10	0.45	6.72	0.3	5.25e-11	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg00717180	chr2:96193071	NA	-0.46	-8.38	-0.36	6.2e-16	HDL cholesterol;
LGG	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.2	0.39	1.19e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27511599	chr7:32358540	NA	0.65	7.18	0.32	2.81e-12	Body mass index;
LGG	cis	rs17666538	0.535	rs1669613	chr8:617565	G/C	cg13264159	chr8:625131	ERICH1	-1.04	-12.13	-0.49	1.39e-29	IgG glycosylation;
LGG	cis	rs4696584	0.816	rs1552638	chr4:155402365	A/G	cg04517429	chr4:155413618	DCHS2	0.32	7.15	0.32	3.51e-12	Folding of antihelix;
LGG	cis	rs1003719	0.715	rs2212742	chr21:38578685	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.81	-0.57	6.77e-41	Eye color traits;
LGG	cis	rs1832871	0.619	rs262826	chr6:158680567	C/T	cg07215822	chr6:158701037	NA	-0.49	-9.76	-0.41	1.43e-20	Height;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg16301924	chr13:53314226	LECT1	-0.48	-9.92	-0.42	3.72e-21	Lewy body disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg11956111	chr2:74710460	TTC31;CCDC142	0.44	7.28	0.32	1.43e-12	Menarche (age at onset);
LGG	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg12011299	chr4:100065546	ADH4	0.43	8.61	0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg25019033	chr10:957182	NA	-0.61	-11.12	-0.46	1.25e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg18876405	chr7:65276391	NA	0.54	9.68	0.41	2.62e-20	Aortic root size;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg12692727	chr7:1102344	C7orf50	0.48	6.71	0.3	5.8200000000000003e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3617	0.539	rs9985365	chr3:52953844	A/G	cg11645453	chr3:52864694	ITIH4	-0.45	-7.66	-0.34	1.12e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14952266	chr13:112191215	NA	-0.41	-7.49	-0.33	3.47e-13	Menarche (age at onset);
LGG	cis	rs68170813	0.559	rs17429146	chr7:106964281	A/G	cg02696742	chr7:106810147	HBP1	-0.71	-10.29	-0.43	1.65e-22	Coronary artery disease;
LGG	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg02002194	chr4:3960332	NA	0.39	7.1	0.31	4.77e-12	Neuroticism;
LGG	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs1493916	0.837	rs2172626	chr18:31410478	C/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg03647317	chr4:187891568	NA	-0.42	-8.81	-0.38	2.46e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs227808	0.812	rs9463009	chr6:44647278	G/A	cg18551225	chr6:44695536	NA	0.48	6.95	0.31	1.21e-11	Male-pattern baldness;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg19168338	chr16:4465731	CORO7	-0.89	-16.84	-0.62	5.34e-50	Schizophrenia;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.77	-0.34	5.18e-14	Skin colour saturation;
LGG	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg15395560	chr15:45543142	SLC28A2	0.42	6.95	0.31	1.27e-11	Glomerular filtration rate;
LGG	trans	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg25482853	chr8:67687455	SGK3	0.97	11.9	0.48	1.09e-28	Obesity-related traits;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.76	-0.34	5.43e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg05692746	chr2:100937584	LONRF2	-0.59	-9.72	-0.41	1.83e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg05665937	chr4:1216051	CTBP1	0.52	9.61	0.41	4.69e-20	Obesity-related traits;
LGG	cis	rs4740619	0.819	rs10756700	chr9:15761808	T/C	cg14451791	chr9:16040625	NA	-0.39	-10.36	-0.43	9.44e-23	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23451424	chr7:82073339	CACNA2D1	0.42	7.43	0.33	5.12e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg02018176	chr4:1364513	KIAA1530	0.44	9.58	0.41	5.86e-20	Obesity-related traits;
LGG	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg13010199	chr12:38710504	ALG10B	-0.6	-11.18	-0.46	7.51e-26	Morning vs. evening chronotype;
LGG	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	15.24	0.58	8.24e-43	Nonalcoholic fatty liver disease;
LGG	cis	rs11671005	0.735	rs11667591	chr19:58937637	G/A	cg13877915	chr19:58951672	ZNF132	0.61	8.68	0.37	6.68e-17	Mean platelet volume;
LGG	trans	rs9929218	0.953	rs12930910	chr16:68762520	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.61	-0.56	4.94e-40	Colorectal cancer;
LGG	cis	rs283228	0.502	rs2852505	chr6:101843474	G/C	cg27451362	chr6:101846650	GRIK2	1.06	16.36	0.61	8e-48	Coenzyme Q10 levels;
LGG	cis	rs5769765	0.773	rs9616383	chr22:50313014	T/C	cg02269571	chr22:50332266	NA	-0.71	-10.93	-0.45	6.82e-25	Schizophrenia;
LGG	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.99	-0.39	6.21e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs3784262	0.740	rs4646582	chr15:58307381	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.89	-0.31	1.79e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg13789015	chr9:136890014	NCRNA00094	0.6	11.16	0.46	8.74e-26	Platelet distribution width;
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.42	-0.44	5.35e-23	Bipolar disorder;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.6	-0.47	1.71e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs4363385	0.747	rs4845509	chr1:152981900	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.14	-0.39	1.96e-18	Inflammatory skin disease;
LGG	cis	rs6815814	0.950	rs56289835	chr4:38811845	G/C	cg06935464	chr4:38784597	TLR10	0.6	8.19	0.36	2.49e-15	Breast cancer;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg07701084	chr6:150067640	NUP43	0.65	12.15	0.49	1.09e-29	Lung cancer;
LGG	cis	rs10193935	0.901	rs222486	chr2:42649664	C/T	cg27598129	chr2:42591480	NA	-0.66	-9.73	-0.41	1.73e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg15736062	chr7:158136485	PTPRN2	0.46	8.51	0.37	2.49e-16	Calcium levels;
LGG	cis	rs9911578	0.935	rs34523895	chr17:57034095	T/C	cg05425664	chr17:57184151	TRIM37	-0.6	-9.69	-0.41	2.43e-20	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs2133450	0.679	rs28378912	chr3:7365156	G/A	cg19930620	chr3:7340148	GRM7	-0.39	-8.49	-0.37	2.83e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs6831352	0.703	rs2602862	chr4:100033221	A/G	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs72781680	0.752	rs72796130	chr2:23919740	T/C	cg08917208	chr2:24149416	ATAD2B	0.83	8.86	0.38	1.71e-17	Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10985070	0.504	rs2296077	chr9:123944943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.52	9.38	0.4	2.85e-19	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03433549	chr12:56498817	PA2G4	0.44	6.66	0.3	7.55e-11	Gut microbiome composition (summer);
LGG	cis	rs17092148	1.000	rs17092148	chr20:33435161	A/C	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.64	-0.33	1.26e-13	Neuroticism;
LGG	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.67e-19	Retinal vascular caliber;
LGG	cis	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg07460842	chr6:66804631	NA	0.95	17.19	0.62	1.4e-51	Exhaled nitric oxide levels;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg15383120	chr6:291909	DUSP22	-0.41	-7.02	-0.31	8.05e-12	Menopause (age at onset);
LGG	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg03315344	chr16:75512273	CHST6	0.57	11.29	0.46	2.83e-26	Dupuytren's disease;
LGG	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg12193833	chr17:30244370	NA	-0.27	-6.97	-0.31	1.09e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2290159	0.800	rs5746187	chr3:12659419	A/G	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg08280861	chr8:58055591	NA	0.53	6.79	0.3	3.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.861	rs4926576	chr1:53226775	C/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	cis	rs977987	0.836	rs7198873	chr16:75474754	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.15	0.43	5.63e-22	Dupuytren's disease;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg15971980	chr6:150254442	NA	-0.42	-7.68	-0.34	9.85e-14	Lung cancer;
LGG	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.2e-54	Cognitive function;
LGG	cis	rs2077654	0.908	rs2077655	chr11:17427862	G/A	cg25308976	chr11:17434268	ABCC8	0.71	8.73	0.38	4.73e-17	Gout;
LGG	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg17211192	chr8:82754475	SNX16	-0.8	-12.57	-0.5	2.24e-31	Diastolic blood pressure;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg03647317	chr4:187891568	NA	-0.41	-8.88	-0.38	1.53e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1957429	0.572	rs3813421	chr14:65347239	G/A	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg16606324	chr3:10149918	C3orf24	0.55	7.14	0.31	3.63e-12	Alzheimer's disease;
LGG	cis	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg00806245	chr18:76673096	NA	-0.57	-6.79	-0.3	3.38e-11	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27467005	chr19:17622279	PGLS	0.46	7.8	0.34	4.24e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg03806693	chr22:41940476	POLR3H	0.94	16.8	0.62	8.08e-50	Vitiligo;
LGG	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.09	-0.31	5.08e-12	Schizophrenia;
LGG	cis	rs240764	0.817	rs239189	chr6:101128787	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.61	0.33	1.5700000000000001e-13	Neuroticism;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs6908034	0.607	rs62404179	chr6:19806272	T/C	cg02682789	chr6:19804855	NA	0.91	8.61	0.37	1.19e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.24	-0.49	4.95e-30	Hemoglobin concentration;
LGG	trans	rs208520	0.690	rs207119	chr6:66786408	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs3790455	1.000	rs1342442	chr1:156466699	A/G	cg14087168	chr1:156450669	MEF2D	-0.46	-7.47	-0.33	4.1e-13	Migraine;
LGG	cis	rs12348691	0.503	rs4743138	chr9:100614296	C/T	cg13688889	chr9:100608707	NA	0.83	16.3	0.6	1.53e-47	Alopecia areata;
LGG	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg02743256	chr7:2109353	MAD1L1	-0.39	-7.29	-0.32	1.37e-12	Neuroticism;
LGG	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg20673091	chr1:2541236	MMEL1	0.78	17.96	0.64	4.12e-55	Ulcerative colitis;
LGG	cis	rs11098499	0.697	rs6832410	chr4:120296800	A/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs66573146	0.572	rs66734745	chr4:6948765	T/C	cg00086871	chr4:6988644	TBC1D14	0.84	8.31	0.36	1.03e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg08470875	chr2:26401718	FAM59B	-0.4	-7.85	-0.34	2.82e-14	Gut microbiome composition (summer);
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg02158880	chr13:53174818	NA	0.44	8.67	0.37	7.1e-17	Lewy body disease;
LGG	cis	rs1109114	0.934	rs1011400	chr5:148611941	G/C	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.22	-0.58	1.08e-42	Body mass index;
LGG	trans	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg22232500	chr2:134024266	NCKAP5	0.55	7.8	0.34	4.22e-14	Bipolar disorder;
LGG	cis	rs7647973	0.626	rs62260723	chr3:49872124	T/C	cg03060546	chr3:49711283	APEH	-0.6	-8.17	-0.36	2.9e-15	Menarche (age at onset);
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.78e-16	Aortic root size;
LGG	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg19913688	chr11:428466	ANO9	-0.68	-8.53	-0.37	2.02e-16	Body mass index;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg06873352	chr17:61820015	STRADA	-0.68	-12.14	-0.49	1.2e-29	Prudent dietary pattern;
LGG	cis	rs477895	0.713	rs67546972	chr11:63962162	G/A	cg04317338	chr11:64019027	PLCB3	0.67	8.19	0.36	2.51e-15	Mean platelet volume;
LGG	cis	rs8141529	0.529	rs5762774	chr22:29149796	G/A	cg15103426	chr22:29168792	CCDC117	0.64	6.93	0.31	1.45e-11	Lymphocyte counts;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg13206674	chr6:150067644	NUP43	0.7	16.12	0.6	9.81e-47	Lung cancer;
LGG	cis	rs10267417	0.657	rs4721842	chr7:19913237	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	6.74	0.3	4.77e-11	Night sleep phenotypes;
LGG	cis	rs7829975	0.572	rs7005000	chr8:8796602	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.74	-0.3	4.61e-11	Mood instability;
LGG	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-9.04	-0.39	4.36e-18	Kawasaki disease;
LGG	trans	rs837841	0.864	rs1660903	chr2:130046679	C/G	cg05555653	chr8:123964437	ZHX2	-0.37	-7.01	-0.31	8.48e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (docetaxel);
LGG	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07570687	chr10:102243282	WNT8B	0.4	7.07	0.31	5.61e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.39	-0.32	7.1e-13	Mean corpuscular volume;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	trans	rs208520	0.690	rs1776365	chr6:66834474	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.64	-0.63	1.19e-53	Exhaled nitric oxide output;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg09699651	chr6:150184138	LRP11	0.53	9.51	0.4	1.04e-19	Lung cancer;
LGG	cis	rs947474	0.838	rs4589176	chr10:6401579	A/G	cg19837174	chr10:6389707	NA	0.63	8.81	0.38	2.59e-17	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs1927790	0.727	rs9554340	chr13:96974112	T/C	cg02571835	chr13:96230311	CLDN10	-0.35	-7.17	-0.32	3.03e-12	Body mass index;
LGG	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg15627072	chr1:2432621	PLCH2	0.39	8.71	0.38	5.6e-17	Multiple sclerosis;
LGG	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg00599393	chr8:22457479	C8orf58	-0.44	-8.01	-0.35	9.62e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11229555	1.000	rs12799215	chr11:58405674	C/T	cg15696309	chr11:58395628	NA	-0.98	-17.6	-0.63	1.81e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs62238980	0.614	rs117256264	chr22:32381750	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs9650657	0.741	rs10100333	chr8:10584288	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.05	-0.31	6.73e-12	Neuroticism;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.95	-0.38	8.57e-18	Menopause (age at onset);
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.18	-0.32	2.71e-12	Skin colour saturation;
LGG	cis	rs9916302	0.904	rs801420	chr17:37466103	C/G	cg00129232	chr17:37814104	STARD3	0.61	11.55	0.47	2.62e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs62400317	0.762	rs12209944	chr6:44788156	G/C	cg20913747	chr6:44695427	NA	-0.66	-10.97	-0.45	4.81e-25	Total body bone mineral density;
LGG	cis	rs2247341	0.928	rs2290011	chr4:1746229	G/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.8	-0.51	2.61e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6977660	0.714	rs12700077	chr7:19791607	A/G	cg05791153	chr7:19748676	TWISTNB	-0.78	-10.58	-0.44	1.46e-23	Thyroid stimulating hormone;
LGG	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg12463550	chr7:65579703	CRCP	0.81	8.69	0.37	6.08e-17	Diabetic kidney disease;
LGG	cis	rs10206020	0.836	rs10202105	chr2:1553301	C/T	cg01028140	chr2:1542097	TPO	-0.52	-9.51	-0.4	1.05e-19	IgG glycosylation;
LGG	cis	rs74781061	0.585	rs750608	chr15:74734615	C/T	cg02384859	chr15:74862662	ARID3B	-0.38	-6.74	-0.3	4.7e-11	Endometriosis;
LGG	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg21479132	chr6:26055353	NA	0.82	8.09	0.35	5.13e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04022019	chr8:104427717	DCAF13;SLC25A32	0.44	7.13	0.31	3.76e-12	Cognitive performance;
LGG	trans	rs9650657	0.623	rs10094497	chr8:10602829	G/T	cg06636001	chr8:8085503	FLJ10661	0.39	7.03	0.31	7.66e-12	Neuroticism;
LGG	cis	rs73198271	0.531	rs17154758	chr8:8653343	G/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7927592	0.513	rs689075	chr11:68194432	A/C	cg16797656	chr11:68205561	LRP5	0.56	10.49	0.44	2.98e-23	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.77	-0.3	4.01e-11	Lung cancer;
LGG	cis	rs4774899	0.966	rs12904070	chr15:57286011	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.12	-0.35	4.25e-15	Urinary tract infection frequency;
LGG	trans	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs8016982	0.633	rs9944085	chr14:81717620	A/T	cg01989461	chr14:81687754	GTF2A1	-0.76	-18.12	-0.64	7.22e-56	Schizophrenia;
LGG	cis	rs66887589	0.777	rs10015883	chr4:120268146	A/G	cg09307838	chr4:120376055	NA	0.47	7.92	0.35	1.74e-14	Diastolic blood pressure;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.67	9.28	0.4	6.29e-19	Lung function (FEV1/FVC);
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg10056627	chr6:42928773	GNMT	0.25	6.93	0.31	1.41e-11	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg10204951	chr7:910479	UNC84A	-0.52	-6.99	-0.31	9.47e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs7666738	0.687	rs6830176	chr4:99093955	G/C	cg05340658	chr4:99064831	C4orf37	0.42	6.8	0.3	3.14e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg04490037	chr7:50633773	DDC	0.32	6.98	0.31	1.01e-11	Body mass index;
LGG	cis	rs7666738	0.830	rs10049627	chr4:99025272	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2153535	0.580	rs7766852	chr6:8472417	C/T	cg23788917	chr6:8435910	SLC35B3	0.54	9.34	0.4	3.92e-19	Motion sickness;
LGG	cis	rs6429082	0.667	rs10802800	chr1:235706283	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.57	-8.74	-0.38	4.29e-17	Adiposity;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg14926445	chr8:58193284	C8orf71	0.86	11.41	0.47	9.88e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9463078	0.565	rs10948183	chr6:44880881	T/C	cg25276700	chr6:44698697	NA	0.34	7.1	0.31	4.74e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg03528353	chr17:61819722	STRADA	0.42	7.07	0.31	5.6e-12	Prudent dietary pattern;
LGG	cis	rs782590	0.967	rs62165172	chr2:55736237	A/G	cg18811423	chr2:55921094	PNPT1	0.87	19.74	0.68	2.15e-63	Metabolic syndrome;
LGG	cis	rs9902453	0.967	rs56129908	chr17:28421382	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.22	0.52	4.57e-34	Coffee consumption (cups per day);
LGG	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg26338869	chr17:61819248	STRADA	0.6	10.05	0.42	1.27e-21	Prudent dietary pattern;
LGG	cis	rs9611565	0.512	rs768414	chr22:42135751	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.75	0.64	3.83e-54	Vitiligo;
LGG	cis	rs9581857	0.579	rs75024088	chr13:27970105	G/T	cg01674679	chr13:27998804	GTF3A	-0.75	-8.38	-0.36	6.41e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs3087591	0.708	rs1129506	chr17:29646032	G/A	cg24425628	chr17:29625626	OMG;NF1	0.58	11.59	0.47	1.92e-27	Hip circumference;
LGG	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg26597838	chr10:835615	NA	0.55	7.1	0.31	4.87e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg19676328	chr12:49525230	TUBA1B	-0.57	-8.49	-0.37	2.9e-16	Total cholesterol levels;
LGG	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs2304069	0.526	rs6863283	chr5:149402448	C/A	cg12661370	chr5:149340060	SLC26A2	0.5	8.5	0.37	2.69e-16	HIV-1 control;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.91	-0.35	1.85e-14	Testicular germ cell tumor;
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg02002194	chr4:3960332	NA	0.39	7.01	0.31	8.52e-12	Neuroticism;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg05313129	chr8:58192883	C8orf71	-0.61	-8.33	-0.36	9.49e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg19143629	chr17:61920732	SMARCD2	-0.41	-7.19	-0.32	2.59e-12	Prudent dietary pattern;
LGG	cis	rs9902453	0.765	rs3102560	chr17:28029938	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.59	0.56	6.28e-40	Coffee consumption (cups per day);
LGG	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.03	-0.31	7.68e-12	Schizophrenia;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg04234412	chr22:24373322	LOC391322	-0.73	-14.93	-0.57	1.97e-41	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7843479	1.000	rs7843479	chr8:21820813	G/T	cg17168535	chr8:21777572	XPO7	0.58	9.45	0.4	1.75e-19	Mean corpuscular volume;
LGG	cis	rs28595532	0.545	rs13144171	chr4:119257458	G/A	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg12432903	chr7:1882776	MAD1L1	0.44	6.78	0.3	3.63e-11	Bipolar disorder;
LGG	cis	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg17971929	chr21:40555470	PSMG1	-0.78	-14.18	-0.55	3.69e-38	Cognitive function;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs3796352	1.000	rs35737577	chr3:53002557	G/C	cg12962167	chr3:53033115	SFMBT1	0.69	7.46	0.33	4.28e-13	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs61931739	0.534	rs11052973	chr12:34029708	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	19.87	0.68	5.68e-64	Calcium levels;
LGG	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg25809561	chr17:30822961	MYO1D	0.41	9.95	0.42	2.82e-21	Schizophrenia;
LGG	cis	rs67311347	1.000	rs13095055	chr3:40505666	G/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.01	-0.31	8.26e-12	Renal cell carcinoma;
LGG	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg08885076	chr2:99613938	TSGA10	-0.32	-6.79	-0.3	3.48e-11	Bipolar disorder;
LGG	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg03788504	chr6:150331562	NA	-0.6	-13.75	-0.54	2.56e-36	Alopecia areata;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18876405	chr7:65276391	NA	0.53	9.55	0.41	7.72e-20	Aortic root size;
LGG	cis	rs4740619	0.716	rs9969817	chr9:15954123	T/A	cg14451791	chr9:16040625	NA	-0.4	-10.1	-0.42	8.33e-22	Body mass index;
LGG	cis	rs1949733	0.701	rs1880024	chr4:8454639	A/G	cg11789530	chr4:8429930	ACOX3	0.74	14.54	0.56	1.05e-39	Response to antineoplastic agents;
LGG	cis	rs2108225	0.934	rs2283044	chr7:107440553	A/G	cg18560240	chr7:107437656	SLC26A3	0.54	9.58	0.41	5.89e-20	Ulcerative colitis;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg02002194	chr4:3960332	NA	-0.49	-9.35	-0.4	3.85e-19	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.58e-12	Lung cancer;
LGG	cis	rs2224391	0.628	rs9504364	chr6:5256072	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.36	-0.32	8.62e-13	Height;
LGG	cis	rs7336332	0.598	rs45622135	chr13:28011594	T/C	cg01674679	chr13:27998804	GTF3A	-0.63	-8.13	-0.35	3.93e-15	Weight;
LGG	cis	rs7781557	0.640	rs6955064	chr7:102579571	T/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.1	-0.35	5.06e-15	Colorectal adenoma (advanced);
LGG	cis	rs897080	0.515	rs1067333	chr2:44626710	C/A	cg00619915	chr2:44497795	NA	-0.5	-7.03	-0.31	7.26e-12	Height;
LGG	trans	rs3857536	0.813	rs7771716	chr6:66946769	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14013300	chr22:29196047	XBP1	0.44	7.58	0.33	1.96e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg21775007	chr8:11205619	TDH	-0.49	-7.91	-0.35	1.9e-14	Neuroticism;
LGG	cis	rs2456568	0.548	rs7105031	chr11:93661207	C/T	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg18538332	chr22:24372958	LOC391322	-0.45	-7.43	-0.33	5.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.02	-0.31	7.88e-12	Menopause (age at onset);
LGG	cis	rs74781061	0.929	rs57271230	chr15:74785359	C/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.04	-0.31	7.08e-12	Endometriosis;
LGG	cis	rs757278	0.591	rs213986	chr7:117259946	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.41	-7.75	-0.34	5.88e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.91	-0.31	1.61e-11	Longevity;
LGG	cis	rs12701220	0.689	rs12536282	chr7:1115650	C/T	cg26769984	chr7:1090371	C7orf50	0.45	7.14	0.32	3.54e-12	Bronchopulmonary dysplasia;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg15558759	chr11:118478939	PHLDB1	-0.45	-8.23	-0.36	1.88e-15	Glioma;
LGG	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg05555928	chr11:63887634	MACROD1	0.6	8.84	0.38	1.98e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg06115741	chr20:33292138	TP53INP2	0.52	8.68	0.37	6.64e-17	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg11494091	chr17:61959527	GH2	0.98	23.83	0.74	1.67e-82	Prudent dietary pattern;
LGG	cis	rs1018836	0.923	rs1476427	chr8:91552791	A/G	cg16814680	chr8:91681699	NA	0.81	14.87	0.57	3.64e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.08e-14	Alzheimer's disease;
LGG	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg08048268	chr3:133502702	NA	-0.45	-7.93	-0.35	1.65e-14	Iron status biomarkers;
LGG	cis	rs8005677	0.828	rs34584578	chr14:23411690	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-7.15	-0.32	3.34e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs1696756	0.638	rs1285274	chr17:77829907	G/A	cg07923794	chr17:77834237	NA	-0.83	-12.68	-0.51	7.94e-32	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.22e-13	Personality dimensions;
LGG	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.65	-8.67	-0.37	7.19e-17	Diabetic retinopathy;
LGG	cis	rs4472734	1.000	rs12751657	chr1:214607849	G/A	cg00063699	chr1:214624242	PTPN14	-0.35	-7.04	-0.31	6.99e-12	Height;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4919087	0.590	rs1088187	chr10:99027581	T/C	cg25902810	chr10:99078978	FRAT1	-0.43	-7.05	-0.31	6.37e-12	Monocyte count;
LGG	cis	rs12579753	0.913	rs17749243	chr12:82178079	A/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.29	-0.46	2.84e-26	Resting heart rate;
LGG	cis	rs36093844	0.800	rs17817331	chr11:85595338	A/G	cg16165120	chr11:85566439	CCDC83	0.43	7.05	0.31	6.58e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.87	-0.3	2.04e-11	Bipolar disorder;
LGG	cis	rs7914558	1.000	rs7081075	chr10:104929191	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.6	0.44	1.15e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9393813	0.868	rs2393963	chr6:27475100	G/C	cg18711553	chr6:27366782	ZNF391	-0.5	-9.54	-0.41	8.07e-20	Bipolar disorder;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.96	-0.31	1.16e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg12708336	chr17:41446283	NA	-0.32	-7.6	-0.33	1.61e-13	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25072359	chr17:41440525	NA	0.52	9.9	0.42	4.45e-21	Menopause (age at onset);
LGG	cis	rs1790761	0.967	rs12573992	chr11:67197757	A/G	cg00290607	chr11:67383545	NA	-0.47	-8.35	-0.36	7.8e-16	Mean corpuscular volume;
LGG	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg15208524	chr1:10270712	KIF1B	0.43	7.5	0.33	3.22e-13	Hepatocellular carcinoma;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08677398	chr8:58056175	NA	0.55	8.35	0.36	8.12e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.526	rs2032215	chr18:44439011	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.91	0.45	8.15e-25	Personality dimensions;
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.14	0.31	3.64e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.22	0.58	1.08e-42	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.0	-0.31	9.21e-12	Neuroticism;
LGG	cis	rs7584330	1.000	rs7584330	chr2:238387228	A/G	cg16989719	chr2:238392110	NA	-0.36	-7.68	-0.34	9.38e-14	Prostate cancer;
LGG	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg21475434	chr5:93447410	FAM172A	0.7	7.1	0.31	4.68e-12	Diabetic retinopathy;
LGG	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs10779751	0.881	rs2744815	chr1:11360957	C/T	cg08854313	chr1:11322531	MTOR	0.73	14.73	0.56	1.44e-40	Body mass index;
LGG	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg02023728	chr11:77925099	USP35	0.45	7.92	0.35	1.72e-14	Testicular germ cell tumor;
LGG	cis	rs4262150	0.639	rs7730082	chr5:152343281	C/T	cg12297329	chr5:152029980	NA	-0.55	-8.76	-0.38	3.82e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs3540	0.597	rs3743409	chr15:91045539	T/A	cg22089800	chr15:90895588	ZNF774	-0.68	-12.65	-0.51	1.07e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg08677398	chr8:58056175	NA	0.48	7.03	0.31	7.27e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2201728	0.702	rs28364305	chr4:100206815	G/T	cg07219303	chr4:100140905	ADH6	-0.36	-6.66	-0.3	7.89e-11	Cardiac Troponin-T levels;
LGG	cis	rs3741798	1.000	rs2160588	chr12:12487447	C/T	cg08615371	chr12:12503544	MANSC1	0.59	6.8	0.3	3.24e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.75	-0.34	6e-14	Systolic blood pressure;
LGG	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg00599393	chr8:22457479	C8orf58	-0.43	-7.97	-0.35	1.23e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7647973	1.000	rs11928090	chr3:49604904	G/A	cg06212747	chr3:49208901	KLHDC8B	0.5	7.84	0.34	3.11e-14	Menarche (age at onset);
LGG	cis	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2658782	0.654	rs2605617	chr11:93243333	T/C	cg15737290	chr11:93063684	CCDC67	0.47	6.94	0.31	1.31e-11	Pulmonary function decline;
LGG	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg04617936	chr2:214353	NA	-0.39	-7.24	-0.32	1.82e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11997175	0.503	rs7013967	chr8:33826107	T/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.34	0.32	9.54e-13	Body mass index;
LGG	cis	rs7666738	0.830	rs13133619	chr4:99067312	C/G	cg05340658	chr4:99064831	C4orf37	-0.49	-8.23	-0.36	1.87e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11608355	0.515	rs1045263	chr12:109974191	A/G	cg05360138	chr12:110035743	NA	0.85	12.22	0.49	5.84e-30	Neuroticism;
LGG	cis	rs612683	0.826	rs7556246	chr1:100828914	A/G	cg06223162	chr1:101003688	GPR88	0.4	9.52	0.4	9.73e-20	Breast cancer;
LGG	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.47	-8.28	-0.36	1.37e-15	IgG glycosylation;
LGG	cis	rs6831352	0.879	rs29001215	chr4:100051722	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.74	-0.41	1.59e-20	Alcohol dependence;
LGG	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.49	-0.33	3.4e-13	Testicular germ cell tumor;
LGG	cis	rs875971	0.862	rs3893216	chr7:65790707	G/C	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg11941060	chr3:133502564	NA	-0.44	-6.99	-0.31	9.43e-12	Iron status biomarkers;
LGG	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg20587970	chr11:113659929	NA	-1.31	-23.91	-0.74	6.8e-83	Hip circumference adjusted for BMI;
LGG	trans	rs8002861	0.935	rs4942256	chr13:44455920	A/T	cg17145862	chr1:211918768	LPGAT1	0.98	26.2	0.77	1.85e-93	Leprosy;
LGG	cis	rs9300255	0.569	rs1716170	chr12:123716513	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1e-13	Neutrophil percentage of white cells;
LGG	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg02297831	chr4:17616191	MED28	-0.42	-7.55	-0.33	2.41e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7202877	0.706	rs8054586	chr16:75410705	G/C	cg03315344	chr16:75512273	CHST6	0.53	7.33	0.32	1.04e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs2594989	1.000	rs2606756	chr3:11358181	G/A	cg01796438	chr3:11312864	ATG7	-0.59	-7.96	-0.35	1.34e-14	Circulating chemerin levels;
LGG	cis	rs10489202	0.583	rs203777	chr1:167876616	C/T	cg24449463	chr1:168025552	DCAF6	-0.58	-9.76	-0.41	1.32e-20	Schizophrenia;
LGG	cis	rs79976124	0.797	rs79522358	chr6:66641140	C/G	cg07460842	chr6:66804631	NA	0.73	12.52	0.5	3.54e-31	Type 2 diabetes;
LGG	cis	rs2120019	1.000	rs60425110	chr15:75333000	T/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-22.62	-0.72	7.18e-77	Blood trace element (Zn levels);
LGG	cis	rs1045714	0.895	rs4721860	chr7:2639994	C/T	cg20813462	chr7:2646259	IQCE	0.55	7.07	0.31	5.66e-12	Urate levels in lean individuals;
LGG	cis	rs10766496	1.000	rs61886892	chr11:18738575	A/C	cg02515468	chr11:18743222	IGSF22	0.46	7.56	0.33	2.25e-13	Diabetic kidney disease;
LGG	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	cis	rs6942756	0.668	rs644723	chr7:129107881	C/T	cg02491457	chr7:128862824	NA	-0.67	-11.62	-0.48	1.45e-27	White matter hyperintensity burden;
LGG	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg04673462	chr1:38461896	NA	0.48	9.43	0.4	1.93e-19	Coronary artery disease;
LGG	cis	rs4919694	1.000	rs3740394	chr10:104634474	A/G	cg04362960	chr10:104952993	NT5C2	1.1	15.39	0.58	1.82e-43	Arsenic metabolism;
LGG	cis	rs9951602	0.512	rs4798994	chr18:76654327	T/G	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg23978390	chr7:1156363	C7orf50	0.46	7.4	0.33	6.31e-13	Bronchopulmonary dysplasia;
LGG	cis	rs17401966	0.931	rs10492972	chr1:10353112	A/G	cg15208524	chr1:10270712	KIF1B	0.44	7.73	0.34	6.87e-14	Hepatocellular carcinoma;
LGG	cis	rs1681739	0.967	rs1681738	chr10:118563000	G/T	cg26264419	chr10:118530958	NA	0.32	6.68	0.3	7.02e-11	Vertical cup-disc ratio;
LGG	cis	rs4936894	0.500	rs12292913	chr11:124171896	T/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.87	-0.45	1.15e-24	Aging (time to death);
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.81e-11	Bipolar disorder;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs7666738	0.830	rs6843777	chr4:98866635	T/A	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs5758511	0.680	rs58654759	chr22:42642576	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.5	8.17	0.35	3e-15	Birth weight;
LGG	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg24189917	chr7:1970923	MAD1L1	-0.43	-6.87	-0.3	2.08e-11	Bipolar disorder;
LGG	cis	rs9400467	0.537	rs12197886	chr6:111491405	C/G	cg15721981	chr6:111408429	SLC16A10	0.59	7.15	0.32	3.43e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs77972916	0.505	rs6736400	chr2:43500804	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.29	-0.43	1.68e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg06121193	chr1:90282411	NA	-0.36	-7.13	-0.31	3.92e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs870825	0.616	rs72705689	chr4:185639894	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	23.18	0.73	1.89e-79	Blood protein levels;
LGG	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg16325326	chr1:53192061	ZYG11B	0.73	16.33	0.6	1.11e-47	Monocyte count;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg25172604	chr17:41446521	NA	-0.3	-7.07	-0.31	5.83e-12	Menopause (age at onset);
LGG	cis	rs12360000	0.800	rs11250869	chr10:1917721	T/C	cg26364871	chr10:1889757	NA	-0.66	-12.06	-0.49	2.59e-29	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.72	-0.56	1.64e-40	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.33	-0.36	9.03e-16	Total body bone mineral density;
LGG	cis	rs713587	0.521	rs35177510	chr2:25089594	C/A	cg04586622	chr2:25135609	ADCY3	0.42	11.21	0.46	5.79e-26	Body mass index in non-asthmatics;
LGG	trans	rs10435719	0.638	rs67146188	chr8:11782433	A/G	cg16141378	chr3:129829833	LOC729375	0.32	7.27	0.32	1.51e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs72717009	0.756	rs10494359	chr1:161463876	G/C	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.95	-0.42	2.76e-21	Rheumatoid arthritis;
LGG	cis	rs62238980	0.614	rs77896321	chr22:32413371	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg11266682	chr4:10021025	SLC2A9	0.52	10.23	0.43	2.7e-22	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9467773	1.000	rs9467774	chr6:26505036	C/A	cg11502198	chr6:26597334	ABT1	0.55	9.4	0.4	2.52e-19	Intelligence (multi-trait analysis);
LGG	cis	rs79057730	0.528	rs6965219	chr7:821807	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.67	7.54	0.33	2.44e-13	Initial pursuit acceleration;
LGG	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	7.8e-18	Motion sickness;
LGG	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg00405596	chr8:11794950	NA	-0.4	-6.76	-0.3	4.14e-11	Morning vs. evening chronotype;
LGG	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.06	0.35	6.62e-15	Coronary artery disease;
LGG	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg05696931	chr1:227175867	NA	-0.42	-8.39	-0.36	5.78e-16	Myeloid white cell count;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg09038676	chr11:67351608	GSTP1	-0.35	-7.15	-0.32	3.41e-12	Mean corpuscular volume;
LGG	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.03	-0.42	1.49e-21	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs2727020	0.595	rs7924311	chr11:49507573	G/A	cg15704280	chr7:45808275	SEPT13	-1.01	-22.47	-0.72	3.66e-76	Coronary artery disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27467005	chr19:17622279	PGLS	-0.43	-7.23	-0.32	2.02e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg22437258	chr11:111473054	SIK2	0.55	9.51	0.4	1.09e-19	Primary sclerosing cholangitis;
LGG	cis	rs79149102	0.579	rs7342601	chr15:75306795	G/T	cg17294928	chr15:75287854	SCAMP5	0.77	8.85	0.38	1.83e-17	Lung cancer;
LGG	cis	rs2239547	0.603	rs6805298	chr3:53096552	A/G	cg11645453	chr3:52864694	ITIH4	-0.65	-10.19	-0.43	3.91e-22	Schizophrenia;
LGG	cis	rs62400317	0.762	rs72865924	chr6:44878943	G/A	cg20913747	chr6:44695427	NA	-0.66	-11.31	-0.47	2.46e-26	Total body bone mineral density;
LGG	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg04842962	chr6:43655489	MRPS18A	-1.1	-24.06	-0.75	1.43e-83	IgG glycosylation;
LGG	cis	rs4774899	0.752	rs2464429	chr15:57348302	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-7.08	-0.31	5.41e-12	Urinary tract infection frequency;
LGG	cis	rs6496932	0.676	rs7183651	chr15:85895721	A/G	cg19183879	chr15:85880815	NA	-0.45	-7.59	-0.33	1.72e-13	Central corneal thickness;Corneal structure;
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg00149659	chr3:10157352	C3orf10	0.76	9.65	0.41	3.37e-20	Alzheimer's disease;
LGG	cis	rs12586317	0.620	rs58320987	chr14:35587726	T/C	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.53	-0.33	2.75e-13	Psoriasis;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg22903471	chr2:27725779	GCKR	-0.57	-12.9	-0.51	1e-32	Total body bone mineral density;
LGG	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg09165964	chr15:75287851	SCAMP5	-1.01	-19.75	-0.68	1.98e-63	Blood trace element (Zn levels);
LGG	cis	rs7769051	0.711	rs9493435	chr6:133088205	A/G	cg22852734	chr6:133119734	C6orf192	1.16	14.4	0.56	4.03e-39	Type 2 diabetes nephropathy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14212197	chr11:62529082	POLR2G	0.42	6.67	0.3	7.39e-11	Cognitive performance;
LGG	cis	rs10499694	0.697	rs3779074	chr7:50612202	A/G	cg14593290	chr7:50529359	DDC	-0.4	-8.08	-0.35	5.54e-15	Body mass index;
LGG	trans	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg06521331	chr12:34319734	NA	0.45	7.98	0.35	1.15e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg05313129	chr8:58192883	C8orf71	-0.78	-12.52	-0.5	3.56e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg26354017	chr1:205819088	PM20D1	0.85	20.25	0.69	8.85e-66	Menarche (age at onset);
LGG	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg20891283	chr12:69753455	YEATS4	1.09	29.07	0.8	1.81e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	7.7	0.34	8.4e-14	Schizophrenia;
LGG	cis	rs1190596	0.525	rs7152627	chr14:102698399	C/T	cg23904247	chr14:102554826	HSP90AA1	-0.24	-6.77	-0.3	3.88e-11	Behavioural disinhibition (generation interaction);
LGG	trans	rs7246760	0.500	rs4325679	chr19:9984679	T/G	cg02900749	chr2:68251473	NA	-0.62	-7.09	-0.31	5.04e-12	Pursuit maintenance gain;
LGG	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg07061783	chr6:25882402	NA	-0.42	-7.35	-0.32	8.88e-13	Intelligence (multi-trait analysis);
LGG	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg20636351	chr8:55087400	NA	-0.3	-6.72	-0.3	5.23e-11	Pelvic organ prolapse (moderate/severe);
LGG	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg08000102	chr2:233561755	GIGYF2	-0.56	-8.96	-0.38	8.2e-18	Coronary artery disease;
LGG	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg21775007	chr8:11205619	TDH	-0.57	-9.55	-0.41	7.83e-20	Neuroticism;
LGG	cis	rs9715521	0.935	rs72634625	chr4:59836434	T/A	cg11281224	chr4:60001000	NA	-0.44	-7.34	-0.32	9.67e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6921919	1.000	rs6922111	chr6:28325308	C/T	cg06606381	chr12:133084897	FBRSL1	-0.49	-7.02	-0.31	7.8e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4363385	0.747	rs946097	chr1:152974732	A/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.41	-0.4	2.28e-19	Inflammatory skin disease;
LGG	trans	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg04991071	chr3:71615924	FOXP1	0.65	7.3	0.32	1.23e-12	Urate levels in overweight individuals;
LGG	cis	rs6541297	0.941	rs2180078	chr1:230280513	T/C	cg20703242	chr1:230279135	GALNT2	0.37	7.56	0.33	2.22e-13	Coronary artery disease;
LGG	cis	rs858239	0.539	rs6945510	chr7:23192240	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.58e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg20786246	chr2:72377174	NA	0.44	6.92	0.31	1.53e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00495681	chr13:53174319	NA	0.58	10.32	0.43	1.32e-22	Lewy body disease;
LGG	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg04568710	chr12:38710424	ALG10B	0.4	8.61	0.37	1.13e-16	Morning vs. evening chronotype;
LGG	cis	rs6444746	0.800	rs60017964	chr3:193486995	G/A	cg22553634	chr3:193489233	NA	0.82	8.75	0.38	3.99e-17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.12	-0.46	1.24e-25	Lung cancer;
LGG	cis	rs17001868	0.568	rs9607701	chr22:40739116	A/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.22	0.43	2.95e-22	Motion sickness;
LGG	cis	rs4595586	0.545	rs12819186	chr12:39356912	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.97	0.45	4.82e-25	Morning vs. evening chronotype;
LGG	cis	rs17534004	1.000	rs71436418	chr13:31455888	G/A	cg00367615	chr13:31480979	C13orf33	0.34	6.87	0.3	2.02e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15557168	chr22:42548783	NA	-0.34	-7.66	-0.34	1.09e-13	Cognitive function;
LGG	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg03806693	chr22:41940476	POLR3H	1.06	17.89	0.64	8.58e-55	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs367615	0.918	rs10051855	chr5:108859958	G/A	cg17395555	chr5:108820864	NA	0.66	9.35	0.4	3.66e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14240646	chr10:27532245	ACBD5	-0.56	-8.63	-0.37	9.78e-17	Breast cancer;
LGG	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.8	-10.4	-0.44	6.58e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg27490568	chr2:178487706	NA	0.51	10.14	0.43	5.96e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7188861	0.768	rs497184	chr16:11389589	G/A	cg01510278	chr16:11456238	NA	0.31	7.4	0.33	6.2800000000000005e-13	HDL cholesterol;
LGG	trans	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg13010199	chr12:38710504	ALG10B	0.46	8.81	0.38	2.49e-17	Morning vs. evening chronotype;
LGG	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg21466736	chr12:48725269	NA	-0.36	-7.23	-0.32	2.02e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg07395648	chr5:131743802	NA	-0.43	-9.47	-0.4	1.39e-19	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs6598955	0.671	rs17163746	chr1:26564230	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-13.13	-0.52	1.02e-33	Obesity-related traits;
LGG	trans	rs2562456	0.833	rs55920089	chr19:21520693	A/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg24503407	chr1:205819492	PM20D1	0.82	19.92	0.68	3.15e-64	Menarche (age at onset);
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08645402	chr16:4508243	NA	0.51	9.17	0.39	1.61e-18	Schizophrenia;
LGG	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.65	-0.37	8.23e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs28735056	0.584	rs35614280	chr18:77636679	C/G	cg05926928	chr17:57297772	GDPD1	0.85	15.42	0.58	1.37e-43	Schizophrenia;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.52	-0.67	2.31e-62	Rheumatoid arthritis;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13012494	chr21:47604986	C21orf56	0.49	8.18	0.36	2.78e-15	Testicular germ cell tumor;
LGG	cis	rs1865760	1.000	rs9393675	chr6:25930116	G/A	cg03264133	chr6:25882463	NA	-0.43	-7.52	-0.33	2.83e-13	Height;
LGG	cis	rs7615952	0.515	rs7637246	chr3:125678706	A/G	cg05084668	chr3:125655381	ALG1L	-0.74	-9.89	-0.42	4.92e-21	Blood pressure (smoking interaction);
LGG	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	20.24	0.69	1.04e-65	Longevity;
LGG	cis	rs10773046	0.740	rs7297429	chr12:124367578	A/C	cg18594669	chr12:124364423	DNAH10	0.34	6.8	0.3	3.28e-11	Osteoarthritis (hip);
LGG	cis	rs509477	1.000	rs531558	chr18:32575286	A/T	cg23791764	chr18:32556832	MAPRE2	-0.52	-9.03	-0.39	4.6e-18	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs2797160	1.000	rs1739371	chr6:126011291	G/A	cg05901451	chr6:126070800	HEY2	0.46	7.77	0.34	5.06e-14	Endometrial cancer;
LGG	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.79	0.54	1.77e-36	Lung cancer in ever smokers;
LGG	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg20913747	chr6:44695427	NA	-0.69	-12.42	-0.5	8.97e-31	Total body bone mineral density;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg13206674	chr6:150067644	NUP43	0.6	13.32	0.53	1.63e-34	Lung cancer;
LGG	cis	rs10875746	0.556	rs4760619	chr12:48499931	A/T	cg24011408	chr12:48396354	COL2A1	-0.63	-7.34	-0.32	9.6e-13	Longevity (90 years and older);
LGG	cis	rs6665290	0.836	rs56029302	chr1:227203390	G/A	cg05696931	chr1:227175867	NA	-0.39	-7.65	-0.34	1.17e-13	Myeloid white cell count;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg17108064	chr15:78857060	CHRNA5	0.45	9.55	0.41	7.73e-20	Sudden cardiac arrest;
LGG	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.21e-66	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg14926445	chr8:58193284	C8orf71	-0.73	-9.29	-0.4	6.02e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.62	0.63	1.57e-53	Cognitive function;
LGG	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	8.29	0.36	1.21e-15	Pulse pressure;
LGG	cis	rs9783347	0.621	rs2037867	chr11:18382021	A/G	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.17	-0.49	9.48e-30	Pancreatic cancer;
LGG	cis	rs10463316	0.779	rs1810084	chr5:150777048	A/G	cg03212797	chr5:150827313	SLC36A1	-0.57	-9.83	-0.42	7.6e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs4901869	0.897	rs12878587	chr14:59339378	C/G	cg02291164	chr14:59296302	NA	0.27	6.79	0.3	3.37e-11	Panic disorder;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg15763984	chr4:1342303	KIAA1530	0.38	6.79	0.3	3.55e-11	Obesity-related traits;
LGG	cis	rs9435341	0.965	rs1730864	chr1:107607810	C/T	cg09367891	chr1:107599246	PRMT6	-0.61	-10.4	-0.44	6.55e-23	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs2688608	0.647	rs2227575	chr10:75677840	C/A	cg10168709	chr10:75599394	CAMK2G	-0.37	-7.37	-0.32	7.71e-13	Inflammatory bowel disease;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	9.99	0.42	2.01e-21	Prudent dietary pattern;
LGG	cis	rs10937275	0.826	rs34695488	chr3:186644463	A/G	cg26193484	chr3:186648175	ST6GAL1	0.9	9.24	0.39	8.76e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg17202724	chr17:61916730	SMARCD2	0.47	10.39	0.43	7.17e-23	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07805959	chr17:2595004	KIAA0664	-0.4	-7.01	-0.31	8.23e-12	Cognitive performance;
LGG	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.69	17.43	0.63	1.15e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2916247	1.000	rs7820440	chr8:93036627	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.39	-0.36	6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg15971980	chr6:150254442	NA	0.46	8.68	0.37	6.56e-17	Lung cancer;
LGG	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.71	-0.3	5.55e-11	Menopause (age at onset);
LGG	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg03929089	chr4:120376271	NA	0.7	9.74	0.41	1.62e-20	Axial length;
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00149659	chr3:10157352	C3orf10	1.15	13.52	0.53	2.54e-35	Alzheimer's disease;
LGG	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg04731861	chr2:219085781	ARPC2	0.28	6.75	0.3	4.4e-11	Ulcerative colitis;
LGG	cis	rs9611565	0.512	rs9611672	chr22:42209922	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-7.66	-0.34	1.07e-13	Vitiligo;
LGG	cis	rs9290877	0.667	rs6763915	chr3:188458283	A/G	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg24803719	chr17:45855879	NA	-0.23	-6.86	-0.3	2.16e-11	IgG glycosylation;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg22963979	chr7:1858916	MAD1L1	-0.49	-9.57	-0.41	6.37e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs11096990	0.855	rs2711933	chr4:39157710	G/A	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.06	0.6	1.78e-46	Lung cancer;
LGG	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21659725	chr3:3221576	CRBN	0.67	12.56	0.5	2.4e-31	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg01864069	chr14:103024347	NA	-0.47	-8.2	-0.36	2.34e-15	Platelet count;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg07142201	chr11:109293216	C11orf87	0.83	16.21	0.6	4.12e-47	Schizophrenia;
LGG	cis	rs9403521	1.000	rs9403523	chr6:144004981	T/C	cg18240653	chr6:144019428	PHACTR2	-0.59	-9.5	-0.4	1.15e-19	Obesity-related traits;
LGG	cis	rs6546550	0.901	rs3771531	chr2:70164034	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.88	-0.34	2.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs7106204	0.541	rs78630920	chr11:24291192	C/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.75	0.38	4.1e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg26597838	chr10:835615	NA	0.95	13.06	0.52	2.04e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.22	0.32	2.12e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs11785693	0.862	rs62491169	chr8:4986425	C/A	cg26367366	chr8:4980734	NA	0.99	15.62	0.59	1.7e-44	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg16141378	chr3:129829833	LOC729375	-0.49	-12.0	-0.49	4.53e-29	Mood instability;
LGG	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.84	-0.34	3.21e-14	Triglycerides;
LGG	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg22437258	chr11:111473054	SIK2	0.56	9.78	0.41	1.14e-20	Primary sclerosing cholangitis;
LGG	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg15664640	chr17:80829946	TBCD	-0.8	-15.83	-0.59	1.94e-45	Breast cancer;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9581857	0.579	rs1759861	chr13:27996406	A/C	cg01674679	chr13:27998804	GTF3A	0.74	8.64	0.37	9.34e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs6424115	0.708	rs2076343	chr1:24129126	A/G	cg15997130	chr1:24165203	NA	-0.44	-10.32	-0.43	1.26e-22	Immature fraction of reticulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06441946	chr5:145583671	RBM27	0.51	8.01	0.35	9.55e-15	Gut microbiome composition (summer);
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg22655195	chr11:130468548	NA	-0.68	-6.85	-0.3	2.3e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.06	-0.31	6.28e-12	Sudden cardiac arrest;
LGG	cis	rs3771570	1.000	rs62193208	chr2:242322430	G/A	cg21155796	chr2:242212141	HDLBP	0.73	9.66	0.41	3.19e-20	Prostate cancer;
LGG	cis	rs3784262	0.669	rs10851632	chr15:58242475	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.8	-0.3	3.31e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11574514	0.744	rs11860125	chr16:67980969	G/C	cg09738193	chr16:67926317	PSKH1	-0.75	-6.97	-0.31	1.07e-11	Crohn's disease;
LGG	cis	rs2274273	0.805	rs8012156	chr14:55552500	G/T	cg04306507	chr14:55594613	LGALS3	0.47	11.55	0.47	2.79e-27	Protein biomarker;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg14664628	chr15:75095509	CSK	0.94	18.27	0.65	1.44e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7523273	0.606	rs2488252	chr1:207938228	C/T	cg22525895	chr1:207977042	MIR29B2	0.6	11.92	0.48	9.08e-29	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg00933542	chr6:150070202	PCMT1	0.41	7.47	0.33	4.04e-13	Lung cancer;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05392644	chr15:78454622	IDH3A	-0.36	-7.28	-0.32	1.44e-12	Liver disease severity in Alagille syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13669089	chr11:31391497	DNAJC24;DCDC1	0.51	7.64	0.33	1.25e-13	Gut microbiome composition (summer);
LGG	cis	rs3820928	0.874	rs4461255	chr2:227846524	C/T	cg11843606	chr2:227700838	RHBDD1	0.47	8.11	0.35	4.65e-15	Pulmonary function;
LGG	cis	rs12980942	0.591	rs1946613	chr19:41767785	C/T	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.49	0.33	3.49e-13	Coronary artery disease;
LGG	cis	rs7226408	0.857	rs72887048	chr18:34483420	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg12486710	chr1:178512616	C1orf220	0.51	10.59	0.44	1.25e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	trans	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs2030746	0.899	rs11686154	chr2:121310937	G/A	cg03661458	chr2:121334411	NA	-0.29	-6.72	-0.3	5.34e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.08	27.32	0.79	1.44e-98	Cognitive ability;
LGG	cis	rs17767392	1.000	rs723966	chr14:71765910	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13732083	chr21:47605072	C21orf56	0.51	8.71	0.38	5.37e-17	Testicular germ cell tumor;
LGG	trans	rs6787172	0.622	rs11717725	chr3:158134920	A/C	cg23275840	chr4:47708675	CORIN	-0.36	-7.44	-0.33	4.91e-13	Subjective well-being;
LGG	cis	rs721917	0.506	rs2758547	chr10:81697124	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.67	-0.34	1.01e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.26e-15	Life satisfaction;
LGG	trans	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg10840412	chr1:235813424	GNG4	0.65	8.71	0.38	5.25e-17	Bipolar disorder;
LGG	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg01620082	chr3:125678407	NA	-0.67	-7.33	-0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg15541040	chr2:3486749	NA	-0.45	-8.26	-0.36	1.54e-15	Neurofibrillary tangles;
LGG	cis	rs701145	0.537	rs1727952	chr3:153871565	C/T	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.77	-0.3	3.91e-11	Testicular germ cell tumor;
LGG	cis	rs2274273	1.000	rs3742566	chr14:55595839	T/A	cg04306507	chr14:55594613	LGALS3	0.61	17.15	0.62	2.24e-51	Protein biomarker;
LGG	cis	rs9863	0.827	rs4930706	chr12:124417338	T/C	cg13487667	chr12:124434373	CCDC92	-0.35	-7.02	-0.31	8.17e-12	White blood cell count;
LGG	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.56	-0.44	1.69e-23	Bladder cancer;
LGG	cis	rs1882538	0.538	rs9649587	chr7:133104569	A/C	cg10665199	chr7:133106180	EXOC4	0.58	10.0	0.42	1.96e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg25554036	chr4:6271136	WFS1	0.61	11.1	0.46	1.54e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.92	0.35	1.82e-14	Height;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17154315	chr8:106331166	ZFPM2	0.59	6.75	0.3	4.49e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.817	rs1705754	chr12:34145569	A/G	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.31e-12	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg25214090	chr10:38739885	LOC399744	0.69	12.12	0.49	1.52e-29	Corneal astigmatism;
LGG	cis	rs17125944	0.615	rs1886786	chr14:53312189	A/T	cg00686598	chr14:53173677	PSMC6	-0.76	-7.81	-0.34	3.85e-14	Alzheimer's disease (late onset);
LGG	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg20503657	chr10:835505	NA	0.75	10.26	0.43	2.23e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs2712184	1.000	rs2712184	chr2:217682779	G/T	cg05032264	chr2:217675019	NA	-0.53	-12.54	-0.5	2.96e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs9287719	0.967	rs2110776	chr2:10748810	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs17221829	0.733	rs10830329	chr11:89390612	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.16e-18	Anxiety in major depressive disorder;
LGG	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg11764359	chr7:65958608	NA	-0.55	-9.44	-0.4	1.78e-19	Aortic root size;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg02725872	chr8:58115012	NA	-0.78	-10.74	-0.45	3.45e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs12366971	chr12:38737687	T/G	cg13010199	chr12:38710504	ALG10B	0.78	16.79	0.62	9.72e-50	Heart rate;
LGG	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg26408565	chr15:76604113	ETFA	-0.39	-6.76	-0.3	4.08e-11	Blood metabolite levels;
LGG	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg23625390	chr15:77176239	SCAPER	-0.57	-10.27	-0.43	1.95e-22	Blood metabolite levels;
LGG	cis	rs7000551	0.715	rs1879792	chr8:22314029	C/A	cg12081754	chr8:22256438	SLC39A14	0.69	13.53	0.53	2.12e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg15556689	chr8:8085844	FLJ10661	0.41	7.11	0.31	4.38e-12	Morning vs. evening chronotype;
LGG	cis	rs11158559	0.865	rs1741490	chr14:65243068	A/G	cg22797773	chr14:65239943	SPTB	-0.42	-7.02	-0.31	7.99e-12	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg26513180	chr16:89883248	FANCA	0.66	7.42	0.33	5.78e-13	Skin colour saturation;
LGG	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg00717180	chr2:96193071	NA	-0.48	-9.21	-0.39	1.12e-18	Coronary artery disease;
LGG	cis	rs888194	0.714	rs10774708	chr12:109893156	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.23	-0.32	2.04e-12	Neuroticism;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg15595755	chr5:1867978	NA	0.52	10.26	0.43	2.17e-22	Cardiovascular disease risk factors;
LGG	cis	rs4731207	0.646	rs67453484	chr7:124454524	T/A	cg05630886	chr7:124431682	NA	0.33	7.52	0.33	2.95e-13	Cutaneous malignant melanoma;
LGG	cis	rs36715	0.868	rs251387	chr5:127547180	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.42	0.33	5.46e-13	Breast cancer;
LGG	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg25838465	chr1:92012736	NA	-0.59	-11.78	-0.48	3.3e-28	Breast cancer;
LGG	cis	rs1003719	0.762	rs6517402	chr21:38447423	A/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.32e-35	Corneal astigmatism;
LGG	cis	rs9303401	0.659	rs62083368	chr17:56878062	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.19e-13	White matter hyperintensity burden;
LGG	cis	rs896854	0.967	rs10808671	chr8:95967372	A/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-9.47	-0.4	1.42e-19	Type 2 diabetes;
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg19635926	chr16:89946313	TCF25	0.71	8.46	0.37	3.52e-16	Skin colour saturation;
LGG	cis	rs9318086	0.712	rs3794339	chr13:24434065	A/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.51	9.91	0.42	4.07e-21	Myopia (pathological);
LGG	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.65	0.48	1.07e-27	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.28e-19	Life satisfaction;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg08677398	chr8:58056175	NA	0.44	7.29	0.32	1.35e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	trans	rs2562456	0.833	rs62110071	chr19:21470903	C/G	cg00806126	chr19:22604979	ZNF98	-0.56	-7.33	-0.32	1.04e-12	Pain;
LGG	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg00850481	chr1:228891306	NA	0.5	8.6	0.37	1.22e-16	Chronic lymphocytic leukemia;
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07648498	chr16:89883185	FANCA	0.41	7.0	0.31	8.81e-12	Vitiligo;
LGG	cis	rs2074193	0.627	rs215396	chr12:47766406	T/G	cg02516419	chr12:47771422	NA	-0.72	-10.6	-0.44	1.16e-23	Migraine with aura;
LGG	cis	rs2282300	0.739	rs1222215	chr11:30347596	C/T	cg25418670	chr11:30344373	C11orf46	-0.57	-7.9	-0.34	2.03e-14	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg05896524	chr21:47604654	C21orf56	0.55	9.34	0.4	4.19e-19	Testicular germ cell tumor;
LGG	cis	rs9549367	0.789	rs3764125	chr13:113897648	A/G	cg18105134	chr13:113819100	PROZ	0.68	13.67	0.54	5.69e-36	Platelet distribution width;
LGG	cis	rs28655083	0.957	rs2171096	chr16:77079043	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.52	-8.51	-0.37	2.39e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05665937	chr4:1216051	CTBP1	0.54	9.93	0.42	3.44e-21	Obesity-related traits;
LGG	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg13512537	chr8:22265999	SLC39A14	-0.47	-8.4	-0.36	5.43e-16	Verbal declarative memory;
LGG	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg26695010	chr11:65641043	EFEMP2	0.51	8.63	0.37	9.55e-17	Eosinophil percentage of white cells;
LGG	cis	rs977987	0.806	rs7202596	chr16:75491072	G/T	cg03315344	chr16:75512273	CHST6	0.54	10.72	0.45	4.06e-24	Dupuytren's disease;
LGG	cis	rs722599	0.683	rs8008475	chr14:75291900	C/T	cg06637938	chr14:75390232	RPS6KL1	0.55	8.97	0.38	7.37e-18	IgG glycosylation;
LGG	cis	rs17453880	0.890	rs60862272	chr5:152009347	A/G	cg12297329	chr5:152029980	NA	-0.86	-21.93	-0.71	1.26e-73	Subjective well-being;
LGG	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg21427119	chr20:30132790	HM13	-0.42	-7.26	-0.32	1.68e-12	Mean corpuscular hemoglobin;
LGG	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg00919237	chr7:87102261	ABCB4	-0.79	-16.07	-0.6	1.73e-46	Gallbladder cancer;
LGG	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg19748678	chr4:122722346	EXOSC9	0.7	14.15	0.55	4.86e-38	Type 2 diabetes;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4417704	0.578	rs4675842	chr2:241876480	C/G	cg14055004	chr2:241860995	NA	-0.29	-7.45	-0.33	4.6e-13	Joint mobility (Beighton score);
LGG	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Vitiligo;
LGG	cis	rs2011503	0.882	rs10407933	chr19:19364319	A/G	cg11584989	chr19:19387371	SF4	0.7	11.56	0.47	2.56e-27	Bipolar disorder;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.22	-0.39	1.02e-18	Longevity;Endometriosis;
LGG	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs9397585	0.857	rs2349433	chr6:153383755	C/T	cg17707550	chr6:153380415	RGS17	-0.62	-14.52	-0.56	1.29e-39	Body mass index;
LGG	cis	rs7582720	1.000	rs72932561	chr2:203848402	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4737010	0.501	rs7000282	chr8:41647493	A/C	cg08923054	chr8:41654455	ANK1	0.83	14.35	0.55	6.88e-39	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg07211511	chr3:129823064	LOC729375	-0.76	-10.9	-0.45	8.68e-25	Blood pressure (smoking interaction);
LGG	cis	rs2456568	0.802	rs1506656	chr11:93639813	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.86	-0.3	2.27e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	8.03	0.35	8.1e-15	Menarche (age at onset);
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.54	0.37	2e-16	Triglycerides;
LGG	cis	rs9354308	0.764	rs2351715	chr6:66585879	A/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9322193	0.607	rs6925151	chr6:150210723	C/T	cg13206674	chr6:150067644	NUP43	0.45	8.19	0.36	2.57e-15	Lung cancer;
LGG	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.65	-0.48	1.07e-27	Hemoglobin concentration;
LGG	cis	rs10883723	0.737	rs11191312	chr10:104278601	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	12.61	0.51	1.54e-31	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs988958	0.526	rs12712821	chr2:42238864	C/T	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.11e-19	Hypospadias;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.14e-12	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg22903471	chr2:27725779	GCKR	-0.59	-13.48	-0.53	3.62e-35	Total body bone mineral density;
LGG	cis	rs41271473	0.948	rs11585206	chr1:228824848	C/T	cg10167378	chr1:228756711	NA	0.56	7.29	0.32	1.31e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7539542	0.556	rs4950888	chr1:202872625	C/T	cg19681188	chr1:202830198	LOC148709	0.53	8.85	0.38	1.93e-17	Mean platelet volume;
LGG	trans	rs28595532	0.720	rs72670226	chr4:119304136	A/G	cg26518628	chr1:97050305	NA	-0.82	-7.11	-0.31	4.43e-12	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08219700	chr8:58056026	NA	0.47	7.05	0.31	6.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.572	rs13073571	chr3:160665720	G/A	cg03342759	chr3:160939853	NMD3	0.45	7.64	0.33	1.26e-13	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.54	0.44	1.92e-23	Obesity-related traits;
LGG	cis	rs9911578	0.757	rs8081906	chr17:56631907	A/T	cg12560992	chr17:57184187	TRIM37	-0.82	-13.2	-0.52	5.58e-34	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg13482628	chr17:19912719	NA	0.64	12.62	0.51	1.42e-31	Schizophrenia;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg02629319	chr4:83821365	THAP9	0.4	7.03	0.31	7.65e-12	Migraine with aura;
LGG	cis	rs10463316	0.862	rs7720582	chr5:150776502	C/T	cg03212797	chr5:150827313	SLC36A1	0.58	10.13	0.43	6.45e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg03060546	chr3:49711283	APEH	0.75	13.48	0.53	3.64e-35	Resting heart rate;
LGG	cis	rs3857067	1.000	rs1588384	chr4:95001354	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.47	-0.33	3.95e-13	QT interval;
LGG	cis	rs8014204	0.566	rs752857	chr14:75130944	C/T	cg06637938	chr14:75390232	RPS6KL1	0.64	11.74	0.48	4.97e-28	Caffeine consumption;
LGG	cis	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg07460842	chr6:66804631	NA	0.93	16.87	0.62	4.16e-50	Exhaled nitric oxide levels;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.39e-34	Obesity-related traits;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.881	rs7152674	chr14:72016613	G/T	cg13720639	chr14:72061746	SIPA1L1	0.37	8.3	0.36	1.14e-15	Mitral valve prolapse;
LGG	cis	rs1497828	0.913	rs2646836	chr1:217550020	A/T	cg04411442	chr1:217543379	NA	0.47	7.97	0.35	1.22e-14	Dialysis-related mortality;
LGG	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.94	-0.49	7.75e-29	Height;
LGG	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.59	0.37	1.39e-16	Aortic root size;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg11645453	chr3:52864694	ITIH4	0.39	6.69	0.3	6.57e-11	Electroencephalogram traits;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.8	0.45	2.17e-24	Longevity;
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg06925179	chr17:43578568	NA	0.42	9.96	0.42	2.69e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.45	-6.85	-0.3	2.37e-11	Huntington's disease progression;
LGG	cis	rs9486719	1.000	rs9400016	chr6:96940883	G/T	cg06623918	chr6:96969491	KIAA0776	-0.7	-9.82	-0.42	8.35e-21	Migraine;Coronary artery disease;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg18357526	chr6:26021779	HIST1H4A	0.87	15.99	0.6	4.03e-46	Intelligence (multi-trait analysis);
LGG	cis	rs888194	0.738	rs7956536	chr12:109980516	A/G	cg19025524	chr12:109796872	NA	0.35	7.13	0.31	3.85e-12	Neuroticism;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.73e-16	Life satisfaction;
LGG	cis	rs56283067	0.887	rs12197593	chr6:44740895	C/T	cg20913747	chr6:44695427	NA	-0.61	-11.07	-0.46	1.94e-25	Total body bone mineral density;
LGG	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24110177	chr3:50126178	RBM5	0.59	10.86	0.45	1.22e-24	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg05484508	chr16:89589025	SPG7	0.47	7.15	0.32	3.42e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6430585	0.528	rs309152	chr2:136657252	C/T	cg07169764	chr2:136633963	MCM6	-1.05	-17.72	-0.64	5.13e-54	Corneal structure;
LGG	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg23625390	chr15:77176239	SCAPER	0.49	9.65	0.41	3.31e-20	Blood metabolite levels;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.17	0.32	3.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs60180747	0.909	rs17200970	chr15:66731045	A/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.58	9.84	0.42	7.08e-21	Testicular germ cell tumor;
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.54	14.37	0.56	5.44e-39	Tonsillectomy;
LGG	cis	rs7555523	0.887	rs10800155	chr1:165723770	A/G	cg24409356	chr1:165738333	TMCO1	0.73	8.93	0.38	9.96e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	trans	rs923375	1.000	rs923375	chr17:3393068	C/T	cg00717808	chr7:794228	HEATR2	-0.38	-6.65	-0.3	8.21e-11	Myopia (pathological);
LGG	cis	rs8017423	0.904	rs12433417	chr14:90804028	A/G	cg04374321	chr14:90722782	PSMC1	-0.87	-17.67	-0.63	8.53e-54	Mortality in heart failure;
LGG	cis	rs7312933	0.670	rs10880269	chr12:42606135	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.22	0.32	2.18e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13754661	chr9:137533360	COL5A1	0.44	7.07	0.31	5.66e-12	Gut microbiome composition (summer);
LGG	trans	rs11039798	0.512	rs3974936	chr11:49005012	C/T	cg03929089	chr4:120376271	NA	0.71	9.93	0.42	3.39e-21	Axial length;
LGG	cis	rs2439831	0.850	rs67541383	chr15:44172548	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	8.64	0.37	9.01e-17	Lung cancer in ever smokers;
LGG	trans	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg26043149	chr18:55253948	FECH	0.4	6.66	0.3	7.69e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12540874	0.500	rs12719030	chr7:50485073	T/C	cg00647317	chr7:50633725	DDC	0.34	8.1	0.35	4.94e-15	Systemic sclerosis;
LGG	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	cis	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.96	-0.42	2.63e-21	Morning vs. evening chronotype;
LGG	cis	rs4671458	0.570	rs17618390	chr2:63831325	C/G	cg17519650	chr2:63277830	OTX1	-0.53	-7.56	-0.33	2.22e-13	Subjective well-being;
LGG	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.6	0.37	1.23e-16	Colorectal cancer;
LGG	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.77	-0.3	3.88e-11	Mean platelet volume;
LGG	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04530015	chr2:215796436	ABCA12	-0.45	-6.78	-0.3	3.71e-11	Neuroblastoma;
LGG	cis	rs2072732	0.821	rs7339938	chr1:2963493	G/C	cg08733933	chr1:2954429	NA	-0.41	-8.36	-0.36	7.32e-16	Plateletcrit;
LGG	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg21100191	chr22:23484243	RTDR1	1.0	22.98	0.73	1.58e-78	Bone mineral density;
LGG	cis	rs6834538	1.000	rs2171280	chr4:113472637	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.53	-8.58	-0.37	1.49e-16	Free thyroxine concentration;
LGG	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg00495681	chr13:53174319	NA	0.8	17.14	0.62	2.44e-51	Lewy body disease;
LGG	cis	rs6142618	0.562	rs4911545	chr20:30711515	A/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg00579200	chr11:133705235	NA	-0.55	-10.76	-0.45	3.07e-24	Childhood ear infection;
LGG	cis	rs11190604	1.000	rs11190558	chr10:102209397	C/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg00405596	chr8:11794950	NA	0.42	7.16	0.32	3.23e-12	Neuroticism;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg11235426	chr6:292522	DUSP22	-0.59	-9.89	-0.42	4.76e-21	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.69	-0.37	6.45e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.25e-14	Skin colour saturation;
LGG	cis	rs763121	0.889	rs1837988	chr22:38901094	A/G	cg06022373	chr22:39101656	GTPBP1	0.85	16.91	0.62	2.53e-50	Menopause (age at onset);
LGG	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg08677398	chr8:58056175	NA	0.59	9.16	0.39	1.64e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.644	rs56394965	chr2:86498349	A/T	cg10973622	chr2:86423274	IMMT	-0.4	-7.22	-0.32	2.16e-12	Night sleep phenotypes;
LGG	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	8.93	0.38	1.01e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.54	0.44	2.01e-23	Aortic root size;
LGG	cis	rs2120243	0.539	rs1545596	chr3:157118526	C/T	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg08684830	chr9:80851119	CEP78	-0.42	-6.76	-0.3	4.22e-11	Body fat mass;
LGG	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7766436	0.621	rs1548236	chr6:22613919	G/A	cg13666174	chr6:22585274	NA	-0.32	-7.61	-0.33	1.53e-13	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.1	-0.31	4.61e-12	Bipolar disorder;
LGG	cis	rs3206736	0.548	rs329243	chr7:35059716	G/A	cg13400248	chr7:35225412	NA	0.55	9.6	0.41	5.07e-20	Diastolic blood pressure;
LGG	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Colorectal cancer;
LGG	cis	rs12477438	0.501	rs896248	chr2:100078475	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.7	-0.3	6.11e-11	Chronic sinus infection;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.21	-0.49	6.36e-30	Schizophrenia;
LGG	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg26441486	chr22:50317300	CRELD2	-0.41	-7.58	-0.33	1.85e-13	Schizophrenia;
LGG	cis	rs7703051	0.520	rs13354746	chr5:74619132	C/T	cg19683494	chr5:74908142	NA	0.51	7.77	0.34	5.19e-14	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LGG	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.37	0.32	7.89e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg03213289	chr20:61660250	NA	0.65	14.15	0.55	4.95e-38	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1046896	1.000	rs1046896	chr17:80685533	A/G	cg16060761	chr17:80687452	NA	0.44	7.65	0.34	1.14e-13	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg11878867	chr6:150167359	LRP11	-0.53	-10.78	-0.45	2.52e-24	Lung cancer;
LGG	cis	rs975722	0.614	rs725188	chr7:117161653	T/G	cg10524701	chr7:117356490	CTTNBP2	0.45	9.77	0.41	1.29e-20	Coronary artery disease;
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.31	-0.53	1.83e-34	Personality dimensions;
LGG	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg08991232	chr8:70746365	SLCO5A1	0.37	6.74	0.3	4.63e-11	Eye color traits;
LGG	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.85e-20	Bone mineral density;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.52	8.84	0.38	2.08e-17	Obesity-related traits;
LGG	trans	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.97	0.42	2.5e-21	Mean corpuscular volume;
LGG	cis	rs7828089	1.000	rs7828089	chr8:22264334	T/G	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.77	-0.3	3.91e-11	Verbal declarative memory;
LGG	trans	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg18335740	chr13:41363409	SLC25A15	0.85	19.64	0.67	6.67e-63	Lewy body disease;
LGG	cis	rs611744	0.647	rs1457211	chr8:109261318	C/T	cg21045802	chr8:109455806	TTC35	-0.5	-9.41	-0.4	2.25e-19	Dupuytren's disease;
LGG	cis	rs752010	0.806	rs11210500	chr1:42089737	A/G	cg06885757	chr1:42089581	HIVEP3	0.57	13.52	0.53	2.45e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4356932	1.000	rs7689664	chr4:76963351	T/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	5.07e-11	Blood protein levels;
LGG	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg20503657	chr10:835505	NA	0.8	11.27	0.46	3.31e-26	Eosinophil percentage of granulocytes;
LGG	trans	rs9747201	0.962	rs34016823	chr17:80095428	G/T	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3784262	0.669	rs4646597	chr15:58300768	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.97	-0.31	1.1e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs8017423	0.967	rs2277514	chr14:90723059	T/C	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs2180341	0.960	rs7773484	chr6:127670779	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg13009111	chr11:71350975	NA	-0.33	-6.92	-0.31	1.53e-11	Neuroticism;
LGG	cis	rs12464559	0.522	rs10180065	chr2:152619007	A/G	cg01189475	chr2:152685088	ARL5A	-0.71	-6.95	-0.31	1.28e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs2587949	0.593	rs1444053	chr3:4196996	T/C	cg16519197	chr3:4211558	NA	-0.38	-7.68	-0.34	9.8e-14	Periodontitis (DPAL);
LGG	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg26695010	chr11:65641043	EFEMP2	0.55	9.43	0.4	2.04e-19	Eosinophil percentage of white cells;
LGG	cis	rs2243480	1.000	rs4145008	chr7:65647511	T/G	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.74	-0.34	6.33e-14	Dementia with Lewy bodies;
LGG	cis	rs4363385	0.510	rs7543689	chr1:153046803	A/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.33	-0.4	4.43e-19	Inflammatory skin disease;
LGG	cis	rs912057	0.833	rs1294426	chr6:6744477	T/C	cg06612196	chr6:6737390	NA	0.46	9.39	0.4	2.71e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg00666640	chr1:248458726	OR2T12	0.59	9.43	0.4	2.03e-19	Common traits (Other);
LGG	cis	rs3857747	0.895	rs34487990	chr7:40412731	G/A	cg00420559	chr7:40367873	C7orf10	0.39	7.75	0.34	5.81e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02503646	chr3:52444059	PHF7;BAP1	0.63	7.14	0.31	3.69e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.96	0.42	2.54e-21	Diabetic retinopathy;
LGG	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg02002194	chr4:3960332	NA	0.42	7.6	0.33	1.64e-13	Retinal vascular caliber;
LGG	cis	rs1318772	0.932	rs11746565	chr5:112934273	T/A	cg12552261	chr5:112820674	MCC	0.68	7.63	0.33	1.32e-13	F-cell distribution;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00552226	chr2:70475288	TIA1	0.52	8.07	0.35	6e-15	Gut microbiome composition (summer);
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs11945232	1.000	rs28609242	chr4:88342497	T/C	cg23841344	chr4:88312519	HSD17B11	-0.52	-9.23	-0.39	9.44e-19	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.45	0.58	9.89e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1707322	0.716	rs28370457	chr1:46172062	C/T	cg03146154	chr1:46216737	IPP	0.56	10.67	0.44	6.72e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.8	-0.3	3.21e-11	Migraine;Coronary artery disease;
LGG	cis	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg00806245	chr18:76673096	NA	-0.55	-6.69	-0.3	6.51e-11	Obesity-related traits;
LGG	trans	rs9929218	0.954	rs112225541	chr16:68755165	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.52	-0.56	1.25e-39	Colorectal cancer;
LGG	cis	rs1278769	0.786	rs3742238	chr13:113540425	C/T	cg00823993	chr13:113535758	ATP11A	0.7	10.42	0.44	5.36e-23	Interstitial lung disease;
LGG	cis	rs55871839	0.533	rs1375193	chr8:59846943	T/C	cg07426533	chr8:59803705	TOX	0.62	13.13	0.52	1.03e-33	Pneumonia;
LGG	cis	rs2303319	1.000	rs3769959	chr2:162249206	C/T	cg13806767	chr2:162164127	PSMD14	0.69	8.02	0.35	8.78e-15	Cognitive function;
LGG	cis	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg05623727	chr3:50126028	RBM5	-0.4	-8.72	-0.38	4.88e-17	Body mass index;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs13082711	0.513	rs66472045	chr3:27242887	G/A	cg02860705	chr3:27208620	NA	0.89	17.79	0.64	2.49e-54	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs116095464	1.000	rs62331562	chr5:349298	G/C	cg22857025	chr5:266934	NA	-1.18	-10.11	-0.43	7.7e-22	Breast cancer;
LGG	cis	rs1014246	1.000	rs1014246	chr10:118466042	C/T	cg14919929	chr10:118506882	NA	0.55	10.11	0.43	7.6e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.39	-0.61	6.21e-48	Asthma;
LGG	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg06951627	chr6:26196580	NA	0.45	6.75	0.3	4.47e-11	Gout;Renal underexcretion gout;
LGG	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg25809561	chr17:30822961	MYO1D	0.34	7.88	0.34	2.4e-14	Schizophrenia;
LGG	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg06219351	chr7:158114137	PTPRN2	-0.78	-15.01	-0.57	8.99e-42	Calcium levels;
LGG	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg09699651	chr6:150184138	LRP11	0.56	10.62	0.44	9.7e-24	Testicular germ cell tumor;
LGG	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.88	-0.66	2.14e-59	Blood trace element (Zn levels);
LGG	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.35	-0.5	1.77e-30	Morning vs. evening chronotype;
LGG	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg03788504	chr6:150331562	NA	0.6	13.84	0.54	1.06e-36	Alopecia areata;
LGG	cis	rs6831352	0.734	rs1453872	chr4:100022482	G/A	cg13256891	chr4:100009986	ADH5	0.54	9.51	0.4	1.02e-19	Alcohol dependence;
LGG	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.24	-0.32	1.92e-12	Schizophrenia;
LGG	trans	rs208520	0.754	rs12204635	chr6:66740779	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.77	0.64	2.95e-54	Exhaled nitric oxide output;
LGG	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg18876405	chr7:65276391	NA	0.49	8.85	0.38	1.93e-17	Aortic root size;
LGG	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg13256891	chr4:100009986	ADH5	0.38	6.74	0.3	4.61e-11	Alcohol dependence;
LGG	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.95	-15.98	-0.6	4.25e-46	Gut microbiome composition (summer);
LGG	cis	rs4917300	0.606	rs7832653	chr8:143111932	A/G	cg06573787	chr8:143070187	NA	0.61	10.21	0.43	3.2e-22	Amyotrophic lateral sclerosis;
LGG	cis	rs4356932	1.000	rs4456983	chr4:76958688	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg06221963	chr1:154839813	KCNN3	-0.51	-9.72	-0.41	1.92e-20	Prostate cancer;
LGG	cis	rs9398803	0.687	rs7743860	chr6:126927717	T/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	Neuroticism;
LGG	cis	rs1476679	1.000	rs34919929	chr7:100012334	G/A	cg22906224	chr7:99728672	NA	-0.43	-6.75	-0.3	4.37e-11	Alzheimer's disease (late onset);
LGG	cis	rs4423214	0.879	rs1630498	chr11:71150785	A/C	cg10847948	chr11:71163743	NADSYN1	0.62	11.28	0.46	2.96e-26	Vitamin D levels;
LGG	cis	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg22496380	chr5:211416	CCDC127	-0.95	-9.41	-0.4	2.33e-19	Breast cancer;
LGG	cis	rs2888674	0.933	rs10267707	chr7:150510973	C/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.25	6.69	0.3	6.5500000000000006e-11	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.23	0.49	5.28e-30	Prudent dietary pattern;
LGG	cis	rs9912468	0.647	rs12603947	chr17:64244505	T/C	cg19474267	chr17:64306194	PRKCA	-0.78	-16.97	-0.62	1.41e-50	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-10.05	-0.42	1.22e-21	Reticulocyte count;
LGG	cis	rs57221529	0.654	rs11740553	chr5:672593	C/T	cg09021430	chr5:549028	NA	-0.7	-9.32	-0.4	4.69e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.73	0.38	4.5e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11627756	0.957	rs6575929	chr14:103149447	T/G	cg12046867	chr14:103022105	NA	0.42	7.87	0.34	2.54e-14	Mean platelet volume;
LGG	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg00198680	chr16:28758506	NA	0.28	6.76	0.3	4.11e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.73	0.34	6.64e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.72	-0.3	5.46e-11	Triglycerides;
LGG	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg11266682	chr4:10021025	SLC2A9	0.53	10.55	0.44	1.84e-23	Bone mineral density;
LGG	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg06481639	chr22:41940642	POLR3H	-0.56	-7.76	-0.34	5.51e-14	Vitiligo;
LGG	cis	rs2066819	1.000	rs57279772	chr12:56698960	G/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg04025307	chr7:1156635	C7orf50	0.53	9.91	0.42	4.18e-21	Longevity;Endometriosis;
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	8.19	0.36	2.58e-15	Neuroticism;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg10064886	chr14:58764945	FLJ31306;ARID4A	0.45	6.66	0.3	7.59e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2587949	0.615	rs2629267	chr3:4192111	A/C	cg16519197	chr3:4211558	NA	-0.35	-7.3	-0.32	1.26e-12	Periodontitis (DPAL);
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	16.65	0.61	4e-49	Personality dimensions;
LGG	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg19784903	chr17:45786737	TBKBP1	0.33	7.27	0.32	1.5e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17162190	0.698	rs4659375	chr1:26804090	G/A	cg23229016	chr1:26872525	RPS6KA1	0.26	6.81	0.3	2.98e-11	Mean corpuscular volume;
LGG	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.78	-0.78	3.86e-96	Height;
LGG	cis	rs9905704	0.846	rs302863	chr17:56698827	A/G	cg12560992	chr17:57184187	TRIM37	-0.44	-6.71	-0.3	5.61e-11	Testicular germ cell tumor;
LGG	cis	rs76419734	0.510	rs28450989	chr4:106630007	G/C	cg11477892	chr4:106580295	NA	-0.42	-6.83	-0.3	2.66e-11	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.29e-23	Prudent dietary pattern;
LGG	cis	rs6743226	0.870	rs10933547	chr2:242230443	C/G	cg10021735	chr2:242295487	FARP2	-0.51	-9.51	-0.4	1.04e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs17286411	0.750	rs4788568	chr16:71913025	C/T	cg03805757	chr16:71968109	PKD1L3	0.34	7.08	0.31	5.46e-12	Blood protein levels;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.64	-0.41	3.67e-20	Aortic root size;
LGG	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg13073564	chr4:8508604	NA	-0.56	-10.93	-0.45	6.86e-25	Response to antineoplastic agents;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg02725872	chr8:58115012	NA	-0.95	-14.1	-0.55	7.75e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg03264133	chr6:25882463	NA	0.51	9.25	0.39	8.61e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.98	-0.31	1.03e-11	Triglycerides;
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg03709012	chr19:19516395	GATAD2A	-0.82	-15.9	-0.59	9.32e-46	Tonsillectomy;
LGG	cis	rs7539542	0.516	rs10732291	chr1:202891168	G/A	cg19681188	chr1:202830198	LOC148709	0.5	8.23	0.36	1.97e-15	Mean platelet volume;
LGG	cis	rs1318772	0.577	rs13358293	chr5:112976714	G/C	cg12552261	chr5:112820674	MCC	0.58	6.88	0.3	1.9e-11	F-cell distribution;
LGG	trans	rs1814175	0.645	rs1851849	chr11:50012164	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.73	-0.68	2.36e-63	Height;
LGG	cis	rs4689642	0.507	rs56211441	chr4:7218738	A/G	cg21353189	chr4:7228343	SORCS2	0.32	6.83	0.3	2.69e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg09307838	chr4:120376055	NA	0.7	11.17	0.46	8.13e-26	Corneal astigmatism;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15687138	chr1:151138326	SCNM1;LYSMD1	-0.43	-7.1	-0.31	4.81e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs28830936	0.966	rs1531140	chr15:42125234	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.82	-0.51	2.1e-32	Diastolic blood pressure;
LGG	cis	rs2120243	0.539	rs1840673	chr3:157117977	A/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg19182353	chr11:118479428	PHLDB1	-0.55	-10.98	-0.45	4.36e-25	Cholesterol, total;
LGG	cis	rs6748734	0.548	rs4441463	chr2:241872597	A/G	cg05025159	chr2:241905733	NA	0.51	10.31	0.43	1.39e-22	Urinary metabolites;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18652453	chr5:68665041	TAF9;RAD17	0.44	6.65	0.3	8.48e-11	Gut microbiome composition (summer);
LGG	cis	rs4936894	0.500	rs4935872	chr11:124075995	A/G	cg27160556	chr11:124181099	OR8D1	-0.42	-9.76	-0.41	1.37e-20	Aging (time to death);
LGG	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg19671926	chr4:122722719	EXOSC9	0.53	8.23	0.36	1.85e-15	Type 2 diabetes;
LGG	cis	rs8114671	0.562	rs6119545	chr20:33522869	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.02	0.31	7.95e-12	Height;
LGG	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2.01e-19	Diabetic retinopathy;
LGG	cis	rs7951870	0.645	rs2070852	chr11:46744925	C/G	cg03339077	chr11:47165057	C11orf49	-0.4	-6.89	-0.31	1.8e-11	Schizophrenia;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg02524346	chr8:600233	NA	-1.26	-10.46	-0.44	3.96e-23	IgG glycosylation;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg05896524	chr21:47604654	C21orf56	0.64	10.82	0.45	1.72e-24	Testicular germ cell tumor;
LGG	trans	rs8129326	0.691	rs9984092	chr21:35784171	A/T	cg07474852	chr4:123073612	NA	-0.47	-8.36	-0.36	7.48e-16	Cancer;
LGG	cis	rs3767633	0.858	rs10753645	chr1:161815364	T/C	cg09175582	chr1:161736000	ATF6	0.74	9.01	0.39	5.4e-18	IgG glycosylation;
LGG	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.18	0.32	2.88e-12	Neuroticism;
LGG	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.7	0.41	2.24e-20	Alcohol dependence;
LGG	cis	rs11229555	0.609	rs34133416	chr11:58184720	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs12517041	0.786	rs34989767	chr5:23249810	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.58	-8.35	-0.36	7.99e-16	Calcium levels;
LGG	cis	rs7666738	0.791	rs17549003	chr4:98969132	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1371614	0.513	rs13010712	chr2:27087709	T/A	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.88	-0.3	1.92e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg19824325	chr16:58548873	SETD6	1.23	11.21	0.46	5.86e-26	Schizophrenia;
LGG	cis	rs283228	0.570	rs2629981	chr6:101782864	C/T	cg27451362	chr6:101846650	GRIK2	0.83	13.22	0.52	4.67e-34	Coenzyme Q10 levels;
LGG	cis	rs10463316	0.894	rs7723379	chr5:150765025	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.2800000000000002e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs3743102	0.591	rs79849356	chr15:83402305	T/C	cg00614314	chr15:82944287	LOC80154	-0.71	-7.09	-0.31	5.01e-12	Colorectal adenoma (advanced);
LGG	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg21775007	chr8:11205619	TDH	0.8	14.19	0.55	3.2e-38	Retinal vascular caliber;
LGG	cis	rs56399783	0.901	rs73033407	chr7:2878857	G/C	cg19731401	chr7:2775893	GNA12	0.36	7.03	0.31	7.53e-12	Childhood ear infection;
LGG	cis	rs74781061	0.860	rs7163775	chr15:74745101	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.32	-0.32	1.08e-12	Endometriosis;
LGG	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24308560	chr3:49941425	MST1R	0.23	7.07	0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2415984	0.579	rs1389606	chr14:46964226	T/C	cg14871534	chr14:47121158	RPL10L	0.58	10.26	0.43	2.2e-22	Number of children ever born;
LGG	cis	rs853679	0.517	rs4713150	chr6:28136212	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs4356932	1.000	rs10003382	chr4:76955473	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.6e-11	Blood protein levels;
LGG	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg03391019	chr1:161927947	ATF6	0.49	6.74	0.3	4.73e-11	IgG glycosylation;
LGG	cis	rs6871536	1.000	rs6596086	chr5:131952222	T/C	cg04303330	chr5:131992430	IL13	0.28	6.88	0.3	1.96e-11	Asthma (childhood onset);
LGG	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.87e-16	Bone mineral density;
LGG	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs4851254	0.961	rs11682173	chr2:100759810	C/T	cg17356467	chr2:100759845	AFF3	0.41	7.1	0.31	4.74e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12348691	0.503	rs7847259	chr9:100600712	A/G	cg13688889	chr9:100608707	NA	-0.83	-16.19	-0.6	4.95e-47	Alopecia areata;
LGG	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg00204512	chr16:28754710	NA	0.24	6.66	0.3	7.62e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.25e-11	Menopause (age at onset);
LGG	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.18e-13	Dupuytren's disease;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.6	-0.44	1.19e-23	Lung cancer;
LGG	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.45	-9.38	-0.4	3.03e-19	Schizophrenia;
LGG	cis	rs7172689	1.000	rs61219147	chr15:81533762	A/G	cg11808699	chr15:81528661	IL16	-0.5	-9.96	-0.42	2.74e-21	Inattentive symptoms;
LGG	cis	rs2074193	0.569	rs11183911	chr12:47769251	A/G	cg02516419	chr12:47771422	NA	0.56	8.6	0.37	1.26e-16	Migraine with aura;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg22433210	chr17:43662623	NA	-0.87	-14.3	-0.55	1.13e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg05335186	chr13:53173507	NA	0.59	13.28	0.53	2.61e-34	Lewy body disease;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg20607798	chr8:58055168	NA	0.63	7.32	0.32	1.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7827545	0.620	rs6578009	chr8:135522989	T/C	cg09855544	chr8:135498122	ZFAT	-0.45	-7.71	-0.34	7.93e-14	Hypertension (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16372595	chr14:20774003	TTC5	0.53	8.62	0.37	1.04e-16	Gut microbiome composition (summer);
LGG	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg23155468	chr6:27110703	HIST1H2BK	0.64	7.53	0.33	2.71e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2617583	0.935	rs1354139	chr5:1451782	T/C	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.22	-0.32	2.13e-12	Breast cancer;
LGG	cis	rs73227498	0.590	rs7720064	chr5:111491473	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.49	-6.68	-0.3	6.66e-11	Thyroid cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11317019	chr17:42219250	C17orf53	0.55	8.36	0.36	7.28e-16	Gut microbiome composition (summer);
LGG	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg19748678	chr4:122722346	EXOSC9	0.51	9.66	0.41	3.01e-20	Type 2 diabetes;
LGG	trans	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	12.43	0.5	7.95e-31	Breast cancer;
LGG	cis	rs62400317	0.859	rs56357385	chr6:45203591	C/T	cg18551225	chr6:44695536	NA	-0.63	-9.97	-0.42	2.35e-21	Total body bone mineral density;
LGG	cis	rs35740288	0.929	rs11635081	chr15:86304260	G/A	cg07943548	chr15:86304357	KLHL25	-0.37	-7.43	-0.33	5.24e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.55	-0.41	7.27e-20	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07939768	chr17:27621433	NUFIP2	0.51	8.72	0.38	4.9e-17	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14580567	chr4:145567271	HHIP	0.46	8.07	0.35	6e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.93	0.35	1.68e-14	Personality dimensions;
LGG	cis	rs826838	0.510	rs10506129	chr12:39224242	A/T	cg13010199	chr12:38710504	ALG10B	0.6	10.91	0.45	7.81e-25	Heart rate;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg05896524	chr21:47604654	C21orf56	0.55	9.62	0.41	4.38e-20	Testicular germ cell tumor;
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg24503407	chr1:205819492	PM20D1	-0.5	-6.66	-0.3	7.76e-11	Prostate-specific antigen levels;
LGG	cis	rs2050392	0.965	rs2480279	chr10:30700032	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.91	-0.45	7.84e-25	Inflammatory bowel disease;
LGG	cis	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.88	0.54	7.18e-37	Bladder cancer;
LGG	cis	rs60871478	0.679	rs62432240	chr7:794813	A/G	cg22643751	chr7:855365	UNC84A	0.44	7.62	0.33	1.42e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs10463316	0.894	rs6579864	chr5:150762181	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2839186	0.596	rs4819217	chr21:47644092	G/T	cg12379764	chr21:47803548	PCNT	-0.47	-7.97	-0.35	1.24e-14	Testicular germ cell tumor;
LGG	cis	rs12367572	0.965	rs11182706	chr12:45223339	T/C	cg03114573	chr12:45410052	DBX2	-0.53	-9.02	-0.39	5.19e-18	Gut microbiome composition (summer);
LGG	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg15412446	chr2:106886593	NA	-0.42	-9.57	-0.41	6.4e-20	Facial morphology (factor 23);
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.72	0.41	1.98e-20	Obesity-related traits;
LGG	cis	rs7241530	0.662	rs12454671	chr18:75908918	G/C	cg14642773	chr18:75888474	NA	0.45	8.74	0.38	4.44e-17	Educational attainment (years of education);
LGG	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg17971929	chr21:40555470	PSMG1	0.86	16.85	0.62	5.21e-50	Cognitive function;
LGG	cis	rs7172677	1.000	rs72730601	chr15:75421720	A/T	cg14664628	chr15:75095509	CSK	0.45	6.9	0.31	1.77e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-10.28	-0.43	1.88e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg23815491	chr16:72088622	HP	0.49	9.19	0.39	1.34e-18	Blood protein levels;
LGG	cis	rs7998202	0.667	rs665813	chr13:113355765	A/G	cg02820901	chr13:113351484	ATP11A	0.62	7.35	0.32	9.1e-13	Glycated hemoglobin levels;
LGG	cis	rs7715811	0.912	rs1502049	chr5:13779935	T/C	cg07548982	chr5:13769939	DNAH5	-0.47	-9.93	-0.42	3.26e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs3768617	0.565	rs7542277	chr1:183063527	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.74	0.38	4.36e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg07701084	chr6:150067640	NUP43	0.62	11.36	0.47	1.45e-26	Lung cancer;
LGG	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg04673462	chr1:38461896	NA	0.47	9.04	0.39	4.22e-18	Coronary artery disease;
LGG	cis	rs11191270	0.554	rs10444022	chr10:104084889	A/G	cg15320455	chr10:103880129	LDB1	0.66	8.54	0.37	2.01e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg16482183	chr6:26056742	HIST1H1C	0.79	11.08	0.46	1.82e-25	Iron status biomarkers;
LGG	cis	rs73086581	1.000	rs113812453	chr20:3963193	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg03709012	chr19:19516395	GATAD2A	0.86	17.48	0.63	6.5e-53	Tonsillectomy;
LGG	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.92	-0.38	1.12e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs4330281	0.765	rs13079096	chr3:17795076	T/A	cg20981856	chr3:17787350	NA	-0.39	-7.05	-0.31	6.5e-12	Schizophrenia;
LGG	cis	rs9326248	0.798	rs10892079	chr11:117016824	T/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.34	0.4	4.02e-19	Blood protein levels;
LGG	cis	rs72781680	0.752	rs72796138	chr2:23926233	C/T	cg08917208	chr2:24149416	ATAD2B	0.85	9.13	0.39	2.18e-18	Lymphocyte counts;
LGG	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.82e-22	Diabetic retinopathy;
LGG	cis	rs2640806	0.505	rs28830572	chr8:97364097	A/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.12	0.31	4.09e-12	Obesity-related traits;
LGG	trans	rs2055729	1.000	rs2055729	chr8:9792662	C/T	cg12395012	chr8:11607386	GATA4	0.41	7.25	0.32	1.81e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2933343	0.729	rs789224	chr3:128598231	A/C	cg11901034	chr3:128598214	ACAD9	-0.45	-6.9	-0.31	1.7e-11	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.86	-0.3	2.17e-11	Lung cancer;
LGG	cis	rs1577917	1.000	rs12213149	chr6:86668644	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.55	-0.53	1.85e-35	Response to antipsychotic treatment;
LGG	cis	rs270601	0.817	rs460089	chr5:131629772	C/G	cg07395648	chr5:131743802	NA	-0.5	-9.85	-0.42	6.82e-21	Acylcarnitine levels;
LGG	cis	rs6087990	0.735	rs2424906	chr20:31359109	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	17.31	0.63	3.94e-52	Ulcerative colitis;
LGG	cis	rs2862064	0.929	rs4704837	chr5:156464212	T/G	cg12943317	chr5:156479607	HAVCR1	-0.87	-10.93	-0.45	6.98e-25	Platelet count;
LGG	cis	rs564799	0.966	rs545232	chr3:159732031	C/T	cg04855961	chr3:159719849	NA	-0.27	-7.49	-0.33	3.49e-13	Systemic lupus erythematosus;
LGG	cis	rs11971779	0.715	rs10265	chr7:139026152	T/G	cg07862535	chr7:139043722	LUC7L2	0.41	6.75	0.3	4.51e-11	Diisocyanate-induced asthma;
LGG	cis	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg07460842	chr6:66804631	NA	0.57	9.55	0.41	7.54e-20	Metabolite levels;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.64	-0.41	3.8e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03771185	chr4:775700	NA	0.61	10.15	0.43	5.29e-22	Gut microbiome composition (summer);
LGG	cis	rs35160687	0.644	rs17738058	chr2:86513203	G/C	cg10973622	chr2:86423274	IMMT	-0.4	-7.13	-0.31	3.78e-12	Night sleep phenotypes;
LGG	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg09303159	chr6:26284866	NA	0.33	7.36	0.32	8.2e-13	Educational attainment;
LGG	cis	rs727505	0.954	rs2170352	chr7:124605584	G/A	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg04025307	chr7:1156635	C7orf50	0.66	10.59	0.44	1.32e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1107366	0.722	rs2364368	chr3:125905080	A/T	cg17230874	chr3:125932073	NA	0.58	11.73	0.48	5.42e-28	Metabolite levels;
LGG	trans	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.19	-0.32	2.59e-12	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.67e-12	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.89	-0.38	1.39e-17	Neuroticism;
LGG	cis	rs13108043	0.543	rs34449424	chr4:87882814	A/C	cg11209507	chr4:87813803	C4orf36	0.6	7.97	0.35	1.27e-14	Red blood cell count;
LGG	cis	rs1322639	1.000	rs1322639	chr6:169587103	G/A	cg04662567	chr6:169592167	NA	0.84	14.3	0.55	1.16e-38	Pulse pressure;
LGG	cis	rs11676348	0.846	rs4674260	chr2:219002376	T/C	cg00012203	chr2:219082015	ARPC2	-0.57	-10.23	-0.43	2.7e-22	Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21243939	chr14:55033137	SAMD4A	0.43	7.17	0.32	3.05e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs921968	0.678	rs660432	chr2:219432127	C/T	cg01130898	chr2:219473002	PLCD4	-0.4	-6.82	-0.3	2.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.36	0.7	5.66e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.44	-8.18	-0.36	2.67e-15	Homoarginine levels;
LGG	cis	rs2708240	0.560	rs4574770	chr7:147559736	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-7.93	-0.35	1.66e-14	QT interval (drug interaction);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09865173	chr10:104952209	NT5C2	0.44	7.3	0.32	1.28e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.8	-0.48	2.84e-28	Alzheimer's disease;
LGG	cis	rs6714710	0.603	rs7421146	chr2:98552271	G/C	cg26665480	chr2:98280029	ACTR1B	0.63	10.27	0.43	2e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg26043149	chr18:55253948	FECH	-0.48	-8.25	-0.36	1.67e-15	Bone mineral density;
LGG	cis	rs10193935	0.901	rs2374405	chr2:42479874	A/C	cg27598129	chr2:42591480	NA	-0.64	-9.65	-0.41	3.35e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg27165867	chr14:105738592	BRF1	-0.43	-7.41	-0.33	6.13e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.95	-0.35	1.43e-14	Mood instability;
LGG	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.11	-0.35	4.53e-15	Triglycerides;
LGG	cis	rs4906332	0.966	rs2065016	chr14:103879656	T/A	cg26031613	chr14:104095156	KLC1	-0.52	-7.97	-0.35	1.27e-14	Coronary artery disease;
LGG	cis	rs12627970	0.565	rs2072872	chr22:39713128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.97	22.48	0.72	3.2e-76	Inflammatory bowel disease;
LGG	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg02254774	chr11:50257496	LOC441601	0.57	6.76	0.3	4.15e-11	Myopia (pathological);
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg03709012	chr19:19516395	GATAD2A	0.78	15.02	0.57	8.07e-42	Tonsillectomy;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.03e-37	Bladder cancer;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.32	3.56e-12	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-13.09	-0.52	1.56e-33	Prudent dietary pattern;
LGG	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg20302533	chr7:39170763	POU6F2	0.58	15.02	0.57	7.67e-42	IgG glycosylation;
LGG	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.3	-0.4	5.58e-19	Retinal vascular caliber;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.35	-0.43	1.03e-22	Tonsillectomy;
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg05335186	chr13:53173507	NA	0.52	10.84	0.45	1.49e-24	Lewy body disease;
LGG	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg03060546	chr3:49711283	APEH	-0.62	-10.33	-0.43	1.24e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg26384229	chr12:38710491	ALG10B	0.96	20.83	0.7	1.69e-68	Morning vs. evening chronotype;
LGG	cis	rs3857536	0.679	rs7740850	chr6:66981033	G/A	cg07460842	chr6:66804631	NA	-0.44	-7.14	-0.31	3.67e-12	Blood trace element (Cu levels);
LGG	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-13.24	-0.52	3.74e-34	Bipolar disorder;
LGG	cis	rs1461503	0.966	rs10892938	chr11:122841921	A/C	cg27398637	chr11:122830231	C11orf63	-0.71	-13.88	-0.54	7.46e-37	Menarche (age at onset);
LGG	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg00857998	chr1:205179979	DSTYK	0.55	8.95	0.38	8.85e-18	Red blood cell count;
LGG	cis	rs62238980	0.614	rs117692225	chr22:32421806	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.76	0.38	3.65e-17	Obesity-related traits;
LGG	trans	rs8073060	0.614	rs72829932	chr17:34055935	A/G	cg19694781	chr19:47549865	TMEM160	1.15	17.22	0.62	9.79e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.4	0.4	2.5e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg22535103	chr8:58192502	C8orf71	-1.0	-15.65	-0.59	1.33e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs4319547	0.695	rs1973463	chr12:122938003	A/G	cg23029597	chr12:123009494	RSRC2	-0.92	-16.81	-0.62	7.27e-50	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18685883	chr3:51705045	TEX264	0.39	6.77	0.3	4.03e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.35	-0.36	7.79e-16	Mood instability;
LGG	cis	rs7192380	0.931	rs9302604	chr16:69576894	A/G	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.28	-0.32	1.4e-12	Sjögren's syndrome;
LGG	cis	rs9381040	0.610	rs9357345	chr6:41025118	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.71	-0.3	5.7e-11	Alzheimer's disease (late onset);
LGG	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.08	0.31	5.39e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.99	-0.31	9.66e-12	Alzheimer's disease (late onset);
LGG	cis	rs6546550	0.901	rs7419837	chr2:70146625	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.69	-9.63	-0.41	4.11e-20	Lung function (FEV1/FVC);
LGG	cis	rs2576037	0.526	rs8095373	chr18:44527895	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.33	-7.25	-0.32	1.81e-12	Personality dimensions;
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.25e-12	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg13206674	chr6:150067644	NUP43	0.68	16.08	0.6	1.45e-46	Lung cancer;
LGG	cis	rs2594989	0.831	rs7651790	chr3:11572610	C/T	cg01796438	chr3:11312864	ATG7	0.54	7.27	0.32	1.59e-12	Circulating chemerin levels;
LGG	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg18876405	chr7:65276391	NA	0.6	11.09	0.46	1.71e-25	Aortic root size;
LGG	trans	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg11430096	chr6:110968061	CDK19	0.66	6.72	0.3	5.48e-11	Prostate cancer;
LGG	cis	rs11122272	0.701	rs2790894	chr1:231505587	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.87	-0.45	1.17e-24	Hemoglobin concentration;
LGG	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.46	-0.37	3.65e-16	Neuroticism;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg19626725	chr5:178986131	RUFY1	0.46	7.54	0.33	2.43e-13	Lung cancer;
LGG	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.18	-0.32	2.81e-12	Prostate-specific antigen levels;
LGG	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg14689365	chr7:158441557	NCAPG2	-0.55	-6.78	-0.3	3.65e-11	Height;
LGG	cis	rs138341189	1	rs138341189	chr11:68224411	GATTGTGCCAAT/G	cg01657329	chr11:68192670	LRP5	-0.57	-7.33	-0.32	1.06e-12	Monobrow;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17422427	chr2:241507521	RNPEPL1	0.49	7.55	0.33	2.28e-13	Gut microbiome composition (summer);
LGG	cis	rs4740619	0.809	rs7855235	chr9:15709741	T/C	cg14451791	chr9:16040625	NA	-0.36	-9.15	-0.39	1.76e-18	Body mass index;
LGG	cis	rs6901004	0.803	rs9387000	chr6:111459941	A/C	cg15721981	chr6:111408429	SLC16A10	-0.44	-7.88	-0.34	2.29e-14	Blood metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg19233923	chr11:63753598	OTUB1	0.4	6.72	0.3	5.45e-11	Bipolar disorder;
LGG	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg11494091	chr17:61959527	GH2	0.6	10.06	0.42	1.18e-21	Height;
LGG	cis	rs701145	0.537	rs377565	chr3:153921953	A/G	cg12800244	chr3:153838788	SGEF	0.81	8.34	0.36	8.8e-16	Coronary artery disease;
LGG	trans	rs4713118	0.619	rs200486	chr6:27779506	C/T	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.41	-0.33	5.98e-13	Parkinson's disease;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08645402	chr16:4508243	NA	0.52	10.0	0.42	1.95e-21	Schizophrenia;
LGG	cis	rs1883415	0.853	rs2760141	chr6:24480897	C/T	cg20631270	chr6:24437470	GPLD1	0.44	7.0	0.31	9.24e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.73	-0.38	4.81e-17	Life satisfaction;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4700695	0.925	rs12657113	chr5:65396959	A/C	cg21114390	chr5:65439923	SFRS12	-0.56	-7.24	-0.32	1.89e-12	Facial morphology (factor 19);
LGG	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs9649465	0.522	rs662705	chr7:123431594	A/C	cg03229431	chr7:123269106	ASB15	0.59	13.66	0.54	6.14e-36	Migraine;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.81e-21	Platelet count;
LGG	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.26	-0.36	1.54e-15	Body mass index;
LGG	cis	rs1062177	1.000	rs2915880	chr5:151147334	G/A	cg00977110	chr5:151150581	G3BP1	0.49	7.85	0.34	2.93e-14	Preschool internalizing problems;
LGG	cis	rs7129556	0.737	rs643388	chr11:77471042	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.36e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs12580194	0.593	rs66902680	chr12:55724080	A/C	cg19537932	chr12:55886519	OR6C68	-0.56	-9.89	-0.42	4.9e-21	Cancer;
LGG	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg07915516	chr16:377344	AXIN1	-0.28	-6.91	-0.31	1.62e-11	Body mass index;
LGG	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg00830817	chr11:109293614	C11orf87	0.42	6.95	0.31	1.26e-11	Schizophrenia;
LGG	cis	rs7172677	0.768	rs72730586	chr15:75354165	G/A	cg14664628	chr15:75095509	CSK	0.61	10.13	0.43	6.2e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs17253792	0.822	rs2147114	chr14:56077118	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.5	0.37	2.61e-16	Retinal vascular caliber;
LGG	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-7.35	-0.32	9.04e-13	Inflammatory skin disease;
LGG	cis	rs6684428	0.536	rs12119683	chr1:56388524	T/A	cg11651538	chr1:56320950	NA	0.41	7.86	0.34	2.67e-14	Airflow obstruction;
LGG	trans	rs12517041	0.938	rs10039693	chr5:23272411	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.62	-8.96	-0.38	7.93e-18	Calcium levels;
LGG	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg02822958	chr2:46747628	ATP6V1E2	-0.48	-8.4	-0.36	5.36e-16	HDL cholesterol;
LGG	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.04e-23	Resting heart rate;
LGG	cis	rs2859741	0.546	rs3845491	chr1:37497521	C/T	cg09363841	chr1:37513479	NA	-0.56	-11.53	-0.47	3.4e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.64	-0.33	1.26e-13	Eosinophil percentage of white cells;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg18402987	chr7:1209562	NA	0.48	8.07	0.35	6.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs283228	0.605	rs643101	chr6:101726103	G/T	cg27451362	chr6:101846650	GRIK2	0.96	14.02	0.55	1.71e-37	Coenzyme Q10 levels;
LGG	cis	rs2073499	1.000	rs2073499	chr3:50374293	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.73	9.74	0.41	1.6e-20	Schizophrenia;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20887711	chr4:1340912	KIAA1530	0.58	11.46	0.47	6.13e-27	Longevity;
LGG	cis	rs3008870	1.000	rs3008873	chr1:67425770	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.43	0.74	1.24e-80	Lymphocyte percentage of white cells;
LGG	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg09448879	chr15:79043637	NA	-0.29	-6.65	-0.3	8.53e-11	Sudden cardiac arrest;
LGG	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-10.96	-0.45	5.43e-25	Vitiligo;
LGG	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.23	0.32	2.01e-12	Bipolar disorder;
LGG	cis	rs11239187	0.512	rs10900073	chr10:45066992	A/G	cg03916630	chr10:45065415	NA	0.34	8.17	0.36	2.87e-15	Body mass index;
LGG	cis	rs10781543	0.776	rs11145760	chr9:139382594	G/A	cg14169450	chr9:139327907	INPP5E	0.37	6.77	0.3	3.99e-11	Monocyte percentage of white cells;
LGG	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4664308	0.618	rs55668231	chr2:160882066	A/G	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.52	-0.47	3.54e-27	Idiopathic membranous nephropathy;
LGG	cis	rs4851254	0.517	rs13020141	chr2:100653842	G/A	cg17356467	chr2:100759845	AFF3	0.47	7.62	0.33	1.44e-13	Intelligence (multi-trait analysis);
LGG	cis	rs787274	0.718	rs4979173	chr9:115627699	A/C	cg13803584	chr9:115635662	SNX30	-0.65	-9.38	-0.4	2.92e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6430585	0.646	rs1057031	chr2:136633962	G/A	cg07169764	chr2:136633963	MCM6	1.3	27.29	0.79	1.87e-98	Corneal structure;
LGG	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg03162506	chr22:38580953	NA	0.42	10.14	0.43	5.84e-22	Breast cancer;
LGG	cis	rs7712401	0.601	rs152039	chr5:122220665	C/T	cg19412675	chr5:122181750	SNX24	0.41	6.85	0.3	2.4e-11	Mean platelet volume;
LGG	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	12.56	0.5	2.47e-31	Lung cancer in ever smokers;
LGG	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg17211192	chr8:82754475	SNX16	0.75	11.57	0.47	2.2e-27	Diastolic blood pressure;
LGG	cis	rs9425766	0.678	rs55829688	chr1:173837306	T/C	cg06124660	chr1:173389066	NA	-0.4	-6.89	-0.3	1.87e-11	Life satisfaction;
LGG	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg08392591	chr16:89556376	ANKRD11	0.61	9.76	0.41	1.35e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg09699651	chr6:150184138	LRP11	0.52	9.33	0.4	4.52e-19	Lung cancer;
LGG	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs7107174	0.892	rs2511167	chr11:77964698	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.79	-0.34	4.54e-14	Testicular germ cell tumor;
LGG	trans	rs931812	0.825	rs34235568	chr8:101895761	C/T	cg20993868	chr7:22813445	NA	0.68	12.68	0.51	7.9e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs714515	0.546	rs1894633	chr1:172331059	A/G	cg01573306	chr1:172330400	DNM3	-0.47	-10.63	-0.44	8.82e-24	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg12923728	chr3:195709715	SDHAP1	0.56	9.38	0.4	2.93e-19	Mean corpuscular volume;
LGG	cis	rs7781557	0.696	rs73192019	chr7:102547081	G/A	cg18108683	chr7:102477205	FBXL13	-0.55	-8.11	-0.35	4.55e-15	Colorectal adenoma (advanced);
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg24829409	chr8:58192753	C8orf71	-0.8	-9.12	-0.39	2.24e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs3889237	0.609	rs56007627	chr17:64781386	C/T	cg09655520	chr17:64786064	PRKCA	-0.36	-6.96	-0.31	1.19e-11	Height;
LGG	cis	rs10905065	0.965	rs7100576	chr10:5784649	G/A	cg11519256	chr10:5708881	ASB13	0.42	7.41	0.33	5.98e-13	Menopause (age at onset);
LGG	cis	rs5769707	0.872	rs5770604	chr22:50030672	G/A	cg06623630	chr22:50017776	C22orf34	-0.37	-7.97	-0.35	1.23e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg06618935	chr21:46677482	NA	-0.48	-9.45	-0.4	1.7e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.31	0.4	5.27e-19	Lung cancer;
LGG	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg19847130	chr8:10466454	RP1L1	0.31	6.94	0.31	1.33e-11	Joint mobility (Beighton score);
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.66	-0.48	1.05e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs883565	0.569	rs784511	chr3:39165548	A/G	cg01426195	chr3:39028469	NA	0.65	14.11	0.55	7.13e-38	Handedness;
LGG	cis	rs2455799	0.552	rs1472697	chr3:15750268	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.02	-0.35	8.55e-15	Mean platelet volume;
LGG	cis	rs1620921	0.783	rs1740448	chr6:161230370	T/C	cg01280913	chr6:161186852	NA	-0.34	-7.1	-0.31	4.62e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg27205649	chr11:78285834	NARS2	0.45	7.6	0.33	1.63e-13	Testicular germ cell tumor;
LGG	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.9	-21.14	-0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs6430585	0.583	rs1435577	chr2:136624947	C/G	cg07169764	chr2:136633963	MCM6	1.28	26.26	0.77	9.73e-94	Corneal structure;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg06719900	chr11:109292894	C11orf87	0.45	8.37	0.36	7.11e-16	Schizophrenia;
LGG	cis	rs2798269	1.000	rs11618032	chr13:22134891	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs6840360	0.642	rs7677131	chr4:152353015	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	4.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1408224	0.678	rs1467605	chr13:47211861	A/C	cg24453118	chr13:47229927	LRCH1	-0.3	-6.92	-0.31	1.5e-11	QRS complex (12-leadsum);
LGG	cis	rs6732160	0.845	rs6718690	chr2:73387162	C/T	cg01422370	chr2:73384389	NA	-0.54	-10.63	-0.44	9.21e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	1.000	rs12787330	chr11:47812311	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs10463554	0.963	rs34772	chr5:102450512	C/A	cg23492399	chr5:102201601	PAM	-0.52	-7.7	-0.34	8.49e-14	Parkinson's disease;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg17202724	chr17:61916730	SMARCD2	-0.63	-15.29	-0.58	5.18e-43	Prudent dietary pattern;
LGG	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg26384229	chr12:38710491	ALG10B	0.68	12.42	0.5	8.98e-31	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4481887	0.927	rs6587444	chr1:248438452	C/T	cg01631408	chr1:248437212	OR2T33	0.59	10.36	0.43	9.37e-23	Common traits (Other);
LGG	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg12386194	chr3:101231763	SENP7	0.44	7.74	0.34	6.21e-14	Colorectal cancer;
LGG	trans	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.65	0.54	6.52e-36	Obesity-related traits;
LGG	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg26655873	chr3:72818019	SHQ1	0.4	8.07	0.35	6.26e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2455799	0.573	rs2455829	chr3:15746937	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.83	-0.34	3.41e-14	Mean platelet volume;
LGG	cis	rs929596	0.531	rs2741012	chr2:234508963	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.2	-0.36	2.32e-15	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg19673125	chr6:150240577	RAET1G	0.34	8.18	0.36	2.83e-15	Testicular germ cell tumor;
LGG	trans	rs17685	0.558	rs60787921	chr7:75792844	C/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs12681288	0.644	rs2600494	chr8:1025517	C/T	cg15309053	chr8:964076	NA	0.35	6.95	0.31	1.28e-11	Schizophrenia;
LGG	cis	rs643506	1.000	rs1788955	chr11:111630998	C/G	cg09085632	chr11:111637200	PPP2R1B	0.58	9.39	0.4	2.72e-19	Breast cancer;
LGG	cis	rs7503807	0.515	rs12946217	chr17:78686566	C/A	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg19524238	chr7:2802976	GNA12	0.38	8.79	0.38	3.04e-17	Height;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg20308403	chr7:2120281	MAD1L1	0.33	6.85	0.3	2.38e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg12463550	chr7:65579703	CRCP	0.81	8.74	0.38	4.21e-17	Diabetic kidney disease;
LGG	cis	rs7107174	1.000	rs10899452	chr11:77995143	A/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.02	-0.31	7.9e-12	Testicular germ cell tumor;
LGG	cis	rs7444	0.941	rs4821108	chr22:21959038	G/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.54	-0.33	2.53e-13	Systemic lupus erythematosus;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.53	-8.81	-0.38	2.62e-17	Renal function-related traits (BUN);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05871607	chr1:28241317	RPA2	0.48	8.37	0.36	6.66e-16	Cognitive performance;
LGG	cis	rs7246865	0.859	rs11670553	chr19:17168151	C/T	cg19418318	chr19:17219073	MYO9B	0.28	7.31	0.32	1.21e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1014246	1.000	rs1014244	chr10:118466150	C/T	cg14919929	chr10:118506882	NA	0.55	10.08	0.42	9.51e-22	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg06108461	chr20:60628389	TAF4	-0.64	-11.11	-0.46	1.39e-25	Body mass index;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg12133103	chr8:75946479	CRISPLD1	0.44	6.72	0.3	5.23e-11	Airflow obstruction;
LGG	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg12463550	chr7:65579703	CRCP	0.52	8.71	0.38	5.52e-17	Aortic root size;
LGG	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.01	-0.31	8.37e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg00364696	chr7:1142433	C7orf50	-0.36	-7.11	-0.31	4.54e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.66	-0.44	7.39e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4650994	0.544	rs2811311	chr1:178617337	A/G	cg19399532	chr1:178512495	C1orf220	-0.52	-10.29	-0.43	1.62e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg16359550	chr11:109292809	C11orf87	0.42	8.23	0.36	1.9e-15	Schizophrenia;
LGG	cis	rs12579753	0.719	rs4418885	chr12:82275845	A/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-8.01	-0.35	9.31e-15	Resting heart rate;
LGG	cis	rs7301016	0.802	rs73139054	chr12:62842227	T/C	cg11441379	chr12:63026424	NA	0.68	8.61	0.37	1.14e-16	IgG glycosylation;
LGG	cis	rs4891159	0.790	rs660029	chr18:74149668	A/G	cg24786174	chr18:74118243	ZNF516	0.64	15.47	0.58	8.39e-44	Longevity;
LGG	trans	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg00711542	chr16:29343894	RUNDC2C	0.4	6.74	0.3	4.59e-11	Menopause (age at onset);
LGG	cis	rs7267979	0.966	rs3002698	chr20:25303379	C/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.87e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1371867	0.555	rs2861348	chr8:101285074	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.6	-0.37	1.23e-16	Atrioventricular conduction;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.2e-12	Lung cancer;
LGG	cis	rs4243830	1.000	rs11811007	chr1:6584657	T/C	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	11.32	0.47	2.1e-26	Body mass index;
LGG	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.88	0.45	1.09e-24	Lung cancer in ever smokers;
LGG	cis	rs3096299	0.935	rs3102387	chr16:89432276	A/C	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.29	-0.32	1.31e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs17428076	0.793	rs3770449	chr2:172692048	C/T	cg21435375	chr2:172878103	MAP1D	0.39	8.35	0.36	7.74e-16	Myopia;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg11814155	chr7:99998594	ZCWPW1	0.64	9.9	0.42	4.46e-21	Platelet count;
LGG	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.02	-0.35	8.84e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg03342759	chr3:160939853	NMD3	-0.57	-9.54	-0.41	8.05e-20	Educational attainment (years of education);
LGG	cis	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg24375607	chr4:120327624	NA	0.62	10.4	0.44	6.52e-23	Corneal astigmatism;
LGG	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg02023728	chr11:77925099	USP35	0.46	8.22	0.36	2e-15	Testicular germ cell tumor;
LGG	trans	rs783540	0.521	rs28719490	chr15:83389440	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.47	-7.53	-0.33	2.67e-13	Schizophrenia;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg11062466	chr8:58055876	NA	0.45	7.37	0.32	8.03e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2290159	0.800	rs3773345	chr3:12642945	G/C	cg23032965	chr3:12705835	RAF1	0.67	9.78	0.41	1.21e-20	Cholesterol, total;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg06558623	chr16:89946397	TCF25	1.16	13.7	0.54	4.17e-36	Skin colour saturation;
LGG	cis	rs7833790	0.660	rs1451995	chr8:82746123	G/C	cg17211192	chr8:82754475	SNX16	0.72	12.0	0.49	4.43e-29	Diastolic blood pressure;
LGG	cis	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg03060546	chr3:49711283	APEH	-0.67	-11.34	-0.47	1.82e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9815354	0.812	rs17215589	chr3:41831203	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.05	0.49	2.73e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9486719	1.000	rs2142652	chr6:96868504	A/C	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs12210905	1.000	rs41269245	chr6:27100096	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg26597838	chr10:835615	NA	0.74	10.32	0.43	1.32e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6430585	0.528	rs16832417	chr2:136744678	C/T	cg07169764	chr2:136633963	MCM6	1.23	22.6	0.72	9.25e-77	Corneal structure;
LGG	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.79	0.3	3.52e-11	Educational attainment;
LGG	cis	rs774359	0.830	rs3849943	chr9:27543382	C/T	cg14173147	chr9:27528300	MOBKL2B	-0.43	-8.25	-0.36	1.61e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	9.8	0.41	1.03e-20	Height;
LGG	cis	rs1355223	0.583	rs2941043	chr11:34870994	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.73	-14.24	-0.55	2.11e-38	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10489202	0.909	rs61809580	chr1:168091602	A/C	cg24449463	chr1:168025552	DCAF6	-0.58	-8.17	-0.36	2.94e-15	Schizophrenia;
LGG	trans	rs12517041	0.938	rs7356572	chr5:23267525	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.92	-0.38	1.08e-17	Calcium levels;
LGG	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg22044901	chr15:68126292	NA	-0.4	-7.08	-0.31	5.36e-12	Obesity;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg09754031	chr1:27652017	TMEM222	0.34	6.68	0.3	7.06e-11	Body fat percentage;
LGG	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.53	0.44	2.25e-23	Blood protein levels;
LGG	cis	rs877282	0.898	rs11253344	chr10:765162	C/T	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.02e-11	Uric acid levels;
LGG	cis	rs11190604	1.000	rs6584379	chr10:102224490	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.92	0.45	7.18e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14082963	chr4:89444434	PIGY	0.39	6.99	0.31	9.62e-12	Obesity-related traits;
LGG	cis	rs751728	0.626	rs57150921	chr6:33737518	T/C	cg07519485	chr6:33762594	MLN	-0.31	-6.98	-0.31	1.02e-11	Crohn's disease;
LGG	cis	rs9547996	0.917	rs9548026	chr13:38282470	G/T	cg17979426	chr13:38220150	TRPC4	-0.42	-8.32	-0.36	9.75e-16	Diastolic blood pressure;
LGG	cis	rs9818758	0.505	rs67286839	chr3:49265744	C/T	cg00383909	chr3:49044727	WDR6	1.01	12.56	0.5	2.38e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7129556	0.520	rs4945185	chr11:77318142	G/A	cg12586386	chr11:77299805	AQP11	0.39	6.66	0.3	7.7e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.5	10.22	0.43	3.03e-22	Personality dimensions;
LGG	cis	rs9487094	0.670	rs6911700	chr6:109997294	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.02	0.35	8.7e-15	Height;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg00864171	chr11:67383662	NA	0.54	9.3	0.4	5.38e-19	Mean corpuscular volume;
LGG	cis	rs2273669	0.667	rs111523655	chr6:109301664	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.82e-16	Prostate cancer;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.61	0.44	1.06e-23	Neuroticism;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	16.1	0.6	1.2e-46	Personality dimensions;
LGG	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs2451279	0.902	rs2485362	chr6:159503086	A/G	cg01046905	chr6:159515345	NA	0.42	8.13	0.35	3.89e-15	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs975739	0.872	rs1146923	chr13:78361945	C/T	cg07847733	chr13:78271382	SLAIN1	0.38	6.88	0.3	1.94e-11	Hair color;
LGG	cis	rs701145	0.585	rs1727920	chr3:153788588	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.97	0.38	7.3e-18	Coronary artery disease;
LGG	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg25986240	chr4:9926439	SLC2A9	-0.44	-9.42	-0.4	2.19e-19	Bone mineral density;
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.35	-8.37	-0.36	6.82e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg08645402	chr16:4508243	NA	0.5	9.62	0.41	4.2e-20	Schizophrenia;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg11245990	chr11:68621969	NA	0.45	9.16	0.39	1.64e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs644799	0.601	rs662168	chr11:95586982	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	12.93	0.52	7.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg25457927	chr22:38595422	NA	-0.4	-9.38	-0.4	2.87e-19	Breast cancer;
LGG	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg10840412	chr1:235813424	GNG4	0.7	9.17	0.39	1.56e-18	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.68e-12	Lung cancer;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg11494091	chr17:61959527	GH2	1.0	24.69	0.75	1.74e-86	Prudent dietary pattern;
LGG	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg25986240	chr4:9926439	SLC2A9	-0.37	-7.56	-0.33	2.18e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg02725872	chr8:58115012	NA	-0.76	-11.25	-0.46	4.03e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs72717009	0.825	rs12746613	chr1:161467042	A/G	cg12643083	chr1:161476548	FCGR2A	0.66	9.95	0.42	2.83e-21	Rheumatoid arthritis;
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.32	0.36	9.61e-16	Aortic root size;
LGG	cis	rs977987	0.771	rs8048527	chr16:75422054	C/A	cg03315344	chr16:75512273	CHST6	0.49	9.91	0.42	4e-21	Dupuytren's disease;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg25072359	chr17:41440525	NA	0.52	9.9	0.42	4.45e-21	Menopause (age at onset);
LGG	cis	rs8053891	0.813	rs16973520	chr16:71996291	T/G	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.77	-0.3	3.98e-11	Coronary artery disease;
LGG	cis	rs2013441	0.866	rs12941200	chr17:20011561	C/A	cg09818912	chr17:20140352	CYTSB	-0.32	-7.01	-0.31	8.35e-12	Obesity-related traits;
LGG	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg00405596	chr8:11794950	NA	-0.4	-6.65	-0.3	8.27e-11	Triglycerides;
LGG	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg02549819	chr16:58548995	SETD6	1.45	13.81	0.54	1.37e-36	Schizophrenia;
LGG	cis	rs17014483	0.749	rs2924348	chr4:89632910	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.8	0.3	3.31e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1035144	0.713	rs2284730	chr14:81464901	T/C	cg06600135	chr14:81408086	NA	0.38	7.22	0.32	2.15e-12	Male sexual orientation;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06916706	chr16:4465613	CORO7	-0.83	-14.16	-0.55	4.28e-38	Schizophrenia;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg27482856	chr7:99214447	ZNF498	0.4	6.86	0.3	2.22e-11	Body mass index;
LGG	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg02297831	chr4:17616191	MED28	0.5	9.41	0.4	2.42e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg03213289	chr20:61660250	NA	0.65	14.0	0.55	2.14e-37	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1580019	0.520	rs6945238	chr7:32646096	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.45	-6.92	-0.31	1.51e-11	Cognitive ability;
LGG	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.13	0.43	6.21e-22	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-6.94	-0.31	1.34e-11	Schizophrenia;
LGG	cis	rs2665103	0.589	rs2134046	chr15:82524544	T/C	cg00614314	chr15:82944287	LOC80154	0.44	7.24	0.32	1.93e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg14675211	chr2:100938903	LONRF2	0.67	11.96	0.49	6.55e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2770102	0.597	rs2181359	chr6:21818196	C/T	cg17050756	chr6:21771976	FLJ22536	-0.35	-7.68	-0.34	9.76e-14	Body mass index;
LGG	cis	rs944722	0.875	rs4796041	chr17:26097541	A/C	cg07704981	chr17:26127537	NOS2	-0.52	-9.12	-0.39	2.35e-18	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs8177253	0.665	rs7646118	chr3:133450039	C/T	cg16414030	chr3:133502952	NA	-0.49	-7.98	-0.35	1.18e-14	Iron status biomarkers;
LGG	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.72	15.29	0.58	5.24e-43	Multiple sclerosis;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.67	-12.4	-0.5	1.04e-30	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg04374321	chr14:90722782	PSMC1	0.5	8.22	0.36	2.03e-15	Longevity;
LGG	cis	rs9309473	0.950	rs6756885	chr2:73805172	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.63	-0.33	1.38e-13	Metabolite levels;
LGG	cis	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg23422044	chr7:1970798	MAD1L1	-0.62	-10.69	-0.44	5.59e-24	Bipolar disorder;
LGG	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg00209037	chr22:46443395	NA	-0.28	-7.83	-0.34	3.36e-14	Dupuytren's disease;
LGG	trans	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7503807	0.935	rs7215534	chr17:78612119	C/T	cg06872548	chr17:78716983	RPTOR	0.45	10.87	0.45	1.12e-24	Obesity;
LGG	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-10.97	-0.45	4.96e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12431410	0.550	rs12894486	chr14:60223065	T/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.32	-0.32	1.12e-12	Schizophrenia;
LGG	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	trans	rs12579753	1.000	rs17748942	chr12:82170478	G/A	cg07923666	chr12:49932857	KCNH3	-0.5	-7.48	-0.33	3.84e-13	Resting heart rate;
LGG	cis	rs7582720	1.000	rs72934518	chr2:203937908	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.4	0.4	2.58e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs35164067	1.000	rs11085730	chr19:10497976	G/A	cg21868191	chr19:10515988	NA	-0.47	-6.96	-0.31	1.16e-11	Inflammatory bowel disease;
LGG	cis	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.12	0.39	2.26e-18	Alzheimer's disease;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-12.31	-0.5	2.46e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg11161011	chr14:65562177	MAX	-0.65	-12.56	-0.5	2.47e-31	Obesity-related traits;
LGG	cis	rs754423	0.582	rs67640320	chr14:52511596	C/G	cg05884192	chr14:52515736	NID2	0.3	6.72	0.3	5.43e-11	Craniofacial microsomia;
LGG	cis	rs9359856	0.564	rs17735590	chr6:90330268	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.72	-9.24	-0.39	8.78e-19	Bipolar disorder;
LGG	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg16586182	chr3:47516702	SCAP	0.74	13.43	0.53	5.65e-35	Colorectal cancer;
LGG	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.34	-0.43	1.1e-22	Bladder cancer;
LGG	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06481639	chr22:41940642	POLR3H	0.54	7.57	0.33	2.05e-13	Vitiligo;
LGG	cis	rs6787391	0.545	rs9876432	chr3:4761185	G/A	cg11584376	chr3:4789075	ITPR1	-0.4	-8.59	-0.37	1.34e-16	Breast cancer;
LGG	cis	rs4988958	0.565	rs6732138	chr2:103009662	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	cis	rs9649465	1.000	rs3958047	chr7:123327936	G/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.62	0.51	1.32e-31	Motion sickness;
LGG	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.83e-11	Aortic root size;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg09327250	chr3:195381832	NA	-0.44	-7.55	-0.33	2.31e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs12586317	0.553	rs78124218	chr14:35570606	G/A	cg16230307	chr14:35515116	FAM177A1	0.88	12.97	0.52	5.04e-33	Psoriasis;
LGG	cis	rs7508	0.694	rs2073573	chr8:17921673	G/T	cg18067069	chr8:17937731	ASAH1	-0.37	-8.6	-0.37	1.26e-16	Atrial fibrillation;
LGG	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg25919922	chr13:100150906	NA	0.8	11.37	0.47	1.36e-26	Obesity-related traits;
LGG	trans	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.05	-0.31	6.71e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9486715	0.867	rs4240553	chr6:96965324	T/C	cg18709589	chr6:96969512	KIAA0776	0.42	8.21	0.36	2.19e-15	Headache;
LGG	cis	rs9359856	0.510	rs74437492	chr6:90338728	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-12.61	-0.51	1.54e-31	Bipolar disorder;
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.48	-0.44	3.35e-23	Bipolar disorder;
LGG	cis	rs4689388	0.926	rs6446480	chr4:6295565	C/T	cg14416269	chr4:6271139	WFS1	0.52	9.35	0.4	3.77e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg07234876	chr8:600039	NA	1.17	11.5	0.47	4.26e-27	IgG glycosylation;
LGG	trans	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg20587970	chr11:113659929	NA	-1.27	-23.19	-0.73	1.65e-79	Hip circumference adjusted for BMI;
LGG	cis	rs62238980	0.614	rs117441849	chr22:32489297	T/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs151997	0.962	rs27476	chr5:50178160	A/T	cg06027927	chr5:50259733	NA	-0.68	-11.09	-0.46	1.62e-25	Callous-unemotional behaviour;
LGG	cis	rs73416724	1.000	rs41281798	chr6:43325787	C/A	cg26312998	chr6:43337775	ZNF318	0.6	8.45	0.37	3.75e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg16507663	chr6:150244633	RAET1G	0.45	8.26	0.36	1.49e-15	Lung cancer;
LGG	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg12081754	chr8:22256438	SLC39A14	0.72	13.77	0.54	2.19e-36	Verbal declarative memory;
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg04064611	chr7:72298987	SBDSP;TYW1B	-0.41	-6.69	-0.3	6.34e-11	Breast cancer;
LGG	cis	rs17253792	0.822	rs17253716	chr14:56153661	G/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs561341	0.609	rs2051810	chr17:30195841	C/T	cg13647721	chr17:30228624	UTP6	-0.73	-9.36	-0.4	3.52e-19	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg23758822	chr17:41437982	NA	0.9	15.9	0.59	1e-45	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg13206674	chr6:150067644	NUP43	0.66	14.66	0.56	3.08e-40	Lung cancer;
LGG	cis	rs6599388	0.803	rs11248057	chr4:906131	C/G	cg08222618	chr4:941054	TMEM175	-0.46	-8.5	-0.37	2.59e-16	Parkinson's disease;
LGG	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg01043669	chr3:72786069	NA	0.4	6.66	0.3	7.77e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10979	0.597	rs9496685	chr6:143908690	G/A	cg25407410	chr6:143891975	LOC285740	-0.56	-8.23	-0.36	1.97e-15	Hypospadias;
LGG	cis	rs1577917	1.000	rs34852683	chr6:86702330	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-12.8	-0.51	2.39e-32	Response to antipsychotic treatment;
LGG	cis	rs367615	0.506	rs1428932	chr5:108792479	A/G	cg17395555	chr5:108820864	NA	-0.8	-14.22	-0.55	2.46e-38	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs8079658	1.000	rs72831444	chr17:63815666	A/G	cg18091269	chr17:63822838	CCDC46	-0.4	-6.76	-0.3	4.16e-11	Post bronchodilator FEV1;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg21782813	chr7:2030301	MAD1L1	0.51	12.24	0.49	4.86e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.44	0.33	4.9e-13	Renal function-related traits (BUN);
LGG	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs4696584	0.877	rs12643014	chr4:155381726	G/A	cg13738195	chr4:155413469	DCHS2	-0.39	-7.29	-0.32	1.31e-12	Folding of antihelix;
LGG	cis	rs7659604	0.502	rs10013916	chr4:122702179	T/G	cg19748678	chr4:122722346	EXOSC9	-0.55	-10.04	-0.42	1.42e-21	Type 2 diabetes;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg27471124	chr11:109292789	C11orf87	0.5	9.81	0.41	9.42e-21	Schizophrenia;
LGG	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg23649088	chr2:200775458	C2orf69	0.8	16.31	0.6	1.43e-47	Osteoporosis;
LGG	cis	rs7666738	0.830	rs7659006	chr4:98934529	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4700695	0.920	rs251303	chr5:65248753	A/C	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.57	-0.33	2.1e-13	Neuroticism;
LGG	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.94	-0.42	3.11e-21	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15806518	chr9:127177817	PSMB7	0.46	7.68	0.34	9.26e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs13102973	0.899	rs13127569	chr4:135900762	C/A	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs12348691	0.503	rs3021523	chr9:100616583	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs929354	0.713	rs3802130	chr7:156965237	A/G	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.4	0.4	2.51e-19	Diabetic retinopathy;
LGG	cis	rs2066819	1.000	rs11171806	chr12:56733531	A/G	cg26714650	chr12:56694279	CS	1.55	15.69	0.59	8.24e-45	Psoriasis vulgaris;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg07414643	chr4:187882934	NA	0.56	11.8	0.48	2.86e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.91	-0.35	1.86e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs4144743	1.000	rs7218524	chr17:45326565	A/G	cg18085866	chr17:45331354	ITGB3	-0.81	-9.69	-0.41	2.49e-20	Body mass index;
LGG	cis	rs3735485	0.678	rs28742146	chr7:45091184	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs3796352	1.000	rs34313969	chr3:52995166	A/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2933343	0.729	rs789230	chr3:128602558	G/A	cg25356066	chr3:128598488	ACAD9	0.48	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.49	-7.28	-0.32	1.48e-12	Total cholesterol levels;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg26513180	chr16:89883248	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg00684032	chr4:1343700	KIAA1530	0.68	14.34	0.55	7.73e-39	Obesity-related traits;
LGG	cis	rs2797160	1.000	rs6933471	chr6:126017029	T/G	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs881375	0.967	rs10739580	chr9:123695282	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.73	0.48	5.18e-28	Rheumatoid arthritis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20707008	chr6:160210612	MRPL18;TCP1	0.4	7.17	0.32	3.06e-12	Bipolar disorder;
LGG	cis	rs981844	1.000	rs10517579	chr4:154666321	T/C	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.22e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	11.6	0.47	1.79e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12478296	0.591	rs4973646	chr2:243001373	C/T	cg06360820	chr2:242988706	NA	0.53	7.34	0.32	9.42e-13	Obesity-related traits;
LGG	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.06	0.39	3.65e-18	Schizophrenia;
LGG	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg24375607	chr4:120327624	NA	-0.52	-8.94	-0.38	9.03e-18	Corneal astigmatism;
LGG	trans	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.51	0.4	1.03e-19	Mean corpuscular volume;
LGG	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg22987457	chr7:157211561	NA	0.38	7.01	0.31	8.65e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg17211192	chr8:82754475	SNX16	-0.78	-12.35	-0.5	1.79e-30	Diastolic blood pressure;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.66	0.41	3e-20	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg12708336	chr17:41446283	NA	-0.33	-8.08	-0.35	5.83e-15	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs72945132	0.882	rs67927691	chr11:70128786	C/A	cg00319359	chr11:70116639	PPFIA1	0.74	8.17	0.35	3.06e-15	Coronary artery disease;
LGG	cis	rs4975616	0.869	rs31484	chr5:1337906	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.21	-0.65	2.86e-56	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00270311	chr16:30366760	CD2BP2	0.4	6.82	0.3	2.86e-11	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs10791097	0.967	rs10894268	chr11:130717153	C/T	cg12179176	chr11:130786555	SNX19	0.72	13.34	0.53	1.3600000000000001e-34	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6542826	0.510	rs7608829	chr2:110043456	G/A	cg20706049	chr2:110026630	SH3RF3	0.34	7.89	0.34	2.22e-14	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.93	0.35	1.69e-14	Cannabis dependence symptom count;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg17178900	chr1:205818956	PM20D1	0.58	13.04	0.52	2.41e-33	Menarche (age at onset);
LGG	cis	rs6740322	0.748	rs6544634	chr2:43471528	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.72	-11.39	-0.47	1.16e-26	Coronary artery disease;
LGG	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.96e-18	Cognitive test performance;
LGG	cis	rs4845570	0.834	rs7007	chr1:151735576	T/C	cg11690979	chr1:151694320	C1orf230	-0.52	-6.94	-0.31	1.35e-11	Coronary artery disease;
LGG	cis	rs1805008	0.535	rs7196459	chr16:90141477	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.87	-7.93	-0.35	1.64e-14	Skin colour saturation;
LGG	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.14	0.39	1.92e-18	Diabetic retinopathy;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg06112835	chr11:68658793	MRPL21	-0.56	-9.4	-0.4	2.52e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg21775007	chr8:11205619	TDH	0.79	13.6	0.53	1.07e-35	Retinal vascular caliber;
LGG	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03264133	chr6:25882463	NA	-0.56	-10.41	-0.44	6.24e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg26838691	chr2:24397539	C2orf84	0.47	6.7	0.3	6.08e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg09699651	chr6:150184138	LRP11	0.46	7.9	0.34	2.03e-14	Lung cancer;
LGG	cis	rs1322639	0.614	rs6925201	chr6:169563357	C/T	cg04662567	chr6:169592167	NA	0.79	11.79	0.48	3.03e-28	Pulse pressure;
LGG	cis	rs7106204	0.514	rs7118022	chr11:24253352	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	trans	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg25214090	chr10:38739885	LOC399744	0.61	10.32	0.43	1.31e-22	Corneal astigmatism;
LGG	cis	rs9354308	0.764	rs9363485	chr6:66614700	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.66	-0.3	7.65e-11	Metabolite levels;
LGG	cis	rs17221829	0.733	rs11018688	chr11:89366824	G/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.09	-0.39	2.82e-18	Anxiety in major depressive disorder;
LGG	cis	rs4731207	0.536	rs34630567	chr7:124630663	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7607369	0.566	rs55658481	chr2:219284215	G/A	cg10223061	chr2:219282414	VIL1	0.4	8.74	0.38	4.46e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg05393297	chr12:53359155	NA	-0.63	-15.31	-0.58	4.2e-43	Cancer (pleiotropy);
LGG	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg10518543	chr12:38710700	ALG10B	0.42	6.77	0.3	4.02e-11	Morning vs. evening chronotype;
LGG	cis	rs9341808	0.618	rs6916507	chr6:80862265	T/C	cg08355045	chr6:80787529	NA	0.41	7.97	0.35	1.26e-14	Sitting height ratio;
LGG	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg23221052	chr5:179740743	GFPT2	-0.59	-9.97	-0.42	2.39e-21	Height;
LGG	cis	rs12477438	0.765	rs1115757	chr2:99660146	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs9916302	0.706	rs4794808	chr17:37531916	C/T	cg00129232	chr17:37814104	STARD3	0.57	8.47	0.37	3.32e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10896676	chr4:187517794	FAT1	0.37	6.71	0.3	5.86e-11	Electrocardiographic conduction measures;
LGG	cis	rs6918586	0.658	rs198840	chr6:26112164	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.71	-0.41	2.11e-20	Schizophrenia;
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg04287289	chr16:89883240	FANCA	0.81	16.81	0.62	7.76e-50	Vitiligo;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.22e-16	Personality dimensions;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.72	-0.41	1.84e-20	Lung cancer;
LGG	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.68	-0.34	9.5e-14	HDL cholesterol;
LGG	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.2	-0.36	2.35e-15	Obesity-related traits;
LGG	cis	rs7617773	0.746	rs6796343	chr3:48282021	C/A	cg11946769	chr3:48343235	NME6	0.69	11.36	0.47	1.47e-26	Coronary artery disease;
LGG	cis	rs975722	0.632	rs6958655	chr7:117093302	G/A	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.27	-0.4	7.29e-19	Coronary artery disease;
LGG	cis	rs9937943	0.615	rs12925346	chr16:74492495	G/C	cg01733217	chr16:74700730	RFWD3	0.67	9.11	0.39	2.5e-18	Neutrophil percentage of white cells;
LGG	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-15.35	-0.58	2.73e-43	Urinary metabolites;
LGG	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.11e-11	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.8	0.38	2.72e-17	Schizophrenia;
LGG	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg00409905	chr10:38381863	ZNF37A	0.41	7.8	0.34	4.02e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs5762813	0.561	rs59224170	chr22:29293162	G/C	cg15103426	chr22:29168792	CCDC117	0.64	6.7	0.3	6.21e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg13877915	chr19:58951672	ZNF132	0.57	8.16	0.35	3.24e-15	Mean platelet volume;
LGG	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg15556689	chr8:8085844	FLJ10661	0.39	6.83	0.3	2.64e-11	Mood instability;
LGG	cis	rs3820881	0.516	rs62279292	chr2:201246400	G/A	cg23516759	chr2:201153734	NA	-0.69	-9.6	-0.41	5.02e-20	Chickenpox;
LGG	cis	rs16976116	0.851	rs28784096	chr15:55503312	C/T	cg11288833	chr15:55489084	RSL24D1	0.56	7.51	0.33	3.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9462027	0.628	rs2744957	chr6:34618516	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.73	-0.45	3.8e-24	Systemic lupus erythematosus;
LGG	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg19338460	chr6:170058176	WDR27	-0.58	-8.07	-0.35	6.27e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.75e-14	Iron status biomarkers;
LGG	cis	rs4474465	0.915	rs10899504	chr11:78157983	C/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.57	-0.37	1.53e-16	Alzheimer's disease (survival time);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07684353	chr15:59664799	MYO1E	0.5	7.42	0.33	5.46e-13	Gut microbiome composition (summer);
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg06697600	chr4:7070879	GRPEL1	-0.55	-9.69	-0.41	2.37e-20	Monocyte percentage of white cells;
LGG	cis	rs4538187	0.906	rs17619753	chr2:63943616	G/A	cg14150252	chr2:64069583	UGP2	-0.47	-9.38	-0.4	3.07e-19	Systolic blood pressure;
LGG	cis	rs80282103	0.764	rs10047383	chr10:1103095	A/G	cg08668510	chr10:1095578	IDI1	0.75	7.67	0.34	9.93e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.36	-0.4	3.49e-19	Height;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg27471124	chr11:109292789	C11orf87	0.46	8.61	0.37	1.16e-16	Schizophrenia;
LGG	cis	rs9916302	0.904	rs602282	chr17:37433021	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.61	-0.47	1.54e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs11608355	0.545	rs2302707	chr12:109893797	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.41e-13	HDL cholesterol;
LGG	cis	rs8060686	0.641	rs75909028	chr16:68089578	A/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.6	-0.33	1.67e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg00166722	chr3:10149974	C3orf24	-0.55	-7.98	-0.35	1.14e-14	Alzheimer's disease;
LGG	cis	rs6426558	0.537	rs689094	chr1:227308909	G/A	cg10327440	chr1:227177885	CDC42BPA	0.61	10.26	0.43	2.07e-22	Neutrophil percentage of white cells;
LGG	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg20476274	chr7:133979776	SLC35B4	0.76	14.94	0.57	1.78e-41	Mean platelet volume;
LGG	cis	rs258892	0.895	rs11960081	chr5:72064490	C/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs711245	0.899	rs848605	chr2:36773260	G/A	cg09467607	chr2:36825704	FEZ2	0.46	9.0	0.39	5.72e-18	Height;
LGG	cis	rs12137294	0.866	rs1172156	chr1:205220087	C/T	cg00889227	chr1:205173544	DSTYK	-0.27	-6.78	-0.3	3.74e-11	Red cell distribution width;
LGG	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.71	-0.38	5.48e-17	Blood metabolite levels;
LGG	cis	rs17539620	0.624	rs62432740	chr6:154836054	C/T	cg17771515	chr6:154831774	CNKSR3	0.61	7.54	0.33	2.44e-13	Lipoprotein (a) levels;
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg02353165	chr6:42928485	GNMT	0.52	16.05	0.6	2.11e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7241530	0.610	rs7243831	chr18:75906420	T/C	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg09873164	chr1:152488093	CRCT1	0.65	16.04	0.6	2.32e-46	Hair morphology;
LGG	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.64	-0.33	1.23e-13	Colorectal cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12646754	chr1:2574751	NA	-0.47	-6.79	-0.3	3.39e-11	Systemic lupus erythematosus;
LGG	cis	rs9309473	1.000	rs6755217	chr2:73641285	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-8.0	-0.35	9.84e-15	Metabolite levels;
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg07005078	chr4:17578674	LAP3	0.38	7.06	0.31	6.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4727027	1.000	rs4727027	chr7:148869277	C/T	cg23583168	chr7:148888333	NA	-0.88	-17.17	-0.62	1.82e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg06521331	chr12:34319734	NA	-0.5	-8.4	-0.36	5.46e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.75	7.55	0.33	2.34e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6456156	0.586	rs7742305	chr6:167485723	C/T	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	cis	rs2250402	0.510	rs2898984	chr15:40324075	G/C	cg20255370	chr15:40268687	EIF2AK4	-0.82	-8.91	-0.38	1.18e-17	Corneal curvature;
LGG	cis	rs919433	0.713	rs6714697	chr2:198484486	C/T	cg00792783	chr2:198669748	PLCL1	0.51	7.99	0.35	1.11e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9517320	0.934	rs9517319	chr13:99125956	T/G	cg07423050	chr13:99094983	FARP1	0.39	7.84	0.34	3.14e-14	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07845895	chr21:34776100	IFNGR2	0.46	6.85	0.3	2.36e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.93	-0.42	3.46e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs208515	0.525	rs10944871	chr6:66690306	A/G	cg07460842	chr6:66804631	NA	0.95	17.4	0.63	1.6e-52	Exhaled nitric oxide levels;
LGG	cis	rs7760949	0.963	rs7453814	chr6:13918291	C/G	cg27413430	chr6:13925136	RNF182	0.44	6.88	0.3	1.94e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.67	-0.48	9.24e-28	Type 2 diabetes;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.11e-13	Tonsillectomy;
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg26578617	chr4:90757533	SNCA	-0.44	-8.68	-0.37	6.85e-17	Dementia with Lewy bodies;
LGG	cis	rs12618769	0.543	rs72819971	chr2:99034846	T/G	cg18455616	chr2:99124870	INPP4A	0.3	8.79	0.38	2.93e-17	Bipolar disorder;
LGG	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg00071950	chr4:10020882	SLC2A9	0.44	9.44	0.4	1.76e-19	Bone mineral density;
LGG	trans	rs8073060	0.586	rs7214742	chr17:33981969	C/A	cg19694781	chr19:47549865	TMEM160	-1.16	-18.0	-0.64	2.54e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.39e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8114671	0.901	rs6119581	chr20:33773689	T/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.22	0.32	2.09e-12	Height;
LGG	trans	rs35110281	0.667	rs4819293	chr21:45125863	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.02	0.39	5.12e-18	Mean corpuscular volume;
LGG	cis	rs67133203	0.904	rs35262273	chr12:51334788	C/T	cg14688905	chr12:51403056	SLC11A2	0.73	10.78	0.45	2.45e-24	Urinary tract infection frequency;
LGG	cis	rs11229555	0.645	rs11229462	chr11:58209931	A/T	cg15696309	chr11:58395628	NA	-0.94	-15.29	-0.58	5.32e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs908922	0.676	rs4845443	chr1:152507156	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.89	-0.57	3.04e-41	Hair morphology;
LGG	cis	rs2247341	0.965	rs11248074	chr4:1743754	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.8	-0.45	2.15e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg17294928	chr15:75287854	SCAMP5	0.65	12.12	0.49	1.51e-29	Breast cancer;
LGG	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	7.52	0.33	2.88e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs36051895	0.664	rs7851455	chr9:5100501	G/C	cg02405213	chr9:5042618	JAK2	-0.83	-16.16	-0.6	6.97e-47	Pediatric autoimmune diseases;
LGG	cis	rs7166081	1.000	rs12901312	chr15:67591972	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.3	-6.67	-0.3	7.2e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg09818912	chr17:20140352	CYTSB	0.33	7.65	0.33	1.2e-13	Schizophrenia;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg26384229	chr12:38710491	ALG10B	0.98	23.13	0.73	3.17e-79	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7666738	0.830	rs6830124	chr4:99054872	C/T	cg05340658	chr4:99064831	C4orf37	-0.5	-8.39	-0.36	5.76e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1784581	0.802	rs9458430	chr6:162426517	G/T	cg17173639	chr6:162384350	PARK2	-0.74	-16.34	-0.6	9.82e-48	Itch intensity from mosquito bite;
LGG	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg09462578	chr12:12878428	APOLD1	-1.03	-20.75	-0.69	4.2e-68	Lymphocyte counts;
LGG	cis	rs36071027	0.577	rs6862399	chr5:158441675	G/T	cg00594129	chr5:158524270	EBF1	0.46	8.29	0.36	1.2e-15	Carotid intima media thickness;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg03175030	chr11:2018143	H19;MIR675	-0.55	-10.07	-0.42	1.04e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs13217239	0.646	rs10456352	chr6:26990358	A/T	cg12292205	chr6:26970375	C6orf41	0.55	10.83	0.45	1.69e-24	Schizophrenia;
LGG	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg08000102	chr2:233561755	GIGYF2	0.57	9.18	0.39	1.42e-18	Coronary artery disease;
LGG	cis	rs7666738	0.753	rs9991512	chr4:99007205	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg05484376	chr2:27715224	FNDC4	0.41	8.74	0.38	4.34e-17	Total body bone mineral density;
LGG	cis	rs9393777	0.623	rs9358946	chr6:26478927	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs8064024	0.650	rs12926178	chr16:4905915	C/T	cg08329684	chr16:4932620	PPL	-0.51	-11.46	-0.47	6.14e-27	Cancer;
LGG	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg14101638	chr12:121416612	HNF1A	0.39	7.92	0.35	1.73e-14	N-glycan levels;
LGG	cis	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg19901468	chr14:105411992	AHNAK2	0.88	19.19	0.67	8.02e-61	Rheumatoid arthritis;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg27471124	chr11:109292789	C11orf87	0.5	9.81	0.41	9.42e-21	Schizophrenia;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	18.62	0.65	3.54e-58	Platelet count;
LGG	cis	rs6028335	0.674	rs8120715	chr20:37598781	G/A	cg16355469	chr20:37678765	NA	0.59	7.86	0.34	2.66e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs77633900	0.614	rs279997	chr15:76949262	T/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.95	-0.42	2.91e-21	Non-glioblastoma glioma;Glioma;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg01585723	chr16:33734837	NA	0.45	7.9	0.34	2.06e-14	Menopause (age at onset);
LGG	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg27539214	chr16:67997921	SLC12A4	0.49	7.46	0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6835098	1.000	rs6814857	chr4:174082805	T/A	cg08422745	chr4:174089978	GALNT7	-0.84	-14.67	-0.56	2.61e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg24110177	chr3:50126178	RBM5	0.63	11.43	0.47	8.03e-27	Body mass index;
LGG	cis	rs7172689	1.000	rs67117127	chr15:81545599	C/G	cg11808699	chr15:81528661	IL16	-0.51	-10.31	-0.43	1.45e-22	Inattentive symptoms;
LGG	cis	rs16976116	0.901	rs28508034	chr15:55499010	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs6811802	1	rs6811802	chr4:78932838	G/C	cg07207937	chr4:78783799	MRPL1	-1.05	-12.75	-0.51	4.06e-32	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.26	0.52	2.91e-34	Colorectal cancer;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.34	-0.32	9.99e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg25358565	chr5:93447407	FAM172A	-0.84	-11.75	-0.48	4.51e-28	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19787033	chr11:77850962	ALG8	0.47	7.25	0.32	1.78e-12	Gut microbiome composition (summer);
LGG	cis	rs929596	0.564	rs2602362	chr2:234516548	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-8.92	-0.38	1.1e-17	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg04287289	chr16:89883240	FANCA	0.56	10.57	0.44	1.51e-23	Vitiligo;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg26155939	chr18:44337853	ST8SIA5	0.37	6.75	0.3	4.56e-11	Personality dimensions;
LGG	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg22980697	chr10:16874865	CUBN	0.36	7.12	0.31	4.03e-12	Platelet distribution width;
LGG	cis	rs6694672	1.000	rs9427660	chr1:196946420	T/A	cg13682187	chr1:196946512	CFHR5	-0.5	-6.79	-0.3	3.52e-11	Asthma;
LGG	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.88	-0.42	5.23e-21	Aortic root size;
LGG	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.83	0.34	3.43e-14	Birth weight;
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg11494091	chr17:61959527	GH2	-0.51	-8.14	-0.35	3.71e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg18681998	chr4:17616180	MED28	0.84	18.67	0.66	2.16e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.93e-13	Retinal vascular caliber;
LGG	cis	rs4900538	0.855	rs1190537	chr14:102887816	C/T	cg18135206	chr14:102964638	TECPR2	-0.67	-11.88	-0.48	1.32e-28	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs35176054	0.818	rs11596328	chr10:105493177	G/T	cg00730670	chr10:105510713	SH3PXD2A	-0.5	-6.85	-0.3	2.33e-11	Atrial fibrillation;
LGG	cis	rs920590	0.524	rs1388948	chr8:19642536	G/A	cg03894339	chr8:19674705	INTS10	0.42	6.98	0.31	1.02e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1030877	1.000	rs2254301	chr2:105880734	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.74	14.82	0.57	5.79e-41	Obesity-related traits;
LGG	cis	rs68170813	0.559	rs12537733	chr7:106965447	A/T	cg02696742	chr7:106810147	HBP1	-0.71	-10.3	-0.43	1.54e-22	Coronary artery disease;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg20887711	chr4:1340912	KIAA1530	0.39	6.7	0.3	6.07e-11	Obesity-related traits;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg27476859	chr7:2772710	GNA12	0.4	6.9	0.31	1.71e-11	Height;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg22907277	chr7:1156413	C7orf50	0.81	11.25	0.46	3.97e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11826116	chr22:39916314	ATF4	-0.41	-6.69	-0.3	6.32e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg27411982	chr8:10470053	RP1L1	0.41	6.72	0.3	5.4e-11	Neuroticism;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg27490568	chr2:178487706	NA	0.4	8.12	0.35	4.28e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg08621203	chr6:150244597	RAET1G	0.53	9.83	0.42	8.06e-21	Lung cancer;
LGG	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg06112835	chr11:68658793	MRPL21	0.6	9.93	0.42	3.51e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9326248	0.861	rs4938352	chr11:117027481	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.78	0.34	4.88e-14	Blood protein levels;
LGG	cis	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	13.04	0.52	2.52e-33	Total body bone mineral density;
LGG	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.31	0.4	5.24e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg19901956	chr11:77921274	USP35	-0.41	-6.66	-0.3	7.95e-11	Testicular germ cell tumor;
LGG	cis	rs7474896	0.559	rs1779075	chr10:38167530	C/G	cg25427524	chr10:38739819	LOC399744	0.5	7.35	0.32	9.1e-13	Obesity (extreme);
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.25	-0.36	1.68e-15	Total body bone mineral density;
LGG	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.05	0.35	7.17e-15	Iron status biomarkers;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.05e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	7.11	0.31	4.32e-12	Longevity;
LGG	cis	rs9302635	0.550	rs35959677	chr16:72200801	G/T	cg01557791	chr16:72042693	DHODH	-0.57	-8.81	-0.38	2.46e-17	Blood protein levels;
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.63e-19	Life satisfaction;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg26354017	chr1:205819088	PM20D1	-0.54	-8.71	-0.38	5.29e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.36e-33	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs2985684	0.846	rs11157693	chr14:50048426	T/C	cg02151108	chr14:50098012	C14orf104	-0.42	-8.91	-0.38	1.14e-17	Carotid intima media thickness;
LGG	cis	rs6088619	0.501	rs6087571	chr20:32912091	A/G	cg24642439	chr20:33292090	TP53INP2	0.77	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg23594656	chr7:65796392	TPST1	0.4	8.8	0.38	2.81e-17	Aortic root size;
LGG	cis	rs703842	1.000	rs10877015	chr12:58167788	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.52	8.12	0.35	4.15e-15	Multiple sclerosis;
LGG	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg13802316	chr11:70253460	CTTN	-0.6	-7.63	-0.33	1.31e-13	Coronary artery disease;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg12016809	chr21:47604291	C21orf56	0.49	8.22	0.36	2e-15	Testicular germ cell tumor;
LGG	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg01448562	chr3:133502909	NA	-0.73	-13.46	-0.53	4.54e-35	Iron status biomarkers;
LGG	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg26043149	chr18:55253948	FECH	0.94	16.08	0.6	1.5e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg22907277	chr7:1156413	C7orf50	0.84	15.11	0.57	3.35e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6977660	0.607	rs12113916	chr7:19781424	G/T	cg05791153	chr7:19748676	TWISTNB	0.76	10.18	0.43	4.32e-22	Thyroid stimulating hormone;
LGG	cis	rs9715521	0.900	rs6819160	chr4:59834879	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.43	-0.33	5.28e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs9814567	1.000	rs1498718	chr3:134205920	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.37	-0.53	1.06e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7827545	0.545	rs4909477	chr8:135562976	A/G	cg17885191	chr8:135476712	NA	0.62	9.25	0.4	8.06e-19	Hypertension (SNP x SNP interaction);
LGG	cis	rs8060686	0.641	rs7192187	chr16:68132109	T/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.66e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12143943	0.966	rs12038102	chr1:204551407	G/A	cg20240347	chr1:204465584	NA	-0.33	-7.12	-0.31	4.01e-12	Cognitive performance;
LGG	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg24692254	chr21:30365293	RNF160	0.56	8.37	0.36	6.88e-16	Cognitive test performance;
LGG	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg01631408	chr1:248437212	OR2T33	-0.37	-7.04	-0.31	7.18e-12	Common traits (Other);
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg26666090	chr16:58549219	SETD6	1.15	10.14	0.43	5.97e-22	Schizophrenia;
LGG	cis	rs7937840	0.562	rs1047739	chr11:61919693	C/T	cg01969543	chr11:61895209	INCENP	-0.42	-7.58	-0.33	1.93e-13	Breast cancer;
LGG	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg13385521	chr17:29058706	SUZ12P	-0.78	-9.28	-0.4	6.53e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.9	-0.31	1.76e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1620921	0.774	rs783154	chr6:161229780	G/T	cg01280913	chr6:161186852	NA	-0.34	-7.1	-0.31	4.61e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1941023	0.503	rs2233238	chr11:60145441	G/C	cg08716584	chr11:60157161	MS4A7	-0.42	-8.46	-0.37	3.49e-16	Congenital heart disease (maternal effect);
LGG	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs1577917	0.771	rs7742201	chr6:86432930	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-11.76	-0.48	3.87e-28	Response to antipsychotic treatment;
LGG	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.44	-0.44	4.54e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg13047869	chr3:10149882	C3orf24	0.48	7.91	0.35	1.88e-14	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21158476	chr5:135527863	LOC389332	0.41	7.03	0.31	7.3e-12	Gut microbiome composition (summer);
LGG	cis	rs12493885	0.769	rs11718319	chr3:153776944	G/A	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg07389463	chr12:132296394	NA	0.45	9.24	0.39	9.2e-19	Migraine;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg24607181	chr17:41446203	NA	-0.29	-6.71	-0.3	5.88e-11	Menopause (age at onset);
LGG	cis	rs4555082	0.874	rs28785556	chr14:105745388	A/T	cg10792982	chr14:105748885	BRF1	0.66	12.55	0.5	2.59e-31	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11158026	0.757	rs17128120	chr14:55474598	C/T	cg04306507	chr14:55594613	LGALS3	0.31	7.14	0.31	3.62e-12	Parkinson's disease;
LGG	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg10818794	chr15:86012489	AKAP13	0.38	8.01	0.35	9.07e-15	Coronary artery disease;
LGG	trans	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-12.87	-0.51	1.31e-32	Body mass index;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg22907277	chr7:1156413	C7orf50	0.42	7.23	0.32	2.04e-12	Longevity;Endometriosis;
LGG	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.13e-15	Initial pursuit acceleration;
LGG	trans	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg05926928	chr17:57297772	GDPD1	-0.9	-12.09	-0.49	2.04e-29	Opioid sensitivity;
LGG	trans	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg24247370	chr13:99142703	STK24	0.39	7.31	0.32	1.2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg08564027	chr20:61660810	NA	1.02	25.07	0.76	2.81e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7818345	0.512	rs4922029	chr8:19304533	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	7.58	0.33	1.92e-13	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs701145	0.585	rs62276840	chr3:153783622	G/C	cg17054900	chr3:154042577	DHX36	-0.77	-9.28	-0.4	6.3e-19	Coronary artery disease;
LGG	cis	rs12724450	0.793	rs34307322	chr1:150329636	A/G	cg03818307	chr1:150480534	ECM1	0.49	6.95	0.31	1.21e-11	Blood protein levels;
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg24397884	chr7:158709396	WDR60	0.9	18.13	0.64	6.58e-56	Height;
LGG	cis	rs888194	0.738	rs2241208	chr12:109962795	G/C	cg08884029	chr12:110012500	MVK;MMAB	-0.34	-6.98	-0.31	1.04e-11	Neuroticism;
LGG	cis	rs13191362	0.507	rs2846536	chr6:163033492	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.6	8.49	0.37	2.77e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.66	-11.66	-0.48	1.05e-27	Longevity;Endometriosis;
LGG	cis	rs9815354	1.000	rs17064124	chr3:41890803	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs526231	0.697	rs253759	chr5:102615675	G/A	cg23492399	chr5:102201601	PAM	-0.54	-6.94	-0.31	1.3e-11	Primary biliary cholangitis;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg15394860	chr11:2017084	H19	0.62	13.93	0.54	4.36e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9487094	0.961	rs34202013	chr6:109674558	A/G	cg16315928	chr6:109776240	MICAL1	0.54	9.21	0.39	1.15e-18	Height;
LGG	cis	rs11971779	0.680	rs4732376	chr7:139098024	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg03647317	chr4:187891568	NA	0.4	8.84	0.38	2.02e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg21798802	chr22:38057573	PDXP	0.61	14.05	0.55	1.38e-37	Fat distribution (HIV);
LGG	cis	rs7927592	0.913	rs7116994	chr11:68254627	C/T	cg16797656	chr11:68205561	LRP5	0.4	7.02	0.31	8.07e-12	Total body bone mineral density;
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg14196790	chr5:131705035	SLC22A5	0.6	7.62	0.33	1.42e-13	Rheumatoid arthritis;
LGG	cis	rs11122272	0.735	rs2572248	chr1:231514942	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs12681287	0.888	rs13042	chr8:87484913	G/A	cg27223183	chr8:87520930	FAM82B	-0.45	-6.96	-0.31	1.18e-11	Caudate activity during reward;
LGG	cis	rs73787773	0.867	rs73227492	chr5:111473369	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.29	-0.36	1.2e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21204139	chr1:64669336	UBE2U	0.33	7.41	0.33	6.12e-13	Menarche (age at onset);
LGG	cis	rs12493885	0.818	rs10935970	chr3:153770237	C/G	cg12800244	chr3:153838788	SGEF	-0.79	-9.49	-0.4	1.24e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs78456975	1.000	rs11883965	chr2:1560062	T/C	cg26248373	chr2:1572462	NA	-0.69	-8.91	-0.38	1.16e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg15269541	chr15:43626905	ADAL	-0.4	-6.75	-0.3	4.37e-11	Lung cancer in ever smokers;
LGG	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg02733842	chr7:1102375	C7orf50	-0.46	-7.29	-0.32	1.33e-12	Bronchopulmonary dysplasia;
LGG	cis	rs6032067	0.929	rs36032462	chr20:43873088	T/C	cg10761708	chr20:43804764	PI3	0.76	11.59	0.47	1.91e-27	Blood protein levels;
LGG	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.23	0.52	4.07e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs703842	1.000	rs10783847	chr12:58196447	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.5	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs1044826	0.642	rs4683464	chr3:139196961	C/T	cg15131784	chr3:139108705	COPB2	0.43	6.98	0.31	1.01e-11	Obesity-related traits;
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg22072935	chr14:105399595	NA	0.52	10.12	0.43	7.21e-22	Rheumatoid arthritis;
LGG	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs8180040	0.966	rs7628631	chr3:47560863	C/T	cg16586182	chr3:47516702	SCAP	0.75	14.37	0.56	5.31e-39	Colorectal cancer;
LGG	cis	rs36051895	0.632	rs12352022	chr9:5161836	T/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.13	-0.55	6.26e-38	Pediatric autoimmune diseases;
LGG	cis	rs9914988	0.943	rs4262997	chr17:27129562	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg25947184	chr8:1697459	NA	0.42	7.34	0.32	9.66e-13	Systolic blood pressure;
LGG	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.59	-0.44	1.34e-23	Response to antipsychotic treatment;
LGG	cis	rs7100689	0.622	rs1340383	chr10:82095968	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.71	0.56	1.86e-40	Post bronchodilator FEV1;
LGG	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.83	-0.45	1.68e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9916302	0.653	rs4239223	chr17:37717004	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-8.73	-0.38	4.53e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs12586317	0.586	rs74243591	chr14:35520917	C/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.41	-0.33	6.13e-13	Psoriasis;
LGG	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.59	-0.61	7.81e-49	Height;
LGG	cis	rs953387	1.000	rs4954567	chr2:136901587	G/T	cg05194412	chr2:137003533	NA	-0.32	-6.88	-0.3	2.01e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg10852096	chr15:79043040	NA	-0.29	-7.98	-0.35	1.16e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs6815814	0.851	rs4129009	chr4:38774889	T/C	cg06935464	chr4:38784597	TLR10	0.54	7.21	0.32	2.31e-12	Breast cancer;
LGG	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg27284194	chr4:1044797	NA	-0.57	-11.76	-0.48	4.22e-28	Recombination rate (males);
LGG	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg00666640	chr1:248458726	OR2T12	0.6	9.83	0.42	7.94e-21	Common traits (Other);
LGG	cis	rs12468557	0.545	rs7587701	chr2:211499959	A/G	cg07063745	chr2:211341572	LANCL1;CPS1	-0.5	-8.68	-0.37	6.65e-17	Body mass index in asthmatics;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg07701084	chr6:150067640	NUP43	0.66	12.45	0.5	6.99e-31	Lung cancer;
LGG	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg12591125	chr7:1885375	MAD1L1	0.46	6.69	0.3	6.45e-11	Bipolar disorder;
LGG	cis	rs3768617	0.510	rs2333621	chr1:183090751	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs3862030	0.810	rs11593710	chr10:104328719	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.42	-0.47	8.87e-27	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs240764	0.555	rs6919283	chr6:101235769	C/T	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg08885076	chr2:99613938	TSGA10	0.42	8.89	0.38	1.4e-17	Chronic sinus infection;
LGG	cis	rs4493873	0.731	rs7846412	chr8:92044528	A/G	cg16814680	chr8:91681699	NA	0.49	8.06	0.35	6.49e-15	Migraine - clinic-based;
LGG	cis	rs11098499	0.863	rs3822194	chr4:120471648	A/G	cg09307838	chr4:120376055	NA	0.78	13.1	0.52	1.47e-33	Corneal astigmatism;
LGG	cis	rs11785400	1.000	rs4266629	chr8:143736635	A/G	cg10596483	chr8:143751796	JRK	0.59	9.7	0.41	2.27e-20	Schizophrenia;
LGG	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs7737355	0.947	rs56228197	chr5:130805475	C/T	cg06307176	chr5:131281290	NA	-0.56	-9.31	-0.4	5.19e-19	Life satisfaction;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg00292662	chr22:38071168	LGALS1	-0.35	-6.75	-0.3	4.4e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1461503	0.966	rs7944630	chr11:122838844	G/A	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs2201728	0.967	rs6532814	chr4:100173968	T/C	cg07219303	chr4:100140905	ADH6	-0.42	-8.39	-0.36	5.75e-16	Cardiac Troponin-T levels;
LGG	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg11502198	chr6:26597334	ABT1	0.54	9.41	0.4	2.33e-19	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12074981	chr18:43547177	KIAA1632	0.47	7.21	0.32	2.28e-12	Gut microbiome composition (summer);
LGG	cis	rs1707322	0.721	rs12069121	chr1:46231984	G/A	cg03146154	chr1:46216737	IPP	0.59	10.82	0.45	1.82e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7000551	0.642	rs2122880	chr8:22375042	C/A	cg12081754	chr8:22256438	SLC39A14	0.68	13.04	0.52	2.48e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg24675658	chr1:53192096	ZYG11B	0.49	9.85	0.42	6.32e-21	Monocyte count;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg17178900	chr1:205818956	PM20D1	-0.39	-7.1	-0.31	4.66e-12	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs10927875	0.596	rs1806990	chr1:16129377	G/A	cg21385522	chr1:16154831	NA	-1.03	-25.72	-0.77	2.81e-91	Dilated cardiomyopathy;
LGG	cis	rs10895140	0.756	rs1939451	chr11:101505632	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	3.91e-17	Lung cancer;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.89	-0.42	4.59e-21	Lung cancer;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg16270222	chr17:41446396	NA	-0.3	-7.21	-0.32	2.26e-12	Menopause (age at onset);
LGG	cis	rs6539288	0.630	rs1055332	chr12:107348625	T/A	cg26297688	chr12:107349093	C12orf23	-0.39	-7.4	-0.33	6.65e-13	Total body bone mineral density;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg27144592	chr16:783916	NARFL	0.4	6.65	0.3	8.49e-11	Height;
LGG	cis	rs151997	1.000	rs27247	chr5:50232299	T/C	cg06027927	chr5:50259733	NA	-0.63	-10.49	-0.44	2.97e-23	Callous-unemotional behaviour;
LGG	cis	rs11098499	0.644	rs10050092	chr4:120532085	T/C	cg09307838	chr4:120376055	NA	0.72	12.47	0.5	5.45e-31	Corneal astigmatism;
LGG	cis	rs1568889	0.838	rs10767708	chr11:28294847	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.1	0.66	2.14e-60	Bipolar disorder;
LGG	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg24375607	chr4:120327624	NA	0.66	10.87	0.45	1.15e-24	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs6028335	0.674	rs67379757	chr20:37671051	C/G	cg16355469	chr20:37678765	NA	0.59	7.95	0.35	1.39e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.07	-0.35	6.17e-15	Mood instability;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06112835	chr11:68658793	MRPL21	0.62	10.42	0.44	5.73e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs72960926	0.590	rs117275111	chr6:74750921	G/A	cg03266952	chr6:74778945	NA	-0.68	-7.01	-0.31	8.24e-12	Metabolite levels (MHPG);
LGG	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.95	-0.31	1.26e-11	Joint mobility (Beighton score);
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg00928816	chr10:63809098	ARID5B	0.4	7.86	0.34	2.71e-14	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.04	-0.35	7.69e-15	Personality dimensions;
LGG	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.07	0.31	5.68e-12	Educational attainment;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg05863683	chr7:1912471	MAD1L1	0.4	8.05	0.35	6.99e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg11366901	chr6:160182831	ACAT2	1.07	17.28	0.63	5.56e-52	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2302729	0.578	rs11062298	chr12:2771709	A/C	cg19945202	chr12:2788847	CACNA1C	-0.74	-12.5	-0.5	4.3e-31	Sleep quality;
LGG	cis	rs7584262	0.535	rs114695310	chr2:42238625	C/T	cg19376973	chr2:42229025	NA	0.7	9.49	0.4	1.23e-19	Bone mineral density;
LGG	trans	rs1997103	1.000	rs10279035	chr7:55412055	C/T	cg20935933	chr6:143382018	AIG1	0.55	8.54	0.37	1.9e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.09	0.39	2.82e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2587949	0.638	rs1838305	chr3:4210967	C/T	cg16519197	chr3:4211558	NA	-0.33	-6.74	-0.3	4.78e-11	Periodontitis (DPAL);
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg02503808	chr4:7069936	GRPEL1	1.01	16.07	0.6	1.61e-46	Monocyte percentage of white cells;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.0	-0.49	4.31e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs36051895	0.632	rs10815167	chr9:5150058	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.34	-0.55	7.82e-39	Pediatric autoimmune diseases;
LGG	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg02733842	chr7:1102375	C7orf50	0.63	7.9	0.34	2.12e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg17376030	chr22:41985996	PMM1	-0.55	-8.93	-0.38	9.8e-18	Vitiligo;
LGG	cis	rs1144	0.537	rs2470944	chr7:104585516	G/C	cg03782966	chr7:104585482	NA	0.35	7.98	0.35	1.16e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg21452805	chr1:244014465	NA	0.59	6.98	0.31	1.05e-11	RR interval (heart rate);
LGG	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg27129171	chr3:47204927	SETD2	0.83	15.95	0.6	5.98e-46	Colorectal cancer;
LGG	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs17060993	0.614	rs7833994	chr8:26871274	A/G	cg19071002	chr6:63940486	NA	-0.56	-7.81	-0.34	3.79e-14	Musician's dystonia;
LGG	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg12395012	chr8:11607386	GATA4	-0.39	-6.92	-0.31	1.49e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-10.25	-0.43	2.43e-22	Pancreatic cancer;
LGG	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs504918	0.802	rs9879566	chr3:124049751	C/T	cg05766129	chr3:123988013	KALRN	0.37	6.67	0.3	7.47e-11	Schizophrenia;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.77	-0.41	1.28e-20	Lung cancer;
LGG	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.85	9.12	0.39	2.32e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-10.47	-0.44	3.59e-23	Height;
LGG	cis	rs6708331	0.517	rs12617812	chr2:70359471	A/G	cg01613454	chr2:70366299	NA	0.56	11.26	0.46	3.69e-26	Obesity-related traits;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.47	-0.37	3.19e-16	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12835684	chr12:53645647	MFSD5	0.42	6.67	0.3	7.22e-11	Cognitive performance;
LGG	cis	rs4319547	0.695	rs4758645	chr12:122946487	G/A	cg23029597	chr12:123009494	RSRC2	-0.87	-16.73	-0.61	1.84e-49	Body mass index;
LGG	cis	rs13082711	0.911	rs35532045	chr3:27515870	A/G	cg02860705	chr3:27208620	NA	0.69	12.3	0.5	2.66e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6754311	0.773	rs680428	chr2:136630757	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-12.92	-0.51	8.31e-33	Mosquito bite size;
LGG	cis	rs8179	0.553	rs42038	chr7:92243719	A/G	cg15732164	chr7:92237376	CDK6	0.52	10.95	0.45	5.64e-25	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs4417704	0.551	rs11886565	chr2:241898520	T/C	cg05025159	chr2:241905733	NA	0.5	10.33	0.43	1.15e-22	Joint mobility (Beighton score);
LGG	cis	rs2880765	0.506	rs719138	chr15:86055062	T/G	cg10818794	chr15:86012489	AKAP13	-0.46	-9.46	-0.4	1.59e-19	Coronary artery disease;
LGG	cis	rs2115630	1.000	rs4633690	chr15:85361960	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.74	-0.3	4.83e-11	P wave terminal force;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03859186	chr16:30596757	ZNF785	0.46	7.1	0.31	4.73e-12	Hip circumference;
LGG	cis	rs9896933	0.779	rs2256316	chr17:80693805	C/G	cg15369054	chr17:80825471	TBCD	0.51	7.14	0.32	3.59e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.25	-0.36	1.63e-15	Blood trace element (Cu levels);
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17712092	chr4:129076599	LARP1B	0.75	14.46	0.56	2.31e-39	Eosinophil percentage of white cells;
LGG	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg15704280	chr7:45808275	SEPT13	-0.88	-13.15	-0.52	8.93e-34	Coronary artery disease;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs4906332	0.966	rs59858038	chr14:103867102	C/T	cg26031613	chr14:104095156	KLC1	-0.54	-8.21	-0.36	2.21e-15	Coronary artery disease;
LGG	cis	rs483069	1.000	rs549944	chr1:34424462	A/G	cg24941457	chr1:34420873	CSMD2	0.48	11.67	0.48	9.59e-28	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs9463078	0.505	rs2038556	chr6:44740568	A/G	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.79e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	trans	rs7395662	0.963	rs60772766	chr11:48721011	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.93	-0.35	1.63e-14	HDL cholesterol;
LGG	cis	rs16986825	0.599	rs34751572	chr22:29170138	C/G	cg15103426	chr22:29168792	CCDC117	0.65	6.76	0.3	4.08e-11	Pancreatic cancer;
LGG	cis	rs371025208	1	rs371025208	chr20:43928602	TGGGTGTGTGTGTGTAGGG/T	cg10761708	chr20:43804764	PI3	0.55	8.36	0.36	7.15e-16	Parental longevity (mother's age at death);
LGG	cis	rs910187	0.538	rs2868849	chr20:45802273	G/A	cg27589058	chr20:45804311	EYA2	-0.38	-10.21	-0.43	3.43e-22	Migraine;
LGG	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg03433033	chr1:76189801	ACADM	-0.45	-7.11	-0.31	4.35e-12	Daytime sleep phenotypes;
LGG	cis	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04787407	chr4:99916511	METAP1	0.56	8.87	0.38	1.55e-17	Gut microbiome composition (summer);
LGG	cis	rs12282928	0.917	rs7115127	chr11:48275890	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.14	-0.31	3.67e-12	Migraine - clinic-based;
LGG	cis	rs5742933	0.857	rs2289226	chr2:190526205	A/G	cg10453823	chr2:190539512	ANKAR	0.48	6.95	0.31	1.23e-11	Ferritin levels;
LGG	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg10122326	chr6:28072925	NA	1.04	8.11	0.35	4.66e-15	Parkinson's disease;
LGG	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg07615347	chr10:60278583	BICC1	0.62	17.62	0.63	1.53e-53	Refractive error;
LGG	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg02574844	chr11:5959923	NA	-0.56	-8.76	-0.38	3.74e-17	DNA methylation (variation);
LGG	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.02	-0.35	8.65e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs6787172	0.702	rs827135	chr3:158064909	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.72	0.38	4.92e-17	Subjective well-being;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11039808	chr5:77591002	AP3B1	-0.46	-6.65	-0.3	8.45e-11	Systemic lupus erythematosus;
LGG	cis	rs1451375	0.617	rs1807066	chr7:50543683	T/C	cg20336341	chr7:50628841	DDC	-0.41	-7.1	-0.31	4.78e-12	Malaria;
LGG	cis	rs12580194	0.593	rs73118998	chr12:55736659	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-9.39	-0.4	2.84e-19	Cancer;
LGG	cis	rs6504108	0.624	rs1860863	chr17:46204678	G/C	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.76	-0.38	3.75e-17	Bone mineral density;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg21782813	chr7:2030301	MAD1L1	-0.52	-13.59	-0.53	1.28e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs62103177	0.561	rs891489	chr18:77637493	G/A	cg20368463	chr18:77673604	PQLC1	-0.51	-7.66	-0.34	1.07e-13	Opioid sensitivity;
LGG	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg15704280	chr7:45808275	SEPT13	-0.61	-10.82	-0.45	1.71e-24	HDL cholesterol;
LGG	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	6.79	0.3	3.39e-11	Bipolar disorder;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04008888	chr11:68622739	NA	-0.54	-11.5	-0.47	4.27e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7917772	0.582	rs12411442	chr10:104349531	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.59e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg07636037	chr3:49044803	WDR6	-0.72	-12.71	-0.51	5.82e-32	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg11878867	chr6:150167359	LRP11	-0.47	-8.17	-0.35	3.02e-15	Lung cancer;
LGG	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.4	0.44	6.7e-23	Diabetic retinopathy;
LGG	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg00686598	chr14:53173677	PSMC6	1.39	15.5	0.58	5.73e-44	Alzheimer's disease (late onset);
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg25072359	chr17:41440525	NA	0.51	10.07	0.42	1.02e-21	Menopause (age at onset);
LGG	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.98	-0.31	1.04e-11	Total cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26084319	chr14:21905280	CHD8	0.45	7.13	0.31	3.96e-12	Gut microbiome composition (summer);
LGG	cis	rs9296092	0.538	rs62405941	chr6:33517297	G/A	cg13560919	chr6:33536144	NA	-1.03	-20.24	-0.69	9.9e-66	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.500	rs9772760	chr8:57986999	G/C	cg02725872	chr8:58115012	NA	-0.53	-8.56	-0.37	1.63e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs593982	1.000	rs470360	chr11:65500530	T/C	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg09307838	chr4:120376055	NA	0.72	12.09	0.49	1.95e-29	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.72	0.41	1.91e-20	Prudent dietary pattern;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg08742575	chr21:47604166	C21orf56	-0.49	-8.65	-0.37	8.4e-17	Testicular germ cell tumor;
LGG	cis	rs8180040	0.800	rs11130126	chr3:47306894	A/G	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6e-39	Colorectal cancer;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg00684032	chr4:1343700	KIAA1530	0.45	9.09	0.39	2.83e-18	Longevity;
LGG	cis	rs1163251	0.902	rs639216	chr1:120217414	C/T	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg11342453	chr6:26196699	NA	0.48	6.69	0.3	6.42e-11	Gout;Renal underexcretion gout;
LGG	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg21475434	chr5:93447410	FAM172A	0.7	7.18	0.32	2.73e-12	Diabetic retinopathy;
LGG	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg04731861	chr2:219085781	ARPC2	0.49	12.36	0.5	1.66e-30	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs17685	0.753	rs10085567	chr7:75734206	A/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.49	0.76	3.31e-90	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	10.93	0.45	6.81e-25	Aortic root size;
LGG	cis	rs17102423	0.594	rs1124752	chr14:65567515	G/T	cg26396452	chr14:65542826	MAX	0.48	10.02	0.42	1.67e-21	Obesity-related traits;
LGG	cis	rs116095464	0.558	rs7356535	chr5:284117	G/T	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17996757	chr7:131013207	MKLN1	0.44	7.59	0.33	1.8e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg03959625	chr15:84868606	LOC388152	0.58	9.31	0.4	5.29e-19	Schizophrenia;
LGG	cis	rs1829883	0.804	rs1608435	chr5:98817492	A/G	cg08333243	chr5:99726346	NA	-0.39	-7.61	-0.33	1.52e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6547631	0.507	rs7355681	chr2:85911339	G/A	cg24620635	chr2:85921963	GNLY	0.43	8.17	0.35	3.06e-15	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02942644	chr3:119217190	C3orf1	0.43	6.85	0.3	2.32e-11	Cognitive performance;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg11062466	chr8:58055876	NA	0.48	8.21	0.36	2.29e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.65	0.37	8.63e-17	Colorectal cancer;
LGG	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg13010199	chr12:38710504	ALG10B	-0.47	-8.41	-0.36	5.29e-16	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27180268	chr17:36003216	DDX52	0.51	7.46	0.33	4.45e-13	Gut microbiome composition (summer);
LGG	cis	rs13177180	0.671	rs35713527	chr5:114833695	C/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.35	-7.58	-0.33	1.93e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs13314892	0.770	rs62252225	chr3:69884055	C/T	cg17445875	chr3:69859618	MITF	-0.41	-7.92	-0.35	1.72e-14	QRS complex (12-leadsum);
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.64e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg19812747	chr11:111475976	SIK2	-0.47	-9.69	-0.41	2.47e-20	Primary sclerosing cholangitis;
LGG	cis	rs9503598	0.778	rs1328688	chr6:3468508	G/A	cg00476032	chr6:3446245	SLC22A23	0.64	13.78	0.54	1.93e-36	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg11050988	chr7:1952600	MAD1L1	-0.33	-8.07	-0.35	6e-15	Schizophrenia;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.09	-0.31	4.95e-12	IgG glycosylation;
LGG	trans	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.44	0.44	4.57e-23	Ulcerative colitis;
LGG	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg16850897	chr7:100343110	ZAN	0.43	6.94	0.31	1.31e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs3733585	0.699	rs6449172	chr4:9966036	A/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg03175030	chr11:2018143	H19;MIR675	-0.6	-11.39	-0.47	1.16e-26	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.45	-9.32	-0.4	4.64e-19	Multiple sclerosis;
LGG	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg25817165	chr18:72167213	CNDP2	-0.64	-12.86	-0.51	1.48e-32	Refractive error;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.66	0.34	1.14e-13	Lung cancer;
LGG	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg10253484	chr15:75165896	SCAMP2	-0.42	-7.23	-0.32	2.06e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs9906944	0.713	rs9899580	chr17:47106878	T/G	cg09029085	chr17:47094198	IGF2BP1	0.31	8.28	0.36	1.36e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs950027	0.967	rs2486280	chr15:45751889	T/C	cg26924012	chr15:45694286	SPATA5L1	0.44	7.62	0.33	1.41e-13	Response to fenofibrate (adiponectin levels);
LGG	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg03160526	chr17:80928410	B3GNTL1	0.5	7.97	0.35	1.27e-14	Glycated hemoglobin levels;
LGG	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg06606381	chr12:133084897	FBRSL1	0.74	7.74	0.34	6.31e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1814175	0.817	rs1390676	chr11:50056778	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.78	-0.48	3.38e-28	Height;
LGG	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs981844	1.000	rs2263434	chr4:154658312	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs9964724	0.767	rs11661878	chr18:35198836	A/G	cg27332583	chr18:35150602	NA	0.36	7.91	0.35	1.86e-14	Educational attainment (years of education);
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs4820539	0.934	rs3788351	chr22:23469181	T/C	cg21100191	chr22:23484243	RTDR1	1.0	22.54	0.72	1.79e-76	Bone mineral density;
LGG	cis	rs9487094	0.689	rs17070591	chr6:109747721	G/A	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.18e-11	Height;
LGG	cis	rs457717	0.767	rs3756521	chr5:75921422	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.4	-7.48	-0.33	3.73e-13	Hearing impairment;
LGG	cis	rs919433	0.679	rs7564924	chr2:198513877	C/T	cg00792783	chr2:198669748	PLCL1	0.56	9.16	0.39	1.72e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg13147721	chr7:65941812	NA	0.76	9.51	0.4	1.04e-19	Diabetic kidney disease;
LGG	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg24565620	chr2:194026	NA	0.7	9.02	0.39	5.13e-18	Blood protein levels;
LGG	cis	rs17014483	0.749	rs2972030	chr4:89631029	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.8	0.3	3.31e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg06028808	chr11:68637592	NA	0.72	12.31	0.5	2.64e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg13647721	chr17:30228624	UTP6	0.7	9.89	0.42	4.7e-21	Hip circumference adjusted for BMI;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05380793	chr13:73301995	C13orf37;C13orf34	0.38	6.73	0.3	5.09e-11	Bilirubin levels;
LGG	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.33	0.47	1.93e-26	Ovarian reserve;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25025968	chr11:4116056	RRM1	0.46	7.36	0.32	8.61e-13	Cognitive performance;
LGG	cis	rs7588746	0.521	rs73054585	chr2:201144386	T/A	cg23649088	chr2:200775458	C2orf69	-0.47	-6.79	-0.3	3.46e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.5	-9.8	-0.41	1.01e-20	Personality dimensions;
LGG	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg22437258	chr11:111473054	SIK2	0.54	9.54	0.41	8.01e-20	Primary sclerosing cholangitis;
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg21508023	chr5:171533930	STK10	-0.4	-6.83	-0.3	2.71e-11	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs709400	0.526	rs11622835	chr14:103967504	G/A	cg26031613	chr14:104095156	KLC1	0.68	8.99	0.39	6.11e-18	Body mass index;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg02127607	chr17:61920694	SMARCD2	-0.39	-6.84	-0.3	2.47e-11	Prudent dietary pattern;
LGG	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg07599136	chr5:415885	AHRR	0.84	11.31	0.47	2.37e-26	Fat distribution (HIV);
LGG	trans	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.3	-0.32	1.3e-12	Joint mobility (Beighton score);
LGG	cis	rs7172677	0.732	rs1867147	chr15:75363357	C/T	cg14664628	chr15:75095509	CSK	0.55	8.48	0.37	2.98e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Myopia (pathological);
LGG	cis	rs2029213	0.523	rs4687715	chr3:53269904	G/A	cg16894138	chr3:53270350	TKT	0.49	9.97	0.42	2.43e-21	Heart rate;
LGG	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.3	-0.32	1.27e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg23758822	chr17:41437982	NA	0.87	15.39	0.58	1.84e-43	Menopause (age at onset);
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.5	-8.27	-0.36	1.49e-15	Bipolar disorder;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.57	0.37	1.54e-16	Platelet count;
LGG	cis	rs698833	0.892	rs698831	chr2:44731117	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	7.15	0.32	3.44e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.22	-0.32	2.21e-12	Schizophrenia;
LGG	cis	rs1878931	0.582	rs9635562	chr16:3416689	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	11.51	0.47	3.91e-27	Body mass index (adult);
LGG	cis	rs1109114	0.714	rs9512	chr5:148639762	G/A	cg06539116	chr5:148597365	ABLIM3	-0.52	-12.79	-0.51	2.7e-32	Body mass index;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg02725872	chr8:58115012	NA	-0.77	-10.96	-0.45	5.02e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.39	0.58	1.8e-43	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17591343	chr1:93646016	TMED5;CCDC18	0.46	7.78	0.34	4.88e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg21775007	chr8:11205619	TDH	-0.46	-7.4	-0.33	6.63e-13	Joint mobility (Beighton score);
LGG	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg25801113	chr15:45476975	SHF	0.88	20.18	0.68	2.05e-65	Uric acid levels;
LGG	cis	rs892961	0.867	rs6501955	chr17:75414443	A/G	cg05865280	chr17:75406074	SEPT9	0.43	10.19	0.43	3.85e-22	Airflow obstruction;
LGG	cis	rs209489	1.000	rs209501	chr6:53188736	C/T	cg15607103	chr6:53167650	ELOVL5	-0.54	-7.68	-0.34	9.37e-14	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg02475777	chr4:1388615	CRIPAK	0.57	10.32	0.43	1.32e-22	Longevity;
LGG	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.67	-0.34	1e-13	Hepatitis;
LGG	trans	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.84	-0.42	6.95e-21	Menarche (age at onset);
LGG	cis	rs6912958	0.781	rs9450738	chr6:88267314	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.69	-0.37	6.54e-17	Monocyte percentage of white cells;
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg14675211	chr2:100938903	LONRF2	-0.64	-11.49	-0.47	4.5e-27	Intelligence (multi-trait analysis);
LGG	cis	rs56307353	0.753	rs62129495	chr19:1962789	T/C	cg07946961	chr19:1955956	C19orf34;CSNK1G2	-0.32	-7.16	-0.32	3.29e-12	Coronary artery disease;
LGG	cis	rs8014204	0.550	rs7152906	chr14:75125540	T/C	cg06637938	chr14:75390232	RPS6KL1	0.67	12.43	0.5	7.92e-31	Caffeine consumption;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg03575189	chr17:44344142	NA	0.48	7.09	0.31	4.97e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs74417235	0.528	rs9324789	chr5:154074362	C/T	cg08754654	chr5:154026448	NA	-0.37	-7.64	-0.33	1.27e-13	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg07870213	chr5:140052090	DND1	0.91	16.21	0.6	3.87e-47	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg18451016	chr1:38461880	NA	0.46	9.6	0.41	4.86e-20	Coronary artery disease;
LGG	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.06	-0.31	6.23e-12	Blood metabolite levels;
LGG	cis	rs1978968	0.912	rs12157484	chr22:18455122	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.61	-0.56	5.02e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs9868809	0.764	rs2633958	chr3:48635432	A/G	cg00383909	chr3:49044727	WDR6	-0.91	-9.1	-0.39	2.69e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.53	0.4	8.81e-20	Mean corpuscular volume;
LGG	cis	rs10484885	0.824	rs11967579	chr6:90540008	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.86	-10.99	-0.45	4.16e-25	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.74	-0.3	4.84e-11	Neuroticism;
LGG	cis	rs7044106	0.791	rs4617229	chr9:123480696	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.22	0.32	2.21e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg18402987	chr7:1209562	NA	0.49	8.33	0.36	9.43e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg20887711	chr4:1340912	KIAA1530	-0.91	-19.92	-0.68	3.28e-64	Longevity;
LGG	cis	rs10089	1.000	rs2898096	chr5:127433214	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.94	0.49	7.46e-29	Ileal carcinoids;
LGG	cis	rs7666738	0.830	rs13134819	chr4:98919885	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.27e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-13.85	-0.54	1.01e-36	Body mass index;
LGG	trans	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.75	-13.8	-0.54	1.58e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9790314	1.000	rs189270	chr3:161063504	T/C	cg04691961	chr3:161091175	C3orf57	-0.64	-15.06	-0.57	5.47e-42	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.25e-11	Obesity-related traits;
LGG	cis	rs6940638	0.615	rs9393801	chr6:27242681	A/G	cg09904177	chr6:26538194	HMGN4	-0.41	-6.99	-0.31	9.85e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.720	rs11204419	chr17:19888997	A/G	cg13482628	chr17:19912719	NA	0.55	10.08	0.42	9.79e-22	Schizophrenia;
LGG	cis	rs9457247	0.765	rs4710171	chr6:167430186	A/G	cg07741184	chr6:167504864	NA	0.42	9.3	0.4	5.52e-19	Crohn's disease;
LGG	cis	rs28595532	0.920	rs114262028	chr4:119734877	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg14500267	chr11:67383377	NA	0.44	8.27	0.36	1.41e-15	Mean corpuscular volume;
LGG	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.96e-12	Calcium levels;
LGG	cis	rs2133450	0.712	rs9990258	chr3:7366452	C/T	cg19930620	chr3:7340148	GRM7	-0.37	-7.99	-0.35	1.1e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs735539	0.593	rs4463942	chr13:21367434	C/T	cg04906043	chr13:21280425	IL17D	-0.45	-7.16	-0.32	3.18e-12	Dental caries;
LGG	cis	rs919433	0.510	rs34631382	chr2:198390009	C/T	cg00792783	chr2:198669748	PLCL1	0.49	7.73	0.34	6.64e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.17	0.35	3.02e-15	Schizophrenia;
LGG	cis	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg06558623	chr16:89946397	TCF25	1.12	12.22	0.49	6.01e-30	Skin colour saturation;
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22569496	chr19:13409671	CACNA1A	0.37	6.86	0.3	2.27e-11	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.46	0.33	4.28e-13	Menopause (age at onset);
LGG	cis	rs910316	1.000	rs12589815	chr14:75544101	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.02	0.49	3.62e-29	Height;
LGG	cis	rs9300255	0.602	rs10744147	chr12:123643729	A/G	cg00376283	chr12:123451042	ABCB9	0.55	8.57	0.37	1.59e-16	Neutrophil percentage of white cells;
LGG	cis	rs6032067	0.641	rs35227660	chr20:43756697	C/G	cg10761708	chr20:43804764	PI3	0.71	10.42	0.44	5.73e-23	Blood protein levels;
LGG	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.36e-13	HDL cholesterol;
LGG	trans	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg25214090	chr10:38739885	LOC399744	0.6	10.23	0.43	2.67e-22	Corneal astigmatism;
LGG	cis	rs6815814	0.861	rs10004195	chr4:38784724	T/A	cg06935464	chr4:38784597	TLR10	0.53	8.63	0.37	9.76e-17	Breast cancer;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.43	0.47	8.11e-27	Electroencephalogram traits;
LGG	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.91	-0.31	1.57e-11	Common traits (Other);
LGG	trans	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	4.06e-15	Blood trace element (Cu levels);
LGG	cis	rs6964587	1.000	rs2282974	chr7:91761617	G/A	cg17063962	chr7:91808500	NA	0.5	9.13	0.39	2.16e-18	Breast cancer;
LGG	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg02836325	chr17:76403955	PGS1	-0.72	-14.47	-0.56	2e-39	HDL cholesterol levels;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs999943	0.774	rs12205634	chr6:33611667	C/G	cg14003231	chr6:33640908	ITPR3	0.65	15.04	0.57	6.33e-42	Obesity (extreme);
LGG	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg06951627	chr6:26196580	NA	0.49	7.37	0.32	8.14e-13	Gout;Renal underexcretion gout;
LGG	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg22875332	chr1:76189707	ACADM	-0.53	-8.1	-0.35	4.81e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06620731	chr12:108909559	FICD	0.44	6.66	0.3	7.69e-11	Gut microbiome composition (summer);
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.62	0.33	1.4e-13	Rheumatoid arthritis;
LGG	cis	rs7660883	0.897	rs236993	chr4:88016874	G/T	cg21988461	chr4:88008667	AFF1	0.34	9.84	0.42	7.37e-21	HDL cholesterol levels;
LGG	cis	rs1971762	0.527	rs4759211	chr12:53930945	T/C	cg06632207	chr12:54070931	ATP5G2	0.22	6.81	0.3	3.09e-11	Height;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg10189774	chr4:17578691	LAP3	0.43	7.67	0.34	1.02e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8064299	0.967	rs878905	chr17:72769411	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.69	13.35	0.53	1.23e-34	Monocyte count;
LGG	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.08	0.42	9.84e-22	Red cell distribution width;
LGG	cis	rs57237364	1	rs57237364	chr7:102465232	CTTT/C	cg18108683	chr7:102477205	FBXL13	-0.71	-15.72	-0.59	6.3e-45	Breast cancer;
LGG	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg08400814	chr5:56204995	C5orf35	0.4	7.14	0.31	3.68e-12	Initial pursuit acceleration;
LGG	cis	rs990171	1.000	rs1465321	chr2:102986618	T/C	cg05295703	chr2:102895712	NA	-0.56	-9.79	-0.41	1.06e-20	Lymphocyte counts;
LGG	cis	rs10206020	0.921	rs72778005	chr2:1573122	C/G	cg12573674	chr2:1569213	NA	-0.64	-10.14	-0.43	5.7e-22	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.72	0.38	5.03e-17	Lung cancer;
LGG	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-15.04	-0.57	6.43e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg03511173	chr18:77590860	NA	0.43	7.2	0.32	2.41e-12	Schizophrenia;
LGG	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg09222892	chr1:25734099	RHCE	0.47	10.19	0.43	3.93e-22	Erythrocyte sedimentation rate;
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.64e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.58	0.41	5.79e-20	Skin colour saturation;
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg13047869	chr3:10149882	C3orf24	0.47	7.88	0.34	2.37e-14	Alzheimer's disease;
LGG	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg06573787	chr8:143070187	NA	-0.48	-8.73	-0.38	4.67e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg19673125	chr6:150240577	RAET1G	0.37	9.06	0.39	3.61e-18	Testicular germ cell tumor;
LGG	cis	rs2629540	0.924	rs2629541	chr10:126425866	G/A	cg08799069	chr10:126477246	METTL10	0.68	12.99	0.52	4.03e-33	Cocaine dependence;
LGG	cis	rs13314892	0.802	rs2114660	chr3:69803691	T/A	cg17445875	chr3:69859618	MITF	-0.33	-6.69	-0.3	6.42e-11	QRS complex (12-leadsum);
LGG	cis	rs875971	0.825	rs10281499	chr7:66048966	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs2230307	0.536	rs2893426	chr1:100528200	G/T	cg24955406	chr1:100503596	HIAT1	0.57	8.21	0.36	2.23e-15	Carotid intima media thickness;
LGG	cis	rs806215	0.547	rs1419967	chr7:127474435	G/C	cg25922125	chr7:127225783	GCC1	-0.47	-6.95	-0.31	1.27e-11	Type 2 diabetes;
LGG	cis	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg09307838	chr4:120376055	NA	0.82	13.61	0.53	9.74e-36	Corneal astigmatism;
LGG	cis	rs807669	0.869	rs1061325	chr22:19184095	T/C	cg02655711	chr22:19163373	SLC25A1	0.54	10.34	0.43	1.09e-22	Metabolite levels;
LGG	cis	rs657075	0.595	rs35724182	chr5:131580301	C/T	cg05556477	chr5:131705319	SLC22A5	0.62	8.16	0.35	3.1e-15	Rheumatoid arthritis;
LGG	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	trans	rs7618501	1.000	rs7618519	chr3:49772708	A/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.74	-0.41	1.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.88	-0.38	1.49e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg16584290	chr5:462447	EXOC3	0.46	9.51	0.4	1.03e-19	Cystic fibrosis severity;
LGG	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg21095983	chr6:86352623	SYNCRIP	-0.59	-10.99	-0.45	4.04e-25	Smooth-surface caries;
LGG	cis	rs11203032	0.831	rs4417181	chr10:90967093	T/C	cg16672925	chr10:90967113	CH25H	0.86	12.06	0.49	2.59e-29	Heart failure;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.13	0.31	3.82e-12	Alzheimer's disease;
LGG	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg12463550	chr7:65579703	CRCP	-0.78	-8.46	-0.37	3.56e-16	Diabetic kidney disease;
LGG	cis	rs6674970	0.518	rs6587552	chr1:151018861	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	0.64	9.71	0.41	2.03e-20	Childhood ear infection;
LGG	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg06138931	chr13:21896616	NA	-0.44	-7.22	-0.32	2.17e-12	White matter hyperintensity burden;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.96	0.31	1.18e-11	Lung cancer;
LGG	cis	rs907683	0.584	rs1058284	chr2:220286142	G/A	cg15015639	chr2:220282977	DES	-0.35	-10.14	-0.43	5.81e-22	Resting heart rate;
LGG	cis	rs887829	0.569	rs871514	chr2:234628529	T/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.83	-0.34	3.34e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs8020289	1.000	rs8016799	chr14:77287600	G/A	cg23436960	chr14:77239540	VASH1	-0.26	-6.77	-0.3	4.03e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs6988985	0.765	rs4641039	chr8:143977819	T/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9487094	0.885	rs11153214	chr6:110015323	A/G	cg01125227	chr6:109776195	MICAL1	0.51	8.66	0.37	8.06e-17	Height;
LGG	trans	rs66887589	0.777	rs4643791	chr4:120265619	A/G	cg25214090	chr10:38739885	LOC399744	-0.4	-7.27	-0.32	1.58e-12	Diastolic blood pressure;
LGG	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg20587970	chr11:113659929	NA	-1.3	-24.25	-0.75	1.8e-84	Hip circumference adjusted for BMI;
LGG	cis	rs8056893	0.885	rs7199750	chr16:68351859	C/G	cg07273125	chr16:68295692	NA	0.36	7.01	0.31	8.51e-12	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs6732160	0.588	rs2043100	chr2:73374096	T/C	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs80282103	0.764	rs12247779	chr10:1107957	T/G	cg08668510	chr10:1095578	IDI1	0.76	8.31	0.36	1.05e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.56	0.33	2.21e-13	Mood instability;
LGG	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.73e-41	Hair morphology;
LGG	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg08109568	chr15:31115862	NA	-0.53	-9.45	-0.4	1.63e-19	Huntington's disease progression;
LGG	cis	rs6977660	0.652	rs10249291	chr7:19844448	C/G	cg07541023	chr7:19748670	TWISTNB	0.58	7.28	0.32	1.41e-12	Thyroid stimulating hormone;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01794932	chr1:1209696	UBE2J2	0.43	6.92	0.31	1.55e-11	Cognitive performance;
LGG	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.46	-0.5	5.94e-31	Height;
LGG	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg07148914	chr20:33460835	GGT7	0.54	8.84	0.38	2.02e-17	Height;
LGG	cis	rs7107174	1.000	rs1893448	chr11:77969180	G/A	cg27205649	chr11:78285834	NARS2	-0.42	-6.88	-0.3	1.93e-11	Testicular germ cell tumor;
LGG	cis	rs753778	0.570	rs6985866	chr8:142210336	C/T	cg18755752	chr8:142205143	DENND3	0.45	9.08	0.39	3.27e-18	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13978767	chr19:7620597	PNPLA6	0.35	6.91	0.31	1.63e-11	Menarche (age at onset);
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs4731207	0.596	rs12540261	chr7:124586837	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.89	-0.34	2.26e-14	Cutaneous malignant melanoma;
LGG	cis	rs1568889	1.000	rs35697240	chr11:28287342	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	14.13	0.55	5.88e-38	Bipolar disorder;
LGG	cis	rs4731207	0.596	rs6952915	chr7:124685952	T/G	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	cis	rs12431410	0.584	rs8018516	chr14:60222977	G/A	cg07950296	chr14:60194823	RTN1	-0.36	-6.94	-0.31	1.3e-11	Schizophrenia;
LGG	cis	rs6964587	0.967	rs34040612	chr7:91798916	G/T	cg17063962	chr7:91808500	NA	0.54	9.81	0.41	8.91e-21	Breast cancer;
LGG	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06108461	chr20:60628389	TAF4	0.86	14.29	0.55	1.2e-38	Body mass index;
LGG	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03517284	chr6:25882590	NA	-0.69	-13.19	-0.52	5.79e-34	Intelligence (multi-trait analysis);
LGG	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	trans	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	9.27	0.4	7.01e-19	Metabolite levels;
LGG	cis	rs988958	0.526	rs12712827	chr2:42244794	T/G	cg27428208	chr2:42229179	NA	0.48	7.53	0.33	2.7e-13	Hypospadias;
LGG	cis	rs2074193	0.627	rs215393	chr12:47765795	A/G	cg02516419	chr12:47771422	NA	-0.72	-10.6	-0.44	1.16e-23	Migraine with aura;
LGG	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg26354017	chr1:205819088	PM20D1	-0.42	-7.2	-0.32	2.44e-12	Menarche (age at onset);
LGG	trans	rs2727020	0.729	rs2204366	chr11:49349367	A/C	cg15704280	chr7:45808275	SEPT13	0.95	19.46	0.67	4.6e-62	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg11494091	chr17:61959527	GH2	0.51	8.2	0.36	2.38e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg14541582	chr5:601475	NA	-0.7	-10.77	-0.45	2.68e-24	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg19357499	chr8:144660631	NAPRT1	0.92	7.05	0.31	6.37e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg24764310	chr7:157512201	PTPRN2	-0.47	-10.16	-0.43	4.95e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.601	rs9502719	chr6:8541032	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.38	0.43	7.74e-23	Motion sickness;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg07077115	chr13:28024429	MTIF3	0.42	6.69	0.3	6.52e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs75059851	0.756	rs11223661	chr11:133851412	G/T	cg20042908	chr11:133852938	NA	-0.75	-13.49	-0.53	3.34e-35	Schizophrenia;
LGG	cis	rs3796352	1.000	rs17052727	chr3:53070914	T/C	cg12962167	chr3:53033115	SFMBT1	0.65	6.86	0.3	2.25e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg01625945	chr7:157512322	PTPRN2	-0.48	-9.84	-0.42	6.87e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs10779751	0.770	rs11581010	chr1:11212458	A/G	cg08854313	chr1:11322531	MTOR	-0.72	-14.17	-0.55	4.02e-38	Body mass index;
LGG	cis	rs4629710	0.568	rs9492880	chr6:131565962	G/T	cg12606694	chr6:131520996	AKAP7	0.48	7.96	0.35	1.3e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg09699651	chr6:150184138	LRP11	0.46	8.13	0.35	3.98e-15	Lung cancer;
LGG	cis	rs10463554	0.927	rs34824	chr5:102438931	A/C	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	trans	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg17830980	chr10:43048298	ZNF37B	0.39	8.8	0.38	2.81e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg13852791	chr20:30311386	BCL2L1	0.8	12.54	0.5	3.01e-31	Mean corpuscular hemoglobin;
LGG	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg26031613	chr14:104095156	KLC1	-0.49	-6.79	-0.3	3.43e-11	Coronary artery disease;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg01988459	chr11:68622903	NA	-0.64	-12.55	-0.5	2.56e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.45	0.33	4.65e-13	Obesity-related traits;
LGG	cis	rs1408799	0.800	rs10809826	chr9:12682663	C/G	cg05274944	chr9:12693694	TYRP1	-0.37	-8.67	-0.37	7.56e-17	Eye color;Blue vs. green eyes;
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18252515	chr7:66147081	NA	-0.42	-7.0	-0.31	8.96e-12	Aortic root size;
LGG	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg04727924	chr7:799746	HEATR2	-0.49	-7.21	-0.32	2.31e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6076065	0.748	rs6137933	chr20:23383103	A/T	cg11657817	chr20:23433608	CST11	0.4	8.2	0.36	2.39e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg09699651	chr6:150184138	LRP11	0.5	8.81	0.38	2.47e-17	Lung cancer;
LGG	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg10189774	chr4:17578691	LAP3	0.38	6.79	0.3	3.4e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7552404	1.000	rs942270	chr1:76177332	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.92	0.51	7.63e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.69	-0.3	6.4e-11	Lung cancer;
LGG	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg01620082	chr3:125678407	NA	-0.63	-6.95	-0.31	1.25e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs938554	0.876	rs7670751	chr4:9938773	A/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.05	0.31	6.62e-12	Blood metabolite levels;
LGG	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg26441486	chr22:50317300	CRELD2	-0.4	-7.43	-0.33	5.11e-13	Schizophrenia;
LGG	cis	rs638893	0.527	rs7933859	chr11:118662045	T/C	cg22253036	chr11:118662786	DDX6	0.49	7.35	0.32	8.79e-13	Vitiligo;
LGG	cis	rs6142618	0.543	rs6142632	chr20:30770448	C/T	cg00028034	chr20:30779307	TSPYL3	0.36	7.86	0.34	2.67e-14	Inflammatory bowel disease;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	trans	rs11098499	0.865	rs2389809	chr4:120377399	T/C	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	cis	rs9341835	0.709	rs4358600	chr6:64153219	G/A	cg00787780	chr6:64151745	NA	0.42	7.62	0.33	1.46e-13	Schizophrenia;
LGG	cis	rs11741688	0.557	rs10043579	chr5:178330174	C/T	cg20935368	chr5:178288625	ZNF354B	0.34	6.91	0.31	1.57e-11	Sleep duration;
LGG	trans	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.88	-0.34	2.44e-14	Triglycerides;
LGG	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg27490568	chr2:178487706	NA	0.53	10.22	0.43	2.92e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9397585	0.824	rs2349199	chr6:153367594	A/T	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.65	0.51	1.05e-31	Colorectal cancer;
LGG	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	15.06	0.57	5.37e-42	Total body bone mineral density;
LGG	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs2640806	0.566	rs2280263	chr8:97342536	A/G	cg22138393	chr8:97340270	PTDSS1	-0.27	-6.94	-0.31	1.29e-11	Obesity-related traits;
LGG	trans	rs2562456	0.833	rs2928211	chr19:21541297	A/G	cg00806126	chr19:22604979	ZNF98	0.58	8.07	0.35	6.27e-15	Pain;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-11.76	-0.48	4.14e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.639	rs72806776	chr5:152346227	T/C	cg12297329	chr5:152029980	NA	-0.56	-8.92	-0.38	1.07e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg17376030	chr22:41985996	PMM1	0.49	7.85	0.34	2.83e-14	Vitiligo;
LGG	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg04691961	chr3:161091175	C3orf57	-0.47	-9.7	-0.41	2.19e-20	Parkinson's disease;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.77	0.3	3.87e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03670115	chr2:172544069	DYNC1I2	0.43	7.09	0.31	4.91e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06642177	chr6:134496341	SGK1	-0.42	-6.99	-0.31	9.55e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.15	-0.35	3.34e-15	HDL cholesterol;
LGG	cis	rs992157	0.767	rs2014615	chr2:219171191	A/G	cg04731861	chr2:219085781	ARPC2	-0.43	-10.43	-0.44	5.02e-23	Colorectal cancer;
LGG	cis	rs1506403	0.945	rs315286	chr7:142827282	T/C	cg11323483	chr7:142828068	PIP	-0.39	-7.08	-0.31	5.53e-12	Cancer;
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg18245976	chr7:158708271	WDR60	-0.55	-9.54	-0.41	8.41e-20	Height;
LGG	cis	rs10489167	1.000	rs12118374	chr1:41165543	A/G	cg11417323	chr1:41160271	NFYC	-0.44	-6.76	-0.3	4.05e-11	Depressive and manic episodes in bipolar disorder;
LGG	trans	rs7939886	0.920	rs12221615	chr11:55999950	G/C	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	cis	rs11112613	0.713	rs55646142	chr12:105949557	G/A	cg03607813	chr12:105948248	NA	0.63	11.11	0.46	1.41e-25	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg04503457	chr17:41445688	NA	0.39	9.4	0.4	2.46e-19	Menopause (age at onset);
LGG	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	trans	rs637571	0.565	rs570387	chr11:65637076	T/C	cg17712092	chr4:129076599	LARP1B	-0.75	-14.53	-0.56	1.1e-39	Eosinophil percentage of white cells;
LGG	cis	rs9640161	0.636	rs56190213	chr7:150025720	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.8	-16.63	-0.61	4.84e-49	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.03	-0.31	7.36e-12	Schizophrenia;
LGG	cis	rs7552404	0.590	rs1565717	chr1:76320441	T/C	cg03433033	chr1:76189801	ACADM	-0.62	-9.11	-0.39	2.42e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.6	-0.33	1.72e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg23306229	chr2:178417860	TTC30B	0.56	7.23	0.32	2.05e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg27471124	chr11:109292789	C11orf87	0.51	9.97	0.42	2.41e-21	Schizophrenia;
LGG	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg12373951	chr3:133503437	NA	0.4	7.03	0.31	7.47e-12	Iron status biomarkers;
LGG	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg02002194	chr4:3960332	NA	-0.43	-7.92	-0.35	1.8e-14	Neuroticism;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg05064044	chr6:292385	DUSP22	-0.65	-11.14	-0.46	1.1e-25	Menopause (age at onset);
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg07537917	chr2:241836409	C2orf54	-0.42	-8.31	-0.36	1.1e-15	Urinary metabolites;
LGG	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.91	-0.31	1.58e-11	Blood metabolite levels;
LGG	cis	rs11229555	0.874	rs11601687	chr11:58338628	T/C	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	9.25e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.54	9.6	0.41	4.97e-20	Total body bone mineral density;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.77	-14.4	-0.56	4.21e-39	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg03528353	chr17:61819722	STRADA	-0.44	-7.5	-0.33	3.28e-13	Prudent dietary pattern;
LGG	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg13263323	chr15:86062960	AKAP13	0.35	7.29	0.32	1.38e-12	Coronary artery disease;
LGG	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg25358565	chr5:93447407	FAM172A	1.21	15.03	0.57	7.54e-42	Diabetic retinopathy;
LGG	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.4	-0.36	5.6e-16	Total body bone mineral density;
LGG	cis	rs2985684	1.000	rs2985684	chr14:50101682	C/G	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs988958	0.958	rs2425	chr2:42285642	G/A	cg19376973	chr2:42229025	NA	0.45	7.29	0.32	1.39e-12	Hypospadias;
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22433210	chr17:43662623	NA	0.92	15.33	0.58	3.46e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg22482690	chr17:47019901	SNF8	-0.34	-6.77	-0.3	3.99e-11	Type 2 diabetes;
LGG	cis	rs4144743	0.759	rs67972765	chr17:45318326	G/A	cg18085866	chr17:45331354	ITGB3	-0.71	-7.42	-0.33	5.5e-13	Body mass index;
LGG	cis	rs2130392	1.000	rs11132254	chr4:185611592	G/T	cg21366198	chr4:185655624	MLF1IP	-0.44	-7.38	-0.32	7.29e-13	Kawasaki disease;
LGG	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	12.0	0.49	4.35e-29	Response to antipsychotic treatment;
LGG	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.57e-13	Refractive error;
LGG	cis	rs7843479	0.965	rs4636204	chr8:21823206	T/G	cg17168535	chr8:21777572	XPO7	0.6	9.82	0.42	8.2e-21	Mean corpuscular volume;
LGG	cis	rs735539	0.555	rs4608189	chr13:21343209	C/T	cg04906043	chr13:21280425	IL17D	-0.46	-7.39	-0.32	6.82e-13	Dental caries;
LGG	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.28	-0.36	1.3e-15	Subjective well-being;
LGG	cis	rs8067545	0.616	rs203465	chr17:19810720	T/G	cg13482628	chr17:19912719	NA	0.52	9.57	0.41	6.27e-20	Schizophrenia;
LGG	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.43	-0.33	5.2e-13	Total cholesterol levels;
LGG	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.83	-0.48	2.17e-28	Mean platelet volume;
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08736216	chr1:53307985	ZYG11A	-0.28	-7.01	-0.31	8.59e-12	Monocyte count;
LGG	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.69	0.34	9.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06850241	chr22:41845214	NA	0.46	7.17	0.32	2.93e-12	Vitiligo;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.75	-0.3	4.44e-11	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.04	0.7	1.8e-69	Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg04287289	chr16:89883240	FANCA	0.9	8.75	0.38	4.1e-17	Skin colour saturation;
LGG	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg07615347	chr10:60278583	BICC1	0.62	17.52	0.63	4.27e-53	Refractive error;
LGG	cis	rs73198271	0.531	rs17630714	chr8:8657681	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.33	0.36	9.18e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.99	0.35	1.1e-14	Retinal vascular caliber;
LGG	cis	rs1577917	0.958	rs12212480	chr6:86458777	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-10.89	-0.45	9.31e-25	Response to antipsychotic treatment;
LGG	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg26384229	chr12:38710491	ALG10B	0.61	11.83	0.48	2.06e-28	Morning vs. evening chronotype;
LGG	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.84	-0.42	7.42e-21	Joint mobility (Beighton score);
LGG	cis	rs7568458	0.905	rs17026396	chr2:85759127	C/T	cg23752985	chr2:85803571	VAMP8	-0.44	-8.66	-0.37	8.02e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2011503	1.000	rs77254326	chr19:19626781	T/G	cg11584989	chr19:19387371	SF4	0.73	11.98	0.49	5.53e-29	Bipolar disorder;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg07701084	chr6:150067640	NUP43	0.71	13.75	0.54	2.5e-36	Lung cancer;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11245990	chr11:68621969	NA	0.4	8.55	0.37	1.83e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg07061783	chr6:25882402	NA	-0.47	-8.0	-0.35	1.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs77956314	0.515	rs7302025	chr12:117442902	C/T	cg02017074	chr12:117425053	FBXW8	0.56	7.74	0.34	6.35e-14	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs7945705	0.902	rs1560569	chr11:8939887	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.34	-7.14	-0.32	3.53e-12	Hemoglobin concentration;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24215159	chr2:4050695	NA	0.35	6.93	0.31	1.46e-11	Electrocardiographic conduction measures;
LGG	cis	rs2154319	0.887	rs6698511	chr1:41545150	A/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.9	-0.38	1.24e-17	Height;
LGG	cis	rs9487051	0.872	rs9374079	chr6:109609619	A/G	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs6740322	0.948	rs6715072	chr2:43562230	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.77	-0.38	3.39e-17	Coronary artery disease;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg11965913	chr1:205819406	PM20D1	0.84	18.25	0.65	1.8e-56	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25179963	chr6:116422123	NT5DC1	0.45	7.38	0.32	7.17e-13	Cognitive performance;
LGG	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg04731861	chr2:219085781	ARPC2	0.28	6.68	0.3	6.91e-11	Ulcerative colitis;
LGG	cis	rs1318772	0.800	rs67881502	chr5:112924906	T/C	cg12552261	chr5:112820674	MCC	0.69	7.31	0.32	1.18e-12	F-cell distribution;
LGG	cis	rs4409675	0.576	rs7356	chr1:28218100	T/C	cg23691781	chr1:28212827	C1orf38	0.43	11.63	0.48	1.28e-27	Corneal astigmatism;
LGG	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg12310025	chr6:25882481	NA	-0.65	-11.97	-0.49	5.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.53	0.47	3.3699999999999996e-27	Obesity-related traits;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg14668632	chr7:2872130	GNA12	-0.37	-7.45	-0.33	4.67e-13	Height;
LGG	trans	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.71	11.11	0.46	1.45e-25	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg19357499	chr8:144660631	NAPRT1	-0.77	-8.69	-0.37	6.41e-17	Attention deficit hyperactivity disorder;
LGG	trans	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg02002194	chr4:3960332	NA	-0.41	-7.84	-0.34	3.16e-14	Neuroticism;
LGG	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.67e-12	Menopause (age at onset);
LGG	cis	rs939658	0.875	rs2177057	chr15:79441441	G/C	cg17916960	chr15:79447300	NA	-0.66	-12.85	-0.51	1.56e-32	Refractive error;
LGG	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs6964587	0.839	rs10236107	chr7:91485461	G/A	cg17063962	chr7:91808500	NA	-0.4	-6.89	-0.3	1.88e-11	Breast cancer;
LGG	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg09165964	chr15:75287851	SCAMP5	1.08	23.71	0.74	5.9e-82	Blood trace element (Zn levels);
LGG	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-13.3	-0.53	2.14e-34	Cognitive function;
LGG	cis	rs9517320	0.534	rs4771306	chr13:99143661	T/C	cg03701759	chr13:99174930	STK24	-0.36	-7.05	-0.31	6.43e-12	Longevity;
LGG	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.73	11.24	0.46	4.34e-26	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00149659	chr3:10157352	C3orf10	0.83	10.68	0.44	5.84e-24	Alzheimer's disease;
LGG	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.81	0.34	3.8e-14	Retinal vascular caliber;
LGG	cis	rs477692	0.569	rs10764883	chr10:131307817	A/G	cg05714579	chr10:131428358	MGMT	0.5	9.66	0.41	3.18e-20	Response to temozolomide;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.22	-0.32	2.16e-12	Menopause (age at onset);
LGG	cis	rs9902453	0.967	rs60176674	chr17:28479854	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.82e-34	Coffee consumption (cups per day);
LGG	cis	rs4731207	0.596	rs1531717	chr7:124644690	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg13736514	chr6:26305472	NA	-0.46	-9.7	-0.41	2.32e-20	Educational attainment;
LGG	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg03563238	chr19:33554763	RHPN2	-0.44	-9.96	-0.42	2.68e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg00149659	chr3:10157352	C3orf10	1.18	13.62	0.53	8.8e-36	Alzheimer's disease;
LGG	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg02023728	chr11:77925099	USP35	0.4	6.95	0.31	1.28e-11	Alzheimer's disease (survival time);
LGG	trans	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg27411982	chr8:10470053	RP1L1	0.42	7.34	0.32	9.73e-13	Mood instability;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.52	-0.5	3.56e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs4942242	0.659	rs1105586	chr13:44232633	C/T	cg19169023	chr15:41853346	TYRO3	0.44	8.39	0.36	6.12e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg00142150	chr22:38071001	LGALS1	0.68	13.09	0.52	1.54e-33	Fat distribution (HIV);
LGG	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg20026190	chr17:76395443	PGS1	0.58	10.13	0.43	6.36e-22	HDL cholesterol levels;
LGG	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.01e-13	Schizophrenia;
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.18	-0.32	2.87e-12	Lung cancer;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.35	-0.32	9.17e-13	Life satisfaction;
LGG	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg17809284	chr5:56205270	C5orf35	-0.48	-8.76	-0.38	3.58e-17	Coronary artery disease;
LGG	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.69	-0.3	6.27e-11	Bone mineral density;
LGG	trans	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg00938859	chr5:1591904	SDHAP3	0.89	12.68	0.51	7.77e-32	Breast cancer;
LGG	cis	rs4538187	1.000	rs13431781	chr2:64086372	A/G	cg19915305	chr2:64069682	UGP2	0.68	15.65	0.59	1.25e-44	Systolic blood pressure;
LGG	cis	rs62064224	0.666	rs7224683	chr17:30642262	A/G	cg18200150	chr17:30822561	MYO1D	0.49	9.09	0.39	2.96e-18	Schizophrenia;
LGG	cis	rs60843830	0.508	rs300750	chr2:208794	T/G	cg21211680	chr2:198530	NA	0.39	6.75	0.3	4.52e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.41	-7.3	-0.32	1.26e-12	Schizophrenia;
LGG	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg21775007	chr8:11205619	TDH	-0.78	-13.31	-0.53	1.87e-34	Retinal vascular caliber;
LGG	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.47e-20	Aortic root size;
LGG	cis	rs9894429	1.000	rs7222241	chr17:79574714	C/G	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.46	0.4	1.53e-19	Bipolar disorder;
LGG	cis	rs11214589	0.651	rs12360992	chr11:113262900	A/C	cg14159747	chr11:113255604	NA	0.3	8.23	0.36	1.9e-15	Neuroticism;
LGG	cis	rs2439831	0.681	rs526450	chr15:43599325	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.89	-0.34	2.19e-14	Lung cancer in ever smokers;
LGG	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg22875332	chr1:76189707	ACADM	0.58	8.51	0.37	2.43e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-12.17	-0.49	9.22e-30	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22496380	chr5:211416	CCDC127	-1.22	-17.12	-0.62	3.01e-51	Breast cancer;
LGG	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg16662043	chr16:48846231	NA	-0.36	-7.12	-0.31	4.23e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7572733	0.840	rs2341510	chr2:198558679	T/C	cg00792783	chr2:198669748	PLCL1	-0.45	-7.52	-0.33	2.93e-13	Dermatomyositis;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg19774624	chr17:42201019	HDAC5	-0.95	-20.43	-0.69	1.27e-66	Total body bone mineral density;
LGG	cis	rs7827545	0.545	rs6578228	chr8:135562422	G/A	cg17885191	chr8:135476712	NA	0.6	8.91	0.38	1.19e-17	Hypertension (SNP x SNP interaction);
LGG	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03517284	chr6:25882590	NA	0.49	8.85	0.38	1.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg27572855	chr1:25598939	RHD	-0.48	-10.61	-0.44	1.12e-23	Erythrocyte sedimentation rate;
LGG	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg25823085	chr7:87105416	ABCB4	0.3	7.45	0.33	4.55e-13	Gallbladder cancer;
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.99	-0.55	2.48e-37	Alzheimer's disease;
LGG	cis	rs6684428	1.000	rs6693526	chr1:56349764	G/A	cg11651538	chr1:56320950	NA	-0.72	-12.77	-0.51	3.43e-32	Airflow obstruction;
LGG	cis	rs9879311	0.966	rs4684684	chr3:10411344	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	7.08	0.31	5.23e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg26597838	chr10:835615	NA	0.53	6.87	0.3	2.05e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg01448562	chr3:133502909	NA	-0.52	-8.7	-0.37	5.9e-17	Iron status biomarkers;
LGG	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg12856521	chr11:46389249	DGKZ	0.54	9.72	0.41	1.87e-20	Leprosy;
LGG	cis	rs4679121	0.642	rs55708952	chr3:126188912	A/G	cg05485589	chr3:126194908	ZXDC	-0.91	-6.71	-0.3	5.53e-11	Pursuit maintenance gain;
LGG	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg08824895	chr13:115047677	UPF3A	0.43	7.29	0.32	1.37e-12	Schizophrenia;
LGG	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-8.0	-0.35	9.77e-15	Mean corpuscular volume;
LGG	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg00262263	chr6:170184901	NA	0.41	7.04	0.31	6.76e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2304069	0.913	rs9324637	chr5:149390947	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.51	0.53	2.74e-35	HIV-1 control;
LGG	cis	rs975722	0.516	rs10255917	chr7:117020596	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	8.56	0.37	1.73e-16	Coronary artery disease;
LGG	cis	rs2013441	0.835	rs2526491	chr17:20097462	A/G	cg13482628	chr17:19912719	NA	-0.41	-6.99	-0.31	9.41e-12	Obesity-related traits;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25072359	chr17:41440525	NA	-0.51	-10.13	-0.43	6.61e-22	Menopause (age at onset);
LGG	cis	rs943466	0.911	rs72880511	chr6:33729820	G/A	cg07519485	chr6:33762594	MLN	0.55	10.86	0.45	1.21e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs10193935	0.901	rs222471	chr2:42638057	C/T	cg27598129	chr2:42591480	NA	0.63	9.41	0.4	2.36e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg06916706	chr16:4465613	CORO7	0.81	13.79	0.54	1.65e-36	Schizophrenia;
LGG	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg08508325	chr11:3079039	CARS	-0.47	-10.08	-0.42	1.01e-21	Longevity;
LGG	cis	rs1003719	0.788	rs2006941	chr21:38467616	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	trans	rs12517041	1.000	rs16892385	chr5:23306170	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs1461503	0.780	rs75981430	chr11:122842469	A/C	cg27398637	chr11:122830231	C11orf63	-0.72	-14.2	-0.55	2.93e-38	Menarche (age at onset);
LGG	cis	rs16912285	0.688	rs12276587	chr11:24280656	C/G	ch.11.24196551F	chr11:24239977	NA	-0.89	-13.22	-0.52	4.44e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2377058	0.882	rs11646741	chr16:89730084	G/C	cg03605463	chr16:89740564	NA	-0.42	-6.68	-0.3	6.96e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03264133	chr6:25882463	NA	0.71	13.74	0.54	2.85e-36	Blood metabolite levels;
LGG	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.87	-0.38	1.65e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.35e-11	Menopause (age at onset);
LGG	cis	rs2115630	0.641	rs11073613	chr15:85185893	G/A	cg12501888	chr15:85177176	SCAND2	-0.5	-7.99	-0.35	1.06e-14	P wave terminal force;
LGG	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg14004847	chr7:1930337	MAD1L1	0.49	7.74	0.34	6.26e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	9.55	0.41	7.58e-20	Height;
LGG	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg02503808	chr4:7069936	GRPEL1	-0.99	-8.6	-0.37	1.27e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4538187	1.000	rs34122334	chr2:64169309	A/G	cg02541582	chr2:64069798	UGP2	-0.62	-14.46	-0.56	2.29e-39	Systolic blood pressure;
LGG	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.87	-0.45	1.17e-24	Migraine;Coronary artery disease;
LGG	trans	rs7395662	0.857	rs116589099	chr11:48786205	A/T	cg15704280	chr7:45808275	SEPT13	0.49	7.99	0.35	1.05e-14	HDL cholesterol;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg02018176	chr4:1364513	KIAA1530	0.45	10.85	0.45	1.34e-24	Longevity;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg16405210	chr4:1374714	KIAA1530	0.51	8.53	0.37	2.12e-16	Obesity-related traits;
LGG	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg26818010	chr10:134567672	INPP5A	-0.6	-9.43	-0.4	2.01e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7011049	0.778	rs12375363	chr8:53868768	A/C	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg12219531	chr12:120966889	COQ5	0.66	10.97	0.45	4.87e-25	High light scatter reticulocyte count;
LGG	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg24623649	chr8:11872141	NA	-0.31	-7.36	-0.32	8.29e-13	Neuroticism;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.01e-42	Menopause (age at onset);
LGG	cis	rs986417	1.000	rs1254323	chr14:60908378	G/A	cg27398547	chr14:60952738	C14orf39	-0.66	-6.66	-0.3	7.72e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg05169099	chr5:481640	SLC9A3	0.46	6.72	0.3	5.3e-11	Fat distribution (HIV);
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg16606324	chr3:10149918	C3orf24	0.53	6.97	0.31	1.13e-11	Alzheimer's disease;
LGG	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg08344181	chr3:125677491	NA	-0.64	-7.23	-0.32	2.05e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs755249	0.508	rs12023553	chr1:39671492	C/A	cg18385671	chr1:39797026	MACF1	-0.47	-9.58	-0.41	5.73e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs372883	0.967	rs1153287	chr21:30685611	C/T	cg24692254	chr21:30365293	RNF160	-0.44	-7.71	-0.34	7.75e-14	Pancreatic cancer;
LGG	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg15596359	chr8:11213517	TDH	-0.35	-7.05	-0.31	6.44e-12	Retinal vascular caliber;
LGG	cis	rs1865760	0.566	rs10807006	chr6:26048752	C/A	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs10876993	0.890	rs4760165	chr12:58063801	C/T	cg18357645	chr12:58087776	OS9	0.67	12.27	0.5	3.74e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7408868	0.908	rs45591935	chr19:15277006	T/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg21605333	chr4:119757512	SEC24D	1.28	12.4	0.5	1.12e-30	Cannabis dependence symptom count;
LGG	cis	rs9902453	0.765	rs2729447	chr17:28099002	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg00012203	chr2:219082015	ARPC2	0.84	17.19	0.62	1.46e-51	Colorectal cancer;
LGG	cis	rs7523273	0.927	rs2796275	chr1:207950490	C/T	cg22525895	chr1:207977042	MIR29B2	0.61	11.29	0.46	2.76e-26	Schizophrenia;
LGG	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg16507663	chr6:150244633	RAET1G	0.48	8.98	0.39	6.78e-18	Lung cancer;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg16507663	chr6:150244633	RAET1G	0.43	8.13	0.35	3.92e-15	Lung cancer;
LGG	cis	rs1018697	1.000	rs7086400	chr10:104562097	G/A	cg04362960	chr10:104952993	NT5C2	0.49	9.0	0.39	5.81e-18	Colorectal adenoma (advanced);
LGG	cis	rs4950322	1.000	rs61230354	chr1:146869891	T/A	cg22381352	chr1:146742008	CHD1L	-0.44	-7.0	-0.31	9.06e-12	Protein quantitative trait loci;
LGG	cis	rs17767392	0.746	rs72728403	chr14:71733375	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.04	-0.35	7.67e-15	Mitral valve prolapse;
LGG	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg07615347	chr10:60278583	BICC1	0.61	16.56	0.61	1.07e-48	Refractive error;
LGG	cis	rs9818758	0.607	rs56004653	chr3:49072228	T/C	cg00383909	chr3:49044727	WDR6	1.11	11.77	0.48	3.8e-28	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11098499	0.863	rs12508173	chr4:120318526	T/C	cg09307838	chr4:120376055	NA	0.8	13.13	0.52	1.11e-33	Corneal astigmatism;
LGG	trans	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg25214090	chr10:38739885	LOC399744	-0.68	-11.56	-0.47	2.51e-27	Corneal astigmatism;
LGG	trans	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg06521331	chr12:34319734	NA	0.43	7.32	0.32	1.09e-12	Morning vs. evening chronotype;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg26944981	chr17:30469748	RHOT1	0.38	6.76	0.3	4.17e-11	Coronary artery disease;
LGG	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg18200150	chr17:30822561	MYO1D	-0.5	-9.58	-0.41	5.85e-20	Schizophrenia;
LGG	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg02151108	chr14:50098012	C14orf104	-0.47	-10.13	-0.43	6.39e-22	Carotid intima media thickness;
LGG	cis	rs5758511	0.514	rs2899354	chr22:42554409	G/T	cg15128208	chr22:42549153	NA	0.75	11.38	0.47	1.22e-26	Birth weight;
LGG	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg04863758	chr4:1303710	MAEA	0.42	7.25	0.32	1.81e-12	Obesity-related traits;
LGG	cis	rs4891159	0.790	rs4891018	chr18:74127082	A/T	cg24786174	chr18:74118243	ZNF516	-0.6	-14.17	-0.55	3.98e-38	Longevity;
LGG	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg00012203	chr2:219082015	ARPC2	0.52	8.97	0.38	7.64e-18	Ulcerative colitis;
LGG	cis	rs11920090	0.932	rs2292622	chr3:170723664	A/G	cg09710316	chr3:170744871	SLC2A2	0.61	8.61	0.37	1.18e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7973719	0.865	rs1057225	chr12:7363574	C/G	cg07052231	chr12:7363540	PEX5	0.4	7.05	0.31	6.69e-12	IgG glycosylation;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg15242686	chr22:24348715	GSTTP1	0.39	7.4	0.33	6.46e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg11062466	chr8:58055876	NA	0.6	9.77	0.41	1.27e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg12633918	chr20:23549525	CST9L	0.33	6.75	0.3	4.54e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg09537434	chr19:41945824	ATP5SL	-0.9	-23.0	-0.73	1.29e-78	Height;
LGG	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.42	0.33	5.59e-13	Total cholesterol levels;
LGG	cis	rs6500395	1.000	rs1909765	chr16:48597358	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.45	0.4	1.67e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4148087	0.929	rs4148085	chr21:43620277	T/A	cg08841829	chr21:43638893	ABCG1	-0.61	-8.4	-0.36	5.56e-16	Eating disorder in bipolar disorder;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.57e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9796	0.870	rs4923890	chr15:41258990	T/C	cg18705301	chr15:41695430	NDUFAF1	0.49	8.61	0.37	1.17e-16	Menopause (age at onset);
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.83	-0.38	2.15e-17	Neuroticism;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.57	0.41	6.31e-20	Obesity-related traits;
LGG	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.86	-0.64	1.18e-54	Systemic lupus erythematosus;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.1	-0.46	1.55e-25	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.02	-0.31	7.7e-12	Bipolar disorder;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05665937	chr4:1216051	CTBP1	0.5	9.28	0.4	6.75e-19	Obesity-related traits;
LGG	cis	rs7582720	1.000	rs72936852	chr2:203775475	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.03	-0.49	3.31e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs9818758	0.607	rs10049462	chr3:49309684	C/T	cg00383909	chr3:49044727	WDR6	1.01	12.54	0.5	3.02e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07863994	chr22:50964211	TYMP;SCO2	0.45	6.76	0.3	4.13e-11	Gut microbiome composition (summer);
LGG	trans	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg07817883	chr1:32538562	TMEM39B	-0.7	-9.83	-0.42	7.94e-21	Monocyte percentage of white cells;
LGG	cis	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.78	-0.64	2.79e-54	Breast cancer;
LGG	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.81	-0.78	2.93e-96	Schizophrenia;
LGG	cis	rs7586879	0.639	rs4077678	chr2:25122840	C/G	cg04586622	chr2:25135609	ADCY3	0.46	12.71	0.51	6.04e-32	Body mass index;
LGG	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg00204512	chr16:28754710	NA	0.26	7.32	0.32	1.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg03929089	chr4:120376271	NA	-0.92	-17.99	-0.64	3.03e-55	Height;
LGG	cis	rs2013441	1.000	rs3850783	chr17:20184501	C/T	cg13482628	chr17:19912719	NA	0.5	9.34	0.4	4.21e-19	Obesity-related traits;
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.87e-12	Prudent dietary pattern;
LGG	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.39	0.82	2.53e-112	Cognitive function;
LGG	cis	rs2153535	0.580	rs7761937	chr6:8459434	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.17	0.49	9.73e-30	Motion sickness;
LGG	cis	rs4901869	0.966	rs12148052	chr14:59338970	C/T	cg02291164	chr14:59296302	NA	0.27	6.79	0.3	3.37e-11	Panic disorder;
LGG	cis	rs8067545	0.750	rs9896411	chr17:19987610	A/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.8	-0.3	3.2e-11	Schizophrenia;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.77	-0.48	3.79e-28	Tonsillectomy;
LGG	cis	rs7296418	0.630	rs11608305	chr12:123791165	C/G	cg00376283	chr12:123451042	ABCB9	0.62	11.5	0.47	4.25e-27	Platelet count;
LGG	cis	rs12135191	0.771	rs7540548	chr1:236498406	G/A	cg21399712	chr1:236511386	NA	-0.41	-7.75	-0.34	5.77e-14	Urate levels (BMI interaction);
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.35	-0.32	8.93e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1816752	0.819	rs7985478	chr13:24991273	C/T	cg02811702	chr13:24901961	NA	0.4	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs7678567	chr4:99057346	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.46	0.37	3.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9314323	0.558	rs58153210	chr8:26271120	C/T	cg11498726	chr8:26250323	BNIP3L	-0.42	-9.03	-0.39	4.62e-18	Red cell distribution width;
LGG	cis	rs7044106	0.690	rs10739569	chr9:123361027	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.2	0.32	2.47e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.47	-0.37	3.26e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg23131131	chr22:24373011	LOC391322	0.5	8.24	0.36	1.76e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg03929089	chr4:120376271	NA	0.84	8.71	0.38	5.6e-17	Myopia (pathological);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06476805	chr3:123304425	PTPLB	0.42	6.99	0.31	9.55e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg23029597	chr12:123009494	RSRC2	-0.93	-17.22	-0.62	9.87e-52	Body mass index;
LGG	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.99	-0.39	6.21e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg07460842	chr6:66804631	NA	1.0	19.91	0.68	3.61e-64	Exhaled nitric oxide output;
LGG	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg09137382	chr11:130731461	NA	0.4	7.41	0.33	6.1e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.68e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12579753	0.719	rs4418884	chr12:82277006	C/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-8.01	-0.35	9.31e-15	Resting heart rate;
LGG	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg00071950	chr4:10020882	SLC2A9	0.38	7.79	0.34	4.39e-14	Bone mineral density;
LGG	cis	rs7586673	0.964	rs34444368	chr2:161954217	G/A	cg22496339	chr2:162101262	NA	-0.34	-6.7	-0.3	6.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9503598	0.636	rs6596974	chr6:3465833	C/T	cg00476032	chr6:3446245	SLC22A23	0.54	10.99	0.45	4.06e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9309473	0.607	rs12478346	chr2:73584360	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-9.05	-0.39	3.97e-18	Metabolite levels;
LGG	cis	rs1185460	0.565	rs2276060	chr11:118919132	G/A	cg23280166	chr11:118938394	VPS11	-0.46	-7.77	-0.34	5.11e-14	Coronary artery disease;
LGG	cis	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg24110177	chr3:50126178	RBM5	0.45	7.49	0.33	3.53e-13	Body mass index;
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.63	-0.37	9.66e-17	Triglycerides;
LGG	trans	rs208520	0.874	rs208491	chr6:66928459	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.46	-0.58	8.96e-44	Exhaled nitric oxide output;
LGG	trans	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg06521331	chr12:34319734	NA	-0.51	-9.48	-0.4	1.37e-19	Bladder cancer;
LGG	cis	rs4481887	0.676	rs946764	chr1:248522033	A/C	cg13385794	chr1:248469461	NA	0.44	8.04	0.35	7.84e-15	Common traits (Other);
LGG	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg13939156	chr17:80058883	NA	-0.4	-7.19	-0.32	2.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02132458	chr4:57333267	SRP72	0.41	7.26	0.32	1.68e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg26677194	chr12:130822605	PIWIL1	0.56	10.0	0.42	1.87e-21	Menopause (age at onset);
LGG	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg04490037	chr7:50633773	DDC	0.33	7.36	0.32	8.73e-13	Systemic sclerosis;
LGG	cis	rs12493885	0.725	rs61791493	chr3:153743573	A/G	cg12800244	chr3:153838788	SGEF	-0.78	-8.78	-0.38	3.27e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.13e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg03452623	chr4:187889614	NA	-1.04	-29.02	-0.8	3e-106	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.45e-22	Menopause (age at onset);
LGG	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.31	0.36	1.08e-15	Mood instability;
LGG	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg04851639	chr8:1020857	NA	-0.37	-8.06	-0.35	6.75e-15	Schizophrenia;
LGG	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg01028140	chr2:1542097	TPO	-0.47	-8.65	-0.37	8.81e-17	IgG glycosylation;
LGG	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg15212455	chr7:39170539	POU6F2	0.37	8.17	0.36	2.95e-15	IgG glycosylation;
LGG	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.68	13.04	0.52	2.47e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs7312933	0.585	rs7969814	chr12:42669657	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.7	0.34	8.54e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7747724	0.715	rs9350280	chr6:20759275	C/T	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.44	-0.4	1.88e-19	Bladder cancer;
LGG	cis	rs6964587	0.967	rs55801687	chr7:91762629	C/A	cg17063962	chr7:91808500	NA	0.5	9.13	0.39	2.16e-18	Breast cancer;
LGG	cis	rs6735179	0.565	rs733376	chr2:1751958	C/A	cg08534653	chr2:1747700	PXDN	0.5	7.42	0.33	5.46e-13	Response to antipsychotic treatment;
LGG	cis	rs1062746	0.738	rs2303764	chr16:87377455	C/G	cg02258303	chr16:87377426	FBXO31	0.61	12.12	0.49	1.52e-29	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg24189917	chr7:1970923	MAD1L1	-0.52	-7.57	-0.33	1.97e-13	Bipolar disorder;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.47	0.37	3.34e-16	Alzheimer's disease;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg15242686	chr22:24348715	GSTTP1	0.52	9.65	0.41	3.39e-20	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs7192750	0.563	rs12921084	chr16:71880965	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.59	0.44	1.27e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.16	-0.35	3.14e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.864	rs4955410	chr3:49181218	A/G	cg06212747	chr3:49208901	KLHDC8B	0.73	12.45	0.5	6.75e-31	Parkinson's disease;
LGG	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.43	0.5	8.14e-31	Motion sickness;
LGG	cis	rs910187	0.678	rs6018330	chr20:45813216	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-8.95	-0.38	8.36e-18	Migraine;
LGG	cis	rs1318772	0.623	rs13160538	chr5:112965930	C/T	cg12552261	chr5:112820674	MCC	0.6	6.71	0.3	5.74e-11	F-cell distribution;
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.7	-0.41	2.31e-20	Platelet count;
LGG	cis	rs9487094	0.670	rs4490694	chr6:109892692	A/T	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs919433	0.588	rs11690163	chr2:198527507	A/T	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9534288	0.797	rs9526132	chr13:46609364	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs4561483	0.514	rs33639	chr16:11989499	A/C	cg08843971	chr16:11963173	GSPT1	-0.64	-16.34	-0.6	1.06e-47	Testicular germ cell tumor;
LGG	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg00343986	chr7:65444356	GUSB	-0.42	-7.28	-0.32	1.43e-12	Aortic root size;
LGG	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs11696845	0.787	rs13043441	chr20:43364308	A/G	cg25301532	chr20:43378953	KCNK15	0.44	10.45	0.44	4.39e-23	Obesity-related traits;
LGG	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg08601574	chr20:25228251	PYGB	0.38	7.92	0.35	1.73e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg03929089	chr4:120376271	NA	0.85	13.27	0.52	2.76e-34	Height;
LGG	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs6594499	0.872	rs10050834	chr5:110427328	C/T	cg04022379	chr5:110408740	TSLP	0.38	6.98	0.31	1.06e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.46	0.33	4.39e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg21948465	chr5:131705150	SLC22A5	0.69	7.65	0.34	1.17e-13	Rheumatoid arthritis;
LGG	cis	rs72720396	0.789	rs12048450	chr1:91199660	G/A	cg13456504	chr1:91191583	NA	0.52	8.23	0.36	1.97e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6882076	1.000	rs12517431	chr5:156392248	C/T	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.42	-0.47	8.85e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs13082711	0.501	rs428239	chr3:27555566	G/C	cg02860705	chr3:27208620	NA	-0.57	-9.81	-0.41	9.19e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04008888	chr11:68622739	NA	-0.57	-11.98	-0.49	5.31e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7301826	0.651	rs10773824	chr12:131298851	G/A	cg11011512	chr12:131303247	STX2	0.41	8.87	0.38	1.61e-17	Plasma plasminogen activator levels;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg25172604	chr17:41446521	NA	0.31	7.23	0.32	2.03e-12	Menopause (age at onset);
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg00405596	chr8:11794950	NA	0.42	7.0	0.31	8.79e-12	Mood instability;
LGG	trans	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg07211511	chr3:129823064	LOC729375	-0.61	-8.33	-0.36	9.34e-16	Blood pressure (smoking interaction);
LGG	trans	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg06521331	chr12:34319734	NA	0.42	7.57	0.33	2.06e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	0.656	rs57137919	chr21:43639018	G/A	cg10192877	chr21:43641690	ABCG1	-0.4	-7.04	-0.31	7.1e-12	Eating disorder in bipolar disorder;
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	cis	rs7289126	0.966	rs2284072	chr22:38633666	A/C	cg25457927	chr22:38595422	NA	-0.32	-7.84	-0.34	3.03e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs950776	0.518	rs12903129	chr15:78819606	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.75	0.3	4.55e-11	Sudden cardiac arrest;
LGG	cis	rs2777491	0.789	rs316617	chr15:41795900	C/T	cg18705301	chr15:41695430	NDUFAF1	0.74	13.91	0.54	5.37e-37	Ulcerative colitis;
LGG	cis	rs6988636	1.000	rs16898097	chr8:124195034	G/C	cg23067535	chr8:124195133	FAM83A	-0.6	-7.17	-0.32	2.95e-12	Urinary uromodulin levels;
LGG	cis	rs9457247	0.515	rs1951459	chr6:167402536	G/A	cg18261144	chr6:167370276	RNASET2	-0.37	-7.61	-0.33	1.5700000000000001e-13	Crohn's disease;
LGG	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg20283391	chr11:68216788	NA	-0.51	-8.36	-0.36	7.29e-16	Total body bone mineral density;
LGG	cis	rs17376456	0.825	rs10079708	chr5:93261796	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs9863	0.861	rs4930725	chr12:124428162	T/A	cg13487667	chr12:124434373	CCDC92	-0.36	-7.27	-0.32	1.59e-12	White blood cell count;
LGG	cis	rs78456975	0.943	rs13385274	chr2:1576791	A/T	cg01028140	chr2:1542097	TPO	-0.46	-7.38	-0.32	7.63e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05665937	chr4:1216051	CTBP1	0.59	10.97	0.45	4.75e-25	Obesity-related traits;
LGG	cis	rs806321	0.548	rs1269268	chr13:50907290	T/A	cg10393508	chr13:50950265	NA	-0.35	-8.85	-0.38	1.92e-17	Multiple sclerosis;
LGG	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg00898013	chr13:113819073	PROZ	0.49	9.93	0.42	3.53e-21	Platelet distribution width;
LGG	trans	rs10838798	0.517	rs1967210	chr11:48096692	G/T	cg03929089	chr4:120376271	NA	-0.72	-8.87	-0.38	1.63e-17	Height;
LGG	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg03929089	chr4:120376271	NA	0.71	9.73	0.41	1.77e-20	Axial length;
LGG	cis	rs10876993	0.890	rs1689584	chr12:58081478	G/A	cg18357645	chr12:58087776	OS9	0.72	13.2	0.52	5.41e-34	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9487094	0.689	rs9487066	chr6:109668910	G/A	cg01125227	chr6:109776195	MICAL1	0.45	8.0	0.35	1e-14	Height;
LGG	cis	rs7617773	0.780	rs13066044	chr3:48377276	C/T	cg11946769	chr3:48343235	NME6	0.71	11.88	0.48	1.42e-28	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.61	-0.53	9.92e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg02175503	chr12:58329896	NA	-0.49	-7.84	-0.34	3.13e-14	Multiple sclerosis;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg00142150	chr22:38071001	LGALS1	0.92	19.63	0.67	6.96e-63	Fat distribution (HIV);
LGG	cis	rs3767633	0.925	rs1394070	chr1:161814020	T/G	cg09175582	chr1:161736000	ATF6	0.74	9.04	0.39	4.22e-18	IgG glycosylation;
LGG	cis	rs11096990	0.892	rs2381349	chr4:39212010	C/T	cg24403649	chr4:39172243	NA	-0.44	-7.42	-0.33	5.73e-13	Cognitive function;
LGG	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg08621203	chr6:150244597	RAET1G	0.39	6.65	0.3	8.05e-11	Lung cancer;
LGG	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg11757124	chr7:157526947	PTPRN2	-0.52	-9.42	-0.4	2.15e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	0.963	rs7125110	chr11:48545507	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	5.92e-13	HDL cholesterol;
LGG	cis	rs7927771	0.965	rs1064608	chr11:47640429	G/C	cg20307385	chr11:47447363	PSMC3	-0.48	-8.65	-0.37	8.32e-17	Subjective well-being;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg21724239	chr8:58056113	NA	0.63	9.11	0.39	2.41e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.46	0.56	2.15e-39	Tonsillectomy;
LGG	cis	rs2073300	1.000	rs115730610	chr20:23442621	G/A	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2073499	0.935	rs57838764	chr3:50374568	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.61	7.03	0.31	7.37e-12	Schizophrenia;
LGG	cis	rs7394190	0.935	rs6480708	chr10:75420114	C/A	cg07699608	chr10:75541558	CHCHD1	0.52	7.5	0.33	3.36e-13	Incident atrial fibrillation;
LGG	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg11693508	chr17:37793320	STARD3	0.72	10.38	0.43	8.06e-23	Bipolar disorder;
LGG	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg20891283	chr12:69753455	YEATS4	0.8	13.17	0.52	6.96e-34	Response to diuretic therapy;
LGG	cis	rs9354352	0.967	rs6455062	chr6:66694131	T/A	cg07460842	chr6:66804631	NA	0.74	13.98	0.54	2.77e-37	Initial pursuit acceleration in psychotic disorders;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23195398	chr19:54704606	RPS9	0.41	6.79	0.3	3.43e-11	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.76	0.3	4.16e-11	Schizophrenia;
LGG	cis	rs6754311	0.773	rs188680	chr2:136630989	A/G	cg07169764	chr2:136633963	MCM6	-0.76	-12.92	-0.51	8.31e-33	Mosquito bite size;
LGG	cis	rs9914544	0.544	rs4244595	chr17:18677329	C/T	cg26378065	chr17:18585709	ZNF286B	0.37	7.02	0.31	7.88e-12	Educational attainment (years of education);
LGG	cis	rs8032158	0.502	rs2136385	chr15:56235245	C/A	cg02198044	chr15:56286336	NEDD4	-0.43	-7.04	-0.31	7.14e-12	Keloid;
LGG	cis	rs4731207	0.596	rs10081375	chr7:124573175	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.86	-0.3	2.16e-11	Cutaneous malignant melanoma;
LGG	cis	rs9487051	0.676	rs11964178	chr6:109562035	A/G	cg21918786	chr6:109611834	NA	-0.38	-7.09	-0.31	5.19e-12	Reticulocyte fraction of red cells;
LGG	cis	rs2888674	1.000	rs717658	chr7:150503637	A/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.26	7.07	0.31	5.61e-12	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs1348850	0.914	rs4341974	chr2:178324879	A/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.6	-0.37	1.27e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg11062466	chr8:58055876	NA	0.56	8.9	0.38	1.27e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7737355	0.898	rs3775998	chr5:130979332	A/G	cg06307176	chr5:131281290	NA	0.57	9.36	0.4	3.5e-19	Life satisfaction;
LGG	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-11.72	-0.48	5.68e-28	Longevity;Endometriosis;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg24503407	chr1:205819492	PM20D1	0.46	7.76	0.34	5.35e-14	Prostate-specific antigen levels;
LGG	cis	rs4819052	0.851	rs7275874	chr21:46671223	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.77	-0.41	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.12	0.43	6.87e-22	Mean corpuscular volume;
LGG	cis	rs9314323	0.767	rs1865305	chr8:26233325	G/A	cg11498726	chr8:26250323	BNIP3L	-0.53	-11.01	-0.46	3.26e-25	Red cell distribution width;
LGG	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg22467129	chr15:76604101	ETFA	0.43	7.26	0.32	1.6e-12	Blood metabolite levels;
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg12813108	chr7:99719912	CNPY4	-0.71	-10.83	-0.45	1.57e-24	Lung function (FEV1/FVC);
LGG	cis	rs3806843	0.576	rs251373	chr5:140252615	C/T	cg19875535	chr5:140030758	IK	-0.38	-7.5	-0.33	3.39e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2964802	0.505	rs13159419	chr5:10824302	C/A	cg14521931	chr5:10832172	NA	-0.74	-16.15	-0.6	7.3e-47	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08677398	chr8:58056175	NA	0.48	7.78	0.34	4.83e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg07777115	chr5:623756	CEP72	-0.62	-7.76	-0.34	5.58e-14	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg08885076	chr2:99613938	TSGA10	0.43	9.13	0.39	2.16e-18	Chronic sinus infection;
LGG	cis	rs7727544	0.735	rs274558	chr5:131721174	A/G	cg24060327	chr5:131705240	SLC22A5	0.49	8.51	0.37	2.46e-16	Blood metabolite levels;
LGG	cis	rs12586317	0.547	rs115019197	chr14:35503764	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.78	-0.34	4.7e-14	Psoriasis;
LGG	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg25486957	chr4:152246857	NA	-0.5	-8.29	-0.36	1.19e-15	Intelligence (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09387687	chr3:110791400	PVRL3	0.37	6.7	0.3	6.22e-11	Obesity-related traits;
LGG	cis	rs4843747	0.671	rs4075598	chr16:88107512	T/C	cg09044154	chr16:88155775	NA	-0.47	-7.03	-0.31	7.35e-12	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1568889	0.838	rs4572130	chr11:28371794	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	18.68	0.66	1.95e-58	Bipolar disorder;
LGG	cis	rs26232	0.583	rs26430	chr5:102365932	G/A	cg23492399	chr5:102201601	PAM	0.46	6.91	0.31	1.6e-11	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg16606324	chr3:10149918	C3orf24	0.51	6.82	0.3	2.89e-11	Alzheimer's disease;
LGG	trans	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg07211511	chr3:129823064	LOC729375	-1.02	-14.78	-0.57	9.18e-41	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-8.37	-0.36	6.66e-16	Lung cancer;
LGG	cis	rs6743226	0.603	rs1106523	chr2:242251539	G/T	cg10021735	chr2:242295487	FARP2	0.4	7.08	0.31	5.21e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7927592	0.913	rs11228287	chr11:68349754	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs698813	0.572	rs12613771	chr2:44490660	C/A	cg00619915	chr2:44497795	NA	-0.6	-8.82	-0.38	2.41e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs7666738	0.753	rs2865957	chr4:99040725	G/A	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs250677	0.687	rs40522	chr5:148442295	G/A	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.67e-12	Breast cancer;
LGG	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg10523679	chr1:76189770	ACADM	0.73	11.2	0.46	6.4e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12586317	0.620	rs12588810	chr14:35554484	C/T	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.65	-0.33	1.19e-13	Psoriasis;
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14159672	chr1:205819179	PM20D1	0.52	9.58	0.41	6.15e-20	Menarche (age at onset);
LGG	cis	rs6840360	0.571	rs1978955	chr4:152509509	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-6.93	-0.31	1.43e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-9.0	-0.39	5.68e-18	Bladder cancer;
LGG	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.9	0.34	2.1e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg13939156	chr17:80058883	NA	0.41	7.32	0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg07414643	chr4:187882934	NA	-0.54	-11.06	-0.46	2.24e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs897984	0.542	rs59061704	chr16:31062704	G/C	cg00531865	chr16:30841666	NA	-0.46	-9.22	-0.39	1.04e-18	Dementia with Lewy bodies;
LGG	cis	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg12395012	chr8:11607386	GATA4	0.42	7.68	0.34	9.72e-14	Monocyte count;
LGG	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg00012203	chr2:219082015	ARPC2	-0.66	-11.5	-0.47	4.24e-27	Colorectal cancer;
LGG	trans	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.56	-0.41	7.08e-20	Bladder cancer;
LGG	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg07061783	chr6:25882402	NA	0.44	7.65	0.33	1.18e-13	Blood metabolite levels;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg05793240	chr7:2802953	GNA12	0.29	7.16	0.32	3.13e-12	Height;
LGG	trans	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.91	-0.35	1.94e-14	Resting heart rate;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08677398	chr8:58056175	NA	0.6	9.4	0.4	2.48e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs12458462	0.851	rs2169249	chr18:77489649	G/A	cg11879182	chr18:77439856	CTDP1	0.79	14.71	0.56	1.9e-40	Monocyte count;
LGG	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg05696931	chr1:227175867	NA	-0.4	-7.95	-0.35	1.46e-14	Myeloid white cell count;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg04166393	chr7:2884313	GNA12	0.45	8.34	0.36	8.73e-16	Height;
LGG	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg10818794	chr15:86012489	AKAP13	0.35	7.43	0.33	5.28e-13	Coronary artery disease;
LGG	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	trans	rs61931739	0.576	rs115230002	chr12:33648787	G/C	cg26384229	chr12:38710491	ALG10B	-0.48	-8.33	-0.36	9.57e-16	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg06521331	chr12:34319734	NA	0.41	7.37	0.32	8.01e-13	Morning vs. evening chronotype;
LGG	cis	rs6586163	0.872	rs7910825	chr10:90743341	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.41	-7.13	-0.31	3.92e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2708240	0.967	rs2247043	chr7:147580236	T/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.46e-11	QT interval (drug interaction);
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.69	0.37	6.29e-17	Renal function-related traits (BUN);
LGG	cis	rs735539	1.000	rs1888001	chr13:21285906	C/G	cg04906043	chr13:21280425	IL17D	-0.56	-9.77	-0.41	1.24e-20	Dental caries;
LGG	cis	rs9325144	0.600	rs34138871	chr12:38735261	A/G	cg26384229	chr12:38710491	ALG10B	0.75	14.97	0.57	1.39e-41	Morning vs. evening chronotype;
LGG	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg04990556	chr1:26633338	UBXN11	-0.68	-14.18	-0.55	3.58e-38	Obesity-related traits;
LGG	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	10.63	0.44	9.54e-24	Hip circumference adjusted for BMI;
LGG	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg16070123	chr10:51489643	NA	0.4	7.23	0.32	2.07e-12	Prostate-specific antigen levels;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.34	-0.4	4.01e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6087771	0.714	rs6058259	chr20:30235302	A/G	cg21427119	chr20:30132790	HM13	-0.4	-7.05	-0.31	6.68e-12	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs8072100	0.846	rs4264433	chr17:45737275	A/T	cg25173405	chr17:45401733	C17orf57	0.49	8.52	0.37	2.19e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9357271	1.000	rs9380741	chr6:38352079	T/G	cg07362130	chr6:38359646	BTBD9	-0.47	-10.79	-0.45	2.3e-24	Restless legs syndrome;
LGG	cis	rs8072548	1	rs8072548	chr17:38164025	T/G	cg17467752	chr17:38218738	THRA	0.62	11.27	0.46	3.29e-26	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.15	-0.43	5.57e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg16141378	chr3:129829833	LOC729375	0.48	11.17	0.46	7.95e-26	Mood instability;
LGG	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg22920501	chr2:26401640	FAM59B	0.41	7.73	0.34	6.98e-14	Gut microbiome composition (summer);
LGG	cis	rs10937275	1.000	rs35461422	chr3:186649678	A/G	cg16751732	chr3:186648392	ST6GAL1	0.72	7.32	0.32	1.1e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	14.96	0.57	1.4e-41	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1010254	0.510	rs2348648	chr5:151714570	C/T	cg12297329	chr5:152029980	NA	-0.47	-6.79	-0.3	3.36e-11	Optic nerve measurement (cup area);
LGG	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg07599136	chr5:415885	AHRR	0.77	10.49	0.44	2.97e-23	Fat distribution (HIV);
LGG	trans	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg02002194	chr4:3960332	NA	-0.47	-9.06	-0.39	3.56e-18	Systolic blood pressure;
LGG	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.94	-0.31	1.3e-11	Triglycerides;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg13206674	chr6:150067644	NUP43	0.62	14.04	0.55	1.53e-37	Lung cancer;
LGG	cis	rs79349575	0.721	rs2291725	chr17:47039132	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.23	0.36	1.93e-15	Type 2 diabetes;
LGG	cis	rs9397585	0.963	rs4385321	chr6:153394728	G/A	cg17707550	chr6:153380415	RGS17	0.49	10.73	0.45	3.76e-24	Body mass index;
LGG	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs17221829	0.733	rs11018725	chr11:89413251	C/T	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.62	-0.37	1.05e-16	Anxiety in major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05447186	chr20:3869454	PANK2	0.44	7.27	0.32	1.58e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg21782813	chr7:2030301	MAD1L1	0.5	11.97	0.49	5.88e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6500395	0.584	rs4028684	chr16:48741222	A/G	cg16662043	chr16:48846231	NA	0.44	8.03	0.35	8.25e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs138880	0.505	rs56248708	chr22:50306969	G/A	cg02269571	chr22:50332266	NA	-0.79	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs1497828	1.000	rs11810416	chr1:217558447	A/G	cg04411442	chr1:217543379	NA	0.46	8.07	0.35	6.21e-15	Dialysis-related mortality;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.74	0.34	6.47e-14	Glycated hemoglobin levels;
LGG	trans	rs853679	1.000	rs853694	chr6:28279100	A/T	cg01620082	chr3:125678407	NA	-0.58	-7.36	-0.32	8.63e-13	Depression;
LGG	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg08621203	chr6:150244597	RAET1G	0.46	7.99	0.35	1.06e-14	Lung cancer;
LGG	cis	rs765787	0.530	rs4775819	chr15:45525966	C/T	cg25801113	chr15:45476975	SHF	0.87	19.63	0.67	7.48e-63	Uric acid levels;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg15971980	chr6:150254442	NA	0.45	8.21	0.36	2.18e-15	Lung cancer;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.29	0.36	1.23e-15	Tonsillectomy;
LGG	cis	rs28655083	0.552	rs76055145	chr16:77124905	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-7.11	-0.31	4.48e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs7072216	0.727	rs7901577	chr10:100164442	A/G	cg26618903	chr10:100175079	PYROXD2	-0.28	-6.8	-0.3	3.28e-11	Metabolite levels;
LGG	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08564027	chr20:61660810	NA	1.02	24.85	0.76	3.16e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg25986240	chr4:9926439	SLC2A9	0.49	10.76	0.45	2.93e-24	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6912958	0.535	rs242283	chr6:88030931	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	13.29	0.53	2.34e-34	Monocyte percentage of white cells;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.27	-0.32	1.58e-12	Tonsillectomy;
LGG	cis	rs4319547	0.698	rs10773178	chr12:122944752	T/C	cg23029597	chr12:123009494	RSRC2	-0.89	-16.97	-0.62	1.38e-50	Body mass index;
LGG	cis	rs67311347	0.524	rs7649168	chr3:40356158	T/C	cg13683864	chr3:40499215	RPL14	-0.8	-15.74	-0.59	4.83e-45	Renal cell carcinoma;
LGG	cis	rs7818345	0.687	rs13275706	chr8:19327151	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.38	8.78	0.38	3.08e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.3	0.43	1.49e-22	Diabetic retinopathy;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg13009111	chr11:71350975	NA	-0.37	-8.53	-0.37	2.06e-16	Monocyte count;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg02018176	chr4:1364513	KIAA1530	0.39	8.67	0.37	7.53e-17	Obesity-related traits;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.71	-12.71	-0.51	5.96e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7945705	0.875	rs10769957	chr11:8809016	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.42	-8.55	-0.37	1.83e-16	Hemoglobin concentration;
LGG	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg00031303	chr3:195681400	NA	0.52	8.11	0.35	4.58e-15	Pancreatic cancer;
LGG	cis	rs2075371	0.637	rs2544165	chr7:133920443	A/G	cg20476274	chr7:133979776	SLC35B4	-0.65	-12.52	-0.5	3.53e-31	Mean platelet volume;
LGG	cis	rs62238980	0.614	rs79592323	chr22:32442742	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs67311347	0.824	rs73073561	chr3:40357298	G/T	cg13683864	chr3:40499215	RPL14	-0.86	-16.63	-0.61	4.78e-49	Renal cell carcinoma;
LGG	cis	rs4460629	0.521	rs7367897	chr1:155083289	A/T	cg13808842	chr1:155066096	NA	-0.33	-8.16	-0.35	3.29e-15	Serum magnesium levels;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06520672	chr19:29704310	UQCRFS1	0.37	7.2	0.32	2.47e-12	Gut microbiome composition (summer);
LGG	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg09936142	chr19:10668400	KRI1	-0.42	-6.95	-0.31	1.25e-11	Inflammatory skin disease;
LGG	cis	rs9486719	1.000	rs2092096	chr6:96870919	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.66	-0.37	7.62e-17	Menopause (age at onset);
LGG	cis	rs2408955	0.522	rs10875721	chr12:48413593	A/G	cg24011408	chr12:48396354	COL2A1	-0.6	-9.93	-0.42	3.41e-21	Glycated hemoglobin levels;
LGG	cis	rs7255045	0.664	rs4614850	chr19:12974636	G/T	cg07955356	chr19:12992479	DNASE2	0.42	7.09	0.31	5.05e-12	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04085336	chr11:67007785	KDM2A	0.47	6.88	0.3	2e-11	Gut microbiome composition (summer);
LGG	cis	rs2354432	0.607	rs55918563	chr1:146718973	G/C	cg25205988	chr1:146714368	CHD1L	-1.45	-15.1	-0.57	3.61e-42	Mitochondrial DNA levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24906202	chr15:73345212	NEO1	-0.45	-6.74	-0.3	4.68e-11	Pancreatic cancer;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs7493	0.950	rs56265549	chr7:95047155	G/A	cg08461772	chr7:95026248	PON3	0.38	8.35	0.36	7.98e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9902453	1.000	rs9897206	chr17:28406108	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.36	-0.53	1.11e-34	Coffee consumption (cups per day);
LGG	cis	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.19	-0.36	2.48e-15	Mood instability;
LGG	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg03806693	chr22:41940476	POLR3H	1.02	17.41	0.63	1.35e-52	Vitiligo;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs239198	0.602	rs9390698	chr6:101296389	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.24	0.32	1.9e-12	Menarche (age at onset);
LGG	cis	rs7301826	0.651	rs4759525	chr12:131316281	T/C	cg11011512	chr12:131303247	STX2	0.41	8.88	0.38	1.48e-17	Plasma plasminogen activator levels;
LGG	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg01620082	chr3:125678407	NA	0.95	9.24	0.39	9.16e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs950169	0.922	rs11633534	chr15:85124642	C/T	cg24253500	chr15:84953950	NA	0.58	10.45	0.44	4.27e-23	Schizophrenia;
LGG	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs9297145	0.585	rs10953281	chr7:98772131	C/T	cg05967295	chr7:98741636	SMURF1	-0.66	-12.12	-0.49	1.53e-29	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs26868	0.766	rs30995	chr16:2248017	C/T	cg02248941	chr16:2239361	CASKIN1	-0.45	-9.19	-0.39	1.28e-18	Height;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg14926445	chr8:58193284	C8orf71	-0.77	-9.45	-0.4	1.71e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.37	-7.33	-0.32	1.04e-12	Prostate cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05930166	chr1:222884917	AIDA;C1orf58	-0.48	-7.07	-0.31	5.75e-12	Systemic lupus erythematosus;
LGG	cis	rs977987	0.843	rs67409275	chr16:75457212	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.4	0.44	6.55e-23	Dupuytren's disease;
LGG	cis	rs7949566	0.647	rs4502008	chr11:126287754	G/T	cg05055844	chr11:126275997	ST3GAL4	0.35	7.12	0.31	4.11e-12	Platelet distribution width;Mean platelet volume;
LGG	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg27624424	chr6:160112604	SOD2	0.64	9.08	0.39	3.16e-18	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.81	15.58	0.59	2.6e-44	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.62	-10.72	-0.45	4.27e-24	Obesity-related traits;
LGG	cis	rs9902453	0.765	rs2264302	chr17:28057095	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.38	-0.56	5.01e-39	Coffee consumption (cups per day);
LGG	trans	rs6426551	1.000	rs6668851	chr1:226545866	C/A	cg27539482	chr13:111589090	NA	-0.5	-7.6	-0.33	1.62e-13	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.86e-11	Electroencephalogram traits;
LGG	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs2421770	0.532	rs7945449	chr11:35369110	C/T	cg10331829	chr11:35343789	SLC1A2	-0.35	-7.69	-0.34	9.01e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.94e-18	Fuchs's corneal dystrophy;
LGG	trans	rs2727020	0.857	rs1917324	chr11:49371759	G/C	cg03929089	chr4:120376271	NA	-0.8	-13.32	-0.53	1.68e-34	Coronary artery disease;
LGG	cis	rs1670533	0.872	rs935969	chr4:1062588	A/G	cg27284194	chr4:1044797	NA	0.54	9.58	0.41	5.84e-20	Recombination rate (females);
LGG	cis	rs10048158	0.565	rs9894829	chr17:64246133	C/T	cg19474267	chr17:64306194	PRKCA	-0.65	-13.6	-0.53	1.14e-35	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg09558872	chr19:9929784	FBXL12	-0.4	-7.12	-0.31	4.27e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs4330281	0.653	rs4243838	chr3:17759733	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.31e-13	Schizophrenia;
LGG	cis	rs68170813	0.523	rs111590023	chr7:107055323	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-9.66	-0.41	3.14e-20	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11673391	chr1:10459052	PGD	0.42	6.91	0.31	1.6e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.44	-0.33	5.05e-13	Life satisfaction;
LGG	cis	rs9948	0.529	rs62152773	chr2:97448073	T/C	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs7566780	0.602	rs1346754	chr2:16683606	G/A	cg09580478	chr2:16689509	NA	0.49	7.44	0.33	4.96e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg18681998	chr4:17616180	MED28	-0.83	-17.6	-0.63	1.92e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3008870	1.000	rs2985824	chr1:67410171	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-22.81	-0.73	9.63e-78	Lymphocyte percentage of white cells;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg06353428	chr16:71660113	MARVELD3	-0.87	-8.15	-0.35	3.48e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg13009111	chr11:71350975	NA	-0.31	-7.03	-0.31	7.52e-12	Systolic blood pressure;
LGG	cis	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg19399532	chr1:178512495	C1orf220	0.43	8.43	0.36	4.35e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1691799	0.867	rs1168311	chr12:66725912	A/C	cg16791601	chr12:66731901	HELB	0.65	15.41	0.58	1.45e-43	White blood cell count (basophil);
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs10189230	0.935	rs3770145	chr2:222345147	T/C	cg14652038	chr2:222343519	EPHA4	0.59	12.1	0.49	1.86e-29	Urate levels in lean individuals;
LGG	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg20570797	chr2:1712800	PXDN	-0.46	-8.36	-0.36	7.68e-16	Response to antipsychotic treatment;
LGG	cis	rs2274273	0.805	rs28660594	chr14:55846174	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.04	0.62	6.49e-51	Protein biomarker;
LGG	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg15268244	chr15:77196840	NA	0.4	7.69	0.34	8.85e-14	Blood metabolite levels;
LGG	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6976053	0.518	rs314353	chr7:100406144	A/G	cg03098644	chr7:100410630	EPHB4	-0.55	-10.84	-0.45	1.48e-24	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg26384229	chr12:38710491	ALG10B	0.87	18.92	0.66	1.53e-59	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs1408799	0.579	rs970945	chr9:12738641	C/T	cg05274944	chr9:12693694	TYRP1	-0.31	-6.82	-0.3	2.86e-11	Eye color;Blue vs. green eyes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16706631	chr6:26204823	HIST1H4E	-0.41	-6.78	-0.3	3.65e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17763188	chr8:6692148	XKR5	-0.4	-6.87	-0.3	2.06e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4262150	0.693	rs4246039	chr5:152302465	G/A	cg12297329	chr5:152029980	NA	0.58	11.24	0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg27523141	chr10:43048294	ZNF37B	0.43	8.51	0.37	2.37e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs7568458	0.846	rs1078004	chr2:85769711	C/G	cg17127132	chr2:85788382	GGCX	0.48	8.49	0.37	2.74e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13319406	0.546	rs6801014	chr3:189832834	T/C	cg03343083	chr3:189718843	LEPREL1	-0.5	-6.8	-0.3	3.17e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.44	-0.33	4.82e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4988958	0.565	rs6760621	chr2:102999952	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	cis	rs9393813	0.529	rs12526864	chr6:27456242	C/T	cg18711553	chr6:27366782	ZNF391	0.48	9.03	0.39	4.78e-18	Bipolar disorder;
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.83	-0.42	7.62e-21	Educational attainment;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg00490583	chr16:1843685	IGFALS	-0.41	-7.08	-0.31	5.48e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2224391	1.000	rs9784870	chr6:5261359	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.55	-0.37	1.84e-16	Height;
LGG	cis	rs6942756	0.956	rs13235668	chr7:128879710	A/G	cg02491457	chr7:128862824	NA	-0.78	-14.38	-0.56	5.03e-39	White matter hyperintensity burden;
LGG	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4820539	1.000	rs5759596	chr22:23475750	G/A	cg21100191	chr22:23484243	RTDR1	1.0	23.21	0.73	1.27e-79	Bone mineral density;
LGG	cis	rs4740619	0.740	rs10810438	chr9:15737731	G/A	cg14451791	chr9:16040625	NA	0.34	8.71	0.38	5.53e-17	Body mass index;
LGG	cis	rs6456156	0.792	rs4710179	chr6:167513692	G/T	cg07741184	chr6:167504864	NA	0.4	8.9	0.38	1.28e-17	Primary biliary cholangitis;
LGG	cis	rs765787	0.530	rs12904265	chr15:45526713	C/T	cg24006582	chr15:45444508	DUOX1	0.68	12.32	0.5	2.39e-30	Uric acid levels;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.77	-0.38	3.45e-17	Menopause (age at onset);
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.62	0.41	4.17e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11250464	0.833	rs4554799	chr10:1407728	C/T	cg08668359	chr10:1443807	ADARB2	0.64	12.4	0.5	1.12e-30	Radiation response;
LGG	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.58e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.0	0.52	3.54e-33	Monocyte percentage of white cells;
LGG	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg26513180	chr16:89883248	FANCA	0.64	11.64	0.48	1.17e-27	Vitiligo;
LGG	cis	rs9296092	0.538	rs34222093	chr6:33519584	G/C	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg11995313	chr8:8860691	ERI1	0.45	7.75	0.34	5.96e-14	Joint mobility (Beighton score);
LGG	trans	rs17685	0.753	rs2286830	chr7:75693963	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.07	-26.21	-0.77	1.69e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs35176054	0.730	rs12772158	chr10:105502410	G/C	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.97	-0.31	1.09e-11	Atrial fibrillation;
LGG	cis	rs2075371	0.871	rs418135	chr7:133949898	A/G	cg20476274	chr7:133979776	SLC35B4	0.73	13.72	0.54	3.55e-36	Mean platelet volume;
LGG	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg20283391	chr11:68216788	NA	-0.49	-8.09	-0.35	5.46e-15	Total body bone mineral density;
LGG	cis	rs8079658	1.000	rs11651498	chr17:63788615	C/T	cg18091269	chr17:63822838	CCDC46	-0.4	-6.68	-0.3	6.74e-11	Post bronchodilator FEV1;
LGG	trans	rs17685	0.753	rs6951943	chr7:75772452	A/G	cg19862616	chr7:65841803	NCRNA00174	1.08	25.83	0.77	9.17e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4731207	0.735	rs12155120	chr7:124478232	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg18200150	chr17:30822561	MYO1D	0.74	16.95	0.62	1.82e-50	Schizophrenia;
LGG	cis	rs250677	0.687	rs250672	chr5:148446110	A/G	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.16	-0.32	3.14e-12	Breast cancer;
LGG	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	7.24	0.32	1.85e-12	Coronary artery disease;
LGG	cis	rs10754283	0.967	rs6428562	chr1:90102665	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.19	-0.32	2.64e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1497828	1.000	rs2818966	chr1:217569557	G/A	cg04411442	chr1:217543379	NA	0.47	8.22	0.36	2.08e-15	Dialysis-related mortality;
LGG	trans	rs9354308	0.903	rs1938064	chr6:66559172	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-8.75	-0.38	3.97e-17	Metabolite levels;
LGG	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.22	0.43	3.01e-22	Motion sickness;
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg07132326	chr6:150258058	NA	0.38	8.06	0.35	6.58e-15	Testicular germ cell tumor;
LGG	cis	rs9788721	0.902	rs17486195	chr15:78865197	A/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.43	-0.33	5.24e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg06654118	chr4:1303317	MAEA	0.4	6.92	0.31	1.52e-11	Obesity-related traits;
LGG	cis	rs9398803	0.651	rs979197	chr6:127075696	C/T	cg19875578	chr6:126661172	C6orf173	-0.49	-9.03	-0.39	4.58e-18	Male-pattern baldness;
LGG	cis	rs763121	0.853	rs5757231	chr22:39071658	C/T	cg21395723	chr22:39101663	GTPBP1	-0.38	-6.68	-0.3	7.06e-11	Menopause (age at onset);
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-6.87	-0.3	2.09e-11	Schizophrenia;
LGG	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg16006841	chr5:176797999	RGS14	0.59	9.4	0.4	2.48e-19	Hemoglobin concentration;Hematocrit;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg02353165	chr6:42928485	GNMT	0.48	14.18	0.55	3.74e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.17	-0.39	1.51e-18	Lung cancer;
LGG	cis	rs11225247	0.536	rs11605915	chr11:102237187	C/T	cg06323957	chr11:102217781	BIRC2	0.79	7.21	0.32	2.35e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs17767392	0.670	rs11627918	chr14:71724408	T/C	cg02058870	chr14:72053146	SIPA1L1	0.34	7.18	0.32	2.82e-12	Mitral valve prolapse;
LGG	cis	rs644799	1.000	rs693364	chr11:95621926	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	12.93	0.51	7.56e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg09699651	chr6:150184138	LRP11	0.54	9.47	0.4	1.42e-19	Lung cancer;
LGG	cis	rs10540	1.000	rs12794284	chr11:477623	C/T	cg03576123	chr11:487126	PTDSS2	-1.31	-17.43	-0.63	1.07e-52	Body mass index;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg24250549	chr1:154909240	PMVK	-0.75	-15.25	-0.58	7.67e-43	Prostate cancer;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg19223190	chr17:80058835	NA	0.43	8.19	0.36	2.55e-15	Life satisfaction;
LGG	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg15704280	chr7:45808275	SEPT13	-0.9	-15.93	-0.6	7.45e-46	Coronary artery disease;
LGG	cis	rs9462027	0.561	rs2235568	chr6:34570094	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.33	-0.43	1.24e-22	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	0.725	rs9420796	chr10:102323092	G/C	cg11040518	chr10:102331378	NA	-0.37	-6.71	-0.3	5.69e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3750082	0.785	rs4720085	chr7:32968136	C/T	cg08946731	chr7:32981826	RP9P	-0.41	-6.89	-0.3	1.88e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.5	-0.33	3.34e-13	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg16141378	chr3:129829833	LOC729375	0.41	8.9	0.38	1.28e-17	Neuroticism;
LGG	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.55	-0.33	2.36e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs4819041	chr21:46659955	C/T	cg06618935	chr21:46677482	NA	-0.43	-8.44	-0.37	4.03e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9393777	0.720	rs34864993	chr6:26970895	C/A	cg08344181	chr3:125677491	NA	-0.58	-7.2	-0.32	2.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-11.56	-0.47	2.49e-27	Response to antipsychotic treatment;
LGG	cis	rs733592	0.524	rs10875726	chr12:48425992	A/G	cg24011408	chr12:48396354	COL2A1	-0.7	-12.42	-0.5	8.85e-31	Plateletcrit;
LGG	cis	rs7166081	0.950	rs8039943	chr15:67656430	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.27	-0.32	1.58e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	19.44	0.67	5.44e-62	Platelet count;
LGG	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg18876405	chr7:65276391	NA	0.6	10.76	0.45	2.97e-24	Aortic root size;
LGG	cis	rs4973397	0.810	rs12694890	chr2:232276553	A/T	cg11378575	chr2:232265004	B3GNT7	-0.56	-9.92	-0.42	3.61e-21	Anti-saccade response;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01353139	chr8:124170018	NA	0.64	7.41	0.33	5.86e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.06	-0.31	6.31e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6087990	0.965	rs742630	chr20:31350664	C/G	cg13636640	chr20:31349939	DNMT3B	1.01	22.05	0.72	3.37e-74	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03533382	chr5:126853128	PRRC1	0.48	7.86	0.34	2.71e-14	Gut microbiome composition (summer);
LGG	trans	rs2018683	0.707	rs2057957	chr7:28974626	A/C	cg19402173	chr7:128379420	CALU	0.53	9.26	0.4	7.37e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs7119	0.717	rs12902896	chr15:77809150	G/T	cg10437265	chr15:77819839	NA	-0.24	-6.77	-0.3	3.92e-11	Type 2 diabetes;
LGG	cis	rs2976388	0.609	rs2585144	chr8:143800269	A/T	cg06565975	chr8:143823917	SLURP1	0.36	9.28	0.4	6.59e-19	Urinary tract infection frequency;
LGG	cis	rs4363385	0.818	rs61811863	chr1:152995721	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.94	-0.38	9.64e-18	Inflammatory skin disease;
LGG	cis	rs9341808	0.754	rs3805885	chr6:80996751	C/G	cg08355045	chr6:80787529	NA	-0.38	-7.44	-0.33	4.86e-13	Sitting height ratio;
LGG	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg08999081	chr20:33150536	PIGU	0.32	7.46	0.33	4.24e-13	Coronary artery disease;
LGG	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg05925327	chr15:68127851	NA	-0.43	-8.81	-0.38	2.51e-17	Restless legs syndrome;
LGG	cis	rs9534288	0.830	rs1126365	chr13:46633196	T/A	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg13607699	chr17:42295918	UBTF	-0.44	-7.08	-0.31	5.3e-12	Total body bone mineral density;
LGG	cis	rs4671458	1.000	rs72813418	chr2:63385242	C/G	cg17519650	chr2:63277830	OTX1	-0.63	-7.81	-0.34	3.78e-14	Subjective well-being;
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg08302650	chr8:145750040	LRRC24;LRRC14	0.32	6.94	0.31	1.35e-11	Age at first birth;
LGG	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg11366901	chr6:160182831	ACAT2	1.05	16.25	0.6	2.54e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10751667	0.666	rs7395267	chr11:962326	C/A	cg22143635	chr11:980567	AP2A2	0.45	8.29	0.36	1.27e-15	Alzheimer's disease (late onset);
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.56	-0.44	1.65e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs77633900	0.614	rs2459363	chr15:76874952	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.37	-0.43	8.32e-23	Non-glioblastoma glioma;Glioma;
LGG	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.39	-0.4	2.83e-19	Retinal vascular caliber;
LGG	trans	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.38	-0.32	7.17e-13	Neuroticism;
LGG	cis	rs6430585	0.528	rs3112496	chr2:136711064	C/T	cg07169764	chr2:136633963	MCM6	1.14	20.28	0.69	6.98e-66	Corneal structure;
LGG	cis	rs9649465	0.967	rs768680	chr7:123364127	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.86	-0.38	1.73e-17	Migraine;
LGG	cis	rs9972944	0.702	rs987931	chr17:63765911	T/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.4	-0.36	5.45e-16	Total body bone mineral density;
LGG	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg25319279	chr11:5960081	NA	-0.57	-8.81	-0.38	2.57e-17	DNA methylation (variation);
LGG	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg12386194	chr3:101231763	SENP7	-0.43	-7.54	-0.33	2.55e-13	Colorectal cancer;
LGG	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg00490583	chr16:1843685	IGFALS	-0.46	-9.97	-0.42	2.5e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg21657780	chr14:105293878	NA	0.55	10.01	0.42	1.75e-21	IgG glycosylation;
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg16141378	chr3:129829833	LOC729375	0.39	8.95	0.38	8.63e-18	Neuroticism;
LGG	cis	rs2033732	0.954	rs1550215	chr8:85093121	A/C	cg05716166	chr8:85095498	RALYL	0.52	8.03	0.35	8.22e-15	Body mass index;
LGG	cis	rs4900538	0.787	rs11704	chr14:102808655	C/G	cg18135206	chr14:102964638	TECPR2	0.68	12.33	0.5	2.06e-30	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2075423	1.000	rs2075423	chr1:214154719	A/C	cg05052969	chr1:214156842	NA	-0.68	-13.74	-0.54	2.76e-36	Type 2 diabetes;
LGG	cis	rs9443189	0.615	rs6453829	chr6:76268509	C/T	cg01950844	chr6:76311363	SENP6	0.76	9.98	0.42	2.22e-21	Prostate cancer;
LGG	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.3	-0.5	2.67e-30	Intelligence (multi-trait analysis);
LGG	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg10167378	chr1:228756711	NA	0.55	7.97	0.35	1.24e-14	Chronic lymphocytic leukemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13497285	chr20:8000588	TMX4	0.45	6.8	0.3	3.24e-11	Gut microbiome composition (summer);
LGG	cis	rs1535500	1.000	rs3734618	chr6:39284184	A/G	cg13075951	chr6:39282393	KCNK17	0.26	6.93	0.31	1.41e-11	Type 2 diabetes;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs3126085	0.935	rs4845745	chr1:152185184	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs350251	0.899	rs183010	chr16:12207306	A/G	cg02910054	chr16:12241554	SNX29	0.41	7.65	0.33	1.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg23782820	chr8:58130467	NA	0.54	7.38	0.32	7.48e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs747782	0.527	rs2279822	chr11:48146114	C/T	cg15704280	chr7:45808275	SEPT13	0.7	7.24	0.32	1.85e-12	Intraocular pressure;
LGG	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg13770153	chr20:60521292	NA	-0.45	-7.51	-0.33	2.97e-13	Body mass index;
LGG	cis	rs6740322	0.895	rs10210125	chr2:43556433	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.58	-0.41	5.78e-20	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.68	0.37	6.66e-17	Platelet count;
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg19717773	chr7:2847554	GNA12	-0.35	-7.85	-0.34	2.86e-14	Height;
LGG	cis	rs2346177	1.000	rs12619985	chr2:46641627	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.41	6.96	0.31	1.18e-11	HDL cholesterol;
LGG	cis	rs2204008	0.805	rs4589389	chr12:37946120	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-13.19	-0.52	5.94e-34	Bladder cancer;
LGG	cis	rs7226408	0.901	rs10502671	chr18:34741111	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg06027949	chr8:82754900	SNX16	-0.48	-6.87	-0.3	2.09e-11	Diastolic blood pressure;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7100689	0.646	rs2039757	chr10:82078868	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.69	0.56	2.33e-40	Post bronchodilator FEV1;
LGG	trans	rs7819412	0.654	rs6987059	chr8:11071057	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.89	-0.34	2.22e-14	Triglycerides;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18247126	chr11:121163951	SC5DL	-0.44	-6.7	-0.3	5.93e-11	Pancreatic cancer;
LGG	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg21775007	chr8:11205619	TDH	-0.55	-8.97	-0.38	7.16e-18	Neuroticism;
LGG	cis	rs11645898	0.687	rs1424241	chr16:72078907	G/A	cg14768367	chr16:72042858	DHODH	-0.68	-9.61	-0.41	4.66e-20	Blood protein levels;
LGG	cis	rs924607	0.900	rs1697950	chr5:616890	G/A	cg09021430	chr5:549028	NA	0.54	10.41	0.44	5.97e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00166722	chr3:10149974	C3orf24	0.54	9.12	0.39	2.24e-18	Alzheimer's disease;
LGG	cis	rs9790314	0.905	rs7613358	chr3:160949296	T/C	cg03342759	chr3:160939853	NMD3	-0.71	-13.6	-0.53	1.17e-35	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg23625390	chr15:77176239	SCAPER	0.49	9.56	0.41	6.92e-20	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17100322	chr6:112194613	FYN	0.46	6.74	0.3	4.8e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg10189774	chr4:17578691	LAP3	0.42	7.37	0.32	7.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.2	0.46	6.04e-26	High light scatter reticulocyte count;
LGG	cis	rs2073499	0.935	rs2526392	chr3:50191191	T/C	cg03645007	chr3:50255295	SLC38A3	-0.63	-7.03	-0.31	7.56e-12	Schizophrenia;
LGG	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.68	0.61	3.07e-49	Personality dimensions;
LGG	cis	rs611744	0.870	rs634216	chr8:109174803	A/G	cg21045802	chr8:109455806	TTC35	0.4	7.15	0.32	3.4e-12	Dupuytren's disease;
LGG	trans	rs79976124	0.837	rs11751994	chr6:66644028	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.19	0.49	8.07e-30	Type 2 diabetes;
LGG	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-7.99	-0.35	1.1e-14	Educational attainment;
LGG	cis	rs4950322	0.857	rs55790545	chr1:146838364	C/A	cg22381352	chr1:146742008	CHD1L	-0.49	-7.99	-0.35	1.09e-14	Protein quantitative trait loci;
LGG	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.65	-11.15	-0.46	9.71e-26	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg04369109	chr6:150039330	LATS1	-0.43	-7.19	-0.32	2.56e-12	Lung cancer;
LGG	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg14186256	chr22:23484241	RTDR1	0.56	9.19	0.39	1.35e-18	Serum parathyroid hormone levels;
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg00149659	chr3:10157352	C3orf10	0.88	11.36	0.47	1.54e-26	Alzheimer's disease;
LGG	cis	rs74781061	0.932	rs7497342	chr15:74948063	A/G	cg02384859	chr15:74862662	ARID3B	-0.32	-6.76	-0.3	4.25e-11	Endometriosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20349687	chr2:88927127	EIF2AK3	0.49	8.25	0.36	1.65e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg08645402	chr16:4508243	NA	0.5	9.53	0.4	8.81e-20	Schizophrenia;
LGG	cis	rs897984	0.721	rs4889525	chr16:30989858	T/C	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05665937	chr4:1216051	CTBP1	-0.5	-8.92	-0.38	1.12e-17	Obesity-related traits;
LGG	cis	rs9636252	0.923	rs13412789	chr2:9267677	A/G	cg20341998	chr2:9276514	NA	0.38	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.51	0.63	4.77e-53	Longevity;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.64	-0.37	9.07e-17	Menopause (age at onset);
LGG	cis	rs9303401	0.580	rs12603808	chr17:56578508	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	14.1	0.55	8.41e-38	Cognitive test performance;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18917495	chr2:74006961	DUSP11	0.4	6.66	0.3	7.69e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg20887711	chr4:1340912	KIAA1530	0.48	8.64	0.37	8.96e-17	Obesity-related traits;
LGG	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.97	0.38	7.53e-18	Morning vs. evening chronotype;
LGG	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg03929089	chr4:120376271	NA	0.85	13.48	0.53	3.76e-35	Coronary artery disease;
LGG	cis	rs2247341	0.515	rs35313041	chr4:1696103	C/T	cg08446824	chr4:1720184	TMEM129	-0.5	-8.86	-0.38	1.74e-17	Hip circumference adjusted for BMI;Height;
LGG	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg17145862	chr1:211918768	LPGAT1	-0.87	-19.83	-0.68	8.34e-64	Leprosy;
LGG	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg16400903	chr5:693638	TPPP	0.47	7.02	0.31	8.12e-12	Obesity-related traits;
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.41	-0.47	9.38e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg26924012	chr15:45694286	SPATA5L1	1.04	22.45	0.72	4.86e-76	Homoarginine levels;
LGG	cis	rs5756391	0.546	rs9607392	chr22:37315592	C/T	cg21209356	chr22:37319042	CSF2RB	0.41	9.42	0.4	2.18e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1372520	0.766	rs2583961	chr4:90779758	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-7.37	-0.32	7.88e-13	Neuroticism;
LGG	cis	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg24375607	chr4:120327624	NA	0.63	10.36	0.43	9e-23	Corneal astigmatism;
LGG	trans	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.55	0.33	2.37e-13	Retinal vascular caliber;
LGG	cis	rs738322	0.577	rs4820320	chr22:38572977	G/A	cg03162506	chr22:38580953	NA	0.31	7.66	0.34	1.08e-13	Cutaneous nevi;
LGG	cis	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg19338460	chr6:170058176	WDR27	-0.85	-10.08	-0.42	9.81e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8017423	0.647	rs12882575	chr14:90820454	C/G	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs883565	0.528	rs4676584	chr3:38965907	C/A	cg01426195	chr3:39028469	NA	0.6	12.72	0.51	5.13e-32	Handedness;
LGG	trans	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg22153745	chr1:153894579	GATAD2B	-0.67	-9.06	-0.39	3.81e-18	Total cholesterol levels;
LGG	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg17689763	chr4:710664	PCGF3	-0.8	-16.79	-0.62	9.45e-50	White blood cell count;
LGG	cis	rs1008375	0.932	rs6857678	chr4:17696964	A/T	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.03	0.39	4.52e-18	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs60180747	1.000	rs77515996	chr15:66708939	C/A	cg07575407	chr15:66541975	MEGF11	0.35	7.01	0.31	8.7e-12	Testicular germ cell tumor;
LGG	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg09467607	chr2:36825704	FEZ2	0.51	9.99	0.42	2.03e-21	Height;
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.75	-0.34	6.07e-14	Life satisfaction;
LGG	cis	rs12579753	0.667	rs11610904	chr12:82300416	A/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.24	-0.32	1.88e-12	Resting heart rate;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg23758822	chr17:41437982	NA	0.84	15.05	0.57	5.67e-42	Menopause (age at onset);
LGG	cis	rs57221529	0.713	rs12521091	chr5:590710	G/T	cg09021430	chr5:549028	NA	-0.7	-9.8	-0.41	9.59e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs1015291	0.708	rs1352905	chr12:19995608	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs7615952	0.599	rs1044215	chr3:125725559	C/G	cg15145296	chr3:125709740	NA	-0.59	-7.72	-0.34	7.25e-14	Blood pressure (smoking interaction);
LGG	cis	rs11096990	0.855	rs75746161	chr4:39169101	G/C	cg24403649	chr4:39172243	NA	-0.49	-7.8	-0.34	4.01e-14	Cognitive function;
LGG	cis	rs6920965	0.561	rs9401851	chr6:126181956	T/C	cg05901451	chr6:126070800	HEY2	-0.44	-7.6	-0.33	1.6e-13	High light scatter reticulocyte count;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07092213	chr7:1199455	ZFAND2A	-0.43	-7.07	-0.31	5.63e-12	Longevity;Endometriosis;
LGG	trans	rs9354308	0.764	rs9363477	chr6:66594243	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.85	-0.3	2.41e-11	Metabolite levels;
LGG	cis	rs1801251	1.000	rs3816334	chr2:233708806	A/G	cg25237894	chr2:233734115	C2orf82	-0.66	-12.57	-0.5	2.17e-31	Coronary artery disease;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04008888	chr11:68622739	NA	-0.51	-11.01	-0.46	3.4e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg06558623	chr16:89946397	TCF25	1.04	12.91	0.51	9.02e-33	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.55e-25	Corneal astigmatism;
LGG	cis	rs9309473	0.851	rs6546850	chr2:73831147	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.3e-14	Metabolite levels;
LGG	cis	rs10937275	1.000	rs10937275	chr3:186650790	A/G	cg16751732	chr3:186648392	ST6GAL1	-0.7	-7.16	-0.32	3.24e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg03929089	chr4:120376271	NA	-0.85	-16.18	-0.6	5.56e-47	Height;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg11062466	chr8:58055876	NA	0.51	7.8	0.34	4.05e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-14.43	-0.56	3.07e-39	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg10756647	chr7:56101905	PSPH	-0.79	-9.6	-0.41	5.17e-20	Diabetic kidney disease;
LGG	cis	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg07460842	chr6:66804631	NA	-0.48	-8.05	-0.35	7.15e-15	Metabolite levels;
LGG	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg25174290	chr11:3078921	CARS	-0.49	-8.35	-0.36	7.86e-16	Calcium levels;
LGG	cis	rs10751667	0.600	rs10794342	chr11:924904	C/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.85e-14	Alzheimer's disease (late onset);
LGG	cis	rs11967485	0.614	rs62434275	chr6:157221532	T/C	cg23222435	chr6:157204239	ARID1B	-0.82	-6.9	-0.31	1.69e-11	Calcium levels;
LGG	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg24692254	chr21:30365293	RNF160	-0.96	-24.76	-0.75	8.07e-87	Dental caries;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg19223190	chr17:80058835	NA	0.43	8.41	0.36	5.29e-16	Life satisfaction;
LGG	cis	rs2455601	0.608	rs1368017	chr11:8867070	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-9.03	-0.39	4.63e-18	Schizophrenia;
LGG	cis	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg09307838	chr4:120376055	NA	0.81	13.49	0.53	3.28e-35	Corneal astigmatism;
LGG	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg02002194	chr4:3960332	NA	0.46	8.35	0.36	8.14e-16	Retinal vascular caliber;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03464378	chr2:75427699	TACR1	0.39	6.86	0.3	2.2e-11	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.25	0.32	1.79e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1358748	0.522	rs1321152	chr1:67583666	A/T	cg02640540	chr1:67518911	SLC35D1	0.55	6.75	0.3	4.41e-11	Tuberculosis;
LGG	cis	rs9534288	0.762	rs1571052	chr13:46554849	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.22	-0.52	4.68e-34	Blood protein levels;
LGG	cis	rs16973500	0.808	rs1049794	chr16:71950450	C/T	cg00732059	chr16:71740210	PHLPP2	-0.61	-9.99	-0.42	2e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg26818010	chr10:134567672	INPP5A	-0.64	-9.75	-0.41	1.45e-20	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs453301	0.506	rs686189	chr8:8623637	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.79	-0.3	3.42e-11	Joint mobility (Beighton score);
LGG	cis	rs11122272	0.670	rs2474632	chr1:231484361	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-10.36	-0.43	9.62e-23	Hemoglobin concentration;
LGG	cis	rs7827545	1.000	rs62523736	chr8:135560916	A/T	cg17885191	chr8:135476712	NA	0.47	7.42	0.33	5.5e-13	Hypertension (SNP x SNP interaction);
LGG	trans	rs78049276	0.736	rs73855810	chr4:148383424	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.65	-0.33	1.18e-13	Pulse pressure;
LGG	cis	rs4700695	0.719	rs1643415	chr5:65447087	T/C	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs12410462	0.636	rs2819515	chr1:227632125	G/A	cg04117972	chr1:227635322	NA	-0.38	-6.92	-0.31	1.53e-11	Major depressive disorder;
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg08888203	chr3:10149979	C3orf24	0.51	7.47	0.33	3.98e-13	Alzheimer's disease;
LGG	cis	rs9381107	0.932	rs9394703	chr6:9455062	C/T	cg14735645	chr6:9486422	NA	0.42	7.13	0.31	3.9e-12	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg01314568	chr7:57830625	NA	-0.48	-7.77	-0.34	5.1e-14	Obesity-related traits;
LGG	cis	rs11700980	0.551	rs62222158	chr21:30110372	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs9596863	1.000	rs9568948	chr13:54437693	A/C	ch.13.53330881F	chr13:54432880	NA	0.49	6.81	0.3	3.12e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs208520	1.000	rs12189683	chr6:66977716	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.86	-14.12	-0.55	6.42e-38	Exhaled nitric oxide output;
LGG	cis	rs4481887	0.893	rs7515080	chr1:248494073	A/G	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.7e-15	Common traits (Other);
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.51	-0.44	2.51e-23	Platelet count;
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg18876405	chr7:65276391	NA	0.55	9.87	0.42	5.52e-21	Aortic root size;
LGG	trans	rs208520	0.526	rs6455072	chr6:66797215	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-32.4	-0.83	4.25e-121	Exhaled nitric oxide output;
LGG	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg06027949	chr8:82754900	SNX16	-0.56	-8.84	-0.38	1.95e-17	Diastolic blood pressure;
LGG	cis	rs3099143	1.000	rs3110381	chr15:77099665	A/T	cg21673338	chr15:77095150	SCAPER	-0.63	-9.98	-0.42	2.31e-21	Recalcitrant atopic dermatitis;
LGG	cis	rs1497828	1.000	rs2646823	chr1:217537011	C/A	cg04411442	chr1:217543379	NA	-0.47	-8.02	-0.35	8.65e-15	Dialysis-related mortality;
LGG	cis	rs3789045	0.774	rs12031912	chr1:204476113	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.43	-8.37	-0.36	6.65e-16	Educational attainment (college completion);
LGG	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.64	-0.41	3.52e-20	Aortic root size;
LGG	cis	rs7301016	0.947	rs11174517	chr12:62899757	A/G	cg11441379	chr12:63026424	NA	-0.66	-8.7	-0.37	5.89e-17	IgG glycosylation;
LGG	cis	rs6541297	0.653	rs4846841	chr1:230302661	A/G	cg05784532	chr1:230284198	GALNT2	0.36	6.68	0.3	6.92e-11	Coronary artery disease;
LGG	cis	rs12210905	0.925	rs10946896	chr6:26988576	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2415984	0.579	rs12147941	chr14:46972907	A/G	cg14871534	chr14:47121158	RPL10L	-0.57	-10.06	-0.42	1.13e-21	Number of children ever born;
LGG	cis	rs8067287	0.625	rs11656106	chr17:16854385	T/C	cg26910001	chr17:16838321	NA	-0.39	-7.71	-0.34	7.98e-14	Diabetic kidney disease;
LGG	trans	rs11098499	0.866	rs12510451	chr4:120289143	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs2688419	0.514	rs822768	chr3:23051162	A/G	cg00327796	chr3:23032191	NA	-0.4	-7.69	-0.34	8.7e-14	Type 2 diabetes;
LGG	cis	rs7011049	0.778	rs6473774	chr8:53875003	G/A	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.44	0.33	4.96e-13	Lung cancer;
LGG	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg03342759	chr3:160939853	NMD3	-0.71	-13.64	-0.54	7.57e-36	Morning vs. evening chronotype;
LGG	cis	rs3087591	0.636	rs736598	chr17:29720470	T/C	cg24425628	chr17:29625626	OMG;NF1	0.59	12.19	0.49	7.58e-30	Hip circumference;
LGG	cis	rs787274	0.850	rs4979176	chr9:115641181	A/G	cg13803584	chr9:115635662	SNX30	0.64	8.82	0.38	2.3e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.63	0.54	8.18e-36	Psoriasis;
LGG	cis	rs3733585	0.725	rs10939636	chr4:9972640	T/G	cg08250081	chr4:10125330	NA	-0.36	-6.81	-0.3	3e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.74	0.38	4.43e-17	Platelet count;
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487051	0.714	rs7774377	chr6:109602443	G/A	cg21918786	chr6:109611834	NA	-0.49	-9.06	-0.39	3.74e-18	Reticulocyte fraction of red cells;
LGG	cis	rs6430585	0.528	rs309142	chr2:136715324	T/C	cg07169764	chr2:136633963	MCM6	1.17	22.22	0.72	5.42e-75	Corneal structure;
LGG	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg05696931	chr1:227175867	NA	-0.41	-8.41	-0.36	5.25e-16	Myeloid white cell count;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg16301924	chr13:53314226	LECT1	-0.46	-9.13	-0.39	2.18e-18	Lewy body disease;
LGG	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.77	0.48	3.74e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg23782820	chr8:58130467	NA	0.56	8.42	0.36	4.81e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg22852734	chr6:133119734	C6orf192	1.32	10.47	0.44	3.78e-23	Type 2 diabetes nephropathy;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	9.96	0.42	2.69e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4642101	0.639	rs9870433	chr3:12853566	T/C	cg05775895	chr3:12838266	CAND2	0.59	10.01	0.42	1.81e-21	QRS complex (12-leadsum);
LGG	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.52	0.5	3.53e-31	Colorectal cancer;
LGG	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg12011299	chr4:100065546	ADH4	0.41	8.9	0.38	1.23e-17	Alcohol dependence;
LGG	trans	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg16141378	chr3:129829833	LOC729375	0.39	9.3	0.4	5.52e-19	Joint mobility (Beighton score);
LGG	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08704250	chr15:31115839	NA	-0.41	-7.13	-0.31	3.82e-12	Huntington's disease progression;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.05	-0.31	6.71e-12	Bipolar disorder;
LGG	cis	rs747650	0.926	rs10838659	chr11:47148210	C/T	cg03339077	chr11:47165057	C11orf49	-0.54	-10.21	-0.43	3.2e-22	Acne (severe);
LGG	cis	rs9636252	0.564	rs6756409	chr2:9280191	G/C	cg20341998	chr2:9276514	NA	0.37	6.94	0.31	1.33e-11	IgG glycosylation;
LGG	cis	rs7937682	0.737	rs682239	chr11:111425105	A/G	cg08305652	chr11:111469057	NA	0.36	7.37	0.32	8.16e-13	Primary sclerosing cholangitis;
LGG	cis	rs2274273	0.661	rs2147964	chr14:55564395	T/G	cg04306507	chr14:55594613	LGALS3	0.49	12.29	0.5	3.12e-30	Protein biomarker;
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.58e-12	Life satisfaction;
LGG	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Vitiligo;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.7	-0.41	2.24e-20	Lung cancer;
LGG	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg23788917	chr6:8435910	SLC35B3	-0.51	-8.54	-0.37	1.91e-16	Motion sickness;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg07701084	chr6:150067640	NUP43	0.7	12.22	0.49	5.92e-30	Lung cancer;
LGG	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg00092383	chr7:157075207	NA	-0.38	-6.66	-0.3	7.59e-11	Body mass index;
LGG	cis	rs10929925	0.863	rs10186410	chr2:6160902	A/G	cg00493617	chr2:6141445	NA	0.33	7.44	0.33	5.04e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07504864	chr6:88412167	NCRNA00120;AKIRIN2	0.46	7.28	0.32	1.48e-12	Cognitive performance;
LGG	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg00631329	chr6:26305371	NA	-0.47	-7.98	-0.35	1.13e-14	Educational attainment;
LGG	trans	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs2495755	chr10:102324649	A/C	cg11040518	chr10:102331378	NA	-0.41	-7.38	-0.32	7.52e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs807669	0.505	rs28651174	chr22:19236489	C/T	cg02655711	chr22:19163373	SLC25A1	0.46	8.09	0.35	5.11e-15	Metabolite levels;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg08645402	chr16:4508243	NA	0.49	9.36	0.4	3.35e-19	Schizophrenia;
LGG	cis	rs1322639	0.697	rs12661910	chr6:169584388	A/G	cg03254818	chr6:169586852	NA	0.65	9.74	0.41	1.6e-20	Pulse pressure;
LGG	cis	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg08824895	chr13:115047677	UPF3A	0.41	6.82	0.3	2.87e-11	Schizophrenia;
LGG	cis	rs3820068	0.705	rs41270255	chr1:15892980	G/A	cg05660106	chr1:15850417	CASP9	1.13	23.72	0.74	5.7e-82	Systolic blood pressure;
LGG	cis	rs6142618	0.562	rs6058528	chr20:30715050	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs714031	0.967	rs4821910	chr22:40067470	T/C	cg21377881	chr22:40064566	CACNA1I	-0.62	-14.71	-0.56	1.75e-40	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.74	-0.34	6.38e-14	Iron status biomarkers;
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg05335186	chr13:53173507	NA	0.44	8.62	0.37	1.05e-16	Lewy body disease;
LGG	cis	rs6459788	0.934	rs10237947	chr7:157258109	G/T	cg05333889	chr7:157238977	NA	0.45	8.69	0.37	6.5e-17	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs17401966	0.800	rs12725210	chr1:10416993	G/A	cg19773385	chr1:10388646	KIF1B	-0.46	-9.84	-0.42	7.24e-21	Hepatocellular carcinoma;
LGG	cis	rs7927771	0.507	rs10838754	chr11:47758532	A/C	cg20307385	chr11:47447363	PSMC3	0.56	10.84	0.45	1.45e-24	Subjective well-being;
LGG	cis	rs10197940	0.662	rs6735771	chr2:152273503	G/A	cg19508488	chr2:152266495	RIF1	-0.57	-10.45	-0.44	4.45e-23	Lung cancer;
LGG	cis	rs9814567	0.752	rs13084192	chr3:134336095	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	11.08	0.46	1.77e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.73	-0.41	1.79e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.92	0.31	1.55e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs427394	0.802	rs274720	chr5:6719933	A/G	cg15145174	chr5:6755386	POLS	-0.4	-7.6	-0.33	1.67e-13	Menopause (age at onset);
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-6.98	-0.31	1.06e-11	Longevity;Endometriosis;
LGG	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg12046867	chr14:103022105	NA	-0.43	-8.62	-0.37	1.06e-16	Platelet count;
LGG	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.47	0.33	4.06e-13	Neuroticism;
LGG	cis	rs28374715	0.578	rs7169543	chr15:41620405	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.68	-0.84	1.36e-126	Ulcerative colitis;
LGG	cis	rs4891159	0.548	rs660342	chr18:74130896	C/G	cg24786174	chr18:74118243	ZNF516	0.68	17.49	0.63	6.01e-53	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19733847	chr19:8571072	NA	0.56	8.92	0.38	1.06e-17	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg01620082	chr3:125678407	NA	-0.66	-7.21	-0.32	2.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg09165964	chr15:75287851	SCAMP5	0.64	11.88	0.48	1.38e-28	Breast cancer;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4302748	0.865	rs59011914	chr7:36185290	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs4237845	0.837	rs7971877	chr12:58287630	T/G	cg02175503	chr12:58329896	NA	0.69	12.91	0.51	9.04e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17376030	chr22:41985996	PMM1	-0.47	-7.67	-0.34	1.03e-13	Vitiligo;
LGG	cis	rs9880211	1.000	rs67949818	chr3:136212978	G/A	cg21827317	chr3:136751795	NA	-0.48	-7.18	-0.32	2.75e-12	Body mass index;Height;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg03188948	chr7:1209495	NA	0.72	10.37	0.43	8.57e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4363385	0.818	rs370162	chr1:153005488	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg19913688	chr11:428466	ANO9	-0.64	-8.24	-0.36	1.74e-15	Body mass index;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs11748327	0.959	rs17718387	chr5:4036227	C/G	cg01025095	chr5:4101132	NA	-0.57	-9.19	-0.39	1.35e-18	Myocardial infarction;
LGG	cis	rs912057	0.671	rs1294425	chr6:6744292	G/A	cg06612196	chr6:6737390	NA	0.5	10.77	0.45	2.8e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.36	-0.75	5.62e-85	Height;
LGG	cis	rs1865760	0.516	rs10807007	chr6:26048931	A/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.06e-14	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00826921	chr3:143692146	C3orf58	0.42	7.16	0.32	3.22e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9549260	0.755	rs2721066	chr13:41156188	C/T	cg21288729	chr13:41239152	FOXO1	-0.34	-6.8	-0.3	3.32e-11	Red blood cell count;
LGG	trans	rs7777754	0.512	rs7785224	chr7:50562361	T/C	cg24289314	chr10:126106425	OAT	-0.35	-6.83	-0.3	2.74e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg01043669	chr3:72786069	NA	0.43	7.1	0.31	4.58e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg16414030	chr3:133502952	NA	-0.56	-8.97	-0.38	7.39e-18	Iron status biomarkers;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22968622	chr17:43663579	NA	-1.02	-19.16	-0.67	1.13e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16035520	chr11:98891820	CNTN5	0.41	6.71	0.3	5.65e-11	Cognitive performance;
LGG	cis	rs6840360	0.571	rs11723395	chr4:152524191	G/A	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	0.866	rs17686622	chr17:20020364	C/G	cg13482628	chr17:19912719	NA	-0.41	-7.0	-0.31	9.08e-12	Obesity-related traits;
LGG	cis	rs17767392	0.836	rs17178387	chr14:71997723	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.54	-0.37	1.91e-16	Mitral valve prolapse;
LGG	trans	rs9354308	0.933	rs12194424	chr6:66574007	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.06	0.42	1.18e-21	Metabolite levels;
LGG	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg02023728	chr11:77925099	USP35	-0.38	-6.74	-0.3	4.83e-11	Alzheimer's disease (survival time);
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.08	0.31	5.36e-12	Prudent dietary pattern;
LGG	cis	rs870825	0.616	rs6552807	chr4:185640531	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.16	0.72	1.03e-74	Blood protein levels;
LGG	trans	rs2243480	1.000	rs35046236	chr7:65408613	T/C	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg04173714	chr15:86211321	AKAP13	0.47	8.13	0.35	4.03e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg03806693	chr22:41940476	POLR3H	-0.76	-12.68	-0.51	7.93e-32	Neuroticism;
LGG	cis	rs3106136	0.527	rs4693376	chr4:95157240	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.83	-0.45	1.67e-24	Capecitabine sensitivity;
LGG	cis	rs9479482	1.000	rs9478354	chr6:150334366	G/A	cg16395133	chr6:150326394	RAET1K	0.27	6.68	0.3	6.97e-11	Alopecia areata;
LGG	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.58	-0.41	6.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.04e-12	Electroencephalogram traits;
LGG	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.07	0.39	3.36e-18	Diabetic retinopathy;
LGG	cis	rs9649465	0.561	rs600081	chr7:123414591	A/T	cg03229431	chr7:123269106	ASB15	0.61	13.98	0.54	2.62e-37	Migraine;
LGG	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs2067615	0.524	rs4964187	chr12:107080313	C/A	cg15890332	chr12:107067104	RFX4	0.44	12.86	0.51	1.45e-32	Heart rate;
LGG	cis	rs853679	0.517	rs9393887	chr6:28059020	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.52	-0.33	2.93e-13	Depression;
LGG	cis	rs7666738	0.830	rs921523	chr4:98841659	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.73	0.34	6.73e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7202877	0.611	rs4888395	chr16:75413715	T/G	cg03315344	chr16:75512273	CHST6	0.53	7.2	0.32	2.5e-12	Type 2 diabetes;Type 1 diabetes;
LGG	trans	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg06521331	chr12:34319734	NA	0.43	7.57	0.33	2.09e-13	Morning vs. evening chronotype;
LGG	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg23806715	chr17:73775811	H3F3B	0.95	10.83	0.45	1.59e-24	Psoriasis;
LGG	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg22916017	chr11:64110731	CCDC88B	0.51	10.55	0.44	1.8e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6586163	0.872	rs7069841	chr10:90741955	T/C	cg03111039	chr10:90751583	FAS;ACTA2	-0.41	-7.22	-0.32	2.09e-12	Chronic lymphocytic leukemia;
LGG	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg22920501	chr2:26401640	FAM59B	-0.4	-7.91	-0.35	1.91e-14	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.908	rs17093657	chr20:30428894	G/A	cg04935436	chr20:30431758	NA	0.39	6.75	0.3	4.36e-11	Mean corpuscular hemoglobin;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11292044	chr12:121837283	RNF34	-0.4	-6.7	-0.3	5.89e-11	Electrocardiographic conduction measures;
LGG	trans	rs1459104	1.000	rs12789864	chr11:55197211	A/C	cg15704280	chr7:45808275	SEPT13	-0.72	-6.85	-0.3	2.32e-11	Body mass index;
LGG	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg02002194	chr4:3960332	NA	0.44	7.93	0.35	1.69e-14	Retinal vascular caliber;
LGG	cis	rs7659604	1.000	rs35901586	chr4:122664757	T/A	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.9	-0.31	1.67e-11	Type 2 diabetes;
LGG	cis	rs7113850	0.541	rs76344090	chr11:24223375	C/G	ch.11.24196551F	chr11:24239977	NA	0.91	10.23	0.43	2.88e-22	Bone fracture in osteoporosis;
LGG	trans	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg09048205	chr5:1608656	LOC728613	-0.52	-8.45	-0.37	3.82e-16	Breast cancer;
LGG	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg16512390	chr1:228756714	NA	0.61	8.07	0.35	6.21e-15	Chronic lymphocytic leukemia;
LGG	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg03806693	chr22:41940476	POLR3H	0.86	14.12	0.55	6.53e-38	Vitiligo;
LGG	cis	rs7819412	0.522	rs10101329	chr8:10990672	C/T	cg21775007	chr8:11205619	TDH	-0.5	-7.62	-0.33	1.45e-13	Triglycerides;
LGG	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs9487051	0.768	rs9480910	chr6:109521707	T/C	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.25e-11	Reticulocyte fraction of red cells;
LGG	cis	rs6977660	0.619	rs12534026	chr7:19788687	T/C	cg05791153	chr7:19748676	TWISTNB	0.62	9.07	0.39	3.42e-18	Thyroid stimulating hormone;
LGG	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.22	0.39	1.03e-18	Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs6908034	0.607	rs112824001	chr6:19804691	C/T	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg02462569	chr6:150064036	NUP43	-0.38	-8.08	-0.35	5.62e-15	Lung cancer;
LGG	cis	rs7945718	0.934	rs11022478	chr11:12741104	T/C	cg25843174	chr11:12811716	TEAD1	0.39	7.98	0.35	1.15e-14	Educational attainment (years of education);
LGG	cis	rs4481887	0.927	rs6671702	chr1:248482851	G/A	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs61160187	0.503	rs377321	chr5:59851740	G/C	cg02684056	chr5:59996105	DEPDC1B	0.41	6.67	0.3	7.16e-11	Educational attainment (years of education);Educational attainment (college completion);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg23634678	chr11:102963104	DCUN1D5	0.4	7.01	0.31	8.45e-12	Body mass index;
LGG	trans	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg23484912	chr5:273055	PDCD6	-0.39	-7.67	-0.34	1e-13	Mean corpuscular volume;
LGG	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg22875332	chr1:76189707	ACADM	0.54	8.42	0.36	4.62e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg16346588	chr10:242978	ZMYND11	-0.44	-6.8	-0.3	3.22e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg08085267	chr17:45401833	C17orf57	-0.57	-11.4	-0.47	1.04e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg21775007	chr8:11205619	TDH	-0.44	-7.23	-0.32	2.05e-12	Systolic blood pressure;
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg07157834	chr1:205819609	PM20D1	-0.44	-7.33	-0.32	1.03e-12	Parkinson's disease;
LGG	cis	rs981844	0.712	rs921882	chr4:154752878	A/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.71	-0.41	2.06e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg05091796	chr16:4465799	CORO7	0.59	9.44	0.4	1.78e-19	Schizophrenia;
LGG	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg26769984	chr7:1090371	C7orf50	0.54	9.8	0.41	9.84e-21	Bronchopulmonary dysplasia;
LGG	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.62	0.44	9.74e-24	Calcium levels;
LGG	cis	rs1878931	0.559	rs11643501	chr16:3392752	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.78	14.17	0.55	4.09e-38	Body mass index (adult);
LGG	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.23	-0.63	9.38e-52	Systemic lupus erythematosus;
LGG	trans	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg24247370	chr13:99142703	STK24	-0.43	-7.91	-0.35	1.86e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.65	-0.37	8.66e-17	IgG glycosylation;
LGG	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.27	-0.32	1.58e-12	Blood metabolite levels;
LGG	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg05677249	chr15:77158041	SCAPER	-0.32	-6.71	-0.3	5.56e-11	Blood metabolite levels;
LGG	cis	rs2708977	0.965	rs2314109	chr2:97243532	A/G	cg01950434	chr2:97203154	ARID5A	-0.58	-9.36	-0.4	3.56e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7646881	0.767	rs73015669	chr3:158456318	C/A	cg19483011	chr3:158453295	NA	-0.6	-8.02	-0.35	8.79e-15	Tetralogy of Fallot;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg13206674	chr6:150067644	NUP43	0.41	8.78	0.38	3.21e-17	Testicular germ cell tumor;
LGG	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg09873164	chr1:152488093	CRCT1	0.61	14.76	0.57	1.13e-40	Hair morphology;
LGG	cis	rs9783347	0.621	rs10832920	chr11:18341869	A/G	cg03595886	chr11:18357587	GTF2H1	-0.51	-12.67	-0.51	8.93e-32	Pancreatic cancer;
LGG	cis	rs40363	0.645	rs1690449	chr16:3520893	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.46	-7.05	-0.31	6.51e-12	Tuberculosis;
LGG	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg13798912	chr7:905769	UNC84A	-0.61	-7.14	-0.31	3.74e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg26597838	chr10:835615	NA	0.76	10.57	0.44	1.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs986417	1.000	rs7159212	chr14:61068725	T/C	cg27398547	chr14:60952738	C14orf39	0.76	7.05	0.31	6.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10861342	1.000	rs10778370	chr12:105603139	T/C	cg23923672	chr12:105501055	KIAA1033	0.82	7.25	0.32	1.78e-12	IgG glycosylation;
LGG	cis	rs2729354	0.903	rs1846568	chr11:57357714	A/C	cg24343310	chr11:57249947	NA	0.36	6.91	0.31	1.6e-11	Blood protein levels;
LGG	cis	rs2046867	0.908	rs2322610	chr3:72793651	C/A	cg25664220	chr3:72788482	NA	-0.31	-8.85	-0.38	1.92e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.3	-0.43	1.59e-22	Colorectal cancer;
LGG	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg11890956	chr21:40555474	PSMG1	-0.69	-11.46	-0.47	6.25e-27	Menarche (age at onset);
LGG	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.46e-12	Neuroticism;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg05091796	chr16:4465799	CORO7	-0.61	-9.92	-0.42	3.55e-21	Schizophrenia;
LGG	cis	rs13132184	0.507	rs34119528	chr4:38023302	C/G	cg24826020	chr4:38070998	TBC1D1	0.5	8.39	0.36	6.12e-16	Verbal declarative memory;
LGG	trans	rs7395662	1.000	rs7928083	chr11:48613148	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	cis	rs3849046	0.846	rs256002	chr5:137895218	C/T	cg10920316	chr5:137946599	NA	0.46	7.43	0.33	5.22e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs10802346	0.545	rs6662672	chr1:246387611	A/C	cg22732515	chr19:44031385	ETHE1	0.54	9.38	0.4	2.91e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.57	-0.37	1.6e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2735413	0.564	rs73580867	chr16:78120953	C/T	cg04733911	chr16:78082701	NA	0.57	8.05	0.35	7.03e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13425677	chr5:56112090	MAP3K1	0.43	6.89	0.3	1.89e-11	Cognitive performance;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg18225595	chr11:63971243	STIP1	0.56	7.28	0.32	1.41e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7107174	1.000	rs55761949	chr11:77993860	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.46	-0.33	4.36e-13	Testicular germ cell tumor;
LGG	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg26513180	chr16:89883248	FANCA	-0.89	-18.97	-0.66	8.54e-60	Vitiligo;
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg26850624	chr5:429559	AHRR	-0.38	-8.0	-0.35	9.76e-15	Cystic fibrosis severity;
LGG	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-7.11	-0.31	4.56e-12	Arsenic metabolism;
LGG	cis	rs7119038	0.509	rs10892259	chr11:118583002	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.76	0.3	4.25e-11	Sjögren's syndrome;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg05025164	chr4:1340916	KIAA1530	-0.49	-8.48	-0.37	3.09e-16	Obesity-related traits;
LGG	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg15704280	chr7:45808275	SEPT13	-1.0	-21.96	-0.71	9.16e-74	Height;
LGG	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg24189917	chr7:1970923	MAD1L1	-0.58	-8.67	-0.37	7.09e-17	Bipolar disorder;
LGG	cis	rs7166081	1.000	rs2033783	chr15:67507768	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.85	-0.3	2.37e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1519814	0.876	rs10955954	chr8:121108052	A/G	cg22335954	chr8:121166405	COL14A1	-0.53	-10.76	-0.45	3.11e-24	Breast cancer;
LGG	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg06238570	chr21:40685208	BRWD1	-0.44	-6.83	-0.3	2.69e-11	Cognitive function;
LGG	cis	rs721399	1.000	rs721399	chr8:18259366	C/T	cg18736775	chr8:18248649	NAT2	0.51	9.01	0.39	5.22e-18	Blood metabolite levels;
LGG	cis	rs2694528	1.000	rs2694528	chr5:60273923	C/A	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.57	-0.33	2.07e-13	Parkinson's disease;
LGG	cis	rs2692947	0.696	rs2576437	chr2:96800417	T/C	cg22654517	chr2:96458247	NA	0.38	8.2	0.36	2.4e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs1816752	0.746	rs9511270	chr13:25018680	C/T	cg22771759	chr13:24902376	NA	0.41	7.0	0.31	9e-12	Obesity-related traits;
LGG	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg05973401	chr12:123451056	ABCB9	-0.49	-7.08	-0.31	5.36e-12	Neutrophil percentage of white cells;
LGG	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg07395648	chr5:131743802	NA	-0.46	-8.6	-0.37	1.21e-16	Breast cancer;Mosquito bite size;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.81	-0.38	2.53e-17	Joint mobility (Beighton score);
LGG	trans	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.65	0.48	1.14e-27	Corneal astigmatism;
LGG	cis	rs1125355	0.622	rs10497201	chr2:159614144	T/C	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.99	-0.35	1.1e-14	Initial pursuit acceleration;
LGG	cis	rs2204008	0.807	rs8186948	chr12:38325101	C/G	cg26384229	chr12:38710491	ALG10B	0.92	20.33	0.69	4.05e-66	Bladder cancer;
LGG	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg03929089	chr4:120376271	NA	0.68	7.47	0.33	3.93e-13	Intraocular pressure;
LGG	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg06353428	chr16:71660113	MARVELD3	0.75	7.03	0.31	7.31e-12	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.13	0.43	6.39e-22	Height;
LGG	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg11279151	chr3:101281821	RG9MTD1	-0.39	-6.95	-0.31	1.23e-11	Colorectal cancer;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2236918	0.932	rs1635501	chr1:242040775	C/T	cg17736920	chr1:242011382	EXO1	0.41	7.18	0.32	2.71e-12	Menopause (age at onset);
LGG	cis	rs975722	0.622	rs213934	chr7:117212723	T/C	cg10524701	chr7:117356490	CTTNBP2	0.46	9.86	0.42	6.01e-21	Coronary artery disease;
LGG	cis	rs7762018	0.556	rs78864023	chr6:170059755	T/A	cg19338460	chr6:170058176	WDR27	-0.85	-10.08	-0.42	9.81e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7572644	0.639	rs74429612	chr2:27993843	C/T	cg27432699	chr2:27873401	GPN1	0.51	7.24	0.32	1.83e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2734839	0.964	rs11214605	chr11:113300601	C/T	cg14159747	chr11:113255604	NA	0.26	6.96	0.31	1.14e-11	Information processing speed;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.09	0.42	9.02e-22	Rheumatoid arthritis;
LGG	cis	rs7474896	0.537	rs2472149	chr10:38262196	A/C	cg00409905	chr10:38381863	ZNF37A	0.47	7.0	0.31	8.98e-12	Obesity (extreme);
LGG	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs11203032	0.908	rs11812888	chr10:90957546	G/T	cg16672925	chr10:90967113	CH25H	0.51	7.95	0.35	1.47e-14	Heart failure;
LGG	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26054232	chr11:68816191	TPCN2	0.49	7.48	0.33	3.75e-13	Gut microbiome composition (summer);
LGG	cis	rs17270561	0.609	rs9393662	chr6:25739670	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs11792861	0.926	rs72607166	chr9:111821530	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.56e-19	Menarche (age at onset);
LGG	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg18851795	chr1:204543875	NA	-0.35	-6.71	-0.3	5.76e-11	Schizophrenia;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg18350739	chr11:68623251	NA	-0.87	-22.71	-0.73	2.85e-77	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4629710	0.545	rs11154621	chr6:131547341	A/G	cg12606694	chr6:131520996	AKAP7	0.47	7.93	0.35	1.64e-14	Multiple myeloma (IgH translocation);
LGG	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg19025524	chr12:109796872	NA	-0.39	-7.81	-0.34	3.73e-14	Neuroticism;
LGG	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg20308403	chr7:2120281	MAD1L1	0.32	6.91	0.31	1.66e-11	Schizophrenia;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.92	0.51	8.24e-33	Prudent dietary pattern;
LGG	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.81	-0.34	3.8e-14	Obesity (extreme);
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg14500267	chr11:67383377	NA	0.46	8.65	0.37	8.65e-17	Mean corpuscular volume;
LGG	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs422424	chr20:25445446	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3747547	0.892	rs56408868	chr9:38003124	G/T	cg13774184	chr9:37916125	SHB	-0.7	-7.18	-0.32	2.73e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg23280166	chr11:118938394	VPS11	-0.43	-7.17	-0.32	2.99e-12	Coronary artery disease;
LGG	cis	rs12613586	1	rs12613586	chr2:112948954	C/T	cg07905836	chr2:113190072	RGPD8;RGPD5	0.69	7.42	0.33	5.8e-13	Neuroticism;
LGG	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg04568710	chr12:38710424	ALG10B	-0.33	-7.2	-0.32	2.43e-12	Heart rate;
LGG	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.11	0.35	4.48e-15	Mean platelet volume;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.4	0.65	3.72e-57	Personality dimensions;
LGG	cis	rs1862618	0.756	rs13356762	chr5:56110992	G/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.66	-0.44	7.08e-24	Initial pursuit acceleration;
LGG	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25427524	chr10:38739819	LOC399744	-0.68	-13.78	-0.54	1.91e-36	Extrinsic epigenetic age acceleration;
LGG	cis	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg13443165	chr9:33130375	B4GALT1	-0.73	-14.4	-0.56	4.22e-39	IgG glycosylation;
LGG	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg12463550	chr7:65579703	CRCP	0.79	8.53	0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	5.08e-18	Lung cancer;
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.05	-0.31	6.48e-12	Aortic root size;
LGG	cis	rs5758511	0.514	rs5751221	chr22:42516366	C/T	cg15128208	chr22:42549153	NA	0.79	12.72	0.51	5.14e-32	Birth weight;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg10185311	chr6:26124167	HIST1H2AC;HIST1H2BC	-0.43	-6.91	-0.31	1.64e-11	Height;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg15971980	chr6:150254442	NA	0.45	8.63	0.37	9.97e-17	Lung cancer;
LGG	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-9.71	-0.41	1.99e-20	Schizophrenia;
LGG	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03517284	chr6:25882590	NA	0.49	9.2	0.39	1.27e-18	Blood metabolite levels;
LGG	cis	rs9916302	0.904	rs602688	chr17:37439496	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.68	-0.59	9.32e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6694672	0.850	rs857027	chr1:197013464	T/C	cg13682187	chr1:196946512	CFHR5	0.49	6.79	0.3	3.36e-11	Asthma;
LGG	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg26924012	chr15:45694286	SPATA5L1	0.41	6.79	0.3	3.39e-11	Uric acid levels;
LGG	cis	rs7715806	0.509	rs34349	chr5:74944868	A/G	cg19683494	chr5:74908142	NA	-0.59	-8.08	-0.35	5.64e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg12438819	chr7:158236134	PTPRN2	0.33	8.63	0.37	9.55e-17	Obesity-related traits;
LGG	cis	rs9354308	0.764	rs9354330	chr6:66603308	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs78663649	0.708	rs79268770	chr19:16601411	A/T	cg10248733	chr19:16607483	C19orf44;CALR3	-0.87	-6.87	-0.3	2.03e-11	White blood cell count;
LGG	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg02574844	chr11:5959923	NA	-0.55	-8.88	-0.38	1.49e-17	DNA methylation (variation);
LGG	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg02023728	chr11:77925099	USP35	0.45	7.85	0.34	2.89e-14	Testicular germ cell tumor;
LGG	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg15997130	chr1:24165203	NA	-0.5	-13.38	-0.53	9.76e-35	Immature fraction of reticulocytes;
LGG	cis	rs4731207	0.698	rs10269011	chr7:124478813	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg27597069	chr6:37321822	RNF8	0.44	7.2	0.32	2.48e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9611519	0.929	rs12484477	chr22:41429084	G/A	cg03806693	chr22:41940476	POLR3H	-0.52	-7.87	-0.34	2.58e-14	Neuroticism;
LGG	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.43	-6.75	-0.3	4.44e-11	Menarche (age at onset);
LGG	trans	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs2227564	0.729	rs2675674	chr10:75652682	G/A	cg00564723	chr10:75632066	CAMK2G	-0.45	-9.04	-0.39	4.15e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs963731	0.579	rs297161	chr2:39332668	G/C	cg04010122	chr2:39346883	SOS1	-0.76	-7.89	-0.34	2.21e-14	Corticobasal degeneration;
LGG	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.9e-21	Cannabis dependence symptom count;
LGG	cis	rs4481887	0.504	rs6587439	chr1:248376070	A/G	cg00666640	chr1:248458726	OR2T12	-0.45	-6.67	-0.3	7.52e-11	Common traits (Other);
LGG	cis	rs12724450	0.793	rs71622694	chr1:150296205	C/T	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.43	-0.33	5.45e-13	Tonsillectomy;
LGG	cis	rs155076	1.000	rs261427	chr13:21860998	G/A	cg11317459	chr13:21872234	NA	-1.23	-20.44	-0.69	1.23e-66	White matter hyperintensity burden;
LGG	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.66	0.41	3.14e-20	Menarche (age at onset);
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg05552183	chr6:42928497	GNMT	0.44	13.19	0.52	5.79e-34	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs773506	0.863	rs2482338	chr9:94037873	A/G	cg14446406	chr9:93919335	NA	-0.45	-8.23	-0.36	1.93e-15	Type 2 diabetes nephropathy;
LGG	cis	rs7208859	0.623	rs11652533	chr17:29060601	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7077256	0.564	rs72835387	chr10:65119858	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.95	-0.31	1.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2011503	1.000	rs4808962	chr19:19579557	A/G	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs6500395	0.889	rs2080507	chr16:48688634	T/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs921968	0.544	rs58827325	chr2:219415166	A/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.13	-0.31	3.92e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg02951883	chr7:2050386	MAD1L1	-0.54	-10.51	-0.44	2.47e-23	Schizophrenia;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg05335186	chr13:53173507	NA	-0.41	-8.31	-0.36	1.06e-15	Lewy body disease;
LGG	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.97	12.73	0.51	4.97e-32	Lung cancer in ever smokers;
LGG	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg20891283	chr12:69753455	YEATS4	-0.78	-15.82	-0.59	2.13e-45	Blood protein levels;
LGG	cis	rs4746818	0.793	rs2805913	chr10:70858062	A/G	cg11621586	chr10:70884670	VPS26A	0.78	13.09	0.52	1.55e-33	Left atrial antero-posterior diameter;
LGG	cis	rs975739	0.657	rs7336778	chr13:78604887	C/T	cg07847733	chr13:78271382	SLAIN1	0.47	8.12	0.35	4.15e-15	Hair color;
LGG	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg09998033	chr7:158218633	PTPRN2	-0.54	-10.0	-0.42	1.83e-21	Obesity-related traits;
LGG	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg12813108	chr7:99719912	CNPY4	-0.77	-15.16	-0.58	1.92e-42	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.72	0.3	5.37e-11	Schizophrenia;
LGG	cis	rs2665103	0.610	rs56398167	chr15:82529823	T/C	cg00614314	chr15:82944287	LOC80154	0.45	7.61	0.33	1.6e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11650494	0.710	rs2233666	chr17:47484286	T/C	cg08112188	chr17:47440006	ZNF652	1.19	12.67	0.51	8.25e-32	Prostate cancer;
LGG	cis	rs4819852	0.958	rs756653	chr22:19976845	G/A	cg07821417	chr22:19972146	ARVCF	0.62	13.05	0.52	2.3e-33	Pulse pressure;
LGG	cis	rs2404602	0.716	rs67920045	chr15:76800084	G/A	cg15268244	chr15:77196840	NA	-0.32	-6.91	-0.31	1.63e-11	Blood metabolite levels;
LGG	cis	rs4750440	0.706	rs1599413	chr10:14019197	C/A	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.83	-0.51	1.94e-32	Adiponectin levels;
LGG	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg27398817	chr8:82754497	SNX16	-0.64	-10.07	-0.42	1.04e-21	Diastolic blood pressure;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg16395133	chr6:150326394	RAET1K	0.27	6.71	0.3	5.69e-11	Alopecia areata;
LGG	cis	rs988958	0.958	rs35771566	chr2:42280358	C/T	cg27252766	chr2:42229092	NA	0.47	7.85	0.34	3.01e-14	Hypospadias;
LGG	cis	rs11190604	0.767	rs10883478	chr10:102162852	C/T	cg07080220	chr10:102295463	HIF1AN	0.57	9.99	0.42	1.99e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg02403541	chr12:121454288	C12orf43	0.73	12.82	0.51	2.13e-32	N-glycan levels;
LGG	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.79	-0.57	8.48e-41	Morning vs. evening chronotype;
LGG	cis	rs847577	0.630	rs2132276	chr7:97826340	G/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.7	-0.3	6.11e-11	Breast cancer;
LGG	cis	rs9783347	1.000	rs1140047	chr11:18327684	G/T	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.13	-0.31	3.9e-12	Pancreatic cancer;
LGG	cis	rs12908161	1.000	rs35630683	chr15:85349231	T/C	cg03959625	chr15:84868606	LOC388152	0.48	6.99	0.31	9.93e-12	Schizophrenia;
LGG	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	trans	rs458649	0.947	rs457961	chr5:4277869	A/G	cg00038233	chr11:123899065	OR10G8	0.44	7.04	0.31	6.98e-12	Endometriosis;
LGG	cis	rs9916302	0.706	rs9890198	chr17:37457480	A/C	cg07936489	chr17:37558343	FBXL20	1.02	15.31	0.58	4.36e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs10504073	0.584	rs7823690	chr8:49943831	G/A	cg00325661	chr8:49890786	NA	0.77	15.09	0.57	4.04e-42	Blood metabolite ratios;
LGG	cis	rs9397585	0.751	rs1538247	chr6:153395344	A/G	cg17707550	chr6:153380415	RGS17	0.4	8.14	0.35	3.72e-15	Body mass index;
LGG	cis	rs9398803	0.865	rs1490388	chr6:126835655	C/T	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg12310025	chr6:25882481	NA	0.72	14.38	0.56	4.94e-39	Blood metabolite levels;
LGG	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg05791153	chr7:19748676	TWISTNB	0.72	9.89	0.42	4.78e-21	Thyroid stimulating hormone;
LGG	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.76	0.3	4.19e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4819052	0.851	rs7276103	chr21:46666078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	8.16	0.35	3.19e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9300255	0.602	rs1716165	chr12:123648881	C/T	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs4132509	1.000	rs320320	chr1:243835186	A/G	cg25706552	chr1:244017396	NA	0.53	8.74	0.38	4.36e-17	RR interval (heart rate);
LGG	cis	rs6496667	0.533	rs2589949	chr15:90955015	C/T	cg22089800	chr15:90895588	ZNF774	0.49	7.9	0.34	2.11e-14	Rheumatoid arthritis;
LGG	cis	rs1127311	0.901	rs11264223	chr1:154565519	G/A	cg11650704	chr1:154556575	ADAR	-0.5	-10.0	-0.42	1.95e-21	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2708977	0.637	rs618454	chr2:97080093	C/G	cg01950434	chr2:97203154	ARID5A	-0.47	-7.16	-0.32	3.28e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4639966	0.836	rs7130875	chr11:118613674	T/C	cg20110707	chr11:118481992	PHLDB1	-0.42	-6.77	-0.3	3.9e-11	Systemic lupus erythematosus;
LGG	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg14664628	chr15:75095509	CSK	0.46	8.67	0.37	7.55e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs11098499	0.954	rs7656252	chr4:120404268	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.99	-0.6	3.93e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs6028335	0.674	rs6028234	chr20:37607869	A/C	cg16355469	chr20:37678765	NA	0.6	7.92	0.35	1.79e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg13010199	chr12:38710504	ALG10B	0.73	14.89	0.57	2.91e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs738322	0.934	rs133016	chr22:38572582	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs611744	0.503	rs13282220	chr8:109263043	T/C	cg18478394	chr8:109455254	TTC35	0.39	7.45	0.33	4.61e-13	Dupuytren's disease;
LGG	trans	rs4714291	0.802	rs7759622	chr6:40114735	C/T	cg02267698	chr19:7991119	CTXN1	-0.61	-9.92	-0.42	3.63e-21	Strep throat;
LGG	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg19812747	chr11:111475976	SIK2	0.41	7.57	0.33	2.09e-13	Primary sclerosing cholangitis;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.4	0.4	2.47e-19	Intelligence (multi-trait analysis);
LGG	cis	rs988958	0.567	rs10184755	chr2:42258948	C/T	cg27252766	chr2:42229092	NA	-0.53	-8.05	-0.35	6.81e-15	Hypospadias;
LGG	trans	rs12310956	0.510	rs2054867	chr12:33835462	C/G	cg13010199	chr12:38710504	ALG10B	-0.43	-8.22	-0.36	2.06e-15	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.23	0.32	2.04e-12	Lung cancer;
LGG	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.35e-12	Total cholesterol levels;
LGG	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.77	-0.34	5e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs870825	0.587	rs28454955	chr4:185632701	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs283228	0.617	rs684160	chr6:101743823	G/A	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs524281	1.000	rs475805	chr11:65848738	G/A	cg14541915	chr11:65894463	PACS1	-0.31	-7.17	-0.32	2.94e-12	Electroencephalogram traits;
LGG	cis	rs6988985	0.693	rs10093796	chr8:143978424	T/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs793571	0.714	rs972801	chr15:58921198	C/T	cg05156742	chr15:59063176	FAM63B	-0.49	-8.0	-0.35	1.02e-14	Schizophrenia;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg06074448	chr4:187884817	NA	-0.59	-12.91	-0.51	8.81e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9296092	0.560	rs17627049	chr6:33537802	G/T	cg13560919	chr6:33536144	NA	-1.04	-21.1	-0.7	9.62e-70	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9886651	0.935	rs36157705	chr8:128797938	A/G	cg24514600	chr8:128805414	PVT1	-0.55	-12.61	-0.51	1.46e-31	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22624212	chr21:44298959	WDR4	0.49	7.85	0.34	2.82e-14	Gut microbiome composition (summer);
LGG	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.73	0.69	5.21e-68	Calcium levels;
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-11.13	-0.46	1.19e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2658782	0.507	rs4457713	chr11:93037430	C/T	cg15737290	chr11:93063684	CCDC67	0.66	10.95	0.45	5.72e-25	Pulmonary function decline;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06169200	chr11:22647380	FANCF	0.42	7.04	0.31	6.82e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg06360820	chr2:242988706	NA	-0.52	-7.67	-0.34	1.04e-13	Obesity-related traits;
LGG	cis	rs2067615	1.000	rs2067615	chr12:107149422	A/T	cg15890332	chr12:107067104	RFX4	-0.32	-9.01	-0.39	5.61e-18	Heart rate;
LGG	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg00919237	chr7:87102261	ABCB4	-0.8	-15.57	-0.59	2.99e-44	Gallbladder cancer;
LGG	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	10.95	0.45	5.56e-25	Mean platelet volume;
LGG	cis	rs3219090	0.586	rs11801168	chr1:226544831	C/T	cg17127702	chr1:226594323	PARP1	-0.32	-9.86	-0.42	6.07e-21	Melanoma;
LGG	cis	rs875971	0.862	rs7809814	chr7:65615397	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.62e-16	Aortic root size;
LGG	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-12.84	-0.51	1.77e-32	Vitamin D levels;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.82	0.34	3.54e-14	Lung cancer;
LGG	cis	rs2905347	0.964	rs2961270	chr7:22622138	C/A	cg18045685	chr7:22629474	NA	-0.79	-17.39	-0.63	1.65e-52	Major depression and alcohol dependence;
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg14926445	chr8:58193284	C8orf71	-0.93	-13.66	-0.54	6.05e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs35103567	chr6:163183400	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.78	0.3	3.73e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.52	-0.5	3.56e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg23221052	chr5:179740743	GFPT2	-0.6	-11.06	-0.46	2.16e-25	Height;
LGG	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg02951883	chr7:2050386	MAD1L1	0.43	7.07	0.31	5.78e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4262150	0.690	rs72795379	chr5:151932354	A/G	cg12297329	chr5:152029980	NA	-0.73	-13.92	-0.54	4.7e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs7122539	0.646	rs569818	chr11:66570749	G/A	cg01599099	chr11:66649832	PC	0.37	7.42	0.33	5.54e-13	HIV-1 susceptibility;
LGG	cis	rs13314892	0.692	rs57317066	chr3:69861072	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs4689388	0.926	rs10937719	chr4:6295322	C/G	cg14416269	chr4:6271139	WFS1	0.51	9.22	0.39	1.01e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9788682	0.747	rs8042374	chr15:78908032	A/G	cg06917634	chr15:78832804	PSMA4	-0.51	-8.05	-0.35	7.15e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg00806245	chr18:76673096	NA	-0.56	-6.71	-0.3	5.8e-11	Obesity-related traits;
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg22072935	chr14:105399595	NA	-0.5	-9.57	-0.41	6.44e-20	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs3784262	0.742	rs28379349	chr15:58202494	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	7.03	0.31	7.67e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6450176	0.633	rs617777	chr5:53330440	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.58	-0.47	1.99e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg22517653	chr1:2918612	NA	-0.45	-7.12	-0.31	4.1e-12	Plateletcrit;
LGG	cis	rs2274273	0.840	rs10150760	chr14:55821548	C/T	cg04306507	chr14:55594613	LGALS3	-0.6	-16.69	-0.61	2.77e-49	Protein biomarker;
LGG	cis	rs9807841	0.545	rs4804514	chr19:10764203	G/T	cg17710535	chr19:10819994	QTRT1	0.48	7.76	0.34	5.4e-14	Inflammatory skin disease;
LGG	cis	rs2635047	0.566	rs8092050	chr18:44796323	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.46	0.33	4.19e-13	Educational attainment;
LGG	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg06028605	chr16:24865363	SLC5A11	0.48	7.9	0.34	2.12e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs735539	0.521	rs2251031	chr13:21414326	G/T	cg04906043	chr13:21280425	IL17D	-0.49	-7.56	-0.33	2.15e-13	Dental caries;
LGG	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg19507638	chr5:93509721	C5orf36	-0.69	-9.66	-0.41	3.22e-20	Diabetic retinopathy;
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs4478137	0.899	rs10857354	chr4:164239841	A/G	cg06758707	chr4:164254230	NPY1R	0.71	12.73	0.51	5.09e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg07541023	chr7:19748670	TWISTNB	0.46	7.21	0.32	2.24e-12	Thyroid stimulating hormone;
LGG	cis	rs10504073	0.565	rs974780	chr8:49930976	G/A	cg00325661	chr8:49890786	NA	0.82	16.47	0.61	2.54e-48	Blood metabolite ratios;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09163117	chr2:239148697	HES6	0.51	7.77	0.34	5.04e-14	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.11e-100	Height;
LGG	trans	rs11098499	0.909	rs28632018	chr4:120386730	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.31	0.5	2.5e-30	Corneal astigmatism;
LGG	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.87	0.34	2.47e-14	Retinal vascular caliber;
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.54	-0.33	2.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg17376030	chr22:41985996	PMM1	-0.55	-9.1	-0.39	2.65e-18	Vitiligo;
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18876405	chr7:65276391	NA	0.5	8.85	0.38	1.87e-17	Aortic root size;
LGG	cis	rs1816854	0.938	rs3764004	chr12:44201451	T/C	cg00106942	chr12:44200524	TWF1	0.42	6.82	0.3	2.92e-11	Inflammatory bowel disease;
LGG	cis	rs6764363	0.527	rs13091420	chr3:277889	A/G	cg02057681	chr3:285234	CHL1	-0.42	-7.52	-0.33	2.78e-13	Sudden cardiac arrest;
LGG	cis	rs7927771	0.839	rs59360790	chr11:47669175	T/C	cg20307385	chr11:47447363	PSMC3	-0.41	-7.24	-0.32	1.85e-12	Subjective well-being;
LGG	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg03477792	chr4:77819574	ANKRD56	0.52	9.39	0.4	2.81e-19	Emphysema distribution in smoking;
LGG	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg16096631	chr1:42092165	HIVEP3	0.72	19.93	0.68	2.79e-64	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg19628046	chr18:33552617	C18orf21	0.5	7.23	0.32	1.95e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg14346243	chr4:90757452	SNCA	-0.4	-8.15	-0.35	3.38e-15	Dementia with Lewy bodies;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26759552	chr7:139877471	LOC100134229;JHDM1D	0.4	6.65	0.3	8.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs644799	0.603	rs1255180	chr11:95472134	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.62	0.33	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07132326	chr6:150258058	NA	0.36	7.72	0.34	7.08e-14	Testicular germ cell tumor;
LGG	cis	rs9393813	0.529	rs4711155	chr6:27446446	C/A	cg18711553	chr6:27366782	ZNF391	-0.47	-9.05	-0.39	3.96e-18	Bipolar disorder;
LGG	cis	rs6500395	1.000	rs1558816	chr16:48704868	T/A	cg16662043	chr16:48846231	NA	-0.37	-7.33	-0.32	1.02e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.66	-0.41	3.1e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg15269541	chr15:43626905	ADAL	0.43	7.61	0.33	1.59e-13	Lung cancer in ever smokers;
LGG	cis	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg07460842	chr6:66804631	NA	0.72	12.6	0.51	1.62e-31	Type 2 diabetes;
LGG	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg27624424	chr6:160112604	SOD2	0.65	9.27	0.4	6.84e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.58	-0.44	1.43e-23	Alzheimer's disease;
LGG	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.49	0.53	3.23e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25172604	chr17:41446521	NA	-0.3	-6.81	-0.3	2.99e-11	Menopause (age at onset);
LGG	cis	rs4732038	0.510	rs12671983	chr7:134273155	T/C	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg17809284	chr5:56205270	C5orf35	0.54	10.16	0.43	4.86e-22	Initial pursuit acceleration;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-10.46	-0.44	3.9699999999999997e-23	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg00938859	chr5:1591904	SDHAP3	-0.8	-11.72	-0.48	5.6e-28	Breast cancer;
LGG	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg12337884	chr13:114819908	RASA3	-0.48	-6.67	-0.3	7.49e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2361710	0.611	rs3816257	chr17:78074446	G/T	cg06718696	chr17:78121285	EIF4A3	-0.55	-8.86	-0.38	1.73e-17	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs3741151	1.000	rs3741149	chr11:73021084	A/G	cg17517138	chr11:73019481	ARHGEF17	-1.0	-10.64	-0.44	8.47e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1594829	0.553	rs17055108	chr8:26160739	G/A	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs593982	1.000	rs74638829	chr11:65495571	C/T	cg08755490	chr11:65554678	OVOL1	-0.74	-10.38	-0.43	7.52e-23	Atopic dermatitis;
LGG	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.74	0.45	3.61e-24	Total body bone mineral density;
LGG	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg26597838	chr10:835615	NA	0.75	10.3	0.43	1.57e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg08888203	chr3:10149979	C3orf24	0.58	9.76	0.41	1.32e-20	Alzheimer's disease;
LGG	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-6.84	-0.3	2.59e-11	Parkinson's disease;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.9	0.38	1.25e-17	Schizophrenia;
LGG	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg07005078	chr4:17578674	LAP3	0.37	6.93	0.31	1.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11920090	0.789	rs73169742	chr3:170756779	C/T	cg09710316	chr3:170744871	SLC2A2	0.7	8.37	0.36	7.09e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2290402	0.536	rs56080039	chr4:886519	G/A	cg00846425	chr4:957561	DGKQ	-0.43	-6.8	-0.3	3.18e-11	Type 2 diabetes;
LGG	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.16	0.66	1.15e-60	Smoking behavior;
LGG	cis	rs34599045	0.522	rs3885994	chr1:152937926	A/C	cg07796016	chr1:152779584	LCE1C	-0.89	-8.56	-0.37	1.69e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs589448	0.902	rs2603089	chr12:69776800	C/T	cg14784868	chr12:69753453	YEATS4	-0.98	-23.85	-0.74	1.32e-82	Cerebrospinal fluid biomarker levels;
LGG	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11987759	chr7:65425863	GUSB	-0.41	-8.03	-0.35	8.28e-15	Aortic root size;
LGG	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.42	0.53	6.19e-35	Colorectal cancer;
LGG	cis	rs2594989	0.943	rs2454502	chr3:11499331	T/C	cg01796438	chr3:11312864	ATG7	-0.52	-7.17	-0.32	2.97e-12	Circulating chemerin levels;
LGG	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg12751644	chr20:60527061	NA	-0.3	-6.73	-0.3	5.03e-11	Body mass index;
LGG	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg01657329	chr11:68192670	LRP5	-0.65	-10.15	-0.43	5.67e-22	Bone mineral density (spine);
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.57e-22	Menopause (age at onset);
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.68	0.3	6.96e-11	Schizophrenia;
LGG	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs74781061	0.929	rs117379081	chr15:74772447	T/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.86	-0.3	2.18e-11	Endometriosis;
LGG	cis	rs3784262	0.669	rs4646592	chr15:58302557	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.97	-0.31	1.1e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg06850241	chr22:41845214	NA	0.45	7.1	0.31	4.71e-12	Vitiligo;
LGG	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg25208724	chr1:156163844	SLC25A44	1.03	17.91	0.64	7.16e-55	Testicular germ cell tumor;
LGG	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg21775007	chr8:11205619	TDH	-0.54	-9.05	-0.39	3.93e-18	Neuroticism;
LGG	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg15704280	chr7:45808275	SEPT13	-0.82	-13.67	-0.54	5.66e-36	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.737	rs10278971	chr7:148780659	A/T	cg23583168	chr7:148888333	NA	-0.81	-15.27	-0.58	6.57e-43	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15087147	chr7:127672169	SND1;LRRC4	0.47	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg24955955	chr5:415729	AHRR	0.81	10.78	0.45	2.51e-24	Fat distribution (HIV);
LGG	cis	rs1122900	1.000	rs1122900	chr5:36689181	A/C	cg24186104	chr5:36689192	NA	-0.5	-11.36	-0.47	1.46e-26	Aggressive periodontitis;
LGG	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.95	0.38	8.47e-18	Rheumatoid arthritis;
LGG	cis	rs9324022	0.929	rs9635184	chr14:101173056	C/T	cg18089426	chr14:101175970	NA	0.7	11.26	0.46	3.61e-26	Plateletcrit;
LGG	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg25019033	chr10:957182	NA	-0.52	-9.61	-0.41	4.61e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	trans	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg27400746	chr16:89904261	SPIRE2	-0.82	-13.45	-0.53	4.65e-35	Skin colour saturation;
LGG	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6032067	0.714	rs6017527	chr20:43886291	G/A	cg10761708	chr20:43804764	PI3	0.58	8.89	0.38	1.33e-17	Blood protein levels;
LGG	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.69	-0.41	2.43e-20	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg06238570	chr21:40685208	BRWD1	-0.44	-6.68	-0.3	6.73e-11	Cognitive function;
LGG	cis	rs514024	0.519	rs6478788	chr9:130376248	G/A	cg13643465	chr9:130375613	STXBP1	0.51	8.84	0.38	2e-17	Eating disorders (purging via substances);
LGG	cis	rs9815354	0.812	rs73828254	chr3:41810180	T/A	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2732480	0.500	rs7966829	chr12:48615603	G/T	cg24011408	chr12:48396354	COL2A1	0.47	7.52	0.33	2.85e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10284592	chr11:57434942	ZDHHC5	0.45	7.49	0.33	3.57e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs77216612	0.835	rs10845621	chr12:12887977	C/T	cg24098013	chr12:12878779	APOLD1	0.5	8.37	0.36	6.84e-16	Lymphocyte counts;
LGG	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.98	0.35	1.2e-14	Homoarginine levels;
LGG	cis	rs8180040	0.701	rs1079276	chr3:47045739	C/G	cg27129171	chr3:47204927	SETD2	0.82	15.62	0.59	1.83e-44	Colorectal cancer;
LGG	cis	rs1790761	0.967	rs7131041	chr11:67230184	A/T	cg00864171	chr11:67383662	NA	-0.42	-6.93	-0.31	1.42e-11	Mean corpuscular volume;
LGG	cis	rs67311347	0.544	rs60329764	chr3:40334621	C/T	cg13683864	chr3:40499215	RPL14	0.82	17.05	0.62	6.23e-51	Renal cell carcinoma;
LGG	cis	rs9534288	0.664	rs1926446	chr13:46629995	A/C	cg15192986	chr13:46630673	CPB2	0.66	14.1	0.55	8.26e-38	Blood protein levels;
LGG	cis	rs62064224	0.675	rs4795693	chr17:30636727	A/G	cg25809561	chr17:30822961	MYO1D	0.33	7.67	0.34	1.01e-13	Schizophrenia;
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg07157834	chr1:205819609	PM20D1	-0.45	-7.39	-0.32	7.14e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07308232	chr7:1071921	C7orf50	-0.56	-10.05	-0.42	1.3e-21	Longevity;Endometriosis;
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg13009111	chr11:71350975	NA	-0.3	-6.66	-0.3	7.58e-11	Mood instability;
LGG	cis	rs735539	0.521	rs2585898	chr13:21400301	T/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.32	-0.32	1.07e-12	Dental caries;
LGG	cis	rs9902453	0.838	rs9646436	chr17:28209059	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	12.81	0.51	2.35e-32	Coffee consumption (cups per day);
LGG	cis	rs853679	0.517	rs9368554	chr6:28082711	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6908034	0.607	rs73376655	chr6:19805664	C/T	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00689492	chr4:1303491	MAEA	0.42	6.72	0.3	5.49e-11	Obesity-related traits;
LGG	cis	rs9595066	0.548	rs9562537	chr13:44755787	G/A	cg04068111	chr13:44716778	NA	-0.55	-8.11	-0.35	4.45e-15	Schizophrenia;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2270450	0.731	rs2216465	chr6:46676019	C/G	cg10156739	chr6:46714674	LOC100287718	-0.35	-8.29	-0.36	1.2e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs6577655	0.517	rs4909295	chr8:135588042	G/A	cg17885191	chr8:135476712	NA	0.59	8.72	0.38	4.84e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg21798802	chr22:38057573	PDXP	0.39	8.58	0.37	1.39e-16	Fat distribution (HIV);
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg26578617	chr4:90757533	SNCA	-0.44	-8.72	-0.38	4.97e-17	Dementia with Lewy bodies;
LGG	cis	rs4891159	0.548	rs10782013	chr18:74128348	C/T	cg24786174	chr18:74118243	ZNF516	0.68	17.4	0.63	1.53e-52	Longevity;
LGG	trans	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.14	-0.31	3.65e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1030877	0.557	rs2278501	chr2:105979506	C/T	cg02079111	chr2:105885981	TGFBRAP1	-0.5	-8.83	-0.38	2.22e-17	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20591167	chr15:99602178	NA	0.56	9.19	0.39	1.36e-18	Gut microbiome composition (summer);
LGG	cis	rs2273669	0.588	rs78276890	chr6:109305299	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.46	0.33	4.17e-13	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.81e-56	Refractive error;
LGG	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.13	-0.31	3.99e-12	Systolic blood pressure;
LGG	cis	rs10927875	0.631	rs945418	chr1:16344730	T/C	cg22431228	chr1:16359049	CLCNKA	-0.45	-7.48	-0.33	3.72e-13	Dilated cardiomyopathy;
LGG	cis	rs854765	0.522	rs63721860	chr17:17829576	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-11.99	-0.49	4.99e-29	Total body bone mineral density;
LGG	cis	rs4076764	0.801	rs6675964	chr1:163375960	A/G	cg06092702	chr1:163392909	NA	-0.41	-7.11	-0.31	4.41e-12	Motion sickness;
LGG	cis	rs2735413	0.874	rs12917942	chr16:78064220	T/G	cg04733911	chr16:78082701	NA	-0.77	-17.79	-0.64	2.47e-54	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg14186256	chr22:23484241	RTDR1	-0.96	-23.72	-0.74	5.69e-82	Bone mineral density;
LGG	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg00717180	chr2:96193071	NA	-0.52	-9.98	-0.42	2.26e-21	Coronary artery disease;
LGG	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg25019033	chr10:957182	NA	-0.52	-9.79	-0.41	1.07e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs9715521	0.775	rs62301193	chr4:59844120	C/T	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg11494091	chr17:61959527	GH2	0.59	9.54	0.41	8.22e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18630855	chr2:37459194	CEBPZ;C2orf56	0.41	6.74	0.3	4.8e-11	Cognitive performance;
LGG	cis	rs6076065	0.723	rs2051093	chr20:23371349	G/A	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs986417	0.818	rs10142842	chr14:61085205	C/T	cg27398547	chr14:60952738	C14orf39	-0.66	-6.72	-0.3	5.29e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.578	rs12582423	chr12:33596502	G/C	cg26384229	chr12:38710491	ALG10B	-0.47	-8.19	-0.36	2.57e-15	Morning vs. evening chronotype;
LGG	cis	rs8016982	0.633	rs72695758	chr14:81720146	T/C	cg01989461	chr14:81687754	GTF2A1	0.77	18.18	0.65	3.82e-56	Schizophrenia;
LGG	cis	rs12579753	0.917	rs12366599	chr12:82212112	C/T	cg07988820	chr12:82153109	PPFIA2	-0.72	-10.44	-0.44	4.66e-23	Resting heart rate;
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.22	-0.39	1.06e-18	Life satisfaction;
LGG	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg13939156	chr17:80058883	NA	-0.4	-7.04	-0.31	7.2e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg09818912	chr17:20140352	CYTSB	-0.34	-7.92	-0.35	1.78e-14	Schizophrenia;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.36	0.36	7.65e-16	Obesity-related traits;
LGG	cis	rs422249	0.720	rs174455	chr11:61656117	A/G	cg19610905	chr11:61596333	FADS2	-0.48	-7.61	-0.33	1.56e-13	Trans fatty acid levels;
LGG	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.38e-29	Prudent dietary pattern;
LGG	trans	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg21775007	chr8:11205619	TDH	0.42	6.73	0.3	5.01e-11	Mood instability;
LGG	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.78	-14.87	-0.57	3.58e-41	Platelet count;
LGG	cis	rs74781061	0.858	rs79923136	chr15:74784560	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.12	-0.31	4.14e-12	Endometriosis;
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg04986931	chr22:39850128	NA	-0.37	-8.22	-0.36	2.05e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	4.85e-22	Menopause (age at onset);
LGG	cis	rs9815354	0.812	rs17282671	chr3:41887455	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.37	0.4	3.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1408799	0.532	rs2181816	chr9:12752760	C/T	cg05274944	chr9:12693694	TYRP1	-0.39	-8.29	-0.36	1.26e-15	Eye color;Blue vs. green eyes;
LGG	trans	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg25214090	chr10:38739885	LOC399744	-0.67	-11.69	-0.48	7.81e-28	Corneal astigmatism;
LGG	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs6964587	0.626	rs4422709	chr7:91510968	A/G	cg17063962	chr7:91808500	NA	-0.43	-7.85	-0.34	2.9e-14	Breast cancer;
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg08888203	chr3:10149979	C3orf24	0.5	8.4	0.36	5.44e-16	Alzheimer's disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16470576	chr5:175815543	NOP16;HIGD2A	0.41	7.1	0.31	4.87e-12	Bipolar disorder;
LGG	cis	rs8032158	0.702	rs35040841	chr15:56124149	A/G	cg02198044	chr15:56286336	NEDD4	-0.53	-9.03	-0.39	4.7e-18	Keloid;
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg11984989	chr7:158649758	WDR60	1.05	24.0	0.74	2.75e-83	Height;
LGG	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg03162506	chr22:38580953	NA	0.36	8.9	0.38	1.27e-17	Cutaneous nevi;
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4948496	1.000	rs6479781	chr10:63805735	G/A	cg07520810	chr10:63809149	ARID5B	-0.36	-6.82	-0.3	2.78e-11	Systemic lupus erythematosus;
LGG	cis	rs13424612	1.000	rs66534347	chr2:240899346	G/A	cg01812947	chr2:240904978	NDUFA10	0.43	7.26	0.32	1.62e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg12310025	chr6:25882481	NA	0.6	11.32	0.47	2.1e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	1.000	rs13237667	chr7:19820288	G/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.55	-0.44	1.83e-23	Prostate cancer;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.87	-0.57	3.6e-41	Prudent dietary pattern;
LGG	cis	rs4776059	1.000	rs4776068	chr15:52947401	G/A	cg22715398	chr15:52968154	KIAA1370	-0.52	-8.67	-0.37	7.19e-17	Schizophrenia;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.4	0.36	5.61e-16	Platelet count;
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7551222	0.721	rs1460036	chr1:204527379	A/G	cg20240347	chr1:204465584	NA	-0.56	-11.29	-0.46	2.7e-26	Schizophrenia;
LGG	trans	rs3774749	0.565	rs6800021	chr3:50190346	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	8.0	0.35	1.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.95	0.31	1.25e-11	Lung cancer;
LGG	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg03030879	chr14:75389066	RPS6KL1	0.37	6.77	0.3	3.82e-11	Caffeine consumption;
LGG	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.67	-0.44	6.47e-24	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg02725872	chr8:58115012	NA	-1.06	-14.82	-0.57	6.26e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs6844506	0.624	rs2665738	chr4:185214172	G/A	cg12654155	chr4:185238627	NA	0.4	6.94	0.31	1.33e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs360798	0.512	rs4461246	chr2:63027671	C/T	cg17519650	chr2:63277830	OTX1	-0.5	-8.28	-0.36	1.3e-15	Coronary artery disease;
LGG	cis	rs1555895	0.521	rs1057303	chr10:853155	T/C	cg10556349	chr10:835070	NA	-0.33	-8.26	-0.36	1.53e-15	Survival in rectal cancer;
LGG	cis	rs1595825	0.891	rs1851779	chr2:198647108	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.5	-0.37	2.55e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg03469862	chr11:68924853	NA	0.46	7.07	0.31	5.85e-12	Blond vs. brown hair color;
LGG	cis	rs1008375	0.966	rs6825133	chr4:17577776	C/T	cg02297831	chr4:17616191	MED28	0.47	8.79	0.38	2.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs7444	0.882	rs5998644	chr22:21953288	T/C	cg05046821	chr22:21984468	YDJC	-0.37	-7.03	-0.31	7.31e-12	Systemic lupus erythematosus;
LGG	cis	rs9309473	0.687	rs7576824	chr2:73611281	C/T	cg20560298	chr2:73613845	ALMS1	0.52	9.46	0.4	1.58e-19	Metabolite levels;
LGG	cis	rs1008375	0.897	rs67455495	chr4:17665238	A/T	cg18681998	chr4:17616180	MED28	-0.85	-17.75	-0.64	3.65e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg17911788	chr17:44343683	NA	0.63	9.68	0.41	2.75e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9894429	0.646	rs7406522	chr17:79615396	G/T	cg18240062	chr17:79603768	NPLOC4	0.61	10.29	0.43	1.72e-22	Eye color traits;
LGG	cis	rs2070433	0.539	rs2839314	chr21:47961067	A/G	cg02959939	chr21:47813025	PCNT	-0.31	-6.89	-0.3	1.88e-11	Lymphocyte counts;
LGG	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14154082	chr13:112174009	NA	0.41	8.92	0.38	1.05e-17	Menarche (age at onset);
LGG	cis	rs988958	0.601	rs11887745	chr2:42238054	C/T	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	trans	rs208520	0.609	rs208436	chr6:66897470	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-11.84	-0.48	1.9e-28	Exhaled nitric oxide output;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25072359	chr17:41440525	NA	0.54	10.2	0.43	3.46e-22	Menopause (age at onset);
LGG	trans	rs7395662	0.857	rs11040074	chr11:48856726	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.09	-0.31	5.05e-12	HDL cholesterol;
LGG	cis	rs4330281	0.647	rs7644389	chr3:17502918	C/T	cg20981856	chr3:17787350	NA	-0.36	-6.85	-0.3	2.41e-11	Schizophrenia;
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.88	-0.34	2.3e-14	Height;
LGG	cis	rs55794721	0.509	rs11249248	chr1:25753051	T/C	cg27572855	chr1:25598939	RHD	0.49	11.26	0.46	3.71e-26	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs16854884	0.632	rs34071449	chr3:143662861	C/T	cg06585982	chr3:143692056	C3orf58	0.62	10.7	0.45	4.85e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs911263	0.603	rs7148073	chr14:68777042	T/C	cg18825221	chr14:68749962	RAD51L1	0.36	7.78	0.34	4.72e-14	Primary biliary cholangitis;
LGG	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg01528321	chr10:82214614	TSPAN14	0.69	11.94	0.49	8.1e-29	Post bronchodilator FEV1;
LGG	cis	rs9890032	0.532	rs1808257	chr17:29039966	A/G	cg19761014	chr17:28927070	LRRC37B2	0.41	6.69	0.3	6.42e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.58	0.33	1.91e-13	Longevity;
LGG	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.29	0.36	1.22e-15	Diabetic kidney disease;
LGG	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-12.42	-0.5	9.13e-31	Schizophrenia;
LGG	cis	rs8133932	0.906	rs79854527	chr21:47156852	G/A	cg11214348	chr21:47283868	PCBP3	-0.43	-7.14	-0.31	3.73e-12	Schizophrenia;
LGG	cis	rs2153535	0.580	rs9378552	chr6:8463748	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.33	0.5	2.03e-30	Motion sickness;
LGG	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.77	-0.51	3.41e-32	Chronic sinus infection;
LGG	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg01620082	chr3:125678407	NA	-0.66	-7.41	-0.33	5.97e-13	Depression;
LGG	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg06623630	chr22:50017776	C22orf34	-0.46	-9.05	-0.39	4.03e-18	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg03968126	chr17:45973027	SP2	0.41	6.9	0.31	1.71e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg06453172	chr10:134556979	INPP5A	-0.49	-7.44	-0.33	4.83e-13	Migraine;
LGG	cis	rs2075466	0.514	rs56040623	chr16:4896913	C/T	cg04440724	chr16:4920505	UBN1	-0.62	-9.17	-0.39	1.55e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg11360546	chr7:1094263	C7orf50	-0.42	-7.52	-0.33	2.86e-13	Longevity;Endometriosis;
LGG	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03576123	chr11:487126	PTDSS2	-1.22	-15.75	-0.59	4.41e-45	Body mass index;
LGG	cis	rs28655083	0.529	rs1847161	chr16:77097796	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.43	7.41	0.33	5.93e-13	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg12856521	chr11:46389249	DGKZ	0.73	12.78	0.51	2.93e-32	Leprosy;
LGG	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg00745463	chr17:30367425	LRRC37B	-0.51	-7.2	-0.32	2.44e-12	Hip circumference adjusted for BMI;
LGG	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg00531865	chr16:30841666	NA	0.54	11.52	0.47	3.71e-27	Dementia with Lewy bodies;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg11050988	chr7:1952600	MAD1L1	0.36	8.59	0.37	1.37e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs34330	0.562	rs7486387	chr12:12866911	G/A	cg04607235	chr12:12878440	APOLD1	-0.6	-8.49	-0.37	2.85e-16	Systemic lupus erythematosus;
LGG	cis	rs9902453	0.716	rs3098949	chr17:27978694	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.24	0.52	3.73e-34	Coffee consumption (cups per day);
LGG	cis	rs10883723	0.738	rs3781290	chr10:104244948	G/C	cg05096777	chr10:104283225	SUFU	0.32	7.05	0.31	6.55e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7017697	1.000	rs10092772	chr8:19686385	A/T	cg03894339	chr8:19674705	INTS10	-0.52	-8.6	-0.37	1.2e-16	Breast cancer;
LGG	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.02	-0.39	5.06e-18	Mood instability;
LGG	trans	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg26384229	chr12:38710491	ALG10B	0.71	14.23	0.55	2.21e-38	Morning vs. evening chronotype;
LGG	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.46	-0.37	3.44e-16	Triglycerides;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs62064224	0.589	rs9889607	chr17:30785585	A/C	cg25809561	chr17:30822961	MYO1D	-0.4	-9.56	-0.41	6.75e-20	Schizophrenia;
LGG	cis	rs4481887	0.732	rs4526647	chr1:248423788	C/G	cg13385794	chr1:248469461	NA	0.43	7.04	0.31	7.16e-12	Common traits (Other);
LGG	cis	rs1707322	0.964	rs6675259	chr1:46502295	G/A	cg03146154	chr1:46216737	IPP	-0.53	-9.95	-0.42	2.91e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11229555	0.645	rs10896775	chr11:58175989	A/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs283228	0.617	rs1066380	chr6:101763121	C/T	cg27451362	chr6:101846650	GRIK2	0.99	15.09	0.57	4.03e-42	Coenzyme Q10 levels;
LGG	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs7208859	0.623	rs11650982	chr17:29129955	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07570687	chr10:102243282	WNT8B	0.41	7.49	0.33	3.59e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs72945132	0.769	rs680571	chr11:70187441	G/A	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.25	-0.36	1.62e-15	Retinal vascular caliber;
LGG	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	12.14	0.49	1.26e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.23e-11	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10607939	chr7:112091280	IFRD1	0.45	6.8	0.3	3.19e-11	Gut microbiome composition (summer);
LGG	cis	rs714031	1.000	rs4821909	chr22:40066418	T/C	cg21377881	chr22:40064566	CACNA1I	-0.6	-14.04	-0.55	1.51e-37	Schizophrenia;
LGG	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg08717414	chr16:71523259	ZNF19	-0.47	-6.74	-0.3	4.63e-11	Blood protein levels;
LGG	cis	rs137887	0.845	rs4838877	chr22:50464740	G/C	cg17558497	chr22:50464837	TTLL8	0.44	8.43	0.36	4.31e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11112613	0.762	rs73184077	chr12:105949999	G/A	cg03607813	chr12:105948248	NA	0.64	11.25	0.46	4.14e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs7312933	0.510	rs61942483	chr12:42499538	T/A	cg01943504	chr12:42538901	GXYLT1	-0.52	-9.46	-0.4	1.52e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13065560	0.505	rs4396821	chr3:38917641	A/C	cg01426195	chr3:39028469	NA	-0.43	-8.93	-0.38	1e-17	Interleukin-18 levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.17.1630550R	chr17:61683872	TACO1	-0.46	-6.66	-0.3	7.56e-11	Systemic lupus erythematosus;
LGG	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.28	-0.32	1.42e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-7.05	-0.31	6.56e-12	Bipolar disorder;
LGG	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	6.76e-11	IgG glycosylation;
LGG	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg19761014	chr17:28927070	LRRC37B2	0.67	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg16268157	chr7:99778414	STAG3	-0.46	-7.47	-0.33	3.97e-13	Lung function (FEV1/FVC);
LGG	cis	rs877282	0.898	rs11253343	chr10:765117	C/T	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.02e-11	Uric acid levels;
LGG	cis	rs4629180	0.675	rs6742474	chr2:102091075	G/A	cg16435561	chr2:102091048	RFX8	0.5	9.19	0.39	1.3e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs7208859	0.673	rs56146117	chr17:29153325	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	9.62	0.41	4.22e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs60180747	1.000	rs17851970	chr15:66612965	C/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	-0.53	-9.49	-0.4	1.22e-19	Testicular germ cell tumor;
LGG	cis	rs700651	0.789	rs2196176	chr2:198904914	A/G	cg00792783	chr2:198669748	PLCL1	0.59	9.27	0.4	6.84e-19	Intracranial aneurysm;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg24250549	chr1:154909240	PMVK	0.76	15.72	0.59	6.44e-45	Prostate cancer;
LGG	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.64e-17	Lung cancer;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs6460942	0.915	rs75732743	chr7:12454095	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-7.04	-0.31	6.98e-12	Coronary artery disease;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.99	-0.35	1.11e-14	Longevity;
LGG	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs61931739	0.500	rs10844862	chr12:34531965	A/T	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.83	-0.38	2.13e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs4253772	0.744	rs1134224	chr22:46633371	A/T	cg24881330	chr22:46731750	TRMU	0.58	7.37	0.32	7.78e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg01069141	chr11:67398826	TBX10;NUDT8	-0.41	-6.99	-0.31	9.79e-12	Mean corpuscular volume;
LGG	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg27523141	chr10:43048294	ZNF37B	-0.36	-7.38	-0.32	7.57e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs62400317	0.859	rs12209175	chr6:45194643	G/C	cg18551225	chr6:44695536	NA	-0.62	-9.74	-0.41	1.66e-20	Total body bone mineral density;
LGG	cis	rs2303745	0.589	rs1864115	chr19:17393327	G/C	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.42	-0.4	2.15e-19	Systemic lupus erythematosus;
LGG	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg27490568	chr2:178487706	NA	0.81	14.31	0.55	1.02e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-8.65	-0.37	8.34e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2742417	1.000	rs2742373	chr3:45784046	C/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.39	-0.32	6.88e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9462027	0.628	rs9357181	chr6:34673833	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.96	0.45	5.39e-25	Systemic lupus erythematosus;
LGG	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg23594656	chr7:65796392	TPST1	0.39	8.5	0.37	2.58e-16	Aortic root size;
LGG	cis	rs13191362	0.507	rs13211655	chr6:163177542	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.64	9.02	0.39	5.06e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.55	-0.37	1.87e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.839	rs6454492	chr6:86483214	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.0	-0.35	1.02e-14	Response to antipsychotic treatment;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.13	0.39	2.17e-18	Bipolar disorder;
LGG	cis	rs7089973	0.624	rs1359080	chr10:116582419	C/A	cg03647239	chr10:116582469	FAM160B1	0.41	7.1	0.31	4.78e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.97	-0.45	4.75e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg09033563	chr22:24373618	LOC391322	0.44	6.79	0.3	3.42e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10267417	0.603	rs10272491	chr7:19946987	T/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.81	0.3	3.01e-11	Night sleep phenotypes;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg20578329	chr17:80767326	TBCD	-0.4	-7.43	-0.33	5.12e-13	Glycated hemoglobin levels;
LGG	cis	rs1838472	0.607	rs9880957	chr3:123979651	C/T	cg05766129	chr3:123988013	KALRN	-0.4	-7.36	-0.32	8.29e-13	Schizophrenia;
LGG	cis	rs7923837	1.000	rs7923837	chr10:94481917	G/A	cg25093409	chr10:94429542	NA	0.38	7.12	0.31	4.27e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg23782820	chr8:58130467	NA	0.54	7.53	0.33	2.71e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs787274	0.619	rs10115576	chr9:115617822	T/C	cg13803584	chr9:115635662	SNX30	-0.62	-8.09	-0.35	5.3e-15	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6754311	0.773	rs4988226	chr2:136610598	A/G	cg07169764	chr2:136633963	MCM6	-0.77	-13.08	-0.52	1.77e-33	Mosquito bite size;
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg24642844	chr7:1081250	C7orf50	-0.79	-13.32	-0.53	1.63e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.4e-11	Blood metabolite levels;
LGG	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg21045802	chr8:109455806	TTC35	0.51	9.62	0.41	4.19e-20	Dupuytren's disease;
LGG	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg10847948	chr11:71163743	NADSYN1	-0.65	-11.84	-0.48	1.94e-28	Vitamin D levels;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs7765175	0.521	rs2842843	chr6:113634650	A/C	cg26552650	chr6:113682475	NA	0.32	6.89	0.3	1.84e-11	Coronary artery calcification;
LGG	trans	rs6601327	0.665	rs12546411	chr8:9655916	T/A	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.54e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	6.94	0.31	1.35e-11	Height;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg13010199	chr12:38710504	ALG10B	0.63	12.95	0.52	5.91e-33	Morning vs. evening chronotype;
LGG	cis	rs5758659	0.652	rs133321	chr22:42405322	A/G	cg15557168	chr22:42548783	NA	-0.34	-7.63	-0.33	1.3e-13	Cognitive function;
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg18258770	chr4:90757814	SNCA	-0.4	-7.32	-0.32	1.09e-12	Dementia with Lewy bodies;
LGG	cis	rs9814567	1.000	rs6769885	chr3:134286913	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.3	-0.53	2.05e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11864453	0.826	rs2072142	chr16:72132713	C/T	cg23815491	chr16:72088622	HP	0.53	11.75	0.48	4.56e-28	Fibrinogen levels;
LGG	trans	rs9650657	0.683	rs7836366	chr8:10585683	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.26	-0.32	1.64e-12	Neuroticism;
LGG	cis	rs7590720	0.704	rs7603645	chr2:216876949	C/G	cg12620499	chr2:216877984	MREG	0.89	19.86	0.68	6.18e-64	Alcohol dependence;
LGG	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg11757124	chr7:157526947	PTPRN2	-0.51	-9.18	-0.39	1.49e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2916247	0.954	rs13273012	chr8:93092337	G/A	cg10183463	chr8:93005414	RUNX1T1	0.37	7.56	0.33	2.16e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4851266	0.898	rs13010010	chr2:100852734	C/T	cg21926883	chr2:100939477	LONRF2	-0.47	-8.58	-0.37	1.47e-16	Educational attainment;
LGG	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs35146811	0.807	rs10228764	chr7:99608029	A/G	cg22906224	chr7:99728672	NA	0.55	8.91	0.38	1.18e-17	Coronary artery disease;
LGG	cis	rs858239	0.600	rs7776649	chr7:23119317	C/T	cg23682824	chr7:23144976	KLHL7	0.45	7.87	0.34	2.57e-14	Cerebrospinal fluid biomarker levels;
LGG	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg00711542	chr16:29343894	RUNDC2C	0.4	6.8	0.3	3.19e-11	Menopause (age at onset);
LGG	cis	rs7944584	0.611	rs10838696	chr11:47363285	A/G	cg20307385	chr11:47447363	PSMC3	-0.66	-13.04	-0.52	2.53e-33	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	cg07928641	chr1:182991847	LAMC1	0.44	8.79	0.38	2.95e-17	Fuchs's corneal dystrophy;
LGG	cis	rs10754283	0.967	rs6698273	chr1:90106791	T/A	cg06121193	chr1:90282411	NA	-0.37	-7.25	-0.32	1.71e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6964587	0.900	rs7783674	chr7:91784212	T/A	cg17063962	chr7:91808500	NA	0.53	9.86	0.42	6.22e-21	Breast cancer;
LGG	cis	rs752010	0.695	rs12123834	chr1:42105727	T/C	cg16096631	chr1:42092165	HIVEP3	0.54	12.73	0.51	4.74e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9487051	0.872	rs9386793	chr6:109610002	C/A	cg12927641	chr6:109611667	NA	-0.37	-7.0	-0.31	9.29e-12	Reticulocyte fraction of red cells;
LGG	cis	rs10193935	0.901	rs1439231	chr2:42542884	G/A	cg27598129	chr2:42591480	NA	-0.59	-8.83	-0.38	2.11e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500395	1.000	rs9922734	chr16:48603192	A/G	cg16662043	chr16:48846231	NA	-0.37	-7.25	-0.32	1.79e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	6.82	0.3	2.8e-11	Schizophrenia;
LGG	cis	rs62238980	0.614	rs117160277	chr22:32417939	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg03538708	chr1:25844672	NA	0.35	6.7	0.3	6.09e-11	Erythrocyte sedimentation rate;
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg22072935	chr14:105399595	NA	0.52	9.9	0.42	4.2e-21	Systemic lupus erythematosus;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg18402987	chr7:1209562	NA	0.4	7.27	0.32	1.59e-12	Longevity;Endometriosis;
LGG	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg03264133	chr6:25882463	NA	-0.38	-6.74	-0.3	4.69e-11	Height;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.8	0.34	4.12e-14	Rheumatoid arthritis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15803506	chr10:135125704	ZNF511	0.38	6.93	0.31	1.42e-11	Menarche (age at onset);
LGG	trans	rs75804782	0.557	rs3769118	chr2:239342542	C/G	cg01134436	chr17:81009848	B3GNTL1	0.66	7.88	0.34	2.35e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9547692	1.000	rs2147168	chr13:37467503	A/C	cg01493522	chr13:37497338	NA	-0.52	-8.74	-0.38	4.34e-17	Coronary artery disease;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg11766577	chr21:47581405	C21orf56	0.49	8.75	0.38	3.88e-17	Testicular germ cell tumor;
LGG	cis	rs644799	0.610	rs1255179	chr11:95472097	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.36	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg06027949	chr8:82754900	SNX16	-0.56	-8.68	-0.37	6.74e-17	Diastolic blood pressure;
LGG	cis	rs12458462	0.892	rs2007483	chr18:77476131	A/T	cg11879182	chr18:77439856	CTDP1	0.79	14.96	0.57	1.53e-41	Monocyte count;
LGG	cis	rs2916247	0.954	rs4735059	chr8:93080265	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.49	-0.33	3.59e-13	Intelligence (multi-trait analysis);
LGG	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg02711726	chr17:80685570	FN3KRP	-0.42	-8.42	-0.36	4.75e-16	Breast cancer;
LGG	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg01028140	chr2:1542097	TPO	-0.48	-8.93	-0.38	1.04e-17	IgG glycosylation;
LGG	cis	rs883565	0.654	rs7642737	chr3:39032469	T/C	cg01426195	chr3:39028469	NA	-0.74	-16.9	-0.62	2.9e-50	Handedness;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.42	0.33	5.61e-13	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19954613	chr22:22020219	PPIL2	0.43	7.23	0.32	2e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4819052	0.851	rs2330012	chr21:46658592	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10865541	0.902	rs10173635	chr2:3421213	G/A	cg11642891	chr2:3452563	TTC15	-0.47	-9.48	-0.4	1.37e-19	Obesity-related traits;
LGG	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.59	-0.41	5.38e-20	Height;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00101895	chr6:108279135	SEC63	0.44	7.11	0.31	4.53e-12	Cognitive performance;
LGG	trans	rs7615952	0.611	rs2971298	chr3:125602713	G/A	cg07211511	chr3:129823064	LOC729375	-1.31	-16.83	-0.62	6.04e-50	Blood pressure (smoking interaction);
LGG	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.18e-12	Hepatitis;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg11342453	chr6:26196699	NA	0.49	6.7	0.3	6.17e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9926296	0.585	rs6500450	chr16:89858024	A/G	cg04287289	chr16:89883240	FANCA	0.79	15.58	0.59	2.73e-44	Vitiligo;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	17.16	0.62	1.96e-51	Personality dimensions;
LGG	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.29	-0.46	2.81e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs963731	0.649	rs6544187	chr2:39232275	G/C	cg04010122	chr2:39346883	SOS1	-0.8	-6.8	-0.3	3.28e-11	Corticobasal degeneration;
LGG	cis	rs2074193	0.543	rs11183927	chr12:47777972	A/G	cg02516419	chr12:47771422	NA	0.7	10.48	0.44	3.37e-23	Migraine with aura;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg13443165	chr9:33130375	B4GALT1	-0.59	-11.53	-0.47	3.4e-27	IgG glycosylation;
LGG	cis	rs763121	0.819	rs5757160	chr22:38989646	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.24	0.65	2.17e-56	Menopause (age at onset);
LGG	cis	rs7605378	1.000	rs769958	chr2:200695901	G/A	cg17644776	chr2:200775616	C2orf69	0.54	8.5	0.37	2.55e-16	Osteoporosis;
LGG	cis	rs4664304	0.802	rs3792175	chr2:160862804	T/A	cg03641300	chr2:160917029	PLA2R1	-0.47	-8.27	-0.36	1.48e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6867032	1.000	rs16902321	chr5:2015148	A/G	cg26168224	chr5:2018326	NA	1.25	29.27	0.81	2.36e-107	Gut microbiome composition (winter);
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg03806693	chr22:41940476	POLR3H	1.05	17.74	0.64	4.31e-54	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg06873352	chr17:61820015	STRADA	-0.67	-11.96	-0.49	6.43e-29	Prudent dietary pattern;
LGG	cis	rs5758511	0.689	rs17002947	chr22:42688532	C/T	cg15128208	chr22:42549153	NA	-0.71	-10.89	-0.45	9.22e-25	Birth weight;
LGG	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.93	-0.35	1.61e-14	Bladder cancer;
LGG	cis	rs16866061	0.926	rs17479770	chr2:225335814	A/G	cg12698349	chr2:225449008	CUL3	0.89	17.96	0.64	4.03e-55	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05379784	chr14:74111382	DNAL1	0.45	7.73	0.34	6.58e-14	Cognitive performance;
LGG	trans	rs6561151	0.681	rs61959998	chr13:44462501	A/T	cg17145862	chr1:211918768	LPGAT1	0.72	11.17	0.46	8.1e-26	Crohn's disease;
LGG	cis	rs9811920	0.609	rs793467	chr3:99539664	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	8.65	0.37	8.45e-17	Axial length;
LGG	cis	rs6762	0.719	rs7936806	chr11:839186	G/C	cg10580341	chr11:889148	CHID1	-0.4	-7.18	-0.32	2.86e-12	Mean platelet volume;
LGG	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg22906224	chr7:99728672	NA	0.56	9.14	0.39	1.9e-18	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	cis	rs7552404	0.961	rs1767458	chr1:76219155	A/G	cg03433033	chr1:76189801	ACADM	0.71	12.5	0.5	4.26e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs11252926	0.563	rs11252290	chr10:461989	C/T	cg00953403	chr17:74099816	EXOC7	0.42	6.97	0.31	1.13e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.48	0.4	1.28e-19	Glomerular filtration rate (creatinine);
LGG	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg13010199	chr12:38710504	ALG10B	0.57	10.72	0.45	4.35e-24	Morning vs. evening chronotype;
LGG	cis	rs7143963	0.943	rs12433126	chr14:103265867	A/T	cg23020514	chr14:103360112	TRAF3	0.54	9.95	0.42	2.89e-21	Body mass index;
LGG	cis	rs8112449	1.000	rs35916055	chr19:10526831	G/A	cg21868191	chr19:10515988	NA	-0.49	-8.42	-0.36	4.64e-16	Multiple sclerosis;Gastritis;
LGG	cis	rs12220238	1.000	rs6480723	chr10:75966366	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7264396	0.635	rs6058358	chr20:34492560	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.35e-12	Total cholesterol levels;
LGG	cis	rs9517313	0.554	rs3809366	chr13:99230266	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.89	-0.45	9.47e-25	Neuroticism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14283194	chr7:91763737	CYP51A1	0.4	6.76	0.3	4.26e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg15556689	chr8:8085844	FLJ10661	0.46	7.77	0.34	5.25e-14	Neuroticism;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg07142201	chr11:109293216	C11orf87	-0.86	-16.8	-0.62	8.12e-50	Schizophrenia;
LGG	cis	rs2274273	0.712	rs6572999	chr14:55527374	T/C	cg04306507	chr14:55594613	LGALS3	0.43	10.87	0.45	1.13e-24	Protein biomarker;
LGG	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg03805757	chr16:71968109	PKD1L3	-0.48	-8.77	-0.38	3.37e-17	Post bronchodilator FEV1;
LGG	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4919044	0.808	rs9419763	chr10:94788965	G/A	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs9815354	0.812	rs17283243	chr3:41914792	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.47	0.4	1.4e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4423214	1.000	rs12797951	chr11:71143266	G/T	cg10847948	chr11:71163743	NADSYN1	0.67	13.21	0.52	5.01e-34	Vitamin D levels;
LGG	trans	rs253959	0.545	rs4920905	chr5:115426468	C/T	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.75	0.3	4.47e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg03188948	chr7:1209495	NA	0.48	7.77	0.34	5.19e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11971779	0.680	rs11765421	chr7:139025094	G/A	cg07862535	chr7:139043722	LUC7L2	0.41	6.7	0.3	5.91e-11	Diisocyanate-induced asthma;
LGG	cis	rs10875746	0.680	rs4760610	chr12:48418225	C/T	cg24011408	chr12:48396354	COL2A1	-0.5	-6.77	-0.3	3.86e-11	Longevity (90 years and older);
LGG	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg22398616	chr13:53314203	LECT1	-0.45	-8.84	-0.38	2.06e-17	Lewy body disease;
LGG	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-7.27	-0.32	1.57e-12	Pulmonary function;
LGG	cis	rs7301826	0.651	rs10744483	chr12:131298206	C/A	cg11011512	chr12:131303247	STX2	0.41	8.9	0.38	1.26e-17	Plasma plasminogen activator levels;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.94	-0.6	6.63e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7582720	1.000	rs72934711	chr2:203709997	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg03060546	chr3:49711283	APEH	-0.65	-10.9	-0.45	8.71e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs8002861	0.967	rs9533691	chr13:44482208	A/G	cg17145862	chr1:211918768	LPGAT1	0.95	23.79	0.74	2.61e-82	Leprosy;
LGG	cis	rs1143633	0.553	rs2723197	chr2:113689747	G/A	cg06771106	chr2:113671356	IL1F7	0.37	7.08	0.31	5.32e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4481887	0.597	rs11488132	chr1:248542353	A/G	cg01631408	chr1:248437212	OR2T33	-0.46	-7.09	-0.31	4.95e-12	Common traits (Other);
LGG	cis	rs9287719	0.967	rs4669596	chr2:10720572	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.07	0.35	5.99e-15	Retinal vascular caliber;
LGG	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg18252515	chr7:66147081	NA	1.44	18.31	0.65	9.38e-57	Diabetic kidney disease;
LGG	trans	rs4714291	0.832	rs7764688	chr6:40115442	G/T	cg02267698	chr19:7991119	CTXN1	-0.62	-10.15	-0.43	5.55e-22	Strep throat;
LGG	trans	rs7746199	0.736	rs13215275	chr6:27647509	G/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.66	0.3	7.74e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7216064	0.861	rs12449312	chr17:65829358	A/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.79	-0.38	3.05e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg16434002	chr17:42200994	HDAC5	-0.51	-9.46	-0.4	1.58e-19	Total body bone mineral density;
LGG	cis	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg08603382	chr10:743973	NA	0.4	7.31	0.32	1.15e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs735860	0.726	rs209519	chr6:53208680	G/A	cg10236188	chr6:53219634	NA	0.35	6.85	0.3	2.42e-11	Glaucoma;
LGG	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg04743876	chr7:130013617	NA	0.37	8.64	0.37	9.05e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.43	-0.33	5.45e-13	Hepatitis;
LGG	trans	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg18393722	chr15:85113863	UBE2QP1	0.41	7.03	0.31	7.24e-12	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	10.89	0.45	9.61e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13191362	0.507	rs13210000	chr6:163176944	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.61	8.76	0.38	3.83e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7107174	1.000	rs901103	chr11:77931346	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.37	-0.32	7.87e-13	Testicular germ cell tumor;
LGG	cis	rs9796	0.553	rs1869908	chr15:41257224	C/A	cg18705301	chr15:41695430	NDUFAF1	0.59	10.13	0.43	6.51e-22	Menopause (age at onset);
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg22618164	chr12:122356400	WDR66	0.38	10.99	0.45	4.08e-25	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg03528353	chr17:61819722	STRADA	0.45	7.65	0.34	1.16e-13	Prudent dietary pattern;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg14789911	chr21:47582049	C21orf56	-0.43	-7.23	-0.32	1.96e-12	Testicular germ cell tumor;
LGG	cis	rs6694672	1.000	rs10754215	chr1:197086669	C/T	cg13682187	chr1:196946512	CFHR5	0.5	7.14	0.31	3.7e-12	Asthma;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.68	-0.34	9.63e-14	Personality dimensions;
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.61	7.28	0.32	1.45e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11676348	0.772	rs12694427	chr2:218945045	C/T	cg00012203	chr2:219082015	ARPC2	-0.48	-8.25	-0.36	1.63e-15	Ulcerative colitis;
LGG	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg22980697	chr10:16874865	CUBN	0.36	7.02	0.31	7.76e-12	Platelet distribution width;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg16325326	chr1:53192061	ZYG11B	0.67	12.07	0.49	2.39e-29	Monocyte count;
LGG	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs7662987	0.517	rs1154406	chr4:100008494	T/C	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.79e-20	Smoking initiation;
LGG	cis	rs9783347	1.000	rs4150566	chr11:18355599	C/G	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.49	-0.33	3.56e-13	Pancreatic cancer;
LGG	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-13.99	-0.54	2.54e-37	Menarche (age at onset);
LGG	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg16586182	chr3:47516702	SCAP	-0.76	-14.79	-0.57	8.53e-41	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-14.8	-0.57	7.05e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg08949735	chr16:89699720	DPEP1	0.46	9.42	0.4	2.09e-19	Vitiligo;
LGG	cis	rs17253792	0.822	rs79022053	chr14:56071721	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs568617	0.626	rs78028320	chr11:65582015	G/A	cg04055107	chr11:65626734	MUS81;CFL1	0.61	7.82	0.34	3.53e-14	Crohn's disease;
LGG	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.26	0.36	1.59e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6740322	0.841	rs10210507	chr2:43556636	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.62	-0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg21775007	chr8:11205619	TDH	-0.45	-7.3	-0.32	1.29e-12	Systolic blood pressure;
LGG	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	18.31	0.65	1.01e-56	Smoking behavior;
LGG	cis	rs10463554	0.963	rs6889592	chr5:102313939	G/A	cg23492399	chr5:102201601	PAM	-0.54	-8.26	-0.36	1.58e-15	Parkinson's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02843535	chr17:18759628	NA	0.47	7.23	0.32	1.95e-12	Gut microbiome composition (summer);
LGG	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg00531865	chr16:30841666	NA	-0.56	-11.42	-0.47	8.56e-27	Multiple myeloma;
LGG	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg11941060	chr3:133502564	NA	0.44	7.02	0.31	8.14e-12	Iron status biomarkers;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14054357	chr17:2607986	KIAA0664	0.38	6.97	0.31	1.09e-11	Electrocardiographic conduction measures;
LGG	trans	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg07393940	chr7:158741817	NA	0.56	10.42	0.44	5.67e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs929354	0.772	rs6459739	chr7:156998863	A/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs11239187	0.530	rs11239149	chr10:45065276	A/G	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	cis	rs2046867	0.818	rs67355490	chr3:72830935	T/C	cg25664220	chr3:72788482	NA	-0.33	-9.14	-0.39	1.98e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1775715	0.707	rs1541262	chr10:32179771	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.72	0.3	5.48e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs738322	0.600	rs7286105	chr22:38557821	A/G	cg03162506	chr22:38580953	NA	0.39	9.97	0.42	2.35e-21	Cutaneous nevi;
LGG	cis	rs13177180	1.000	rs13177180	chr5:114880593	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.35	-7.65	-0.33	1.2e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs9547692	0.938	rs7333607	chr13:37462010	A/G	cg02985381	chr13:37494744	SMAD9	0.68	12.25	0.49	4.52e-30	Coronary artery disease;
LGG	cis	rs2797160	0.967	rs984041	chr6:126021328	A/T	cg05901451	chr6:126070800	HEY2	0.45	7.73	0.34	6.78e-14	Endometrial cancer;
LGG	cis	rs3771570	0.901	rs3771585	chr2:242400723	G/A	cg21155796	chr2:242212141	HDLBP	0.59	8.04	0.35	7.55e-15	Prostate cancer;
LGG	trans	rs12517041	1.000	rs10052113	chr5:23287871	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs2074193	0.569	rs61927896	chr12:47775686	A/G	cg02516419	chr12:47771422	NA	0.57	8.59	0.37	1.38e-16	Migraine with aura;
LGG	cis	rs11122272	0.735	rs2250749	chr1:231485763	C/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.44	-0.33	4.98e-13	Hemoglobin concentration;
LGG	cis	rs3091242	0.933	rs909833	chr1:25754140	C/G	cg27572855	chr1:25598939	RHD	0.48	10.95	0.45	5.68e-25	Erythrocyte sedimentation rate;
LGG	cis	rs12230513	0.793	rs11171550	chr12:55933641	A/C	cg19537932	chr12:55886519	OR6C68	-0.39	-7.09	-0.31	5.07e-12	Contrast sensitivity;
LGG	cis	rs6795744	0.570	rs114230864	chr3:14054815	G/A	cg19554555	chr3:13937349	NA	0.57	7.37	0.32	7.9e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04008888	chr11:68622739	NA	-0.55	-11.7	-0.48	6.94e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg22398616	chr13:53314203	LECT1	-0.49	-10.31	-0.43	1.4e-22	Lewy body disease;
LGG	cis	rs2011503	1.000	rs76790018	chr19:19652157	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.78	-11.99	-0.49	4.78e-29	Cognitive test performance;
LGG	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.79	0.41	1.06e-20	Longevity;
LGG	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg16400903	chr5:693638	TPPP	0.45	6.87	0.3	2.05e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs12701220	0.895	rs3808348	chr7:1028448	C/T	cg00990874	chr7:1149470	C7orf50	-0.66	-9.77	-0.41	1.26e-20	Bronchopulmonary dysplasia;
LGG	trans	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs7607369	0.680	rs533760	chr2:219381405	T/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs7928758	0.848	rs56766695	chr11:134276302	A/G	cg15243474	chr11:134282918	B3GAT1	0.82	12.25	0.49	4.52e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-9.41	-0.4	2.41e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.11	0.7	9.12e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.76	-0.41	1.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg21058520	chr6:100914733	NA	0.39	6.77	0.3	3.88e-11	Neuroticism;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.17	-0.58	1.82e-42	Platelet count;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg07167872	chr1:205819463	PM20D1	0.56	11.41	0.47	9.4e-27	Menarche (age at onset);
LGG	cis	rs7166081	1.000	rs12443279	chr15:67561355	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.89e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg19812747	chr11:111475976	SIK2	-0.49	-9.85	-0.42	6.44e-21	Primary sclerosing cholangitis;
LGG	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg08000102	chr2:233561755	GIGYF2	0.64	10.06	0.42	1.2e-21	Schizophrenia;
LGG	cis	rs17504614	0.815	rs72838785	chr2:51085023	G/A	cg23851515	chr2:51057218	NRXN1	0.39	6.71	0.3	5.8e-11	Educational attainment (years of education);
LGG	cis	rs308971	0.563	rs167408	chr3:12088448	A/G	cg15873301	chr3:12045459	SYN2	0.56	7.25	0.32	1.75e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs2455799	0.613	rs2654654	chr3:15789242	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	trans	rs8002861	0.664	rs2325089	chr13:44450222	C/G	cg12856521	chr11:46389249	DGKZ	-0.5	-8.97	-0.38	7.52e-18	Leprosy;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.43	-0.69	1.36e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs975739	0.832	rs1766357	chr13:78371838	A/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.73	0.3	5.07e-11	Hair color;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg03395511	chr6:291903	DUSP22	-0.66	-11.15	-0.46	9.43e-26	Menopause (age at onset);
LGG	cis	rs12493885	0.818	rs10935970	chr3:153770237	C/G	cg17054900	chr3:154042577	DHX36	-0.62	-7.89	-0.34	2.14e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs8002861	0.935	rs9533678	chr13:44463409	C/T	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg11673840	chr17:47092156	IGF2BP1	-0.38	-6.69	-0.3	6.38e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs528418	0.592	rs9376920	chr6:145670957	A/C	cg03642472	chr6:145670687	NA	0.55	7.13	0.31	3.98e-12	Methadone dose in opioid dependence;
LGG	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg07636037	chr3:49044803	WDR6	-0.76	-13.13	-0.52	1.07e-33	Menarche (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01130127	chr19:51228821	CLEC11A	0.38	6.76	0.3	4.16e-11	Obesity-related traits;
LGG	cis	rs1577917	1.000	rs13194429	chr6:86646705	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.38	-0.53	9.5e-35	Response to antipsychotic treatment;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg24642844	chr7:1081250	C7orf50	-0.8	-9.97	-0.42	2.38e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6579956	0.537	rs4629587	chr5:152062577	A/T	cg12297329	chr5:152029980	NA	-0.46	-7.43	-0.33	5.26e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.9e-17	Lung cancer;
LGG	cis	rs1124376	0.935	rs6550307	chr3:20097885	G/A	cg05072819	chr3:20081367	KAT2B	0.63	8.16	0.35	3.28e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	0.812	rs59583650	chr3:41809063	A/G	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.7	-0.37	5.98e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg23034840	chr1:205782522	SLC41A1	0.51	8.26	0.36	1.54e-15	Menarche (age at onset);
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.53	0.41	8.72e-20	Schizophrenia;
LGG	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.21	0.36	2.23e-15	Retinal vascular caliber;
LGG	cis	rs2463822	1.000	rs115395195	chr11:62100353	G/A	cg06239285	chr11:62104954	ASRGL1	-1.17	-15.44	-0.58	1.11e-43	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg22681709	chr2:178499509	PDE11A	-0.5	-9.13	-0.39	2.11e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.74e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.36e-11	Menopause (age at onset);
LGG	cis	rs3741151	1.000	rs57893472	chr11:73042826	C/T	cg17517138	chr11:73019481	ARHGEF17	1.0	10.19	0.43	3.88e-22	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs3849046	0.790	rs188731	chr5:137881104	T/C	cg10920316	chr5:137946599	NA	0.45	7.38	0.32	7.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg04455712	chr21:45112962	RRP1B	0.51	9.54	0.41	8.46e-20	Mean corpuscular volume;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg18402987	chr7:1209562	NA	0.5	8.36	0.36	7.23e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9783347	1.000	rs4150650	chr11:18374279	G/A	cg15585147	chr11:18324498	HPS5	0.41	8.8	0.38	2.74e-17	Pancreatic cancer;
LGG	cis	rs10884984	0.802	rs1334944	chr10:112266046	C/T	cg18756771	chr10:112261994	DUSP5	0.66	11.94	0.49	7.47e-29	Facial morphology (factor 22);
LGG	cis	rs2535633	0.631	rs2581827	chr3:52966558	C/T	cg11645453	chr3:52864694	ITIH4	-0.47	-7.83	-0.34	3.31e-14	Body mass index;
LGG	cis	rs7727544	0.582	rs3805681	chr5:131537860	T/G	cg07395648	chr5:131743802	NA	-0.39	-8.52	-0.37	2.24e-16	Blood metabolite levels;
LGG	cis	rs4930561	0.765	rs4930564	chr11:67983281	C/T	cg16338278	chr11:67432957	ALDH3B2	-0.41	-7.46	-0.33	4.43e-13	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg12432903	chr7:1882776	MAD1L1	0.44	7.02	0.31	7.71e-12	Bipolar disorder;
LGG	cis	rs10463316	0.894	rs6579863	chr5:150761946	A/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg15537850	chr8:144661051	NAPRT1	0.91	7.31	0.32	1.17e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs6708331	0.941	rs6720799	chr2:70372029	A/G	cg01613454	chr2:70366299	NA	-0.52	-9.1	-0.39	2.61e-18	Obesity-related traits;
LGG	cis	rs1506636	0.646	rs805779	chr7:123214835	C/T	cg03229431	chr7:123269106	ASB15	-0.56	-12.31	-0.5	2.62e-30	Plateletcrit;Platelet count;
LGG	cis	rs11112613	0.595	rs871219	chr12:105938519	C/A	cg03607813	chr12:105948248	NA	0.6	10.01	0.42	1.71e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.66	-0.3	7.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9403521	0.580	rs9376772	chr6:143960454	T/C	cg18240653	chr6:144019428	PHACTR2	-0.52	-7.92	-0.35	1.78e-14	Obesity-related traits;
LGG	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg03929089	chr4:120376271	NA	-0.44	-7.03	-0.31	7.34e-12	HDL cholesterol;
LGG	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg08999081	chr20:33150536	PIGU	0.33	7.96	0.35	1.3e-14	Coronary artery disease;
LGG	cis	rs17301259	0.509	rs7805337	chr7:88397853	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.87	-0.3	2.04e-11	Heschl's gyrus morphology;
LGG	cis	rs1010254	0.510	rs55726523	chr5:151756407	C/T	cg12297329	chr5:152029980	NA	-0.51	-7.18	-0.32	2.83e-12	Optic nerve measurement (cup area);
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg02353165	chr6:42928485	GNMT	0.48	14.49	0.56	1.61e-39	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg07928641	chr1:182991847	LAMC1	0.49	10.0	0.42	1.92e-21	Colorectal cancer;
LGG	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg09904177	chr6:26538194	HMGN4	0.79	18.43	0.65	2.75e-57	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	cis	rs7917772	0.582	rs10786685	chr10:104323103	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.58	10.73	0.45	3.99e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9914988	0.943	rs4795465	chr17:27151498	A/G	cg20469991	chr17:27169893	C17orf63	0.59	7.35	0.32	9.04e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg12373951	chr3:133503437	NA	0.4	7.02	0.31	8.1e-12	Iron status biomarkers;
LGG	cis	rs13260300	0.551	rs2588298	chr8:75553385	T/G	cg22993706	chr8:75542856	NA	0.51	10.71	0.45	4.55e-24	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.28	0.36	1.3e-15	Diabetic kidney disease;
LGG	cis	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg13443165	chr9:33130375	B4GALT1	-0.73	-11.97	-0.49	5.75e-29	IgG glycosylation;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg24112000	chr20:60950667	NA	-0.35	-7.83	-0.34	3.37e-14	Colorectal cancer;
LGG	cis	rs1355223	0.902	rs1597962	chr11:34727172	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.7	-0.3	6.11e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs7939886	0.920	rs7112815	chr11:55960104	T/C	cg15704280	chr7:45808275	SEPT13	0.83	7.78	0.34	4.68e-14	Myopia (pathological);
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg22963979	chr7:1858916	MAD1L1	-0.52	-10.28	-0.43	1.88e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg16096631	chr1:42092165	HIVEP3	0.49	11.47	0.47	5.53e-27	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs12476592	0.602	rs262483	chr2:63877246	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.91	-0.31	1.65e-11	Childhood ear infection;
LGG	cis	rs11628318	0.563	rs1190344	chr14:103097912	A/G	cg12046867	chr14:103022105	NA	-0.47	-9.28	-0.4	6.35e-19	Platelet count;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.5	-8.05	-0.35	6.86e-15	Renal function-related traits (BUN);
LGG	cis	rs9733	0.650	rs6698495	chr1:150564476	T/C	cg13175981	chr1:150552382	MCL1	0.6	10.4	0.44	6.64e-23	Tonsillectomy;
LGG	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.18	-0.32	2.8e-12	Blood metabolite levels;
LGG	cis	rs858239	0.539	rs6965833	chr7:23192366	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.87	0.3	2.13e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.78	-0.51	2.97e-32	Blood trace element (Zn levels);
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.89	-0.38	1.38e-17	Aortic root size;
LGG	cis	rs888194	0.725	rs2241210	chr12:109950144	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.15	-0.32	3.31e-12	Neuroticism;
LGG	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg09165964	chr15:75287851	SCAMP5	-0.57	-10.67	-0.44	6.36e-24	Caffeine consumption;
LGG	cis	rs11098499	0.866	rs7665125	chr4:120402079	G/T	cg24375607	chr4:120327624	NA	0.58	9.73	0.41	1.79e-20	Corneal astigmatism;
LGG	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2346177	0.542	rs718849	chr2:46698116	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.05	0.39	3.93e-18	HDL cholesterol;
LGG	cis	rs4256922	0.715	rs10994247	chr10:52499303	C/G	cg12289553	chr10:52500425	ASAH2B	-0.45	-8.47	-0.37	3.26e-16	Urate levels in lean individuals;
LGG	cis	rs2404602	0.735	rs3765115	chr15:76673716	T/C	cg15268244	chr15:77196840	NA	0.44	9.56	0.41	7.15e-20	Blood metabolite levels;
LGG	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24308560	chr3:49941425	MST1R	-0.22	-6.79	-0.3	3.34e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg15704280	chr7:45808275	SEPT13	0.89	14.2	0.55	3.06e-38	Coronary artery disease;
LGG	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg12893428	chr3:195717962	SDHAP1	0.41	7.74	0.34	6.47e-14	Pancreatic cancer;
LGG	cis	rs8077889	0.750	rs34462326	chr17:41932210	T/C	cg26893861	chr17:41843967	DUSP3	0.89	12.23	0.49	5.49e-30	Triglycerides;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg15112475	chr7:1198522	ZFAND2A	-0.39	-7.09	-0.31	5.17e-12	Longevity;Endometriosis;
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs9309473	1.000	rs10190219	chr2:73658331	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.84	-0.34	3.17e-14	Metabolite levels;
LGG	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg01221209	chr5:554886	NA	-0.45	-6.74	-0.3	4.62e-11	Obesity-related traits;
LGG	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.25	0.6	2.5e-47	Glomerular filtration rate (creatinine);
LGG	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg22467129	chr15:76604101	ETFA	-0.47	-8.04	-0.35	7.72e-15	Blood metabolite levels;
LGG	cis	rs778371	0.522	rs10205801	chr2:233597196	G/A	cg08000102	chr2:233561755	GIGYF2	0.62	10.65	0.44	7.78e-24	Schizophrenia;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	9.41	0.4	2.29e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2130392	0.892	rs11728389	chr4:185622046	C/T	cg21366198	chr4:185655624	MLF1IP	0.46	8.02	0.35	8.96e-15	Kawasaki disease;
LGG	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg27286337	chr10:134555280	INPP5A	0.89	13.1	0.52	1.48e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6456156	0.524	rs6932740	chr6:167466439	G/A	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.65	0.41	3.28e-20	Total body bone mineral density;
LGG	trans	rs3960554	0.808	rs57721466	chr7:75710049	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.28	0.5	3.21e-30	Eotaxin levels;
LGG	cis	rs975739	1.000	rs1668618	chr13:78386137	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs564799	0.966	rs523886	chr3:159734858	G/A	cg04855961	chr3:159719849	NA	-0.28	-7.48	-0.33	3.85e-13	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4557101	0.526	rs7627890	chr3:73532069	C/T	cg24173753	chr3:73529447	PDZRN3	-0.37	-7.93	-0.35	1.71e-14	QT interval;
LGG	cis	rs7435	0.539	rs2838460	chr21:45398853	C/A	cg24928023	chr21:45395775	AGPAT3	0.35	6.64	0.3	8.61e-11	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LGG	cis	rs806215	1.000	rs806214	chr7:127237003	C/T	cg25922125	chr7:127225783	GCC1	-0.77	-10.38	-0.43	7.53e-23	Type 2 diabetes;
LGG	trans	rs7746199	0.736	rs17750424	chr6:27701122	T/C	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg00129232	chr17:37814104	STARD3	-0.75	-16.32	-0.6	1.22e-47	Asthma;
LGG	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg00666640	chr1:248458726	OR2T12	-0.62	-10.19	-0.43	3.77e-22	Common traits (Other);
LGG	cis	rs72781680	0.716	rs17045975	chr2:24099611	A/T	cg08917208	chr2:24149416	ATAD2B	-0.65	-8.46	-0.37	3.64e-16	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08280861	chr8:58055591	NA	0.53	6.8	0.3	3.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4478858	0.735	rs4622114	chr1:31772571	A/G	cg19084893	chr1:31688959	NA	0.3	6.66	0.3	7.8e-11	Alcohol dependence;
LGG	cis	rs7084402	0.967	rs1593678	chr10:60291548	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.85e-13	Refractive error;
LGG	cis	rs12617721	0.756	rs3754889	chr2:99088633	T/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg11040518	chr10:102331378	NA	0.36	6.73	0.3	5.05e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs16912285	0.748	rs58504811	chr11:24252020	T/G	ch.11.24196551F	chr11:24239977	NA	0.91	13.07	0.52	1.9e-33	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs514406	0.893	rs499195	chr1:53344907	C/T	cg24675658	chr1:53192096	ZYG11B	-0.49	-9.58	-0.41	5.82e-20	Monocyte count;
LGG	cis	rs1044826	0.642	rs295470	chr3:139213903	A/G	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.36e-11	Obesity-related traits;
LGG	cis	rs3008870	0.959	rs1886686	chr1:67390468	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05491587	chr18:77659695	KCNG2	-0.53	-7.06	-0.31	6.06e-12	Opioid sensitivity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03586379	chr3:140660603	SLC25A36	0.6	6.95	0.31	1.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs7695597	0.708	rs938015	chr4:185176699	C/T	cg12654155	chr4:185238627	NA	0.39	7.08	0.31	5.32e-12	Night sleep phenotypes;
LGG	cis	rs2742417	1.000	rs2742435	chr3:45740863	C/T	cg04837898	chr3:45731254	SACM1L	-0.39	-7.39	-0.32	7.06e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.88e-19	Aortic root size;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.81	-0.34	3.91e-14	Longevity;
LGG	trans	rs1997103	0.871	rs1997101	chr7:55399652	A/T	cg20935933	chr6:143382018	AIG1	0.59	9.14	0.39	1.96e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.58	-0.33	1.86e-13	Initial pursuit acceleration;
LGG	cis	rs503734	0.502	rs571391	chr3:100963154	C/T	cg27318481	chr3:100970896	IMPG2	-0.52	-12.27	-0.5	3.62e-30	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08677398	chr8:58056175	NA	0.51	8.06	0.35	6.56e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg13206674	chr6:150067644	NUP43	-0.4	-6.81	-0.3	2.98e-11	Lung cancer;
LGG	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg23531748	chr20:60969906	CABLES2	0.43	7.76	0.34	5.62e-14	Colorectal cancer;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.81e-21	Platelet count;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs11622475	1.000	rs2236246	chr14:104379206	A/C	cg20488157	chr14:104394430	TDRD9	-0.53	-8.87	-0.38	1.57e-17	Bipolar disorder;
LGG	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg20891283	chr12:69753455	YEATS4	0.7	13.51	0.53	2.67e-35	Blood protein levels;
LGG	cis	rs8060686	0.641	rs8058690	chr16:68136622	T/G	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.66e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg01221209	chr5:554886	NA	-0.46	-6.81	-0.3	3e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg18225595	chr11:63971243	STIP1	0.5	6.83	0.3	2.67e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4363385	0.818	rs61811862	chr1:152995668	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.09e-16	Inflammatory skin disease;
LGG	cis	rs477692	1.000	rs503660	chr10:131418999	A/G	cg05714579	chr10:131428358	MGMT	0.57	11.94	0.49	7.54e-29	Response to temozolomide;
LGG	cis	rs7172689	1.000	rs66628172	chr15:81543823	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.31	-0.43	1.45e-22	Inattentive symptoms;
LGG	cis	rs73787773	0.867	rs7731129	chr5:111495510	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.72	-8.6	-0.37	1.25e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7113850	0.541	rs2896686	chr11:24213156	G/A	ch.11.24196551F	chr11:24239977	NA	0.94	11.22	0.46	5.19e-26	Bone fracture in osteoporosis;
LGG	cis	rs62400317	0.826	rs12194628	chr6:45329376	G/C	cg18551225	chr6:44695536	NA	-0.61	-9.84	-0.42	7.26e-21	Total body bone mineral density;
LGG	cis	rs9815354	0.767	rs73071238	chr3:41992243	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.65	-0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs4919694	0.572	rs7080935	chr10:104929113	C/A	cg04362960	chr10:104952993	NT5C2	0.89	13.43	0.53	5.89e-35	Arsenic metabolism;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg02462569	chr6:150064036	NUP43	-0.35	-7.25	-0.32	1.81e-12	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22174410	chr3:42641766	NKTR	0.44	7.07	0.31	5.88e-12	Cognitive performance;
LGG	cis	rs807029	0.577	rs7902510	chr10:102757934	C/T	cg04662943	chr10:102668895	NA	0.47	6.77	0.3	3.86e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7975161	0.521	rs4630362	chr12:104727744	G/C	cg25273343	chr12:104657179	TXNRD1	-0.82	-7.56	-0.33	2.15e-13	Toenail selenium levels;
LGG	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg07382826	chr16:28625726	SULT1A1	0.41	8.36	0.36	7.63e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8141529	0.529	rs2301428	chr22:29214606	G/C	cg15103426	chr22:29168792	CCDC117	0.66	6.87	0.3	2.06e-11	Lymphocyte counts;
LGG	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg12923728	chr3:195709715	SDHAP1	-0.64	-12.1	-0.49	1.81e-29	Bronchopulmonary dysplasia;
LGG	trans	rs7395662	0.963	rs7483713	chr11:48629214	A/T	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs4481887	1.000	rs10788781	chr1:248494262	C/T	cg00666640	chr1:248458726	OR2T12	0.62	9.95	0.42	2.86e-21	Common traits (Other);
LGG	cis	rs56011263	0.687	rs4690293	chr4:706101	A/G	cg20735989	chr4:730612	PCGF3	-0.61	-10.65	-0.44	7.65e-24	White blood cell count;
LGG	cis	rs17221829	0.692	rs55823055	chr11:89388744	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.26	-0.4	7.46e-19	Anxiety in major depressive disorder;
LGG	cis	rs990171	1.000	rs11694658	chr2:103045020	A/G	cg05295703	chr2:102895712	NA	-0.53	-9.06	-0.39	3.57e-18	Lymphocyte counts;
LGG	trans	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg06521331	chr12:34319734	NA	-0.41	-7.12	-0.31	4.15e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-8.03	-0.35	7.89e-15	Vitiligo;
LGG	cis	rs4356203	0.905	rs9919600	chr11:17079745	A/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg01988459	chr11:68622903	NA	-0.62	-12.55	-0.5	2.76e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs2764980	1.000	rs2814925	chr10:3284061	A/G	cg11630169	chr10:3283847	NA	-0.44	-10.57	-0.44	1.61e-23	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.04	0.57	6.41e-42	Platelet count;
LGG	cis	rs1023500	0.505	rs134885	chr22:42673811	C/G	cg04733989	chr22:42467013	NAGA	0.51	8.98	0.39	6.68e-18	Schizophrenia;
LGG	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.47	-0.44	3.55e-23	Bladder cancer;
LGG	cis	rs4819052	0.645	rs2838817	chr21:46631698	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	7.55	0.33	2.36e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	24.15	0.75	5.7e-84	IgG glycosylation;
LGG	cis	rs240764	0.782	rs7748644	chr6:101166809	T/G	cg09795085	chr6:101329169	ASCC3	-0.45	-7.9	-0.34	2e-14	Neuroticism;
LGG	cis	rs7267979	1.000	rs2257420	chr20:25275890	C/A	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	3.15e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7444	0.941	rs2283789	chr22:21944478	T/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.7	-0.34	8.36e-14	Systemic lupus erythematosus;
LGG	cis	rs17376456	0.877	rs10476601	chr5:93402522	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08753297	chr6:56716612	DST	0.42	7.03	0.31	7.59e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2694528	0.920	rs1867598	chr5:60137959	A/G	cg11474532	chr5:59995715	DEPDC1B	0.73	7.68	0.34	9.66e-14	Parkinson's disease;
LGG	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11668638	chr6:42952412	PPP2R5D	0.52	8.37	0.36	7.08e-16	Gut microbiome composition (summer);
LGG	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg23422044	chr7:1970798	MAD1L1	0.64	11.05	0.46	2.35e-25	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg21724239	chr8:58056113	NA	0.42	6.75	0.3	4.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2439831	0.867	rs2447211	chr15:43936351	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.69	0.41	2.5e-20	Lung cancer in ever smokers;
LGG	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-15.53	-0.59	4.55e-44	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25172604	chr17:41446521	NA	-0.3	-7.17	-0.32	3.04e-12	Menopause (age at onset);
LGG	cis	rs9322193	0.576	rs7452592	chr6:150196581	A/G	cg16507663	chr6:150244633	RAET1G	0.46	6.81	0.3	3.07e-11	Lung cancer;
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22618164	chr12:122356400	WDR66	0.42	13.33	0.53	1.58e-34	Mean corpuscular volume;
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.17	-0.32	3.04e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg04287289	chr16:89883240	FANCA	0.84	7.81	0.34	3.81e-14	Skin colour saturation;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg20302533	chr7:39170763	POU6F2	0.55	13.57	0.53	1.46e-35	IgG glycosylation;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.92	0.38	1.11e-17	Retinal vascular caliber;
LGG	trans	rs2204008	0.515	rs11495471	chr12:38027178	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.88e-18	Bladder cancer;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg18350739	chr11:68623251	NA	-0.87	-22.45	-0.72	4.75e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	8.87	0.38	1.54e-17	Bipolar disorder;
LGG	cis	rs1707322	1.000	rs785490	chr1:46577124	T/C	cg03146154	chr1:46216737	IPP	-0.54	-9.36	-0.4	3.44e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2274273	0.868	rs6573007	chr14:55625938	T/G	cg04306507	chr14:55594613	LGALS3	0.66	18.68	0.66	1.85e-58	Protein biomarker;
LGG	cis	rs10206020	0.921	rs9678719	chr2:1549628	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.15	-0.39	1.85e-18	IgG glycosylation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13703666	chr11:66115419	B3GNT1	0.44	7.1	0.31	4.7e-12	Cognitive performance;
LGG	trans	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.37	0.47	1.34e-26	Obesity-related traits;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg16507663	chr6:150244633	RAET1G	0.48	8.88	0.38	1.45e-17	Lung cancer;
LGG	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs10464366	0.544	rs12668821	chr7:39167846	T/A	cg20302533	chr7:39170763	POU6F2	0.58	15.01	0.57	8.91e-42	IgG glycosylation;
LGG	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg16576597	chr16:28551801	NUPR1	0.43	10.12	0.43	6.95e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg04851639	chr8:1020857	NA	-0.43	-9.0	-0.39	5.69e-18	Schizophrenia;
LGG	cis	rs754466	0.606	rs12356375	chr10:79594514	C/A	cg17075019	chr10:79541650	NA	-0.96	-20.96	-0.7	4.53e-69	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	trans	rs9657904	0.901	rs57520912	chr3:105563176	G/A	cg14088669	chr1:158435396	OR10K1	-0.38	-6.69	-0.3	6.62e-11	Multiple sclerosis;
LGG	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs422249	0.512	rs174583	chr11:61609750	A/G	cg19610905	chr11:61596333	FADS2	0.73	13.39	0.53	8.95e-35	Trans fatty acid levels;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.94	0.35	1.58e-14	Prostate cancer;
LGG	cis	rs9952991	0.622	rs547268	chr18:12823056	G/T	cg23598886	chr18:12777645	NA	0.51	7.43	0.33	5.24e-13	Inflammatory skin disease;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.19	-0.39	1.28e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4664304	0.966	rs925407	chr2:160767502	A/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.48	-0.33	3.86e-13	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14470647	chr9:107690075	ABCA1	0.47	7.44	0.33	5.08e-13	Cognitive performance;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	19.28	0.67	3.12e-61	Alzheimer's disease;
LGG	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg09085632	chr11:111637200	PPP2R1B	1.21	32.82	0.84	6.11e-123	Primary sclerosing cholangitis;
LGG	cis	rs7301016	0.948	rs12370404	chr12:62923340	T/C	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	cis	rs758324	0.947	rs7708140	chr5:131252396	A/G	cg06307176	chr5:131281290	NA	0.53	8.85	0.38	1.8e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs2948294	0.566	rs13261997	chr8:8112295	C/T	cg16141378	chr3:129829833	LOC729375	-0.43	-9.97	-0.42	2.36e-21	Red cell distribution width;
LGG	cis	rs5769765	0.542	rs5770725	chr22:50256309	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.61	7.09	0.31	4.92e-12	Schizophrenia;
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.54	-0.41	8.5e-20	Monocyte percentage of white cells;
LGG	cis	rs2307022	0.542	rs4783624	chr16:68409947	T/C	cg07273125	chr16:68295692	NA	0.44	9.61	0.41	4.65e-20	Body mass index;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.89e-13	Menopause (age at onset);
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg13047869	chr3:10149882	C3orf24	0.47	7.89	0.34	2.2e-14	Alzheimer's disease;
LGG	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg26769984	chr7:1090371	C7orf50	0.41	7.03	0.31	7.38e-12	Bronchopulmonary dysplasia;
LGG	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-12.69	-0.51	7.03e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.540	rs13140070	chr4:122713899	C/T	cg19748678	chr4:122722346	EXOSC9	-0.55	-9.92	-0.42	3.56e-21	Type 2 diabetes;
LGG	trans	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.77	-0.41	1.28e-20	Morning vs. evening chronotype;
LGG	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg15664640	chr17:80829946	TBCD	-0.66	-8.93	-0.38	1.04e-17	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg03517284	chr6:25882590	NA	-0.44	-7.09	-0.31	5.18e-12	Iron status biomarkers;
LGG	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.86	0.34	2.66e-14	Retinal vascular caliber;
LGG	cis	rs3540	0.512	rs8033818	chr15:91075535	C/T	cg22089800	chr15:90895588	ZNF774	-0.66	-12.28	-0.5	3.31e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs10504130	0.569	rs11784869	chr8:52819511	C/A	cg24946253	chr8:52722146	PXDNL	-0.45	-6.65	-0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7255045	0.743	rs10426080	chr19:12957850	A/G	cg07955356	chr19:12992479	DNASE2	0.43	7.25	0.32	1.74e-12	Mean corpuscular volume;
LGG	cis	rs7538876	0.903	rs7528427	chr1:17746273	C/T	cg10329579	chr1:17754830	RCC2	-0.52	-10.05	-0.42	1.29e-21	Basal cell carcinoma;
LGG	cis	rs7107174	1.000	rs1399196	chr11:78071876	A/G	cg02023728	chr11:77925099	USP35	0.45	8.1	0.35	4.97e-15	Testicular germ cell tumor;
LGG	cis	rs1355223	1.000	rs12792532	chr11:34765782	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.27	-0.32	1.59e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7084402	0.967	rs7100474	chr10:60273121	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.17	0.32	3.03e-12	Refractive error;
LGG	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.31e-14	Coronary artery disease;
LGG	cis	rs4237845	0.837	rs7963992	chr12:58295949	G/C	cg02175503	chr12:58329896	NA	0.68	12.89	0.51	1.1e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9807841	0.592	rs10401513	chr19:10778763	A/T	cg17710535	chr19:10819994	QTRT1	0.51	8.33	0.36	9.07e-16	Inflammatory skin disease;
LGG	trans	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg18187862	chr3:45730750	SACM1L	-0.68	-11.02	-0.46	3.09e-25	Primary sclerosing cholangitis;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg04898316	chr2:110371848	SEPT10;ANKRD57	0.42	7.14	0.31	3.54e-12	Coronary artery disease;
LGG	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg10621924	chr7:39171070	POU6F2	0.45	9.1	0.39	2.67e-18	IgG glycosylation;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07685180	chr8:600429	NA	-0.92	-9.55	-0.41	7.71e-20	IgG glycosylation;
LGG	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg02023728	chr11:77925099	USP35	0.46	7.84	0.34	3.05e-14	Testicular germ cell tumor;
LGG	cis	rs1577917	0.958	rs1838958	chr6:86563968	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs1003719	0.715	rs2252893	chr21:38507572	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	trans	rs9467711	0.651	rs35069699	chr6:25957282	C/T	cg06606381	chr12:133084897	FBRSL1	-0.8	-7.3	-0.32	1.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs67133203	0.606	rs12820559	chr12:51565619	T/C	cg14688905	chr12:51403056	SLC11A2	0.65	9.92	0.42	3.75e-21	Urinary tract infection frequency;
LGG	trans	rs9354308	0.966	rs1909533	chr6:66565658	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	9.98	0.42	2.19e-21	Metabolite levels;
LGG	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg04743876	chr7:130013617	NA	0.37	8.64	0.37	9.05e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7647973	0.580	rs2117938	chr3:49263850	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.74	-13.46	-0.53	4.52e-35	Menarche (age at onset);
LGG	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14442939	chr10:27389572	ANKRD26	0.53	8.24	0.36	1.85e-15	Breast cancer;
LGG	cis	rs9470366	0.545	rs4711457	chr6:36633160	T/C	cg08179530	chr6:36648295	CDKN1A	-0.66	-11.61	-0.47	1.53e-27	QRS duration;
LGG	cis	rs10875746	0.551	rs12322348	chr12:48707699	T/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.21	-0.32	2.32e-12	Longevity (90 years and older);
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg04632378	chr13:21900426	NA	0.39	7.88	0.34	2.28e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9463078	0.764	rs9369516	chr6:44833598	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.56	-0.37	1.65e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg15556689	chr8:8085844	FLJ10661	0.41	7.14	0.31	3.64e-12	Retinal vascular caliber;
LGG	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-8.77	-0.38	3.37e-17	Schizophrenia;
LGG	cis	rs9611519	0.589	rs8138917	chr22:41412425	T/C	cg03806693	chr22:41940476	POLR3H	-0.46	-7.49	-0.33	3.54e-13	Neuroticism;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.54e-39	Lung cancer;
LGG	cis	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg13010199	chr12:38710504	ALG10B	0.74	15.2	0.58	1.35e-42	Heart rate;
LGG	cis	rs6424115	0.679	rs2294495	chr1:24075876	C/T	cg15997130	chr1:24165203	NA	-0.39	-8.74	-0.38	4.3e-17	Immature fraction of reticulocytes;
LGG	cis	rs12410462	0.901	rs2814090	chr1:227658444	C/G	cg04117972	chr1:227635322	NA	-0.6	-10.08	-0.42	9.87e-22	Major depressive disorder;
LGG	cis	rs6594713	0.679	rs17388260	chr5:112764578	C/A	cg12552261	chr5:112820674	MCC	0.65	8.23	0.36	1.86e-15	Brain cytoarchitecture;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21862992	chr11:68658383	NA	0.5	8.4	0.36	5.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7726354	0.793	rs6883200	chr5:56010025	C/G	cg27303933	chr5:56029418	NA	0.49	6.79	0.3	3.36e-11	Breast cancer (early onset);
LGG	cis	rs3087591	0.922	rs2905788	chr17:29480295	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.37e-39	Hip circumference;
LGG	cis	rs7226408	0.857	rs72887089	chr18:34506836	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.98	-0.31	1.01e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs7010267	0.935	rs6415470	chr8:119955111	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.45	0.44	4.43e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg16797656	chr11:68205561	LRP5	0.54	10.14	0.43	6.06e-22	Total body bone mineral density;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg18538332	chr22:24372958	LOC391322	-0.47	-7.48	-0.33	3.67e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10463316	0.894	rs6880137	chr5:150755232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7851660	0.809	rs10818241	chr9:100661972	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs6764363	0.587	rs35762438	chr3:279853	G/C	cg02057681	chr3:285234	CHL1	-0.45	-8.31	-0.36	1.09e-15	Sudden cardiac arrest;
LGG	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg07936489	chr17:37558343	FBXL20	1.01	15.24	0.58	8.39e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs11920090	0.932	rs7635100	chr3:170695711	G/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.77	-0.3	3.8e-11	Parkinson's disease;
LGG	cis	rs7617773	0.539	rs35460860	chr3:48392085	A/T	cg11946769	chr3:48343235	NME6	0.51	8.65	0.37	8.5e-17	Coronary artery disease;
LGG	cis	rs12488721	1	rs12488721	chr3:135992645	T/C	cg21827317	chr3:136751795	NA	0.45	7.85	0.34	2.97e-14	Neuroticism;
LGG	cis	rs2587949	0.571	rs2248969	chr3:4230023	T/C	cg16519197	chr3:4211558	NA	-0.37	-7.39	-0.32	7.09e-13	Periodontitis (DPAL);
LGG	trans	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg26043149	chr18:55253948	FECH	-0.46	-7.98	-0.35	1.12e-14	Bone mineral density;
LGG	cis	rs62400317	0.826	rs12192890	chr6:45182434	A/G	cg20913747	chr6:44695427	NA	-0.63	-10.25	-0.43	2.31e-22	Total body bone mineral density;
LGG	cis	rs4919087	1.000	rs61863767	chr10:99084426	C/T	cg25902810	chr10:99078978	FRAT1	0.52	9.63	0.41	3.93e-20	Monocyte count;
LGG	trans	rs1814175	0.817	rs28502006	chr11:50049930	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.77	-0.48	3.73e-28	Height;
LGG	cis	rs1387259	0.929	rs2956703	chr12:48670294	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.7	0.34	8.04e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg00857998	chr1:205179979	DSTYK	0.59	9.6	0.41	5.23e-20	Red blood cell count;
LGG	trans	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg23173402	chr1:227635558	NA	0.57	9.03	0.39	4.56e-18	Major depressive disorder;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7444	0.941	rs5998599	chr22:21941981	A/G	cg05046821	chr22:21984468	YDJC	-0.38	-6.93	-0.31	1.39e-11	Systemic lupus erythematosus;
LGG	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs4865875	1.000	rs13155441	chr5:54106957	G/A	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg05234568	chr11:5960015	NA	-0.66	-10.57	-0.44	1.54e-23	DNA methylation (variation);
LGG	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.15	-0.35	3.4e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.46	-0.44	3.82e-23	Lung cancer;
LGG	cis	rs12762955	0.561	rs7918118	chr10:1042823	C/A	cg25019033	chr10:957182	NA	0.34	7.05	0.31	6.68e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs7617773	0.780	rs13067450	chr3:48337206	C/T	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg25947184	chr8:1697459	NA	0.47	8.21	0.36	2.14e-15	Systolic blood pressure;
LGG	cis	rs350251	0.868	rs350232	chr16:12190947	G/C	cg02910054	chr16:12241554	SNX29	0.44	7.79	0.34	4.59e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.583	rs2176623	chr15:76568579	C/T	cg23625390	chr15:77176239	SCAPER	0.42	7.89	0.34	2.27e-14	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.926	rs4662725	chr2:128141320	G/A	cg10021288	chr2:128175891	PROC	-0.65	-13.43	-0.53	5.94e-35	Protein C levels;
LGG	cis	rs4253772	0.575	rs9615956	chr22:46749634	C/T	cg09461388	chr22:46763229	CELSR1	-0.72	-7.04	-0.31	7.19e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg27411982	chr8:10470053	RP1L1	0.42	7.05	0.31	6.35e-12	Morning vs. evening chronotype;
LGG	trans	rs561341	1.000	rs7216102	chr17:30259450	A/G	cg27661571	chr11:113659931	NA	-0.57	-8.23	-0.36	1.89e-15	Hip circumference adjusted for BMI;
LGG	cis	rs453301	0.571	rs2929452	chr8:9084465	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.14	-0.35	3.71e-15	Joint mobility (Beighton score);
LGG	cis	rs367943	0.712	rs26966	chr5:112740434	T/C	cg12552261	chr5:112820674	MCC	0.58	10.62	0.44	1e-23	Type 2 diabetes;
LGG	cis	rs4730250	0.707	rs257375	chr7:106799043	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1.04e-23	Osteoarthritis;
LGG	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.66	-0.41	2.99e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs4132509	0.948	rs12048930	chr1:243940076	C/T	cg25706552	chr1:244017396	NA	0.51	8.32	0.36	1.01e-15	RR interval (heart rate);
LGG	cis	rs9914988	0.887	rs11650282	chr17:27090741	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs4819052	0.851	rs2838840	chr21:46668494	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.18	0.52	6.51e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs12579753	0.872	rs11519752	chr12:82207300	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.92	-0.35	1.81e-14	Resting heart rate;
LGG	trans	rs9944715	1.000	rs8094070	chr18:43849640	G/A	cg01718231	chr17:29326311	RNF135	-0.43	-6.75	-0.3	4.4e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs721917	0.506	rs2253875	chr10:81659202	C/A	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.94	-12.35	-0.5	1.69e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg21775007	chr8:11205619	TDH	0.43	6.83	0.3	2.62e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.27	-0.32	1.54e-12	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg23758822	chr17:41437982	NA	0.9	15.82	0.59	2.25e-45	Menopause (age at onset);
LGG	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg06606381	chr12:133084897	FBRSL1	-1.23	-10.93	-0.45	6.94e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg08717414	chr16:71523259	ZNF19	-0.47	-7.1	-0.31	4.64e-12	Post bronchodilator FEV1;
LGG	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.04	0.31	7.2e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7765175	0.698	rs3851201	chr6:113677076	T/C	cg26552650	chr6:113682475	NA	0.34	7.51	0.33	2.97e-13	Coronary artery calcification;
LGG	cis	rs7712401	0.580	rs439739	chr5:122318421	G/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24497897	chr11:65658826	CCDC85B	0.42	7.13	0.31	3.92e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.69	-0.3	6.33e-11	Mood instability;
LGG	cis	rs9911578	1.000	rs1494977	chr17:56863064	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.96	-0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1949733	1.000	rs3103099	chr4:8511567	G/A	cg11789530	chr4:8429930	ACOX3	-0.89	-16.84	-0.62	5.56e-50	Response to antineoplastic agents;
LGG	cis	rs12478296	1.000	rs57603292	chr2:243028537	G/A	cg06360820	chr2:242988706	NA	-0.95	-11.88	-0.48	1.4e-28	Obesity-related traits;
LGG	cis	rs7017914	0.967	rs6991329	chr8:71593425	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.39	-7.07	-0.31	5.61e-12	Bone mineral density;
LGG	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg14541582	chr5:601475	NA	-0.7	-10.84	-0.45	1.46e-24	Obesity-related traits;
LGG	cis	rs9972944	0.702	rs987929	chr17:63765856	A/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2131877	0.830	rs62290331	chr3:194843799	C/T	cg07250128	chr3:194833983	C3orf21	0.42	6.81	0.3	3.03e-11	Non-small cell lung cancer;
LGG	cis	rs17162190	0.698	rs12093376	chr1:26849973	T/C	cg23229016	chr1:26872525	RPS6KA1	0.26	6.97	0.31	1.12e-11	Mean corpuscular volume;
LGG	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg27432699	chr2:27873401	GPN1	0.69	13.9	0.54	5.93e-37	Oral cavity cancer;
LGG	cis	rs858239	0.601	rs6948469	chr7:23174766	G/T	cg23682824	chr7:23144976	KLHL7	0.43	7.11	0.31	4.36e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg06026331	chr20:60912101	LAMA5	0.4	7.54	0.33	2.43e-13	Colorectal cancer;
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.82	-0.48	2.36e-28	Alzheimer's disease;
LGG	cis	rs9527	0.571	rs12219246	chr10:104613355	A/G	cg04362960	chr10:104952993	NT5C2	0.52	9.59	0.41	5.5e-20	Arsenic metabolism;
LGG	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.31	0.4	5.22e-19	Height;
LGG	cis	rs7666738	0.830	rs6532720	chr4:99043781	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25445244	chr19:37064171	ZNF529	0.53	8.24	0.36	1.73e-15	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs7937890	0.560	rs2597194	chr11:14497269	C/T	cg02886208	chr11:14281011	SPON1	-0.42	-7.71	-0.34	7.51e-14	Mitochondrial DNA levels;
LGG	trans	rs961253	0.513	rs2182710	chr20:6363207	T/C	cg21095983	chr6:86352623	SYNCRIP	0.4	6.79	0.3	3.54e-11	Colorectal cancer;
LGG	cis	rs7589342	0.929	rs7590652	chr2:106440306	A/G	cg14210321	chr2:106509881	NCK2	-0.52	-8.92	-0.38	1.13e-17	Addiction;
LGG	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.31	0.55	9.79e-39	IgG glycosylation;
LGG	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg15269541	chr15:43626905	ADAL	-0.42	-7.24	-0.32	1.94e-12	Lung cancer in ever smokers;
LGG	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg06453172	chr10:134556979	INPP5A	-0.58	-8.65	-0.37	8.54e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs72781680	0.664	rs2712076	chr2:23993366	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	8.46	0.37	3.46e-16	Lymphocyte counts;
LGG	cis	rs3770081	1.000	rs17027011	chr2:86406556	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.56	0.33	2.22e-13	Facial emotion recognition (sad faces);
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg19318889	chr4:1322082	MAEA	0.46	8.0	0.35	1.02e-14	Longevity;
LGG	cis	rs8072100	0.713	rs4968257	chr17:45430534	A/G	cg25173405	chr17:45401733	C17orf57	-0.56	-9.44	-0.4	1.9e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9513627	1.000	rs73556181	chr13:100122092	G/A	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg11789530	chr4:8429930	ACOX3	-0.67	-10.96	-0.45	5.38e-25	Response to antineoplastic agents;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	11.15	0.46	9.39e-26	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25107268	chr6:89673349	RNGTT	0.48	8.2	0.36	2.33e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg27570249	chr15:65688530	IGDCC4	0.29	7.15	0.32	3.44e-12	Menarche (age at onset);
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg01673284	chr16:4527211	HMOX2	0.33	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs7395662	1.000	rs55834832	chr11:48562583	T/G	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg10782380	chr11:9113167	SCUBE2	0.45	6.67	0.3	7.33e-11	Hip circumference;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02993943	chr7:39605861	C7orf36	0.44	7.37	0.32	8.06e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg27411982	chr8:10470053	RP1L1	0.43	7.47	0.33	3.93e-13	Joint mobility (Beighton score);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25302936	chr8:67579596	VCPIP1	0.42	6.85	0.3	2.4e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2197308	0.692	rs1904964	chr12:37933241	T/A	cg26384229	chr12:38710491	ALG10B	0.95	21.47	0.71	1.81e-71	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.79	14.41	0.56	3.59e-39	Subjective well-being;
LGG	cis	rs12476592	0.602	rs11125977	chr2:63809549	C/T	cg17519650	chr2:63277830	OTX1	0.48	7.4	0.33	6.58e-13	Childhood ear infection;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs4423214	0.547	rs11234030	chr11:71236967	G/A	cg10847948	chr11:71163743	NADSYN1	0.57	8.72	0.38	5.04e-17	Vitamin D levels;
LGG	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg04398451	chr17:18023971	MYO15A	0.8	17.29	0.63	4.9e-52	Total body bone mineral density;
LGG	cis	rs4144743	1.000	rs72823474	chr17:45321776	G/C	cg18085866	chr17:45331354	ITGB3	-0.78	-9.92	-0.42	3.55e-21	Body mass index;
LGG	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.03	-0.83	1.67e-119	Myeloid white cell count;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg11062466	chr8:58055876	NA	0.47	8.02	0.35	8.46e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11168618	0.846	rs11168592	chr12:48865079	C/T	cg24011408	chr12:48396354	COL2A1	0.49	8.04	0.35	7.5e-15	Adiponectin levels;
LGG	cis	rs4833079	0.562	rs11944291	chr4:38631620	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.48	7.98	0.35	1.12e-14	Body mass index;
LGG	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg25025879	chr12:53359317	NA	-0.43	-8.23	-0.36	1.89e-15	Prostate cancer;
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.38	0.36	6.33e-16	Bipolar disorder;
LGG	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg25482853	chr8:67687455	SGK3	1.03	13.3	0.53	2.14e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg03511173	chr18:77590860	NA	-0.41	-6.84	-0.3	2.59e-11	Schizophrenia;
LGG	cis	rs9341808	0.718	rs9352801	chr6:80817468	G/T	cg08355045	chr6:80787529	NA	0.42	8.17	0.36	2.89e-15	Sitting height ratio;
LGG	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.48	7.74	0.34	6.38e-14	Eosinophil percentage of white cells;
LGG	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg03391019	chr1:161927947	ATF6	0.51	7.43	0.33	5.3e-13	IgG glycosylation;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs11098499	0.505	rs75122014	chr4:120362426	G/C	cg24375607	chr4:120327624	NA	0.68	11.23	0.46	4.79e-26	Corneal astigmatism;
LGG	cis	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs7166081	1.000	rs4776922	chr15:67634437	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs9403521	0.898	rs12198291	chr6:143975600	G/A	cg18240653	chr6:144019428	PHACTR2	-0.63	-9.84	-0.42	7.41e-21	Obesity-related traits;
LGG	cis	rs11225247	0.881	rs11604008	chr11:102259744	T/A	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1832871	0.619	rs827861	chr6:158710074	C/A	cg07215822	chr6:158701037	NA	-0.47	-9.22	-0.39	1.09e-18	Height;
LGG	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.39	-0.47	1.11e-26	Type 2 diabetes;
LGG	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.11	0.49	1.61e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs2708977	0.901	rs6753667	chr2:97160382	G/A	cg01950434	chr2:97203154	ARID5A	-0.59	-9.4	-0.4	2.42e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg18357526	chr6:26021779	HIST1H4A	0.58	9.88	0.42	5.28e-21	Height;
LGG	cis	rs16854884	0.632	rs62267390	chr3:143644067	A/T	cg06585982	chr3:143692056	C3orf58	0.66	11.63	0.48	1.28e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs8179	0.645	rs11764331	chr7:92282624	C/T	cg15732164	chr7:92237376	CDK6	-0.53	-9.9	-0.42	4.45e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg17127132	chr2:85788382	GGCX	0.49	8.48	0.37	3.13e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.63	-0.41	3.87e-20	Bladder cancer;
LGG	trans	rs11875185	0.510	rs75615152	chr18:55649529	T/C	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs8016947	0.583	rs7140505	chr14:35830213	C/G	cg03549618	chr14:35838977	NA	0.36	7.36	0.32	8.41e-13	Psoriasis;
LGG	cis	rs7928758	0.943	rs11823810	chr11:134270070	A/G	cg22777979	chr11:134283252	B3GAT1	0.9	11.94	0.49	7.55e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg21963583	chr11:68658836	MRPL21	0.59	9.82	0.42	8.71e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35740288	0.689	rs11630688	chr15:86253279	C/T	cg04173714	chr15:86211321	AKAP13	0.42	7.11	0.31	4.53e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.63	0.51	1.29e-31	Mean corpuscular hemoglobin;
LGG	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15305172	chr6:116892775	RWDD1	0.4	6.76	0.3	4.28e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.24	-0.46	4.25e-26	Intelligence (multi-trait analysis);
LGG	cis	rs4663969	0.541	rs11902131	chr2:234594269	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.14	-0.35	3.77e-15	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.28	-0.58	5.43e-43	Chronic sinus infection;
LGG	cis	rs4716602	0.596	rs28451598	chr7:156158974	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.53	-0.4	9.06e-20	Anti-saccade response;
LGG	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.39e-12	Diabetic retinopathy;
LGG	cis	rs6495367	1.000	rs4778882	chr15:79382019	A/G	cg17916960	chr15:79447300	NA	0.53	9.4	0.4	2.56e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.89	-0.31	1.82e-11	Caffeine consumption;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.33	-0.32	1.06e-12	Lung cancer;
LGG	cis	rs6496044	0.568	rs10468112	chr15:86073424	G/C	cg10818794	chr15:86012489	AKAP13	-0.31	-6.69	-0.3	6.63e-11	Interstitial lung disease;
LGG	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg16141378	chr3:129829833	LOC729375	0.36	8.04	0.35	7.84e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9479482	0.686	rs2010259	chr6:150385475	C/T	cg03788504	chr6:150331562	NA	-0.51	-10.8	-0.45	2.16e-24	Alopecia areata;
LGG	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg01028140	chr2:1542097	TPO	-0.48	-8.92	-0.38	1.09e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.29	-0.32	1.31e-12	Menopause (age at onset);
LGG	cis	rs709400	1.000	rs861536	chr14:104167564	A/G	cg26031613	chr14:104095156	KLC1	1.13	25.71	0.77	3.14e-91	Body mass index;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.39e-15	Lymphocyte counts;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14042131	chr11:48003169	PTPRJ	-0.51	-7.43	-0.33	5.16e-13	Systemic lupus erythematosus;
LGG	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg08344181	chr3:125677491	NA	-0.64	-7.59	-0.33	1.81e-13	Depression;
LGG	cis	rs6840360	0.582	rs6535796	chr4:152304728	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.1	0.31	4.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2115630	0.818	rs7176522	chr15:85215383	C/G	cg12501888	chr15:85177176	SCAND2	-0.46	-7.5	-0.33	3.29e-13	P wave terminal force;
LGG	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.22	-0.36	2.08e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.41	0.36	4.95e-16	Morning vs. evening chronotype;
LGG	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg03733263	chr8:22462867	KIAA1967	1.1	29.35	0.81	9.97e-108	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10462794	0.853	rs10063884	chr5:4505482	C/T	cg18482690	chr5:4511582	NA	0.41	7.25	0.32	1.72e-12	DNA methylation (variation);
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.88	-0.34	2.43e-14	IgG glycosylation;
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs2806561	0.664	rs55764475	chr1:23318983	C/T	cg19743168	chr1:23544995	NA	0.38	7.68	0.34	9.63e-14	Height;
LGG	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg07835443	chr16:89734986	C16orf55	-0.39	-6.92	-0.31	1.52e-11	Hemoglobin concentration;
LGG	cis	rs9790314	0.905	rs4856739	chr3:160986710	A/C	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs4253772	0.550	rs739164	chr22:46684558	C/T	cg24881330	chr22:46731750	TRMU	-0.76	-9.29	-0.4	6.27e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11750568	0.933	rs7719616	chr5:178536584	A/G	cg10208897	chr5:178548229	ADAMTS2	0.43	7.12	0.31	4.19e-12	Height;
LGG	trans	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.12e-19	Gout;
LGG	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg03213289	chr20:61660250	NA	-0.65	-14.36	-0.56	6.04e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg03342759	chr3:160939853	NMD3	0.57	9.8	0.41	9.8e-21	Morning vs. evening chronotype;
LGG	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg17971929	chr21:40555470	PSMG1	-0.55	-9.38	-0.4	3.04e-19	Menarche (age at onset);
LGG	cis	rs9333075	0.507	rs7091231	chr10:15739261	G/A	cg14364212	chr10:15760690	ITGA8	0.47	9.71	0.41	2.08e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00761968	chr13:53314142	LECT1	-0.37	-7.9	-0.34	2.07e-14	Lewy body disease;
LGG	cis	rs6800768	0.633	rs62255803	chr3:24149030	T/C	cg10674438	chr3:24145617	LOC152024	-0.53	-9.5	-0.4	1.11e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.28	-0.36	1.3e-15	Subjective well-being;
LGG	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg06494592	chr3:125709126	NA	-0.54	-6.8	-0.3	3.26e-11	Blood pressure (smoking interaction);
LGG	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg01448562	chr3:133502909	NA	-0.45	-7.59	-0.33	1.82e-13	Iron status biomarkers;
LGG	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg16329650	chr2:213403929	ERBB4	0.78	16.75	0.61	1.45e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg19168338	chr16:4465731	CORO7	-0.74	-13.85	-0.54	9.67e-37	Schizophrenia;
LGG	cis	rs11585357	0.843	rs72633805	chr1:17617471	A/T	cg08277548	chr1:17600880	PADI3	-0.73	-8.17	-0.35	3.07e-15	Hair shape;
LGG	cis	rs528418	0.592	rs4896794	chr6:145688313	C/G	cg03642472	chr6:145670687	NA	0.58	7.66	0.34	1.07e-13	Methadone dose in opioid dependence;
LGG	cis	rs7833790	0.777	rs7815272	chr8:82691809	T/G	cg17211192	chr8:82754475	SNX16	-0.74	-11.47	-0.47	5.52e-27	Diastolic blood pressure;
LGG	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg08999081	chr20:33150536	PIGU	0.3	7.17	0.32	3e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.97	-0.42	2.53e-21	Body mass index;
LGG	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08564027	chr20:61660810	NA	1.0	21.85	0.71	3.02e-73	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs755249	0.567	rs4660208	chr1:39722214	A/G	cg18385671	chr1:39797026	MACF1	0.44	7.35	0.32	8.81e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.5e-18	Motion sickness;
LGG	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	cis	rs71403859	0.667	rs12920890	chr16:71787588	G/A	cg03805757	chr16:71968109	PKD1L3	-0.53	-7.24	-0.32	1.86e-12	Post bronchodilator FEV1;
LGG	cis	rs2688419	0.537	rs711725	chr3:23053020	A/T	cg00327796	chr3:23032191	NA	0.38	7.48	0.33	3.83e-13	Type 2 diabetes;
LGG	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs754466	0.830	rs61854186	chr10:79703255	G/A	cg17075019	chr10:79541650	NA	-0.81	-13.47	-0.53	4.07e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.76	-0.34	5.6e-14	Neuroticism;
LGG	cis	rs539514	0.627	rs2328954	chr13:76300271	T/C	cg04757411	chr13:76259545	LMO7	-0.27	-6.99	-0.31	9.54e-12	Type 1 diabetes;
LGG	cis	rs11608355	0.545	rs61941585	chr12:109905222	C/T	cg05360138	chr12:110035743	NA	0.85	11.91	0.48	9.85e-29	Neuroticism;
LGG	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06634786	chr22:41940651	POLR3H	0.72	11.9	0.48	1.12e-28	Vitiligo;
LGG	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg02487422	chr3:49467188	NICN1	0.41	6.85	0.3	2.31e-11	Parkinson's disease;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2916247	0.865	rs7813262	chr8:93157419	C/T	cg10183463	chr8:93005414	RUNX1T1	0.38	7.96	0.35	1.34e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.573	rs4696249	chr4:152264647	A/G	cg25486957	chr4:152246857	NA	-0.41	-7.31	-0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.35	-0.32	8.96e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6960043	0.738	rs10950548	chr7:15057728	G/A	cg19272540	chr7:15055459	NA	0.35	7.75	0.34	5.89e-14	Type 2 diabetes;
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg24623649	chr8:11872141	NA	0.31	7.21	0.32	2.29e-12	Neuroticism;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07677032	chr17:61819896	STRADA	0.68	12.64	0.51	1.11e-31	Prudent dietary pattern;
LGG	cis	rs12210905	1.000	rs9393803	chr6:27257714	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	trans	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.05	-0.35	7.07e-15	Breast cancer;
LGG	cis	rs7617773	0.514	rs11130166	chr3:48388056	A/G	cg11946769	chr3:48343235	NME6	0.51	8.76	0.38	3.79e-17	Coronary artery disease;
LGG	cis	rs9814567	0.727	rs9809344	chr3:134342758	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.93	-0.45	6.62e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4262150	0.883	rs12153071	chr5:152247852	C/A	cg12297329	chr5:152029980	NA	-0.66	-12.47	-0.5	5.85e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.48	-0.33	3.81e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2708240	1.000	rs2710139	chr7:147570807	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.74	-0.3	4.65e-11	QT interval (drug interaction);
LGG	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg03929089	chr4:120376271	NA	-0.51	-8.53	-0.37	2.13e-16	Height;
LGG	cis	rs7737355	0.755	rs1151481	chr5:130926374	A/C	cg06307176	chr5:131281290	NA	0.53	8.65	0.37	8.69e-17	Life satisfaction;
LGG	trans	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.79e-39	Exhaled nitric oxide output;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.82e-11	Menopause (age at onset);
LGG	cis	rs36051895	0.659	rs62543863	chr9:5085417	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.57	-0.56	7.86e-40	Pediatric autoimmune diseases;
LGG	cis	rs12220238	1.000	rs7909664	chr10:75869754	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.6	0.47	1.81e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg21435375	chr2:172878103	MAP1D	0.3	6.84	0.3	2.59e-11	Schizophrenia;
LGG	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg00990874	chr7:1149470	C7orf50	-0.65	-9.29	-0.4	6.14e-19	Bronchopulmonary dysplasia;
LGG	cis	rs858239	0.636	rs7808488	chr7:23221870	T/C	cg23682824	chr7:23144976	KLHL7	0.4	6.79	0.3	3.52e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7558370	0.737	rs17017879	chr2:3713658	C/G	cg16123090	chr2:3699210	NA	0.77	7.37	0.32	7.76e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg09426994	chr11:118478258	PHLDB1	0.45	8.27	0.36	1.4e-15	Systemic lupus erythematosus;
LGG	cis	rs2764208	0.535	rs7763832	chr6:34693960	C/G	cg07306190	chr6:34760872	UHRF1BP1	0.45	7.77	0.34	4.95e-14	Systemic lupus erythematosus;
LGG	cis	rs12618769	0.625	rs78518453	chr2:99213899	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.79	0.34	4.51e-14	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg11494091	chr17:61959527	GH2	0.52	8.31	0.36	1.08e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs698813	0.604	rs2340814	chr2:44490977	C/T	cg00619915	chr2:44497795	NA	-0.6	-8.88	-0.38	1.45e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs7296418	0.663	rs28450974	chr12:123861420	G/A	cg05973401	chr12:123451056	ABCB9	0.43	7.3	0.32	1.27e-12	Platelet count;
LGG	cis	rs9470366	0.816	rs7742159	chr6:36619452	A/C	cg08179530	chr6:36648295	CDKN1A	0.6	8.61	0.37	1.15e-16	QRS duration;
LGG	cis	rs2236918	1.000	rs2236918	chr1:242017826	C/G	cg17736920	chr1:242011382	EXO1	-0.52	-9.43	-0.4	1.95e-19	Menopause (age at onset);
LGG	cis	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs2050392	0.517	rs602966	chr10:30755853	C/T	cg25182066	chr10:30743637	MAP3K8	-0.66	-14.08	-0.55	1.04e-37	Inflammatory bowel disease;
LGG	cis	rs9863	0.931	rs4765335	chr12:124430812	G/A	cg13487667	chr12:124434373	CCDC92	-0.36	-7.18	-0.32	2.85e-12	White blood cell count;
LGG	cis	rs10463554	0.759	rs34781	chr5:102454439	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Parkinson's disease;
LGG	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg09998033	chr7:158218633	PTPRN2	-0.44	-7.99	-0.35	1.07e-14	Obesity-related traits;
LGG	cis	rs7512552	0.768	rs7517441	chr1:150283643	A/T	cg15654264	chr1:150340011	RPRD2	-0.44	-9.02	-0.39	4.92e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	8.8e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4664308	0.810	rs62175552	chr2:160937220	T/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-17.95	-0.64	4.34e-55	Idiopathic membranous nephropathy;
LGG	cis	rs2735413	0.564	rs17776122	chr16:78106286	C/T	cg04733911	chr16:78082701	NA	0.57	7.97	0.35	1.22e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs4731207	0.596	rs1481337	chr7:124667796	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.14	-0.32	3.58e-12	Cutaneous malignant melanoma;
LGG	cis	rs9649465	0.967	rs12537989	chr7:123308195	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs68170813	0.559	rs2299422	chr7:106959832	A/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.76	-0.45	3.1e-24	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs787274	1.000	rs9409123	chr9:115507165	G/A	cg13803584	chr9:115635662	SNX30	0.56	7.54	0.33	2.46e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs634534	0.622	rs1308733	chr11:65720841	T/C	cg26695010	chr11:65641043	EFEMP2	0.59	10.42	0.44	5.72e-23	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg22903471	chr2:27725779	GCKR	-0.38	-8.39	-0.36	6.14e-16	Oral cavity cancer;
LGG	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg22771759	chr13:24902376	NA	0.42	7.24	0.32	1.88e-12	Obesity-related traits;
LGG	trans	rs17685	0.712	rs6953342	chr7:75776753	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	24.81	0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg27624424	chr6:160112604	SOD2	0.69	10.23	0.43	2.85e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1185460	0.967	rs1784459	chr11:118938388	C/A	cg23280166	chr11:118938394	VPS11	0.6	11.23	0.46	4.71e-26	Coronary artery disease;
LGG	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.45	-0.37	3.69e-16	Morning vs. evening chronotype;
LGG	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.69e-11	Schizophrenia;
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg17734273	chr15:78292508	TBC1D2B	0.35	7.27	0.32	1.56e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.84e-40	Cognitive test performance;
LGG	cis	rs834603	0.546	rs1704973	chr7:47483705	T/C	cg23694490	chr7:47445681	TNS3	-0.4	-11.49	-0.47	4.69e-27	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2594989	0.887	rs6442253	chr3:11474238	T/C	cg01796438	chr3:11312864	ATG7	-0.52	-6.95	-0.31	1.21e-11	Circulating chemerin levels;
LGG	cis	rs9815354	1.000	rs6803560	chr3:41824480	A/G	cg03022575	chr3:42003672	ULK4	0.61	7.89	0.34	2.2e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg01043669	chr3:72786069	NA	0.43	7.15	0.32	3.3e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.57	0.33	1.99e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg21798802	chr22:38057573	PDXP	0.61	14.01	0.55	1.94e-37	Fat distribution (HIV);
LGG	cis	rs2131877	0.871	rs58948928	chr3:194866789	C/A	cg07250128	chr3:194833983	C3orf21	0.41	6.81	0.3	3.03e-11	Non-small cell lung cancer;
LGG	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg27205649	chr11:78285834	NARS2	-0.43	-7.21	-0.32	2.32e-12	Testicular germ cell tumor;
LGG	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg04703951	chr17:43578652	NA	0.39	7.69	0.34	8.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs981844	0.683	rs2405423	chr4:154749823	C/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.12	-0.39	2.3e-18	Erythrocyte sedimentation rate;
LGG	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.55e-20	Depression;
LGG	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg04691961	chr3:161091175	C3orf57	-0.57	-12.57	-0.5	2.12e-31	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs13125537	chr4:98978428	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.545	rs73148639	chr7:65855329	A/T	cg11764359	chr7:65958608	NA	0.64	9.89	0.42	4.77e-21	Aortic root size;
LGG	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg05425664	chr17:57184151	TRIM37	0.57	9.1	0.39	2.79e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4704846	1.000	rs2902306	chr5:156531561	C/T	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.4	-0.33	6.3e-13	Blood protein levels;
LGG	cis	rs2120019	1.000	rs7168680	chr15:75369212	G/A	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.53	-0.61	1.45e-48	Blood trace element (Zn levels);
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg14004847	chr7:1930337	MAD1L1	0.57	9.95	0.42	2.8e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg21055462	chr7:100276975	NA	0.36	7.39	0.32	7.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	12.32	0.5	2.4e-30	Colorectal cancer;
LGG	cis	rs12220238	1.000	rs12355771	chr10:75894404	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.79	11.19	0.46	6.91e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6750047	0.625	rs336037	chr2:38261124	T/C	cg07380506	chr2:38303506	CYP1B1	-0.43	-7.0	-0.31	8.93e-12	Cutaneous malignant melanoma;Melanoma;
LGG	trans	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.47	-0.44	3.63e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg00012203	chr2:219082015	ARPC2	0.83	16.64	0.61	4.63e-49	Colorectal cancer;
LGG	trans	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.13	-0.39	2.12e-18	Bladder cancer;
LGG	cis	rs10895140	0.756	rs7126770	chr11:101507638	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2236918	0.932	rs1776131	chr1:242024245	T/A	cg17736920	chr1:242011382	EXO1	0.49	8.84	0.38	1.96e-17	Menopause (age at onset);
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg11168104	chr5:1857477	NA	-0.4	-6.99	-0.31	9.92e-12	Cardiovascular disease risk factors;
LGG	cis	rs807669	0.525	rs2073740	chr22:19196112	A/C	cg02655711	chr22:19163373	SLC25A1	-0.5	-8.95	-0.38	8.83e-18	Metabolite levels;
LGG	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg00495681	chr13:53174319	NA	0.55	9.78	0.41	1.21e-20	Lewy body disease;
LGG	cis	rs6743376	0.556	rs2515394	chr2:113817765	C/T	cg05949173	chr2:113825882	IL1F10	0.48	9.17	0.39	1.57e-18	Inflammatory biomarkers;
LGG	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.22	-0.43	2.93e-22	Bipolar disorder;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.02	0.52	3e-33	Tonsillectomy;
LGG	trans	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.71	-0.41	2.06e-20	Blood pressure (smoking interaction);
LGG	trans	rs1997103	1.000	rs2140915	chr7:55410699	G/C	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12956009	0.518	rs1560902	chr18:44898765	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.42	0.33	5.59e-13	Educational attainment (years of education);
LGG	cis	rs933688	1.000	rs2052553	chr5:90729906	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.1	17.62	0.63	1.44e-53	Smoking behavior;
LGG	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.0	-0.31	9.04e-12	Systemic lupus erythematosus;
LGG	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg08847335	chr10:891726	LARP4B	-0.51	-9.22	-0.39	1.08e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg17971929	chr21:40555470	PSMG1	0.88	17.66	0.63	9.92e-54	Cognitive function;
LGG	cis	rs2153535	0.580	rs6918391	chr6:8461178	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.52	0.5	3.46e-31	Motion sickness;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08280861	chr8:58055591	NA	0.63	7.76	0.34	5.54e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.938	rs355747	chr3:153962973	T/C	cg17054900	chr3:154042577	DHX36	0.97	12.06	0.49	2.66e-29	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs504918	1.000	rs11718311	chr3:124094960	G/A	cg05766129	chr3:123988013	KALRN	-0.37	-6.74	-0.3	4.87e-11	Schizophrenia;
LGG	cis	rs4853012	0.838	rs2177707	chr2:74356850	A/G	cg20891558	chr2:74357851	NA	0.5	9.2	0.39	1.25e-18	Gestational age at birth (maternal effect);
LGG	cis	rs17767392	0.718	rs35609708	chr14:71843844	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.94	-0.38	9e-18	Mitral valve prolapse;
LGG	cis	rs4948102	0.727	rs4948097	chr7:56056571	A/G	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs12291225	0.546	rs12291662	chr11:14342949	T/C	cg19336497	chr11:14380999	RRAS2	-0.63	-13.46	-0.53	4.57e-35	Sense of smell;
LGG	trans	rs9944715	1.000	rs11082518	chr18:43842032	G/A	cg01718231	chr17:29326311	RNF135	-0.42	-6.82	-0.3	2.82e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs9912468	1.000	rs12940610	chr17:64312463	A/G	cg19474267	chr17:64306194	PRKCA	-0.96	-27.75	-0.79	1.56e-100	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.18	0.36	2.79e-15	Schizophrenia;
LGG	cis	rs2470578	0.766	rs2596681	chr3:17320850	A/T	cg20981856	chr3:17787350	NA	-0.35	-6.68	-0.3	6.95e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11243835	chr10:116581808	FAM160B1	0.45	6.74	0.3	4.74e-11	Gut microbiome composition (summer);
LGG	cis	rs4642101	0.537	rs4997708	chr3:12839603	G/A	cg24848339	chr3:12840334	CAND2	0.43	9.79	0.41	1.08e-20	QRS complex (12-leadsum);
LGG	cis	rs367943	0.799	rs10478135	chr5:112976905	C/A	cg12552261	chr5:112820674	MCC	0.58	10.0	0.42	1.84e-21	Type 2 diabetes;
LGG	cis	rs12497850	0.931	rs11705888	chr3:48817289	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.75	0.3	4.32e-11	Parkinson's disease;
LGG	cis	rs10463554	0.927	rs158404	chr5:102415910	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs3816183	0.626	rs4297935	chr2:42818377	T/G	cg14631114	chr2:43023945	NA	0.34	6.89	0.3	1.87e-11	Hypospadias;
LGG	cis	rs751728	0.965	rs2013381	chr6:33763837	C/T	cg25922239	chr6:33757077	LEMD2	0.69	12.35	0.5	1.77e-30	Crohn's disease;
LGG	cis	rs875971	0.862	rs7786892	chr7:65628876	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.34	-0.36	8.35e-16	Aortic root size;
LGG	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.53	-0.5	3.22e-31	Bipolar disorder;
LGG	cis	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs28595532	0.545	rs13132957	chr4:119250841	G/C	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs67460515	0.926	rs66508859	chr3:160946351	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.6	-0.41	5.03e-20	Parkinson's disease;
LGG	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.6	0.37	1.24e-16	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg15017067	chr4:17643749	FAM184B	0.3	6.73	0.3	4.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg08280861	chr8:58055591	NA	0.5	6.73	0.3	5.07e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg18200150	chr17:30822561	MYO1D	0.51	9.6	0.41	5.1e-20	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09039206	chr10:60028728	CISD1;IPMK	0.58	6.82	0.3	2.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.57e-12	Lung cancer;
LGG	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.28	-0.5	3.48e-30	Depression;
LGG	cis	rs55692411	0.537	rs71326904	chr3:49991060	C/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.86	-0.34	2.78e-14	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg24503407	chr1:205819492	PM20D1	0.57	11.41	0.47	9.86e-27	Menarche (age at onset);
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	0.669	rs4646554	chr15:58355437	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.87	-0.3	2.14e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2735413	0.599	rs76440854	chr16:78080883	A/G	cg04733911	chr16:78082701	NA	0.57	7.47	0.33	3.98e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs11225247	1.000	rs11225243	chr11:102275302	C/A	cg06323957	chr11:102217781	BIRC2	0.78	6.9	0.31	1.72e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg16386425	chr10:429943	DIP2C	-0.37	-7.5	-0.33	3.28e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg19635926	chr16:89946313	TCF25	0.74	7.31	0.32	1.19e-12	Skin colour saturation;
LGG	trans	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg18335740	chr13:41363409	SLC25A15	0.88	21.32	0.7	8.64e-71	Lewy body disease;
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg14159672	chr1:205819179	PM20D1	-0.44	-6.97	-0.31	1.09e-11	Parkinson's disease;
LGG	cis	rs4938330	0.608	rs3830008	chr11:117093764	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.57	-0.33	2.06e-13	Blood protein levels;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs11098499	0.954	rs11734241	chr4:120416872	A/G	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs2273669	0.667	rs75675305	chr6:109324353	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-8.68	-0.37	6.65e-17	Prostate cancer;
LGG	cis	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg12395012	chr8:11607386	GATA4	0.66	10.92	0.45	7.44e-25	Myopia (pathological);
LGG	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg25427524	chr10:38739819	LOC399744	0.5	7.3	0.32	1.27e-12	Obesity (extreme);
LGG	cis	rs9815354	0.857	rs73073252	chr3:42016891	C/T	cg03022575	chr3:42003672	ULK4	0.68	8.06	0.35	6.76e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6901004	0.803	rs1040903	chr6:111470153	A/C	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.71	-0.34	7.92e-14	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg24631222	chr15:78858424	CHRNA5	0.43	6.85	0.3	2.4e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20786246	chr2:72377174	NA	0.4	7.08	0.31	5.24e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs774359	0.797	rs774355	chr9:27515794	G/T	cg14173147	chr9:27528300	MOBKL2B	0.43	8.86	0.38	1.74e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.49	0.33	3.6e-13	Joint mobility (Beighton score);
LGG	cis	rs7169223	0.615	rs11630027	chr15:79096983	C/A	cg03762349	chr15:79060523	ADAMTS7	-0.34	-6.89	-0.3	1.88e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.71	-0.34	7.54e-14	Mean corpuscular hemoglobin;
LGG	cis	rs4713118	0.513	rs183244	chr6:28031838	C/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.9	-0.31	1.69e-11	Parkinson's disease;
LGG	cis	rs600231	0.665	rs1784859	chr11:65220749	A/G	cg17120908	chr11:65337727	SSSCA1	0.49	8.73	0.38	4.5e-17	Bone mineral density;
LGG	cis	rs4730250	0.707	rs257386	chr7:106807783	C/G	cg02696742	chr7:106810147	HBP1	-0.83	-11.57	-0.47	2.25e-27	Osteoarthritis;
LGG	cis	rs6831352	1.000	rs6831352	chr4:100063525	T/C	cg12011299	chr4:100065546	ADH4	0.45	9.2	0.39	1.25e-18	Alcohol dependence;
LGG	cis	rs283228	0.798	rs2251796	chr6:101765373	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg19147804	chr7:1989927	MAD1L1	0.46	8.53	0.37	2.13e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4845570	0.850	rs11204892	chr1:151768048	A/G	cg07092448	chr1:151763213	TDRKH	1.16	24.08	0.75	1.1e-83	Coronary artery disease;
LGG	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg18424134	chr6:126068038	NA	0.21	6.82	0.3	2.95e-11	Brugada syndrome;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.22	-0.52	4.49e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg13047869	chr3:10149882	C3orf24	0.55	9.32	0.4	4.58e-19	Alzheimer's disease;
LGG	cis	rs12188164	0.812	rs10072668	chr5:422752	T/C	cg00049323	chr5:472564	LOC25845	-0.33	-6.77	-0.3	3.83e-11	Cystic fibrosis severity;
LGG	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.97	-0.31	1.11e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs317689	0.718	rs315122	chr12:69771073	G/T	cg14784868	chr12:69753453	YEATS4	0.7	11.0	0.46	3.72e-25	Response to diuretic therapy;
LGG	cis	rs10791097	0.694	rs7926167	chr11:130745045	T/C	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs490234	0.841	rs490333	chr9:128354569	T/C	cg14078157	chr9:128172775	NA	0.43	8.0	0.35	1.01e-14	Mean arterial pressure;
LGG	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.68	-0.54	4.95e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs9487094	0.626	rs4141930	chr6:110060818	C/T	cg16315928	chr6:109776240	MICAL1	0.43	7.53	0.33	2.72e-13	Height;
LGG	cis	rs9487094	0.961	rs3778477	chr6:109776058	C/G	cg01125227	chr6:109776195	MICAL1	0.57	9.66	0.41	3.08e-20	Height;
LGG	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.16	-0.35	3.25e-15	Small cell lung carcinoma;
LGG	cis	rs9902453	1.000	rs4328498	chr17:28344276	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.3	-0.53	2e-34	Coffee consumption (cups per day);
LGG	cis	rs796364	0.755	rs6739563	chr2:201134216	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.62	7.61	0.33	1.53e-13	Schizophrenia;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20887711	chr4:1340912	KIAA1530	0.48	8.64	0.37	8.96e-17	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg03538708	chr1:25844672	NA	0.35	6.7	0.3	6.09e-11	Erythrocyte sedimentation rate;
LGG	cis	rs7100689	0.646	rs11202751	chr10:82147802	G/A	cg01528321	chr10:82214614	TSPAN14	0.88	15.58	0.59	2.52e-44	Post bronchodilator FEV1;
LGG	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs12956009	0.583	rs1821446	chr18:44894422	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.11	0.31	4.29e-12	Educational attainment (years of education);
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.35	0.55	7.03e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.46	0.4	1.5700000000000001e-19	Coronary artery disease;
LGG	cis	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.91	-0.38	1.2e-17	Mean corpuscular volume;
LGG	cis	rs4909189	1.000	rs12698214	chr7:158136204	T/G	cg25566285	chr7:158114605	PTPRN2	0.7	11.57	0.47	2.22e-27	Response to amphetamines;
LGG	cis	rs921968	0.541	rs687747	chr2:219399627	T/C	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs16870629	0.541	rs2334955	chr5:1062444	A/G	cg17097710	chr5:1061055	SLC12A7	-0.42	-7.33	-0.32	1e-12	QT interval;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg07766779	chr6:149887504	C6orf72	0.59	7.03	0.31	7.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	1.000	rs7646144	chr3:41853125	T/A	cg03022575	chr3:42003672	ULK4	0.7	8.81	0.38	2.55e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.02	0.35	8.72e-15	Lung cancer;
LGG	cis	rs8016982	0.651	rs9806027	chr14:81668707	G/C	cg01989461	chr14:81687754	GTF2A1	0.74	17.2	0.62	1.29e-51	Schizophrenia;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg08916839	chr5:415575	AHRR	0.99	14.13	0.55	5.8e-38	Fat distribution (HIV);
LGG	cis	rs1909881	1.000	rs10091727	chr8:96504556	C/T	cg04203453	chr8:96504381	NA	-1.09	-18.65	-0.65	2.63e-58	Obesity-related traits;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.85	-0.3	2.43e-11	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.567	rs3770005	chr2:178528874	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.41	-0.36	5.12e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4253772	0.550	rs9615913	chr22:46668515	A/T	cg24881330	chr22:46731750	TRMU	-0.72	-8.74	-0.38	4.28e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg15268244	chr15:77196840	NA	-0.43	-9.55	-0.41	7.54e-20	Blood metabolite levels;
LGG	trans	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg10756647	chr7:56101905	PSPH	0.82	9.55	0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs7084402	1.000	rs7084402	chr10:60265404	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.4	-0.33	6.44e-13	Refractive error;
LGG	cis	rs6748734	1.000	rs4344931	chr2:241818527	A/C	cg26818257	chr2:241905806	NA	0.37	7.09	0.31	4.93e-12	Urinary metabolites;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.3	0.36	1.18e-15	Longevity;
LGG	cis	rs9976767	0.896	rs9975920	chr21:43818656	A/G	cg23042151	chr21:43824109	UBASH3A	-0.48	-10.0	-0.42	1.87e-21	Type 1 diabetes;
LGG	cis	rs9398803	0.687	rs4549631	chr6:126966308	A/G	cg19875578	chr6:126661172	C6orf173	0.5	9.27	0.4	7e-19	Male-pattern baldness;
LGG	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg10792982	chr14:105748885	BRF1	0.59	12.12	0.49	1.43e-29	Mean platelet volume;Platelet distribution width;
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg18050959	chr15:68126178	NA	-0.37	-6.93	-0.31	1.39e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Electroencephalogram traits;
LGG	cis	rs12291225	0.679	rs11023170	chr11:14294909	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.67	-0.48	9.48e-28	Sense of smell;
LGG	cis	rs7572733	0.534	rs771009	chr2:198691082	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.15	0.46	9.41e-26	Dermatomyositis;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg09359103	chr1:154839909	KCNN3	-0.48	-9.49	-0.4	1.25e-19	Prostate cancer;
LGG	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg08250081	chr4:10125330	NA	0.38	7.32	0.32	1.11e-12	Bone mineral density;
LGG	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg00277334	chr10:82204260	NA	-0.35	-7.68	-0.34	9.63e-14	Post bronchodilator FEV1;
LGG	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg05044414	chr3:183734942	ABCC5	0.79	17.17	0.62	1.69e-51	Anterior chamber depth;
LGG	cis	rs6840360	0.642	rs56301462	chr4:152452128	T/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.11	0.31	4.33e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs7116698	chr11:77995191	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.46	-0.33	4.36e-13	Testicular germ cell tumor;
LGG	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg05793240	chr7:2802953	GNA12	0.29	7.28	0.32	1.43e-12	Height;
LGG	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg20587970	chr11:113659929	NA	-0.9	-14.14	-0.55	5.74e-38	Hip circumference adjusted for BMI;
LGG	cis	rs9549260	0.664	rs1360719	chr13:41225874	G/C	cg21288729	chr13:41239152	FOXO1	0.33	6.72	0.3	5.34e-11	Red blood cell count;
LGG	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Vitiligo;
LGG	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	18.98	0.66	7.35e-60	Primary sclerosing cholangitis;
LGG	cis	rs1801251	1.000	rs2100053	chr2:233719516	G/T	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.24	-0.39	8.82e-19	Coronary artery disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02873371	chr16:53537209	AKTIP	0.62	7.19	0.32	2.64e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.45	8.35	0.36	7.74e-16	Longevity;
LGG	cis	rs9902453	1.000	rs12600855	chr17:28279591	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.52	0.53	2.36e-35	Coffee consumption (cups per day);
LGG	cis	rs11585357	0.895	rs72633808	chr1:17618665	A/G	cg08277548	chr1:17600880	PADI3	-0.73	-8.29	-0.36	1.21e-15	Hair shape;
LGG	cis	rs8067545	0.750	rs34290687	chr17:19991211	G/A	cg13482628	chr17:19912719	NA	0.64	12.73	0.51	4.95e-32	Schizophrenia;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9472414	0.622	rs7381290	chr6:44733725	T/G	cg20913747	chr6:44695427	NA	0.48	7.29	0.32	1.4e-12	Height;
LGG	trans	rs4650994	1.000	rs4650995	chr1:178517316	C/T	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17221829	0.703	rs10765229	chr11:89392575	T/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.16e-18	Anxiety in major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16035520	chr11:98891820	CNTN5	0.44	7.46	0.33	4.35e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg13009111	chr11:71350975	NA	0.3	6.7	0.3	6.04e-11	Neuroticism;
LGG	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg20891558	chr2:74357851	NA	0.49	9.29	0.4	6.01e-19	Gestational age at birth (maternal effect);
LGG	cis	rs2404602	0.532	rs12591100	chr15:76700801	C/A	cg15268244	chr15:77196840	NA	0.36	8.13	0.35	4.02e-15	Blood metabolite levels;
LGG	cis	rs8062405	1.000	rs62037365	chr16:28868962	C/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.33e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg10760299	chr15:45669010	GATM	0.41	8.09	0.35	5.23e-15	Homoarginine levels;
LGG	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg06212747	chr3:49208901	KLHDC8B	0.43	7.0	0.31	9.21e-12	Resting heart rate;
LGG	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg20307385	chr11:47447363	PSMC3	-0.43	-6.87	-0.3	2.12e-11	Migraine - clinic-based;
LGG	trans	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08862035	chr2:2617432	NA	0.43	6.99	0.31	9.47e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg13628971	chr7:2884303	GNA12	0.32	6.67	0.3	7.31e-11	Height;
LGG	cis	rs6450176	0.909	rs6898870	chr5:53293107	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.06	-0.46	2.23e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg23730037	chr7:158596552	ESYT2	-0.48	-8.63	-0.37	9.89e-17	Height;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg18379455	chr17:41446167	NA	-0.32	-7.27	-0.32	1.53e-12	Menopause (age at onset);
LGG	cis	rs537930	0.925	rs299374	chr5:134340942	C/T	cg24576358	chr5:134350122	NA	0.46	9.4	0.4	2.57e-19	Height;
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg10053473	chr17:62856997	LRRC37A3	0.78	13.79	0.54	1.81e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07725658	chr4:71705655	GRSF1	-0.41	-7.22	-0.32	2.19e-12	Brain structure;
LGG	cis	rs950027	0.967	rs2643718	chr15:45794662	T/C	cg26924012	chr15:45694286	SPATA5L1	0.41	7.11	0.31	4.45e-12	Response to fenofibrate (adiponectin levels);
LGG	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.48e-31	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18827097	chr2:3522506	ADI1	0.52	8.19	0.36	2.63e-15	Gut microbiome composition (summer);
LGG	cis	rs9902453	0.791	rs28492945	chr17:28223982	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.04	0.55	1.47e-37	Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.51	0.33	3.03e-13	Lung cancer;
LGG	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-24.13	-0.75	6.58e-84	Primary sclerosing cholangitis;
LGG	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg04058563	chr4:185651563	MLF1IP	-0.33	-6.67	-0.3	7.46e-11	Kawasaki disease;
LGG	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	13.5	0.53	3.03e-35	Total body bone mineral density;
LGG	cis	rs11122272	0.701	rs2011383	chr1:231479788	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.41	-0.44	6.29e-23	Hemoglobin concentration;
LGG	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg24130564	chr14:104152367	KLC1	-0.77	-17.19	-0.62	1.33e-51	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs6446196	chr3:49004723	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.29e-11	Parkinson's disease;
LGG	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.82	0.34	3.73e-14	Retinal vascular caliber;
LGG	cis	rs1008375	0.931	rs2109519	chr4:17695453	A/G	cg18681998	chr4:17616180	MED28	0.74	15.24	0.58	8.53e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7000551	0.619	rs2443506	chr8:22373383	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	11.69	0.48	7.66e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1185460	0.967	rs1184902	chr11:118945337	A/G	cg23280166	chr11:118938394	VPS11	0.6	11.19	0.46	7.11e-26	Coronary artery disease;
LGG	cis	rs6547741	0.967	rs4665996	chr2:27814343	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.44	0.47	7.47e-27	Schizophrenia;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg26174226	chr8:58114915	NA	-0.48	-7.16	-0.32	3.23e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3857067	0.806	rs72665629	chr4:95112160	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	trans	rs4427176	0.507	rs13276965	chr8:9579252	T/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs9308731	1.000	rs2015454	chr2:111872148	A/G	cg18081430	chr2:111878091	BCL2L11	-0.32	-6.84	-0.3	2.47e-11	Chronic lymphocytic leukemia;
LGG	cis	rs6834538	0.964	rs4834280	chr4:113396655	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.48	0.37	3.05e-16	Free thyroxine concentration;
LGG	cis	rs1506636	1.000	rs684548	chr7:123397102	A/T	cg03229431	chr7:123269106	ASB15	0.73	18.17	0.65	4.5e-56	Plateletcrit;Platelet count;
LGG	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.27	0.4	6.92e-19	Diabetic retinopathy;
LGG	cis	rs7192380	0.571	rs10852456	chr16:69605613	G/T	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.59	-0.33	1.79e-13	Sjögren's syndrome;
LGG	cis	rs12135191	0.967	rs10924993	chr1:236459785	A/C	cg21399712	chr1:236511386	NA	-0.39	-7.53	-0.33	2.72e-13	Urate levels (BMI interaction);
LGG	cis	rs11190604	1.000	rs12358187	chr10:102284449	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.97	0.49	5.85e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6977660	0.714	rs12334001	chr7:19814399	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.57	0.44	1.48e-23	Thyroid stimulating hormone;
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.74	-0.34	6.15e-14	Skin colour saturation;
LGG	cis	rs870825	0.616	rs10025167	chr4:185649551	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg06886374	chr16:1844152	IGFALS	-0.49	-9.5	-0.4	1.1e-19	Insulin-like growth factors;
LGG	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg14784868	chr12:69753453	YEATS4	0.44	6.84	0.3	2.56e-11	Response to diuretic therapy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05457941	chr1:149858211	HIST2H2BE;HIST2H2AC	0.48	8.22	0.36	2.01e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg13385794	chr1:248469461	NA	0.5	8.61	0.37	1.13e-16	Common traits (Other);
LGG	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg26597838	chr10:835615	NA	0.64	9.49	0.4	1.24e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg21479132	chr6:26055353	NA	0.79	7.61	0.33	1.51e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs208520	1.000	rs9453663	chr6:66976077	A/G	cg07460842	chr6:66804631	NA	0.9	14.8	0.57	7.18e-41	Exhaled nitric oxide output;
LGG	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15644404	chr18:77186268	NFATC1	-0.8	-9.98	-0.42	2.18e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6977660	0.714	rs12334267	chr7:19810265	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	8.16	0.35	3.2e-15	Thyroid stimulating hormone;
LGG	cis	rs55871839	1.000	rs55871839	chr8:59816868	T/C	cg07426533	chr8:59803705	TOX	0.42	8.46	0.37	3.45e-16	Pneumonia;
LGG	cis	rs4700695	0.719	rs27584	chr5:65445232	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-12.12	-0.49	1.47e-29	Monocyte count;
LGG	cis	rs2712184	0.756	rs2712164	chr2:217659916	G/A	cg05032264	chr2:217675019	NA	-0.44	-9.62	-0.41	4.22e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg18110333	chr6:292329	DUSP22	-0.7	-12.01	-0.49	4.02e-29	Menopause (age at onset);
LGG	cis	rs709400	0.832	rs55864158	chr14:104068579	G/A	cg24130564	chr14:104152367	KLC1	-0.41	-7.6	-0.33	1.66e-13	Body mass index;
LGG	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.23	-0.36	1.95e-15	Mood instability;
LGG	cis	rs1555322	0.530	rs2425049	chr20:33874720	C/T	cg03689076	chr20:33865952	NA	0.6	8.66	0.37	7.67e-17	Attention deficit hyperactivity disorder;
LGG	cis	rs988958	0.567	rs34291746	chr2:42259859	A/G	cg27252766	chr2:42229092	NA	0.52	7.72	0.34	7.11e-14	Hypospadias;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04696559	chr5:36152378	SKP2;LMBRD2	0.43	7.41	0.33	5.95e-13	Bipolar disorder;
LGG	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.69	-0.34	9.01e-14	Cognitive test performance;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg26354017	chr1:205819088	PM20D1	0.73	17.06	0.62	5.51e-51	Monocyte percentage of white cells;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg23302884	chr18:44338147	ST8SIA5	0.45	8.89	0.38	1.4e-17	Personality dimensions;
LGG	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg26384229	chr12:38710491	ALG10B	0.67	12.12	0.49	1.45e-29	Resting heart rate;
LGG	cis	rs17767392	0.681	rs4899390	chr14:71680348	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.98	-0.31	1.01e-11	Mitral valve prolapse;
LGG	cis	rs8133932	0.701	rs7280054	chr21:47301246	T/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.31	-0.32	1.18e-12	Schizophrenia;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.48	-0.33	3.88e-13	Tonsillectomy;
LGG	cis	rs929596	0.597	rs10173355	chr2:234597321	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.69	-0.44	5.38e-24	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07280387	chr12:120763487	PLA2G1B	0.4	6.81	0.3	3.09e-11	Bipolar disorder;
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07308232	chr7:1071921	C7orf50	-0.59	-10.76	-0.45	3.04e-24	Longevity;Endometriosis;
LGG	cis	rs116095464	1.000	rs3936676	chr5:353677	T/C	cg22857025	chr5:266934	NA	-1.22	-10.79	-0.45	2.26e-24	Breast cancer;
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.47	-0.37	3.19e-16	Prostate cancer;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.01	0.31	8.43e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	7.29	0.32	1.35e-12	Obesity-related traits;
LGG	cis	rs939658	0.805	rs35484723	chr15:79441032	A/G	cg17916960	chr15:79447300	NA	-0.66	-12.8	-0.51	2.6e-32	Refractive error;
LGG	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg02002194	chr4:3960332	NA	-0.37	-6.78	-0.3	3.72e-11	Retinal vascular caliber;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.53	0.84	5.72e-126	Prudent dietary pattern;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.77	-0.34	5.28e-14	Neuroticism;
LGG	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg06917634	chr15:78832804	PSMA4	-0.64	-9.76	-0.41	1.39e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg21605333	chr4:119757512	SEC24D	1.45	14.6	0.56	5.32e-40	Cannabis dependence symptom count;
LGG	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg01191920	chr7:158217561	PTPRN2	-0.84	-20.5	-0.69	6.32e-67	Obesity-related traits;
LGG	cis	rs7294478	0.710	rs7139082	chr12:7256639	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.33	-8.45	-0.37	3.91e-16	Neuritic plaque;
LGG	cis	rs9393692	0.620	rs6930616	chr6:26331969	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.15	-0.39	1.85e-18	Educational attainment;
LGG	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.86	-0.3	2.22e-11	Total body bone mineral density;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.76	-0.41	1.35e-20	Lung cancer;
LGG	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg25457927	chr22:38595422	NA	-0.36	-8.34	-0.36	8.29e-16	Breast cancer;
LGG	cis	rs4566357	0.615	rs3769643	chr2:227917270	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.06	-0.39	3.56e-18	Coronary artery disease;
LGG	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg11317459	chr13:21872234	NA	-1.18	-19.42	-0.67	6.9e-62	White matter hyperintensity burden;
LGG	cis	rs7336332	0.598	rs74563672	chr13:28010660	A/G	cg01674679	chr13:27998804	GTF3A	-0.63	-8.13	-0.35	3.93e-15	Weight;
LGG	cis	rs1009647	0.633	rs11626485	chr14:55826764	A/G	cg04306507	chr14:55594613	LGALS3	0.46	7.67	0.34	1.02e-13	Testicular germ cell tumor;
LGG	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg04450456	chr4:17643702	FAM184B	0.34	7.59	0.33	1.8e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs208520	0.690	rs1563929	chr6:66702108	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.25	0.63	7.66e-52	Exhaled nitric oxide output;
LGG	cis	rs7216064	0.906	rs78452260	chr17:65848522	G/T	cg12091567	chr17:66097778	LOC651250	-0.64	-9.38	-0.4	2.9e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs12410462	0.551	rs12092295	chr1:227836291	C/T	cg04117972	chr1:227635322	NA	0.43	7.97	0.35	1.28e-14	Major depressive disorder;
LGG	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg20608306	chr11:116969690	SIK3	0.42	13.45	0.53	5.05e-35	Blood protein levels;
LGG	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.09e-47	Breast cancer;
LGG	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.17	0.39	1.52e-18	Lung cancer in ever smokers;
LGG	cis	rs981844	0.775	rs1020704	chr4:154736494	C/T	cg14289246	chr4:154710475	SFRP2	0.66	11.0	0.46	3.6e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs7662987	0.517	rs2602866	chr4:100034997	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.71	-0.45	4.58e-24	Alzheimer's disease;
LGG	cis	rs6964587	0.626	rs35849169	chr7:91507313	A/G	cg17063962	chr7:91808500	NA	0.42	7.6	0.33	1.66e-13	Breast cancer;
LGG	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg00376283	chr12:123451042	ABCB9	0.66	12.35	0.5	1.82e-30	Platelet count;
LGG	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg23649088	chr2:200775458	C2orf69	0.54	7.85	0.34	2.88e-14	Schizophrenia;
LGG	cis	rs5756813	0.754	rs11089854	chr22:38148882	G/A	cg24232236	chr22:38142998	TRIOBP	0.35	6.93	0.31	1.46e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7215564	0.908	rs7501497	chr17:78660738	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.77	0.3	3.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg02886208	chr11:14281011	SPON1	-0.42	-8.51	-0.37	2.5e-16	Mitochondrial DNA levels;
LGG	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg12253571	chr8:8283032	NA	-0.31	-6.71	-0.3	5.66e-11	Mood instability;
LGG	cis	rs12476592	0.602	rs7570031	chr2:63792265	A/G	cg17519650	chr2:63277830	OTX1	-0.46	-7.09	-0.31	5.17e-12	Childhood ear infection;
LGG	cis	rs2274273	0.624	rs67795323	chr14:55797833	G/A	cg04306507	chr14:55594613	LGALS3	0.53	12.56	0.5	2.43e-31	Protein biomarker;
LGG	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.76	-0.41	1.41e-20	Retinal vascular caliber;
LGG	cis	rs994014	0.534	rs11732090	chr4:82287714	C/G	cg07938847	chr4:82126349	PRKG2	-0.28	-6.8	-0.3	3.17e-11	Height;
LGG	cis	rs300774	0.925	rs365967	chr2:123233	G/A	cg04617936	chr2:214353	NA	-0.49	-7.37	-0.32	7.97e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs3206736	0.548	rs6963995	chr7:35058349	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.29	0.32	1.34e-12	Diastolic blood pressure;
LGG	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg02297831	chr4:17616191	MED28	0.47	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1788820	0.957	rs1652342	chr18:21099583	C/T	cg14672496	chr18:21087552	C18orf8	0.39	7.32	0.32	1.11e-12	Body mass index;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04020211	chr5:179763432	GFPT2	0.37	7.17	0.32	3.03e-12	Menarche (age at onset);
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg14137381	chr5:502291	SLC9A3	-0.33	-6.85	-0.3	2.36e-11	Cystic fibrosis severity;
LGG	cis	rs923375	0.604	rs35156626	chr17:3357244	T/C	cg16505927	chr17:3375209	SPATA22	0.5	7.35	0.32	9.28e-13	Myopia (pathological);
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.67	-0.37	7.18e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs208515	0.525	rs10944863	chr6:66676238	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	17.09	0.62	4.15e-51	Exhaled nitric oxide levels;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-9.84	-0.42	7.28e-21	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg12463550	chr7:65579703	CRCP	0.74	8.05	0.35	6.98e-15	Diabetic kidney disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02202141	chr3:35681158	NA	0.46	7.56	0.33	2.18e-13	Cognitive performance;
LGG	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.89	-0.42	4.7e-21	Mean corpuscular volume;
LGG	trans	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-8.46	-0.37	3.45e-16	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs758324	0.947	rs2133707	chr5:131181280	C/T	cg06307176	chr5:131281290	NA	0.57	9.43	0.4	1.95e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.91	-0.31	1.59e-11	Caffeine consumption;
LGG	cis	rs473651	0.935	rs540636	chr2:239358341	T/C	cg21699342	chr2:239360505	ASB1	0.39	7.46	0.33	4.19e-13	Multiple system atrophy;
LGG	cis	rs4330281	0.647	rs6780587	chr3:17709796	C/T	cg20981856	chr3:17787350	NA	-0.38	-7.09	-0.31	5.21e-12	Schizophrenia;
LGG	cis	rs60843830	1.000	rs62114544	chr2:269679	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.4	0.36	5.37e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg18252515	chr7:66147081	NA	1.43	20.57	0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-11.44	-0.47	7.11e-27	Alzheimer's disease;
LGG	cis	rs11169552	0.510	rs7956591	chr12:50948886	A/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.63e-14	Colorectal cancer;
LGG	cis	rs7568458	0.684	rs60012532	chr2:85752474	A/C	cg17127132	chr2:85788382	GGCX	0.49	7.88	0.34	2.44e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs62238980	0.614	rs117721418	chr22:32394519	C/T	cg00543991	chr22:32367038	NA	0.8	8.86	0.38	1.71e-17	Childhood ear infection;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	15.13	0.58	2.49e-42	Platelet count;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.46	-0.53	4.54e-35	Personality dimensions;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs7980799	0.905	rs4244865	chr12:33511917	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.35	-0.36	7.69e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.26	-0.43	2.24e-22	Colorectal cancer;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg19680485	chr15:31195859	MTMR15	-0.48	-7.77	-0.34	5.25e-14	Huntington's disease progression;
LGG	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.85	-0.34	2.91e-14	Joint mobility (Beighton score);
LGG	cis	rs4660214	0.666	rs596062	chr1:39826005	A/G	cg18385671	chr1:39797026	MACF1	0.47	9.9	0.42	4.43e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg09307838	chr4:120376055	NA	0.8	13.44	0.53	5.28e-35	Corneal astigmatism;
LGG	cis	rs9309473	0.687	rs11126399	chr2:73613341	G/A	cg20560298	chr2:73613845	ALMS1	-0.52	-9.4	-0.4	2.48e-19	Metabolite levels;
LGG	cis	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	trans	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg26043149	chr18:55253948	FECH	-0.5	-8.1	-0.35	5.05e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7737355	0.773	rs4706023	chr5:130882379	T/C	cg06307176	chr5:131281290	NA	0.51	8.58	0.37	1.46e-16	Life satisfaction;
LGG	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.82	8.71	0.38	5.54e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1997103	0.954	rs1917769	chr7:55392325	T/A	cg20935933	chr6:143382018	AIG1	0.58	9.07	0.39	3.38e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3099143	1.000	rs901008	chr15:77097018	C/A	cg21673338	chr15:77095150	SCAPER	-0.65	-10.39	-0.43	7.24e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs13102973	0.864	rs7435952	chr4:135900983	C/T	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.39	6.73	0.3	5.09e-11	Schizophrenia;
LGG	cis	rs7133214	0.771	rs11049127	chr12:27922074	T/C	cg04279139	chr12:27925367	LOC100133893	-0.33	-7.03	-0.31	7.42e-12	Gut microbiota (functional units);
LGG	trans	rs8129326	0.805	rs9984075	chr21:35784117	T/A	cg07474852	chr4:123073612	NA	0.42	7.3	0.32	1.28e-12	Cancer;
LGG	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg07061783	chr6:25882402	NA	-0.43	-7.43	-0.33	5.22e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.947	rs6596009	chr5:130608093	C/A	cg06307176	chr5:131281290	NA	0.49	7.34	0.32	9.97e-13	Life satisfaction;
LGG	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	6.06e-14	Testicular germ cell tumor;
LGG	cis	rs7241530	0.610	rs4799266	chr18:75895923	G/A	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg03264133	chr6:25882463	NA	-0.45	-7.2	-0.32	2.48e-12	Iron status biomarkers;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.82	0.84	6.15e-123	Prudent dietary pattern;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03576123	chr11:487126	PTDSS2	-1.21	-15.58	-0.59	2.5e-44	Body mass index;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.14	0.52	9.77e-34	Prudent dietary pattern;
LGG	cis	rs72781680	1.000	rs72781675	chr2:24232092	G/A	cg08917208	chr2:24149416	ATAD2B	0.88	9.36	0.4	3.41e-19	Lymphocyte counts;
LGG	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg00343986	chr7:65444356	GUSB	0.46	8.08	0.35	5.64e-15	Aortic root size;
LGG	cis	rs231513	1.000	rs231519	chr17:41961051	C/T	cg26893861	chr17:41843967	DUSP3	0.57	6.92	0.31	1.54e-11	Cognitive function;
LGG	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg06618935	chr21:46677482	NA	-0.49	-9.42	-0.4	2.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9399135	0.935	rs11754504	chr6:135321509	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg08392591	chr16:89556376	ANKRD11	0.43	6.68	0.3	6.77e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	13.92	0.54	4.6e-37	Neuroticism;
LGG	cis	rs4734806	1.000	rs34989786	chr8:105711201	T/G	cg01675814	chr8:105601641	LRP12	0.54	7.27	0.32	1.53e-12	Periodontitis (DPAL);
LGG	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.18	-0.43	4.27e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs774359	0.750	rs812858	chr9:27545467	C/T	cg14173147	chr9:27528300	MOBKL2B	0.46	8.05	0.35	6.81e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs36051895	0.632	rs10974984	chr9:5150427	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-14.47	-0.56	2e-39	Pediatric autoimmune diseases;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	7.73	0.34	6.72e-14	Schizophrenia;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg16141378	chr3:129829833	LOC729375	0.43	10.05	0.42	1.29e-21	Neuroticism;
LGG	cis	rs1318772	1.000	rs10519354	chr5:112689650	C/G	cg12552261	chr5:112820674	MCC	-0.69	-8.51	-0.37	2.39e-16	F-cell distribution;
LGG	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg11812906	chr14:75593930	NEK9	0.55	10.24	0.43	2.47e-22	Height;
LGG	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.13	0.39	2.1e-18	HDL cholesterol;
LGG	trans	rs1459104	1.000	rs34382934	chr11:55315256	C/T	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.82e-11	Body mass index;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg13628971	chr7:2884303	GNA12	0.49	9.65	0.41	3.27e-20	Height;
LGG	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	-0.73	-7.03	-0.31	7.5e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg11812906	chr14:75593930	NEK9	-0.54	-10.08	-0.42	9.68e-22	Height;
LGG	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.52	-8.62	-0.37	1.07e-16	Cognitive test performance;
LGG	cis	rs12049351	0.665	rs66521073	chr1:229570518	C/G	cg13547644	chr1:229569608	ACTA1	0.32	7.01	0.31	8.65e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08280861	chr8:58055591	NA	0.52	6.99	0.31	9.85e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs745080	0.519	rs7155960	chr14:52960422	G/T	cg23333723	chr14:53022898	GPR137C	0.39	8.11	0.35	4.53e-15	Orofacial clefts;
LGG	cis	rs9487094	1.000	rs9480933	chr6:109671391	C/G	cg16315928	chr6:109776240	MICAL1	0.46	7.73	0.34	6.84e-14	Height;
LGG	cis	rs2243480	1.000	rs2462569	chr7:65474846	C/T	cg12463550	chr7:65579703	CRCP	-0.73	-8.19	-0.36	2.49e-15	Diabetic kidney disease;
LGG	cis	rs36051895	0.659	rs3780367	chr9:5068755	T/G	cg02405213	chr9:5042618	JAK2	-0.84	-16.06	-0.6	1.89e-46	Pediatric autoimmune diseases;
LGG	cis	rs1023500	0.529	rs133375	chr22:42466509	C/G	cg15557168	chr22:42548783	NA	-0.4	-8.56	-0.37	1.69e-16	Schizophrenia;
LGG	cis	rs2766692	1.000	rs2766692	chr14:100684192	C/T	cg14866419	chr14:100704911	YY1	0.61	9.49	0.4	1.22e-19	Electroencephalographic traits in alcoholism;
LGG	trans	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.34e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg13010199	chr12:38710504	ALG10B	0.58	10.97	0.45	4.72e-25	Morning vs. evening chronotype;
LGG	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs8067287	0.802	rs11650590	chr17:16836300	C/T	cg26910001	chr17:16838321	NA	-0.49	-9.17	-0.39	1.57e-18	Diabetic kidney disease;
LGG	cis	rs10883723	0.810	rs7093028	chr10:104259417	A/G	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2204008	0.547	rs12318267	chr12:38250905	T/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.17	-0.49	9.6e-30	Bladder cancer;
LGG	cis	rs10186029	0.680	rs11689451	chr2:213937840	C/T	cg08319019	chr2:214017104	IKZF2	0.45	8.07	0.35	6.07e-15	Systemic sclerosis;
LGG	cis	rs7312933	0.703	rs11181378	chr12:42600658	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.22	0.32	2.18e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs858239	0.600	rs1468592	chr7:23140647	C/T	cg23682824	chr7:23144976	KLHL7	-0.45	-7.75	-0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05025164	chr4:1340916	KIAA1530	0.47	8.07	0.35	6.27e-15	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs55794497	chr4:119764664	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs2404602	0.735	rs12906143	chr15:76709523	T/A	cg15268244	chr15:77196840	NA	0.45	9.76	0.41	1.42e-20	Blood metabolite levels;
LGG	cis	rs1881509	0.660	rs7926201	chr11:1428780	A/G	cg07067744	chr11:1421172	BRSK2	0.35	6.93	0.31	1.39e-11	Heroin dependence;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg13880726	chr7:1868755	MAD1L1	0.39	6.91	0.31	1.62e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7924176	0.564	rs4564273	chr10:75989912	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.42	-7.03	-0.31	7.44e-12	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg04863758	chr4:1303710	MAEA	0.45	7.82	0.34	3.7e-14	Obesity-related traits;
LGG	cis	rs798554	0.523	rs1182197	chr7:2863289	A/C	cg04166393	chr7:2884313	GNA12	0.41	8.08	0.35	5.53e-15	Height;
LGG	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg19980929	chr12:42632907	YAF2	0.34	7.64	0.33	1.23e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs11764590	0.715	rs62444907	chr7:2083267	C/T	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.27	-0.4	6.83e-19	Neuroticism;
LGG	cis	rs7394190	0.748	rs4082339	chr10:75539812	C/T	cg07699608	chr10:75541558	CHCHD1	-0.56	-7.21	-0.32	2.3e-12	Incident atrial fibrillation;
LGG	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg02297831	chr4:17616191	MED28	0.5	9.53	0.4	9.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs61989804	0.702	rs8016230	chr14:65720556	G/A	cg15999311	chr14:65749247	NA	0.65	6.97	0.31	1.1e-11	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.4e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9398803	0.687	rs853986	chr6:127023336	C/G	cg19875578	chr6:126661172	C6orf173	-0.52	-9.66	-0.41	3.15e-20	Male-pattern baldness;
LGG	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	8.89	0.38	1.32e-17	Mood instability;
LGG	cis	rs6088590	0.965	rs6120727	chr20:33374102	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.37	0.58	2.16e-43	Coronary artery disease;
LGG	trans	rs2548003	0.565	rs2554899	chr5:28741116	C/T	cg12623145	chr2:97778927	ANKRD36	0.48	6.71	0.3	5.62e-11	Hip geometry;
LGG	cis	rs9611565	0.694	rs79008	chr22:41850500	C/T	cg06634786	chr22:41940651	POLR3H	-0.76	-12.39	-0.5	1.24e-30	Vitiligo;
LGG	cis	rs2735413	0.875	rs4888737	chr16:78083819	A/G	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4604732	0.588	rs4925551	chr1:247631724	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.22	0.39	1.05e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg08847335	chr10:891726	LARP4B	-0.5	-9.02	-0.39	5.05e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs17767392	1.000	rs35122644	chr14:71780768	C/T	cg02058870	chr14:72053146	SIPA1L1	0.47	9.52	0.4	9.68e-20	Mitral valve prolapse;
LGG	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg11584989	chr19:19387371	SF4	0.79	13.08	0.52	1.64e-33	Bipolar disorder;
LGG	cis	rs9810089	0.814	rs2688600	chr3:136252596	C/A	cg21827317	chr3:136751795	NA	0.47	8.36	0.36	7.5e-16	Gestational age at birth (child effect);
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.76	0.3	4.11e-11	Longevity;
LGG	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.72	0.3	5.48e-11	Homoarginine levels;
LGG	cis	rs209489	0.892	rs77429675	chr6:53147972	G/A	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg18350739	chr11:68623251	NA	-0.87	-21.9	-0.71	1.7e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.18e-12	Bladder cancer;
LGG	cis	rs17767392	0.813	rs8003478	chr14:72120363	C/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.17	0.36	2.91e-15	Mitral valve prolapse;
LGG	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg06623630	chr22:50017776	C22orf34	-0.49	-9.91	-0.42	4.04e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs929596	0.793	rs2741045	chr2:234580140	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-9.77	-0.41	1.32e-20	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs9296092	0.517	rs7743445	chr6:33470600	G/T	cg13560919	chr6:33536144	NA	-0.92	-16.58	-0.61	8.08e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12477438	0.798	rs6759354	chr2:99632195	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.21	-0.49	6.61e-30	Chronic sinus infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04041942	chr8:28747613	INTS9;HMBOX1	-0.51	-7.52	-0.33	2.92e-13	Systemic lupus erythematosus;
LGG	cis	rs67311347	1.000	rs9834052	chr3:40399060	G/A	cg13683864	chr3:40499215	RPL14	-0.99	-20.2	-0.68	1.63e-65	Renal cell carcinoma;
LGG	trans	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg08344181	chr3:125677491	NA	-0.81	-8.03	-0.35	8.13e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg20891558	chr2:74357851	NA	0.49	8.8	0.38	2.63e-17	Gestational age at birth (maternal effect);
LGG	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.5	-8.0	-0.35	9.96e-15	Mean platelet volume;
LGG	cis	rs67311347	0.577	rs11712626	chr3:40259927	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-14.89	-0.57	2.87e-41	Renal cell carcinoma;
LGG	cis	rs10463316	0.709	rs3857426	chr5:150789831	C/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.25	-0.43	2.37e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg27476859	chr7:2772710	GNA12	0.39	6.83	0.3	2.7e-11	Height;
LGG	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg03806693	chr22:41940476	POLR3H	-0.66	-10.95	-0.45	5.67e-25	Neuroticism;
LGG	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg10661904	chr17:79619235	PDE6G	-0.51	-10.35	-0.43	9.76e-23	Eye color traits;
LGG	trans	rs747782	0.639	rs61649224	chr11:48057640	G/A	cg15704280	chr7:45808275	SEPT13	0.71	7.28	0.32	1.42e-12	Intraocular pressure;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg08555160	chr16:69166339	CHTF8;CIRH1A	0.46	6.8	0.3	3.17e-11	Hip circumference;
LGG	cis	rs11605924	0.901	rs7105751	chr11:45856973	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.47	-7.83	-0.34	3.28e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg06618935	chr21:46677482	NA	-0.53	-9.36	-0.4	3.54e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg16359550	chr11:109292809	C11orf87	0.39	7.82	0.34	3.71e-14	Schizophrenia;
LGG	cis	rs9479482	0.678	rs3903885	chr6:150364128	G/A	cg03788504	chr6:150331562	NA	-0.42	-8.94	-0.38	9.24e-18	Alopecia areata;
LGG	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg25358565	chr5:93447407	FAM172A	-0.86	-11.72	-0.48	5.87e-28	Diabetic retinopathy;
LGG	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg03078520	chr22:18463400	MICAL3	-0.68	-14.67	-0.56	2.81e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05217755	chr19:42758976	ERF	0.45	6.65	0.3	8.09e-11	Gut microbiome composition (summer);
LGG	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg00990874	chr7:1149470	C7orf50	-0.65	-9.38	-0.4	3.03e-19	Bronchopulmonary dysplasia;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg19524238	chr7:2802976	GNA12	0.38	9.03	0.39	4.65e-18	Height;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg11062466	chr8:58055876	NA	0.47	8.13	0.35	3.82e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00427086	chr15:52861396	ARPP19	0.41	7.12	0.31	4.09e-12	Bilirubin levels;
LGG	cis	rs7077256	0.564	rs35322962	chr10:65211780	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2164273	0.523	rs1435279	chr8:11158387	C/A	cg02002194	chr4:3960332	NA	-0.4	-7.22	-0.32	2.17e-12	Extraversion;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg05896524	chr21:47604654	C21orf56	-0.63	-11.56	-0.47	2.4200000000000002e-27	Testicular germ cell tumor;
LGG	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg24229701	chr12:130821962	PIWIL1	0.45	7.83	0.34	3.39e-14	Menopause (age at onset);
LGG	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg14993813	chr1:46806288	NSUN4	-0.55	-9.16	-0.39	1.69e-18	Menopause (age at onset);
LGG	cis	rs2648832	0.613	rs2608029	chr8:129170126	C/G	cg27509867	chr8:129165585	NA	0.34	8.08	0.35	5.67e-15	Tonsillectomy;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7916697	0.520	rs12265247	chr10:70038398	A/G	cg04882175	chr6:131122610	NA	-0.46	-6.91	-0.31	1.62e-11	Optic disc area;
LGG	cis	rs1107366	0.722	rs2364368	chr3:125905080	A/T	cg11252792	chr3:125932053	NA	0.6	12.05	0.49	2.82e-29	Metabolite levels;
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg27411982	chr8:10470053	RP1L1	0.42	7.18	0.32	2.74e-12	Mood instability;
LGG	cis	rs34734847	0.703	rs7978125	chr12:121167039	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-7.19	-0.32	2.57e-12	Mean corpuscular volume;
LGG	cis	rs4704846	0.614	rs2862717	chr5:156499054	C/T	cg12943317	chr5:156479607	HAVCR1	-0.59	-8.08	-0.35	5.56e-15	Blood protein levels;
LGG	cis	rs41271473	1.000	rs41270189	chr1:228878888	C/T	cg16512390	chr1:228756714	NA	0.48	6.71	0.3	5.63e-11	Chronic lymphocytic leukemia;
LGG	cis	rs12493885	0.654	rs11925207	chr3:153699886	C/T	cg12800244	chr3:153838788	SGEF	-0.81	-8.64	-0.37	9.01e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6539288	0.563	rs11113122	chr12:107211325	T/C	cg15890332	chr12:107067104	RFX4	0.36	10.39	0.43	7.16e-23	Total body bone mineral density;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg10295955	chr4:187884368	NA	1.14	29.78	0.81	1.17e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06470251	chr20:60548479	NA	0.48	8.31	0.36	1.05e-15	Body mass index;
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg08888203	chr3:10149979	C3orf24	0.56	9.57	0.41	6.42e-20	Alzheimer's disease;
LGG	trans	rs6601327	0.603	rs10104807	chr8:9669775	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.43	0.33	5.23e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg13385521	chr17:29058706	SUZ12P	0.93	10.83	0.45	1.6e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7077256	0.564	rs17813795	chr10:65187911	A/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01376672	chr12:121790273	ANAPC5	0.54	8.13	0.35	4.06e-15	Gut microbiome composition (summer);
LGG	cis	rs28595532	1.000	rs115004746	chr4:119642137	C/T	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg22916017	chr11:64110731	CCDC88B	0.51	10.76	0.45	3.04e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs67311347	0.544	rs1454492	chr3:40352884	C/T	cg13683864	chr3:40499215	RPL14	-0.8	-15.57	-0.59	2.96e-44	Renal cell carcinoma;
LGG	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.72e-22	DNA methylation (variation);
LGG	cis	rs7147624	1.000	rs2411354	chr14:66062132	T/C	cg03016385	chr14:66212404	NA	-0.78	-9.64	-0.41	3.58e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2243480	1.000	rs2961102	chr7:65424658	A/G	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg21211680	chr2:198530	NA	-1.17	-19.67	-0.67	4.66e-63	Blood protein levels;
LGG	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg04000281	chr11:63949212	NA	-0.45	-8.66	-0.37	7.99e-17	Platelet count;
LGG	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.04	-0.31	6.84e-12	Schizophrenia;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	7.77	0.34	5.25e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg11161011	chr14:65562177	MAX	-0.71	-14.24	-0.55	1.95e-38	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07210839	chr7:150595735	NA	0.48	7.46	0.33	4.28e-13	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.08	0.31	5.25e-12	Longevity;
LGG	cis	rs4481887	1.000	rs4508046	chr1:248488988	T/C	cg01631408	chr1:248437212	OR2T33	-0.55	-9.84	-0.42	6.99e-21	Common traits (Other);
LGG	cis	rs6750047	0.585	rs168054	chr2:38260282	C/G	cg07380506	chr2:38303506	CYP1B1	-0.42	-6.98	-0.31	1.05e-11	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg16147221	chr4:10020634	SLC2A9	0.38	6.98	0.31	1.04e-11	Bone mineral density;
LGG	cis	rs9517320	1.000	rs7994160	chr13:99132749	C/A	cg07423050	chr13:99094983	FARP1	0.41	8.32	0.36	1.02e-15	Longevity;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg02018176	chr4:1364513	KIAA1530	0.33	6.98	0.31	1.03e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.87	-0.45	1.14e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	10.9	0.45	9.08e-25	Ulcerative colitis;
LGG	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg08847533	chr14:75593920	NEK9	0.54	9.77	0.41	1.22e-20	Height;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	15.56	0.59	3.27e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4474465	0.920	rs10899532	chr11:78208470	T/G	cg27205649	chr11:78285834	NARS2	0.5	8.49	0.37	2.87e-16	Alzheimer's disease (survival time);
LGG	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg17809284	chr5:56205270	C5orf35	-0.36	-6.91	-0.31	1.59e-11	Coronary artery disease;
LGG	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg22437258	chr11:111473054	SIK2	0.54	9.54	0.41	8.01e-20	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04677623	chr19:45349329	PVRL2	0.39	7.33	0.32	1.04e-12	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg18681998	chr4:17616180	MED28	0.85	18.14	0.64	6.1e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.23	-0.32	1.96e-12	Sudden cardiac arrest;
LGG	cis	rs2204008	0.641	rs66876045	chr12:38205713	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.34	0.53	1.45e-34	Bladder cancer;
LGG	cis	rs9303401	0.659	rs9303399	chr17:56672309	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.85	0.57	4.32e-41	Cognitive test performance;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.94	0.42	3.14e-21	Prudent dietary pattern;
LGG	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg09307838	chr4:120376055	NA	0.81	13.53	0.53	2.3e-35	Corneal astigmatism;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg20978937	chr14:105399321	PLD4	-0.5	-11.46	-0.47	6.16e-27	Rheumatoid arthritis;
LGG	cis	rs9462027	0.628	rs9469909	chr6:34813077	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.32	-0.47	2.13e-26	Systemic lupus erythematosus;
LGG	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg18351406	chr4:77819688	ANKRD56	0.45	7.77	0.34	5.23e-14	Emphysema distribution in smoking;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg00364696	chr7:1142433	C7orf50	-0.38	-7.38	-0.32	7.58e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg18225595	chr11:63971243	STIP1	0.57	7.47	0.33	4.15e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg20283391	chr11:68216788	NA	-0.48	-7.91	-0.35	1.89e-14	Total body bone mineral density;
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.12	-0.46	1.29e-25	Neuroticism;
LGG	cis	rs12286929	0.679	rs11601041	chr11:115083348	A/G	cg04055981	chr11:115044050	NA	0.36	6.79	0.3	3.35e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs314370	0.951	rs12705095	chr7:100484381	T/G	cg10426581	chr7:100472382	SRRT	0.51	7.02	0.31	7.95e-12	Resting heart rate;
LGG	cis	rs2404602	0.536	rs7163946	chr15:76766049	C/G	cg23625390	chr15:77176239	SCAPER	0.39	7.32	0.32	1.08e-12	Blood metabolite levels;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.63	0.37	1.01e-16	Schizophrenia;
LGG	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.837	rs11168504	chr12:37964922	G/T	cg26384229	chr12:38710491	ALG10B	0.97	21.96	0.71	9.23e-74	Bladder cancer;
LGG	cis	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg02972257	chr16:68554789	NA	-0.52	-7.82	-0.34	3.57e-14	Ulcerative colitis;
LGG	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg16262614	chr3:133464971	TF	0.48	8.87	0.38	1.56e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs3825932	0.961	rs2870085	chr15:79234268	T/C	cg25744700	chr15:79237217	CTSH	0.34	6.67	0.3	7.37e-11	Type 1 diabetes;
LGG	trans	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg16141378	chr3:129829833	LOC729375	0.38	8.52	0.37	2.23e-16	Neuroticism;
LGG	cis	rs362296	0.698	rs362266	chr4:3259632	C/G	cg06533319	chr4:3265114	C4orf44	0.5	9.63	0.41	3.98e-20	Parental longevity (mother's age at death);
LGG	cis	rs7173389	1.000	rs8039168	chr15:73664723	A/T	cg01796676	chr15:73680284	NA	0.51	8.63	0.37	1.02e-16	Resting heart rate;
LGG	cis	rs7326068	0.610	rs8000601	chr13:21339384	G/A	cg04906043	chr13:21280425	IL17D	-0.46	-7.4	-0.33	6.33e-13	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs244899	0.901	rs173435	chr5:167907217	A/G	cg06604206	chr5:167912465	RARS	-0.55	-11.9	-0.48	1.08e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.7	0.3	6.17e-11	Bone mineral density;
LGG	cis	rs7666738	0.830	rs9998682	chr4:98939009	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06481639	chr22:41940642	POLR3H	0.48	6.86	0.3	2.21e-11	Vitiligo;
LGG	cis	rs9581857	0.615	rs79793528	chr13:28007823	G/A	cg01674679	chr13:27998804	GTF3A	-0.68	-7.87	-0.34	2.56e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08800530	chr5:175788722	KIAA1191	0.51	8.58	0.37	1.48e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg22105103	chr4:187893119	NA	0.57	10.95	0.45	5.81e-25	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05522046	chr3:52931664	TMEM110	0.48	7.29	0.32	1.35e-12	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.4e-35	Personality dimensions;
LGG	cis	rs6032067	0.714	rs6104055	chr20:43822962	A/G	cg10761708	chr20:43804764	PI3	0.58	8.88	0.38	1.51e-17	Blood protein levels;
LGG	cis	rs6963495	0.818	rs75116202	chr7:105160059	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2282300	0.739	rs1222208	chr11:30361377	A/C	cg25418670	chr11:30344373	C11orf46	-0.56	-7.81	-0.34	3.79e-14	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg24375607	chr4:120327624	NA	0.6	10.12	0.43	6.84e-22	Corneal astigmatism;
LGG	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg07549998	chr6:150325970	RAET1K	-0.37	-6.96	-0.31	1.14e-11	Alopecia areata;
LGG	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg11764359	chr7:65958608	NA	-0.61	-9.01	-0.39	5.45e-18	Aortic root size;
LGG	cis	rs782590	0.902	rs782600	chr2:55848040	T/C	cg18811423	chr2:55921094	PNPT1	0.86	19.75	0.68	2.03e-63	Metabolic syndrome;
LGG	cis	rs9381040	0.610	rs2268191	chr6:41027653	G/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.71	-0.3	5.7e-11	Alzheimer's disease (late onset);
LGG	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.01e-12	Diabetic retinopathy;
LGG	cis	rs7580658	0.680	rs6710535	chr2:128190960	C/G	cg10021288	chr2:128175891	PROC	0.67	13.91	0.54	5.58e-37	Protein C levels;
LGG	cis	rs6860806	0.507	rs273912	chr5:131661349	A/C	cg07395648	chr5:131743802	NA	0.49	9.95	0.42	2.92e-21	Breast cancer;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg01879757	chr17:41196368	BRCA1	-0.47	-9.25	-0.39	8.53e-19	Menopause (age at onset);
LGG	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg13010199	chr12:38710504	ALG10B	0.56	11.12	0.46	1.24e-25	Heart rate;
LGG	cis	rs42648	0.905	rs42622	chr7:89956824	A/G	cg25739043	chr7:89950458	NA	-0.42	-8.88	-0.38	1.47e-17	Homocysteine levels;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.27	-0.36	1.38e-15	Life satisfaction;
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg13699009	chr12:122356056	WDR66	0.56	15.6	0.59	2.09e-44	Mean corpuscular volume;
LGG	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.95e-14	Hepatitis;
LGG	cis	rs2735413	0.875	rs8055298	chr16:78084868	C/G	cg04733911	chr16:78082701	NA	0.78	18.6	0.65	4.24e-58	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1691799	0.899	rs903587	chr12:66746061	C/A	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg19901468	chr14:105411992	AHNAK2	0.88	18.14	0.64	5.94e-56	Rheumatoid arthritis;
LGG	cis	rs6866344	0.697	rs6873150	chr5:178125704	G/A	cg03877680	chr5:178157825	ZNF354A	0.78	12.5	0.5	4.47e-31	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25397718	chr9:140317786	EXD3;NOXA1	0.56	8.42	0.36	4.89e-16	Gut microbiome composition (summer);
LGG	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg25664220	chr3:72788482	NA	0.34	9.74	0.41	1.61e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2976388	0.590	rs13254346	chr8:143823863	G/C	cg06565975	chr8:143823917	SLURP1	-0.53	-13.45	-0.53	4.75e-35	Urinary tract infection frequency;
LGG	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs1018836	0.632	rs7002775	chr8:91476765	C/T	cg16814680	chr8:91681699	NA	0.66	11.19	0.46	6.59e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1021993	0.545	rs1006316	chr1:209550461	T/C	cg24446417	chr1:209558027	NA	-0.74	-11.14	-0.46	1.1e-25	Gut microbiome composition (winter);
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.32	-0.53	1.62e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs514024	0.700	rs553083	chr9:130491483	C/T	cg13643465	chr9:130375613	STXBP1	0.58	10.97	0.45	4.67e-25	Eating disorders (purging via substances);
LGG	cis	rs12044355	0.516	rs2356383	chr1:231742973	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.68	-12.16	-0.49	1.06e-29	Alzheimer's disease;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg20503657	chr10:835505	NA	0.52	6.81	0.3	3.05e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs3806843	0.576	rs155363	chr5:140301543	A/G	cg19875535	chr5:140030758	IK	0.38	7.57	0.33	1.98e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10754283	0.967	rs7515375	chr1:90109854	T/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7572733	0.935	rs1401093	chr2:198779839	C/T	cg00792783	chr2:198669748	PLCL1	-0.49	-8.27	-0.36	1.39e-15	Dermatomyositis;
LGG	cis	rs2455799	0.573	rs2455830	chr3:15749213	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.79	-0.34	4.57e-14	Mean platelet volume;
LGG	cis	rs9875589	0.915	rs62234597	chr3:13963780	G/A	cg19554555	chr3:13937349	NA	0.72	13.93	0.54	4.27e-37	Ovarian reserve;
LGG	trans	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg23484912	chr5:273055	PDCD6	0.42	8.5	0.37	2.67e-16	Pancreatic cancer;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs6743226	0.603	rs60515663	chr2:242214258	G/A	cg10021735	chr2:242295487	FARP2	0.41	7.14	0.31	3.64e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg01206211	chr2:36825736	FEZ2	0.43	7.84	0.34	3.04e-14	Height;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg03352830	chr11:487213	PTDSS2	0.85	10.77	0.45	2.72e-24	Body mass index;
LGG	cis	rs2153535	0.580	rs2143355	chr6:8517856	T/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg18350739	chr11:68623251	NA	-0.83	-21.29	-0.7	1.31e-70	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10274279	0.660	rs4716760	chr7:157376644	A/G	cg09270525	chr7:157391030	PTPRN2	-0.79	-13.26	-0.52	3.16e-34	Myopia (pathological);
LGG	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg27661571	chr11:113659931	NA	-0.7	-9.56	-0.41	7.06e-20	Hip circumference adjusted for BMI;
LGG	cis	rs11166927	0.716	rs4736094	chr8:140802186	G/A	cg16909799	chr8:140841666	TRAPPC9	0.47	9.37	0.4	3.27e-19	Pediatric non-alcoholic fatty liver disease activity score;
LGG	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg27661571	chr11:113659931	NA	0.69	9.17	0.39	1.51e-18	Hip circumference adjusted for BMI;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	3.16e-16	Personality dimensions;
LGG	cis	rs7010267	0.570	rs7009768	chr8:120041303	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.5	0.37	2.62e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs2718058	0.515	rs1584611	chr7:37874039	T/C	cg15028436	chr7:37888078	TXNDC3	0.67	12.01	0.49	4.01e-29	Alzheimer's disease (late onset);
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg21775445	chr20:1373916	FKBP1A	0.42	6.65	0.3	8.08e-11	Mitral valve prolapse;
LGG	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg01152986	chr16:58549298	SETD6	0.84	7.31	0.32	1.15e-12	Schizophrenia;
LGG	trans	rs3780486	0.505	rs10217267	chr9:33146528	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	14.83	0.57	5.47e-41	IgG glycosylation;
LGG	cis	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg24110177	chr3:50126178	RBM5	0.4	6.82	0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6445975	0.667	rs3773004	chr3:58269451	A/G	cg24175188	chr3:58374923	PXK	0.4	7.57	0.33	1.98e-13	Systemic lupus erythematosus;
LGG	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg00745463	chr17:30367425	LRRC37B	-0.68	-9.76	-0.41	1.35e-20	Hip circumference adjusted for BMI;
LGG	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg05234568	chr11:5960015	NA	-0.65	-10.56	-0.44	1.67e-23	DNA methylation (variation);
LGG	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg15309053	chr8:964076	NA	0.34	6.86	0.3	2.19e-11	Schizophrenia;
LGG	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg17911788	chr17:44343683	NA	0.51	8.01	0.35	9.3e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg20503657	chr10:835505	NA	0.51	7.06	0.31	6.11e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs4843747	0.749	rs8053309	chr16:88044980	G/A	cg06374794	chr16:88002281	BANP	0.43	7.64	0.33	1.23e-13	Menopause (age at onset);
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.88	-0.42	5.04e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg25319279	chr11:5960081	NA	-0.44	-7.08	-0.31	5.27e-12	DNA methylation (variation);
LGG	trans	rs11976180	1.000	rs2961119	chr7:143755852	T/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.37	-6.8	-0.3	3.3e-11	Obesity-related traits;
LGG	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg08603382	chr10:743973	NA	0.38	7.01	0.31	8.5e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs7786877	0.626	rs11770389	chr7:100221218	T/G	cg16850897	chr7:100343110	ZAN	-0.59	-8.11	-0.35	4.61e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2154319	0.887	rs6600366	chr1:41559612	C/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.0	-0.39	5.91e-18	Height;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg23782820	chr8:58130467	NA	0.57	8.43	0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs58365910	1	rs58365910	chr15:78849034	T/C	cg18825076	chr15:78729989	IREB2	-0.48	-7.68	-0.34	9.51e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.94	0.49	7.59e-29	Lymphocyte counts;
LGG	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg24764310	chr7:157512201	PTPRN2	-0.46	-9.99	-0.42	2e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg20891283	chr12:69753455	YEATS4	0.49	7.55	0.33	2.34e-13	Response to diuretic therapy;
LGG	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.88e-13	Neuroticism;
LGG	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg11520003	chr13:113540631	ATP11A	-0.37	-7.73	-0.34	6.63e-14	Interstitial lung disease;
LGG	cis	rs7264396	0.623	rs6060504	chr20:34197619	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.14	0.31	3.61e-12	Total cholesterol levels;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg24250549	chr1:154909240	PMVK	-0.71	-14.05	-0.55	1.38e-37	Prostate cancer;
LGG	cis	rs7586879	1.000	rs1865687	chr2:25112885	G/A	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs7173743	0.756	rs8034804	chr15:79129600	C/T	cg00540400	chr15:79124168	NA	0.39	7.96	0.35	1.32e-14	Coronary artery disease;
LGG	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg26384229	chr12:38710491	ALG10B	0.72	14.25	0.55	1.91e-38	Bladder cancer;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.63	10.28	0.43	1.83e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7923837	0.616	rs12219514	chr10:94466439	A/G	cg27639046	chr2:171608303	NA	-0.37	-7.3	-0.32	1.29e-12	Body mass index;Multiple sclerosis;
LGG	trans	rs208520	0.690	rs207094	chr6:66799009	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs58688157	0.542	rs7926440	chr11:589819	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-7.39	-0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs7666738	0.753	rs10004827	chr4:99037953	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs654950	0.806	rs7550496	chr1:42043834	G/A	cg16096631	chr1:42092165	HIVEP3	0.41	8.83	0.38	2.09e-17	Airway imaging phenotypes;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg02733842	chr7:1102375	C7orf50	0.68	10.19	0.43	3.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.56	0.65	6.86e-58	Morning vs. evening chronotype;
LGG	cis	rs3020736	0.500	rs6002614	chr22:42501802	G/A	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg22168489	chr12:122356033	WDR66	0.44	10.31	0.43	1.36e-22	Mean corpuscular volume;
LGG	cis	rs11225247	0.772	rs12275349	chr11:102237720	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.61	0.33	1.55e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg12893428	chr3:195717962	SDHAP1	0.51	10.74	0.45	3.6e-24	Pancreatic cancer;
LGG	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.4	0.36	5.63e-16	Mood instability;
LGG	cis	rs6088580	0.634	rs1205344	chr20:32918298	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.26	-0.36	1.56e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs11574514	1.000	rs8049622	chr16:67800927	G/C	cg09738193	chr16:67926317	PSKH1	-0.71	-6.93	-0.31	1.38e-11	Crohn's disease;
LGG	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2916247	0.954	rs2165905	chr8:93006556	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.57	-0.37	1.58e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.94	0.35	1.59e-14	Response to antipsychotic treatment;
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	0.8	12.26	0.5	3.98e-30	Alzheimer's disease;
LGG	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4804815	0.697	rs73008237	chr19:7841188	T/C	cg00970558	chr19:7854469	CLEC4GP1	0.65	9.71	0.41	1.99e-20	Neutrophil count;
LGG	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs4746818	1.000	rs7091695	chr10:70964997	A/G	cg11621586	chr10:70884670	VPS26A	-1.09	-15.72	-0.59	5.99e-45	Left atrial antero-posterior diameter;
LGG	cis	rs6988985	0.728	rs6471570	chr8:143957405	A/C	cg10324643	chr8:143916377	GML	0.39	7.85	0.34	2.89e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs13260300	0.536	rs2588299	chr8:75531385	T/C	cg22993706	chr8:75542856	NA	0.41	7.93	0.35	1.67e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.21	-0.49	6.73e-30	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg13607699	chr17:42295918	UBTF	0.54	9.02	0.39	5.08e-18	Total body bone mineral density;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.4	-0.47	1.04e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg23029597	chr12:123009494	RSRC2	-0.51	-9.01	-0.39	5.29e-18	Body mass index;
LGG	cis	rs45544231	0.544	rs1123428	chr16:52577835	A/T	cg09051775	chr16:52580266	TOX3	0.43	7.34	0.32	9.47e-13	Restless legs syndrome;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	6.13e-37	Prudent dietary pattern;
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.26	-0.4	7.64e-19	Aortic root size;
LGG	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg11845111	chr2:191398756	TMEM194B	0.36	8.06	0.35	6.73e-15	Pulse pressure;
LGG	cis	rs1847202	0.859	rs4566476	chr3:72948995	G/C	cg25664220	chr3:72788482	NA	-0.26	-7.64	-0.33	1.28e-13	Motion sickness;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.21	20.25	0.69	9.06e-66	Platelet count;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09319946	chr13:25497353	CENPJ	-0.41	-6.86	-0.3	2.22e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4731207	0.596	rs10274384	chr7:124650437	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg02640540	chr1:67518911	SLC35D1	-0.41	-6.7	-0.3	6.07e-11	Lymphocyte percentage of white cells;
LGG	trans	rs11875185	0.510	rs80318643	chr18:55645347	G/A	cg15513957	chr14:69354734	ACTN1	-0.97	-9.53	-0.4	8.96e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg00800038	chr16:89945340	TCF25	-0.69	-8.03	-0.35	8.13e-15	Skin colour saturation;
LGG	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.39	-0.32	6.99e-13	HDL cholesterol;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg23131131	chr22:24373011	LOC391322	-0.46	-7.68	-0.34	9.38e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs701145	0.585	rs1713804	chr3:153799122	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs2735413	0.564	rs6564508	chr16:78116575	T/C	cg04733911	chr16:78082701	NA	0.56	7.86	0.34	2.81e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.61e-16	Life satisfaction;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg03188948	chr7:1209495	NA	0.46	8.62	0.37	1.11e-16	Longevity;Endometriosis;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.1	-0.6	1.28e-46	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27313501	chr16:2034198	GFER	0.51	7.65	0.33	1.14e-13	Gut microbiome composition (summer);
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.58	-0.41	6e-20	Lung cancer;
LGG	cis	rs1550582	0.662	rs7812708	chr8:135500832	C/T	cg17885191	chr8:135476712	NA	0.94	16.63	0.61	5.08e-49	Educational attainment;
LGG	cis	rs11711311	1.000	rs12637067	chr3:113527606	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.41	-0.33	6.16e-13	IgG glycosylation;
LGG	cis	rs2133450	0.745	rs7642946	chr3:7365494	A/G	cg19930620	chr3:7340148	GRM7	-0.38	-8.24	-0.36	1.8e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs4919044	0.733	rs12413378	chr10:94759305	A/G	cg05127821	chr10:94822908	CYP26C1	-0.43	-6.9	-0.31	1.66e-11	Coronary artery disease;
LGG	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg18850127	chr7:39170497	POU6F2	0.37	8.39	0.36	5.9e-16	Intelligence (multi-trait analysis);
LGG	cis	rs73416724	0.858	rs4466248	chr6:43279652	T/C	cg26312998	chr6:43337775	ZNF318	-0.54	-7.51	-0.33	2.98e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg11812906	chr14:75593930	NEK9	0.45	8.05	0.35	7.15e-15	Height;
LGG	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg25554036	chr4:6271136	WFS1	0.65	12.48	0.5	5.09e-31	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1843834	0.539	rs3912999	chr2:225390089	C/T	cg22455342	chr2:225449267	CUL3	0.85	14.73	0.56	1.52e-40	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2645694	0.626	rs2645704	chr4:77830805	T/C	cg10057126	chr4:77819792	ANKRD56	0.35	6.67	0.3	7.4e-11	Emphysema distribution in smoking;
LGG	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-10.24	-0.43	2.47e-22	Height;
LGG	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg04568710	chr12:38710424	ALG10B	0.37	7.91	0.35	1.87e-14	Morning vs. evening chronotype;
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg08373610	chr2:198540621	RFTN2	0.42	7.21	0.32	2.22e-12	Leprosy;
LGG	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs4919694	1.000	rs58317752	chr10:104799267	T/A	cg04362960	chr10:104952993	NT5C2	1.07	14.88	0.57	3.26e-41	Arsenic metabolism;
LGG	cis	rs9916302	0.904	rs6503503	chr17:37514373	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	2.93e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg11245990	chr11:68621969	NA	0.43	9.06	0.39	3.75e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs503734	0.666	rs13322987	chr3:101234358	A/G	cg27318481	chr3:100970896	IMPG2	0.36	7.2	0.32	2.44e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11039808	chr5:77591002	AP3B1	0.48	8.09	0.35	5.13e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2011503	0.943	rs756997	chr19:19467085	G/C	cg11584989	chr19:19387371	SF4	-0.76	-12.66	-0.51	9.36e-32	Bipolar disorder;
LGG	cis	rs593982	1.000	rs576663	chr11:65498942	G/T	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs709400	0.633	rs7160208	chr14:103965528	G/A	cg26031613	chr14:104095156	KLC1	0.77	13.53	0.53	2.18e-35	Body mass index;
LGG	cis	rs921968	0.643	rs523396	chr2:219338789	T/G	cg02985541	chr2:219472218	PLCD4	0.29	6.9	0.31	1.67e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07455504	chr16:1080144	NA	0.37	7.08	0.31	5.31e-12	Menarche (age at onset);
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.0	-0.82	4.98e-115	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg04568710	chr12:38710424	ALG10B	0.4	8.37	0.36	6.78e-16	Morning vs. evening chronotype;
LGG	trans	rs1032833	0.732	rs111540484	chr2:180051438	G/A	cg23654767	chr2:101192981	PDCL3	0.73	8.62	0.37	1.05e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg10523679	chr1:76189770	ACADM	-0.72	-11.06	-0.46	2.2e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35306767	0.668	rs12356612	chr10:1055055	C/T	cg25019033	chr10:957182	NA	-0.54	-10.06	-0.42	1.16e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs972578	0.765	rs7286299	chr22:43392856	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.44	-0.33	4.82e-13	Mean platelet volume;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg15971980	chr6:150254442	NA	0.44	8.32	0.36	9.83e-16	Lung cancer;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg16590910	chr6:42928470	GNMT	0.42	11.92	0.48	9.72e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg20913747	chr6:44695427	NA	-0.58	-8.84	-0.38	1.99e-17	Total body bone mineral density;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg08621203	chr6:150244597	RAET1G	0.4	6.81	0.3	2.99e-11	Lung cancer;
LGG	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg09085632	chr11:111637200	PPP2R1B	1.06	20.54	0.69	4.06e-67	Primary sclerosing cholangitis;
LGG	cis	rs4493873	0.869	rs1138489	chr8:92080575	G/A	cg16814680	chr8:91681699	NA	0.44	6.77	0.3	3.92e-11	Migraine - clinic-based;
LGG	cis	rs7215564	0.908	rs7501544	chr17:78660946	T/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	cis	rs10791097	0.694	rs4370948	chr11:130755700	A/C	cg12179176	chr11:130786555	SNX19	0.84	17.54	0.63	3.41e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg19168338	chr16:4465731	CORO7	-0.89	-16.67	-0.61	3.33e-49	Schizophrenia;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.3e-12	Lung cancer;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.54	-9.34	-0.4	4.13e-19	Longevity;Endometriosis;
LGG	cis	rs1595825	0.945	rs2139050	chr2:198852636	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.87	-0.3	2.1e-11	Ulcerative colitis;
LGG	cis	rs9517302	0.615	rs9517306	chr13:99097962	T/C	cg24044564	chr13:99115944	STK24	0.48	6.74	0.3	4.73e-11	Obesity-related traits;
LGG	cis	rs2204008	0.837	rs34381557	chr12:38181983	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg08280861	chr8:58055591	NA	0.5	6.75	0.3	4.44e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs34091558	1	rs34091558	chr1:201886769	TA/T	cg10061532	chr1:201886748	LMOD1	0.37	7.63	0.33	1.33e-13	Breast size;
LGG	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg16680214	chr1:154839983	KCNN3	0.37	7.11	0.31	4.49e-12	Prostate cancer;
LGG	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg17230874	chr3:125932073	NA	-0.82	-16.82	-0.62	6.73e-50	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs17428076	0.874	rs12619041	chr2:172600716	A/C	cg21435375	chr2:172878103	MAP1D	-0.37	-7.98	-0.35	1.15e-14	Myopia;
LGG	cis	rs9487051	0.837	rs1915834	chr6:109597624	C/A	cg21918786	chr6:109611834	NA	-0.42	-7.73	-0.34	6.96e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9487094	0.644	rs9320286	chr6:109724937	G/A	cg16315928	chr6:109776240	MICAL1	0.39	6.73	0.3	5.11e-11	Height;
LGG	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.86	-0.3	2.22e-11	Neuroticism;
LGG	cis	rs2070677	0.866	rs2492664	chr10:135387240	G/T	cg20169779	chr10:135381914	SYCE1	-1.03	-13.32	-0.53	1.65e-34	Gout;
LGG	cis	rs7582720	1.000	rs72928613	chr2:203839628	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.76	9.08	0.39	3.15e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs9467711	0.606	rs9358932	chr6:26362705	A/G	cg01620082	chr3:125678407	NA	0.64	7.06	0.31	6.31e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7635838	0.565	rs347594	chr3:11249528	C/T	cg00170343	chr3:11313890	ATG7	0.4	6.89	0.3	1.88e-11	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15072735	chr9:72375102	PTAR1	0.44	6.98	0.31	1.03e-11	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.506	rs6993610	chr8:10330994	C/G	cg02002194	chr4:3960332	NA	0.39	6.85	0.3	2.29e-11	Neuroticism;
LGG	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2932538	0.744	rs6537742	chr1:113085197	G/T	cg22162597	chr1:113214053	CAPZA1	0.56	9.79	0.41	1.07e-20	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1595825	0.945	rs1518369	chr2:198859183	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-7.04	-0.31	6.76e-12	Ulcerative colitis;
LGG	cis	rs637571	0.607	rs575479	chr11:65690300	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.46	7.39	0.32	6.82e-13	Eosinophil percentage of white cells;
LGG	cis	rs2880765	0.835	rs6497206	chr15:86029225	A/G	cg13263323	chr15:86062960	AKAP13	-0.36	-7.45	-0.33	4.64e-13	Coronary artery disease;
LGG	cis	rs250677	0.687	rs40523	chr5:148444186	A/T	cg18129178	chr5:148520854	ABLIM3	0.44	7.09	0.31	4.94e-12	Breast cancer;
LGG	cis	rs7011049	0.778	rs72648430	chr8:53872396	G/A	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.13	0.39	2.13e-18	Blood metabolite levels;
LGG	cis	rs11122272	0.525	rs2739517	chr1:231537914	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.54e-12	Hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.38	0.56	5.25e-39	Lung cancer;
LGG	cis	rs1519814	0.659	rs7817075	chr8:121032846	G/C	cg22335954	chr8:121166405	COL14A1	-0.48	-8.77	-0.38	3.52e-17	Breast cancer;
LGG	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg25237894	chr2:233734115	C2orf82	0.66	12.71	0.51	6.05e-32	Coronary artery disease;
LGG	cis	rs3780486	0.846	rs6476402	chr9:33148552	G/A	cg13443165	chr9:33130375	B4GALT1	-0.72	-13.82	-0.54	1.28e-36	IgG glycosylation;
LGG	cis	rs17227506	0.504	rs13282162	chr8:13416411	A/G	cg03566418	chr8:13424080	C8orf48	0.55	8.32	0.36	9.68e-16	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg25319279	chr11:5960081	NA	-0.48	-7.36	-0.32	8.34e-13	DNA methylation (variation);
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07308232	chr7:1071921	C7orf50	-0.53	-9.87	-0.42	5.71e-21	Longevity;Endometriosis;
LGG	cis	rs8017423	0.967	rs11628812	chr14:90713720	G/T	cg04374321	chr14:90722782	PSMC1	-0.86	-18.44	-0.65	2.45e-57	Mortality in heart failure;
LGG	cis	rs7192380	0.965	rs7187634	chr16:69663371	T/C	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.68	-0.34	9.47e-14	Sjögren's syndrome;
LGG	cis	rs477692	1.000	rs565974	chr10:131423274	C/T	cg05714579	chr10:131428358	MGMT	0.56	11.5	0.47	4.42e-27	Response to temozolomide;
LGG	cis	rs2880765	0.743	rs8028240	chr15:86013248	A/G	cg10818794	chr15:86012489	AKAP13	-0.37	-7.69	-0.34	9.01e-14	Coronary artery disease;
LGG	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.67	0.34	1.06e-13	Mood instability;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.1	0.31	4.79e-12	Longevity;
LGG	cis	rs853679	0.517	rs868987	chr6:28110148	A/G	cg18032046	chr6:28092343	ZSCAN16	0.57	7.63	0.33	1.32e-13	Depression;
LGG	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.53	-10.31	-0.43	1.46e-22	Aortic root size;
LGG	cis	rs2153535	0.580	rs1414351	chr6:8476634	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs7147624	1.000	rs8021889	chr14:66214811	A/G	cg03016385	chr14:66212404	NA	-0.76	-9.25	-0.39	8.22e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.95e-13	Uric acid levels;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.723	rs12138452	chr1:209886578	T/A	cg23920097	chr1:209922102	NA	-0.43	-6.89	-0.3	1.87e-11	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15286372	chr6:53659348	LRRC1	0.5	7.42	0.33	5.49e-13	Gut microbiome composition (summer);
LGG	cis	rs11190604	1.000	rs2495760	chr10:102318771	T/C	cg07080220	chr10:102295463	HIF1AN	0.73	11.89	0.48	1.24e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9658691	0.646	rs7909414	chr10:90754744	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.94	10.13	0.43	6.6e-22	Mosquito bite size;
LGG	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg27489772	chr12:121021490	NA	0.55	7.22	0.32	2.17e-12	Type 1 diabetes nephropathy;
LGG	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg09467607	chr2:36825704	FEZ2	0.52	9.71	0.41	2.07e-20	Height;
LGG	cis	rs17208368	0.628	rs8060118	chr16:55092141	A/G	cg11181171	chr16:55090946	NA	0.45	7.42	0.33	5.82e-13	Hypospadias;
LGG	cis	rs62025270	0.632	rs1807309	chr15:86211757	G/A	cg25843651	chr15:86329602	KLHL25	0.57	8.58	0.37	1.42e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg05313129	chr8:58192883	C8orf71	-0.81	-12.3	-0.5	2.74e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg23978390	chr7:1156363	C7orf50	0.47	8.09	0.35	5.23e-15	Longevity;Endometriosis;
LGG	cis	rs6540556	0.723	rs9430016	chr1:209916884	A/G	cg05527609	chr1:210001259	C1orf107	-0.49	-6.66	-0.3	7.73e-11	Red blood cell count;
LGG	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs701145	0.537	rs1713842	chr3:153786243	T/A	cg12800244	chr3:153838788	SGEF	-0.79	-8.84	-0.38	2.03e-17	Coronary artery disease;
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg15394860	chr11:2017084	H19	0.64	14.17	0.55	4.12e-38	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg02900749	chr2:68251473	NA	-1.07	-11.62	-0.48	1.51e-27	Pursuit maintenance gain;
LGG	cis	rs943466	0.911	rs73746509	chr6:33729825	C/T	cg07519485	chr6:33762594	MLN	0.56	11.04	0.46	2.64e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.17	0.39	1.52e-18	Lung cancer in ever smokers;
LGG	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg14664628	chr15:75095509	CSK	-0.89	-18.1	-0.64	9.26e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs798554	0.660	rs2644275	chr7:2854010	G/A	cg05793240	chr7:2802953	GNA12	0.33	7.97	0.35	1.28e-14	Height;
LGG	cis	rs7072216	0.763	rs10732782	chr10:100166506	C/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs11190604	1.000	rs2495747	chr10:102328247	C/T	cg07570687	chr10:102243282	WNT8B	0.43	7.1	0.31	4.7e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.62	0.51	1.34e-31	Alzheimer's disease;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg24101359	chr6:42928495	GNMT	-0.52	-14.43	-0.56	2.92e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg02002194	chr4:3960332	NA	0.42	7.8	0.34	4.24e-14	Triglycerides;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg04025307	chr7:1156635	C7orf50	0.72	15.03	0.57	7.12e-42	Longevity;Endometriosis;
LGG	cis	rs3767633	0.858	rs6698065	chr1:161891528	G/A	cg09175582	chr1:161736000	ATF6	0.74	9.2	0.39	1.18e-18	IgG glycosylation;
LGG	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg01420254	chr6:26195488	NA	0.91	12.29	0.5	3.19e-30	Gout;Renal underexcretion gout;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg14490972	chr6:43484812	POLR1C;YIPF3	-0.46	-7.24	-0.32	1.94e-12	Coronary artery disease;
LGG	cis	rs6558530	0.666	rs28376731	chr8:1696252	C/A	cg25947184	chr8:1697459	NA	0.46	8.04	0.35	7.44e-15	Systolic blood pressure;
LGG	trans	rs7939886	0.920	rs7117192	chr11:56078402	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.1e-13	Myopia (pathological);
LGG	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg15704280	chr7:45808275	SEPT13	-0.97	-19.56	-0.67	1.56e-62	Height;
LGG	cis	rs459571	0.920	rs433402	chr9:136898627	A/G	cg13789015	chr9:136890014	NCRNA00094	0.58	10.87	0.45	1.14e-24	Platelet distribution width;
LGG	cis	rs9790314	0.589	rs9790132	chr3:160627289	A/T	cg04691961	chr3:161091175	C3orf57	0.42	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.92	0.35	1.82e-14	Platelet count;
LGG	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg27129171	chr3:47204927	SETD2	-0.82	-14.92	-0.57	2.3e-41	Colorectal cancer;
LGG	cis	rs7927771	0.826	rs7925389	chr11:47466790	A/T	cg20307385	chr11:47447363	PSMC3	-0.57	-10.37	-0.43	8.71e-23	Subjective well-being;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.01	15.3	0.58	4.63e-43	Smoking behavior;
LGG	cis	rs1719271	0.908	rs1684049	chr15:65196776	C/A	cg11671771	chr15:65133392	PLEKHO2	-0.51	-6.95	-0.31	1.29e-11	Platelet count;
LGG	cis	rs2594989	0.806	rs2606746	chr3:11375120	A/G	cg01796438	chr3:11312864	ATG7	-0.42	-6.66	-0.3	7.68e-11	Circulating chemerin levels;
LGG	cis	rs72945132	0.882	rs72949081	chr11:70219070	A/G	cg14191688	chr11:70257035	CTTN	0.6	8.49	0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs4561483	0.545	rs9927446	chr16:11957164	A/T	cg08843971	chr16:11963173	GSPT1	0.57	13.83	0.54	1.15e-36	Testicular germ cell tumor;
LGG	cis	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg21775007	chr8:11205619	TDH	-0.56	-8.75	-0.38	4.05e-17	Retinal vascular caliber;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg27471124	chr11:109292789	C11orf87	0.5	9.82	0.42	8.11e-21	Schizophrenia;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.42	-0.33	5.83e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg21782813	chr7:2030301	MAD1L1	-0.48	-11.1	-0.46	1.46e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg06916706	chr16:4465613	CORO7	-0.91	-14.72	-0.56	1.62e-40	Schizophrenia;
LGG	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg14227996	chr4:17616232	MED28	0.68	8.03	0.35	8.42e-15	Opioid sensitivity;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg27022615	chr11:70049105	FADD	0.43	7.23	0.32	1.98e-12	Menarche (age at onset);
LGG	cis	rs13082711	0.522	rs479302	chr3:27363033	A/G	cg02860705	chr3:27208620	NA	0.59	11.21	0.46	5.94e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg00405596	chr8:11794950	NA	0.44	7.45	0.33	4.58e-13	Mood instability;
LGG	cis	rs6772849	0.930	rs13434160	chr3:128374770	T/C	cg08795948	chr3:128337044	NA	0.66	11.36	0.47	1.57e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg19773385	chr1:10388646	KIF1B	-0.51	-10.61	-0.44	1.07e-23	Hepatocellular carcinoma;
LGG	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg11642891	chr2:3452563	TTC15	-0.46	-9.02	-0.39	5.05e-18	Obesity-related traits;
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg14675211	chr2:100938903	LONRF2	0.69	12.48	0.5	5.33e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.643	rs4264589	chr2:3481098	G/T	cg15541040	chr2:3486749	NA	-0.45	-8.28	-0.36	1.33e-15	Neurofibrillary tangles;
LGG	trans	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.79	-15.0	-0.57	9.31e-42	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2617583	0.967	rs2550948	chr5:1450444	C/T	cg07151155	chr5:1473589	LPCAT1	-0.37	-7.45	-0.33	4.67e-13	Breast cancer;
LGG	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg02811702	chr13:24901961	NA	0.41	7.84	0.34	3.12e-14	Obesity-related traits;
LGG	cis	rs60180747	0.909	rs76095247	chr15:66593468	A/C	cg07575407	chr15:66541975	MEGF11	0.41	7.93	0.35	1.65e-14	Testicular germ cell tumor;
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs4430311	0.723	rs10158245	chr1:243833397	A/C	cg25706552	chr1:244017396	NA	-0.64	-15.1	-0.57	3.61e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs2736345	0.516	rs7844858	chr8:11392659	T/A	cg06636001	chr8:8085503	FLJ10661	0.39	6.71	0.3	5.63e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs6840360	0.593	rs4696106	chr4:152606818	A/G	cg22705602	chr4:152727874	NA	-0.37	-8.88	-0.38	1.5e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.896	rs1976704	chr17:76401318	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.96	0.6	5.21e-46	HDL cholesterol levels;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.08e-13	Lung cancer;
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg07005078	chr4:17578674	LAP3	0.38	7.04	0.31	6.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.27e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg01420254	chr6:26195488	NA	0.91	12.28	0.5	3.29e-30	Gout;Renal underexcretion gout;
LGG	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg20488157	chr14:104394430	TDRD9	-0.56	-8.95	-0.38	8.44e-18	Bipolar disorder;
LGG	cis	rs4237845	0.804	rs10877034	chr12:58286444	T/C	cg02175503	chr12:58329896	NA	0.68	12.82	0.51	2.02e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg06212747	chr3:49208901	KLHDC8B	0.55	8.61	0.37	1.15e-16	Menarche (age at onset);
LGG	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg23950597	chr19:37808831	NA	0.58	8.29	0.36	1.2e-15	Coronary artery calcification;
LGG	cis	rs4253772	0.638	rs6007845	chr22:46718417	A/T	cg24881330	chr22:46731750	TRMU	-0.8	-9.81	-0.41	8.99e-21	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.51	-0.5	3.96e-31	Lymphocyte counts;
LGG	cis	rs5742933	0.857	rs1233291	chr2:190690951	G/C	cg04003228	chr2:190539410	ANKAR	0.46	6.75	0.3	4.52e-11	Ferritin levels;
LGG	cis	rs6867032	0.687	rs4998338	chr5:2015910	A/G	cg26168224	chr5:2018326	NA	1.29	31.13	0.82	1.3e-115	Gut microbiome composition (winter);
LGG	cis	rs10089	0.953	rs10463839	chr5:127519675	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	10.84	0.45	1.45e-24	Ileal carcinoids;
LGG	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg19847130	chr8:10466454	RP1L1	-0.31	-6.77	-0.3	3.93e-11	Mood instability;
LGG	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.68	-0.41	2.66e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs3096299	0.692	rs4785565	chr16:89515759	T/C	cg08392591	chr16:89556376	ANKRD11	0.54	8.66	0.37	8.08e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg08297393	chr2:100937505	LONRF2	-0.42	-7.32	-0.32	1.1e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11644362	1.000	rs72782620	chr16:12987416	T/A	cg06890432	chr16:12997467	SHISA9	-0.32	-7.0	-0.31	9.3e-12	Positive affect;Subjective well-being;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs9462027	0.606	rs7756009	chr6:34715395	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg15611164	chr12:129277819	SLC15A4	0.31	6.79	0.3	3.36e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	10.45	0.44	4.4e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.46	-0.4	1.54e-19	Common traits (Other);
LGG	cis	rs6541297	1.000	rs4846839	chr1:230284924	A/G	cg20703242	chr1:230279135	GALNT2	0.36	7.48	0.33	3.7e-13	Coronary artery disease;
LGG	cis	rs11711311	1.000	rs10212375	chr3:113471336	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.49	0.53	3.15e-35	IgG glycosylation;
LGG	cis	rs6089584	0.566	rs6061401	chr20:60607482	G/A	cg06470251	chr20:60548479	NA	0.4	7.04	0.31	7.14e-12	Body mass index;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00290607	chr11:67383545	NA	0.66	12.88	0.51	1.19e-32	Mean corpuscular volume;
LGG	trans	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg06521331	chr12:34319734	NA	0.43	7.67	0.34	9.99e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg19847130	chr8:10466454	RP1L1	-0.3	-6.66	-0.3	7.83e-11	Mood instability;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	trans	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg17712092	chr4:129076599	LARP1B	0.48	6.76	0.3	4.27e-11	Inflammatory bowel disease;
LGG	cis	rs11626933	1.000	rs45463097	chr14:90744188	G/A	cg14092571	chr14:90743983	NA	-0.81	-16.56	-0.61	1.06e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs896854	0.654	rs896846	chr8:95972453	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.77e-17	Type 2 diabetes;
LGG	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs60843830	1.000	rs56167434	chr2:282137	G/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	14.14	0.55	5.66e-38	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3020736	0.500	rs9620026	chr22:42498578	C/T	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.64	0.63	1.26e-53	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13694772	chr3:9773336	BRPF1	0.42	7.25	0.32	1.76e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg14926445	chr8:58193284	C8orf71	-0.45	-7.14	-0.31	3.62e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg15971980	chr6:150254442	NA	0.44	7.63	0.33	1.37e-13	Lung cancer;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25172604	chr17:41446521	NA	0.3	6.96	0.31	1.21e-11	Menopause (age at onset);
LGG	cis	rs477895	1.000	rs7939107	chr11:64034773	C/T	cg04317338	chr11:64019027	PLCB3	0.59	6.66	0.3	7.8e-11	Mean platelet volume;
LGG	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg16751781	chr15:78858589	CHRNA5	-0.45	-8.89	-0.38	1.41e-17	Sudden cardiac arrest;
LGG	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.32	-0.36	9.63e-16	Glycated hemoglobin levels;
LGG	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg25427524	chr10:38739819	LOC399744	-0.51	-7.43	-0.33	5.4e-13	Obesity (extreme);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10035607	chr16:30366449	CD2BP2	0.42	6.96	0.31	1.18e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg04851639	chr8:1020857	NA	-0.43	-9.46	-0.4	1.51e-19	Schizophrenia;
LGG	cis	rs28595532	0.920	rs115317002	chr4:119722809	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.16	0.43	4.84e-22	Cannabis dependence symptom count;
LGG	cis	rs988958	1.000	rs988959	chr2:42287389	C/T	cg27428208	chr2:42229179	NA	0.38	6.78	0.3	3.57e-11	Hypospadias;
LGG	cis	rs7712401	0.601	rs246274	chr5:122280803	A/C	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs9914544	0.652	rs7207570	chr17:18723995	C/T	cg26306683	chr17:18585705	ZNF286B	0.41	7.65	0.33	1.18e-13	Educational attainment (years of education);
LGG	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg06634786	chr22:41940651	POLR3H	0.67	10.9	0.45	9.03e-25	Vitiligo;
LGG	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.42	0.36	4.79e-16	Gout;
LGG	cis	rs9487094	0.885	rs3799839	chr6:109702193	T/C	cg16315928	chr6:109776240	MICAL1	0.53	9.19	0.39	1.36e-18	Height;
LGG	cis	rs9902453	0.584	rs3809790	chr17:27955540	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-12.37	-0.5	1.47e-30	Coffee consumption (cups per day);
LGG	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.46	0.56	2.2e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.78	-0.34	4.62e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg08603382	chr10:743973	NA	0.45	7.97	0.35	1.22e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22168489	chr12:122356033	WDR66	0.44	10.31	0.43	1.36e-22	Mean corpuscular volume;
LGG	cis	rs7106204	0.534	rs79801698	chr11:24346448	T/C	ch.11.24196551F	chr11:24239977	NA	0.85	8.95	0.38	8.51e-18	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg24247370	chr13:99142703	STK24	-0.4	-7.2	-0.32	2.47e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9300255	0.698	rs4759416	chr12:123746357	C/G	cg05973401	chr12:123451056	ABCB9	0.51	7.69	0.34	8.8e-14	Neutrophil percentage of white cells;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.35	-0.32	8.92e-13	Menopause (age at onset);
LGG	cis	rs1577917	1.000	rs12203924	chr6:86776412	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.06	-0.52	2.18e-33	Response to antipsychotic treatment;
LGG	cis	rs10892173	0.566	rs111578166	chr11:117666714	G/T	cg04064380	chr11:117688259	NA	-0.52	-7.48	-0.33	3.78e-13	Myopia;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.09	-0.31	4.9e-12	Personality dimensions;
LGG	cis	rs4889911	1.000	rs4889792	chr17:77839845	G/A	cg07923794	chr17:77834237	NA	0.63	7.91	0.34	1.94e-14	Electroencephalogram traits;
LGG	cis	rs35146811	0.586	rs6964754	chr7:99589404	G/A	cg22906224	chr7:99728672	NA	0.53	8.48	0.37	2.94e-16	Coronary artery disease;
LGG	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs3820068	0.608	rs58140482	chr1:16043979	A/G	cg05660106	chr1:15850417	CASP9	0.76	13.98	0.54	2.79e-37	Systolic blood pressure;
LGG	cis	rs17221829	0.703	rs1962258	chr11:89380687	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	trans	rs11976180	1.000	rs2961120	chr7:143756585	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.76e-11	Educational attainment;
LGG	cis	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg12395012	chr8:11607386	GATA4	0.41	7.39	0.32	6.93e-13	Monocyte count;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.46	0.4	1.52e-19	Longevity;
LGG	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.82	0.42	8.35e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.76	-0.78	5.01e-96	Schizophrenia;
LGG	cis	rs10751667	0.666	rs7950967	chr11:955638	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.67e-15	Alzheimer's disease (late onset);
LGG	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.97	0.31	1.07e-11	Hair morphology;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg02158880	chr13:53174818	NA	0.37	7.0	0.31	9.25e-12	Lewy body disease;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg04450456	chr4:17643702	FAM184B	0.33	7.34	0.32	9.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00495681	chr13:53174319	NA	0.74	15.27	0.58	6.51e-43	Lewy body disease;
LGG	cis	rs35110281	0.511	rs2298562	chr21:45085236	A/G	cg04455712	chr21:45112962	RRP1B	0.56	10.59	0.44	1.32e-23	Mean corpuscular volume;
LGG	cis	rs6977660	0.505	rs9639338	chr7:19869778	T/A	cg07541023	chr7:19748670	TWISTNB	0.5	6.69	0.3	6.51e-11	Thyroid stimulating hormone;
LGG	cis	rs2072732	0.861	rs12036378	chr1:2955158	G/A	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg03162506	chr22:38580953	NA	0.4	9.78	0.41	1.14e-20	Breast cancer;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg11301795	chr4:187892539	NA	-0.94	-25.09	-0.76	2.29e-88	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.39	-0.43	6.91e-23	Depression;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07677032	chr17:61819896	STRADA	-0.56	-9.83	-0.42	7.64e-21	Prudent dietary pattern;
LGG	trans	rs2048656	0.540	rs55868514	chr8:9680400	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.96	0.35	1.36e-14	Schizophrenia;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg11764359	chr7:65958608	NA	-0.74	-13.34	-0.53	1.41e-34	Aortic root size;
LGG	cis	rs17428076	0.836	rs57775770	chr2:172687731	T/C	cg21435375	chr2:172878103	MAP1D	0.4	8.65	0.37	8.23e-17	Myopia;
LGG	cis	rs362272	0.505	rs3129310	chr4:3301388	T/G	cg06533319	chr4:3265114	C4orf44	-0.35	-7.15	-0.32	3.3e-12	Serum sulfate level;
LGG	cis	rs4684776	1.000	rs11712187	chr3:11448866	G/A	cg24705426	chr3:11550659	ATG7	-0.42	-7.64	-0.33	1.27e-13	Small vessel stroke;
LGG	cis	rs12200782	0.510	rs9467731	chr6:26379358	C/T	cg27193005	chr6:26382695	BTN2A2	-0.49	-7.01	-0.31	8.51e-12	Small cell lung carcinoma;
LGG	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs34734847	0.842	rs696337	chr12:121159380	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-7.45	-0.33	4.55e-13	Mean corpuscular volume;
LGG	cis	rs10463316	0.862	rs13354553	chr5:150758128	G/A	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.67	-0.44	6.56e-24	Metabolite levels (Pyroglutamine);
LGG	trans	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg02030672	chr11:45687055	CHST1	0.53	9.72	0.41	1.94e-20	Obesity-related traits;
LGG	cis	rs2154319	0.887	rs7531344	chr1:41507431	C/G	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.56	-0.37	1.65e-16	Height;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25161386	chr17:27621177	NUFIP2	0.42	7.48	0.33	3.79e-13	Bilirubin levels;
LGG	cis	rs4891159	0.790	rs8087557	chr18:74116848	G/C	cg24786174	chr18:74118243	ZNF516	-0.58	-13.49	-0.53	3.13e-35	Longevity;
LGG	cis	rs4950322	0.580	rs72706428	chr1:146581801	G/A	cg22381352	chr1:146742008	CHD1L	-0.43	-7.29	-0.32	1.32e-12	Protein quantitative trait loci;
LGG	cis	rs7572733	0.967	rs976179	chr2:198880378	A/T	cg00792783	chr2:198669748	PLCL1	-0.47	-7.84	-0.34	3.24e-14	Dermatomyositis;
LGG	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg00334542	chr7:100209784	MOSPD3	-0.61	-8.53	-0.37	2.14e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg20368463	chr18:77673604	PQLC1	-0.55	-7.96	-0.35	1.35e-14	Opioid sensitivity;
LGG	cis	rs757278	0.513	rs214163	chr7:117293552	A/C	cg10524701	chr7:117356490	CTTNBP2	0.43	7.48	0.33	3.79e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs8044868	0.530	rs7201866	chr16:72086534	A/T	cg23815491	chr16:72088622	HP	0.37	7.84	0.34	3.11e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs3849046	0.817	rs34629616	chr5:137868606	T/C	cg10920316	chr5:137946599	NA	0.43	6.78	0.3	3.73e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4911259	0.513	rs4287835	chr20:31457337	T/C	cg13636640	chr20:31349939	DNMT3B	-0.64	-11.69	-0.48	7.9e-28	Inflammatory bowel disease;
LGG	cis	rs2905347	0.737	rs2010437	chr7:22631180	C/G	cg23521230	chr7:22704884	NA	-0.41	-7.49	-0.33	3.43e-13	Major depression and alcohol dependence;
LGG	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg16606324	chr3:10149918	C3orf24	0.6	6.91	0.31	1.61e-11	Alzheimer's disease;
LGG	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs774359	0.789	rs2814709	chr9:27513298	G/A	cg14173147	chr9:27528300	MOBKL2B	0.45	8.59	0.37	1.31e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	trans	rs9354308	0.809	rs9345693	chr6:66550984	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.06	-0.35	6.46e-15	Metabolite levels;
LGG	cis	rs4538187	0.712	rs11684093	chr2:63901261	T/C	cg19915305	chr2:64069682	UGP2	-0.5	-8.97	-0.38	7.54e-18	Systolic blood pressure;
LGG	cis	rs2120019	1.000	rs2083731	chr15:75368538	A/C	cg09165964	chr15:75287851	SCAMP5	-0.97	-19.1	-0.66	2.04e-60	Blood trace element (Zn levels);
LGG	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg16329650	chr2:213403929	ERBB4	0.47	8.26	0.36	1.56e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg06719900	chr11:109292894	C11orf87	0.44	8.11	0.35	4.7e-15	Schizophrenia;
LGG	cis	rs7124681	0.584	rs12226590	chr11:47571808	T/C	cg20307385	chr11:47447363	PSMC3	0.56	11.04	0.46	2.62e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg25214090	chr10:38739885	LOC399744	0.71	12.56	0.5	2.38e-31	Corneal astigmatism;
LGG	cis	rs2072499	0.966	rs2842865	chr1:156159532	G/A	cg24450063	chr1:156163899	SLC25A44	1.25	32.46	0.83	2.22e-121	Testicular germ cell tumor;
LGG	cis	rs9325144	0.723	rs11169519	chr12:39177441	G/A	cg04568710	chr12:38710424	ALG10B	-0.33	-6.76	-0.3	4.14e-11	Morning vs. evening chronotype;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg06398735	chr10:21822968	MLLT10	0.5	6.72	0.3	5.5e-11	QT interval;
LGG	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg25358565	chr5:93447407	FAM172A	-0.84	-11.6	-0.47	1.78e-27	Diabetic retinopathy;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.48e-17	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.07	-0.49	2.32e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg14004847	chr7:1930337	MAD1L1	0.52	9.55	0.41	7.27e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs4936894	0.500	rs4564350	chr11:124108910	T/C	cg27160556	chr11:124181099	OR8D1	-0.45	-10.43	-0.44	5.17e-23	Aging (time to death);
LGG	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg17376030	chr22:41985996	PMM1	-0.55	-8.89	-0.38	1.32e-17	Vitiligo;
LGG	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.7	0.48	7.13e-28	Resting heart rate;
LGG	cis	rs2467099	0.504	rs2608881	chr17:73936653	C/G	cg23806715	chr17:73775811	H3F3B	0.45	6.93	0.31	1.39e-11	Systolic blood pressure;
LGG	cis	rs7172689	1.000	rs67940821	chr15:81538750	G/A	cg11808699	chr15:81528661	IL16	-0.51	-10.19	-0.43	3.74e-22	Inattentive symptoms;
LGG	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-9.13	-0.39	2.14e-18	Vitiligo;
LGG	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3806843	1.000	rs10053586	chr5:140210760	T/C	cg19875535	chr5:140030758	IK	0.48	9.88	0.42	5.07e-21	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg23920097	chr1:209922102	NA	-0.5	-8.97	-0.38	7.17e-18	Red blood cell count;
LGG	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.54	-0.47	2.85e-27	Neuroticism;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg12463550	chr7:65579703	CRCP	0.75	7.89	0.34	2.17e-14	Diabetic kidney disease;
LGG	cis	rs4460629	0.742	rs7365544	chr1:155068748	C/A	cg13808842	chr1:155066096	NA	-0.29	-6.9	-0.31	1.68e-11	Serum magnesium levels;
LGG	cis	rs2668423	1.000	rs2526140	chr19:1374450	G/C	cg02639931	chr19:1387894	NDUFS7	-0.84	-14.43	-0.56	2.94e-39	Nonalcoholic fatty liver disease;
LGG	trans	rs9467711	0.538	rs9467626	chr6:25873746	C/A	cg01620082	chr3:125678407	NA	-0.68	-6.68	-0.3	6.96e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.623	rs34756112	chr17:29113016	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17453880	0.890	rs12522261	chr5:152054825	G/A	cg10931792	chr5:152022470	NA	0.4	8.61	0.37	1.17e-16	Subjective well-being;
LGG	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg18854424	chr1:2615690	NA	0.34	7.07	0.31	5.86e-12	Multiple sclerosis;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg11878867	chr6:150167359	LRP11	-0.49	-10.03	-0.42	1.48e-21	Lung cancer;
LGG	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg09222892	chr1:25734099	RHCE	0.45	9.31	0.4	5.11e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11890956	chr21:40555474	PSMG1	-1.16	-27.53	-0.79	1.57e-99	Cognitive function;
LGG	trans	rs629535	0.814	rs56301437	chr8:70108518	C/T	cg21567404	chr3:27674614	NA	-0.4	-6.78	-0.3	3.73e-11	Dupuytren's disease;
LGG	cis	rs11748327	0.919	rs10512704	chr5:4048803	T/C	cg01025095	chr5:4101132	NA	-0.55	-9.05	-0.39	4.11e-18	Myocardial infarction;
LGG	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg15704280	chr7:45808275	SEPT13	0.77	8.88	0.38	1.49e-17	Axial length;
LGG	cis	rs6424115	0.790	rs72874118	chr1:24177800	A/G	cg15997130	chr1:24165203	NA	-0.48	-12.92	-0.51	8.03e-33	Immature fraction of reticulocytes;
LGG	cis	rs3008870	0.816	rs1118392	chr1:67366549	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.82	-17.15	-0.62	2.24e-51	Lymphocyte percentage of white cells;
LGG	cis	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.15	-0.46	9.72e-26	Morning vs. evening chronotype;
LGG	trans	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg07817883	chr1:32538562	TMEM39B	1.22	11.5	0.47	4.1e-27	Granulocyte percentage of myeloid white cells;
LGG	trans	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg02800362	chr5:177631904	HNRNPAB	0.77	13.56	0.53	1.64e-35	Obesity-related traits;
LGG	cis	rs12200782	1.000	rs12207181	chr6:26431285	C/T	cg11502198	chr6:26597334	ABT1	-0.83	-6.81	-0.3	3.07e-11	Small cell lung carcinoma;
LGG	cis	rs13191362	1.000	rs13195226	chr6:163006421	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs877282	0.945	rs71491303	chr10:772884	G/T	cg17470449	chr10:769945	NA	0.65	8.35	0.36	8.26e-16	Uric acid levels;
LGG	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.74	-0.34	6.49e-14	Mood instability;
LGG	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.23	-0.43	2.85e-22	Body mass index;
LGG	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg24503407	chr1:205819492	PM20D1	-0.82	-20.08	-0.68	5.9e-65	Menarche (age at onset);
LGG	cis	rs4631830	0.863	rs57263518	chr10:51519154	A/G	cg10326726	chr10:51549505	MSMB	-0.68	-14.21	-0.55	2.82e-38	Prostate-specific antigen levels;
LGG	cis	rs7246760	0.867	rs66880218	chr19:9774155	A/G	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	trans	rs11875185	0.588	rs75475611	chr18:55639129	A/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4423214	0.840	rs1792315	chr11:71165547	C/T	cg10847948	chr11:71163743	NADSYN1	0.63	11.15	0.46	9.4e-26	Vitamin D levels;
LGG	trans	rs11088226	0.645	rs2409457	chr21:33929895	T/C	cg09050820	chr6:167586206	TCP10L2	0.88	12.71	0.51	5.73e-32	Gastritis;
LGG	cis	rs9914544	0.628	rs9908821	chr17:18679404	A/G	cg26306683	chr17:18585705	ZNF286B	0.39	7.53	0.33	2.63e-13	Educational attainment (years of education);
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs11885103	0.791	rs2683985	chr2:593690	A/G	cg21195176	chr2:593345	NA	0.41	7.79	0.34	4.59e-14	Heschl's gyrus morphology;
LGG	cis	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg21775007	chr8:11205619	TDH	-0.46	-6.98	-0.31	1.01e-11	Neuroticism;
LGG	cis	rs4730250	0.554	rs112665932	chr7:106916121	A/G	cg02696742	chr7:106810147	HBP1	-0.69	-8.83	-0.38	2.24e-17	Osteoarthritis;
LGG	cis	rs17221829	0.673	rs11018676	chr11:89362728	T/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	cis	rs7937612	0.543	rs538661	chr11:120309851	C/T	cg24566217	chr11:120254723	ARHGEF12	0.37	8.57	0.37	1.59e-16	Intraocular pressure;
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.12	-0.43	7.16e-22	Total body bone mineral density;
LGG	cis	rs757278	0.591	rs4727855	chr7:117305374	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.4	-7.08	-0.31	5.54e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11890956	chr21:40555474	PSMG1	-0.74	-12.87	-0.51	1.25e-32	Menarche (age at onset);
LGG	cis	rs4727027	0.800	rs10952796	chr7:148813138	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.93	0.31	1.45e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg27661571	chr11:113659931	NA	-0.64	-9.14	-0.39	2.04e-18	Hip circumference adjusted for BMI;
LGG	cis	rs28785552	0.800	rs10853854	chr19:53232128	A/G	cg10871876	chr19:53194124	ZNF83	-0.75	-15.75	-0.59	4.56e-45	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs12971120	0.891	rs2278159	chr18:72178161	T/C	cg26446133	chr18:72167187	CNDP2	-0.67	-13.37	-0.53	1.08e-34	Refractive error;
LGG	trans	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.47	1.91e-27	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9815354	0.680	rs73073274	chr3:42022810	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs2055729	1.000	rs2055729	chr8:9792662	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.92	0.31	1.51e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2373794	0.646	rs9309052	chr2:40349369	T/C	cg17740179	chr2:40377776	SLC8A1	0.86	17.5	0.63	5.07e-53	Asthma;
LGG	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg02811702	chr13:24901961	NA	0.39	7.37	0.32	7.96e-13	Obesity-related traits;
LGG	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg19468946	chr17:37922297	IKZF3	-0.43	-7.7	-0.34	8.46e-14	Self-reported allergy;
LGG	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	1.000	rs10824151	chr10:76092179	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.72	9.15	0.39	1.89e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs17767392	0.781	rs8015644	chr14:71842729	C/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.11	0.35	4.42e-15	Mitral valve prolapse;
LGG	cis	rs137603	0.966	rs470079	chr22:39708333	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.45	-7.58	-0.33	1.92e-13	Primary biliary cholangitis;
LGG	cis	rs858239	0.601	rs987257	chr7:23147840	G/A	cg23682824	chr7:23144976	KLHL7	0.42	7.14	0.31	3.7e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs977987	0.806	rs2865530	chr16:75414376	G/T	cg03315344	chr16:75512273	CHST6	0.5	10.15	0.43	5.44e-22	Dupuytren's disease;
LGG	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.37	-0.43	8.47e-23	Depression;
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg19774624	chr17:42201019	HDAC5	-0.93	-19.92	-0.68	3.07e-64	Total body bone mineral density;
LGG	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7551222	0.752	rs4252718	chr1:204512195	A/T	cg20240347	chr1:204465584	NA	0.55	11.38	0.47	1.2e-26	Schizophrenia;
LGG	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2742417	1.000	rs2673058	chr3:45735618	A/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.48	-0.33	3.64e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs12282928	0.592	rs7119161	chr11:48343565	C/T	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	trans	rs75804782	0.641	rs56396448	chr2:239335234	C/T	cg01134436	chr17:81009848	B3GNTL1	0.86	8.99	0.39	6.26e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2153535	0.580	rs7453115	chr6:8447261	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.59	-0.37	1.35e-16	Prostate cancer;
LGG	cis	rs10193935	0.901	rs13426988	chr2:42604081	G/A	cg27598129	chr2:42591480	NA	-0.7	-9.9	-0.42	4.39e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25072359	chr17:41440525	NA	0.52	9.97	0.42	2.54e-21	Menopause (age at onset);
LGG	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg03162506	chr22:38580953	NA	0.36	9.38	0.4	2.97e-19	Cutaneous nevi;
LGG	cis	rs2270450	0.650	rs9367255	chr6:46714466	C/T	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.51e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs9595066	0.627	rs9562536	chr13:44731588	G/A	cg04068111	chr13:44716778	NA	-0.5	-7.44	-0.33	5.05e-13	Schizophrenia;
LGG	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg16482183	chr6:26056742	HIST1H1C	0.56	9.22	0.39	1.08e-18	Iron status biomarkers;
LGG	cis	rs2070488	1.000	rs13089394	chr3:38446309	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.38	0.63	1.83e-52	Electrocardiographic conduction measures;
LGG	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg13798912	chr7:905769	UNC84A	-0.6	-6.81	-0.3	3.04e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg05692746	chr2:100937584	LONRF2	-0.64	-11.99	-0.49	4.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg01879757	chr17:41196368	BRCA1	-0.45	-8.88	-0.38	1.48e-17	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg02002194	chr4:3960332	NA	-0.44	-8.08	-0.35	5.68e-15	Retinal vascular caliber;
LGG	cis	rs6032067	0.636	rs6032094	chr20:43912637	G/A	cg10761708	chr20:43804764	PI3	0.57	8.85	0.38	1.8e-17	Blood protein levels;
LGG	cis	rs4639966	0.836	rs73001486	chr11:118629364	G/A	cg20309703	chr11:118481025	PHLDB1	-0.5	-7.49	-0.33	3.5e-13	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06422693	chr4:48833587	OCIAD1	0.44	7.4	0.33	6.61e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs17221829	0.703	rs11018682	chr11:89364451	A/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.08	-0.39	3.08e-18	Anxiety in major depressive disorder;
LGG	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.54	-0.41	8.28e-20	Blood metabolite levels;
LGG	cis	rs6754311	0.593	rs1438305	chr2:136502792	C/G	cg07169764	chr2:136633963	MCM6	-0.78	-13.66	-0.54	6.03e-36	Mosquito bite size;
LGG	cis	rs504918	0.556	rs73188162	chr3:123967920	A/G	cg05766129	chr3:123988013	KALRN	-0.59	-10.46	-0.44	3.89e-23	Schizophrenia;
LGG	trans	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.86	-0.38	1.67e-17	Bladder cancer;
LGG	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg09060608	chr5:178986726	RUFY1	0.48	7.74	0.34	6.5e-14	Lung cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26266703	chr8:144699630	TSTA3	0.49	7.34	0.32	9.48e-13	Hip circumference;
LGG	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.67	-8.08	-0.35	5.66e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg26513180	chr16:89883248	FANCA	0.85	9.13	0.39	2.18e-18	Skin colour saturation;
LGG	cis	rs629922	0.671	rs513039	chr11:114037158	G/A	cg25009965	chr11:114031120	ZBTB16	0.49	6.77	0.3	3.96e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg14088196	chr11:70211408	PPFIA1	0.95	13.22	0.52	4.62e-34	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs6997458	0.742	rs1908075	chr8:86346796	G/T	cg02393479	chr8:86352350	CA3	-0.31	-6.78	-0.3	3.6e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg00701064	chr4:6280414	WFS1	0.76	17.28	0.63	5.6e-52	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.7	-0.37	5.66e-17	Bone mineral density;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs4950322	0.570	rs72692975	chr1:146805238	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.61	-10.42	-0.44	5.39e-23	Obesity-related traits;
LGG	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg10587741	chr22:38071170	LGALS1	-0.33	-6.71	-0.3	5.6e-11	Glioblastoma;Glioma;
LGG	cis	rs3862435	0.572	rs2601186	chr15:90926921	A/G	cg22089800	chr15:90895588	ZNF774	0.55	6.73	0.3	5.18e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg04025307	chr7:1156635	C7orf50	0.64	8.36	0.36	7.53e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs9911578	0.967	rs8182277	chr17:57144367	C/T	cg12560992	chr17:57184187	TRIM37	0.93	16.59	0.61	7.27e-49	Intelligence (multi-trait analysis);
LGG	cis	rs9487051	0.768	rs442405	chr6:109526980	T/G	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.47e-11	Reticulocyte fraction of red cells;
LGG	cis	rs4474465	0.790	rs4492845	chr11:78260161	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.81	-0.3	3.07e-11	Alzheimer's disease (survival time);
LGG	cis	rs79839061	0.732	rs35177456	chr4:828994	C/T	cg07828340	chr4:882639	GAK	0.82	7.62	0.33	1.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs963731	0.579	rs297145	chr2:39321241	T/C	cg04010122	chr2:39346883	SOS1	-0.78	-7.97	-0.35	1.26e-14	Corticobasal degeneration;
LGG	trans	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg16141378	chr3:129829833	LOC729375	0.33	7.48	0.33	3.8e-13	Joint mobility (Beighton score);
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg11598736	chr3:195384522	SDHAP2	0.79	10.69	0.45	5.25e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs12447804	0.645	rs11076220	chr16:58113155	G/A	cg03859792	chr16:58121049	NA	0.63	9.92	0.42	3.55e-21	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2692947	0.770	rs2315417	chr2:96500289	T/C	cg22654517	chr2:96458247	NA	0.36	7.45	0.33	4.69e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6001027	0.517	rs2284060	chr22:38543453	A/G	cg25457927	chr22:38595422	NA	-0.29	-6.8	-0.3	3.23e-11	Melanoma;
LGG	cis	rs9611519	0.894	rs4821990	chr22:41438710	A/C	cg03806693	chr22:41940476	POLR3H	-0.54	-8.27	-0.36	1.41e-15	Neuroticism;
LGG	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11764359	chr7:65958608	NA	0.54	9.0	0.39	6.09e-18	Aortic root size;
LGG	cis	rs498079	0.544	rs509904	chr6:133517082	A/T	cg14343214	chr6:133562056	EYA4	-0.29	-7.12	-0.31	4.01e-12	Total body bone mineral density;
LGG	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg06917634	chr15:78832804	PSMA4	0.54	8.76	0.38	3.66e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9914988	0.887	rs8078402	chr17:27145124	T/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg07061783	chr6:25882402	NA	-0.42	-7.38	-0.32	7.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg19223190	chr17:80058835	NA	0.46	8.93	0.38	9.99e-18	Life satisfaction;
LGG	cis	rs4936894	0.500	rs10893168	chr11:124079739	A/C	cg27160556	chr11:124181099	OR8D1	-0.42	-9.82	-0.42	8.76e-21	Aging (time to death);
LGG	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg27411982	chr8:10470053	RP1L1	-0.39	-6.65	-0.3	8.34e-11	Mood instability;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19473369	chr15:99190447	NA	-0.4	-6.75	-0.3	4.45e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg25660036	chr4:7070649	GRPEL1	-0.49	-7.14	-0.31	3.65e-12	Monocyte percentage of white cells;
LGG	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.03e-11	Aortic root size;
LGG	cis	rs897984	0.571	rs7184567	chr16:31021078	C/T	cg00531865	chr16:30841666	NA	-0.52	-10.68	-0.44	5.76e-24	Dementia with Lewy bodies;
LGG	cis	rs9948	0.655	rs17119564	chr2:97384728	G/A	cg01990225	chr2:97406019	LMAN2L	-0.76	-7.51	-0.33	3.04e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.82	0.3	2.78e-11	Vitiligo;
LGG	cis	rs10050311	0.698	rs4693780	chr4:87641219	A/G	cg11209507	chr4:87813803	C4orf36	-0.54	-7.32	-0.32	1.11e-12	Insulin-related traits;
LGG	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg16070123	chr10:51489643	NA	0.41	7.49	0.33	3.42e-13	Prostate-specific antigen levels;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg14004847	chr7:1930337	MAD1L1	0.58	10.44	0.44	4.5e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg00290607	chr11:67383545	NA	0.52	9.33	0.4	4.24e-19	Mean corpuscular volume;
LGG	cis	rs11229555	0.645	rs12800531	chr11:58180099	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3812831	0.654	rs6560933	chr13:114937294	A/G	cg22348356	chr13:114891224	RASA3	-0.44	-8.84	-0.38	2.04e-17	Schizophrenia;
LGG	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.49	8.93	0.38	1.03e-17	Rheumatoid arthritis;
LGG	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg06766960	chr11:133703094	NA	-0.55	-10.88	-0.45	1.03e-24	Childhood ear infection;
LGG	cis	rs10214930	0.697	rs12535844	chr7:27689824	G/T	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	trans	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg25482853	chr8:67687455	SGK3	0.95	12.17	0.49	9.15e-30	Obesity-related traits;
LGG	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg14227996	chr4:17616232	MED28	0.69	8.39	0.36	5.89e-16	Opioid sensitivity;
LGG	cis	rs28595532	0.920	rs115472708	chr4:119773407	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs13403149	0.588	rs823240	chr2:2846442	T/C	cg02105481	chr2:2853515	NA	-0.32	-7.05	-0.31	6.63e-12	Smoking initiation;
LGG	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-7.69	-0.34	9.17e-14	Total body bone mineral density;
LGG	cis	rs789859	1.000	rs789859	chr3:194405888	G/T	cg02072170	chr3:194406190	FAM43A	0.36	6.83	0.3	2.68e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg14049380	chr3:52805078	NEK4	-0.38	-6.68	-0.3	7.09e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg27129171	chr3:47204927	SETD2	-0.72	-12.52	-0.5	3.55e-31	Birth weight;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg16507663	chr6:150244633	RAET1G	0.45	8.39	0.36	6.03e-16	Lung cancer;
LGG	cis	rs1506636	0.962	rs12666044	chr7:123320580	T/A	cg03229431	chr7:123269106	ASB15	-0.73	-17.94	-0.64	4.89e-55	Plateletcrit;Platelet count;
LGG	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg05163923	chr11:71159392	DHCR7	-0.69	-13.65	-0.54	6.7e-36	Vitamin D levels;
LGG	cis	rs3087591	0.881	rs2905804	chr17:29519995	T/C	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs881375	0.967	rs10435844	chr9:123668199	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg12193833	chr17:30244370	NA	-0.28	-7.08	-0.31	5.38e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2290159	0.752	rs73130368	chr3:12667374	C/T	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs787274	1.000	rs2796027	chr9:115529404	A/T	cg13803584	chr9:115635662	SNX30	-0.57	-7.24	-0.32	1.94e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10276381	1.000	rs10260837	chr7:28181129	C/T	cg23620719	chr7:28220237	JAZF1	0.81	10.4	0.44	6.83e-23	Crohn's disease;
LGG	cis	rs3733585	0.699	rs1079128	chr4:9951221	T/C	cg25986240	chr4:9926439	SLC2A9	0.39	8.05	0.35	6.81e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg20991723	chr1:152506922	NA	-0.71	-14.48	-0.56	1.9e-39	Hair morphology;
LGG	cis	rs10274279	1.000	rs55941863	chr7:157372989	C/G	cg09270525	chr7:157391030	PTPRN2	0.73	9.5	0.4	1.1e-19	Myopia (pathological);
LGG	cis	rs1348850	0.651	rs1901824	chr2:178225466	T/C	cg27490568	chr2:178487706	NA	0.37	7.53	0.33	2.64e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7181230	0.848	rs1010879	chr15:40333915	G/A	cg22705835	chr10:65332833	REEP3	-0.61	-10.01	-0.42	1.78e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs12220238	1.000	rs10824113	chr10:75969018	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg16576083	chr14:105354267	KIAA0284	0.59	10.1	0.42	8.4e-22	IgG glycosylation;
LGG	cis	rs8067545	0.532	rs4925074	chr17:19962554	C/T	cg13482628	chr17:19912719	NA	0.53	8.8	0.38	2.78e-17	Schizophrenia;
LGG	cis	rs1595825	1.000	rs1440091	chr2:198879457	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-7.29	-0.32	1.31e-12	Ulcerative colitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17663101	chr3:49131524	QRICH1	0.52	8.43	0.36	4.26e-16	Cognitive performance;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg20607798	chr8:58055168	NA	0.64	7.53	0.33	2.76e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg02461776	chr11:598696	PHRF1	0.53	8.24	0.36	1.83e-15	Systemic lupus erythematosus;
LGG	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.43	-0.44	5.16e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9837602	0.507	rs793448	chr3:99532949	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.49	-0.37	2.89e-16	Breast cancer;
LGG	cis	rs988958	0.565	rs11894536	chr2:42238134	T/A	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs709400	0.633	rs10141433	chr14:103962559	A/G	cg26031613	chr14:104095156	KLC1	0.79	13.99	0.55	2.47e-37	Body mass index;
LGG	cis	rs2708377	0.858	rs68045377	chr12:11294452	T/C	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.63	-6.86	-0.3	2.28e-11	Bitter taste perception;
LGG	cis	rs8133932	0.701	rs2330327	chr21:47305177	A/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.22	-0.32	2.1e-12	Schizophrenia;
LGG	cis	rs13191362	0.935	rs34540135	chr6:162934351	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.72	0.3	5.31e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg12193833	chr17:30244370	NA	-0.29	-6.77	-0.3	3.89e-11	Hip circumference adjusted for BMI;
LGG	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg20913747	chr6:44695427	NA	-0.67	-11.96	-0.49	6.62e-29	Total body bone mineral density;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.17	-0.32	2.95e-12	Total body bone mineral density;
LGG	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Vitiligo;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg02733842	chr7:1102375	C7orf50	0.68	10.49	0.44	3.12e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3096299	0.702	rs2086824	chr16:89471246	G/T	cg06640241	chr16:89574553	SPG7	-0.51	-8.6	-0.37	1.26e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs9443645	0.527	rs12194642	chr6:79538791	G/A	cg18132916	chr6:79620363	NA	-0.27	-7.07	-0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg12705353	chr12:122356852	WDR66	0.24	6.68	0.3	6.72e-11	Mean corpuscular volume;
LGG	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg00343986	chr7:65444356	GUSB	0.49	8.7	0.37	5.76e-17	Aortic root size;
LGG	trans	rs7916697	0.626	rs3858144	chr10:70011354	A/G	cg04882175	chr6:131122610	NA	-0.44	-6.99	-0.31	9.93e-12	Optic disc area;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21012871	chr20:42939451	FITM2	0.45	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs7166081	1.000	rs35151633	chr15:67568265	T/C	cg05925327	chr15:68127851	NA	-0.33	-7.09	-0.31	5.03e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg03929089	chr4:120376271	NA	0.74	8.57	0.37	1.57e-16	Axial length;
LGG	cis	rs929354	1.000	rs1182385	chr7:157040583	C/T	cg00092383	chr7:157075207	NA	0.42	7.49	0.33	3.46e-13	Body mass index;
LGG	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21582582	chr3:182698605	DCUN1D1	0.52	9.74	0.41	1.61e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8056893	0.807	rs7200049	chr16:68360454	C/T	cg07273125	chr16:68295692	NA	0.36	6.88	0.3	1.95e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs889398	0.617	rs3790083	chr16:69895286	C/T	cg00738113	chr16:70207722	CLEC18C	0.27	7.73	0.34	6.86e-14	Body mass index;
LGG	cis	rs7296418	0.883	rs1727312	chr12:123642220	G/T	cg05973401	chr12:123451056	ABCB9	0.48	8.0	0.35	1.04e-14	Platelet count;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15860595	chr10:11846900	NA	0.35	6.82	0.3	2.9100000000000002e-11	Electrocardiographic conduction measures;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	4.96e-12	Lung cancer;
LGG	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	7.84	0.34	3.22e-14	Retinal vascular caliber;
LGG	trans	rs9650657	0.665	rs1897207	chr8:10615235	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.76	-0.3	4.11e-11	Neuroticism;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	-0.5	-9.65	-0.41	3.32e-20	Prudent dietary pattern;
LGG	cis	rs3815700	0.925	rs395136	chr19:33106742	A/G	cg02997394	chr19:33096574	ANKRD27	0.55	8.9	0.38	1.31e-17	Eosinophilic esophagitis;
LGG	cis	rs67366981	1.000	rs2287383	chr14:77713036	C/G	cg22824376	chr14:77648248	TMEM63C	0.69	7.36	0.32	8.35e-13	Obsessive-compulsive symptoms;
LGG	cis	rs496300	0.899	rs672948	chr21:44793448	A/T	cg10251070	chr21:44781958	NA	0.26	6.95	0.31	1.21e-11	Metabolic syndrome;
LGG	cis	rs875971	0.545	rs2420456	chr7:65745606	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.57	0.44	1.54e-23	Aortic root size;
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg20003494	chr4:90757398	SNCA	-0.4	-7.8	-0.34	4.24e-14	Dementia with Lewy bodies;
LGG	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg23625390	chr15:77176239	SCAPER	-0.71	-13.92	-0.54	4.85e-37	Blood metabolite levels;
LGG	cis	rs3806843	0.608	rs155364	chr5:140346468	T/A	cg19875535	chr5:140030758	IK	0.38	7.5	0.33	3.18e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg07701084	chr6:150067640	NUP43	0.63	11.41	0.47	9.76e-27	Lung cancer;
LGG	cis	rs7737355	0.853	rs11745955	chr5:130605143	C/T	cg06307176	chr5:131281290	NA	0.48	8.05	0.35	7.12e-15	Life satisfaction;
LGG	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg01324343	chr3:183735012	ABCC5	0.85	18.08	0.64	1.08e-55	Anterior chamber depth;
LGG	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg11502198	chr6:26597334	ABT1	0.69	12.09	0.49	2.01e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1465370	0.568	rs10253113	chr7:130009311	A/G	cg04743876	chr7:130013617	NA	0.31	6.8	0.3	3.23e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11815991	chr20:30193098	ID1	0.52	8.9	0.38	1.22e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs4330281	0.666	rs10433560	chr3:17803974	C/T	cg20981856	chr3:17787350	NA	-0.39	-7.01	-0.31	8.29e-12	Schizophrenia;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg11062466	chr8:58055876	NA	0.43	7.04	0.31	7.15e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19300475	chr17:27230118	DHRS13	0.46	6.74	0.3	4.74e-11	Hip circumference;
LGG	trans	rs8002861	0.935	rs1819595	chr13:44429716	T/A	cg17145862	chr1:211918768	LPGAT1	0.98	25.48	0.76	3.72e-90	Leprosy;
LGG	trans	rs1997103	0.954	rs4947505	chr7:55409448	T/C	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2599510	0.811	rs2710615	chr2:32791222	A/T	cg02381751	chr2:32503542	YIPF4	0.48	7.69	0.34	9e-14	Interleukin-18 levels;
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	3e-27	Intelligence (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11699826	chr1:26438425	PDIK1L	0.37	6.66	0.3	7.69e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg24848339	chr3:12840334	CAND2	0.38	8.31	0.36	1.08e-15	QRS complex (12-leadsum);
LGG	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs611744	0.647	rs12675265	chr8:109268805	C/T	cg18478394	chr8:109455254	TTC35	0.43	8.51	0.37	2.38e-16	Dupuytren's disease;
LGG	cis	rs9479482	0.967	rs34006533	chr6:150350574	C/A	cg16395133	chr6:150326394	RAET1K	0.27	6.67	0.3	7.48e-11	Alopecia areata;
LGG	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs921968	0.643	rs678218	chr2:219379709	C/A	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.37	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Vitiligo;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.06	0.46	2.16e-25	Alzheimer's disease;
LGG	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg00204512	chr16:28754710	NA	0.26	7.3	0.32	1.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs61931739	0.534	rs11052974	chr12:34029877	T/G	cg13010199	chr12:38710504	ALG10B	0.57	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs4774899	0.899	rs12906335	chr15:57487091	A/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.29	-0.32	1.36e-12	Urinary tract infection frequency;
LGG	cis	rs4926611	0.762	rs2950250	chr1:54042714	T/G	cg23596471	chr1:54105337	GLIS1	0.39	7.92	0.35	1.82e-14	Hand grip strength;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg11301795	chr4:187892539	NA	-0.95	-25.55	-0.76	1.81e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9828933	0.882	rs3733127	chr3:63988174	C/T	cg17941049	chr3:63904683	ATXN7	0.6	7.3	0.32	1.25e-12	Type 2 diabetes;
LGG	cis	rs72945132	0.882	rs58039907	chr11:70183336	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	cis	rs7107174	1.000	rs10793311	chr11:78104399	G/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs4262150	0.660	rs72806705	chr5:152334841	C/T	cg12297329	chr5:152029980	NA	-0.69	-11.53	-0.47	3.14e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg22920501	chr2:26401640	FAM59B	0.44	8.96	0.38	8.13e-18	Gut microbiome composition (summer);
LGG	cis	rs4950322	0.563	rs6700783	chr1:146583569	A/T	cg22381352	chr1:146742008	CHD1L	-0.43	-7.31	-0.32	1.15e-12	Protein quantitative trait loci;
LGG	trans	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Bladder cancer;
LGG	cis	rs11203032	0.831	rs7076185	chr10:90923524	G/A	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	cis	rs2303319	1.000	rs12467117	chr2:162226315	G/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs8038465	0.568	rs62004592	chr15:73878019	A/G	cg15420318	chr15:73925796	NPTN	0.5	8.52	0.37	2.28e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg03528353	chr17:61819722	STRADA	-0.43	-7.31	-0.32	1.22e-12	Prudent dietary pattern;
LGG	cis	rs4889855	0.614	rs7221663	chr17:78484166	T/C	cg16591659	chr17:78472290	NA	-0.42	-9.38	-0.4	2.9e-19	Fractional excretion of uric acid;
LGG	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg10760299	chr15:45669010	GATM	0.4	8.0	0.35	9.82e-15	Homoarginine levels;
LGG	cis	rs42648	0.596	rs194524	chr7:89861832	G/A	cg25739043	chr7:89950458	NA	-0.33	-6.97	-0.31	1.09e-11	Homocysteine levels;
LGG	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg00383909	chr3:49044727	WDR6	0.46	7.49	0.33	3.63e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9640161	0.742	rs2108853	chr7:150017589	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.67	-0.59	1.06e-44	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg24247370	chr13:99142703	STK24	-0.39	-7.11	-0.31	4.48e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9972944	0.756	rs6504357	chr17:63770621	C/T	cg07283582	chr17:63770753	CCDC46	-0.42	-8.26	-0.36	1.5e-15	Total body bone mineral density;
LGG	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.6	0.33	1.61e-13	Eosinophil percentage of white cells;
LGG	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg16724585	chr3:197361211	NA	-0.49	-8.51	-0.37	2.45e-16	Pancreatic cancer;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg14926445	chr8:58193284	C8orf71	-0.69	-8.28	-0.36	1.34e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12681287	0.547	rs9942792	chr8:87509046	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg03022368	chr16:83986702	OSGIN1	0.47	9.41	0.4	2.28e-19	Pursuit maintenance gain;
LGG	cis	rs514024	0.700	rs505268	chr9:130493724	C/T	cg13643465	chr9:130375613	STXBP1	0.59	11.03	0.46	2.94e-25	Eating disorders (purging via substances);
LGG	cis	rs3540	0.921	rs8034050	chr15:91000206	C/T	cg22089800	chr15:90895588	ZNF774	0.54	8.53	0.37	2.17e-16	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs11792861	0.888	rs57314245	chr9:111813832	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	10.35	0.43	1.03e-22	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13379871	chr10:22610507	BMI1	0.46	6.69	0.3	6.51e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.582	rs11708813	chr3:160589852	G/A	cg03342759	chr3:160939853	NMD3	0.45	7.41	0.33	6.05e-13	Morning vs. evening chronotype;
LGG	cis	rs11690935	0.959	rs4668412	chr2:172619770	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.76	-0.78	5.01e-96	Schizophrenia;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04008888	chr11:68622739	NA	-0.57	-11.98	-0.49	5.31e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12928939	0.815	rs61753635	chr16:71660404	G/A	cg08717414	chr16:71523259	ZNF19	-0.48	-7.21	-0.32	2.34e-12	Post bronchodilator FEV1;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07035315	chr22:18483421	MICAL3	0.48	7.81	0.34	3.82e-14	Gut microbiome composition (summer);
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.41	-0.53	7.13e-35	Aortic root size;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg03188948	chr7:1209495	NA	0.66	6.66	0.3	7.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg24189917	chr7:1970923	MAD1L1	0.52	7.98	0.35	1.13e-14	Bipolar disorder;
LGG	cis	rs12476592	0.602	rs262514	chr2:63890920	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15660466	chr17:49230788	NME1;NME1-NME2	0.44	7.32	0.32	1.11e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs3784262	0.740	rs33960206	chr15:58288731	C/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.05	-0.31	6.69e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs8177253	0.665	rs8177178	chr3:133463272	G/A	cg01448562	chr3:133502909	NA	-0.56	-9.16	-0.39	1.73e-18	Iron status biomarkers;
LGG	cis	rs236352	0.538	rs9470426	chr6:36846988	T/C	cg03410223	chr6:36853544	C6orf89	0.44	8.36	0.36	7.59e-16	Heart rate;
LGG	cis	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg24110177	chr3:50126178	RBM5	0.61	11.22	0.46	5.22e-26	Body mass index;
LGG	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09263875	chr16:632152	PIGQ	0.65	13.25	0.52	3.45e-34	Height;
LGG	cis	rs4595586	0.545	rs2218761	chr12:39393593	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11723896	chr17:34136427	TAF15	0.45	6.71	0.3	5.63e-11	Gut microbiome composition (summer);
LGG	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg16386425	chr10:429943	DIP2C	0.42	8.44	0.37	4.17e-16	Psychosis in Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03266380	chr8:23315297	ENTPD4	0.48	7.24	0.32	1.87e-12	Gut microbiome composition (summer);
LGG	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg17710535	chr19:10819994	QTRT1	0.44	7.03	0.31	7.33e-12	Inflammatory skin disease;
LGG	cis	rs72781680	1.000	rs17763442	chr2:24255991	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.72	0.41	1.93e-20	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.690	rs207118	chr6:66788948	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs9297145	1.000	rs10953280	chr7:98763405	A/G	cg05967295	chr7:98741636	SMURF1	-0.96	-19.04	-0.66	3.95e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg12016809	chr21:47604291	C21orf56	0.6	10.56	0.44	1.65e-23	Testicular germ cell tumor;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs9341808	0.754	rs10806185	chr6:80954511	G/A	cg08355045	chr6:80787529	NA	0.4	7.66	0.34	1.06e-13	Sitting height ratio;
LGG	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.12	0.35	4.26e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7666738	0.800	rs13107147	chr4:99028753	C/T	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.58e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs67311347	1.000	rs11715214	chr3:40403004	C/A	cg13683864	chr3:40499215	RPL14	-0.99	-20.18	-0.68	1.93e-65	Renal cell carcinoma;
LGG	trans	rs8002861	0.870	rs4942254	chr13:44451820	C/T	cg12856521	chr11:46389249	DGKZ	0.39	6.8	0.3	3.32e-11	Leprosy;
LGG	cis	rs10540	1.000	rs12419716	chr11:503385	C/G	cg03352830	chr11:487213	PTDSS2	0.86	10.9	0.45	8.63e-25	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11837864	chr2:220043521	FAM134A	0.5	7.95	0.35	1.45e-14	Gut microbiome composition (summer);
LGG	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg17201900	chr20:34330562	RBM39	0.52	7.08	0.31	5.54e-12	Total cholesterol levels;
LGG	cis	rs6565180	0.926	rs4787643	chr16:30393660	G/A	cg17640201	chr16:30407289	ZNF48	0.84	16.21	0.6	3.93e-47	Tonsillectomy;
LGG	trans	rs6787172	0.651	rs4680436	chr3:158159317	C/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.78	-0.3	3.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.666	rs6723101	chr2:3484443	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.48	-0.37	3e-16	Neurofibrillary tangles;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg07453218	chr19:1490525	REEP6;PCSK4	0.39	6.9	0.31	1.67e-11	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06133097	chr7:32552212	AVL9	-0.39	-7.37	-0.32	7.88e-13	Cognitive ability;
LGG	cis	rs4481887	0.962	rs10788769	chr1:248457426	C/T	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.6e-15	Common traits (Other);
LGG	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg25174290	chr11:3078921	CARS	-0.51	-9.24	-0.39	8.89e-19	Calcium levels;
LGG	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg02002194	chr4:3960332	NA	0.44	8.05	0.35	6.82e-15	Retinal vascular caliber;
LGG	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg13482628	chr17:19912719	NA	0.53	9.61	0.41	4.63e-20	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.17	-0.32	2.97e-12	Skin colour saturation;
LGG	cis	rs17014483	0.749	rs2924935	chr4:89640567	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.6	6.81	0.3	2.98e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	trans	rs8073060	0.518	rs225285	chr17:33931084	G/C	cg19694781	chr19:47549865	TMEM160	-0.76	-12.17	-0.49	9.26e-30	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs4363385	0.818	rs11205176	chr1:153002481	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.99	-0.39	6.58e-18	Inflammatory skin disease;
LGG	cis	rs2115630	0.967	rs8027779	chr15:85255385	T/C	cg12501888	chr15:85177176	SCAND2	-0.42	-7.03	-0.31	7.52e-12	P wave terminal force;
LGG	cis	rs4330281	0.647	rs7648883	chr3:17407522	C/T	cg20981856	chr3:17787350	NA	0.36	6.79	0.3	3.56e-11	Schizophrenia;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.54	0.33	2.43e-13	Obesity-related traits;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.53	9.59	0.41	5.4e-20	Longevity;
LGG	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg17971929	chr21:40555470	PSMG1	0.6	10.24	0.43	2.6e-22	Cognitive function;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16611736	chr16:25123254	LCMT1	0.41	7.13	0.31	3.89e-12	Bipolar disorder;
LGG	cis	rs3820928	0.900	rs6754155	chr2:227784961	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.83	-0.34	3.47e-14	Pulmonary function;
LGG	cis	rs780096	0.967	rs1260333	chr2:27748624	A/G	cg22903471	chr2:27725779	GCKR	-0.36	-7.45	-0.33	4.46e-13	Total body bone mineral density;
LGG	trans	rs783540	0.843	rs28374463	chr15:83299364	A/C	cg16105309	chr15:79090380	ADAMTS7	0.43	7.61	0.33	1.5700000000000001e-13	Schizophrenia;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg22535103	chr8:58192502	C8orf71	-0.49	-7.91	-0.35	1.91e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03313666	chr22:38142162	TRIOBP	0.45	6.94	0.31	1.32e-11	Gut microbiome composition (summer);
LGG	trans	rs6787172	0.622	rs7610713	chr3:158072257	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.27	-0.32	1.49e-12	Subjective well-being;
LGG	cis	rs4789693	0.679	rs7213057	chr17:80378939	T/C	cg19579500	chr17:80346614	NA	0.51	8.89	0.38	1.32e-17	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs826838	1.000	rs11169031	chr12:39056738	T/C	cg26384229	chr12:38710491	ALG10B	1.01	25.6	0.77	1.04e-90	Heart rate;
LGG	cis	rs71391092	1	rs71391092	chr16:74567075	C/G	cg01733217	chr16:74700730	RFWD3	-0.73	-9.51	-0.4	1.01e-19	Schizophrenia;
LGG	trans	rs2204008	0.645	rs9989043	chr12:38238505	G/A	cg06521331	chr12:34319734	NA	0.43	7.56	0.33	2.22e-13	Bladder cancer;
LGG	cis	rs2455799	0.613	rs11128760	chr3:15873407	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.88	-0.34	2.29e-14	Mean platelet volume;
LGG	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg17145862	chr1:211918768	LPGAT1	0.95	24.14	0.75	5.77e-84	Leprosy;
LGG	cis	rs4789452	1.000	rs35825162	chr17:75373188	G/A	cg06761530	chr17:75373219	SEPT9	-0.38	-7.51	-0.33	3.08e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs3735485	0.800	rs4724348	chr7:45059239	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6743226	0.603	rs10933546	chr2:242225998	T/A	cg10021735	chr2:242295487	FARP2	0.4	7.08	0.31	5.49e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs11074306	0.561	rs4778192	chr15:28080061	C/T	cg26402630	chr15:28053930	OCA2	0.35	7.09	0.31	4.93e-12	Uveal melanoma;
LGG	cis	rs67366981	1.000	rs8006732	chr14:77713070	T/G	cg22824376	chr14:77648248	TMEM63C	0.69	7.36	0.32	8.35e-13	Obsessive-compulsive symptoms;
LGG	cis	rs7617773	0.817	rs13072018	chr3:48320332	G/A	cg11946769	chr3:48343235	NME6	0.7	11.61	0.47	1.52e-27	Coronary artery disease;
LGG	cis	rs56283067	0.887	rs12215095	chr6:44756910	T/C	cg20913747	chr6:44695427	NA	-0.65	-11.06	-0.46	2.18e-25	Total body bone mineral density;
LGG	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26306683	chr17:18585705	ZNF286B	0.46	8.61	0.37	1.12e-16	Educational attainment (years of education);
LGG	cis	rs7100689	0.784	rs3120977	chr10:82075324	C/G	cg01528321	chr10:82214614	TSPAN14	0.89	16.12	0.6	1.05e-46	Post bronchodilator FEV1;
LGG	cis	rs6060717	0.654	rs6060686	chr20:34512606	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	6.72	0.3	5.39e-11	Hip circumference adjusted for BMI;
LGG	cis	rs5995756	0.627	rs1008677	chr22:40009336	C/T	cg21377881	chr22:40064566	CACNA1I	-0.33	-6.73	-0.3	5.1e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg21775007	chr8:11205619	TDH	-0.45	-7.33	-0.32	1.02e-12	Joint mobility (Beighton score);
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg00684032	chr4:1343700	KIAA1530	0.42	8.22	0.36	2.14e-15	Longevity;
LGG	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs72781680	1.000	rs72788278	chr2:24095285	A/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.59	0.41	5.59e-20	Lymphocyte counts;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	16.98	0.62	1.22e-50	Tonsillectomy;
LGG	cis	rs9894429	0.538	rs9747080	chr17:79606704	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	11.56	0.47	2.56e-27	Eye color traits;
LGG	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg22437258	chr11:111473054	SIK2	0.56	9.65	0.41	3.39e-20	Primary sclerosing cholangitis;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs7666738	0.830	rs9998803	chr4:99002519	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2404602	0.503	rs284909	chr15:76736628	C/T	cg15268244	chr15:77196840	NA	-0.36	-8.09	-0.35	5.45e-15	Blood metabolite levels;
LGG	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.17	0.75	4.23e-84	Chronic sinus infection;
LGG	cis	rs7000551	0.751	rs1482337	chr8:22395509	A/G	cg12081754	chr8:22256438	SLC39A14	-0.62	-11.78	-0.48	3.5e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12495954	chr16:53738234	FTO;RPGRIP1L	0.42	7.05	0.31	6.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.55	-0.41	7.32e-20	Joint mobility (Beighton score);
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg00149659	chr3:10157352	C3orf10	0.76	9.54	0.41	8.07e-20	Alzheimer's disease;
LGG	cis	rs7659604	0.582	rs3217780	chr4:122737278	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.88	0.54	6.94e-37	Type 2 diabetes;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7e-23	Bipolar disorder;
LGG	cis	rs58235267	0.591	rs2162014	chr2:63345507	C/A	cg17519650	chr2:63277830	OTX1	0.53	9.61	0.41	4.77e-20	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs4432842	0.646	rs10037593	chr5:57057919	C/T	cg08523694	chr5:57076192	NA	0.5	8.98	0.39	6.9e-18	Birth weight;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg13880726	chr7:1868755	MAD1L1	0.39	6.97	0.31	1.07e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs62064224	0.530	rs8073708	chr17:30680493	T/C	cg18200150	chr17:30822561	MYO1D	0.48	9.2	0.39	1.21e-18	Schizophrenia;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg21963583	chr11:68658836	MRPL21	0.59	9.7	0.41	2.31e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg23958373	chr8:599963	NA	1.17	11.81	0.48	2.66e-28	IgG glycosylation;
LGG	cis	rs4727443	0.966	rs66748925	chr7:99589843	A/G	cg12813108	chr7:99719912	CNPY4	-0.48	-9.09	-0.39	2.94e-18	Interstitial lung disease;
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg16339924	chr4:17578868	LAP3	0.63	11.06	0.46	2.19e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2227564	0.794	rs2688624	chr10:75695724	T/G	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.75	-0.38	4.08e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9354308	0.838	rs9445595	chr6:66537559	C/G	cg07460842	chr6:66804631	NA	-0.49	-8.35	-0.36	8.21e-16	Metabolite levels;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg11494091	chr17:61959527	GH2	-1.03	-25.66	-0.77	5.65e-91	Prudent dietary pattern;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg20830447	chr12:46764929	SLC38A2	0.73	7.0	0.31	9.18e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs67460515	0.500	rs1868105	chr3:160645335	A/G	cg03342759	chr3:160939853	NMD3	-0.67	-10.98	-0.45	4.54e-25	Parkinson's disease;
LGG	cis	rs2249694	1.000	rs2249695	chr10:135352168	T/C	cg20169779	chr10:135381914	SYCE1	0.54	7.94	0.35	1.51e-14	Obesity-related traits;
LGG	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs2511185	chr11:77982496	C/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.09	-0.31	4.9e-12	Testicular germ cell tumor;
LGG	cis	rs36071027	0.615	rs34569927	chr5:158421240	A/C	cg18496440	chr5:158532302	NA	0.41	6.81	0.3	3.04e-11	Carotid intima media thickness;
LGG	cis	rs7208859	0.673	rs60020217	chr17:29185054	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg26174226	chr8:58114915	NA	-0.61	-7.13	-0.31	3.93e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02530464	chr5:176449541	ZNF346	0.5	7.74	0.34	6.49e-14	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg05169160	chr2:178484487	TTC30A	0.34	6.78	0.3	3.67e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1003719	0.715	rs35199609	chr21:38510262	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.0	-0.57	1e-41	Eye color traits;
LGG	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg02151108	chr14:50098012	C14orf104	-0.46	-9.9	-0.42	4.23e-21	Carotid intima media thickness;
LGG	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg17230874	chr3:125932073	NA	0.49	9.06	0.39	3.63e-18	Metabolite levels;
LGG	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.96	-0.35	1.38e-14	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.542	rs10440343	chr4:120309787	G/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25340675	chr3:121468720	GOLGB1	0.46	7.43	0.33	5.41e-13	Cognitive performance;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07184698	chr5:40756196	TTC33	-0.39	-6.69	-0.3	6.4e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs6504108	0.624	rs12452956	chr17:46273937	C/T	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.64e-15	Body mass index;
LGG	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg03929089	chr4:120376271	NA	0.83	8.62	0.37	1.07e-16	Myopia (pathological);
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs10876993	0.928	rs1689594	chr12:58057156	T/C	cg18357645	chr12:58087776	OS9	0.7	13.0	0.52	3.67e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.66e-21	Bipolar disorder;
LGG	cis	rs1519814	0.956	rs7016388	chr8:121101865	A/G	cg22335954	chr8:121166405	COL14A1	-0.52	-10.52	-0.44	2.42e-23	Breast cancer;
LGG	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs4665809	1.000	rs2384323	chr2:26306473	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.73	-0.34	6.7e-14	Gut microbiome composition (summer);
LGG	cis	rs3820928	0.904	rs59135978	chr2:227857763	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.49	-0.33	3.48e-13	Pulmonary function;
LGG	cis	rs2455601	0.507	rs7948452	chr11:8877704	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.47	-9.76	-0.41	1.33e-20	Schizophrenia;
LGG	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg13939156	chr17:80058883	NA	0.41	7.36	0.32	8.38e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.7	0.37	5.79e-17	Bipolar disorder;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27144592	chr16:783916	NARFL	0.4	6.77	0.3	3.93e-11	Height;
LGG	cis	rs2286885	0.965	rs741024	chr9:129251821	A/G	cg14319473	chr9:129242481	FAM125B	-0.45	-8.57	-0.37	1.53e-16	Intraocular pressure;
LGG	cis	rs4631830	0.863	rs2843546	chr10:51518688	A/C	cg16070123	chr10:51489643	NA	-0.39	-6.98	-0.31	1.04e-11	Prostate-specific antigen levels;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1371867	0.875	rs1660320	chr8:101337579	A/C	cg06636551	chr8:101224915	SPAG1	-0.46	-8.62	-0.37	1.07e-16	Atrioventricular conduction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02690350	chr17:27620209	NUFIP2	0.49	8.43	0.36	4.51e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg10523679	chr1:76189770	ACADM	-0.7	-11.01	-0.46	3.31e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg01244601	chr4:120671846	NA	-0.37	-6.98	-0.31	1.04e-11	Corneal astigmatism;
LGG	cis	rs2455826	0.834	rs2470530	chr3:15688758	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.07	-0.31	5.71e-12	Inflammatory skin disease;
LGG	cis	rs4639966	0.758	rs11217013	chr11:118624919	G/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.31	-0.32	1.17e-12	Systemic lupus erythematosus;
LGG	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg11477892	chr4:106580295	NA	-0.42	-6.89	-0.3	1.87e-11	Post bronchodilator FEV1;
LGG	cis	rs7444	0.825	rs2256609	chr22:21925017	A/G	cg15846791	chr22:21984385	YDJC	-0.47	-7.04	-0.31	6.77e-12	Systemic lupus erythematosus;
LGG	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.47	0.4	1.4e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06656553	chr16:89960601	TCF25	-0.71	-7.0	-0.31	8.87e-12	Skin colour saturation;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg12419862	chr22:24373484	LOC391322	-0.89	-18.11	-0.64	8.42e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs929354	0.772	rs3802125	chr7:156970563	A/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.33	-0.32	1.04e-12	Body mass index;
LGG	cis	rs2953174	0.507	rs4234123	chr2:241541640	C/T	cg07929629	chr2:241523174	NA	0.61	10.11	0.43	7.39e-22	Bipolar disorder;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.13	-0.46	1.19e-25	IgG glycosylation;
LGG	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg03806693	chr22:41940476	POLR3H	0.82	14.46	0.56	2.37e-39	Vitiligo;
LGG	cis	rs12780845	0.540	rs10904904	chr10:17240640	G/C	cg01003015	chr10:17271136	VIM	-0.43	-7.43	-0.33	5.4e-13	Homocysteine levels;
LGG	cis	rs56283067	0.886	rs2023311	chr6:44678306	A/T	cg20913747	chr6:44695427	NA	-0.64	-11.36	-0.47	1.56e-26	Total body bone mineral density;
LGG	cis	rs7444	0.941	rs73166632	chr22:21946173	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs2273669	0.667	rs12212402	chr6:109306681	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.59	-10.03	-0.42	1.53e-21	Obesity-related traits;
LGG	cis	rs9381040	0.748	rs9357348	chr6:41154232	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-7.06	-0.31	6.27e-12	Alzheimer's disease (late onset);
LGG	cis	rs2964802	0.505	rs6865234	chr5:10829742	C/A	cg14521931	chr5:10832172	NA	-0.74	-16.09	-0.6	1.32e-46	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs5750830	0.649	rs5750808	chr22:39790987	G/A	cg04986931	chr22:39850128	NA	0.35	8.02	0.35	8.67e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9547996	0.879	rs9547953	chr13:38138863	C/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.87	-0.3	2.04e-11	Diastolic blood pressure;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2070488	0.804	rs2268755	chr3:38501916	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.75	-14.91	-0.57	2.51e-41	Electrocardiographic conduction measures;
LGG	cis	rs736801	0.808	rs2706403	chr5:131799012	A/G	cg21138405	chr5:131827807	IRF1	0.28	6.73	0.3	5.12e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.17	-0.7	4.47e-70	Gut microbiome composition (summer);
LGG	cis	rs7717393	1.000	rs1857770	chr5:155769455	T/G	cg04435420	chr5:155754009	SGCD	1.14	12.82	0.51	2.04e-32	Egg allergy;
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg02158880	chr13:53174818	NA	0.69	15.9	0.59	9.3e-46	Lewy body disease;
LGG	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg08392591	chr16:89556376	ANKRD11	0.59	9.38	0.4	2.9e-19	Multiple myeloma (IgH translocation);
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg04703951	chr17:43578652	NA	0.39	7.95	0.35	1.45e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg00225070	chr15:80189496	MTHFS	0.37	6.88	0.3	1.98e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg22535103	chr8:58192502	C8orf71	-0.76	-10.31	-0.43	1.47e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg04935436	chr20:30431758	NA	0.41	7.32	0.32	1.1e-12	Mean corpuscular hemoglobin;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.34e-18	Obesity-related traits;
LGG	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg22517653	chr1:2918612	NA	-0.46	-7.0	-0.31	9.24e-12	Plateletcrit;
LGG	cis	rs11673344	0.864	rs7256213	chr19:37511491	T/C	cg27390819	chr19:37464633	NA	-0.39	-6.82	-0.3	2.77e-11	Obesity-related traits;
LGG	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.19	-0.43	4.05e-22	Diabetic kidney disease;
LGG	cis	rs963731	0.737	rs79756054	chr2:39338998	A/G	cg04010122	chr2:39346883	SOS1	0.82	7.98	0.35	1.13e-14	Corticobasal degeneration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04921814	chr1:145575587	PIAS3	-0.48	-7.04	-0.31	7.1e-12	Systemic lupus erythematosus;
LGG	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg00825309	chr19:58991885	ZNF446	-0.47	-9.59	-0.41	5.52e-20	Uric acid clearance;
LGG	cis	rs7202877	0.656	rs8048677	chr16:75392028	C/G	cg03315344	chr16:75512273	CHST6	0.53	7.33	0.32	1.04e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9549260	0.755	rs9566553	chr13:41174231	A/G	cg21288729	chr13:41239152	FOXO1	0.33	6.67	0.3	7.31e-11	Red blood cell count;
LGG	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg21475434	chr5:93447410	FAM172A	0.69	7.13	0.31	3.9e-12	Diabetic retinopathy;
LGG	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14442939	chr10:27389572	ANKRD26	0.52	9.41	0.4	2.33e-19	Breast cancer;
LGG	cis	rs28374715	0.532	rs316604	chr15:41775221	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.56	-0.84	4.37e-126	Ulcerative colitis;
LGG	cis	rs6456042	0.756	rs3099265	chr6:166581751	C/G	cg11088901	chr6:166572345	T	-0.36	-7.38	-0.32	7.47e-13	Asthma;
LGG	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg05768032	chr16:30646687	NA	0.42	7.07	0.31	5.75e-12	Multiple myeloma;
LGG	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg11871910	chr12:69753446	YEATS4	0.69	13.32	0.53	1.72e-34	Blood protein levels;
LGG	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg23335576	chr14:104009727	NA	0.49	8.59	0.37	1.36e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.61	0.41	4.82e-20	Bipolar disorder;
LGG	trans	rs281288	0.666	rs653749	chr15:47644528	A/G	cg26991296	chr17:20841833	NA	-0.34	-6.79	-0.3	3.52e-11	Positive affect;
LGG	trans	rs1973993	0.603	rs56827884	chr1:97021972	T/C	cg10631902	chr5:14652156	NA	-0.4	-7.14	-0.31	3.56e-12	Weight;
LGG	cis	rs16944613	0.588	rs8042497	chr15:91110331	T/A	cg22089800	chr15:90895588	ZNF774	-0.57	-6.98	-0.31	1.02e-11	Colorectal cancer;
LGG	cis	rs4304924	0.500	rs7339081	chr13:79235501	A/G	cg01819759	chr13:79234251	RNF219	0.52	8.09	0.35	5.43e-15	Large artery stroke;
LGG	cis	rs7582720	1.000	rs72932590	chr2:203884308	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.39	0.4	2.76e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7659604	0.539	rs1507995	chr4:122748308	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	13.73	0.54	3.15e-36	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27182764	chr1:168148096	TIPRL	0.47	6.91	0.31	1.59e-11	Gut microbiome composition (summer);
LGG	cis	rs5742933	0.652	rs10210345	chr2:190619486	G/C	cg04003228	chr2:190539410	ANKAR	-0.51	-7.45	-0.33	4.67e-13	Ferritin levels;
LGG	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.23	-0.32	2.07e-12	Aortic root size;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01939479	chr15:31195982	MTMR15	-0.44	-6.66	-0.3	7.72e-11	Pancreatic cancer;
LGG	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg06521331	chr12:34319734	NA	-0.4	-7.24	-0.32	1.91e-12	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08677398	chr8:58056175	NA	0.54	8.19	0.36	2.57e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs459571	0.883	rs2520096	chr9:136919416	A/G	cg13789015	chr9:136890014	NCRNA00094	0.56	10.47	0.44	3.62e-23	Platelet distribution width;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.19	-0.32	2.63e-12	Lung cancer;
LGG	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg05775895	chr3:12838266	CAND2	0.8	15.62	0.59	1.75e-44	QRS complex (12-leadsum);
LGG	cis	rs9467711	0.651	rs66790453	chr6:26107088	C/T	cg21479132	chr6:26055353	NA	0.72	7.03	0.31	7.64e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg04989706	chr14:50066350	PPIL5	-0.61	-10.17	-0.43	4.61e-22	Carotid intima media thickness;
LGG	cis	rs3820068	0.580	rs7556473	chr1:15996858	C/T	cg05660106	chr1:15850417	CASP9	-0.74	-13.26	-0.52	3.06e-34	Systolic blood pressure;
LGG	cis	rs7020830	0.571	rs3780335	chr9:37376587	A/G	cg14294708	chr9:37120828	ZCCHC7	-0.93	-14.31	-0.55	1.04e-38	Schizophrenia;
LGG	cis	rs758324	0.773	rs6870930	chr5:131110125	A/C	cg06307176	chr5:131281290	NA	-0.54	-8.93	-0.38	1.01e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9467773	0.595	rs13207371	chr6:26591074	G/A	cg09904177	chr6:26538194	HMGN4	0.63	12.26	0.5	4.06e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4774899	1.000	rs12905900	chr15:57322886	G/A	cg08128148	chr15:57256372	TCF12	-0.33	-7.85	-0.34	3.02e-14	Urinary tract infection frequency;
LGG	cis	rs4662750	0.580	rs4662745	chr2:128352863	T/G	cg10021288	chr2:128175891	PROC	0.37	6.97	0.31	1.12e-11	Renal cell carcinoma;
LGG	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg26384229	chr12:38710491	ALG10B	0.85	19.14	0.66	1.42e-60	Bladder cancer;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09217309	chr6:150244204	RAET1G	0.42	7.54	0.33	2.56e-13	Testicular germ cell tumor;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-14.42	-0.56	3.41e-39	Schizophrenia;
LGG	cis	rs472402	0.580	rs3736316	chr5:6656210	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.42	-6.71	-0.3	5.57e-11	Response to amphetamines;
LGG	cis	rs920590	0.560	rs3758061	chr8:19674033	C/T	cg03894339	chr8:19674705	INTS10	-0.56	-9.3	-0.4	5.65e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3771570	1.000	rs55634485	chr2:242268994	T/C	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs760805	0.965	rs11249203	chr1:25258585	G/C	cg22509179	chr1:25234806	RUNX3	-0.66	-13.98	-0.54	2.69e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs847649	1.000	rs12537977	chr7:102539230	C/T	cg18108683	chr7:102477205	FBXL13	-0.63	-13.61	-0.53	9.89e-36	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.14	0.39	1.9e-18	Lung cancer in ever smokers;
LGG	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg14983838	chr19:29218262	NA	0.55	7.25	0.32	1.8e-12	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs28595532	0.920	rs114162429	chr4:119741078	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs1620921	0.653	rs9365221	chr6:161276676	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg07659893	chr17:61819838	STRADA	-0.48	-8.11	-0.35	4.7e-15	Prudent dietary pattern;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2282300	0.739	rs12577729	chr11:30257377	C/T	cg25418670	chr11:30344373	C11orf46	-0.56	-7.82	-0.34	3.51e-14	Morning vs. evening chronotype;
LGG	cis	rs10462794	1.000	rs10462794	chr5:4488245	C/T	cg18482690	chr5:4511582	NA	0.38	6.7	0.3	6.22e-11	DNA methylation (variation);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg22622676	chr1:214780880	CENPF	-0.3	-6.74	-0.3	4.8e-11	Iris color (L* coordinate);
LGG	cis	rs4509693	1.000	rs4244340	chr10:102499268	G/C	cg24179445	chr10:102496915	NA	0.37	6.78	0.3	3.67e-11	Alzheimer's disease;
LGG	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg16586182	chr3:47516702	SCAP	0.8	15.27	0.58	6.29e-43	Colorectal cancer;
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg17951613	chr5:131705445	SLC22A5	-0.64	-7.28	-0.32	1.4e-12	Rheumatoid arthritis;
LGG	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.22	0.36	2.06e-15	Mood instability;
LGG	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.26	-0.32	1.68e-12	Mean corpuscular hemoglobin;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01141237	chr2:198175400	NA	0.42	6.92	0.31	1.5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1018836	0.700	rs10504894	chr8:91516436	G/A	cg16814680	chr8:91681699	NA	-0.73	-12.39	-0.5	1.24e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs861020	1.000	rs674433	chr1:209964875	A/C	cg05527609	chr1:210001259	C1orf107	-0.71	-9.82	-0.42	8.21e-21	Orofacial clefts;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.73	0.54	3.12e-36	Prudent dietary pattern;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.52	-0.37	2.31e-16	Obesity-related traits;
LGG	trans	rs4650994	0.935	rs12039531	chr1:178515612	G/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.1	-0.35	4.82e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25427524	chr10:38739819	LOC399744	0.7	14.19	0.55	3.47e-38	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	0.882	rs9468300	chr6:28126840	C/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.51	-0.4	1.02e-19	Depression;
LGG	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg03929089	chr4:120376271	NA	-0.79	-13.24	-0.52	3.69e-34	Coronary artery disease;
LGG	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg06138931	chr13:21896616	NA	-0.44	-7.26	-0.32	1.63e-12	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02976054	chr21:37528768	NA	0.46	6.83	0.3	2.63e-11	Gut microbiome composition (summer);
LGG	cis	rs10050311	0.800	rs2230600	chr4:87690998	C/T	cg11209507	chr4:87813803	C4orf36	-0.53	-6.67	-0.3	7.42e-11	Insulin-related traits;
LGG	cis	rs858239	0.601	rs15775	chr7:23164701	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.37	0.32	8.15e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7264396	0.635	rs6121102	chr20:34544274	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.1	-0.31	4.71e-12	Total cholesterol levels;
LGG	cis	rs7166081	1.000	rs12148134	chr15:67592098	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.72	-0.3	5.24e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12220238	1.000	rs3812638	chr10:75896072	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.77	10.25	0.43	2.37e-22	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs6743376	0.556	rs2441375	chr2:113817268	T/C	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.17e-18	Inflammatory biomarkers;
LGG	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg16662043	chr16:48846231	NA	0.37	7.24	0.32	1.88e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.24	0.39	8.88e-19	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14492347	chr15:85292323	ZNF592	0.49	7.37	0.32	7.8e-13	Gut microbiome composition (summer);
LGG	cis	rs3008870	0.755	rs2815364	chr1:67498384	C/T	cg02640540	chr1:67518911	SLC35D1	0.36	7.07	0.31	5.85e-12	Lymphocyte percentage of white cells;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs17401966	0.838	rs12139981	chr1:10390696	T/C	cg19773385	chr1:10388646	KIF1B	-0.46	-9.87	-0.42	5.52e-21	Hepatocellular carcinoma;
LGG	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg03352830	chr11:487213	PTDSS2	0.85	9.96	0.42	2.7e-21	Body mass index;
LGG	cis	rs745821	0.701	rs753328	chr18:48108008	C/T	cg18923635	chr18:48083994	NA	-0.42	-7.66	-0.34	1.12e-13	Diastolic blood pressure;
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	11.19	0.46	6.99e-26	Total body bone mineral density;
LGG	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg09380636	chr19:4791861	FEM1A	0.53	6.78	0.3	3.66e-11	Skin pigmentation;
LGG	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg02733842	chr7:1102375	C7orf50	0.62	7.55	0.33	2.35e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg10596483	chr8:143751796	JRK	0.52	8.18	0.36	2.74e-15	Schizophrenia;
LGG	cis	rs988958	0.567	rs11894613	chr2:42268392	T/C	cg19376973	chr2:42229025	NA	0.58	9.46	0.4	1.53e-19	Hypospadias;
LGG	cis	rs8051149	0.688	rs12444670	chr16:87870312	C/T	cg01412419	chr16:87856264	NA	0.62	10.46	0.44	4.05e-23	Blood metabolite levels;
LGG	cis	rs1577917	0.959	rs2816822	chr6:86658292	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.78	-0.41	1.19e-20	Response to antipsychotic treatment;
LGG	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.85	0.45	1.39e-24	Blood protein levels;
LGG	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg21775007	chr8:11205619	TDH	0.81	14.22	0.55	2.44e-38	Retinal vascular caliber;
LGG	cis	rs12893668	0.581	rs34843146	chr14:104079864	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-10.03	-0.42	1.47e-21	Reticulocyte count;
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs4731207	0.565	rs1031959	chr7:124627313	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.62e-11	Cutaneous malignant melanoma;
LGG	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg16414030	chr3:133502952	NA	0.6	10.45	0.44	4.16e-23	Iron status biomarkers;
LGG	cis	rs6546550	0.835	rs13002091	chr2:70118388	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.05	-0.35	6.9e-15	Prevalent atrial fibrillation;
LGG	cis	rs7447593	0.626	rs3812036	chr5:176813404	C/T	cg16006841	chr5:176797999	RGS14	0.54	8.25	0.36	1.6e-15	Urinary electrolytes (magnesium/calcium ratio);
LGG	trans	rs36715	1.000	rs40527	chr5:127550252	A/C	cg16011800	chr17:1958478	HIC1	-0.46	-6.91	-0.31	1.6e-11	Breast cancer;
LGG	cis	rs2544527	0.624	rs2693027	chr2:15926773	C/T	cg26669897	chr2:15909070	NA	0.27	6.79	0.3	3.5e-11	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.29	-0.36	1.21e-15	Subjective well-being;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg18379455	chr17:41446167	NA	-0.33	-7.94	-0.35	1.57e-14	Menopause (age at onset);
LGG	cis	rs11166927	1.000	rs12549587	chr8:140804310	G/A	cg16909799	chr8:140841666	TRAPPC9	0.6	12.61	0.51	1.57e-31	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs62238980	0.614	rs77017871	chr22:32382145	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs7945705	0.719	rs2012680	chr11:8996059	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.42	-0.36	4.59e-16	Hemoglobin concentration;
LGG	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg26513180	chr16:89883248	FANCA	0.74	8.61	0.37	1.18e-16	Skin colour saturation;
LGG	cis	rs3816183	0.720	rs4332966	chr2:43083831	T/G	cg14631114	chr2:43023945	NA	0.46	8.18	0.36	2.66e-15	Hypospadias;
LGG	cis	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.67	0.73	4.38e-77	Homoarginine levels;
LGG	cis	rs4148087	1.000	rs4148094	chr21:43635381	C/T	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	cis	rs908922	0.676	rs7545336	chr1:152527863	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs709400	0.663	rs11628969	chr14:103940911	G/A	cg26031613	chr14:104095156	KLC1	0.79	14.01	0.55	1.96e-37	Body mass index;
LGG	cis	rs56283067	0.886	rs56110323	chr6:44679934	G/A	cg18551225	chr6:44695536	NA	-0.65	-11.35	-0.47	1.59e-26	Total body bone mineral density;
LGG	cis	rs4740619	0.782	rs7036285	chr9:15711143	G/A	cg14451791	chr9:16040625	NA	0.33	8.37	0.36	7.09e-16	Body mass index;
LGG	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg12751644	chr20:60527061	NA	-0.32	-7.01	-0.31	8.48e-12	Body mass index;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.83	-0.59	2.11e-45	Tonsillectomy;
LGG	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.35	0.43	9.72e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11676348	0.755	rs62183956	chr2:219046122	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.42	6.96	0.31	1.18e-11	Ulcerative colitis;
LGG	cis	rs2540226	0.575	rs4670954	chr2:39908324	G/C	cg02886589	chr2:39892450	TMEM178	0.3	8.39	0.36	6.09e-16	Personality dimensions;
LGG	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.53	8.81	0.38	2.46e-17	Response to antipsychotic treatment;
LGG	cis	rs73416724	1.000	rs73416724	chr6:43337802	A/G	cg26312998	chr6:43337775	ZNF318	0.6	8.55	0.37	1.83e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11190604	1.000	rs2495741	chr10:102331795	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.85e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8013055	0.796	rs4075104	chr14:106000214	C/A	cg25008857	chr14:105974488	NA	0.56	9.52	0.4	9.28e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs3126085	0.935	rs72696975	chr1:152206090	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-7.24	-0.32	1.94e-12	Atopic dermatitis;
LGG	cis	rs757278	0.537	rs739797	chr7:117368587	G/A	cg10524701	chr7:117356490	CTTNBP2	0.41	6.74	0.3	4.67e-11	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs4740619	0.819	rs12352779	chr9:15700723	G/A	cg14451791	chr9:16040625	NA	0.33	8.44	0.37	3.98e-16	Body mass index;
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg07005078	chr4:17578674	LAP3	0.37	6.87	0.3	2.03e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.26e-21	Aortic root size;
LGG	cis	rs9463078	0.764	rs10948187	chr6:44921320	A/G	cg25276700	chr6:44698697	NA	0.4	8.53	0.37	2.1e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg07777115	chr5:623756	CEP72	-0.62	-7.96	-0.35	1.35e-14	Obesity-related traits;
LGG	cis	rs13401104	0.716	rs12463651	chr2:237128272	A/G	cg15742758	chr2:237126235	ASB18	0.48	7.86	0.34	2.68e-14	Educational attainment;
LGG	cis	rs9487094	0.626	rs12204548	chr6:110036707	C/T	cg16315928	chr6:109776240	MICAL1	0.47	8.06	0.35	6.38e-15	Height;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.81	-0.48	2.58e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg06027949	chr8:82754900	SNX16	-0.55	-8.6	-0.37	1.23e-16	Diastolic blood pressure;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg14416269	chr4:6271139	WFS1	0.47	8.09	0.35	5.22e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg02389323	chr16:88786976	FAM38A	1.05	12.81	0.51	2.35e-32	Plateletcrit;
LGG	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03264133	chr6:25882463	NA	-0.65	-11.72	-0.48	5.78e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9682041	0.696	rs6798399	chr3:170086482	G/A	cg11886554	chr3:170076028	SKIL	0.67	8.59	0.37	1.35e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10895140	0.709	rs4511256	chr11:101510986	A/C	cg23650423	chr11:101454676	TRPC6	-0.42	-6.8	-0.3	3.16e-11	Menarche (age at onset);
LGG	cis	rs922107	0.934	rs12118131	chr1:90041187	T/C	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.58	-0.33	1.91e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg06872548	chr17:78716983	RPTOR	0.45	10.85	0.45	1.34e-24	Obesity;
LGG	cis	rs9815354	1.000	rs1615543	chr3:41906404	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs806215	1.000	rs2106187	chr7:127241353	C/T	cg25922125	chr7:127225783	GCC1	0.75	10.24	0.43	2.62e-22	Type 2 diabetes;
LGG	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg19784903	chr17:45786737	TBKBP1	-0.32	-6.98	-0.31	1.04e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	trans	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg24247370	chr13:99142703	STK24	-0.37	-6.78	-0.3	3.67e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.87	-0.45	1.14e-24	Lung cancer;
LGG	cis	rs883565	0.655	rs6599002	chr3:39076073	T/C	cg01426195	chr3:39028469	NA	-0.73	-17.11	-0.62	3.4e-51	Handedness;
LGG	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.64	-0.37	9.26e-17	IgG glycosylation;
LGG	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.3	0.4	5.37e-19	Height;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg13206674	chr6:150067644	NUP43	-0.61	-13.33	-0.53	1.59e-34	Lung cancer;
LGG	cis	rs2839186	0.605	rs2839174	chr21:47676934	T/C	cg12016809	chr21:47604291	C21orf56	0.42	6.82	0.3	2.84e-11	Testicular germ cell tumor;
LGG	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg13647721	chr17:30228624	UTP6	0.61	8.02	0.35	8.91e-15	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg22681709	chr2:178499509	PDE11A	-0.49	-8.93	-0.38	1.02e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11700980	0.636	rs116954706	chr21:30219404	T/A	cg08807101	chr21:30365312	RNF160	-0.63	-6.74	-0.3	4.66e-11	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg24829409	chr8:58192753	C8orf71	-0.69	-9.47	-0.4	1.48e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7219021	1.000	rs2032843	chr17:46847524	T/A	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.76	-0.3	4.28e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs3740909	1.000	rs3740911	chr11:125889755	C/T	cg24940576	chr11:125904314	CDON	-0.48	-7.51	-0.33	2.97e-13	Blood protein levels;
LGG	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.86	-0.42	5.93e-21	Aortic root size;
LGG	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.89	17.48	0.63	6.3e-53	Subjective well-being;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.21	0.43	3.32e-22	Prudent dietary pattern;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21610999	chr17:8661909	SPDYE4	-0.56	-7.05	-0.31	6.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg01678292	chr8:41522873	ANK1	0.35	8.17	0.35	3.06e-15	Type 2 diabetes;
LGG	cis	rs73198271	0.700	rs10103282	chr8:8650757	T/G	cg01851573	chr8:8652454	MFHAS1	0.37	6.82	0.3	2.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2274273	0.837	rs7142857	chr14:55704128	C/T	cg04306507	chr14:55594613	LGALS3	0.63	17.37	0.63	2.05e-52	Protein biomarker;
LGG	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.89	0.48	1.18e-28	Rheumatoid arthritis;
LGG	cis	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg21775007	chr8:11205619	TDH	0.84	15.26	0.58	6.65e-43	Retinal vascular caliber;
LGG	trans	rs1814175	0.645	rs2140602	chr11:50022800	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	1.99e-57	Platelet count;
LGG	cis	rs3799379	0.550	rs2072804	chr6:26391190	G/A	cg12826209	chr6:26865740	GUSBL1	0.46	7.06	0.31	6.31e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg17462356	chr17:80056334	FASN	0.44	6.67	0.3	7.35e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs35306767	0.807	rs72778228	chr10:938435	A/G	cg26597838	chr10:835615	NA	0.95	12.82	0.51	1.97e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs4538187	0.760	rs11558741	chr2:64124722	C/A	cg19915305	chr2:64069682	UGP2	-0.66	-13.5	-0.53	2.96e-35	Systolic blood pressure;
LGG	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg01221209	chr5:554886	NA	-0.5	-7.26	-0.32	1.67e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.78	-0.3	3.57e-11	Bipolar disorder;
LGG	cis	rs6714710	0.603	rs35505530	chr2:98506910	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.5	0.4	1.13e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg13628971	chr7:2884303	GNA12	0.48	9.54	0.41	8.1e-20	Height;
LGG	cis	rs721399	1.000	rs11787313	chr8:18260026	G/C	cg18736775	chr8:18248649	NAT2	0.52	9.12	0.39	2.31e-18	Blood metabolite levels;
LGG	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.4	-0.63	1.56e-52	Chronic sinus infection;
LGG	cis	rs7945718	0.591	rs7937898	chr11:12703561	G/T	cg25843174	chr11:12811716	TEAD1	-0.33	-7.24	-0.32	1.94e-12	Educational attainment (years of education);
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg04287289	chr16:89883240	FANCA	-0.59	-6.83	-0.3	2.74e-11	Skin colour saturation;
LGG	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg26384229	chr12:38710491	ALG10B	-0.81	-17.18	-0.62	1.52e-51	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-9.04	-0.39	4.15e-18	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27139077	chr15:43622721	ADAL;LCMT2	-0.43	-6.89	-0.3	1.81e-11	Pancreatic cancer;
LGG	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs745080	0.603	rs17725312	chr14:53065714	C/T	cg23333723	chr14:53022898	GPR137C	-0.44	-8.34	-0.36	8.86e-16	Orofacial clefts;
LGG	trans	rs6076960	0.846	rs6053962	chr20:6176915	A/G	cg17788362	chr6:86352627	SYNCRIP	0.5	8.39	0.36	6e-16	Smooth-surface caries;
LGG	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	13.75	0.54	2.65e-36	Type 2 diabetes;
LGG	cis	rs36051895	0.697	rs11788790	chr9:5092263	G/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.14	-0.58	2.44e-42	Pediatric autoimmune diseases;
LGG	trans	rs9914544	0.545	rs9912713	chr17:18771145	G/A	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.16e-13	Educational attainment (years of education);
LGG	trans	rs4714291	1.000	rs6925661	chr6:39995063	T/C	cg02267698	chr19:7991119	CTXN1	0.51	7.79	0.34	4.32e-14	Strep throat;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg19223190	chr17:80058835	NA	0.44	8.65	0.37	8.44e-17	Life satisfaction;
LGG	cis	rs2730245	0.527	rs1188974	chr7:158665748	C/T	cg18245976	chr7:158708271	WDR60	-0.58	-7.68	-0.34	9.8e-14	Height;
LGG	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.66	10.61	0.44	1.11e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7638995	0.878	rs1995665	chr3:69183140	A/C	cg26574240	chr3:69171822	LMOD3	-0.77	-11.67	-0.48	9.59e-28	Alzheimer's disease (late onset);
LGG	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.76	0.57	1.09e-40	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg18258770	chr4:90757814	SNCA	-0.4	-7.29	-0.32	1.36e-12	Dementia with Lewy bodies;
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-10.9	-0.45	8.73e-25	Personality dimensions;
LGG	cis	rs7017914	0.967	rs34905858	chr8:71659450	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.44e-11	Bone mineral density;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg06654118	chr4:1303317	MAEA	0.49	8.55	0.37	1.86e-16	Obesity-related traits;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg19006130	chr11:118478252	PHLDB1	0.4	7.17	0.32	2.98e-12	Cholesterol, total;
LGG	cis	rs35264875	1.000	rs72919412	chr11:68826855	G/T	cg23845249	chr11:68861649	NA	0.44	7.82	0.34	3.69e-14	Blond vs. brown hair color;
LGG	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg21535247	chr6:8435926	SLC35B3	-0.5	-8.17	-0.35	3.03e-15	Motion sickness;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19524238	chr7:2802976	GNA12	0.4	9.21	0.39	1.16e-18	Height;
LGG	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg07274523	chr3:49395745	GPX1	-0.53	-8.43	-0.36	4.31e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-7.8	-0.34	4.05e-14	Electroencephalogram traits;
LGG	cis	rs2342371	0.848	rs4916497	chr3:196198533	T/C	cg15048948	chr3:196158458	UBXN7	-0.4	-6.78	-0.3	3.74e-11	Fat distribution (HIV);
LGG	cis	rs1348850	0.958	rs10930800	chr2:178459669	T/C	cg27490568	chr2:178487706	NA	0.46	8.98	0.39	6.72e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11877825	1.000	rs11877777	chr18:10566405	C/A	cg25239095	chr18:10589360	NA	0.49	9.27	0.4	7.3e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.1	0.46	1.52e-25	Bone mineral density;
LGG	cis	rs367943	0.665	rs11950173	chr5:112960995	C/T	cg12552261	chr5:112820674	MCC	0.52	9.02	0.39	4.86e-18	Type 2 diabetes;
LGG	cis	rs12431410	0.550	rs7150949	chr14:60228960	T/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.28	-0.32	1.44e-12	Schizophrenia;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg18350739	chr11:68623251	NA	-0.89	-21.51	-0.71	1.16e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs506338	0.517	rs12269736	chr11:64471986	T/C	cg19395706	chr11:64412079	NRXN2	0.41	7.84	0.34	3.11e-14	Body mass index;Urate levels;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26617929	chr16:1858877	NA	-0.6	-8.62	-0.37	1.1e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1620921	0.593	rs9355844	chr6:161268967	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2797369	0.553	rs17673031	chr6:101312270	T/C	cg27451362	chr6:101846650	GRIK2	0.68	9.17	0.39	1.59e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs72827839	0.846	rs41280120	chr17:46114692	C/G	cg02219949	chr17:45927392	SP6	0.54	8.12	0.35	4.13e-15	Ease of getting up in the morning;
LGG	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs3087591	1.000	rs7220268	chr17:29451910	T/C	cg24425628	chr17:29625626	OMG;NF1	0.71	13.93	0.54	4.44e-37	Hip circumference;
LGG	cis	rs66887589	0.967	rs59516282	chr4:120502016	G/A	cg09307838	chr4:120376055	NA	-0.48	-8.3	-0.36	1.13e-15	Diastolic blood pressure;
LGG	cis	rs28830936	0.966	rs2241522	chr15:42127734	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.13	-0.52	1.08e-33	Diastolic blood pressure;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.98	0.39	6.9e-18	Platelet count;
LGG	cis	rs8133932	0.724	rs11701130	chr21:47041808	A/C	cg11214348	chr21:47283868	PCBP3	0.44	7.3	0.32	1.23e-12	Schizophrenia;
LGG	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	2.98e-11	Corneal structure;
LGG	cis	rs7945705	0.875	rs2568065	chr11:8889648	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.9	-0.34	2.05e-14	Hemoglobin concentration;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg20366258	chr2:113404078	SLC20A1	0.41	6.85	0.3	2.3e-11	Menarche (age at onset);
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg16145915	chr7:1198662	ZFAND2A	0.51	8.96	0.38	8.1e-18	Longevity;Endometriosis;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.17	-0.49	9.76e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.16	0.32	3.15e-12	Longevity;
LGG	cis	rs911263	0.603	rs2877455	chr14:68760986	C/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.19	0.36	2.57e-15	Primary biliary cholangitis;
LGG	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg11871910	chr12:69753446	YEATS4	0.8	13.63	0.54	8.02e-36	Response to diuretic therapy;
LGG	cis	rs1348850	0.526	rs2141157	chr2:178374112	C/T	cg23306229	chr2:178417860	TTC30B	0.72	8.77	0.38	3.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11673344	0.931	rs1234251	chr19:37671256	G/C	cg27390819	chr19:37464633	NA	-0.39	-6.98	-0.31	1.01e-11	Obesity-related traits;
LGG	cis	rs4363385	0.818	rs1415966	chr1:153002864	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	cis	rs36071027	0.577	rs11740411	chr5:158396215	C/T	cg00594129	chr5:158524270	EBF1	0.45	8.09	0.35	5.32e-15	Carotid intima media thickness;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.63	-0.37	9.57e-17	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs10479542	0.549	rs4376229	chr5:179042971	A/G	cg26516362	chr5:178986906	RUFY1	0.4	6.76	0.3	4.24e-11	Lung cancer;
LGG	cis	rs9814567	1.000	rs2887797	chr3:134202506	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.8	-0.51	2.44e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg17911788	chr17:44343683	NA	0.47	7.94	0.35	1.56e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4006360	0.551	rs11868548	chr17:39237132	C/G	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.45	-0.47	6.94e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	12.68	0.51	7.88e-32	Lymphocyte counts;
LGG	cis	rs17689437	0.671	rs1645937	chr16:68593844	T/G	cg02972257	chr16:68554789	NA	-0.45	-7.51	-0.33	2.97e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs5758659	0.679	rs134870	chr22:42652317	T/C	cg15128208	chr22:42549153	NA	-0.49	-9.71	-0.41	2e-20	Cognitive function;
LGG	cis	rs7524258	0.900	rs6670323	chr1:7301947	C/A	cg07173049	chr1:7289937	CAMTA1	0.72	16.85	0.62	4.91e-50	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg16606324	chr3:10149918	C3orf24	0.55	7.29	0.32	1.32e-12	Alzheimer's disease;
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg19524238	chr7:2802976	GNA12	0.37	8.44	0.37	4.14e-16	Height;
LGG	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	8.77	0.38	3.48e-17	Cognitive test performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05826237	chr19:1095571	POLR2E	0.43	7.38	0.32	7.41e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6445975	0.666	rs12489103	chr3:58373167	G/C	cg24175188	chr3:58374923	PXK	-0.54	-8.83	-0.38	2.11e-17	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.605	rs4697710	chr4:10122649	T/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.72	0.34	7.28e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.22	-0.32	2.18e-12	Iron status biomarkers;
LGG	cis	rs6500395	1.000	rs7201196	chr16:48674030	C/T	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg03351412	chr1:154909251	PMVK	0.67	12.86	0.51	1.43e-32	Prostate cancer;
LGG	cis	rs1577917	0.771	rs9362232	chr6:86353622	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.83	-0.34	3.35e-14	Response to antipsychotic treatment;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08409687	chr2:201936025	NDUFB3;FAM126B	0.4	7.38	0.32	7.32e-13	Bilirubin levels;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00495681	chr13:53174319	NA	0.57	10.21	0.43	3.31e-22	Lewy body disease;
LGG	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg01420254	chr6:26195488	NA	0.88	11.57	0.47	2.33e-27	Gout;Renal underexcretion gout;
LGG	cis	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07988820	chr12:82153109	PPFIA2	0.75	10.92	0.45	7.25e-25	Resting heart rate;
LGG	cis	rs2050392	0.517	rs2771242	chr10:30762973	C/T	cg25182066	chr10:30743637	MAP3K8	-0.63	-13.23	-0.52	4.04e-34	Inflammatory bowel disease;
LGG	trans	rs35849525	0.814	rs35491931	chr3:49993462	T/A	cg21659725	chr3:3221576	CRBN	0.46	6.71	0.3	5.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg20503657	chr10:835505	NA	0.77	10.63	0.44	9.28e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs10876993	0.890	rs1585781	chr12:58056701	T/G	cg18357645	chr12:58087776	OS9	0.7	13.0	0.52	3.67e-33	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg17830980	chr10:43048298	ZNF37B	0.39	8.84	0.38	1.99e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs8073060	0.614	rs225279	chr17:33974214	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6787391	0.933	rs6774387	chr3:4749545	A/G	cg11584376	chr3:4789075	ITPR1	0.35	7.23	0.32	1.99e-12	Breast cancer;
LGG	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-11.87	-0.48	1.52e-28	Migraine;Coronary artery disease;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25072359	chr17:41440525	NA	0.49	9.66	0.41	3.08e-20	Menopause (age at onset);
LGG	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg02461776	chr11:598696	PHRF1	0.49	7.13	0.31	3.99e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs78366141	0.649	rs57956471	chr4:89724384	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.08	8.75	0.38	4.07e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.5	-7.49	-0.33	3.43e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg06969265	chr17:73775802	H3F3B	0.93	10.35	0.43	9.74e-23	Psoriasis;
LGG	trans	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg06606381	chr12:133084897	FBRSL1	-0.72	-7.13	-0.31	3.88e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg25019033	chr10:957182	NA	-0.53	-8.84	-0.38	1.94e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.41	-0.36	5.22e-16	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.11	-0.31	4.4e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs3857536	0.704	rs7775899	chr6:66969860	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.04	-0.31	7.19e-12	Blood trace element (Cu levels);
LGG	cis	rs4474465	0.850	rs10751292	chr11:78242201	C/G	cg02023728	chr11:77925099	USP35	-0.39	-6.91	-0.31	1.66e-11	Alzheimer's disease (survival time);
LGG	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg03709012	chr19:19516395	GATAD2A	-0.61	-10.07	-0.42	1.07e-21	Tonsillectomy;
LGG	cis	rs6598955	0.543	rs60676610	chr1:26543421	G/C	cg04990556	chr1:26633338	UBXN11	0.71	10.47	0.44	3.52e-23	Obesity-related traits;
LGG	cis	rs6121246	0.567	rs6060297	chr20:30198560	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.75	0.38	3.99e-17	Mean corpuscular hemoglobin;
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg16606324	chr3:10149918	C3orf24	0.54	7.17	0.32	2.97e-12	Alzheimer's disease;
LGG	cis	rs9398803	0.965	rs9388486	chr6:126661154	C/T	cg19875578	chr6:126661172	C6orf173	-0.53	-9.59	-0.41	5.6e-20	Male-pattern baldness;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01341218	chr17:43662625	NA	0.69	11.2	0.46	6.24e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs490234	0.812	rs7875713	chr9:128268903	G/T	cg14078157	chr9:128172775	NA	-0.45	-8.48	-0.37	2.98e-16	Mean arterial pressure;
LGG	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.4	-0.36	5.46e-16	Triglycerides;
LGG	cis	rs981844	0.775	rs17299561	chr4:154765480	C/T	cg14289246	chr4:154710475	SFRP2	0.67	10.96	0.45	5.17e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs2798269	0.934	rs12865749	chr13:22081377	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.72	-0.3	5.31e-11	PR segment;
LGG	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg25427524	chr10:38739819	LOC399744	0.5	7.35	0.32	9.1e-13	Obesity (extreme);
LGG	cis	rs10991814	1.000	rs79093642	chr9:93985704	A/G	cg14446406	chr9:93919335	NA	-0.76	-8.49	-0.37	2.74e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.87	-0.42	5.45e-21	Morning vs. evening chronotype;
LGG	cis	rs6429082	0.905	rs12405889	chr1:235597252	A/C	cg26050004	chr1:235667680	B3GALNT2	-0.43	-7.16	-0.32	3.1e-12	Adiposity;
LGG	cis	rs6784615	0.744	rs2878549	chr3:52449047	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.7	-7.72	-0.34	7.29e-14	Waist-hip ratio;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg02951883	chr7:2050386	MAD1L1	0.62	11.91	0.48	9.95e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg24006582	chr15:45444508	DUOX1	-0.63	-11.43	-0.47	8.01e-27	Uric acid levels;
LGG	cis	rs74925218	1	rs74925218	chr15:78796732	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-7.78	-0.34	4.92e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs929354	0.772	rs6967764	chr7:156994964	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs9815354	0.680	rs73073290	chr3:42027684	T/G	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.49e-12	Prudent dietary pattern;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.74e-15	IgG glycosylation;
LGG	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg08305652	chr11:111469057	NA	-0.43	-8.55	-0.37	1.78e-16	Primary sclerosing cholangitis;
LGG	cis	rs11112613	0.775	rs12371537	chr12:105971425	T/C	cg03607813	chr12:105948248	NA	0.56	9.74	0.41	1.61e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs3126085	0.935	rs4845751	chr1:152208997	T/C	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.04	0.46	2.61e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg11252792	chr3:125932053	NA	0.6	12.04	0.49	3.21e-29	Metabolite levels;
LGG	cis	rs2463822	0.748	rs2513038	chr11:62081329	A/C	cg06239285	chr11:62104954	ASRGL1	1.14	15.42	0.58	1.32e-43	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2195525	0.572	rs10892351	chr11:119218530	T/G	cg01451205	chr11:119252210	USP2	0.43	7.14	0.31	3.75e-12	Urate levels;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9393813	1.000	rs9393813	chr6:27331596	C/A	cg18711553	chr6:27366782	ZNF391	0.53	9.94	0.42	3.22e-21	Bipolar disorder;
LGG	cis	rs17376456	0.877	rs10040648	chr5:93490301	G/C	cg25358565	chr5:93447407	FAM172A	1.31	16.12	0.6	9.75e-47	Diabetic retinopathy;
LGG	trans	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg25042112	chr7:64838748	ZNF92	-0.47	-6.69	-0.3	6.64e-11	Pain;
LGG	cis	rs988958	0.565	rs6753186	chr2:42235998	C/T	cg27428208	chr2:42229179	NA	0.48	7.66	0.34	1.09e-13	Hypospadias;
LGG	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.97	0.38	7.47e-18	Motion sickness;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.6	-0.44	1.15e-23	Lung cancer;
LGG	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3741404	0.560	rs7938819	chr11:63910116	G/A	cg05555928	chr11:63887634	MACROD1	0.38	6.91	0.31	1.58e-11	Platelet count;
LGG	cis	rs17253792	0.822	rs17683614	chr14:56041058	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs7166081	1.000	rs16950776	chr15:67510604	G/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs922107	0.967	rs1885746	chr1:90015719	A/C	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.54	-0.33	2.47e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs2760061	0.784	rs708116	chr1:228198196	C/A	cg01200585	chr1:228362443	C1orf69	0.47	8.18	0.36	2.8e-15	Diastolic blood pressure;
LGG	cis	rs611744	0.507	rs1579924	chr8:109324884	G/T	cg18478394	chr8:109455254	TTC35	0.42	8.2	0.36	2.31e-15	Dupuytren's disease;
LGG	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.67	-0.44	6.67e-24	Height;
LGG	cis	rs9814567	1.000	rs9813774	chr3:134227100	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.35e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg00024416	chr22:24240387	NA	0.43	6.73	0.3	5.17e-11	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.66	-0.48	1.03e-27	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.823	rs2701903	chr8:1004029	A/G	cg08648136	chr8:956695	NA	-0.36	-7.63	-0.33	1.33e-13	Schizophrenia;
LGG	cis	rs2708240	1.000	rs2247149	chr7:147581161	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.84	-0.3	2.48e-11	QT interval (drug interaction);
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.75	0.34	6.05e-14	Monocyte count;
LGG	cis	rs41271473	0.526	rs28593014	chr1:228743576	G/A	cg16512390	chr1:228756714	NA	0.61	8.07	0.35	6.21e-15	Chronic lymphocytic leukemia;
LGG	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.95	0.35	1.42e-14	Retinal vascular caliber;
LGG	cis	rs929354	0.772	rs10229630	chr7:157004790	C/T	cg17757837	chr7:157058334	UBE3C	0.75	15.06	0.57	5.18e-42	Body mass index;
LGG	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.11	-0.49	1.61e-29	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg02002194	chr4:3960332	NA	0.39	7.2	0.32	2.39e-12	Joint mobility (Beighton score);
LGG	trans	rs5756813	0.727	rs13055462	chr22:38184685	A/G	cg19894588	chr14:64061835	NA	-0.63	-10.07	-0.42	1.08e-21	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1577917	0.545	rs9344548	chr6:86487337	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	8.07	0.35	6.11e-15	Response to antipsychotic treatment;
LGG	cis	rs1005224	0.853	rs61980778	chr14:76151532	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	0.41	6.74	0.3	4.8e-11	Large artery stroke;
LGG	cis	rs9815354	1.000	rs1717006	chr3:41940448	A/C	cg03022575	chr3:42003672	ULK4	0.65	8.31	0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs490234	0.718	rs2133386	chr9:128173838	C/A	cg14078157	chr9:128172775	NA	-0.49	-9.25	-0.39	8.52e-19	Mean arterial pressure;
LGG	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.94	-0.35	1.58e-14	Initial pursuit acceleration;
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.17	-0.35	3.04e-15	Bipolar disorder;
LGG	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg11494091	chr17:61959527	GH2	0.61	10.42	0.44	5.7e-23	Height;
LGG	cis	rs11971779	0.680	rs4732379	chr7:139122814	T/C	cg07862535	chr7:139043722	LUC7L2	0.45	7.39	0.32	6.87e-13	Diisocyanate-induced asthma;
LGG	cis	rs1801251	1.000	rs67013068	chr2:233608253	G/C	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	6.78e-32	Coronary artery disease;
LGG	trans	rs9650657	0.623	rs11250066	chr8:10600467	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.37	-0.32	7.75e-13	Neuroticism;
LGG	cis	rs7119	0.931	rs7176875	chr15:77832675	A/G	cg17802220	chr15:77601643	NA	0.32	6.82	0.3	2.87e-11	Type 2 diabetes;
LGG	cis	rs6142618	0.562	rs6142614	chr20:30712265	T/C	cg00028034	chr20:30779307	TSPYL3	0.36	7.82	0.34	3.63e-14	Inflammatory bowel disease;
LGG	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.73	0.56	1.45e-40	Cognitive test performance;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.28	-0.32	1.43e-12	Life satisfaction;
LGG	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg02002194	chr4:3960332	NA	0.39	6.73	0.3	5.19e-11	Triglycerides;
LGG	cis	rs8067545	0.603	rs10083830	chr17:19965883	G/A	cg13482628	chr17:19912719	NA	0.59	11.0	0.46	3.65e-25	Schizophrenia;
LGG	cis	rs7296418	0.885	rs1727305	chr12:123633382	T/C	cg00376283	chr12:123451042	ABCB9	0.67	12.3	0.5	2.82e-30	Platelet count;
LGG	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg07615347	chr10:60278583	BICC1	0.62	17.4	0.63	1.54e-52	Refractive error;
LGG	cis	rs1568889	1.000	rs7102106	chr11:28343953	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.97	0.54	2.96e-37	Bipolar disorder;
LGG	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.77	0.51	3.36e-32	Alzheimer's disease;
LGG	cis	rs10865541	0.935	rs4353680	chr2:3393188	T/C	cg13173536	chr2:3403300	TTC15	-0.33	-6.74	-0.3	4.82e-11	Obesity-related traits;
LGG	cis	rs4604732	0.642	rs7549312	chr1:247640078	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.55	0.37	1.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs62209	0.752	rs11256939	chr10:11009166	T/G	cg26901096	chr10:10994189	LOC254312	0.61	9.1	0.39	2.8e-18	Alzheimer's disease (late onset);
LGG	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg05444541	chr17:17804740	TOM1L2	-0.68	-15.68	-0.59	9.23e-45	Total body bone mineral density;
LGG	cis	rs1728785	1.000	rs1749791	chr16:68572347	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs708547	0.647	rs1718830	chr4:57888510	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg12070911	chr6:150209640	RAET1E	0.32	7.87	0.34	2.46e-14	Lung cancer;
LGG	cis	rs6504108	0.624	rs2060876	chr17:46322966	G/A	cg02219949	chr17:45927392	SP6	0.42	7.7	0.34	8.1e-14	Body mass index;
LGG	cis	rs1941023	0.584	rs950803	chr11:60152563	A/T	cg08716584	chr11:60157161	MS4A7	0.42	8.5	0.37	2.69e-16	Congenital heart disease (maternal effect);
LGG	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg18854424	chr1:2615690	NA	-0.35	-7.51	-0.33	3.16e-13	Ulcerative colitis;
LGG	cis	rs2180341	1.000	rs6569479	chr6:127606588	A/G	cg27446573	chr6:127587934	RNF146	1.08	21.01	0.7	2.59e-69	Breast cancer;
LGG	cis	rs758324	0.617	rs246842	chr5:131401801	C/T	cg06307176	chr5:131281290	NA	-0.46	-6.89	-0.3	1.85e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4363385	0.818	rs406350	chr1:153007492	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs2735413	0.564	rs74316728	chr16:78099653	C/T	cg04733911	chr16:78082701	NA	0.6	8.05	0.35	7.09e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.91	0.38	1.19e-17	Longevity;
LGG	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg17971929	chr21:40555470	PSMG1	-0.89	-17.39	-0.63	1.67e-52	Cognitive function;
LGG	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg18245976	chr7:158708271	WDR60	0.45	7.4	0.33	6.51e-13	Height;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-11.06	-0.46	2.22e-25	Neuroticism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04798930	chr2:37193060	STRN	0.4	6.85	0.3	2.34e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15506890	chr2:3487001	NA	-0.56	-10.53	-0.44	2.21e-23	Neurofibrillary tangles;
LGG	cis	rs4727027	0.804	rs13231262	chr7:148886058	C/T	cg23583168	chr7:148888333	NA	-0.88	-17.25	-0.63	7.46e-52	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs883565	0.696	rs6599007	chr3:39114445	A/C	cg01426195	chr3:39028469	NA	-0.7	-15.93	-0.6	6.94e-46	Handedness;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25072359	chr17:41440525	NA	0.54	10.21	0.43	3.17e-22	Menopause (age at onset);
LGG	cis	rs599083	0.530	rs491347	chr11:68169688	G/A	cg01657329	chr11:68192670	LRP5	0.62	10.23	0.43	2.85e-22	Bone mineral density (spine);
LGG	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg13385521	chr17:29058706	SUZ12P	0.79	8.81	0.38	2.46e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg01620082	chr3:125678407	NA	-0.59	-6.77	-0.3	3.9e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1555322	0.872	rs2425033	chr20:33855626	T/C	cg17927777	chr20:33865990	NA	0.64	7.99	0.35	1.06e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg08888203	chr3:10149979	C3orf24	0.54	9.18	0.39	1.42e-18	Alzheimer's disease;
LGG	cis	rs68170813	0.559	rs74387778	chr7:106963213	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.72e-22	Coronary artery disease;
LGG	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.62	0.33	1.4e-13	Total cholesterol levels;
LGG	cis	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-7.55	-0.33	2.38e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.82	-0.34	3.48e-14	Restless legs syndrome;
LGG	cis	rs3087591	0.960	rs4795587	chr17:29587917	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.32	-0.55	9.58e-39	Hip circumference;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg11965913	chr1:205819406	PM20D1	-0.49	-8.59	-0.37	1.37e-16	Menarche (age at onset);
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg11062466	chr8:58055876	NA	0.52	9.03	0.39	4.74e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg15596359	chr8:11213517	TDH	-0.34	-6.9	-0.31	1.69e-11	Retinal vascular caliber;
LGG	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg16141378	chr3:129829833	LOC729375	0.4	9.44	0.4	1.81e-19	Joint mobility (Beighton score);
LGG	cis	rs1270639	0.778	rs2530404	chr7:157445995	C/T	cg13357408	chr7:157437802	PTPRN2	-0.64	-10.45	-0.44	4.13e-23	Colorectal cancer;
LGG	cis	rs7824557	0.591	rs2060457	chr8:11213250	C/T	cg15596359	chr8:11213517	TDH	-0.41	-8.49	-0.37	2.77e-16	Retinal vascular caliber;
LGG	cis	rs3741151	0.773	rs73544767	chr11:73204619	C/T	cg17517138	chr11:73019481	ARHGEF17	0.85	8.16	0.35	3.24e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05665937	chr4:1216051	CTBP1	0.65	12.47	0.5	5.61e-31	Obesity-related traits;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg09858108	chr8:58055024	NA	0.42	6.64	0.3	8.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15369054	chr17:80825471	TBCD	-0.55	-9.47	-0.4	1.49e-19	Breast cancer;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.93	-0.31	1.43e-11	Lung cancer;
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.3	5.07e-11	Aortic root size;
LGG	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg09537434	chr19:41945824	ATP5SL	-0.88	-23.18	-0.73	1.83e-79	Height;
LGG	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.05	-0.31	6.69e-12	Educational attainment;
LGG	cis	rs4851254	0.626	rs71413861	chr2:100673501	A/G	cg17356467	chr2:100759845	AFF3	0.46	7.41	0.33	6.01e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.647	rs6814221	chr4:90805501	C/T	cg20003494	chr4:90757398	SNCA	-0.34	-6.66	-0.3	7.56e-11	Dementia with Lewy bodies;
LGG	cis	rs1793639	0.777	rs10894496	chr11:131967658	C/G	cg26088269	chr11:131983984	NTM	0.37	7.16	0.32	3.27e-12	Myopia;
LGG	cis	rs7833790	0.724	rs6473299	chr8:82676936	A/G	cg23324259	chr8:82754387	SNX16	-0.43	-6.88	-0.3	1.97e-11	Diastolic blood pressure;
LGG	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg03701759	chr13:99174930	STK24	-0.36	-6.98	-0.31	1.06e-11	Neuroticism;
LGG	cis	rs10426930	0.690	rs710956	chr19:5054510	T/C	cg08036796	chr19:5034282	KDM4B	-0.3	-6.71	-0.3	5.69e-11	Monocyte percentage of white cells;
LGG	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg04317338	chr11:64019027	PLCB3	0.64	7.75	0.34	5.88e-14	Mean platelet volume;
LGG	cis	rs3816183	0.626	rs4411758	chr2:42925165	G/A	cg14631114	chr2:43023945	NA	0.36	6.96	0.31	1.16e-11	Hypospadias;
LGG	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.55	0.44	1.81e-23	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23400208	chr10:60936031	PHYHIPL	0.4	6.65	0.3	8.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10083830	0.696	rs12949710	chr17:19977838	T/A	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Immature fraction of reticulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09295382	chr4:106068032	TET2	0.39	6.65	0.3	8.36e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11875185	0.510	rs111937485	chr18:55631656	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6138458	1.000	rs6114984	chr20:24976610	A/G	cg26195577	chr20:24973756	C20orf3	1.24	25.98	0.77	1.77e-92	Blood protein levels;
LGG	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.44	-8.97	-0.38	7.4e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg21605333	chr4:119757512	SEC24D	1.28	12.4	0.5	1.12e-30	Cannabis dependence symptom count;
LGG	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.93	0.35	1.71e-14	Response to antipsychotic treatment;
LGG	cis	rs1691799	0.899	rs2951656	chr12:66732273	T/G	cg16791601	chr12:66731901	HELB	-0.64	-14.98	-0.57	1.23e-41	White blood cell count (basophil);
LGG	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg13770153	chr20:60521292	NA	-0.54	-8.53	-0.37	2.17e-16	Body mass index;
LGG	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg01324343	chr3:183735012	ABCC5	0.87	18.31	0.65	9.85e-57	Anterior chamber depth;
LGG	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.28	0.5	3.21e-30	Cognitive test performance;
LGG	cis	rs3858526	0.834	rs10838989	chr11:5978057	A/G	cg05234568	chr11:5960015	NA	-0.66	-10.59	-0.44	1.35e-23	DNA methylation (variation);
LGG	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg01448562	chr3:133502909	NA	-0.55	-8.87	-0.38	1.65e-17	Iron status biomarkers;
LGG	cis	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.2e-12	Bladder cancer;
LGG	cis	rs12476592	0.602	rs262505	chr2:63861786	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.86	-0.3	2.27e-11	Childhood ear infection;
LGG	trans	rs35110281	0.805	rs2838318	chr21:44991825	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	10.15	0.43	5.24e-22	Mean corpuscular volume;
LGG	trans	rs61931739	0.620	rs815052	chr12:33727270	C/A	cg26384229	chr12:38710491	ALG10B	0.48	8.6	0.37	1.21e-16	Morning vs. evening chronotype;
LGG	trans	rs826838	0.806	rs826873	chr12:39121305	G/A	cg06521331	chr12:34319734	NA	0.43	7.69	0.34	8.85e-14	Heart rate;
LGG	cis	rs919433	0.519	rs700656	chr2:198653667	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.03	0.46	2.86e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg15596359	chr8:11213517	TDH	-0.4	-8.26	-0.36	1.55e-15	Retinal vascular caliber;
LGG	cis	rs9816226	0.591	rs77805826	chr3:185798025	C/T	cg00760338	chr3:185826511	ETV5	-0.83	-10.1	-0.42	8.14e-22	Obesity;Body mass index;
LGG	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-12.19	-0.49	7.78e-30	Migraine;Coronary artery disease;
LGG	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.66	-0.3	7.88e-11	Arsenic metabolism;
LGG	cis	rs300774	0.841	rs2926788	chr2:199410	G/A	cg04617936	chr2:214353	NA	0.59	8.49	0.37	2.85e-16	Suicide attempts in bipolar disorder;
LGG	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs8020289	1.000	rs7152947	chr14:77292093	C/T	cg23436960	chr14:77239540	VASH1	0.26	6.84	0.3	2.54e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	trans	rs1962073	0.507	rs7460226	chr8:10197718	A/G	cg02002194	chr4:3960332	NA	-0.4	-6.69	-0.3	6.31e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs2120243	0.874	rs2316709	chr3:157150247	C/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	6.93	0.31	1.37e-11	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9527	0.590	rs3740386	chr10:104931051	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-6.96	-0.31	1.2e-11	Arsenic metabolism;
LGG	cis	rs17818399	0.547	rs7607633	chr2:46759427	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-11.1	-0.46	1.49e-25	Height;
LGG	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-7.95	-0.35	1.44e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg25664220	chr3:72788482	NA	-0.33	-8.89	-0.38	1.33e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9790314	0.686	rs2306061	chr3:160787502	C/T	cg03342759	chr3:160939853	NMD3	-0.55	-9.12	-0.39	2.23e-18	Morning vs. evening chronotype;
LGG	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg26513180	chr16:89883248	FANCA	0.93	20.46	0.69	1.01e-66	Vitiligo;
LGG	cis	rs73086581	0.838	rs11906481	chr20:4028706	C/T	cg02187196	chr20:3869020	PANK2	0.67	9.45	0.4	1.71e-19	Response to antidepressants in depression;
LGG	cis	rs1007190	0.881	rs3744470	chr17:42983901	A/T	cg15406952	chr17:42872593	NA	1.08	13.8	0.54	1.62e-36	DNA methylation (variation);
LGG	cis	rs7474896	0.559	rs2753880	chr10:38173338	G/A	cg00409905	chr10:38381863	ZNF37A	0.51	7.58	0.33	1.92e-13	Obesity (extreme);
LGG	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs9929218	0.508	rs1559366	chr16:68799611	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	18.5	0.65	1.24e-57	Colorectal cancer;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.41	0.36	5.27e-16	Schizophrenia;
LGG	cis	rs7507204	0.680	rs12975645	chr19:3419132	A/G	cg08380311	chr19:3435252	NFIC	0.8	12.01	0.49	4.27e-29	Height;
LGG	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4319547	0.915	rs10773208	chr12:122970156	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.69	-10.31	-0.43	1.47e-22	Body mass index;
LGG	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg18252515	chr7:66147081	NA	-0.4	-6.89	-0.31	1.8e-11	Aortic root size;
LGG	cis	rs2404602	0.647	rs12903586	chr15:77168240	G/A	cg15268244	chr15:77196840	NA	0.48	10.16	0.43	5.08e-22	Blood metabolite levels;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.91	-0.42	4.16e-21	Personality dimensions;
LGG	cis	rs6714710	0.580	rs11690737	chr2:98461953	C/T	cg26665480	chr2:98280029	ACTR1B	0.58	9.47	0.4	1.49e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg23815491	chr16:72088622	HP	-0.5	-11.46	-0.47	6.15e-27	Fibrinogen levels;
LGG	cis	rs7726839	0.540	rs72703078	chr5:594987	A/C	cg01221209	chr5:554886	NA	-0.46	-6.98	-0.31	1.01e-11	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs2424713	chr20:25418482	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.28	0.43	1.77e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg11965913	chr1:205819406	PM20D1	0.95	23.04	0.73	8.4e-79	Menarche (age at onset);
LGG	trans	rs2204008	0.754	rs11181244	chr12:38302454	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.78e-17	Bladder cancer;
LGG	cis	rs12618769	0.597	rs72819981	chr2:99040696	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.39e-17	Bipolar disorder;
LGG	cis	rs988958	0.675	rs1866668	chr2:42222004	C/T	cg19376973	chr2:42229025	NA	0.62	9.72	0.41	1.8899999999999998e-20	Hypospadias;
LGG	cis	rs7666738	0.830	rs4699603	chr4:99056172	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17818399	0.547	rs4953400	chr2:46777208	T/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.12	0.31	4.02e-12	Height;
LGG	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg24812749	chr6:127587940	RNF146	0.96	16.0	0.6	3.62e-46	Breast cancer;
LGG	cis	rs2964802	0.505	rs7737359	chr5:10832104	A/G	cg14521931	chr5:10832172	NA	-0.73	-15.14	-0.58	2.38e-42	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.72	-0.3	5.21e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9682041	0.877	rs6804688	chr3:170071191	T/G	cg11886554	chr3:170076028	SKIL	0.66	8.82	0.38	2.38e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs240764	0.621	rs11155636	chr6:101201243	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-7.92	-0.35	1.82e-14	Neuroticism;
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.47	0.4	1.41e-19	Height;
LGG	cis	rs11098499	0.866	rs11098506	chr4:120284971	A/G	cg09307838	chr4:120376055	NA	0.73	12.25	0.49	4.47e-30	Corneal astigmatism;
LGG	cis	rs1355223	0.902	rs860712	chr11:34743494	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.25	-0.43	2.41e-22	Subjective well-being;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg04772025	chr11:68637568	NA	0.75	12.91	0.51	8.36e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg23166289	chr1:210001082	C1orf107	-0.39	-7.25	-0.32	1.72e-12	Orofacial clefts;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7512552	0.839	rs832622	chr1:150392830	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.14	0.39	1.91e-18	Motion sickness;
LGG	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.8	-0.34	4.21e-14	Myopia (pathological);
LGG	cis	rs9790314	0.586	rs16832279	chr3:161120483	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.87	-0.38	1.64e-17	Morning vs. evening chronotype;
LGG	cis	rs6732160	0.774	rs11890053	chr2:73373448	G/A	cg01422370	chr2:73384389	NA	0.54	10.47	0.44	3.7e-23	Intelligence (multi-trait analysis);
LGG	trans	rs9929218	1.000	rs28450087	chr16:68803726	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.86	-0.51	1.4e-32	Colorectal cancer;
LGG	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg27102117	chr16:15229624	NA	-0.56	-10.17	-0.43	4.63e-22	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6544311	0.531	rs6544310	chr2:40346502	C/T	cg17740179	chr2:40377776	SLC8A1	-0.45	-7.94	-0.35	1.55e-14	QT interval;
LGG	cis	rs8180040	0.900	rs4858894	chr3:47484953	C/G	cg16586182	chr3:47516702	SCAP	-0.77	-15.35	-0.58	2.75e-43	Colorectal cancer;
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg26769984	chr7:1090371	C7orf50	0.42	8.39	0.36	5.82e-16	Bronchopulmonary dysplasia;
LGG	cis	rs12153243	1.000	rs12153156	chr5:142898251	A/T	cg13907255	chr5:142895549	NA	-0.4	-7.58	-0.33	1.91e-13	Migraine;
LGG	cis	rs9815354	0.680	rs10510730	chr3:41849013	C/G	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1249910	0.695	rs13092258	chr3:112403171	C/G	cg02954903	chr3:112359935	CCDC80	0.41	7.29	0.32	1.39e-12	Diabetic kidney disease;
LGG	cis	rs3820068	0.608	rs12734937	chr1:16047726	T/C	cg05660106	chr1:15850417	CASP9	0.75	13.55	0.53	1.75e-35	Systolic blood pressure;
LGG	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg01028140	chr2:1542097	TPO	-0.52	-8.35	-0.36	8.08e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs754466	0.580	rs12357670	chr10:79558180	T/C	cg17075019	chr10:79541650	NA	-0.97	-21.03	-0.7	2.15e-69	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500395	0.928	rs2080509	chr16:48690915	T/C	cg04672837	chr16:48644449	N4BP1	-0.53	-8.84	-0.38	2e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2067615	0.579	rs10778502	chr12:107090201	T/C	cg15890332	chr12:107067104	RFX4	0.39	11.29	0.46	2.69e-26	Heart rate;
LGG	cis	rs986417	0.818	rs7156317	chr14:61087740	G/A	cg27398547	chr14:60952738	C14orf39	0.67	6.93	0.31	1.39e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7444	0.941	rs5998619	chr22:21945851	G/A	cg05046821	chr22:21984468	YDJC	-0.38	-6.93	-0.31	1.39e-11	Systemic lupus erythematosus;
LGG	cis	rs9303401	0.573	rs62081879	chr17:57181524	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.13e-17	Cognitive test performance;
LGG	cis	rs283228	0.837	rs2350100	chr6:101717977	T/C	cg27451362	chr6:101846650	GRIK2	0.57	8.76	0.38	3.66e-17	Coenzyme Q10 levels;
LGG	cis	rs7017914	0.967	rs6993170	chr8:71693519	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.87	-0.3	2.13e-11	Bone mineral density;
LGG	cis	rs62400317	0.723	rs1329709	chr6:44974956	G/T	cg20913747	chr6:44695427	NA	-0.66	-11.24	-0.46	4.56e-26	Total body bone mineral density;
LGG	cis	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-7.27	-0.32	1.54e-12	Neuroticism;
LGG	cis	rs6121246	0.909	rs7272062	chr20:30259145	A/G	cg13852791	chr20:30311386	BCL2L1	0.77	12.46	0.5	6.17e-31	Mean corpuscular hemoglobin;
LGG	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg04568710	chr12:38710424	ALG10B	0.39	8.22	0.36	2.04e-15	Morning vs. evening chronotype;
LGG	cis	rs7226408	0.857	rs2162389	chr18:34437033	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1550582	1.000	rs754234	chr8:135512875	A/G	cg17885191	chr8:135476712	NA	0.67	10.45	0.44	4.42e-23	Educational attainment;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg21724239	chr8:58056113	NA	0.45	7.0	0.31	9.02e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs13082711	0.911	rs34316374	chr3:27437385	G/C	cg02860705	chr3:27208620	NA	0.74	13.53	0.53	2.28e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3733585	0.699	rs7657340	chr4:9966772	A/T	cg08250081	chr4:10125330	NA	-0.35	-6.71	-0.3	5.8e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12136530	0.593	rs12403329	chr1:19735793	G/C	cg17081867	chr1:19768096	CAPZB	-0.32	-6.75	-0.3	4.32e-11	Lead levels in blood;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.4	0.47	1.05e-26	Schizophrenia;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg16141378	chr3:129829833	LOC729375	0.41	9.57	0.41	6.21e-20	Neuroticism;
LGG	cis	rs13260300	0.657	rs7843996	chr8:75496849	A/G	cg22993706	chr8:75542856	NA	0.37	7.02	0.31	7.96e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.52	-0.47	3.46e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9473924	0.505	rs7768747	chr6:50931762	G/A	cg14470998	chr6:50812995	TFAP2B	0.65	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs4918072	0.793	rs7918848	chr10:105701265	T/G	cg11005552	chr10:105648138	OBFC1	0.45	7.25	0.32	1.71e-12	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg09264619	chr17:80180166	NA	-0.36	-7.03	-0.31	7.6e-12	Life satisfaction;
LGG	cis	rs11514810	1.000	rs4076699	chr7:1435521	C/T	cg22426938	chr7:1423890	NA	-0.55	-6.9	-0.31	1.68e-11	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs6918586	0.658	rs198814	chr6:26127759	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.79	-0.41	1.05e-20	Schizophrenia;
LGG	cis	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg21775007	chr8:11205619	TDH	-0.43	-6.99	-0.31	9.93e-12	Systolic blood pressure;
LGG	cis	rs6141769	0.542	rs28548540	chr20:31294655	A/G	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.86	-0.3	2.16e-11	Subjective well-being;
LGG	trans	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.13	0.43	6.66e-22	Metabolite levels;
LGG	cis	rs1941023	0.606	rs7926219	chr11:60180335	C/T	cg08716584	chr11:60157161	MS4A7	-0.39	-7.57	-0.33	2e-13	Congenital heart disease (maternal effect);
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00933542	chr6:150070202	PCMT1	0.38	7.05	0.31	6.65e-12	Lung cancer;
LGG	cis	rs4789693	0.872	rs28612648	chr17:80403386	G/A	cg04308225	chr17:80449738	NA	0.59	8.56	0.37	1.73e-16	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs9389248	0.708	rs7750574	chr6:135350932	G/C	cg22676075	chr6:135203613	NA	0.43	7.56	0.33	2.23e-13	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9583531	0.660	rs61971611	chr13:111335319	C/T	cg24331049	chr13:111365604	ING1	-0.73	-7.46	-0.33	4.22e-13	Coronary artery disease;
LGG	cis	rs815815	0.608	rs815808	chr2:47381097	C/T	cg27223769	chr2:47403360	CALM2	0.6	8.79	0.38	3.05e-17	Dialysis-related mortality;
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg05484376	chr2:27715224	FNDC4	0.46	9.9	0.42	4.26e-21	Total body bone mineral density;
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.35	0.36	7.75e-16	Bipolar disorder;
LGG	cis	rs6558174	0.802	rs6558171	chr8:22487422	T/C	cg03733263	chr8:22462867	KIAA1967	0.62	9.81	0.41	8.82e-21	Breast cancer;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	9.77	0.41	1.25e-20	Tonsillectomy;
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg07936489	chr17:37558343	FBXL20	0.83	15.38	0.58	2e-43	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02571920	chr17:56084885	SFRS1	0.45	7.63	0.33	1.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Electroencephalogram traits;
LGG	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.24	-0.58	8.21e-43	Colorectal cancer;
LGG	cis	rs9296092	0.517	rs9461876	chr6:33516657	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.7	-0.69	7.11e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs785830	0.749	rs543379	chr9:265469	T/G	cg14500300	chr9:211689	NA	0.3	7.44	0.33	4.83e-13	Platelet distribution width;
LGG	cis	rs11098499	1.000	rs11726229	chr4:120211580	C/T	cg09307838	chr4:120376055	NA	0.69	11.18	0.46	7.3e-26	Corneal astigmatism;
LGG	trans	rs8002861	0.905	rs12874590	chr13:44433363	C/T	cg17145862	chr1:211918768	LPGAT1	-0.9	-20.79	-0.69	2.59e-68	Leprosy;
LGG	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs1465370	0.682	rs7811409	chr7:130024701	G/C	cg06917763	chr7:130033247	NA	0.36	7.8	0.34	4.2e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.37	0.32	7.75e-13	Neuroticism;
LGG	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg16586182	chr3:47516702	SCAP	-0.53	-8.9	-0.38	1.23e-17	Birth weight;
LGG	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.9	-0.42	4.31e-21	Glomerular filtration rate;
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs216026	0.689	rs216052	chr12:2766942	A/G	cg19945202	chr12:2788847	CACNA1C	0.64	9.44	0.4	1.86e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs704010	0.669	rs704008	chr10:80842552	A/G	cg17823346	chr10:80848143	ZMIZ1	0.3	7.02	0.31	7.85e-12	Breast cancer;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs701145	0.762	rs896014	chr3:153842691	A/G	cg12800244	chr3:153838788	SGEF	0.79	8.54	0.37	2e-16	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.92	-0.45	7.67e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1014246	0.826	rs11197802	chr10:118472000	T/A	cg14919929	chr10:118506882	NA	-0.62	-12.57	-0.5	2.15e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs698833	1.000	rs698834	chr2:44736957	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	7.17	0.32	3.02e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg12560992	chr17:57184187	TRIM37	0.54	8.61	0.37	1.12e-16	Testicular germ cell tumor;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.45	0.58	9.89e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2247341	0.965	rs1530588	chr4:1742779	G/A	cg08446824	chr4:1720184	TMEM129	-0.68	-12.83	-0.51	1.81e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs35740288	0.753	rs4843095	chr15:86275131	T/G	cg04173714	chr15:86211321	AKAP13	0.42	7.2	0.32	2.53e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs228769	0.562	rs228779	chr17:42091213	A/G	cg19774624	chr17:42201019	HDAC5	0.51	7.14	0.32	3.55e-12	Bone mineral density (hip);Bone mineral density (spine);
LGG	trans	rs9650657	0.769	rs1115866	chr8:10638333	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.85	-0.3	2.39e-11	Neuroticism;
LGG	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg03264133	chr6:25882463	NA	-0.44	-6.86	-0.3	2.15e-11	Iron status biomarkers;
LGG	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg16584290	chr5:462447	EXOC3	0.47	9.52	0.4	9.63e-20	Cystic fibrosis severity;
LGG	cis	rs7666738	0.925	rs2865952	chr4:99040305	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.64	0.3	8.62e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9473924	0.505	rs7738924	chr6:50850600	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg17294928	chr15:75287854	SCAMP5	-0.88	-8.5	-0.37	2.63e-16	Lung cancer;
LGG	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg08847533	chr14:75593920	NEK9	0.55	10.18	0.43	4.06e-22	Height;
LGG	trans	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg26043149	chr18:55253948	FECH	0.44	7.06	0.31	6.03e-12	Bone mineral density;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg08621203	chr6:150244597	RAET1G	0.44	7.08	0.31	5.42e-12	Lung cancer;
LGG	cis	rs6540556	0.723	rs6752	chr1:209908100	G/A	cg23920097	chr1:209922102	NA	-0.44	-7.4	-0.33	6.64e-13	Red blood cell count;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg16507663	chr6:150244633	RAET1G	0.45	8.3	0.36	1.13e-15	Lung cancer;
LGG	cis	rs439731	0.518	rs2260241	chr16:1075147	G/A	cg10140104	chr16:1060680	NA	-0.59	-8.59	-0.37	1.29e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg05973401	chr12:123451056	ABCB9	0.51	7.38	0.32	7.45e-13	Neutrophil percentage of white cells;
LGG	cis	rs7617773	0.780	rs7653336	chr3:48369464	T/A	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs34929064	0.536	rs2905306	chr7:22638818	C/T	cg23521230	chr7:22704884	NA	-0.43	-7.69	-0.34	8.65e-14	Major depression and alcohol dependence;
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.84	-0.3	2.53e-11	Total body bone mineral density;
LGG	cis	rs1707322	0.752	rs10789467	chr1:46118745	C/G	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.56	-0.47	2.53e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs75920871	1.000	rs79974099	chr11:116802581	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.0	-0.31	8.94e-12	Subjective well-being;
LGG	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg19508488	chr2:152266495	RIF1	0.6	10.74	0.45	3.63e-24	Lung cancer;
LGG	cis	rs3816183	0.547	rs7581704	chr2:42726886	G/C	cg14631114	chr2:43023945	NA	0.43	7.9	0.34	2.1e-14	Hypospadias;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12401738	chr4:39460100	LIAS;RPL9	-0.51	-7.82	-0.34	3.55e-14	Systemic lupus erythematosus;
LGG	cis	rs7917772	0.503	rs11191330	chr10:104306160	G/T	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-9.9	-0.42	4.32e-21	Common traits (Other);
LGG	cis	rs3806843	0.900	rs2563280	chr5:140131530	G/C	cg19875535	chr5:140030758	IK	-0.53	-10.98	-0.45	4.48e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.77	-0.54	2.07e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.83	-0.34	3.4e-14	Neuroticism;
LGG	cis	rs9771228	0.862	rs215625	chr7:32358313	G/A	cg27532318	chr7:32358331	NA	-0.43	-6.75	-0.3	4.47e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg08999081	chr20:33150536	PIGU	0.39	9.88	0.42	4.96e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs8032158	1.000	rs66462353	chr15:56186767	T/C	cg02198044	chr15:56286336	NEDD4	-0.71	-12.24	-0.49	5e-30	Keloid;
LGG	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.74	-0.45	3.47e-24	Vitiligo;
LGG	cis	rs760805	1.000	rs4649037	chr1:25258301	G/T	cg22509179	chr1:25234806	RUNX3	-0.66	-14.06	-0.55	1.18e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9300255	0.602	rs2851435	chr12:123712416	G/A	cg00376283	chr12:123451042	ABCB9	0.57	8.65	0.37	8.32e-17	Neutrophil percentage of white cells;
LGG	cis	rs5742933	0.857	rs13021611	chr2:190564764	A/T	cg04003228	chr2:190539410	ANKAR	-0.49	-7.14	-0.32	3.53e-12	Ferritin levels;
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg03517284	chr6:25882590	NA	-0.89	-17.07	-0.62	4.76e-51	Intelligence (multi-trait analysis);
LGG	cis	rs1883415	0.534	rs2760145	chr6:24478813	T/C	cg20631270	chr6:24437470	GPLD1	0.49	8.52	0.37	2.19e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.31	-0.43	1.38e-22	Hepatocellular carcinoma;
LGG	cis	rs8031584	0.652	rs2691683	chr15:31135060	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.54	8.1	0.35	5.06e-15	Huntington's disease progression;
LGG	cis	rs6087771	0.650	rs6060395	chr20:30219823	G/C	cg13852791	chr20:30311386	BCL2L1	0.83	13.38	0.53	9.2e-35	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.43	-7.11	-0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs9400467	0.537	rs12202418	chr6:111451467	A/G	cg15721981	chr6:111408429	SLC16A10	0.58	7.14	0.32	3.53e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.29	7.05	0.31	6.51e-12	Calcium levels;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg10505658	chr17:80084571	CCDC57	0.42	8.51	0.37	2.45e-16	Life satisfaction;
LGG	cis	rs12738007	0.933	rs61783707	chr1:29543700	A/T	cg01115565	chr1:29584222	PTPRU	-0.28	-7.37	-0.32	8.05e-13	Schizophrenia;
LGG	cis	rs526231	0.543	rs26258	chr5:102549721	A/C	cg23492399	chr5:102201601	PAM	-0.56	-8.24	-0.36	1.82e-15	Primary biliary cholangitis;
LGG	cis	rs7044106	0.791	rs10984995	chr9:123479210	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.58	0.61	8.16e-49	Hip circumference adjusted for BMI;
LGG	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg09904177	chr6:26538194	HMGN4	0.44	6.7	0.3	6.05e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08744769	chr2:70142523	MXD1	0.55	8.22	0.36	2.03e-15	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.621	rs3774800	chr3:49334768	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.67	-11.69	-0.48	7.85e-28	Menarche (age at onset);
LGG	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.73	-0.34	6.92e-14	Neuroticism;
LGG	cis	rs7129556	0.954	rs4509797	chr11:77263203	C/T	cg12586386	chr11:77299805	AQP11	-0.5	-8.47	-0.37	3.2e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.92	-0.35	1.81e-14	Morning vs. evening chronotype;
LGG	cis	rs10865541	0.869	rs6747650	chr2:3451507	G/A	cg11642891	chr2:3452563	TTC15	-0.4	-7.59	-0.33	1.74e-13	Obesity-related traits;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg21171335	chr12:122356390	WDR66	0.28	7.6	0.33	1.64e-13	Mean corpuscular volume;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.9	-19.21	-0.67	6.34e-61	Personality dimensions;
LGG	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg00631329	chr6:26305371	NA	-0.46	-7.69	-0.34	9.14e-14	Educational attainment;
LGG	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg23625390	chr15:77176239	SCAPER	-0.74	-14.79	-0.57	8.35e-41	Blood metabolite levels;
LGG	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs6964587	1.000	rs4727266	chr7:91570129	C/T	cg17063962	chr7:91808500	NA	-0.48	-8.59	-0.37	1.34e-16	Breast cancer;
LGG	cis	rs7843479	0.601	rs10109521	chr8:21829948	G/A	cg17168535	chr8:21777572	XPO7	0.81	15.9	0.59	9.6e-46	Mean corpuscular volume;
LGG	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs9914988	0.725	rs9905510	chr17:27092325	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12297814	chr1:201197846	IGFN1	0.4	7.57	0.33	2.1e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7639513	0.520	rs4684111	chr3:12729485	T/G	cg23032965	chr3:12705835	RAF1	0.73	11.54	0.47	3.12e-27	Itch intensity from mosquito bite;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17524854	chr12:67663046	CAND1	0.48	7.97	0.35	1.23e-14	Gut microbiome composition (summer);
LGG	trans	rs6921919	0.806	rs213230	chr6:28330264	A/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.74	-0.3	4.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg11764359	chr7:65958608	NA	-0.63	-10.96	-0.45	5.08e-25	Aortic root size;
LGG	trans	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.84	-0.42	6.87e-21	Morning vs. evening chronotype;
LGG	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg12751644	chr20:60527061	NA	-0.3	-6.72	-0.3	5.19e-11	Body mass index;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.57	0.37	1.54e-16	Alzheimer's disease;
LGG	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03970501	chr16:22202118	NA	0.46	6.78	0.3	3.73e-11	Gut microbiome composition (summer);
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04772025	chr11:68637568	NA	0.77	13.8	0.54	1.59e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg08994789	chr17:28903642	LRRC37B2	0.72	9.19	0.39	1.31e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg13010199	chr12:38710504	ALG10B	0.52	10.06	0.42	1.13e-21	Morning vs. evening chronotype;
LGG	cis	rs17604090	0.877	rs57253003	chr7:29686556	T/C	cg19413766	chr7:29689036	LOC646762	-0.62	-7.94	-0.35	1.59e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg12458913	chr13:53173898	NA	0.51	8.65	0.37	8.26e-17	Lewy body disease;
LGG	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg13271783	chr10:134563150	INPP5A	-0.49	-7.85	-0.34	2.97e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg16606324	chr3:10149918	C3orf24	0.53	6.97	0.31	1.13e-11	Alzheimer's disease;
LGG	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.39	-0.4	2.79e-19	Height;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-9.04	-0.39	4.44e-18	Lung function (FEV1/FVC);
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.32	-0.32	1.14e-12	Joint mobility (Beighton score);
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg17911788	chr17:44343683	NA	0.62	9.47	0.4	1.47e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg19847130	chr8:10466454	RP1L1	0.33	6.89	0.3	1.83e-11	Neuroticism;
LGG	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.86	0.51	1.36e-32	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg04267008	chr7:1944627	MAD1L1	-0.46	-7.85	-0.34	2.87e-14	Schizophrenia;
LGG	cis	rs138249	0.699	rs138221	chr22:50555299	G/T	cg07310406	chr22:50524374	MLC1	0.4	7.86	0.34	2.72e-14	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03537747	chr2:27886640	SLC4A1AP;SUPT7L	0.46	7.66	0.34	1.07e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6735179	0.755	rs13421140	chr2:1774009	C/T	cg10160682	chr2:1713001	PXDN	-0.5	-7.77	-0.34	5.03e-14	Response to antipsychotic treatment;
LGG	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.12e-11	Total body bone mineral density;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9513627	1.000	rs2147625	chr13:100140645	G/T	cg25919922	chr13:100150906	NA	0.74	7.98	0.35	1.13e-14	Obesity-related traits;
LGG	cis	rs10463316	0.894	rs6579865	chr5:150762335	A/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg03437886	chr1:178698946	RALGPS2	-0.35	-6.65	-0.3	8.36e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.64	-0.54	7.77e-36	Response to antipsychotic treatment;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24478630	chr2:74692696	MOGS	0.4	7.09	0.31	4.9e-12	Obesity-related traits;
LGG	cis	rs9948	1.000	rs59244622	chr2:97501632	C/T	cg01990225	chr2:97406019	LMAN2L	-0.64	-6.84	-0.3	2.59e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs7394190	0.748	rs3781216	chr10:75522404	G/A	cg07699608	chr10:75541558	CHCHD1	0.54	7.05	0.31	6.33e-12	Incident atrial fibrillation;
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg11360546	chr7:1094263	C7orf50	0.38	6.82	0.3	2.86e-11	Longevity;Endometriosis;
LGG	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg09021430	chr5:549028	NA	-0.81	-12.83	-0.51	1.8e-32	Obesity-related traits;
LGG	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg04287289	chr16:89883240	FANCA	0.8	16.57	0.61	9.15e-49	Vitiligo;
LGG	cis	rs12618769	0.597	rs1847550	chr2:99052299	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.64	-10.7	-0.45	4.88e-24	Renal function-related traits (BUN);
LGG	cis	rs9487094	0.670	rs2024849	chr6:109818291	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.0	0.35	1.04e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.02	0.31	8.12e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6604026	0.922	rs11586570	chr1:93305371	A/C	cg22128645	chr1:93425802	FAM69A	-0.41	-7.7	-0.34	8.06e-14	Multiple sclerosis;
LGG	cis	rs651907	0.967	rs641432	chr3:101587566	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.38	7.37	0.32	7.89e-13	Colorectal cancer;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.63	-0.37	1.02e-16	Prudent dietary pattern;
LGG	cis	rs537930	0.925	rs299365	chr5:134332469	T/G	cg24576358	chr5:134350122	NA	0.45	9.24	0.39	8.87e-19	Height;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg18404041	chr3:52824283	ITIH1	0.55	10.56	0.44	1.73e-23	Bipolar disorder;
LGG	cis	rs2658782	0.789	rs56091149	chr11:93073640	A/C	cg15737290	chr11:93063684	CCDC67	-0.64	-9.31	-0.4	5.31e-19	Pulmonary function decline;
LGG	cis	rs3806933	0.522	rs11241095	chr5:110439509	A/G	cg04022379	chr5:110408740	TSLP	0.48	8.01	0.35	9.46e-15	Eosinophilic esophagitis;
LGG	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg07636037	chr3:49044803	WDR6	0.96	20.81	0.7	2.14e-68	Menarche (age at onset);
LGG	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg12223502	chr10:5658492	NA	0.36	6.95	0.31	1.28e-11	Breast cancer;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.07	-0.31	5.68e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg13565492	chr6:43139072	SRF	-0.82	-14.3	-0.55	1.09e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07077507	chr14:89290791	TTC8	0.49	8.34	0.36	8.72e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg10523679	chr1:76189770	ACADM	0.81	14.77	0.57	9.91e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11225247	1.000	rs78847320	chr11:102301890	G/A	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs6088590	0.561	rs2295444	chr20:33173883	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.55	0.47	2.71e-27	Coronary artery disease;
LGG	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.37e-12	Electroencephalogram traits;
LGG	cis	rs11122272	0.705	rs2486742	chr1:231507254	G/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.25e-13	Hemoglobin concentration;
LGG	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg13852791	chr20:30311386	BCL2L1	0.67	8.89	0.38	1.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2133450	0.526	rs56129834	chr3:7345582	A/T	cg19930620	chr3:7340148	GRM7	-0.42	-9.41	-0.4	2.24e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs2635047	0.638	rs2571008	chr18:44649950	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.12	0.31	4.22e-12	Educational attainment;
LGG	cis	rs9790314	1.000	rs9850455	chr3:161017192	G/A	cg03342759	chr3:160939853	NMD3	-0.65	-11.89	-0.48	1.21e-28	Morning vs. evening chronotype;
LGG	cis	rs7551222	0.647	rs3014606	chr1:204464150	C/G	cg20240347	chr1:204465584	NA	0.45	7.85	0.34	2.96e-14	Schizophrenia;
LGG	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg14782152	chr13:114913410	NA	-0.33	-6.67	-0.3	7.21e-11	Schizophrenia;
LGG	cis	rs227833	1.000	rs227835	chr6:44682316	A/G	cg20913747	chr6:44695427	NA	0.46	7.86	0.34	2.79e-14	Monobrow;
LGG	cis	rs3806843	0.576	rs246028	chr5:140333513	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.77	0.3	3.99e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs4262150	0.810	rs72799107	chr5:152053404	C/T	cg12297329	chr5:152029980	NA	-0.81	-15.25	-0.58	7.72e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs79839061	0.656	rs28662837	chr4:879776	G/A	cg07828340	chr4:882639	GAK	0.93	9.96	0.42	2.68e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg14983838	chr19:29218262	NA	0.71	11.76	0.48	4.09e-28	Methadone dose in opioid dependence;
LGG	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05901451	chr6:126070800	HEY2	-0.83	-17.91	-0.64	6.95e-55	Brugada syndrome;
LGG	cis	rs40363	0.645	rs250630	chr16:3524242	C/T	cg21433313	chr16:3507492	NAT15	0.41	6.65	0.3	8.44e-11	Tuberculosis;
LGG	cis	rs10979	1.000	rs6905264	chr6:143894378	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.42	0.36	4.59e-16	Neuroticism;
LGG	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.34	0.43	1.09e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.75	-0.9	6.77e-174	Myeloid white cell count;
LGG	cis	rs2201728	0.677	rs13134764	chr4:100212173	A/T	cg07219303	chr4:100140905	ADH6	-0.36	-6.65	-0.3	8.49e-11	Cardiac Troponin-T levels;
LGG	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg15522984	chr1:182991683	LAMC1	-0.49	-10.19	-0.43	3.85e-22	Colorectal cancer;
LGG	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg09307838	chr4:120376055	NA	-0.81	-13.62	-0.53	9.08e-36	Corneal astigmatism;
LGG	cis	rs7572733	0.514	rs770659	chr2:198669754	G/C	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Dermatomyositis;
LGG	cis	rs600231	0.665	rs12790095	chr11:65326086	T/G	cg17120908	chr11:65337727	SSSCA1	-0.63	-11.05	-0.46	2.27e-25	Bone mineral density;
LGG	cis	rs17122278	1.000	rs17092756	chr11:118457630	G/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs79349575	0.783	rs4793995	chr17:47019399	A/C	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs2070488	0.965	rs7372386	chr3:38484175	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.65	0.63	1.1e-53	Electrocardiographic conduction measures;
LGG	cis	rs7619833	0.542	rs11129287	chr3:27497310	C/T	cg02860705	chr3:27208620	NA	0.46	8.91	0.38	1.2e-17	Breast cancer;
LGG	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-16.28	-0.6	1.86e-47	Lymphocyte percentage of white cells;
LGG	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs6089584	0.606	rs2273989	chr20:60579138	G/A	cg06108461	chr20:60628389	TAF4	-0.68	-12.17	-0.49	8.97e-30	Body mass index;
LGG	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg11657817	chr20:23433608	CST11	0.4	8.07	0.35	6.2e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg19147804	chr7:1989927	MAD1L1	0.53	10.08	0.42	1.01e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.67	0.3	7.25e-11	Electroencephalogram traits;
LGG	cis	rs2905347	0.624	rs2905323	chr7:22705723	T/C	cg18045685	chr7:22629474	NA	-0.73	-15.54	-0.59	3.86e-44	Major depression and alcohol dependence;
LGG	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.89	-0.34	2.18e-14	Colorectal cancer;
LGG	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs12422267	0.536	rs58521339	chr12:132609486	T/C	cg09764611	chr12:132620959	NA	-0.56	-8.37	-0.36	6.86e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs28489187	0.683	rs1554597	chr1:85877098	C/T	cg16011679	chr1:85725395	C1orf52	-0.34	-6.74	-0.3	4.79e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs1124376	0.748	rs67713322	chr3:20148258	G/T	cg05072819	chr3:20081367	KAT2B	0.62	8.37	0.36	6.66e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7717393	0.786	rs17053449	chr5:155769993	A/G	cg12904904	chr5:155754151	SGCD	-0.61	-6.76	-0.3	4.09e-11	Egg allergy;
LGG	cis	rs7582720	1.000	rs72934745	chr2:203744454	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.67	0.41	2.78e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg04861929	chr11:109293070	C11orf87	0.51	9.47	0.4	1.45e-19	Schizophrenia;
LGG	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.68	0.3	6.9e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg00294572	chr6:26285232	NA	0.42	7.82	0.34	3.73e-14	Educational attainment;
LGG	cis	rs963731	0.649	rs1869514	chr2:39205796	C/T	cg04010122	chr2:39346883	SOS1	-0.73	-6.64	-0.3	8.56e-11	Corticobasal degeneration;
LGG	cis	rs17767392	0.958	rs2108049	chr14:71962394	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.23	-0.39	9.94e-19	Mitral valve prolapse;
LGG	cis	rs1847202	0.859	rs6805260	chr3:72933767	C/T	cg25664220	chr3:72788482	NA	-0.26	-7.59	-0.33	1.82e-13	Motion sickness;
LGG	cis	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg12591125	chr7:1885375	MAD1L1	0.48	7.43	0.33	5.39e-13	Bipolar disorder;
LGG	cis	rs10870270	1.000	rs10870232	chr10:133738537	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.84	-0.51	1.76e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg06521331	chr12:34319734	NA	0.44	8.05	0.35	7.06e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4538187	1.000	rs7590399	chr2:64081466	C/A	cg02541582	chr2:64069798	UGP2	0.6	14.1	0.55	7.75e-38	Systolic blood pressure;
LGG	cis	rs6952809	0.532	rs10272548	chr7:2439467	G/A	cg23289794	chr7:2394357	EIF3B	-0.8	-10.1	-0.42	8.62e-22	Multiple sclerosis;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg16583315	chr14:65563665	MAX	0.4	8.12	0.35	4.32e-15	Obesity-related traits;
LGG	cis	rs10884984	0.739	rs4918524	chr10:112281786	C/T	cg18756771	chr10:112261994	DUSP5	-0.72	-13.24	-0.52	3.79e-34	Facial morphology (factor 22);
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg07677032	chr17:61819896	STRADA	0.65	11.8	0.48	2.7e-28	Prudent dietary pattern;
LGG	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg17023122	chr1:144479586	NA	0.31	6.86	0.3	2.26e-11	Hip geometry;
LGG	cis	rs708547	0.647	rs12621	chr4:57897570	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	8.53	0.37	2.09e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs2710642	0.962	rs7567923	chr2:63085848	C/T	cg17519650	chr2:63277830	OTX1	-0.49	-8.07	-0.35	6.28e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs2013441	0.579	rs34370440	chr17:20003430	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.68	-0.3	6.89e-11	Obesity-related traits;
LGG	cis	rs1909881	0.935	rs55786995	chr8:96504299	T/C	cg04203453	chr8:96504381	NA	-1.09	-18.48	-0.65	1.56e-57	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs4973053	chr2:233670099	G/A	cg25237894	chr2:233734115	C2orf82	-0.66	-12.58	-0.5	1.95e-31	Coronary artery disease;
LGG	cis	rs919433	0.679	rs6757632	chr2:198530266	C/T	cg00792783	chr2:198669748	PLCL1	0.55	8.99	0.39	6.36e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17453880	0.929	rs55869831	chr5:151957634	A/C	cg12297329	chr5:152029980	NA	-0.87	-22.15	-0.72	1.16e-74	Subjective well-being;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.26	-0.7	1.77e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.22	-0.36	2.02e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs62400317	0.859	rs62400313	chr6:45256366	A/T	cg20913747	chr6:44695427	NA	-0.61	-10.22	-0.43	3.02e-22	Total body bone mineral density;
LGG	cis	rs10752881	1.000	rs12403189	chr1:182983832	G/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.76	0.34	5.63e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9902453	0.934	rs4427857	chr17:28457989	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.14	0.52	9.37e-34	Coffee consumption (cups per day);
LGG	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs896854	0.967	rs13257021	chr8:95965695	A/G	cg13393036	chr8:95962371	TP53INP1	-0.27	-7.17	-0.32	2.93e-12	Type 2 diabetes;
LGG	cis	rs4732038	0.625	rs782878	chr7:134233011	A/G	cg06906464	chr7:134288099	NA	-0.49	-11.03	-0.46	2.74e-25	Longevity;
LGG	cis	rs1008375	0.900	rs3822235	chr4:17694916	C/T	cg02297831	chr4:17616191	MED28	-0.42	-7.56	-0.33	2.24e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-17.86	-0.64	1.22e-54	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2273669	0.667	rs12201821	chr6:109340291	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs3735485	0.843	rs4724340	chr7:45035122	C/T	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg18129748	chr3:49941408	MST1R	-0.22	-6.99	-0.31	9.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16680214	chr1:154839983	KCNN3	-0.49	-9.75	-0.41	1.46e-20	Prostate cancer;
LGG	cis	rs10927875	0.550	rs12121918	chr1:16183556	C/A	cg07117364	chr1:16154769	NA	-0.51	-7.51	-0.33	3.03e-13	Dilated cardiomyopathy;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	7.87	0.34	2.6e-14	Longevity;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg22753661	chr15:79092743	ADAMTS7	0.41	6.98	0.31	1.02e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg04608330	chr12:45269318	NELL2	-0.63	-11.08	-0.46	1.82e-25	Gut microbiome composition (summer);
LGG	cis	rs6580649	0.941	rs57054831	chr12:48486892	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs9547692	0.878	rs9531990	chr13:37449605	T/C	cg01493522	chr13:37497338	NA	-0.51	-8.5	-0.37	2.59e-16	Coronary artery disease;
LGG	cis	rs4246215	1	rs4246215	chr11:61564299	G/T	cg19610905	chr11:61596333	FADS2	-0.77	-14.28	-0.55	1.33e-38	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);Platelet count;Inflammatory bowel disease;Trans fatty acid levels;Crohn's disease;Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);Red blood cell fatty acid levels;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);
LGG	cis	rs72781680	0.848	rs715646	chr2:24010566	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20887711	chr4:1340912	KIAA1530	0.51	9.53	0.4	8.85e-20	Obesity-related traits;
LGG	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg17046650	chr2:3699563	NA	0.97	11.0	0.46	3.73e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3857067	0.804	rs6821438	chr4:95091911	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.81	-0.34	3.84e-14	QT interval;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg21724239	chr8:58056113	NA	0.6	9.25	0.39	8.61e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.93	-0.45	6.77e-25	Lung cancer;
LGG	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-11.77	-0.48	3.6e-28	Morning vs. evening chronotype;
LGG	cis	rs1957429	0.614	rs1957416	chr14:65369329	C/T	cg23373153	chr14:65346875	NA	-0.94	-9.15	-0.39	1.8e-18	Pediatric areal bone mineral density (radius);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11317343	chr5:177580912	NHP2	0.52	7.9	0.34	2.1e-14	Gut microbiome composition (summer);
LGG	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg02985381	chr13:37494744	SMAD9	0.69	12.17	0.49	9.51e-30	Coronary artery disease;
LGG	cis	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg24308560	chr3:49941425	MST1R	0.22	6.88	0.3	1.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7769051	0.522	rs73550455	chr6:133096633	A/G	cg22852734	chr6:133119734	C6orf192	1.29	10.29	0.43	1.68e-22	Type 2 diabetes nephropathy;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs9325144	0.560	rs2387923	chr12:38662677	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.7e-51	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg14675211	chr2:100938903	LONRF2	0.47	7.38	0.32	7.61e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2798269	0.831	rs11148157	chr13:22137608	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.71	-13.24	-0.52	3.81e-34	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05025164	chr4:1340916	KIAA1530	0.47	8.06	0.35	6.42e-15	Obesity-related traits;
LGG	cis	rs244731	1.000	rs244729	chr5:176539018	C/G	cg17509989	chr5:176798049	RGS14	0.5	7.01	0.31	8.34e-12	Urate levels in lean individuals;
LGG	cis	rs1927790	0.727	rs4771932	chr13:96950542	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.99	-0.31	9.95e-12	Body mass index;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs9457247	1.000	rs385113	chr6:167403971	A/G	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs7255045	0.665	rs2014639	chr19:12975021	G/C	cg07955356	chr19:12992479	DNASE2	0.44	6.83	0.3	2.69e-11	Mean corpuscular volume;
LGG	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.95	-0.38	8.48e-18	Lung cancer;
LGG	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg01620082	chr3:125678407	NA	-0.58	-7.31	-0.32	1.16e-12	Depression;
LGG	cis	rs861020	0.630	rs655713	chr1:210006438	C/T	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs4665809	0.590	rs13016300	chr2:26468365	G/C	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs11785693	0.862	rs11784262	chr8:4996942	G/A	cg26367366	chr8:4980734	NA	0.99	15.07	0.57	5.05e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.62	-0.41	4.33e-20	Response to antipsychotic treatment;
LGG	cis	rs1185460	0.546	rs2508948	chr11:118951642	A/T	cg24687335	chr11:118901407	SLC37A4	-0.58	-10.15	-0.43	5.45e-22	Coronary artery disease;
LGG	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.61	0.33	1.51e-13	Neuroticism;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.5	-0.33	3.19e-13	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs2402757	chr7:124611713	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs3820928	0.874	rs13393894	chr2:227880543	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.65	-0.34	1.16e-13	Pulmonary function;
LGG	cis	rs2549003	1.000	rs2070723	chr5:131823187	A/G	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	trans	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg14791747	chr16:20752902	THUMPD1	0.51	7.53	0.33	2.6e-13	Cognitive test performance;
LGG	cis	rs2617583	0.967	rs2617594	chr5:1448288	A/G	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.1	-0.31	4.74e-12	Breast cancer;
LGG	cis	rs4481887	0.741	rs6682953	chr1:248535626	T/C	cg00666640	chr1:248458726	OR2T12	0.53	8.95	0.38	8.65e-18	Common traits (Other);
LGG	cis	rs4474465	1.000	rs2063726	chr11:78183533	T/C	cg02023728	chr11:77925099	USP35	0.39	6.8	0.3	3.17e-11	Alzheimer's disease (survival time);
LGG	cis	rs10751667	0.666	rs4074235	chr11:977511	C/G	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs9783347	1.000	rs9988866	chr11:18392983	A/T	cg15585147	chr11:18324498	HPS5	0.42	8.81	0.38	2.56e-17	Pancreatic cancer;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg04863758	chr4:1303710	MAEA	0.42	7.24	0.32	1.84e-12	Obesity-related traits;
LGG	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg17545662	chr6:170176663	C6orf70	0.7	8.94	0.38	9.05e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.32	0.43	1.35e-22	Motion sickness;
LGG	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.31	0.55	9.79e-39	IgG glycosylation;
LGG	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg10792982	chr14:105748885	BRF1	0.56	11.14	0.46	1.04e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.61e-12	Bipolar disorder;
LGG	cis	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg06609049	chr19:2785107	THOP1	0.96	16.0	0.6	3.42e-46	Total cholesterol levels;
LGG	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg16386425	chr10:429943	DIP2C	0.41	7.74	0.34	6.4e-14	Psychosis in Alzheimer's disease;
LGG	trans	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.94	-0.38	9.68e-18	Mean corpuscular volume;
LGG	cis	rs2421770	0.561	rs3899569	chr11:35358513	C/T	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.61	-0.33	1.53e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-9.7	-0.41	2.19e-20	Common traits (Other);
LGG	cis	rs975722	0.638	rs7779353	chr7:117327512	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.46	-9.62	-0.41	4.19e-20	Coronary artery disease;
LGG	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg13010199	chr12:38710504	ALG10B	0.76	16.24	0.6	2.86e-47	Heart rate;
LGG	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg20488157	chr14:104394430	TDRD9	-0.56	-8.96	-0.38	8.02e-18	Bipolar disorder;
LGG	cis	rs8179	0.514	rs10269774	chr7:92253972	A/G	cg15732164	chr7:92237376	CDK6	0.47	10.04	0.42	1.37e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs1991651	0.578	rs13259086	chr8:10490218	G/C	cg15556689	chr8:8085844	FLJ10661	0.4	6.8	0.3	3.16e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg00405596	chr8:11794950	NA	0.44	7.4	0.33	6.6e-13	Mood instability;
LGG	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.08e-14	Vitiligo;
LGG	trans	rs9964724	0.582	rs11662561	chr18:35198916	C/T	cg22027860	chr2:113033717	ZC3H6	-0.49	-6.67	-0.3	7.3e-11	Educational attainment (years of education);
LGG	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.06e-15	Breast cancer;
LGG	cis	rs2760061	0.626	rs672977	chr1:228120288	A/C	cg02753203	chr1:228287806	NA	-0.64	-11.95	-0.49	6.97e-29	Diastolic blood pressure;
LGG	cis	rs11677416	1.000	rs1878321	chr2:113544434	A/G	cg27083787	chr2:113543245	IL1A	0.53	8.82	0.38	2.35e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2735413	0.837	rs4888735	chr16:78083742	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg25287198	chr4:183728479	NA	0.48	7.67	0.34	1.03e-13	Pediatric autoimmune diseases;
LGG	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs433406	0.733	rs2512656	chr11:131371921	T/C	cg27203895	chr11:131369037	NTM	0.78	18.35	0.65	6.67e-57	Male fertility;
LGG	cis	rs2439831	0.681	rs3742969	chr15:43621947	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	12.72	0.51	5.2e-32	Lung cancer in ever smokers;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs112591243	0.685	rs2839282	chr21:47902822	C/G	cg10657630	chr21:48055338	PRMT2	-0.85	-7.24	-0.32	1.85e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs5756391	0.546	rs9610607	chr22:37315759	T/C	cg21209356	chr22:37319042	CSF2RB	0.41	9.32	0.4	4.64e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg10505658	chr17:80084571	CCDC57	-0.39	-7.9	-0.34	2.08e-14	Life satisfaction;
LGG	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg25019033	chr10:957182	NA	-0.55	-10.08	-0.42	9.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg00531865	chr16:30841666	NA	-0.62	-13.25	-0.52	3.47e-34	Multiple myeloma;
LGG	cis	rs2708977	1.000	rs2708977	chr2:97230074	G/A	cg01950434	chr2:97203154	ARID5A	-0.6	-9.62	-0.41	4.13e-20	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg00938859	chr5:1591904	SDHAP3	0.84	12.11	0.49	1.67e-29	Breast cancer;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs151997	0.893	rs27607	chr5:50228977	A/G	cg06027927	chr5:50259733	NA	-0.63	-10.44	-0.44	4.63e-23	Callous-unemotional behaviour;
LGG	trans	rs561341	0.783	rs512698	chr17:30292507	G/T	cg20587970	chr11:113659929	NA	-1.34	-24.01	-0.74	2.48e-83	Hip circumference adjusted for BMI;
LGG	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24110177	chr3:50126178	RBM5	-0.57	-10.48	-0.44	3.3e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg19847130	chr8:10466454	RP1L1	0.34	7.57	0.33	2.05e-13	Neuroticism;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg21618713	chr4:153701330	ARFIP1;TIGD4	0.42	6.91	0.31	1.6e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1008375	1.000	rs4698198	chr4:17656536	G/A	cg15017067	chr4:17643749	FAM184B	0.32	7.43	0.33	5.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15557168	chr22:42548783	NA	-0.38	-8.55	-0.37	1.74e-16	Cognitive function;
LGG	cis	rs6665290	0.904	rs6690803	chr1:227189106	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.84	-0.34	3.03e-14	Myeloid white cell count;
LGG	cis	rs6963495	0.818	rs73190200	chr7:105165856	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4851266	0.966	rs13017207	chr2:100841235	G/A	cg21926883	chr2:100939477	LONRF2	-0.44	-7.93	-0.35	1.66e-14	Educational attainment;
LGG	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg12292205	chr6:26970375	C6orf41	-0.75	-15.05	-0.57	5.67e-42	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg21138405	chr5:131827807	IRF1	0.38	10.04	0.42	1.33e-21	Asthma (sex interaction);
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg19168338	chr16:4465731	CORO7	0.73	13.11	0.52	1.26e-33	Schizophrenia;
LGG	cis	rs11676348	0.846	rs4674257	chr2:218988774	A/G	cg00012203	chr2:219082015	ARPC2	-0.55	-9.78	-0.41	1.16e-20	Ulcerative colitis;
LGG	trans	rs9929218	0.954	rs57688464	chr16:68826109	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-12.0	-0.49	4.69e-29	Colorectal cancer;
LGG	cis	rs8114671	0.836	rs6060140	chr20:33566507	G/A	cg24642439	chr20:33292090	TP53INP2	0.52	8.44	0.37	4e-16	Height;
LGG	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22968622	chr17:43663579	NA	-0.78	-15.06	-0.57	5.29e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23291098	chr14:68283748	ZFYVE26	-0.47	-6.9	-0.31	1.69e-11	Systemic lupus erythematosus;
LGG	cis	rs7000551	0.505	rs4872499	chr8:22293306	A/G	cg12081754	chr8:22256438	SLC39A14	-0.93	-16.29	-0.6	1.73e-47	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg27476859	chr7:2772710	GNA12	-0.74	-13.92	-0.54	4.76e-37	Loneliness (linear analysis);
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.78	-15.52	-0.59	4.74e-44	Longevity;Endometriosis;
LGG	cis	rs950169	0.810	rs2879976	chr15:85109578	G/A	cg03959625	chr15:84868606	LOC388152	0.58	9.32	0.4	4.85e-19	Schizophrenia;
LGG	cis	rs9815354	0.812	rs4434125	chr3:42004681	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg06558623	chr16:89946397	TCF25	1.21	14.11	0.55	7.42e-38	Skin colour saturation;
LGG	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.54	0.5	2.93e-31	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg01673284	chr16:4527211	HMOX2	0.33	6.85	0.3	2.42e-11	Schizophrenia;
LGG	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg16339924	chr4:17578868	LAP3	0.61	10.49	0.44	2.96e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2694528	1.000	rs162246	chr5:60290686	G/A	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.57	-0.33	2.07e-13	Parkinson's disease;
LGG	cis	rs9462027	0.727	rs3798352	chr6:34734809	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.1	-0.46	1.53e-25	Systemic lupus erythematosus;
LGG	cis	rs754466	0.580	rs10430529	chr10:79582623	C/A	cg17075019	chr10:79541650	NA	-0.97	-21.13	-0.7	6.8e-70	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2180341	0.618	rs4502958	chr6:127593113	G/A	cg24812749	chr6:127587940	RNF146	0.64	10.79	0.45	2.28e-24	Breast cancer;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg01262667	chr19:19385393	TM6SF2	0.47	11.85	0.48	1.79e-28	Tonsillectomy;
LGG	cis	rs8017423	0.967	rs7147952	chr14:90720831	G/A	cg04374321	chr14:90722782	PSMC1	0.89	18.93	0.66	1.29e-59	Mortality in heart failure;
LGG	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.95	0.68	2.36e-64	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs888194	0.738	rs10850358	chr12:109991050	A/G	cg19025524	chr12:109796872	NA	-0.35	-7.06	-0.31	5.99e-12	Neuroticism;
LGG	cis	rs2032447	0.839	rs6901039	chr6:26000885	A/C	cg12310025	chr6:25882481	NA	-0.56	-9.92	-0.42	3.73e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11890956	chr21:40555474	PSMG1	-0.71	-12.28	-0.5	3.23e-30	Menarche (age at onset);
LGG	cis	rs11885103	0.818	rs2724912	chr2:593301	A/G	cg21195176	chr2:593345	NA	0.42	7.94	0.35	1.56e-14	Heschl's gyrus morphology;
LGG	cis	rs12155623	0.834	rs16939055	chr8:49824013	T/G	cg22283653	chr8:49824208	NA	0.52	9.55	0.41	7.62e-20	Sudden cardiac arrest;
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.25	-0.43	2.35e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7811417	0.505	rs1473119	chr7:21564835	A/G	cg03697024	chr7:21583438	DNAH11	-0.3	-7.16	-0.32	3.17e-12	Schizophrenia;
LGG	cis	rs9902453	0.689	rs56788338	chr17:28186557	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.38	0.56	4.82e-39	Coffee consumption (cups per day);
LGG	cis	rs7928758	0.832	rs56007027	chr11:134270955	G/A	cg25213107	chr11:134282864	B3GAT1	1.06	13.47	0.53	4.05e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04772025	chr11:68637568	NA	-0.71	-12.71	-0.51	5.96e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg12310025	chr6:25882481	NA	-0.58	-11.1	-0.46	1.51e-25	Blood metabolite levels;
LGG	trans	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg06916706	chr16:4465613	CORO7	-0.92	-16.89	-0.62	3.37e-50	Schizophrenia;
LGG	cis	rs73001065	1.000	rs73001065	chr19:19460541	G/C	cg03709012	chr19:19516395	GATAD2A	0.96	7.38	0.32	7.46e-13	LDL cholesterol;
LGG	cis	rs7267979	0.586	rs6037057	chr20:25182089	T/C	cg06421707	chr20:25228305	PYGB	0.39	7.91	0.34	1.97e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2742417	0.603	rs2742398	chr3:45759036	A/G	cg04837898	chr3:45731254	SACM1L	-0.49	-9.78	-0.41	1.2e-20	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs17253792	0.822	rs79618862	chr14:56093971	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.77	-0.41	1.24e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4891159	0.756	rs3892540	chr18:74118058	C/T	cg24786174	chr18:74118243	ZNF516	-0.59	-13.5	-0.53	2.86e-35	Longevity;
LGG	cis	rs4319547	0.661	rs10846830	chr12:122897220	C/G	cg23029597	chr12:123009494	RSRC2	-0.93	-17.35	-0.63	2.65e-52	Body mass index;
LGG	cis	rs55863869	0.748	rs2291310	chr2:179623758	C/T	cg02880032	chr2:179629472	TTN	-0.47	-6.67	-0.3	7.31e-11	QT interval;
LGG	cis	rs6964587	0.967	rs10429103	chr7:91598443	T/A	cg17063962	chr7:91808500	NA	0.48	8.54	0.37	1.93e-16	Breast cancer;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.8	0.38	2.75e-17	Alzheimer's disease;
LGG	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.39	0.4	2.63e-19	Fuchs's corneal dystrophy;
LGG	cis	rs758324	0.648	rs31474	chr5:131405027	A/G	cg06307176	chr5:131281290	NA	-0.42	-6.77	-0.3	3.99e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2594989	0.887	rs9985349	chr3:11591200	T/G	cg01796438	chr3:11312864	ATG7	0.45	6.78	0.3	3.79e-11	Circulating chemerin levels;
LGG	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg10402321	chr1:26617780	UBXN11	-0.36	-7.0	-0.31	9.15e-12	Obesity-related traits;
LGG	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg04842962	chr6:43655489	MRPS18A	0.79	14.98	0.57	1.22e-41	IgG glycosylation;
LGG	cis	rs2046867	0.774	rs9820293	chr3:72876237	T/A	cg26655873	chr3:72818019	SHQ1	0.38	7.66	0.34	1.13e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg26677194	chr12:130822605	PIWIL1	0.56	9.73	0.41	1.69e-20	Menopause (age at onset);
LGG	cis	rs2797369	0.771	rs2813643	chr6:101575509	G/T	cg27451362	chr6:101846650	GRIK2	0.69	8.75	0.38	4.02e-17	Renal function-related traits (eGRFcrea);
LGG	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.84	-0.3	2.55e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6547631	0.502	rs77067405	chr2:85927739	G/T	cg19805943	chr2:85933069	NA	0.32	6.77	0.3	3.98e-11	Blood protein levels;
LGG	trans	rs11098499	0.866	rs6824111	chr4:120285968	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs4474465	1.000	rs11237500	chr11:78163636	G/A	cg02023728	chr11:77925099	USP35	0.4	6.9	0.31	1.75e-11	Alzheimer's disease (survival time);
LGG	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.32	0.36	9.83e-16	Colorectal cancer;
LGG	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	cg07245641	chr1:182991651	LAMC1	0.41	9.25	0.39	8.62e-19	Colorectal cancer;
LGG	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg00198680	chr16:28758506	NA	0.28	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.1	0.55	8.14e-38	Bladder cancer;
LGG	cis	rs972578	0.668	rs12106550	chr22:43336637	T/G	cg01576275	chr22:43409880	NA	-0.24	-7.14	-0.32	3.6e-12	Mean platelet volume;
LGG	cis	rs9902453	1.000	rs7212497	chr17:28335949	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.4	-0.33	6.5e-13	Longevity;Endometriosis;
LGG	cis	rs12135191	0.933	rs962487	chr1:236472587	T/A	cg21399712	chr1:236511386	NA	-0.41	-7.92	-0.35	1.75e-14	Urate levels (BMI interaction);
LGG	cis	rs990171	0.908	rs731628	chr2:103082571	C/T	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	cis	rs10504130	0.569	rs76746661	chr8:52681766	T/A	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.18	0.46	7.42e-26	Mean platelet volume;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.74	-0.38	4.39e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	trans	rs3780486	0.846	rs7850878	chr9:33126570	A/G	cg04842962	chr6:43655489	MRPS18A	1.11	24.57	0.75	6.17e-86	IgG glycosylation;
LGG	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg12591125	chr7:1885375	MAD1L1	0.42	7.18	0.32	2.87e-12	Bipolar disorder;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg02353165	chr6:42928485	GNMT	0.47	14.06	0.55	1.2e-37	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg24375607	chr4:120327624	NA	-0.69	-11.35	-0.47	1.62e-26	Corneal astigmatism;
LGG	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg09044154	chr16:88155775	NA	-0.48	-7.36	-0.32	8.63e-13	Menopause (age at onset);
LGG	trans	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs2073499	1.000	rs45536634	chr3:50400081	G/A	cg03645007	chr3:50255295	SLC38A3	0.61	6.68	0.3	6.66e-11	Schizophrenia;
LGG	cis	rs8078723	0.966	rs57968500	chr17:38145828	A/G	cg17467752	chr17:38218738	THRA	0.74	14.02	0.55	1.83e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs888194	0.699	rs7304862	chr12:109988891	T/G	cg19025524	chr12:109796872	NA	-0.35	-7.07	-0.31	5.83e-12	Neuroticism;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg21948465	chr5:131705150	SLC22A5	0.68	7.53	0.33	2.7e-13	Rheumatoid arthritis;
LGG	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.68	0.44	5.91e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.85e-41	Hair morphology;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.97	-0.42	2.35e-21	IgG glycosylation;
LGG	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.12e-25	Corneal astigmatism;
LGG	cis	rs11690935	1.000	rs6433311	chr2:172549248	A/G	cg13550731	chr2:172543902	DYNC1I2	1.06	27.65	0.79	4.47e-100	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.78	0.38	3.09e-17	Lung cancer;
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg07308232	chr7:1071921	C7orf50	-0.72	-14.32	-0.55	9.27e-39	Longevity;Endometriosis;
LGG	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg26138144	chr22:38071188	LGALS1	0.68	15.47	0.58	7.83e-44	Fat distribution (HIV);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09732282	chr15:58474918	AQP9	0.43	7.28	0.32	1.43e-12	Gut microbiome composition (summer);
LGG	trans	rs9818758	0.556	rs9814987	chr3:49207849	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-6.78	-0.3	3.69e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.59	-10.04	-0.42	1.38e-21	Menarche (age at onset);
LGG	trans	rs1422110	0.513	rs1422105	chr5:85448371	A/C	cg01787110	chr1:109008453	NBPF6	0.53	9.4	0.4	2.55e-19	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08017756	chr2:100939284	LONRF2	0.28	6.76	0.3	4.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg19223190	chr17:80058835	NA	0.44	8.5	0.37	2.61e-16	Life satisfaction;
LGG	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg12253571	chr8:8283032	NA	0.31	6.83	0.3	2.7e-11	Mood instability;
LGG	cis	rs1318772	1.000	rs26986	chr5:112777570	T/G	cg12552261	chr5:112820674	MCC	0.69	7.72	0.34	7e-14	F-cell distribution;
LGG	cis	rs4731207	0.698	rs2402753	chr7:124448259	A/G	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03503975	chr22:46518455	NA	-0.49	-7.49	-0.33	3.56e-13	Pancreatic cancer;
LGG	cis	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg09307838	chr4:120376055	NA	0.68	11.75	0.48	4.47e-28	Corneal astigmatism;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.584	rs2164554	chr3:143755528	A/G	cg06585982	chr3:143692056	C3orf58	0.57	9.64	0.41	3.56e-20	Economic and political preferences (feminism/equality);
LGG	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.35e-16	Retinal vascular caliber;
LGG	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg17545662	chr6:170176663	C6orf70	0.7	8.95	0.38	8.96e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs854765	0.547	rs2955355	chr17:17948475	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.74	-14.73	-0.56	1.51e-40	Total body bone mineral density;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11677416	1.000	rs3783559	chr2:113529837	A/G	cg27083787	chr2:113543245	IL1A	0.51	8.54	0.37	1.97e-16	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs9534288	0.797	rs992631	chr13:46591989	A/G	cg15192986	chr13:46630673	CPB2	0.62	13.68	0.54	5.2e-36	Blood protein levels;
LGG	cis	rs2976388	0.609	rs2585148	chr8:143796193	C/G	cg06565975	chr8:143823917	SLURP1	0.37	9.4	0.4	2.6e-19	Urinary tract infection frequency;
LGG	trans	rs916888	0.610	rs199454	chr17:44800110	G/A	cg22968622	chr17:43663579	NA	-0.78	-15.24	-0.58	8.43e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6688613	0.694	rs11576455	chr1:166811970	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.55	8.37	0.36	7.08e-16	Refractive astigmatism;
LGG	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg06917634	chr15:78832804	PSMA4	0.63	9.72	0.41	1.96e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9326248	0.581	rs7120706	chr11:116830087	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-10.81	-0.45	1.86e-24	Blood protein levels;
LGG	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	cg07245641	chr1:182991651	LAMC1	0.41	8.93	0.38	1.03e-17	Colorectal cancer;
LGG	cis	rs943466	1.000	rs6940353	chr6:33752550	G/A	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	1.99e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg26155939	chr18:44337853	ST8SIA5	0.38	6.97	0.31	1.07e-11	Personality dimensions;
LGG	cis	rs708547	0.836	rs1277287	chr4:57853147	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.72	11.56	0.47	2.52e-27	Response to bleomycin (chromatid breaks);
LGG	cis	rs73193808	0.614	rs4817274	chr21:30553617	A/G	cg03476357	chr21:30257390	N6AMT1	0.4	6.71	0.3	5.84e-11	Coronary artery disease;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04156016	chr5:1868137	NA	0.32	7.02	0.31	8.03e-12	Cardiovascular disease risk factors;
LGG	cis	rs1497828	1.000	rs2646837	chr1:217550380	T/C	cg04411442	chr1:217543379	NA	0.47	8.09	0.35	5.17e-15	Dialysis-related mortality;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs7928758	0.767	rs10894810	chr11:134273559	C/T	cg22777979	chr11:134283252	B3GAT1	0.56	8.56	0.37	1.7e-16	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg21643262	chr8:144646939	NA	-0.46	-7.15	-0.32	3.45e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs3741404	0.620	rs2236647	chr11:63964605	A/G	cg05555928	chr11:63887634	MACROD1	0.43	7.96	0.35	1.35e-14	Platelet count;
LGG	cis	rs17376456	0.542	rs10070350	chr5:93103753	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg04546413	chr19:29218101	NA	0.82	11.85	0.48	1.79e-28	Methadone dose in opioid dependence;
LGG	cis	rs1010254	0.510	rs2348421	chr5:151759901	T/C	cg12297329	chr5:152029980	NA	-0.51	-7.25	-0.32	1.8e-12	Optic nerve measurement (cup area);
LGG	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg00376283	chr12:123451042	ABCB9	-0.61	-11.27	-0.46	3.31e-26	Platelet count;
LGG	cis	rs2050392	0.624	rs303435	chr10:30731491	T/C	cg25182066	chr10:30743637	MAP3K8	-0.6	-12.34	-0.5	1.94e-30	Inflammatory bowel disease;
LGG	cis	rs1577917	0.958	rs12209259	chr6:86502348	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.25	-0.49	4.62e-30	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.830	rs2735309	chr21:40715313	C/T	cg11644478	chr21:40555479	PSMG1	0.84	14.79	0.57	8.04e-41	Cognitive function;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg20309703	chr11:118481025	PHLDB1	0.67	13.25	0.52	3.35e-34	Systemic lupus erythematosus;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg11494091	chr17:61959527	GH2	0.51	8.31	0.36	1.06e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.09	0.35	5.35e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg11584989	chr19:19387371	SF4	0.73	12.23	0.49	5.22e-30	Bipolar disorder;
LGG	cis	rs6964587	0.610	rs2888850	chr7:91430027	T/C	cg17063962	chr7:91808500	NA	0.41	7.46	0.33	4.31e-13	Breast cancer;
LGG	cis	rs2370759	1.000	rs16933243	chr10:32615135	T/C	cg01819863	chr10:32635814	EPC1	1.11	15.62	0.59	1.71e-44	Sexual dysfunction (female);
LGG	cis	rs9796	0.621	rs7170049	chr15:41484287	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.66	-0.41	3.02e-20	Menopause (age at onset);
LGG	cis	rs9894429	0.634	rs11655346	chr17:79572399	A/G	cg18240062	chr17:79603768	NPLOC4	-0.61	-10.13	-0.43	6.58e-22	Eye color traits;
LGG	cis	rs9650657	0.645	rs9969657	chr8:10515278	A/G	cg19847130	chr8:10466454	RP1L1	-0.31	-6.86	-0.3	2.25e-11	Neuroticism;
LGG	cis	rs975739	0.902	rs1279386	chr13:78374180	A/T	cg07847733	chr13:78271382	SLAIN1	0.36	6.65	0.3	8.08e-11	Hair color;
LGG	cis	rs10504130	0.542	rs1589079	chr8:52836299	T/C	cg22653915	chr8:52722023	PXDNL	-0.54	-9.69	-0.41	2.37e-20	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11971779	0.680	rs28579232	chr7:139073116	C/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9944715	0.954	rs7231430	chr18:43823472	C/T	cg26436583	chr18:43649176	PSTPIP2	0.35	6.66	0.3	7.72e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg00934597	chr7:893267	UNC84A	-0.54	-8.92	-0.38	1.12e-17	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg24375607	chr4:120327624	NA	0.62	10.44	0.44	4.72e-23	Corneal astigmatism;
LGG	cis	rs9309473	0.607	rs10198301	chr2:73581600	T/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.8	-0.38	2.79e-17	Metabolite levels;
LGG	cis	rs11122272	0.735	rs2808597	chr1:231532351	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08295258	chr5:102455984	GIN1	0.39	6.69	0.3	6.48e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7660883	1.000	rs72877984	chr4:87985721	G/A	cg21988461	chr4:88008667	AFF1	-0.31	-8.46	-0.37	3.48e-16	HDL cholesterol levels;
LGG	cis	rs11785693	0.909	rs11784246	chr8:4970497	A/G	cg26367366	chr8:4980734	NA	0.99	15.22	0.58	1.05e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7586879	0.639	rs6749170	chr2:25110962	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.69	0.51	7.35e-32	Body mass index;
LGG	cis	rs6840360	0.582	rs4473638	chr4:152322146	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.35	0.32	9.15e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.679	rs3102338	chr16:89442250	C/G	cg06640241	chr16:89574553	SPG7	0.67	11.51	0.47	3.99e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7666738	0.830	rs60411337	chr4:99046617	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs75920871	0.588	rs7118591	chr11:116908457	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.57	8.33	0.36	9.21e-16	Subjective well-being;
LGG	cis	rs2286885	0.965	rs10819167	chr9:129241716	T/A	cg14319473	chr9:129242481	FAM125B	0.46	8.69	0.37	6.3e-17	Intraocular pressure;
LGG	cis	rs11098499	0.913	rs56122576	chr4:120129336	A/G	cg09307838	chr4:120376055	NA	0.64	10.31	0.43	1.4e-22	Corneal astigmatism;
LGG	cis	rs999943	0.846	rs10947422	chr6:33611351	G/A	cg14003231	chr6:33640908	ITPR3	0.61	14.29	0.55	1.29e-38	Obesity (extreme);
LGG	cis	rs3859192	0.577	rs25645	chr17:38173143	G/A	cg17467752	chr17:38218738	THRA	-0.58	-9.73	-0.41	1.69e-20	White blood cell count;
LGG	cis	rs9911578	1.000	rs304292	chr17:56824123	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.91e-21	Intelligence (multi-trait analysis);
LGG	cis	rs992157	0.737	rs3731860	chr2:219156979	G/A	cg00012203	chr2:219082015	ARPC2	-0.67	-11.61	-0.47	1.65e-27	Colorectal cancer;
LGG	cis	rs597583	0.671	rs4938401	chr11:117399605	T/G	cg27161313	chr11:117392002	DSCAML1	-0.63	-10.04	-0.42	1.32e-21	Putamen volume;
LGG	cis	rs9947295	0.649	rs9946157	chr18:11734171	C/T	cg14735704	chr18:11749182	GNAL	0.5	7.03	0.31	7.56e-12	QT interval (drug interaction);
LGG	cis	rs9611519	1.000	rs5751069	chr22:41627775	C/G	cg03806693	chr22:41940476	POLR3H	-0.57	-9.03	-0.39	4.53e-18	Neuroticism;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.65	0.37	8.22e-17	Prudent dietary pattern;
LGG	cis	rs9513627	1.000	rs73556181	chr13:100122092	G/A	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs8017423	0.935	rs3742668	chr14:90767759	G/A	cg04374321	chr14:90722782	PSMC1	-0.83	-16.71	-0.61	2.26e-49	Mortality in heart failure;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs854765	0.647	rs854767	chr17:18018263	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-13.89	-0.54	6.75e-37	Total body bone mineral density;
LGG	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg19500275	chr17:80737654	TBCD	0.52	6.67	0.3	7.51e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1018836	0.774	rs35159732	chr8:91633094	A/G	cg16814680	chr8:91681699	NA	-0.84	-15.05	-0.57	6.09e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.45	-0.44	4.44e-23	Neuroticism;
LGG	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg03733263	chr8:22462867	KIAA1967	-0.93	-20.63	-0.69	1.61e-67	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs210138	0.832	rs375555	chr6:33557741	T/C	cg04201373	chr6:33551533	GGNBP1	0.34	6.8	0.3	3.25e-11	Testicular germ cell tumor;
LGG	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.96	-0.64	3.95e-55	Morning vs. evening chronotype;
LGG	cis	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs74781061	0.929	rs4887155	chr15:74804460	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.15	-0.32	3.35e-12	Endometriosis;
LGG	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21659725	chr3:3221576	CRBN	-0.67	-12.53	-0.5	3.37e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.4	-7.65	-0.33	1.19e-13	Obesity-related traits;
LGG	cis	rs4262150	0.883	rs11167597	chr5:152155205	T/A	cg12297329	chr5:152029980	NA	-0.7	-12.73	-0.51	4.97e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.01	0.64	2.4e-55	Refractive error;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.82	0.3	2.9100000000000002e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7191700	0.509	rs415595	chr16:11363692	A/G	cg00044050	chr16:11439710	C16orf75	0.52	8.84	0.38	1.96e-17	Multiple sclerosis;
LGG	cis	rs1357245	0.692	rs73036931	chr3:27205135	G/A	cg02860705	chr3:27208620	NA	-0.38	-6.92	-0.31	1.52e-11	Breast cancer;
LGG	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg21459583	chr1:227974177	NA	0.71	10.2	0.43	3.69e-22	Major depressive disorder;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.25	-0.36	1.62e-15	Life satisfaction;
LGG	cis	rs72960926	1.000	rs72969247	chr6:75071533	G/T	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.88e-11	Metabolite levels (MHPG);
LGG	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg16141378	chr3:129829833	LOC729375	0.34	7.67	0.34	1e-13	Monocyte count;
LGG	cis	rs2173063	1.000	rs56240024	chr15:93129834	G/A	cg07052004	chr15:93132129	NA	0.65	7.36	0.32	8.71e-13	Subcutaneous adipose tissue;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg02711726	chr17:80685570	FN3KRP	0.43	8.01	0.35	9.26e-15	Glycated hemoglobin levels;
LGG	cis	rs250677	0.687	rs250667	chr5:148455134	A/G	cg18129178	chr5:148520854	ABLIM3	0.46	7.55	0.33	2.31e-13	Breast cancer;
LGG	cis	rs9487094	0.744	rs13212535	chr6:110034391	G/A	cg16315928	chr6:109776240	MICAL1	0.52	8.34	0.36	8.46e-16	Height;
LGG	cis	rs7712401	0.562	rs246267	chr5:122256104	A/T	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs7312933	0.558	rs61926593	chr12:42818912	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.65	0.33	1.2e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.75	-0.3	4.56e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs920590	0.684	rs59565447	chr8:19668430	A/T	cg03894339	chr8:19674705	INTS10	0.65	10.54	0.44	2.02e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4851254	0.618	rs4851243	chr2:100639482	G/A	cg17356467	chr2:100759845	AFF3	0.47	7.62	0.33	1.44e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.647	rs7633601	chr3:17734215	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.5	-0.33	3.23e-13	Schizophrenia;
LGG	cis	rs6669008	1.000	rs55912359	chr1:114167099	C/T	cg13572289	chr1:114447746	DCLRE1B;AP4B1	-0.39	-8.56	-0.37	1.63e-16	Bacteremia;
LGG	cis	rs1800469	1.000	rs2241712	chr19:41869756	C/T	cg08477640	chr19:41863820	B9D2	0.42	7.59	0.33	1.72e-13	Colorectal cancer;
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20814179	chr4:940893	TMEM175	0.57	12.1	0.49	1.72e-29	Sjögren's syndrome;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16536329	chr5:178368185	ZNF454	0.38	6.74	0.3	4.77e-11	Bilirubin levels;
LGG	trans	rs10983614	1.000	rs7867776	chr9:120072627	A/G	cg17274400	chr12:8234945	NECAP1	0.4	7.19	0.32	2.54e-12	Survival in pancreatic cancer;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg05368731	chr17:41323189	NBR1	0.97	19.01	0.66	5.38e-60	Menopause (age at onset);
LGG	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.43	7.36	0.32	8.54e-13	Longevity;
LGG	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.37	0.4	3.15e-19	Gout;Renal underexcretion gout;
LGG	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg08807101	chr21:30365312	RNF160	0.54	8.94	0.38	9.28e-18	Pancreatic cancer;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01516881	chr6:292596	DUSP22	-0.7	-11.87	-0.48	1.54e-28	Menopause (age at onset);
LGG	cis	rs7241530	0.662	rs9946782	chr18:75888634	C/T	cg14642773	chr18:75888474	NA	0.47	9.87	0.42	5.62e-21	Educational attainment (years of education);
LGG	cis	rs9911578	1.000	rs9807057	chr17:56889952	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.55e-45	Intelligence (multi-trait analysis);
LGG	cis	rs8020289	0.560	rs7142548	chr14:77250908	C/T	cg23436960	chr14:77239540	VASH1	-0.37	-11.17	-0.46	8.28e-26	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.93	0.38	9.88e-18	Axial length;
LGG	cis	rs6732160	0.809	rs13406142	chr2:73384098	A/G	cg01422370	chr2:73384389	NA	0.54	10.6	0.44	1.21e-23	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.954	rs3733519	chr4:120423448	A/G	cg25214090	chr10:38739885	LOC399744	0.69	12.32	0.5	2.23e-30	Corneal astigmatism;
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg14773178	chr5:1868261	NA	0.39	8.47	0.37	3.35e-16	Cardiovascular disease risk factors;
LGG	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	8.27	0.36	1.49e-15	Height;
LGG	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg12011299	chr4:100065546	ADH4	0.39	7.95	0.35	1.46e-14	Alcohol dependence;
LGG	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-9.91	-0.42	3.95e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9393813	0.529	rs2393964	chr6:27475144	A/C	cg18711553	chr6:27366782	ZNF391	-0.47	-8.95	-0.38	8.51e-18	Bipolar disorder;
LGG	cis	rs10992471	0.756	rs3758229	chr9:95078852	G/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-6.97	-0.31	1.07e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs1691799	0.899	rs1168310	chr12:66726355	A/G	cg16791601	chr12:66731901	HELB	0.66	15.44	0.58	1.15e-43	White blood cell count (basophil);
LGG	cis	rs10504130	0.569	rs34319820	chr8:52689874	C/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.86	-0.34	2.76e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs4690686	0.538	rs10520346	chr4:177259088	C/G	cg17059388	chr4:177262070	NA	0.96	21.31	0.7	9.53e-71	Essential tremor;
LGG	cis	rs6901004	0.933	rs12208141	chr6:111572138	A/G	cg15721981	chr6:111408429	SLC16A10	-0.46	-8.17	-0.35	3.05e-15	Blood metabolite levels;
LGG	cis	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05491587	chr18:77659695	KCNG2	-0.52	-7.03	-0.31	7.57e-12	Opioid sensitivity;
LGG	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg22990158	chr14:24802150	ADCY4	-0.3	-6.67	-0.3	7.29e-11	Height;
LGG	cis	rs7301826	0.627	rs10773823	chr12:131294501	C/T	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs9581857	0.547	rs9319374	chr13:28047587	A/C	cg01674679	chr13:27998804	GTF3A	-0.66	-7.68	-0.34	9.65e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs9596863	0.898	rs9568920	chr13:54352810	A/T	ch.13.53330881F	chr13:54432880	NA	0.53	7.21	0.32	2.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg23034840	chr1:205782522	SLC41A1	-0.75	-8.59	-0.37	1.34e-16	Prostate-specific antigen levels;
LGG	cis	rs6735179	0.798	rs12475777	chr2:1773830	A/G	cg10160682	chr2:1713001	PXDN	0.49	7.68	0.34	9.38e-14	Response to antipsychotic treatment;
LGG	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg22852734	chr6:133119734	C6orf192	0.99	11.98	0.49	5.2e-29	Type 2 diabetes nephropathy;
LGG	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22496380	chr5:211416	CCDC127	-1.25	-17.88	-0.64	1e-54	Breast cancer;
LGG	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg04034577	chr2:241836375	C2orf54	-0.53	-11.52	-0.47	3.5e-27	Urinary metabolites;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg02297831	chr4:17616191	MED28	0.49	8.82	0.38	2.36e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9911578	0.874	rs302865	chr17:56756977	A/G	cg12560992	chr17:57184187	TRIM37	0.82	14.36	0.56	6.19e-39	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg12070911	chr6:150209640	RAET1E	0.31	7.45	0.33	4.6e-13	Lung cancer;
LGG	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs877282	0.898	rs11253340	chr10:764786	G/T	cg17470449	chr10:769945	NA	0.56	6.83	0.3	2.65e-11	Uric acid levels;
LGG	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg07930552	chr6:133119739	C6orf192	0.85	11.23	0.46	4.83e-26	Type 2 diabetes nephropathy;
LGG	cis	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg00383909	chr3:49044727	WDR6	1.02	12.5	0.5	4.35e-31	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LGG	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg04455712	chr21:45112962	RRP1B	0.54	10.48	0.44	3.46e-23	Mean corpuscular volume;
LGG	cis	rs2236918	0.932	rs2526697	chr1:242040129	A/G	cg17736920	chr1:242011382	EXO1	-0.43	-7.76	-0.34	5.67e-14	Menopause (age at onset);
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.58	-0.47	2.09e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.706	rs9899069	chr17:37540772	A/G	cg00129232	chr17:37814104	STARD3	0.57	8.47	0.37	3.32e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7633857	0.532	rs9873705	chr3:160768818	A/T	cg03342759	chr3:160939853	NMD3	-0.59	-10.05	-0.42	1.26e-21	Educational attainment (years of education);
LGG	cis	rs7312933	0.702	rs10785333	chr12:42586470	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.46	-7.13	-0.31	3.86e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.2	0.39	1.24e-18	Blood protein levels;
LGG	cis	rs3096299	0.838	rs2035481	chr16:89420356	A/C	cg06640241	chr16:89574553	SPG7	0.61	10.18	0.43	4.3e-22	Multiple myeloma (IgH translocation);
LGG	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.98	0.39	6.85e-18	Axial length;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg16141378	chr3:129829833	LOC729375	-0.4	-9.55	-0.41	7.63e-20	Joint mobility (Beighton score);
LGG	cis	rs66887589	0.934	rs7681980	chr4:120533223	G/A	cg09307838	chr4:120376055	NA	-0.49	-8.48	-0.37	3.11e-16	Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25172604	chr17:41446521	NA	-0.3	-6.85	-0.3	2.35e-11	Menopause (age at onset);
LGG	cis	rs56283067	0.811	rs62435997	chr6:44692169	C/T	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.6e-29	Total body bone mineral density;
LGG	cis	rs17428076	0.874	rs12614709	chr2:172680872	C/G	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	trans	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg01620082	chr3:125678407	NA	-0.62	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1048238	0.506	rs10927867	chr1:16177285	A/G	cg22431228	chr1:16359049	CLCNKA	-0.41	-7.39	-0.32	7.01e-13	Systolic blood pressure;
LGG	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg19748678	chr4:122722346	EXOSC9	0.67	13.68	0.54	4.97e-36	Type 2 diabetes;
LGG	cis	rs6456156	0.603	rs2345754	chr6:167484361	T/C	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.47	0.37	3.19e-16	Retinal vascular caliber;
LGG	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs2012796	1.000	rs10450894	chr14:81825172	T/A	cg02996355	chr14:81879375	NA	0.52	8.3	0.36	1.18e-15	Night sleep phenotypes;
LGG	cis	rs12477438	0.501	rs896248	chr2:100078475	A/G	cg23527387	chr2:100056660	REV1	0.42	9.39	0.4	2.68e-19	Chronic sinus infection;
LGG	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg13010199	chr12:38710504	ALG10B	0.52	9.98	0.42	2.24e-21	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4919694	0.901	rs79331374	chr10:104882913	G/A	cg04362960	chr10:104952993	NT5C2	1.06	15.1	0.57	3.38e-42	Arsenic metabolism;
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.3	0.4	5.6e-19	Triglycerides;
LGG	cis	rs36051895	0.632	rs1571438	chr9:5140313	A/C	cg02405213	chr9:5042618	JAK2	-0.77	-15.17	-0.58	1.67e-42	Pediatric autoimmune diseases;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.61	-0.37	1.17e-16	Morning vs. evening chronotype;
LGG	cis	rs2011503	1.000	rs2916070	chr19:19524105	C/T	cg11584989	chr19:19387371	SF4	0.73	11.8	0.48	2.69e-28	Bipolar disorder;
LGG	trans	rs826838	1.000	rs826891	chr12:39100824	A/G	cg06521331	chr12:34319734	NA	0.45	8.29	0.36	1.21e-15	Heart rate;
LGG	cis	rs12643440	0.538	rs879572	chr4:17148487	G/C	cg22650099	chr4:17144496	NA	-0.51	-8.82	-0.38	2.39e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs4750440	0.706	rs4237437	chr10:14018711	G/A	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.75	-0.51	4.19e-32	Adiponectin levels;
LGG	cis	rs6547741	0.904	rs2384628	chr2:27774702	T/G	cg27432699	chr2:27873401	GPN1	0.7	14.49	0.56	1.71e-39	Oral cavity cancer;
LGG	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.06e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.23	0.39	9.74e-19	Triglycerides;
LGG	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs12724450	0.793	rs34347495	chr1:150286494	T/C	cg03818307	chr1:150480534	ECM1	0.5	6.78	0.3	3.79e-11	Blood protein levels;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg05313129	chr8:58192883	C8orf71	-0.78	-12.23	-0.49	5.55e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs13082711	0.911	rs77685358	chr3:27519158	C/T	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.24e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg09448879	chr15:79043637	NA	0.48	10.31	0.43	1.4e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs12210905	0.925	rs12200985	chr6:27004892	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	9.74	0.41	1.68e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2952156	0.920	rs2517951	chr17:37853097	C/T	cg00129232	chr17:37814104	STARD3	-0.73	-15.38	-0.58	2.02e-43	Asthma;
LGG	trans	rs9388451	0.626	rs1343116	chr6:126069702	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-11.55	-0.47	2.71e-27	Brugada syndrome;
LGG	cis	rs3771570	1.000	rs3771564	chr2:242355701	G/A	cg21155796	chr2:242212141	HDLBP	0.77	10.25	0.43	2.32e-22	Prostate cancer;
LGG	cis	rs10484885	0.757	rs12201016	chr6:90149275	C/T	cg13799429	chr6:90582589	CASP8AP2	0.58	7.01	0.31	8.39e-12	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	8.12	0.35	4.16e-15	Personality dimensions;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.26	-0.58	7.28e-43	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.28e-19	Obesity-related traits;
LGG	cis	rs9303401	0.612	rs2526370	chr17:56487636	G/C	cg12560992	chr17:57184187	TRIM37	0.45	7.08	0.31	5.31e-12	Cognitive test performance;
LGG	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03264133	chr6:25882463	NA	0.61	11.39	0.47	1.12e-26	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01438737	chr20:42086396	SFRS6	0.47	7.69	0.34	8.86e-14	Cognitive performance;
LGG	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.47	0.53	4.15e-35	Cognitive test performance;
LGG	trans	rs208520	0.955	rs208532	chr6:66961280	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs9290877	0.667	rs6766661	chr3:188456581	T/C	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs870825	0.616	rs7674952	chr4:185622327	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs8014204	0.967	rs1319171	chr14:75334096	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.82	-16.67	-0.61	3.28e-49	Caffeine consumption;
LGG	cis	rs7843479	0.898	rs4311656	chr8:21802276	T/G	cg17168535	chr8:21777572	XPO7	0.61	9.94	0.42	3.14e-21	Mean corpuscular volume;
LGG	cis	rs763121	0.925	rs5757165	chr22:38994577	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	16.95	0.62	1.79e-50	Menopause (age at onset);
LGG	cis	rs6489882	0.872	rs7132797	chr12:113375036	A/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.85	-0.3	2.41e-11	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23704066	chr7:96339024	SHFM1	0.41	7.01	0.31	8.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	10.49	0.44	3.04e-23	Total body bone mineral density;
LGG	cis	rs67478160	0.584	rs12433009	chr14:104196405	C/G	cg26031613	chr14:104095156	KLC1	-0.47	-7.53	-0.33	2.74e-13	Schizophrenia;
LGG	cis	rs2030746	0.521	rs13415147	chr2:121329768	A/G	cg13274077	chr2:121334614	NA	-0.37	-9.19	-0.39	1.38e-18	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg09448879	chr15:79043637	NA	0.44	10.24	0.43	2.5e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg04000281	chr11:63949212	NA	-0.37	-7.32	-0.32	1.07e-12	Platelet count;
LGG	cis	rs12410462	0.681	rs6682883	chr1:227635598	G/A	cg21459583	chr1:227974177	NA	0.55	8.02	0.35	8.61e-15	Major depressive disorder;
LGG	trans	rs877282	0.853	rs7069720	chr10:754487	A/G	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg11062466	chr8:58055876	NA	0.53	8.63	0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9486719	0.857	rs3798293	chr6:97033370	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.77	-0.48	3.77e-28	Migraine;Coronary artery disease;
LGG	cis	rs2481665	0.772	rs6661862	chr1:62534854	A/C	cg18591186	chr1:62594603	INADL	0.47	9.28	0.4	6.43e-19	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7811142	1.000	rs7803454	chr7:99991548	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.47	-0.58	7.99e-44	Platelet count;
LGG	cis	rs1978968	0.717	rs28406897	chr22:18402012	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.54	-0.41	8e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg24623649	chr8:11872141	NA	-0.29	-6.84	-0.3	2.5e-11	Systolic blood pressure;
LGG	cis	rs9473924	0.542	rs2744504	chr6:50798668	G/C	cg14470998	chr6:50812995	TFAP2B	0.69	8.27	0.36	1.48e-15	Body mass index;
LGG	cis	rs2916247	1.000	rs11779617	chr8:93034215	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.19	-0.36	2.52e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11874712	1.000	rs7235373	chr18:43653763	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.95	-0.45	5.7e-25	Migraine - clinic-based;
LGG	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg04691961	chr3:161091175	C3orf57	0.46	9.71	0.41	2e-20	Morning vs. evening chronotype;
LGG	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26306683	chr17:18585705	ZNF286B	0.48	9.03	0.39	4.57e-18	Educational attainment (years of education);
LGG	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.54	-9.51	-0.4	1.03e-19	Response to antipsychotic treatment;
LGG	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.69	0.37	6.43e-17	Colorectal cancer;
LGG	trans	rs208520	0.674	rs207103	chr6:66795568	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs7267979	0.727	rs4815431	chr20:25532405	T/C	cg06421707	chr20:25228305	PYGB	-0.41	-8.58	-0.37	1.47e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7928758	0.887	rs79256507	chr11:134263728	C/A	cg25213107	chr11:134282864	B3GAT1	1.26	14.05	0.55	1.37e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs774359	0.789	rs814030	chr9:27515194	G/C	cg21249376	chr9:27528432	MOBKL2B	0.45	8.67	0.37	7.32e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	trans	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg10756647	chr7:56101905	PSPH	-0.82	-9.8	-0.41	9.84e-21	Diabetic kidney disease;
LGG	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg08847335	chr10:891726	LARP4B	-0.47	-8.57	-0.37	1.59e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs4716602	0.573	rs34810003	chr7:156160883	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.51	-0.4	1.04e-19	Anti-saccade response;
LGG	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg01678292	chr8:41522873	ANK1	-0.35	-8.2	-0.36	2.46e-15	Type 2 diabetes;
LGG	cis	rs12136530	0.774	rs12137192	chr1:19763458	C/G	cg17081867	chr1:19768096	CAPZB	-0.36	-8.34	-0.36	8.41e-16	Lead levels in blood;
LGG	cis	rs4730250	0.711	rs117026964	chr7:107063656	C/A	cg02696742	chr7:106810147	HBP1	-0.68	-8.71	-0.38	5.35e-17	Osteoarthritis;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20620272	chr3:167968129	C3orf50	0.4	7.1	0.31	4.86e-12	Body mass index;
LGG	cis	rs9457247	0.902	rs366938	chr6:167403538	T/C	cg07741184	chr6:167504864	NA	0.32	6.97	0.31	1.08e-11	Crohn's disease;
LGG	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	7.47	0.33	4.06e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg08975724	chr8:8085496	FLJ10661	0.54	10.8	0.45	2.2e-24	Mood instability;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg19006130	chr11:118478252	PHLDB1	-0.4	-6.8	-0.3	3.28e-11	Cholesterol, total;
LGG	cis	rs4740619	0.688	rs9969816	chr9:15954045	T/G	cg14451791	chr9:16040625	NA	-0.4	-10.1	-0.42	8.33e-22	Body mass index;
LGG	cis	rs1971762	0.545	rs6580949	chr12:53924293	T/C	cg06632207	chr12:54070931	ATP5G2	0.22	6.67	0.3	7.3e-11	Height;
LGG	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.72	-0.3	5.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg23825213	chr18:77623475	KCNG2	-0.4	-7.11	-0.31	4.39e-12	Schizophrenia;
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg05335186	chr13:53173507	NA	0.79	20.87	0.7	1.21e-68	Lewy body disease;
LGG	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg18252515	chr7:66147081	NA	-1.33	-19.0	-0.66	6e-60	Diabetic kidney disease;
LGG	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.37	-0.4	3.15e-19	Common traits (Other);
LGG	cis	rs36715	0.953	rs36706	chr5:127556698	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.46	7.23	0.32	2.01e-12	Breast cancer;
LGG	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.45	-7.87	-0.34	2.6e-14	Caffeine consumption;
LGG	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	9.82	0.42	8.29e-21	Longevity;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6694672	1.000	rs7554757	chr1:196973054	A/T	cg13682187	chr1:196946512	CFHR5	0.54	7.06	0.31	6.13e-12	Asthma;
LGG	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs8180040	0.587	rs62246398	chr3:47066203	A/C	cg16586182	chr3:47516702	SCAP	0.73	13.23	0.52	3.98e-34	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18500714	chr14:100706288	YY1	0.48	7.74	0.34	6.49e-14	Cognitive performance;
LGG	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs888194	1.000	rs888194	chr12:109986918	C/G	cg08884029	chr12:110012500	MVK;MMAB	-0.36	-7.5	-0.33	3.27e-13	Neuroticism;
LGG	cis	rs7737355	0.812	rs244738	chr5:130851170	A/G	cg06307176	chr5:131281290	NA	0.51	8.48	0.37	3.03e-16	Life satisfaction;
LGG	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.77	-0.34	5.25e-14	Systemic lupus erythematosus;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg09826692	chr7:83378891	NA	-0.36	-7.11	-0.31	4.32e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg06521331	chr12:34319734	NA	0.51	9.46	0.4	1.5e-19	Bladder cancer;
LGG	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg11494091	chr17:61959527	GH2	0.52	8.37	0.36	6.9e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4975616	0.710	rs27996	chr5:1345474	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.56	-9.73	-0.41	1.74e-20	Lung cancer;
LGG	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg02002194	chr4:3960332	NA	0.48	9.1	0.39	2.72e-18	Neuroticism;
LGG	cis	rs11677416	1.000	rs6542093	chr2:113528536	G/A	cg27083787	chr2:113543245	IL1A	0.53	8.78	0.38	3.11e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg18357526	chr6:26021779	HIST1H4A	0.88	16.44	0.61	3.8e-48	Intelligence (multi-trait analysis);
LGG	cis	rs2251381	0.520	rs873651	chr21:30781848	G/A	cg24692254	chr21:30365293	RNF160	0.55	9.26	0.4	7.96e-19	Selective IgA deficiency;
LGG	cis	rs735539	0.958	rs1075690	chr13:21279690	G/A	cg04906043	chr13:21280425	IL17D	-0.61	-10.47	-0.44	3.71e-23	Dental caries;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.14	0.52	9.77e-34	Prudent dietary pattern;
LGG	cis	rs6486730	1.000	rs6486730	chr12:129275027	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.44	-7.9	-0.34	2.02e-14	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.87	0.38	1.65e-17	Alzheimer's disease;
LGG	cis	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.95	-0.45	5.73e-25	Resting heart rate;
LGG	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg01620082	chr3:125678407	NA	-0.94	-9.0	-0.39	5.74e-18	Squamous cell lung carcinoma;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.59	0.37	1.33e-16	Prudent dietary pattern;
LGG	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg27129171	chr3:47204927	SETD2	0.86	16.07	0.6	1.7e-46	Colorectal cancer;
LGG	cis	rs17092148	0.790	rs6058079	chr20:33142873	G/A	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.79	-0.3	3.38e-11	Neuroticism;
LGG	cis	rs11792861	0.591	rs7027874	chr9:111717112	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	11.89	0.48	1.27e-28	Menarche (age at onset);
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	cis	rs6942756	0.806	rs6467240	chr7:128984018	T/C	cg02491457	chr7:128862824	NA	-0.61	-11.37	-0.47	1.36e-26	White matter hyperintensity burden;
LGG	trans	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg26043149	chr18:55253948	FECH	-0.4	-6.74	-0.3	4.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.43	0.4	2.06e-19	Schizophrenia;
LGG	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg12924262	chr12:102091054	CHPT1	-0.64	-12.62	-0.51	1.37e-31	Blood protein levels;
LGG	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.31	-0.43	1.42e-22	Neuroticism;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.63e-14	Blood trace element (Cu levels);
LGG	cis	rs477692	0.673	rs1970197	chr10:131359588	C/T	cg05714579	chr10:131428358	MGMT	0.43	8.06	0.35	6.33e-15	Response to temozolomide;
LGG	trans	rs7615952	0.611	rs9681518	chr3:125615130	A/G	cg07211511	chr3:129823064	LOC729375	-1.32	-16.28	-0.6	1.94e-47	Blood pressure (smoking interaction);
LGG	cis	rs757081	0.667	rs644419	chr11:17212375	C/T	cg15432903	chr11:17409602	KCNJ11	0.53	8.75	0.38	4.05e-17	Systolic blood pressure;
LGG	cis	rs11122272	0.668	rs1122131	chr1:231476501	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.54	-9.38	-0.4	2.98e-19	Hemoglobin concentration;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	12.0	0.49	4.32e-29	Obesity-related traits;
LGG	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg18245976	chr7:158708271	WDR60	-0.58	-10.34	-0.43	1.09e-22	Height;
LGG	cis	rs10193935	0.681	rs13396880	chr2:42374700	G/T	cg27598129	chr2:42591480	NA	-0.61	-8.41	-0.36	5.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3820928	0.874	rs10189579	chr2:227864876	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.44	-0.33	4.79e-13	Pulmonary function;
LGG	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg08807101	chr21:30365312	RNF160	0.56	8.72	0.38	4.96e-17	Cognitive test performance;
LGG	cis	rs7312774	0.618	rs7968263	chr12:107330844	C/A	cg16260113	chr12:107380972	MTERFD3	0.92	8.41	0.36	5.11e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs55665837	1.000	rs11023216	chr11:14437153	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.9	-0.38	1.3e-17	Vitamin D levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg22605179	chr22:29664171	EWSR1;RHBDD3	0.42	6.87	0.3	2.1e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg15395560	chr15:45543142	SLC28A2	0.42	6.95	0.31	1.27e-11	Glomerular filtration rate;
LGG	cis	rs2470578	0.792	rs2733521	chr3:17243164	G/A	cg20981856	chr3:17787350	NA	0.36	6.83	0.3	2.67e-11	Schizophrenia;
LGG	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.44e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7917772	0.628	rs4604806	chr10:104373904	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.69	0.48	7.59e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.45	-0.33	4.75e-13	Mood instability;
LGG	cis	rs751728	1.000	rs6925273	chr6:33732448	A/G	cg25922239	chr6:33757077	LEMD2	0.67	11.73	0.48	5.13e-28	Crohn's disease;
LGG	cis	rs11166927	0.904	rs2242180	chr8:140819783	G/T	cg16909799	chr8:140841666	TRAPPC9	0.56	11.63	0.48	1.33e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.66	-0.34	1.07e-13	IgG glycosylation;
LGG	cis	rs7927592	0.913	rs2236708	chr11:68378045	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.54	-0.37	1.88e-16	Total body bone mineral density;
LGG	cis	rs11018904	0.768	rs35389990	chr11:89978683	T/C	cg27158573	chr11:89632121	NA	-0.5	-7.75	-0.34	5.93e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11608355	0.810	rs2217972	chr12:109857612	C/T	cg19025524	chr12:109796872	NA	-0.41	-6.89	-0.31	1.81e-11	Neuroticism;
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg26116260	chr4:7069785	GRPEL1	1.12	19.96	0.68	2.06e-64	Monocyte percentage of white cells;
LGG	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg00647317	chr7:50633725	DDC	-0.34	-7.55	-0.33	2.31e-13	Malaria;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg19635926	chr16:89946313	TCF25	0.73	7.35	0.32	9.19e-13	Skin colour saturation;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.8	0.38	2.76e-17	Hypertriglyceridemia;
LGG	cis	rs12360000	0.770	rs12251959	chr10:1902277	C/T	cg26364871	chr10:1889757	NA	-0.72	-14.15	-0.55	5.16e-38	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs73001065	0.711	rs58489806	chr19:19456917	C/T	cg03709012	chr19:19516395	GATAD2A	0.9	8.94	0.38	9.05e-18	LDL cholesterol;
LGG	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg02002194	chr4:3960332	NA	-0.49	-9.16	-0.39	1.7e-18	Neuroticism;
LGG	cis	rs4665809	1.000	rs12469163	chr2:26283587	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.11	-0.52	1.27e-33	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.72	-0.3	5.38e-11	Mood instability;
LGG	cis	rs7113850	0.541	rs7933381	chr11:24237534	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	10.51	0.44	2.65e-23	Bone fracture in osteoporosis;
LGG	cis	rs708547	0.647	rs1277308	chr4:57897864	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	8.63	0.37	1.02e-16	Response to bleomycin (chromatid breaks);
LGG	trans	rs9929218	1.000	rs13330350	chr16:68800849	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.81	-0.51	2.22e-32	Colorectal cancer;
LGG	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.42	-0.4	2.2e-19	Myopia (pathological);
LGG	cis	rs11690935	0.655	rs12052995	chr2:172537212	A/G	cg13550731	chr2:172543902	DYNC1I2	0.69	14.16	0.55	4.61e-38	Schizophrenia;
LGG	cis	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg09307838	chr4:120376055	NA	0.79	12.98	0.52	4.66e-33	Corneal astigmatism;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg20779314	chr1:147067924	BCL9	-0.42	-6.95	-0.31	1.28e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7659604	1.000	rs34952897	chr4:122664409	C/T	cg19748678	chr4:122722346	EXOSC9	0.51	9.67	0.41	2.88e-20	Type 2 diabetes;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-10.82	-0.45	1.7e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg13010199	chr12:38710504	ALG10B	-0.78	-16.77	-0.61	1.19e-49	Heart rate;
LGG	cis	rs11191270	1.000	rs11191270	chr10:104124605	C/T	cg15320455	chr10:103880129	LDB1	0.5	6.96	0.31	1.14e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg02023728	chr11:77925099	USP35	0.44	7.78	0.34	4.77e-14	Testicular germ cell tumor;
LGG	cis	rs36071027	0.615	rs17643640	chr5:158407296	C/G	cg18496440	chr5:158532302	NA	0.41	6.96	0.31	1.19e-11	Carotid intima media thickness;
LGG	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06481639	chr22:41940642	POLR3H	0.54	7.61	0.33	1.53e-13	Vitiligo;
LGG	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	1.04e-23	Hip circumference adjusted for BMI;
LGG	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg09029085	chr17:47094198	IGF2BP1	0.31	8.25	0.36	1.66e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs986417	0.901	rs1884095	chr14:61017024	C/G	cg27398547	chr14:60952738	C14orf39	0.71	6.8	0.3	3.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4363385	0.818	rs679378	chr1:153011716	G/A	cg13444842	chr1:152974279	SPRR3	-0.41	-8.48	-0.37	3.12e-16	Inflammatory skin disease;
LGG	cis	rs7614311	0.636	rs73117045	chr3:63910613	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.69	-0.34	8.92e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg13482628	chr17:19912719	NA	0.62	12.35	0.5	1.72e-30	Schizophrenia;
LGG	cis	rs7937612	1.000	rs12417256	chr11:120337519	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.8	-0.51	2.58e-32	Intraocular pressure;
LGG	cis	rs4917300	0.632	rs4917293	chr8:143116851	G/T	cg06573787	chr8:143070187	NA	0.55	9.11	0.39	2.51e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs2916247	0.954	rs2996058	chr8:93179441	G/C	cg10183463	chr8:93005414	RUNX1T1	0.35	7.14	0.31	3.62e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg19847130	chr8:10466454	RP1L1	-0.36	-7.47	-0.33	4.15e-13	Neuroticism;
LGG	cis	rs7666738	0.830	rs11097582	chr4:98772201	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.74	0.34	6.45e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg18129748	chr3:49941408	MST1R	0.22	7.15	0.32	3.46e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7143963	0.636	rs8004192	chr14:103337253	T/C	cg23020514	chr14:103360112	TRAF3	0.4	8.28	0.36	1.35e-15	Body mass index;
LGG	cis	rs6032067	0.929	rs13038355	chr20:43805555	C/T	cg10761708	chr20:43804764	PI3	0.76	11.92	0.48	9.04e-29	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25409040	chr11:33183343	CSTF3	0.45	7.29	0.32	1.34e-12	Cognitive performance;
LGG	cis	rs4242434	0.819	rs1871902	chr8:22470710	G/A	cg02227867	chr8:22457446	C8orf58	-0.41	-7.84	-0.34	3.24e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg12927641	chr6:109611667	NA	0.37	7.06	0.31	6e-12	Reticulocyte fraction of red cells;
LGG	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.65	-0.37	8.49e-17	IgG glycosylation;
LGG	cis	rs929354	0.685	rs1808217	chr7:157002741	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.45e-13	Body mass index;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg01765077	chr12:122356316	WDR66	0.28	7.69	0.34	8.9e-14	Mean corpuscular volume;
LGG	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg21918786	chr6:109611834	NA	-0.48	-8.93	-0.38	1e-17	Reticulocyte fraction of red cells;
LGG	cis	rs17767392	0.846	rs12127	chr14:71956270	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.87	-0.38	1.65e-17	Mitral valve prolapse;
LGG	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg25382214	chr1:3105252	PRDM16	-0.39	-7.16	-0.32	3.09e-12	Migraine;
LGG	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg00092383	chr7:157075207	NA	0.39	6.74	0.3	4.6e-11	Body mass index;
LGG	cis	rs2885056	0.783	rs73007347	chr19:10650649	C/T	cg06392426	chr19:10676186	KRI1	0.71	11.75	0.48	4.45e-28	Red cell distribution width;
LGG	cis	rs6032067	0.777	rs34343273	chr20:43795293	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs10876993	0.928	rs1689592	chr12:58057773	C/T	cg18357645	chr12:58087776	OS9	0.71	13.08	0.52	1.69e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg05064044	chr6:292385	DUSP22	-0.5	-8.67	-0.37	7.29e-17	Menopause (age at onset);
LGG	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.36	0.32	8.62e-13	Bladder cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg14189758	chr20:36156486	BLCAP	0.41	6.72	0.3	5.27e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg13010199	chr12:38710504	ALG10B	0.69	13.46	0.53	4.41e-35	Morning vs. evening chronotype;
LGG	cis	rs41005	0.967	rs193927	chr2:8108055	G/A	cg03155496	chr2:8117019	LOC339788	0.88	19.72	0.68	2.78e-63	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05025164	chr4:1340916	KIAA1530	0.44	7.37	0.32	8.13e-13	Obesity-related traits;
LGG	cis	rs11690935	0.959	rs7608403	chr2:172646765	A/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.12	-0.31	4.27e-12	Schizophrenia;
LGG	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Aortic root size;
LGG	cis	rs6963495	0.818	rs818621	chr7:105173029	T/C	cg21420622	chr7:105162941	PUS7	-0.45	-7.05	-0.31	6.48e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7100689	0.622	rs10749569	chr10:82129892	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg11890956	chr21:40555474	PSMG1	-0.95	-19.24	-0.67	4.69e-61	Cognitive function;
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.52	8.37	0.36	6.96e-16	Renal function-related traits (BUN);
LGG	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg14092988	chr3:52407081	DNAH1	0.42	11.07	0.46	1.91e-25	Bipolar disorder;
LGG	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23630158	chr17:74722648	C17orf95;JMJD6	0.44	6.91	0.31	1.62e-11	Gut microbiome composition (summer);
LGG	cis	rs7572644	0.640	rs11901133	chr2:28069713	T/G	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.06	-0.31	6.15e-12	Testicular germ cell tumor;
LGG	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg21775007	chr8:11205619	TDH	0.49	8.04	0.35	7.75e-15	Triglycerides;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	trans	rs8002861	0.658	rs9533635	chr13:44397921	C/A	cg12856521	chr11:46389249	DGKZ	-0.49	-8.82	-0.38	2.34e-17	Leprosy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07725729	chr8:11141895	MTMR9	0.46	6.67	0.3	7.16e-11	Gut microbiome composition (summer);
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.3	0.4	5.61e-19	Electroencephalogram traits;
LGG	cis	rs4363385	0.818	rs368912	chr1:153016204	C/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.87	-0.38	1.58e-17	Inflammatory skin disease;
LGG	cis	rs12039371	1.000	rs12133341	chr1:183984306	A/C	cg01436608	chr1:184005534	GLT25D2	0.54	6.94	0.31	1.33e-11	Antipsychotic drug-induced QTc interval change in schizophrenia;
LGG	cis	rs6784615	0.744	rs6810027	chr3:52524574	A/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.66	7.53	0.33	2.76e-13	Waist-hip ratio;
LGG	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Myopia (pathological);
LGG	cis	rs7524258	0.900	rs7544004	chr1:7314529	A/C	cg07173049	chr1:7289937	CAMTA1	0.65	15.54	0.59	4.16e-44	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9487094	0.922	rs1048203	chr6:109762236	G/A	cg16315928	chr6:109776240	MICAL1	0.56	9.45	0.4	1.64e-19	Height;
LGG	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.67	-0.44	6.53e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg00166722	chr3:10149974	C3orf24	0.55	9.04	0.39	4.3e-18	Alzheimer's disease;
LGG	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg12046867	chr14:103022105	NA	-0.8	-16.07	-0.6	1.72e-46	Platelet count;
LGG	cis	rs11877825	0.826	rs1893879	chr18:10583247	G/A	cg07277756	chr18:10589357	NA	0.58	10.44	0.44	4.8e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg20573242	chr4:122745356	CCNA2	0.55	10.14	0.43	5.69e-22	Type 2 diabetes;
LGG	cis	rs12681366	0.614	rs3099397	chr8:95479319	A/G	cg13257157	chr8:95487014	RAD54B	0.38	7.02	0.31	8.02e-12	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg21659725	chr3:3221576	CRBN	0.63	11.63	0.48	1.32e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg23782820	chr8:58130467	NA	0.54	7.55	0.33	2.39e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg17691542	chr6:26056736	HIST1H1C	0.75	12.76	0.51	3.76e-32	Height;
LGG	cis	rs61008539	0.893	rs7783487	chr7:860160	A/C	cg05535760	chr7:792225	HEATR2	-0.45	-7.85	-0.34	2.98e-14	Perceived unattractiveness to mosquitoes;
LGG	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg10523679	chr1:76189770	ACADM	0.71	10.37	0.43	8.55e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg23985595	chr17:80112537	CCDC57	0.38	7.5	0.33	3.23e-13	Life satisfaction;
LGG	cis	rs539514	0.637	rs552030	chr13:76322065	G/T	cg04757411	chr13:76259545	LMO7	-0.31	-7.77	-0.34	5.13e-14	Type 1 diabetes;
LGG	cis	rs870825	0.860	rs11132253	chr4:185595472	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	18.71	0.66	1.31e-58	Blood protein levels;
LGG	cis	rs910873	0.505	rs6059961	chr20:33231490	T/C	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.25	-0.32	1.71e-12	Melanoma;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg13126279	chr21:47581558	C21orf56	0.52	9.33	0.4	4.42e-19	Testicular germ cell tumor;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05833251	chr14:23938784	NGDN	-0.48	-7.0	-0.31	8.98e-12	Systemic lupus erythematosus;
LGG	cis	rs2976388	0.506	rs2572902	chr8:143791387	A/G	cg06565975	chr8:143823917	SLURP1	0.35	8.9	0.38	1.24e-17	Urinary tract infection frequency;
LGG	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-8.06	-0.35	6.67e-15	Mean corpuscular volume;
LGG	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.01	-0.52	3.38e-33	Vitamin D levels;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.68e-13	Menopause (age at onset);
LGG	cis	rs798766	0.779	rs3134866	chr4:1723265	A/G	cg05874882	chr4:1763078	NA	-0.47	-6.74	-0.3	4.82e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.08e-12	Electroencephalogram traits;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg11584989	chr19:19387371	SF4	0.4	7.34	0.32	9.36e-13	Tonsillectomy;
LGG	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg16208657	chr15:68119293	LBXCOR1	-0.34	-6.74	-0.3	4.72e-11	Obesity;
LGG	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs2708240	1.000	rs2538990	chr7:147580041	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.28	7.18	0.32	2.84e-12	QT interval (drug interaction);
LGG	cis	rs12049351	0.774	rs3738187	chr1:229683264	G/A	cg13547644	chr1:229569608	ACTA1	0.28	6.65	0.3	8.04e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg04111992	chr7:158790115	NA	-0.37	-7.22	-0.32	2.1e-12	Facial morphology (factor 20);
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg21926883	chr2:100939477	LONRF2	-0.68	-16.14	-0.6	8.21e-47	Intelligence (multi-trait analysis);
LGG	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.41	-0.33	6.15e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2456568	0.570	rs1827932	chr11:93663319	A/T	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs68170813	0.522	rs12531187	chr7:106963650	C/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.72e-22	Coronary artery disease;
LGG	cis	rs1270639	0.778	rs2530403	chr7:157445639	C/T	cg13357408	chr7:157437802	PTPRN2	0.66	10.64	0.44	8.48e-24	Colorectal cancer;
LGG	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg08733933	chr1:2954429	NA	-0.43	-8.5	-0.37	2.59e-16	Plateletcrit;
LGG	cis	rs8258	0.501	rs474490	chr11:117287794	T/G	cg15227623	chr11:117232454	CEP164	0.45	7.35	0.32	8.76e-13	Pulse pressure;
LGG	cis	rs7927592	0.871	rs113020558	chr11:68296832	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.43	-0.36	4.5e-16	Total body bone mineral density;
LGG	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.53	-6.7	-0.3	6.17e-11	Iron status biomarkers;
LGG	cis	rs4774899	1.000	rs2116066	chr15:57254778	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-7.98	-0.35	1.12e-14	Urinary tract infection frequency;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg12458913	chr13:53173898	NA	0.77	15.75	0.59	4.77e-45	Lewy body disease;
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.77	0.38	3.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg16141378	chr3:129829833	LOC729375	0.42	9.81	0.41	8.9e-21	Neuroticism;
LGG	cis	rs17854409	0.764	rs16983293	chr20:61479056	A/G	cg06598544	chr20:61472147	COL9A3	-0.99	-9.02	-0.39	4.86e-18	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.59	-0.44	1.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg17202724	chr17:61916730	SMARCD2	-0.49	-10.97	-0.45	4.77e-25	Prudent dietary pattern;
LGG	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg06573787	chr8:143070187	NA	0.5	8.78	0.38	3.18e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs1728785	0.901	rs1645974	chr16:68564774	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg21211680	chr2:198530	NA	1.28	15.96	0.6	5.23e-46	Blood protein levels;
LGG	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.38	-0.36	6.42e-16	Restless legs syndrome;
LGG	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.03	0.49	3.31e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9810089	0.843	rs834304	chr3:136111658	G/T	cg21827317	chr3:136751795	NA	0.44	7.57	0.33	2.05e-13	Gestational age at birth (child effect);
LGG	cis	rs10979	0.571	rs6909701	chr6:143922918	C/G	cg25407410	chr6:143891975	LOC285740	-0.48	-7.11	-0.31	4.51e-12	Hypospadias;
LGG	cis	rs17253792	0.822	rs79262019	chr14:56092704	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs2463822	0.583	rs17709552	chr11:62040519	A/G	cg06239285	chr11:62104954	ASRGL1	-0.98	-11.98	-0.49	5.22e-29	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg24642439	chr20:33292090	TP53INP2	0.42	6.64	0.3	8.6e-11	Height;
LGG	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.67	0.37	7.37e-17	Longevity;
LGG	cis	rs2304069	1.000	rs2304069	chr5:149406733	G/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	7.7	0.34	8.08e-14	HIV-1 control;
LGG	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg06916706	chr16:4465613	CORO7	-0.98	-16.95	-0.62	1.78e-50	Schizophrenia;
LGG	cis	rs644799	1.000	rs12786522	chr11:95522858	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.37	0.32	8.16e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19236745	chr11:33182890	CSTF3	0.42	6.68	0.3	7.04e-11	Cognitive performance;
LGG	trans	rs11039798	1.000	rs10838942	chr11:48557163	C/G	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.18e-17	Axial length;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg07677032	chr17:61819896	STRADA	-0.68	-12.54	-0.5	3.03e-31	Prudent dietary pattern;
LGG	cis	rs4481887	0.636	rs10788761	chr1:248410663	C/T	cg01631408	chr1:248437212	OR2T33	-0.45	-7.58	-0.33	1.94e-13	Common traits (Other);
LGG	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.07	0.42	1.04e-21	Motion sickness;
LGG	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg13385794	chr1:248469461	NA	0.49	8.28	0.36	1.3e-15	Common traits (Other);
LGG	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.5	-0.33	3.23e-13	Mean corpuscular hemoglobin;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg04143929	chr2:100879511	NA	-0.5	-7.46	-0.33	4.33e-13	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.58e-12	Prudent dietary pattern;
LGG	cis	rs295140	0.967	rs4673906	chr2:201163812	G/T	cg25099087	chr2:201172481	SPATS2L	0.27	6.74	0.3	4.66e-11	QT interval;
LGG	cis	rs12618769	0.597	rs72819972	chr2:99035113	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.57	0.37	1.51e-16	Bipolar disorder;
LGG	cis	rs7503807	0.688	rs731452	chr17:78599052	G/T	cg16980736	chr17:78789706	RPTOR	-0.37	-6.7	-0.3	6.01e-11	Obesity;
LGG	cis	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg06609049	chr19:2785107	THOP1	0.61	9.5	0.4	1.15e-19	Total cholesterol levels;
LGG	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.29	-0.36	1.23e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs992157	0.643	rs10191283	chr2:219056755	G/A	cg00012203	chr2:219082015	ARPC2	0.82	16.54	0.61	1.32e-48	Colorectal cancer;
LGG	cis	rs6032067	0.929	rs13039083	chr20:43878838	T/A	cg10761708	chr20:43804764	PI3	0.76	11.87	0.48	1.43e-28	Blood protein levels;
LGG	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg26677194	chr12:130822605	PIWIL1	0.57	10.19	0.43	3.92e-22	Menopause (age at onset);
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.11	0.43	7.41e-22	Height;
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.88	0.7	9.88e-69	Alzheimer's disease;
LGG	cis	rs9457247	0.508	rs9459874	chr6:167504127	A/G	cg07741184	chr6:167504864	NA	-0.37	-8.75	-0.38	3.86e-17	Crohn's disease;
LGG	cis	rs763121	0.853	rs1569492	chr22:38975511	A/G	cg06022373	chr22:39101656	GTPBP1	-0.76	-14.93	-0.57	1.92e-41	Menopause (age at onset);
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.74	-0.38	4.39e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs9972944	0.756	rs7207587	chr17:63766307	C/T	cg07283582	chr17:63770753	CCDC46	-0.42	-8.27	-0.36	1.42e-15	Total body bone mineral density;
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg04503457	chr17:41445688	NA	-0.39	-9.39	-0.4	2.82e-19	Menopause (age at onset);
LGG	cis	rs4713118	0.513	rs149962	chr6:28015918	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.02	-0.31	7.95e-12	Parkinson's disease;
LGG	cis	rs9309473	0.583	rs35885918	chr2:73612234	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-9.07	-0.39	3.35e-18	Metabolite levels;
LGG	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg07541023	chr7:19748670	TWISTNB	-0.63	-8.68	-0.37	6.61e-17	Thyroid stimulating hormone;
LGG	cis	rs2718058	0.550	rs2392522	chr7:37801783	C/T	cg24998770	chr7:37888106	TXNDC3	-0.42	-7.04	-0.31	7.08e-12	Alzheimer's disease (late onset);
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg12708336	chr17:41446283	NA	-0.31	-7.41	-0.33	5.85e-13	Menopause (age at onset);
LGG	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg18240062	chr17:79603768	NPLOC4	-0.47	-7.17	-0.32	2.94e-12	Eye color traits;
LGG	trans	rs7395662	0.963	rs11039950	chr11:48737471	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.11	0.35	4.42e-15	HDL cholesterol;
LGG	cis	rs7572733	0.935	rs1850633	chr2:198829582	T/G	cg00792783	chr2:198669748	PLCL1	0.49	8.3	0.36	1.14e-15	Dermatomyositis;
LGG	cis	rs9462027	0.628	rs2814953	chr6:34697767	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.82	-0.45	1.8e-24	Systemic lupus erythematosus;
LGG	cis	rs6088580	0.634	rs6579165	chr20:32994715	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.97e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9783347	0.961	rs2061163	chr11:18322924	A/C	cg15585147	chr11:18324498	HPS5	0.43	9.1	0.39	2.76e-18	Pancreatic cancer;
LGG	trans	rs6940638	1.000	rs12204280	chr6:27033104	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg06634786	chr22:41940651	POLR3H	0.68	10.94	0.45	6.12e-25	Vitiligo;
LGG	trans	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg20587970	chr11:113659929	NA	-1.3	-24.23	-0.75	2.28e-84	Hip circumference adjusted for BMI;
LGG	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.72e-21	HDL cholesterol;
LGG	cis	rs11971779	0.616	rs6965143	chr7:139026608	C/G	cg07862535	chr7:139043722	LUC7L2	0.41	6.75	0.3	4.51e-11	Diisocyanate-induced asthma;
LGG	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.98	-0.31	1.01e-11	Lung cancer;
LGG	cis	rs62400317	0.859	rs17288250	chr6:45192022	T/A	cg20913747	chr6:44695427	NA	-0.64	-10.3	-0.43	1.53e-22	Total body bone mineral density;
LGG	cis	rs10861342	1.000	rs11112403	chr12:105586649	A/G	cg23923672	chr12:105501055	KIAA1033	0.81	7.3	0.32	1.26e-12	IgG glycosylation;
LGG	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg17971929	chr21:40555470	PSMG1	0.87	17.62	0.63	1.57e-53	Cognitive function;
LGG	cis	rs68170813	0.652	rs17403088	chr7:107111373	C/A	cg02696742	chr7:106810147	HBP1	-0.67	-8.55	-0.37	1.83e-16	Coronary artery disease;
LGG	cis	rs6909430	1.000	rs9372780	chr6:98723574	T/G	cg12860156	chr6:98744658	NA	-0.45	-7.51	-0.33	3.15e-13	Quantitative traits;
LGG	cis	rs1298908	0.639	rs2236568	chr10:82035923	C/A	cg01528321	chr10:82214614	TSPAN14	0.45	7.62	0.33	1.4e-13	Diabetic kidney disease;
LGG	cis	rs459571	0.959	rs410876	chr9:136893867	C/A	cg13789015	chr9:136890014	NCRNA00094	0.58	10.79	0.45	2.31e-24	Platelet distribution width;
LGG	cis	rs9517320	1.000	rs12864890	chr13:99126457	T/C	cg07423050	chr13:99094983	FARP1	0.39	8.03	0.35	8.23e-15	Longevity;
LGG	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Colorectal cancer;
LGG	cis	rs17092148	0.887	rs6059936	chr20:33184249	C/T	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs4409675	0.913	rs4072744	chr1:28271039	A/T	cg23691781	chr1:28212827	C1orf38	-0.31	-7.27	-0.32	1.57e-12	Corneal astigmatism;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2074585	0.802	rs2589940	chr15:90931363	C/T	cg22089800	chr15:90895588	ZNF774	0.71	13.07	0.52	1.97e-33	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs4262150	0.883	rs72804778	chr5:152309607	G/A	cg12297329	chr5:152029980	NA	-0.62	-11.32	-0.47	2.18e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.830	rs2842966	chr6:160141592	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.67	11.24	0.46	4.58e-26	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7098414	0.511	rs7071752	chr10:82159539	C/A	cg01528321	chr10:82214614	TSPAN14	0.69	12.59	0.51	1.82e-31	Post bronchodilator FEV1;
LGG	cis	rs7444	0.941	rs2070512	chr22:21949411	A/C	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs113835537	0.529	rs2305532	chr11:66298594	C/T	cg24851651	chr11:66362959	CCS	0.45	7.77	0.34	5.26e-14	Airway imaging phenotypes;
LGG	cis	rs3126085	0.935	rs6587647	chr1:152192631	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.38e-17	Atopic dermatitis;
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg08925882	chr11:67350491	GSTP1	-0.35	-6.94	-0.31	1.33e-11	Mean corpuscular volume;
LGG	cis	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.3	-0.4	5.38e-19	Mood instability;
LGG	cis	rs11649743	1.000	rs62073542	chr17:36079565	G/A	cg21250756	chr17:36077300	HNF1B	0.37	9.81	0.41	9.32e-21	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg18258770	chr4:90757814	SNCA	0.42	7.79	0.34	4.49e-14	Dementia with Lewy bodies;
LGG	trans	rs28595532	0.557	rs13435618	chr4:119308814	C/T	cg26518628	chr1:97050305	NA	-0.9	-12.51	-0.5	3.96e-31	Cannabis dependence symptom count;
LGG	cis	rs3806843	1.000	rs7701755	chr5:140182101	G/T	cg19875535	chr5:140030758	IK	0.51	10.4	0.44	6.34e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg15145296	chr3:125709740	NA	-0.61	-7.91	-0.34	1.94e-14	Blood pressure (smoking interaction);
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg11584989	chr19:19387371	SF4	0.68	11.32	0.47	2.25e-26	Bipolar disorder;
LGG	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg24253500	chr15:84953950	NA	0.43	7.3	0.32	1.25e-12	Schizophrenia;
LGG	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg12011299	chr4:100065546	ADH4	-0.4	-7.83	-0.34	3.27e-14	Smoking initiation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06642177	chr6:134496341	SGK1	0.5	8.09	0.35	5.42e-15	Cognitive performance;
LGG	cis	rs10911251	0.509	rs4652780	chr1:183105923	G/C	cg07245641	chr1:182991651	LAMC1	0.4	9.16	0.39	1.72e-18	Colorectal cancer;
LGG	cis	rs986417	0.818	rs1998189	chr14:60974987	A/T	cg27398547	chr14:60952738	C14orf39	0.71	6.92	0.31	1.56e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9815354	0.904	rs62258655	chr3:41932330	G/A	cg03022575	chr3:42003672	ULK4	-0.66	-8.45	-0.37	3.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs73001065	0.901	rs73004933	chr19:19675696	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	7.09	0.31	5.07e-12	LDL cholesterol;
LGG	cis	rs6142618	0.543	rs6141639	chr20:30810276	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	7.96	0.35	1.37e-14	Inflammatory bowel disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24942226	chr6:99281500	POU3F2	0.6	6.88	0.3	2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.626	rs4952910	chr2:42912517	C/T	cg14631114	chr2:43023945	NA	0.35	6.94	0.31	1.32e-11	Hypospadias;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13922124	chr7:105221991	EFCAB10	0.47	7.27	0.32	1.49e-12	Gut microbiome composition (summer);
LGG	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.95	-0.31	1.27e-11	Neuroticism;
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.97	0.38	7.28e-18	Total body bone mineral density;
LGG	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg06637938	chr14:75390232	RPS6KL1	0.57	10.45	0.44	4.4e-23	Height;
LGG	cis	rs17227506	0.606	rs6985004	chr8:13440282	G/C	cg03566418	chr8:13424080	C8orf48	0.63	10.01	0.42	1.81e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4262150	0.883	rs11167604	chr5:152282430	A/C	cg12297329	chr5:152029980	NA	0.59	11.3	0.46	2.67e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10426930	0.714	rs858422	chr19:5049483	T/C	cg18473234	chr19:5097819	KDM4B	-0.42	-7.24	-0.32	1.82e-12	Monocyte percentage of white cells;
LGG	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg12193833	chr17:30244370	NA	-0.29	-6.97	-0.31	1.07e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	7.73	0.34	6.66e-14	Schizophrenia;
LGG	cis	rs9467711	0.591	rs3734523	chr6:25925987	G/A	cg21479132	chr6:26055353	NA	0.75	6.98	0.31	1.05e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6076065	0.962	rs2424529	chr20:23369317	A/G	cg11657817	chr20:23433608	CST11	0.35	6.91	0.31	1.66e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg02649063	chr16:55794731	CES4	0.48	7.96	0.35	1.33e-14	Response to dabigatran etexilate treatment;
LGG	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg06453172	chr10:134556979	INPP5A	-0.5	-7.71	-0.34	7.62e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg21659725	chr3:3221576	CRBN	-0.55	-7.49	-0.33	3.63e-13	Menarche (age at onset);
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg02725872	chr8:58115012	NA	-0.94	-12.99	-0.52	3.94e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs4959677	0.935	rs4959676	chr6:2495566	G/A	cg23817096	chr6:1620687	NA	-0.31	-7.48	-0.33	3.87e-13	Orthostatic hypotension;
LGG	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-12.89	-0.51	1.08e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.51e-24	Diabetic retinopathy;
LGG	cis	rs3820928	0.874	rs12105952	chr2:227864521	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.77	-0.34	5.18e-14	Pulmonary function;
LGG	cis	rs908922	0.676	rs11205031	chr1:152527662	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.96	-0.57	1.42e-41	Hair morphology;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	8.36	0.36	7.38e-16	Obesity-related traits;
LGG	trans	rs1814175	0.615	rs10839378	chr11:49806943	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.46	-0.61	2.99e-48	Height;
LGG	cis	rs9926296	0.656	rs2376883	chr16:89826926	A/G	cg04287289	chr16:89883240	FANCA	0.52	9.28	0.4	6.39e-19	Vitiligo;
LGG	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.48e-14	Bone mineral density;
LGG	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-7.02	-0.31	8.19e-12	Uric acid levels;
LGG	cis	rs9398803	0.650	rs1101559	chr6:127047683	C/T	cg19875578	chr6:126661172	C6orf173	-0.5	-9.1	-0.39	2.63e-18	Male-pattern baldness;
LGG	cis	rs938554	0.876	rs6823324	chr4:9932359	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.04	0.31	6.93e-12	Blood metabolite levels;
LGG	cis	rs5758511	0.689	rs62240864	chr22:42563889	C/T	cg15128208	chr22:42549153	NA	0.74	10.43	0.44	5e-23	Birth weight;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-8.93	-0.38	1.04e-17	Vitiligo;
LGG	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg19774624	chr17:42201019	HDAC5	0.64	11.38	0.47	1.29e-26	Total body bone mineral density;
LGG	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg00383909	chr3:49044727	WDR6	1.02	11.49	0.47	4.63e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9649213	0.614	rs9640655	chr7:98017099	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.34	-0.36	8.84e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg10587741	chr22:38071170	LGALS1	0.82	21.87	0.71	2.34e-73	Fat distribution (HIV);
LGG	cis	rs3820068	0.603	rs72647118	chr1:15956535	G/T	cg05660106	chr1:15850417	CASP9	0.84	17.0	0.62	1.04e-50	Systolic blood pressure;
LGG	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.11	-0.31	4.32e-12	Monocyte count;
LGG	cis	rs9929218	0.953	rs9927329	chr16:68750331	C/T	cg02972257	chr16:68554789	NA	0.44	6.74	0.3	4.79e-11	Colorectal cancer;
LGG	cis	rs807669	0.903	rs807668	chr22:19162686	A/G	cg02655711	chr22:19163373	SLC25A1	0.78	16.19	0.6	4.85e-47	Metabolite levels;
LGG	cis	rs6964587	1.000	rs7781066	chr7:91691946	G/T	cg17063962	chr7:91808500	NA	0.48	8.47	0.37	3.25e-16	Breast cancer;
LGG	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg02733842	chr7:1102375	C7orf50	-0.46	-6.93	-0.31	1.44e-11	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg05665937	chr4:1216051	CTBP1	0.57	10.52	0.44	2.44e-23	Obesity-related traits;
LGG	cis	rs13098911	0.540	rs9845382	chr3:46111759	C/T	cg12691230	chr3:46064611	XCR1	-0.51	-6.97	-0.31	1.07e-11	Celiac disease;
LGG	cis	rs943466	1.000	rs747692	chr6:33737436	C/T	cg07519485	chr6:33762594	MLN	0.54	10.74	0.45	3.7e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1419980	0.673	rs10845432	chr12:7728131	T/C	cg10578777	chr12:7781093	NA	0.61	8.24	0.36	1.78e-15	HDL cholesterol levels;
LGG	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg08499158	chr17:42289980	UBTF	-0.39	-7.01	-0.31	8.69e-12	Total body bone mineral density;
LGG	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg14664628	chr15:75095509	CSK	-1.13	-25.85	-0.77	7.48e-92	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4319547	0.626	rs12423420	chr12:122938466	G/A	cg23029597	chr12:123009494	RSRC2	-0.87	-16.36	-0.61	8.15e-48	Body mass index;
LGG	trans	rs2190422	0.678	rs2190420	chr7:103072998	T/G	cg21537297	chr8:144298583	GPIHBP1	-0.4	-6.68	-0.3	6.76e-11	Morning vs. evening chronotype;
LGG	cis	rs12681287	0.640	rs10086340	chr8:87446789	G/T	cg27223183	chr8:87520930	FAM82B	-0.55	-7.97	-0.35	1.28e-14	Caudate activity during reward;
LGG	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg11040518	chr10:102331378	NA	-0.35	-6.66	-0.3	7.99e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg13802316	chr11:70253460	CTTN	-0.52	-7.4	-0.33	6.33e-13	Coronary artery disease;
LGG	cis	rs4740619	0.846	rs10733302	chr9:15764196	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.93	-0.45	7.02e-25	Body mass index;
LGG	cis	rs75059851	0.756	rs73036081	chr11:133840156	C/T	cg20042908	chr11:133852938	NA	-0.77	-14.33	-0.55	8.49e-39	Schizophrenia;
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg22168489	chr12:122356033	WDR66	0.41	9.3	0.4	5.77e-19	Mean corpuscular volume;
LGG	cis	rs806795	0.513	rs80292109	chr6:26237068	A/G	cg13736514	chr6:26305472	NA	-0.39	-7.0	-0.31	8.85e-12	Mosquito bite size;
LGG	cis	rs1185460	0.547	rs666741	chr11:118911350	A/C	cg24687335	chr11:118901407	SLC37A4	-0.62	-11.38	-0.47	1.3e-26	Coronary artery disease;
LGG	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.46	-8.22	-0.36	2.13e-15	Coronary artery disease;
LGG	cis	rs3806843	0.676	rs2563304	chr5:140072057	C/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2797369	0.713	rs9498519	chr6:101560755	G/A	cg27451362	chr6:101846650	GRIK2	-0.84	-11.2	-0.46	6.29e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg08461457	chr11:2027003	NA	0.4	7.89	0.34	2.23e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg27400746	chr16:89904261	SPIRE2	-0.9	-15.37	-0.58	2.29e-43	Skin colour saturation;
LGG	cis	rs953387	1.000	rs4954568	chr2:136910690	T/A	cg05194412	chr2:137003533	NA	-0.32	-6.86	-0.3	2.18e-11	Arthritis (juvenile idiopathic);
LGG	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg13010199	chr12:38710504	ALG10B	-0.52	-9.67	-0.41	2.96e-20	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg21724239	chr8:58056113	NA	0.5	7.59	0.33	1.78e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08645402	chr16:4508243	NA	-0.49	-9.28	-0.4	6.47e-19	Schizophrenia;
LGG	cis	rs2463822	1.000	rs72921498	chr11:62113090	C/T	cg06239285	chr11:62104954	ASRGL1	-1.13	-15.72	-0.59	6.28e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.71	-0.38	5.56e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg01181863	chr3:195395398	SDHAP2	-0.73	-13.09	-0.52	1.51e-33	Bronchopulmonary dysplasia;
LGG	cis	rs36051895	0.695	rs4527935	chr9:5016455	A/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.71	-0.56	1.91e-40	Pediatric autoimmune diseases;
LGG	cis	rs894344	0.650	rs16905182	chr8:135576794	C/A	cg09855544	chr8:135498122	ZFAT	0.43	7.77	0.34	5.29e-14	Systolic blood pressure;
LGG	cis	rs910316	1.000	rs175426	chr14:75624134	C/T	cg11812906	chr14:75593930	NEK9	-0.52	-9.81	-0.41	8.96e-21	Height;
LGG	cis	rs12048904	0.595	rs10493937	chr1:101342650	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.66	-15.92	-0.59	7.63e-46	Multiple sclerosis;
LGG	cis	rs490234	0.756	rs2416963	chr9:128241414	C/T	cg14078157	chr9:128172775	NA	-0.44	-8.19	-0.36	2.6e-15	Mean arterial pressure;
LGG	cis	rs7904985	0.924	rs2217223	chr10:88111630	A/G	cg07322936	chr10:88137208	NA	0.52	8.28	0.36	1.31e-15	Barrett's esophagus;
LGG	cis	rs2859741	0.528	rs2359647	chr1:37483054	A/T	cg09363841	chr1:37513479	NA	-0.57	-11.47	-0.47	5.84e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs7432375	0.966	rs7618871	chr3:136400420	G/T	cg21827317	chr3:136751795	NA	-0.48	-8.66	-0.37	7.69e-17	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg06654118	chr4:1303317	MAEA	0.4	7.01	0.31	8.73e-12	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs17222691	chr17:56771096	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.95	0.57	1.63e-41	Cognitive test performance;
LGG	cis	rs7011049	0.915	rs78887309	chr8:53860016	A/C	cg26025543	chr8:53854495	NA	0.75	9.68	0.41	2.58e-20	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg22535103	chr8:58192502	C8orf71	-0.96	-12.63	-0.51	1.26e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	0.935	rs60515555	chr6:126000638	T/G	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	cis	rs7843479	1.000	rs66824050	chr8:21815425	T/G	cg17168535	chr8:21777572	XPO7	0.6	9.74	0.41	1.65e-20	Mean corpuscular volume;
LGG	cis	rs4132509	0.744	rs12031994	chr1:243917309	T/C	cg21452805	chr1:244014465	NA	0.94	9.28	0.4	6.78e-19	RR interval (heart rate);
LGG	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg00711542	chr16:29343894	RUNDC2C	0.41	6.83	0.3	2.64e-11	Menopause (age at onset);
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg08355456	chr11:67383691	NA	0.48	8.13	0.35	3.92e-15	Mean corpuscular volume;
LGG	trans	rs9914544	0.545	rs4924940	chr17:18800092	T/C	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg05555928	chr11:63887634	MACROD1	0.58	8.61	0.37	1.16e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9783347	1.000	rs4150579	chr11:18357180	C/T	cg15585147	chr11:18324498	HPS5	-0.42	-8.66	-0.37	7.75e-17	Pancreatic cancer;
LGG	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg07148914	chr20:33460835	GGT7	0.53	8.64	0.37	8.85e-17	Height;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.12	0.35	4.14e-15	Prostate cancer;
LGG	cis	rs367943	0.698	rs2217296	chr5:112973829	A/T	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg01420254	chr6:26195488	NA	0.84	10.98	0.45	4.48e-25	Gout;Renal underexcretion gout;
LGG	cis	rs9504361	0.808	rs2277096	chr6:564515	G/T	cg13471009	chr6:564609	EXOC2	-0.37	-8.05	-0.35	7.06e-15	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg07511668	chr11:68622177	NA	0.51	9.54	0.41	8.08e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg02127607	chr17:61920694	SMARCD2	-0.44	-7.82	-0.34	3.49e-14	Prudent dietary pattern;
LGG	cis	rs7552404	0.960	rs12134854	chr1:76137606	A/G	cg03433033	chr1:76189801	ACADM	0.8	14.4	0.56	4.3e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg25214090	chr10:38739885	LOC399744	0.61	11.09	0.46	1.64e-25	Corneal astigmatism;
LGG	cis	rs372883	0.638	rs117213	chr21:30720536	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-9.87	-0.42	5.37e-21	Pancreatic cancer;
LGG	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.45	0.44	4.38e-23	Retinal vascular caliber;
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.42	-0.4	2.1e-19	Neuroticism;
LGG	cis	rs7011049	0.915	rs66905540	chr8:53862641	A/G	cg26025543	chr8:53854495	NA	0.6	8.48	0.37	2.95e-16	Systolic blood pressure;
LGG	cis	rs2836974	0.568	rs429955	chr21:40539760	G/A	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.26e-36	Cognitive function;
LGG	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg18681998	chr4:17616180	MED28	0.89	20.45	0.69	1.02e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4740619	0.590	rs4247294	chr9:16030960	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.78	-0.45	2.42e-24	Body mass index;
LGG	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs7614311	0.636	rs73130576	chr3:63890875	T/C	cg22134162	chr3:63841271	THOC7	-0.45	-8.13	-0.35	3.98e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs4737010	0.644	rs522407	chr8:41610969	G/A	cg17182837	chr8:41585554	ANK1	0.45	7.01	0.31	8.46e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs929354	0.742	rs7806775	chr7:156947199	A/G	cg05182265	chr7:156933206	UBE3C	-0.37	-7.49	-0.33	3.41e-13	Body mass index;
LGG	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg05082376	chr22:42548792	NA	0.37	7.84	0.34	3.16e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg23743428	chr13:21893420	NA	-0.51	-11.26	-0.46	3.71e-26	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg00334542	chr7:100209784	MOSPD3	-0.52	-7.32	-0.32	1.11e-12	Other erythrocyte phenotypes;
LGG	cis	rs9831754	0.704	rs9823412	chr3:78457646	T/C	cg06138941	chr3:78371609	NA	-0.81	-15.66	-0.59	1.19e-44	Calcium levels;
LGG	cis	rs2070677	0.542	rs7086127	chr10:135393731	T/C	cg20169779	chr10:135381914	SYCE1	-0.99	-12.64	-0.51	1.15e-31	Gout;
LGG	cis	rs758324	0.947	rs476428	chr5:131301615	G/A	cg06307176	chr5:131281290	NA	-0.58	-9.45	-0.4	1.74e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9815354	0.812	rs73075234	chr3:42051801	G/A	cg03022575	chr3:42003672	ULK4	0.66	7.92	0.35	1.75e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1062177	1.000	rs2964612	chr5:151198750	G/A	cg00977110	chr5:151150581	G3BP1	0.5	7.88	0.34	2.36e-14	Preschool internalizing problems;
LGG	cis	rs228437	1.000	rs6934385	chr6:134916471	A/G	cg24504307	chr6:134963096	NA	0.4	7.55	0.33	2.36e-13	Melanoma;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg00800038	chr16:89945340	TCF25	-0.71	-9.35	-0.4	3.72e-19	Skin colour saturation;
LGG	cis	rs1009647	0.656	rs10147254	chr14:55850315	C/A	cg04306507	chr14:55594613	LGALS3	0.53	12.6	0.51	1.59e-31	Testicular germ cell tumor;
LGG	cis	rs6088590	1.000	rs6087626	chr20:33347328	C/T	cg08999081	chr20:33150536	PIGU	0.32	7.46	0.33	4.36e-13	Coronary artery disease;
LGG	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg00383909	chr3:49044727	WDR6	0.43	7.09	0.31	5.09e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7193541	0.684	rs9931225	chr16:74699293	T/C	cg01733217	chr16:74700730	RFWD3	1.11	36.04	0.86	1.95e-136	Multiple myeloma;
LGG	cis	rs6087990	0.735	rs2424928	chr20:31388636	T/C	cg13636640	chr20:31349939	DNMT3B	0.83	17.38	0.63	1.84e-52	Ulcerative colitis;
LGG	cis	rs3820928	0.874	rs1949807	chr2:227891861	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.63	-0.33	1.34e-13	Pulmonary function;
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg09264619	chr17:80180166	NA	-0.37	-7.5	-0.33	3.35e-13	Life satisfaction;
LGG	cis	rs3733585	0.624	rs76574510	chr4:9953252	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.45	-0.37	3.67e-16	Systolic blood pressure;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3925075	0.966	rs12935192	chr16:31359330	G/A	cg02846316	chr16:31340340	ITGAM	0.41	8.15	0.35	3.51e-15	IgA nephropathy;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs11729753	chr4:98803267	T/A	cg05340658	chr4:99064831	C4orf37	0.46	7.36	0.32	8.41e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.09	-0.42	9.33e-22	Type 2 diabetes;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.8	-0.41	9.6e-21	Personality dimensions;
LGG	cis	rs11650494	0.908	rs11658111	chr17:47383994	C/T	cg08112188	chr17:47440006	ZNF652	1.27	15.26	0.58	6.92e-43	Prostate cancer;
LGG	cis	rs4950322	0.570	rs72692963	chr1:146802821	G/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs7017914	0.934	rs6992879	chr8:71699283	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.52	-0.33	2.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg13902645	chr11:5959945	NA	-0.64	-9.93	-0.42	3.53e-21	DNA methylation (variation);
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg02592271	chr2:27665507	KRTCAP3	0.31	8.3	0.36	1.14e-15	Total body bone mineral density;
LGG	cis	rs6088590	0.687	rs13044899	chr20:33287078	G/A	cg08999081	chr20:33150536	PIGU	0.35	8.54	0.37	1.99e-16	Coronary artery disease;
LGG	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs12410462	0.591	rs903692	chr1:227732721	A/G	cg21459583	chr1:227974177	NA	0.36	6.85	0.3	2.31e-11	Major depressive disorder;
LGG	cis	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg06521331	chr12:34319734	NA	-0.41	-7.22	-0.32	2.2e-12	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-12.89	-0.51	1.07e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg11584989	chr19:19387371	SF4	0.73	12.23	0.49	5.22e-30	Bipolar disorder;
LGG	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg00129232	chr17:37814104	STARD3	-0.6	-11.36	-0.47	1.56e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	7.83	0.34	3.47e-14	Joint mobility (Beighton score);
LGG	trans	rs7181230	0.848	rs7497289	chr15:40333657	G/A	cg22705835	chr10:65332833	REEP3	-0.61	-9.92	-0.42	3.55e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs380904	0.519	rs1377663	chr8:144644787	T/A	cg21643262	chr8:144646939	NA	-0.52	-7.79	-0.34	4.35e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg25664220	chr3:72788482	NA	-0.28	-7.73	-0.34	6.74e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg24846343	chr22:24311635	DDTL	0.61	12.66	0.51	9.43e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.93	0.38	1e-17	Schizophrenia;
LGG	cis	rs6577655	0.501	rs879104	chr8:135609537	G/A	cg17885191	chr8:135476712	NA	0.44	7.1	0.31	4.75e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21465180	chr2:54682970	SPTBN1	0.47	7.47	0.33	4.05e-13	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg09307838	chr4:120376055	NA	-0.59	-9.53	-0.41	8.74e-20	Corneal astigmatism;
LGG	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg00757033	chr12:89920650	WDR51B	0.65	9.58	0.41	6.15e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs283228	0.617	rs600842	chr6:101744450	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.51	-0.5	3.88e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	9.48	0.4	1.32e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.29e-18	Motion sickness;
LGG	cis	rs6878727	0.815	rs9885338	chr5:123725320	G/A	cg01806427	chr5:123737813	NA	0.32	6.76	0.3	4.19e-11	Breast cancer;
LGG	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg01620082	chr3:125678407	NA	-0.56	-7.2	-0.32	2.38e-12	Depression;
LGG	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg12419862	chr22:24373484	LOC391322	-0.84	-15.09	-0.57	3.78e-42	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg16606324	chr3:10149918	C3orf24	-0.52	-6.91	-0.31	1.56e-11	Alzheimer's disease;
LGG	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg21782813	chr7:2030301	MAD1L1	0.56	14.47	0.56	2.06e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs7571561	0.625	rs6712295	chr2:213275113	A/G	cg16329650	chr2:213403929	ERBB4	0.47	6.86	0.3	2.27e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg02002194	chr4:3960332	NA	0.44	7.98	0.35	1.13e-14	Neuroticism;
LGG	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg02487422	chr3:49467188	NICN1	0.43	6.96	0.31	1.16e-11	Resting heart rate;
LGG	cis	rs11997175	1.000	rs7838577	chr8:33760802	A/G	ch.8.33884649F	chr8:33765107	NA	0.36	6.71	0.3	5.81e-11	Body mass index;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	18.73	0.66	1.07e-58	Personality dimensions;
LGG	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.3e-14	Aortic root size;
LGG	cis	rs9463078	0.625	rs500773	chr6:44888464	C/T	cg25276700	chr6:44698697	NA	-0.33	-6.88	-0.3	1.9e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9902453	0.817	rs12941382	chr17:28410124	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.46	-0.53	4.39e-35	Coffee consumption (cups per day);
LGG	cis	rs2649	0.518	rs4984250	chr15:63866834	A/T	cg22599514	chr15:63798201	USP3	0.44	7.37	0.32	7.87e-13	Aortic root size;
LGG	cis	rs7756236	0.521	rs6907437	chr6:36625021	A/G	cg08179530	chr6:36648295	CDKN1A	0.42	6.69	0.3	6.51e-11	QRS duration;
LGG	cis	rs17453880	0.929	rs11951715	chr5:151953104	A/G	cg12297329	chr5:152029980	NA	-0.86	-21.92	-0.71	1.35e-73	Subjective well-being;
LGG	cis	rs7584262	0.822	rs1550428	chr2:42240763	C/G	cg19376973	chr2:42229025	NA	0.65	9.64	0.41	3.72e-20	Bone mineral density;
LGG	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.69	0.34	9.04e-14	Mood instability;
LGG	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg17971929	chr21:40555470	PSMG1	0.84	16.0	0.6	3.54e-46	Cognitive function;
LGG	cis	rs7914558	1.000	rs1926030	chr10:104855656	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.58	0.44	1.45e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17767392	0.846	rs12884929	chr14:71788946	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.69	-0.37	6.3e-17	Mitral valve prolapse;
LGG	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg13385794	chr1:248469461	NA	0.48	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.92	-0.38	1.06e-17	Lymphocyte counts;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-10.98	-0.45	4.23e-25	Neuroticism;
LGG	cis	rs6735179	0.566	rs13416067	chr2:1755898	C/T	cg20570797	chr2:1712800	PXDN	-0.43	-6.79	-0.3	3.49e-11	Response to antipsychotic treatment;
LGG	cis	rs11168618	0.740	rs7312017	chr12:48954225	C/G	cg24011408	chr12:48396354	COL2A1	0.41	6.66	0.3	7.61e-11	Adiponectin levels;
LGG	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg27661571	chr11:113659931	NA	-0.72	-9.61	-0.41	4.53e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg18357526	chr6:26021779	HIST1H4A	0.47	7.86	0.34	2.72e-14	Height;
LGG	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg08822215	chr16:89438651	ANKRD11	-0.36	-7.03	-0.31	7.28e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.72	-0.41	1.84e-20	Primary sclerosing cholangitis;
LGG	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg01221209	chr5:554886	NA	-0.48	-7.75	-0.34	6.05e-14	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2070488	0.804	rs13092473	chr3:38458958	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.69	0.56	2.14e-40	Electrocardiographic conduction measures;
LGG	cis	rs12282928	1.000	rs1566730	chr11:48250854	G/A	cg26585981	chr11:48327164	OR4S1	0.41	6.72	0.3	5.22e-11	Migraine - clinic-based;
LGG	cis	rs546131	0.642	rs512013	chr11:34842225	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.13	0.31	3.8e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.7e-36	Lung cancer;
LGG	cis	rs2455799	0.613	rs9848007	chr3:15852593	T/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.81	-0.34	3.78e-14	Mean platelet volume;
LGG	cis	rs6912958	0.582	rs242285	chr6:88070743	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	13.2	0.52	5.32e-34	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25898425	chr17:7137333	DVL2	0.46	7.12	0.31	4.22e-12	Gut microbiome composition (summer);
LGG	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11987759	chr7:65425863	GUSB	0.37	6.74	0.3	4.71e-11	Aortic root size;
LGG	cis	rs76419734	0.510	rs2553446	chr4:106696476	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.66	-0.34	1.13e-13	Post bronchodilator FEV1;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17281638	chr2:33952673	MYADML	0.37	6.94	0.31	1.31e-11	Electrocardiographic conduction measures;
LGG	cis	rs17253792	0.822	rs17253723	chr14:56154015	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.47	8.2	0.36	2.37e-15	Longevity;
LGG	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27297192	chr10:134578999	INPP5A	0.31	7.06	0.31	5.94e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg04287289	chr16:89883240	FANCA	0.89	8.77	0.38	3.39e-17	Skin colour saturation;
LGG	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg21972741	chr5:435613	AHRR	0.49	8.89	0.38	1.4e-17	Cystic fibrosis severity;
LGG	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.89	-10.97	-0.45	4.96e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3849570	0.695	rs6804587	chr3:81873423	T/C	cg07356753	chr3:81810745	GBE1	-0.47	-7.62	-0.33	1.49e-13	Waist circumference;Body mass index;
LGG	cis	rs10463554	0.963	rs257319	chr5:102445827	T/A	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	cis	rs4262150	0.641	rs7379700	chr5:152325534	C/T	cg12297329	chr5:152029980	NA	0.57	10.89	0.45	9.29e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	1.000	rs975323	chr3:161021322	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-14.74	-0.57	1.33e-40	Morning vs. evening chronotype;
LGG	cis	rs2084898	0.527	rs605374	chr11:120005633	A/C	cg07435449	chr11:120005650	TRIM29	0.73	14.12	0.55	6.4e-38	Stroke (pediatric);
LGG	cis	rs3750450	0.718	rs10119402	chr9:111938125	G/T	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg23306229	chr2:178417860	TTC30B	0.69	9.23	0.39	9.69e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.57e-22	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.4	0.63	1.48e-52	Obesity-related traits;
LGG	trans	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-10.08	-0.42	9.4e-22	Diabetic retinopathy;
LGG	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs61990749	0.597	rs10148373	chr14:78280199	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	6.78	0.3	3.71e-11	Fibroblast growth factor basic levels;
LGG	cis	rs7166081	1.000	rs8042007	chr15:67652976	C/T	cg24231037	chr15:68117551	LBXCOR1	0.32	7.28	0.32	1.4e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.23	0.49	5.13e-30	Prudent dietary pattern;
LGG	cis	rs4732038	0.565	rs782542	chr7:134269242	A/G	cg06906464	chr7:134288099	NA	-0.72	-20.88	-0.7	1.07e-68	Longevity;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.548	rs2069616	chr5:131408077	A/G	cg07395648	chr5:131743802	NA	-0.4	-8.54	-0.37	1.88e-16	Blood metabolite levels;
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.28	8.11	0.35	4.55e-15	IgG glycosylation;
LGG	trans	rs11039798	1.000	rs7928243	chr11:48589192	A/T	cg03929089	chr4:120376271	NA	0.74	8.6	0.37	1.23e-16	Axial length;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-15.92	-0.59	7.83e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9878978	0.722	rs13072674	chr3:2460712	A/C	cg21928760	chr3:2462534	CNTN4	0.46	8.86	0.38	1.77e-17	Blood pressure (smoking interaction);
LGG	cis	rs4780401	0.703	rs3190321	chr16:11773662	C/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.18	-0.32	2.81e-12	Rheumatoid arthritis;
LGG	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.87	-10.58	-0.44	1.43e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1348850	0.789	rs13027959	chr2:178275887	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.48	-0.37	3.05e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9341808	0.718	rs12208016	chr6:80823563	G/A	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg18279126	chr7:2041391	MAD1L1	0.32	6.84	0.3	2.59e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs745821	0.701	rs75376611	chr18:48099877	A/G	cg18923635	chr18:48083994	NA	0.42	7.57	0.33	2.02e-13	Diastolic blood pressure;
LGG	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.98e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7766436	0.885	rs4712698	chr6:22592807	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg15971980	chr6:150254442	NA	0.44	8.87	0.38	1.66e-17	Lung cancer;
LGG	trans	rs5756813	0.833	rs5756819	chr22:38188195	A/C	cg19894588	chr14:64061835	NA	0.68	11.56	0.47	2.44e-27	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9828933	0.766	rs864975	chr3:63885615	T/C	cg17941049	chr3:63904683	ATXN7	-0.7	-7.09	-0.31	5.07e-12	Type 2 diabetes;
LGG	cis	rs607541	1.000	rs674568	chr15:45936587	A/T	cg26924012	chr15:45694286	SPATA5L1	0.51	7.12	0.31	4.23e-12	Obesity-related traits;
LGG	cis	rs7173743	0.756	rs12903613	chr15:79129076	G/T	cg00540400	chr15:79124168	NA	0.39	8.01	0.35	9.52e-15	Coronary artery disease;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg00495681	chr13:53174319	NA	0.51	9.13	0.39	2.1e-18	Lewy body disease;
LGG	cis	rs2073300	1.000	rs6137960	chr20:23442886	G/A	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.86	0.34	2.64e-14	Colorectal cancer;
LGG	cis	rs4315565	0.688	rs11887395	chr2:69270926	A/G	cg13358873	chr2:69271042	ANTXR1	-0.51	-8.25	-0.36	1.64e-15	Height;
LGG	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg00049323	chr5:472564	LOC25845	0.4	8.77	0.38	3.34e-17	Cystic fibrosis severity;
LGG	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.08	-0.31	5.49e-12	Schizophrenia;
LGG	cis	rs12600053	0.687	rs11149686	chr16:84847247	A/G	cg09249803	chr16:84846936	NA	0.36	7.71	0.34	7.59e-14	Asthma (childhood onset);
LGG	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.83	-0.34	3.37e-14	HDL cholesterol;
LGG	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg12310025	chr6:25882481	NA	-0.56	-10.87	-0.45	1.2e-24	Blood metabolite levels;
LGG	cis	rs8114671	0.836	rs2425012	chr20:33581955	G/A	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.34	-0.36	8.52e-16	Height;
LGG	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg17749961	chr2:30669863	LCLAT1	0.68	9.61	0.41	4.75e-20	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.27	-0.58	6.51e-43	Prudent dietary pattern;
LGG	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs367943	0.608	rs2972669	chr5:112983599	C/T	cg12552261	chr5:112820674	MCC	-0.51	-8.96	-0.38	8.03e-18	Type 2 diabetes;
LGG	cis	rs9815354	0.812	rs73073358	chr3:41842527	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg02002194	chr4:3960332	NA	-0.4	-7.1	-0.31	4.59e-12	Retinal vascular caliber;
LGG	cis	rs638893	1.000	rs583905	chr11:118695908	G/A	cg22253036	chr11:118662786	DDX6	0.43	7.14	0.31	3.61e-12	Vitiligo;
LGG	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg11984989	chr7:158649758	WDR60	1.01	14.36	0.56	5.89e-39	Height;
LGG	cis	rs10267417	0.603	rs12668717	chr7:19932912	G/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs8016982	0.674	rs6574631	chr14:81675772	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	18.88	0.66	2.23e-59	Schizophrenia;
LGG	cis	rs12200782	0.929	rs72836467	chr6:26353927	A/G	cg11502198	chr6:26597334	ABT1	-0.76	-6.82	-0.3	2.77e-11	Small cell lung carcinoma;
LGG	cis	rs459571	0.959	rs455381	chr9:136905577	C/A	cg13789015	chr9:136890014	NCRNA00094	0.59	11.09	0.46	1.68e-25	Platelet distribution width;
LGG	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.07	-0.35	6.08e-15	Retinal vascular caliber;
LGG	cis	rs483180	0.511	rs496195	chr1:120207182	A/G	cg19096424	chr1:120255104	PHGDH	-0.57	-10.24	-0.43	2.52e-22	Macular telangiectasia type 2;
LGG	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg13010199	chr12:38710504	ALG10B	0.65	13.4	0.53	7.47e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9783347	1.000	rs3740711	chr11:18379839	T/C	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.41	-0.33	5.93e-13	Pancreatic cancer;
LGG	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15369054	chr17:80825471	TBCD	0.51	6.99	0.31	9.63e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs807669	0.544	rs2040771	chr22:19161935	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	9.99	0.42	2.04e-21	Metabolite levels;
LGG	cis	rs2455601	0.638	rs2742484	chr11:8988083	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-10.97	-0.45	4.75e-25	Schizophrenia;
LGG	cis	rs7959452	0.535	rs4761228	chr12:69682327	G/A	cg14784868	chr12:69753453	YEATS4	0.71	13.11	0.52	1.26e-33	Blood protein levels;
LGG	cis	rs847649	0.692	rs10257317	chr7:102447056	T/C	cg18108683	chr7:102477205	FBXL13	-0.7	-15.64	-0.59	1.4e-44	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7192750	0.617	rs9929256	chr16:72040032	A/C	cg06353428	chr16:71660113	MARVELD3	0.9	8.7	0.37	5.89e-17	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-15.77	-0.59	3.64e-45	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.967	rs1719854	chr12:39127707	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg00919237	chr7:87102261	ABCB4	-0.78	-15.87	-0.59	1.37e-45	Gallbladder cancer;
LGG	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg22771759	chr13:24902376	NA	0.41	6.86	0.3	2.2e-11	Obesity-related traits;
LGG	cis	rs28595532	0.623	rs34958556	chr4:119222074	C/T	cg21605333	chr4:119757512	SEC24D	0.88	9.54	0.41	8.08e-20	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs774359	0.789	rs2492815	chr9:27490296	T/C	cg22262168	chr9:27528999	MOBKL2B	0.44	6.77	0.3	3.89e-11	Amyotrophic lateral sclerosis;
LGG	trans	rs459571	0.834	rs379417	chr9:136890704	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.88	-0.48	1.3e-28	Platelet distribution width;
LGG	cis	rs11834862	0.598	rs11246996	chr12:132690579	C/A	cg16245054	chr12:132698494	GALNT9	-0.46	-6.87	-0.3	2.04e-11	Anti-saccade response;
LGG	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6665290	0.904	rs11578103	chr1:227189642	C/A	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs10979	0.557	rs9285501	chr6:143915121	G/C	cg25407410	chr6:143891975	LOC285740	-0.54	-7.92	-0.35	1.74e-14	Hypospadias;
LGG	cis	rs7312933	0.966	rs7977365	chr12:42513127	G/A	cg19980929	chr12:42632907	YAF2	0.35	7.77	0.34	5.14e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Vitiligo;
LGG	cis	rs2070488	0.804	rs7372452	chr3:38444298	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.64	0.56	3.68e-40	Electrocardiographic conduction measures;
LGG	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.69	0.3	6.44e-11	Vitiligo;
LGG	cis	rs7666738	0.830	rs1834645	chr4:98979593	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.91	0.35	1.87e-14	Longevity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg25618087	chr8:30890555	PURG;WRN	0.59	6.81	0.3	2.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg13334819	chr7:99746414	C7orf59	0.5	7.83	0.34	3.44e-14	Coronary artery disease;
LGG	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.33e-17	Self-reported allergy;
LGG	cis	rs8114671	0.967	rs12481169	chr20:33794510	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-7.33	-0.32	1.05e-12	Height;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09217309	chr6:150244204	RAET1G	0.41	7.47	0.33	3.99e-13	Testicular germ cell tumor;
LGG	cis	rs963731	0.579	rs297158	chr2:39328640	T/C	cg04010122	chr2:39346883	SOS1	-0.77	-7.21	-0.32	2.33e-12	Corticobasal degeneration;
LGG	cis	rs8027181	0.617	rs12439200	chr15:73086731	A/G	cg02923145	chr15:73089643	NA	0.47	8.99	0.39	6.53e-18	Triglyceride levels;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg14912033	chr15:79043428	NA	-0.4	-10.32	-0.43	1.33e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.25	0.55	1.86e-38	Tonsillectomy;
LGG	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg26513180	chr16:89883248	FANCA	-0.54	-9.53	-0.4	8.94e-20	Vitiligo;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg04025307	chr7:1156635	C7orf50	0.64	8.32	0.36	9.83e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg18258770	chr4:90757814	SNCA	-0.4	-7.25	-0.32	1.81e-12	Dementia with Lewy bodies;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg26001287	chr2:111877753	BCL2L11	-0.38	-7.71	-0.34	7.83e-14	Chronic lymphocytic leukemia;
LGG	trans	rs1032833	0.732	rs115960966	chr2:180020702	C/T	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg14912033	chr15:79043428	NA	0.35	7.14	0.31	3.7e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs4650994	0.625	rs6681354	chr1:178526279	A/G	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg27205649	chr11:78285834	NARS2	0.43	7.05	0.31	6.4e-12	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4716602	0.596	rs10266659	chr7:156159278	A/G	cg16983916	chr7:156159713	NA	-0.49	-9.58	-0.41	5.92e-20	Anti-saccade response;
LGG	cis	rs1847202	0.859	rs4501056	chr3:72948908	A/T	cg25664220	chr3:72788482	NA	-0.26	-7.63	-0.33	1.32e-13	Motion sickness;
LGG	cis	rs988958	0.526	rs36109745	chr2:42252990	C/A	cg19376973	chr2:42229025	NA	0.64	9.53	0.4	8.85e-20	Hypospadias;
LGG	cis	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg00614314	chr15:82944287	LOC80154	0.46	7.82	0.34	3.56e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg02158880	chr13:53174818	NA	-0.43	-8.49	-0.37	2.87e-16	Lewy body disease;
LGG	cis	rs11700980	0.551	rs59945036	chr21:30118962	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.69	-0.3	6.66e-11	QRS complex (12-leadsum);
LGG	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg06623630	chr22:50017776	C22orf34	-0.36	-7.6	-0.33	1.67e-13	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.82	0.34	3.61e-14	Retinal vascular caliber;
LGG	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.67	-0.44	6.51e-24	Calcium levels;
LGG	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.01	-0.42	1.78e-21	Menarche (age at onset);
LGG	cis	rs9818758	0.607	rs113186424	chr3:49272726	T/C	cg00383909	chr3:49044727	WDR6	0.98	12.38	0.5	1.34e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg12560992	chr17:57184187	TRIM37	-0.87	-15.26	-0.58	6.65e-43	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg25986240	chr4:9926439	SLC2A9	-0.49	-10.8	-0.45	2.05e-24	Bone mineral density;
LGG	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg08048268	chr3:133502702	NA	-0.6	-11.02	-0.46	3.07e-25	Iron status biomarkers;
LGG	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.89e-21	Diabetic retinopathy;
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg26174226	chr8:58114915	NA	-0.53	-7.42	-0.33	5.83e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs4843747	0.671	rs4075998	chr16:88106776	G/A	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg18876405	chr7:65276391	NA	-0.55	-9.74	-0.41	1.59e-20	Aortic root size;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg14789659	chr10:63809073	ARID5B	-0.35	-6.86	-0.3	2.26e-11	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11644478	chr21:40555479	PSMG1	-0.73	-13.3	-0.53	2.13e-34	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10268889	chr4:24474079	NA	0.48	7.28	0.32	1.47e-12	Gut microbiome composition (summer);
LGG	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.91e-35	Resting heart rate;
LGG	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.32	7.01e-13	Schizophrenia;
LGG	cis	rs12928939	0.723	rs71403864	chr16:71695030	C/T	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.06	-0.39	3.73e-18	Post bronchodilator FEV1;
LGG	cis	rs3741151	0.686	rs7941359	chr11:73158119	A/G	cg17517138	chr11:73019481	ARHGEF17	0.71	7.83	0.34	3.42e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs881375	0.967	rs7039505	chr9:123705945	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.71	0.48	6.15e-28	Rheumatoid arthritis;
LGG	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg27129171	chr3:47204927	SETD2	0.64	10.76	0.45	3.02e-24	Birth weight;
LGG	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs4917300	0.605	rs1388800	chr8:143106264	C/T	cg26003909	chr8:143102224	NA	0.34	7.52	0.33	2.88e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg06191203	chr2:152266755	RIF1	0.46	8.16	0.35	3.12e-15	Lung cancer;
LGG	cis	rs73198271	0.599	rs10103169	chr8:8650698	T/A	cg01851573	chr8:8652454	MFHAS1	0.37	6.82	0.3	2.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9811920	0.928	rs2130369	chr3:99873317	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.45	7.87	0.34	2.52e-14	Axial length;
LGG	cis	rs504918	1.000	rs1838669	chr3:124080743	T/C	cg05766129	chr3:123988013	KALRN	-0.39	-7.08	-0.31	5.3e-12	Schizophrenia;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs7106204	0.748	rs11827778	chr11:24211321	G/A	ch.11.24196551F	chr11:24239977	NA	1.04	16.23	0.6	3.06e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7737355	0.773	rs27450	chr5:131006082	A/G	cg06307176	chr5:131281290	NA	0.53	8.75	0.38	4.1e-17	Life satisfaction;
LGG	cis	rs240764	0.578	rs12215909	chr6:101227598	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.58e-15	Neuroticism;
LGG	cis	rs504918	0.588	rs6779809	chr3:123964485	A/T	cg05766129	chr3:123988013	KALRN	0.58	10.59	0.44	1.34e-23	Schizophrenia;
LGG	cis	rs9393777	0.546	rs35589403	chr6:27219491	C/G	cg12292205	chr6:26970375	C6orf41	-0.63	-9.16	-0.39	1.71e-18	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg24375607	chr4:120327624	NA	0.69	11.15	0.46	1.01e-25	Corneal astigmatism;
LGG	cis	rs9357271	0.652	rs62397055	chr6:38432656	C/T	cg07362130	chr6:38359646	BTBD9	-0.38	-7.49	-0.33	3.49e-13	Restless legs syndrome;
LGG	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg07936489	chr17:37558343	FBXL20	-0.52	-8.84	-0.38	1.97e-17	Asthma;
LGG	trans	rs9329221	0.537	rs1351876	chr8:9984777	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.5	-0.37	2.66e-16	Neuroticism;
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg07414643	chr4:187882934	NA	0.56	11.49	0.47	4.89e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12493885	0.769	rs61791510	chr3:153754666	G/T	cg17054900	chr3:154042577	DHX36	-0.72	-8.91	-0.38	1.21e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg24450063	chr1:156163899	SLC25A44	1.23	31.14	0.82	1.19e-115	Testicular germ cell tumor;
LGG	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg27490568	chr2:178487706	NA	0.47	9.35	0.4	3.79e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	9.2	0.39	1.2e-18	Cognitive test performance;
LGG	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg21475434	chr5:93447410	FAM172A	0.7	7.17	0.32	3.02e-12	Diabetic retinopathy;
LGG	trans	rs1422110	0.543	rs768240	chr5:85420954	C/T	cg01787110	chr1:109008453	NBPF6	-0.77	-13.05	-0.52	2.37e-33	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg24565620	chr2:194026	NA	0.72	7.45	0.33	4.55e-13	Blood protein levels;
LGG	cis	rs490234	0.552	rs3122938	chr9:128157326	A/G	cg14078157	chr9:128172775	NA	0.57	10.78	0.45	2.47e-24	Mean arterial pressure;
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.87	-0.3	2.05e-11	Aortic root size;
LGG	cis	rs963731	0.649	rs2924710	chr2:39302757	G/C	cg04010122	chr2:39346883	SOS1	-0.82	-7.6	-0.33	1.61e-13	Corticobasal degeneration;
LGG	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.95	0.52	5.79e-33	IgG glycosylation;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg10387901	chr3:15106641	MRPS25	0.43	6.65	0.3	8.39e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg11494091	chr17:61959527	GH2	0.62	10.61	0.44	1.12e-23	Height;
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.81	0.48	2.61e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg27523141	chr10:43048294	ZNF37B	0.32	6.72	0.3	5.44e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg05360138	chr12:110035743	NA	0.59	8.88	0.38	1.53e-17	Neuroticism;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.78	-0.3	3.59e-11	Height;
LGG	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg19336497	chr11:14380999	RRAS2	-0.56	-11.53	-0.47	3.27e-27	Sense of smell;
LGG	cis	rs9503598	0.644	rs10498663	chr6:3430439	C/T	cg00476032	chr6:3446245	SLC22A23	-0.43	-8.44	-0.37	4.04e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs924476	chr16:48556847	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.94	0.38	9.62e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1003719	0.762	rs3787780	chr21:38462614	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.82	16.63	0.61	4.81e-49	Eye color traits;
LGG	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg10792982	chr14:105748885	BRF1	0.65	13.0	0.52	3.7e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.24	0.32	1.89e-12	Life satisfaction;
LGG	cis	rs7215564	0.908	rs74000898	chr17:78653532	A/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg09640425	chr7:158790006	NA	-0.36	-6.75	-0.3	4.45e-11	Facial morphology (factor 20);
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg05861140	chr6:150128134	PCMT1	-0.4	-8.01	-0.35	9.16e-15	Lung cancer;
LGG	cis	rs12497850	0.931	rs7430198	chr3:48988760	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.96	0.45	5.2e-25	Parkinson's disease;
LGG	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg03433033	chr1:76189801	ACADM	-0.76	-12.49	-0.5	4.6e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.32	-8.38	-0.36	6.6e-16	IgG glycosylation;
LGG	cis	rs1847202	0.793	rs11918132	chr3:72952144	C/T	cg25664220	chr3:72788482	NA	-0.25	-7.28	-0.32	1.44e-12	Motion sickness;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg06558623	chr16:89946397	TCF25	1.06	13.05	0.52	2.35e-33	Interleukin-17 levels;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg04106633	chr4:1044584	NA	-0.36	-7.72	-0.34	7.34e-14	Recombination rate (males);
LGG	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.23	-0.32	2.04e-12	Caffeine consumption;
LGG	trans	rs7819412	0.558	rs4841483	chr8:10908354	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.33	0.32	1.03e-12	Triglycerides;
LGG	cis	rs2798269	0.966	rs1200039	chr13:22110476	A/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.02	-0.31	7.88e-12	PR segment;
LGG	cis	rs36093844	0.706	rs76504433	chr11:85554260	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.4	-0.33	6.47e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03499777	chr13:98085463	RAP2A	0.42	7.22	0.32	2.17e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6762644	0.507	rs13075137	chr3:4765093	C/T	cg11584376	chr3:4789075	ITPR1	-0.4	-8.5	-0.37	2.69e-16	Breast cancer;
LGG	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg16576597	chr16:28551801	NUPR1	0.43	10.26	0.43	2.23e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4430311	0.723	rs12144559	chr1:243723214	C/A	cg25706552	chr1:244017396	NA	-0.64	-15.25	-0.58	8.02e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg11494091	chr17:61959527	GH2	0.6	10.18	0.43	4.39e-22	Height;
LGG	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg01221209	chr5:554886	NA	-0.48	-7.03	-0.31	7.47e-12	Obesity-related traits;
LGG	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.52e-13	Aortic root size;
LGG	trans	rs1493916	0.744	rs7504560	chr18:31312148	A/G	cg27147174	chr7:100797783	AP1S1	-0.65	-12.01	-0.49	4.15e-29	Life satisfaction;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04709771	chr16:646395	RAB40C	0.37	6.92	0.31	1.48e-11	Height;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg11878867	chr6:150167359	LRP11	-0.53	-11.05	-0.46	2.45e-25	Lung cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg25550677	chr6:43027568	KLC4;MRPL2	-0.36	-6.67	-0.3	7.4e-11	Brain structure;
LGG	cis	rs4538187	0.585	rs329478	chr2:64257746	A/G	cg19915305	chr2:64069682	UGP2	0.62	12.3	0.5	2.9e-30	Systolic blood pressure;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg06968155	chr5:131705112	SLC22A5	-0.65	-7.69	-0.34	9.16e-14	Rheumatoid arthritis;
LGG	cis	rs60695258	0.529	rs340630	chr4:87958395	G/A	cg11209507	chr4:87813803	C4orf36	-0.46	-7.93	-0.35	1.65e-14	Hematocrit;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg13206674	chr6:150067644	NUP43	0.63	14.33	0.55	8.58e-39	Lung cancer;
LGG	cis	rs75920871	0.557	rs11216275	chr11:116975704	T/G	cg01368799	chr11:117014884	PAFAH1B2	-0.53	-7.16	-0.32	3.14e-12	Subjective well-being;
LGG	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg02227867	chr8:22457446	C8orf58	-0.43	-8.08	-0.35	5.87e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03941577	chr4:26862456	STIM2	0.43	6.87	0.3	2.12e-11	Hip circumference;
LGG	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg02487422	chr3:49467188	NICN1	0.58	10.68	0.44	5.81e-24	Resting heart rate;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.61	-0.33	1.5e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg20476274	chr7:133979776	SLC35B4	0.77	15.5	0.58	5.94e-44	Mean platelet volume;
LGG	cis	rs10895140	0.709	rs1938865	chr11:101502034	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.85	-0.3	2.37e-11	Menarche (age at onset);
LGG	cis	rs6714710	0.603	rs12104810	chr2:98443658	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg15704280	chr7:45808275	SEPT13	-1.02	-22.9	-0.73	3.54e-78	Coronary artery disease;
LGG	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg17050807	chr22:42548356	NA	-0.34	-6.65	-0.3	8.34e-11	Cognitive function;
LGG	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg15128208	chr22:42549153	NA	0.79	12.59	0.51	1.77e-31	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08677398	chr8:58056175	NA	0.57	8.78	0.38	3.24e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08677398	chr8:58056175	NA	0.5	7.88	0.34	2.43e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.784	rs75694945	chr11:48865463	C/T	cg15704280	chr7:45808275	SEPT13	0.5	8.2	0.36	2.37e-15	HDL cholesterol;
LGG	cis	rs2280630	0.529	rs4342048	chr3:39012943	A/G	cg01426195	chr3:39028469	NA	-0.66	-14.13	-0.55	5.79e-38	Verbal declarative memory;
LGG	cis	rs6787391	0.545	rs7645905	chr3:4758244	T/G	cg11584376	chr3:4789075	ITPR1	-0.4	-8.49	-0.37	2.73e-16	Breast cancer;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.74	13.91	0.54	5.17e-37	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs490234	0.719	rs13296519	chr9:128471924	G/T	cg14078157	chr9:128172775	NA	-0.45	-8.06	-0.35	6.55e-15	Mean arterial pressure;
LGG	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg14101638	chr12:121416612	HNF1A	0.43	9.43	0.4	2.05e-19	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9309473	1.000	rs10175180	chr2:73673123	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.54	-0.33	2.52e-13	Metabolite levels;
LGG	cis	rs61931739	0.500	rs11053243	chr12:34514155	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.96	-0.42	2.63e-21	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.82	-17.24	-0.63	8.11e-52	Personality dimensions;
LGG	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs9921192	0.967	rs251737	chr16:4318305	C/T	cg07945448	chr16:4304224	NA	0.42	6.77	0.3	4.02e-11	Prostate-specific antigen levels;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.83	-0.45	1.61e-24	Triglycerides;
LGG	cis	rs6445975	0.617	rs60962024	chr3:58390212	G/A	cg24175188	chr3:58374923	PXK	-0.55	-8.93	-0.38	9.96e-18	Systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	21.18	0.7	3.9e-70	Homoarginine levels;
LGG	cis	rs155076	1.000	rs261432	chr13:21865915	G/C	cg14456004	chr13:21872349	NA	-1.2	-19.49	-0.67	3.12e-62	White matter hyperintensity burden;
LGG	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg10518543	chr12:38710700	ALG10B	0.41	6.69	0.3	6.41e-11	Morning vs. evening chronotype;
LGG	cis	rs2304069	0.779	rs245080	chr5:149354805	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.69	-11.22	-0.46	5.2e-26	HIV-1 control;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.25	-0.32	1.82e-12	Bipolar disorder;
LGG	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22857025	chr5:266934	NA	1.2	12.57	0.5	2.3e-31	Breast cancer;
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-12.79	-0.51	2.65e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2798269	0.966	rs2093804	chr13:22138384	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs9300255	0.602	rs1051431	chr12:123645803	G/A	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	cis	rs7943191	0.768	rs34065644	chr11:62371938	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.6	12.86	0.51	1.42e-32	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs941408	1.000	rs941406	chr19:2803623	A/G	cg06609049	chr19:2785107	THOP1	0.6	9.35	0.4	3.66e-19	Total cholesterol levels;
LGG	cis	rs2016266	0.614	rs7303922	chr12:53654219	A/G	cg04065151	chr12:53682969	ESPL1	-0.57	-8.78	-0.38	3.2e-17	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs897080	0.589	rs1067380	chr2:44646834	A/C	cg00619915	chr2:44497795	NA	-0.5	-6.95	-0.31	1.28e-11	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16032384	chr1:17766173	RCC2	0.45	7.3	0.32	1.3e-12	Cognitive performance;
LGG	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.46	0.33	4.35e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.65	-0.41	3.35e-20	Aortic root size;
LGG	cis	rs933688	0.818	rs10052492	chr5:90759930	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	16.18	0.6	5.52e-47	Smoking behavior;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg02002194	chr4:3960332	NA	0.39	6.71	0.3	5.6e-11	Neuroticism;
LGG	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg04166393	chr7:2884313	GNA12	0.44	8.34	0.36	8.72e-16	Height;
LGG	cis	rs11792861	0.816	rs17792434	chr9:111667319	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.32	0.43	1.29e-22	Menarche (age at onset);
LGG	cis	rs6107516	0.645	rs6107515	chr20:4671381	T/G	cg02413285	chr20:4668134	PRNP	-0.56	-8.9	-0.38	1.29e-17	Creutzfeldt-Jakob disease (variant);Creutzfeldt-Jakob disease (sporadic);
LGG	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg08200770	chr17:80723486	TBCD	-0.46	-8.03	-0.35	7.91e-15	Glycated hemoglobin levels;
LGG	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg24375607	chr4:120327624	NA	0.53	9.01	0.39	5.44e-18	Corneal astigmatism;
LGG	cis	rs2274273	0.710	rs67395212	chr14:55591939	T/A	cg04306507	chr14:55594613	LGALS3	0.51	11.91	0.48	1.05e-28	Protein biomarker;
LGG	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg02503808	chr4:7069936	GRPEL1	-0.97	-13.77	-0.54	2.05e-36	Monocyte percentage of white cells;
LGG	cis	rs910187	0.537	rs6122556	chr20:45763924	T/A	cg27589058	chr20:45804311	EYA2	-0.29	-6.89	-0.3	1.89e-11	Migraine;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-7.01	-0.31	8.63e-12	Schizophrenia;
LGG	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg13312174	chr5:178288687	ZNF354B	-0.35	-6.95	-0.31	1.28e-11	Sleep duration;
LGG	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg16325326	chr1:53192061	ZYG11B	0.86	23.86	0.74	1.26e-82	Monocyte count;
LGG	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg15395560	chr15:45543142	SLC28A2	0.43	7.21	0.32	2.36e-12	Glomerular filtration rate;
LGG	cis	rs7312774	0.618	rs12316286	chr12:107343020	C/A	cg16260113	chr12:107380972	MTERFD3	0.94	8.76	0.38	3.59e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg04156418	chr7:157293606	NA	0.6	13.53	0.53	2.19e-35	Inattentive symptoms;
LGG	trans	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg19694781	chr19:47549865	TMEM160	-0.42	-7.14	-0.31	3.63e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7264396	0.690	rs17093156	chr20:34438583	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.34	-0.32	9.39e-13	Total cholesterol levels;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg02725872	chr8:58115012	NA	-0.96	-14.29	-0.55	1.23e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.567	rs6120879	chr20:30202961	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.68	-0.34	9.31e-14	Mean corpuscular hemoglobin;
LGG	cis	rs56161922	1.000	rs56235509	chr1:207839769	C/G	cg09557387	chr1:207818395	CR1L	0.99	9.69	0.41	2.36e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs2694528	0.844	rs4699961	chr5:60073219	A/T	cg11474532	chr5:59995715	DEPDC1B	0.74	7.79	0.34	4.57e-14	Parkinson's disease;
LGG	cis	rs7927771	0.524	rs7929014	chr11:47776283	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs35771425	0.564	rs17267554	chr1:211540144	A/G	cg10512769	chr1:211675356	NA	0.61	8.2	0.36	2.33e-15	Educational attainment (years of education);
LGG	cis	rs4788570	0.615	rs8053745	chr16:71689693	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	20.73	0.69	5.14e-68	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.53	0.33	2.6e-13	Rheumatoid arthritis;
LGG	cis	rs10155981	0.510	rs78815495	chr7:22584529	C/T	cg06110297	chr7:22589830	NA	-0.65	-6.86	-0.3	2.16e-11	Bilirubin levels;
LGG	cis	rs1395	0.744	rs1975384	chr2:27542041	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-7.08	-0.31	5.22e-12	Blood metabolite levels;
LGG	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg24375607	chr4:120327624	NA	0.62	10.16	0.43	5.2e-22	Corneal astigmatism;
LGG	cis	rs9916302	0.904	rs4795357	chr17:37569551	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.37	-0.47	1.42e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs4474465	0.850	rs10899552	chr11:78262262	G/A	cg27205649	chr11:78285834	NARS2	0.49	8.41	0.36	5.08e-16	Alzheimer's disease (survival time);
LGG	cis	rs7219021	0.739	rs4793993	chr17:47008546	C/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.96	-0.31	1.19e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7216064	1.000	rs1976053	chr17:65833002	C/G	cg12091567	chr17:66097778	LOC651250	-0.63	-9.28	-0.4	6.36e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg25866889	chr13:114914595	NA	-0.36	-7.18	-0.32	2.81e-12	Schizophrenia;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg01145232	chr6:150245071	RAET1G	-0.53	-9.54	-0.41	8.15e-20	Lung cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg21442773	chr1:236029828	LYST	0.42	6.96	0.31	1.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs2797160	1.000	rs1935772	chr6:125994708	T/C	cg05901451	chr6:126070800	HEY2	-0.42	-7.1	-0.31	4.8e-12	Endometrial cancer;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg05863683	chr7:1912471	MAD1L1	0.4	7.25	0.32	1.81e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9583531	0.714	rs76166228	chr13:111343774	T/C	cg24331049	chr13:111365604	ING1	-0.73	-7.41	-0.33	6.13e-13	Coronary artery disease;
LGG	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg13902645	chr11:5959945	NA	-0.65	-10.95	-0.45	5.79e-25	DNA methylation (variation);
LGG	cis	rs6963495	0.818	rs73192124	chr7:105171528	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.79	0.34	4.59e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg20308403	chr7:2120281	MAD1L1	0.34	7.17	0.32	2.94e-12	Schizophrenia;
LGG	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg06421707	chr20:25228305	PYGB	0.54	11.69	0.48	7.48e-28	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs774359	0.789	rs2440620	chr9:27497621	T/C	cg21249376	chr9:27528432	MOBKL2B	0.47	8.86	0.38	1.77e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.95	-0.31	1.28e-11	Schizophrenia;
LGG	cis	rs9811920	0.809	rs4577503	chr3:99657922	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-9.04	-0.39	4.26e-18	Axial length;
LGG	cis	rs12893668	0.667	rs11844466	chr14:104066422	G/A	cg23335576	chr14:104009727	NA	0.5	8.64	0.37	9.01e-17	Reticulocyte count;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg07005078	chr4:17578674	LAP3	0.39	7.05	0.31	6.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg19442545	chr10:75533431	FUT11	-0.45	-7.34	-0.32	9.62e-13	Inflammatory bowel disease;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg11062466	chr8:58055876	NA	0.43	7.6	0.33	1.6e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.99	-0.35	1.06e-14	HDL cholesterol;
LGG	cis	rs68170813	0.559	rs56933300	chr7:106953278	A/AGGACCTCGGCAGAAGCC	cg02696742	chr7:106810147	HBP1	-0.72	-9.41	-0.4	2.35e-19	Coronary artery disease;
LGG	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.12	0.31	4.13e-12	Retinal vascular caliber;
LGG	cis	rs2797160	1.000	rs1739357	chr6:126019655	T/G	cg05901451	chr6:126070800	HEY2	0.47	7.85	0.34	2.86e-14	Endometrial cancer;
LGG	cis	rs10789491	1.000	rs2218191	chr1:47130628	C/T	cg15501359	chr1:47185051	KIAA0494	0.67	13.07	0.52	1.89e-33	Response to hepatitis C treatment;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.93	-0.38	1.04e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1451375	0.652	rs7779110	chr7:50625651	T/C	cg20336341	chr7:50628841	DDC	0.52	9.61	0.41	4.54e-20	Malaria;
LGG	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.54	11.8	0.48	2.75e-28	Hemoglobin concentration;
LGG	trans	rs1422110	1.000	rs1422110	chr5:85466140	C/T	cg01787110	chr1:109008453	NBPF6	-0.54	-8.57	-0.37	1.55e-16	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7172689	1.000	rs61637497	chr15:81533445	C/A	cg11808699	chr15:81528661	IL16	-0.5	-9.8	-0.41	9.97e-21	Inattentive symptoms;
LGG	cis	rs9400467	0.537	rs55831749	chr6:111430282	T/C	cg15721981	chr6:111408429	SLC16A10	0.54	6.67	0.3	7.11e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs2735413	0.563	rs72800907	chr16:78046372	T/C	cg04733911	chr16:78082701	NA	0.57	7.47	0.33	4.16e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6500395	0.584	rs1345433	chr16:48738222	A/G	cg16662043	chr16:48846231	NA	0.44	7.89	0.34	2.22e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02523617	chr4:39699380	UBE2K	0.63	7.1	0.31	4.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg09264619	chr17:80180166	NA	-0.39	-7.71	-0.34	7.78e-14	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04206329	chr16:30597253	ZNF785	0.49	7.43	0.33	5.43e-13	Gut microbiome composition (summer);
LGG	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg16797656	chr11:68205561	LRP5	0.39	6.94	0.31	1.31e-11	Total body bone mineral density;
LGG	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg17294928	chr15:75287854	SCAMP5	0.64	12.12	0.49	1.48e-29	Breast cancer;
LGG	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg00666640	chr1:248458726	OR2T12	0.6	9.77	0.41	1.3e-20	Common traits (Other);
LGG	cis	rs6831352	0.918	rs34936974	chr4:100052384	A/G	cg12011299	chr4:100065546	ADH4	0.41	8.26	0.36	1.5e-15	Alcohol dependence;
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg12395012	chr8:11607386	GATA4	-0.38	-6.9	-0.31	1.69e-11	Neuroticism;
LGG	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.44	0.33	5.01e-13	Cystic fibrosis severity;
LGG	cis	rs9300255	0.602	rs2682434	chr12:123694724	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg22072935	chr14:105399595	NA	0.52	9.89	0.42	4.68e-21	Rheumatoid arthritis;
LGG	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.62e-22	Diabetic kidney disease;
LGG	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg04226714	chr8:49833948	SNAI2	-0.48	-8.78	-0.38	3.27e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7980687	0.628	rs2851443	chr12:123694250	C/T	cg00376283	chr12:123451042	ABCB9	0.66	11.47	0.47	5.57e-27	Height;Educational attainment;Head circumference (infant);
LGG	trans	rs7474896	0.616	rs1985260	chr10:38434090	C/T	cg17830980	chr10:43048298	ZNF37B	-0.46	-6.97	-0.31	1.08e-11	Obesity (extreme);
LGG	cis	rs9596863	0.898	rs9568914	chr13:54341107	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.18	0.32	2.84e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4474465	0.688	rs10899553	chr11:78265210	A/G	cg27205649	chr11:78285834	NARS2	0.52	8.92	0.38	1.11e-17	Alzheimer's disease (survival time);
LGG	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg26811252	chr16:29126840	RRN3P2	0.69	10.86	0.45	1.21e-24	Menopause (age at onset);
LGG	cis	rs7923609	0.967	rs10761729	chr10:64995604	G/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.76	-0.3	4.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs877282	1.000	rs11253366	chr10:773386	C/T	cg17470449	chr10:769945	NA	0.63	8.05	0.35	7.11e-15	Uric acid levels;
LGG	cis	rs10895140	0.666	rs7112189	chr11:101508638	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20379012	chr8:126103681	NSMCE2;KIAA0196	0.45	7.65	0.33	1.21e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs701145	0.585	rs357473	chr3:153895147	C/T	cg17054900	chr3:154042577	DHX36	0.88	10.22	0.43	3.1e-22	Coronary artery disease;
LGG	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg25482853	chr8:67687455	SGK3	0.95	12.17	0.49	9.15e-30	Obesity-related traits;
LGG	cis	rs6456156	0.774	rs1012656	chr6:167525303	G/C	cg07741184	chr6:167504864	NA	-0.32	-7.09	-0.31	5.16e-12	Primary biliary cholangitis;
LGG	cis	rs990171	1.000	rs6750020	chr2:102994714	G/A	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.33e-21	Lymphocyte counts;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	12.25	0.49	4.43e-30	Obesity-related traits;
LGG	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1461503	0.932	rs10790544	chr11:122838330	T/C	cg27398637	chr11:122830231	C11orf63	-0.72	-14.33	-0.55	7.93e-39	Menarche (age at onset);
LGG	cis	rs7747724	0.713	rs4712538	chr6:20734076	A/C	cg13405222	chr6:20811065	CDKAL1	0.43	7.9	0.34	2.01e-14	Bladder cancer;
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs8062405	0.723	rs762633	chr16:28608341	T/C	cg16576597	chr16:28551801	NUPR1	0.44	10.16	0.43	5.02e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9902453	0.967	rs56326816	chr17:28492805	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.26	0.52	2.95e-34	Coffee consumption (cups per day);
LGG	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs35110281	0.720	rs162393	chr21:44942692	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.39	0.47	1.1e-26	Mean corpuscular volume;
LGG	trans	rs11875185	0.510	rs112514590	chr18:55621138	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10276381	1.000	rs7796417	chr7:28186119	G/C	cg23620719	chr7:28220237	JAZF1	0.81	10.42	0.44	5.57e-23	Crohn's disease;
LGG	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg07777115	chr5:623756	CEP72	-0.61	-7.7	-0.34	8.51e-14	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.48	0.33	3.72e-13	Refractive error;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg01673284	chr16:4527211	HMOX2	0.36	7.17	0.32	3.01e-12	Schizophrenia;
LGG	cis	rs4888262	0.545	rs12716768	chr16:74556486	A/G	cg01733217	chr16:74700730	RFWD3	-0.63	-10.89	-0.45	9.71e-25	Testicular germ cell tumor;
LGG	cis	rs7309	0.935	rs11884495	chr2:162059969	A/T	cg22496339	chr2:162101262	NA	-0.53	-11.74	-0.48	4.96e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs1256531	0.661	rs7143525	chr14:66178767	G/T	cg15999311	chr14:65749247	NA	0.84	6.94	0.31	1.29e-11	Conduct disorder (symptom count);
LGG	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg21605333	chr4:119757512	SEC24D	1.34	12.58	0.5	2.09e-31	Cannabis dependence symptom count;
LGG	cis	rs17767392	0.834	rs61991191	chr14:71739204	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.67	-0.37	7.06e-17	Mitral valve prolapse;
LGG	trans	rs6011368	1.000	rs6011368	chr20:62886504	T/C	cg13869341	chr1:15865	WASH5P	0.57	10.07	0.42	1.02e-21	Clozapine-induced cytotoxicity;
LGG	cis	rs7552167	0.925	rs3932666	chr1:24511566	G/A	cg17246694	chr1:24480847	IL28RA	0.52	6.74	0.3	4.87e-11	Psoriasis vulgaris;
LGG	cis	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg06521331	chr12:34319734	NA	0.41	7.31	0.32	1.19e-12	Morning vs. evening chronotype;
LGG	cis	rs3096299	0.869	rs748941	chr16:89440754	T/A	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.35	-0.32	8.87e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs539514	0.627	rs9544035	chr13:76293789	C/T	cg04757411	chr13:76259545	LMO7	-0.27	-7.07	-0.31	5.71e-12	Type 1 diabetes;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg19077165	chr18:44547161	KATNAL2	-0.69	-13.18	-0.52	6.35e-34	Personality dimensions;
LGG	cis	rs7944584	0.655	rs2856653	chr11:47361084	T/C	cg20307385	chr11:47447363	PSMC3	-0.66	-12.97	-0.52	5.06e-33	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg19507638	chr5:93509721	C5orf36	-0.73	-9.97	-0.42	2.42e-21	Diabetic retinopathy;
LGG	cis	rs7666738	0.830	rs3846443	chr4:99032666	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.39e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg05665937	chr4:1216051	CTBP1	0.57	10.71	0.45	4.58e-24	Obesity-related traits;
LGG	cis	rs4774830	0.744	rs62045232	chr15:56284419	A/G	cg05129572	chr15:56138634	NEDD4	0.7	6.8	0.3	3.27e-11	Delta-5 desaturase activity;
LGG	cis	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.54e-68	Diabetic kidney disease;
LGG	cis	rs2439831	0.702	rs2467402	chr15:44024490	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	-0.71	-8.47	-0.37	3.27e-16	Lung cancer in ever smokers;
LGG	cis	rs7786808	0.741	rs7789415	chr7:158227617	C/T	cg01191920	chr7:158217561	PTPRN2	-0.92	-24.41	-0.75	3.44e-85	Obesity-related traits;
LGG	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-10.98	-0.45	4.48e-25	Bipolar disorder;
LGG	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15557168	chr22:42548783	NA	-0.34	-7.56	-0.33	2.21e-13	Cognitive function;
LGG	cis	rs9503598	0.543	rs4959832	chr6:3435112	A/C	cg00476032	chr6:3446245	SLC22A23	-0.37	-7.03	-0.31	7.55e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs5758511	0.773	rs73165164	chr22:42355549	T/C	cg15128208	chr22:42549153	NA	0.57	8.92	0.38	1.07e-17	Birth weight;
LGG	cis	rs5756391	0.546	rs4821561	chr22:37311877	A/G	cg21209356	chr22:37319042	CSF2RB	-0.4	-9.14	-0.39	1.97e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs8141529	0.732	rs5762788	chr22:29174770	G/T	cg02153584	chr22:29168773	CCDC117	0.71	11.98	0.49	5.55e-29	Lymphocyte counts;
LGG	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg15665833	chr6:26285013	NA	0.36	6.64	0.3	8.6e-11	Educational attainment;
LGG	cis	rs8133932	0.667	rs760436	chr21:47278055	C/T	cg11214348	chr21:47283868	PCBP3	0.44	7.76	0.34	5.61e-14	Schizophrenia;
LGG	cis	rs701145	0.585	rs1534386	chr3:153819035	C/G	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg27284194	chr4:1044797	NA	0.56	11.32	0.47	2.08e-26	Recombination rate (males);
LGG	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg00376283	chr12:123451042	ABCB9	0.65	10.36	0.43	8.9e-23	Neutrophil percentage of white cells;
LGG	cis	rs4702718	0.616	rs267978	chr5:10719804	A/G	cg14521931	chr5:10832172	NA	-0.45	-8.39	-0.36	6.09e-16	Obesity-related traits;
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00864171	chr11:67383662	NA	-0.49	-8.56	-0.37	1.67e-16	Mean corpuscular volume;
LGG	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg22875332	chr1:76189707	ACADM	0.6	9.71	0.41	2.06e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg13147721	chr7:65941812	NA	-0.81	-9.61	-0.41	4.72e-20	Diabetic kidney disease;
LGG	trans	rs783540	0.934	rs1594511	chr15:83307063	T/A	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.65	-0.3	8.24e-11	Schizophrenia;
LGG	cis	rs1620921	0.711	rs1782632	chr6:161249412	A/G	cg01280913	chr6:161186852	NA	-0.34	-7.0	-0.31	9.24e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg13385794	chr1:248469461	NA	0.5	8.48	0.37	2.94e-16	Common traits (Other);
LGG	cis	rs576982	1	rs576982	chr15:78870803	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-7.76	-0.34	5.37e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-13.36	-0.53	1.19e-34	Bladder cancer;
LGG	cis	rs1577917	0.958	rs36035797	chr6:86562880	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg16339924	chr4:17578868	LAP3	0.65	10.8	0.45	2.18e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9560113	1.000	rs9555810	chr13:112181437	C/G	cg14952266	chr13:112191215	NA	-0.41	-7.55	-0.33	2.35e-13	Menarche (age at onset);
LGG	cis	rs939658	0.805	rs35318825	chr15:79447098	C/A	cg17916960	chr15:79447300	NA	-0.65	-12.38	-0.5	1.31e-30	Refractive error;
LGG	trans	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.99	0.42	2.12e-21	Metabolite levels;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg14773178	chr5:1868261	NA	0.36	7.93	0.35	1.61e-14	Cardiovascular disease risk factors;
LGG	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.5	-0.33	3.32e-13	Coronary artery disease;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg08645402	chr16:4508243	NA	0.48	8.09	0.35	5.37e-15	Schizophrenia;
LGG	trans	rs3780486	0.846	rs10971419	chr9:33124161	T/C	cg04842962	chr6:43655489	MRPS18A	1.11	24.49	0.75	1.42e-85	IgG glycosylation;
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs4595586	0.545	rs7976609	chr12:39394317	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs6665290	0.901	rs12410103	chr1:227197408	T/C	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg11502198	chr6:26597334	ABT1	0.56	9.38	0.4	3.05e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg06046430	chr4:77819534	ANKRD56	0.55	11.1	0.46	1.52e-25	Emphysema distribution in smoking;
LGG	cis	rs3741798	1.000	rs61922027	chr12:12486444	C/T	cg08615371	chr12:12503544	MANSC1	0.6	6.87	0.3	2.06e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	11.24	0.46	4.35e-26	Parkinson's disease;
LGG	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg10326726	chr10:51549505	MSMB	-0.67	-14.04	-0.55	1.52e-37	Prostate-specific antigen levels;
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg19774624	chr17:42201019	HDAC5	-0.83	-16.37	-0.61	7.62e-48	Total body bone mineral density;
LGG	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg06238570	chr21:40685208	BRWD1	0.44	6.81	0.3	3.1e-11	Cognitive function;
LGG	cis	rs7444	0.941	rs5754426	chr22:21980638	T/C	cg11654148	chr22:21984483	YDJC	-0.38	-7.29	-0.32	1.31e-12	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs6547631	0.628	rs2886768	chr2:85927555	A/C	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.85e-11	Blood protein levels;
LGG	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg13944838	chr5:179740914	GFPT2	-0.68	-12.57	-0.5	2.25e-31	Height;
LGG	cis	rs1801251	1.000	rs2305137	chr2:233712049	G/A	cg25237894	chr2:233734115	C2orf82	-0.66	-12.55	-0.5	2.64e-31	Coronary artery disease;
LGG	cis	rs4330281	0.647	rs7636787	chr3:17433760	G/C	cg20981856	chr3:17787350	NA	0.35	6.72	0.3	5.41e-11	Schizophrenia;
LGG	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg03254818	chr6:169586852	NA	-0.47	-9.74	-0.41	1.61e-20	Pulse pressure;
LGG	cis	rs6834538	0.597	rs9991830	chr4:113485372	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.93	0.38	1.03e-17	Free thyroxine concentration;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07677032	chr17:61819896	STRADA	0.66	12.1	0.49	1.76e-29	Prudent dietary pattern;
LGG	cis	rs9462027	0.628	rs2744949	chr6:34633862	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.22e-24	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.38e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7572644	0.723	rs13023003	chr2:28032137	G/C	cg27432699	chr2:27873401	GPN1	0.47	6.82	0.3	2.8e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs10754283	0.901	rs4520403	chr1:90112840	T/G	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs35110281	0.712	rs167930	chr21:44946625	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.93	-0.38	1.04e-17	Mean corpuscular volume;
LGG	cis	rs12444795	0.853	rs77120311	chr16:4898636	A/G	cg04440724	chr16:4920505	UBN1	-0.6	-8.78	-0.38	3.29e-17	Cancer;
LGG	cis	rs7586879	0.796	rs916486	chr2:25082629	C/A	cg04586622	chr2:25135609	ADCY3	0.36	8.64	0.37	9.4e-17	Body mass index;
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.87	-0.3	2.04e-11	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18654971	chr5:54469363	MIR449C;CDC20B	0.44	7.0	0.31	8.79e-12	Gut microbiome composition (summer);
LGG	cis	rs2304069	0.545	rs1864998	chr5:149389465	C/T	cg12661370	chr5:149340060	SLC26A2	0.51	8.48	0.37	3.05e-16	HIV-1 control;
LGG	cis	rs13108043	0.573	rs35245331	chr4:87924755	G/T	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13126279	chr21:47581558	C21orf56	-0.47	-8.24	-0.36	1.83e-15	Testicular germ cell tumor;
LGG	cis	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.79	-0.3	3.49e-11	Joint mobility (Beighton score);
LGG	cis	rs741702	0.928	rs116374652	chr19:13014235	T/C	cg11738485	chr19:12877000	HOOK2	-0.43	-6.79	-0.3	3.54e-11	Red blood cell traits;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg02733842	chr7:1102375	C7orf50	0.43	7.42	0.33	5.51e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs123509	0.913	rs339661	chr3:42753904	G/A	cg10144569	chr3:42726640	KBTBD5	0.5	7.38	0.32	7.55e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1335587	0.550	rs3916909	chr13:102085009	C/G	cg13538571	chr13:102108074	ITGBL1	-0.36	-6.81	-0.3	3.06e-11	Obesity-related traits;
LGG	cis	rs7493	0.901	rs17879517	chr7:95030646	T/C	cg17330251	chr7:94953956	PON1	-0.42	-8.01	-0.35	9.44e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg09303159	chr6:26284866	NA	0.37	8.22	0.36	2.06e-15	Educational attainment;
LGG	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg25986240	chr4:9926439	SLC2A9	0.48	10.25	0.43	2.44e-22	Bone mineral density;
LGG	cis	rs887829	0.667	rs7577677	chr2:234590616	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.4	-0.36	5.53e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9457247	0.624	rs2239826	chr6:167504880	T/C	cg07741184	chr6:167504864	NA	0.45	10.47	0.44	3.73e-23	Crohn's disease;
LGG	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.06	-0.31	6.14e-12	Blood metabolite levels;
LGG	cis	rs4740619	0.766	rs12341679	chr9:15746168	G/A	cg14451791	chr9:16040625	NA	0.33	8.56	0.37	1.68e-16	Body mass index;
LGG	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg11764359	chr7:65958608	NA	0.71	12.91	0.51	8.77e-33	Aortic root size;
LGG	cis	rs13191362	1.000	rs67646369	chr6:163003233	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2346177	0.542	rs6757564	chr2:46702619	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-11.78	-0.48	3.48e-28	HDL cholesterol;
LGG	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg05526886	chr2:227700861	RHBDD1	-0.42	-7.34	-0.32	9.47e-13	Pulmonary function;
LGG	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg06074448	chr4:187884817	NA	-0.58	-12.75	-0.51	4.07e-32	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9650657	0.585	rs7830317	chr8:10700254	A/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.41	-0.33	5.97e-13	Neuroticism;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg11494091	chr17:61959527	GH2	1.03	25.54	0.76	2.06e-90	Prudent dietary pattern;
LGG	cis	rs8077889	0.619	rs1230399	chr17:41845403	C/T	cg26893861	chr17:41843967	DUSP3	-1.08	-25.41	-0.76	8.14e-90	Triglycerides;
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.07e-15	Aortic root size;
LGG	cis	rs3815700	1.000	rs8109990	chr19:33095636	A/G	cg02997394	chr19:33096574	ANKRD27	0.88	13.3	0.53	2.07e-34	Eosinophilic esophagitis;
LGG	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg20935368	chr5:178288625	ZNF354B	0.34	6.91	0.31	1.57e-11	Sleep duration;
LGG	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg26655873	chr3:72818019	SHQ1	0.37	7.11	0.31	4.55e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs74781061	0.929	rs4324083	chr15:74771480	G/A	cg02384859	chr15:74862662	ARID3B	-0.33	-6.86	-0.3	2.18e-11	Endometriosis;
LGG	cis	rs36051895	0.659	rs11999076	chr9:5037694	C/T	cg02405213	chr9:5042618	JAK2	-0.84	-16.66	-0.61	3.71e-49	Pediatric autoimmune diseases;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg05091796	chr16:4465799	CORO7	-0.8	-13.88	-0.54	7.39e-37	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18276145	chr4:72052432	SLC4A4	0.62	7.02	0.31	8.14e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9296092	0.538	rs62407566	chr6:33535786	C/T	cg13560919	chr6:33536144	NA	-1.04	-20.78	-0.69	2.97e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7166081	1.000	rs4776922	chr15:67634437	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.87	-0.3	2.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg09222892	chr1:25734099	RHCE	0.47	10.14	0.43	5.74e-22	Erythrocyte sedimentation rate;
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg05791153	chr7:19748676	TWISTNB	0.96	12.61	0.51	1.49e-31	Thyroid stimulating hormone;
LGG	cis	rs9972944	0.692	rs8071561	chr17:63763434	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.68e-16	Total body bone mineral density;
LGG	cis	rs7216064	1.000	rs7208663	chr17:65885171	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-9.11	-0.39	2.43e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6541297	1.000	rs6541296	chr1:230281953	A/G	cg20703242	chr1:230279135	GALNT2	0.37	7.55	0.33	2.31e-13	Coronary artery disease;
LGG	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg26513180	chr16:89883248	FANCA	0.72	12.49	0.5	4.62e-31	Vitiligo;
LGG	cis	rs1978968	0.763	rs34364976	chr22:18462027	C/T	cg03078520	chr22:18463400	MICAL3	-0.68	-14.66	-0.56	3.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.47	6.84	0.3	2.57e-11	Total cholesterol levels;
LGG	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.64	-0.37	9.37e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg14228332	chr4:119757509	SEC24D	0.95	9.45	0.4	1.63e-19	Cannabis dependence symptom count;
LGG	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg03342759	chr3:160939853	NMD3	0.44	7.32	0.32	1.1e-12	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.22e-11	Educational attainment;
LGG	cis	rs9987353	0.522	rs2929466	chr8:9063899	G/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.5	-0.33	3.34e-13	Recombination measurement;
LGG	trans	rs11039798	1.000	rs10769383	chr11:48592510	C/G	cg15704280	chr7:45808275	SEPT13	0.77	9.01	0.39	5.57e-18	Axial length;
LGG	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.49	8.25	0.36	1.61e-15	Personality dimensions;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg18032289	chr17:61959525	GH2	-0.45	-7.6	-0.33	1.63e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7412746	0.658	rs72704682	chr1:150897677	A/T	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-8.93	-0.38	1.03e-17	Headache;
LGG	trans	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	8.38	0.36	6.22e-16	Mean corpuscular volume;
LGG	cis	rs6976053	0.846	rs34005963	chr7:100501755	G/A	cg03098644	chr7:100410630	EPHB4	-0.41	-7.32	-0.32	1.12e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2455799	0.573	rs2470520	chr3:15762920	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-8.07	-0.35	5.93e-15	Mean platelet volume;
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.67e-44	Prostate cancer;
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg21775007	chr8:11205619	TDH	0.44	7.18	0.32	2.77e-12	Mood instability;
LGG	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg15268244	chr15:77196840	NA	0.49	10.47	0.44	3.69e-23	Blood metabolite levels;
LGG	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg19847130	chr8:10466454	RP1L1	0.32	6.94	0.31	1.33e-11	Neuroticism;
LGG	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	23.73	0.74	5.13e-82	Chronic sinus infection;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg17451422	chr2:61293253	KIAA1841	-0.4	-6.8	-0.3	3.27e-11	Brain structure;
LGG	cis	rs35762459	1	rs35762459	chr11:8844653	T/TA	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-9.61	-0.41	4.65e-20	Immature fraction of reticulocytes;
LGG	cis	rs11001765	0.530	rs11516634	chr10:78127124	G/C	cg16072382	chr10:78096093	C10orf11	0.5	6.79	0.3	3.55e-11	Chin dimples;
LGG	cis	rs6964587	1.000	rs17164263	chr7:91581566	T/A	cg17063962	chr7:91808500	NA	-0.48	-8.62	-0.37	1.09e-16	Breast cancer;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs858239	0.600	rs10235786	chr7:23139940	T/C	cg23682824	chr7:23144976	KLHL7	0.45	7.75	0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg13628971	chr7:2884303	GNA12	0.51	9.94	0.42	3.07e-21	Height;
LGG	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg03929089	chr4:120376271	NA	-0.72	-8.39	-0.36	5.84e-16	D-dimer levels;
LGG	cis	rs7940866	0.740	rs7131121	chr11:130806424	A/G	cg12179176	chr11:130786555	SNX19	0.77	14.87	0.57	3.79e-41	Schizophrenia;
LGG	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg13147721	chr7:65941812	NA	-0.83	-9.92	-0.42	3.55e-21	Diabetic kidney disease;
LGG	cis	rs10463554	0.927	rs34820	chr5:102436868	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.44	-0.33	5.04e-13	Parkinson's disease;
LGG	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.16	-0.35	3.23e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7523273	0.606	rs2796262	chr1:207915180	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.85	0.48	1.76e-28	Schizophrenia;
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg03847636	chr4:7070632	GRPEL1	-0.48	-6.74	-0.3	4.8e-11	Monocyte percentage of white cells;
LGG	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg22432760	chr17:80829718	TBCD	0.39	6.66	0.3	7.74e-11	Breast cancer;
LGG	cis	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2070433	0.851	rs1029231	chr21:47931653	A/G	cg12379764	chr21:47803548	PCNT	0.5	7.16	0.32	3.17e-12	Lymphocyte counts;
LGG	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.7	-0.37	5.71e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	1.07e-29	Prudent dietary pattern;
LGG	cis	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg13010199	chr12:38710504	ALG10B	0.7	14.01	0.55	2.05e-37	Bladder cancer;
LGG	cis	rs2386661	0.826	rs7092383	chr10:5671101	A/C	cg26603656	chr10:5671107	NA	0.39	7.76	0.34	5.59e-14	Breast cancer;
LGG	trans	rs9393777	0.764	rs35565446	chr6:27145341	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.46	-0.4	1.5700000000000001e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9443645	0.670	rs79209669	chr6:79719623	C/G	cg18132916	chr6:79620363	NA	-0.3	-8.37	-0.36	7.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7766436	0.767	rs6456498	chr6:22603610	A/G	cg13666174	chr6:22585274	NA	0.36	8.57	0.37	1.53e-16	Coronary artery disease;
LGG	cis	rs2797369	0.600	rs861752	chr6:101282955	G/A	cg27451362	chr6:101846650	GRIK2	0.68	9.31	0.4	5.32e-19	Renal function-related traits (eGRFcrea);
LGG	cis	rs4740619	0.619	rs1410450	chr9:16037123	A/C	cg14451791	chr9:16040625	NA	-0.44	-11.8	-0.48	2.71e-28	Body mass index;
LGG	cis	rs7444	0.882	rs9621715	chr22:21942007	G/A	cg05046821	chr22:21984468	YDJC	-0.4	-7.12	-0.31	4.19e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.24e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12049351	0.612	rs7555749	chr1:229602284	C/A	cg13547644	chr1:229569608	ACTA1	0.32	7.0	0.31	9.03e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs9611519	0.894	rs8136923	chr22:41470522	G/A	cg06634786	chr22:41940651	POLR3H	-0.42	-6.67	-0.3	7.12e-11	Neuroticism;
LGG	trans	rs9325144	0.600	rs7965877	chr12:38743697	G/T	cg23762105	chr12:34175262	ALG10	-0.33	-6.75	-0.3	4.45e-11	Morning vs. evening chronotype;
LGG	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06699216	chr8:19333253	CSGALNACT1	-0.36	-7.62	-0.33	1.49e-13	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.35	0.32	9.25e-13	Monocyte count;
LGG	cis	rs6684428	1.000	rs12124871	chr1:56372247	C/T	cg11651538	chr1:56320950	NA	-0.75	-12.99	-0.52	3.9e-33	Airflow obstruction;
LGG	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs782590	0.902	rs782602	chr2:55849309	A/G	cg18811423	chr2:55921094	PNPT1	0.87	19.87	0.68	5.37e-64	Metabolic syndrome;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg14004847	chr7:1930337	MAD1L1	-0.61	-10.91	-0.45	8.17e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg25214090	chr10:38739885	LOC399744	0.67	12.01	0.49	4.05e-29	Corneal astigmatism;
LGG	cis	rs1059312	0.771	rs11059922	chr12:129290418	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.46	0.37	3.42e-16	Systemic lupus erythematosus;
LGG	cis	rs3740909	1.000	rs4426144	chr11:125888213	C/T	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs1475911	0.708	rs56185023	chr21:43521538	T/C	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-9.68	-0.41	2.56e-20	IgG glycosylation;
LGG	trans	rs2562456	0.793	rs7259396	chr19:21523463	G/A	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs3789045	1.000	rs12046747	chr1:204593696	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.6	-0.37	1.22e-16	Educational attainment (college completion);
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg19147804	chr7:1989927	MAD1L1	-0.48	-8.86	-0.38	1.76e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs240764	0.746	rs151572	chr6:101110984	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg05791153	chr7:19748676	TWISTNB	0.8	10.2	0.43	3.57e-22	Thyroid stimulating hormone;
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.86e-12	Bipolar disorder;
LGG	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg24759859	chr6:86352639	SYNCRIP	0.42	6.92	0.31	1.48e-11	Smooth-surface caries;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs941408	1.000	rs941407	chr19:2812153	A/G	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.47	-0.44	3.65e-23	Total cholesterol levels;
LGG	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg09818912	chr17:20140352	CYTSB	-0.31	-7.11	-0.31	4.32e-12	Obesity-related traits;
LGG	cis	rs858239	0.669	rs6461687	chr7:23116580	A/G	cg23682824	chr7:23144976	KLHL7	0.46	7.94	0.35	1.52e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4774899	0.932	rs17239431	chr15:57526756	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.26	-0.32	1.6e-12	Urinary tract infection frequency;
LGG	cis	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg06521331	chr12:34319734	NA	0.41	6.89	0.31	1.79e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.42e-16	Obesity-related traits;
LGG	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg27427491	chr17:78079615	GAA	-0.28	-6.92	-0.31	1.51e-11	Yeast infection;
LGG	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg15736062	chr7:158136485	PTPRN2	-0.54	-9.57	-0.41	6.52e-20	Response to amphetamines;
LGG	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.93	-0.57	1.99e-41	Morning vs. evening chronotype;
LGG	cis	rs2718058	0.704	rs2722295	chr7:37834426	C/T	cg24998770	chr7:37888106	TXNDC3	0.41	7.13	0.31	3.9e-12	Alzheimer's disease (late onset);
LGG	cis	rs73193808	0.639	rs7277858	chr21:30552877	T/C	cg03476357	chr21:30257390	N6AMT1	0.41	6.82	0.3	2.88e-11	Coronary artery disease;
LGG	cis	rs11700980	0.551	rs2832018	chr21:30111639	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.79	0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg06917634	chr15:78832804	PSMA4	-0.42	-6.86	-0.3	2.2e-11	Sudden cardiac arrest;
LGG	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg03264133	chr6:25882463	NA	-0.46	-7.5	-0.33	3.27e-13	Iron status biomarkers;
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.46e-30	Intelligence (multi-trait analysis);
LGG	cis	rs60695258	0.512	rs2053769	chr4:87908007	T/C	cg11209507	chr4:87813803	C4orf36	-0.49	-8.35	-0.36	8e-16	Hematocrit;
LGG	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.86	-9.24	-0.39	8.68e-19	Diabetic retinopathy;
LGG	cis	rs4356975	0.563	rs11932131	chr4:69949547	G/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.69	0.3	6.51e-11	Obesity-related traits;
LGG	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg25986240	chr4:9926439	SLC2A9	-0.45	-9.17	-0.39	1.56e-18	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs6141769	0.569	rs6119935	chr20:31270570	C/A	cg13636640	chr20:31349939	DNMT3B	-0.49	-7.25	-0.32	1.82e-12	Subjective well-being;
LGG	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg14088196	chr11:70211408	PPFIA1	0.95	13.35	0.53	1.23e-34	Coronary artery disease;
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.58	0.33	1.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	22.86	0.73	5.61e-78	Height;
LGG	cis	rs1595825	1.000	rs2165237	chr2:198875003	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-7.18	-0.32	2.72e-12	Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	2.84e-31	Motion sickness;
LGG	cis	rs4319547	0.662	rs35417323	chr12:123090572	G/T	cg23029597	chr12:123009494	RSRC2	-0.5	-8.78	-0.38	3.25e-17	Body mass index;
LGG	trans	rs9354308	0.764	rs2211636	chr6:66596815	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs8114671	0.805	rs4616	chr20:33590358	C/T	cg07148914	chr20:33460835	GGT7	-0.51	-8.38	-0.36	6.58e-16	Height;
LGG	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.51	0.37	2.48e-16	Alzheimer's disease (survival time);
LGG	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg05169160	chr2:178484487	TTC30A	0.34	6.66	0.3	7.91e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4566357	1.000	rs3765192	chr2:227927536	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.0	-0.31	9.1e-12	Coronary artery disease;
LGG	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-15.19	-0.58	1.48e-42	Platelet count;
LGG	cis	rs1030877	1.000	rs2576743	chr2:105901337	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.72	14.49	0.56	1.7e-39	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00347862	chr15:71184758	LRRC49;THAP10	0.42	6.87	0.3	2.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2239547	0.603	rs2276825	chr3:52886605	T/C	cg11645453	chr3:52864694	ITIH4	0.71	11.24	0.46	4.28e-26	Schizophrenia;
LGG	cis	rs28595532	0.920	rs55726697	chr4:119742863	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg05444541	chr17:17804740	TOM1L2	-0.58	-12.61	-0.51	1.55e-31	Total body bone mineral density;
LGG	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg03959625	chr15:84868606	LOC388152	0.47	7.08	0.31	5.34e-12	Schizophrenia;
LGG	cis	rs1775715	0.737	rs2778661	chr10:32159191	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.69	0.3	6.44e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg27129171	chr3:47204927	SETD2	0.85	16.49	0.61	2.2e-48	Colorectal cancer;
LGG	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg00204512	chr16:28754710	NA	0.27	7.47	0.33	3.96e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8014204	0.935	rs4903267	chr14:75360419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.85	-18.22	-0.65	2.46e-56	Caffeine consumption;
LGG	cis	rs526231	0.543	rs34783	chr5:102457041	C/A	cg23492399	chr5:102201601	PAM	-0.57	-8.34	-0.36	8.82e-16	Primary biliary cholangitis;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg13396858	chr9:134249466	NA	-0.39	-6.74	-0.3	4.73e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1040	0.727	rs7382431	chr6:169621829	A/T	cg04662567	chr6:169592167	NA	-0.46	-8.03	-0.35	8.28e-15	Joint mobility (Beighton score);
LGG	cis	rs1882510	0.903	rs74505593	chr2:102915212	A/G	cg05295703	chr2:102895712	NA	1.04	18.46	0.65	2.05e-57	Blood protein levels;
LGG	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-17.78	-0.64	2.65e-54	Systemic lupus erythematosus;
LGG	cis	rs7911264	0.572	rs7071912	chr10:94416229	T/G	cg25093409	chr10:94429542	NA	0.43	8.78	0.38	3.18e-17	Inflammatory bowel disease;
LGG	cis	rs11677416	1.000	rs6542090	chr2:113524795	T/C	cg27083787	chr2:113543245	IL1A	0.53	8.8	0.38	2.8e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg18654377	chr3:49208889	KLHDC8B	0.5	7.87	0.34	2.61e-14	Menarche (age at onset);
LGG	cis	rs11098499	0.954	rs59866101	chr4:120296591	T/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg15369054	chr17:80825471	TBCD	0.5	7.37	0.32	8.17e-13	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg11812906	chr14:75593930	NEK9	-0.52	-9.54	-0.41	7.89e-20	Height;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs8077059	1.000	rs2058104	chr17:55816722	A/G	cg12582317	chr17:55822272	NA	0.4	7.2	0.32	2.42e-12	Sex hormone-binding globulin levels;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00631329	chr6:26305371	NA	-0.5	-9.11	-0.39	2.5e-18	Educational attainment;
LGG	cis	rs4919694	1.000	rs76892505	chr10:104719290	G/A	cg04362960	chr10:104952993	NT5C2	1.05	13.48	0.53	3.47e-35	Arsenic metabolism;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.27e-17	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07080220	chr10:102295463	HIF1AN	0.72	12.38	0.5	1.31e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg03162506	chr22:38580953	NA	-0.35	-9.12	-0.39	2.35e-18	Cutaneous nevi;
LGG	cis	rs9398803	0.723	rs2793051	chr6:127064918	C/T	cg19875578	chr6:126661172	C6orf173	-0.49	-8.93	-0.38	9.75e-18	Male-pattern baldness;
LGG	cis	rs4319547	0.760	rs61954973	chr12:123074168	T/C	cg23029597	chr12:123009494	RSRC2	-0.97	-18.68	-0.66	1.85e-58	Body mass index;
LGG	cis	rs920590	0.573	rs12547934	chr8:19680736	T/C	cg03894339	chr8:19674705	INTS10	-0.54	-9.15	-0.39	1.83e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg06636001	chr8:8085503	FLJ10661	0.67	13.7	0.54	4.16e-36	Neuroticism;
LGG	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg07541023	chr7:19748670	TWISTNB	0.6	8.61	0.37	1.14e-16	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg20607798	chr8:58055168	NA	0.64	7.56	0.33	2.11e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.932	rs2230437	chr5:476353	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.72	0.34	7.23e-14	Cystic fibrosis severity;
LGG	cis	rs11229555	0.598	rs1893902	chr11:58190747	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.55e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg26318627	chr11:63887540	MACROD1	-0.47	-6.76	-0.3	4.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10464366	0.746	rs6945547	chr7:39145389	C/G	cg20302533	chr7:39170763	POU6F2	0.54	13.26	0.52	3.01e-34	IgG glycosylation;
LGG	trans	rs801193	0.901	rs4273746	chr7:66301111	C/T	cg18876405	chr7:65276391	NA	-0.6	-10.65	-0.44	8.01e-24	Aortic root size;
LGG	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg05082376	chr22:42548792	NA	0.37	7.87	0.34	2.5e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs11203032	0.831	rs12570154	chr10:90951027	T/C	cg16672925	chr10:90967113	CH25H	0.79	11.29	0.46	2.87e-26	Heart failure;
LGG	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg08875078	chr22:50639485	SELO	0.51	8.72	0.38	4.85e-17	Obesity-related traits;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07234876	chr8:600039	NA	1.3	12.64	0.51	1.13e-31	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg24642844	chr7:1081250	C7orf50	-0.52	-9.67	-0.41	2.96e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg19673125	chr6:150240577	RAET1G	0.35	8.46	0.37	3.56e-16	Testicular germ cell tumor;
LGG	cis	rs189798	0.807	rs330912	chr8:8996294	C/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.34	0.32	9.64e-13	Myopia (pathological);
LGG	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg11764359	chr7:65958608	NA	-0.64	-10.95	-0.45	5.89e-25	Aortic root size;
LGG	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.53	-12.56	-0.5	2.5e-31	Oropharynx cancer;
LGG	cis	rs1385374	0.858	rs959989	chr12:129292708	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg00700412	chr12:58011837	NA	-0.5	-10.48	-0.44	3.36e-23	Multiple sclerosis;
LGG	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.71	0.34	7.67e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2243480	1.000	rs1499613	chr7:65730860	G/A	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs1801251	1.000	rs6724117	chr2:233593660	T/G	cg25237894	chr2:233734115	C2orf82	0.66	12.7	0.51	6.62e-32	Coronary artery disease;
LGG	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.02	0.31	8.15e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs34929064	0.718	rs2097676	chr7:22732805	A/T	cg18045685	chr7:22629474	NA	0.59	8.44	0.37	4.13e-16	Major depression and alcohol dependence;
LGG	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg10513866	chr5:139070639	NA	0.41	8.0	0.35	1.03e-14	Schizophrenia;
LGG	cis	rs10463554	0.927	rs158396	chr5:102411719	G/A	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.58e-13	Parkinson's disease;
LGG	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.5	-0.37	2.7e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	1.04e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1978968	1.000	rs7291169	chr22:18449038	A/G	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg16270222	chr17:41446396	NA	-0.3	-7.34	-0.32	9.54e-13	Menopause (age at onset);
LGG	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg17376030	chr22:41985996	PMM1	0.66	10.81	0.45	2.01e-24	Vitiligo;
LGG	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.98	-0.45	4.36e-25	DNA methylation (variation);
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg02725872	chr8:58115012	NA	-0.85	-12.31	-0.5	2.51e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.603	rs10258214	chr7:19911906	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	7.54	0.33	2.54e-13	Night sleep phenotypes;
LGG	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.28	-0.32	1.49e-12	HDL cholesterol;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09593402	chr5:96270297	LNPEP	0.4	7.04	0.31	7.15e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9640161	0.830	rs36069544	chr7:150061538	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-10.31	-0.43	1.38e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.97	-0.31	1.1e-11	Mean corpuscular hemoglobin;
LGG	cis	rs4731207	0.570	rs7784616	chr7:124677194	C/G	cg05630886	chr7:124431682	NA	-0.32	-7.43	-0.33	5.18e-13	Cutaneous malignant melanoma;
LGG	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg20302533	chr7:39170763	POU6F2	0.33	7.84	0.34	3.12e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg19455335	chr8:22457658	C8orf58	0.43	8.64	0.37	9.05e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg22044901	chr15:68126292	NA	-0.42	-7.31	-0.32	1.18e-12	Obesity;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg18252515	chr7:66147081	NA	-1.32	-18.42	-0.65	3.11e-57	Diabetic kidney disease;
LGG	cis	rs17401966	0.838	rs34636442	chr1:10427459	T/G	cg19773385	chr1:10388646	KIF1B	-0.46	-9.86	-0.42	6.27e-21	Hepatocellular carcinoma;
LGG	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg04287289	chr16:89883240	FANCA	-0.44	-7.65	-0.33	1.19e-13	Vitiligo;
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg00405596	chr8:11794950	NA	0.39	6.71	0.3	5.57e-11	Mood instability;
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg01059449	chr18:44338099	ST8SIA5	0.32	7.11	0.31	4.29e-12	Personality dimensions;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg00990874	chr7:1149470	C7orf50	-0.81	-14.31	-0.55	1.05e-38	Bronchopulmonary dysplasia;
LGG	cis	rs10779751	1.000	rs1064261	chr1:11288758	C/T	cg08854313	chr1:11322531	MTOR	0.72	15.84	0.59	1.75e-45	Body mass index;
LGG	trans	rs58106596	0.605	rs58212470	chr2:232561579	C/T	cg01370599	chr3:116745421	NA	0.69	10.38	0.43	7.64e-23	White blood cell count;Lymphocyte counts;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg13939156	chr17:80058883	NA	0.47	9.15	0.39	1.83e-18	Life satisfaction;
LGG	cis	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.92	-0.35	1.78e-14	Joint mobility (Beighton score);
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg11905131	chr22:24372483	LOC391322	0.41	7.11	0.31	4.3e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.17	-0.39	1.54e-18	Longevity;Endometriosis;
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg00149659	chr3:10157352	C3orf10	1.18	13.27	0.52	2.74e-34	Alzheimer's disease;
LGG	cis	rs745080	0.519	rs1006237	chr14:53001304	C/T	cg23333723	chr14:53022898	GPR137C	-0.4	-7.97	-0.35	1.21e-14	Orofacial clefts;
LGG	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.51	0.58	5.37e-44	Coronary artery disease;
LGG	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.63	-0.44	9.3e-24	Hip circumference adjusted for BMI;
LGG	cis	rs3762637	0.943	rs28372690	chr3:122283095	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-9.93	-0.42	3.43e-21	LDL cholesterol levels;
LGG	cis	rs7580658	0.637	rs3902960	chr2:127988242	G/C	cg10021288	chr2:128175891	PROC	-0.61	-12.46	-0.5	6.49e-31	Protein C levels;
LGG	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.27e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg20503657	chr10:835505	NA	0.96	12.76	0.51	3.54e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.32	0.36	1.01e-15	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.84	-10.37	-0.43	8.44e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6582630	0.572	rs1969363	chr12:38514872	A/G	cg13010199	chr12:38710504	ALG10B	0.56	11.29	0.46	2.83e-26	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9646954	0.542	rs3828193	chr2:101031561	A/C	cg14675211	chr2:100938903	LONRF2	-0.67	-11.88	-0.48	1.36e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10911363	0.592	rs2702180	chr1:183517971	T/C	cg23894439	chr1:183413866	NA	0.46	8.57	0.37	1.5e-16	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.14	-24.76	-0.75	7.75e-87	Chronic sinus infection;
LGG	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg15704280	chr7:45808275	SEPT13	-0.81	-12.12	-0.49	1.42e-29	Coronary artery disease;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg21782813	chr7:2030301	MAD1L1	0.56	14.47	0.56	1.96e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg16797656	chr11:68205561	LRP5	0.39	6.86	0.3	2.17e-11	Total body bone mineral density;
LGG	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.9	0.57	2.72e-41	Cognitive test performance;
LGG	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.35	-0.36	7.7e-16	Mean corpuscular volume;
LGG	cis	rs8060686	0.545	rs17688076	chr16:68286427	C/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.7	-0.3	6.06e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs8179	0.645	rs56201652	chr7:92278116	G/A	cg15732164	chr7:92237376	CDK6	-0.52	-10.0	-0.42	1.86e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs9300255	0.602	rs1402274	chr12:123686224	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.23e-11	Educational attainment;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.04e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00495681	chr13:53174319	NA	0.69	13.34	0.53	1.42e-34	Lewy body disease;
LGG	cis	rs2797369	0.656	rs705613	chr6:101355991	A/C	cg27451362	chr6:101846650	GRIK2	0.7	9.82	0.42	8.53e-21	Renal function-related traits (eGRFcrea);
LGG	trans	rs783540	0.934	rs8043401	chr15:83356259	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.42	-0.33	5.82e-13	Schizophrenia;
LGG	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg11644478	chr21:40555479	PSMG1	-0.6	-10.03	-0.42	1.45e-21	Menarche (age at onset);
LGG	cis	rs9486719	1.000	rs12197411	chr6:97039621	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.79	-0.3	3.53e-11	Migraine;Coronary artery disease;
LGG	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg20503657	chr10:835505	NA	0.75	10.32	0.43	1.31e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs56283067	0.886	rs12205657	chr6:44680615	C/T	cg18551225	chr6:44695536	NA	-0.65	-11.43	-0.47	7.72e-27	Total body bone mineral density;
LGG	cis	rs6456156	0.586	rs12528323	chr6:167461645	A/G	cg07741184	chr6:167504864	NA	0.4	9.03	0.39	4.5e-18	Primary biliary cholangitis;
LGG	cis	rs774359	0.797	rs774352	chr9:27516590	C/T	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.14	-0.35	3.79e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.38e-19	Aortic root size;
LGG	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg11871910	chr12:69753446	YEATS4	0.72	14.32	0.55	9.44e-39	Blood protein levels;
LGG	cis	rs7923609	0.756	rs7090758	chr10:65335315	T/C	cg02276361	chr10:65351566	REEP3	-0.31	-6.92	-0.31	1.49e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg23533926	chr12:111358616	MYL2	-0.4	-6.7	-0.3	6.18e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24568646	chr21:30446238	CCT8	-0.46	-6.75	-0.3	4.49e-11	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.69	-0.34	8.86e-14	Testicular germ cell tumor;
LGG	cis	rs12681287	0.640	rs7816275	chr8:87373404	A/G	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	trans	rs13256369	0.774	rs13260303	chr8:8587342	A/C	cg02002194	chr4:3960332	NA	-0.42	-7.53	-0.33	2.6e-13	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.49e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11711311	1.000	rs4362695	chr3:113534856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.03	-0.35	7.91e-15	IgG glycosylation;
LGG	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg05692746	chr2:100937584	LONRF2	-0.57	-9.26	-0.4	7.53e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg08109568	chr15:31115862	NA	-0.55	-9.16	-0.39	1.69e-18	Huntington's disease progression;
LGG	cis	rs953492	0.701	rs1796846	chr1:243306924	A/G	cg02356786	chr1:243265016	LOC731275	-0.39	-7.07	-0.31	5.66e-12	Diastolic blood pressure;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03647317	chr4:187891568	NA	-0.41	-9.14	-0.39	2.04e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs526231	0.511	rs55810112	chr5:102362349	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.52	-0.37	2.33e-16	Primary biliary cholangitis;
LGG	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg00919237	chr7:87102261	ABCB4	-0.78	-15.62	-0.59	1.73e-44	Gallbladder cancer;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg26783146	chr16:4423632	VASN;CORO7	0.44	8.19	0.36	2.5e-15	Schizophrenia;
LGG	cis	rs9636252	0.851	rs11885891	chr2:9264724	A/G	cg20341998	chr2:9276514	NA	0.36	6.91	0.31	1.59e-11	IgG glycosylation;
LGG	cis	rs171408	0.842	rs355134	chr3:8613844	A/G	cg03557445	chr3:8615444	LOH3CR2A	-0.51	-9.27	-0.4	6.93e-19	Mitral valve prolapse;
LGG	cis	rs2408955	0.521	rs7301003	chr12:48550227	A/G	cg24011408	chr12:48396354	COL2A1	0.56	9.36	0.4	3.59e-19	Glycated hemoglobin levels;
LGG	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg05555928	chr11:63887634	MACROD1	0.73	9.97	0.42	2.39e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9303401	0.659	rs35797125	chr17:56736547	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg09307838	chr4:120376055	NA	0.73	12.6	0.51	1.6e-31	Corneal astigmatism;
LGG	cis	rs2455601	0.638	rs3815991	chr11:9007669	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.67	10.5	0.44	2.85e-23	Schizophrenia;
LGG	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.16	-0.35	3.17e-15	Triglycerides;
LGG	cis	rs80282103	0.867	rs12241632	chr10:1069070	A/T	cg08668510	chr10:1095578	IDI1	0.68	7.9	0.34	2.04e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs8064024	0.681	rs1395602	chr16:4911239	A/C	cg08329684	chr16:4932620	PPL	0.52	11.84	0.48	1.88e-28	Cancer;
LGG	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	15.43	0.58	1.19e-43	Menarche (age at onset);
LGG	cis	rs2798269	0.902	rs12869776	chr13:22103294	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.41	-6.96	-0.31	1.18e-11	PR segment;
LGG	cis	rs9863	0.896	rs12824567	chr12:124495203	G/C	cg13487667	chr12:124434373	CCDC92	-0.37	-7.32	-0.32	1.1e-12	White blood cell count;
LGG	cis	rs9640161	0.750	rs3800780	chr7:150027284	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.79	-16.51	-0.61	1.65e-48	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs17102423	0.964	rs868814	chr14:65584508	C/T	cg26396452	chr14:65542826	MAX	0.44	8.65	0.37	8.39e-17	Obesity-related traits;
LGG	trans	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg06521331	chr12:34319734	NA	0.46	8.31	0.36	1.07e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg19507638	chr5:93509721	C5orf36	-0.66	-9.39	-0.4	2.77e-19	Diabetic retinopathy;
LGG	cis	rs9534288	0.789	rs4942470	chr13:46636652	A/G	cg15192986	chr13:46630673	CPB2	-0.79	-16.45	-0.61	3.34e-48	Blood protein levels;
LGG	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.58	-0.37	1.41e-16	Eosinophil percentage of white cells;
LGG	cis	rs1867631	0.959	rs11208914	chr1:67049728	C/T	cg13052034	chr1:66999238	SGIP1	0.45	8.75	0.38	4.02e-17	Menopause (age at onset);
LGG	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg24558204	chr6:135376177	HBS1L	0.54	9.42	0.4	2.11e-19	Red blood cell count;
LGG	cis	rs889398	0.641	rs7200258	chr16:69897469	T/G	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.74	-0.34	6.25e-14	Body mass index;
LGG	cis	rs2415984	0.600	rs61990993	chr14:46850479	C/G	cg14871534	chr14:47121158	RPL10L	-0.56	-9.39	-0.4	2.83e-19	Number of children ever born;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.46	0.44	3.95e-23	Obesity-related traits;
LGG	cis	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg18937875	chr11:14930189	NA	-0.48	-7.83	-0.34	3.31e-14	Vitamin D levels;
LGG	trans	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg18187862	chr3:45730750	SACM1L	-0.42	-6.93	-0.31	1.46e-11	Primary sclerosing cholangitis;
LGG	cis	rs2294693	0.891	rs4714421	chr6:40992837	C/T	cg14769373	chr6:40998127	UNC5CL	-0.42	-7.08	-0.31	5.49e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs12220238	1.000	rs10824078	chr10:75892120	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.28	0.46	3.1e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13390975	chr5:34915890	BRIX1;RAD1	0.4	6.87	0.3	2.07e-11	Bipolar disorder;
LGG	cis	rs6952809	0.516	rs6952959	chr7:2440722	C/T	cg23289794	chr7:2394357	EIF3B	-0.8	-10.1	-0.42	8.62e-22	Multiple sclerosis;
LGG	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg22906224	chr7:99728672	NA	0.58	9.02	0.39	5.16e-18	Coronary artery disease;
LGG	cis	rs4538187	0.737	rs36033991	chr2:64150441	A/G	cg14150252	chr2:64069583	UGP2	-0.5	-9.81	-0.42	8.77e-21	Systolic blood pressure;
LGG	cis	rs2120019	1.000	rs2120019	chr15:75334184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.32	-0.65	8.65e-57	Blood trace element (Zn levels);
LGG	cis	rs17030434	0.834	rs28658020	chr4:154759048	C/T	cg14289246	chr4:154710475	SFRP2	-0.62	-10.14	-0.43	5.97e-22	Electrocardiographic conduction measures;
LGG	cis	rs75920871	0.588	rs1815789	chr11:116834953	T/C	cg20608306	chr11:116969690	SIK3	-0.41	-10.8	-0.45	2.18e-24	Subjective well-being;
LGG	cis	rs80282103	0.618	rs2387299	chr10:1163427	A/G	cg08668510	chr10:1095578	IDI1	0.75	7.34	0.32	9.63e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs8032158	1.000	rs11633263	chr15:56135559	A/C	cg02198044	chr15:56286336	NEDD4	-0.69	-11.81	-0.48	2.58e-28	Keloid;
LGG	cis	rs8133932	0.654	rs7277632	chr21:47327542	A/G	cg11214348	chr21:47283868	PCBP3	0.43	7.71	0.34	8.02e-14	Schizophrenia;
LGG	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg03959625	chr15:84868606	LOC388152	0.55	8.77	0.38	3.56e-17	Schizophrenia;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg12463550	chr7:65579703	CRCP	-0.53	-8.69	-0.37	6.38e-17	Aortic root size;
LGG	cis	rs4936894	0.500	rs11219502	chr11:124084433	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.77	-0.45	2.65e-24	Aging (time to death);
LGG	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg12463550	chr7:65579703	CRCP	0.83	8.75	0.38	3.99e-17	Diabetic kidney disease;
LGG	trans	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg05926928	chr17:57297772	GDPD1	0.56	9.24	0.39	9.17e-19	Schizophrenia;
LGG	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg16070123	chr10:51489643	NA	0.39	7.27	0.32	1.59e-12	Prostate-specific antigen levels;
LGG	cis	rs4936894	0.500	rs10790666	chr11:124176977	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.99	-0.45	4.11e-25	Aging (time to death);
LGG	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg26384229	chr12:38710491	ALG10B	0.98	22.24	0.72	4.35e-75	Bladder cancer;
LGG	trans	rs6601450	0.540	rs7824231	chr8:10273958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.59	-0.33	1.72e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.75e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9400467	0.537	rs12212282	chr6:111524838	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.12	0.31	4.04e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4776059	1.000	rs2414166	chr15:52901977	C/T	cg22715398	chr15:52968154	KIAA1370	-0.51	-8.66	-0.37	7.97e-17	Schizophrenia;
LGG	cis	rs7617773	0.780	rs3197223	chr3:48335857	C/T	cg11946769	chr3:48343235	NME6	0.72	12.05	0.49	2.94e-29	Coronary artery disease;
LGG	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg00857998	chr1:205179979	DSTYK	0.47	6.95	0.31	1.25e-11	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6787172	0.677	rs1193505	chr3:157994327	G/A	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	3.01e-17	Subjective well-being;
LGG	trans	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg27661571	chr11:113659931	NA	-0.62	-8.96	-0.38	7.83e-18	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.88e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14234898	chr6:75953566	COX7A2	0.42	7.07	0.31	5.62e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg25706552	chr1:244017396	NA	0.51	8.37	0.36	6.8e-16	RR interval (heart rate);
LGG	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg10792982	chr14:105748885	BRF1	0.66	12.92	0.51	8.31e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs8020289	1.000	rs10151888	chr14:77290233	C/T	cg23436960	chr14:77239540	VASH1	-0.25	-6.65	-0.3	8.43e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04124586	chr1:8585852	RERE	0.38	7.05	0.31	6.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.61	-8.89	-0.38	1.32e-17	Iron status biomarkers;
LGG	cis	rs11685299	1	rs11685299	chr2:225391296	C/A	cg12698349	chr2:225449008	CUL3	0.93	19.29	0.67	2.78e-61	Schizophrenia;
LGG	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg26384229	chr12:38710491	ALG10B	0.97	20.55	0.69	3.71e-67	Morning vs. evening chronotype;
LGG	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	8.03	0.35	8.31e-15	HIV-1 control;
LGG	cis	rs2247341	1.000	rs2247341	chr4:1701317	C/T	cg07465881	chr4:1713556	SLBP	-0.46	-7.35	-0.32	9.13e-13	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.76	-0.34	5.6e-14	Skin colour saturation;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg22903471	chr2:27725779	GCKR	-0.58	-13.25	-0.52	3.39e-34	Total body bone mineral density;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg07701084	chr6:150067640	NUP43	0.64	12.06	0.49	2.53e-29	Lung cancer;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg16606324	chr3:10149918	C3orf24	0.54	7.13	0.31	3.82e-12	Alzheimer's disease;
LGG	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.54	0.33	2.47e-13	Schizophrenia;
LGG	cis	rs3806843	1.000	rs3756342	chr5:140165624	G/A	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg11814155	chr7:99998594	ZCWPW1	0.61	9.33	0.4	4.46e-19	Platelet count;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.23	-0.46	4.89e-26	IgG glycosylation;
LGG	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.07	-0.39	3.33e-18	Primary sclerosing cholangitis;
LGG	cis	rs9534288	0.797	rs7331368	chr13:46609062	G/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.23e-34	Blood protein levels;
LGG	cis	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg00383909	chr3:49044727	WDR6	0.99	12.39	0.5	1.24e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9309473	1.000	rs11674602	chr2:73723185	A/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.66	-0.34	1.1e-13	Metabolite levels;
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7937612	0.965	rs10790378	chr11:120220268	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.51	-0.5	3.92e-31	Intraocular pressure;
LGG	cis	rs2549003	1.000	rs2549007	chr5:131826875	T/C	cg00578828	chr5:131826934	IRF1	-0.38	-6.71	-0.3	5.86e-11	Asthma (sex interaction);
LGG	cis	rs7312933	0.703	rs10492388	chr12:42608001	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	7.29	0.32	1.32e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg20503657	chr10:835505	NA	-0.53	-8.63	-0.37	1.02e-16	Eosinophil percentage of granulocytes;
LGG	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg20587970	chr11:113659929	NA	1.06	14.47	0.56	2.04e-39	Hip circumference adjusted for BMI;
LGG	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg24110177	chr3:50126178	RBM5	0.53	8.14	0.35	3.78e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.34	-8.87	-0.38	1.66e-17	IgG glycosylation;
LGG	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg09873164	chr1:152488093	CRCT1	0.65	16.06	0.6	1.82e-46	Hair morphology;
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg18240062	chr17:79603768	NPLOC4	0.62	10.37	0.43	8.41e-23	Eye color traits;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.1	-0.39	2.79e-18	Response to antipsychotic treatment;
LGG	cis	rs739401	0.611	rs3782069	chr11:3033275	G/A	cg05729581	chr11:3078854	CARS	-0.53	-9.14	-0.39	1.96e-18	Longevity;
LGG	cis	rs34172651	0.517	rs200528	chr16:24759131	A/G	cg02428538	chr16:24856791	SLC5A11	0.72	11.09	0.46	1.68e-25	Intelligence (multi-trait analysis);
LGG	cis	rs926392	0.932	rs6513588	chr20:37686281	T/C	cg16355469	chr20:37678765	NA	0.46	7.6	0.33	1.64e-13	Dialysis-related mortality;
LGG	trans	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg18198730	chr1:247681584	NA	0.73	12.3	0.5	2.69e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs11168618	0.567	rs12372687	chr12:48811799	G/T	cg24011408	chr12:48396354	COL2A1	0.48	7.72	0.34	7.39e-14	Adiponectin levels;
LGG	trans	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4595586	0.545	rs1562729	chr12:39406179	T/G	cg26384229	chr12:38710491	ALG10B	0.6	10.9	0.45	8.89e-25	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg09307838	chr4:120376055	NA	-0.6	-9.65	-0.41	3.34e-20	Corneal astigmatism;
LGG	cis	rs7737355	0.853	rs6873582	chr5:130892741	A/G	cg06307176	chr5:131281290	NA	0.56	9.36	0.4	3.57e-19	Life satisfaction;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg13047869	chr3:10149882	C3orf24	0.53	8.99	0.39	6.44e-18	Alzheimer's disease;
LGG	cis	rs3820068	0.603	rs72647138	chr1:15980929	C/T	cg05660106	chr1:15850417	CASP9	0.85	17.35	0.63	2.58e-52	Systolic blood pressure;
LGG	cis	rs79149102	0.579	rs12593476	chr15:75282092	A/C	cg17294928	chr15:75287854	SCAMP5	-0.81	-8.59	-0.37	1.39e-16	Lung cancer;
LGG	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg02640540	chr1:67518911	SLC35D1	0.36	7.15	0.32	3.51e-12	Lymphocyte percentage of white cells;
LGG	cis	rs6466055	0.720	rs1121194	chr7:104981133	T/C	cg04380332	chr7:105027541	SRPK2	0.38	7.29	0.32	1.37e-12	Schizophrenia;
LGG	cis	rs6088590	0.603	rs6579186	chr20:33282198	G/C	cg24642439	chr20:33292090	TP53INP2	0.64	11.24	0.46	4.39e-26	Coronary artery disease;
LGG	trans	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg18335740	chr13:41363409	SLC25A15	0.51	9.28	0.4	6.55e-19	Lewy body disease;
LGG	cis	rs597583	0.806	rs11603366	chr11:117396505	G/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.27	-0.36	1.4e-15	Putamen volume;
LGG	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg02002194	chr4:3960332	NA	-0.46	-8.76	-0.38	3.68e-17	Mood instability;
LGG	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg03098644	chr7:100410630	EPHB4	0.49	7.25	0.32	1.8e-12	Other erythrocyte phenotypes;
LGG	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.1	-0.46	1.56e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs6750047	0.566	rs1157185	chr2:38285735	C/T	cg07380506	chr2:38303506	CYP1B1	0.47	7.81	0.34	3.98e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg08847335	chr10:891726	LARP4B	0.55	9.28	0.4	6.46e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7607369	0.580	rs17573724	chr2:219652141	T/A	cg01130898	chr2:219473002	PLCD4	0.42	7.15	0.32	3.51e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs2635047	0.648	rs4986203	chr18:44597092	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.61	10.77	0.45	2.84e-24	Educational attainment;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.38e-17	Prudent dietary pattern;
LGG	cis	rs4720575	0.839	rs10255464	chr7:47097043	A/G	cg00036614	chr7:47093842	NA	-0.5	-9.96	-0.42	2.72e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.09e-19	Obesity-related traits;
LGG	cis	rs9377188	0.570	rs7776117	chr6:149362214	A/G	cg21368479	chr6:149415018	NA	0.26	6.7	0.3	6.25e-11	Cancer;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.16e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Depression;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.92	0.35	1.72e-14	Obesity-related traits;
LGG	cis	rs7926971	0.704	rs4463830	chr11:12659331	C/T	cg25843174	chr11:12811716	TEAD1	0.32	6.86	0.3	2.24e-11	Height;
LGG	cis	rs4774899	0.898	rs2593235	chr15:57541201	G/A	cg08128148	chr15:57256372	TCF12	-0.32	-7.45	-0.33	4.7e-13	Urinary tract infection frequency;
LGG	cis	rs62238980	0.614	rs76222062	chr22:32457049	T/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2131877	0.750	rs873120	chr3:194853489	C/G	cg07250128	chr3:194833983	C3orf21	0.41	6.88	0.3	2e-11	Non-small cell lung cancer;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.87	0.38	1.65e-17	Lung cancer;
LGG	cis	rs806215	0.526	rs12673293	chr7:127520162	T/G	cg25922125	chr7:127225783	GCC1	-0.47	-6.95	-0.31	1.21e-11	Type 2 diabetes;
LGG	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg08603382	chr10:743973	NA	0.38	6.97	0.31	1.13e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg18225595	chr11:63971243	STIP1	0.55	7.27	0.32	1.59e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.95	0.62	1.68e-50	Smoking behavior;
LGG	cis	rs7072216	0.763	rs6584205	chr10:100173806	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.6e-12	Metabolite levels;
LGG	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg22517653	chr1:2918612	NA	-0.48	-7.37	-0.32	8.09e-13	Plateletcrit;
LGG	cis	rs2820315	0.867	rs2820317	chr1:201878537	G/C	cg10061532	chr1:201886748	LMOD1	0.32	6.89	0.31	1.8e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.82	-0.3	2.88e-11	Bipolar disorder;
LGG	cis	rs9926296	0.605	rs6500453	chr16:89858657	C/G	cg07648498	chr16:89883185	FANCA	0.4	6.9	0.31	1.7e-11	Vitiligo;
LGG	cis	rs17767392	0.595	rs61174376	chr14:71654869	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.17	-0.32	3.05e-12	Mitral valve prolapse;
LGG	cis	rs9715521	0.935	rs56025348	chr4:59836741	T/G	cg11281224	chr4:60001000	NA	-0.43	-7.28	-0.32	1.48e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.4	-8.16	-0.35	3.2e-15	Schizophrenia;
LGG	cis	rs9487094	0.626	rs3799845	chr6:110027717	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.08	0.35	5.8e-15	Height;
LGG	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-9.69	-0.41	2.43e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.49e-17	Lung cancer;
LGG	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg20587970	chr11:113659929	NA	1.11	14.31	0.55	1.03e-38	Hip circumference adjusted for BMI;
LGG	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-9.23	-0.39	9.36e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07810927	chr1:16302303	ZBTB17	0.4	6.65	0.3	8.03e-11	Gut microbiome composition (summer);
LGG	cis	rs7928758	0.887	rs60337613	chr11:134264255	T/C	cg25213107	chr11:134282864	B3GAT1	1.2	14.34	0.55	7.76e-39	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg17425144	chr1:10567563	PEX14	0.39	8.09	0.35	5.26e-15	Hepatocellular carcinoma;
LGG	cis	rs6594713	0.757	rs13154300	chr5:112719356	T/C	cg12552261	chr5:112820674	MCC	0.51	6.72	0.3	5.37e-11	Brain cytoarchitecture;
LGG	cis	rs17689437	0.522	rs1728778	chr16:68628851	G/A	cg02972257	chr16:68554789	NA	-0.42	-6.76	-0.3	4.29e-11	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs9534288	0.700	rs7331032	chr13:46609040	C/T	cg15192986	chr13:46630673	CPB2	-0.61	-13.49	-0.53	3.16e-35	Blood protein levels;
LGG	cis	rs7582180	0.838	rs6754867	chr2:100895081	A/G	cg08297393	chr2:100937505	LONRF2	0.45	7.67	0.34	1.03e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.32	0.43	1.29e-22	Height;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.45	0.53	4.94e-35	Lung cancer;
LGG	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg05444541	chr17:17804740	TOM1L2	0.6	13.98	0.54	2.77e-37	Total body bone mineral density;
LGG	cis	rs6881634	0.768	rs4704495	chr5:77624910	C/T	cg11446398	chr5:77624930	NA	0.46	10.38	0.43	7.71e-23	Hippocampal atrophy;
LGG	cis	rs1355223	0.506	rs7131229	chr11:34869328	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.52	8.29	0.36	1.24e-15	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10267417	0.556	rs10229052	chr7:19965180	C/T	cg05791153	chr7:19748676	TWISTNB	0.54	6.92	0.31	1.47e-11	Night sleep phenotypes;
LGG	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg06212747	chr3:49208901	KLHDC8B	0.72	12.37	0.5	1.4e-30	Parkinson's disease;
LGG	cis	rs68170813	0.559	rs80307895	chr7:106907781	T/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.52	-0.44	2.38e-23	Coronary artery disease;
LGG	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg07541023	chr7:19748670	TWISTNB	0.5	6.69	0.3	6.51e-11	Night sleep phenotypes;
LGG	cis	rs11719291	0.915	rs9834996	chr3:48754877	G/T	cg00383909	chr3:49044727	WDR6	0.92	11.62	0.48	1.45e-27	Cognitive function;
LGG	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-10.39	-0.43	7.02e-23	Response to antipsychotic treatment;
LGG	cis	rs2880765	0.835	rs11633604	chr15:86031579	T/G	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs60180747	1.000	rs74634457	chr15:66835704	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.64	11.33	0.47	1.97e-26	Testicular germ cell tumor;
LGG	cis	rs10893109	0.538	rs7951061	chr11:123783957	C/T	cg12387464	chr11:123775935	OR8D4	0.38	8.27	0.36	1.46e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs6489882	0.867	rs4767036	chr12:113369177	T/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.6	-0.33	1.64e-13	Chronic lymphocytic leukemia;
LGG	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	7.99	0.35	1.12e-14	Coronary artery disease;
LGG	cis	rs10191773	0.589	rs11691239	chr2:112950600	A/C	cg04979063	chr2:113191202	RGPD5;RGPD8	-0.73	-8.77	-0.38	3.51e-17	Yeast infection;
LGG	cis	rs3780378	0.935	rs7875908	chr9:5081334	C/T	cg02405213	chr9:5042618	JAK2	-0.5	-8.71	-0.38	5.61e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2658782	0.547	rs10765602	chr11:93048165	G/T	cg15737290	chr11:93063684	CCDC67	0.66	10.98	0.45	4.44e-25	Pulmonary function decline;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg06925179	chr17:43578568	NA	-0.39	-9.28	-0.4	6.51e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.67	-0.48	9.35e-28	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.777	rs2049130	chr12:38444837	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.4	-0.36	5.55e-16	Bladder cancer;
LGG	trans	rs11662586	0.517	rs7228070	chr18:77698967	C/T	cg05926928	chr17:57297772	GDPD1	0.65	11.26	0.46	3.67e-26	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-11.76	-0.48	4.14e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.921	rs688354	chr11:111438762	A/G	cg22437258	chr11:111473054	SIK2	0.51	8.67	0.37	7.53e-17	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg07701084	chr6:150067640	NUP43	0.68	11.91	0.48	1.06e-28	Lung cancer;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.94e-18	Menopause (age at onset);
LGG	cis	rs6032067	0.777	rs34073275	chr20:43788917	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs498079	0.544	rs509904	chr6:133517082	A/T	cg02446647	chr6:133562101	EYA4	-0.31	-7.69	-0.34	8.81e-14	Total body bone mineral density;
LGG	cis	rs12478296	1.000	rs73007140	chr2:243010756	T/C	cg06360820	chr2:242988706	NA	-0.87	-11.16	-0.46	8.95e-26	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg02269571	chr22:50332266	NA	0.65	8.47	0.37	3.4e-16	Schizophrenia;
LGG	cis	rs7666738	0.830	rs34313689	chr4:99013689	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs370915	1.000	rs9685837	chr4:187818466	C/T	cg19519643	chr4:187840862	NA	-0.48	-8.78	-0.38	3.27e-17	Gout;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg05552183	chr6:42928497	GNMT	0.43	12.86	0.51	1.39e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.36	-0.32	8.36e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg03469862	chr11:68924853	NA	0.46	7.13	0.31	3.9e-12	Blond vs. brown hair color;
LGG	trans	rs8002861	0.664	rs2218497	chr13:44428793	G/A	cg17145862	chr1:211918768	LPGAT1	0.79	17.22	0.62	1.06e-51	Leprosy;
LGG	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg01493522	chr13:37497338	NA	-0.5	-8.38	-0.36	6.29e-16	Coronary artery disease;
LGG	cis	rs12505749	0.542	rs4864585	chr4:57360635	A/G	cg07846311	chr4:57371927	ARL9	-0.32	-7.84	-0.34	3.19e-14	Airflow obstruction;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg00012203	chr2:219082015	ARPC2	-0.69	-12.44	-0.5	7.59e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs3617	0.573	rs2336667	chr3:52916363	C/T	cg11645453	chr3:52864694	ITIH4	-0.45	-7.59	-0.33	1.76e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4937291	0.966	rs873411	chr11:112208482	C/T	cg12822818	chr11:112096781	PTS	0.43	6.71	0.3	5.56e-11	Interleukin-18 levels;
LGG	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg02018176	chr4:1364513	KIAA1530	0.42	9.32	0.4	4.89e-19	Obesity-related traits;
LGG	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg01620082	chr3:125678407	NA	0.82	8.87	0.38	1.63e-17	Depression;
LGG	cis	rs9399135	0.967	rs2183709	chr6:135377091	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.54e-19	Red blood cell count;
LGG	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg08400814	chr5:56204995	C5orf35	-0.38	-6.74	-0.3	4.85e-11	Coronary artery disease;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.44	8.07	0.35	6.05e-15	Schizophrenia;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.92	-0.45	7.65e-25	Lung cancer;
LGG	cis	rs10870270	0.956	rs4131689	chr10:133744328	A/C	cg08754478	chr10:133766260	PPP2R2D	0.68	12.49	0.5	4.6e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg24675658	chr1:53192096	ZYG11B	-0.53	-10.93	-0.45	6.7e-25	Monocyte count;
LGG	trans	rs61931739	0.511	rs2035659	chr12:33826241	T/C	cg26384229	chr12:38710491	ALG10B	0.5	9.04	0.39	4.21e-18	Morning vs. evening chronotype;
LGG	cis	rs6138458	1.000	rs6114980	chr20:24974288	A/G	cg26195577	chr20:24973756	C20orf3	1.24	25.98	0.77	1.77e-92	Blood protein levels;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.87	-0.42	5.61e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.42	-0.5	9.02e-31	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.15	-0.46	1.01e-25	IgG glycosylation;
LGG	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg08344181	chr3:125677491	NA	-0.58	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.32	0.58	3.64e-43	Platelet count;
LGG	cis	rs7011049	0.778	rs6981481	chr8:53866409	T/C	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs77372450	0.636	rs28621556	chr5:156997323	C/G	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs4971059	0.507	rs11264321	chr1:155085898	C/A	cg13808842	chr1:155066096	NA	-0.32	-8.12	-0.35	4.12e-15	Breast cancer;
LGG	trans	rs8073060	0.586	rs225288	chr17:33929291	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.42	-0.63	1.22e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.68	-0.3	6.68e-11	Lung cancer;
LGG	cis	rs4601821	0.583	rs1893696	chr11:113206275	G/A	cg14373873	chr11:113211441	TTC12	0.41	8.05	0.35	7.27e-15	Alcoholic chronic pancreatitis;
LGG	trans	rs826838	0.872	rs826878	chr12:39088837	A/T	cg06521331	chr12:34319734	NA	0.47	8.7	0.37	6e-17	Heart rate;
LGG	cis	rs2191566	0.761	rs446016	chr19:44501518	A/G	cg20607764	chr19:44506953	ZNF230	-0.41	-7.25	-0.32	1.7e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg12826209	chr6:26865740	GUSBL1	0.79	8.24	0.36	1.76e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2274273	0.935	rs8004787	chr14:55607366	C/T	cg04306507	chr14:55594613	LGALS3	0.65	18.42	0.65	2.94e-57	Protein biomarker;
LGG	trans	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-31.9	-0.83	6.05e-119	Exhaled nitric oxide output;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.91	0.34	1.92e-14	Renal function-related traits (BUN);
LGG	cis	rs1018697	1.000	rs1018696	chr10:104549066	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.02	0.39	5.16e-18	Colorectal adenoma (advanced);
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-6.68	-0.3	6.71e-11	Neuroticism;
LGG	cis	rs4474465	0.915	rs10899512	chr11:78171338	G/A	cg02023728	chr11:77925099	USP35	0.4	7.15	0.32	3.31e-12	Alzheimer's disease (survival time);
LGG	cis	rs2298450	0.717	rs2835328	chr21:37622915	A/C	cg02919814	chr21:37666008	DOPEY2	-0.45	-7.98	-0.35	1.13e-14	Schizophrenia;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12894336	chr3:47823524	SMARCC1	0.48	7.35	0.32	8.86e-13	Gut microbiome composition (summer);
LGG	trans	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs58688157	0.705	rs12803132	chr11:586696	A/G	cg03576123	chr11:487126	PTDSS2	-0.49	-6.71	-0.3	5.83e-11	Systemic lupus erythematosus;
LGG	cis	rs4722585	0.605	rs10268883	chr7:26200417	C/T	cg07876897	chr7:26191696	NFE2L3	0.36	7.25	0.32	1.8e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs926938	0.527	rs360580	chr1:115462334	A/G	cg12756093	chr1:115239321	AMPD1	0.44	8.22	0.36	2.11e-15	Autism;
LGG	cis	rs76917914	0.820	rs6478539	chr9:100818720	C/T	cg03040243	chr9:100819229	NANS	0.48	6.69	0.3	6.5500000000000006e-11	Immature fraction of reticulocytes;
LGG	cis	rs2797369	0.824	rs2399557	chr6:101611952	G/A	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs4664304	0.802	rs62175470	chr2:160858255	G/C	cg03641300	chr2:160917029	PLA2R1	-0.46	-8.12	-0.35	4.38e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.92	-11.74	-0.48	4.71e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs16867321	0.614	rs12693245	chr2:181445110	T/C	cg23363182	chr2:181467187	NA	0.43	8.58	0.37	1.43e-16	Obesity;
LGG	trans	rs6011368	0.740	rs6062678	chr20:62888802	G/T	cg13869341	chr1:15865	WASH5P	0.53	9.48	0.4	1.36e-19	Clozapine-induced cytotoxicity;
LGG	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg19554555	chr3:13937349	NA	-0.54	-9.89	-0.42	4.54e-21	Ovarian reserve;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.48	0.47	5.16e-27	Electroencephalogram traits;
LGG	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs2880765	0.743	rs11630410	chr15:86004741	T/A	cg10818794	chr15:86012489	AKAP13	-0.36	-7.52	-0.33	2.87e-13	Coronary artery disease;
LGG	cis	rs734999	0.549	rs2764845	chr1:2528999	G/T	cg20673091	chr1:2541236	MMEL1	-0.77	-18.79	-0.66	6.1e-59	Ulcerative colitis;
LGG	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.58	-0.44	1.4e-23	Breast cancer;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs5756391	0.568	rs10222238	chr22:37318014	G/T	cg21209356	chr22:37319042	CSF2RB	0.42	9.66	0.41	3.17e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg24247370	chr13:99142703	STK24	-0.37	-6.78	-0.3	3.67e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06634786	chr22:41940651	POLR3H	0.79	13.07	0.52	1.86e-33	Vitiligo;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg22907277	chr7:1156413	C7orf50	0.7	8.79	0.38	2.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3087591	0.960	rs2953009	chr17:29498387	A/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03517284	chr6:25882590	NA	-0.49	-9.08	-0.39	3.22e-18	Height;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.37e-50	Platelet distribution width;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg17467752	chr17:38218738	THRA	-0.46	-7.28	-0.32	1.42e-12	Self-reported allergy;
LGG	cis	rs1062177	1.000	rs2915887	chr5:151205504	C/T	cg00977110	chr5:151150581	G3BP1	0.5	7.82	0.34	3.64e-14	Preschool internalizing problems;
LGG	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg13939156	chr17:80058883	NA	0.46	8.24	0.36	1.77e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg11062466	chr8:58055876	NA	0.62	9.71	0.41	2.14e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg08297393	chr2:100937505	LONRF2	-0.57	-9.82	-0.42	8.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs7531317	chr1:152528439	A/C	cg09873164	chr1:152488093	CRCT1	0.61	14.93	0.57	2.05e-41	Hair morphology;
LGG	trans	rs2727020	0.521	rs1909220	chr11:49572109	T/C	cg03929089	chr4:120376271	NA	-0.87	-13.36	-0.53	1.14e-34	Coronary artery disease;
LGG	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg16400903	chr5:693638	TPPP	0.45	6.92	0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs8077889	0.956	rs4793025	chr17:41841621	T/C	cg26893861	chr17:41843967	DUSP3	1.01	17.3	0.63	4.28e-52	Triglycerides;
LGG	cis	rs2235642	0.685	rs2667681	chr16:1653206	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.29	0.4	6.01e-19	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs9811920	0.638	rs793461	chr3:99615758	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs3733585	0.726	rs4306953	chr4:9955776	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.13e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs5769765	0.954	rs5770707	chr22:50244533	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.57	-0.33	2.05e-13	Schizophrenia;
LGG	trans	rs6787172	0.622	rs56387731	chr3:158097720	A/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs6456042	1.000	rs9459577	chr6:166534389	C/A	cg11088901	chr6:166572345	T	-0.35	-7.28	-0.32	1.44e-12	Asthma;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg22535103	chr8:58192502	C8orf71	-0.99	-15.16	-0.58	1.99e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.2	-0.43	3.57e-22	Total body bone mineral density;
LGG	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.91	-0.31	1.59e-11	Inflammatory bowel disease;
LGG	cis	rs9682041	1.000	rs6444920	chr3:170090374	A/G	cg11886554	chr3:170076028	SKIL	1.01	12.08	0.49	2.21e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg09085632	chr11:111637200	PPP2R1B	0.69	11.93	0.48	8.34e-29	Primary sclerosing cholangitis;
LGG	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg23166289	chr1:210001082	C1orf107	0.4	7.32	0.32	1.07e-12	Orofacial clefts;
LGG	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.1	-0.31	4.82e-12	Lung cancer;
LGG	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg15971980	chr6:150254442	NA	-0.44	-8.21	-0.36	2.2e-15	Lung cancer;
LGG	cis	rs4664304	0.772	rs6737904	chr2:160872526	G/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.57	-0.37	1.59e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12476592	0.602	rs10865337	chr2:63720906	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.9	-0.31	1.76e-11	Childhood ear infection;
LGG	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg25554036	chr4:6271136	WFS1	0.61	11.48	0.47	5.26e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg27624424	chr6:160112604	SOD2	0.64	9.32	0.4	4.76e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1018836	0.923	rs10956748	chr8:91621537	T/A	cg16814680	chr8:91681699	NA	-0.85	-15.78	-0.59	3.44e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg25703541	chr22:24373054	LOC391322	-0.87	-17.03	-0.62	7.57e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7909791	0.678	rs10883932	chr10:105623956	T/A	cg11005552	chr10:105648138	OBFC1	0.64	9.62	0.41	4.43e-20	White matter hyperintensity burden;
LGG	cis	rs4589502	0.925	rs4259997	chr15:67153310	A/G	cg18595228	chr15:67193261	NA	-0.53	-7.44	-0.33	4.96e-13	Lung cancer (smoking interaction);
LGG	cis	rs11098499	0.754	rs17049949	chr4:120255290	A/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	cis	rs1465370	0.682	rs2239604	chr7:130021331	C/T	cg25718383	chr7:130020096	CPA1	0.33	8.51	0.37	2.37e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.16	-0.49	1.06e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs72991	0.793	rs891438	chr11:121227541	C/T	cg27192990	chr6:129479024	LAMA2	-0.42	-7.07	-0.31	5.91e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2016266	0.819	rs1976938	chr12:53661925	C/T	cg04065151	chr12:53682969	ESPL1	-0.59	-9.56	-0.41	7e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs16837677	1.000	rs12408743	chr1:156735751	G/C	cg14991358	chr1:156767203	PRCC	0.76	7.93	0.35	1.64e-14	Sjögren's syndrome;
LGG	cis	rs3126085	0.935	rs3120659	chr1:152293202	A/G	cg26876637	chr1:152193138	HRNR	-0.53	-8.64	-0.37	8.98e-17	Atopic dermatitis;
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg12458913	chr13:53173898	NA	0.67	13.13	0.52	1.09e-33	Lewy body disease;
LGG	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg22437258	chr11:111473054	SIK2	0.56	9.65	0.41	3.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs6800768	0.633	rs60706278	chr3:24101424	T/A	cg10674438	chr3:24145617	LOC152024	-0.49	-8.74	-0.38	4.37e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.04	0.52	2.64e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs12310956	0.531	rs10772110	chr12:33841755	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.29	0.36	1.22e-15	Morning vs. evening chronotype;
LGG	cis	rs3747547	0.818	rs7027227	chr9:37929809	C/G	cg13774184	chr9:37916125	SHB	0.71	8.81	0.38	2.45e-17	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.21	-0.43	3.41e-22	Neuroticism;
LGG	cis	rs926392	0.589	rs6093115	chr20:37693817	T/C	cg16355469	chr20:37678765	NA	0.59	9.28	0.4	6.39e-19	Dialysis-related mortality;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20257096	chr14:21851954	SUPT16H	-0.47	-6.88	-0.3	1.92e-11	Systemic lupus erythematosus;
LGG	cis	rs6500395	1.000	rs1106386	chr16:48593065	C/A	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs244731	0.920	rs67008484	chr5:176735383	T/C	cg17509989	chr5:176798049	RGS14	0.59	8.13	0.35	3.88e-15	Urate levels in lean individuals;
LGG	cis	rs72772090	0.539	rs11748328	chr5:96169916	T/G	cg00188032	chr5:96141721	ERAP1	0.55	7.21	0.32	2.36e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs780096	0.587	rs1049817	chr2:27550967	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.6	-0.33	1.63e-13	Total body bone mineral density;
LGG	cis	rs7100689	0.577	rs2236569	chr10:82043576	G/A	cg01528321	chr10:82214614	TSPAN14	0.83	14.4	0.56	3.96e-39	Post bronchodilator FEV1;
LGG	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg25664220	chr3:72788482	NA	-0.34	-9.21	-0.39	1.14e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.14	-0.49	1.27e-29	Height;
LGG	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg21775007	chr8:11205619	TDH	-0.77	-13.41	-0.53	7.33e-35	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-9.85	-0.42	6.35e-21	Morning vs. evening chronotype;
LGG	cis	rs113835537	0.597	rs10896129	chr11:66338300	T/C	cg24851651	chr11:66362959	CCS	0.49	8.35	0.36	7.83e-16	Airway imaging phenotypes;
LGG	cis	rs250677	0.917	rs36066	chr5:148419771	A/G	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.17	-0.32	3.07e-12	Breast cancer;
LGG	cis	rs3733585	0.753	rs1122141	chr4:9947278	T/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.48	-0.33	3.88e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.94	0.31	1.37e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2712184	0.655	rs1003622	chr2:217653608	A/G	cg05032264	chr2:217675019	NA	-0.43	-9.46	-0.4	1.56e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.14	-0.35	3.78e-15	Mood instability;
LGG	cis	rs4731207	0.596	rs6959632	chr7:124691046	A/T	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs11625487	0.505	rs12887556	chr14:77966473	C/G	cg20045696	chr14:77926864	AHSA1	0.47	7.1	0.31	4.79e-12	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg19143629	chr17:61920732	SMARCD2	-0.4	-6.81	-0.3	3.1e-11	Prudent dietary pattern;
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.37	-0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs950776	0.518	rs12916483	chr15:78832397	G/A	cg17108064	chr15:78857060	CHRNA5	0.47	10.02	0.42	1.66e-21	Sudden cardiac arrest;
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.698	rs4552839	chr7:124499514	T/C	cg05630886	chr7:124431682	NA	-0.34	-7.93	-0.35	1.64e-14	Cutaneous malignant melanoma;
LGG	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg06873352	chr17:61820015	STRADA	0.49	7.56	0.33	2.12e-13	Height;
LGG	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg25319279	chr11:5960081	NA	0.55	9.5	0.4	1.16e-19	DNA methylation (variation);
LGG	cis	rs765787	0.530	rs12915027	chr15:45512626	G/A	cg26924012	chr15:45694286	SPATA5L1	0.41	6.67	0.3	7.26e-11	Uric acid levels;
LGG	cis	rs6694672	1.000	rs12731209	chr1:196947139	C/T	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.8e-11	Asthma;
LGG	cis	rs1465370	0.800	rs62471721	chr7:130016470	G/A	cg25718383	chr7:130020096	CPA1	0.32	8.49	0.37	2.74e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg08847533	chr14:75593920	NEK9	-0.62	-11.94	-0.49	7.73e-29	Height;
LGG	cis	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg06521331	chr12:34319734	NA	-0.5	-8.37	-0.36	7.1e-16	Resting heart rate;
LGG	cis	rs2562456	0.561	rs12610883	chr19:21750059	A/G	cg00806126	chr19:22604979	ZNF98	-0.64	-9.46	-0.4	1.61e-19	Pain;
LGG	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.53	-0.33	2.71e-13	Restless legs syndrome;
LGG	cis	rs2635047	0.713	rs9950812	chr18:44765943	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.36	0.36	7.46e-16	Educational attainment;
LGG	cis	rs7508	0.694	rs2410447	chr8:17923147	T/C	cg18067069	chr8:17937731	ASAH1	-0.38	-8.8	-0.38	2.78e-17	Atrial fibrillation;
LGG	cis	rs7940866	0.903	rs1820353	chr11:130870765	A/G	cg12179176	chr11:130786555	SNX19	0.71	12.96	0.52	5.34e-33	Schizophrenia;
LGG	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg18188782	chr20:61659543	NA	0.4	6.71	0.3	5.64e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs975722	0.967	rs1208525	chr7:117335157	C/T	cg10524701	chr7:117356490	CTTNBP2	0.52	11.76	0.48	4.06e-28	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.64	13.51	0.53	2.62e-35	Obesity-related traits;
LGG	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs72949976	0.934	rs13406406	chr2:214034826	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-9.85	-0.42	6.32e-21	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.38	0.5	1.34e-30	Corneal astigmatism;
LGG	cis	rs6028335	0.610	rs73110616	chr20:37552943	C/T	cg16355469	chr20:37678765	NA	0.51	6.81	0.3	2.97e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.59	0.72	1.04e-76	Bladder cancer;
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-8.97	-0.38	7.2e-18	Urate levels;
LGG	cis	rs17253792	0.822	rs74053651	chr14:56125366	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.51	-0.5	3.89e-31	Putamen volume;
LGG	cis	rs9325144	0.600	rs7312522	chr12:38730423	A/G	cg04568710	chr12:38710424	ALG10B	0.4	8.46	0.37	3.65e-16	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs5754344	chr22:21963786	A/G	cg22858872	chr22:21984481	YDJC	-0.37	-6.76	-0.3	4.12e-11	Systemic lupus erythematosus;
LGG	cis	rs6032067	0.777	rs13037087	chr20:43834313	T/C	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.33	-0.36	9.58e-16	Height;
LGG	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.39e-12	Diabetic retinopathy;
LGG	cis	rs6831352	0.918	rs7670638	chr4:100059807	G/C	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs2249625	0.526	rs17725666	chr6:72889711	G/A	cg27608224	chr6:72922399	RIMS1	-0.33	-7.4	-0.33	6.53e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg13699009	chr12:122356056	WDR66	0.56	14.51	0.56	1.37e-39	Mean corpuscular volume;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.81e-13	Electroencephalogram traits;
LGG	cis	rs77741769	0.571	rs12371178	chr12:121309129	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.13	0.39	2.1e-18	Mean corpuscular volume;
LGG	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg03929089	chr4:120376271	NA	-0.8	-15.51	-0.58	5.49e-44	Height;
LGG	cis	rs1055129	0.560	rs2666003	chr17:73942976	G/A	cg08125733	chr17:73851984	WBP2	0.42	7.15	0.32	3.46e-12	White matter hyperintensity burden;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg27400746	chr16:89904261	SPIRE2	-1.12	-16.78	-0.61	1.04e-49	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11920090	0.720	rs5394	chr3:170744893	G/A	cg09710316	chr3:170744871	SLC2A2	0.69	8.77	0.38	3.31e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.33	0.36	9.37e-16	Schizophrenia;
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13732083	chr21:47605072	C21orf56	0.5	8.58	0.37	1.49e-16	Testicular germ cell tumor;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg25172604	chr17:41446521	NA	-0.3	-7.17	-0.32	2.99e-12	Menopause (age at onset);
LGG	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg08498830	chr11:832797	CD151	-0.46	-7.22	-0.32	2.11e-12	Mean platelet volume;
LGG	trans	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg06875740	chr19:51307921	C19orf48	-0.64	-8.07	-0.35	5.89e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4740619	0.846	rs7023275	chr9:15650504	C/T	cg14451791	chr9:16040625	NA	0.34	8.84	0.38	1.97e-17	Body mass index;
LGG	cis	rs757110	0.770	rs1557765	chr11:17403639	T/C	cg04705435	chr11:17411270	KCNJ11	0.43	8.52	0.37	2.29e-16	Type 2 diabetes;
LGG	cis	rs10088262	0.629	rs12541177	chr8:124800273	G/T	cg02993010	chr8:124780839	FAM91A1	-0.68	-10.53	-0.44	2.26e-23	Pancreatic cancer;
LGG	cis	rs9911578	0.967	rs6503883	chr17:56917543	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.32e-35	Corneal astigmatism;
LGG	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg14683738	chr19:37701593	ZNF585B	-0.42	-6.86	-0.3	2.2e-11	Coronary artery calcification;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.34	0.36	8.71e-16	Schizophrenia;
LGG	cis	rs1978968	1.000	rs5992921	chr22:18445263	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs1044826	0.642	rs167187	chr3:139237008	C/T	cg15131784	chr3:139108705	COPB2	-0.41	-6.76	-0.3	4.23e-11	Obesity-related traits;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg24846343	chr22:24311635	DDTL	0.61	12.23	0.49	5.14e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9814567	1.000	rs62271513	chr3:134298412	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.71	12.84	0.51	1.73e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg27661571	chr11:113659931	NA	-0.63	-8.95	-0.38	8.56e-18	Hip circumference adjusted for BMI;
LGG	cis	rs12368653	0.840	rs10877020	chr12:58188014	G/A	cg02175503	chr12:58329896	NA	-0.51	-8.72	-0.38	4.87e-17	Multiple sclerosis;
LGG	cis	rs2916247	1.000	rs10089969	chr8:93060896	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg02753203	chr1:228287806	NA	0.94	19.57	0.67	1.41e-62	Diastolic blood pressure;
LGG	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg04362960	chr10:104952993	NT5C2	0.57	10.8	0.45	2.08e-24	Arsenic metabolism;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg20887711	chr4:1340912	KIAA1530	0.48	8.65	0.37	8.5e-17	Obesity-related traits;
LGG	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.28	-0.36	1.35e-15	Retinal vascular caliber;
LGG	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg12395012	chr8:11607386	GATA4	0.42	7.5	0.33	3.29e-13	Monocyte count;
LGG	cis	rs6594713	0.717	rs17331844	chr5:112914426	G/T	cg12552261	chr5:112820674	MCC	0.62	8.42	0.36	4.9e-16	Brain cytoarchitecture;
LGG	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg05623727	chr3:50126028	RBM5	-0.35	-7.14	-0.31	3.61e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2120019	1.000	rs67544533	chr15:75361539	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-16.88	-0.62	3.62e-50	Blood trace element (Zn levels);
LGG	cis	rs372883	0.600	rs1236460	chr21:30615513	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-10.08	-0.42	1e-21	Pancreatic cancer;
LGG	trans	rs7777677	0.925	rs4726547	chr7:142370582	C/T	cg18540325	chr9:33795118	PRSS3	-0.43	-7.29	-0.32	1.33e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11644478	chr21:40555479	PSMG1	-0.64	-10.76	-0.45	2.94e-24	Menarche (age at onset);
LGG	cis	rs9547996	0.959	rs7330679	chr13:38235907	C/G	cg17979426	chr13:38220150	TRPC4	-0.43	-8.68	-0.37	6.98e-17	Diastolic blood pressure;
LGG	cis	rs4308124	0.708	rs7585313	chr2:111975203	A/G	cg04571233	chr2:111982156	NA	-0.6	-9.86	-0.42	6.27e-21	Vitiligo;
LGG	cis	rs780094	0.500	rs4665991	chr2:27766284	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.86	0.3	2.18e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs4862307	0.836	rs11132220	chr4:184997247	A/T	cg06737308	chr4:185021514	ENPP6	-0.39	-6.77	-0.3	3.83e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7177699	0.557	rs9920968	chr15:79118747	G/A	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.3e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs17030434	0.953	rs11099906	chr4:154691690	A/T	cg14289246	chr4:154710475	SFRP2	-0.76	-11.76	-0.48	4.21e-28	Electrocardiographic conduction measures;
LGG	cis	rs2640806	0.505	rs1106551	chr8:97353418	T/G	cg22138393	chr8:97340270	PTDSS1	0.28	7.28	0.32	1.46e-12	Obesity-related traits;
LGG	cis	rs2802728	0.881	rs4658569	chr1:243583274	C/G	cg05593162	chr1:243577377	SDCCAG8	-0.47	-6.76	-0.3	4.14e-11	Toenail selenium levels;
LGG	cis	rs62238980	0.614	rs75143283	chr22:32413768	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7226408	0.779	rs72896202	chr18:34766272	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.01	-0.31	8.49e-12	Obesity-related traits;
LGG	cis	rs4148087	0.858	rs28435557	chr21:43634623	A/G	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.86	-0.38	1.7e-17	Life satisfaction;
LGG	trans	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.76e-13	HDL cholesterol;
LGG	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg22044901	chr15:68126292	NA	-0.41	-6.85	-0.3	2.33e-11	Restless legs syndrome;
LGG	cis	rs6065	0.618	rs16954342	chr17:4907103	G/A	cg01912298	chr17:4872499	CAMTA2;SPAG7	-0.64	-8.18	-0.36	2.83e-15	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03965827	chr15:50979356	TRPM7	0.43	7.69	0.34	9.2e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg14668632	chr7:2872130	GNA12	-0.33	-6.97	-0.31	1.06e-11	Height;
LGG	trans	rs783540	0.967	rs55972423	chr15:83258954	C/G	cg16105309	chr15:79090380	ADAMTS7	0.41	7.28	0.32	1.4e-12	Schizophrenia;
LGG	trans	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2404602	0.574	rs4886795	chr15:76642218	G/C	cg23625390	chr15:77176239	SCAPER	-0.62	-10.84	-0.45	1.44e-24	Blood metabolite levels;
LGG	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg13802316	chr11:70253460	CTTN	-0.56	-7.35	-0.32	9.01e-13	Coronary artery disease;
LGG	cis	rs10262624	1.000	rs9769098	chr7:23916732	C/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg18876405	chr7:65276391	NA	0.54	9.58	0.41	5.95e-20	Aortic root size;
LGG	cis	rs933688	0.509	rs7731341	chr5:90524105	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.51	-6.75	-0.3	4.54e-11	Smoking behavior;
LGG	cis	rs1790761	0.967	rs7479801	chr11:67213748	G/T	cg00290607	chr11:67383545	NA	-0.49	-8.76	-0.38	3.77e-17	Mean corpuscular volume;
LGG	cis	rs8017423	0.608	rs12588149	chr14:90822676	G/A	cg04374321	chr14:90722782	PSMC1	-0.64	-12.61	-0.51	1.57e-31	Mortality in heart failure;
LGG	cis	rs9487051	0.639	rs2884012	chr6:109598221	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.29e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1003719	0.762	rs9975361	chr21:38450025	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs11971779	0.666	rs7786851	chr7:139007020	C/G	cg07862535	chr7:139043722	LUC7L2	-0.48	-7.04	-0.31	7.17e-12	Diisocyanate-induced asthma;
LGG	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg25208724	chr1:156163844	SLC25A44	-1.28	-32.82	-0.84	6.15e-123	Testicular germ cell tumor;
LGG	cis	rs34638952	0.601	rs7219105	chr17:27434446	A/T	cg27392559	chr17:27410759	MYO18A	-0.38	-7.22	-0.32	2.16e-12	Sitting height ratio;
LGG	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06951969	chr15:66996086	SMAD6	0.48	7.06	0.31	6.03e-12	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs774359	0.789	rs2484316	chr9:27527173	T/C	cg21249376	chr9:27528432	MOBKL2B	0.43	8.22	0.36	2e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs8060686	0.641	rs8044014	chr16:68209872	T/C	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.22	-0.32	2.12e-12	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07147218	chr11:65769464	EIF1AD;BANF1	0.49	7.29	0.32	1.31e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg05025164	chr4:1340916	KIAA1530	-0.57	-10.06	-0.42	1.16e-21	Obesity-related traits;
LGG	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg26384229	chr12:38710491	ALG10B	0.66	11.78	0.48	3.29e-28	Morning vs. evening chronotype;
LGG	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg04691961	chr3:161091175	C3orf57	0.38	7.28	0.32	1.42e-12	Parkinson's disease;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	8.05e-21	Skin colour saturation;
LGG	cis	rs988958	0.565	rs6752691	chr2:42235581	C/T	cg27252766	chr2:42229092	NA	0.52	7.38	0.32	7.6e-13	Hypospadias;
LGG	cis	rs2070677	0.736	rs7099806	chr10:135414896	C/T	cg20169779	chr10:135381914	SYCE1	-1.0	-10.68	-0.44	5.91e-24	Gout;
LGG	cis	rs7568458	0.837	rs35565292	chr2:85790316	T/A	cg17127132	chr2:85788382	GGCX	0.47	7.99	0.35	1.08e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1372520	0.577	rs1811443	chr4:90747883	G/C	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs2274273	0.623	rs1187881	chr14:55489197	G/A	cg04306507	chr14:55594613	LGALS3	-0.42	-10.09	-0.42	9.32e-22	Protein biomarker;
LGG	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg08250081	chr4:10125330	NA	-0.38	-7.45	-0.33	4.48e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.39	9.01	0.39	5.46e-18	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs735539	0.598	rs2290144	chr13:21265658	C/G	cg04906043	chr13:21280425	IL17D	-0.49	-8.09	-0.35	5.2e-15	Dental caries;
LGG	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg11584989	chr19:19387371	SF4	0.78	13.02	0.52	3.18e-33	Bipolar disorder;
LGG	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	cis	rs503425	0.546	rs540716	chr11:118685015	C/T	cg19182353	chr11:118479428	PHLDB1	-0.49	-6.98	-0.31	1.06e-11	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00166722	chr3:10149974	C3orf24	0.5	7.94	0.35	1.55e-14	Alzheimer's disease;
LGG	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.12e-14	Colorectal cancer;
LGG	cis	rs6500395	0.926	rs11076572	chr16:48623621	T/G	cg04672837	chr16:48644449	N4BP1	0.53	8.64	0.37	9.51e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9583531	0.600	rs2119479	chr13:111371181	A/C	cg24331049	chr13:111365604	ING1	0.86	16.01	0.6	3.13e-46	Coronary artery disease;
LGG	cis	rs6500395	0.584	rs1420698	chr16:48740708	C/G	cg16662043	chr16:48846231	NA	0.44	8.03	0.35	7.92e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs72960926	1.000	rs72958945	chr6:75109509	G/C	cg03266952	chr6:74778945	NA	-0.68	-6.8	-0.3	3.25e-11	Metabolite levels (MHPG);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07713796	chr22:43435589	TTLL1	-0.39	-7.07	-0.31	5.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2075466	0.588	rs17832589	chr16:4878588	G/T	cg04440724	chr16:4920505	UBN1	0.63	9.26	0.4	7.72e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs9362426	0.608	rs6454611	chr6:88110105	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.44	8.5	0.37	2.64e-16	Depressive episodes in bipolar disorder;
LGG	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg18240062	chr17:79603768	NPLOC4	0.62	10.41	0.44	6.07e-23	Eye color traits;
LGG	cis	rs4954585	0.593	rs12691881	chr2:137029668	A/G	cg07169764	chr2:136633963	MCM6	-0.46	-7.3	-0.32	1.3e-12	Colorectal cancer;
LGG	cis	rs1620921	0.524	rs12214168	chr6:161195801	C/T	cg01280913	chr6:161186852	NA	-0.51	-10.52	-0.44	2.44e-23	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.86	-0.3	2.16e-11	Retinal vascular caliber;
LGG	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.04e-23	Resting heart rate;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.03	-0.39	4.54e-18	Bladder cancer;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	8.94	0.38	9.09e-18	Obesity-related traits;
LGG	cis	rs6076065	0.925	rs6083106	chr20:23368809	A/C	cg11657817	chr20:23433608	CST11	0.34	6.88	0.3	1.96e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg24623649	chr8:11872141	NA	-0.32	-7.8	-0.34	4.12e-14	Neuroticism;
LGG	cis	rs2016266	0.855	rs1379610	chr12:53681683	A/G	cg04065151	chr12:53682969	ESPL1	0.61	9.73	0.41	1.7e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7584330	0.666	rs937386	chr2:238364039	C/T	cg16989719	chr2:238392110	NA	-0.34	-6.67	-0.3	7.14e-11	Prostate cancer;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.74	-0.38	4.29e-17	Personality dimensions;
LGG	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.6	-0.33	1.66e-13	Eosinophil percentage of white cells;
LGG	cis	rs1506636	0.924	rs4370458	chr7:123260968	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.28	-0.65	1.31e-56	Plateletcrit;Platelet count;
LGG	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	9.15	0.39	1.79e-18	Cognitive test performance;
LGG	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg00647317	chr7:50633725	DDC	0.36	8.7	0.38	5.65e-17	Systemic sclerosis;
LGG	cis	rs2000999	0.514	rs12928056	chr16:72225574	C/A	cg04254540	chr16:71951199	KIAA0174	-0.59	-6.86	-0.3	2.17e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs10754283	0.967	rs10801761	chr1:90115269	C/T	cg21401794	chr1:90099060	LRRC8C	0.58	12.33	0.5	2.03e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg26174226	chr8:58114915	NA	-0.6	-8.63	-0.37	9.85e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg05044414	chr3:183734942	ABCC5	0.71	13.22	0.52	4.33e-34	Anterior chamber depth;
LGG	cis	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg21775007	chr8:11205619	TDH	-0.79	-14.03	-0.55	1.64e-37	Retinal vascular caliber;
LGG	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg02187348	chr16:89574699	SPG7	0.5	7.65	0.33	1.19e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg04025307	chr7:1156635	C7orf50	0.79	16.62	0.61	5.56e-49	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-31.95	-0.83	3.55e-119	Prudent dietary pattern;
LGG	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg06238570	chr21:40685208	BRWD1	0.43	6.7	0.3	6.23e-11	Cognitive function;
LGG	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg12560992	chr17:57184187	TRIM37	-0.8	-13.58	-0.53	1.42e-35	Intelligence (multi-trait analysis);
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg23131131	chr22:24373011	LOC391322	-0.47	-7.73	-0.34	6.57e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Vitiligo;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-19.14	-0.66	1.37e-60	Cognitive function;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg07659893	chr17:61819838	STRADA	0.48	8.01	0.35	9.14e-15	Prudent dietary pattern;
LGG	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg11494091	chr17:61959527	GH2	0.45	6.71	0.3	5.7e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7301016	1.000	rs11174495	chr12:62864931	A/G	cg11441379	chr12:63026424	NA	0.66	8.78	0.38	3.16e-17	IgG glycosylation;
LGG	cis	rs9486719	0.843	rs976357	chr6:96849679	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	9.82	0.42	8.34e-21	Migraine;Coronary artery disease;
LGG	cis	rs2286885	1.000	rs2286886	chr9:129246177	T/C	cg14319473	chr9:129242481	FAM125B	0.45	8.37	0.36	7.1e-16	Intraocular pressure;
LGG	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.54	0.37	1.89e-16	Hypertriglyceridemia;
LGG	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.22	0.32	2.12e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4409675	0.576	rs10751725	chr1:28216191	A/C	cg23691781	chr1:28212827	C1orf38	-0.42	-11.45	-0.47	6.43e-27	Corneal astigmatism;
LGG	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg08704250	chr15:31115839	NA	-0.43	-7.9	-0.34	2.05e-14	Huntington's disease progression;
LGG	cis	rs6547631	0.622	rs1437744	chr2:85925084	G/A	cg24620635	chr2:85921963	GNLY	0.49	9.91	0.42	4.03e-21	Blood protein levels;
LGG	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.17	0.55	4.02e-38	IgG glycosylation;
LGG	cis	rs8064024	0.676	rs56919624	chr16:4877593	C/A	cg04440724	chr16:4920505	UBN1	-0.44	-9.19	-0.39	1.31e-18	Cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23260799	chr11:451101	PTDSS2	0.44	6.81	0.3	3.1e-11	Gut microbiome composition (summer);
LGG	cis	rs2290405	0.527	rs6829987	chr4:932974	C/G	cg24922022	chr4:827675	NA	-0.4	-8.28	-0.36	1.37e-15	Systemic sclerosis;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg06654118	chr4:1303317	MAEA	-0.42	-7.03	-0.31	7.39e-12	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1018836	0.786	rs7016220	chr8:91606848	A/G	cg16814680	chr8:91681699	NA	-0.76	-14.01	-0.55	1.93e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg08704250	chr15:31115839	NA	-0.42	-7.8	-0.34	4.03e-14	Huntington's disease progression;
LGG	trans	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg18335740	chr13:41363409	SLC25A15	-0.52	-9.39	-0.4	2.71e-19	Lewy body disease;
LGG	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.26e-12	HDL cholesterol;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-12.4	-0.5	1.1e-30	Schizophrenia;
LGG	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.18	0.36	2.84e-15	Headache;
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.31	-0.63	4.08e-52	Skin colour saturation;
LGG	trans	rs28595532	0.720	rs72670228	chr4:119309516	T/C	cg26518628	chr1:97050305	NA	-0.82	-7.05	-0.31	6.4e-12	Cannabis dependence symptom count;
LGG	cis	rs1532815	0.959	rs1354510	chr1:165175515	A/G	cg03428399	chr1:165174748	LMX1A	0.55	11.35	0.47	1.67e-26	Response to acetaminophen (hepatotoxicity);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg25976786	chr12:53662079	ESPL1	0.41	6.76	0.3	4.04e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg07747251	chr5:1868357	NA	0.46	7.99	0.35	1.11e-14	Cardiovascular disease risk factors;
LGG	cis	rs12493885	0.769	rs61791509	chr3:153753178	T/C	cg12800244	chr3:153838788	SGEF	-0.76	-8.54	-0.37	1.88e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1829883	0.835	rs2845982	chr5:98879638	C/A	cg08333243	chr5:99726346	NA	0.36	6.91	0.31	1.57e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35771425	0.600	rs12743458	chr1:211482619	A/G	cg10512769	chr1:211675356	NA	-0.63	-8.34	-0.36	8.43e-16	Educational attainment (years of education);
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.69	12.51	0.5	3.77e-31	Obesity-related traits;
LGG	cis	rs7215564	0.908	rs36077104	chr17:78661757	T/A	cg06153925	chr17:78755379	RPTOR	0.38	6.67	0.3	7.39e-11	Myopia (pathological);
LGG	cis	rs1784581	0.761	rs7741581	chr6:162435250	C/T	cg17173639	chr6:162384350	PARK2	0.77	18.13	0.64	6.74e-56	Itch intensity from mosquito bite;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg08888203	chr3:10149979	C3orf24	0.52	8.78	0.38	3.16e-17	Alzheimer's disease;
LGG	cis	rs4330281	0.647	rs9847461	chr3:17607956	C/G	cg20981856	chr3:17787350	NA	0.41	7.64	0.33	1.3e-13	Schizophrenia;
LGG	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1707322	1.000	rs7517560	chr1:46425943	A/G	cg03146154	chr1:46216737	IPP	0.53	10.08	0.42	9.8e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs807669	0.903	rs807667	chr22:19161327	A/G	cg02655711	chr22:19163373	SLC25A1	-0.8	-16.19	-0.6	4.89e-47	Metabolite levels;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.33	-0.36	9.12e-16	IgG glycosylation;
LGG	cis	rs17776563	0.614	rs11637762	chr15:89146534	A/C	cg05013243	chr15:89149849	MIR1179	0.33	6.87	0.3	2.12e-11	Thyroid hormone levels;
LGG	trans	rs11039798	0.920	rs8186465	chr11:48796771	T/C	cg03929089	chr4:120376271	NA	0.74	8.51	0.37	2.35e-16	Axial length;
LGG	cis	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.92	-0.74	6.2e-83	Primary sclerosing cholangitis;
LGG	trans	rs6956675	1.000	rs1879843	chr7:62586129	A/G	cg01314568	chr7:57830625	NA	-0.51	-8.07	-0.35	6.1e-15	Obesity-related traits;
LGG	cis	rs9814567	0.762	rs13093893	chr3:134292131	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	11.25	0.46	4.01e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	trans	rs11098499	0.908	rs12504149	chr4:120318577	G/A	cg25214090	chr10:38739885	LOC399744	0.71	12.61	0.51	1.5e-31	Corneal astigmatism;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg04025307	chr7:1156635	C7orf50	0.78	16.23	0.6	3.25e-47	Longevity;Endometriosis;
LGG	cis	rs17221829	0.769	rs11018674	chr11:89357113	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.14	-0.39	1.94e-18	Anxiety in major depressive disorder;
LGG	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg18351406	chr4:77819688	ANKRD56	0.45	7.77	0.34	5.23e-14	Emphysema distribution in smoking;
LGG	cis	rs4499344	0.535	rs7260509	chr19:33121595	G/A	cg02997394	chr19:33096574	ANKRD27	-0.37	-7.02	-0.31	8.09e-12	Mean platelet volume;
LGG	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg16147221	chr4:10020634	SLC2A9	0.37	6.72	0.3	5.26e-11	Bone mineral density;
LGG	trans	rs9657904	0.950	rs9874600	chr3:105576201	C/G	cg14088669	chr1:158435396	OR10K1	0.39	6.81	0.3	3.07e-11	Multiple sclerosis;
LGG	cis	rs4750440	0.702	rs4748066	chr10:14029313	A/T	cg27542038	chr10:14027202	FRMD4A	0.68	13.78	0.54	1.93e-36	Adiponectin levels;
LGG	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.43	7.01	0.31	8.22e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2050392	0.630	rs303427	chr10:30739780	G/A	cg25182066	chr10:30743637	MAP3K8	-0.55	-11.29	-0.46	2.88e-26	Inflammatory bowel disease;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg26174226	chr8:58114915	NA	-0.55	-7.53	-0.33	2.76e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.7	0.54	4.29e-36	Lung cancer;
LGG	cis	rs2224391	0.910	rs7752203	chr6:5260812	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-8.46	-0.37	3.52e-16	Height;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9399135	0.935	rs949547	chr6:135343499	C/G	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg01238044	chr22:24384105	GSTT1	-0.47	-7.9	-0.34	2.02e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg01028140	chr2:1542097	TPO	-0.43	-8.16	-0.35	3.24e-15	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04513197	chr1:100504319	HIAT1	0.49	7.79	0.34	4.32e-14	Gut microbiome composition (summer);
LGG	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg02175503	chr12:58329896	NA	0.55	9.03	0.39	4.55e-18	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.92	-10.1	-0.43	8e-22	Diabetic retinopathy;
LGG	cis	rs6445975	0.666	rs12635366	chr3:58398466	A/G	cg24175188	chr3:58374923	PXK	0.56	9.13	0.39	2.11e-18	Systemic lupus erythematosus;
LGG	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg05901451	chr6:126070800	HEY2	-0.74	-14.11	-0.55	7.65e-38	Brugada syndrome;
LGG	cis	rs9357271	1.000	rs4714153	chr6:38352646	T/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.76	-0.45	2.95e-24	Restless legs syndrome;
LGG	cis	rs8067545	0.750	rs888423	chr17:19999409	G/A	cg09818912	chr17:20140352	CYTSB	-0.3	-6.96	-0.31	1.15e-11	Schizophrenia;
LGG	cis	rs2862774	0.598	rs721870	chr2:113805806	T/G	cg05949173	chr2:113825882	IL1F10	-0.44	-7.01	-0.31	8.24e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg15017067	chr4:17643749	FAM184B	0.3	6.88	0.3	1.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12682352	0.652	rs1567398	chr8:8726804	A/C	cg16141378	chr3:129829833	LOC729375	0.39	9.09	0.39	2.95e-18	Neuroticism;
LGG	cis	rs35123781	1.000	rs585101	chr5:139058454	T/C	cg21230503	chr5:139085173	NA	0.3	7.23	0.32	2.03e-12	Schizophrenia;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg17178900	chr1:205818956	PM20D1	0.58	13.0	0.52	3.77e-33	Menarche (age at onset);
LGG	cis	rs7474896	0.559	rs1735629	chr10:38178309	C/T	cg25427524	chr10:38739819	LOC399744	0.51	7.49	0.33	3.55e-13	Obesity (extreme);
LGG	cis	rs9814567	0.806	rs4535271	chr3:134321669	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7210837	0.656	rs11654911	chr17:16793581	T/C	cg11294312	chr17:28900046	NA	-0.73	-9.09	-0.39	2.84e-18	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg16586182	chr3:47516702	SCAP	-0.58	-9.81	-0.41	9.28e-21	Birth weight;
LGG	cis	rs78487399	0.808	rs7564886	chr2:43733028	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.89	-0.31	1.82e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9399135	0.967	rs13218642	chr6:135309940	A/G	cg22676075	chr6:135203613	NA	0.36	6.65	0.3	8.12e-11	Red blood cell count;
LGG	cis	rs1691799	0.867	rs1027399	chr12:66760942	G/A	cg16791601	chr12:66731901	HELB	-0.65	-15.48	-0.58	7.12e-44	White blood cell count (basophil);
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.62	12.48	0.5	5.19e-31	Prudent dietary pattern;
LGG	cis	rs6868223	0.617	rs10066043	chr5:33643395	A/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.67	0.59	9.99e-45	Mortality in heart failure;
LGG	cis	rs9534288	0.762	rs9534285	chr13:46601902	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg11787828	chr6:97345624	NDUFAF4	-0.44	-6.99	-0.31	9.67e-12	Sitting height ratio;
LGG	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs782590	0.967	rs6545506	chr2:55798108	A/G	cg18811423	chr2:55921094	PNPT1	-0.88	-19.9	-0.68	3.8e-64	Metabolic syndrome;
LGG	cis	rs4237845	0.611	rs10877036	chr12:58321650	A/G	cg02175503	chr12:58329896	NA	-0.83	-17.64	-0.63	1.25e-53	Intelligence (multi-trait analysis);
LGG	cis	rs13102973	0.965	rs13131455	chr4:135883112	A/C	cg14419869	chr4:135874104	NA	-0.56	-10.61	-0.44	1.1e-23	Subjective well-being;
LGG	cis	rs9911578	0.842	rs12450766	chr17:56832965	G/C	cg05425664	chr17:57184151	TRIM37	0.63	9.69	0.41	2.38e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1358748	0.522	rs4655516	chr1:67579882	A/C	cg02640540	chr1:67518911	SLC35D1	0.55	6.75	0.3	4.41e-11	Tuberculosis;
LGG	cis	rs3213961	0.554	rs8256	chr2:33789068	C/G	cg04131969	chr2:33951647	MYADML	0.5	7.98	0.35	1.14e-14	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	trans	rs826838	1.000	rs11610522	chr12:38687575	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.59	-0.33	1.74e-13	Heart rate;
LGG	trans	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg02002194	chr4:3960332	NA	-0.39	-6.9	-0.31	1.76e-11	Retinal vascular caliber;
LGG	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg15704280	chr7:45808275	SEPT13	0.8	11.82	0.48	2.29e-28	Coronary artery disease;
LGG	trans	rs7824557	0.670	rs2736381	chr8:11132766	A/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.22	-0.36	2.06e-15	Retinal vascular caliber;
LGG	cis	rs1577917	0.917	rs2197651	chr6:86495442	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-14.86	-0.57	3.84e-41	Response to antipsychotic treatment;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.17	0.62	1.7e-51	Alzheimer's disease;
LGG	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg12310025	chr6:25882481	NA	-0.45	-7.18	-0.32	2.86e-12	Height;
LGG	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.42	6.89	0.3	1.83e-11	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg00717180	chr2:96193071	NA	-0.5	-9.33	-0.4	4.42e-19	Coronary artery disease;
LGG	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-16.87	-0.62	4.24e-50	Blood trace element (Zn levels);
LGG	cis	rs13191362	0.507	rs2849511	chr6:163139050	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-6.88	-0.3	1.97e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg07701084	chr6:150067640	NUP43	0.7	13.34	0.53	1.42e-34	Lung cancer;
LGG	cis	rs36051895	0.559	rs1590268	chr9:5209433	T/A	cg02405213	chr9:5042618	JAK2	-0.62	-10.97	-0.45	4.9e-25	Pediatric autoimmune diseases;
LGG	cis	rs11190604	1.000	rs9419897	chr10:102246125	T/C	cg07080220	chr10:102295463	HIF1AN	0.65	11.19	0.46	6.8e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6500395	0.962	rs9941275	chr16:48573428	A/G	cg16662043	chr16:48846231	NA	0.37	7.16	0.32	3.26e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3857067	0.806	rs6532472	chr4:95110113	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs6964587	0.967	rs2282969	chr7:91583772	T/C	cg17063962	chr7:91808500	NA	-0.48	-8.49	-0.37	2.82e-16	Breast cancer;
LGG	cis	rs1401999	1.000	rs2872249	chr3:183636273	T/A	cg05044414	chr3:183734942	ABCC5	0.77	17.05	0.62	6.3e-51	Anterior chamber depth;
LGG	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg14664628	chr15:75095509	CSK	-0.8	-16.61	-0.61	6.02e-49	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs2727020	0.681	rs2866362	chr11:49379316	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.88	-0.42	5.07e-21	Coronary artery disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04620101	chr15:101835123	SNRPA1	-0.41	-6.72	-0.3	5.34e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg07274523	chr3:49395745	GPX1	0.55	9.07	0.39	3.49e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	2.01e-31	Motion sickness;
LGG	trans	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.38	-0.36	6.22e-16	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2270927	0.510	rs2937748	chr5:75572032	T/G	cg13563193	chr19:33072644	PDCD5	0.76	9.35	0.4	3.68e-19	Mean corpuscular volume;
LGG	cis	rs11190604	0.767	rs3750723	chr10:102172989	T/C	cg07570687	chr10:102243282	WNT8B	0.4	7.06	0.31	6.3e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs9300255	0.544	rs1716157	chr12:123670473	T/C	cg00376283	chr12:123451042	ABCB9	0.64	9.93	0.42	3.35e-21	Neutrophil percentage of white cells;
LGG	cis	rs2964802	0.505	rs4410623	chr5:10832271	A/C	cg14521931	chr5:10832172	NA	0.75	16.56	0.61	1.01e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Aortic root size;
LGG	cis	rs9788682	0.894	rs4461039	chr15:78817447	A/T	cg24631222	chr15:78858424	CHRNA5	-0.47	-7.32	-0.32	1.13e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.28	-0.36	1.28e-15	Systolic blood pressure;
LGG	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.85	0.64	1.32e-54	Cognitive function;
LGG	cis	rs2467099	0.679	rs2608882	chr17:73934130	G/A	cg23806715	chr17:73775811	H3F3B	0.49	7.32	0.32	1.1e-12	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.72e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.33	-0.32	1.07e-12	Mood instability;
LGG	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg06532163	chr17:45867833	NA	0.54	9.1	0.39	2.75e-18	IgG glycosylation;
LGG	trans	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg26384229	chr12:38710491	ALG10B	-0.92	-18.86	-0.66	2.67e-59	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.63	0.33	1.34e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs227808	0.812	rs9472324	chr6:44647374	C/T	cg18551225	chr6:44695536	NA	0.47	6.74	0.3	4.67e-11	Male-pattern baldness;
LGG	cis	rs897984	0.762	rs1870293	chr16:30970941	T/C	cg00531865	chr16:30841666	NA	0.52	10.72	0.45	4.23e-24	Dementia with Lewy bodies;
LGG	cis	rs7408868	1.000	rs7249525	chr19:15277309	G/A	cg14696996	chr19:15285081	NOTCH3	1.07	13.12	0.52	1.15e-33	Pulse pressure;
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg14074117	chr16:1909714	C16orf73	-0.54	-7.86	-0.34	2.66e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg26174226	chr8:58114915	NA	-0.57	-7.67	-0.34	1.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12464559	0.522	rs7583060	chr2:152620943	C/A	cg01189475	chr2:152685088	ARL5A	0.73	7.38	0.32	7.35e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs701145	0.585	rs1727957	chr3:153870407	G/A	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs9393777	0.545	rs56303243	chr6:26485727	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	11.47	0.47	5.76e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.647	rs9853571	chr3:17640071	T/C	cg20981856	chr3:17787350	NA	0.4	7.48	0.33	3.66e-13	Schizophrenia;
LGG	cis	rs2880765	0.706	rs7172006	chr15:86053359	A/G	cg10818794	chr15:86012489	AKAP13	-0.34	-6.76	-0.3	4.08e-11	Coronary artery disease;
LGG	cis	rs2361710	1.000	rs2361710	chr17:78111877	C/T	cg06718696	chr17:78121285	EIF4A3	-0.47	-7.81	-0.34	3.95e-14	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs4132509	1.000	rs10803158	chr1:243923229	A/G	cg25706552	chr1:244017396	NA	0.55	8.88	0.38	1.43e-17	RR interval (heart rate);
LGG	cis	rs643506	0.874	rs625477	chr11:111661686	A/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.95	0.31	1.25e-11	Breast cancer;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.55	-0.33	2.32e-13	Colorectal cancer;
LGG	cis	rs9815354	0.723	rs79741604	chr3:41947321	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.12e-24	Corneal astigmatism;
LGG	cis	rs11645898	0.935	rs11640722	chr16:72172300	C/T	cg14768367	chr16:72042858	DHODH	-0.82	-10.99	-0.45	3.92e-25	Blood protein levels;
LGG	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.47	8.05	0.35	7.18e-15	Cognitive test performance;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.64	0.44	8.14e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs3008870	0.920	rs1925413	chr1:67417101	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.35	0.74	2.84e-80	Lymphocyte percentage of white cells;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg15921436	chr17:44337874	NA	0.59	12.45	0.5	7.13e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6763768	0.710	rs13080668	chr3:53443354	C/T	cg16894138	chr3:53270350	TKT	-0.45	-8.23	-0.36	1.86e-15	Bacterial meningitis;
LGG	cis	rs13102973	0.965	rs9998499	chr4:135869362	G/A	cg14419869	chr4:135874104	NA	-0.57	-10.93	-0.45	6.52e-25	Subjective well-being;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg16270222	chr17:41446396	NA	0.3	7.21	0.32	2.35e-12	Menopause (age at onset);
LGG	cis	rs9783347	0.621	rs4150678	chr11:18384170	C/G	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.17	-0.49	9.03e-30	Pancreatic cancer;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg22907277	chr7:1156413	C7orf50	-0.65	-11.82	-0.48	2.32e-28	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.3	-0.4	5.42e-19	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.36e-18	Motion sickness;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs9596837	0.514	rs7990240	chr13:54207018	T/A	ch.13.53330881F	chr13:54432880	NA	0.43	6.94	0.31	1.35e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs61931739	0.592	rs708140	chr12:33719563	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs9911578	0.967	rs4132925	chr17:56938016	C/G	cg05425664	chr17:57184151	TRIM37	0.63	10.04	0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16949933	chr10:32734823	CCDC7	0.42	6.74	0.3	4.8e-11	Cognitive performance;
LGG	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg09165964	chr15:75287851	SCAMP5	0.55	9.99	0.42	2.09e-21	Breast cancer;
LGG	cis	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	8.64	0.37	9.26e-17	Breast cancer;
LGG	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg15309053	chr8:964076	NA	0.43	9.2	0.39	1.2e-18	Schizophrenia;
LGG	cis	rs10266483	0.562	rs10949887	chr7:63752080	C/T	cg24201672	chr7:64023550	ZNF680	-0.46	-6.66	-0.3	7.56e-11	Response to statin therapy;
LGG	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg03477792	chr4:77819574	ANKRD56	0.48	8.18	0.36	2.68e-15	Emphysema distribution in smoking;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg11062466	chr8:58055876	NA	0.47	8.17	0.36	2.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg00578828	chr5:131826934	IRF1	0.41	7.47	0.33	4.04e-13	Asthma (sex interaction);
LGG	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg12573674	chr2:1569213	NA	-0.64	-10.13	-0.43	6.39e-22	IgG glycosylation;
LGG	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.87	0.3	2.12e-11	Bone mineral density;
LGG	cis	rs2737618	0.722	rs2737673	chr1:200081710	T/C	cg21825944	chr1:200113062	NR5A2	-0.59	-11.36	-0.47	1.57e-26	Uric acid levels;
LGG	cis	rs3857067	0.806	rs4693002	chr4:95115302	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.84	-0.34	3.19e-14	QT interval;
LGG	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg24848339	chr3:12840334	CAND2	0.38	8.68	0.37	7.05e-17	QRS complex (12-leadsum);
LGG	cis	rs11748327	0.543	rs56209239	chr5:4086431	T/A	cg01025095	chr5:4101132	NA	-0.63	-10.22	-0.43	2.9e-22	Myocardial infarction;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg08677398	chr8:58056175	NA	0.44	7.09	0.31	5.03e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.690	rs7614375	chr3:160851331	A/T	cg03342759	chr3:160939853	NMD3	-0.6	-10.77	-0.45	2.66e-24	Morning vs. evening chronotype;
LGG	cis	rs4865875	0.792	rs4519880	chr5:54102195	C/T	cg22421804	chr5:54100067	NA	0.53	7.61	0.33	1.58e-13	Sense of smell;
LGG	cis	rs476633	0.691	rs28568756	chr15:41539371	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.6	-10.64	-0.44	8.45e-24	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg00684032	chr4:1343700	KIAA1530	0.43	8.65	0.37	8.25e-17	Longevity;
LGG	cis	rs17453880	0.929	rs4958321	chr5:152020604	G/T	cg10931792	chr5:152022470	NA	0.4	8.7	0.37	5.85e-17	Subjective well-being;
LGG	cis	rs2735413	0.564	rs8051817	chr16:78121254	C/T	cg04733911	chr16:78082701	NA	0.57	7.99	0.35	1.1e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs853679	0.556	rs34588114	chr6:28080628	C/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	cis	rs9362426	1.000	rs1203156	chr6:88079694	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.51	9.84	0.42	7.28e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs4774899	1.000	rs12916237	chr15:57249294	T/C	cg08128148	chr15:57256372	TCF12	-0.34	-8.02	-0.35	8.62e-15	Urinary tract infection frequency;
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.93	-0.42	3.41e-21	Bipolar disorder;
LGG	cis	rs9644630	0.930	rs6586839	chr8:19365543	A/T	cg01280390	chr8:19363452	CSGALNACT1	-0.62	-17.82	-0.64	1.8e-54	Oropharynx cancer;
LGG	cis	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg17376030	chr22:41985996	PMM1	0.55	8.55	0.37	1.81e-16	Vitiligo;
LGG	cis	rs61935443	0.832	rs7308359	chr12:95272904	G/T	cg21533806	chr12:95267307	NA	0.51	7.11	0.31	4.54e-12	Schizophrenia;
LGG	trans	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.0	0.31	8.85e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg08648136	chr8:956695	NA	0.43	9.09	0.39	2.84e-18	Schizophrenia;
LGG	cis	rs4664308	1.000	rs17831161	chr2:160909360	A/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs1348850	0.567	rs7605493	chr2:178534983	C/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.57	-0.37	1.56e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9309473	0.904	rs78450880	chr2:73821381	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.74	-0.34	6.14e-14	Metabolite levels;
LGG	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg19507638	chr5:93509721	C5orf36	0.42	6.9	0.31	1.75e-11	Diabetic retinopathy;
LGG	cis	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.82	-0.42	8.58e-21	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg00495681	chr13:53174319	NA	0.82	17.67	0.63	8.81e-54	Lewy body disease;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.07	28.13	0.79	2.92e-102	Prudent dietary pattern;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	7.29	0.32	1.34e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg15208524	chr1:10270712	KIF1B	0.43	7.44	0.33	4.85e-13	Hepatocellular carcinoma;
LGG	cis	rs9596863	1.000	rs1977889	chr13:54442809	C/T	ch.13.53330881F	chr13:54432880	NA	-0.52	-7.11	-0.31	4.48e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.79	-0.38	2.97e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg26384229	chr12:38710491	ALG10B	0.8	16.08	0.6	1.57e-46	Morning vs. evening chronotype;
LGG	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.66e-23	Chronic sinus infection;
LGG	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg12654349	chr5:56205094	C5orf35	-0.37	-6.73	-0.3	4.95e-11	Coronary artery disease;
LGG	cis	rs911263	0.603	rs12890109	chr14:68781593	C/A	cg18825221	chr14:68749962	RAD51L1	0.39	8.52	0.37	2.32e-16	Primary biliary cholangitis;
LGG	cis	rs1801251	1.000	rs283468	chr2:233658309	C/T	cg25237894	chr2:233734115	C2orf82	0.63	11.49	0.47	4.8400000000000004e-27	Coronary artery disease;
LGG	cis	rs8180040	0.726	rs4682837	chr3:46999707	C/T	cg27129171	chr3:47204927	SETD2	0.82	15.26	0.58	6.67e-43	Colorectal cancer;
LGG	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg20578329	chr17:80767326	TBCD	0.43	7.42	0.33	5.72e-13	Breast cancer;
LGG	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg02002194	chr4:3960332	NA	-0.39	-6.82	-0.3	2.77e-11	Retinal vascular caliber;
LGG	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg08499158	chr17:42289980	UBTF	-0.4	-7.61	-0.33	1.51e-13	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs1408799	0.745	rs10756405	chr9:12748234	C/T	cg05274944	chr9:12693694	TYRP1	0.33	7.76	0.34	5.44e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg07142201	chr11:109293216	C11orf87	0.49	8.06	0.35	6.58e-15	Schizophrenia;
LGG	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.42	0.4	2.21e-19	Mood instability;
LGG	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.66	-0.3	7.86e-11	Myopia (pathological);
LGG	cis	rs308971	0.656	rs307606	chr3:12067126	A/T	cg15873301	chr3:12045459	SYN2	0.54	7.8	0.34	4.2e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg12923728	chr3:195709715	SDHAP1	-0.8	-15.09	-0.57	4.01e-42	Pancreatic cancer;
LGG	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08380311	chr19:3435252	NFIC	1.04	25.08	0.76	2.72e-88	Height;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.13	-0.35	4.01e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs1864754	chr17:56688789	G/T	cg25039879	chr17:56429692	SUPT4H1	-0.64	-9.05	-0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs6735179	0.603	rs736868	chr2:1748429	T/C	cg10160682	chr2:1713001	PXDN	-0.54	-9.37	-0.4	3.1e-19	Response to antipsychotic treatment;
LGG	cis	rs17453880	0.781	rs17113485	chr5:151978353	A/G	cg12297329	chr5:152029980	NA	-0.87	-22.03	-0.72	4.29e-74	Subjective well-being;
LGG	cis	rs11748327	0.959	rs961620	chr5:4068633	C/T	cg01025095	chr5:4101132	NA	-0.58	-9.32	-0.4	4.74e-19	Myocardial infarction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02977157	chr20:13765764	C20orf7;ESF1	0.43	6.98	0.31	1.05e-11	Cognitive performance;
LGG	cis	rs35740288	0.770	rs34058174	chr15:86174462	G/T	cg04173714	chr15:86211321	AKAP13	0.46	8.44	0.37	4.15e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7572644	0.679	rs9679543	chr2:28050951	C/T	cg27432699	chr2:27873401	GPN1	0.46	6.89	0.31	1.78e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15231809	chr18:14747082	ANKRD30B	0.38	7.38	0.32	7.27e-13	Pancreatic cancer;
LGG	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs10155981	0.510	rs4722157	chr7:22583941	G/A	cg05062323	chr7:22590069	NA	-0.74	-9.72	-0.41	1.95e-20	Bilirubin levels;
LGG	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg15704280	chr7:45808275	SEPT13	0.77	10.72	0.45	4.16e-24	Axial length;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04856096	chr8:68255097	ARFGEF1	0.43	7.18	0.32	2.86e-12	Cognitive performance;
LGG	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg20503657	chr10:835505	NA	0.95	13.02	0.52	3.16e-33	Eosinophil percentage of granulocytes;
LGG	trans	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg10756647	chr7:56101905	PSPH	0.73	6.98	0.31	1.01e-11	Diabetic kidney disease;
LGG	cis	rs6696846	0.765	rs61822565	chr1:205077332	T/C	cg00857998	chr1:205179979	DSTYK	0.56	9.04	0.39	4.32e-18	Red blood cell count;
LGG	trans	rs45509595	0.841	rs200485	chr6:27775697	G/C	cg08344181	chr3:125677491	NA	-0.65	-7.68	-0.34	9.23e-14	Breast cancer;
LGG	cis	rs6840360	0.571	rs4696274	chr4:152528478	C/A	cg25486957	chr4:152246857	NA	-0.5	-8.24	-0.36	1.74e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg13010199	chr12:38710504	ALG10B	0.7	14.16	0.55	4.57e-38	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15188491	chr1:146644106	PRKAB2	0.52	7.76	0.34	5.52e-14	Gut microbiome composition (summer);
LGG	cis	rs9309473	0.528	rs7573275	chr2:73552542	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.26	-0.36	1.54e-15	Metabolite levels;
LGG	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg16141378	chr3:129829833	LOC729375	0.41	9.28	0.4	6.55e-19	Triglycerides;
LGG	cis	rs4727027	0.866	rs12666477	chr7:148812322	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.86	0.3	2.17e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg02725872	chr8:58115012	NA	-0.95	-12.32	-0.5	2.33e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg25237894	chr2:233734115	C2orf82	0.66	12.54	0.5	2.85e-31	Coronary artery disease;
LGG	trans	rs9929218	0.551	rs2274239	chr16:68725783	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.07	27.92	0.79	2.67e-101	Colorectal cancer;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2270450	0.650	rs9349373	chr6:46706593	G/A	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.72	-0.45	4.24e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs4563143	0.663	rs5025682	chr19:29238670	A/C	cg04546413	chr19:29218101	NA	0.73	12.54	0.5	2.88e-31	Methadone dose in opioid dependence;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07535477	chr12:50017486	PRPF40B	0.46	6.94	0.31	1.34e-11	Gut microbiome composition (summer);
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.93	-0.42	3.53e-21	Educational attainment;
LGG	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg25174290	chr11:3078921	CARS	-0.61	-12.26	-0.5	3.9e-30	Longevity;
LGG	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg01200585	chr1:228362443	C1orf69	0.47	8.2	0.36	2.32e-15	Diastolic blood pressure;
LGG	cis	rs7619833	0.620	rs2370946	chr3:27260283	A/G	cg02860705	chr3:27208620	NA	-0.41	-8.08	-0.35	5.87e-15	Breast cancer;
LGG	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg08975724	chr8:8085496	FLJ10661	0.38	6.99	0.31	9.55e-12	Monocyte count;
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.78e-18	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.63	-0.44	9.05e-24	Lung cancer;
LGG	cis	rs3857067	0.806	rs10008044	chr4:95092850	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.81	-0.34	3.84e-14	QT interval;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg24829409	chr8:58192753	C8orf71	-0.86	-13.6	-0.53	1.1e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.12	-0.39	2.35e-18	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.569	rs35878747	chr5:93094070	C/A	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.64	-0.44	8.6e-24	Aortic root size;
LGG	cis	rs765787	0.530	rs12905246	chr15:45500841	C/T	cg24006582	chr15:45444508	DUOX1	0.67	12.42	0.5	8.93e-31	Uric acid levels;
LGG	cis	rs35306767	0.855	rs12774985	chr10:904245	C/T	cg08847335	chr10:891726	LARP4B	-0.54	-9.1	-0.39	2.66e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs8133932	0.736	rs2839020	chr21:47280001	A/G	cg11214348	chr21:47283868	PCBP3	0.44	7.76	0.34	5.5e-14	Schizophrenia;
LGG	cis	rs6087990	0.899	rs4911110	chr20:31392366	C/T	cg13636640	chr20:31349939	DNMT3B	-0.97	-21.35	-0.7	6.54e-71	Ulcerative colitis;
LGG	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg18357526	chr6:26021779	HIST1H4A	0.55	9.52	0.4	9.49e-20	Blood metabolite levels;
LGG	trans	rs7944735	0.567	rs77684932	chr11:48024893	A/G	cg15704280	chr7:45808275	SEPT13	0.74	7.36	0.32	8.7e-13	Intraocular pressure;
LGG	cis	rs11748327	0.959	rs57367478	chr5:4044357	C/T	cg01025095	chr5:4101132	NA	-0.58	-9.31	-0.4	4.97e-19	Myocardial infarction;
LGG	trans	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	trans	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.79	0.34	4.53e-14	Joint mobility (Beighton score);
LGG	cis	rs8141529	0.778	rs763073	chr22:29215542	G/A	cg02153584	chr22:29168773	CCDC117	0.68	11.39	0.47	1.17e-26	Lymphocyte counts;
LGG	cis	rs477692	0.875	rs7091540	chr10:131420276	C/T	cg05714579	chr10:131428358	MGMT	-0.67	-14.24	-0.55	2.08e-38	Response to temozolomide;
LGG	cis	rs2953145	0.568	rs1133352	chr2:241522252	A/G	cg07929629	chr2:241523174	NA	-0.64	-10.95	-0.45	5.78e-25	Bipolar disorder;
LGG	cis	rs834603	0.575	rs1799371	chr7:47467436	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs295140	0.605	rs3739119	chr2:201194279	C/A	cg23649088	chr2:200775458	C2orf69	-0.39	-6.73	-0.3	5.04e-11	QT interval;
LGG	cis	rs9486719	1.000	rs35487471	chr6:96879715	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs13065560	0.594	rs4364115	chr3:38895359	C/T	cg01426195	chr3:39028469	NA	-0.44	-9.29	-0.4	5.84e-19	Interleukin-18 levels;
LGG	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg11644478	chr21:40555479	PSMG1	0.92	18.02	0.64	2.23e-55	Cognitive function;
LGG	cis	rs7742824	1.000	rs57139546	chr6:44067745	T/C	cg04074908	chr6:44101190	TMEM63B	0.68	13.11	0.52	1.24e-33	Major depressive disorder;
LGG	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg06611532	chr13:114900021	NA	0.29	7.17	0.32	2.9e-12	Schizophrenia;
LGG	trans	rs116095464	0.558	rs10077076	chr5:231940	C/T	cg00938859	chr5:1591904	SDHAP3	0.89	13.16	0.52	7.66e-34	Breast cancer;
LGG	cis	rs8072100	0.777	rs9914653	chr17:45537395	T/C	cg25173405	chr17:45401733	C17orf57	-0.48	-8.46	-0.37	3.57e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6831256	0.583	rs10937929	chr4:3483037	C/T	cg13455623	chr4:3480656	DOK7	0.49	9.38	0.4	3.01e-19	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.42	0.44	5.54e-23	Diabetic retinopathy;
LGG	cis	rs2486288	0.656	rs7165039	chr15:45570413	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.91	-0.45	8.14e-25	Glomerular filtration rate;
LGG	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg05044414	chr3:183734942	ABCC5	0.78	17.22	0.62	9.76e-52	Anterior chamber depth;
LGG	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs1153858	1.000	rs1613559	chr15:45622116	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.33	0.32	1e-12	Homoarginine levels;
LGG	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg22437258	chr11:111473054	SIK2	0.52	8.98	0.39	7.02e-18	Primary sclerosing cholangitis;
LGG	cis	rs796364	0.806	rs79156935	chr2:200913822	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs7107174	1.000	rs7104222	chr11:78007169	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.67e-13	Testicular germ cell tumor;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg00837987	chr8:588849	NA	-0.74	-6.68	-0.3	7.08e-11	IgG glycosylation;
LGG	cis	rs10911232	0.524	rs4652773	chr1:183054827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.75	0.38	3.92e-17	Hypertriglyceridemia;
LGG	cis	rs9914988	0.943	rs2043032	chr17:27136692	A/G	cg20469991	chr17:27169893	C17orf63	-0.64	-7.47	-0.33	4.15e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg22643751	chr7:855365	UNC84A	0.37	7.12	0.31	4.21e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9487051	0.768	rs1766814	chr6:109526696	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.47e-11	Reticulocyte fraction of red cells;
LGG	cis	rs74054849	0.571	rs4645995	chr1:15849003	C/G	cg05660106	chr1:15850417	CASP9	-0.87	-7.71	-0.34	7.56e-14	Alcoholic chronic pancreatitis;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.72	-0.34	7.35e-14	Menopause (age at onset);
LGG	cis	rs11628318	0.539	rs57749886	chr14:103095652	C/T	cg01864069	chr14:103024347	NA	-0.45	-8.04	-0.35	7.4e-15	Platelet count;
LGG	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.92e-20	Red blood cell count;
LGG	cis	rs2154319	0.887	rs7525193	chr1:41520712	T/C	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.95	-0.38	8.4e-18	Height;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.4	0.84	2.1e-125	Prudent dietary pattern;
LGG	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg16751781	chr15:78858589	CHRNA5	-0.43	-8.1	-0.35	4.88e-15	Sudden cardiac arrest;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs1881797	1.000	rs1881797	chr1:247689532	A/G	cg11166453	chr1:247681781	NA	0.63	10.44	0.44	4.82e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6964587	1.000	rs6960867	chr7:91712698	A/G	cg17063962	chr7:91808500	NA	0.47	8.26	0.36	1.53e-15	Breast cancer;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.3e-13	Menopause (age at onset);
LGG	cis	rs11758351	0.660	rs2143345	chr6:26229148	C/T	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.27	-0.32	1.58e-12	Total cholesterol levels;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg27338695	chr8:41435702	AGPAT6	-0.4	-6.88	-0.3	1.94e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs11122272	0.735	rs2739515	chr1:231514681	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs9929218	1.000	rs9928847	chr16:68797893	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.84	-0.51	1.76e-32	Colorectal cancer;
LGG	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg21399703	chr1:247681439	NA	0.67	11.93	0.49	8.25e-29	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg24350395	chr1:243288625	CEP170	0.38	7.35	0.32	8.77e-13	Hematocrit;Hemoglobin concentration;Red blood cell count;
LGG	cis	rs9326248	0.581	rs12804122	chr11:116902616	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.85	0.45	1.39e-24	Blood protein levels;
LGG	cis	rs2836974	0.931	rs2776307	chr21:40713833	C/G	cg11644478	chr21:40555479	PSMG1	-0.82	-14.67	-0.56	2.75e-40	Cognitive function;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.22	-0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.01	-0.35	9.69e-15	IgG glycosylation;
LGG	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg00071950	chr4:10020882	SLC2A9	0.38	7.73	0.34	6.55e-14	Bone mineral density;
LGG	cis	rs7715806	0.500	rs17563700	chr5:74986045	A/G	cg19683494	chr5:74908142	NA	0.52	6.94	0.31	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg03961551	chr1:25251730	RUNX3	0.47	12.09	0.49	2.03e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17125944	0.505	rs77949716	chr14:53204234	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-7.77	-0.34	5.01e-14	Alzheimer's disease (late onset);
LGG	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg00990874	chr7:1149470	C7orf50	-0.72	-11.39	-0.47	1.13e-26	Bronchopulmonary dysplasia;
LGG	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg06212747	chr3:49208901	KLHDC8B	0.46	6.76	0.3	4.17e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg10326726	chr10:51549505	MSMB	-0.67	-13.78	-0.54	1.88e-36	Prostate-specific antigen levels;
LGG	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg16386425	chr10:429943	DIP2C	-0.45	-8.96	-0.38	8.24e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs4622507	0.527	rs4628965	chr16:55044354	A/G	cg09947736	chr16:55091198	NA	-0.52	-7.72	-0.34	7.24e-14	Social communication problems;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	8.7	0.37	5.89e-17	Renal function-related traits (BUN);
LGG	trans	rs877282	0.838	rs34778553	chr10:796865	T/C	cg22713356	chr15:30763199	NA	0.57	8.61	0.37	1.19e-16	Uric acid levels;
LGG	cis	rs2797160	1.000	rs4897153	chr6:126003403	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-7.47	-0.33	3.98e-13	Endometrial cancer;
LGG	cis	rs6840360	0.557	rs4696261	chr4:152322659	C/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.1	0.31	4.85e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12230513	0.732	rs7971742	chr12:55848486	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-10.97	-0.45	4.7e-25	Contrast sensitivity;
LGG	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17830980	chr10:43048298	ZNF37B	0.35	7.6	0.33	1.62e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs244899	0.935	rs590784	chr5:167917504	G/T	cg06604206	chr5:167912465	RARS	-0.52	-11.55	-0.47	2.65e-27	Response to platinum-based chemotherapy (carboplatin);
LGG	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg16105309	chr15:79090380	ADAMTS7	0.44	7.77	0.34	5.15e-14	Schizophrenia;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	6.9	0.31	1.74e-11	Schizophrenia;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg05861140	chr6:150128134	PCMT1	-0.39	-8.74	-0.38	4.42e-17	Lung cancer;
LGG	cis	rs950169	0.580	rs35516100	chr15:85195430	C/T	cg03959625	chr15:84868606	LOC388152	0.48	7.13	0.31	3.77e-12	Schizophrenia;
LGG	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg06872548	chr17:78716983	RPTOR	0.46	11.12	0.46	1.22e-25	Obesity;
LGG	cis	rs988958	0.526	rs10195970	chr2:42249643	C/T	cg27252766	chr2:42229092	NA	0.49	6.99	0.31	9.83e-12	Hypospadias;
LGG	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.38	0.4	3.08e-19	Cannabis dependence symptom count;
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.29	0.32	1.38e-12	Tonsillectomy;
LGG	trans	rs116095464	0.558	rs10462754	chr5:246669	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.43	0.53	6.09e-35	Breast cancer;
LGG	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg26384229	chr12:38710491	ALG10B	-0.89	-19.93	-0.68	2.85e-64	Bladder cancer;
LGG	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs6867032	0.527	rs4975790	chr5:2010376	C/T	cg26168224	chr5:2018326	NA	0.92	17.35	0.63	2.61e-52	Gut microbiome composition (winter);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01693193	chr11:2705153	KCNQ1;KCNQ1OT1	0.39	6.71	0.3	5.68e-11	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg06521331	chr12:34319734	NA	-0.49	-8.63	-0.37	9.68e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.38	-0.43	8.04e-23	Bipolar disorder;
LGG	cis	rs2640806	0.645	rs17781008	chr8:97337656	C/T	cg22138393	chr8:97340270	PTDSS1	-0.32	-8.18	-0.36	2.71e-15	Obesity-related traits;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg04267008	chr7:1944627	MAD1L1	-0.59	-9.34	-0.4	4.04e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.85	0.48	1.71e-28	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	trans	rs6787172	0.702	rs1724704	chr3:158031155	T/A	cg23275840	chr4:47708675	CORIN	0.42	8.94	0.38	9.6e-18	Subjective well-being;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.59	-0.37	1.34e-16	Lung cancer;
LGG	cis	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg09021430	chr5:549028	NA	-0.74	-10.57	-0.44	1.54e-23	Lung disease severity in cystic fibrosis;
LGG	trans	rs9354308	0.702	rs2351716	chr6:66585927	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs6466055	0.692	rs4727621	chr7:105028370	T/C	cg04380332	chr7:105027541	SRPK2	-0.4	-7.47	-0.33	4.12e-13	Schizophrenia;
LGG	cis	rs2933343	0.679	rs789221	chr3:128591625	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-6.96	-0.31	1.15e-11	IgG glycosylation;
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg18876405	chr7:65276391	NA	-0.53	-9.44	-0.4	1.9e-19	Aortic root size;
LGG	trans	rs11976180	1.000	rs2961126	chr7:143762736	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg22105103	chr4:187893119	NA	0.58	11.12	0.46	1.22e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2294693	0.945	rs9369253	chr6:40986538	A/G	cg14769373	chr6:40998127	UNC5CL	-0.41	-6.8	-0.3	3.3e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs7301826	0.967	rs4759790	chr12:131296390	T/G	cg11011512	chr12:131303247	STX2	0.35	7.59	0.33	1.79e-13	Plasma plasminogen activator levels;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.39	0.69	2.06e-66	Alzheimer's disease;
LGG	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg12800244	chr3:153838788	SGEF	0.57	8.2	0.36	2.45e-15	Coronary artery disease;
LGG	cis	rs7617773	0.817	rs13100815	chr3:48287449	A/C	cg11946769	chr3:48343235	NME6	0.69	11.38	0.47	1.28e-26	Coronary artery disease;
LGG	cis	rs773506	0.589	rs773507	chr9:93974553	G/T	cg14446406	chr9:93919335	NA	0.44	7.25	0.32	1.73e-12	Type 2 diabetes nephropathy;
LGG	cis	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7192750	0.586	rs8044342	chr16:71869532	A/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.59	0.44	1.34e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7717393	0.786	rs10043401	chr5:155790030	A/C	cg12904904	chr5:155754151	SGCD	0.64	7.45	0.33	4.53e-13	Egg allergy;
LGG	cis	rs7226408	0.857	rs56822468	chr18:34448917	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.77	-0.41	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg16586182	chr3:47516702	SCAP	0.77	15.38	0.58	2.11e-43	Colorectal cancer;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.08	-0.35	5.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6940638	0.606	rs6456771	chr6:27232395	G/A	cg09904177	chr6:26538194	HMGN4	-0.43	-6.68	-0.3	6.76e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.49	-0.4	1.22e-19	Brugada syndrome;
LGG	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg19942237	chr7:29603211	PRR15	-0.28	-6.72	-0.3	5.47e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	11.62	0.48	1.45e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg18850127	chr7:39170497	POU6F2	0.62	15.12	0.58	2.82e-42	IgG glycosylation;
LGG	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg04673462	chr1:38461896	NA	-0.46	-7.58	-0.33	1.91e-13	Coronary artery disease;
LGG	cis	rs9916302	0.861	rs3889368	chr17:37683231	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.68	-0.59	9.69e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.06	0.46	2.16e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg10840412	chr1:235813424	GNG4	0.5	6.76	0.3	4.27e-11	Bipolar disorder;
LGG	cis	rs13401104	0.716	rs6750934	chr2:237125551	G/C	cg15742758	chr2:237126235	ASB18	0.45	7.58	0.33	1.95e-13	Educational attainment;
LGG	cis	rs11711311	1.000	rs9826808	chr3:113455644	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.54e-13	IgG glycosylation;
LGG	cis	rs503734	0.586	rs10936607	chr3:101126327	T/C	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-10.36	-0.43	9.62e-23	Chronic sinus infection;
LGG	cis	rs9303280	0.806	rs12709365	chr17:38027400	A/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.94	-0.38	9.12e-18	Self-reported allergy;
LGG	cis	rs4639966	0.684	rs487177	chr11:118657297	C/G	cg20309703	chr11:118481025	PHLDB1	-0.48	-7.26	-0.32	1.66e-12	Systemic lupus erythematosus;
LGG	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg02931644	chr1:25747376	RHCE	0.41	9.06	0.39	3.68e-18	Erythrocyte sedimentation rate;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg13047869	chr3:10149882	C3orf24	0.46	7.54	0.33	2.56e-13	Alzheimer's disease;
LGG	cis	rs17253792	0.822	rs75663029	chr14:56092385	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.5	0.4	1.12e-19	Mood instability;
LGG	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.81	-0.3	3.12e-11	Cutaneous nevi;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.73	13.98	0.54	2.62e-37	Obesity-related traits;
LGG	trans	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.62	10.25	0.43	2.39e-22	Metabolite levels;
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg03806693	chr22:41940476	POLR3H	-1.11	-19.95	-0.68	2.27e-64	Vitiligo;
LGG	cis	rs2204008	0.774	rs12810027	chr12:38212165	A/G	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg03342759	chr3:160939853	NMD3	-0.77	-13.86	-0.54	8.74e-37	Parkinson's disease;
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs17767392	0.958	rs722633	chr14:71898788	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.88	-0.38	1.48e-17	Mitral valve prolapse;
LGG	cis	rs2415984	0.541	rs12433740	chr14:46933240	G/T	cg14871534	chr14:47121158	RPL10L	0.44	7.41	0.33	6.17e-13	Number of children ever born;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg17907628	chr7:2473529	CHST12	0.42	7.69	0.34	9.19e-14	Body fat percentage;
LGG	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.57	12.96	0.52	5.46e-33	Multiple sclerosis;
LGG	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs11112613	0.713	rs11112592	chr12:105951702	C/T	cg03607813	chr12:105948248	NA	-0.58	-10.66	-0.44	6.93e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01044731	chr13:24554006	NA	-0.47	-6.7	-0.3	6.2e-11	Systemic lupus erythematosus;
LGG	cis	rs60733400	0.667	rs4385650	chr1:2499898	G/A	cg18854424	chr1:2615690	NA	0.38	7.72	0.34	7.3e-14	Multiple sclerosis;
LGG	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg05834625	chr6:170176447	C6orf70	0.43	6.91	0.31	1.63e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg06212747	chr3:49208901	KLHDC8B	0.51	7.77	0.34	5.09e-14	Menarche (age at onset);
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.33	-7.23	-0.32	2.01e-12	Schizophrenia;
LGG	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-12.51	-0.5	4.06e-31	Menarche (age at onset);
LGG	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg16141378	chr3:129829833	LOC729375	0.46	10.86	0.45	1.28e-24	Mood instability;
LGG	cis	rs12220238	0.596	rs11001083	chr10:76370949	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.64	7.98	0.35	1.13e-14	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9341835	0.772	rs4710254	chr6:64137609	C/T	cg00787780	chr6:64151745	NA	0.42	7.68	0.34	9.46e-14	Schizophrenia;
LGG	cis	rs17384381	1.000	rs36110608	chr1:85852936	A/C	cg16011679	chr1:85725395	C1orf52	0.6	10.43	0.44	5.27e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-16.37	-0.61	7.68e-48	Longevity;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.79e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4743820	0.651	rs10733738	chr9:93929352	G/A	cg14446406	chr9:93919335	NA	0.9	15.21	0.58	1.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9341808	1.000	rs9341808	chr6:80953257	C/A	cg08355045	chr6:80787529	NA	0.38	7.59	0.33	1.73e-13	Sitting height ratio;
LGG	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg12751644	chr20:60527061	NA	-0.29	-6.93	-0.31	1.38e-11	Body mass index;
LGG	cis	rs9814567	1.000	rs1880377	chr3:134270468	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg03929089	chr4:120376271	NA	-0.43	-7.08	-0.31	5.43e-12	HDL cholesterol;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg26554054	chr8:600488	NA	1.17	11.77	0.48	3.66e-28	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08167039	chr1:762232	NCRNA00115;LOC643837	0.46	7.08	0.31	5.5e-12	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.603	rs10250128	chr7:19940123	G/T	cg05791153	chr7:19748676	TWISTNB	0.51	6.69	0.3	6.6e-11	Night sleep phenotypes;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.79	0.48	3.14e-28	Prudent dietary pattern;
LGG	cis	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg22437258	chr11:111473054	SIK2	-0.43	-7.18	-0.32	2.87e-12	Primary sclerosing cholangitis;
LGG	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg14541582	chr5:601475	NA	-0.37	-6.71	-0.3	5.87e-11	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22618164	chr12:122356400	WDR66	-0.36	-10.8	-0.45	2.1e-24	Mean corpuscular volume;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.19	-0.43	4.04e-22	Lymphocyte counts;
LGG	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.85	0.3	2.35e-11	Myopia (pathological);
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.89	0.38	1.32e-17	Neuroticism;
LGG	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg24692254	chr21:30365293	RNF160	0.86	19.68	0.67	4.11e-63	Dental caries;
LGG	cis	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg15596359	chr8:11213517	TDH	0.38	7.85	0.34	2.91e-14	Retinal vascular caliber;
LGG	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs9790314	1.000	rs1478565	chr3:161027464	C/T	cg03342759	chr3:160939853	NMD3	-0.64	-11.37	-0.47	1.38e-26	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.95	0.38	8.46e-18	Aortic root size;
LGG	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-17.19	-0.62	1.39e-51	Exhaled nitric oxide output;
LGG	trans	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg07211511	chr3:129823064	LOC729375	-0.66	-9.07	-0.39	3.34e-18	Blood pressure (smoking interaction);
LGG	cis	rs55665837	1.000	rs10047457	chr11:14439459	T/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.96e-17	Vitamin D levels;
LGG	cis	rs7558370	0.867	rs9941596	chr2:3717667	C/T	cg17046650	chr2:3699563	NA	0.71	7.23	0.32	1.96e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs853679	0.517	rs1947862	chr6:28105196	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs13082711	0.648	rs13085782	chr3:27404390	C/G	cg02860705	chr3:27208620	NA	1.07	19.04	0.66	4.14e-60	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg25427524	chr10:38739819	LOC399744	-0.51	-7.48	-0.33	3.84e-13	Obesity (extreme);
LGG	cis	rs7568458	0.660	rs6722691	chr2:85758352	C/T	cg17127132	chr2:85788382	GGCX	0.49	8.1	0.35	4.91e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9467773	0.620	rs2451731	chr6:26624822	A/C	cg09904177	chr6:26538194	HMGN4	0.67	13.92	0.54	4.74e-37	Intelligence (multi-trait analysis);
LGG	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg25811766	chr13:21894605	NA	0.53	7.14	0.31	3.71e-12	White matter hyperintensity burden;
LGG	cis	rs12210905	1.000	rs72843629	chr6:27175215	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.03	-0.31	7.36e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4293296	0.525	rs28429558	chr14:54827875	A/G	cg11186706	chr14:54815745	NA	0.57	8.06	0.35	6.6e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg25114630	chr15:101792522	CHSY1	-0.56	-9.77	-0.41	1.3e-20	Corneal structure;
LGG	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg25801113	chr15:45476975	SHF	0.87	19.81	0.68	1.05e-63	Uric acid levels;
LGG	cis	rs9341808	0.718	rs35447745	chr6:80816748	T/C	cg08355045	chr6:80787529	NA	0.42	8.17	0.36	2.89e-15	Sitting height ratio;
LGG	trans	rs9858542	0.953	rs34363169	chr3:49537712	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.56	-0.37	1.69e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7222240	1.000	rs2157838	chr17:43169281	C/G	cg24806326	chr17:43207588	PLCD3	0.46	7.89	0.34	2.18e-14	Craniofacial microsomia;
LGG	trans	rs9354308	0.714	rs9294668	chr6:66598877	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs7666738	0.830	rs4334758	chr4:98971875	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg02733842	chr7:1102375	C7orf50	-0.45	-7.46	-0.33	4.32e-13	Bronchopulmonary dysplasia;
LGG	cis	rs7587476	0.784	rs62202001	chr2:215690359	C/G	cg04004882	chr2:215674386	BARD1	0.55	8.05	0.35	6.95e-15	Neuroblastoma;
LGG	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.33	-0.32	1.04e-12	HDL cholesterol;
LGG	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg19524238	chr7:2802976	GNA12	0.33	7.99	0.35	1.05e-14	Height;
LGG	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg24375607	chr4:120327624	NA	0.67	11.17	0.46	8.29e-26	Corneal astigmatism;
LGG	cis	rs11690935	0.959	rs7562356	chr2:172626611	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.14	-0.78	9.43e-98	Schizophrenia;
LGG	cis	rs4849845	0.612	rs3806491	chr2:121008675	G/A	cg15425061	chr2:121036351	RALB	0.38	7.01	0.31	8.37e-12	Mean platelet volume;
LGG	cis	rs9354308	0.764	rs9885896	chr6:66595931	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs1707322	1.000	rs1612419	chr1:46546945	T/C	cg03146154	chr1:46216737	IPP	-0.53	-9.58	-0.41	6.09e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs360798	0.512	rs7562149	chr2:63008414	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-7.4	-0.33	6.6e-13	Coronary artery disease;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17376030	chr22:41985996	PMM1	0.6	9.42	0.4	2.16e-19	Vitiligo;
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.02e-13	Bipolar disorder;
LGG	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg26248373	chr2:1572462	NA	-0.88	-15.18	-0.58	1.58e-42	IgG glycosylation;
LGG	cis	rs898097	0.578	rs6502021	chr17:80907728	T/C	cg15664640	chr17:80829946	TBCD	0.57	11.47	0.47	5.58e-27	Breast cancer;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10149470	0.549	rs9652403	chr14:104036024	G/C	cg26031613	chr14:104095156	KLC1	0.52	8.42	0.36	4.92e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs12210905	0.925	rs72838260	chr6:27008168	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.56	-7.54	-0.33	2.52e-13	Hip circumference adjusted for BMI;
LGG	cis	rs2652834	0.950	rs2729789	chr15:63400345	G/A	cg05507819	chr15:63340323	TPM1	0.6	8.02	0.35	8.62e-15	HDL cholesterol;
LGG	cis	rs9604529	0.759	rs79192570	chr13:114625570	G/A	cg04826882	chr13:114838756	RASA3	-0.56	-7.77	-0.34	5.03e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.51e-12	Refractive error;
LGG	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	12.51	0.5	3.97e-31	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs7657497	chr4:99044028	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.06e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg04911050	chr16:677664	RAB40C	0.33	6.65	0.3	8.4e-11	Height;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs453329	chr20:25440593	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.25	0.43	2.3e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg20587970	chr11:113659929	NA	-1.36	-23.03	-0.73	9.13e-79	Hip circumference adjusted for BMI;
LGG	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg06636001	chr8:8085503	FLJ10661	0.57	10.96	0.45	5.05e-25	Neuroticism;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg03575189	chr17:44344142	NA	0.49	7.19	0.32	2.69e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg12373951	chr3:133503437	NA	0.39	6.95	0.31	1.23e-11	Iron status biomarkers;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.81	0.3	3.1e-11	Schizophrenia;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg06719900	chr11:109292894	C11orf87	0.43	8.09	0.35	5.42e-15	Schizophrenia;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs5756813	0.688	rs34891095	chr22:38126582	C/T	cg19171272	chr22:38449367	NA	0.41	7.03	0.31	7.39e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.7e-15	IgG glycosylation;
LGG	cis	rs8031584	0.678	rs4779496	chr15:31151054	A/G	cg08109568	chr15:31115862	NA	-0.59	-10.02	-0.42	1.55e-21	Huntington's disease progression;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.5	-0.56	1.58e-39	Tonsillectomy;
LGG	cis	rs9828933	0.808	rs3733125	chr3:63981635	C/T	cg17941049	chr3:63904683	ATXN7	0.72	7.07	0.31	5.8e-12	Type 2 diabetes;
LGG	cis	rs9937943	0.614	rs35148538	chr16:74613575	G/C	cg01733217	chr16:74700730	RFWD3	0.62	7.95	0.35	1.39e-14	Neutrophil percentage of white cells;
LGG	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg24375607	chr4:120327624	NA	-0.56	-9.3	-0.4	5.59e-19	Corneal astigmatism;
LGG	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.04	-0.7	1.84e-69	Gut microbiome composition (summer);
LGG	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg13647721	chr17:30228624	UTP6	0.6	7.69	0.34	8.63e-14	Hip circumference adjusted for BMI;
LGG	cis	rs17039065	0.920	rs73838436	chr4:109446477	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.38	-0.36	6.45e-16	Retinal vascular caliber;
LGG	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg03538708	chr1:25844672	NA	0.36	6.71	0.3	5.83e-11	Erythrocyte sedimentation rate;
LGG	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg00666640	chr1:248458726	OR2T12	-0.54	-8.71	-0.38	5.4e-17	Common traits (Other);
LGG	cis	rs7617773	0.817	rs6801801	chr3:48326433	T/C	cg11946769	chr3:48343235	NME6	0.64	10.73	0.45	3.97e-24	Coronary artery disease;
LGG	cis	rs7927771	0.832	rs4752994	chr11:47411065	A/T	cg20307385	chr11:47447363	PSMC3	0.57	10.36	0.43	9.33e-23	Subjective well-being;
LGG	cis	rs6815814	0.950	rs11725779	chr4:38811668	G/A	cg06935464	chr4:38784597	TLR10	0.6	8.19	0.36	2.49e-15	Breast cancer;
LGG	cis	rs774359	0.789	rs2246591	chr9:27507804	A/G	cg14173147	chr9:27528300	MOBKL2B	0.45	8.67	0.37	7.13e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg15268244	chr15:77196840	NA	-0.33	-7.23	-0.32	2e-12	Blood metabolite levels;
LGG	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg06916706	chr16:4465613	CORO7	-0.91	-14.72	-0.56	1.62e-40	Schizophrenia;
LGG	cis	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.34	-0.4	4.03e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9287719	0.934	rs6706763	chr2:10751407	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs62158211	1.000	rs4618068	chr2:114109355	C/T	cg17784749	chr2:114082611	LOC440839	0.62	8.77	0.38	3.55e-17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg11062466	chr8:58055876	NA	0.56	8.89	0.38	1.34e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.528	rs7950093	chr11:116963519	G/T	cg20608306	chr11:116969690	SIK3	-0.39	-10.51	-0.44	2.51e-23	Subjective well-being;
LGG	cis	rs7814319	0.933	rs13261747	chr8:97238769	A/G	cg20787634	chr8:97240163	UQCRB	-0.78	-18.75	-0.66	9.2e-59	Lung function (FVC);
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.78	0.3	3.64e-11	Schizophrenia;
LGG	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg03929089	chr4:120376271	NA	-0.81	-15.7	-0.59	7.88e-45	Height;
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg05941027	chr17:61774174	LIMD2	0.33	8.01	0.35	9.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs2236267	0.726	rs6574991	chr14:88603502	T/C	cg18078958	chr14:88630771	NA	-0.31	-7.24	-0.32	1.91e-12	Food antigen IgG levels;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg05863683	chr7:1912471	MAD1L1	0.41	7.95	0.35	1.46e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg13699009	chr12:122356056	WDR66	0.56	14.84	0.57	4.77e-41	Mean corpuscular volume;
LGG	cis	rs72615157	0.539	rs72615159	chr7:99674286	G/A	cg12813108	chr7:99719912	CNPY4	-0.83	-16.48	-0.61	2.42e-48	Lung function (FEV1/FVC);
LGG	cis	rs12453935	0.640	rs56294609	chr17:59933432	G/T	cg14757157	chr17:59911755	BRIP1	0.34	6.76	0.3	4.16e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg18402987	chr7:1209562	NA	0.74	11.25	0.46	4.15e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs225245	0.817	rs225302	chr17:33922396	C/T	cg05299278	chr17:33885742	SLFN14	0.41	7.74	0.34	6.1e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg11812906	chr14:75593930	NEK9	-0.45	-8.2	-0.36	2.34e-15	Height;
LGG	cis	rs9902453	0.757	rs12453308	chr17:28441604	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.18	0.52	6.57e-34	Coffee consumption (cups per day);
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg22907277	chr7:1156413	C7orf50	0.81	11.63	0.48	1.37e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7017914	0.967	rs56112621	chr8:71588394	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	cis	rs4862750	0.957	rs2375916	chr4:187903923	A/G	cg07414643	chr4:187882934	NA	0.52	10.92	0.45	7.18e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17253792	0.822	rs10147380	chr14:56054354	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	cis	rs921968	0.542	rs630858	chr2:219409689	C/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg11494091	chr17:61959527	GH2	1.03	26.22	0.77	1.46e-93	Prudent dietary pattern;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg21782813	chr7:2030301	MAD1L1	0.46	11.09	0.46	1.61e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.5	-0.4	1.15e-19	Lung cancer;
LGG	cis	rs7289126	0.966	rs4820329	chr22:38646063	G/A	cg25457927	chr22:38595422	NA	-0.32	-7.71	-0.34	7.64e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.56e-20	Childhood ear infection;
LGG	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg08470875	chr2:26401718	FAM59B	-0.4	-7.74	-0.34	6.15e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg19524238	chr7:2802976	GNA12	0.32	7.88	0.34	2.31e-14	Height;
LGG	cis	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg21775007	chr8:11205619	TDH	-0.53	-8.69	-0.37	6.23e-17	Triglycerides;
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.06	0.46	2.16e-25	Alzheimer's disease;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.55	-0.33	2.31e-13	Life satisfaction;
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg17202724	chr17:61916730	SMARCD2	-0.41	-7.93	-0.35	1.71e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg08000102	chr2:233561755	GIGYF2	0.58	9.52	0.4	9.68e-20	Coronary artery disease;
LGG	cis	rs4240897	0.935	rs3766744	chr1:12043717	G/A	cg07603449	chr1:11986842	KIAA2013	-0.26	-7.2	-0.32	2.51e-12	Tuberculosis;
LGG	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	7.32	0.32	1.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.67	-0.3	7.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04772025	chr11:68637568	NA	0.72	12.55	0.5	2.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg00800038	chr16:89945340	TCF25	-0.71	-8.45	-0.37	3.74e-16	Skin colour saturation;
LGG	cis	rs72634258	0.945	rs17367289	chr1:8053135	C/T	cg00042356	chr1:8021962	PARK7	-0.55	-8.37	-0.36	7.11e-16	Inflammatory bowel disease;
LGG	cis	rs17453880	0.700	rs34967219	chr5:152032949	C/T	cg10931792	chr5:152022470	NA	-0.41	-8.88	-0.38	1.46e-17	Subjective well-being;
LGG	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg04240660	chr16:89714849	CHMP1A	-0.41	-7.22	-0.32	2.15e-12	Hemoglobin concentration;
LGG	cis	rs8179	0.761	rs42032	chr7:92237426	G/A	cg15732164	chr7:92237376	CDK6	-0.59	-11.82	-0.48	2.44e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs477895	0.713	rs35095324	chr11:63948412	G/A	cg04317338	chr11:64019027	PLCB3	0.67	8.2	0.36	2.44e-15	Mean platelet volume;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.62	0.33	1.46e-13	Testicular germ cell tumor;
LGG	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg04691961	chr3:161091175	C3orf57	-0.56	-12.74	-0.51	4.48e-32	Morning vs. evening chronotype;
LGG	cis	rs13065560	0.594	rs4575820	chr3:38886179	A/G	cg01426195	chr3:39028469	NA	0.41	8.41	0.36	4.96e-16	Interleukin-18 levels;
LGG	cis	rs2249694	0.960	rs7084384	chr10:135412322	A/G	cg20169779	chr10:135381914	SYCE1	-0.51	-7.88	-0.34	2.37e-14	Obesity-related traits;
LGG	cis	rs13418717	0.793	rs4663054	chr2:127639995	C/T	cg25501666	chr2:127640322	NA	-1.24	-10.03	-0.42	1.49e-21	Heart failure;
LGG	cis	rs11690935	0.959	rs2674484	chr2:172574612	G/A	cg21435375	chr2:172878103	MAP1D	-0.3	-6.77	-0.3	3.97e-11	Schizophrenia;
LGG	cis	rs12155623	0.592	rs12682003	chr8:49865454	G/T	cg00325661	chr8:49890786	NA	0.5	8.76	0.38	3.71e-17	Sudden cardiac arrest;
LGG	cis	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07988820	chr12:82153109	PPFIA2	-0.78	-12.01	-0.49	4.25e-29	Resting heart rate;
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg15147215	chr3:52552868	STAB1	-0.4	-8.13	-0.35	4.09e-15	Bipolar disorder;
LGG	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg00405596	chr8:11794950	NA	0.65	11.52	0.47	3.54e-27	Neuroticism;
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg02158880	chr13:53174818	NA	-0.41	-8.08	-0.35	5.79e-15	Lewy body disease;
LGG	cis	rs826838	0.651	rs1843892	chr12:38616965	A/G	cg26384229	chr12:38710491	ALG10B	0.83	17.35	0.63	2.67e-52	Heart rate;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg04863758	chr4:1303710	MAEA	0.43	7.31	0.32	1.18e-12	Obesity-related traits;
LGG	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.91	0.48	1.02e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	trans	rs10506458	1.000	rs12580997	chr12:63433420	G/A	cg22491629	chr6:157744540	C6orf35	-0.92	-13.15	-0.52	8.77e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9354308	0.764	rs12697927	chr6:66612018	G/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg24375607	chr4:120327624	NA	0.65	10.47	0.44	3.7e-23	Corneal astigmatism;
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.68	8.88	0.38	1.5e-17	Lung function (FEV1/FVC);
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg23743428	chr13:21893420	NA	-0.49	-10.79	-0.45	2.38e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs968451	0.951	rs5750789	chr22:39725280	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	11.65	0.48	1.08e-27	Primary biliary cholangitis;
LGG	cis	rs7923609	0.967	rs7915779	chr10:65244244	G/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.7	-0.3	6.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg13009111	chr11:71350975	NA	-0.31	-6.72	-0.3	5.23e-11	Neuroticism;
LGG	cis	rs12724450	0.793	rs74124663	chr1:150388948	A/G	cg03818307	chr1:150480534	ECM1	0.49	7.17	0.32	2.93e-12	Blood protein levels;
LGG	cis	rs7129220	0.512	rs1867137	chr11:10228809	G/A	cg01453529	chr11:10209919	SBF2	-0.47	-7.7	-0.34	8.04e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24717029	chr18:60384542	PHLPP1	0.41	6.94	0.31	1.34e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00490583	chr16:1843685	IGFALS	-0.42	-7.07	-0.31	5.65e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg05484508	chr16:89589025	SPG7	0.46	7.59	0.33	1.76e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6445975	0.715	rs4681836	chr3:58267287	C/T	cg24175188	chr3:58374923	PXK	0.4	7.59	0.33	1.78e-13	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2289328	0.823	rs35565646	chr15:40660515	G/A	cg13931752	chr15:40660718	DISP2	0.36	7.55	0.33	2.37e-13	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg08499158	chr17:42289980	UBTF	0.58	11.0	0.46	3.66e-25	Total body bone mineral density;
LGG	cis	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg08930214	chr7:62859557	LOC100287834	0.44	7.56	0.33	2.23e-13	Obesity-related traits;
LGG	cis	rs4748857	0.947	rs6482263	chr10:23604518	T/C	cg18853376	chr10:23633759	C10orf67	0.37	7.07	0.31	5.68e-12	Systemic lupus erythematosus;
LGG	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.14	0.39	1.91e-18	Myopia (pathological);
LGG	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	10.83	0.45	1.66e-24	Lung cancer in ever smokers;
LGG	cis	rs1670533	1.000	rs4690212	chr4:1054898	T/C	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.99	0.39	6.46e-18	Aortic root size;
LGG	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.86	-0.45	1.24e-24	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.83	0.38	2.17e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06752270	chr8:42397250	C8orf40;SLC20A2	0.4	6.65	0.3	8.3e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12857786	chr4:83934023	LIN54	0.55	8.44	0.37	4.09e-16	Gut microbiome composition (summer);
LGG	cis	rs2011503	0.941	rs4808944	chr19:19426613	A/C	cg11584989	chr19:19387371	SF4	0.79	13.22	0.52	4.37e-34	Bipolar disorder;
LGG	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg09845145	chr15:78292470	TBC1D2B	-0.63	-10.06	-0.42	1.2e-21	Coronary artery disease or large artery stroke;
LGG	cis	rs6784615	0.744	rs575476	chr3:52459175	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.7	-7.88	-0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.91	0.31	1.62e-11	Neuroticism;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg12016809	chr21:47604291	C21orf56	-0.55	-9.75	-0.41	1.52e-20	Testicular germ cell tumor;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg06925179	chr17:43578568	NA	0.42	9.79	0.41	1.05e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.52	-0.4	9.61e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8072100	0.666	rs9913503	chr17:45776330	T/G	cg19784903	chr17:45786737	TBKBP1	-0.33	-6.71	-0.3	5.6e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.34e-12	Lung cancer;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02475777	chr4:1388615	CRIPAK	-0.58	-10.5	-0.44	2.69e-23	Longevity;
LGG	cis	rs3747547	0.818	rs7859715	chr9:37948322	A/C	cg13774184	chr9:37916125	SHB	-0.76	-8.74	-0.38	4.36e-17	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs17453880	0.929	rs12522239	chr5:152054873	C/G	cg12297329	chr5:152029980	NA	-0.9	-23.74	-0.74	4.58e-82	Subjective well-being;
LGG	cis	rs4713118	0.527	rs9461433	chr6:28095172	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.88	15.35	0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs2303759	0.918	rs4802597	chr19:49872085	C/T	cg13373371	chr19:49828787	SLC6A16	0.36	6.73	0.3	5.17e-11	Multiple sclerosis;
LGG	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg02527881	chr3:46936655	PTH1R	-0.33	-8.04	-0.35	7.82e-15	Birth weight;
LGG	cis	rs10937275	0.826	rs35508867	chr3:186643240	C/T	cg16751732	chr3:186648392	ST6GAL1	0.69	7.02	0.31	8.05e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6714710	0.580	rs17489915	chr2:98420431	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs61990749	0.571	rs2364841	chr14:78284036	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.66	6.88	0.3	1.97e-11	Fibroblast growth factor basic levels;
LGG	cis	rs7633857	0.537	rs1580253	chr3:160767150	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.7	-0.41	2.31e-20	Educational attainment (years of education);
LGG	cis	rs561341	1.000	rs506766	chr17:30289659	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.31	-0.43	1.46e-22	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg01673284	chr16:4527211	HMOX2	0.35	6.83	0.3	2.69e-11	Schizophrenia;
LGG	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg04143929	chr2:100879511	NA	-0.49	-7.66	-0.34	1.11e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2862064	0.932	rs1553317	chr5:156479424	A/C	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.9	-0.45	8.46e-25	Platelet count;
LGG	cis	rs1451375	0.794	rs11238133	chr7:50542914	A/C	cg14593290	chr7:50529359	DDC	-0.45	-8.29	-0.36	1.22e-15	Malaria;
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.06e-19	Life satisfaction;
LGG	trans	rs7939886	0.920	rs11227145	chr11:55839278	C/A	cg03929089	chr4:120376271	NA	0.79	8.19	0.36	2.51e-15	Myopia (pathological);
LGG	cis	rs11874712	0.688	rs11659478	chr18:43650488	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.57	-13.23	-0.52	4.05e-34	Migraine - clinic-based;
LGG	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg13334819	chr7:99746414	C7orf59	-0.49	-7.56	-0.33	2.12e-13	Coronary artery disease;
LGG	cis	rs3816183	1.000	rs2304656	chr2:43019730	A/G	cg14631114	chr2:43023945	NA	0.49	8.84	0.38	2.06e-17	Hypospadias;
LGG	cis	rs12220238	0.722	rs11001087	chr10:76384602	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.51	6.81	0.3	3.02e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10911457	0.667	rs4634865	chr1:183895721	C/A	cg18131582	chr1:183912305	GLT25D2	0.27	6.69	0.3	6.3e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg03342759	chr3:160939853	NMD3	-0.62	-11.28	-0.46	3.1e-26	Morning vs. evening chronotype;
LGG	cis	rs4243971	0.516	rs6141695	chr20:30969050	T/C	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.76e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg08392591	chr16:89556376	ANKRD11	0.45	6.93	0.31	1.41e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs6964587	0.773	rs2097810	chr7:91977226	G/A	cg17063962	chr7:91808500	NA	0.49	8.38	0.36	6.59e-16	Breast cancer;
LGG	cis	rs7617773	0.780	rs6782166	chr3:48351683	A/G	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs727563	0.635	rs5751141	chr22:42107745	A/G	cg06481639	chr22:41940642	POLR3H	0.51	7.19	0.32	2.68e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-13.21	-0.52	5.02e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg11235426	chr6:292522	DUSP22	0.6	10.14	0.43	6.12e-22	Menopause (age at onset);
LGG	cis	rs908922	0.651	rs4240885	chr1:152529850	G/C	cg09873164	chr1:152488093	CRCT1	0.61	14.76	0.57	1.13e-40	Hair morphology;
LGG	cis	rs6977660	0.619	rs2158379	chr7:19783977	A/G	cg07541023	chr7:19748670	TWISTNB	0.5	7.51	0.33	3.17e-13	Thyroid stimulating hormone;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27499259	chr13:28400924	NA	0.45	6.98	0.31	1.03e-11	Gut microbiome composition (summer);
LGG	trans	rs9784649	0.641	rs72755823	chr5:25075537	T/C	cg11038491	chr20:34638489	LOC647979	-0.79	-10.71	-0.45	4.48e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7762018	0.891	rs7764839	chr6:170146351	C/A	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg11494091	chr17:61959527	GH2	-0.68	-11.8	-0.48	2.76e-28	Height;
LGG	cis	rs79146658	0.688	rs12693171	chr2:179748447	A/G	cg17765952	chr2:179737173	CCDC141	-0.56	-8.55	-0.37	1.78e-16	Diastolic blood pressure;
LGG	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg08344181	chr3:125677491	NA	-0.83	-8.02	-0.35	8.74e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg07621104	chr11:117668040	DSCAML1	0.65	9.21	0.39	1.13e-18	Myopia;
LGG	cis	rs67311347	0.640	rs7434088	chr3:40297288	T/C	cg13683864	chr3:40499215	RPL14	-0.8	-15.5	-0.58	6.24e-44	Renal cell carcinoma;
LGG	cis	rs894344	0.650	rs7841159	chr8:135593713	T/C	cg09855544	chr8:135498122	ZFAT	0.42	7.51	0.33	3.03e-13	Systolic blood pressure;
LGG	cis	rs6735179	0.550	rs2382559	chr2:1757522	T/C	cg08534653	chr2:1747700	PXDN	0.45	7.04	0.31	6.97e-12	Response to antipsychotic treatment;
LGG	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.29	0.32	1.34e-12	Bladder cancer;
LGG	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg21211680	chr2:198530	NA	1.22	21.17	0.7	4.61e-70	Blood protein levels;
LGG	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.45	0.33	4.76e-13	Total cholesterol levels;
LGG	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2.01e-21	Height;
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg21775007	chr8:11205619	TDH	0.51	8.58	0.37	1.45e-16	Neuroticism;
LGG	cis	rs11190604	1.000	rs7070776	chr10:102264672	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.47	0.33	4.02e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9914544	1.000	rs1634409	chr17:18836177	C/T	cg26306683	chr17:18585705	ZNF286B	0.47	8.8	0.38	2.63e-17	Educational attainment (years of education);
LGG	cis	rs981844	0.712	rs6855093	chr4:154754050	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs4132509	0.793	rs4478795	chr1:243844576	C/T	cg21452805	chr1:244014465	NA	0.93	9.96	0.42	2.61e-21	RR interval (heart rate);
LGG	trans	rs6601327	0.767	rs10109026	chr8:9411986	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.75	-0.34	5.95e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg18876405	chr7:65276391	NA	0.58	10.46	0.44	3.95e-23	Aortic root size;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg14668632	chr7:2872130	GNA12	-0.38	-7.84	-0.34	3.2e-14	Height;
LGG	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg01262667	chr19:19385393	TM6SF2	0.35	6.9	0.31	1.71e-11	Bipolar disorder;
LGG	cis	rs2404602	0.647	rs11072618	chr15:77019342	A/G	cg15268244	chr15:77196840	NA	0.49	10.41	0.44	5.91e-23	Blood metabolite levels;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13126279	chr21:47581558	C21orf56	-0.55	-10.08	-0.42	9.98e-22	Testicular germ cell tumor;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.44	-0.33	5.04e-13	Menopause (age at onset);
LGG	trans	rs561341	1.000	rs564714	chr17:30318404	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs6688613	0.694	rs12562794	chr1:166828957	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.56	8.8	0.38	2.8e-17	Refractive astigmatism;
LGG	cis	rs1018836	0.828	rs7012741	chr8:91536065	A/G	cg16814680	chr8:91681699	NA	-0.69	-11.88	-0.48	1.4e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9911578	1.000	rs11869828	chr17:56609525	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7945718	0.839	rs763373	chr11:12840342	C/G	cg25843174	chr11:12811716	TEAD1	-0.34	-6.65	-0.3	8.19e-11	Educational attainment (years of education);
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.52	-0.37	2.26e-16	Obesity-related traits;
LGG	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-11.82	-0.48	2.41e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg25427524	chr10:38739819	LOC399744	0.61	11.23	0.46	5.01e-26	Extrinsic epigenetic age acceleration;
LGG	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.04	0.83	1.47e-119	Chronic sinus infection;
LGG	cis	rs6882076	1.000	rs4704825	chr5:156382308	A/G	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.78	-0.48	3.46e-28	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg11766577	chr21:47581405	C21orf56	-0.47	-8.07	-0.35	6.24e-15	Testicular germ cell tumor;
LGG	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.82	-0.42	8.35e-21	Body mass index;
LGG	trans	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-10.46	-0.44	4.11e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12476592	0.602	rs2305157	chr2:63822785	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.73	-0.3	5.16e-11	Childhood ear infection;
LGG	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	18.72	0.66	1.18e-58	Smoking behavior;
LGG	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg19680485	chr15:31195859	MTMR15	0.53	9.25	0.4	8.02e-19	Huntington's disease progression;
LGG	cis	rs3857536	0.813	rs4710580	chr6:66935200	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.16e-14	Blood trace element (Cu levels);
LGG	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg04287289	chr16:89883240	FANCA	0.78	16.14	0.6	8.43e-47	Vitiligo;
LGG	trans	rs2727020	0.523	rs7948958	chr11:49506749	G/A	cg11707556	chr5:10655725	ANKRD33B	0.65	11.24	0.46	4.23e-26	Coronary artery disease;
LGG	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.4	0.63	1.46e-52	Sudden cardiac arrest;
LGG	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.11	-0.52	1.27e-33	Gut microbiome composition (summer);
LGG	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs36093844	0.660	rs895256	chr11:85535209	G/A	cg16165120	chr11:85566439	CCDC83	-0.46	-6.67	-0.3	7.4e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs17401966	0.931	rs4846213	chr1:10399178	A/G	cg15208524	chr1:10270712	KIF1B	0.42	7.32	0.32	1.13e-12	Hepatocellular carcinoma;
LGG	cis	rs4642101	0.662	rs4034942	chr3:12836792	C/T	cg24848339	chr3:12840334	CAND2	0.45	10.91	0.45	7.91e-25	QRS complex (12-leadsum);
LGG	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg23625390	chr15:77176239	SCAPER	0.48	9.11	0.39	2.48e-18	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg11608241	chr8:8085544	FLJ10661	0.29	6.66	0.3	7.88e-11	Retinal vascular caliber;
LGG	cis	rs459193	1.000	rs459193	chr5:55806751	A/G	cg26646659	chr5:55776364	NA	0.3	6.78	0.3	3.65e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg24134504	chr18:76639479	NA	-0.47	-8.21	-0.36	2.21e-15	Obesity-related traits;
LGG	cis	rs258892	0.841	rs266425	chr5:72132531	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.17	-0.43	4.42e-22	Height;
LGG	cis	rs2242116	1.000	rs2242116	chr3:46941116	A/G	cg02527881	chr3:46936655	PTH1R	-0.39	-9.54	-0.41	7.96e-20	Birth weight;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg26082838	chr20:14318410	FLRT3;MACROD2	0.33	6.69	0.3	6.32e-11	Liver disease severity in Alagille syndrome;
LGG	trans	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.52	0.4	9.67e-20	Diabetic kidney disease;
LGG	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.9	0.34	2.08e-14	Longevity;
LGG	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Aortic root size;
LGG	cis	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg21479132	chr6:26055353	NA	0.7	6.67	0.3	7.12e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.48	0.33	3.79e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12210905	1.000	rs12214848	chr6:27063348	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.87	-0.34	2.6e-14	Hip circumference adjusted for BMI;
LGG	trans	rs7246760	1.000	rs67507476	chr19:9852948	G/A	cg02900749	chr2:68251473	NA	-1.08	-11.64	-0.48	1.22e-27	Pursuit maintenance gain;
LGG	cis	rs9290065	0.622	rs6797798	chr3:160646598	G/A	cg04691961	chr3:161091175	C3orf57	0.41	8.38	0.36	6.59e-16	Kawasaki disease;
LGG	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg14593290	chr7:50529359	DDC	0.5	8.75	0.38	3.86e-17	Malaria;
LGG	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg02743256	chr7:2109353	MAD1L1	-0.34	-6.89	-0.3	1.84e-11	Bipolar disorder;
LGG	cis	rs2797369	0.552	rs2813646	chr6:101580650	A/C	cg27451362	chr6:101846650	GRIK2	0.83	11.4	0.47	1.03e-26	Renal function-related traits (eGRFcrea);
LGG	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg06636001	chr8:8085503	FLJ10661	0.57	11.09	0.46	1.68e-25	Retinal vascular caliber;
LGG	cis	rs2016266	1.000	rs10783573	chr12:53728369	G/A	cg04065151	chr12:53682969	ESPL1	-0.5	-8.5	-0.37	2.55e-16	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs5769765	0.955	rs5769761	chr22:50263641	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs9368481	1.000	rs9368481	chr6:26961761	C/T	cg18867708	chr6:26865862	GUSBL1	-0.46	-7.65	-0.33	1.19e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582720	0.943	rs72932575	chr2:203866857	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs5769765	1.000	rs2319458	chr22:50236306	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.49	0.33	3.59e-13	Schizophrenia;
LGG	cis	rs11190604	1.000	rs28522614	chr10:102323141	T/A	cg07080220	chr10:102295463	HIF1AN	0.71	11.45	0.47	7e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs867371	1.000	rs1501372	chr15:82468455	C/T	cg00614314	chr15:82944287	LOC80154	0.59	9.83	0.42	7.52e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4363385	0.747	rs4240866	chr1:152954875	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg24829409	chr8:58192753	C8orf71	-0.89	-13.85	-0.54	1e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs8064299	0.967	rs878907	chr17:72769694	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.69	13.34	0.53	1.35e-34	Monocyte count;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	7.51	0.33	3.17e-13	Renal function-related traits (BUN);
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg10295955	chr4:187884368	NA	-1.14	-29.54	-0.81	1.34e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	cis	rs3740909	1.000	rs78161553	chr11:125884231	T/C	cg24940576	chr11:125904314	CDON	-0.48	-7.53	-0.33	2.63e-13	Blood protein levels;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg22535103	chr8:58192502	C8orf71	-1.0	-15.34	-0.58	3.14e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.706	rs6037069	chr20:25234166	C/T	cg08601574	chr20:25228251	PYGB	0.37	7.48	0.33	3.69e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	cis	rs208520	0.874	rs208517	chr6:66947040	G/T	cg07460842	chr6:66804631	NA	-0.92	-15.89	-0.59	1.11e-45	Exhaled nitric oxide output;
LGG	cis	rs7806994	1	rs7806994	chr7:56139505	A/T	cg14187409	chr7:56174376	CHCHD2	0.61	7.21	0.32	2.29e-12	PR interval in Tripanosoma cruzi seropositivity;
LGG	trans	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg26043149	chr18:55253948	FECH	-0.6	-9.9	-0.42	4.19e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.64	-0.41	3.69e-20	Aortic root size;
LGG	cis	rs634534	0.622	rs1192168	chr11:65730945	T/G	cg26695010	chr11:65641043	EFEMP2	-0.6	-10.66	-0.44	6.92e-24	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.37	0.32	7.85e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg27624424	chr6:160112604	SOD2	0.72	10.27	0.43	1.95e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17683430	0.558	rs4488763	chr22:32380164	C/G	cg02631450	chr22:32366979	NA	0.65	7.86	0.34	2.73e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.99	-0.35	1.09e-14	Skin colour saturation;
LGG	trans	rs3858145	0.505	rs12765827	chr10:70046578	G/A	cg04882175	chr6:131122610	NA	0.51	7.16	0.32	3.18e-12	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs7512552	0.839	rs1627235	chr1:150358858	C/T	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg18335740	chr13:41363409	SLC25A15	0.62	12.42	0.5	9.07e-31	Lewy body disease;
LGG	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg17294928	chr15:75287854	SCAMP5	0.42	6.77	0.3	3.94e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.46	0.37	3.58e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg23743428	chr13:21893420	NA	-0.42	-6.95	-0.31	1.25e-11	White matter hyperintensity burden;
LGG	cis	rs8180040	0.902	rs73081205	chr3:47517670	A/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.66e-44	Colorectal cancer;
LGG	cis	rs4805272	0.539	rs17591634	chr19:29331628	A/C	cg14983838	chr19:29218262	NA	-0.67	-9.24	-0.39	8.96e-19	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.14	-0.31	3.64e-12	Mood instability;
LGG	cis	rs9894429	0.671	rs6565616	chr17:79612161	C/T	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	cis	rs17376456	0.825	rs12188163	chr5:93250608	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.93	-10.42	-0.44	5.6e-23	Diabetic retinopathy;
LGG	cis	rs67133203	0.665	rs34481246	chr12:51535470	G/A	cg14688905	chr12:51403056	SLC11A2	0.71	10.75	0.45	3.2e-24	Urinary tract infection frequency;
LGG	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg08999081	chr20:33150536	PIGU	0.44	11.33	0.47	1.99e-26	Coronary artery disease;
LGG	cis	rs4716602	0.596	rs10258969	chr7:156157753	A/G	cg16983916	chr7:156159713	NA	-0.48	-9.35	-0.4	3.79e-19	Anti-saccade response;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.9	-0.38	1.28e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg03452623	chr4:187889614	NA	-1.03	-30.34	-0.82	4.15e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs981844	1.000	rs72731674	chr4:154667447	C/A	cg14289246	chr4:154710475	SFRP2	0.69	11.56	0.47	2.4e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs3735485	0.843	rs4563792	chr7:45036644	G/A	cg03440944	chr7:45023329	C7orf40	0.57	9.74	0.41	1.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1256061	0.603	rs10148269	chr14:64736924	A/G	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs11748327	0.839	rs67950492	chr5:4072054	A/T	cg01025095	chr5:4101132	NA	-0.6	-9.71	-0.41	2.1e-20	Myocardial infarction;
LGG	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg12463550	chr7:65579703	CRCP	0.52	8.72	0.38	5.15e-17	Aortic root size;
LGG	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.44	-0.58	1.15e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7674212	0.539	rs7676041	chr4:104126421	T/A	cg16532752	chr4:104119610	CENPE	-0.41	-7.1	-0.31	4.74e-12	Type 2 diabetes;
LGG	cis	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.12	-0.39	2.23e-18	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg11764359	chr7:65958608	NA	-0.73	-13.0	-0.52	3.76e-33	Aortic root size;
LGG	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	11.29	0.46	2.94e-26	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15951691	chr7:150065937	REPIN1	0.46	6.91	0.31	1.6e-11	Gut microbiome composition (summer);
LGG	cis	rs10463554	0.927	rs34375	chr5:102401123	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg01262667	chr19:19385393	TM6SF2	-0.35	-8.14	-0.35	3.6e-15	Tonsillectomy;
LGG	cis	rs7565124	1.000	rs7568106	chr2:20261969	G/A	cg24657347	chr2:20261756	NA	-0.76	-14.96	-0.57	1.47e-41	Major depressive disorder;
LGG	trans	rs9354308	0.764	rs1938065	chr6:66608617	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.68	-0.3	6.93e-11	Metabolite levels;
LGG	cis	rs10489202	1.000	rs12404574	chr1:167961235	C/T	cg24449463	chr1:168025552	DCAF6	0.6	10.0	0.42	1.95e-21	Schizophrenia;
LGG	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11890956	chr21:40555474	PSMG1	-1.21	-30.81	-0.82	3.5e-114	Cognitive function;
LGG	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg13699009	chr12:122356056	WDR66	0.56	14.53	0.56	1.14e-39	Mean corpuscular volume;
LGG	cis	rs9290065	0.538	rs898682	chr3:160773133	G/C	cg03342759	chr3:160939853	NMD3	-0.56	-9.19	-0.39	1.3e-18	Kawasaki disease;
LGG	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg03078520	chr22:18463400	MICAL3	0.68	14.67	0.56	2.8e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.4	0.4	2.54e-19	Bone mineral density;
LGG	cis	rs1371867	0.846	rs924057	chr8:101266157	A/G	cg06636551	chr8:101224915	SPAG1	0.47	8.71	0.38	5.52e-17	Atrioventricular conduction;
LGG	cis	rs6540556	0.678	rs12094117	chr1:209888435	G/T	cg23920097	chr1:209922102	NA	-0.43	-6.87	-0.3	2.13e-11	Red blood cell count;
LGG	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg13736514	chr6:26305472	NA	-0.47	-9.65	-0.41	3.4e-20	Educational attainment;
LGG	cis	rs4702718	0.577	rs2918392	chr5:10704797	T/C	cg14521931	chr5:10832172	NA	0.44	8.21	0.36	2.15e-15	Obesity-related traits;
LGG	cis	rs4849975	0.510	rs13431927	chr2:3713706	G/C	cg17046650	chr2:3699563	NA	0.71	9.0	0.39	5.93e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01174096	chr2:196521556	SLC39A10	-0.46	-6.94	-0.31	1.34e-11	Systemic lupus erythematosus;
LGG	cis	rs12410462	0.636	rs2819511	chr1:227698474	A/G	cg23173402	chr1:227635558	NA	0.38	7.24	0.32	1.94e-12	Major depressive disorder;
LGG	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg10057126	chr4:77819792	ANKRD56	0.35	6.67	0.3	7.4e-11	Emphysema distribution in smoking;
LGG	cis	rs2153535	0.580	rs4587214	chr6:8454119	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.67e-22	Motion sickness;
LGG	cis	rs1568889	1.000	rs9783375	chr11:28033667	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.31	0.55	9.88e-39	Bipolar disorder;
LGG	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg00012203	chr2:219082015	ARPC2	0.86	17.52	0.63	4.19e-53	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.35e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg27523141	chr10:43048294	ZNF37B	0.39	7.59	0.33	1.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs896854	0.654	rs13274945	chr8:95986626	C/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.73	-0.38	4.78e-17	Type 2 diabetes;
LGG	trans	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	24.95	0.76	1.02e-87	IgG glycosylation;
LGG	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.57	0.33	2.01e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1696756	0.877	rs2587500	chr17:77827362	A/T	cg07923794	chr17:77834237	NA	-0.76	-11.74	-0.48	5e-28	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.25	0.32	1.79e-12	Schizophrenia;
LGG	cis	rs6735179	0.603	rs10164788	chr2:1753379	G/A	cg10160682	chr2:1713001	PXDN	-0.53	-9.18	-0.39	1.44e-18	Response to antipsychotic treatment;
LGG	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.73	0.41	1.73e-20	Height;
LGG	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.18	0.32	2.78e-12	Total cholesterol levels;
LGG	cis	rs8072100	0.846	rs7214799	chr17:45702099	C/T	cg08085267	chr17:45401833	C17orf57	0.51	9.58	0.41	5.73e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg24623649	chr8:11872141	NA	-0.31	-7.43	-0.33	5.19e-13	Neuroticism;
LGG	cis	rs34172651	0.917	rs12923476	chr16:24798079	G/A	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.24	-0.36	1.81e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs9473924	0.542	rs56240592	chr6:50815514	T/A	cg14470998	chr6:50812995	TFAP2B	0.69	8.31	0.36	1.06e-15	Body mass index;
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg03036210	chr16:89904091	SPIRE2	-0.63	-7.66	-0.34	1.09e-13	Skin colour saturation;
LGG	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.54	-0.33	2.44e-13	Mood instability;
LGG	cis	rs9815354	1.000	rs9869440	chr3:41763155	G/C	cg03022575	chr3:42003672	ULK4	0.6	7.66	0.34	1.12e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg22437258	chr11:111473054	SIK2	0.51	8.87	0.38	1.57e-17	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12523403	chr19:12779890	MORG1;C19orf56	0.49	7.79	0.34	4.57e-14	Gut microbiome composition (summer);
LGG	cis	rs763121	0.962	rs138711	chr22:39139913	C/T	cg06022373	chr22:39101656	GTPBP1	0.52	7.97	0.35	1.25e-14	Menopause (age at onset);
LGG	cis	rs72945132	0.882	rs12278125	chr11:70134016	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs9547996	1.000	rs28373781	chr13:38218758	A/G	cg17979426	chr13:38220150	TRPC4	-0.44	-8.34	-0.36	8.78e-16	Diastolic blood pressure;
LGG	cis	rs7937682	0.774	rs59921976	chr11:111473088	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.66	-0.74	1.07e-81	Primary sclerosing cholangitis;
LGG	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg20302533	chr7:39170763	POU6F2	0.48	11.9	0.48	1.16e-28	IgG glycosylation;
LGG	cis	rs12318506	0.826	rs11180438	chr12:75668035	T/G	cg04728562	chr12:75699417	CAPS2	-1.12	-9.43	-0.4	1.91e-19	Coronary artery calcification;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.69	0.34	8.62e-14	Schizophrenia;
LGG	cis	rs611744	0.506	rs4735054	chr8:109261780	A/C	cg18478394	chr8:109455254	TTC35	-0.47	-9.69	-0.41	2.46e-20	Dupuytren's disease;
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg03709012	chr19:19516395	GATAD2A	0.79	14.65	0.56	3.34e-40	Tonsillectomy;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.75	0.3	4.5e-11	Schizophrenia;
LGG	cis	rs9287719	0.967	rs6733416	chr2:10738684	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg13852791	chr20:30311386	BCL2L1	-0.64	-8.54	-0.37	1.98e-16	Mean corpuscular hemoglobin;
LGG	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg13944838	chr5:179740914	GFPT2	-0.7	-12.94	-0.52	6.87e-33	Height;
LGG	cis	rs875971	0.545	rs73136346	chr7:65566082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.32	-0.43	1.27e-22	Aortic root size;
LGG	cis	rs5771225	0.544	rs13055135	chr22:50672479	A/G	cg08875078	chr22:50639485	SELO	0.51	7.47	0.33	4.02e-13	Late-onset Alzheimer's disease;
LGG	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg08461772	chr7:95026248	PON3	0.37	7.99	0.35	1.1e-14	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.56	-8.42	-0.36	4.73e-16	Body mass index;
LGG	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg05234568	chr11:5960015	NA	-0.62	-10.02	-0.42	1.61e-21	DNA methylation (variation);
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.84	0.64	1.53e-54	Platelet count;
LGG	trans	rs61931739	0.534	rs28548399	chr12:34188151	G/A	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.93	-0.52	7.28e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg24397884	chr7:158709396	WDR60	1.1	16.83	0.62	6.32e-50	Height;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12493885	0.725	rs61791493	chr3:153743573	A/G	cg17054900	chr3:154042577	DHX36	-0.72	-8.85	-0.38	1.82e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.16	0.32	3.27e-12	Height;
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22633769	chr20:60982531	CABLES2	0.54	8.49	0.37	2.81e-16	Colorectal cancer;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg18110333	chr6:292329	DUSP22	-0.69	-11.83	-0.48	2.21e-28	Menopause (age at onset);
LGG	cis	rs2050392	0.517	rs7096279	chr10:30759608	C/T	cg25182066	chr10:30743637	MAP3K8	-0.66	-13.88	-0.54	7.27e-37	Inflammatory bowel disease;
LGG	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05959577	chr3:48129425	MAP4	-0.47	-7.16	-0.32	3.19e-12	Systemic lupus erythematosus;
LGG	cis	rs9462027	0.651	rs7752390	chr6:34790624	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg06219351	chr7:158114137	PTPRN2	0.71	14.04	0.55	1.47e-37	Calcium levels;
LGG	cis	rs11203032	0.831	rs11203024	chr10:90955239	G/T	cg16672925	chr10:90967113	CH25H	0.79	11.33	0.47	2.03e-26	Heart failure;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.05	-0.42	1.22e-21	Lung cancer;
LGG	cis	rs11677416	1.000	rs6542094	chr2:113528625	A/G	cg27083787	chr2:113543245	IL1A	0.53	8.78	0.38	3.11e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7172689	1.000	rs28418832	chr15:81551648	T/G	cg11808699	chr15:81528661	IL16	-0.49	-10.14	-0.43	5.88e-22	Inattentive symptoms;
LGG	cis	rs9916302	0.904	rs2338797	chr17:37548241	G/A	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.91	-0.35	1.88e-14	Life satisfaction;
LGG	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg04450456	chr4:17643702	FAM184B	0.32	6.89	0.3	1.87e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg23782820	chr8:58130467	NA	0.46	7.33	0.32	1.04e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs9360167	chr6:66591357	C/A	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs4595586	0.546	rs10876163	chr12:39244915	G/A	cg13010199	chr12:38710504	ALG10B	0.59	10.77	0.45	2.82e-24	Morning vs. evening chronotype;
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg22077389	chr15:40226273	EIF2AK4	-0.6	-8.43	-0.36	4.58e-16	Response to haloperidol in psychosis;
LGG	cis	rs2735413	0.875	rs8045975	chr16:78090187	C/G	cg04733911	chr16:78082701	NA	0.78	18.57	0.65	6.16e-58	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs79839061	0.610	rs62297062	chr4:869698	C/T	cg07828340	chr4:882639	GAK	0.86	9.13	0.39	2.1e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.39	-6.73	-0.3	5.15e-11	Vitiligo;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.02	-0.49	3.73e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs4704187	0.687	rs6869345	chr5:74378742	C/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	cis	rs854037	0.698	rs11739073	chr5:57070991	T/A	cg08523694	chr5:57076192	NA	0.52	7.24	0.32	1.87e-12	Birth weight;
LGG	cis	rs4948275	0.530	rs2393853	chr10:63167688	C/G	cg02023345	chr10:63212226	TMEM26	0.41	7.79	0.34	4.32e-14	Night sleep phenotypes;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs9394438	0.529	rs10947681	chr6:37547073	C/A	cg00985040	chr6:37553208	NA	-0.41	-9.32	-0.4	4.81e-19	IgG glycosylation;
LGG	cis	rs9807989	0.507	rs1592459	chr2:103031569	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.1	0.31	4.82e-12	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.91e-14	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.61e-13	Lung cancer;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg11494091	chr17:61959527	GH2	-1.14	-34.55	-0.85	2.92e-130	Prudent dietary pattern;
LGG	cis	rs3816788	0.596	rs4872083	chr8:21770372	C/T	cg17168535	chr8:21777572	XPO7	0.68	12.81	0.51	2.28e-32	Lung cancer in ever smokers;
LGG	cis	rs1109114	0.844	rs1808828	chr5:148630191	C/A	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.27	-0.46	3.33e-26	Body mass index;
LGG	cis	rs11809207	0.574	rs2783631	chr1:26504756	C/T	cg23602478	chr1:26503979	CNKSR1	0.33	8.45	0.37	3.67e-16	Height;
LGG	cis	rs3126085	0.932	rs11204949	chr1:152219797	A/C	cg26876637	chr1:152193138	HRNR	-0.49	-6.98	-0.31	1e-11	Atopic dermatitis;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg14991984	chr1:99470129	LPPR5	-0.33	-6.65	-0.3	8.05e-11	Iris color (L* coordinate);
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs10186029	0.676	rs4673721	chr2:213941643	T/G	cg08319019	chr2:214017104	IKZF2	0.45	7.92	0.35	1.73e-14	Systemic sclerosis;
LGG	cis	rs6909430	0.901	rs9320980	chr6:98685930	G/A	cg12860156	chr6:98744658	NA	-0.45	-7.61	-0.33	1.5700000000000001e-13	Quantitative traits;
LGG	cis	rs3789045	0.707	rs61421373	chr1:204560440	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.9	-0.38	1.25e-17	Educational attainment (college completion);
LGG	cis	rs1256061	0.603	rs1256037	chr14:64743301	G/A	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs3771570	1.000	rs56222556	chr2:242364119	G/A	cg21155796	chr2:242212141	HDLBP	0.75	9.95	0.42	2.8e-21	Prostate cancer;
LGG	trans	rs7181230	0.885	rs4924413	chr15:40348697	G/A	cg22705835	chr10:65332833	REEP3	-0.61	-10.13	-0.43	6.2e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs4919044	0.808	rs835256	chr10:94779550	C/T	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.09	-0.31	5.14e-12	Coronary artery disease;
LGG	cis	rs977987	0.864	rs37593	chr16:75496907	T/C	cg07303275	chr16:75499416	TMEM170A	-0.43	-7.63	-0.33	1.39e-13	Dupuytren's disease;
LGG	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg02389323	chr16:88786976	FAM38A	0.95	12.28	0.5	3.25e-30	Plateletcrit;
LGG	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.05	-0.31	6.71e-12	Crohn's disease;
LGG	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.53	-8.54	-0.37	2.01e-16	Menarche (age at onset);
LGG	cis	rs368123	1.000	rs370586	chr6:160719569	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs796364	0.813	rs4672686	chr2:201065044	A/G	cg23649088	chr2:200775458	C2orf69	0.59	8.62	0.37	1.06e-16	Schizophrenia;
LGG	trans	rs11989744	0.597	rs2033788	chr8:23574847	G/T	cg03492747	chr16:86543808	FOXF1	-0.56	-9.84	-0.42	7.19e-21	Waist-hip ratio;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg21724239	chr8:58056113	NA	0.53	7.92	0.35	1.82e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4845570	1.000	rs11586946	chr1:151769806	G/A	cg07092448	chr1:151763213	TDRKH	-1.17	-18.1	-0.64	9.54e-56	Coronary artery disease;
LGG	cis	rs9527	0.545	rs7100369	chr10:104956218	C/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.16e-12	Arsenic metabolism;
LGG	cis	rs8072100	0.738	rs9900123	chr17:45549055	T/C	cg08085267	chr17:45401833	C17orf57	-0.49	-8.99	-0.39	6.28e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs61931739	0.500	rs11053223	chr12:34481947	T/A	cg26384229	chr12:38710491	ALG10B	0.96	21.25	0.7	1.9e-70	Morning vs. evening chronotype;
LGG	trans	rs7178375	1.000	rs28693590	chr15:31195021	A/G	cg04373760	chr16:53404718	NA	0.57	8.6	0.37	1.22e-16	Hypertriglyceridemia;
LGG	cis	rs2249694	0.960	rs2515642	chr10:135352013	C/T	cg20169779	chr10:135381914	SYCE1	0.49	7.52	0.33	2.83e-13	Obesity-related traits;
LGG	cis	rs1707322	0.721	rs11211178	chr1:46227566	G/T	cg03146154	chr1:46216737	IPP	0.59	10.9	0.45	8.54e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9768139	0.708	rs10262596	chr7:158114495	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	cis	rs300774	1.000	rs436446	chr2:106409	T/C	cg04617936	chr2:214353	NA	-0.5	-7.47	-0.33	4.06e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs68170813	0.617	rs17486	chr7:107112890	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-8.55	-0.37	1.83e-16	Coronary artery disease;
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg24575275	chr7:1094737	C7orf50	-0.37	-7.03	-0.31	7.32e-12	Longevity;Endometriosis;
LGG	cis	rs10214930	0.697	rs9639552	chr7:27575523	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.87	0.3	2.03e-11	Hypospadias;
LGG	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg06636001	chr8:8085503	FLJ10661	0.46	8.31	0.36	1.08e-15	Retinal vascular caliber;
LGG	cis	rs6489882	0.902	rs7966314	chr12:113372539	C/T	cg25319449	chr12:113376135	OAS3	0.4	7.23	0.32	2.02e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7648466	0.544	rs2172247	chr3:46214670	T/C	cg12441928	chr3:46249985	CCR1	-0.45	-8.82	-0.38	2.41e-17	Eotaxin levels;
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06850241	chr22:41845214	NA	-0.45	-7.0	-0.31	8.92e-12	Vitiligo;
LGG	cis	rs9880211	0.800	rs35210994	chr3:136496136	A/C	cg21827317	chr3:136751795	NA	-0.47	-6.85	-0.3	2.33e-11	Body mass index;Height;
LGG	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg00666640	chr1:248458726	OR2T12	0.6	9.76	0.41	1.39e-20	Common traits (Other);
LGG	cis	rs8114671	0.562	rs1013677	chr20:33468793	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	7.3	0.32	1.26e-12	Height;
LGG	cis	rs6977660	0.653	rs28537170	chr7:19814239	T/G	cg07541023	chr7:19748670	TWISTNB	0.63	8.21	0.36	2.29e-15	Thyroid stimulating hormone;
LGG	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	9.57	0.41	6.57e-20	Systolic blood pressure;
LGG	cis	rs9814567	0.752	rs4306899	chr3:134334513	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.62	10.75	0.45	3.3e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.54	-0.44	2.07e-23	IgG glycosylation;
LGG	cis	rs4655582	0.510	rs12022410	chr1:66153933	A/G	cg04111102	chr1:66153794	NA	0.27	6.84	0.3	2.49e-11	Fibrinogen levels;
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.02	0.52	3e-33	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg18379455	chr17:41446167	NA	-0.31	-7.05	-0.31	6.65e-12	Menopause (age at onset);
LGG	cis	rs4740619	0.819	rs7873152	chr9:15555458	C/T	cg14451791	chr9:16040625	NA	-0.33	-8.31	-0.36	1.07e-15	Body mass index;
LGG	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.18	-0.32	2.83e-12	Hemoglobin concentration;
LGG	cis	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg00383909	chr3:49044727	WDR6	0.98	12.38	0.5	1.33e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7107174	1.000	rs7128666	chr11:78102363	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	5.97e-11	Height;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-6.74	-0.3	4.73e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.56	-0.37	1.68e-16	Menarche (age at onset);
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.13	-0.31	3.82e-12	Prostate cancer;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs9457247	0.967	rs2149092	chr6:167372978	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs5750830	0.595	rs4821892	chr22:39795683	G/C	cg04986931	chr22:39850128	NA	0.34	7.73	0.34	6.62e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg02297831	chr4:17616191	MED28	0.5	9.24	0.39	8.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3540	0.597	rs12708583	chr15:91050271	C/T	cg22089800	chr15:90895588	ZNF774	0.65	11.83	0.48	2.1e-28	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs17021463	0.902	rs2865352	chr4:95253263	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.51	-9.47	-0.4	1.47e-19	Testicular germ cell tumor;
LGG	cis	rs12580194	0.593	rs12296692	chr12:55756851	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.95	-0.42	2.98e-21	Cancer;
LGG	cis	rs754423	0.631	rs1497085	chr14:52521243	G/C	cg06782686	chr14:52535964	NID2	-0.3	-6.67	-0.3	7.18e-11	Craniofacial microsomia;
LGG	cis	rs12579753	1.000	rs12821073	chr12:82183260	G/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.86	-0.45	1.29e-24	Resting heart rate;
LGG	cis	rs12195424	0.558	rs78565972	chr6:56302845	C/A	cg07152817	chr6:56299822	NA	-0.99	-9.97	-0.42	2.46e-21	Cerebrospinal fluid clusterin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03784229	chr7:30175455	C7orf41	0.47	6.94	0.31	1.36e-11	Gut microbiome composition (summer);
LGG	cis	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg05084668	chr3:125655381	ALG1L	1.11	12.76	0.51	3.49e-32	Blood pressure (smoking interaction);
LGG	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.53	-0.9	4.32e-173	Myeloid white cell count;
LGG	cis	rs7633770	0.786	rs1607737	chr3:46681846	G/C	cg11219411	chr3:46661640	NA	0.59	14.09	0.55	9.36e-38	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg07615347	chr10:60278583	BICC1	0.63	17.84	0.64	1.52e-54	Refractive error;
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg16359550	chr11:109292809	C11orf87	0.42	8.23	0.36	1.9e-15	Schizophrenia;
LGG	cis	rs8044868	0.530	rs7940	chr16:72146441	C/G	cg23815491	chr16:72088622	HP	0.38	8.15	0.35	3.48e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg06558623	chr16:89946397	TCF25	1.19	13.42	0.53	6.68e-35	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11610702	chr7:39773227	LOC349114	0.54	8.0	0.35	1.01e-14	Gut microbiome composition (summer);
LGG	cis	rs919433	0.889	rs788004	chr2:198219032	C/T	cg00792783	chr2:198669748	PLCL1	0.44	6.99	0.31	9.8e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs240764	0.658	rs2132168	chr6:101178491	G/A	cg09795085	chr6:101329169	ASCC3	-0.49	-8.33	-0.36	9.33e-16	Neuroticism;
LGG	cis	rs73193808	0.590	rs9982010	chr21:30568176	G/A	cg03476357	chr21:30257390	N6AMT1	0.42	7.0	0.31	9.04e-12	Coronary artery disease;
LGG	cis	rs965513	0.627	rs7848973	chr9:100588839	A/G	cg13688889	chr9:100608707	NA	-0.57	-11.08	-0.46	1.75e-25	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs34638952	0.577	rs8076604	chr17:27438469	G/A	cg27392559	chr17:27410759	MYO18A	-0.37	-7.05	-0.31	6.62e-12	Sitting height ratio;
LGG	cis	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg12395012	chr8:11607386	GATA4	-0.45	-8.0	-0.35	1e-14	Myopia (pathological);
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4073582	0.576	rs556595	chr11:66058082	T/G	cg14036092	chr11:66035641	RAB1B	0.44	7.48	0.33	3.75e-13	Gout;
LGG	cis	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.36	-0.4	3.44e-19	Morning vs. evening chronotype;
LGG	cis	rs919433	0.679	rs9967823	chr2:198531529	A/G	cg00792783	chr2:198669748	PLCL1	0.55	9.01	0.39	5.38e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs12347191	0.500	rs907578	chr9:100622883	A/G	cg13688889	chr9:100608707	NA	-0.82	-16.1	-0.6	1.18e-46	Orofacial clefts;
LGG	cis	rs7267979	1.000	rs2500446	chr20:25339664	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.87e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7614311	0.552	rs73117078	chr3:63942084	G/A	cg22134162	chr3:63841271	THOC7	-0.43	-7.47	-0.33	3.96e-13	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs3206736	0.548	rs1649221	chr7:34987758	G/A	cg13400248	chr7:35225412	NA	0.53	9.3	0.4	5.54e-19	Diastolic blood pressure;
LGG	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27532318	chr7:32358331	NA	0.85	8.34	0.36	8.51e-16	Body mass index;
LGG	cis	rs34467563	0.872	rs6997112	chr8:97366258	G/A	cg22138393	chr8:97340270	PTDSS1	0.3	6.7	0.3	5.88e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs950776	0.745	rs36045869	chr15:78929498	C/T	cg17108064	chr15:78857060	CHRNA5	0.34	6.66	0.3	7.77e-11	Sudden cardiac arrest;
LGG	cis	rs798554	0.797	rs798497	chr7:2795957	A/G	cg18446336	chr7:2847575	GNA12	-0.29	-6.98	-0.31	1.02e-11	Height;
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg16339924	chr4:17578868	LAP3	0.63	10.99	0.45	4.16e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs564799	0.966	rs6441289	chr3:159732882	T/C	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg12886942	chr2:66802661	NA	-0.37	-7.18	-0.32	2.89e-12	Brain structure;
LGG	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg16662043	chr16:48846231	NA	0.38	7.46	0.33	4.17e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg00666640	chr1:248458726	OR2T12	0.56	9.64	0.41	3.73e-20	Common traits (Other);
LGG	cis	rs10905065	0.861	rs10752069	chr10:5752403	A/G	cg11519256	chr10:5708881	ASB13	0.41	7.19	0.32	2.61e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg04863758	chr4:1303710	MAEA	0.45	7.74	0.34	6.45e-14	Obesity-related traits;
LGG	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg11871910	chr12:69753446	YEATS4	0.91	21.36	0.7	5.89e-71	Blood protein levels;
LGG	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg09408571	chr1:101003634	GPR88	-0.32	-8.1	-0.35	5.03e-15	Breast cancer;
LGG	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg20503657	chr10:835505	NA	0.52	6.85	0.3	2.31e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs9948	0.786	rs62152774	chr2:97448377	A/G	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg06521331	chr12:34319734	NA	-0.42	-7.2	-0.32	2.43e-12	Heart rate;
LGG	cis	rs28830936	1.000	rs17676742	chr15:41903048	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.46	-0.5	5.98e-31	Diastolic blood pressure;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg14926445	chr8:58193284	C8orf71	-0.71	-8.49	-0.37	2.8e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07303308	chr7:128695042	LOC286016;TNPO3	0.45	7.17	0.32	2.99e-12	Cognitive performance;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg12386194	chr3:101231763	SENP7	0.45	7.85	0.34	3e-14	Colorectal cancer;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.62	-0.41	4.2e-20	Obesity-related traits;
LGG	cis	rs12497850	0.931	rs4072859	chr3:49032205	G/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.83	-0.3	2.73e-11	Parkinson's disease;
LGG	cis	rs4380275	0.965	rs4315562	chr2:772723	A/G	cg14072418	chr2:740025	NA	-0.41	-7.61	-0.33	1.6e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg03929089	chr4:120376271	NA	0.76	12.18	0.49	8.46e-30	Coronary artery disease;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02950623	chr16:14379524	NA	0.49	7.28	0.32	1.42e-12	Hip circumference;
LGG	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg14541582	chr5:601475	NA	-0.37	-7.13	-0.31	3.89e-12	Ulcerative colitis;
LGG	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.91	0.42	4.08e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4936891	0.577	rs4936885	chr11:123905876	C/A	cg22125253	chr11:123886957	OR10G4	-0.54	-9.11	-0.39	2.47e-18	Male fertility;
LGG	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.93	-0.35	1.65e-14	Bone mineral density;
LGG	cis	rs7567389	0.510	rs6755028	chr2:128195442	G/A	cg10021288	chr2:128175891	PROC	-0.37	-6.84	-0.3	2.46e-11	Self-rated health;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg12379764	chr21:47803548	PCNT	0.5	8.17	0.35	2.97e-15	Testicular germ cell tumor;
LGG	cis	rs921968	0.643	rs2556384	chr2:219532903	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.22	0.32	2.14e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10751667	0.643	rs11246348	chr11:939476	G/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.6e-14	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12143943	0.966	rs12135707	chr1:204556223	C/T	cg20240347	chr1:204465584	NA	-0.33	-7.19	-0.32	2.69e-12	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17187048	chr2:122407283	CLASP1	0.43	7.51	0.33	3.06e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs832540	0.931	rs33318	chr5:56208414	G/T	cg17809284	chr5:56205270	C5orf35	-0.35	-6.75	-0.3	4.33e-11	Coronary artery disease;
LGG	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	8.36	0.36	7.64e-16	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.794	rs61991247	chr14:71860318	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.07	0.39	3.33e-18	Mitral valve prolapse;
LGG	cis	rs11971779	0.680	rs7795520	chr7:139079207	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.44e-12	Diisocyanate-induced asthma;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.41	-0.53	7.19e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs694739	0.628	rs11606081	chr11:64137875	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.77e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04854107	chr15:38544003	SPRED1	0.43	7.2	0.32	2.45e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs7107174	0.892	rs10899487	chr11:78085474	G/A	cg02023728	chr11:77925099	USP35	0.45	7.74	0.34	6.32e-14	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	cg15522984	chr1:182991683	LAMC1	0.4	7.57	0.33	2.09e-13	Fuchs's corneal dystrophy;
LGG	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	trans	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg13565492	chr6:43139072	SRF	-0.79	-9.84	-0.42	7.25e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.16	12.61	0.51	1.48e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.65	0.37	8.68e-17	Bipolar disorder;
LGG	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg08847335	chr10:891726	LARP4B	-0.51	-9.21	-0.39	1.17e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14159672	chr1:205819179	PM20D1	0.78	16.69	0.61	2.67e-49	Menarche (age at onset);
LGG	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg24692254	chr21:30365293	RNF160	-0.73	-14.15	-0.55	5.06e-38	Dental caries;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.62	0.37	1.08e-16	Personality dimensions;
LGG	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg10523679	chr1:76189770	ACADM	0.79	13.95	0.54	3.66e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3096299	0.585	rs3114881	chr16:89422632	T/C	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.73	-0.3	5.09e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg03264133	chr6:25882463	NA	-0.7	-13.05	-0.52	2.34e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg00825309	chr19:58991885	ZNF446	-0.42	-7.98	-0.35	1.17e-14	Uric acid clearance;
LGG	cis	rs2502399	0.898	rs774575	chr6:113509950	G/A	cg20413948	chr6:113544930	NA	0.29	6.93	0.31	1.4e-11	Plasma clusterin levels;
LGG	cis	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.77	0.3	4.02e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	8.07	0.35	6.14e-15	Hip circumference adjusted for BMI;
LGG	cis	rs12286929	0.607	rs10891808	chr11:115071301	T/C	cg04055981	chr11:115044050	NA	-0.38	-7.16	-0.32	3.14e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10875746	0.624	rs11168498	chr12:48655088	A/G	cg24011408	chr12:48396354	COL2A1	-0.59	-7.56	-0.33	2.24e-13	Longevity (90 years and older);
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg04287289	chr16:89883240	FANCA	0.77	7.59	0.33	1.81e-13	Skin colour saturation;
LGG	cis	rs8141529	0.748	rs6519766	chr22:29269991	A/G	cg02153584	chr22:29168773	CCDC117	-0.61	-9.99	-0.42	2.03e-21	Lymphocyte counts;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05165339	chr4:1420672	NA	0.34	8.53	0.37	2.03e-16	Longevity;
LGG	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.18	-0.32	2.77e-12	HDL cholesterol;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg05863683	chr7:1912471	MAD1L1	0.41	7.69	0.34	8.81e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg09303159	chr6:26284866	NA	0.39	8.77	0.38	3.41e-17	Educational attainment;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg26174226	chr8:58114915	NA	-0.47	-7.17	-0.32	3.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs694739	1.000	rs11231757	chr11:64106317	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.76	14.55	0.56	9.06e-40	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg24189917	chr7:1970923	MAD1L1	-0.59	-8.93	-0.38	9.95e-18	Bipolar disorder;
LGG	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6694672	0.867	rs616675	chr1:197257556	C/T	cg13682187	chr1:196946512	CFHR5	0.47	6.66	0.3	7.82e-11	Asthma;
LGG	trans	rs6787172	0.622	rs6778370	chr3:158094422	A/G	cg23275840	chr4:47708675	CORIN	0.35	7.33	0.32	1.02e-12	Subjective well-being;
LGG	cis	rs10751667	0.857	rs7481221	chr11:966813	G/A	cg22143635	chr11:980567	AP2A2	-0.88	-9.43	-0.4	2.06e-19	Alzheimer's disease (late onset);
LGG	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg23461800	chr14:103021989	NA	0.53	8.41	0.36	5.01e-16	Platelet count;
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg05552183	chr6:42928497	GNMT	0.43	12.79	0.51	2.75e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.92e-12	Electroencephalogram traits;
LGG	cis	rs3735485	0.738	rs11771107	chr7:45134135	A/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.13	-0.39	2.21e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg03709012	chr19:19516395	GATAD2A	0.98	15.57	0.59	2.99e-44	Nonalcoholic fatty liver disease;
LGG	trans	rs9329221	0.648	rs4512422	chr8:10258889	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.91	-0.35	1.86e-14	Neuroticism;
LGG	trans	rs2270927	0.834	rs4496693	chr5:75576729	T/C	cg13563193	chr19:33072644	PDCD5	0.84	11.44	0.47	7.19e-27	Mean corpuscular volume;
LGG	cis	rs35306767	0.953	rs35174953	chr10:961191	C/A	cg25019033	chr10:957182	NA	-0.6	-12.68	-0.51	7.51e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs9487094	0.961	rs12192847	chr6:109801631	G/A	cg01125227	chr6:109776195	MICAL1	0.54	8.96	0.38	7.94e-18	Height;
LGG	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg13256891	chr4:100009986	ADH5	-0.55	-9.7	-0.41	2.16e-20	Alcohol dependence;
LGG	cis	rs62238980	0.614	rs76853252	chr22:32455857	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12756686	chr19:29218302	NA	0.7	11.81	0.48	2.56e-28	Methadone dose in opioid dependence;
LGG	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg02023728	chr11:77925099	USP35	0.43	7.75	0.34	5.78e-14	Testicular germ cell tumor;
LGG	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg08603382	chr10:743973	NA	0.39	7.14	0.31	3.74e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg23173402	chr1:227635558	NA	0.62	10.36	0.43	9e-23	Major depressive disorder;
LGG	cis	rs7222240	1.000	rs8070631	chr17:43120500	C/G	cg24806326	chr17:43207588	PLCD3	0.45	7.54	0.33	2.5e-13	Craniofacial microsomia;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg11878867	chr6:150167359	LRP11	-0.58	-12.59	-0.5	1.88e-31	Lung cancer;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.1	-0.31	4.65e-12	Bipolar disorder;
LGG	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.89	-0.38	1.34e-17	Retinal vascular caliber;
LGG	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg11846333	chr4:119757529	SEC24D	0.84	7.74	0.34	6.52e-14	Cannabis dependence symptom count;
LGG	cis	rs1497828	0.956	rs2646820	chr1:217526479	A/T	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	cis	rs763121	0.853	rs2072794	chr22:39150543	G/T	cg06022373	chr22:39101656	GTPBP1	0.84	15.3	0.58	4.4e-43	Menopause (age at onset);
LGG	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15557168	chr22:42548783	NA	-0.41	-9.08	-0.39	3.12e-18	Cognitive function;
LGG	cis	rs738322	0.555	rs6001027	chr22:38545619	A/G	cg25457927	chr22:38595422	NA	-0.42	-10.49	-0.44	3.11e-23	Cutaneous nevi;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-15.99	-0.6	3.9e-46	Platelet count;
LGG	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.26	-0.32	1.66e-12	Inflammatory bowel disease;
LGG	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg06885757	chr1:42089581	HIVEP3	-0.57	-13.26	-0.52	2.92e-34	Airway imaging phenotypes;
LGG	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs9926296	0.715	rs467035	chr16:89740285	C/G	cg03605463	chr16:89740564	NA	-0.58	-10.41	-0.44	5.84e-23	Vitiligo;
LGG	cis	rs911555	0.755	rs6575988	chr14:103900827	G/T	cg24130564	chr14:104152367	KLC1	0.37	7.01	0.31	8.28e-12	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg13628971	chr7:2884303	GNA12	0.49	9.46	0.4	1.5e-19	Height;
LGG	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg23625390	chr15:77176239	SCAPER	0.42	7.87	0.34	2.58e-14	Blood metabolite levels;
LGG	trans	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg06875740	chr19:51307921	C19orf48	-0.72	-6.78	-0.3	3.62e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6450176	0.909	rs80213371	chr5:53300874	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.16	-0.46	8.79e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.42	-9.62	-0.41	4.39e-20	Oropharynx cancer;
LGG	cis	rs3862030	0.720	rs1056744	chr10:104236687	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.17	-0.43	4.74e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg18402987	chr7:1209562	NA	0.4	7.29	0.32	1.38e-12	Longevity;Endometriosis;
LGG	cis	rs3924048	0.574	rs34494202	chr1:12612868	G/A	cg00291366	chr1:12616550	NA	0.37	9.01	0.39	5.5e-18	Optic cup area;
LGG	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03264133	chr6:25882463	NA	-0.6	-11.42	-0.47	8.52e-27	Blood metabolite levels;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg04166393	chr7:2884313	GNA12	0.45	8.34	0.36	8.67e-16	Height;
LGG	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg09029085	chr17:47094198	IGF2BP1	0.3	7.92	0.35	1.83e-14	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs3820928	1.000	rs10167422	chr2:227777554	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.37	-0.32	8.05e-13	Pulmonary function;
LGG	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.09e-22	Height;
LGG	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.19	-0.39	1.32e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs11711311	1.000	rs11711311	chr3:113430599	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.56	-0.33	2.24e-13	IgG glycosylation;
LGG	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg13010199	chr12:38710504	ALG10B	0.44	8.41	0.36	4.95e-16	Morning vs. evening chronotype;
LGG	cis	rs367615	0.512	rs246104	chr5:108700982	A/C	cg17395555	chr5:108820864	NA	-0.73	-11.55	-0.47	2.62e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14240646	chr10:27532245	ACBD5	-0.55	-8.19	-0.36	2.66e-15	Breast cancer;
LGG	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26571142	chr19:49140646	SEC1;DBP	-0.39	-6.97	-0.31	1.07e-11	Pancreatic cancer;
LGG	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.11	0.52	1.31e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg09033563	chr22:24373618	LOC391322	-0.5	-8.51	-0.37	2.48e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14236043	chr10:45567048	NA	-0.42	-6.96	-0.31	1.19e-11	Menarche (age at onset);
LGG	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg07395648	chr5:131743802	NA	-0.53	-11.2	-0.46	6.42e-26	Breast cancer;Mosquito bite size;
LGG	cis	rs7226408	0.857	rs2034215	chr18:34529163	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.74e-22	Cannabis dependence symptom count;
LGG	trans	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs889398	0.771	rs1500337	chr16:69901884	C/T	cg00738113	chr16:70207722	CLEC18C	0.24	6.85	0.3	2.34e-11	Body mass index;
LGG	cis	rs2236267	0.693	rs2755080	chr14:88595886	A/G	cg18078958	chr14:88630771	NA	-0.29	-6.76	-0.3	4.05e-11	Food antigen IgG levels;
LGG	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg06654118	chr4:1303317	MAEA	0.44	7.58	0.33	1.89e-13	Obesity-related traits;
LGG	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg13607699	chr17:42295918	UBTF	-0.41	-6.65	-0.3	8.53e-11	Total body bone mineral density;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.96	0.31	1.16e-11	Aortic root size;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.59	-10.03	-0.42	1.44e-21	Longevity;Endometriosis;
LGG	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.76	-0.34	5.61e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs10089	1.000	rs2054444	chr5:127493206	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.73	-11.06	-0.46	2.09e-25	Ileal carcinoids;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg15971980	chr6:150254442	NA	0.44	8.22	0.36	1.99e-15	Lung cancer;
LGG	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg02002194	chr4:3960332	NA	0.41	7.21	0.32	2.23e-12	Neuroticism;
LGG	cis	rs17102423	1.000	rs17102423	chr14:65604728	G/T	cg26396452	chr14:65542826	MAX	0.43	8.65	0.37	8.49e-17	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01297674	chr2:122406765	CLASP1	0.45	7.68	0.34	9.37e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs3960554	0.741	rs10232162	chr7:75702505	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.5	5.6e-31	Eotaxin levels;
LGG	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg05890377	chr2:74357713	NA	0.45	9.26	0.4	7.77e-19	Gestational age at birth (maternal effect);
LGG	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.89e-32	Motion sickness;
LGG	cis	rs7106204	0.514	rs12293105	chr11:24256048	T/C	ch.11.24196551F	chr11:24239977	NA	0.97	14.76	0.57	1.09e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9517320	1.000	rs9584857	chr13:99128572	T/C	cg07423050	chr13:99094983	FARP1	0.4	8.06	0.35	6.42e-15	Longevity;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg02429669	chr19:52430771	ZNF613	-0.44	-6.92	-0.31	1.51e-11	Alzheimer's disease (survival time);
LGG	cis	rs793571	0.544	rs12912699	chr15:58917021	T/C	cg05156742	chr15:59063176	FAM63B	0.57	9.87	0.42	5.42e-21	Schizophrenia;
LGG	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg13010199	chr12:38710504	ALG10B	0.56	11.09	0.46	1.59e-25	Heart rate;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg02951883	chr7:2050386	MAD1L1	0.74	15.35	0.58	2.65e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	13.3	0.53	2.14e-34	Prudent dietary pattern;
LGG	cis	rs875971	0.545	rs75577046	chr7:65958716	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.52e-23	Aortic root size;
LGG	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-10.04	-0.42	1.36e-21	Hepatocellular carcinoma;
LGG	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg06766960	chr11:133703094	NA	-0.58	-11.49	-0.47	4.52e-27	Childhood ear infection;
LGG	cis	rs732765	0.734	rs2270424	chr14:75159007	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.5	-6.76	-0.3	4.16e-11	Non-small cell lung cancer;
LGG	cis	rs834603	0.575	rs1704970	chr7:47466512	C/T	cg23694490	chr7:47445681	TNS3	-0.43	-12.21	-0.49	6.17e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08273200	chr1:39338480	MYCBP	0.43	7.01	0.31	8.57e-12	Gut microbiome composition (summer);
LGG	cis	rs4919044	0.641	rs12357515	chr10:94725508	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.09	-0.31	4.92e-12	Coronary artery disease;
LGG	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg06550200	chr5:1325588	CLPTM1L	0.64	11.25	0.46	4.12e-26	Lung cancer;
LGG	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg24375607	chr4:120327624	NA	0.67	10.97	0.45	4.71e-25	Corneal astigmatism;
LGG	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.559	rs6060915	chr20:30330306	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	18.87	0.66	2.45e-59	Mean corpuscular hemoglobin;
LGG	cis	rs9783347	1.000	rs4353250	chr11:18323517	T/C	cg03595886	chr11:18357587	GTF2H1	-0.35	-7.07	-0.31	5.88e-12	Pancreatic cancer;
LGG	cis	rs17221829	0.616	rs75627051	chr11:89360903	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.13	-0.39	2.19e-18	Anxiety in major depressive disorder;
LGG	trans	rs9329221	0.736	rs2001337	chr8:10251154	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.42	0.33	5.78e-13	Neuroticism;
LGG	cis	rs2742417	1.000	rs2673057	chr3:45735730	A/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.39	-0.32	6.87e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07988820	chr12:82153109	PPFIA2	-0.79	-12.13	-0.49	1.41e-29	Resting heart rate;
LGG	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg21055462	chr7:100276975	NA	0.35	6.78	0.3	3.71e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs243505	0.660	rs3779037	chr7:148539323	T/C	cg18940274	chr7:148469757	CUL1	-0.35	-6.66	-0.3	7.98e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	2.03e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg15971980	chr6:150254442	NA	0.47	8.56	0.37	1.71e-16	Lung cancer;
LGG	cis	rs11792861	0.591	rs10979613	chr9:111687584	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	12.06	0.49	2.66e-29	Menarche (age at onset);
LGG	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg08847335	chr10:891726	LARP4B	-0.54	-9.11	-0.39	2.45e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg06374794	chr16:88002281	BANP	0.45	8.46	0.37	3.59e-16	Menopause (age at onset);
LGG	cis	rs2013441	1.000	rs2703787	chr17:20158665	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6.11e-11	Obesity-related traits;
LGG	cis	rs763121	0.853	rs35565791	chr22:39063011	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs17253792	0.915	rs78498383	chr14:56177585	C/T	cg01858014	chr14:56050164	KTN1	-0.8	-10.36	-0.43	9.02e-23	Putamen volume;
LGG	cis	rs1801251	1.000	rs1801251	chr2:233633460	G/A	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	4.96e-19	Coronary artery disease;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.59	-0.41	5.45e-20	Lung cancer;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg22907277	chr7:1156413	C7orf50	0.43	7.66	0.34	1.09e-13	Longevity;Endometriosis;
LGG	cis	rs1801251	0.711	rs2592117	chr2:233735693	C/T	cg25237894	chr2:233734115	C2orf82	-0.73	-15.72	-0.59	6.54e-45	Coronary artery disease;
LGG	cis	rs2635047	0.638	rs2571002	chr18:44665052	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.1	0.31	4.84e-12	Educational attainment;
LGG	cis	rs67311347	0.544	rs7652439	chr3:40349948	G/T	cg13683864	chr3:40499215	RPL14	-0.61	-9.32	-0.4	4.86e-19	Renal cell carcinoma;
LGG	cis	rs17376456	0.542	rs1453003	chr5:93151611	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.71	-9.54	-0.41	8.02e-20	Diabetic retinopathy;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg25072359	chr17:41440525	NA	0.52	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.35	-0.43	1.03e-22	Tonsillectomy;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.75e-12	Lung cancer;
LGG	cis	rs6763768	0.962	rs3774414	chr3:53532755	A/G	cg16894138	chr3:53270350	TKT	-0.35	-6.77	-0.3	3.99e-11	Bacterial meningitis;
LGG	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg05639522	chr1:247681581	NA	0.6	10.29	0.43	1.6400000000000001e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg16141378	chr3:129829833	LOC729375	-0.47	-11.73	-0.48	5.13e-28	Systolic blood pressure;
LGG	cis	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg22920501	chr2:26401640	FAM59B	0.45	8.98	0.38	7.09e-18	Gut microbiome composition (summer);
LGG	cis	rs4423214	0.802	rs2276358	chr11:71184498	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg21559469	chr19:19431446	KIAA0892;SF4	0.6	6.98	0.31	1.06e-11	Nonalcoholic fatty liver disease;
LGG	cis	rs4696584	0.581	rs1552639	chr4:155402499	G/A	cg13738195	chr4:155413469	DCHS2	-0.37	-7.43	-0.33	5.32e-13	Folding of antihelix;
LGG	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg20821713	chr7:1055600	C7orf50	-0.51	-8.02	-0.35	8.72e-15	Bronchopulmonary dysplasia;
LGG	cis	rs3785574	0.962	rs9944483	chr17:61783553	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	-0.54	-8.71	-0.38	5.36e-17	Height;
LGG	cis	rs12210905	0.844	rs7773336	chr6:26993555	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.56	0.37	1.63e-16	Platelet count;
LGG	cis	rs644799	0.710	rs56384142	chr11:95502075	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.65	0.63	1.1e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7953508	0.506	rs1316740	chr12:93968288	C/A	cg18151635	chr12:93972918	NA	-0.56	-10.37	-0.43	8.2000000000000006e-23	Pubertal anthropometrics;
LGG	trans	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg25214090	chr10:38739885	LOC399744	0.56	10.38	0.43	7.62e-23	Educational attainment;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.18e-14	Restless legs syndrome;
LGG	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.14	-25.34	-0.76	1.61e-89	Primary sclerosing cholangitis;
LGG	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.86	0.3	2.21e-11	Glycated hemoglobin levels;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg21862992	chr11:68658383	NA	0.45	7.79	0.34	4.46e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg11161011	chr14:65562177	MAX	-0.63	-11.97	-0.49	5.8e-29	Obesity-related traits;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg18350739	chr11:68623251	NA	-0.87	-22.1	-0.72	2.07e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.98	0.31	1.04e-11	Lung cancer;
LGG	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg17108064	chr15:78857060	CHRNA5	-0.46	-10.03	-0.42	1.49e-21	Sudden cardiac arrest;
LGG	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-11.65	-0.48	1.09e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs9868809	0.772	rs2302295	chr3:48690110	T/C	cg00383909	chr3:49044727	WDR6	0.82	9.76	0.41	1.38e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9341835	0.709	rs9359467	chr6:64154975	G/C	cg00787780	chr6:64151745	NA	0.41	7.56	0.33	2.22e-13	Schizophrenia;
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.67	-0.54	5.8e-36	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07618175	chr6:163834452	QKI	0.42	6.7	0.3	6.15e-11	Cognitive performance;
LGG	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg24331049	chr13:111365604	ING1	0.92	16.83	0.62	6.43e-50	Coronary artery disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg00130309	chr20:25677623	ZNF337	-0.4	-6.92	-0.31	1.5e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.35	-0.36	7.7e-16	Mean corpuscular volume;
LGG	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg11812906	chr14:75593930	NEK9	0.46	8.5	0.37	2.53e-16	Height;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg00106254	chr7:1943704	MAD1L1	0.46	8.46	0.37	3.43e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg03452623	chr4:187889614	NA	-1.04	-29.28	-0.81	2.08e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg11871910	chr12:69753446	YEATS4	0.81	13.73	0.54	3.16e-36	Response to diuretic therapy;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg01238044	chr22:24384105	GSTT1	-0.47	-7.97	-0.35	1.27e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs950169	0.922	rs11639244	chr15:84832650	G/A	cg24253500	chr15:84953950	NA	0.56	10.29	0.43	1.73e-22	Schizophrenia;
LGG	cis	rs9487094	0.961	rs9480948	chr6:109728351	A/G	cg16315928	chr6:109776240	MICAL1	0.55	9.33	0.4	4.33e-19	Height;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.35	0.53	1.24e-34	Obesity-related traits;
LGG	cis	rs765787	0.530	rs28897155	chr15:45533974	T/C	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.61	-0.33	1.5700000000000001e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6542826	0.510	rs7600011	chr2:110046399	C/T	cg20706049	chr2:110026630	SH3RF3	0.32	7.56	0.33	2.15e-13	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs72945132	0.882	rs12295111	chr11:70131882	C/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs783147	0.652	rs1782627	chr6:161196800	A/G	cg01280913	chr6:161186852	NA	0.35	7.4	0.33	6.33e-13	Lp (a) levels;
LGG	cis	rs1978968	0.731	rs9605466	chr22:18461056	A/T	cg03078520	chr22:18463400	MICAL3	-0.68	-14.66	-0.56	3.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg04772025	chr11:68637568	NA	0.74	13.07	0.52	1.92e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4774899	0.837	rs10518894	chr15:57403598	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.66	-0.3	7.69e-11	Urinary tract infection frequency;
LGG	cis	rs3806843	0.548	rs246056	chr5:140325600	G/A	cg19875535	chr5:140030758	IK	0.37	7.41	0.33	5.92e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2845885	0.793	rs56241103	chr11:63882364	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.69	8.27	0.36	1.46e-15	Body mass index;
LGG	cis	rs593982	1.000	rs56257941	chr11:65505641	C/T	cg08755490	chr11:65554678	OVOL1	-0.74	-10.4	-0.44	6.45e-23	Atopic dermatitis;
LGG	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22857025	chr5:266934	NA	-1.41	-12.65	-0.51	9.96e-32	Breast cancer;
LGG	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg18252515	chr7:66147081	NA	-1.37	-19.11	-0.66	1.82e-60	Diabetic kidney disease;
LGG	cis	rs11264213	0.901	rs7542179	chr1:36461122	A/G	cg27506609	chr1:36549197	TEKT2	-0.58	-7.09	-0.31	5.21e-12	Schizophrenia;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04575467	chr8:41997444	NA	0.37	6.68	0.3	6.76e-11	Body mass index;
LGG	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.4	7.17	0.32	2.94e-12	Cystic fibrosis severity;
LGG	cis	rs963731	0.649	rs1377861	chr2:39293858	T/C	cg04010122	chr2:39346883	SOS1	-0.82	-7.62	-0.33	1.49e-13	Corticobasal degeneration;
LGG	cis	rs13424612	0.896	rs12466838	chr2:240893427	G/A	cg01812947	chr2:240904978	NDUFA10	0.43	7.1	0.31	4.82e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs9487094	0.961	rs752262	chr6:109770999	G/C	cg16315928	chr6:109776240	MICAL1	0.57	9.62	0.41	4.38e-20	Height;
LGG	cis	rs9815354	1.000	rs1716685	chr3:41925301	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.62e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9462027	0.628	rs9469891	chr6:34767396	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs11875185	0.510	rs75988376	chr18:55635377	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-6.86	-0.3	2.19e-11	Height;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs892961	0.836	rs8071497	chr17:75414358	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.19	0.43	3.85e-22	Airflow obstruction;
LGG	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6912958	0.967	rs6914299	chr6:88149176	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.83	-0.45	1.62e-24	Monocyte percentage of white cells;
LGG	cis	rs35160687	0.901	rs13017338	chr2:86501553	T/C	cg10973622	chr2:86423274	IMMT	0.39	6.67	0.3	7.11e-11	Night sleep phenotypes;
LGG	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg05163923	chr11:71159392	DHCR7	0.72	14.01	0.55	2.03e-37	Vitamin D levels;
LGG	cis	rs9303401	0.573	rs67378767	chr17:57194237	G/T	cg25039879	chr17:56429692	SUPT4H1	0.58	8.22	0.36	2e-15	Cognitive test performance;
LGG	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg12924262	chr12:102091054	CHPT1	0.65	12.85	0.51	1.59e-32	Blood protein levels;
LGG	cis	rs9326248	0.530	rs11216171	chr11:116749113	T/A	cg20608306	chr11:116969690	SIK3	0.3	7.67	0.34	1.04e-13	Blood protein levels;
LGG	cis	rs34929064	0.846	rs2905340	chr7:22727198	G/A	cg18045685	chr7:22629474	NA	-0.52	-9.35	-0.4	3.72e-19	Major depression and alcohol dependence;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg06532163	chr17:45867833	NA	0.53	7.91	0.35	1.91e-14	IgG glycosylation;
LGG	cis	rs12136530	0.593	rs881246	chr1:19733255	C/A	cg17081867	chr1:19768096	CAPZB	-0.32	-6.7	-0.3	6.01e-11	Lead levels in blood;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg25937216	chr8:58172855	NA	-0.58	-9.36	-0.4	3.53e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs28588043	0.702	rs56053729	chr1:170986415	G/T	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg03433033	chr1:76189801	ACADM	0.83	15.41	0.58	1.56e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg04469686	chr1:162760199	HSD17B7	0.4	6.67	0.3	7.38e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7927771	0.507	rs12366244	chr11:47882130	C/A	cg20307385	chr11:47447363	PSMC3	0.57	11.14	0.46	1.05e-25	Subjective well-being;
LGG	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg07541023	chr7:19748670	TWISTNB	0.47	7.4	0.33	6.47e-13	Thyroid stimulating hormone;
LGG	trans	rs7937682	0.855	rs539553	chr11:111477333	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.09	0.39	2.83e-18	Primary sclerosing cholangitis;
LGG	cis	rs9398803	0.865	rs2130603	chr6:126826819	A/C	cg19875578	chr6:126661172	C6orf173	0.56	10.22	0.43	2.95e-22	Male-pattern baldness;
LGG	cis	rs17655565	0.533	rs12825729	chr12:52706854	G/A	cg08257133	chr12:52711352	KRT83	0.64	13.43	0.53	6.01e-35	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs1348850	0.597	rs4893964	chr2:178447658	G/T	cg27490568	chr2:178487706	NA	0.65	11.6	0.47	1.81e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17401966	0.838	rs2105212	chr1:10281012	T/C	cg15208524	chr1:10270712	KIF1B	0.45	7.8	0.34	4.08e-14	Hepatocellular carcinoma;
LGG	cis	rs10769945	0.605	rs656757	chr11:1966106	G/A	cg15394860	chr11:2017084	H19	0.53	11.2	0.46	6.4e-26	DNA methylation (variation);
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg23302884	chr18:44338147	ST8SIA5	0.45	9.06	0.39	3.73e-18	Personality dimensions;
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs3206736	0.548	rs73110557	chr7:35068057	T/C	cg13400248	chr7:35225412	NA	0.55	9.51	0.4	1.07e-19	Diastolic blood pressure;
LGG	cis	rs7923609	0.756	rs6479908	chr10:65333648	C/G	cg02276361	chr10:65351566	REEP3	-0.31	-6.9	-0.31	1.67e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs5769765	0.955	rs4075330	chr22:50303249	G/A	cg02269571	chr22:50332266	NA	-0.66	-10.44	-0.44	4.6e-23	Schizophrenia;
LGG	trans	rs8073060	0.559	rs72829925	chr17:34049778	C/A	cg19694781	chr19:47549865	TMEM160	1.16	18.04	0.64	1.79e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	11.71	0.48	6.3e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs11758351	0.500	rs76607472	chr6:26191557	C/T	cg02612650	chr6:26195910	NA	0.88	6.84	0.3	2.54e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9747201	1.000	rs12943668	chr17:80109930	C/T	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2236267	0.726	rs1940532	chr14:88612417	C/T	cg18078958	chr14:88630771	NA	0.3	7.02	0.31	8.11e-12	Food antigen IgG levels;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.5e-16	Lung cancer;
LGG	cis	rs1018836	0.884	rs2073640	chr8:91594853	A/G	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	4.7e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.53	-0.44	2.23e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.54	0.53	2.05e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs61931739	0.853	rs10844751	chr12:34099651	T/G	cg06521331	chr12:34319734	NA	0.41	7.4	0.33	6.65e-13	Morning vs. evening chronotype;
LGG	cis	rs17445240	0.515	rs6760466	chr2:3707136	T/C	cg20720597	chr2:3699334	NA	0.6	8.24	0.36	1.8e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7312774	0.609	rs2374656	chr12:107380411	A/C	cg16260113	chr12:107380972	MTERFD3	0.92	7.1	0.31	4.66e-12	Severe influenza A (H1N1) infection;
LGG	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg24692254	chr21:30365293	RNF160	-0.73	-14.21	-0.55	2.77e-38	Dental caries;
LGG	cis	rs1550582	0.548	rs11538239	chr8:135490539	A/G	cg09855544	chr8:135498122	ZFAT	-0.51	-7.88	-0.34	2.4e-14	Educational attainment;
LGG	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg03060546	chr3:49711283	APEH	0.57	8.79	0.38	3.03e-17	Resting heart rate;
LGG	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07080220	chr10:102295463	HIF1AN	0.64	10.96	0.45	5.04e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8017423	0.967	rs11159957	chr14:90715972	A/G	cg04374321	chr14:90722782	PSMC1	-0.86	-17.76	-0.64	3.56e-54	Mortality in heart failure;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-8.84	-0.38	2e-17	Lung cancer;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg24315188	chr7:77428849	PHTF2;TMEM60	-0.42	-6.71	-0.3	5.81e-11	Height;
LGG	cis	rs3540	0.883	rs6496676	chr15:90988384	A/T	cg22089800	chr15:90895588	ZNF774	0.49	7.55	0.33	2.39e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2404618	0.653	rs28412344	chr8:1460750	G/A	cg13402656	chr8:1511478	DLGAP2	-0.67	-11.85	-0.48	1.8e-28	Lung cancer;
LGG	cis	rs8072100	0.870	rs10432035	chr17:45624913	G/C	cg25173405	chr17:45401733	C17orf57	0.46	7.89	0.34	2.13e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg02002194	chr4:3960332	NA	0.43	7.56	0.33	2.21e-13	Neuroticism;
LGG	cis	rs2273669	0.667	rs12215344	chr6:109329641	A/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg23978390	chr7:1156363	C7orf50	0.44	7.36	0.32	8.36e-13	Longevity;Endometriosis;
LGG	cis	rs112591243	0.685	rs78463142	chr21:47964481	A/G	cg10657630	chr21:48055338	PRMT2	0.87	7.53	0.33	2.64e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg04772025	chr11:68637568	NA	0.74	13.31	0.53	1.87e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7202877	0.706	rs37605	chr16:75506572	G/C	cg03315344	chr16:75512273	CHST6	-0.5	-6.69	-0.3	6.5e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs1957429	0.520	rs72625648	chr14:65344602	A/G	cg23373153	chr14:65346875	NA	-0.97	-9.81	-0.41	9.32e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg07243736	chr16:783730	NARFL	0.42	7.21	0.32	2.22e-12	Height;
LGG	cis	rs10911363	0.592	rs2702203	chr1:183462513	A/T	cg23894439	chr1:183413866	NA	0.49	9.21	0.39	1.18e-18	Systemic lupus erythematosus;
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg18876405	chr7:65276391	NA	-0.55	-9.78	-0.41	1.2e-20	Aortic root size;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg00106254	chr7:1943704	MAD1L1	0.43	7.58	0.33	1.93e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1691799	0.867	rs1168309	chr12:66726439	A/G	cg16791601	chr12:66731901	HELB	0.67	15.92	0.59	8.02e-46	White blood cell count (basophil);
LGG	cis	rs721399	0.539	rs2898476	chr8:18266924	G/A	cg18736775	chr8:18248649	NAT2	-0.76	-11.4	-0.47	1.05e-26	Blood metabolite levels;
LGG	trans	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg02002194	chr4:3960332	NA	0.38	6.96	0.31	1.19e-11	Joint mobility (Beighton score);
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg08461457	chr11:2027003	NA	0.39	7.64	0.33	1.22e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg15596359	chr8:11213517	TDH	-0.4	-8.13	-0.35	3.95e-15	Retinal vascular caliber;
LGG	cis	rs2734839	0.537	rs6277	chr11:113283459	G/A	cg14159747	chr11:113255604	NA	0.31	8.31	0.36	1.08e-15	Information processing speed;
LGG	cis	rs11690935	0.959	rs11897196	chr2:172585595	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22037798	chr1:231473786	C1orf124;EXOC8	0.55	9.08	0.39	3.19e-18	Cognitive performance;
LGG	cis	rs1185460	0.967	rs1784460	chr11:118938371	A/T	cg23280166	chr11:118938394	VPS11	-0.62	-11.79	-0.48	3.2e-28	Coronary artery disease;
LGG	cis	rs8064029	0.803	rs11861487	chr16:4872760	A/G	cg04440724	chr16:4920505	UBN1	0.56	6.79	0.3	3.46e-11	Cancer;
LGG	trans	rs208520	0.690	rs1885100	chr6:66871047	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.76	-0.64	3.27e-54	Exhaled nitric oxide output;
LGG	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg00339695	chr16:24857497	SLC5A11	-0.4	-6.77	-0.3	3.85e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.16	0.32	3.21e-12	Prudent dietary pattern;
LGG	cis	rs6594499	0.872	rs10045255	chr5:110438357	C/T	cg04022379	chr5:110408740	TSLP	-0.4	-7.46	-0.33	4.19e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7762018	0.607	rs79355059	chr6:170062157	T/C	cg06875740	chr19:51307921	C19orf48	-0.66	-6.83	-0.3	2.66e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.43e-15	Bipolar disorder;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13012163	chr14:23235724	OXA1L	0.39	6.92	0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs941873	0.868	rs7332	chr10:81114060	G/A	cg09469691	chr10:81107165	PPIF	0.63	11.2	0.46	6.02e-26	Height;
LGG	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.62	-10.53	-0.44	2.16e-23	Colonoscopy-negative controls vs population controls;
LGG	cis	rs59197085	0.636	rs58320939	chr7:128462843	T/A	cg00734629	chr7:128471146	FLNC	0.34	6.98	0.31	1.03e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs2345546	1	rs2345546	chr16:25427472	C/T	cg08360281	chr16:25269390	ZKSCAN2	0.88	11.13	0.46	1.2e-25	Major depression and alcohol dependence;
LGG	cis	rs2153535	0.580	rs6597326	chr6:8482019	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs2708977	0.637	rs597420	chr2:97070353	T/C	cg01950434	chr2:97203154	ARID5A	-0.46	-6.99	-0.31	9.81e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.75	-0.41	1.52e-20	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	11.58	0.47	2.17e-27	Lung cancer in ever smokers;
LGG	cis	rs4330281	0.631	rs11128836	chr3:17683892	T/C	cg20981856	chr3:17787350	NA	-0.38	-7.0	-0.31	9.09e-12	Schizophrenia;
LGG	cis	rs2243480	0.522	rs1638736	chr7:66092308	A/T	cg18252515	chr7:66147081	NA	-1.26	-14.03	-0.55	1.63e-37	Diabetic kidney disease;
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.2	-0.32	2.46e-12	Bipolar disorder;
LGG	cis	rs10880689	1	rs10880689	chr12:37930102	A/G	cg13010199	chr12:38710504	ALG10B	0.65	13.38	0.53	9.09e-35	Resting heart rate;
LGG	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg00290607	chr11:67383545	NA	-0.5	-8.98	-0.39	6.87e-18	Mean corpuscular volume;
LGG	cis	rs3847687	1.000	rs3847687	chr12:131525053	C/T	cg06093039	chr12:131527216	GPR133	0.28	7.2	0.32	2.48e-12	Longevity;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.72	-0.45	4.23e-24	Lung cancer;
LGG	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg16586182	chr3:47516702	SCAP	-0.57	-9.68	-0.41	2.57e-20	Birth weight;
LGG	cis	rs236907	0.640	rs235875	chr1:171613756	A/G	cg01410279	chr1:171621941	MYOC	0.4	6.74	0.3	4.69e-11	Mean platelet volume;
LGG	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg11871910	chr12:69753446	YEATS4	0.42	6.71	0.3	5.65e-11	Response to diuretic therapy;
LGG	cis	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs13082711	0.522	rs640065	chr3:27363937	A/T	cg02860705	chr3:27208620	NA	0.52	9.18	0.39	1.39e-18	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.89	0.45	9.96e-25	Aortic root size;
LGG	cis	rs9796	0.870	rs2927061	chr15:41302219	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.46	-7.8	-0.34	4e-14	Menopause (age at onset);
LGG	cis	rs5743618	0.537	rs28413898	chr4:38768669	A/G	cg06935464	chr4:38784597	TLR10	0.37	6.74	0.3	4.61e-11	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg14391382	chr7:866102	UNC84A	0.53	9.24	0.39	9.11e-19	Subjective well-being;
LGG	cis	rs17428076	0.794	rs62182446	chr2:172821223	G/A	cg21435375	chr2:172878103	MAP1D	0.41	7.58	0.33	1.92e-13	Myopia;
LGG	trans	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.604	rs2853116	chr11:133707063	A/G	cg15485101	chr11:133734466	NA	0.59	10.39	0.43	7.41e-23	Childhood ear infection;
LGG	cis	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg25885449	chr18:77638415	KCNG2	0.42	8.89	0.38	1.38e-17	Schizophrenia;
LGG	cis	rs67385638	0.962	rs72872549	chr11:5290053	C/T	cg12559170	chr11:5275217	HBG2	0.58	13.08	0.52	1.72e-33	Hemoglobin levels;
LGG	cis	rs988958	0.526	rs10177811	chr2:42263580	G/A	cg19376973	chr2:42229025	NA	0.68	9.54	0.41	8.06e-20	Hypospadias;
LGG	cis	rs1843834	0.721	rs1601730	chr2:225590153	G/A	cg22455342	chr2:225449267	CUL3	0.49	8.34	0.36	8.34e-16	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.96	-0.35	1.32e-14	IgG glycosylation;
LGG	trans	rs853679	0.599	rs188015	chr6:27877446	T/A	cg08344181	chr3:125677491	NA	-0.68	-7.98	-0.35	1.15e-14	Depression;
LGG	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs7241530	0.662	rs35308826	chr18:75903736	T/C	cg14642773	chr18:75888474	NA	0.47	9.31	0.4	5.36e-19	Educational attainment (years of education);
LGG	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg16414030	chr3:133502952	NA	-0.52	-8.33	-0.36	9.28e-16	Iron status biomarkers;
LGG	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-12.39	-0.5	1.21e-30	Menarche (age at onset);
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4819852	0.958	rs2238787	chr22:19976406	G/A	cg07821417	chr22:19972146	ARVCF	0.62	13.05	0.52	2.3e-33	Pulse pressure;
LGG	cis	rs1318772	0.932	rs11739848	chr5:112948757	A/G	cg12552261	chr5:112820674	MCC	0.64	7.3	0.32	1.23e-12	F-cell distribution;
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28680850	0.541	rs4876041	chr8:1370441	T/C	cg06035437	chr8:1398411	NA	-0.64	-9.04	-0.39	4.24e-18	Triglycerides;
LGG	cis	rs7927771	0.524	rs6485763	chr11:47627302	C/T	cg20307385	chr11:47447363	PSMC3	0.58	11.4	0.47	1.08e-26	Subjective well-being;
LGG	trans	rs11875185	0.510	rs75621165	chr18:55647204	A/G	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.7e-51	Morning vs. evening chronotype;
LGG	cis	rs10751667	0.666	rs6597967	chr11:950583	G/T	cg22143635	chr11:980567	AP2A2	0.42	7.77	0.34	5.17e-14	Alzheimer's disease (late onset);
LGG	cis	rs929354	0.713	rs7798816	chr7:156940574	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg22348356	chr13:114891224	RASA3	0.41	7.88	0.34	2.42e-14	Schizophrenia;
LGG	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.22	0.32	2.09e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12477438	0.520	rs2309604	chr2:100090098	A/G	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg22426938	chr7:1423890	NA	-0.64	-8.79	-0.38	3e-17	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs3733585	0.674	rs7375643	chr4:9955239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.15	-0.39	1.8e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.88e-27	Corneal astigmatism;
LGG	cis	rs4589502	0.800	rs12595796	chr15:67202599	A/G	cg18595228	chr15:67193261	NA	-0.49	-6.78	-0.3	3.71e-11	Lung cancer (smoking interaction);
LGG	cis	rs12681288	0.550	rs59004371	chr8:962393	T/C	cg08648136	chr8:956695	NA	0.44	9.39	0.4	2.76e-19	Schizophrenia;
LGG	cis	rs372883	0.507	rs8132992	chr21:30750561	T/C	cg08807101	chr21:30365312	RNF160	0.54	8.94	0.38	9.64e-18	Pancreatic cancer;
LGG	trans	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg06521331	chr12:34319734	NA	0.46	8.09	0.35	5.2e-15	Bladder cancer;
LGG	cis	rs8133932	0.906	rs77809339	chr21:47097331	G/A	cg11214348	chr21:47283868	PCBP3	-0.43	-7.12	-0.31	4.13e-12	Schizophrenia;
LGG	cis	rs1830074	1	rs1830074	chr7:6718674	T/C	cg09896999	chr7:6746977	ZNF12	-0.55	-8.89	-0.38	1.33e-17	Body mass index;
LGG	cis	rs7580658	0.509	rs12477653	chr2:127952081	C/T	cg10021288	chr2:128175891	PROC	-0.44	-8.53	-0.37	2.1e-16	Protein C levels;
LGG	cis	rs11083475	0.714	rs7248584	chr19:39258110	C/T	cg07403899	chr19:39283540	NA	-0.24	-6.89	-0.3	1.88e-11	Heart rate;
LGG	trans	rs28735056	1.000	rs56376220	chr18:77609462	C/T	cg05926928	chr17:57297772	GDPD1	-0.5	-7.78	-0.34	4.81e-14	Schizophrenia;
LGG	cis	rs1007190	0.881	rs11079378	chr17:42957462	A/G	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9640161	0.750	rs4395803	chr7:150025367	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.8	-17.06	-0.62	5.74e-51	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg26384229	chr12:38710491	ALG10B	0.82	16.67	0.61	3.36e-49	Morning vs. evening chronotype;
LGG	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg13660082	chr14:53194042	PSMC6	-0.55	-8.11	-0.35	4.65e-15	Alzheimer's disease (late onset);
LGG	cis	rs12282928	0.729	rs7932309	chr11:48345179	T/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.29	-0.4	5.99e-19	Triglycerides;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.56	-0.37	1.65e-16	Neuroticism;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg16405210	chr4:1374714	KIAA1530	-0.48	-8.2	-0.36	2.39e-15	Obesity-related traits;
LGG	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg09324608	chr17:30823087	MYO1D	0.28	6.68	0.3	6.83e-11	Schizophrenia;
LGG	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.9	-0.38	1.28e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg27490568	chr2:178487706	NA	0.57	11.03	0.46	2.79e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	9.4	0.4	2.53e-19	Lung cancer in ever smokers;
LGG	cis	rs6120849	0.754	rs6087667	chr20:33651887	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs8103771	0.826	rs3865481	chr19:54352596	A/G	cg11662224	chr19:54385416	PRKCG	-0.74	-6.77	-0.3	3.86e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.33	0.43	1.19e-22	Diabetic retinopathy;
LGG	cis	rs870825	0.616	rs12502860	chr4:185636105	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg13206674	chr6:150067644	NUP43	0.66	14.92	0.57	2.16e-41	Lung cancer;
LGG	cis	rs1003719	0.582	rs2835634	chr21:38528270	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.32	-0.58	3.59e-43	Eye color traits;
LGG	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg12395012	chr8:11607386	GATA4	-0.37	-6.7	-0.3	6.01e-11	Mood instability;
LGG	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.43	-0.4	1.91e-19	Neuroticism;
LGG	cis	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.17	0.35	3.02e-15	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1120392	chr6:8487053	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.29	0.55	1.21e-38	IgG glycosylation;
LGG	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg12982090	chr3:42733453	KBTBD5	0.95	15.57	0.59	2.87e-44	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs36051895	0.659	rs67006981	chr9:5070401	A/G	cg02405213	chr9:5042618	JAK2	-0.83	-15.83	-0.59	1.99e-45	Pediatric autoimmune diseases;
LGG	cis	rs72781680	0.898	rs7563564	chr2:23993404	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12379764	chr21:47803548	PCNT	-0.58	-8.98	-0.39	6.75e-18	Testicular germ cell tumor;
LGG	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.75	-0.34	5.71e-14	Mean corpuscular volume;
LGG	cis	rs17384381	0.953	rs12130145	chr1:85828970	G/C	cg16011679	chr1:85725395	C1orf52	0.62	10.58	0.44	1.41e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9611519	0.780	rs5751071	chr22:41656332	G/A	cg06634786	chr22:41940651	POLR3H	-0.52	-8.65	-0.37	8.21e-17	Neuroticism;
LGG	trans	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg07211511	chr3:129823064	LOC729375	-0.65	-9.04	-0.39	4.37e-18	Blood pressure (smoking interaction);
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg11050988	chr7:1952600	MAD1L1	-0.39	-9.36	-0.4	3.4e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.17	-0.39	1.51e-18	Lung cancer;
LGG	cis	rs78487399	0.808	rs6752448	chr2:43682596	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg18402987	chr7:1209562	NA	0.4	7.3	0.32	1.27e-12	Longevity;Endometriosis;
LGG	cis	rs9486715	0.867	rs4839834	chr6:96882109	C/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17227506	0.630	rs67670052	chr8:13443474	G/C	cg03566418	chr8:13424080	C8orf48	0.63	10.01	0.42	1.81e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1059312	0.808	rs12816551	chr12:129295616	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.73	-0.69	5.16e-68	Systemic lupus erythematosus;
LGG	cis	rs889312	0.500	rs252903	chr5:56117952	A/G	cg12654349	chr5:56205094	C5orf35	-0.38	-6.75	-0.3	4.38e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.65e-12	Mean corpuscular hemoglobin;
LGG	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg20608306	chr11:116969690	SIK3	-0.38	-10.38	-0.43	7.79e-23	Subjective well-being;
LGG	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18252515	chr7:66147081	NA	-0.44	-7.52	-0.33	2.84e-13	Aortic root size;
LGG	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg21605333	chr4:119757512	SEC24D	1.49	15.01	0.57	8.47e-42	Cannabis dependence symptom count;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg22968622	chr17:43663579	NA	1.08	21.13	0.7	6.78e-70	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9308433	0.529	rs55760458	chr1:214491536	G/C	cg06198575	chr1:214491504	SMYD2	0.51	7.81	0.34	3.99e-14	IgG glycosylation;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg06719900	chr11:109292894	C11orf87	0.74	14.94	0.57	1.89e-41	Schizophrenia;
LGG	cis	rs6735179	0.579	rs13396623	chr2:1758481	T/C	cg08534653	chr2:1747700	PXDN	0.45	7.04	0.31	6.97e-12	Response to antipsychotic treatment;
LGG	cis	rs889398	0.594	rs2133799	chr16:69913026	C/T	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.45	-0.33	4.62e-13	Body mass index;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	cis	rs950169	0.579	rs881983	chr15:84647308	C/T	cg24253500	chr15:84953950	NA	0.44	7.12	0.31	4.19e-12	Schizophrenia;
LGG	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.38e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6582630	0.555	rs6582503	chr12:38557886	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.59	-0.37	1.38e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs11771526	0.710	rs7804577	chr7:32373104	A/G	cg27511599	chr7:32358540	NA	0.6	7.06	0.31	5.97e-12	Body mass index;
LGG	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg18252515	chr7:66147081	NA	-0.44	-7.66	-0.34	1.09e-13	Aortic root size;
LGG	cis	rs9467773	1.000	rs6910899	chr6:26524339	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.41	0.4	2.33e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11785400	0.793	rs11785012	chr8:143748355	G/A	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.07e-14	Schizophrenia;
LGG	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21582582	chr3:182698605	DCUN1D1	0.39	6.9	0.31	1.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs733592	0.504	rs2261608	chr12:48721634	A/T	cg24011408	chr12:48396354	COL2A1	0.69	11.53	0.47	3.15e-27	Plateletcrit;
LGG	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.69	0.59	8.26e-45	Prostate cancer;
LGG	cis	rs4538187	1.000	rs4538187	chr2:64103741	C/T	cg19915305	chr2:64069682	UGP2	0.68	15.55	0.59	3.54e-44	Systolic blood pressure;
LGG	cis	rs8072100	1.000	rs4794048	chr17:45763073	A/C	cg25173405	chr17:45401733	C17orf57	-0.48	-8.37	-0.36	7e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1018836	0.886	rs7817954	chr8:91535105	G/A	cg16814680	chr8:91681699	NA	-0.78	-13.93	-0.54	4.36e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg20368463	chr18:77673604	PQLC1	-0.48	-8.22	-0.36	2.13e-15	Schizophrenia;
LGG	cis	rs6750047	0.932	rs11124631	chr2:38274908	A/G	cg07380506	chr2:38303506	CYP1B1	-0.44	-7.51	-0.33	3.15e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs1975974	1.000	rs111981054	chr17:21725592	C/G	cg18423549	chr17:21743878	NA	-0.46	-6.66	-0.3	7.75e-11	Psoriasis;
LGG	cis	rs2299587	0.582	rs10112000	chr8:17910669	G/A	cg18067069	chr8:17937731	ASAH1	-0.34	-8.15	-0.35	3.54e-15	Economic and political preferences;
LGG	cis	rs7155454	0.935	rs4466998	chr14:65475540	C/A	cg26396452	chr14:65542826	MAX	0.36	6.83	0.3	2.73e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs6674970	0.541	rs2902811	chr1:151010521	G/C	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.65	-9.58	-0.41	6.16e-20	Childhood ear infection;
LGG	trans	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg25214090	chr10:38739885	LOC399744	0.62	10.74	0.45	3.68e-24	Corneal astigmatism;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg08645402	chr16:4508243	NA	-0.47	-8.26	-0.36	1.49e-15	Schizophrenia;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg09264619	chr17:80180166	NA	0.37	7.4	0.33	6.62e-13	Life satisfaction;
LGG	cis	rs2073300	0.609	rs6137939	chr20:23390206	C/T	cg12062639	chr20:23401060	NAPB	-0.93	-9.03	-0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.61	-0.33	1.52e-13	Joint mobility (Beighton score);
LGG	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg06951627	chr6:26196580	NA	0.47	7.02	0.31	7.91e-12	Gout;Renal underexcretion gout;
LGG	cis	rs4356203	0.905	rs7946165	chr11:17078627	T/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg14541582	chr5:601475	NA	-0.68	-10.59	-0.44	1.28e-23	Obesity-related traits;
LGG	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg06634786	chr22:41940651	POLR3H	0.77	12.68	0.51	7.55e-32	Vitiligo;
LGG	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Myopia (pathological);
LGG	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.9	-0.45	8.91e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg16482183	chr6:26056742	HIST1H1C	0.69	9.29	0.4	5.88e-19	Iron status biomarkers;
LGG	cis	rs2276314	0.857	rs28530656	chr18:33588700	C/T	cg05985134	chr18:33552581	C18orf21	-0.63	-10.18	-0.43	4.22e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7172689	1.000	rs6495553	chr15:81532069	T/C	cg11808699	chr15:81528661	IL16	-0.48	-9.91	-0.42	3.95e-21	Inattentive symptoms;
LGG	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.85	-0.34	2.83e-14	Retinal vascular caliber;
LGG	cis	rs10870270	1.000	rs10159943	chr10:133744744	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.61	-0.51	1.47e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg06028808	chr11:68637592	NA	0.7	12.1	0.49	1.85e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1620921	0.901	rs783180	chr6:161168961	G/T	cg01280913	chr6:161186852	NA	-0.35	-7.33	-0.32	1.06e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs754466	0.561	rs11002344	chr10:79709725	A/T	cg17075019	chr10:79541650	NA	-0.67	-8.76	-0.38	3.74e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs42648	1.000	rs42658	chr7:89981915	T/A	cg25739043	chr7:89950458	NA	-0.33	-6.83	-0.3	2.62e-11	Homocysteine levels;
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	trans	rs6787172	0.702	rs827113	chr3:157979704	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.36e-17	Subjective well-being;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg04025307	chr7:1156635	C7orf50	0.79	14.75	0.57	1.23e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg17145862	chr1:211918768	LPGAT1	-0.98	-25.42	-0.76	7.02e-90	Leprosy;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.51	-0.33	3e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs8044995	0.636	rs117761434	chr16:68254196	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	Schizophrenia;
LGG	cis	rs600550	0.557	rs1899572	chr11:60086024	C/A	cg05040360	chr11:60102449	MS4A6E	-0.34	-7.42	-0.33	5.47e-13	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg26656751	chr17:43910226	CRHR1	-0.35	-7.08	-0.31	5.39e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17125944	0.686	rs12435704	chr14:53346574	T/C	cg00686598	chr14:53173677	PSMC6	-0.73	-7.82	-0.34	3.63e-14	Alzheimer's disease (late onset);
LGG	cis	rs4959677	0.935	rs3966800	chr6:2493113	A/T	cg23817096	chr6:1620687	NA	-0.32	-7.38	-0.32	7.37e-13	Orthostatic hypotension;
LGG	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg04691961	chr3:161091175	C3orf57	-0.66	-16.08	-0.6	1.57e-46	Morning vs. evening chronotype;
LGG	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.76	-0.45	2.95e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.44	-0.37	4.19e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs514406	0.861	rs6588443	chr1:53250650	G/A	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.72	-0.66	1.24e-58	Monocyte count;
LGG	trans	rs7824557	0.564	rs7834572	chr8:11236685	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs2803122	0.502	rs1329731	chr9:19234908	C/T	cg13469590	chr9:19229767	NA	-0.38	-7.99	-0.35	1.09e-14	Pulse pressure;
LGG	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg17211192	chr8:82754475	SNX16	-0.79	-12.54	-0.5	2.79e-31	Diastolic blood pressure;
LGG	cis	rs4132509	0.843	rs12034588	chr1:243784392	T/A	cg25706552	chr1:244017396	NA	0.52	7.8	0.34	4.06e-14	RR interval (heart rate);
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg11831286	chr5:66300433	MAST4	0.47	6.98	0.31	1.02e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	9.22	0.39	1.06e-18	Height;
LGG	cis	rs4595586	0.545	rs1356265	chr12:39403696	A/G	cg26384229	chr12:38710491	ALG10B	0.58	10.7	0.45	5.11e-24	Morning vs. evening chronotype;
LGG	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.67	-0.34	1e-13	Multiple myeloma (hyperdiploidy);
LGG	trans	rs1459104	1.000	rs35097999	chr11:55048103	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.85	0.3	2.32e-11	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11761572	chr19:39390455	SIRT2;NFKBIB	-0.48	-6.93	-0.31	1.39e-11	Systemic lupus erythematosus;
LGG	cis	rs11096990	0.576	rs2008679	chr4:39268005	A/C	cg24403649	chr4:39172243	NA	-0.38	-6.78	-0.3	3.66e-11	Cognitive function;
LGG	cis	rs17818399	0.815	rs17768018	chr2:46862011	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.18	-0.39	1.39e-18	Height;
LGG	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg15145296	chr3:125709740	NA	-0.61	-7.88	-0.34	2.43e-14	Blood pressure (smoking interaction);
LGG	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs62103177	0.683	rs62101232	chr18:77722454	T/C	cg05926928	chr17:57297772	GDPD1	1.1	14.72	0.56	1.67e-40	Opioid sensitivity;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg13939156	chr17:80058883	NA	-0.44	-8.59	-0.37	1.36e-16	Life satisfaction;
LGG	trans	rs853679	0.567	rs1005126	chr6:28367623	C/G	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.72	-0.3	5.22e-11	Depression;
LGG	cis	rs72717009	0.825	rs61802846	chr1:161473873	A/C	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs35740288	0.770	rs11630286	chr15:86202529	T/C	cg07943548	chr15:86304357	KLHL25	-0.33	-6.68	-0.3	6.73e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7918232	0.627	rs10829165	chr10:27319465	A/G	cg14240646	chr10:27532245	ACBD5	-0.6	-10.34	-0.43	1.1e-22	Breast cancer;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.44	-0.33	4.85e-13	Longevity;Endometriosis;
LGG	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-7.99	-0.35	1.05e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17453880	0.929	rs6869129	chr5:152028136	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs35146811	0.700	rs2950520	chr7:99827148	T/C	cg22906224	chr7:99728672	NA	-0.58	-9.21	-0.39	1.1e-18	Coronary artery disease;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.36e-18	Lung cancer;
LGG	cis	rs4731207	0.662	rs4283967	chr7:124540535	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs7095944	0.644	rs965484	chr10:126453481	T/C	cg08799069	chr10:126477246	METTL10	-0.48	-10.78	-0.45	2.61e-24	Asthma;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2279817	0.818	rs867984	chr1:17982559	G/A	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-8.39	-0.36	5.91e-16	Neuroticism;
LGG	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg16851482	chr4:6955953	TBC1D14	0.27	6.82	0.3	2.87e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.27	0.4	7.21e-19	Life satisfaction;
LGG	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Vitiligo;
LGG	cis	rs9894429	0.608	rs8477	chr17:79618059	C/T	cg18240062	chr17:79603768	NPLOC4	0.61	10.1	0.42	8.3e-22	Eye color traits;
LGG	cis	rs4262150	0.810	rs115323899	chr5:151953203	C/A	cg12297329	chr5:152029980	NA	-0.81	-15.87	-0.59	1.37e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	trans	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg02002194	chr4:3960332	NA	0.37	6.99	0.31	9.71e-12	Joint mobility (Beighton score);
LGG	cis	rs7172118	1	rs7172118	chr15:78862453	C/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.49	-0.33	3.49e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.61	-0.44	1.07e-23	Depression;
LGG	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg08297393	chr2:100937505	LONRF2	-0.52	-9.54	-0.41	8.14e-20	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00349413	chr17:48171948	PDK2	0.52	8.23	0.36	1.98e-15	Gut microbiome composition (summer);
LGG	cis	rs4838594	0.563	rs4838598	chr10:49679413	A/G	cg17291251	chr10:49678358	ARHGAP22	0.54	11.45	0.47	6.75e-27	Daytime sleep phenotypes;
LGG	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7712401	0.623	rs7723798	chr5:122369717	C/G	cg19412675	chr5:122181750	SNX24	0.43	7.01	0.31	8.58e-12	Mean platelet volume;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg25703541	chr22:24373054	LOC391322	-0.86	-16.34	-0.6	9.87e-48	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2549003	1.000	rs2070726	chr5:131821738	C/A	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.38	-0.47	1.32e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26019096	chr17:7218470	GPS2	-0.4	-6.72	-0.3	5.43e-11	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg20587970	chr11:113659929	NA	-1.33	-23.45	-0.74	9.69e-81	Hip circumference adjusted for BMI;
LGG	cis	rs12618769	0.597	rs3754892	chr2:99063318	T/A	cg18455616	chr2:99124870	INPP4A	0.3	8.58	0.37	1.42e-16	Bipolar disorder;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01341218	chr17:43662625	NA	-0.87	-14.9	-0.57	2.83e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg10253484	chr15:75165896	SCAMP2	-0.39	-6.66	-0.3	7.55e-11	Breast cancer;
LGG	trans	rs3780486	0.505	rs1411609	chr9:33137303	C/T	cg20290983	chr6:43655470	MRPS18A	0.81	15.78	0.59	3.49e-45	IgG glycosylation;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg03727229	chr11:118479170	PHLDB1	0.37	6.65	0.3	8.22e-11	Cholesterol, total;
LGG	trans	rs2562456	0.876	rs2359144	chr19:21590636	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.36	-0.32	8.33e-13	Pain;
LGG	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg01221209	chr5:554886	NA	-0.49	-7.77	-0.34	5.22e-14	Obesity-related traits;
LGG	cis	rs950776	0.593	rs601079	chr15:78869579	T/A	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.11	-0.31	4.43e-12	Sudden cardiac arrest;
LGG	cis	rs13082711	1.000	rs34234262	chr3:27539188	G/A	cg02860705	chr3:27208620	NA	0.84	14.83	0.57	5.73e-41	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.07	0.68	6.43e-65	Alzheimer's disease;
LGG	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.56	-0.37	1.71e-16	Alzheimer's disease (survival time);
LGG	trans	rs1997103	1.000	rs6954474	chr7:55404847	A/G	cg20935933	chr6:143382018	AIG1	0.58	9.0	0.39	5.94e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg02002194	chr4:3960332	NA	-0.4	-7.22	-0.32	2.21e-12	Mood instability;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09392386	chr17:63557887	AXIN2	-0.46	-7.14	-0.31	3.58e-12	Pancreatic cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15749322	chr11:82905199	ANKRD42	0.46	7.48	0.33	3.68e-13	Cognitive performance;
LGG	cis	rs2455826	0.917	rs2471809	chr3:15680525	G/A	cg16303742	chr3:15540471	COLQ	0.4	7.02	0.31	7.98e-12	Inflammatory skin disease;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg00800038	chr16:89945340	TCF25	-0.67	-7.59	-0.33	1.79e-13	Skin colour saturation;
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg13264159	chr8:625131	ERICH1	-1.05	-12.45	-0.5	6.79e-31	IgG glycosylation;
LGG	cis	rs9296092	0.521	rs56332659	chr6:33537887	T/C	cg13560919	chr6:33536144	NA	-1.0	-19.91	-0.68	3.38e-64	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg21724239	chr8:58056113	NA	0.42	6.68	0.3	6.95e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10883723	0.962	rs1056739	chr10:104236542	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.85	0.51	1.56e-32	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs6598955	0.724	rs12132137	chr1:26631243	C/T	cg10402321	chr1:26617780	UBXN11	-0.35	-6.79	-0.3	3.52e-11	Obesity-related traits;
LGG	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.13e-11	Alzheimer's disease (survival time);
LGG	cis	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg03060546	chr3:49711283	APEH	-0.61	-8.36	-0.36	7.33e-16	Menarche (age at onset);
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-20.48	-0.69	7.55e-67	Prudent dietary pattern;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg06640241	chr16:89574553	SPG7	0.83	14.87	0.57	3.62e-41	Multiple myeloma (IgH translocation);
LGG	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.43e-19	Obesity-related traits;
LGG	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg23625390	chr15:77176239	SCAPER	0.65	13.1	0.52	1.41e-33	Blood metabolite levels;
LGG	cis	rs2985684	0.948	rs12886130	chr14:50082753	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-8.53	-0.37	2.13e-16	Carotid intima media thickness;
LGG	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.91	-0.38	1.21e-17	Aortic root size;
LGG	cis	rs9527	0.640	rs7089061	chr10:104723015	C/A	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11890956	chr21:40555474	PSMG1	-0.73	-12.7	-0.51	6.64e-32	Menarche (age at onset);
LGG	cis	rs2404602	0.647	rs11072616	chr15:76985269	T/C	cg23625390	chr15:77176239	SCAPER	-0.72	-14.31	-0.55	1.01e-38	Blood metabolite levels;
LGG	cis	rs300774	0.925	rs300737	chr2:170576	A/G	cg04617936	chr2:214353	NA	-0.47	-7.14	-0.31	3.71e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg07308232	chr7:1071921	C7orf50	-0.65	-12.86	-0.51	1.45e-32	Longevity;Endometriosis;
LGG	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg23302884	chr18:44338147	ST8SIA5	0.35	6.71	0.3	5.79e-11	Educational attainment;
LGG	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg16339924	chr4:17578868	LAP3	0.59	10.31	0.43	1.46e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7084402	1.000	rs28426375	chr10:60285478	T/A	cg09696939	chr10:60272079	BICC1	-0.36	-6.84	-0.3	2.52e-11	Refractive error;
LGG	cis	rs7712401	0.601	rs30048	chr5:122270393	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.24	0.32	1.88e-12	Mean platelet volume;
LGG	cis	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg00405596	chr8:11794950	NA	0.43	7.29	0.32	1.32e-12	Monocyte count;
LGG	cis	rs10416265	0.527	rs7246814	chr19:33538414	G/T	cg27124370	chr19:33622961	WDR88	0.54	9.9	0.42	4.41e-21	Bone properties (heel);
LGG	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg14912033	chr15:79043428	NA	0.36	8.4	0.36	5.42e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs2030746	0.521	rs6750309	chr2:121332191	A/G	cg03661458	chr2:121334411	NA	-0.42	-10.58	-0.44	1.39e-23	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg22037798	chr1:231473786	C1orf124;EXOC8	-0.41	-6.78	-0.3	3.61e-11	Leprosy;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7091068	0.522	rs10882322	chr10:95483273	C/G	cg20715218	chr10:95462985	C10orf4	0.67	11.15	0.46	9.88e-26	Urinary tract infection frequency;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg04861929	chr11:109293070	C11orf87	0.66	11.76	0.48	4e-28	Schizophrenia;
LGG	cis	rs56235845	0.685	rs35630910	chr5:176757841	A/C	cg17509989	chr5:176798049	RGS14	0.68	10.77	0.45	2.69e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs2952156	0.920	rs9675194	chr17:37833805	A/G	cg07936489	chr17:37558343	FBXL20	-0.48	-8.1	-0.35	4.8e-15	Asthma;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg10351095	chr21:47802916	PCNT	0.39	6.83	0.3	2.64e-11	Testicular germ cell tumor;
LGG	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs6732160	0.845	rs13413175	chr2:73389916	T/C	cg01422370	chr2:73384389	NA	0.55	10.97	0.45	4.93e-25	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Electroencephalogram traits;
LGG	cis	rs7937612	0.501	rs7116481	chr11:120238413	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.38	-8.66	-0.37	8.04e-17	Intraocular pressure;
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg18252515	chr7:66147081	NA	0.41	6.73	0.3	5.08e-11	Aortic root size;
LGG	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg21475434	chr5:93447410	FAM172A	-0.69	-7.12	-0.31	4.17e-12	Diabetic retinopathy;
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg02002194	chr4:3960332	NA	0.42	7.63	0.33	1.33e-13	Neuroticism;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg18350739	chr11:68623251	NA	-0.85	-20.6	-0.69	2.07e-67	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3540	0.553	rs12592611	chr15:91004093	C/T	cg22089800	chr15:90895588	ZNF774	0.7	13.0	0.52	3.83e-33	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs11229555	0.645	rs6591475	chr11:58193551	G/T	cg15696309	chr11:58395628	NA	0.93	15.16	0.58	1.91e-42	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4262150	0.544	rs4958554	chr5:151903294	T/G	cg12297329	chr5:152029980	NA	-0.64	-11.76	-0.48	4.13e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs3942852	0.759	rs905475	chr11:48149755	C/T	cg15704280	chr7:45808275	SEPT13	-0.65	-9.13	-0.39	2.2e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg08677398	chr8:58056175	NA	0.6	9.02	0.39	5e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs208515	0.556	rs10455193	chr6:66691456	G/A	cg07460842	chr6:66804631	NA	0.95	17.19	0.62	1.4e-51	Exhaled nitric oxide levels;
LGG	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.2	-0.43	3.53e-22	Bladder cancer;
LGG	cis	rs7107174	1.000	rs7112234	chr11:78102470	G/A	cg02023728	chr11:77925099	USP35	0.44	7.88	0.34	2.42e-14	Testicular germ cell tumor;
LGG	cis	rs225245	0.782	rs321599	chr17:33905745	C/T	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4918072	0.798	rs36038963	chr10:105707042	C/T	cg11005552	chr10:105648138	OBFC1	0.69	9.97	0.42	2.44e-21	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg11062466	chr8:58055876	NA	0.5	8.1	0.35	4.86e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11105298	0.891	rs10858903	chr12:89927972	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.27	-0.4	6.97e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg27432699	chr2:27873401	GPN1	-0.52	-8.92	-0.38	1.06e-17	Total body bone mineral density;
LGG	cis	rs9815354	0.716	rs73087368	chr3:41930379	A/G	cg03022575	chr3:42003672	ULK4	0.82	9.5	0.4	1.11e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13102973	0.965	rs6535051	chr4:135874869	G/A	cg14419869	chr4:135874104	NA	-0.57	-10.91	-0.45	8.18e-25	Subjective well-being;
LGG	cis	rs2224391	0.617	rs67307669	chr6:5293095	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.51	-7.08	-0.31	5.46e-12	Height;
LGG	cis	rs2235642	0.582	rs11643891	chr16:1565540	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.3	6.87	0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg00761968	chr13:53314142	LECT1	-0.36	-7.57	-0.33	2e-13	Lewy body disease;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg14159672	chr1:205819179	PM20D1	-0.65	-13.86	-0.54	8.6e-37	Monocyte percentage of white cells;
LGG	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.78	-0.3	3.77e-11	Restless legs syndrome;
LGG	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg19980929	chr12:42632907	YAF2	-0.34	-7.72	-0.34	7.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3816183	0.626	rs6544568	chr2:42811406	C/T	cg14631114	chr2:43023945	NA	0.34	6.82	0.3	2.84e-11	Hypospadias;
LGG	cis	rs503734	0.666	rs1019677	chr3:101263573	C/T	cg27318481	chr3:100970896	IMPG2	0.35	7.17	0.32	2.95e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2749592	1.000	rs2749592	chr10:38258842	A/C	cg00409905	chr10:38381863	ZNF37A	-0.45	-7.58	-0.33	1.87e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg21435375	chr2:172878103	MAP1D	-0.33	-7.24	-0.32	1.94e-12	Schizophrenia;
LGG	cis	rs4684776	1.000	rs7621218	chr3:11442013	A/G	cg24705426	chr3:11550659	ATG7	0.39	7.28	0.32	1.44e-12	Small vessel stroke;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21647170	chr7:56119546	CCT6A;PSPH	0.47	7.11	0.31	4.36e-12	Gut microbiome composition (summer);
LGG	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg20219074	chr11:18656078	SPTY2D1	0.84	15.97	0.6	4.59e-46	Breast cancer;
LGG	cis	rs3947	0.789	rs9009	chr8:11702006	A/T	cg00262122	chr8:11665843	FDFT1	0.45	6.74	0.3	4.75e-11	Blood protein levels;
LGG	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg04450456	chr4:17643702	FAM184B	0.34	7.61	0.33	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	0.958	rs3857480	chr6:86535149	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.18	-0.49	8.18e-30	Response to antipsychotic treatment;
LGG	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.54	0.37	2.01e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg27539214	chr16:67997921	SLC12A4	-0.51	-7.71	-0.34	8.02e-14	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.84	-0.45	1.5e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs4679904	0.842	rs11721112	chr3:160289284	T/C	cg20378687	chr3:160281681	KPNA4	-0.36	-6.79	-0.3	3.51e-11	Primary biliary cholangitis;
LGG	cis	rs977987	0.806	rs766521	chr16:75424154	A/G	cg07303275	chr16:75499416	TMEM170A	-0.37	-6.76	-0.3	4.22e-11	Dupuytren's disease;
LGG	cis	rs6694672	0.681	rs10732296	chr1:197137151	A/G	cg13682187	chr1:196946512	CFHR5	0.48	6.81	0.3	3.05e-11	Asthma;
LGG	cis	rs424971	0.966	rs147968	chr16:85945839	C/T	cg10334323	chr16:85945517	IRF8	0.33	6.87	0.3	2.03e-11	Monocyte count;
LGG	cis	rs3736594	0.527	rs62141279	chr2:27771415	C/T	cg27432699	chr2:27873401	GPN1	0.57	8.57	0.37	1.52e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.83	0.34	3.35e-14	Rheumatoid arthritis;
LGG	trans	rs61931739	0.517	rs2636073	chr12:34063049	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.58	0.56	6.62e-40	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05665937	chr4:1216051	CTBP1	0.38	6.92	0.31	1.54e-11	Longevity;
LGG	cis	rs12210905	1.000	rs12198077	chr6:27169307	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.0	-0.35	9.97e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7927592	0.956	rs7116899	chr11:68385535	G/T	cg16797656	chr11:68205561	LRP5	0.38	6.81	0.3	3.13e-11	Total body bone mineral density;
LGG	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg03929089	chr4:120376271	NA	0.62	8.84	0.38	1.98e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg27490568	chr2:178487706	NA	0.64	11.52	0.47	3.52e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg08600765	chr20:34638493	LOC647979	-0.74	-10.54	-0.44	1.93e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9487094	0.922	rs10872034	chr6:109807239	A/T	cg16315928	chr6:109776240	MICAL1	0.52	8.63	0.37	9.98e-17	Height;
LGG	cis	rs10193935	0.901	rs7594010	chr2:42534896	C/T	cg27598129	chr2:42591480	NA	-0.64	-9.63	-0.41	3.93e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12431410	0.550	rs1952037	chr14:60179994	G/A	cg07950296	chr14:60194823	RTN1	-0.39	-7.53	-0.33	2.64e-13	Schizophrenia;
LGG	cis	rs11252926	0.537	rs6560836	chr10:444997	C/T	cg16346588	chr10:242978	ZMYND11	0.4	6.84	0.3	2.5e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg11584989	chr19:19387371	SF4	0.74	12.11	0.49	1.57e-29	Bipolar disorder;
LGG	cis	rs801193	0.967	rs2707853	chr7:66214010	G/A	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.21e-25	Aortic root size;
LGG	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg12395012	chr8:11607386	GATA4	0.4	7.12	0.31	4.12e-12	Retinal vascular caliber;
LGG	cis	rs4696584	0.877	rs72725345	chr4:155387524	G/A	cg13738195	chr4:155413469	DCHS2	-0.39	-7.27	-0.32	1.56e-12	Folding of antihelix;
LGG	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg20673091	chr1:2541236	MMEL1	-0.75	-18.21	-0.65	2.77e-56	Ulcerative colitis;
LGG	cis	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs9863	0.861	rs55990776	chr12:124447466	A/G	cg13487667	chr12:124434373	CCDC92	-0.38	-7.49	-0.33	3.44e-13	White blood cell count;
LGG	cis	rs911555	0.723	rs56227024	chr14:103861706	A/G	cg24130564	chr14:104152367	KLC1	0.36	6.77	0.3	3.91e-11	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.5	0.53	2.87e-35	Colorectal cancer;
LGG	cis	rs11676348	0.805	rs12694428	chr2:218958820	G/A	cg00012203	chr2:219082015	ARPC2	-0.49	-8.57	-0.37	1.54e-16	Ulcerative colitis;
LGG	cis	rs920590	0.527	rs79929516	chr8:19650050	G/C	cg01411142	chr8:19674711	INTS10	0.7	10.52	0.44	2.41e-23	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg10213457	chr13:21517772	NA	0.44	6.88	0.3	1.96e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.15	-0.35	3.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.45	0.37	3.86e-16	Coronary artery disease;
LGG	cis	rs7923837	0.634	rs1544210	chr10:94487801	G/A	cg25093409	chr10:94429542	NA	-0.4	-7.51	-0.33	3.13e-13	Body mass index;Multiple sclerosis;
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	19.43	0.67	6.2e-62	Birth weight;
LGG	cis	rs4595586	0.545	rs4768505	chr12:39380338	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.5	0.65	1.23e-57	Menopause (age at onset);
LGG	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg25427524	chr10:38739819	LOC399744	0.52	7.73	0.34	6.85e-14	Obesity (extreme);
LGG	trans	rs7777754	0.512	rs4470989	chr7:50562698	T/A	cg24289314	chr10:126106425	OAT	-0.35	-6.84	-0.3	2.52e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs7077256	0.564	rs12762599	chr10:65192539	A/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28719689	0.730	rs62483952	chr8:1259343	G/A	cg22761795	chr8:1265118	NA	0.8	7.79	0.34	4.55e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs209489	0.892	rs80141683	chr6:53112374	A/G	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.77	-0.45	2.64e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs972578	0.967	rs2267477	chr22:43334574	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.75	-0.3	4.38e-11	Mean platelet volume;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg05165339	chr4:1420672	NA	-0.3	-8.0	-0.35	9.97e-15	Longevity;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4865875	1.000	rs10471923	chr5:54107727	C/T	cg22421804	chr5:54100067	NA	0.51	7.58	0.33	1.92e-13	Sense of smell;
LGG	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs8014204	0.747	rs2070598	chr14:75360906	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.67	-12.77	-0.51	3.32e-32	Caffeine consumption;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.24	0.58	8.34e-43	Lung cancer;
LGG	cis	rs4356932	0.688	rs59291856	chr4:76970801	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06634786	chr22:41940651	POLR3H	-0.78	-12.3	-0.5	2.77e-30	Vitiligo;
LGG	cis	rs4243830	0.579	rs10779794	chr1:6612651	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-12.06	-0.49	2.61e-29	Body mass index;
LGG	cis	rs1707322	0.721	rs6429574	chr1:46134054	A/G	cg03146154	chr1:46216737	IPP	0.55	10.81	0.45	1.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10053473	chr17:62856997	LRRC37A3	-0.86	-14.24	-0.55	2.03e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg08048268	chr3:133502702	NA	-0.45	-7.93	-0.35	1.61e-14	Iron status biomarkers;
LGG	cis	rs2643217	0.953	rs903531	chr15:38998635	G/A	cg10631289	chr15:39006617	NA	-0.44	-7.64	-0.33	1.26e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg00825309	chr19:58991885	ZNF446	-0.48	-9.82	-0.42	8.72e-21	Uric acid clearance;
LGG	cis	rs5998509	1	rs5998509	chr22:21917479	C/T	cg22858872	chr22:21984481	YDJC	-0.37	-6.73	-0.3	5.14e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg21970626	chr13:21893289	NA	-0.42	-7.01	-0.31	8.5e-12	White matter hyperintensity burden;
LGG	trans	rs1997103	1.000	rs10224446	chr7:55413147	C/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.36e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1451375	0.959	rs6962356	chr7:50621941	T/C	cg20336341	chr7:50628841	DDC	0.34	6.7	0.3	6.12e-11	Malaria;
LGG	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg03563238	chr19:33554763	RHPN2	-0.43	-9.97	-0.42	2.44e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.15	0.39	1.79e-18	Cognitive test performance;
LGG	cis	rs473651	0.506	rs561264	chr2:239329979	G/T	cg18131467	chr2:239335373	ASB1	0.78	13.12	0.52	1.15e-33	Multiple system atrophy;
LGG	cis	rs5753037	0.543	rs131284	chr22:30157589	T/C	cg01021169	chr22:30184971	ASCC2	-0.38	-7.5	-0.33	3.4e-13	Type 1 diabetes;
LGG	cis	rs6964587	1.000	rs10228800	chr7:91610111	T/G	cg17063962	chr7:91808500	NA	0.48	8.52	0.37	2.29e-16	Breast cancer;
LGG	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.29	0.32	1.36e-12	Refractive error;
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg02002194	chr4:3960332	NA	0.46	8.78	0.38	3.12e-17	Systolic blood pressure;
LGG	cis	rs7618501	0.602	rs2240327	chr3:50113034	C/T	cg05623727	chr3:50126028	RBM5	0.37	7.98	0.35	1.17e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7122257	0.507	rs7110986	chr11:11161248	A/G	cg16931664	chr11:11169707	NA	-0.25	-7.25	-0.32	1.7e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg04568710	chr12:38710424	ALG10B	-0.32	-6.75	-0.3	4.44e-11	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.65	0.34	1.16e-13	Cannabis dependence symptom count;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.86e-11	Bipolar disorder;
LGG	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg02002194	chr4:3960332	NA	0.39	7.08	0.31	5.48e-12	Morning vs. evening chronotype;
LGG	cis	rs3748682	0.861	rs12563037	chr1:38258644	C/G	cg12658694	chr1:38397304	INPP5B	-0.37	-6.92	-0.31	1.48e-11	Hypothyroidism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15393197	chr17:37213172	NA	-0.45	-7.28	-0.32	1.47e-12	Pancreatic cancer;
LGG	cis	rs62238980	0.614	rs117338422	chr22:32399226	C/G	cg00543991	chr22:32367038	NA	0.8	8.88	0.38	1.46e-17	Childhood ear infection;
LGG	cis	rs35146811	0.659	rs863450	chr7:99821685	C/T	cg13334819	chr7:99746414	C7orf59	0.49	7.52	0.33	2.79e-13	Coronary artery disease;
LGG	cis	rs7927592	1.000	rs7927592	chr11:68369960	G/A	cg16797656	chr11:68205561	LRP5	0.39	6.87	0.3	2.02e-11	Total body bone mineral density;
LGG	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg24759859	chr6:86352639	SYNCRIP	0.43	7.22	0.32	2.1e-12	Smooth-surface caries;
LGG	cis	rs13420028	0.651	rs4580433	chr2:133193857	G/A	cg02570563	chr2:133174168	GPR39	0.4	6.78	0.3	3.77e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs35146811	0.700	rs858513	chr7:99825558	G/A	cg22906224	chr7:99728672	NA	-0.57	-9.34	-0.4	4.06e-19	Coronary artery disease;
LGG	cis	rs9527	0.590	rs12415199	chr10:104895536	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs6692729	0.966	rs6426548	chr1:227013878	C/T	cg08708961	chr1:227070630	PSEN2	-0.28	-7.24	-0.32	1.83e-12	Electrodermal activity;
LGG	cis	rs12493885	0.818	rs1521324	chr3:153758863	G/T	cg17054900	chr3:154042577	DHX36	-0.76	-8.99	-0.39	6.26e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-15.53	-0.59	4.38e-44	Total body bone mineral density;
LGG	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg23899408	chr19:12877188	HOOK2	0.48	7.81	0.34	3.92e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs79839061	0.656	rs11726912	chr4:887868	A/C	cg07828340	chr4:882639	GAK	0.94	9.98	0.42	2.19e-21	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.748	rs1584918	chr21:45042419	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.75	0.48	4.39e-28	Mean corpuscular volume;
LGG	trans	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.37	-7.85	-0.34	3.01e-14	Obesity-related traits;
LGG	cis	rs71403859	0.803	rs10500562	chr16:71627731	A/C	cg08717414	chr16:71523259	ZNF19	-1.13	-14.85	-0.57	4.57e-41	Post bronchodilator FEV1;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07578611	chr18:77627476	KCNG2	0.38	6.89	0.3	1.82e-11	Pancreatic cancer;
LGG	cis	rs4731207	0.596	rs6957525	chr7:124656377	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg16339924	chr4:17578868	LAP3	0.65	11.12	0.46	1.29e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs738322	0.805	rs2016755	chr22:38539604	A/G	cg25457927	chr22:38595422	NA	-0.38	-9.39	-0.4	2.72e-19	Cutaneous nevi;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10892158	chr8:24857894	NA	0.41	6.86	0.3	2.18e-11	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.86	-0.38	1.71e-17	Neuroticism;
LGG	cis	rs6467136	0.560	rs12666432	chr7:127082952	A/G	cg25922125	chr7:127225783	GCC1	-0.43	-6.74	-0.3	4.84e-11	Type 2 diabetes;
LGG	cis	rs4262150	0.883	rs55826179	chr5:152162776	G/A	cg12297329	chr5:152029980	NA	-0.7	-12.73	-0.51	4.97e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg08975724	chr8:8085496	FLJ10661	0.36	6.79	0.3	3.49e-11	Systolic blood pressure;
LGG	cis	rs2635047	0.682	rs7242976	chr18:44797159	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.45	0.33	4.69e-13	Educational attainment;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg11062466	chr8:58055876	NA	0.48	8.21	0.36	2.29e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg26617929	chr16:1858877	NA	-0.49	-6.97	-0.31	1.07e-11	Insulin-like growth factors;
LGG	cis	rs2307022	0.629	rs2863975	chr16:68382447	T/C	cg07273125	chr16:68295692	NA	0.44	9.82	0.42	8.47e-21	Body mass index;
LGG	cis	rs35146811	0.735	rs858506	chr7:99820050	T/C	cg13334819	chr7:99746414	C7orf59	0.48	7.52	0.33	2.88e-13	Coronary artery disease;
LGG	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg02753203	chr1:228287806	NA	0.76	14.83	0.57	5.19e-41	Diastolic blood pressure;
LGG	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg04733989	chr22:42467013	NAGA	0.51	9.03	0.39	4.55e-18	Schizophrenia;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.57e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11711311	1.000	rs9826465	chr3:113432254	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.11	-0.35	4.49e-15	IgG glycosylation;
LGG	cis	rs9815354	0.812	rs73073229	chr3:42007850	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19156483	chr2:164592571	FIGN	-0.35	-6.96	-0.31	1.17e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs11608355	0.545	rs1073779	chr12:109894721	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6743376	0.556	rs2515392	chr2:113817181	C/T	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.17e-18	Inflammatory biomarkers;
LGG	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg27490568	chr2:178487706	NA	0.46	9.27	0.4	7.18e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4740619	0.587	rs10756740	chr9:16037723	T/C	cg14451791	chr9:16040625	NA	-0.43	-11.42	-0.47	8.47e-27	Body mass index;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg13126279	chr21:47581558	C21orf56	-0.56	-10.12	-0.43	7.2e-22	Testicular germ cell tumor;
LGG	cis	rs9902453	0.726	rs4795523	chr17:28176314	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.97	0.54	2.8e-37	Coffee consumption (cups per day);
LGG	cis	rs774359	0.763	rs10435784	chr9:27490332	T/G	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.31	-0.36	1.06e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs757081	0.667	rs12577418	chr11:17101554	C/G	cg15432903	chr11:17409602	KCNJ11	-0.52	-8.57	-0.37	1.57e-16	Systolic blood pressure;
LGG	cis	rs7582180	0.764	rs4851293	chr2:100925106	A/T	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.51	0.33	3.17e-13	Schizophrenia;
LGG	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.4	0.33	6.39e-13	Neuroticism;
LGG	cis	rs7819412	0.505	rs67849263	chr8:11007544	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-6.8	-0.3	3.31e-11	Triglycerides;
LGG	cis	rs7945718	0.905	rs10831908	chr11:12812419	G/A	cg25843174	chr11:12811716	TEAD1	0.42	8.79	0.38	3e-17	Educational attainment (years of education);
LGG	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs738321	0.757	rs3788535	chr22:38534045	T/C	cg25457927	chr22:38595422	NA	-0.4	-9.39	-0.4	2.8e-19	Breast cancer;
LGG	cis	rs950776	0.518	rs3813571	chr15:78832792	G/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.69	0.3	6.47e-11	Sudden cardiac arrest;
LGG	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg23324259	chr8:82754387	SNX16	-0.46	-7.38	-0.32	7.27e-13	Diastolic blood pressure;
LGG	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg04398451	chr17:18023971	MYO15A	-0.73	-15.39	-0.58	1.88e-43	Total body bone mineral density;
LGG	cis	rs62400317	0.793	rs12190367	chr6:45208938	A/G	cg20913747	chr6:44695427	NA	-0.63	-10.2	-0.43	3.49e-22	Total body bone mineral density;
LGG	cis	rs757278	0.608	rs4500028	chr7:117342315	T/A	cg10524701	chr7:117356490	CTTNBP2	0.47	8.48	0.37	3.1e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg05555928	chr11:63887634	MACROD1	-0.58	-9.7	-0.41	2.21e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.51e-17	DNA methylation (variation);
LGG	cis	rs1348850	0.526	rs2218575	chr2:178368997	C/A	cg23306229	chr2:178417860	TTC30B	0.72	8.71	0.38	5.4e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs72772090	0.539	rs55996659	chr5:96114150	A/G	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14928532	chr9:133454630	LOC100272217;FUBP3	0.42	7.16	0.32	3.11e-12	Bipolar disorder;
LGG	cis	rs367943	0.608	rs4705564	chr5:112980196	G/C	cg12552261	chr5:112820674	MCC	0.51	8.89	0.38	1.4e-17	Type 2 diabetes;
LGG	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg06623630	chr22:50017776	C22orf34	-0.34	-7.11	-0.31	4.36e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.58	-0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg01864069	chr14:103024347	NA	-0.75	-12.1	-0.49	1.8e-29	Platelet count;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.7	-0.3	5.93e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.55	-0.47	2.62e-27	Mean platelet volume;Platelet distribution width;
LGG	trans	rs61931739	0.534	rs11053075	chr12:34207009	A/G	cg26384229	chr12:38710491	ALG10B	-0.81	-16.31	-0.6	1.44e-47	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.14	0.46	1.07e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.3	-0.32	1.24e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4740619	0.933	rs1396708	chr9:15705479	C/A	cg14451791	chr9:16040625	NA	-0.38	-9.53	-0.4	9.17e-20	Body mass index;
LGG	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07080220	chr10:102295463	HIF1AN	0.58	10.08	0.42	9.38e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg10818794	chr15:86012489	AKAP13	-0.36	-7.54	-0.33	2.44e-13	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25190999	chr2:8826175	NA	0.49	7.14	0.31	3.55e-12	Gut microbiome composition (summer);
LGG	cis	rs75920871	0.528	rs7935913	chr11:116944348	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.5	7.35	0.32	8.91e-13	Subjective well-being;
LGG	cis	rs1185460	0.967	rs11217137	chr11:118931030	A/G	cg23280166	chr11:118938394	VPS11	0.56	10.05	0.42	1.2e-21	Coronary artery disease;
LGG	trans	rs1814175	0.817	rs7929173	chr11:49944007	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.39e-97	Height;
LGG	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.33	-0.36	9.5e-16	Aortic root size;
LGG	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs4319547	0.695	rs6488939	chr12:122858250	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.58	-8.56	-0.37	1.64e-16	Body mass index;
LGG	cis	rs9811920	0.609	rs793466	chr3:99609837	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg18761221	chr20:60518478	NA	-0.64	-10.42	-0.44	5.63e-23	Obesity-related traits;
LGG	cis	rs12135191	0.869	rs7540513	chr1:236474815	C/A	cg21399712	chr1:236511386	NA	-0.41	-7.8	-0.34	4.18e-14	Urate levels (BMI interaction);
LGG	cis	rs16837677	0.826	rs12407769	chr1:156727529	G/C	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.29e-14	Sjögren's syndrome;
LGG	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.11	0.35	4.54e-15	Homoarginine levels;
LGG	cis	rs12579753	0.956	rs7965168	chr12:82184467	C/A	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.41	-0.47	9.82e-27	Resting heart rate;
LGG	cis	rs10744422	1.000	rs12255	chr12:123350204	C/T	cg25930673	chr12:123319894	HIP1R	-0.66	-8.0	-0.35	1e-14	Schizophrenia;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21747090	chr2:27597821	SNX17	-0.37	-6.7	-0.3	6.12e-11	Menopause (age at onset);
LGG	cis	rs1669338	0.588	rs7629889	chr3:3187643	C/T	cg16797762	chr3:3221439	CRBN	-0.92	-12.27	-0.5	3.62e-30	White matter integrity;
LGG	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.28	-0.46	3.09e-26	Type 2 diabetes;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg23758822	chr17:41437982	NA	0.9	15.86	0.59	1.52e-45	Menopause (age at onset);
LGG	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg18188782	chr20:61659543	NA	0.39	6.69	0.3	6.47e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.4	-7.42	-0.33	5.59e-13	Personality dimensions;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg07677032	chr17:61819896	STRADA	0.68	12.46	0.5	6.2e-31	Prudent dietary pattern;
LGG	trans	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.5	0.33	3.24e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1010254	0.510	rs1363418	chr5:151699834	G/T	cg12297329	chr5:152029980	NA	0.46	6.69	0.3	6.32e-11	Optic nerve measurement (cup area);
LGG	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg16414030	chr3:133502952	NA	0.58	9.98	0.42	2.31e-21	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06012509	chr6:43027269	KLC4;MRPL2	0.45	7.51	0.33	3.11e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3806843	0.735	rs801183	chr5:140091115	C/T	cg16577123	chr5:140027231	NDUFA2;IK	0.42	6.66	0.3	7.55e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg02900749	chr2:68251473	NA	-1.02	-10.53	-0.44	2.18e-23	Pursuit maintenance gain;
LGG	cis	rs2594989	1.000	rs2594994	chr3:11339960	T/A	cg01796438	chr3:11312864	ATG7	-0.6	-8.34	-0.36	8.62e-16	Circulating chemerin levels;
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg02503808	chr4:7069936	GRPEL1	1.04	16.06	0.6	1.81e-46	Monocyte percentage of white cells;
LGG	cis	rs79839061	0.610	rs17781499	chr4:889384	C/A	cg07828340	chr4:882639	GAK	0.93	9.96	0.42	2.65e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4073221	0.520	rs13072195	chr3:18199498	C/T	cg07694806	chr3:18168406	NA	-0.64	-8.08	-0.35	5.62e-15	Parkinson's disease;
LGG	cis	rs9473924	0.542	rs35546156	chr6:50829785	C/T	cg14470998	chr6:50812995	TFAP2B	0.69	8.09	0.35	5.11e-15	Body mass index;
LGG	cis	rs2274273	0.806	rs7146752	chr14:55738907	A/G	cg04306507	chr14:55594613	LGALS3	0.63	17.82	0.64	1.82e-54	Protein biomarker;
LGG	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.7e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg21366198	chr4:185655624	MLF1IP	0.45	7.83	0.34	3.27e-14	Kawasaki disease;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.69	-0.34	9.06e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9972944	0.729	rs6504348	chr17:63763049	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.36	-0.36	7.48e-16	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9937943	0.721	rs8059315	chr16:74506447	C/G	cg01733217	chr16:74700730	RFWD3	0.64	9.09	0.39	2.85e-18	Neutrophil percentage of white cells;
LGG	cis	rs8067545	0.532	rs35915823	chr17:19973397	A/G	cg13482628	chr17:19912719	NA	0.52	8.73	0.38	4.81e-17	Schizophrenia;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.44	-0.37	4.05e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.99	-0.35	1.04e-14	Neuroticism;
LGG	cis	rs2963155	0.518	rs853178	chr5:142634799	C/T	cg17617527	chr5:142782415	NR3C1	0.95	13.02	0.52	3.09e-33	Breast cancer;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg08621203	chr6:150244597	RAET1G	0.46	8.1	0.35	4.86e-15	Lung cancer;
LGG	cis	rs774359	0.797	rs10738775	chr9:27514318	T/A	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.5	-0.37	2.65e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs208520	0.874	rs208514	chr6:66945520	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-15.04	-0.57	6.85e-42	Exhaled nitric oxide output;
LGG	cis	rs2120019	0.608	rs8042558	chr15:75320433	G/T	cg17294928	chr15:75287854	SCAMP5	-0.96	-18.65	-0.65	2.65e-58	Blood trace element (Zn levels);
LGG	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg24623649	chr8:11872141	NA	-0.31	-7.28	-0.32	1.47e-12	Triglycerides;
LGG	cis	rs11864453	0.560	rs6499561	chr16:72148404	A/G	cg01557791	chr16:72042693	DHODH	-0.52	-9.67	-0.41	2.89e-20	Fibrinogen levels;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg15971980	chr6:150254442	NA	0.45	9.04	0.39	4.33e-18	Lung cancer;
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.0	-0.42	1.95e-21	Tonsillectomy;
LGG	cis	rs2404602	0.647	rs12913024	chr15:77145216	C/T	cg23625390	chr15:77176239	SCAPER	-0.74	-14.7	-0.56	2.08e-40	Blood metabolite levels;
LGG	cis	rs6909430	0.901	rs1601733	chr6:98557239	A/G	cg12860156	chr6:98744658	NA	-0.44	-7.2	-0.32	2.47e-12	Quantitative traits;
LGG	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg02269571	chr22:50332266	NA	0.64	10.17	0.43	4.62e-22	Schizophrenia;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg07167872	chr1:205819463	PM20D1	0.68	14.14	0.55	5.73e-38	Menarche (age at onset);
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg24690094	chr11:67383802	NA	0.51	9.14	0.39	2e-18	Mean corpuscular volume;
LGG	cis	rs6554196	0.508	rs2237037	chr4:55525930	A/C	cg18836493	chr4:55524333	KIT	-0.43	-8.06	-0.35	6.61e-15	Monocyte count;
LGG	cis	rs12704876	0.509	rs1608741	chr7:96354206	G/A	cg03808172	chr7:96339361	SHFM1	0.54	9.69	0.41	2.37e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs758324	0.797	rs422130	chr5:131325888	A/G	cg06307176	chr5:131281290	NA	0.51	7.44	0.33	4.91e-13	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2439831	0.681	rs825739	chr15:43592428	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	12.58	0.5	1.95e-31	Lung cancer in ever smokers;
LGG	cis	rs6693295	0.755	rs1933530	chr1:246231677	T/G	cg11798871	chr1:246315928	SMYD3	-0.42	-6.76	-0.3	4.05e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs950169	0.922	rs62029585	chr15:84951874	C/G	cg03959625	chr15:84868606	LOC388152	0.56	8.68	0.37	6.77e-17	Schizophrenia;
LGG	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.82	-0.62	7.14e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11041264	chr20:33872554	EIF6	-0.45	-7.49	-0.33	3.57e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg07701084	chr6:150067640	NUP43	-0.68	-13.17	-0.52	7.29e-34	Lung cancer;
LGG	cis	rs2120019	1.000	rs12324912	chr15:75361006	G/A	cg09165964	chr15:75287851	SCAMP5	-1.0	-19.95	-0.68	2.24e-64	Blood trace element (Zn levels);
LGG	cis	rs600231	0.665	rs1626021	chr11:65226187	A/G	cg17120908	chr11:65337727	SSSCA1	-0.5	-8.92	-0.38	1.08e-17	Bone mineral density;
LGG	cis	rs875971	0.965	rs28682868	chr7:65689809	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.86	-0.57	4.04e-41	Aortic root size;
LGG	cis	rs7808935	0.914	rs11971132	chr7:27985867	G/C	cg22168087	chr7:27702803	HIBADH	0.65	8.93	0.38	1.01e-17	Prostate cancer;
LGG	cis	rs938554	0.744	rs6449137	chr4:9932479	A/T	cg25986240	chr4:9926439	SLC2A9	0.42	8.28	0.36	1.29e-15	Blood metabolite levels;
LGG	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg02269571	chr22:50332266	NA	0.64	10.17	0.43	4.62e-22	Schizophrenia;
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg12458913	chr13:53173898	NA	0.62	11.77	0.48	3.81e-28	Lewy body disease;
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg21972741	chr5:435613	AHRR	0.49	8.43	0.36	4.3e-16	Cystic fibrosis severity;
LGG	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.69	0.54	4.57e-36	Type 2 diabetes;
LGG	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14373873	chr11:113211441	TTC12	0.41	8.46	0.37	3.5e-16	Information processing speed;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs6964587	1.000	rs7791138	chr7:91686789	A/G	cg17063962	chr7:91808500	NA	0.49	8.7	0.37	6.06e-17	Breast cancer;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg13009111	chr11:71350975	NA	0.32	7.18	0.32	2.78e-12	Neuroticism;
LGG	cis	rs908922	0.676	rs526099	chr1:152497811	T/C	cg03606772	chr1:152487856	CRCT1	0.31	7.37	0.32	8.07e-13	Hair morphology;
LGG	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg11871910	chr12:69753446	YEATS4	0.76	15.93	0.59	7.52e-46	Blood protein levels;
LGG	cis	rs7216064	0.953	rs4791046	chr17:65851973	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.83	-0.38	2.17e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.11	-0.35	4.59e-15	Life satisfaction;
LGG	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg09307838	chr4:120376055	NA	0.77	12.71	0.51	5.65e-32	Corneal astigmatism;
LGG	cis	rs9287719	0.967	rs6432126	chr2:10757101	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.37	0.32	7.76e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs950027	0.549	rs1719250	chr15:45609773	A/G	cg15395560	chr15:45543142	SLC28A2	-0.39	-6.65	-0.3	8.11e-11	Response to fenofibrate (adiponectin levels);
LGG	cis	rs727505	0.821	rs67167896	chr7:124614127	T/C	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs75804782	0.625	rs1039887	chr2:239434892	A/G	cg18131467	chr2:239335373	ASB1	-0.59	-6.94	-0.31	1.36e-11	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg11693508	chr17:37793320	STARD3	0.63	9.16	0.39	1.74e-18	Bipolar disorder;
LGG	cis	rs2599510	0.729	rs1135484	chr2:32749060	G/A	cg02381751	chr2:32503542	YIPF4	0.5	8.17	0.35	2.98e-15	Interleukin-18 levels;
LGG	cis	rs3087591	0.919	rs2018624	chr17:29560777	T/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.51	-0.56	1.34e-39	Hip circumference;
LGG	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg03894339	chr8:19674705	INTS10	0.63	10.23	0.43	2.8e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.32	-0.55	8.81e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg13468214	chr4:1046988	NA	0.36	8.28	0.36	1.3e-15	Recombination rate (males);
LGG	cis	rs6694672	1.000	rs928440	chr1:196950350	G/A	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.8e-11	Asthma;
LGG	cis	rs3768617	0.528	rs6672093	chr1:183079853	T/C	cg15522984	chr1:182991683	LAMC1	0.44	8.78	0.38	3.29e-17	Fuchs's corneal dystrophy;
LGG	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.81	-0.3	3.04e-11	Alzheimer's disease (survival time);
LGG	cis	rs477692	0.905	rs514963	chr10:131419707	C/T	cg05714579	chr10:131428358	MGMT	0.64	13.14	0.52	9.64e-34	Response to temozolomide;
LGG	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg26441486	chr22:50317300	CRELD2	0.41	7.71	0.34	7.52e-14	Schizophrenia;
LGG	cis	rs9948	0.529	rs62156222	chr2:97410988	C/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.62e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg25173405	chr17:45401733	C17orf57	0.49	8.51	0.37	2.41e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg27587195	chr5:112824172	MCC	-0.48	-7.63	-0.33	1.36e-13	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg05692746	chr2:100937584	LONRF2	-0.65	-11.85	-0.48	1.81e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg26174226	chr8:58114915	NA	-0.5	-7.37	-0.32	8.03e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02071572	chr4:1403502	NA	-0.39	-6.8	-0.3	3.24e-11	Longevity;
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.4	-0.33	6.65e-13	Life satisfaction;
LGG	cis	rs9463078	0.691	rs17288278	chr6:45298482	G/A	cg25276700	chr6:44698697	NA	0.32	6.78	0.3	3.6e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11630290	0.736	rs72752925	chr15:64146100	C/G	cg12036633	chr15:63758958	NA	-0.61	-7.1	-0.31	4.64e-12	Iris characteristics;
LGG	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg03342759	chr3:160939853	NMD3	-0.76	-13.39	-0.53	8.77e-35	Parkinson's disease;
LGG	cis	rs9916302	0.904	rs620686	chr17:37453617	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.0	0.6	3.49e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs1801251	1.000	rs7587309	chr2:233705702	G/T	cg25237894	chr2:233734115	C2orf82	-0.65	-12.4	-0.5	1.11e-30	Coronary artery disease;
LGG	cis	rs12912251	1.000	rs2132157	chr15:38992547	A/G	cg01338139	chr15:38987640	C15orf53	-0.52	-8.19	-0.36	2.62e-15	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-9.9	-0.42	4.32e-21	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg14675211	chr2:100938903	LONRF2	0.47	7.38	0.32	7.61e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7580658	0.963	rs12052483	chr2:128136820	T/G	cg10021288	chr2:128175891	PROC	-0.65	-13.43	-0.53	5.94e-35	Protein C levels;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg02158880	chr13:53174818	NA	0.36	6.83	0.3	2.65e-11	Lewy body disease;
LGG	cis	rs8114671	0.935	rs6060282	chr20:33767066	C/T	cg07148914	chr20:33460835	GGT7	0.43	6.88	0.3	1.94e-11	Height;
LGG	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg21399703	chr1:247681439	NA	-0.68	-12.2	-0.49	6.78e-30	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg01314568	chr7:57830625	NA	-0.52	-8.16	-0.35	3.21e-15	Obesity-related traits;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.12	-0.39	2.23e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06098346	chr12:48499667	PFKM;SENP1	-0.46	-6.97	-0.31	1.08e-11	Gut microbiome composition (summer);
LGG	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg02574844	chr11:5959923	NA	-0.59	-9.07	-0.39	3.29e-18	DNA methylation (variation);
LGG	cis	rs1577917	0.771	rs7452605	chr6:86240951	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	12.01	0.49	4.16e-29	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg15268244	chr15:77196840	NA	-0.32	-7.1	-0.31	4.86e-12	Blood metabolite levels;
LGG	cis	rs58688157	0.705	rs12419694	chr11:598033	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.76	-0.34	5.43e-14	Systemic lupus erythematosus;
LGG	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg03929089	chr4:120376271	NA	0.72	8.37	0.36	7e-16	Axial length;
LGG	cis	rs2108225	0.934	rs2190392	chr7:107452685	T/C	cg18560240	chr7:107437656	SLC26A3	-0.56	-9.89	-0.42	4.66e-21	Ulcerative colitis;
LGG	trans	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6089584	0.816	rs4134440	chr20:60624296	A/G	cg12751644	chr20:60527061	NA	-0.31	-6.92	-0.31	1.47e-11	Body mass index;
LGG	trans	rs10506458	1.000	rs10506458	chr12:63445092	G/A	cg22491629	chr6:157744540	C6orf35	-0.91	-12.54	-0.5	2.8e-31	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.22	0.68	1.29e-65	Platelet count;
LGG	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg27121462	chr16:89883253	FANCA	0.61	11.26	0.46	3.83e-26	Vitiligo;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg02733842	chr7:1102375	C7orf50	0.42	7.46	0.33	4.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28489187	0.706	rs3087894	chr1:85787118	G/C	cg16011679	chr1:85725395	C1orf52	0.35	6.71	0.3	5.62e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7715811	1.000	rs7715552	chr5:13769959	A/T	cg07548982	chr5:13769939	DNAH5	-0.47	-9.85	-0.42	6.48e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.28	0.32	1.49e-12	Hip circumference adjusted for BMI;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg04008888	chr11:68622739	NA	-0.55	-11.73	-0.48	5.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3540	0.597	rs7498113	chr15:91051192	C/G	cg22089800	chr15:90895588	ZNF774	-0.68	-12.4	-0.5	1.14e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs936229	0.749	rs8042694	chr15:75225415	G/A	cg14664628	chr15:75095509	CSK	-0.89	-17.02	-0.62	8.79e-51	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs7980799	0.649	rs11052736	chr12:33669583	T/C	cg13010199	chr12:38710504	ALG10B	0.46	8.25	0.36	1.69e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs12478296	1.000	rs55767645	chr2:242999350	G/A	cg18898632	chr2:242989856	NA	-0.9	-9.66	-0.41	3.09e-20	Obesity-related traits;
LGG	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg07382826	chr16:28625726	SULT1A1	0.41	8.86	0.38	1.68e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7226408	0.600	rs1485820	chr18:34699047	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.12	-0.39	2.37e-18	Obesity-related traits;
LGG	cis	rs2836974	0.666	rs1888487	chr21:40683259	A/G	cg06238570	chr21:40685208	BRWD1	-0.54	-8.92	-0.38	1.08e-17	Cognitive function;
LGG	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Bladder cancer;
LGG	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg12219531	chr12:120966889	COQ5	0.67	11.14	0.46	1.06e-25	High light scatter reticulocyte count;
LGG	cis	rs2816062	0.813	rs2816040	chr1:18889536	C/T	cg18795169	chr1:18902165	NA	1.06	32.15	0.83	4.94e-120	Urate levels in lean individuals;
LGG	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.87	-0.42	5.64e-21	Primary sclerosing cholangitis;
LGG	cis	rs6696846	0.777	rs9651228	chr1:205049383	A/G	cg00857998	chr1:205179979	DSTYK	0.48	7.78	0.34	4.61e-14	Red blood cell count;
LGG	cis	rs35079168	0.923	rs10858276	chr9:137287913	C/T	cg00753924	chr9:137298813	RXRA	-0.38	-7.18	-0.32	2.77e-12	Intelligence;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg26174226	chr8:58114915	NA	-0.6	-8.24	-0.36	1.8e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs929596	1.000	rs929596	chr2:234674476	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.79	-13.9	-0.54	5.66e-37	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.0	-0.31	9.32e-12	Joint mobility (Beighton score);
LGG	cis	rs1153858	0.943	rs11070454	chr15:45680252	C/T	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs988958	0.567	rs13005448	chr2:42267903	A/C	cg27428208	chr2:42229179	NA	0.5	8.65	0.37	8.41e-17	Hypospadias;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.34	-0.5	1.98e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07570687	chr10:102243282	WNT8B	0.46	7.93	0.35	1.7e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs283228	0.798	rs1872512	chr6:101832200	A/C	cg27451362	chr6:101846650	GRIK2	0.69	10.79	0.45	2.22e-24	Coenzyme Q10 levels;
LGG	cis	rs67311347	1.000	rs112619360	chr3:40432645	T/G	cg13683864	chr3:40499215	RPL14	-1.1	-24.2	-0.75	3.06e-84	Renal cell carcinoma;
LGG	cis	rs9595066	0.627	rs4941486	chr13:44749157	G/A	cg04068111	chr13:44716778	NA	-0.52	-8.04	-0.35	7.81e-15	Schizophrenia;
LGG	trans	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg22358067	chr17:16797159	NA	-0.52	-7.32	-0.32	1.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13082711	0.522	rs480238	chr3:27347577	A/T	cg02860705	chr3:27208620	NA	0.59	11.13	0.46	1.15e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3806843	0.735	rs2563306	chr5:140070017	C/T	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg06112835	chr11:68658793	MRPL21	-0.55	-9.24	-0.39	8.98e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01570182	chr17:44337453	NA	-0.62	-10.29	-0.43	1.67e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg13206674	chr6:150067644	NUP43	0.66	14.85	0.57	4.42e-41	Lung cancer;
LGG	cis	rs7599312	0.534	rs6751692	chr2:213408120	C/T	cg20637307	chr2:213403960	ERBB4	0.74	16.77	0.61	1.09e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs62400317	0.762	rs62436411	chr6:44940706	T/G	cg20913747	chr6:44695427	NA	-0.65	-11.16	-0.46	9.09e-26	Total body bone mineral density;
LGG	cis	rs4561483	0.801	rs33623	chr16:12007435	A/G	cg08843971	chr16:11963173	GSPT1	0.68	18.6	0.65	4.51e-58	Testicular germ cell tumor;
LGG	cis	rs73001065	0.551	rs10424702	chr19:19508013	A/G	cg03709012	chr19:19516395	GATAD2A	0.96	11.11	0.46	1.35e-25	LDL cholesterol;
LGG	trans	rs12310956	0.532	rs7306007	chr12:33975209	C/G	cg26384229	chr12:38710491	ALG10B	0.73	14.67	0.56	2.87e-40	Morning vs. evening chronotype;
LGG	cis	rs4919087	0.748	rs701815	chr10:98975893	A/C	cg25902810	chr10:99078978	FRAT1	-0.43	-7.45	-0.33	4.49e-13	Monocyte count;
LGG	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg04117972	chr1:227635322	NA	0.73	11.71	0.48	6.57e-28	Major depressive disorder;
LGG	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg08400814	chr5:56204995	C5orf35	-0.44	-6.85	-0.3	2.35e-11	Initial pursuit acceleration;
LGG	cis	rs9463078	0.727	rs9463054	chr6:44917197	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.49	-0.37	2.79e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg13482628	chr17:19912719	NA	0.52	9.53	0.4	8.89e-20	Schizophrenia;
LGG	cis	rs10927875	0.722	rs1763606	chr1:16338282	A/G	cg22431228	chr1:16359049	CLCNKA	-0.44	-7.14	-0.31	3.74e-12	Dilated cardiomyopathy;
LGG	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-13.59	-0.53	1.19e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs8067545	0.611	rs16960697	chr17:20027718	A/G	cg09818912	chr17:20140352	CYTSB	-0.33	-7.65	-0.33	1.19e-13	Schizophrenia;
LGG	cis	rs2742417	1.000	rs17328701	chr3:45734258	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.4	-0.44	6.84e-23	Bipolar disorder;
LGG	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs4704846	0.614	rs2862718	chr5:156500626	G/A	cg12943317	chr5:156479607	HAVCR1	-0.58	-8.0	-0.35	9.88e-15	Blood protein levels;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg13397359	chr6:42928475	GNMT	0.58	15.95	0.6	6.06e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg25358565	chr5:93447407	FAM172A	1.37	17.05	0.62	6.38e-51	Diabetic retinopathy;
LGG	cis	rs6694672	1.000	rs4915309	chr1:197048781	A/T	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.79	-0.34	4.59e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg24006582	chr15:45444508	DUOX1	-0.7	-13.54	-0.53	2.08e-35	Uric acid levels;
LGG	cis	rs6547631	0.622	rs4240201	chr2:85925667	G/A	cg19805943	chr2:85933069	NA	0.32	6.8	0.3	3.17e-11	Blood protein levels;
LGG	cis	rs4481887	0.927	rs4381224	chr1:248456826	A/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.68	-0.41	2.68e-20	Common traits (Other);
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg18681998	chr4:17616180	MED28	0.85	18.86	0.66	2.89e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg14952266	chr13:112191215	NA	0.52	10.93	0.45	6.56e-25	Hepatitis;
LGG	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.58	-0.56	6.68e-40	Headache;
LGG	trans	rs12579753	0.917	rs7138651	chr12:82253615	A/G	cg07923666	chr12:49932857	KCNH3	0.43	6.79	0.3	3.51e-11	Resting heart rate;
LGG	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.63	-11.06	-0.46	2.23e-25	Chronic sinus infection;
LGG	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg16980736	chr17:78789706	RPTOR	0.67	8.63	0.37	1.02e-16	Myopia (pathological);
LGG	cis	rs4819052	0.851	rs2838850	chr21:46671445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.76	0.38	3.62e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9303401	0.614	rs66480139	chr17:57101538	G/A	cg25039879	chr17:56429692	SUPT4H1	0.56	8.02	0.35	8.64e-15	Cognitive test performance;
LGG	cis	rs9952991	0.883	rs11663253	chr18:12789556	A/G	cg23544223	chr18:12777786	NA	-0.57	-8.39	-0.36	5.76e-16	Inflammatory skin disease;
LGG	cis	rs7766436	0.767	rs13200993	chr6:22612912	C/T	cg13666174	chr6:22585274	NA	-0.37	-8.69	-0.37	6.42e-17	Coronary artery disease;
LGG	cis	rs4919694	0.901	rs12251035	chr10:104671459	A/C	cg04362960	chr10:104952993	NT5C2	1.06	14.78	0.57	9.05e-41	Arsenic metabolism;
LGG	cis	rs9868809	0.505	rs11706983	chr3:48738678	A/G	cg00383909	chr3:49044727	WDR6	0.92	11.43	0.47	8.27e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6063312	1.000	rs11699576	chr20:47349878	A/C	cg18078177	chr20:47281410	PREX1	0.74	8.98	0.39	6.92e-18	Tonometry;
LGG	cis	rs1693575	0.770	rs1786342	chr8:101676363	T/C	cg06874326	chr8:101662790	SNX31	-0.34	-6.8	-0.3	3.31e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg21926883	chr2:100939477	LONRF2	-0.66	-15.33	-0.58	3.46e-43	Intelligence (multi-trait analysis);
LGG	cis	rs4302748	0.862	rs11980735	chr7:36183683	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs7572733	0.534	rs10931794	chr2:198776140	C/T	cg00792783	chr2:198669748	PLCL1	-0.69	-11.11	-0.46	1.36e-25	Dermatomyositis;
LGG	cis	rs1003719	0.613	rs9978998	chr21:38535848	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs6459804	1.000	rs6459804	chr7:157510195	C/T	cg01625945	chr7:157512322	PTPRN2	-0.47	-11.15	-0.46	9.61e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11971779	0.584	rs34762928	chr7:139113168	T/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	10.25	0.43	2.29e-22	Mood instability;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg26297688	chr12:107349093	C12orf23	0.38	7.21	0.32	2.32e-12	Total body bone mineral density;
LGG	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg08461772	chr7:95026248	PON3	0.36	7.5	0.33	3.2e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs67311347	1.000	rs7628796	chr3:40507332	G/A	cg13683864	chr3:40499215	RPL14	1.16	29.59	0.81	8.26e-109	Renal cell carcinoma;
LGG	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg14191688	chr11:70257035	CTTN	0.56	8.2	0.36	2.39e-15	Coronary artery disease;
LGG	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21747090	chr2:27597821	SNX17	0.37	6.75	0.3	4.35e-11	Total body bone mineral density;
LGG	cis	rs10267417	0.603	rs10264406	chr7:19915167	T/A	cg05791153	chr7:19748676	TWISTNB	0.53	6.81	0.3	2.95e-11	Night sleep phenotypes;
LGG	cis	rs12618769	0.597	rs72821946	chr2:99142411	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.57	-0.5	2.19e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.49	0.37	2.91e-16	Prostate cancer;
LGG	cis	rs6964587	0.967	rs34863529	chr7:91644341	C/G	cg17063962	chr7:91808500	NA	0.49	8.65	0.37	8.26e-17	Breast cancer;
LGG	cis	rs36715	0.868	rs2546147	chr5:127552590	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.45	7.17	0.32	2.9e-12	Breast cancer;
LGG	cis	rs1408799	0.579	rs10124197	chr9:12746651	A/G	cg05274944	chr9:12693694	TYRP1	-0.31	-6.87	-0.3	2.11e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs704	0.585	rs3093680	chr17:26664806	T/C	cg10342447	chr17:26645325	TMEM97	-0.52	-9.8	-0.41	9.59e-21	Osteoprotegerin levels;
LGG	cis	rs6732160	0.588	rs2043099	chr2:73374156	G/A	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2413583	0.591	rs12483879	chr22:39719148	C/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	7.97	0.35	1.25e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.62	-0.33	1.44e-13	Obesity;
LGG	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.58	0.33	1.89e-13	Neuroticism;
LGG	cis	rs2797369	0.713	rs2813648	chr6:101582492	C/T	cg27451362	chr6:101846650	GRIK2	0.79	10.53	0.44	2.1e-23	Renal function-related traits (eGRFcrea);
LGG	trans	rs61931739	0.517	rs4931748	chr12:34140827	C/T	cg13010199	chr12:38710504	ALG10B	0.58	11.11	0.46	1.37e-25	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.73	-0.34	6.86e-14	Schizophrenia;
LGG	cis	rs477692	0.789	rs506915	chr10:131398005	A/G	cg05714579	chr10:131428358	MGMT	0.5	10.17	0.43	4.72e-22	Response to temozolomide;
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg26554054	chr8:600488	NA	1.17	11.78	0.48	3.24e-28	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.38e-12	Menopause (age at onset);
LGG	cis	rs564799	0.966	rs571099	chr3:159732564	T/G	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs7927771	0.965	rs35985502	chr11:47847428	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg20308403	chr7:2120281	MAD1L1	0.35	7.39	0.32	6.74e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg03929089	chr4:120376271	NA	0.59	6.96	0.31	1.14e-11	Body mass index;
LGG	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	13.08	0.52	1.78e-33	Monocyte count;
LGG	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg08975724	chr8:8085496	FLJ10661	0.37	6.7	0.3	5.9e-11	Retinal vascular caliber;
LGG	cis	rs6032067	0.777	rs55767422	chr20:43802497	A/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs643506	0.845	rs7114594	chr11:111768113	A/G	cg09085632	chr11:111637200	PPP2R1B	0.43	6.86	0.3	2.19e-11	Breast cancer;
LGG	cis	rs1816752	0.837	rs7139748	chr13:24985669	G/A	cg02811702	chr13:24901961	NA	0.39	7.2	0.32	2.4e-12	Obesity-related traits;
LGG	cis	rs2075423	1.000	rs2075423	chr1:214154719	A/C	cg10769146	chr1:214156644	NA	-0.44	-7.61	-0.33	1.58e-13	Type 2 diabetes;
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg16434002	chr17:42200994	HDAC5	-0.49	-8.18	-0.36	2.74e-15	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg06219351	chr7:158114137	PTPRN2	-0.76	-14.71	-0.56	1.75e-40	Calcium levels;
LGG	cis	rs5758659	0.652	rs133305	chr22:42395960	C/T	cg15128208	chr22:42549153	NA	-0.37	-7.51	-0.33	3.1e-13	Cognitive function;
LGG	cis	rs10857712	0.703	rs12253520	chr10:135235321	C/A	cg19904058	chr10:135279010	LOC619207	-0.28	-6.8	-0.3	3.33e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.22	0.32	2.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6831352	0.918	rs7670060	chr4:100059568	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg05165339	chr4:1420672	NA	-0.36	-9.1	-0.39	2.73e-18	Longevity;
LGG	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg12386194	chr3:101231763	SENP7	0.73	12.51	0.5	3.74e-31	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4493873	0.869	rs12542178	chr8:92107070	A/G	cg16814680	chr8:91681699	NA	0.44	6.89	0.31	1.81e-11	Migraine - clinic-based;
LGG	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg18252515	chr7:66147081	NA	1.2	15.55	0.59	3.58e-44	Diabetic kidney disease;
LGG	cis	rs9596863	0.634	rs2806731	chr13:54290333	C/T	ch.13.53330881F	chr13:54432880	NA	-0.44	-6.86	-0.3	2.18e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6912958	1.000	rs9450701	chr6:88173167	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-10.34	-0.43	1.09e-22	Monocyte percentage of white cells;
LGG	cis	rs9467160	0.871	rs13205780	chr6:24448687	C/T	cg20631270	chr6:24437470	GPLD1	0.51	7.65	0.33	1.2e-13	Liver enzyme levels;
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.77	-0.45	2.68e-24	Bipolar disorder;
LGG	trans	rs3749237	0.964	rs11717463	chr3:49808981	C/T	cg21659725	chr3:3221576	CRBN	0.75	11.6	0.47	1.68e-27	Resting heart rate;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.18e-20	Aortic root size;
LGG	cis	rs4742903	1.000	rs7350148	chr9:106883085	T/G	cg14250997	chr9:106856677	SMC2	0.39	8.17	0.36	2.91e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.76	-0.34	5.62e-14	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.25e-14	Lung cancer;
LGG	cis	rs988958	0.679	rs10171410	chr2:42224842	A/G	cg19376973	chr2:42229025	NA	0.64	9.87	0.42	5.6e-21	Hypospadias;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.19	0.36	2.6e-15	Tonsillectomy;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.74	-0.34	6.42e-14	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs79605389	chr22:32413385	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs1505368	0.563	rs1394798	chr2:213230641	G/A	cg20637307	chr2:213403960	ERBB4	0.47	9.2	0.39	1.23e-18	Symmetrical dimethylarginine levels;
LGG	cis	rs4262150	0.667	rs11746423	chr5:152257512	G/T	cg12297329	chr5:152029980	NA	0.6	11.67	0.48	8.96e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1348850	0.958	rs10930799	chr2:178459325	G/C	cg27490568	chr2:178487706	NA	0.46	8.94	0.38	9.13e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg13880726	chr7:1868755	MAD1L1	0.46	7.79	0.34	4.33e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7250872	0.606	rs2289286	chr19:1822668	T/C	cg18850929	chr19:1828978	REXO1	0.48	7.84	0.34	3.08e-14	Bipolar disorder;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-6.81	-0.3	3.07e-11	Schizophrenia;
LGG	cis	rs2073300	0.536	rs6137947	chr20:23414630	C/A	cg12062639	chr20:23401060	NAPB	0.92	8.7	0.37	5.96e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg07882059	chr11:68924751	NA	0.39	7.1	0.31	4.62e-12	Blond vs. brown hair color;
LGG	cis	rs7044106	0.791	rs10984997	chr9:123481206	T/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.19	0.32	2.55e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.4	-8.17	-0.36	2.91e-15	Prostate cancer;
LGG	cis	rs2933343	1.000	rs789232	chr3:128603080	T/G	cg25356066	chr3:128598488	ACAD9	0.46	6.83	0.3	2.63e-11	IgG glycosylation;
LGG	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg14227996	chr4:17616232	MED28	0.75	9.21	0.39	1.1e-18	Opioid sensitivity;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg05493394	chr6:133562035	EYA4	0.31	8.44	0.37	4.13e-16	Total body bone mineral density;
LGG	cis	rs2486288	0.656	rs1706767	chr15:45569099	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.51	-8.97	-0.38	7.24e-18	Glomerular filtration rate;
LGG	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.54	-0.44	1.99e-23	Initial pursuit acceleration;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg05468351	chr5:21459598	LOC728411	0.41	7.2	0.32	2.48e-12	Body mass index;
LGG	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-7.05	-0.31	6.39e-12	Educational attainment;
LGG	cis	rs62238980	0.614	rs117305417	chr22:32400975	T/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs11158026	0.757	rs8019220	chr14:55453469	C/T	cg04306507	chr14:55594613	LGALS3	0.32	7.3	0.32	1.27e-12	Parkinson's disease;
LGG	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14154082	chr13:112174009	NA	0.42	9.24	0.39	9.2e-19	Menarche (age at onset);
LGG	cis	rs12464483	0.556	rs2609934	chr2:30895979	G/A	cg12454169	chr2:30669597	LCLAT1	0.53	7.64	0.33	1.28e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs61931739	1.000	rs12424741	chr12:34022771	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-7.9	-0.34	2.1e-14	Morning vs. evening chronotype;
LGG	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg08392591	chr16:89556376	ANKRD11	-0.47	-7.39	-0.32	6.79e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11608355	0.545	rs11612500	chr12:109897136	T/C	cg05360138	chr12:110035743	NA	0.84	12.07	0.49	2.25e-29	Neuroticism;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Electroencephalogram traits;
LGG	cis	rs4662945	0.603	rs10496678	chr2:130262209	C/T	cg05962382	chr2:130345044	NA	-0.47	-8.2	-0.36	2.39e-15	Response to cytidine analogues (gemcitabine);
LGG	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.91	0.35	1.88e-14	Cannabis dependence symptom count;
LGG	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg23202291	chr11:1979235	NA	0.44	8.75	0.38	3.88e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs877282	0.898	rs11253349	chr10:765897	C/G	cg22713356	chr15:30763199	NA	0.51	7.51	0.33	3.17e-13	Uric acid levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10130446	chr14:55658398	DLGAP5	0.49	8.41	0.36	5.16e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs2028299	0.920	rs2118847	chr15:90408847	C/G	cg23731826	chr15:90371692	NA	0.35	7.89	0.34	2.15e-14	Type 2 diabetes;
LGG	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.33	0.43	1.24e-22	Neutrophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19057882	chr20:37101373	RALGAPB	0.45	7.25	0.32	1.8e-12	Cognitive performance;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.73	-0.3	4.88e-11	Personality dimensions;
LGG	cis	rs17767392	0.756	rs11626445	chr14:71739134	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.71	-0.38	5.25e-17	Mitral valve prolapse;
LGG	trans	rs2562456	0.876	rs2650844	chr19:21602090	A/T	cg00806126	chr19:22604979	ZNF98	-0.54	-7.29	-0.32	1.32e-12	Pain;
LGG	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg13271783	chr10:134563150	INPP5A	-0.47	-7.29	-0.32	1.39e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs2933343	0.700	rs1680788	chr3:128625318	C/T	cg11901034	chr3:128598214	ACAD9	-0.44	-6.65	-0.3	8.31e-11	IgG glycosylation;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.52e-12	Menopause (age at onset);
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs2694528	0.858	rs1989653	chr5:60390090	A/C	cg11474532	chr5:59995715	DEPDC1B	0.67	7.22	0.32	2.15e-12	Parkinson's disease;
LGG	cis	rs367943	0.965	rs644154	chr5:112799080	G/T	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.2e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs2180341	1.000	rs4895822	chr6:127642703	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs113084984	0.718	rs7568108	chr2:11683324	C/T	cg07314298	chr2:11723111	GREB1	0.36	6.76	0.3	4.22e-11	Breast cancer;
LGG	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.76	0.34	5.56e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6708331	0.540	rs9677885	chr2:70381819	A/G	cg01613454	chr2:70366299	NA	0.53	10.77	0.45	2.77e-24	Obesity-related traits;
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.57e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4689642	0.507	rs10020947	chr4:7222407	A/C	cg21353189	chr4:7228343	SORCS2	0.33	6.95	0.31	1.25e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs9397585	0.857	rs9479487	chr6:153371002	T/C	cg17707550	chr6:153380415	RGS17	0.63	14.83	0.57	5.59e-41	Body mass index;
LGG	cis	rs981844	0.712	rs1037648	chr4:154737877	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09672890	chr17:70536484	NA	0.49	7.74	0.34	6.36e-14	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.839	rs12664634	chr6:86579414	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.15	-0.35	3.55e-15	Response to antipsychotic treatment;
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.45	-0.4	1.66e-19	Neuroticism;
LGG	cis	rs4430311	0.571	rs1379700	chr1:243909402	A/G	cg25706552	chr1:244017396	NA	-0.61	-13.86	-0.54	8.36e-37	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg04503457	chr17:41445688	NA	-0.38	-8.71	-0.38	5.47e-17	Menopause (age at onset);
LGG	cis	rs7666738	0.830	rs28852677	chr4:99039509	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.79	0.41	1.06e-20	Joint mobility (Beighton score);
LGG	cis	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.81	0.34	3.81e-14	Neuroticism;
LGG	cis	rs7937682	0.575	rs7950926	chr11:111776437	G/C	cg09085632	chr11:111637200	PPP2R1B	0.98	19.59	0.67	1.15e-62	Primary sclerosing cholangitis;
LGG	trans	rs7395662	0.591	rs12807777	chr11:48593754	A/T	cg03929089	chr4:120376271	NA	-0.53	-8.97	-0.38	7.18e-18	HDL cholesterol;
LGG	cis	rs9815354	0.556	rs56201224	chr3:42004427	A/C	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg03576123	chr11:487126	PTDSS2	-1.21	-15.58	-0.59	2.5e-44	Body mass index;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg00830817	chr11:109293614	C11orf87	0.42	6.74	0.3	4.62e-11	Schizophrenia;
LGG	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.23	-0.39	9.8e-19	Common traits (Other);
LGG	cis	rs4665809	1.000	rs1560868	chr2:26281459	A/T	cg22920501	chr2:26401640	FAM59B	0.38	7.41	0.33	5.87e-13	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg03264133	chr6:25882463	NA	-0.4	-6.99	-0.31	9.35e-12	Height;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10262624	1.000	rs2106747	chr7:23911499	A/G	cg09690326	chr7:23720549	C7orf46	-0.32	-6.67	-0.3	7.5e-11	Schizophrenia;
LGG	cis	rs11690935	0.877	rs13024846	chr2:172835803	C/T	cg21435375	chr2:172878103	MAP1D	-0.32	-7.08	-0.31	5.4e-12	Schizophrenia;
LGG	cis	rs12230513	0.732	rs7294659	chr12:55866519	T/C	cg19537932	chr12:55886519	OR6C68	-0.61	-10.92	-0.45	7.38e-25	Contrast sensitivity;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg16147221	chr4:10020634	SLC2A9	0.36	6.75	0.3	4.5e-11	Bone mineral density;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2694528	0.858	rs74366686	chr5:60461194	C/A	cg11474532	chr5:59995715	DEPDC1B	0.68	7.32	0.32	1.14e-12	Parkinson's disease;
LGG	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.36e-18	Motion sickness;
LGG	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9472414	0.680	rs34577161	chr6:44696401	A/G	cg20913747	chr6:44695427	NA	0.49	7.43	0.33	5.21e-13	Height;
LGG	cis	rs8141529	0.509	rs7287124	chr22:29239157	A/G	cg15103426	chr22:29168792	CCDC117	0.66	9.93	0.42	3.28e-21	Lymphocyte counts;
LGG	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg02886208	chr11:14281011	SPON1	-0.35	-6.79	-0.3	3.37e-11	Sense of smell;
LGG	cis	rs1318772	1.000	rs35451724	chr5:112683992	G/A	cg12552261	chr5:112820674	MCC	0.71	8.35	0.36	8.12e-16	F-cell distribution;
LGG	cis	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg00405596	chr8:11794950	NA	-0.39	-6.7	-0.3	6.02e-11	Systolic blood pressure;
LGG	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg11764359	chr7:65958608	NA	0.71	12.92	0.51	7.77e-33	Aortic root size;
LGG	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg00579200	chr11:133705235	NA	-0.52	-10.07	-0.42	1.06e-21	Childhood ear infection;
LGG	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06470251	chr20:60548479	NA	0.46	8.19	0.36	2.58e-15	Body mass index;
LGG	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.44	7.21	0.32	2.28e-12	Longevity;
LGG	cis	rs12579753	0.879	rs7958657	chr12:82135067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.34	-0.5	1.92e-30	Resting heart rate;
LGG	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs9486715	0.867	rs2499775	chr6:97007340	C/T	cg06623918	chr6:96969491	KIAA0776	-0.79	-16.06	-0.6	1.95e-46	Headache;
LGG	cis	rs9443645	0.901	rs6454092	chr6:79701972	G/A	cg18132916	chr6:79620363	NA	-0.3	-8.27	-0.36	1.41e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg24112000	chr20:60950667	NA	-0.36	-7.78	-0.34	4.85e-14	Colorectal cancer;
LGG	cis	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg07460842	chr6:66804631	NA	-1.14	-32.18	-0.83	3.52e-120	Exhaled nitric oxide output;
LGG	cis	rs7524258	0.903	rs4908609	chr1:7292910	G/A	cg07173049	chr1:7289937	CAMTA1	0.78	19.42	0.67	6.95e-62	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9309473	0.607	rs7567343	chr2:73596605	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-8.58	-0.37	1.45e-16	Metabolite levels;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.95	0.35	1.44e-14	Renal function-related traits (BUN);
LGG	cis	rs12791968	0.649	rs3802785	chr11:44995441	C/T	cg11846598	chr11:44996168	LOC221122	-0.53	-8.32	-0.36	1.03e-15	Inhibitory control;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg01570182	chr17:44337453	NA	-0.66	-10.88	-0.45	1.08e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10463554	0.759	rs34815	chr5:102434265	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.4	-0.36	5.47e-16	Parkinson's disease;
LGG	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg02631450	chr22:32366979	NA	0.99	9.34	0.4	4.17e-19	Childhood ear infection;
LGG	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg05623727	chr3:50126028	RBM5	-0.38	-8.38	-0.36	6.55e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.02	-0.31	8.04e-12	IgG glycosylation;
LGG	cis	rs1003719	0.788	rs8133549	chr21:38447489	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs2011503	0.941	rs2010506	chr19:19387356	C/T	cg01262667	chr19:19385393	TM6SF2	0.34	6.7	0.3	6.13e-11	Bipolar disorder;
LGG	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg25173405	chr17:45401733	C17orf57	0.52	8.73	0.38	4.69e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs929354	1.000	rs1182391	chr7:157038368	T/C	cg05182265	chr7:156933206	UBE3C	0.34	6.73	0.3	5.17e-11	Body mass index;
LGG	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg20311673	chr2:1746207	PXDN	-0.39	-6.75	-0.3	4.5e-11	Response to antipsychotic treatment;
LGG	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg07928641	chr1:182991847	LAMC1	-0.48	-9.85	-0.42	6.81e-21	Hypertriglyceridemia;
LGG	trans	rs9354308	0.868	rs9363458	chr6:66552798	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.06	-0.35	6.46e-15	Metabolite levels;
LGG	trans	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.31	-0.32	1.16e-12	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg06634786	chr22:41940651	POLR3H	0.79	13.0	0.52	3.6e-33	Vitiligo;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	trans	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg07393940	chr7:158741817	NA	-0.58	-10.78	-0.45	2.57e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11644478	chr21:40555479	PSMG1	-0.74	-13.43	-0.53	6.05e-35	Cognitive function;
LGG	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg13075951	chr6:39282393	KCNK17	0.26	6.87	0.3	2.04e-11	Type 2 diabetes;
LGG	trans	rs7939886	0.920	rs60073283	chr11:56094356	A/C	cg15704280	chr7:45808275	SEPT13	0.8	7.23	0.32	1.97e-12	Myopia (pathological);
LGG	cis	rs7827545	0.545	rs57219802	chr8:135554231	C/T	cg17885191	chr8:135476712	NA	0.64	9.42	0.4	2.19e-19	Hypertension (SNP x SNP interaction);
LGG	trans	rs561341	0.941	rs8081016	chr17:30331751	A/G	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.47e-83	Hip circumference adjusted for BMI;
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg07005078	chr4:17578674	LAP3	0.36	6.73	0.3	4.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00689492	chr4:1303491	MAEA	0.5	8.54	0.37	1.94e-16	Obesity-related traits;
LGG	cis	rs7084402	0.870	rs4948525	chr10:60361270	G/A	cg07615347	chr10:60278583	BICC1	0.61	16.41	0.61	5.08e-48	Refractive error;
LGG	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg21926883	chr2:100939477	LONRF2	-0.68	-15.97	-0.6	4.56e-46	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.72	-0.34	7.17e-14	Colorectal cancer;
LGG	cis	rs9914988	0.943	rs9890377	chr17:27111111	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2204008	0.623	rs4882302	chr12:38415608	T/A	cg04568710	chr12:38710424	ALG10B	-0.41	-9.19	-0.39	1.29e-18	Bladder cancer;
LGG	trans	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.38	0.36	6.45e-16	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-10.51	-0.44	2.63e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg19812747	chr11:111475976	SIK2	-0.49	-10.3	-0.43	1.49e-22	Primary sclerosing cholangitis;
LGG	cis	rs10484885	0.878	rs72921959	chr6:90591326	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-11.01	-0.46	3.23e-25	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.34e-16	Life satisfaction;
LGG	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg00717180	chr2:96193071	NA	-0.47	-8.85	-0.38	1.91e-17	HDL cholesterol;
LGG	cis	rs7119	0.717	rs62009071	chr15:77817886	C/G	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs4561483	0.603	rs11544193	chr16:12009304	C/A	cg08843971	chr16:11963173	GSPT1	0.59	14.54	0.56	1.02e-39	Testicular germ cell tumor;
LGG	trans	rs11039798	1.000	rs11530232	chr11:48622376	C/T	cg03929089	chr4:120376271	NA	0.74	7.85	0.34	2.93e-14	Axial length;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17164693	chr10:124913828	BUB3	0.43	6.72	0.3	5.47e-11	Gut microbiome composition (summer);
LGG	cis	rs4750440	0.540	rs11258766	chr10:14016196	G/A	cg00551146	chr10:14014579	FRMD4A	0.31	7.28	0.32	1.43e-12	Adiponectin levels;
LGG	cis	rs2011503	1.000	rs8101219	chr19:19643715	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs2693698	0.502	rs1257444	chr14:99687211	A/G	cg07440398	chr14:99712966	BCL11B	0.5	10.24	0.43	2.6e-22	Schizophrenia;
LGG	cis	rs17345786	1.000	rs73863360	chr3:101316837	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	8.9	0.38	1.24e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.57	0.53	1.47e-35	Prudent dietary pattern;
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg07538946	chr5:131705188	SLC22A5	0.61	7.13	0.31	3.78e-12	Rheumatoid arthritis;
LGG	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg25174290	chr11:3078921	CARS	0.74	15.83	0.59	2.06e-45	Longevity;
LGG	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-12.18	-0.49	8.26e-30	Vitiligo;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs143626010	1	rs143626010	chr16:28539398	GTGTA/G	cg07382826	chr16:28625726	SULT1A1	0.43	9.08	0.39	3.07e-18	Mosquito bite size;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg02475777	chr4:1388615	CRIPAK	0.58	10.47	0.44	3.57e-23	Longevity;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.82	-0.3	2.82e-11	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg06558623	chr16:89946397	TCF25	1.19	12.93	0.52	7.08e-33	Skin colour saturation;
LGG	trans	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg06875740	chr19:51307921	C19orf48	-0.65	-6.82	-0.3	2.77e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.84	-14.51	-0.56	1.42e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg17764715	chr19:33622953	WDR88	0.52	9.49	0.4	1.26e-19	Colorectal cancer;
LGG	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	7.85e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.09	-0.31	4.94e-12	Iron status biomarkers;
LGG	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg11890956	chr21:40555474	PSMG1	1.18	30.85	0.82	2.21e-114	Cognitive function;
LGG	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.85	-0.34	2.89e-14	Iron status biomarkers;
LGG	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.82	0.34	3.53e-14	Electroencephalogram traits;
LGG	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15684116	chr1:153700070	INTS3	0.48	7.48	0.33	3.75e-13	Gut microbiome composition (summer);
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg18350739	chr11:68623251	NA	-0.89	-23.03	-0.73	8.53e-79	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg04156016	chr5:1868137	NA	0.32	7.06	0.31	6.23e-12	Cardiovascular disease risk factors;
LGG	cis	rs6500395	1.000	rs9930199	chr16:48571263	A/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	14.54	0.56	1.02e-39	Menarche (age at onset);
LGG	cis	rs3857536	0.719	rs9363555	chr6:66930332	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.74	-0.34	6.51e-14	Blood trace element (Cu levels);
LGG	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg12386194	chr3:101231763	SENP7	0.72	12.53	0.5	3.31e-31	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2282802	0.635	rs270162	chr5:139539090	A/G	cg26211634	chr5:139558579	C5orf32	-0.32	-6.83	-0.3	2.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.97	0.31	1.12e-11	Lung cancer;
LGG	cis	rs6028335	0.610	rs28578430	chr20:37542467	G/A	cg16355469	chr20:37678765	NA	0.52	6.9	0.31	1.75e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.88e-22	Diabetic kidney disease;
LGG	cis	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.3	0.32	1.26e-12	Systolic blood pressure;
LGG	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg02002194	chr4:3960332	NA	0.4	7.13	0.31	3.96e-12	Neuroticism;
LGG	cis	rs4689642	0.507	rs10023421	chr4:7222461	T/G	cg21353189	chr4:7228343	SORCS2	0.33	7.13	0.31	3.8e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs9354308	0.764	rs9345710	chr6:66588391	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs747650	0.699	rs4237547	chr11:47236405	C/G	cg03339077	chr11:47165057	C11orf49	-0.52	-9.72	-0.41	1.94e-20	Acne (severe);
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg14668632	chr7:2872130	GNA12	-0.37	-7.57	-0.33	2.02e-13	Height;
LGG	cis	rs11098499	0.754	rs28652763	chr4:120242312	C/T	cg24375607	chr4:120327624	NA	0.6	10.09	0.42	8.88e-22	Corneal astigmatism;
LGG	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs11239187	0.523	rs34118524	chr10:45089937	T/C	cg03916630	chr10:45065415	NA	0.42	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg12438819	chr7:158236134	PTPRN2	0.3	7.97	0.35	1.26e-14	Obesity-related traits;
LGG	trans	rs11782517	0.883	rs13267960	chr8:10107064	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-7.24	-0.32	1.84e-12	Nose size;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg20476274	chr7:133979776	SLC35B4	0.5	8.97	0.38	7.35e-18	Mean platelet volume;
LGG	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.36	-0.32	8.51e-13	Uric acid levels;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg08355456	chr11:67383691	NA	0.54	9.49	0.4	1.27e-19	Mean corpuscular volume;
LGG	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.84	-10.64	-0.44	8.75e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.3e-14	Aortic root size;
LGG	cis	rs17021463	0.617	rs12499187	chr4:95323917	A/G	cg11021082	chr4:95130006	SMARCAD1	0.48	7.6	0.33	1.62e-13	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg18621852	chr3:10150065	C3orf24	0.41	6.89	0.3	1.86e-11	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.33	0.43	1.18e-22	Prudent dietary pattern;
LGG	cis	rs7312933	0.558	rs11181502	chr12:42823833	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	8.15	0.35	3.39e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6496667	0.557	rs2589951	chr15:90958392	T/C	cg22089800	chr15:90895588	ZNF774	0.5	8.18	0.36	2.76e-15	Rheumatoid arthritis;
LGG	cis	rs8064299	0.967	rs7420	chr17:72765215	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.67	-12.98	-0.52	4.57e-33	Monocyte count;
LGG	cis	rs12496230	1.000	rs3899502	chr3:66856411	A/G	cg04995300	chr3:66848608	NA	-0.5	-7.53	-0.33	2.66e-13	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09884257	chr4:6988322	TBC1D14	0.45	7.6	0.33	1.62e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg11764359	chr7:65958608	NA	0.8	14.97	0.57	1.29e-41	Aortic root size;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.88	-0.45	1.01e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg12708336	chr17:41446283	NA	0.34	8.23	0.36	1.87e-15	Menopause (age at onset);
LGG	cis	rs35740288	0.822	rs11638720	chr15:86229273	C/T	cg04173714	chr15:86211321	AKAP13	0.47	8.14	0.35	3.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11608355	0.545	rs12819142	chr12:109896316	G/T	cg05360138	chr12:110035743	NA	0.85	11.91	0.48	9.85e-29	Neuroticism;
LGG	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15506890	chr2:3487001	NA	-0.55	-10.64	-0.44	8.51e-24	Neurofibrillary tangles;
LGG	cis	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg26384229	chr12:38710491	ALG10B	0.76	15.45	0.58	9.69e-44	Morning vs. evening chronotype;
LGG	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Neuroticism;
LGG	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.27e-17	Retinal vascular caliber;
LGG	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.91	0.38	1.13e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs737008	0.922	rs28567501	chr16:11378928	C/A	cg00044050	chr16:11439710	C16orf75	-0.45	-6.68	-0.3	6.78e-11	Obesity-related traits;
LGG	cis	rs4740619	0.967	rs6474944	chr9:15670445	C/T	cg14451791	chr9:16040625	NA	0.38	9.83	0.42	7.71e-21	Body mass index;
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26897989	chr16:1907736	C16orf73	-0.85	-13.94	-0.54	4.02e-37	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.84	14.59	0.56	6.43e-40	Exhaled nitric oxide levels;
LGG	cis	rs1451375	0.669	rs59086818	chr7:50653830	G/A	cg00647317	chr7:50633725	DDC	-0.32	-7.37	-0.32	7.69e-13	Malaria;
LGG	cis	rs10937275	0.624	rs17774519	chr3:186665247	G/A	cg16751732	chr3:186648392	ST6GAL1	0.68	6.85	0.3	2.37e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9399135	0.527	rs61738492	chr6:135282771	G/A	cg22676075	chr6:135203613	NA	0.46	8.01	0.35	9.4e-15	Red blood cell count;
LGG	trans	rs61931739	0.621	rs843785	chr12:33729308	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.58	-0.37	1.43e-16	Morning vs. evening chronotype;
LGG	cis	rs77633900	0.614	rs157757	chr15:76855927	G/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.2	-0.39	1.2e-18	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4430311	0.723	rs7528450	chr1:243789305	T/A	cg25706552	chr1:244017396	NA	-0.64	-15.74	-0.59	5.33e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs7071206	0.898	rs28706743	chr10:79394329	T/G	cg07817648	chr10:79422355	NA	-0.8	-14.67	-0.56	2.61e-40	Bone mineral density;
LGG	cis	rs644799	0.544	rs1150360	chr11:95512060	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.25	0.52	3.34e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg02002194	chr4:3960332	NA	0.43	7.99	0.35	1.06e-14	Monocyte count;
LGG	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg23324259	chr8:82754387	SNX16	0.44	7.08	0.31	5.53e-12	Diastolic blood pressure;
LGG	cis	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.67	-0.56	2.8e-40	IgG glycosylation;
LGG	cis	rs7044106	0.791	rs10985000	chr9:123484115	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.47	7.56	0.33	2.22e-13	Hip circumference adjusted for BMI;
LGG	trans	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg18187862	chr3:45730750	SACM1L	-0.68	-11.82	-0.48	2.28e-28	Primary sclerosing cholangitis;
LGG	cis	rs72799341	1.000	rs7185007	chr16:30927509	C/T	cg00531865	chr16:30841666	NA	-0.51	-9.0	-0.39	5.75e-18	Diastolic blood pressure;
LGG	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg22232500	chr2:134024266	NCKAP5	0.58	8.14	0.35	3.61e-15	Bipolar disorder;
LGG	cis	rs7523273	0.606	rs761275	chr1:207972154	A/C	cg22525895	chr1:207977042	MIR29B2	-0.61	-12.07	-0.49	2.32e-29	Schizophrenia;
LGG	cis	rs9783347	1.000	rs4150550	chr11:18350898	C/G	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.58	-0.33	1.85e-13	Pancreatic cancer;
LGG	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg17809284	chr5:56205270	C5orf35	0.54	10.19	0.43	3.78e-22	Initial pursuit acceleration;
LGG	trans	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.53	9.25	0.39	8.53e-19	Blood metabolite levels;
LGG	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg26408565	chr15:76604113	ETFA	-0.39	-6.68	-0.3	6.74e-11	Blood metabolite levels;
LGG	cis	rs6998277	0.830	rs12543046	chr8:103603809	A/G	cg10187029	chr8:103597600	NA	-1.02	-19.7	-0.68	3.36e-63	Migraine;
LGG	cis	rs11792861	0.851	rs4542004	chr9:111814478	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	10.39	0.43	7.28e-23	Menarche (age at onset);
LGG	cis	rs36051895	0.632	rs10758674	chr9:5163645	G/A	cg02405213	chr9:5042618	JAK2	-0.76	-14.77	-0.57	1.02e-40	Pediatric autoimmune diseases;
LGG	cis	rs3870371	0.955	rs58702755	chr8:122702478	A/G	cg15679747	chr8:122755315	NA	-0.36	-6.87	-0.3	2.1e-11	Periodontal disease-related phenotypes;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.91	-0.31	1.59e-11	Systolic blood pressure;
LGG	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg21466736	chr12:48725269	NA	-0.4	-8.04	-0.35	7.57e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4629710	0.592	rs11154622	chr6:131547578	C/T	cg12606694	chr6:131520996	AKAP7	0.51	8.36	0.36	7.38e-16	Multiple myeloma (IgH translocation);
LGG	trans	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.04	-0.39	4.26e-18	Bladder cancer;
LGG	trans	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.61	-0.41	4.66e-20	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00373665	chr1:234735703	NA	0.47	7.13	0.31	3.94e-12	Gut microbiome composition (summer);
LGG	trans	rs7395662	1.000	rs115224187	chr11:48757499	G/A	cg00717180	chr2:96193071	NA	0.39	6.75	0.3	4.41e-11	HDL cholesterol;
LGG	cis	rs2544527	0.586	rs2544534	chr2:15906466	T/C	cg26669897	chr2:15909070	NA	0.37	9.28	0.4	6.55e-19	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg20120463	chr17:44301886	NA	-0.47	-7.27	-0.32	1.53e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9814567	1.000	rs6801596	chr3:134252114	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.38	-0.53	9.07e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.44	0.4	1.9e-19	Bipolar disorder;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg19500098	chr13:21900506	NA	0.42	8.45	0.37	3.86e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17453880	0.929	rs4958324	chr5:152022385	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.95	-0.74	4.87e-83	Subjective well-being;
LGG	trans	rs3780486	0.846	rs10116966	chr9:33122370	T/A	cg04842962	chr6:43655489	MRPS18A	1.12	24.66	0.75	2.33e-86	IgG glycosylation;
LGG	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg08470875	chr2:26401718	FAM59B	-0.4	-7.87	-0.34	2.61e-14	Gut microbiome composition (summer);
LGG	cis	rs2120019	0.938	rs1867150	chr15:75321139	T/C	cg09165964	chr15:75287851	SCAMP5	-1.08	-23.48	-0.74	7.17e-81	Blood trace element (Zn levels);
LGG	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-7.08	-0.31	5.23e-12	Diastolic blood pressure;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs6429082	0.702	rs7532018	chr1:235706290	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.54	-8.35	-0.36	7.75e-16	Adiposity;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04709771	chr16:646395	RAB40C	0.37	6.84	0.3	2.57e-11	Height;
LGG	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-14.81	-0.57	6.69e-41	Chronic sinus infection;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	0.960	rs11868459	chr17:29458197	C/T	cg24425628	chr17:29625626	OMG;NF1	0.72	14.12	0.55	6.44e-38	Hip circumference;
LGG	cis	rs7572733	0.935	rs7587598	chr2:198842244	A/G	cg00792783	chr2:198669748	PLCL1	0.46	7.65	0.34	1.14e-13	Dermatomyositis;
LGG	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-10.96	-0.45	5.32e-25	Body mass index;
LGG	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.55e-14	Neuroticism;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg21856205	chr7:94953877	PON1	-0.47	-11.97	-0.49	6.02e-29	Paraoxonase activity;
LGG	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg03929089	chr4:120376271	NA	-0.47	-7.87	-0.34	2.45e-14	HDL cholesterol;
LGG	cis	rs1519814	0.915	rs10808507	chr8:121166429	G/A	cg22335954	chr8:121166405	COL14A1	-0.57	-11.72	-0.48	5.74e-28	Breast cancer;
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg26750617	chr12:132293702	NA	-0.39	-8.44	-0.37	4.17e-16	Migraine;
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg26513180	chr16:89883248	FANCA	0.72	7.93	0.35	1.62e-14	Skin colour saturation;
LGG	cis	rs870825	0.860	rs72689284	chr4:185596680	A/G	cg04058563	chr4:185651563	MLF1IP	1.08	20.51	0.69	5.61e-67	Blood protein levels;
LGG	cis	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg05084668	chr3:125655381	ALG1L	-0.88	-11.03	-0.46	2.84e-25	Blood pressure (smoking interaction);
LGG	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.43	0.33	5.39e-13	Retinal vascular caliber;
LGG	cis	rs9487094	0.626	rs7773950	chr6:109815440	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.67	0.34	1.05e-13	Height;
LGG	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg19468946	chr17:37922297	IKZF3	0.38	6.98	0.31	1.03e-11	Self-reported allergy;
LGG	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg21545522	chr1:205238299	TMCC2	0.49	8.99	0.39	6.38e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.7	-0.56	1.93e-40	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg11878867	chr6:150167359	LRP11	-0.53	-11.04	-0.46	2.48e-25	Lung cancer;
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg26150922	chr2:100937072	LONRF2	0.59	11.74	0.48	5.07e-28	Intelligence (multi-trait analysis);
LGG	cis	rs67460515	0.892	rs35100811	chr3:161084046	A/C	cg04691961	chr3:161091175	C3orf57	-0.49	-10.12	-0.43	7.08e-22	Parkinson's disease;
LGG	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg27471124	chr11:109292789	C11orf87	-0.82	-18.16	-0.64	4.78e-56	Schizophrenia;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg22907277	chr7:1156413	C7orf50	0.68	12.4	0.5	1.12e-30	Longevity;Endometriosis;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg06656553	chr16:89960601	TCF25	-0.61	-6.83	-0.3	2.72e-11	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg16141378	chr3:129829833	LOC729375	-0.35	-8.33	-0.36	9.38e-16	Monocyte count;
LGG	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg26384229	chr12:38710491	ALG10B	-1.01	-25.79	-0.77	1.39e-91	Heart rate;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13012494	chr21:47604986	C21orf56	0.5	8.55	0.37	1.84e-16	Testicular germ cell tumor;
LGG	cis	rs7177699	0.526	rs7166764	chr15:79123509	T/G	cg00540400	chr15:79124168	NA	0.52	11.17	0.46	8.36e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg22907277	chr7:1156413	C7orf50	0.84	14.94	0.57	1.79e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg15128208	chr22:42549153	NA	0.74	10.82	0.45	1.84e-24	Birth weight;
LGG	cis	rs17227506	0.739	rs13256026	chr8:13438743	A/T	cg03566418	chr8:13424080	C8orf48	0.44	6.8	0.3	3.33e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	cis	rs6088580	0.634	rs2225837	chr20:33005634	C/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.61	-0.41	4.78e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7552404	1.000	rs11163924	chr1:76132070	A/C	cg03433033	chr1:76189801	ACADM	-0.81	-13.22	-0.52	4.29e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17504614	0.591	rs17504439	chr2:51073449	C/T	cg23851515	chr2:51057218	NRXN1	0.44	7.08	0.31	5.27e-12	Educational attainment (years of education);
LGG	cis	rs9815354	1.000	rs6781326	chr3:41777028	T/C	cg03022575	chr3:42003672	ULK4	0.61	7.81	0.34	3.95e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs509477	0.851	rs1941751	chr18:32577017	G/A	cg23791764	chr18:32556832	MAPRE2	-0.55	-8.91	-0.38	1.15e-17	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7551222	0.752	rs4951389	chr1:204475834	G/T	cg20240347	chr1:204465584	NA	-0.55	-11.34	-0.47	1.77e-26	Schizophrenia;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs11588062	0.601	rs4660344	chr1:46805222	A/G	cg08947153	chr1:46664340	POMGNT1	0.41	7.26	0.32	1.61e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs4363385	0.747	rs2879489	chr1:152970465	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.25	-0.39	8.29e-19	Inflammatory skin disease;
LGG	cis	rs7084402	0.967	rs1658467	chr10:60295316	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg08888203	chr3:10149979	C3orf24	0.34	6.7	0.3	6.05e-11	Alzheimer's disease;
LGG	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06481639	chr22:41940642	POLR3H	0.58	8.41	0.36	5.08e-16	Vitiligo;
LGG	cis	rs12200782	0.649	rs4490658	chr6:26385113	A/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs6066825	0.644	rs926629	chr20:47335736	A/G	cg18078177	chr20:47281410	PREX1	0.48	7.99	0.35	1.11e-14	Colorectal cancer;
LGG	cis	rs283228	0.617	rs500305	chr6:101746602	C/T	cg27451362	chr6:101846650	GRIK2	0.87	13.63	0.54	8.49e-36	Coenzyme Q10 levels;
LGG	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg21699342	chr2:239360505	ASB1	0.4	7.7	0.34	8.17e-14	Multiple system atrophy;
LGG	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.66	7.14	0.32	3.57e-12	Facial emotion recognition (sad faces);
LGG	cis	rs12681288	0.862	rs4735981	chr8:1018437	A/C	cg08648136	chr8:956695	NA	0.37	7.81	0.34	3.97e-14	Schizophrenia;
LGG	cis	rs3820928	0.874	rs10210963	chr2:227821845	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	3.01e-14	Pulmonary function;
LGG	cis	rs910316	1.000	rs10146482	chr14:75574087	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	10.54	0.44	2.03e-23	Height;
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg03160526	chr17:80928410	B3GNTL1	-0.49	-7.92	-0.35	1.73e-14	Glycated hemoglobin levels;
LGG	cis	rs72781680	0.898	rs72786278	chr2:24063243	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs7503807	0.515	rs12944407	chr17:78691979	C/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs62400317	0.859	rs11966878	chr6:45328265	C/T	cg20913747	chr6:44695427	NA	0.61	9.91	0.42	4.05e-21	Total body bone mineral density;
LGG	trans	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.95	-0.38	8.41e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg16141378	chr3:129829833	LOC729375	-0.49	-12.28	-0.5	3.39e-30	Neuroticism;
LGG	cis	rs41342147	0.660	rs11690506	chr2:242284166	T/C	cg10173475	chr2:242152697	ANO7	-0.59	-9.07	-0.39	3.52e-18	Vitiligo;
LGG	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.39	-0.4	2.68e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	8.9	0.38	1.29e-17	Iron status biomarkers;
LGG	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg02574844	chr11:5959923	NA	-0.57	-8.83	-0.38	2.23e-17	DNA methylation (variation);
LGG	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-11.05	-0.46	2.31e-25	Prostate cancer;
LGG	cis	rs7089973	0.604	rs11196947	chr10:116601372	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs709400	0.628	rs7155014	chr14:103863970	C/G	cg26031613	chr14:104095156	KLC1	0.77	13.7	0.54	4.13e-36	Body mass index;
LGG	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg08847533	chr14:75593920	NEK9	-0.6	-11.25	-0.46	3.97e-26	Height;
LGG	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg13385521	chr17:29058706	SUZ12P	0.8	9.44	0.4	1.78e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.4	0.63	1.52e-52	Chronic sinus infection;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg15242686	chr22:24348715	GSTTP1	-0.38	-7.08	-0.31	5.48e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs877282	1.000	rs71494928	chr10:769134	A/G	cg17470449	chr10:769945	NA	0.64	7.92	0.35	1.82e-14	Uric acid levels;
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-9.48	-0.4	1.3e-19	Skin colour saturation;
LGG	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg26248373	chr2:1572462	NA	-0.8	-11.26	-0.46	3.64e-26	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7927592	0.763	rs596494	chr11:68251054	T/G	cg16797656	chr11:68205561	LRP5	0.52	10.12	0.43	7.15e-22	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg00405596	chr8:11794950	NA	-0.44	-7.33	-0.32	1.05e-12	Neuroticism;
LGG	cis	rs9494142	0.592	rs1547247	chr6:135390836	C/T	cg24558204	chr6:135376177	HBS1L	0.6	9.4	0.4	2.55e-19	Lymphocyte counts;Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3820068	0.581	rs2861387	chr1:15951296	G/A	cg05660106	chr1:15850417	CASP9	0.84	17.04	0.62	6.96e-51	Systolic blood pressure;
LGG	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg15522984	chr1:182991683	LAMC1	0.46	9.22	0.39	1.03e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6840360	0.615	rs1877188	chr4:152607931	T/C	cg22705602	chr4:152727874	NA	-0.38	-9.34	-0.4	4.11e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg02985381	chr13:37494744	SMAD9	0.69	12.28	0.5	3.39e-30	Coronary artery disease;
LGG	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg08344181	chr3:125677491	NA	-0.71	-7.62	-0.33	1.42e-13	Urinary tract infection frequency;
LGG	trans	rs7615952	0.512	rs34651730	chr3:125358640	T/C	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.69e-13	Height;
LGG	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.98	19.44	0.67	5.44e-62	Platelet count;
LGG	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg21545522	chr1:205238299	TMCC2	0.49	9.08	0.39	3.03e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg20887711	chr4:1340912	KIAA1530	0.49	9.1	0.39	2.76e-18	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2572253	chr1:231512768	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.12	-0.31	4.17e-12	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg11062466	chr8:58055876	NA	0.63	9.83	0.42	7.76e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg25214090	chr10:38739885	LOC399744	0.67	11.79	0.48	2.98e-28	Corneal astigmatism;
LGG	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27297192	chr10:134578999	INPP5A	0.31	7.33	0.32	1.04e-12	Migraine;
LGG	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00198680	chr16:28758506	NA	0.3	7.54	0.33	2.55e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.07	-0.35	6.24e-15	Mood instability;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg10360139	chr7:1886902	MAD1L1	0.4	7.18	0.32	2.86e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07093942	chr16:68278871	PLA2G15	0.41	6.97	0.31	1.12e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2247341	0.965	rs11730727	chr4:1738313	T/C	cg08446824	chr4:1720184	TMEM129	-0.67	-12.64	-0.51	1.14e-31	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg21545522	chr1:205238299	TMCC2	-0.38	-7.4	-0.33	6.61e-13	Red blood cell count;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg13264159	chr8:625131	ERICH1	-1.0	-10.94	-0.45	6.01e-25	IgG glycosylation;
LGG	cis	rs9902453	0.845	rs7209622	chr17:28256807	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.12	0.55	6.54e-38	Coffee consumption (cups per day);
LGG	cis	rs1971256	0.500	rs6925359	chr6:151798783	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-7.55	-0.33	2.36e-13	Endometriosis;
LGG	cis	rs7667	1.000	rs10753559	chr1:19698026	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	0.42	7.35	0.32	8.97e-13	Crohn's disease and psoriasis;
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.14	-0.32	3.53e-12	Bipolar disorder;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg05552183	chr6:42928497	GNMT	0.44	13.07	0.52	1.82e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10463316	0.894	rs10042030	chr5:150768028	T/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.18	-0.43	4.4e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs36051895	0.695	rs12347727	chr9:5000811	A/G	cg02405213	chr9:5042618	JAK2	-0.78	-14.29	-0.55	1.27e-38	Pediatric autoimmune diseases;
LGG	cis	rs838147	0.563	rs281379	chr19:49214274	C/T	cg13540341	chr19:49222985	MAMSTR	-0.36	-8.27	-0.36	1.46e-15	Dietary macronutrient intake;
LGG	cis	rs963731	0.579	rs297142	chr2:39319448	G/A	cg04010122	chr2:39346883	SOS1	-0.78	-7.88	-0.34	2.36e-14	Corticobasal degeneration;
LGG	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg22437258	chr11:111473054	SIK2	0.4	6.98	0.31	1.05e-11	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.06	0.31	6.04e-12	Lung cancer;
LGG	cis	rs9322193	0.566	rs5024811	chr6:150246034	A/G	cg11878867	chr6:150167359	LRP11	0.46	8.12	0.35	4.14e-15	Lung cancer;
LGG	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs3106136	0.967	rs11097409	chr4:95168515	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.97	-0.35	1.21e-14	Capecitabine sensitivity;
LGG	cis	rs9400467	0.506	rs10457238	chr6:111762593	C/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.72	0.3	5.26e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.73	-0.3	5.04e-11	Menarche (age at onset);
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7953508	0.711	rs11107120	chr12:93985482	T/C	cg18151635	chr12:93972918	NA	-0.47	-8.13	-0.35	3.93e-15	Pubertal anthropometrics;
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg18404041	chr3:52824283	ITIH1	-0.6	-11.59	-0.47	1.93e-27	Bipolar disorder;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg15147215	chr3:52552868	STAB1	-0.38	-7.37	-0.32	7.65e-13	Electroencephalogram traits;
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.42	-0.33	5.52e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3735485	0.738	rs10243448	chr7:45094765	G/C	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs365132	0.818	rs6879982	chr5:176351330	A/T	cg16309518	chr5:176445507	NA	-0.52	-11.33	-0.47	1.9e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs990171	1.000	rs1861246	chr2:102966783	T/C	cg05295703	chr2:102895712	NA	-0.55	-9.77	-0.41	1.22e-20	Lymphocyte counts;
LGG	cis	rs8020289	1.000	rs2242625	chr14:77292642	A/G	cg23436960	chr14:77239540	VASH1	0.26	6.72	0.3	5.35e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs787274	0.557	rs10124939	chr9:115654683	T/C	cg13803584	chr9:115635662	SNX30	-0.65	-6.83	-0.3	2.66e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2066819	0.892	rs112931321	chr12:56667894	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.24	-0.6	2.78e-47	Psoriasis vulgaris;
LGG	cis	rs763121	0.853	rs5750626	chr22:38977890	G/C	cg06022373	chr22:39101656	GTPBP1	0.86	17.25	0.63	7.51e-52	Menopause (age at onset);
LGG	cis	rs4788570	0.584	rs6499534	chr16:71755278	C/G	cg06353428	chr16:71660113	MARVELD3	1.27	20.86	0.7	1.23e-68	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.94	-0.38	9.41e-18	Aortic root size;
LGG	trans	rs11039798	0.841	rs7294179	chr11:48765408	G/A	cg15704280	chr7:45808275	SEPT13	0.74	7.87	0.34	2.45e-14	Axial length;
LGG	cis	rs3849046	0.817	rs9968657	chr5:137920430	A/G	cg10920316	chr5:137946599	NA	0.43	6.86	0.3	2.2e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs17221829	0.733	rs11600976	chr11:89360842	A/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	cis	rs8078723	0.630	rs60137005	chr17:38129996	A/T	cg17467752	chr17:38218738	THRA	0.59	10.8	0.45	2.12e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4474465	0.850	rs10793332	chr11:78270020	C/G	cg02023728	chr11:77925099	USP35	-0.38	-6.73	-0.3	5.06e-11	Alzheimer's disease (survival time);
LGG	cis	rs2798269	1.000	rs2476638	chr13:22133729	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.88	-0.3	1.96e-11	PR segment;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg25358565	chr5:93447407	FAM172A	-0.69	-9.97	-0.42	2.47e-21	Diabetic retinopathy;
LGG	trans	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg08862035	chr2:2617432	NA	0.43	7.01	0.31	8.5e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4774899	1.000	rs2583108	chr15:57245778	A/G	cg08128148	chr15:57256372	TCF12	-0.33	-7.94	-0.35	1.55e-14	Urinary tract infection frequency;
LGG	cis	rs4077515	0.874	rs3812560	chr9:139269905	T/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.45	0.33	4.77e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6500395	1.000	rs1486412	chr16:48651750	A/T	cg04672837	chr16:48644449	N4BP1	0.55	9.04	0.39	4.23e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg12193833	chr17:30244370	NA	-0.27	-7.19	-0.32	2.58e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7191439	0.858	rs11076702	chr16:88774569	A/C	cg27087555	chr16:88793112	FAM38A	-1.41	-17.95	-0.64	4.55e-55	Plateletcrit;
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg09303159	chr6:26284866	NA	0.34	7.91	0.34	1.93e-14	Educational attainment;
LGG	cis	rs9640161	0.830	rs35840727	chr7:150063204	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.56	-10.15	-0.43	5.37e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4780401	0.933	rs4584833	chr16:11798758	C/T	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.1	-0.31	4.68e-12	Rheumatoid arthritis;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.68	-0.41	2.61e-20	Triglycerides;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.5e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.687	rs1538956	chr6:126964026	G/T	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs13102973	0.640	rs13140829	chr4:135838818	T/C	cg14419869	chr4:135874104	NA	0.51	9.51	0.4	1.01e-19	Subjective well-being;
LGG	cis	rs11690935	0.688	rs7600835	chr2:172521827	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.72	-14.77	-0.57	1.05e-40	Schizophrenia;
LGG	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7849585	0.825	rs62579864	chr9:139139032	C/A	cg14094347	chr9:139131620	QSOX2	0.48	9.4	0.4	2.51e-19	Height;
LGG	cis	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.9	-0.34	2.04e-14	Blood trace element (Cu levels);
LGG	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	9.56	0.41	6.72e-20	Mood instability;
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06634786	chr22:41940651	POLR3H	0.79	13.0	0.52	3.6e-33	Vitiligo;
LGG	cis	rs1719271	0.831	rs1719269	chr15:65183104	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.24	-0.32	1.93e-12	Platelet count;
LGG	trans	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg26384229	chr12:38710491	ALG10B	0.6	11.33	0.47	1.93e-26	Morning vs. evening chronotype;
LGG	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg23335576	chr14:104009727	NA	0.48	8.27	0.36	1.38e-15	Reticulocyte count;
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg03351412	chr1:154909251	PMVK	0.66	12.7	0.51	6.57e-32	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19586645	chr17:73266642	MIF4GD	0.46	6.89	0.3	1.82e-11	Gut microbiome composition (summer);
LGG	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg13256891	chr4:100009986	ADH5	-0.54	-9.57	-0.41	6.41e-20	Alcohol dependence;
LGG	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg18200150	chr17:30822561	MYO1D	0.82	19.51	0.67	2.54e-62	Schizophrenia;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg11752832	chr7:134001865	SLC35B4	0.64	11.58	0.47	2.12e-27	Mean platelet volume;
LGG	cis	rs9397585	0.857	rs1933259	chr6:153379163	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.43e-39	Body mass index;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs11105298	0.891	rs10858899	chr12:89923811	G/C	cg00757033	chr12:89920650	WDR51B	0.64	9.38	0.4	2.91e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2072732	0.821	rs12034573	chr1:2948020	C/T	cg08733933	chr1:2954429	NA	-0.38	-7.94	-0.35	1.55e-14	Plateletcrit;
LGG	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.09	-0.42	8.86e-22	Lung cancer;
LGG	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.75	-0.3	4.47e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1568889	0.838	rs10458896	chr11:28057957	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.63e-61	Bipolar disorder;
LGG	cis	rs10979	0.965	rs9496674	chr6:143886106	G/T	cg25407410	chr6:143891975	LOC285740	-0.71	-12.42	-0.5	8.7e-31	Hypospadias;
LGG	trans	rs12517041	1.000	rs10520888	chr5:23280539	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.04	-0.46	2.5e-25	Calcium levels;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.07	0.42	1.04e-21	Schizophrenia;
LGG	trans	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg26043149	chr18:55253948	FECH	-0.4	-6.67	-0.3	7.44e-11	Bone mineral density;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-12.64	-0.51	1.1e-31	Schizophrenia;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg12463550	chr7:65579703	CRCP	-0.49	-8.2	-0.36	2.37e-15	Aortic root size;
LGG	cis	rs7914558	0.899	rs7913682	chr10:104684392	T/A	cg04362960	chr10:104952993	NT5C2	0.53	10.07	0.42	1.03e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs3735485	0.800	rs6951022	chr7:45055115	T/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9914544	0.545	rs12600851	chr17:18767518	T/A	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.53	-0.33	2.7e-13	Educational attainment (years of education);
LGG	cis	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg21775007	chr8:11205619	TDH	-0.45	-6.96	-0.31	1.16e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs7572644	0.640	rs4666022	chr2:28057823	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	12.55	0.5	2.68e-31	High light scatter reticulocyte count;
LGG	cis	rs300774	1.000	rs300797	chr2:107140	G/A	cg04617936	chr2:214353	NA	-0.46	-6.9	-0.31	1.69e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg27205649	chr11:78285834	NARS2	-0.43	-7.11	-0.31	4.56e-12	Testicular germ cell tumor;
LGG	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.14e-14	HDL cholesterol;
LGG	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg20387954	chr3:183756860	HTR3D	0.69	14.03	0.55	1.66e-37	Anterior chamber depth;
LGG	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg00086871	chr4:6988644	TBC1D14	1.06	9.65	0.41	3.3e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7188861	0.768	rs62023624	chr16:11399603	C/A	cg01510278	chr16:11456238	NA	0.31	7.38	0.32	7.47e-13	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23609821	chr14:20937494	PNP	0.48	7.02	0.31	8.19e-12	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg20003494	chr4:90757398	SNCA	0.41	8.17	0.36	2.87e-15	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg24829409	chr8:58192753	C8orf71	-0.79	-10.61	-0.44	1.09e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4711336	0.664	rs4713663	chr6:33674197	G/A	cg14003231	chr6:33640908	ITPR3	0.3	6.96	0.31	1.2e-11	Height;
LGG	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg17691542	chr6:26056736	HIST1H1C	0.55	9.73	0.41	1.81e-20	Height;
LGG	cis	rs9916302	0.752	rs8071300	chr17:37508524	G/C	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.92e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs910316	1.000	rs8017642	chr14:75590822	G/A	cg06637938	chr14:75390232	RPS6KL1	0.57	10.51	0.44	2.52e-23	Height;
LGG	cis	rs9354308	0.764	rs9345697	chr6:66572280	G/T	cg07460842	chr6:66804631	NA	-0.4	-6.91	-0.31	1.6e-11	Metabolite levels;
LGG	cis	rs2916247	0.954	rs11784233	chr8:93080925	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.39	-7.82	-0.34	3.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.578	rs6925065	chr6:101178856	C/T	cg09795085	chr6:101329169	ASCC3	0.47	8.11	0.35	4.43e-15	Neuroticism;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.54	-0.41	8.44e-20	Lung cancer;
LGG	cis	rs559928	0.606	rs60394481	chr11:63909035	G/A	cg05555928	chr11:63887634	MACROD1	-0.78	-10.46	-0.44	3.82e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1801251	0.893	rs6733151	chr2:233592341	A/C	cg25237894	chr2:233734115	C2orf82	0.65	12.69	0.51	7.34e-32	Coronary artery disease;
LGG	cis	rs709400	1.000	rs3783404	chr14:104118498	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.79e-16	Body mass index;
LGG	cis	rs896854	0.552	rs2515236	chr8:95934907	A/G	cg16049864	chr8:95962084	TP53INP1	0.33	6.84	0.3	2.48e-11	Type 2 diabetes;
LGG	cis	rs5769765	0.955	rs2295406	chr22:50260169	G/A	cg02269571	chr22:50332266	NA	0.63	10.09	0.42	8.75e-22	Schizophrenia;
LGG	trans	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs16976116	0.901	rs2899581	chr15:55491643	T/C	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-8.69	-0.37	6.19e-17	Aortic root size;
LGG	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg15103426	chr22:29168792	CCDC117	0.59	8.76	0.38	3.78e-17	Lymphocyte counts;
LGG	trans	rs12517041	1.000	rs2081951	chr5:23287576	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07362569	chr17:61921086	SMARCD2	-0.49	-9.44	-0.4	1.86e-19	Prudent dietary pattern;
LGG	cis	rs1801251	0.778	rs778340	chr2:233734083	C/T	cg25237894	chr2:233734115	C2orf82	-0.72	-15.39	-0.58	1.87e-43	Coronary artery disease;
LGG	cis	rs78456975	1.000	rs11903168	chr2:1560497	C/G	cg26248373	chr2:1572462	NA	-0.69	-8.88	-0.38	1.51e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1869026	1.000	rs2311600	chr2:121340676	A/G	cg13274077	chr2:121334614	NA	-0.32	-7.53	-0.33	2.63e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Electroencephalogram traits;
LGG	cis	rs988958	0.567	rs10193034	chr2:42249064	G/A	cg27252766	chr2:42229092	NA	0.57	8.4	0.36	5.53e-16	Hypospadias;
LGG	cis	rs7428	1.000	rs72840063	chr2:85550396	T/A	cg24342717	chr2:85555507	TGOLN2	-0.48	-7.51	-0.33	3.01e-13	Ear protrusion;
LGG	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg11317459	chr13:21872234	NA	-1.18	-19.46	-0.67	4.49e-62	White matter hyperintensity burden;
LGG	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg13012494	chr21:47604986	C21orf56	0.5	8.56	0.37	1.64e-16	Testicular germ cell tumor;
LGG	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.3	-0.69	5.07e-66	Diabetic kidney disease;
LGG	cis	rs12999616	0.817	rs17695937	chr2:98327875	A/G	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.35	3.7e-15	Colorectal cancer;
LGG	cis	rs209489	0.892	rs75679723	chr6:53148841	C/T	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00290607	chr11:67383545	NA	0.65	12.5	0.5	4.3e-31	Mean corpuscular volume;
LGG	cis	rs7998202	0.667	rs282586	chr13:113351474	T/C	cg17218041	chr13:113365319	ATP11A	-0.47	-7.77	-0.34	5.16e-14	Glycated hemoglobin levels;
LGG	cis	rs10492096	0.947	rs10849483	chr12:6635374	G/A	cg13857086	chr12:6580257	VAMP1	0.51	7.27	0.32	1.5e-12	Hip geometry;
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg08888203	chr3:10149979	C3orf24	0.53	9.03	0.39	4.71e-18	Alzheimer's disease;
LGG	cis	rs4751006	0.543	rs17692028	chr10:128783983	C/T	cg05702161	chr10:128779687	DOCK1	-1.0	-10.8	-0.45	2.11e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg07701084	chr6:150067640	NUP43	0.44	7.93	0.35	1.69e-14	Testicular germ cell tumor;
LGG	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg16586182	chr3:47516702	SCAP	0.7	12.26	0.5	4.02e-30	Colorectal cancer;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg07120314	chr15:79043507	NA	0.53	11.07	0.46	1.93e-25	Diastolic blood pressure;
LGG	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg02227867	chr8:22457446	C8orf58	0.45	8.44	0.37	4.1e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg06521331	chr12:34319734	NA	0.4	6.75	0.3	4.33e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6840360	0.574	rs2709844	chr4:152368212	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg00166722	chr3:10149974	C3orf24	0.52	8.78	0.38	3.21e-17	Alzheimer's disease;
LGG	cis	rs10155981	0.510	rs28579868	chr7:22593997	T/C	cg05062323	chr7:22590069	NA	-0.76	-9.38	-0.4	3.07e-19	Bilirubin levels;
LGG	trans	rs9467711	0.606	rs9379855	chr6:26364930	C/T	cg06606381	chr12:133084897	FBRSL1	0.8	8.41	0.36	5.15e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg00579200	chr11:133705235	NA	0.57	11.09	0.46	1.63e-25	Childhood ear infection;
LGG	trans	rs9944715	0.954	rs7228365	chr18:43817832	A/G	cg01718231	chr17:29326311	RNF135	-0.42	-6.66	-0.3	7.68e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs12540874	0.670	rs3887826	chr7:50544961	G/A	cg00647317	chr7:50633725	DDC	0.35	8.43	0.36	4.57e-16	Systemic sclerosis;
LGG	cis	rs9875589	0.509	rs2168718	chr3:14084157	A/G	cg19554555	chr3:13937349	NA	-0.55	-9.99	-0.42	2.06e-21	Ovarian reserve;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg12395012	chr8:11607386	GATA4	0.39	6.95	0.31	1.24e-11	Neuroticism;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.73	-0.38	4.76e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11885103	0.791	rs11686772	chr2:584563	C/T	cg21195176	chr2:593345	NA	0.4	7.5	0.33	3.35e-13	Heschl's gyrus morphology;
LGG	cis	rs457717	0.730	rs2431361	chr5:75949043	C/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.67	0.3	7.32e-11	Hearing impairment;
LGG	cis	rs9811920	0.638	rs7629426	chr3:99652577	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.97	-0.38	7.32e-18	Axial length;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00684032	chr4:1343700	KIAA1530	0.5	9.97	0.42	2.46e-21	Obesity-related traits;
LGG	cis	rs57590327	0.555	rs3943556	chr3:81738892	G/C	cg07356753	chr3:81810745	GBE1	-0.51	-8.25	-0.36	1.69e-15	Extraversion;
LGG	trans	rs2018683	0.711	rs1874977	chr7:28968083	A/G	cg19402173	chr7:128379420	CALU	-0.55	-9.38	-0.4	3.05e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg00405596	chr8:11794950	NA	-0.41	-6.95	-0.31	1.26e-11	Neuroticism;
LGG	cis	rs741702	0.928	rs10451496	chr19:13017876	C/T	cg11738485	chr19:12877000	HOOK2	-0.43	-6.92	-0.31	1.52e-11	Red blood cell traits;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg05368731	chr17:41323189	NBR1	0.9	16.46	0.61	2.9e-48	Menopause (age at onset);
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs4731207	0.596	rs6466968	chr7:124583357	C/T	cg05630886	chr7:124431682	NA	0.3	7.03	0.31	7.49e-12	Cutaneous malignant melanoma;
LGG	cis	rs13102973	0.617	rs11734991	chr4:135885411	T/G	cg14419869	chr4:135874104	NA	0.47	7.96	0.35	1.37e-14	Subjective well-being;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.03e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12282928	0.959	rs1109905	chr11:48284000	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.07	-0.31	5.92e-12	Migraine - clinic-based;
LGG	cis	rs9682041	0.561	rs7616830	chr3:170146445	A/G	cg11886554	chr3:170076028	SKIL	0.68	8.09	0.35	5.28e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs1816752	0.583	rs6490918	chr13:25002115	G/A	cg02811702	chr13:24901961	NA	-0.4	-7.37	-0.32	8.09e-13	Obesity-related traits;
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg23985595	chr17:80112537	CCDC57	0.39	7.62	0.33	1.49e-13	Life satisfaction;
LGG	cis	rs2066819	0.892	rs117305040	chr12:56657888	A/G	cg26714650	chr12:56694279	CS	-1.57	-16.15	-0.6	7.32e-47	Psoriasis vulgaris;
LGG	cis	rs17221829	0.965	rs10830355	chr11:89443429	C/T	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.36	-0.32	8.54e-13	Anxiety in major depressive disorder;
LGG	cis	rs28595532	0.920	rs56162974	chr4:119742333	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs714515	0.934	rs12405515	chr1:172357441	G/T	cg01573306	chr1:172330400	DNM3	0.33	7.34	0.32	9.48e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.22	-0.32	2.22e-12	Myopia (pathological);
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg26513180	chr16:89883248	FANCA	1.0	9.64	0.41	3.56e-20	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.75	0.54	2.57e-36	Prudent dietary pattern;
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs6882046	0.513	rs35148765	chr5:88046158	C/A	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg05775895	chr3:12838266	CAND2	0.63	11.05	0.46	2.46e-25	QRS complex (12-leadsum);
LGG	cis	rs921968	0.541	rs3770216	chr2:219443717	A/G	cg01130898	chr2:219473002	PLCD4	0.44	7.57	0.33	2.06e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs8056064	0.739	rs34271157	chr16:82819635	G/A	cg08271366	chr16:82816457	CDH13	-0.46	-8.19	-0.36	2.49e-15	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs7010267	0.711	rs10955908	chr8:119904557	C/A	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.84	-0.42	7.27e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs4803468	1.000	rs6508977	chr19:41909346	A/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-23.17	-0.73	1.94e-79	Height;
LGG	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg10792982	chr14:105748885	BRF1	0.67	13.37	0.53	1.03e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg15971980	chr6:150254442	NA	0.42	6.78	0.3	3.73e-11	Lung cancer;
LGG	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-7.05	-0.31	6.71e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg07005078	chr4:17578674	LAP3	0.38	6.96	0.31	1.2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-16.24	-0.6	2.89e-47	Menarche (age at onset);
LGG	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	4.21e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05455876	chr16:2215900	TRAF7	0.43	7.39	0.32	7.08e-13	Pancreatic cancer;
LGG	trans	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.84	0.38	1.96e-17	Systolic blood pressure;
LGG	cis	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19171272	chr22:38449367	NA	-0.51	-9.33	-0.4	4.52e-19	Glioblastoma;Glioma;
LGG	cis	rs17092148	0.887	rs2889849	chr20:33164277	A/G	cg12302830	chr20:33297742	TP53INP2	-0.42	-6.8	-0.3	3.15e-11	Neuroticism;
LGG	cis	rs7647973	0.922	rs57273516	chr3:49483074	A/G	cg06212747	chr3:49208901	KLHDC8B	0.51	8.05	0.35	6.87e-15	Menarche (age at onset);
LGG	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-9.08	-0.39	3.12e-18	Diabetic retinopathy;
LGG	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg11494091	chr17:61959527	GH2	0.61	10.26	0.43	2.09e-22	Height;
LGG	cis	rs9807989	0.507	rs13021177	chr2:103056493	A/G	cg03938978	chr2:103052716	IL18RAP	0.4	9.35	0.4	3.64e-19	Asthma;
LGG	cis	rs7512552	0.809	rs2794679	chr1:150324857	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2011503	1.000	rs58074958	chr19:19570555	G/C	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg09795085	chr6:101329169	ASCC3	-0.42	-6.92	-0.31	1.51e-11	Neuroticism;
LGG	cis	rs950776	0.714	rs17408276	chr15:78881618	T/C	cg22563815	chr15:78856949	CHRNA5	0.29	7.04	0.31	6.93e-12	Sudden cardiac arrest;
LGG	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.34	0.32	9.46e-13	Electroencephalogram traits;
LGG	cis	rs11098499	0.754	rs9999724	chr4:120239944	C/T	cg09307838	chr4:120376055	NA	0.73	12.43	0.5	8.39e-31	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg16507663	chr6:150244633	RAET1G	0.47	8.79	0.38	2.97e-17	Lung cancer;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg14159672	chr1:205819179	PM20D1	0.77	16.47	0.61	2.76e-48	Menarche (age at onset);
LGG	cis	rs17453880	0.929	rs10037655	chr5:152040281	C/T	cg10931792	chr5:152022470	NA	0.4	8.82	0.38	2.32e-17	Subjective well-being;
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs9902453	0.808	rs10445400	chr17:28183059	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.81	0.54	1.37e-36	Coffee consumption (cups per day);
LGG	cis	rs1691799	0.899	rs1060724	chr12:66740444	T/C	cg16791601	chr12:66731901	HELB	-0.65	-15.53	-0.59	4.42e-44	White blood cell count (basophil);
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg20607798	chr8:58055168	NA	0.57	6.86	0.3	2.26e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg15522984	chr1:182991683	LAMC1	-0.49	-10.15	-0.43	5.25e-22	Colorectal cancer;
LGG	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18876405	chr7:65276391	NA	0.59	11.06	0.46	2.11e-25	Aortic root size;
LGG	cis	rs17014483	0.749	rs2924350	chr4:89626391	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.62	7.12	0.31	4.2e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1333657	0.582	rs9366353	chr6:10281784	T/C	cg03826642	chr6:10268858	NA	0.37	7.11	0.31	4.29e-12	Orofacial clefts;
LGG	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs457717	0.730	rs460482	chr5:75944018	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.76	0.3	4.18e-11	Hearing impairment;
LGG	cis	rs6762	0.748	rs7936838	chr11:839093	G/C	cg08498830	chr11:832797	CD151	-0.44	-7.04	-0.31	6.83e-12	Mean platelet volume;
LGG	cis	rs9549367	0.789	rs912012	chr13:113886152	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-8.69	-0.37	6.29e-17	Platelet distribution width;
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg22398616	chr13:53314203	LECT1	-0.49	-9.66	-0.41	3.14e-20	Lewy body disease;
LGG	cis	rs17039065	0.920	rs6835731	chr4:109466981	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	7.07	0.31	5.85e-12	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.657	rs10244989	chr7:19935283	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	7.38	0.32	7.32e-13	Night sleep phenotypes;
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.25	-0.46	4.12e-26	Prostate cancer;
LGG	cis	rs35740288	0.770	rs1871285	chr15:86152487	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs17685	0.712	rs11770149	chr7:75791644	G/A	cg19862616	chr7:65841803	NCRNA00174	1.04	23.45	0.74	1.01e-80	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg06221963	chr1:154839813	KCNN3	-0.5	-9.96	-0.42	2.75e-21	Prostate cancer;
LGG	trans	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs17767392	0.881	rs35866366	chr14:71849185	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.69	-0.37	6.26e-17	Mitral valve prolapse;
LGG	cis	rs78456975	0.689	rs10194040	chr2:1543293	T/G	cg01028140	chr2:1542097	TPO	-0.58	-10.02	-0.42	1.68e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7267979	0.549	rs6138537	chr20:25184466	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.1	0.42	8.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.81	0.38	2.63e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg07315970	chr11:57513407	BTBD18	-0.34	-6.96	-0.31	1.18e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35160687	0.644	rs2367232	chr2:86541491	A/G	cg10973622	chr2:86423274	IMMT	-0.39	-6.93	-0.31	1.43e-11	Night sleep phenotypes;
LGG	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg02733842	chr7:1102375	C7orf50	-0.58	-8.88	-0.38	1.51e-17	Bronchopulmonary dysplasia;
LGG	cis	rs4243830	0.737	rs56036909	chr1:6608503	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.78	11.85	0.48	1.75e-28	Body mass index;
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg05484376	chr2:27715224	FNDC4	-0.47	-10.28	-0.43	1.81e-22	Total body bone mineral density;
LGG	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg03469862	chr11:68924853	NA	0.44	6.76	0.3	4.11e-11	Blond vs. brown hair color;
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg02398342	chr17:80708632	TBCD;FN3K	-0.45	-7.78	-0.34	4.65e-14	Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10671167	chr7:39988923	CDK13	0.5	7.92	0.35	1.78e-14	Gut microbiome composition (summer);
LGG	cis	rs2342371	0.848	rs5016648	chr3:196207989	A/G	cg15048948	chr3:196158458	UBXN7	-0.42	-6.95	-0.31	1.27e-11	Fat distribution (HIV);
LGG	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.44	0.33	5.05e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg11965913	chr1:205819406	PM20D1	-0.53	-8.29	-0.36	1.24e-15	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg19338460	chr6:170058176	WDR27	-0.71	-9.33	-0.4	4.54e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.28	0.43	1.86e-22	Personality dimensions;
LGG	trans	rs7404843	0.852	rs111259294	chr16:15511930	C/T	cg02716450	chr16:28638775	NA	0.71	7.14	0.31	3.74e-12	Testicular germ cell tumor;
LGG	cis	rs1966248	0.543	rs1855895	chr6:134118977	A/G	cg25632230	chr6:134101081	NA	-0.34	-7.5	-0.33	3.19e-13	Coronary artery disease;
LGG	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg16301924	chr13:53314226	LECT1	-0.35	-6.93	-0.31	1.44e-11	Lewy body disease;
LGG	cis	rs7667	0.881	rs12031691	chr1:19750909	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.38	-6.75	-0.3	4.39e-11	Crohn's disease and psoriasis;
LGG	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg14784868	chr12:69753453	YEATS4	0.9	20.16	0.68	2.39e-65	Blood protein levels;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg07606381	chr6:8435919	SLC35B3	0.7	12.61	0.51	1.48e-31	Motion sickness;
LGG	cis	rs7762018	1.000	rs6912959	chr6:170126224	G/A	cg17545662	chr6:170176663	C6orf70	0.68	8.58	0.37	1.49e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg12310025	chr6:25882481	NA	-0.62	-11.54	-0.47	3.07e-27	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg24503407	chr1:205819492	PM20D1	0.84	20.39	0.69	2.12e-66	Menarche (age at onset);
LGG	trans	rs1994135	0.630	rs11052757	chr12:33719879	A/G	cg26384229	chr12:38710491	ALG10B	0.76	14.12	0.55	6.89e-38	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25341789	chr19:3506185	FZR1	0.47	7.32	0.32	1.08e-12	Gut microbiome composition (summer);
LGG	trans	rs72991	0.594	rs4936624	chr11:121236913	C/G	cg27192990	chr6:129479024	LAMA2	-0.59	-9.37	-0.4	3.18e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg18187862	chr3:45730750	SACM1L	-0.53	-8.67	-0.37	7.61e-17	Primary sclerosing cholangitis;
LGG	cis	rs10937275	0.826	rs35508867	chr3:186643240	C/T	cg26193484	chr3:186648175	ST6GAL1	0.87	9.04	0.39	4.28e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10779751	0.770	rs11121696	chr1:11238063	A/G	cg08854313	chr1:11322531	MTOR	-0.68	-13.27	-0.52	2.83e-34	Body mass index;
LGG	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg03342759	chr3:160939853	NMD3	-0.67	-11.75	-0.48	4.41e-28	Morning vs. evening chronotype;
LGG	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg26384229	chr12:38710491	ALG10B	1.0	24.95	0.76	1.02e-87	Heart rate;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.958	rs10806337	chr6:86474249	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.85	-0.45	1.39e-24	Response to antipsychotic treatment;
LGG	cis	rs12496230	1.000	rs13100186	chr3:66831642	T/C	cg04995300	chr3:66848608	NA	0.52	7.4	0.33	6.34e-13	Type 2 diabetes;
LGG	cis	rs4954585	0.659	rs4072435	chr2:137013901	C/T	cg07169764	chr2:136633963	MCM6	-0.46	-7.34	-0.32	9.96e-13	Colorectal cancer;
LGG	cis	rs1941023	0.503	rs7952244	chr11:60132164	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-8.34	-0.36	8.66e-16	Congenital heart disease (maternal effect);
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.93	-0.45	6.52e-25	Lung cancer;
LGG	cis	rs4148883	0.689	rs1154415	chr4:99999033	T/C	cg12011299	chr4:100065546	ADH4	0.39	8.24	0.36	1.81e-15	Alcohol dependence;
LGG	cis	rs7647973	0.890	rs73073004	chr3:49490020	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-7.28	-0.32	1.43e-12	Menarche (age at onset);
LGG	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg03929089	chr4:120376271	NA	0.69	11.6	0.47	1.7e-27	Coronary artery disease;
LGG	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg24623649	chr8:11872141	NA	0.29	6.71	0.3	5.71e-11	Myopia (pathological);
LGG	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.37	7.02	0.31	8.14e-12	Alzheimer's disease (late onset);
LGG	cis	rs67311347	1.000	rs67680017	chr3:40533164	C/T	cg24209194	chr3:40518798	ZNF619	0.46	7.26	0.32	1.67e-12	Renal cell carcinoma;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.916	rs4142546	chr6:86505311	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.22e-17	Response to antipsychotic treatment;
LGG	cis	rs2486288	0.656	rs6493143	chr15:45570781	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.85	-0.45	1.42e-24	Glomerular filtration rate;
LGG	cis	rs10819861	0.621	rs7025349	chr9:98847691	C/T	cg14508093	chr9:98862825	NA	-0.29	-6.76	-0.3	4.09e-11	Electrocardiographic traits;
LGG	cis	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.74	0.71	9.56e-73	Bladder cancer;
LGG	cis	rs4077515	1.000	rs10870077	chr9:139263891	C/G	cg21253087	chr9:139290292	SNAPC4	0.35	6.91	0.31	1.57e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs72772090	0.539	rs114006288	chr5:96118004	C/T	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9457247	0.765	rs1060404	chr6:167429467	A/G	cg07741184	chr6:167504864	NA	0.42	9.34	0.4	3.99e-19	Crohn's disease;
LGG	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg03806693	chr22:41940476	POLR3H	-0.95	-17.29	-0.63	5.06e-52	Vitiligo;
LGG	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.32	0.36	9.65e-16	Monocyte count;
LGG	cis	rs58785573	0.570	rs1824652	chr4:38644597	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.44	7.07	0.31	5.84e-12	Lymphocyte percentage of white cells;
LGG	cis	rs4262150	0.764	rs17452991	chr5:151938965	C/G	cg12297329	chr5:152029980	NA	0.74	14.14	0.55	5.71e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.862	rs6805234	chr3:72829869	A/G	cg01043669	chr3:72786069	NA	0.41	7.03	0.31	7.29e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs9914544	0.564	rs7223173	chr17:18805887	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.65	-0.33	1.18e-13	Educational attainment (years of education);
LGG	trans	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.84	-0.34	3.2e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg05342682	chr7:94953680	PON1	-0.33	-7.84	-0.34	3.06e-14	Paraoxonase activity;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.42	-7.52	-0.33	2.82e-13	Schizophrenia;
LGG	cis	rs1451375	0.652	rs10249420	chr7:50623451	C/G	cg14593290	chr7:50529359	DDC	-0.51	-8.97	-0.38	7.65e-18	Malaria;
LGG	cis	rs4566357	1.000	rs6705783	chr2:227923268	C/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.02	-0.31	7.78e-12	Coronary artery disease;
LGG	cis	rs7264396	0.635	rs6060660	chr20:34476649	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.3	-0.32	1.23e-12	Total cholesterol levels;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs4803468	1.000	rs10417997	chr19:41902361	G/A	cg14132834	chr19:41945861	ATP5SL	-0.48	-9.58	-0.41	5.99e-20	Height;
LGG	cis	rs11229555	0.874	rs17567523	chr11:58354081	G/A	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	9.25e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28647808	0.881	rs7040821	chr9:136263584	C/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08280861	chr8:58055591	NA	0.64	8.1	0.35	4.88e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs8064024	0.599	rs2456779	chr16:4925817	G/C	cg04440724	chr16:4920505	UBN1	-0.52	-10.57	-0.44	1.53e-23	Cancer;
LGG	cis	rs1595825	0.945	rs16826320	chr2:198845623	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.87	-0.3	2.1e-11	Ulcerative colitis;
LGG	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg19524238	chr7:2802976	GNA12	0.32	7.85	0.34	2.86e-14	Height;
LGG	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.89	0.38	1.33e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9788682	1.000	rs7181245	chr15:78814389	C/T	cg24631222	chr15:78858424	CHRNA5	0.46	7.13	0.31	3.76e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7572733	0.905	rs700693	chr2:198730015	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.59e-16	Dermatomyositis;
LGG	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26306683	chr17:18585705	ZNF286B	0.46	8.7	0.37	5.84e-17	Educational attainment (years of education);
LGG	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg02931644	chr1:25747376	RHCE	-0.42	-9.22	-0.39	1.03e-18	Erythrocyte sedimentation rate;
LGG	cis	rs477692	0.637	rs10829598	chr10:131319774	C/G	cg05714579	chr10:131428358	MGMT	0.45	8.51	0.37	2.4e-16	Response to temozolomide;
LGG	cis	rs34599045	0.522	rs12750261	chr1:152913068	G/A	cg07796016	chr1:152779584	LCE1C	-0.86	-8.03	-0.35	7.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8014204	0.836	rs12888998	chr14:75292662	G/T	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.95	-0.31	1.27e-11	Caffeine consumption;
LGG	cis	rs4319547	0.695	rs4758666	chr12:122902840	C/T	cg23029597	chr12:123009494	RSRC2	-0.89	-16.87	-0.62	3.92e-50	Body mass index;
LGG	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.56	0.44	1.65e-23	Aortic root size;
LGG	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg08847533	chr14:75593920	NEK9	0.63	12.12	0.49	1.43e-29	Height;
LGG	cis	rs1163251	0.756	rs539799	chr1:120208472	C/T	cg19096424	chr1:120255104	PHGDH	0.47	8.48	0.37	3.09e-16	Blood metabolite levels;
LGG	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg23625390	chr15:77176239	SCAPER	0.49	9.56	0.41	6.83e-20	Blood metabolite levels;
LGG	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg15309053	chr8:964076	NA	0.42	8.35	0.36	7.98e-16	Schizophrenia;
LGG	cis	rs3206736	0.548	rs328925	chr7:35037327	G/A	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs9463078	0.809	rs6899845	chr6:45043352	A/C	cg25276700	chr6:44698697	NA	-0.38	-8.11	-0.35	4.61e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg26384229	chr12:38710491	ALG10B	0.73	14.27	0.55	1.44e-38	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.93	-0.35	1.64e-14	Personality dimensions;
LGG	cis	rs1008375	0.843	rs59112113	chr4:17685336	A/T	cg18681998	chr4:17616180	MED28	0.82	17.08	0.62	4.57e-51	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2562456	0.793	rs61445561	chr19:21504032	A/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg24308560	chr3:49941425	MST1R	-0.22	-6.78	-0.3	3.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg13683864	chr3:40499215	RPL14	-1.16	-28.35	-0.8	3.12e-103	Renal cell carcinoma;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs2307022	0.586	rs2166768	chr16:68406907	G/T	cg07273125	chr16:68295692	NA	0.44	9.89	0.42	4.85e-21	Body mass index;
LGG	cis	rs4971059	0.608	rs7366138	chr1:155088350	G/A	cg13808842	chr1:155066096	NA	-0.32	-7.66	-0.34	1.08e-13	Breast cancer;
LGG	trans	rs561341	0.739	rs1978116	chr17:30220978	A/C	cg27661571	chr11:113659931	NA	-0.47	-6.91	-0.31	1.64e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13191362	0.507	rs2849525	chr6:163126652	A/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-6.68	-0.3	7.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-7.15	-0.32	3.35e-12	Bipolar disorder;
LGG	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.65	0.51	1.09e-31	Motion sickness;
LGG	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.35	-0.32	9.01e-13	Joint mobility (Beighton score);
LGG	cis	rs36051895	0.632	rs7029084	chr9:5174638	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-15.08	-0.57	4.55e-42	Pediatric autoimmune diseases;
LGG	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Bladder cancer;
LGG	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg13263323	chr15:86062960	AKAP13	0.35	7.2	0.32	2.38e-12	Coronary artery disease;
LGG	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg01324343	chr3:183735012	ABCC5	0.86	17.99	0.64	2.8e-55	Anterior chamber depth;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23881936	chr19:44555966	ZNF223	0.44	7.12	0.31	4.22e-12	Cognitive performance;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.27	0.36	1.43e-15	Obesity-related traits;
LGG	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.53	9.2	0.39	1.2e-18	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs9791712	chr7:66105163	C/G	cg11764359	chr7:65958608	NA	-0.73	-12.47	-0.5	5.66e-31	Aortic root size;
LGG	cis	rs738322	0.935	rs2413503	chr22:38568944	A/T	cg03162506	chr22:38580953	NA	0.36	9.41	0.4	2.32e-19	Cutaneous nevi;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs365132	0.846	rs812246	chr5:176327644	G/A	cg16309518	chr5:176445507	NA	-0.5	-10.95	-0.45	5.57e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs883565	0.792	rs784490	chr3:39173530	C/T	cg01426195	chr3:39028469	NA	-0.61	-11.06	-0.46	2.23e-25	Handedness;
LGG	cis	rs8180040	0.966	rs13072802	chr3:47346415	G/C	cg16586182	chr3:47516702	SCAP	-0.77	-15.17	-0.58	1.82e-42	Colorectal cancer;
LGG	cis	rs4919044	0.808	rs4917898	chr10:94808637	T/A	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs2371030	0.833	rs2371034	chr2:211578153	G/A	cg18417063	chr2:211583084	NA	-0.56	-10.44	-0.44	4.56e-23	Non-small cell lung cancer;
LGG	cis	rs10270805	0.504	rs6945425	chr7:16505341	A/G	cg08416764	chr7:16501619	SOSTDC1	-0.5	-7.39	-0.32	6.99e-13	Response to statin therapy;
LGG	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.56	-0.41	6.95e-20	Diabetic retinopathy;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.26e-25	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	0.935	rs10797834	chr1:183048749	T/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs11039798	0.764	rs11039771	chr11:48513273	C/T	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.6e-16	Axial length;
LGG	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg12667521	chr19:29218732	NA	0.62	9.39	0.4	2.77e-19	Methadone dose in opioid dependence;
LGG	cis	rs13191362	1.000	rs67487119	chr6:163102657	A/C	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.69	0.51	7.06e-32	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-16.16	-0.6	6.73e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.51e-33	Tonsillectomy;
LGG	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg00204512	chr16:28754710	NA	0.26	7.3	0.32	1.26e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12367572	0.501	rs11182829	chr12:45484189	C/T	cg03114573	chr12:45410052	DBX2	0.52	8.95	0.38	8.53e-18	Gut microbiome composition (summer);
LGG	cis	rs4642101	0.561	rs9812144	chr3:12805910	G/A	cg05775895	chr3:12838266	CAND2	0.56	9.56	0.41	7.12e-20	QRS complex (12-leadsum);
LGG	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg18089519	chr11:763339	TALDO1	-0.45	-8.04	-0.35	7.71e-15	Breast cancer;
LGG	cis	rs490234	0.756	rs925473	chr9:128228026	A/G	cg14078157	chr9:128172775	NA	-0.47	-8.9	-0.38	1.23e-17	Mean arterial pressure;
LGG	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.38	0.4	3.06e-19	Rheumatoid arthritis;
LGG	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.95	0.57	1.59e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg15704280	chr7:45808275	SEPT13	0.81	14.54	0.56	9.67e-40	Coronary artery disease;
LGG	cis	rs4774899	0.966	rs10518899	chr15:57491182	G/A	cg08128148	chr15:57256372	TCF12	-0.29	-6.78	-0.3	3.76e-11	Urinary tract infection frequency;
LGG	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg23029597	chr12:123009494	RSRC2	-0.97	-18.68	-0.66	1.89e-58	Body mass index;
LGG	cis	rs7091068	0.616	rs6583905	chr10:95504022	T/G	cg20715218	chr10:95462985	C10orf4	0.69	10.13	0.43	6.45e-22	Urinary tract infection frequency;
LGG	cis	rs2289700	0.518	rs77362013	chr15:79167260	T/C	cg14582193	chr15:79152553	NA	-0.51	-6.88	-0.3	1.99e-11	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00706505	chr3:49142215	QARS	0.48	7.18	0.32	2.77e-12	Gut microbiome composition (summer);
LGG	trans	rs208520	0.802	rs4710315	chr6:66887594	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-16.72	-0.61	1.99e-49	Exhaled nitric oxide output;
LGG	cis	rs1949733	0.666	rs3103070	chr4:8508825	A/G	cg13073564	chr4:8508604	NA	0.54	10.56	0.44	1.69e-23	Response to antineoplastic agents;
LGG	cis	rs7937890	0.504	rs2575847	chr11:14471172	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.89	-0.34	2.15e-14	Mitochondrial DNA levels;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4e-19	Life satisfaction;
LGG	cis	rs7582720	1.000	rs72934763	chr2:203758396	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.23	0.39	9.79e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13421350	0.579	rs59374567	chr2:173377302	C/T	cg15021238	chr2:173305865	ITGA6	-0.8	-8.63	-0.37	1.03e-16	Diabetic kidney disease;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.63	-11.04	-0.46	2.55e-25	Obesity-related traits;
LGG	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg03517284	chr6:25882590	NA	0.43	7.05	0.31	6.73e-12	Iron status biomarkers;
LGG	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg13385521	chr17:29058706	SUZ12P	0.93	10.81	0.45	1.89e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.91	-0.35	1.88e-14	Life satisfaction;
LGG	cis	rs7927592	0.913	rs11228268	chr11:68287447	A/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg07636037	chr3:49044803	WDR6	0.78	14.0	0.55	2.16e-37	Menarche (age at onset);
LGG	cis	rs2070433	0.539	rs1008549	chr21:47959698	C/T	cg12379764	chr21:47803548	PCNT	0.7	12.15	0.49	1.15e-29	Lymphocyte counts;
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.62	10.82	0.45	1.7e-24	Total body bone mineral density;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.81	0.38	2.63e-17	Schizophrenia;
LGG	trans	rs6787172	0.622	rs73170348	chr3:158087754	C/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	trans	rs208520	0.802	rs1342959	chr6:66883329	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-16.98	-0.62	1.31e-50	Exhaled nitric oxide output;
LGG	cis	rs10489202	0.686	rs12754453	chr1:167844896	A/T	cg24449463	chr1:168025552	DCAF6	-0.54	-7.29	-0.32	1.38e-12	Schizophrenia;
LGG	cis	rs9660992	0.710	rs55671824	chr1:205249814	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.68	0.3	6.93e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg17644776	chr2:200775616	C2orf69	-0.54	-7.3	-0.32	1.23e-12	Schizophrenia;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.77	0.38	3.57e-17	Obesity-related traits;
LGG	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg03258749	chr1:151040405	MLLT11	-0.49	-8.76	-0.38	3.66e-17	Childhood ear infection;
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg26116260	chr4:7069785	GRPEL1	1.14	21.47	0.71	1.87e-71	Monocyte percentage of white cells;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg03351412	chr1:154909251	PMVK	0.67	12.9	0.51	9.59e-33	Prostate cancer;
LGG	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.83	0.38	2.25e-17	Vitiligo;
LGG	trans	rs629535	0.814	rs545720	chr8:70063370	T/C	cg21567404	chr3:27674614	NA	0.4	6.74	0.3	4.86e-11	Dupuytren's disease;
LGG	trans	rs12310956	0.532	rs1525904	chr12:33962448	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs7267979	0.789	rs4815400	chr20:25292560	T/C	cg06421707	chr20:25228305	PYGB	-0.43	-9.0	-0.39	5.82e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9880211	1.000	rs6774964	chr3:136275582	G/A	cg21827317	chr3:136751795	NA	-0.48	-7.24	-0.32	1.86e-12	Body mass index;Height;
LGG	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.43	0.4	1.97e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs227808	0.754	rs9472321	chr6:44642884	C/G	cg18551225	chr6:44695536	NA	0.49	7.07	0.31	5.59e-12	Male-pattern baldness;
LGG	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg02811702	chr13:24901961	NA	0.41	7.84	0.34	3.12e-14	Obesity-related traits;
LGG	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27532318	chr7:32358331	NA	0.74	7.6	0.33	1.64e-13	Body mass index;
LGG	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.56	-0.5	2.44e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.02e-20	Diabetic retinopathy;
LGG	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.62	-0.33	1.49e-13	Triglycerides;
LGG	cis	rs4700695	0.925	rs4700692	chr5:65396279	T/C	cg21114390	chr5:65439923	SFRS12	-0.56	-7.12	-0.31	4.24e-12	Facial morphology (factor 19);
LGG	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.22	-0.7	2.71e-70	Coronary artery disease;
LGG	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11690935	0.959	rs6745143	chr2:172650382	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.61	-0.78	2.37e-95	Schizophrenia;
LGG	cis	rs34929064	0.629	rs17375307	chr7:22729376	G/A	cg18045685	chr7:22629474	NA	0.6	8.62	0.37	1.1e-16	Major depression and alcohol dependence;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg20607798	chr8:58055168	NA	0.69	7.86	0.34	2.79e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs834603	0.687	rs4724578	chr7:47482829	A/C	cg23694490	chr7:47445681	TNS3	0.45	12.34	0.5	1.91e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs8058578	0.945	rs8058961	chr16:30809063	G/A	cg00531865	chr16:30841666	NA	-0.57	-11.66	-0.48	9.79e-28	Multiple myeloma;
LGG	cis	rs1665650	0.874	rs66688522	chr10:118493393	G/A	cg14919929	chr10:118506882	NA	-0.49	-8.62	-0.37	1.04e-16	Colorectal cancer;
LGG	cis	rs11190604	1.000	rs2495739	chr10:102335507	C/T	cg11040518	chr10:102331378	NA	-0.36	-6.81	-0.3	3.05e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11650494	0.908	rs57390430	chr17:47374886	G/A	cg11430096	chr6:110968061	CDK19	0.64	6.75	0.3	4.39e-11	Prostate cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15186685	chr8:38089171	DDHD2	0.5	7.67	0.34	1.05e-13	Hip circumference;
LGG	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07080220	chr10:102295463	HIF1AN	0.72	12.32	0.5	2.31e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg06212747	chr3:49208901	KLHDC8B	0.72	12.91	0.51	8.6e-33	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.24e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.54	-7.71	-0.34	7.67e-14	Menarche (age at onset);
LGG	cis	rs10904908	1.000	rs7903402	chr10:17259772	C/T	cg01003015	chr10:17271136	VIM	-0.54	-8.86	-0.38	1.68e-17	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs3820928	0.874	rs1917125	chr2:227798981	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg00343986	chr7:65444356	GUSB	0.39	6.72	0.3	5.27e-11	Aortic root size;
LGG	cis	rs10028187	0.616	rs17379636	chr4:154406678	A/G	cg24020152	chr4:154419554	KIAA0922	0.43	10.0	0.42	1.84e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs755249	0.532	rs17343193	chr1:39881468	T/A	cg18385671	chr1:39797026	MACF1	0.44	7.45	0.33	4.64e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9912468	1.000	rs9893075	chr17:64311249	C/T	cg19474267	chr17:64306194	PRKCA	-0.96	-27.75	-0.79	1.56e-100	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs9297145	0.565	rs12705030	chr7:98765041	A/G	cg05967295	chr7:98741636	SMURF1	-0.68	-12.22	-0.49	5.75e-30	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19541837	chr11:71823834	C11orf51	0.43	7.29	0.32	1.37e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg21782813	chr7:2030301	MAD1L1	0.48	11.89	0.48	1.2e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs8067545	0.750	rs4925085	chr17:20000131	G/T	cg13482628	chr17:19912719	NA	0.63	12.47	0.5	5.42e-31	Schizophrenia;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.92	-0.38	1.06e-17	Lymphocyte counts;
LGG	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg05887092	chr17:76393375	PGS1	-0.74	-16.38	-0.61	7.02e-48	HDL cholesterol levels;
LGG	cis	rs6456156	0.846	rs7774396	chr6:167519786	G/A	cg07741184	chr6:167504864	NA	0.41	9.07	0.39	3.34e-18	Primary biliary cholangitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05867925	chr6:26033854	HIST1H2AB	0.43	7.21	0.32	2.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg08975724	chr8:8085496	FLJ10661	0.35	6.65	0.3	8.29e-11	Mood instability;
LGG	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg09021430	chr5:549028	NA	-0.7	-9.8	-0.41	9.59e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10802521	chr3:52805072	NEK4	-0.41	-7.11	-0.31	4.38e-12	Electroencephalogram traits;
LGG	cis	rs2224391	1.000	rs2753248	chr6:5262154	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.18	-0.36	2.69e-15	Height;
LGG	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg26597838	chr10:835615	NA	0.95	12.75	0.51	4.16e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7617773	0.817	rs17647717	chr3:48305456	C/T	cg11946769	chr3:48343235	NME6	0.69	11.18	0.46	7.44e-26	Coronary artery disease;
LGG	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg13010199	chr12:38710504	ALG10B	0.69	14.13	0.55	6.05e-38	Bladder cancer;
LGG	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg21427119	chr20:30132790	HM13	-0.58	-8.97	-0.38	7.37e-18	Mean corpuscular hemoglobin;
LGG	cis	rs41278232	1.000	rs73153149	chr20:62656325	G/A	cg03065311	chr20:62601662	ZNF512B	0.65	9.14	0.39	2e-18	Tonsillectomy;
LGG	cis	rs1044826	0.619	rs57357132	chr3:139118358	A/T	cg15131784	chr3:139108705	COPB2	-0.42	-6.94	-0.31	1.37e-11	Obesity-related traits;
LGG	cis	rs698833	0.926	rs786407	chr2:44735865	T/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	6.68	0.3	6.9e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9649465	0.967	rs7809453	chr7:123301940	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.95	-0.38	8.33e-18	Migraine;
LGG	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-8.9	-0.38	1.25e-17	Schizophrenia;
LGG	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg26396452	chr14:65542826	MAX	0.44	8.93	0.38	1.04e-17	Obesity-related traits;
LGG	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.38	-0.4	2.85e-19	Neuroticism;
LGG	cis	rs3747547	0.892	rs11789441	chr9:37993303	G/T	cg13774184	chr9:37916125	SHB	-0.7	-7.18	-0.32	2.73e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs3087591	1.000	rs2040791	chr17:29627297	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.56	-0.56	8.57e-40	Hip circumference;
LGG	cis	rs943466	1.000	rs4711346	chr6:33730996	C/G	cg07519485	chr6:33762594	MLN	0.56	11.34	0.47	1.83e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs11096990	0.634	rs12648793	chr4:39286093	T/C	cg24403649	chr4:39172243	NA	-0.37	-6.73	-0.3	5.18e-11	Cognitive function;
LGG	cis	rs258892	0.895	rs2338790	chr5:72055184	A/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg00666640	chr1:248458726	OR2T12	0.5	8.35	0.36	7.81e-16	Common traits (Other);
LGG	cis	rs2735413	0.564	rs7191314	chr16:78084236	C/A	cg04733911	chr16:78082701	NA	0.55	7.5	0.33	3.38e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg05368731	chr17:41323189	NBR1	0.95	18.86	0.66	2.81e-59	Menopause (age at onset);
LGG	cis	rs9398803	0.965	rs6919397	chr6:126659043	A/C	cg19875578	chr6:126661172	C6orf173	0.54	9.66	0.41	3.08e-20	Male-pattern baldness;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.69	-0.37	6.11e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg18479299	chr3:125709523	NA	0.6	7.78	0.34	4.91e-14	Blood pressure (smoking interaction);
LGG	cis	rs1497406	0.744	rs12057175	chr1:16508375	A/G	cg20430773	chr1:16534157	ARHGEF19	0.3	8.4	0.36	5.62e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg13482628	chr17:19912719	NA	0.6	11.87	0.48	1.54e-28	Schizophrenia;
LGG	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg21385522	chr1:16154831	NA	-0.56	-9.77	-0.41	1.26e-20	Systolic blood pressure;
LGG	cis	rs9357271	1.000	rs4140443	chr6:38347952	T/G	cg07362130	chr6:38359646	BTBD9	-0.48	-10.84	-0.45	1.55e-24	Restless legs syndrome;
LGG	trans	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs9325144	0.723	rs11169518	chr12:39177237	C/A	cg04568710	chr12:38710424	ALG10B	-0.33	-6.8	-0.3	3.32e-11	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs4919087	0.715	rs1253387	chr10:99032968	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.35	-0.32	9.19e-13	Monocyte count;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg24642844	chr7:1081250	C7orf50	-0.45	-8.45	-0.37	3.87e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	0.966	rs454723	chr20:25438928	G/C	cg06421707	chr20:25228305	PYGB	0.47	10.11	0.43	7.82e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-17.32	-0.63	3.46e-52	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10282920	chr2:95831790	ZNF2	0.44	7.33	0.32	1.05e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg24375607	chr4:120327624	NA	0.58	9.63	0.41	3.81e-20	Corneal astigmatism;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs977987	0.836	rs7199062	chr16:75474827	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.28	0.43	1.8e-22	Dupuytren's disease;
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg12310025	chr6:25882481	NA	-0.41	-7.35	-0.32	8.97e-13	Height;
LGG	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg09307838	chr4:120376055	NA	0.81	13.64	0.54	7.2e-36	Corneal astigmatism;
LGG	cis	rs4689388	0.926	rs11725494	chr4:6293855	C/T	cg25554036	chr4:6271136	WFS1	0.62	11.87	0.48	1.42e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7927771	0.524	rs2869024	chr11:47674101	G/A	cg20307385	chr11:47447363	PSMC3	-0.55	-10.7	-0.45	5.24e-24	Subjective well-being;
LGG	trans	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.96	0.42	2.76e-21	Mean corpuscular volume;
LGG	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg03264133	chr6:25882463	NA	-0.5	-7.94	-0.35	1.51e-14	Iron status biomarkers;
LGG	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg27279351	chr12:120934652	DYNLL1	0.8	13.0	0.52	3.7e-33	High light scatter reticulocyte count;
LGG	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	13.49	0.53	3.34e-35	Cognitive test performance;
LGG	cis	rs561341	1.000	rs542132	chr17:30307193	A/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25433682	chr16:30407049	ZNF48	0.55	8.13	0.35	4.05e-15	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.68	0.37	6.57e-17	Platelet count;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg20607798	chr8:58055168	NA	0.66	7.45	0.33	4.51e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg25039879	chr17:56429692	SUPT4H1	0.65	9.34	0.4	4.18e-19	Cognitive test performance;
LGG	cis	rs7428	0.545	rs7572750	chr2:85552186	C/A	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.8	-0.54	1.56e-36	Ear protrusion;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17309464	chr19:36705192	ZNF565;ZNF146	0.42	7.14	0.31	3.62e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs35110281	0.782	rs9981790	chr21:45045052	G/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.2	-0.39	1.28e-18	Mean corpuscular volume;
LGG	cis	rs988958	0.565	rs11889038	chr2:42238233	G/A	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg21782813	chr7:2030301	MAD1L1	0.52	13.13	0.52	1.07e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs6668108	1	rs6668108	chr1:165691320	A/G	cg24409356	chr1:165738333	TMCO1	0.79	9.32	0.4	4.78e-19	Intraocular pressure;
LGG	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs9875589	0.509	rs1844107	chr3:14065319	C/G	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.64	0.67	6.79e-63	Smoking behavior;
LGG	trans	rs7395662	0.929	rs7946248	chr11:48613516	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs477692	0.583	rs12415589	chr10:131428336	C/G	cg05714579	chr10:131428358	MGMT	-0.88	-21.99	-0.71	6.24e-74	Response to temozolomide;
LGG	cis	rs6831352	0.842	rs1230156	chr4:99989626	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.12	0.35	4.37e-15	Alcohol dependence;
LGG	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs4740619	0.716	rs1539171	chr9:15776138	G/T	cg14451791	chr9:16040625	NA	0.35	8.77	0.38	3.56e-17	Body mass index;
LGG	cis	rs2304069	0.954	rs1962603	chr5:149393006	G/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.53	0.53	2.18e-35	HIV-1 control;
LGG	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg02733842	chr7:1102375	C7orf50	-0.47	-7.29	-0.32	1.33e-12	Bronchopulmonary dysplasia;
LGG	cis	rs9487094	1.000	rs36035949	chr6:109736614	G/A	cg01125227	chr6:109776195	MICAL1	0.48	8.2	0.36	2.45e-15	Height;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg26384229	chr12:38710491	ALG10B	-0.68	-13.26	-0.52	3.14e-34	Bladder cancer;
LGG	cis	rs2963155	0.518	rs853184	chr5:142640901	C/T	cg17617527	chr5:142782415	NR3C1	0.96	12.87	0.51	1.25e-32	Breast cancer;
LGG	cis	rs6988985	0.589	rs6471580	chr8:143986701	A/G	cg10324643	chr8:143916377	GML	0.43	9.02	0.39	4.91e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.63	0.79	5.57e-100	Cognitive ability;
LGG	cis	rs8067545	0.611	rs11653630	chr17:20189046	C/T	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.54e-22	Schizophrenia;
LGG	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg23173402	chr1:227635558	NA	0.6	9.89	0.42	4.82e-21	Major depressive disorder;
LGG	cis	rs9790314	1.000	rs336585	chr3:161081670	A/G	cg04691961	chr3:161091175	C3orf57	-0.65	-15.5	-0.58	6.17e-44	Morning vs. evening chronotype;
LGG	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg09426994	chr11:118478258	PHLDB1	-0.43	-7.49	-0.33	3.61e-13	Cholesterol, total;
LGG	cis	rs7568458	0.870	rs6733913	chr2:85757379	T/C	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.44e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg12728061	chr1:2383438	NA	-0.46	-10.97	-0.45	4.81e-25	Non-obstructive azoospermia;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.11	0.31	4.49e-12	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24410064	chr7:7222050	C1GALT1	0.45	7.63	0.33	1.37e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4302748	0.862	rs11768269	chr7:36172741	A/G	cg24442661	chr7:36192818	EEPD1	0.54	7.19	0.32	2.61e-12	Platelet count;
LGG	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	trans	rs9467711	0.606	rs9379897	chr6:26601526	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.95	-0.31	1.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg02073558	chr3:44770973	ZNF501	0.65	11.61	0.47	1.54e-27	Depressive symptoms;
LGG	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.44	-7.18	-0.32	2.81e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg18252515	chr7:66147081	NA	1.4	20.59	0.69	2.23e-67	Diabetic kidney disease;
LGG	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.53	-0.37	2.07e-16	Calcium levels;
LGG	cis	rs2130392	0.886	rs3806796	chr4:185652147	G/A	cg21366198	chr4:185655624	MLF1IP	0.45	7.85	0.34	2.86e-14	Kawasaki disease;
LGG	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.15	-26.08	-0.77	6.62e-93	Primary sclerosing cholangitis;
LGG	cis	rs2153535	0.580	rs2327050	chr6:8440630	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg24575275	chr7:1094737	C7orf50	-0.36	-6.96	-0.31	1.19e-11	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03609269	chr1:53393023	SCP2	0.49	7.5	0.33	3.26e-13	Gut microbiome composition (summer);
LGG	cis	rs9796	0.717	rs2947494	chr15:41375741	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.88	-0.42	4.99e-21	Menopause (age at onset);
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.2	-0.36	2.36e-15	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.861	rs1571979	chr1:53237526	G/A	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.97	-0.66	8.25e-60	Monocyte count;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg05863683	chr7:1912471	MAD1L1	0.4	7.95	0.35	1.49e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02018176	chr4:1364513	KIAA1530	0.44	10.33	0.43	1.2e-22	Longevity;
LGG	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs7444	0.882	rs140492	chr22:21923144	A/C	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.85e-11	Systemic lupus erythematosus;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22111723	chr13:21872664	NA	-0.48	-7.07	-0.31	5.9e-12	Systemic lupus erythematosus;
LGG	cis	rs10463554	0.963	rs10463555	chr5:102319037	A/C	cg23492399	chr5:102201601	PAM	-0.54	-8.34	-0.36	8.32e-16	Parkinson's disease;
LGG	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg15162869	chr22:32027605	PISD	-0.7	-7.37	-0.32	7.92e-13	Age-related hearing impairment;
LGG	cis	rs2201728	0.702	rs13120304	chr4:100196294	A/T	cg07219303	chr4:100140905	ADH6	-0.36	-6.66	-0.3	8.02e-11	Cardiac Troponin-T levels;
LGG	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.66	-0.34	1.13e-13	Neuroticism;
LGG	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Cannabis dependence symptom count;
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg18252515	chr7:66147081	NA	0.43	7.04	0.31	6.98e-12	Aortic root size;
LGG	cis	rs6582630	0.512	rs11182667	chr12:38588392	C/A	cg13010199	chr12:38710504	ALG10B	-0.55	-11.1	-0.46	1.46e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg13385794	chr1:248469461	NA	0.49	8.31	0.36	1.05e-15	Common traits (Other);
LGG	cis	rs11209002	1.000	rs10749771	chr1:67573730	A/G	cg02640540	chr1:67518911	SLC35D1	0.46	6.84	0.3	2.5e-11	Crohn's disease;
LGG	cis	rs2467099	0.504	rs55956362	chr17:73901294	G/T	cg23806715	chr17:73775811	H3F3B	0.48	7.41	0.33	6.23e-13	Systolic blood pressure;
LGG	cis	rs4671458	0.894	rs76262922	chr2:63513191	G/A	cg17519650	chr2:63277830	OTX1	-0.63	-7.08	-0.31	5.23e-12	Subjective well-being;
LGG	cis	rs13082711	0.911	rs13089870	chr3:27447626	C/T	cg02860705	chr3:27208620	NA	0.71	13.29	0.53	2.32e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7084402	0.967	rs1649062	chr10:60309326	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.45	-0.44	4.49e-23	Bone mineral density;
LGG	cis	rs72781680	0.716	rs2712050	chr2:24059408	A/C	cg08917208	chr2:24149416	ATAD2B	0.64	8.27	0.36	1.41e-15	Lymphocyte counts;
LGG	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs9505454	chr6:8478532	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg04455712	chr21:45112962	RRP1B	0.49	9.25	0.39	8.43e-19	Mean corpuscular volume;
LGG	cis	rs4917300	0.606	rs6583567	chr8:143114617	A/G	cg06573787	chr8:143070187	NA	0.59	9.86	0.42	6.13e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs5758659	0.519	rs133307	chr22:42396568	C/A	cg15557168	chr22:42548783	NA	-0.34	-7.69	-0.34	8.76e-14	Cognitive function;
LGG	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.77	-0.38	3.32e-17	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22433210	chr17:43662623	NA	0.64	10.96	0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06108461	chr20:60628389	TAF4	-1.07	-21.62	-0.71	3.49e-72	Body mass index;
LGG	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg22120825	chr2:201024476	NA	-0.48	-6.79	-0.3	3.37e-11	Schizophrenia;
LGG	cis	rs3768617	0.510	rs10797837	chr1:183075121	C/G	cg07928641	chr1:182991847	LAMC1	0.47	9.33	0.4	4.36e-19	Fuchs's corneal dystrophy;
LGG	cis	rs72945132	0.882	rs11235967	chr11:70191691	T/C	cg14088196	chr11:70211408	PPFIA1	0.93	13.11	0.52	1.31e-33	Coronary artery disease;
LGG	cis	rs5756391	0.523	rs2049908	chr22:37311089	A/G	cg21209356	chr22:37319042	CSF2RB	0.4	9.22	0.39	1.03e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.73	-0.38	4.81e-17	Lung cancer;
LGG	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg25801113	chr15:45476975	SHF	0.87	19.81	0.68	1.05e-63	Uric acid levels;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/A	cg11965913	chr1:205819406	PM20D1	0.81	17.65	0.63	1.09e-53	Menarche (age at onset);
LGG	cis	rs3735485	0.843	rs12533346	chr7:45020889	A/G	cg03440944	chr7:45023329	C7orf40	0.56	9.63	0.41	4.02e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-9.4	-0.4	2.52e-19	Lung function (FEV1/FVC);
LGG	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.07e-22	Colorectal cancer;
LGG	cis	rs7084783	0.622	rs61606504	chr10:105348767	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.54	9.63	0.41	4.12e-20	Fear of pain;
LGG	trans	rs12517041	1.000	rs12517041	chr5:23301908	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05985712	chr3:32726336	CNOT10	0.46	6.82	0.3	2.77e-11	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg26578617	chr4:90757533	SNCA	-0.44	-8.8	-0.38	2.75e-17	Dementia with Lewy bodies;
LGG	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.77	-0.48	3.54e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.862	rs62251657	chr3:72832076	C/T	cg26655873	chr3:72818019	SHQ1	0.35	6.88	0.3	1.93e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg03469862	chr11:68924853	NA	0.46	7.07	0.31	5.85e-12	Blond vs. brown hair color;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	9.04e-12	Lung cancer;
LGG	cis	rs7166081	1.000	rs35008245	chr15:67614967	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.68	-0.3	6.89e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs2235573	0.868	rs4821737	chr22:38500382	G/T	cg19171272	chr22:38449367	NA	0.43	8.28	0.36	1.29e-15	Glioblastoma;Glioma;
LGG	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.23	0.43	2.89e-22	Arsenic metabolism;
LGG	cis	rs3126085	0.935	rs7534716	chr1:152198654	A/G	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs11671005	0.779	rs3794970	chr19:58986260	C/T	cg13877915	chr19:58951672	ZNF132	-0.62	-8.21	-0.36	2.17e-15	Mean platelet volume;
LGG	cis	rs10197940	0.648	rs7587301	chr2:152347600	A/G	cg19508488	chr2:152266495	RIF1	0.46	8.24	0.36	1.81e-15	Lung cancer;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.54	14.56	0.56	7.94e-40	Tonsillectomy;
LGG	cis	rs7084783	0.967	rs7067666	chr10:105332452	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.38	6.66	0.3	7.6e-11	Fear of pain;
LGG	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.42e-31	Motion sickness;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg08742575	chr21:47604166	C21orf56	0.49	8.55	0.37	1.79e-16	Testicular germ cell tumor;
LGG	cis	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg15971980	chr6:150254442	NA	0.43	8.14	0.35	3.68e-15	Lung cancer;
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00290607	chr11:67383545	NA	-0.63	-11.38	-0.47	1.3e-26	Mean corpuscular volume;
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.76	15.61	0.59	1.91e-44	Age at first birth;
LGG	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.62	-8.32	-0.36	1.02e-15	Smoking behavior;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.44	-0.44	4.5e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.76	-0.51	3.56e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg23625390	chr15:77176239	SCAPER	-0.68	-12.0	-0.49	4.42e-29	Blood metabolite levels;
LGG	cis	rs7129556	0.701	rs10899399	chr11:77409832	C/T	cg12586386	chr11:77299805	AQP11	0.45	7.39	0.32	7.05e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg21453758	chr17:80185943	SLC16A3	0.35	7.29	0.32	1.37e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2710642	0.678	rs11125946	chr2:63298150	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-8.45	-0.37	3.83e-16	LDL cholesterol levels;LDL cholesterol;
LGG	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg27053975	chr1:166958233	MAEL	-0.47	-6.66	-0.3	7.62e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs3740909	1.000	rs11821242	chr11:125883418	A/C	cg24940576	chr11:125904314	CDON	-0.47	-7.27	-0.32	1.51e-12	Blood protein levels;
LGG	trans	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg24247370	chr13:99142703	STK24	0.37	6.65	0.3	8.49e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03759824	chr8:50822565	NA	0.39	6.68	0.3	6.71e-11	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg13385521	chr17:29058706	SUZ12P	0.93	10.68	0.44	6.02e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1920116	0.710	rs6772936	chr3:169566453	C/G	cg08193579	chr3:169529701	LRRC34	0.42	7.36	0.32	8.21e-13	Glioma (high-grade);
LGG	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.53	0.33	2.65e-13	Electroencephalogram traits;
LGG	cis	rs1707322	0.717	rs3014246	chr1:46086077	C/T	cg03146154	chr1:46216737	IPP	-0.57	-10.89	-0.45	9.39e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9783347	1.000	rs1140047	chr11:18327684	G/T	cg15585147	chr11:18324498	HPS5	0.44	9.37	0.4	3.21e-19	Pancreatic cancer;
LGG	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg08700190	chr5:6636046	SRD5A1	-0.33	-7.08	-0.31	5.24e-12	Response to amphetamines;
LGG	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg08508325	chr11:3079039	CARS	0.43	8.46	0.37	3.45e-16	Calcium levels;
LGG	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.21	0.52	4.83e-34	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.644	rs11687392	chr2:86502663	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.78	0.3	3.66e-11	Night sleep phenotypes;
LGG	cis	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg19468946	chr17:37922297	IKZF3	-0.38	-6.93	-0.31	1.4e-11	Self-reported allergy;
LGG	cis	rs765787	0.530	rs2668751	chr15:45517293	T/C	cg24006582	chr15:45444508	DUOX1	-0.66	-12.63	-0.51	1.25e-31	Uric acid levels;
LGG	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg10402321	chr1:26617780	UBXN11	-0.36	-7.0	-0.31	9.25e-12	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg13852791	chr20:30311386	BCL2L1	0.65	8.55	0.37	1.78e-16	Mean corpuscular hemoglobin;
LGG	cis	rs2880765	0.835	rs4360875	chr15:86040394	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.23	-0.32	1.99e-12	Coronary artery disease;
LGG	cis	rs4478037	0.822	rs9825335	chr3:33123292	A/C	cg19404215	chr3:33155277	CRTAP	0.74	9.24	0.39	9.27e-19	Major depressive disorder;
LGG	trans	rs7181230	0.885	rs28826672	chr15:40360366	G/T	cg22705835	chr10:65332833	REEP3	-0.62	-10.13	-0.43	6.6e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.54	-0.47	3.03e-27	Extrinsic epigenetic age acceleration;
LGG	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.53	8.75	0.38	4.11e-17	Colorectal cancer;
LGG	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.95	-0.31	1.27e-11	Mood instability;
LGG	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg00080972	chr5:178986291	RUFY1	-0.41	-6.93	-0.31	1.38e-11	Lung cancer;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg12633918	chr20:23549525	CST9L	-0.33	-6.72	-0.3	5.2e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2456568	0.709	rs12806128	chr11:93634972	C/T	cg26875233	chr11:93583750	C11orf90	0.36	7.02	0.31	8e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs7523273	0.512	rs2761435	chr1:207918466	C/G	cg22525895	chr1:207977042	MIR29B2	0.51	9.95	0.42	2.93e-21	Schizophrenia;
LGG	cis	rs2635047	0.600	rs2635056	chr18:44710568	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.68	0.34	9.66e-14	Educational attainment;
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg00078996	chr12:132293329	NA	-0.35	-7.21	-0.32	2.33e-12	Migraine;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.63	-0.54	7.96e-36	Alzheimer's disease;
LGG	cis	rs1153858	1.000	rs4775937	chr15:45678614	C/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs3096299	0.589	rs3114898	chr16:89392315	C/T	cg02187348	chr16:89574699	SPG7	0.4	6.69	0.3	6.65e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg19635926	chr16:89946313	TCF25	0.81	8.42	0.36	4.65e-16	Skin colour saturation;
LGG	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg24397884	chr7:158709396	WDR60	-1.08	-16.53	-0.61	1.36e-48	Height;
LGG	cis	rs58688157	0.883	rs34793529	chr11:575800	T/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.58	-8.51	-0.37	2.37e-16	Systemic lupus erythematosus;
LGG	trans	rs7944735	0.575	rs34972471	chr11:48050391	G/A	cg03929089	chr4:120376271	NA	0.67	9.25	0.39	8.03e-19	Intraocular pressure;
LGG	cis	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg13647721	chr17:30228624	UTP6	0.66	8.57	0.37	1.61e-16	Hip circumference adjusted for BMI;
LGG	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg09904177	chr6:26538194	HMGN4	0.6	9.04	0.39	4.24e-18	Small cell lung carcinoma;
LGG	cis	rs9875589	0.509	rs2607757	chr3:14081948	A/G	cg19554555	chr3:13937349	NA	0.57	10.21	0.43	3.26e-22	Ovarian reserve;
LGG	cis	rs75920871	1.000	rs61905706	chr11:116883777	G/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.99e-12	Subjective well-being;
LGG	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg04935436	chr20:30431758	NA	0.39	6.74	0.3	4.61e-11	Mean corpuscular hemoglobin;
LGG	cis	rs734999	0.505	rs4648659	chr1:2560903	T/G	cg15627072	chr1:2432621	PLCH2	-0.36	-8.15	-0.35	3.37e-15	Ulcerative colitis;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.36	-7.26	-0.32	1.67e-12	Schizophrenia;
LGG	cis	rs7107174	0.901	rs2512522	chr11:77925855	G/C	cg02023728	chr11:77925099	USP35	0.45	7.87	0.34	2.52e-14	Testicular germ cell tumor;
LGG	cis	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.22	-0.46	5.34e-26	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.4	0.36	5.61e-16	Platelet count;
LGG	trans	rs877282	0.945	rs35342920	chr10:790484	T/C	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg18032289	chr17:61959525	GH2	-0.38	-6.66	-0.3	7.97e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs35110281	0.667	rs4819288	chr21:45120173	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.98	0.42	2.25e-21	Mean corpuscular volume;
LGG	cis	rs3747547	0.892	rs11789473	chr9:37954424	T/G	cg13774184	chr9:37916125	SHB	-0.71	-6.99	-0.31	9.69e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs28655083	0.529	rs285022	chr16:77099730	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.93	0.31	1.39e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg11040518	chr10:102331378	NA	-0.36	-6.73	-0.3	5.12e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg00092383	chr7:157075207	NA	0.4	6.93	0.31	1.43e-11	Body mass index;
LGG	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg16070123	chr10:51489643	NA	0.41	7.42	0.33	5.59e-13	Prostate-specific antigen levels;
LGG	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs8028182	0.636	rs8029112	chr15:75808972	T/C	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs11931598	1.000	rs11931598	chr4:7047102	A/G	cg26116260	chr4:7069785	GRPEL1	0.43	7.58	0.33	1.97e-13	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs7107174	1.000	rs7113042	chr11:78035832	C/T	cg02023728	chr11:77925099	USP35	-0.46	-8.22	-0.36	2.04e-15	Testicular germ cell tumor;
LGG	cis	rs990171	1.000	rs6737668	chr2:103093081	C/T	cg05295703	chr2:102895712	NA	-0.52	-8.95	-0.38	8.9e-18	Lymphocyte counts;
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg06494592	chr3:125709126	NA	-0.56	-7.08	-0.31	5.36e-12	Blood pressure (smoking interaction);
LGG	cis	rs7566780	0.575	rs7605502	chr2:16689951	A/T	cg09580478	chr2:16689509	NA	0.46	7.25	0.32	1.72e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs28374715	0.635	rs8023530	chr15:41647775	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.19	-27.31	-0.79	1.5e-98	Ulcerative colitis;
LGG	cis	rs9393813	0.516	rs4711152	chr6:27380202	C/T	cg18711553	chr6:27366782	ZNF391	0.49	9.44	0.4	1.77e-19	Bipolar disorder;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10883723	0.810	rs2296585	chr10:104245549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.1	0.55	8.19e-38	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7944735	0.508	rs7115371	chr11:47564587	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.49e-11	Intraocular pressure;
LGG	cis	rs988958	0.526	rs12712821	chr2:42238864	C/T	cg27428208	chr2:42229179	NA	0.5	7.61	0.33	1.51e-13	Hypospadias;
LGG	cis	rs208520	0.837	rs208486	chr6:66926255	A/T	cg07460842	chr6:66804631	NA	-0.93	-16.02	-0.6	2.96e-46	Exhaled nitric oxide output;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg09038676	chr11:67351608	GSTP1	-0.37	-7.48	-0.33	3.69e-13	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg12463550	chr7:65579703	CRCP	0.75	8.09	0.35	5.29e-15	Diabetic kidney disease;
LGG	cis	rs73001065	0.818	rs12610185	chr19:19721722	G/A	cg03709012	chr19:19516395	GATAD2A	0.79	7.2	0.32	2.37e-12	LDL cholesterol;
LGG	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg20026190	chr17:76395443	PGS1	0.57	10.1	0.42	8.26e-22	HDL cholesterol levels;
LGG	cis	rs4740619	0.846	rs10810427	chr9:15687161	C/G	cg14451791	chr9:16040625	NA	0.33	8.19	0.36	2.64e-15	Body mass index;
LGG	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg08508325	chr11:3079039	CARS	0.39	7.25	0.32	1.81e-12	Calcium levels;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19626725	chr5:178986131	RUFY1	-0.42	-6.89	-0.31	1.79e-11	Lung cancer;
LGG	cis	rs12348691	0.503	rs6478423	chr9:100592030	C/T	cg13688889	chr9:100608707	NA	-0.83	-16.27	-0.6	2.15e-47	Alopecia areata;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg01570551	chr7:23719851	C7orf46	0.34	7.2	0.32	2.41e-12	Schizophrenia;
LGG	cis	rs1983891	0.742	rs4711677	chr6:41555862	G/A	cg20194872	chr6:41519635	FOXP4	0.54	9.33	0.4	4.46e-19	Prostate cancer;
LGG	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.4	-0.36	5.62e-16	Myopia (pathological);
LGG	cis	rs11123610	0.520	rs7576146	chr2:3718393	A/C	cg26344334	chr2:3718215	ALLC	-0.48	-8.34	-0.36	8.6e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.51	0.4	1e-19	Diabetic retinopathy;
LGG	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg02975922	chr3:195473998	MUC4	-0.53	-8.7	-0.37	5.74e-17	Pancreatic cancer;
LGG	cis	rs1348850	0.872	rs13004955	chr2:178398923	A/T	cg27490568	chr2:178487706	NA	-0.52	-10.21	-0.43	3.39e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg03162506	chr22:38580953	NA	0.37	9.67	0.41	2.97e-20	Cutaneous nevi;
LGG	trans	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.28	-0.36	1.33e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg02158880	chr13:53174818	NA	0.68	15.81	0.59	2.47e-45	Lewy body disease;
LGG	trans	rs6582630	0.519	rs4294627	chr12:38293982	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.71	-0.38	5.32e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs735539	0.521	rs693489	chr13:21423005	A/G	cg04906043	chr13:21280425	IL17D	-0.46	-7.32	-0.32	1.11e-12	Dental caries;
LGG	cis	rs1185460	0.547	rs34150933	chr11:118911039	C/T	cg12636538	chr11:118901039	SLC37A4	-0.65	-13.66	-0.54	6.18e-36	Coronary artery disease;
LGG	cis	rs4730779	0.935	rs10278130	chr7:117022604	A/G	cg10524701	chr7:117356490	CTTNBP2	0.4	8.7	0.37	5.83e-17	Waist circumference;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg01673284	chr16:4527211	HMOX2	0.32	6.67	0.3	7.51e-11	Schizophrenia;
LGG	cis	rs139371	0.684	rs139312	chr22:39499369	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.8	-0.3	3.18e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs6121246	0.567	rs6060344	chr20:30207316	A/G	cg21427119	chr20:30132790	HM13	-0.58	-9.0	-0.39	5.68e-18	Mean corpuscular hemoglobin;
LGG	cis	rs75059851	0.756	rs11223656	chr11:133842973	T/A	cg17703048	chr11:133852993	NA	-0.88	-15.97	-0.6	4.93e-46	Schizophrenia;
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19717773	chr7:2847554	GNA12	0.32	6.76	0.3	4.22e-11	Height;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.89	0.34	2.14e-14	Lung cancer;
LGG	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.63	0.33	1.31e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11361923	1	rs11361923	chr14:77862679	GC/G	cg20045696	chr14:77926864	AHSA1	-0.42	-7.06	-0.31	5.97e-12	Sum basophil neutrophil counts;White blood cell count;Granulocyte count;
LGG	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg12667521	chr19:29218732	NA	0.63	9.42	0.4	2.11e-19	Methadone dose in opioid dependence;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg10935494	chr17:80760059	TBCD	-0.39	-7.51	-0.33	3.1400000000000003e-13	Glycated hemoglobin levels;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg12395012	chr8:11607386	GATA4	0.38	6.82	0.3	2.86e-11	Triglycerides;
LGG	cis	rs7619833	0.606	rs11711853	chr3:27317846	C/A	cg02860705	chr3:27208620	NA	0.39	7.43	0.33	5.12e-13	Breast cancer;
LGG	cis	rs2013441	1.000	rs2703821	chr17:20121526	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	7.07	0.31	5.58e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg01557791	chr16:72042693	DHODH	-0.63	-11.42	-0.47	8.55e-27	Fibrinogen levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg22539505	chr3:50330110	IFRD2	0.41	6.89	0.3	1.89e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg04398451	chr17:18023971	MYO15A	0.66	13.87	0.54	8.26e-37	Total body bone mineral density;
LGG	cis	rs6456042	1.000	rs3099291	chr6:166528913	A/G	cg11088901	chr6:166572345	T	0.38	7.83	0.34	3.26e-14	Asthma;
LGG	cis	rs7928758	0.945	rs56330625	chr11:134280067	G/A	cg22777979	chr11:134283252	B3GAT1	0.85	10.98	0.45	4.42e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10905065	0.866	rs10795547	chr10:5827074	A/G	cg11519256	chr10:5708881	ASB13	-0.4	-6.95	-0.31	1.28e-11	Menopause (age at onset);
LGG	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg10845886	chr2:3471009	TTC15	-0.45	-8.83	-0.38	2.14e-17	Neurofibrillary tangles;
LGG	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg06885757	chr1:42089581	HIVEP3	0.48	10.4	0.44	6.41e-23	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7500448	0.523	rs8061888	chr16:83021429	A/G	cg03011928	chr16:83023240	CDH13	-0.33	-7.39	-0.32	7.06e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Pulse pressure;Coronary artery disease;
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg04166393	chr7:2884313	GNA12	0.48	9.29	0.4	5.81e-19	Height;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg08645402	chr16:4508243	NA	0.5	8.48	0.37	3.1e-16	Schizophrenia;
LGG	trans	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg22535103	chr8:58192502	C8orf71	-1.0	-13.24	-0.52	3.76e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7766436	0.922	rs11753523	chr6:22602094	G/A	cg13666174	chr6:22585274	NA	-0.48	-10.75	-0.45	3.36e-24	Coronary artery disease;
LGG	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.84	-0.59	1.85e-45	Gallbladder cancer;
LGG	cis	rs4900069	0.872	rs7146000	chr14:91593248	C/T	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.41	-7.03	-0.31	7.42e-12	Resting heart rate;
LGG	trans	rs561341	0.714	rs473535	chr17:30312365	A/G	cg20587970	chr11:113659929	NA	-1.33	-23.46	-0.74	9.28e-81	Hip circumference adjusted for BMI;
LGG	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9557207	1.000	rs12869170	chr13:99883315	C/A	cg24509225	chr13:100037070	UBAC2	0.69	12.38	0.5	1.37e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7973719	0.833	rs11044332	chr12:7358768	C/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.08	-0.35	5.51e-15	IgG glycosylation;
LGG	trans	rs35847492	1.000	rs35847492	chr8:9276025	G/C	cg06636001	chr8:8085503	FLJ10661	0.48	7.78	0.34	4.91e-14	Neuroticism;
LGG	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.65	7.2	0.32	2.4e-12	Initial pursuit acceleration;
LGG	cis	rs1497828	0.956	rs2646818	chr1:217525655	A/T	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	cis	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg19539972	chr4:7069911	GRPEL1	0.68	10.01	0.42	1.8e-21	Monocyte percentage of white cells;
LGG	cis	rs35110281	0.811	rs9980185	chr21:45057905	A/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.5	-0.4	1.11e-19	Mean corpuscular volume;
LGG	cis	rs7666738	0.791	rs2903142	chr4:99040071	C/T	cg05340658	chr4:99064831	C4orf37	0.49	8.23	0.36	1.99e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs74781061	0.789	rs11852291	chr15:74749965	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs75920871	1.000	rs59294170	chr11:116841446	A/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	7.78e-12	Subjective well-being;
LGG	cis	rs911263	0.603	rs10141370	chr14:68776170	G/A	cg18825221	chr14:68749962	RAD51L1	0.36	7.78	0.34	4.72e-14	Primary biliary cholangitis;
LGG	cis	rs9326248	0.539	rs660443	chr11:116760693	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.5	0.44	2.89e-23	Blood protein levels;
LGG	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg14541582	chr5:601475	NA	-0.72	-10.97	-0.45	4.84e-25	Obesity-related traits;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg05091796	chr16:4465799	CORO7	-0.81	-13.56	-0.53	1.6e-35	Schizophrenia;
LGG	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg11941060	chr3:133502564	NA	-0.49	-8.25	-0.36	1.64e-15	Iron status biomarkers;
LGG	cis	rs10937275	0.826	rs71322421	chr3:186640688	T/A	cg24050613	chr3:186648279	ST6GAL1	0.84	8.59	0.37	1.32e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg03264133	chr6:25882463	NA	-0.4	-7.03	-0.31	7.59e-12	Height;
LGG	cis	rs6977660	0.714	rs12530537	chr7:19822641	A/G	cg05791153	chr7:19748676	TWISTNB	-0.72	-9.94	-0.42	3.02e-21	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2013441	1.000	rs2703802	chr17:20101039	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.67	12.24	0.49	4.8e-30	Obesity-related traits;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg04008888	chr11:68622739	NA	-0.55	-11.7	-0.48	6.8e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1030877	0.557	rs2576752	chr2:105978761	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.51	8.95	0.38	8.47e-18	Obesity-related traits;
LGG	cis	rs5769765	1.000	rs761879	chr22:50241210	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	11.08	0.46	1.88e-25	Schizophrenia;
LGG	cis	rs62400317	0.762	rs62436374	chr6:44874785	C/G	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs12681288	0.862	rs7814231	chr8:1021103	A/G	cg08648136	chr8:956695	NA	0.37	7.96	0.35	1.31e-14	Schizophrenia;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg08621203	chr6:150244597	RAET1G	0.46	8.03	0.35	7.86e-15	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00832308	chr18:13218884	C18orf1	0.44	6.99	0.31	9.67e-12	Gut microbiome composition (summer);
LGG	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg07080220	chr10:102295463	HIF1AN	0.74	12.38	0.5	1.38e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg09904177	chr6:26538194	HMGN4	0.68	14.07	0.55	1.11e-37	Intelligence (multi-trait analysis);
LGG	trans	rs9929218	0.953	rs3118227	chr16:68734855	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-15.17	-0.58	1.71e-42	Colorectal cancer;
LGG	cis	rs477895	0.887	rs12793347	chr11:64117491	G/A	cg22916017	chr11:64110731	CCDC88B	-0.53	-6.85	-0.3	2.35e-11	Mean platelet volume;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.91	-14.34	-0.55	7.44e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4789693	1.000	rs4789693	chr17:80421870	A/C	cg04308225	chr17:80449738	NA	0.61	9.1	0.39	2.71e-18	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs9397585	0.857	rs6930145	chr6:153372172	G/C	cg17707550	chr6:153380415	RGS17	0.62	14.69	0.56	2.25e-40	Body mass index;
LGG	cis	rs73787773	1.000	rs73787773	chr5:111471712	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.63	-7.86	-0.34	2.71e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4975616	0.686	rs37011	chr5:1348798	A/T	cg07493874	chr5:1342172	CLPTM1L	-0.78	-15.81	-0.59	2.45e-45	Lung cancer;
LGG	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg09818912	chr17:20140352	CYTSB	0.31	7.17	0.32	2.96e-12	Schizophrenia;
LGG	trans	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg05926928	chr17:57297772	GDPD1	-0.55	-9.07	-0.39	3.49e-18	Schizophrenia;
LGG	cis	rs4639966	0.836	rs10892282	chr11:118627778	C/G	cg20309703	chr11:118481025	PHLDB1	0.49	7.37	0.32	8.06e-13	Systemic lupus erythematosus;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7119	0.717	rs11636412	chr15:77767291	C/T	cg05673287	chr15:77411982	SGK269	-0.44	-9.67	-0.41	2.9e-20	Type 2 diabetes;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg26150922	chr2:100937072	LONRF2	-0.58	-11.25	-0.46	4.07e-26	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs1713839	chr3:153829105	A/G	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs9462027	0.583	rs9469902	chr6:34793768	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.21	-0.46	5.64e-26	Systemic lupus erythematosus;
LGG	cis	rs2013441	0.670	rs35317166	chr17:19959820	T/A	cg13482628	chr17:19912719	NA	0.53	8.75	0.38	3.85e-17	Obesity-related traits;
LGG	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.4	-0.4	2.56e-19	Sudden cardiac arrest;
LGG	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg07541023	chr7:19748670	TWISTNB	0.48	7.6	0.33	1.7e-13	Thyroid stimulating hormone;
LGG	cis	rs9308731	0.644	rs1054873	chr2:111876148	G/A	cg26001287	chr2:111877753	BCL2L11	-0.35	-6.96	-0.31	1.2e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg19554555	chr3:13937349	NA	-0.54	-9.77	-0.41	1.28e-20	Ovarian reserve;
LGG	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg26384229	chr12:38710491	ALG10B	0.85	18.06	0.64	1.4e-55	Heart rate;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25568561	chr14:102276087	PPP2R5C	0.38	6.7	0.3	6.21e-11	Obesity-related traits;
LGG	cis	rs4740619	0.935	rs10810408	chr9:15601971	G/A	cg14451791	chr9:16040625	NA	-0.37	-9.47	-0.4	1.44e-19	Body mass index;
LGG	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg03351412	chr1:154909251	PMVK	0.48	8.36	0.36	7.53e-16	Prostate cancer;
LGG	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.59	-0.33	1.76e-13	Colorectal cancer;
LGG	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.27e-11	Aortic root size;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg11965913	chr1:205819406	PM20D1	0.85	18.51	0.65	1.2e-57	Menarche (age at onset);
LGG	cis	rs36071027	0.554	rs34366240	chr5:158425013	C/A	cg18496440	chr5:158532302	NA	0.42	6.96	0.31	1.15e-11	Carotid intima media thickness;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg01988459	chr11:68622903	NA	-0.64	-12.76	-0.51	3.59e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06115535	chr2:131100015	IMP4;CCDC115	0.45	7.09	0.31	5.14e-12	Cognitive performance;
LGG	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.1	-0.31	4.83e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg15147215	chr3:52552868	STAB1	-0.39	-7.88	-0.34	2.34e-14	Cognitive function;
LGG	cis	rs858239	0.539	rs870476	chr7:23193271	C/T	cg23682824	chr7:23144976	KLHL7	0.41	6.88	0.3	1.91e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7582180	0.874	rs7601442	chr2:100897351	T/A	cg08297393	chr2:100937505	LONRF2	-0.56	-9.76	-0.41	1.42e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10864302	0.525	rs72642823	chr1:7427402	C/A	cg08923594	chr1:7462176	CAMTA1	0.68	8.21	0.36	2.29e-15	Photic sneeze reflex;
LGG	trans	rs800082	1.000	rs9289678	chr3:144307096	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.51	0.37	2.47e-16	Smoking behavior;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg05861140	chr6:150128134	PCMT1	-0.3	-6.81	-0.3	3.06e-11	Testicular germ cell tumor;
LGG	cis	rs9357271	1.000	rs7764502	chr6:38366137	T/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.81	-0.45	1.97e-24	Restless legs syndrome;
LGG	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.75	-0.3	4.43e-11	Schizophrenia;
LGG	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.69	-0.37	6.08e-17	Life satisfaction;
LGG	cis	rs1620921	0.594	rs67136969	chr6:161273433	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9790314	1.000	rs4273380	chr3:160950314	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs36093844	0.800	rs79349553	chr11:85567836	G/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.19	-0.32	2.57e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs1467026	0.719	rs17037220	chr3:12818103	A/G	cg05775895	chr3:12838266	CAND2	0.73	14.03	0.55	1.63e-37	P wave duration;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08677398	chr8:58056175	NA	0.48	8.01	0.35	9.41e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.744	rs13204787	chr6:109939486	A/G	cg16315928	chr6:109776240	MICAL1	0.49	7.68	0.34	9.3e-14	Height;
LGG	cis	rs4650994	1.000	rs10913568	chr1:178513411	C/T	cg12486710	chr1:178512616	C1orf220	0.42	8.57	0.37	1.58e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.87	-0.3	2.03e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17453880	0.571	rs2961759	chr5:151939650	A/G	cg12297329	chr5:152029980	NA	-0.58	-11.52	-0.47	3.47e-27	Subjective well-being;
LGG	cis	rs77106637	0.932	rs3814730	chr11:72555553	G/A	cg03713592	chr11:72463424	ARAP1	0.38	7.18	0.32	2.77e-12	Type 2 diabetes;
LGG	cis	rs6743376	0.556	rs1530548	chr2:113817402	G/A	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.17e-18	Inflammatory biomarkers;
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.45	0.58	1e-43	Platelet count;
LGG	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg14829155	chr15:31115871	NA	-0.67	-11.29	-0.46	2.74e-26	Huntington's disease progression;
LGG	cis	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg19338460	chr6:170058176	WDR27	-0.69	-9.38	-0.4	3.06e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs8073060	0.544	rs8072676	chr17:33999517	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg03528353	chr17:61819722	STRADA	0.43	7.33	0.32	1.03e-12	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	cis	rs6988985	0.728	rs4736311	chr8:143952700	A/G	cg10324643	chr8:143916377	GML	0.37	7.45	0.33	4.69e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7166081	1.000	rs8026870	chr15:67511389	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.0	-0.31	9.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs620875	0.660	rs522715	chr11:126862957	G/T	cg06504925	chr11:126872760	NA	-0.49	-7.08	-0.31	5.51e-12	Response to antipsychotic treatment;
LGG	trans	rs459571	1.000	rs459571	chr9:136912626	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.77	-0.48	3.83e-28	Platelet distribution width;
LGG	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg13010199	chr12:38710504	ALG10B	0.71	14.88	0.57	3.14e-41	Heart rate;
LGG	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg26384229	chr12:38710491	ALG10B	1.06	28.12	0.79	3.3e-102	Heart rate;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.37	6.7	0.3	6.2e-11	Longevity;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg06654118	chr4:1303317	MAEA	0.41	6.98	0.31	1.02e-11	Obesity-related traits;
LGG	cis	rs10823500	0.777	rs10999196	chr10:71982305	T/C	cg02100629	chr10:71892760	AIFM2	-0.29	-6.88	-0.3	1.96e-11	Blood protein levels;
LGG	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.79	11.72	0.48	5.79e-28	Schizophrenia;
LGG	cis	rs4819388	0.751	rs2838530	chr21:45638504	A/G	cg01992765	chr21:45622493	NA	0.48	9.07	0.39	3.28e-18	Celiac disease;
LGG	cis	rs7785730	0.625	rs6948651	chr7:28083007	C/T	cg17702455	chr7:28058989	JAZF1	-0.44	-7.92	-0.35	1.73e-14	Free thyroxine concentration;
LGG	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg11890956	chr21:40555474	PSMG1	1.21	30.85	0.82	2.18e-114	Cognitive function;
LGG	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg12432903	chr7:1882776	MAD1L1	0.54	8.19	0.36	2.5e-15	Bipolar disorder;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9487094	0.670	rs12197180	chr6:109821890	A/T	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs9796	0.621	rs9972349	chr15:41491656	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.91	-0.42	4.17e-21	Menopause (age at onset);
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.44	0.4	1.78e-19	Height;
LGG	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.76	-0.41	1.37e-20	Sudden cardiac arrest;
LGG	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg22044901	chr15:68126292	NA	-0.41	-7.12	-0.31	4.23e-12	Obesity;
LGG	cis	rs854765	0.587	rs4077828	chr17:17833644	A/T	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.21	-0.72	6.16e-75	Total body bone mineral density;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00761968	chr13:53314142	LECT1	0.34	7.24	0.32	1.92e-12	Lewy body disease;
LGG	trans	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg26384229	chr12:38710491	ALG10B	-0.95	-20.16	-0.68	2.51e-65	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.519	rs1544002	chr2:178529534	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-7.82	-0.34	3.5e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.8	0.34	4.19e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs2439831	0.867	rs2278860	chr15:43659046	C/T	cg15269541	chr15:43626905	ADAL	0.44	7.68	0.34	9.81e-14	Lung cancer in ever smokers;
LGG	cis	rs2084898	1.000	rs7116650	chr11:120041917	C/T	cg07435449	chr11:120005650	TRIM29	-0.66	-7.77	-0.34	5.07e-14	Stroke (pediatric);
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg11584989	chr19:19387371	SF4	0.4	7.13	0.31	3.9e-12	Tonsillectomy;
LGG	cis	rs7301016	0.948	rs11174537	chr12:62929827	G/C	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg14851468	chr5:179071604	C5orf60	0.39	6.64	0.3	8.57e-11	Lung cancer;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.13e-66	Alzheimer's disease;
LGG	cis	rs6867032	1.000	rs2129472	chr5:2016247	G/A	cg26168224	chr5:2018326	NA	1.29	31.13	0.82	1.41e-115	Gut microbiome composition (winter);
LGG	cis	rs7178909	0.872	rs17241560	chr15:90429202	T/A	cg19708238	chr15:90437601	AP3S2	0.4	6.67	0.3	7.25e-11	Common traits (Other);
LGG	cis	rs9790314	1.000	rs1382428	chr3:161032386	A/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.31	-0.47	2.41e-26	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.53	-0.37	2.06e-16	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00367659	chr17:33288544	CCT6B;ZNF830	0.44	7.55	0.33	2.27e-13	Bipolar disorder;
LGG	cis	rs67311347	0.869	rs7646899	chr3:40366982	A/G	cg13683864	chr3:40499215	RPL14	-0.96	-19.16	-0.67	1.09e-60	Renal cell carcinoma;
LGG	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg04568710	chr12:38710424	ALG10B	0.36	7.76	0.34	5.34e-14	Bladder cancer;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg12070911	chr6:150209640	RAET1E	0.28	6.88	0.3	1.99e-11	Lung cancer;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg05091796	chr16:4465799	CORO7	-0.78	-12.9	-0.51	9.4e-33	Schizophrenia;
LGG	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg08888203	chr3:10149979	C3orf24	0.35	6.68	0.3	6.82e-11	Alzheimer's disease;
LGG	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg22432760	chr17:80829718	TBCD	0.4	6.85	0.3	2.35e-11	Breast cancer;
LGG	cis	rs11264213	0.686	rs12041193	chr1:36412760	C/T	cg27506609	chr1:36549197	TEKT2	0.64	8.15	0.35	3.43e-15	Schizophrenia;
LGG	cis	rs11169552	0.510	rs11169532	chr12:51119935	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.43	-0.33	5.33e-13	Colorectal cancer;
LGG	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg14664628	chr15:75095509	CSK	-0.55	-10.8	-0.45	2.16e-24	Breast cancer;
LGG	cis	rs10540	0.541	rs7480899	chr11:438459	T/C	cg19913688	chr11:428466	ANO9	0.7	10.82	0.45	1.78e-24	Body mass index;
LGG	cis	rs7173743	0.756	rs8032771	chr15:79126059	A/G	cg00540400	chr15:79124168	NA	0.43	9.02	0.39	5.07e-18	Coronary artery disease;
LGG	cis	rs3741151	1.000	rs75004180	chr11:73024739	A/G	cg17517138	chr11:73019481	ARHGEF17	1.0	10.21	0.43	3.23e-22	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs701145	0.585	rs1713854	chr3:153848030	T/C	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs4262150	0.544	rs17548854	chr5:151901555	C/A	cg12297329	chr5:152029980	NA	-0.64	-11.64	-0.48	1.2e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7100689	0.622	rs4933378	chr10:82147057	T/C	cg01528321	chr10:82214614	TSPAN14	0.88	15.59	0.59	2.42e-44	Post bronchodilator FEV1;
LGG	cis	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.74	0.3	4.67e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6696846	1.000	rs6696846	chr1:205041952	C/T	cg00857998	chr1:205179979	DSTYK	0.52	8.23	0.36	1.88e-15	Red blood cell count;
LGG	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg03433033	chr1:76189801	ACADM	0.62	9.37	0.4	3.29e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9397585	0.857	rs9397125	chr6:153368447	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.67	0.56	2.8e-40	Body mass index;
LGG	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-13.42	-0.53	6.23e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.84e-21	Prudent dietary pattern;
LGG	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.96	0.31	1.16e-11	Parkinson's disease;
LGG	cis	rs9300255	0.770	rs12299125	chr12:123862447	C/T	cg00376283	chr12:123451042	ABCB9	-0.53	-7.96	-0.35	1.34e-14	Neutrophil percentage of white cells;
LGG	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	16.18	0.6	5.24e-47	Subjective well-being;
LGG	cis	rs7216064	1.000	rs6504549	chr17:65888784	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-9.26	-0.4	7.84e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2075371	1.000	rs1421485	chr7:133985181	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.45	0.58	1e-43	Mean platelet volume;
LGG	cis	rs80282103	0.618	rs17155886	chr10:1145182	A/G	cg08668510	chr10:1095578	IDI1	0.74	7.55	0.33	2.41e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg15068132	chr12:102092402	CHPT1	-0.36	-6.67	-0.3	7.19e-11	Blood protein levels;
LGG	cis	rs1467026	0.584	rs11712581	chr3:12807781	T/C	cg05775895	chr3:12838266	CAND2	0.72	13.21	0.52	4.9e-34	P wave duration;
LGG	cis	rs8072100	0.967	rs11871606	chr17:45732774	G/T	cg08085267	chr17:45401833	C17orf57	0.59	11.76	0.48	4.13e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg23306229	chr2:178417860	TTC30B	0.72	8.09	0.35	5.32e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.01	0.39	5.38e-18	Alzheimer's disease;
LGG	cis	rs9398803	0.865	rs2152876	chr6:126761228	A/G	cg19875578	chr6:126661172	C6orf173	-0.6	-10.96	-0.45	5.37e-25	Male-pattern baldness;
LGG	cis	rs6840360	0.642	rs7676493	chr4:152426765	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.41	0.33	6.07e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg12756686	chr19:29218302	NA	0.7	11.37	0.47	1.35e-26	Methadone dose in opioid dependence;
LGG	cis	rs12479064	0.526	rs7597045	chr2:99992572	C/G	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	cis	rs9815354	1.000	rs9311288	chr3:41804581	C/G	cg03022575	chr3:42003672	ULK4	0.6	7.71	0.34	7.71e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1372520	0.627	rs2583964	chr4:90727218	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.74e-15	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	3.07e-48	Diabetic retinopathy;
LGG	cis	rs6594499	0.872	rs7723819	chr5:110427347	A/G	cg04022379	chr5:110408740	TSLP	-0.38	-6.76	-0.3	4.13e-11	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs2898857	0.524	rs2119931	chr17:47429834	A/G	cg11430096	chr6:110968061	CDK19	-0.47	-8.16	-0.35	3.17e-15	Cancer;
LGG	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg23583168	chr7:148888333	NA	-0.84	-15.8	-0.59	2.86e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	cis	rs752010	0.756	rs6600380	chr1:42054814	C/T	cg06885757	chr1:42089581	HIVEP3	-0.53	-11.29	-0.46	2.76e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs77741769	0.571	rs7969140	chr12:121303626	T/C	cg02419362	chr12:121203948	SPPL3	0.52	9.07	0.39	3.47e-18	Mean corpuscular volume;
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	11.12	0.46	1.24e-25	Personality dimensions;
LGG	cis	rs4774899	1.000	rs12899036	chr15:57476452	C/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.35	-0.32	8.77e-13	Urinary tract infection frequency;
LGG	cis	rs10743315	0.557	rs74669613	chr12:19313696	T/C	cg02471346	chr12:19282374	PLEKHA5	0.86	8.42	0.36	4.68e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs921968	0.643	rs596076	chr2:219451015	T/G	cg01130898	chr2:219473002	PLCD4	-0.4	-6.95	-0.31	1.25e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg00339695	chr16:24857497	SLC5A11	0.39	6.69	0.3	6.27e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs67460515	0.500	rs9832109	chr3:160723364	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-8.03	-0.35	8.17e-15	Parkinson's disease;
LGG	trans	rs9354352	0.935	rs9354354	chr6:66699333	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.73	-13.53	-0.53	2.22e-35	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs9902453	0.845	rs58606097	chr17:28020379	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg20246863	chr2:73402720	NA	-0.27	-6.88	-0.3	1.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs10014845	chr4:120301077	T/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs3743102	0.591	rs12148608	chr15:83382102	A/G	cg00614314	chr15:82944287	LOC80154	0.75	7.8	0.34	4.28e-14	Colorectal adenoma (advanced);
LGG	cis	rs2229238	0.866	rs61403567	chr1:154504927	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.11e-11	Coronary heart disease;
LGG	cis	rs8095374	0.967	rs718515	chr18:43856297	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.38	-8.25	-0.36	1.7e-15	Clinical laboratory measurements;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg19168338	chr16:4465731	CORO7	-0.92	-17.82	-0.64	1.83e-54	Schizophrenia;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg18402987	chr7:1209562	NA	0.67	9.29	0.4	5.95e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg00938859	chr5:1591904	SDHAP3	0.82	8.77	0.38	3.54e-17	Breast cancer;
LGG	cis	rs796364	0.901	rs4673762	chr2:201065171	C/G	cg23649088	chr2:200775458	C2orf69	0.59	8.62	0.37	1.06e-16	Schizophrenia;
LGG	cis	rs12190007	0.846	rs6905725	chr6:169730253	G/C	cg16388071	chr6:169726476	NA	-0.4	-7.87	-0.34	2.59e-14	Obesity-related traits;
LGG	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg02187348	chr16:89574699	SPG7	0.57	9.39	0.4	2.76e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs7296418	0.961	rs1790121	chr12:123604492	G/A	cg00376283	chr12:123451042	ABCB9	0.66	12.18	0.49	8.65e-30	Platelet count;
LGG	trans	rs1973993	0.745	rs986427	chr1:96932736	A/G	cg10631902	chr5:14652156	NA	-0.51	-10.4	-0.44	6.82e-23	Weight;
LGG	cis	rs2075371	1.000	rs1421484	chr7:133979795	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg01879757	chr17:41196368	BRCA1	-0.42	-8.49	-0.37	2.93e-16	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg07837209	chr13:79184101	NA	-0.39	-7.05	-0.31	6.35e-12	Large artery stroke;
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg10952591	chr14:67827467	EIF2S1;ATP6V1D	-0.41	-7.12	-0.31	4.02e-12	Monocyte count;
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg19717773	chr7:2847554	GNA12	-0.34	-7.08	-0.31	5.25e-12	Height;
LGG	cis	rs59918340	0.764	rs4961256	chr8:142229946	G/A	cg03653399	chr8:142233436	SLC45A4	0.42	8.28	0.36	1.31e-15	Immature fraction of reticulocytes;
LGG	cis	rs12130219	1.000	rs12130219	chr1:152162106	A/G	cg25272121	chr1:152190972	HRNR	0.4	6.9	0.31	1.68e-11	Inflammatory skin disease;
LGG	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg11995313	chr8:8860691	ERI1	0.43	7.18	0.32	2.8e-12	Joint mobility (Beighton score);
LGG	cis	rs883565	0.792	rs784498	chr3:39180099	A/G	cg01426195	chr3:39028469	NA	0.6	10.6	0.44	1.16e-23	Handedness;
LGG	cis	rs875971	0.522	rs1917563	chr7:65415647	C/T	cg11987759	chr7:65425863	GUSB	0.41	7.87	0.34	2.5e-14	Aortic root size;
LGG	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.65	-0.3	8.34e-11	Self-reported allergy;
LGG	cis	rs4302748	0.909	rs35766501	chr7:36186069	G/A	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs9487051	0.676	rs9386775	chr6:109561779	T/C	cg21918786	chr6:109611834	NA	-0.37	-6.82	-0.3	2.94e-11	Reticulocyte fraction of red cells;
LGG	cis	rs7312933	0.618	rs7315968	chr12:42637086	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.66	0.34	1.08e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs11098499	0.604	rs17051352	chr4:120581427	G/A	cg09307838	chr4:120376055	NA	0.76	12.31	0.5	2.55e-30	Corneal astigmatism;
LGG	trans	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg10756647	chr7:56101905	PSPH	-0.8	-9.34	-0.4	4.14e-19	Diabetic kidney disease;
LGG	cis	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg06521331	chr12:34319734	NA	-0.66	-12.24	-0.49	4.76e-30	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg11266682	chr4:10021025	SLC2A9	0.48	9.5	0.4	1.09e-19	Bone mineral density;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.49	-8.8	-0.38	2.72e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg11245990	chr11:68621969	NA	0.39	8.46	0.37	3.59e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.92e-14	Bipolar disorder;
LGG	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg00376283	chr12:123451042	ABCB9	0.65	10.49	0.44	2.99e-23	Neutrophil percentage of white cells;
LGG	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg18876405	chr7:65276391	NA	0.55	9.86	0.42	5.93e-21	Aortic root size;
LGG	cis	rs62025270	0.688	rs7182210	chr15:86265782	A/C	cg25843651	chr15:86329602	KLHL25	0.58	9.01	0.39	5.38e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs9300255	0.739	rs4759415	chr12:123743674	C/T	cg00376283	chr12:123451042	ABCB9	-0.64	-10.26	-0.43	2.2e-22	Neutrophil percentage of white cells;
LGG	cis	rs7766436	0.885	rs12111199	chr6:22578106	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.89	-0.48	1.2e-28	Coronary artery disease;
LGG	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.17	0.35	2.95e-15	Colorectal cancer;
LGG	cis	rs72781680	0.821	rs17046004	chr2:24144873	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.67	0.37	7.33e-17	Lymphocyte counts;
LGG	cis	rs17428076	0.749	rs62182439	chr2:172799794	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.86	0.42	5.95e-21	Myopia;
LGG	cis	rs1953600	0.540	rs2784773	chr10:81919800	A/G	cg04850286	chr10:81895943	PLAC9	-0.4	-8.36	-0.36	7.63e-16	Sarcoidosis;
LGG	cis	rs3785574	0.743	rs2727334	chr17:61969063	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.52	8.25	0.36	1.66e-15	Height;
LGG	trans	rs6601327	0.641	rs9644704	chr8:9560169	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.8	-0.34	4.04e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg23978390	chr7:1156363	C7orf50	0.57	9.87	0.42	5.53e-21	Longevity;Endometriosis;
LGG	cis	rs7241530	0.585	rs34901621	chr18:75891116	C/T	cg14642773	chr18:75888474	NA	0.46	9.05	0.39	3.9e-18	Educational attainment (years of education);
LGG	cis	rs10046574	0.519	rs7799873	chr7:135214030	C/T	cg27474649	chr7:135195673	CNOT4	0.7	8.93	0.38	1.03e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg13010199	chr12:38710504	ALG10B	0.46	8.78	0.38	3.3e-17	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08448040	chr3:13521693	HDAC11	0.48	7.26	0.32	1.63e-12	Gut microbiome composition (summer);
LGG	cis	rs9878978	0.964	rs17194406	chr3:2488631	T/C	cg21928760	chr3:2462534	CNTN4	0.4	8.8	0.38	2.75e-17	Blood pressure (smoking interaction);
LGG	cis	rs9814567	0.752	rs6779326	chr3:134330027	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.6	-0.44	1.2e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07362569	chr17:61921086	SMARCD2	-0.48	-8.96	-0.38	7.86e-18	Prudent dietary pattern;
LGG	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg21775007	chr8:11205619	TDH	0.65	11.44	0.47	7.13e-27	Retinal vascular caliber;
LGG	cis	rs921968	0.643	rs552882	chr2:219401726	G/A	cg02985541	chr2:219472218	PLCD4	0.29	6.86	0.3	2.17e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs17401966	0.838	rs11121551	chr1:10435170	T/C	cg19773385	chr1:10388646	KIF1B	-0.46	-9.66	-0.41	3.08e-20	Hepatocellular carcinoma;
LGG	cis	rs755249	0.567	rs16825942	chr1:39662618	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.26	0.32	1.68e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg04553112	chr3:125709451	NA	-0.55	-7.0	-0.31	9.29e-12	Blood pressure (smoking interaction);
LGG	cis	rs28374715	0.662	rs28587487	chr15:41495460	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-17.98	-0.64	3.25e-55	Ulcerative colitis;
LGG	cis	rs3820068	0.603	rs932602	chr1:15986087	A/G	cg05660106	chr1:15850417	CASP9	0.81	16.2	0.6	4.3e-47	Systolic blood pressure;
LGG	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg23649088	chr2:200775458	C2orf69	-0.39	-6.73	-0.3	5.04e-11	QT interval;
LGG	cis	rs7523050	0.643	rs35662800	chr1:109400816	C/A	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs13418717	1.000	rs13418717	chr2:127662897	A/T	cg25501666	chr2:127640322	NA	-0.97	-8.15	-0.35	3.53e-15	Heart failure;
LGG	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg09818912	chr17:20140352	CYTSB	-0.33	-7.77	-0.34	4.99e-14	Schizophrenia;
LGG	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.67	0.51	8.6e-32	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12807537	chr10:80827367	ZMIZ1;LOC283050	0.48	7.67	0.34	1.02e-13	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03038816	chr19:49149549	SEC1;CA11	0.56	8.58	0.37	1.45e-16	Gut microbiome composition (summer);
LGG	cis	rs11792861	0.851	rs17552292	chr9:111891954	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.03	0.39	4.71e-18	Menarche (age at onset);
LGG	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg19997662	chr15:101784653	CHSY1	-0.84	-17.87	-0.64	1.05e-54	Corneal structure;
LGG	cis	rs2692947	0.770	rs58730124	chr2:96413338	T/C	cg22654517	chr2:96458247	NA	0.38	7.51	0.33	3.02e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7666738	0.819	rs13120307	chr4:99036100	A/C	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg26818257	chr2:241905806	NA	0.38	7.4	0.33	6.27e-13	Urinary metabolites;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg14580567	chr4:145567271	HHIP	0.39	6.92	0.31	1.53e-11	Body mass index;
LGG	cis	rs2070488	0.775	rs1132064	chr3:38566519	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.16	-0.55	4.33e-38	Electrocardiographic conduction measures;
LGG	cis	rs459571	0.959	rs378740	chr9:136890876	C/A	cg13789015	chr9:136890014	NCRNA00094	0.6	11.02	0.46	3.06e-25	Platelet distribution width;
LGG	cis	rs8012	0.517	rs9384	chr19:13010643	G/T	cg06417478	chr19:12876846	HOOK2	-0.4	-6.73	-0.3	4.98e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.58	0.41	5.86e-20	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs11768761	chr7:1069807	A/G	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.66	-0.34	1.07e-13	Longevity;Endometriosis;
LGG	cis	rs2742417	0.603	rs1019129	chr3:45780780	T/C	cg04837898	chr3:45731254	SACM1L	-0.46	-9.14	-0.39	1.97e-18	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24568646	chr21:30446238	CCT8	0.45	7.65	0.33	1.18e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg12395012	chr8:11607386	GATA4	0.42	7.3	0.32	1.27e-12	Neuroticism;
LGG	cis	rs2075371	0.932	rs1035328	chr7:133978419	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	14.47	0.56	2.08e-39	Mean platelet volume;
LGG	cis	rs9398803	0.830	rs1490387	chr6:126834083	C/A	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs921968	0.643	rs585859	chr2:219383121	C/T	cg01130898	chr2:219473002	PLCD4	-0.39	-6.76	-0.3	4.23e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg04727924	chr7:799746	HEATR2	-0.48	-7.65	-0.33	1.18e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg00814883	chr7:100076585	TSC22D4	-0.75	-9.88	-0.42	5.1e-21	Platelet count;
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18099408	chr3:52552593	STAB1	-0.33	-6.88	-0.3	1.96e-11	Cognitive function;
LGG	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg05639522	chr1:247681581	NA	-0.65	-10.85	-0.45	1.41e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2075466	0.588	rs111618721	chr16:4877866	A/T	cg04440724	chr16:4920505	UBN1	-0.64	-9.28	-0.4	6.46e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7524258	0.900	rs6577425	chr1:7306338	G/T	cg07173049	chr1:7289937	CAMTA1	0.71	16.68	0.61	2.88e-49	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs7539542	0.556	rs4950889	chr1:202874786	T/C	cg19681188	chr1:202830198	LOC148709	0.53	8.85	0.38	1.93e-17	Mean platelet volume;
LGG	cis	rs11648796	0.717	rs10682	chr16:767430	C/G	cg07343612	chr16:622815	PIGQ	-0.53	-8.74	-0.38	4.31e-17	Height;
LGG	cis	rs1355223	0.506	rs1509660	chr11:34865017	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.41	-0.36	5.08e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg08085267	chr17:45401833	C17orf57	-0.58	-11.66	-0.48	9.77e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-8.57	-0.37	1.53e-16	Alzheimer's disease (survival time);
LGG	trans	rs3857536	0.706	rs2157963	chr6:66945449	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg23009067	chr7:2775923	GNA12	-0.27	-6.84	-0.3	2.58e-11	Loneliness (linear analysis);
LGG	cis	rs2346177	0.967	rs4953374	chr2:46654401	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.4	6.88	0.3	1.93e-11	HDL cholesterol;
LGG	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.19	-0.32	2.56e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-7.99	-0.35	1.12e-14	Longevity;Endometriosis;
LGG	cis	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs2011503	0.941	rs55822665	chr19:19383298	C/T	cg11584989	chr19:19387371	SF4	0.76	12.77	0.51	3.47e-32	Bipolar disorder;
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg01988459	chr11:68622903	NA	0.43	9.05	0.39	4.06e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg02002194	chr4:3960332	NA	0.45	8.1	0.35	4.99e-15	Retinal vascular caliber;
LGG	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.6	-0.37	1.22e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13126279	chr21:47581558	C21orf56	0.53	9.48	0.4	1.37e-19	Testicular germ cell tumor;
LGG	cis	rs992157	0.717	rs11692780	chr2:219149163	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.25	-0.43	2.34e-22	Colorectal cancer;
LGG	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg07936489	chr17:37558343	FBXL20	-0.97	-15.04	-0.57	6.28e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.91	-0.31	1.56e-11	Neuroticism;
LGG	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg17691542	chr6:26056736	HIST1H1C	0.55	9.65	0.41	3.43e-20	Height;
LGG	cis	rs4731207	0.844	rs2267707	chr7:124397026	T/C	cg05630886	chr7:124431682	NA	0.31	6.84	0.3	2.48e-11	Cutaneous malignant melanoma;
LGG	cis	rs8141529	0.600	rs16986838	chr22:29312578	C/T	cg15103426	chr22:29168792	CCDC117	0.62	7.11	0.31	4.32e-12	Lymphocyte counts;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg02018176	chr4:1364513	KIAA1530	-0.42	-9.53	-0.41	8.63e-20	Obesity-related traits;
LGG	cis	rs988958	0.675	rs35297530	chr2:42224825	G/C	cg27428208	chr2:42229179	NA	0.54	9.29	0.4	6.13e-19	Hypospadias;
LGG	cis	rs1577917	0.538	rs6454483	chr6:86418283	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.62	11.17	0.46	8.39e-26	Response to antipsychotic treatment;
LGG	cis	rs9815354	0.812	rs113528686	chr3:41951547	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9397585	0.599	rs654845	chr6:153408920	T/C	cg17707550	chr6:153380415	RGS17	-0.45	-10.19	-0.43	3.92e-22	Body mass index;
LGG	cis	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg00409905	chr10:38381863	ZNF37A	0.66	13.71	0.54	3.64e-36	Extrinsic epigenetic age acceleration;
LGG	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07570687	chr10:102243282	WNT8B	0.42	6.93	0.31	1.41e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17453880	0.963	rs6868331	chr5:151950825	A/G	cg12297329	chr5:152029980	NA	-0.82	-19.2	-0.67	7.38e-61	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06343212	chr7:84815881	NA	0.41	6.77	0.3	3.95e-11	Cognitive performance;
LGG	cis	rs6815814	0.861	rs4543123	chr4:38792524	A/G	cg06935464	chr4:38784597	TLR10	0.56	8.96	0.38	8.15e-18	Breast cancer;
LGG	cis	rs7463659	0.845	rs35797542	chr8:135464721	T/C	cg17885191	chr8:135476712	NA	-0.39	-6.65	-0.3	8.32e-11	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg12395012	chr8:11607386	GATA4	0.42	7.44	0.33	5.1e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg00530320	chr1:46809349	NSUN4	0.46	8.48	0.37	3.01e-16	Menopause (age at onset);
LGG	cis	rs4642101	0.737	rs6767504	chr3:12826667	C/T	cg24848339	chr3:12840334	CAND2	0.41	9.35	0.4	3.84e-19	QRS complex (12-leadsum);
LGG	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg24375607	chr4:120327624	NA	0.66	10.47	0.44	3.68e-23	Corneal astigmatism;
LGG	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07080220	chr10:102295463	HIF1AN	0.58	9.86	0.42	6.22e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg26354017	chr1:205819088	PM20D1	0.99	27.95	0.79	1.97e-101	Menarche (age at onset);
LGG	cis	rs4750440	0.706	rs4748065	chr10:14019876	G/T	cg00551146	chr10:14014579	FRMD4A	0.29	6.96	0.31	1.2e-11	Adiponectin levels;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg11584989	chr19:19387371	SF4	-0.42	-7.67	-0.34	1.02e-13	Tonsillectomy;
LGG	cis	rs7566780	0.661	rs6531148	chr2:16650233	A/G	cg09580478	chr2:16689509	NA	0.46	6.73	0.3	4.97e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg05368731	chr17:41323189	NBR1	0.89	17.33	0.63	3.1e-52	Menopause (age at onset);
LGG	cis	rs12618769	0.625	rs113342082	chr2:99034198	G/A	cg18455616	chr2:99124870	INPP4A	0.3	8.75	0.38	4.14e-17	Bipolar disorder;
LGG	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.58	-0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.45	-6.82	-0.3	2.77e-11	Parkinson's disease;
LGG	cis	rs9815354	0.812	rs73069209	chr3:41939781	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.58	0.41	5.76e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs62400317	0.826	rs12205468	chr6:45310285	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.2800000000000002e-22	Total body bone mineral density;
LGG	cis	rs9611565	0.918	rs4822024	chr22:41757647	G/A	cg06634786	chr22:41940651	POLR3H	-0.72	-11.86	-0.48	1.68e-28	Vitiligo;
LGG	trans	rs17685	0.753	rs1639617	chr7:75701728	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.91	0.77	3.84e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25742201	chr17:35306863	AATF	-0.49	-7.22	-0.32	2.21e-12	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	6.95	0.31	1.22e-11	Schizophrenia;
LGG	cis	rs10979	1.000	rs1416205	chr6:143889397	T/C	cg25407410	chr6:143891975	LOC285740	-0.72	-12.47	-0.5	5.68e-31	Hypospadias;
LGG	cis	rs7010267	0.570	rs6469794	chr8:120016099	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.88	0.38	1.44e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs73191547	0.965	rs12548428	chr8:10030698	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.68	-0.34	9.4e-14	Schizophrenia;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.71	-13.24	-0.52	3.64e-34	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.0	0.31	8.93e-12	Prudent dietary pattern;
LGG	cis	rs17021463	0.966	rs7657789	chr4:95178589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.35	-0.47	1.6e-26	Testicular germ cell tumor;
LGG	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg23752985	chr2:85803571	VAMP8	0.45	8.74	0.38	4.17e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs42648	0.596	rs194511	chr7:89846727	A/G	cg25739043	chr7:89950458	NA	-0.34	-6.96	-0.31	1.17e-11	Homocysteine levels;
LGG	cis	rs710216	0.536	rs710222	chr1:43413653	A/G	cg12656391	chr1:43425156	SLC2A1	-0.35	-7.29	-0.32	1.37e-12	Red cell distribution width;
LGG	cis	rs990171	0.710	rs2310220	chr2:102951851	G/A	cg05295703	chr2:102895712	NA	-0.61	-11.22	-0.46	5.45e-26	Lymphocyte counts;
LGG	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg03453431	chr7:157225567	NA	-0.47	-8.2	-0.36	2.42e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs4363385	0.588	rs11586559	chr1:153025714	G/A	cg13444842	chr1:152974279	SPRR3	-0.49	-9.75	-0.41	1.5e-20	Inflammatory skin disease;
LGG	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.64e-21	Diabetic retinopathy;
LGG	trans	rs1728785	1.000	rs3203684	chr16:68600440	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-10.35	-0.43	9.99e-23	Ulcerative colitis;
LGG	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg08508325	chr11:3079039	CARS	0.41	7.87	0.34	2.6e-14	Calcium levels;
LGG	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg08885076	chr2:99613938	TSGA10	-0.57	-11.54	-0.47	2.98e-27	Chronic sinus infection;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg00495681	chr13:53174319	NA	0.57	10.65	0.44	7.49e-24	Lewy body disease;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs4774899	1.000	rs7170133	chr15:57283194	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.18	-0.36	2.77e-15	Urinary tract infection frequency;
LGG	cis	rs6835098	0.924	rs7672108	chr4:174165126	A/G	cg08422745	chr4:174089978	GALNT7	0.79	14.08	0.55	9.62e-38	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs11945232	0.790	rs6816224	chr4:88346510	G/A	cg23841344	chr4:88312519	HSD17B11	-0.45	-8.04	-0.35	7.72e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.44	0.4	1.9e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6430585	0.528	rs309133	chr2:136751842	A/C	cg07169764	chr2:136633963	MCM6	1.14	20.05	0.68	7.81e-65	Corneal structure;
LGG	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.57	-10.23	-0.43	2.83e-22	Educational attainment;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs209489	1.000	rs209520	chr6:53209842	T/C	cg15607103	chr6:53167650	ELOVL5	-0.54	-7.63	-0.33	1.37e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9487051	0.714	rs1546722	chr6:109625797	A/G	cg21918786	chr6:109611834	NA	-0.49	-9.05	-0.39	3.85e-18	Reticulocyte fraction of red cells;
LGG	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg13385794	chr1:248469461	NA	0.49	8.21	0.36	2.25e-15	Common traits (Other);
LGG	trans	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.44	-0.4	1.77e-19	Diabetic kidney disease;
LGG	cis	rs4891159	0.513	rs2554831	chr18:74113513	C/G	cg24786174	chr18:74118243	ZNF516	0.69	17.11	0.62	3.24e-51	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06231882	chr16:81040594	CENPN;C16orf61	0.55	8.36	0.36	7.65e-16	Gut microbiome composition (summer);
LGG	cis	rs8064299	0.597	rs2016126	chr17:72784932	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.55	0.72	1.55e-76	Monocyte count;
LGG	cis	rs17213078	0.510	rs17032713	chr2:106886839	T/C	cg15412446	chr2:106886593	NA	-0.42	-9.44	-0.4	1.81e-19	Facial morphology (factor 23);
LGG	cis	rs972578	0.967	rs9623737	chr22:43406680	G/T	cg01576275	chr22:43409880	NA	-0.24	-7.13	-0.31	3.95e-12	Mean platelet volume;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.45	-0.44	4.29e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg10760299	chr15:45669010	GATM	0.4	8.01	0.35	9.16e-15	Homoarginine levels;
LGG	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.57	-0.44	1.59e-23	Cannabis dependence symptom count;
LGG	cis	rs9547692	1.000	rs1328042	chr13:37466947	G/A	cg02985381	chr13:37494744	SMAD9	0.69	12.2	0.49	6.75e-30	Coronary artery disease;
LGG	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs55728055	0.661	rs1018488	chr22:31992376	A/G	cg01338084	chr22:32026380	PISD	1.4	11.69	0.48	7.91e-28	Age-related hearing impairment;
LGG	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg27476859	chr7:2772710	GNA12	0.51	9.66	0.41	3.17e-20	Height;
LGG	trans	rs6787172	0.702	rs827129	chr3:158013249	C/T	cg23275840	chr4:47708675	CORIN	-0.4	-8.53	-0.37	2.16e-16	Subjective well-being;
LGG	cis	rs300774	0.800	rs393008	chr2:125639	A/G	cg04617936	chr2:214353	NA	-0.49	-7.37	-0.32	7.97e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs9911578	0.835	rs9303398	chr17:56484257	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-13.64	-0.54	7.91e-36	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	0.711	rs2460426	chr7:65623129	A/G	cg12463550	chr7:65579703	CRCP	-0.79	-8.53	-0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1018697	1.000	rs10748830	chr10:104548382	A/C	cg04362960	chr10:104952993	NT5C2	0.49	9.03	0.39	4.76e-18	Colorectal adenoma (advanced);
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.815	rs3819325	chr3:49843723	T/C	cg21659725	chr3:3221576	CRBN	0.93	20.71	0.69	6.36e-68	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.36	0.32	8.64e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg00290607	chr11:67383545	NA	-0.64	-11.51	-0.47	4.09e-27	Mean corpuscular volume;
LGG	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg26655873	chr3:72818019	SHQ1	0.37	7.45	0.33	4.77e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7712401	0.601	rs397731	chr5:122322959	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs763121	0.853	rs6519120	chr22:38991393	A/C	cg06022373	chr22:39101656	GTPBP1	-0.86	-16.21	-0.6	3.76e-47	Menopause (age at onset);
LGG	cis	rs774359	0.797	rs774351	chr9:27516640	A/C	cg14173147	chr9:27528300	MOBKL2B	0.43	9.03	0.39	4.76e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs651907	0.557	rs1056579	chr3:101397877	T/G	cg12386194	chr3:101231763	SENP7	0.45	7.97	0.35	1.27e-14	Colorectal cancer;
LGG	cis	rs2354432	0.607	rs3820130	chr1:146724003	A/G	cg25205988	chr1:146714368	CHD1L	-1.41	-14.91	-0.57	2.33e-41	Mitochondrial DNA levels;
LGG	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.73	-0.45	3.81e-24	Morning vs. evening chronotype;
LGG	cis	rs7647973	0.516	rs4955418	chr3:49200627	A/G	cg07636037	chr3:49044803	WDR6	0.99	21.84	0.71	3.47e-73	Menarche (age at onset);
LGG	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg13647721	chr17:30228624	UTP6	0.62	8.06	0.35	6.45e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg24397884	chr7:158709396	WDR60	1.1	16.83	0.62	6.32e-50	Height;
LGG	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg03929089	chr4:120376271	NA	0.62	8.69	0.37	6.47e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs16944613	0.541	rs7494949	chr15:91090394	C/G	cg26821196	chr15:91095069	CRTC3	0.57	8.63	0.37	9.92e-17	Colorectal cancer;
LGG	cis	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg21775007	chr8:11205619	TDH	-0.82	-14.28	-0.55	1.38e-38	Retinal vascular caliber;
LGG	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg15890332	chr12:107067104	RFX4	0.31	8.36	0.36	7.48e-16	Total body bone mineral density;
LGG	cis	rs2486288	0.656	rs12440356	chr15:45567529	T/C	cg26924012	chr15:45694286	SPATA5L1	0.63	11.02	0.46	3.2e-25	Glomerular filtration rate;
LGG	cis	rs2133450	0.967	rs67921811	chr3:7342220	C/T	cg19930620	chr3:7340148	GRM7	-0.38	-8.56	-0.37	1.74e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg08677398	chr8:58056175	NA	0.5	7.91	0.34	1.97e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg26655873	chr3:72818019	SHQ1	0.38	7.71	0.34	7.69e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7474896	0.537	rs1208587	chr10:38207759	A/G	cg25427524	chr10:38739819	LOC399744	0.5	7.53	0.33	2.65e-13	Obesity (extreme);
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg00405596	chr8:11794950	NA	-0.43	-6.95	-0.31	1.25e-11	Neuroticism;
LGG	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg02811702	chr13:24901961	NA	0.41	7.37	0.32	8.04e-13	Obesity-related traits;
LGG	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg02023728	chr11:77925099	USP35	0.44	7.56	0.33	2.22e-13	Testicular germ cell tumor;
LGG	cis	rs922107	1.000	rs922107	chr1:90022796	A/G	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.58	-0.33	1.91e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.44	-0.44	4.74e-23	Aortic root size;
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.1	-0.31	4.6e-12	Bipolar disorder;
LGG	cis	rs12643440	0.511	rs10489115	chr4:17127327	C/G	cg22650099	chr4:17144496	NA	0.47	7.3	0.32	1.28e-12	Metabolite levels (Pyroglutamine);
LGG	trans	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.95	0.35	1.46e-14	Obesity-related traits;
LGG	trans	rs4925166	1	rs4925166	chr17:18210810	T/G	cg11797803	chr17:34750834	TBC1D3H;TBC1D3C	0.32	6.87	0.3	2.1e-11	Multiple sclerosis;
LGG	cis	rs73086581	1.000	rs73086540	chr20:3950850	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs523522	0.673	rs643372	chr12:121022640	C/G	cg12219531	chr12:120966889	COQ5	0.67	11.15	0.46	1.02e-25	High light scatter reticulocyte count;
LGG	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.26	-0.32	1.67e-12	IgG glycosylation;
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.05	0.39	4e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-7.85	-0.34	2.98e-14	Hemoglobin concentration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06083525	chr1:27216957	GPN2	0.42	6.74	0.3	4.76e-11	Cognitive performance;
LGG	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.92	0.42	3.68e-21	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.76e-12	Lung cancer;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.51	0.4	1.03e-19	Alzheimer's disease;
LGG	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg13010199	chr12:38710504	ALG10B	-0.73	-14.8	-0.57	7.05e-41	Bladder cancer;
LGG	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg17911788	chr17:44343683	NA	-0.45	-7.59	-0.33	1.73e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9513627	1.000	rs7338761	chr13:100119731	A/G	cg15490075	chr13:100150979	NA	-0.68	-7.07	-0.31	5.58e-12	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.26	-0.32	1.65e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	0.676	rs2222392	chr6:109602303	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.99	-0.35	1.05e-14	Reticulocyte fraction of red cells;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05165339	chr4:1420672	NA	-0.29	-7.78	-0.34	4.64e-14	Longevity;
LGG	cis	rs4891159	0.790	rs72975925	chr18:74143902	G/A	cg24786174	chr18:74118243	ZNF516	-0.56	-12.87	-0.51	1.33e-32	Longevity;
LGG	cis	rs4478858	0.735	rs6685728	chr1:31802550	T/C	cg19084893	chr1:31688959	NA	0.32	6.84	0.3	2.51e-11	Alcohol dependence;
LGG	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.68	0.48	8.36e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.52	-0.47	3.73e-27	Height;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs8179	0.514	rs2282978	chr7:92264410	A/G	cg15732164	chr7:92237376	CDK6	-0.47	-10.0	-0.42	1.85e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12496657	chr2:105488809	NA	0.45	7.46	0.33	4.43e-13	Cognitive performance;
LGG	cis	rs4780355	0.619	rs918737	chr16:11439639	T/C	cg00044050	chr16:11439710	C16orf75	-0.5	-8.08	-0.35	5.66e-15	Crohn's disease and psoriasis;
LGG	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg21095983	chr6:86352623	SYNCRIP	0.56	10.46	0.44	3.86e-23	Smooth-surface caries;
LGG	cis	rs11112613	0.775	rs10507194	chr12:105959488	G/A	cg03607813	chr12:105948248	NA	0.55	9.38	0.4	2.95e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs432925	0.625	rs1150188	chr16:355870	G/C	cg06233593	chr16:337645	AXIN1	0.42	7.5	0.33	3.31e-13	Morning vs. evening chronotype;
LGG	cis	rs17321999	0.516	rs7587320	chr2:30496783	C/T	cg05247661	chr2:30472410	LBH	0.61	7.53	0.33	2.62e-13	Systemic lupus erythematosus;
LGG	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg16070123	chr10:51489643	NA	0.4	7.43	0.33	5.28e-13	Prostate-specific antigen levels;
LGG	cis	rs9911578	1.000	rs3744108	chr17:56585872	G/C	cg12560992	chr17:57184187	TRIM37	-0.89	-15.74	-0.59	5.2e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12282928	1.000	rs12288484	chr11:48327476	G/T	cg20307385	chr11:47447363	PSMC3	0.44	7.04	0.31	6.96e-12	Migraine - clinic-based;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs7100689	0.646	rs7081889	chr10:82165427	C/A	cg01528321	chr10:82214614	TSPAN14	0.89	16.67	0.61	3.36e-49	Post bronchodilator FEV1;
LGG	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.39	-0.47	1.2e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs741702	0.928	rs1010222	chr19:13048608	A/G	cg06417478	chr19:12876846	HOOK2	0.42	6.97	0.31	1.07e-11	Red blood cell traits;
LGG	cis	rs7572733	0.555	rs13395030	chr2:198750806	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.2e-12	HDL cholesterol;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.21	0.32	2.35e-12	Prudent dietary pattern;
LGG	cis	rs4650994	0.816	rs2093770	chr1:178604633	C/A	cg12486710	chr1:178512616	C1orf220	-0.4	-7.94	-0.35	1.58e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs55788414	0.932	rs2317123	chr16:81182636	A/T	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	6.07e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg24623649	chr8:11872141	NA	-0.32	-7.74	-0.34	6.42e-14	Systolic blood pressure;
LGG	cis	rs10426930	0.752	rs56249413	chr19:5036730	G/A	cg18473234	chr19:5097819	KDM4B	0.45	7.69	0.34	9.22e-14	Monocyte percentage of white cells;
LGG	cis	rs4478858	0.602	rs4949370	chr1:31723889	G/C	cg07096763	chr1:31971752	NA	0.26	6.75	0.3	4.32e-11	Alcohol dependence;
LGG	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg03788504	chr6:150331562	NA	-0.59	-13.7	-0.54	4.02e-36	Alopecia areata;
LGG	cis	rs7829975	0.508	rs4841006	chr8:8501474	T/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.25	-0.32	1.76e-12	Mood instability;
LGG	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.63	-10.57	-0.44	1.54e-23	Renal function-related traits (BUN);
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-10.53	-0.44	2.26e-23	Prudent dietary pattern;
LGG	cis	rs787274	1.000	rs10124260	chr9:115559341	T/C	cg13803584	chr9:115635662	SNX30	-0.59	-7.48	-0.33	3.75e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4906332	0.811	rs2756138	chr14:103996733	C/G	cg23335576	chr14:104009727	NA	-0.47	-7.49	-0.33	3.52e-13	Coronary artery disease;
LGG	cis	rs9517313	0.584	rs9556974	chr13:99216302	G/C	cg07423050	chr13:99094983	FARP1	-0.58	-11.2	-0.46	6.51e-26	Neuroticism;
LGG	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg21132104	chr15:45694354	SPATA5L1	0.65	9.32	0.4	4.66e-19	Homoarginine levels;
LGG	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg08470875	chr2:26401718	FAM59B	-0.36	-6.75	-0.3	4.51e-11	Gut microbiome composition (summer);
LGG	cis	rs2617583	0.599	rs2975226	chr5:1445616	A/T	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.04	-0.31	7.14e-12	Breast cancer;
LGG	cis	rs1909881	0.605	rs3133797	chr8:96478453	A/T	cg04203453	chr8:96504381	NA	-0.62	-11.33	-0.47	1.9e-26	Obesity-related traits;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	8.54	0.37	1.91e-16	Schizophrenia;
LGG	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-9.5	-0.4	1.16e-19	Educational attainment;
LGG	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg12473912	chr3:136751656	NA	0.43	7.62	0.33	1.42e-13	Neuroticism;
LGG	cis	rs9462027	0.628	rs998278	chr6:34765584	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.27e-25	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg06916706	chr16:4465613	CORO7	0.89	17.03	0.62	7.4e-51	Schizophrenia;
LGG	cis	rs7084402	0.934	rs1593673	chr10:60294170	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs13406665	1	rs13406665	chr2:30498653	G/A	cg05247661	chr2:30472410	LBH	0.65	8.13	0.35	4.03e-15	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs12643440	0.538	rs16894418	chr4:17141112	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg26513180	chr16:89883248	FANCA	0.98	9.28	0.4	6.75e-19	Skin colour saturation;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08219700	chr8:58056026	NA	0.44	6.86	0.3	2.18e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs71583474	chr5:131661810	C/T	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	cis	rs6868223	1.000	rs57395688	chr5:33637324	G/T	cg10594543	chr5:33649717	ADAMTS12	0.57	12.69	0.51	7.28e-32	Mortality in heart failure;
LGG	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg13010199	chr12:38710504	ALG10B	0.56	10.81	0.45	2.01e-24	Bladder cancer;
LGG	cis	rs11229555	0.645	rs56228632	chr11:58187444	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.58	-10.12	-0.43	7.21e-22	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03662217	chr21:35747882	FAM165B	0.48	7.41	0.33	5.89e-13	Gut microbiome composition (summer);
LGG	cis	rs10845606	1.000	rs10845606	chr12:12834894	G/T	cg04607235	chr12:12878440	APOLD1	-0.53	-7.52	-0.33	2.85e-13	Systemic lupus erythematosus;
LGG	cis	rs807669	0.903	rs756651	chr22:19179367	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	16.12	0.6	1.01e-46	Metabolite levels;
LGG	cis	rs3820928	0.874	rs13419455	chr2:227850465	C/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.68	-0.34	9.85e-14	Pulmonary function;
LGG	cis	rs2470578	0.766	rs283908	chr3:17334741	T/C	cg20981856	chr3:17787350	NA	0.36	6.87	0.3	2.13e-11	Schizophrenia;
LGG	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg13683864	chr3:40499215	RPL14	1.16	28.84	0.8	1.92e-105	Renal cell carcinoma;
LGG	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.84	0.34	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.87	0.34	2.61e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9814567	0.964	rs9833753	chr3:134213665	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.3	-0.53	2.07e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02825527	chr7:2087843	MAD1L1	-0.37	-7.26	-0.32	1.64e-12	Neuroticism;
LGG	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7552404	0.765	rs211717	chr1:76106969	G/A	cg10523679	chr1:76189770	ACADM	-0.82	-14.55	-0.56	9.39e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs66887589	0.616	rs6822808	chr4:120217365	C/A	cg25214090	chr10:38739885	LOC399744	0.44	7.86	0.34	2.63e-14	Diastolic blood pressure;
LGG	cis	rs9400467	0.537	rs1150081	chr6:111479016	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.7	0.3	6.15e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs737693	1.000	rs17361668	chr11:102720344	A/T	cg19620758	chr11:102826565	MMP13	0.53	6.64	0.3	8.58e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg18200150	chr17:30822561	MYO1D	0.78	18.1	0.64	9.4e-56	Schizophrenia;
LGG	cis	rs2290159	0.706	rs6442319	chr3:12647029	G/A	cg23032965	chr3:12705835	RAF1	0.68	9.85	0.42	6.56e-21	Cholesterol, total;
LGG	cis	rs9368481	0.761	rs7775041	chr6:27009512	T/A	cg18867708	chr6:26865862	GUSBL1	-0.44	-7.27	-0.32	1.53e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg13271783	chr10:134563150	INPP5A	-0.59	-8.67	-0.37	7.24e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs988958	0.526	rs13424159	chr2:42239495	A/G	cg19376973	chr2:42229025	NA	0.63	9.43	0.4	1.97e-19	Hypospadias;
LGG	cis	rs2117029	0.586	rs10875928	chr12:49556303	A/G	cg24176009	chr12:49580217	TUBA1A	0.64	12.41	0.5	9.93e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.41	-0.36	5.18e-16	Total body bone mineral density;
LGG	cis	rs910187	0.678	rs6124965	chr20:45812957	T/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.07	-0.39	3.28e-18	Migraine;
LGG	cis	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg07777115	chr5:623756	CEP72	-0.56	-7.06	-0.31	6.22e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6496667	0.557	rs2601201	chr15:90958000	C/T	cg22089800	chr15:90895588	ZNF774	0.51	8.46	0.37	3.42e-16	Rheumatoid arthritis;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg11859384	chr17:80120422	CCDC57	0.44	7.8	0.34	4.01e-14	Life satisfaction;
LGG	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.16	0.43	4.92e-22	Colorectal cancer;
LGG	cis	rs10883723	0.810	rs7069356	chr10:104254359	G/C	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs61931739	0.583	rs1873010	chr12:33756375	T/C	cg26384229	chr12:38710491	ALG10B	0.47	8.38	0.36	6.63e-16	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.56	-0.33	2.21e-13	Personality dimensions;
LGG	cis	rs17767392	1.000	rs34528013	chr14:71767848	T/C	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs17092148	1.000	rs6060040	chr20:33359054	G/C	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.79	-0.34	4.39e-14	Neuroticism;
LGG	cis	rs36093844	0.752	rs75639684	chr11:85571576	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.16	-0.32	3.12e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7927592	0.546	rs497261	chr11:68192244	T/C	cg16797656	chr11:68205561	LRP5	0.55	10.27	0.43	1.91e-22	Total body bone mineral density;
LGG	cis	rs9296092	0.517	rs11752179	chr6:33534713	G/T	cg13560919	chr6:33536144	NA	-1.04	-21.43	-0.71	2.78e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs972578	0.668	rs4820487	chr22:43238055	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.8	-0.3	3.19e-11	Mean platelet volume;
LGG	cis	rs367943	0.666	rs7717422	chr5:112704089	A/G	cg12552261	chr5:112820674	MCC	0.57	10.27	0.43	1.94e-22	Type 2 diabetes;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.35	-0.36	7.71e-16	Skin colour saturation;
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg19635926	chr16:89946313	TCF25	0.67	7.95	0.35	1.46e-14	Skin colour saturation;
LGG	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.73	8.04	0.35	7.84e-15	Smoking behavior;
LGG	cis	rs10991814	0.925	rs10991808	chr9:93946379	C/T	cg14446406	chr9:93919335	NA	0.65	7.87	0.34	2.45e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs4771450	1.000	rs4771450	chr13:103969491	A/G	cg02987523	chr13:103978230	NA	0.32	6.88	0.3	1.97e-11	Uric acid levels;
LGG	cis	rs72717009	0.825	rs6671753	chr1:161478708	G/A	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg20608306	chr11:116969690	SIK3	0.42	13.39	0.53	8.42e-35	Blood protein levels;
LGG	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg20813462	chr7:2646259	IQCE	0.54	7.0	0.31	8.85e-12	Urate levels in lean individuals;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg12070911	chr6:150209640	RAET1E	0.3	7.42	0.33	5.65e-13	Lung cancer;
LGG	cis	rs17221829	0.521	rs76384137	chr11:89327266	T/A	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.19	-0.36	2.51e-15	Anxiety in major depressive disorder;
LGG	cis	rs55962025	0.711	rs116275868	chr4:3231148	G/C	cg06533319	chr4:3265114	C4orf44	0.35	6.82	0.3	2.77e-11	Parental longevity (mother's age at death);
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg19524238	chr7:2802976	GNA12	0.3	7.4	0.33	6.37e-13	Height;
LGG	trans	rs11098499	0.575	rs9996586	chr4:120326942	A/G	cg25214090	chr10:38739885	LOC399744	0.38	6.92	0.31	1.5e-11	Corneal astigmatism;
LGG	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs4481887	0.508	rs4347239	chr1:248401116	A/G	cg01631408	chr1:248437212	OR2T33	-0.42	-7.05	-0.31	6.63e-12	Common traits (Other);
LGG	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg16141378	chr3:129829833	LOC729375	-0.49	-12.33	-0.5	2.19e-30	Systolic blood pressure;
LGG	cis	rs910187	0.571	rs3746489	chr20:45801716	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-8.92	-0.38	1.05e-17	Migraine;
LGG	cis	rs2708977	0.698	rs772161	chr2:97043803	C/A	cg01950434	chr2:97203154	ARID5A	-0.5	-7.66	-0.34	1.09e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9359856	0.529	rs72919916	chr6:90489773	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.63	-0.41	4.12e-20	Bipolar disorder;
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg00149659	chr3:10157352	C3orf10	-0.74	-9.12	-0.39	2.29e-18	Alzheimer's disease;
LGG	cis	rs4948102	0.653	rs6593294	chr7:56063201	G/C	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-8.21	-0.36	2.2e-15	Cognitive test performance;
LGG	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg03433033	chr1:76189801	ACADM	-0.77	-12.15	-0.49	1.14e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg15212455	chr7:39170539	POU6F2	0.4	8.52	0.37	2.33e-16	IgG glycosylation;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs4481887	0.800	rs10788780	chr1:248483598	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs7241530	0.610	rs34094237	chr18:75891662	T/G	cg14642773	chr18:75888474	NA	0.47	9.08	0.39	3.22e-18	Educational attainment (years of education);
LGG	cis	rs8180040	0.701	rs13066214	chr3:47033937	C/T	cg27129171	chr3:47204927	SETD2	0.81	15.38	0.58	2.08e-43	Colorectal cancer;
LGG	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg18898632	chr2:242989856	NA	-0.7	-8.44	-0.37	4e-16	Obesity-related traits;
LGG	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg19913688	chr11:428466	ANO9	-0.68	-8.59	-0.37	1.33e-16	Body mass index;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.49	0.37	2.78e-16	Obesity-related traits;
LGG	cis	rs7412746	0.634	rs72704658	chr1:150833010	T/C	cg15448220	chr1:150897856	SETDB1	0.39	7.16	0.32	3.09e-12	Melanoma;
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.49	-0.53	3.32e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg26516362	chr5:178986906	RUFY1	-0.42	-7.67	-0.34	9.99e-14	Lung cancer;
LGG	cis	rs2235649	0.753	rs4316755	chr16:1849916	T/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.16e-11	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04064611	chr7:72298987	SBDSP;TYW1B	0.43	7.13	0.31	3.99e-12	Cognitive performance;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.52e-17	Prudent dietary pattern;
LGG	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg00409905	chr10:38381863	ZNF37A	0.67	13.65	0.54	6.67e-36	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg21479132	chr6:26055353	NA	0.85	8.37	0.36	6.94e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9784649	1.000	rs6864025	chr5:24960691	G/C	cg11038491	chr20:34638489	LOC647979	-0.53	-7.06	-0.31	6.17e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg08305652	chr11:111469057	NA	-0.36	-7.48	-0.33	3.77e-13	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.72e-18	Lung cancer;
LGG	cis	rs4950322	0.570	rs4950392	chr1:146736548	G/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs782590	0.837	rs782585	chr2:55922930	C/T	cg18811423	chr2:55921094	PNPT1	0.95	23.5	0.74	5.87e-81	Metabolic syndrome;
LGG	cis	rs4076764	1.000	rs12740984	chr1:163422151	A/G	cg24596788	chr1:163392923	NA	0.68	12.9	0.51	9.34e-33	Motion sickness;
LGG	cis	rs2712184	0.756	rs2024489	chr2:217661530	A/G	cg05032264	chr2:217675019	NA	-0.43	-9.27	-0.4	7.09e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs385076	0.502	rs13013695	chr2:32391231	G/A	cg02381751	chr2:32503542	YIPF4	-0.47	-6.76	-0.3	4.2e-11	Interleukin-18 levels;
LGG	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.38	6.82	0.3	2.78e-11	Educational attainment;
LGG	cis	rs1670533	0.818	rs6835141	chr4:1070140	G/T	cg27284194	chr4:1044797	NA	0.54	9.87	0.42	5.68e-21	Recombination rate (females);
LGG	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg01092361	chr6:42185687	MRPS10	0.91	12.12	0.49	1.48e-29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs11191205	0.686	rs11191088	chr10:103437266	C/G	cg15320455	chr10:103880129	LDB1	-0.54	-7.97	-0.35	1.24e-14	Intelligence (multi-trait analysis);
LGG	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.14	-0.43	6.08e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04800394	chr3:197677333	RPL35A;IQCG	0.42	6.93	0.31	1.46e-11	Cognitive performance;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg07870213	chr5:140052090	DND1	0.69	13.35	0.53	1.33e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg12193833	chr17:30244370	NA	-0.29	-6.73	-0.3	5.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg04287289	chr16:89883240	FANCA	0.73	7.72	0.34	7.21e-14	Skin colour saturation;
LGG	trans	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg16141378	chr3:129829833	LOC729375	0.38	8.32	0.36	1e-15	Neuroticism;
LGG	trans	rs9467711	0.651	rs34197618	chr6:26083519	T/C	cg08344181	chr3:125677491	NA	-0.79	-7.04	-0.31	7.17e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11718455	0.960	rs13065591	chr3:43996585	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.66	-0.3	7.71e-11	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg14092988	chr3:52407081	DNAH1	-0.29	-7.63	-0.33	1.37e-13	Bipolar disorder;
LGG	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg25319279	chr11:5960081	NA	-0.46	-7.74	-0.34	6.22e-14	DNA methylation (variation);
LGG	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.01	0.74	2.47e-83	Chronic sinus infection;
LGG	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg01221209	chr5:554886	NA	-0.48	-7.04	-0.31	6.94e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8135665	0.600	rs8139025	chr22:38450881	G/C	cg19171272	chr22:38449367	NA	-0.46	-8.42	-0.36	4.61e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs2718058	0.519	rs2722243	chr7:37873467	A/C	cg15028436	chr7:37888078	TXNDC3	0.8	14.37	0.56	5.3e-39	Alzheimer's disease (late onset);
LGG	cis	rs9916302	0.898	rs8072297	chr17:37478048	A/T	cg07936489	chr17:37558343	FBXL20	0.83	15.41	0.58	1.43e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	0.901	rs10899497	chr11:78124534	T/C	cg02023728	chr11:77925099	USP35	0.44	7.72	0.34	7.44e-14	Testicular germ cell tumor;
LGG	trans	rs3942852	0.806	rs4752808	chr11:48141252	G/A	cg03929089	chr4:120376271	NA	-0.65	-9.1	-0.39	2.69e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg13147721	chr7:65941812	NA	0.85	10.31	0.43	1.39e-22	Diabetic kidney disease;
LGG	cis	rs9400467	0.506	rs12198788	chr6:111686791	C/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21179092	chr12:124196769	ATP6V0A2	0.44	6.72	0.3	5.49e-11	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs3816183	1.000	rs3816179	chr2:43015401	T/C	cg14631114	chr2:43023945	NA	0.51	9.59	0.41	5.27e-20	Hypospadias;
LGG	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.94e-11	Aortic root size;
LGG	cis	rs7662987	0.517	rs2602878	chr4:100039953	T/G	cg13256891	chr4:100009986	ADH5	0.56	9.6	0.41	4.94e-20	Smoking initiation;
LGG	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	cg15522984	chr1:182991683	LAMC1	0.46	8.86	0.38	1.74e-17	Colorectal cancer;
LGG	cis	rs6743376	0.556	rs6733859	chr2:113819382	C/T	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.16e-18	Inflammatory biomarkers;
LGG	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg17689763	chr4:710664	PCGF3	-0.8	-16.63	-0.61	4.88e-49	White blood cell count;
LGG	trans	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.54	0.33	2.59e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	0.579	rs34370440	chr17:20003430	A/G	cg13482628	chr17:19912719	NA	0.53	9.88	0.42	5.28e-21	Obesity-related traits;
LGG	cis	rs4363385	0.667	rs11803197	chr1:152934420	G/A	cg07796016	chr1:152779584	LCE1C	-0.45	-7.21	-0.32	2.22e-12	Inflammatory skin disease;
LGG	cis	rs7085104	0.660	rs3781286	chr10:104595719	C/T	cg04362960	chr10:104952993	NT5C2	0.49	9.12	0.39	2.27e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00933542	chr6:150070202	PCMT1	0.38	7.07	0.31	5.68e-12	Lung cancer;
LGG	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs981844	1.000	rs2606335	chr4:154656536	T/C	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	8.26e-27	Response to statins (LDL cholesterol change);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04553410	chr7:150864885	GBX1	-0.46	-7.04	-0.31	7.07e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-10.43	-0.44	5.22e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg13073564	chr4:8508604	NA	-0.55	-10.99	-0.45	3.96e-25	Response to antineoplastic agents;
LGG	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.39	6.65	0.3	8.42e-11	Carotid intima media thickness;
LGG	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg05623727	chr3:50126028	RBM5	0.33	7.04	0.31	7.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4538187	0.853	rs2439183	chr2:64287632	C/T	cg14150252	chr2:64069583	UGP2	-0.49	-9.3	-0.4	5.53e-19	Systolic blood pressure;
LGG	cis	rs10779751	0.922	rs2746637	chr1:11275588	A/G	cg08854313	chr1:11322531	MTOR	0.74	16.64	0.61	4.67e-49	Body mass index;
LGG	cis	rs6676180	0.555	rs871665	chr1:119772663	C/T	cg05756136	chr1:119680316	WARS2	-0.4	-9.57	-0.41	6.25e-20	Monobrow;
LGG	cis	rs17384381	0.859	rs28529751	chr1:85910951	G/A	cg16011679	chr1:85725395	C1orf52	0.55	9.42	0.4	2.1e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2880765	0.835	rs11638498	chr15:86023018	T/C	cg10818794	chr15:86012489	AKAP13	-0.39	-8.28	-0.36	1.3e-15	Coronary artery disease;
LGG	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.07	-0.35	5.96e-15	Morning vs. evening chronotype;
LGG	cis	rs1971762	0.509	rs784567	chr12:53894465	C/T	cg06632207	chr12:54070931	ATP5G2	-0.23	-6.88	-0.3	1.92e-11	Height;
LGG	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg20587970	chr11:113659929	NA	-1.18	-20.76	-0.69	3.84e-68	Hip circumference adjusted for BMI;
LGG	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg21459583	chr1:227974177	NA	0.57	8.31	0.36	1.06e-15	Major depressive disorder;
LGG	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-10.25	-0.43	2.39e-22	Coronary artery disease;
LGG	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg09021430	chr5:549028	NA	-0.67	-9.01	-0.39	5.42e-18	Obesity-related traits;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg24250549	chr1:154909240	PMVK	0.74	15.16	0.58	1.98e-42	Prostate cancer;
LGG	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg05484508	chr16:89589025	SPG7	0.43	6.85	0.3	2.36e-11	Multiple myeloma (IgH translocation);
LGG	trans	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg26384229	chr12:38710491	ALG10B	0.63	12.52	0.5	3.68e-31	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs2084898	0.943	rs477337	chr11:120000885	T/C	cg07435449	chr11:120005650	TRIM29	0.68	8.34	0.36	8.65e-16	Stroke (pediatric);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14093289	chr19:33622866	WDR88	0.31	6.72	0.3	5.31e-11	Menarche (age at onset);
LGG	trans	rs61931739	0.686	rs708145	chr12:33731580	G/A	cg13010199	chr12:38710504	ALG10B	0.36	6.67	0.3	7.36e-11	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.62	0.63	1.43e-53	Cognitive function;
LGG	cis	rs1109114	0.844	rs3816159	chr5:148624898	G/A	cg06539116	chr5:148597365	ABLIM3	-0.46	-11.07	-0.46	2.06e-25	Body mass index;
LGG	cis	rs11583043	0.575	rs12759611	chr1:101587145	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	7.76	0.34	5.32e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.14	0.55	5.53e-38	Cognitive test performance;
LGG	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg21775007	chr8:11205619	TDH	0.47	7.7	0.34	8.26e-14	Mood instability;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg16507663	chr6:150244633	RAET1G	0.41	7.65	0.34	1.14e-13	Lung cancer;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs8014204	0.836	rs7153700	chr14:75268544	C/T	cg06637938	chr14:75390232	RPS6KL1	0.77	15.61	0.59	1.91e-44	Caffeine consumption;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg16606324	chr3:10149918	C3orf24	0.55	7.18	0.32	2.89e-12	Alzheimer's disease;
LGG	cis	rs1564271	0.506	rs1148163	chr10:26929671	G/C	cg13837822	chr10:26931731	LOC731789	0.39	6.66	0.3	7.84e-11	Overall survival in serous epithelial ovarian cancer treated with paclitaxel and cisplatin;
LGG	cis	rs1847202	1.000	rs6768747	chr3:72933319	A/G	cg25664220	chr3:72788482	NA	-0.25	-7.63	-0.33	1.37e-13	Motion sickness;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg06916706	chr16:4465613	CORO7	-0.71	-12.42	-0.5	8.87e-31	Schizophrenia;
LGG	trans	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg00953403	chr17:74099816	EXOC7	0.41	6.92	0.31	1.52e-11	Psychosis in Alzheimer's disease;
LGG	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg21095983	chr6:86352623	SYNCRIP	0.61	11.36	0.47	1.47e-26	Smooth-surface caries;
LGG	cis	rs7000551	0.715	rs7828610	chr8:22307326	C/T	cg12081754	chr8:22256438	SLC39A14	0.71	13.99	0.55	2.33e-37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.67	-0.37	7.58e-17	Alcohol dependence;
LGG	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6547631	0.622	rs10192752	chr2:85926142	T/G	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs9487094	0.778	rs13214717	chr6:109894354	C/A	cg01125227	chr6:109776195	MICAL1	0.51	8.54	0.37	2e-16	Height;
LGG	cis	rs2228479	1.000	rs62052186	chr16:89969567	A/T	cg06558623	chr16:89946397	TCF25	1.2	14.12	0.55	6.52e-38	Skin colour saturation;
LGG	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	11.96	0.49	6.35e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17208368	0.628	rs56318516	chr16:55095572	C/G	cg11181171	chr16:55090946	NA	0.46	7.63	0.33	1.37e-13	Hypospadias;
LGG	cis	rs8067545	0.512	rs4925071	chr17:19954499	T/C	cg13482628	chr17:19912719	NA	0.53	8.8	0.38	2.78e-17	Schizophrenia;
LGG	cis	rs2075371	1.000	rs2544210	chr7:133971535	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	15.42	0.58	1.42e-43	Mean platelet volume;
LGG	cis	rs2354432	0.607	rs7537483	chr1:146709877	C/G	cg25205988	chr1:146714368	CHD1L	1.42	13.71	0.54	3.83e-36	Mitochondrial DNA levels;
LGG	cis	rs2562456	0.876	rs11085468	chr19:21751889	C/T	cg00806126	chr19:22604979	ZNF98	-0.64	-9.72	-0.41	1.86e-20	Pain;
LGG	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg18876405	chr7:65276391	NA	0.68	13.14	0.52	9.68e-34	Aortic root size;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg26513180	chr16:89883248	FANCA	1.02	9.6	0.41	5.06e-20	Skin colour saturation;
LGG	cis	rs3816183	1.000	rs10204098	chr2:43017502	A/G	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19846264	chr17:4125408	ANKFY1	0.43	7.77	0.34	5.16e-14	Menarche (age at onset);
LGG	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.59	10.0	0.42	1.91e-21	Colorectal cancer;
LGG	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg18252515	chr7:66147081	NA	-0.74	-11.79	-0.48	3.11e-28	Corneal structure;
LGG	trans	rs66887589	0.592	rs2175383	chr4:120215836	C/A	cg25214090	chr10:38739885	LOC399744	0.45	8.05	0.35	6.86e-15	Diastolic blood pressure;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg00684032	chr4:1343700	KIAA1530	-0.49	-9.65	-0.41	3.4e-20	Obesity-related traits;
LGG	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.44	0.72	4.93e-76	Breast cancer;
LGG	cis	rs3008870	0.755	rs1535365	chr1:67497613	T/C	cg02640540	chr1:67518911	SLC35D1	0.36	6.94	0.31	1.33e-11	Lymphocyte percentage of white cells;
LGG	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.31	-0.32	1.19e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9487094	0.670	rs12528781	chr6:109929308	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.02	0.35	8.96e-15	Height;
LGG	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.52	-8.83	-0.38	2.17e-17	Cognitive test performance;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg16524936	chr4:1340807	KIAA1530	-0.49	-7.6	-0.33	1.61e-13	Obesity-related traits;
LGG	cis	rs17453880	0.929	rs12517065	chr5:152054583	A/T	cg10931792	chr5:152022470	NA	-0.4	-8.58	-0.37	1.44e-16	Subjective well-being;
LGG	cis	rs4538187	0.853	rs6546032	chr2:64075076	A/C	cg14150252	chr2:64069583	UGP2	0.51	9.51	0.4	1.04e-19	Systolic blood pressure;
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.65	-0.41	3.3e-20	Neuroticism;
LGG	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg26384229	chr12:38710491	ALG10B	0.92	20.35	0.69	3.19e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs738322	0.967	rs132985	chr22:38563471	C/T	cg03162506	chr22:38580953	NA	0.35	8.97	0.38	7.45e-18	Cutaneous nevi;
LGG	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.55	-0.33	2.36e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13132184	0.507	rs73241092	chr4:38094897	G/A	cg24826020	chr4:38070998	TBC1D1	0.49	8.16	0.35	3.23e-15	Verbal declarative memory;
LGG	cis	rs10791097	1.000	rs10791098	chr11:130718711	T/G	cg12179176	chr11:130786555	SNX19	0.75	14.29	0.55	1.24e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs72827839	0.846	rs74992250	chr17:46272986	G/C	cg02219949	chr17:45927392	SP6	0.54	8.12	0.35	4.34e-15	Ease of getting up in the morning;
LGG	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg18795169	chr1:18902165	NA	-1.06	-34.39	-0.85	1.39e-129	Urate levels in lean individuals;
LGG	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg16506815	chr2:162101123	NA	0.26	6.71	0.3	5.84e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg06925179	chr17:43578568	NA	0.32	8.27	0.36	1.41e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs526231	0.511	rs26255	chr5:102554100	T/A	cg23492399	chr5:102201601	PAM	-0.56	-8.21	-0.36	2.21e-15	Primary biliary cholangitis;
LGG	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.96	0.71	8.63e-74	Bladder cancer;
LGG	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	8.1	0.35	4.87e-15	Intelligence (multi-trait analysis);
LGG	trans	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg14791747	chr16:20752902	THUMPD1	-0.51	-9.05	-0.39	3.95e-18	Cognitive test performance;
LGG	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.47	-0.33	3.99e-13	Neuroticism;
LGG	trans	rs783540	0.934	rs10400906	chr15:83297138	A/G	cg18393722	chr15:85113863	UBE2QP1	0.4	6.71	0.3	5.65e-11	Schizophrenia;
LGG	cis	rs1355223	0.867	rs7944030	chr11:34691738	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.35	-0.32	9.13e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg01221209	chr5:554886	NA	-0.44	-6.67	-0.3	7.35e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05231509	chr11:108094111	ATM;NPAT	0.41	6.84	0.3	2.52e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg01585723	chr16:33734837	NA	0.45	7.84	0.34	3.09e-14	Menopause (age at onset);
LGG	cis	rs17209837	0.607	rs2072384	chr7:87082868	A/T	cg25823085	chr7:87105416	ABCB4	0.3	7.45	0.33	4.62e-13	Gallbladder cancer;
LGG	cis	rs11122272	0.735	rs2437148	chr1:231513979	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs6732160	0.596	rs7605923	chr2:73402333	T/C	cg01422370	chr2:73384389	NA	0.48	9.11	0.39	2.54e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.61	0.37	1.15e-16	Lung cancer;
LGG	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg25358565	chr5:93447407	FAM172A	1.39	17.13	0.62	2.67e-51	Diabetic retinopathy;
LGG	cis	rs17023223	0.537	rs12086549	chr1:119614337	A/T	cg05756136	chr1:119680316	WARS2	0.44	8.99	0.39	6.25e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs698833	0.962	rs698832	chr2:44734823	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	-0.44	-6.77	-0.3	4e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs17767392	1.000	rs17767523	chr14:71880739	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg24112000	chr20:60950667	NA	0.34	7.76	0.34	5.46e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs539514	0.690	rs480929	chr13:76312773	G/A	cg04757411	chr13:76259545	LMO7	-0.27	-6.9	-0.31	1.67e-11	Type 1 diabetes;
LGG	cis	rs10979	0.964	rs9321922	chr6:143895231	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg16507663	chr6:150244633	RAET1G	0.44	8.29	0.36	1.22e-15	Lung cancer;
LGG	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg15764593	chr10:829463	NA	-0.55	-9.0	-0.39	5.65e-18	Uric acid levels;
LGG	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg04525384	chr16:1557733	TELO2	0.45	7.2	0.32	2.45e-12	Coronary artery disease;
LGG	trans	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg02002194	chr4:3960332	NA	0.49	9.16	0.39	1.62e-18	Mood instability;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg23782820	chr8:58130467	NA	0.53	7.39	0.32	7.02e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11585357	0.843	rs72646796	chr1:17612503	T/C	cg08277548	chr1:17600880	PADI3	-0.75	-8.35	-0.36	8.11e-16	Hair shape;
LGG	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg17509989	chr5:176798049	RGS14	-0.85	-14.63	-0.56	4.17e-40	Hemoglobin concentration;Hematocrit;
LGG	cis	rs16944613	0.588	rs6496697	chr15:91131832	C/T	cg26821196	chr15:91095069	CRTC3	-0.51	-8.02	-0.35	8.84e-15	Colorectal cancer;
LGG	trans	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg06606381	chr12:133084897	FBRSL1	-1.04	-8.37	-0.36	6.78e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg16325326	chr1:53192061	ZYG11B	-0.9	-25.83	-0.77	9.4e-92	Monocyte count;
LGG	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.67	12.9	0.51	9.22e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg03959625	chr15:84868606	LOC388152	0.49	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs11235843	0.636	rs6592531	chr11:73412354	C/T	cg18195628	chr11:73498948	MRPL48	-0.51	-7.12	-0.31	4.14e-12	Hand grip strength;
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg00187635	chr16:83986795	OSGIN1	0.55	10.08	0.42	9.86e-22	Pursuit maintenance gain;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg15971980	chr6:150254442	NA	0.45	8.48	0.37	3.11e-16	Lung cancer;
LGG	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.29	-0.36	1.21e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs8052073	chr16:48682696	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7444	0.941	rs181363	chr22:21932264	A/G	cg22858872	chr22:21984481	YDJC	-0.35	-6.8	-0.3	3.27e-11	Systemic lupus erythematosus;
LGG	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs3816183	1.000	rs920392	chr2:43019364	G/C	cg14631114	chr2:43023945	NA	0.49	9.21	0.39	1.15e-18	Hypospadias;
LGG	cis	rs2421770	0.532	rs7115450	chr11:35344345	A/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.4	-0.33	6.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs9944715	0.906	rs7505861	chr18:43745406	A/G	cg26436583	chr18:43649176	PSTPIP2	0.41	7.84	0.34	3.12e-14	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg08461772	chr7:95026248	PON3	0.36	7.62	0.33	1.46e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg22643751	chr7:855365	UNC84A	-0.48	-11.29	-0.46	2.91e-26	Perceived unattractiveness to mosquitoes;
LGG	trans	rs9354308	0.764	rs9354322	chr6:66586195	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs6088580	0.634	rs4911420	chr20:32998654	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.32	-0.36	9.76e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.4	-0.4	2.49e-19	Lung cancer;
LGG	cis	rs2688608	0.839	rs2633310	chr10:75594050	G/T	cg23231163	chr10:75533350	FUT11	0.42	7.0	0.31	9e-12	Inflammatory bowel disease;
LGG	cis	rs2643217	0.953	rs1495186	chr15:38991456	C/T	cg10631289	chr15:39006617	NA	-0.44	-7.58	-0.33	1.89e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg27286337	chr10:134555280	INPP5A	0.87	14.1	0.55	8e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17221829	0.733	rs10830337	chr11:89407049	C/T	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.54	-0.37	1.91e-16	Anxiety in major depressive disorder;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg23829577	chr6:160183769	ACAT2	0.45	6.65	0.3	8.05e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs7110818	0.510	rs1892953	chr11:76272542	C/T	cg17647271	chr11:76299819	NA	-0.39	-6.88	-0.3	1.97e-11	Gut microbiota (functional units);
LGG	cis	rs6784615	0.744	rs164637	chr3:52265215	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.72	7.7	0.34	8.05e-14	Waist-hip ratio;
LGG	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg24253500	chr15:84953950	NA	0.6	10.94	0.45	5.97e-25	Schizophrenia;
LGG	cis	rs66573146	0.561	rs67245546	chr4:6947164	T/C	cg26116260	chr4:7069785	GRPEL1	-0.97	-8.73	-0.38	4.79e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2916247	1.000	rs10100101	chr8:93041761	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.39	-0.36	6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg10760299	chr15:45669010	GATM	0.41	8.07	0.35	6.23e-15	Homoarginine levels;
LGG	cis	rs11585357	0.709	rs735281	chr1:17616194	T/C	cg08277548	chr1:17600880	PADI3	0.62	7.49	0.33	3.46e-13	Hair shape;
LGG	cis	rs244731	1.000	rs244731	chr5:176539679	C/T	cg17509989	chr5:176798049	RGS14	0.55	7.58	0.33	1.93e-13	Urate levels in lean individuals;
LGG	cis	rs1371867	0.846	rs1788182	chr8:101334620	C/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg24209194	chr3:40518798	ZNF619	0.47	7.37	0.32	8.1e-13	Renal cell carcinoma;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.56	0.41	6.94e-20	Bipolar disorder;
LGG	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.72	0.34	7.4e-14	Glycated hemoglobin levels;
LGG	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg14673194	chr17:80132900	CCDC57	0.46	8.28	0.36	1.38e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs77372450	0.636	rs73305048	chr5:157017847	A/G	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.54	-0.37	1.94e-16	Triglycerides;
LGG	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7727544	0.545	rs3916443	chr5:131369079	T/C	cg07395648	chr5:131743802	NA	-0.35	-6.83	-0.3	2.63e-11	Blood metabolite levels;
LGG	cis	rs17376456	0.877	rs10476597	chr5:93367172	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.93	-10.18	-0.43	4.23e-22	Diabetic retinopathy;
LGG	cis	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg22852734	chr6:133119734	C6orf192	1.18	15.06	0.57	5.13e-42	Type 2 diabetes nephropathy;
LGG	cis	rs896854	0.654	rs28716845	chr8:95974485	A/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.84	-0.3	2.56e-11	Neuroticism;
LGG	cis	rs2153535	0.525	rs1335644	chr6:8488041	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-9.18	-0.39	1.44e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.609	rs812657	chr3:99566329	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.85	-0.38	1.85e-17	Axial length;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg15309223	chr1:54519091	TMEM59;C1orf83	0.4	7.21	0.32	2.32e-12	Obesity-related traits;
LGG	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg13073564	chr4:8508604	NA	-0.51	-10.36	-0.43	9.59e-23	Response to antineoplastic agents;
LGG	cis	rs858239	0.539	rs2141305	chr7:23191899	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.88	0.3	1.98e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.07	-0.42	1.06e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	11.44	0.47	7.39e-27	Coronary artery disease;
LGG	cis	rs12980942	0.810	rs3745295	chr19:41785282	T/G	cg25627403	chr19:41769009	HNRNPUL1	0.5	6.76	0.3	4.17e-11	Coronary artery disease;
LGG	cis	rs79349575	0.783	rs832410	chr17:46972865	C/T	cg16584676	chr17:46985605	UBE2Z	0.47	8.12	0.35	4.24e-15	Type 2 diabetes;
LGG	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg18245976	chr7:158708271	WDR60	-0.55	-9.7	-0.41	2.29e-20	Height;
LGG	cis	rs7726354	0.793	rs60588964	chr5:56006008	A/C	cg27303933	chr5:56029418	NA	0.48	6.77	0.3	3.83e-11	Breast cancer (early onset);
LGG	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7146395	1	rs7146395	chr14:75228647	A/C	cg06637938	chr14:75390232	RPS6KL1	0.5	8.07	0.35	5.95e-15	Platelet count;
LGG	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg27446573	chr6:127587934	RNF146	1.12	21.81	0.71	4.69e-73	Breast cancer;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg01673284	chr16:4527211	HMOX2	-0.32	-6.66	-0.3	7.95e-11	Schizophrenia;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg22907277	chr7:1156413	C7orf50	0.83	14.13	0.55	5.79e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1707322	0.685	rs11211177	chr1:46226349	A/G	cg03146154	chr1:46216737	IPP	0.62	10.48	0.44	3.23e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs9362426	0.608	rs9444494	chr6:88119001	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.45	-8.43	-0.36	4.26e-16	Depressive episodes in bipolar disorder;
LGG	cis	rs571497	0.697	rs62128260	chr19:7833876	T/A	cg00371453	chr19:7854482	CLEC4GP1	0.77	8.43	0.36	4.48e-16	Monocyte count;
LGG	cis	rs9354308	0.809	rs9363461	chr6:66557574	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.22	-0.36	2.06e-15	Metabolite levels;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02475777	chr4:1388615	CRIPAK	0.58	10.5	0.44	2.7e-23	Longevity;
LGG	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg19748678	chr4:122722346	EXOSC9	0.67	13.4	0.53	7.56e-35	Type 2 diabetes;
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg00830817	chr11:109293614	C11orf87	0.47	7.41	0.33	5.98e-13	Schizophrenia;
LGG	cis	rs2742417	0.603	rs13059502	chr3:45781380	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs561341	0.883	rs7219239	chr17:30212016	A/G	cg12193833	chr17:30244370	NA	0.28	6.99	0.31	9.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.73	0.41	1.82e-20	Tonsillectomy;
LGG	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg22676075	chr6:135203613	NA	0.44	7.57	0.33	2e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7236492	0.515	rs8086051	chr18:77173158	C/T	cg05753993	chr18:77199432	NFATC1	0.41	6.76	0.3	4.07e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-7.66	-0.34	1.07e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7589342	0.628	rs35622044	chr2:106404095	G/A	cg16077055	chr2:106428750	NCK2	0.3	7.24	0.32	1.89e-12	Addiction;
LGG	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7147624	1.000	rs7153497	chr14:65998415	A/G	cg03016385	chr14:66212404	NA	-0.79	-9.37	-0.4	3.1400000000000002e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg25726756	chr21:47582351	C21orf56	-0.31	-6.65	-0.3	8.04e-11	Testicular germ cell tumor;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg11014794	chr10:93999688	CPEB3	0.41	6.7	0.3	5.96e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg19673125	chr6:150240577	RAET1G	0.36	8.88	0.38	1.45e-17	Testicular germ cell tumor;
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg09263875	chr16:632152	PIGQ	0.64	12.63	0.51	1.21e-31	Height;
LGG	cis	rs10771431	1.000	rs10771431	chr12:9380859	C/T	cg22349387	chr12:9600060	DDX12	-0.28	-6.81	-0.3	3.12e-11	Breast size;
LGG	cis	rs2832191	0.647	rs11170	chr21:30378090	C/T	cg08807101	chr21:30365312	RNF160	0.9	18.25	0.65	1.78e-56	Dental caries;
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs2276314	0.857	rs28791905	chr18:33602213	G/A	cg05985134	chr18:33552581	C18orf21	0.63	9.72	0.41	1.88e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs28530618	0.603	rs13043743	chr20:31257083	C/T	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.7	-0.3	6.23e-11	Birth weight;
LGG	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg10596483	chr8:143751796	JRK	0.58	9.62	0.41	4.15e-20	Schizophrenia;
LGG	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg18188782	chr20:61659543	NA	0.41	6.88	0.3	1.9e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg03351412	chr1:154909251	PMVK	0.59	10.42	0.44	5.71e-23	Prostate cancer;
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg20102877	chr2:27665638	KRTCAP3	-0.29	-6.73	-0.3	5.09e-11	Total body bone mineral density;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg26354017	chr1:205819088	PM20D1	0.52	8.67	0.37	7.39e-17	Prostate-specific antigen levels;
LGG	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.04	-0.7	1.84e-69	Gut microbiome composition (summer);
LGG	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg19812747	chr11:111475976	SIK2	-0.45	-9.06	-0.39	3.58e-18	Primary sclerosing cholangitis;
LGG	cis	rs368123	1.000	rs399367	chr6:160719030	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.96	-0.42	2.58e-21	Schizophrenia;
LGG	cis	rs11096990	0.634	rs10010352	chr4:39242277	A/G	cg24403649	chr4:39172243	NA	0.39	6.86	0.3	2.28e-11	Cognitive function;
LGG	cis	rs12477438	0.501	rs11692336	chr2:99740606	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs10791323	0.592	rs2851115	chr11:133705381	C/A	cg15485101	chr11:133734466	NA	0.59	10.4	0.44	6.6e-23	Childhood ear infection;
LGG	cis	rs950169	0.541	rs10795	chr15:85177297	G/A	cg24253500	chr15:84953950	NA	0.41	6.96	0.31	1.18e-11	Schizophrenia;
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg02503808	chr4:7069936	GRPEL1	0.89	14.03	0.55	1.56e-37	Monocyte percentage of white cells;
LGG	cis	rs72781680	0.898	rs72788214	chr2:24087621	A/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.09	0.39	2.8e-18	Lymphocyte counts;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg25072359	chr17:41440525	NA	0.46	7.53	0.33	2.74e-13	Menopause (age at onset);
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13732083	chr21:47605072	C21orf56	0.51	8.8	0.38	2.64e-17	Testicular germ cell tumor;
LGG	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	7.85e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg17340268	chr14:105411764	AHNAK2	-0.39	-7.34	-0.32	9.79e-13	Rheumatoid arthritis;
LGG	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg02811702	chr13:24901961	NA	0.4	7.45	0.33	4.54e-13	Obesity-related traits;
LGG	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg14191688	chr11:70257035	CTTN	0.52	7.59	0.33	1.73e-13	Coronary artery disease;
LGG	cis	rs477692	0.612	rs58103386	chr10:131319958	C/A	cg05714579	chr10:131428358	MGMT	0.45	8.51	0.37	2.4e-16	Response to temozolomide;
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg11984989	chr7:158649758	WDR60	0.94	19.63	0.67	7.49e-63	Height;
LGG	cis	rs7246865	0.906	rs2278997	chr19:17166981	G/A	cg19418318	chr19:17219073	MYO9B	0.29	7.66	0.34	1.12e-13	Reticulocyte fraction of red cells;
LGG	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg17294928	chr15:75287854	SCAMP5	0.67	11.97	0.49	6.19e-29	Caffeine consumption;
LGG	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg12773197	chr13:112238673	NA	-0.35	-7.18	-0.32	2.71e-12	Hepatitis;
LGG	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg25706552	chr1:244017396	NA	0.55	6.68	0.3	6.87e-11	RR interval (heart rate);
LGG	cis	rs1971762	0.509	rs10783592	chr12:54037430	G/A	cg06632207	chr12:54070931	ATP5G2	0.23	7.26	0.32	1.65e-12	Height;
LGG	cis	rs11676348	0.774	rs11683524	chr2:218984604	G/A	cg04731861	chr2:219085781	ARPC2	0.29	6.98	0.31	9.96e-12	Ulcerative colitis;
LGG	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg10935138	chr17:73851978	WBP2	0.51	7.34	0.32	9.58e-13	Psoriasis;
LGG	cis	rs9649465	0.967	rs12706546	chr7:123353414	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-9.04	-0.39	4.42e-18	Migraine;
LGG	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg02975922	chr3:195473998	MUC4	-0.45	-7.27	-0.32	1.51e-12	Mean corpuscular volume;
LGG	cis	rs4974559	0.739	rs35571200	chr4:1268129	G/A	cg02980000	chr4:1222292	CTBP1	-0.83	-10.06	-0.42	1.12e-21	Systolic blood pressure;
LGG	cis	rs7975161	0.608	rs10861169	chr12:104610640	C/T	cg25273343	chr12:104657179	TXNRD1	-0.58	-9.49	-0.4	1.2e-19	Toenail selenium levels;
LGG	cis	rs2370759	0.891	rs77706860	chr10:32628537	C/T	cg01819863	chr10:32635814	EPC1	1.07	12.89	0.51	1.04e-32	Sexual dysfunction (female);
LGG	cis	rs4702718	0.651	rs2930048	chr5:10698569	C/G	cg14521931	chr5:10832172	NA	0.44	8.41	0.36	5.04e-16	Obesity-related traits;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg15383120	chr6:291909	DUSP22	-0.53	-8.74	-0.38	4.38e-17	Menopause (age at onset);
LGG	cis	rs2346177	0.519	rs4563285	chr2:46669944	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-11.86	-0.48	1.63e-28	HDL cholesterol;
LGG	cis	rs4566357	0.595	rs2272203	chr2:227914655	C/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.03	-0.39	4.53e-18	Coronary artery disease;
LGG	cis	rs721399	1.000	rs1390360	chr8:18261493	G/A	cg18736775	chr8:18248649	NAT2	0.53	9.26	0.4	7.9e-19	Blood metabolite levels;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.22	-0.49	5.84e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs4242434	0.819	rs2291230	chr8:22463697	C/G	cg02227867	chr8:22457446	C8orf58	-0.41	-7.95	-0.35	1.42e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs929596	0.785	rs17862875	chr2:234649302	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-13.42	-0.53	6.14e-35	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs9859260	1.000	rs9990392	chr3:195798522	C/T	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.98	-0.31	1.02e-11	Mean corpuscular volume;
LGG	cis	rs8133932	0.668	rs3788226	chr21:47300115	A/G	cg11214348	chr21:47283868	PCBP3	-0.44	-7.62	-0.33	1.48e-13	Schizophrenia;
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs2737618	0.674	rs2737683	chr1:200092448	G/A	cg21825944	chr1:200113062	NR5A2	-0.61	-11.68	-0.48	8.52e-28	Uric acid levels;
LGG	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg02931644	chr1:25747376	RHCE	0.44	9.65	0.41	3.24e-20	Erythrocyte sedimentation rate;
LGG	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs76693355	0.541	rs2276035	chr11:120346360	G/A	cg15690696	chr11:120217718	ARHGEF12	-0.44	-6.9	-0.31	1.73e-11	Intraocular pressure;
LGG	cis	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.31	-0.47	2.32e-26	Resting heart rate;
LGG	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg16586182	chr3:47516702	SCAP	0.77	15.23	0.58	9.26e-43	Colorectal cancer;
LGG	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg20040747	chr15:74715105	SEMA7A	0.4	8.66	0.37	8.13e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg11235426	chr6:292522	DUSP22	-0.59	-9.92	-0.42	3.74e-21	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26625369	chr10:12237905	NUDT5;CDC123	0.44	6.81	0.3	2.98e-11	Gut microbiome composition (summer);
LGG	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs503734	0.666	rs4683900	chr3:101134696	C/T	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.18e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg11764359	chr7:65958608	NA	0.79	14.76	0.57	1.07e-40	Aortic root size;
LGG	cis	rs1008375	0.932	rs9291660	chr4:17663414	A/G	cg02297831	chr4:17616191	MED28	0.47	8.38	0.36	6.48e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg00188032	chr5:96141721	ERAP1	0.55	7.38	0.32	7.47e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2153535	0.580	rs1414344	chr6:8471365	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs7241530	0.662	rs55841218	chr18:75902133	G/A	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.12	0.31	4.24e-12	Lung cancer;
LGG	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg26384229	chr12:38710491	ALG10B	0.92	20.75	0.69	4.12e-68	Bladder cancer;
LGG	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg17644776	chr2:200775616	C2orf69	-0.59	-7.48	-0.33	3.75e-13	Schizophrenia;
LGG	cis	rs10540	1.000	rs61876333	chr11:487136	G/A	cg03352830	chr11:487213	PTDSS2	0.85	10.24	0.43	2.64e-22	Body mass index;
LGG	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg12091567	chr17:66097778	LOC651250	0.78	12.93	0.51	7.42e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4148883	0.689	rs2851275	chr4:100024883	A/G	cg13256891	chr4:100009986	ADH5	0.4	7.14	0.32	3.56e-12	Alcohol dependence;
LGG	cis	rs4689388	0.856	rs1046314	chr4:6303955	A/G	cg14416269	chr4:6271139	WFS1	-0.46	-8.59	-0.37	1.31e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7106204	0.800	rs7120940	chr11:24236485	C/A	ch.11.24196551F	chr11:24239977	NA	1.0	16.16	0.6	6.54e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs738322	0.870	rs5750558	chr22:38582497	G/A	cg03162506	chr22:38580953	NA	-0.38	-9.65	-0.41	3.43e-20	Cutaneous nevi;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-12.94	-0.52	6.51e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs13260300	0.572	rs8181010	chr8:75489782	G/A	cg22993706	chr8:75542856	NA	0.38	7.2	0.32	2.38e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg18876405	chr7:65276391	NA	-0.59	-11.13	-0.46	1.19e-25	Aortic root size;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.8	-0.34	4.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.8	-0.41	1.02e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs57046232	0.552	rs1305008	chr20:6324198	T/G	cg21095983	chr6:86352623	SYNCRIP	0.42	6.95	0.31	1.22e-11	Colorectal cancer;
LGG	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07685180	chr8:600429	NA	1.05	10.43	0.44	4.97e-23	IgG glycosylation;
LGG	cis	rs2188554	0.675	rs4285411	chr7:117015125	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	7.5	0.33	3.36e-13	Esophageal adenocarcinoma;
LGG	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.93	0.62	2.19e-50	Hip circumference adjusted for BMI;
LGG	cis	rs4132509	0.696	rs12023642	chr1:243767826	T/G	cg21452805	chr1:244014465	NA	0.87	8.46	0.37	3.43e-16	RR interval (heart rate);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.59	0.37	1.38e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg02297831	chr4:17616191	MED28	-0.49	-8.82	-0.38	2.29e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs611744	0.538	rs13257548	chr8:109273185	G/A	cg18478394	chr8:109455254	TTC35	0.49	10.07	0.42	1.07e-21	Dupuytren's disease;
LGG	cis	rs2976388	0.692	rs2978983	chr8:143765842	A/G	cg06565975	chr8:143823917	SLURP1	0.35	8.93	0.38	1.02e-17	Urinary tract infection frequency;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg08280861	chr8:58055591	NA	0.58	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4077515	0.839	rs1132005	chr9:139296927	T/C	cg21253087	chr9:139290292	SNAPC4	0.38	7.76	0.34	5.31e-14	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg02227867	chr8:22457446	C8orf58	0.43	8.32	0.36	9.78e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11026091	1.000	rs7104488	chr11:3259830	C/T	cg16851282	chr11:3254011	MRGPRE	0.33	6.69	0.3	6.47e-11	Multiple sclerosis;
LGG	cis	rs10769780	0.518	rs931378	chr11:7336536	C/T	cg21672572	chr11:7369177	SYT9	0.32	6.78	0.3	3.79e-11	Phospholipid levels (plasma);
LGG	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.35	-0.36	8.1e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7928758	0.887	rs11822913	chr11:134271645	T/A	cg15243474	chr11:134282918	B3GAT1	1.15	15.58	0.59	2.55e-44	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg03342759	chr3:160939853	NMD3	-0.49	-8.13	-0.35	3.94e-15	Morning vs. evening chronotype;
LGG	cis	rs9926296	0.682	rs645019	chr16:89716883	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-9.35	-0.4	3.85e-19	Vitiligo;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00986762	chr1:36107072	PSMB2	0.4	7.08	0.31	5.29e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg13232821	chr7:50628718	DDC	0.37	7.55	0.33	2.38e-13	Malaria;
LGG	cis	rs870825	0.549	rs7699919	chr4:185648610	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9926296	0.618	rs8058179	chr16:89846987	C/T	cg04287289	chr16:89883240	FANCA	-0.49	-9.04	-0.39	4.29e-18	Vitiligo;
LGG	cis	rs7312933	0.558	rs1796394	chr12:42826359	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-7.68	-0.34	9.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.79	14.07	0.55	1.13e-37	Alzheimer's disease;
LGG	cis	rs4936894	0.500	rs79849070	chr11:124115765	T/A	cg27160556	chr11:124181099	OR8D1	-0.47	-10.93	-0.45	7e-25	Aging (time to death);
LGG	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg03894339	chr8:19674705	INTS10	0.56	8.78	0.38	3.29e-17	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.84	-0.42	6.95e-21	Triglycerides;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg25031040	chr20:271432	C20orf96	0.5	6.75	0.3	4.51e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg02353165	chr6:42928485	GNMT	0.47	14.12	0.55	6.54e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs929354	0.772	rs10228145	chr7:157007337	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.8e-13	Body mass index;
LGG	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs77669868	1.000	rs77669868	chr11:114040394	A/G	cg01914181	chr11:114070210	ZBTB16	0.55	6.76	0.3	4.25e-11	Monocyte percentage of white cells;
LGG	cis	rs17504614	0.597	rs17569942	chr2:51077479	T/C	cg08066024	chr2:51057548	NRXN1	0.56	8.66	0.37	8.14e-17	Educational attainment (years of education);
LGG	cis	rs6495367	1.000	rs13380109	chr15:79378775	G/A	cg17916960	chr15:79447300	NA	0.5	8.83	0.38	2.22e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg15103426	chr22:29168792	CCDC117	0.62	8.93	0.38	9.94e-18	Lymphocyte counts;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.2e-31	Prostate cancer;
LGG	cis	rs9682041	0.561	rs9856511	chr3:170140165	C/G	cg11886554	chr3:170076028	SKIL	0.6	7.2	0.32	2.39e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs1009647	0.614	rs60726667	chr14:55857923	G/C	cg04306507	chr14:55594613	LGALS3	0.47	7.72	0.34	7.29e-14	Testicular germ cell tumor;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg05665937	chr4:1216051	CTBP1	0.48	8.38	0.36	6.49e-16	Obesity-related traits;
LGG	cis	rs868036	0.681	rs3784718	chr15:68098004	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.4	-0.33	6.37e-13	Restless legs syndrome;
LGG	cis	rs10908907	1.000	rs10908907	chr9:92249584	A/G	cg01515543	chr9:92254510	LOC100129066	-0.42	-7.77	-0.34	5.1e-14	Alcoholism (heaviness of drinking);
LGG	trans	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg06521331	chr12:34319734	NA	0.44	7.93	0.35	1.61e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5742933	0.857	rs10931430	chr2:190542186	T/C	cg10453823	chr2:190539512	ANKAR	-0.46	-6.75	-0.3	4.52e-11	Ferritin levels;
LGG	trans	rs1493916	0.905	rs12455290	chr18:31398778	A/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.33	-0.53	1.47e-34	Life satisfaction;
LGG	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg06634786	chr22:41940651	POLR3H	-0.65	-10.89	-0.45	9.28e-25	Vitiligo;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg16606324	chr3:10149918	C3orf24	0.53	6.95	0.31	1.23e-11	Alzheimer's disease;
LGG	cis	rs17253792	0.915	rs75862063	chr14:56177769	G/T	cg01858014	chr14:56050164	KTN1	-0.78	-10.01	-0.42	1.77e-21	Putamen volume;
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg16141378	chr3:129829833	LOC729375	0.39	9.3	0.4	5.39e-19	Systolic blood pressure;
LGG	cis	rs2404602	0.735	rs12903874	chr15:76693318	A/T	cg15268244	chr15:77196840	NA	0.45	9.81	0.41	8.98e-21	Blood metabolite levels;
LGG	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.91	0.35	1.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.6.143706070F	chr6:143664377	NA	0.43	7.23	0.32	2e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10214930	0.624	rs13244903	chr7:27688911	A/G	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg26818257	chr2:241905806	NA	0.51	11.59	0.47	1.85e-27	Urinary metabolites;
LGG	cis	rs4363385	0.818	rs1048296	chr1:153012240	A/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs1691799	0.867	rs1168342	chr12:66758734	A/T	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	cis	rs6424115	1.000	rs35385477	chr1:24155924	G/A	cg24699146	chr1:24152579	HMGCL	0.26	7.53	0.33	2.74e-13	Immature fraction of reticulocytes;
LGG	cis	rs1048238	0.506	rs10927866	chr1:16175317	C/T	cg22431228	chr1:16359049	CLCNKA	-0.39	-7.23	-0.32	1.95e-12	Systolic blood pressure;
LGG	cis	rs3796352	1.000	rs35174175	chr3:53041509	T/C	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6831352	0.918	rs2851246	chr4:100046104	A/G	cg12011299	chr4:100065546	ADH4	0.43	8.61	0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg19784903	chr17:45786737	TBKBP1	0.34	7.13	0.31	3.78e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3126085	0.935	rs11204947	chr1:152218257	G/T	cg26876637	chr1:152193138	HRNR	-0.52	-8.35	-0.36	8.1e-16	Atopic dermatitis;
LGG	cis	rs4321325	0.733	rs75834205	chr2:127947237	G/T	cg11380483	chr2:127933992	NA	0.64	8.74	0.38	4.35e-17	Protein C levels;
LGG	cis	rs6840360	0.642	rs7678823	chr4:152357119	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6968355	0.799	rs2017598	chr7:104592969	A/C	cg03782966	chr7:104585482	NA	0.44	7.96	0.35	1.38e-14	Myopia (pathological);
LGG	cis	rs4849975	0.510	rs28548099	chr2:3710938	G/A	cg17046650	chr2:3699563	NA	0.69	9.31	0.4	5.32e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.41	-0.47	9.39e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs735539	0.574	rs10870743	chr13:21258756	C/A	cg04906043	chr13:21280425	IL17D	-0.53	-8.73	-0.38	4.73e-17	Dental caries;
LGG	cis	rs17604090	0.938	rs28457783	chr7:29687058	T/G	cg19413766	chr7:29689036	LOC646762	-0.58	-7.2	-0.32	2.49e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-8.04	-0.35	7.66e-15	Vitiligo;
LGG	cis	rs988958	0.567	rs11892988	chr2:42246149	C/G	cg27428208	chr2:42229179	NA	0.52	9.1	0.39	2.68e-18	Hypospadias;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg02733842	chr7:1102375	C7orf50	-0.45	-7.37	-0.32	7.75e-13	Bronchopulmonary dysplasia;
LGG	cis	rs9972944	0.756	rs2024273	chr17:63768972	A/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg16583315	chr14:65563665	MAX	0.36	7.03	0.31	7.41e-12	Obesity-related traits;
LGG	cis	rs5742933	0.817	rs5742938	chr2:190649958	G/A	cg04003228	chr2:190539410	ANKAR	-0.47	-6.89	-0.3	1.88e-11	Ferritin levels;
LGG	cis	rs11098499	0.909	rs79704848	chr4:120309351	T/A	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs3796352	1.000	rs58660500	chr3:53086573	C/T	cg12962167	chr3:53033115	SFMBT1	0.75	7.46	0.33	4.42e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.03	-26.43	-0.78	1.54e-94	Chronic sinus infection;
LGG	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-15.2	-0.58	1.26e-42	Total body bone mineral density;
LGG	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs72781680	0.821	rs2339887	chr2:24198376	G/A	cg08917208	chr2:24149416	ATAD2B	0.66	8.72	0.38	5.21e-17	Lymphocyte counts;
LGG	cis	rs7927771	0.725	rs11570094	chr11:47359706	A/C	cg20307385	chr11:47447363	PSMC3	0.47	8.03	0.35	8.1e-15	Subjective well-being;
LGG	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14240646	chr10:27532245	ACBD5	-0.66	-9.57	-0.41	6.32e-20	Breast cancer;
LGG	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg21211680	chr2:198530	NA	1.26	17.02	0.62	8.24e-51	Blood protein levels;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg27532560	chr4:187881888	NA	-0.59	-12.79	-0.51	2.85e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2455799	0.613	rs12485852	chr3:15914511	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-7.75	-0.34	6.02e-14	Mean platelet volume;
LGG	cis	rs1008375	0.933	rs6449324	chr4:17694880	G/C	cg18681998	chr4:17616180	MED28	0.72	14.69	0.56	2.31e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3820928	0.874	rs10182307	chr2:227875360	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.36	-0.32	8.5e-13	Pulmonary function;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.58	0.67	1.29e-62	Platelet count;
LGG	cis	rs981844	0.961	rs62325084	chr4:154662603	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	trans	rs35110281	0.744	rs230645	chr21:44918607	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.55	-9.56	-0.41	7.06e-20	Mean corpuscular volume;
LGG	cis	rs9354308	0.764	rs1587435	chr6:66615365	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs4788570	0.697	rs2334877	chr16:71833332	C/T	cg06353428	chr16:71660113	MARVELD3	1.23	20.56	0.69	3.24e-67	Intelligence (multi-trait analysis);
LGG	cis	rs10155981	0.510	rs4722158	chr7:22584183	G/A	cg05062323	chr7:22590069	NA	-0.77	-8.77	-0.38	3.35e-17	Bilirubin levels;
LGG	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg06532163	chr17:45867833	NA	0.55	9.29	0.4	6.18e-19	IgG glycosylation;
LGG	cis	rs6684428	0.656	rs10888945	chr1:56362002	C/T	cg11651538	chr1:56320950	NA	-0.47	-8.31	-0.36	1.04e-15	Airflow obstruction;
LGG	cis	rs910187	0.605	rs6124961	chr20:45804467	G/C	cg27589058	chr20:45804311	EYA2	-0.37	-9.91	-0.42	3.89e-21	Migraine;
LGG	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg27053975	chr1:166958233	MAEL	-0.47	-6.65	-0.3	8.18e-11	Obesity-related traits;
LGG	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg24803719	chr17:45855879	NA	-0.3	-8.5	-0.37	2.55e-16	IgG glycosylation;
LGG	cis	rs7226408	0.600	rs1147759	chr18:34400466	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.1	-0.35	4.75e-15	Obesity-related traits;
LGG	cis	rs3219090	0.962	rs2695235	chr1:226602556	A/G	cg17127702	chr1:226594323	PARP1	0.39	12.35	0.5	1.69e-30	Melanoma;
LGG	cis	rs2797160	1.000	rs2797160	chr6:126010116	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-9.39	-0.4	2.76e-19	Intelligence (multi-trait analysis);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16677955	chr1:32930380	ZBTB8B	-0.41	-6.9	-0.31	1.72e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2479724	0.846	rs1536702	chr6:41869950	T/A	cg17623882	chr6:41773611	USP49	-0.51	-8.95	-0.38	8.75e-18	Menarche (age at onset);
LGG	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.66	-0.34	1.11e-13	Migraine;Coronary artery disease;
LGG	cis	rs503425	0.688	rs2510902	chr11:118700218	G/A	cg20309703	chr11:118481025	PHLDB1	-0.49	-6.7	-0.3	6.14e-11	Systemic lupus erythematosus;
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs9463078	0.605	rs9472407	chr6:44908800	T/C	cg25276700	chr6:44698697	NA	0.34	7.15	0.32	3.47e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.73	-0.41	1.71e-20	Intelligence (multi-trait analysis);
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg07120314	chr15:79043507	NA	-0.68	-15.13	-0.58	2.55e-42	Coronary artery disease or large artery stroke;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg05793240	chr7:2802953	GNA12	0.36	8.01	0.35	9.38e-15	Height;
LGG	cis	rs7651736	0.636	rs60985825	chr3:136755496	G/T	cg21827317	chr3:136751795	NA	-0.63	-11.5	-0.47	4.12e-27	Neuroticism;
LGG	cis	rs8017423	0.740	rs8003095	chr14:90680643	A/T	cg04374321	chr14:90722782	PSMC1	0.85	18.24	0.65	2.01e-56	Mortality in heart failure;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg12379764	chr21:47803548	PCNT	0.45	7.72	0.34	7.05e-14	Testicular germ cell tumor;
LGG	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg05775895	chr3:12838266	CAND2	0.69	12.77	0.51	3.3e-32	QRS complex (12-leadsum);
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg20887711	chr4:1340912	KIAA1530	0.63	12.45	0.5	6.67e-31	Longevity;
LGG	cis	rs2439831	0.850	rs28509275	chr15:44098105	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	9.6	0.41	4.89e-20	Lung cancer in ever smokers;
LGG	cis	rs9381107	0.932	rs16892279	chr6:9483186	A/G	cg14735645	chr6:9486422	NA	-0.5	-8.14	-0.35	3.61e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6500395	0.926	rs1039343	chr16:48577507	T/G	cg04672837	chr16:48644449	N4BP1	0.57	9.42	0.4	2.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9790314	0.521	rs2122527	chr3:161091636	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.96	-0.42	2.74e-21	Morning vs. evening chronotype;
LGG	trans	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs6982240	0.514	rs10481414	chr8:142275326	T/C	cg20799268	chr8:142275649	NA	-0.25	-6.96	-0.31	1.17e-11	Tonsillectomy;
LGG	cis	rs2016266	0.964	rs61754164	chr12:53684619	A/G	cg04065151	chr12:53682969	ESPL1	0.63	10.52	0.44	2.36e-23	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg23594656	chr7:65796392	TPST1	-0.36	-8.03	-0.35	8.23e-15	Aortic root size;
LGG	cis	rs988958	0.600	rs10189068	chr2:42247361	G/A	cg27428208	chr2:42229179	NA	0.52	8.78	0.38	3.27e-17	Hypospadias;
LGG	cis	rs6032067	0.929	rs6017504	chr20:43818920	G/A	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs28595532	0.920	rs115485705	chr4:119733286	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg02855558	chr7:158107723	PTPRN2	-0.38	-6.86	-0.3	2.24e-11	Calcium levels;
LGG	cis	rs2242194	0.816	rs11264296	chr1:154994750	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.7	15.97	0.6	4.75e-46	Schizophrenia;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg03528353	chr17:61819722	STRADA	0.44	7.57	0.33	2.05e-13	Prudent dietary pattern;
LGG	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg13010199	chr12:38710504	ALG10B	0.64	13.48	0.53	3.7e-35	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.18	0.32	2.73e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.29	-0.36	1.26e-15	Total body bone mineral density;
LGG	cis	rs11971779	0.680	rs66491565	chr7:139088977	C/G	cg07862535	chr7:139043722	LUC7L2	0.5	8.14	0.35	3.71e-15	Diisocyanate-induced asthma;
LGG	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg14227996	chr4:17616232	MED28	0.73	8.93	0.38	1.02e-17	Opioid sensitivity;
LGG	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg25173405	chr17:45401733	C17orf57	-0.76	-12.76	-0.51	3.57e-32	Coronary artery disease;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg18350739	chr11:68623251	NA	-0.87	-22.17	-0.72	9.23e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.7	-0.34	8.04e-14	Life satisfaction;
LGG	cis	rs8058578	1.000	rs7198250	chr16:30746822	C/A	cg05768032	chr16:30646687	NA	0.42	7.1	0.31	4.71e-12	Multiple myeloma;
LGG	trans	rs11227306	0.934	rs11227313	chr11:65588938	C/T	cg17712092	chr4:129076599	LARP1B	0.63	10.61	0.44	1.12e-23	DNA methylation (variation);
LGG	cis	rs17092148	1.000	rs57131731	chr20:33392739	C/T	cg12302830	chr20:33297742	TP53INP2	0.46	7.75	0.34	5.97e-14	Neuroticism;
LGG	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg16584676	chr17:46985605	UBE2Z	-0.52	-9.25	-0.39	8.6e-19	Type 2 diabetes;
LGG	cis	rs2315504	0.509	rs3760335	chr17:39026061	T/A	cg05063374	chr17:38953512	KRT28	-0.41	-7.55	-0.33	2.3e-13	Height;
LGG	cis	rs2652834	0.851	rs7170462	chr15:63345622	A/G	cg05507819	chr15:63340323	TPM1	0.61	8.13	0.35	3.96e-15	HDL cholesterol;
LGG	cis	rs7917772	0.582	rs4285804	chr10:104386309	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-10.7	-0.45	4.83e-24	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg09033563	chr22:24373618	LOC391322	-0.5	-8.46	-0.37	3.42e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9354308	0.901	rs55832318	chr6:66560086	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.05	0.42	1.28e-21	Metabolite levels;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	17.84	0.64	1.53e-54	Platelet count;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg11878867	chr6:150167359	LRP11	0.51	10.3	0.43	1.54e-22	Lung cancer;
LGG	cis	rs6032067	0.516	rs2743334	chr20:43919745	A/G	cg10761708	chr20:43804764	PI3	0.5	7.99	0.35	1.06e-14	Blood protein levels;
LGG	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg20290983	chr6:43655470	MRPS18A	1.05	17.71	0.64	5.66e-54	IgG glycosylation;
LGG	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg17710535	chr19:10819994	QTRT1	0.45	7.2	0.32	2.52e-12	Inflammatory skin disease;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg23330828	chr3:129611968	TMCC1	-0.39	-6.65	-0.3	8.08e-11	Brain structure;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.546	rs10939672	chr4:10052136	A/G	cg11266682	chr4:10021025	SLC2A9	0.52	10.12	0.43	6.81e-22	Bone mineral density;
LGG	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg03162506	chr22:38580953	NA	0.37	8.89	0.38	1.34e-17	Breast cancer;
LGG	cis	rs4268898	0.662	rs17789375	chr2:24502554	G/T	cg06627628	chr2:24431161	ITSN2	-0.76	-12.15	-0.49	1.09e-29	Asthma;
LGG	cis	rs939658	0.728	rs12904789	chr15:79412589	G/A	cg17916960	chr15:79447300	NA	-0.63	-12.0	-0.49	4.68e-29	Refractive error;
LGG	cis	rs6752107	0.967	rs3816234	chr2:234185999	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.77	0.34	5.03e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs8078723	0.866	rs7502514	chr17:38188844	A/G	cg17467752	chr17:38218738	THRA	-0.8	-15.82	-0.59	2.19e-45	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.89	0.7	9.74e-69	Alzheimer's disease;
LGG	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.29	0.4	5.99e-19	Rheumatoid arthritis;
LGG	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg26396452	chr14:65542826	MAX	0.45	9.24	0.39	9.26e-19	Obesity-related traits;
LGG	cis	rs589448	0.872	rs315111	chr12:69784695	G/A	cg14784868	chr12:69753453	YEATS4	1.0	24.26	0.75	1.66e-84	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9815354	0.857	rs9852020	chr3:41830206	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6732160	0.845	rs6546809	chr2:73389681	A/C	cg01422370	chr2:73384389	NA	0.56	11.02	0.46	2.98e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2227564	0.729	rs2633306	chr10:75652447	G/T	cg00564723	chr10:75632066	CAMK2G	0.42	8.73	0.38	4.59e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.7	0.45	5.2e-24	Longevity;
LGG	cis	rs4481887	0.708	rs6688853	chr1:248548006	G/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.88	-0.3	1.96e-11	Common traits (Other);
LGG	trans	rs826838	1.000	rs10880963	chr12:38748408	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.67	-0.34	1e-13	Heart rate;
LGG	cis	rs7215564	0.908	rs7501674	chr17:78662177	C/T	cg06153925	chr17:78755379	RPTOR	0.38	6.75	0.3	4.4e-11	Myopia (pathological);
LGG	trans	rs11088226	0.681	rs2833899	chr21:33933263	T/C	cg09050820	chr6:167586206	TCP10L2	0.9	12.68	0.51	7.79e-32	Gastritis;
LGG	trans	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.01	-0.31	8.45e-12	Monocyte count;
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg11965913	chr1:205819406	PM20D1	0.46	7.15	0.32	3.46e-12	Parkinson's disease;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07362569	chr17:61921086	SMARCD2	-0.5	-9.57	-0.41	6.55e-20	Prudent dietary pattern;
LGG	cis	rs17253792	0.822	rs79921041	chr14:56090779	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg03188948	chr7:1209495	NA	0.4	6.98	0.31	1.05e-11	Longevity;Endometriosis;
LGG	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs317689	0.690	rs317630	chr12:69637847	T/C	cg20891283	chr12:69753455	YEATS4	0.44	6.71	0.3	5.7e-11	Response to diuretic therapy;
LGG	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg09021430	chr5:549028	NA	-0.72	-10.18	-0.43	4.06e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs9560113	0.959	rs4771756	chr13:112176083	T/G	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg02002194	chr4:3960332	NA	0.42	7.61	0.33	1.53e-13	Retinal vascular caliber;
LGG	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-10.12	-0.43	6.77e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6430585	0.583	rs2304370	chr2:136561735	G/A	cg07169764	chr2:136633963	MCM6	1.14	21.9	0.71	1.7e-73	Corneal structure;
LGG	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg17747265	chr1:1875780	NA	0.49	8.35	0.36	7.98e-16	Body mass index;
LGG	cis	rs4704187	0.687	rs4235683	chr5:74415088	T/C	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs11626933	1.000	rs61986782	chr14:90751344	C/T	cg14092571	chr14:90743983	NA	-0.81	-16.54	-0.61	1.28e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs4509693	1.000	rs6584392	chr10:102497166	G/A	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	cis	rs11626933	1.000	rs3825661	chr14:90767607	C/T	cg14092571	chr14:90743983	NA	0.77	15.97	0.6	4.58e-46	Gut microbiota (bacterial taxa);
LGG	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg12591125	chr7:1885375	MAD1L1	0.46	6.85	0.3	2.39e-11	Bipolar disorder;
LGG	cis	rs9398803	0.865	rs9372840	chr6:126822635	A/C	cg19875578	chr6:126661172	C6orf173	0.56	10.22	0.43	2.95e-22	Male-pattern baldness;
LGG	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.56	-0.63	2.97e-53	Bladder cancer;
LGG	cis	rs7100689	0.646	rs7098045	chr10:82123856	G/C	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs883565	0.740	rs6599006	chr3:39114276	T/G	cg01426195	chr3:39028469	NA	-0.7	-15.93	-0.6	6.94e-46	Handedness;
LGG	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg08048268	chr3:133502702	NA	-0.6	-11.29	-0.46	2.87e-26	Iron status biomarkers;
LGG	cis	rs912057	0.932	rs1294404	chr6:6735022	G/A	cg06612196	chr6:6737390	NA	0.41	7.98	0.35	1.2e-14	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19671926	chr4:122722719	EXOSC9	0.55	8.48	0.37	3.13e-16	Type 2 diabetes;
LGG	cis	rs8016982	0.662	rs7148100	chr14:81678096	A/G	cg01989461	chr14:81687754	GTF2A1	0.57	9.02	0.39	5.09e-18	Schizophrenia;
LGG	cis	rs9859260	0.961	rs34221479	chr3:195798600	T/C	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.94	-0.31	1.29e-11	Mean corpuscular volume;
LGG	cis	rs2832191	0.716	rs2692625	chr21:30446360	C/G	cg08807101	chr21:30365312	RNF160	0.92	19.49	0.67	3.36e-62	Dental caries;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16890600	chr5:98265530	NA	0.49	7.47	0.33	3.9e-13	Gut microbiome composition (summer);
LGG	cis	rs1728785	0.818	rs1728772	chr16:68584526	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs1372520	0.684	rs2583979	chr4:90750588	A/T	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg18154014	chr19:37997991	ZNF793	-0.43	-7.87	-0.34	2.54e-14	Coronary artery calcification;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg01391346	chr6:99873300	SFRS18	0.46	6.96	0.31	1.16e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs9358372	0.504	rs12665631	chr6:20791539	T/G	cg13405222	chr6:20811065	CDKAL1	0.62	13.36	0.53	1.11e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	7.48	0.33	3.68e-13	Educational attainment;
LGG	trans	rs61931739	0.620	rs7979562	chr12:33707023	C/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.6	-0.37	1.25e-16	Morning vs. evening chronotype;
LGG	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg03060546	chr3:49711283	APEH	-0.57	-6.87	-0.3	2.13e-11	Cognitive function;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg05335186	chr13:53173507	NA	-0.41	-8.28	-0.36	1.3e-15	Lewy body disease;
LGG	cis	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.03	-0.35	8.32e-15	Joint mobility (Beighton score);
LGG	cis	rs742614	0.533	rs6059498	chr20:32447282	T/C	cg06304546	chr20:32448765	NA	-0.71	-14.1	-0.55	8.13e-38	Stearic acid (18:0) levels;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg18252515	chr7:66147081	NA	0.44	7.35	0.32	9.03e-13	Aortic root size;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.21	-0.43	3.2800000000000002e-22	Lung cancer;
LGG	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg19717773	chr7:2847554	GNA12	-0.39	-8.93	-0.38	9.83e-18	Height;
LGG	cis	rs7122539	0.734	rs9971487	chr11:66666996	T/C	cg01599099	chr11:66649832	PC	0.47	9.31	0.4	5.02e-19	HIV-1 susceptibility;
LGG	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.81	-0.34	3.83e-14	Iron status biomarkers;
LGG	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg18850127	chr7:39170497	POU6F2	0.51	11.68	0.48	8.49e-28	IgG glycosylation;
LGG	cis	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg00405596	chr8:11794950	NA	0.61	10.57	0.44	1.53e-23	Monocyte count;
LGG	cis	rs55633855	0.516	rs2136792	chr11:88165514	G/A	cg08522340	chr11:88068493	CTSC	-0.4	-6.95	-0.31	1.24e-11	Body mass index;
LGG	cis	rs2072732	0.861	rs56176404	chr1:2940998	A/G	cg08733933	chr1:2954429	NA	-0.46	-8.81	-0.38	2.47e-17	Plateletcrit;
LGG	cis	rs3857536	0.706	rs7755994	chr6:66891747	T/C	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.07	-0.49	2.33e-29	Height;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.61	-0.37	1.19e-16	Lung cancer;
LGG	cis	rs56161922	0.730	rs74231794	chr1:207850717	G/A	cg09557387	chr1:207818395	CR1L	0.95	9.51	0.4	1.03e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs7166081	0.950	rs72625778	chr15:67590103	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg03162506	chr22:38580953	NA	0.37	9.63	0.41	3.84e-20	Cutaneous nevi;
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.68	-12.52	-0.5	3.63e-31	Personality dimensions;
LGG	cis	rs6466055	0.720	rs13239067	chr7:105011629	T/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.92	-0.31	1.48e-11	Schizophrenia;
LGG	cis	rs713587	0.520	rs530951	chr2:25307005	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-7.9	-0.34	2.03e-14	Body mass index in non-asthmatics;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg06112835	chr11:68658793	MRPL21	0.6	9.82	0.42	8.31e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg09137382	chr11:130731461	NA	0.36	6.79	0.3	3.4e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4950322	0.570	rs72692980	chr1:146809568	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs758324	0.812	rs477086	chr5:131284610	C/T	cg06307176	chr5:131281290	NA	-0.49	-8.07	-0.35	6.28e-15	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg00599393	chr8:22457479	C8orf58	-0.43	-7.92	-0.35	1.82e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg00198680	chr16:28758506	NA	0.28	6.93	0.31	1.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4704846	1.000	rs6861025	chr5:156519097	C/T	cg12943317	chr5:156479607	HAVCR1	-0.55	-7.09	-0.31	5.02e-12	Blood protein levels;
LGG	cis	rs9992101	0.645	rs4272041	chr4:77330682	A/G	cg17010112	chr4:77227123	STBD1	-0.45	-9.28	-0.4	6.45e-19	Creatinine levels;
LGG	cis	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17253792	0.915	rs79100824	chr14:56179606	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-10.01	-0.42	1.77e-21	Putamen volume;
LGG	cis	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg07460842	chr6:66804631	NA	0.96	18.04	0.64	1.68e-55	Exhaled nitric oxide output;
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.4e-17	Bipolar disorder;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-10.21	-0.43	3.16e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.05	0.35	7.15e-15	Alcohol dependence;
LGG	cis	rs6539288	0.589	rs1037013	chr12:107219308	A/G	cg15890332	chr12:107067104	RFX4	0.36	10.24	0.43	2.56e-22	Total body bone mineral density;
LGG	cis	rs12477438	0.715	rs6724476	chr2:99627316	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs7572733	0.515	rs11891555	chr2:198853540	G/T	cg00792783	chr2:198669748	PLCL1	0.69	11.27	0.46	3.39e-26	Dermatomyositis;
LGG	cis	rs2197308	0.740	rs1842595	chr12:37906223	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.77	-0.51	3.26e-32	Morning vs. evening chronotype;
LGG	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	11.59	0.47	1.93e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg18825076	chr15:78729989	IREB2	-0.45	-7.34	-0.32	9.67e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.18	-0.36	2.77e-15	Neuroticism;
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.75	-0.48	4.45e-28	Personality dimensions;
LGG	cis	rs7267979	1.000	rs6083813	chr20:25337671	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.41	-0.44	5.95e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1552244	0.808	rs7615088	chr3:10035896	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	trans	rs1997103	1.000	rs7779040	chr7:55412947	T/C	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.36e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1620921	0.505	rs4709467	chr6:161203079	G/A	cg01280913	chr6:161186852	NA	-0.5	-10.24	-0.43	2.51e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg20978937	chr14:105399321	PLD4	0.49	11.1	0.46	1.46e-25	Rheumatoid arthritis;
LGG	cis	rs7599312	0.553	rs6710653	chr2:213404893	A/G	cg20637307	chr2:213403960	ERBB4	0.75	16.9	0.62	3.06e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7737355	1.000	rs59808242	chr5:130754894	G/A	cg06307176	chr5:131281290	NA	-0.55	-9.27	-0.4	6.82e-19	Life satisfaction;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg17178900	chr1:205818956	PM20D1	0.69	16.33	0.6	1.12e-47	Menarche (age at onset);
LGG	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13314892	0.764	rs62251027	chr3:69862454	C/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg17202724	chr17:61916730	SMARCD2	0.54	12.39	0.5	1.18e-30	Prudent dietary pattern;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg21862992	chr11:68658383	NA	0.51	8.41	0.36	5.04e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs972578	0.765	rs2092664	chr22:43270440	A/C	cg01576275	chr22:43409880	NA	-0.23	-6.93	-0.31	1.45e-11	Mean platelet volume;
LGG	cis	rs62244186	0.659	rs9873072	chr3:44516496	G/A	cg02073558	chr3:44770973	ZNF501	0.64	11.6	0.47	1.76e-27	Depressive symptoms;
LGG	cis	rs9389248	0.690	rs2072826	chr6:135253558	G/C	cg22676075	chr6:135203613	NA	-0.48	-8.42	-0.36	4.77e-16	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg26875233	chr11:93583750	C11orf90	-0.43	-8.26	-0.36	1.58e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg13009111	chr11:71350975	NA	0.4	9.22	0.39	1.09e-18	Monocyte count;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.14	-0.35	3.65e-15	HDL cholesterol;
LGG	cis	rs546131	0.642	rs473848	chr11:34851977	A/C	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.35	0.32	9.09e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs7122539	0.722	rs2380760	chr11:66647431	T/C	cg01599099	chr11:66649832	PC	0.45	9.14	0.39	1.93e-18	HIV-1 susceptibility;
LGG	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.15	0.35	3.43e-15	Birth weight;
LGG	trans	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17830980	chr10:43048298	ZNF37B	0.45	10.01	0.42	1.78e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs17270561	0.609	rs4711098	chr6:25734339	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs1788820	0.917	rs1788825	chr18:21109250	T/C	cg14672496	chr18:21087552	C18orf8	0.4	7.42	0.33	5.49e-13	Body mass index;
LGG	cis	rs2066819	1.000	rs78495928	chr12:56635080	G/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg09021430	chr5:549028	NA	-0.7	-9.8	-0.41	9.59e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-11.09	-0.46	1.65e-25	Height;
LGG	cis	rs7177699	0.557	rs72749206	chr15:79122948	G/A	cg00540400	chr15:79124168	NA	-0.51	-10.63	-0.44	9e-24	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs911555	0.755	rs975892	chr14:103883349	A/T	cg24130564	chr14:104152367	KLC1	-0.4	-7.37	-0.32	7.74e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.844	rs7126949	chr11:48972166	A/G	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.51e-17	DNA methylation (variation);
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg18350739	chr11:68623251	NA	-0.87	-22.85	-0.73	6.48e-78	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2282300	0.739	rs35229181	chr11:30241698	A/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.75	-0.34	6e-14	Morning vs. evening chronotype;
LGG	cis	rs2011503	1.000	rs2905422	chr19:19460703	A/G	cg11584989	chr19:19387371	SF4	-0.78	-12.38	-0.5	1.32e-30	Bipolar disorder;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs2342371	0.727	rs6772271	chr3:196193763	C/T	cg15048948	chr3:196158458	UBXN7	-0.43	-7.09	-0.31	5.05e-12	Fat distribution (HIV);
LGG	cis	rs1045714	0.895	rs73035504	chr7:2642878	G/A	cg14042143	chr7:2646782	IQCE	0.8	12.28	0.5	3.45e-30	Urate levels in lean individuals;
LGG	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg03929089	chr4:120376271	NA	-0.45	-7.19	-0.32	2.61e-12	HDL cholesterol;
LGG	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg14154082	chr13:112174009	NA	0.35	7.59	0.33	1.72e-13	Menarche (age at onset);
LGG	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg14675211	chr2:100938903	LONRF2	0.68	12.18	0.49	8.52e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6912958	1.000	rs9294379	chr6:88152535	C/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.68	-0.44	5.93e-24	Monocyte percentage of white cells;
LGG	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg24375607	chr4:120327624	NA	0.64	10.61	0.44	1.1e-23	Corneal astigmatism;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg23758822	chr17:41437982	NA	0.84	15.29	0.58	5.02e-43	Menopause (age at onset);
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg10950524	chr7:2139216	MAD1L1	0.33	7.0	0.31	8.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3762637	1.000	rs6790051	chr3:122192846	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs5769707	0.521	rs5770633	chr22:50062427	G/A	cg20744362	chr22:50050164	C22orf34	0.42	7.39	0.32	6.76e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg19357499	chr8:144660631	NAPRT1	0.92	7.05	0.31	6.37e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg08677398	chr8:58056175	NA	0.45	7.41	0.33	5.87e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.562	rs6975534	chr7:124686461	G/T	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs11190604	1.000	rs11190596	chr10:102293238	C/G	cg07570687	chr10:102243282	WNT8B	0.45	7.56	0.33	2.13e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg01191920	chr7:158217561	PTPRN2	-0.9	-22.16	-0.72	1.11e-74	Obesity-related traits;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.36	-0.47	1.48e-26	Schizophrenia;
LGG	cis	rs1461503	0.838	rs7126962	chr11:122830551	T/C	cg27398637	chr11:122830231	C11orf63	-0.74	-15.35	-0.58	2.74e-43	Menarche (age at onset);
LGG	cis	rs2797369	0.665	rs4533995	chr6:101613110	A/T	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs1620921	0.505	rs9456588	chr6:161212564	C/G	cg01280913	chr6:161186852	NA	-0.47	-9.5	-0.4	1.16e-19	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg00761968	chr13:53314142	LECT1	-0.36	-7.62	-0.33	1.49e-13	Lewy body disease;
LGG	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg07870213	chr5:140052090	DND1	0.92	17.08	0.62	4.25e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg21775007	chr8:11205619	TDH	-0.42	-7.08	-0.31	5.53e-12	Joint mobility (Beighton score);
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg04080417	chr5:1859792	NA	-0.53	-8.7	-0.37	5.78e-17	Cardiovascular disease risk factors;
LGG	trans	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg12045294	chr17:78518616	RPTOR	-0.46	-7.05	-0.31	6.66e-12	Glycated hemoglobin levels;
LGG	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9549367	0.789	rs2302757	chr13:113909339	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.6	-0.37	1.2e-16	Platelet distribution width;
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg13699009	chr12:122356056	WDR66	0.53	14.19	0.55	3.47e-38	Mean corpuscular volume;
LGG	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg03342759	chr3:160939853	NMD3	-0.58	-9.77	-0.41	1.22e-20	Educational attainment (years of education);
LGG	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg24397884	chr7:158709396	WDR60	-1.05	-25.19	-0.76	7.83e-89	Height;
LGG	cis	rs4474465	0.790	rs10793331	chr11:78270000	C/T	cg27205649	chr11:78285834	NARS2	0.52	8.96	0.38	8.29e-18	Alzheimer's disease (survival time);
LGG	cis	rs1707322	0.963	rs6690652	chr1:46376692	G/T	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg05707623	chr12:122985044	ZCCHC8	0.63	9.25	0.39	8.59e-19	Body mass index;
LGG	cis	rs12210905	1.000	rs9368499	chr6:27254332	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7917772	0.582	rs10786691	chr10:104364652	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.49e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.65	-0.37	8.42e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2371030	1.000	rs2193618	chr2:211573464	A/G	cg18417063	chr2:211583084	NA	-0.62	-11.12	-0.46	1.27e-25	Non-small cell lung cancer;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg16339924	chr4:17578868	LAP3	0.61	10.5	0.44	2.71e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg27432699	chr2:27873401	GPN1	0.51	8.55	0.37	1.84e-16	Total body bone mineral density;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg02772935	chr3:125709198	NA	-0.55	-7.09	-0.31	5.11e-12	Blood pressure (smoking interaction);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.59	-10.08	-0.42	9.93e-22	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27020264	chr7:86689237	KIAA1324L	0.43	6.77	0.3	4.01e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs561341	1.000	rs546748	chr17:30324293	A/C	cg13647721	chr17:30228624	UTP6	0.65	8.66	0.37	7.69e-17	Hip circumference adjusted for BMI;
LGG	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg14456004	chr13:21872349	NA	1.14	18.31	0.65	9.7e-57	White matter hyperintensity burden;
LGG	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18867708	chr6:26865862	GUSBL1	-0.47	-7.81	-0.34	3.89e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg00495681	chr13:53174319	NA	0.68	12.97	0.52	4.97e-33	Lewy body disease;
LGG	cis	rs4776059	1.000	rs12914502	chr15:52911335	A/G	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.47	-0.37	3.19e-16	Schizophrenia;
LGG	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg18681998	chr4:17616180	MED28	0.85	18.19	0.65	3.63e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs11165623	0.602	rs6677110	chr1:97018734	A/C	cg10631902	chr5:14652156	NA	-0.44	-8.98	-0.39	6.76e-18	Hip circumference;Waist circumference;
LGG	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg02002194	chr4:3960332	NA	0.38	7.08	0.31	5.47e-12	Neuroticism;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.71	-0.56	1.9e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg05044414	chr3:183734942	ABCC5	0.76	16.16	0.6	6.61e-47	Anterior chamber depth;
LGG	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.54	0.53	2.05e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg27124370	chr19:33622961	WDR88	0.47	6.67	0.3	7.43e-11	Bone properties (heel);
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7103648	0.966	rs10838702	chr11:47410888	G/T	cg20307385	chr11:47447363	PSMC3	0.95	22.42	0.72	6.36e-76	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.73e-13	HDL cholesterol;
LGG	cis	rs60180747	0.544	rs11635096	chr15:66568700	G/A	cg07575407	chr15:66541975	MEGF11	0.63	13.62	0.53	9.25e-36	Testicular germ cell tumor;
LGG	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg14952266	chr13:112191215	NA	0.52	10.94	0.45	6.44e-25	Hepatitis;
LGG	cis	rs3617	0.539	rs4687687	chr3:52948332	A/G	cg11645453	chr3:52864694	ITIH4	-0.45	-7.54	-0.33	2.43e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	0.786	rs4945262	chr11:77990831	T/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.27e-13	Testicular germ cell tumor;
LGG	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg07382826	chr16:28625726	SULT1A1	0.38	7.81	0.34	3.96e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs2531992	0.686	rs2531989	chr16:4028145	G/A	cg05927578	chr16:4029543	ADCY9	0.76	10.86	0.45	1.28e-24	Waist circumference;
LGG	cis	rs881375	0.900	rs1930786	chr9:123691469	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.71	0.48	6.51e-28	Rheumatoid arthritis;
LGG	cis	rs6500395	0.962	rs9937568	chr16:48612361	C/T	cg04672837	chr16:48644449	N4BP1	-0.53	-8.59	-0.37	1.39e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10895140	0.756	rs947992	chr11:101485041	A/T	cg23650423	chr11:101454676	TRPC6	0.45	6.98	0.31	1.06e-11	Menarche (age at onset);
LGG	cis	rs7546668	1.000	rs4646061	chr1:15829916	G/A	cg21858823	chr1:15850916	CASP9	0.37	6.88	0.3	1.99e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs7084402	0.967	rs1649059	chr10:60312599	T/C	cg07615347	chr10:60278583	BICC1	0.63	17.94	0.64	4.95e-55	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12069248	chr11:65628378	MUS81	0.47	6.81	0.3	3.03e-11	Gut microbiome composition (summer);
LGG	cis	rs3096299	0.754	rs3096320	chr16:89403057	C/A	cg06640241	chr16:89574553	SPG7	0.56	9.14	0.39	2.04e-18	Multiple myeloma (IgH translocation);
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs11203032	0.831	rs7477966	chr10:90924258	A/G	cg16672925	chr10:90967113	CH25H	0.77	10.97	0.45	4.63e-25	Heart failure;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.45	8.6	0.37	1.26e-16	Obesity-related traits;
LGG	cis	rs10791323	0.660	rs10791330	chr11:133727535	C/T	cg06766960	chr11:133703094	NA	-0.55	-10.94	-0.45	6.08e-25	Childhood ear infection;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg19147804	chr7:1989927	MAD1L1	-0.5	-9.87	-0.42	5.44e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg20336341	chr7:50628841	DDC	-0.41	-7.1	-0.31	4.76e-12	Malaria;
LGG	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.06	-0.35	6.5e-15	Monocyte count;
LGG	cis	rs56283067	0.740	rs111810959	chr6:44709460	C/A	cg20913747	chr6:44695427	NA	-0.62	-11.16	-0.46	8.64e-26	Total body bone mineral density;
LGG	cis	rs9487051	0.676	rs1521905	chr6:109594515	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.09	0.31	5.14e-12	Retinal vascular caliber;
LGG	cis	rs1018836	0.923	rs62526886	chr8:91627676	G/A	cg16814680	chr8:91681699	NA	-0.85	-15.93	-0.6	6.94e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg03351412	chr1:154909251	PMVK	0.66	12.29	0.5	3.05e-30	Prostate cancer;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg22237598	chr2:160569678	MARCH7	-0.44	-6.79	-0.3	3.53e-11	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01519350	chr3:137906342	ARMC8	0.56	8.97	0.38	7.25e-18	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.7	-0.56	2.05e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs7647973	0.769	rs7434187	chr3:49032967	C/T	cg07636037	chr3:49044803	WDR6	0.91	16.68	0.61	2.8e-49	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24906202	chr15:73345212	NEO1	0.5	8.07	0.35	6.22e-15	Cognitive performance;
LGG	cis	rs11190604	0.767	rs77769532	chr10:102193646	T/C	cg07570687	chr10:102243282	WNT8B	0.42	7.5	0.33	3.36e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg08677398	chr8:58056175	NA	0.45	7.11	0.31	4.51e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg27121462	chr16:89883253	FANCA	0.61	11.2	0.46	6.28e-26	Vitiligo;
LGG	cis	rs4948102	0.686	rs11771788	chr7:56158040	T/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.06	0.31	6.31e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Colorectal cancer;
LGG	cis	rs9868809	0.772	rs28452701	chr3:48708575	C/T	cg00383909	chr3:49044727	WDR6	0.83	10.0	0.42	1.97e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1577917	0.916	rs4706252	chr6:86555180	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs6912958	0.967	rs9450688	chr6:88159276	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.64	-0.44	8.38e-24	Monocyte percentage of white cells;
LGG	cis	rs4417704	0.577	rs7591322	chr2:241900403	T/C	cg05025159	chr2:241905733	NA	0.53	10.83	0.45	1.56e-24	Joint mobility (Beighton score);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12183124	chr6:43507374	XPO5	0.41	7.21	0.32	2.33e-12	Menarche (age at onset);
LGG	cis	rs17122278	1.000	rs73023350	chr11:118449396	G/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.74	-0.3	4.71e-11	Total cholesterol levels;
LGG	cis	rs2985684	0.802	rs10150823	chr14:50051751	C/T	cg04989706	chr14:50066350	PPIL5	-0.6	-9.82	-0.42	8.1899999999999992e-21	Carotid intima media thickness;
LGG	cis	rs10193935	0.901	rs9309082	chr2:42581412	A/G	cg27598129	chr2:42591480	NA	-0.67	-10.01	-0.42	1.72e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7524258	0.835	rs7543228	chr1:7306538	G/C	cg07173049	chr1:7289937	CAMTA1	0.72	16.69	0.61	2.52e-49	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9890032	0.520	rs2321926	chr17:29041552	T/C	cg19761014	chr17:28927070	LRRC37B2	0.42	6.81	0.3	2.98e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg06470251	chr20:60548479	NA	0.5	8.09	0.35	5.25e-15	Body mass index;
LGG	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg00686598	chr14:53173677	PSMC6	1.35	14.47	0.56	2.05e-39	Alzheimer's disease (late onset);
LGG	cis	rs2732480	0.500	rs12828309	chr12:48641160	C/T	cg21466736	chr12:48725269	NA	-0.36	-7.33	-0.32	1.06e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.22e-45	HDL cholesterol levels;
LGG	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg00531865	chr16:30841666	NA	-0.68	-16.27	-0.6	2.08e-47	Dementia with Lewy bodies;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.6	-0.41	5.07e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2645694	0.626	rs2645709	chr4:77824474	G/A	cg03477792	chr4:77819574	ANKRD56	0.53	9.42	0.4	2.19e-19	Emphysema distribution in smoking;
LGG	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.47	0.37	3.32e-16	Thyroid stimulating hormone;
LGG	cis	rs9747201	0.926	rs35131420	chr17:80103631	T/C	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs657075	0.595	rs3749753	chr5:131587131	C/T	cg05556477	chr5:131705319	SLC22A5	0.63	8.22	0.36	2.06e-15	Rheumatoid arthritis;
LGG	cis	rs72945132	0.825	rs2277273	chr11:70223992	T/C	cg13802316	chr11:70253460	CTTN	-0.57	-7.41	-0.33	5.85e-13	Coronary artery disease;
LGG	cis	rs5753037	0.702	rs5752961	chr22:30188084	C/T	cg01021169	chr22:30184971	ASCC2	-0.36	-7.19	-0.32	2.7e-12	Type 1 diabetes;
LGG	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.22	-0.43	2.95e-22	Chronic sinus infection;
LGG	cis	rs5750830	0.594	rs9611169	chr22:39783027	C/T	cg04986931	chr22:39850128	NA	0.34	7.66	0.34	1.13e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25443968	chr17:21118207	TMEM11	0.48	7.85	0.34	3.02e-14	Gut microbiome composition (summer);
LGG	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg10483660	chr13:112241077	NA	0.43	9.0	0.39	5.68e-18	Menarche (age at onset);
LGG	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.24	-0.32	1.83e-12	Bone mineral density;
LGG	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg11166453	chr1:247681781	NA	0.63	10.26	0.43	2.22e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg06886374	chr16:1844152	IGFALS	-0.45	-8.08	-0.35	5.83e-15	Insulin-like growth factors;
LGG	cis	rs2635047	0.811	rs17785603	chr18:44769534	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.37	0.36	6.88e-16	Educational attainment;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.47	-0.47	5.6e-27	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg06112835	chr11:68658793	MRPL21	0.65	10.59	0.44	1.26e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7106204	0.764	rs79427715	chr11:24247046	G/A	ch.11.24196551F	chr11:24239977	NA	0.97	10.8	0.45	2.04e-24	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs8072100	0.817	rs12449647	chr17:45548958	C/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.38	-0.4	2.87e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3780378	0.682	rs7861755	chr9:5273180	C/T	cg02405213	chr9:5042618	JAK2	-0.4	-7.01	-0.31	8.33e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4696584	0.590	rs10002053	chr4:155416900	G/A	cg04517429	chr4:155413618	DCHS2	-0.27	-6.7	-0.3	6.14e-11	Folding of antihelix;
LGG	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg01657329	chr11:68192670	LRP5	0.47	8.13	0.35	3.9e-15	Total body bone mineral density;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg08835221	chr22:38071607	LGALS1	0.27	7.53	0.33	2.67e-13	Fat distribution (HIV);
LGG	cis	rs758324	0.773	rs10069521	chr5:131174215	A/G	cg06307176	chr5:131281290	NA	0.53	8.66	0.37	7.9e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg05484376	chr2:27715224	FNDC4	0.43	9.38	0.4	2.93e-19	Total body bone mineral density;
LGG	cis	rs10791323	0.582	rs2723613	chr11:133706696	G/A	cg00579200	chr11:133705235	NA	-0.58	-11.15	-0.46	1.01e-25	Childhood ear infection;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.59	-0.41	5.63e-20	Life satisfaction;
LGG	cis	rs1878931	0.507	rs34370895	chr16:3396319	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.67	-9.93	-0.42	3.31e-21	Body mass index (adult);
LGG	cis	rs1348850	0.914	rs4893950	chr2:178304885	T/C	cg27490568	chr2:178487706	NA	0.51	10.05	0.42	1.29e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10789491	1.000	rs1440487	chr1:47167075	C/T	cg15501359	chr1:47185051	KIAA0494	-0.74	-14.56	-0.56	8.28e-40	Response to hepatitis C treatment;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg16268157	chr7:99778414	STAG3	-0.49	-8.18	-0.36	2.75e-15	Lung function (FEV1/FVC);
LGG	cis	rs68170813	0.559	rs7807648	chr7:106965091	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-10.01	-0.42	1.78e-21	Coronary artery disease;
LGG	cis	rs796364	0.512	rs1653290	chr2:201078165	A/T	cg17644776	chr2:200775616	C2orf69	0.51	6.7	0.3	5.91e-11	Schizophrenia;
LGG	cis	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg09085632	chr11:111637200	PPP2R1B	0.99	19.0	0.66	6.15e-60	Primary sclerosing cholangitis;
LGG	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg10057126	chr4:77819792	ANKRD56	0.35	6.67	0.3	7.4e-11	Emphysema distribution in smoking;
LGG	cis	rs2204008	0.660	rs2320745	chr12:38239101	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.23	0.32	2.05e-12	Bladder cancer;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg10407489	chr4:1043616	NA	0.33	7.69	0.34	8.71e-14	Recombination rate (males);
LGG	trans	rs12579753	0.917	rs11610365	chr12:82218108	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.98	-0.35	1.16e-14	Resting heart rate;
LGG	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	trans	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs2692947	0.644	rs1168975	chr2:96814075	G/A	cg22654517	chr2:96458247	NA	0.36	7.28	0.32	1.43e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7444	0.941	rs11089629	chr22:21958872	T/G	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs2114646	0.652	rs4616448	chr2:170639015	C/A	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.23e-11	Obesity-related traits;
LGG	cis	rs7527798	0.592	rs11118345	chr1:207854827	A/T	cg09232269	chr1:207846808	CR1L	-0.38	-7.26	-0.32	1.63e-12	Erythrocyte sedimentation rate;
LGG	cis	rs7188861	0.768	rs181694	chr16:11384829	C/T	cg01510278	chr16:11456238	NA	0.3	7.31	0.32	1.15e-12	HDL cholesterol;
LGG	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg23796481	chr11:64053134	BAD;GPR137	-0.56	-9.73	-0.41	1.78e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9309473	1.000	rs10496193	chr2:73773503	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.48	-0.33	3.73e-13	Metabolite levels;
LGG	cis	rs7666738	0.753	rs28463863	chr4:98844444	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.19	0.36	2.58e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7818345	0.845	rs11785649	chr8:19268233	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.71	0.3	5.86e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs1966248	0.543	rs12213745	chr6:134111891	G/A	cg25632230	chr6:134101081	NA	-0.34	-7.58	-0.33	1.88e-13	Coronary artery disease;
LGG	cis	rs11239187	0.530	rs10793548	chr10:45064764	C/T	cg03916630	chr10:45065415	NA	0.37	9.18	0.39	1.43e-18	Body mass index;
LGG	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg22437258	chr11:111473054	SIK2	-0.54	-9.61	-0.41	4.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs8031584	0.723	rs11632229	chr15:31179534	A/G	cg14829155	chr15:31115871	NA	0.66	11.84	0.48	1.99e-28	Huntington's disease progression;
LGG	cis	rs7932354	0.710	rs10838621	chr11:46851459	C/T	cg03339077	chr11:47165057	C11orf49	-0.44	-7.98	-0.35	1.18e-14	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg14668632	chr7:2872130	GNA12	-0.33	-7.01	-0.31	8.68e-12	Height;
LGG	cis	rs6539267	0.748	rs1921953	chr12:106721012	C/T	cg00173435	chr12:106696525	TCP11L2	0.5	7.53	0.33	2.68e-13	Tourette syndrome;
LGG	cis	rs55788414	0.932	rs4365300	chr16:81184460	C/T	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7917772	0.582	rs7075269	chr10:104365724	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.72	0.48	5.63e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs36051895	0.632	rs10974980	chr9:5140671	C/G	cg02405213	chr9:5042618	JAK2	-0.77	-14.46	-0.56	2.36e-39	Pediatric autoimmune diseases;
LGG	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.75	-0.3	4.33e-11	Bipolar disorder;
LGG	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg11266682	chr4:10021025	SLC2A9	0.56	11.23	0.46	4.6e-26	Bone mineral density;
LGG	cis	rs2273669	0.667	rs9688896	chr6:109364698	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.94	-0.31	1.32e-11	Schizophrenia;
LGG	cis	rs698813	0.642	rs1837702	chr2:44492444	T/A	cg00619915	chr2:44497795	NA	-0.61	-8.87	-0.38	1.58e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21442773	chr1:236029828	LYST	0.4	6.94	0.31	1.33e-11	Bilirubin levels;
LGG	cis	rs787274	1.000	rs787278	chr9:115473531	C/A	cg13803584	chr9:115635662	SNX30	0.54	6.76	0.3	4.16e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs36051895	0.664	rs7847141	chr9:5097171	A/T	cg02405213	chr9:5042618	JAK2	-0.83	-16.21	-0.6	3.98e-47	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg00933542	chr6:150070202	PCMT1	0.4	7.3	0.32	1.27e-12	Lung cancer;
LGG	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg06108461	chr20:60628389	TAF4	-0.63	-11.02	-0.46	3.18e-25	Body mass index;
LGG	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.15	-0.35	3.36e-15	Neuroticism;
LGG	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg21775007	chr8:11205619	TDH	0.44	6.9	0.31	1.71e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.01	-0.31	8.22e-12	Blood metabolite levels;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg04234412	chr22:24373322	LOC391322	-0.71	-13.92	-0.54	4.65e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4746818	1.000	rs6480385	chr10:70904785	A/T	cg11621586	chr10:70884670	VPS26A	1.18	21.68	0.71	1.77e-72	Left atrial antero-posterior diameter;
LGG	cis	rs7923609	0.967	rs10509186	chr10:65207018	C/T	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg24829409	chr8:58192753	C8orf71	-0.79	-10.57	-0.44	1.52e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.77	0.34	5.23e-14	Retinal vascular caliber;
LGG	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15541040	chr2:3486749	NA	-0.46	-8.37	-0.36	6.76e-16	Neurofibrillary tangles;
LGG	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.41	0.44	5.94e-23	Calcium levels;
LGG	cis	rs9457247	0.935	rs1044059	chr6:167369897	C/A	cg07741184	chr6:167504864	NA	-0.32	-7.02	-0.31	7.99e-12	Crohn's disease;
LGG	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.15	0.49	1.1e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2239547	0.657	rs3755803	chr3:52866157	C/G	cg11645453	chr3:52864694	ITIH4	0.72	11.25	0.46	4.12e-26	Schizophrenia;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs908922	0.676	rs6687126	chr1:152530894	T/G	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs17253792	0.822	rs112374071	chr14:56061919	C/T	cg01858014	chr14:56050164	KTN1	-0.93	-12.13	-0.49	1.34e-29	Putamen volume;
LGG	cis	rs7615952	0.546	rs2979338	chr3:125343126	G/T	cg21696256	chr3:125484277	NA	-0.46	-6.87	-0.3	2.02e-11	Blood pressure (smoking interaction);
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg00976097	chr5:421733	AHRR	-0.45	-7.18	-0.32	2.71e-12	Cystic fibrosis severity;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg11062466	chr8:58055876	NA	0.47	8.17	0.36	2.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7133214	0.771	rs9668702	chr12:27919491	T/G	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.98	-0.31	1.06e-11	Gut microbiota (functional units);
LGG	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg24623649	chr8:11872141	NA	-0.32	-7.78	-0.34	4.76e-14	Neuroticism;
LGG	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg00031303	chr3:195681400	NA	0.53	8.35	0.36	8.19e-16	Pancreatic cancer;
LGG	trans	rs9657904	0.704	rs6788366	chr3:105573324	T/A	cg14088669	chr1:158435396	OR10K1	0.42	7.96	0.35	1.3e-14	Multiple sclerosis;
LGG	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs7091068	0.522	rs11187621	chr10:95483074	T/C	cg20715218	chr10:95462985	C10orf4	0.67	11.15	0.46	9.88e-26	Urinary tract infection frequency;
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg18245976	chr7:158708271	WDR60	-0.59	-10.8	-0.45	2.14e-24	Height;
LGG	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg08470875	chr2:26401718	FAM59B	0.41	7.11	0.31	4.5e-12	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.84	-0.45	1.46e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg09307838	chr4:120376055	NA	0.47	8.03	0.35	8e-15	Diastolic blood pressure;
LGG	cis	rs526231	0.543	rs34767	chr5:102489511	A/C	cg23492399	chr5:102201601	PAM	-0.57	-8.49	-0.37	2.88e-16	Primary biliary cholangitis;
LGG	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.72	0.3	5.46e-11	Parkinson's disease;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.58	-10.0	-0.42	1.83e-21	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg16339924	chr4:17578868	LAP3	0.58	10.07	0.42	1.09e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	18.54	0.65	8.61e-58	Platelet count;
LGG	cis	rs6456156	0.586	rs12525855	chr6:167480013	T/G	cg07741184	chr6:167504864	NA	0.4	9.26	0.4	7.66e-19	Primary biliary cholangitis;
LGG	cis	rs4684776	1.000	rs2442798	chr3:11487891	G/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.33	-0.36	9.43e-16	Small vessel stroke;
LGG	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg00101154	chr16:420108	MRPL28	-0.62	-10.09	-0.42	9.17e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg09264619	chr17:80180166	NA	-0.53	-10.29	-0.43	1.67e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg27432699	chr2:27873401	GPN1	-0.5	-8.7	-0.37	5.99e-17	Total body bone mineral density;
LGG	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg26513180	chr16:89883248	FANCA	-0.92	-19.6	-0.67	1.03e-62	Vitiligo;
LGG	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg23324259	chr8:82754387	SNX16	-0.47	-7.51	-0.33	3.16e-13	Diastolic blood pressure;
LGG	cis	rs8114671	0.647	rs6060267	chr20:33734012	A/G	cg24642439	chr20:33292090	TP53INP2	0.53	8.7	0.37	5.8e-17	Height;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg11301795	chr4:187892539	NA	-0.95	-24.86	-0.76	2.89e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs62158211	0.955	rs1823125	chr2:114090412	C/T	cg17784749	chr2:114082611	LOC440839	-0.65	-9.39	-0.4	2.69e-19	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs11229555	0.874	rs10896794	chr11:58339124	T/C	cg15696309	chr11:58395628	NA	-0.99	-17.67	-0.63	9.25e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg14926445	chr8:58193284	C8orf71	-0.72	-9.24	-0.39	8.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9863	0.861	rs11057396	chr12:124419062	A/C	cg13487667	chr12:124434373	CCDC92	-0.36	-7.15	-0.32	3.49e-12	White blood cell count;
LGG	trans	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg16141378	chr3:129829833	LOC729375	0.34	7.8	0.34	4.12e-14	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-8.02	-0.35	8.61e-15	Diabetic retinopathy;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	7.18	0.32	2.78e-12	Schizophrenia;
LGG	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg14664628	chr15:75095509	CSK	0.51	9.07	0.39	3.37e-18	Systemic lupus erythematosus;
LGG	cis	rs9399135	0.967	rs13191501	chr6:135366880	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.21e-20	Red blood cell count;
LGG	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg13385794	chr1:248469461	NA	0.48	8.12	0.35	4.41e-15	Common traits (Other);
LGG	trans	rs6787172	0.641	rs9860241	chr3:157845169	G/A	cg23275840	chr4:47708675	CORIN	0.4	8.15	0.35	3.47e-15	Subjective well-being;
LGG	cis	rs1595825	0.891	rs73054867	chr2:198700417	C/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.7	-0.3	6.08e-11	Ulcerative colitis;
LGG	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg24375607	chr4:120327624	NA	0.55	9.5	0.4	1.14e-19	Corneal astigmatism;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs9399135	0.967	rs9373122	chr6:135373534	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.61	0.41	4.58e-20	Red blood cell count;
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs9513627	0.915	rs73556182	chr13:100122107	A/G	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs7172677	0.960	rs1602360	chr15:75420761	G/A	cg14664628	chr15:75095509	CSK	-0.43	-6.65	-0.3	8.06e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11711311	0.712	rs4682139	chr3:113331859	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.6	11.72	0.48	6.02e-28	IgG glycosylation;
LGG	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg12756686	chr19:29218302	NA	0.7	11.4	0.47	1.09e-26	Methadone dose in opioid dependence;
LGG	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg01028140	chr2:1542097	TPO	-0.47	-7.61	-0.33	1.56e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1806153	0.673	rs592859	chr11:31819335	C/G	cg11990419	chr11:31841155	NA	-0.36	-7.52	-0.33	2.91e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg02725872	chr8:58115012	NA	-0.95	-12.91	-0.51	9.19e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs6694672	1.000	rs1332663	chr1:197109042	C/T	cg13682187	chr1:196946512	CFHR5	0.5	6.9	0.31	1.73e-11	Asthma;
LGG	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg08188268	chr10:116634841	FAM160B1	0.31	7.02	0.31	8.15e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.35e-31	Prudent dietary pattern;
LGG	cis	rs4075765	0.881	rs72887674	chr11:26215675	G/A	cg19182008	chr11:26298241	NA	0.78	7.55	0.33	2.29e-13	Cannabis dependence symptom count;
LGG	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.13e-11	Alzheimer's disease (survival time);
LGG	trans	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg20587970	chr11:113659929	NA	-1.16	-19.76	-0.68	1.69e-63	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.75	14.5	0.56	1.49e-39	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg26338869	chr17:61819248	STRADA	-0.58	-9.77	-0.41	1.25e-20	Prudent dietary pattern;
LGG	trans	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg22358067	chr17:16797159	NA	0.52	7.43	0.33	5.19e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4740619	0.741	rs10756729	chr9:15973712	A/T	cg14451791	chr9:16040625	NA	-0.39	-9.84	-0.42	7.28e-21	Body mass index;
LGG	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg23166289	chr1:210001082	C1orf107	0.34	6.91	0.31	1.57e-11	Orofacial clefts;
LGG	cis	rs9783347	1.000	rs9783347	chr11:18384938	A/G	cg15585147	chr11:18324498	HPS5	0.42	8.86	0.38	1.72e-17	Pancreatic cancer;
LGG	cis	rs1707322	0.721	rs11211163	chr1:46153548	C/T	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg07701084	chr6:150067640	NUP43	0.68	13.11	0.52	1.3e-33	Lung cancer;
LGG	cis	rs3733418	0.799	rs35680343	chr4:165953134	T/G	cg10852876	chr4:165953100	TRIM60	-0.52	-7.29	-0.32	1.37e-12	Obesity-related traits;
LGG	cis	rs7444	0.941	rs73166622	chr22:21938863	G/C	cg05046821	chr22:21984468	YDJC	-0.38	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	cis	rs6598955	0.671	rs57386998	chr1:26569821	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.17e-15	Obesity-related traits;
LGG	cis	rs11771526	0.901	rs62457473	chr7:32306990	G/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg08648136	chr8:956695	NA	0.33	6.72	0.3	5.21e-11	Schizophrenia;
LGG	cis	rs72634258	0.554	rs34020118	chr1:7895015	C/T	cg00042356	chr1:8021962	PARK7	0.63	7.24	0.32	1.83e-12	Inflammatory bowel disease;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-15.4	-0.58	1.6e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg18200150	chr17:30822561	MYO1D	0.75	17.15	0.62	2.15e-51	Schizophrenia;
LGG	cis	rs208520	0.690	rs207091	chr6:66799847	G/T	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07614371	chr15:38746870	FAM98B	-0.47	-6.98	-0.31	1.05e-11	Systemic lupus erythematosus;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg01114163	chr5:1856713	NA	-0.41	-7.19	-0.32	2.58e-12	Cardiovascular disease risk factors;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02525785	chr17:7117684	DLG4	0.48	7.01	0.31	8.61e-12	Gut microbiome composition (summer);
LGG	cis	rs7463659	0.904	rs4075462	chr8:135462617	T/C	cg09855544	chr8:135498122	ZFAT	-0.47	-8.69	-0.37	6.11e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2071303	0.836	rs198835	chr6:26113994	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.59	-0.41	5.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs357468	chr3:153898560	A/G	cg17054900	chr3:154042577	DHX36	0.88	10.21	0.43	3.42e-22	Coronary artery disease;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg03647317	chr4:187891568	NA	-0.42	-8.86	-0.38	1.79e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg08305652	chr11:111469057	NA	0.43	8.82	0.38	2.3e-17	Primary sclerosing cholangitis;
LGG	cis	rs3008870	1.000	rs3008856	chr1:67387901	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs10819861	0.611	rs10760747	chr9:98851504	A/G	cg14508093	chr9:98862825	NA	-0.28	-6.69	-0.3	6.29e-11	Electrocardiographic traits;
LGG	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.63	0.41	3.97e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12500482	0.935	rs12644638	chr4:2413461	C/T	cg26444097	chr4:2432313	NA	-0.38	-9.87	-0.42	5.46e-21	Cognitive function;
LGG	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.29	-0.55	1.23e-38	Heart rate;
LGG	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	17.47	0.63	7.59e-53	Hip circumference adjusted for BMI;
LGG	cis	rs3099143	1.000	rs2063542	chr15:77149498	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-10.45	-0.44	4.39e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg20991723	chr1:152506922	NA	-0.73	-14.99	-0.57	1.09e-41	Hair morphology;
LGG	trans	rs10838798	0.523	rs4752917	chr11:48241639	A/G	cg03929089	chr4:120376271	NA	-0.48	-7.92	-0.35	1.73e-14	Height;
LGG	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg24253500	chr15:84953950	NA	0.43	7.12	0.31	4.19e-12	Schizophrenia;
LGG	cis	rs11771526	0.901	rs41519845	chr7:32315443	A/T	cg13207630	chr7:32358064	NA	0.7	7.35	0.32	8.76e-13	Body mass index;
LGG	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg03128945	chr5:622914	CEP72	-0.43	-7.1	-0.31	4.81e-12	Obesity-related traits;
LGG	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg12573674	chr2:1569213	NA	-0.61	-9.84	-0.42	7.43e-21	IgG glycosylation;
LGG	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg02158880	chr13:53174818	NA	0.64	14.82	0.57	5.98e-41	Lewy body disease;
LGG	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg06212747	chr3:49208901	KLHDC8B	0.52	8.1	0.35	4.99e-15	Menarche (age at onset);
LGG	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.12	0.31	4.18e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.71e-21	Hypertriglyceridemia;
LGG	cis	rs953387	1.000	rs4954568	chr2:136910690	T/A	cg07169764	chr2:136633963	MCM6	0.54	8.99	0.39	6.49e-18	Arthritis (juvenile idiopathic);
LGG	trans	rs11250097	0.543	rs68164957	chr8:10799489	A/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.65	-0.3	8.18e-11	Neuroticism;
LGG	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12826209	chr6:26865740	GUSBL1	0.57	7.03	0.31	7.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.71	-0.34	7.73e-14	Sudden cardiac arrest;
LGG	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.4	-6.89	-0.31	1.77e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs763121	1.000	rs763121	chr22:38879940	C/T	cg06022373	chr22:39101656	GTPBP1	-0.79	-15.57	-0.59	2.85e-44	Menopause (age at onset);
LGG	cis	rs300774	0.925	rs300740	chr2:164169	G/A	cg04617936	chr2:214353	NA	-0.46	-6.92	-0.31	1.51e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg00919237	chr7:87102261	ABCB4	-0.78	-15.65	-0.59	1.3e-44	Gallbladder cancer;
LGG	cis	rs2444240	0.967	rs470370	chr11:120013984	C/T	cg16005559	chr11:120040616	NA	0.32	7.15	0.32	3.45e-12	Corneal curvature;
LGG	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	12.4	0.5	1.11e-30	Response to antipsychotic treatment;
LGG	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.61e-25	Bone mineral density;
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg11494091	chr17:61959527	GH2	0.56	8.89	0.38	1.35e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg11062466	chr8:58055876	NA	0.53	8.8	0.38	2.64e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg16301924	chr13:53314226	LECT1	-0.46	-9.2	-0.39	1.2e-18	Lewy body disease;
LGG	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11644478	chr21:40555479	PSMG1	-0.73	-13.39	-0.53	8.61e-35	Cognitive function;
LGG	cis	rs12681366	0.734	rs10504936	chr8:95392055	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.77	0.3	3.82e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg10057126	chr4:77819792	ANKRD56	0.36	6.95	0.31	1.26e-11	Emphysema distribution in smoking;
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.36	9.88	0.42	5.1e-21	IgG glycosylation;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg12070911	chr6:150209640	RAET1E	0.28	7.03	0.31	7.38e-12	Testicular germ cell tumor;
LGG	cis	rs977987	0.933	rs1834014	chr16:75501274	G/A	cg03315344	chr16:75512273	CHST6	0.57	11.28	0.46	2.99e-26	Dupuytren's disease;
LGG	cis	rs270601	0.739	rs1979981	chr5:131601720	G/A	cg07395648	chr5:131743802	NA	-0.36	-7.37	-0.32	7.76e-13	Acylcarnitine levels;
LGG	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg20387954	chr3:183756860	HTR3D	0.48	9.28	0.4	6.36e-19	Anterior chamber depth;
LGG	cis	rs1519814	0.696	rs7832657	chr8:121036632	C/T	cg22335954	chr8:121166405	COL14A1	-0.48	-8.82	-0.38	2.43e-17	Breast cancer;
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg13009111	chr11:71350975	NA	-0.32	-7.05	-0.31	6.42e-12	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg15971980	chr6:150254442	NA	0.44	8.26	0.36	1.6e-15	Lung cancer;
LGG	cis	rs11711311	0.712	rs3773683	chr3:113341007	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.2	-0.32	2.39e-12	IgG glycosylation;
LGG	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg00204512	chr16:28754710	NA	0.26	7.06	0.31	6.33e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9938149	0.736	rs6540223	chr16:88321436	A/G	cg05435882	chr16:88311214	NA	0.38	6.69	0.3	6.4e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg19077165	chr18:44547161	KATNAL2	-0.42	-7.01	-0.31	8.73e-12	Educational attainment;
LGG	cis	rs13191362	0.507	rs2023038	chr6:163119280	C/G	cg21926612	chr6:163149169	PACRG;PARK2	-0.62	-8.63	-0.37	1.02e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg15068132	chr12:102092402	CHPT1	-0.37	-6.78	-0.3	3.57e-11	Blood protein levels;
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg16141378	chr3:129829833	LOC729375	0.4	8.91	0.38	1.22e-17	Triglycerides;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg21171335	chr12:122356390	WDR66	0.3	8.58	0.37	1.5e-16	Mean corpuscular volume;
LGG	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.61	-0.41	4.84e-20	Aortic root size;
LGG	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg02002194	chr4:3960332	NA	0.45	8.17	0.35	2.88e-15	Retinal vascular caliber;
LGG	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs477692	1.000	rs7475154	chr10:131440584	C/T	cg05714579	chr10:131428358	MGMT	-0.58	-11.75	-0.48	4.45e-28	Response to temozolomide;
LGG	cis	rs7927771	0.524	rs7932703	chr11:47769936	A/C	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg13628971	chr7:2884303	GNA12	0.55	11.75	0.48	4.37e-28	Height;
LGG	cis	rs2744971	0.507	rs2814950	chr6:34658363	C/A	cg07306190	chr6:34760872	UHRF1BP1	0.45	7.71	0.34	7.55e-14	Height;
LGG	cis	rs2354432	0.607	rs59689207	chr1:146722484	G/A	cg25205988	chr1:146714368	CHD1L	-1.45	-15.1	-0.57	3.61e-42	Mitochondrial DNA levels;
LGG	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs2224391	0.628	rs2773310	chr6:5250828	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.33	-0.32	1.02e-12	Height;
LGG	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg25173405	chr17:45401733	C17orf57	-0.73	-13.0	-0.52	3.75e-33	Glaucoma (primary open-angle);
LGG	cis	rs3813567	0.759	rs7163204	chr15:78953740	G/A	cg05914723	chr15:78953907	NA	0.49	7.02	0.31	8.13e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs7582720	0.943	rs114372659	chr2:203715514	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg08085267	chr17:45401833	C17orf57	0.63	12.95	0.52	5.7e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7246657	0.722	rs2972438	chr19:38210847	A/G	cg23950597	chr19:37808831	NA	-0.54	-7.59	-0.33	1.77e-13	Coronary artery calcification;
LGG	cis	rs7264396	0.580	rs2064511	chr20:34448810	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.49	-6.74	-0.3	4.62e-11	Total cholesterol levels;
LGG	cis	rs778371	0.697	rs11893358	chr2:233636922	T/C	cg08000102	chr2:233561755	GIGYF2	0.73	12.35	0.5	1.68e-30	Schizophrenia;
LGG	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs5762813	0.566	rs28360615	chr22:29338656	G/C	cg15103426	chr22:29168792	CCDC117	0.6	6.97	0.31	1.08e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg14338887	chr6:42928500	GNMT	0.27	8.76	0.38	3.57e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7666738	0.611	rs34982650	chr4:98819530	T/A	cg05340658	chr4:99064831	C4orf37	0.48	7.81	0.34	3.83e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.67	-0.37	7.2e-17	Alcohol dependence;
LGG	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg06028605	chr16:24865363	SLC5A11	0.48	7.63	0.33	1.34e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.3	0.32	1.31e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6121246	0.529	rs56153385	chr20:30187609	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg17467752	chr17:38218738	THRA	-0.45	-7.23	-0.32	2.06e-12	Self-reported allergy;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22215258	chr2:172544429	DYNC1I2	0.38	6.7	0.3	5.88e-11	Bilirubin levels;
LGG	trans	rs7178375	1.000	rs11070678	chr15:31219764	A/G	cg04373760	chr16:53404718	NA	0.56	8.45	0.37	3.84e-16	Hypertriglyceridemia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19478983	chr7:120590592	ING3	-0.51	-7.48	-0.33	3.84e-13	Systemic lupus erythematosus;
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.83	-0.3	2.69e-11	Aortic root size;
LGG	cis	rs9287719	0.967	rs6727768	chr2:10757479	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs503734	0.666	rs7631506	chr3:101242614	A/C	cg27318481	chr3:100970896	IMPG2	0.36	7.26	0.32	1.7e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6831352	0.819	rs13832	chr4:99993075	C/A	cg13256891	chr4:100009986	ADH5	0.51	8.95	0.38	8.42e-18	Alcohol dependence;
LGG	trans	rs36715	1.000	rs2617621	chr5:127546266	A/C	cg16011800	chr17:1958478	HIC1	-0.47	-6.84	-0.3	2.51e-11	Breast cancer;
LGG	cis	rs2540226	0.515	rs2716693	chr2:39895556	A/G	cg02886589	chr2:39892450	TMEM178	0.3	8.52	0.37	2.22e-16	Personality dimensions;
LGG	cis	rs2072499	0.750	rs909269	chr1:156192028	C/T	cg24450063	chr1:156163899	SLC25A44	1.03	17.36	0.63	2.34e-52	Testicular germ cell tumor;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22959961	chr5:138739503	SPATA24	-0.43	-6.94	-0.31	1.32e-11	Pancreatic cancer;
LGG	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg03847636	chr4:7070632	GRPEL1	0.52	6.67	0.3	7.13e-11	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs2880765	0.545	rs11631739	chr15:86012578	T/C	cg19183879	chr15:85880815	NA	-0.5	-9.42	-0.4	2.09e-19	Coronary artery disease;
LGG	cis	rs6430585	0.640	rs58301703	chr2:136532225	G/A	cg07169764	chr2:136633963	MCM6	1.27	24.04	0.75	1.79e-83	Corneal structure;
LGG	cis	rs1318772	0.932	rs348939	chr5:112824737	G/C	cg12552261	chr5:112820674	MCC	-0.67	-7.57	-0.33	2.01e-13	F-cell distribution;
LGG	cis	rs7179456	0.610	rs650366	chr15:59061142	A/G	cg05156742	chr15:59063176	FAM63B	0.6	10.15	0.43	5.32e-22	Asperger disorder;
LGG	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg19980929	chr12:42632907	YAF2	-0.34	-7.81	-0.34	3.76e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.57	-0.47	2.22e-27	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17680792	chr3:23986459	NR1D2	0.42	6.73	0.3	4.9e-11	Gut microbiome composition (summer);
LGG	cis	rs4319547	0.656	rs10773088	chr12:122828069	A/T	cg23029597	chr12:123009494	RSRC2	-0.9	-16.71	-0.61	2.1e-49	Body mass index;
LGG	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg27147174	chr7:100797783	AP1S1	-0.69	-13.14	-0.52	9.73e-34	Life satisfaction;
LGG	cis	rs7737355	0.947	rs3776028	chr5:130789750	G/A	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.9e-19	Life satisfaction;
LGG	cis	rs735539	0.521	rs9315905	chr13:21404969	A/G	cg04906043	chr13:21280425	IL17D	0.45	7.23	0.32	2.06e-12	Dental caries;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.31	0.32	1.21e-12	Schizophrenia;
LGG	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs2072499	0.750	rs2241109	chr1:156173082	C/T	cg24450063	chr1:156163899	SLC25A44	1.06	18.65	0.66	2.52e-58	Testicular germ cell tumor;
LGG	cis	rs7226408	0.857	rs72890514	chr18:34588028	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs7843479	0.524	rs1031884	chr8:21788984	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.02	0.6	2.8600000000000002e-46	Mean corpuscular volume;
LGG	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg26655873	chr3:72818019	SHQ1	0.37	7.52	0.33	2.92e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg05335186	chr13:53173507	NA	0.75	18.66	0.66	2.25e-58	Lewy body disease;
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg10207240	chr12:122356781	WDR66	0.27	8.26	0.36	1.5e-15	Mean corpuscular volume;
LGG	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.0	-0.35	9.92e-15	Triglycerides;
LGG	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-9.97	-0.42	2.48e-21	Morning vs. evening chronotype;
LGG	cis	rs2270450	0.650	rs1862008	chr6:46710279	A/G	cg10156739	chr6:46714674	LOC100287718	-0.49	-10.89	-0.45	9.93e-25	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg05091796	chr16:4465799	CORO7	-0.96	-16.71	-0.61	2.09e-49	Schizophrenia;
LGG	cis	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg19847130	chr8:10466454	RP1L1	0.34	7.24	0.32	1.91e-12	Neuroticism;
LGG	trans	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg20587970	chr11:113659929	NA	-1.42	-24.91	-0.76	1.57e-87	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg08645402	chr16:4508243	NA	0.51	8.88	0.38	1.5e-17	Schizophrenia;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.68	-0.3	6.71e-11	Neuroticism;
LGG	trans	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg16141378	chr3:129829833	LOC729375	0.44	10.49	0.44	2.94e-23	Mood instability;
LGG	cis	rs35740288	0.857	rs11632034	chr15:86284072	C/T	cg07943548	chr15:86304357	KLHL25	-0.35	-6.83	-0.3	2.68e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg17691542	chr6:26056736	HIST1H1C	0.69	11.38	0.47	1.22e-26	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04928693	chr1:155178248	MTX1;THBS3	0.53	8.15	0.35	3.42e-15	Gut microbiome composition (summer);
LGG	cis	rs1983891	0.742	rs6920495	chr6:41554182	A/G	cg20194872	chr6:41519635	FOXP4	0.54	9.17	0.39	1.51e-18	Prostate cancer;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg13880726	chr7:1868755	MAD1L1	0.38	6.69	0.3	6.65e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs55823223	0.504	rs56098714	chr17:73860303	T/C	cg14829360	chr17:73884958	NA	-0.84	-15.39	-0.58	1.79e-43	Psoriasis;
LGG	cis	rs4950322	0.570	rs72691041	chr1:146738743	G/A	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs7219021	0.926	rs12150249	chr17:46852108	A/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.76	-0.3	4.14e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs4478858	0.735	rs6676354	chr1:31800746	A/T	cg19084893	chr1:31688959	NA	0.32	6.8	0.3	3.26e-11	Alcohol dependence;
LGG	cis	rs877282	1.000	rs34257857	chr10:772993	C/A	cg17470449	chr10:769945	NA	0.65	8.35	0.36	8.26e-16	Uric acid levels;
LGG	cis	rs2587949	0.571	rs2600136	chr3:4208947	T/C	cg16519197	chr3:4211558	NA	-0.32	-6.76	-0.3	4.21e-11	Periodontitis (DPAL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02776251	chr12:62654319	USP15	0.45	7.44	0.33	4.86e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.556	rs4665322	chr2:26434605	C/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.2	-0.39	1.25e-18	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.529	rs6058196	chr20:30194714	A/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	trans	rs11039798	0.544	rs114343057	chr11:48558172	C/T	cg15704280	chr7:45808275	SEPT13	0.72	9.97	0.42	2.47e-21	Axial length;
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.93	-0.48	8.81e-29	Alzheimer's disease;
LGG	trans	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg25482853	chr8:67687455	SGK3	0.95	12.0	0.49	4.34e-29	Obesity-related traits;
LGG	cis	rs10875746	0.669	rs10875770	chr12:48600520	A/G	cg24011408	chr12:48396354	COL2A1	-0.56	-7.36	-0.32	8.32e-13	Longevity (90 years and older);
LGG	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.79	0.38	3.05e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg00789671	chr3:195488493	MUC4	0.6	8.59	0.37	1.32e-16	Lung disease severity in cystic fibrosis;
LGG	trans	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.63	0.37	9.89e-17	Mood instability;
LGG	cis	rs988958	0.565	rs4952399	chr2:42289107	A/G	cg27428208	chr2:42229179	NA	-0.42	-8.57	-0.37	1.57e-16	Hypospadias;
LGG	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg18188782	chr20:61659543	NA	0.4	6.78	0.3	3.66e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11098499	0.909	rs28884220	chr4:120307211	A/G	cg24375607	chr4:120327624	NA	0.67	10.9	0.45	8.83e-25	Corneal astigmatism;
LGG	cis	rs611744	0.506	rs13280454	chr8:109263240	A/G	cg18478394	chr8:109455254	TTC35	0.41	8.29	0.36	1.28e-15	Dupuytren's disease;
LGG	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg00405596	chr8:11794950	NA	-0.45	-7.64	-0.33	1.25e-13	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.41	0.4	2.29e-19	Morning vs. evening chronotype;
LGG	cis	rs6462411	1.000	rs2097899	chr7:3912603	A/G	cg18022346	chr7:3920534	SDK1	-0.35	-6.84	-0.3	2.53e-11	Quantitative traits;
LGG	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg05890377	chr2:74357713	NA	0.49	9.3	0.4	5.55e-19	Gestational age at birth (maternal effect);
LGG	cis	rs62283056	0.512	rs752854	chr4:6281961	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.67	0.34	1.03e-13	Cisplatin-induced ototoxicity;
LGG	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg20991723	chr1:152506922	NA	0.7	14.31	0.55	1.02e-38	Hair morphology;
LGG	cis	rs4746059	0.541	rs10999481	chr10:72477417	C/T	cg18679544	chr10:72432482	ADAMTS14	0.51	8.66	0.37	8.05e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9976767	0.608	rs9784208	chr21:43824986	A/G	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.42	-0.53	6.45e-35	Type 1 diabetes;
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg07120314	chr15:79043507	NA	0.72	17.31	0.63	3.75e-52	Coronary artery disease or large artery stroke;
LGG	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg22643751	chr7:855365	UNC84A	0.35	6.67	0.3	7.4e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg22907277	chr7:1156413	C7orf50	0.5	7.44	0.33	5.06e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7444	0.941	rs4821112	chr22:21964761	G/A	cg05046821	chr22:21984468	YDJC	-0.38	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	cis	rs490234	0.841	rs1755936	chr9:128388991	C/G	cg14078157	chr9:128172775	NA	-0.44	-8.17	-0.35	2.98e-15	Mean arterial pressure;
LGG	cis	rs7615952	0.546	rs2979340	chr3:125341384	C/T	cg21696256	chr3:125484277	NA	-0.46	-6.87	-0.3	2.02e-11	Blood pressure (smoking interaction);
LGG	cis	rs11025559	0.773	rs16906274	chr11:20470142	T/C	cg19653624	chr11:20408972	PRMT3	-0.49	-8.06	-0.35	6.57e-15	Pursuit maintenance gain;
LGG	cis	rs7659604	0.846	rs60340409	chr4:122666355	G/C	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.1	-0.31	4.68e-12	Type 2 diabetes;
LGG	cis	rs2764208	0.860	rs205286	chr6:34551334	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.54	-0.44	1.93e-23	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs774359	0.789	rs700795	chr9:27520508	A/G	cg21249376	chr9:27528432	MOBKL2B	0.45	8.47	0.37	3.38e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs1032833	0.732	rs2028906	chr2:180028772	C/T	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs1790761	0.806	rs35787427	chr11:67255877	C/T	cg24690094	chr11:67383802	NA	-0.4	-6.79	-0.3	3.47e-11	Mean corpuscular volume;
LGG	cis	rs7192750	0.501	rs6499542	chr16:71859830	A/T	cg06353428	chr16:71660113	MARVELD3	0.68	10.58	0.44	1.47e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4974559	0.739	rs6599298	chr4:1298122	A/G	cg02980000	chr4:1222292	CTBP1	0.8	9.12	0.39	2.23e-18	Systolic blood pressure;
LGG	trans	rs11875185	0.915	rs17064165	chr18:55626396	G/T	cg15513957	chr14:69354734	ACTN1	0.67	7.54	0.33	2.55e-13	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs910187	0.678	rs1046659	chr20:45817068	G/A	cg27589058	chr20:45804311	EYA2	-0.37	-9.7	-0.41	2.19e-20	Migraine;
LGG	cis	rs6964587	1.000	rs60147309	chr7:91736098	C/G	cg17063962	chr7:91808500	NA	0.5	9.04	0.39	4.45e-18	Breast cancer;
LGG	cis	rs9486719	0.948	rs2472881	chr6:96862562	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg13206674	chr6:150067644	NUP43	-0.41	-7.17	-0.32	3.04e-12	Lung cancer;
LGG	cis	rs897984	0.609	rs4889609	chr16:31026427	A/G	cg02466173	chr16:30829666	NA	-0.44	-7.85	-0.34	2.93e-14	Dementia with Lewy bodies;
LGG	cis	rs6764363	0.587	rs455635	chr3:285316	G/T	cg02057681	chr3:285234	CHL1	0.42	7.68	0.34	9.85e-14	Sudden cardiac arrest;
LGG	trans	rs10242455	0.571	rs11972210	chr7:99206943	A/C	cg09045935	chr12:6379348	NA	0.91	8.14	0.35	3.77e-15	Blood metabolite levels;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg09359103	chr1:154839909	KCNN3	-0.52	-10.74	-0.45	3.59e-24	Prostate cancer;
LGG	cis	rs908922	0.676	rs10888492	chr1:152499908	G/C	cg03606772	chr1:152487856	CRCT1	0.31	7.27	0.32	1.59e-12	Hair morphology;
LGG	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg09201001	chr11:18656081	SPTY2D1	0.99	21.23	0.7	2.26e-70	Breast cancer;
LGG	cis	rs2594989	0.836	rs347607	chr3:11268021	A/C	cg00170343	chr3:11313890	ATG7	-0.54	-6.75	-0.3	4.46e-11	Circulating chemerin levels;
LGG	cis	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg08975724	chr8:8085496	FLJ10661	0.42	8.1	0.35	4.8e-15	Neuroticism;
LGG	cis	rs11169552	0.510	rs10783372	chr12:50952524	C/A	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.68e-14	Colorectal cancer;
LGG	trans	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.07	0.42	1.07e-21	Metabolite levels;
LGG	cis	rs3126085	0.935	rs41267154	chr1:152286367	C/A	cg26876637	chr1:152193138	HRNR	-0.51	-8.02	-0.35	8.96e-15	Atopic dermatitis;
LGG	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.46	-0.33	4.45e-13	Height;
LGG	trans	rs8002861	0.875	rs12869697	chr13:44439169	T/C	cg12856521	chr11:46389249	DGKZ	-0.4	-6.79	-0.3	3.48e-11	Leprosy;
LGG	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg18198730	chr1:247681584	NA	0.7	12.35	0.5	1.78e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Gut microbiome composition (summer);
LGG	cis	rs7587476	0.784	rs36086595	chr2:215680293	A/G	cg04004882	chr2:215674386	BARD1	0.54	7.8	0.34	4.02e-14	Neuroblastoma;
LGG	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.67	-0.44	6.34e-24	Primary sclerosing cholangitis;
LGG	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg19183879	chr15:85880815	NA	-0.49	-9.29	-0.4	6e-19	Coronary artery disease;
LGG	cis	rs7639513	0.545	rs55977822	chr3:12704438	C/A	cg23032965	chr3:12705835	RAF1	0.7	10.98	0.45	4.43e-25	Itch intensity from mosquito bite;
LGG	cis	rs1497828	1.000	rs1497828	chr1:217527024	C/G	cg04411442	chr1:217543379	NA	0.46	7.98	0.35	1.13e-14	Dialysis-related mortality;
LGG	cis	rs7927771	0.524	rs7107792	chr11:47669249	A/C	cg20307385	chr11:47447363	PSMC3	0.55	10.77	0.45	2.8e-24	Subjective well-being;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.38	-0.4	2.95e-19	Lung cancer;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg21724239	chr8:58056113	NA	0.5	7.6	0.33	1.62e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.37	-7.1	-0.31	4.66e-12	Educational attainment;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7177699	0.557	rs4389113	chr15:79121739	G/A	cg00540400	chr15:79124168	NA	-0.54	-11.32	-0.47	2.06e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg00564723	chr10:75632066	CAMK2G	-0.3	-6.84	-0.3	2.52e-11	Inflammatory bowel disease;
LGG	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg19847130	chr8:10466454	RP1L1	0.33	7.05	0.31	6.35e-12	Neuroticism;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	13.3	0.53	2.09e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.35	-0.32	8.9e-13	Life satisfaction;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg11814155	chr7:99998594	ZCWPW1	0.58	9.03	0.39	4.64e-18	Platelet count;
LGG	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.71	-0.3	5.79e-11	Neuroticism;
LGG	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.65	0.54	7.06e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.42	0.65	3.02e-57	Platelet count;
LGG	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg00319359	chr11:70116639	PPFIA1	0.74	8.11	0.35	4.55e-15	Coronary artery disease;
LGG	cis	rs4273100	0.526	rs2074280	chr17:18917915	A/G	cg25447019	chr17:19030144	GRAPL	-0.59	-8.54	-0.37	1.89e-16	Schizophrenia;
LGG	cis	rs2594989	0.887	rs2442799	chr3:11488640	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.26	-0.32	1.64e-12	Circulating chemerin levels;
LGG	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs754466	1.000	rs12220328	chr10:79681482	G/C	cg17075019	chr10:79541650	NA	-0.81	-13.8	-0.54	1.57e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg01620082	chr3:125678407	NA	-0.82	-8.97	-0.38	7.13e-18	Depression;
LGG	cis	rs2117029	0.586	rs7954521	chr12:49545640	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.84	0.51	1.73e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg23933602	chr10:16859644	RSU1	1.01	25.18	0.76	9.3e-89	Platelet distribution width;
LGG	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg00666640	chr1:248458726	OR2T12	-0.59	-9.59	-0.41	5.38e-20	Common traits (Other);
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.82	-0.3	2.84e-11	Prostate cancer;
LGG	cis	rs12493885	0.725	rs11718646	chr3:153741996	C/T	cg12800244	chr3:153838788	SGEF	-0.78	-8.78	-0.38	3.27e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg08645402	chr16:4508243	NA	0.48	8.91	0.38	1.15e-17	Schizophrenia;
LGG	trans	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.95	0.35	1.46e-14	Obesity-related traits;
LGG	cis	rs2273669	0.667	rs117412830	chr6:109336617	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs1021993	0.545	rs4844820	chr1:209554465	G/A	cg24446417	chr1:209558027	NA	-0.75	-11.42	-0.47	9.1e-27	Gut microbiome composition (winter);
LGG	cis	rs6735179	0.529	rs1364648	chr2:1754932	A/G	cg10160682	chr2:1713001	PXDN	0.5	8.6	0.37	1.21e-16	Response to antipsychotic treatment;
LGG	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg27279351	chr12:120934652	DYNLL1	0.77	12.19	0.49	7.62e-30	High light scatter reticulocyte count;
LGG	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg27165867	chr14:105738592	BRF1	-0.45	-7.16	-0.32	3.18e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1577917	0.816	rs9353349	chr6:86707725	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	11.44	0.47	7.07e-27	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg15971980	chr6:150254442	NA	0.46	8.71	0.38	5.28e-17	Lung cancer;
LGG	trans	rs4714291	0.963	rs1923489	chr6:40023088	T/C	cg02267698	chr19:7991119	CTXN1	0.59	9.09	0.39	2.87e-18	Strep throat;
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg22168489	chr12:122356033	WDR66	-0.39	-9.25	-0.39	8.49e-19	Mean corpuscular volume;
LGG	trans	rs3812049	0.784	rs2568928	chr5:127487603	C/T	cg16011800	chr17:1958478	HIC1	0.65	9.79	0.41	1.08e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs2797369	0.713	rs4432986	chr6:101504022	T/C	cg27451362	chr6:101846650	GRIK2	-0.85	-11.39	-0.47	1.19e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs1451375	0.652	rs7803788	chr7:50625898	A/G	cg20336341	chr7:50628841	DDC	-0.52	-9.54	-0.41	8.37e-20	Malaria;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.53	0.33	2.69e-13	Schizophrenia;
LGG	cis	rs1793639	1.000	rs1793639	chr11:131931531	G/A	cg13908476	chr11:131942942	NTM	0.45	9.27	0.4	6.98e-19	Myopia;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.74	0.38	4.42e-17	Lung cancer;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.23	0.39	9.52e-19	Lung cancer;
LGG	cis	rs727505	1.000	rs720613	chr7:124452670	C/T	cg23710748	chr7:124431027	NA	-0.5	-9.53	-0.4	9.12e-20	Lewy body disease;
LGG	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg25919922	chr13:100150906	NA	-0.74	-7.6	-0.33	1.69e-13	Obesity-related traits;
LGG	cis	rs548181	1.000	rs548181	chr11:125461709	A/G	cg03464685	chr11:125439445	EI24	1.3	19.56	0.67	1.58e-62	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9811920	0.609	rs704583	chr3:99643693	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs6735179	0.837	rs6745451	chr2:1776761	C/T	cg10160682	chr2:1713001	PXDN	-0.47	-7.49	-0.33	3.55e-13	Response to antipsychotic treatment;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.32	0.32	1.09e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg08822215	chr16:89438651	ANKRD11	-0.35	-6.79	-0.3	3.53e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs8067545	0.640	rs10083840	chr17:19965972	A/G	cg13482628	chr17:19912719	NA	0.58	10.85	0.45	1.32e-24	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12589749	chr1:54304061	TMEM48	0.45	6.96	0.31	1.18e-11	Gut microbiome composition (summer);
LGG	cis	rs7712401	0.601	rs154506	chr5:122202781	A/G	cg19412675	chr5:122181750	SNX24	0.41	6.73	0.3	4.94e-11	Mean platelet volume;
LGG	cis	rs4819852	0.958	rs2238784	chr22:19972559	G/A	cg07821417	chr22:19972146	ARVCF	0.61	12.9	0.51	9.46e-33	Pulse pressure;
LGG	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Myopia (pathological);
LGG	cis	rs9911578	0.935	rs420878	chr17:56709077	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7572263	0.528	rs6731295	chr2:209071327	G/A	cg00164906	chr2:209055251	C2orf80	-0.5	-7.78	-0.34	4.87e-14	Glioma;Non-glioblastoma glioma;
LGG	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.2e-12	HDL cholesterol;
LGG	cis	rs3806843	0.933	rs2337987	chr5:140188383	T/G	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02463440	chr8:22132932	PIWIL2	0.49	10.96	0.45	5.41e-25	Hypertriglyceridemia;
LGG	cis	rs11690935	0.632	rs6433323	chr2:172873060	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.72	-14.74	-0.57	1.33e-40	Schizophrenia;
LGG	cis	rs13314892	0.881	rs55947901	chr3:69832377	A/C	cg17445875	chr3:69859618	MITF	-0.36	-7.39	-0.32	6.93e-13	QRS complex (12-leadsum);
LGG	cis	rs12497850	0.864	rs7431857	chr3:48900347	G/A	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12200560	0.505	rs11153095	chr6:97078592	T/C	cg06623918	chr6:96969491	KIAA0776	-0.44	-7.4	-0.33	6.34e-13	Coronary heart disease;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.55e-20	Prudent dietary pattern;
LGG	trans	rs2562456	0.833	rs2562507	chr19:21726337	C/T	cg25042112	chr7:64838748	ZNF92	0.46	6.67	0.3	7.35e-11	Pain;
LGG	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg14829360	chr17:73884958	NA	0.69	13.05	0.52	2.23e-33	Psoriasis;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg06925179	chr17:43578568	NA	0.41	9.63	0.41	4.1e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9926296	0.656	rs7191144	chr16:89823393	C/T	cg23057051	chr16:89984268	MC1R	-0.36	-6.84	-0.3	2.55e-11	Vitiligo;
LGG	cis	rs1256531	0.661	rs7154876	chr14:66164800	C/T	cg15999311	chr14:65749247	NA	0.83	6.97	0.31	1.09e-11	Conduct disorder (symptom count);
LGG	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.64	-0.37	9.33e-17	Mood instability;
LGG	cis	rs7301826	0.557	rs7953184	chr12:131284852	T/G	cg11011512	chr12:131303247	STX2	-0.41	-8.77	-0.38	3.43e-17	Plasma plasminogen activator levels;
LGG	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg03806693	chr22:41940476	POLR3H	-1.04	-17.63	-0.63	1.39e-53	Vitiligo;
LGG	cis	rs727505	0.954	rs67146030	chr7:124561790	T/G	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01835742	chr2:201728833	CLK1	0.46	7.12	0.31	4.23e-12	Gut microbiome composition (summer);
LGG	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg23461800	chr14:103021989	NA	-0.56	-9.84	-0.42	6.85e-21	Platelet count;
LGG	cis	rs9291683	0.509	rs6849717	chr4:9958719	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.6	-0.33	1.72e-13	Bone mineral density;
LGG	cis	rs11758351	0.500	rs76607472	chr6:26191557	C/T	cg23601095	chr6:26197514	HIST1H3D	0.89	6.75	0.3	4.55e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg26597838	chr10:835615	NA	-0.54	-7.16	-0.32	3.19e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg02187348	chr16:89574699	SPG7	0.58	9.71	0.41	2.07e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08280861	chr8:58055591	NA	0.64	7.83	0.34	3.37e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.641	rs12532953	chr7:106865920	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-10.98	-0.45	4.42e-25	Coronary artery disease;
LGG	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg26875233	chr11:93583750	C11orf90	-0.43	-8.26	-0.36	1.58e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.47	-0.37	3.26e-16	Primary sclerosing cholangitis;
LGG	cis	rs6066825	0.644	rs6019393	chr20:47334435	G/C	cg18078177	chr20:47281410	PREX1	0.47	7.83	0.34	3.27e-14	Colorectal cancer;
LGG	trans	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs4819052	0.851	rs2330011	chr21:46658498	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.17	0.35	2.96e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.18	-0.43	4.32e-22	Total body bone mineral density;
LGG	cis	rs920590	0.758	rs7011322	chr8:19661937	C/T	cg01411142	chr8:19674711	INTS10	0.46	7.31	0.32	1.2e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9457247	1.000	rs400176	chr6:167406238	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg03517284	chr6:25882590	NA	-0.45	-7.3	-0.32	1.22e-12	Iron status biomarkers;
LGG	cis	rs1577917	0.958	rs66807489	chr6:86440702	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.42	-0.5	9.3e-31	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg23625390	chr15:77176239	SCAPER	-0.69	-13.43	-0.53	5.76e-35	Blood metabolite levels;
LGG	cis	rs6120849	0.707	rs6088690	chr20:33633326	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.67	0.3	7.23e-11	Protein C levels;
LGG	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2070677	0.935	rs11101869	chr10:135400631	C/T	cg20169779	chr10:135381914	SYCE1	-0.99	-13.1	-0.52	1.36e-33	Gout;
LGG	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg27624424	chr6:160112604	SOD2	0.65	9.26	0.4	7.67e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg18187862	chr3:45730750	SACM1L	0.66	11.0	0.46	3.68e-25	Primary sclerosing cholangitis;
LGG	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.51	-0.33	2.98e-13	Obesity;
LGG	cis	rs27434	0.607	rs34750	chr5:96142806	G/C	cg16492584	chr5:96139282	ERAP1	-0.35	-6.97	-0.31	1.12e-11	Ankylosing spondylitis;
LGG	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs8062405	0.755	rs62034325	chr16:28538640	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.03	0.42	1.54e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs6724607	0.905	rs7603849	chr2:191438741	A/C	cg21644426	chr2:191273491	MFSD6	0.6	10.38	0.43	7.61e-23	Pulse pressure;
LGG	cis	rs9549367	0.713	rs11620600	chr13:113829090	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-10.1	-0.42	8.41e-22	Platelet distribution width;
LGG	cis	rs4804815	0.780	rs75533704	chr19:7840557	G/T	cg00371453	chr19:7854482	CLEC4GP1	0.71	10.69	0.44	5.68e-24	Neutrophil count;
LGG	cis	rs7551222	0.752	rs4252687	chr1:204497335	G/C	cg20240347	chr1:204465584	NA	-0.55	-11.12	-0.46	1.25e-25	Schizophrenia;
LGG	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg05368731	chr17:41323189	NBR1	0.97	18.98	0.66	7.56e-60	Menopause (age at onset);
LGG	trans	rs11650494	0.908	rs77338752	chr17:47372328	A/C	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.66e-12	Prostate cancer;
LGG	cis	rs9355610	0.927	rs2757041	chr6:167370532	C/G	cg18261144	chr6:167370276	RNASET2	-0.38	-7.62	-0.33	1.42e-13	Graves' disease;
LGG	cis	rs611744	0.631	rs681963	chr8:109255032	C/A	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.71	0.34	7.8500000000000006e-14	Morning vs. evening chronotype;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg18446336	chr7:2847575	GNA12	-0.3	-7.14	-0.32	3.53e-12	Height;
LGG	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg13482628	chr17:19912719	NA	-0.54	-10.17	-0.43	4.7e-22	Schizophrenia;
LGG	cis	rs10861342	0.892	rs77479670	chr12:105516631	C/T	cg23923672	chr12:105501055	KIAA1033	0.78	7.01	0.31	8.28e-12	IgG glycosylation;
LGG	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.47e-11	Dupuytren's disease;
LGG	cis	rs208520	0.690	rs207107	chr6:66794385	T/C	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-14.01	-0.55	1.92e-37	Neuroticism;
LGG	cis	rs977987	0.806	rs4888389	chr16:75395228	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs3820928	0.874	rs4675133	chr2:227843010	A/G	cg11843606	chr2:227700838	RHBDD1	0.46	7.79	0.34	4.44e-14	Pulmonary function;
LGG	cis	rs972578	1.000	rs4822247	chr22:43403290	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.89	-0.31	1.8e-11	Mean platelet volume;
LGG	cis	rs727505	0.754	rs55859595	chr7:124783083	G/T	cg23710748	chr7:124431027	NA	-0.44	-8.58	-0.37	1.47e-16	Lewy body disease;
LGG	trans	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg23758822	chr17:41437982	NA	0.87	15.47	0.58	7.84e-44	Menopause (age at onset);
LGG	cis	rs6977660	0.714	rs728156	chr7:19826309	G/C	cg05791153	chr7:19748676	TWISTNB	0.76	10.06	0.42	1.15e-21	Thyroid stimulating hormone;
LGG	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg02002194	chr4:3960332	NA	0.46	8.28	0.36	1.37e-15	Retinal vascular caliber;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21862992	chr11:68658383	NA	0.52	8.44	0.37	4.03e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs721399	0.539	rs12676857	chr8:18266572	T/C	cg18736775	chr8:18248649	NAT2	-0.76	-11.72	-0.48	6.07e-28	Blood metabolite levels;
LGG	trans	rs62458065	0.513	rs9655340	chr7:32535920	A/G	cg00845942	chr12:64062724	DPY19L2	0.58	7.66	0.34	1.09e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.83	-0.3	2.76e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	13.62	0.53	9.22e-36	Cognitive test performance;
LGG	cis	rs9463078	0.764	rs3799971	chr6:44819319	G/C	cg25276700	chr6:44698697	NA	-0.41	-8.63	-0.37	1.01e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs3806843	0.900	rs3756334	chr5:140213796	G/A	cg19875535	chr5:140030758	IK	0.5	10.22	0.43	3.01e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2404602	0.647	rs3812909	chr15:77176200	A/T	cg15268244	chr15:77196840	NA	0.48	10.26	0.43	2.07e-22	Blood metabolite levels;
LGG	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs1461503	0.534	rs4293127	chr11:122804263	G/C	cg27398637	chr11:122830231	C11orf63	-0.62	-12.18	-0.49	8.57e-30	Menarche (age at onset);
LGG	cis	rs8072100	0.840	rs12452796	chr17:45479733	G/T	cg25173405	chr17:45401733	C17orf57	0.49	8.53	0.37	2.11e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26304141	chr20:30865424	KIF3B	0.43	6.69	0.3	6.28e-11	Gut microbiome composition (summer);
LGG	cis	rs7814319	0.674	rs7836698	chr8:97242849	C/T	cg20787634	chr8:97240163	UQCRB	-0.67	-13.65	-0.54	6.71e-36	Lung function (FVC);
LGG	trans	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.56	-0.37	1.65e-16	Neuroticism;
LGG	cis	rs151997	0.962	rs27714	chr5:50180396	G/C	cg06027927	chr5:50259733	NA	0.68	11.16	0.46	8.97e-26	Callous-unemotional behaviour;
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg18402987	chr7:1209562	NA	0.64	7.08	0.31	5.46e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs61906588	0.628	rs7948548	chr11:116360293	A/G	cg12564567	chr11:116371188	NA	0.37	6.88	0.3	1.93e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs7605378	1.000	rs2346662	chr2:200679158	C/T	cg23649088	chr2:200775458	C2orf69	0.53	9.0	0.39	5.81e-18	Osteoporosis;
LGG	cis	rs1018836	0.851	rs7004287	chr8:91620842	G/C	cg16814680	chr8:91681699	NA	-0.84	-16.17	-0.6	6.13e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg23649088	chr2:200775458	C2orf69	0.8	16.31	0.6	1.43e-47	Osteoporosis;
LGG	cis	rs4684776	1.000	rs13092966	chr3:11448232	C/T	cg24705426	chr3:11550659	ATG7	-0.41	-7.45	-0.33	4.66e-13	Small vessel stroke;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.49	8.97	0.38	7.62e-18	Obesity-related traits;
LGG	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs745080	0.674	rs2168823	chr14:53027908	C/T	cg23333723	chr14:53022898	GPR137C	-0.29	-6.84	-0.3	2.57e-11	Orofacial clefts;
LGG	cis	rs6708331	0.517	rs6743372	chr2:70352640	G/T	cg01613454	chr2:70366299	NA	0.55	10.91	0.45	7.8e-25	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg23302884	chr18:44338147	ST8SIA5	0.48	9.8	0.41	1.02e-20	Personality dimensions;
LGG	cis	rs10744422	0.800	rs1696320	chr12:123269814	A/G	cg25930673	chr12:123319894	HIP1R	-0.68	-8.12	-0.35	4.29e-15	Schizophrenia;
LGG	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg11502198	chr6:26597334	ABT1	-0.91	-7.65	-0.33	1.2e-13	Small cell lung carcinoma;
LGG	cis	rs2694528	0.800	rs158696	chr5:60330171	C/A	cg11474532	chr5:59995715	DEPDC1B	-0.68	-7.28	-0.32	1.43e-12	Parkinson's disease;
LGG	cis	rs3126085	0.877	rs7537633	chr1:152223333	T/G	cg26876637	chr1:152193138	HRNR	0.55	8.98	0.39	6.85e-18	Atopic dermatitis;
LGG	cis	rs7192380	0.825	rs3811348	chr16:69782855	C/T	cg00738113	chr16:70207722	CLEC18C	0.31	8.94	0.38	9.68e-18	Sjögren's syndrome;
LGG	cis	rs9354308	0.727	rs2351720	chr6:66602762	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.57	-0.33	2.01e-13	Neuroticism;
LGG	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.74	0.51	4.35e-32	Alzheimer's disease;
LGG	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.64	-9.57	-0.41	6.6e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3806843	0.735	rs813897	chr5:140070029	T/C	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs561341	1.000	rs7210970	chr17:30262169	G/A	cg00745463	chr17:30367425	LRRC37B	-0.59	-8.49	-0.37	2.89e-16	Hip circumference adjusted for BMI;
LGG	cis	rs16944613	0.541	rs13313427	chr15:91090768	G/A	cg26821196	chr15:91095069	CRTC3	0.58	8.79	0.38	2.97e-17	Colorectal cancer;
LGG	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg12439423	chr8:41522721	ANK1	0.46	8.56	0.37	1.69e-16	Type 2 diabetes;
LGG	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.42	6.84	0.3	2.48e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.13e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg12705353	chr12:122356852	WDR66	0.24	6.75	0.3	4.49e-11	Mean corpuscular volume;
LGG	cis	rs72772090	0.539	rs10515247	chr5:96111726	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.6	-9.17	-0.39	1.57e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg04995300	chr3:66848608	NA	0.52	7.59	0.33	1.77e-13	Type 2 diabetes;
LGG	trans	rs11875185	0.510	rs17754594	chr18:55605457	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.79	-0.38	3.01e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.89	0.34	2.16e-14	Personality dimensions;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs4474465	0.850	rs11237546	chr11:78266924	T/C	cg02023728	chr11:77925099	USP35	-0.38	-6.83	-0.3	2.7e-11	Alzheimer's disease (survival time);
LGG	cis	rs4589502	0.512	rs7183242	chr15:67096658	A/G	cg09911534	chr15:67153556	NA	-0.45	-7.35	-0.32	8.79e-13	Lung cancer (smoking interaction);
LGG	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs380904	0.519	rs10102146	chr8:144649156	G/A	cg21643262	chr8:144646939	NA	0.53	7.92	0.35	1.75e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1707322	1.000	rs11211243	chr1:46455433	G/C	cg03146154	chr1:46216737	IPP	0.53	9.95	0.42	2.96e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	cis	rs11122272	0.637	rs2808593	chr1:231524228	G/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs11644362	0.966	rs35678048	chr16:12989235	A/G	cg08528231	chr16:12997261	SHISA9	-0.36	-7.31	-0.32	1.16e-12	Positive affect;Subjective well-being;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14414971	chr7:3340979	SDK1	0.46	7.91	0.35	1.91e-14	Menarche (age at onset);
LGG	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	10.05	0.42	1.26e-21	Lung cancer in ever smokers;
LGG	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg01324343	chr3:183735012	ABCC5	0.87	18.07	0.64	1.2e-55	Anterior chamber depth;
LGG	cis	rs17401966	0.838	rs946501	chr1:10309580	C/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.45	-0.44	4.2e-23	Hepatocellular carcinoma;
LGG	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.74	0.34	6.28e-14	Homoarginine levels;
LGG	cis	rs2298450	0.550	rs9977284	chr21:37654627	T/A	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.88	-0.38	1.43e-17	Schizophrenia;
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs55665837	0.520	rs10766189	chr11:14733923	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.4	-0.33	6.41e-13	Vitamin D levels;
LGG	cis	rs3087591	0.659	rs2214538	chr17:29636570	C/T	cg24425628	chr17:29625626	OMG;NF1	0.59	12.29	0.5	2.94e-30	Hip circumference;
LGG	cis	rs774359	0.830	rs2814707	chr9:27536397	C/T	cg14173147	chr9:27528300	MOBKL2B	0.46	8.69	0.37	6.23e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.86	-0.45	1.28e-24	Alzheimer's disease;
LGG	cis	rs10262624	0.935	rs4722283	chr7:23906214	C/G	cg09690326	chr7:23720549	C7orf46	0.33	6.9	0.31	1.76e-11	Schizophrenia;
LGG	cis	rs7192750	0.586	rs8050488	chr16:71911470	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg24623649	chr8:11872141	NA	-0.3	-7.03	-0.31	7.31e-12	Retinal vascular caliber;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg27286069	chr11:118481882	PHLDB1	0.51	9.3	0.4	5.41e-19	Cholesterol, total;
LGG	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg15017067	chr4:17643749	FAM184B	0.31	7.3	0.32	1.3e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg07636037	chr3:49044803	WDR6	0.95	20.32	0.69	4.23e-66	Menarche (age at onset);
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.36	-0.32	8.33e-13	Longevity;Endometriosis;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06500355	chr6:111804104	REV3L	-0.5	-8.41	-0.36	5.25e-16	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs11722228	0.549	rs73212863	chr4:10104173	C/T	cg26043149	chr18:55253948	FECH	0.95	16.33	0.6	1.16e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg07414643	chr4:187882934	NA	0.56	11.66	0.48	9.82e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17092148	0.887	rs2144956	chr20:33145868	G/A	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.79	-0.3	3.38e-11	Neuroticism;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg02711726	chr17:80685570	FN3KRP	-0.47	-8.32	-0.36	9.98e-16	Glycated hemoglobin levels;
LGG	cis	rs9325144	0.748	rs1523121	chr12:39209652	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-9.19	-0.39	1.3e-18	Morning vs. evening chronotype;
LGG	cis	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg24110177	chr3:50126178	RBM5	-0.41	-7.0	-0.31	9.09e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	23.99	0.74	2.91e-83	IgG glycosylation;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg12070911	chr6:150209640	RAET1E	0.33	8.19	0.36	2.52e-15	Lung cancer;
LGG	cis	rs9303401	0.659	rs34382037	chr17:56643550	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg09307838	chr4:120376055	NA	0.79	13.13	0.52	1.07e-33	Corneal astigmatism;
LGG	cis	rs7666738	0.830	rs28618180	chr4:98912184	A/C	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2463822	1.000	rs1881534	chr11:62085083	A/G	cg06239285	chr11:62104954	ASRGL1	1.17	15.93	0.59	7.32e-46	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs8180040	0.903	rs7636423	chr3:47309134	C/G	cg16586182	chr3:47516702	SCAP	-0.79	-15.44	-0.58	1.09e-43	Colorectal cancer;
LGG	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.3	-0.58	4.59e-43	Chronic sinus infection;
LGG	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg25019033	chr10:957182	NA	-0.5	-8.33	-0.36	9.35e-16	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16140913	chr4:8430389	ACOX3	0.51	7.9	0.34	2.02e-14	Gut microbiome composition (summer);
LGG	cis	rs2013441	1.000	rs9900166	chr17:20192969	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6e-11	Obesity-related traits;
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg11984989	chr7:158649758	WDR60	1.05	23.03	0.73	9.34e-79	Height;
LGG	cis	rs4926611	0.863	rs7527338	chr1:54077731	C/T	cg23596471	chr1:54105337	GLIS1	0.42	8.23	0.36	1.92e-15	Hand grip strength;
LGG	cis	rs6956675	1.000	rs10280052	chr7:62600311	C/T	cg08930214	chr7:62859557	LOC100287834	0.46	7.47	0.33	4.04e-13	Obesity-related traits;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg03188948	chr7:1209495	NA	0.64	8.39	0.36	5.95e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7027203	0.964	rs7853688	chr9:96523254	C/A	cg14598338	chr9:96623480	NA	0.48	8.22	0.36	2.12e-15	DNA methylation (variation);
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg24250549	chr1:154909240	PMVK	0.75	15.04	0.57	6.81e-42	Prostate cancer;
LGG	cis	rs7444	0.883	rs7445	chr22:21977047	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.78	-0.3	3.77e-11	Systemic lupus erythematosus;
LGG	cis	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg07274523	chr3:49395745	GPX1	0.58	9.79	0.41	1.11e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg13206674	chr6:150067644	NUP43	0.61	13.56	0.53	1.6e-35	Lung cancer;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08677398	chr8:58056175	NA	0.47	7.76	0.34	5.6e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2688419	0.565	rs1094607	chr3:23062581	C/A	cg00327796	chr3:23032191	NA	-0.35	-6.79	-0.3	3.53e-11	Type 2 diabetes;
LGG	trans	rs6825911	0.597	rs6533514	chr4:111337840	A/G	cg10580549	chr19:53101634	ZNF137	0.52	6.88	0.3	1.9e-11	Blood pressure;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg04267008	chr7:1944627	MAD1L1	-0.56	-8.9	-0.38	1.27e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.78	-0.48	3.31e-28	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg18681998	chr4:17616180	MED28	0.82	18.24	0.65	2.06e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg19643841	chr6:79944399	HMGN3	0.4	7.12	0.31	4.24e-12	Eye color traits;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg06654118	chr4:1303317	MAEA	0.46	8.15	0.35	3.47e-15	Obesity-related traits;
LGG	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg01557791	chr16:72042693	DHODH	-0.46	-8.4	-0.36	5.51e-16	Fibrinogen levels;
LGG	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.24	0.36	1.74e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.8	0.54	1.52e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1862618	0.802	rs832560	chr5:56124423	T/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.94	-0.35	1.58e-14	Initial pursuit acceleration;
LGG	cis	rs7781557	0.640	rs73192025	chr7:102591489	T/C	cg18108683	chr7:102477205	FBXL13	-0.54	-7.99	-0.35	1.09e-14	Colorectal adenoma (advanced);
LGG	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.2	-0.43	3.6e-22	Glycated hemoglobin levels;
LGG	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg22120825	chr2:201024476	NA	0.51	6.74	0.3	4.59e-11	Schizophrenia;
LGG	cis	rs7765175	0.698	rs1074617	chr6:113667707	G/A	cg26552650	chr6:113682475	NA	0.32	7.2	0.32	2.42e-12	Coronary artery calcification;
LGG	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs883565	0.771	rs3736573	chr3:39129742	A/C	cg01426195	chr3:39028469	NA	-0.66	-13.48	-0.53	3.49e-35	Handedness;
LGG	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg20568497	chr10:133558893	NA	0.35	7.37	0.32	7.77e-13	Survival in rectal cancer;
LGG	cis	rs9329289	0.610	rs10903783	chr10:2540623	C/T	cg15501526	chr10:2543763	NA	0.46	8.91	0.38	1.19e-17	Age-related hearing impairment;
LGG	cis	rs9381040	0.610	rs6941090	chr6:41043465	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.68	-0.3	6.83e-11	Alzheimer's disease (late onset);
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.74	0.34	6.48e-14	Schizophrenia;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.65	-0.41	3.3e-20	Life satisfaction;
LGG	cis	rs9581857	0.685	rs9319372	chr13:28042796	C/T	cg01674679	chr13:27998804	GTF3A	0.66	7.71	0.34	7.73e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg06521331	chr12:34319734	NA	-0.4	-6.92	-0.31	1.49e-11	Morning vs. evening chronotype;
LGG	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	cis	rs6831352	0.918	rs2851251	chr4:100044111	A/G	cg12011299	chr4:100065546	ADH4	0.42	8.33	0.36	9.27e-16	Alcohol dependence;
LGG	cis	rs4665809	1.000	rs2891490	chr2:26325927	T/C	cg22920501	chr2:26401640	FAM59B	-0.39	-7.83	-0.34	3.47e-14	Gut microbiome composition (summer);
LGG	cis	rs3806843	0.735	rs801185	chr5:140068869	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg12473912	chr3:136751656	NA	0.53	9.4	0.4	2.6e-19	Neuroticism;
LGG	cis	rs250677	1.000	rs36069	chr5:148417253	G/C	cg18129178	chr5:148520854	ABLIM3	-0.41	-7.27	-0.32	1.51e-12	Breast cancer;
LGG	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17691542	chr6:26056736	HIST1H1C	1.13	18.5	0.65	1.31e-57	Iron status biomarkers;
LGG	cis	rs1003719	0.788	rs2835586	chr21:38461326	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs16854884	0.586	rs6782789	chr3:143746691	G/A	cg06585982	chr3:143692056	C3orf58	0.68	12.34	0.5	1.84e-30	Economic and political preferences (feminism/equality);
LGG	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.7	0.34	8.11e-14	Rheumatoid arthritis;
LGG	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg22517653	chr1:2918612	NA	-0.43	-6.87	-0.3	2.02e-11	Plateletcrit;
LGG	cis	rs9815354	0.812	rs60659106	chr3:41949569	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg06521331	chr12:34319734	NA	-0.44	-7.74	-0.34	6.32e-14	Heart rate;
LGG	cis	rs2346177	0.874	rs4953372	chr2:46651624	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.46	-7.99	-0.35	1.05e-14	HDL cholesterol;
LGG	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg26384229	chr12:38710491	ALG10B	0.79	15.7	0.59	7.53e-45	Morning vs. evening chronotype;
LGG	trans	rs1005277	0.522	rs1208684	chr10:38093936	G/A	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.94	-0.42	3.12e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.26	0.32	1.63e-12	Electroencephalogram traits;
LGG	cis	rs11514810	1.000	rs7812242	chr7:1431747	C/T	cg22426938	chr7:1423890	NA	-0.66	-8.3	-0.36	1.17e-15	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs8135665	0.600	rs3026685	chr22:38462680	C/T	cg13116946	chr22:38479732	SLC16A8	0.53	8.32	0.36	1.02e-15	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs17767392	0.958	rs34469007	chr14:71916923	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.03	-0.39	4.58e-18	Mitral valve prolapse;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg23758822	chr17:41437982	NA	0.87	15.4	0.58	1.61e-43	Menopause (age at onset);
LGG	cis	rs7267979	1.000	rs2482930	chr20:25334115	G/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.87e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1728785	0.901	rs1170437	chr16:68607943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.49	0.44	3.12e-23	Ulcerative colitis;
LGG	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.36	-0.5	1.61e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4950322	0.570	rs4950404	chr1:146791552	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs2290416	0.892	rs61652493	chr8:144669164	G/A	cg16316162	chr8:144660157	NAPRT1	0.75	6.78	0.3	3.66e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg05793240	chr7:2802953	GNA12	0.34	7.5	0.33	3.22e-13	Height;
LGG	cis	rs9547996	0.879	rs2209230	chr13:38187158	A/G	cg13634560	chr13:38173852	POSTN	-0.34	-6.75	-0.3	4.4e-11	Diastolic blood pressure;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg06558623	chr16:89946397	TCF25	0.9	11.73	0.48	5.47e-28	Skin colour saturation;
LGG	cis	rs787274	0.557	rs2147646	chr9:115669173	C/G	cg13803584	chr9:115635662	SNX30	-0.65	-6.94	-0.31	1.3e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2153535	0.580	rs9406174	chr6:8516764	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs10214930	0.671	rs6948460	chr7:27690238	T/A	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	cis	rs7717393	0.786	rs10044891	chr5:155781866	G/A	cg12904904	chr5:155754151	SGCD	0.65	7.52	0.33	2.91e-13	Egg allergy;
LGG	cis	rs1994135	0.647	rs1351681	chr12:33698724	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.61	-0.37	1.19e-16	Resting heart rate;
LGG	cis	rs6435862	0.500	rs12477063	chr2:215673664	C/T	cg04004882	chr2:215674386	BARD1	-0.62	-10.95	-0.45	5.91e-25	Neuroblastoma (high-risk);
LGG	trans	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg06521331	chr12:34319734	NA	-0.5	-8.76	-0.38	3.76e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17433780	0.808	rs1074541	chr1:89509499	A/G	cg09516651	chr1:89888402	LOC400759	0.77	18.59	0.65	5.03e-58	Carotid intima media thickness;
LGG	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg16339924	chr4:17578868	LAP3	0.53	8.85	0.38	1.84e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	16.18	0.6	5.24e-47	Subjective well-being;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.25	0.55	1.83e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.44	-0.4	1.85e-19	Extrinsic epigenetic age acceleration;
LGG	trans	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg06521331	chr12:34319734	NA	0.42	7.68	0.34	9.7e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg05091796	chr16:4465799	CORO7	-0.65	-10.69	-0.45	5.32e-24	Schizophrenia;
LGG	cis	rs9372078	1.000	rs9372078	chr6:150913961	T/A	cg01013955	chr6:150918915	NA	0.31	6.67	0.3	7.37e-11	Panic disorder;
LGG	cis	rs67460515	0.563	rs13085336	chr3:160880599	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.32	-0.36	1.02e-15	Parkinson's disease;
LGG	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.34	0.5	1.93e-30	Colorectal cancer;
LGG	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg08999081	chr20:33150536	PIGU	0.41	10.43	0.44	5.25e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs7927592	0.763	rs1193699	chr11:68249480	C/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.55	-0.44	1.88e-23	Total body bone mineral density;
LGG	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg07274523	chr3:49395745	GPX1	0.58	9.82	0.42	8.35e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6940638	0.715	rs9348751	chr6:27067190	T/A	cg12826209	chr6:26865740	GUSBL1	0.47	7.86	0.34	2.74e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11150038	0.510	rs2204894	chr16:78099457	A/G	cg04733911	chr16:78082701	NA	0.62	8.69	0.37	6.36e-17	Colorectal or endometrial cancer;
LGG	cis	rs2282802	0.660	rs7726176	chr5:139547971	T/A	cg26211634	chr5:139558579	C5orf32	-0.35	-7.76	-0.34	5.6e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs6450176	0.587	rs10471884	chr5:53344135	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.54	-0.47	3.06e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1355223	0.902	rs11607035	chr11:34718911	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.7	-0.3	6.12e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg03894339	chr8:19674705	INTS10	-0.66	-10.83	-0.45	1.66e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs58688157	0.960	rs702966	chr11:611919	C/G	cg16486109	chr11:613632	IRF7	0.41	7.4	0.33	6.48e-13	Systemic lupus erythematosus;
LGG	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg24189917	chr7:1970923	MAD1L1	-0.42	-6.99	-0.31	9.75e-12	Bipolar disorder;
LGG	cis	rs10979	0.965	rs9496679	chr6:143896741	G/T	cg25407410	chr6:143891975	LOC285740	-0.73	-12.58	-0.5	2.1e-31	Hypospadias;
LGG	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.76e-43	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg04935436	chr20:30431758	NA	0.41	7.24	0.32	1.87e-12	Mean corpuscular hemoglobin;
LGG	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	5.16e-24	Aortic root size;
LGG	cis	rs637571	0.607	rs574586	chr11:65697083	G/A	cg26695010	chr11:65641043	EFEMP2	-0.5	-8.25	-0.36	1.67e-15	Eosinophil percentage of white cells;
LGG	cis	rs35264875	0.846	rs72930625	chr11:68867120	T/A	cg07882059	chr11:68924751	NA	0.4	7.14	0.32	3.56e-12	Blond vs. brown hair color;
LGG	cis	rs10267417	0.603	rs10244374	chr7:19863170	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	7.52	0.33	2.85e-13	Night sleep phenotypes;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg05313129	chr8:58192883	C8orf71	0.73	10.33	0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg21659725	chr3:3221576	CRBN	-0.46	-7.6	-0.33	1.69e-13	Menarche (age at onset);
LGG	cis	rs9790314	0.747	rs1610158	chr3:160815050	A/G	cg04691961	chr3:161091175	C3orf57	0.54	11.27	0.46	3.25e-26	Morning vs. evening chronotype;
LGG	cis	rs1465370	0.720	rs5011387	chr7:130017149	C/T	cg25718383	chr7:130020096	CPA1	0.32	8.42	0.36	4.83e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs26232	0.583	rs154258	chr5:102363623	G/A	cg23492399	chr5:102201601	PAM	0.51	7.64	0.33	1.27e-13	Rheumatoid arthritis;
LGG	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.85	-0.45	1.36e-24	Neuroticism;
LGG	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	8.36	0.36	7.34e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg17108064	chr15:78857060	CHRNA5	-0.44	-9.2	-0.39	1.2e-18	Sudden cardiac arrest;
LGG	cis	rs7727544	0.514	rs3846728	chr5:131436217	G/A	cg07395648	chr5:131743802	NA	-0.39	-8.41	-0.36	4.97e-16	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.565	rs61869210	chr10:104437175	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.57	9.61	0.41	4.52e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg02631450	chr22:32366979	NA	1.01	9.67	0.41	2.84e-20	Childhood ear infection;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.2100000000000001e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg20637307	chr2:213403960	ERBB4	0.47	8.69	0.37	6.07e-17	Symmetrical dimethylarginine levels;
LGG	cis	rs2708240	1.000	rs2538977	chr7:147584571	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.28	-7.07	-0.31	5.86e-12	QT interval (drug interaction);
LGG	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.19	-0.39	1.32e-18	Gut microbiome composition (summer);
LGG	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-10.98	-0.45	4.34e-25	Neuroticism;
LGG	cis	rs258892	0.895	rs465388	chr5:72135899	C/T	cg21869765	chr5:72125136	TNPO1	0.42	6.69	0.3	6.29e-11	Small cell lung carcinoma;
LGG	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg08498830	chr11:832797	CD151	-0.45	-7.35	-0.32	9.21e-13	Mean platelet volume;
LGG	cis	rs16854884	0.837	rs13083068	chr3:143801642	G/T	cg06585982	chr3:143692056	C3orf58	0.56	9.38	0.4	2.97e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.66	-0.44	7.31e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.93	-0.49	8.17e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs774359	0.797	rs10738774	chr9:27506051	G/A	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.19	-0.36	2.48e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs4481887	1.000	rs10888358	chr1:248471467	C/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.73	-0.41	1.76e-20	Common traits (Other);
LGG	trans	rs6787172	0.633	rs2693529	chr3:157975178	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.74	13.99	0.55	2.34e-37	Colorectal cancer;
LGG	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	12.2	0.49	6.91e-30	Lung cancer in ever smokers;
LGG	cis	rs11971779	0.584	rs7786469	chr7:139094621	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs1109114	0.844	rs2304609	chr5:148627503	C/T	cg06539116	chr5:148597365	ABLIM3	-0.48	-11.46	-0.47	6.22e-27	Body mass index;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg18402987	chr7:1209562	NA	0.72	7.76	0.34	5.62e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg06827562	chr3:125932279	NA	0.57	13.48	0.53	3.56e-35	Metabolite levels;
LGG	cis	rs2635047	0.967	rs2571001	chr18:44665083	C/A	cg19077165	chr18:44547161	KATNAL2	-0.52	-9.19	-0.39	1.31e-18	Educational attainment;
LGG	cis	rs3780486	0.813	rs3780488	chr9:33133812	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.75	-0.57	1.19e-40	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs929596	0.556	rs4477910	chr2:234643737	A/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-10.24	-0.43	2.53e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg04503457	chr17:41445688	NA	-0.37	-8.8	-0.38	2.81e-17	Menopause (age at onset);
LGG	cis	rs67133203	0.768	rs12811508	chr12:51529231	C/G	cg14688905	chr12:51403056	SLC11A2	0.71	10.75	0.45	3.2e-24	Urinary tract infection frequency;
LGG	cis	rs2273669	0.588	rs12205061	chr6:109338161	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.01	0.39	5.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1018836	0.923	rs10956720	chr8:91576222	C/T	cg16814680	chr8:91681699	NA	-0.79	-14.41	-0.56	3.56e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg02002194	chr4:3960332	NA	-0.48	-9.23	-0.39	9.69e-19	Joint mobility (Beighton score);
LGG	cis	rs9849248	0.627	rs73148006	chr3:88134502	T/C	cg14530983	chr3:88190749	ZNF654	0.57	7.86	0.34	2.67e-14	Menarche (age at onset);
LGG	cis	rs6500637	0.619	rs77997837	chr16:4944256	C/T	cg04440724	chr16:4920505	UBN1	-0.55	-9.43	-0.4	1.93e-19	Cancer;
LGG	cis	rs4948102	1.000	rs4948102	chr7:56097265	C/G	cg17215666	chr7:56131930	SUMF2	0.45	6.95	0.31	1.22e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs9460578	0.537	rs62399349	chr6:20815480	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.65	0.63	1.06e-53	Breast cancer;
LGG	cis	rs2361718	0.603	rs12951255	chr17:78085597	A/G	cg27427491	chr17:78079615	GAA	-0.31	-7.49	-0.33	3.55e-13	Yeast infection;
LGG	cis	rs990171	0.913	rs6729638	chr2:102996022	C/T	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.33e-21	Lymphocyte counts;
LGG	cis	rs2013441	0.866	rs2526471	chr17:20151673	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg04731861	chr2:219085781	ARPC2	0.52	13.45	0.53	4.95e-35	Colorectal cancer;
LGG	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	5.9e-15	Retinal vascular caliber;
LGG	cis	rs11583043	1.000	rs3861734	chr1:101489461	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.11	0.35	4.55e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs796364	0.760	rs56285751	chr2:200919836	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-6.97	-0.31	1.11e-11	Schizophrenia;
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg16141378	chr3:129829833	LOC729375	-0.5	-12.65	-0.51	1.01e-31	Mood instability;
LGG	cis	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg07777115	chr5:623756	CEP72	-0.51	-6.76	-0.3	4.09e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs60695258	0.550	rs340648	chr4:87940940	A/G	cg01323104	chr4:87958903	AFF1	-0.25	-6.98	-0.31	1.02e-11	Hematocrit;
LGG	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg12373951	chr3:133503437	NA	0.4	6.98	0.31	1.03e-11	Iron status biomarkers;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00166722	chr3:10149974	C3orf24	0.56	8.1	0.35	4.75e-15	Alzheimer's disease;
LGG	cis	rs79057730	0.599	rs4333501	chr7:803244	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.73	8.25	0.36	1.72e-15	Initial pursuit acceleration;
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	4.94e-22	Intelligence (multi-trait analysis);
LGG	cis	rs12282928	0.699	rs4752916	chr11:48228788	C/T	cg26585981	chr11:48327164	OR4S1	0.4	7.02	0.31	7.71e-12	Migraine - clinic-based;
LGG	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg17595323	chr11:93583763	C11orf90	-0.45	-8.08	-0.35	5.83e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs4481887	0.893	rs10888347	chr1:248448566	T/C	cg13385794	chr1:248469461	NA	0.45	7.67	0.34	1.05e-13	Common traits (Other);
LGG	cis	rs62400317	0.762	rs9367210	chr6:44863395	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg15485101	chr11:133734466	NA	0.52	9.24	0.39	8.79e-19	Childhood ear infection;
LGG	cis	rs975739	0.872	rs1144385	chr13:78363371	G/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.81	0.3	3.05e-11	Hair color;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg21782813	chr7:2030301	MAD1L1	0.56	14.51	0.56	1.32e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	6.98	0.31	1.01e-11	Resting heart rate;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.07	0.31	5.57e-12	Schizophrenia;
LGG	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.82	0.51	2.04e-32	Obesity-related traits;
LGG	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg05425664	chr17:57184151	TRIM37	0.44	7.24	0.32	1.84e-12	Testicular germ cell tumor;
LGG	cis	rs1475911	1.000	rs34421316	chr21:43513989	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.48	-8.61	-0.37	1.15e-16	IgG glycosylation;
LGG	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg10792982	chr14:105748885	BRF1	0.57	11.52	0.47	3.73e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7975161	0.520	rs4502051	chr12:104695569	A/T	cg25273343	chr12:104657179	TXNRD1	-0.76	-7.38	-0.32	7.44e-13	Toenail selenium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13754859	chr14:24584296	DCAF11	0.54	8.38	0.36	6.43e-16	Gut microbiome composition (summer);
LGG	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	cg07928641	chr1:182991847	LAMC1	0.47	9.48	0.4	1.29e-19	Colorectal cancer;
LGG	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg00531865	chr16:30841666	NA	-0.52	-10.2	-0.43	3.58e-22	Multiple myeloma;
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg13607699	chr17:42295918	UBTF	0.75	12.42	0.5	9.18e-31	Total body bone mineral density;
LGG	cis	rs7084402	0.967	rs1658470	chr10:60292383	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.97e-13	Refractive error;
LGG	cis	rs4788570	0.538	rs59364668	chr16:71569229	A/T	cg06353428	chr16:71660113	MARVELD3	-1.04	-14.06	-0.55	1.27e-37	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06594919	chr10:102827590	NA	0.45	7.27	0.32	1.53e-12	Gut microbiome composition (summer);
LGG	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg05973401	chr12:123451056	ABCB9	-0.51	-7.67	-0.34	1.05e-13	Neutrophil percentage of white cells;
LGG	cis	rs2120243	0.539	rs9878474	chr3:157123147	A/G	cg24825693	chr3:157122686	VEPH1	0.6	14.05	0.55	1.4e-37	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs1408224	0.688	rs842406	chr13:47230194	A/G	cg24453118	chr13:47229927	LRCH1	0.3	6.85	0.3	2.43e-11	QRS complex (12-leadsum);
LGG	cis	rs7119	0.717	rs35284122	chr15:77804568	G/T	cg10437265	chr15:77819839	NA	0.25	6.82	0.3	2.8e-11	Type 2 diabetes;
LGG	cis	rs972578	0.765	rs2899365	chr22:43278220	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.95e-11	Mean platelet volume;
LGG	cis	rs11971779	0.680	rs6978680	chr7:139112048	A/G	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.07	-0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg12698349	chr2:225449008	CUL3	0.7	11.85	0.48	1.81e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs10791097	0.720	rs6590516	chr11:130733393	G/T	cg12179176	chr11:130786555	SNX19	0.8	16.21	0.6	4.13e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1867631	0.958	rs7536188	chr1:67087926	A/T	cg13052034	chr1:66999238	SGIP1	-0.48	-9.47	-0.4	1.47e-19	Menopause (age at onset);
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg05025164	chr4:1340916	KIAA1530	0.65	12.26	0.49	4.13e-30	Longevity;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.59	-0.37	1.35e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1566085	0.704	rs11786465	chr8:142654221	T/C	cg26331504	chr8:142652174	NA	-0.3	-6.93	-0.31	1.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs28595532	0.920	rs116106661	chr4:119749794	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7647973	0.626	rs9835157	chr3:49797769	G/A	cg13072238	chr3:49761600	GMPPB	0.55	7.5	0.33	3.31e-13	Menarche (age at onset);
LGG	cis	rs2976388	0.566	rs4736373	chr8:143792357	G/C	cg06565975	chr8:143823917	SLURP1	-0.51	-12.64	-0.51	1.13e-31	Urinary tract infection frequency;
LGG	cis	rs12474201	0.775	rs7584870	chr2:46973400	A/T	cg06386533	chr2:46925753	SOCS5	0.75	14.22	0.55	2.58e-38	Height;
LGG	cis	rs2046867	0.818	rs6792109	chr3:72867091	C/T	cg26655873	chr3:72818019	SHQ1	0.36	7.03	0.31	7.59e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9463078	0.691	rs4398713	chr6:45003928	C/T	cg25276700	chr6:44698697	NA	0.32	6.68	0.3	6.84e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg15394860	chr11:2017084	H19	0.63	13.76	0.54	2.23e-36	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7241530	0.689	rs6506735	chr18:75888482	C/T	cg14642773	chr18:75888474	NA	-0.47	-10.16	-0.43	5.06e-22	Educational attainment (years of education);
LGG	cis	rs11155671	0.530	rs7763849	chr6:150206380	C/T	cg13206674	chr6:150067644	NUP43	0.41	8.62	0.37	1.07e-16	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs906134	chr7:65444288	G/C	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs11690935	0.550	rs62183801	chr2:172867475	G/A	cg13550731	chr2:172543902	DYNC1I2	0.63	12.0	0.49	4.59e-29	Schizophrenia;
LGG	trans	rs10805346	0.501	rs4604059	chr4:10115065	C/T	cg26043149	chr18:55253948	FECH	-0.39	-6.86	-0.3	2.23e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	cis	rs12477438	0.501	rs6715321	chr2:100109001	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.46	7.17	0.32	2.93e-12	Chronic sinus infection;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg26174226	chr8:58114915	NA	-0.56	-7.58	-0.33	1.85e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg08999081	chr20:33150536	PIGU	-0.29	-6.74	-0.3	4.86e-11	Height;
LGG	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg07636037	chr3:49044803	WDR6	0.93	15.76	0.59	4.25e-45	Menarche (age at onset);
LGG	cis	rs1707322	0.752	rs6662164	chr1:46146230	T/A	cg03146154	chr1:46216737	IPP	0.54	10.49	0.44	3.1e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.93	-0.45	6.72e-25	Neuroticism;
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg16141378	chr3:129829833	LOC729375	0.44	9.96	0.42	2.66e-21	Neuroticism;
LGG	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.18	0.49	8.52e-30	Intelligence (multi-trait analysis);
LGG	trans	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.8	-0.34	4.11e-14	Endometrial cancer;
LGG	cis	rs9457247	0.967	rs1211447	chr6:167381979	C/T	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg14088196	chr11:70211408	PPFIA1	0.83	11.66	0.48	1.04e-27	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.1	0.35	4.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7267979	0.549	rs11698185	chr20:25181998	T/C	cg06421707	chr20:25228305	PYGB	0.41	8.32	0.36	9.63e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1568889	0.938	rs6484358	chr11:28260364	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.77	0.57	1.03e-40	Bipolar disorder;
LGG	cis	rs727505	1.000	rs10233596	chr7:124556659	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.71	-0.41	2e-20	Lewy body disease;
LGG	trans	rs2018683	0.624	rs2286220	chr7:28998699	G/C	cg19402173	chr7:128379420	CALU	-0.73	-13.24	-0.52	3.6e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3820068	0.608	rs10927836	chr1:16034368	G/C	cg05660106	chr1:15850417	CASP9	0.76	13.98	0.54	2.79e-37	Systolic blood pressure;
LGG	cis	rs981844	0.816	rs62325151	chr4:154730595	A/G	cg14289246	chr4:154710475	SFRP2	0.71	11.59	0.47	1.89e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs1018836	0.892	rs4735210	chr8:91549399	G/T	cg16814680	chr8:91681699	NA	-0.73	-13.12	-0.52	1.22e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg24759859	chr6:86352639	SYNCRIP	0.44	7.21	0.32	2.24e-12	Smooth-surface caries;
LGG	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg20302533	chr7:39170763	POU6F2	0.48	11.13	0.46	1.14e-25	IgG glycosylation;
LGG	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	cis	rs11645898	0.511	rs72787023	chr16:72031105	T/C	cg14768367	chr16:72042858	DHODH	-0.63	-8.93	-0.38	9.89e-18	Blood protein levels;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg07061783	chr6:25882402	NA	-0.58	-9.76	-0.41	1.43e-20	Intelligence (multi-trait analysis);
LGG	cis	rs72615157	0.539	rs12673441	chr7:99670328	A/T	cg12813108	chr7:99719912	CNPY4	-0.82	-16.41	-0.61	5.02e-48	Lung function (FEV1/FVC);
LGG	cis	rs4704187	0.687	rs4621537	chr5:74362222	A/G	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs239198	0.602	rs9377236	chr6:101289960	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.21	0.32	2.36e-12	Menarche (age at onset);
LGG	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg21775007	chr8:11205619	TDH	-0.48	-7.73	-0.34	6.6e-14	Neuroticism;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg24101359	chr6:42928495	GNMT	0.53	14.77	0.57	9.59e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg04025307	chr7:1156635	C7orf50	0.6	8.32	0.36	1.01e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504130	0.569	rs10958305	chr8:52819024	T/C	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11074306	0.561	rs931663	chr15:28070281	A/G	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs7106204	0.614	rs117122818	chr11:24245880	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.37	0.43	8.76e-23	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs883565	0.792	rs810743	chr3:39185968	A/G	cg01426195	chr3:39028469	NA	0.6	10.27	0.43	2.05e-22	Handedness;
LGG	trans	rs61332075	0.501	rs55706928	chr2:239445806	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	8.56	0.37	1.62e-16	Lung function (FEV1/FVC);
LGG	cis	rs12476592	0.602	rs6708804	chr2:63807269	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.92	-0.31	1.55e-11	Childhood ear infection;
LGG	cis	rs5769707	0.632	rs135877	chr22:50014002	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.81	-0.41	9.44e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4144743	0.702	rs16941733	chr17:45318289	T/C	cg18085866	chr17:45331354	ITGB3	-0.71	-7.42	-0.33	5.5e-13	Body mass index;
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg00149659	chr3:10157352	C3orf10	0.73	9.32	0.4	4.62e-19	Alzheimer's disease;
LGG	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg11859384	chr17:80120422	CCDC57	0.4	7.03	0.31	7.25e-12	Life satisfaction;
LGG	cis	rs2131877	0.868	rs57475252	chr3:194878430	G/A	cg07250128	chr3:194833983	C3orf21	0.4	7.71	0.34	7.96e-14	Non-small cell lung cancer;
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg09303159	chr6:26284866	NA	-0.35	-7.93	-0.35	1.7e-14	Educational attainment;
LGG	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg06606381	chr12:133084897	FBRSL1	-1.09	-10.38	-0.43	8.04e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2522056	1.000	rs7730247	chr5:131781288	A/C	cg07395648	chr5:131743802	NA	0.4	6.96	0.31	1.2e-11	Lymphocyte counts;Fibrinogen;
LGG	cis	rs9486719	1.000	rs2472884	chr6:96863965	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.41	0.44	5.96e-23	Migraine;Coronary artery disease;
LGG	cis	rs7737355	0.947	rs10041744	chr5:130860852	C/T	cg06307176	chr5:131281290	NA	0.56	9.3	0.4	5.67e-19	Life satisfaction;
LGG	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	6.24e-21	Neuroticism;
LGG	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs10875746	0.669	rs17122812	chr12:48597053	A/G	cg24011408	chr12:48396354	COL2A1	-0.58	-7.47	-0.33	3.96e-13	Longevity (90 years and older);
LGG	cis	rs11711311	1.000	rs9851731	chr3:113502651	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.63	-13.01	-0.52	3.31e-33	IgG glycosylation;
LGG	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14154082	chr13:112174009	NA	0.42	9.31	0.4	5.04e-19	Menarche (age at onset);
LGG	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg02187348	chr16:89574699	SPG7	0.45	7.39	0.32	7.12e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg01620082	chr3:125678407	NA	0.67	7.57	0.33	1.98e-13	Depression;
LGG	cis	rs2396545	0.634	rs35788385	chr11:570094	G/A	cg03909863	chr11:638404	DRD4	-0.46	-7.12	-0.31	4.18e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg00383909	chr3:49044727	WDR6	0.44	7.21	0.32	2.28e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7586879	0.521	rs7597332	chr2:25075675	A/G	cg04586622	chr2:25135609	ADCY3	0.41	10.54	0.44	1.94e-23	Body mass index;
LGG	cis	rs7191439	0.858	rs2340973	chr16:88773396	G/A	cg27087555	chr16:88793112	FAM38A	-1.4	-17.69	-0.64	7.1e-54	Plateletcrit;
LGG	cis	rs7666738	0.830	rs60994860	chr4:99046753	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs5758511	0.773	rs62240999	chr22:42355563	C/G	cg15128208	chr22:42549153	NA	0.57	8.92	0.38	1.07e-17	Birth weight;
LGG	cis	rs4780401	0.609	rs8055247	chr16:11827543	G/A	cg01061890	chr16:11836724	TXNDC11	-0.7	-13.25	-0.52	3.28e-34	Rheumatoid arthritis;
LGG	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.68	-0.41	2.64e-20	Common traits (Other);
LGG	cis	rs7945718	0.905	rs4454698	chr11:12720560	A/G	cg25843174	chr11:12811716	TEAD1	-0.39	-7.95	-0.35	1.45e-14	Educational attainment (years of education);
LGG	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	cis	rs9815354	0.812	rs10510732	chr3:42007339	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3741151	0.764	rs79892955	chr11:73096280	G/T	cg17517138	chr11:73019481	ARHGEF17	0.96	9.33	0.4	4.51e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg02071572	chr4:1403502	NA	0.39	6.7	0.3	6.18e-11	Longevity;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg23782820	chr8:58130467	NA	0.58	8.63	0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2289583	0.517	rs2004278	chr15:75264363	C/T	cg10253484	chr15:75165896	SCAMP2	0.51	7.54	0.33	2.47e-13	Systemic lupus erythematosus;
LGG	cis	rs2154319	0.887	rs721651	chr1:41563329	A/C	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.58	-0.37	1.41e-16	Height;
LGG	trans	rs7937682	0.632	rs4441050	chr11:111772506	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs8141529	0.515	rs13056243	chr22:29349306	A/G	cg02153584	chr22:29168773	CCDC117	-0.55	-6.85	-0.3	2.29e-11	Lymphocyte counts;
LGG	cis	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg22496380	chr5:211416	CCDC127	-1.06	-10.37	-0.43	8.49e-23	Breast cancer;
LGG	cis	rs1387259	0.929	rs2634666	chr12:48663670	G/T	cg21466736	chr12:48725269	NA	-0.37	-7.37	-0.32	8.1e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs926938	0.765	rs2268701	chr1:115233046	C/T	cg12756093	chr1:115239321	AMPD1	-0.56	-10.92	-0.45	7.34e-25	Autism;
LGG	cis	rs9560113	0.573	rs61955236	chr13:112242861	G/A	cg14154082	chr13:112174009	NA	0.36	7.84	0.34	3.14e-14	Menarche (age at onset);
LGG	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg21238619	chr17:78079768	GAA	-0.33	-7.19	-0.32	2.66e-12	Yeast infection;
LGG	cis	rs9644630	0.745	rs7816777	chr8:19371767	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.48	-10.9	-0.45	9.15e-25	Oropharynx cancer;
LGG	cis	rs11203032	0.831	rs4933494	chr10:90917892	T/A	cg16672925	chr10:90967113	CH25H	0.76	10.66	0.44	7.38e-24	Heart failure;
LGG	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg27624424	chr6:160112604	SOD2	0.63	9.14	0.39	1.99e-18	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs765787	0.530	rs7167731	chr15:45510900	T/C	cg25801113	chr15:45476975	SHF	-0.87	-19.03	-0.66	4.54e-60	Uric acid levels;
LGG	cis	rs4330281	0.647	rs34485427	chr3:17694291	C/A	cg20981856	chr3:17787350	NA	-0.4	-7.54	-0.33	2.46e-13	Schizophrenia;
LGG	cis	rs17767392	0.881	rs1859643	chr14:72055468	G/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.46	-0.37	3.58e-16	Mitral valve prolapse;
LGG	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.38	-0.32	7.51e-13	HDL cholesterol;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02342362	chr19:12792713	DHPS	0.5	8.61	0.37	1.12e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs240764	0.511	rs9377232	chr6:101240430	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.04	0.31	6.8e-12	Neuroticism;
LGG	cis	rs17767392	0.781	rs8008605	chr14:72045544	C/G	cg02058870	chr14:72053146	SIPA1L1	-0.41	-7.89	-0.34	2.2e-14	Mitral valve prolapse;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	8.43	0.36	4.57e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11771526	0.901	rs10244622	chr7:32302960	C/T	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00294572	chr6:26285232	NA	0.41	7.54	0.33	2.48e-13	Educational attainment;
LGG	trans	rs9302065	0.636	rs2389235	chr13:95955623	G/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.47	8.36	0.36	7.38e-16	Blood metabolite levels;
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg10852096	chr15:79043040	NA	-0.29	-8.37	-0.36	6.8e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.87	-0.34	2.58e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg07274523	chr3:49395745	GPX1	0.55	9.09	0.39	2.83e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9733	0.650	rs11204680	chr1:150587140	T/G	cg13175981	chr1:150552382	MCL1	0.58	10.05	0.42	1.21e-21	Tonsillectomy;
LGG	cis	rs12681287	0.647	rs2953510	chr8:87341914	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.05e-13	Caudate activity during reward;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-6.96	-0.31	1.2e-11	Schizophrenia;
LGG	trans	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs9682041	0.696	rs13101192	chr3:170080752	C/G	cg11886554	chr3:170076028	SKIL	0.68	8.67	0.37	7.2e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs7000551	0.689	rs6993341	chr8:22310933	T/C	cg12081754	chr8:22256438	SLC39A14	0.69	13.47	0.53	3.87e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg05169099	chr5:481640	SLC9A3	0.48	6.96	0.31	1.18e-11	Fat distribution (HIV);
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg07747251	chr5:1868357	NA	0.46	9.38	0.4	3.04e-19	Cardiovascular disease risk factors;
LGG	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg12927641	chr6:109611667	NA	-0.38	-7.21	-0.32	2.35e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.21	-0.6	3.82e-47	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18845289	chr12:121124611	MLEC	0.46	7.03	0.31	7.47e-12	Gut microbiome composition (summer);
LGG	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg24253500	chr15:84953950	NA	0.58	10.48	0.44	3.39e-23	Schizophrenia;
LGG	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.29	0.63	5.01e-52	Sudden cardiac arrest;
LGG	cis	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-13.37	-0.53	1.08e-34	Heart rate;
LGG	cis	rs2131877	0.956	rs955825	chr3:194870922	T/C	cg07250128	chr3:194833983	C3orf21	0.41	7.64	0.33	1.3e-13	Non-small cell lung cancer;
LGG	cis	rs3806843	0.576	rs251368	chr5:140241027	G/T	cg19875535	chr5:140030758	IK	-0.36	-7.39	-0.32	6.92e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	9.46	0.4	1.52e-19	Lung cancer in ever smokers;
LGG	cis	rs2602381	0.620	rs2741050	chr2:234583183	T/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.61e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs28374715	0.681	rs59000092	chr15:41626148	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.18	-26.33	-0.77	4.71e-94	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-12.5	-0.5	4.23e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg07005078	chr4:17578674	LAP3	0.38	6.91	0.31	1.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.37	0.4	3.31e-19	Colorectal cancer;
LGG	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2708977	0.933	rs6576972	chr2:97152446	C/T	cg01950434	chr2:97203154	ARID5A	-0.58	-9.39	-0.4	2.77e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.63	-0.41	3.93e-20	Aortic root size;
LGG	cis	rs9611519	0.780	rs2284079	chr22:41658632	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-8.58	-0.37	1.41e-16	Neuroticism;
LGG	cis	rs12220238	0.841	rs11000952	chr10:76037336	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.86	0.38	1.75e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.02e-34	Skin colour saturation;
LGG	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg27205649	chr11:78285834	NARS2	0.5	8.58	0.37	1.43e-16	Alzheimer's disease (survival time);
LGG	cis	rs2274273	0.686	rs11624679	chr14:55624244	G/A	cg04306507	chr14:55594613	LGALS3	0.52	12.11	0.49	1.56e-29	Protein biomarker;
LGG	cis	rs7727544	0.661	rs273900	chr5:131694606	G/A	cg07395648	chr5:131743802	NA	-0.55	-13.14	-0.52	9.83e-34	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08078772	chr17:66244589	AMZ2	0.43	6.85	0.3	2.41e-11	Gut microbiome composition (summer);
LGG	cis	rs988958	0.567	rs34291746	chr2:42259859	A/G	cg19376973	chr2:42229025	NA	0.66	10.36	0.43	9.05e-23	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02594498	chr15:22893147	CYFIP1	0.48	8.01	0.35	9.38e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7914558	1.000	rs10883837	chr10:104896486	G/A	cg04362960	chr10:104952993	NT5C2	0.54	10.41	0.44	6.01e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg22044901	chr15:68126292	NA	-0.43	-7.84	-0.34	3.11e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg05926928	chr17:57297772	GDPD1	1.36	21.89	0.71	1.99e-73	Opioid sensitivity;
LGG	cis	rs8031584	0.918	rs35784593	chr15:31254588	G/A	cg08109568	chr15:31115862	NA	-0.53	-9.45	-0.4	1.63e-19	Huntington's disease progression;
LGG	trans	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs8063761	0.589	rs4238833	chr16:90050689	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.72	13.03	0.52	2.88e-33	Squamous cell carcinoma;
LGG	cis	rs3820928	0.874	rs3752896	chr2:227886925	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.64	-0.33	1.28e-13	Pulmonary function;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg05091796	chr16:4465799	CORO7	-0.77	-12.61	-0.51	1.45e-31	Schizophrenia;
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-12.75	-0.51	4.19e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs7312933	0.510	rs1907705	chr12:42451122	T/A	cg01943504	chr12:42538901	GXYLT1	-0.51	-9.32	-0.4	4.69e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	17.01	0.62	9.38e-51	Platelet count;
LGG	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg19418458	chr7:158789849	NA	0.53	10.93	0.45	7.01e-25	Facial morphology (factor 20);
LGG	cis	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19171272	chr22:38449367	NA	-0.49	-8.85	-0.38	1.85e-17	Glioblastoma;Glioma;
LGG	trans	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg17830980	chr10:43048298	ZNF37B	-0.45	-10.02	-0.42	1.63e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg08297393	chr2:100937505	LONRF2	-0.45	-7.73	-0.34	6.52e-14	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.12	0.43	7.04e-22	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.06e-17	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06794263	chr15:93447445	CHD2	0.51	7.8	0.34	4.22e-14	Gut microbiome composition (summer);
LGG	cis	rs7216064	0.953	rs4791048	chr17:65848994	G/A	cg12091567	chr17:66097778	LOC651250	-0.64	-9.48	-0.4	1.29e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.34	-0.58	2.97e-43	Platelet count;
LGG	trans	rs61931739	0.500	rs11053273	chr12:34547255	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg05535760	chr7:792225	HEATR2	-0.79	-11.08	-0.46	1.77e-25	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11122272	0.766	rs2790870	chr1:231543823	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.26	-0.32	1.65e-12	Hemoglobin concentration;
LGG	cis	rs4731207	0.596	rs1471572	chr7:124650942	C/A	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.58	-0.33	1.88e-13	Menopause (age at onset);
LGG	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg24812749	chr6:127587940	RNF146	0.66	11.19	0.46	6.62e-26	Breast cancer;
LGG	cis	rs17376456	0.877	rs10050465	chr5:93349963	C/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.7	-0.41	2.25e-20	Diabetic retinopathy;
LGG	trans	rs7395662	0.895	rs1945183	chr11:48502427	T/A	cg03929089	chr4:120376271	NA	-0.44	-7.04	-0.31	6.89e-12	HDL cholesterol;
LGG	cis	rs7085104	0.572	rs284860	chr10:104572963	T/C	cg04362960	chr10:104952993	NT5C2	-0.45	-8.23	-0.36	1.88e-15	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs9948	0.786	rs111237064	chr2:97456578	T/C	cg01990225	chr2:97406019	LMAN2L	-0.67	-6.96	-0.31	1.14e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.53	-6.78	-0.3	3.57e-11	Smoking behavior;
LGG	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.87	-0.3	2.11e-11	Iron status biomarkers;
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.65e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9815354	0.812	rs55748698	chr3:41805233	G/A	cg03022575	chr3:42003672	ULK4	0.79	9.09	0.39	2.81e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg26446133	chr18:72167187	CNDP2	-0.74	-16.91	-0.62	2.68e-50	Refractive error;
LGG	cis	rs4788570	0.578	rs9934789	chr16:71662467	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	20.59	0.69	2.42e-67	Intelligence (multi-trait analysis);
LGG	cis	rs2795502	1.000	rs2795496	chr10:43337842	G/A	cg20628663	chr10:43360327	NA	-0.4	-8.07	-0.35	5.93e-15	Blood protein levels;
LGG	cis	rs477692	0.569	rs1771448	chr10:131296201	A/G	cg05714579	chr10:131428358	MGMT	-0.5	-9.87	-0.42	5.5e-21	Response to temozolomide;
LGG	cis	rs17125944	0.615	rs2025632	chr14:53294319	T/C	cg00686598	chr14:53173677	PSMC6	-0.82	-8.79	-0.38	2.91e-17	Alzheimer's disease (late onset);
LGG	cis	rs9457247	0.663	rs2237277	chr6:167442107	G/A	cg07741184	chr6:167504864	NA	0.4	8.77	0.38	3.34e-17	Crohn's disease;
LGG	cis	rs9487094	0.744	rs13199519	chr6:109709175	G/A	cg01125227	chr6:109776195	MICAL1	0.54	9.06	0.39	3.68e-18	Height;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.61	10.09	0.42	9.06e-22	Obesity-related traits;
LGG	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg16386425	chr10:429943	DIP2C	0.41	8.25	0.36	1.65e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05665937	chr4:1216051	CTBP1	0.37	6.73	0.3	5e-11	Longevity;
LGG	trans	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg26043149	chr18:55253948	FECH	0.41	6.73	0.3	5.12e-11	Bone mineral density;
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs7589342	0.862	rs10469862	chr2:106509907	C/T	cg14210321	chr2:106509881	NCK2	-0.57	-9.94	-0.42	3.11e-21	Addiction;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.46e-23	Intelligence (multi-trait analysis);
LGG	cis	rs56283067	0.847	rs1283948	chr6:44691702	C/T	cg18551225	chr6:44695536	NA	-0.69	-12.12	-0.49	1.49e-29	Total body bone mineral density;
LGG	cis	rs2455799	0.634	rs4685266	chr3:15908766	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.7	-0.34	8.13e-14	Mean platelet volume;
LGG	cis	rs9487094	0.813	rs67857472	chr6:109680328	C/T	cg16315928	chr6:109776240	MICAL1	0.51	8.48	0.37	3.04e-16	Height;
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg03264133	chr6:25882463	NA	-0.43	-7.49	-0.33	3.43e-13	Height;
LGG	cis	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg00495681	chr13:53174319	NA	0.69	13.91	0.54	5.07e-37	Lewy body disease;
LGG	cis	rs735539	0.521	rs2762985	chr13:21384371	G/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.01	-0.35	9.44e-15	Dental caries;
LGG	trans	rs1962073	0.667	rs4521760	chr8:10274188	C/A	cg16141378	chr3:129829833	LOC729375	0.33	7.33	0.32	1.05e-12	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs75059851	0.756	rs11223651	chr11:133841034	A/G	cg17703048	chr11:133852993	NA	0.88	16.23	0.6	3.22e-47	Schizophrenia;
LGG	cis	rs911555	0.755	rs7147664	chr14:103963420	G/A	cg24130564	chr14:104152367	KLC1	-0.4	-7.32	-0.32	1.1e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.591	rs9787073	chr1:182974328	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.36	6.89	0.31	1.79e-11	Fuchs's corneal dystrophy;
LGG	trans	rs55986470	0.817	rs10177049	chr2:239422169	G/T	cg01134436	chr17:81009848	B3GNTL1	0.57	6.68	0.3	6.79e-11	Chronotype;
LGG	cis	rs11608355	0.521	rs9888353	chr12:109843594	G/A	cg19025524	chr12:109796872	NA	-0.57	-12.28	-0.5	3.47e-30	Neuroticism;
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.43	0.36	4.47e-16	Bipolar disorder;
LGG	cis	rs2172802	0.659	rs2343251	chr4:62492671	C/A	cg04118610	chr4:62707027	LPHN3	0.62	11.06	0.46	2.11e-25	Partial epilepsies;
LGG	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg06890432	chr16:12997467	SHISA9	-0.32	-6.87	-0.3	2.07e-11	Positive affect;Subjective well-being;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.675	rs4851313	chr2:101029002	A/G	cg26150922	chr2:100937072	LONRF2	0.56	10.71	0.45	4.63e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs10500098	chr7:124658055	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17818399	0.620	rs6544906	chr2:46863872	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-8.02	-0.35	8.52e-15	Height;
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg02002194	chr4:3960332	NA	0.43	7.5	0.33	3.22e-13	Neuroticism;
LGG	cis	rs6976053	0.810	rs3757869	chr7:100493998	T/G	cg03098644	chr7:100410630	EPHB4	-0.41	-7.43	-0.33	5.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs782590	0.837	rs2627769	chr2:55927288	G/C	cg18811423	chr2:55921094	PNPT1	0.95	23.28	0.73	6.15e-80	Metabolic syndrome;
LGG	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg23625390	chr15:77176239	SCAPER	-0.68	-13.29	-0.53	2.17e-34	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25218905	chr12:92538613	BTG1	0.39	6.86	0.3	2.22e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.46	-0.4	1.52e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg10503236	chr1:231470652	EXOC8	0.38	7.33	0.32	1.05e-12	Hemoglobin concentration;
LGG	cis	rs17021463	0.645	rs12651347	chr4:95334650	G/A	cg11021082	chr4:95130006	SMARCAD1	0.51	7.79	0.34	4.56e-14	Testicular germ cell tumor;
LGG	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.18	0.32	2.76e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.41	-0.36	5.1e-16	Tonsillectomy;
LGG	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg19847130	chr8:10466454	RP1L1	0.31	6.97	0.31	1.08e-11	Neuroticism;
LGG	cis	rs4242434	0.927	rs7843828	chr8:22463623	C/T	cg19455335	chr8:22457658	C8orf58	-0.45	-9.32	-0.4	4.92e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg22307297	chr20:60903441	LAMA5	0.43	8.52	0.37	2.18e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg13385794	chr1:248469461	NA	-0.42	-7.34	-0.32	9.92e-13	Common traits (Other);
LGG	cis	rs11158198	0.738	rs910879	chr14:58571252	T/G	cg15908186	chr14:58618357	C14orf37	0.52	8.96	0.38	7.92e-18	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg02002194	chr4:3960332	NA	0.44	8.14	0.35	3.76e-15	Monocyte count;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25072359	chr17:41440525	NA	0.51	9.8	0.41	1.02e-20	Menopause (age at onset);
LGG	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-9.25	-0.39	8.32e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.902	rs10763557	chr10:60341515	C/T	cg09696939	chr10:60272079	BICC1	-0.39	-7.61	-0.33	1.52e-13	Refractive error;
LGG	cis	rs2777491	0.957	rs2015781	chr15:41648967	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.9	-0.68	4.05e-64	Ulcerative colitis;
LGG	cis	rs7937612	1.000	rs7933086	chr11:120269308	A/G	cg24566217	chr11:120254723	ARHGEF12	0.53	12.8	0.51	2.39e-32	Intraocular pressure;
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg06558623	chr16:89946397	TCF25	1.24	13.52	0.53	2.52e-35	Skin colour saturation;
LGG	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.38	-0.4	3.01e-19	Neuroticism;
LGG	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	cis	rs7252981	0.632	rs739461	chr19:19715794	T/C	cg11584989	chr19:19387371	SF4	-0.47	-7.96	-0.35	1.33e-14	Perceived unattractiveness to mosquitoes;
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.21	-0.32	2.34e-12	Menopause (age at onset);
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.75e-26	Bipolar disorder;
LGG	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg12011299	chr4:100065546	ADH4	0.39	7.94	0.35	1.52e-14	Alcohol dependence;
LGG	cis	rs738321	0.711	rs5995541	chr22:38553411	C/T	cg03162506	chr22:38580953	NA	0.41	10.0	0.42	1.93e-21	Breast cancer;
LGG	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs3857067	0.806	rs7654565	chr4:95112939	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs2070677	0.935	rs4351775	chr10:135402200	C/T	cg20169779	chr10:135381914	SYCE1	-1.01	-13.48	-0.53	3.59e-35	Gout;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs42648	0.806	rs6951894	chr7:89893945	A/G	cg25739043	chr7:89950458	NA	-0.38	-8.03	-0.35	8.32e-15	Homocysteine levels;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg11878867	chr6:150167359	LRP11	-0.49	-10.03	-0.42	1.48e-21	Lung cancer;
LGG	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	12.39	0.5	1.21e-30	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.67	-0.41	2.9e-20	Joint mobility (Beighton score);
LGG	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	trans	rs10506458	0.915	rs2013050	chr12:63394310	C/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.43	-0.53	5.84e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg06637938	chr14:75390232	RPS6KL1	0.57	10.36	0.43	9.42e-23	Height;
LGG	cis	rs929354	0.772	rs1182365	chr7:157017255	A/T	cg00092383	chr7:157075207	NA	0.39	6.78	0.3	3.58e-11	Body mass index;
LGG	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg08109568	chr15:31115862	NA	-0.51	-8.48	-0.37	2.98e-16	Huntington's disease progression;
LGG	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg05535760	chr7:792225	HEATR2	0.79	12.65	0.51	1.06e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs1816752	0.875	rs7993132	chr13:24987041	C/T	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	cis	rs11650494	0.710	rs73987293	chr17:47474728	A/G	cg08112188	chr17:47440006	ZNF652	1.13	12.68	0.51	8.14e-32	Prostate cancer;
LGG	cis	rs28595532	0.920	rs17324884	chr4:119771477	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18644191	chr1:99730224	LPPR4	0.45	6.97	0.31	1.1e-11	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.638	rs113496706	chr3:42028574	G/T	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.39	0.32	6.86e-13	Educational attainment;
LGG	cis	rs13191362	1.000	rs4489133	chr6:163137793	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.03	0.31	7.63e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs35740288	0.742	rs4843087	chr15:86172855	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.46	0.37	3.44e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg21775007	chr8:11205619	TDH	0.43	6.69	0.3	6.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8020289	0.957	rs2103452	chr14:77281081	C/T	cg23436960	chr14:77239540	VASH1	-0.26	-6.97	-0.31	1.1e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg25145360	chr17:19651881	ALDH3A1	-0.82	-19.55	-0.67	1.77e-62	Response to paliperidone in schizophrenia (CGI-S score);
LGG	trans	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.68	-0.41	2.54e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6121246	0.647	rs6088855	chr20:30225792	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	10.33	0.43	1.2e-22	Mean corpuscular hemoglobin;
LGG	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg21427119	chr20:30132790	HM13	-0.4	-6.85	-0.3	2.32e-11	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg11878867	chr6:150167359	LRP11	-0.53	-11.15	-0.46	9.53e-26	Lung cancer;
LGG	cis	rs12421382	0.659	rs11604254	chr11:109392413	G/A	cg16359550	chr11:109292809	C11orf87	0.41	7.82	0.34	3.67e-14	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22548000	chr2:32391035	SLC30A6	0.48	7.76	0.34	5.63e-14	Cognitive performance;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00761968	chr13:53314142	LECT1	-0.37	-7.95	-0.35	1.48e-14	Lewy body disease;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg05692746	chr2:100937584	LONRF2	-0.57	-9.46	-0.4	1.59e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.48e-13	Obesity-related traits;
LGG	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg00990874	chr7:1149470	C7orf50	-0.7	-11.16	-0.46	8.67e-26	Bronchopulmonary dysplasia;
LGG	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.25	0.36	1.61e-15	Mood instability;
LGG	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg03098644	chr7:100410630	EPHB4	0.47	7.18	0.32	2.83e-12	Other erythrocyte phenotypes;
LGG	trans	rs561341	0.882	rs563539	chr17:30307958	A/G	cg27661571	chr11:113659931	NA	-0.65	-9.42	-0.4	2.12e-19	Hip circumference adjusted for BMI;
LGG	cis	rs11581903	0.929	rs6679249	chr1:53050461	A/G	cg19751897	chr1:52520827	TXNDC12;BTF3L4	-0.48	-7.09	-0.31	4.94e-12	Joint mobility (Beighton score);
LGG	trans	rs2197308	0.631	rs4882308	chr12:38446252	G/C	cg06521331	chr12:34319734	NA	0.44	8.04	0.35	7.62e-15	Morning vs. evening chronotype;
LGG	cis	rs9463078	0.804	rs6458428	chr6:45179815	A/C	cg25276700	chr6:44698697	NA	-0.38	-7.71	-0.34	8.02e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg18335740	chr13:41363409	SLC25A15	0.61	12.3	0.5	2.84e-30	Lewy body disease;
LGG	cis	rs12145833	0.596	rs12123491	chr1:243297924	C/G	cg02356786	chr1:243265016	LOC731275	0.6	6.74	0.3	4.72e-11	Obesity (early onset extreme);
LGG	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg20821713	chr7:1055600	C7orf50	-0.48	-7.75	-0.34	5.72e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg11644478	chr21:40555479	PSMG1	-0.59	-9.98	-0.42	2.16e-21	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg07701084	chr6:150067640	NUP43	0.68	12.96	0.52	5.3e-33	Lung cancer;
LGG	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.73	0.3	5.12e-11	Glycated hemoglobin levels;
LGG	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg06636001	chr8:8085503	FLJ10661	-0.71	-14.73	-0.56	1.55e-40	Schizophrenia;
LGG	cis	rs2832191	0.791	rs2832187	chr21:30485543	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.87	-0.62	3.93e-50	Dental caries;
LGG	cis	rs2602836	0.830	rs2602874	chr4:100039396	A/T	cg12011299	chr4:100065546	ADH4	0.53	12.32	0.5	2.25e-30	HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs1062177	1.000	rs2347596	chr5:151179199	T/C	cg00977110	chr5:151150581	G3BP1	0.5	7.99	0.35	1.11e-14	Preschool internalizing problems;
LGG	cis	rs1109114	0.816	rs2963495	chr5:148596375	G/T	cg06539116	chr5:148597365	ABLIM3	-0.63	-16.37	-0.61	7.45e-48	Body mass index;
LGG	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg17376030	chr22:41985996	PMM1	0.44	7.22	0.32	2.1e-12	Vitiligo;
LGG	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg05425664	chr17:57184151	TRIM37	-0.63	-9.99	-0.42	2.09e-21	Intelligence (multi-trait analysis);
LGG	cis	rs477692	0.699	rs528549	chr10:131381574	A/G	cg05714579	chr10:131428358	MGMT	0.48	9.41	0.4	2.31e-19	Response to temozolomide;
LGG	cis	rs7666738	0.830	rs6846739	chr4:99016647	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4743820	0.620	rs10991786	chr9:93917158	T/C	cg14446406	chr9:93919335	NA	-0.9	-15.07	-0.57	4.61e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg14675211	chr2:100938903	LONRF2	-0.5	-8.14	-0.35	3.64e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs11076573	chr16:48632758	A/G	cg04672837	chr16:48644449	N4BP1	0.56	9.21	0.39	1.17e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7975161	0.580	rs10735393	chr12:104680661	G/T	cg25273343	chr12:104657179	TXNRD1	-0.62	-7.12	-0.31	4.23e-12	Toenail selenium levels;
LGG	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs3824867	0.920	rs7111873	chr11:47469439	A/G	cg20307385	chr11:47447363	PSMC3	0.47	7.55	0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs2303319	1.000	rs62194493	chr2:162218614	G/A	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs9487094	0.813	rs11753645	chr6:109695054	T/C	cg16315928	chr6:109776240	MICAL1	0.51	8.56	0.37	1.62e-16	Height;
LGG	cis	rs4853012	0.838	rs58759652	chr2:74344902	A/T	cg19729930	chr2:74357872	NA	0.54	11.51	0.47	3.99e-27	Gestational age at birth (maternal effect);
LGG	cis	rs490234	0.841	rs497531	chr9:128314664	C/T	cg14078157	chr9:128172775	NA	0.44	8.25	0.36	1.69e-15	Mean arterial pressure;
LGG	cis	rs79149102	0.579	rs58645417	chr15:75325858	T/G	cg17294928	chr15:75287854	SCAMP5	-0.82	-8.9	-0.38	1.32e-17	Lung cancer;
LGG	trans	rs190945449	1	rs190945449	chr6:26828359	C/T	cg01620082	chr3:125678407	NA	-0.78	-7.94	-0.35	1.55e-14	Urinary tract infection frequency;
LGG	cis	rs7566780	0.758	rs62114564	chr2:16706080	G/T	cg09580478	chr2:16689509	NA	-0.5	-7.26	-0.32	1.65e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14154082	chr13:112174009	NA	-0.4	-8.94	-0.38	9.27e-18	Menarche (age at onset);
LGG	cis	rs8064024	0.619	rs4141486	chr16:4896780	A/C	cg08329684	chr16:4932620	PPL	0.52	11.74	0.48	4.69e-28	Cancer;
LGG	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-13.04	-0.52	2.63e-33	Bipolar disorder;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg19147804	chr7:1989927	MAD1L1	0.53	10.45	0.44	4.23e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg02018176	chr4:1364513	KIAA1530	0.42	9.45	0.4	1.7e-19	Obesity-related traits;
LGG	trans	rs1728785	0.818	rs1069289	chr16:68585317	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.97	0.45	4.72e-25	Ulcerative colitis;
LGG	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24308560	chr3:49941425	MST1R	0.22	6.87	0.3	2.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg16301924	chr13:53314226	LECT1	-0.44	-8.87	-0.38	1.57e-17	Lewy body disease;
LGG	cis	rs2451279	0.565	rs2451256	chr6:159507338	A/G	cg01046905	chr6:159515345	NA	-0.34	-7.17	-0.32	2.92e-12	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg23985595	chr17:80112537	CCDC57	0.39	7.76	0.34	5.43e-14	Life satisfaction;
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg16268157	chr7:99778414	STAG3	0.49	8.18	0.36	2.67e-15	Lung function (FEV1/FVC);
LGG	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg24375607	chr4:120327624	NA	-0.67	-10.9	-0.45	9.1e-25	Corneal astigmatism;
LGG	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	cis	rs9910055	0.509	rs9916444	chr17:42313512	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.38	6.77	0.3	3.99e-11	Total body bone mineral density;
LGG	cis	rs11209002	0.567	rs2755268	chr1:67539881	T/C	cg02640540	chr1:67518911	SLC35D1	0.4	6.71	0.3	5.72e-11	Crohn's disease;
LGG	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg12386194	chr3:101231763	SENP7	0.73	12.81	0.51	2.3e-32	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.69e-21	Menopause (age at onset);
LGG	cis	rs35146811	0.695	rs1727132	chr7:99812297	T/C	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.79e-13	Coronary artery disease;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.4	0.36	5.66e-16	Schizophrenia;
LGG	trans	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg27661571	chr11:113659931	NA	-0.52	-7.24	-0.32	1.83e-12	Hip circumference adjusted for BMI;
LGG	cis	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg03060546	chr3:49711283	APEH	0.57	8.71	0.38	5.47e-17	Resting heart rate;
LGG	cis	rs4731207	0.503	rs1481325	chr7:124625753	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs3806843	0.619	rs2569160	chr5:140028774	T/C	cg19875535	chr5:140030758	IK	-0.59	-12.19	-0.49	7.53e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg04662567	chr6:169592167	NA	-0.81	-11.63	-0.48	1.35e-27	Pulse pressure;
LGG	cis	rs2073499	1.000	rs2301639	chr3:50380661	G/A	cg03645007	chr3:50255295	SLC38A3	0.61	6.68	0.3	6.66e-11	Schizophrenia;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg12070911	chr6:150209640	RAET1E	0.33	8.15	0.35	3.4e-15	Lung cancer;
LGG	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-7.28	-0.32	1.49e-12	Electroencephalogram traits;
LGG	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg11317459	chr13:21872234	NA	1.39	27.17	0.78	6.87e-98	White matter hyperintensity burden;
LGG	cis	rs17767392	1.000	rs7142180	chr14:71759895	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.21e-18	Mitral valve prolapse;
LGG	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg02951883	chr7:2050386	MAD1L1	0.46	7.85	0.34	2.97e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs736408	0.812	rs2071507	chr3:52826707	G/A	cg14092988	chr3:52407081	DNAH1	0.33	8.42	0.36	4.91e-16	Bipolar disorder;
LGG	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.0	0.64	2.58e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs73198271	1.000	rs4840356	chr8:8607527	A/G	cg16141378	chr3:129829833	LOC729375	0.37	6.88	0.3	1.94e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs6825911	0.723	rs1318244	chr4:111359510	G/A	cg10580549	chr19:53101634	ZNF137	0.55	6.97	0.31	1.1e-11	Blood pressure;
LGG	trans	rs4819388	0.915	rs4818892	chr21:45650085	A/G	cg17383793	chr5:52405638	MOCS2	0.45	7.08	0.31	5.42e-12	Celiac disease;
LGG	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg12179176	chr11:130786555	SNX19	0.84	17.68	0.63	8.06e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.6	-0.51	1.66e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.37	-0.36	6.66e-16	IgG glycosylation;
LGG	cis	rs3096299	0.685	rs2911244	chr16:89521860	A/G	cg08392591	chr16:89556376	ANKRD11	0.55	8.58	0.37	1.46e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs3741151	0.773	rs58564192	chr11:73228904	G/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.87	0.34	2.57e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.64	-0.33	1.29e-13	Systemic lupus erythematosus;
LGG	cis	rs6460942	1.000	rs7796485	chr7:12405676	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.86	-0.3	2.19e-11	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg04863758	chr4:1303710	MAEA	0.42	7.28	0.32	1.46e-12	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.01e-42	Menopause (age at onset);
LGG	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15541040	chr2:3486749	NA	-0.42	-7.39	-0.32	6.89e-13	Neurofibrillary tangles;
LGG	trans	rs7618501	1.000	rs7648987	chr3:49868455	A/G	cg21659725	chr3:3221576	CRBN	0.92	20.44	0.69	1.22e-66	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.737	rs6544197	chr2:39315388	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-7.99	-0.35	1.11e-14	Corticobasal degeneration;
LGG	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-9.92	-0.42	3.69e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9902453	0.765	rs2169810	chr17:28167941	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.91	0.54	5.11e-37	Coffee consumption (cups per day);
LGG	trans	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.46	0.33	4.21e-13	Homoarginine levels;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg26769984	chr7:1090371	C7orf50	0.43	8.68	0.37	6.65e-17	Bronchopulmonary dysplasia;
LGG	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg18245976	chr7:158708271	WDR60	-0.58	-7.62	-0.33	1.46e-13	Height;
LGG	cis	rs1927790	0.727	rs12583988	chr13:96991602	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.94	-0.31	1.33e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16580737	chr3:154797589	MME	0.43	7.06	0.31	6.05e-12	Gut microbiome composition (summer);
LGG	cis	rs10865541	0.870	rs6548161	chr2:3424350	A/G	cg11642891	chr2:3452563	TTC15	-0.46	-9.33	-0.4	4.51e-19	Obesity-related traits;
LGG	cis	rs7546	0.505	rs760118	chr16:4940994	A/G	cg08329684	chr16:4932620	PPL	-0.56	-12.61	-0.51	1.45e-31	Cancer;
LGG	cis	rs1408799	0.711	rs10960732	chr9:12633495	G/A	cg05274944	chr9:12693694	TYRP1	0.33	7.58	0.33	1.9e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs9815354	0.680	rs114478966	chr3:42007050	T/C	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg08344181	chr3:125677491	NA	-0.83	-8.09	-0.35	5.23e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg11473876	chr11:109292803	C11orf87	0.46	9.37	0.4	3.11e-19	Schizophrenia;
LGG	trans	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg06521331	chr12:34319734	NA	0.46	8.13	0.35	3.94e-15	Bladder cancer;
LGG	cis	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg21775007	chr8:11205619	TDH	0.81	14.4	0.56	4.02e-39	Retinal vascular caliber;
LGG	cis	rs12410462	1.000	rs16847833	chr1:227626662	G/A	cg23173402	chr1:227635558	NA	0.62	10.35	0.43	1.01e-22	Major depressive disorder;
LGG	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg15017067	chr4:17643749	FAM184B	0.29	6.69	0.3	6.51e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11229555	0.598	rs7930623	chr11:58197641	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs72781680	0.898	rs72782113	chr2:24024952	G/C	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg23250157	chr14:64679961	SYNE2	0.38	6.66	0.3	7.76e-11	Atrial fibrillation;
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.45	-0.33	4.57e-13	Bipolar disorder;
LGG	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs7582720	0.775	rs72938351	chr2:204151503	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	8.33	0.36	9.03e-16	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9788721	0.934	rs1317286	chr15:78896129	A/G	cg17108064	chr15:78857060	CHRNA5	-0.35	-7.15	-0.32	3.38e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs10883723	0.810	rs7094366	chr10:104274730	C/G	cg05096777	chr10:104283225	SUFU	0.33	7.2	0.32	2.37e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27312727	chr5:77590915	AP3B1	-0.45	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg15764593	chr10:829463	NA	-0.67	-9.86	-0.42	5.81e-21	Uric acid levels;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	7.41	0.33	6.11e-13	Obesity-related traits;
LGG	cis	rs757278	0.591	rs1429568	chr7:117305816	T/C	cg10524701	chr7:117356490	CTTNBP2	0.42	7.54	0.33	2.59e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs9393777	0.920	rs34071253	chr6:27391802	C/T	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.65	-0.44	7.53e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs12282928	0.513	rs7948537	chr11:48342072	T/A	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg02733842	chr7:1102375	C7orf50	0.66	7.96	0.35	1.38e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.778	rs6505219	chr17:29265621	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.55	-7.19	-0.32	2.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11098499	0.954	rs6849561	chr4:120409694	C/G	cg25214090	chr10:38739885	LOC399744	-0.72	-12.85	-0.51	1.58e-32	Corneal astigmatism;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.58	-11.39	-0.47	1.13e-26	Prudent dietary pattern;
LGG	cis	rs61906588	0.587	rs6589547	chr11:116361705	C/A	cg12564567	chr11:116371188	NA	-0.38	-7.07	-0.31	5.85e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs834603	0.735	rs7801481	chr7:47447215	A/T	cg23694490	chr7:47445681	TNS3	-0.47	-13.7	-0.54	4.28e-36	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg19761014	chr17:28927070	LRRC37B2	0.7	8.75	0.38	3.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg01209934	chr8:27950298	ELP3	0.4	6.87	0.3	2.04e-11	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg04008888	chr11:68622739	NA	-0.55	-11.9	-0.48	1.11e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4481887	0.893	rs10888337	chr1:248428227	A/G	cg13385794	chr1:248469461	NA	-0.47	-7.94	-0.35	1.53e-14	Common traits (Other);
LGG	cis	rs981844	1.000	rs2405430	chr4:154658391	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.63	0.33	1.38e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.17	0.39	1.52e-18	Lung cancer in ever smokers;
LGG	cis	rs11677416	0.885	rs4849119	chr2:113523463	G/C	cg27083787	chr2:113543245	IL1A	0.54	8.98	0.39	6.96e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs757278	0.552	rs4730794	chr7:117311123	A/G	cg10524701	chr7:117356490	CTTNBP2	0.43	7.75	0.34	5.89e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs9326248	0.559	rs4938334	chr11:116931042	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.94	0.45	6.22e-25	Blood protein levels;
LGG	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.59e-15	Obesity-related traits;
LGG	cis	rs701145	0.585	rs1713804	chr3:153799122	A/G	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.61	-9.96	-0.42	2.73e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs1218582	0.772	rs4845694	chr1:154911651	C/G	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.2e-31	Prostate cancer;
LGG	cis	rs75920871	0.841	rs77250716	chr11:116877353	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs3820068	0.532	rs78917815	chr1:15920821	A/G	cg05660106	chr1:15850417	CASP9	0.87	17.62	0.63	1.46e-53	Systolic blood pressure;
LGG	cis	rs754423	0.515	rs768022	chr14:52553180	G/C	cg12071775	chr14:52591786	NA	0.41	6.85	0.3	2.36e-11	Craniofacial microsomia;
LGG	cis	rs10231759	0.617	rs56077833	chr7:150513046	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.43	0.36	4.39e-16	Height;
LGG	cis	rs7264396	0.635	rs6058355	chr20:34491343	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.35e-12	Total cholesterol levels;
LGG	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.31	0.6	1.33e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12580194	0.593	rs11171430	chr12:55755254	A/G	cg19537932	chr12:55886519	OR6C68	-0.55	-10.17	-0.43	4.66e-22	Cancer;
LGG	cis	rs6694672	1.000	rs1571964	chr1:197113073	G/A	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.69e-12	Asthma;
LGG	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg03929089	chr4:120376271	NA	0.87	16.34	0.6	1.03e-47	Coronary artery disease;
LGG	cis	rs367943	1.000	rs348963	chr5:112819027	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.3	-0.55	1.07e-38	Type 2 diabetes;
LGG	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg20818283	chr2:191399100	TMEM194B	0.29	6.93	0.31	1.4e-11	Pulse pressure;
LGG	cis	rs2540226	0.539	rs2716694	chr2:39911336	A/G	cg02886589	chr2:39892450	TMEM178	0.29	8.25	0.36	1.7e-15	Personality dimensions;
LGG	cis	rs2075371	1.000	rs2244694	chr7:133987093	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.45	0.58	1e-43	Mean platelet volume;
LGG	trans	rs2562456	0.793	rs3853838	chr19:21601994	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.08	-0.35	5.55e-15	Retinal vascular caliber;
LGG	cis	rs9815354	0.812	rs73071236	chr3:41992042	A/G	cg03022575	chr3:42003672	ULK4	0.79	9.25	0.4	8.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs926392	0.572	rs6129156	chr20:37672209	A/C	cg16355469	chr20:37678765	NA	0.62	9.81	0.41	9.17e-21	Dialysis-related mortality;
LGG	cis	rs6426558	0.559	rs7549520	chr1:227258858	G/C	cg10327440	chr1:227177885	CDC42BPA	0.61	10.24	0.43	2.52e-22	Neutrophil percentage of white cells;
LGG	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg15522984	chr1:182991683	LAMC1	0.48	9.92	0.42	3.7e-21	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg02725872	chr8:58115012	NA	-1.04	-14.01	-0.55	2.01e-37	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg11878867	chr6:150167359	LRP11	-0.54	-10.91	-0.45	7.95e-25	Lung cancer;
LGG	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg23815491	chr16:72088622	HP	0.5	11.07	0.46	1.99e-25	Fibrinogen levels;
LGG	cis	rs28830936	1.000	rs11629678	chr15:41932530	G/A	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-6.78	-0.3	3.69e-11	Diastolic blood pressure;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg11878867	chr6:150167359	LRP11	-0.55	-11.81	-0.48	2.6e-28	Lung cancer;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.93	-0.35	1.61e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2279817	0.863	rs12749985	chr1:18026004	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.66	-12.01	-0.49	4.08e-29	Neuroticism;
LGG	cis	rs977987	0.806	rs4887824	chr16:75441613	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg00086871	chr4:6988644	TBC1D14	1.09	10.08	0.42	1.02e-21	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg10556349	chr10:835070	NA	-0.27	-6.69	-0.3	6.27e-11	Survival in rectal cancer;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.22	-0.49	5.63e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg14689365	chr7:158441557	NCAPG2	0.59	10.35	0.43	1.04e-22	Height;
LGG	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg00990874	chr7:1149470	C7orf50	-0.8	-14.42	-0.56	3.29e-39	Bronchopulmonary dysplasia;
LGG	cis	rs888405	0.541	rs697287	chr3:64211102	G/A	cg25818214	chr3:64211155	PRICKLE2	0.44	7.71	0.34	7.61e-14	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.4	0.36	5.43e-16	Educational attainment;
LGG	cis	rs2456568	0.531	rs7105060	chr11:93661268	C/A	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	11.62	0.48	1.44e-27	Prudent dietary pattern;
LGG	cis	rs981844	0.712	rs55656103	chr4:154757478	T/C	cg14289246	chr4:154710475	SFRP2	0.61	10.4	0.44	6.75e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs10979	1.000	rs9386034	chr6:143890572	T/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.4	-0.5	1.11e-30	Hypospadias;
LGG	cis	rs4731207	0.596	rs7799523	chr7:124592033	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.47e-11	Cutaneous malignant melanoma;
LGG	cis	rs62238980	0.614	rs17683430	chr22:32487700	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs12464559	0.649	rs10171724	chr2:152672482	T/A	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs2274273	1.000	rs10140857	chr14:55619611	G/C	cg04306507	chr14:55594613	LGALS3	0.58	15.49	0.58	6.92e-44	Protein biomarker;
LGG	cis	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg09307838	chr4:120376055	NA	0.81	13.56	0.53	1.66e-35	Corneal astigmatism;
LGG	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg21747090	chr2:27597821	SNX17	-0.38	-6.91	-0.31	1.66e-11	Total body bone mineral density;
LGG	cis	rs8038465	0.592	rs1542579	chr15:73935897	A/G	cg15420318	chr15:73925796	NPTN	0.5	8.56	0.37	1.7e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg02297831	chr4:17616191	MED28	0.52	10.03	0.42	1.54e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12286929	0.687	rs6589485	chr11:115083875	G/A	cg04055981	chr11:115044050	NA	-0.38	-7.21	-0.32	2.36e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.61	-0.37	1.15e-16	Morning vs. evening chronotype;
LGG	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg27535305	chr1:53392650	SCP2	0.35	8.0	0.35	1.02e-14	Monocyte count;
LGG	cis	rs6032067	0.929	rs35475980	chr20:43821080	A/T	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs7011049	0.722	rs115570683	chr8:53867155	T/C	cg26025543	chr8:53854495	NA	0.59	8.37	0.36	6.86e-16	Systolic blood pressure;
LGG	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg06238570	chr21:40685208	BRWD1	-0.54	-8.86	-0.38	1.7e-17	Cognitive function;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs909674	0.818	rs5757681	chr22:39845547	A/G	cg04986931	chr22:39850128	NA	0.39	8.53	0.37	2.14e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs8114671	1.000	rs8114671	chr20:33789142	C/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.41	-0.33	5.95e-13	Height;
LGG	cis	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg24623649	chr8:11872141	NA	-0.3	-7.01	-0.31	8.47e-12	Retinal vascular caliber;
LGG	cis	rs28374715	0.557	rs11855854	chr15:41434729	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-16.08	-0.6	1.54e-46	Ulcerative colitis;
LGG	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg25823085	chr7:87105416	ABCB4	0.3	7.4	0.33	6.54e-13	Gallbladder cancer;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg16606324	chr3:10149918	C3orf24	0.56	7.46	0.33	4.22e-13	Alzheimer's disease;
LGG	cis	rs8180040	0.764	rs12629262	chr3:47196580	C/T	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs4409675	0.576	rs2815707	chr1:28238880	T/C	cg23691781	chr1:28212827	C1orf38	0.42	10.93	0.45	6.65e-25	Corneal astigmatism;
LGG	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg13114125	chr14:105738426	BRF1	0.83	17.03	0.62	7.8e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4639966	0.836	rs4499035	chr11:118610463	C/T	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.25	-0.36	1.69e-15	Systemic lupus erythematosus;
LGG	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg03264133	chr6:25882463	NA	-0.53	-9.97	-0.42	2.39e-21	Blood metabolite levels;
LGG	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg17294928	chr15:75287854	SCAMP5	0.65	12.12	0.49	1.44e-29	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg07132326	chr6:150258058	NA	0.39	8.25	0.36	1.66e-15	Testicular germ cell tumor;
LGG	cis	rs1793639	0.967	rs1793638	chr11:131931753	A/G	cg13908476	chr11:131942942	NTM	0.44	9.21	0.39	1.14e-18	Myopia;
LGG	cis	rs9388451	0.807	rs1268070	chr6:126041164	A/G	cg10911889	chr6:126070802	HEY2	0.42	6.86	0.3	2.23e-11	Brugada syndrome;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24465118	chr20:47895107	C20orf199;SNORD12C;ZNFX1	0.42	6.8	0.3	3.16e-11	Cognitive performance;
LGG	cis	rs7124681	0.528	rs74608150	chr11:47696214	A/T	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	2.01e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs11165623	0.602	rs7517055	chr1:97007781	C/G	cg10631902	chr5:14652156	NA	-0.45	-9.47	-0.4	1.39e-19	Hip circumference;Waist circumference;
LGG	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg14784868	chr12:69753453	YEATS4	-0.66	-12.25	-0.49	4.26e-30	Blood protein levels;
LGG	trans	rs12517041	1.000	rs4701365	chr5:23315034	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.1e-25	Calcium levels;
LGG	trans	rs7615952	0.673	rs7632557	chr3:125634881	G/C	cg07211511	chr3:129823064	LOC729375	-1.37	-20.72	-0.69	6.04e-68	Blood pressure (smoking interaction);
LGG	cis	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg09904177	chr6:26538194	HMGN4	-0.58	-7.89	-0.34	2.26e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12286929	0.637	rs7125361	chr11:115080042	C/G	cg04055981	chr11:115044050	NA	0.36	6.66	0.3	7.68e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-15.94	-0.6	6.45e-46	Platelet count;
LGG	cis	rs6723226	0.572	rs176404	chr2:32638846	T/C	cg02381751	chr2:32503542	YIPF4	-0.57	-9.65	-0.41	3.35e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg04568710	chr12:38710424	ALG10B	-0.35	-7.38	-0.32	7.32e-13	Morning vs. evening chronotype;
LGG	cis	rs28588043	1.000	rs28863252	chr1:170975632	C/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.47	-0.33	3.91e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs9902453	0.967	rs8072664	chr17:28333385	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	trans	rs1032833	0.732	rs80238877	chr2:179959713	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.68	0.37	6.76e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7267979	0.866	rs6138609	chr20:25570985	T/A	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7980799	0.682	rs10437795	chr12:33635336	C/G	cg26384229	chr12:38710491	ALG10B	-0.66	-12.12	-0.49	1.48e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-12.09	-0.49	1.89e-29	HDL cholesterol;
LGG	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.01	-0.31	8.7e-12	Triglycerides;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.91	-0.38	1.14e-17	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-8.06	-0.35	6.55e-15	Life satisfaction;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg13397359	chr6:42928475	GNMT	0.57	15.91	0.59	8.54e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2018055	0.618	rs6568978	chr6:117796163	A/G	cg14611402	chr6:117803162	DCBLD1	0.31	8.96	0.38	7.77e-18	Diastolic blood pressure;
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	4.94e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-6.96	-0.31	1.19e-11	Alzheimer's disease (late onset);
LGG	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg15269541	chr15:43626905	ADAL	-0.42	-7.01	-0.31	8.47e-12	Lung cancer in ever smokers;
LGG	cis	rs12724450	0.546	rs79696733	chr1:150434843	C/T	cg03818307	chr1:150480534	ECM1	0.49	7.19	0.32	2.61e-12	Blood protein levels;
LGG	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg06346307	chr22:19949965	COMT	0.35	9.2	0.39	1.27e-18	Blood metabolite levels;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.54	0.56	9.75e-40	Lung cancer;
LGG	cis	rs9916302	0.851	rs4390625	chr17:37620347	A/G	cg00129232	chr17:37814104	STARD3	-0.6	-11.24	-0.46	4.21e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg11764359	chr7:65958608	NA	0.63	10.87	0.45	1.14e-24	Aortic root size;
LGG	cis	rs7133214	0.771	rs11049142	chr12:27929774	A/G	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.91	-0.31	1.58e-11	Gut microbiota (functional units);
LGG	cis	rs4901847	1.000	rs4901847	chr14:58559241	C/T	cg15908186	chr14:58618357	C14orf37	0.54	9.64	0.41	3.61e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs741702	0.892	rs11085824	chr19:13001547	A/G	cg11738485	chr19:12877000	HOOK2	-0.45	-7.14	-0.32	3.56e-12	Red blood cell traits;
LGG	cis	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg19761014	chr17:28927070	LRRC37B2	0.63	7.63	0.33	1.34e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.58	-0.37	1.47e-16	Menarche (age at onset);
LGG	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11792861	0.589	rs2176692	chr9:111927723	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	7.7	0.34	8.3e-14	Menarche (age at onset);
LGG	cis	rs74781061	0.929	rs12442097	chr15:74847133	A/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.12	-0.31	4.26e-12	Endometriosis;
LGG	cis	rs952623	0.501	rs1000869	chr7:39082227	A/G	cg15212455	chr7:39170539	POU6F2	0.3	6.81	0.3	3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11644362	0.903	rs2014726	chr16:12992849	T/C	cg06890432	chr16:12997467	SHISA9	-0.32	-6.95	-0.31	1.25e-11	Positive affect;Subjective well-being;
LGG	trans	rs7395662	0.929	rs8186263	chr11:48737935	A/T	cg03929089	chr4:120376271	NA	-0.44	-7.15	-0.32	3.34e-12	HDL cholesterol;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22433210	chr17:43662623	NA	-0.63	-10.83	-0.45	1.62e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.92	0.42	3.68e-21	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg18681998	chr4:17616180	MED28	0.82	17.79	0.64	2.44e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23556447	chr6:90529595	MDN1	0.49	8.16	0.35	3.23e-15	Cognitive performance;
LGG	cis	rs7766436	0.553	rs55936918	chr6:22610269	A/T	cg13666174	chr6:22585274	NA	-0.4	-7.16	-0.32	3.25e-12	Coronary artery disease;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg09346547	chr7:75189280	HIP1	-0.33	-7.11	-0.31	4.39e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg26031613	chr14:104095156	KLC1	-0.59	-9.38	-0.4	2.92e-19	Reticulocyte count;
LGG	cis	rs6933660	0.646	rs3736176	chr6:151773320	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.84	18.19	0.65	3.65e-56	Menarche (age at onset);
LGG	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg03735888	chr19:58951602	ZNF132	0.41	8.32	0.36	9.76e-16	Uric acid clearance;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06481639	chr22:41940642	POLR3H	-0.56	-8.22	-0.36	2.14e-15	Vitiligo;
LGG	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg03929089	chr4:120376271	NA	0.89	17.15	0.62	2.04e-51	Height;
LGG	cis	rs9715521	0.645	rs13134207	chr4:59848379	G/T	cg11281224	chr4:60001000	NA	-0.45	-7.45	-0.33	4.73e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9467711	0.591	rs68149500	chr6:26111271	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.76	7.81	0.34	3.81e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72945132	0.882	rs7129843	chr11:70180381	G/A	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.53e-15	Coronary artery disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11162385	chr20:25604740	NANP	0.4	7.05	0.31	6.73e-12	Bipolar disorder;
LGG	cis	rs4727027	0.736	rs12704084	chr7:148915050	C/G	cg23583168	chr7:148888333	NA	-0.88	-17.98	-0.64	3.26e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00170564	chr12:107714106	BTBD11	0.42	7.02	0.31	8.16e-12	Gut microbiome composition (summer);
LGG	cis	rs6450176	0.909	rs2448	chr5:53302354	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.26	-0.46	3.66e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg05425664	chr17:57184151	TRIM37	0.57	9.07	0.39	3.47e-18	Intelligence (multi-trait analysis);
LGG	cis	rs11969893	0.850	rs9498418	chr6:101331838	A/T	cg12253828	chr6:101329408	ASCC3	1.04	9.13	0.39	2.13e-18	Economic and political preferences (immigration/crime);
LGG	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg15627072	chr1:2432621	PLCH2	0.36	8.13	0.35	4.05e-15	Ulcerative colitis;
LGG	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.47	9.64	0.41	3.67e-20	Aortic root size;
LGG	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10940138	0.779	rs17321143	chr5:67247066	T/C	ch.5.1281357F	chr5:67228439	NA	0.74	12.5	0.5	4.41e-31	Menarche (age at onset);
LGG	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs526231	0.578	rs2112886	chr5:102251382	C/T	cg23492399	chr5:102201601	PAM	0.61	9.38	0.4	2.99e-19	Primary biliary cholangitis;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.29	-0.36	1.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17420218	chr2:20102066	TTC32	0.43	6.96	0.31	1.15e-11	Cognitive performance;
LGG	cis	rs4901847	0.562	rs11627221	chr14:58617216	G/T	cg15908186	chr14:58618357	C14orf37	0.67	12.44	0.5	7.61e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7586879	0.828	rs9631061	chr2:25109804	C/T	cg04586622	chr2:25135609	ADCY3	0.35	8.49	0.37	2.87e-16	Body mass index;
LGG	cis	rs75059851	0.756	rs11223654	chr11:133841579	C/T	cg20042908	chr11:133852938	NA	-0.76	-14.2	-0.55	3.1e-38	Schizophrenia;
LGG	cis	rs67460515	0.531	rs1585483	chr3:160843111	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-8.44	-0.37	3.98e-16	Parkinson's disease;
LGG	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24110177	chr3:50126178	RBM5	-0.56	-10.15	-0.43	5.25e-22	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.967	rs2911256	chr16:89485096	G/C	cg08392591	chr16:89556376	ANKRD11	0.45	7.08	0.31	5.46e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2197308	0.765	rs10880643	chr12:37926452	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.54	-0.63	3.44e-53	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.629	rs7761762	chr6:86205968	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	10.16	0.43	5.03e-22	Response to antipsychotic treatment;
LGG	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg17201900	chr20:34330562	RBM39	0.5	6.75	0.3	4.45e-11	Total cholesterol levels;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.59	10.07	0.42	1.05e-21	Obesity-related traits;
LGG	cis	rs4595586	0.546	rs2056159	chr12:39270417	C/G	cg13010199	chr12:38710504	ALG10B	0.6	10.86	0.45	1.28e-24	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.57	0.33	2.05e-13	Response to antipsychotic treatment;
LGG	cis	rs13424612	1.000	rs4854058	chr2:240923677	C/A	cg01812947	chr2:240904978	NDUFA10	0.42	7.06	0.31	6.31e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg23034840	chr1:205782522	SLC41A1	-0.73	-14.06	-0.55	1.2e-37	Monocyte percentage of white cells;
LGG	cis	rs4555082	0.957	rs3825762	chr14:105752404	T/C	cg10792982	chr14:105748885	BRF1	0.56	11.13	0.46	1.12e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11969893	0.737	rs1854483	chr6:101378117	G/A	cg12253828	chr6:101329408	ASCC3	1.11	9.62	0.41	4.23e-20	Economic and political preferences (immigration/crime);
LGG	cis	rs787274	1.000	rs885387	chr9:115596390	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg05973401	chr12:123451056	ABCB9	0.47	7.87	0.34	2.57e-14	Platelet count;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg23131131	chr22:24373011	LOC391322	-0.49	-8.08	-0.35	5.78e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg25358565	chr5:93447407	FAM172A	1.32	16.4	0.61	5.75e-48	Diabetic retinopathy;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg09038676	chr11:67351608	GSTP1	-0.36	-7.24	-0.32	1.83e-12	Mean corpuscular volume;
LGG	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg05535760	chr7:792225	HEATR2	-0.81	-11.47	-0.47	5.43e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg15971980	chr6:150254442	NA	0.44	8.29	0.36	1.28e-15	Lung cancer;
LGG	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg01194073	chr14:101175302	NA	0.45	6.74	0.3	4.86e-11	Plateletcrit;
LGG	cis	rs6740322	0.748	rs13432574	chr2:43544328	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.72	-0.41	1.85e-20	Coronary artery disease;
LGG	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg02743256	chr7:2109353	MAD1L1	-0.38	-7.16	-0.32	3.22e-12	Neuroticism;
LGG	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg14500267	chr11:67383377	NA	-0.41	-7.31	-0.32	1.17e-12	Mean corpuscular volume;
LGG	cis	rs7649275	0.938	rs2612029	chr3:53773492	T/C	cg21503701	chr3:53781065	CACNA1D	-0.5	-7.36	-0.32	8.39e-13	Trans fatty acid levels;
LGG	cis	rs7255045	0.742	rs10420014	chr19:12960947	G/T	cg07955356	chr19:12992479	DNASE2	0.45	6.81	0.3	3.01e-11	Mean corpuscular volume;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.76	-0.3	4.25e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7589342	0.839	rs35812588	chr2:106432201	C/T	cg16077055	chr2:106428750	NCK2	0.32	8.39	0.36	6.16e-16	Addiction;
LGG	trans	rs453301	0.574	rs10081437	chr8:8948979	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.46	-0.33	4.35e-13	Joint mobility (Beighton score);
LGG	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.55	0.44	1.76e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2224391	0.628	rs11752747	chr6:5272671	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-6.77	-0.3	3.96e-11	Height;
LGG	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg24764310	chr7:157512201	PTPRN2	-0.46	-10.01	-0.42	1.68e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs7829975	0.560	rs17154599	chr8:8551418	C/T	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.95e-13	Mood instability;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg21963583	chr11:68658836	MRPL21	0.6	10.3	0.43	1.6e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12915845	0.584	rs7403482	chr15:89062709	A/T	cg05013243	chr15:89149849	MIR1179	0.35	7.28	0.32	1.47e-12	Menarche (age at onset);
LGG	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg20387954	chr3:183756860	HTR3D	0.65	13.31	0.53	1.79e-34	Anterior chamber depth;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg02725872	chr8:58115012	NA	-0.92	-12.31	-0.5	2.61e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21862992	chr11:68658383	NA	0.5	8.55	0.37	1.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs11096990	0.855	rs2711935	chr4:39162457	A/G	cg24403649	chr4:39172243	NA	-0.48	-7.64	-0.33	1.24e-13	Cognitive function;
LGG	cis	rs7527798	0.592	rs12411037	chr1:207857158	T/C	cg09232269	chr1:207846808	CR1L	-0.38	-7.26	-0.32	1.62e-12	Erythrocyte sedimentation rate;
LGG	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.56	-0.37	1.63e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.3	-0.4	5.61e-19	Retinal vascular caliber;
LGG	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg08508325	chr11:3079039	CARS	0.38	7.0	0.31	9.24e-12	Calcium levels;
LGG	cis	rs4474465	0.646	rs10793335	chr11:78279005	C/G	cg27205649	chr11:78285834	NARS2	0.6	11.17	0.46	8.52e-26	Alzheimer's disease (survival time);
LGG	cis	rs765787	0.530	rs11636395	chr15:45535684	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.34	-0.32	9.45e-13	Uric acid levels;
LGG	cis	rs7674212	0.570	rs2251634	chr4:104082349	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-7.34	-0.32	9.77e-13	Type 2 diabetes;
LGG	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg09448879	chr15:79043637	NA	-0.35	-7.16	-0.32	3.25e-12	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg16751781	chr15:78858589	CHRNA5	0.42	7.74	0.34	6.25e-14	Sudden cardiac arrest;
LGG	cis	rs12949688	0.682	rs7503947	chr17:55838518	C/A	cg12582317	chr17:55822272	NA	0.53	12.47	0.5	5.61e-31	Schizophrenia;
LGG	cis	rs868036	0.915	rs4489954	chr15:68072075	A/C	cg08079166	chr15:68083412	MAP2K5	-0.37	-8.29	-0.36	1.24e-15	Restless legs syndrome;
LGG	cis	rs10193935	1.000	rs13424523	chr2:42413562	T/G	cg27598129	chr2:42591480	NA	-0.64	-9.41	-0.4	2.35e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	6.01e-22	Menopause (age at onset);
LGG	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.95	0.35	1.4e-14	Iron status biomarkers;
LGG	cis	rs11122272	0.735	rs2486729	chr1:231535584	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs7824557	0.527	rs10109537	chr8:11239640	C/T	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.37e-17	Retinal vascular caliber;
LGG	cis	rs10791097	0.694	rs1050071	chr11:130747231	C/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.8e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg11168104	chr5:1857477	NA	-0.4	-7.0	-0.31	9.24e-12	Cardiovascular disease risk factors;
LGG	trans	rs9467711	0.606	rs9357006	chr6:26364628	A/C	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs12517041	1.000	rs10057246	chr5:23294721	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg18252515	chr7:66147081	NA	-1.4	-19.23	-0.67	5.22e-61	Diabetic kidney disease;
LGG	cis	rs12135191	0.967	rs11577253	chr1:236465227	A/T	cg21399712	chr1:236511386	NA	-0.39	-7.54	-0.33	2.46e-13	Urate levels (BMI interaction);
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.68	0.34	9.3e-14	Prostate cancer;
LGG	cis	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg06636001	chr8:8085503	FLJ10661	0.58	11.44	0.47	7.08e-27	Mood instability;
LGG	trans	rs1941687	0.797	rs12607190	chr18:31394699	G/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.66	-0.37	7.7e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10504130	0.569	rs4534123	chr8:52677857	G/T	cg22653915	chr8:52722023	PXDNL	0.43	6.87	0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg17340268	chr14:105411764	AHNAK2	0.39	7.13	0.31	3.79e-12	Rheumatoid arthritis;
LGG	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21659725	chr3:3221576	CRBN	0.55	9.51	0.4	1.06e-19	Body mass index;
LGG	cis	rs6121246	0.738	rs6121242	chr20:30410877	T/C	cg13852791	chr20:30311386	BCL2L1	0.79	12.72	0.51	5.46e-32	Mean corpuscular hemoglobin;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg06873352	chr17:61820015	STRADA	0.65	12.04	0.49	3.09e-29	Prudent dietary pattern;
LGG	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	cg07928641	chr1:182991847	LAMC1	0.44	8.51	0.37	2.5e-16	Colorectal cancer;
LGG	cis	rs10504130	0.502	rs877248	chr8:52851634	G/A	cg13492337	chr8:52722140	PXDNL	-0.5	-7.62	-0.33	1.41e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg08822215	chr16:89438651	ANKRD11	0.36	7.03	0.31	7.21e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg00689492	chr4:1303491	MAEA	0.44	7.61	0.33	1.5e-13	Obesity-related traits;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg15971980	chr6:150254442	NA	0.42	6.83	0.3	2.7e-11	Lung cancer;
LGG	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg17467752	chr17:38218738	THRA	-0.45	-7.17	-0.32	3.04e-12	Self-reported allergy;
LGG	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.09	0.35	5.17e-15	Prostate cancer;
LGG	cis	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg00405596	chr8:11794950	NA	0.63	10.78	0.45	2.5300000000000002e-24	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg00777063	chr17:45855553	NA	-0.32	-6.7	-0.3	6.03e-11	IgG glycosylation;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03226425	chr6:170151538	C6orf70;TCTE3	0.39	7.14	0.31	3.6e-12	Body mass index;
LGG	cis	rs12545109	0.800	rs1992122	chr8:57409467	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.82	-0.3	2.78e-11	Obesity-related traits;
LGG	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg11644478	chr21:40555479	PSMG1	0.89	15.65	0.59	1.29e-44	Cognitive function;
LGG	cis	rs7267979	1.000	rs6115191	chr20:25440478	C/T	cg06421707	chr20:25228305	PYGB	0.47	9.98	0.42	2.15e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.84	0.45	1.55e-24	Parkinson's disease;
LGG	cis	rs7091068	0.536	rs503758	chr10:95406935	C/A	cg20715218	chr10:95462985	C10orf4	-0.61	-9.63	-0.41	4.1e-20	Urinary tract infection frequency;
LGG	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.42	-0.4	2.14e-19	Personality dimensions;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18455759	chr8:126443767	TRIB1	0.44	7.22	0.32	2.12e-12	Cognitive performance;
LGG	cis	rs6834538	0.931	rs6854311	chr4:113545454	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	8.42	0.36	4.79e-16	Free thyroxine concentration;
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.74	0.3	4.67e-11	Vitiligo;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg05729581	chr11:3078854	CARS	-0.53	-9.37	-0.4	3.33e-19	Longevity;
LGG	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.96	-0.42	2.68e-21	Response to antipsychotic treatment;
LGG	cis	rs7814319	0.966	rs6993518	chr8:97256341	T/A	cg20787634	chr8:97240163	UQCRB	-0.77	-18.72	-0.66	1.2e-58	Lung function (FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11416447	chr7:86781551	DMTF1	0.45	6.94	0.31	1.32e-11	Gut microbiome composition (summer);
LGG	cis	rs9816226	1.000	rs61587156	chr3:185831583	T/G	cg00760338	chr3:185826511	ETV5	-0.89	-12.99	-0.52	3.94e-33	Obesity;Body mass index;
LGG	cis	rs7226408	0.600	rs1246241	chr18:34418491	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.21	-0.36	2.24e-15	Obesity-related traits;
LGG	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg03929089	chr4:120376271	NA	0.73	8.44	0.37	4.12e-16	Axial length;
LGG	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg16662043	chr16:48846231	NA	0.39	7.62	0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg19539972	chr4:7069911	GRPEL1	0.68	9.9	0.42	4.5e-21	Monocyte percentage of white cells;
LGG	trans	rs9354308	0.899	rs2802057	chr6:66548093	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.07	0.42	1.07e-21	Metabolite levels;
LGG	trans	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.58	9.07	0.39	3.49e-18	Ulcerative colitis;
LGG	cis	rs2280630	0.529	rs784505	chr3:39168757	G/A	cg01426195	chr3:39028469	NA	0.71	15.59	0.59	2.34e-44	Verbal declarative memory;
LGG	cis	rs2067615	0.965	rs2204886	chr12:107128090	T/A	cg15890332	chr12:107067104	RFX4	0.3	8.48	0.37	3.04e-16	Heart rate;
LGG	cis	rs10851411	0.697	rs17709867	chr15:42800767	C/T	cg21293051	chr15:42870591	STARD9	0.51	7.13	0.31	3.88e-12	Glucose homeostasis traits;
LGG	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg16141378	chr3:129829833	LOC729375	-0.41	-9.59	-0.41	5.54e-20	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10681256	chr3:47324572	KIF9;KLHL18	0.43	6.71	0.3	5.78e-11	Gut microbiome composition (summer);
LGG	cis	rs112591243	0.570	rs4819254	chr21:47887462	T/A	cg10657630	chr21:48055338	PRMT2	0.85	7.41	0.33	6.18e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.62	10.38	0.43	7.83e-23	Response to antipsychotic treatment;
LGG	cis	rs2735413	0.918	rs34094825	chr16:78081392	G/C	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.97	-8.57	-0.37	1.52e-16	Facial emotion recognition (sad faces);
LGG	cis	rs7551222	0.716	rs7541589	chr1:204542521	G/A	cg20240347	chr1:204465584	NA	-0.56	-11.18	-0.46	7.16e-26	Schizophrenia;
LGG	cis	rs2084898	0.882	rs60336713	chr11:120054885	C/T	cg13907859	chr11:120009124	TRIM29	0.87	11.35	0.47	1.7e-26	Stroke (pediatric);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs11608355	0.557	rs759971	chr12:109826046	A/T	cg19025524	chr12:109796872	NA	-0.58	-12.94	-0.52	6.45e-33	Neuroticism;
LGG	cis	rs6546550	0.901	rs6741449	chr2:70156589	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.03	-0.35	7.95e-15	Prevalent atrial fibrillation;
LGG	trans	rs4841097	0.876	rs6601288	chr8:8943430	A/T	cg02002194	chr4:3960332	NA	-0.39	-7.07	-0.31	5.77e-12	Platelet distribution width;
LGG	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-8.01	-0.35	9.6e-15	Schizophrenia;
LGG	trans	rs11088226	0.581	rs2833856	chr21:33877691	A/G	cg09050820	chr6:167586206	TCP10L2	-0.47	-7.64	-0.33	1.27e-13	Gastritis;
LGG	cis	rs283228	0.876	rs2787579	chr6:101818217	G/A	cg27451362	chr6:101846650	GRIK2	0.54	9.06	0.39	3.79e-18	Coenzyme Q10 levels;
LGG	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.41e-11	Blood metabolite levels;
LGG	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg21435375	chr2:172878103	MAP1D	-0.33	-7.44	-0.33	4.77e-13	Schizophrenia;
LGG	cis	rs2587949	0.593	rs2686721	chr3:4208774	T/C	cg16519197	chr3:4211558	NA	-0.36	-7.3	-0.32	1.24e-12	Periodontitis (DPAL);
LGG	cis	rs9291683	0.530	rs882223	chr4:9981625	A/C	cg00071950	chr4:10020882	SLC2A9	0.38	7.79	0.34	4.49e-14	Bone mineral density;
LGG	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg25358565	chr5:93447407	FAM172A	1.36	16.72	0.61	1.94e-49	Diabetic retinopathy;
LGG	cis	rs638893	0.578	rs500254	chr11:118678780	A/G	cg13782932	chr11:118662891	DDX6	-0.38	-7.09	-0.31	5.08e-12	Vitiligo;
LGG	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg26769984	chr7:1090371	C7orf50	0.55	9.37	0.4	3.23e-19	Bronchopulmonary dysplasia;
LGG	cis	rs7659604	0.540	rs9998385	chr4:122676673	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg11301795	chr4:187892539	NA	-0.94	-24.92	-0.76	1.46e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3820068	0.705	rs4646085	chr1:15825411	A/T	cg05660106	chr1:15850417	CASP9	1.1	25.53	0.76	2.29e-90	Systolic blood pressure;
LGG	cis	rs4629180	0.540	rs6747670	chr2:102130368	T/C	cg16435561	chr2:102091048	RFX8	0.48	8.97	0.38	7.41e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs7089973	0.872	rs36036948	chr10:116631649	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.61	0.33	1.51e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1008375	0.966	rs6832962	chr4:17652133	T/C	cg18681998	chr4:17616180	MED28	0.85	18.24	0.65	1.97e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.97	0.49	6.06e-29	Obesity-related traits;
LGG	cis	rs62064224	0.589	rs9904964	chr17:30662832	A/G	cg18200150	chr17:30822561	MYO1D	-0.47	-8.96	-0.38	8.13e-18	Schizophrenia;
LGG	trans	rs7980799	0.935	rs10772076	chr12:33553574	A/C	cg26384229	chr12:38710491	ALG10B	-0.52	-9.12	-0.39	2.22e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2404602	0.647	rs920712	chr15:77033934	G/A	cg23625390	chr15:77176239	SCAPER	-0.72	-14.17	-0.55	3.89e-38	Blood metabolite levels;
LGG	cis	rs12824058	0.831	rs55726136	chr12:130810312	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs12476592	0.543	rs4671510	chr2:63742880	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	trans	rs12517041	0.810	rs2356714	chr5:23284785	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.84	-0.45	1.55e-24	Calcium levels;
LGG	cis	rs72945132	0.714	rs66542029	chr11:70196302	A/T	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs1620921	0.935	rs11060	chr6:161173946	T/G	cg01280913	chr6:161186852	NA	-0.34	-7.05	-0.31	6.37e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs174601	0.861	rs174547	chr11:61570783	C/T	cg19610905	chr11:61596333	FADS2	0.8	14.44	0.56	2.84e-39	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs9880211	0.800	rs35880395	chr3:136507090	C/T	cg21827317	chr3:136751795	NA	-0.48	-7.05	-0.31	6.74e-12	Body mass index;Height;
LGG	trans	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.94	-0.31	1.35e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs774359	0.789	rs10967972	chr9:27523082	C/G	cg22262168	chr9:27528999	MOBKL2B	0.45	6.78	0.3	3.77e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg13880726	chr7:1868755	MAD1L1	0.46	8.07	0.35	6.12e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs12410462	0.581	rs4329477	chr1:227552494	A/G	cg23173402	chr1:227635558	NA	-0.48	-8.36	-0.36	7.14e-16	Major depressive disorder;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.64	-0.33	1.24e-13	Longevity;Endometriosis;
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-10.33	-0.43	1.15e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.75	0.3	4.51e-11	Schizophrenia;
LGG	cis	rs752092	1.000	rs8033360	chr15:101778710	C/A	cg19997662	chr15:101784653	CHSY1	-0.85	-18.48	-0.65	1.61e-57	Corneal structure;
LGG	cis	rs10089	1.000	rs72794401	chr5:127517626	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.06	0.46	2.14e-25	Ileal carcinoids;
LGG	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg14952266	chr13:112191215	NA	0.42	8.3	0.36	1.13e-15	Hepatitis;
LGG	cis	rs17504614	0.597	rs75882045	chr2:51082996	C/T	cg23851515	chr2:51057218	NRXN1	0.77	11.23	0.46	5.01e-26	Educational attainment (years of education);
LGG	cis	rs7849585	1.000	rs7849585	chr9:139111870	G/T	cg14094347	chr9:139131620	QSOX2	-0.48	-9.92	-0.42	3.55e-21	Height;
LGG	cis	rs9487094	0.813	rs12524502	chr6:109654221	A/G	cg01125227	chr6:109776195	MICAL1	0.47	7.97	0.35	1.22e-14	Height;
LGG	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.88	-0.34	2.44e-14	HDL cholesterol;
LGG	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.73	0.54	3.21e-36	IgG glycosylation;
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg03395511	chr6:291903	DUSP22	-0.44	-7.64	-0.33	1.28e-13	Menopause (age at onset);
LGG	cis	rs929596	0.755	rs4148324	chr2:234672722	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.74	-13.75	-0.54	2.67e-36	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs35362007	0.530	rs11621250	chr14:96011442	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.79	9.89	0.42	4.92e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.83	-0.59	2.11e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10845606	1.000	rs10845605	chr12:12833468	T/C	cg09462578	chr12:12878428	APOLD1	-0.51	-7.15	-0.32	3.41e-12	Systemic lupus erythematosus;
LGG	cis	rs787274	0.850	rs10733599	chr9:115634234	A/T	cg13803584	chr9:115635662	SNX30	-0.68	-7.75	-0.34	5.85e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7523273	1.000	rs12410786	chr1:207976205	T/A	cg22525895	chr1:207977042	MIR29B2	-0.63	-11.8	-0.48	2.77e-28	Schizophrenia;
LGG	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-11.9	-0.48	1.11e-28	Parkinson's disease;
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg18225595	chr11:63971243	STIP1	0.56	7.37	0.32	8.17e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs12517041	1.000	rs13156787	chr5:23280382	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.08	-0.46	1.88e-25	Calcium levels;
LGG	cis	rs11158026	0.757	rs8012152	chr14:55425567	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.84	0.3	2.53e-11	Parkinson's disease;
LGG	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg16400903	chr5:693638	TPPP	0.45	6.92	0.31	1.51e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs3762637	1.000	rs12638866	chr3:122194382	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs7520050	0.667	rs11211176	chr1:46223086	C/T	cg03146154	chr1:46216737	IPP	-0.37	-7.56	-0.33	2.21e-13	Red blood cell count;Reticulocyte count;
LGG	cis	rs3781458	0.803	rs7088656	chr10:126324077	G/A	cg08799069	chr10:126477246	METTL10	-0.33	-6.68	-0.3	6.76e-11	Male-pattern baldness;
LGG	cis	rs8017423	0.967	rs4904663	chr14:90729565	G/T	cg04374321	chr14:90722782	PSMC1	0.9	19.49	0.67	3.31e-62	Mortality in heart failure;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.02	0.39	4.87e-18	Lung cancer;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.74	9.88	0.42	5.28e-21	Lung function (FEV1/FVC);
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.46	-0.37	3.51e-16	Aortic root size;
LGG	cis	rs911263	0.603	rs1956528	chr14:68788968	C/T	cg18825221	chr14:68749962	RAD51L1	-0.34	-7.27	-0.32	1.54e-12	Primary biliary cholangitis;
LGG	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg10511902	chr14:91842949	CCDC88C	0.45	6.68	0.3	6.72e-11	Alzheimer disease and age of onset;
LGG	cis	rs4950322	0.570	rs17356219	chr1:146737343	A/C	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs9815354	1.000	rs61744388	chr3:41756965	C/T	cg03022575	chr3:42003672	ULK4	0.61	7.61	0.33	1.5e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs34421088	0.540	rs4841517	chr8:11132007	C/G	cg02002194	chr4:3960332	NA	0.38	6.66	0.3	7.6e-11	Neuroticism;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg23594656	chr7:65796392	TPST1	0.41	9.21	0.39	1.14e-18	Aortic root size;
LGG	trans	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg06521331	chr12:34319734	NA	0.44	7.84	0.34	3.21e-14	Bladder cancer;
LGG	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.04	-0.42	1.32e-21	Morning vs. evening chronotype;
LGG	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26378065	chr17:18585709	ZNF286B	-0.49	-8.88	-0.38	1.44e-17	Educational attainment (years of education);
LGG	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-6.75	-0.3	4.47e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03643709	chr15:41186784	VPS18	0.45	6.65	0.3	8.49e-11	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg12070911	chr6:150209640	RAET1E	0.31	7.54	0.33	2.56e-13	Lung cancer;
LGG	cis	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg03060546	chr3:49711283	APEH	-0.62	-10.27	-0.43	2.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7113850	0.541	rs76671714	chr11:24231278	C/G	ch.11.24196551F	chr11:24239977	NA	0.9	10.12	0.43	7.17e-22	Bone fracture in osteoporosis;
LGG	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg25358565	chr5:93447407	FAM172A	1.28	15.17	0.58	1.7e-42	Diabetic retinopathy;
LGG	cis	rs7904368	0.754	rs17139234	chr10:16849732	G/T	cg23933602	chr10:16859644	RSU1	0.65	9.44	0.4	1.76e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1385374	0.800	rs12321679	chr12:129284791	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	6.87	0.3	2.08e-11	Systemic lupus erythematosus;
LGG	cis	rs240764	0.680	rs239234	chr6:101101234	G/A	cg09795085	chr6:101329169	ASCC3	0.44	7.6	0.33	1.62e-13	Neuroticism;
LGG	cis	rs73416724	0.841	rs78415183	chr6:43394041	T/G	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.72e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11771526	0.901	rs28709683	chr7:32301989	A/G	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.94	-0.31	1.36e-11	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	6.15e-38	Bladder cancer;
LGG	cis	rs17767392	0.813	rs61989379	chr14:71964406	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.92	-0.38	1.08e-17	Mitral valve prolapse;
LGG	cis	rs2997447	0.655	rs12094933	chr1:26374779	T/C	cg19633962	chr1:26362018	EXTL1	-0.56	-7.8	-0.34	4.18e-14	QRS complex (12-leadsum);
LGG	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4132509	1.000	rs10927076	chr1:243958293	A/G	cg25706552	chr1:244017396	NA	0.53	8.16	0.35	3.13e-15	RR interval (heart rate);
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.11	0.46	1.37e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6882046	0.513	rs446219	chr5:88005827	T/C	cg22951263	chr5:87985283	NA	-0.54	-10.06	-0.42	1.12e-21	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs9303401	0.659	rs34556735	chr17:56694447	A/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.16e-17	Cognitive test performance;
LGG	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg15823100	chr22:32027580	PISD	-0.74	-8.42	-0.36	4.89e-16	Age-related hearing impairment;
LGG	cis	rs7091068	0.616	rs7920366	chr10:95497178	A/T	cg20715218	chr10:95462985	C10orf4	0.68	9.96	0.42	2.74e-21	Urinary tract infection frequency;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg11766577	chr21:47581405	C21orf56	-0.51	-8.77	-0.38	3.47e-17	Testicular germ cell tumor;
LGG	cis	rs804292	1.000	rs804292	chr8:11643915	C/T	cg26752888	chr8:11627280	NEIL2	-1.0	-16.69	-0.61	2.66e-49	Alcohol dependence;Nicotine use;
LGG	cis	rs2502399	0.898	rs7753145	chr6:113507826	T/C	cg20413948	chr6:113544930	NA	0.3	6.94	0.31	1.35e-11	Plasma clusterin levels;
LGG	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.27	0.36	1.47e-15	Alzheimer's disease (survival time);
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-9.02	-0.39	5.21e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.67	-0.37	7.22e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs10231759	0.583	rs17173612	chr7:150503360	T/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.39	8.46	0.37	3.49e-16	Height;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs7666738	0.791	rs7658177	chr4:99035192	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7927592	0.731	rs11228275	chr11:68303980	G/A	cg16797656	chr11:68205561	LRP5	-0.5	-9.71	-0.41	2.08e-20	Total body bone mineral density;
LGG	cis	rs2303319	1.000	rs76063526	chr2:162230834	A/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs6793245	0.845	rs4073796	chr3:38590849	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.52	-8.72	-0.38	4.92e-17	QT interval;
LGG	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg22044901	chr15:68126292	NA	-0.41	-7.34	-0.32	9.72e-13	Obesity;
LGG	cis	rs2120243	0.874	rs2316706	chr3:157160061	A/C	cg24825693	chr3:157122686	VEPH1	-0.35	-7.38	-0.32	7.52e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4740619	0.544	rs7047045	chr9:15826794	G/A	cg14451791	chr9:16040625	NA	0.32	7.93	0.35	1.62e-14	Body mass index;
LGG	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg27572855	chr1:25598939	RHD	0.52	11.59	0.47	1.95e-27	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs9911578	1.000	rs4793952	chr17:56608465	C/T	cg05425664	chr17:57184151	TRIM37	0.64	10.19	0.43	3.95e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs2511156	chr11:77971167	G/C	cg02023728	chr11:77925099	USP35	0.43	7.25	0.32	1.78e-12	Testicular germ cell tumor;
LGG	cis	rs17208368	0.628	rs4784472	chr16:55092857	T/C	cg11181171	chr16:55090946	NA	0.46	7.67	0.34	9.97e-14	Hypospadias;
LGG	cis	rs67311347	0.866	rs56331709	chr3:40356558	A/C	cg13683864	chr3:40499215	RPL14	-0.86	-16.69	-0.61	2.74e-49	Renal cell carcinoma;
LGG	cis	rs8112449	0.822	rs34246431	chr19:10549968	T/C	cg21868191	chr19:10515988	NA	-0.48	-8.03	-0.35	8.15e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs36051895	0.632	rs10974969	chr9:5125336	G/A	cg02405213	chr9:5042618	JAK2	-0.8	-15.07	-0.57	4.6e-42	Pediatric autoimmune diseases;
LGG	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg11764359	chr7:65958608	NA	0.63	10.94	0.45	6.37e-25	Aortic root size;
LGG	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg06481639	chr22:41940642	POLR3H	-0.47	-7.23	-0.32	1.97e-12	Vitiligo;
LGG	cis	rs1109114	0.816	rs2010360	chr5:148636096	A/G	cg06539116	chr5:148597365	ABLIM3	-0.48	-11.84	-0.48	1.91e-28	Body mass index;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.91	-0.35	1.85e-14	Testicular germ cell tumor;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-8.15	-0.35	3.45e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7247513	0.897	rs12979146	chr19:12717904	C/T	cg01871581	chr19:12707946	ZNF490	-0.45	-9.18	-0.39	1.49e-18	Bipolar disorder;
LGG	cis	rs11753937	0.887	rs402020	chr6:133609328	A/G	cg05493394	chr6:133562035	EYA4	0.24	6.78	0.3	3.62e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9527	0.615	rs12248123	chr10:104735366	A/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.86	-0.3	2.17e-11	Arsenic metabolism;
LGG	cis	rs7226408	0.857	rs7228810	chr18:34722050	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs6787391	0.933	rs6762644	chr3:4742276	A/G	cg11584376	chr3:4789075	ITPR1	-0.34	-6.89	-0.3	1.86e-11	Breast cancer;
LGG	trans	rs9650657	0.675	rs2409658	chr8:10668965	A/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.13	-0.31	3.91e-12	Neuroticism;
LGG	cis	rs858239	0.600	rs6461690	chr7:23135534	A/G	cg23682824	chr7:23144976	KLHL7	0.42	7.35	0.32	9.24e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1670533	1.000	rs10007978	chr4:1060984	A/T	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.4e-21	Recombination rate (females);
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-14.57	-0.56	7.36e-40	Platelet count;
LGG	cis	rs13102973	0.965	rs11099306	chr4:135895674	A/G	cg14419869	chr4:135874104	NA	0.56	10.67	0.44	6.66e-24	Subjective well-being;
LGG	cis	rs477895	0.941	rs12808002	chr11:64110932	C/T	cg22916017	chr11:64110731	CCDC88B	-0.54	-7.22	-0.32	2.16e-12	Mean platelet volume;
LGG	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs11229555	0.645	rs11229431	chr11:58181253	A/G	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg02297831	chr4:17616191	MED28	0.5	9.46	0.4	1.6e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.6	-0.47	1.73e-27	Height;
LGG	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.66	0.34	1.07e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs986417	1.000	rs1254255	chr14:60831342	G/A	cg27398547	chr14:60952738	C14orf39	-0.7	-6.74	-0.3	4.71e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg24848339	chr3:12840334	CAND2	-0.44	-10.27	-0.43	1.93e-22	QRS complex (12-leadsum);
LGG	cis	rs3784262	0.934	rs7164408	chr15:58259336	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.39	-0.36	6.08e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg26695010	chr11:65641043	EFEMP2	0.51	8.7	0.37	5.82e-17	Eosinophil percentage of white cells;
LGG	cis	rs9557207	1.000	rs9554587	chr13:100040654	A/G	cg24509225	chr13:100037070	UBAC2	0.7	12.56	0.5	2.49e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg26384229	chr12:38710491	ALG10B	0.92	20.7	0.69	7.19e-68	Bladder cancer;
LGG	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg23602478	chr1:26503979	CNKSR1	0.34	8.47	0.37	3.19e-16	Height;
LGG	cis	rs9902453	0.900	rs9910970	chr17:28478329	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.14	0.52	9.8e-34	Coffee consumption (cups per day);
LGG	cis	rs1562975	0.609	rs12505944	chr4:109411822	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	8.31	0.36	1.08e-15	Height;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg11062466	chr8:58055876	NA	0.54	8.87	0.38	1.56e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.626	rs7773950	chr6:109815440	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	6.9e-15	Height;
LGG	cis	rs4979906	1.000	rs11002244	chr10:79446207	T/C	cg07817648	chr10:79422355	NA	-0.48	-7.68	-0.34	9.74e-14	Mortality in heart failure;
LGG	cis	rs6964587	0.692	rs2299233	chr7:91626953	C/T	cg17063962	chr7:91808500	NA	-0.49	-9.07	-0.39	3.43e-18	Breast cancer;
LGG	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.35	0.32	9.13e-13	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg10760299	chr15:45669010	GATM	0.41	8.14	0.35	3.75e-15	Homoarginine levels;
LGG	cis	rs11122272	0.766	rs2790871	chr1:231543555	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.26	-0.32	1.65e-12	Hemoglobin concentration;
LGG	trans	rs2048656	0.637	rs10107396	chr8:9673152	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.0	0.35	1.01e-14	Schizophrenia;
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg27411982	chr8:10470053	RP1L1	0.44	7.48	0.33	3.76e-13	Myopia (pathological);
LGG	cis	rs77956314	0.515	rs4767473	chr12:117365506	C/T	cg02017074	chr12:117425053	FBXW8	0.56	7.72	0.34	7.39e-14	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs9640161	0.830	rs1051823	chr7:150070814	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.14	-0.43	5.83e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7552404	0.961	rs1061337	chr1:76227022	A/G	cg22875332	chr1:76189707	ACADM	0.61	9.74	0.41	1.58e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.65	-9.33	-0.4	4.36e-19	Childhood ear infection;
LGG	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg24231037	chr15:68117551	LBXCOR1	-0.29	-7.05	-0.31	6.59e-12	Restless legs syndrome;
LGG	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg04450456	chr4:17643702	FAM184B	0.31	6.74	0.3	4.61e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg24253500	chr15:84953950	NA	0.42	6.92	0.31	1.53e-11	Schizophrenia;
LGG	cis	rs4363385	0.510	rs2068678	chr1:152906956	G/A	cg13444842	chr1:152974279	SPRR3	-0.47	-9.31	-0.4	5.36e-19	Inflammatory skin disease;
LGG	cis	rs832540	0.629	rs6888317	chr5:56093307	A/G	cg12654349	chr5:56205094	C5orf35	0.42	7.28	0.32	1.45e-12	Coronary artery disease;
LGG	cis	rs9937943	0.616	rs12923487	chr16:74644112	G/T	cg01733217	chr16:74700730	RFWD3	0.64	8.47	0.37	3.31e-16	Neutrophil percentage of white cells;
LGG	cis	rs6792151	0.549	rs9855322	chr3:171550323	C/T	cg26441893	chr3:171559851	TMEM212	-0.4	-7.33	-0.32	1.01e-12	Red cell distribution width;
LGG	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-7.63	-0.33	1.35e-13	Total body bone mineral density;
LGG	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg00531865	chr16:30841666	NA	-0.45	-9.06	-0.39	3.56e-18	Response to metformin (IC50);
LGG	cis	rs6554196	0.508	rs6554200	chr4:55529409	G/C	cg18836493	chr4:55524333	KIT	-0.43	-8.01	-0.35	9.71e-15	Monocyte count;
LGG	cis	rs12971120	0.947	rs34676212	chr18:72170006	A/G	cg26446133	chr18:72167187	CNDP2	-0.74	-16.75	-0.61	1.45e-49	Refractive error;
LGG	trans	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg06521331	chr12:34319734	NA	-0.44	-7.86	-0.34	2.79e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs593982	0.925	rs3953806	chr11:65505153	C/T	cg08755490	chr11:65554678	OVOL1	-0.74	-10.4	-0.44	6.45e-23	Atopic dermatitis;
LGG	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg16486109	chr11:613632	IRF7	0.42	7.18	0.32	2.85e-12	Systemic lupus erythematosus;
LGG	cis	rs2735413	0.918	rs12931394	chr16:78081629	G/A	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs17321999	0.516	rs12472981	chr2:30502879	T/C	cg05247661	chr2:30472410	LBH	0.65	8.07	0.35	6e-15	Systemic lupus erythematosus;
LGG	cis	rs3820928	0.904	rs1835159	chr2:227764057	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.41	-0.33	6.22e-13	Pulmonary function;
LGG	cis	rs7582180	0.764	rs10460478	chr2:100919735	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-10.93	-0.45	6.82e-25	Intelligence (multi-trait analysis);
LGG	cis	rs1256061	0.669	rs1256065	chr14:64698932	G/T	cg23250157	chr14:64679961	SYNE2	0.39	6.98	0.31	1.05e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4481887	0.676	rs1544177	chr1:248524683	C/G	cg00666640	chr1:248458726	OR2T12	0.51	8.67	0.37	7.12e-17	Common traits (Other);
LGG	cis	rs2213920	0.516	rs71505546	chr9:118158372	G/A	cg13918206	chr9:118159781	DEC1	-0.77	-10.54	-0.44	2e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg06618935	chr21:46677482	NA	-0.49	-9.42	-0.4	2.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	14.51	0.56	1.37e-39	Coronary artery disease;
LGG	cis	rs7769051	1.000	rs12204027	chr6:133122831	A/G	cg07930552	chr6:133119739	C6orf192	0.86	12.07	0.49	2.36e-29	Type 2 diabetes nephropathy;
LGG	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg06889755	chr6:150326021	RAET1K	0.39	8.0	0.35	9.84e-15	Alopecia areata;
LGG	cis	rs3096299	0.586	rs4572400	chr16:89533516	T/A	cg08392591	chr16:89556376	ANKRD11	0.56	8.6	0.37	1.25e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.93	0.31	1.45e-11	Lung cancer;
LGG	cis	rs8014204	0.762	rs10138360	chr14:75293386	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.65	-11.73	-0.48	5.27e-28	Caffeine consumption;
LGG	cis	rs2764208	0.535	rs2744962	chr6:34594440	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.43	-0.33	5.44e-13	Systemic lupus erythematosus;
LGG	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg21475434	chr5:93447410	FAM172A	0.71	7.24	0.32	1.9e-12	Diabetic retinopathy;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18252515	chr7:66147081	NA	0.41	6.94	0.31	1.32e-11	Aortic root size;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg16590910	chr6:42928470	GNMT	0.42	11.89	0.48	1.19e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.77	-0.41	1.26e-20	Lung cancer;
LGG	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg18240062	chr17:79603768	NPLOC4	-0.61	-10.23	-0.43	2.79e-22	Eye color traits;
LGG	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02711726	chr17:80685570	FN3KRP	-0.57	-9.88	-0.42	4.98e-21	Glycated hemoglobin levels;
LGG	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.41	-6.66	-0.3	7.56e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2708240	1.000	rs2538983	chr7:147581837	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.38e-11	QT interval (drug interaction);
LGG	cis	rs17253792	0.822	rs8009608	chr14:56062590	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs228437	1.000	rs228436	chr6:134896913	A/T	cg24504307	chr6:134963096	NA	0.39	7.45	0.33	4.72e-13	Melanoma;
LGG	cis	rs61931739	0.817	rs10772144	chr12:34242463	A/C	cg06521331	chr12:34319734	NA	-0.4	-6.92	-0.31	1.56e-11	Morning vs. evening chronotype;
LGG	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg20387954	chr3:183756860	HTR3D	0.57	10.77	0.45	2.82e-24	Anterior chamber depth;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs12615966	0.789	rs6758786	chr2:105367587	A/G	cg16465502	chr2:105461796	NA	-0.85	-10.13	-0.43	6.66e-22	Pancreatic cancer;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03452623	chr4:187889614	NA	-1.04	-31.82	-0.83	1.32e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12618769	0.652	rs3769708	chr2:99187650	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.66	0.34	1.08e-13	Bipolar disorder;
LGG	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg00666640	chr1:248458726	OR2T12	0.45	6.76	0.3	4.18e-11	Common traits (Other);
LGG	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg11693508	chr17:37793320	STARD3	0.51	7.24	0.32	1.89e-12	Bipolar disorder;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg10207240	chr12:122356781	WDR66	0.28	8.49	0.37	2.92e-16	Mean corpuscular volume;
LGG	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg01620082	chr3:125678407	NA	-0.62	-7.59	-0.33	1.78e-13	Depression;
LGG	cis	rs1190596	0.689	rs2224460	chr14:102563797	A/T	cg23904247	chr14:102554826	HSP90AA1	-0.28	-7.64	-0.33	1.28e-13	Behavioural disinhibition (generation interaction);
LGG	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.2	0.32	2.45e-12	Mood instability;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg08742575	chr21:47604166	C21orf56	0.5	8.72	0.38	5.05e-17	Testicular germ cell tumor;
LGG	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg08807101	chr21:30365312	RNF160	0.6	9.92	0.42	3.71e-21	Pancreatic cancer;
LGG	cis	rs599083	0.569	rs685095	chr11:68170376	C/T	cg01657329	chr11:68192670	LRP5	0.62	10.15	0.43	5.64e-22	Bone mineral density (spine);
LGG	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	8.16	0.35	3.3e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg09904177	chr6:26538194	HMGN4	0.71	14.88	0.57	3.4e-41	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.629	rs7245672	chr19:19699963	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.48	-12.01	-0.49	3.96e-29	Tonsillectomy;
LGG	cis	rs10267417	0.603	rs28510133	chr7:19935487	A/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs9287719	0.967	rs7605461	chr2:10738134	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg17809284	chr5:56205270	C5orf35	0.67	10.78	0.45	2.42e-24	Initial pursuit acceleration;
LGG	cis	rs6938	0.534	rs11636892	chr15:75266049	G/C	cg14664628	chr15:75095509	CSK	-0.55	-10.44	-0.44	4.65e-23	Breast cancer;
LGG	cis	rs2046867	0.818	rs2208	chr3:72871773	A/G	cg25664220	chr3:72788482	NA	0.32	8.82	0.38	2.33e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs13177180	0.723	rs766454	chr5:114896050	A/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.4	-8.88	-0.38	1.46e-17	Conotruncal heart defects (inherited effects);
LGG	cis	rs9487051	0.714	rs6930733	chr6:109631587	T/C	cg21918786	chr6:109611834	NA	-0.49	-9.11	-0.39	2.48e-18	Reticulocyte fraction of red cells;
LGG	cis	rs4849845	0.653	rs3925970	chr2:121018153	C/A	cg15425061	chr2:121036351	RALB	0.38	6.94	0.31	1.31e-11	Mean platelet volume;
LGG	cis	rs7940866	1.000	rs7940866	chr11:130817579	A/T	cg12179176	chr11:130786555	SNX19	-0.67	-12.16	-0.49	1.04e-29	Schizophrenia;
LGG	cis	rs4566357	1.000	rs10933167	chr2:227925969	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.06	-0.31	6.07e-12	Coronary artery disease;
LGG	cis	rs7772486	0.558	rs702322	chr6:146007166	G/A	cg13319975	chr6:146136371	FBXO30	0.41	6.75	0.3	4.43e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg23950597	chr19:37808831	NA	0.67	9.4	0.4	2.55e-19	Coronary artery calcification;
LGG	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs801193	0.935	rs3800820	chr7:66147178	C/T	cg18252515	chr7:66147081	NA	0.41	6.92	0.31	1.47e-11	Aortic root size;
LGG	cis	rs11190604	0.607	rs12220970	chr10:102175269	G/A	cg07570687	chr10:102243282	WNT8B	0.41	7.33	0.32	1.05e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Electroencephalogram traits;
LGG	cis	rs9486719	1.000	rs13210597	chr6:96969694	C/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.91	-0.45	7.97e-25	Migraine;Coronary artery disease;
LGG	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.79	0.3	3.43e-11	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg16339924	chr4:17578868	LAP3	0.57	9.94	0.42	3.04e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.99e-12	Calcium levels;
LGG	cis	rs1062746	0.520	rs17770965	chr16:87328597	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-7.74	-0.34	6.1e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs11920090	0.932	rs61169219	chr3:170720021	G/C	cg09710316	chr3:170744871	SLC2A2	0.6	8.52	0.37	2.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg13126279	chr21:47581558	C21orf56	0.45	7.41	0.33	6.18e-13	Testicular germ cell tumor;
LGG	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.4	-0.47	1.03e-26	Hemoglobin concentration;
LGG	cis	rs6909430	0.901	rs17058256	chr6:98629062	A/G	cg12860156	chr6:98744658	NA	0.46	7.7	0.34	8.35e-14	Quantitative traits;
LGG	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg22903471	chr2:27725779	GCKR	0.39	8.75	0.38	4.14e-17	Oral cavity cancer;
LGG	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg23920097	chr1:209922102	NA	-0.48	-8.47	-0.37	3.4e-16	Red blood cell count;
LGG	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.83e-41	Hair morphology;
LGG	trans	rs6003958	1	rs6003958	chr22:24264089	T/G	cg06437703	chr8:37914619	EIF4EBP1	0.75	10.99	0.45	4.06e-25	S-phenylmercapturic acid levels in smokers;
LGG	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.04	0.39	4.32e-18	Blood metabolite levels;
LGG	cis	rs870825	0.616	rs28563856	chr4:185635581	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs4566357	0.576	rs6750845	chr2:227911037	T/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.11	-0.39	2.48e-18	Coronary artery disease;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.02	-17.36	-0.63	2.22e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.65	0.37	8.49e-17	Mood instability;
LGG	cis	rs56775891	0.959	rs11663602	chr18:77578191	G/T	cg13263691	chr18:77568018	NA	0.79	14.27	0.55	1.56e-38	Schizophrenia;
LGG	cis	rs1062177	0.951	rs2915876	chr5:151150745	C/A	cg00977110	chr5:151150581	G3BP1	0.51	8.1	0.35	4.93e-15	Preschool internalizing problems;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13831459	chr10:101380774	SLC25A28	0.59	6.75	0.3	4.51e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs7155454	0.901	rs4586342	chr14:65473875	G/C	cg26396452	chr14:65542826	MAX	0.36	6.87	0.3	2.02e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs1620921	0.621	rs2489966	chr6:161262874	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg09461388	chr22:46763229	CELSR1	-0.6	-6.77	-0.3	3.9e-11	LDL cholesterol;Cholesterol, total;
LGG	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg16141378	chr3:129829833	LOC729375	0.35	7.46	0.33	4.27e-13	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23434654	chr5:121648409	SNCAIP	-0.48	-7.06	-0.31	6.07e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.614	rs12948536	chr17:56580413	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	14.26	0.55	1.7e-38	Cognitive test performance;
LGG	cis	rs56091001	0.528	rs9616387	chr22:50313219	G/A	cg02269571	chr22:50332266	NA	-0.9	-10.66	-0.44	7.2e-24	Acne (severe);
LGG	cis	rs4517514	0.509	rs2156434	chr11:89896417	A/G	cg14505434	chr11:89522851	NA	0.61	7.81	0.34	3.85e-14	Trans fatty acid levels;
LGG	cis	rs9303401	0.659	rs11079358	chr17:56920949	G/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.83e-18	Cognitive test performance;
LGG	cis	rs9640161	0.711	rs3735170	chr7:150034184	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.78	-16.07	-0.6	1.62e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.59e-13	Uric acid levels;
LGG	cis	rs365132	0.875	rs187114	chr5:176364039	A/G	cg16309518	chr5:176445507	NA	-0.5	-10.74	-0.45	3.66e-24	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10791323	0.517	rs1120245	chr11:133745290	A/G	cg00579200	chr11:133705235	NA	-0.51	-9.78	-0.41	1.12e-20	Childhood ear infection;
LGG	cis	rs1707322	0.963	rs4459051	chr1:46451203	A/G	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg21055462	chr7:100276975	NA	0.45	9.31	0.4	5.04e-19	Other erythrocyte phenotypes;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg03575189	chr17:44344142	NA	0.47	6.84	0.3	2.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Myopia (pathological);
LGG	trans	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg02002194	chr4:3960332	NA	-0.38	-7.15	-0.32	3.45e-12	Joint mobility (Beighton score);
LGG	cis	rs7000551	0.581	rs11787182	chr8:22256727	T/C	cg13512537	chr8:22265999	SLC39A14	-0.44	-7.06	-0.31	6.3e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs1847505	0.562	rs78216531	chr13:61463118	T/C	cg25164009	chr13:61490935	NA	0.61	9.81	0.41	8.86e-21	Polychlorinated biphenyl levels;
LGG	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.27	-0.5	3.67e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208487	0.684	rs12449852	chr17:37632088	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-8.27	-0.36	1.39e-15	Primary biliary cholangitis;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg00938859	chr5:1591904	SDHAP3	0.81	8.43	0.36	4.34e-16	Breast cancer;
LGG	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg01221209	chr5:554886	NA	-0.46	-7.0	-0.31	9.12e-12	Obesity-related traits;
LGG	cis	rs4716602	0.898	rs10275754	chr7:156161763	A/G	cg16983916	chr7:156159713	NA	-0.39	-6.9	-0.31	1.69e-11	Anti-saccade response;
LGG	cis	rs67366981	1.000	rs56357623	chr14:77697393	C/A	cg22824376	chr14:77648248	TMEM63C	0.74	8.1	0.35	4.96e-15	Obsessive-compulsive symptoms;
LGG	trans	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-9.79	-0.41	1.1e-20	Brugada syndrome;
LGG	cis	rs1065656	0.553	rs344359	chr16:1838640	T/C	cg26897989	chr16:1907736	C16orf73	0.73	11.5	0.47	4.44e-27	Insulin-like growth factors;
LGG	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg03806693	chr22:41940476	POLR3H	-0.96	-17.16	-0.62	1.88e-51	Vitiligo;
LGG	cis	rs9354308	0.738	rs4379273	chr6:66582222	T/G	cg07460842	chr6:66804631	NA	-0.41	-6.88	-0.3	1.99e-11	Metabolite levels;
LGG	trans	rs747782	0.536	rs59205786	chr11:47758152	T/C	cg15704280	chr7:45808275	SEPT13	0.63	6.82	0.3	2.81e-11	Intraocular pressure;
LGG	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.29e-18	Rheumatoid arthritis;
LGG	cis	rs2737618	0.574	rs2252801	chr1:200076652	C/T	cg21825944	chr1:200113062	NR5A2	-0.52	-9.67	-0.41	2.76e-20	Uric acid levels;
LGG	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg15664640	chr17:80829946	TBCD	-0.63	-9.42	-0.4	2.07e-19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs6665290	0.935	rs6670924	chr1:227196048	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg02153584	chr22:29168773	CCDC117	0.56	6.77	0.3	4.01e-11	Lymphocyte counts;
LGG	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.5	-0.37	2.65e-16	Lung cancer;
LGG	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg20503657	chr10:835505	NA	0.74	10.06	0.42	1.2e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg14789911	chr21:47582049	C21orf56	-0.39	-6.69	-0.3	6.5500000000000006e-11	Testicular germ cell tumor;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.44	-8.53	-0.37	2.15e-16	Schizophrenia;
LGG	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg00919237	chr7:87102261	ABCB4	-0.79	-15.94	-0.6	6.34e-46	Gallbladder cancer;
LGG	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-6.75	-0.3	4.32e-11	Parkinson's disease;
LGG	cis	rs300703	0.935	rs10167992	chr2:263270	C/T	cg21211680	chr2:198530	NA	-1.23	-15.67	-0.59	1.04e-44	Blood protein levels;
LGG	cis	rs950027	0.620	rs2467862	chr15:45643843	T/G	cg26924012	chr15:45694286	SPATA5L1	0.69	12.5	0.5	4.17e-31	Response to fenofibrate (adiponectin levels);
LGG	cis	rs524281	0.861	rs10896081	chr11:65880354	A/T	cg16950941	chr11:66035639	RAB1B	-0.47	-6.82	-0.3	2.82e-11	Electroencephalogram traits;
LGG	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-6.89	-0.3	1.88e-11	Neuroticism;
LGG	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg13010199	chr12:38710504	ALG10B	0.59	11.09	0.46	1.73e-25	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.2e-17	Lung cancer;
LGG	cis	rs7586879	0.789	rs13404163	chr2:25126616	A/G	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	trans	rs7395662	1.000	rs4882019	chr11:48598748	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.45e-13	HDL cholesterol;
LGG	cis	rs10267417	0.603	rs12666801	chr7:19885864	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	8.16	0.35	3.09e-15	Night sleep phenotypes;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.42	-0.4	2.14e-19	Menopause (age at onset);
LGG	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg06634786	chr22:41940651	POLR3H	-0.74	-12.49	-0.5	4.91e-31	Vitiligo;
LGG	cis	rs67460515	0.892	rs34771618	chr3:161059795	A/C	cg03342759	chr3:160939853	NMD3	-0.75	-13.34	-0.53	1.42e-34	Parkinson's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12250496	chr4:62066787	NA	0.48	7.95	0.35	1.46e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs10871290	0.650	rs28484753	chr16:74489395	G/C	cg01733217	chr16:74700730	RFWD3	0.71	12.86	0.51	1.44e-32	Breast cancer;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-17.31	-0.63	3.8e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg12525768	chr7:29689996	LOC646762	0.55	7.84	0.34	3.18e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs735860	0.763	rs2817111	chr6:53125700	G/C	cg10236188	chr6:53219634	NA	-0.39	-7.65	-0.34	1.14e-13	Glaucoma;
LGG	trans	rs2727020	0.729	rs1164685	chr11:49293660	G/A	cg03929089	chr4:120376271	NA	0.91	18.27	0.65	1.54e-56	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	trans	rs11039798	1.000	rs8188963	chr11:48685693	C/A	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs1881396	0.891	rs62131879	chr2:27755112	T/G	cg27432699	chr2:27873401	GPN1	0.56	8.51	0.37	2.51e-16	Nonalcoholic fatty liver disease;
LGG	cis	rs4356975	0.545	rs35749478	chr4:69949580	A/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.69	0.3	6.51e-11	Obesity-related traits;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg19635926	chr16:89946313	TCF25	-0.69	-8.02	-0.35	8.81e-15	Skin colour saturation;
LGG	trans	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.7	0.56	1.99e-40	Bladder cancer;
LGG	cis	rs56399783	0.901	rs56356906	chr7:2774383	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.26	0.32	1.69e-12	Childhood ear infection;
LGG	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.41	0.33	6.23e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2274273	0.745	rs748017	chr14:55542300	A/G	cg04306507	chr14:55594613	LGALS3	0.45	11.01	0.46	3.29e-25	Protein biomarker;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg08297393	chr2:100937505	LONRF2	0.56	10.63	0.44	8.89e-24	Intelligence (multi-trait analysis);
LGG	trans	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg24247370	chr13:99142703	STK24	-0.37	-6.74	-0.3	4.82e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2299587	0.582	rs7011029	chr8:17897804	G/A	cg18067069	chr8:17937731	ASAH1	-0.31	-7.36	-0.32	8.34e-13	Economic and political preferences;
LGG	cis	rs709082	0.522	rs2138537	chr3:191551479	C/G	cg14875394	chr3:191581259	NA	0.36	6.67	0.3	7.32e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6541297	0.775	rs4846910	chr1:230291441	C/A	cg20703242	chr1:230279135	GALNT2	0.39	7.42	0.33	5.75e-13	Coronary artery disease;
LGG	cis	rs2120243	0.539	rs6441126	chr3:157095016	C/T	cg24825693	chr3:157122686	VEPH1	-0.55	-12.64	-0.51	1.1e-31	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-9.92	-0.42	3.59e-21	Height;
LGG	cis	rs5769765	0.908	rs9616211	chr22:50317676	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.12	0.31	4.26e-12	Schizophrenia;
LGG	trans	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.96	0.42	2.69e-21	Mean corpuscular volume;
LGG	cis	rs6692729	0.933	rs2236915	chr1:227079222	C/G	cg08708961	chr1:227070630	PSEN2	-0.31	-7.88	-0.34	2.4e-14	Electrodermal activity;
LGG	trans	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg02002194	chr4:3960332	NA	-0.39	-7.23	-0.32	2.01e-12	Retinal vascular caliber;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg11905131	chr22:24372483	LOC391322	0.4	6.78	0.3	3.73e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1455244	0.700	rs7229302	chr18:11508904	G/T	cg06719391	chr11:2554330	KCNQ1	0.42	6.87	0.3	2.12e-11	Schizophrenia;
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10802521	chr3:52805072	NEK4	-0.39	-6.98	-0.31	1.06e-11	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00006032	chr14:66974439	GPHN	0.39	7.0	0.31	8.88e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7246760	0.748	rs113745845	chr19:9736226	G/A	cg02900749	chr2:68251473	NA	-0.98	-9.86	-0.42	6.13e-21	Pursuit maintenance gain;
LGG	cis	rs7808935	0.768	rs739704	chr7:27989768	G/A	cg22168087	chr7:27702803	HIBADH	0.63	9.19	0.39	1.32e-18	Prostate cancer;
LGG	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs539514	0.690	rs2761398	chr13:76316933	C/A	cg04757411	chr13:76259545	LMO7	-0.26	-6.86	-0.3	2.28e-11	Type 1 diabetes;
LGG	cis	rs9398803	0.651	rs4895813	chr6:126975786	G/T	cg19875578	chr6:126661172	C6orf173	0.52	9.7	0.41	2.27e-20	Male-pattern baldness;
LGG	cis	rs4148087	1.000	rs8126971	chr21:43636412	C/T	cg08841829	chr21:43638893	ABCG1	-0.62	-9.04	-0.39	4.29e-18	Eating disorder in bipolar disorder;
LGG	cis	rs4926611	1.000	rs6687923	chr1:54113854	A/C	cg23596471	chr1:54105337	GLIS1	0.41	8.59	0.37	1.34e-16	Hand grip strength;
LGG	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg11518657	chr1:67396239	MIER1	0.51	7.47	0.33	4.08e-13	Lymphocyte percentage of white cells;
LGG	cis	rs4716602	0.596	rs36013171	chr7:156160511	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.49	-0.4	1.25e-19	Anti-saccade response;
LGG	cis	rs9354308	0.764	rs4710542	chr6:66584434	C/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.72	0.48	5.87e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17401966	0.931	rs11121545	chr1:10411211	A/G	cg15208524	chr1:10270712	KIF1B	0.43	7.46	0.33	4.28e-13	Hepatocellular carcinoma;
LGG	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg18851795	chr1:204543875	NA	-0.36	-6.88	-0.3	1.89e-11	Schizophrenia;
LGG	cis	rs7582720	0.832	rs116426890	chr2:204196618	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.23	0.39	9.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12431410	0.892	rs10133536	chr14:60160841	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.14	0.31	3.75e-12	Schizophrenia;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.89	0.42	4.71e-21	Longevity;
LGG	cis	rs9796	0.621	rs1659228	chr15:41471978	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.95	-0.42	2.79e-21	Menopause (age at onset);
LGG	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg27129171	chr3:47204927	SETD2	0.82	15.0	0.57	9.88e-42	Colorectal cancer;
LGG	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.73	0.38	4.5e-17	Neuroticism;
LGG	cis	rs78456975	1.000	rs72776298	chr2:1570163	C/G	cg26248373	chr2:1572462	NA	-0.66	-8.06	-0.35	6.79e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.71	-0.3	5.84e-11	Obesity;
LGG	cis	rs1620921	0.592	rs9347456	chr6:161276965	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.05e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1003719	0.725	rs2187101	chr21:38452379	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.54	0.63	3.59e-53	Eye color traits;
LGG	cis	rs80282103	0.618	rs11250249	chr10:1116999	T/C	cg08668510	chr10:1095578	IDI1	0.88	8.03	0.35	8.04e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.3e-22	Asthma (sex interaction);
LGG	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg12395012	chr8:11607386	GATA4	-0.39	-7.31	-0.32	1.18e-12	Monocyte count;
LGG	cis	rs9834373	0.853	rs13322524	chr3:78495720	A/G	cg06138941	chr3:78371609	NA	-0.51	-9.04	-0.39	4.42e-18	Protein quantitative trait loci;
LGG	trans	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs698813	0.763	rs786614	chr2:44590567	C/G	cg00619915	chr2:44497795	NA	-0.48	-6.67	-0.3	7.53e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.71	-0.45	4.58e-24	Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10267417	0.603	rs4994102	chr7:19939704	T/A	cg05791153	chr7:19748676	TWISTNB	0.53	6.86	0.3	2.19e-11	Night sleep phenotypes;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13732083	chr21:47605072	C21orf56	0.44	7.19	0.32	2.6e-12	Testicular germ cell tumor;
LGG	cis	rs2842992	0.830	rs1475123	chr6:160178007	A/G	cg27624424	chr6:160112604	SOD2	0.63	8.88	0.38	1.5e-17	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18099408	chr3:52552593	STAB1	0.34	6.85	0.3	2.4e-11	Electroencephalogram traits;
LGG	cis	rs72772090	0.539	rs3335	chr5:96115070	T/G	cg00188032	chr5:96141721	ERAP1	0.54	7.19	0.32	2.7e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17039065	1.000	rs72889357	chr4:109378955	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.68	0.3	6.98e-11	Gut microbiome composition (summer);
LGG	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.54	12.8	0.51	2.52e-32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3099143	1.000	rs2011635	chr15:77134891	T/A	cg21673338	chr15:77095150	SCAPER	-0.65	-10.49	-0.44	3.19e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs68170813	0.641	rs79328953	chr7:106901557	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.77	-0.45	2.81e-24	Coronary artery disease;
LGG	cis	rs4417704	0.551	rs10204458	chr2:241899236	C/G	cg26818257	chr2:241905806	NA	0.49	10.82	0.45	1.77e-24	Joint mobility (Beighton score);
LGG	cis	rs950169	0.579	rs62027818	chr15:84661145	T/C	cg24253500	chr15:84953950	NA	0.45	7.2	0.32	2.51e-12	Schizophrenia;
LGG	cis	rs10197940	0.578	rs1061305	chr2:152346979	T/C	cg19508488	chr2:152266495	RIF1	0.48	8.53	0.37	2.08e-16	Lung cancer;
LGG	cis	rs950776	0.518	rs55690619	chr15:78833612	A/G	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.44	-0.4	1.81e-19	Sudden cardiac arrest;
LGG	cis	rs72781680	0.898	rs17462433	chr2:24012758	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs9875589	0.509	rs4685062	chr3:14066409	T/C	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	trans	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg23762105	chr12:34175262	ALG10	-0.34	-7.03	-0.31	7.38e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1461503	0.903	rs7124683	chr11:122834036	A/G	cg27398637	chr11:122830231	C11orf63	0.67	13.66	0.54	6.02e-36	Menarche (age at onset);
LGG	cis	rs4356932	1.000	rs4241579	chr4:76947284	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs9397585	0.791	rs1415892	chr6:153373145	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.5	0.56	1.52e-39	Body mass index;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg01171360	chr6:293285	DUSP22	-0.42	-7.21	-0.32	2.36e-12	Menopause (age at onset);
LGG	cis	rs5769765	0.913	rs2319462	chr22:50263370	C/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	trans	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg07817883	chr1:32538562	TMEM39B	1.17	11.52	0.47	3.45e-27	Granulocyte percentage of myeloid white cells;
LGG	cis	rs35740288	0.770	rs11630968	chr15:86118001	C/T	cg04173714	chr15:86211321	AKAP13	0.48	8.88	0.38	1.46e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg19673125	chr6:150240577	RAET1G	0.34	8.24	0.36	1.79e-15	Lung cancer;
LGG	cis	rs2735413	0.752	rs11642442	chr16:78080800	A/C	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02640306	chr2:191745287	GLS	0.47	7.65	0.33	1.16e-13	Cognitive performance;
LGG	cis	rs12478296	1.000	rs56162244	chr2:243018690	A/G	cg18898632	chr2:242989856	NA	-0.76	-9.46	-0.4	1.6e-19	Obesity-related traits;
LGG	cis	rs7219021	0.674	rs9904761	chr17:46956830	C/G	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.74	-0.3	4.67e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-11.44	-0.47	7.33e-27	Longevity;Endometriosis;
LGG	cis	rs1062177	1.000	rs12654573	chr5:151207473	T/G	cg00977110	chr5:151150581	G3BP1	0.5	7.87	0.34	2.51e-14	Preschool internalizing problems;
LGG	cis	rs34044649	0.806	rs1675568	chr7:155650822	G/C	cg17395211	chr7:155654226	NA	-0.38	-7.24	-0.32	1.93e-12	Triptolide cytotoxicity;
LGG	cis	rs9297145	0.585	rs4729521	chr7:98780520	G/T	cg05967295	chr7:98741636	SMURF1	-0.65	-11.67	-0.48	9.16e-28	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.37	0.43	8.52e-23	Lung cancer in ever smokers;
LGG	cis	rs2928148	0.522	rs11858278	chr15:41416276	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.78	-13.16	-0.52	7.75e-34	Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg16405210	chr4:1374714	KIAA1530	-0.66	-12.25	-0.49	4.54e-30	Longevity;
LGG	cis	rs881375	1.000	rs6478486	chr9:123655329	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.97	0.49	6.02e-29	Rheumatoid arthritis;
LGG	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg07332563	chr6:291687	DUSP22	-0.57	-9.42	-0.4	2.06e-19	Menopause (age at onset);
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg25703541	chr22:24373054	LOC391322	-0.96	-19.84	-0.68	7.87e-64	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.67	-0.3	7.32e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs6601327	0.613	rs12677507	chr8:9481687	G/C	cg16141378	chr3:129829833	LOC729375	0.35	7.81	0.34	3.77e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs12477438	0.520	rs62155809	chr2:100084008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.75	-0.3	4.44e-11	Chronic sinus infection;
LGG	cis	rs10895140	0.665	rs7119886	chr11:101507117	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs41005	1.000	rs193932	chr2:8107383	C/T	cg03155496	chr2:8117019	LOC339788	-0.87	-17.94	-0.64	5.17e-55	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs4727027	0.933	rs12704063	chr7:148827909	T/C	cg23583168	chr7:148888333	NA	-0.88	-17.14	-0.62	2.44e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17534004	1.000	rs12870594	chr13:31462909	T/C	cg00367615	chr13:31480979	C13orf33	0.34	6.86	0.3	2.24e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg16386425	chr10:429943	DIP2C	0.38	7.34	0.32	9.82e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs4740619	0.544	rs9407648	chr9:15826530	T/C	cg14451791	chr9:16040625	NA	0.32	7.93	0.35	1.62e-14	Body mass index;
LGG	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06634786	chr22:41940651	POLR3H	-0.65	-10.99	-0.45	4.05e-25	Vitiligo;
LGG	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.4	-0.58	1.71e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9527	0.590	rs10509764	chr10:104776475	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-6.97	-0.31	1.13e-11	Arsenic metabolism;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg07167872	chr1:205819463	PM20D1	0.69	14.73	0.56	1.51e-40	Menarche (age at onset);
LGG	cis	rs11122272	0.735	rs2749707	chr1:231527316	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.21	-0.46	5.68e-26	Hemoglobin concentration;
LGG	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2797160	0.904	rs1418637	chr6:125992553	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.42	-7.1	-0.31	4.76e-12	Endometrial cancer;
LGG	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.5	-0.44	2.85e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7523273	0.606	rs10449303	chr1:207961058	A/G	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.91	-0.48	1.02e-28	Schizophrenia;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03688707	chr13:76124424	UCHL3	0.39	6.81	0.3	2.95e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9381040	0.610	rs9394758	chr6:41017821	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.75	-0.3	4.49e-11	Alzheimer's disease (late onset);
LGG	cis	rs9287719	0.837	rs4233883	chr2:10755596	A/G	cg02196655	chr2:10830764	NOL10	-0.42	-7.14	-0.31	3.74e-12	Prostate cancer;
LGG	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg14784868	chr12:69753453	YEATS4	0.7	11.1	0.46	1.58e-25	Response to diuretic therapy;
LGG	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg06827562	chr3:125932279	NA	0.67	16.61	0.61	5.89e-49	Metabolite levels;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.24	0.43	2.51e-22	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs2282802	0.651	rs13353827	chr5:139654537	T/C	cg26211634	chr5:139558579	C5orf32	0.35	7.67	0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	1.000	rs4074170	chr17:28381141	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs6582630	0.555	rs7305352	chr12:38473800	T/C	cg26384229	chr12:38710491	ALG10B	0.99	23.25	0.73	8.9e-80	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6772849	0.768	rs4521246	chr3:128421166	A/G	cg08795948	chr3:128337044	NA	-0.64	-10.09	-0.42	9.03e-22	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4888262	0.545	rs4888270	chr16:74698576	A/G	cg01733217	chr16:74700730	RFWD3	0.94	19.85	0.68	6.77e-64	Testicular germ cell tumor;
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg16208657	chr15:68119293	LBXCOR1	-0.37	-7.24	-0.32	1.91e-12	Obesity;
LGG	cis	rs4363385	0.720	rs1338179	chr1:152981548	T/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.03	-0.39	4.64e-18	Inflammatory skin disease;
LGG	trans	rs2562456	0.833	rs1932087	chr19:21521427	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.65	-0.33	1.2e-13	Pain;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.81e-13	Bipolar disorder;
LGG	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg08859206	chr1:53392774	SCP2	0.47	9.41	0.4	2.36e-19	Monocyte count;
LGG	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg13397359	chr6:42928475	GNMT	0.43	9.23	0.39	9.38e-19	Blood protein levels;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.54	0.33	2.56e-13	Rheumatoid arthritis;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg15971980	chr6:150254442	NA	0.42	6.78	0.3	3.74e-11	Lung cancer;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg24110177	chr3:50126178	RBM5	-0.39	-6.75	-0.3	4.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.560	rs6582561	chr12:38666821	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.89	-0.51	1.04e-32	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.34e-11	Aortic root size;
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	11.87	0.48	1.52e-28	Total body bone mineral density;
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg08017756	chr2:100939284	LONRF2	-0.31	-7.31	-0.32	1.19e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2708240	0.666	rs2710117	chr7:147601772	T/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-7.83	-0.34	3.38e-14	QT interval (drug interaction);
LGG	cis	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	15.1	0.57	3.67e-42	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00933542	chr6:150070202	PCMT1	0.38	6.93	0.31	1.41e-11	Lung cancer;
LGG	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.63e-19	Diabetic retinopathy;
LGG	cis	rs11711311	0.736	rs13320940	chr3:113400954	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.77	-0.34	4.93e-14	IgG glycosylation;
LGG	cis	rs3768617	0.510	rs10752896	chr1:183068516	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.45	0.4	1.64e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg12458913	chr13:53173898	NA	-0.62	-11.91	-0.48	9.95e-29	Lewy body disease;
LGG	cis	rs7089973	0.872	rs7909566	chr10:116629136	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs367943	1.000	rs348941	chr5:112824166	G/C	cg12552261	chr5:112820674	MCC	-0.73	-13.58	-0.53	1.31e-35	Type 2 diabetes;
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg05368731	chr17:41323189	NBR1	0.96	18.92	0.66	1.43e-59	Menopause (age at onset);
LGG	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.83	-0.38	2.23e-17	Neuroticism;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg09264619	chr17:80180166	NA	0.37	7.36	0.32	8.42e-13	Life satisfaction;
LGG	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.61	-0.33	1.53e-13	Total cholesterol levels;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg08888203	chr3:10149979	C3orf24	0.56	9.57	0.41	6.42e-20	Alzheimer's disease;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.46	7.67	0.34	1.02e-13	Obesity-related traits;
LGG	cis	rs62400317	0.859	rs62436760	chr6:45112604	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.35	-0.43	1.03e-22	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg11166453	chr1:247681781	NA	0.63	9.92	0.42	3.79e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6942756	1.000	rs6467243	chr7:129001508	A/G	cg02491457	chr7:128862824	NA	-0.69	-12.48	-0.5	5.01e-31	White matter hyperintensity burden;
LGG	cis	rs74781061	0.932	rs11072496	chr15:74920532	C/T	cg02384859	chr15:74862662	ARID3B	-0.33	-6.9	-0.31	1.71e-11	Endometriosis;
LGG	cis	rs7618501	0.633	rs6792892	chr3:49995518	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-10.15	-0.43	5.25e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25072359	chr17:41440525	NA	0.51	9.7	0.41	2.29e-20	Menopause (age at onset);
LGG	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg08125733	chr17:73851984	WBP2	0.42	7.04	0.31	7.02e-12	White matter hyperintensity burden;
LGG	trans	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.85	-0.38	1.92e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9818758	0.607	rs9847839	chr3:49289003	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-6.79	-0.3	3.56e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg10204951	chr7:910479	UNC84A	-0.53	-7.08	-0.31	5.35e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9354308	0.764	rs9445607	chr6:66570492	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs4700695	0.925	rs1845481	chr5:65397527	A/C	cg21114390	chr5:65439923	SFRS12	-0.56	-7.24	-0.32	1.89e-12	Facial morphology (factor 19);
LGG	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg01221209	chr5:554886	NA	-0.51	-7.58	-0.33	1.95e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg02353165	chr6:42928485	GNMT	0.47	14.09	0.55	9.2e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07308232	chr7:1071921	C7orf50	-0.58	-10.65	-0.44	7.99e-24	Longevity;Endometriosis;
LGG	trans	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04565464	chr8:145669602	NFKBIL2	0.4	7.13	0.31	3.82e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1267303	0.642	rs2404611	chr1:46997127	C/G	cg25110126	chr1:46999211	NA	0.57	8.76	0.38	3.76e-17	Monobrow;
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.56	-0.37	1.71e-16	Personality dimensions;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.59	11.59	0.47	1.91e-27	Obesity-related traits;
LGG	cis	rs1829883	1.000	rs1916599	chr5:98774240	C/G	cg08333243	chr5:99726346	NA	-0.39	-7.53	-0.33	2.61e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-7.06	-0.31	6.04e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg26816564	chr1:7831052	VAMP3	0.74	11.81	0.48	2.63e-28	Inflammatory bowel disease;
LGG	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.19	-0.55	3.29e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14073117	chr9:4792649	RCL1	0.42	6.75	0.3	4.36e-11	Cognitive performance;
LGG	cis	rs4700695	0.614	rs446618	chr5:65210062	G/A	cg21114390	chr5:65439923	SFRS12	0.6	7.02	0.31	7.86e-12	Facial morphology (factor 19);
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4737010	0.501	rs34342524	chr8:41633857	G/A	cg17182837	chr8:41585554	ANK1	0.65	9.6	0.41	5.2e-20	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg27661571	chr11:113659931	NA	-0.66	-7.39	-0.32	6.7e-13	Hip circumference adjusted for BMI;
LGG	cis	rs3087591	0.573	rs731758	chr17:29723000	C/G	cg24425628	chr17:29625626	OMG;NF1	0.56	11.35	0.47	1.67e-26	Hip circumference;
LGG	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	cis	rs1348850	0.801	rs11890163	chr2:178327134	G/A	cg27490568	chr2:178487706	NA	0.77	12.04	0.49	3.23e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.65	0.44	7.46e-24	Lung function (FEV1/FVC);
LGG	cis	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.71	0.38	5.34e-17	Mood instability;
LGG	cis	rs8067545	0.611	rs2703771	chr17:20130154	C/G	cg09818912	chr17:20140352	CYTSB	0.32	7.42	0.33	5.52e-13	Schizophrenia;
LGG	cis	rs9463078	0.625	rs679713	chr6:44899632	T/C	cg25276700	chr6:44698697	NA	-0.33	-6.88	-0.3	1.93e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg22349387	chr12:9600060	DDX12	-0.28	-6.97	-0.31	1.12e-11	Breast size;
LGG	cis	rs67133203	0.851	rs12820966	chr12:51488422	A/C	cg14688905	chr12:51403056	SLC11A2	0.67	10.19	0.43	3.94e-22	Urinary tract infection frequency;
LGG	cis	rs1401999	0.932	rs4148557	chr3:183733784	A/G	cg20387954	chr3:183756860	HTR3D	0.69	14.03	0.55	1.66e-37	Anterior chamber depth;
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	7.5	0.33	3.31e-13	Renal function-related traits (BUN);
LGG	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.49	-0.33	3.63e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2777491	1.000	rs2777491	chr15:41735710	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.18	-0.68	1.89e-65	Ulcerative colitis;
LGG	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg11890956	chr21:40555474	PSMG1	1.17	29.85	0.81	5.75e-110	Cognitive function;
LGG	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg06766960	chr11:133703094	NA	-0.57	-11.15	-0.46	1.02e-25	Childhood ear infection;
LGG	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg07936489	chr17:37558343	FBXL20	1.0	15.63	0.59	1.55e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8031584	0.918	rs3817498	chr15:31268781	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-7.14	-0.31	3.7e-12	Huntington's disease progression;
LGG	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg04065206	chr12:109973212	UBE3B	-0.47	-6.85	-0.3	2.39e-11	Neuroticism;
LGG	cis	rs7208859	0.573	rs8078182	chr17:29149664	C/T	cg19761014	chr17:28927070	LRRC37B2	0.6	7.47	0.33	3.94e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04832268	chr17:18022959	MYO15A	-0.37	-6.67	-0.3	7.45e-11	Cognitive performance;
LGG	cis	rs11190604	1.000	rs2489051	chr10:102351785	C/T	cg07080220	chr10:102295463	HIF1AN	-0.69	-11.92	-0.48	9.2e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.7	-0.34	8.46e-14	Lung cancer;
LGG	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg26384229	chr12:38710491	ALG10B	0.77	14.21	0.55	2.81e-38	Resting heart rate;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.71e-15	Obesity-related traits;
LGG	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.85	-0.38	1.85e-17	Neuroticism;
LGG	cis	rs4731207	0.596	rs34555990	chr7:124587844	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6466055	0.699	rs4496901	chr7:104898337	G/T	cg04380332	chr7:105027541	SRPK2	0.38	7.07	0.31	5.58e-12	Schizophrenia;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07677032	chr17:61819896	STRADA	0.56	9.94	0.42	3.05e-21	Prudent dietary pattern;
LGG	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15128208	chr22:42549153	NA	0.5	10.22	0.43	2.93e-22	Cognitive function;
LGG	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg03806693	chr22:41940476	POLR3H	-0.8	-13.8	-0.54	1.61e-36	Vitiligo;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg09148494	chr19:55866345	COX6B2;FAM71E2	-0.38	-7.83	-0.34	3.46e-14	Iris color (L* coordinate);
LGG	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.7	0.54	4.04e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.86	-0.54	8.55e-37	Tonsillectomy;
LGG	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.7	0.34	8.44e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	trans	rs7615952	0.688	rs12638240	chr3:125541238	G/A	cg07211511	chr3:129823064	LOC729375	-1.02	-14.72	-0.56	1.62e-40	Blood pressure (smoking interaction);
LGG	cis	rs11700980	0.551	rs2832013	chr21:30110940	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.67	-0.3	7.13e-11	QRS complex (12-leadsum);
LGG	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.35e-12	Lung cancer;
LGG	cis	rs368123	1.000	rs544271	chr6:160702685	T/C	cg07349212	chr6:160770346	SLC22A3	-0.33	-7.09	-0.31	5.02e-12	Waist circumference;
LGG	cis	rs2549003	1.000	rs3846732	chr5:131816087	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.48	0.33	3.64e-13	Asthma (sex interaction);
LGG	cis	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-13.32	-0.53	1.74e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6813479	0.594	rs1031711	chr4:137737358	A/C	cg16185213	chr4:137733633	NA	0.39	7.11	0.31	4.51e-12	Longevity;
LGG	cis	rs11622475	0.911	rs55908053	chr14:104386173	T/C	cg12183467	chr14:104352244	NA	-0.46	-7.98	-0.35	1.19e-14	Bipolar disorder;
LGG	cis	rs1707322	0.964	rs785483	chr1:46559171	T/C	cg03146154	chr1:46216737	IPP	-0.53	-9.58	-0.41	5.85e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7572733	0.515	rs1401096	chr2:198823828	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg18681998	chr4:17616180	MED28	0.81	18.1	0.64	9.22e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs943466	1.000	rs751096	chr6:33742838	C/T	cg07519485	chr6:33762594	MLN	-0.54	-10.75	-0.45	3.37e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs4919087	0.851	rs2297987	chr10:98989454	C/T	cg25902810	chr10:99078978	FRAT1	-0.42	-7.48	-0.33	3.82e-13	Monocyte count;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs921968	0.510	rs2577761	chr2:219462500	G/A	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs11096990	0.855	rs56275407	chr4:39178844	T/G	cg24403649	chr4:39172243	NA	-0.46	-7.58	-0.33	1.86e-13	Cognitive function;
LGG	cis	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs9381040	0.655	rs2294695	chr6:41036770	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-6.67	-0.3	7.44e-11	Alzheimer's disease (late onset);
LGG	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.5	-7.82	-0.34	3.6e-14	Menarche (age at onset);
LGG	cis	rs300774	0.925	rs300714	chr2:138106	G/A	cg04617936	chr2:214353	NA	-0.5	-7.67	-0.34	9.9e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg04166393	chr7:2884313	GNA12	0.46	9.15	0.39	1.75e-18	Height;
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg24690094	chr11:67383802	NA	-0.56	-9.7	-0.41	2.29e-20	Mean corpuscular volume;
LGG	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg21053147	chr12:120880522	NA	0.53	8.04	0.35	7.35e-15	Type 1 diabetes nephropathy;
LGG	cis	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg01221209	chr5:554886	NA	-0.48	-7.7	-0.34	8.35e-14	Obesity-related traits;
LGG	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg09307838	chr4:120376055	NA	0.72	12.47	0.5	5.74e-31	Corneal astigmatism;
LGG	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18876405	chr7:65276391	NA	-0.59	-11.13	-0.46	1.17e-25	Aortic root size;
LGG	cis	rs9362426	0.503	rs34977536	chr6:88112368	T/C	cg22010963	chr6:88119922	C6orf165	-0.31	-6.75	-0.3	4.4e-11	Depressive episodes in bipolar disorder;
LGG	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.25	-0.43	2.37e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	1.000	rs11039819	chr11:48562181	G/T	cg00717180	chr2:96193071	NA	-0.42	-7.48	-0.33	3.65e-13	HDL cholesterol;
LGG	cis	rs6665290	0.935	rs17600669	chr1:227201871	A/G	cg05696931	chr1:227175867	NA	-0.4	-7.86	-0.34	2.73e-14	Myeloid white cell count;
LGG	cis	rs6752107	0.936	rs10187822	chr2:234206474	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.6	0.47	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg02725872	chr8:58115012	NA	-0.8	-11.74	-0.48	4.74e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs10949834	0.504	rs13238778	chr7:73567709	G/A	cg07137043	chr7:73588983	EIF4H	-0.6	-9.34	-0.4	4.14e-19	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.16	0.32	3.2e-12	Lung cancer;
LGG	cis	rs12425451	0.518	rs7311791	chr12:3139613	C/T	cg05389053	chr12:3131226	TEAD4	0.69	12.2	0.49	7.37e-30	Narcolepsy with cataplexy;
LGG	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-13.05	-0.52	2.21e-33	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg01341218	chr17:43662625	NA	-0.86	-14.62	-0.56	4.71e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.9	0.42	4.52e-21	Mean corpuscular volume;
LGG	trans	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.45	0.33	4.49e-13	Joint mobility (Beighton score);
LGG	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.29	0.53	2.3e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17154702	0.510	rs7831224	chr8:8656647	C/T	cg01851573	chr8:8652454	MFHAS1	0.47	7.75	0.34	5.81e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs2652834	0.898	rs10162675	chr15:63370358	T/C	cg05507819	chr15:63340323	TPM1	-0.59	-7.85	-0.34	2.89e-14	HDL cholesterol;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg01516881	chr6:292596	DUSP22	-0.69	-11.77	-0.48	3.64e-28	Menopause (age at onset);
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg00689492	chr4:1303491	MAEA	0.52	9.21	0.39	1.14e-18	Obesity-related traits;
LGG	cis	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg08250081	chr4:10125330	NA	-0.48	-9.25	-0.39	8.2e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs832540	0.629	rs10940512	chr5:56082094	G/C	cg12654349	chr5:56205094	C5orf35	-0.43	-7.5	-0.33	3.4e-13	Coronary artery disease;
LGG	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.9e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.89	-0.42	4.87e-21	Electroencephalogram traits;
LGG	cis	rs7917772	0.636	rs10786708	chr10:104526245	C/T	cg04362960	chr10:104952993	NT5C2	-0.47	-7.75	-0.34	5.84e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7582180	0.629	rs4851295	chr2:100945605	T/C	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg09021430	chr5:549028	NA	-0.71	-10.04	-0.42	1.39e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg26655873	chr3:72818019	SHQ1	0.36	7.09	0.31	4.93e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs57590327	0.528	rs11707026	chr3:81694044	C/A	cg07356753	chr3:81810745	GBE1	-0.49	-7.64	-0.33	1.22e-13	Extraversion;
LGG	cis	rs7072216	0.763	rs2147900	chr10:100174721	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.2	-0.32	2.42e-12	Metabolite levels;
LGG	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg04455712	chr21:45112962	RRP1B	0.51	9.69	0.41	2.37e-20	Mean corpuscular volume;
LGG	cis	rs8072100	0.805	rs67919208	chr17:45771873	T/C	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.02	-0.35	8.43e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg21775007	chr8:11205619	TDH	0.46	7.51	0.33	3.13e-13	Mood instability;
LGG	cis	rs2227564	0.729	rs2675676	chr10:75648287	A/C	cg00564723	chr10:75632066	CAMK2G	-0.44	-8.9	-0.38	1.3e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg06968155	chr5:131705112	SLC22A5	0.72	8.29	0.36	1.21e-15	Rheumatoid arthritis;
LGG	cis	rs2072732	0.861	rs12033927	chr1:2937550	A/G	cg08733933	chr1:2954429	NA	-0.47	-8.86	-0.38	1.77e-17	Plateletcrit;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.4e-35	Personality dimensions;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs57024841	0.500	rs6560652	chr9:139830940	C/T	cg00693599	chr9:139836323	FBXW5	-0.4	-7.03	-0.31	7.58e-12	Beta-trace protein levels;
LGG	cis	rs9583531	0.760	rs1887200	chr13:111393137	A/C	cg24331049	chr13:111365604	ING1	-0.88	-13.25	-0.52	3.4e-34	Coronary artery disease;
LGG	cis	rs9807989	0.507	rs2058659	chr2:103054556	A/G	cg03938978	chr2:103052716	IL18RAP	-0.42	-9.68	-0.41	2.54e-20	Asthma;
LGG	cis	rs7493	0.755	rs17166859	chr7:94995519	T/C	cg08461772	chr7:95026248	PON3	0.38	8.19	0.36	2.66e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	0.41	7.0	0.31	8.97e-12	Bipolar disorder;
LGG	cis	rs12431410	0.550	rs2882301	chr14:60235820	G/A	cg07950296	chr14:60194823	RTN1	-0.4	-7.58	-0.33	1.87e-13	Schizophrenia;
LGG	cis	rs6500395	0.928	rs723807	chr16:48691443	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3789045	0.774	rs12028476	chr1:204476361	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.43	-8.37	-0.36	6.65e-16	Educational attainment (college completion);
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08280861	chr8:58055591	NA	0.67	8.14	0.35	3.66e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg22398616	chr13:53314203	LECT1	-0.34	-6.68	-0.3	6.91e-11	Lewy body disease;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg18538332	chr22:24372958	LOC391322	-0.43	-7.06	-0.31	5.94e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10754283	0.967	rs7528433	chr1:90114071	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4330281	0.715	rs6796448	chr3:17801811	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.36	-0.32	8.24e-13	Schizophrenia;
LGG	cis	rs2404602	0.735	rs2436994	chr15:76801063	G/C	cg23625390	chr15:77176239	SCAPER	-0.65	-13.05	-0.52	2.34e-33	Blood metabolite levels;
LGG	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.19	0.39	1.31e-18	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg14926445	chr8:58193284	C8orf71	-0.82	-10.53	-0.44	2.19e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	8.05	0.35	7.18e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs295140	1.000	rs67190025	chr2:201172086	C/T	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.2	-0.52	5.22e-34	Life satisfaction;
LGG	cis	rs4917300	0.606	rs6583566	chr8:143114541	G/A	cg26003909	chr8:143102224	NA	-0.33	-6.75	-0.3	4.51e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs73193808	0.590	rs9981735	chr21:30567864	G/A	cg03476357	chr21:30257390	N6AMT1	0.41	6.91	0.31	1.6e-11	Coronary artery disease;
LGG	cis	rs72781680	1.000	rs111229211	chr2:24167417	T/G	cg08917208	chr2:24149416	ATAD2B	0.82	8.82	0.38	2.33e-17	Lymphocyte counts;
LGG	cis	rs4262150	0.846	rs72801007	chr5:152196711	C/G	cg12297329	chr5:152029980	NA	-0.68	-12.82	-0.51	2.03e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg05084668	chr3:125655381	ALG1L	-1.06	-12.3	-0.5	2.86e-30	Blood pressure (smoking interaction);
LGG	cis	rs77633900	0.772	rs284898	chr15:76750695	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7084402	0.935	rs2393449	chr10:60343030	A/G	cg07615347	chr10:60278583	BICC1	0.62	17.65	0.63	1.13e-53	Refractive error;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-7.97	-0.35	1.22e-14	Lung cancer;
LGG	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.53	-0.37	2.09e-16	Triglycerides;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05025164	chr4:1340916	KIAA1530	-0.84	-16.1	-0.6	1.24e-46	Longevity;
LGG	cis	rs262150	0.625	rs117651953	chr7:158780563	G/A	cg19418458	chr7:158789849	NA	0.46	6.69	0.3	6.36e-11	Facial morphology (factor 20);
LGG	cis	rs2033732	0.706	rs1866086	chr8:85071556	G/C	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.8e-12	Body mass index;
LGG	cis	rs6743226	0.901	rs12478458	chr2:242237856	A/G	cg10021735	chr2:242295487	FARP2	0.52	9.53	0.41	8.8e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24688926	chr19:6737877	GPR108	0.45	6.68	0.3	6.8e-11	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg09307838	chr4:120376055	NA	0.68	11.75	0.48	4.47e-28	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs6976053	0.935	rs6954151	chr7:100484917	C/T	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.72e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs2227564	0.729	rs2688617	chr10:75646147	A/T	cg00564723	chr10:75632066	CAMK2G	-0.45	-9.06	-0.39	3.69e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1009647	0.614	rs17253702	chr14:55583883	C/T	cg04306507	chr14:55594613	LGALS3	0.47	7.99	0.35	1.06e-14	Testicular germ cell tumor;
LGG	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg10168709	chr10:75599394	CAMK2G	-0.35	-6.92	-0.31	1.51e-11	Inflammatory bowel disease;
LGG	cis	rs1577917	0.771	rs9362237	chr6:86409064	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.41	0.63	1.43e-52	Response to antipsychotic treatment;
LGG	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.1	0.31	4.87e-12	Aortic root size;
LGG	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4690686	0.731	rs11941845	chr4:177276526	G/A	cg17059388	chr4:177262070	NA	0.74	16.16	0.6	6.36e-47	Essential tremor;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-8.37	-0.36	7.04e-16	Personality dimensions;
LGG	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg13798912	chr7:905769	UNC84A	-0.57	-7.11	-0.31	4.37e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg19168338	chr16:4465731	CORO7	-0.89	-18.01	-0.64	2.29e-55	Schizophrenia;
LGG	cis	rs1318772	0.932	rs1035409	chr5:112850963	G/A	cg12552261	chr5:112820674	MCC	0.67	7.61	0.33	1.52e-13	F-cell distribution;
LGG	cis	rs73416724	1.000	rs4714675	chr6:43287893	T/C	cg26312998	chr6:43337775	ZNF318	-0.55	-7.84	-0.34	3.2e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.51	-0.53	2.64e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.45	0.37	3.84e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6466055	0.867	rs10241415	chr7:104948076	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.93	0.31	1.44e-11	Schizophrenia;
LGG	cis	rs72781680	0.898	rs12619592	chr2:23971415	C/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.01	0.39	5.52e-18	Lymphocyte counts;
LGG	cis	rs1256531	0.661	rs11847101	chr14:66201373	G/C	cg15999311	chr14:65749247	NA	0.76	6.86	0.3	2.15e-11	Conduct disorder (symptom count);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg08219700	chr8:58056026	NA	0.47	7.09	0.31	4.9e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg14541582	chr5:601475	NA	-0.69	-10.89	-0.45	9.94e-25	Obesity-related traits;
LGG	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.57	0.33	2.03e-13	Glycated hemoglobin levels;
LGG	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-9.14	-0.39	1.93e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs807669	0.557	rs712958	chr22:19167409	T/C	cg02655711	chr22:19163373	SLC25A1	0.67	12.76	0.51	3.49e-32	Metabolite levels;
LGG	cis	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg19399532	chr1:178512495	C1orf220	-0.5	-9.99	-0.42	2.08e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.0	0.31	8.95e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs7918232	0.941	rs4749230	chr10:27441218	C/T	cg14240646	chr10:27532245	ACBD5	-0.77	-10.81	-0.45	1.99e-24	Breast cancer;
LGG	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg03806693	chr22:41940476	POLR3H	-0.55	-8.86	-0.38	1.67e-17	Neuroticism;
LGG	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00292662	chr22:38071168	LGALS1	0.64	14.76	0.57	1.06e-40	Fat distribution (HIV);
LGG	cis	rs6912958	0.630	rs9450726	chr6:88236728	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.43	-7.38	-0.32	7.34e-13	Monocyte percentage of white cells;
LGG	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.47	-0.33	3.96e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.89e-32	Motion sickness;
LGG	cis	rs6963495	0.818	rs73192107	chr7:105168095	G/A	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg26396452	chr14:65542826	MAX	0.45	8.77	0.38	3.38e-17	Obesity-related traits;
LGG	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg08484992	chr16:88977278	CBFA2T3	0.3	7.01	0.31	8.67e-12	Social autistic-like traits;
LGG	cis	rs1949733	1.000	rs3103067	chr4:8511223	A/G	cg11789530	chr4:8429930	ACOX3	0.81	15.35	0.58	2.66e-43	Response to antineoplastic agents;
LGG	cis	rs3762637	1.000	rs16845530	chr3:122142447	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.91	-0.45	8.02e-25	LDL cholesterol levels;
LGG	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg24110177	chr3:50126178	RBM5	-0.6	-10.74	-0.45	3.52e-24	Intelligence (multi-trait analysis);
LGG	cis	rs975739	0.902	rs1668633	chr13:78371890	C/T	cg07847733	chr13:78271382	SLAIN1	0.38	6.84	0.3	2.5e-11	Hair color;
LGG	cis	rs7660520	0.524	rs6839881	chr4:183729137	A/T	cg04181038	chr4:183730758	NA	0.55	8.36	0.36	7.5e-16	Pediatric autoimmune diseases;
LGG	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.92	0.35	1.76e-14	Birth weight;
LGG	cis	rs55883249	1.000	rs62119428	chr2:9743332	T/C	cg23886495	chr2:9695866	ADAM17	0.66	9.57	0.41	6.56e-20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs9326248	0.581	rs10892061	chr11:116886114	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.77	0.45	2.82e-24	Blood protein levels;
LGG	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs11711311	1.000	rs62268169	chr3:113493860	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.87	0.54	7.53e-37	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs55863869	0.748	rs4894037	chr2:179623142	C/T	cg02880032	chr2:179629472	TTN	-0.47	-6.71	-0.3	5.75e-11	QT interval;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg14074117	chr16:1909714	C16orf73	-0.51	-7.5	-0.33	3.21e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg13256891	chr4:100009986	ADH5	0.38	6.94	0.31	1.36e-11	Alcohol dependence;
LGG	cis	rs4363385	0.693	rs4845497	chr1:152904162	T/C	cg07796016	chr1:152779584	LCE1C	-0.46	-7.19	-0.32	2.59e-12	Inflammatory skin disease;
LGG	trans	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2070997	0.816	rs6597642	chr9:133725767	C/T	cg13397898	chr9:133768931	QRFP	0.34	6.82	0.3	2.86e-11	Response to amphetamines;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22539505	chr3:50330110	IFRD2	0.41	7.01	0.31	8.25e-12	Bipolar disorder;
LGG	cis	rs123509	0.913	rs339686	chr3:42769688	T/C	cg10144569	chr3:42726640	KBTBD5	0.51	7.61	0.33	1.59e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg02772935	chr3:125709198	NA	-0.55	-6.99	-0.31	9.48e-12	Blood pressure (smoking interaction);
LGG	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg19336497	chr11:14380999	RRAS2	-0.39	-7.43	-0.33	5.41e-13	Vitamin D levels;
LGG	cis	rs561341	0.714	rs547473	chr17:30297560	T/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.75e-23	Hip circumference adjusted for BMI;
LGG	cis	rs193541	0.530	rs1466371	chr5:122083788	T/C	cg19412675	chr5:122181750	SNX24	0.52	8.33	0.36	9.09e-16	Glucose homeostasis traits;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg05896524	chr21:47604654	C21orf56	0.55	9.34	0.4	4.19e-19	Testicular germ cell tumor;
LGG	cis	rs834603	0.687	rs11763044	chr7:47481602	G/A	cg23694490	chr7:47445681	TNS3	0.45	12.36	0.5	1.6e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7106204	1.000	rs4244512	chr11:24217355	A/G	ch.11.24196551F	chr11:24239977	NA	-0.95	-12.43	-0.5	8.56e-31	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg20026190	chr17:76395443	PGS1	0.58	10.24	0.43	2.52e-22	HDL cholesterol levels;
LGG	cis	rs6834538	0.964	rs2087110	chr4:113411791	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.75	0.38	4.05e-17	Free thyroxine concentration;
LGG	cis	rs73157695	0.521	rs55918937	chr21:47184033	C/T	cg11214348	chr21:47283868	PCBP3	-0.52	-9.86	-0.42	6.02e-21	Myopia;
LGG	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg18478394	chr8:109455254	TTC35	0.44	8.36	0.36	7.59e-16	Dupuytren's disease;
LGG	cis	rs7107174	1.000	rs2510041	chr11:77945284	G/A	cg27205649	chr11:78285834	NARS2	-0.44	-7.32	-0.32	1.14e-12	Testicular germ cell tumor;
LGG	cis	rs1008375	1.000	rs114490726	chr4:17680898	T/C	cg18681998	chr4:17616180	MED28	0.82	18.24	0.65	2.06e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.58	-0.37	1.42e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs11875185	0.510	rs17754552	chr18:55597539	G/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4731207	0.596	rs10255638	chr7:124576255	C/T	cg05630886	chr7:124431682	NA	0.3	6.85	0.3	2.33e-11	Cutaneous malignant melanoma;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.31	0.36	1.04e-15	Schizophrenia;
LGG	cis	rs644799	1.000	rs473155	chr11:95596873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	12.97	0.52	4.78e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	0.931	rs6822196	chr4:135855582	T/A	cg14419869	chr4:135874104	NA	0.57	10.85	0.45	1.37e-24	Subjective well-being;
LGG	cis	rs2228479	0.702	rs17177891	chr16:89799950	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.53	0.37	2.02e-16	Skin colour saturation;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg14668821	chr17:77704760	ENPP7	0.42	8.26	0.36	1.52e-15	Menopause (age at onset);
LGG	cis	rs4132509	0.947	rs7517340	chr1:243710190	T/C	cg21452805	chr1:244014465	NA	-0.6	-6.88	-0.3	1.97e-11	RR interval (heart rate);
LGG	cis	rs6752107	0.837	rs3792108	chr2:234184952	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.12	0.52	1.15e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg00149659	chr3:10157352	C3orf10	0.82	10.69	0.44	5.39e-24	Alzheimer's disease;
LGG	cis	rs7296418	0.961	rs1790122	chr12:123606739	G/A	cg05973401	chr12:123451056	ABCB9	0.45	7.55	0.33	2.34e-13	Platelet count;
LGG	cis	rs8060686	0.641	rs8064114	chr16:68240185	G/A	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.23	-0.32	2.03e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg11642891	chr2:3452563	TTC15	-0.46	-8.91	-0.38	1.14e-17	Obesity-related traits;
LGG	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.85e-12	Schizophrenia;
LGG	cis	rs4423214	1.000	rs12807718	chr11:71171170	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.06	-0.52	2.09e-33	Vitamin D levels;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.67	-0.37	7.52e-17	Obesity-related traits;
LGG	cis	rs714515	0.934	rs10752943	chr1:172354992	C/T	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6500395	0.735	rs7204345	chr16:48666726	T/C	cg04672837	chr16:48644449	N4BP1	0.5	8.43	0.36	4.32e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg25566285	chr7:158114605	PTPRN2	-0.74	-13.59	-0.53	1.27e-35	Calcium levels;
LGG	cis	rs1620921	0.563	rs55900705	chr6:161264920	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg21858823	chr1:15850916	CASP9	0.36	7.66	0.34	1.06e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg13010199	chr12:38710504	ALG10B	-0.57	-11.07	-0.46	1.92e-25	Morning vs. evening chronotype;
LGG	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg11859384	chr17:80120422	CCDC57	0.47	8.15	0.35	3.33e-15	Life satisfaction;
LGG	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg15557168	chr22:42548783	NA	0.4	8.66	0.37	7.83e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.95	-0.31	1.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11074306	0.561	rs9806736	chr15:28073481	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.37	0.32	7.69e-13	Uveal melanoma;
LGG	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg03034668	chr16:1723424	CRAMP1L	-0.43	-6.88	-0.3	1.93e-11	Coronary artery disease;
LGG	cis	rs607541	1.000	rs593126	chr15:45935777	G/A	cg26924012	chr15:45694286	SPATA5L1	0.53	7.39	0.32	7e-13	Obesity-related traits;
LGG	cis	rs853679	0.517	rs9348796	chr6:28126202	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.49	-0.37	2.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg18681998	chr4:17616180	MED28	0.73	14.69	0.56	2.31e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-13.19	-0.52	5.86e-34	Cognitive function;
LGG	trans	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg05926928	chr17:57297772	GDPD1	1.27	18.82	0.66	4.21e-59	Opioid sensitivity;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg23978390	chr7:1156363	C7orf50	0.51	8.68	0.37	6.79e-17	Longevity;Endometriosis;
LGG	cis	rs1978968	1.000	rs28434757	chr22:18451554	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-12.89	-0.51	1.05e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs9534288	0.797	rs1326401	chr13:46571602	A/G	cg15192986	chr13:46630673	CPB2	0.59	12.92	0.51	7.92e-33	Blood protein levels;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg02725872	chr8:58115012	NA	-0.92	-11.94	-0.49	7.77e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg13298116	chr11:62369859	EML3;MTA2	0.61	13.25	0.52	3.34e-34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9581857	0.556	rs9581861	chr13:28039991	C/T	cg01674679	chr13:27998804	GTF3A	-0.59	-8.11	-0.35	4.72e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.62	-11.97	-0.49	5.67e-29	Obesity-related traits;
LGG	cis	rs977987	0.872	rs4243111	chr16:75320827	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.95	0.42	2.96e-21	Dupuytren's disease;
LGG	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg16797656	chr11:68205561	LRP5	0.39	6.8	0.3	3.27e-11	Total body bone mineral density;
LGG	cis	rs7296418	0.630	rs28419092	chr12:123812629	G/C	cg00376283	chr12:123451042	ABCB9	0.62	11.48	0.47	5.14e-27	Platelet count;
LGG	cis	rs8056064	1.000	rs67218876	chr16:82787584	A/G	cg08271366	chr16:82816457	CDH13	-0.39	-6.86	-0.3	2.19e-11	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs9303280	0.870	rs6503524	chr17:38069809	C/T	cg00129232	chr17:37814104	STARD3	0.45	8.34	0.36	8.77e-16	Self-reported allergy;
LGG	cis	rs1719271	0.831	rs1719262	chr15:65185904	T/A	cg11671771	chr15:65133392	PLEKHO2	-0.5	-6.91	-0.31	1.62e-11	Platelet count;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02475777	chr4:1388615	CRIPAK	0.6	10.74	0.45	3.55e-24	Longevity;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg24503407	chr1:205819492	PM20D1	0.51	9.69	0.41	2.4e-20	Prostate cancer;
LGG	cis	rs3845702	0.736	rs9288045	chr2:180814194	G/A	cg01881094	chr2:180872142	CWC22	-1.24	-16.6	-0.61	7.11e-49	Schizophrenia;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs8073060	0.586	rs2626625	chr17:34027607	C/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg01620082	chr3:125678407	NA	-1.04	-10.0	-0.42	1.91e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg00717180	chr2:96193071	NA	-0.46	-8.38	-0.36	6.2e-16	HDL cholesterol;
LGG	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17453880	0.890	rs28842566	chr5:152048590	A/G	cg10931792	chr5:152022470	NA	0.42	9.01	0.39	5.63e-18	Subjective well-being;
LGG	trans	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg01570182	chr17:44337453	NA	0.71	11.48	0.47	4.98e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg05623727	chr3:50126028	RBM5	0.41	8.93	0.38	1.05e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6719977	0.543	rs4953604	chr2:42957539	T/C	cg14631114	chr2:43023945	NA	0.48	10.17	0.43	4.7e-22	Hyperactive-impulsive symptoms;
LGG	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg15268244	chr15:77196840	NA	0.44	9.67	0.41	2.83e-20	Blood metabolite levels;
LGG	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-10.4	-0.44	6.45e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6840360	0.615	rs4696267	chr4:152464500	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg22907277	chr7:1156413	C7orf50	0.43	7.33	0.32	1e-12	Longevity;Endometriosis;
LGG	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg08807101	chr21:30365312	RNF160	0.92	19.46	0.67	4.25e-62	Dental caries;
LGG	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	15.59	0.59	2.4e-44	Platelet count;
LGG	cis	rs780094	0.500	rs1919127	chr2:27801493	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	5.1e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg01943577	chr7:158741284	NA	-0.44	-8.05	-0.35	7.2e-15	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17420218	chr2:20102066	TTC32	-0.46	-6.76	-0.3	4.05e-11	Systemic lupus erythematosus;
LGG	cis	rs2640806	0.505	rs11984998	chr8:97364014	T/C	cg22138393	chr8:97340270	PTDSS1	0.27	7.14	0.32	3.55e-12	Obesity-related traits;
LGG	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg07395648	chr5:131743802	NA	-0.51	-11.81	-0.48	2.48e-28	Blood metabolite levels;
LGG	trans	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg06521331	chr12:34319734	NA	0.42	7.34	0.32	9.98e-13	Morning vs. evening chronotype;
LGG	cis	rs524281	0.817	rs7115081	chr11:65853541	A/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs986417	0.901	rs1061108	chr14:60978071	C/G	cg27398547	chr14:60952738	C14orf39	0.73	7.13	0.31	3.8e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10173297	0.686	rs1965733	chr2:3709129	T/C	cg16123090	chr2:3699210	NA	0.58	7.81	0.34	3.81e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg05775895	chr3:12838266	CAND2	-0.66	-11.66	-0.48	1.02e-27	QRS complex (12-leadsum);
LGG	cis	rs1062753	0.527	rs6002560	chr22:42356886	C/T	cg15128208	chr22:42549153	NA	-0.4	-7.42	-0.33	5.62e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7737355	0.812	rs2158294	chr5:130878215	A/G	cg06307176	chr5:131281290	NA	0.52	8.65	0.37	8.71e-17	Life satisfaction;
LGG	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-13.9	-0.54	6.1e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12580194	0.593	rs61956269	chr12:55768023	C/T	cg19537932	chr12:55886519	OR6C68	-0.55	-10.02	-0.42	1.6e-21	Cancer;
LGG	cis	rs36093844	0.752	rs17817308	chr11:85593529	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.12	-0.31	4.24e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg11941060	chr3:133502564	NA	-0.49	-8.29	-0.36	1.25e-15	Iron status biomarkers;
LGG	cis	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.59	-0.41	5.53e-20	Morning vs. evening chronotype;
LGG	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg15627072	chr1:2432621	PLCH2	0.36	7.96	0.35	1.31e-14	Ulcerative colitis;
LGG	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg20335179	chr10:1068567	C10orf110;IDI2	0.35	6.71	0.3	5.61e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs36051895	0.559	rs72701682	chr9:5208025	A/G	cg02405213	chr9:5042618	JAK2	-0.64	-10.91	-0.45	7.92e-25	Pediatric autoimmune diseases;
LGG	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg13802316	chr11:70253460	CTTN	-0.65	-8.88	-0.38	1.46e-17	Coronary artery disease;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.2	-0.36	2.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg27144592	chr16:783916	NARFL	0.8	13.85	0.54	9.73e-37	Height;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	11.62	0.48	1.49e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs74417235	0.684	rs7723610	chr5:154053349	A/C	cg08754654	chr5:154026448	NA	0.52	10.7	0.45	5.09e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.37	0.32	7.87e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2742417	0.603	rs2253979	chr3:45773320	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4242434	0.819	rs7843128	chr8:22473465	T/C	cg03733263	chr8:22462867	KIAA1967	1.05	27.26	0.78	2.48e-98	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7113850	0.541	rs56679749	chr11:24235649	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.47	0.44	3.72e-23	Bone fracture in osteoporosis;
LGG	cis	rs1371867	0.846	rs1660353	chr8:101250907	C/T	cg06636551	chr8:101224915	SPAG1	0.47	8.86	0.38	1.67e-17	Atrioventricular conduction;
LGG	cis	rs9549260	0.709	rs9549240	chr13:41186644	T/G	cg21288729	chr13:41239152	FOXO1	0.33	6.68	0.3	6.85e-11	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16644510	chr1:45672524	ZSWIM5	0.49	7.59	0.33	1.82e-13	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg12253571	chr8:8283032	NA	-0.31	-6.76	-0.3	4.22e-11	Mood instability;
LGG	cis	rs7630877	0.719	rs12489992	chr3:179664925	A/C	cg18765712	chr3:179670323	PEX5L	0.42	6.71	0.3	5.59e-11	Type 2 diabetes;
LGG	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg23335576	chr14:104009727	NA	0.49	8.57	0.37	1.52e-16	Reticulocyte count;
LGG	cis	rs2797160	1.000	rs9321050	chr6:126001568	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-7.6	-0.33	1.65e-13	Endometrial cancer;
LGG	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.96	-0.31	1.14e-11	Vitiligo;
LGG	trans	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg26043149	chr18:55253948	FECH	-0.5	-8.14	-0.35	3.64e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2108225	0.872	rs4618632	chr7:107440952	T/G	cg18560240	chr7:107437656	SLC26A3	-0.57	-10.03	-0.42	1.47e-21	Ulcerative colitis;
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg22398616	chr13:53314203	LECT1	0.4	8.11	0.35	4.46e-15	Lewy body disease;
LGG	cis	rs11122272	0.735	rs2790882	chr1:231532783	A/G	cg10503236	chr1:231470652	EXOC8	0.37	7.15	0.32	3.37e-12	Hemoglobin concentration;
LGG	cis	rs2573652	0.722	rs12595247	chr15:100541689	C/T	cg14911520	chr15:100542628	ADAMTS17	-0.31	-7.64	-0.33	1.26e-13	Height;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-10.96	-0.45	5.4e-25	Lung cancer;
LGG	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg20019365	chr2:219134978	PNKD;AAMP	0.58	9.82	0.42	8.33e-21	Colorectal cancer;
LGG	cis	rs977987	0.778	rs2113232	chr16:75391185	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	trans	rs28735056	1.000	rs3826576	chr18:77633976	G/A	cg05926928	chr17:57297772	GDPD1	-0.5	-7.69	-0.34	8.75e-14	Schizophrenia;
LGG	trans	rs11875185	0.510	rs17692755	chr18:55595886	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.56	11.18	0.46	7.64e-26	Obesity-related traits;
LGG	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg07636037	chr3:49044803	WDR6	0.95	20.5	0.69	6.54e-67	Menarche (age at onset);
LGG	cis	rs4689388	0.929	rs1046320	chr4:6304344	C/T	cg00701064	chr4:6280414	WFS1	0.69	15.12	0.57	2.9e-42	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg07511668	chr11:68622177	NA	0.51	9.82	0.42	8.64e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.83	-0.3	2.68e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2718058	0.639	rs2718036	chr7:37775288	T/A	cg15028436	chr7:37888078	TXNDC3	0.63	9.97	0.42	2.5e-21	Alzheimer's disease (late onset);
LGG	cis	rs11166927	0.904	rs2242181	chr8:140819819	C/T	cg16909799	chr8:140841666	TRAPPC9	0.56	11.65	0.48	1.08e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg27205649	chr11:78285834	NARS2	0.51	8.79	0.38	2.91e-17	Alzheimer's disease (survival time);
LGG	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg22022881	chr2:105853494	NA	-0.35	-7.21	-0.32	2.29e-12	Type 2 diabetes;
LGG	cis	rs11645898	0.748	rs72791112	chr16:72204069	T/A	cg14768367	chr16:72042858	DHODH	-0.76	-10.17	-0.43	4.64e-22	Blood protein levels;
LGG	trans	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg06521331	chr12:34319734	NA	-0.57	-9.57	-0.41	6.51e-20	Bladder cancer;
LGG	trans	rs17685	0.753	rs1574107	chr7:75685047	A/C	cg19862616	chr7:65841803	NCRNA00174	1.06	25.24	0.76	4.56e-89	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2180341	0.521	rs12203812	chr6:127617816	A/T	cg27446573	chr6:127587934	RNF146	0.64	11.13	0.46	1.16e-25	Breast cancer;
LGG	cis	rs4330281	0.606	rs9867064	chr3:17792574	C/T	cg20981856	chr3:17787350	NA	-0.39	-7.06	-0.31	6.01e-12	Schizophrenia;
LGG	cis	rs12928939	0.517	rs8049508	chr16:71978313	C/T	cg03805757	chr16:71968109	PKD1L3	-0.66	-13.43	-0.53	5.64e-35	Post bronchodilator FEV1;
LGG	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.83	18.22	0.65	2.55e-56	Menarche (age at onset);
LGG	cis	rs61931739	0.658	rs4476006	chr12:34237154	A/C	cg06521331	chr12:34319734	NA	-0.41	-7.4	-0.33	6.63e-13	Morning vs. evening chronotype;
LGG	cis	rs7000551	0.689	rs12545909	chr8:22310052	A/G	cg12081754	chr8:22256438	SLC39A14	-0.69	-13.33	-0.53	1.53e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9359856	0.564	rs11962292	chr6:90476788	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.14	-0.43	5.91e-22	Bipolar disorder;
LGG	cis	rs4788570	0.615	rs9888756	chr16:71740477	G/A	cg06353428	chr16:71660113	MARVELD3	1.26	21.1	0.7	9.93e-70	Intelligence (multi-trait analysis);
LGG	cis	rs2470578	0.766	rs2596680	chr3:17320823	C/G	cg20981856	chr3:17787350	NA	0.35	6.71	0.3	5.81e-11	Schizophrenia;
LGG	cis	rs4423214	1.000	rs11600860	chr11:71164019	T/C	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg27446573	chr6:127587934	RNF146	1.14	22.44	0.72	4.93e-76	Breast cancer;
LGG	cis	rs3126085	1.000	rs11588170	chr1:152286032	C/T	cg26876637	chr1:152193138	HRNR	-0.49	-7.07	-0.31	5.75e-12	Atopic dermatitis;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg24829409	chr8:58192753	C8orf71	-0.83	-12.75	-0.51	4.12e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.66	-0.44	6.95e-24	Lung cancer;
LGG	cis	rs10463316	0.817	rs7708940	chr5:150789051	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.23	-0.43	2.75e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3816183	0.585	rs12712856	chr2:42868673	C/A	cg14631114	chr2:43023945	NA	0.34	6.81	0.3	3.04e-11	Hypospadias;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg02781704	chr3:194033517	NA	-0.42	-6.94	-0.31	1.32e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs804280	0.544	rs804276	chr8:11625008	G/A	cg12395012	chr8:11607386	GATA4	-0.57	-11.01	-0.46	3.28e-25	Myopia (pathological);
LGG	cis	rs9467711	0.606	rs9379852	chr6:26357278	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9902453	0.967	rs8082175	chr17:28430303	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.13	0.52	1.1e-33	Coffee consumption (cups per day);
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.26	-0.7	1.77e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.59	-0.33	1.81e-13	Neuroticism;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg01988459	chr11:68622903	NA	-0.64	-12.66	-0.51	9.26e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg16586182	chr3:47516702	SCAP	0.73	13.25	0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.29	-0.4	6.06e-19	Response to antipsychotic treatment;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg24642844	chr7:1081250	C7orf50	-0.45	-8.44	-0.37	4.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg11161011	chr14:65562177	MAX	-0.65	-12.48	-0.5	4.92e-31	Obesity-related traits;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg03452623	chr4:187889614	NA	-1.04	-29.28	-0.81	2.08e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3858526	0.833	rs4758184	chr11:5926719	A/G	cg25319279	chr11:5960081	NA	-0.53	-8.61	-0.37	1.18e-16	DNA methylation (variation);
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.31	0.36	1.09e-15	Schizophrenia;
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg04013166	chr16:89971882	TCF25	0.53	7.06	0.31	6.28e-12	Skin colour saturation;
LGG	cis	rs7937682	0.889	rs1784787	chr11:111486125	T/A	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs6964587	1.000	rs12531366	chr7:91683849	C/G	cg17063962	chr7:91808500	NA	0.47	8.33	0.36	9.55e-16	Breast cancer;
LGG	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs793571	0.544	rs11638244	chr15:58907151	A/T	cg05156742	chr15:59063176	FAM63B	0.54	9.61	0.41	4.64e-20	Schizophrenia;
LGG	cis	rs35771425	0.626	rs6677230	chr1:211652902	A/C	cg10512769	chr1:211675356	NA	-0.89	-18.6	-0.65	4.61e-58	Educational attainment (years of education);
LGG	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg03929089	chr4:120376271	NA	-0.53	-8.9	-0.38	1.27e-17	HDL cholesterol;
LGG	cis	rs2204008	0.537	rs11170128	chr12:38006632	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.47	0.53	4.03e-35	Bladder cancer;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs1805008	0.561	rs8046635	chr16:90123493	C/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.62	-6.89	-0.3	1.85e-11	Skin colour saturation;
LGG	cis	rs1417569	0.546	rs2994623	chr10:31192193	G/C	cg00428179	chr10:31322131	ZNF438	-0.37	-8.81	-0.38	2.61e-17	Tuberculosis;
LGG	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.72	-0.41	1.92e-20	Systolic blood pressure;
LGG	trans	rs4714291	0.963	rs12194361	chr6:40116264	T/G	cg02267698	chr19:7991119	CTXN1	-0.59	-9.25	-0.39	8.01e-19	Strep throat;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.86	0.66	2.81e-59	Platelet count;
LGG	cis	rs938554	0.513	rs3775946	chr4:9995256	A/G	cg25986240	chr4:9926439	SLC2A9	-0.39	-7.05	-0.31	6.49e-12	Blood metabolite levels;
LGG	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg26924012	chr15:45694286	SPATA5L1	1.02	20.48	0.69	7.99e-67	Homoarginine levels;
LGG	cis	rs9291683	0.595	rs13150928	chr4:10052961	G/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.76	-0.38	3.7e-17	Bone mineral density;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07167872	chr1:205819463	PM20D1	0.58	11.59	0.47	1.93e-27	Menarche (age at onset);
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg02524346	chr8:600233	NA	1.17	11.68	0.48	8.12e-28	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-8.77	-0.38	3.49e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg02631450	chr22:32366979	NA	0.99	9.56	0.41	7.14e-20	Childhood ear infection;
LGG	cis	rs3749237	0.595	rs4855861	chr3:49525962	G/T	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.27e-23	Resting heart rate;
LGG	trans	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.72	-0.3	5.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg08733933	chr1:2954429	NA	-0.42	-8.41	-0.36	5.1e-16	Plateletcrit;
LGG	cis	rs12681287	0.640	rs12678720	chr8:87457929	T/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs9296092	0.538	rs35381461	chr6:33519751	T/C	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.86	-0.3	2.24e-11	Aortic root size;
LGG	trans	rs7746199	0.668	rs34864796	chr6:27459923	G/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-10.38	-0.43	8.04e-23	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg20387954	chr3:183756860	HTR3D	0.64	12.56	0.5	2.37e-31	Anterior chamber depth;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19541837	chr11:71823834	C11orf51	-0.49	-7.21	-0.32	2.34e-12	Systemic lupus erythematosus;
LGG	cis	rs35110281	0.837	rs2838342	chr21:45077865	G/A	cg04455712	chr21:45112962	RRP1B	0.52	10.01	0.42	1.8e-21	Mean corpuscular volume;
LGG	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg05096777	chr10:104283225	SUFU	0.33	7.36	0.32	8.73e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.54	-0.37	2.01e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs8002861	0.905	rs11617551	chr13:44443977	T/C	cg12856521	chr11:46389249	DGKZ	-0.4	-6.85	-0.3	2.4e-11	Leprosy;
LGG	cis	rs4319547	0.656	rs28730465	chr12:122863864	A/C	cg05707623	chr12:122985044	ZCCHC8	0.66	9.78	0.41	1.16e-20	Body mass index;
LGG	cis	rs8044868	0.530	rs2241411	chr16:72144493	T/C	cg23815491	chr16:72088622	HP	0.38	8.12	0.35	4.18e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.27	-0.36	1.44e-15	Subjective well-being;
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.66	11.66	0.48	9.73e-28	Lymphocyte counts;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg22168489	chr12:122356033	WDR66	0.45	11.11	0.46	1.41e-25	Mean corpuscular volume;
LGG	cis	rs703842	1.000	rs3825079	chr12:58203354	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.54	8.3	0.36	1.11e-15	Multiple sclerosis;
LGG	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.47	0.56	2.14e-39	Colorectal cancer;
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg19223190	chr17:80058835	NA	0.43	8.37	0.36	6.83e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.81	0.41	8.82e-21	Prudent dietary pattern;
LGG	trans	rs2243480	0.803	rs403089	chr7:65517723	T/C	cg10756647	chr7:56101905	PSPH	0.83	9.55	0.41	7.4e-20	Diabetic kidney disease;
LGG	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg07308232	chr7:1071921	C7orf50	-0.46	-8.67	-0.37	7.28e-17	Longevity;Endometriosis;
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg16301924	chr13:53314226	LECT1	-0.37	-7.37	-0.32	8.17e-13	Lewy body disease;
LGG	trans	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.88e-18	Bladder cancer;
LGG	cis	rs13191362	1.000	rs35424047	chr6:163029715	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.14	0.32	3.55e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs116095464	0.558	rs7713524	chr5:276200	C/T	cg00938859	chr5:1591904	SDHAP3	-0.92	-13.96	-0.54	3.24e-37	Breast cancer;
LGG	cis	rs1475718	0.526	rs7854734	chr9:137122410	C/G	cg21243944	chr9:137118148	NA	0.29	7.5	0.33	3.39e-13	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10195295	chr12:21809973	LDHB	0.49	7.5	0.33	3.32e-13	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.1	0.52	1.38e-33	Obesity-related traits;
LGG	cis	rs35146811	0.520	rs1015538	chr7:99626035	A/G	cg13334819	chr7:99746414	C7orf59	0.42	6.71	0.3	5.8200000000000003e-11	Coronary artery disease;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg15383120	chr6:291909	DUSP22	-0.42	-7.16	-0.32	3.11e-12	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17227014	chr4:6642450	MRFAP1	0.42	6.74	0.3	4.59e-11	Cognitive performance;
LGG	cis	rs10463554	1.000	rs12656131	chr5:102325878	C/T	cg23492399	chr5:102201601	PAM	0.51	7.87	0.34	2.6e-14	Parkinson's disease;
LGG	cis	rs7463256	0.966	rs6557643	chr8:23097802	A/G	cg14349055	chr8:23104193	CHMP7	-0.81	-16.03	-0.6	2.59e-46	Attention deficit hyperactivity disorder;
LGG	cis	rs9951602	0.512	rs3859325	chr18:76652175	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg17691542	chr6:26056736	HIST1H1C	0.48	8.51	0.37	2.38e-16	Height;
LGG	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.59	8.15	0.35	3.42e-15	Diabetic retinopathy;
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.77e-13	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg19761014	chr17:28927070	LRRC37B2	0.67	7.77	0.34	5.13e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-7.21	-0.32	2.36e-12	Subjective well-being;
LGG	cis	rs7398996	1	rs7398996	chr12:53659448	C/T	cg04065151	chr12:53682969	ESPL1	-0.59	-9.56	-0.41	7e-20	Total body bone mineral density (age 45-60);
LGG	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-7.03	-0.31	7.67e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg03806693	chr22:41940476	POLR3H	0.96	16.03	0.6	2.58e-46	Vitiligo;
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg26138144	chr22:38071188	LGALS1	0.91	24.08	0.75	1.11e-83	Fat distribution (HIV);
LGG	cis	rs6964587	1.000	rs13239875	chr7:91716104	G/A	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.21e-16	Breast cancer;
LGG	cis	rs1707322	0.691	rs28495425	chr1:46187320	T/G	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs755249	0.501	rs2490945	chr1:39837344	T/C	cg18385671	chr1:39797026	MACF1	0.49	9.97	0.42	2.53e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7928758	0.943	rs11824649	chr11:134279352	T/C	cg15243474	chr11:134282918	B3GAT1	1.05	13.62	0.53	9.16e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7939886	0.920	rs11231794	chr11:55765776	T/C	cg15704280	chr7:45808275	SEPT13	0.88	9.21	0.39	1.1e-18	Myopia (pathological);
LGG	cis	rs10743315	0.732	rs7309621	chr12:19453372	T/C	cg02471346	chr12:19282374	PLEKHA5	0.61	6.94	0.31	1.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg18446336	chr7:2847575	GNA12	-0.31	-8.2	-0.36	2.36e-15	Height;
LGG	cis	rs68170813	0.599	rs6466162	chr7:106902625	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.4	-0.44	6.33e-23	Coronary artery disease;
LGG	cis	rs12048904	0.619	rs10875346	chr1:101328083	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	17.88	0.64	9.73e-55	Multiple sclerosis;
LGG	cis	rs10929925	0.966	rs2609185	chr2:6160607	T/C	cg00493617	chr2:6141445	NA	0.33	7.48	0.33	3.81e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg03315344	chr16:75512273	CHST6	0.54	10.69	0.44	5.44e-24	Dupuytren's disease;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg24829409	chr8:58192753	C8orf71	-0.7	-9.5	-0.4	1.1e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.64	-0.41	3.67e-20	Height;
LGG	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg07636037	chr3:49044803	WDR6	0.77	13.28	0.53	2.62e-34	Menarche (age at onset);
LGG	cis	rs6894268	0.722	rs6422331	chr5:179002951	G/T	cg22014891	chr5:179071901	C5orf60	-0.36	-7.25	-0.32	1.8e-12	Eating disorders;
LGG	trans	rs783540	0.656	rs783538	chr15:83253143	C/G	cg16105309	chr15:79090380	ADAMTS7	0.47	7.9	0.34	2.03e-14	Schizophrenia;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg13699009	chr12:122356056	WDR66	0.57	15.95	0.6	5.69e-46	Mean corpuscular volume;
LGG	cis	rs4664304	0.595	rs2667004	chr2:160862094	G/A	cg03641300	chr2:160917029	PLA2R1	-0.41	-7.28	-0.32	1.44e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9487094	0.961	rs3778477	chr6:109776058	C/G	cg16315928	chr6:109776240	MICAL1	0.57	9.5	0.4	1.11e-19	Height;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	trans	rs11875185	0.510	rs112770901	chr18:55630320	A/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11098499	0.754	rs878372	chr4:120238780	A/C	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg13009111	chr11:71350975	NA	-0.31	-6.78	-0.3	3.61e-11	Systolic blood pressure;
LGG	cis	rs17253792	0.822	rs8018142	chr14:56173288	C/T	cg01858014	chr14:56050164	KTN1	-0.86	-12.04	-0.49	2.99e-29	Putamen volume;
LGG	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.52	0.33	2.83e-13	Systemic lupus erythematosus;
LGG	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg25664220	chr3:72788482	NA	-0.32	-8.89	-0.38	1.33e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg10756647	chr7:56101905	PSPH	0.81	9.37	0.4	3.2e-19	Diabetic kidney disease;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg08984996	chr6:5258521	LYRM4	-0.49	-7.91	-0.35	1.96e-14	Apolipoprotein A-IV levels;
LGG	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg16482183	chr6:26056742	HIST1H1C	0.61	9.61	0.41	4.56e-20	Iron status biomarkers;
LGG	cis	rs8072100	1.000	rs8065437	chr17:45721653	C/T	cg19784903	chr17:45786737	TBKBP1	-0.32	-7.07	-0.31	5.86e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12579753	0.619	rs11115089	chr12:82311132	T/C	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.32	-0.32	1.11e-12	Resting heart rate;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24717875	chr5:140700272	TAF7	-0.45	-6.91	-0.31	1.61e-11	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	9.92	0.42	3.8e-21	Aortic root size;
LGG	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg03929089	chr4:120376271	NA	-0.54	-9.08	-0.39	3.18e-18	HDL cholesterol;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg25522355	chr18:65184600	DSEL	0.46	7.44	0.33	5e-13	Response to platinum-based chemotherapy (carboplatin);
LGG	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs6750047	0.932	rs2116232	chr2:38268718	C/A	cg07380506	chr2:38303506	CYP1B1	0.44	7.54	0.33	2.5e-13	Cutaneous malignant melanoma;Melanoma;
LGG	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg15704280	chr7:45808275	SEPT13	0.68	9.56	0.41	6.91e-20	Axial length;
LGG	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg16662043	chr16:48846231	NA	0.37	7.25	0.32	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.59	-0.53	1.26e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg04727924	chr7:799746	HEATR2	-0.45	-6.78	-0.3	3.57e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.63	-0.44	8.98e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7927592	0.956	rs7102273	chr11:68385579	T/C	cg20283391	chr11:68216788	NA	-0.49	-8.05	-0.35	7.04e-15	Total body bone mineral density;
LGG	cis	rs1355223	0.573	rs7127169	chr11:34727846	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.16	-0.32	3.15e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg02127607	chr17:61920694	SMARCD2	-0.39	-6.84	-0.3	2.55e-11	Prudent dietary pattern;
LGG	cis	rs477895	0.941	rs35692796	chr11:64110805	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	7.68	0.34	9.3e-14	Mean platelet volume;
LGG	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg23306229	chr2:178417860	TTC30B	0.56	7.28	0.32	1.45e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.71e-12	Lung cancer;
LGG	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.12	-0.46	1.24e-25	Hemoglobin concentration;
LGG	cis	rs896854	0.654	rs6982393	chr8:95980708	T/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.94	-0.38	9.65e-18	Type 2 diabetes;
LGG	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg00717180	chr2:96193071	NA	-0.44	-7.95	-0.35	1.48e-14	HDL cholesterol;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg25407064	chr15:40226267	EIF2AK4	-0.64	-7.91	-0.35	1.88e-14	Response to haloperidol in psychosis;
LGG	cis	rs7017914	0.934	rs62508771	chr8:71692688	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs7010267	0.544	rs6984287	chr8:120054122	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.8	0.38	2.7e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs7084402	1.000	rs34774248	chr10:60269691	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	cis	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg01181863	chr3:195395398	SDHAP2	0.49	7.46	0.33	4.23e-13	Mean corpuscular volume;
LGG	cis	rs9902453	0.715	rs2628176	chr17:28139292	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.47	-0.53	4.02e-35	Coffee consumption (cups per day);
LGG	cis	rs11191205	0.644	rs11191061	chr10:103366069	T/C	cg15320455	chr10:103880129	LDB1	0.51	7.39	0.32	6.83e-13	Intelligence (multi-trait analysis);
LGG	cis	rs503734	0.502	rs348885	chr3:100976219	C/G	cg27318481	chr3:100970896	IMPG2	-0.57	-13.12	-0.52	1.22e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28595532	0.920	rs17325192	chr4:119780345	A/G	cg21605333	chr4:119757512	SEC24D	-1.19	-13.41	-0.53	7.45e-35	Cannabis dependence symptom count;
LGG	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.17	0.35	3e-15	Iron status biomarkers;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.65	-0.3	8.15e-11	Obesity-related traits;
LGG	cis	rs9326248	0.581	rs12225187	chr11:116793231	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.33	0.43	1.21e-22	Blood protein levels;
LGG	cis	rs72720396	0.789	rs10922910	chr1:91199862	G/T	cg13456504	chr1:91191583	NA	0.52	8.25	0.36	1.62e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg11366901	chr6:160182831	ACAT2	1.08	16.69	0.61	2.52e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs25645	0.800	rs34003767	chr17:38194296	A/G	cg17467752	chr17:38218738	THRA	-0.7	-12.38	-0.5	1.37e-30	Myeloid white cell count;
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.5	-0.44	2.76e-23	Bipolar disorder;
LGG	cis	rs2046867	0.908	rs2322613	chr3:72819453	A/C	cg25664220	chr3:72788482	NA	-0.32	-8.96	-0.38	8.26e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.68	-0.3	6.7e-11	Total body bone mineral density;
LGG	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.48	0.53	3.73e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs758324	0.947	rs28537859	chr5:131237277	C/G	cg06307176	chr5:131281290	NA	-0.57	-9.38	-0.4	3.04e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2120243	0.592	rs7618502	chr3:157095544	C/G	cg24825693	chr3:157122686	VEPH1	-0.46	-10.62	-0.44	9.9899999999999993e-24	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.87e-16	Lung cancer;
LGG	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.48	-0.47	5.25e-27	Coronary artery disease;
LGG	cis	rs12971120	0.891	rs3794953	chr18:72180519	C/T	cg26446133	chr18:72167187	CNDP2	-0.67	-13.44	-0.53	5.36e-35	Refractive error;
LGG	cis	rs79146658	0.688	rs7573700	chr2:179712737	C/T	cg17765952	chr2:179737173	CCDC141	-0.59	-8.49	-0.37	2.83e-16	Diastolic blood pressure;
LGG	cis	rs12618769	0.625	rs72819984	chr2:99044762	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	1.97e-16	Bipolar disorder;
LGG	cis	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg06374794	chr16:88002281	BANP	-0.46	-8.58	-0.37	1.47e-16	Menopause (age at onset);
LGG	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.23	0.7	2.42e-70	Morning vs. evening chronotype;
LGG	cis	rs10895140	0.756	rs2508737	chr11:101469559	C/T	cg04553838	chr11:101454733	TRPC6	-0.41	-6.66	-0.3	7.7e-11	Menarche (age at onset);
LGG	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.53	-0.33	2.64e-13	Life satisfaction;
LGG	cis	rs4430311	1.000	rs2953327	chr1:244025317	C/T	cg25706552	chr1:244017396	NA	-0.68	-17.68	-0.63	7.97e-54	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg09307838	chr4:120376055	NA	-0.67	-11.61	-0.47	1.55e-27	Corneal astigmatism;
LGG	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg03929089	chr4:120376271	NA	0.71	9.82	0.42	8.24e-21	Axial length;
LGG	cis	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg07460842	chr6:66804631	NA	0.95	17.21	0.62	1.11e-51	Exhaled nitric oxide levels;
LGG	cis	rs11971779	0.680	rs6963867	chr7:139059964	T/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs2067615	0.579	rs9651957	chr12:107170128	A/G	cg15890332	chr12:107067104	RFX4	0.4	11.66	0.48	1.04e-27	Heart rate;
LGG	cis	rs7928758	0.943	rs77478906	chr11:134264596	T/C	cg22777979	chr11:134283252	B3GAT1	0.96	12.11	0.49	1.64e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12153243	0.686	rs4392659	chr5:142938964	A/G	cg13907255	chr5:142895549	NA	-0.47	-8.18	-0.36	2.77e-15	Migraine;
LGG	cis	rs6835098	0.961	rs11737748	chr4:174130503	T/C	cg08422745	chr4:174089978	GALNT7	0.85	14.52	0.56	1.28e-39	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs503734	1.000	rs503734	chr3:101023748	A/G	cg27318481	chr3:100970896	IMPG2	-0.37	-7.95	-0.35	1.48e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg12560992	chr17:57184187	TRIM37	-0.59	-9.08	-0.39	3.18e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7614311	0.731	rs56126667	chr3:63866286	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-8.08	-0.35	5.78e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.65	0.44	7.98e-24	Personality dimensions;
LGG	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg26354017	chr1:205819088	PM20D1	0.46	7.68	0.34	9.35e-14	Parkinson's disease;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-14.11	-0.55	7.24e-38	Height;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.33	0.32	1.03e-12	Prudent dietary pattern;
LGG	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg05729581	chr11:3078854	CARS	-0.55	-9.69	-0.41	2.43e-20	Longevity;
LGG	cis	rs3791406	1.000	rs3791412	chr2:240031088	A/G	cg14550559	chr2:240039617	HDAC4	-0.45	-8.02	-0.35	8.7e-15	Skin aging (microtopography measurement);
LGG	cis	rs62238980	0.614	rs77112134	chr22:32394449	C/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg07978099	chr16:83986941	OSGIN1	0.64	10.1	0.42	8.21e-22	Pursuit maintenance gain;
LGG	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg03114573	chr12:45410052	DBX2	-0.7	-12.87	-0.51	1.32e-32	Gut microbiome composition (summer);
LGG	cis	rs7843479	0.601	rs10453141	chr8:21847235	T/C	cg17168535	chr8:21777572	XPO7	0.8	15.55	0.59	3.42e-44	Mean corpuscular volume;
LGG	trans	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.48	0.71	1.58e-71	Morning vs. evening chronotype;
LGG	trans	rs941408	0.515	rs4624312	chr19:2774460	T/C	cg22153745	chr1:153894579	GATAD2B	-0.57	-8.62	-0.37	1.07e-16	Total cholesterol levels;
LGG	cis	rs7937682	0.564	rs9633937	chr11:111372799	C/T	cg09085632	chr11:111637200	PPP2R1B	0.66	11.35	0.47	1.64e-26	Primary sclerosing cholangitis;
LGG	cis	rs2075371	0.966	rs2244690	chr7:133987039	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.45	0.58	1e-43	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg00933542	chr6:150070202	PCMT1	0.4	7.13	0.31	3.9e-12	Lung cancer;
LGG	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg04691961	chr3:161091175	C3orf57	-0.49	-10.05	-0.42	1.23e-21	Parkinson's disease;
LGG	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg02389323	chr16:88786976	FAM38A	1.09	12.93	0.52	7.27e-33	Plateletcrit;
LGG	trans	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.29	0.32	1.34e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg06521331	chr12:34319734	NA	0.46	8.11	0.35	4.61e-15	Morning vs. evening chronotype;
LGG	cis	rs1355223	0.902	rs286858	chr11:34717357	T/C	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.83	0.3	2.71e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg21100191	chr22:23484243	RTDR1	0.98	22.33	0.72	1.61e-75	Bone mineral density;
LGG	cis	rs8016982	0.674	rs61980899	chr14:81676844	T/C	cg01989461	chr14:81687754	GTF2A1	0.79	18.77	0.66	7.09e-59	Schizophrenia;
LGG	cis	rs6032067	0.777	rs62208416	chr20:43803226	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg12310025	chr6:25882481	NA	-0.53	-10.21	-0.43	3.27e-22	Blood metabolite levels;
LGG	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg21775007	chr8:11205619	TDH	0.82	14.6	0.56	5.72e-40	Retinal vascular caliber;
LGG	cis	rs17604090	1.000	rs17661896	chr7:29692708	G/A	cg19413766	chr7:29689036	LOC646762	-0.59	-7.23	-0.32	2e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.72	-0.56	1.68e-40	Platelet count;
LGG	trans	rs225245	0.817	rs225290	chr17:33927904	C/G	cg19694781	chr19:47549865	TMEM160	-0.41	-7.06	-0.31	6.01e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4423214	0.550	rs4944885	chr11:71114075	C/T	cg10847948	chr11:71163743	NADSYN1	-0.52	-9.85	-0.42	6.61e-21	Vitamin D levels;
LGG	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg14101638	chr12:121416612	HNF1A	0.4	8.11	0.35	4.46e-15	N-glycan levels;
LGG	cis	rs17021463	0.617	rs35368920	chr4:95325588	C/T	cg11021082	chr4:95130006	SMARCAD1	0.49	7.69	0.34	9.15e-14	Testicular germ cell tumor;
LGG	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12591125	chr7:1885375	MAD1L1	0.46	7.12	0.31	4.03e-12	Bipolar disorder;
LGG	cis	rs35123781	0.696	rs13179952	chr5:139070573	C/G	cg21230503	chr5:139085173	NA	0.37	8.6	0.37	1.21e-16	Schizophrenia;
LGG	trans	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg25214090	chr10:38739885	LOC399744	0.57	10.39	0.43	7.1e-23	Corneal astigmatism;
LGG	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg06026331	chr20:60912101	LAMA5	0.61	10.37	0.43	8.26e-23	Colorectal cancer;
LGG	cis	rs703842	0.892	rs1021469	chr12:58208164	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	8.11	0.35	4.66e-15	Multiple sclerosis;
LGG	trans	rs9944715	1.000	rs9952972	chr18:43842617	T/A	cg01718231	chr17:29326311	RNF135	-0.42	-6.8	-0.3	3.23e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs909685	1.000	rs909685	chr22:39747671	T/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.61	10.25	0.43	2.26e-22	Rheumatoid arthritis;
LGG	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg23422044	chr7:1970798	MAD1L1	-0.7	-11.55	-0.47	2.62e-27	Bipolar disorder;
LGG	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg13010199	chr12:38710504	ALG10B	0.57	10.61	0.44	1.11e-23	Morning vs. evening chronotype;
LGG	cis	rs537930	0.560	rs877812	chr5:134346304	G/A	cg24576358	chr5:134350122	NA	0.45	10.1	0.43	7.94e-22	Height;
LGG	cis	rs13132184	0.510	rs55767827	chr4:38056537	A/G	cg24826020	chr4:38070998	TBC1D1	0.5	7.88	0.34	2.34e-14	Verbal declarative memory;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg02725872	chr8:58115012	NA	-0.77	-11.04	-0.46	2.68e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg22771759	chr13:24902376	NA	0.46	7.85	0.34	2.86e-14	Obesity-related traits;
LGG	cis	rs7432375	0.583	rs1609391	chr3:136615268	G/A	cg12473912	chr3:136751656	NA	0.41	6.81	0.3	3.04e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6867032	0.874	rs4975786	chr5:2004724	T/C	cg26168224	chr5:2018326	NA	-1.14	-20.27	-0.69	7.45e-66	Gut microbiome composition (winter);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03837627	chr17:28443756	CCDC55;MIR423	0.46	7.87	0.34	2.5e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs17122278	1.000	rs17742	chr11:118473385	T/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	cis	rs6977660	0.941	rs5017192	chr7:19820114	C/T	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg26306683	chr17:18585705	ZNF286B	0.38	7.29	0.32	1.38e-12	Educational attainment (years of education);
LGG	cis	rs11671005	0.695	rs8106061	chr19:58917990	G/A	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.85	-0.3	2.42e-11	Mean platelet volume;
LGG	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg02461776	chr11:598696	PHRF1	0.52	7.94	0.35	1.58e-14	Systemic lupus erythematosus;
LGG	cis	rs7312933	0.524	rs11181465	chr12:42765098	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.17	0.35	2.97e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11958594	chr17:80055299	FASN	0.46	6.84	0.3	2.44e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs9517320	0.967	rs7997785	chr13:99127985	T/A	cg07423050	chr13:99094983	FARP1	0.4	8.12	0.35	4.34e-15	Longevity;
LGG	trans	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.98	0.42	2.19e-21	Mean corpuscular volume;
LGG	trans	rs853679	0.607	rs34950484	chr6:28278688	G/A	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs910187	0.678	rs6122561	chr20:45813809	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.3	-0.4	5.63e-19	Migraine;
LGG	cis	rs67311347	0.822	rs11709089	chr3:40351484	C/T	cg13683864	chr3:40499215	RPL14	-0.86	-16.8	-0.62	8.55e-50	Renal cell carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27329298	chr6:117924070	GOPC	0.43	7.43	0.33	5.18e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9487051	0.676	rs1608041	chr6:109595903	G/A	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.01e-14	Reticulocyte fraction of red cells;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg23202291	chr11:1979235	NA	0.39	7.42	0.33	5.69e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg05308233	chr10:104796373	CNNM2	-0.32	-7.23	-0.32	2.04e-12	Arsenic metabolism;
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg18245976	chr7:158708271	WDR60	-0.55	-9.49	-0.4	1.26e-19	Height;
LGG	cis	rs10791323	0.572	rs10750551	chr11:133737462	G/A	cg06766960	chr11:133703094	NA	-0.54	-10.72	-0.45	4.11e-24	Childhood ear infection;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg23758822	chr17:41437982	NA	0.86	14.96	0.57	1.4e-41	Menopause (age at onset);
LGG	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg07303275	chr16:75499416	TMEM170A	0.38	6.82	0.3	2.81e-11	Dupuytren's disease;
LGG	cis	rs11914070	0.928	rs13054104	chr22:18961405	A/G	cg12798833	chr22:18958832	DGCR5	-0.58	-9.53	-0.41	8.55e-20	Gait variability;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.69	-0.3	6.64e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs72781680	0.898	rs112985192	chr2:24102797	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.62e-18	Lymphocyte counts;
LGG	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg16583315	chr14:65563665	MAX	-0.36	-6.9	-0.31	1.7e-11	Obesity-related traits;
LGG	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.33	-0.32	1.03e-12	Neuroticism;
LGG	cis	rs2404602	0.647	rs11631959	chr15:77040048	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.68	-0.56	2.36e-40	Blood metabolite levels;
LGG	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.7	0.38	5.64e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6663390	0.510	rs2267896	chr1:208080972	C/T	cg03990033	chr1:208084030	CD34	-0.57	-7.65	-0.34	1.14e-13	Facial morphology (factor 18);
LGG	cis	rs2764208	0.535	rs2744963	chr6:34592731	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-7.15	-0.32	3.49e-12	Systemic lupus erythematosus;
LGG	cis	rs9311474	1.000	rs2276834	chr3:52325759	A/G	cg14092988	chr3:52407081	DNAH1	0.28	7.23	0.32	2.07e-12	Electroencephalogram traits;
LGG	cis	rs3540	0.533	rs12916560	chr15:91056259	A/C	cg22089800	chr15:90895588	ZNF774	-0.67	-12.27	-0.5	3.79e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6752107	0.935	rs1596017	chr2:234147930	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.64	0.48	1.24e-27	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs9354308	0.727	rs9345720	chr6:66615832	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.24	-0.32	1.87e-12	Metabolite levels;
LGG	cis	rs2439831	0.850	rs68079546	chr15:44136957	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.24	0.43	2.54e-22	Lung cancer in ever smokers;
LGG	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03264133	chr6:25882463	NA	-0.67	-12.0	-0.49	4.63e-29	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.2e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg22862634	chr11:62369728	EML3;MTA2	-0.55	-11.62	-0.48	1.46e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg03804240	chr11:118481350	PHLDB1	0.41	8.55	0.37	1.79e-16	Cholesterol, total;
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.21	-0.49	6.49e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg00857998	chr1:205179979	DSTYK	0.5	7.9	0.34	2.03e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9397585	0.857	rs6937857	chr6:153387430	A/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs897984	0.762	rs12930545	chr16:30938811	A/G	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	cis	rs977987	0.806	rs4888386	chr16:75389740	A/G	cg03315344	chr16:75512273	CHST6	0.52	10.65	0.44	7.86e-24	Dupuytren's disease;
LGG	cis	rs8067545	0.611	rs2107565	chr17:20088492	C/T	cg13482628	chr17:19912719	NA	-0.54	-10.14	-0.43	6.04e-22	Schizophrenia;
LGG	cis	rs10463554	0.824	rs427430	chr5:102432024	G/A	cg23492399	chr5:102201601	PAM	-0.52	-7.74	-0.34	6.14e-14	Parkinson's disease;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg23355997	chr17:7154831	DULLARD;C17orf81	0.37	6.86	0.3	2.24e-11	Coronary artery disease;
LGG	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg16400903	chr5:693638	TPPP	0.45	6.87	0.3	2.05e-11	Obesity-related traits;
LGG	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg14664628	chr15:75095509	CSK	-0.56	-10.6	-0.44	1.22e-23	Breast cancer;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg12813108	chr7:99719912	CNPY4	-0.64	-10.05	-0.42	1.23e-21	Lung function (FEV1/FVC);
LGG	cis	rs4665809	0.525	rs10865402	chr2:26535383	A/G	cg22920501	chr2:26401640	FAM59B	-0.32	-6.9	-0.31	1.73e-11	Gut microbiome composition (summer);
LGG	cis	rs6977660	0.714	rs12672320	chr7:19813594	G/T	cg05791153	chr7:19748676	TWISTNB	0.75	10.48	0.44	3.31e-23	Thyroid stimulating hormone;
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17219203	chr10:38645113	HSD17B7P2	0.47	7.37	0.32	8.14e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg08601574	chr20:25228251	PYGB	-0.37	-7.6	-0.33	1.68e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	trans	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg05926928	chr17:57297772	GDPD1	-0.43	-6.97	-0.31	1.08e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07562742	chr4:153455963	FBXW7	0.64	9.66	0.41	3.02e-20	Gut microbiome composition (summer);
LGG	cis	rs7312933	0.558	rs1796382	chr12:42840955	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.13	-0.35	3.96e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9287719	0.967	rs4669593	chr2:10701908	C/T	cg02196655	chr2:10830764	NOL10	-0.42	-7.14	-0.32	3.57e-12	Prostate cancer;
LGG	trans	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg12045294	chr17:78518616	RPTOR	-0.46	-7.12	-0.31	4.07e-12	Glycated hemoglobin levels;
LGG	cis	rs7129556	0.520	rs10793257	chr11:77309533	T/C	cg12586386	chr11:77299805	AQP11	0.4	6.94	0.31	1.36e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.68	0.37	6.66e-17	Aortic root size;
LGG	cis	rs9880211	1.000	rs6767889	chr3:136365455	T/A	cg21827317	chr3:136751795	NA	-0.49	-7.29	-0.32	1.32e-12	Body mass index;Height;
LGG	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.63	-0.41	3.98e-20	Retinal vascular caliber;
LGG	cis	rs912057	0.671	rs1294420	chr6:6742752	C/T	cg06612196	chr6:6737390	NA	0.5	10.78	0.45	2.41e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg03078520	chr22:18463400	MICAL3	-0.59	-11.13	-0.46	1.18e-25	Presence of antiphospholipid antibodies;
LGG	cis	rs975739	0.872	rs1144386	chr13:78364585	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.8	0.3	3.26e-11	Hair color;
LGG	cis	rs6768930	0.509	rs4530498	chr3:57724602	A/G	cg01571842	chr3:57934672	NA	0.3	6.7	0.3	5.92e-11	Obesity-related traits;
LGG	cis	rs6087990	0.701	rs1997797	chr20:31387954	C/G	cg13636640	chr20:31349939	DNMT3B	0.81	16.71	0.61	2.18e-49	Ulcerative colitis;
LGG	cis	rs2290159	0.948	rs9852128	chr3:12635623	A/G	cg23032965	chr3:12705835	RAF1	0.55	8.36	0.36	7.63e-16	Cholesterol, total;
LGG	cis	rs1568889	1.000	rs6484346	chr11:28040767	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	15.38	0.58	1.96e-43	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06916706	chr16:4465613	CORO7	-0.93	-16.88	-0.62	3.77e-50	Schizophrenia;
LGG	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg13512537	chr8:22265999	SLC39A14	-0.45	-7.3	-0.32	1.25e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.56	-0.33	2.26e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.41	-0.36	5.13e-16	Total body bone mineral density;
LGG	cis	rs9318086	0.600	rs9507185	chr13:24473734	G/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.17	0.39	1.56e-18	Myopia (pathological);
LGG	cis	rs2494938	0.730	rs846505	chr6:40527634	A/C	cg14084896	chr6:40530702	LRFN2	-0.31	-6.97	-0.31	1.11e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.77e-12	Diabetic retinopathy;
LGG	cis	rs4740619	0.525	rs2153725	chr9:15828664	C/A	cg14451791	chr9:16040625	NA	0.31	7.73	0.34	6.95e-14	Body mass index;
LGG	cis	rs60695258	0.594	rs6531946	chr4:87965391	T/A	cg01323104	chr4:87958903	AFF1	0.24	6.95	0.31	1.25e-11	Hematocrit;
LGG	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs1018836	0.818	rs715057	chr8:91624340	T/C	cg16814680	chr8:91681699	NA	-0.84	-16.13	-0.6	8.61e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7222240	1.000	rs7209081	chr17:43106394	T/A	cg24806326	chr17:43207588	PLCD3	0.47	7.84	0.34	3.06e-14	Craniofacial microsomia;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.62	-0.44	9.93e-24	Aortic root size;
LGG	cis	rs2540226	0.539	rs10186346	chr2:39914192	C/T	cg02886589	chr2:39892450	TMEM178	0.3	8.4	0.36	5.62e-16	Personality dimensions;
LGG	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg01620082	chr3:125678407	NA	-0.87	-8.97	-0.38	7.62e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg19455335	chr8:22457658	C8orf58	-0.34	-7.02	-0.31	7.86e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg02428538	chr16:24856791	SLC5A11	-0.66	-10.19	-0.43	3.79e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg18198730	chr1:247681584	NA	0.73	12.3	0.5	2.69e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10911232	0.507	rs10797819	chr1:183006911	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs262150	0.659	rs73167293	chr7:158772638	C/T	cg19418458	chr7:158789849	NA	0.46	6.88	0.3	1.97e-11	Facial morphology (factor 20);
LGG	trans	rs853679	0.882	rs4713139	chr6:28092685	C/T	cg08344181	chr3:125677491	NA	-0.65	-7.73	-0.34	6.73e-14	Depression;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	trans	rs17685	0.712	rs7794454	chr7:75776010	A/G	cg19862616	chr7:65841803	NCRNA00174	-1.06	-24.81	-0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs950169	0.922	rs6603022	chr15:84830170	T/C	cg03959625	chr15:84868606	LOC388152	-0.54	-8.62	-0.37	1.1e-16	Schizophrenia;
LGG	trans	rs2281558	0.583	rs7260957	chr20:25722462	A/G	cg25917747	chr17:21561886	NA	0.51	7.12	0.31	4.18e-12	Peripheral arterial disease (traffic-related air pollution interaction);Calcium levels;
LGG	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg09307838	chr4:120376055	NA	0.79	13.23	0.52	3.99e-34	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg08621203	chr6:150244597	RAET1G	0.42	7.15	0.32	3.34e-12	Lung cancer;
LGG	cis	rs2075371	0.637	rs13245165	chr7:133951492	A/T	cg11752832	chr7:134001865	SLC35B4	0.57	10.0	0.42	1.9e-21	Mean platelet volume;
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.43	-0.36	4.34e-16	Personality dimensions;
LGG	cis	rs7737355	1.000	rs30736	chr5:130724240	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.73	-0.38	4.78e-17	Life satisfaction;
LGG	cis	rs60843830	0.517	rs58416198	chr2:175580	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.64	10.04	0.42	1.34e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs35110281	0.840	rs2838331	chr21:45026728	A/G	cg04455712	chr21:45112962	RRP1B	-0.51	-9.33	-0.4	4.39e-19	Mean corpuscular volume;
LGG	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg24375607	chr4:120327624	NA	0.67	11.0	0.46	3.52e-25	Corneal astigmatism;
LGG	cis	rs6088580	0.634	rs6119497	chr20:33012529	T/A	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg13010199	chr12:38710504	ALG10B	-0.44	-8.08	-0.35	5.83e-15	Morning vs. evening chronotype;
LGG	cis	rs17021463	0.902	rs13102926	chr4:95245527	C/T	cg11021082	chr4:95130006	SMARCAD1	0.53	9.83	0.42	7.48e-21	Testicular germ cell tumor;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg08645402	chr16:4508243	NA	0.53	10.29	0.43	1.65e-22	Schizophrenia;
LGG	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03878208	chr11:72483293	STARD10	0.5	7.22	0.32	2.16e-12	Type 2 diabetes;
LGG	cis	rs4819052	0.808	rs11909411	chr21:46676556	A/C	cg06618935	chr21:46677482	NA	-0.48	-9.45	-0.4	1.76e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Schizophrenia;
LGG	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.27	-0.32	1.51e-12	Blood metabolite levels;
LGG	cis	rs4423214	0.959	rs11606611	chr11:71164046	C/G	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs6732160	0.588	rs3891890	chr2:73378049	A/G	cg01422370	chr2:73384389	NA	0.57	9.98	0.42	2.17e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7712401	0.601	rs154500	chr5:122211991	T/G	cg19412675	chr5:122181750	SNX24	0.42	6.89	0.3	1.88e-11	Mean platelet volume;
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg23594656	chr7:65796392	TPST1	-0.41	-9.15	-0.39	1.86e-18	Aortic root size;
LGG	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.61	-0.69	1.84e-67	Diabetic kidney disease;
LGG	cis	rs1994135	0.630	rs11052760	chr12:33724949	A/T	cg06521331	chr12:34319734	NA	-0.51	-8.44	-0.37	4.22e-16	Resting heart rate;
LGG	cis	rs1882538	0.538	rs7783217	chr7:133104117	C/G	cg10665199	chr7:133106180	EXOC4	-0.59	-9.91	-0.42	4.17e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.8	0.41	9.74e-21	Menarche (age at onset);
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.61	-0.56	5.24e-40	Prudent dietary pattern;
LGG	cis	rs9462027	0.583	rs2814995	chr6:34621171	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.73	-0.45	3.72e-24	Systemic lupus erythematosus;
LGG	cis	rs4356203	0.905	rs11024158	chr11:17125168	G/A	cg15432903	chr11:17409602	KCNJ11	0.39	7.24	0.32	1.9e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg18681998	chr4:17616180	MED28	0.83	18.51	0.65	1.21e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.18	0.46	7.72e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg16230307	chr14:35515116	FAM177A1	0.88	13.03	0.52	2.91e-33	Psoriasis;
LGG	trans	rs194045	0.511	rs1611991	chr16:29151593	C/T	cg17334114	chr3:133646504	NA	0.5	6.74	0.3	4.71e-11	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9487051	0.872	rs9480923	chr6:109607369	G/C	cg12927641	chr6:109611667	NA	-0.38	-7.16	-0.32	3.14e-12	Reticulocyte fraction of red cells;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.19	-0.32	2.66e-12	Bipolar disorder;
LGG	cis	rs897984	0.574	rs11647284	chr16:31077335	G/A	cg00531865	chr16:30841666	NA	-0.47	-9.32	-0.4	4.87e-19	Dementia with Lewy bodies;
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg16606324	chr3:10149918	C3orf24	0.57	7.32	0.32	1.07e-12	Alzheimer's disease;
LGG	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs7503807	0.515	rs12944407	chr17:78691979	C/T	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs4509693	1.000	rs4509693	chr10:102501571	C/T	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.28e-11	Alzheimer's disease;
LGG	trans	rs8002861	0.846	rs12869521	chr13:44478346	A/G	cg12856521	chr11:46389249	DGKZ	-0.45	-7.88	-0.34	2.4e-14	Leprosy;
LGG	cis	rs11190604	1.000	rs11190569	chr10:102227409	C/T	cg07080220	chr10:102295463	HIF1AN	0.61	10.76	0.45	3.08e-24	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14580567	chr4:145567271	HHIP	0.45	7.65	0.33	1.14e-13	Cognitive performance;
LGG	cis	rs17345786	0.798	rs4257518	chr3:101281709	C/T	cg11279151	chr3:101281821	RG9MTD1	0.68	12.91	0.51	9.06e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs644799	1.000	rs644799	chr11:95564259	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.31	0.7	9.9e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg19727166	chr6:117804670	DCBLD1	0.4	6.94	0.31	1.35e-11	Bipolar disorder;
LGG	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg19748678	chr4:122722346	EXOSC9	0.5	9.5	0.4	1.1e-19	Type 2 diabetes;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs1010254	0.559	rs114133296	chr5:151730255	G/A	cg12297329	chr5:152029980	NA	-0.47	-6.79	-0.3	3.36e-11	Optic nerve measurement (cup area);
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg08621203	chr6:150244597	RAET1G	0.54	10.06	0.42	1.18e-21	Testicular germ cell tumor;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg05025164	chr4:1340916	KIAA1530	0.5	8.78	0.38	3.19e-17	Obesity-related traits;
LGG	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg05169160	chr2:178484487	TTC30A	0.34	6.72	0.3	5.29e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg07835181	chr16:1525278	CLCN7	-0.68	-11.64	-0.48	1.18e-27	Bone mineral density;
LGG	cis	rs1018836	0.847	rs35409073	chr8:91648036	G/T	cg16814680	chr8:91681699	NA	-0.85	-15.78	-0.59	3.53e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg21171335	chr12:122356390	WDR66	0.28	7.87	0.34	2.48e-14	Mean corpuscular volume;
LGG	cis	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg13789015	chr9:136890014	NCRNA00094	0.46	6.86	0.3	2.16e-11	Mosquito bite size;
LGG	cis	rs4478037	0.822	rs4320035	chr3:33113697	C/G	cg19404215	chr3:33155277	CRTAP	-0.8	-9.36	-0.4	3.37e-19	Major depressive disorder;
LGG	cis	rs4595586	0.545	rs3911798	chr12:39389901	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.7	0.45	4.86e-24	Morning vs. evening chronotype;
LGG	cis	rs4851266	1.000	rs11690335	chr2:100826429	A/G	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	trans	rs526821	0.595	rs551665	chr11:55343268	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs1784581	1.000	rs1784581	chr6:162401127	A/C	cg17173639	chr6:162384350	PARK2	-0.84	-21.05	-0.7	1.62e-69	Itch intensity from mosquito bite;
LGG	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs42648	0.869	rs3810891	chr7:89908851	A/G	cg25739043	chr7:89950458	NA	-0.44	-9.33	-0.4	4.28e-19	Homocysteine levels;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg20887711	chr4:1340912	KIAA1530	0.9	18.96	0.66	9.52e-60	Longevity;
LGG	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.67	0.37	7.4e-17	Fuchs's corneal dystrophy;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.62	0.33	1.44e-13	Menopause (age at onset);
LGG	cis	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg09307838	chr4:120376055	NA	0.78	13.1	0.52	1.47e-33	Corneal astigmatism;
LGG	cis	rs2204008	0.616	rs1607852	chr12:38398125	G/A	cg26384229	chr12:38710491	ALG10B	0.99	22.24	0.72	4.67e-75	Bladder cancer;
LGG	cis	rs7615952	0.546	rs2979333	chr3:125360343	T/A	cg21696256	chr3:125484277	NA	-0.45	-6.87	-0.3	2.06e-11	Blood pressure (smoking interaction);
LGG	cis	rs6032067	0.777	rs13038342	chr20:43800232	C/T	cg10761708	chr20:43804764	PI3	0.75	11.83	0.48	2.11e-28	Blood protein levels;
LGG	cis	rs6976053	0.935	rs4727469	chr7:100509163	C/T	cg03098644	chr7:100410630	EPHB4	-0.39	-6.79	-0.3	3.52e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg06481639	chr22:41940642	POLR3H	0.54	7.61	0.33	1.55e-13	Vitiligo;
LGG	cis	rs2635047	0.967	rs2576060	chr18:44637106	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-7.76	-0.34	5.54e-14	Educational attainment;
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg17178900	chr1:205818956	PM20D1	-0.42	-7.37	-0.32	7.96e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00109274	chr13:42623032	DGKH	0.47	7.82	0.34	3.64e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.57	-0.41	6.31e-20	Lung cancer;
LGG	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg04469686	chr1:162760199	HSD17B7	0.45	7.41	0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9815354	0.812	rs939561	chr3:42057101	G/A	cg03022575	chr3:42003672	ULK4	-0.6	-7.55	-0.33	2.33e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	9.05	0.39	3.95e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7765175	0.926	rs2842829	chr6:113678598	G/A	cg26552650	chr6:113682475	NA	-0.32	-6.74	-0.3	4.59e-11	Coronary artery calcification;
LGG	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg26031613	chr14:104095156	KLC1	0.59	9.38	0.4	3.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.5	-8.78	-0.38	3.25e-17	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs6815814	0.808	rs4833093	chr4:38789740	G/T	cg06935464	chr4:38784597	TLR10	0.55	8.92	0.38	1.11e-17	Breast cancer;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg01238044	chr22:24384105	GSTT1	-0.4	-6.77	-0.3	4.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1978968	0.701	rs9618179	chr22:18476909	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.52	-10.54	-0.44	1.93e-23	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.08	-0.42	9.9700000000000009e-22	Lung cancer;
LGG	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg15103426	chr22:29168792	CCDC117	0.74	11.88	0.48	1.38e-28	Lymphocyte counts;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.49	0.83	1.68e-121	Prudent dietary pattern;
LGG	cis	rs2070488	0.775	rs2051214	chr3:38560303	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-14.56	-0.56	8.32e-40	Electrocardiographic conduction measures;
LGG	cis	rs2842992	0.789	rs2295901	chr6:160201295	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.86	0.34	2.68e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4924935	1.000	rs1737947	chr17:18831432	A/G	cg26306683	chr17:18585705	ZNF286B	-0.42	-7.03	-0.31	7.46e-12	Pancreatic cancer;
LGG	trans	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg22232500	chr2:134024266	NCKAP5	0.61	8.3	0.36	1.13e-15	Bipolar disorder;
LGG	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	10.0	0.42	1.98e-21	Colorectal cancer;
LGG	cis	rs10463316	0.862	rs7700650	chr5:150776473	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.19	-0.43	3.97e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4906332	1.000	rs34347076	chr14:103955069	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-7.61	-0.33	1.6e-13	Coronary artery disease;
LGG	cis	rs4788570	0.625	rs2247603	chr16:71609364	G/A	cg06353428	chr16:71660113	MARVELD3	-1.24	-18.48	-0.65	1.53e-57	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs8058578	1.000	rs7204278	chr16:30730274	A/G	cg05768032	chr16:30646687	NA	0.42	7.07	0.31	5.84e-12	Multiple myeloma;
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg03847636	chr4:7070632	GRPEL1	-0.54	-7.25	-0.32	1.72e-12	Monocyte percentage of white cells;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg25703541	chr22:24373054	LOC391322	-0.91	-17.69	-0.63	7.35e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg25482853	chr8:67687455	SGK3	1.03	13.12	0.52	1.21e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs6964587	1.000	rs6968870	chr7:91661111	G/C	cg17063962	chr7:91808500	NA	0.46	8.13	0.35	4.06e-15	Breast cancer;
LGG	cis	rs9487051	0.676	rs7773775	chr6:109600339	T/C	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.31e-14	Reticulocyte fraction of red cells;
LGG	trans	rs7395662	0.926	rs12288788	chr11:48686863	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.09	-0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Bladder cancer;
LGG	cis	rs9796	0.689	rs9888710	chr15:41446153	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.61	-0.41	4.52e-20	Menopause (age at onset);
LGG	trans	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg01620082	chr3:125678407	NA	-0.97	-8.96	-0.38	8.07e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs6087990	0.735	rs6058883	chr20:31365719	C/T	cg13636640	chr20:31349939	DNMT3B	-0.84	-17.48	-0.63	6.37e-53	Ulcerative colitis;
LGG	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg18357526	chr6:26021779	HIST1H4A	0.61	10.72	0.45	4.22e-24	Blood metabolite levels;
LGG	cis	rs2075371	0.966	rs2544225	chr7:133995838	A/C	cg20476274	chr7:133979776	SLC35B4	0.77	15.28	0.58	5.66e-43	Mean platelet volume;
LGG	cis	rs924607	0.510	rs1709542	chr5:662543	A/G	cg07001201	chr5:642380	CEP72	-0.41	-6.83	-0.3	2.71e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs727505	0.564	rs68107250	chr7:124870200	G/A	cg23710748	chr7:124431027	NA	-0.44	-8.19	-0.36	2.58e-15	Lewy body disease;
LGG	trans	rs11252926	0.537	rs4881274	chr10:459940	G/A	cg00953403	chr17:74099816	EXOC7	0.41	6.76	0.3	4.2e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs28829049	0.570	rs12060125	chr1:19391108	A/G	cg13387374	chr1:19411106	UBR4	-0.38	-7.0	-0.31	8.76e-12	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.920	rs115688334	chr4:119770805	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs9916302	0.706	rs8182252	chr17:37727950	T/C	cg00129232	chr17:37814104	STARD3	0.62	10.09	0.42	9.22e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs2652822	0.935	rs12594313	chr15:63436662	A/G	cg02713581	chr15:63449717	RPS27L	0.49	8.35	0.36	8.06e-16	Metabolic traits;
LGG	cis	rs3741151	0.764	rs73548680	chr11:73271335	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11585357	0.895	rs4625336	chr1:17630964	G/T	cg08277548	chr1:17600880	PADI3	-0.74	-8.54	-0.37	1.94e-16	Hair shape;
LGG	cis	rs4716602	0.596	rs10949585	chr7:156165258	A/C	cg16983916	chr7:156159713	NA	-0.5	-9.64	-0.41	3.74e-20	Anti-saccade response;
LGG	cis	rs36051895	0.632	rs966871	chr9:5121070	A/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.78	-0.59	3.48e-45	Pediatric autoimmune diseases;
LGG	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg11161011	chr14:65562177	MAX	-0.57	-10.8	-0.45	2.09e-24	Obesity-related traits;
LGG	cis	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg09307838	chr4:120376055	NA	0.49	8.3	0.36	1.13e-15	Diastolic blood pressure;
LGG	cis	rs7444	0.882	rs5998644	chr22:21953288	T/C	cg15846791	chr22:21984385	YDJC	-0.45	-7.13	-0.31	3.83e-12	Systemic lupus erythematosus;
LGG	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg00129232	chr17:37814104	STARD3	-0.75	-16.32	-0.6	1.22e-47	Asthma;
LGG	cis	rs975722	0.622	rs43031	chr7:117107061	A/G	cg10524701	chr7:117356490	CTTNBP2	0.43	9.47	0.4	1.47e-19	Coronary artery disease;
LGG	cis	rs4718428	1.000	rs1830070	chr7:66349671	T/C	cg18252515	chr7:66147081	NA	-0.61	-10.17	-0.43	4.44e-22	Corneal structure;
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.21	0.36	2.21e-15	Height;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg18854735	chr1:1822972	GNB1	-0.48	-7.5	-0.33	3.26e-13	Coronary artery disease;
LGG	cis	rs12731740	1.000	rs34129533	chr1:208032959	G/A	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.06	-0.31	6.29e-12	Biomedical quantitative traits;
LGG	cis	rs12540874	0.507	rs4947644	chr7:50618876	C/T	cg00647317	chr7:50633725	DDC	-0.42	-10.42	-0.44	5.54e-23	Systemic sclerosis;
LGG	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg13256891	chr4:100009986	ADH5	0.59	11.58	0.47	2.13e-27	Alcohol dependence;
LGG	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg06092702	chr1:163392909	NA	-0.47	-8.27	-0.36	1.39e-15	Motion sickness;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg03528353	chr17:61819722	STRADA	-0.43	-7.29	-0.32	1.32e-12	Prudent dietary pattern;
LGG	cis	rs12618769	0.652	rs2276603	chr2:99205962	C/T	cg18455616	chr2:99124870	INPP4A	-0.27	-7.74	-0.34	6.32e-14	Bipolar disorder;
LGG	cis	rs950776	0.518	rs12906846	chr15:78825295	G/A	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19590063	chr11:84431918	DLG2	0.43	7.17	0.32	3.07e-12	Cognitive performance;
LGG	cis	rs7107174	1.000	rs11601196	chr11:78043431	A/C	cg02023728	chr11:77925099	USP35	0.46	7.91	0.34	1.97e-14	Testicular germ cell tumor;
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2011503	1.000	rs2965178	chr19:19482911	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.37	-7.5	-0.33	3.4e-13	Bipolar disorder;
LGG	cis	rs3126085	0.935	rs3126088	chr1:152305785	A/G	cg26876637	chr1:152193138	HRNR	-0.51	-7.97	-0.35	1.27e-14	Atopic dermatitis;
LGG	cis	rs9976767	0.932	rs9784206	chr21:43823380	T/G	cg23042151	chr21:43824109	UBASH3A	-0.46	-9.54	-0.41	8.38e-20	Type 1 diabetes;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg17971929	chr21:40555470	PSMG1	0.89	17.57	0.63	2.49e-53	Cognitive function;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.4	-7.38	-0.32	7.24e-13	Personality dimensions;
LGG	cis	rs9308731	1.000	rs6542334	chr2:111907214	G/A	cg26001287	chr2:111877753	BCL2L11	-0.39	-7.82	-0.34	3.48e-14	Chronic lymphocytic leukemia;
LGG	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg24848339	chr3:12840334	CAND2	0.44	10.37	0.43	8.85e-23	QRS complex (12-leadsum);
LGG	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08045932	chr20:61659980	NA	0.59	12.84	0.51	1.67e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg06654118	chr4:1303317	MAEA	0.49	8.6	0.37	1.22e-16	Obesity-related traits;
LGG	cis	rs9309473	0.898	rs9807961	chr2:73694043	A/G	cg20560298	chr2:73613845	ALMS1	-0.43	-7.27	-0.32	1.54e-12	Metabolite levels;
LGG	cis	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg00405596	chr8:11794950	NA	0.44	7.29	0.32	1.39e-12	Triglycerides;
LGG	cis	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17490921	chr11:116658887	ZNF259	0.44	7.23	0.32	2.04e-12	Cognitive performance;
LGG	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg27490568	chr2:178487706	NA	0.35	7.18	0.32	2.88e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.29	0.32	1.35e-12	Retinal vascular caliber;
LGG	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg03733263	chr8:22462867	KIAA1967	1.05	26.94	0.78	7.41e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1997103	1.000	rs2331063	chr7:55408914	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7737355	0.947	rs11750739	chr5:130911743	C/T	cg06307176	chr5:131281290	NA	0.52	8.63	0.37	9.57e-17	Life satisfaction;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.14	0.52	9.76e-34	Lung cancer;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.35	-0.43	1.02e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg02002194	chr4:3960332	NA	0.5	9.41	0.4	2.37e-19	Myopia (pathological);
LGG	cis	rs9549260	0.755	rs2721045	chr13:41162632	T/A	cg21288729	chr13:41239152	FOXO1	0.33	6.73	0.3	4.88e-11	Red blood cell count;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs7551222	0.784	rs2045624	chr1:204584385	C/G	cg20240347	chr1:204465584	NA	0.38	6.89	0.3	1.82e-11	Schizophrenia;
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	3.2e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25450986	chr17:38574356	TOP2A	0.41	6.83	0.3	2.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg19168338	chr16:4465731	CORO7	0.75	13.07	0.52	1.84e-33	Schizophrenia;
LGG	cis	rs2204008	0.748	rs11180579	chr12:38237830	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.78	0.54	1.94e-36	Bladder cancer;
LGG	cis	rs17253792	0.822	rs75999534	chr14:56036413	A/T	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.37	-0.36	6.7e-16	Body mass index;
LGG	cis	rs1949733	0.959	rs2688242	chr4:8429943	T/G	cg11789530	chr4:8429930	ACOX3	0.88	16.96	0.62	1.51e-50	Response to antineoplastic agents;
LGG	cis	rs7786877	0.500	rs2272572	chr7:100285888	C/T	cg00334542	chr7:100209784	MOSPD3	-0.52	-7.07	-0.31	5.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg00198680	chr16:28758506	NA	0.28	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12724450	0.793	rs34696422	chr1:150380392	T/G	cg03818307	chr1:150480534	ECM1	0.51	7.17	0.32	2.99e-12	Blood protein levels;
LGG	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg01338084	chr22:32026380	PISD	1.44	11.73	0.48	5.29e-28	Age-related hearing impairment;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg00405596	chr8:11794950	NA	-0.6	-10.37	-0.43	8.25e-23	Monocyte count;
LGG	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg16268157	chr7:99778414	STAG3	-0.49	-8.13	-0.35	3.9e-15	Lung function (FEV1/FVC);
LGG	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.33	-0.36	9.29e-16	Retinal vascular caliber;
LGG	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg17830980	chr10:43048298	ZNF37B	-0.45	-10.01	-0.42	1.69e-21	Extrinsic epigenetic age acceleration;
LGG	trans	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg16141378	chr3:129829833	LOC729375	0.3	6.66	0.3	7.7e-11	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19830245	chr17:17141047	FLCN	0.41	7.07	0.31	5.83e-12	Gut microbiome composition (summer);
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg20363699	chr7:23626180	CLK2P	0.29	6.81	0.3	2.98e-11	Schizophrenia;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.08e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.883	rs1415749	chr6:86779084	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	9.47	0.4	1.39e-19	Response to antipsychotic treatment;
LGG	cis	rs4650994	0.525	rs4650991	chr1:178511165	C/T	cg19399532	chr1:178512495	C1orf220	0.56	11.13	0.46	1.16e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg19507638	chr5:93509721	C5orf36	-0.69	-9.5	-0.4	1.1e-19	Diabetic retinopathy;
LGG	trans	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg16724585	chr3:197361211	NA	-0.49	-8.39	-0.36	6.05e-16	Pancreatic cancer;
LGG	cis	rs4742903	0.967	rs10991120	chr9:106909051	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.21	0.36	2.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7202877	0.706	rs8055609	chr16:75402088	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.33	0.32	1.04e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg13397359	chr6:42928475	GNMT	0.63	18.63	0.65	3.34e-58	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs826838	0.967	rs7963716	chr12:38876090	C/T	cg13010199	chr12:38710504	ALG10B	0.77	15.7	0.59	7.74e-45	Heart rate;
LGG	cis	rs3889237	0.965	rs4791041	chr17:64779125	A/C	cg09655520	chr17:64786064	PRKCA	-0.42	-8.89	-0.38	1.41e-17	Height;
LGG	cis	rs2070488	0.930	rs928813	chr3:38528537	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.22	0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs7208859	0.725	rs9915802	chr17:29173058	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.36	-0.32	8.34e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23054379	chr1:176176226	RFWD2	0.43	7.09	0.31	5.08e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05665937	chr4:1216051	CTBP1	0.48	8.71	0.38	5.53e-17	Obesity-related traits;
LGG	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.26	0.4	7.37e-19	Triglycerides;
LGG	trans	rs2235573	0.789	rs4821733	chr22:38449394	A/G	cg19894588	chr14:64061835	NA	-0.47	-8.02	-0.35	8.75e-15	Glioblastoma;Glioma;
LGG	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg07274523	chr3:49395745	GPX1	0.57	9.43	0.4	1.98e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9815354	0.951	rs55835726	chr3:41763049	C/T	cg03022575	chr3:42003672	ULK4	0.68	8.6	0.37	1.26e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9815354	0.951	rs9837273	chr3:41813104	T/C	cg03022575	chr3:42003672	ULK4	0.61	7.81	0.34	3.93e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg11764359	chr7:65958608	NA	-0.8	-14.93	-0.57	2.07e-41	Aortic root size;
LGG	cis	rs7928758	0.943	rs75842822	chr11:134265236	C/T	cg22777979	chr11:134283252	B3GAT1	0.96	12.11	0.49	1.64e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2180341	0.855	rs4308584	chr6:127714874	A/G	cg24812749	chr6:127587940	RNF146	0.72	11.8	0.48	2.9e-28	Breast cancer;
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.07	-0.55	1.06e-37	Alzheimer's disease;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg18918831	chr3:195489782	MUC4	0.66	9.12	0.39	2.38e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs329674	0.516	rs329650	chr11:133765897	C/T	cg06766960	chr11:133703094	NA	-0.65	-7.82	-0.34	3.54e-14	Bipolar disorder;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg13395646	chr4:1353034	KIAA1530	0.46	7.86	0.34	2.69e-14	Obesity-related traits;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18026142	chr3:11685426	VGLL4	0.39	6.78	0.3	3.76e-11	Body mass index;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg00409905	chr10:38381863	ZNF37A	-0.62	-11.56	-0.47	2.4200000000000002e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06108461	chr20:60628389	TAF4	0.75	13.62	0.53	9.06e-36	Body mass index;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg24846343	chr22:24311635	DDTL	0.56	10.79	0.45	2.29e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg12432903	chr7:1882776	MAD1L1	0.54	8.19	0.36	2.5e-15	Bipolar disorder;
LGG	cis	rs79349575	0.778	rs12950328	chr17:46967061	C/T	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.74e-11	Type 2 diabetes;
LGG	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg15704280	chr7:45808275	SEPT13	-0.62	-11.23	-0.46	4.91e-26	HDL cholesterol;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	10.23	0.43	2.75e-22	Tonsillectomy;
LGG	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg10661904	chr17:79619235	PDE6G	-0.39	-7.93	-0.35	1.71e-14	Eye color traits;
LGG	cis	rs11690935	0.959	rs6705200	chr2:172637600	A/G	cg21435375	chr2:172878103	MAP1D	-0.31	-7.04	-0.31	6.76e-12	Schizophrenia;
LGG	cis	rs972578	0.692	rs9607978	chr22:43284334	G/A	cg01576275	chr22:43409880	NA	-0.23	-7.08	-0.31	5.36e-12	Mean platelet volume;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs4789452	0.716	rs1105410	chr17:75383942	C/T	cg06761530	chr17:75373219	SEPT9	-0.36	-6.88	-0.3	1.9e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg24006582	chr15:45444508	DUOX1	0.67	12.24	0.49	4.88e-30	Uric acid levels;
LGG	trans	rs61931739	0.635	rs1852224	chr12:33963080	A/C	cg26384229	chr12:38710491	ALG10B	0.59	11.11	0.46	1.42e-25	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.96	0.31	1.18e-11	Lung cancer;
LGG	cis	rs4555082	0.874	rs10151638	chr14:105761592	T/C	cg06808227	chr14:105710500	BRF1	-0.61	-10.84	-0.45	1.5e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4731207	0.596	rs922712	chr7:124607050	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg18446336	chr7:2847575	GNA12	0.32	8.49	0.37	2.8e-16	Height;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.14	-0.35	3.62e-15	Personality dimensions;
LGG	cis	rs6500395	0.926	rs1039342	chr16:48577498	G/A	cg16662043	chr16:48846231	NA	0.37	7.08	0.31	5.29e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6594499	0.542	rs4530809	chr5:110462230	A/G	cg04022379	chr5:110408740	TSLP	0.41	7.26	0.32	1.6e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6963495	0.818	rs56251768	chr7:105165591	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg11707556	chr5:10655725	ANKRD33B	0.39	6.89	0.3	1.89e-11	Coronary artery disease;
LGG	cis	rs968451	0.619	rs2267407	chr22:39747050	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	9.92	0.42	3.59e-21	Primary biliary cholangitis;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg08621203	chr6:150244597	RAET1G	0.41	7.04	0.31	6.96e-12	Lung cancer;
LGG	cis	rs875971	0.929	rs6970860	chr7:65976634	A/G	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	trans	rs61931739	0.658	rs708142	chr12:33719872	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg14703610	chr5:56206110	C5orf35	0.4	6.91	0.31	1.56e-11	Coronary artery disease;
LGG	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	trans	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg18335740	chr13:41363409	SLC25A15	-0.54	-9.53	-0.4	8.67e-20	Lewy body disease;
LGG	cis	rs3857747	0.694	rs4534056	chr7:40450567	A/C	cg00420559	chr7:40367873	C7orf10	-0.39	-7.92	-0.35	1.77e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg25338242	chr13:114786047	RASA3	0.41	7.5	0.33	3.23e-13	Schizophrenia;
LGG	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.35	-0.32	9.05e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs2201728	0.702	rs6811453	chr4:100194977	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.96	-0.31	1.2e-11	Cardiac Troponin-T levels;
LGG	cis	rs12410462	0.681	rs113984727	chr1:227553917	C/A	cg04117972	chr1:227635322	NA	0.55	9.07	0.39	3.39e-18	Major depressive disorder;
LGG	trans	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9814567	0.896	rs6790338	chr3:134208167	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.92	-0.51	7.9e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg24565620	chr2:194026	NA	-0.71	-8.76	-0.38	3.84e-17	Blood protein levels;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg12288994	chr5:1860383	NA	0.78	15.5	0.58	6.12e-44	Cardiovascular disease risk factors;
LGG	trans	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg05926928	chr17:57297772	GDPD1	0.64	11.22	0.46	5.48e-26	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs4891159	0.790	rs7234653	chr18:74111988	C/T	cg24786174	chr18:74118243	ZNF516	-0.57	-13.31	-0.53	1.83e-34	Longevity;
LGG	cis	rs412000	0.554	rs2680700	chr17:56440542	G/T	cg25039879	chr17:56429692	SUPT4H1	0.5	8.11	0.35	4.6e-15	Primary tooth development (time to first tooth eruption);
LGG	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.75	-9.01	-0.39	5.29e-18	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.45	-0.33	4.64e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.601	rs1737581	chr6:8539138	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.13	0.43	6.59e-22	Motion sickness;
LGG	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs919433	0.648	rs787975	chr2:198248128	C/T	cg00792783	chr2:198669748	PLCL1	0.49	7.78	0.34	4.66e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9581943	1.000	rs9581943	chr13:28493997	G/A	cg16302790	chr13:28498334	PDX1	0.53	8.91	0.38	1.13e-17	Pancreatic cancer;
LGG	cis	rs12220238	0.722	rs6480744	chr10:76398989	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.51	6.75	0.3	4.52e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs35160687	0.644	rs9309635	chr2:86499402	G/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.37	-6.77	-0.3	3.88e-11	Night sleep phenotypes;
LGG	cis	rs1021993	0.545	rs17014396	chr1:209548885	C/T	cg24446417	chr1:209558027	NA	-0.75	-11.23	-0.46	4.73e-26	Gut microbiome composition (winter);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03811533	chr7:100860907	PLOD3;ZNHIT1	0.46	6.85	0.3	2.32e-11	Gut microbiome composition (summer);
LGG	cis	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg07460842	chr6:66804631	NA	0.89	14.69	0.56	2.26e-40	Exhaled nitric oxide output;
LGG	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.63e-14	Cystic fibrosis severity;
LGG	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg21132104	chr15:45694354	SPATA5L1	0.69	10.51	0.44	2.66e-23	Homoarginine levels;
LGG	cis	rs4481887	0.861	rs6681336	chr1:248482756	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.69	-0.3	6.56e-11	Aortic root size;
LGG	cis	rs6500395	1.000	rs9936467	chr16:48677983	T/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs80262450	1	rs80262450	chr18:12818922	G/A	cg23598886	chr18:12777645	NA	-0.67	-7.68	-0.34	9.26e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.94	-0.35	1.54e-14	Morning vs. evening chronotype;
LGG	cis	rs9790314	1.000	rs7638668	chr3:161047283	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-11.15	-0.46	9.75e-26	Morning vs. evening chronotype;
LGG	cis	rs2119480	0.927	rs11069863	chr13:111329665	T/C	cg08400494	chr13:111318490	CARS2	-0.31	-7.34	-0.32	9.74e-13	Diastolic blood pressure;
LGG	cis	rs6688613	0.649	rs11584352	chr1:166850372	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.53	7.91	0.35	1.91e-14	Refractive astigmatism;
LGG	cis	rs2658782	0.901	rs7116173	chr11:93222311	C/T	cg15737290	chr11:93063684	CCDC67	-0.51	-7.46	-0.33	4.23e-13	Pulmonary function decline;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.86e-21	Diabetic retinopathy;
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	9.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7566780	0.725	rs4832646	chr2:16702399	G/C	cg09580478	chr2:16689509	NA	-0.49	-7.22	-0.32	2.1e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs4742903	0.904	rs971969	chr9:106929798	A/C	cg14250997	chr9:106856677	SMC2	0.39	8.1	0.35	4.96e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2066819	1.000	rs76466034	chr12:56719450	G/A	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg21926883	chr2:100939477	LONRF2	0.5	9.55	0.41	7.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6424115	0.594	rs10799802	chr1:24009544	C/T	cg15997130	chr1:24165203	NA	0.33	7.79	0.34	4.51e-14	Immature fraction of reticulocytes;
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.6	7.2	0.32	2.49e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg11189052	chr15:85197271	WDR73	-0.56	-9.12	-0.39	2.29e-18	P wave terminal force;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg26174226	chr8:58114915	NA	-0.54	-7.55	-0.33	2.3e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs116095464	0.558	rs10057299	chr5:242135	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	cis	rs12286929	0.617	rs11607801	chr11:115077367	A/C	cg04055981	chr11:115044050	NA	0.37	6.84	0.3	2.45e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.91e-39	Exhaled nitric oxide output;
LGG	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg08847533	chr14:75593920	NEK9	0.62	11.82	0.48	2.28e-28	Height;
LGG	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg04731861	chr2:219085781	ARPC2	0.48	12.58	0.5	2.05e-31	Colorectal cancer;
LGG	trans	rs7246760	0.867	rs3859512	chr19:9932831	C/T	cg02900749	chr2:68251473	NA	-1.08	-11.55	-0.47	2.69e-27	Pursuit maintenance gain;
LGG	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.14e-15	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs11122272	0.733	rs2749700	chr1:231522734	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.53	-0.47	3.34e-27	Hemoglobin concentration;
LGG	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg23583168	chr7:148888333	NA	0.85	16.31	0.6	1.44e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg20891558	chr2:74357851	NA	0.49	9.47	0.4	1.47e-19	Gestational age at birth (maternal effect);
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.92	-0.38	1.05e-17	Dementia with Lewy bodies;
LGG	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg18252515	chr7:66147081	NA	-0.75	-11.94	-0.49	7.88e-29	Corneal structure;
LGG	cis	rs2597513	0.860	rs2655228	chr3:13563020	G/T	cg24006715	chr3:13568212	NA	0.63	10.46	0.44	3.86e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg11812906	chr14:75593930	NEK9	0.54	10.2	0.43	3.59e-22	Height;
LGG	cis	rs11969893	0.737	rs4098482	chr6:101377808	C/T	cg12253828	chr6:101329408	ASCC3	1.11	9.62	0.41	4.23e-20	Economic and political preferences (immigration/crime);
LGG	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg01620082	chr3:125678407	NA	-0.93	-9.41	-0.4	2.37e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg16950941	chr11:66035639	RAB1B	0.55	10.24	0.43	2.49e-22	Gout;
LGG	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg14664628	chr15:75095509	CSK	-0.51	-9.04	-0.39	4.21e-18	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs919433	0.889	rs12472355	chr2:198205840	C/A	cg00792783	chr2:198669748	PLCL1	-0.45	-7.01	-0.31	8.62e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9309473	1.000	rs7582606	chr2:73813945	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.6	-0.33	1.68e-13	Metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25148336	chr3:15468722	EAF1;METTL6	0.46	7.77	0.34	5.13e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1348850	0.632	rs11682717	chr2:178499240	C/G	cg22681709	chr2:178499509	PDE11A	-0.53	-9.65	-0.41	3.43e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1401999	0.606	rs939335	chr3:183745663	A/G	cg05044414	chr3:183734942	ABCC5	0.72	14.74	0.57	1.35e-40	Anterior chamber depth;
LGG	cis	rs1461503	0.932	rs6589962	chr11:122843535	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	trans	rs11039798	0.610	rs11530356	chr11:48836290	C/A	cg03929089	chr4:120376271	NA	0.74	8.53	0.37	2.09e-16	Axial length;
LGG	cis	rs4330281	0.647	rs13065637	chr3:17710414	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs17209837	0.607	rs4148810	chr7:87102251	C/T	cg25823085	chr7:87105416	ABCB4	0.29	7.37	0.32	7.89e-13	Gallbladder cancer;
LGG	cis	rs380904	0.517	rs11775744	chr8:144649192	A/G	cg21643262	chr8:144646939	NA	-0.52	-7.74	-0.34	6.37e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4865875	0.901	rs10045765	chr5:54120518	T/A	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg02187348	chr16:89574699	SPG7	0.44	7.14	0.32	3.55e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.64	0.33	1.22e-13	Schizophrenia;
LGG	cis	rs4481887	0.861	rs4644528	chr1:248472508	T/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs3849570	0.961	rs3849571	chr3:81777716	A/C	cg07356753	chr3:81810745	GBE1	-0.49	-8.01	-0.35	9.39e-15	Waist circumference;Body mass index;
LGG	trans	rs2018683	0.707	rs1021691	chr7:28974496	C/T	cg19402173	chr7:128379420	CALU	-0.53	-9.24	-0.39	8.65e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs7572263	0.528	rs13025862	chr2:209072106	C/T	cg00164906	chr2:209055251	C2orf80	-0.5	-7.78	-0.34	4.69e-14	Glioma;Non-glioblastoma glioma;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg13628971	chr7:2884303	GNA12	0.37	7.76	0.34	5.63e-14	Height;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2273669	0.667	rs11153154	chr6:109357324	G/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.62	-0.37	1.1e-16	Prostate cancer;
LGG	cis	rs12368653	0.582	rs2307095	chr12:58026001	G/A	cg00700412	chr12:58011837	NA	0.43	8.68	0.37	6.64e-17	Multiple sclerosis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg07058086	chr8:29120186	KIF13B	0.46	7.13	0.31	3.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg02023728	chr11:77925099	USP35	-0.45	-7.98	-0.35	1.18e-14	Testicular germ cell tumor;
LGG	cis	rs11753937	0.887	rs385859	chr6:133614799	A/G	cg05493394	chr6:133562035	EYA4	0.26	7.11	0.31	4.39e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg04287289	chr16:89883240	FANCA	0.84	7.81	0.34	3.81e-14	Skin colour saturation;
LGG	cis	rs6066825	0.644	rs761271	chr20:47315637	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.08	0.35	5.82e-15	Colorectal cancer;
LGG	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg11644478	chr21:40555479	PSMG1	-0.75	-13.77	-0.54	2.08e-36	Cognitive function;
LGG	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg16691251	chr5:66510806	NA	-0.33	-6.9	-0.31	1.75e-11	Breast cancer;
LGG	cis	rs62380364	0.602	rs610217	chr5:88065263	G/A	cg22951263	chr5:87985283	NA	-0.54	-9.99	-0.42	2.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg06713675	chr4:122721982	EXOSC9	-0.43	-7.04	-0.31	6.75e-12	Type 2 diabetes;
LGG	cis	rs12220238	1.000	rs7076721	chr10:75996682	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.73	0.48	5.15e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.38	0.36	6.33e-16	Type 2 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26260369	chr14:68141723	VTI1B	0.42	6.87	0.3	2.07e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9457247	1.000	rs406095	chr6:167409087	C/T	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-11.42	-0.47	9.11e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg12463550	chr7:65579703	CRCP	0.49	8.18	0.36	2.83e-15	Aortic root size;
LGG	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg13482628	chr17:19912719	NA	0.52	9.57	0.41	6.7e-20	Schizophrenia;
LGG	cis	rs9790314	0.871	rs336551	chr3:161109720	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.31	-0.47	2.32e-26	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg02002194	chr4:3960332	NA	-0.39	-6.94	-0.31	1.29e-11	Retinal vascular caliber;
LGG	cis	rs9992101	0.645	rs907446	chr4:77254804	C/T	cg17010112	chr4:77227123	STBD1	-0.46	-9.47	-0.4	1.4e-19	Creatinine levels;
LGG	cis	rs2204008	0.811	rs11525004	chr12:38333807	T/A	cg13010199	chr12:38710504	ALG10B	0.7	14.11	0.55	7.38e-38	Bladder cancer;
LGG	cis	rs11239187	0.548	rs10793543	chr10:45060288	C/A	cg03916630	chr10:45065415	NA	0.36	8.68	0.37	6.65e-17	Body mass index;
LGG	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg23625390	chr15:77176239	SCAPER	-0.71	-14.12	-0.55	6.45e-38	Blood metabolite levels;
LGG	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg16329650	chr2:213403929	ERBB4	0.78	16.56	0.61	1.02e-48	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1461503	0.900	rs3751047	chr11:122828439	G/A	cg27398637	chr11:122830231	C11orf63	-0.74	-15.35	-0.58	2.74e-43	Menarche (age at onset);
LGG	cis	rs17253792	0.822	rs75115817	chr14:56069537	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs10743315	0.557	rs17505005	chr12:19296294	C/T	cg02471346	chr12:19282374	PLEKHA5	0.66	6.99	0.31	9.77e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs3798296	chr6:97052286	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.84	-0.3	2.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg06212747	chr3:49208901	KLHDC8B	-0.55	-7.87	-0.34	2.53e-14	Menarche (age at onset);
LGG	cis	rs9810259	0.522	rs9875338	chr3:12296469	A/G	cg22839075	chr3:12045461	SYN2	0.4	6.85	0.3	2.38e-11	Platelet count;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.97e-22	Menopause (age at onset);
LGG	cis	rs9389248	0.690	rs2294321	chr6:135253048	T/G	cg24558204	chr6:135376177	HBS1L	-0.57	-9.66	-0.41	3.18e-20	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs929596	0.563	rs1105880	chr2:234601965	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.69	-0.37	6.36e-17	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs1538970	0.781	rs34768551	chr1:46020408	G/A	cg05343316	chr1:45956843	TESK2	0.77	12.45	0.5	6.63e-31	Platelet count;
LGG	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg00290607	chr11:67383545	NA	-0.52	-9.26	-0.4	7.43e-19	Mean corpuscular volume;
LGG	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs2304069	0.954	rs4705408	chr5:149412545	A/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.57	-7.57	-0.33	2.07e-13	HIV-1 control;
LGG	cis	rs2797369	0.656	rs846790	chr6:101353919	A/C	cg27451362	chr6:101846650	GRIK2	0.77	10.65	0.44	7.41e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs9814567	1.000	rs1814337	chr3:134200682	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.05	-0.52	2.26e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10193935	0.901	rs17029344	chr2:42444287	T/C	cg27598129	chr2:42591480	NA	-0.62	-9.21	-0.39	1.16e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01565703	chr14:103245090	TRAF3	-0.47	-7.26	-0.32	1.61e-12	Systemic lupus erythematosus;
LGG	cis	rs2735413	0.750	rs76833828	chr16:78070995	A/T	cg04733911	chr16:78082701	NA	0.62	10.13	0.43	6.3e-22	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs28830936	0.934	rs3959569	chr15:42115747	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.94	-0.52	6.57e-33	Diastolic blood pressure;
LGG	cis	rs929354	0.772	rs2301914	chr7:157000176	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.62	0.59	1.69e-44	Body mass index;
LGG	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.35	-21.46	-0.71	1.89e-71	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7086627	0.515	rs7077373	chr10:82211615	C/T	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg13009111	chr11:71350975	NA	0.31	6.89	0.3	1.86e-11	Neuroticism;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg00689492	chr4:1303491	MAEA	-0.47	-7.97	-0.35	1.24e-14	Obesity-related traits;
LGG	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg13628971	chr7:2884303	GNA12	0.51	10.2	0.43	3.67e-22	Height;
LGG	cis	rs6088580	0.634	rs1205336	chr20:32926336	G/A	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.26	-0.4	7.51e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs909674	0.734	rs5757675	chr22:39838892	G/T	cg04986931	chr22:39850128	NA	0.4	8.74	0.38	4.44e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs7395662	1.000	rs4882134	chr11:48598795	A/C	cg03929089	chr4:120376271	NA	-0.45	-7.22	-0.32	2.09e-12	HDL cholesterol;
LGG	cis	rs35849525	1.000	rs35849525	chr3:50067350	T/C	cg24110177	chr3:50126178	RBM5	-0.54	-8.18	-0.36	2.66e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.571	rs1822346	chr4:152525303	G/C	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg13770153	chr20:60521292	NA	-0.5	-8.14	-0.35	3.78e-15	Body mass index;
LGG	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27511599	chr7:32358540	NA	0.64	7.12	0.31	4.18e-12	Body mass index;
LGG	cis	rs4950322	0.542	rs28381210	chr1:146673507	C/A	cg22381352	chr1:146742008	CHD1L	-0.46	-7.63	-0.33	1.34e-13	Protein quantitative trait loci;
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs4740619	0.766	rs11515218	chr9:15802840	C/T	cg14451791	chr9:16040625	NA	0.33	8.22	0.36	2.03e-15	Body mass index;
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg14346243	chr4:90757452	SNCA	-0.39	-7.87	-0.34	2.57e-14	Dementia with Lewy bodies;
LGG	cis	rs13095912	0.819	rs11918734	chr3:185296602	T/C	cg11274856	chr3:185301563	NA	0.49	7.97	0.35	1.24e-14	Systolic blood pressure;
LGG	cis	rs6032067	0.777	rs62208385	chr20:43789823	A/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg11812906	chr14:75593930	NEK9	0.54	10.14	0.43	6.09e-22	Height;
LGG	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-10.95	-0.45	5.64e-25	Morning vs. evening chronotype;
LGG	cis	rs2072499	1.000	rs2253809	chr1:156172125	T/C	cg25208724	chr1:156163844	SLC25A44	1.23	29.89	0.81	3.8e-110	Testicular germ cell tumor;
LGG	cis	rs1843834	0.505	rs2140508	chr2:225355839	G/T	cg22455342	chr2:225449267	CUL3	0.85	14.97	0.57	1.34e-41	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs9911578	0.935	rs304261	chr17:56813782	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.96	-0.42	2.73e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg17376030	chr22:41985996	PMM1	0.55	9.12	0.39	2.28e-18	Vitiligo;
LGG	cis	rs9581857	0.556	rs1885990	chr13:28040502	C/T	cg01674679	chr13:27998804	GTF3A	-0.58	-8.05	-0.35	6.82e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg23029597	chr12:123009494	RSRC2	-0.89	-16.92	-0.62	2.35e-50	Body mass index;
LGG	cis	rs2816316	1.000	rs2760521	chr1:192525276	G/A	cg02586212	chr1:192544902	RGS1	0.42	8.57	0.37	1.57e-16	Celiac disease;
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18252515	chr7:66147081	NA	0.41	6.94	0.31	1.32e-11	Aortic root size;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg00381974	chr18:44260357	ST8SIA5	-0.35	-6.78	-0.3	3.73e-11	Migraine with aura;
LGG	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg25358565	chr5:93447407	FAM172A	-1.26	-15.38	-0.58	2.01e-43	Diabetic retinopathy;
LGG	cis	rs72781680	1.000	rs6731001	chr2:24192952	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg15049968	chr18:44337910	ST8SIA5	-0.36	-6.74	-0.3	4.79e-11	Personality dimensions;
LGG	trans	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg12045294	chr17:78518616	RPTOR	-0.46	-7.06	-0.31	6.07e-12	Glycated hemoglobin levels;
LGG	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg10326726	chr10:51549505	MSMB	0.7	14.15	0.55	5e-38	Prostate-specific antigen levels;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg11473876	chr11:109292803	C11orf87	0.46	9.37	0.4	3.11e-19	Schizophrenia;
LGG	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg15440763	chr7:158190612	PTPRN2	-0.43	-8.92	-0.38	1.07e-17	Obesity-related traits;
LGG	cis	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg07636037	chr3:49044803	WDR6	0.44	6.79	0.3	3.41e-11	Resting heart rate;
LGG	cis	rs3824867	0.920	rs7105122	chr11:47449544	A/G	cg20307385	chr11:47447363	PSMC3	0.45	7.16	0.32	3.28e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.31	0.36	1.05e-15	Bipolar disorder;
LGG	cis	rs17001868	1.000	rs73167022	chr22:40797256	A/T	cg07138101	chr22:40742427	ADSL	0.62	6.82	0.3	2.9100000000000002e-11	Mammographic density (dense area);
LGG	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg07274523	chr3:49395745	GPX1	0.55	8.96	0.38	8.12e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg19554555	chr3:13937349	NA	0.75	14.39	0.56	4.53e-39	Ovarian reserve;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01148728	chr11:117198424	CEP164	-0.48	-7.11	-0.31	4.38e-12	Systemic lupus erythematosus;
LGG	cis	rs240764	0.507	rs9404031	chr6:101211298	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.15	0.32	3.4e-12	Neuroticism;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3762637	0.882	rs9856011	chr3:122093570	G/A	cg24169773	chr3:122142474	KPNA1	-0.57	-9.12	-0.39	2.34e-18	LDL cholesterol levels;
LGG	cis	rs988958	0.637	rs7595175	chr2:42220015	T/C	cg27428208	chr2:42229179	NA	0.55	9.41	0.4	2.35e-19	Hypospadias;
LGG	cis	rs4819052	0.819	rs34818688	chr21:46672416	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.93	0.38	1.04e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg11987759	chr7:65425863	GUSB	0.37	7.24	0.32	1.91e-12	Calcium levels;
LGG	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-6.98	-0.31	1.02e-11	Schizophrenia;
LGG	cis	rs7107174	1.000	rs10899485	chr11:78072383	C/T	cg02023728	chr11:77925099	USP35	-0.45	-8.1	-0.35	4.97e-15	Testicular germ cell tumor;
LGG	cis	rs56399783	0.901	rs17132594	chr7:2775102	G/A	cg19731401	chr7:2775893	GNA12	0.37	7.51	0.33	3.12e-13	Childhood ear infection;
LGG	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg21665744	chr7:39171113	POU6F2	0.34	7.07	0.31	5.57e-12	IgG glycosylation;
LGG	cis	rs9796	0.835	rs11856848	chr15:41370961	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.52	-9.06	-0.39	3.65e-18	Menopause (age at onset);
LGG	cis	rs2239815	0.576	rs10427628	chr22:29239766	T/C	cg02153584	chr22:29168773	CCDC117	0.56	7.34	0.32	9.39e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg12661370	chr5:149340060	SLC26A2	0.5	8.28	0.36	1.29e-15	HIV-1 control;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg11764359	chr7:65958608	NA	-0.72	-12.89	-0.51	1.09e-32	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16418258	chr15:42840397	LRRC57;HAUS2	0.49	7.47	0.33	4.12e-13	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg22437258	chr11:111473054	SIK2	-0.48	-8.09	-0.35	5.34e-15	Primary sclerosing cholangitis;
LGG	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg15083037	chr5:83017644	HAPLN1	-0.32	-6.68	-0.3	6.99e-11	Prostate cancer;
LGG	cis	rs62380364	0.602	rs589544	chr5:88064462	T/C	cg22951263	chr5:87985283	NA	-0.54	-10.01	-0.42	1.76e-21	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg09307838	chr4:120376055	NA	0.71	11.81	0.48	2.59e-28	Corneal astigmatism;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg01988459	chr11:68622903	NA	-0.63	-12.78	-0.51	3.04e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg16482183	chr6:26056742	HIST1H1C	-0.52	-8.41	-0.36	5.14e-16	Iron status biomarkers;
LGG	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-18.28	-0.65	1.34e-56	Vitiligo;
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.05	0.46	2.43e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9810089	0.843	rs518972	chr3:136039268	C/A	cg21827317	chr3:136751795	NA	0.47	8.23	0.36	1.91e-15	Gestational age at birth (child effect);
LGG	cis	rs4731207	0.751	rs4584095	chr7:124500210	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg05692746	chr2:100937584	LONRF2	-0.59	-9.4	-0.4	2.46e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs11772102	chr7:91558326	A/T	cg17063962	chr7:91808500	NA	-0.49	-8.62	-0.37	1.05e-16	Breast cancer;
LGG	cis	rs283228	0.550	rs549135	chr6:101833972	G/T	cg02011392	chr6:101847541	GRIK2	0.51	6.97	0.31	1.09e-11	Coenzyme Q10 levels;
LGG	cis	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg13147721	chr7:65941812	NA	0.73	9.75	0.41	1.5e-20	Diabetic kidney disease;
LGG	cis	rs9399135	0.967	rs3756799	chr6:135341011	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.87e-20	Red blood cell count;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-10.29	-0.43	1.62e-22	Lung cancer;
LGG	cis	rs9815354	1.000	rs9874975	chr3:41764300	G/A	cg03022575	chr3:42003672	ULK4	0.6	7.6	0.33	1.6e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg19077165	chr18:44547161	KATNAL2	0.55	9.94	0.42	3.08e-21	Personality dimensions;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23633679	chr1:173793655	CENPL;DARS2	0.38	6.69	0.3	6.56e-11	Bipolar disorder;
LGG	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg24675658	chr1:53192096	ZYG11B	0.61	13.3	0.53	2.01e-34	Monocyte count;
LGG	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19717773	chr7:2847554	GNA12	-0.37	-8.62	-0.37	1.1e-16	Height;
LGG	cis	rs67311347	1.000	rs72861689	chr3:40435890	A/G	cg13683864	chr3:40499215	RPL14	-1.08	-24.03	-0.74	2.02e-83	Renal cell carcinoma;
LGG	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-8.9	-0.38	1.31e-17	Obesity-related traits;
LGG	cis	rs6684428	0.706	rs12119904	chr1:56327241	G/T	cg11651538	chr1:56320950	NA	-0.72	-13.35	-0.53	1.26e-34	Airflow obstruction;
LGG	cis	rs2802728	0.881	rs66691749	chr1:243539532	A/C	cg05593162	chr1:243577377	SDCCAG8	0.5	6.99	0.31	9.8e-12	Toenail selenium levels;
LGG	cis	rs1577917	0.958	rs12192033	chr6:86472559	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.44	-0.5	7.46e-31	Response to antipsychotic treatment;
LGG	cis	rs2016266	0.859	rs7953656	chr12:53738433	G/T	cg04065151	chr12:53682969	ESPL1	-0.52	-8.29	-0.36	1.24e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg25986240	chr4:9926439	SLC2A9	-0.37	-7.56	-0.33	2.18e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg24110177	chr3:50126178	RBM5	0.44	7.26	0.32	1.65e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg27411982	chr8:10470053	RP1L1	0.41	7.11	0.31	4.39e-12	Neuroticism;
LGG	cis	rs2932538	0.922	rs4838961	chr1:113163967	T/C	cg22162597	chr1:113214053	CAPZA1	-0.61	-11.55	-0.47	2.69e-27	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs12230513	0.732	rs12582120	chr12:55830064	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-11.03	-0.46	2.88e-25	Contrast sensitivity;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg07341007	chr3:195489909	MUC4	0.55	8.21	0.36	2.22e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs3761847	0.651	rs1323472	chr9:123826335	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.53	9.74	0.41	1.58e-20	Rheumatoid arthritis;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg20887711	chr4:1340912	KIAA1530	0.67	13.29	0.53	2.34e-34	Obesity-related traits;
LGG	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg25457927	chr22:38595422	NA	-0.36	-8.53	-0.37	2.11e-16	Cutaneous nevi;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg03395511	chr6:291903	DUSP22	-0.51	-8.8	-0.38	2.83e-17	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg13147721	chr7:65941812	NA	-0.73	-10.0	-0.42	1.83e-21	Diabetic kidney disease;
LGG	trans	rs1997103	0.863	rs6956287	chr7:55415107	T/C	cg20935933	chr6:143382018	AIG1	0.54	7.97	0.35	1.23e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	cis	rs365132	1.000	rs353468	chr5:176445494	A/T	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg04166393	chr7:2884313	GNA12	-0.45	-8.27	-0.36	1.41e-15	Height;
LGG	cis	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg26384229	chr12:38710491	ALG10B	-0.85	-19.44	-0.67	5.45e-62	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg26043149	chr18:55253948	FECH	-0.48	-8.29	-0.36	1.23e-15	Bone mineral density;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.45	-0.33	4.72e-13	Menopause (age at onset);
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06850241	chr22:41845214	NA	-0.43	-6.66	-0.3	7.59e-11	Vitiligo;
LGG	cis	rs9381040	0.631	rs13216201	chr6:41162060	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.44	-7.51	-0.33	2.99e-13	Alzheimer's disease (late onset);
LGG	cis	rs2243480	1.000	rs431076	chr7:65600320	A/C	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs9878978	0.893	rs13091098	chr3:2463850	A/G	cg21928760	chr3:2462534	CNTN4	0.41	8.93	0.38	9.99e-18	Blood pressure (smoking interaction);
LGG	cis	rs6963495	0.745	rs55906043	chr7:105165367	T/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg09264619	chr17:80180166	NA	0.37	7.38	0.32	7.22e-13	Life satisfaction;
LGG	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg10847948	chr11:71163743	NADSYN1	0.58	8.63	0.37	1e-16	Vitamin D levels;
LGG	cis	rs597583	0.806	rs12224853	chr11:117394822	A/G	cg27161313	chr11:117392002	DSCAML1	0.52	8.43	0.36	4.37e-16	Putamen volume;
LGG	cis	rs2011503	0.883	rs17216041	chr19:19366643	C/T	cg11584989	chr19:19387371	SF4	0.76	12.6	0.51	1.66e-31	Bipolar disorder;
LGG	cis	rs6909430	0.808	rs9688806	chr6:98630881	C/T	cg12860156	chr6:98744658	NA	-0.43	-7.0	-0.31	9.12e-12	Quantitative traits;
LGG	cis	rs7107174	0.901	rs2510053	chr11:77959435	T/C	cg02023728	chr11:77925099	USP35	0.44	7.8	0.34	4.1e-14	Testicular germ cell tumor;
LGG	cis	rs4731207	0.596	rs4624966	chr7:124626471	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.75	-0.3	4.55e-11	Cutaneous malignant melanoma;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg02985366	chr16:32360428	NA	-0.45	-7.03	-0.31	7.35e-12	Menopause (age at onset);
LGG	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	29.79	0.81	1.1e-109	Prudent dietary pattern;
LGG	cis	rs1395	0.710	rs58965570	chr2:27481460	C/T	cg23587288	chr2:27483067	SLC30A3	-0.33	-7.43	-0.33	5.31e-13	Blood metabolite levels;
LGG	cis	rs4417704	0.551	rs7594525	chr2:241893722	G/C	cg05025159	chr2:241905733	NA	0.52	10.58	0.44	1.38e-23	Joint mobility (Beighton score);
LGG	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg18876405	chr7:65276391	NA	0.49	8.84	0.38	2.01e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02668984	chr17:48172022	PDK2	0.53	8.42	0.36	4.9e-16	Gut microbiome composition (summer);
LGG	cis	rs9828933	0.938	rs2578011	chr3:64004819	C/T	cg17941049	chr3:63904683	ATXN7	0.67	8.19	0.36	2.48e-15	Type 2 diabetes;
LGG	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg21535247	chr6:8435926	SLC35B3	-0.6	-10.35	-0.43	9.9e-23	Motion sickness;
LGG	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.27e-18	Blood metabolite levels;
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.51	8.8	0.38	2.67e-17	Longevity;
LGG	cis	rs6547631	0.622	rs1561285	chr2:85924384	C/G	cg24620635	chr2:85921963	GNLY	0.5	10.07	0.42	1.1e-21	Blood protein levels;
LGG	trans	rs3206736	0.548	rs2021177	chr7:35020188	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.4	6.98	0.31	1.01e-11	Diastolic blood pressure;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg26155939	chr18:44337853	ST8SIA5	-0.38	-6.95	-0.31	1.27e-11	Personality dimensions;
LGG	cis	rs34638952	0.577	rs8080082	chr17:27456591	A/G	cg13672501	chr17:27410685	MYO18A	-0.4	-7.23	-0.32	2.02e-12	Sitting height ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03670158	chr17:41323431	NBR1	0.52	8.35	0.36	7.71e-16	Gut microbiome composition (summer);
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg04632378	chr13:21900426	NA	0.43	9.38	0.4	2.97e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3812831	0.543	rs389108	chr13:114925389	A/G	cg22348356	chr13:114891224	RASA3	0.38	7.33	0.32	1.02e-12	Schizophrenia;
LGG	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.4	6.99	0.31	9.34e-12	Homoarginine levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26517889	chr13:25497356	CENPJ	0.42	6.95	0.31	1.22e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7512552	0.839	rs11581351	chr1:150440200	G/C	cg15654264	chr1:150340011	RPRD2	0.46	9.36	0.4	3.54e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11971779	0.680	rs4728465	chr7:139069061	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	8.14	0.35	3.71e-15	Diisocyanate-induced asthma;
LGG	cis	rs2777491	0.957	rs316614	chr15:41746625	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.16	-0.68	2.32e-65	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04849788	chr3:160283695	KPNA4	0.42	6.69	0.3	6.53e-11	Gut microbiome composition (summer);
LGG	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.62e-33	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg27661571	chr11:113659931	NA	-0.67	-9.58	-0.41	5.98e-20	Hip circumference adjusted for BMI;
LGG	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg18225595	chr11:63971243	STIP1	0.63	12.2	0.49	7.32e-30	Platelet count;
LGG	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.56e-14	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07962051	chr8:9412923	TNKS	-0.47	-7.34	-0.32	9.8e-13	Systemic lupus erythematosus;
LGG	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg03264133	chr6:25882463	NA	-0.6	-11.42	-0.47	8.52e-27	Blood metabolite levels;
LGG	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg26655873	chr3:72818019	SHQ1	0.35	7.15	0.32	3.48e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs5015933	0.902	rs13291306	chr9:128124798	A/T	cg14078157	chr9:128172775	NA	-0.38	-7.3	-0.32	1.22e-12	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09440289	chr12:15475990	PTPRO	0.43	7.15	0.32	3.32e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7582720	1.000	rs116382857	chr2:203751932	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs17767392	0.747	rs61989240	chr14:71708610	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.27	-0.32	1.52e-12	Mitral valve prolapse;
LGG	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg12395012	chr8:11607386	GATA4	-0.39	-6.74	-0.3	4.79e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg16127683	chr15:40268777	EIF2AK4	-0.83	-10.79	-0.45	2.23e-24	Response to haloperidol in psychosis;
LGG	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg24699146	chr1:24152579	HMGCL	0.26	7.82	0.34	3.61e-14	Immature fraction of reticulocytes;
LGG	trans	rs11039798	0.588	rs10838923	chr11:48534864	C/G	cg03929089	chr4:120376271	NA	0.66	9.16	0.39	1.71e-18	Axial length;
LGG	cis	rs10901296	0.660	rs2855197	chr9:133764406	A/G	cg13397898	chr9:133768931	QRFP	0.43	8.43	0.36	4.4e-16	Bilirubin levels;
LGG	cis	rs6065	0.618	rs16942618	chr17:4877358	G/A	cg03443944	chr17:4872326	CAMTA2;SPAG7	-0.53	-6.86	-0.3	2.27e-11	Platelet count;
LGG	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg21775007	chr8:11205619	TDH	-0.46	-6.89	-0.3	1.87e-11	Neuroticism;
LGG	cis	rs7827545	1.000	rs4909909	chr8:135564627	T/C	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs11055008	0.935	rs10845601	chr12:12820134	A/G	cg04607235	chr12:12878440	APOLD1	0.49	8.42	0.36	4.91e-16	Pulse pressure;
LGG	cis	rs6860806	0.507	rs2631372	chr5:131703578	C/G	cg07395648	chr5:131743802	NA	-0.4	-7.8	-0.34	4.09e-14	Breast cancer;
LGG	cis	rs11792861	0.816	rs28361111	chr9:111761012	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.08	0.42	9.87e-22	Menarche (age at onset);
LGG	cis	rs714515	0.934	rs9425591	chr1:172358697	G/T	cg01573306	chr1:172330400	DNM3	0.34	7.55	0.33	2.39e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs1639906	0.527	rs1639919	chr7:2262934	C/G	cg08027265	chr7:2291960	NA	-0.55	-10.89	-0.45	9.42e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs981844	0.696	rs17030349	chr4:154636039	C/T	cg14289246	chr4:154710475	SFRP2	0.63	10.17	0.43	4.74e-22	Response to statins (LDL cholesterol change);
LGG	trans	rs2018683	1.000	rs4719962	chr7:28999237	G/A	cg19402173	chr7:128379420	CALU	-0.78	-14.91	-0.57	2.41e-41	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.84	-0.45	1.46e-24	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05052031	chr3:33138450	TMPPE;GLB1	0.5	7.45	0.33	4.54e-13	Gut microbiome composition (summer);
LGG	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg05793240	chr7:2802953	GNA12	0.3	7.25	0.32	1.79e-12	Height;
LGG	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.88	-0.3	1.95e-11	Aortic root size;
LGG	cis	rs9899728	0.572	rs9915968	chr17:73059616	G/C	cg27626185	chr17:73056755	KCTD2	-0.61	-8.97	-0.38	7.45e-18	Alzheimer's disease or small vessel stroke;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg17427856	chr6:90539462	CASP8AP2	0.41	7.04	0.31	7.08e-12	Bipolar disorder;
LGG	cis	rs4713118	0.513	rs149954	chr6:28035246	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.84	-0.3	2.54e-11	Parkinson's disease;
LGG	cis	rs7215564	0.908	rs34143200	chr17:78673008	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.14e-15	Myopia (pathological);
LGG	cis	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.87	0.71	2.45e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6908034	0.607	rs79162793	chr6:19813065	A/G	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07080220	chr10:102295463	HIF1AN	0.58	10.08	0.42	9.38e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg21775007	chr8:11205619	TDH	-0.52	-8.54	-0.37	1.89e-16	Triglycerides;
LGG	cis	rs10791323	0.593	rs2282604	chr11:133714672	A/G	cg15485101	chr11:133734466	NA	0.58	10.23	0.43	2.82e-22	Childhood ear infection;
LGG	cis	rs138249	0.505	rs138219	chr22:50548985	T/C	cg07310406	chr22:50524374	MLC1	0.61	11.45	0.47	6.52e-27	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs2952156	0.920	rs732084	chr17:37834357	A/C	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.87e-16	Asthma;
LGG	trans	rs9657904	0.826	rs4894957	chr3:105578155	T/C	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.39e-14	Multiple sclerosis;
LGG	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg06937548	chr11:34938143	PDHX;APIP	-0.58	-10.03	-0.42	1.46e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg11764359	chr7:65958608	NA	0.75	13.49	0.53	3.11e-35	Aortic root size;
LGG	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.62	-0.48	1.5e-27	Schizophrenia;
LGG	trans	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.5	0.5	4.23e-31	Corneal astigmatism;
LGG	cis	rs1832871	0.579	rs828006	chr6:158775014	T/C	cg07215822	chr6:158701037	NA	0.48	9.57	0.41	6.42e-20	Height;
LGG	cis	rs826838	0.559	rs4882276	chr12:38611994	T/C	cg13010199	chr12:38710504	ALG10B	0.56	11.12	0.46	1.24e-25	Heart rate;
LGG	cis	rs847577	0.722	rs7790120	chr7:97712831	C/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.67	-0.3	7.49e-11	Breast cancer;
LGG	cis	rs7827545	1.000	rs6995244	chr8:135568959	A/G	cg09855544	chr8:135498122	ZFAT	0.46	7.76	0.34	5.53e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs10089	1.000	rs9968597	chr5:127455383	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	12.01	0.49	4.02e-29	Ileal carcinoids;
LGG	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg22987457	chr7:157211561	NA	0.36	6.74	0.3	4.83e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1620921	0.505	rs34797199	chr6:161203769	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.92	-0.31	1.53e-11	Arsenic metabolism;
LGG	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.11	0.35	4.54e-15	Homoarginine levels;
LGG	cis	rs11997175	0.549	rs4357253	chr8:33652458	G/A	ch.8.33884649F	chr8:33765107	NA	0.38	7.13	0.31	3.96e-12	Body mass index;
LGG	cis	rs9972944	0.729	rs1895035	chr17:63777711	G/A	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg00689492	chr4:1303491	MAEA	-0.44	-7.39	-0.32	7.12e-13	Obesity-related traits;
LGG	cis	rs7192380	1.000	rs11647110	chr16:69589363	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.79	-0.34	4.45e-14	Sjögren's syndrome;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21937593	chr3:167098088	ZBBX	0.61	7.08	0.31	5.31e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9487051	0.676	rs13195816	chr6:109598624	T/C	cg21918786	chr6:109611834	NA	-0.5	-9.19	-0.39	1.32e-18	Reticulocyte fraction of red cells;
LGG	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg26318627	chr11:63887540	MACROD1	-0.38	-6.86	-0.3	2.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.75e-19	Life satisfaction;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg03188948	chr7:1209495	NA	0.63	8.13	0.35	3.98e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg23782820	chr8:58130467	NA	0.44	6.67	0.3	7.2e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4478858	0.775	rs6701861	chr1:31708125	A/C	cg19084893	chr1:31688959	NA	0.37	8.04	0.35	7.83e-15	Alcohol dependence;
LGG	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg03517284	chr6:25882590	NA	-0.49	-9.37	-0.4	3.19e-19	Blood metabolite levels;
LGG	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4731207	0.698	rs12538333	chr7:124508357	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs10895140	0.756	rs2513180	chr11:101492630	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	19.75	0.68	1.97e-63	Platelet count;
LGG	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg25019033	chr10:957182	NA	-0.5	-8.36	-0.36	7.16e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs4555082	0.872	rs7153832	chr14:105730563	G/T	cg06808227	chr14:105710500	BRF1	-0.63	-11.21	-0.46	5.82e-26	Mean platelet volume;Platelet distribution width;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01811416	chr1:227127838	CABC1	0.38	6.68	0.3	6.75e-11	Obesity-related traits;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.61	-0.44	1.1e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs11836207	chr12:34315177	G/A	cg26384229	chr12:38710491	ALG10B	0.72	14.45	0.56	2.38e-39	Morning vs. evening chronotype;
LGG	cis	rs9326248	0.861	rs4938348	chr11:117021877	G/C	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.74	0.34	6.32e-14	Blood protein levels;
LGG	cis	rs12618769	0.597	rs4851136	chr2:99060873	A/T	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.56e-17	Bipolar disorder;
LGG	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19717773	chr7:2847554	GNA12	-0.34	-7.29	-0.32	1.31e-12	Height;
LGG	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg27147174	chr7:100797783	AP1S1	-0.7	-13.44	-0.53	5.45e-35	Life satisfaction;
LGG	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.38	0.32	7.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg18379455	chr17:41446167	NA	-0.33	-6.65	-0.3	8.22e-11	Menopause (age at onset);
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs8016982	0.633	rs8015423	chr14:81719357	C/T	cg01989461	chr14:81687754	GTF2A1	0.78	18.5	0.65	1.34e-57	Schizophrenia;
LGG	cis	rs7927771	0.965	rs4752881	chr11:47898535	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-8.48	-0.37	3e-16	Subjective well-being;
LGG	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg08400814	chr5:56204995	C5orf35	-0.43	-6.99	-0.31	9.72e-12	Initial pursuit acceleration;
LGG	cis	rs2346177	0.554	rs36006825	chr2:46708945	G/T	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-12.02	-0.49	3.82e-29	HDL cholesterol;
LGG	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg05707623	chr12:122985044	ZCCHC8	0.63	9.25	0.39	8.59e-19	Body mass index;
LGG	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.32e-42	Colorectal cancer;
LGG	cis	rs10050311	0.586	rs2054592	chr4:87673445	G/A	cg11209507	chr4:87813803	C4orf36	0.54	6.99	0.31	9.43e-12	Insulin-related traits;
LGG	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.61	0.51	1.58e-31	Motion sickness;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg03806693	chr22:41940476	POLR3H	-0.94	-16.82	-0.62	6.83e-50	Vitiligo;
LGG	cis	rs17641971	0.684	rs10957363	chr8:49999175	T/A	cg00325661	chr8:49890786	NA	0.57	10.82	0.45	1.78e-24	Blood metabolite levels;
LGG	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg19717773	chr7:2847554	GNA12	0.31	6.66	0.3	7.86e-11	Height;
LGG	cis	rs9527	0.545	rs35756290	chr10:104585572	G/A	cg04362960	chr10:104952993	NT5C2	0.46	8.02	0.35	8.89e-15	Arsenic metabolism;
LGG	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg21605333	chr4:119757512	SEC24D	1.48	14.95	0.57	1.65e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg22535103	chr8:58192502	C8orf71	-0.92	-11.7	-0.48	6.82e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	19.43	0.67	6.2e-62	Birth weight;
LGG	cis	rs892961	0.899	rs7222532	chr17:75413302	G/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.84	0.38	1.95e-17	Educational attainment;
LGG	cis	rs1691799	0.899	rs1168304	chr12:66738667	A/C	cg16791601	chr12:66731901	HELB	-0.66	-15.53	-0.59	4.4e-44	White blood cell count (basophil);
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.29e-12	Menopause (age at onset);
LGG	cis	rs7072216	0.763	rs4475861	chr10:100164989	C/T	cg26618903	chr10:100175079	PYROXD2	-0.28	-6.93	-0.31	1.46e-11	Metabolite levels;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs7973719	0.868	rs6486910	chr12:7356479	G/A	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.62e-12	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg19143629	chr17:61920732	SMARCD2	0.41	7.18	0.32	2.79e-12	Prudent dietary pattern;
LGG	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg16751781	chr15:78858589	CHRNA5	0.47	9.2	0.39	1.24e-18	Sudden cardiac arrest;
LGG	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg27511599	chr7:32358540	NA	-0.56	-6.68	-0.3	6.76e-11	Body mass index;
LGG	cis	rs45544231	0.544	rs8052175	chr16:52577142	C/T	cg09051775	chr16:52580266	TOX3	-0.43	-7.4	-0.33	6.6e-13	Restless legs syndrome;
LGG	cis	rs7605378	1.000	rs796363	chr2:200693668	T/C	cg23649088	chr2:200775458	C2orf69	0.53	8.98	0.39	7.04e-18	Osteoporosis;
LGG	cis	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg06521331	chr12:34319734	NA	0.41	6.89	0.3	1.89e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.46	0.37	3.63e-16	Neuroticism;
LGG	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg23594656	chr7:65796392	TPST1	-0.32	-6.84	-0.3	2.49e-11	Aortic root size;
LGG	cis	rs72945132	0.882	rs59398290	chr11:70134819	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.46	-0.47	6.07e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs66569888	0.789	rs1317569	chr2:106735490	C/A	cg16099169	chr2:106886729	NA	-0.3	-6.65	-0.3	8.31e-11	Facial morphology (factor 23);
LGG	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.95	0.35	1.43e-14	HDL cholesterol;
LGG	cis	rs9783347	1.000	rs10741741	chr11:18342081	C/T	cg15585147	chr11:18324498	HPS5	-0.4	-8.61	-0.37	1.12e-16	Pancreatic cancer;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.73	-0.48	5.44e-28	Obesity-related traits;
LGG	cis	rs41271473	1.000	rs55956922	chr1:228872549	T/A	cg16512390	chr1:228756714	NA	0.48	6.71	0.3	5.61e-11	Chronic lymphocytic leukemia;
LGG	cis	rs17776563	0.887	rs58548047	chr15:89123073	T/C	cg05013243	chr15:89149849	MIR1179	-0.48	-9.96	-0.42	2.7e-21	Thyroid hormone levels;
LGG	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg15268244	chr15:77196840	NA	-0.35	-7.79	-0.34	4.35e-14	Blood metabolite levels;
LGG	cis	rs4700695	1.000	rs111339	chr5:65420347	T/A	cg21114390	chr5:65439923	SFRS12	-0.56	-6.89	-0.3	1.86e-11	Facial morphology (factor 19);
LGG	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg08807101	chr21:30365312	RNF160	-0.68	-11.67	-0.48	8.89e-28	Cognitive test performance;
LGG	cis	rs2299587	0.582	rs7014461	chr8:17908838	C/T	cg18067069	chr8:17937731	ASAH1	-0.33	-7.97	-0.35	1.24e-14	Economic and political preferences;
LGG	cis	rs4148087	1.000	rs9975154	chr21:43639741	C/G	cg10192877	chr21:43641690	ABCG1	-0.4	-6.98	-0.31	1e-11	Eating disorder in bipolar disorder;
LGG	cis	rs4148087	1.000	rs28485452	chr21:43615131	G/A	cg08841829	chr21:43638893	ABCG1	-0.6	-7.83	-0.34	3.4e-14	Eating disorder in bipolar disorder;
LGG	cis	rs774359	0.830	rs3849943	chr9:27543382	C/T	cg21249376	chr9:27528432	MOBKL2B	-0.42	-7.9	-0.34	2.04e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs10888329	0.744	rs6587433	chr1:248355279	G/A	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Autism spectrum disorder;
LGG	cis	rs3820881	1.000	rs3820881	chr2:201254049	C/G	cg23516759	chr2:201153734	NA	-0.42	-6.72	-0.3	5.27e-11	Chickenpox;
LGG	trans	rs55986470	0.817	rs59736380	chr2:239404689	A/G	cg01134436	chr17:81009848	B3GNTL1	0.64	7.22	0.32	2.09e-12	Chronotype;
LGG	cis	rs2153535	0.580	rs4960421	chr6:8459292	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs4849845	0.598	rs3889223	chr2:121024432	A/G	cg15425061	chr2:121036351	RALB	0.37	6.74	0.3	4.84e-11	Mean platelet volume;
LGG	cis	rs509477	1.000	rs7236052	chr18:32574540	A/G	cg23791764	chr18:32556832	MAPRE2	-0.52	-8.62	-0.37	1.04e-16	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg27400746	chr16:89904261	SPIRE2	-0.97	-15.44	-0.58	1.05e-43	Skin colour saturation;
LGG	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg16414030	chr3:133502952	NA	-0.65	-11.63	-0.48	1.3e-27	Iron status biomarkers;
LGG	cis	rs6840360	0.573	rs4696080	chr4:152276465	A/T	cg25486957	chr4:152246857	NA	-0.41	-7.11	-0.31	4.33e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.666	rs13219952	chr6:109712287	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.93	0.35	1.63e-14	Height;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.47	-7.78	-0.34	4.84e-14	Longevity;Endometriosis;
LGG	cis	rs9329289	0.632	rs2452187	chr10:2551147	C/G	cg15501526	chr10:2543763	NA	0.67	12.38	0.5	1.34e-30	Age-related hearing impairment;
LGG	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg05729581	chr11:3078854	CARS	-0.52	-8.56	-0.37	1.67e-16	Longevity;
LGG	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg15736062	chr7:158136485	PTPRN2	-0.41	-7.94	-0.35	1.55e-14	Calcium levels;
LGG	cis	rs10463316	0.817	rs11167545	chr5:150778076	C/T	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.61	-0.41	4.55e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2694528	0.844	rs10471496	chr5:60068347	G/A	cg11474532	chr5:59995715	DEPDC1B	0.73	7.57	0.33	1.99e-13	Parkinson's disease;
LGG	cis	rs9815354	1.000	rs7616844	chr3:41874343	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.12	-0.39	2.26e-18	Vitiligo;
LGG	cis	rs9517320	0.534	rs9556963	chr13:99157026	G/A	cg07423050	chr13:99094983	FARP1	-0.57	-11.03	-0.46	2.93e-25	Longevity;
LGG	cis	rs12928939	0.517	rs12445641	chr16:71967783	C/T	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.42	-0.53	6.19e-35	Post bronchodilator FEV1;
LGG	cis	rs7727544	0.545	rs17674015	chr5:131361778	C/A	cg07395648	chr5:131743802	NA	-0.35	-6.81	-0.3	3.09e-11	Blood metabolite levels;
LGG	cis	rs17125944	0.505	rs17125746	chr14:53236079	C/T	cg00686598	chr14:53173677	PSMC6	1.32	15.08	0.57	4.4e-42	Alzheimer's disease (late onset);
LGG	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg13877915	chr19:58951672	ZNF132	0.59	8.38	0.36	6.39e-16	Mean platelet volume;
LGG	cis	rs2455799	0.594	rs11928773	chr3:15925135	A/G	cg16303742	chr3:15540471	COLQ	-0.38	-7.54	-0.33	2.58e-13	Mean platelet volume;
LGG	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg21926883	chr2:100939477	LONRF2	-0.49	-9.45	-0.4	1.63e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10911363	0.592	rs2761581	chr1:183474850	G/C	cg23894439	chr1:183413866	NA	0.48	9.11	0.39	2.5e-18	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.97	-0.31	1.08e-11	Height;
LGG	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg24687335	chr11:118901407	SLC37A4	-0.6	-11.06	-0.46	2.18e-25	Coronary artery disease;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.73	-13.28	-0.53	2.54e-34	Obesity-related traits;
LGG	cis	rs4478037	0.822	rs9817393	chr3:33117069	A/G	cg19404215	chr3:33155277	CRTAP	0.82	9.69	0.41	2.45e-20	Major depressive disorder;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg08677398	chr8:58056175	NA	0.48	7.05	0.31	6.44e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12493885	0.769	rs11710560	chr3:153777276	A/G	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs941408	0.515	rs759066	chr19:2775337	G/T	cg19676328	chr12:49525230	TUBA1B	-0.61	-8.06	-0.35	6.76e-15	Total cholesterol levels;
LGG	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg02825527	chr7:2087843	MAD1L1	-0.35	-7.01	-0.31	8.31e-12	Neuroticism;
LGG	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg13802316	chr11:70253460	CTTN	-0.6	-7.64	-0.33	1.24e-13	Coronary artery disease;
LGG	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.65	-0.41	3.5e-20	Mood instability;
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-9.32	-0.4	4.83e-19	Skin colour saturation;
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-6.89	-0.3	1.83e-11	Bipolar disorder;
LGG	cis	rs2599510	0.783	rs13399071	chr2:32793783	C/T	cg02381751	chr2:32503542	YIPF4	0.51	8.31	0.36	1.1e-15	Interleukin-18 levels;
LGG	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.56	-0.33	2.24e-13	Obesity (extreme);
LGG	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg27490568	chr2:178487706	NA	0.69	12.94	0.52	6.43e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2976388	0.669	rs2585135	chr8:143814193	A/G	cg06565975	chr8:143823917	SLURP1	-0.39	-9.83	-0.42	7.82e-21	Urinary tract infection frequency;
LGG	cis	rs8067545	0.611	rs12936443	chr17:20033446	T/G	cg09818912	chr17:20140352	CYTSB	-0.33	-7.65	-0.33	1.19e-13	Schizophrenia;
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg08888203	chr3:10149979	C3orf24	0.49	8.29	0.36	1.24e-15	Alzheimer's disease;
LGG	cis	rs11096990	0.593	rs4580660	chr4:39153836	G/A	cg24403649	chr4:39172243	NA	0.39	7.03	0.31	7.21e-12	Cognitive function;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.95	13.74	0.54	2.96e-36	Platelet count;
LGG	trans	rs526821	0.574	rs11230156	chr11:55334809	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.29	0.43	1.74e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs354225	0.586	rs966003	chr2:54884870	C/T	cg26097391	chr2:54893211	SPTBN1	0.3	7.74	0.34	6.41e-14	Schizophrenia;
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg00149659	chr3:10157352	C3orf10	0.73	8.81	0.38	2.58e-17	Alzheimer's disease;
LGG	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg17376030	chr22:41985996	PMM1	-0.63	-10.14	-0.43	5.98e-22	Vitiligo;
LGG	cis	rs7264396	0.635	rs6119672	chr20:34479767	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.23	-0.32	2.05e-12	Total cholesterol levels;
LGG	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg19455335	chr8:22457658	C8orf58	-0.39	-8.11	-0.35	4.6e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.739	rs72799176	chr5:152154526	T/C	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs853679	0.517	rs9393886	chr6:28050039	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs56283067	0.578	rs12197755	chr6:45387495	T/G	cg20913747	chr6:44695427	NA	-0.52	-7.62	-0.33	1.47e-13	Total body bone mineral density;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.66	-0.44	6.81e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7100689	0.646	rs11202725	chr10:82136276	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.54e-54	Breast cancer;
LGG	cis	rs1010254	0.510	rs72806351	chr5:151681110	A/T	cg12297329	chr5:152029980	NA	-0.49	-7.0	-0.31	8.84e-12	Optic nerve measurement (cup area);
LGG	cis	rs3806843	1.000	rs10223116	chr5:140192643	C/T	cg19875535	chr5:140030758	IK	0.49	10.07	0.42	1.03e-21	Depressive symptoms (multi-trait analysis);
LGG	cis	rs60843830	0.661	rs11674325	chr2:105517	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.32	0.4	4.63e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11733284	0.515	rs10025104	chr4:47855999	T/C	cg21463140	chr4:47913142	NFXL1	-0.34	-8.37	-0.36	7.04e-16	Renal underexcretion gout;Gout;
LGG	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg16141378	chr3:129829833	LOC729375	-0.41	-9.07	-0.39	3.34e-18	Retinal vascular caliber;
LGG	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.75	0.3	4.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs7508	0.653	rs7387912	chr8:17920337	C/T	cg18067069	chr8:17937731	ASAH1	0.36	7.71	0.34	7.52e-14	Atrial fibrillation;
LGG	cis	rs4732038	0.605	rs73164856	chr7:134233851	C/T	cg06906464	chr7:134288099	NA	-0.51	-11.76	-0.48	3.91e-28	Longevity;
LGG	cis	rs8032158	1.000	rs66462353	chr15:56186767	T/C	cg05129572	chr15:56138634	NEDD4	-0.41	-6.76	-0.3	4.23e-11	Keloid;
LGG	trans	rs1268083	0.546	rs9398785	chr6:126057748	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-8.81	-0.38	2.44e-17	Migraine;
LGG	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg13114125	chr14:105738426	BRF1	-0.85	-16.2	-0.6	4.44e-47	Mean platelet volume;Platelet distribution width;
LGG	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.89	0.38	1.34e-17	Morning vs. evening chronotype;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg22223655	chr18:67872902	RTTN	0.4	6.7	0.3	5.96e-11	Prudent dietary pattern;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg24503407	chr1:205819492	PM20D1	-0.69	-16.37	-0.61	7.33e-48	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg26338869	chr17:61819248	STRADA	-0.47	-7.7	-0.34	8.56e-14	Prudent dietary pattern;
LGG	cis	rs870825	0.929	rs10027213	chr4:185579871	C/G	cg04058563	chr4:185651563	MLF1IP	0.97	18.12	0.64	7.78e-56	Blood protein levels;
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.15	0.32	3.41e-12	Myopia (pathological);
LGG	cis	rs12493885	0.818	rs55681005	chr3:153759257	G/T	cg17054900	chr3:154042577	DHX36	-0.76	-8.99	-0.39	6.26e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15369054	chr17:80825471	TBCD	0.39	7.74	0.34	6.09e-14	Breast cancer;
LGG	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg00376283	chr12:123451042	ABCB9	0.66	11.49	0.47	4.76e-27	Neutrophil percentage of white cells;
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11011602	chr9:136215029	SNORD24;MED22;RPL7A	0.42	6.93	0.31	1.46e-11	Cognitive performance;
LGG	cis	rs2916247	0.954	rs6471319	chr8:93090594	G/A	cg10183463	chr8:93005414	RUNX1T1	0.38	7.73	0.34	6.7e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08280861	chr8:58055591	NA	-0.6	-7.86	-0.34	2.66e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg10756647	chr7:56101905	PSPH	0.81	9.48	0.4	1.29e-19	Diabetic kidney disease;
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg14675211	chr2:100938903	LONRF2	0.66	11.53	0.47	3.36e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.905	rs7995492	chr13:25013023	A/T	cg22771759	chr13:24902376	NA	0.41	7.07	0.31	5.9e-12	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7085104	0.660	rs7902804	chr10:104585405	A/T	cg04362960	chr10:104952993	NT5C2	0.52	9.81	0.41	8.82e-21	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs9682041	0.696	rs35177863	chr3:170090006	A/G	cg11886554	chr3:170076028	SKIL	0.67	8.65	0.37	8.42e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10779751	1.000	rs4845858	chr1:11304720	C/T	cg08854313	chr1:11322531	MTOR	0.78	18.51	0.65	1.18e-57	Body mass index;
LGG	cis	rs9818758	0.607	rs71324929	chr3:49044713	C/T	cg00383909	chr3:49044727	WDR6	1.13	13.63	0.54	8.12e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs919433	0.684	rs55775495	chr2:198245965	C/T	cg00792783	chr2:198669748	PLCL1	0.43	6.77	0.3	3.9e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11225247	0.772	rs11501344	chr11:102228252	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.53	0.33	2.69e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs10193935	0.792	rs13430031	chr2:42499968	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.37	-0.4	3.15e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6087990	0.899	rs6058893	chr20:31392777	C/T	cg13636640	chr20:31349939	DNMT3B	0.96	21.43	0.71	2.66e-71	Ulcerative colitis;
LGG	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg06453172	chr10:134556979	INPP5A	-0.47	-7.47	-0.33	4.09e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	6e-13	HDL cholesterol;
LGG	cis	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs1355223	0.902	rs1258468	chr11:34729731	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.98	-0.31	1.01e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs72781680	0.756	rs2712059	chr2:24020539	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	8.23	0.36	1.94e-15	Lymphocyte counts;
LGG	cis	rs11150038	0.826	rs7203483	chr16:78085836	C/T	cg04733911	chr16:78082701	NA	0.66	9.25	0.39	8.48e-19	Colorectal or endometrial cancer;
LGG	cis	rs892961	0.932	rs7216116	chr17:75405078	C/T	cg05865280	chr17:75406074	SEPT9	0.42	9.7	0.41	2.22e-20	Airflow obstruction;
LGG	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs7615952	0.546	rs11718647	chr3:125352022	G/A	cg21696256	chr3:125484277	NA	-0.46	-7.01	-0.31	8.71e-12	Blood pressure (smoking interaction);
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.93	0.31	1.4e-11	Schizophrenia;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	10.15	0.43	5.49e-22	Iron status biomarkers;
LGG	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.55	-0.63	3e-53	Breast cancer;
LGG	cis	rs12476592	0.602	rs4671065	chr2:63791131	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg13207630	chr7:32358064	NA	0.8	7.92	0.35	1.74e-14	Body mass index;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg24503407	chr1:205819492	PM20D1	-0.48	-8.15	-0.35	3.49e-15	Parkinson's disease;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.28	0.55	1.37e-38	Platelet count;
LGG	cis	rs9790314	0.695	rs7630763	chr3:160864865	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-11.2	-0.46	6.21e-26	Morning vs. evening chronotype;
LGG	cis	rs7945705	0.905	rs2568054	chr11:8876029	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.37	-7.74	-0.34	6.08e-14	Hemoglobin concentration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23674647	chr1:92001147	NA	-0.3	-6.72	-0.3	5.25e-11	Cognitive performance;
LGG	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg18131467	chr2:239335373	ASB1	0.98	21.88	0.71	2.23e-73	Multiple system atrophy;
LGG	cis	rs2013441	1.000	rs9896709	chr17:20180550	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg12573674	chr2:1569213	NA	-0.65	-10.37	-0.43	8.53e-23	IgG glycosylation;
LGG	cis	rs12540874	0.542	rs10238413	chr7:50648184	G/A	cg04490037	chr7:50633773	DDC	0.34	7.27	0.32	1.59e-12	Systemic sclerosis;
LGG	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.01	-0.31	8.73e-12	HDL cholesterol;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg11878867	chr6:150167359	LRP11	-0.54	-11.07	-0.46	2.04e-25	Lung cancer;
LGG	cis	rs12711979	0.509	rs10187740	chr2:3823965	A/G	cg17052675	chr2:3827356	NA	0.5	9.85	0.42	6.79e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg07701084	chr6:150067640	NUP43	0.45	8.33	0.36	9.23e-16	Testicular germ cell tumor;
LGG	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-10.0	-0.42	1.85e-21	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-11.78	-0.48	3.46e-28	Personality dimensions;
LGG	cis	rs10504073	0.584	rs60449482	chr8:49974865	G/A	cg00325661	chr8:49890786	NA	0.79	15.42	0.58	1.41e-43	Blood metabolite ratios;
LGG	trans	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.52	-0.44	2.29e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs55788414	0.932	rs28514797	chr16:81185070	G/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04530015	chr2:215796436	ABCA12	-0.42	-6.87	-0.3	2.02e-11	Neuroblastoma;
LGG	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg03258749	chr1:151040405	MLLT11	-0.46	-8.52	-0.37	2.28e-16	Childhood ear infection;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.44	-8.49	-0.37	2.81e-16	Personality dimensions;
LGG	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.88	0.38	1.52e-17	Mood instability;
LGG	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.32	-0.4	4.62e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01840575	chr2:38977957	SFRS7	0.49	7.98	0.35	1.15e-14	Cognitive performance;
LGG	cis	rs56283067	0.847	rs11962872	chr6:44690740	T/G	cg18551225	chr6:44695536	NA	-0.7	-12.29	-0.5	3.17e-30	Total body bone mineral density;
LGG	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg04455712	chr21:45112962	RRP1B	0.52	9.63	0.41	3.95e-20	Mean corpuscular volume;
LGG	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg05535760	chr7:792225	HEATR2	-0.81	-11.61	-0.47	1.53e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg00800038	chr16:89945340	TCF25	-0.69	-8.03	-0.35	8.13e-15	Skin colour saturation;
LGG	cis	rs60843830	1.000	rs17713396	chr2:227201	C/T	cg12623918	chr2:306882	NA	0.51	9.5	0.4	1.13e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6964587	1.000	rs7455444	chr7:91639313	C/T	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg27129171	chr3:47204927	SETD2	0.83	15.37	0.58	2.29e-43	Colorectal cancer;
LGG	cis	rs34599045	0.522	rs12755214	chr1:152906716	A/C	cg07796016	chr1:152779584	LCE1C	-0.83	-7.8	-0.34	4.19e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg00800038	chr16:89945340	TCF25	-0.73	-9.07	-0.39	3.34e-18	Skin colour saturation;
LGG	cis	rs350251	0.868	rs350231	chr16:12186376	T/G	cg02910054	chr16:12241554	SNX29	0.43	7.68	0.34	9.24e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg21775007	chr8:11205619	TDH	-0.43	-6.98	-0.31	1.05e-11	Neuroticism;
LGG	cis	rs3806843	1.000	rs2240695	chr5:140168151	G/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7246760	1.000	rs67509260	chr19:9864321	C/T	cg02900749	chr2:68251473	NA	-1.07	-11.62	-0.48	1.51e-27	Pursuit maintenance gain;
LGG	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.53	-0.33	2.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs11168618	0.875	rs11458	chr12:48888594	C/T	cg24011408	chr12:48396354	COL2A1	0.5	8.01	0.35	9.09e-15	Adiponectin levels;
LGG	cis	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg12193833	chr17:30244370	NA	-0.28	-6.91	-0.31	1.6e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12765878	0.580	rs11191822	chr10:105599770	T/G	cg11005552	chr10:105648138	OBFC1	-0.71	-12.08	-0.49	2.11e-29	Coronary artery disease;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg20308403	chr7:2120281	MAD1L1	0.33	6.97	0.31	1.07e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11764590	0.671	rs56226325	chr7:2078981	C/T	cg02743256	chr7:2109353	MAD1L1	-0.38	-7.2	-0.32	2.5e-12	Neuroticism;
LGG	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg23625390	chr15:77176239	SCAPER	-0.71	-14.23	-0.55	2.13e-38	Blood metabolite levels;
LGG	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg26408565	chr15:76604113	ETFA	-0.39	-6.73	-0.3	5.11e-11	Blood metabolite levels;
LGG	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg27624424	chr6:160112604	SOD2	0.59	9.24	0.39	8.72e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.7e-51	Morning vs. evening chronotype;
LGG	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-7.4	-0.33	6.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg05313129	chr8:58192883	C8orf71	-0.79	-12.25	-0.49	4.39e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs17685	0.753	rs1639609	chr7:75683581	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.5	0.76	3.06e-90	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs4650994	0.544	rs2811314	chr1:178619183	C/T	cg12486710	chr1:178512616	C1orf220	-0.48	-9.87	-0.42	5.49e-21	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.64	-10.82	-0.45	1.71e-24	Coronary artery disease;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg13880726	chr7:1868755	MAD1L1	0.42	7.06	0.31	6.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.684	rs4886819	chr15:76901698	C/T	cg15268244	chr15:77196840	NA	0.48	10.17	0.43	4.51e-22	Blood metabolite levels;
LGG	cis	rs72945132	0.882	rs12278741	chr11:70135742	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs4430311	0.600	rs12117580	chr1:243826674	T/C	cg25706552	chr1:244017396	NA	-0.59	-12.71	-0.51	5.76e-32	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg13010199	chr12:38710504	ALG10B	-0.47	-9.13	-0.39	2.17e-18	Morning vs. evening chronotype;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11295777	chr19:6110313	RFX2	-0.41	-7.14	-0.31	3.6e-12	Brain structure;
LGG	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg12386194	chr3:101231763	SENP7	0.42	7.32	0.32	1.08e-12	Colorectal cancer;
LGG	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-12.41	-0.5	1.02e-30	Chronic sinus infection;
LGG	cis	rs2066819	1.000	rs808919	chr12:56647911	C/G	cg26714650	chr12:56694279	CS	1.44	17.62	0.63	1.54e-53	Psoriasis vulgaris;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.75	-0.38	3.87e-17	Lung cancer;
LGG	trans	rs61931739	0.500	rs9919726	chr12:34510783	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.43	0.65	2.76e-57	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13393195	chr12:113659153	TPCN1;IQCD	0.47	7.1	0.31	4.73e-12	Gut microbiome composition (summer);
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg12437481	chr16:420112	MRPL28	-0.47	-7.64	-0.33	1.29e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs3807766	0.601	rs757863	chr7:77671381	C/T	cg25914921	chr7:77669867	MAGI2	-0.33	-6.73	-0.3	5.04e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21843114	chr4:26334859	RBPJ	-0.56	-6.65	-0.3	8.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6693567	0.565	rs6684939	chr1:150440563	G/A	cg15654264	chr1:150340011	RPRD2	-0.32	-6.68	-0.3	6.88e-11	Migraine;
LGG	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg26396452	chr14:65542826	MAX	0.48	10.02	0.42	1.64e-21	Obesity-related traits;
LGG	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.84e-46	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	9.86	0.42	5.9e-21	Retinal vascular caliber;
LGG	cis	rs2274273	0.563	rs79163357	chr14:55738449	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.68	0.51	7.67e-32	Protein biomarker;
LGG	cis	rs4845570	1.000	rs4845579	chr1:151770138	C/T	cg07092448	chr1:151763213	TDRKH	-1.17	-25.19	-0.76	7.95e-89	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.67	0.34	9.91e-14	Homoarginine levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10532262	chr3:172428426	NCEH1	0.46	7.92	0.35	1.84e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1670533	1.000	rs6827357	chr4:1059202	A/C	cg27284194	chr4:1044797	NA	0.56	9.63	0.41	4.09e-20	Recombination rate (females);
LGG	cis	rs4689388	0.824	rs4467645	chr4:6294305	C/T	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6894268	0.762	rs4701136	chr5:179025550	A/G	cg22014891	chr5:179071901	C5orf60	-0.38	-7.58	-0.33	1.92e-13	Eating disorders;
LGG	cis	rs9513627	0.831	rs7319727	chr13:100125541	A/T	cg25919922	chr13:100150906	NA	-0.71	-7.27	-0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.51	-9.04	-0.39	4.31e-18	Longevity;Endometriosis;
LGG	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	5.98e-45	HDL cholesterol levels;
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg13047869	chr3:10149882	C3orf24	0.45	7.29	0.32	1.33e-12	Alzheimer's disease;
LGG	cis	rs11671005	0.735	rs1122955	chr19:58946203	C/T	cg13877915	chr19:58951672	ZNF132	0.59	8.24	0.36	1.85e-15	Mean platelet volume;
LGG	cis	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg26850624	chr5:429559	AHRR	-0.37	-7.93	-0.35	1.69e-14	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16342037	chr11:74303494	POLD3	0.46	6.95	0.31	1.25e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.81	-0.3	2.98e-11	Menopause (age at onset);
LGG	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg02269571	chr22:50332266	NA	-0.59	-9.23	-0.39	9.94e-19	Schizophrenia;
LGG	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg12856521	chr11:46389249	DGKZ	0.96	14.36	0.56	5.87e-39	Crohn's disease;
LGG	cis	rs13191362	1.000	rs34591938	chr6:163087003	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.98	9.98	0.42	2.28e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs56307353	0.753	rs34318825	chr19:1961342	T/C	cg07946961	chr19:1955956	C19orf34;CSNK1G2	-0.32	-7.16	-0.32	3.29e-12	Coronary artery disease;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg05165339	chr4:1420672	NA	-0.35	-8.73	-0.38	4.77e-17	Longevity;
LGG	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg03605463	chr16:89740564	NA	-0.41	-6.8	-0.3	3.2e-11	Hemoglobin concentration;
LGG	cis	rs2439831	0.867	rs2260160	chr15:43895643	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.65	-0.3	8.07e-11	Lung cancer in ever smokers;
LGG	cis	rs9527	0.568	rs12772775	chr10:104702999	C/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.76	-0.3	4.07e-11	Arsenic metabolism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04022019	chr8:104427717	DCAF13;SLC25A32	0.44	7.45	0.33	4.67e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs17122278	0.577	rs537975	chr11:118362869	T/C	cg27286069	chr11:118481882	PHLDB1	0.48	6.94	0.31	1.31e-11	Total cholesterol levels;
LGG	cis	rs9487094	0.922	rs2236582	chr6:109765818	C/G	cg16315928	chr6:109776240	MICAL1	-0.57	-9.54	-0.41	8.29e-20	Height;
LGG	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg25517755	chr10:38738941	LOC399744	-0.35	-6.73	-0.3	5.06e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg21724239	chr8:58056113	NA	0.42	6.66	0.3	7.74e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg22907277	chr7:1156413	C7orf50	0.69	8.77	0.38	3.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12582317	chr17:55822272	NA	0.69	19.86	0.68	5.79e-64	Schizophrenia;
LGG	trans	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg06437703	chr8:37914619	EIF4EBP1	0.63	11.11	0.46	1.4e-25	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9443645	0.527	rs9352663	chr6:79558164	T/C	cg18132916	chr6:79620363	NA	-0.26	-7.0	-0.31	9.24e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-7.89	-0.34	2.21e-14	IgG glycosylation;
LGG	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.7	0.51	6.49e-32	Coronary artery disease;
LGG	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg17971929	chr21:40555470	PSMG1	-0.56	-9.39	-0.4	2.65e-19	Menarche (age at onset);
LGG	cis	rs6748734	0.581	rs4675847	chr2:241865156	A/G	cg14055004	chr2:241860995	NA	0.31	7.79	0.34	4.43e-14	Urinary metabolites;
LGG	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08862035	chr2:2617432	NA	0.42	6.94	0.31	1.37e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02759489	chr4:55098483	PDGFRA	-0.41	-6.87	-0.3	2.09e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	15.04	0.57	6.42e-42	Cognitive test performance;
LGG	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg04064380	chr11:117688259	NA	-0.5	-7.25	-0.32	1.81e-12	Myopia;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.16	0.52	8.28e-34	Mean platelet volume;
LGG	cis	rs11606709	1	rs11606709	chr11:46730522	A/G	cg03339077	chr11:47165057	C11orf49	-0.43	-7.27	-0.32	1.55e-12	Total body bone mineral density;
LGG	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg02753203	chr1:228287806	NA	0.93	19.34	0.67	1.54e-61	Diastolic blood pressure;
LGG	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	cis	rs17253792	0.822	rs11546	chr14:56146357	G/A	cg01858014	chr14:56050164	KTN1	-0.93	-12.77	-0.51	3.33e-32	Putamen volume;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg12708336	chr17:41446283	NA	-0.31	-7.23	-0.32	1.98e-12	Menopause (age at onset);
LGG	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg13147721	chr7:65941812	NA	-0.76	-8.94	-0.38	9.05e-18	Gout;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg14500267	chr11:67383377	NA	0.46	8.55	0.37	1.86e-16	Mean corpuscular volume;
LGG	cis	rs9926296	0.605	rs12709094	chr16:89853017	A/G	cg27121462	chr16:89883253	FANCA	0.61	11.26	0.46	3.83e-26	Vitiligo;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg12288994	chr5:1860383	NA	0.77	15.41	0.58	1.44e-43	Cardiovascular disease risk factors;
LGG	cis	rs55871839	0.708	rs13268621	chr8:59811724	T/G	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs6121246	0.523	rs6060286	chr20:30197663	C/A	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs921968	0.541	rs667251	chr2:219384384	C/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg11366901	chr6:160182831	ACAT2	1.04	16.83	0.62	6.43e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15557168	chr22:42548783	NA	-0.33	-7.38	-0.32	7.46e-13	Cognitive function;
LGG	cis	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg19399532	chr1:178512495	C1orf220	0.57	11.58	0.47	2.14e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2777491	0.957	rs919961	chr15:41651721	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.9	-0.68	4.05e-64	Ulcerative colitis;
LGG	cis	rs7546668	1.000	rs4233534	chr1:15842329	C/T	cg21858823	chr1:15850916	CASP9	0.38	6.94	0.31	1.3e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs6967414	1.000	rs6967414	chr7:6749758	G/A	cg09896999	chr7:6746977	ZNF12	-0.59	-6.85	-0.3	2.37e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs600231	0.542	rs11227198	chr11:65237974	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.71	-0.38	5.56e-17	Bone mineral density;
LGG	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg09165964	chr15:75287851	SCAMP5	0.66	12.0	0.49	4.34e-29	Caffeine consumption;
LGG	cis	rs4430311	0.600	rs12691547	chr1:243819070	A/G	cg25706552	chr1:244017396	NA	-0.6	-13.06	-0.52	2.13e-33	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs990171	1.000	rs6716784	chr2:103048467	T/G	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.41	-7.9	-0.34	2e-14	Schizophrenia;
LGG	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg07636037	chr3:49044803	WDR6	0.92	17.51	0.63	4.6e-53	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.83	-0.38	2.25e-17	Lung cancer;
LGG	trans	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg10756647	chr7:56101905	PSPH	0.91	12.53	0.5	3.36e-31	Diabetic kidney disease;
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg06558623	chr16:89946397	TCF25	0.91	11.98	0.49	5.59e-29	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	trans	rs2727020	0.612	rs9787891	chr11:49413494	G/A	cg03929089	chr4:120376271	NA	-0.88	-15.59	-0.59	2.37e-44	Coronary artery disease;
LGG	cis	rs3733585	0.682	rs13124563	chr4:9927553	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	9.15	0.39	1.78e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8032158	0.702	rs12910830	chr15:56122664	T/C	cg05129572	chr15:56138634	NEDD4	-0.4	-6.94	-0.31	1.34e-11	Keloid;
LGG	cis	rs2455601	0.786	rs56680262	chr11:8971555	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.72	-12.27	-0.5	3.69e-30	Schizophrenia;
LGG	cis	rs9894429	0.789	rs8074989	chr17:79598728	G/C	cg10661904	chr17:79619235	PDE6G	-0.39	-7.93	-0.35	1.7e-14	Eye color traits;
LGG	cis	rs3793683	0.965	rs3829131	chr10:134564627	A/G	cg27286337	chr10:134555280	INPP5A	-1.03	-22.31	-0.72	2.03e-75	Migraine;
LGG	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg01864069	chr14:103024347	NA	-0.68	-11.91	-0.48	1.01e-28	Platelet count;
LGG	cis	rs7143963	0.636	rs28483070	chr14:103292110	T/C	cg23020514	chr14:103360112	TRAF3	0.42	8.72	0.38	5.2e-17	Body mass index;
LGG	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.28	0.4	6.36e-19	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg18252515	chr7:66147081	NA	-1.43	-20.76	-0.69	3.88e-68	Diabetic kidney disease;
LGG	cis	rs12474201	0.894	rs4952842	chr2:46925730	C/A	cg06386533	chr2:46925753	SOCS5	0.79	14.66	0.56	2.89e-40	Height;
LGG	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg04568710	chr12:38710424	ALG10B	0.41	8.79	0.38	3.04e-17	Morning vs. evening chronotype;
LGG	cis	rs250677	0.958	rs36067	chr5:148417553	T/G	cg18129178	chr5:148520854	ABLIM3	-0.42	-7.12	-0.31	4.08e-12	Breast cancer;
LGG	cis	rs10937275	0.826	rs13061952	chr3:186658866	C/G	cg13419791	chr3:186648285	ST6GAL1	0.71	7.62	0.33	1.46e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs612683	0.524	rs584350	chr1:100908324	A/G	cg06223162	chr1:101003688	GPR88	0.39	9.3	0.4	5.56e-19	Breast cancer;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.59	-0.56	6.29e-40	Platelet count;
LGG	cis	rs2307022	0.548	rs1465471	chr16:68396377	C/T	cg07273125	chr16:68295692	NA	0.41	8.94	0.38	9.38e-18	Body mass index;
LGG	cis	rs17227506	1.000	rs17227506	chr8:13458794	C/T	cg03566418	chr8:13424080	C8orf48	0.49	7.7	0.34	8.05e-14	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs10089	1.000	rs13356473	chr5:127478250	T/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.77	0.48	3.58e-28	Ileal carcinoids;
LGG	cis	rs3825932	0.961	rs11855406	chr15:79234864	C/T	cg25744700	chr15:79237217	CTSH	-0.36	-6.99	-0.31	9.75e-12	Type 1 diabetes;
LGG	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg22974920	chr21:40686053	BRWD1	-0.42	-6.65	-0.3	8.44e-11	Cognitive function;
LGG	cis	rs896854	0.654	rs4735337	chr8:95973465	T/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.73e-17	Type 2 diabetes;
LGG	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.25	0.36	1.62e-15	Retinal vascular caliber;
LGG	cis	rs7824557	0.602	rs7817658	chr8:11206543	A/G	cg21775007	chr8:11205619	TDH	0.83	14.63	0.56	4.08e-40	Retinal vascular caliber;
LGG	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg24375607	chr4:120327624	NA	0.58	9.78	0.41	1.18e-20	Corneal astigmatism;
LGG	cis	rs7729447	0.566	rs3828591	chr5:32713108	G/C	cg16267343	chr5:32710456	NPR3	0.44	6.91	0.31	1.64e-11	Blood pressure;
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7512552	0.780	rs55823828	chr1:150467296	G/C	cg15654264	chr1:150340011	RPRD2	0.45	9.25	0.39	8.33e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg18876405	chr7:65276391	NA	0.55	9.86	0.42	6.09e-21	Aortic root size;
LGG	cis	rs1163251	0.837	rs660073	chr1:120245173	T/C	cg19096424	chr1:120255104	PHGDH	0.66	12.01	0.49	4.27e-29	Blood metabolite levels;
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg06558623	chr16:89946397	TCF25	1.1	12.09	0.49	1.98e-29	Skin colour saturation;
LGG	cis	rs2549003	1.000	rs7701588	chr5:131819970	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs2000999	0.778	rs12445401	chr16:72148419	A/G	cg23815491	chr16:72088622	HP	0.44	7.62	0.33	1.47e-13	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	trans	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-9.78	-0.41	1.17e-20	Hepatocellular carcinoma;
LGG	cis	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg11502198	chr6:26597334	ABT1	-0.88	-7.04	-0.31	7.18e-12	Small cell lung carcinoma;
LGG	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg03929089	chr4:120376271	NA	-0.64	-9.09	-0.39	2.87e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg07362569	chr17:61921086	SMARCD2	0.49	9.55	0.41	7.31e-20	Prudent dietary pattern;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg11584989	chr19:19387371	SF4	0.78	13.02	0.52	3.18e-33	Bipolar disorder;
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg04025307	chr7:1156635	C7orf50	0.67	8.5	0.37	2.64e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00109274	chr13:42623032	DGKH	0.49	8.03	0.35	8.22e-15	Cognitive performance;
LGG	cis	rs7843479	0.582	rs7818254	chr8:21798316	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.45	0.61	3.35e-48	Mean corpuscular volume;
LGG	cis	rs4722166	0.695	rs7787893	chr7:22774437	A/G	cg05265849	chr7:22767390	IL6	0.39	7.64	0.33	1.27e-13	Lung cancer;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.68e-14	Lung cancer;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg04156016	chr5:1868137	NA	0.33	7.14	0.31	3.63e-12	Cardiovascular disease risk factors;
LGG	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg04851639	chr8:1020857	NA	-0.42	-9.16	-0.39	1.63e-18	Schizophrenia;
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg26513180	chr16:89883248	FANCA	0.83	8.66	0.37	8.16e-17	Skin colour saturation;
LGG	cis	rs6032067	0.636	rs17335251	chr20:43902946	T/A	cg10761708	chr20:43804764	PI3	0.58	8.77	0.38	3.36e-17	Blood protein levels;
LGG	cis	rs7572644	0.640	rs4564736	chr2:28069543	A/T	cg27432699	chr2:27873401	GPN1	0.45	6.88	0.3	1.94e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg11965913	chr1:205819406	PM20D1	0.85	18.66	0.66	2.35e-58	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07076099	chr15:44487728	FRMD5	0.44	7.19	0.32	2.67e-12	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.04	-0.46	2.62e-25	Neuroticism;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.2	-0.36	2.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.69	0.34	8.8e-14	Neutrophil percentage of white cells;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.27	-0.32	1.54e-12	Height;
LGG	cis	rs2404602	0.716	rs67418609	chr15:76627089	C/A	cg15268244	chr15:77196840	NA	-0.34	-7.37	-0.32	7.96e-13	Blood metabolite levels;
LGG	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg25664220	chr3:72788482	NA	-0.29	-7.91	-0.35	1.91e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg19812747	chr11:111475976	SIK2	0.48	9.83	0.42	7.54e-21	Primary sclerosing cholangitis;
LGG	cis	rs9910055	0.639	rs11656871	chr17:42269141	G/C	cg13607699	chr17:42295918	UBTF	0.56	9.22	0.39	1.01e-18	Total body bone mineral density;
LGG	cis	rs7914558	0.932	rs4307650	chr10:104959852	C/A	cg04362960	chr10:104952993	NT5C2	0.55	10.67	0.44	6.75e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs910316	0.967	rs4899549	chr14:75647494	G/A	cg11812906	chr14:75593930	NEK9	-0.5	-9.13	-0.39	2.08e-18	Height;
LGG	cis	rs367615	0.679	rs10070786	chr5:108815081	T/G	cg17395555	chr5:108820864	NA	0.88	15.97	0.6	4.83e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg08280861	chr8:58055591	NA	0.54	6.91	0.31	1.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00149659	chr3:10157352	C3orf10	0.88	11.16	0.46	8.83e-26	Alzheimer's disease;
LGG	cis	rs7208859	0.623	rs11651858	chr17:29170718	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg05484508	chr16:89589025	SPG7	0.42	6.84	0.3	2.5e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg25801113	chr15:45476975	SHF	0.88	19.84	0.68	7.44e-64	Uric acid levels;
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.38	-0.32	7.37e-13	Neuroticism;
LGG	cis	rs11098499	0.754	rs34425882	chr4:120253177	G/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs12615966	1.000	rs72830442	chr2:105375329	G/C	cg16465502	chr2:105461796	NA	0.89	10.59	0.44	1.28e-23	Pancreatic cancer;
LGG	cis	rs1555322	0.530	rs8122819	chr20:33881586	C/T	cg17927777	chr20:33865990	NA	0.65	9.34	0.4	4.09e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs9309473	1.000	rs10186501	chr2:73697844	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.54	-0.33	2.52e-13	Metabolite levels;
LGG	cis	rs17169635	0.765	rs2290360	chr7:134555261	C/G	cg02516134	chr7:134575187	CALD1	-0.41	-8.24	-0.36	1.73e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs1018836	0.847	rs4735225	chr8:91569100	G/C	cg16814680	chr8:91681699	NA	-0.8	-14.83	-0.57	5.24e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg18110333	chr6:292329	DUSP22	-0.68	-11.37	-0.47	1.43e-26	Menopause (age at onset);
LGG	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg25566285	chr7:158114605	PTPRN2	0.89	19.59	0.67	1.12e-62	Calcium levels;
LGG	cis	rs2456568	0.503	rs4254038	chr11:93666978	T/C	cg17595323	chr11:93583763	C11orf90	-0.46	-7.88	-0.34	2.41e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.65	11.52	0.47	3.56e-27	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17774058	chr20:6748719	BMP2	0.56	8.84	0.38	1.96e-17	Gut microbiome composition (summer);
LGG	cis	rs4664308	1.000	rs4664308	chr2:160917497	A/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.18	-0.65	3.95e-56	Idiopathic membranous nephropathy;
LGG	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg18681998	chr4:17616180	MED28	0.87	19.94	0.68	2.59e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg25809561	chr17:30822961	MYO1D	-0.41	-9.71	-0.41	2.05e-20	Schizophrenia;
LGG	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg15268244	chr15:77196840	NA	0.48	10.27	0.43	1.91e-22	Blood metabolite levels;
LGG	cis	rs735539	0.521	rs575063	chr13:21422911	A/C	cg04906043	chr13:21280425	IL17D	-0.5	-7.83	-0.34	3.37e-14	Dental caries;
LGG	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs2289583	0.544	rs6495132	chr15:75255322	C/T	cg10253484	chr15:75165896	SCAMP2	0.48	7.43	0.33	5.28e-13	Systemic lupus erythematosus;
LGG	cis	rs2334880	0.678	rs12444714	chr16:71452606	C/T	cg06353428	chr16:71660113	MARVELD3	-0.75	-10.16	-0.43	5.18e-22	Malaria;
LGG	cis	rs9952991	0.941	rs2847278	chr18:12778715	C/T	cg23544223	chr18:12777786	NA	0.62	9.35	0.4	3.76e-19	Inflammatory skin disease;
LGG	cis	rs9596863	1.000	rs4471558	chr13:54413349	A/T	ch.13.53330881F	chr13:54432880	NA	0.53	7.58	0.33	1.96e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.72	0.45	4.4e-24	Lewy body disease;
LGG	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.35	0.4	3.89e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.868	rs872375	chr11:67205978	G/A	cg00864171	chr11:67383662	NA	-0.41	-6.74	-0.3	4.76e-11	Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-6.95	-0.31	1.25e-11	Lung cancer;
LGG	cis	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.17	-0.32	2.91e-12	Red cell distribution width;
LGG	cis	rs7552404	1.000	rs11161510	chr1:76210289	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-9.96	-0.42	2.71e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1475911	0.744	rs12481958	chr21:43517269	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.46	-8.58	-0.37	1.49e-16	IgG glycosylation;
LGG	cis	rs62238980	0.614	rs17683310	chr22:32477445	A/G	cg02631450	chr22:32366979	NA	-0.98	-9.24	-0.39	9.16e-19	Childhood ear infection;
LGG	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg08400814	chr5:56204995	C5orf35	-0.47	-7.5	-0.33	3.24e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.51	-0.37	2.39e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2412208	0.816	rs7525119	chr1:7061430	C/T	cg20434152	chr1:7120926	CAMTA1	-0.43	-8.6	-0.37	1.24e-16	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg11062466	chr8:58055876	NA	0.48	8.3	0.36	1.16e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11239187	0.530	rs11239135	chr10:45062092	G/A	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.24e-18	Body mass index;
LGG	cis	rs1018836	0.631	rs9987133	chr8:91470730	T/C	cg16814680	chr8:91681699	NA	-0.61	-10.18	-0.43	4.26e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg02023728	chr11:77925099	USP35	0.47	8.24	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.7	0.34	8.1e-14	Lung cancer;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.75	-0.38	4.14e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9902453	1.000	rs6505158	chr17:28403348	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.36	-0.53	1.11e-34	Coffee consumption (cups per day);
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.92	-0.31	1.53e-11	Total body bone mineral density;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg11050988	chr7:1952600	MAD1L1	-0.38	-9.03	-0.39	4.59e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs75920871	0.623	rs7930409	chr11:116958943	A/G	cg20608306	chr11:116969690	SIK3	-0.34	-8.0	-0.35	1.04e-14	Subjective well-being;
LGG	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg24759859	chr6:86352639	SYNCRIP	0.44	7.43	0.33	5.13e-13	Smooth-surface caries;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.67	12.15	0.49	1.11e-29	Obesity-related traits;
LGG	cis	rs8141529	0.702	rs469990	chr22:29304200	A/T	cg02153584	chr22:29168773	CCDC117	0.58	9.35	0.4	3.8e-19	Lymphocyte counts;
LGG	cis	rs4926298	1.000	rs8104231	chr19:13159569	A/T	cg04657146	chr19:12876947	HOOK2	-0.41	-6.9	-0.31	1.68e-11	Bipolar disorder;
LGG	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg07943548	chr15:86304357	KLHL25	0.32	6.64	0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg01200585	chr1:228362443	C1orf69	0.47	8.23	0.36	1.85e-15	Diastolic blood pressure;
LGG	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg12193833	chr17:30244370	NA	-0.29	-6.89	-0.3	1.84e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg01200585	chr1:228362443	C1orf69	0.47	8.09	0.35	5.14e-15	Diastolic blood pressure;
LGG	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg20503657	chr10:835505	NA	0.75	10.3	0.43	1.48e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg22907277	chr7:1156413	C7orf50	0.85	15.16	0.58	1.84e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.61	0.41	4.8e-20	Diabetic retinopathy;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg07791516	chr6:150247246	NA	0.32	7.1	0.31	4.65e-12	Testicular germ cell tumor;
LGG	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs2594989	0.895	rs439738	chr3:11322577	G/C	cg01796438	chr3:11312864	ATG7	-0.6	-8.33	-0.36	8.98e-16	Circulating chemerin levels;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg26513180	chr16:89883248	FANCA	0.98	9.11	0.39	2.4e-18	Skin colour saturation;
LGG	cis	rs4803468	1.000	rs3816037	chr19:41918009	C/T	cg14132834	chr19:41945861	ATP5SL	-0.49	-9.65	-0.41	3.28e-20	Height;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg15971980	chr6:150254442	NA	0.44	8.3	0.36	1.15e-15	Lung cancer;
LGG	cis	rs7737355	0.947	rs193458	chr5:130816284	G/C	cg06307176	chr5:131281290	NA	0.55	9.17	0.39	1.6e-18	Life satisfaction;
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs9443645	0.901	rs9448590	chr6:79606429	C/G	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7143963	0.580	rs3783385	chr14:103367667	G/A	cg23020514	chr14:103360112	TRAF3	0.36	7.24	0.32	1.84e-12	Body mass index;
LGG	cis	rs10911363	0.573	rs2761580	chr1:183516989	A/T	cg23894439	chr1:183413866	NA	0.46	8.51	0.37	2.36e-16	Systemic lupus erythematosus;
LGG	cis	rs72717009	0.825	rs7529225	chr1:161479352	G/A	cg23840854	chr1:161414152	NA	-0.73	-8.85	-0.38	1.93e-17	Rheumatoid arthritis;
LGG	cis	rs7607369	0.714	rs55900247	chr2:219618708	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.03	0.31	7.48e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs11235843	0.636	rs10736793	chr11:73402576	A/C	cg18195628	chr11:73498948	MRPL48	-0.51	-7.25	-0.32	1.81e-12	Hand grip strength;
LGG	cis	rs208520	1.000	rs208537	chr6:66963544	A/G	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs2760061	0.583	rs697763	chr1:228192622	G/C	cg02753203	chr1:228287806	NA	0.92	18.72	0.66	1.3e-58	Diastolic blood pressure;
LGG	cis	rs8048589	0.898	rs11648235	chr16:12181079	C/T	cg02910054	chr16:12241554	SNX29	0.42	6.68	0.3	6.81e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs873946	0.529	rs12258248	chr10:134573767	A/G	cg06453172	chr10:134556979	INPP5A	-0.47	-7.54	-0.33	2.54e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg18154014	chr19:37997991	ZNF793	0.67	11.52	0.47	3.71e-27	Coronary artery calcification;
LGG	cis	rs16866061	1.000	rs12470077	chr2:225334971	T/C	cg12698349	chr2:225449008	CUL3	0.92	19.09	0.66	2.48e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg00012203	chr2:219082015	ARPC2	0.85	17.33	0.63	3.3e-52	Colorectal cancer;
LGG	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg20628663	chr10:43360327	NA	0.4	8.76	0.38	3.68e-17	Blood protein levels;
LGG	cis	rs1891275	0.508	rs7099557	chr10:93445364	C/G	cg07889827	chr10:93443413	NA	-0.25	-6.64	-0.3	8.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs77633900	0.502	rs116917406	chr15:76922940	T/C	cg21673338	chr15:77095150	SCAPER	-0.67	-9.41	-0.4	2.42e-19	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg13385794	chr1:248469461	NA	0.45	8.0	0.35	1.02e-14	Common traits (Other);
LGG	cis	rs988958	0.565	rs13030999	chr2:42237410	T/C	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19717773	chr7:2847554	GNA12	-0.35	-7.07	-0.31	5.91e-12	Height;
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.03	-0.39	4.6e-18	Neuroticism;
LGG	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.78	-0.3	3.58e-11	Neuroticism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04887335	chr3:196044632	TCTEX1D2	0.4	6.66	0.3	7.99e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg11062466	chr8:58055876	NA	0.51	7.8	0.34	4.05e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2040771	0.770	rs2518840	chr22:19255856	A/C	cg02655711	chr22:19163373	SLC25A1	0.48	8.54	0.37	1.92e-16	Metabolite levels (small molecules and protein measures);
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg26668828	chr6:292823	DUSP22	-0.7	-12.2	-0.49	6.91e-30	Menopause (age at onset);
LGG	cis	rs10048158	0.742	rs4791078	chr17:64210014	A/C	cg19474267	chr17:64306194	PRKCA	-0.7	-14.02	-0.55	1.88e-37	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs17445240	1.000	rs17445240	chr2:3703041	C/T	cg16123090	chr2:3699210	NA	-0.81	-8.99	-0.39	6.27e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7474896	0.537	rs1022449	chr10:38279467	T/A	cg00409905	chr10:38381863	ZNF37A	0.45	6.66	0.3	7.6e-11	Obesity (extreme);
LGG	trans	rs656319	0.565	rs73189192	chr8:9910639	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.05	0.31	6.35e-12	Myopia (pathological);
LGG	trans	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg18187862	chr3:45730750	SACM1L	0.57	9.25	0.39	8.5e-19	Primary sclerosing cholangitis;
LGG	cis	rs7945705	0.905	rs7947631	chr11:8844909	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.36	-7.35	-0.32	9.18e-13	Hemoglobin concentration;
LGG	cis	rs9549367	0.789	rs9549365	chr13:113907391	C/T	cg00898013	chr13:113819073	PROZ	0.42	8.53	0.37	2.17e-16	Platelet distribution width;
LGG	cis	rs10884984	0.874	rs11195162	chr10:112279717	G/T	cg18756771	chr10:112261994	DUSP5	0.68	11.29	0.46	2.81e-26	Facial morphology (factor 22);
LGG	cis	rs10779751	0.632	rs2748876	chr1:11134157	T/G	cg08854313	chr1:11322531	MTOR	0.72	14.89	0.57	3e-41	Body mass index;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg00149659	chr3:10157352	C3orf10	0.86	11.06	0.46	2.16e-25	Alzheimer's disease;
LGG	cis	rs7106204	1.000	rs7931691	chr11:24221123	C/A	ch.11.24196551F	chr11:24239977	NA	0.94	12.17	0.49	9.54e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg21058520	chr6:100914733	NA	-0.41	-6.94	-0.31	1.36e-11	Neuroticism;
LGG	cis	rs9557207	0.951	rs12429568	chr13:99985898	A/G	cg24509225	chr13:100037070	UBAC2	0.7	11.6	0.47	1.74e-27	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg16584290	chr5:462447	EXOC3	-0.43	-8.91	-0.38	1.2e-17	Cystic fibrosis severity;
LGG	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.7	0.45	4.91e-24	Morning vs. evening chronotype;
LGG	cis	rs3764563	0.935	rs585680	chr19:15687802	T/G	cg20725493	chr19:15740067	CYP4F8	0.57	6.7	0.3	6.03e-11	Inflammatory biomarkers;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.05	-0.39	4.12e-18	Obesity-related traits;
LGG	cis	rs11096990	0.855	rs3796524	chr4:39195987	A/G	cg24403649	chr4:39172243	NA	-0.47	-7.74	-0.34	6.23e-14	Cognitive function;
LGG	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg13482628	chr17:19912719	NA	-0.54	-10.23	-0.43	2.83e-22	Schizophrenia;
LGG	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg10523679	chr1:76189770	ACADM	-0.42	-6.89	-0.3	1.89e-11	Daytime sleep phenotypes;
LGG	cis	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg19847130	chr8:10466454	RP1L1	-0.32	-6.83	-0.3	2.6e-11	Neuroticism;
LGG	trans	rs9929218	0.954	rs9929479	chr16:68821271	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.15	-0.49	1.13e-29	Colorectal cancer;
LGG	cis	rs7107174	1.000	rs2512549	chr11:77940163	A/G	cg02023728	chr11:77925099	USP35	-0.43	-7.66	-0.34	1.11e-13	Testicular germ cell tumor;
LGG	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg02002194	chr4:3960332	NA	-0.38	-6.79	-0.3	3.38e-11	Retinal vascular caliber;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.43	6.68	0.3	6.78e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg11062466	chr8:58055876	NA	-0.61	-9.81	-0.41	9.3e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg18479299	chr3:125709523	NA	-0.59	-7.46	-0.33	4.26e-13	Blood pressure (smoking interaction);
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg23594656	chr7:65796392	TPST1	0.41	9.21	0.39	1.14e-18	Aortic root size;
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg14346243	chr4:90757452	SNCA	-0.39	-7.82	-0.34	3.63e-14	Dementia with Lewy bodies;
LGG	cis	rs6901004	0.839	rs783086	chr6:111561713	G/A	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.41	-0.33	6.08e-13	Blood metabolite levels;
LGG	cis	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.82e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs897984	0.759	rs13708	chr16:31000809	G/A	cg02466173	chr16:30829666	NA	0.46	8.38	0.36	6.56e-16	Dementia with Lewy bodies;
LGG	cis	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg15596359	chr8:11213517	TDH	-0.4	-8.36	-0.36	7.39e-16	Retinal vascular caliber;
LGG	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg03517284	chr6:25882590	NA	-0.42	-7.0	-0.31	9.31e-12	Iron status biomarkers;
LGG	cis	rs35160687	0.644	rs2113615	chr2:86517602	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.91	0.31	1.64e-11	Night sleep phenotypes;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg08621203	chr6:150244597	RAET1G	0.45	7.53	0.33	2.64e-13	Lung cancer;
LGG	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.12	-0.35	4.14e-15	Coronary artery disease;
LGG	cis	rs7247513	0.790	rs8112964	chr19:12752173	C/T	cg01871581	chr19:12707946	ZNF490	-0.4	-8.04	-0.35	7.52e-15	Bipolar disorder;
LGG	cis	rs9443189	0.813	rs2133191	chr6:76440761	C/T	cg01950844	chr6:76311363	SENP6	-0.53	-7.05	-0.31	6.35e-12	Prostate cancer;
LGG	cis	rs17221829	0.521	rs7952498	chr11:89322065	T/C	cg02982614	chr11:89391479	FOLH1B	-0.37	-8.41	-0.36	5.01e-16	Anxiety in major depressive disorder;
LGG	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	trans	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.35	-0.43	1.05e-22	Mood instability;
LGG	trans	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs9972944	0.756	rs12600343	chr17:63764721	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.86e-16	Total body bone mineral density;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.47e-20	Educational attainment;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.48	-0.4	1.34e-19	Retinal vascular caliber;
LGG	cis	rs4262150	0.960	rs7736377	chr5:152309801	G/A	cg12297329	chr5:152029980	NA	0.59	11.08	0.46	1.82e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg23188684	chr11:67383651	NA	0.51	8.66	0.37	7.79e-17	Mean corpuscular volume;
LGG	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg24848339	chr3:12840334	CAND2	0.43	10.11	0.43	7.65e-22	QRS complex (12-leadsum);
LGG	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg19183879	chr15:85880815	NA	0.5	9.44	0.4	1.88e-19	Coronary artery disease;
LGG	cis	rs6964587	1.000	rs7797834	chr7:91743150	C/T	cg17063962	chr7:91808500	NA	-0.5	-9.17	-0.39	1.55e-18	Breast cancer;
LGG	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs6466055	0.720	rs1204066	chr7:104971987	G/T	cg04380332	chr7:105027541	SRPK2	0.38	7.07	0.31	5.6e-12	Schizophrenia;
LGG	cis	rs7208859	0.573	rs73267873	chr17:29068457	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.88	-0.38	1.44e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72772090	0.539	rs72773986	chr5:96159717	G/A	cg00188032	chr5:96141721	ERAP1	0.53	6.92	0.31	1.56e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.42	-0.44	5.33e-23	Bipolar disorder;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.29e-23	Prudent dietary pattern;
LGG	cis	rs6088580	0.609	rs6059844	chr20:33036482	A/G	cg06115741	chr20:33292138	TP53INP2	0.52	8.57	0.37	1.53e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs834603	0.735	rs11764365	chr7:47447541	G/A	cg23694490	chr7:47445681	TNS3	0.47	13.64	0.54	7.83e-36	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs12210905	0.688	rs72845031	chr6:27535404	C/T	cg15325629	chr6:28072465	NA	0.95	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg27211696	chr2:191398769	TMEM194B	-0.41	-9.66	-0.41	3.09e-20	Pulse pressure;
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.99	-0.31	9.63e-12	Total body bone mineral density;
LGG	cis	rs7789940	1.000	rs7789940	chr7:75951230	A/G	cg10167463	chr7:75959203	YWHAG	-0.49	-8.18	-0.36	2.69e-15	Multiple sclerosis;
LGG	cis	rs763121	0.853	rs2267394	chr22:39101633	T/C	cg06022373	chr22:39101656	GTPBP1	0.91	18.9	0.66	1.89e-59	Menopause (age at onset);
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg15242686	chr22:24348715	GSTTP1	-0.46	-8.5	-0.37	2.54e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg22963979	chr7:1858916	MAD1L1	-0.35	-6.82	-0.3	2.94e-11	Schizophrenia;
LGG	cis	rs4481887	0.927	rs4244181	chr1:248471118	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.73	-0.41	1.76e-20	Common traits (Other);
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg21782813	chr7:2030301	MAD1L1	0.56	14.24	0.55	2.11e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs79911532	0.551	rs74999892	chr7:75756464	T/C	cg15148918	chr7:75625777	STYXL1	-0.7	-7.96	-0.35	1.34e-14	Mononucleosis;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg15971980	chr6:150254442	NA	0.44	7.97	0.35	1.25e-14	Lung cancer;
LGG	cis	rs9894429	1.000	rs12948099	chr17:79600799	C/G	cg10661904	chr17:79619235	PDE6G	-0.42	-8.61	-0.37	1.19e-16	Eye color traits;
LGG	cis	rs73416724	1.000	rs1214762	chr6:43355151	C/T	cg26312998	chr6:43337775	ZNF318	-0.54	-7.75	-0.34	5.84e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35160687	0.862	rs12476706	chr2:86528370	C/T	cg10973622	chr2:86423274	IMMT	0.45	7.53	0.33	2.62e-13	Night sleep phenotypes;
LGG	trans	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-14.72	-0.56	1.68e-40	Chronic sinus infection;
LGG	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg26695010	chr11:65641043	EFEMP2	-0.6	-10.56	-0.44	1.66e-23	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.12	-0.55	6.52e-38	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00743585	chr12:3000370	TULP3	0.48	7.1	0.31	4.78e-12	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.38	0.32	7.58e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.94	-0.38	8.99e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	0.681	rs13329567	chr15:68104367	C/T	cg22044901	chr15:68126292	NA	-0.4	-6.78	-0.3	3.71e-11	Restless legs syndrome;
LGG	cis	rs7737355	0.812	rs251015	chr5:131029683	A/G	cg06307176	chr5:131281290	NA	0.51	8.54	0.37	1.94e-16	Life satisfaction;
LGG	trans	rs7819412	1.000	rs2409722	chr8:11039816	T/G	cg16141378	chr3:129829833	LOC729375	0.4	9.41	0.4	2.39e-19	Triglycerides;
LGG	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg06060754	chr5:176797920	RGS14	0.44	7.4	0.33	6.57e-13	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs11677416	1.000	rs17561	chr2:113537223	C/A	cg27083787	chr2:113543245	IL1A	0.53	9.01	0.39	5.42e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs9360166	chr6:66590974	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.71	-0.3	5.64e-11	Metabolite levels;
LGG	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.91	-0.31	1.61e-11	Blood metabolite levels;
LGG	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg08109568	chr15:31115862	NA	0.47	8.41	0.36	5.08e-16	Huntington's disease progression;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs2239547	0.563	rs9876403	chr3:52916916	C/T	cg11645453	chr3:52864694	ITIH4	0.69	10.7	0.45	4.99e-24	Schizophrenia;
LGG	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg09596252	chr17:78655493	RPTOR	0.44	7.98	0.35	1.17e-14	Obesity;
LGG	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg00383909	chr3:49044727	WDR6	0.45	7.42	0.33	5.58e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7582720	1.000	rs115953525	chr2:203744445	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.46	7.21	0.32	2.36e-12	Bipolar disorder;
LGG	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg13010199	chr12:38710504	ALG10B	-0.63	-13.4	-0.53	8.21e-35	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16269716	chr1:150241781	APH1A	0.44	6.68	0.3	6.74e-11	Gut microbiome composition (summer);
LGG	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg16701003	chr16:89028210	CBFA2T3	0.51	8.09	0.35	5.33e-15	Social autistic-like traits;
LGG	cis	rs11758351	0.778	rs41266801	chr6:26197493	C/A	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg05793240	chr7:2802953	GNA12	0.31	7.51	0.33	2.99e-13	Height;
LGG	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.09	-0.31	5.01e-12	Caffeine consumption;
LGG	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg10661904	chr17:79619235	PDE6G	0.41	8.25	0.36	1.69e-15	Eye color traits;
LGG	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.43	8.48	0.37	3.13e-16	Ovarian reserve;
LGG	trans	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg26384229	chr12:38710491	ALG10B	0.74	14.83	0.57	5.45e-41	Morning vs. evening chronotype;
LGG	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.72e-22	Menopause (age at onset);
LGG	trans	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg24247370	chr13:99142703	STK24	-0.37	-6.88	-0.3	1.95e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg16329650	chr2:213403929	ERBB4	0.52	9.47	0.4	1.42e-19	Symmetrical dimethylarginine levels;
LGG	cis	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.24e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.83	0.3	2.74e-11	Lung cancer;
LGG	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg21385522	chr1:16154831	NA	1.03	19.01	0.66	5.29e-60	Dilated cardiomyopathy;
LGG	cis	rs1018836	0.923	rs13268594	chr8:91588545	G/T	cg16814680	chr8:91681699	NA	-0.82	-15.05	-0.57	5.81e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1847505	0.914	rs7990897	chr13:61524612	G/A	cg25164009	chr13:61490935	NA	-0.61	-9.77	-0.41	1.22e-20	Polychlorinated biphenyl levels;
LGG	cis	rs10895140	0.756	rs1938830	chr11:101507022	A/C	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs9290065	0.519	rs6770180	chr3:160703786	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.7	-0.37	5.68e-17	Kawasaki disease;
LGG	trans	rs11650494	0.908	rs74830554	chr17:47431950	G/A	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.66e-12	Prostate cancer;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg16590910	chr6:42928470	GNMT	0.42	11.97	0.49	5.96e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08219700	chr8:58056026	NA	0.46	7.03	0.31	7.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg20848291	chr7:100343083	ZAN	-0.69	-10.12	-0.43	7.04e-22	Other erythrocyte phenotypes;
LGG	cis	rs4819052	0.851	rs2877019	chr21:46658647	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg19980929	chr12:42632907	YAF2	0.4	8.96	0.38	7.92e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs757278	0.591	rs4730795	chr7:117337912	A/C	cg10524701	chr7:117356490	CTTNBP2	-0.46	-8.23	-0.36	1.91e-15	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs6500395	0.588	rs3785138	chr16:48588614	T/C	cg04672837	chr16:48644449	N4BP1	0.5	8.58	0.37	1.44e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.55	0.44	1.88e-23	Testicular germ cell tumor;
LGG	cis	rs2404618	0.593	rs7829532	chr8:1485190	C/A	cg02903104	chr8:1507517	DLGAP2	0.35	7.22	0.32	2.11e-12	Lung cancer;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.39	-0.5	1.2e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs28551159	1	rs28551159	chr6:26376368	A/G	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Urinary tract infection frequency;
LGG	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.93	-18.37	-0.65	5.33e-57	Homoarginine levels;
LGG	cis	rs457717	0.730	rs461273	chr5:75946138	C/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.31	-6.77	-0.3	4.02e-11	Hearing impairment;
LGG	cis	rs9287719	0.934	rs10201077	chr2:10752426	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs79149102	0.579	rs74247779	chr15:75397131	G/A	cg17294928	chr15:75287854	SCAMP5	-0.74	-7.44	-0.33	4.95e-13	Lung cancer;
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg26150922	chr2:100937072	LONRF2	-0.61	-11.98	-0.49	5.47e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg03351412	chr1:154909251	PMVK	0.58	9.95	0.42	2.82e-21	Prostate cancer;
LGG	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.25e-22	Cognitive ability;
LGG	cis	rs4731207	0.698	rs28409696	chr7:124562515	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	trans	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg00938859	chr5:1591904	SDHAP3	0.93	13.74	0.54	2.93e-36	Breast cancer;
LGG	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.74	0.41	1.62e-20	Menopause (age at onset);
LGG	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-12.45	-0.5	6.95e-31	Vitiligo;
LGG	cis	rs9522267	0.737	rs9522276	chr13:112220208	C/T	cg10483660	chr13:112241077	NA	-0.38	-8.02	-0.35	8.66e-15	Hepatitis;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1532815	0.959	rs16841013	chr1:165174959	C/T	cg03428399	chr1:165174748	LMX1A	0.55	11.32	0.47	2.08e-26	Response to acetaminophen (hepatotoxicity);
LGG	trans	rs28595532	0.841	rs114976553	chr4:119496056	A/G	cg26518628	chr1:97050305	NA	-0.83	-6.82	-0.3	2.85e-11	Cannabis dependence symptom count;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg19847130	chr8:10466454	RP1L1	-0.31	-6.93	-0.31	1.38e-11	Mood instability;
LGG	cis	rs9503598	0.610	rs1328687	chr6:3468377	A/C	cg00476032	chr6:3446245	SLC22A23	0.54	10.98	0.45	4.19e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.659	rs62081315	chr17:56781468	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-8.88	-0.38	1.48e-17	Educational attainment;
LGG	cis	rs9911578	0.935	rs7216698	chr17:57007495	G/A	cg12560992	chr17:57184187	TRIM37	0.83	14.76	0.57	1.11e-40	Intelligence (multi-trait analysis);
LGG	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs4845570	1.000	rs1054479	chr1:151746079	A/T	cg07092448	chr1:151763213	TDRKH	-1.1	-18.22	-0.65	2.57e-56	Coronary artery disease;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg06636001	chr8:8085503	FLJ10661	0.68	14.11	0.55	7.04e-38	Neuroticism;
LGG	cis	rs2153535	0.580	rs9328479	chr6:8519646	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.87e-18	Motion sickness;
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	cis	rs807669	0.807	rs698422	chr22:19205826	A/T	cg02655711	chr22:19163373	SLC25A1	0.64	12.79	0.51	2.82e-32	Metabolite levels;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.27	-0.32	1.54e-12	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs1427223	chr10:60290966	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.09	0.64	1.06e-55	Refractive error;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.4	-0.36	5.68e-16	Personality dimensions;
LGG	cis	rs8077889	0.871	rs17675370	chr17:41900030	T/C	cg26893861	chr17:41843967	DUSP3	0.94	15.79	0.59	3.06e-45	Triglycerides;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg16141378	chr3:129829833	LOC729375	0.42	9.7	0.41	2.21e-20	Triglycerides;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg20368463	chr18:77673604	PQLC1	0.56	7.41	0.33	6.21e-13	Opioid sensitivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03218988	chr11:62341521	EEF1G	0.43	7.24	0.32	1.84e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	6e-13	HDL cholesterol;
LGG	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	8.95	0.38	8.39e-18	Schizophrenia;
LGG	cis	rs2354432	0.599	rs6693667	chr1:146817245	A/T	cg25205988	chr1:146714368	CHD1L	1.15	12.91	0.51	8.73e-33	Mitochondrial DNA levels;
LGG	cis	rs6840360	0.571	rs7695866	chr4:152488110	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.96	-0.35	1.36e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg25703541	chr22:24373054	LOC391322	0.85	13.68	0.54	5.26e-36	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs975722	0.546	rs6966838	chr7:117083580	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	8.34	0.36	8.51e-16	Coronary artery disease;
LGG	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.76	-0.41	1.38e-20	Intraocular pressure;
LGG	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg14154082	chr13:112174009	NA	-0.35	-7.61	-0.33	1.5700000000000001e-13	Menarche (age at onset);
LGG	cis	rs78487399	0.614	rs13422551	chr2:43724682	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.64	-7.04	-0.31	6.95e-12	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs6594713	0.717	rs13174075	chr5:112795352	A/T	cg12552261	chr5:112820674	MCC	0.63	8.61	0.37	1.14e-16	Brain cytoarchitecture;
LGG	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23598886	chr18:12777645	NA	0.73	10.22	0.43	3.06e-22	Inflammatory skin disease;
LGG	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg26384229	chr12:38710491	ALG10B	0.68	12.39	0.5	1.19e-30	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2836974	0.590	rs11911822	chr21:40607843	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-13.21	-0.52	4.75e-34	Cognitive function;
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg13736514	chr6:26305472	NA	-0.5	-10.11	-0.43	7.8e-22	Educational attainment;
LGG	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg06623630	chr22:50017776	C22orf34	-0.5	-9.76	-0.41	1.42e-20	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg12033943	chr19:37341734	ZNF345	0.4	6.69	0.3	6.35e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs143536437	1	rs143536437	chr15:30898332	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.97	-15.71	-0.59	6.71e-45	Epilepsy (remission after treatment);
LGG	cis	rs929354	0.772	rs6459738	chr7:156998532	T/G	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs7000551	0.689	rs7007673	chr8:22316687	G/T	cg12081754	chr8:22256438	SLC39A14	0.68	13.33	0.53	1.52e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	trans	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg18187862	chr3:45730750	SACM1L	0.66	10.89	0.45	9.98e-25	Primary sclerosing cholangitis;
LGG	cis	rs950776	0.518	rs8053	chr15:78841220	T/C	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.72	-0.3	5.33e-11	Sudden cardiac arrest;
LGG	cis	rs1466045	0.641	rs10833333	chr11:3162183	T/C	cg01418188	chr11:3145609	OSBPL5	0.29	7.0	0.31	8.96e-12	Cisplatin-induced ototoxicity;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25785477	chr4:130014987	SCLT1;C4orf33	-0.49	-7.23	-0.32	2.06e-12	Systemic lupus erythematosus;
LGG	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg06028605	chr16:24865363	SLC5A11	0.51	8.49	0.37	2.93e-16	Intelligence (multi-trait analysis);
LGG	trans	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.07	0.39	3.42e-18	Resting heart rate;
LGG	cis	rs9790314	1.000	rs460508	chr3:161091089	C/G	cg03342759	chr3:160939853	NMD3	0.61	10.43	0.44	5e-23	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs4319547	0.695	rs10773103	chr12:122856532	A/G	cg23029597	chr12:123009494	RSRC2	0.94	17.35	0.63	2.6e-52	Body mass index;
LGG	trans	rs11098499	0.708	rs10005237	chr4:120237897	T/C	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.59	10.23	0.43	2.87e-22	Birth weight;
LGG	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.32	-0.47	2.14e-26	Coronary artery disease;
LGG	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03517284	chr6:25882590	NA	0.52	9.72	0.41	1.84e-20	Blood metabolite levels;
LGG	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12893428	chr3:195717962	SDHAP1	0.48	10.06	0.42	1.16e-21	Pancreatic cancer;
LGG	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.54	0.37	1.98e-16	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg15394860	chr11:2017084	H19	0.6	12.72	0.51	5.12e-32	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg22467129	chr15:76604101	ETFA	0.42	7.06	0.31	6.23e-12	Blood metabolite levels;
LGG	cis	rs4704846	1.000	rs57297671	chr5:156507427	T/C	cg12943317	chr5:156479607	HAVCR1	-0.62	-7.64	-0.33	1.27e-13	Blood protein levels;
LGG	cis	rs6840360	0.557	rs1143036	chr4:152329404	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	8.1e-12	Intelligence (multi-trait analysis);
LGG	cis	rs56775891	1.000	rs4799088	chr18:77573548	A/G	cg13263691	chr18:77568018	NA	0.82	14.68	0.56	2.42e-40	Schizophrenia;
LGG	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs17221829	0.733	rs7945304	chr11:89372524	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.16	-0.39	1.69e-18	Anxiety in major depressive disorder;
LGG	cis	rs7818345	0.967	rs4554480	chr8:19284072	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.75	0.3	4.36e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs11122272	0.735	rs2011357	chr1:231480208	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.15	-0.43	5.39e-22	Hemoglobin concentration;
LGG	cis	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg07460842	chr6:66804631	NA	-0.46	-7.79	-0.34	4.58e-14	Blood trace element (Cu levels);
LGG	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg05623727	chr3:50126028	RBM5	-0.4	-8.48	-0.37	3.04e-16	Menarche (age at onset);
LGG	cis	rs6547631	0.622	rs10180547	chr2:85926305	G/A	cg19805943	chr2:85933069	NA	0.32	6.71	0.3	5.88e-11	Blood protein levels;
LGG	cis	rs9486715	0.830	rs1475748	chr6:97034143	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.43	-0.61	4.19e-48	Headache;
LGG	cis	rs6684428	0.536	rs6588591	chr1:56402956	A/G	cg11651538	chr1:56320950	NA	-0.47	-8.48	-0.37	3.16e-16	Airflow obstruction;
LGG	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg14228332	chr4:119757509	SEC24D	0.99	10.14	0.43	6.09e-22	Cannabis dependence symptom count;
LGG	trans	rs12517041	1.000	rs1428629	chr5:23311989	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.75	-0.48	4.27e-28	Calcium levels;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.56e-21	Prudent dietary pattern;
LGG	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg02836325	chr17:76403955	PGS1	-0.71	-14.26	-0.55	1.74e-38	HDL cholesterol levels;
LGG	cis	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg26384229	chr12:38710491	ALG10B	-0.7	-13.35	-0.53	1.27e-34	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.820	rs6829903	chr4:120506884	C/T	cg09307838	chr4:120376055	NA	0.8	13.36	0.53	1.17e-34	Corneal astigmatism;
LGG	cis	rs9964724	0.767	rs7233417	chr18:35200180	C/T	cg27332583	chr18:35150602	NA	0.36	7.64	0.33	1.29e-13	Educational attainment (years of education);
LGG	trans	rs8002861	0.626	rs9533634	chr13:44397815	T/C	cg12856521	chr11:46389249	DGKZ	-0.48	-8.67	-0.37	7.25e-17	Leprosy;
LGG	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg08250081	chr4:10125330	NA	0.4	7.81	0.34	3.77e-14	Bone mineral density;
LGG	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg19847130	chr8:10466454	RP1L1	0.32	7.01	0.31	8.36e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4660214	0.666	rs6698791	chr1:39934776	A/T	cg18385671	chr1:39797026	MACF1	-0.49	-9.6	-0.41	4.87e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01148728	chr11:117198424	CEP164	0.39	7.09	0.31	5.14e-12	Obesity-related traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22250145	chr11:72853119	FCHSD2	0.62	7.07	0.31	5.76e-12	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.655	rs35764203	chr4:185639078	C/A	cg04058563	chr4:185651563	MLF1IP	1.04	22.77	0.73	1.54e-77	Blood protein levels;
LGG	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg07005078	chr4:17578674	LAP3	0.37	6.88	0.3	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.2	0.32	2.4e-12	Educational attainment;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12143110	chr17:79146738	LOC388428	0.45	7.99	0.35	1.1e-14	Menarche (age at onset);
LGG	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg23306229	chr2:178417860	TTC30B	0.6	7.57	0.33	1.97e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7917772	0.536	rs12357172	chr10:104388549	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.7	12.3	0.5	2.85e-30	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg21153622	chr11:89784906	NA	-0.6	-6.71	-0.3	5.66e-11	Trans fatty acid levels;
LGG	cis	rs7945705	0.967	rs10840141	chr11:8902218	T/C	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.42	0.33	5.74e-13	Hemoglobin concentration;
LGG	trans	rs7939886	0.920	rs10896157	chr11:56037621	T/G	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg27541892	chr1:1571801	CDK11B	-0.61	-10.76	-0.45	3.07e-24	Body mass index;
LGG	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg00684032	chr4:1343700	KIAA1530	0.39	7.27	0.32	1.59e-12	Obesity-related traits;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg01341218	chr17:43662625	NA	0.96	16.79	0.62	8.99e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35771425	1.000	rs7554421	chr1:211592087	G/C	cg10512769	chr1:211675356	NA	-0.7	-11.48	-0.47	4.93e-27	Educational attainment (years of education);
LGG	trans	rs56346965	1.000	rs2192008	chr2:191545147	C/T	cg23802518	chr10:80827482	ZMIZ1;LOC283050	-0.42	-6.65	-0.3	8.25e-11	Bone mineral density (Ward's triangle area);
LGG	trans	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.95	0.45	5.49e-25	Corneal astigmatism;
LGG	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.36e-12	Vitiligo;
LGG	cis	rs959260	0.623	rs2164244	chr17:73325244	C/T	cg14668889	chr17:73230827	NUP85	-0.52	-8.75	-0.38	3.99e-17	Systemic lupus erythematosus;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.96	0.49	6.59e-29	Tonsillectomy;
LGG	trans	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs763121	0.853	rs9610986	chr22:39025277	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	17.8	0.64	2.18e-54	Menopause (age at onset);
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg19717773	chr7:2847554	GNA12	-0.31	-6.65	-0.3	8.22e-11	Height;
LGG	cis	rs11583043	0.575	rs56403901	chr1:101586047	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.47	7.76	0.34	5.32e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs936229	0.768	rs936226	chr15:75069282	C/T	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.69	-0.41	2.45e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7523273	0.606	rs1830764	chr1:207917052	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.85	0.48	1.74e-28	Schizophrenia;
LGG	cis	rs9486719	1.000	rs2472887	chr6:96865437	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs41271473	0.718	rs4500282	chr1:228878375	T/A	cg16512390	chr1:228756714	NA	0.44	7.03	0.31	7.65e-12	Chronic lymphocytic leukemia;
LGG	cis	rs17767392	0.670	rs61989245	chr14:71719976	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.33	-7.42	-0.33	5.53e-13	Mitral valve prolapse;
LGG	cis	rs35160687	0.623	rs11689971	chr2:86474471	A/G	cg10973622	chr2:86423274	IMMT	-0.42	-7.41	-0.33	6.08e-13	Night sleep phenotypes;
LGG	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.17e-13	Refractive error;
LGG	trans	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg00938859	chr5:1591904	SDHAP3	0.8	7.74	0.34	6.3e-14	Breast cancer;
LGG	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs2415984	0.579	rs12185007	chr14:46976217	G/A	cg14871534	chr14:47121158	RPL10L	-0.56	-9.81	-0.41	9.16e-21	Number of children ever born;
LGG	cis	rs11650494	0.710	rs74619404	chr17:47484445	C/T	cg08112188	chr17:47440006	ZNF652	1.19	12.66	0.51	9.16e-32	Prostate cancer;
LGG	cis	rs9487051	0.802	rs9487039	chr6:109610163	A/T	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs10078	0.898	rs2241598	chr5:438564	C/T	cg07599136	chr5:415885	AHRR	-0.57	-9.08	-0.39	3.1e-18	Fat distribution (HIV);
LGG	cis	rs9513627	0.920	rs7984052	chr13:100177225	G/A	cg25919922	chr13:100150906	NA	0.73	7.75	0.34	6.03e-14	Obesity-related traits;
LGG	cis	rs1018836	0.923	rs10808615	chr8:91569704	A/T	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	5.12e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.37	0.43	8.62e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg12924262	chr12:102091054	CHPT1	0.66	13.27	0.52	2.85e-34	Blood protein levels;
LGG	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg10253484	chr15:75165896	SCAMP2	-0.42	-7.02	-0.31	8.19e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1190596	0.830	rs2298877	chr14:102548224	T/C	cg23904247	chr14:102554826	HSP90AA1	-0.26	-6.89	-0.3	1.85e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs11650494	0.908	rs117853079	chr17:47421593	G/C	cg08112188	chr17:47440006	ZNF652	1.33	15.68	0.59	9.63e-45	Prostate cancer;
LGG	cis	rs7202877	0.706	rs247438	chr16:75432649	C/G	cg03315344	chr16:75512273	CHST6	-0.52	-7.05	-0.31	6.61e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs2797369	0.656	rs668932	chr6:101348050	A/G	cg27451362	chr6:101846650	GRIK2	0.76	10.51	0.44	2.49e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs4363385	0.782	rs4845515	chr1:153003871	G/T	cg13444842	chr1:152974279	SPRR3	-0.4	-8.23	-0.36	1.91e-15	Inflammatory skin disease;
LGG	cis	rs4664308	0.710	rs13001911	chr2:161020703	G/C	cg03641300	chr2:160917029	PLA2R1	-0.72	-13.73	-0.54	2.98e-36	Idiopathic membranous nephropathy;
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg22875332	chr1:76189707	ACADM	0.54	8.11	0.35	4.44e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg11366901	chr6:160182831	ACAT2	0.99	15.22	0.58	9.98e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs57590327	0.504	rs11712243	chr3:81840674	T/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.06	-0.35	6.56e-15	Extraversion;
LGG	cis	rs3096299	0.685	rs4329923	chr16:89560178	C/T	cg02187348	chr16:89574699	SPG7	0.63	10.53	0.44	2.12e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs854765	0.619	rs6502636	chr17:17983817	A/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.93	-0.51	7.5e-33	Total body bone mineral density;
LGG	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg03929089	chr4:120376271	NA	-0.44	-7.09	-0.31	5.2e-12	HDL cholesterol;
LGG	cis	rs10214930	0.671	rs12530626	chr7:27689808	A/T	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14664575	chr19:40476624	PSMC4	0.45	7.28	0.32	1.47e-12	Cognitive performance;
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs55665837	1.000	rs34382046	chr11:14451318	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.72	-0.38	4.94e-17	Vitamin D levels;
LGG	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg09085632	chr11:111637200	PPP2R1B	1.17	25.96	0.77	2.2e-92	Primary sclerosing cholangitis;
LGG	cis	rs7666738	0.830	rs7661264	chr4:98961574	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg01270228	chr10:1369114	ADARB2	0.51	9.49	0.4	1.22e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg16507663	chr6:150244633	RAET1G	0.45	8.52	0.37	2.21e-16	Lung cancer;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg06916706	chr16:4465613	CORO7	-0.71	-12.19	-0.49	7.68e-30	Schizophrenia;
LGG	cis	rs9341808	0.718	rs1324123	chr6:80932894	G/A	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.81e-14	Sitting height ratio;
LGG	cis	rs4472734	0.813	rs4394613	chr1:214622818	A/G	cg00063699	chr1:214624242	PTPN14	-0.42	-9.06	-0.39	3.68e-18	Height;
LGG	cis	rs36093844	0.800	rs76464398	chr11:85583898	C/T	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2587949	0.593	rs795299	chr3:4169219	G/C	cg16519197	chr3:4211558	NA	-0.36	-7.21	-0.32	2.28e-12	Periodontitis (DPAL);
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.84	0.42	6.94e-21	Coronary artery disease;
LGG	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg09021430	chr5:549028	NA	-0.72	-10.11	-0.43	7.65e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs6901004	0.596	rs411604	chr6:111565847	A/G	cg15721981	chr6:111408429	SLC16A10	-0.54	-9.21	-0.39	1.16e-18	Blood metabolite levels;
LGG	cis	rs7737355	0.617	rs245800	chr5:130677591	T/A	cg06307176	chr5:131281290	NA	-0.48	-8.02	-0.35	8.68e-15	Life satisfaction;
LGG	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.68	-0.3	6.97e-11	Blood metabolite levels;
LGG	cis	rs1697139	0.604	rs874550	chr5:66530945	C/T	cg11553311	chr5:66541588	NA	-0.43	-9.8	-0.41	9.64e-21	Breast cancer;
LGG	trans	rs11976180	1.000	rs1533266	chr7:143766714	G/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.84	-0.3	2.46e-11	Obesity-related traits;
LGG	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	13.94	0.54	4.1e-37	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00149659	chr3:10157352	C3orf10	0.86	11.06	0.46	2.16e-25	Alzheimer's disease;
LGG	cis	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg24110177	chr3:50126178	RBM5	0.57	10.52	0.44	2.27e-23	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg13010199	chr12:38710504	ALG10B	0.75	15.95	0.6	5.89e-46	Heart rate;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg20887711	chr4:1340912	KIAA1530	0.51	9.37	0.4	3.18e-19	Obesity-related traits;
LGG	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.75	-0.41	1.52e-20	Common traits (Other);
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.18e-12	Menopause (age at onset);
LGG	cis	rs600231	0.508	rs17146964	chr11:65249145	C/T	cg17120908	chr11:65337727	SSSCA1	0.59	8.65	0.37	8.55e-17	Bone mineral density;
LGG	cis	rs1023500	0.551	rs133355	chr22:42440285	G/A	cg05082376	chr22:42548792	NA	-0.36	-7.33	-0.32	1.03e-12	Schizophrenia;
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.94	0.42	3e-21	Tonsillectomy;
LGG	cis	rs7274811	0.744	rs6141962	chr20:32110312	T/C	cg21523528	chr20:32077966	CBFA2T2	0.4	6.67	0.3	7.5e-11	Height;
LGG	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.71	-0.3	5.86e-11	Educational attainment;
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg10802521	chr3:52805072	NEK4	0.42	7.17	0.32	3.02e-12	Bipolar disorder;
LGG	cis	rs12410462	0.581	rs7543931	chr1:227550976	A/T	cg04117972	chr1:227635322	NA	0.56	9.39	0.4	2.82e-19	Major depressive disorder;
LGG	cis	rs600231	0.542	rs10896010	chr11:65246220	C/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.65	-0.37	8.55e-17	Bone mineral density;
LGG	cis	rs9462027	0.583	rs7755982	chr6:34715297	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg13147721	chr7:65941812	NA	0.83	10.06	0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs2836950	0.545	rs2836956	chr21:40623018	C/G	cg17971929	chr21:40555470	PSMG1	0.54	9.27	0.4	7.24e-19	Menarche (age at onset);
LGG	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg08297393	chr2:100937505	LONRF2	0.56	10.46	0.44	3.83e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	0.833	rs10793317	chr11:78212011	G/A	cg02023728	chr11:77925099	USP35	-0.38	-6.76	-0.3	4.25e-11	Alzheimer's disease (survival time);
LGG	cis	rs1018836	0.773	rs7837109	chr8:91639178	C/T	cg16814680	chr8:91681699	NA	-0.84	-16.16	-0.6	6.71e-47	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg05091796	chr16:4465799	CORO7	-0.75	-12.49	-0.5	4.66e-31	Schizophrenia;
LGG	cis	rs208520	0.874	rs208518	chr6:66948501	C/G	cg07460842	chr6:66804631	NA	0.92	15.92	0.59	8.26e-46	Exhaled nitric oxide output;
LGG	cis	rs7937890	0.559	rs2575825	chr11:14472096	T/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.89	-0.34	2.15e-14	Mitochondrial DNA levels;
LGG	cis	rs10743315	0.643	rs58663385	chr12:19337070	T/C	cg02471346	chr12:19282374	PLEKHA5	0.61	6.83	0.3	2.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.04e-11	Bone mineral density;
LGG	cis	rs6500395	0.775	rs7198145	chr16:48666500	A/C	cg04672837	chr16:48644449	N4BP1	0.51	8.62	0.37	1.08e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.94	0.31	1.31e-11	Resting heart rate;
LGG	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs11966931	0.744	rs11964352	chr6:108137600	T/C	cg04749840	chr6:108095067	SCML4	0.46	9.15	0.39	1.81e-18	Neutrophil percentage of white cells;
LGG	trans	rs7395662	0.548	rs4882000	chr11:48546496	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.86	-0.38	1.73e-17	HDL cholesterol;
LGG	cis	rs11098499	0.657	rs9996569	chr4:120299004	G/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg02002194	chr4:3960332	NA	0.47	8.38	0.36	6.29e-16	Retinal vascular caliber;
LGG	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg20498895	chr3:12883366	SNORA7A;RPL32	-0.4	-6.69	-0.3	6.56e-11	Corneal astigmatism;
LGG	cis	rs877282	0.898	rs12354872	chr10:763362	G/A	cg17470449	chr10:769945	NA	0.55	6.72	0.3	5.4e-11	Uric acid levels;
LGG	cis	rs9487094	0.922	rs2236582	chr6:109765818	C/G	cg01125227	chr6:109776195	MICAL1	-0.55	-9.23	-0.39	9.72e-19	Height;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg01673284	chr16:4527211	HMOX2	-0.37	-7.34	-0.32	9.73e-13	Schizophrenia;
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.63	11.87	0.48	1.52e-28	Total body bone mineral density;
LGG	cis	rs6087990	0.806	rs1474738	chr20:31380309	G/A	cg13636640	chr20:31349939	DNMT3B	0.93	19.71	0.68	3.21e-63	Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7107174	1.000	rs10793300	chr11:78019582	T/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs62025270	0.632	rs7181796	chr15:86233009	C/G	cg25843651	chr15:86329602	KLHL25	0.58	8.7	0.37	5.77e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs9308731	1.000	rs6750599	chr2:111893869	A/T	cg19992207	chr2:111874495	ACOXL	0.38	7.14	0.32	3.58e-12	Chronic lymphocytic leukemia;
LGG	cis	rs4595586	0.756	rs7137139	chr12:39364013	C/T	cg26384229	chr12:38710491	ALG10B	0.5	9.36	0.4	3.46e-19	Morning vs. evening chronotype;
LGG	cis	rs2777491	0.574	rs11635906	chr15:41779260	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.26	-28.0	-0.79	1.1e-101	Ulcerative colitis;
LGG	cis	rs9815354	0.904	rs6776724	chr3:41841270	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.29	0.36	1.24e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs295137	0.836	rs10804097	chr2:201104924	A/T	cg17644776	chr2:200775616	C2orf69	0.5	8.36	0.36	7.32e-16	Asthma (bronchodilator response);
LGG	cis	rs13082711	0.911	rs11719386	chr3:27505636	G/C	cg02860705	chr3:27208620	NA	0.73	13.24	0.52	3.72e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.56	0.41	6.92e-20	Bipolar disorder;
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg26516362	chr5:178986906	RUFY1	-0.47	-8.35	-0.36	7.75e-16	Lung cancer;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg18402987	chr7:1209562	NA	0.39	7.0	0.31	8.83e-12	Longevity;Endometriosis;
LGG	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg15268244	chr15:77196840	NA	0.44	9.81	0.41	9.51e-21	Blood metabolite levels;
LGG	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg25811766	chr13:21894605	NA	-0.55	-7.33	-0.32	1.03e-12	White matter hyperintensity burden;
LGG	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg06115741	chr20:33292138	TP53INP2	0.5	8.24	0.36	1.85e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2018055	1.000	rs13207962	chr6:117817099	G/A	cg14611402	chr6:117803162	DCBLD1	0.29	7.99	0.35	1.06e-14	Diastolic blood pressure;
LGG	cis	rs593982	0.843	rs565267	chr11:65473597	T/C	cg08755490	chr11:65554678	OVOL1	0.72	8.71	0.38	5.51e-17	Atopic dermatitis;
LGG	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.2	0.7	3.22e-70	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.659	rs9607815	chr22:41950671	A/T	cg06634786	chr22:41940651	POLR3H	-0.79	-12.68	-0.51	8.11e-32	Vitiligo;
LGG	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg02891314	chr5:179741120	GFPT2	-0.63	-11.67	-0.48	8.87e-28	Height;
LGG	cis	rs4845570	1.000	rs17568246	chr1:151736456	A/G	cg07092448	chr1:151763213	TDRKH	-1.08	-15.82	-0.59	2.24e-45	Coronary artery disease;
LGG	cis	rs4642101	0.618	rs11128614	chr3:12819212	A/G	cg05775895	chr3:12838266	CAND2	0.77	14.84	0.57	5.14e-41	QRS complex (12-leadsum);
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg04553112	chr3:125709451	NA	-0.55	-7.0	-0.31	9.03e-12	Blood pressure (smoking interaction);
LGG	cis	rs6489882	0.867	rs4766675	chr12:113365453	A/T	cg25319449	chr12:113376135	OAS3	-0.43	-7.42	-0.33	5.68e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7223966	1.000	rs6504182	chr17:61823672	T/C	cg05941027	chr17:61774174	LIMD2	0.34	8.76	0.38	3.74e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13096357	0.520	rs17080319	chr3:48732480	T/C	cg00383909	chr3:49044727	WDR6	0.92	11.49	0.47	4.54e-27	Cognitive ability (multi-trait analysis);
LGG	cis	rs295140	1.000	rs1431766	chr2:201191034	A/G	cg25099087	chr2:201172481	SPATS2L	0.27	6.79	0.3	3.37e-11	QT interval;
LGG	cis	rs2249694	0.920	rs1536826	chr10:135357239	A/C	cg20169779	chr10:135381914	SYCE1	0.5	7.46	0.33	4.33e-13	Obesity-related traits;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg06028808	chr11:68637592	NA	0.71	12.09	0.49	1.97e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23248424	chr5:179741104	GFPT2	-0.59	-10.96	-0.45	5.18e-25	Height;
LGG	cis	rs7267979	1.000	rs6050561	chr20:25334855	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.41	-0.44	5.95e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10802521	chr3:52805072	NEK4	-0.41	-7.12	-0.31	4.13e-12	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23187205	chr6:109416245	SESN1;C6orf182	0.49	7.63	0.33	1.31e-13	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg16141378	chr3:129829833	LOC729375	0.4	9.12	0.39	2.26e-18	Retinal vascular caliber;
LGG	cis	rs6430585	0.583	rs7561565	chr2:136640787	A/C	cg07169764	chr2:136633963	MCM6	1.28	26.65	0.78	1.63e-95	Corneal structure;
LGG	cis	rs4595586	0.545	rs1839402	chr12:39371615	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.77	0.45	2.67e-24	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.76	-0.38	3.57e-17	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs7802007	chr7:124638034	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.91	-0.35	1.87e-14	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg01620082	chr3:125678407	NA	-0.65	-7.16	-0.32	3.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg08645402	chr16:4508243	NA	0.5	9.53	0.4	9.15e-20	Schizophrenia;
LGG	cis	rs4713118	0.621	rs4713134	chr6:28034121	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.7	-0.3	6.1e-11	Parkinson's disease;
LGG	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.91	-0.38	1.2e-17	Aortic root size;
LGG	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg12463550	chr7:65579703	CRCP	0.73	8.33	0.36	9.56e-16	Diabetic kidney disease;
LGG	cis	rs12282928	1.000	rs10838845	chr11:48280299	C/T	cg26585981	chr11:48327164	OR4S1	0.43	6.95	0.31	1.24e-11	Migraine - clinic-based;
LGG	cis	rs2629540	0.781	rs2293064	chr10:126396511	C/G	cg08799069	chr10:126477246	METTL10	0.61	11.95	0.49	6.83e-29	Cocaine dependence;
LGG	trans	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.44	0.33	4.78e-13	Joint mobility (Beighton score);
LGG	cis	rs6121246	0.559	rs10439607	chr20:30258541	G/A	cg13852791	chr20:30311386	BCL2L1	0.91	17.27	0.63	6.21e-52	Mean corpuscular hemoglobin;
LGG	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg05775895	chr3:12838266	CAND2	0.66	11.9	0.48	1.11e-28	QRS complex (12-leadsum);
LGG	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg11366901	chr6:160182831	ACAT2	1.08	16.69	0.61	2.52e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg01472538	chr16:58549086	SETD6	0.98	8.84	0.38	2.07e-17	Schizophrenia;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg06873352	chr17:61820015	STRADA	-0.57	-9.85	-0.42	6.66e-21	Prudent dietary pattern;
LGG	trans	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.31	-0.55	1e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg15971980	chr6:150254442	NA	0.45	8.39	0.36	6.1e-16	Lung cancer;
LGG	cis	rs4262150	0.846	rs111658964	chr5:152190325	T/C	cg12297329	chr5:152029980	NA	-0.69	-13.35	-0.53	1.32e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs9515201	0.740	rs9555695	chr13:111033125	C/T	cg06243866	chr13:111019493	COL4A2	-0.64	-12.34	-0.5	1.92e-30	White matter hyperintensity burden;
LGG	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12229367	chr17:55822335	NA	0.45	8.6	0.37	1.28e-16	Schizophrenia;
LGG	cis	rs755249	0.567	rs67020650	chr1:39668015	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.26	0.32	1.68e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3087591	0.960	rs2952979	chr17:29474298	T/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.5	0.56	1.44e-39	Hip circumference;
LGG	cis	rs514406	0.861	rs2477741	chr1:53265278	A/G	cg24675658	chr1:53192096	ZYG11B	0.48	9.66	0.41	3.15e-20	Monocyte count;
LGG	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.23	0.36	1.87e-15	Colorectal cancer;
LGG	cis	rs798554	0.567	rs1182190	chr7:2869391	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-7.45	-0.33	4.68e-13	Height;
LGG	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg17150306	chr7:855575	UNC84A	-0.34	-6.97	-0.31	1.07e-11	Perceived unattractiveness to mosquitoes;
LGG	cis	rs10504073	0.626	rs6472220	chr8:50008477	C/A	cg00325661	chr8:49890786	NA	0.69	13.45	0.53	4.6e-35	Blood metabolite ratios;
LGG	cis	rs208520	0.690	rs207108	chr6:66794096	T/C	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg19635926	chr16:89946313	TCF25	0.76	7.36	0.32	8.19e-13	Skin colour saturation;
LGG	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg02023728	chr11:77925099	USP35	0.47	8.36	0.36	7.28e-16	Testicular germ cell tumor;
LGG	cis	rs16854884	0.710	rs1867607	chr3:143809274	T/C	cg06585982	chr3:143692056	C3orf58	0.51	8.3	0.36	1.11e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs944722	0.749	rs8081248	chr17:26081964	A/G	cg07704981	chr17:26127537	NOS2	-0.46	-8.1	-0.35	4.93e-15	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg22907277	chr7:1156413	C7orf50	0.61	10.9	0.45	9.13e-25	Longevity;Endometriosis;
LGG	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg03342759	chr3:160939853	NMD3	-0.72	-12.01	-0.49	4.04e-29	Parkinson's disease;
LGG	cis	rs11096990	0.855	rs2711934	chr4:39157874	C/T	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg17691542	chr6:26056736	HIST1H1C	0.47	8.38	0.36	6.45e-16	Height;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	cis	rs977987	0.872	rs1559339	chr16:75318646	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.1	0.42	8.35e-22	Dupuytren's disease;
LGG	cis	rs10504073	0.584	rs4873092	chr8:49974053	T/C	cg00325661	chr8:49890786	NA	0.76	14.83	0.57	5.51e-41	Blood metabolite ratios;
LGG	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg03162506	chr22:38580953	NA	0.4	9.97	0.42	2.35e-21	Cutaneous nevi;
LGG	cis	rs751728	0.544	rs2281820	chr6:33768897	A/G	cg07519485	chr6:33762594	MLN	-0.34	-7.52	-0.33	2.85e-13	Crohn's disease;
LGG	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.66	11.7	0.48	7.26e-28	Blood protein levels;
LGG	cis	rs7572733	0.555	rs7561950	chr2:198754244	C/T	cg00792783	chr2:198669748	PLCL1	0.68	11.13	0.46	1.15e-25	Dermatomyositis;
LGG	cis	rs10193935	0.901	rs10175378	chr2:42456267	A/C	cg27598129	chr2:42591480	NA	-0.63	-9.43	-0.4	2.03e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg08999081	chr20:33150536	PIGU	0.44	11.14	0.46	1.03e-25	Coronary artery disease;
LGG	trans	rs4843747	0.573	rs7499959	chr16:88110422	C/G	cg26811252	chr16:29126840	RRN3P2	0.55	8.73	0.38	4.6e-17	Menopause (age at onset);
LGG	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.7	0.37	5.99e-17	Neuroticism;
LGG	cis	rs7584330	0.704	rs7602387	chr2:238356795	A/G	cg16989719	chr2:238392110	NA	-0.32	-6.72	-0.3	5.39e-11	Prostate cancer;
LGG	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.18	-0.52	6.54e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg05941027	chr17:61774174	LIMD2	-0.35	-8.96	-0.38	7.91e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	trans	rs2562456	0.754	rs62109226	chr19:21536913	T/C	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg15596359	chr8:11213517	TDH	-0.34	-7.14	-0.32	3.54e-12	Retinal vascular caliber;
LGG	cis	rs9595066	0.627	rs4942287	chr13:44734696	C/T	cg04068111	chr13:44716778	NA	0.51	7.78	0.34	4.77e-14	Schizophrenia;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg18350739	chr11:68623251	NA	-0.86	-22.31	-0.72	2.11e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs807669	0.548	rs5746685	chr22:19192596	C/G	cg02655711	chr22:19163373	SLC25A1	-0.46	-8.28	-0.36	1.36e-15	Metabolite levels;
LGG	cis	rs2280018	0.963	rs11075255	chr16:15166232	A/G	cg27102117	chr16:15229624	NA	0.5	9.67	0.41	2.92e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6740322	1.000	rs6756736	chr2:43558743	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.76	-0.38	3.72e-17	Coronary artery disease;
LGG	cis	rs151234	0.741	rs151227	chr16:28549508	C/T	cg01378222	chr16:28622494	SULT1A1	-0.7	-9.75	-0.41	1.48e-20	Platelet distribution width;
LGG	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg14784868	chr12:69753453	YEATS4	0.9	20.08	0.68	5.59e-65	Blood protein levels;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06873352	chr17:61820015	STRADA	0.72	13.45	0.53	4.86e-35	Prudent dietary pattern;
LGG	cis	rs7216064	0.734	rs12942774	chr17:65967562	A/G	cg12091567	chr17:66097778	LOC651250	0.48	7.64	0.33	1.27e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00046560	chr15:101835624	SNRPA1	0.38	6.73	0.3	4.99e-11	Obesity-related traits;
LGG	cis	rs3760775	1.000	rs3760775	chr19:5841356	A/C	cg25387410	chr19:5844109	FUT3	0.62	6.87	0.3	2.04e-11	Vitamin B12 levels;Elevated serum carcinoembryonic antigen levels;Tumor biomarkers;
LGG	cis	rs67311347	0.868	rs10865895	chr3:40378677	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.36	-0.69	2.87e-66	Renal cell carcinoma;
LGG	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.57	-0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9942416	0.660	rs2047059	chr5:75008193	T/C	cg19683494	chr5:74908142	NA	0.45	7.16	0.32	3.16e-12	Age-related disease endophenotypes;
LGG	cis	rs3741151	0.686	rs11823913	chr11:73141627	C/G	cg17517138	chr11:73019481	ARHGEF17	0.77	8.28	0.36	1.33e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs5758511	0.773	rs10154700	chr22:42365073	G/T	cg15128208	chr22:42549153	NA	0.58	9.11	0.39	2.55e-18	Birth weight;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02463426	chr19:16683387	SLC35E1	0.46	7.52	0.33	2.96e-13	Cognitive performance;
LGG	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg06027949	chr8:82754900	SNX16	-0.49	-7.0	-0.31	9.28e-12	Diastolic blood pressure;
LGG	cis	rs13102973	0.867	rs4543187	chr4:135906850	G/A	cg14419869	chr4:135874104	NA	0.45	8.23	0.36	1.92e-15	Subjective well-being;
LGG	cis	rs6429082	0.518	rs1812350	chr1:235659920	C/A	cg26050004	chr1:235667680	B3GALNT2	0.84	17.26	0.63	6.35e-52	Adiposity;
LGG	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937890	0.559	rs10766184	chr11:14542577	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.87	-0.34	2.52e-14	Mitochondrial DNA levels;
LGG	cis	rs7091068	0.616	rs4322326	chr10:95483382	A/T	cg20715218	chr10:95462985	C10orf4	0.71	11.13	0.46	1.16e-25	Urinary tract infection frequency;
LGG	cis	rs11250098	0.548	rs7843470	chr8:10784492	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.43	-0.33	5.17e-13	Morning vs. evening chronotype;
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs503734	1.000	rs348866	chr3:100992385	C/T	cg27318481	chr3:100970896	IMPG2	-0.36	-7.78	-0.34	4.93e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg07541023	chr7:19748670	TWISTNB	0.47	7.4	0.33	6.47e-13	Thyroid stimulating hormone;
LGG	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg23740940	chr11:68924746	NA	0.43	6.95	0.31	1.29e-11	Blond vs. brown hair color;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.48	-0.44	3.2e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg22618164	chr12:122356400	WDR66	0.33	9.78	0.41	1.2e-20	Mean corpuscular volume;
LGG	cis	rs9287719	0.934	rs6432111	chr2:10744620	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs3960554	0.597	rs3807880	chr7:75864208	T/C	cg19862616	chr7:65841803	NCRNA00174	0.63	10.21	0.43	3.29e-22	Eotaxin levels;
LGG	cis	rs6087990	0.871	rs4911252	chr20:31330115	A/G	cg13636640	chr20:31349939	DNMT3B	-0.9	-19.09	-0.66	2.26e-60	Ulcerative colitis;
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg21775007	chr8:11205619	TDH	0.46	7.52	0.33	2.83e-13	Mood instability;
LGG	cis	rs2594989	1.000	rs2594990	chr3:11317897	G/T	cg01796438	chr3:11312864	ATG7	-0.61	-8.46	-0.37	3.64e-16	Circulating chemerin levels;
LGG	cis	rs35110281	0.693	rs2838344	chr21:45089877	C/T	cg04455712	chr21:45112962	RRP1B	0.54	10.36	0.43	9.25e-23	Mean corpuscular volume;
LGG	cis	rs60871478	0.947	rs62432866	chr7:809281	T/G	cg27478167	chr7:817139	HEATR2	-0.44	-7.07	-0.31	5.62e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs4716602	0.622	rs57131976	chr7:156167072	A/C	cg16983916	chr7:156159713	NA	-0.48	-9.34	-0.4	4e-19	Anti-saccade response;
LGG	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.06	0.42	1.15e-21	Cognitive ability;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25072359	chr17:41440525	NA	0.53	9.95	0.42	2.99e-21	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16448126	chr12:123921461	RILPL2	0.4	6.76	0.3	4.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1348850	0.914	rs6710575	chr2:178377311	C/T	cg27490568	chr2:178487706	NA	0.5	9.82	0.42	8.71e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3820928	0.845	rs13415319	chr2:227878936	G/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.52	-0.33	2.78e-13	Pulmonary function;
LGG	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.42	-0.33	5.76e-13	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04654153	chr2:176962658	NA	0.41	6.71	0.3	5.7e-11	Cognitive performance;
LGG	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.18e-17	Axial length;
LGG	cis	rs8067545	0.532	rs17759609	chr17:19992514	C/G	cg13482628	chr17:19912719	NA	0.53	8.74	0.38	4.27e-17	Schizophrenia;
LGG	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	trans	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg20290983	chr6:43655470	MRPS18A	0.8	15.53	0.59	4.57e-44	IgG glycosylation;
LGG	cis	rs9834373	0.821	rs13314576	chr3:78485637	T/C	cg06138941	chr3:78371609	NA	-0.52	-9.25	-0.4	8.04e-19	Protein quantitative trait loci;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08651674	chr6:7108441	RREB1	0.41	6.94	0.31	1.35e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12615966	0.651	rs72830473	chr2:105411202	C/A	cg16465502	chr2:105461796	NA	0.99	11.39	0.47	1.17e-26	Pancreatic cancer;
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	trans	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg26384229	chr12:38710491	ALG10B	0.7	12.95	0.52	6.16e-33	Resting heart rate;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg25918303	chr11:106889334	GUCY1A2	-0.4	-7.14	-0.31	3.62e-12	Brain structure;
LGG	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.99e-12	Calcium levels;
LGG	trans	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.08	-0.31	5.47e-12	Life satisfaction;
LGG	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg00129232	chr17:37814104	STARD3	-0.59	-10.83	-0.45	1.59e-24	Lung function (FEV1);
LGG	cis	rs571497	0.756	rs560634	chr19:7831953	G/T	cg00371453	chr19:7854482	CLEC4GP1	0.61	6.88	0.3	1.91e-11	Monocyte count;
LGG	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg17644776	chr2:200775616	C2orf69	-0.62	-8.46	-0.37	3.44e-16	Schizophrenia;
LGG	cis	rs151997	1.000	rs32483	chr5:50205230	C/T	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg26597838	chr10:835615	NA	0.75	10.37	0.43	8.39e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg07395648	chr5:131743802	NA	-0.44	-9.64	-0.41	3.67e-20	Blood metabolite levels;
LGG	cis	rs78456975	0.546	rs72776254	chr2:1527881	C/T	cg26248373	chr2:1572462	NA	-0.7	-8.42	-0.36	4.67e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg18595228	chr15:67193261	NA	-0.62	-9.89	-0.42	4.69e-21	Lung cancer (smoking interaction);
LGG	cis	rs72781680	0.800	rs72780112	chr2:23991182	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg00745463	chr17:30367425	LRRC37B	-0.45	-7.14	-0.31	3.69e-12	Hip circumference adjusted for BMI;
LGG	trans	rs11722228	0.549	rs62288521	chr4:10099772	G/A	cg26043149	chr18:55253948	FECH	0.95	16.17	0.6	6.24e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1079204	1.000	rs13423003	chr2:219111341	G/C	cg05728596	chr2:219128475	GPBAR1	1.09	10.23	0.43	2.84e-22	Smooth-surface caries;
LGG	cis	rs858239	0.632	rs1985769	chr7:23122506	T/G	cg23682824	chr7:23144976	KLHL7	0.43	7.54	0.33	2.52e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9297145	0.678	rs62473007	chr7:98749598	G/C	cg05967295	chr7:98741636	SMURF1	0.93	15.38	0.58	2e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs427394	1.000	rs182135	chr5:6747453	G/A	cg15145174	chr5:6755386	POLS	-0.37	-7.0	-0.31	8.86e-12	Menopause (age at onset);
LGG	cis	rs2629540	0.847	rs34032724	chr10:126408869	T/G	cg08799069	chr10:126477246	METTL10	0.65	13.09	0.52	1.64e-33	Cocaine dependence;
LGG	cis	rs738321	0.725	rs4821747	chr22:38538856	T/C	cg03162506	chr22:38580953	NA	0.4	9.65	0.41	3.39e-20	Breast cancer;
LGG	cis	rs4936894	0.500	rs4936911	chr11:124076220	C/G	cg27160556	chr11:124181099	OR8D1	-0.44	-10.12	-0.43	7.21e-22	Aging (time to death);
LGG	cis	rs4740619	0.661	rs10756722	chr9:15932659	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.15	-0.43	5.47e-22	Body mass index;
LGG	cis	rs11877825	0.826	rs9946239	chr18:10567346	A/G	cg25239095	chr18:10589360	NA	-0.49	-9.22	-0.39	1.04e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg04287289	chr16:89883240	FANCA	-0.79	-16.61	-0.61	6.01e-49	Vitiligo;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24295300	chr19:4043300	NA	-0.41	-7.71	-0.34	7.58e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7113850	0.541	rs74702708	chr11:24226866	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	10.26	0.43	2.1e-22	Bone fracture in osteoporosis;
LGG	cis	rs4774899	0.698	rs2951903	chr15:57366404	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.81	-0.3	3.12e-11	Urinary tract infection frequency;
LGG	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg01017244	chr2:74357527	NA	0.46	8.62	0.37	1.11e-16	Gestational age at birth (maternal effect);
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08862035	chr2:2617432	NA	0.42	6.83	0.3	2.6e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg22232500	chr2:134024266	NCKAP5	0.68	9.63	0.41	4.02e-20	Bipolar disorder;
LGG	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg13010199	chr12:38710504	ALG10B	0.48	8.82	0.38	2.28e-17	Resting heart rate;
LGG	cis	rs644799	0.710	rs564480	chr11:95561741	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.97	0.64	3.63e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg24112000	chr20:60950667	NA	-0.36	-8.41	-0.36	5.15e-16	Colorectal cancer;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg19143629	chr17:61920732	SMARCD2	-0.41	-6.89	-0.31	1.78e-11	Prudent dietary pattern;
LGG	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.77	0.3	3.87e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg11693508	chr17:37793320	STARD3	0.73	10.41	0.44	5.81e-23	Bipolar disorder;
LGG	cis	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg00166722	chr3:10149974	C3orf24	0.54	8.85	0.38	1.93e-17	Alzheimer's disease;
LGG	cis	rs6087990	0.871	rs1007122	chr20:31346001	C/T	cg13636640	chr20:31349939	DNMT3B	0.87	17.73	0.64	4.43e-54	Ulcerative colitis;
LGG	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.73	-0.34	6.95e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	26.54	0.78	5.29e-95	Cognitive ability;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg11905131	chr22:24372483	LOC391322	0.43	7.43	0.33	5.3e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2404602	0.647	rs11632765	chr15:76974261	A/T	cg15268244	chr15:77196840	NA	-0.48	-10.45	-0.44	4.31e-23	Blood metabolite levels;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.93	-0.38	1.01e-17	Lymphocyte counts;
LGG	cis	rs12612619	0.542	rs6710065	chr2:27076557	C/T	cg12045002	chr2:27069975	DPYSL5	-0.32	-7.04	-0.31	6.98e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs7143963	1.000	rs8022110	chr14:103328158	C/T	cg23020514	chr14:103360112	TRAF3	0.51	9.91	0.42	3.86e-21	Body mass index;
LGG	trans	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.73	0.48	5.24e-28	Mean corpuscular volume;
LGG	cis	rs1707322	0.721	rs4330955	chr1:46217485	G/C	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4430311	0.688	rs2125232	chr1:243759210	C/T	cg25706552	chr1:244017396	NA	-0.64	-15.38	-0.58	2.05e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg12454169	chr2:30669597	LCLAT1	0.53	7.61	0.33	1.51e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.95	-0.49	7.13e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	cis	rs73086581	0.947	rs11906612	chr20:3903634	C/T	cg02187196	chr20:3869020	PANK2	0.88	12.14	0.49	1.29e-29	Response to antidepressants in depression;
LGG	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9878978	1.000	rs62233806	chr3:2475478	G/T	cg21928760	chr3:2462534	CNTN4	0.4	8.7	0.38	5.66e-17	Blood pressure (smoking interaction);
LGG	cis	rs425535	0.824	rs189511	chr4:74828639	T/C	cg01447579	chr4:74847100	PF4	0.55	6.67	0.3	7.09e-11	Blood protein levels;
LGG	cis	rs2346160	0.899	rs206974	chr6:167690300	G/A	cg20683250	chr6:167653907	NA	-0.42	-6.83	-0.3	2.64e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7119	0.689	rs8040318	chr15:77803660	A/C	cg10437265	chr15:77819839	NA	0.25	6.87	0.3	2.03e-11	Type 2 diabetes;
LGG	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg19847130	chr8:10466454	RP1L1	0.33	7.08	0.31	5.24e-12	Triglycerides;
LGG	cis	rs4731207	0.596	rs7782410	chr7:124571104	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.4	-0.36	5.47e-16	Tonsillectomy;
LGG	cis	rs9549367	0.713	rs2480949	chr13:113853149	T/C	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg08888203	chr3:10149979	C3orf24	0.54	8.82	0.38	2.37e-17	Alzheimer's disease;
LGG	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg05623727	chr3:50126028	RBM5	-0.4	-8.63	-0.37	9.71e-17	Body mass index;
LGG	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.85	0.45	1.41e-24	Morning vs. evening chronotype;
LGG	cis	rs757081	0.667	rs17473243	chr11:17266259	G/A	cg15432903	chr11:17409602	KCNJ11	-0.55	-9.06	-0.39	3.67e-18	Systolic blood pressure;
LGG	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg05393297	chr12:53359155	NA	-0.65	-15.63	-0.59	1.55e-44	Cancer (pleiotropy);
LGG	cis	rs908922	0.676	rs4845789	chr1:152528100	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs7107174	0.901	rs2450133	chr11:77925759	A/C	cg02023728	chr11:77925099	USP35	0.45	7.87	0.34	2.52e-14	Testicular germ cell tumor;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22111723	chr13:21872664	NA	0.43	7.17	0.32	2.93e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg12813108	chr7:99719912	CNPY4	-0.62	-9.58	-0.41	6.06e-20	Lung function (FEV1/FVC);
LGG	trans	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	6.66	0.3	7.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg07777115	chr5:623756	CEP72	-0.52	-7.01	-0.31	8.47e-12	Obesity-related traits;
LGG	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg08975724	chr8:8085496	FLJ10661	0.47	9.07	0.39	3.48e-18	Retinal vascular caliber;
LGG	cis	rs4953318	0.704	rs10495927	chr2:46352499	A/G	cg12428440	chr2:46370979	PRKCE	0.43	8.18	0.36	2.81e-15	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.51e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg26597838	chr10:835615	NA	0.96	12.66	0.51	9.02e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg20744362	chr22:50050164	C22orf34	0.39	6.88	0.3	1.97e-11	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1945213	0.694	rs34390414	chr11:55863367	T/G	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs611744	0.647	rs585077	chr8:109245497	C/T	cg21045802	chr8:109455806	TTC35	0.5	9.34	0.4	4.11e-19	Dupuytren's disease;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg02018176	chr4:1364513	KIAA1530	0.47	10.91	0.45	8.39e-25	Obesity-related traits;
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg16141378	chr3:129829833	LOC729375	0.42	9.71	0.41	1.99e-20	Triglycerides;
LGG	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-14.69	-0.56	2.34e-40	Pancreatic cancer;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg16606324	chr3:10149918	C3orf24	0.64	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	cis	rs4959677	0.725	rs1680831	chr6:2503945	C/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.42	-0.36	4.72e-16	Orthostatic hypotension;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg02733842	chr7:1102375	C7orf50	0.75	10.98	0.45	4.52e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.54	-0.37	1.91e-16	Schizophrenia;
LGG	trans	rs877282	0.629	rs78997110	chr10:764388	A/G	cg22713356	chr15:30763199	NA	0.52	7.53	0.33	2.72e-13	Uric acid levels;
LGG	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg05555928	chr11:63887634	MACROD1	-0.64	-9.13	-0.39	2.16e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9644630	0.932	rs4273861	chr8:19352703	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.61	17.25	0.63	7.29e-52	Oropharynx cancer;
LGG	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Colorectal cancer;
LGG	cis	rs4788570	0.655	rs7359478	chr16:71825445	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	20.52	0.69	5.19e-67	Intelligence (multi-trait analysis);
LGG	trans	rs1941687	0.527	rs12608181	chr18:31339351	T/G	cg27147174	chr7:100797783	AP1S1	-0.65	-12.21	-0.49	6.5e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11239187	0.586	rs11239177	chr10:45123379	C/T	cg03916630	chr10:45065415	NA	-0.29	-6.74	-0.3	4.58e-11	Body mass index;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20997463	chr12:53689079	PFDN5	-0.42	-7.2	-0.32	2.52e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11169552	0.510	rs10506294	chr12:51070554	C/T	cg12884762	chr12:50931848	DIP2B	0.4	7.49	0.33	3.6e-13	Colorectal cancer;
LGG	cis	rs62238980	0.614	rs77489541	chr22:32413863	G/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg00990874	chr7:1149470	C7orf50	-0.45	-7.67	-0.34	1.04e-13	Bronchopulmonary dysplasia;
LGG	cis	rs2294693	0.891	rs9369256	chr6:40998344	G/C	cg14769373	chr6:40998127	UNC5CL	-0.42	-7.3	-0.32	1.29e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.31	0.63	3.98e-52	Chronic sinus infection;
LGG	cis	rs9815354	0.638	rs113712591	chr3:42050624	C/T	cg03022575	chr3:42003672	ULK4	0.74	8.27	0.36	1.39e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg22398616	chr13:53314203	LECT1	-0.55	-12.18	-0.49	8.81e-30	Lewy body disease;
LGG	trans	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg16141378	chr3:129829833	LOC729375	0.4	8.85	0.38	1.93e-17	Mood instability;
LGG	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.48	7.98	0.35	1.13e-14	Colorectal cancer;
LGG	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg17054900	chr3:154042577	DHX36	0.49	7.43	0.33	5.2e-13	Coronary artery disease;
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg27121462	chr16:89883253	FANCA	0.62	11.64	0.48	1.24e-27	Vitiligo;
LGG	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.01e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg20848291	chr7:100343083	ZAN	-0.6	-8.2	-0.36	2.32e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26431298	chr1:156737036	PRCC	0.38	6.88	0.3	1.99e-11	Obesity-related traits;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg12458913	chr13:53173898	NA	0.56	10.0	0.42	1.97e-21	Lewy body disease;
LGG	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg05535760	chr7:792225	HEATR2	0.77	12.12	0.49	1.5e-29	Cerebrospinal P-tau181p levels;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs13102973	0.899	rs13104662	chr4:135904615	C/T	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg13986417	chr12:110012484	MVK;MMAB	-0.32	-6.92	-0.31	1.53e-11	Neuroticism;
LGG	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg18850127	chr7:39170497	POU6F2	0.35	8.17	0.35	2.98e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00149659	chr3:10157352	C3orf10	0.76	9.75	0.41	1.48e-20	Alzheimer's disease;
LGG	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg13271783	chr10:134563150	INPP5A	-0.5	-7.65	-0.33	1.18e-13	Migraine;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.85	-16.96	-0.62	1.58e-50	Hip circumference adjusted for BMI;
LGG	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg09517075	chr8:22133004	PIWIL2	0.43	9.48	0.4	1.34e-19	Hypertriglyceridemia;
LGG	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg03929089	chr4:120376271	NA	-0.64	-8.92	-0.38	1.1e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6940638	0.688	rs6456766	chr6:27019575	G/A	cg12826209	chr6:26865740	GUSBL1	0.47	7.9	0.34	2.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9462027	0.606	rs1201874	chr6:34549810	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.54	-0.44	2.03e-23	Systemic lupus erythematosus;
LGG	cis	rs832540	0.593	rs252912	chr5:56195792	C/T	cg12654349	chr5:56205094	C5orf35	-0.43	-7.44	-0.33	4.79e-13	Coronary artery disease;
LGG	cis	rs2244613	0.882	rs7204940	chr16:55794983	C/G	cg27396498	chr16:55794478	CES4	0.45	8.42	0.36	4.88e-16	Response to dabigatran etexilate treatment;
LGG	cis	rs9902453	1.000	rs62070270	chr17:28263980	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.37	0.53	1.02e-34	Coffee consumption (cups per day);
LGG	cis	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg07362569	chr17:61921086	SMARCD2	-0.38	-6.97	-0.31	1.11e-11	Prudent dietary pattern;
LGG	cis	rs9512730	0.553	rs9507904	chr13:28049506	C/T	cg04070771	chr13:27998621	GTF3A	0.49	7.61	0.33	1.51e-13	Schizophrenia;
LGG	cis	rs7945718	0.621	rs10831891	chr11:12676140	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.2	0.32	2.46e-12	Educational attainment (years of education);
LGG	cis	rs1691799	0.867	rs1168297	chr12:66735644	T/C	cg16791601	chr12:66731901	HELB	-0.65	-15.53	-0.59	4.42e-44	White blood cell count (basophil);
LGG	cis	rs727505	0.954	rs59673207	chr7:124596982	G/C	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.21	-0.72	5.91e-75	Total body bone mineral density;
LGG	cis	rs34734847	1.000	rs35360964	chr12:121156290	T/C	cg21892295	chr12:121157589	UNC119B	-0.47	-8.83	-0.38	2.18e-17	Mean corpuscular volume;
LGG	cis	rs9581857	0.579	rs75326986	chr13:27997758	C/T	cg01674679	chr13:27998804	GTF3A	-0.77	-9.08	-0.39	3.07e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg04662567	chr6:169592167	NA	-0.78	-11.41	-0.47	9.83e-27	Pulse pressure;
LGG	cis	rs10895140	0.709	rs2154999	chr11:101517406	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs6489882	0.867	rs6489867	chr12:113363550	C/T	cg25319449	chr12:113376135	OAS3	-0.38	-6.95	-0.31	1.28e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7589342	0.831	rs10169998	chr2:106452253	A/G	cg14210321	chr2:106509881	NCK2	-0.53	-9.13	-0.39	2.2e-18	Addiction;
LGG	cis	rs1801251	0.778	rs2675957	chr2:233754364	C/T	cg08000102	chr2:233561755	GIGYF2	-0.45	-7.32	-0.32	1.08e-12	Coronary artery disease;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg08188268	chr10:116634841	FAM160B1	-0.33	-7.21	-0.32	2.22e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7089973	0.624	rs10885614	chr10:116609098	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.67	-12.26	-0.5	3.95e-30	Hip circumference adjusted for BMI;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.77	11.16	0.46	8.62e-26	Lung function (FEV1/FVC);
LGG	cis	rs10870270	0.957	rs3829156	chr10:133789386	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.66	-11.96	-0.49	6.38e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg20308403	chr7:2120281	MAD1L1	0.33	7.18	0.32	2.82e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs77741769	0.571	rs3809313	chr12:121329967	T/C	cg02419362	chr12:121203948	SPPL3	0.54	9.3	0.4	5.66e-19	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs10807701	chr7:65724686	C/A	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs727505	0.954	rs67870530	chr7:124591878	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.6	-0.41	5e-20	Lewy body disease;
LGG	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.44	-0.5	7.48e-31	Bipolar disorder;
LGG	cis	rs11608355	0.515	rs2287191	chr12:109931741	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg10546459	chr2:36825355	FEZ2	0.6	9.66	0.41	3.19e-20	Height;
LGG	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg14668821	chr17:77704760	ENPP7	0.42	8.33	0.36	9.34e-16	Menopause (age at onset);
LGG	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.15	-0.35	3.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3796352	1.000	rs71301804	chr3:53073314	C/A	cg12962167	chr3:53033115	SFMBT1	0.7	7.16	0.32	3.09e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.03	-0.35	8.14e-15	Restless legs syndrome;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06445916	chr8:42268472	NA	0.43	7.71	0.34	7.73e-14	Electrocardiographic conduction measures;
LGG	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg25358565	chr5:93447407	FAM172A	0.85	11.66	0.48	1.04e-27	Diabetic retinopathy;
LGG	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg18876405	chr7:65276391	NA	-0.64	-12.06	-0.49	2.48e-29	Aortic root size;
LGG	cis	rs7769051	0.711	rs7758531	chr6:133085302	T/C	cg07930552	chr6:133119739	C6orf192	0.86	11.25	0.46	4.06e-26	Type 2 diabetes nephropathy;
LGG	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg11707556	chr5:10655725	ANKRD33B	0.66	11.28	0.46	2.97e-26	Coronary artery disease;
LGG	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg02227867	chr8:22457446	C8orf58	0.39	7.3	0.32	1.28e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg17201900	chr20:34330562	RBM39	0.5	6.78	0.3	3.67e-11	Total cholesterol levels;
LGG	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.92	-0.38	1.05e-17	Colorectal cancer;
LGG	cis	rs2274273	0.967	rs10147667	chr14:55570849	C/T	cg04306507	chr14:55594613	LGALS3	-0.57	-14.41	-0.56	3.54e-39	Protein biomarker;
LGG	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.24	-0.43	2.52e-22	Hip circumference adjusted for BMI;
LGG	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg17788362	chr6:86352627	SYNCRIP	0.53	9.26	0.4	7.38e-19	Smooth-surface caries;
LGG	trans	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg25214090	chr10:38739885	LOC399744	0.61	10.73	0.45	3.83e-24	Corneal astigmatism;
LGG	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.79	-0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs4919087	0.851	rs3781373	chr10:99080585	C/T	cg25902810	chr10:99078978	FRAT1	0.5	9.04	0.39	4.13e-18	Monocyte count;
LGG	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.74	-0.3	4.69e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.74	-15.27	-0.58	6.24e-43	Obesity-related traits;
LGG	cis	rs78487399	0.808	rs10189235	chr2:43745520	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.64	-0.3	8.61e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs1109114	0.844	rs12152968	chr5:148622345	C/T	cg06539116	chr5:148597365	ABLIM3	-0.45	-10.84	-0.45	1.46e-24	Body mass index;
LGG	cis	rs6089584	0.893	rs2281735	chr20:60582540	T/A	cg06470251	chr20:60548479	NA	0.48	8.2	0.36	2.38e-15	Body mass index;
LGG	cis	rs2798269	0.966	rs11148158	chr13:22137743	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs490234	0.841	rs1250736	chr9:128438005	A/G	cg14078157	chr9:128172775	NA	0.39	7.36	0.32	8.4e-13	Mean arterial pressure;
LGG	cis	rs9359856	0.510	rs17293240	chr6:90396370	C/T	cg13799429	chr6:90582589	CASP8AP2	0.84	13.04	0.52	2.57e-33	Bipolar disorder;
LGG	cis	rs16866061	1.000	rs11686590	chr2:225334070	A/G	cg12698349	chr2:225449008	CUL3	0.92	19.09	0.66	2.48e-60	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs709400	0.628	rs11622356	chr14:103912195	C/T	cg26031613	chr14:104095156	KLC1	0.79	13.67	0.54	5.37e-36	Body mass index;
LGG	cis	rs244293	0.695	rs9303360	chr17:53001456	T/C	cg19360675	chr17:53046073	COX11;STXBP4	-0.43	-7.16	-0.32	3.25e-12	Menarche (age at onset);
LGG	cis	rs9815354	0.638	rs17284933	chr3:42029835	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.37e-16	IgG glycosylation;
LGG	cis	rs8133932	0.724	rs11701249	chr21:47050714	G/A	cg11214348	chr21:47283868	PCBP3	-0.4	-6.67	-0.3	7.22e-11	Schizophrenia;
LGG	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg11871910	chr12:69753446	YEATS4	0.69	13.32	0.53	1.63e-34	Blood protein levels;
LGG	cis	rs4629180	0.675	rs4851459	chr2:102109006	T/A	cg16435561	chr2:102091048	RFX8	0.47	8.65	0.37	8.68e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs972578	0.715	rs4820485	chr22:43212432	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.88	-0.3	1.97e-11	Mean platelet volume;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.36	0.69	2.77e-66	Alzheimer's disease;
LGG	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.58	0.47	2.02e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2594989	0.887	rs2443717	chr3:11521493	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.61	-0.33	1.6e-13	Circulating chemerin levels;
LGG	cis	rs7737355	0.947	rs6864145	chr5:130637861	C/T	cg06307176	chr5:131281290	NA	0.51	8.49	0.37	2.93e-16	Life satisfaction;
LGG	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg00473462	chr5:472545	LOC25845	0.36	6.78	0.3	3.77e-11	Cystic fibrosis severity;
LGG	trans	rs11039798	0.545	rs7118670	chr11:48532056	C/T	cg03929089	chr4:120376271	NA	0.68	9.29	0.4	5.84e-19	Axial length;
LGG	cis	rs67133203	0.851	rs12370820	chr12:51430718	T/G	cg14688905	chr12:51403056	SLC11A2	0.75	11.2	0.46	6.48e-26	Urinary tract infection frequency;
LGG	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.75	0.64	3.83e-54	Vitiligo;
LGG	cis	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg09307838	chr4:120376055	NA	0.49	8.46	0.37	3.53e-16	Diastolic blood pressure;
LGG	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg21427119	chr20:30132790	HM13	-0.5	-8.31	-0.36	1.1e-15	Mean corpuscular hemoglobin;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg04025307	chr7:1156635	C7orf50	0.87	18.96	0.66	9.6e-60	Longevity;Endometriosis;
LGG	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15369054	chr17:80825471	TBCD	-0.5	-6.93	-0.31	1.43e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg19524238	chr7:2802976	GNA12	0.41	9.48	0.4	1.33e-19	Height;
LGG	cis	rs988958	0.567	rs11899374	chr2:42220752	G/T	cg27428208	chr2:42229179	NA	0.56	9.21	0.39	1.15e-18	Hypospadias;
LGG	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.52	-8.08	-0.35	5.66e-15	Menarche (age at onset);
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.56	9.41	0.4	2.33e-19	Tonsillectomy;
LGG	cis	rs1371867	0.846	rs1788196	chr8:101290088	C/T	cg06636551	chr8:101224915	SPAG1	-0.45	-8.47	-0.37	3.17e-16	Atrioventricular conduction;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.89	0.3	1.88e-11	Schizophrenia;
LGG	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg16070123	chr10:51489643	NA	-0.36	-6.68	-0.3	6.77e-11	Prostate-specific antigen levels;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.03	26.86	0.78	1.74e-96	Prudent dietary pattern;
LGG	cis	rs7602441	0.521	rs1434985	chr2:14767916	C/T	cg06545361	chr2:14773388	FAM84A	0.83	7.89	0.34	2.13e-14	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs9487094	0.696	rs12191353	chr6:109941975	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.74	0.34	6.48e-14	Height;
LGG	cis	rs7474896	0.583	rs11011346	chr10:38009483	C/T	cg25427524	chr10:38739819	LOC399744	-0.48	-6.78	-0.3	3.74e-11	Obesity (extreme);
LGG	cis	rs911555	0.723	rs12894652	chr14:103926024	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.19	0.32	2.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.08	-0.39	3.14e-18	Common traits (Other);
LGG	cis	rs17641971	0.684	rs4873100	chr8:50025772	G/A	cg00325661	chr8:49890786	NA	0.55	10.57	0.44	1.57e-23	Blood metabolite levels;
LGG	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.61	-0.41	4.76e-20	Triglycerides;
LGG	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg00504896	chr12:9437009	LOC642846	-0.44	-8.07	-0.35	6.21e-15	Breast size;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg11473876	chr11:109292803	C11orf87	0.46	9.13	0.39	2.09e-18	Schizophrenia;
LGG	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	cis	rs12681287	0.604	rs34227066	chr8:87449366	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg21775007	chr8:11205619	TDH	0.62	10.22	0.43	2.92e-22	Retinal vascular caliber;
LGG	cis	rs4845570	1.000	rs6659705	chr1:151769750	T/C	cg07092448	chr1:151763213	TDRKH	-1.13	-17.8	-0.64	2.27e-54	Coronary artery disease;
LGG	trans	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-10.39	-0.43	7.39e-23	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.95	0.49	7.03e-29	Prudent dietary pattern;
LGG	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg25457927	chr22:38595422	NA	0.43	11.06	0.46	2.15e-25	Cutaneous nevi;
LGG	trans	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg22232500	chr2:134024266	NCKAP5	0.56	8.01	0.35	9.32e-15	Bipolar disorder;
LGG	cis	rs2244613	0.507	rs7205803	chr16:55794849	C/T	cg04521981	chr16:55850985	CES1	0.47	6.97	0.31	1.12e-11	Response to dabigatran etexilate treatment;
LGG	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg05425664	chr17:57184151	TRIM37	-0.68	-11.03	-0.46	2.83e-25	Intelligence (multi-trait analysis);
LGG	cis	rs4237845	1.000	rs4237845	chr12:58302436	A/G	cg02175503	chr12:58329896	NA	-0.74	-14.21	-0.55	2.79e-38	Intelligence (multi-trait analysis);
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg07520810	chr10:63809149	ARID5B	0.41	7.78	0.34	4.63e-14	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07791516	chr6:150247246	NA	0.33	6.78	0.3	3.69e-11	Lung cancer;
LGG	cis	rs7444	0.825	rs73166630	chr22:21945978	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.77	-0.34	5.13e-14	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	31.82	0.83	1.38e-118	Chronic sinus infection;
LGG	cis	rs4262150	0.767	rs17550343	chr5:151945366	C/G	cg12297329	chr5:152029980	NA	-0.8	-15.47	-0.58	7.82e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs2070488	0.775	rs2051213	chr3:38560254	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.72	0.56	1.67e-40	Electrocardiographic conduction measures;
LGG	cis	rs11722228	0.522	rs12503195	chr4:10082772	T/C	cg08250081	chr4:10125330	NA	0.63	12.81	0.51	2.36e-32	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7511006	0.858	rs2294402	chr22:50654428	T/G	cg08875078	chr22:50639485	SELO	0.54	9.27	0.4	6.99e-19	Obesity-related traits;
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg12395012	chr8:11607386	GATA4	-0.38	-6.97	-0.31	1.11e-11	Mood instability;
LGG	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg02002194	chr4:3960332	NA	-0.48	-9.09	-0.39	2.83e-18	Mean corpuscular hemoglobin;
LGG	cis	rs17453880	0.929	rs6897983	chr5:151994224	T/C	cg10931792	chr5:152022470	NA	0.38	8.19	0.36	2.61e-15	Subjective well-being;
LGG	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg03162506	chr22:38580953	NA	-0.38	-9.64	-0.41	3.74e-20	Cutaneous nevi;
LGG	trans	rs9467711	1.000	rs6908156	chr6:26322861	C/T	cg06606381	chr12:133084897	FBRSL1	-0.63	-7.09	-0.31	5.14e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg02002194	chr4:3960332	NA	0.39	6.88	0.3	1.99e-11	Neuroticism;
LGG	cis	rs1348850	0.914	rs8941	chr2:178406481	C/T	cg27490568	chr2:178487706	NA	0.51	10.05	0.42	1.23e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg06636001	chr8:8085503	FLJ10661	0.59	11.41	0.47	9.82e-27	Triglycerides;
LGG	cis	rs8032158	1.000	rs8038646	chr15:56263346	T/C	cg02198044	chr15:56286336	NEDD4	-0.73	-12.75	-0.51	4.01e-32	Keloid;
LGG	cis	rs603424	0.551	rs646767	chr10:102084897	A/G	cg10365880	chr10:102089681	PKD2L1	-0.44	-6.69	-0.3	6.38e-11	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LGG	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs72781680	0.716	rs2712061	chr2:24026411	G/A	cg08917208	chr2:24149416	ATAD2B	0.63	8.17	0.36	2.87e-15	Lymphocyte counts;
LGG	cis	rs17021463	0.673	rs57939388	chr4:95282365	A/G	cg11021082	chr4:95130006	SMARCAD1	0.39	6.79	0.3	3.39e-11	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg14154082	chr13:112174009	NA	0.35	7.65	0.34	1.14e-13	Menarche (age at onset);
LGG	cis	rs62244186	0.541	rs9859879	chr3:44840166	G/A	cg02073558	chr3:44770973	ZNF501	0.86	18.74	0.66	1.03e-58	Depressive symptoms;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.89e-19	Aortic root size;
LGG	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg05985134	chr18:33552581	C18orf21	0.64	10.13	0.43	6.42e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg05313129	chr8:58192883	C8orf71	0.6	8.63	0.37	1.03e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.6	-7.94	-0.35	1.57e-14	Smoking behavior;
LGG	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.72	0.3	5.5e-11	Renal cell carcinoma;
LGG	cis	rs62244186	0.516	rs11922470	chr3:44777795	C/T	cg02073558	chr3:44770973	ZNF501	0.94	22.19	0.72	7.96e-75	Depressive symptoms;
LGG	cis	rs3126085	0.935	rs11586114	chr1:152299767	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.09	-0.31	4.92e-12	Atopic dermatitis;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.12	-0.31	4.17e-12	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg16270222	chr17:41446396	NA	-0.31	-7.26	-0.32	1.66e-12	Menopause (age at onset);
LGG	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg00571178	chr13:114841904	RASA3	-0.57	-10.24	-0.43	2.53e-22	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs1816752	0.870	rs9581029	chr13:24999285	C/A	cg02811702	chr13:24901961	NA	0.38	7.16	0.32	3.24e-12	Obesity-related traits;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg06636001	chr8:8085503	FLJ10661	0.52	9.71	0.41	2.03e-20	Neuroticism;
LGG	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.57e-11	Bladder cancer;
LGG	cis	rs7216064	1.000	rs7223813	chr17:65945840	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.05	-0.39	3.89e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg01579765	chr21:45077557	HSF2BP	-0.32	-7.14	-0.32	3.52e-12	Mean corpuscular volume;
LGG	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.5	0.37	2.64e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06481639	chr22:41940642	POLR3H	-0.64	-9.17	-0.39	1.59e-18	Vitiligo;
LGG	cis	rs8051149	0.652	rs4843719	chr16:87882695	C/A	cg01412419	chr16:87856264	NA	0.46	8.75	0.38	3.85e-17	Blood metabolite levels;
LGG	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.71	-0.3	5.8200000000000003e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	trans	rs2018683	0.600	rs717891	chr7:29000374	C/T	cg19402173	chr7:128379420	CALU	-0.59	-8.98	-0.39	6.97e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs7568458	0.527	rs35416445	chr2:85773659	A/G	cg17127132	chr2:85788382	GGCX	0.52	8.17	0.36	2.93e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4443100	0.535	rs13055979	chr22:23474085	C/T	cg21100191	chr22:23484243	RTDR1	0.56	8.59	0.37	1.31e-16	Serum parathyroid hormone levels;
LGG	cis	rs4474465	0.850	rs4945289	chr11:78245334	G/T	cg27205649	chr11:78285834	NARS2	0.49	8.54	0.37	1.91e-16	Alzheimer's disease (survival time);
LGG	cis	rs11920090	0.932	rs5402	chr3:170727739	T/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.59	0.37	1.33e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg15763984	chr4:1342303	KIAA1530	0.37	6.65	0.3	8.09e-11	Obesity-related traits;
LGG	cis	rs9462027	0.628	rs9462020	chr6:34751265	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg19507638	chr5:93509721	C5orf36	0.42	6.9	0.31	1.75e-11	Diabetic retinopathy;
LGG	trans	rs7824557	0.583	rs2736292	chr8:11234500	A/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.89	-0.34	2.18e-14	Retinal vascular caliber;
LGG	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg24253500	chr15:84953950	NA	-0.56	-10.29	-0.43	1.65e-22	Schizophrenia;
LGG	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg16511985	chr3:153974050	SGEF	0.46	7.51	0.33	3.03e-13	Coronary artery disease;
LGG	cis	rs701145	0.537	rs1713847	chr3:153791107	C/A	cg17054900	chr3:154042577	DHX36	0.79	9.38	0.4	2.9e-19	Coronary artery disease;
LGG	cis	rs72772090	0.539	rs56319744	chr5:96141938	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.87	-0.38	1.65e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg05091796	chr16:4465799	CORO7	-0.62	-10.21	-0.43	3.37e-22	Schizophrenia;
LGG	cis	rs1927702	0.586	rs10810525	chr9:16038177	C/G	cg14451791	chr9:16040625	NA	0.3	7.19	0.32	2.55e-12	Body mass index;
LGG	cis	rs9902453	0.845	rs3102558	chr17:28023142	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.44	0.37	4.12e-16	Prostate cancer;
LGG	cis	rs3820928	0.874	rs10167086	chr2:227792729	A/T	cg11843606	chr2:227700838	RHBDD1	0.45	7.85	0.34	3.01e-14	Pulmonary function;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4629180	0.586	rs1509495	chr2:102134834	C/T	cg16435561	chr2:102091048	RFX8	0.47	8.76	0.38	3.78e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02475777	chr4:1388615	CRIPAK	0.6	10.78	0.45	2.61e-24	Longevity;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05052031	chr3:33138450	TMPPE;GLB1	-0.44	-6.8	-0.3	3.27e-11	Pancreatic cancer;
LGG	cis	rs77372450	0.636	rs13356635	chr5:157014121	A/T	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg22857025	chr5:266934	NA	-1.52	-26.24	-0.77	1.17e-93	Breast cancer;
LGG	cis	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg00405596	chr8:11794950	NA	0.43	6.91	0.31	1.63e-11	Systolic blood pressure;
LGG	cis	rs7927771	1.000	rs12361031	chr11:47783076	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg11494091	chr17:61959527	GH2	0.99	24.35	0.75	6.69e-85	Prudent dietary pattern;
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg16268157	chr7:99778414	STAG3	-0.46	-7.17	-0.32	2.94e-12	Lung function (FEV1/FVC);
LGG	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg03806693	chr22:41940476	POLR3H	-1.05	-17.79	-0.64	2.39e-54	Vitiligo;
LGG	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	10.29	0.43	1.66e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12898370	0.561	rs11630770	chr15:77469643	A/G	cg17802220	chr15:77601643	NA	0.46	7.1	0.31	4.83e-12	Risky sexual behaviors (alcohol dependence interaction);
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg07142201	chr11:109293216	C11orf87	0.85	16.5	0.61	1.92e-48	Schizophrenia;
LGG	cis	rs36093844	0.706	rs78680968	chr11:85543480	C/T	cg16165120	chr11:85566439	CCDC83	-0.45	-7.07	-0.31	5.59e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24208426	chr11:3819031	PGAP2;NUP98	-0.49	-7.16	-0.32	3.28e-12	Systemic lupus erythematosus;
LGG	cis	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg21775007	chr8:11205619	TDH	0.44	6.86	0.3	2.21e-11	Morning vs. evening chronotype;
LGG	cis	rs72781680	0.800	rs72790306	chr2:24111311	T/G	cg08917208	chr2:24149416	ATAD2B	0.93	10.1	0.42	8.39e-22	Lymphocyte counts;
LGG	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg09163369	chr1:210001066	C1orf107	-0.38	-6.65	-0.3	8.28e-11	Orofacial clefts;
LGG	cis	rs2905347	0.560	rs2905312	chr7:22682942	T/C	cg18045685	chr7:22629474	NA	-0.74	-16.06	-0.6	1.85e-46	Major depression and alcohol dependence;
LGG	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg27411982	chr8:10470053	RP1L1	0.41	7.08	0.31	5.47e-12	Mood instability;
LGG	cis	rs523522	0.602	rs7132474	chr12:120866996	A/C	cg27279351	chr12:120934652	DYNLL1	0.58	7.51	0.33	3.06e-13	High light scatter reticulocyte count;
LGG	cis	rs2236918	1.000	rs1776137	chr1:242027045	A/G	cg17736920	chr1:242011382	EXO1	0.5	9.0	0.39	5.89e-18	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs60733400	0.782	rs4648564	chr1:2562169	C/T	cg20673091	chr1:2541236	MMEL1	-0.76	-18.57	-0.65	5.88e-58	Multiple sclerosis;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg17202724	chr17:61916730	SMARCD2	0.62	14.66	0.56	2.94e-40	Prudent dietary pattern;
LGG	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg03733263	chr8:22462867	KIAA1967	1.06	27.01	0.78	3.73e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2451279	0.902	rs2451258	chr6:159506600	C/T	cg01046905	chr6:159515345	NA	0.42	8.06	0.35	6.33e-15	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs11209002	0.524	rs2815386	chr1:67541996	A/G	cg02640540	chr1:67518911	SLC35D1	0.39	6.65	0.3	8.13e-11	Crohn's disease;
LGG	cis	rs1920116	0.778	rs12489230	chr3:169558821	C/T	cg08193579	chr3:169529701	LRRC34	0.42	7.28	0.32	1.47e-12	Glioma (high-grade);
LGG	cis	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg06521331	chr12:34319734	NA	0.41	6.79	0.3	3.56e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.03	0.42	1.43e-21	Motion sickness;
LGG	cis	rs4356203	0.870	rs214915	chr11:17241773	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2274273	0.686	rs68083077	chr14:55574428	G/A	cg04306507	chr14:55594613	LGALS3	0.51	11.91	0.48	1.03e-28	Protein biomarker;
LGG	cis	rs10883723	0.810	rs13287	chr10:104240438	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	14.81	0.57	6.38e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg04362960	chr10:104952993	NT5C2	0.58	10.92	0.45	7.41e-25	Arsenic metabolism;
LGG	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.3	-0.36	1.13e-15	Mood instability;
LGG	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg24642439	chr20:33292090	TP53INP2	0.58	9.81	0.41	9.28e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg16301924	chr13:53314226	LECT1	-0.4	-8.19	-0.36	2.49e-15	Lewy body disease;
LGG	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg18105134	chr13:113819100	PROZ	0.73	15.11	0.57	3.14e-42	Platelet distribution width;
LGG	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	2e-18	Blood metabolite levels;
LGG	cis	rs11122272	0.735	rs2295420	chr1:231485640	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.93	-0.45	6.5e-25	Hemoglobin concentration;
LGG	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg12432903	chr7:1882776	MAD1L1	0.53	8.07	0.35	5.96e-15	Bipolar disorder;
LGG	cis	rs11122272	0.735	rs2486736	chr1:231521478	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	10.79	0.45	2.33e-24	Hemoglobin concentration;
LGG	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg08885076	chr2:99613938	TSGA10	-0.42	-7.89	-0.34	2.22e-14	Chronic sinus infection;
LGG	cis	rs10463554	0.927	rs158253	chr5:102405206	G/A	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs17208368	0.628	rs2397356	chr16:55098986	C/G	cg09947736	chr16:55091198	NA	0.67	12.98	0.52	4.43e-33	Hypospadias;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24933173	chr15:45492494	SHF	-0.46	-6.7	-0.3	6.13e-11	Systemic lupus erythematosus;
LGG	cis	rs977987	0.843	rs60730309	chr16:75431769	C/G	cg03315344	chr16:75512273	CHST6	0.51	10.27	0.43	2.01e-22	Dupuytren's disease;
LGG	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg19748678	chr4:122722346	EXOSC9	0.68	13.66	0.54	6.05e-36	Type 2 diabetes;
LGG	cis	rs4900538	0.963	rs4906205	chr14:102932447	A/G	cg18135206	chr14:102964638	TECPR2	0.8	16.13	0.6	8.77e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg16414030	chr3:133502952	NA	-0.51	-8.19	-0.36	2.62e-15	Iron status biomarkers;
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.2e-19	Bipolar disorder;
LGG	cis	rs9326248	0.520	rs7127881	chr11:116880798	G/A	cg20608306	chr11:116969690	SIK3	0.4	12.61	0.51	1.45e-31	Blood protein levels;
LGG	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.67	-0.44	6.35e-24	Breast cancer;
LGG	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.53	0.53	2.14e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg02725872	chr8:58115012	NA	0.91	12.78	0.51	3.1e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.56	0.41	7.26e-20	Colorectal cancer;
LGG	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg06606381	chr12:133084897	FBRSL1	0.71	8.31	0.36	1.06e-15	Depression;
LGG	cis	rs6712932	1.000	rs10170234	chr2:105841841	C/G	cg26874229	chr2:105853672	NA	-0.33	-7.05	-0.31	6.56e-12	Type 2 diabetes;
LGG	cis	rs2692947	0.770	rs72823920	chr2:96430876	G/A	cg22654517	chr2:96458247	NA	0.38	7.49	0.33	3.46e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg24130564	chr14:104152367	KLC1	0.74	15.71	0.59	6.89e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4690686	0.500	rs12501181	chr4:177264851	G/A	cg17059388	chr4:177262070	NA	1.02	23.76	0.74	3.52e-82	Essential tremor;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.96	-15.2	-0.58	1.23e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg05163923	chr11:71159392	DHCR7	-0.64	-11.28	-0.46	3.05e-26	Vitamin D levels;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.15	0.52	9.01e-34	Prudent dietary pattern;
LGG	cis	rs4787491	0.679	rs12933575	chr16:30022564	A/G	cg06326092	chr16:30034487	C16orf92	0.42	8.44	0.37	4.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs72991	0.740	rs297503	chr11:121264426	A/G	cg27192990	chr6:129479024	LAMA2	0.44	7.16	0.32	3.17e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg03929089	chr4:120376271	NA	-1.03	-24.74	-0.75	1.01e-86	Height;
LGG	cis	rs7927771	0.832	rs11039212	chr11:47393303	A/T	cg20307385	chr11:47447363	PSMC3	0.58	10.64	0.44	8.55e-24	Subjective well-being;
LGG	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3816183	0.626	rs2132534	chr2:42803365	T/C	cg14631114	chr2:43023945	NA	0.34	6.74	0.3	4.74e-11	Hypospadias;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg22980697	chr10:16874865	CUBN	0.38	7.39	0.32	6.96e-13	Platelet distribution width;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.27	-0.32	1.52e-12	Mean corpuscular volume;
LGG	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6480314	0.706	rs2394465	chr10:69984106	C/A	cg18338521	chr10:69995036	NA	0.31	6.67	0.3	7.5e-11	Optic nerve measurement (disc area);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg16497921	chr11:28129676	KIF18A;METT5D1	-0.46	-7.07	-0.31	5.72e-12	Pancreatic cancer;
LGG	cis	rs113835537	0.529	rs3892818	chr11:66240191	C/T	cg24851651	chr11:66362959	CCS	0.45	7.86	0.34	2.75e-14	Airway imaging phenotypes;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16524936	chr4:1340807	KIAA1530	-0.47	-7.83	-0.34	3.37e-14	Longevity;
LGG	cis	rs2236918	0.901	rs1776132	chr1:242024473	C/G	cg17736920	chr1:242011382	EXO1	0.5	8.95	0.38	8.8e-18	Menopause (age at onset);
LGG	cis	rs77741769	0.591	rs73413868	chr12:121301732	T/C	cg02419362	chr12:121203948	SPPL3	0.52	9.07	0.39	3.47e-18	Mean corpuscular volume;
LGG	cis	rs703842	0.575	rs701006	chr12:58106836	C/T	cg18357645	chr12:58087776	OS9	-0.5	-8.99	-0.39	6.52e-18	Multiple sclerosis;
LGG	cis	rs62400317	0.859	rs11965706	chr6:45141441	T/A	cg18551225	chr6:44695536	NA	-0.63	-10.22	-0.43	2.97e-22	Total body bone mineral density;
LGG	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg22875332	chr1:76189707	ACADM	0.53	7.55	0.33	2.27e-13	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6732160	0.741	rs6546806	chr2:73386160	T/C	cg01422370	chr2:73384389	NA	0.53	10.47	0.44	3.75e-23	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs735539	0.555	rs8001310	chr13:21339700	G/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.43	-0.33	5.43e-13	Dental caries;
LGG	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg13939156	chr17:80058883	NA	-0.46	-9.13	-0.39	2.17e-18	Life satisfaction;
LGG	cis	rs2640806	0.505	rs7818838	chr8:97359279	A/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.15	0.32	3.39e-12	Obesity-related traits;
LGG	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg09855544	chr8:135498122	ZFAT	0.46	7.69	0.34	8.97e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.81	-0.45	1.9e-24	Hemoglobin concentration;
LGG	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg21665744	chr7:39171113	POU6F2	0.38	7.31	0.32	1.16e-12	IgG glycosylation;
LGG	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg26597838	chr10:835615	NA	0.56	7.26	0.32	1.59e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs514406	0.793	rs12081018	chr1:53217542	C/A	cg16325326	chr1:53192061	ZYG11B	-0.75	-17.94	-0.64	5.29e-55	Monocyte count;
LGG	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg08400814	chr5:56204995	C5orf35	0.45	7.32	0.32	1.14e-12	Initial pursuit acceleration;
LGG	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.92e-21	Lung cancer;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg01145232	chr6:150245071	RAET1G	0.48	8.64	0.37	9.16e-17	Lung cancer;
LGG	cis	rs68170813	0.652	rs76742243	chr7:107144202	G/A	cg02696742	chr7:106810147	HBP1	-0.68	-8.63	-0.37	9.68e-17	Coronary artery disease;
LGG	cis	rs7614311	0.731	rs73130544	chr3:63868596	G/A	cg22134162	chr3:63841271	THOC7	-0.45	-8.08	-0.35	5.78e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs4888262	0.545	rs58136167	chr16:74700628	G/A	cg01733217	chr16:74700730	RFWD3	0.94	19.94	0.68	2.64e-64	Testicular germ cell tumor;
LGG	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.69	-0.3	6.42e-11	Sudden cardiac arrest;
LGG	cis	rs11644362	1.000	rs4505301	chr16:12989467	A/G	cg06890432	chr16:12997467	SHISA9	-0.32	-7.0	-0.31	9.33e-12	Positive affect;Subjective well-being;
LGG	cis	rs3768617	0.510	rs3768619	chr1:183092404	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg02725872	chr8:58115012	NA	-0.89	-12.11	-0.49	1.56e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs8014204	0.533	rs12434646	chr14:75178693	C/T	cg06637938	chr14:75390232	RPS6KL1	0.64	11.86	0.48	1.62e-28	Caffeine consumption;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg00689492	chr4:1303491	MAEA	0.45	7.87	0.34	2.6e-14	Obesity-related traits;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg04156016	chr5:1868137	NA	0.32	7.2	0.32	2.5e-12	Cardiovascular disease risk factors;
LGG	cis	rs7264396	0.790	rs6060539	chr20:34239382	C/T	cg17201900	chr20:34330562	RBM39	0.5	6.78	0.3	3.67e-11	Total cholesterol levels;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.85	0.48	1.86e-28	Obesity-related traits;
LGG	cis	rs9443189	0.526	rs775060	chr6:76373567	G/A	cg01950844	chr6:76311363	SENP6	-0.76	-9.95	-0.42	2.8e-21	Prostate cancer;
LGG	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg16797656	chr11:68205561	LRP5	-0.51	-9.94	-0.42	3.02e-21	Total body bone mineral density;
LGG	trans	rs6787172	0.629	rs1095640	chr3:157970566	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.65e-13	Schizophrenia;
LGG	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg08603382	chr10:743973	NA	0.59	10.8	0.45	2.14e-24	Psychosis in Alzheimer's disease;
LGG	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg16141378	chr3:129829833	LOC729375	0.37	8.33	0.36	9.15e-16	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs6993813	0.872	rs4424291	chr8:120018735	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.87	0.3	2.13e-11	Bone mineral density (hip);
LGG	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg13736514	chr6:26305472	NA	-0.42	-8.91	-0.38	1.2e-17	Educational attainment;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs73416724	0.688	rs10498755	chr6:43330756	C/T	cg26312998	chr6:43337775	ZNF318	0.58	6.65	0.3	8.24e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.675	rs7597889	chr2:42220091	T/C	cg19376973	chr2:42229025	NA	0.61	9.83	0.42	7.7e-21	Hypospadias;
LGG	cis	rs17030434	0.834	rs1456399	chr4:154735242	C/T	cg14289246	chr4:154710475	SFRP2	-0.59	-9.59	-0.41	5.62e-20	Electrocardiographic conduction measures;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg11645453	chr3:52864694	ITIH4	0.39	6.74	0.3	4.58e-11	Electroencephalogram traits;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg04861929	chr11:109293070	C11orf87	0.52	9.73	0.41	1.74e-20	Schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg18350792	chr12:112563442	TRAFD1	0.39	6.68	0.3	7.08e-11	Bilirubin levels;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg21548813	chr6:291882	DUSP22	-0.75	-13.42	-0.53	6.61e-35	Menopause (age at onset);
LGG	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg13010199	chr12:38710504	ALG10B	-0.64	-13.32	-0.53	1.72e-34	Morning vs. evening chronotype;
LGG	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg21775007	chr8:11205619	TDH	0.43	6.87	0.3	2.07e-11	Joint mobility (Beighton score);
LGG	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg00071950	chr4:10020882	SLC2A9	0.39	7.98	0.35	1.19e-14	Bone mineral density;
LGG	trans	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.8	-0.34	4.03e-14	Morning vs. evening chronotype;
LGG	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	cis	rs2063714	0.640	rs9397978	chr6:157193250	A/G	cg23222435	chr6:157204239	ARID1B	0.41	7.09	0.31	5.09e-12	Sitting height ratio;
LGG	cis	rs2180341	0.814	rs6919277	chr6:127738050	T/C	cg24812749	chr6:127587940	RNF146	0.71	11.24	0.46	4.31e-26	Breast cancer;
LGG	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.27	0.4	7.17e-19	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg03929089	chr4:120376271	NA	-0.66	-11.85	-0.48	1.8e-28	Coronary artery disease;
LGG	cis	rs9815354	0.767	rs17280980	chr3:41810949	A/T	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg08645402	chr16:4508243	NA	0.43	7.38	0.32	7.24e-13	Schizophrenia;
LGG	trans	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg27411982	chr8:10470053	RP1L1	0.44	7.82	0.34	3.71e-14	Joint mobility (Beighton score);
LGG	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg25554036	chr4:6271136	WFS1	0.54	9.45	0.4	1.7e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11098499	0.865	rs3956464	chr4:120256764	T/C	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	trans	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.81	-0.38	2.5e-17	Bladder cancer;
LGG	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.44	0.33	5.05e-13	Total cholesterol levels;
LGG	cis	rs6540556	0.723	rs11119327	chr1:209883804	T/C	cg23920097	chr1:209922102	NA	-0.42	-6.81	-0.3	3.09e-11	Red blood cell count;
LGG	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg13683864	chr3:40499215	RPL14	-1.13	-25.74	-0.77	2.28e-91	Renal cell carcinoma;
LGG	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.34	-0.32	9.42e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg18129748	chr3:49941408	MST1R	0.22	6.89	0.31	1.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.88	0.34	2.28e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2227564	0.672	rs2461864	chr10:75659872	A/T	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.16	-0.39	1.68e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg08198773	chr8:1697536	NA	0.44	7.79	0.34	4.5e-14	Systolic blood pressure;
LGG	cis	rs8180040	0.726	rs7625070	chr3:47095518	A/G	cg16586182	chr3:47516702	SCAP	-0.8	-15.43	-0.58	1.2e-43	Colorectal cancer;
LGG	cis	rs7572644	0.699	rs10170872	chr2:28164553	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16638945	chr6:166139905	NA	-0.36	-6.94	-0.31	1.29e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.51	-0.4	1.02e-19	Life satisfaction;
LGG	cis	rs1978968	1.000	rs11704733	chr22:18446212	T/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs42648	0.564	rs39284	chr7:89791981	T/C	cg04070188	chr7:89809444	NA	-0.28	-6.79	-0.3	3.37e-11	Homocysteine levels;
LGG	cis	rs7618915	0.547	rs2268026	chr3:52778347	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.08	0.35	5.6e-15	Bipolar disorder;
LGG	cis	rs951366	0.903	rs823114	chr1:205719532	G/A	cg14893161	chr1:205819251	PM20D1	0.61	11.79	0.48	2.99e-28	Menarche (age at onset);
LGG	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-10.8	-0.45	2.06e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2011503	1.000	rs4808205	chr19:19645493	T/G	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.58e-29	Bipolar disorder;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.38	-8.94	-0.38	9.61e-18	Schizophrenia;
LGG	cis	rs700651	0.856	rs9288280	chr2:198744324	A/G	cg00792783	chr2:198669748	PLCL1	0.69	11.25	0.46	3.91e-26	Intracranial aneurysm;
LGG	cis	rs6933660	0.744	rs3800279	chr6:151766162	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	8.87	0.38	1.6e-17	Menarche (age at onset);
LGG	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg14019146	chr3:50243930	SLC38A3	-0.41	-8.68	-0.37	6.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs1806153	0.673	rs2071164	chr11:31833542	C/G	cg11990419	chr11:31841155	NA	0.34	7.13	0.31	3.82e-12	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs752010	0.714	rs7515948	chr1:42079046	T/G	cg16096631	chr1:42092165	HIVEP3	0.74	20.97	0.7	3.93e-69	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg12310025	chr6:25882481	NA	-0.52	-9.59	-0.41	5.69e-20	Blood metabolite levels;
LGG	cis	rs7412746	0.658	rs11204750	chr1:150939744	C/A	cg15448220	chr1:150897856	SETDB1	0.4	7.38	0.32	7.22e-13	Melanoma;
LGG	cis	rs72781680	0.799	rs2712084	chr2:24003051	A/G	cg08917208	chr2:24149416	ATAD2B	0.64	8.3	0.36	1.12e-15	Lymphocyte counts;
LGG	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg03929089	chr4:120376271	NA	0.8	11.08	0.46	1.74e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg00129232	chr17:37814104	STARD3	-0.74	-15.36	-0.58	2.62e-43	Asthma;
LGG	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg06212747	chr3:49208901	KLHDC8B	0.62	10.32	0.43	1.28e-22	Parkinson's disease;
LGG	cis	rs3206736	0.548	rs7779894	chr7:35061509	C/T	cg13400248	chr7:35225412	NA	0.55	9.57	0.41	6.45e-20	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11978873	chr1:226251224	H3F3A;LOC440926	-0.48	-7.08	-0.31	5.39e-12	Systemic lupus erythematosus;
LGG	cis	rs774359	0.789	rs2814709	chr9:27513298	G/A	cg21249376	chr9:27528432	MOBKL2B	0.45	8.54	0.37	1.91e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg12432903	chr7:1882776	MAD1L1	0.5	7.71	0.34	7.88e-14	Bipolar disorder;
LGG	cis	rs9783347	0.714	rs10766471	chr11:18367130	C/T	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.24	-0.49	4.82e-30	Pancreatic cancer;
LGG	cis	rs11971779	0.680	rs6961812	chr7:139043808	A/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs9300255	0.510	rs1790086	chr12:123672518	A/G	cg00376283	chr12:123451042	ABCB9	0.63	9.74	0.41	1.57e-20	Neutrophil percentage of white cells;
LGG	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg12292205	chr6:26970375	C6orf41	-0.75	-15.05	-0.57	5.67e-42	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg26384229	chr12:38710491	ALG10B	0.97	21.99	0.71	6.89e-74	Bladder cancer;
LGG	cis	rs6456156	0.773	rs6456159	chr6:167529272	T/A	cg07741184	chr6:167504864	NA	-0.3	-6.83	-0.3	2.69e-11	Primary biliary cholangitis;
LGG	cis	rs9992101	0.645	rs17252554	chr4:77303621	C/T	cg17010112	chr4:77227123	STBD1	-0.46	-9.4	-0.4	2.57e-19	Creatinine levels;
LGG	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg10621924	chr7:39171070	POU6F2	0.48	9.95	0.42	2.87e-21	IgG glycosylation;
LGG	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg13647721	chr17:30228624	UTP6	0.7	9.9	0.42	4.21e-21	Hip circumference adjusted for BMI;
LGG	cis	rs3735485	0.738	rs28497645	chr7:45091614	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.62	-0.41	4.26e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.31	-6.98	-0.31	1.06e-11	Restless legs syndrome;
LGG	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	8.28	0.36	1.37e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.84	-0.38	1.99e-17	Bladder cancer;
LGG	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15644404	chr18:77186268	NFATC1	-0.81	-10.11	-0.43	7.74e-22	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7385804	0.633	rs221795	chr7:100283261	C/T	cg21055462	chr7:100276975	NA	-0.31	-6.71	-0.3	5.74e-11	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs78487399	0.808	rs76851696	chr2:43746062	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.91	-0.31	1.6e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs1580019	0.813	rs2044839	chr7:32500805	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.66	0.59	1.21e-44	Cognitive ability;
LGG	cis	rs9951602	0.512	rs1599635	chr18:76643819	G/A	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs6839203	chr4:98839814	C/G	cg05340658	chr4:99064831	C4orf37	0.47	7.71	0.34	7.8e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.24	0.65	1.98e-56	Personality dimensions;
LGG	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg18225595	chr11:63971243	STIP1	-0.48	-9.33	-0.4	4.41e-19	Platelet count;
LGG	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg22878388	chr2:105853796	NA	-0.45	-8.3	-0.36	1.15e-15	Type 2 diabetes;
LGG	cis	rs72945132	0.882	rs17160039	chr11:70145489	A/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs2239547	0.657	rs4687554	chr3:52864135	T/C	cg11645453	chr3:52864694	ITIH4	0.72	11.23	0.46	4.78e-26	Schizophrenia;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.72	0.34	7.26e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6694672	1.000	rs1888991	chr1:197110822	A/G	cg13682187	chr1:196946512	CFHR5	0.5	6.95	0.31	1.26e-11	Asthma;
LGG	cis	rs2012796	0.956	rs10450940	chr14:81825326	C/A	cg02996355	chr14:81879375	NA	0.52	8.36	0.36	7.56e-16	Night sleep phenotypes;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.04	0.46	2.61e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg02002194	chr4:3960332	NA	0.55	10.58	0.44	1.44e-23	Triglycerides;
LGG	cis	rs9815354	0.904	rs73073235	chr3:42012693	C/A	cg03022575	chr3:42003672	ULK4	0.78	9.06	0.39	3.74e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7666738	0.830	rs4392515	chr4:98957431	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.48	0.37	2.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17739167	0.550	rs6493013	chr15:42224824	T/C	cg20935245	chr15:42234343	EHD4	0.44	8.55	0.37	1.85e-16	Monocyte count;
LGG	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.03	0.42	1.52e-21	Retinal vascular caliber;
LGG	cis	rs1707322	1.000	rs10890360	chr1:46338444	C/T	cg03146154	chr1:46216737	IPP	0.54	10.46	0.44	4.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3106136	0.967	rs12645192	chr4:95181525	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.21	-0.36	2.25e-15	Capecitabine sensitivity;
LGG	cis	rs9487094	0.626	rs10457192	chr6:109828474	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.76	0.34	5.57e-14	Height;
LGG	cis	rs9467711	0.591	rs35249036	chr6:26026163	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.52	0.33	2.95e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs897080	0.552	rs1067369	chr2:44652654	A/T	cg00619915	chr2:44497795	NA	-0.49	-6.85	-0.3	2.35e-11	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04910183	chr1:193090988	CDC73	0.43	6.77	0.3	3.94e-11	Cognitive performance;
LGG	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.07	-0.35	5.95e-15	Total body bone mineral density;
LGG	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg16123090	chr2:3699210	NA	0.56	7.52	0.33	2.82e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2180341	0.538	rs3756993	chr6:127651551	A/C	cg27446573	chr6:127587934	RNF146	0.73	13.28	0.53	2.62e-34	Breast cancer;
LGG	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.23	0.32	2.03e-12	Joint mobility (Beighton score);
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg12310025	chr6:25882481	NA	-0.51	-9.4	-0.4	2.59e-19	Height;
LGG	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg26655873	chr3:72818019	SHQ1	0.34	6.69	0.3	6.36e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	14.81	0.57	6.92e-41	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2016266	0.964	rs1609474	chr12:53676814	C/T	cg04065151	chr12:53682969	ESPL1	0.58	10.16	0.43	5.1e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2013441	0.866	rs1009082	chr17:20062959	G/A	cg13482628	chr17:19912719	NA	0.4	6.92	0.31	1.53e-11	Obesity-related traits;
LGG	cis	rs875971	1.000	rs1968225	chr7:65874773	T/C	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg22916017	chr11:64110731	CCDC88B	0.51	10.75	0.45	3.32e-24	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs17376456	0.825	rs10054790	chr5:93272520	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs10911232	0.507	rs10797815	chr1:182996827	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs11229555	1.000	rs11229555	chr11:58408687	G/T	cg15696309	chr11:58395628	NA	-0.98	-17.67	-0.63	8.55e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00166722	chr3:10149974	C3orf24	0.49	8.34	0.36	8.55e-16	Alzheimer's disease;
LGG	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg08949735	chr16:89699720	DPEP1	-0.48	-10.08	-0.42	9.65e-22	Vitiligo;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg02733842	chr7:1102375	C7orf50	0.6	8.76	0.38	3.7e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.67	-0.51	8.82e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg19784903	chr17:45786737	TBKBP1	-0.32	-7.04	-0.31	7.03e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg02733842	chr7:1102375	C7orf50	-0.48	-7.81	-0.34	3.79e-14	Bronchopulmonary dysplasia;
LGG	cis	rs1209950	1.000	rs1013841	chr21:40173345	A/G	cg01359822	chr21:40176597	ETS2	0.33	7.53	0.33	2.68e-13	Non-small cell lung cancer (survival);
LGG	cis	rs6815814	0.851	rs4274855	chr4:38777471	C/T	cg06935464	chr4:38784597	TLR10	0.55	7.69	0.34	8.93e-14	Breast cancer;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.21e-20	Life satisfaction;
LGG	cis	rs116095464	1.000	rs3777237	chr5:307641	C/T	cg22496380	chr5:211416	CCDC127	-1.3	-11.18	-0.46	7.81e-26	Breast cancer;
LGG	cis	rs12971120	1.000	rs734559	chr18:72179579	G/A	cg26446133	chr18:72167187	CNDP2	-0.69	-14.63	-0.56	4.28e-40	Refractive error;
LGG	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg00277334	chr10:82204260	NA	-0.35	-7.76	-0.34	5.62e-14	Post bronchodilator FEV1;
LGG	cis	rs17604090	0.887	rs850013	chr7:29666530	T/C	cg19413766	chr7:29689036	LOC646762	-0.63	-8.62	-0.37	1.07e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg24011408	chr12:48396354	COL2A1	0.52	8.28	0.36	1.29e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs9633740	1.000	rs7910643	chr10:82251769	G/A	cg01528321	chr10:82214614	TSPAN14	1.04	16.3	0.6	1.53e-47	Post bronchodilator FEV1;
LGG	cis	rs13394619	0.744	rs10929759	chr2:11722012	C/G	cg07314298	chr2:11723111	GREB1	0.51	10.88	0.45	1.08e-24	Endometriosis;
LGG	cis	rs11718455	0.960	rs11921942	chr3:44007957	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.81	-0.3	3.1e-11	Coronary artery disease;
LGG	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.15	0.43	5.41e-22	Aortic root size;
LGG	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg01221209	chr5:554886	NA	-0.45	-6.73	-0.3	5.19e-11	Obesity-related traits;
LGG	cis	rs12410462	0.581	rs73102371	chr1:227554880	G/A	cg23173402	chr1:227635558	NA	0.45	7.39	0.32	6.96e-13	Major depressive disorder;
LGG	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03878208	chr11:72483293	STARD10	0.52	7.22	0.32	2.19e-12	Type 2 diabetes;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.15e-12	Aortic root size;
LGG	cis	rs4690686	0.500	rs3921993	chr4:177263284	A/G	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs4363385	0.747	rs10399896	chr1:152975083	T/A	cg13444842	chr1:152974279	SPRR3	-0.45	-9.39	-0.4	2.63e-19	Inflammatory skin disease;
LGG	cis	rs9815354	1.000	rs1717033	chr3:41910216	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.24	0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs55665837	0.961	rs60622588	chr11:14456998	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-8.72	-0.38	4.94e-17	Vitamin D levels;
LGG	cis	rs7959452	0.590	rs11177619	chr12:69758871	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.53	-0.33	2.77e-13	Blood protein levels;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg16590910	chr6:42928470	GNMT	0.37	10.42	0.44	5.51e-23	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	17.38	0.63	1.9e-52	Smoking behavior;
LGG	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg03474202	chr17:45855739	NA	0.27	7.75	0.34	6.03e-14	IgG glycosylation;
LGG	cis	rs4901869	0.966	rs12878614	chr14:59339477	A/C	cg02291164	chr14:59296302	NA	0.27	6.82	0.3	2.86e-11	Panic disorder;
LGG	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg02836325	chr17:76403955	PGS1	-0.7	-14.17	-0.55	4.18e-38	HDL cholesterol levels;
LGG	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs4262150	0.672	rs17568427	chr5:152357770	C/T	cg12297329	chr5:152029980	NA	-0.53	-7.97	-0.35	1.23e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05603623	chr19:8008081	TIMM44	0.45	7.68	0.34	9.49e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6840360	0.642	rs1899550	chr4:152407236	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12464559	0.522	rs4414677	chr2:152624932	A/C	cg01189475	chr2:152685088	ARL5A	-0.73	-7.32	-0.32	1.08e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs7737355	0.947	rs6596027	chr5:130879547	A/G	cg06307176	chr5:131281290	NA	0.56	9.28	0.4	6.35e-19	Life satisfaction;
LGG	cis	rs12220238	0.915	rs11000945	chr10:76030739	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.88	0.38	1.54e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.56	0.56	8.59e-40	Colorectal cancer;
LGG	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg20578329	chr17:80767326	TBCD	-0.46	-7.98	-0.35	1.19e-14	Breast cancer;
LGG	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg05313129	chr8:58192883	C8orf71	-0.62	-7.7	-0.34	8.54e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.71	-0.48	6.64e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs4714291	0.963	rs2475496	chr6:39963850	A/G	cg02267698	chr19:7991119	CTXN1	0.6	9.25	0.39	8.51e-19	Strep throat;
LGG	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg11494091	chr17:61959527	GH2	0.6	10.03	0.42	1.44e-21	Height;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.79	0.45	2.31e-24	Personality dimensions;
LGG	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	7.26	0.32	1.65e-12	Body mass index;
LGG	cis	rs4423214	0.765	rs2002064	chr11:71163420	A/G	cg05163923	chr11:71159392	DHCR7	-0.63	-10.94	-0.45	6.13e-25	Vitamin D levels;
LGG	cis	rs3099143	1.000	rs3102712	chr15:77058926	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-9.91	-0.42	3.99e-21	Recalcitrant atopic dermatitis;
LGG	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs7503807	0.515	rs12453034	chr17:78682756	G/A	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs7927592	0.546	rs638076	chr11:68202580	A/G	cg16797656	chr11:68205561	LRP5	0.57	10.96	0.45	5.34e-25	Total body bone mineral density;
LGG	cis	rs9403521	1.000	rs9390126	chr6:143980432	A/G	cg18240653	chr6:144019428	PHACTR2	-0.65	-10.11	-0.43	7.47e-22	Obesity-related traits;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg04267008	chr7:1944627	MAD1L1	-0.44	-7.31	-0.32	1.19e-12	Schizophrenia;
LGG	cis	rs11792861	0.890	rs57387569	chr9:111920392	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	8.38	0.36	6.45e-16	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg16586182	chr3:47516702	SCAP	-0.44	-7.25	-0.32	1.71e-12	Birth weight;
LGG	cis	rs12200782	0.649	rs9467747	chr6:26389072	G/A	cg27193005	chr6:26382695	BTN2A2	-0.51	-7.33	-0.32	1.03e-12	Small cell lung carcinoma;
LGG	cis	rs11748327	0.959	rs11738257	chr5:4058398	T/C	cg01025095	chr5:4101132	NA	-0.57	-9.28	-0.4	6.29e-19	Myocardial infarction;
LGG	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	6.81	0.3	2.97e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9487094	0.670	rs13199135	chr6:109909842	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.69	0.34	8.76e-14	Height;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.69	-9.95	-0.42	2.78e-21	Lung function (FEV1/FVC);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10038085	chr1:165797905	UCK2	0.46	7.6	0.33	1.69e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.966	rs1860599	chr4:17638900	T/C	cg02297831	chr4:17616191	MED28	0.5	9.32	0.4	4.68e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg07615347	chr10:60278583	BICC1	0.63	17.85	0.64	1.3e-54	Refractive error;
LGG	cis	rs2077654	1.000	rs2077654	chr11:17427901	C/G	cg25308976	chr11:17434268	ABCC8	-0.67	-8.31	-0.36	1.05e-15	Gout;
LGG	cis	rs953387	0.744	rs115224560	chr2:136896041	T/A	cg07169764	chr2:136633963	MCM6	0.56	9.35	0.4	3.8e-19	Arthritis (juvenile idiopathic);
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg23978390	chr7:1156363	C7orf50	0.44	6.66	0.3	7.7e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg26043149	chr18:55253948	FECH	-0.48	-7.81	-0.34	3.95e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04788221	chr20:61427686	C20orf20	0.48	7.6	0.33	1.68e-13	Gut microbiome composition (summer);
LGG	cis	rs61884328	0.777	rs61897777	chr11:47133604	C/G	cg03339077	chr11:47165057	C11orf49	0.63	6.8	0.3	3.22e-11	Total body bone mineral density (age over 60);
LGG	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg15596359	chr8:11213517	TDH	0.43	9.01	0.39	5.3e-18	Retinal vascular caliber;
LGG	trans	rs8002861	0.967	rs7994883	chr13:44478805	A/G	cg17145862	chr1:211918768	LPGAT1	-0.94	-24.34	-0.75	7.43e-85	Leprosy;
LGG	cis	rs6723226	0.961	rs13010404	chr2:32848854	T/G	cg02381751	chr2:32503542	YIPF4	-0.65	-10.82	-0.45	1.72e-24	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.47e-20	Educational attainment;
LGG	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg26802063	chr5:78281964	ARSB	0.52	8.59	0.37	1.36e-16	Blood and toenail selenium levels;Blood trace element (Se levels);
LGG	cis	rs11741688	0.597	rs6880072	chr5:178334480	G/C	cg09339527	chr5:178322752	ZFP2	-0.41	-7.54	-0.33	2.52e-13	Sleep duration;
LGG	cis	rs17453880	0.643	rs7701534	chr5:151952520	T/G	cg12297329	chr5:152029980	NA	-0.86	-21.57	-0.71	5.94e-72	Subjective well-being;
LGG	cis	rs56804039	0.895	rs11776995	chr8:8385547	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-6.87	-0.3	2.08e-11	Cervical cancer;
LGG	cis	rs7568458	0.684	rs1048739	chr2:85764968	T/G	cg17127132	chr2:85788382	GGCX	0.51	8.11	0.35	4.46e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10754283	0.967	rs2185195	chr1:90106697	T/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.14	0.49	1.26e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4740619	0.740	rs7467156	chr9:15746300	A/G	cg14451791	chr9:16040625	NA	0.34	8.74	0.38	4.43e-17	Body mass index;
LGG	trans	rs1032833	0.732	rs879539	chr2:180003331	A/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg11062466	chr8:58055876	NA	0.54	8.86	0.38	1.72e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg27490568	chr2:178487706	NA	0.4	8.16	0.35	3.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs262150	0.501	rs1062610	chr7:158821175	C/T	cg04111992	chr7:158790115	NA	-0.35	-7.03	-0.31	7.29e-12	Facial morphology (factor 20);
LGG	cis	rs3126085	0.877	rs11204968	chr1:152250211	A/T	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg01236616	chr12:121019343	POP5	1.26	22.13	0.72	1.42e-74	Type 1 diabetes nephropathy;
LGG	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg25358565	chr5:93447407	FAM172A	1.32	16.31	0.6	1.38e-47	Diabetic retinopathy;
LGG	cis	rs4460629	0.712	rs11264313	chr1:155076505	A/G	cg13808842	chr1:155066096	NA	-0.29	-6.98	-0.31	1.01e-11	Serum magnesium levels;
LGG	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg00919237	chr7:87102261	ABCB4	-0.79	-16.01	-0.6	3.19e-46	Gallbladder cancer;
LGG	trans	rs2018683	0.523	rs886834	chr7:29021336	G/A	cg19402173	chr7:128379420	CALU	-0.59	-9.64	-0.41	3.51e-20	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs7226408	0.857	rs72888996	chr18:34580055	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg05863683	chr7:1912471	MAD1L1	0.49	9.43	0.4	1.98e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19717773	chr7:2847554	GNA12	-0.36	-8.14	-0.35	3.7e-15	Height;
LGG	cis	rs6977660	0.598	rs10239147	chr7:19787459	T/C	cg07541023	chr7:19748670	TWISTNB	0.58	8.24	0.36	1.82e-15	Thyroid stimulating hormone;
LGG	cis	rs2688608	0.736	rs2227566	chr10:75673731	C/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.06	-0.31	5.94e-12	Inflammatory bowel disease;
LGG	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg15128208	chr22:42549153	NA	0.76	11.44	0.47	7.51e-27	Birth weight;
LGG	cis	rs36051895	0.632	rs10974987	chr9:5169302	G/T	cg02405213	chr9:5042618	JAK2	-0.79	-14.76	-0.57	1.13e-40	Pediatric autoimmune diseases;
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.44	0.61	3.58e-48	Diabetic retinopathy;
LGG	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	cg15522984	chr1:182991683	LAMC1	0.43	8.74	0.38	4.26e-17	Colorectal cancer;
LGG	cis	rs9814567	0.727	rs4435681	chr3:134344435	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.93	-0.45	6.86e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17428076	0.831	rs3736499	chr2:172690418	C/T	cg21435375	chr2:172878103	MAP1D	0.41	8.83	0.38	2.19e-17	Myopia;
LGG	cis	rs11605924	0.901	rs11038672	chr11:45846498	C/G	ch.11.939596F	chr11:45881766	CRY2	-0.48	-8.08	-0.35	5.84e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs10911363	0.550	rs10911353	chr1:183489203	G/A	cg23894439	chr1:183413866	NA	0.49	9.12	0.39	2.27e-18	Systemic lupus erythematosus;
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15320075	chr8:145703422	NA	-0.72	-14.04	-0.55	1.51e-37	Age at first birth;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.36	-6.7	-0.3	6.14e-11	Personality dimensions;
LGG	cis	rs651907	0.557	rs62284199	chr3:101478531	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.91	0.54	5.15e-37	Colorectal cancer;
LGG	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg04455712	chr21:45112962	RRP1B	-0.52	-9.82	-0.42	8.36e-21	Mean corpuscular volume;
LGG	cis	rs975722	1.000	rs6466619	chr7:117357909	T/C	cg10524701	chr7:117356490	CTTNBP2	0.52	11.86	0.48	1.56e-28	Coronary artery disease;
LGG	cis	rs9403521	0.673	rs11155315	chr6:143975157	A/G	cg18240653	chr6:144019428	PHACTR2	-0.61	-10.14	-0.43	5.72e-22	Obesity-related traits;
LGG	cis	rs6882046	0.513	rs647983	chr5:88048071	T/C	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs854765	0.520	rs7219324	chr17:17909775	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.71	-13.39	-0.53	8.67e-35	Total body bone mineral density;
LGG	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	5.92e-14	Testicular germ cell tumor;
LGG	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg00666640	chr1:248458726	OR2T12	0.54	9.05	0.39	3.95e-18	Common traits (Other);
LGG	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.35	0.36	8.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs8031584	0.958	rs34909055	chr15:31284170	C/T	cg08109568	chr15:31115862	NA	-0.52	-9.21	-0.39	1.1e-18	Huntington's disease progression;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.38	0.36	6.59e-16	Obesity-related traits;
LGG	cis	rs6942756	1.000	rs6980385	chr7:128943615	G/A	cg02491457	chr7:128862824	NA	-0.75	-13.64	-0.54	7.22e-36	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20274746	chr5:65221372	ERBB2IP	0.49	7.31	0.32	1.19e-12	Gut microbiome composition (summer);
LGG	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.65e-15	Common traits (Other);
LGG	cis	rs7267979	1.000	rs7019	chr20:25278278	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.18	-0.62	1.56e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg12463550	chr7:65579703	CRCP	-0.44	-6.85	-0.3	2.32e-11	Aortic root size;
LGG	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg08305652	chr11:111469057	NA	-0.43	-8.46	-0.37	3.54e-16	Primary sclerosing cholangitis;
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg11984989	chr7:158649758	WDR60	0.96	20.44	0.69	1.22e-66	Height;
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25464034	chr11:450264	PTDSS2	0.45	6.75	0.3	4.55e-11	Gut microbiome composition (summer);
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg21862992	chr11:68658383	NA	0.49	8.25	0.36	1.7e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs751728	1.000	rs4711351	chr6:33754592	G/A	cg25922239	chr6:33757077	LEMD2	0.7	12.27	0.5	3.81e-30	Crohn's disease;
LGG	trans	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.92e-30	Corneal astigmatism;
LGG	cis	rs8067545	0.578	rs4925091	chr17:20066988	T/C	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.59e-22	Schizophrenia;
LGG	cis	rs10870270	1.000	rs7199	chr10:133769848	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.61	-0.53	1.06e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg14074117	chr16:1909714	C16orf73	-0.54	-8.02	-0.35	8.53e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4262150	0.810	rs10046082	chr5:151961446	C/T	cg12297329	chr5:152029980	NA	-0.82	-16.37	-0.61	7.38e-48	Bipolar disorder and schizophrenia;
LGG	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg11642891	chr2:3452563	TTC15	-0.46	-9.02	-0.39	5.05e-18	Obesity-related traits;
LGG	cis	rs6868223	0.617	rs12152900	chr5:33645810	C/T	cg10594543	chr5:33649717	ADAMTS12	0.67	15.48	0.58	7.11e-44	Mortality in heart failure;
LGG	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg23231163	chr10:75533350	FUT11	0.42	7.04	0.31	7.2e-12	Inflammatory bowel disease;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg00814883	chr7:100076585	TSC22D4	-0.69	-10.14	-0.43	5.85e-22	Platelet count;
LGG	cis	rs7103648	1.000	rs11039225	chr11:47430599	G/A	cg20307385	chr11:47447363	PSMC3	0.97	24.08	0.75	1.16e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs5758659	0.714	rs6002626	chr22:42517989	C/G	cg15557168	chr22:42548783	NA	0.37	8.25	0.36	1.62e-15	Cognitive function;
LGG	cis	rs2236918	0.664	rs1776158	chr1:242017658	C/T	cg17736920	chr1:242011382	EXO1	0.39	7.06	0.31	6.09e-12	Menopause (age at onset);
LGG	cis	rs4665809	0.680	rs3955310	chr2:26290828	T/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.72	-0.34	7.43e-14	Gut microbiome composition (summer);
LGG	cis	rs10504073	0.584	rs4873307	chr8:49950417	C/T	cg00325661	chr8:49890786	NA	0.79	15.57	0.59	3.06e-44	Blood metabolite ratios;
LGG	cis	rs28785552	0.796	rs8112908	chr19:53248041	C/T	cg10871876	chr19:53194124	ZNF83	0.71	14.35	0.55	6.56e-39	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.97	17.27	0.63	6.19e-52	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9443645	0.810	rs9443637	chr6:79714708	C/T	cg18132916	chr6:79620363	NA	-0.26	-7.02	-0.31	7.96e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.25e-31	Motion sickness;
LGG	cis	rs2354432	0.556	rs2353977	chr1:146839637	G/T	cg25205988	chr1:146714368	CHD1L	1.19	11.62	0.48	1.48e-27	Mitochondrial DNA levels;
LGG	cis	rs28830936	1.000	rs12440747	chr15:42036690	G/A	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-7.08	-0.31	5.23e-12	Diastolic blood pressure;
LGG	cis	rs7587476	0.784	rs13026390	chr2:215687075	C/T	cg04004882	chr2:215674386	BARD1	-0.54	-7.88	-0.34	2.3e-14	Neuroblastoma;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.29	0.55	1.19e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7552404	0.924	rs1146581	chr1:76213024	T/G	cg22875332	chr1:76189707	ACADM	0.58	9.84	0.42	7.24e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14159672	chr1:205819179	PM20D1	0.77	16.67	0.61	3.44e-49	Menarche (age at onset);
LGG	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg16751781	chr15:78858589	CHRNA5	-0.42	-8.01	-0.35	9.31e-15	Sudden cardiac arrest;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg11245990	chr11:68621969	NA	0.42	9.0	0.39	5.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8028182	0.636	rs8030802	chr15:75813153	A/G	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	trans	rs28595532	0.720	rs72670225	chr4:119302167	C/T	cg26518628	chr1:97050305	NA	-0.81	-7.07	-0.31	5.64e-12	Cannabis dependence symptom count;
LGG	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg13647721	chr17:30228624	UTP6	0.6	7.57	0.33	2.08e-13	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg09307838	chr4:120376055	NA	0.73	12.19	0.49	7.97e-30	Corneal astigmatism;
LGG	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg21798802	chr22:38057573	PDXP	0.4	8.78	0.38	3.13e-17	Fat distribution (HIV);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12375025	chr18:67873125	RTTN	0.42	6.9	0.31	1.72e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.98	0.35	1.19e-14	Prostate cancer;
LGG	trans	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs6541297	0.645	rs2103827	chr1:230298285	T/A	cg05784532	chr1:230284198	GALNT2	0.47	7.11	0.31	4.29e-12	Coronary artery disease;
LGG	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg18854424	chr1:2615690	NA	0.34	6.79	0.3	3.36e-11	Multiple sclerosis;
LGG	trans	rs11039798	0.614	rs8188910	chr11:48825740	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.96	0.38	8.01e-18	Axial length;
LGG	cis	rs1712517	0.524	rs4917384	chr10:104995788	T/C	cg04362960	chr10:104952993	NT5C2	0.49	8.02	0.35	8.93e-15	Migraine;
LGG	cis	rs34467563	0.535	rs6985074	chr8:97340925	A/T	cg22138393	chr8:97340270	PTDSS1	0.33	8.47	0.37	3.22e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6564851	0.545	rs8044334	chr16:81248935	T/G	cg00163702	chr16:81254719	PKD1L2	0.36	8.22	0.36	2.03e-15	Carotenoid and tocopherol levels;
LGG	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.49	-0.44	3.18e-23	Hepatocellular carcinoma;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg11693508	chr17:37793320	STARD3	0.51	7.25	0.32	1.81e-12	Bipolar disorder;
LGG	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg24011408	chr12:48396354	COL2A1	0.5	8.02	0.35	8.68e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg01238044	chr22:24384105	GSTT1	-0.45	-7.94	-0.35	1.53e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7312774	0.618	rs61061573	chr12:107372758	T/C	cg16260113	chr12:107380972	MTERFD3	1.12	10.42	0.44	5.78e-23	Severe influenza A (H1N1) infection;
LGG	cis	rs10206020	0.885	rs11885392	chr2:1578182	C/A	cg01028140	chr2:1542097	TPO	-0.44	-8.23	-0.36	1.98e-15	IgG glycosylation;
LGG	cis	rs514406	1.000	rs514406	chr1:53330458	A/G	cg24675658	chr1:53192096	ZYG11B	-0.44	-7.29	-0.32	1.31e-12	Monocyte count;
LGG	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg21132104	chr15:45694354	SPATA5L1	0.71	10.19	0.43	4.04e-22	Homoarginine levels;
LGG	cis	rs11191205	0.644	rs3095791	chr10:103383836	T/C	cg15320455	chr10:103880129	LDB1	0.46	6.71	0.3	5.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs3925075	1.000	rs4506917	chr16:31347350	T/G	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs1577917	0.785	rs1885607	chr6:86394905	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	11.69	0.48	7.83e-28	Response to antipsychotic treatment;
LGG	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.69	-0.34	9.04e-14	HDL cholesterol;
LGG	cis	rs516946	0.666	rs6986080	chr8:41488038	G/C	cg01678292	chr8:41522873	ANK1	0.33	7.39	0.32	6.99e-13	Type 2 diabetes;
LGG	cis	rs7928758	0.887	rs11822935	chr11:134271771	T/C	cg15243474	chr11:134282918	B3GAT1	1.16	15.72	0.59	5.95e-45	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg24112000	chr20:60950667	NA	-0.38	-9.03	-0.39	4.79e-18	Colorectal cancer;
LGG	cis	rs4731207	0.698	rs7789859	chr7:124519472	C/G	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-9.5	-0.4	1.12e-19	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.34	-0.5	1.98e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg15921436	chr17:44337874	NA	0.59	12.79	0.51	2.67e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7326068	0.524	rs2497484	chr13:21199265	C/T	cg04906043	chr13:21280425	IL17D	0.4	6.94	0.31	1.34e-11	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs2276314	0.857	rs4799409	chr18:33592602	C/T	cg19628046	chr18:33552617	C18orf21	0.52	7.51	0.33	2.99e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7209395	0.960	rs62063615	chr17:64184287	C/T	cg19474267	chr17:64306194	PRKCA	0.52	8.01	0.35	9.63e-15	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08409687	chr2:201936025	NDUFB3;FAM126B	0.43	7.58	0.33	1.86e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9457247	0.765	rs10455982	chr6:167448728	C/T	cg07741184	chr6:167504864	NA	0.43	9.51	0.4	1.07e-19	Crohn's disease;
LGG	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg11707556	chr5:10655725	ANKRD33B	0.59	10.25	0.43	2.44e-22	Coronary artery disease;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg11859384	chr17:80120422	CCDC57	0.47	8.21	0.36	2.18e-15	Life satisfaction;
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg00149659	chr3:10157352	C3orf10	0.74	9.26	0.4	7.76e-19	Alzheimer's disease;
LGG	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg04731861	chr2:219085781	ARPC2	-0.44	-10.47	-0.44	3.51e-23	Colorectal cancer;
LGG	cis	rs2072732	0.756	rs7514166	chr1:2949607	G/C	cg08733933	chr1:2954429	NA	-0.43	-8.68	-0.37	6.57e-17	Plateletcrit;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs926392	0.896	rs4812357	chr20:37683071	C/T	cg16355469	chr20:37678765	NA	-0.47	-7.95	-0.35	1.4e-14	Dialysis-related mortality;
LGG	cis	rs3796352	1.000	rs116616340	chr3:53132371	C/G	cg12962167	chr3:53033115	SFMBT1	0.62	6.71	0.3	5.68e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs11750568	0.967	rs6864279	chr5:178515060	G/T	cg10208897	chr5:178548229	ADAMTS2	-0.43	-6.98	-0.31	1.04e-11	Height;
LGG	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.18	-0.77	2.24e-93	Renal cell carcinoma;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10262624	1.000	rs10238070	chr7:23909791	G/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs2243480	0.708	rs35310401	chr7:65390359	A/G	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs4824093	0.535	rs73441802	chr22:50273916	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.83	-7.19	-0.32	2.57e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg19223190	chr17:80058835	NA	0.44	8.57	0.37	1.51e-16	Life satisfaction;
LGG	cis	rs9828933	0.752	rs28675788	chr3:63942188	C/G	cg17941049	chr3:63904683	ATXN7	0.69	7.64	0.33	1.22e-13	Type 2 diabetes;
LGG	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.6	0.33	1.7e-13	Educational attainment;
LGG	cis	rs911263	0.603	rs2145423	chr14:68796930	A/G	cg18825221	chr14:68749962	RAD51L1	0.35	7.74	0.34	6.41e-14	Primary biliary cholangitis;
LGG	cis	rs870825	0.616	rs6552809	chr4:185643984	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.3	0.72	2.34e-75	Blood protein levels;
LGG	cis	rs2018055	0.618	rs7764024	chr6:117796127	C/T	cg14611402	chr6:117803162	DCBLD1	0.31	8.96	0.38	7.77e-18	Diastolic blood pressure;
LGG	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.39e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.36e-12	Total cholesterol levels;
LGG	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg26384229	chr12:38710491	ALG10B	0.91	21.05	0.7	1.71e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg05425664	chr17:57184151	TRIM37	0.71	11.54	0.47	3.12e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.62e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11055008	0.868	rs10845602	chr12:12825237	A/G	cg04607235	chr12:12878440	APOLD1	-0.51	-8.68	-0.37	6.78e-17	Pulse pressure;
LGG	cis	rs2067615	0.579	rs10778506	chr12:107143260	T/C	cg15890332	chr12:107067104	RFX4	0.41	12.01	0.49	4.06e-29	Heart rate;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg07120314	chr15:79043507	NA	-0.69	-16.22	-0.6	3.59e-47	Coronary artery disease or large artery stroke;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg02018176	chr4:1364513	KIAA1530	-0.48	-11.09	-0.46	1.6e-25	Obesity-related traits;
LGG	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.96	0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg15948088	chr11:109293068	C11orf87	0.45	8.08	0.35	5.81e-15	Schizophrenia;
LGG	cis	rs2120243	0.845	rs2305619	chr3:157154861	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.31	6.66	0.3	7.63e-11	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg25437947	chr8:17941982	ASAH1	-0.41	-7.11	-0.31	4.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.73	0.59	5.57e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2235573	0.625	rs8142174	chr22:38427963	C/T	cg19171272	chr22:38449367	NA	-0.52	-10.01	-0.42	1.78e-21	Glioblastoma;Glioma;
LGG	cis	rs9400467	0.537	rs111262375	chr6:111418816	C/G	cg15721981	chr6:111408429	SLC16A10	0.57	7.05	0.31	6.38e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs2916247	0.954	rs7012562	chr8:93020557	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.62	-0.37	1.05e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg23758822	chr17:41437982	NA	0.88	15.69	0.59	8.2e-45	Menopause (age at onset);
LGG	cis	rs701145	0.556	rs355771	chr3:154039385	G/C	cg16511985	chr3:153974050	SGEF	0.51	8.5	0.37	2.53e-16	Coronary artery disease;
LGG	cis	rs295140	0.933	rs10931900	chr2:201177193	T/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.86	0.3	2.16e-11	QT interval;
LGG	cis	rs12497850	0.931	rs7626445	chr3:49114544	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.72	0.3	5.32e-11	Parkinson's disease;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.75e-13	Prudent dietary pattern;
LGG	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.28	-0.43	1.87e-22	Morning vs. evening chronotype;
LGG	cis	rs727505	0.954	rs59379598	chr7:124596903	C/G	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg03517284	chr6:25882590	NA	-0.41	-7.4	-0.33	6.42e-13	Height;
LGG	cis	rs7168592	1.000	rs59465739	chr15:101732717	A/T	cg24254196	chr15:101719523	CHSY1	-0.64	-7.01	-0.31	8.55e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs7587476	0.861	rs17488049	chr2:215651750	G/A	cg04530015	chr2:215796436	ABCA12	-0.44	-6.76	-0.3	4.07e-11	Neuroblastoma;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25517755	chr10:38738941	LOC399744	-0.38	-6.86	-0.3	2.24e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4302748	0.818	rs11771125	chr7:36190426	C/T	cg24442661	chr7:36192818	EEPD1	0.59	7.43	0.33	5.34e-13	Platelet count;
LGG	cis	rs12474201	0.925	rs17822294	chr2:46960004	G/A	cg06386533	chr2:46925753	SOCS5	0.8	14.83	0.57	5.54e-41	Height;
LGG	cis	rs17067123	0.539	rs11735192	chr4:180065076	A/C	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs79911532	0.515	rs10235228	chr7:75833282	G/A	cg15148918	chr7:75625777	STYXL1	-0.55	-6.74	-0.3	4.76e-11	Mononucleosis;
LGG	cis	rs4774899	0.752	rs7168387	chr15:57398934	C/T	cg08128148	chr15:57256372	TCF12	0.29	7.03	0.31	7.5e-12	Urinary tract infection frequency;
LGG	cis	rs897080	0.552	rs1085443	chr2:44635015	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.88	9.26	0.4	7.82e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg00579200	chr11:133705235	NA	-0.59	-11.28	-0.46	3.07e-26	Childhood ear infection;
LGG	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	14.88	0.57	3.46e-41	IgG glycosylation;
LGG	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg04546413	chr19:29218101	NA	0.64	8.7	0.37	5.91e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs10882165	0.547	rs4918904	chr10:94961320	A/T	cg13743231	chr10:94958683	NA	-0.34	-6.66	-0.3	7.94e-11	Refractive error;
LGG	cis	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg24189917	chr7:1970923	MAD1L1	-0.61	-8.97	-0.38	7.55e-18	Bipolar disorder;
LGG	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg26384229	chr12:38710491	ALG10B	0.92	20.84	0.7	1.66e-68	Bladder cancer;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.3	-7.57	-0.33	1.98e-13	IgG glycosylation;
LGG	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg24375607	chr4:120327624	NA	0.6	10.26	0.43	2.18e-22	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.35e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7226408	0.857	rs117376812	chr18:34549886	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs9902453	0.868	rs9896012	chr17:28470091	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.15	0.52	9.16e-34	Coffee consumption (cups per day);
LGG	cis	rs9486715	0.838	rs4839840	chr6:96941149	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	15.92	0.59	7.84e-46	Headache;
LGG	trans	rs1728785	0.892	rs1170427	chr16:68603852	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.15	-0.35	3.31e-15	Hip circumference adjusted for BMI;
LGG	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.31	-0.53	1.82e-34	Vitamin D levels;
LGG	cis	rs2244613	0.706	rs7200011	chr16:55794768	C/A	cg02649063	chr16:55794731	CES4	0.45	7.54	0.33	2.47e-13	Response to dabigatran etexilate treatment;
LGG	cis	rs7944584	0.545	rs7118178	chr11:47659135	G/A	cg20307385	chr11:47447363	PSMC3	0.84	16.76	0.61	1.29e-49	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg07701084	chr6:150067640	NUP43	0.7	13.42	0.53	6.16e-35	Lung cancer;
LGG	cis	rs4742903	0.935	rs10991186	chr9:106996153	C/T	cg14250997	chr9:106856677	SMC2	-0.38	-7.82	-0.34	3.65e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.18	0.7	4.2e-70	Chronic sinus infection;
LGG	cis	rs7927771	0.524	rs11039345	chr11:47720228	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.17	0.46	7.88e-26	Subjective well-being;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg05335186	chr13:53173507	NA	0.49	10.3	0.43	1.58e-22	Lewy body disease;
LGG	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs367943	0.666	rs6594704	chr5:112692834	A/T	cg12552261	chr5:112820674	MCC	0.56	10.09	0.42	8.95e-22	Type 2 diabetes;
LGG	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.49e-15	Common traits (Other);
LGG	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg01028140	chr2:1542097	TPO	-0.54	-8.62	-0.37	1.05e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg05861140	chr6:150128134	PCMT1	0.3	6.96	0.31	1.17e-11	Testicular germ cell tumor;
LGG	cis	rs9715521	0.868	rs12650159	chr4:59818550	C/T	cg11281224	chr4:60001000	NA	-0.44	-7.15	-0.32	3.35e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg08677398	chr8:58056175	NA	0.44	7.36	0.32	8.23e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.603	rs9638768	chr7:19869522	C/T	cg05791153	chr7:19748676	TWISTNB	-0.62	-7.86	-0.34	2.66e-14	Night sleep phenotypes;
LGG	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18252515	chr7:66147081	NA	0.41	6.93	0.31	1.44e-11	Aortic root size;
LGG	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	8.22	0.36	2.12e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.78	-0.38	3.19e-17	Bone mineral density;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs55871839	0.547	rs3780001	chr8:59872615	G/T	cg07426533	chr8:59803705	TOX	-0.6	-12.8	-0.51	2.52e-32	Pneumonia;
LGG	cis	rs11711311	1.000	rs28394480	chr3:113485143	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.51e-13	IgG glycosylation;
LGG	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Lung cancer in ever smokers;
LGG	cis	rs9457247	0.534	rs9355610	chr6:167383075	G/A	cg18261144	chr6:167370276	RNASET2	-0.38	-7.68	-0.34	9.5e-14	Crohn's disease;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg23758822	chr17:41437982	NA	0.85	15.51	0.58	5.51e-44	Menopause (age at onset);
LGG	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.7	0.54	4.13e-36	Bladder cancer;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13012494	chr21:47604986	C21orf56	-0.5	-8.23	-0.36	1.89e-15	Testicular germ cell tumor;
LGG	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg15596359	chr8:11213517	TDH	-0.41	-8.3	-0.36	1.15e-15	Retinal vascular caliber;
LGG	cis	rs6665290	0.669	rs12406714	chr1:227177061	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.07	-0.83	1.1e-119	Myeloid white cell count;
LGG	cis	rs694739	1.000	rs1783521	chr11:64106291	T/C	cg02228329	chr11:64053129	BAD;GPR137	0.84	17.24	0.63	8.3e-52	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2373794	1.000	rs2373794	chr2:40354477	C/G	cg17740179	chr2:40377776	SLC8A1	0.95	20.13	0.68	3.45e-65	Asthma;
LGG	cis	rs4470077	1.000	rs12879078	chr14:55899415	C/T	cg04306507	chr14:55594613	LGALS3	0.38	6.78	0.3	3.58e-11	Platelet count;
LGG	trans	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg11430096	chr6:110968061	CDK19	0.64	6.87	0.3	2.09e-11	Prostate cancer;
LGG	cis	rs8112449	0.822	rs7260594	chr19:10548136	C/T	cg21868191	chr19:10515988	NA	-0.48	-8.03	-0.35	8.15e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs7827545	1.000	rs1372659	chr8:135566779	T/A	cg17885191	chr8:135476712	NA	0.44	6.99	0.31	9.83e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14555127	chr7:35841578	SEPT7	0.45	7.61	0.33	1.52e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs13294100	0.929	rs1028594	chr9:17583310	A/G	cg11213383	chr9:17579734	SH3GL2	-0.63	-11.5	-0.47	4.29e-27	Parkinson's disease;
LGG	cis	rs7607369	0.618	rs62193298	chr2:219655211	T/G	cg01130898	chr2:219473002	PLCD4	0.41	6.74	0.3	4.65e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs10489202	0.657	rs201540	chr1:167992883	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-10.57	-0.44	1.52e-23	Schizophrenia;
LGG	cis	rs10504073	0.565	rs12056536	chr8:49890132	C/T	cg00325661	chr8:49890786	NA	-0.8	-16.11	-0.6	1.1e-46	Blood metabolite ratios;
LGG	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.16	-0.49	1.03e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg26513180	chr16:89883248	FANCA	0.98	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.27	-0.36	1.39e-15	Gut microbiome composition (summer);
LGG	cis	rs62283056	0.512	rs4568307	chr4:6284965	A/G	cg00701064	chr4:6280414	WFS1	0.67	13.16	0.52	7.67e-34	Cisplatin-induced ototoxicity;
LGG	cis	rs13102973	0.965	rs11731021	chr4:135850391	G/T	cg14419869	chr4:135874104	NA	0.56	10.7	0.45	5.24e-24	Subjective well-being;
LGG	cis	rs5769765	1.000	rs910800	chr22:50278642	C/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.54	-0.33	2.51e-13	Schizophrenia;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg06968155	chr5:131705112	SLC22A5	0.75	8.62	0.37	1.04e-16	Rheumatoid arthritis;
LGG	cis	rs8114671	0.562	rs6088655	chr20:33527838	A/G	cg07148914	chr20:33460835	GGT7	0.53	8.83	0.38	2.16e-17	Height;
LGG	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.29	-0.4	6.17e-19	Height;
LGG	cis	rs8067545	0.750	rs7208365	chr17:19998017	T/G	cg13482628	chr17:19912719	NA	0.62	12.29	0.5	3.17e-30	Schizophrenia;
LGG	cis	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg21775007	chr8:11205619	TDH	-0.56	-8.78	-0.38	3.16e-17	Retinal vascular caliber;
LGG	cis	rs367615	0.879	rs56689485	chr5:108879828	A/T	cg17395555	chr5:108820864	NA	0.65	9.03	0.39	4.69e-18	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg20019365	chr2:219134978	PNKD;AAMP	0.67	11.47	0.47	5.68e-27	Colorectal cancer;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg02158880	chr13:53174818	NA	0.47	9.76	0.41	1.37e-20	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11665588	chr11:94963991	SESN3	0.45	6.83	0.3	2.6e-11	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.87	0.54	8.26e-37	Lung cancer in ever smokers;
LGG	cis	rs6426558	0.537	rs56219094	chr1:227340191	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.63	-10.52	-0.44	2.45e-23	Neutrophil percentage of white cells;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg13699009	chr12:122356056	WDR66	0.55	15.18	0.58	1.64e-42	Mean corpuscular volume;
LGG	cis	rs7666738	0.830	rs3857217	chr4:99034347	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.45	0.37	3.75e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4629180	0.675	rs10195061	chr2:102093974	T/G	cg16435561	chr2:102091048	RFX8	0.49	9.14	0.39	1.92e-18	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs7939886	0.841	rs11227702	chr11:56034774	A/C	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15128208	chr22:42549153	NA	-0.43	-8.74	-0.38	4.25e-17	Cognitive function;
LGG	cis	rs990171	1.000	rs990171	chr2:103086770	A/C	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs929354	1.000	rs929354	chr7:157045557	C/T	cg17757837	chr7:157058334	UBE3C	-0.82	-17.56	-0.63	2.74e-53	Body mass index;
LGG	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.42	-0.36	4.84e-16	Monocyte count;
LGG	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg03959625	chr15:84868606	LOC388152	0.47	7.04	0.31	6.96e-12	Schizophrenia;
LGG	cis	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.99	-0.49	4.91e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg02002194	chr4:3960332	NA	0.47	8.92	0.38	1.09e-17	Systolic blood pressure;
LGG	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg00599393	chr8:22457479	C8orf58	0.43	7.74	0.34	6.24e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg14703610	chr5:56206110	C5orf35	0.39	6.77	0.3	3.88e-11	Coronary artery disease;
LGG	cis	rs959260	0.557	rs55762977	chr17:73309338	A/G	cg14668889	chr17:73230827	NUP85	0.57	9.34	0.4	4.01e-19	Systemic lupus erythematosus;
LGG	cis	rs477692	0.837	rs543454	chr10:131420536	T/C	cg05714579	chr10:131428358	MGMT	0.65	13.64	0.54	7.6e-36	Response to temozolomide;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg26338869	chr17:61819248	STRADA	0.59	9.81	0.41	9.35e-21	Prudent dietary pattern;
LGG	cis	rs3020736	0.500	rs6002605	chr22:42494335	A/G	cg05082376	chr22:42548792	NA	0.37	7.74	0.34	6.19e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11150308	chr17:74068434	SRP68	-0.4	-6.7	-0.3	6.2e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg02187348	chr16:89574699	SPG7	-0.56	-9.48	-0.4	1.35e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.73	0.34	6.79e-14	Lung cancer;
LGG	cis	rs876084	0.505	rs6469899	chr8:121102762	C/T	cg06265175	chr8:121136014	COL14A1	0.49	9.8	0.41	9.56e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs765787	0.530	rs12915804	chr15:45512562	T/C	cg25801113	chr15:45476975	SHF	-0.87	-19.06	-0.66	3.19e-60	Uric acid levels;
LGG	cis	rs2274273	0.624	rs11848575	chr14:55755788	A/G	cg04306507	chr14:55594613	LGALS3	0.54	12.59	0.51	1.76e-31	Protein biomarker;
LGG	cis	rs432925	0.600	rs214247	chr16:349221	A/G	cg06233593	chr16:337645	AXIN1	0.42	7.78	0.34	4.69e-14	Morning vs. evening chronotype;
LGG	cis	rs4538187	1.000	rs4671071	chr2:64085638	C/T	cg14150252	chr2:64069583	UGP2	0.5	9.99	0.42	2.11e-21	Systolic blood pressure;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07494914	chr16:46461571	NA	0.43	7.9	0.34	2.05e-14	Menarche (age at onset);
LGG	cis	rs5769765	0.505	rs4561759	chr22:50256686	C/T	cg02269571	chr22:50332266	NA	0.66	8.76	0.38	3.6e-17	Schizophrenia;
LGG	trans	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg12045294	chr17:78518616	RPTOR	-0.47	-7.27	-0.32	1.5e-12	Glycated hemoglobin levels;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg22903471	chr2:27725779	GCKR	-0.54	-12.32	-0.5	2.29e-30	Total body bone mineral density;
LGG	cis	rs2274273	0.870	rs8013713	chr14:55841252	A/G	cg04306507	chr14:55594613	LGALS3	-0.62	-17.22	-0.62	1.02e-51	Protein biomarker;
LGG	cis	rs6546550	0.935	rs3771541	chr2:70031797	C/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-7.18	-0.32	2.87e-12	Prevalent atrial fibrillation;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.79	-14.63	-0.56	4.22e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.18e-12	HDL cholesterol;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13732083	chr21:47605072	C21orf56	0.52	8.95	0.38	8.66e-18	Testicular germ cell tumor;
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg10056627	chr6:42928773	GNMT	0.26	7.21	0.32	2.23e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg25754956	chr12:51612065	POU6F1	0.61	10.18	0.43	4.33e-22	Cisplatin-induced ototoxicity;
LGG	cis	rs9674544	0.757	rs4410130	chr17:47122942	C/T	cg20966754	chr17:47091339	IGF2BP1	0.37	7.11	0.31	4.43e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs58649573	0.552	rs10760307	chr9:126786733	C/G	cg14112217	chr9:126806003	NA	-0.37	-7.28	-0.32	1.47e-12	Post-traumatic stress disorder;
LGG	cis	rs11608355	0.597	rs10850070	chr12:109793882	A/G	cg19025524	chr12:109796872	NA	-0.6	-13.17	-0.52	7.53e-34	Neuroticism;
LGG	cis	rs6831352	0.879	rs2851255	chr4:100042103	C/G	cg12011299	chr4:100065546	ADH4	0.4	7.71	0.34	7.99e-14	Alcohol dependence;
LGG	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg16141378	chr3:129829833	LOC729375	0.36	8.04	0.35	7.84e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8133932	0.608	rs413246	chr21:47346066	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.97	-0.35	1.26e-14	Schizophrenia;
LGG	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg18876405	chr7:65276391	NA	0.63	11.25	0.46	4.09e-26	Aortic root size;
LGG	cis	rs1862618	0.671	rs2591966	chr5:56233688	T/G	cg08400814	chr5:56204995	C5orf35	0.39	7.07	0.31	5.8e-12	Initial pursuit acceleration;
LGG	cis	rs600550	0.558	rs4444096	chr11:60094004	G/C	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.76	-0.34	5.39e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg21017887	chr14:105400489	NA	0.43	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.37	0.4	3.32e-19	Height;
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg18252515	chr7:66147081	NA	0.41	6.93	0.31	1.44e-11	Aortic root size;
LGG	trans	rs11976180	1.000	rs2951363	chr7:143754724	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.95	-0.31	1.28e-11	Obesity-related traits;
LGG	cis	rs6714710	0.603	rs6757357	chr2:98491750	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.47	0.4	1.4e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10504130	0.666	rs7833668	chr8:52853886	A/G	cg24946253	chr8:52722146	PXDNL	0.43	6.8	0.3	3.31e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg20368463	chr18:77673604	PQLC1	-0.52	-10.08	-0.42	9.71e-22	Schizophrenia;
LGG	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs7980799	0.816	rs4587807	chr12:33510115	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.85	-0.38	1.89e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs28595532	0.702	rs116320061	chr4:119384600	C/T	cg26518628	chr1:97050305	NA	-0.84	-7.79	-0.34	4.35e-14	Cannabis dependence symptom count;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg19492446	chr18:35145650	BRUNOL4	-0.41	-6.94	-0.31	1.36e-11	Hematological and biochemical traits;
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	trans	rs7944735	0.508	rs76472587	chr11:47881487	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.88	0.3	1.98e-11	Intraocular pressure;
LGG	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg26248373	chr2:1572462	NA	-0.71	-9.18	-0.39	1.39e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs783540	0.846	rs783539	chr15:83254070	A/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.69	-0.3	6.34e-11	Schizophrenia;
LGG	trans	rs1814175	0.645	rs847630	chr11:49926360	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs1707322	1.000	rs11211205	chr1:46321874	C/T	cg03146154	chr1:46216737	IPP	0.54	10.49	0.44	3.14e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg04673462	chr1:38461896	NA	-0.49	-8.98	-0.39	6.87e-18	Coronary artery disease;
LGG	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	13.03	0.52	2.83e-33	Alzheimer's disease;
LGG	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg03342759	chr3:160939853	NMD3	-0.76	-13.57	-0.53	1.53e-35	Parkinson's disease;
LGG	cis	rs9462027	0.628	rs6457795	chr6:34819366	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.26	-0.46	3.55e-26	Systemic lupus erythematosus;
LGG	cis	rs10779751	0.770	rs12075896	chr1:11200350	C/A	cg08854313	chr1:11322531	MTOR	-0.71	-14.57	-0.56	7.28e-40	Body mass index;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.92	0.38	1.07e-17	Mood instability;
LGG	cis	rs7222240	1.000	rs12103720	chr17:43180617	C/T	cg24806326	chr17:43207588	PLCD3	0.46	7.95	0.35	1.49e-14	Craniofacial microsomia;
LGG	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.4	0.36	5.37e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.13	-0.31	3.96e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg18357526	chr6:26021779	HIST1H4A	0.43	7.16	0.32	3.29e-12	Height;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg21782813	chr7:2030301	MAD1L1	-0.49	-11.71	-0.48	6.18e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg23131131	chr22:24373011	LOC391322	-0.53	-9.06	-0.39	3.59e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.24	0.43	2.54e-22	Lung cancer in ever smokers;
LGG	cis	rs12476592	0.602	rs964880	chr2:63826932	C/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg18252515	chr7:66147081	NA	-0.75	-12.01	-0.49	3.93e-29	Corneal structure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26361052	chr2:70417980	C2orf42	0.46	7.13	0.31	3.97e-12	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.86	0.3	2.18e-11	Triglycerides;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs17208368	0.628	rs12449074	chr16:55092597	C/T	cg09947736	chr16:55091198	NA	0.68	12.72	0.51	5.57e-32	Hypospadias;
LGG	cis	rs9547692	0.793	rs556429	chr13:37487021	C/A	cg02985381	chr13:37494744	SMAD9	0.66	11.39	0.47	1.13e-26	Coronary artery disease;
LGG	cis	rs7944584	0.563	rs2280231	chr11:47600438	C/T	cg20307385	chr11:47447363	PSMC3	0.85	17.08	0.62	4.44e-51	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.91	-0.31	1.61e-11	Systolic blood pressure;
LGG	cis	rs2455799	0.613	rs13071161	chr3:15958166	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.29	-0.32	1.33e-12	Mean platelet volume;
LGG	cis	rs2985684	1.000	rs2985696	chr14:50094913	C/A	cg04989706	chr14:50066350	PPIL5	-0.51	-7.95	-0.35	1.41e-14	Carotid intima media thickness;
LGG	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.12	26.59	0.78	2.93e-95	Chronic sinus infection;
LGG	cis	rs36093844	0.752	rs1445505	chr11:85584722	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9522267	0.643	rs9522279	chr13:112221296	C/T	cg14952266	chr13:112191215	NA	0.42	8.14	0.35	3.75e-15	Hepatitis;
LGG	cis	rs17875496	0.912	rs3898677	chr15:81596562	T/C	cg19620333	chr15:81596332	IL16	0.48	9.53	0.41	8.66e-20	Number of common colds;
LGG	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	10.8	0.45	2.15e-24	Height;
LGG	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg04287289	chr16:89883240	FANCA	0.49	8.73	0.38	4.53e-17	Vitiligo;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg16507663	chr6:150244633	RAET1G	0.52	10.63	0.44	9.28e-24	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs807669	0.548	rs9605957	chr22:19187375	G/A	cg02655711	chr22:19163373	SLC25A1	0.59	11.09	0.46	1.63e-25	Metabolite levels;
LGG	cis	rs9381040	0.610	rs9367094	chr6:41017860	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.75	-0.3	4.49e-11	Alzheimer's disease (late onset);
LGG	cis	rs11785693	0.862	rs11782343	chr8:5001642	C/G	cg26367366	chr8:4980734	NA	0.97	14.37	0.56	5.67e-39	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs747782	0.528	rs4370963	chr11:48433943	C/G	cg03929089	chr4:120376271	NA	0.71	8.3	0.36	1.17e-15	Intraocular pressure;
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg14675211	chr2:100938903	LONRF2	0.67	12.09	0.49	1.98e-29	Intelligence (multi-trait analysis);
LGG	trans	rs2235573	0.527	rs139879	chr22:38364552	T/C	cg19894588	chr14:64061835	NA	0.63	10.48	0.44	3.2e-23	Glioblastoma;Glioma;
LGG	cis	rs9894429	1.000	rs9747349	chr17:79584297	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19161053	chr7:99036702	CPSF4;PTCD1	0.48	7.33	0.32	1.04e-12	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg18963800	chr10:38644991	HSD17B7P2	0.46	7.47	0.33	3.91e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs593982	0.719	rs11606668	chr11:65472758	A/G	cg08755490	chr11:65554678	OVOL1	-0.5	-7.87	-0.34	2.52e-14	Atopic dermatitis;
LGG	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg14456004	chr13:21872349	NA	-1.22	-19.63	-0.67	7.5e-63	White matter hyperintensity burden;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg02733842	chr7:1102375	C7orf50	0.59	9.76	0.41	1.38e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg04662567	chr6:169592167	NA	-0.85	-11.7	-0.48	6.85e-28	Pulse pressure;
LGG	cis	rs10992471	0.756	rs1121979	chr9:95140218	G/A	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.15	-0.32	3.43e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14893161	chr1:205819251	PM20D1	1.01	26.65	0.78	1.51e-95	Menarche (age at onset);
LGG	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg18850127	chr7:39170497	POU6F2	0.64	16.19	0.6	4.93e-47	IgG glycosylation;
LGG	cis	rs3781663	0.526	rs7936612	chr11:70019182	A/G	cg06393558	chr11:69982916	ANO1	-0.4	-7.83	-0.34	3.3e-14	Survival in rectal cancer;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.14	0.31	3.68e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.77	14.37	0.56	5.38e-39	Obesity-related traits;
LGG	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg21775007	chr8:11205619	TDH	-0.45	-7.51	-0.33	3.05e-13	Neuroticism;
LGG	cis	rs13421350	0.579	rs57404607	chr2:173377277	G/T	cg15021238	chr2:173305865	ITGA6	-0.8	-8.63	-0.37	1.03e-16	Diabetic kidney disease;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.67e-44	Prostate cancer;
LGG	cis	rs902774	0.554	rs4919749	chr12:53358034	C/T	cg05393297	chr12:53359155	NA	-0.58	-14.93	-0.57	1.96e-41	Prostate cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04075035	chr5:54602880	DHX29;SKIV2L2	0.42	7.15	0.32	3.35e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg26924012	chr15:45694286	SPATA5L1	1.04	21.85	0.71	3.05e-73	Homoarginine levels;
LGG	cis	rs1185460	0.546	rs474201	chr11:118958229	G/A	cg24687335	chr11:118901407	SLC37A4	0.57	10.33	0.43	1.16e-22	Coronary artery disease;
LGG	cis	rs10850519	0.751	rs11067630	chr12:115943907	C/T	cg18639984	chr12:115943877	NA	-0.42	-9.09	-0.39	2.99e-18	Diastolic blood pressure;
LGG	cis	rs6834538	0.655	rs4428348	chr4:113423989	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.45	7.47	0.33	3.9e-13	Free thyroxine concentration;
LGG	cis	rs6546324	0.615	rs4233939	chr2:67782735	A/C	cg18237512	chr2:67827392	NA	-0.38	-6.91	-0.31	1.66e-11	Endometriosis;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2562456	0.917	rs2681376	chr19:21715525	T/G	cg25042112	chr7:64838748	ZNF92	0.46	6.65	0.3	8.33e-11	Pain;
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg15556689	chr8:8085844	FLJ10661	0.46	8.15	0.35	3.52e-15	Neuroticism;
LGG	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs6032067	0.683	rs16989769	chr20:43780475	A/G	cg10761708	chr20:43804764	PI3	-0.58	-8.97	-0.38	7.49e-18	Blood protein levels;
LGG	cis	rs7364180	0.515	rs6002503	chr22:42208672	A/G	cg17376030	chr22:41985996	PMM1	0.39	7.08	0.31	5.49e-12	Alzheimer's disease biomarkers;
LGG	cis	rs12286929	0.556	rs11605461	chr11:115053011	C/T	cg04055981	chr11:115044050	NA	-0.36	-6.86	-0.3	2.21e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg18856731	chr12:58011764	NA	-0.35	-7.11	-0.31	4.5e-12	Multiple sclerosis;
LGG	cis	rs752010	0.574	rs10890157	chr1:42117689	C/G	cg06885757	chr1:42089581	HIVEP3	0.5	11.2	0.46	6.43e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6838801	0.857	rs903044	chr4:77578750	A/G	cg17476223	chr4:77663285	SHROOM3	0.38	6.82	0.3	2.86e-11	Cleft lip with or without cleft palate;
LGG	cis	rs4493873	0.674	rs7016665	chr8:92050911	A/C	cg16814680	chr8:91681699	NA	0.49	7.9	0.34	2.11e-14	Migraine - clinic-based;
LGG	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg10664184	chr19:17420304	DDA1	-0.53	-8.2	-0.36	2.4e-15	Systemic lupus erythematosus;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	10.54	0.44	1.97e-23	Lung function (FEV1/FVC);
LGG	cis	rs718857	0.826	rs10990993	chr9:106684088	C/A	cg14250997	chr9:106856677	SMC2	0.33	6.74	0.3	4.8e-11	Breast cancer;
LGG	cis	rs3857067	1.000	rs3846292	chr4:95027717	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.82	-0.34	3.72e-14	QT interval;
LGG	cis	rs4237845	0.537	rs10747787	chr12:58260657	A/G	cg02175503	chr12:58329896	NA	0.52	8.89	0.38	1.36e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs45500192	chr22:42177899	A/G	cg03806693	chr22:41940476	POLR3H	-1.05	-17.67	-0.63	9.24e-54	Vitiligo;
LGG	cis	rs990171	0.955	rs6734736	chr2:103062880	C/T	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	trans	rs11165623	0.564	rs9887887	chr1:96996930	A/G	cg10631902	chr5:14652156	NA	-0.44	-9.25	-0.39	8.01e-19	Hip circumference;Waist circumference;
LGG	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg25885449	chr18:77638415	KCNG2	0.36	6.78	0.3	3.66e-11	Schizophrenia;
LGG	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg01411142	chr8:19674711	INTS10	0.42	6.89	0.3	1.87e-11	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg06521331	chr12:34319734	NA	0.4	6.7	0.3	5.92e-11	Morning vs. evening chronotype;
LGG	cis	rs9649465	0.542	rs616297	chr7:123426949	A/G	cg03229431	chr7:123269106	ASB15	0.61	14.08	0.55	9.95e-38	Migraine;
LGG	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg08861369	chr16:85671714	KIAA0182	0.43	6.77	0.3	3.87e-11	Platelet distribution width;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg07701084	chr6:150067640	NUP43	-0.68	-12.61	-0.51	1.57e-31	Lung cancer;
LGG	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2976388	0.609	rs2585140	chr8:143806896	A/G	cg06565975	chr8:143823917	SLURP1	0.36	9.28	0.4	6.73e-19	Urinary tract infection frequency;
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg27476859	chr7:2772710	GNA12	0.46	8.76	0.38	3.68e-17	Height;
LGG	cis	rs2239815	0.515	rs5762829	chr22:29228130	A/G	cg15103426	chr22:29168792	CCDC117	0.65	7.96	0.35	1.37e-14	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs7937682	0.564	rs1944114	chr11:111366460	T/C	cg09085632	chr11:111637200	PPP2R1B	0.64	10.89	0.45	9.78e-25	Primary sclerosing cholangitis;
LGG	cis	rs1728785	0.901	rs1645934	chr16:68564490	T/A	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs3219090	0.962	rs1828446	chr1:226601320	G/A	cg17127702	chr1:226594323	PARP1	0.38	12.32	0.5	2.22e-30	Melanoma;
LGG	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.91	-10.19	-0.43	3.87e-22	Diabetic retinopathy;
LGG	cis	rs4144027	0.904	rs10438244	chr14:104346185	A/G	cg20488157	chr14:104394430	TDRD9	0.39	6.69	0.3	6.44e-11	Blood metabolite levels;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs8067545	0.717	rs9907788	chr17:20008903	T/C	cg09818912	chr17:20140352	CYTSB	-0.3	-6.92	-0.31	1.55e-11	Schizophrenia;
LGG	cis	rs72634258	0.945	rs12748993	chr1:8129507	A/G	cg00042356	chr1:8021962	PARK7	0.78	10.24	0.43	2.57e-22	Inflammatory bowel disease;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs7215564	0.908	rs77750710	chr17:78717117	C/T	cg06153925	chr17:78755379	RPTOR	0.42	7.23	0.32	1.99e-12	Myopia (pathological);
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg16301924	chr13:53314226	LECT1	-0.48	-9.98	-0.42	2.2e-21	Lewy body disease;
LGG	trans	rs7819412	0.505	rs17782536	chr8:11021682	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.09	-0.31	5.08e-12	Triglycerides;
LGG	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.69	-12.27	-0.5	3.83e-30	Platelet count;
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg24503407	chr1:205819492	PM20D1	0.57	11.41	0.47	9.86e-27	Menarche (age at onset);
LGG	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs9863	0.861	rs4765219	chr12:124440110	G/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.33	-0.32	1.03e-12	White blood cell count;
LGG	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg18165381	chr3:44552316	NA	-0.41	-6.87	-0.3	2.01e-11	Depressive symptoms;
LGG	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg00071950	chr4:10020882	SLC2A9	0.38	7.79	0.34	4.39e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg00745463	chr17:30367425	LRRC37B	0.54	7.33	0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg20673091	chr1:2541236	MMEL1	0.78	18.07	0.64	1.29e-55	Ulcerative colitis;
LGG	trans	rs9929218	1.000	rs9936621	chr16:68798682	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.8	-0.51	2.52e-32	Colorectal cancer;
LGG	cis	rs7717393	1.000	rs72813881	chr5:155760241	C/T	cg19569526	chr5:155754265	SGCD	0.85	7.87	0.34	2.45e-14	Egg allergy;
LGG	cis	rs2288073	0.965	rs10173949	chr2:24410256	A/C	cg06627628	chr2:24431161	ITSN2	-0.67	-10.78	-0.45	2.46e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs561341	0.941	rs17780086	chr17:30343282	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.7	0.34	8.24e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4906332	1.000	rs17680085	chr14:103953154	T/C	cg26031613	chr14:104095156	KLC1	-0.51	-7.74	-0.34	6.23e-14	Coronary artery disease;
LGG	cis	rs138249	0.898	rs84504	chr22:50559247	G/A	cg07310406	chr22:50524374	MLC1	0.41	8.09	0.35	5.18e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.591	rs59149651	chr1:227877251	T/C	cg04117972	chr1:227635322	NA	0.44	8.09	0.35	5.13e-15	Major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01840575	chr2:38977957	SFRS7	0.45	7.63	0.33	1.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg26655873	chr3:72818019	SHQ1	0.34	6.8	0.3	3.2e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	trans	rs67340775	0.541	rs200979	chr6:27852357	G/A	cg08344181	chr3:125677491	NA	-0.52	-6.65	-0.3	8.49e-11	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg08645402	chr16:4508243	NA	0.53	9.71	0.41	2.07e-20	Schizophrenia;
LGG	cis	rs17401966	0.931	rs3737155	chr1:10459779	G/A	cg19773385	chr1:10388646	KIF1B	-0.47	-9.21	-0.39	1.1e-18	Hepatocellular carcinoma;
LGG	cis	rs12220238	0.722	rs12360087	chr10:76373904	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.56	7.35	0.32	8.8e-13	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg02631450	chr22:32366979	NA	0.99	9.39	0.4	2.74e-19	Childhood ear infection;
LGG	cis	rs6740322	0.895	rs6710656	chr2:43566941	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.55	-0.41	7.52e-20	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs1348850	0.918	rs12622298	chr2:178450651	C/T	cg22681709	chr2:178499509	PDE11A	-0.41	-7.48	-0.33	3.65e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs73416724	1.000	rs76823934	chr6:43359424	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.97e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17067123	0.614	rs6850226	chr4:180052577	T/G	cg26610307	chr4:180072759	NA	-0.51	-7.12	-0.31	4.09e-12	Response to hepatitis C treatment;
LGG	cis	rs4700695	0.719	rs27077	chr5:65445342	C/T	cg21114390	chr5:65439923	SFRS12	0.72	10.57	0.44	1.57e-23	Facial morphology (factor 19);
LGG	trans	rs208515	0.525	rs10944870	chr6:66687757	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.2	0.62	1.28e-51	Exhaled nitric oxide levels;
LGG	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg05552183	chr6:42928497	GNMT	0.31	7.42	0.33	5.62e-13	Blood protein levels;
LGG	cis	rs644799	1.000	rs11021319	chr11:95523123	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.79	0.54	1.82e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2013441	0.711	rs1682297	chr17:20384920	C/T	cg13482628	chr17:19912719	NA	0.44	7.78	0.34	4.9e-14	Obesity-related traits;
LGG	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.52	12.31	0.5	2.42e-30	Oropharynx cancer;
LGG	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg18854424	chr1:2615690	NA	0.36	7.19	0.32	2.64e-12	Ulcerative colitis;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.4	-0.33	6.65e-13	Blood metabolite levels;
LGG	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.76	0.3	4.07e-11	Renal cell carcinoma;
LGG	cis	rs2777491	0.915	rs7178777	chr15:41634588	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.46	-0.67	4.67e-62	Ulcerative colitis;
LGG	cis	rs2456568	0.803	rs10765642	chr11:93640355	C/T	cg26875233	chr11:93583750	C11orf90	0.34	6.74	0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs8062405	1.000	rs62037364	chr16:28868695	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.9	-0.42	4.39e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg16387850	chr1:46982889	NA	0.31	6.72	0.3	5.48e-11	Monobrow;
LGG	cis	rs2051773	0.567	rs7130826	chr11:17037793	T/G	cg15432903	chr11:17409602	KCNJ11	-0.43	-6.66	-0.3	7.64e-11	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	trans	rs5744897	0.708	rs34504371	chr12:133279469	G/A	cg04991071	chr3:71615924	FOXP1	0.6	6.88	0.3	1.91e-11	Urate levels in overweight individuals;
LGG	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg00405596	chr8:11794950	NA	0.63	10.82	0.45	1.73e-24	Monocyte count;
LGG	cis	rs9309473	0.904	rs79145598	chr2:73821382	T/A	cg20560298	chr2:73613845	ALMS1	-0.49	-7.95	-0.35	1.44e-14	Metabolite levels;
LGG	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.56	-9.92	-0.42	3.67e-21	Lung cancer;
LGG	cis	rs55665837	1.000	rs12295888	chr11:14450531	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-8.73	-0.38	4.81e-17	Vitamin D levels;
LGG	cis	rs7166081	1.000	rs35722009	chr15:67625533	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.73	-0.3	5.04e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg20573242	chr4:122745356	CCNA2	0.42	7.74	0.34	6.34e-14	Type 2 diabetes;
LGG	trans	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg06521331	chr12:34319734	NA	0.45	8.07	0.35	5.89e-15	Bladder cancer;
LGG	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg25114630	chr15:101792522	CHSY1	0.57	9.79	0.41	1.04e-20	Corneal structure;
LGG	cis	rs10504130	0.502	rs10087958	chr8:52866669	A/G	cg22653915	chr8:52722023	PXDNL	-0.49	-8.57	-0.37	1.56e-16	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9359856	0.510	rs78649003	chr6:90454644	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-12.94	-0.52	6.68e-33	Bipolar disorder;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg05313129	chr8:58192883	C8orf71	-0.47	-8.12	-0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9788721	0.967	rs55853698	chr15:78857939	T/G	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.55	-0.33	2.27e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs66887589	0.934	rs2389873	chr4:120554714	A/G	cg09307838	chr4:120376055	NA	-0.48	-8.31	-0.36	1.05e-15	Diastolic blood pressure;
LGG	trans	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg07211511	chr3:129823064	LOC729375	-0.67	-9.25	-0.39	8.45e-19	Blood pressure (smoking interaction);
LGG	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.14	-0.31	3.67e-12	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.31e-13	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02697074	chr17:40761760	FAM134C;TUBG1	0.51	7.75	0.34	5.71e-14	Gut microbiome composition (summer);
LGG	cis	rs5758511	0.689	rs56906457	chr22:42628335	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.13	0.31	3.96e-12	Birth weight;
LGG	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.41	0.33	5.95e-13	Hemoglobin concentration;
LGG	cis	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs1322639	0.614	rs9364356	chr6:169567108	G/A	cg03254818	chr6:169586852	NA	0.56	8.53	0.37	2.16e-16	Pulse pressure;
LGG	cis	rs910187	0.591	rs13041142	chr20:45788979	C/T	cg27589058	chr20:45804311	EYA2	-0.31	-7.82	-0.34	3.59e-14	Migraine;
LGG	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14159747	chr11:113255604	NA	0.31	8.39	0.36	5.9e-16	Neuroticism;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Electroencephalogram traits;
LGG	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg16583315	chr14:65563665	MAX	-0.36	-6.99	-0.31	9.81e-12	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6952809	0.532	rs6953297	chr7:2440874	C/G	cg23289794	chr7:2394357	EIF3B	-0.76	-9.68	-0.41	2.54e-20	Multiple sclerosis;
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg03351412	chr1:154909251	PMVK	0.67	13.01	0.52	3.38e-33	Prostate cancer;
LGG	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.32	0.32	1.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.61	0.37	1.19e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17270561	0.562	rs12199626	chr6:26013604	G/A	cg17691542	chr6:26056736	HIST1H1C	1.11	17.79	0.64	2.49e-54	Iron status biomarkers;
LGG	cis	rs3806843	1.000	rs10057161	chr5:140156831	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg16339924	chr4:17578868	LAP3	0.63	11.03	0.46	2.87e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs56399783	0.901	rs17132624	chr7:2778496	G/A	cg19731401	chr7:2775893	GNA12	0.38	7.66	0.34	1.1e-13	Childhood ear infection;
LGG	trans	rs853679	0.546	rs13213152	chr6:28349698	A/G	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg00686598	chr14:53173677	PSMC6	1.39	15.5	0.58	5.73e-44	Alzheimer's disease (late onset);
LGG	cis	rs2131877	0.956	rs12631516	chr3:194872631	T/G	cg07250128	chr3:194833983	C3orf21	0.41	7.64	0.33	1.3e-13	Non-small cell lung cancer;
LGG	cis	rs72827839	0.740	rs72825548	chr17:46231108	A/G	cg02219949	chr17:45927392	SP6	0.53	7.99	0.35	1.1e-14	Ease of getting up in the morning;
LGG	trans	rs7916697	0.593	rs3740587	chr10:70020802	G/A	cg04882175	chr6:131122610	NA	0.44	6.83	0.3	2.6e-11	Optic disc area;
LGG	cis	rs7917772	0.604	rs10883756	chr10:104400112	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.1	-0.39	2.67e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2115630	1.000	rs58581703	chr15:85276935	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.86	-0.3	2.23e-11	P wave terminal force;
LGG	cis	rs6748734	0.581	rs4234092	chr2:241866389	T/C	cg26818257	chr2:241905806	NA	0.51	10.72	0.45	4.31e-24	Urinary metabolites;
LGG	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Vitiligo;
LGG	cis	rs4986172	0.726	rs12051846	chr17:43226887	A/G	cg10701640	chr17:43249399	NA	0.43	7.48	0.33	3.64e-13	Height;
LGG	trans	rs61931739	0.649	rs815046	chr12:33720602	C/T	cg13010199	chr12:38710504	ALG10B	0.36	6.65	0.3	8.23e-11	Morning vs. evening chronotype;
LGG	trans	rs9914544	0.678	rs28374894	chr17:18761659	C/A	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.57	-0.33	2.01e-13	Educational attainment (years of education);
LGG	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs929596	0.556	rs10168416	chr2:234597087	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.49	-0.44	2.93e-23	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg16141378	chr3:129829833	LOC729375	0.4	8.99	0.39	6.4e-18	Neuroticism;
LGG	cis	rs1363119	1.000	rs1363119	chr19:18444809	C/T	cg02383626	chr19:18455508	PGPEP1	-0.76	-17.1	-0.62	3.46e-51	Intelligence (multi-trait analysis);
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01585723	chr16:33734837	NA	0.45	7.87	0.34	2.54e-14	Menopause (age at onset);
LGG	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs36051895	0.664	rs1034072	chr9:5088903	T/A	cg02405213	chr9:5042618	JAK2	-0.8	-14.57	-0.56	7.23e-40	Pediatric autoimmune diseases;
LGG	cis	rs919433	0.679	rs10497806	chr2:198508951	G/A	cg00792783	chr2:198669748	PLCL1	0.57	9.22	0.39	1.02e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9309473	0.948	rs13391552	chr2:73818936	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.61	-0.33	1.58e-13	Metabolite levels;
LGG	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6840360	0.615	rs4696290	chr4:152631472	A/G	cg22705602	chr4:152727874	NA	-0.4	-9.84	-0.42	6.9299999999999992e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6918586	0.532	rs198800	chr6:26139933	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.32	-0.4	4.8e-19	Schizophrenia;
LGG	cis	rs16866061	0.515	rs1027340	chr2:225370554	C/A	cg22455342	chr2:225449267	CUL3	0.44	7.28	0.32	1.44e-12	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg04691961	chr3:161091175	C3orf57	-0.69	-16.87	-0.62	4.05e-50	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg06916706	chr16:4465613	CORO7	-0.75	-13.15	-0.52	8.54e-34	Schizophrenia;
LGG	cis	rs2282300	0.739	rs34224414	chr11:30251041	T/G	cg25418670	chr11:30344373	C11orf46	-0.57	-7.92	-0.35	1.8e-14	Morning vs. evening chronotype;
LGG	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6912958	0.702	rs6906769	chr6:88235949	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.55	-0.37	1.87e-16	Monocyte percentage of white cells;
LGG	cis	rs71403859	0.502	rs8051974	chr16:71488771	C/T	cg08717414	chr16:71523259	ZNF19	-1.28	-17.91	-0.64	7.15e-55	Post bronchodilator FEV1;
LGG	trans	rs7824557	0.736	rs35392635	chr8:11164349	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.21	0.36	2.14e-15	Retinal vascular caliber;
LGG	cis	rs2735413	0.875	rs4888736	chr16:78083784	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg21659725	chr3:3221576	CRBN	0.55	8.61	0.37	1.14e-16	Intelligence (multi-trait analysis);
LGG	cis	rs36071027	0.615	rs34569927	chr5:158421240	A/C	cg00594129	chr5:158524270	EBF1	0.45	8.05	0.35	7.04e-15	Carotid intima media thickness;
LGG	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg11987759	chr7:65425863	GUSB	0.38	7.39	0.32	6.71e-13	Aortic root size;
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg13009111	chr11:71350975	NA	0.3	6.85	0.3	2.43e-11	Neuroticism;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.33	-0.36	9.16e-16	IgG glycosylation;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs774359	0.789	rs17779457	chr9:27488092	G/T	cg22262168	chr9:27528999	MOBKL2B	-0.46	-7.32	-0.32	1.11e-12	Amyotrophic lateral sclerosis;
LGG	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg20368463	chr18:77673604	PQLC1	0.42	7.51	0.33	3.16e-13	Schizophrenia;
LGG	cis	rs4950322	0.518	rs11811023	chr1:146581118	C/T	cg22381352	chr1:146742008	CHD1L	0.41	7.05	0.31	6.57e-12	Protein quantitative trait loci;
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg05555928	chr11:63887634	MACROD1	-0.78	-10.75	-0.45	3.15e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg20573242	chr4:122745356	CCNA2	0.52	9.59	0.41	5.42e-20	Type 2 diabetes;
LGG	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19413766	chr7:29689036	LOC646762	-0.53	-7.49	-0.33	3.44e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.73	0.38	4.58e-17	Schizophrenia;
LGG	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg17747265	chr1:1875780	NA	0.5	8.5	0.37	2.57e-16	Body mass index;
LGG	cis	rs3806843	0.966	rs10060640	chr5:140211226	G/A	cg19875535	chr5:140030758	IK	0.49	10.09	0.42	9.25e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs5758659	0.652	rs133336	chr22:42416303	C/T	cg15128208	chr22:42549153	NA	-0.39	-7.84	-0.34	3.02e-14	Cognitive function;
LGG	cis	rs8032158	0.963	rs7182397	chr15:56181052	A/T	cg02198044	chr15:56286336	NEDD4	-0.7	-11.82	-0.48	2.41e-28	Keloid;
LGG	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg07395648	chr5:131743802	NA	0.56	13.07	0.52	1.81e-33	Blood metabolite levels;
LGG	cis	rs12210905	0.925	rs72838243	chr6:26984198	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7312774	0.618	rs7953088	chr12:107334539	G/C	cg16260113	chr12:107380972	MTERFD3	0.91	8.47	0.37	3.18e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs9660992	0.710	rs1180721	chr1:205232696	T/C	cg00857998	chr1:205179979	DSTYK	0.47	6.86	0.3	2.15e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-7.07	-0.31	5.93e-12	Dementia with Lewy bodies;
LGG	cis	rs11676348	0.791	rs6726126	chr2:218952233	G/A	cg00012203	chr2:219082015	ARPC2	-0.56	-9.95	-0.42	2.91e-21	Ulcerative colitis;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-7.05	-0.31	6.71e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1018836	0.798	rs28568272	chr8:91652958	A/G	cg16814680	chr8:91681699	NA	-0.98	-20.23	-0.68	1.2e-65	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1869026	1.000	rs1869026	chr2:121341281	G/T	cg22272644	chr2:121334640	NA	-0.3	-7.12	-0.31	4.12e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17597773	0.674	rs12117818	chr1:221001483	A/T	cg15450098	chr1:221057561	HLX	-0.38	-6.78	-0.3	3.56e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500596	0.570	rs8055628	chr16:4447477	G/A	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.29	-0.32	1.36e-12	Schizophrenia;
LGG	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg01324343	chr3:183735012	ABCC5	0.85	18.13	0.64	6.85e-56	Anterior chamber depth;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06845991	chr7:90032834	CLDN12	-0.41	-6.85	-0.3	2.31e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg06521331	chr12:34319734	NA	0.48	8.56	0.37	1.67e-16	Bladder cancer;
LGG	cis	rs6580649	0.943	rs1990029	chr12:48407987	C/T	cg24011408	chr12:48396354	COL2A1	0.61	7.47	0.33	3.97e-13	Lung cancer;
LGG	trans	rs1459104	0.706	rs35228933	chr11:55027673	G/A	cg15704280	chr7:45808275	SEPT13	0.76	7.11	0.31	4.43e-12	Body mass index;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg27490568	chr2:178487706	NA	0.34	6.97	0.31	1.09e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg15971980	chr6:150254442	NA	0.43	8.13	0.35	4.07e-15	Lung cancer;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07659893	chr17:61819838	STRADA	0.47	7.75	0.34	5.94e-14	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg05941027	chr17:61774174	LIMD2	0.34	8.07	0.35	6.31e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3813359	0.660	rs11154573	chr6:130683885	C/T	cg23281432	chr6:130554730	NA	0.49	6.97	0.31	1.1e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg17211192	chr8:82754475	SNX16	0.7	11.53	0.47	3.35e-27	Diastolic blood pressure;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs889398	0.677	rs68161338	chr16:69823778	T/G	cg00738113	chr16:70207722	CLEC18C	0.24	6.69	0.3	6.34e-11	Body mass index;
LGG	cis	rs11018904	0.906	rs55685917	chr11:89964365	T/C	cg16176437	chr11:89678848	NA	0.41	6.94	0.31	1.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg11878867	chr6:150167359	LRP11	-0.6	-12.81	-0.51	2.28e-32	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12297711	chr1:203595834	ATP2B4	0.45	6.69	0.3	6.45e-11	Gut microbiome composition (summer);
LGG	cis	rs727505	0.721	rs11536526	chr7:124749441	G/A	cg23710748	chr7:124431027	NA	-0.43	-8.17	-0.35	3.02e-15	Lewy body disease;
LGG	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg25486957	chr4:152246857	NA	-0.52	-8.39	-0.36	6.1e-16	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg11965913	chr1:205819406	PM20D1	0.85	18.54	0.65	8.59e-58	Menarche (age at onset);
LGG	cis	rs12220238	1.000	rs115418388	chr10:75976296	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9398803	0.865	rs9398810	chr6:126815604	C/A	cg19875578	chr6:126661172	C6orf173	0.57	10.27	0.43	1.92e-22	Male-pattern baldness;
LGG	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg07636037	chr3:49044803	WDR6	0.82	14.45	0.56	2.51e-39	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	trans	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg13565492	chr6:43139072	SRF	-0.8	-10.47	-0.44	3.55e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs72781680	0.904	rs72796340	chr2:24143622	T/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs7927592	0.956	rs2510384	chr11:68391837	C/A	cg16797656	chr11:68205561	LRP5	0.4	6.96	0.31	1.17e-11	Total body bone mineral density;
LGG	cis	rs10769945	0.606	rs217236	chr11:1981259	T/C	cg23202291	chr11:1979235	NA	-0.45	-9.04	-0.39	4.34e-18	DNA methylation (variation);
LGG	cis	rs9916302	0.851	rs12936646	chr17:37647450	A/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.49	-0.47	4.51e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg26384229	chr12:38710491	ALG10B	1.0	25.04	0.76	4.08e-88	Heart rate;
LGG	cis	rs9814567	0.929	rs9815297	chr3:134215052	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.43	-0.53	5.66e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17253792	0.822	rs28681420	chr14:56088403	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.43	0.33	5.26e-13	Lung cancer;
LGG	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg19761014	chr17:28927070	LRRC37B2	-0.67	-8.58	-0.37	1.43e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg11502198	chr6:26597334	ABT1	0.57	9.8	0.41	9.92e-21	Intelligence (multi-trait analysis);
LGG	cis	rs16854884	0.657	rs1867609	chr3:143752916	A/G	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	trans	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.67	-0.34	1.02e-13	Heart rate;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs12042938	0.507	rs1655302	chr1:231731528	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.78	-15.31	-0.58	4.23e-43	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs8048589	0.577	rs8055516	chr16:12180198	A/T	cg02910054	chr16:12241554	SNX29	0.43	7.2	0.32	2.4e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg09021430	chr5:549028	NA	-0.72	-10.21	-0.43	3.32e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs774359	0.871	rs3849941	chr9:27538948	A/G	cg14173147	chr9:27528300	MOBKL2B	-0.42	-8.01	-0.35	9.47e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs11098499	0.865	rs9994730	chr4:120381564	A/C	cg09307838	chr4:120376055	NA	0.81	13.56	0.53	1.66e-35	Corneal astigmatism;
LGG	cis	rs6998277	0.830	rs965661	chr8:103597586	C/T	cg10187029	chr8:103597600	NA	1.02	19.16	0.67	1.08e-60	Migraine;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4889609	0.834	rs72785520	chr16:31070778	C/T	cg02466173	chr16:30829666	NA	-0.38	-6.72	-0.3	5.24e-11	Response to metformin (IC50);
LGG	cis	rs7301826	0.627	rs1077317	chr12:131314977	C/T	cg11011512	chr12:131303247	STX2	0.41	8.87	0.38	1.56e-17	Plasma plasminogen activator levels;
LGG	cis	rs9457247	0.967	rs2015864	chr6:167381476	T/C	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs9916302	0.752	rs9901219	chr17:37558369	T/G	cg00129232	chr17:37814104	STARD3	0.58	9.49	0.4	1.19e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs4731207	0.596	rs1871770	chr7:124630839	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg19455335	chr8:22457658	C8orf58	0.41	8.33	0.36	9.32e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11875185	0.510	rs75523605	chr18:55632903	A/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.12e-14	IgG glycosylation;
LGG	cis	rs4474465	1.000	rs11237510	chr11:78173584	G/A	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg25986240	chr4:9926439	SLC2A9	-0.43	-9.18	-0.39	1.45e-18	Bone mineral density;
LGG	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg00198680	chr16:28758506	NA	0.29	7.2	0.32	2.52e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg12432903	chr7:1882776	MAD1L1	0.52	7.75	0.34	5.9e-14	Bipolar disorder;
LGG	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg20503657	chr10:835505	NA	0.75	10.28	0.43	1.9e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs4417704	0.525	rs12694990	chr2:241883621	C/G	cg05025159	chr2:241905733	NA	0.48	9.92	0.42	3.63e-21	Joint mobility (Beighton score);
LGG	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg09033563	chr22:24373618	LOC391322	-0.43	-6.66	-0.3	7.79e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg04149295	chr10:70884716	VPS26A	0.48	7.16	0.32	3.29e-12	Left atrial antero-posterior diameter;
LGG	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg18876405	chr7:65276391	NA	-0.65	-11.81	-0.48	2.64e-28	Aortic root size;
LGG	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-13.85	-0.54	1.01e-36	Body mass index;
LGG	cis	rs10489202	0.632	rs3767476	chr1:168066940	C/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.22	-0.43	3.08e-22	Schizophrenia;
LGG	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg21775007	chr8:11205619	TDH	0.46	7.49	0.33	3.53e-13	Mood instability;
LGG	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg07928641	chr1:182991847	LAMC1	-0.49	-9.98	-0.42	2.27e-21	Colorectal cancer;
LGG	cis	rs34638952	0.577	rs55913184	chr17:27455189	T/G	cg27392559	chr17:27410759	MYO18A	-0.37	-6.85	-0.3	2.43e-11	Sitting height ratio;
LGG	cis	rs2285947	0.967	rs2285948	chr7:21584229	T/C	cg03697024	chr7:21583438	DNAH11	0.35	8.62	0.37	1.06e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs919433	0.927	rs7592748	chr2:198170688	G/A	cg00792783	chr2:198669748	PLCL1	-0.45	-7.05	-0.31	6.49e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7572733	0.840	rs4850437	chr2:198569051	T/G	cg00792783	chr2:198669748	PLCL1	-0.42	-7.01	-0.31	8.46e-12	Dermatomyositis;
LGG	cis	rs651907	0.640	rs1091664	chr3:101618690	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.39	6.96	0.31	1.2e-11	Colorectal cancer;
LGG	trans	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.7	-0.3	6.22e-11	Monocyte count;
LGG	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg26384229	chr12:38710491	ALG10B	0.93	20.4	0.69	1.82e-66	Bladder cancer;
LGG	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg17971929	chr21:40555470	PSMG1	0.88	17.79	0.64	2.47e-54	Cognitive function;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.56e-12	Lung cancer;
LGG	trans	rs6601327	0.575	rs6994574	chr8:9578255	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.73	-0.34	6.64e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08109568	chr15:31115862	NA	-0.61	-10.28	-0.43	1.79e-22	Huntington's disease progression;
LGG	cis	rs1371867	0.875	rs1788173	chr8:101330939	A/G	cg06636551	chr8:101224915	SPAG1	0.46	8.57	0.37	1.57e-16	Atrioventricular conduction;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg08621203	chr6:150244597	RAET1G	0.46	7.97	0.35	1.22e-14	Lung cancer;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.64	0.61	4.33e-49	Personality dimensions;
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg12463550	chr7:65579703	CRCP	-0.49	-8.2	-0.36	2.37e-15	Aortic root size;
LGG	cis	rs4925386	1.000	rs1889201	chr20:60923075	C/T	cg06026331	chr20:60912101	LAMA5	-0.46	-8.82	-0.38	2.42e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6735179	0.566	rs13416067	chr2:1755898	C/T	cg10160682	chr2:1713001	PXDN	-0.47	-7.27	-0.32	1.52e-12	Response to antipsychotic treatment;
LGG	cis	rs4740619	0.846	rs7042475	chr9:15642883	A/G	cg14451791	chr9:16040625	NA	0.35	8.96	0.38	8.24e-18	Body mass index;
LGG	trans	rs561341	0.941	rs736678	chr17:30347423	G/T	cg20587970	chr11:113659929	NA	-1.35	-23.97	-0.74	3.85e-83	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg04025307	chr7:1156635	C7orf50	0.64	8.54	0.37	1.95e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.87	0.3	2.14e-11	Longevity;
LGG	cis	rs12479064	0.666	rs11887935	chr2:100127570	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-10.0	-0.42	1.96e-21	Chronic sinus infection;
LGG	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg27490568	chr2:178487706	NA	0.47	9.15	0.39	1.87e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs888194	0.690	rs7954144	chr12:110015893	A/G	cg19025524	chr12:109796872	NA	-0.36	-7.11	-0.31	4.37e-12	Neuroticism;
LGG	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg19507638	chr5:93509721	C5orf36	0.4	6.72	0.3	5.31e-11	Diabetic retinopathy;
LGG	cis	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg15596359	chr8:11213517	TDH	-0.4	-8.53	-0.37	2.04e-16	Retinal vascular caliber;
LGG	cis	rs4538187	1.000	rs10183479	chr2:64085114	G/A	cg02541582	chr2:64069798	UGP2	0.61	14.46	0.56	2.21e-39	Systolic blood pressure;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.02	0.52	2.99e-33	Obesity-related traits;
LGG	cis	rs754466	0.606	rs56402185	chr10:79585848	G/A	cg17075019	chr10:79541650	NA	-0.96	-21.25	-0.7	1.87e-70	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg11814155	chr7:99998594	ZCWPW1	0.59	9.09	0.39	2.86e-18	Platelet count;
LGG	cis	rs1030877	0.521	rs2576747	chr2:105978676	A/T	cg02079111	chr2:105885981	TGFBRAP1	0.51	8.94	0.38	9.53e-18	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.14e-20	Diabetic retinopathy;
LGG	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg19774624	chr17:42201019	HDAC5	0.64	11.43	0.47	8.04e-27	Total body bone mineral density;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg11473876	chr11:109292803	C11orf87	0.48	9.47	0.4	1.43e-19	Schizophrenia;
LGG	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg13560919	chr6:33536144	NA	-0.42	-7.83	-0.34	3.26e-14	Crohn's disease;
LGG	cis	rs6960043	0.818	rs1558318	chr7:15065612	A/T	cg19272540	chr7:15055459	NA	-0.35	-7.79	-0.34	4.49e-14	Type 2 diabetes;
LGG	cis	rs2013441	1.000	rs2703818	chr17:20119976	T/A	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs2070488	0.965	rs3762791	chr3:38568828	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.62	-0.63	1.53e-53	Electrocardiographic conduction measures;
LGG	cis	rs887829	0.570	rs12623271	chr2:234599941	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.94	-0.35	1.51e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg14675211	chr2:100938903	LONRF2	0.47	7.29	0.32	1.37e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12681287	0.640	rs13258126	chr8:87453378	G/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.61	-0.41	4.51e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4478137	0.931	rs7687423	chr4:164250797	C/T	cg06758707	chr4:164254230	NPY1R	-0.69	-12.54	-0.5	3.06e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg23825981	chr20:60982038	CABLES2	-0.39	-6.84	-0.3	2.47e-11	Blood metabolite levels;
LGG	cis	rs490234	0.934	rs7865246	chr9:128269511	T/C	cg14078157	chr9:128172775	NA	-0.41	-7.67	-0.34	1.02e-13	Mean arterial pressure;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg00495681	chr13:53174319	NA	0.53	9.24	0.39	9.18e-19	Lewy body disease;
LGG	cis	rs1957429	0.520	rs77606588	chr14:65356268	G/A	cg23373153	chr14:65346875	NA	-0.93	-8.92	-0.38	1.09e-17	Pediatric areal bone mineral density (radius);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24792749	chr19:33166123	ANKRD27;RGS9BP	0.45	6.77	0.3	4e-11	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg03929089	chr4:120376271	NA	-0.53	-8.89	-0.38	1.33e-17	HDL cholesterol;
LGG	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg06618935	chr21:46677482	NA	-0.44	-8.68	-0.37	6.85e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04923620	chr10:28031330	MKX	0.39	7.06	0.31	6.26e-12	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs12950390	0.853	rs11079792	chr17:45863311	T/C	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.1e-14	IgG glycosylation;
LGG	cis	rs72960926	0.744	rs72964209	chr6:74861734	C/T	cg03266952	chr6:74778945	NA	-0.62	-6.71	-0.3	5.75e-11	Metabolite levels (MHPG);
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.65e-12	Prudent dietary pattern;
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.5	0.4	1.14e-19	Bipolar disorder;
LGG	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg04362960	chr10:104952993	NT5C2	-0.46	-7.67	-0.34	1e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.54	8.73	0.38	4.82e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4906332	1.000	rs35224956	chr14:103900481	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.91	-0.35	1.9e-14	Coronary artery disease;
LGG	trans	rs1728785	0.892	rs1103955	chr16:68588488	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs1385374	0.858	rs3765107	chr12:129278310	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.89	0.3	1.82e-11	Systemic lupus erythematosus;
LGG	cis	rs7264396	0.676	rs6060727	chr20:34556000	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg22398616	chr13:53314203	LECT1	-0.4	-8.14	-0.35	3.74e-15	Lewy body disease;
LGG	cis	rs9457247	0.935	rs1794697	chr6:167395410	C/T	cg07741184	chr6:167504864	NA	0.32	7.08	0.31	5.5e-12	Crohn's disease;
LGG	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg06115741	chr20:33292138	TP53INP2	-0.45	-7.7	-0.34	8.11e-14	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.85e-15	Obesity-related traits;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.21	-0.32	2.34e-12	Lung cancer;
LGG	cis	rs8032158	0.614	rs60890210	chr15:56114778	G/A	cg02198044	chr15:56286336	NEDD4	-0.54	-8.42	-0.36	4.66e-16	Keloid;
LGG	trans	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs11785400	0.793	rs1056012	chr8:143740167	A/G	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs2304069	0.733	rs216138	chr5:149437190	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.74	11.22	0.46	5.37e-26	HIV-1 control;
LGG	cis	rs638893	0.636	rs493720	chr11:118604678	T/C	cg13782932	chr11:118662891	DDX6	0.37	6.87	0.3	2.1e-11	Vitiligo;
LGG	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg13944838	chr5:179740914	GFPT2	-0.7	-12.94	-0.52	6.87e-33	Height;
LGG	cis	rs735539	1.000	rs2290143	chr13:21280363	A/G	cg04906043	chr13:21280425	IL17D	0.61	10.5	0.44	2.87e-23	Dental caries;
LGG	cis	rs4911259	0.552	rs13041458	chr20:31467376	G/T	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.92	-0.48	9.59e-29	Inflammatory bowel disease;
LGG	cis	rs7000551	0.751	rs2100291	chr8:22374551	C/T	cg12081754	chr8:22256438	SLC39A14	0.65	12.3	0.5	2.72e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg10402321	chr1:26617780	UBXN11	0.34	6.75	0.3	4.54e-11	Obesity-related traits;
LGG	cis	rs34638952	0.577	rs55913184	chr17:27455189	T/G	cg13672501	chr17:27410685	MYO18A	-0.39	-7.01	-0.31	8.69e-12	Sitting height ratio;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09507928	chr5:140027484	IK;NDUFA2	0.41	6.93	0.31	1.38e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs12477438	0.798	rs4622780	chr2:99631760	C/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.4	-0.5	1.08e-30	Chronic sinus infection;
LGG	cis	rs6466055	0.739	rs10953474	chr7:104923005	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs1153858	0.723	rs1719238	chr15:45594766	C/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.42	-7.37	-0.32	8.04e-13	Homoarginine levels;
LGG	cis	rs7552404	0.727	rs6678348	chr1:76332463	C/T	cg22875332	chr1:76189707	ACADM	0.53	8.22	0.36	2.01e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg06521331	chr12:34319734	NA	0.38	6.72	0.3	5.44e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg26354017	chr1:205819088	PM20D1	0.79	17.8	0.64	2.32e-54	Menarche (age at onset);
LGG	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg11189052	chr15:85197271	WDR73	-0.55	-9.01	-0.39	5.42e-18	P wave terminal force;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.83	12.97	0.52	4.95e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg08564027	chr20:61660810	NA	1.02	25.54	0.76	1.95e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1109114	0.816	rs2963490	chr5:148594477	A/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.91	-0.59	9.24e-46	Body mass index;
LGG	cis	rs6764363	0.545	rs331858	chr3:316550	A/T	cg02057681	chr3:285234	CHL1	0.41	7.44	0.33	4.96e-13	Sudden cardiac arrest;
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.24	-0.52	3.76e-34	Aortic root size;
LGG	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.12	0.31	4.09e-12	Neuroticism;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.12e-14	Colorectal cancer;
LGG	cis	rs9487094	0.744	rs11964533	chr6:110059000	G/A	cg01125227	chr6:109776195	MICAL1	0.5	8.14	0.35	3.56e-15	Height;
LGG	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.55	0.33	2.28e-13	Electroencephalogram traits;
LGG	trans	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg24247370	chr13:99142703	STK24	-0.37	-6.8	-0.3	3.29e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg00531865	chr16:30841666	NA	-0.54	-10.28	-0.43	1.83e-22	Dementia with Lewy bodies;
LGG	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg01181863	chr3:195395398	SDHAP2	0.65	11.51	0.47	3.85e-27	Bronchopulmonary dysplasia;
LGG	cis	rs6964587	0.626	rs1011372	chr7:91509867	T/C	cg17063962	chr7:91808500	NA	-0.44	-7.91	-0.35	1.86e-14	Breast cancer;
LGG	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	1.94e-11	HDL cholesterol;
LGG	cis	rs9943753	0.525	rs983307	chr12:109815103	T/G	cg19025524	chr12:109796872	NA	-0.53	-11.41	-0.47	9.66e-27	HDL cholesterol;
LGG	cis	rs1670533	1.000	rs11725984	chr4:1087338	C/T	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs1577917	1.000	rs6940458	chr6:86644992	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.84	-0.51	1.68e-32	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01206537	chr2:201171336	SPATS2L	0.42	6.91	0.31	1.66e-11	Gut microbiome composition (summer);
LGG	cis	rs8060686	0.545	rs10500543	chr16:68281311	T/C	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.47	-0.33	4.13e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg26260386	chr4:140477698	SETD7	-0.44	-7.38	-0.32	7.56e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2073499	0.935	rs2526400	chr3:50186948	A/G	cg03645007	chr3:50255295	SLC38A3	-0.59	-6.66	-0.3	7.8e-11	Schizophrenia;
LGG	cis	rs7503807	0.515	rs12939413	chr17:78679449	C/T	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg22963979	chr7:1858916	MAD1L1	0.43	8.57	0.37	1.6e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg00631329	chr6:26305371	NA	-0.54	-10.04	-0.42	1.32e-21	Educational attainment;
LGG	cis	rs644799	0.965	rs3789960	chr11:95509037	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs5756813	0.668	rs6000881	chr22:38154544	G/A	cg19894588	chr14:64061835	NA	0.44	7.38	0.32	7.44e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7572733	0.773	rs10196961	chr2:198513930	G/A	cg00792783	chr2:198669748	PLCL1	0.4	6.65	0.3	8.46e-11	Dermatomyositis;
LGG	cis	rs3806843	0.576	rs246017	chr5:140335060	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13606434	chr7:5464498	TNRC18	0.44	7.13	0.31	3.91e-12	Gut microbiome composition (summer);
LGG	cis	rs7219021	0.961	rs7209108	chr17:46863898	C/T	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.77	-0.3	3.82e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.59	-0.37	1.35e-16	Diabetic retinopathy;
LGG	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg24879335	chr3:133465180	TF	0.44	7.31	0.32	1.21e-12	Iron status biomarkers (transferrin levels);
LGG	cis	rs9902453	0.868	rs8066731	chr17:28523121	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	12.69	0.51	6.92e-32	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05744073	chr17:1953268	MIR132	0.47	7.44	0.33	5.07e-13	Gut microbiome composition (summer);
LGG	cis	rs1620921	0.967	rs1247551	chr6:161187517	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.44	-0.33	5e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs936229	0.654	rs762551	chr15:75041917	C/A	cg10253484	chr15:75165896	SCAMP2	-0.62	-9.14	-0.39	1.93e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs654950	1.000	rs679449	chr1:41988634	G/T	cg16096631	chr1:42092165	HIVEP3	-0.43	-9.69	-0.41	2.42e-20	Airway imaging phenotypes;
LGG	cis	rs7824557	0.564	rs13260727	chr8:11232860	A/G	cg15596359	chr8:11213517	TDH	-0.39	-8.12	-0.35	4.22e-15	Retinal vascular caliber;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.11	-0.35	4.66e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg24331049	chr13:111365604	ING1	0.92	16.89	0.62	3.43e-50	Coronary artery disease;
LGG	cis	rs7481584	0.926	rs12806061	chr11:3008404	G/A	cg08468577	chr11:2973342	NAP1L4	-0.38	-7.94	-0.35	1.54e-14	Calcium levels;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg07341007	chr3:195489909	MUC4	0.58	8.32	0.36	1.02e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs11096990	0.634	rs4975002	chr4:39288353	T/G	cg24403649	chr4:39172243	NA	-0.37	-6.68	-0.3	6.77e-11	Cognitive function;
LGG	cis	rs7590720	0.819	rs1344694	chr2:216893637	T/G	cg12620499	chr2:216877984	MREG	0.83	16.99	0.62	1.13e-50	Alcohol dependence;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg06558623	chr16:89946397	TCF25	1.18	12.89	0.51	1.05e-32	Skin colour saturation;
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18099408	chr3:52552593	STAB1	-0.37	-7.19	-0.32	2.71e-12	Bipolar disorder;
LGG	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.8	-0.34	4.2e-14	Height;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg08219700	chr8:58056026	NA	0.53	11.57	0.47	2.36e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg21427119	chr20:30132790	HM13	-0.58	-8.97	-0.38	7.37e-18	Mean corpuscular hemoglobin;
LGG	trans	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.7	0.37	6.04e-17	Joint mobility (Beighton score);
LGG	cis	rs17767392	0.918	rs72728427	chr14:71769989	T/C	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs8072100	0.713	rs57427906	chr17:45494014	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2070433	0.799	rs7279002	chr21:47910523	C/T	cg12379764	chr21:47803548	PCNT	-0.5	-7.29	-0.32	1.35e-12	Lymphocyte counts;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs4711336	0.638	rs4713664	chr6:33674198	A/G	cg14003231	chr6:33640908	ITPR3	0.29	6.81	0.3	3.04e-11	Height;
LGG	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.26e-36	Cognitive function;
LGG	cis	rs2797160	1.000	rs2797161	chr6:126010789	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.49	0.33	3.55e-13	Endometrial cancer;
LGG	cis	rs6993813	0.837	rs4335155	chr8:120013469	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.28	6.97	0.31	1.11e-11	Bone mineral density (hip);
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.54e-21	Lung cancer;
LGG	cis	rs4474465	1.000	rs11237508	chr11:78173297	C/T	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs11209002	1.000	rs10732838	chr1:67577955	C/T	cg02640540	chr1:67518911	SLC35D1	0.46	6.89	0.3	1.86e-11	Crohn's disease;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg22618164	chr12:122356400	WDR66	0.38	11.29	0.46	2.88e-26	Mean corpuscular volume;
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	10.49	0.44	3.04e-23	Total body bone mineral density;
LGG	cis	rs2439831	0.867	rs3101443	chr15:43912372	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	10.14	0.43	5.86e-22	Lung cancer in ever smokers;
LGG	cis	rs367943	0.712	rs7734304	chr5:112730165	G/A	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.58e-23	Type 2 diabetes;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg00515161	chr17:59940900	BRIP1	-0.37	-7.04	-0.31	6.77e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7129220	0.588	rs61878625	chr11:10123136	T/C	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10744422	0.800	rs839363	chr12:123276924	C/T	cg25930673	chr12:123319894	HIP1R	-0.68	-8.15	-0.35	3.35e-15	Schizophrenia;
LGG	cis	rs4891159	0.790	rs17059379	chr18:74160316	A/T	cg24786174	chr18:74118243	ZNF516	0.57	13.2	0.52	5.68e-34	Longevity;
LGG	cis	rs9397585	0.857	rs4870164	chr6:153390797	T/C	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs13418717	0.793	rs57113328	chr2:127667120	G/A	cg25501666	chr2:127640322	NA	1.06	8.0	0.35	1.02e-14	Heart failure;
LGG	cis	rs209489	0.892	rs17543881	chr6:53126116	A/G	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs12643440	0.538	rs4299576	chr4:17140108	G/A	cg22650099	chr4:17144496	NA	-0.5	-8.52	-0.37	2.34e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs11971779	0.700	rs11763942	chr7:139005795	A/T	cg07862535	chr7:139043722	LUC7L2	0.48	6.81	0.3	2.95e-11	Diisocyanate-induced asthma;
LGG	cis	rs3770081	1.000	rs3770090	chr2:86263288	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.93	-0.31	1.38e-11	Facial emotion recognition (sad faces);
LGG	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg01966878	chr4:90757139	SNCA	0.34	6.86	0.3	2.16e-11	Dementia with Lewy bodies;
LGG	cis	rs6694672	0.850	rs1034162	chr1:197088303	G/A	cg13682187	chr1:196946512	CFHR5	0.51	7.21	0.32	2.3e-12	Asthma;
LGG	cis	rs7011049	1.000	rs72643599	chr8:53854434	A/G	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07093111	chr17:18585732	ZNF286B	0.43	6.98	0.31	1e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg05552183	chr6:42928497	GNMT	0.49	15.28	0.58	5.4e-43	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs77106637	1.000	rs77106637	chr11:72478320	G/A	cg03878208	chr11:72483293	STARD10	0.53	6.97	0.31	1.12e-11	Type 2 diabetes;
LGG	cis	rs10895140	0.756	rs2154993	chr11:101505179	A/C	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs6696846	0.716	rs6593921	chr1:205062861	A/G	cg00857998	chr1:205179979	DSTYK	0.49	7.91	0.35	1.85e-14	Red blood cell count;
LGG	cis	rs71386921	1	rs71386921	chr10:27478698	AAT/A	cg14240646	chr10:27532245	ACBD5	-0.74	-10.98	-0.45	4.47e-25	Breast cancer;
LGG	cis	rs368123	0.924	rs449349	chr6:160725253	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.07	-0.31	5.88e-12	Waist circumference;
LGG	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14240646	chr10:27532245	ACBD5	-0.75	-10.33	-0.43	1.18e-22	Breast cancer;
LGG	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg19700328	chr14:106028568	NA	-0.6	-10.1	-0.42	8.12e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2688608	0.698	rs2633323	chr10:75694826	G/A	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.21	-0.32	2.33e-12	Inflammatory bowel disease;
LGG	cis	rs4740619	0.544	rs1009468	chr9:15825230	A/G	cg14451791	chr9:16040625	NA	0.32	7.93	0.35	1.61e-14	Body mass index;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.65e-54	Menopause (age at onset);
LGG	cis	rs13314892	0.764	rs6805306	chr3:69862153	T/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01358551	chr19:47353761	AP2S1	-0.51	-7.65	-0.33	1.19e-13	Systemic lupus erythematosus;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25533547	chr2:73053217	EXOC6B	-0.5	-7.32	-0.32	1.1e-12	Systemic lupus erythematosus;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg11814155	chr7:99998594	ZCWPW1	0.6	8.97	0.38	7.42e-18	Platelet count;
LGG	cis	rs5756391	0.546	rs5756405	chr22:37310954	A/G	cg21209356	chr22:37319042	CSF2RB	0.4	9.22	0.39	1.03e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4901847	0.609	rs11158198	chr14:58576320	G/T	cg15908186	chr14:58618357	C14orf37	-0.65	-11.88	-0.48	1.38e-28	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs79349575	0.783	rs12603969	chr17:47034419	A/G	cg16584676	chr17:46985605	UBE2Z	0.5	8.46	0.37	3.52e-16	Type 2 diabetes;
LGG	cis	rs787274	0.557	rs7040954	chr9:115666959	C/T	cg13803584	chr9:115635662	SNX30	-0.68	-7.47	-0.33	4.14e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2188561	0.615	rs13226711	chr7:107395342	G/A	cg16793755	chr7:107334138	SLC26A4	0.41	7.23	0.32	2.03e-12	Alcohol consumption;
LGG	cis	rs972578	0.668	rs5759013	chr22:43289473	A/G	cg01576275	chr22:43409880	NA	0.23	6.99	0.31	9.51e-12	Mean platelet volume;
LGG	cis	rs2213920	0.619	rs2188047	chr9:118256660	G/C	cg13918206	chr9:118159781	DEC1	0.56	7.52	0.33	2.93e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.5e-14	Bipolar disorder;
LGG	cis	rs35146811	0.660	rs3779046	chr7:99779243	A/G	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs2708240	0.666	rs2538962	chr7:147600604	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.32	-7.86	-0.34	2.78e-14	QT interval (drug interaction);
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.75	-0.3	4.45e-11	Height;
LGG	cis	rs6138458	1.000	rs227627	chr20:24912107	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs4950322	0.518	rs61838951	chr1:146587663	T/C	cg22381352	chr1:146742008	CHD1L	-0.42	-7.14	-0.31	3.64e-12	Protein quantitative trait loci;
LGG	cis	rs11711311	0.712	rs6764048	chr3:113332859	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.6	-11.76	-0.48	4.04e-28	IgG glycosylation;
LGG	cis	rs7937682	0.889	rs542424	chr11:111477698	T/C	cg19812747	chr11:111475976	SIK2	-0.51	-10.71	-0.45	4.43e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-8.38	-0.36	6.5e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs4684776	1.000	rs13067424	chr3:11426741	A/G	cg24705426	chr3:11550659	ATG7	-0.42	-7.48	-0.33	3.71e-13	Small vessel stroke;
LGG	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg21775007	chr8:11205619	TDH	0.41	6.69	0.3	6.35e-11	Mood instability;
LGG	cis	rs4356932	0.967	rs4386624	chr4:76946139	G/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.7	-0.3	6.25e-11	Blood protein levels;
LGG	cis	rs11605924	0.792	rs10838524	chr11:45870177	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.5	-8.52	-0.37	2.19e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2576037	0.901	rs2060416	chr18:44576240	G/C	cg23302884	chr18:44338147	ST8SIA5	0.36	7.09	0.31	4.9e-12	Personality dimensions;
LGG	cis	rs9611519	0.964	rs2179744	chr22:41621714	G/A	cg03806693	chr22:41940476	POLR3H	-0.49	-7.68	-0.34	9.43e-14	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09771049	chr17:66031798	KPNA2	0.38	6.7	0.3	5.92e-11	Obesity-related traits;
LGG	trans	rs28735056	0.903	rs56185453	chr18:77638297	A/G	cg05926928	chr17:57297772	GDPD1	-0.72	-12.9	-0.51	1.01e-32	Schizophrenia;
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg10056627	chr6:42928773	GNMT	0.26	7.24	0.32	1.86e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.47e-13	Lung cancer;
LGG	cis	rs4731207	0.565	rs7776744	chr7:124599749	A/G	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.6e-11	Cutaneous malignant melanoma;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.31	-0.4	5.08e-19	Personality dimensions;
LGG	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg18898632	chr2:242989856	NA	-0.72	-8.74	-0.38	4.35e-17	Obesity-related traits;
LGG	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg02002194	chr4:3960332	NA	0.41	7.35	0.32	8.94e-13	Neuroticism;
LGG	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs6456156	0.846	rs7749827	chr6:167515624	C/T	cg07741184	chr6:167504864	NA	-0.34	-7.58	-0.33	1.85e-13	Primary biliary cholangitis;
LGG	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs10046574	0.561	rs11505984	chr7:135208359	G/A	cg27474649	chr7:135195673	CNOT4	0.73	9.2	0.39	1.21e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg12437481	chr16:420112	MRPL28	-0.54	-8.5	-0.37	2.54e-16	Morning vs. evening chronotype;
LGG	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg03114573	chr12:45410052	DBX2	-0.51	-8.77	-0.38	3.35e-17	Gut microbiome composition (summer);
LGG	cis	rs11690935	1.000	rs312925	chr2:172563922	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.07	-27.44	-0.79	3.98e-99	Schizophrenia;
LGG	cis	rs921968	0.541	rs7574429	chr2:219498759	T/G	cg01130898	chr2:219473002	PLCD4	-0.47	-8.1	-0.35	4.95e-15	Mean corpuscular hemoglobin concentration;
LGG	cis	rs151997	0.537	rs11746939	chr5:50268856	G/A	cg06027927	chr5:50259733	NA	0.61	10.0	0.42	1.98e-21	Callous-unemotional behaviour;
LGG	cis	rs17208368	0.628	rs12449074	chr16:55092597	C/T	cg11181171	chr16:55090946	NA	0.45	7.32	0.32	1.08e-12	Hypospadias;
LGG	cis	rs9359856	0.564	rs17228548	chr6:90439164	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.69	-0.41	2.41e-20	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.41	-0.33	6.05e-13	Lung cancer;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg00761968	chr13:53314142	LECT1	-0.44	-9.7	-0.41	2.19e-20	Lewy body disease;
LGG	cis	rs6743226	0.626	rs59542139	chr2:242213649	T/C	cg10021735	chr2:242295487	FARP2	0.41	7.14	0.31	3.64e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg00106254	chr7:1943704	MAD1L1	-0.38	-6.65	-0.3	8.3e-11	Schizophrenia;
LGG	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg05082376	chr22:42548792	NA	0.39	8.06	0.35	6.65e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg05046597	chr7:148823741	ZNF398;ZNF425	0.44	7.53	0.33	2.71e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs10743315	0.557	rs77344887	chr12:19312751	C/T	cg02471346	chr12:19282374	PLEKHA5	0.85	8.21	0.36	2.24e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10048158	0.646	rs6933	chr17:64208230	C/T	cg19474267	chr17:64306194	PRKCA	-0.56	-10.87	-0.45	1.14e-24	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg25809561	chr17:30822961	MYO1D	0.4	9.67	0.41	2.91e-20	Schizophrenia;
LGG	cis	rs9314323	0.964	rs3808576	chr8:26266834	G/A	cg11498726	chr8:26250323	BNIP3L	-0.55	-11.61	-0.47	1.54e-27	Red cell distribution width;
LGG	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg10370574	chr19:1840461	REXO1	0.46	7.04	0.31	6.93e-12	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24687639	chr15:41576060	LOC729082	0.47	7.03	0.31	7.28e-12	Gut microbiome composition (summer);
LGG	cis	rs3760047	0.609	rs2541639	chr16:205035	C/T	cg25425005	chr16:202905	HBZ	-0.6	-9.84	-0.42	7.09e-21	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1620921	0.505	rs9458025	chr6:161203435	T/C	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.86	-0.42	5.89e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.901	rs12714179	chr2:86514958	T/C	cg10973622	chr2:86423274	IMMT	0.39	6.68	0.3	6.71e-11	Night sleep phenotypes;
LGG	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.1e-22	Motion sickness;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.48	-7.92	-0.35	1.78e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs7727544	0.505	rs721121	chr5:131406433	T/G	cg07395648	chr5:131743802	NA	-0.4	-8.53	-0.37	2.11e-16	Blood metabolite levels;
LGG	cis	rs7085104	0.572	rs284858	chr10:104573936	T/C	cg04362960	chr10:104952993	NT5C2	-0.44	-8.03	-0.35	8.09e-15	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs6960043	0.818	rs1974620	chr7:15065467	A/G	cg19272540	chr7:15055459	NA	0.34	7.63	0.33	1.31e-13	Type 2 diabetes;
LGG	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.84	-0.51	1.63e-32	Chronic sinus infection;
LGG	cis	rs7107174	1.000	rs2512542	chr11:77981780	G/A	cg02023728	chr11:77925099	USP35	0.43	7.62	0.33	1.42e-13	Testicular germ cell tumor;
LGG	cis	rs826838	1.000	rs826889	chr12:39101076	G/A	cg26384229	chr12:38710491	ALG10B	-0.88	-20.78	-0.69	3.12e-68	Heart rate;
LGG	cis	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.99	-0.49	4.97e-29	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.42	-0.4	2.21e-19	Bladder cancer;
LGG	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg08392591	chr16:89556376	ANKRD11	0.55	8.64	0.37	9.29e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg04691961	chr3:161091175	C3orf57	-0.39	-8.01	-0.35	9.4e-15	Educational attainment (years of education);
LGG	cis	rs72781680	1.000	rs12620594	chr2:24194490	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Myopia (pathological);
LGG	trans	rs12517041	0.938	rs34995120	chr5:23273260	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.62	-9.0	-0.39	5.91e-18	Calcium levels;
LGG	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg23625390	chr15:77176239	SCAPER	0.49	9.62	0.41	4.32e-20	Blood metabolite levels;
LGG	cis	rs1009647	0.583	rs68175860	chr14:55633590	T/C	cg04306507	chr14:55594613	LGALS3	0.47	7.92	0.35	1.75e-14	Testicular germ cell tumor;
LGG	cis	rs477895	0.653	rs2875749	chr11:63903878	C/A	cg04317338	chr11:64019027	PLCB3	0.67	8.21	0.36	2.25e-15	Mean platelet volume;
LGG	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg00334542	chr7:100209784	MOSPD3	-0.52	-7.32	-0.32	1.11e-12	Other erythrocyte phenotypes;
LGG	cis	rs2749592	0.588	rs2505192	chr10:38395023	G/A	cg25427524	chr10:38739819	LOC399744	-0.7	-13.94	-0.54	3.92e-37	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2599510	0.811	rs2243844	chr2:32775984	G/T	cg02381751	chr2:32503542	YIPF4	0.49	8.13	0.35	3.93e-15	Interleukin-18 levels;
LGG	trans	rs8129326	0.718	rs11088282	chr21:35793107	C/T	cg07474852	chr4:123073612	NA	0.49	8.56	0.37	1.67e-16	Cancer;
LGG	cis	rs9807989	0.507	rs6749014	chr2:103006448	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs9816226	0.591	rs57912727	chr3:185804583	A/C	cg00760338	chr3:185826511	ETV5	-0.82	-10.14	-0.43	6.07e-22	Obesity;Body mass index;
LGG	cis	rs1577917	0.727	rs9444361	chr6:86400900	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.89	17.7	0.64	6.08e-54	Response to antipsychotic treatment;
LGG	cis	rs9868809	0.505	rs56735597	chr3:48765168	A/G	cg00383909	chr3:49044727	WDR6	0.97	12.15	0.49	1.13e-29	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.6	-0.44	1.17e-23	Lung cancer;
LGG	cis	rs7666738	0.830	rs13124904	chr4:98856973	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs36093844	0.752	rs7127501	chr11:85564305	C/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.03	-0.31	7.45e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs907612	0.638	rs11041476	chr11:1875067	C/T	cg05305434	chr11:1874049	LSP1	0.39	10.45	0.44	4.34e-23	Monocyte percentage of white cells;Monocyte count;Granulocyte percentage of myeloid white cells;
LGG	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg18551225	chr6:44695536	NA	-0.68	-11.36	-0.47	1.51e-26	Total body bone mineral density;
LGG	trans	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11123610	0.520	rs66557864	chr2:3720812	C/A	cg26344334	chr2:3718215	ALLC	-0.49	-8.34	-0.36	8.55e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7107174	0.892	rs10431155	chr11:78121978	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.3	-0.32	1.29e-12	Testicular germ cell tumor;
LGG	cis	rs7586879	1.000	rs10175064	chr2:25117537	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs7166081	1.000	rs1444936	chr15:67635549	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg11235426	chr6:292522	DUSP22	-0.61	-10.13	-0.43	6.32e-22	Menopause (age at onset);
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg02002194	chr4:3960332	NA	0.5	9.69	0.41	2.42e-20	Neuroticism;
LGG	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.47e-24	Aortic root size;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg05165339	chr4:1420672	NA	0.31	8.27	0.36	1.41e-15	Obesity-related traits;
LGG	cis	rs9309473	1.000	rs10187192	chr2:73713500	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-7.95	-0.35	1.43e-14	Metabolite levels;
LGG	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.82	-0.42	8.73e-21	Diabetic retinopathy;
LGG	cis	rs9640161	0.789	rs36035506	chr7:150057843	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-11.25	-0.46	4.2e-26	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg13880726	chr7:1868755	MAD1L1	0.45	7.87	0.34	2.62e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg08200770	chr17:80723486	TBCD	-0.5	-9.41	-0.4	2.31e-19	Glycated hemoglobin levels;
LGG	cis	rs3806843	0.576	rs246008	chr5:140338485	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11098499	0.697	rs4560394	chr4:120313435	T/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg26384229	chr12:38710491	ALG10B	-0.68	-13.19	-0.52	5.96e-34	Bladder cancer;
LGG	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg25019033	chr10:957182	NA	-0.58	-10.78	-0.45	2.43e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs10911232	0.507	rs4651138	chr1:183001312	C/A	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs17776563	0.593	rs68180975	chr15:89147322	G/C	cg05013243	chr15:89149849	MIR1179	-0.33	-6.83	-0.3	2.74e-11	Thyroid hormone levels;
LGG	cis	rs754466	1.000	rs2278218	chr10:79680399	G/A	cg17075019	chr10:79541650	NA	-0.81	-13.85	-0.54	1e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg02975922	chr3:195473998	MUC4	-0.45	-6.94	-0.31	1.31e-11	Pancreatic cancer;
LGG	cis	rs2304069	1.000	rs10072275	chr5:149401596	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.86	0.54	9.09e-37	HIV-1 control;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.01	-0.31	8.7e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs2309617	chr2:99976291	A/C	cg23527387	chr2:100056660	REV1	-0.44	-9.64	-0.41	3.7e-20	Chronic sinus infection;
LGG	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.49e-32	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16470576	chr5:175815543	NOP16;HIGD2A	0.44	7.23	0.32	2.05e-12	Cognitive performance;
LGG	trans	rs3774749	0.565	rs2188151	chr3:50201924	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.49	-0.37	2.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg07274523	chr3:49395745	GPX1	0.55	9.21	0.39	1.15e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg23649088	chr2:200775458	C2orf69	-0.63	-8.24	-0.36	1.74e-15	Schizophrenia;
LGG	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg26695010	chr11:65641043	EFEMP2	0.47	7.41	0.33	6.19e-13	Breast cancer;
LGG	trans	rs2235573	0.527	rs139862	chr22:38351986	T/C	cg19894588	chr14:64061835	NA	0.63	10.31	0.43	1.4e-22	Glioblastoma;Glioma;
LGG	cis	rs9359856	0.529	rs6935307	chr6:90295350	A/G	cg13799429	chr6:90582589	CASP8AP2	0.7	8.85	0.38	1.83e-17	Bipolar disorder;
LGG	cis	rs7928758	0.943	rs7929612	chr11:134268634	C/T	cg22777979	chr11:134283252	B3GAT1	0.92	12.13	0.49	1.31e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9296092	0.560	rs9469511	chr6:33530930	T/G	cg13560919	chr6:33536144	NA	-1.03	-21.19	-0.7	3.66e-70	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs11785400	1.000	rs6997670	chr8:143737915	G/A	cg24634471	chr8:143751801	JRK	0.53	8.55	0.37	1.75e-16	Schizophrenia;
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg11062466	chr8:58055876	NA	0.43	7.21	0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4356975	0.527	rs4385139	chr4:69991629	C/G	cg27372994	chr4:70080453	UGT2B11	0.39	7.02	0.31	8.06e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.0	-0.31	9.26e-12	Lung cancer;
LGG	cis	rs4604732	0.588	rs4356092	chr1:247632668	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	9.01	0.39	5.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg13385521	chr17:29058706	SUZ12P	0.85	10.07	0.42	1.05e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.46	8.03	0.35	8.12e-15	Longevity;
LGG	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.29	0.32	1.35e-12	Height;
LGG	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg13902645	chr11:5959945	NA	-0.73	-11.68	-0.48	8.49e-28	DNA methylation (variation);
LGG	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg25809561	chr17:30822961	MYO1D	0.34	7.84	0.34	3.09e-14	Schizophrenia;
LGG	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13102973	0.640	rs11737779	chr4:135831516	C/T	cg14419869	chr4:135874104	NA	0.52	9.83	0.42	7.86e-21	Subjective well-being;
LGG	cis	rs35110281	0.714	rs2282526	chr21:45080552	A/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.52	-0.4	9.98e-20	Mean corpuscular volume;
LGG	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg13877915	chr19:58951672	ZNF132	0.59	8.38	0.36	6.39e-16	Mean platelet volume;
LGG	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.82	-0.3	2.9100000000000002e-11	Retinal vascular caliber;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19717773	chr7:2847554	GNA12	0.31	6.81	0.3	3.02e-11	Height;
LGG	trans	rs75804782	0.641	rs77448526	chr2:239353487	A/C	cg01134436	chr17:81009848	B3GNTL1	0.83	8.68	0.37	7.01e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg27454842	chr22:32027588	PISD	-0.6	-6.85	-0.3	2.33e-11	Age-related hearing impairment;
LGG	cis	rs9543976	0.858	rs8192763	chr13:76179170	A/T	cg01531495	chr13:76123901	UCHL3	0.64	7.74	0.34	6.17e-14	Diabetic retinopathy;
LGG	cis	rs2130392	0.961	rs2696035	chr4:185612953	A/G	cg04058563	chr4:185651563	MLF1IP	0.45	9.49	0.4	1.26e-19	Kawasaki disease;
LGG	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg02002194	chr4:3960332	NA	-0.4	-7.2	-0.32	2.5e-12	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg11062466	chr8:58055876	NA	0.61	9.86	0.42	6.12e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7849585	0.792	rs4842134	chr9:139130364	G/A	cg14094347	chr9:139131620	QSOX2	-0.48	-9.04	-0.39	4.32e-18	Height;
LGG	cis	rs12908161	0.959	rs12908699	chr15:85240403	G/T	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	9.2e-12	Schizophrenia;
LGG	cis	rs8014204	0.762	rs10148293	chr14:75296831	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.64	-11.81	-0.48	2.46e-28	Caffeine consumption;
LGG	cis	rs3820928	0.874	rs2396452	chr2:227838040	T/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.8	-0.34	4.26e-14	Pulmonary function;
LGG	cis	rs1665650	0.957	rs1665645	chr10:118487954	C/T	cg14919929	chr10:118506882	NA	0.49	8.61	0.37	1.15e-16	Colorectal cancer;
LGG	cis	rs12200782	1.000	rs12211201	chr6:26461461	A/G	cg11502198	chr6:26597334	ABT1	-0.83	-6.86	-0.3	2.2e-11	Small cell lung carcinoma;
LGG	cis	rs3764563	0.935	rs10408443	chr19:15715973	C/T	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.9	-0.34	2.12e-14	Inflammatory biomarkers;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.2	0.43	3.56e-22	Longevity;
LGG	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg10483660	chr13:112241077	NA	0.43	8.93	0.38	1.02e-17	Menarche (age at onset);
LGG	cis	rs3741151	0.687	rs724111	chr11:73238645	G/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.89	0.34	2.18e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg17294928	chr15:75287854	SCAMP5	0.56	10.24	0.43	2.47e-22	Breast cancer;
LGG	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg12219531	chr12:120966889	COQ5	0.63	10.35	0.43	1.03e-22	High light scatter reticulocyte count;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg26354017	chr1:205819088	PM20D1	0.87	20.82	0.7	2.02e-68	Menarche (age at onset);
LGG	cis	rs9309473	0.607	rs1403412	chr2:73598092	T/C	cg20560298	chr2:73613845	ALMS1	-0.45	-8.32	-0.36	9.83e-16	Metabolite levels;
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.41	-0.36	5.05e-16	IgG glycosylation;
LGG	cis	rs7215564	0.908	rs34547024	chr17:78661373	C/G	cg06153925	chr17:78755379	RPTOR	0.4	6.94	0.31	1.37e-11	Myopia (pathological);
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg27400746	chr16:89904261	SPIRE2	1.13	16.94	0.62	1.96e-50	Skin colour saturation;
LGG	trans	rs2204008	0.774	rs7304438	chr12:38361146	T/G	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Bladder cancer;
LGG	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg17691542	chr6:26056736	HIST1H1C	1.11	17.51	0.63	5.01e-53	Iron status biomarkers;
LGG	cis	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg13010199	chr12:38710504	ALG10B	0.67	13.18	0.52	6.26e-34	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg20587970	chr11:113659929	NA	0.89	13.84	0.54	1.01e-36	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg16270222	chr17:41446396	NA	-0.3	-7.31	-0.32	1.15e-12	Menopause (age at onset);
LGG	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs1707322	0.927	rs11211194	chr1:46282084	C/T	cg03146154	chr1:46216737	IPP	0.54	10.32	0.43	1.32e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg02389323	chr16:88786976	FAM38A	0.9	11.29	0.46	2.77e-26	Plateletcrit;
LGG	cis	rs9309473	1.000	rs9309473	chr2:73743982	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-8.01	-0.35	9.24e-15	Metabolite levels;
LGG	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg10189774	chr4:17578691	LAP3	0.39	6.93	0.31	1.4e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg16339924	chr4:17578868	LAP3	0.65	10.96	0.45	5.22e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06632829	chr19:45394476	TOMM40	0.52	8.07	0.35	6.04e-15	Gut microbiome composition (summer);
LGG	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg19748678	chr4:122722346	EXOSC9	0.67	13.16	0.52	7.71e-34	Type 2 diabetes;
LGG	cis	rs11771526	0.901	rs13438711	chr7:32297310	G/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs9326248	0.769	rs499910	chr11:116763034	G/A	cg20608306	chr11:116969690	SIK3	0.3	7.72	0.34	7.37e-14	Blood protein levels;
LGG	cis	rs1707322	1.000	rs4454479	chr1:46423555	G/A	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.49	8.11	0.35	4.44e-15	Total body bone mineral density;
LGG	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg02631450	chr22:32366979	NA	0.95	9.12	0.39	2.27e-18	Childhood ear infection;
LGG	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18876405	chr7:65276391	NA	-0.6	-11.42	-0.47	8.59e-27	Aortic root size;
LGG	cis	rs7571561	0.554	rs13400881	chr2:213280504	A/C	cg16329650	chr2:213403929	ERBB4	0.46	6.85	0.3	2.39e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (maternal effect);
LGG	cis	rs2073300	0.609	rs34648279	chr20:23402935	T/G	cg12062639	chr20:23401060	NAPB	0.92	8.72	0.38	4.86e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11122272	0.735	rs2355873	chr1:231477442	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.37	-0.32	8.04e-13	Hemoglobin concentration;
LGG	cis	rs362272	0.525	rs2471347	chr4:3044435	A/G	cg02566259	chr4:3043199	NA	-0.34	-8.72	-0.38	5.03e-17	Serum sulfate level;
LGG	cis	rs7264396	0.570	rs1970576	chr20:34336720	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.26	0.32	1.61e-12	Total cholesterol levels;
LGG	cis	rs7715811	1.000	rs12153762	chr5:13778890	A/G	cg07548982	chr5:13769939	DNAH5	-0.47	-9.93	-0.42	3.37e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg19454999	chr17:41278357	BRCA1;NBR2	0.44	6.73	0.3	5.19e-11	Menopause (age at onset);
LGG	cis	rs1978968	0.717	rs28406897	chr22:18402012	T/C	cg03078520	chr22:18463400	MICAL3	-0.52	-9.98	-0.42	2.33e-21	Presence of antiphospholipid antibodies;
LGG	cis	rs1595825	0.891	rs1440086	chr2:198906354	A/G	cg00982548	chr2:198649783	BOLL	-0.53	-7.08	-0.31	5.32e-12	Ulcerative colitis;
LGG	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg05194412	chr2:137003533	NA	-0.31	-6.66	-0.3	7.81e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs57502260	0.704	rs17149179	chr11:68351722	C/T	cg01657329	chr11:68192670	LRP5	-0.57	-7.34	-0.32	9.46e-13	Total body bone mineral density (age 45-60);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25264554	chr3:142166789	XRN1	0.43	6.95	0.31	1.24e-11	Cognitive performance;
LGG	cis	rs11190604	1.000	rs74650218	chr10:102293830	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	12.04	0.49	3.03e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.22	-0.39	1.09e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs8078723	1.000	rs6503530	chr17:38161823	T/C	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20786246	chr2:72377174	NA	0.39	6.99	0.31	9.8e-12	Bipolar disorder;
LGG	cis	rs929354	0.742	rs2006844	chr7:157002851	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.45e-13	Body mass index;
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	trans	rs9929218	0.953	rs3114411	chr16:68734591	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.86	14.99	0.57	1.04e-41	Colorectal cancer;
LGG	cis	rs9534288	0.797	rs9534276	chr13:46574317	T/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg01765077	chr12:122356316	WDR66	0.29	8.1	0.35	4.9e-15	Mean corpuscular volume;
LGG	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg13786083	chr1:19110734	NA	-0.4	-6.9	-0.31	1.73e-11	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs1909881	0.504	rs73697827	chr8:96494108	G/A	cg04203453	chr8:96504381	NA	-0.78	-11.96	-0.49	6.7e-29	Obesity-related traits;
LGG	trans	rs75804782	0.580	rs72987332	chr2:239362529	G/T	cg01134436	chr17:81009848	B3GNTL1	0.85	8.92	0.38	1.06e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.599	rs2863717	chr10:104519829	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.99	-0.35	1.1e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.18e-20	Aortic root size;
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg15394860	chr11:2017084	H19	0.63	13.81	0.54	1.49e-36	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs60180747	0.544	rs11632542	chr15:66560071	A/G	cg07575407	chr15:66541975	MEGF11	-0.62	-13.37	-0.53	9.99e-35	Testicular germ cell tumor;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg05863683	chr7:1912471	MAD1L1	-0.36	-7.17	-0.32	2.9e-12	Schizophrenia;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.9	-0.45	8.65e-25	Lung cancer;
LGG	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg20387954	chr3:183756860	HTR3D	0.66	13.59	0.53	1.21e-35	Anterior chamber depth;
LGG	cis	rs2028299	0.879	rs28678152	chr15:90449523	T/C	cg23731826	chr15:90371692	NA	0.35	7.74	0.34	6.33e-14	Type 2 diabetes;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	trans	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.79e-13	HDL cholesterol;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08838602	chr8:65483645	NA	0.37	7.64	0.33	1.26e-13	Menarche (age at onset);
LGG	cis	rs61990749	0.597	rs1048147	chr14:78139988	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.11	-0.31	4.42e-12	Fibroblast growth factor basic levels;
LGG	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-12.86	-0.51	1.47e-32	Morning vs. evening chronotype;
LGG	cis	rs7091068	0.522	rs866674	chr10:95487515	A/G	cg20715218	chr10:95462985	C10orf4	0.66	10.94	0.45	6.43e-25	Urinary tract infection frequency;
LGG	cis	rs10991814	0.920	rs16907297	chr9:94008934	T/C	cg14446406	chr9:93919335	NA	-0.75	-8.42	-0.36	4.68e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs11792861	0.541	rs838824	chr9:111670707	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.51	-8.28	-0.36	1.37e-15	Menarche (age at onset);
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg13752114	chr3:195489708	MUC4	0.66	9.06	0.39	3.69e-18	Lung disease severity in cystic fibrosis;
LGG	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.42	-7.57	-0.33	2.07e-13	Schizophrenia;
LGG	cis	rs4363385	0.720	rs1611755	chr1:152956420	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1e-17	Inflammatory skin disease;
LGG	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg06917763	chr7:130033247	NA	0.34	7.45	0.33	4.63e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3816183	1.000	rs3816185	chr2:43015902	G/A	cg14631114	chr2:43023945	NA	0.51	9.59	0.41	5.27e-20	Hypospadias;
LGG	cis	rs2070433	0.851	rs10854484	chr21:47926702	T/C	cg12379764	chr21:47803548	PCNT	0.52	7.36	0.32	8.42e-13	Lymphocyte counts;
LGG	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.82	-0.42	8.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg12463550	chr7:65579703	CRCP	-0.78	-8.38	-0.36	6.34e-16	Diabetic kidney disease;
LGG	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg00277334	chr10:82204260	NA	-0.52	-12.52	-0.5	3.49e-31	Post bronchodilator FEV1;
LGG	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg02002194	chr4:3960332	NA	-0.5	-9.42	-0.4	2.19e-19	Myopia (pathological);
LGG	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg02403541	chr12:121454288	C12orf43	0.53	8.8	0.38	2.75e-17	N-glycan levels;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg18402987	chr7:1209562	NA	0.66	9.14	0.39	2.01e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11875185	0.510	rs77583660	chr18:55619360	T/C	cg15513957	chr14:69354734	ACTN1	-0.9	-9.04	-0.39	4.41e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-16.5	-0.61	1.88e-48	Tonsillectomy;
LGG	trans	rs9467711	0.651	rs13210041	chr6:26037601	G/A	cg01620082	chr3:125678407	NA	-0.86	-7.48	-0.33	3.7e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	trans	rs12545912	0.863	rs7015787	chr8:9580712	G/A	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg13256891	chr4:100009986	ADH5	-0.55	-9.54	-0.41	7.88e-20	Alcohol dependence;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07971952	chr13:113434690	ATP11A	0.4	6.91	0.31	1.57e-11	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22371845	chr8:140718096	NA	0.5	7.74	0.34	6.21e-14	Gut microbiome composition (summer);
LGG	cis	rs7617773	0.817	rs17786132	chr3:48249420	C/G	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.35	0.4	3.71e-19	Retinal vascular caliber;
LGG	cis	rs12249377	0.519	rs10881838	chr10:92590233	A/G	cg14313238	chr10:92632228	RPP30	0.4	7.14	0.31	3.65e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.81	0.3	3.01e-11	Longevity;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg14191688	chr11:70257035	CTTN	0.57	8.49	0.37	2.9e-16	Coronary artery disease;
LGG	cis	rs9583531	0.689	rs9515273	chr13:111383427	G/C	cg15841412	chr13:111365552	ING1	0.46	6.74	0.3	4.74e-11	Coronary artery disease;
LGG	cis	rs11158198	0.643	rs7151771	chr14:58580310	C/T	cg15908186	chr14:58618357	C14orf37	0.51	8.9	0.38	1.29e-17	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs7395662	1.000	rs10838966	chr11:48589723	C/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs6743226	0.603	rs10933548	chr2:242234837	T/C	cg10021735	chr2:242295487	FARP2	0.4	6.96	0.31	1.2e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	18.66	0.66	2.31e-58	Platelet count;
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg03517284	chr6:25882590	NA	-0.39	-6.96	-0.31	1.16e-11	Height;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.12	-0.57	2.86e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-9.56	-0.41	6.84e-20	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.6	-0.33	1.64e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs35661897	0.920	rs12478549	chr2:227329662	T/A	cg03426602	chr2:227312417	NA	-0.45	-6.87	-0.3	2.12e-11	Urinary tract infection frequency;
LGG	cis	rs4144027	0.967	rs72712857	chr14:104362673	T/C	cg26031613	chr14:104095156	KLC1	-0.42	-6.89	-0.31	1.79e-11	Blood metabolite levels;
LGG	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg04398451	chr17:18023971	MYO15A	-0.87	-20.09	-0.68	5.23e-65	Total body bone mineral density;
LGG	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.4	0.4	2.42e-19	Gout;Renal underexcretion gout;
LGG	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg04617936	chr2:214353	NA	-0.38	-7.2	-0.32	2.4e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10668150	chr5:56469580	GPBP1	0.68	7.56	0.33	2.14e-13	Intelligence (multi-trait analysis);
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.79	11.08	0.46	1.74e-25	Lung function (FEV1/FVC);
LGG	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg03929089	chr4:120376271	NA	-1.03	-24.47	-0.75	1.76e-85	Height;
LGG	cis	rs72781680	0.898	rs72780191	chr2:24007122	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.41	0.4	2.28e-19	Lymphocyte counts;
LGG	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg19645103	chr12:69753606	YEATS4	-0.48	-6.69	-0.3	6.3e-11	Response to diuretic therapy;
LGG	trans	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg07393940	chr7:158741817	NA	0.57	10.63	0.44	9.21e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7666738	0.678	rs7670805	chr4:99008763	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.37	0.36	7.12e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6601327	0.665	rs10107992	chr8:9653287	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.89	-0.3	1.82e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9467773	1.000	rs1321479	chr6:26501897	C/T	cg09904177	chr6:26538194	HMGN4	-0.69	-14.98	-0.57	1.21e-41	Intelligence (multi-trait analysis);
LGG	cis	rs10864302	0.525	rs2153862	chr1:7417411	T/C	cg08923594	chr1:7462176	CAMTA1	0.65	7.99	0.35	1.07e-14	Photic sneeze reflex;
LGG	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg05677249	chr15:77158041	SCAPER	-0.31	-6.66	-0.3	7.61e-11	Blood metabolite levels;
LGG	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg15485101	chr11:133734466	NA	0.61	10.62	0.44	1.04e-23	Childhood ear infection;
LGG	cis	rs6831352	0.691	rs2602887	chr4:100041473	A/G	cg13256891	chr4:100009986	ADH5	0.5	8.33	0.36	9.02e-16	Alcohol dependence;
LGG	cis	rs11874712	1.000	rs28699609	chr18:43674879	A/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg27489772	chr12:121021490	NA	-0.59	-7.8	-0.34	4.1e-14	Type 1 diabetes nephropathy;
LGG	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.7	-0.41	2.33e-20	Alcohol dependence;
LGG	cis	rs854765	0.964	rs854810	chr17:18006421	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-10.73	-0.45	3.83e-24	Total body bone mineral density;
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg24690094	chr11:67383802	NA	-0.55	-9.64	-0.41	3.69e-20	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg03959625	chr15:84868606	LOC388152	-0.55	-8.7	-0.37	5.84e-17	Schizophrenia;
LGG	cis	rs4702718	0.574	rs2918395	chr5:10701251	A/G	cg18867653	chr5:10760375	DAP	0.28	6.94	0.31	1.34e-11	Obesity-related traits;
LGG	trans	rs7613875	0.578	rs4688753	chr3:50074773	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.8	-0.3	3.3e-11	Body mass index;
LGG	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00149659	chr3:10157352	C3orf10	-1.18	-14.21	-0.55	2.67e-38	Alzheimer's disease;
LGG	cis	rs9916302	0.706	rs4795375	chr17:37662932	T/C	cg07936489	chr17:37558343	FBXL20	-0.99	-15.34	-0.58	2.95e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7444	0.882	rs5754217	chr22:21939675	G/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.88	0.3	1.94e-11	Glycated hemoglobin levels;
LGG	cis	rs4268898	0.610	rs72791170	chr2:24449776	C/T	cg06627628	chr2:24431161	ITSN2	-0.77	-12.47	-0.5	5.9e-31	Asthma;
LGG	cis	rs9916302	0.904	rs634365	chr17:37436966	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.45	-0.47	6.57e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg24147849	chr3:100053372	NIT2	0.43	7.46	0.33	4.2e-13	Bipolar disorder;
LGG	cis	rs2797369	0.546	rs1740479	chr6:101481015	C/G	cg27451362	chr6:101846650	GRIK2	0.84	11.25	0.46	3.94e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs975739	0.604	rs9318510	chr13:78588657	G/C	cg07847733	chr13:78271382	SLAIN1	0.48	7.96	0.35	1.31e-14	Hair color;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg08835221	chr22:38071607	LGALS1	0.28	7.7	0.34	8.18e-14	Fat distribution (HIV);
LGG	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.03	-0.39	4.52e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9633740	1.000	rs7922621	chr10:82251544	C/A	cg01528321	chr10:82214614	TSPAN14	1.04	16.3	0.6	1.53e-47	Post bronchodilator FEV1;
LGG	cis	rs17221829	0.720	rs10765237	chr11:89453598	T/G	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.52	-0.33	2.94e-13	Anxiety in major depressive disorder;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg21963583	chr11:68658836	MRPL21	0.57	9.94	0.42	3.13e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.13	-0.31	3.98e-12	Prostate cancer;
LGG	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg17046650	chr2:3699563	NA	0.93	10.64	0.44	8.56e-24	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs56346965	1.000	rs2192008	chr2:191545147	C/T	cg18238734	chr12:26986119	ITPR2	-0.44	-6.87	-0.3	2.14e-11	Bone mineral density (Ward's triangle area);
LGG	cis	rs700651	0.789	rs1976772	chr2:198868201	G/T	cg00792783	chr2:198669748	PLCL1	0.66	10.5	0.44	2.91e-23	Intracranial aneurysm;
LGG	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg11789530	chr4:8429930	ACOX3	-0.68	-11.03	-0.46	2.84e-25	Response to antineoplastic agents;
LGG	cis	rs3020736	0.500	rs6519306	chr22:42501217	T/C	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	6.13e-34	Prudent dietary pattern;
LGG	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg05973401	chr12:123451056	ABCB9	-0.45	-6.69	-0.3	6.31e-11	Neutrophil percentage of white cells;
LGG	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg03060546	chr3:49711283	APEH	0.57	8.79	0.38	2.9e-17	Resting heart rate;
LGG	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg18479299	chr3:125709523	NA	-0.57	-7.35	-0.32	9.14e-13	Blood pressure (smoking interaction);
LGG	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg04935436	chr20:30431758	NA	0.41	7.22	0.32	2.11e-12	Mean corpuscular hemoglobin;
LGG	trans	rs9354308	0.764	rs9354330	chr6:66603308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs1682825	0.858	rs76037015	chr3:10761118	G/A	cg23512531	chr3:10780469	NA	0.58	7.68	0.34	9.38e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs977987	0.836	rs7200053	chr16:75474618	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.17	0.43	4.49e-22	Dupuytren's disease;
LGG	cis	rs73416724	0.925	rs79641366	chr6:43279144	T/C	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9325144	0.555	rs10748433	chr12:38696352	C/G	cg26384229	chr12:38710491	ALG10B	0.76	15.34	0.58	3.14e-43	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg08888203	chr3:10149979	C3orf24	0.57	7.76	0.34	5.3e-14	Alzheimer's disease;
LGG	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg15268244	chr15:77196840	NA	-0.32	-7.2	-0.32	2.45e-12	Blood metabolite levels;
LGG	cis	rs6735179	0.688	rs2382564	chr2:1763701	A/G	cg20570797	chr2:1712800	PXDN	-0.46	-8.39	-0.36	5.83e-16	Response to antipsychotic treatment;
LGG	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg21775007	chr8:11205619	TDH	-0.5	-7.91	-0.34	1.93e-14	Triglycerides;
LGG	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg11693508	chr17:37793320	STARD3	-0.62	-9.76	-0.41	1.34e-20	Bipolar disorder;
LGG	cis	rs2991971	0.967	rs512026	chr1:46009946	G/T	cg24296786	chr1:45957014	TESK2	0.39	6.86	0.3	2.27e-11	High light scatter reticulocyte count;
LGG	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.98	-0.52	4.5e-33	Alzheimer's disease;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13012494	chr21:47604986	C21orf56	0.49	8.13	0.35	3.97e-15	Testicular germ cell tumor;
LGG	cis	rs1801251	0.963	rs35362030	chr2:233612845	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.48	0.5	5e-31	Coronary artery disease;
LGG	cis	rs11169552	0.510	rs17124930	chr12:51115935	A/G	cg12884762	chr12:50931848	DIP2B	-0.4	-7.63	-0.33	1.38e-13	Colorectal cancer;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25072359	chr17:41440525	NA	0.54	10.21	0.43	3.17e-22	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.31	0.5	2.65e-30	Prudent dietary pattern;
LGG	trans	rs2562456	0.833	rs1626404	chr19:21483788	C/A	cg00806126	chr19:22604979	ZNF98	-0.56	-7.54	-0.33	2.53e-13	Pain;
LGG	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg02466173	chr16:30829666	NA	-0.39	-6.83	-0.3	2.63e-11	Dementia with Lewy bodies;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00149659	chr3:10157352	C3orf10	0.83	10.79	0.45	2.21e-24	Alzheimer's disease;
LGG	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	7.51	0.33	3.08e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10911363	0.570	rs2702204	chr1:183457396	A/G	cg09173681	chr1:183549694	NCF2	0.36	8.3	0.36	1.15e-15	Systemic lupus erythematosus;
LGG	cis	rs7582720	0.943	rs72934550	chr2:203983940	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.3	0.4	5.46e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg25214090	chr10:38739885	LOC399744	0.7	12.32	0.5	2.37e-30	Corneal astigmatism;
LGG	cis	rs7712401	0.601	rs246320	chr5:122308581	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs1062177	1.000	rs2964571	chr5:151171256	C/T	cg00977110	chr5:151150581	G3BP1	0.5	8.03	0.35	7.96e-15	Preschool internalizing problems;
LGG	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.31	0.43	1.4e-22	Diabetic retinopathy;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs13126513	0.519	rs12641768	chr4:100558594	C/A	cg05468953	chr4:100565104	NA	0.42	8.28	0.36	1.36e-15	Metabolite levels (MHPG);
LGG	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg20891283	chr12:69753455	YEATS4	0.72	13.51	0.53	2.68e-35	Blood protein levels;
LGG	cis	rs2463822	0.920	rs28678254	chr11:62151875	G/C	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.68	-0.59	9.08e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs9916302	0.800	rs8069451	chr17:37504933	C/T	cg00129232	chr17:37814104	STARD3	-0.63	-11.76	-0.48	4.14e-28	Glomerular filtration rate (creatinine);
LGG	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg11941060	chr3:133502564	NA	-0.48	-8.08	-0.35	5.59e-15	Iron status biomarkers;
LGG	cis	rs61931739	0.500	rs11615231	chr12:34413330	T/C	cg06521331	chr12:34319734	NA	-0.59	-10.25	-0.43	2.27e-22	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg22920501	chr2:26401640	FAM59B	-0.45	-9.35	-0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg04149295	chr10:70884716	VPS26A	0.48	7.15	0.32	3.38e-12	Left atrial antero-posterior diameter;
LGG	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4430311	0.688	rs12746623	chr1:243963175	G/A	cg25706552	chr1:244017396	NA	-0.65	-16.22	-0.6	3.65e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg03806693	chr22:41940476	POLR3H	0.99	16.69	0.61	2.53e-49	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg16482183	chr6:26056742	HIST1H1C	0.5	7.95	0.35	1.4e-14	Iron status biomarkers;
LGG	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg17689763	chr4:710664	PCGF3	-0.79	-16.6	-0.61	6.49e-49	White blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10310756	chr6:112408973	TUBE1;C6orf225	0.49	7.42	0.33	5.69e-13	Gut microbiome composition (summer);
LGG	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg16486109	chr11:613632	IRF7	0.42	7.07	0.31	5.6e-12	Systemic lupus erythematosus;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg24846343	chr22:24311635	DDTL	0.62	12.77	0.51	3.2e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	1.000	rs9375499	chr6:127618072	T/C	cg24812749	chr6:127587940	RNF146	0.96	15.74	0.59	4.98e-45	Breast cancer;
LGG	cis	rs10791097	0.694	rs7107595	chr11:130758556	C/T	cg12179176	chr11:130786555	SNX19	0.83	16.93	0.62	2.09e-50	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs714515	0.934	rs7517737	chr1:172341975	C/A	cg01573306	chr1:172330400	DNM3	0.34	7.44	0.33	4.93e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg01579765	chr21:45077557	HSF2BP	0.4	8.63	0.37	9.66e-17	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs11920090	0.932	rs11711437	chr3:170726363	C/G	cg09710316	chr3:170744871	SLC2A2	0.6	8.59	0.37	1.34e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.44	-0.4	1.87e-19	Lung cancer;
LGG	cis	rs6429082	0.702	rs2131922	chr1:235705001	G/T	cg26050004	chr1:235667680	B3GALNT2	-0.52	-7.98	-0.35	1.14e-14	Adiposity;
LGG	cis	rs6762	0.692	rs5030778	chr11:836008	T/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.5	-8.02	-0.35	8.94e-15	Mean platelet volume;
LGG	cis	rs17209837	0.831	rs56223611	chr7:87083157	C/A	cg00919237	chr7:87102261	ABCB4	-0.68	-11.06	-0.46	2.18e-25	Gallbladder cancer;
LGG	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.49	-0.47	4.62e-27	Height;
LGG	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.45	-9.0	-0.39	6.05e-18	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1420338	0.869	rs1362452	chr7:34170519	G/A	cg01275685	chr7:34179230	BMPER	-0.53	-9.83	-0.42	7.68e-21	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.72	0.3	5.4e-11	Height;
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.5	-8.49	-0.37	2.78e-16	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4740619	0.846	rs1592099	chr9:15765856	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.43	-0.44	5.01e-23	Body mass index;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs10884984	0.826	rs12355696	chr10:112281649	T/A	cg18756771	chr10:112261994	DUSP5	0.67	11.09	0.46	1.6e-25	Facial morphology (factor 22);
LGG	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg05697835	chr1:2722811	NA	0.3	7.08	0.31	5.42e-12	Ulcerative colitis;
LGG	trans	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg08344181	chr3:125677491	NA	0.58	6.8	0.3	3.17e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11785400	1.000	rs3824208	chr8:143743653	C/G	cg24634471	chr8:143751801	JRK	0.53	8.56	0.37	1.62e-16	Schizophrenia;
LGG	cis	rs11690935	0.571	rs1008151	chr2:172912098	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	13.62	0.53	8.94e-36	Schizophrenia;
LGG	cis	rs10489202	1.000	rs4656564	chr1:167928992	T/C	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs4959677	0.901	rs13200224	chr6:2485653	C/T	cg20147862	chr6:2634573	C6orf195	-0.41	-9.03	-0.39	4.51e-18	Orthostatic hypotension;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.77e-14	Personality dimensions;
LGG	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg12560992	chr17:57184187	TRIM37	0.93	16.69	0.61	2.65e-49	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs7914558	0.966	rs12571568	chr10:104891396	C/G	cg04362960	chr10:104952993	NT5C2	0.55	10.41	0.44	6.06e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11168187	0.943	rs2077621	chr12:47981845	C/T	cg12761788	chr12:48120090	P11	0.48	7.48	0.33	3.71e-13	Vertical cup-disc ratio;
LGG	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg02248941	chr16:2239361	CASKIN1	0.38	7.44	0.33	4.93e-13	Height;
LGG	cis	rs2640806	0.505	rs7838015	chr8:97352592	T/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.32	0.32	1.08e-12	Obesity-related traits;
LGG	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg07636037	chr3:49044803	WDR6	0.78	13.89	0.54	6.59e-37	Menarche (age at onset);
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg19901468	chr14:105411992	AHNAK2	0.89	18.71	0.66	1.45e-58	Rheumatoid arthritis;
LGG	trans	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs9790314	0.818	rs6797066	chr3:161008725	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.75e-37	Morning vs. evening chronotype;
LGG	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7192380	0.895	rs2917671	chr16:69758741	A/T	cg00738113	chr16:70207722	CLEC18C	0.28	7.83	0.34	3.3e-14	Sjögren's syndrome;
LGG	cis	rs1519814	0.696	rs4871031	chr8:121031777	T/C	cg22335954	chr8:121166405	COL14A1	-0.48	-8.66	-0.37	7.65e-17	Breast cancer;
LGG	cis	rs7220401	0.515	rs8080772	chr17:28413129	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.56	-9.17	-0.39	1.57e-18	Coronary artery disease;
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg00149659	chr3:10157352	C3orf10	1.18	13.62	0.53	8.8e-36	Alzheimer's disease;
LGG	cis	rs7666738	0.830	rs2015828	chr4:98984594	A/G	cg05340658	chr4:99064831	C4orf37	0.49	8.28	0.36	1.38e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09742170	chr7:25021208	OSBPL3	-0.44	-7.58	-0.33	1.85e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4363385	0.510	rs7531076	chr1:153039167	G/T	cg13444842	chr1:152974279	SPRR3	-0.46	-9.32	-0.4	4.91e-19	Inflammatory skin disease;
LGG	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg11794728	chr13:74707860	KLF12	-0.44	-7.03	-0.31	7.22e-12	C-reactive protein levels;Esophageal cancer (squamous cell);
LGG	cis	rs7215564	0.908	rs35725122	chr17:78663275	A/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.23	-0.36	1.96e-15	Myopia (pathological);
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg26150922	chr2:100937072	LONRF2	-0.57	-11.04	-0.46	2.59e-25	Intelligence (multi-trait analysis);
LGG	cis	rs7953249	0.935	rs7135337	chr12:121404155	A/C	cg14101638	chr12:121416612	HNF1A	-0.37	-8.53	-0.37	2.04e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg11494091	chr17:61959527	GH2	-0.68	-11.86	-0.48	1.61e-28	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12841375	chr6:52929709	FBXO9	0.48	7.6	0.33	1.69e-13	Gut microbiome composition (summer);
LGG	trans	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg21659725	chr3:3221576	CRBN	0.63	11.82	0.48	2.39e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg19147804	chr7:1989927	MAD1L1	-0.54	-11.16	-0.46	8.78e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.764	rs62246375	chr3:47014464	G/A	cg16586182	chr3:47516702	SCAP	0.73	13.51	0.53	2.77e-35	Colorectal cancer;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.2	0.32	2.37e-12	Height;
LGG	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg09998033	chr7:158218633	PTPRN2	0.46	8.38	0.36	6.44e-16	Obesity-related traits;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg18252515	chr7:66147081	NA	0.41	6.92	0.31	1.5e-11	Aortic root size;
LGG	trans	rs1493916	0.870	rs8097667	chr18:31387003	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.71	-0.38	5.53e-17	Life satisfaction;
LGG	cis	rs240764	0.619	rs3818233	chr6:101086372	C/G	cg09795085	chr6:101329169	ASCC3	-0.4	-6.74	-0.3	4.66e-11	Neuroticism;
LGG	cis	rs10463316	0.832	rs1019467	chr5:150734323	A/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.39	-0.43	7.35e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs9815354	0.767	rs6805140	chr3:41995791	A/G	cg03022575	chr3:42003672	ULK4	0.78	9.14	0.39	2.01e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg06798480	chr3:9439221	SETD5;LOC440944	-0.39	-6.7	-0.3	6.1e-11	Brain structure;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.79	0.54	1.79e-36	Lung cancer;
LGG	cis	rs10276381	1.000	rs10276381	chr7:28190121	A/G	cg23620719	chr7:28220237	JAZF1	-0.82	-10.66	-0.44	7.32e-24	Crohn's disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14585611	chr2:175260420	CIR1;SCRN3	0.38	6.8	0.3	3.3e-11	Bilirubin levels;
LGG	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.88	-0.3	1.93e-11	Blood metabolite levels;
LGG	cis	rs7222240	1.000	rs73311379	chr17:43107589	C/T	cg24806326	chr17:43207588	PLCD3	0.47	7.83	0.34	3.44e-14	Craniofacial microsomia;
LGG	cis	rs7552404	0.727	rs6683437	chr1:76316619	G/A	cg22875332	chr1:76189707	ACADM	0.54	8.1	0.35	4.75e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs938554	0.657	rs9994216	chr4:9984541	G/T	cg25986240	chr4:9926439	SLC2A9	-0.35	-6.68	-0.3	6.77e-11	Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg08280861	chr8:58055591	NA	0.51	6.75	0.3	4.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg02972257	chr16:68554789	NA	-0.56	-8.27	-0.36	1.41e-15	Ulcerative colitis;
LGG	cis	rs2735413	0.564	rs73580821	chr16:78110304	A/G	cg04733911	chr16:78082701	NA	0.58	8.06	0.35	6.52e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	8.07	0.35	5.93e-15	Lymphocyte percentage of white cells;
LGG	cis	rs9783347	1.000	rs4150564	chr11:18355308	G/A	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs9649213	0.614	rs3944111	chr7:98005766	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.48	-8.26	-0.36	1.57e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs2749592	0.725	rs9417245	chr10:37826322	C/T	cg25427524	chr10:38739819	LOC399744	0.47	8.54	0.37	1.91e-16	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10267417	0.603	rs7789051	chr7:19956618	A/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.59e-11	Night sleep phenotypes;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	trans	rs7939886	0.920	rs7936219	chr11:55977335	C/T	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14159672	chr1:205819179	PM20D1	-0.48	-7.63	-0.33	1.31e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs1691799	0.899	rs1168306	chr12:66738900	A/G	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.22e-44	White blood cell count (basophil);
LGG	cis	rs7666738	0.535	rs6850010	chr4:98971601	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.09	0.35	5.24e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg21545522	chr1:205238299	TMCC2	0.36	6.96	0.31	1.15e-11	Red blood cell count;
LGG	cis	rs13082711	0.522	rs9310842	chr3:27369765	A/T	cg02860705	chr3:27208620	NA	-0.65	-12.46	-0.5	6.5e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg03188948	chr7:1209495	NA	0.48	7.74	0.34	6.45e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26663469	chr17:26662463	TNFAIP1;IFT20	0.55	8.39	0.36	5.96e-16	Gut microbiome composition (summer);
LGG	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg17691542	chr6:26056736	HIST1H1C	0.91	13.38	0.53	9.25e-35	Iron status biomarkers;
LGG	cis	rs9796	0.621	rs537244	chr15:41469313	G/T	cg18705301	chr15:41695430	NDUFAF1	0.58	9.96	0.42	2.7e-21	Menopause (age at onset);
LGG	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-9.82	-0.42	8.61e-21	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg06481639	chr22:41940642	POLR3H	-0.53	-7.89	-0.34	2.25e-14	Vitiligo;
LGG	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg16583315	chr14:65563665	MAX	-0.35	-6.85	-0.3	2.29e-11	Obesity-related traits;
LGG	cis	rs935334	1.000	rs8006048	chr14:76683508	G/A	cg14073839	chr14:76668648	C14orf118	-0.41	-6.79	-0.3	3.38e-11	Blood pressure;
LGG	cis	rs2299587	0.897	rs3850744	chr8:17784203	A/G	cg18067069	chr8:17937731	ASAH1	-0.28	-6.65	-0.3	8.39e-11	Economic and political preferences;
LGG	cis	rs12210905	1.000	rs72842200	chr6:27068036	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg13256891	chr4:100009986	ADH5	0.55	9.5	0.4	1.16e-19	Smoking initiation;
LGG	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.81	-0.38	2.53e-17	Post bronchodilator FEV1;
LGG	cis	rs11191205	0.774	rs11191203	chr10:103824920	C/T	cg00857846	chr10:103824917	HPS6	0.73	9.13	0.39	2.13e-18	Intelligence (multi-trait analysis);
LGG	cis	rs721917	0.526	rs2256574	chr10:81685039	A/G	cg25562619	chr10:81652821	NA	-0.33	-7.56	-0.33	2.14e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs9894429	0.934	rs35868252	chr17:79575472	C/G	cg10661904	chr17:79619235	PDE6G	0.42	8.53	0.37	2.03e-16	Eye color traits;
LGG	cis	rs3020736	0.500	rs8143153	chr22:42515637	G/C	cg04733989	chr22:42467013	NAGA	-0.59	-10.62	-0.44	1.01e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4774830	0.744	rs62046392	chr15:56312554	C/G	cg05129572	chr15:56138634	NEDD4	0.71	6.88	0.3	1.93e-11	Delta-5 desaturase activity;
LGG	cis	rs7818345	0.640	rs13267801	chr8:19326834	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.44	-9.72	-0.41	1.88e-20	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.5	0.61	2.01e-48	Hip circumference adjusted for BMI;
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg13264159	chr8:625131	ERICH1	-0.96	-9.89	-0.42	4.75e-21	IgG glycosylation;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.71	-13.04	-0.52	2.44e-33	Obesity-related traits;
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg10295955	chr4:187884368	NA	-1.13	-31.59	-0.83	1.33e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17376456	0.542	rs10476588	chr5:93208330	C/T	cg25358565	chr5:93447407	FAM172A	-0.83	-11.57	-0.47	2.36e-27	Diabetic retinopathy;
LGG	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs4262150	0.667	rs4533947	chr5:152260682	A/G	cg12297329	chr5:152029980	NA	-0.6	-11.87	-0.48	1.49e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	1.000	rs1006441	chr11:77932126	G/C	cg02023728	chr11:77925099	USP35	0.45	7.86	0.34	2.69e-14	Testicular germ cell tumor;
LGG	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg02002194	chr4:3960332	NA	0.39	6.89	0.3	1.79e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg03528353	chr17:61819722	STRADA	-0.4	-6.75	-0.3	4.54e-11	Prudent dietary pattern;
LGG	cis	rs524281	0.773	rs11227413	chr11:65883696	G/A	cg16950941	chr11:66035639	RAB1B	-0.46	-6.7	-0.3	6.14e-11	Electroencephalogram traits;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg19182353	chr11:118479428	PHLDB1	0.55	11.7	0.48	6.93e-28	Systemic lupus erythematosus;
LGG	cis	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg06521331	chr12:34319734	NA	-0.41	-6.74	-0.3	4.78e-11	Morning vs. evening chronotype;
LGG	trans	rs11039798	0.588	rs12294395	chr11:48476860	C/T	cg15704280	chr7:45808275	SEPT13	0.73	9.99	0.42	2e-21	Axial length;
LGG	cis	rs2131877	0.830	rs11710992	chr3:194881572	C/T	cg07250128	chr3:194833983	C3orf21	0.44	7.31	0.32	1.2e-12	Non-small cell lung cancer;
LGG	trans	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.9	-0.42	4.39e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.28	-0.32	1.42e-12	Refractive error;
LGG	cis	rs1994135	0.617	rs10743824	chr12:33733764	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.77	-0.34	5.12e-14	Resting heart rate;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg03735888	chr19:58951602	ZNF132	0.44	8.74	0.38	4.33e-17	Uric acid clearance;
LGG	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg21775007	chr8:11205619	TDH	-0.77	-13.41	-0.53	7.33e-35	Retinal vascular caliber;
LGG	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg25356066	chr3:128598488	ACAD9	0.47	7.15	0.32	3.46e-12	IgG glycosylation;
LGG	cis	rs67311347	0.544	rs9868700	chr3:40345408	G/A	cg13683864	chr3:40499215	RPL14	-0.81	-16.06	-0.6	1.8e-46	Renal cell carcinoma;
LGG	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg19773385	chr1:10388646	KIF1B	0.35	7.8	0.34	4.12e-14	Hepatocellular carcinoma;
LGG	cis	rs7584262	0.736	rs10174871	chr2:42263018	G/A	cg27252766	chr2:42229092	NA	0.5	6.79	0.3	3.51e-11	Bone mineral density;
LGG	cis	rs6984449	0.508	rs62496184	chr8:19319423	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.5	12.63	0.51	1.24e-31	Educational attainment;
LGG	cis	rs9341808	0.718	rs3805922	chr6:80891989	A/G	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.89e-14	Sitting height ratio;
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg01765077	chr12:122356316	WDR66	0.29	7.8	0.34	4.1e-14	Mean corpuscular volume;
LGG	cis	rs12724450	0.793	rs58853199	chr1:150378212	A/G	cg03818307	chr1:150480534	ECM1	0.5	7.04	0.31	7.05e-12	Blood protein levels;
LGG	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.68	-0.37	6.82e-17	Aortic root size;
LGG	cis	rs737693	0.920	rs17368814	chr11:102748695	C/T	cg19620758	chr11:102826565	MMP13	-0.51	-6.9	-0.31	1.69e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7208859	0.623	rs216446	chr17:28933718	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.39	-0.47	1.2e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg08621203	chr6:150244597	RAET1G	0.42	7.21	0.32	2.3e-12	Lung cancer;
LGG	cis	rs9834373	0.922	rs9850240	chr3:78501897	G/A	cg06138941	chr3:78371609	NA	-0.52	-9.28	-0.4	6.57e-19	Protein quantitative trait loci;
LGG	cis	rs988958	0.566	rs7599890	chr2:42247958	A/G	cg27428208	chr2:42229179	NA	0.52	8.78	0.38	3.17e-17	Hypospadias;
LGG	cis	rs2298450	0.563	rs55801841	chr21:37630745	G/A	cg02919814	chr21:37666008	DOPEY2	-0.5	-9.08	-0.39	3.07e-18	Schizophrenia;
LGG	cis	rs9818758	0.556	rs9872660	chr3:49378832	G/T	cg00383909	chr3:49044727	WDR6	0.57	8.18	0.36	2.69e-15	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4330281	0.647	rs6768666	chr3:17692937	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.53	-0.33	2.62e-13	Schizophrenia;
LGG	cis	rs12738007	1.000	rs12738007	chr1:29521705	C/T	cg01115565	chr1:29584222	PTPRU	-0.28	-7.52	-0.33	2.95e-13	Schizophrenia;
LGG	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg08975724	chr8:8085496	FLJ10661	0.46	8.99	0.39	6.11e-18	Parkinson's disease;
LGG	cis	rs367943	0.608	rs6594744	chr5:112990207	T/C	cg12552261	chr5:112820674	MCC	0.5	8.9	0.38	1.3e-17	Type 2 diabetes;
LGG	cis	rs9325144	0.625	rs12227353	chr12:38734542	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.86	-0.45	1.24e-24	Morning vs. evening chronotype;
LGG	cis	rs13102973	0.899	rs17496	chr4:135900227	C/T	cg14419869	chr4:135874104	NA	-0.46	-8.29	-0.36	1.28e-15	Subjective well-being;
LGG	cis	rs6964587	0.773	rs10488514	chr7:91951842	C/A	cg17063962	chr7:91808500	NA	0.49	8.44	0.37	3.95e-16	Breast cancer;
LGG	cis	rs72717009	0.825	rs867624	chr1:161467837	A/T	cg12643083	chr1:161476548	FCGR2A	-0.65	-9.75	-0.41	1.5e-20	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00631329	chr6:26305371	NA	0.52	9.75	0.41	1.47e-20	Educational attainment;
LGG	cis	rs28655083	0.785	rs7404856	chr16:77130339	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.58	9.54	0.41	8.04e-20	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs58106596	0.747	rs72994902	chr2:232585117	G/T	cg01370599	chr3:116745421	NA	0.59	8.11	0.35	4.61e-15	White blood cell count;Lymphocyte counts;
LGG	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs28719689	0.541	rs28376074	chr8:1274394	A/T	cg22761795	chr8:1265118	NA	0.83	9.03	0.39	4.79e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7909791	0.632	rs3818278	chr10:105665323	G/T	cg11005552	chr10:105648138	OBFC1	0.65	9.54	0.41	8.44e-20	White matter hyperintensity burden;
LGG	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg02002194	chr4:3960332	NA	0.41	7.47	0.33	4.05e-13	Multiple myeloma (hyperdiploidy);
LGG	trans	rs6582630	0.502	rs11181214	chr12:38298313	C/A	cg06521331	chr12:34319734	NA	-0.49	-8.6	-0.37	1.27e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.47	7.29	0.32	1.33e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg06481639	chr22:41940642	POLR3H	0.56	7.95	0.35	1.44e-14	Vitiligo;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg04503457	chr17:41445688	NA	-0.39	-9.39	-0.4	2.82e-19	Menopause (age at onset);
LGG	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg23649088	chr2:200775458	C2orf69	-0.8	-16.1	-0.6	1.25e-46	Osteoporosis;
LGG	trans	rs6601327	0.540	rs6982148	chr8:9581070	G/C	cg16141378	chr3:129829833	LOC729375	0.36	8.12	0.35	4.13e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8005745	0.614	rs1957757	chr14:62196948	T/C	cg01748970	chr14:62088363	NA	-0.82	-9.85	-0.42	6.72e-21	Select biomarker traits;
LGG	cis	rs116095464	0.558	rs6555058	chr5:226376	C/T	cg22857025	chr5:266934	NA	1.41	24.04	0.75	1.82e-83	Breast cancer;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	25.25	0.76	4.12e-89	IgG glycosylation;
LGG	cis	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.46	0.33	4.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9486719	0.690	rs2092094	chr6:96844123	G/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg04287289	chr16:89883240	FANCA	0.89	8.67	0.37	7.41e-17	Skin colour saturation;
LGG	cis	rs12453935	0.640	rs2066962	chr17:59916524	T/A	cg14757157	chr17:59911755	BRIP1	0.34	6.64	0.3	8.58e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	trans	rs2727020	0.754	rs10839226	chr11:49150883	C/G	cg03929089	chr4:120376271	NA	-0.46	-7.81	-0.34	3.9e-14	Coronary artery disease;
LGG	cis	rs6908034	0.607	rs76525593	chr6:19809170	G/T	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs62209	0.948	rs201086	chr10:11016076	A/G	cg26901096	chr10:10994189	LOC254312	0.45	7.5	0.33	3.34e-13	Alzheimer's disease (late onset);
LGG	cis	rs3818285	1.000	rs3818285	chr10:111635212	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.41	-6.65	-0.3	8.18e-11	Superior crus of antihelix expression;
LGG	trans	rs9657904	0.813	rs4243427	chr3:105559821	T/C	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.4e-14	Multiple sclerosis;
LGG	cis	rs7577696	0.785	rs2294179	chr2:32354005	G/A	cg02381751	chr2:32503542	YIPF4	-0.41	-6.67	-0.3	7.31e-11	Inflammatory biomarkers;
LGG	cis	rs963731	0.649	rs10172085	chr2:39257125	G/A	cg04010122	chr2:39346883	SOS1	-0.73	-6.66	-0.3	7.69e-11	Corticobasal degeneration;
LGG	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00198680	chr16:28758506	NA	0.29	7.34	0.32	9.43e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.12	0.31	4.2e-12	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.22	-0.39	1.07e-18	Menopause (age at onset);
LGG	cis	rs2842992	0.915	rs2842985	chr6:160085434	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.48	0.47	4.95e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4262150	0.764	rs2964231	chr5:151929983	C/T	cg12297329	chr5:152029980	NA	-0.69	-13.13	-0.52	1.08e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs4689388	0.890	rs4689398	chr4:6302199	C/T	cg14416269	chr4:6271139	WFS1	0.5	9.33	0.4	4.5e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.23	-0.46	4.84e-26	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1325195	0.507	rs10798652	chr1:179061427	A/G	cg11624085	chr17:8464688	MYH10	0.45	8.31	0.36	1.1e-15	IgE grass sensitization;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.53	0.84	5.72e-126	Prudent dietary pattern;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg24829409	chr8:58192753	C8orf71	-0.64	-8.26	-0.36	1.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.636	rs1165157	chr6:25792250	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg07027305	chr7:2059796	MAD1L1	-0.33	-7.15	-0.32	3.35e-12	Bipolar disorder;
LGG	cis	rs66823261	0.778	rs2906332	chr8:194943	C/T	cg27532244	chr8:182981	ZNF596;RPL23AP53	-0.74	-10.79	-0.45	2.29e-24	Breast cancer (estrogen-receptor negative);Breast cancer;
LGG	cis	rs4774899	1.000	rs12910094	chr15:57432559	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.38	-0.32	7.42e-13	Urinary tract infection frequency;
LGG	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.57	0.44	1.56e-23	Cognitive test performance;
LGG	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.84	-0.38	2.03e-17	Mood instability;
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg14675211	chr2:100938903	LONRF2	0.61	10.68	0.44	6.11e-24	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.909	rs17046118	chr4:120387496	T/G	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg01238044	chr22:24384105	GSTT1	0.43	7.28	0.32	1.45e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1620921	0.625	rs68027339	chr6:161272813	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs738321	0.794	rs6001026	chr22:38545363	C/T	cg03162506	chr22:38580953	NA	0.39	9.5	0.4	1.11e-19	Breast cancer;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg02353165	chr6:42928485	GNMT	0.47	14.22	0.55	2.5e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg11584989	chr19:19387371	SF4	-0.75	-12.26	-0.5	4.02e-30	Bipolar disorder;
LGG	cis	rs11098499	0.954	rs12506546	chr4:120301618	T/C	cg09307838	chr4:120376055	NA	0.8	13.2	0.52	5.27e-34	Corneal astigmatism;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg05925327	chr15:68127851	NA	-0.33	-6.85	-0.3	2.42e-11	Obesity;
LGG	cis	rs17221829	0.710	rs12421890	chr11:89391799	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.16e-18	Anxiety in major depressive disorder;
LGG	cis	rs644148	0.836	rs2686775	chr19:45000059	C/T	cg15540054	chr19:45004280	ZNF180	-0.57	-10.84	-0.45	1.54e-24	Personality dimensions;
LGG	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg13852791	chr20:30311386	BCL2L1	-0.77	-12.46	-0.5	6.17e-31	Mean corpuscular hemoglobin;
LGG	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-13.57	-0.53	1.48e-35	Menarche (age at onset);
LGG	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.77	-0.51	3.39e-32	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.29	0.43	1.73e-22	Neuroticism;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg12692727	chr7:1102344	C7orf50	0.49	6.82	0.3	2.77e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9577381	0.628	rs9577380	chr13:112575568	A/G	cg25344322	chr13:112575014	NA	-0.4	-6.91	-0.31	1.66e-11	Axial length;
LGG	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg26150922	chr2:100937072	LONRF2	-0.53	-9.29	-0.4	5.96e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.693	rs6690672	chr1:152930564	C/T	cg07796016	chr1:152779584	LCE1C	-0.48	-7.6	-0.33	1.66e-13	Inflammatory skin disease;
LGG	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.08	-0.35	5.83e-15	Height;
LGG	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg13010199	chr12:38710504	ALG10B	0.71	14.09	0.55	9.43e-38	Bladder cancer;
LGG	cis	rs4595586	0.545	rs7967931	chr12:39375162	A/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg11301795	chr4:187892539	NA	-0.95	-24.69	-0.75	1.67e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10979	1.000	rs1416208	chr6:143889241	T/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.5	-0.5	4.17e-31	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18062138	chr3:193310749	OPA1	0.4	6.8	0.3	3.34e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg18335740	chr13:41363409	SLC25A15	0.84	20.03	0.68	9.54e-65	Lewy body disease;
LGG	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg22681709	chr2:178499509	PDE11A	-0.44	-6.93	-0.31	1.4e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs34599045	0.522	rs79402685	chr1:152920629	A/T	cg07796016	chr1:152779584	LCE1C	-0.87	-8.05	-0.35	6.84e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7551222	0.721	rs4951080	chr1:204533284	A/G	cg18851795	chr1:204543875	NA	-0.35	-6.69	-0.3	6.57e-11	Schizophrenia;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg00908189	chr16:619842	PIGQ	0.88	16.8	0.62	8.83e-50	Height;
LGG	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg03128945	chr5:622914	CEP72	-0.43	-7.1	-0.31	4.81e-12	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	1.000	rs7527079	chr1:46413450	C/G	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.07	0.39	3.42e-18	Lung cancer in ever smokers;
LGG	cis	rs11722228	0.549	rs73212830	chr4:10078759	A/T	cg08250081	chr4:10125330	NA	0.67	12.24	0.49	5.09e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.07	-0.31	5.77e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1318772	1.000	rs66629800	chr5:112712238	G/T	cg12552261	chr5:112820674	MCC	0.67	7.78	0.34	4.63e-14	F-cell distribution;
LGG	cis	rs9487051	0.752	rs9372209	chr6:109601684	T/C	cg21918786	chr6:109611834	NA	-0.42	-7.88	-0.34	2.37e-14	Reticulocyte fraction of red cells;
LGG	cis	rs11971779	0.838	rs58074268	chr7:139108925	C/T	cg07862535	chr7:139043722	LUC7L2	0.63	9.91	0.42	4.03e-21	Diisocyanate-induced asthma;
LGG	trans	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs42648	0.748	rs12673914	chr7:89943389	C/T	cg25739043	chr7:89950458	NA	-0.36	-7.47	-0.33	3.97e-13	Homocysteine levels;
LGG	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.65	-0.41	3.4e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.11	-0.35	4.43e-15	IgG glycosylation;
LGG	cis	rs17767392	0.834	rs56362777	chr14:71735418	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.79	-0.38	3e-17	Mitral valve prolapse;
LGG	cis	rs6831352	0.918	rs13129488	chr4:100053025	G/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs7301826	0.651	rs1973834	chr12:131280157	C/T	cg11011512	chr12:131303247	STX2	0.41	8.79	0.38	2.95e-17	Plasma plasminogen activator levels;
LGG	cis	rs6964587	1.000	rs2282971	chr7:91584356	A/G	cg17063962	chr7:91808500	NA	0.44	7.97	0.35	1.28e-14	Breast cancer;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs9487051	0.743	rs388526	chr6:109543425	C/G	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5.04e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg02297831	chr4:17616191	MED28	0.47	8.31	0.36	1.05e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg10840412	chr1:235813424	GNG4	0.51	6.88	0.3	1.93e-11	Bipolar disorder;
LGG	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg00976097	chr5:421733	AHRR	-0.41	-6.94	-0.31	1.33e-11	Cystic fibrosis severity;
LGG	cis	rs11586313	0.546	rs1330703	chr1:152867349	A/T	cg13444842	chr1:152974279	SPRR3	-0.4	-7.71	-0.34	7.72e-14	Vitamin D levels;
LGG	cis	rs28647808	0.748	rs28721280	chr9:136267318	C/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg26752003	chr8:145688521	CYHR1	0.54	11.74	0.48	5.03e-28	Age at first birth;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg08888203	chr3:10149979	C3orf24	0.56	9.37	0.4	3.12e-19	Alzheimer's disease;
LGG	cis	rs7267979	1.000	rs2184000	chr20:25395878	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg11663600	chr3:49941416	MST1R	0.24	6.69	0.3	6.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg03788504	chr6:150331562	NA	-0.6	-13.75	-0.54	2.69e-36	Alopecia areata;
LGG	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg01003211	chr7:1472830	NA	-0.59	-8.57	-0.37	1.52e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.83	0.54	1.18e-36	Prudent dietary pattern;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04248157	chr5:169930938	KCNIP1	0.45	7.62	0.33	1.47e-13	Menarche (age at onset);
LGG	cis	rs12142240	0.660	rs72886903	chr1:46813860	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.8	-0.3	3.26e-11	Menopause (age at onset);
LGG	cis	rs8180040	0.587	rs1466741	chr3:47247214	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-14.73	-0.56	1.47e-40	Colorectal cancer;
LGG	cis	rs12956009	0.583	rs35970525	chr18:44882625	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.4e-12	Educational attainment (years of education);
LGG	cis	rs10911363	0.592	rs10911354	chr1:183489278	G/A	cg09173681	chr1:183549694	NCF2	0.36	8.23	0.36	1.96e-15	Systemic lupus erythematosus;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14107273	chr22:21271661	CRKL	0.48	7.1	0.31	4.81e-12	Hip circumference;
LGG	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg08975724	chr8:8085496	FLJ10661	0.42	7.71	0.34	7.7e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9834373	0.853	rs9862616	chr3:78491944	A/G	cg06138941	chr3:78371609	NA	-0.52	-9.25	-0.4	8.04e-19	Protein quantitative trait loci;
LGG	cis	rs7089973	0.624	rs61867965	chr10:116574794	A/T	cg03647239	chr10:116582469	FAM160B1	0.41	6.8	0.3	3.17e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg19077165	chr18:44547161	KATNAL2	-0.4	-6.68	-0.3	6.96e-11	Educational attainment;
LGG	cis	rs2486288	0.656	rs1060896	chr15:45554267	C/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.7	0.3	5.97e-11	Glomerular filtration rate;
LGG	cis	rs3796352	1.000	rs61172708	chr3:52996052	T/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4631830	0.863	rs3123078	chr10:51524971	A/G	cg10326726	chr10:51549505	MSMB	0.69	14.56	0.56	8.51e-40	Prostate-specific antigen levels;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.72	0.34	7.1e-14	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08999915	chr3:44727106	NA	0.46	6.73	0.3	4.99e-11	Gut microbiome composition (summer);
LGG	cis	rs6546550	0.935	rs10865380	chr2:70091246	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.16	-0.35	3.21e-15	Prevalent atrial fibrillation;
LGG	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg06808227	chr14:105710500	BRF1	-0.66	-12.11	-0.49	1.67e-29	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3784262	0.669	rs4646623	chr15:58257123	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.23	-0.32	2.05e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg08621203	chr6:150244597	RAET1G	0.41	6.87	0.3	2.11e-11	Lung cancer;
LGG	cis	rs12500482	0.509	rs1203784	chr4:2427108	T/C	cg26444097	chr4:2432313	NA	-0.42	-9.66	-0.41	3.16e-20	Cognitive function;
LGG	cis	rs11834862	0.653	rs11246997	chr12:132690684	G/A	cg16245054	chr12:132698494	GALNT9	-0.44	-6.7	-0.3	6.01e-11	Anti-saccade response;
LGG	cis	rs4901847	0.643	rs36051876	chr14:58596241	C/T	cg15908186	chr14:58618357	C14orf37	0.69	12.87	0.51	1.31e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs5753037	0.585	rs7954	chr22:30184950	A/G	cg01021169	chr22:30184971	ASCC2	-0.42	-8.49	-0.37	2.88e-16	Type 1 diabetes;
LGG	cis	rs72945132	0.522	rs4367974	chr11:70248900	C/T	cg13802316	chr11:70253460	CTTN	-0.6	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs4742903	0.846	rs7022158	chr9:106924872	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.15	0.35	3.32e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs73198271	1.000	rs11775476	chr8:8607869	T/C	cg16141378	chr3:129829833	LOC729375	0.37	6.91	0.31	1.63e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg16096631	chr1:42092165	HIVEP3	-0.42	-8.9	-0.38	1.25e-17	Airway imaging phenotypes;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg21220147	chr1:229694657	ABCB10	0.44	6.88	0.3	1.91e-11	Lung cancer in ever smokers;
LGG	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs12926788	0.689	rs7186308	chr16:24848471	A/G	cg00339695	chr16:24857497	SLC5A11	0.4	6.86	0.3	2.28e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09217309	chr6:150244204	RAET1G	0.44	8.07	0.35	6.18e-15	Testicular germ cell tumor;
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06850241	chr22:41845214	NA	-0.44	-7.08	-0.31	5.24e-12	Vitiligo;
LGG	cis	rs12220238	0.915	rs61045754	chr10:76153125	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.52	0.37	2.28e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs12893668	0.572	rs7148857	chr14:104143237	C/G	cg23335576	chr14:104009727	NA	0.42	7.15	0.32	3.3e-12	Reticulocyte count;
LGG	cis	rs4936894	0.500	rs7924537	chr11:124154243	T/C	cg27160556	chr11:124181099	OR8D1	-0.45	-10.38	-0.43	7.58e-23	Aging (time to death);
LGG	cis	rs1805017	0.525	rs9381480	chr6:46724131	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-9.89	-0.42	4.8e-21	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs7662987	0.517	rs2851265	chr4:100029684	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.86	0.34	2.79e-14	Smoking initiation;
LGG	cis	rs9549260	0.755	rs7993233	chr13:41219434	T/A	cg21288729	chr13:41239152	FOXO1	0.33	6.7	0.3	6.23e-11	Red blood cell count;
LGG	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg11812906	chr14:75593930	NEK9	0.54	9.94	0.42	3.15e-21	Height;
LGG	cis	rs2842992	0.830	rs1998365	chr6:160179535	A/T	cg11366901	chr6:160182831	ACAT2	1.06	16.74	0.61	1.64e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs910873	0.505	rs67260051	chr20:33448417	C/T	cg12302830	chr20:33297742	TP53INP2	0.45	7.39	0.32	6.99e-13	Melanoma;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs3784262	0.679	rs11071366	chr15:58334244	A/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-7.94	-0.35	1.52e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg09873164	chr1:152488093	CRCT1	-0.61	-14.96	-0.57	1.48e-41	Hair morphology;
LGG	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.6	-0.33	1.62e-13	Other erythrocyte phenotypes;
LGG	cis	rs8056893	0.885	rs6499167	chr16:68337798	T/A	cg07273125	chr16:68295692	NA	0.37	6.9	0.31	1.71e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg00405596	chr8:11794950	NA	-0.4	-6.72	-0.3	5.36e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs875971	0.502	rs11769702	chr7:65720516	A/C	cg11764359	chr7:65958608	NA	0.62	9.32	0.4	4.9e-19	Aortic root size;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg18765753	chr7:1198926	ZFAND2A	-0.42	-7.01	-0.31	8.43e-12	Longevity;Endometriosis;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg12379764	chr21:47803548	PCNT	-0.4	-6.94	-0.31	1.35e-11	Testicular germ cell tumor;
LGG	cis	rs7659604	1.000	rs6846232	chr4:122664805	A/G	cg20573242	chr4:122745356	CCNA2	0.42	7.6	0.33	1.7e-13	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07280387	chr12:120763487	PLA2G1B	0.46	7.37	0.32	8.14e-13	Cognitive performance;
LGG	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg14092571	chr14:90743983	NA	0.42	7.57	0.33	2.02e-13	Longevity;
LGG	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg13986417	chr12:110012484	MVK;MMAB	-0.31	-6.79	-0.3	3.44e-11	Neuroticism;
LGG	cis	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg22437258	chr11:111473054	SIK2	0.58	9.97	0.42	2.52e-21	Primary sclerosing cholangitis;
LGG	cis	rs1783925	1.000	rs1783925	chr11:125304009	C/T	cg03464685	chr11:125439445	EI24	0.59	9.42	0.4	2.09e-19	Formal thought disorder in schizophrenia;
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg00405596	chr8:11794950	NA	0.42	6.96	0.31	1.15e-11	Neuroticism;
LGG	cis	rs11064837	0.504	rs7310148	chr12:120053730	G/A	cg25937854	chr12:120150414	CIT	-0.58	-10.23	-0.43	2.67e-22	Schizophrenia;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg11941060	chr3:133502564	NA	0.49	8.25	0.36	1.64e-15	Iron status biomarkers;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg11878867	chr6:150167359	LRP11	-0.49	-10.13	-0.43	6.67e-22	Lung cancer;
LGG	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.19	0.52	5.95e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs283228	0.550	rs522650	chr6:101811685	C/T	cg27451362	chr6:101846650	GRIK2	1.02	15.49	0.58	6.54e-44	Coenzyme Q10 levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15067401	chr12:88536400	TMTC3;CEP290	0.4	6.78	0.3	3.76e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3771570	0.901	rs6757876	chr2:242245570	T/C	cg21155796	chr2:242212141	HDLBP	0.64	8.71	0.38	5.41e-17	Prostate cancer;
LGG	cis	rs3820068	0.581	rs6693694	chr1:15980135	G/T	cg05660106	chr1:15850417	CASP9	0.84	17.26	0.63	6.39e-52	Systolic blood pressure;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	7.76	0.34	5.63e-14	Lung function (FEV1/FVC);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10168850	chr5:16465928	ZNF622	0.41	6.76	0.3	4.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2404602	1.000	rs2404602	chr15:77030792	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.66	-0.34	1.12e-13	Blood metabolite levels;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.85	-0.3	2.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9644630	0.672	rs4486225	chr8:19313404	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.93	-0.42	3.54e-21	Oropharynx cancer;
LGG	cis	rs877282	0.838	rs11253373	chr10:774857	A/G	cg17470449	chr10:769945	NA	0.6	7.43	0.33	5.4e-13	Uric acid levels;
LGG	cis	rs1881797	1.000	rs1881794	chr1:247682920	G/C	cg11166453	chr1:247681781	NA	-0.65	-10.29	-0.43	1.66e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.54	-0.33	2.49e-13	Subjective well-being;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07939768	chr17:27621433	NUFIP2	0.37	6.68	0.3	6.8e-11	Obesity-related traits;
LGG	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg19847130	chr8:10466454	RP1L1	0.31	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs9309473	0.687	rs10165862	chr2:73610743	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-8.79	-0.38	3.03e-17	Metabolite levels;
LGG	cis	rs62064224	0.553	rs9896320	chr17:30689814	G/A	cg18200150	chr17:30822561	MYO1D	0.47	9.0	0.39	5.88e-18	Schizophrenia;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg07511668	chr11:68622177	NA	0.52	9.95	0.42	2.89e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7765175	0.598	rs2842842	chr6:113632998	G/A	cg26552650	chr6:113682475	NA	0.33	7.14	0.31	3.66e-12	Coronary artery calcification;
LGG	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg03474202	chr17:45855739	NA	0.27	7.92	0.35	1.76e-14	IgG glycosylation;
LGG	cis	rs4077515	0.967	rs3829110	chr9:139269198	A/G	cg21253087	chr9:139290292	SNAPC4	0.35	7.05	0.31	6.54e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9788682	0.747	rs3743078	chr15:78894759	C/G	cg07120314	chr15:79043507	NA	-0.38	-7.16	-0.32	3.11e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs722599	0.748	rs3742783	chr14:75377008	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.17	-0.43	4.66e-22	IgG glycosylation;
LGG	trans	rs11875185	0.588	rs79171341	chr18:55646401	T/C	cg15513957	chr14:69354734	ACTN1	-0.98	-9.47	-0.4	1.43e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.65	-0.37	8.53e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11971779	0.818	rs12056045	chr7:139025430	C/G	cg07862535	chr7:139043722	LUC7L2	0.66	9.92	0.42	3.74e-21	Diisocyanate-induced asthma;
LGG	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg11965913	chr1:205819406	PM20D1	-0.52	-8.02	-0.35	8.55e-15	Parkinson's disease;
LGG	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg14228332	chr4:119757509	SEC24D	1.0	10.23	0.43	2.9e-22	Cannabis dependence symptom count;
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.91	-0.38	1.2e-17	Aortic root size;
LGG	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg13683864	chr3:40499215	RPL14	-1.12	-24.78	-0.76	6.17e-87	Renal cell carcinoma;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.04e-12	Bipolar disorder;
LGG	cis	rs8180040	0.681	rs9818382	chr3:47193034	C/T	cg27129171	chr3:47204927	SETD2	0.82	14.92	0.57	2.3e-41	Colorectal cancer;
LGG	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg00850481	chr1:228891306	NA	-0.51	-8.76	-0.38	3.72e-17	Chronic lymphocytic leukemia;
LGG	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg16486109	chr11:613632	IRF7	0.41	7.32	0.32	1.09e-12	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.34e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.85	0.54	9.55e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.16	0.32	3.17e-12	Neuroticism;
LGG	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.54	-0.33	2.54e-13	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.44	-7.55	-0.33	2.39e-13	Total body bone mineral density;
LGG	cis	rs637571	0.522	rs566590	chr11:65754062	C/T	cg26695010	chr11:65641043	EFEMP2	-0.54	-9.19	-0.39	1.31e-18	Eosinophil percentage of white cells;
LGG	cis	rs11098499	0.863	rs10019674	chr4:120443489	C/T	cg24375607	chr4:120327624	NA	-0.67	-10.82	-0.45	1.75e-24	Corneal astigmatism;
LGG	trans	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg06875740	chr19:51307921	C19orf48	-0.61	-8.11	-0.35	4.64e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg21401794	chr1:90099060	LRRC8C	0.58	12.27	0.5	3.68e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12402800	chr5:56204917	C5orf35	-0.44	-6.68	-0.3	6.95e-11	Initial pursuit acceleration;
LGG	cis	rs868036	0.881	rs12708496	chr15:68054098	T/C	cg05925327	chr15:68127851	NA	0.37	8.46	0.37	3.54e-16	Restless legs syndrome;
LGG	cis	rs9952991	0.941	rs8096138	chr18:12808140	C/G	cg23598886	chr18:12777645	NA	-0.65	-8.76	-0.38	3.59e-17	Inflammatory skin disease;
LGG	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.41	-6.85	-0.3	2.31e-11	Large artery stroke;
LGG	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.81e-15	IgG glycosylation;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg05484376	chr2:27715224	FNDC4	0.44	9.58	0.41	5.79e-20	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs13217239	0.646	rs12209886	chr6:26984757	G/A	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg21775007	chr8:11205619	TDH	-0.55	-9.08	-0.39	3.15e-18	Triglycerides;
LGG	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18867708	chr6:26865862	GUSBL1	-0.47	-7.81	-0.34	3.85e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26887302	chr17:27181995	ERAL1	0.4	6.67	0.3	7.29e-11	Bipolar disorder;
LGG	cis	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg21479132	chr6:26055353	NA	0.78	7.72	0.34	7.08e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg02002194	chr4:3960332	NA	-0.43	-8.03	-0.35	7.9e-15	Myopia (pathological);
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg11062466	chr8:58055876	NA	0.6	10.03	0.42	1.52e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg12395012	chr8:11607386	GATA4	-0.41	-7.39	-0.32	6.75e-13	Monocyte count;
LGG	cis	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.78	-0.57	9.13e-41	IgG glycosylation;
LGG	cis	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg05084668	chr3:125655381	ALG1L	-0.75	-10.64	-0.44	8.49e-24	Blood pressure (smoking interaction);
LGG	cis	rs4732038	0.510	rs4529385	chr7:134271270	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs9596837	0.514	rs2785813	chr13:54275031	A/C	ch.13.53330881F	chr13:54432880	NA	-0.41	-6.69	-0.3	6.3e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg06636001	chr8:8085503	FLJ10661	0.61	11.88	0.48	1.38e-28	Neuroticism;
LGG	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg05677249	chr15:77158041	SCAPER	-0.31	-6.66	-0.3	7.61e-11	Blood metabolite levels;
LGG	cis	rs10089	1.000	rs4836363	chr5:127462737	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg22072935	chr14:105399595	NA	0.53	10.49	0.44	2.99e-23	Rheumatoid arthritis;
LGG	cis	rs4740619	0.875	rs2891002	chr9:15780528	A/T	cg14451791	chr9:16040625	NA	-0.4	-10.51	-0.44	2.69e-23	Body mass index;
LGG	cis	rs9863	0.861	rs11833002	chr12:124446616	G/A	cg13487667	chr12:124434373	CCDC92	-0.36	-7.19	-0.32	2.63e-12	White blood cell count;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg23306229	chr2:178417860	TTC30B	0.54	6.94	0.31	1.34e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs75920871	0.588	rs4548653	chr11:116903316	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.49	-0.37	2.91e-16	Subjective well-being;
LGG	cis	rs2120019	1.000	rs1867146	chr15:75354971	C/G	cg09165964	chr15:75287851	SCAMP5	-1.01	-19.5	-0.67	2.96e-62	Blood trace element (Zn levels);
LGG	trans	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-16.34	-0.6	9.83e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2652822	0.555	rs77171305	chr15:63536230	C/A	cg02713581	chr15:63449717	RPS27L	0.42	6.86	0.3	2.25e-11	Metabolic traits;
LGG	cis	rs9896933	0.887	rs78483419	chr17:80870884	T/C	cg19500275	chr17:80737654	TBCD	0.51	6.87	0.3	2.02e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.62	0.44	1.04e-23	Morning vs. evening chronotype;
LGG	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg05552183	chr6:42928497	GNMT	0.31	7.47	0.33	4.06e-13	Blood protein levels;
LGG	cis	rs7928758	0.887	rs78760579	chr11:134281332	T/G	cg22777979	chr11:134283252	B3GAT1	1.06	13.13	0.52	1.08e-33	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4148883	0.689	rs1311621	chr4:100014018	T/C	cg12011299	chr4:100065546	ADH4	0.41	8.68	0.37	6.61e-17	Alcohol dependence;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg23941434	chr5:147162161	JAKMIP2	0.72	6.8	0.3	3.19e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs6466055	0.777	rs11765899	chr7:104923002	T/C	cg04380332	chr7:105027541	SRPK2	0.38	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs67133203	0.904	rs7975147	chr12:51425549	A/G	cg14688905	chr12:51403056	SLC11A2	0.8	12.25	0.49	4.45e-30	Urinary tract infection frequency;
LGG	cis	rs17767392	0.918	rs17767410	chr14:71771967	C/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg03098644	chr7:100410630	EPHB4	0.52	7.84	0.34	3.11e-14	Other erythrocyte phenotypes;
LGG	cis	rs3771570	0.901	rs4675963	chr2:242324763	G/A	cg21155796	chr2:242212141	HDLBP	0.64	9.08	0.39	3.09e-18	Prostate cancer;
LGG	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg05026014	chr4:1749153	NA	-0.3	-8.0	-0.35	1.03e-14	Hip circumference adjusted for BMI;Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15811235	chr17:8152823	PFAS;C17orf68	0.42	7.08	0.31	5.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs204247	0.565	rs411094	chr6:13718264	C/A	cg07534331	chr6:13574296	SIRT5	0.48	6.85	0.3	2.33e-11	Breast cancer;
LGG	cis	rs74781061	0.860	rs77655065	chr15:74755040	C/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.29	-0.32	1.32e-12	Endometriosis;
LGG	cis	rs67311347	1.000	rs11714032	chr3:40431605	G/A	cg13683864	chr3:40499215	RPL14	-1.15	-26.09	-0.77	5.69e-93	Renal cell carcinoma;
LGG	cis	rs1474256	0.708	rs74485555	chr15:79454077	C/T	cg17916960	chr15:79447300	NA	0.43	6.96	0.31	1.2e-11	Bronchopulmonary dysplasia;
LGG	cis	rs73787773	0.867	rs73787782	chr5:111494104	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.69	-8.48	-0.37	3.11e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2694528	0.841	rs79299974	chr5:60350961	A/G	cg11474532	chr5:59995715	DEPDC1B	0.73	7.4	0.33	6.35e-13	Parkinson's disease;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.12	-0.31	4.19e-12	Personality dimensions;
LGG	trans	rs9354308	0.738	rs1818051	chr6:66569582	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23475371	chr21:31311842	GRIK1	0.45	7.13	0.31	3.94e-12	Gut microbiome composition (summer);
LGG	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg23815491	chr16:72088622	HP	0.5	11.17	0.46	7.97e-26	Fibrinogen levels;
LGG	trans	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg05059571	chr16:84539110	KIAA1609	0.53	9.93	0.42	3.44e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs62400317	0.826	rs11968637	chr6:45348633	G/A	cg20913747	chr6:44695427	NA	-0.6	-10.12	-0.43	7.27e-22	Total body bone mineral density;
LGG	cis	rs1534166	0.647	rs13321680	chr3:133507119	G/T	cg01448562	chr3:133502909	NA	0.41	7.01	0.31	8.56e-12	Alcohol consumption (transferrin glycosylation);
LGG	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg21775007	chr8:11205619	TDH	-0.51	-8.28	-0.36	1.32e-15	Neuroticism;
LGG	cis	rs1669338	0.507	rs4685606	chr3:3177973	T/G	cg16797762	chr3:3221439	CRBN	-0.98	-12.95	-0.52	5.97e-33	White matter integrity;
LGG	cis	rs3806843	0.966	rs2563266	chr5:140136915	C/A	cg19875535	chr5:140030758	IK	-0.53	-10.95	-0.45	5.89e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs12203493	chr6:86758642	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.06	-0.52	2.18e-33	Response to antipsychotic treatment;
LGG	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg03806693	chr22:41940476	POLR3H	-0.98	-17.56	-0.63	2.79e-53	Vitiligo;
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg05484376	chr2:27715224	FNDC4	0.46	9.96	0.42	2.7e-21	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.15	-20.15	-0.68	2.7e-65	Alzheimer's disease;
LGG	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg00990874	chr7:1149470	C7orf50	-0.7	-11.46	-0.47	5.87e-27	Bronchopulmonary dysplasia;
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg07157834	chr1:205819609	PM20D1	0.43	7.12	0.31	4.26e-12	Parkinson's disease;
LGG	cis	rs11628318	0.508	rs3950014	chr14:103069889	G/A	cg12046867	chr14:103022105	NA	-0.76	-13.08	-0.52	1.68e-33	Platelet count;
LGG	cis	rs73086581	0.617	rs2300213	chr20:3986723	T/C	cg02187196	chr20:3869020	PANK2	-0.48	-7.29	-0.32	1.33e-12	Response to antidepressants in depression;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg25072359	chr17:41440525	NA	0.46	7.39	0.32	7.03e-13	Menopause (age at onset);
LGG	cis	rs6840360	0.615	rs12647616	chr4:152607662	G/A	cg22705602	chr4:152727874	NA	-0.38	-9.37	-0.4	3.1400000000000002e-19	Intelligence (multi-trait analysis);
LGG	cis	rs721917	0.506	rs2758558	chr10:81683578	G/C	cg25562619	chr10:81652821	NA	-0.35	-7.91	-0.35	1.88e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs9915657	0.870	rs11077595	chr17:70130030	C/T	cg09344028	chr17:70110421	NA	0.47	10.46	0.44	3.8e-23	Thyroid hormone levels;
LGG	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg20488157	chr14:104394430	TDRD9	0.57	9.25	0.4	8.01e-19	Bipolar disorder;
LGG	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg18850127	chr7:39170497	POU6F2	0.65	16.33	0.6	1.11e-47	IgG glycosylation;
LGG	trans	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg10756647	chr7:56101905	PSPH	0.74	7.18	0.32	2.81e-12	Diabetic kidney disease;
LGG	cis	rs9649465	1.000	rs3779260	chr7:123348315	A/G	cg03229431	chr7:123269106	ASB15	0.4	8.75	0.38	3.94e-17	Migraine;
LGG	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.39	-0.4	2.78e-19	Neuroticism;
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.14	-0.32	3.53e-12	Bipolar disorder;
LGG	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg21644426	chr2:191273491	MFSD6	0.58	10.0	0.42	1.89e-21	Pulse pressure;
LGG	cis	rs17125944	0.686	rs7141335	chr14:53336934	C/T	cg00686598	chr14:53173677	PSMC6	-0.7	-7.5	-0.33	3.38e-13	Alzheimer's disease (late onset);
LGG	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg01620082	chr3:125678407	NA	-0.67	-7.1	-0.31	4.83e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3087591	1.000	rs2854331	chr17:29711728	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.63	-0.56	4.17e-40	Hip circumference;
LGG	cis	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg06328724	chr19:37958752	ZNF570;ZNF569	-0.48	-6.79	-0.3	3.39e-11	Coronary artery calcification;
LGG	cis	rs7666738	0.716	rs9994641	chr4:99101605	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.78	0.3	3.67e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6723226	0.708	rs2710627	chr2:32758627	A/G	cg02381751	chr2:32503542	YIPF4	0.68	11.08	0.46	1.85e-25	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.930	rs2292644	chr17:76394449	C/T	cg02836325	chr17:76403955	PGS1	-0.72	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg05868516	chr6:26286170	HIST1H4H	0.4	6.7	0.3	5.98e-11	Educational attainment;
LGG	cis	rs171408	0.895	rs355130	chr3:8612086	G/T	cg03557445	chr3:8615444	LOH3CR2A	-0.5	-8.86	-0.38	1.71e-17	Mitral valve prolapse;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.77	-0.38	3.45e-17	Menopause (age at onset);
LGG	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg26248373	chr2:1572462	NA	-0.69	-9.31	-0.4	5.12e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.02	-0.39	5.04e-18	Bladder cancer;
LGG	cis	rs9534288	0.830	rs1548325	chr13:46635101	A/G	cg15192986	chr13:46630673	CPB2	-0.8	-17.58	-0.63	2.31e-53	Blood protein levels;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.5	-0.37	2.68e-16	Life satisfaction;
LGG	cis	rs17767392	0.813	rs7152842	chr14:71849740	A/G	cg02058870	chr14:72053146	SIPA1L1	0.39	8.19	0.36	2.48e-15	Mitral valve prolapse;
LGG	cis	rs35306767	0.855	rs11253499	chr10:944090	A/C	cg08847335	chr10:891726	LARP4B	-0.49	-8.75	-0.38	3.97e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs8017423	0.967	rs6575117	chr14:90715412	G/A	cg04374321	chr14:90722782	PSMC1	0.86	18.26	0.65	1.74e-56	Mortality in heart failure;
LGG	cis	rs4696584	0.696	rs72731014	chr4:155410650	T/C	cg13738195	chr4:155413469	DCHS2	-0.38	-7.66	-0.34	1.11e-13	Folding of antihelix;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs73198271	0.960	rs12155530	chr8:8610964	C/T	cg16141378	chr3:129829833	LOC729375	0.38	7.01	0.31	8.41e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6960043	0.818	rs2191349	chr7:15064309	G/T	cg19272540	chr7:15055459	NA	-0.35	-7.81	-0.34	3.93e-14	Type 2 diabetes;
LGG	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19671926	chr4:122722719	EXOSC9	0.48	7.47	0.33	4.16e-13	Type 2 diabetes;
LGG	cis	rs4805272	0.512	rs7245724	chr19:29341679	C/T	cg12756686	chr19:29218302	NA	0.59	7.89	0.34	2.19e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7267979	0.816	rs422148	chr20:25512604	G/C	cg06421707	chr20:25228305	PYGB	0.42	8.67	0.37	7.45e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3093024	0.874	rs3093018	chr6:167539805	C/T	cg07741184	chr6:167504864	NA	-0.33	-7.34	-0.32	9.9e-13	Rheumatoid arthritis;
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs6429082	0.608	rs4659836	chr1:235564412	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.92	-0.38	1.05e-17	Adiposity;
LGG	cis	rs6918586	0.658	rs198830	chr6:26118246	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.79	-0.41	1.07e-20	Schizophrenia;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-9.08	-0.39	3.09e-18	Lung cancer;
LGG	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Body mass index;
LGG	cis	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg15148918	chr7:75625777	STYXL1	-0.7	-8.0	-0.35	9.72e-15	Mononucleosis;
LGG	cis	rs10791097	0.519	rs74866549	chr11:130730380	A/G	cg09137382	chr11:130731461	NA	0.4	7.52	0.33	2.85e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9834373	0.887	rs71324630	chr3:78486657	G/A	cg06138941	chr3:78371609	NA	-0.52	-9.24	-0.39	8.76e-19	Protein quantitative trait loci;
LGG	cis	rs17030434	1.000	rs12651051	chr4:154722114	A/G	cg14289246	chr4:154710475	SFRP2	-0.73	-11.15	-0.46	1.01e-25	Electrocardiographic conduction measures;
LGG	cis	rs9814567	0.762	rs13071253	chr3:134316653	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	11.44	0.47	7.28e-27	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07132326	chr6:150258058	NA	0.39	8.23	0.36	1.88e-15	Testicular germ cell tumor;
LGG	cis	rs7605378	0.528	rs281787	chr2:200784238	C/T	cg17644776	chr2:200775616	C2orf69	-0.71	-12.8	-0.51	2.47e-32	Osteoporosis;
LGG	cis	rs7853377	0.723	rs7020300	chr9:86550647	A/G	cg12437157	chr9:86433764	GKAP1	0.38	6.68	0.3	6.94e-11	Height;
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-8.2	-0.36	2.37e-15	Aortic root size;
LGG	trans	rs4332037	0.826	rs4721188	chr7:1953615	G/A	cg11693508	chr17:37793320	STARD3	-0.55	-8.07	-0.35	6.07e-15	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.22	0.49	5.7e-30	Prudent dietary pattern;
LGG	cis	rs2985684	0.894	rs6572586	chr14:50021941	A/C	cg02151108	chr14:50098012	C14orf104	-0.41	-8.86	-0.38	1.79e-17	Carotid intima media thickness;
LGG	cis	rs1577917	0.739	rs9450318	chr6:86427177	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	10.04	0.42	1.38e-21	Response to antipsychotic treatment;
LGG	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg01943504	chr12:42538901	GXYLT1	-0.4	-6.67	-0.3	7.46e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg03342759	chr3:160939853	NMD3	0.67	10.9	0.45	8.76e-25	Parkinson's disease;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06634786	chr22:41940651	POLR3H	0.76	12.14	0.49	1.25e-29	Vitiligo;
LGG	cis	rs11122272	0.735	rs2486734	chr1:231531392	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs68170813	0.559	rs6947675	chr7:106817184	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-11.12	-0.46	1.31e-25	Coronary artery disease;
LGG	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg08648136	chr8:956695	NA	0.35	7.11	0.31	4.55e-12	Schizophrenia;
LGG	cis	rs2290159	0.800	rs11128607	chr3:12673275	A/G	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.03e-20	Cholesterol, total;
LGG	cis	rs7914558	1.000	rs10509757	chr10:104752960	C/T	cg04362960	chr10:104952993	NT5C2	0.54	10.48	0.44	3.41e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg12386194	chr3:101231763	SENP7	0.42	7.39	0.32	6.83e-13	Colorectal cancer;
LGG	cis	rs4906332	0.933	rs35999760	chr14:103924481	A/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.85	-0.34	2.97e-14	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg24829409	chr8:58192753	C8orf71	-0.68	-9.3	-0.4	5.38e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	0.967	rs6941022	chr6:26553531	T/C	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg07460842	chr6:66804631	NA	0.93	17.02	0.62	8.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs6840360	0.571	rs4696272	chr4:152528229	A/G	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg14979609	chr8:8086686	FLJ10661	0.27	6.65	0.3	8.1e-11	Retinal vascular caliber;
LGG	cis	rs7617773	0.817	rs9853804	chr3:48327729	T/C	cg11946769	chr3:48343235	NME6	0.63	10.57	0.44	1.48e-23	Coronary artery disease;
LGG	trans	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg22232500	chr2:134024266	NCKAP5	0.68	9.22	0.39	1.05e-18	Bipolar disorder;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12476592	0.571	rs196125	chr2:63859268	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-6.76	-0.3	4.05e-11	Childhood ear infection;
LGG	cis	rs6537837	1.000	rs7537507	chr1:110131105	G/A	cg05049280	chr1:110155535	GNAT2	0.35	7.15	0.32	3.5e-12	Major depressive disorder;
LGG	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg04455712	chr21:45112962	RRP1B	0.5	9.65	0.41	3.39e-20	Mean corpuscular volume;
LGG	cis	rs620875	0.841	rs619457	chr11:126859490	T/G	cg06504925	chr11:126872760	NA	-0.53	-7.44	-0.33	5.09e-13	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.765	rs17708262	chr2:99696313	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.89e-22	Chronic sinus infection;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg24247370	chr13:99142703	STK24	-0.36	-6.7	-0.3	6.02e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg09201001	chr11:18656081	SPTY2D1	0.99	20.69	0.69	7.97e-68	Breast cancer;
LGG	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg03929089	chr4:120376271	NA	0.67	6.89	0.3	1.81e-11	Intraocular pressure;
LGG	trans	rs747782	0.528	rs624348	chr11:48400795	G/A	cg15704280	chr7:45808275	SEPT13	-0.76	-8.94	-0.38	9.52e-18	Intraocular pressure;
LGG	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.08e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6840360	0.642	rs2709815	chr4:152363772	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg16751781	chr15:78858589	CHRNA5	-0.38	-7.12	-0.31	4.07e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4253772	0.550	rs6008598	chr22:46704243	C/T	cg00784671	chr22:46762841	CELSR1	-0.56	-7.2	-0.32	2.38e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12586317	0.532	rs2415268	chr14:35638753	C/T	cg16230307	chr14:35515116	FAM177A1	0.4	7.1	0.31	4.78e-12	Psoriasis;
LGG	trans	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg06521331	chr12:34319734	NA	-0.48	-8.4	-0.36	5.55e-16	Bladder cancer;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.71	-0.34	7.78e-14	Skin colour saturation;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg09303159	chr6:26284866	NA	0.34	7.91	0.34	1.93e-14	Educational attainment;
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.48	8.1	0.35	4.82e-15	Birth weight;
LGG	cis	rs13177180	0.600	rs256989	chr5:114911565	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.41	9.12	0.39	2.35e-18	Conotruncal heart defects (inherited effects);
LGG	cis	rs11676348	0.838	rs17844697	chr2:218999255	G/A	cg04731861	chr2:219085781	ARPC2	0.29	7.0	0.31	8.76e-12	Ulcerative colitis;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg24829409	chr8:58192753	C8orf71	-0.48	-8.3	-0.36	1.18e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs612683	0.602	rs12565245	chr1:101019326	T/G	cg06223162	chr1:101003688	GPR88	0.48	11.31	0.47	2.43e-26	Breast cancer;
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg13009111	chr11:71350975	NA	0.38	8.71	0.38	5.42e-17	Monocyte count;
LGG	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg03609598	chr5:56110824	MAP3K1	0.51	7.57	0.33	2.01e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27263386	chr21:33984714	C21orf59	0.52	7.86	0.34	2.65e-14	Gut microbiome composition (summer);
LGG	cis	rs11931598	0.509	rs13140943	chr4:6977109	A/G	cg04207632	chr4:6986609	TBC1D14	-0.42	-7.93	-0.35	1.67e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs883115	0.748	rs10799588	chr1:224819109	A/G	cg01808320	chr1:224927238	CNIH3	-0.45	-8.27	-0.36	1.47e-15	Cancer;
LGG	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg25338242	chr13:114786047	RASA3	0.43	7.8	0.34	4.18e-14	Schizophrenia;
LGG	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.93	-9.96	-0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg01346077	chr3:125931526	NA	0.41	9.95	0.42	2.83e-21	Metabolite levels;
LGG	cis	rs9487094	0.961	rs11153175	chr6:109682521	T/C	cg01125227	chr6:109776195	MICAL1	0.51	8.82	0.38	2.41e-17	Height;
LGG	cis	rs11608355	0.545	rs2302709	chr12:109893697	A/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs858239	0.600	rs6461691	chr7:23139345	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.5	0.33	3.38e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs614226	1.000	rs616157	chr12:120925795	T/C	cg21053147	chr12:120880522	NA	0.59	9.15	0.39	1.82e-18	Type 1 diabetes nephropathy;
LGG	trans	rs6787172	0.702	rs864332	chr3:158020378	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.89	0.38	1.37e-17	Subjective well-being;
LGG	cis	rs6807915	0.603	rs9823123	chr3:12288569	A/C	cg15873301	chr3:12045459	SYN2	-0.43	-7.29	-0.32	1.38e-12	Leprosy;
LGG	cis	rs6445975	0.617	rs13071422	chr3:58398813	A/G	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.61	-0.69	1.84e-67	Diabetic kidney disease;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg19168338	chr16:4465731	CORO7	-0.73	-13.39	-0.53	8.25e-35	Schizophrenia;
LGG	trans	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4237845	0.844	rs4628718	chr12:58301600	A/C	cg02175503	chr12:58329896	NA	0.64	11.36	0.47	1.55e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs4710543	chr6:66584671	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs6546324	0.580	rs6724133	chr2:67858671	A/G	cg18237512	chr2:67827392	NA	-0.38	-6.65	-0.3	8.12e-11	Endometriosis;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg21963583	chr11:68658836	MRPL21	0.6	10.49	0.44	2.94e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs240764	0.621	rs6925316	chr6:101209137	C/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs975739	0.657	rs7981105	chr13:78616077	G/A	cg07847733	chr13:78271382	SLAIN1	0.47	8.19	0.36	2.49e-15	Hair color;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg09303159	chr6:26284866	NA	0.34	7.88	0.34	2.32e-14	Educational attainment;
LGG	cis	rs12210905	0.925	rs72838238	chr6:26971681	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg09873164	chr1:152488093	CRCT1	0.62	15.44	0.58	1.06e-43	Hair morphology;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20296188	chr17:77397067	HRNBP3	-0.51	-7.48	-0.33	3.65e-13	Systemic lupus erythematosus;
LGG	cis	rs988958	0.527	rs1440100	chr2:42291069	T/C	cg27428208	chr2:42229179	NA	0.38	7.72	0.34	7.28e-14	Hypospadias;
LGG	cis	rs13260300	0.613	rs13248835	chr8:75499635	G/A	cg22993706	chr8:75542856	NA	0.37	6.99	0.31	9.51e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.45e-15	Obesity-related traits;
LGG	cis	rs7572733	0.935	rs10497809	chr2:198825668	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.16	0.35	3.09e-15	Dermatomyositis;
LGG	trans	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg20587970	chr11:113659929	NA	1.1	14.79	0.57	8.09e-41	Hip circumference adjusted for BMI;
LGG	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg08470875	chr2:26401718	FAM59B	-0.37	-6.84	-0.3	2.59e-11	Gut microbiome composition (summer);
LGG	trans	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg25482853	chr8:67687455	SGK3	0.67	9.62	0.41	4.3e-20	Obesity-related traits;
LGG	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg09324608	chr17:30823087	MYO1D	0.3	7.0	0.31	8.78e-12	Schizophrenia;
LGG	cis	rs1707322	0.752	rs28550303	chr1:46188914	G/T	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3126085	1.000	rs72696969	chr1:152196339	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-6.99	-0.31	9.83e-12	Atopic dermatitis;
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03517284	chr6:25882590	NA	-0.51	-9.55	-0.41	7.54e-20	Height;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	1.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2421770	0.532	rs10768129	chr11:35362489	C/T	cg10331829	chr11:35343789	SLC1A2	0.34	7.64	0.33	1.22e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs12451471	0.529	rs2278620	chr17:78083565	G/A	cg06718696	chr17:78121285	EIF4A3	0.89	14.42	0.56	3.31e-39	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg11890956	chr21:40555474	PSMG1	1.0	21.46	0.71	1.95e-71	Cognitive function;
LGG	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	8.94e-13	Morning vs. evening chronotype;
LGG	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg03929089	chr4:120376271	NA	0.69	8.13	0.35	3.82e-15	Intraocular pressure;
LGG	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg13010199	chr12:38710504	ALG10B	0.52	9.97	0.42	2.37e-21	Morning vs. evening chronotype;
LGG	cis	rs758324	0.947	rs1604080	chr5:131176644	A/G	cg06307176	chr5:131281290	NA	-0.57	-9.29	-0.4	6.16e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.11e-11	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14689355	chr2:148602399	ACVR2A	0.45	6.79	0.3	3.46e-11	Gut microbiome composition (summer);
LGG	cis	rs7267979	0.565	rs4815432	chr20:25556403	A/C	cg06421707	chr20:25228305	PYGB	-0.36	-7.61	-0.33	1.59e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg04287289	chr16:89883240	FANCA	-0.77	-15.6	-0.59	2.21e-44	Vitiligo;
LGG	cis	rs9290065	0.519	rs1562465	chr3:160701442	G/A	cg03342759	chr3:160939853	NMD3	-0.53	-9.03	-0.39	4.48e-18	Kawasaki disease;
LGG	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	6.8	0.3	3.14e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg25986240	chr4:9926439	SLC2A9	0.71	16.24	0.6	2.87e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1783925	1.000	rs2845845	chr11:125303663	A/G	cg03464685	chr11:125439445	EI24	-0.55	-8.82	-0.38	2.33e-17	Formal thought disorder in schizophrenia;
LGG	cis	rs13177180	0.671	rs2052834	chr5:114952645	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-9.59	-0.41	5.27e-20	Conotruncal heart defects (inherited effects);
LGG	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg17108064	chr15:78857060	CHRNA5	0.45	9.55	0.41	7.73e-20	Sudden cardiac arrest;
LGG	cis	rs2404602	0.684	rs11072600	chr15:76867915	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-13.77	-0.54	2.08e-36	Blood metabolite levels;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.77	-0.3	4.02e-11	Alzheimer's disease (survival time);
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg06475006	chr16:89985975	MC1R	-0.59	-6.95	-0.31	1.23e-11	Skin colour saturation;
LGG	cis	rs1008375	1.000	rs10939756	chr4:17693867	C/T	cg02297831	chr4:17616191	MED28	0.45	8.33	0.36	9.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2797160	0.935	rs1739379	chr6:126012593	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.45	0.33	4.62e-13	Endometrial cancer;
LGG	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg08048268	chr3:133502702	NA	-0.67	-12.83	-0.51	1.92e-32	Iron status biomarkers;
LGG	cis	rs11074306	0.561	rs9806345	chr15:28071732	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.36	0.32	8.21e-13	Uveal melanoma;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.49	-0.4	1.24e-19	Personality dimensions;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg24829409	chr8:58192753	C8orf71	-0.84	-13.02	-0.52	2.95e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg05044414	chr3:183734942	ABCC5	0.78	17.33	0.63	3.05e-52	Anterior chamber depth;
LGG	cis	rs12148488	0.763	rs4886648	chr15:75308837	G/A	cg17294928	chr15:75287854	SCAMP5	0.67	12.02	0.49	3.73e-29	Caffeine consumption;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.95	-0.42	2.94e-21	Platelet count;
LGG	cis	rs4478137	0.501	rs6811330	chr4:164230038	G/T	cg06758707	chr4:164254230	NPY1R	-0.54	-8.0	-0.35	1.02e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.23	-0.49	5.25e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs975722	0.516	rs10264075	chr7:117001366	G/T	cg10524701	chr7:117356490	CTTNBP2	0.4	8.62	0.37	1.06e-16	Coronary artery disease;
LGG	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg10523679	chr1:76189770	ACADM	-0.69	-10.92	-0.45	7.49e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg20887711	chr4:1340912	KIAA1530	0.94	21.05	0.7	1.57e-69	Longevity;
LGG	cis	rs62064224	0.509	rs2302276	chr17:30791503	C/T	cg18200150	chr17:30822561	MYO1D	0.51	9.72	0.41	1.86e-20	Schizophrenia;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg23758822	chr17:41437982	NA	0.85	14.6	0.56	5.35e-40	Menopause (age at onset);
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg27471124	chr11:109292789	C11orf87	0.47	9.48	0.4	1.29e-19	Schizophrenia;
LGG	trans	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg03517284	chr6:25882590	NA	-0.45	-6.64	-0.3	8.54e-11	Iron status biomarkers;
LGG	cis	rs17039065	0.920	rs11737760	chr4:109441230	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.64	0.33	1.23e-13	Gut microbiome composition (summer);
LGG	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg00578828	chr5:131826934	IRF1	-0.4	-7.28	-0.32	1.44e-12	Asthma (sex interaction);
LGG	trans	rs1814175	0.519	rs10839291	chr11:49514321	G/A	cg15704280	chr7:45808275	SEPT13	0.87	13.72	0.54	3.54e-36	Height;
LGG	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg18478394	chr8:109455254	TTC35	0.46	9.28	0.4	6.63e-19	Dupuytren's disease;
LGG	cis	rs7945705	0.902	rs10769979	chr11:9010659	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.78	0.3	3.58e-11	Hemoglobin concentration;
LGG	trans	rs1814175	0.791	rs10769625	chr11:49869887	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs584438	0.780	rs2015561	chr17:38593294	A/G	cg09358481	chr17:38600305	IGFBP4	-0.46	-8.8	-0.38	2.7e-17	Height;
LGG	cis	rs972578	0.765	rs4822215	chr22:43273891	T/G	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.95e-11	Mean platelet volume;
LGG	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg20978937	chr14:105399321	PLD4	0.49	10.77	0.45	2.75e-24	Rheumatoid arthritis;
LGG	trans	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg16141378	chr3:129829833	LOC729375	-0.42	-10.02	-0.42	1.62e-21	Retinal vascular caliber;
LGG	cis	rs4631830	0.832	rs2611513	chr10:51515457	A/G	cg10326726	chr10:51549505	MSMB	0.64	13.46	0.53	4.21e-35	Prostate-specific antigen levels;
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg10587741	chr22:38071170	LGALS1	-0.83	-22.62	-0.72	7.43e-77	Fat distribution (HIV);
LGG	trans	rs8002861	0.664	rs9533662	chr13:44435988	T/A	cg17145862	chr1:211918768	LPGAT1	0.8	17.37	0.63	2.18e-52	Leprosy;
LGG	cis	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg10911889	chr6:126070802	HEY2	0.44	7.61	0.33	1.6e-13	Brugada syndrome;
LGG	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.7	-0.41	2.17e-20	Primary sclerosing cholangitis;
LGG	cis	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.89	-0.31	1.8e-11	Neuroticism;
LGG	trans	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg15268244	chr15:77196840	NA	0.48	10.11	0.43	7.62e-22	Blood metabolite levels;
LGG	cis	rs910187	0.565	rs62201406	chr20:45770920	C/T	cg27589058	chr20:45804311	EYA2	-0.29	-6.86	-0.3	2.23e-11	Migraine;
LGG	cis	rs5750830	0.594	rs5757648	chr22:39775156	G/A	cg04986931	chr22:39850128	NA	0.35	7.68	0.34	9.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	1.000	rs76784350	chr2:27764278	A/G	cg22903471	chr2:27725779	GCKR	0.39	8.77	0.38	3.32e-17	Oral cavity cancer;
LGG	cis	rs701145	0.585	rs1632688	chr3:153874139	C/A	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs7666738	0.791	rs10013680	chr4:99023030	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.72	0.34	7.46e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1322639	0.614	rs6900200	chr6:169566173	T/C	cg04662567	chr6:169592167	NA	-0.79	-11.46	-0.47	5.96e-27	Pulse pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04139429	chr1:113615595	LRIG2	-0.43	-6.92	-0.31	1.49e-11	Pancreatic cancer;
LGG	cis	rs11064837	0.525	rs739422	chr12:120042506	T/C	cg25937854	chr12:120150414	CIT	-0.59	-10.32	-0.43	1.25e-22	Schizophrenia;
LGG	cis	rs2470578	0.792	rs283907	chr3:17336419	C/T	cg20981856	chr3:17787350	NA	-0.35	-6.71	-0.3	5.81e-11	Schizophrenia;
LGG	cis	rs13102973	0.965	rs10434072	chr4:135867883	C/T	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs11676348	0.846	rs11677534	chr2:219007060	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-9.9	-0.42	4.32e-21	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.78	-0.3	3.57e-11	Total body bone mineral density;
LGG	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.8	0.34	4e-14	Colorectal cancer;
LGG	cis	rs763121	0.962	rs2071887	chr22:38879010	A/T	cg06022373	chr22:39101656	GTPBP1	0.76	15.04	0.57	6.69e-42	Menopause (age at onset);
LGG	trans	rs1814175	0.817	rs10769648	chr11:50013992	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg22907277	chr7:1156413	C7orf50	0.62	8.09	0.35	5.16e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg11859384	chr17:80120422	CCDC57	0.46	8.09	0.35	5.46e-15	Life satisfaction;
LGG	cis	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.61	-17.19	-0.62	1.43e-51	Oropharynx cancer;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3096299	0.506	rs3114863	chr16:89438667	G/C	cg08822215	chr16:89438651	ANKRD11	-0.5	-9.44	-0.4	1.9e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.94	-0.35	1.53e-14	Bladder cancer;
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg11645453	chr3:52864694	ITIH4	0.39	6.77	0.3	3.94e-11	Bipolar disorder;
LGG	cis	rs9309473	0.950	rs11126412	chr2:73887634	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.78	-0.34	4.91e-14	Metabolite levels;
LGG	cis	rs3768617	1.000	rs3768617	chr1:183092500	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.34	6.73	0.3	4.99e-11	Fuchs's corneal dystrophy;
LGG	cis	rs10979	0.679	rs9403510	chr6:143892174	C/T	cg25407410	chr6:143891975	LOC285740	-0.61	-9.87	-0.42	5.45e-21	Hypospadias;
LGG	cis	rs35740288	0.721	rs17637276	chr15:86243520	T/C	cg04173714	chr15:86211321	AKAP13	0.46	7.79	0.34	4.5e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2131877	0.871	rs62290352	chr3:194864191	G/A	cg07250128	chr3:194833983	C3orf21	0.41	6.71	0.3	5.68e-11	Non-small cell lung cancer;
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg13009111	chr11:71350975	NA	0.39	8.9	0.38	1.31e-17	Monocyte count;
LGG	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg22601191	chr20:60968625	CABLES2	0.4	7.7	0.34	8.37e-14	Colorectal cancer;
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.68	-0.54	5.33e-36	Tonsillectomy;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs74417235	0.610	rs13178134	chr5:154063032	A/T	cg08754654	chr5:154026448	NA	-0.41	-8.32	-0.36	1.01e-15	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs9815354	1.000	rs2625668	chr3:41905930	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7666738	0.830	rs34412187	chr4:99010454	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.58	-0.47	2.14e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7408868	1.000	rs7245814	chr19:15274503	A/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs16912285	0.535	rs7936178	chr11:24252515	G/T	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg03605463	chr16:89740564	NA	0.61	11.08	0.46	1.78e-25	Vitiligo;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03595861	chr6:26126282	NA	0.47	7.5	0.33	3.39e-13	Cognitive performance;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.61	0.53	9.86e-36	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg08677398	chr8:58056175	NA	0.45	7.15	0.32	3.33e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg04287289	chr16:89883240	FANCA	0.77	7.46	0.33	4.38e-13	Skin colour saturation;
LGG	cis	rs4474465	1.000	rs10899502	chr11:78141021	C/T	cg27205649	chr11:78285834	NARS2	-0.52	-8.73	-0.38	4.52e-17	Alzheimer's disease (survival time);
LGG	cis	rs10267417	0.603	rs13243056	chr7:19894101	A/C	cg05791153	chr7:19748676	TWISTNB	0.6	7.9	0.34	2.06e-14	Night sleep phenotypes;
LGG	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg12463550	chr7:65579703	CRCP	-0.77	-8.33	-0.36	9.17e-16	Diabetic kidney disease;
LGG	cis	rs208520	0.661	rs7740835	chr6:66865548	G/A	cg07460842	chr6:66804631	NA	-0.97	-18.06	-0.64	1.47e-55	Exhaled nitric oxide output;
LGG	cis	rs7633770	0.786	rs6442012	chr3:46686346	A/G	cg11219411	chr3:46661640	NA	0.59	13.89	0.54	6.57e-37	Coronary artery disease;
LGG	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg10792982	chr14:105748885	BRF1	0.68	14.15	0.55	4.84e-38	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg16400903	chr5:693638	TPPP	0.45	6.92	0.31	1.48e-11	Obesity-related traits;
LGG	cis	rs3850699	0.926	rs12570611	chr10:104421679	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.86	-0.3	2.28e-11	Prostate cancer;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.47	-0.37	3.38e-16	Obesity-related traits;
LGG	cis	rs9859260	0.710	rs34906439	chr3:195779706	A/G	cg00031303	chr3:195681400	NA	-0.44	-6.75	-0.3	4.34e-11	Mean corpuscular volume;
LGG	cis	rs988958	0.567	rs34291746	chr2:42259859	A/G	cg27428208	chr2:42229179	NA	0.54	9.05	0.39	3.84e-18	Hypospadias;
LGG	cis	rs7191439	0.722	rs6500491	chr16:88783521	T/C	cg02389323	chr16:88786976	FAM38A	1.09	12.76	0.51	3.72e-32	Plateletcrit;
LGG	cis	rs8180040	0.653	rs6808742	chr3:47051512	G/A	cg16586182	chr3:47516702	SCAP	-0.81	-15.7	-0.59	7.36e-45	Colorectal cancer;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.24	-0.32	1.88e-12	Menopause (age at onset);
LGG	cis	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg12395012	chr8:11607386	GATA4	0.39	7.3	0.32	1.25e-12	Neuroticism;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	-1.16	-18.69	-0.66	1.76e-58	Platelet count;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg06637938	chr14:75390232	RPS6KL1	0.57	10.47	0.44	3.54e-23	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07242783	chr1:28052377	FAM76A	-0.52	-7.9	-0.34	2.03e-14	Gut microbiome composition (summer);
LGG	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg07636037	chr3:49044803	WDR6	0.84	14.71	0.56	1.81e-40	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg12070911	chr6:150209640	RAET1E	0.28	6.79	0.3	3.45e-11	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11477847	chr17:4693856	NA	0.47	7.56	0.33	2.12e-13	Cognitive performance;
LGG	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg14952266	chr13:112191215	NA	0.52	11.02	0.46	2.96e-25	Hepatitis;
LGG	cis	rs4242434	0.927	rs3736147	chr8:22471824	A/G	cg02227867	chr8:22457446	C8orf58	0.45	8.51	0.37	2.47e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg01879757	chr17:41196368	BRCA1	-0.41	-8.34	-0.36	8.79e-16	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg15971980	chr6:150254442	NA	0.45	8.59	0.37	1.36e-16	Lung cancer;
LGG	trans	rs7923837	0.713	rs10882099	chr10:94460650	T/C	cg27639046	chr2:171608303	NA	-0.35	-6.88	-0.3	1.96e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg06951627	chr6:26196580	NA	0.48	7.11	0.31	4.51e-12	Gout;Renal underexcretion gout;
LGG	cis	rs9549367	0.789	rs9549708	chr13:113891887	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.02	-0.55	1.74e-37	Platelet distribution width;
LGG	cis	rs300703	0.816	rs449725	chr2:202993	C/G	cg24565620	chr2:194026	NA	0.66	9.13	0.39	2.16e-18	Blood protein levels;
LGG	cis	rs2066819	1.000	rs2643623	chr12:56689725	G/C	cg26714650	chr12:56694279	CS	1.49	18.31	0.65	9.68e-57	Psoriasis vulgaris;
LGG	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.05	-0.39	3.84e-18	Common traits (Other);
LGG	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.71	-0.3	5.73e-11	Neuroticism;
LGG	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg21775007	chr8:11205619	TDH	0.62	10.24	0.43	2.53e-22	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg04863758	chr4:1303710	MAEA	0.45	7.73	0.34	6.98e-14	Obesity-related traits;
LGG	cis	rs11168618	0.626	rs7310960	chr12:48860117	T/G	cg24011408	chr12:48396354	COL2A1	-0.42	-6.69	-0.3	6.5e-11	Adiponectin levels;
LGG	cis	rs875971	0.545	rs10261710	chr7:65714189	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.38	0.43	7.65e-23	Aortic root size;
LGG	cis	rs2294693	0.947	rs6924722	chr6:41002195	C/T	cg14769373	chr6:40998127	UNC5CL	0.42	7.39	0.32	6.79e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg11062466	chr8:58055876	NA	0.61	9.69	0.41	2.43e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.518	rs56034065	chr4:185655402	A/G	cg04058563	chr4:185651563	MLF1IP	1.0	16.52	0.61	1.5e-48	Blood protein levels;
LGG	cis	rs701145	0.537	rs437396	chr3:153923273	A/G	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs79526483	chr22:32539822	T/G	cg00543991	chr22:32367038	NA	0.79	8.54	0.37	1.97e-16	Childhood ear infection;
LGG	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07080220	chr10:102295463	HIF1AN	0.66	11.34	0.47	1.84e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.57	0.67	1.39e-62	Platelet count;
LGG	cis	rs2274273	1.000	rs2274273	chr14:55614636	A/G	cg04306507	chr14:55594613	LGALS3	-0.6	-17.02	-0.62	8.53e-51	Protein biomarker;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-9.0	-0.39	5.97e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs910316	0.967	rs7146523	chr14:75659880	T/C	cg11812906	chr14:75593930	NEK9	-0.53	-9.72	-0.41	1.97e-20	Height;
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg04483336	chr17:5323402	RPAIN;NUP88	-0.41	-6.97	-0.31	1.07e-11	Select biomarker traits;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.56	-0.33	2.17e-13	Neuroticism;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.25	-0.32	1.71e-12	Mean corpuscular volume;
LGG	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.83	0.38	2.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.57	-0.41	6.25e-20	Retinal vascular caliber;
LGG	cis	rs9393813	0.529	rs2064093	chr6:27442247	C/T	cg18711553	chr6:27366782	ZNF391	0.48	9.13	0.39	2.06e-18	Bipolar disorder;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	8.96	0.38	8.03e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs62064224	0.905	rs9891969	chr17:30627085	C/T	cg18200150	chr17:30822561	MYO1D	0.66	13.85	0.54	9.46e-37	Schizophrenia;
LGG	cis	rs870825	0.655	rs28451943	chr4:185645572	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04891921	chr3:134514173	EPHB1	0.4	7.18	0.32	2.78e-12	Obesity-related traits;
LGG	cis	rs10929925	0.966	rs9678299	chr2:6160751	T/G	cg00493617	chr2:6141445	NA	0.33	7.45	0.33	4.49e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg15268244	chr15:77196840	NA	0.31	6.81	0.3	2.99e-11	Blood metabolite levels;
LGG	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.41	0.33	6.22e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg18129748	chr3:49941408	MST1R	-0.22	-6.9	-0.31	1.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12155623	0.803	rs6987879	chr8:49808062	T/C	cg00325661	chr8:49890786	NA	-0.44	-7.49	-0.33	3.45e-13	Sudden cardiac arrest;
LGG	cis	rs11690935	1.000	rs34542126	chr2:172542705	C/T	cg13550731	chr2:172543902	DYNC1I2	1.05	26.96	0.78	6.11e-97	Schizophrenia;
LGG	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	7.46	0.33	4.3e-13	HIV-1 control;
LGG	cis	rs6669919	0.540	rs11579048	chr1:211681919	C/G	cg10512769	chr1:211675356	NA	-0.95	-23.61	-0.74	1.73e-81	Intelligence (multi-trait analysis);
LGG	trans	rs7916697	0.593	rs10762198	chr10:70023053	A/G	cg04882175	chr6:131122610	NA	0.43	6.77	0.3	4.01e-11	Optic disc area;
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg17202724	chr17:61916730	SMARCD2	0.42	8.44	0.37	4.04e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg24397884	chr7:158709396	WDR60	0.87	17.1	0.62	3.54e-51	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16536329	chr5:178368185	ZNF454	0.44	7.25	0.32	1.76e-12	Cognitive performance;
LGG	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg22961513	chr11:14280813	SPON1	-0.3	-6.74	-0.3	4.67e-11	Sense of smell;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.27	0.55	1.47e-38	Platelet count;
LGG	cis	rs977987	0.806	rs4888425	chr16:75476363	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.22	0.43	3e-22	Dupuytren's disease;
LGG	cis	rs28595532	1.000	rs114912871	chr4:119697004	G/C	cg21605333	chr4:119757512	SEC24D	1.41	13.12	0.52	1.21e-33	Cannabis dependence symptom count;
LGG	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg10326726	chr10:51549505	MSMB	0.69	14.74	0.57	1.31e-40	Prostate-specific antigen levels;
LGG	cis	rs3820068	0.581	rs6669417	chr1:15922371	G/T	cg05660106	chr1:15850417	CASP9	0.78	15.98	0.6	4.24e-46	Systolic blood pressure;
LGG	cis	rs7100689	0.577	rs873395	chr10:82037215	C/T	cg01528321	chr10:82214614	TSPAN14	-0.8	-13.56	-0.53	1.7000000000000001e-35	Post bronchodilator FEV1;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.88	-0.45	1.05e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.09	0.35	5.39e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs894734	0.535	rs2366143	chr12:54323256	G/A	cg12374095	chr12:54320830	NA	-0.38	-6.83	-0.3	2.76e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	trans	rs8073060	0.586	rs225305	chr17:33921160	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-17.15	-0.62	2.14e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs972578	0.765	rs5751397	chr22:43272792	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.87	-0.3	2.08e-11	Mean platelet volume;
LGG	cis	rs9788682	0.748	rs637137	chr15:78873976	T/A	cg06917634	chr15:78832804	PSMA4	-0.5	-7.72	-0.34	7.47e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9810089	0.934	rs570621	chr3:136000743	A/G	cg21827317	chr3:136751795	NA	0.45	7.86	0.34	2.73e-14	Gestational age at birth (child effect);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03876184	chr2:27886755	SUPT7L;SLC4A1AP	0.43	7.14	0.31	3.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2273669	0.915	rs6908714	chr6:109294336	T/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.44	-7.55	-0.33	2.37e-13	Longevity;Endometriosis;
LGG	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.27	-0.4	6.98e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg18357526	chr6:26021779	HIST1H4A	0.6	10.58	0.44	1.43e-23	Blood metabolite levels;
LGG	cis	rs6871536	1.000	rs6894017	chr5:131952398	G/A	cg04303330	chr5:131992430	IL13	0.29	7.02	0.31	7.9e-12	Asthma (childhood onset);
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Bipolar disorder;
LGG	trans	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg18335740	chr13:41363409	SLC25A15	-0.64	-13.28	-0.53	2.55e-34	Lewy body disease;
LGG	cis	rs12618769	0.597	rs2278208	chr2:99154229	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.71	0.34	7.61e-14	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg16141378	chr3:129829833	LOC729375	0.32	7.69	0.34	8.66e-14	Mood instability;
LGG	cis	rs472402	0.580	rs7720479	chr5:6640049	A/G	cg08700190	chr5:6636046	SRD5A1	-0.33	-7.04	-0.31	6.82e-12	Response to amphetamines;
LGG	cis	rs929354	1.000	rs1182377	chr7:157048403	T/C	cg00092383	chr7:157075207	NA	0.4	6.88	0.3	1.92e-11	Body mass index;
LGG	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg02297831	chr4:17616191	MED28	0.5	9.41	0.4	2.42e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg22433210	chr17:43662623	NA	-0.64	-11.15	-0.46	1e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	10.32	0.43	1.28e-22	Obesity-related traits;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.959	rs12902070	chr15:84793558	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.91	0.38	1.18e-17	Schizophrenia;
LGG	cis	rs11112613	1.000	rs11112613	chr12:106003786	A/G	cg03607813	chr12:105948248	NA	0.53	7.78	0.34	4.78e-14	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs12410462	0.591	rs2819496	chr1:227733902	G/A	cg21459583	chr1:227974177	NA	0.36	6.85	0.3	2.31e-11	Major depressive disorder;
LGG	cis	rs6867032	1.000	rs4975794	chr5:2015330	A/G	cg26168224	chr5:2018326	NA	-1.25	-29.61	-0.81	6.68e-109	Gut microbiome composition (winter);
LGG	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.14	0.58	2.44e-42	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg06453172	chr10:134556979	INPP5A	-0.58	-8.65	-0.37	8.54e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3796619	1.000	rs28620427	chr4:1086247	T/G	cg27284194	chr4:1044797	NA	0.57	11.7	0.48	6.86e-28	Recombination rate (males);
LGG	cis	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg24375607	chr4:120327624	NA	0.62	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg23302884	chr18:44338147	ST8SIA5	0.35	6.77	0.3	3.85e-11	Personality dimensions;
LGG	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg03689076	chr20:33865952	NA	-0.66	-9.33	-0.4	4.38e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs2011503	0.882	rs10423874	chr19:19359500	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.0	0.31	8.99e-12	Bipolar disorder;
LGG	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg11812906	chr14:75593930	NEK9	0.46	8.26	0.36	1.57e-15	Height;
LGG	cis	rs6743226	0.934	rs7565186	chr2:242249822	A/G	cg10021735	chr2:242295487	FARP2	0.53	9.64	0.41	3.6e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg06212747	chr3:49208901	KLHDC8B	0.54	8.46	0.37	3.44e-16	Menarche (age at onset);
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg19147804	chr7:1989927	MAD1L1	0.54	10.57	0.44	1.57e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs17767392	0.881	rs8006300	chr14:72050162	C/T	cg02058870	chr14:72053146	SIPA1L1	-0.43	-8.97	-0.38	7.24e-18	Mitral valve prolapse;
LGG	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.25	-0.78	2.75e-98	Schizophrenia;
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg22444338	chr7:1054449	C7orf50	0.43	9.24	0.39	9.17e-19	Bronchopulmonary dysplasia;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-7.97	-0.35	1.25e-14	Life satisfaction;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg24642844	chr7:1081250	C7orf50	-0.69	-12.64	-0.51	1.15e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.25	0.43	2.35e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.64	0.37	9.01e-17	Lung cancer;
LGG	trans	rs62458065	0.568	rs62466415	chr7:32518254	C/T	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.43	-0.33	5.14e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg02725872	chr8:58115012	NA	-0.88	-11.42	-0.47	8.52e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg14092988	chr3:52407081	DNAH1	0.34	8.9	0.38	1.28e-17	Bipolar disorder;
LGG	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg18252515	chr7:66147081	NA	-1.31	-18.96	-0.66	9.96e-60	Diabetic kidney disease;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg15242686	chr22:24348715	GSTTP1	0.39	7.25	0.32	1.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4740619	0.766	rs10810440	chr9:15754631	A/G	cg14451791	chr9:16040625	NA	0.32	8.31	0.36	1.05e-15	Body mass index;
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg02503808	chr4:7069936	GRPEL1	0.9	14.17	0.55	4.16e-38	Monocyte percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02977157	chr20:13765764	C20orf7;ESF1	0.47	8.12	0.35	4.37e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs8067545	0.750	rs35003563	chr17:19989218	G/A	cg13482628	chr17:19912719	NA	0.62	12.41	0.5	1e-30	Schizophrenia;
LGG	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08564027	chr20:61660810	NA	1.03	26.31	0.77	5.58e-94	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg10204951	chr7:910479	UNC84A	-0.53	-7.05	-0.31	6.36e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg11062466	chr8:58055876	NA	0.48	7.85	0.34	2.85e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.27	0.55	1.52e-38	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.63	0.33	1.31e-13	Menopause (age at onset);
LGG	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg23815491	chr16:72088622	HP	0.51	9.55	0.41	7.79e-20	Blood protein levels;
LGG	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg06532163	chr17:45867833	NA	0.51	7.82	0.34	3.72e-14	IgG glycosylation;
LGG	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	11.68	0.48	8.19e-28	Hemoglobin concentration;
LGG	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs708547	0.874	rs1718837	chr4:57871203	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	11.68	0.48	8.51e-28	Response to bleomycin (chromatid breaks);
LGG	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg08305652	chr11:111469057	NA	0.41	8.12	0.35	4.22e-15	Primary sclerosing cholangitis;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.63	9.75	0.41	1.52e-20	Renal function-related traits (BUN);
LGG	trans	rs804280	0.593	rs2645396	chr8:11608126	C/A	cg02002194	chr4:3960332	NA	-0.48	-7.12	-0.31	4.24e-12	Myopia (pathological);
LGG	cis	rs9287719	0.870	rs728135	chr2:10745132	A/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs6601327	0.641	rs11785923	chr8:9587674	G/C	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.95	-0.35	1.39e-14	Menarche (age at onset);
LGG	trans	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.44	-0.37	3.99e-16	Retinal vascular caliber;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg02297831	chr4:17616191	MED28	0.51	9.67	0.41	2.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4262150	1.000	rs4262150	chr5:152288453	G/T	cg12297329	chr5:152029980	NA	-0.59	-11.32	-0.47	2.11e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs877282	0.945	rs10904555	chr10:787740	C/A	cg22713356	chr15:30763199	NA	0.57	8.64	0.37	8.93e-17	Uric acid levels;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.65	0.37	8.51e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7914558	0.966	rs2065977	chr10:104729415	C/T	cg04362960	chr10:104952993	NT5C2	0.54	10.3	0.43	1.57e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.2	-0.43	3.63e-22	Glycated hemoglobin levels;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg23958373	chr8:599963	NA	1.39	13.35	0.53	1.26e-34	IgG glycosylation;
LGG	cis	rs3741151	1.000	rs7122825	chr11:73061324	C/T	cg17517138	chr11:73019481	ARHGEF17	1.02	10.47	0.44	3.63e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7267979	0.727	rs2474765	chr20:25245950	G/T	cg06421707	chr20:25228305	PYGB	0.44	9.23	0.39	9.38e-19	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg19538502	chr15:40226259	EIF2AK4	0.53	6.92	0.31	1.55e-11	Response to haloperidol in psychosis;
LGG	cis	rs3849570	0.695	rs1851930	chr3:81895318	T/G	cg07356753	chr3:81810745	GBE1	-0.44	-7.04	-0.31	6.86e-12	Waist circumference;Body mass index;
LGG	cis	rs701145	0.537	rs1358403	chr3:153862757	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.82e-19	Coronary artery disease;
LGG	cis	rs9972944	0.691	rs10083837	chr17:63775311	C/G	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs17092148	0.887	rs6059928	chr20:33167349	A/G	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.94	-0.31	1.35e-11	Neuroticism;
LGG	cis	rs1978968	1.000	rs1076539	chr22:18439598	A/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.66	-0.51	9.87e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.521	rs56227677	chr2:239449867	C/T	cg01134436	chr17:81009848	B3GNTL1	0.75	8.42	0.36	4.82e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg10580341	chr11:889148	CHID1	-0.38	-7.0	-0.31	9.29e-12	Mean platelet volume;
LGG	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg06191203	chr2:152266755	RIF1	-0.46	-7.86	-0.34	2.73e-14	Lung cancer;
LGG	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.61	0.63	1.75e-53	Cognitive function;
LGG	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg00343986	chr7:65444356	GUSB	0.49	8.64	0.37	9.12e-17	Aortic root size;
LGG	cis	rs78487399	0.710	rs7590220	chr2:43702151	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.72	-0.3	5.46e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg18200150	chr17:30822561	MYO1D	-0.69	-14.58	-0.56	6.91e-40	Schizophrenia;
LGG	trans	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.54	9.55	0.41	7.86e-20	Metabolite levels;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.56	-9.41	-0.4	2.37e-19	Longevity;Endometriosis;
LGG	cis	rs965513	0.627	rs10124220	chr9:100583074	T/C	cg13688889	chr9:100608707	NA	-0.57	-11.04	-0.46	2.51e-25	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs7246657	0.722	rs968073	chr19:38192021	G/A	cg14683738	chr19:37701593	ZNF585B	-0.42	-6.98	-0.31	1.04e-11	Coronary artery calcification;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-7.15	-0.32	3.33e-12	Obesity-related traits;
LGG	cis	rs763121	0.853	rs35522482	chr22:39063015	C/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg24764310	chr7:157512201	PTPRN2	-0.48	-10.27	-0.43	1.9e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs17067123	0.614	rs72712851	chr4:180066258	A/G	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs9368481	0.700	rs6911401	chr6:26913214	C/G	cg12292205	chr6:26970375	C6orf41	0.73	14.22	0.55	2.39e-38	Autism spectrum disorder or schizophrenia;
LGG	cis	rs638893	0.636	rs583213	chr11:118669178	G/T	cg13782932	chr11:118662891	DDX6	0.38	7.0	0.31	8.96e-12	Vitiligo;
LGG	cis	rs9783347	0.621	rs11024613	chr11:18326542	T/C	cg03595886	chr11:18357587	GTF2H1	-0.49	-11.86	-0.48	1.7e-28	Pancreatic cancer;
LGG	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg06606381	chr12:133084897	FBRSL1	1.11	10.29	0.43	1.69e-22	Intelligence (multi-trait analysis);
LGG	cis	rs13102973	0.965	rs4864244	chr4:135866959	A/G	cg14419869	chr4:135874104	NA	0.58	11.05	0.46	2.43e-25	Subjective well-being;
LGG	cis	rs67460515	0.892	rs11711413	chr3:160998910	C/G	cg03342759	chr3:160939853	NMD3	-0.77	-13.86	-0.54	8.74e-37	Parkinson's disease;
LGG	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg08198773	chr8:1697536	NA	0.45	7.98	0.35	1.17e-14	Systolic blood pressure;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs7727544	0.836	rs10463892	chr5:131598705	T/C	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.77	-0.3	3.89e-11	Blood metabolite levels;
LGG	cis	rs3739821	0.789	rs10987787	chr9:130729153	C/G	cg21181453	chr9:130700954	DPM2	0.34	7.83	0.34	3.41e-14	Glaucoma (primary angle closure);
LGG	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg12654349	chr5:56205094	C5orf35	-0.62	-9.82	-0.42	8.69e-21	Initial pursuit acceleration;
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg14675211	chr2:100938903	LONRF2	0.61	10.69	0.45	5.36e-24	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg22563815	chr15:78856949	CHRNA5	0.3	7.3	0.32	1.28e-12	Sudden cardiac arrest;
LGG	cis	rs35146811	0.624	rs1727134	chr7:99813672	T/C	cg22906224	chr7:99728672	NA	-0.57	-9.32	-0.4	4.72e-19	Coronary artery disease;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17209837	0.573	rs45537841	chr7:87110640	C/T	cg00919237	chr7:87102261	ABCB4	-0.8	-16.12	-0.6	1.05e-46	Gallbladder cancer;
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg16590910	chr6:42928470	GNMT	0.46	13.4	0.53	7.46e-35	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs35160687	0.644	rs11680025	chr2:86545338	C/T	cg10973622	chr2:86423274	IMMT	-0.38	-6.72	-0.3	5.45e-11	Night sleep phenotypes;
LGG	cis	rs9914988	0.887	rs34644886	chr17:27168327	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.26	-0.32	1.62e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg00405596	chr8:11794950	NA	-0.41	-6.97	-0.31	1.12e-11	Mood instability;
LGG	cis	rs7312933	0.618	rs12366848	chr12:42682215	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.63	0.33	1.32e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs709400	0.628	rs10141120	chr14:103923008	T/C	cg26031613	chr14:104095156	KLC1	0.78	13.99	0.55	2.38e-37	Body mass index;
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.81	-0.48	2.61e-28	Alzheimer's disease;
LGG	cis	rs7247513	1.000	rs8104385	chr19:12700284	G/A	cg01871581	chr19:12707946	ZNF490	-0.45	-9.19	-0.39	1.33e-18	Bipolar disorder;
LGG	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.63	14.42	0.56	3.25e-39	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	9.16	0.39	1.69e-18	Obesity-related traits;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.55	-0.33	2.39e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs8141529	0.529	rs34718288	chr22:29194797	C/G	cg15103426	chr22:29168792	CCDC117	0.67	7.04	0.31	7.03e-12	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14633800	chr9:101389525	GABBR2	0.43	7.32	0.32	1.1e-12	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs12325866	chr17:61755974	G/A	cg05941027	chr17:61774174	LIMD2	0.37	9.49	0.4	1.22e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg18196295	chr10:418757	DIP2C	0.64	13.07	0.52	1.85e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg08564027	chr20:61660810	NA	1.02	25.49	0.76	3.43e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg12698349	chr2:225449008	CUL3	0.7	12.01	0.49	4.2e-29	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs35306767	0.714	rs11250228	chr10:1074887	A/G	cg26597838	chr10:835615	NA	0.49	6.72	0.3	5.44e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs16976116	0.951	rs9300	chr15:55489065	G/A	cg11288833	chr15:55489084	RSL24D1	0.56	7.64	0.33	1.27e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6694672	1.000	rs6694672	chr1:196945789	T/G	cg13682187	chr1:196946512	CFHR5	-0.49	-6.73	-0.3	5.11e-11	Asthma;
LGG	cis	rs11190604	0.767	rs7078070	chr10:102166415	A/C	cg07570687	chr10:102243282	WNT8B	0.39	7.02	0.31	7.87e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.64e-12	Mean corpuscular hemoglobin;
LGG	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg11707556	chr5:10655725	ANKRD33B	0.49	9.66	0.41	3.06e-20	Coronary artery disease;
LGG	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1.05e-13	Neutrophil percentage of white cells;
LGG	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.64	-8.15	-0.35	3.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7944735	1.000	rs7944735	chr11:47955608	G/C	cg15704280	chr7:45808275	SEPT13	0.71	8.61	0.37	1.2e-16	Intraocular pressure;
LGG	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.88	-0.34	2.37e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6063312	1.000	rs6095261	chr20:47346494	C/A	cg18078177	chr20:47281410	PREX1	0.74	8.83	0.38	2.18e-17	Tonometry;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs13126513	0.708	rs4368610	chr4:100453746	G/T	cg05468953	chr4:100565104	NA	0.42	8.26	0.36	1.54e-15	Metabolite levels (MHPG);
LGG	cis	rs11239187	0.530	rs10900066	chr10:45060550	G/A	cg03916630	chr10:45065415	NA	0.36	8.68	0.37	6.65e-17	Body mass index;
LGG	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22857025	chr5:266934	NA	-1.46	-25.67	-0.77	4.84e-91	Breast cancer;
LGG	cis	rs9467773	0.620	rs9461276	chr6:26595168	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.72	0.51	5.1e-32	Intelligence (multi-trait analysis);
LGG	trans	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg21659725	chr3:3221576	CRBN	-0.55	-9.64	-0.41	3.69e-20	Body mass index;
LGG	trans	rs75804782	0.521	rs1123472	chr2:239414355	C/T	cg01134436	chr17:81009848	B3GNTL1	-0.79	-8.77	-0.38	3.56e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9354308	0.764	rs9363475	chr6:66588340	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg05868516	chr6:26286170	HIST1H4H	0.43	7.31	0.32	1.19e-12	Educational attainment;
LGG	trans	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg21659725	chr3:3221576	CRBN	0.57	9.88	0.42	5.34e-21	Body mass index;
LGG	cis	rs72772090	0.710	rs11739280	chr5:96074147	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.53	8.16	0.35	3.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs367615	0.660	rs10061221	chr5:108839038	C/T	cg17395555	chr5:108820864	NA	0.88	16.01	0.6	3.03e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-10.43	-0.44	5.22e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.43	-7.1	-0.31	4.57e-12	Resting heart rate;
LGG	trans	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg19894588	chr14:64061835	NA	0.43	6.87	0.3	2.12e-11	Glioblastoma;Glioma;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg10950524	chr7:2139216	MAD1L1	0.32	6.85	0.3	2.36e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9486719	0.947	rs11755945	chr6:96908038	G/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs2073300	0.609	rs6137937	chr20:23385419	G/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4454254	1.000	rs4454254	chr8:141060027	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.31	-7.85	-0.34	2.83e-14	Pulse pressure;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg05692746	chr2:100937584	LONRF2	0.47	6.8	0.3	3.27e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.960	rs8025842	chr15:90995471	C/T	cg22089800	chr15:90895588	ZNF774	0.56	9.27	0.4	7.16e-19	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs11971779	0.553	rs10269108	chr7:139106332	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.87	-0.34	2.5e-14	Mean platelet volume;
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg12437481	chr16:420112	MRPL28	-0.46	-7.35	-0.32	9.08e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg09640425	chr7:158790006	NA	0.37	6.92	0.31	1.56e-11	Facial morphology (factor 20);
LGG	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.21	0.75	2.93e-84	Chronic sinus infection;
LGG	cis	rs9810259	0.508	rs6442309	chr3:12301166	A/G	cg22839075	chr3:12045461	SYN2	-0.4	-6.78	-0.3	3.59e-11	Platelet count;
LGG	cis	rs4730250	0.670	rs9641380	chr7:106868151	C/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.92	-0.45	7.42e-25	Osteoarthritis;
LGG	cis	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg26384229	chr12:38710491	ALG10B	-0.82	-17.81	-0.64	1.89e-54	Bladder cancer;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.29	-0.32	1.37e-12	Lung cancer;
LGG	cis	rs2764208	0.501	rs2744953	chr6:34656462	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-7.71	-0.34	7.97e-14	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.628	rs11250129	chr8:11202154	G/A	cg21775007	chr8:11205619	TDH	0.81	14.53	0.56	1.08e-39	Retinal vascular caliber;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg20887711	chr4:1340912	KIAA1530	0.9	19.77	0.68	1.56e-63	Longevity;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg18446336	chr7:2847575	GNA12	-0.29	-6.9	-0.31	1.69e-11	Height;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg07701084	chr6:150067640	NUP43	0.63	11.87	0.48	1.43e-28	Lung cancer;
LGG	cis	rs1790761	0.967	rs1638588	chr11:67199706	C/A	cg00290607	chr11:67383545	NA	-0.48	-8.57	-0.37	1.6e-16	Mean corpuscular volume;
LGG	cis	rs2070488	0.775	rs6599204	chr3:38525734	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.73	14.57	0.56	7.23e-40	Electrocardiographic conduction measures;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-12.06	-0.49	2.58e-29	Prudent dietary pattern;
LGG	trans	rs11098499	0.754	rs7689729	chr4:120256192	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.41	-0.33	6.11e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg00405596	chr8:11794950	NA	-0.42	-6.78	-0.3	3.68e-11	Neuroticism;
LGG	cis	rs7590368	0.779	rs3856465	chr2:10916670	C/T	cg15705551	chr2:10952987	PDIA6	0.55	7.57	0.33	2e-13	Educational attainment (years of education);
LGG	cis	rs72627123	0.500	rs7359018	chr14:74521008	T/C	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.5	6.8	0.3	3.16e-11	Morning vs. evening chronotype;
LGG	cis	rs977987	0.843	rs4888372	chr16:75313485	G/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.67	0.3	7.21e-11	Dupuytren's disease;
LGG	cis	rs9462027	0.628	rs9469859	chr6:34722902	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.47	-0.47	5.82e-27	Systemic lupus erythematosus;
LGG	cis	rs13421350	1.000	rs10210544	chr2:173314339	A/G	cg15021238	chr2:173305865	ITGA6	-0.41	-6.81	-0.3	3.03e-11	Diabetic kidney disease;
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg13628971	chr7:2884303	GNA12	0.5	9.69	0.41	2.46e-20	Height;
LGG	cis	rs1878931	0.668	rs2074366	chr16:3439676	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.0	22.32	0.72	1.91e-75	Body mass index (adult);
LGG	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.39	6.85	0.3	2.34e-11	Red cell distribution width;Reticulocyte count;
LGG	cis	rs4696584	0.816	rs56223712	chr4:155403065	G/A	cg13738195	chr4:155413469	DCHS2	-0.37	-7.43	-0.33	5.32e-13	Folding of antihelix;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.79	0.59	3.08e-45	Lung cancer;
LGG	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs9399137	0.507	rs4895437	chr6:135317354	G/A	cg22676075	chr6:135203613	NA	0.42	7.3	0.32	1.25e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg24375607	chr4:120327624	NA	0.65	10.57	0.44	1.53e-23	Corneal astigmatism;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.76	0.3	4.08e-11	Schizophrenia;
LGG	cis	rs12493885	0.725	rs73158427	chr3:153721493	T/A	cg17054900	chr3:154042577	DHX36	-0.59	-7.68	-0.34	9.53e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg00717180	chr2:96193071	NA	0.4	7.16	0.32	3.17e-12	Coronary artery disease;
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.32	-8.39	-0.36	5.91e-16	IgG glycosylation;
LGG	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs35740288	0.770	rs1382534	chr15:86142170	A/T	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.08e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg18187862	chr3:45730750	SACM1L	0.63	10.33	0.43	1.22e-22	Primary sclerosing cholangitis;
LGG	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg26585981	chr11:48327164	OR4S1	-0.4	-7.02	-0.31	7.71e-12	Migraine - clinic-based;
LGG	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-9.22	-0.39	1.03e-18	Erythrocyte sedimentation rate;
LGG	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg13010199	chr12:38710504	ALG10B	-0.59	-11.87	-0.48	1.55e-28	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.35	-0.43	1.03e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg14926445	chr8:58193284	C8orf71	-0.87	-13.12	-0.52	1.19e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.37e-16	Lung cancer;
LGG	cis	rs1707322	1.000	rs4460583	chr1:46449918	C/G	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2635047	0.811	rs28471970	chr18:44788439	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.59	0.33	1.75e-13	Educational attainment;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08645402	chr16:4508243	NA	0.55	10.05	0.42	1.23e-21	Schizophrenia;
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg13009111	chr11:71350975	NA	-0.32	-6.95	-0.31	1.28e-11	Triglycerides;
LGG	cis	rs10979	0.965	rs9390111	chr6:143894272	T/C	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs3099143	1.000	rs4886832	chr15:77121196	G/A	cg21673338	chr15:77095150	SCAPER	0.65	10.63	0.44	8.89e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg03264133	chr6:25882463	NA	0.49	8.82	0.38	2.3e-17	Blood metabolite levels;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.45	0.61	3.31e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3736594	0.959	rs10209020	chr2:27980944	C/T	cg27432699	chr2:27873401	GPN1	-0.55	-9.09	-0.39	2.97e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7172689	1.000	rs28455908	chr15:81547313	T/C	cg11808699	chr15:81528661	IL16	-0.5	-10.24	-0.43	2.61e-22	Inattentive symptoms;
LGG	cis	rs2088885	1.000	rs6772621	chr3:170977841	A/C	cg18052528	chr3:170975382	TNIK	-0.28	-6.89	-0.31	1.79e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs9790314	0.696	rs9290069	chr3:160890946	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-10.82	-0.45	1.82e-24	Morning vs. evening chronotype;
LGG	cis	rs113835537	0.529	rs78999944	chr11:66251228	C/G	cg24851651	chr11:66362959	CCS	0.43	7.54	0.33	2.48e-13	Airway imaging phenotypes;
LGG	cis	rs853679	0.517	rs9348793	chr6:28084189	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs774359	0.830	rs3849942	chr9:27543281	T/C	cg14173147	chr9:27528300	MOBKL2B	-0.45	-8.6	-0.37	1.25e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs490234	0.552	rs2841327	chr9:128156503	G/A	cg14078157	chr9:128172775	NA	-0.57	-10.92	-0.45	7.31e-25	Mean arterial pressure;
LGG	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg01403660	chr11:68851641	TPCN2	0.51	7.16	0.32	3.14e-12	Blond vs. brown hair color;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12407844	chr14:60558421	C14orf135	0.46	7.43	0.33	5.2e-13	Cognitive performance;
LGG	cis	rs3857747	0.931	rs10261478	chr7:40388695	G/A	cg00420559	chr7:40367873	C7orf10	0.41	8.12	0.35	4.3e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.52e-21	Lymphocyte counts;
LGG	cis	rs921968	0.541	rs523937	chr2:219437596	G/C	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	trans	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg00953403	chr17:74099816	EXOC7	0.41	6.79	0.3	3.38e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg19338460	chr6:170058176	WDR27	-0.59	-8.07	-0.35	6.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7236492	0.748	rs78531995	chr18:77198370	C/T	cg05753993	chr18:77199432	NFATC1	0.36	6.78	0.3	3.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11203032	0.831	rs12217507	chr10:90922828	G/A	cg16672925	chr10:90967113	CH25H	0.77	10.97	0.45	4.63e-25	Heart failure;
LGG	cis	rs7267979	1.000	rs4815409	chr20:25346697	C/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.49	-7.26	-0.32	1.66e-12	Huntington's disease progression;
LGG	cis	rs8044868	0.530	rs8059437	chr16:72116467	A/G	cg23815491	chr16:72088622	HP	0.38	8.35	0.36	7.88e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.33	-6.87	-0.3	2.07e-11	Schizophrenia;
LGG	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg13607699	chr17:42295918	UBTF	-0.9	-18.76	-0.66	8.19e-59	Total body bone mineral density;
LGG	cis	rs6976053	0.846	rs12666785	chr7:100476229	C/T	cg03098644	chr7:100410630	EPHB4	-0.43	-7.59	-0.33	1.79e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs701145	0.556	rs355762	chr3:154012614	G/A	cg17054900	chr3:154042577	DHX36	0.47	7.24	0.32	1.84e-12	Coronary artery disease;
LGG	cis	rs739401	0.611	rs417957	chr11:3046231	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.55	-0.53	1.88e-35	Longevity;
LGG	cis	rs12431410	0.550	rs10138254	chr14:60209188	A/G	cg07950296	chr14:60194823	RTN1	-0.37	-7.15	-0.32	3.34e-12	Schizophrenia;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg06719900	chr11:109292894	C11orf87	0.44	8.48	0.37	3.06e-16	Schizophrenia;
LGG	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg03733263	chr8:22462867	KIAA1967	1.06	26.62	0.78	2.25e-95	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7666738	0.830	rs10012003	chr4:99064881	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.52e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg08888203	chr3:10149979	C3orf24	0.52	8.85	0.38	1.87e-17	Alzheimer's disease;
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg24503407	chr1:205819492	PM20D1	0.46	8.59	0.37	1.34e-16	Menarche (age at onset);
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg13395646	chr4:1353034	KIAA1530	0.52	9.05	0.39	3.83e-18	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.71e-12	Refractive error;
LGG	cis	rs9357271	1.000	rs742515	chr6:38347691	G/A	cg07362130	chr6:38359646	BTBD9	-0.43	-9.89	-0.42	4.57e-21	Restless legs syndrome;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs3106136	0.967	rs2306802	chr4:95186055	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.84	-0.34	3.23e-14	Capecitabine sensitivity;
LGG	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg19729930	chr2:74357872	NA	0.54	11.51	0.47	3.99e-27	Gestational age at birth (maternal effect);
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg02071572	chr4:1403502	NA	0.42	7.18	0.32	2.83e-12	Longevity;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg06558623	chr16:89946397	TCF25	0.89	11.77	0.48	3.56e-28	Skin colour saturation;
LGG	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg15997130	chr1:24165203	NA	-0.5	-13.6	-0.53	1.15e-35	Immature fraction of reticulocytes;
LGG	cis	rs2249694	1.000	rs4240522	chr10:135355557	C/T	cg20169779	chr10:135381914	SYCE1	0.51	7.83	0.34	3.38e-14	Obesity-related traits;
LGG	cis	rs8133932	0.701	rs2839021	chr21:47280016	C/T	cg13695288	chr21:47294981	PCBP3	0.35	7.19	0.32	2.58e-12	Schizophrenia;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg11494091	chr17:61959527	GH2	0.99	24.18	0.75	4.11e-84	Prudent dietary pattern;
LGG	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs9512730	0.527	rs11619784	chr13:27999643	A/G	cg04070771	chr13:27998621	GTF3A	0.58	8.82	0.38	2.34e-17	Schizophrenia;
LGG	cis	rs10267417	0.603	rs10266969	chr7:19903452	G/A	cg05791153	chr7:19748676	TWISTNB	0.6	7.86	0.34	2.72e-14	Night sleep phenotypes;
LGG	cis	rs1018836	0.544	rs2063978	chr8:91459525	C/T	cg16814680	chr8:91681699	NA	-0.48	-7.93	-0.35	1.7e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10884984	0.874	rs67599406	chr10:112276556	G/A	cg18756771	chr10:112261994	DUSP5	0.67	11.27	0.46	3.48e-26	Facial morphology (factor 22);
LGG	cis	rs11771526	1.000	rs6462350	chr7:32342000	G/A	cg13207630	chr7:32358064	NA	0.76	7.57	0.33	2.01e-13	Body mass index;
LGG	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs7666738	0.830	rs1876192	chr4:98727555	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg03476357	chr21:30257390	N6AMT1	-0.58	-8.8	-0.38	2.66e-17	Cognitive test performance;
LGG	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg06618935	chr21:46677482	NA	-0.44	-8.53	-0.37	2.08e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg15704280	chr7:45808275	SEPT13	0.49	7.99	0.35	1.05e-14	HDL cholesterol;
LGG	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg19500275	chr17:80737654	TBCD	0.53	7.07	0.31	5.56e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs939658	0.626	rs11631406	chr15:79445789	C/T	cg17916960	chr15:79447300	NA	-0.57	-10.26	-0.43	2.18e-22	Refractive error;
LGG	cis	rs11018874	0.597	rs4268468	chr11:89886284	C/T	cg14505434	chr11:89522851	NA	0.63	9.29	0.4	6.23e-19	White blood cell types;
LGG	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg00405596	chr8:11794950	NA	0.43	7.32	0.32	1.08e-12	Mood instability;
LGG	trans	rs9393777	0.841	rs13207082	chr6:27251379	A/G	cg01620082	chr3:125678407	NA	-0.9	-9.38	-0.4	2.88e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11785400	0.793	rs3735993	chr8:143741170	G/A	cg24634471	chr8:143751801	JRK	0.5	7.72	0.34	7.28e-14	Schizophrenia;
LGG	cis	rs988958	0.526	rs720043	chr2:42239044	T/C	cg27252766	chr2:42229092	NA	0.47	6.72	0.3	5.28e-11	Hypospadias;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	14.72	0.56	1.58e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1975974	0.574	rs59896566	chr17:21733621	C/T	cg18423549	chr17:21743878	NA	-0.51	-7.76	-0.34	5.53e-14	Psoriasis;
LGG	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg26818010	chr10:134567672	INPP5A	-0.53	-8.56	-0.37	1.73e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs62064224	0.589	rs756785	chr17:30812845	T/C	cg25809561	chr17:30822961	MYO1D	0.39	9.18	0.39	1.39e-18	Schizophrenia;
LGG	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7615952	0.599	rs7631268	chr3:125755664	T/A	cg06494592	chr3:125709126	NA	-0.54	-6.81	-0.3	3.08e-11	Blood pressure (smoking interaction);
LGG	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg26384229	chr12:38710491	ALG10B	-0.72	-13.62	-0.53	9.26e-36	Morning vs. evening chronotype;
LGG	trans	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg10756647	chr7:56101905	PSPH	0.79	9.29	0.4	5.9e-19	Diabetic kidney disease;
LGG	trans	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.54	0.41	8e-20	Diabetic kidney disease;
LGG	cis	rs9878978	0.722	rs35763288	chr3:2513663	C/T	cg21928760	chr3:2462534	CNTN4	0.35	6.86	0.3	2.27e-11	Blood pressure (smoking interaction);
LGG	cis	rs9457247	0.967	rs402191	chr6:167405553	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.67	-12.51	-0.5	3.83e-31	Menarche (age at onset);
LGG	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg23231163	chr10:75533350	FUT11	-0.4	-6.67	-0.3	7.46e-11	Inflammatory bowel disease;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.22	-0.32	2.17e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg03806693	chr22:41940476	POLR3H	-1.14	-20.38	-0.69	2.3e-66	Vitiligo;
LGG	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.68	16.26	0.6	2.37e-47	Calcium levels;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg08707078	chr7:23720292	C7orf46	0.4	9.19	0.39	1.37e-18	Schizophrenia;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg11062466	chr8:58055876	NA	0.45	7.5	0.33	3.23e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	17.49	0.63	5.75e-53	Platelet count;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21963583	chr11:68658836	MRPL21	0.6	10.33	0.43	1.18e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2239547	0.563	rs2581820	chr3:53020544	A/G	cg11645453	chr3:52864694	ITIH4	-0.67	-10.39	-0.43	6.95e-23	Schizophrenia;
LGG	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-14.22	-0.55	2.41e-38	Response to antipsychotic treatment;
LGG	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg02002194	chr4:3960332	NA	0.51	10.36	0.43	9.18e-23	Mood instability;
LGG	cis	rs2842992	0.789	rs2475566	chr6:160148741	C/T	cg27624424	chr6:160112604	SOD2	0.67	9.64	0.41	3.8e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg19147804	chr7:1989927	MAD1L1	-0.53	-9.94	-0.42	3.19e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.25	-0.36	1.62e-15	IgG glycosylation;
LGG	cis	rs28830936	1.000	rs17677991	chr15:42032383	C/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-7.08	-0.31	5.23e-12	Diastolic blood pressure;
LGG	cis	rs9814567	0.806	rs11927539	chr3:134319448	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.79	0.41	1.05e-20	Colorectal cancer;
LGG	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-11.18	-0.46	7.63e-26	Height;
LGG	cis	rs77633900	0.614	rs2459360	chr15:76868664	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-10.37	-0.43	8.32e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs28830936	0.966	rs11635067	chr15:42124673	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.93	-0.52	7.23e-33	Diastolic blood pressure;
LGG	cis	rs11098499	0.954	rs7436506	chr4:120393769	T/C	cg24375607	chr4:120327624	NA	0.67	11.05	0.46	2.42e-25	Corneal astigmatism;
LGG	cis	rs9325144	0.560	rs12424821	chr12:38649951	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18124201	chr20:46414952	SULF2	0.4	6.74	0.3	4.59e-11	Bipolar disorder;
LGG	cis	rs6580649	0.941	rs4760683	chr12:48516296	T/C	cg24011408	chr12:48396354	COL2A1	-0.53	-6.66	-0.3	7.69e-11	Lung cancer;
LGG	cis	rs77972916	0.611	rs11693190	chr2:43602415	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-8.81	-0.38	2.48e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4642101	0.765	rs3901665	chr3:12824610	C/A	cg24848339	chr3:12840334	CAND2	0.42	9.7	0.41	2.21e-20	QRS complex (12-leadsum);
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.49	-0.53	3.24e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs16976116	0.951	rs3759862	chr15:55483104	C/A	cg11288833	chr15:55489084	RSL24D1	0.54	7.44	0.33	4.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg15268244	chr15:77196840	NA	-0.34	-7.52	-0.33	2.82e-13	Blood metabolite levels;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.55	-0.33	2.37e-13	Blood pressure (smoking interaction);
LGG	cis	rs1712517	0.545	rs3740381	chr10:105046689	G/C	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.48e-15	Migraine;
LGG	cis	rs757278	0.513	rs213989	chr7:117267511	C/A	cg10524701	chr7:117356490	CTTNBP2	0.45	7.74	0.34	6.16e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7428	0.527	rs7608892	chr2:85542718	G/A	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.89	-0.54	6.64e-37	Ear protrusion;
LGG	cis	rs9581857	0.579	rs76657892	chr13:27997604	A/G	cg01674679	chr13:27998804	GTF3A	-0.74	-8.73	-0.38	4.75e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs12477438	0.539	rs55815229	chr2:99944392	C/T	cg23527387	chr2:100056660	REV1	0.44	9.7	0.41	2.25e-20	Chronic sinus infection;
LGG	cis	rs4665809	1.000	rs7588802	chr2:26277789	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.66	-0.34	1.06e-13	Gut microbiome composition (summer);
LGG	cis	rs2070433	0.660	rs11701034	chr21:47793235	A/G	cg12379764	chr21:47803548	PCNT	0.7	9.8	0.41	9.67e-21	Lymphocyte counts;
LGG	cis	rs2718058	0.630	rs2709120	chr7:37809412	T/C	cg24998770	chr7:37888106	TXNDC3	0.45	7.22	0.32	2.18e-12	Alzheimer's disease (late onset);
LGG	cis	rs4363385	0.747	rs1338180	chr1:152981404	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.81e-18	Inflammatory skin disease;
LGG	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs12681366	0.734	rs3019146	chr8:95414106	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.69	0.3	6.4e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs62238980	0.614	rs4820067	chr22:32430097	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs4466137	0.645	rs6894022	chr5:82982945	T/C	cg16102102	chr5:83017553	HAPLN1	-0.53	-10.46	-0.44	3.79e-23	Prostate cancer;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs8067545	0.611	rs1974745	chr17:20059824	C/G	cg13482628	chr17:19912719	NA	0.54	10.22	0.43	2.93e-22	Schizophrenia;
LGG	cis	rs4319547	0.695	rs4758643	chr12:122924819	A/T	cg23029597	chr12:123009494	RSRC2	-0.93	-17.17	-0.62	1.73e-51	Body mass index;
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs11971779	0.680	rs11772026	chr7:139052589	T/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	trans	rs6787172	0.702	rs1526191	chr3:158018165	G/A	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs79349575	0.811	rs12601072	chr17:46997998	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs968567	0.705	rs174573	chr11:61600327	G/A	cg19610905	chr11:61596333	FADS2	-0.74	-11.65	-0.48	1.15e-27	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	trans	rs9467711	0.790	rs10484439	chr6:26309908	G/A	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.55	-0.41	7.62e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9790314	0.690	rs6783085	chr3:160830929	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.29	-0.43	1.71e-22	Morning vs. evening chronotype;
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg07915516	chr16:377344	AXIN1	0.28	7.38	0.32	7.17e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg23649088	chr2:200775458	C2orf69	0.39	6.81	0.3	3.1e-11	Asthma (bronchodilator response);
LGG	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg24011408	chr12:48396354	COL2A1	0.5	7.86	0.34	2.66e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg04025307	chr7:1156635	C7orf50	0.81	14.73	0.56	1.43e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.0	-0.52	3.76e-33	Aortic root size;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg23758822	chr17:41437982	NA	0.9	15.64	0.59	1.41e-44	Menopause (age at onset);
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.06e-43	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2587949	0.615	rs795301	chr3:4168641	T/C	cg16519197	chr3:4211558	NA	-0.35	-7.1	-0.31	4.85e-12	Periodontitis (DPAL);
LGG	cis	rs2011503	0.891	rs2965186	chr19:19497195	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.65	-0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.55	-0.41	7.54e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8044868	0.548	rs3852784	chr16:72185001	G/A	cg23815491	chr16:72088622	HP	0.37	7.8	0.34	4.23e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs12200560	0.505	rs984519	chr6:97076223	A/G	cg06623918	chr6:96969491	KIAA0776	-0.44	-7.52	-0.33	2.84e-13	Coronary heart disease;
LGG	cis	rs3771570	0.901	rs9052	chr2:242434809	G/T	cg21155796	chr2:242212141	HDLBP	0.57	7.73	0.34	6.59e-14	Prostate cancer;
LGG	cis	rs60012524	1	rs60012524	chr2:99559117	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-10.77	-0.45	2.65e-24	Chronic sinus infection;
LGG	cis	rs1185460	0.967	rs1784461	chr11:118937985	G/A	cg23280166	chr11:118938394	VPS11	0.6	11.25	0.46	4.08e-26	Coronary artery disease;
LGG	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg01200585	chr1:228362443	C1orf69	-0.44	-7.79	-0.34	4.56e-14	Diastolic blood pressure;
LGG	cis	rs35306767	0.903	rs7077278	chr10:911291	A/G	cg08847335	chr10:891726	LARP4B	0.51	9.22	0.39	1.05e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg17595323	chr11:93583763	C11orf90	-0.43	-7.66	-0.34	1.08e-13	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs72991	0.793	rs10750190	chr11:121236195	T/G	cg27192990	chr6:129479024	LAMA2	-0.45	-7.62	-0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg13402656	chr8:1511478	DLGAP2	-0.62	-10.79	-0.45	2.29e-24	Lung cancer;
LGG	cis	rs926938	0.618	rs360617	chr1:115404099	G/A	cg12756093	chr1:115239321	AMPD1	0.46	8.65	0.37	8.49e-17	Autism;
LGG	cis	rs926938	0.765	rs12407408	chr1:115234275	A/G	cg12756093	chr1:115239321	AMPD1	0.55	10.42	0.44	5.67e-23	Autism;
LGG	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg00376283	chr12:123451042	ABCB9	0.62	9.35	0.4	3.81e-19	Neutrophil percentage of white cells;
LGG	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg14416269	chr4:6271139	WFS1	0.52	9.51	0.4	1.07e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg24209194	chr3:40518798	ZNF619	0.44	6.98	0.31	1.01e-11	Renal cell carcinoma;
LGG	cis	rs2836950	1.000	rs2836950	chr21:40604429	C/G	cg11644478	chr21:40555479	PSMG1	-0.54	-8.54	-0.37	1.91e-16	Menarche (age at onset);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.96	0.42	2.72e-21	Prudent dietary pattern;
LGG	trans	rs9467603	1.000	rs6939997	chr6:25821224	C/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.65	-0.3	8.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4742903	0.904	rs10820628	chr9:107007188	G/T	cg14250997	chr9:106856677	SMC2	0.37	7.61	0.33	1.6e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs17689437	0.647	rs820799	chr16:68559537	C/A	cg02972257	chr16:68554789	NA	-0.42	-7.09	-0.31	5.07e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.19	-0.36	2.56e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs981844	0.712	rs1350189	chr4:154744951	A/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.75	-0.41	1.53e-20	Response to statins (LDL cholesterol change);
LGG	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.49	-0.47	4.8e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3796352	1.000	rs11718752	chr3:53130745	T/C	cg12962167	chr3:53033115	SFMBT1	0.64	6.99	0.31	9.36e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs908922	0.676	rs478926	chr1:152511533	G/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.61	-0.33	1.58e-13	HDL cholesterol;
LGG	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg15704280	chr7:45808275	SEPT13	0.69	9.86	0.42	6.02e-21	Intraocular pressure;
LGG	cis	rs734999	0.566	rs4648563	chr1:2536002	C/G	cg15627072	chr1:2432621	PLCH2	0.37	8.06	0.35	6.35e-15	Ulcerative colitis;
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.01	0.35	9.62e-15	Prostate cancer;
LGG	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.6	-0.51	1.65e-31	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg23758822	chr17:41437982	NA	0.84	15.05	0.57	6.18e-42	Menopause (age at onset);
LGG	cis	rs17665859	0.844	rs73175035	chr8:460615	A/C	cg17960703	chr8:356704	FBXO25	0.94	8.27	0.36	1.46e-15	Bilirubin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19986472	chr17:41561315	DHX8	0.42	6.92	0.31	1.52e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	0.42	6.74	0.3	4.7e-11	Cognitive performance;
LGG	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg12402800	chr5:56204917	C5orf35	0.46	6.98	0.31	1.04e-11	Initial pursuit acceleration;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.84e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-7.93	-0.35	1.62e-14	Menarche (age at onset);
LGG	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg02753203	chr1:228287806	NA	-0.64	-11.64	-0.48	1.19e-27	Diastolic blood pressure;
LGG	cis	rs368123	1.000	rs370301	chr6:160738743	C/G	cg07349212	chr6:160770346	SLC22A3	-0.36	-7.8	-0.34	4.04e-14	Waist circumference;
LGG	cis	rs6977660	0.714	rs10236607	chr7:19818620	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.1	0.42	8.39e-22	Thyroid stimulating hormone;
LGG	cis	rs2235642	0.750	rs763152	chr16:1658056	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	9.01	0.39	5.58e-18	Coronary artery disease;
LGG	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg16850897	chr7:100343110	ZAN	0.49	8.13	0.35	3.88e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12580194	0.593	rs61957884	chr12:55720177	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.44	-0.4	1.76e-19	Cancer;
LGG	cis	rs7296418	0.961	rs949143	chr12:123595163	G/A	cg05973401	chr12:123451056	ABCB9	0.46	7.79	0.34	4.48e-14	Platelet count;
LGG	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg05793240	chr7:2802953	GNA12	0.31	7.45	0.33	4.73e-13	Height;
LGG	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg19628046	chr18:33552617	C18orf21	0.5	7.35	0.32	9.16e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4950322	0.570	rs4950400	chr1:146791101	C/G	cg22381352	chr1:146742008	CHD1L	0.5	8.12	0.35	4.15e-15	Protein quantitative trait loci;
LGG	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg12419862	chr22:24373484	LOC391322	0.88	13.34	0.53	1.42e-34	S-phenylmercapturic acid levels in smokers;
LGG	cis	rs12824058	0.831	rs4759655	chr12:130815740	A/G	cg23887609	chr12:130822674	PIWIL1	-0.55	-9.66	-0.41	3.2e-20	Menopause (age at onset);
LGG	cis	rs17253792	0.915	rs79894275	chr14:56180285	C/T	cg01858014	chr14:56050164	KTN1	-0.78	-10.01	-0.42	1.77e-21	Putamen volume;
LGG	trans	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg16141378	chr3:129829833	LOC729375	0.33	7.69	0.34	9.13e-14	Monocyte count;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg06916706	chr16:4465613	CORO7	-1.11	-21.37	-0.7	5.13e-71	Schizophrenia;
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.36	0.43	9.29e-23	Total body bone mineral density;
LGG	cis	rs10850519	0.751	rs11613201	chr12:115944305	C/T	cg18639984	chr12:115943877	NA	-0.42	-9.05	-0.39	3.84e-18	Diastolic blood pressure;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.04	0.31	6.8e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-14.24	-0.55	1.95e-38	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	6.84e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs703842	0.616	rs10783850	chr12:58229377	T/C	cg02175503	chr12:58329896	NA	0.49	7.72	0.34	7.18e-14	Multiple sclerosis;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg01400477	chr2:170218258	LRP2	0.38	6.75	0.3	4.31e-11	Eye color traits;
LGG	cis	rs4696584	0.877	rs72725351	chr4:155397357	A/C	cg04517429	chr4:155413618	DCHS2	-0.31	-7.01	-0.31	8.61e-12	Folding of antihelix;
LGG	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg01620082	chr3:125678407	NA	-1.1	-10.41	-0.44	5.92e-23	Depression;
LGG	cis	rs11771526	0.786	rs11768955	chr7:32378706	T/C	cg27532318	chr7:32358331	NA	0.85	7.43	0.33	5.17e-13	Body mass index;
LGG	trans	rs11039798	0.623	rs6485879	chr11:48587984	G/T	cg15704280	chr7:45808275	SEPT13	0.74	10.2	0.43	3.47e-22	Axial length;
LGG	cis	rs12425451	0.520	rs10774107	chr12:3171510	C/T	cg05389053	chr12:3131226	TEAD4	0.41	7.21	0.32	2.34e-12	Narcolepsy with cataplexy;
LGG	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.47	-7.53	-0.33	2.76e-13	Body mass index;
LGG	cis	rs7159888	0.510	rs10047879	chr14:65760543	C/A	cg15999311	chr14:65749247	NA	0.44	7.62	0.33	1.48e-13	IgG glycosylation;N-glycan levels;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs2013441	1.000	rs2013441	chr17:20023099	G/A	cg13482628	chr17:19912719	NA	0.51	9.47	0.4	1.48e-19	Obesity-related traits;
LGG	cis	rs151997	0.925	rs27287	chr5:50195567	C/A	cg06027927	chr5:50259733	NA	0.67	10.94	0.45	6.22e-25	Callous-unemotional behaviour;
LGG	trans	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg26384229	chr12:38710491	ALG10B	0.75	13.93	0.54	4.44e-37	Resting heart rate;
LGG	cis	rs12586317	0.547	rs77780729	chr14:35496176	C/A	cg05294307	chr14:35346193	BAZ1A	-0.56	-7.9	-0.34	2.03e-14	Psoriasis;
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.81	0.64	2.07e-54	Alzheimer's disease;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs7312933	0.618	rs7954523	chr12:42681508	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.63	0.33	1.32e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg01620082	chr3:125678407	NA	-0.74	-7.34	-0.32	9.88e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	trans	rs9657904	0.774	rs6795961	chr3:105524643	A/G	cg14088669	chr1:158435396	OR10K1	-0.43	-7.83	-0.34	3.46e-14	Multiple sclerosis;
LGG	trans	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.16e-27	Corneal astigmatism;
LGG	cis	rs11209002	0.571	rs7531772	chr1:67555516	T/C	cg02640540	chr1:67518911	SLC35D1	0.42	7.4	0.33	6.4e-13	Crohn's disease;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg02297831	chr4:17616191	MED28	-0.51	-9.56	-0.41	7.2e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs10883501	chr10:102238326	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.06	0.46	2.16e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.83	-0.42	7.49e-21	Triglycerides;
LGG	cis	rs67460515	0.567	rs34691229	chr3:160876897	G/T	cg04691961	chr3:161091175	C3orf57	-0.44	-8.59	-0.37	1.35e-16	Parkinson's disease;
LGG	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.53	-0.74	4.33e-81	Primary sclerosing cholangitis;
LGG	cis	rs854765	0.547	rs7212167	chr17:17913504	G/A	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.5	-0.61	1.93e-48	Total body bone mineral density;
LGG	cis	rs8062405	0.755	rs12445823	chr16:28588049	A/C	cg16576597	chr16:28551801	NUPR1	0.43	10.14	0.43	5.88e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11167764	1.000	rs10057309	chr5:141479870	T/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.85	-0.3	2.35e-11	Crohn's disease;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg25072359	chr17:41440525	NA	0.53	9.91	0.42	3.91e-21	Menopause (age at onset);
LGG	cis	rs13088281	1.000	rs13088281	chr3:53147576	A/C	cg12962167	chr3:53033115	SFMBT1	-0.69	-7.13	-0.31	3.97e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	9.25	0.39	8.49e-19	Height;
LGG	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.99	-0.74	2.92e-83	Primary sclerosing cholangitis;
LGG	cis	rs17641971	0.684	rs11990854	chr8:49992048	T/C	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17168838	chr19:54663528	LENG1	0.46	7.71	0.34	8.01e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.46	-0.37	3.43e-16	Retinal vascular caliber;
LGG	cis	rs7119	0.717	rs10519167	chr15:77723027	G/T	cg17802220	chr15:77601643	NA	-0.55	-12.35	-0.5	1.69e-30	Type 2 diabetes;
LGG	cis	rs9818758	0.607	rs73074866	chr3:49626666	C/T	cg00383909	chr3:49044727	WDR6	1.12	13.3	0.53	2.02e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg05335186	chr13:53173507	NA	0.43	8.48	0.37	3.07e-16	Lewy body disease;
LGG	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg17718321	chr1:152188247	HRNR	-0.42	-8.72	-0.38	4.92e-17	Inflammatory skin disease;
LGG	trans	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg02002194	chr4:3960332	NA	0.38	7.13	0.31	3.95e-12	Joint mobility (Beighton score);
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg11494091	chr17:61959527	GH2	-0.55	-8.89	-0.38	1.41e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg09904177	chr6:26538194	HMGN4	0.38	6.88	0.3	1.98e-11	Schizophrenia;
LGG	cis	rs7814319	0.966	rs13276829	chr8:97274990	G/A	cg20787634	chr8:97240163	UQCRB	-0.74	-16.91	-0.62	2.68e-50	Lung function (FVC);
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.0	-16.98	-0.62	1.26e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg05535760	chr7:792225	HEATR2	-0.77	-11.26	-0.46	3.55e-26	Cerebrospinal P-tau181p levels;
LGG	cis	rs7666738	0.830	rs1426662	chr4:98990319	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs477692	0.647	rs11016853	chr10:131443990	A/G	cg05714579	chr10:131428358	MGMT	-0.71	-15.98	-0.6	4.14e-46	Response to temozolomide;
LGG	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg07936489	chr17:37558343	FBXL20	0.85	15.99	0.6	3.77e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7737355	0.773	rs31252	chr5:130833433	T/C	cg06307176	chr5:131281290	NA	0.53	8.96	0.38	8.18e-18	Life satisfaction;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.7	-0.59	7.94e-45	Skin colour saturation;
LGG	cis	rs17453880	0.700	rs12655008	chr5:151999029	T/C	cg12297329	chr5:152029980	NA	0.68	14.86	0.57	3.91e-41	Subjective well-being;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.68	-0.37	6.94e-17	Life satisfaction;
LGG	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg16400903	chr5:693638	TPPP	0.45	6.83	0.3	2.7e-11	Obesity-related traits;
LGG	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg10494973	chr17:80897199	TBCD	-0.39	-6.78	-0.3	3.68e-11	Breast cancer;
LGG	cis	rs514406	0.861	rs12038438	chr1:53230581	A/T	cg24675658	chr1:53192096	ZYG11B	0.49	9.77	0.41	1.28e-20	Monocyte count;
LGG	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg05535760	chr7:792225	HEATR2	-0.84	-11.87	-0.48	1.53e-28	Cerebrospinal P-tau181p levels;
LGG	cis	rs13102973	1.000	rs4401503	chr4:135905125	G/A	cg14419869	chr4:135874104	NA	0.55	10.15	0.43	5.66e-22	Subjective well-being;
LGG	cis	rs2242663	0.861	rs1044522	chr11:66335832	G/A	cg01599099	chr11:66649832	PC	0.44	8.36	0.36	7.57e-16	Bipolar disorder;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg25811766	chr13:21894605	NA	0.75	13.76	0.54	2.32e-36	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.68	-0.41	2.58e-20	Life satisfaction;
LGG	cis	rs7103648	0.897	rs35032070	chr11:47408592	G/A	cg20307385	chr11:47447363	PSMC3	0.93	20.78	0.69	2.9e-68	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg02158880	chr13:53174818	NA	0.47	9.58	0.41	5.88e-20	Lewy body disease;
LGG	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs704	0.628	rs241775	chr17:26644668	C/T	cg10342447	chr17:26645325	TMEM97	0.42	7.83	0.34	3.46e-14	Osteoprotegerin levels;
LGG	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg18245976	chr7:158708271	WDR60	0.61	8.06	0.35	6.4e-15	Height;
LGG	cis	rs300703	0.515	rs300695	chr2:182644	C/A	cg24565620	chr2:194026	NA	0.65	10.23	0.43	2.77e-22	Blood protein levels;
LGG	cis	rs6964587	0.773	rs59242586	chr7:91918145	A/G	cg17063962	chr7:91808500	NA	0.47	8.17	0.35	3.05e-15	Breast cancer;
LGG	cis	rs7264396	0.790	rs3787164	chr20:34228866	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.65	-0.33	1.21e-13	Total cholesterol levels;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.72	-13.33	-0.53	1.47e-34	Lymphocyte counts;
LGG	cis	rs4660214	0.666	rs3116398	chr1:39779802	C/T	cg18385671	chr1:39797026	MACF1	-0.46	-9.47	-0.4	1.4e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7766436	0.524	rs1317258	chr6:22513446	G/A	cg13666174	chr6:22585274	NA	-0.44	-8.68	-0.37	7.03e-17	Coronary artery disease;
LGG	cis	rs6784615	0.744	rs4687614	chr3:52492085	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.6	-7.41	-0.33	5.97e-13	Waist-hip ratio;
LGG	cis	rs798766	1.000	rs2236786	chr4:1719294	T/C	cg00006948	chr4:1768889	NA	0.5	6.67	0.3	7.52e-11	Bladder cancer;Urinary bladder cancer;
LGG	trans	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.54	-9.71	-0.41	2.01e-20	Brugada syndrome;
LGG	cis	rs6976053	0.868	rs3087504	chr7:100486088	C/T	cg03098644	chr7:100410630	EPHB4	-0.4	-7.04	-0.31	6.88e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg12432903	chr7:1882776	MAD1L1	0.5	8.01	0.35	9.29e-15	Bipolar disorder;
LGG	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg20503657	chr10:835505	NA	0.54	7.08	0.31	5.29e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7481584	0.517	rs80872	chr11:3049984	G/T	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	trans	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs9467773	0.620	rs1490488	chr6:26614808	T/C	cg09904177	chr6:26538194	HMGN4	0.68	14.0	0.55	2.08e-37	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg22903471	chr2:27725779	GCKR	-0.36	-7.97	-0.35	1.21e-14	Oral cavity cancer;
LGG	cis	rs12579753	1.000	rs10862373	chr12:82250657	A/G	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.61	-0.44	1.09e-23	Resting heart rate;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21862992	chr11:68658383	NA	0.51	8.67	0.37	7.34e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4917300	0.606	rs4917286	chr8:143113916	A/G	cg06573787	chr8:143070187	NA	0.6	10.02	0.42	1.57e-21	Amyotrophic lateral sclerosis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05918376	chr6:168898226	SMOC2	0.37	6.89	0.3	1.86e-11	Electrocardiographic conduction measures;
LGG	cis	rs2153535	0.562	rs10458225	chr6:8386004	G/A	cg23788917	chr6:8435910	SLC35B3	-0.52	-8.78	-0.38	3.08e-17	Motion sickness;
LGG	trans	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	3.9e-11	Cognitive function;
LGG	cis	rs4888262	0.526	rs4404098	chr16:74570050	G/A	cg01733217	chr16:74700730	RFWD3	0.81	15.86	0.59	1.45e-45	Testicular germ cell tumor;
LGG	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg12463550	chr7:65579703	CRCP	0.5	8.24	0.36	1.77e-15	Aortic root size;
LGG	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg05425664	chr17:57184151	TRIM37	-0.43	-6.75	-0.3	4.32e-11	Testicular germ cell tumor;
LGG	cis	rs4566357	1.000	rs2177598	chr2:227922900	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	cis	rs6445975	0.666	rs4681683	chr3:58347685	C/G	cg24175188	chr3:58374923	PXK	0.54	8.79	0.38	2.93e-17	Systemic lupus erythematosus;
LGG	cis	rs77633900	0.614	rs2468120	chr15:76909975	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-10.3	-0.43	1.49e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25072359	chr17:41440525	NA	0.52	10.15	0.43	5.51e-22	Menopause (age at onset);
LGG	cis	rs9790314	0.871	rs336561	chr3:161125305	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.36	-0.47	1.44e-26	Morning vs. evening chronotype;
LGG	cis	rs10782582	0.593	rs6673786	chr1:76149637	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-6.85	-0.3	2.37e-11	Daytime sleep phenotypes;
LGG	cis	rs12681287	0.640	rs7460650	chr8:87474085	A/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg06521331	chr12:34319734	NA	0.39	6.68	0.3	7.08e-11	Morning vs. evening chronotype;
LGG	cis	rs2073499	1.000	rs6776145	chr3:50316119	C/T	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.61	-7.11	-0.31	4.47e-12	Schizophrenia;
LGG	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.58	-0.41	5.94e-20	Parkinson's disease;
LGG	trans	rs62103177	0.564	rs7228971	chr18:77738025	C/T	cg14227996	chr4:17616232	MED28	-0.61	-7.24	-0.32	1.83e-12	Opioid sensitivity;
LGG	cis	rs283228	0.550	rs2787582	chr6:101814576	T/C	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6142618	0.562	rs6089193	chr20:30729488	T/C	cg00028034	chr20:30779307	TSPYL3	0.34	7.52	0.33	2.84e-13	Inflammatory bowel disease;
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.17	0.58	1.75e-42	Alzheimer's disease;
LGG	cis	rs7166081	0.950	rs12915601	chr15:67631271	T/C	cg05925327	chr15:68127851	NA	-0.33	-6.97	-0.31	1.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7914558	0.966	rs56946876	chr10:104653545	T/C	cg04362960	chr10:104952993	NT5C2	0.52	9.87	0.42	5.71e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24038780	chr13:78271500	SLAIN1	0.48	7.38	0.32	7.61e-13	Gut microbiome composition (summer);
LGG	trans	rs2235573	0.517	rs4821727	chr22:38393423	C/A	cg19894588	chr14:64061835	NA	0.58	9.73	0.41	1.74e-20	Glioblastoma;Glioma;
LGG	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.12	-0.39	2.35e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1005224	0.926	rs7143743	chr14:76127805	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-6.91	-0.31	1.65e-11	Large artery stroke;
LGG	cis	rs13177180	0.698	rs372702	chr5:114862608	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.34	7.36	0.32	8.33e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.6	-0.47	1.74e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.72	-0.41	1.84e-20	Lung cancer;
LGG	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg21862992	chr11:68658383	NA	0.5	8.35	0.36	7.95e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg06873352	chr17:61820015	STRADA	0.73	13.71	0.54	3.97e-36	Prudent dietary pattern;
LGG	cis	rs7226408	0.857	rs11660125	chr18:34476622	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4595586	0.655	rs11170269	chr12:39387077	G/A	cg26384229	chr12:38710491	ALG10B	0.47	8.47	0.37	3.18e-16	Morning vs. evening chronotype;
LGG	cis	rs870825	0.616	rs7694899	chr4:185625390	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.55	0.72	1.49e-76	Blood protein levels;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg05368731	chr17:41323189	NBR1	0.97	18.98	0.66	7.56e-60	Menopause (age at onset);
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-9.97	-0.42	2.36e-21	Platelet count;
LGG	cis	rs9527	0.590	rs1926037	chr10:104878010	A/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.17e-26	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg03606772	chr1:152487856	CRCT1	0.31	7.34	0.32	9.75e-13	Hair morphology;
LGG	cis	rs7953508	0.711	rs11107116	chr12:93978504	G/T	cg18151635	chr12:93972918	NA	-0.49	-8.66	-0.37	7.71e-17	Pubertal anthropometrics;
LGG	cis	rs8072100	0.713	rs9899859	chr17:45513049	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.24	-0.36	1.84e-15	Retinal vascular caliber;
LGG	cis	rs4356932	1.000	rs1554013	chr4:76933484	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.41	-6.82	-0.3	2.78e-11	Blood protein levels;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.43	-0.33	5.2e-13	Personality dimensions;
LGG	cis	rs7619833	0.719	rs571978	chr3:27344193	A/G	cg02860705	chr3:27208620	NA	0.39	7.48	0.33	3.82e-13	Breast cancer;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg08824895	chr13:115047677	UPF3A	0.41	6.95	0.31	1.28e-11	Schizophrenia;
LGG	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	trans	rs62458065	0.713	rs921406	chr7:32486205	G/C	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.89	-0.3	1.79e-11	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs227584	0.501	rs62078931	chr17:42198059	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.49	-9.35	-0.4	3.76e-19	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs9625935	0.518	rs5752972	chr22:30250312	A/T	cg01021169	chr22:30184971	ASCC2	0.35	6.82	0.3	2.81e-11	Tonsillectomy;
LGG	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg16230307	chr14:35515116	FAM177A1	0.61	9.24	0.39	8.95e-19	Psoriasis;
LGG	cis	rs6430585	0.528	rs111682961	chr2:136653848	C/T	cg07169764	chr2:136633963	MCM6	1.24	22.57	0.72	1.32e-76	Corneal structure;
LGG	trans	rs7939886	0.920	rs11227273	chr11:55893034	T/G	cg02254774	chr11:50257496	LOC441601	0.58	6.76	0.3	4.06e-11	Myopia (pathological);
LGG	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg02023728	chr11:77925099	USP35	-0.38	-6.75	-0.3	4.53e-11	Alzheimer's disease (survival time);
LGG	cis	rs972578	0.791	rs9611953	chr22:43279282	A/G	cg01576275	chr22:43409880	NA	-0.23	-7.0	-0.31	9.33e-12	Mean platelet volume;
LGG	cis	rs2439831	0.850	rs2439832	chr15:43779686	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	11.78	0.48	3.37e-28	Lung cancer in ever smokers;
LGG	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg00938859	chr5:1591904	SDHAP3	0.89	13.16	0.52	8.07e-34	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19410845	chr2:84686791	SUCLG1	0.43	7.44	0.33	4.84e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg13385794	chr1:248469461	NA	-0.5	-8.47	-0.37	3.24e-16	Common traits (Other);
LGG	cis	rs9790314	0.690	rs1903423	chr3:160842252	A/G	cg03342759	chr3:160939853	NMD3	-0.6	-10.9	-0.45	8.56e-25	Morning vs. evening chronotype;
LGG	cis	rs35771425	0.551	rs35711226	chr1:211523564	T/C	cg10512769	chr1:211675356	NA	-0.63	-8.31	-0.36	1.1e-15	Educational attainment (years of education);
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14159672	chr1:205819179	PM20D1	0.44	6.95	0.31	1.26e-11	Parkinson's disease;
LGG	trans	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg23762105	chr12:34175262	ALG10	-0.34	-6.84	-0.3	2.55e-11	Morning vs. evening chronotype;
LGG	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg07882059	chr11:68924751	NA	0.41	7.39	0.32	6.87e-13	Blond vs. brown hair color;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg00761968	chr13:53314142	LECT1	0.39	8.48	0.37	2.95e-16	Lewy body disease;
LGG	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg16797656	chr11:68205561	LRP5	-0.38	-6.76	-0.3	4.14e-11	Total body bone mineral density;
LGG	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg05425664	chr17:57184151	TRIM37	-0.63	-9.99	-0.42	2.09e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16524936	chr4:1340807	KIAA1530	-0.45	-7.36	-0.32	8.41e-13	Longevity;
LGG	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg06827562	chr3:125932279	NA	-0.5	-12.03	-0.49	3.37e-29	Metabolite levels;
LGG	cis	rs28830936	0.966	rs1107858	chr15:41968226	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.56	-12.9	-0.51	9.7e-33	Diastolic blood pressure;
LGG	cis	rs11098499	0.909	rs28581362	chr4:120283548	T/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs2735413	0.564	rs4324138	chr16:78101372	A/C	cg04733911	chr16:78082701	NA	0.6	8.68	0.37	6.8e-17	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg12313892	chr15:70169052	NA	0.39	7.22	0.32	2.12e-12	Electrocardiographic conduction measures;
LGG	cis	rs6489785	0.735	rs11065286	chr12:121271734	C/T	cg02419362	chr12:121203948	SPPL3	-0.42	-6.97	-0.31	1.09e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10782582	0.593	rs11579752	chr1:76178694	C/T	cg03433033	chr1:76189801	ACADM	-0.43	-6.72	-0.3	5.33e-11	Daytime sleep phenotypes;
LGG	cis	rs7618915	0.570	rs11130312	chr3:52675055	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs796364	0.806	rs203766	chr2:200902672	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-9.34	-0.4	3.94e-19	Schizophrenia;
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.87e-12	Life satisfaction;
LGG	cis	rs11229555	0.598	rs12276438	chr11:58185419	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg25457927	chr22:38595422	NA	-0.41	-10.6	-0.44	1.24e-23	Cutaneous nevi;
LGG	cis	rs9783347	0.621	rs11024606	chr11:18317864	C/A	cg03595886	chr11:18357587	GTF2H1	-0.49	-12.0	-0.49	4.69e-29	Pancreatic cancer;
LGG	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg16339924	chr4:17578868	LAP3	0.58	10.21	0.43	3.36e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.86	-0.3	2.23e-11	Blood metabolite levels;
LGG	trans	rs1032833	0.732	rs75929971	chr2:179959838	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.68	0.37	6.76e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs3008870	0.755	rs10749766	chr1:67376921	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.75	15.38	0.58	2.05e-43	Lymphocyte percentage of white cells;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	6.12e-20	Life satisfaction;
LGG	cis	rs12505749	0.542	rs4618376	chr4:57345659	G/A	cg07846311	chr4:57371927	ARL9	-0.32	-7.94	-0.35	1.52e-14	Airflow obstruction;
LGG	cis	rs7508	0.680	rs7386629	chr8:17920361	A/G	cg18067069	chr8:17937731	ASAH1	0.38	8.52	0.37	2.3e-16	Atrial fibrillation;
LGG	cis	rs35146811	0.586	rs12666107	chr7:99778019	G/C	cg22906224	chr7:99728672	NA	0.54	8.24	0.36	1.78e-15	Coronary artery disease;
LGG	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.4	0.44	6.32e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg01420254	chr6:26195488	NA	0.83	10.75	0.45	3.37e-24	Gout;Renal underexcretion gout;
LGG	cis	rs9358372	0.929	rs4712553	chr6:20818539	T/A	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.47	-0.58	7.84e-44	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg05941027	chr17:61774174	LIMD2	0.31	7.3	0.32	1.3e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-20.92	-0.7	6.71e-69	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7212938	0.509	rs62068170	chr17:38103210	G/A	cg17467752	chr17:38218738	THRA	0.47	7.83	0.34	3.47e-14	Asthma and hay fever;
LGG	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg17644776	chr2:200775616	C2orf69	-0.6	-7.09	-0.31	4.9e-12	Schizophrenia;
LGG	cis	rs7119	0.717	rs12901100	chr15:77815558	T/A	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs9397585	0.637	rs687508	chr6:153406657	G/A	cg17707550	chr6:153380415	RGS17	-0.44	-9.77	-0.41	1.29e-20	Body mass index;
LGG	cis	rs9341808	0.718	rs10943696	chr6:80901272	C/G	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	trans	rs6940638	0.956	rs12199218	chr6:27025281	T/C	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.2	-0.32	2.52e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg12070911	chr6:150209640	RAET1E	0.29	7.05	0.31	6.68e-12	Lung cancer;
LGG	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	8.49	0.37	2.84e-16	Coronary artery disease;
LGG	trans	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg25214090	chr10:38739885	LOC399744	-0.57	-10.13	-0.43	6.35e-22	Corneal astigmatism;
LGG	cis	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg17545662	chr6:170176663	C6orf70	0.7	8.98	0.38	7.08e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg15621731	chr19:5074616	KDM4B	0.31	7.52	0.33	2.86e-13	Monocyte percentage of white cells;
LGG	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.52	0.47	3.48e-27	Mean platelet volume;
LGG	cis	rs36051895	0.589	rs4560849	chr9:5203866	C/G	cg02405213	chr9:5042618	JAK2	-0.73	-13.3	-0.53	2.07e-34	Pediatric autoimmune diseases;
LGG	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg09873164	chr1:152488093	CRCT1	0.64	15.59	0.59	2.34e-44	Hair morphology;
LGG	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4808199	0.847	rs34647936	chr19:19548239	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.39	0.32	7.01e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs858239	0.665	rs6964665	chr7:23211352	G/A	cg23682824	chr7:23144976	KLHL7	0.41	6.88	0.3	1.95e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.26	0.36	1.51e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs698833	0.926	rs1067399	chr2:44678648	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.79	0.3	3.5e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.98	-0.39	6.86e-18	Mean corpuscular volume;
LGG	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg08564027	chr20:61660810	NA	-1.03	-26.01	-0.77	1.37e-92	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9815354	1.000	rs1125203	chr3:41760895	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.59	0.33	1.76e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1568889	1.000	rs61889046	chr11:28297024	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	14.67	0.56	2.64e-40	Bipolar disorder;
LGG	cis	rs4363385	0.720	rs1415967	chr1:152965585	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.08	-0.39	3.1e-18	Inflammatory skin disease;
LGG	cis	rs2635047	0.638	rs2571006	chr18:44718515	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.62	0.33	1.44e-13	Educational attainment;
LGG	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg08400814	chr5:56204995	C5orf35	-0.44	-7.07	-0.31	5.7e-12	Initial pursuit acceleration;
LGG	cis	rs259282	0.524	rs4805006	chr19:33124136	G/T	cg02997394	chr19:33096574	ANKRD27	-0.39	-7.46	-0.33	4.38e-13	Schizophrenia;
LGG	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg17749961	chr2:30669863	LCLAT1	0.7	9.97	0.42	2.52e-21	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs9815354	0.812	rs73073355	chr3:41842332	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3735485	0.598	rs10251344	chr7:45096436	G/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2072499	0.932	rs2540183	chr1:156164885	C/G	cg06970220	chr1:156163860	SLC25A44	0.46	6.77	0.3	3.85e-11	Testicular germ cell tumor;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg02475777	chr4:1388615	CRIPAK	0.4	7.22	0.32	2.08e-12	Longevity;
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.72	-0.38	5.15e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10905876	chr6:56716656	DST	0.42	6.71	0.3	5.7e-11	Cognitive performance;
LGG	cis	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.67	0.59	1e-44	Platelet count;
LGG	cis	rs2735413	0.794	rs55951868	chr16:78078804	C/A	cg04733911	chr16:78082701	NA	-0.75	-17.37	-0.63	2.04e-52	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7264396	0.635	rs6058365	chr20:34508092	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.96	-0.31	1.17e-11	Total cholesterol levels;
LGG	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg21401794	chr1:90099060	LRRC8C	0.55	10.38	0.43	7.73e-23	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9527	0.662	rs10786714	chr10:104598606	G/C	cg04362960	chr10:104952993	NT5C2	0.51	9.13	0.39	2.12e-18	Arsenic metabolism;
LGG	cis	rs1408799	0.679	rs7025953	chr9:12760718	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	4.99e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	10.89	0.45	1e-24	Longevity;
LGG	cis	rs55883249	1.000	rs10495571	chr2:9736066	A/G	cg23886495	chr2:9695866	ADAM17	0.63	9.03	0.39	4.56e-18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04602207	chr12:104324023	LOC253724;HSP90B1	0.39	7.01	0.31	8.3e-12	Obesity-related traits;
LGG	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.31	-0.5	2.56e-30	Height;
LGG	cis	rs4731207	0.564	rs6977313	chr7:124681732	C/T	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	trans	rs9325144	0.505	rs901635	chr12:38646572	A/C	cg06521331	chr12:34319734	NA	0.41	6.95	0.31	1.26e-11	Morning vs. evening chronotype;
LGG	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19524238	chr7:2802976	GNA12	0.32	7.86	0.34	2.77e-14	Height;
LGG	trans	rs11989744	0.843	rs10481325	chr8:23560896	G/A	cg03492747	chr16:86543808	FOXF1	0.55	8.39	0.36	6.15e-16	Waist-hip ratio;
LGG	cis	rs10979	1.000	rs9484767	chr6:143887912	C/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.47	-0.5	5.64e-31	Hypospadias;
LGG	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-10.03	-0.42	1.54e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg11584989	chr19:19387371	SF4	0.43	7.8	0.34	4.28e-14	Tonsillectomy;
LGG	cis	rs4604732	0.603	rs10802513	chr1:247633919	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.37	0.36	6.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2235642	0.601	rs2235647	chr16:1601331	C/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.43	0.33	5.2e-13	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs4595586	0.655	rs7953715	chr12:39325539	T/C	cg13010199	chr12:38710504	ALG10B	0.36	6.86	0.3	2.27e-11	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.529	rs850851	chr17:42177674	C/T	cg19774624	chr17:42201019	HDAC5	0.64	11.33	0.47	1.89e-26	Total body bone mineral density;
LGG	cis	rs897080	0.552	rs1067388	chr2:44642482	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	3.93e-11	Height;
LGG	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg26076054	chr5:421317	AHRR	-0.48	-7.95	-0.35	1.48e-14	Cystic fibrosis severity;
LGG	cis	rs7481584	0.961	rs729662	chr11:3028140	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.3	-0.36	1.18e-15	Calcium levels;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.57	9.99	0.42	2.07e-21	Longevity;
LGG	cis	rs11877825	0.762	rs9676152	chr18:10571440	C/T	cg25239095	chr18:10589360	NA	0.49	9.0	0.39	6.02e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.22	-0.39	1.07e-18	Neuroticism;
LGG	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-16.81	-0.62	7.72e-50	Chronic sinus infection;
LGG	cis	rs981844	0.816	rs56109239	chr4:154726500	A/G	cg14289246	chr4:154710475	SFRP2	0.73	11.89	0.48	1.25e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs3780378	0.967	rs62543876	chr9:5085859	G/C	cg02405213	chr9:5042618	JAK2	-0.48	-8.27	-0.36	1.48e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.02e-24	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs208520	0.690	rs12208977	chr6:66725257	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.71	0.64	5.77e-54	Exhaled nitric oxide output;
LGG	cis	rs9359856	0.564	rs56281344	chr6:90445393	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-9.86	-0.42	5.97e-21	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-13.47	-0.53	3.9e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg01620082	chr3:125678407	NA	-0.74	-8.16	-0.35	3.22e-15	Depression;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs7552404	0.727	rs2172508	chr1:76320215	A/G	cg10523679	chr1:76189770	ACADM	0.72	11.22	0.46	5.06e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.53	-0.37	2.05e-16	Triglycerides;
LGG	cis	rs8060686	0.545	rs12444188	chr16:68282077	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.7	-0.3	6.06e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4262150	0.883	rs72802882	chr5:152242673	C/T	cg12297329	chr5:152029980	NA	-0.66	-12.4	-0.5	1.12e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.754	rs938056	chr4:120237453	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.13	0.46	1.13e-25	Corneal astigmatism;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg19168338	chr16:4465731	CORO7	-0.78	-14.82	-0.57	6.11e-41	Schizophrenia;
LGG	cis	rs9611519	1.000	rs6002271	chr22:41566595	C/T	cg03806693	chr22:41940476	POLR3H	-0.56	-8.55	-0.37	1.85e-16	Neuroticism;
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.47	-0.33	4.04e-13	Personality dimensions;
LGG	cis	rs10056811	0.556	rs55810502	chr5:74380959	A/G	cg19683494	chr5:74908142	NA	0.48	6.7	0.3	5.92e-11	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg04863758	chr4:1303710	MAEA	0.45	7.99	0.35	1.08e-14	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg09699651	chr6:150184138	LRP11	0.54	9.33	0.4	4.31e-19	Lung cancer;
LGG	cis	rs8056893	0.543	rs3785115	chr16:68372573	T/G	cg07273125	chr16:68295692	NA	0.39	8.5	0.37	2.72e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4423214	0.840	rs1792231	chr11:71182681	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	8.45e-26	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01384173	chr19:17564348	NA	0.44	6.87	0.3	2.11e-11	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.840	rs12482317	chr21:40588241	A/G	cg11644478	chr21:40555479	PSMG1	-0.56	-9.06	-0.39	3.65e-18	Menarche (age at onset);
LGG	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg01346077	chr3:125931526	NA	0.43	11.17	0.46	8e-26	Metabolite levels;
LGG	cis	rs8072100	0.713	rs4968318	chr17:45451894	G/A	cg25173405	chr17:45401733	C17orf57	-0.54	-9.0	-0.39	5.68e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9660992	0.710	rs1768587	chr1:205236432	C/T	cg21545522	chr1:205238299	TMCC2	0.49	8.98	0.39	6.64e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg13986417	chr12:110012484	MVK;MMAB	-0.49	-10.92	-0.45	7.3e-25	Age-related nuclear cataracts;
LGG	cis	rs2075371	0.966	rs1646646	chr7:133996905	G/T	cg11752832	chr7:134001865	SLC35B4	0.63	11.57	0.47	2.36e-27	Mean platelet volume;
LGG	cis	rs10489202	1.000	rs17485889	chr1:168018840	G/T	cg24449463	chr1:168025552	DCAF6	-0.62	-10.15	-0.43	5.59e-22	Schizophrenia;
LGG	cis	rs7940866	0.801	rs2113929	chr11:130835974	G/A	cg12179176	chr11:130786555	SNX19	0.73	13.66	0.54	6.13e-36	Schizophrenia;
LGG	trans	rs11875185	0.510	rs78947735	chr18:55593153	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	cis	rs3796619	1.000	rs11247973	chr4:1094314	G/A	cg27284194	chr4:1044797	NA	0.56	11.48	0.47	5.27e-27	Recombination rate (males);
LGG	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg02002194	chr4:3960332	NA	0.41	7.19	0.32	2.68e-12	Triglycerides;
LGG	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg16141378	chr3:129829833	LOC729375	0.38	8.27	0.36	1.45e-15	Retinal vascular caliber;
LGG	cis	rs7192750	0.586	rs2335710	chr16:71923181	C/G	cg06353428	chr16:71660113	MARVELD3	-0.66	-10.46	-0.44	4.05e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg02002194	chr4:3960332	NA	0.39	7.05	0.31	6.64e-12	Mood instability;
LGG	cis	rs8017423	0.874	rs2149656	chr14:90707508	A/C	cg04374321	chr14:90722782	PSMC1	0.87	18.22	0.65	2.59e-56	Mortality in heart failure;
LGG	cis	rs1577917	0.958	rs2875456	chr6:86602284	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.9	-0.42	4.53e-21	Response to antipsychotic treatment;
LGG	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2041895	0.509	rs7976343	chr12:107296028	T/C	cg15890332	chr12:107067104	RFX4	0.3	6.82	0.3	2.8e-11	Glaucoma (low intraocular pressure);
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg23782820	chr8:58130467	NA	0.53	7.42	0.33	5.78e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg06521331	chr12:34319734	NA	0.45	7.93	0.35	1.66e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8077889	0.917	rs58080788	chr17:41902909	A/G	cg26893861	chr17:41843967	DUSP3	0.9	15.49	0.58	6.74e-44	Triglycerides;
LGG	cis	rs774359	0.789	rs2764331	chr9:27492934	C/T	cg21249376	chr9:27528432	MOBKL2B	0.46	8.64	0.37	9.27e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-11.33	-0.47	2.06e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg18446336	chr7:2847575	GNA12	-0.31	-8.15	-0.35	3.47e-15	Height;
LGG	cis	rs3768617	0.510	rs2224933	chr1:183095765	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7590720	1.000	rs4674051	chr2:216907512	G/C	cg12620499	chr2:216877984	MREG	0.76	13.88	0.54	7.25e-37	Alcohol dependence;
LGG	cis	rs3008870	0.701	rs2815367	chr1:67500762	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.22	0.58	1.03e-42	Lymphocyte percentage of white cells;
LGG	cis	rs36051895	0.659	rs58345215	chr9:5043767	A/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.58	-0.59	2.61e-44	Pediatric autoimmune diseases;
LGG	cis	rs4665809	1.000	rs6729757	chr2:26285102	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.76	-0.34	5.59e-14	Gut microbiome composition (summer);
LGG	cis	rs908922	0.676	rs1337340	chr1:152508260	T/C	cg03606772	chr1:152487856	CRCT1	0.29	6.97	0.31	1.07e-11	Hair morphology;
LGG	cis	rs9398803	0.605	rs112166936	chr6:126733140	A/C	cg19875578	chr6:126661172	C6orf173	0.57	10.39	0.43	7.12e-23	Male-pattern baldness;
LGG	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg08297393	chr2:100937505	LONRF2	-0.53	-10.05	-0.42	1.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg07677032	chr17:61819896	STRADA	-0.61	-10.66	-0.44	6.81e-24	Prudent dietary pattern;
LGG	cis	rs4727443	0.736	rs11761882	chr7:99581469	T/C	cg12813108	chr7:99719912	CNPY4	-0.41	-7.33	-0.32	1.03e-12	Interstitial lung disease;
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.79	-0.3	3.36e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs912057	0.833	rs1294424	chr6:6744135	G/A	cg06612196	chr6:6737390	NA	0.46	9.35	0.4	3.7e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg15383120	chr6:291909	DUSP22	-0.54	-8.92	-0.38	1.06e-17	Menopause (age at onset);
LGG	cis	rs12532878	0.652	rs11768465	chr7:100198386	C/T	cg00334542	chr7:100209784	MOSPD3	-0.56	-8.06	-0.35	6.35e-15	Mean corpuscular hemoglobin;
LGG	cis	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg07460842	chr6:66804631	NA	0.96	17.75	0.64	3.69e-54	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg11062466	chr8:58055876	NA	0.44	7.35	0.32	9.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg05793240	chr7:2802953	GNA12	0.36	8.44	0.37	3.97e-16	Height;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03670158	chr17:41323431	NBR1	0.39	6.67	0.3	7.5e-11	Menarche (age at onset);
LGG	cis	rs5758511	0.680	rs5758688	chr22:42662501	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.43	0.33	5.2e-13	Birth weight;
LGG	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg00188032	chr5:96141721	ERAP1	0.53	7.24	0.32	1.86e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.3e-14	Tonsillectomy;
LGG	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg13628971	chr7:2884303	GNA12	0.56	11.92	0.48	9.19e-29	Height;
LGG	cis	rs7551222	0.663	rs1563828	chr1:204516577	A/G	cg20240347	chr1:204465584	NA	-0.53	-10.63	-0.44	9.22e-24	Schizophrenia;
LGG	cis	rs4604732	0.631	rs12031721	chr1:247623773	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.08	0.39	3.16e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs780094	0.544	rs780108	chr2:27684957	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.95	-0.35	1.45e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs12200782	1.000	rs12199239	chr6:26432570	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.16	-0.32	3.17e-12	Small cell lung carcinoma;
LGG	cis	rs807669	0.933	rs712959	chr22:19159015	C/T	cg02655711	chr22:19163373	SLC25A1	0.67	13.35	0.53	1.22e-34	Metabolite levels;
LGG	cis	rs9783347	0.621	rs11024613	chr11:18326542	T/C	cg15585147	chr11:18324498	HPS5	0.31	7.09	0.31	5.18e-12	Pancreatic cancer;
LGG	cis	rs61931739	0.500	rs7137392	chr12:34447074	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	trans	rs58106596	0.660	rs62197212	chr2:232562727	G/A	cg01370599	chr3:116745421	NA	0.82	12.03	0.49	3.52e-29	White blood cell count;Lymphocyte counts;
LGG	trans	rs35110281	0.627	rs56369437	chr21:44970275	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	11.43	0.47	7.85e-27	Mean corpuscular volume;
LGG	cis	rs941873	0.868	rs2181080	chr10:81121960	A/G	cg09469691	chr10:81107165	PPIF	0.63	10.98	0.45	4.3e-25	Height;
LGG	cis	rs7432375	1.000	rs10935186	chr3:136346206	T/C	cg12473912	chr3:136751656	NA	0.4	6.85	0.3	2.36e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13305585	chr1:235530624	TBCE	0.44	6.74	0.3	4.73e-11	Gut microbiome composition (summer);
LGG	cis	rs9462027	0.628	rs10738078	chr6:34693917	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs4787491	0.704	rs35605010	chr16:30033428	A/G	cg06326092	chr16:30034487	C16orf92	0.42	8.45	0.37	3.75e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs2013441	1.000	rs2703804	chr17:20107195	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs59197085	0.636	rs57072537	chr7:128435596	G/C	cg00734629	chr7:128471146	FLNC	0.34	6.65	0.3	8.36e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.57	0.37	1.52e-16	Alzheimer's disease;
LGG	cis	rs875971	0.964	rs9691480	chr7:65944306	A/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.13	0.43	6.27e-22	Schizophrenia;
LGG	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs6942756	1.000	rs6949950	chr7:128914818	G/A	cg02491457	chr7:128862824	NA	-0.76	-13.92	-0.54	4.73e-37	White matter hyperintensity burden;
LGG	cis	rs3741151	0.773	rs17244596	chr11:73179236	A/G	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4959677	0.935	rs4959187	chr6:2494871	A/G	cg23817096	chr6:1620687	NA	-0.31	-7.44	-0.33	4.99e-13	Orthostatic hypotension;
LGG	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.48	-0.33	3.76e-13	HDL cholesterol;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg06558623	chr16:89946397	TCF25	1.04	13.26	0.52	3.07e-34	Skin colour saturation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15238008	chr12:9600875	DDX12	0.42	7.04	0.31	7.05e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08109568	chr15:31115862	NA	-0.51	-7.81	-0.34	3.87e-14	Huntington's disease progression;
LGG	trans	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.7	0.48	6.83e-28	Corneal astigmatism;
LGG	trans	rs2018683	0.707	rs7799357	chr7:28970118	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.27	-0.4	7.34e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs4262150	0.667	rs2069117	chr5:152244551	A/C	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg04863758	chr4:1303710	MAEA	0.42	7.19	0.32	2.68e-12	Obesity-related traits;
LGG	cis	rs55883249	0.957	rs10495572	chr2:9734859	C/G	cg23886495	chr2:9695866	ADAM17	-0.63	-8.99	-0.39	6.42e-18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.55	-0.5	2.68e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.14e-14	HDL cholesterol;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs7760949	0.963	rs9382681	chr6:13915051	A/G	cg27413430	chr6:13925136	RNF182	0.43	6.7	0.3	6.04e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg15704280	chr7:45808275	SEPT13	-0.85	-16.7	-0.61	2.33e-49	Height;
LGG	cis	rs854037	0.595	rs35602156	chr5:57174009	C/T	cg08523694	chr5:57076192	NA	0.51	6.82	0.3	2.92e-11	Birth weight;
LGG	cis	rs2307022	0.541	rs1111572	chr16:68378749	G/A	cg07273125	chr16:68295692	NA	0.37	7.83	0.34	3.36e-14	Body mass index;
LGG	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.07e-16	Platelet distribution width;
LGG	cis	rs6732160	0.932	rs13417029	chr2:73380423	T/G	cg01422370	chr2:73384389	NA	0.53	10.16	0.43	5.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs116095464	0.558	rs6879656	chr5:264428	T/C	cg22496380	chr5:211416	CCDC127	-1.31	-18.5	-0.65	1.28e-57	Breast cancer;
LGG	cis	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg25427524	chr10:38739819	LOC399744	0.57	10.05	0.42	1.22e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.07	-0.78	1.9e-97	Height;
LGG	trans	rs1997103	1.000	rs2177805	chr7:55404381	T/A	cg20935933	chr6:143382018	AIG1	0.57	8.88	0.38	1.48e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3770081	1.000	rs11899576	chr2:86256193	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.93	-0.31	1.38e-11	Facial emotion recognition (sad faces);
LGG	trans	rs3857536	0.813	rs9363554	chr6:66930183	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.44	-7.37	-0.32	7.75e-13	Blood trace element (Cu levels);
LGG	cis	rs3820068	0.705	rs72645808	chr1:15870118	G/C	cg05660106	chr1:15850417	CASP9	1.15	25.31	0.76	2.29e-89	Systolic blood pressure;
LGG	cis	rs2131877	0.645	rs7644678	chr3:194876849	G/C	cg07250128	chr3:194833983	C3orf21	0.33	7.07	0.31	5.67e-12	Non-small cell lung cancer;
LGG	trans	rs1941687	0.797	rs7227708	chr18:31393091	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg13293535	chr8:11597251	GATA4	0.3	6.96	0.31	1.17e-11	Morning vs. evening chronotype;
LGG	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg05696931	chr1:227175867	NA	-0.43	-8.68	-0.37	6.62e-17	Myeloid white cell count;
LGG	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.51	-0.44	2.5e-23	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs12579753	0.917	rs11115058	chr12:82263427	T/C	cg07923666	chr12:49932857	KCNH3	-0.43	-6.65	-0.3	8.31e-11	Resting heart rate;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18124201	chr20:46414952	SULF2	0.52	8.44	0.37	4.05e-16	Cognitive performance;
LGG	cis	rs10193935	0.901	rs1496329	chr2:42688797	T/C	cg27598129	chr2:42591480	NA	0.67	9.72	0.41	1.84e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9354308	0.838	rs7769057	chr6:66540229	T/C	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	cis	rs7084402	0.967	rs1649042	chr10:60328663	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg18721089	chr20:30220636	NA	-0.52	-7.85	-0.34	2.94e-14	Mean corpuscular hemoglobin;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2046867	0.862	rs9827405	chr3:72827115	C/T	cg26655873	chr3:72818019	SHQ1	0.37	7.45	0.33	4.77e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7737355	0.812	rs2549017	chr5:130692045	A/G	cg06307176	chr5:131281290	NA	0.48	7.71	0.34	8.02e-14	Life satisfaction;
LGG	cis	rs8017423	0.647	rs12883000	chr14:90820557	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.68	10.52	0.44	2.39e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1497828	0.956	rs2815224	chr1:217529327	T/C	cg04411442	chr1:217543379	NA	-0.47	-8.02	-0.35	8.51e-15	Dialysis-related mortality;
LGG	cis	rs2797369	0.574	rs2764274	chr6:101668637	A/G	cg27451362	chr6:101846650	GRIK2	-0.46	-7.17	-0.32	2.9e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs6740322	0.643	rs13390381	chr2:43534414	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.57	-0.37	1.58e-16	Coronary artery disease;
LGG	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg17644776	chr2:200775616	C2orf69	-0.63	-8.02	-0.35	9.03e-15	Chickenpox;
LGG	cis	rs6032067	1.000	rs6032059	chr20:43852443	A/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs2032447	0.798	rs807214	chr6:26061769	G/C	cg12310025	chr6:25882481	NA	-0.56	-10.58	-0.44	1.42e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg13939156	chr17:80058883	NA	0.5	10.01	0.42	1.82e-21	Life satisfaction;
LGG	trans	rs10802346	0.515	rs1113270	chr1:246423217	A/G	cg13514129	chr1:39547527	MACF1	0.69	12.7	0.51	6.71e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.83	0.42	7.56e-21	Lymphocyte counts;
LGG	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8008758	0.517	rs1772028	chr14:101693861	C/G	cg26224664	chr14:101693935	NA	-0.86	-20.46	-0.69	9.78e-67	Body mass index (alcohol intake interaction);
LGG	trans	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg07393940	chr7:158741817	NA	0.56	10.37	0.43	8.81e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6684428	0.505	rs6684261	chr1:56359669	C/T	cg11651538	chr1:56320950	NA	0.35	6.98	0.31	1.02e-11	Airflow obstruction;
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.44	-0.56	2.72e-39	Bipolar disorder and schizophrenia;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg19641404	chr2:232826272	DIS3L2	-0.4	-6.97	-0.31	1.13e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs11945232	0.929	rs28736552	chr4:88356111	T/C	cg23841344	chr4:88312519	HSD17B11	-0.5	-8.64	-0.37	8.91e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.09	0.31	4.91e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6601327	0.670	rs7004937	chr8:9420961	T/A	cg12395012	chr8:11607386	GATA4	-0.39	-6.89	-0.3	1.82e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg12011299	chr4:100065546	ADH4	0.38	7.12	0.31	4.13e-12	Alcohol dependence;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg04025307	chr7:1156635	C7orf50	0.81	14.63	0.56	4.09e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg12292205	chr6:26970375	C6orf41	0.75	14.75	0.57	1.28e-40	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4731207	0.565	rs1994025	chr7:124663859	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.08	-0.31	5.26e-12	Cutaneous malignant melanoma;
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg06558623	chr16:89946397	TCF25	1.11	10.94	0.45	6.28e-25	Skin colour saturation;
LGG	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg05729581	chr11:3078854	CARS	0.41	6.8	0.3	3.14e-11	Calcium levels;
LGG	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.2	-0.58	1.25e-42	Colorectal cancer;
LGG	cis	rs13102973	0.899	rs13122646	chr4:135906123	T/C	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.03e-15	Subjective well-being;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs17092148	0.887	rs6059937	chr20:33186200	G/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs7444	0.882	rs9621715	chr22:21942007	G/A	cg22858872	chr22:21984481	YDJC	-0.37	-6.82	-0.3	2.95e-11	Systemic lupus erythematosus;
LGG	cis	rs12318506	0.826	rs11180431	chr12:75661200	G/A	cg04728562	chr12:75699417	CAPS2	-1.1	-9.51	-0.4	1.04e-19	Coronary artery calcification;
LGG	cis	rs9462027	0.606	rs2814984	chr6:34597513	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.36	-0.43	9.59e-23	Systemic lupus erythematosus;
LGG	trans	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg06521331	chr12:34319734	NA	-0.53	-9.61	-0.41	4.65e-20	Bladder cancer;
LGG	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg16482183	chr6:26056742	HIST1H1C	0.74	12.58	0.5	2.04e-31	Height;
LGG	cis	rs1059312	0.966	rs7135968	chr12:129280066	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	7.39	0.32	7.12e-13	Systemic lupus erythematosus;
LGG	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg05753993	chr18:77199432	NFATC1	0.36	6.78	0.3	3.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg16920238	chr17:80076378	CCDC57	0.36	8.35	0.36	7.76e-16	Life satisfaction;
LGG	cis	rs757081	0.648	rs214907	chr11:17244779	G/A	cg15432903	chr11:17409602	KCNJ11	-0.43	-7.86	-0.34	2.72e-14	Systolic blood pressure;
LGG	cis	rs7202877	0.706	rs247450	chr16:75490017	C/A	cg03315344	chr16:75512273	CHST6	-0.52	-7.09	-0.31	5.12e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs17683430	0.702	rs117303909	chr22:32377614	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7647973	1.000	rs6446262	chr3:49401153	T/C	cg07636037	chr3:49044803	WDR6	0.78	13.63	0.54	8e-36	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13436085	chr3:183904316	ABCF3	0.43	7.09	0.31	4.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg11644478	chr21:40555479	PSMG1	0.92	16.78	0.61	1.01e-49	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09882526	chr7:66767408	PMS2L4;STAG3L4	0.47	6.93	0.31	1.44e-11	Gut microbiome composition (summer);
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs875971	0.528	rs801213	chr7:66014918	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.81	-0.41	8.89e-21	Aortic root size;
LGG	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs524281	0.692	rs11227395	chr11:65829637	A/C	cg16950941	chr11:66035639	RAB1B	-0.51	-8.11	-0.35	4.68e-15	Electroencephalogram traits;
LGG	cis	rs3782089	1.000	rs11600543	chr11:65298939	G/A	cg00206168	chr11:65308501	LTBP3	0.71	7.78	0.34	4.78e-14	Height;
LGG	trans	rs1459104	0.714	rs67321261	chr11:54911368	A/G	cg15704280	chr7:45808275	SEPT13	0.78	7.74	0.34	6.5e-14	Body mass index;
LGG	cis	rs17818399	0.501	rs13413254	chr2:46802934	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.51	-9.04	-0.39	4.2e-18	Height;
LGG	cis	rs7215564	0.818	rs34754307	chr17:78652758	C/G	cg16980736	chr17:78789706	RPTOR	-0.63	-8.42	-0.36	4.75e-16	Myopia (pathological);
LGG	cis	rs3768617	0.782	rs12143211	chr1:182990172	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.36	6.87	0.3	2.06e-11	Fuchs's corneal dystrophy;
LGG	cis	rs62238980	0.614	rs56199077	chr22:32436213	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.61	-11.05	-0.46	2.35e-25	Lymphocyte counts;
LGG	cis	rs6665290	0.904	rs1186	chr1:227177731	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg14673194	chr17:80132900	CCDC57	-0.44	-7.69	-0.34	8.62e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg26384229	chr12:38710491	ALG10B	-0.85	-19.76	-0.68	1.74e-63	Heart rate;
LGG	cis	rs73193808	0.639	rs9984810	chr21:30553380	C/G	cg03476357	chr21:30257390	N6AMT1	0.4	6.71	0.3	5.84e-11	Coronary artery disease;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg15595755	chr5:1867978	NA	0.53	10.42	0.44	5.66e-23	Cardiovascular disease risk factors;
LGG	cis	rs7737355	0.812	rs3776013	chr5:130867404	C/T	cg06307176	chr5:131281290	NA	0.51	8.59	0.37	1.33e-16	Life satisfaction;
LGG	cis	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg05623727	chr3:50126028	RBM5	0.39	8.49	0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs68170813	0.559	rs113422695	chr7:107070208	T/A	cg02696742	chr7:106810147	HBP1	-0.7	-9.71	-0.41	2.01e-20	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	2.92e-18	Motion sickness;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg11814155	chr7:99998594	ZCWPW1	0.62	9.71	0.41	2e-20	Platelet count;
LGG	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg17911788	chr17:44343683	NA	-0.48	-8.24	-0.36	1.8e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg00339104	chr7:32930089	KBTBD2	-0.42	-6.99	-0.31	9.59e-12	Body fat percentage;
LGG	cis	rs12220238	0.915	rs1908334	chr10:75991721	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.85	0.48	1.82e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08109568	chr15:31115862	NA	-0.53	-8.79	-0.38	3e-17	Huntington's disease progression;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg04008888	chr11:68622739	NA	-0.54	-11.63	-0.48	1.32e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.39	-0.4	2.77e-19	Obesity-related traits;
LGG	cis	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg24110177	chr3:50126178	RBM5	0.4	6.89	0.3	1.82e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2692947	0.673	rs1168965	chr2:96787899	C/G	cg22654517	chr2:96458247	NA	-0.37	-7.6	-0.33	1.69e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1595825	0.945	rs59553483	chr2:198855201	T/C	cg00982548	chr2:198649783	BOLL	-0.51	-6.99	-0.31	9.44e-12	Ulcerative colitis;
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg06873352	chr17:61820015	STRADA	0.49	7.66	0.34	1.07e-13	Height;
LGG	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg17509989	chr5:176798049	RGS14	-0.77	-12.63	-0.51	1.28e-31	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg03474202	chr17:45855739	NA	0.24	6.7	0.3	6.19e-11	IgG glycosylation;
LGG	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs9354308	0.764	rs9453474	chr6:66603577	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg13385521	chr17:29058706	SUZ12P	0.68	8.16	0.35	3.13e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs3110496	0.671	rs3115094	chr17:27913807	C/G	cg22961402	chr17:27913793	GIT1	0.3	6.93	0.31	1.45e-11	Height;
LGG	cis	rs4423214	1.000	rs2040323	chr11:71172783	A/C	cg05163923	chr11:71159392	DHCR7	0.72	14.09	0.55	9.19e-38	Vitamin D levels;
LGG	cis	rs10493773	0.775	rs11161649	chr1:86165446	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.64	-12.87	-0.51	1.26e-32	Urate levels in overweight individuals;
LGG	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.12	-0.31	4.17e-12	Alzheimer's disease (late onset);
LGG	cis	rs7727544	0.716	rs4705926	chr5:131561758	C/T	cg07395648	chr5:131743802	NA	-0.41	-8.86	-0.38	1.69e-17	Blood metabolite levels;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.61	9.81	0.41	8.79e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10214930	0.697	rs12537499	chr7:27591595	A/G	cg22168087	chr7:27702803	HIBADH	-0.46	-6.83	-0.3	2.75e-11	Hypospadias;
LGG	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	cis	rs12220238	1.000	rs8255	chr10:75879750	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.82	0.48	2.39e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9557207	0.756	rs9585023	chr13:99870462	T/C	cg24509225	chr13:100037070	UBAC2	0.65	11.97	0.49	5.99e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs10861342	1.000	rs10861354	chr12:105524294	T/C	cg23923672	chr12:105501055	KIAA1033	0.75	7.24	0.32	1.87e-12	IgG glycosylation;
LGG	cis	rs8028182	0.636	rs4886712	chr15:75812888	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6831352	0.838	rs2851250	chr4:100044113	G/C	cg12011299	chr4:100065546	ADH4	0.42	8.33	0.36	9.27e-16	Alcohol dependence;
LGG	cis	rs2635047	0.569	rs9958817	chr18:44786481	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.85	0.3	2.29e-11	Educational attainment;
LGG	cis	rs4731207	0.698	rs7796150	chr7:124521217	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.87	-0.34	2.58e-14	Cutaneous malignant melanoma;
LGG	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.78	-0.34	4.85e-14	Neuroticism;
LGG	cis	rs9467773	0.649	rs2145318	chr6:26496603	T/A	cg09904177	chr6:26538194	HMGN4	0.67	13.75	0.54	2.48e-36	Intelligence (multi-trait analysis);
LGG	cis	rs2236267	0.726	rs12431598	chr14:88630812	G/A	cg18078958	chr14:88630771	NA	0.34	7.95	0.35	1.43e-14	Food antigen IgG levels;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg09699651	chr6:150184138	LRP11	0.48	8.47	0.37	3.39e-16	Lung cancer;
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.31	-0.43	1.46e-22	Tonsillectomy;
LGG	cis	rs4787491	0.729	rs7191849	chr16:30023157	T/C	cg06326092	chr16:30034487	C16orf92	0.42	8.44	0.37	4.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg10845886	chr2:3471009	TTC15	-0.44	-8.75	-0.38	4.06e-17	Neurofibrillary tangles;
LGG	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	7.06	0.31	6.3e-12	Platelet count;
LGG	cis	rs2988277	0.737	rs2949668	chr1:167434721	T/C	cg09179987	chr1:167433047	CD247	0.36	7.78	0.34	4.92e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs826838	0.967	rs7136593	chr12:39128265	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs7107174	1.000	rs2510054	chr11:77959659	A/G	cg27205649	chr11:78285834	NARS2	0.45	7.56	0.33	2.12e-13	Testicular germ cell tumor;
LGG	cis	rs7129220	0.588	rs7129047	chr11:10143942	C/A	cg01453529	chr11:10209919	SBF2	-0.42	-6.7	-0.3	6.14e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg21724239	chr8:58056113	NA	0.56	8.18	0.36	2.78e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg04166393	chr7:2884313	GNA12	0.43	8.06	0.35	6.36e-15	Height;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.94	0.38	9.19e-18	Schizophrenia;
LGG	cis	rs1793639	0.616	rs11222940	chr11:131985721	A/C	cg13908476	chr11:131942942	NTM	-0.52	-10.2	-0.43	3.7e-22	Myopia;
LGG	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg24110177	chr3:50126178	RBM5	0.57	10.48	0.44	3.46e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs9453475	chr6:66603657	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs2290402	0.536	rs45486093	chr4:875671	T/C	cg09237302	chr4:906077	GAK	-0.42	-7.15	-0.32	3.44e-12	Type 2 diabetes;
LGG	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs806215	0.547	rs712719	chr7:127357644	G/A	cg25922125	chr7:127225783	GCC1	-0.51	-7.38	-0.32	7.35e-13	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs1008375	0.966	rs4698642	chr4:17679174	A/T	cg16339924	chr4:17578868	LAP3	0.59	10.31	0.43	1.46e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04927004	chr20:61809348	MIR124-3	0.34	6.66	0.3	7.97e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs877282	0.898	rs10904546	chr10:757222	A/G	cg22713356	chr15:30763199	NA	0.48	7.23	0.32	2.03e-12	Uric acid levels;
LGG	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg26688816	chr2:46740690	ATP6V1E2	0.58	10.54	0.44	2.03e-23	Height;
LGG	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.72	7.95	0.35	1.45e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg21171335	chr12:122356390	WDR66	0.29	7.97	0.35	1.26e-14	Mean corpuscular volume;
LGG	cis	rs1555895	0.656	rs10752020	chr10:840608	G/T	cg09361094	chr10:834503	NA	0.3	8.01	0.35	9.61e-15	Survival in rectal cancer;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.63	-0.48	1.28e-27	Coronary artery disease;
LGG	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg24058013	chr18:77568902	NA	-0.46	-7.55	-0.33	2.34e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg16329650	chr2:213403929	ERBB4	0.5	8.11	0.35	4.65e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4959677	0.935	rs4320420	chr6:2496046	G/A	cg23817096	chr6:1620687	NA	-0.31	-7.3	-0.32	1.24e-12	Orthostatic hypotension;
LGG	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg12615879	chr12:58013172	SLC26A10	0.3	6.76	0.3	4.06e-11	Multiple sclerosis;
LGG	cis	rs6743376	0.556	rs2515401	chr2:113820476	C/T	cg05949173	chr2:113825882	IL1F10	-0.51	-9.74	-0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg02836325	chr17:76403955	PGS1	-0.72	-14.51	-0.56	1.3e-39	HDL cholesterol levels;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs8017423	0.935	rs11624246	chr14:90734826	A/G	cg04374321	chr14:90722782	PSMC1	-0.88	-17.91	-0.64	6.88e-55	Mortality in heart failure;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.55	0.44	1.85e-23	Personality dimensions;
LGG	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	cis	rs35771425	0.600	rs12729996	chr1:211469497	A/C	cg10512769	chr1:211675356	NA	-0.62	-8.35	-0.36	8.05e-16	Educational attainment (years of education);
LGG	cis	rs17401966	1.000	rs17410793	chr1:10391886	A/G	cg19773385	chr1:10388646	KIF1B	-0.47	-9.68	-0.41	2.7e-20	Hepatocellular carcinoma;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg07511668	chr11:68622177	NA	0.5	9.66	0.41	3.03e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6032067	0.852	rs6032053	chr20:43829935	G/T	cg10761708	chr20:43804764	PI3	0.76	11.83	0.48	2.1e-28	Blood protein levels;
LGG	cis	rs61931739	0.500	rs1843736	chr12:34012080	C/G	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	trans	rs826838	0.967	rs1719858	chr12:39124505	C/T	cg06521331	chr12:34319734	NA	0.44	7.92	0.35	1.78e-14	Heart rate;
LGG	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg00101154	chr16:420108	MRPL28	-0.49	-7.03	-0.31	7.67e-12	Body mass index;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg03528353	chr17:61819722	STRADA	0.45	7.56	0.33	2.16e-13	Prudent dietary pattern;
LGG	cis	rs1707322	0.717	rs1135812	chr1:46095272	T/C	cg03146154	chr1:46216737	IPP	0.57	10.77	0.45	2.64e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2456568	0.508	rs1607403	chr11:93660514	A/G	cg17595323	chr11:93583763	C11orf90	-0.44	-7.94	-0.35	1.5e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.37	-0.69	2.47e-66	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.719	rs2965945	chr16:89514017	T/C	cg05484508	chr16:89589025	SPG7	0.42	6.79	0.3	3.42e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-8.19	-0.36	2.65e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg25039879	chr17:56429692	SUPT4H1	0.63	8.91	0.38	1.2e-17	Cognitive test performance;
LGG	cis	rs7918232	0.941	rs6482598	chr10:27426375	T/C	cg14442939	chr10:27389572	ANKRD26	0.72	11.01	0.46	3.5e-25	Breast cancer;
LGG	cis	rs7294478	0.597	rs6487298	chr12:7256280	C/T	cg01074767	chr12:7262137	C1RL;LOC283314	-0.5	-11.87	-0.48	1.52e-28	Neuritic plaque;
LGG	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg16141378	chr3:129829833	LOC729375	0.4	9.28	0.4	6.46e-19	Triglycerides;
LGG	cis	rs1185460	0.546	rs7114961	chr11:118914388	G/C	cg12636538	chr11:118901039	SLC37A4	-0.64	-13.29	-0.53	2.17e-34	Coronary artery disease;
LGG	cis	rs921968	0.541	rs576901	chr2:219424364	A/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.14	-0.31	3.68e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6011674	1.000	rs75824619	chr20:61856471	T/C	cg14895298	chr20:61867178	BIRC7	-0.43	-6.87	-0.3	2.08e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs8141529	0.529	rs66471734	chr22:29215803	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Lymphocyte counts;
LGG	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg14784868	chr12:69753453	YEATS4	0.9	20.16	0.68	2.39e-65	Blood protein levels;
LGG	cis	rs13065560	0.659	rs4676476	chr3:38882009	C/T	cg01426195	chr3:39028469	NA	-0.46	-9.59	-0.41	5.63e-20	Interleukin-18 levels;
LGG	cis	rs2816316	0.731	rs9803887	chr1:192523557	G/T	cg02586212	chr1:192544902	RGS1	0.42	8.4	0.36	5.59e-16	Celiac disease;
LGG	cis	rs16973500	1.000	rs16973500	chr16:71965196	C/T	cg00732059	chr16:71740210	PHLPP2	-0.54	-8.84	-0.38	2.05e-17	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.78	0.69	2.91e-68	Alzheimer's disease;
LGG	cis	rs3925075	1.000	rs4889543	chr16:31340216	C/T	cg02846316	chr16:31340340	ITGAM	0.4	7.82	0.34	3.65e-14	IgA nephropathy;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14212634	chr20:3189677	ITPA	-0.48	-7.02	-0.31	8e-12	Systemic lupus erythematosus;
LGG	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	20.76	0.69	3.7e-68	Homoarginine levels;
LGG	cis	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg24375607	chr4:120327624	NA	0.62	10.3	0.43	1.53e-22	Corneal astigmatism;
LGG	cis	rs7827545	0.644	rs7386524	chr8:135534005	T/C	cg17885191	chr8:135476712	NA	-0.5	-8.2	-0.36	2.33e-15	Hypertension (SNP x SNP interaction);
LGG	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	8.44	0.37	4.11e-16	Height;
LGG	trans	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg00938859	chr5:1591904	SDHAP3	0.86	11.93	0.48	8.69e-29	Breast cancer;
LGG	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg03929089	chr4:120376271	NA	-0.68	-12.15	-0.49	1.1e-29	Coronary artery disease;
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg09845145	chr15:78292470	TBC1D2B	0.65	11.95	0.49	7.2e-29	Coronary artery disease or large artery stroke;
LGG	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.64	0.33	1.22e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7615952	0.611	rs7632305	chr3:125634767	C/T	cg05084668	chr3:125655381	ALG1L	-1.17	-13.6	-0.53	1.07e-35	Blood pressure (smoking interaction);
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg25072359	chr17:41440525	NA	0.53	10.24	0.43	2.6e-22	Menopause (age at onset);
LGG	trans	rs7178375	1.000	rs7169064	chr15:31210862	C/T	cg04373760	chr16:53404718	NA	0.53	8.08	0.35	5.83e-15	Hypertriglyceridemia;
LGG	cis	rs17655565	1.000	rs17126640	chr12:52704991	C/T	cg08257133	chr12:52711352	KRT83	0.51	7.03	0.31	7.37e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs986417	1.000	rs2144114	chr14:61064210	T/C	cg27398547	chr14:60952738	C14orf39	0.76	7.05	0.31	6.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs34734847	0.787	rs1814851	chr12:121128633	C/G	cg21892295	chr12:121157589	UNC119B	-0.4	-7.54	-0.33	2.56e-13	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs34421088	0.532	rs4515509	chr8:11172123	A/T	cg02002194	chr4:3960332	NA	-0.44	-7.78	-0.34	4.76e-14	Neuroticism;
LGG	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.6e-15	Common traits (Other);
LGG	cis	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg24623649	chr8:11872141	NA	0.3	6.96	0.31	1.2e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	trans	rs4714291	1.000	rs1100098	chr6:40026044	A/G	cg02267698	chr19:7991119	CTXN1	0.53	7.87	0.34	2.53e-14	Strep throat;
LGG	cis	rs12464559	0.649	rs4664066	chr2:152632406	T/C	cg01189475	chr2:152685088	ARL5A	0.75	6.77	0.3	3.93e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs4319547	0.915	rs7314638	chr12:122983460	A/G	cg23029597	chr12:123009494	RSRC2	-0.96	-18.2	-0.65	3.02e-56	Body mass index;
LGG	cis	rs77972916	0.505	rs6756575	chr2:43528519	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.27	-0.43	1.95e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs953387	0.910	rs10928558	chr2:136926222	T/C	cg07169764	chr2:136633963	MCM6	0.55	8.98	0.39	6.94e-18	Arthritis (juvenile idiopathic);
LGG	cis	rs2117029	0.767	rs12580349	chr12:49436724	C/T	cg24176009	chr12:49580217	TUBA1A	-0.46	-8.35	-0.36	7.84e-16	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	0.544	rs9864664	chr3:40336226	T/C	cg13683864	chr3:40499215	RPL14	-0.8	-15.82	-0.59	2.21e-45	Renal cell carcinoma;
LGG	cis	rs1696756	1.000	rs1696756	chr17:77827973	C/T	cg07923794	chr17:77834237	NA	-0.68	-10.92	-0.45	7.45e-25	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.78	0.3	3.64e-11	Schizophrenia;
LGG	cis	rs12908161	1.000	rs62019469	chr15:85321220	T/C	cg24253500	chr15:84953950	NA	0.41	6.76	0.3	4.28e-11	Schizophrenia;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.49	-8.71	-0.38	5.56e-17	Obesity-related traits;
LGG	cis	rs208520	0.874	rs208473	chr6:66917265	G/C	cg07460842	chr6:66804631	NA	-0.93	-16.16	-0.6	6.79e-47	Exhaled nitric oxide output;
LGG	cis	rs8141529	0.529	rs5762814	chr22:29203964	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.15	0.32	3.3e-12	Lymphocyte counts;
LGG	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg06634786	chr22:41940651	POLR3H	0.67	10.8	0.45	2.11e-24	Vitiligo;
LGG	cis	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs68170813	0.559	rs1018947	chr7:106851939	A/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.72	-0.45	4.27e-24	Coronary artery disease;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg03395511	chr6:291903	DUSP22	-0.5	-8.54	-0.37	1.95e-16	Menopause (age at onset);
LGG	cis	rs17453880	0.929	rs10041415	chr5:152041409	T/C	cg10931792	chr5:152022470	NA	0.41	8.88	0.38	1.53e-17	Subjective well-being;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg06916706	chr16:4465613	CORO7	-0.71	-12.3	-0.5	2.89e-30	Schizophrenia;
LGG	cis	rs7582720	1.000	rs1541853	chr2:203835177	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08677398	chr8:58056175	NA	0.58	8.85	0.38	1.86e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg12708336	chr17:41446283	NA	0.31	7.21	0.32	2.31e-12	Menopause (age at onset);
LGG	cis	rs1577917	1.000	rs12201880	chr6:86627007	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs7598759	0.548	rs11686485	chr2:232360697	C/T	cg19187155	chr2:232395269	NMUR1	0.53	9.96	0.42	2.56e-21	Noise-induced hearing loss;
LGG	cis	rs9393777	0.588	rs4518487	chr6:26467531	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	11.64	0.48	1.2100000000000001e-27	Intelligence (multi-trait analysis);
LGG	cis	rs68170813	0.559	rs12537342	chr7:106943563	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1e-23	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.78	0.34	4.62e-14	Lung cancer;
LGG	cis	rs6912958	0.515	rs381782	chr6:88040649	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	12.99	0.52	4.17e-33	Monocyte percentage of white cells;
LGG	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	9.3	0.4	5.41e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.800	rs10028921	chr4:98962630	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg26384229	chr12:38710491	ALG10B	0.98	22.14	0.72	1.26e-74	Bladder cancer;
LGG	cis	rs7552404	0.924	rs1303169	chr1:76195041	T/C	cg22875332	chr1:76189707	ACADM	0.6	10.73	0.45	3.78e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.87	0.3	2.14e-11	Aortic root size;
LGG	trans	rs561341	0.882	rs16967101	chr17:30377162	A/G	cg20587970	chr11:113659929	NA	-1.32	-23.07	-0.73	6.12e-79	Hip circumference adjusted for BMI;
LGG	cis	rs11920090	0.932	rs61791066	chr3:170713380	T/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.46	0.37	3.63e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6692729	0.931	rs1296171	chr1:227059606	C/G	cg08708961	chr1:227070630	PSEN2	-0.31	-7.87	-0.34	2.58e-14	Electrodermal activity;
LGG	cis	rs9916302	0.861	rs12150493	chr17:37586154	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs1920116	0.778	rs7647824	chr3:169552381	A/G	cg00832555	chr3:169529716	LRRC34	0.38	6.66	0.3	7.76e-11	Glioma (high-grade);
LGG	cis	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	5.27e-55	Exhaled nitric oxide output;
LGG	cis	rs9467773	0.620	rs2504600	chr6:26648334	C/A	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	trans	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg26043149	chr18:55253948	FECH	0.44	7.3	0.32	1.23e-12	Bone mineral density;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-8.22	-0.36	2.1e-15	Schizophrenia;
LGG	cis	rs1915146	0.967	rs7086481	chr10:126844523	A/T	cg03862225	chr10:126850454	CTBP2	-0.27	-7.69	-0.34	9.18e-14	Menarche (age at onset);
LGG	cis	rs16937	0.711	rs4951172	chr1:205137578	A/G	cg00889227	chr1:205173544	DSTYK	0.3	7.56	0.33	2.22e-13	Schizophrenia;
LGG	cis	rs7267979	0.844	rs4423675	chr20:25402778	A/G	cg06421707	chr20:25228305	PYGB	-0.43	-9.08	-0.39	3.1e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12580194	0.593	rs61956291	chr12:55797964	G/C	cg19537932	chr12:55886519	OR6C68	-0.58	-10.51	-0.44	2.68e-23	Cancer;
LGG	cis	rs7394190	0.748	rs60632610	chr10:75415677	C/T	cg07699608	chr10:75541558	CHCHD1	0.57	7.83	0.34	3.37e-14	Incident atrial fibrillation;
LGG	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs10193935	1.000	rs10210866	chr2:42387879	A/G	cg27598129	chr2:42591480	NA	-0.6	-9.01	-0.39	5.37e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12586317	0.576	rs10143314	chr14:35637904	A/T	cg05294307	chr14:35346193	BAZ1A	0.39	7.22	0.32	2.1e-12	Psoriasis;
LGG	cis	rs7666738	0.830	rs1120708	chr4:98931260	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg08923669	chr16:420230	MRPL28	-0.47	-7.46	-0.33	4.33e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs12670798	0.547	rs7797607	chr7:21615938	A/G	cg04471919	chr7:21584483	DNAH11	0.3	7.15	0.32	3.49e-12	Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg21644426	chr2:191273491	MFSD6	0.6	10.37	0.43	8.72e-23	Pulse pressure;
LGG	cis	rs11748327	0.543	rs67916023	chr5:4086492	C/G	cg01025095	chr5:4101132	NA	-0.63	-10.22	-0.43	2.9e-22	Myocardial infarction;
LGG	cis	rs12579753	0.917	rs10778834	chr12:82199742	A/C	cg07988820	chr12:82153109	PPFIA2	-0.72	-10.27	-0.43	1.93e-22	Resting heart rate;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3820928	0.874	rs4234064	chr2:227857497	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.34	-0.32	9.39e-13	Pulmonary function;
LGG	cis	rs7582180	0.903	rs13031712	chr2:100896512	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-9.75	-0.41	1.53e-20	Intelligence (multi-trait analysis);
LGG	cis	rs35771425	0.529	rs7556054	chr1:211380445	C/T	cg10512769	chr1:211675356	NA	-0.63	-8.02	-0.35	8.9e-15	Educational attainment (years of education);
LGG	cis	rs3087591	1.000	rs8068801	chr17:29570587	G/T	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.75	-0.57	1.17e-40	Hip circumference;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9487094	0.961	rs12209691	chr6:109786432	C/T	cg01125227	chr6:109776195	MICAL1	0.58	9.74	0.41	1.56e-20	Height;
LGG	cis	rs295140	0.805	rs11890234	chr2:201206706	C/T	cg04283868	chr2:201171347	SPATS2L	0.41	6.79	0.3	3.37e-11	QT interval;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg26578617	chr4:90757533	SNCA	0.44	8.67	0.37	7.33e-17	Dementia with Lewy bodies;
LGG	cis	rs6460942	0.915	rs6968695	chr7:12443878	G/C	cg06484146	chr7:12443880	VWDE	-0.42	-7.45	-0.33	4.69e-13	Coronary artery disease;
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.25	-0.43	2.33e-22	Glycated hemoglobin levels;
LGG	cis	rs62400317	0.731	rs12214435	chr6:44906717	G/A	cg18551225	chr6:44695536	NA	-0.68	-11.26	-0.46	3.57e-26	Total body bone mineral density;
LGG	cis	rs10540	1.000	rs61876335	chr11:488878	T/C	cg03352830	chr11:487213	PTDSS2	0.86	10.98	0.45	4.34e-25	Body mass index;
LGG	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg02158880	chr13:53174818	NA	0.67	15.46	0.58	8.91e-44	Lewy body disease;
LGG	cis	rs6960043	0.905	rs10231021	chr7:15060429	T/A	cg19272540	chr7:15055459	NA	-0.37	-8.34	-0.36	8.89e-16	Type 2 diabetes;
LGG	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg25706552	chr1:244017396	NA	0.52	7.09	0.31	4.93e-12	RR interval (heart rate);
LGG	cis	rs60843830	1.000	rs55946380	chr2:268293	A/G	cg12623918	chr2:306882	NA	0.53	9.86	0.42	6.01e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg18876405	chr7:65276391	NA	0.68	13.0	0.52	3.53e-33	Aortic root size;
LGG	cis	rs4417704	0.551	rs4077132	chr2:241889937	A/G	cg14055004	chr2:241860995	NA	0.28	7.51	0.33	3.01e-13	Joint mobility (Beighton score);
LGG	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs9357271	1.000	rs9470867	chr6:38358860	C/T	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	cis	rs17270561	0.779	rs12209218	chr6:25887776	C/A	cg16482183	chr6:26056742	HIST1H1C	0.75	11.31	0.47	2.26e-26	Iron status biomarkers;
LGG	cis	rs7192750	0.527	rs30433	chr16:72145404	T/C	cg14768367	chr16:72042858	DHODH	0.78	8.3	0.36	1.18e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg11247378	chr22:39784982	NA	-0.31	-8.93	-0.38	1.04e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs11971779	0.680	rs7788777	chr7:139055193	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg27034935	chr5:153873021	NA	0.3	6.79	0.3	3.43e-11	Menarche (age at onset);
LGG	cis	rs4538187	1.000	rs6731508	chr2:64094506	G/C	cg02541582	chr2:64069798	UGP2	0.61	13.75	0.54	2.54e-36	Systolic blood pressure;
LGG	cis	rs7814319	0.700	rs11995989	chr8:97264456	C/G	cg20787634	chr8:97240163	UQCRB	-0.66	-13.36	-0.53	1.17e-34	Lung function (FVC);
LGG	cis	rs9790314	0.586	rs67077657	chr3:161138521	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.79	-0.38	3.03e-17	Morning vs. evening chronotype;
LGG	cis	rs526231	0.543	rs17154913	chr5:102328490	C/G	cg23492399	chr5:102201601	PAM	-0.59	-9.13	-0.39	2.09e-18	Primary biliary cholangitis;
LGG	cis	rs2731664	0.792	rs1130857	chr5:176863519	G/C	cg23176889	chr5:176863531	GRK6	-0.65	-12.77	-0.51	3.47e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1395	0.778	rs4665960	chr2:27467598	C/T	cg23587288	chr2:27483067	SLC30A3	-0.3	-6.67	-0.3	7.16e-11	Blood metabolite levels;
LGG	cis	rs35160687	0.644	rs57270703	chr2:86516873	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.91	0.31	1.66e-11	Night sleep phenotypes;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg15971980	chr6:150254442	NA	0.4	7.48	0.33	3.82e-13	Lung cancer;
LGG	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.61	-0.37	1.13e-16	Calcium levels;
LGG	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg20891283	chr12:69753455	YEATS4	-0.68	-12.7	-0.51	6.21e-32	Blood protein levels;
LGG	cis	rs11122272	0.735	rs2486740	chr1:231517552	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs13260300	0.657	rs3802201	chr8:75516199	G/C	cg22993706	chr8:75542856	NA	0.41	7.97	0.35	1.25e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg20587970	chr11:113659929	NA	-1.31	-23.53	-0.74	4.13e-81	Hip circumference adjusted for BMI;
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg10896456	chr17:42255109	ASB16;C17orf65	-0.57	-10.57	-0.44	1.49e-23	Total body bone mineral density;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.7	14.02	0.55	1.85e-37	Obesity-related traits;
LGG	cis	rs2084898	1.000	rs73004786	chr11:120058833	G/A	cg13907859	chr11:120009124	TRIM29	0.86	11.31	0.47	2.33e-26	Stroke (pediatric);
LGG	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg11742103	chr11:62369870	EML3;MTA2	-0.55	-12.84	-0.51	1.74e-32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.63	-12.43	-0.5	7.96e-31	Obesity-related traits;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg21862992	chr11:68658383	NA	-0.5	-8.4	-0.36	5.44e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs17685	0.753	rs4728550	chr7:75670988	C/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.77	-0.77	1.82e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs7980799	0.935	rs1905427	chr12:33534368	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.53	-0.37	2.13e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2072732	0.861	rs10909865	chr1:2956163	A/G	cg22517653	chr1:2918612	NA	-0.46	-6.99	-0.31	9.75e-12	Plateletcrit;
LGG	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.18	0.65	3.87e-56	Refractive error;
LGG	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.84	-9.04	-0.39	4.28e-18	Corneal curvature;
LGG	cis	rs8017423	0.967	rs3825662	chr14:90723152	A/G	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs1816752	0.905	rs6490927	chr13:25013940	C/G	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	trans	rs61931739	0.513	rs4931760	chr12:33898361	T/C	cg26384229	chr12:38710491	ALG10B	0.65	12.48	0.5	5.24e-31	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04590956	chr2:70057467	GMCL1	0.52	8.11	0.35	4.59e-15	Gut microbiome composition (summer);
LGG	cis	rs3735485	0.689	rs4599721	chr7:45059711	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.52	0.4	9.6e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2735413	0.875	rs12923229	chr16:78080302	C/A	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg26384229	chr12:38710491	ALG10B	0.93	21.24	0.7	2.22e-70	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03132935	chr11:118901768	SLC37A4	0.47	7.0	0.31	8.86e-12	Gut microbiome composition (summer);
LGG	cis	rs7932354	0.528	rs4752962	chr11:47141670	C/G	cg03339077	chr11:47165057	C11orf49	0.54	10.03	0.42	1.48e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.85e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2421770	0.532	rs7110991	chr11:35343239	A/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.4	-0.33	6.27e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs9649465	1.000	rs13230338	chr7:123373622	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	trans	rs6787172	0.652	rs827166	chr3:158019665	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	trans	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.51	-0.4	1.08e-19	Brugada syndrome;
LGG	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs9399137	0.507	rs35571217	chr6:135290355	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs988958	0.565	rs13417438	chr2:42237876	A/G	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.34	-0.32	9.39e-13	Total cholesterol levels;
LGG	trans	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg06521331	chr12:34319734	NA	0.5	9.38	0.4	3.07e-19	Bladder cancer;
LGG	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.24	-0.63	8.08e-52	Response to antipsychotic treatment;
LGG	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.46	-0.4	1.55e-19	Neuroticism;
LGG	cis	rs17039065	0.920	rs78730199	chr4:109470973	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.17	0.32	3.08e-12	Gut microbiome composition (summer);
LGG	cis	rs910316	1.000	rs910316	chr14:75626042	A/C	cg08847533	chr14:75593920	NEK9	0.61	11.45	0.47	6.8e-27	Height;
LGG	cis	rs6456156	0.586	rs7762156	chr6:167485831	A/T	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	cis	rs17376456	0.877	rs13165147	chr5:93422214	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.37	0.43	8.61e-23	Diabetic retinopathy;
LGG	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.7	0.64	6.5e-54	Cognitive function;
LGG	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg00934597	chr7:893267	UNC84A	-0.5	-8.49	-0.37	2.93e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs2742417	0.603	rs2742395	chr3:45758595	A/G	cg04837898	chr3:45731254	SACM1L	-0.48	-9.58	-0.41	6.12e-20	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg09044154	chr16:88155775	NA	-0.5	-7.32	-0.32	1.14e-12	Menopause (age at onset);
LGG	cis	rs17253792	0.915	rs28663681	chr14:56178820	A/T	cg01858014	chr14:56050164	KTN1	-0.78	-10.01	-0.42	1.77e-21	Putamen volume;
LGG	cis	rs3096299	0.589	rs3114898	chr16:89392315	C/T	cg06640241	chr16:89574553	SPG7	0.62	10.73	0.45	3.95e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.44	-0.5	7.6e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11920090	0.932	rs56819515	chr3:170712913	T/A	cg09710316	chr3:170744871	SLC2A2	0.56	7.73	0.34	6.55e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7766436	0.621	rs2294825	chr6:22597820	G/T	cg13666174	chr6:22585274	NA	0.33	7.84	0.34	3.22e-14	Coronary artery disease;
LGG	cis	rs7826238	0.623	rs2976893	chr8:8338219	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.68	-0.34	9.3e-14	Systolic blood pressure;
LGG	cis	rs9393777	0.513	rs9368448	chr6:26649355	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs6697863	chr1:248495588	G/A	cg00666640	chr1:248458726	OR2T12	0.62	9.99	0.42	2.08e-21	Common traits (Other);
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs638893	0.528	rs521910	chr11:118610629	C/T	cg22253036	chr11:118662786	DDX6	-0.45	-7.06	-0.31	6.14e-12	Vitiligo;
LGG	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05665937	chr4:1216051	CTBP1	0.49	9.09	0.39	2.81e-18	Obesity-related traits;
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg13009111	chr11:71350975	NA	-0.32	-6.83	-0.3	2.75e-11	Triglycerides;
LGG	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg06145435	chr7:1022769	CYP2W1	0.3	6.64	0.3	8.6e-11	Longevity;Endometriosis;
LGG	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.8	-0.76	5.37e-87	Height;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg23782820	chr8:58130467	NA	0.54	7.46	0.33	4.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03517284	chr6:25882590	NA	-0.59	-11.25	-0.46	4.16e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs6840360	0.571	rs4696275	chr4:152530981	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.600	rs2952975	chr17:29490992	A/G	cg24425628	chr17:29625626	OMG;NF1	0.65	9.4	0.4	2.57e-19	Hip circumference;
LGG	cis	rs9815354	0.812	rs73073323	chr3:41834051	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.53	0.33	2.74e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1008375	1.000	rs2215450	chr4:17675394	T/G	cg07005078	chr4:17578674	LAP3	0.38	7.12	0.31	4.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4356932	0.935	rs4605683	chr4:76979327	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg21665744	chr7:39171113	POU6F2	0.43	8.74	0.38	4.21e-17	IgG glycosylation;
LGG	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	cis	rs9549367	0.762	rs9549694	chr13:113870510	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-13.9	-0.54	5.64e-37	Platelet distribution width;
LGG	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg06238570	chr21:40685208	BRWD1	0.44	6.73	0.3	5.01e-11	Cognitive function;
LGG	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg06697600	chr4:7070879	GRPEL1	-0.51	-9.14	-0.39	1.9e-18	Monocyte percentage of white cells;
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg06028808	chr11:68637592	NA	0.72	12.33	0.5	2.08e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs854765	0.929	rs854766	chr17:18012775	A/G	cg05444541	chr17:17804740	TOM1L2	-0.6	-14.26	-0.55	1.62e-38	Total body bone mineral density;
LGG	cis	rs6580649	0.941	rs11613485	chr12:48462455	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs10267417	0.603	rs10260797	chr7:19890181	A/G	cg05791153	chr7:19748676	TWISTNB	0.63	8.21	0.36	2.28e-15	Night sleep phenotypes;
LGG	cis	rs172166	0.611	rs203882	chr6:28078502	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.12	-0.31	4.2e-12	Cardiac Troponin-T levels;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg01673284	chr16:4527211	HMOX2	0.32	6.79	0.3	3.43e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg08621203	chr6:150244597	RAET1G	0.47	8.15	0.35	3.36e-15	Lung cancer;
LGG	cis	rs1729951	0.575	rs1654923	chr3:136692620	A/T	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-8.31	-0.36	1.09e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg05335186	chr13:53173507	NA	0.43	8.51	0.37	2.35e-16	Lewy body disease;
LGG	cis	rs755249	0.567	rs72661925	chr1:39669537	T/A	cg18385671	chr1:39797026	MACF1	0.44	7.26	0.32	1.68e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg16950941	chr11:66035639	RAB1B	0.56	10.49	0.44	2.95e-23	Gout;
LGG	cis	rs2718058	0.613	rs2718037	chr7:37777846	G/C	cg15028436	chr7:37888078	TXNDC3	0.62	9.85	0.42	6.63e-21	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg13565492	chr6:43139072	SRF	-0.89	-15.44	-0.58	1.16e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg06766960	chr11:133703094	NA	-0.56	-10.9	-0.45	8.47e-25	Childhood ear infection;
LGG	cis	rs4466137	0.553	rs16898	chr5:82986149	T/C	cg16102102	chr5:83017553	HAPLN1	-0.53	-10.8	-0.45	2.16e-24	Prostate cancer;
LGG	cis	rs7086627	0.515	rs10887899	chr10:82210214	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	11.69	0.48	7.67e-28	Post bronchodilator FEV1;
LGG	cis	rs7666738	0.753	rs17027308	chr4:99091088	T/A	cg05340658	chr4:99064831	C4orf37	0.45	7.31	0.32	1.18e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg18225595	chr11:63971243	STIP1	-0.53	-7.19	-0.32	2.63e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs736408	0.562	rs1014969	chr3:52808341	G/A	cg18099408	chr3:52552593	STAB1	-0.35	-6.84	-0.3	2.48e-11	Bipolar disorder;
LGG	cis	rs6993813	0.843	rs17176952	chr8:120042383	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16571354	chr17:36508031	SOCS7	0.47	6.83	0.3	2.74e-11	Hip circumference;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.5	8.6	0.37	1.23e-16	Longevity;
LGG	cis	rs2075371	1.000	rs2241336	chr7:133979578	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.76	0.45	3.05e-24	Mean platelet volume;
LGG	cis	rs708547	0.914	rs2412760	chr4:57735192	A/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-8.21	-0.36	2.25e-15	Response to bleomycin (chromatid breaks);
LGG	cis	rs6772849	1.000	rs2712373	chr3:128308055	T/C	cg08795948	chr3:128337044	NA	0.53	8.74	0.38	4.31e-17	Monocyte percentage of white cells;Monocyte count;
LGG	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.74	-0.34	6.26e-14	Triglycerides;
LGG	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs758324	0.947	rs1948704	chr5:131171653	A/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.51e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.29	-0.32	1.38e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05025164	chr4:1340916	KIAA1530	0.44	7.48	0.33	3.66e-13	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs35110281	0.712	rs1454648	chr21:45053815	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	12.0	0.49	4.44e-29	Mean corpuscular volume;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.811	rs60708039	chr17:46999373	C/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	trans	rs7615952	0.866	rs13063119	chr3:125643847	G/A	cg07211511	chr3:129823064	LOC729375	-1.37	-21.84	-0.71	3.26e-73	Blood pressure (smoking interaction);
LGG	cis	rs7666738	0.830	rs10031292	chr4:99056877	A/G	cg05340658	chr4:99064831	C4orf37	0.49	8.3	0.36	1.12e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg16141378	chr3:129829833	LOC729375	-0.32	-7.47	-0.33	3.93e-13	Joint mobility (Beighton score);
LGG	cis	rs1395	0.571	rs114507490	chr2:27527246	T/A	cg22903471	chr2:27725779	GCKR	-0.43	-7.1	-0.31	4.8e-12	Blood metabolite levels;
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.49	-0.4	1.27e-19	Triglycerides;
LGG	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg21435375	chr2:172878103	MAP1D	-0.3	-6.76	-0.3	4.17e-11	Schizophrenia;
LGG	cis	rs6964587	1.000	rs7802788	chr7:91736874	A/G	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.48e-18	Breast cancer;
LGG	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	-0.49	-8.23	-0.36	1.98e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg16141378	chr3:129829833	LOC729375	-0.41	-10.18	-0.43	4.17e-22	Neuroticism;
LGG	cis	rs6748734	0.901	rs6720357	chr2:241830296	A/C	cg04034577	chr2:241836375	C2orf54	-0.53	-11.1	-0.46	1.51e-25	Urinary metabolites;
LGG	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg00701064	chr4:6280414	WFS1	0.76	17.28	0.63	5.6e-52	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.59	0.33	1.82e-13	Colorectal cancer;
LGG	cis	rs45544231	0.569	rs1420529	chr16:52558673	T/G	cg09051775	chr16:52580266	TOX3	-0.41	-6.81	-0.3	3.1e-11	Restless legs syndrome;
LGG	cis	rs7084402	0.935	rs10763564	chr10:60360423	C/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.23	-0.32	1.95e-12	Refractive error;
LGG	cis	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg13789015	chr9:136890014	NCRNA00094	0.49	7.28	0.32	1.4e-12	Mosquito bite size;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg05863683	chr7:1912471	MAD1L1	0.39	7.66	0.34	1.06e-13	Schizophrenia;
LGG	cis	rs701145	0.585	rs1527800	chr3:153875075	A/G	cg12800244	chr3:153838788	SGEF	0.77	8.28	0.36	1.37e-15	Coronary artery disease;
LGG	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg15557168	chr22:42548783	NA	0.41	8.8	0.38	2.67e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	17.55	0.63	3.13e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg00364696	chr7:1142433	C7orf50	-0.4	-7.74	-0.34	6.39e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8064024	0.719	rs17137286	chr16:4852892	G/C	cg08329684	chr16:4932620	PPL	0.38	8.01	0.35	9.14e-15	Cancer;
LGG	cis	rs9522267	0.535	rs4773393	chr13:112229755	A/G	cg10483660	chr13:112241077	NA	-0.36	-7.88	-0.34	2.39e-14	Hepatitis;
LGG	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg13256891	chr4:100009986	ADH5	-0.57	-9.57	-0.41	6.62e-20	Alcohol dependence;
LGG	cis	rs7444	0.941	rs140498	chr22:21927064	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	cis	rs908922	0.651	rs6671924	chr1:152485830	T/C	cg03606772	chr1:152487856	CRCT1	0.29	6.84	0.3	2.59e-11	Hair morphology;
LGG	cis	rs7552404	0.924	rs2275378	chr1:76198436	T/C	cg22875332	chr1:76189707	ACADM	0.62	10.87	0.45	1.12e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs112591243	0.685	rs2839362	chr21:48024626	G/A	cg10657630	chr21:48055338	PRMT2	0.87	7.64	0.33	1.25e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs57905270	1.000	rs57905270	chr2:228486714	G/T	cg12489444	chr2:228498029	C2orf83	-0.57	-8.36	-0.36	7.23e-16	Accelerated cognitive decline after conversion of mild cognitive impairment to Alzheimer's disease (Alzhiemer's diagnosis trajectory interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15139745	chr19:42927668	LIPE	0.37	6.73	0.3	5.1e-11	Gut microbiome composition (summer);
LGG	cis	rs12474201	0.928	rs7594523	chr2:46935791	G/C	cg06386533	chr2:46925753	SOCS5	0.79	14.88	0.57	3.22e-41	Height;
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg16434002	chr17:42200994	HDAC5	-0.48	-8.27	-0.36	1.43e-15	Total body bone mineral density;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.65	-0.41	3.33e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg26384229	chr12:38710491	ALG10B	0.82	16.66	0.61	3.53e-49	Morning vs. evening chronotype;
LGG	cis	rs1707322	1.000	rs9429186	chr1:46539687	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.81	-0.41	9.31e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09368129	chr5:140071347	HARS2;HARS	0.47	6.95	0.31	1.23e-11	Gut microbiome composition (summer);
LGG	cis	rs4006360	0.524	rs6503601	chr17:39280487	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.48	-9.53	-0.4	9.02e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs17253792	0.822	rs17685102	chr14:56129214	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.83	-10.27	-0.43	2e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7172689	0.908	rs11638043	chr15:81569939	T/C	cg11808699	chr15:81528661	IL16	-0.46	-9.61	-0.41	4.54e-20	Inattentive symptoms;
LGG	cis	rs2777491	1.000	rs11631770	chr15:41737059	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.99	-19.7	-0.68	3.31e-63	Ulcerative colitis;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs6138458	1.000	rs227615	chr20:24908721	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg05025164	chr4:1340916	KIAA1530	0.44	7.61	0.33	1.52e-13	Obesity-related traits;
LGG	cis	rs344364	0.511	rs12596510	chr16:1949480	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs847649	0.692	rs10279449	chr7:102462636	T/C	cg18108683	chr7:102477205	FBXL13	-0.71	-15.86	-0.59	1.4e-45	Morning vs. evening chronotype;
LGG	cis	rs28655083	1.000	rs1843456	chr16:77072393	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.68	-0.34	9.5e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06223186	chr7:1544111	INTS1	-0.39	-6.72	-0.3	5.32e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26714650	chr12:56694279	CS	1.49	18.31	0.65	9.68e-57	Psoriasis vulgaris;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg24607181	chr17:41446203	NA	-0.29	-6.68	-0.3	6.74e-11	Menopause (age at onset);
LGG	cis	rs1801251	0.964	rs13007783	chr2:233566679	G/A	cg25237894	chr2:233734115	C2orf82	0.65	12.29	0.5	2.99e-30	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03082763	chr19:12662438	ZNF564	0.4	6.8	0.3	3.34e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg08621203	chr6:150244597	RAET1G	0.54	10.06	0.42	1.18e-21	Testicular germ cell tumor;
LGG	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.43	0.33	5.39e-13	Retinal vascular caliber;
LGG	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg14664628	chr15:75095509	CSK	-0.49	-8.73	-0.38	4.81e-17	Airflow obstruction;
LGG	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg11887960	chr12:57824829	NA	0.58	7.01	0.31	8.3e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.33	-0.36	9.56e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.49	-0.4	1.18e-19	Mood instability;
LGG	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg22535103	chr8:58192502	C8orf71	-0.8	-10.65	-0.44	7.49e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs8141529	0.600	rs16986825	chr22:29300306	C/T	cg15103426	chr22:29168792	CCDC117	0.63	7.3	0.32	1.22e-12	Lymphocyte counts;
LGG	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.56	7.51	0.33	3.05e-13	Smoking behavior;
LGG	cis	rs10504073	0.647	rs11997959	chr8:50014044	C/T	cg00325661	chr8:49890786	NA	0.7	13.75	0.54	2.65e-36	Blood metabolite ratios;
LGG	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg03474202	chr17:45855739	NA	-0.27	-8.01	-0.35	9.18e-15	IgG glycosylation;
LGG	cis	rs3789045	0.688	rs6668637	chr1:204452295	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.42	-8.17	-0.36	2.94e-15	Educational attainment (college completion);
LGG	cis	rs4969178	0.965	rs11077364	chr17:76400337	C/A	cg05887092	chr17:76393375	PGS1	0.72	15.99	0.6	3.83e-46	HDL cholesterol levels;
LGG	cis	rs490234	0.966	rs534214	chr9:128369224	A/G	cg14078157	chr9:128172775	NA	-0.39	-7.28	-0.32	1.46e-12	Mean arterial pressure;
LGG	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg11764359	chr7:65958608	NA	0.69	12.16	0.49	1.07e-29	Aortic root size;
LGG	cis	rs10875746	0.551	rs1471997	chr12:48723595	G/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.31	-0.32	1.15e-12	Longevity (90 years and older);
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg24848339	chr3:12840334	CAND2	0.38	8.29	0.36	1.24e-15	P wave duration;
LGG	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.12	-0.31	4.11e-12	Blood metabolite levels;
LGG	cis	rs8005677	1.000	rs10148215	chr14:23382345	C/T	cg25600027	chr14:23388339	RBM23	-0.44	-7.27	-0.32	1.58e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs745821	0.879	rs1025686	chr18:48147127	A/G	cg18923635	chr18:48083994	NA	0.41	6.95	0.31	1.24e-11	Diastolic blood pressure;
LGG	cis	rs2213920	0.920	rs9408871	chr9:118263618	C/T	cg13918206	chr9:118159781	DEC1	0.49	6.68	0.3	6.9e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	cg15522984	chr1:182991683	LAMC1	0.45	9.01	0.39	5.43e-18	Colorectal cancer;
LGG	cis	rs2731664	0.792	rs335434	chr5:176867276	A/G	cg23176889	chr5:176863531	GRK6	-0.63	-11.94	-0.49	7.88e-29	Intelligence (multi-trait analysis);
LGG	cis	rs11969893	0.850	rs9390697	chr6:101294431	G/A	cg12253828	chr6:101329408	ASCC3	1.2	10.18	0.43	4.34e-22	Economic and political preferences (immigration/crime);
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg05665937	chr4:1216051	CTBP1	0.49	9.19	0.39	1.3e-18	Obesity-related traits;
LGG	cis	rs2712184	0.729	rs4674115	chr2:217659628	C/G	cg05032264	chr2:217675019	NA	-0.44	-9.67	-0.41	2.93e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg06481639	chr22:41940642	POLR3H	-0.55	-7.73	-0.34	6.63e-14	Vitiligo;
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22168489	chr12:122356033	WDR66	0.42	10.14	0.43	6.15e-22	Mean corpuscular volume;
LGG	cis	rs4819052	0.851	rs2838849	chr21:46671027	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.13	0.52	1.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3857067	0.806	rs6532471	chr4:95108584	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.35	1.87e-14	QT interval;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.62	12.46	0.5	6.07e-31	Obesity-related traits;
LGG	cis	rs7712401	0.601	rs246322	chr5:122307269	C/T	cg19412675	chr5:122181750	SNX24	-0.42	-6.96	-0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs7551222	0.716	rs12041075	chr1:204492153	C/G	cg20240347	chr1:204465584	NA	-0.56	-11.27	-0.46	3.45e-26	Schizophrenia;
LGG	trans	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg05552183	chr6:42928497	GNMT	0.44	13.13	0.52	1.07e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs59197085	0.636	rs730931	chr7:128462273	C/G	cg00734629	chr7:128471146	FLNC	0.34	6.98	0.31	1.03e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs9341808	0.754	rs9341810	chr6:80974838	G/A	cg08355045	chr6:80787529	NA	0.39	7.52	0.33	2.87e-13	Sitting height ratio;
LGG	cis	rs2845885	0.744	rs3802932	chr11:63988045	G/A	cg18375707	chr11:64034959	PLCB3	-0.68	-7.14	-0.31	3.68e-12	Body mass index;
LGG	trans	rs73411413	0.608	rs7126170	chr11:1539387	C/A	cg13381631	chr10:46776799	NA	-0.54	-9.23	-0.39	9.56e-19	Myringotomy;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.9	0.31	1.69e-11	Lung cancer;
LGG	cis	rs10791323	0.519	rs329663	chr11:133754543	A/G	cg00579200	chr11:133705235	NA	-0.55	-10.86	-0.45	1.29e-24	Childhood ear infection;
LGG	cis	rs7666738	0.830	rs7687958	chr4:99014495	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12959622	chr20:47895410	SNORD12B;C20orf199;SNORD12C;MIR1259;ZNFX1	0.44	7.2	0.32	2.39e-12	Cognitive performance;
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.65	-0.37	8.53e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg02151108	chr14:50098012	C14orf104	0.43	9.17	0.39	1.53e-18	Carotid intima media thickness;
LGG	cis	rs7647973	0.626	rs9830730	chr3:49675875	G/C	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg24607181	chr17:41446203	NA	-0.31	-7.22	-0.32	2.21e-12	Menopause (age at onset);
LGG	cis	rs709400	0.628	rs3783394	chr14:103858673	G/A	cg26031613	chr14:104095156	KLC1	0.8	13.65	0.54	6.95e-36	Body mass index;
LGG	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.52	-9.08	-0.39	3.08e-18	Educational attainment;
LGG	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg26384229	chr12:38710491	ALG10B	-0.68	-13.22	-0.52	4.38e-34	Bladder cancer;
LGG	cis	rs11122272	0.735	rs2474623	chr1:231513993	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.47	0.33	4.06e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg06532163	chr17:45867833	NA	0.52	8.96	0.38	8.09e-18	IgG glycosylation;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg03036210	chr16:89904091	SPIRE2	0.55	7.64	0.33	1.23e-13	Skin colour saturation;
LGG	cis	rs258892	0.895	rs34782328	chr5:72060974	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs796364	1.000	rs35594306	chr2:200775125	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.11	-0.35	4.73e-15	Schizophrenia;
LGG	trans	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.96	0.49	6.3e-29	Obesity-related traits;
LGG	cis	rs9486719	1.000	rs12208011	chr6:96991105	G/A	cg18709589	chr6:96969512	KIAA0776	-0.48	-7.24	-0.32	1.82e-12	Migraine;Coronary artery disease;
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.07e-12	Bipolar disorder;
LGG	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg05084668	chr3:125655381	ALG1L	-0.54	-7.32	-0.32	1.1e-12	Blood pressure (smoking interaction);
LGG	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg05444541	chr17:17804740	TOM1L2	0.4	8.56	0.37	1.72e-16	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg17691542	chr6:26056736	HIST1H1C	0.68	11.29	0.46	2.72e-26	Iron status biomarkers;
LGG	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg13798912	chr7:905769	UNC84A	-0.59	-7.37	-0.32	7.92e-13	Cerebrospinal P-tau181p levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09320993	chr14:95623691	DICER1;FLJ45244	0.6	6.8	0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.2	-0.55	3.1e-38	Alzheimer's disease;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	7.87	0.34	2.52e-14	Renal function-related traits (BUN);
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs16937	0.662	rs11588199	chr1:205164580	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.58e-13	Schizophrenia;
LGG	cis	rs72781680	1.000	rs12616899	chr2:24165235	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22496380	chr5:211416	CCDC127	-1.35	-18.33	-0.65	8.18e-57	Breast cancer;
LGG	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs2735413	0.564	rs73578752	chr16:78107554	G/A	cg04733911	chr16:78082701	NA	0.57	7.96	0.35	1.32e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg22903471	chr2:27725779	GCKR	0.38	8.62	0.37	1.06e-16	Oral cavity cancer;
LGG	trans	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg11441553	chr12:57614120	NXPH4	-0.57	-7.1	-0.31	4.6e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1018836	0.631	rs2205157	chr8:91472384	C/T	cg16814680	chr8:91681699	NA	-0.61	-10.18	-0.43	4.26e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg12179176	chr11:130786555	SNX19	0.84	17.41	0.63	1.42e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs17767392	0.670	rs72726701	chr14:71728329	C/T	cg02058870	chr14:72053146	SIPA1L1	0.35	7.37	0.32	8.1e-13	Mitral valve prolapse;
LGG	cis	rs1185460	0.546	rs17075	chr11:118959331	A/G	cg23280166	chr11:118938394	VPS11	-0.45	-7.87	-0.34	2.51e-14	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07222113	chr8:104427719	DCAF13;SLC25A32	0.39	7.07	0.31	5.92e-12	Obesity-related traits;
LGG	cis	rs963731	0.649	rs12622969	chr2:39343183	C/G	cg04010122	chr2:39346883	SOS1	0.75	7.68	0.34	9.65e-14	Corticobasal degeneration;
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg04709771	chr16:646395	RAB40C	0.37	6.75	0.3	4.37e-11	Height;
LGG	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg04450456	chr4:17643702	FAM184B	0.34	7.55	0.33	2.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg23782820	chr8:58130467	NA	0.54	7.56	0.33	2.11e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg09873164	chr1:152488093	CRCT1	0.64	15.62	0.59	1.68e-44	Hair morphology;
LGG	cis	rs1318772	0.866	rs13161969	chr5:112865809	A/C	cg12552261	chr5:112820674	MCC	0.68	7.64	0.33	1.22e-13	F-cell distribution;
LGG	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.72	-0.41	1.93e-20	Common traits (Other);
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs7617773	0.851	rs6775179	chr3:48313418	T/C	cg11946769	chr3:48343235	NME6	0.63	10.58	0.44	1.43e-23	Coronary artery disease;
LGG	cis	rs6725041	0.819	rs10196424	chr2:213089563	A/T	cg20637307	chr2:213403960	ERBB4	-0.36	-6.85	-0.3	2.39e-11	QT interval (ambient particulate matter interaction);
LGG	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.75	-0.3	4.32e-11	Neuroticism;
LGG	cis	rs9858542	0.543	rs2230929	chr3:49343175	G/A	cg00383909	chr3:49044727	WDR6	0.58	8.16	0.35	3.26e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg04861929	chr11:109293070	C11orf87	0.85	16.85	0.62	4.9e-50	Schizophrenia;
LGG	cis	rs7619833	0.658	rs479566	chr3:27326999	T/C	cg02860705	chr3:27208620	NA	0.39	7.5	0.33	3.25e-13	Breast cancer;
LGG	cis	rs11252926	0.550	rs10904148	chr10:454551	G/T	cg16386425	chr10:429943	DIP2C	-0.47	-9.68	-0.41	2.74e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs35771425	0.956	rs35014256	chr1:211587701	A/G	cg10512769	chr1:211675356	NA	-0.73	-11.7	-0.48	7.14e-28	Educational attainment (years of education);
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg15971980	chr6:150254442	NA	0.45	8.5	0.37	2.55e-16	Lung cancer;
LGG	cis	rs6728642	0.519	rs59131346	chr2:97566768	C/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-8.3	-0.36	1.16e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.19	-0.32	2.6e-12	Inflammatory bowel disease;
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg12310025	chr6:25882481	NA	-0.94	-18.54	-0.65	8.88e-58	Intelligence (multi-trait analysis);
LGG	cis	rs2088885	1.000	rs4894459	chr3:170980869	A/T	cg18052528	chr3:170975382	TNIK	-0.27	-6.75	-0.3	4.47e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs36093844	0.800	rs75203358	chr11:85567390	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.19	-0.32	2.57e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6032067	0.777	rs34163611	chr20:43778990	T/C	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.5e-28	Blood protein levels;
LGG	cis	rs2075371	0.674	rs11771785	chr7:134013249	A/G	cg11752832	chr7:134001865	SLC35B4	-0.46	-7.64	-0.33	1.3e-13	Mean platelet volume;
LGG	cis	rs240764	0.580	rs4839789	chr6:101233235	T/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.42	-7.08	-0.31	5.32e-12	Personality dimensions;
LGG	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg13271783	chr10:134563150	INPP5A	-0.52	-8.01	-0.35	9.35e-15	Migraine;
LGG	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg08508325	chr11:3079039	CARS	0.39	7.48	0.33	3.85e-13	Calcium levels;
LGG	cis	rs2836974	0.831	rs11911149	chr21:40528375	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg21724239	chr8:58056113	NA	0.45	6.69	0.3	6.37e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-0.74	-10.69	-0.44	5.64e-24	Lung function (FEV1/FVC);
LGG	cis	rs11170468	0.697	rs7304000	chr12:39432408	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-6.79	-0.3	3.51e-11	Body mass index;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.18	0.32	2.75e-12	Menopause (age at onset);
LGG	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs4075765	0.764	rs72872775	chr11:26261122	A/G	cg19182008	chr11:26298241	NA	0.98	8.78	0.38	3.29e-17	Cannabis dependence symptom count;
LGG	cis	rs7044106	0.762	rs3903886	chr9:123383646	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.46	-7.46	-0.33	4.36e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7481584	0.624	rs12417389	chr11:3035304	G/C	cg25174290	chr11:3078921	CARS	-0.51	-9.21	-0.39	1.1e-18	Calcium levels;
LGG	trans	rs6601327	0.606	rs7006985	chr8:9564437	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.64	-0.33	1.24e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg03098644	chr7:100410630	EPHB4	0.53	8.03	0.35	8.04e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7932354	0.528	rs7479189	chr11:47057009	T/A	cg03339077	chr11:47165057	C11orf49	-0.53	-10.06	-0.42	1.11e-21	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08417425	chr5:153784856	GALNT10	0.59	6.87	0.3	2.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.44	8.53	0.37	2.08e-16	Schizophrenia;
LGG	cis	rs832540	0.931	rs832534	chr5:56213672	G/A	cg12654349	chr5:56205094	C5orf35	-0.4	-7.19	-0.32	2.53e-12	Coronary artery disease;
LGG	cis	rs7166081	1.000	rs4776906	chr15:67520617	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg19147804	chr7:1989927	MAD1L1	0.58	11.61	0.47	1.63e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.929	rs1844524	chr12:34094709	A/T	cg13010199	chr12:38710504	ALG10B	-0.46	-9.05	-0.39	3.92e-18	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs9462027	0.628	rs6921363	chr6:34770820	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.07	-0.46	1.9e-25	Systemic lupus erythematosus;
LGG	cis	rs3789045	0.560	rs4626956	chr1:204407298	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.59	-10.69	-0.44	5.46e-24	Educational attainment (college completion);
LGG	trans	rs877282	0.945	rs12776447	chr10:790625	A/G	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	trans	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg21775007	chr8:11205619	TDH	0.45	7.41	0.33	5.94e-13	Systolic blood pressure;
LGG	cis	rs2486288	0.656	rs12915314	chr15:45551491	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	trans	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2236918	0.687	rs2797600	chr1:242029331	C/T	cg17736920	chr1:242011382	EXO1	0.38	6.9	0.31	1.77e-11	Menopause (age at onset);
LGG	cis	rs12540874	0.759	rs12718572	chr7:50573325	C/T	cg04490037	chr7:50633773	DDC	0.35	7.49	0.33	3.61e-13	Systemic sclerosis;
LGG	cis	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	10.44	0.44	4.88e-23	Mood instability;
LGG	trans	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg00711542	chr16:29343894	RUNDC2C	0.4	6.73	0.3	5.09e-11	Menopause (age at onset);
LGG	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.26	-0.6	2.31e-47	Intelligence (multi-trait analysis);
LGG	cis	rs7110818	0.510	rs6592647	chr11:76280432	A/T	cg17647271	chr11:76299819	NA	0.39	6.9	0.31	1.73e-11	Gut microbiota (functional units);
LGG	cis	rs7929679	0.571	rs11032860	chr11:34799345	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.41	6.93	0.31	1.39e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs7483296	0.705	rs2513642	chr11:115421994	G/A	cg02820646	chr11:115398838	NA	0.39	6.8	0.3	3.23e-11	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg19635926	chr16:89946313	TCF25	0.7	8.13	0.35	4.09e-15	Skin colour saturation;
LGG	cis	rs7666738	0.830	rs13110410	chr4:98920018	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.77e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72717009	0.825	rs9427399	chr1:161476533	T/C	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs1865760	1.000	rs9358893	chr6:25921761	A/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.01	0.42	1.75e-21	Height;
LGG	cis	rs4740619	0.870	rs4961713	chr9:15868769	G/C	cg14451791	chr9:16040625	NA	-0.39	-9.91	-0.42	4.06e-21	Body mass index;
LGG	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.27	-0.32	1.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs57221529	0.654	rs72707041	chr5:677152	G/A	cg25482853	chr8:67687455	SGK3	0.99	11.44	0.47	7.23e-27	Lung disease severity in cystic fibrosis;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.77	0.68	1.54e-63	Platelet count;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.96	0.31	1.16e-11	Lung cancer;
LGG	cis	rs2273669	0.667	rs11153155	chr6:109359963	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs4356203	0.870	rs7936310	chr11:17270288	C/T	cg15432903	chr11:17409602	KCNJ11	0.38	7.1	0.31	4.61e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.01	-0.31	8.7e-12	Primary sclerosing cholangitis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19147428	chr4:184922646	STOX2	0.38	6.9	0.31	1.73e-11	Electrocardiographic conduction measures;
LGG	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg00578828	chr5:131826934	IRF1	0.4	7.23	0.32	2.03e-12	Asthma (sex interaction);
LGG	cis	rs2688608	0.725	rs2633314	chr10:75683590	C/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.19	-0.32	2.56e-12	Inflammatory bowel disease;
LGG	cis	rs867371	0.502	rs28610286	chr15:82525655	C/T	cg00614314	chr15:82944287	LOC80154	0.47	7.8	0.34	4.05e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs10463554	0.553	rs72785712	chr5:102324397	A/G	cg23492399	chr5:102201601	PAM	-0.59	-9.05	-0.39	3.87e-18	Parkinson's disease;
LGG	cis	rs7524258	0.868	rs4243824	chr1:7289777	G/A	cg07173049	chr1:7289937	CAMTA1	0.76	17.91	0.64	6.56e-55	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg25019033	chr10:957182	NA	0.56	9.43	0.4	2e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg04234412	chr22:24373322	LOC391322	-0.64	-11.66	-0.48	9.97e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.67	0.41	2.85e-20	Schizophrenia;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg22907277	chr7:1156413	C7orf50	0.45	7.53	0.33	2.65e-13	Longevity;Endometriosis;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.75	0.34	5.91e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6120849	0.754	rs6088691	chr20:33633758	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.67	0.3	7.23e-11	Protein C levels;
LGG	cis	rs357618	1.000	rs357627	chr5:150850260	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.77	-0.3	3.81e-11	Basophil percentage of white cells;
LGG	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg08999081	chr20:33150536	PIGU	-0.3	-6.78	-0.3	3.6e-11	Coronary artery disease;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg08355456	chr11:67383691	NA	-0.48	-7.15	-0.32	3.41e-12	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg07870213	chr5:140052090	DND1	0.92	17.09	0.62	3.95e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21862992	chr11:68658383	NA	0.52	8.49	0.37	2.91e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.65	0.33	1.19e-13	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.6	0.63	1.89e-53	Refractive error;
LGG	cis	rs9522267	0.535	rs7339347	chr13:112237920	C/T	cg14952266	chr13:112191215	NA	0.52	10.89	0.45	9.65e-25	Hepatitis;
LGG	cis	rs427394	0.659	rs274678	chr5:6752385	A/G	cg15145174	chr5:6755386	POLS	0.43	7.91	0.34	1.95e-14	Menopause (age at onset);
LGG	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-9.87	-0.42	5.64e-21	Schizophrenia;
LGG	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg03924115	chr9:133768966	QRFP	0.4	6.98	0.31	1.05e-11	Response to amphetamines;
LGG	cis	rs2455799	0.613	rs11706879	chr3:15957130	A/C	cg16303742	chr3:15540471	COLQ	-0.37	-7.28	-0.32	1.46e-12	Mean platelet volume;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03314080	chr2:178129903	NFE2L2	0.37	6.67	0.3	7.35e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg00204512	chr16:28754710	NA	0.26	7.3	0.32	1.27e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.87	-0.34	2.53e-14	Testicular germ cell tumor;
LGG	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.49	0.4	1.19e-19	Blood metabolite levels;
LGG	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg26384229	chr12:38710491	ALG10B	0.73	14.68	0.56	2.43e-40	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.06	-22.89	-0.73	4e-78	Primary sclerosing cholangitis;
LGG	cis	rs7191439	0.728	rs8043637	chr16:88781125	T/C	cg27087555	chr16:88793112	FAM38A	-1.4	-18.0	-0.64	2.53e-55	Plateletcrit;
LGG	cis	rs2115630	1.000	rs8037423	chr15:85355494	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.7	-0.3	5.96e-11	P wave terminal force;
LGG	cis	rs9902453	0.967	rs11080121	chr17:28528842	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	12.85	0.51	1.55e-32	Coffee consumption (cups per day);
LGG	cis	rs894344	0.748	rs16905190	chr8:135598265	C/T	cg09855544	chr8:135498122	ZFAT	-0.39	-7.04	-0.31	7.12e-12	Systolic blood pressure;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg06028808	chr11:68637592	NA	0.75	13.16	0.52	7.71e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9868809	0.505	rs28657585	chr3:48736216	A/T	cg00383909	chr3:49044727	WDR6	0.9	11.22	0.46	5.15e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg25801113	chr15:45476975	SHF	0.87	19.83	0.68	8.4e-64	Uric acid levels;
LGG	cis	rs9790314	0.846	rs4856738	chr3:160986637	C/G	cg03342759	chr3:160939853	NMD3	-0.71	-13.69	-0.54	4.46e-36	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg08677398	chr8:58056175	NA	0.47	7.84	0.34	3.21e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3736485	0.578	rs11638106	chr15:51969295	C/T	cg13474965	chr15:52030001	LYSMD2	0.4	6.69	0.3	6.38e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06850241	chr22:41845214	NA	-0.45	-6.83	-0.3	2.71e-11	Vitiligo;
LGG	cis	rs34172651	0.545	rs7185291	chr16:24714679	C/T	cg02428538	chr16:24856791	SLC5A11	0.37	6.77	0.3	3.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.540	rs480400	chr16:28574615	A/G	cg00198680	chr16:28758506	NA	0.28	7.18	0.32	2.78e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7444	0.941	rs9619386	chr22:21979938	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.75	-0.3	4.48e-11	Systemic lupus erythematosus;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg04865506	chr17:29422776	NF1	-0.37	-6.87	-0.3	2.1e-11	Iris color (L* coordinate);
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg10852096	chr15:79043040	NA	-0.28	-8.07	-0.35	6.1e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs9790314	0.718	rs9847866	chr3:160758275	A/G	cg04691961	chr3:161091175	C3orf57	-0.45	-9.4	-0.4	2.5e-19	Morning vs. evening chronotype;
LGG	cis	rs9512730	0.553	rs6491211	chr13:28049533	A/G	cg04070771	chr13:27998621	GTF3A	0.48	7.28	0.32	1.49e-12	Schizophrenia;
LGG	trans	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg10756647	chr7:56101905	PSPH	0.78	9.3	0.4	5.55e-19	Diabetic kidney disease;
LGG	cis	rs1691799	0.867	rs6581677	chr12:66770379	C/G	cg16791601	chr12:66731901	HELB	-0.66	-15.71	-0.59	7.18e-45	White blood cell count (basophil);
LGG	cis	rs9951602	0.512	rs12455566	chr18:76655926	A/G	cg24134504	chr18:76639479	NA	-0.47	-8.28	-0.36	1.34e-15	Obesity-related traits;
LGG	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg15454534	chr1:248569605	OR2T1	0.38	6.93	0.31	1.44e-11	Common traits (Other);
LGG	cis	rs2404602	0.647	rs11072628	chr15:77107761	C/A	cg15268244	chr15:77196840	NA	0.49	10.37	0.43	8.39e-23	Blood metabolite levels;
LGG	cis	rs7010267	0.570	rs2326193	chr8:120029709	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.3	7.85	0.34	2.99e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs60843830	0.661	rs6755432	chr2:106692	T/C	cg12623918	chr2:306882	NA	0.38	7.01	0.31	8.49e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.68	-0.3	6.8e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6597981	0.592	rs10902218	chr11:743813	C/T	cg01741372	chr11:783889	NA	-0.7	-14.5	-0.56	1.51e-39	Breast cancer;
LGG	cis	rs208520	0.955	rs9345808	chr6:67008262	C/T	cg07460842	chr6:66804631	NA	0.7	11.02	0.46	3.08e-25	Exhaled nitric oxide output;
LGG	cis	rs2033732	0.706	rs7830484	chr8:85068154	C/G	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-10.9	-0.45	9.08e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg10763598	chr19:19431466	KIAA0892;SF4	0.61	7.68	0.34	9.73e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs9815354	0.556	rs60966614	chr3:42005166	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.59	0.37	1.3e-16	Coronary artery disease;
LGG	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	8.29	0.36	1.23e-15	Mean platelet volume;
LGG	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	cis	rs6674970	0.518	rs15740	chr1:151040435	G/A	cg03258749	chr1:151040405	MLLT11	-0.55	-9.27	-0.4	6.99e-19	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg15971980	chr6:150254442	NA	0.47	8.65	0.37	8.58e-17	Lung cancer;
LGG	cis	rs4268898	0.722	rs6723257	chr2:24391129	A/G	cg06627628	chr2:24431161	ITSN2	0.48	7.75	0.34	6.03e-14	Asthma;
LGG	cis	rs2404602	0.692	rs58973160	chr15:77000342	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.09e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg19223190	chr17:80058835	NA	0.44	8.45	0.37	3.85e-16	Life satisfaction;
LGG	cis	rs7106204	0.609	rs12788438	chr11:24284068	G/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.71	0.41	2e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.4	-0.36	5.53e-16	Cognitive function;
LGG	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26850624	chr5:429559	AHRR	-0.37	-8.1	-0.35	4.89e-15	Cystic fibrosis severity;
LGG	cis	rs514024	0.668	rs2039204	chr9:130371107	T/A	cg13643465	chr9:130375613	STXBP1	0.57	10.29	0.43	1.69e-22	Eating disorders (purging via substances);
LGG	cis	rs2070488	0.745	rs7649153	chr3:38467753	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	11.91	0.48	1.02e-28	Electrocardiographic conduction measures;
LGG	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg17201900	chr20:34330562	RBM39	-0.54	-7.23	-0.32	1.97e-12	Total cholesterol levels;
LGG	cis	rs6960043	0.782	rs4721401	chr7:15064896	T/G	cg19272540	chr7:15055459	NA	-0.35	-7.83	-0.34	3.45e-14	Type 2 diabetes;
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.67	-0.34	1.01e-13	Monocyte count;
LGG	cis	rs2836950	0.502	rs12627205	chr21:40630027	C/T	cg11890956	chr21:40555474	PSMG1	-0.74	-12.9	-0.51	9.72e-33	Menarche (age at onset);
LGG	trans	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs727505	1.000	rs28392553	chr7:124442944	C/T	cg23710748	chr7:124431027	NA	-0.51	-9.75	-0.41	1.47e-20	Lewy body disease;
LGG	cis	rs4417704	0.551	rs6754171	chr2:241896013	G/C	cg14055004	chr2:241860995	NA	0.28	7.22	0.32	2.16e-12	Joint mobility (Beighton score);
LGG	trans	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg10756647	chr7:56101905	PSPH	0.8	9.37	0.4	3.17e-19	Diabetic kidney disease;
LGG	cis	rs1372520	0.684	rs2619341	chr4:90741773	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.21	-0.36	2.25e-15	Neuroticism;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg11062466	chr8:58055876	NA	-0.6	-10.2	-0.43	3.69e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.22	0.32	2.17e-12	Lung cancer;
LGG	cis	rs2732480	0.500	rs2732461	chr12:48692802	C/A	cg24011408	chr12:48396354	COL2A1	0.49	7.77	0.34	4.95e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14020129	chr2:10091270	GRHL1	0.49	7.34	0.32	9.75e-13	Gut microbiome composition (summer);
LGG	trans	rs11875185	0.510	rs75751725	chr18:55599503	C/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg23034840	chr1:205782522	SLC41A1	0.61	10.14	0.43	6.03e-22	Menarche (age at onset);
LGG	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21659725	chr3:3221576	CRBN	-0.62	-10.06	-0.42	1.17e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg08193579	chr3:169529701	LRRC34	-0.36	-7.42	-0.33	5.77e-13	Renal cell carcinoma;
LGG	cis	rs77741769	0.571	rs11065292	chr12:121289155	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.17	0.39	1.55e-18	Mean corpuscular volume;
LGG	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg27129171	chr3:47204927	SETD2	-0.79	-15.46	-0.58	9.17e-44	Colorectal cancer;
LGG	cis	rs78487399	0.808	rs79271345	chr2:43746094	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.91	-0.31	1.6e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.96	0.35	1.35e-14	Schizophrenia;
LGG	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.77	0.64	2.93e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7552404	0.727	rs1144336	chr1:76277421	C/A	cg03433033	chr1:76189801	ACADM	0.62	9.4	0.4	2.57e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.16e-16	Aortic root size;
LGG	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg17294928	chr15:75287854	SCAMP5	0.7	13.07	0.52	1.92e-33	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs67311347	1.000	rs56992941	chr3:40472434	A/T	cg13683864	chr3:40499215	RPL14	-1.01	-21.27	-0.7	1.56e-70	Renal cell carcinoma;
LGG	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg25986240	chr4:9926439	SLC2A9	-0.35	-7.19	-0.32	2.56e-12	Bone mineral density;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16405210	chr4:1374714	KIAA1530	-0.81	-15.21	-0.58	1.18e-42	Longevity;
LGG	cis	rs7599312	0.534	rs7607363	chr2:213402705	A/G	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	6.2e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs62103177	0.673	rs36087369	chr18:77589596	C/G	cg14227996	chr4:17616232	MED28	0.53	7.33	0.32	1e-12	Opioid sensitivity;
LGG	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.56e-22	Motion sickness;
LGG	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg22916017	chr11:64110731	CCDC88B	0.47	9.45	0.4	1.66e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17727855	chr9:108007124	SLC44A1	0.59	6.88	0.3	1.97e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg15556689	chr8:8085844	FLJ10661	0.47	7.99	0.35	1.07e-14	Red cell distribution width;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14330621	chr9:98080957	FANCC	0.4	7.49	0.33	3.59e-13	Menarche (age at onset);
LGG	cis	rs4742903	0.875	rs1605449	chr9:106976397	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.31	0.36	1.05e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7568458	0.709	rs2028898	chr2:85777270	G/A	cg17127132	chr2:85788382	GGCX	0.52	8.17	0.36	2.93e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs6601327	0.600	rs7828039	chr8:9654757	G/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.97	-0.31	1.11e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4819052	0.724	rs9753962	chr21:46661384	G/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs950169	0.881	rs62029599	chr15:84956565	A/C	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg06092702	chr1:163392909	NA	-0.47	-8.37	-0.36	6.95e-16	Motion sickness;
LGG	cis	rs3816183	0.586	rs6757452	chr2:42764713	T/A	cg14631114	chr2:43023945	NA	0.44	8.16	0.35	3.16e-15	Hypospadias;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg10056627	chr6:42928773	GNMT	0.26	7.01	0.31	8.65e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg24829409	chr8:58192753	C8orf71	-0.48	-8.3	-0.36	1.18e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg01529538	chr14:23388837	RBM23	0.37	6.75	0.3	4.34e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs11785693	0.862	rs73183606	chr8:4986999	C/T	cg26367366	chr8:4980734	NA	0.99	15.82	0.59	2.26e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs317689	0.819	rs317667	chr12:69703754	G/T	cg11871910	chr12:69753446	YEATS4	0.47	7.56	0.33	2.12e-13	Response to diuretic therapy;
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg04553112	chr3:125709451	NA	-0.54	-6.87	-0.3	2.03e-11	Blood pressure (smoking interaction);
LGG	trans	rs2562456	0.793	rs116057198	chr19:21508451	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	cis	rs60871478	0.588	rs56205589	chr7:910419	G/A	cg22643751	chr7:855365	UNC84A	-0.43	-7.52	-0.33	2.78e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs11750568	0.967	rs1549602	chr5:178512136	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.42	-6.8	-0.3	3.22e-11	Height;
LGG	trans	rs931726	0.906	rs6805252	chr3:134937763	G/T	cg20349687	chr2:88927127	EIF2AK3	-0.44	-6.71	-0.3	5.59e-11	Sitting height ratio;
LGG	cis	rs9303280	0.806	rs12232498	chr17:38040363	T/C	cg00129232	chr17:37814104	STARD3	-0.47	-8.8	-0.38	2.7e-17	Self-reported allergy;
LGG	cis	rs7589342	0.929	rs6719896	chr2:106428404	C/G	cg16077055	chr2:106428750	NCK2	-0.33	-8.8	-0.38	2.64e-17	Addiction;
LGG	cis	rs10463554	0.892	rs1898673	chr5:102293380	G/C	cg23492399	chr5:102201601	PAM	-0.56	-8.59	-0.37	1.37e-16	Parkinson's disease;
LGG	cis	rs12468557	0.545	rs7587791	chr2:211499979	A/C	cg07063745	chr2:211341572	LANCL1;CPS1	-0.5	-8.68	-0.37	6.65e-17	Body mass index in asthmatics;
LGG	cis	rs7647973	0.626	rs62262722	chr3:49769419	G/C	cg13072238	chr3:49761600	GMPPB	0.53	6.77	0.3	3.93e-11	Menarche (age at onset);
LGG	cis	rs17854409	0.536	rs3765464	chr20:61485236	T/C	cg05147244	chr20:61493195	TCFL5	0.76	7.41	0.33	6.21e-13	Obesity-related traits;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.65	-0.33	1.2e-13	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2239547	0.603	rs7644973	chr3:53082937	C/T	cg11645453	chr3:52864694	ITIH4	0.65	9.91	0.42	4.05e-21	Schizophrenia;
LGG	cis	rs9325144	0.600	rs12297194	chr12:38735803	A/G	cg26384229	chr12:38710491	ALG10B	-0.75	-14.99	-0.57	1.05e-41	Morning vs. evening chronotype;
LGG	cis	rs2708240	0.577	rs2373269	chr7:147567018	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	0.33	7.92	0.35	1.81e-14	QT interval (drug interaction);
LGG	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.66	-0.37	7.67e-17	Triglycerides;
LGG	cis	rs9309711	0.643	rs10188449	chr2:3480366	T/C	cg15506890	chr2:3487001	NA	-0.53	-10.16	-0.43	5.11e-22	Neurofibrillary tangles;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.53	-8.77	-0.38	3.49e-17	Prudent dietary pattern;
LGG	cis	rs6747952	0.866	rs6726348	chr2:239084119	C/T	cg17459225	chr2:239074497	NA	0.43	7.81	0.34	3.81e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.27	-0.52	2.87e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs68170813	0.559	rs80153759	chr7:106944145	C/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1e-23	Coronary artery disease;
LGG	cis	rs2280630	1.000	rs2280630	chr3:39195964	C/T	cg23654821	chr3:39188656	CSRNP1	0.28	7.27	0.32	1.5e-12	Verbal declarative memory;
LGG	cis	rs3106136	0.967	rs282448	chr4:95141411	T/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.96	-0.35	1.34e-14	Capecitabine sensitivity;
LGG	trans	rs3942852	0.703	rs11039513	chr11:48107204	C/T	cg15704280	chr7:45808275	SEPT13	0.7	10.02	0.42	1.65e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg14926445	chr8:58193284	C8orf71	0.44	6.85	0.3	2.36e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg05973401	chr12:123451056	ABCB9	-0.49	-7.85	-0.34	2.87e-14	Neutrophil percentage of white cells;
LGG	trans	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg25214090	chr10:38739885	LOC399744	0.56	10.23	0.43	2.76e-22	Corneal astigmatism;
LGG	cis	rs2070488	1.000	rs4147025	chr3:38456531	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.48	0.63	6.26e-53	Electrocardiographic conduction measures;
LGG	cis	rs10884984	0.770	rs7077433	chr10:112284336	A/C	cg18756771	chr10:112261994	DUSP5	0.67	12.04	0.49	3.22e-29	Facial morphology (factor 22);
LGG	trans	rs4427176	0.507	rs4841206	chr8:9583627	G/A	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Mosquito bite size;
LGG	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg24375607	chr4:120327624	NA	0.64	10.47	0.44	3.78e-23	Corneal astigmatism;
LGG	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg08499158	chr17:42289980	UBTF	-0.43	-8.16	-0.35	3.15e-15	Total body bone mineral density;
LGG	cis	rs10911363	0.592	rs4047798	chr1:183421406	C/T	cg09173681	chr1:183549694	NCF2	-0.38	-8.54	-0.37	1.96e-16	Systemic lupus erythematosus;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.66	11.78	0.48	3.52e-28	Lymphocyte counts;
LGG	cis	rs12615966	1.000	rs12618379	chr2:105386854	C/T	cg16465502	chr2:105461796	NA	0.87	10.49	0.44	3.02e-23	Pancreatic cancer;
LGG	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9462027	0.628	rs9469857	chr6:34719793	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.27	-0.43	2.05e-22	Systemic lupus erythematosus;
LGG	cis	rs2404602	0.608	rs12911035	chr15:76606591	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.8	-0.3	3.27e-11	Blood metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26116045	chr3:43663699	ANO10	0.41	6.77	0.3	3.84e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg23978390	chr7:1156363	C7orf50	0.45	7.54	0.33	2.54e-13	Longevity;Endometriosis;
LGG	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg16141378	chr3:129829833	LOC729375	-0.45	-10.98	-0.45	4.51e-25	Mood instability;
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10802521	chr3:52805072	NEK4	-0.4	-7.17	-0.32	2.92e-12	Bipolar disorder;
LGG	cis	rs7737355	0.812	rs798414	chr5:130696450	C/T	cg06307176	chr5:131281290	NA	-0.49	-8.11	-0.35	4.47e-15	Life satisfaction;
LGG	trans	rs79976124	0.842	rs1548154	chr6:66624910	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.24	0.49	4.73e-30	Type 2 diabetes;
LGG	cis	rs1577917	1.000	rs12192992	chr6:86609915	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.97	-0.42	2.4e-21	Response to antipsychotic treatment;
LGG	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	cis	rs17428076	0.831	rs55957712	chr2:172587956	C/T	cg21435375	chr2:172878103	MAP1D	0.41	8.77	0.38	3.38e-17	Myopia;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg02951883	chr7:2050386	MAD1L1	-0.79	-16.12	-0.6	1.01e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.4	-0.58	1.62e-43	Body mass index;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2712184	0.875	rs2541381	chr2:217683836	G/T	cg05032264	chr2:217675019	NA	-0.42	-9.16	-0.39	1.66e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs1055129	0.655	rs3744006	chr17:73838816	G/A	cg14829360	chr17:73884958	NA	-0.43	-7.82	-0.34	3.65e-14	White matter hyperintensity burden;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg06112835	chr11:68658793	MRPL21	0.59	9.94	0.42	3.09e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2562456	0.917	rs2650825	chr19:21699225	A/G	cg00806126	chr19:22604979	ZNF98	-0.62	-8.85	-0.38	1.8e-17	Pain;
LGG	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg08222618	chr4:941054	TMEM175	0.59	10.8	0.45	2.18e-24	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs503734	0.502	rs348861	chr3:100955259	G/A	cg27318481	chr3:100970896	IMPG2	-0.57	-13.1	-0.52	1.46e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10895140	0.756	rs2508256	chr11:101494900	G/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs2798269	1.000	rs12429479	chr13:22145941	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.88	-0.3	1.94e-11	PR segment;
LGG	cis	rs17767392	0.915	rs7147434	chr14:71811526	G/T	cg02058870	chr14:72053146	SIPA1L1	0.47	9.3	0.4	5.63e-19	Mitral valve prolapse;
LGG	cis	rs2439831	0.850	rs12440573	chr15:44108997	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.42	0.4	2.07e-19	Lung cancer in ever smokers;
LGG	cis	rs9487094	0.922	rs971434	chr6:109977308	C/T	cg16315928	chr6:109776240	MICAL1	0.54	9.12	0.39	2.36e-18	Height;
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg24692254	chr21:30365293	RNF160	-1.03	-29.71	-0.81	2.35e-109	Dental caries;
LGG	cis	rs9309711	0.643	rs4535074	chr2:3481637	A/G	cg10845886	chr2:3471009	TTC15	-0.48	-9.75	-0.41	1.54e-20	Neurofibrillary tangles;
LGG	cis	rs2857078	0.627	rs1476512	chr17:42330122	C/T	cg13607699	chr17:42295918	UBTF	-0.55	-9.78	-0.41	1.2e-20	Red cell distribution width;Reticulocyte count;
LGG	cis	rs989128	0.517	rs1809284	chr17:48632310	A/G	cg20467136	chr17:48638190	CACNA1G	0.46	6.93	0.31	1.43e-11	Type 2 diabetes;
LGG	cis	rs4319547	0.695	rs10773152	chr12:122910180	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.66	-0.41	3.08e-20	Body mass index;
LGG	cis	rs548181	0.536	rs503288	chr11:125461787	C/T	cg03464685	chr11:125439445	EI24	-1.21	-20.34	-0.69	3.47e-66	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.41	-6.91	-0.31	1.58e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs440932	0.887	rs398801	chr8:9031704	A/T	cg16141378	chr3:129829833	LOC729375	0.33	6.98	0.31	1.02e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs3087591	0.960	rs9896041	chr17:29571326	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.82	-0.57	5.98e-41	Hip circumference;
LGG	cis	rs8063761	0.689	rs4785763	chr16:90066936	G/T	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.64	-10.96	-0.45	5.38e-25	Squamous cell carcinoma;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.86e-26	Bipolar disorder;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg05793240	chr7:2802953	GNA12	0.34	7.73	0.34	6.78e-14	Height;
LGG	cis	rs7589342	0.791	rs4438504	chr2:106461035	A/C	cg14210321	chr2:106509881	NCK2	-0.57	-9.86	-0.42	6.03e-21	Addiction;
LGG	cis	rs739401	1.000	rs739401	chr11:3036324	C/T	cg05729581	chr11:3078854	CARS	0.5	8.77	0.38	3.36e-17	Longevity;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg13206674	chr6:150067644	NUP43	0.42	9.07	0.39	3.52e-18	Testicular germ cell tumor;
LGG	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg20578329	chr17:80767326	TBCD	-0.47	-8.16	-0.35	3.19e-15	Breast cancer;
LGG	trans	rs9329221	0.657	rs17694485	chr8:10114458	A/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.02	-0.35	8.65e-15	Neuroticism;
LGG	trans	rs2574985	0.739	rs3011797	chr10:52318372	C/T	cg18558237	chr10:81444220	LOC650623	0.44	6.73	0.3	5e-11	Subjective well-being;
LGG	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg11789530	chr4:8429930	ACOX3	-0.67	-10.94	-0.45	6.1e-25	Response to antineoplastic agents;
LGG	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-7.04	-0.31	7.09e-12	Renal cell carcinoma;
LGG	cis	rs2976388	0.609	rs2585150	chr8:143792669	C/T	cg06565975	chr8:143823917	SLURP1	0.35	9.03	0.39	4.78e-18	Urinary tract infection frequency;
LGG	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg10483660	chr13:112241077	NA	0.35	6.9	0.31	1.67e-11	Menarche (age at onset);
LGG	cis	rs11608355	1.000	rs11608355	chr12:109879292	T/C	cg19025524	chr12:109796872	NA	-0.49	-9.16	-0.39	1.68e-18	Neuroticism;
LGG	cis	rs736408	0.632	rs2240919	chr3:52831701	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.49	0.33	3.55e-13	Bipolar disorder;
LGG	trans	rs6787172	0.742	rs2362972	chr3:158163272	C/A	cg23275840	chr4:47708675	CORIN	-0.39	-8.39	-0.36	6.05e-16	Subjective well-being;
LGG	cis	rs9549367	0.713	rs2146750	chr13:113822530	A/G	cg18105134	chr13:113819100	PROZ	0.71	14.31	0.55	9.9e-39	Platelet distribution width;
LGG	trans	rs8073060	0.544	rs7210966	chr17:33986334	G/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.21	-0.65	2.86e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.44	0.58	1.11e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg19147804	chr7:1989927	MAD1L1	-0.6	-11.86	-0.48	1.57e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.62	-0.41	4.28e-20	Prostate cancer;
LGG	cis	rs1801251	0.727	rs283482	chr2:233646920	A/T	cg25237894	chr2:233734115	C2orf82	0.49	9.29	0.4	6.22e-19	Coronary artery disease;
LGG	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26306683	chr17:18585705	ZNF286B	-0.39	-7.43	-0.33	5.17e-13	Educational attainment (years of education);
LGG	cis	rs7928758	1.000	rs7928758	chr11:134265967	T/G	cg25213107	chr11:134282864	B3GAT1	1.09	13.63	0.54	7.97e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7727544	1.000	rs10076701	chr5:131596419	A/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.88	-0.3	2e-11	Blood metabolite levels;
LGG	cis	rs1127311	0.905	rs6699729	chr1:154582896	A/T	cg11650704	chr1:154556575	ADAR	-0.49	-9.53	-0.41	8.8e-20	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg03517284	chr6:25882590	NA	0.62	11.91	0.48	9.93e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.57	-8.49	-0.37	2.73e-16	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17492891	chr22:41843204	TOB2	0.48	7.57	0.33	2.03e-13	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs17401966	0.838	rs1013953	chr1:10319459	T/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.78	-0.45	2.6e-24	Hepatocellular carcinoma;
LGG	cis	rs17253792	0.822	rs10129890	chr14:56040413	A/T	cg01858014	chr14:56050164	KTN1	-0.87	-11.23	-0.46	4.6e-26	Putamen volume;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.77	-0.54	2.03e-36	Alzheimer's disease;
LGG	cis	rs1707322	0.963	rs11211229	chr1:46400517	A/C	cg03146154	chr1:46216737	IPP	0.54	10.15	0.43	5.47e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.517	rs10772139	chr12:34186178	A/T	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs8020289	1.000	rs10133337	chr14:77286526	A/T	cg23436960	chr14:77239540	VASH1	-0.25	-6.67	-0.3	7.17e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg00376283	chr12:123451042	ABCB9	0.66	12.09	0.49	1.95e-29	Platelet count;
LGG	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs258892	0.895	rs10042574	chr5:72085684	C/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.73	-0.3	5.05e-11	Small cell lung carcinoma;
LGG	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.22e-12	Neuroticism;
LGG	cis	rs9814567	1.000	rs9828815	chr3:134265749	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10876993	0.855	rs10877007	chr12:58100058	T/A	cg18357645	chr12:58087776	OS9	0.7	12.45	0.5	6.78e-31	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs11098499	0.863	rs12498539	chr4:120468370	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.57	0.47	2.27e-27	Corneal astigmatism;
LGG	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg12654349	chr5:56205094	C5orf35	-0.37	-6.69	-0.3	6.33e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg11584989	chr19:19387371	SF4	0.44	7.88	0.34	2.34e-14	Tonsillectomy;
LGG	cis	rs950776	0.684	rs11637635	chr15:78877150	A/G	cg16751781	chr15:78858589	CHRNA5	-0.43	-8.09	-0.35	5.44e-15	Sudden cardiac arrest;
LGG	cis	rs9354352	0.791	rs4710306	chr6:66700271	A/G	cg07460842	chr6:66804631	NA	-0.68	-12.46	-0.5	6.29e-31	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg20913747	chr6:44695427	NA	-0.52	-7.59	-0.33	1.8e-13	Total body bone mineral density;
LGG	cis	rs2587949	0.571	rs2600138	chr3:4208596	G/C	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.76e-11	Periodontitis (DPAL);
LGG	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.73	0.38	4.52e-17	Myopia (pathological);
LGG	cis	rs72772090	0.539	rs11749811	chr5:96115925	C/T	cg00188032	chr5:96141721	ERAP1	0.55	7.25	0.32	1.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.78	0.34	4.68e-14	Glycated hemoglobin levels;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-8.2	-0.36	2.3e-15	Mean corpuscular volume;
LGG	cis	rs2204008	0.805	rs7296063	chr12:37964775	T/G	cg26384229	chr12:38710491	ALG10B	0.97	22.24	0.72	4.27e-75	Bladder cancer;
LGG	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg12463550	chr7:65579703	CRCP	0.78	8.51	0.37	2.43e-16	Diabetic kidney disease;
LGG	cis	rs7932354	0.554	rs6485721	chr11:47040854	A/G	cg03339077	chr11:47165057	C11orf49	-0.52	-9.86	-0.42	5.9e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25427524	chr10:38739819	LOC399744	-0.66	-12.22	-0.49	5.69e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg05096777	chr10:104283225	SUFU	0.32	7.0	0.31	9.19e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3733585	0.673	rs4580649	chr4:9948461	G/A	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.16	-0.35	3.13e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9487094	0.600	rs10457193	chr6:109828567	C/T	cg16315928	chr6:109776240	MICAL1	0.46	8.09	0.35	5.25e-15	Height;
LGG	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.11	-0.43	7.37e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg22907277	chr7:1156413	C7orf50	0.84	14.93	0.57	2e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg02002194	chr4:3960332	NA	0.47	8.7	0.37	5.68e-17	Neuroticism;
LGG	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg25767906	chr1:53392781	SCP2	-0.37	-7.37	-0.32	8.05e-13	Monocyte count;
LGG	cis	rs28830936	0.966	rs17733613	chr15:41917585	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.54	-12.46	-0.5	6.26e-31	Diastolic blood pressure;
LGG	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	11.02	0.46	3e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11645898	0.935	rs8047881	chr16:72193906	A/G	cg14768367	chr16:72042858	DHODH	-0.74	-10.11	-0.43	7.91e-22	Blood protein levels;
LGG	cis	rs7589342	0.899	rs879900	chr2:106494347	A/G	cg14210321	chr2:106509881	NCK2	-0.57	-10.07	-0.42	1.1e-21	Addiction;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.89	-0.38	1.36e-17	Lung cancer;
LGG	cis	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg21775007	chr8:11205619	TDH	0.61	10.14	0.43	6.02e-22	Retinal vascular caliber;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg05868516	chr6:26286170	HIST1H4H	0.44	7.49	0.33	3.6e-13	Educational attainment;
LGG	cis	rs36051895	0.664	rs10974960	chr9:5095842	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.08	-0.6	1.57e-46	Pediatric autoimmune diseases;
LGG	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs875971	0.545	rs2173571	chr7:65770379	G/A	cg11764359	chr7:65958608	NA	0.63	9.45	0.4	1.68e-19	Aortic root size;
LGG	trans	rs877282	0.891	rs11595385	chr10:800539	A/G	cg22713356	chr15:30763199	NA	0.57	8.48	0.37	3.14e-16	Uric acid levels;
LGG	cis	rs2235642	0.928	rs56289115	chr16:1608934	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	9.94	0.42	3.08e-21	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25759457	chr1:172502420	C1orf9	0.4	7.15	0.32	3.37e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.75	0.38	3.99e-17	Prudent dietary pattern;
LGG	cis	rs10504073	0.584	rs56134839	chr8:49918899	C/T	cg00325661	chr8:49890786	NA	0.82	16.57	0.61	9.7e-49	Blood metabolite ratios;
LGG	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00855626	chr19:5690231	RPL36	0.47	6.88	0.3	1.98e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	1.000	rs1993891	chr3:161047467	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-14.96	-0.57	1.49e-41	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.501	rs7563462	chr2:100063708	T/C	cg23527387	chr2:100056660	REV1	0.42	9.46	0.4	1.52e-19	Chronic sinus infection;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02018176	chr4:1364513	KIAA1530	0.48	11.49	0.47	4.85e-27	Longevity;
LGG	cis	rs9470366	0.509	rs4713996	chr6:36629714	C/T	cg08179530	chr6:36648295	CDKN1A	-0.66	-11.63	-0.48	1.37e-27	QRS duration;
LGG	cis	rs4820539	1.000	rs885964	chr22:23461003	G/C	cg14186256	chr22:23484241	RTDR1	1.0	25.57	0.77	1.43e-90	Bone mineral density;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg25545336	chr2:223520958	FARSB	-0.46	-7.49	-0.33	3.58e-13	Height;
LGG	cis	rs2354432	0.607	rs9782976	chr1:146825049	A/G	cg25205988	chr1:146714368	CHD1L	1.14	13.0	0.52	3.58e-33	Mitochondrial DNA levels;
LGG	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg06697600	chr4:7070879	GRPEL1	-0.49	-7.72	-0.34	7.25e-14	Monocyte percentage of white cells;
LGG	cis	rs7927771	0.524	rs7929725	chr11:47881740	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	1.92e-25	Subjective well-being;
LGG	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg16141378	chr3:129829833	LOC729375	0.32	7.27	0.32	1.59e-12	Acne (severe);
LGG	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg00504896	chr12:9437009	LOC642846	-0.61	-12.96	-0.52	5.53e-33	Breast size;
LGG	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg18225595	chr11:63971243	STIP1	0.53	10.58	0.44	1.47e-23	Platelet count;
LGG	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.65e-26	Hemoglobin concentration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg24337644	chr2:234262978	DGKD	0.63	7.3	0.32	1.26e-12	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs78487399	0.808	rs17030845	chr2:43687879	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.85	-0.3	2.31e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg00319359	chr11:70116639	PPFIA1	0.76	8.3	0.36	1.15e-15	Coronary artery disease;
LGG	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg13852791	chr20:30311386	BCL2L1	0.77	12.43	0.5	8.14e-31	Mean corpuscular hemoglobin;
LGG	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg13770153	chr20:60521292	NA	-0.49	-7.84	-0.34	3.08e-14	Body mass index;
LGG	cis	rs6918586	0.658	rs198809	chr6:26128766	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.78	-0.41	1.13e-20	Schizophrenia;
LGG	cis	rs11098499	0.604	rs2389882	chr4:120566733	A/C	cg24375607	chr4:120327624	NA	0.64	10.34	0.43	1.12e-22	Corneal astigmatism;
LGG	cis	rs9894429	1.000	rs11651264	chr17:79576394	A/G	cg18240062	chr17:79603768	NPLOC4	-0.75	-13.86	-0.54	8.31e-37	Eye color traits;
LGG	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27201871	chr17:79212816	C17orf56;C17orf89	-0.46	-6.68	-0.3	7.08e-11	Systemic lupus erythematosus;
LGG	cis	rs1620921	0.563	rs2465850	chr6:161281175	T/C	cg01280913	chr6:161186852	NA	-0.37	-7.64	-0.33	1.23e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs12643440	0.538	rs2314602	chr4:17144535	A/G	cg22650099	chr4:17144496	NA	-0.51	-8.68	-0.37	6.69e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg09754948	chr16:28834200	ATXN2L	0.46	7.04	0.31	6.88e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12586317	0.620	rs17103042	chr14:35575428	T/C	cg16230307	chr14:35515116	FAM177A1	0.87	12.99	0.52	4.16e-33	Psoriasis;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg08621203	chr6:150244597	RAET1G	0.42	7.15	0.32	3.34e-12	Lung cancer;
LGG	cis	rs4561483	0.801	rs33620	chr16:12008546	C/G	cg08843971	chr16:11963173	GSPT1	-0.68	-18.56	-0.65	6.74e-58	Testicular germ cell tumor;
LGG	cis	rs9911578	1.000	rs3744109	chr17:56594197	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg11871910	chr12:69753446	YEATS4	0.66	12.34	0.5	1.92e-30	Response to diuretic therapy;
LGG	cis	rs7113874	0.524	rs4929945	chr11:8625451	C/T	cg23764900	chr11:8616102	STK33	0.4	6.89	0.3	1.83e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.96	0.38	7.71e-18	Alzheimer's disease;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.91e-60	Menopause (age at onset);
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-10.17	-0.43	4.61e-22	Lymphocyte counts;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg25811766	chr13:21894605	NA	0.8	16.12	0.6	9.65e-47	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg07538946	chr5:131705188	SLC22A5	0.65	7.59	0.33	1.75e-13	Rheumatoid arthritis;
LGG	cis	rs1965732	0.504	rs13004799	chr2:3716456	G/A	cg15327641	chr2:3715039	ALLC	0.34	7.46	0.33	4.34e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1371867	0.846	rs1660316	chr8:101333049	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs763121	0.853	rs4821810	chr22:39072098	C/G	cg06022373	chr22:39101656	GTPBP1	0.92	19.23	0.67	5.33e-61	Menopause (age at onset);
LGG	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8060686	0.545	rs11043	chr16:68262958	G/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-6.93	-0.31	1.46e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg23601095	chr6:26197514	HIST1H3D	0.72	9.21	0.39	1.11e-18	Gout;Renal underexcretion gout;
LGG	cis	rs6489785	0.701	rs1732395	chr12:121361389	T/C	cg02419362	chr12:121203948	SPPL3	0.45	7.07	0.31	5.63e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg12395012	chr8:11607386	GATA4	0.38	6.83	0.3	2.61e-11	Neuroticism;
LGG	cis	rs1977876	0.929	rs6679498	chr1:211712690	A/G	cg01575408	chr1:211752895	SLC30A1	0.48	6.89	0.3	1.87e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg02002194	chr4:3960332	NA	0.47	9.07	0.39	3.47e-18	Neuroticism;
LGG	cis	rs876084	0.545	rs10096311	chr8:121102031	A/G	cg06265175	chr8:121136014	COL14A1	0.47	9.58	0.41	5.76e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	7.31	0.32	1.16e-12	Renal function-related traits (BUN);
LGG	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.29	-0.53	2.24e-34	Retinal vascular caliber;
LGG	cis	rs3820928	0.874	rs7605032	chr2:227847630	T/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.14e-14	Pulmonary function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05213609	chr16:51185407	SALL1	0.45	7.46	0.33	4.27e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7619833	0.719	rs653465	chr3:27343644	A/G	cg02860705	chr3:27208620	NA	-0.41	-7.74	-0.34	6.4e-14	Breast cancer;
LGG	cis	rs9906944	0.864	rs9902512	chr17:47094274	C/G	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.95	-0.31	1.26e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg12310025	chr6:25882481	NA	-0.72	-13.57	-0.53	1.46e-35	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	cis	rs72634258	0.554	rs12741937	chr1:7897622	A/T	cg26816564	chr1:7831052	VAMP3	0.8	11.33	0.47	2.01e-26	Inflammatory bowel disease;
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg04025307	chr7:1156635	C7orf50	0.63	8.3	0.36	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1800795	0.901	rs2069833	chr7:22767664	C/T	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	9.38e-16	Cerebrospinal fluid clusterin levels in APOEe4- carriers;
LGG	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	5.14e-20	Hypertriglyceridemia;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02711726	chr17:80685570	FN3KRP	-0.44	-8.37	-0.36	6.65e-16	Glycated hemoglobin levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08415592	chr22:36648973	APOL1	-0.56	-7.76	-0.34	5.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg11062466	chr8:58055876	NA	0.62	9.71	0.41	2.14e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.592	rs61927752	chr12:33697205	T/C	cg06521331	chr12:34319734	NA	0.4	6.94	0.31	1.33e-11	Morning vs. evening chronotype;
LGG	cis	rs2012796	0.872	rs59397507	chr14:81821334	A/G	cg02996355	chr14:81879375	NA	0.52	8.22	0.36	2.03e-15	Night sleep phenotypes;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	0.920	rs9348759	chr6:27290888	C/T	cg15325629	chr6:28072465	NA	0.84	6.73	0.3	4.88e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2197308	0.643	rs1842597	chr12:37862142	C/G	cg26384229	chr12:38710491	ALG10B	-0.84	-18.28	-0.65	1.36e-56	Morning vs. evening chronotype;
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07685180	chr8:600429	NA	0.76	8.41	0.36	5.29e-16	IgG glycosylation;
LGG	cis	rs2224391	0.628	rs2753240	chr6:5254124	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.38	-0.32	7.43e-13	Height;
LGG	cis	rs4742903	0.740	rs4596709	chr9:106978756	G/C	cg14250997	chr9:106856677	SMC2	0.4	8.2	0.36	2.46e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.82	-0.38	2.39e-17	Lung cancer;
LGG	cis	rs2916247	1.000	rs7830403	chr8:93008852	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.42	-8.77	-0.38	3.37e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4849845	0.598	rs3933620	chr2:121034936	A/T	cg15425061	chr2:121036351	RALB	0.37	6.7	0.3	6.04e-11	Mean platelet volume;
LGG	trans	rs11098499	0.955	rs4145951	chr4:120155817	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.05	0.46	2.29e-25	Corneal astigmatism;
LGG	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg26384229	chr12:38710491	ALG10B	-0.87	-19.72	-0.68	2.77e-63	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs490234	0.841	rs829311	chr9:128394623	C/T	cg14078157	chr9:128172775	NA	-0.4	-7.4	-0.33	6.58e-13	Mean arterial pressure;
LGG	cis	rs73110464	0.505	rs2682296	chr12:53308265	G/A	cg05393297	chr12:53359155	NA	-0.29	-7.04	-0.31	7.05e-12	Cancer (pleiotropy);
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.65	0.33	1.19e-13	Lung cancer;
LGG	cis	rs300703	0.542	rs67993758	chr2:179594	C/T	cg24565620	chr2:194026	NA	0.65	10.24	0.43	2.59e-22	Blood protein levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03324837	chr17:61044407	NA	0.44	7.73	0.34	6.62e-14	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7923837	1.000	rs11187144	chr10:94469980	T/C	cg25093409	chr10:94429542	NA	0.4	7.29	0.32	1.36e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs9397585	0.759	rs9384067	chr6:153369336	A/G	cg17707550	chr6:153380415	RGS17	0.63	14.82	0.57	5.76e-41	Body mass index;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg21724239	chr8:58056113	NA	0.53	7.58	0.33	1.92e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg24397884	chr7:158709396	WDR60	0.87	17.1	0.62	3.54e-51	Height;
LGG	trans	rs9354308	0.868	rs4388276	chr6:66546565	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.28	-0.36	1.29e-15	Metabolite levels;
LGG	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.02e-24	Schizophrenia;
LGG	cis	rs4731207	0.698	rs10255209	chr7:124554927	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.71	-0.34	7.67e-14	Cutaneous malignant melanoma;
LGG	cis	rs11225247	1.000	rs11547915	chr11:102272839	C/A	cg06323957	chr11:102217781	BIRC2	0.8	6.79	0.3	3.39e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs4075765	0.764	rs17308964	chr11:26273971	A/G	cg19182008	chr11:26298241	NA	0.98	9.09	0.39	2.96e-18	Cannabis dependence symptom count;
LGG	cis	rs7928758	0.887	rs74639401	chr11:134264213	C/T	cg15243474	chr11:134282918	B3GAT1	1.26	16.28	0.6	1.93e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.29	0.32	1.34e-12	Hair morphology;
LGG	cis	rs12643440	0.538	rs62296683	chr4:17137441	C/G	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg22437258	chr11:111473054	SIK2	0.4	6.98	0.31	1.05e-11	Primary sclerosing cholangitis;
LGG	cis	rs4731207	0.596	rs1585967	chr7:124613344	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs3820068	0.559	rs6675334	chr1:15923580	A/T	cg05660106	chr1:15850417	CASP9	0.83	17.08	0.62	4.32e-51	Systolic blood pressure;
LGG	cis	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.69	0.34	8.67e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3126085	0.515	rs11204995	chr1:152359168	C/T	cg26876637	chr1:152193138	HRNR	-0.43	-6.67	-0.3	7.24e-11	Atopic dermatitis;
LGG	cis	rs79057730	1.000	rs79057730	chr7:784943	C/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.87	9.44	0.4	1.79e-19	Initial pursuit acceleration;
LGG	cis	rs11123610	0.520	rs60644898	chr2:3718646	G/A	cg26344334	chr2:3718215	ALLC	-0.48	-8.34	-0.36	8.6e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4555082	0.834	rs1473672	chr14:105721981	G/T	cg10792982	chr14:105748885	BRF1	0.67	13.42	0.53	6.38e-35	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.63	-0.41	4e-20	Triglycerides;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg21782813	chr7:2030301	MAD1L1	0.5	12.49	0.5	4.52e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs1015291	0.708	rs1565591	chr12:19997707	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.17	-0.32	2.94e-12	Diastolic blood pressure;
LGG	cis	rs10752881	0.839	rs6692207	chr1:183085304	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	cis	rs1065656	0.500	rs2575352	chr16:1835393	A/G	cg26697477	chr16:1836234	NUBP2	0.44	6.67	0.3	7.46e-11	Insulin-like growth factors;
LGG	cis	rs514024	0.708	rs574771	chr9:130483831	C/T	cg13643465	chr9:130375613	STXBP1	0.57	10.49	0.44	3e-23	Eating disorders (purging via substances);
LGG	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.33	0.4	4.55e-19	Height;
LGG	cis	rs4319547	0.695	rs4758662	chr12:122924778	G/A	cg23029597	chr12:123009494	RSRC2	-0.93	-17.17	-0.62	1.73e-51	Body mass index;
LGG	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg06481639	chr22:41940642	POLR3H	0.51	7.43	0.33	5.18e-13	Vitiligo;
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs7122539	0.722	rs7119426	chr11:66649612	A/G	cg01599099	chr11:66649832	PC	0.45	9.05	0.39	4.07e-18	HIV-1 susceptibility;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg03528353	chr17:61819722	STRADA	0.39	6.75	0.3	4.33e-11	Prudent dietary pattern;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.41	0.61	5.12e-48	Lymphocyte counts;
LGG	cis	rs7568458	0.870	rs1058588	chr2:85808871	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-8.14	-0.35	3.61e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg19223190	chr17:80058835	NA	-0.45	-8.68	-0.37	6.89e-17	Life satisfaction;
LGG	cis	rs939658	0.935	rs2204069	chr15:79449335	A/G	cg17916960	chr15:79447300	NA	0.65	12.65	0.51	1.04e-31	Refractive error;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.87	-0.38	1.58e-17	Menopause (age at onset);
LGG	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-8.74	-0.38	4.21e-17	Electroencephalogram traits;
LGG	trans	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg02002194	chr4:3960332	NA	0.43	8.02	0.35	8.87e-15	Triglycerides;
LGG	cis	rs3206736	0.548	rs328900	chr7:35020280	C/T	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.19e-19	Diastolic blood pressure;
LGG	cis	rs911119	1.000	rs73318135	chr20:23618571	T/G	cg16589663	chr20:23618590	CST3	0.48	6.76	0.3	4.11e-11	Chronic kidney disease;
LGG	cis	rs9287719	0.967	rs10203785	chr2:10752508	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.31	0.47	2.39e-26	Corneal astigmatism;
LGG	trans	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg14222797	chr10:16859974	RSU1	-0.66	-7.62	-0.33	1.41e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.05	-0.57	5.94e-42	Platelet count;
LGG	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12582317	chr17:55822272	NA	0.69	20.1	0.68	4.8e-65	Schizophrenia;
LGG	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg16339924	chr4:17578868	LAP3	0.64	10.61	0.44	1.07e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17208368	0.628	rs12447137	chr16:55093833	A/G	cg09947736	chr16:55091198	NA	0.69	13.13	0.52	1.04e-33	Hypospadias;
LGG	cis	rs13102973	0.933	rs7656595	chr4:135875693	G/A	cg14419869	chr4:135874104	NA	0.58	10.99	0.45	4.16e-25	Subjective well-being;
LGG	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-8.39	-0.36	5.81e-16	Blood protein levels;
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg25517755	chr10:38738941	LOC399744	-0.38	-6.82	-0.3	2.92e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10484885	0.824	rs72919976	chr6:90526686	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-10.84	-0.45	1.55e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12195424	0.730	rs74957402	chr6:56303627	A/T	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4731207	0.535	rs1552120	chr7:124639238	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-10.07	-0.42	1.05e-21	Chronic sinus infection;
LGG	cis	rs17092148	1.000	rs6060047	chr20:33367400	G/T	cg12302830	chr20:33297742	TP53INP2	0.46	7.74	0.34	6.46e-14	Neuroticism;
LGG	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.92	0.51	8.35e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs9354308	0.868	rs7743811	chr6:66540028	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-7.96	-0.35	1.35e-14	Metabolite levels;
LGG	cis	rs2862064	1.000	rs2862064	chr5:156445827	C/G	cg12943317	chr5:156479607	HAVCR1	-0.79	-10.49	-0.44	3.07e-23	Platelet count;
LGG	cis	rs9863	0.828	rs12833624	chr12:124476873	C/T	cg13487667	chr12:124434373	CCDC92	-0.34	-6.87	-0.3	2.14e-11	White blood cell count;
LGG	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg25947184	chr8:1697459	NA	0.44	7.61	0.33	1.54e-13	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02064237	chr5:178323492	ZFP2	0.43	6.96	0.31	1.2e-11	Gut microbiome composition (summer);
LGG	cis	rs747650	0.892	rs1976143	chr11:47225534	G/A	cg03339077	chr11:47165057	C11orf49	-0.55	-10.37	-0.43	8.19e-23	Acne (severe);
LGG	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg08847533	chr14:75593920	NEK9	0.63	12.02	0.49	3.62e-29	Height;
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg05941027	chr17:61774174	LIMD2	-0.38	-9.8	-0.41	1.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11595794	chr4:186317094	ANKRD37	0.49	7.47	0.33	4.06e-13	Gut microbiome composition (summer);
LGG	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg04455712	chr21:45112962	RRP1B	-0.52	-9.51	-0.4	1.06e-19	Mean corpuscular volume;
LGG	cis	rs7618915	0.547	rs68021750	chr3:52624769	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg20607798	chr8:58055168	NA	0.63	7.43	0.33	5.39e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.522	rs6088736	chr20:30195166	C/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	1.000	rs73609764	chr8:58192971	G/A	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.614	rs4822053	chr22:42212936	C/A	cg17376030	chr22:41985996	PMM1	0.54	9.11	0.39	2.47e-18	Vitiligo;
LGG	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.18	-0.32	2.85e-12	Triglycerides;
LGG	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07570687	chr10:102243282	WNT8B	0.44	7.37	0.32	8.05e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs283228	0.798	rs2518174	chr6:101799965	A/G	cg27451362	chr6:101846650	GRIK2	0.71	11.33	0.47	1.97e-26	Coenzyme Q10 levels;
LGG	cis	rs9768139	0.524	rs7779175	chr7:158136918	C/T	cg06219351	chr7:158114137	PTPRN2	0.71	12.69	0.51	7.03e-32	Calcium levels;
LGG	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg09324608	chr17:30823087	MYO1D	0.33	8.02	0.35	8.89e-15	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23858532	chr4:154073915	TRIM2	0.45	6.95	0.31	1.27e-11	Gut microbiome composition (summer);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10667969	chr3:149181941	NA	0.41	7.12	0.31	4.28e-12	Body fat percentage;
LGG	trans	rs2204008	0.543	rs2387018	chr12:38065638	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.02	-0.39	5.01e-18	Bladder cancer;
LGG	cis	rs12286929	0.606	rs11823428	chr11:115071222	C/A	cg04055981	chr11:115044050	NA	0.38	7.1	0.31	4.82e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.96	0.54	3.1e-37	Lung cancer;
LGG	cis	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg21775007	chr8:11205619	TDH	0.54	8.86	0.38	1.76e-17	Neuroticism;
LGG	cis	rs73416724	1.000	rs77529883	chr6:43364634	C/G	cg26312998	chr6:43337775	ZNF318	0.6	8.45	0.37	3.85e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23247000	chr7:138794512	ZC3HAV1	0.45	7.7	0.34	8.49e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg11814155	chr7:99998594	ZCWPW1	0.61	8.94	0.38	9.54e-18	Platelet count;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-21.96	-0.71	9.54e-74	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.7	-0.45	4.85e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs308971	0.521	rs184262	chr3:12134740	A/G	cg15873301	chr3:12045459	SYN2	0.52	6.66	0.3	7.78e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs17301259	0.509	rs10232993	chr7:88407594	T/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.01	-0.31	8.67e-12	Heschl's gyrus morphology;
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg04450456	chr4:17643702	FAM184B	0.32	6.9	0.31	1.71e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4308124	0.708	rs28766030	chr2:111962429	T/C	cg04571233	chr2:111982156	NA	-0.6	-9.9	-0.42	4.32e-21	Vitiligo;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg00830817	chr11:109293614	C11orf87	0.4	6.77	0.3	4.02e-11	Schizophrenia;
LGG	trans	rs629535	0.814	rs654452	chr8:70074344	C/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg00800038	chr16:89945340	TCF25	-0.7	-7.96	-0.35	1.33e-14	Skin colour saturation;
LGG	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.61	0.41	4.55e-20	Mood instability;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-10.07	-0.42	1.1e-21	Depression;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg04503457	chr17:41445688	NA	-0.4	-9.42	-0.4	2.14e-19	Menopause (age at onset);
LGG	cis	rs9443645	0.869	rs11754419	chr6:79729648	A/G	cg18132916	chr6:79620363	NA	-0.3	-8.42	-0.36	4.84e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2798269	1.000	rs11148128	chr13:22066611	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.92	-0.31	1.46e-11	PR segment;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg11062466	chr8:58055876	NA	0.56	8.89	0.38	1.34e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11018904	0.906	rs12793836	chr11:89953493	C/T	cg27158573	chr11:89632121	NA	-0.41	-7.32	-0.32	1.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg01200585	chr1:228362443	C1orf69	-0.49	-8.12	-0.35	4.31e-15	Diastolic blood pressure;
LGG	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg12310025	chr6:25882481	NA	-0.4	-7.16	-0.32	3.28e-12	Height;
LGG	trans	rs208520	0.874	rs208512	chr6:66943869	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-15.08	-0.57	4.13e-42	Exhaled nitric oxide output;
LGG	trans	rs61931739	0.658	rs10772149	chr12:34285498	A/G	cg13010199	chr12:38710504	ALG10B	0.47	9.02	0.39	5.18e-18	Morning vs. evening chronotype;
LGG	cis	rs62064224	0.533	rs11657826	chr17:30790386	T/A	cg09324608	chr17:30823087	MYO1D	0.33	8.05	0.35	7.14e-15	Schizophrenia;
LGG	cis	rs9463078	0.547	rs9472336	chr6:44710392	G/A	cg25276700	chr6:44698697	NA	0.4	8.01	0.35	9.21e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08871016	chr21:45079232	HSF2BP;RRP1B	0.42	7.01	0.31	8.69e-12	Cognitive performance;
LGG	cis	rs3816183	0.793	rs11124894	chr2:43032241	A/G	cg14631114	chr2:43023945	NA	-0.47	-8.65	-0.37	8.38e-17	Hypospadias;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18036763	chr22:45404910	PHF21B	0.49	7.91	0.35	1.94e-14	Cognitive performance;
LGG	trans	rs9914544	0.545	rs7222748	chr17:18787976	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.92	-0.35	1.78e-14	Educational attainment (years of education);
LGG	cis	rs6860806	0.531	rs270612	chr5:131637338	G/A	cg07395648	chr5:131743802	NA	-0.49	-9.82	-0.42	8.75e-21	Breast cancer;
LGG	cis	rs9287719	0.967	rs6432119	chr2:10753687	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs76419734	0.510	rs12511885	chr4:106662118	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	10.91	0.45	8.29e-25	Post bronchodilator FEV1;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.42	-0.53	6.17e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02714062	chr19:18668982	C19orf50	0.54	8.37	0.36	6.81e-16	Gut microbiome composition (summer);
LGG	cis	rs12493885	0.725	rs57740056	chr3:153744530	A/C	cg17054900	chr3:154042577	DHX36	-0.62	-8.04	-0.35	7.6e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17767392	0.846	rs34911660	chr14:71752344	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.72	-0.38	5.02e-17	Mitral valve prolapse;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.26	0.55	1.6e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg19524238	chr7:2802976	GNA12	0.37	8.98	0.39	6.87e-18	Height;
LGG	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg26384229	chr12:38710491	ALG10B	1.08	29.82	0.81	8.13e-110	Heart rate;
LGG	cis	rs2760061	0.598	rs2796056	chr1:228122901	G/A	cg18477163	chr1:228402036	OBSCN	-0.26	-7.13	-0.31	3.81e-12	Diastolic blood pressure;
LGG	cis	rs9937943	0.667	rs35253850	chr16:74599103	T/C	cg01733217	chr16:74700730	RFWD3	0.66	9.35	0.4	3.61e-19	Neutrophil percentage of white cells;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.76	-0.38	3.82e-17	Life satisfaction;
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.54e-11	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09000178	chr16:67063319	CBFB	0.48	7.78	0.34	4.78e-14	Cognitive performance;
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs12580194	0.593	rs73326725	chr12:55749222	G/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05571164	chr3:23958917	NKIRAS1;RPL15	-0.39	-6.82	-0.3	2.78e-11	Brain structure;
LGG	cis	rs4865875	0.892	rs7728303	chr5:54101523	C/T	cg22421804	chr5:54100067	NA	-0.51	-7.72	-0.34	7.13e-14	Sense of smell;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg26138144	chr22:38071188	LGALS1	0.9	23.73	0.74	4.81e-82	Fat distribution (HIV);
LGG	trans	rs73198271	0.960	rs10503392	chr8:8609555	G/C	cg16141378	chr3:129829833	LOC729375	0.39	7.07	0.31	5.89e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4478858	0.775	rs6701667	chr1:31707971	A/C	cg19084893	chr1:31688959	NA	0.36	7.49	0.33	3.4e-13	Alcohol dependence;
LGG	cis	rs853679	0.517	rs6941992	chr6:28106141	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs910316	0.967	rs8007539	chr14:75664953	T/C	cg11812906	chr14:75593930	NEK9	-0.54	-9.86	-0.42	6.05e-21	Height;
LGG	cis	rs11628318	0.805	rs749543	chr14:103057250	C/A	cg12046867	chr14:103022105	NA	-0.66	-12.58	-0.5	2.09e-31	Platelet count;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg13206674	chr6:150067644	NUP43	0.66	14.45	0.56	2.41e-39	Lung cancer;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg14490972	chr6:43484812	POLR1C;YIPF3	0.47	7.14	0.31	3.73e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg26150922	chr2:100937072	LONRF2	0.59	11.34	0.47	1.85e-26	Intelligence (multi-trait analysis);
LGG	trans	rs4650994	0.525	rs11806608	chr1:178511375	T/C	cg05059571	chr16:84539110	KIAA1609	-0.6	-11.56	-0.47	2.48e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg20503657	chr10:835505	NA	0.47	6.66	0.3	7.66e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs9309473	1.000	rs7586463	chr2:73798476	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs2067615	0.931	rs1216006	chr12:107187780	G/A	cg15890332	chr12:107067104	RFX4	0.3	8.42	0.36	4.89e-16	Heart rate;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg02353165	chr6:42928485	GNMT	0.46	13.47	0.53	3.96e-35	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.46	9.19	0.39	1.35e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25415508	chr15:43622652	ADAL;LCMT2	0.49	7.04	0.31	7e-12	Gut microbiome composition (summer);
LGG	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg05234568	chr11:5960015	NA	-0.67	-11.33	-0.47	1.99e-26	DNA methylation (variation);
LGG	cis	rs975722	0.517	rs4148711	chr7:117230645	T/A	cg10524701	chr7:117356490	CTTNBP2	0.38	7.58	0.33	1.88e-13	Coronary artery disease;
LGG	cis	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.1	-0.39	2.63e-18	Mean corpuscular volume;
LGG	trans	rs61931739	0.513	rs2200555	chr12:33899381	C/G	cg26384229	chr12:38710491	ALG10B	0.65	12.5	0.5	4.35e-31	Morning vs. evening chronotype;
LGG	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg14673194	chr17:80132900	CCDC57	0.42	7.33	0.32	1.06e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.35	-8.03	-0.35	8.29e-15	Obesity;
LGG	trans	rs75804782	0.641	rs72987304	chr2:239345532	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.55	0.37	1.76e-16	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.91	-0.31	1.58e-11	Heart rate;
LGG	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.15	0.39	1.79e-18	Diabetic kidney disease;
LGG	cis	rs2921073	0.604	rs2979140	chr8:8267202	T/A	cg08975724	chr8:8085496	FLJ10661	0.37	6.85	0.3	2.33e-11	Parkinson's disease;
LGG	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg04568710	chr12:38710424	ALG10B	-0.4	-8.66	-0.37	8.17e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17689437	0.625	rs7499785	chr16:68601285	A/C	cg02972257	chr16:68554789	NA	0.45	7.69	0.34	8.92e-14	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs12476592	0.602	rs6546007	chr2:63724795	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.91	-0.31	1.64e-11	Childhood ear infection;
LGG	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg07061783	chr6:25882402	NA	0.39	6.79	0.3	3.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg22072935	chr14:105399595	NA	0.45	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs1355223	0.525	rs55796371	chr11:34872769	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.36	-0.36	7.56e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs11711311	1.000	rs7649590	chr3:113447267	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.63	0.51	1.29e-31	IgG glycosylation;
LGG	cis	rs4665809	0.590	rs17528653	chr2:26507724	T/C	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Gut microbiome composition (summer);
LGG	cis	rs2688419	0.537	rs528649	chr3:23051934	C/T	cg00327796	chr3:23032191	NA	0.4	7.41	0.33	5.85e-13	Type 2 diabetes;
LGG	cis	rs7193541	0.684	rs7201320	chr16:74694058	T/G	cg01733217	chr16:74700730	RFWD3	1.1	35.23	0.85	4.15e-133	Multiple myeloma;
LGG	cis	rs155076	1.000	rs598754	chr13:21845010	C/A	cg11317459	chr13:21872234	NA	-1.18	-19.46	-0.67	4.49e-62	White matter hyperintensity burden;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg01059449	chr18:44338099	ST8SIA5	0.36	7.9	0.34	2.1e-14	Personality dimensions;
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07685180	chr8:600429	NA	0.83	8.56	0.37	1.71e-16	IgG glycosylation;
LGG	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg03909863	chr11:638404	DRD4	-0.41	-6.82	-0.3	2.86e-11	Systemic lupus erythematosus;
LGG	cis	rs6500395	1.000	rs1872654	chr16:48671050	C/T	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg17911788	chr17:44343683	NA	0.47	7.94	0.35	1.56e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3748682	0.731	rs9729719	chr1:38298207	G/A	cg12658694	chr1:38397304	INPP5B	0.38	7.05	0.31	6.6e-12	Hypothyroidism;
LGG	cis	rs193541	0.632	rs30036	chr5:122278260	A/G	cg19412675	chr5:122181750	SNX24	0.55	8.72	0.38	5.04e-17	Glucose homeostasis traits;
LGG	cis	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg21775007	chr8:11205619	TDH	-0.52	-8.11	-0.35	4.57e-15	Triglycerides;
LGG	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs12893668	0.667	rs8017628	chr14:104047428	C/T	cg23335576	chr14:104009727	NA	0.48	8.38	0.36	6.6e-16	Reticulocyte count;
LGG	cis	rs11168187	0.843	rs3764017	chr12:48120899	G/T	cg12761788	chr12:48120090	P11	0.51	8.86	0.38	1.73e-17	Vertical cup-disc ratio;
LGG	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg11812906	chr14:75593930	NEK9	0.46	8.35	0.36	7.96e-16	Height;
LGG	cis	rs11098499	0.909	rs11098530	chr4:120413154	C/T	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs7568458	0.840	rs2886722	chr2:85742297	C/T	cg17127132	chr2:85788382	GGCX	-0.42	-6.96	-0.31	1.15e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2762353	0.902	rs1165199	chr6:25809087	C/T	cg18357526	chr6:26021779	HIST1H4A	0.56	9.75	0.41	1.45e-20	Blood metabolite levels;
LGG	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17453880	0.929	rs6886482	chr5:152031320	G/C	cg12297329	chr5:152029980	NA	-0.9	-23.63	-0.74	1.38e-81	Subjective well-being;
LGG	cis	rs4595586	0.545	rs12823721	chr12:39386461	G/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs4664308	0.618	rs4665138	chr2:160890427	C/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.62	-0.48	1.46e-27	Idiopathic membranous nephropathy;
LGG	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg00376283	chr12:123451042	ABCB9	0.61	9.26	0.4	7.96e-19	Neutrophil percentage of white cells;
LGG	cis	rs2274273	0.870	rs10139083	chr14:55782735	C/A	cg04306507	chr14:55594613	LGALS3	0.62	16.92	0.62	2.42e-50	Protein biomarker;
LGG	cis	rs7769051	0.522	rs11965927	chr6:133101353	T/C	cg22852734	chr6:133119734	C6orf192	1.36	11.23	0.46	4.84e-26	Type 2 diabetes nephropathy;
LGG	cis	rs6430585	0.528	rs660002	chr2:136723504	C/T	cg07169764	chr2:136633963	MCM6	1.16	22.21	0.72	5.84e-75	Corneal structure;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21963583	chr11:68658836	MRPL21	0.6	10.1	0.42	8.27e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7662987	0.517	rs2602845	chr4:100023944	T/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg18357526	chr6:26021779	HIST1H4A	0.59	10.27	0.43	1.95e-22	Height;
LGG	trans	rs970548	0.688	rs1059696	chr10:45934437	G/A	cg14222797	chr10:16859974	RSU1	-0.63	-7.52	-0.33	2.84e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg15704280	chr7:45808275	SEPT13	-0.93	-18.96	-0.66	9.95e-60	Coronary artery disease;
LGG	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11644478	chr21:40555479	PSMG1	-0.93	-17.42	-0.63	1.19e-52	Cognitive function;
LGG	cis	rs9486719	0.948	rs2472906	chr6:96875318	G/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs1165472	0.526	rs10443215	chr1:56112774	C/T	cg11523071	chr1:56160889	NA	0.31	7.18	0.32	2.82e-12	Paclitaxel-induced neuropathy;
LGG	trans	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg06875740	chr19:51307921	C19orf48	-0.66	-8.25	-0.36	1.7e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.76	-0.3	4.29e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs283228	0.617	rs775039	chr6:101782533	T/G	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.0	0.49	4.4e-29	Prudent dietary pattern;
LGG	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg25019033	chr10:957182	NA	-0.52	-9.54	-0.41	8.28e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.03	0.7	2.14e-69	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg12310025	chr6:25882481	NA	0.55	10.5	0.44	2.73e-23	Blood metabolite levels;
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg15921436	chr17:44337874	NA	0.57	11.87	0.48	1.52e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.41	-0.33	5.92e-13	Skin colour saturation;
LGG	cis	rs7192380	0.895	rs2917670	chr16:69758963	T/C	cg00738113	chr16:70207722	CLEC18C	0.3	8.34	0.36	8.84e-16	Sjögren's syndrome;
LGG	cis	rs7614311	0.636	rs56165216	chr3:63916620	C/T	cg22134162	chr3:63841271	THOC7	-0.43	-7.87	-0.34	2.49e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs60180747	0.909	rs112095287	chr15:66792087	C/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.38	0.43	8.13e-23	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs7572733	0.905	rs1866664	chr2:198860428	T/C	cg00792783	chr2:198669748	PLCL1	0.48	8.19	0.36	2.58e-15	Dermatomyositis;
LGG	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg26119090	chr2:26468346	HADHA;HADHB	0.8	13.01	0.52	3.41e-33	Gut microbiome composition (summer);
LGG	cis	rs2732480	0.577	rs2634684	chr12:48730875	C/T	cg21466736	chr12:48725269	NA	0.41	8.25	0.36	1.64e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg02462569	chr6:150064036	NUP43	-0.39	-8.32	-0.36	9.66e-16	Lung cancer;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg07701084	chr6:150067640	NUP43	0.7	13.41	0.53	6.81e-35	Lung cancer;
LGG	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.31e-17	Retinal vascular caliber;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg23302884	chr18:44338147	ST8SIA5	0.38	7.7	0.34	8.24e-14	Personality dimensions;
LGG	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.36	0.36	7.47e-16	Menarche (age at onset);
LGG	trans	rs1459104	0.714	rs36018195	chr11:55172856	G/A	cg15704280	chr7:45808275	SEPT13	0.71	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.46	-0.33	4.32e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	7.15	0.32	3.37e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs939658	0.683	rs8024572	chr15:79465600	A/G	cg17916960	chr15:79447300	NA	0.53	9.97	0.42	2.46e-21	Refractive error;
LGG	cis	rs4356203	0.870	rs214925	chr11:17234584	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.18	-0.32	2.84e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.93	-0.64	5.74e-55	Refractive error;
LGG	cis	rs10911251	0.528	rs2182020	chr1:183074964	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Colorectal cancer;
LGG	cis	rs7084402	0.967	rs11815274	chr10:60328891	A/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.42	-0.63	1.25e-52	Refractive error;
LGG	cis	rs9303401	0.614	rs34550282	chr17:57092788	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.62	0.53	8.78e-36	Cognitive test performance;
LGG	cis	rs6840360	1.000	rs2007218	chr4:152643972	A/G	cg22705602	chr4:152727874	NA	0.27	6.93	0.31	1.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.570	rs9905073	chr17:45468296	G/A	cg08085267	chr17:45401833	C17orf57	-0.51	-9.36	-0.4	3.44e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg07701084	chr6:150067640	NUP43	0.61	11.4	0.47	1.08e-26	Lung cancer;
LGG	cis	rs6964587	1.000	rs2282972	chr7:91666369	C/T	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.77e-16	Breast cancer;
LGG	cis	rs963731	0.522	rs297148	chr2:39323166	A/G	cg04010122	chr2:39346883	SOS1	-0.91	-8.03	-0.35	8.34e-15	Corticobasal degeneration;
LGG	cis	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg05623727	chr3:50126028	RBM5	0.39	8.61	0.37	1.13e-16	Body mass index;
LGG	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Neuroticism;
LGG	trans	rs7939886	0.920	rs12223248	chr11:55887633	A/C	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.43e-15	Myopia (pathological);
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg05941027	chr17:61774174	LIMD2	-0.35	-8.93	-0.38	1.04e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7940866	0.646	rs10894293	chr11:130824213	C/T	cg12179176	chr11:130786555	SNX19	-0.71	-13.1	-0.52	1.39e-33	Schizophrenia;
LGG	cis	rs7524258	0.778	rs12028181	chr1:7315085	C/T	cg07173049	chr1:7289937	CAMTA1	-0.64	-14.45	-0.56	2.37e-39	Tourette's syndrome or obsessive-compulsive disorder;
LGG	trans	rs3857536	0.813	rs2040594	chr6:66943966	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.68	-0.34	9.8e-14	Blood trace element (Cu levels);
LGG	cis	rs3768617	0.510	rs729819	chr1:183109034	G/A	cg07245641	chr1:182991651	LAMC1	0.38	8.21	0.36	2.17e-15	Fuchs's corneal dystrophy;
LGG	cis	rs908922	0.523	rs4845786	chr1:152510144	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.14	-0.55	5.49e-38	Hair morphology;
LGG	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg06951627	chr6:26196580	NA	0.46	6.87	0.3	2.07e-11	Gout;Renal underexcretion gout;
LGG	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.54	-0.61	1.31e-48	Height;
LGG	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4330281	0.630	rs7431897	chr3:17762335	G/T	cg20981856	chr3:17787350	NA	-0.39	-7.36	-0.32	8.74e-13	Schizophrenia;
LGG	cis	rs17401966	0.931	rs11585794	chr1:10443867	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.76	0.34	5.3e-14	Hepatocellular carcinoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08184047	chr17:79849980	ANAPC11;THOC4	0.42	6.73	0.3	5.13e-11	Cognitive performance;
LGG	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg20283391	chr11:68216788	NA	-0.49	-8.03	-0.35	8.02e-15	Total body bone mineral density;
LGG	trans	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg18187862	chr3:45730750	SACM1L	0.45	7.52	0.33	2.83e-13	Primary sclerosing cholangitis;
LGG	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg03433033	chr1:76189801	ACADM	0.65	8.64	0.37	9.04e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3008870	0.755	rs2815366	chr1:67499930	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.71	14.67	0.56	2.8e-40	Lymphocyte percentage of white cells;
LGG	cis	rs7572733	0.555	rs10202569	chr2:198934726	C/G	cg00792783	chr2:198669748	PLCL1	0.6	9.41	0.4	2.26e-19	Dermatomyositis;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg04861929	chr11:109293070	C11orf87	0.55	10.06	0.42	1.15e-21	Schizophrenia;
LGG	trans	rs1814175	0.817	rs11040474	chr11:49708441	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.19	-0.78	5.35e-98	Height;
LGG	cis	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.05	-0.46	2.38e-25	Resting heart rate;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg21862992	chr11:68658383	NA	0.51	8.58	0.37	1.46e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg21775007	chr8:11205619	TDH	0.83	14.62	0.56	4.6e-40	Retinal vascular caliber;
LGG	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.08e-14	Height;
LGG	cis	rs11608355	0.545	rs11615949	chr12:109894347	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	trans	rs1478897	0.898	rs2248700	chr8:11393745	G/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.83	-0.3	2.65e-11	Systemic lupus erythematosus;
LGG	cis	rs17253792	0.822	rs10151664	chr14:56029533	A/G	cg01858014	chr14:56050164	KTN1	-0.82	-11.17	-0.46	8.45e-26	Putamen volume;
LGG	cis	rs17776563	0.614	rs55893434	chr15:89131779	A/G	cg05013243	chr15:89149849	MIR1179	-0.34	-6.98	-0.31	1.05e-11	Thyroid hormone levels;
LGG	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg25664220	chr3:72788482	NA	-0.32	-8.77	-0.38	3.32e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs367943	0.698	rs2195373	chr5:112998798	G/C	cg12552261	chr5:112820674	MCC	0.55	9.94	0.42	3.16e-21	Type 2 diabetes;
LGG	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.55	-0.63	3e-53	Breast cancer;
LGG	cis	rs868036	0.681	rs28626095	chr15:68066729	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.32	-6.98	-0.31	1.06e-11	Restless legs syndrome;
LGG	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg03293884	chr10:82215075	TSPAN14	-0.43	-8.7	-0.37	6.04e-17	Post bronchodilator FEV1;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs9815354	1.000	rs9838965	chr3:41927938	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9596863	0.784	rs4242932	chr13:54448513	A/C	ch.13.53330881F	chr13:54432880	NA	-0.49	-7.75	-0.34	5.72e-14	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg13147721	chr7:65941812	NA	-0.84	-10.29	-0.43	1.7e-22	Diabetic kidney disease;
LGG	cis	rs7503807	0.515	rs12453034	chr17:78682756	G/A	cg06872548	chr17:78716983	RPTOR	0.37	6.95	0.31	1.28e-11	Obesity;
LGG	cis	rs959260	0.557	rs12936583	chr17:73304710	A/C	cg14668889	chr17:73230827	NUP85	0.53	9.11	0.39	2.43e-18	Systemic lupus erythematosus;
LGG	cis	rs1920116	0.778	rs6807681	chr3:169562443	C/T	cg08193579	chr3:169529701	LRRC34	0.42	7.36	0.32	8.71e-13	Glioma (high-grade);
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg11584989	chr19:19387371	SF4	0.44	7.88	0.34	2.34e-14	Tonsillectomy;
LGG	cis	rs240764	0.697	rs239195	chr6:101132368	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.7	0.3	6.24e-11	Neuroticism;
LGG	cis	rs4819052	0.684	rs914216	chr21:46698298	T/G	cg06618935	chr21:46677482	NA	-0.51	-9.83	-0.42	7.93e-21	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06557630	chr16:49889701	NA	0.59	6.69	0.3	6.48e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs9875589	0.628	rs62234602	chr3:14002170	A/G	cg19554555	chr3:13937349	NA	0.7	12.75	0.51	3.84e-32	Ovarian reserve;
LGG	cis	rs17433780	0.836	rs61798917	chr1:89506093	G/A	cg09516651	chr1:89888402	LOC400759	0.73	17.12	0.62	2.79e-51	Carotid intima media thickness;
LGG	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg19729930	chr2:74357872	NA	0.53	11.54	0.47	2.9e-27	Gestational age at birth (maternal effect);
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.94	-0.38	9.12e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-10.14	-0.43	5.94e-22	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg23131131	chr22:24373011	LOC391322	-0.5	-8.11	-0.35	4.62e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg08603382	chr10:743973	NA	0.42	7.73	0.34	6.7e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg03606772	chr1:152487856	CRCT1	0.29	6.7	0.3	6.13e-11	Hair morphology;
LGG	cis	rs12135191	0.771	rs12144786	chr1:236495893	C/T	cg21399712	chr1:236511386	NA	-0.41	-7.73	-0.34	6.82e-14	Urate levels (BMI interaction);
LGG	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.74	0.3	4.76e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs3736594	0.513	rs62138965	chr2:27816593	T/C	cg27432699	chr2:27873401	GPN1	0.57	8.48	0.37	3.02e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9733	0.818	rs6694531	chr1:150683512	C/A	cg13175981	chr1:150552382	MCL1	0.54	9.12	0.39	2.24e-18	Tonsillectomy;
LGG	cis	rs56307353	0.781	rs10425937	chr19:1959021	A/G	cg07946961	chr19:1955956	C19orf34;CSNK1G2	-0.32	-7.11	-0.31	4.52e-12	Coronary artery disease;
LGG	cis	rs6693567	0.565	rs35784258	chr1:150405882	T/C	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs2204008	0.775	rs11514369	chr12:38305411	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.59	0.69	2.29e-67	Bladder cancer;
LGG	cis	rs11630290	0.806	rs11631544	chr15:64098557	A/G	cg12036633	chr15:63758958	NA	-0.54	-7.61	-0.33	1.54e-13	Iris characteristics;
LGG	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.42	-0.33	5.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10743315	0.732	rs71539461	chr12:19443360	G/A	cg02471346	chr12:19282374	PLEKHA5	0.63	7.09	0.31	4.97e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	9.9700000000000009e-22	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03578541	chr16:72128063	TXNL4B;DHX38	0.46	6.98	0.31	1e-11	Gut microbiome composition (summer);
LGG	cis	rs12220238	0.730	rs11000899	chr10:75913055	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.87	0.45	1.13e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg05868516	chr6:26286170	HIST1H4H	0.45	7.58	0.33	1.93e-13	Educational attainment;
LGG	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg19680485	chr15:31195859	MTMR15	-0.46	-7.58	-0.33	1.93e-13	Huntington's disease progression;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg02018176	chr4:1364513	KIAA1530	-0.46	-11.04	-0.46	2.59e-25	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs11816064	chr10:931176	A/C	cg25019033	chr10:957182	NA	-0.55	-10.01	-0.42	1.79e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.51	-0.63	5e-53	Chronic sinus infection;
LGG	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.06	-0.31	6.13e-12	HDL cholesterol;
LGG	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.65	-10.73	-0.45	3.91e-24	Coronary artery disease;
LGG	cis	rs3806843	0.900	rs2563287	chr5:140124786	C/T	cg19875535	chr5:140030758	IK	0.52	10.93	0.45	6.84e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.98	0.42	2.2e-21	Joint mobility (Beighton score);
LGG	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg08297393	chr2:100937505	LONRF2	-0.42	-7.43	-0.33	5.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.903	rs6050482	chr20:25226327	C/T	cg06421707	chr20:25228305	PYGB	0.5	10.8	0.45	2.15e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg15948088	chr11:109293068	C11orf87	0.51	8.94	0.38	9.52e-18	Schizophrenia;
LGG	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	19.71	0.68	2.91e-63	Smoking behavior;
LGG	cis	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	5.23e-14	Bone mineral density;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.649	rs860088	chr12:33721807	T/C	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs7712401	0.601	rs35334805	chr5:122335261	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg00262122	chr8:11665843	FDFT1	0.45	7.3	0.32	1.23e-12	Myopia (pathological);
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.76	0.45	2.89e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.76	-0.38	3.82e-17	Life satisfaction;
LGG	cis	rs3849570	0.925	rs2873054	chr3:81888255	A/C	cg07356753	chr3:81810745	GBE1	-0.43	-6.97	-0.31	1.11e-11	Waist circumference;Body mass index;
LGG	cis	rs4950322	0.570	rs4950316	chr1:146745375	G/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	trans	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19894588	chr14:64061835	NA	-0.57	-9.05	-0.39	3.91e-18	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12949688	0.967	rs2332966	chr17:55819335	T/C	cg12229367	chr17:55822335	NA	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs9815354	0.953	rs13088394	chr3:41951715	G/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.32	-0.36	1.02e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs929354	0.772	rs6459737	chr7:156975136	G/A	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg26818257	chr2:241905806	NA	0.39	7.46	0.33	4.18e-13	Urinary metabolites;
LGG	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.63	-11.47	-0.47	5.85e-27	Obesity-related traits;
LGG	cis	rs7651736	1.000	rs7651736	chr3:136760598	A/G	cg21827317	chr3:136751795	NA	0.62	11.83	0.48	2.2e-28	Neuroticism;
LGG	cis	rs7267979	0.789	rs6050472	chr20:25219852	A/G	cg08601574	chr20:25228251	PYGB	0.37	7.54	0.33	2.51e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg16751781	chr15:78858589	CHRNA5	0.47	9.21	0.39	1.11e-18	Sudden cardiac arrest;
LGG	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.32	-0.36	9.9e-16	Myopia (pathological);
LGG	cis	rs2153535	0.580	rs1335636	chr6:8465047	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg06558623	chr16:89946397	TCF25	-1.03	-13.34	-0.53	1.47e-34	Skin colour saturation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20366603	chr17:7218821	GPS2	0.47	7.91	0.35	1.89e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.51	8.0	0.35	9.74e-15	Bipolar disorder;
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.27	0.32	1.52e-12	Neuroticism;
LGG	cis	rs7301826	1.000	rs10773822	chr12:131289107	C/G	cg11011512	chr12:131303247	STX2	0.35	7.55	0.33	2.34e-13	Plasma plasminogen activator levels;
LGG	cis	rs6540556	0.608	rs7532324	chr1:209918090	C/T	cg23920097	chr1:209922102	NA	-0.42	-7.39	-0.32	6.73e-13	Red blood cell count;
LGG	cis	rs1555895	0.633	rs7913077	chr10:845969	T/C	cg09361094	chr10:834503	NA	-0.29	-7.68	-0.34	9.32e-14	Survival in rectal cancer;
LGG	cis	rs6087990	0.735	rs4911261	chr20:31391360	A/G	cg13636640	chr20:31349939	DNMT3B	0.83	17.21	0.62	1.11e-51	Ulcerative colitis;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.51	-0.67	2.48e-62	Rheumatoid arthritis;
LGG	cis	rs994014	0.612	rs17499131	chr4:82208126	C/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.25	-0.32	1.76e-12	Height;
LGG	trans	rs1728785	1.000	rs889561	chr16:68605741	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs240764	0.507	rs9390682	chr6:101219119	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.15	0.32	3.4e-12	Neuroticism;
LGG	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg19812747	chr11:111475976	SIK2	0.48	9.43	0.4	1.91e-19	Primary sclerosing cholangitis;
LGG	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Vitiligo;
LGG	trans	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg11430096	chr6:110968061	CDK19	0.68	7.06	0.31	5.97e-12	Prostate cancer;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.77	0.48	3.55e-28	Obesity-related traits;
LGG	trans	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.67	-0.41	2.97e-20	Neuroticism;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg03188948	chr7:1209495	NA	0.48	7.73	0.34	6.76e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.3	-0.36	1.17e-15	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4888262	0.508	rs7193583	chr16:74649589	C/G	cg01733217	chr16:74700730	RFWD3	0.9	18.32	0.65	8.41e-57	Testicular germ cell tumor;
LGG	cis	rs9398803	0.723	rs853969	chr6:127061318	C/T	cg19875578	chr6:126661172	C6orf173	0.54	9.8	0.41	9.73e-21	Male-pattern baldness;
LGG	cis	rs4262150	0.672	rs72806712	chr5:152341536	T/C	cg12297329	chr5:152029980	NA	-0.58	-9.37	-0.4	3.3e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg04287289	chr16:89883240	FANCA	-0.4	-7.02	-0.31	7.97e-12	Vitiligo;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.85	0.59	1.66e-45	Lung cancer;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.6	-0.47	1.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2916247	1.000	rs6988317	chr8:93042221	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.42	-0.36	4.6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11676348	0.935	rs2230054	chr2:219000310	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-8.78	-0.38	3.29e-17	Ulcerative colitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09947615	chr4:42659549	ATP8A1	0.44	6.95	0.31	1.25e-11	Cognitive performance;
LGG	cis	rs2455799	0.613	rs13080234	chr3:15852492	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.83	-0.34	3.32e-14	Mean platelet volume;
LGG	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg13385794	chr1:248469461	NA	-0.46	-7.61	-0.33	1.54e-13	Common traits (Other);
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg21972741	chr5:435613	AHRR	0.49	8.55	0.37	1.83e-16	Cystic fibrosis severity;
LGG	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.22	-0.49	5.64e-30	Height;
LGG	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg06238570	chr21:40685208	BRWD1	-0.51	-8.56	-0.37	1.7e-16	Cognitive function;
LGG	trans	rs1814175	0.817	rs4405313	chr11:50013636	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.06	-0.35	6.5e-15	Monocyte count;
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg05692746	chr2:100937584	LONRF2	-0.64	-11.65	-0.48	1.14e-27	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.31	0.32	1.2e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4948496	1.000	rs12357548	chr10:63803472	A/G	cg16389209	chr10:63809121	ARID5B	0.36	6.94	0.31	1.33e-11	Systemic lupus erythematosus;
LGG	cis	rs9303401	0.646	rs7342863	chr17:57227010	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	8.08	0.35	5.62e-15	Cognitive test performance;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs912057	0.671	rs1294435	chr6:6745455	G/A	cg06612196	chr6:6737390	NA	0.49	10.42	0.44	5.36e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg11644478	chr21:40555479	PSMG1	-0.71	-12.51	-0.5	4.02e-31	Cognitive function;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs7584330	0.704	rs72620821	chr2:238362615	C/A	cg16989719	chr2:238392110	NA	-0.34	-6.71	-0.3	5.85e-11	Prostate cancer;
LGG	cis	rs1497828	0.956	rs2810768	chr1:217563928	T/C	cg04411442	chr1:217543379	NA	0.46	7.9	0.34	2.11e-14	Dialysis-related mortality;
LGG	cis	rs7072216	0.727	rs942809	chr10:100168001	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.87e-12	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00876541	chr19:10515578	MIR1181;CDC37	0.49	7.42	0.33	5.47e-13	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg24623649	chr8:11872141	NA	0.32	7.5	0.33	3.3e-13	Neuroticism;
LGG	cis	rs1577917	0.958	rs12199832	chr6:86652748	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg06850241	chr22:41845214	NA	-0.44	-7.22	-0.32	2.11e-12	Vitiligo;
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg18681998	chr4:17616180	MED28	0.84	18.52	0.65	1.01e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg02002194	chr4:3960332	NA	0.39	6.99	0.31	9.62e-12	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg03036210	chr16:89904091	SPIRE2	-0.6	-7.41	-0.33	6.12e-13	Skin colour saturation;
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg18446336	chr7:2847575	GNA12	-0.29	-7.08	-0.31	5.23e-12	Height;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg05335186	chr13:53173507	NA	0.47	9.53	0.41	8.63e-20	Lewy body disease;
LGG	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.75	-0.3	4.39e-11	Neuroticism;
LGG	trans	rs7395662	0.963	rs11039772	chr11:48513892	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.52	-0.33	2.88e-13	HDL cholesterol;
LGG	cis	rs6964587	1.000	rs6946356	chr7:91727385	G/A	cg17063962	chr7:91808500	NA	0.47	8.34	0.36	8.39e-16	Breast cancer;
LGG	cis	rs963731	0.649	rs61405040	chr2:39350372	T/C	cg04010122	chr2:39346883	SOS1	0.95	8.35	0.36	7.95e-16	Corticobasal degeneration;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg05665937	chr4:1216051	CTBP1	-0.51	-9.13	-0.39	2.07e-18	Obesity-related traits;
LGG	cis	rs6735179	0.588	rs6726313	chr2:1756908	C/T	cg08534653	chr2:1747700	PXDN	0.45	7.03	0.31	7.45e-12	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.14	0.6	7.8e-47	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06730340	chr3:9811714	CAMK1	-0.43	-6.67	-0.3	7.15e-11	Pancreatic cancer;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg25072359	chr17:41440525	NA	0.49	9.61	0.41	4.71e-20	Menopause (age at onset);
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.09e-13	Tonsillectomy;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg00689492	chr4:1303491	MAEA	0.51	8.94	0.38	9.13e-18	Obesity-related traits;
LGG	trans	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg16141378	chr3:129829833	LOC729375	0.34	7.71	0.34	7.71e-14	Mood instability;
LGG	cis	rs3219090	0.705	rs2695237	chr1:226603635	T/C	cg17127702	chr1:226594323	PARP1	0.38	12.28	0.5	3.31e-30	Melanoma;
LGG	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg12560992	chr17:57184187	TRIM37	0.93	16.69	0.61	2.65e-49	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.600	rs6461692	chr7:23139695	G/C	cg23682824	chr7:23144976	KLHL7	0.43	7.4	0.33	6.48e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs477895	0.568	rs34838337	chr11:63870892	T/C	cg04317338	chr11:64019027	PLCB3	0.58	7.06	0.31	6.19e-12	Mean platelet volume;
LGG	cis	rs738322	0.719	rs34066050	chr22:38612604	G/A	cg03162506	chr22:38580953	NA	-0.38	-9.8	-0.41	9.62e-21	Cutaneous nevi;
LGG	cis	rs7208859	0.673	rs11651802	chr17:29159660	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.01	-0.39	5.46e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg02733842	chr7:1102375	C7orf50	0.59	9.17	0.39	1.52e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9341808	0.754	rs3812126	chr6:80952701	A/G	cg08355045	chr6:80787529	NA	-0.41	-8.04	-0.35	7.63e-15	Sitting height ratio;
LGG	cis	rs10463316	0.817	rs6880228	chr5:150778145	A/T	cg03212797	chr5:150827313	SLC36A1	0.56	9.63	0.41	4.01e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg21045802	chr8:109455806	TTC35	0.53	9.96	0.42	2.56e-21	Dupuytren's disease;
LGG	cis	rs2798269	0.604	rs6490662	chr13:22153280	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-7.12	-0.31	4.18e-12	PR segment;
LGG	cis	rs28374715	0.609	rs8043237	chr15:41514298	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.01	-17.95	-0.64	4.74e-55	Ulcerative colitis;
LGG	cis	rs2587949	0.615	rs2629256	chr3:4190422	A/G	cg16519197	chr3:4211558	NA	-0.33	-6.84	-0.3	2.58e-11	Periodontitis (DPAL);
LGG	trans	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.37e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg17328964	chr8:145687451	CYHR1	0.5	9.06	0.39	3.82e-18	Age at first birth;
LGG	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.04	-0.49	3.21e-29	Response to antipsychotic treatment;
LGG	cis	rs12493885	0.725	rs4679728	chr3:153732761	G/C	cg17054900	chr3:154042577	DHX36	-0.72	-8.75	-0.38	3.92e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1707322	0.721	rs61784800	chr1:46178112	A/G	cg03146154	chr1:46216737	IPP	-0.56	-11.09	-0.46	1.64e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs4716602	0.827	rs10270019	chr7:156158973	T/C	cg16983916	chr7:156159713	NA	-0.39	-6.93	-0.31	1.39e-11	Anti-saccade response;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.11	0.31	4.53e-12	Lung cancer;
LGG	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.85	-0.3	2.41e-11	Retinal vascular caliber;
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.11e-12	Electroencephalogram traits;
LGG	cis	rs4330281	0.669	rs13320647	chr3:17589880	G/T	cg20981856	chr3:17787350	NA	-0.39	-7.22	-0.32	2.13e-12	Schizophrenia;
LGG	cis	rs6977660	0.941	rs10273208	chr7:19816371	T/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.44	0.33	4.79e-13	Thyroid stimulating hormone;
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.91	-0.35	1.91e-14	Obesity;
LGG	cis	rs7635838	0.819	rs7637414	chr3:11522228	C/G	cg00170343	chr3:11313890	ATG7	0.4	6.67	0.3	7.29e-11	HDL cholesterol;
LGG	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg27478167	chr7:817139	HEATR2	-0.43	-6.94	-0.31	1.3e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.66	11.73	0.48	5.24e-28	Obesity-related traits;
LGG	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg07303275	chr16:75499416	TMEM170A	0.41	7.33	0.32	1.01e-12	Dupuytren's disease;
LGG	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg21775007	chr8:11205619	TDH	-0.79	-13.87	-0.54	8e-37	Retinal vascular caliber;
LGG	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg26384229	chr12:38710491	ALG10B	-0.65	-11.82	-0.48	2.35e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg02002194	chr4:3960332	NA	0.4	7.05	0.31	6.45e-12	Neuroticism;
LGG	cis	rs9611519	0.780	rs9611528	chr22:41648502	T/C	cg06634786	chr22:41940651	POLR3H	-0.5	-8.33	-0.36	8.93e-16	Neuroticism;
LGG	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.75e-21	Schizophrenia;
LGG	cis	rs988958	0.567	rs10184755	chr2:42258948	C/T	cg19376973	chr2:42229025	NA	-0.65	-10.32	-0.43	1.29e-22	Hypospadias;
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg03732007	chr1:2071316	PRKCZ	-0.3	-8.06	-0.35	6.8e-15	Height;
LGG	cis	rs2836974	0.568	rs414850	chr21:40543337	A/C	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.23e-17	Cognitive function;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10698964	chr15:50647173	FLJ10038;GABPB1;LOC100129387	0.48	7.69	0.34	9.05e-14	Cognitive performance;
LGG	cis	rs12477438	0.520	rs6542865	chr2:99764521	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs1754541	1.000	rs1212212	chr1:101621894	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.39	6.8	0.3	3.28e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg06916706	chr16:4465613	CORO7	-0.84	-14.68	-0.56	2.41e-40	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13162615	chr17:58469452	USP32	0.6	6.81	0.3	3.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg18105134	chr13:113819100	PROZ	-0.68	-13.99	-0.55	2.38e-37	Platelet distribution width;
LGG	cis	rs6762	0.550	rs8672	chr11:838634	C/G	cg08498830	chr11:832797	CD151	-0.44	-7.03	-0.31	7.27e-12	Mean platelet volume;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg15971980	chr6:150254442	NA	0.43	7.43	0.33	5.38e-13	Lung cancer;
LGG	cis	rs4474465	1.000	rs4944200	chr11:78166930	C/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.58	-0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs6580649	1.000	rs6580649	chr12:48410517	A/G	cg24011408	chr12:48396354	COL2A1	0.6	7.42	0.33	5.76e-13	Lung cancer;
LGG	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg11764359	chr7:65958608	NA	0.71	12.91	0.51	8.77e-33	Aortic root size;
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg13010199	chr12:38710504	ALG10B	0.57	10.85	0.45	1.41e-24	Morning vs. evening chronotype;
LGG	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.48	-9.05	-0.39	3.98e-18	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs8064024	0.513	rs1049207	chr16:4934564	C/G	cg08329684	chr16:4932620	PPL	-0.57	-12.97	-0.52	4.97e-33	Cancer;
LGG	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-8.53	-0.37	2.16e-16	Height;
LGG	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg20608306	chr11:116969690	SIK3	0.34	8.92	0.38	1.08e-17	Blood protein levels;
LGG	cis	rs789852	0.681	rs711981	chr3:194329482	G/A	cg18000598	chr3:194342907	TMEM44	-0.71	-7.44	-0.33	5.01e-13	QT interval;
LGG	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg08508325	chr11:3079039	CARS	0.41	7.89	0.34	2.15e-14	Calcium levels;
LGG	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.74	0.34	6.42e-14	Eosinophil percentage of white cells;
LGG	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.69	-0.3	6.61e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4262150	0.672	rs72797254	chr5:152012507	T/C	cg12297329	chr5:152029980	NA	-0.81	-16.01	-0.6	3.27e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg14092988	chr3:52407081	DNAH1	0.31	8.15	0.35	3.55e-15	Bipolar disorder;
LGG	cis	rs4423214	1.000	rs12419279	chr11:71139061	T/A	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.28	-0.53	2.59e-34	Vitamin D levels;
LGG	cis	rs9341808	0.791	rs1324122	chr6:80946061	G/A	cg08355045	chr6:80787529	NA	0.39	7.54	0.33	2.58e-13	Sitting height ratio;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg18446336	chr7:2847575	GNA12	-0.28	-6.75	-0.3	4.38e-11	Height;
LGG	cis	rs56161922	1.000	rs74184055	chr1:207852226	G/A	cg09557387	chr1:207818395	CR1L	0.95	9.51	0.4	1.03e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.1	-0.31	4.6e-12	Bipolar disorder;
LGG	cis	rs72717009	0.825	rs7539468	chr1:161477066	G/A	cg23840854	chr1:161414152	NA	-0.73	-8.81	-0.38	2.45e-17	Rheumatoid arthritis;
LGG	trans	rs2243480	1.000	rs316322	chr7:65611233	G/C	cg10756647	chr7:56101905	PSPH	0.82	9.5	0.4	1.12e-19	Diabetic kidney disease;
LGG	cis	rs1707322	1.000	rs11211222	chr1:46367757	T/C	cg03146154	chr1:46216737	IPP	0.54	10.37	0.43	8.54e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs758324	0.947	rs72793242	chr5:131242506	A/T	cg06307176	chr5:131281290	NA	-0.57	-9.43	-0.4	2.01e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2274273	0.588	rs2297816	chr14:55833038	A/G	cg04306507	chr14:55594613	LGALS3	0.5	11.6	0.47	1.78e-27	Protein biomarker;
LGG	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg03606772	chr1:152487856	CRCT1	0.29	6.7	0.3	6.13e-11	Hair morphology;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg00109274	chr13:42623032	DGKH	0.47	6.66	0.3	7.61e-11	Breast cancer;
LGG	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.43e-31	Motion sickness;
LGG	trans	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg00938859	chr5:1591904	SDHAP3	0.89	13.15	0.52	8.81e-34	Breast cancer;
LGG	cis	rs3812049	0.737	rs790155	chr5:127498380	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.91	0.42	4.16e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.25	0.55	1.9e-38	Obesity-related traits;
LGG	cis	rs2373794	0.884	rs4952491	chr2:40372775	G/A	cg17740179	chr2:40377776	SLC8A1	-0.88	-18.79	-0.66	5.78e-59	Asthma;
LGG	cis	rs2120243	0.874	rs2316708	chr3:157150299	G/A	cg24825693	chr3:157122686	VEPH1	-0.36	-7.67	-0.34	1.02e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7567389	0.504	rs2069898	chr2:128174227	T/C	cg10021288	chr2:128175891	PROC	0.38	6.71	0.3	5.7e-11	Self-rated health;
LGG	cis	rs11696845	0.626	rs1111032	chr20:43378770	A/G	cg25301532	chr20:43378953	KCNK15	0.48	12.13	0.49	1.31e-29	Obesity-related traits;
LGG	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg12463550	chr7:65579703	CRCP	0.81	8.69	0.37	6.08e-17	Diabetic kidney disease;
LGG	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-8.61	-0.37	1.12e-16	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26332365	chr19:2721063	DIRAS1	0.47	7.03	0.31	7.27e-12	Gut microbiome composition (summer);
LGG	cis	rs9309473	1.000	rs13428235	chr2:73633430	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.04	-0.35	7.59e-15	Metabolite levels;
LGG	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg00071950	chr4:10020882	SLC2A9	-0.38	-7.84	-0.34	3.11e-14	Bone mineral density;
LGG	cis	rs4740619	0.617	rs1328275	chr9:16027029	T/C	cg14451791	chr9:16040625	NA	-0.42	-11.23	-0.46	4.93e-26	Body mass index;
LGG	trans	rs2797160	0.651	rs1269176	chr6:126029682	A/T	cg05039488	chr6:79577232	IRAK1BP1	-0.49	-8.57	-0.37	1.6e-16	Endometrial cancer;
LGG	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg17294928	chr15:75287854	SCAMP5	-0.76	-8.52	-0.37	2.22e-16	Lung cancer;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20887711	chr4:1340912	KIAA1530	0.94	20.96	0.7	4.28e-69	Longevity;
LGG	cis	rs2239547	0.522	rs6768844	chr3:53004620	A/G	cg11645453	chr3:52864694	ITIH4	-0.67	-10.52	-0.44	2.33e-23	Schizophrenia;
LGG	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg11871910	chr12:69753446	YEATS4	0.92	22.2	0.72	6.71e-75	Blood protein levels;
LGG	cis	rs6539288	0.641	rs12318060	chr12:107340612	T/C	cg15890332	chr12:107067104	RFX4	0.32	8.41	0.36	5.03e-16	Total body bone mineral density;
LGG	cis	rs9660992	0.674	rs56198325	chr1:205265450	G/A	cg21545522	chr1:205238299	TMCC2	0.46	8.24	0.36	1.8e-15	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg17951613	chr5:131705445	SLC22A5	-0.61	-6.82	-0.3	2.82e-11	Rheumatoid arthritis;
LGG	cis	rs10991814	0.920	rs7874056	chr9:94087622	A/C	cg14446406	chr9:93919335	NA	-0.69	-8.0	-0.35	1.02e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs7191439	0.728	rs4238687	chr16:88788903	T/G	cg27087555	chr16:88793112	FAM38A	-1.41	-20.83	-0.7	1.71e-68	Plateletcrit;
LGG	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg02002194	chr4:3960332	NA	0.39	7.11	0.31	4.57e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg09222892	chr1:25734099	RHCE	-0.46	-9.58	-0.41	6.01e-20	Erythrocyte sedimentation rate;
LGG	cis	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg06609049	chr19:2785107	THOP1	0.61	9.57	0.41	6.22e-20	Total cholesterol levels;
LGG	cis	rs7236492	0.810	rs9957497	chr18:77227217	A/G	cg15644404	chr18:77186268	NFATC1	-0.77	-9.58	-0.41	5.95e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg00647317	chr7:50633725	DDC	-0.34	-7.55	-0.33	2.31e-13	Malaria;
LGG	cis	rs986417	0.901	rs10150982	chr14:60987006	T/G	cg27398547	chr14:60952738	C14orf39	0.71	6.82	0.3	2.93e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg00800038	chr16:89945340	TCF25	-0.65	-8.43	-0.36	4.49e-16	Skin colour saturation;
LGG	cis	rs10504130	0.569	rs4573262	chr8:52674809	A/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs62400317	0.826	rs4544895	chr6:45271917	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.29	-0.43	1.67e-22	Total body bone mineral density;
LGG	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.81	-0.3	3.02e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4356932	1.000	rs4302486	chr4:76953077	C/T	cg25799590	chr4:76943062	CXCL10;ART3	0.4	6.73	0.3	4.91e-11	Blood protein levels;
LGG	cis	rs3617	0.625	rs2240917	chr3:52851137	T/C	cg11645453	chr3:52864694	ITIH4	0.42	7.09	0.31	5.11e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs66573146	0.831	rs67315413	chr4:6987910	T/C	cg07817883	chr1:32538562	TMEM39B	1.26	12.0	0.49	4.34e-29	Granulocyte percentage of myeloid white cells;
LGG	trans	rs7939886	0.920	rs17145425	chr11:55950030	A/G	cg15704280	chr7:45808275	SEPT13	0.83	7.79	0.34	4.46e-14	Myopia (pathological);
LGG	cis	rs1153858	0.887	rs7164139	chr15:45670851	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.11	-0.31	4.54e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg11757124	chr7:157526947	PTPRN2	-0.79	-14.23	-0.55	2.18e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs34044649	0.840	rs1731840	chr7:155651490	C/A	cg17395211	chr7:155654226	NA	-0.37	-7.18	-0.32	2.81e-12	Triptolide cytotoxicity;
LGG	cis	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg09307838	chr4:120376055	NA	0.49	8.46	0.37	3.53e-16	Diastolic blood pressure;
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg13009111	chr11:71350975	NA	-0.3	-6.68	-0.3	7.04e-11	Systolic blood pressure;
LGG	cis	rs2439831	1.000	rs527921	chr15:43770416	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.92	-11.32	-0.47	2.23e-26	Lung cancer in ever smokers;
LGG	cis	rs877426	0.681	rs58312371	chr13:114837577	C/T	cg27119904	chr13:114814333	RASA3	0.36	7.34	0.32	9.85e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs11096990	0.892	rs6815686	chr4:39199791	A/T	cg24403649	chr4:39172243	NA	-0.48	-7.92	-0.35	1.78e-14	Cognitive function;
LGG	cis	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg14541582	chr5:601475	NA	-0.71	-10.17	-0.43	4.55e-22	Ulcerative colitis;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.914	rs4893823	chr2:178285811	C/T	cg27490568	chr2:178487706	NA	-0.51	-10.16	-0.43	4.85e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17818399	0.749	rs35625984	chr2:46805908	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.69	-11.45	-0.47	6.42e-27	Height;
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg12379764	chr21:47803548	PCNT	-0.43	-7.44	-0.33	5.07e-13	Testicular germ cell tumor;
LGG	cis	rs9916302	0.904	rs11078897	chr17:37415870	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.63	-0.48	1.27e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs972578	0.791	rs713776	chr22:43396094	A/G	cg01576275	chr22:43409880	NA	-0.25	-7.52	-0.33	2.87e-13	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.52	-0.4	9.84e-20	Lung cancer;
LGG	cis	rs981844	0.775	rs17299246	chr4:154743504	C/T	cg14289246	chr4:154710475	SFRP2	0.67	10.75	0.45	3.17e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs17376456	0.597	rs10866760	chr5:93338335	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.54	-7.65	-0.34	1.16e-13	Diabetic retinopathy;
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg13699009	chr12:122356056	WDR66	0.49	12.9	0.51	9.73e-33	Mean corpuscular volume;
LGG	cis	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg00383909	chr3:49044727	WDR6	0.44	7.35	0.32	9.28e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs516946	1.000	rs10109812	chr8:41524899	A/G	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs2046867	0.908	rs62251654	chr3:72816488	C/T	cg25664220	chr3:72788482	NA	-0.32	-8.78	-0.38	3.3e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17253792	0.545	rs35466279	chr14:56017022	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg25319279	chr11:5960081	NA	-0.58	-8.88	-0.38	1.47e-17	DNA methylation (variation);
LGG	cis	rs8114671	0.869	rs1407202	chr20:33651967	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.4	-0.36	5.49e-16	Height;
LGG	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.16	-0.32	3.18e-12	Neuroticism;
LGG	cis	rs787274	1.000	rs4979148	chr9:115553399	C/T	cg13803584	chr9:115635662	SNX30	-0.57	-7.86	-0.34	2.71e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg08222618	chr4:941054	TMEM175	0.82	20.4	0.69	1.83e-66	Sjögren's syndrome;
LGG	cis	rs2455799	0.574	rs2455801	chr3:15701857	C/T	cg16303742	chr3:15540471	COLQ	-0.42	-8.32	-0.36	9.73e-16	Mean platelet volume;
LGG	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg15627072	chr1:2432621	PLCH2	0.35	7.57	0.33	2.04e-13	Ulcerative colitis;
LGG	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.37	-0.36	7.07e-16	Mood instability;
LGG	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.42	-0.36	4.7e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1055129	0.560	rs56248937	chr17:73915153	T/A	cg14829360	chr17:73884958	NA	-0.54	-10.47	-0.44	3.77e-23	White matter hyperintensity burden;
LGG	cis	rs16854884	1.000	rs11924473	chr3:143787075	C/G	cg06585982	chr3:143692056	C3orf58	0.55	8.58	0.37	1.49e-16	Economic and political preferences (feminism/equality);
LGG	cis	rs7248779	0.512	rs7250002	chr19:2413188	A/G	cg22729335	chr19:2427816	TIMM13	1.18	25.78	0.77	1.62e-91	Cortisol levels (saliva);
LGG	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg21130718	chr4:1044621	NA	0.39	7.63	0.33	1.31e-13	Recombination rate (males);
LGG	trans	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.19e-12	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs9914242	chr17:29216245	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.67	-7.92	-0.35	1.83e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4909189	0.957	rs11766348	chr7:158135857	G/A	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.48	-0.4	1.34e-19	Response to amphetamines;
LGG	cis	rs2559856	1.000	rs2695292	chr12:102087290	G/A	cg12924262	chr12:102091054	CHPT1	0.66	13.1	0.52	1.41e-33	Blood protein levels;
LGG	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg07343612	chr16:622815	PIGQ	-0.54	-8.92	-0.38	1.08e-17	Height;
LGG	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg00599393	chr8:22457479	C8orf58	-0.49	-8.59	-0.37	1.32e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2734839	0.929	rs2734835	chr11:113291343	T/G	cg14159747	chr11:113255604	NA	0.28	7.34	0.32	9.48e-13	Information processing speed;
LGG	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg16339924	chr4:17578868	LAP3	0.51	8.5	0.37	2.54e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg12661370	chr5:149340060	SLC26A2	0.49	8.26	0.36	1.49e-15	HIV-1 control;
LGG	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg02023728	chr11:77925099	USP35	0.43	7.5	0.33	3.28e-13	Testicular germ cell tumor;
LGG	cis	rs367943	1.000	rs1057827	chr5:112823768	T/C	cg27587195	chr5:112824172	MCC	0.46	7.43	0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg24747557	chr10:131355152	MGMT	0.31	6.77	0.3	3.88e-11	Response to temozolomide;
LGG	cis	rs11122272	0.638	rs2739514	chr1:231514806	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.91	-0.45	7.92e-25	Hemoglobin concentration;
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg11766577	chr21:47581405	C21orf56	0.56	10.36	0.43	9.29e-23	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg18252515	chr7:66147081	NA	-1.43	-20.63	-0.69	1.61e-67	Diabetic kidney disease;
LGG	cis	rs4948275	0.550	rs10994742	chr10:63132240	A/T	cg03237606	chr10:63212265	TMEM26	0.48	8.78	0.38	3.15e-17	Night sleep phenotypes;
LGG	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.7e-18	Primary sclerosing cholangitis;
LGG	cis	rs7647973	1.000	rs10865956	chr3:49581559	C/A	cg07636037	chr3:49044803	WDR6	0.78	13.95	0.54	3.44e-37	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs2717559	0.542	rs11777634	chr8:143887957	C/T	cg07661805	chr8:143867942	LY6D	-0.3	-8.04	-0.35	7.38e-15	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05431828	chr3:51534252	VPRBP	0.46	6.9	0.31	1.73e-11	Gut microbiome composition (summer);
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.73e-15	Electroencephalogram traits;
LGG	cis	rs4700695	0.697	rs251319	chr5:65239468	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.53	0.33	2.65e-13	Facial morphology (factor 19);
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg13047869	chr3:10149882	C3orf24	0.46	7.33	0.32	1.05e-12	Alzheimer's disease;
LGG	cis	rs7552404	0.924	rs1858536	chr1:76161595	G/T	cg03433033	chr1:76189801	ACADM	0.81	15.06	0.57	5.32e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9487051	0.702	rs368467	chr6:109519451	T/C	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.65e-13	Reticulocyte fraction of red cells;
LGG	cis	rs13160562	0.509	rs26501	chr5:96100764	G/C	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.2	0.32	2.44e-12	Alcohol dependence;
LGG	cis	rs4423214	1.000	rs28364617	chr11:71159764	T/G	cg05163923	chr11:71159392	DHCR7	0.71	14.01	0.55	1.89e-37	Vitamin D levels;
LGG	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.94	0.31	1.3e-11	Bipolar disorder;
LGG	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg06637938	chr14:75390232	RPS6KL1	0.77	15.38	0.58	2.09e-43	Caffeine consumption;
LGG	cis	rs7208859	0.673	rs2269916	chr17:29233763	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	15.44	0.58	1.07e-43	Alzheimer's disease;
LGG	cis	rs28588043	0.877	rs28817631	chr1:170974368	G/C	cg03458344	chr1:170964477	C1orf129	-0.51	-7.3	-0.32	1.28e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs1568889	0.548	rs34906813	chr11:28508819	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.61	9.08	0.39	3.07e-18	Bipolar disorder;
LGG	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19671926	chr4:122722719	EXOSC9	0.46	7.06	0.31	6.08e-12	Type 2 diabetes;
LGG	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg09238746	chr17:78121135	EIF4A3	-0.82	-14.23	-0.55	2.21e-38	Yeast infection;
LGG	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg03433033	chr1:76189801	ACADM	-0.78	-12.63	-0.51	1.23e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg07001201	chr5:642380	CEP72	-0.41	-6.8	-0.3	3.16e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs721399	0.539	rs10087857	chr8:18267461	G/C	cg18736775	chr8:18248649	NAT2	-0.76	-11.7	-0.48	7.03e-28	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg05868516	chr6:26286170	HIST1H4H	0.45	7.66	0.34	1.09e-13	Educational attainment;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg15123824	chr2:85581917	ELMOD3;RETSAT	0.41	6.92	0.31	1.54e-11	Body mass index;
LGG	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg14222797	chr10:16859974	RSU1	0.71	8.21	0.36	2.27e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs981844	0.603	rs13132437	chr4:154748006	T/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.74	-0.41	1.68e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs6500395	1.000	rs11640463	chr16:48644434	A/T	cg04672837	chr16:48644449	N4BP1	0.55	9.07	0.39	3.5e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.64	-0.51	1.19e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg13385521	chr17:29058706	SUZ12P	0.82	9.45	0.4	1.76e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8180040	0.871	rs11716661	chr3:47517773	G/T	cg27129171	chr3:47204927	SETD2	-0.78	-14.99	-0.57	1.06e-41	Colorectal cancer;
LGG	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23544223	chr18:12777786	NA	0.61	9.28	0.4	6.32e-19	Inflammatory skin disease;
LGG	cis	rs7474896	0.537	rs2749588	chr10:38269457	C/G	cg25427524	chr10:38739819	LOC399744	-0.51	-7.59	-0.33	1.73e-13	Obesity (extreme);
LGG	cis	rs7444	0.941	rs2283790	chr22:21956653	C/T	cg22858872	chr22:21984481	YDJC	0.36	6.65	0.3	8.43e-11	Systemic lupus erythematosus;
LGG	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg09417038	chr21:47716443	C21orf57	0.39	7.85	0.34	2.97e-14	Testicular germ cell tumor;
LGG	cis	rs453301	0.686	rs7814328	chr8:8876229	T/C	cg11995313	chr8:8860691	ERI1	0.45	7.69	0.34	8.68e-14	Joint mobility (Beighton score);
LGG	cis	rs7444	0.941	rs11089629	chr22:21958872	T/G	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg07303275	chr16:75499416	TMEM170A	0.43	7.57	0.33	2.08e-13	Dupuytren's disease;
LGG	cis	rs34734847	1.000	rs3752531	chr12:121157851	A/G	cg21892295	chr12:121157589	UNC119B	-0.47	-8.96	-0.38	8.23e-18	Mean corpuscular volume;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg02772935	chr3:125709198	NA	-0.55	-7.05	-0.31	6.33e-12	Blood pressure (smoking interaction);
LGG	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg00898013	chr13:113819073	PROZ	-0.5	-9.9	-0.42	4.39e-21	Platelet distribution width;
LGG	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg22852734	chr6:133119734	C6orf192	1.23	9.58	0.41	5.81e-20	Type 2 diabetes nephropathy;
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-7.02	-0.31	8.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg05096777	chr10:104283225	SUFU	0.32	7.1	0.31	4.67e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs1739374	chr6:126011825	C/T	cg05901451	chr6:126070800	HEY2	0.44	7.49	0.33	3.43e-13	Endometrial cancer;
LGG	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.97	0.35	1.22e-14	Restless legs syndrome;
LGG	trans	rs11650494	0.908	rs111834333	chr17:47411814	C/T	cg11430096	chr6:110968061	CDK19	0.65	6.88	0.3	1.9e-11	Prostate cancer;
LGG	cis	rs6840360	0.615	rs4696266	chr4:152463421	A/G	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.588	rs11039782	chr11:48524785	A/G	cg03929089	chr4:120376271	NA	0.7	9.59	0.41	5.7e-20	Axial length;
LGG	cis	rs1707322	0.752	rs11211152	chr1:46114157	C/T	cg03146154	chr1:46216737	IPP	0.56	10.79	0.45	2.32e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7011049	1.000	rs72643579	chr8:53846705	C/A	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs7586879	1.000	rs7586879	chr2:25116977	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs11718455	0.960	rs34454748	chr3:44055091	C/T	cg21419209	chr3:44054225	NA	-0.45	-7.13	-0.31	3.92e-12	Coronary artery disease;
LGG	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg08198773	chr8:1697536	NA	-0.4	-6.86	-0.3	2.22e-11	Systolic blood pressure;
LGG	cis	rs8180040	0.800	rs6768221	chr3:47296899	C/G	cg16586182	chr3:47516702	SCAP	0.74	13.46	0.53	4.28e-35	Colorectal cancer;
LGG	cis	rs9486715	0.867	rs9373829	chr6:96897201	A/C	cg18709589	chr6:96969512	KIAA0776	-0.37	-7.02	-0.31	7.93e-12	Headache;
LGG	cis	rs2952156	0.920	rs14050	chr17:37828072	C/T	cg00129232	chr17:37814104	STARD3	-0.7	-14.46	-0.56	2.23e-39	Asthma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18451983	chr6:139695471	CITED2	-0.45	-7.68	-0.34	9.72e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6032067	0.714	rs35665166	chr20:43865006	A/G	cg10761708	chr20:43804764	PI3	0.57	8.76	0.38	3.76e-17	Blood protein levels;
LGG	cis	rs2251260	1.000	rs2251244	chr14:62023264	A/C	cg23386212	chr14:62041363	NA	0.7	11.44	0.47	7.38e-27	Yeast infection;
LGG	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg22961513	chr11:14280813	SPON1	-0.34	-8.29	-0.36	1.2e-15	Mitochondrial DNA levels;
LGG	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.95	-0.57	1.66e-41	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05232016	chr5:71604469	MRPS27	0.48	7.46	0.33	4.2e-13	Gut microbiome composition (summer);
LGG	cis	rs2018055	0.644	rs62433102	chr6:117802733	A/G	cg14611402	chr6:117803162	DCBLD1	0.3	8.92	0.38	1.06e-17	Diastolic blood pressure;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.31	6.74	0.3	4.67e-11	Schizophrenia;
LGG	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg27478167	chr7:817139	HEATR2	-0.44	-6.99	-0.31	9.55e-12	Cerebrospinal P-tau181p levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08211972	chr14:35008877	EAPP	0.45	6.67	0.3	7.41e-11	Gut microbiome composition (summer);
LGG	cis	rs796364	0.951	rs1105964	chr2:201000776	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.66	-0.37	7.67e-17	Schizophrenia;
LGG	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg12463550	chr7:65579703	CRCP	0.74	8.06	0.35	6.67e-15	Diabetic kidney disease;
LGG	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg11502198	chr6:26597334	ABT1	0.54	9.36	0.4	3.53e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12431410	0.892	rs1957989	chr14:60161154	C/T	cg07950296	chr14:60194823	RTN1	0.38	7.23	0.32	1.99e-12	Schizophrenia;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.42e-27	Rheumatoid arthritis;
LGG	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.97	-0.31	1.08e-11	Systolic blood pressure;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg10150615	chr22:24372951	LOC391322	0.4	6.66	0.3	7.66e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4595586	0.545	rs2197941	chr12:39402223	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs4538187	0.760	rs116503511	chr2:64155736	T/C	cg02541582	chr2:64069798	UGP2	-0.59	-12.55	-0.5	2.69e-31	Systolic blood pressure;
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.52	0.47	3.73e-27	Bipolar disorder;
LGG	cis	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg16807089	chr7:143582499	FAM115A	0.57	7.41	0.33	6.1e-13	Obesity-related traits;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13126279	chr21:47581558	C21orf56	-0.55	-9.97	-0.42	2.48e-21	Testicular germ cell tumor;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg14926445	chr8:58193284	C8orf71	-0.8	-9.74	-0.41	1.63e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg02002194	chr4:3960332	NA	-0.37	-6.71	-0.3	5.61e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7551222	0.752	rs12133735	chr1:204556836	G/T	cg20240347	chr1:204465584	NA	-0.48	-9.71	-0.41	2.14e-20	Schizophrenia;
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.57	-10.61	-0.44	1.09e-23	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg23057051	chr16:89984268	MC1R	-0.36	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs7208859	0.673	rs9899525	chr17:29120296	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs56283067	0.847	rs10456118	chr6:44692825	G/T	cg18551225	chr6:44695536	NA	-0.7	-12.4	-0.5	1.11e-30	Total body bone mineral density;
LGG	cis	rs7666738	0.791	rs7657399	chr4:98851861	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg12636538	chr11:118901039	SLC37A4	-0.62	-12.54	-0.5	2.9e-31	Coronary artery disease;
LGG	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg10483660	chr13:112241077	NA	0.36	7.14	0.31	3.63e-12	Menarche (age at onset);
LGG	cis	rs36051895	0.530	rs7036833	chr9:5226484	G/A	cg02405213	chr9:5042618	JAK2	-0.65	-11.9	-0.48	1.09e-28	Pediatric autoimmune diseases;
LGG	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.29	-0.32	1.34e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07704495	chr21:43916519	RSPH1	0.42	6.76	0.3	4.1e-11	Cognitive performance;
LGG	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg21238619	chr17:78079768	GAA	-0.37	-7.7	-0.34	8.27e-14	Yeast infection;
LGG	cis	rs3735485	0.800	rs4724344	chr7:45052352	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg15971980	chr6:150254442	NA	0.43	8.03	0.35	8.42e-15	Lung cancer;
LGG	trans	rs853679	0.607	rs13199906	chr6:27834139	C/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg15664640	chr17:80829946	TBCD	-0.46	-8.48	-0.37	3.08e-16	Glycated hemoglobin levels;
LGG	cis	rs283228	0.617	rs489458	chr6:101742573	T/C	cg27451362	chr6:101846650	GRIK2	0.86	13.5	0.53	3.05e-35	Coenzyme Q10 levels;
LGG	cis	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg21775007	chr8:11205619	TDH	-0.52	-7.83	-0.34	3.45e-14	Triglycerides;
LGG	cis	rs12368653	0.666	rs1050045	chr12:58115271	A/G	cg00700412	chr12:58011837	NA	0.37	7.51	0.33	3.12e-13	Multiple sclerosis;
LGG	trans	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg27661571	chr11:113659931	NA	-0.73	-9.73	-0.41	1.8e-20	Hip circumference adjusted for BMI;
LGG	cis	rs929596	0.793	rs2741046	chr2:234580249	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-10.05	-0.42	1.3e-21	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg18335740	chr13:41363409	SLC25A15	0.55	10.3	0.43	1.59e-22	Lewy body disease;
LGG	cis	rs17039065	0.920	rs17039063	chr4:109381134	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.93	0.31	1.41e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg18402987	chr7:1209562	NA	0.72	10.98	0.45	4.37e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg03188948	chr7:1209495	NA	0.63	8.3	0.36	1.14e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3916	0.911	rs7313271	chr12:121152667	C/T	cg21892295	chr12:121157589	UNC119B	-0.41	-7.26	-0.32	1.6e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs972578	0.791	rs9607955	chr22:43216733	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.91	-0.31	1.62e-11	Mean platelet volume;
LGG	cis	rs8064024	0.557	rs7193783	chr16:4949608	A/C	cg04440724	chr16:4920505	UBN1	0.48	9.36	0.4	3.47e-19	Cancer;
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg16507663	chr6:150244633	RAET1G	-0.44	-7.07	-0.31	5.76e-12	Lung cancer;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg04156016	chr5:1868137	NA	0.32	6.99	0.31	9.74e-12	Cardiovascular disease risk factors;
LGG	cis	rs2290402	0.536	rs4690203	chr4:881228	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-6.78	-0.3	3.58e-11	Type 2 diabetes;
LGG	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg09021430	chr5:549028	NA	-0.81	-12.73	-0.51	4.69e-32	Obesity-related traits;
LGG	cis	rs7617773	0.539	rs2017859	chr3:48382261	G/A	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg03701759	chr13:99174930	STK24	-0.36	-6.91	-0.31	1.64e-11	Longevity;
LGG	cis	rs9324022	0.626	rs10873520	chr14:101175967	G/A	cg18089426	chr14:101175970	NA	0.69	12.52	0.5	3.45e-31	Plateletcrit;
LGG	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.47	0.44	3.59e-23	Thyroid stimulating hormone;
LGG	cis	rs6547741	1.000	rs7604798	chr2:27824940	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg06916706	chr16:4465613	CORO7	-0.92	-16.2	-0.6	4.6e-47	Schizophrenia;
LGG	cis	rs7106204	0.748	rs4360697	chr11:24217160	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	16.19	0.6	5.04e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs79349575	0.749	rs1057902	chr17:47005588	C/T	cg22482690	chr17:47019901	SNF8	0.36	6.97	0.31	1.1e-11	Type 2 diabetes;
LGG	cis	rs9358372	1.000	rs4446563	chr6:20827072	G/A	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.35	-0.58	2.8e-43	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4975616	0.804	rs459961	chr5:1337106	T/A	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.31	-0.65	9.89e-57	Lung cancer;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.45	0.4	1.7e-19	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.23	0.39	9.96e-19	Bipolar disorder;
LGG	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg22920501	chr2:26401640	FAM59B	0.38	7.56	0.33	2.16e-13	Gut microbiome composition (summer);
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.81	-0.45	1.94e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13065938	chr1:186344998	TPR;C1orf27;MIR548F1	0.44	7.75	0.34	6.03e-14	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg12070911	chr6:150209640	RAET1E	0.32	7.66	0.34	1.14e-13	Lung cancer;
LGG	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs858239	0.632	rs6952947	chr7:23121042	C/G	cg23682824	chr7:23144976	KLHL7	-0.44	-7.59	-0.33	1.76e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7267979	0.789	rs62213729	chr20:25363426	C/T	cg06421707	chr20:25228305	PYGB	-0.37	-7.67	-0.34	1.03e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg24829409	chr8:58192753	C8orf71	-0.89	-13.51	-0.53	2.58e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs17060993	0.618	rs7459975	chr8:26846424	C/T	cg19071002	chr6:63940486	NA	-0.49	-6.89	-0.3	1.78e-11	Musician's dystonia;
LGG	cis	rs2629540	0.889	rs17624662	chr10:126408146	A/C	cg08799069	chr10:126477246	METTL10	0.65	13.04	0.52	2.52e-33	Cocaine dependence;
LGG	cis	rs9300255	0.537	rs1790101	chr12:123704844	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs910316	0.810	rs77939209	chr14:75670070	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.5	-0.4	1.16e-19	Height;
LGG	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.43e-20	Menopause (age at onset);
LGG	cis	rs1018836	0.923	rs9643308	chr8:91625399	A/C	cg16814680	chr8:91681699	NA	-0.84	-15.72	-0.59	6.06e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs870825	0.616	rs6843185	chr4:185649878	A/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.97	0.73	1.73e-78	Blood protein levels;
LGG	cis	rs6429082	0.715	rs2291687	chr1:235594182	A/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-9.06	-0.39	3.8e-18	Adiposity;
LGG	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg20587970	chr11:113659929	NA	-1.35	-24.03	-0.74	1.91e-83	Hip circumference adjusted for BMI;
LGG	cis	rs3106136	1.000	rs3106136	chr4:95153349	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.11	-0.35	4.54e-15	Capecitabine sensitivity;
LGG	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg01028140	chr2:1542097	TPO	-0.55	-8.55	-0.37	1.82e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6750795	0.502	rs11685196	chr2:232381298	A/G	cg19187155	chr2:232395269	NMUR1	0.46	8.2	0.36	2.43e-15	Height;
LGG	cis	rs11190604	1.000	rs11190607	chr10:102303614	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4076764	0.958	rs10917748	chr1:163400377	T/C	cg24596788	chr1:163392923	NA	-0.72	-13.75	-0.54	2.62e-36	Motion sickness;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.25	-0.32	1.74e-12	Prostate cancer;
LGG	cis	rs975722	0.646	rs34256873	chr7:117101285	A/C	cg10524701	chr7:117356490	CTTNBP2	0.42	9.35	0.4	3.73e-19	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.23	-0.39	1e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00567536	chr3:47422272	PTPN23	0.45	6.81	0.3	2.99e-11	Gut microbiome composition (summer);
LGG	trans	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg26518628	chr1:97050305	NA	-0.85	-8.7	-0.37	5.78e-17	Cannabis dependence symptom count;
LGG	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg03653399	chr8:142233436	SLC45A4	-0.44	-8.69	-0.37	6.51e-17	Immature fraction of reticulocytes;
LGG	trans	rs2727020	0.894	rs2866361	chr11:49372481	A/G	cg03929089	chr4:120376271	NA	-0.8	-13.38	-0.53	9.33e-35	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs736801	0.607	rs11739135	chr5:131733397	C/G	cg07395648	chr5:131743802	NA	-0.59	-12.93	-0.52	6.94e-33	Breast cancer;Mosquito bite size;
LGG	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg14593290	chr7:50529359	DDC	-0.66	-11.87	-0.48	1.53e-28	Malaria;
LGG	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.31	-0.5	2.57e-30	Height;
LGG	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg00504896	chr12:9437009	LOC642846	-0.53	-10.23	-0.43	2.84e-22	Breast size;
LGG	cis	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg12432903	chr7:1882776	MAD1L1	0.48	7.13	0.31	3.78e-12	Bipolar disorder;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs17453880	0.929	rs6868043	chr5:152031752	T/C	cg10931792	chr5:152022470	NA	0.41	8.95	0.38	8.35e-18	Subjective well-being;
LGG	trans	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2862064	1.000	rs1948760	chr5:156442784	T/A	cg12943317	chr5:156479607	HAVCR1	-0.76	-10.14	-0.43	5.86e-22	Platelet count;
LGG	cis	rs858239	0.600	rs6961406	chr7:23134891	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.35	0.32	9.24e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.49	0.4	1.27e-19	Alzheimer's disease;
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg03351412	chr1:154909251	PMVK	0.67	12.87	0.51	1.34e-32	Prostate cancer;
LGG	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg02574844	chr11:5959923	NA	-0.59	-10.19	-0.43	3.78e-22	DNA methylation (variation);
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	6.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.44	0.33	4.9e-13	Renal function-related traits (BUN);
LGG	cis	rs3857067	1.000	rs1397027	chr4:95013562	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.5	-0.33	3.38e-13	QT interval;
LGG	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	13.85	0.54	9.99e-37	Neutrophil percentage of white cells;
LGG	cis	rs8031584	0.678	rs35098644	chr15:31145440	A/G	cg14829155	chr15:31115871	NA	-0.66	-11.01	-0.46	3.28e-25	Huntington's disease progression;
LGG	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-11.93	-0.48	8.35e-29	Bladder cancer;
LGG	cis	rs10484885	0.793	rs1465954	chr6:90475013	G/A	cg13799429	chr6:90582589	CASP8AP2	0.86	13.4	0.53	7.83e-35	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2439831	0.850	rs544122	chr15:43775732	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	11.02	0.46	2.97e-25	Lung cancer in ever smokers;
LGG	cis	rs2692947	0.644	rs1168974	chr2:96814928	G/A	cg22654517	chr2:96458247	NA	0.36	7.28	0.32	1.47e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs6815814	0.898	rs1873195	chr4:38891173	C/T	cg06935464	chr4:38784597	TLR10	0.56	7.94	0.35	1.54e-14	Breast cancer;
LGG	cis	rs11971779	0.680	rs1986447	chr7:139082080	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg11211951	chr8:145729740	GPT	-0.52	-12.15	-0.49	1.17e-29	Age at first birth;
LGG	trans	rs783540	0.934	rs783532	chr15:83249367	C/T	cg16105309	chr15:79090380	ADAMTS7	0.41	7.24	0.32	1.84e-12	Schizophrenia;
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	15.74	0.59	5.03e-45	Alzheimer's disease;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg14092988	chr3:52407081	DNAH1	0.3	8.03	0.35	8.08e-15	Bipolar disorder;
LGG	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.96	-0.35	1.34e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg13334819	chr7:99746414	C7orf59	-0.46	-7.14	-0.32	3.53e-12	Coronary artery disease;
LGG	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.48	0.4	1.32e-19	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs9399137	0.507	rs28384513	chr6:135376209	T/G	cg22676075	chr6:135203613	NA	0.4	6.97	0.31	1.09e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7937612	1.000	rs10892576	chr11:120294423	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.07	-0.52	1.96e-33	Intraocular pressure;
LGG	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg00898013	chr13:113819073	PROZ	0.42	8.54	0.37	1.97e-16	Platelet distribution width;
LGG	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.17	0.6	5.99e-47	Hip circumference adjusted for BMI;
LGG	cis	rs7267979	0.903	rs2474766	chr20:25246153	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.57	0.44	1.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs74781061	0.929	rs12441932	chr15:74909999	C/G	cg02384859	chr15:74862662	ARID3B	-0.35	-6.83	-0.3	2.74e-11	Endometriosis;
LGG	cis	rs4262150	0.883	rs72802841	chr5:152205965	C/G	cg12297329	chr5:152029980	NA	-0.67	-12.49	-0.5	4.88e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs244899	0.967	rs2432642	chr5:167921047	C/G	cg06604206	chr5:167912465	RARS	-0.53	-11.71	-0.48	6.65e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg09467607	chr2:36825704	FEZ2	-0.52	-10.08	-0.42	9.82e-22	Height;
LGG	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	trans	rs561341	0.882	rs2428337	chr17:30299467	C/T	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs6723226	0.650	rs6729952	chr2:32764922	T/C	cg02381751	chr2:32503542	YIPF4	0.51	8.44	0.37	3.98e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2120243	0.845	rs2305619	chr3:157154861	A/G	cg24825693	chr3:157122686	VEPH1	-0.36	-7.63	-0.33	1.33e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg22432760	chr17:80829718	TBCD	0.39	6.84	0.3	2.53e-11	Breast cancer;
LGG	cis	rs11190604	1.000	rs7078799	chr10:102301447	G/A	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg27129171	chr3:47204927	SETD2	-0.78	-13.63	-0.54	8.27e-36	Colorectal cancer;
LGG	cis	rs1210638	0.545	rs6518507	chr22:18976479	C/G	cg12798833	chr22:18958832	DGCR5	-0.54	-9.55	-0.41	7.59e-20	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs2270927	0.510	rs7730153	chr5:75579762	A/G	cg13563193	chr19:33072644	PDCD5	-0.84	-10.62	-0.44	1.01e-23	Mean corpuscular volume;
LGG	cis	rs950169	0.922	rs4842946	chr15:84942331	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.69	0.37	6.32e-17	Schizophrenia;
LGG	cis	rs57502260	1.000	rs56312530	chr11:68219415	G/A	cg01657329	chr11:68192670	LRP5	-0.56	-7.21	-0.32	2.36e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs12410462	0.551	rs10047205	chr1:227831498	A/G	cg04117972	chr1:227635322	NA	-0.43	-8.05	-0.35	7.14e-15	Major depressive disorder;
LGG	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg06223162	chr1:101003688	GPR88	-0.43	-10.5	-0.44	2.87e-23	Breast cancer;
LGG	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg17077180	chr1:38461687	NA	0.39	8.6	0.37	1.28e-16	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs2046867	0.908	rs11927126	chr3:72806622	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.46	0.33	4.45e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11847263	0.525	rs1256536	chr14:65762476	A/G	cg15999311	chr14:65749247	NA	0.43	7.6	0.33	1.61e-13	IgG monogalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG digalactosylation phenotypes (multivariate analysis);IgG monosialylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG glycosylation;
LGG	trans	rs7395662	1.000	rs7944356	chr11:48610154	C/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs2282300	0.739	rs7942129	chr11:30224692	G/A	cg25418670	chr11:30344373	C11orf46	-0.57	-7.9	-0.34	2.03e-14	Morning vs. evening chronotype;
LGG	cis	rs8051149	0.625	rs74039983	chr16:87882539	A/G	cg01412419	chr16:87856264	NA	0.45	8.61	0.37	1.18e-16	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17337118	chr15:79574993	ANKRD34C	0.42	6.77	0.3	3.96e-11	Gut microbiome composition (summer);
LGG	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.42	-0.33	5.53e-13	Morning vs. evening chronotype;
LGG	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg25919922	chr13:100150906	NA	-0.74	-7.6	-0.33	1.69e-13	Obesity-related traits;
LGG	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Bladder cancer;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.73	0.38	4.61e-17	Lung cancer;
LGG	cis	rs7103648	1.000	rs2293579	chr11:47440758	G/A	cg20307385	chr11:47447363	PSMC3	0.98	24.06	0.75	1.48e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs3617	0.625	rs56019197	chr3:52874753	T/C	cg11645453	chr3:52864694	ITIH4	-0.44	-7.38	-0.32	7.49e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.54	-0.37	1.96e-16	Neuroticism;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.74	-0.34	6.41e-14	Menopause (age at onset);
LGG	cis	rs35110281	0.720	rs162374	chr21:44927089	T/C	cg01579765	chr21:45077557	HSF2BP	0.39	8.73	0.38	4.82e-17	Mean corpuscular volume;
LGG	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg24253500	chr15:84953950	NA	0.42	7.1	0.31	4.88e-12	Schizophrenia;
LGG	cis	rs12765878	0.675	rs3752946	chr10:105670849	A/T	cg11005552	chr10:105648138	OBFC1	0.94	20.84	0.7	1.56e-68	Coronary artery disease;
LGG	cis	rs10421328	0.784	rs12983292	chr19:19787767	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	7.57	0.33	2.09e-13	Parental longevity (combined parental age at death);
LGG	cis	rs113835537	0.529	rs3819247	chr11:66293779	T/C	cg24851651	chr11:66362959	CCS	0.46	7.91	0.35	1.89e-14	Airway imaging phenotypes;
LGG	cis	rs10463316	0.832	rs246483	chr5:150731062	C/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.29e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg27105630	chr8:38126556	PPAPDC1B	0.45	6.75	0.3	4.5e-11	Hip circumference;
LGG	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg05425664	chr17:57184151	TRIM37	-0.6	-9.39	-0.4	2.7e-19	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.19	0.43	3.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg02227867	chr8:22457446	C8orf58	-0.41	-7.94	-0.35	1.51e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg15971980	chr6:150254442	NA	0.44	8.43	0.36	4.56e-16	Lung cancer;
LGG	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg12501888	chr15:85177176	SCAND2	-0.55	-9.09	-0.39	2.85e-18	Schizophrenia;
LGG	cis	rs1003719	0.680	rs2835668	chr21:38580151	C/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.83	-0.57	5.4e-41	Eye color traits;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.89e-126	Prudent dietary pattern;
LGG	cis	rs6598955	0.543	rs3795687	chr1:26560745	G/A	cg04990556	chr1:26633338	UBXN11	0.72	10.72	0.45	4.17e-24	Obesity-related traits;
LGG	cis	rs897984	0.683	rs8046001	chr16:30833321	C/T	cg00531865	chr16:30841666	NA	-0.7	-16.87	-0.62	3.86e-50	Dementia with Lewy bodies;
LGG	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.94	0.45	5.96e-25	Morning vs. evening chronotype;
LGG	cis	rs6580649	0.941	rs58046797	chr12:48487619	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs3858526	0.796	rs9645652	chr11:5944264	C/T	cg05234568	chr11:5960015	NA	-0.67	-11.33	-0.47	1.99e-26	DNA methylation (variation);
LGG	cis	rs41271473	0.687	rs12078883	chr1:228875567	C/T	cg16512390	chr1:228756714	NA	0.44	6.97	0.31	1.11e-11	Chronic lymphocytic leukemia;
LGG	cis	rs564799	0.931	rs6771363	chr3:159730682	A/G	cg04855961	chr3:159719849	NA	-0.28	-7.62	-0.33	1.44e-13	Systemic lupus erythematosus;
LGG	cis	rs7617773	0.817	rs4131362	chr3:48329036	A/C	cg11946769	chr3:48343235	NME6	0.63	10.61	0.44	1.07e-23	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg04025307	chr7:1156635	C7orf50	0.68	8.63	0.37	9.91e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg07211511	chr3:129823064	LOC729375	-0.63	-8.58	-0.37	1.44e-16	Blood pressure (smoking interaction);
LGG	trans	rs12517041	1.000	rs1366453	chr5:23283409	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs858239	0.539	rs4377861	chr7:23185969	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.83	0.3	2.61e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs780094	0.500	rs4665382	chr2:27783801	T/C	cg27432699	chr2:27873401	GPN1	0.45	6.76	0.3	4.06e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs7084402	0.934	rs1658428	chr10:60330917	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs9964724	0.826	rs9961847	chr18:35181225	G/A	cg27332583	chr18:35150602	NA	-0.39	-8.28	-0.36	1.35e-15	Educational attainment (years of education);
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg24642844	chr7:1081250	C7orf50	-0.81	-13.52	-0.53	2.36e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg13699009	chr12:122356056	WDR66	-0.47	-12.39	-0.5	1.14e-30	Mean corpuscular volume;
LGG	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.7	0.3	6e-11	Menopause (age at onset);
LGG	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.46	7.74	0.34	6.42e-14	Cystic fibrosis severity;
LGG	cis	rs13260300	0.645	rs7017318	chr8:75514755	C/T	cg22993706	chr8:75542856	NA	0.41	7.95	0.35	1.49e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs12220238	1.000	rs11000900	chr10:75918440	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	10.98	0.45	4.51e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg26818010	chr10:134567672	INPP5A	-0.73	-11.03	-0.46	2.89e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7208859	0.573	rs7222803	chr17:29119897	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.25	-0.36	1.67e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.1	0.42	8.16e-22	Iron status biomarkers;
LGG	trans	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg26043149	chr18:55253948	FECH	0.96	17.29	0.63	4.71e-52	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	0.575	rs59424848	chr8:57999219	T/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.97	-0.31	1.11e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9937943	0.667	rs9938426	chr16:74523739	C/G	cg01733217	chr16:74700730	RFWD3	-0.63	-8.39	-0.36	6.16e-16	Neutrophil percentage of white cells;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.52	0.37	2.28e-16	Obesity-related traits;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.02	-0.42	1.62e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25836159	chr5:76326301	AGGF1	-0.48	-7.35	-0.32	8.95e-13	Pancreatic cancer;
LGG	cis	rs7793919	0.652	rs10228886	chr7:4783224	C/T	cg09789173	chr7:4769017	FOXK1	-0.69	-14.31	-0.55	1.02e-38	Mosquito bite size;
LGG	cis	rs2635047	0.811	rs12956009	chr18:44768024	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.37	0.36	6.88e-16	Educational attainment;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07677032	chr17:61819896	STRADA	0.65	12.03	0.49	3.53e-29	Prudent dietary pattern;
LGG	cis	rs877282	0.583	rs11253429	chr10:823234	A/C	cg15764593	chr10:829463	NA	-0.69	-9.72	-0.41	1.94e-20	Uric acid levels;
LGG	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs892961	0.806	rs35489990	chr17:75412312	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs6138458	0.620	rs2151462	chr20:24911823	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs938554	0.578	rs7663032	chr4:9993838	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-7.51	-0.33	3.07e-13	Blood metabolite levels;
LGG	cis	rs9467773	1.000	rs6940053	chr6:26562122	C/T	cg11502198	chr6:26597334	ABT1	0.57	9.96	0.42	2.72e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4974559	0.947	rs12639938	chr4:1343135	G/C	cg02980000	chr4:1222292	CTBP1	0.65	7.88	0.34	2.31e-14	Systolic blood pressure;
LGG	cis	rs5758659	0.729	rs134866	chr22:42650663	C/T	cg15128208	chr22:42549153	NA	-0.49	-9.87	-0.42	5.64e-21	Cognitive function;
LGG	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-12.13	-0.49	1.32e-29	Morning vs. evening chronotype;
LGG	cis	rs9473924	0.505	rs7756058	chr6:50904438	G/A	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg02002194	chr4:3960332	NA	-0.52	-10.09	-0.42	8.69e-22	Systolic blood pressure;
LGG	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg23188684	chr11:67383651	NA	-0.42	-6.8	-0.3	3.21e-11	Mean corpuscular volume;
LGG	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg03098644	chr7:100410630	EPHB4	0.52	7.83	0.34	3.44e-14	Other erythrocyte phenotypes;
LGG	cis	rs6918586	0.615	rs198824	chr6:26122783	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.52	-0.4	9.33e-20	Schizophrenia;
LGG	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.84e-40	Cognitive test performance;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg11245990	chr11:68621969	NA	-0.38	-8.32	-0.36	1.03e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs7584127	chr2:100001941	G/A	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs17401966	0.931	rs17034821	chr1:10414645	A/G	cg15208524	chr1:10270712	KIF1B	0.43	7.41	0.33	6.01e-13	Hepatocellular carcinoma;
LGG	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Myopia (pathological);
LGG	cis	rs6866344	0.697	rs11749438	chr5:178131245	C/T	cg10224037	chr5:178157518	ZNF354A	0.73	11.37	0.47	1.33e-26	Neutrophil percentage of white cells;
LGG	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg00204512	chr16:28754710	NA	0.26	7.2	0.32	2.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg20673091	chr1:2541236	MMEL1	-0.75	-17.93	-0.64	5.34e-55	Ulcerative colitis;
LGG	trans	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.07	0.39	3.28e-18	Neuroticism;
LGG	cis	rs17453880	0.853	rs60025184	chr5:151965130	G/A	cg12297329	chr5:152029980	NA	-0.86	-21.98	-0.71	7.27e-74	Subjective well-being;
LGG	cis	rs2916247	0.954	rs1484562	chr8:93131247	T/C	cg10183463	chr8:93005414	RUNX1T1	0.37	7.73	0.34	6.87e-14	Intelligence (multi-trait analysis);
LGG	cis	rs929596	0.785	rs6714634	chr2:234664765	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.72	12.82	0.51	2.03e-32	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.15e-18	Bladder cancer;
LGG	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg13271783	chr10:134563150	INPP5A	-0.59	-8.67	-0.37	7.24e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg25358565	chr5:93447407	FAM172A	1.37	17.05	0.62	6.38e-51	Diabetic retinopathy;
LGG	cis	rs854765	0.583	rs4925126	chr17:17798633	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.68	13.73	0.54	2.98e-36	Total body bone mineral density;
LGG	cis	rs11167764	1.000	rs6580220	chr5:141480558	G/A	cg08523384	chr5:141488047	NDFIP1	-0.37	-6.94	-0.31	1.37e-11	Crohn's disease;
LGG	cis	rs9398803	0.687	rs9482757	chr6:126923877	A/C	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.92e-19	Male-pattern baldness;
LGG	cis	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs2587949	0.571	rs931302	chr3:4210614	T/C	cg16519197	chr3:4211558	NA	0.37	7.42	0.33	5.49e-13	Periodontitis (DPAL);
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg18681998	chr4:17616180	MED28	0.83	18.35	0.65	6.74e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72827839	0.802	rs12951323	chr17:46027565	A/C	cg02219949	chr17:45927392	SP6	-0.47	-7.38	-0.32	7.3e-13	Ease of getting up in the morning;
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14159672	chr1:205819179	PM20D1	0.48	7.61	0.33	1.56e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	trans	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg24247370	chr13:99142703	STK24	-0.37	-6.86	-0.3	2.23e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	0.895	rs11039869	chr11:48622312	C/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs6547631	0.682	rs4832186	chr2:85929674	C/T	cg24620635	chr2:85921963	GNLY	0.56	11.24	0.46	4.47e-26	Blood protein levels;
LGG	cis	rs4478037	0.822	rs77355992	chr3:33107518	T/C	cg19404215	chr3:33155277	CRTAP	0.78	8.96	0.38	8.13e-18	Major depressive disorder;
LGG	cis	rs9868809	0.772	rs2286651	chr3:48694147	G/A	cg00383909	chr3:49044727	WDR6	0.84	10.04	0.42	1.33e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg11040518	chr10:102331378	NA	-0.4	-7.21	-0.32	2.34e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs611744	0.647	rs587340	chr8:109246032	C/A	cg18478394	chr8:109455254	TTC35	0.42	8.41	0.36	5.01e-16	Dupuytren's disease;
LGG	cis	rs2692947	0.726	rs13019188	chr2:96774199	A/G	cg22654517	chr2:96458247	NA	-0.39	-8.37	-0.36	6.83e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs3820928	0.845	rs13419076	chr2:227873028	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.52	-0.33	2.89e-13	Pulmonary function;
LGG	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs2011503	0.941	rs2074302	chr19:19381728	G/C	cg11584989	chr19:19387371	SF4	0.74	12.47	0.5	5.68e-31	Bipolar disorder;
LGG	cis	rs9912468	0.933	rs35183571	chr17:64305015	T/C	cg19474267	chr17:64306194	PRKCA	0.94	25.33	0.76	1.88e-89	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2832191	0.791	rs28633762	chr21:30500070	C/T	cg08807101	chr21:30365312	RNF160	-0.82	-16.77	-0.61	1.16e-49	Dental caries;
LGG	cis	rs2963155	0.518	rs862489	chr5:142634355	T/C	cg17617527	chr5:142782415	NR3C1	0.94	12.77	0.51	3.34e-32	Breast cancer;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22433210	chr17:43662623	NA	0.89	14.41	0.56	3.67e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2153535	0.541	rs9405386	chr6:8458067	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.44e-18	Motion sickness;
LGG	cis	rs9948	0.521	rs62156206	chr2:97357108	G/A	cg01990225	chr2:97406019	LMAN2L	-0.71	-6.92	-0.31	1.47e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00631329	chr6:26305371	NA	-0.54	-9.63	-0.41	4.03e-20	Educational attainment;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg18926786	chr6:150244388	RAET1G	0.31	6.81	0.3	3.06e-11	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs539514	0.690	rs776527	chr13:76317794	G/A	cg04757411	chr13:76259545	LMO7	-0.27	-7.05	-0.31	6.56e-12	Type 1 diabetes;
LGG	cis	rs28374715	0.635	rs28557159	chr15:41657353	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.19	-27.31	-0.79	1.5e-98	Ulcerative colitis;
LGG	cis	rs7666738	0.830	rs11942114	chr4:99066261	C/G	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.18e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.52	-8.36	-0.36	7.26e-16	Longevity;
LGG	cis	rs7113874	0.589	rs935370	chr11:8486846	G/T	cg23764900	chr11:8616102	STK33	0.41	7.2	0.32	2.44e-12	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg00761968	chr13:53314142	LECT1	-0.4	-8.66	-0.37	7.78e-17	Lewy body disease;
LGG	cis	rs10929925	0.931	rs34907471	chr2:6145027	C/A	cg00493617	chr2:6141445	NA	0.31	6.85	0.3	2.41e-11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.6	-0.37	1.21e-16	Restless legs syndrome;
LGG	cis	rs7336332	0.569	rs7988412	chr13:28000282	C/T	cg01674679	chr13:27998804	GTF3A	-0.65	-8.6	-0.37	1.23e-16	Weight;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.15	-0.58	2.09e-42	Prudent dietary pattern;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21889078	chr8:56675203	TMEM68	-0.54	-6.94	-0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7814319	1.000	rs7814319	chr8:97263418	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-17.45	-0.63	8.86e-53	Lung function (FVC);
LGG	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg18721089	chr20:30220636	NA	-0.51	-7.67	-0.34	1.02e-13	Mean corpuscular hemoglobin;
LGG	cis	rs651907	0.535	rs35799195	chr3:101521927	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs2117029	0.553	rs1991427	chr12:49557958	C/T	cg24176009	chr12:49580217	TUBA1A	0.63	12.16	0.49	1.02e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1465370	0.682	rs62471720	chr7:130016359	C/G	cg04743876	chr7:130013617	NA	0.37	8.61	0.37	1.16e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs13401104	0.716	rs10204147	chr2:237130344	A/C	cg15742758	chr2:237126235	ASB18	0.44	7.65	0.33	1.18e-13	Educational attainment;
LGG	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-25.18	-0.76	8.67e-89	Primary sclerosing cholangitis;
LGG	cis	rs4700695	0.719	rs36923	chr5:65464783	G/C	cg21114390	chr5:65439923	SFRS12	-0.72	-10.57	-0.44	1.61e-23	Facial morphology (factor 19);
LGG	cis	rs2285947	0.838	rs976516	chr7:21581561	A/G	cg23045935	chr7:21583304	DNAH11	0.4	8.36	0.36	7.16e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg25173405	chr17:45401733	C17orf57	0.48	8.5	0.37	2.54e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17125944	0.556	rs1952088	chr14:53319832	A/C	cg00686598	chr14:53173677	PSMC6	-0.71	-7.31	-0.32	1.16e-12	Alzheimer's disease (late onset);
LGG	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg14784868	chr12:69753453	YEATS4	0.66	11.96	0.49	6.26e-29	Response to diuretic therapy;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs1348850	0.914	rs10170546	chr2:178248790	C/T	cg27490568	chr2:178487706	NA	0.5	10.13	0.43	6.57e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12476592	0.571	rs7584404	chr2:63794342	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs4650994	1.000	rs4077194	chr1:178533832	A/C	cg19399532	chr1:178512495	C1orf220	-0.43	-8.49	-0.37	2.78e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs151997	0.630	rs26064	chr5:50217806	T/C	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs1059312	0.808	rs10847694	chr12:129292457	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.51	0.37	2.46e-16	Systemic lupus erythematosus;
LGG	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Body mass index;
LGG	cis	rs763014	1.000	rs7205409	chr16:642610	A/G	cg07343612	chr16:622815	PIGQ	-0.73	-15.05	-0.57	5.72e-42	Height;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg15971980	chr6:150254442	NA	0.44	8.16	0.35	3.13e-15	Lung cancer;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg00166722	chr3:10149974	C3orf24	0.57	8.09	0.35	5.2e-15	Alzheimer's disease;
LGG	cis	rs78366141	0.649	rs77135481	chr4:89689680	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.94	8.41	0.36	5e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs4740619	0.619	rs4741558	chr9:16038787	G/T	cg14451791	chr9:16040625	NA	-0.44	-11.73	-0.48	5.44e-28	Body mass index;
LGG	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg05973401	chr12:123451056	ABCB9	0.44	7.41	0.33	6.07e-13	Platelet count;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	14.51	0.56	1.32e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg08603382	chr10:743973	NA	-0.42	-7.62	-0.33	1.4e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg13798912	chr7:905769	UNC84A	0.57	7.08	0.31	5.51e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.31	0.32	1.19e-12	Skin colour saturation;
LGG	trans	rs208520	0.690	rs851465	chr6:66840293	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.67	-0.63	8.49e-54	Exhaled nitric oxide output;
LGG	cis	rs6489882	0.934	rs7299132	chr12:113376913	T/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs6977660	0.660	rs10239332	chr7:19824465	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.45	0.37	3.87e-16	Thyroid stimulating hormone;
LGG	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg12893428	chr3:195717962	SDHAP1	-0.5	-10.68	-0.44	6.02e-24	Pancreatic cancer;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3617	0.572	rs2256332	chr3:52855865	A/G	cg11645453	chr3:52864694	ITIH4	-0.44	-7.53	-0.33	2.61e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22091798	chr11:62446605	UBXN1	0.44	6.66	0.3	7.97e-11	Gut microbiome composition (summer);
LGG	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08704250	chr15:31115839	NA	-0.41	-7.45	-0.33	4.48e-13	Huntington's disease progression;
LGG	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg19507638	chr5:93509721	C5orf36	-0.69	-9.65	-0.41	3.33e-20	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.85	0.3	2.42e-11	Lung cancer;
LGG	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg21775007	chr8:11205619	TDH	-0.47	-7.47	-0.33	4.15e-13	Neuroticism;
LGG	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	12.92	0.51	8.03e-33	Coronary artery disease;
LGG	cis	rs7649275	1.000	rs2633724	chr3:53752120	T/C	cg21503701	chr3:53781065	CACNA1D	-0.48	-7.04	-0.31	6.94e-12	Trans fatty acid levels;
LGG	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.76	8.39	0.36	5.79e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.56	-0.37	1.69e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs155076	1.000	rs567166	chr13:21837519	T/C	cg14456004	chr13:21872349	NA	-1.15	-17.93	-0.64	5.35e-55	White matter hyperintensity burden;
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg16141378	chr3:129829833	LOC729375	-0.44	-10.57	-0.44	1.6e-23	Mood instability;
LGG	cis	rs367615	0.537	rs10463600	chr5:108663636	G/A	cg17395555	chr5:108820864	NA	0.75	12.16	0.49	9.94e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs308971	0.563	rs2618389	chr3:12048734	C/T	cg15873301	chr3:12045459	SYN2	0.55	7.04	0.31	7.1e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs992157	0.804	rs7559525	chr2:219150307	A/G	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	1.87e-29	Colorectal cancer;
LGG	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg02753203	chr1:228287806	NA	-0.65	-11.9	-0.48	1.09e-28	Diastolic blood pressure;
LGG	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg25566285	chr7:158114605	PTPRN2	0.91	20.48	0.69	7.82e-67	Calcium levels;
LGG	cis	rs9291683	0.566	rs13144709	chr4:10044182	C/T	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs67133203	0.904	rs2285228	chr12:51383343	C/G	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs17221829	0.733	rs2388105	chr11:89355317	A/G	cg02982614	chr11:89391479	FOLH1B	0.4	8.91	0.38	1.2e-17	Anxiety in major depressive disorder;
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg21775007	chr8:11205619	TDH	-0.41	-6.74	-0.3	4.73e-11	Joint mobility (Beighton score);
LGG	cis	rs688020	1.000	rs688020	chr7:4228553	C/T	cg24441899	chr7:4244372	SDK1	0.41	8.47	0.37	3.19e-16	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LGG	cis	rs8180040	0.676	rs13098228	chr3:47138253	A/G	cg16586182	chr3:47516702	SCAP	-0.77	-14.06	-0.55	1.2e-37	Colorectal cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00661245	chr8:11660924	FDFT1	-0.42	-7.37	-0.32	8e-13	Pancreatic cancer;
LGG	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg27454842	chr22:32027588	PISD	-0.59	-6.75	-0.3	4.57e-11	Age-related hearing impairment;
LGG	cis	rs11997175	0.574	rs12156280	chr8:33650277	C/T	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.09e-12	Body mass index;
LGG	cis	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg10518543	chr12:38710700	ALG10B	0.41	6.68	0.3	6.88e-11	Morning vs. evening chronotype;
LGG	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg09263875	chr16:632152	PIGQ	0.67	13.45	0.53	4.82e-35	Height;
LGG	cis	rs6840360	0.967	rs10028961	chr4:152668224	A/G	cg22705602	chr4:152727874	NA	-0.27	-6.73	-0.3	4.98e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg17294928	chr15:75287854	SCAMP5	-0.57	-10.45	-0.44	4.33e-23	Caffeine consumption;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg07870213	chr5:140052090	DND1	-0.68	-13.18	-0.52	6.83e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8072100	0.934	rs6504872	chr17:45438952	C/T	cg08085267	chr17:45401833	C17orf57	-0.67	-13.95	-0.54	3.57e-37	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs714515	0.934	rs9425298	chr1:172358834	T/C	cg01573306	chr1:172330400	DNM3	0.34	7.42	0.33	5.49e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4330281	0.626	rs13353435	chr3:17430574	T/C	cg20981856	chr3:17787350	NA	0.35	6.65	0.3	8.43e-11	Schizophrenia;
LGG	cis	rs13177180	0.673	rs256977	chr5:114886310	C/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.35	-7.61	-0.33	1.5700000000000001e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg26384229	chr12:38710491	ALG10B	1.07	29.11	0.8	1.18e-106	Heart rate;
LGG	cis	rs929354	0.742	rs2051877	chr7:157008813	A/T	cg17757837	chr7:157058334	UBE3C	0.77	15.73	0.59	5.82e-45	Body mass index;
LGG	cis	rs4319547	0.656	rs2173582	chr12:122824694	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-16.82	-0.62	7.03e-50	Body mass index;
LGG	cis	rs1707322	1.000	rs1707338	chr1:46511981	T/G	cg03146154	chr1:46216737	IPP	-0.53	-10.07	-0.42	1.08e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8077059	0.885	rs9905339	chr17:55824331	A/G	cg12582317	chr17:55822272	NA	0.41	7.37	0.32	7.92e-13	Sex hormone-binding globulin levels;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.05	0.31	6.34e-12	Schizophrenia;
LGG	cis	rs713587	0.713	rs1982200	chr2:25205427	C/T	cg04586622	chr2:25135609	ADCY3	-0.38	-9.72	-0.41	1.97e-20	Body mass index in non-asthmatics;
LGG	cis	rs911555	0.755	rs1116095	chr14:103931879	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.18	0.32	2.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg02811702	chr13:24901961	NA	0.39	7.19	0.32	2.59e-12	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.65e-26	Hemoglobin concentration;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.55	8.59	0.37	1.38e-16	Longevity;
LGG	trans	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg05926928	chr17:57297772	GDPD1	0.58	9.45	0.4	1.7e-19	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01311285	chr4:177116639	SPATA4	0.43	7.28	0.32	1.46e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.81	-0.3	3e-11	Schizophrenia;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.32	-0.36	1e-15	Longevity;Endometriosis;
LGG	cis	rs4704187	0.687	rs7720620	chr5:74366023	A/G	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs1048238	0.506	rs10737911	chr1:16167855	C/T	cg22431228	chr1:16359049	CLCNKA	0.39	6.95	0.31	1.21e-11	Systolic blood pressure;
LGG	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.06	18.45	0.65	2.28e-57	Gut microbiome composition (summer);
LGG	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg22875332	chr1:76189707	ACADM	0.52	7.26	0.32	1.64e-12	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7208859	0.673	rs56846352	chr17:29119188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.59	7.42	0.33	5.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	3.79e-44	Lung cancer;
LGG	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg17971929	chr21:40555470	PSMG1	-0.86	-17.05	-0.62	6.27e-51	Cognitive function;
LGG	cis	rs13102973	0.965	rs4469136	chr4:135850051	C/T	cg14419869	chr4:135874104	NA	0.56	10.7	0.45	5.24e-24	Subjective well-being;
LGG	cis	rs10911232	0.507	rs4652767	chr1:183002483	G/C	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07638904	chr22:19166425	SLC25A1	-0.39	-6.71	-0.3	5.72e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs3870371	1.000	rs12334795	chr8:122692531	A/C	cg15679747	chr8:122755315	NA	0.36	6.92	0.31	1.52e-11	Periodontal disease-related phenotypes;
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs7843479	0.965	rs11775479	chr8:21859991	C/T	cg17168535	chr8:21777572	XPO7	0.59	9.57	0.41	6.42e-20	Mean corpuscular volume;
LGG	cis	rs1348850	0.914	rs7591807	chr2:178252986	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-8.18	-0.36	2.85e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1003719	0.667	rs13050226	chr21:38457708	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.72	13.15	0.52	8.77e-34	Eye color traits;
LGG	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg05084668	chr3:125655381	ALG1L	-0.56	-7.48	-0.33	3.78e-13	Blood pressure (smoking interaction);
LGG	cis	rs3087591	0.919	rs2285892	chr17:29553485	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.41	-0.56	3.54e-39	Hip circumference;
LGG	cis	rs950776	0.616	rs647041	chr15:78880481	T/C	cg06917634	chr15:78832804	PSMA4	-0.72	-14.17	-0.55	3.89e-38	Sudden cardiac arrest;
LGG	cis	rs367943	0.665	rs4401566	chr5:112963356	A/G	cg12552261	chr5:112820674	MCC	0.53	9.5	0.4	1.1e-19	Type 2 diabetes;
LGG	cis	rs12586317	0.511	rs11540758	chr14:35498485	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.76	-0.34	5.64e-14	Psoriasis;
LGG	trans	rs10506458	1.000	rs11174759	chr12:63444363	A/T	cg22491629	chr6:157744540	C6orf35	-0.91	-12.64	-0.51	1.13e-31	Hemostatic factors and hematological phenotypes;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs2342371	0.715	rs9846106	chr3:196126539	G/A	cg15048948	chr3:196158458	UBXN7	0.62	10.52	0.44	2.3e-23	Fat distribution (HIV);
LGG	cis	rs950776	0.642	rs58946838	chr15:78961449	A/C	cg03762349	chr15:79060523	ADAMTS7	0.35	7.53	0.33	2.66e-13	Sudden cardiac arrest;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.59	-0.56	6.29e-40	Platelet count;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.35	-0.36	8.03e-16	Skin colour saturation;
LGG	cis	rs4330281	0.647	rs17043539	chr3:17426748	C/G	cg20981856	chr3:17787350	NA	0.36	6.77	0.3	3.93e-11	Schizophrenia;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg12458913	chr13:53173898	NA	0.56	10.08	0.42	1.02e-21	Lewy body disease;
LGG	trans	rs637571	0.607	rs575479	chr11:65690300	T/G	cg17712092	chr4:129076599	LARP1B	0.88	17.79	0.64	2.59e-54	Eosinophil percentage of white cells;
LGG	cis	rs7647973	0.922	rs6809851	chr3:49309787	C/A	cg06212747	chr3:49208901	KLHDC8B	0.52	8.13	0.35	4.03e-15	Menarche (age at onset);
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.94	-0.31	1.34e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg24247370	chr13:99142703	STK24	-0.4	-7.31	-0.32	1.2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg19847130	chr8:10466454	RP1L1	-0.31	-6.81	-0.3	3.04e-11	Neuroticism;
LGG	cis	rs10779751	1.000	rs1205592	chr1:11305663	C/T	cg08854313	chr1:11322531	MTOR	0.75	16.66	0.61	3.55e-49	Body mass index;
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07685180	chr8:600429	NA	1.22	11.8	0.48	2.88e-28	IgG glycosylation;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg21911579	chr5:131705225	SLC22A5	0.7	7.71	0.34	7.78e-14	Rheumatoid arthritis;
LGG	cis	rs963731	0.649	rs1470915	chr2:39247336	G/A	cg04010122	chr2:39346883	SOS1	-0.81	-7.08	-0.31	5.37e-12	Corticobasal degeneration;
LGG	cis	rs3087591	0.960	rs2071009	chr17:29558082	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.43	-0.56	3.02e-39	Hip circumference;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	trans	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	cis	rs13190036	1.000	rs7714695	chr5:176557445	C/T	cg06733329	chr5:176740039	MXD3	0.49	6.78	0.3	3.77e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.51e-13	Obesity-related traits;
LGG	cis	rs2658782	1.000	rs2019814	chr11:93168885	A/G	cg15737290	chr11:93063684	CCDC67	0.58	8.48	0.37	2.99e-16	Pulmonary function decline;
LGG	cis	rs16976116	0.951	rs28706531	chr15:55477072	G/A	cg11288833	chr15:55489084	RSL24D1	0.55	7.51	0.33	3.05e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17253792	0.822	rs77420254	chr14:56069646	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs758324	0.853	rs4705902	chr5:131150267	C/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs72827839	0.802	rs1986693	chr17:46026156	A/G	cg02219949	chr17:45927392	SP6	-0.48	-7.42	-0.33	5.54e-13	Ease of getting up in the morning;
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.54	0.33	2.58e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg15208524	chr1:10270712	KIF1B	0.42	7.41	0.33	6.21e-13	Hepatocellular carcinoma;
LGG	cis	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06634786	chr22:41940651	POLR3H	-0.8	-12.58	-0.5	2.08e-31	Vitiligo;
LGG	trans	rs208520	0.874	rs208485	chr6:66925654	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.43	-0.58	1.18e-43	Exhaled nitric oxide output;
LGG	trans	rs11088226	0.801	rs2833886	chr21:33923872	C/A	cg09050820	chr6:167586206	TCP10L2	0.68	10.57	0.44	1.58e-23	Gastritis;
LGG	cis	rs2797160	1.000	rs9401843	chr6:126004124	T/C	cg05901451	chr6:126070800	HEY2	-0.45	-7.47	-0.33	3.98e-13	Endometrial cancer;
LGG	trans	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.967	rs6657988	chr1:90106745	G/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.14	0.49	1.26e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs11676348	0.811	rs4674255	chr2:218987325	C/T	cg00012203	chr2:219082015	ARPC2	-0.55	-9.77	-0.41	1.24e-20	Ulcerative colitis;
LGG	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.7	-0.41	2.23e-20	Body mass index;
LGG	cis	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg12591125	chr7:1885375	MAD1L1	0.45	6.72	0.3	5.2e-11	Bipolar disorder;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg05091796	chr16:4465799	CORO7	-0.82	-13.95	-0.54	3.54e-37	Schizophrenia;
LGG	cis	rs6580649	0.941	rs1793931	chr12:48396505	G/T	cg24011408	chr12:48396354	COL2A1	0.68	8.51	0.37	2.37e-16	Lung cancer;
LGG	cis	rs12615966	0.584	rs72830474	chr2:105414217	C/T	cg16465502	chr2:105461796	NA	1.01	11.58	0.47	2.15e-27	Pancreatic cancer;
LGG	cis	rs4639966	0.579	rs2186780	chr11:118605451	C/T	cg19182353	chr11:118479428	PHLDB1	-0.55	-7.67	-0.34	1.02e-13	Systemic lupus erythematosus;
LGG	cis	rs988958	0.840	rs10176250	chr2:42303086	C/T	cg19376973	chr2:42229025	NA	0.4	6.68	0.3	6.74e-11	Hypospadias;
LGG	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.25e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg03733263	chr8:22462867	KIAA1967	1.03	25.33	0.76	1.76e-89	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg09238746	chr17:78121135	EIF4A3	0.42	7.37	0.32	7.89e-13	Yeast infection;
LGG	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg08508325	chr11:3079039	CARS	-0.58	-12.06	-0.49	2.63e-29	Type 2 diabetes;
LGG	cis	rs7914558	0.966	rs12766205	chr10:104893568	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.41	0.44	6.06e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.22	-0.39	1.07e-18	Obesity-related traits;
LGG	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg09021430	chr5:549028	NA	-0.69	-9.65	-0.41	3.44e-20	Obesity-related traits;
LGG	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg14088196	chr11:70211408	PPFIA1	0.94	13.5	0.53	2.86e-35	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.08	-0.35	5.55e-15	Breast cancer;
LGG	trans	rs6787172	0.702	rs2693542	chr3:158026979	A/T	cg23275840	chr4:47708675	CORIN	0.41	8.89	0.38	1.33e-17	Subjective well-being;
LGG	cis	rs17453880	0.929	rs4958571	chr5:152030714	A/C	cg10931792	chr5:152022470	NA	-0.41	-8.93	-0.38	1.04e-17	Subjective well-being;
LGG	cis	rs41342147	0.660	rs12468518	chr2:242264626	G/A	cg10173475	chr2:242152697	ANO7	-0.58	-8.75	-0.38	4.01e-17	Vitiligo;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg13047869	chr3:10149882	C3orf24	-0.55	-9.19	-0.39	1.34e-18	Alzheimer's disease;
LGG	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg03258749	chr1:151040405	MLLT11	-0.45	-8.06	-0.35	6.77e-15	Childhood ear infection;
LGG	cis	rs4938330	0.680	rs4938329	chr11:116928112	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.23	-0.43	2.71e-22	Blood protein levels;
LGG	trans	rs13219787	0.915	rs13214703	chr6:27941387	A/G	cg12734449	chr6:30038004	PPP1R11	0.89	8.32	0.36	1.02e-15	Mean corpuscular volume;Hemoglobin levels;Mean corpuscular hemoglobin;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg17951613	chr5:131705445	SLC22A5	0.63	7.22	0.32	2.14e-12	Rheumatoid arthritis;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19717773	chr7:2847554	GNA12	-0.33	-6.87	-0.3	2.03e-11	Height;
LGG	cis	rs12597458	0.763	rs3213422	chr16:72042682	A/C	cg23815491	chr16:72088622	HP	-0.43	-9.38	-0.4	3.06e-19	Prostate cancer;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.86	0.34	2.72e-14	Lung cancer;
LGG	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg01472538	chr16:58549086	SETD6	0.98	8.84	0.38	1.94e-17	Schizophrenia;
LGG	cis	rs17092148	1.000	rs3787223	chr20:33331385	C/T	cg12302830	chr20:33297742	TP53INP2	0.46	7.62	0.33	1.41e-13	Neuroticism;
LGG	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg08400814	chr5:56204995	C5orf35	-0.49	-7.8	-0.34	4.04e-14	Initial pursuit acceleration;
LGG	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs950169	0.800	rs4842847	chr15:84931199	G/A	cg24253500	chr15:84953950	NA	0.58	10.27	0.43	2.07e-22	Schizophrenia;
LGG	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg21435375	chr2:172878103	MAP1D	-0.31	-7.06	-0.31	6.3e-12	Schizophrenia;
LGG	cis	rs1185460	0.967	rs4545564	chr11:118937518	T/C	cg23280166	chr11:118938394	VPS11	0.61	11.29	0.46	2.73e-26	Coronary artery disease;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.5	0.37	2.63e-16	Personality dimensions;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg02725872	chr8:58115012	NA	-0.86	-11.4	-0.47	1.03e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg08250081	chr4:10125330	NA	0.42	8.39	0.36	6.04e-16	Bone mineral density;
LGG	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg06636001	chr8:8085503	FLJ10661	0.49	8.83	0.38	2.15e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1707322	0.663	rs3935296	chr1:46180470	T/C	cg03146154	chr1:46216737	IPP	-0.56	-11.02	-0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4737010	0.501	rs3758128	chr8:41657366	G/A	cg17182837	chr8:41585554	ANK1	-0.58	-7.53	-0.33	2.75e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.35	0.36	8.05e-16	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.17	-0.32	3.08e-12	Life satisfaction;
LGG	cis	rs28655083	1.000	rs8045658	chr16:77056343	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.47	-7.43	-0.33	5.44e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11608355	0.515	rs34038572	chr12:109901657	A/G	cg05360138	chr12:110035743	NA	0.85	12.24	0.49	4.97e-30	Neuroticism;
LGG	cis	rs795544	0.507	rs1995389	chr5:13785118	G/A	cg07548982	chr5:13769939	DNAH5	-0.41	-8.2	-0.36	2.39e-15	Corneal astigmatism;
LGG	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg10523679	chr1:76189770	ACADM	0.75	13.97	0.54	2.82e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3740540	0.530	rs2362503	chr10:126290538	T/C	cg04949429	chr10:126290192	LHPP	0.61	11.75	0.48	4.64e-28	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9660992	0.590	rs1779411	chr1:205238530	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.87	0.3	2.06e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs12479064	0.724	rs6748200	chr2:100080895	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.71	-10.39	-0.43	7.09e-23	Chronic sinus infection;
LGG	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.35	0.43	9.72e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8067545	0.750	rs28666381	chr17:19984809	C/G	cg13482628	chr17:19912719	NA	0.62	12.41	0.5	9.76e-31	Schizophrenia;
LGG	trans	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.62	0.33	1.46e-13	Myopia (pathological);
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg06917634	chr15:78832804	PSMA4	0.82	17.09	0.62	3.96e-51	Sudden cardiac arrest;
LGG	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg27624424	chr6:160112604	SOD2	0.66	9.54	0.41	8.1e-20	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs10877945	0.901	rs12826619	chr12:63392391	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.35	-6.71	-0.3	5.58e-11	Obesity-related traits;
LGG	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg26384229	chr12:38710491	ALG10B	0.93	20.44	0.69	1.14e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg01557791	chr16:72042693	DHODH	-0.58	-9.09	-0.39	2.82e-18	Blood protein levels;
LGG	cis	rs4006360	0.635	rs1848811	chr17:39235963	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.53	-11.67	-0.48	9.51e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg07234876	chr8:600039	NA	1.15	11.49	0.47	4.8400000000000004e-27	IgG glycosylation;
LGG	cis	rs10463554	0.892	rs257313	chr5:102420647	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.47	-0.33	3.9e-13	Parkinson's disease;
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.12	-0.31	4.02e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08045932	chr20:61659980	NA	0.6	12.93	0.52	7.24e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7412746	0.658	rs12067685	chr1:150952917	T/C	cg15448220	chr1:150897856	SETDB1	0.39	7.04	0.31	6.9e-12	Melanoma;
LGG	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-14.45	-0.56	2.46e-39	Presence of antiphospholipid antibodies;
LGG	cis	rs13095912	0.785	rs6783023	chr3:185330189	A/G	cg11274856	chr3:185301563	NA	0.48	7.81	0.34	3.92e-14	Systolic blood pressure;
LGG	cis	rs6982240	0.514	rs10095322	chr8:142262327	A/G	cg20799268	chr8:142275649	NA	-0.25	-6.98	-0.31	1.02e-11	Tonsillectomy;
LGG	cis	rs7635838	0.617	rs346074	chr3:11294310	T/C	cg00170343	chr3:11313890	ATG7	0.55	9.51	0.4	1.01e-19	HDL cholesterol;
LGG	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg02227867	chr8:22457446	C8orf58	-0.4	-7.63	-0.33	1.39e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.65	-0.33	1.21e-13	Triglycerides;
LGG	cis	rs9473924	0.505	rs9473938	chr6:50874050	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg05861140	chr6:150128134	PCMT1	-0.41	-8.49	-0.37	2.76e-16	Lung cancer;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.39	0.32	7.01e-13	Menopause (age at onset);
LGG	trans	rs56116382	0.604	rs9858428	chr3:49877585	G/T	cg21659725	chr3:3221576	CRBN	-0.7	-7.33	-0.32	1.02e-12	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	trans	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg27661571	chr11:113659931	NA	-0.67	-9.28	-0.4	6.53e-19	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.52	0.33	2.91e-13	Obesity-related traits;
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg07005078	chr4:17578674	LAP3	0.38	6.83	0.3	2.7e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1355223	0.573	rs286865	chr11:34719916	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.47	7.36	0.32	8.23e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs5769765	0.908	rs7410318	chr22:50317049	T/C	cg26441486	chr22:50317300	CRELD2	0.39	6.72	0.3	5.39e-11	Schizophrenia;
LGG	cis	rs4849975	0.510	rs13431927	chr2:3713706	G/C	cg16123090	chr2:3699210	NA	0.62	7.48	0.33	3.74e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.52e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15557168	chr22:42548783	NA	0.34	7.79	0.34	4.49e-14	Cognitive function;
LGG	cis	rs9457247	0.967	rs1794694	chr6:167404751	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs6445975	1.000	rs7653734	chr3:58372885	T/C	cg24175188	chr3:58374923	PXK	-0.53	-9.54	-0.41	8.18e-20	Systemic lupus erythematosus;
LGG	cis	rs6424115	0.931	rs2982390	chr1:24147830	G/C	cg24699146	chr1:24152579	HMGCL	0.26	7.8	0.34	4.17e-14	Immature fraction of reticulocytes;
LGG	cis	rs7000551	0.532	rs4872486	chr8:22256359	G/T	cg12081754	chr8:22256438	SLC39A14	1.14	27.62	0.79	5.86e-100	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9814567	0.963	rs9844537	chr3:134238341	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.35	-0.53	1.23e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00287711	chr11:85338379	TMEM126B;DLG2	-0.46	-6.74	-0.3	4.67e-11	Systemic lupus erythematosus;
LGG	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.64	0.63	1.27e-53	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg21659725	chr3:3221576	CRBN	-0.49	-7.28	-0.32	1.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg09448879	chr15:79043637	NA	-0.54	-13.54	-0.53	2.1e-35	Coronary artery disease or large artery stroke;
LGG	cis	rs2243480	0.901	rs35087093	chr7:65405208	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg14668632	chr7:2872130	GNA12	-0.33	-6.99	-0.31	9.52e-12	Height;
LGG	cis	rs523522	0.962	rs4767912	chr12:120981202	A/G	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	trans	rs61931739	0.534	rs1843733	chr12:34047626	T/C	cg26384229	chr12:38710491	ALG10B	0.72	14.53	0.56	1.15e-39	Morning vs. evening chronotype;
LGG	cis	rs9393777	0.513	rs9393737	chr6:26617306	A/G	cg12826209	chr6:26865740	GUSBL1	-0.83	-12.2	-0.49	6.84e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.42	-0.36	4.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7106204	0.764	rs57490470	chr11:24234370	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	10.42	0.44	5.54e-23	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs889398	0.741	rs7192213	chr16:69926280	G/A	cg00738113	chr16:70207722	CLEC18C	-0.25	-7.13	-0.31	3.89e-12	Body mass index;
LGG	cis	rs1348850	0.668	rs6734683	chr2:178494012	C/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.42	-0.33	5.79e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs943466	0.704	rs11759971	chr6:33715324	A/T	cg07519485	chr6:33762594	MLN	0.49	8.46	0.37	3.53e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg22398616	chr13:53314203	LECT1	-0.45	-9.42	-0.4	2.18e-19	Lewy body disease;
LGG	cis	rs7786808	0.760	rs10259321	chr7:158221038	G/A	cg01191920	chr7:158217561	PTPRN2	0.85	21.37	0.7	5.3e-71	Obesity-related traits;
LGG	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg24308560	chr3:49941425	MST1R	-0.22	-6.7	-0.3	6.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6834538	0.577	rs13106473	chr4:113542066	C/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.5	8.3	0.36	1.19e-15	Free thyroxine concentration;
LGG	trans	rs1997103	1.000	rs6950311	chr7:55400990	G/A	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg26384229	chr12:38710491	ALG10B	0.86	18.61	0.65	3.87e-58	Morning vs. evening chronotype;
LGG	trans	rs6598955	0.671	rs12116908	chr1:26587918	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-13.04	-0.52	2.54e-33	Obesity-related traits;
LGG	cis	rs11252926	0.673	rs553326	chr10:749238	G/T	cg08603382	chr10:743973	NA	-0.58	-11.11	-0.46	1.35e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg08035479	chr8:58172643	NA	-0.53	-8.11	-0.35	4.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs11071942	chr15:67516948	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1062177	0.756	rs2964592	chr5:151115688	A/G	cg00977110	chr5:151150581	G3BP1	-0.46	-7.43	-0.33	5.2e-13	Preschool internalizing problems;
LGG	cis	rs12791968	0.765	rs12226848	chr11:45009204	C/T	cg11846598	chr11:44996168	LOC221122	-0.54	-9.01	-0.39	5.5e-18	Inhibitory control;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.54	-10.57	-0.44	1.53e-23	Prudent dietary pattern;
LGG	cis	rs9611565	0.545	rs5758432	chr22:42111693	T/C	cg17376030	chr22:41985996	PMM1	-0.67	-10.77	-0.45	2.84e-24	Vitiligo;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg22907277	chr7:1156413	C7orf50	0.45	7.83	0.34	3.41e-14	Longevity;Endometriosis;
LGG	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg05163923	chr11:71159392	DHCR7	0.72	14.18	0.55	3.56e-38	Vitamin D levels;
LGG	cis	rs2455601	0.638	rs2742485	chr11:8986787	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-11.05	-0.46	2.3e-25	Schizophrenia;
LGG	cis	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg24692254	chr21:30365293	RNF160	0.6	10.16	0.43	4.83e-22	Cognitive test performance;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00993799	chr7:104653126	LOC100216545	-0.53	-7.83	-0.34	3.45e-14	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.673	rs1347360	chr17:28914532	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.59e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14431619	chr19:11266544	SPC24	0.43	6.73	0.3	4.99e-11	Gut microbiome composition (summer);
LGG	cis	rs897984	0.806	rs12924903	chr16:30928970	C/T	cg00531865	chr16:30841666	NA	-0.55	-11.23	-0.46	4.79e-26	Dementia with Lewy bodies;
LGG	cis	rs801193	0.569	rs13226966	chr7:66233623	A/G	cg18252515	chr7:66147081	NA	-0.45	-7.7	-0.34	8.6e-14	Aortic root size;
LGG	cis	rs17453880	0.929	rs6868043	chr5:152031752	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.63	-0.74	1.38e-81	Subjective well-being;
LGG	cis	rs2439831	1.000	rs101094	chr15:43787322	C/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs4888262	0.526	rs6564145	chr16:74621129	G/A	cg01733217	chr16:74700730	RFWD3	0.88	17.99	0.64	2.93e-55	Testicular germ cell tumor;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.2e-14	Prudent dietary pattern;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg16318349	chr1:154917307	PBXIP1	0.25	6.83	0.3	2.69e-11	Prostate cancer;
LGG	cis	rs6963495	0.818	rs73190181	chr7:105162907	A/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07080220	chr10:102295463	HIF1AN	-0.56	-9.79	-0.41	1.1e-20	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg27661571	chr11:113659931	NA	-0.58	-8.44	-0.37	4.09e-16	Hip circumference adjusted for BMI;
LGG	cis	rs7512552	0.803	rs9435997	chr1:150289496	G/A	cg15654264	chr1:150340011	RPRD2	-0.44	-9.08	-0.39	3.15e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7927771	0.524	rs7116346	chr11:47883880	G/A	cg20307385	chr11:47447363	PSMC3	-0.54	-10.55	-0.44	1.77e-23	Subjective well-being;
LGG	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	8.17	0.35	2.96e-15	Type 2 diabetes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05826237	chr19:1095571	POLR2E	-0.45	-6.72	-0.3	5.38e-11	Systemic lupus erythematosus;
LGG	cis	rs972578	0.715	rs5758969	chr22:43228969	A/C	cg01576275	chr22:43409880	NA	-0.22	-6.74	-0.3	4.77e-11	Mean platelet volume;
LGG	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg01620082	chr3:125678407	NA	-1.05	-9.87	-0.42	5.69e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs262150	0.579	rs73167299	chr7:158784367	C/T	cg19418458	chr7:158789849	NA	0.45	7.05	0.31	6.53e-12	Facial morphology (factor 20);
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.73	13.27	0.52	2.81e-34	Obesity-related traits;
LGG	cis	rs2717559	0.542	rs2717560	chr8:143881670	G/A	cg07661805	chr8:143867942	LY6D	-0.3	-8.01	-0.35	9.34e-15	Urinary tract infection frequency;
LGG	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-18.15	-0.64	5.26e-56	Primary sclerosing cholangitis;
LGG	cis	rs12220238	0.908	rs10824077	chr10:75887038	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.83	-11.73	-0.48	5.5e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-9.42	-0.4	2.1e-19	Bronchopulmonary dysplasia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19088795	chr3:171757303	FNDC3B	0.45	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-6.87	-0.3	2.03e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21659725	chr3:3221576	CRBN	0.92	20.09	0.68	5.38e-65	Intelligence (multi-trait analysis);
LGG	trans	rs6787172	0.702	rs1204962	chr3:157967597	C/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00689492	chr4:1303491	MAEA	0.46	7.96	0.35	1.38e-14	Obesity-related traits;
LGG	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.36	-7.6	-0.33	1.68e-13	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.15	-0.39	1.8e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.57	0.47	2.24e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.42	-0.36	4.73e-16	Schizophrenia;
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.67	-0.3	7.17e-11	Obesity-related traits;
LGG	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg26924012	chr15:45694286	SPATA5L1	0.59	9.88	0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs6121246	0.697	rs7269866	chr20:30232504	G/A	cg21427119	chr20:30132790	HM13	-0.5	-8.26	-0.36	1.59e-15	Mean corpuscular hemoglobin;
LGG	cis	rs6909430	0.901	rs1386550	chr6:98552535	A/G	cg12860156	chr6:98744658	NA	-0.42	-7.03	-0.31	7.47e-12	Quantitative traits;
LGG	cis	rs2013441	1.000	rs1561974	chr17:20196144	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.91e-19	Obesity-related traits;
LGG	cis	rs2832191	0.903	rs11700687	chr21:30486767	A/G	cg08807101	chr21:30365312	RNF160	-0.8	-15.65	-0.59	1.33e-44	Dental caries;
LGG	cis	rs1003719	0.762	rs34273703	chr21:38475019	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg23887609	chr12:130822674	PIWIL1	0.55	9.69	0.41	2.49e-20	Menopause (age at onset);
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg24575275	chr7:1094737	C7orf50	-0.38	-7.51	-0.33	3.15e-13	Longevity;Endometriosis;
LGG	cis	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg10402321	chr1:26617780	UBXN11	-0.37	-7.18	-0.32	2.78e-12	Obesity-related traits;
LGG	cis	rs4974559	0.739	rs10029534	chr4:1322908	C/A	cg02980000	chr4:1222292	CTBP1	0.81	8.99	0.39	6.54e-18	Systolic blood pressure;
LGG	cis	rs883565	0.655	rs4645092	chr3:39051718	G/A	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	trans	rs11165623	0.792	rs6593599	chr1:96911468	C/T	cg10631902	chr5:14652156	NA	-0.6	-14.34	-0.55	7.56e-39	Hip circumference;Waist circumference;
LGG	trans	rs208520	0.802	rs4710314	chr6:66883656	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-16.98	-0.62	1.31e-50	Exhaled nitric oxide output;
LGG	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg13385794	chr1:248469461	NA	0.44	8.17	0.36	2.94e-15	Common traits (Other);
LGG	cis	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.87	-0.3	2.07e-11	Triglycerides;
LGG	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs941408	0.928	rs2741991	chr19:2802092	T/C	cg06609049	chr19:2785107	THOP1	0.61	9.63	0.41	4e-20	Total cholesterol levels;
LGG	cis	rs7666738	0.962	rs4699605	chr4:99064379	A/G	cg05340658	chr4:99064831	C4orf37	0.44	7.05	0.31	6.51e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11676348	0.729	rs13013361	chr2:218947515	A/T	cg00012203	chr2:219082015	ARPC2	-0.54	-9.49	-0.4	1.23e-19	Ulcerative colitis;
LGG	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg22437258	chr11:111473054	SIK2	0.55	9.43	0.4	1.98e-19	Primary sclerosing cholangitis;
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg02002194	chr4:3960332	NA	0.41	7.61	0.33	1.55e-13	Triglycerides;
LGG	cis	rs11583043	0.874	rs6577222	chr1:101420502	C/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	6.8	0.3	3.2e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs12908161	1.000	rs11637142	chr15:85295927	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.24	0.32	1.84e-12	Schizophrenia;
LGG	cis	rs6088580	0.602	rs6059840	chr20:33030405	G/A	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.57e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg19338460	chr6:170058176	WDR27	-0.9	-9.38	-0.4	3.06e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11190604	1.000	rs10786596	chr10:102282126	C/A	cg07080220	chr10:102295463	HIF1AN	0.69	11.72	0.48	6.09e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg19455335	chr8:22457658	C8orf58	-0.47	-9.42	-0.4	2.21e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9314323	1.000	rs9314323	chr8:26243136	A/G	cg11498726	chr8:26250323	BNIP3L	-0.54	-11.19	-0.46	6.74e-26	Red cell distribution width;
LGG	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg10621924	chr7:39171070	POU6F2	0.48	10.03	0.42	1.44e-21	IgG glycosylation;
LGG	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.67	-0.37	7.09e-17	Joint mobility (Beighton score);
LGG	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg06027949	chr8:82754900	SNX16	-0.53	-8.31	-0.36	1.09e-15	Diastolic blood pressure;
LGG	cis	rs16854884	0.558	rs60367530	chr3:143719294	G/A	cg06585982	chr3:143692056	C3orf58	0.56	9.64	0.41	3.55e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs1200821	0.535	rs1938417	chr10:37687520	A/C	cg00409905	chr10:38381863	ZNF37A	0.44	8.37	0.36	6.63e-16	Hemostatic factors and hematological phenotypes;
LGG	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg14228332	chr4:119757509	SEC24D	-1.0	-10.03	-0.42	1.48e-21	Cannabis dependence symptom count;
LGG	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg18252515	chr7:66147081	NA	1.31	18.5	0.65	1.25e-57	Diabetic kidney disease;
LGG	trans	rs8002861	0.810	rs2275252	chr13:44454374	A/C	cg17145862	chr1:211918768	LPGAT1	0.97	25.36	0.76	1.33e-89	Leprosy;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.62	-0.41	4.28e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs73787773	0.644	rs78790140	chr5:111476097	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.2	-0.32	2.44e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4566357	0.615	rs10178098	chr2:227914425	C/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.08	-0.39	3.14e-18	Coronary artery disease;
LGG	cis	rs12220238	0.722	rs4745750	chr10:76394003	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.5	6.72	0.3	5.22e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg11584989	chr19:19387371	SF4	-0.74	-12.1	-0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.37	-0.36	6.79e-16	Mean corpuscular volume;
LGG	cis	rs1552244	0.938	rs67667957	chr3:10167264	G/C	cg16606324	chr3:10149918	C3orf24	0.54	7.01	0.31	8.34e-12	Alzheimer's disease;
LGG	cis	rs4409675	0.576	rs2078328	chr1:28224976	A/G	cg23691781	chr1:28212827	C1orf38	0.39	10.46	0.44	4.08e-23	Corneal astigmatism;
LGG	cis	rs67397200	0.590	rs12327712	chr19:17424947	T/G	cg04248312	chr19:17393744	ANKLE1	-0.39	-7.27	-0.32	1.52e-12	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LGG	cis	rs12422267	0.609	rs11246940	chr12:132623473	A/G	cg08270023	chr12:132619174	NA	-0.43	-7.07	-0.31	5.82e-12	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg08677398	chr8:58056175	NA	0.42	6.69	0.3	6.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7712401	0.601	rs436546	chr5:122322790	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18073970	chr1:184006765	GLT25D2	0.39	6.7	0.3	5.88e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg05484376	chr2:27715224	FNDC4	0.41	8.9	0.38	1.28e-17	Total body bone mineral density;
LGG	cis	rs6028335	0.674	rs12625983	chr20:37603936	C/T	cg16355469	chr20:37678765	NA	-0.6	-7.95	-0.35	1.4e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg04607235	chr12:12878440	APOLD1	-0.63	-9.11	-0.39	2.47e-18	Systemic lupus erythematosus;
LGG	cis	rs10504130	0.569	rs4292675	chr8:52679974	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9398803	0.687	rs1340952	chr6:126951510	C/T	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.89e-20	Male-pattern baldness;
LGG	cis	rs9341808	0.935	rs2322633	chr6:80845989	C/T	cg08355045	chr6:80787529	NA	-0.38	-7.64	-0.33	1.24e-13	Sitting height ratio;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg05279229	chr7:1896384	MAD1L1	-0.38	-6.94	-0.31	1.31e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.830	rs35951881	chr4:98999474	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17534004	1.000	rs35646895	chr13:31469604	C/T	cg00367615	chr13:31480979	C13orf33	0.36	7.25	0.32	1.77e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7241530	0.585	rs11872676	chr18:75892288	A/C	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.22e-18	Educational attainment (years of education);
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg05861140	chr6:150128134	PCMT1	-0.41	-9.15	-0.39	1.8e-18	Lung cancer;
LGG	cis	rs6089584	0.527	rs927589	chr20:60606363	A/G	cg06108461	chr20:60628389	TAF4	-0.72	-13.0	-0.52	3.55e-33	Body mass index;
LGG	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg19168338	chr16:4465731	CORO7	-0.92	-17.17	-0.62	1.73e-51	Schizophrenia;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.95	0.6	5.6e-46	Lung cancer;
LGG	cis	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg24375607	chr4:120327624	NA	0.65	10.59	0.44	1.32e-23	Corneal astigmatism;
LGG	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	1.87e-29	Colorectal cancer;
LGG	cis	rs981844	1.000	rs2606329	chr4:154654643	A/C	cg14289246	chr4:154710475	SFRP2	0.7	11.69	0.48	8.02e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs4665809	0.567	rs6711402	chr2:26430983	A/G	cg08470875	chr2:26401718	FAM59B	-0.42	-7.96	-0.35	1.37e-14	Gut microbiome composition (summer);
LGG	cis	rs6871536	1.000	rs10052993	chr5:131969279	G/T	cg04303330	chr5:131992430	IL13	0.28	6.87	0.3	2.14e-11	Asthma (childhood onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03698729	chr19:2328812	SPPL2B;LSM7	0.6	6.87	0.3	2.09e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg16141378	chr3:129829833	LOC729375	-0.4	-9.86	-0.42	6.06e-21	Mood instability;
LGG	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg13256891	chr4:100009986	ADH5	0.38	6.76	0.3	4.2e-11	Alcohol dependence;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg22907277	chr7:1156413	C7orf50	0.71	9.22	0.39	1.02e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4727027	0.933	rs10238826	chr7:148830888	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	3.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg07777115	chr5:623756	CEP72	-0.56	-7.1	-0.31	4.77e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg00071950	chr4:10020882	SLC2A9	0.4	8.18	0.36	2.75e-15	Bone mineral density;
LGG	cis	rs6580649	0.941	rs1018973	chr12:48441692	C/G	cg24011408	chr12:48396354	COL2A1	0.55	6.83	0.3	2.73e-11	Lung cancer;
LGG	cis	rs35110281	0.592	rs10211901	chr21:45122573	G/A	cg04455712	chr21:45112962	RRP1B	0.48	8.72	0.38	5.05e-17	Mean corpuscular volume;
LGG	trans	rs7939886	0.920	rs11227222	chr11:55876393	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-8.83	-0.38	2.18e-17	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs2297497	chr20:25297909	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.38	-0.43	7.79e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg16885296	chr6:26284938	NA	0.39	8.41	0.36	5.19e-16	Educational attainment;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs4417704	0.551	rs55978049	chr2:241890228	A/C	cg14055004	chr2:241860995	NA	0.28	7.47	0.33	4.07e-13	Joint mobility (Beighton score);
LGG	cis	rs4975616	0.869	rs421284	chr5:1325590	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.19	-0.65	3.45e-56	Lung cancer;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-7.51	-0.33	3.17e-13	Height;
LGG	cis	rs5771242	0.769	rs4838865	chr22:50664612	A/G	cg16473166	chr22:50639996	SELO	0.65	9.3	0.4	5.66e-19	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs4417704	0.551	rs4675843	chr2:241875494	C/T	cg05025159	chr2:241905733	NA	0.46	9.53	0.4	8.83e-20	Joint mobility (Beighton score);
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg16590910	chr6:42928470	GNMT	0.42	11.79	0.48	3.17e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.3	-0.43	1.57e-22	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04054600	chr11:67121358	LOC100130987;POLD4	0.42	6.97	0.31	1.12e-11	Cognitive performance;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg00689492	chr4:1303491	MAEA	0.46	7.89	0.34	2.16e-14	Obesity-related traits;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg21782813	chr7:2030301	MAD1L1	0.48	11.72	0.48	5.77e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs457717	1.000	rs2431349	chr5:75921330	C/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.34	6.76	0.3	4.08e-11	Hearing impairment;
LGG	cis	rs9487094	0.670	rs10457195	chr6:109855472	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs9902453	1.000	rs4533340	chr17:28277951	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.64	0.54	7.37e-36	Coffee consumption (cups per day);
LGG	cis	rs73072330	1.000	rs17729010	chr3:47912703	A/G	cg04507495	chr3:47563649	NA	-1.0	-8.96	-0.38	8e-18	Stem cell growth factor beta levels;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.15e-23	Lymphocyte counts;
LGG	cis	rs9462027	0.628	rs6925623	chr6:34800896	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg19147804	chr7:1989927	MAD1L1	0.38	7.35	0.32	9.32e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs8017423	1.000	rs8015379	chr14:90679432	C/T	cg04374321	chr14:90722782	PSMC1	0.85	18.18	0.65	3.98e-56	Mortality in heart failure;
LGG	cis	rs58688157	0.960	rs10902178	chr11:612843	T/G	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.57	7.68	0.34	9.71e-14	Smoking behavior;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg06968155	chr5:131705112	SLC22A5	0.77	8.78	0.38	3.16e-17	Rheumatoid arthritis;
LGG	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg02221750	chr19:17393354	ANKLE1	0.63	9.35	0.4	3.83e-19	Systemic lupus erythematosus;
LGG	cis	rs644799	0.710	rs10831427	chr11:95508383	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.65	0.63	1.1e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs11090056	chr22:42095904	A/C	cg03806693	chr22:41940476	POLR3H	0.91	14.95	0.57	1.62e-41	Vitiligo;
LGG	cis	rs75920871	0.528	rs11216244	chr11:116912730	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	cis	rs6132905	0.520	rs2422823	chr20:2646333	C/A	cg01629329	chr20:2633258	NOP56;MIR1292	0.45	7.9	0.34	2.06e-14	Mumps;
LGG	cis	rs1829883	0.898	rs13184400	chr5:98784722	G/A	cg08333243	chr5:99726346	NA	-0.39	-7.51	-0.33	3e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	trans	rs5756813	0.661	rs7286550	chr22:38196760	G/A	cg19894588	chr14:64061835	NA	-0.64	-10.23	-0.43	2.8e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs798554	0.644	rs7783400	chr7:2894434	A/C	cg05793240	chr7:2802953	GNA12	-0.36	-8.57	-0.37	1.61e-16	Height;
LGG	cis	rs701145	0.585	rs1727893	chr3:153849866	A/C	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs10464366	0.597	rs10951590	chr7:39091043	C/T	cg20302533	chr7:39170763	POU6F2	0.31	7.26	0.32	1.65e-12	IgG glycosylation;
LGG	cis	rs11168618	1.000	rs10875830	chr12:48937510	C/T	cg24011408	chr12:48396354	COL2A1	0.49	7.97	0.35	1.25e-14	Adiponectin levels;
LGG	cis	rs367943	0.698	rs10050530	chr5:112971042	A/C	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg00701064	chr4:6280414	WFS1	-0.73	-15.23	-0.58	9.48e-43	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12780845	0.540	rs6602180	chr10:17192362	T/C	cg01003015	chr10:17271136	VIM	0.43	7.44	0.33	5.07e-13	Homocysteine levels;
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg16141378	chr3:129829833	LOC729375	0.39	9.01	0.39	5.45e-18	Neuroticism;
LGG	cis	rs13082711	0.863	rs66743193	chr3:27471958	G/A	cg02860705	chr3:27208620	NA	0.83	15.01	0.57	9.23e-42	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg03264133	chr6:25882463	NA	-0.41	-7.36	-0.32	8.42e-13	Height;
LGG	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg04568710	chr12:38710424	ALG10B	0.34	6.77	0.3	4.02e-11	Bladder cancer;
LGG	cis	rs4740619	0.689	rs10810509	chr9:15955666	C/T	cg14451791	chr9:16040625	NA	-0.39	-9.94	-0.42	3.18e-21	Body mass index;
LGG	trans	rs1728785	1.000	rs4783656	chr16:68580722	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	trans	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg13565492	chr6:43139072	SRF	-0.76	-9.15	-0.39	1.89e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg19628046	chr18:33552617	C18orf21	0.51	7.48	0.33	3.88e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs67478160	0.595	rs8022783	chr14:104245573	T/C	cg26031613	chr14:104095156	KLC1	-0.46	-7.54	-0.33	2.55e-13	Schizophrenia;
LGG	cis	rs9303401	0.538	rs12603174	chr17:56489279	T/C	cg25039879	chr17:56429692	SUPT4H1	0.72	10.21	0.43	3.4e-22	Cognitive test performance;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg00012203	chr2:219082015	ARPC2	0.66	11.72	0.48	5.67e-28	Colorectal cancer;
LGG	cis	rs600550	0.588	rs2304933	chr11:60102507	G/T	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.8	-0.34	4.09e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg09855544	chr8:135498122	ZFAT	0.45	7.67	0.34	1.05e-13	Hypertension (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.59e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg15485101	chr11:133734466	NA	0.58	10.33	0.43	1.17e-22	Childhood ear infection;
LGG	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.72	15.25	0.58	7.8e-43	Menarche (age at onset);
LGG	cis	rs4561483	0.815	rs7198817	chr16:11945778	C/A	cg08843971	chr16:11963173	GSPT1	0.59	14.35	0.55	7e-39	Testicular germ cell tumor;
LGG	cis	rs4478137	0.931	rs3967762	chr4:164244976	T/C	cg06758707	chr4:164254230	NPY1R	0.71	12.67	0.51	8.73e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs8031584	0.958	rs34294266	chr15:31246840	A/G	cg19680485	chr15:31195859	MTMR15	-0.47	-7.62	-0.33	1.45e-13	Huntington's disease progression;
LGG	cis	rs7000551	0.700	rs2469761	chr8:22367274	A/G	cg12081754	chr8:22256438	SLC39A14	0.64	11.99	0.49	4.72e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-9.73	-0.41	1.76e-20	Chronic sinus infection;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg07511668	chr11:68622177	NA	0.51	9.73	0.41	1.81e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs933688	1.000	rs10474353	chr5:90732285	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	19.41	0.67	7.43e-62	Smoking behavior;
LGG	cis	rs834603	0.575	rs2462638	chr7:47471286	A/G	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.61e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7084402	0.967	rs1649015	chr10:60289031	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg04898316	chr2:110371848	SEPT10;ANKRD57	-0.4	-7.01	-0.31	8.75e-12	Blood metabolite levels;
LGG	trans	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-10.65	-0.44	7.56e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6546550	0.901	rs10205487	chr2:70151471	C/T	cg02498382	chr2:70120550	SNRNP27	0.43	7.94	0.35	1.53e-14	Prevalent atrial fibrillation;
LGG	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg10760299	chr15:45669010	GATM	0.37	6.98	0.31	1.01e-11	Homoarginine levels;
LGG	cis	rs79976124	0.800	rs10944857	chr6:66637078	C/T	cg07460842	chr6:66804631	NA	0.73	12.59	0.51	1.78e-31	Type 2 diabetes;
LGG	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	cis	rs35771425	1.000	rs60555365	chr1:211590328	G/T	cg10512769	chr1:211675356	NA	-0.74	-11.97	-0.49	5.93e-29	Educational attainment (years of education);
LGG	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg13397898	chr9:133768931	QRFP	0.39	8.84	0.38	2.02e-17	Response to amphetamines;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.65	-0.37	8.34e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-7.05	-0.31	6.71e-12	Crohn's disease;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg25174290	chr11:3078921	CARS	0.74	15.69	0.59	8.72e-45	Longevity;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10799590	0.964	rs1603918	chr1:224827497	G/T	cg01808320	chr1:224927238	CNIH3	0.37	6.77	0.3	3.88e-11	Opioid dependence;
LGG	cis	rs9527	0.590	rs10883830	chr10:104851285	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.81	0.45	1.96e-24	Arsenic metabolism;
LGG	cis	rs2354432	0.607	rs7537279	chr1:146673642	A/G	cg25205988	chr1:146714368	CHD1L	1.05	9.27	0.4	6.89e-19	Mitochondrial DNA levels;
LGG	trans	rs7819412	0.522	rs13276708	chr8:10989206	T/C	cg16141378	chr3:129829833	LOC729375	0.32	6.71	0.3	5.74e-11	Triglycerides;
LGG	trans	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg17712092	chr4:129076599	LARP1B	0.55	9.15	0.39	1.78e-18	Breast cancer;
LGG	cis	rs506338	0.517	rs490192	chr11:64471369	C/T	cg19395706	chr11:64412079	NRXN2	0.41	7.99	0.35	1.07e-14	Body mass index;Urate levels;
LGG	cis	rs4950322	0.570	rs72692979	chr1:146807832	T/C	cg22381352	chr1:146742008	CHD1L	-0.51	-8.33	-0.36	9.38e-16	Protein quantitative trait loci;
LGG	cis	rs7660883	1.000	rs2045592	chr4:88014346	C/G	cg21988461	chr4:88008667	AFF1	0.34	9.25	0.4	8.11e-19	HDL cholesterol levels;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg23782820	chr8:58130467	NA	0.58	8.58	0.37	1.42e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.53	0.4	8.83e-20	Mean corpuscular volume;
LGG	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs4356932	1.000	rs4619915	chr4:76955201	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg15440763	chr7:158190612	PTPRN2	0.5	10.54	0.44	1.95e-23	Obesity-related traits;
LGG	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg15557168	chr22:42548783	NA	-0.47	-10.29	-0.43	1.62e-22	Schizophrenia;
LGG	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg00198680	chr16:28758506	NA	0.28	6.78	0.3	3.69e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg23173402	chr1:227635558	NA	0.61	10.01	0.42	1.69e-21	Major depressive disorder;
LGG	cis	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg26384229	chr12:38710491	ALG10B	1.05	27.74	0.79	1.73e-100	Heart rate;
LGG	cis	rs9896933	0.830	rs113051447	chr17:80791806	A/G	cg20578329	chr17:80767326	TBCD	-0.75	-11.93	-0.48	8.81e-29	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.16	-0.35	3.12e-15	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg11062466	chr8:58055876	NA	0.61	9.73	0.41	1.7e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04530015	chr2:215796436	ABCA12	0.46	8.43	0.36	4.28e-16	Neuroblastoma;
LGG	trans	rs3857536	0.740	rs9354391	chr6:66890183	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.48	8.27	0.36	1.46e-15	Blood trace element (Cu levels);
LGG	cis	rs6032067	0.641	rs17423416	chr20:43758144	G/T	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	trans	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg05585630	chr7:157510462	PTPRN2	-0.66	-13.75	-0.54	2.55e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06558623	chr16:89946397	TCF25	1.17	13.36	0.53	1.14e-34	Skin colour saturation;
LGG	cis	rs7945718	0.621	rs7939509	chr11:12688130	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	trans	rs12517041	1.000	rs7723641	chr5:23298305	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.03e-25	Calcium levels;
LGG	cis	rs35110281	0.782	rs2246602	chr21:45064296	C/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.53	-0.4	9.01e-20	Mean corpuscular volume;
LGG	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg03929089	chr4:120376271	NA	-0.82	-14.92	-0.57	2.15e-41	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05533552	chr11:34074141	CAPRIN1	0.49	8.02	0.35	8.61e-15	Cognitive performance;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.33	-0.32	1.02e-12	Menopause (age at onset);
LGG	cis	rs9303401	0.527	rs12946522	chr17:56768103	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	13.66	0.54	6.5e-36	Cognitive test performance;
LGG	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg06241208	chr11:30344200	C11orf46	-0.51	-6.66	-0.3	7.75e-11	Morning vs. evening chronotype;
LGG	cis	rs7301826	0.651	rs10734979	chr12:131288954	T/C	cg11011512	chr12:131303247	STX2	0.41	8.91	0.38	1.2e-17	Plasma plasminogen activator levels;
LGG	cis	rs1030877	0.960	rs3792050	chr2:105902255	T/C	cg02079111	chr2:105885981	TGFBRAP1	-0.72	-13.64	-0.54	7.62e-36	Obesity-related traits;
LGG	cis	rs9487094	0.677	rs4428538	chr6:109730848	C/T	cg01125227	chr6:109776195	MICAL1	0.49	7.57	0.33	2.05e-13	Height;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg03517284	chr6:25882590	NA	-0.38	-6.78	-0.3	3.76e-11	Height;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg20790798	chr5:1857306	NA	-0.42	-6.9	-0.31	1.68e-11	Cardiovascular disease risk factors;
LGG	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.43	0.4	1.92e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12431410	0.550	rs10135659	chr14:60229697	T/C	cg07950296	chr14:60194823	RTN1	-0.38	-7.32	-0.32	1.12e-12	Schizophrenia;
LGG	cis	rs892961	0.899	rs747482	chr17:75412109	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.27	0.43	2e-22	Airflow obstruction;
LGG	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs6942756	0.806	rs7788327	chr7:128986519	C/T	cg02491457	chr7:128862824	NA	-0.61	-11.36	-0.47	1.48e-26	White matter hyperintensity burden;
LGG	cis	rs9814567	0.686	rs1404289	chr3:134358109	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	11.2	0.46	6.46e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7589342	0.839	rs1465641	chr2:106438936	C/T	cg16077055	chr2:106428750	NCK2	0.31	8.26	0.36	1.56e-15	Addiction;
LGG	cis	rs751728	0.865	rs751726	chr6:33764386	G/A	cg25922239	chr6:33757077	LEMD2	0.69	12.35	0.5	1.77e-30	Crohn's disease;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.3	0.32	1.27e-12	Electroencephalogram traits;
LGG	cis	rs2334880	0.678	rs66778248	chr16:71451424	A/G	cg06353428	chr16:71660113	MARVELD3	-0.79	-10.81	-0.45	1.94e-24	Malaria;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3870371	0.911	rs11785053	chr8:122702041	G/T	cg15679747	chr8:122755315	NA	-0.35	-6.73	-0.3	4.93e-11	Periodontal disease-related phenotypes;
LGG	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg08733933	chr1:2954429	NA	-0.44	-8.73	-0.38	4.7e-17	Plateletcrit;
LGG	cis	rs2479724	0.935	rs2254936	chr6:41846569	A/G	cg17623882	chr6:41773611	USP49	-0.52	-9.28	-0.4	6.38e-19	Menarche (age at onset);
LGG	cis	rs4959677	0.689	rs1994124	chr6:2509443	C/T	cg23817096	chr6:1620687	NA	-0.34	-8.21	-0.36	2.21e-15	Orthostatic hypotension;
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg08222618	chr4:941054	TMEM175	0.81	19.4	0.67	8.8e-62	Sjögren's syndrome;
LGG	cis	rs9487094	0.885	rs1358997	chr6:109701660	G/C	cg01125227	chr6:109776195	MICAL1	0.52	9.06	0.39	3.63e-18	Height;
LGG	cis	rs1983170	0.736	rs745731	chr1:92011467	G/T	cg25838465	chr1:92012736	NA	0.51	6.93	0.31	1.42e-11	Eosinophil percentage of white cells;
LGG	cis	rs4716602	0.596	rs10267031	chr7:156159649	A/G	cg16983916	chr7:156159713	NA	-0.49	-9.58	-0.41	5.92e-20	Anti-saccade response;
LGG	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg08859206	chr1:53392774	SCP2	-0.35	-6.78	-0.3	3.71e-11	Monocyte count;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11771526	0.792	rs28394389	chr7:32298509	C/T	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs6997458	0.651	rs2403105	chr8:86343133	A/G	cg02393479	chr8:86352350	CA3	-0.33	-7.12	-0.31	4.26e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11599315	0.507	rs12217329	chr10:1341897	A/G	cg09624528	chr10:1369823	ADARB2	0.56	10.9	0.45	8.81e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.2	-0.32	2.46e-12	Bipolar disorder;
LGG	cis	rs3845702	0.866	rs3914458	chr2:180862606	A/G	cg01881094	chr2:180872142	CWC22	-0.92	-14.26	-0.55	1.65e-38	Schizophrenia;
LGG	cis	rs6032067	0.929	rs13039108	chr20:43829584	T/C	cg10761708	chr20:43804764	PI3	0.76	11.83	0.48	2.1e-28	Blood protein levels;
LGG	cis	rs9467711	0.584	rs34391493	chr6:26022648	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	7.26	0.32	1.64e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.32	0.32	1.09e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg23335576	chr14:104009727	NA	0.42	7.16	0.32	3.15e-12	Reticulocyte count;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg14926445	chr8:58193284	C8orf71	-0.82	-10.6	-0.44	1.17e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs782590	0.935	rs62165197	chr2:55801812	C/T	cg18811423	chr2:55921094	PNPT1	0.89	20.4	0.69	1.75e-66	Metabolic syndrome;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg07167872	chr1:205819463	PM20D1	0.69	14.77	0.57	1.04e-40	Menarche (age at onset);
LGG	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg06027949	chr8:82754900	SNX16	-0.47	-7.47	-0.33	3.93e-13	Diastolic blood pressure;
LGG	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.59	0.37	1.32e-16	Obesity-related traits;
LGG	cis	rs45544231	0.569	rs12443621	chr16:52548037	A/G	cg09051775	chr16:52580266	TOX3	-0.4	-6.75	-0.3	4.32e-11	Restless legs syndrome;
LGG	cis	rs11630290	0.736	rs7174738	chr15:64144813	A/T	cg12036633	chr15:63758958	NA	-0.55	-6.88	-0.3	1.95e-11	Iris characteristics;
LGG	cis	rs10540	1.000	rs61877775	chr11:521462	C/T	cg19913688	chr11:428466	ANO9	-0.66	-7.69	-0.34	9.13e-14	Body mass index;
LGG	trans	rs9914544	0.545	rs2305064	chr17:18770733	G/A	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.16e-13	Educational attainment (years of education);
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.03	0.57	7.39e-42	Alzheimer's disease;
LGG	cis	rs72945132	0.619	rs34053053	chr11:70260598	C/T	cg14088196	chr11:70211408	PPFIA1	0.73	9.89	0.42	4.61e-21	Coronary artery disease;
LGG	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg26384229	chr12:38710491	ALG10B	0.9	19.95	0.68	2.35e-64	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg20003494	chr4:90757398	SNCA	-0.37	-7.23	-0.32	1.97e-12	Dementia with Lewy bodies;
LGG	cis	rs1062177	1.000	rs2964576	chr5:151150602	T/G	cg00977110	chr5:151150581	G3BP1	0.5	8.0	0.35	1.04e-14	Preschool internalizing problems;
LGG	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg24375607	chr4:120327624	NA	0.67	11.06	0.46	2.21e-25	Corneal astigmatism;
LGG	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg18681998	chr4:17616180	MED28	0.81	18.01	0.64	2.3e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs67133203	0.904	rs12831269	chr12:51398441	C/T	cg14688905	chr12:51403056	SLC11A2	0.79	12.17	0.49	9.48e-30	Urinary tract infection frequency;
LGG	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.65	-0.48	1.07e-27	Response to antipsychotic treatment;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg21798802	chr22:38057573	PDXP	0.61	14.05	0.55	1.38e-37	Fat distribution (HIV);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17398851	chr19:47777507	PRR24	0.37	6.71	0.3	5.53e-11	Gut microbiome composition (summer);
LGG	cis	rs922692	1.000	rs922692	chr15:78984214	C/A	cg00540400	chr15:79124168	NA	-0.34	-6.78	-0.3	3.64e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs78456975	0.739	rs28913003	chr2:1519620	A/T	cg26248373	chr2:1572462	NA	-0.73	-9.43	-0.4	1.92e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7248779	1.000	rs7248779	chr19:2403564	G/T	cg22729335	chr19:2427816	TIMM13	-0.67	-12.36	-0.5	1.52e-30	Cortisol levels (saliva);
LGG	cis	rs9581857	0.579	rs79904593	chr13:27996893	G/A	cg01674679	chr13:27998804	GTF3A	-0.74	-8.28	-0.36	1.31e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg09904177	chr6:26538194	HMGN4	-0.38	-6.77	-0.3	3.92e-11	Schizophrenia;
LGG	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg05639522	chr1:247681581	NA	0.61	10.32	0.43	1.35e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs78487399	0.808	rs10169346	chr2:43741105	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.78	-0.3	3.71e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs11628318	0.614	rs7145737	chr14:103121784	T/A	cg01864069	chr14:103024347	NA	0.66	9.35	0.4	3.68e-19	Platelet count;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.22	0.68	1.29e-65	Platelet count;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.33	0.4	4.31e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7119	0.931	rs12901998	chr15:77833524	G/T	cg17802220	chr15:77601643	NA	-0.33	-6.88	-0.3	1.92e-11	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.44	-0.37	4e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs4776922	chr15:67634437	A/G	cg05925327	chr15:68127851	NA	-0.33	-6.97	-0.31	1.1e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg00898013	chr13:113819073	PROZ	0.44	8.78	0.38	3.19e-17	Platelet distribution width;
LGG	cis	rs11608355	0.515	rs3742018	chr12:109949134	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01352810	chr12:133707387	ZNF10	0.46	7.63	0.33	1.32e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs864537	0.676	rs2056625	chr1:167420299	G/A	cg09179987	chr1:167433047	CD247	0.42	8.94	0.38	9.64e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs7226408	0.802	rs11664299	chr18:34485969	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs17445240	1.000	rs17445240	chr2:3703041	C/T	cg20720597	chr2:3699334	NA	-0.88	-9.52	-0.4	9.33e-20	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs728616	0.681	rs56184245	chr10:82018556	C/T	cg27171509	chr10:82033454	MAT1A	-0.44	-6.83	-0.3	2.7e-11	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7598759	0.712	rs6735961	chr2:232334414	T/C	cg19187155	chr2:232395269	NMUR1	0.42	7.48	0.33	3.82e-13	Noise-induced hearing loss;
LGG	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg08847533	chr14:75593920	NEK9	0.62	11.86	0.48	1.62e-28	Height;
LGG	cis	rs1008375	0.868	rs6816286	chr4:17698088	A/G	cg18681998	chr4:17616180	MED28	0.73	15.1	0.57	3.41e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6834538	1.000	rs6834538	chr4:113544152	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	8.42	0.36	4.79e-16	Free thyroxine concentration;
LGG	trans	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg19894588	chr14:64061835	NA	-0.57	-8.88	-0.38	1.52e-17	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs7824557	0.564	rs2736288	chr8:11228100	G/A	cg02002194	chr4:3960332	NA	0.42	7.46	0.33	4.22e-13	Retinal vascular caliber;
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg15691649	chr6:25882328	NA	-0.39	-6.76	-0.3	4.16e-11	Urate levels;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.21	-0.32	2.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.81	-0.34	3.93e-14	Psoriasis;
LGG	cis	rs763121	0.853	rs9622833	chr22:39000397	G/A	cg06022373	chr22:39101656	GTPBP1	0.86	17.24	0.63	8.38e-52	Menopause (age at onset);
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg21775007	chr8:11205619	TDH	-0.45	-7.49	-0.33	3.57e-13	Neuroticism;
LGG	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg00319359	chr11:70116639	PPFIA1	0.71	7.68	0.34	9.66e-14	Coronary artery disease;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.4	-7.81	-0.34	3.88e-14	Schizophrenia;
LGG	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18881776	chr1:28052146	FAM76A	0.43	7.04	0.31	6.84e-12	Cognitive performance;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05025164	chr4:1340916	KIAA1530	0.58	10.42	0.44	5.43e-23	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	cis	rs9790314	0.638	rs6764019	chr3:160638851	A/C	cg04691961	chr3:161091175	C3orf57	0.43	8.99	0.39	6.23e-18	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg16141378	chr3:129829833	LOC729375	0.44	10.59	0.44	1.35e-23	Mood instability;
LGG	cis	rs11214589	0.651	rs11214595	chr11:113259658	G/T	cg14159747	chr11:113255604	NA	0.31	8.46	0.37	3.58e-16	Neuroticism;
LGG	trans	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.7	-0.34	8.42e-14	Joint mobility (Beighton score);
LGG	cis	rs2235649	0.789	rs9929803	chr16:1852748	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.39	-6.72	-0.3	5.41e-11	Blood metabolite levels;
LGG	cis	rs4824093	0.610	rs56810176	chr22:50303149	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.0	-0.31	9.29e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg06212747	chr3:49208901	KLHDC8B	0.71	12.17	0.49	9.22e-30	Parkinson's disease;
LGG	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg01244601	chr4:120671846	NA	0.36	6.85	0.3	2.37e-11	Corneal astigmatism;
LGG	cis	rs1346	0.580	rs10791819	chr11:65363865	A/G	cg17120908	chr11:65337727	SSSCA1	-0.45	-6.68	-0.3	6.8e-11	Vertical cup-disc ratio;Optic cup area;
LGG	cis	rs3857747	0.759	rs34398005	chr7:40399535	C/A	cg00420559	chr7:40367873	C7orf10	0.4	8.03	0.35	8.06e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg21775007	chr8:11205619	TDH	-0.49	-8.13	-0.35	3.85e-15	Neuroticism;
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.08	-0.35	5.63e-15	Personality dimensions;
LGG	cis	rs56283067	0.847	rs1552196	chr6:44698265	A/G	cg18551225	chr6:44695536	NA	0.71	11.95	0.49	6.98e-29	Total body bone mineral density;
LGG	cis	rs1124376	1.000	rs9819628	chr3:20140837	A/G	cg05072819	chr3:20081367	KAT2B	-0.62	-8.29	-0.36	1.21e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg15971980	chr6:150254442	NA	0.45	8.94	0.38	9.48e-18	Testicular germ cell tumor;
LGG	cis	rs708547	1.000	rs10003229	chr4:57809598	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.59	-9.07	-0.39	3.3e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs1577917	0.958	rs67024565	chr6:86553997	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.52	-0.56	1.18e-39	Response to antipsychotic treatment;
LGG	cis	rs55665837	0.519	rs10832297	chr11:14757737	C/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.41	-0.33	6.12e-13	Vitamin D levels;
LGG	cis	rs4642101	0.680	rs6442330	chr3:12820501	A/G	cg24848339	chr3:12840334	CAND2	0.45	10.41	0.44	6.25e-23	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.13	0.39	2.07e-18	Lung cancer;
LGG	cis	rs778371	0.834	rs778364	chr2:233777859	A/G	cg08000102	chr2:233561755	GIGYF2	0.52	7.48	0.33	3.66e-13	Schizophrenia;
LGG	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg20573242	chr4:122745356	CCNA2	0.53	9.66	0.41	3.12e-20	Type 2 diabetes;
LGG	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg17971929	chr21:40555470	PSMG1	0.85	16.43	0.61	3.88e-48	Cognitive function;
LGG	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.82	-0.38	2.33e-17	Mean corpuscular volume;
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg13607699	chr17:42295918	UBTF	0.56	9.22	0.39	1.01e-18	Total body bone mineral density;
LGG	trans	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg02002194	chr4:3960332	NA	0.39	6.96	0.31	1.13e-11	Mood instability;
LGG	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg04568710	chr12:38710424	ALG10B	0.34	6.84	0.3	2.54e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1048238	0.846	rs945417	chr1:16344625	C/G	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.4	-0.4	2.61e-19	Systolic blood pressure;
LGG	cis	rs4481887	0.745	rs4540687	chr1:248476099	C/G	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.64	-11.32	-0.47	2.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4237845	0.742	rs6650219	chr12:58289100	T/C	cg02175503	chr12:58329896	NA	0.67	12.63	0.51	1.3e-31	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.18e-20	Aortic root size;
LGG	cis	rs3813359	0.545	rs6908798	chr6:130554677	G/A	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6445975	0.726	rs6762098	chr3:58468428	A/C	cg24175188	chr3:58374923	PXK	0.44	8.0	0.35	1.02e-14	Systemic lupus erythematosus;
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg02158880	chr13:53174818	NA	0.4	7.27	0.32	1.59e-12	Lewy body disease;
LGG	cis	rs10463554	0.963	rs34382	chr5:102396225	G/C	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs6866344	0.570	rs4266420	chr5:178137161	C/G	cg03877680	chr5:178157825	ZNF354A	0.82	14.29	0.55	1.28e-38	Neutrophil percentage of white cells;
LGG	cis	rs6784615	0.590	rs1035002	chr3:52488202	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.57	-0.33	1.98e-13	Waist-hip ratio;
LGG	cis	rs7011049	0.778	rs111899960	chr8:53870132	A/G	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.24	0.49	4.9e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg22771759	chr13:24902376	NA	0.42	7.06	0.31	6.17e-12	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg13206674	chr6:150067644	NUP43	0.6	13.23	0.52	3.94e-34	Lung cancer;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.77e-12	Lung cancer;
LGG	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.14	-0.32	3.55e-12	Total cholesterol levels;
LGG	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.95	0.38	8.85e-18	Motion sickness;
LGG	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg15921436	chr17:44337874	NA	0.49	10.43	0.44	5.07e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs523395	0.630	rs616111	chr1:120269991	C/G	cg19096424	chr1:120255104	PHGDH	-0.61	-10.91	-0.45	8.28e-25	Red blood cell count;
LGG	cis	rs10504073	0.584	rs4873300	chr8:49902201	C/G	cg00325661	chr8:49890786	NA	0.82	16.47	0.61	2.54e-48	Blood metabolite ratios;
LGG	cis	rs1451375	0.572	rs11575463	chr7:50547173	A/G	cg14593290	chr7:50529359	DDC	-0.67	-12.01	-0.49	4.27e-29	Malaria;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13126279	chr21:47581558	C21orf56	-0.49	-8.64	-0.37	9.42e-17	Testicular germ cell tumor;
LGG	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.22	-0.43	3.1e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg25358565	chr5:93447407	FAM172A	1.28	15.96	0.6	5.5e-46	Diabetic retinopathy;
LGG	cis	rs4975616	0.869	rs452932	chr5:1330253	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.42	-0.47	8.71e-27	Lung cancer;
LGG	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.38	0.43	7.5e-23	Mean platelet volume;
LGG	cis	rs13191362	0.507	rs1954806	chr6:163051858	G/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-7.94	-0.35	1.51e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.58	9.21	0.39	1.1e-18	Renal function-related traits (BUN);
LGG	cis	rs3857747	0.931	rs4286851	chr7:40363150	C/T	cg00420559	chr7:40367873	C7orf10	-0.4	-7.93	-0.35	1.67e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02398342	chr17:80708632	TBCD;FN3K	-0.5	-9.59	-0.41	5.31e-20	Glycated hemoglobin levels;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.47	-0.37	3.19e-16	Skin colour saturation;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs10883723	0.810	rs11191304	chr10:104255284	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2071403	0.901	rs56217611	chr2:1400070	T/C	cg06500727	chr2:1417164	TPO	-0.53	-10.04	-0.42	1.41e-21	Thyroid peroxidase antibody positivity;
LGG	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs62400317	0.859	rs28583363	chr6:45231336	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs4846580	0.660	rs10863486	chr1:219906948	C/T	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	cis	rs9815354	1.000	rs9820192	chr3:41889281	G/A	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg13385521	chr17:29058706	SUZ12P	-0.81	-9.57	-0.41	6.23e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.12e-12	Bipolar disorder;
LGG	cis	rs62238980	0.614	rs78940018	chr22:32419975	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12187437	chr12:66524584	LLPH	0.53	8.23	0.36	1.99e-15	Gut microbiome composition (summer);
LGG	cis	rs13191362	0.935	rs35049401	chr6:162968464	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.11	0.31	4.47e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9913711	0.868	rs7216619	chr17:70079708	C/A	cg09344028	chr17:70110421	NA	0.39	7.51	0.33	3.04e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13303229	chr5:154136254	LARP1	0.44	6.99	0.31	9.36e-12	Cognitive performance;
LGG	cis	rs2251381	0.750	rs2776250	chr21:30528094	T/G	cg24692254	chr21:30365293	RNF160	0.83	17.33	0.63	3.07e-52	Selective IgA deficiency;
LGG	trans	rs12579753	1.000	rs12827923	chr12:82242067	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.9e-14	Resting heart rate;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.81	-0.3	3.09e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.729	rs7924782	chr11:49267249	A/G	cg03929089	chr4:120376271	NA	-0.9	-17.92	-0.64	6.3e-55	Coronary artery disease;
LGG	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg18105134	chr13:113819100	PROZ	-0.77	-16.56	-0.61	1e-48	Platelet distribution width;
LGG	cis	rs4924935	0.851	rs12936834	chr17:18807078	A/G	cg26378065	chr17:18585709	ZNF286B	0.43	6.8	0.3	3.19e-11	Pancreatic cancer;
LGG	cis	rs56146971	0.714	rs55709253	chr14:91853363	T/C	cg14409461	chr14:91925021	SMEK1	-0.41	-6.89	-0.3	1.85e-11	Alzheimer disease and age of onset;
LGG	cis	rs916888	0.821	rs199509	chr17:44858728	G/A	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg17809284	chr5:56205270	C5orf35	-0.53	-8.67	-0.37	7.46e-17	Initial pursuit acceleration;
LGG	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg23533926	chr12:111358616	MYL2	-0.42	-6.91	-0.31	1.57e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	9.07	0.39	3.4e-18	Bipolar disorder;
LGG	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg05623727	chr3:50126028	RBM5	-0.34	-6.68	-0.3	6.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00049323	chr5:472564	LOC25845	0.4	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg13683864	chr3:40499215	RPL14	1.15	28.93	0.8	7.63e-106	Renal cell carcinoma;
LGG	cis	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg26384229	chr12:38710491	ALG10B	1.0	25.41	0.76	7.52e-90	Heart rate;
LGG	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg14227996	chr4:17616232	MED28	0.72	8.65	0.37	8.42e-17	Opioid sensitivity;
LGG	cis	rs9987353	0.589	rs1053036	chr8:9060077	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.12	-0.31	4.05e-12	Recombination measurement;
LGG	cis	rs9814567	1.000	rs2370578	chr3:134199612	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.6	-0.51	1.62e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10979	1.000	rs9403506	chr6:143887805	C/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.43	-0.5	8.03e-31	Hypospadias;
LGG	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg08000102	chr2:233561755	GIGYF2	0.59	9.37	0.4	3.13e-19	Coronary artery disease;
LGG	cis	rs2535633	0.602	rs2581816	chr3:53014657	C/T	cg11645453	chr3:52864694	ITIH4	0.48	7.82	0.34	3.52e-14	Body mass index;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg09264619	chr17:80180166	NA	-0.36	-7.23	-0.32	1.97e-12	Life satisfaction;
LGG	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg21435375	chr2:172878103	MAP1D	-0.32	-7.46	-0.33	4.43e-13	Schizophrenia;
LGG	cis	rs2562456	0.874	rs2562408	chr19:21709881	C/G	cg00806126	chr19:22604979	ZNF98	0.65	9.46	0.4	1.51e-19	Pain;
LGG	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.53	-0.37	2.15e-16	Bone mineral density;
LGG	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg21385522	chr1:16154831	NA	0.73	13.24	0.52	3.83e-34	Dilated cardiomyopathy;
LGG	cis	rs2594989	0.895	rs2442789	chr3:11540188	C/T	cg01796438	chr3:11312864	ATG7	-0.53	-7.36	-0.32	8.42e-13	Circulating chemerin levels;
LGG	cis	rs12195424	0.730	rs1323318	chr6:56305925	C/G	cg07152817	chr6:56299822	NA	-0.59	-6.99	-0.31	9.38e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs7246760	0.609	rs57889827	chr19:9777459	T/C	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs6735179	0.607	rs10202812	chr2:1746468	A/T	cg20311673	chr2:1746207	PXDN	-0.4	-6.83	-0.3	2.66e-11	Response to antipsychotic treatment;
LGG	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg07636037	chr3:49044803	WDR6	0.59	10.31	0.43	1.42e-22	Resting heart rate;
LGG	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg14983838	chr19:29218262	NA	0.72	11.47	0.47	5.39e-27	Methadone dose in opioid dependence;
LGG	cis	rs6866344	0.697	rs62392832	chr5:178134395	T/C	cg03877680	chr5:178157825	ZNF354A	0.76	12.26	0.5	4.06e-30	Neutrophil percentage of white cells;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs5769765	0.862	rs9616774	chr22:50290599	G/A	cg02269571	chr22:50332266	NA	-0.63	-10.19	-0.43	4.05e-22	Schizophrenia;
LGG	cis	rs992157	0.835	rs10932769	chr2:219147245	T/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.23	-0.43	2.75e-22	Colorectal cancer;
LGG	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg16230307	chr14:35515116	FAM177A1	0.61	9.23	0.39	1e-18	Psoriasis;
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.61	-0.41	4.71e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7917772	0.582	rs12779854	chr10:104358474	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.45	-0.47	6.53e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs16866061	0.962	rs16825685	chr2:225434256	C/G	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.35	0.5	1.7e-30	Coronary artery disease;
LGG	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg18196295	chr10:418757	DIP2C	0.52	9.88	0.42	5.11e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg00531865	chr16:30841666	NA	0.54	10.2	0.43	3.6e-22	Dementia with Lewy bodies;
LGG	cis	rs8135665	0.600	rs8142379	chr22:38450971	G/A	cg13116946	chr22:38479732	SLC16A8	0.53	8.7	0.37	6.04e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs13065560	0.594	rs4234133	chr3:38888021	T/C	cg01426195	chr3:39028469	NA	-0.46	-9.52	-0.4	9.32e-20	Interleukin-18 levels;
LGG	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg09222892	chr1:25734099	RHCE	0.45	9.42	0.4	2.16e-19	Erythrocyte sedimentation rate;
LGG	trans	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	7.79	0.34	4.44e-14	Retinal vascular caliber;
LGG	cis	rs4478137	0.931	rs11100488	chr4:164237660	C/A	cg06758707	chr4:164254230	NPY1R	0.72	12.86	0.51	1.47e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9611565	0.512	rs1534932	chr22:42150146	C/T	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Vitiligo;
LGG	cis	rs10979	1.000	rs6570565	chr6:143899531	C/T	cg25407410	chr6:143891975	LOC285740	-0.71	-11.7	-0.48	6.92e-28	Hypospadias;
LGG	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg18357526	chr6:26021779	HIST1H4A	0.94	18.14	0.64	6.14e-56	Intelligence (multi-trait analysis);
LGG	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg09222892	chr1:25734099	RHCE	0.48	10.5	0.44	2.92e-23	Erythrocyte sedimentation rate;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg03392679	chr3:71773917	EIF4E3	-0.41	-6.79	-0.3	3.51e-11	Height;
LGG	cis	rs10752881	1.000	rs10797808	chr1:182979623	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05468351	chr5:21459598	LOC728411	0.37	6.77	0.3	3.91e-11	Obesity-related traits;
LGG	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg06212747	chr3:49208901	KLHDC8B	0.73	13.05	0.52	2.19e-33	Menarche (age at onset);
LGG	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg04492858	chr10:133558786	NA	0.43	8.65	0.37	8.64e-17	Survival in rectal cancer;
LGG	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19748678	chr4:122722346	EXOSC9	-0.46	-8.21	-0.36	2.21e-15	Type 2 diabetes;
LGG	cis	rs4478858	0.684	rs7521463	chr1:31761936	T/A	cg19084893	chr1:31688959	NA	0.32	6.88	0.3	2e-11	Alcohol dependence;
LGG	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg01557791	chr16:72042693	DHODH	0.58	10.93	0.45	7.07e-25	Fibrinogen levels;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06864046	chr12:89746505	DUSP6	0.48	7.64	0.33	1.23e-13	Gut microbiome composition (summer);
LGG	cis	rs1318772	0.932	rs348922	chr5:112837147	C/T	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs2404602	0.647	rs11072625	chr15:77084984	A/G	cg23625390	chr15:77176239	SCAPER	0.7	13.68	0.54	5.22e-36	Blood metabolite levels;
LGG	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg17734273	chr15:78292508	TBC1D2B	0.29	6.83	0.3	2.75e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs7737355	1.000	rs7737355	chr5:130604811	T/A	cg06307176	chr5:131281290	NA	0.51	8.47	0.37	3.37e-16	Life satisfaction;
LGG	cis	rs9467773	0.620	rs2504566	chr6:26660488	G/C	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg18350739	chr11:68623251	NA	0.52	11.96	0.49	6.51e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4730250	0.581	rs3779500	chr7:106792704	T/C	cg02696742	chr7:106810147	HBP1	0.79	11.12	0.46	1.24e-25	Osteoarthritis;
LGG	cis	rs981844	0.714	rs6822142	chr4:154683524	C/T	cg14289246	chr4:154710475	SFRP2	-0.6	-10.69	-0.44	5.4e-24	Response to statins (LDL cholesterol change);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14321365	chr9:134001527	NUP214	0.44	7.09	0.31	4.94e-12	Gut microbiome composition (summer);
LGG	cis	rs4268898	0.760	rs55863105	chr2:24570695	C/T	cg06627628	chr2:24431161	ITSN2	0.42	7.11	0.31	4.55e-12	Asthma;
LGG	trans	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg27411982	chr8:10470053	RP1L1	0.47	8.06	0.35	6.55e-15	Joint mobility (Beighton score);
LGG	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.42	-0.47	9.07e-27	Coronary artery disease;
LGG	cis	rs208520	0.690	rs207114	chr6:66791703	C/T	cg07460842	chr6:66804631	NA	-0.98	-18.47	-0.65	1.84e-57	Exhaled nitric oxide output;
LGG	cis	rs17208368	0.628	rs8060014	chr16:55092421	C/T	cg09947736	chr16:55091198	NA	0.67	12.61	0.51	1.5e-31	Hypospadias;
LGG	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs910316	1.000	rs10142626	chr14:75555636	A/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.65	0.44	7.45e-24	Height;
LGG	cis	rs8067545	0.518	rs7222987	chr17:20055765	A/G	cg09818912	chr17:20140352	CYTSB	-0.33	-7.67	-0.34	9.95e-14	Schizophrenia;
LGG	cis	rs2455601	0.786	rs3763913	chr11:8951230	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.76	-13.42	-0.53	6.39e-35	Schizophrenia;
LGG	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.12	0.68	3.85e-65	Primary sclerosing cholangitis;
LGG	cis	rs9362426	0.526	rs7773804	chr6:88116150	T/A	cg22010963	chr6:88119922	C6orf165	-0.31	-6.79	-0.3	3.52e-11	Depressive episodes in bipolar disorder;
LGG	cis	rs4561483	0.832	rs33645	chr16:11985201	T/C	cg08843971	chr16:11963173	GSPT1	-0.67	-18.16	-0.64	4.97e-56	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg08621203	chr6:150244597	RAET1G	0.46	7.91	0.35	1.91e-14	Lung cancer;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg18316613	chr7:23719636	C7orf46	0.35	8.08	0.35	5.88e-15	Schizophrenia;
LGG	cis	rs736801	0.891	rs11242115	chr5:131826413	G/C	cg21138405	chr5:131827807	IRF1	-0.31	-7.05	-0.31	6.51e-12	Breast cancer;Mosquito bite size;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.16	-0.35	3.23e-15	Aortic root size;
LGG	cis	rs5769765	0.773	rs58375955	chr22:50312630	A/G	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	7.65e-13	Schizophrenia;
LGG	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-8.53	-0.37	2.13e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6723226	0.881	rs10181198	chr2:32686582	A/G	cg02381751	chr2:32503542	YIPF4	0.74	12.12	0.49	1.5e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.71	0.34	8.01e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg14668632	chr7:2872130	GNA12	-0.36	-7.45	-0.33	4.63e-13	Height;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.66	-0.34	1.13e-13	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25841139	chr20:17949502	C20orf72;SNX5	0.5	7.43	0.33	5.2e-13	Gut microbiome composition (summer);
LGG	cis	rs1570884	0.516	rs9316463	chr13:50176844	G/A	cg08779649	chr13:50194554	NA	0.37	9.27	0.4	7e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg09873164	chr1:152488093	CRCT1	0.62	14.32	0.55	9.2e-39	Hair morphology;
LGG	cis	rs10267417	0.589	rs3956536	chr7:19937238	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	6.74	0.3	4.61e-11	Night sleep phenotypes;
LGG	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg03476357	chr21:30257390	N6AMT1	-0.43	-7.41	-0.33	6.15e-13	Cognitive test performance;
LGG	trans	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg05059571	chr16:84539110	KIAA1609	-0.57	-10.85	-0.45	1.39e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04352115	chr16:29801967	KIF22	0.45	6.71	0.3	5.65e-11	Gut microbiome composition (summer);
LGG	cis	rs3741151	0.773	rs28400367	chr11:73112421	C/A	cg17517138	chr11:73019481	ARHGEF17	0.87	8.48	0.37	3.02e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg06917634	chr15:78832804	PSMA4	-0.84	-17.73	-0.64	4.54e-54	Sudden cardiac arrest;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg13206674	chr6:150067644	NUP43	0.67	15.32	0.58	3.7e-43	Lung cancer;
LGG	cis	rs4423214	0.610	rs3763856	chr11:71125345	G/A	cg10847948	chr11:71163743	NADSYN1	-0.53	-10.01	-0.42	1.75e-21	Vitamin D levels;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	18.22	0.65	2.55e-56	Platelet count;
LGG	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.75	-0.34	5.71e-14	Diabetic retinopathy;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.74	13.79	0.54	1.72e-36	Obesity-related traits;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg15212455	chr7:39170539	POU6F2	0.4	8.55	0.37	1.87e-16	IgG glycosylation;
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg04287289	chr16:89883240	FANCA	0.84	8.04	0.35	7.52e-15	Skin colour saturation;
LGG	cis	rs16973500	0.732	rs1549292	chr16:71983664	A/C	cg00732059	chr16:71740210	PHLPP2	-0.61	-10.08	-0.42	9.79e-22	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs16854884	0.657	rs16854772	chr3:143703890	A/G	cg06585982	chr3:143692056	C3orf58	0.6	10.23	0.43	2.88e-22	Economic and political preferences (feminism/equality);
LGG	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg00405596	chr8:11794950	NA	0.42	7.07	0.31	5.69e-12	Neuroticism;
LGG	cis	rs1008375	1.000	rs11737138	chr4:17657986	G/A	cg04450456	chr4:17643702	FAM184B	0.34	7.61	0.33	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs936229	0.690	rs2472299	chr15:75033400	C/T	cg10253484	chr15:75165896	SCAMP2	0.61	9.14	0.39	2.02e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg13732083	chr21:47605072	C21orf56	-0.52	-8.43	-0.36	4.52e-16	Testicular germ cell tumor;
LGG	cis	rs887829	0.588	rs4663969	chr2:234655313	C/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.67	-0.34	9.9e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg09873164	chr1:152488093	CRCT1	0.62	15.01	0.57	8.62e-42	Hair morphology;
LGG	cis	rs1983891	1.000	rs6458228	chr6:41543793	C/A	cg20194872	chr6:41519635	FOXP4	0.59	10.27	0.43	1.95e-22	Prostate cancer;
LGG	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.33e-12	Obesity-related traits;
LGG	cis	rs317689	0.680	rs315140	chr12:69790780	A/T	cg11871910	chr12:69753446	YEATS4	0.79	13.42	0.53	6.63e-35	Response to diuretic therapy;
LGG	trans	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.15	0.32	3.37e-12	Retinal vascular caliber;
LGG	trans	rs783540	0.609	rs803686	chr15:83219340	G/A	cg16105309	chr15:79090380	ADAMTS7	0.51	8.3	0.36	1.17e-15	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg25358565	chr5:93447407	FAM172A	1.39	17.14	0.62	2.41e-51	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg27535305	chr1:53392650	SCP2	0.34	7.57	0.33	2.02e-13	Monocyte count;
LGG	cis	rs6942756	0.774	rs891545	chr7:128866616	A/C	cg02491457	chr7:128862824	NA	0.65	12.41	0.5	9.69e-31	White matter hyperintensity burden;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg11878867	chr6:150167359	LRP11	-0.49	-9.73	-0.41	1.81e-20	Lung cancer;
LGG	cis	rs9596863	0.898	rs7983436	chr13:54388598	T/A	ch.13.53330881F	chr13:54432880	NA	0.52	6.9	0.31	1.67e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg18478394	chr8:109455254	TTC35	0.43	8.51	0.37	2.38e-16	Dupuytren's disease;
LGG	cis	rs11677416	1.000	rs61381693	chr2:113525912	C/A	cg27083787	chr2:113543245	IL1A	0.54	8.99	0.39	6.37e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs72781680	1.000	rs56339200	chr2:24188194	C/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs2777491	0.915	rs8036498	chr15:41603276	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.33	-0.67	1.71e-61	Ulcerative colitis;
LGG	cis	rs972578	1.000	rs714003	chr22:43369766	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.14	0.39	1.9e-18	Lung cancer in ever smokers;
LGG	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.46	7.28	0.32	1.43e-12	Fear of minor pain;
LGG	cis	rs977987	0.806	rs1549306	chr16:75415341	A/G	cg03315344	chr16:75512273	CHST6	0.49	9.83	0.42	7.61e-21	Dupuytren's disease;
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg03264133	chr6:25882463	NA	0.43	7.66	0.34	1.11e-13	Height;
LGG	cis	rs3824867	0.920	rs3740684	chr11:47468820	C/T	cg20307385	chr11:47447363	PSMC3	0.48	7.64	0.33	1.27e-13	Mean corpuscular hemoglobin;
LGG	cis	rs8077889	1.000	rs4793035	chr17:41887753	C/T	cg26893861	chr17:41843967	DUSP3	0.94	15.67	0.59	1.02e-44	Triglycerides;
LGG	cis	rs6728642	0.519	rs6718420	chr2:97572470	C/T	cg26665480	chr2:98280029	ACTR1B	-0.67	-8.1	-0.35	4.97e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17703990	chr19:58428046	ZNF417	0.44	6.88	0.3	1.96e-11	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-10.27	-0.43	1.94e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs858239	0.601	rs10239760	chr7:23149950	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.14	0.31	3.73e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4538187	1.000	rs6710763	chr2:64068788	G/T	cg14150252	chr2:64069583	UGP2	0.49	9.77	0.41	1.23e-20	Systolic blood pressure;
LGG	cis	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg22857025	chr5:266934	NA	-1.48	-25.61	-0.77	8.99e-91	Breast cancer;
LGG	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.38	-0.32	7.46e-13	HDL cholesterol;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	8.0	0.35	9.79e-15	Obesity-related traits;
LGG	cis	rs9326248	0.689	rs4516002	chr11:116999059	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	7.37	0.32	8.17e-13	Blood protein levels;
LGG	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg15309053	chr8:964076	NA	-0.36	-7.23	-0.32	1.99e-12	Schizophrenia;
LGG	trans	rs637571	0.510	rs4930320	chr11:65576788	C/G	cg17712092	chr4:129076599	LARP1B	-0.66	-12.23	-0.49	5.33e-30	Eosinophil percentage of white cells;
LGG	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs7927771	1.000	rs4752857	chr11:47655752	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-8.61	-0.37	1.16e-16	Subjective well-being;
LGG	cis	rs1982963	0.906	rs2029976	chr14:52505811	C/T	cg05884192	chr14:52515736	NID2	-0.34	-7.55	-0.33	2.38e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs584438	0.873	rs1009570	chr17:38596425	A/G	cg09358481	chr17:38600305	IGFBP4	0.46	8.87	0.38	1.58e-17	Height;
LGG	cis	rs4642101	0.561	rs6766744	chr3:12801843	C/T	cg05775895	chr3:12838266	CAND2	0.55	9.12	0.39	2.28e-18	QRS complex (12-leadsum);
LGG	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg05793240	chr7:2802953	GNA12	0.32	7.77	0.34	5.17e-14	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02625641	chr15:59041175	ADAM10	0.46	7.67	0.34	1e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg09264619	chr17:80180166	NA	0.52	9.97	0.42	2.37e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg18335740	chr13:41363409	SLC25A15	0.85	19.75	0.68	1.97e-63	Lewy body disease;
LGG	cis	rs3126085	0.825	rs4845428	chr1:152225261	T/C	cg26876637	chr1:152193138	HRNR	0.55	8.97	0.38	7.58e-18	Atopic dermatitis;
LGG	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.6	-0.44	1.2e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9397585	0.791	rs3910736	chr6:153412476	C/T	cg17707550	chr6:153380415	RGS17	0.42	8.89	0.38	1.34e-17	Body mass index;
LGG	cis	rs8017423	1.000	rs4900028	chr14:90685594	C/T	cg04374321	chr14:90722782	PSMC1	0.86	18.34	0.65	7.14e-57	Mortality in heart failure;
LGG	trans	rs7395662	1.000	rs8189391	chr11:48859789	A/G	cg00717180	chr2:96193071	NA	0.43	7.61	0.33	1.53e-13	HDL cholesterol;
LGG	cis	rs2832191	0.791	rs2832186	chr21:30484151	A/C	cg24692254	chr21:30365293	RNF160	-0.95	-24.13	-0.75	6.65e-84	Dental caries;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs1775715	0.707	rs2808094	chr10:32133756	T/C	cg14930904	chr10:32216787	ARHGAP12	0.34	6.72	0.3	5.41e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs62400317	0.859	rs12214749	chr6:45307906	A/G	cg20913747	chr6:44695427	NA	-0.61	-10.45	-0.44	4.42e-23	Total body bone mineral density;
LGG	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg00101154	chr16:420108	MRPL28	0.47	7.02	0.31	8.13e-12	Body mass index;
LGG	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.16	0.35	3.27e-15	Triglycerides;
LGG	cis	rs9581857	0.615	rs9581848	chr13:28003997	C/T	cg01674679	chr13:27998804	GTF3A	-0.68	-7.82	-0.34	3.58e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10035607	chr16:30366449	CD2BP2	0.46	7.49	0.33	3.61e-13	Cognitive performance;
LGG	trans	rs12579753	0.917	rs4842410	chr12:82219225	A/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.99	-0.35	1.05e-14	Resting heart rate;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.31	-0.43	1.36e-22	Platelet count;
LGG	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	2e-18	Blood metabolite levels;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.84	-10.59	-0.44	1.27e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	cis	rs68170813	0.559	rs77671232	chr7:106939202	A/G	cg02696742	chr7:106810147	HBP1	-0.7	-10.16	-0.43	4.86e-22	Coronary artery disease;
LGG	cis	rs9543976	1.000	rs55927305	chr13:76135349	A/G	cg01531495	chr13:76123901	UCHL3	-0.64	-7.6	-0.33	1.7e-13	Diabetic retinopathy;
LGG	cis	rs7615952	0.576	rs66671308	chr3:125793526	T/G	cg15145296	chr3:125709740	NA	-0.61	-7.83	-0.34	3.4e-14	Blood pressure (smoking interaction);
LGG	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.48	0.5	5.3e-31	Colorectal cancer;
LGG	cis	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.41	1.76e-20	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21836426	chr4:184580106	RWDD4A;C4orf41	0.44	7.03	0.31	7.45e-12	Cognitive performance;
LGG	trans	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.64	-0.41	3.64e-20	Neuroticism;
LGG	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.61	8.84	0.38	1.98e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.54	-0.61	1.28e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg26384229	chr12:38710491	ALG10B	0.94	21.29	0.7	1.2e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25172604	chr17:41446521	NA	-0.3	-6.65	-0.3	8.2e-11	Menopause (age at onset);
LGG	cis	rs4950322	1.000	rs4950429	chr1:146871957	A/T	cg22381352	chr1:146742008	CHD1L	-0.44	-6.95	-0.31	1.27e-11	Protein quantitative trait loci;
LGG	cis	rs763121	0.853	rs4821816	chr22:39113134	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	18.78	0.66	6.84e-59	Menopause (age at onset);
LGG	cis	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg00745463	chr17:30367425	LRRC37B	-0.48	-7.05	-0.31	6.43e-12	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs34929064	0.958	rs4722167	chr7:22740312	G/A	cg18045685	chr7:22629474	NA	0.53	8.26	0.36	1.56e-15	Major depression and alcohol dependence;
LGG	cis	rs3771570	1.000	rs62193210	chr2:242323616	G/A	cg21155796	chr2:242212141	HDLBP	0.74	9.69	0.41	2.41e-20	Prostate cancer;
LGG	cis	rs17604090	0.793	rs17136535	chr7:29689158	C/T	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.29	0.4	6.27e-19	Blood metabolite levels;
LGG	cis	rs6909430	0.665	rs2502947	chr6:98623103	A/T	cg12860156	chr6:98744658	NA	-0.38	-6.78	-0.3	3.59e-11	Quantitative traits;
LGG	cis	rs1371867	0.875	rs1619759	chr8:101337560	T/C	cg06636551	chr8:101224915	SPAG1	-0.47	-8.66	-0.37	7.68e-17	Atrioventricular conduction;
LGG	cis	rs8028182	0.636	rs28432989	chr15:75768297	T/C	cg20655648	chr15:75932815	IMP3	0.46	7.53	0.33	2.65e-13	Sudden cardiac arrest;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12960782	chr5:59996455	DEPDC1B	0.39	6.8	0.3	3.31e-11	Bipolar disorder;
LGG	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg00092383	chr7:157075207	NA	-0.39	-6.7	-0.3	5.95e-11	Body mass index;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs4006360	0.646	rs3843966	chr17:39250840	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.19	-0.46	7.04e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs473651	0.740	rs502349	chr2:239318389	C/T	cg08773314	chr2:239334832	ASB1	0.36	6.74	0.3	4.8e-11	Multiple system atrophy;
LGG	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg20244327	chr10:3283946	NA	-0.33	-8.69	-0.37	6.11e-17	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs4319547	0.661	rs10773172	chr12:122939655	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.92	-0.42	3.57e-21	Body mass index;
LGG	cis	rs1545257	0.505	rs7595372	chr2:24632122	A/C	cg06627628	chr2:24431161	ITSN2	-0.41	-6.9	-0.31	1.72e-11	Sjögren's syndrome;
LGG	trans	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg16507663	chr6:150244633	RAET1G	0.43	8.07	0.35	5.93e-15	Lung cancer;
LGG	cis	rs1348850	0.831	rs7606235	chr2:178401288	T/C	cg27490568	chr2:178487706	NA	0.53	10.36	0.43	9.1e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.65	-8.91	-0.38	1.17e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11677416	1.000	rs4848303	chr2:113552698	A/G	cg27083787	chr2:113543245	IL1A	0.54	9.0	0.39	5.89e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2153535	0.580	rs2327057	chr6:8443319	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.15	0.43	5.28e-22	Motion sickness;
LGG	cis	rs4319547	0.697	rs7974262	chr12:122896385	C/T	cg05707623	chr12:122985044	ZCCHC8	0.67	9.85	0.42	6.72e-21	Body mass index;
LGG	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg03806693	chr22:41940476	POLR3H	0.95	16.39	0.61	6.24e-48	Vitiligo;
LGG	cis	rs72960926	1.000	rs56168999	chr6:75121136	A/G	cg03266952	chr6:74778945	NA	-0.68	-6.8	-0.3	3.25e-11	Metabolite levels (MHPG);
LGG	cis	rs2760061	0.505	rs708109	chr1:228190657	C/T	cg01200585	chr1:228362443	C1orf69	0.48	8.06	0.35	6.76e-15	Diastolic blood pressure;
LGG	trans	rs1945213	0.659	rs11227133	chr11:55836620	T/C	cg11707556	chr5:10655725	ANKRD33B	0.47	6.93	0.31	1.42e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.65	0.44	7.92e-24	Lung cancer in ever smokers;
LGG	cis	rs7666738	0.830	rs13121766	chr4:98935766	A/C	cg05340658	chr4:99064831	C4orf37	0.48	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.51	-0.47	3.92e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7666738	0.830	rs6848397	chr4:98946738	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs877282	0.891	rs12767062	chr10:797961	C/T	cg22713356	chr15:30763199	NA	0.58	8.69	0.37	6.18e-17	Uric acid levels;
LGG	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg02297831	chr4:17616191	MED28	-0.51	-9.73	-0.41	1.83e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.31	0.43	1.43e-22	Prudent dietary pattern;
LGG	cis	rs698813	0.674	rs6544751	chr2:44495845	A/G	cg00619915	chr2:44497795	NA	-0.61	-8.59	-0.37	1.3e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs36051895	0.659	rs7859390	chr9:5062473	A/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.98	-0.57	1.19e-41	Pediatric autoimmune diseases;
LGG	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg23505145	chr19:12996616	KLF1	0.41	7.33	0.32	1.06e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10463554	0.927	rs34806	chr5:102428437	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.58e-13	Parkinson's disease;
LGG	cis	rs17739794	0.517	rs6982473	chr8:773986	G/T	cg11667643	chr8:748456	NA	-0.39	-7.15	-0.32	3.34e-12	Clozapine-induced cytotoxicity;
LGG	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.66	0.37	7.89e-17	Aortic root size;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25427524	chr10:38739819	LOC399744	-0.62	-11.54	-0.47	3.03e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9309473	1.000	rs7564890	chr2:73641853	T/C	cg20560298	chr2:73613845	ALMS1	-0.48	-7.9	-0.34	2.11e-14	Metabolite levels;
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.07	-0.55	1.08e-37	Alzheimer's disease;
LGG	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg19847130	chr8:10466454	RP1L1	-0.3	-6.72	-0.3	5.28e-11	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14369405	chr18:32556760	MAPRE2	0.43	7.3	0.32	1.25e-12	Cognitive performance;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg23166955	chr16:30077191	ALDOA	0.47	6.71	0.3	5.8200000000000003e-11	Breast cancer;
LGG	cis	rs7106204	0.609	rs16912391	chr11:24310637	G/A	ch.11.24196551F	chr11:24239977	NA	0.88	9.61	0.41	4.65e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2180341	0.960	rs9401952	chr6:127677027	A/C	cg24812749	chr6:127587940	RNF146	0.97	16.03	0.6	2.67e-46	Breast cancer;
LGG	cis	rs17401966	0.838	rs9332414	chr1:10326963	C/T	cg19773385	chr1:10388646	KIF1B	-0.48	-10.65	-0.44	7.74e-24	Hepatocellular carcinoma;
LGG	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg27129171	chr3:47204927	SETD2	0.83	16.0	0.6	3.3e-46	Colorectal cancer;
LGG	cis	rs11945232	1.000	rs11945232	chr4:88342369	A/G	cg23841344	chr4:88312519	HSD17B11	-0.49	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.821	rs56155624	chr4:120291026	C/G	cg25214090	chr10:38739885	LOC399744	0.62	10.36	0.43	9.2e-23	Corneal astigmatism;
LGG	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.12	-0.39	2.35e-18	Gut microbiome composition (summer);
LGG	cis	rs9309473	1.000	rs58603761	chr2:73726605	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.57	-0.33	2.06e-13	Metabolite levels;
LGG	trans	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.18	0.49	8.52e-30	Corneal astigmatism;
LGG	trans	rs9650657	0.801	rs4841437	chr8:10596795	T/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.85	-0.34	2.9e-14	Neuroticism;
LGG	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs2032447	0.672	rs9379811	chr6:25955197	G/C	cg03264133	chr6:25882463	NA	-0.7	-13.07	-0.52	1.97e-33	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg25019033	chr10:957182	NA	-0.54	-9.96	-0.42	2.63e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg10326726	chr10:51549505	MSMB	0.54	10.71	0.45	4.67e-24	Prostate-specific antigen levels;
LGG	trans	rs2204008	0.654	rs1733410	chr12:38132172	G/A	cg06521331	chr12:34319734	NA	0.45	8.07	0.35	5.89e-15	Bladder cancer;
LGG	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg26655873	chr3:72818019	SHQ1	0.33	7.02	0.31	7.71e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.95	0.35	1.43e-14	Obesity-related traits;
LGG	cis	rs4474465	0.920	rs12222907	chr11:78219726	C/T	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg03929089	chr4:120376271	NA	-0.86	-12.92	-0.51	7.96e-33	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06899844	chr16:30662123	PRR14	-0.44	-6.8	-0.3	3.32e-11	Pancreatic cancer;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg02725872	chr8:58115012	NA	-0.88	-12.02	-0.49	3.59e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.13	-0.31	3.99e-12	Systolic blood pressure;
LGG	cis	rs67133203	0.904	rs10506298	chr12:51373158	A/G	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.57e-30	Urinary tract infection frequency;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg10150615	chr22:24372951	LOC391322	-0.41	-6.7	-0.3	6.11e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.04e-43	Prudent dietary pattern;
LGG	cis	rs12200560	0.505	rs60879781	chr6:97075466	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs9549367	0.756	rs3861723	chr13:113910926	A/G	cg18105134	chr13:113819100	PROZ	-0.66	-13.58	-0.53	1.38e-35	Platelet distribution width;
LGG	cis	rs4689642	0.709	rs11729619	chr4:7224489	T/C	cg21353189	chr4:7228343	SORCS2	0.39	8.95	0.38	8.56e-18	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg01879757	chr17:41196368	BRCA1	0.4	8.42	0.36	4.78e-16	Menopause (age at onset);
LGG	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg21435375	chr2:172878103	MAP1D	-0.33	-7.31	-0.32	1.16e-12	Schizophrenia;
LGG	trans	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg06606381	chr12:133084897	FBRSL1	-0.64	-8.23	-0.36	1.91e-15	Depression;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02325324	chr13:23489846	NA	0.42	7.01	0.31	8.22e-12	Cognitive performance;
LGG	cis	rs701145	0.537	rs1713815	chr3:153872445	T/C	cg12800244	chr3:153838788	SGEF	0.76	8.94	0.38	9.58e-18	Coronary artery disease;
LGG	cis	rs2072499	0.932	rs3001790	chr1:156165290	T/G	cg25208724	chr1:156163844	SLC25A44	1.26	31.22	0.82	5.64e-116	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.52e-12	Lung cancer;
LGG	cis	rs7727544	0.647	rs7721882	chr5:131418948	A/G	cg07395648	chr5:131743802	NA	-0.42	-9.03	-0.39	4.64e-18	Blood metabolite levels;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs941873	0.836	rs6480931	chr10:81108482	T/C	cg09469691	chr10:81107165	PPIF	0.56	9.6	0.41	4.98e-20	Height;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg19524238	chr7:2802976	GNA12	0.36	8.17	0.35	2.99e-15	Height;
LGG	cis	rs6743376	0.556	rs1530553	chr2:113818171	G/A	cg05949173	chr2:113825882	IL1F10	0.48	9.06	0.39	3.7e-18	Inflammatory biomarkers;
LGG	cis	rs11711311	0.955	rs1048892	chr3:113464859	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.12	0.55	6.4e-38	IgG glycosylation;
LGG	cis	rs57221529	0.766	rs72703026	chr5:572383	G/A	cg09021430	chr5:549028	NA	-0.73	-10.36	-0.43	9.13e-23	Lung disease severity in cystic fibrosis;
LGG	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg27147174	chr7:100797783	AP1S1	0.57	9.9	0.42	4.21e-21	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.62	10.11	0.43	7.36e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs17756712	0.527	rs1193742	chr6:635629	T/C	cg14374089	chr6:596013	EXOC2	0.56	8.61	0.37	1.19e-16	Vertical cup-disc ratio;
LGG	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg10621924	chr7:39171070	POU6F2	0.4	8.45	0.37	3.8e-16	IgG glycosylation;
LGG	cis	rs9783347	1.000	rs4150673	chr11:18383449	A/C	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.33	-0.32	1.06e-12	Pancreatic cancer;
LGG	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg03731646	chr18:74499372	NA	0.37	6.9	0.31	1.72e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LGG	cis	rs2153535	0.580	rs6421949	chr6:8531769	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.67	0.51	8.22e-32	Motion sickness;
LGG	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg20302533	chr7:39170763	POU6F2	0.5	11.54	0.47	2.97e-27	IgG glycosylation;
LGG	cis	rs62244186	0.659	rs12108134	chr3:44543030	A/G	cg18165381	chr3:44552316	NA	0.4	6.69	0.3	6.49e-11	Depressive symptoms;
LGG	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg10847948	chr11:71163743	NADSYN1	0.63	11.35	0.47	1.59e-26	Vitamin D levels;
LGG	cis	rs2075064	0.903	rs7034780	chr9:126788935	A/G	cg14112217	chr9:126806003	NA	0.39	7.65	0.33	1.2e-13	Waist circumference;
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	trans	rs8073060	0.586	rs72829933	chr17:34056406	C/T	cg19694781	chr19:47549865	TMEM160	1.15	15.8	0.59	2.67e-45	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1784581	0.674	rs1784592	chr6:162387365	T/A	cg17173639	chr6:162384350	PARK2	-0.76	-17.12	-0.62	3.02e-51	Itch intensity from mosquito bite;
LGG	cis	rs1867631	1.000	rs10789212	chr1:67128155	G/A	cg13052034	chr1:66999238	SGIP1	0.45	8.66	0.37	7.92e-17	Menopause (age at onset);
LGG	cis	rs6142618	0.562	rs6142621	chr20:30735807	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs514406	0.644	rs4926928	chr1:53210163	G/T	cg16325326	chr1:53192061	ZYG11B	0.89	23.43	0.74	1.18e-80	Monocyte count;
LGG	cis	rs2481665	0.739	rs6674622	chr1:62534938	A/G	cg18591186	chr1:62594603	INADL	-0.45	-9.22	-0.39	1.02e-18	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11758351	0.660	rs56398712	chr6:26213868	A/G	cg23601095	chr6:26197514	HIST1H3D	0.71	9.02	0.39	5.2e-18	Gout;Renal underexcretion gout;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25468005	chr11:71282718	NA	0.3	6.81	0.3	3.06e-11	Menarche (age at onset);
LGG	cis	rs883115	0.846	rs4654057	chr1:224796339	A/G	cg01808320	chr1:224927238	CNIH3	-0.42	-7.7	-0.34	8.25e-14	Cancer;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs2404602	0.647	rs11855296	chr15:77092962	C/T	cg15268244	chr15:77196840	NA	0.49	10.39	0.43	7e-23	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.57	-0.33	1.99e-13	Lung cancer;
LGG	cis	rs7717393	1.000	rs13358340	chr5:155757872	C/T	cg12904904	chr5:155754151	SGCD	0.88	8.54	0.37	2e-16	Egg allergy;
LGG	trans	rs10877945	1.000	rs10877944	chr12:63430109	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.37	7.05	0.31	6.63e-12	Obesity-related traits;
LGG	cis	rs7824557	0.564	rs4631424	chr8:11236809	T/C	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg21782813	chr7:2030301	MAD1L1	0.41	9.19	0.39	1.33e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7927997	0.708	rs10160518	chr11:76296671	A/G	cg17647271	chr11:76299819	NA	-0.48	-8.6	-0.37	1.23e-16	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg05692746	chr2:100937584	LONRF2	-0.46	-7.02	-0.31	7.97e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.18e-27	Height;
LGG	cis	rs9527	0.571	rs7904113	chr10:104633114	G/T	cg04362960	chr10:104952993	NT5C2	0.55	10.24	0.43	2.49e-22	Arsenic metabolism;
LGG	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg26384229	chr12:38710491	ALG10B	0.94	22.22	0.72	5.52e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6866344	0.570	rs1132338	chr5:178139442	T/G	cg03877680	chr5:178157825	ZNF354A	0.83	14.29	0.55	1.21e-38	Neutrophil percentage of white cells;
LGG	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg22232500	chr2:134024266	NCKAP5	0.67	9.21	0.39	1.13e-18	Bipolar disorder;
LGG	cis	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg09307838	chr4:120376055	NA	0.73	12.27	0.5	3.63e-30	Corneal astigmatism;
LGG	cis	rs638893	0.636	rs493720	chr11:118604678	T/C	cg22253036	chr11:118662786	DDX6	0.44	6.7	0.3	6.13e-11	Vitiligo;
LGG	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg21862992	chr11:68658383	NA	0.5	8.38	0.36	6.58e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.23	0.39	9.96e-19	Bipolar disorder;
LGG	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg25319279	chr11:5960081	NA	-0.48	-7.33	-0.32	1.07e-12	DNA methylation (variation);
LGG	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg11871910	chr12:69753446	YEATS4	1.05	28.86	0.8	1.55e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8064024	0.764	rs3827528	chr16:4853092	T/C	cg08329684	chr16:4932620	PPL	0.38	8.01	0.35	9.14e-15	Cancer;
LGG	cis	rs78456975	0.527	rs10184112	chr2:1571112	A/G	cg26248373	chr2:1572462	NA	-0.89	-15.04	-0.57	6.36e-42	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg21475434	chr5:93447410	FAM172A	0.66	6.77	0.3	3.92e-11	Diabetic retinopathy;
LGG	cis	rs6076065	0.748	rs6076055	chr20:23333917	G/C	cg12633918	chr20:23549525	CST9L	-0.33	-6.84	-0.3	2.53e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg22907277	chr7:1156413	C7orf50	0.77	9.98	0.42	2.22e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg20368463	chr18:77673604	PQLC1	-0.5	-9.02	-0.39	5.13e-18	Schizophrenia;
LGG	cis	rs12143943	0.966	rs4950953	chr1:204575481	A/G	cg20240347	chr1:204465584	NA	-0.31	-6.69	-0.3	6.31e-11	Cognitive performance;
LGG	cis	rs35306767	0.714	rs28512382	chr10:1092195	G/C	cg26597838	chr10:835615	NA	0.52	6.79	0.3	3.42e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg20814179	chr4:940893	TMEM175	0.52	10.73	0.45	4e-24	Sjögren's syndrome;
LGG	cis	rs1920116	0.778	rs34058457	chr3:169554741	G/T	cg08193579	chr3:169529701	LRRC34	0.42	7.18	0.32	2.71e-12	Glioma (high-grade);
LGG	trans	rs783540	0.867	rs11855735	chr15:83296545	A/T	cg16105309	chr15:79090380	ADAMTS7	-0.39	-6.84	-0.3	2.5e-11	Schizophrenia;
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	7.34	0.32	9.83e-13	Renal function-related traits (BUN);
LGG	cis	rs9463078	0.817	rs9369523	chr6:44908728	T/C	cg25276700	chr6:44698697	NA	-0.38	-7.97	-0.35	1.22e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs9354308	0.753	rs1938103	chr6:66600308	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.43	7.1	0.31	4.78e-12	Metabolite levels;
LGG	cis	rs4535700	0.501	rs28828764	chr7:55988679	T/C	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	3.84e-11	Macular telangiectasia type 2;
LGG	trans	rs72991	0.793	rs1560406	chr11:121238585	C/G	cg27192990	chr6:129479024	LAMA2	-0.43	-7.34	-0.32	9.84e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2562456	1.000	rs2359155	chr19:21671869	C/A	cg25042112	chr7:64838748	ZNF92	0.45	6.7	0.3	6.06e-11	Pain;
LGG	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	7.96	0.35	1.3e-14	Cognitive test performance;
LGG	cis	rs61931739	0.500	rs7963282	chr12:34535255	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg06074448	chr4:187884817	NA	-0.59	-13.04	-0.52	2.43e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9357271	1.000	rs9470865	chr6:38354624	G/A	cg07362130	chr6:38359646	BTBD9	-0.47	-10.76	-0.45	2.95e-24	Restless legs syndrome;
LGG	cis	rs2273669	0.915	rs10872027	chr6:109289540	T/C	cg05315195	chr6:109294784	ARMC2	-0.52	-7.34	-0.32	9.61e-13	Prostate cancer;
LGG	cis	rs7666738	0.791	rs6828752	chr4:99063382	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6754311	0.773	rs309130	chr2:136631031	C/A	cg07169764	chr2:136633963	MCM6	-0.75	-12.63	-0.51	1.2e-31	Mosquito bite size;
LGG	cis	rs4891159	0.790	rs689885	chr18:74110563	T/G	cg24786174	chr18:74118243	ZNF516	0.57	13.31	0.53	1.9e-34	Longevity;
LGG	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.9	0.79	3.37e-101	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07343367	chr7:32530145	LSM5	-0.43	-7.11	-0.31	4.42e-12	Pancreatic cancer;
LGG	cis	rs870825	0.655	rs28661636	chr4:185634218	A/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg24690094	chr11:67383802	NA	-0.39	-6.67	-0.3	7.52e-11	Mean corpuscular volume;
LGG	cis	rs2742417	0.967	rs1883096	chr3:45750015	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6489882	0.966	rs6489881	chr12:113381217	A/T	cg25319449	chr12:113376135	OAS3	-0.39	-6.98	-0.31	9.98e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11890956	chr21:40555474	PSMG1	1.17	29.85	0.81	5.75e-110	Cognitive function;
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.72e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9486719	1.000	rs12208124	chr6:97027942	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.74	-0.45	3.64e-24	Migraine;Coronary artery disease;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg13009111	chr11:71350975	NA	-0.31	-6.82	-0.3	2.78e-11	Neuroticism;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg01709316	chr16:2732203	KCTD5	-0.36	-6.9	-0.31	1.67e-11	Iris color (L* coordinate);
LGG	cis	rs17221829	0.733	rs11018684	chr11:89364863	A/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	cis	rs17767392	0.645	rs72726657	chr14:71669966	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.08	-0.31	5.41e-12	Mitral valve prolapse;
LGG	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22496380	chr5:211416	CCDC127	-0.86	-6.73	-0.3	5.16e-11	Asthma (childhood onset);
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg12386194	chr3:101231763	SENP7	0.42	7.37	0.32	7.68e-13	Colorectal cancer;
LGG	cis	rs9400467	0.537	rs55643604	chr6:111490648	T/G	cg15721981	chr6:111408429	SLC16A10	0.59	7.15	0.32	3.43e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4642101	0.737	rs4447735	chr3:12825513	C/T	cg24848339	chr3:12840334	CAND2	0.43	10.08	0.42	9.67e-22	QRS complex (12-leadsum);
LGG	cis	rs9859260	1.000	rs2300777	chr3:195790811	A/C	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.84	-0.3	2.59e-11	Mean corpuscular volume;
LGG	cis	rs4930103	0.619	rs739905	chr11:1980360	G/C	cg15394860	chr11:2017084	H19	0.58	12.63	0.51	1.27e-31	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg24692254	chr21:30365293	RNF160	-0.96	-24.74	-0.75	9.56e-87	Dental caries;
LGG	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg20368463	chr18:77673604	PQLC1	0.56	7.41	0.33	6.21e-13	Opioid sensitivity;
LGG	cis	rs7681440	0.904	rs7698219	chr4:90771351	C/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.5	-0.33	3.25e-13	Dementia with Lewy bodies;
LGG	cis	rs9300255	0.602	rs1790095	chr12:123681222	G/A	cg00376283	chr12:123451042	ABCB9	0.64	10.2	0.43	3.65e-22	Neutrophil percentage of white cells;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg11766577	chr21:47581405	C21orf56	-0.49	-8.15	-0.35	3.54e-15	Testicular germ cell tumor;
LGG	cis	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg13010199	chr12:38710504	ALG10B	0.77	16.45	0.61	3.35e-48	Heart rate;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19212674	chr4:71571625	RUFY3	0.41	7.32	0.32	1.14e-12	Parental extreme longevity (95 years and older);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08588455	chr17:40761604	FAM134C;TUBG1	0.49	7.4	0.33	6.59e-13	Gut microbiome composition (summer);
LGG	cis	rs9964724	1.000	rs4799949	chr18:35155910	C/T	cg27332583	chr18:35150602	NA	-0.43	-8.83	-0.38	2.11e-17	Educational attainment (years of education);
LGG	cis	rs457717	0.730	rs429703	chr5:75943712	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.91	0.31	1.57e-11	Hearing impairment;
LGG	cis	rs8179	0.645	rs12531820	chr7:92257392	A/G	cg15732164	chr7:92237376	CDK6	-0.49	-9.23	-0.39	9.49e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13012494	chr21:47604986	C21orf56	-0.63	-10.46	-0.44	4.03e-23	Testicular germ cell tumor;
LGG	cis	rs7666738	0.830	rs7674095	chr4:99048158	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27286337	chr10:134555280	INPP5A	0.87	13.63	0.54	8.05e-36	Migraine;
LGG	cis	rs7267979	0.903	rs6115101	chr20:25229564	C/A	cg08601574	chr20:25228251	PYGB	0.33	6.81	0.3	3.07e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg13397359	chr6:42928475	GNMT	0.64	18.88	0.66	2.21e-59	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12911832	0.727	rs682619	chr15:59098773	T/C	cg05156742	chr15:59063176	FAM63B	0.6	10.79	0.45	2.39e-24	Schizophrenia;
LGG	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg21475434	chr5:93447410	FAM172A	0.69	7.12	0.31	4.17e-12	Diabetic retinopathy;
LGG	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg11789530	chr4:8429930	ACOX3	-0.64	-12.19	-0.49	8.07e-30	Response to antineoplastic agents;
LGG	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg18681998	chr4:17616180	MED28	0.78	15.67	0.59	1.01e-44	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26114595	chr17:28395749	EFCAB5	0.38	6.75	0.3	4.34e-11	Menarche (age at onset);
LGG	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg01028140	chr2:1542097	TPO	-0.47	-8.81	-0.38	2.57e-17	IgG glycosylation;
LGG	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg09307838	chr4:120376055	NA	0.64	10.27	0.43	1.91e-22	Corneal astigmatism;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg27532560	chr4:187881888	NA	0.6	13.65	0.54	7.03e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.36	-0.43	9.16e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs4262150	0.739	rs4958328	chr5:152127005	C/A	cg12297329	chr5:152029980	NA	-0.69	-12.73	-0.51	4.9e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17373728	0.710	rs12544686	chr8:76218074	C/T	cg07016329	chr8:76221503	NA	-0.61	-11.25	-0.46	4.15e-26	Diabetic kidney disease;
LGG	cis	rs17807624	0.702	rs7815172	chr8:11453671	T/C	cg00405596	chr8:11794950	NA	0.42	6.74	0.3	4.73e-11	Systemic lupus erythematosus;
LGG	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01523860	chr4:103747967	UBE2D3	0.39	7.05	0.31	6.68e-12	Obesity-related traits;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg13395646	chr4:1353034	KIAA1530	-0.47	-8.37	-0.36	7.1e-16	Longevity;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg24503407	chr1:205819492	PM20D1	0.83	20.11	0.68	4.36e-65	Menarche (age at onset);
LGG	trans	rs11650494	0.710	rs11654557	chr17:47390136	A/G	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.66e-12	Prostate cancer;
LGG	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg08392591	chr16:89556376	ANKRD11	0.43	6.7	0.3	5.93e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs74781061	0.858	rs8023865	chr15:74853604	G/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.03	-0.31	7.56e-12	Endometriosis;
LGG	cis	rs7432375	0.610	rs7621932	chr3:136517016	C/T	cg21827317	chr3:136751795	NA	0.44	7.96	0.35	1.33e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9486719	1.000	rs13207333	chr6:96882254	T/C	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.5	-0.33	3.24e-13	Life satisfaction;
LGG	cis	rs56399783	0.901	rs79932907	chr7:2827901	C/G	cg19731401	chr7:2775893	GNA12	0.36	7.39	0.32	7.01e-13	Childhood ear infection;
LGG	cis	rs6918586	0.594	rs198842	chr6:26111448	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.71	-0.41	2.11e-20	Schizophrenia;
LGG	cis	rs2735413	0.881	rs12923218	chr16:78080274	C/G	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg18446336	chr7:2847575	GNA12	-0.39	-10.44	-0.44	4.74e-23	Height;
LGG	cis	rs911555	0.504	rs61995761	chr14:104075712	T/C	cg26031613	chr14:104095156	KLC1	0.59	9.38	0.4	3.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg05555928	chr11:63887634	MACROD1	-0.79	-10.81	-0.45	1.94e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13545763	chr17:47755325	SPOP	0.47	7.44	0.33	5.05e-13	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg02073558	chr3:44770973	ZNF501	0.85	18.64	0.65	2.97e-58	Depressive symptoms;
LGG	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg13010199	chr12:38710504	ALG10B	0.69	13.75	0.54	2.54e-36	Bladder cancer;
LGG	cis	rs17039065	1.000	rs72889364	chr4:109383977	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.600	rs322651	chr18:34616966	A/G	cg15022739	chr18:34823045	BRUNOL4	0.43	9.33	0.4	4.45e-19	Obesity-related traits;
LGG	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg15948088	chr11:109293068	C11orf87	0.46	8.28	0.36	1.32e-15	Schizophrenia;
LGG	cis	rs6466055	0.720	rs10227302	chr7:105021829	C/G	cg04380332	chr7:105027541	SRPK2	-0.39	-7.23	-0.32	2.01e-12	Schizophrenia;
LGG	cis	rs7107174	1.000	rs2512537	chr11:77971947	T/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs739401	0.611	rs7109088	chr11:3027485	G/T	cg05729581	chr11:3078854	CARS	-0.54	-9.25	-0.4	8.1e-19	Longevity;
LGG	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg04731861	chr2:219085781	ARPC2	0.48	12.18	0.49	8.8e-30	Colorectal cancer;
LGG	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	6.72e-22	Axial length;
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg03709012	chr19:19516395	GATAD2A	-0.84	-17.06	-0.62	5.5e-51	Tonsillectomy;
LGG	cis	rs7444	0.941	rs738127	chr22:21968221	G/A	cg15846791	chr22:21984385	YDJC	-0.44	-6.73	-0.3	5.15e-11	Systemic lupus erythematosus;
LGG	cis	rs61931739	0.534	rs2389276	chr12:34097891	T/C	cg06521331	chr12:34319734	NA	-0.61	-11.51	-0.47	4.04e-27	Morning vs. evening chronotype;
LGG	cis	rs700651	0.821	rs700663	chr2:198670478	T/A	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Intracranial aneurysm;
LGG	cis	rs9815354	0.680	rs73073239	chr3:42014597	G/C	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.13	-0.35	4.06e-15	Neuroticism;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg24623649	chr8:11872141	NA	-0.3	-6.67	-0.3	7.39e-11	Neuroticism;
LGG	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.04e-21	Aortic root size;
LGG	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg25664220	chr3:72788482	NA	-0.34	-9.03	-0.39	4.71e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg08198773	chr8:1697536	NA	0.44	7.72	0.34	7.02e-14	Systolic blood pressure;
LGG	cis	rs9486715	0.867	rs9384628	chr6:96960232	T/C	cg18709589	chr6:96969512	KIAA0776	0.41	8.2	0.36	2.3e-15	Headache;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg14926445	chr8:58193284	C8orf71	-0.73	-9.27	-0.4	7.1e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.616	rs4263438	chr4:185624238	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs3815700	1.000	rs8109885	chr19:33095557	A/G	cg02997394	chr19:33096574	ANKRD27	0.88	13.3	0.53	2.07e-34	Eosinophilic esophagitis;
LGG	cis	rs79976124	0.842	rs74881738	chr6:66621825	T/G	cg07460842	chr6:66804631	NA	0.74	12.34	0.5	1.96e-30	Type 2 diabetes;
LGG	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.84e-16	Aortic root size;
LGG	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs9487094	0.848	rs1322816	chr6:109703727	C/A	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.75e-18	Height;
LGG	cis	rs4742903	0.935	rs975253	chr9:106928260	G/C	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.33e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs16837677	1.000	rs59156054	chr1:156748185	T/C	cg14991358	chr1:156767203	PRCC	0.76	7.93	0.35	1.64e-14	Sjögren's syndrome;
LGG	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg26384229	chr12:38710491	ALG10B	0.94	22.14	0.72	1.31e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1401999	0.690	rs1402001	chr3:183642751	A/G	cg01324343	chr3:183735012	ABCC5	0.65	12.66	0.51	9.16e-32	Anterior chamber depth;
LGG	cis	rs7267979	0.932	rs424487	chr20:25468131	C/G	cg06421707	chr20:25228305	PYGB	0.47	10.08	0.42	9.58e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs77372450	0.636	rs6889910	chr5:157014912	A/T	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.7	0.37	5.79e-17	Schizophrenia;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs703842	1.000	rs11172342	chr12:58187758	G/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.36	0.36	7.45e-16	Multiple sclerosis;
LGG	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg18279126	chr7:2041391	MAD1L1	-0.32	-6.96	-0.31	1.14e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg10840412	chr1:235813424	GNG4	0.66	8.77	0.38	3.4e-17	Bipolar disorder;
LGG	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg15269541	chr15:43626905	ADAL	0.43	7.56	0.33	2.15e-13	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9463078	0.838	rs9357470	chr6:45065613	C/T	cg25276700	chr6:44698697	NA	-0.37	-7.78	-0.34	4.64e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg14230542	chr1:110577941	FAM40A	0.4	7.02	0.31	7.96e-12	Body mass index;
LGG	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-8.29	-0.36	1.23e-15	Schizophrenia;
LGG	trans	rs62103177	0.608	rs8088089	chr18:77832154	A/G	cg05926928	chr17:57297772	GDPD1	-0.94	-12.03	-0.49	3.52e-29	Opioid sensitivity;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27144592	chr16:783916	NARFL	0.4	6.69	0.3	6.36e-11	Height;
LGG	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg06115741	chr20:33292138	TP53INP2	0.56	8.81	0.38	2.45e-17	Coronary artery disease;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg09060608	chr5:178986726	RUFY1	-0.5	-9.04	-0.39	4.21e-18	Lung cancer;
LGG	cis	rs12586317	0.547	rs13379372	chr14:35483882	A/C	cg16230307	chr14:35515116	FAM177A1	0.92	13.63	0.54	8.18e-36	Psoriasis;
LGG	cis	rs4639966	0.723	rs11217022	chr11:118641606	A/G	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.41	-0.33	6.15e-13	Systemic lupus erythematosus;
LGG	cis	rs6565180	1.000	rs11862806	chr16:30364071	A/G	cg17640201	chr16:30407289	ZNF48	-0.87	-17.48	-0.63	6.24e-53	Tonsillectomy;
LGG	cis	rs4750440	0.706	rs1599414	chr10:14019519	G/A	cg00551146	chr10:14014579	FRMD4A	0.29	6.95	0.31	1.27e-11	Adiponectin levels;
LGG	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.93	0.62	2.23e-50	Anterior chamber depth;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	8.26	0.36	1.58e-15	Longevity;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.2	-0.36	2.43e-15	Personality dimensions;
LGG	cis	rs6912958	0.559	rs242279	chr6:88048191	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.03	0.52	2.76e-33	Monocyte percentage of white cells;
LGG	cis	rs6450176	0.625	rs35027270	chr5:53289068	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.85	-13.59	-0.53	1.2e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg11965913	chr1:205819406	PM20D1	0.85	18.61	0.65	3.81e-58	Menarche (age at onset);
LGG	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.75	-0.3	4.43e-11	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg11789530	chr4:8429930	ACOX3	0.74	14.46	0.56	2.34e-39	Response to antineoplastic agents;
LGG	cis	rs2373794	1.000	rs435923	chr2:40377632	G/T	cg17740179	chr2:40377776	SLC8A1	-0.98	-22.25	-0.72	3.96e-75	Asthma;
LGG	trans	rs2727020	0.576	rs10839305	chr11:49598733	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.42	-0.47	8.97e-27	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.67	-0.3	7.51e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs970548	0.606	rs12355888	chr10:45931564	G/T	cg14222797	chr10:16859974	RSU1	-0.74	-8.31	-0.36	1.07e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.69	-0.3	6.62e-11	Retinal vascular caliber;
LGG	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg05535760	chr7:792225	HEATR2	0.8	12.54	0.5	2.91e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.39	0.32	6.91e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2404602	0.647	rs12898416	chr15:77042292	C/G	cg23625390	chr15:77176239	SCAPER	-0.71	-13.77	-0.54	2.1e-36	Blood metabolite levels;
LGG	cis	rs6663390	0.831	rs3754171	chr1:208086939	T/C	cg00387621	chr1:208086895	NA	0.65	7.1	0.31	4.79e-12	Facial morphology (factor 18);
LGG	cis	rs526231	0.511	rs56235607	chr5:102372606	G/A	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg00424166	chr6:150045504	NUP43	-0.33	-6.89	-0.31	1.8e-11	Lung cancer;
LGG	cis	rs911555	0.574	rs34251103	chr14:103860063	A/G	cg24130564	chr14:104152367	KLC1	0.37	6.85	0.3	2.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6963495	0.818	rs6973263	chr7:105170293	A/G	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg08807101	chr21:30365312	RNF160	0.59	9.69	0.41	2.36e-20	Pancreatic cancer;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	10.08	0.42	9.69e-22	Tonsillectomy;
LGG	cis	rs721917	0.506	rs78834655	chr10:81644442	A/G	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs763121	0.853	rs5750630	chr22:38985818	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.06	0.62	5.48e-51	Menopause (age at onset);
LGG	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg05552183	chr6:42928497	GNMT	0.31	7.47	0.33	4.06e-13	Blood protein levels;
LGG	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg05802129	chr4:122689817	NA	-0.42	-7.27	-0.32	1.52e-12	Type 2 diabetes;
LGG	cis	rs4363385	0.667	rs454245	chr1:153031979	A/C	cg13444842	chr1:152974279	SPRR3	0.4	8.15	0.35	3.49e-15	Inflammatory skin disease;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs6089584	0.888	rs6587283	chr20:60613727	A/C	cg06108461	chr20:60628389	TAF4	-1.01	-19.86	-0.68	6.27e-64	Body mass index;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.99	-0.35	1.1e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9837602	0.529	rs793458	chr3:99520169	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.43	-0.36	4.55e-16	Breast cancer;
LGG	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12893428	chr3:195717962	SDHAP1	0.51	10.64	0.44	8.64e-24	Pancreatic cancer;
LGG	cis	rs4974559	0.847	rs28477912	chr4:1331350	C/T	cg02980000	chr4:1222292	CTBP1	0.63	7.6	0.33	1.66e-13	Systolic blood pressure;
LGG	cis	rs8014204	0.753	rs6574199	chr14:75356103	T/C	cg03030879	chr14:75389066	RPS6KL1	0.39	7.22	0.32	2.14e-12	Caffeine consumption;
LGG	trans	rs800082	0.698	rs800070	chr3:144346614	A/T	cg24215973	chr2:240111563	HDAC4	-0.72	-13.28	-0.53	2.41e-34	Smoking behavior;
LGG	cis	rs6539288	0.630	rs3759316	chr12:107370210	A/C	cg15890332	chr12:107067104	RFX4	0.29	7.63	0.33	1.38e-13	Total body bone mineral density;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-26.05	-0.77	8.81e-93	Prudent dietary pattern;
LGG	cis	rs4799950	1	rs4799950	chr18:35170045	C/G	cg27332583	chr18:35150602	NA	-0.47	-10.13	-0.43	6.45e-22	Educational attainment;
LGG	cis	rs7918232	0.662	rs10741125	chr10:27288925	G/A	cg14240646	chr10:27532245	ACBD5	-0.56	-8.12	-0.35	4.12e-15	Breast cancer;
LGG	cis	rs28655083	0.529	rs285018	chr16:77099065	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	8.12	0.35	4.29e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.42e-14	Huntington's disease progression;
LGG	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	7.9	0.34	2.02e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11748327	0.959	rs11743330	chr5:4044065	C/T	cg01025095	chr5:4101132	NA	-0.58	-9.31	-0.4	4.97e-19	Myocardial infarction;
LGG	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg03929089	chr4:120376271	NA	-0.97	-20.41	-0.69	1.71e-66	Coronary artery disease;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08147523	chr2:1276773	SNTG2	0.37	7.04	0.31	7.2e-12	Electrocardiographic conduction measures;
LGG	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11644478	chr21:40555479	PSMG1	0.92	17.51	0.63	4.55e-53	Cognitive function;
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg23188684	chr11:67383651	NA	0.5	8.42	0.36	4.91e-16	Mean corpuscular volume;
LGG	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg18681998	chr4:17616180	MED28	0.81	18.1	0.64	9.22e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.68	8.57	0.37	1.59e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4684776	0.877	rs1499082	chr3:11427955	T/C	cg24705426	chr3:11550659	ATG7	-0.42	-7.48	-0.33	3.71e-13	Small vessel stroke;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg26354017	chr1:205819088	PM20D1	-0.85	-19.47	-0.67	4.01e-62	Menarche (age at onset);
LGG	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg18964960	chr10:1102726	WDR37	-0.45	-6.65	-0.3	8.54e-11	Response to angiotensin II receptor blocker therapy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06752163	chr3:170588210	RPL22L1	0.43	7.53	0.33	2.75e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06097357	chr14:35591625	PPP2R3C;KIAA0391	0.47	7.16	0.32	3.16e-12	Gut microbiome composition (summer);
LGG	trans	rs4714291	0.925	rs847755	chr6:40030378	T/C	cg02267698	chr19:7991119	CTXN1	0.59	9.06	0.39	3.79e-18	Strep throat;
LGG	cis	rs55665837	0.778	rs11023212	chr11:14431709	G/A	cg19336497	chr11:14380999	RRAS2	-0.48	-9.26	-0.4	7.87e-19	Vitamin D levels;
LGG	cis	rs5756391	0.782	rs4821557	chr22:37299499	A/G	cg21209356	chr22:37319042	CSF2RB	0.36	8.36	0.36	7.42e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7937682	0.924	rs513425	chr11:111504861	C/T	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs12580194	0.593	rs60873827	chr12:55717769	T/C	cg19537932	chr12:55886519	OR6C68	-0.58	-10.09	-0.42	9.23e-22	Cancer;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg18402987	chr7:1209562	NA	0.65	9.05	0.39	3.95e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6964587	0.836	rs757040	chr7:91552016	A/G	cg17063962	chr7:91808500	NA	-0.45	-7.68	-0.34	9.28e-14	Breast cancer;
LGG	cis	rs1348850	0.872	rs4893959	chr2:178400204	G/A	cg27490568	chr2:178487706	NA	0.5	10.1	0.43	7.94e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs42648	0.569	rs110360	chr7:89856608	C/T	cg25739043	chr7:89950458	NA	-0.34	-7.0	-0.31	9.26e-12	Homocysteine levels;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.52	-0.4	9.57e-20	Life satisfaction;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg07701084	chr6:150067640	NUP43	0.7	13.65	0.54	6.72e-36	Lung cancer;
LGG	cis	rs283228	0.617	rs638255	chr6:101738142	G/A	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	trans	rs1459104	0.641	rs12790762	chr11:54933709	T/A	cg15704280	chr7:45808275	SEPT13	0.73	7.45	0.33	4.63e-13	Body mass index;
LGG	trans	rs12579753	0.917	rs12311988	chr12:82177209	C/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.77	-0.34	5.07e-14	Resting heart rate;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.49	7.31	0.32	1.16e-12	Renal function-related traits (BUN);
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.51	-0.37	2.39e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-20.85	-0.7	1.4e-68	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg18681998	chr4:17616180	MED28	0.87	20.11	0.68	3.95e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9409565	0.826	rs9409778	chr9:97242839	G/A	cg05679027	chr9:99775184	HIATL2	-0.5	-8.15	-0.35	3.31e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2016266	0.819	rs10747662	chr12:53669821	A/T	cg04065151	chr12:53682969	ESPL1	-0.59	-9.53	-0.41	8.59e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4132509	1.000	rs10754807	chr1:243804158	G/A	cg21452805	chr1:244014465	NA	0.61	7.45	0.33	4.75e-13	RR interval (heart rate);
LGG	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.55	0.37	1.84e-16	Retinal vascular caliber;
LGG	cis	rs10875746	0.669	rs11168508	chr12:48683511	G/C	cg24011408	chr12:48396354	COL2A1	-0.58	-7.63	-0.33	1.36e-13	Longevity (90 years and older);
LGG	cis	rs2559856	0.935	rs7970952	chr12:102081577	C/T	cg15068132	chr12:102092402	CHPT1	-0.37	-6.73	-0.3	5.08e-11	Blood protein levels;
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg13736514	chr6:26305472	NA	0.48	10.0	0.42	1.95e-21	Educational attainment;
LGG	cis	rs2862064	0.929	rs2088917	chr5:156432215	A/G	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.8	-0.45	2.05e-24	Platelet count;
LGG	trans	rs6787172	0.651	rs9809952	chr3:158098444	A/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs6582630	0.555	rs34884627	chr12:38443831	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.45	-0.44	4.25e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs514406	0.861	rs2448792	chr1:53268313	T/C	cg24675658	chr1:53192096	ZYG11B	0.48	9.54	0.41	7.98e-20	Monocyte count;
LGG	cis	rs9814567	0.964	rs12492930	chr3:134222722	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.29	-0.53	2.3e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg19524238	chr7:2802976	GNA12	0.4	9.05	0.39	3.99e-18	Height;
LGG	cis	rs921968	0.541	rs2556391	chr2:219556346	T/C	cg01130898	chr2:219473002	PLCD4	0.48	8.11	0.35	4.65e-15	Mean corpuscular hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24775172	chr19:37329431	ZNF790	0.5	7.9	0.34	2.03e-14	Gut microbiome composition (summer);
LGG	cis	rs559928	0.606	rs11600628	chr11:63976027	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.52	0.33	2.87e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13082711	0.911	rs17019721	chr3:27424799	A/G	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.69e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1784581	0.588	rs9346893	chr6:162417511	C/G	cg17173639	chr6:162384350	PARK2	0.64	13.4	0.53	7.53e-35	Itch intensity from mosquito bite;
LGG	cis	rs350251	0.899	rs2664186	chr16:12210702	G/T	cg02910054	chr16:12241554	SNX29	-0.42	-7.77	-0.34	4.98e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6542826	0.584	rs6542824	chr2:110045136	C/T	cg20706049	chr2:110026630	SH3RF3	-0.31	-7.29	-0.32	1.35e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.44	-0.33	5e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2976388	1.000	rs2920298	chr8:143763043	A/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg21972741	chr5:435613	AHRR	0.46	7.99	0.35	1.05e-14	Cystic fibrosis severity;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg05861140	chr6:150128134	PCMT1	-0.3	-6.81	-0.3	3.06e-11	Lung cancer;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg14675211	chr2:100938903	LONRF2	0.66	11.69	0.48	7.84e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	0.892	rs2090095	chr11:78034020	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.55	-0.33	2.34e-13	Testicular germ cell tumor;
LGG	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.55	-0.44	1.83e-23	Total cholesterol levels;
LGG	cis	rs12493885	0.769	rs57354204	chr3:153755718	C/T	cg17054900	chr3:154042577	DHX36	-0.63	-8.06	-0.35	6.5e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg17830980	chr10:43048298	ZNF37B	0.62	14.31	0.55	9.97e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs6840360	0.681	rs4519779	chr4:152301185	G/A	cg17217059	chr4:152329364	FAM160A1	0.22	7.6	0.33	1.67e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg23262073	chr20:60523788	NA	-0.61	-9.49	-0.4	1.25e-19	Obesity-related traits;
LGG	cis	rs4073221	0.520	rs13065273	chr3:18194852	T/C	cg07694806	chr3:18168406	NA	-0.62	-7.93	-0.35	1.66e-14	Parkinson's disease;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05665937	chr4:1216051	CTBP1	0.49	9.0	0.39	5.96e-18	Obesity-related traits;
LGG	cis	rs72772090	0.908	rs11750510	chr5:96042095	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.44	-7.02	-0.31	7.75e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs314370	1.000	rs12705089	chr7:100465355	C/T	cg10426581	chr7:100472382	SRRT	0.53	7.34	0.32	9.65e-13	Resting heart rate;
LGG	cis	rs6032067	1.000	rs2233896	chr20:43850400	C/A	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg11062466	chr8:58055876	NA	0.48	8.02	0.35	8.58e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00495681	chr13:53174319	NA	0.56	10.41	0.44	6.3e-23	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17774305	chr12:50505649	C12orf62	0.44	6.77	0.3	3.82e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	6.09e-49	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.699	rs12498150	chr4:9950537	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.3e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12310956	0.532	rs6488187	chr12:33975029	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.33	-0.47	1.97e-26	Morning vs. evening chronotype;
LGG	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03517284	chr6:25882590	NA	-0.63	-11.96	-0.49	6.33e-29	Intelligence (multi-trait analysis);
LGG	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.82	-14.95	-0.57	1.57e-41	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs10819861	0.575	rs10760780	chr9:98872791	A/G	cg14508093	chr9:98862825	NA	-0.31	-7.18	-0.32	2.75e-12	Electrocardiographic traits;
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.28	0.46	2.95e-26	Tonsillectomy;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.32	0.36	9.59e-16	Lung cancer;
LGG	cis	rs9399137	0.507	rs61738647	chr6:135282735	T/C	cg24558204	chr6:135376177	HBS1L	0.6	10.24	0.43	2.47e-22	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg06873352	chr17:61820015	STRADA	0.59	10.37	0.43	8.74e-23	Prudent dietary pattern;
LGG	cis	rs9902453	0.769	rs7210288	chr17:28243473	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.73	0.54	3.15e-36	Coffee consumption (cups per day);
LGG	trans	rs9354308	0.764	rs6931427	chr6:66568995	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs7143963	0.636	rs7157267	chr14:103350813	T/C	cg23020514	chr14:103360112	TRAF3	0.39	7.93	0.35	1.65e-14	Body mass index;
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.6	10.66	0.44	6.95e-24	Bipolar disorder;
LGG	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg14500267	chr11:67383377	NA	-0.41	-7.48	-0.33	3.84e-13	Mean corpuscular volume;
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg09303159	chr6:26284866	NA	0.32	7.13	0.31	3.86e-12	Educational attainment;
LGG	cis	rs7914558	1.000	rs7077097	chr10:104945463	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.69	0.44	5.42e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.95	-0.35	1.45e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs7647973	1.000	rs11720542	chr3:49357427	A/G	cg07636037	chr3:49044803	WDR6	0.77	13.44	0.53	5.35e-35	Menarche (age at onset);
LGG	cis	rs9309473	1.000	rs10193972	chr2:73717656	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.65	-0.33	1.19e-13	Metabolite levels;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg05313129	chr8:58192883	C8orf71	-0.78	-12.29	-0.5	3.11e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7010267	0.773	rs13439134	chr8:119918868	G/C	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.8	-0.41	9.71e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs963731	0.579	rs10200058	chr2:39341253	C/T	cg04010122	chr2:39346883	SOS1	0.78	8.11	0.35	4.69e-15	Corticobasal degeneration;
LGG	cis	rs3735485	0.843	rs10235175	chr7:45032666	A/G	cg03440944	chr7:45023329	C7orf40	-0.57	-9.83	-0.42	7.88e-21	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1059312	0.669	rs11059917	chr12:129287925	T/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.7	-13.93	-0.54	4.21e-37	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg11040518	chr10:102331378	NA	-0.37	-6.83	-0.3	2.64e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17209837	1.000	rs4148805	chr7:87106365	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-12.06	-0.49	2.69e-29	Gallbladder cancer;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07677032	chr17:61819896	STRADA	-0.67	-12.62	-0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg08949735	chr16:89699720	DPEP1	-0.35	-6.93	-0.31	1.46e-11	Hemoglobin concentration;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.57	0.41	6.28e-20	Longevity;
LGG	trans	rs6601327	0.549	rs2175846	chr8:9644976	G/T	cg16141378	chr3:129829833	LOC729375	-0.35	-8.07	-0.35	6.16e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.8e-16	Life satisfaction;
LGG	cis	rs11864453	0.514	rs2269918	chr16:72134831	C/A	cg23815491	chr16:72088622	HP	0.5	11.27	0.46	3.47e-26	Fibrinogen levels;
LGG	trans	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.75	-0.3	4.54e-11	Pancreatic cancer;
LGG	cis	rs9815354	0.812	rs17218504	chr3:41987278	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3858526	0.839	rs10466484	chr11:5943696	A/G	cg05234568	chr11:5960015	NA	-0.67	-11.25	-0.46	4.2e-26	DNA methylation (variation);
LGG	cis	rs7084783	0.519	rs2281584	chr10:105358980	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.45	7.83	0.34	3.31e-14	Fear of pain;
LGG	cis	rs9815354	0.812	rs56994465	chr3:42061606	A/G	cg03022575	chr3:42003672	ULK4	0.65	7.91	0.35	1.89e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg15921436	chr17:44337874	NA	0.6	12.92	0.51	8.01e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg11494091	chr17:61959527	GH2	0.51	8.38	0.36	6.46e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg23505145	chr19:12996616	KLF1	-0.39	-6.97	-0.31	1.09e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.01	-0.31	8.26e-12	Renal cell carcinoma;
LGG	cis	rs763121	0.815	rs12168758	chr22:38997269	C/G	cg06022373	chr22:39101656	GTPBP1	0.78	15.79	0.59	3.04e-45	Menopause (age at onset);
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg03188948	chr7:1209495	NA	0.49	7.83	0.34	3.37e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2276314	0.857	rs62101379	chr18:33584902	G/A	cg05985134	chr18:33552581	C18orf21	0.63	9.74	0.41	1.58e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.38	0.53	9.33e-35	Lung cancer;
LGG	cis	rs11608355	0.521	rs7976839	chr12:109830534	C/A	cg19025524	chr12:109796872	NA	-0.58	-12.94	-0.52	6.38e-33	Neuroticism;
LGG	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg09307838	chr4:120376055	NA	0.81	13.53	0.53	2.25e-35	Corneal astigmatism;
LGG	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.12	-0.49	1.5e-29	Height;
LGG	cis	rs4075765	0.649	rs56186968	chr11:26273084	C/A	cg19182008	chr11:26298241	NA	1.0	9.01	0.39	5.36e-18	Cannabis dependence symptom count;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.8	0.3	3.21e-11	Longevity;
LGG	cis	rs853679	0.517	rs9368552	chr6:28068426	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7618501	1.000	rs6785549	chr3:49736565	G/A	cg24110177	chr3:50126178	RBM5	0.4	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.963	rs26262	chr5:102545163	T/G	cg23492399	chr5:102201601	PAM	-0.5	-7.48	-0.33	3.84e-13	Parkinson's disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg03595861	chr6:26126282	NA	0.42	6.93	0.31	1.45e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.28	0.46	3.12e-26	Mean corpuscular volume;
LGG	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.11	-0.35	4.53e-15	Triglycerides;
LGG	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg15704280	chr7:45808275	SEPT13	0.85	8.82	0.38	2.37e-17	Myopia (pathological);
LGG	cis	rs77633900	0.772	rs157768	chr15:76833779	C/T	cg21673338	chr15:77095150	SCAPER	-0.63	-8.43	-0.36	4.35e-16	Non-glioblastoma glioma;Glioma;
LGG	trans	rs57221529	0.709	rs4957056	chr5:570105	T/C	cg25482853	chr8:67687455	SGK3	1.04	13.46	0.53	4.27e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg07615347	chr10:60278583	BICC1	0.62	17.46	0.63	8.18e-53	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04521675	chr8:66556930	MTFR1	0.48	7.18	0.32	2.81e-12	Gut microbiome composition (summer);
LGG	cis	rs2694528	1.000	rs4699963	chr5:60138590	C/T	cg11474532	chr5:59995715	DEPDC1B	0.73	7.7	0.34	8.06e-14	Parkinson's disease;
LGG	cis	rs42648	0.837	rs7786771	chr7:89924767	G/A	cg25739043	chr7:89950458	NA	-0.44	-9.26	-0.4	7.69e-19	Homocysteine levels;
LGG	cis	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg24110177	chr3:50126178	RBM5	-0.4	-6.88	-0.3	1.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.17	-0.52	6.97e-34	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20988798	chr7:75677766	MDH2;STYXL1	0.47	7.02	0.31	7.88e-12	Gut microbiome composition (summer);
LGG	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.75	0.38	4.09e-17	Hypertriglyceridemia;
LGG	cis	rs11997175	0.574	rs7001404	chr8:33645219	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.16e-12	Body mass index;
LGG	cis	rs561341	1.000	rs68140514	chr17:30335781	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.6	-0.44	1.22e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg16606324	chr3:10149918	C3orf24	-0.53	-7.1	-0.31	4.78e-12	Alzheimer's disease;
LGG	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg11644478	chr21:40555479	PSMG1	0.92	16.39	0.61	6.06e-48	Cognitive function;
LGG	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.22	-0.46	5.14e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35740288	0.580	rs34526042	chr15:86339956	C/T	cg04173714	chr15:86211321	AKAP13	0.41	6.83	0.3	2.67e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs758324	0.947	rs7725924	chr5:131118165	C/G	cg06307176	chr5:131281290	NA	0.57	9.47	0.4	1.47e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg23484912	chr5:273055	PDCD6	0.45	9.14	0.39	1.99e-18	Pancreatic cancer;
LGG	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg04672837	chr16:48644449	N4BP1	0.51	8.4	0.36	5.53e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg19904058	chr10:135279010	LOC619207	-0.28	-6.82	-0.3	2.77e-11	Systemic lupus erythematosus;
LGG	trans	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.66	0.48	1.02e-27	Corneal astigmatism;
LGG	trans	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg21659725	chr3:3221576	CRBN	0.66	12.3	0.5	2.91e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2227564	0.645	rs2633309	chr10:75654086	G/A	cg00564723	chr10:75632066	CAMK2G	-0.43	-9.25	-0.4	8.02e-19	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2239547	0.657	rs7638524	chr3:52874861	G/A	cg11645453	chr3:52864694	ITIH4	0.71	11.06	0.46	2.11e-25	Schizophrenia;
LGG	cis	rs4356932	1.000	rs13130221	chr4:76955617	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.71	-0.34	7.89e-14	Diastolic blood pressure;
LGG	cis	rs907683	0.570	rs2666104	chr2:220281010	C/T	cg15015639	chr2:220282977	DES	-0.35	-8.97	-0.38	7.45e-18	Resting heart rate;
LGG	cis	rs17767392	0.794	rs61989255	chr14:71729657	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.58	-0.37	1.42e-16	Mitral valve prolapse;
LGG	cis	rs11157436	0.602	rs928955	chr14:22634169	T/C	cg00994629	chr14:22694547	NA	0.33	7.13	0.31	3.98e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.46e-16	Life satisfaction;
LGG	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.14	-0.35	3.68e-15	Small cell lung carcinoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04273556	chr9:35096672	PIGO	-0.43	-7.13	-0.31	3.82e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs55788414	0.932	rs9921748	chr16:81181783	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs10191773	0.535	rs11685514	chr2:113100014	C/T	cg23609528	chr2:113191194	RGPD5;RGPD8	0.56	6.85	0.3	2.29e-11	Yeast infection;
LGG	cis	rs9287719	0.774	rs4997811	chr2:10755538	T/C	cg02196655	chr2:10830764	NOL10	-0.41	-6.91	-0.31	1.59e-11	Prostate cancer;
LGG	cis	rs977987	0.778	rs12930452	chr16:75462055	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.86	0.42	6.15e-21	Dupuytren's disease;
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg12813108	chr7:99719912	CNPY4	-0.57	-8.85	-0.38	1.84e-17	Lung function (FEV1/FVC);
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg14092988	chr3:52407081	DNAH1	0.31	8.15	0.35	3.44e-15	Bipolar disorder;
LGG	cis	rs4664308	0.935	rs4665148	chr2:160917901	A/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.18	-0.65	3.95e-56	Idiopathic membranous nephropathy;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg13397359	chr6:42928475	GNMT	0.57	15.68	0.59	9.12e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.48	0.56	1.78e-39	Colorectal cancer;
LGG	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg24110177	chr3:50126178	RBM5	-0.56	-10.29	-0.43	1.7e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2286885	1.000	rs10760439	chr9:129250830	A/C	cg14319473	chr9:129242481	FAM125B	0.44	7.97	0.35	1.25e-14	Intraocular pressure;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.18e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21862992	chr11:68658383	NA	0.5	8.49	0.37	2.72e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.83	0.3	2.64e-11	Schizophrenia;
LGG	cis	rs977987	0.806	rs4888383	chr16:75386349	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs6840360	0.642	rs4696092	chr4:152412603	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	1.000	rs7917717	chr10:60269100	C/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.87	-0.64	1.07e-54	Refractive error;
LGG	cis	rs12410462	0.581	rs7547204	chr1:227560909	C/T	cg04117972	chr1:227635322	NA	0.72	11.07	0.46	1.94e-25	Major depressive disorder;
LGG	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg10523679	chr1:76189770	ACADM	0.41	6.96	0.31	1.21e-11	Daytime sleep phenotypes;
LGG	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg12395012	chr8:11607386	GATA4	-0.39	-6.9	-0.31	1.71e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg00666640	chr1:248458726	OR2T12	0.54	8.57	0.37	1.61e-16	Common traits (Other);
LGG	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.94	-0.35	1.58e-14	Initial pursuit acceleration;
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg05793240	chr7:2802953	GNA12	0.36	8.03	0.35	8.23e-15	Height;
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg23129478	chr18:44337922	ST8SIA5	0.37	7.01	0.31	8.74e-12	Personality dimensions;
LGG	trans	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg02002194	chr4:3960332	NA	-0.44	-8.17	-0.35	2.99e-15	Neuroticism;
LGG	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg08847533	chr14:75593920	NEK9	-0.55	-10.1	-0.42	8.42e-22	Height;
LGG	cis	rs68170813	0.559	rs74774133	chr7:106941449	T/C	cg02696742	chr7:106810147	HBP1	-0.72	-10.39	-0.43	7.33e-23	Coronary artery disease;
LGG	cis	rs4731207	0.698	rs7781148	chr7:124458044	G/A	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs6993813	0.872	rs7018198	chr8:120048033	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.82	0.3	2.94e-11	Bone mineral density (hip);
LGG	trans	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.78	-0.34	4.85e-14	Heart rate;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.25e-20	Life satisfaction;
LGG	cis	rs8177253	1.000	rs8177261	chr3:133480588	A/C	cg11941060	chr3:133502564	NA	-0.49	-8.29	-0.36	1.25e-15	Iron status biomarkers;
LGG	cis	rs1552244	0.554	rs17050705	chr3:10046398	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.3	-0.43	1.6e-22	Alzheimer's disease;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2645694	0.626	rs904050	chr4:77826089	T/G	cg06046430	chr4:77819534	ANKRD56	0.55	11.31	0.47	2.33e-26	Emphysema distribution in smoking;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg08730330	chr17:61904790	PSMC5;FTSJ3	0.4	6.77	0.3	3.81e-11	Prudent dietary pattern;
LGG	cis	rs9815354	1.000	rs9840037	chr3:41827522	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.3	0.36	1.19e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7020830	0.516	rs36047049	chr9:37375472	G/T	cg14294708	chr9:37120828	ZCCHC7	0.95	15.48	0.58	7.16e-44	Schizophrenia;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg00495681	chr13:53174319	NA	0.56	10.39	0.43	7.26e-23	Lewy body disease;
LGG	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg07915516	chr16:377344	AXIN1	-0.29	-7.3	-0.32	1.25e-12	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg07005078	chr4:17578674	LAP3	0.38	6.89	0.31	1.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.78	-0.3	3.68e-11	Lung cancer;
LGG	cis	rs3785574	1.000	rs2955245	chr17:61979845	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.5	-7.43	-0.33	5.4e-13	Height;
LGG	cis	rs2180341	1.000	rs3798853	chr6:127636823	C/T	cg27446573	chr6:127587934	RNF146	-1.13	-22.0	-0.71	5.71e-74	Breast cancer;
LGG	cis	rs35771425	0.600	rs41275358	chr1:211475042	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.27	-0.36	1.39e-15	Educational attainment (years of education);
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.12	-32.97	-0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs2836974	0.897	rs1541102	chr21:40628765	C/T	cg17971929	chr21:40555470	PSMG1	0.88	17.76	0.64	3.47e-54	Cognitive function;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.8	-0.34	4.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs41005	1.000	rs41008	chr2:8108588	G/T	cg03155496	chr2:8117019	LOC339788	0.88	19.72	0.68	2.78e-63	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg00990874	chr7:1149470	C7orf50	-0.71	-11.14	-0.46	1.02e-25	Bronchopulmonary dysplasia;
LGG	cis	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg17545662	chr6:170176663	C6orf70	0.66	8.68	0.37	6.64e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6764363	0.527	rs4003413	chr3:280987	C/A	cg02057681	chr3:285234	CHL1	-0.42	-7.52	-0.33	2.87e-13	Sudden cardiac arrest;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07677032	chr17:61819896	STRADA	0.66	12.11	0.49	1.65e-29	Prudent dietary pattern;
LGG	cis	rs2108225	1.000	rs2108226	chr7:107453279	A/C	cg18560240	chr7:107437656	SLC26A3	-0.54	-9.62	-0.41	4.37e-20	Ulcerative colitis;
LGG	cis	rs6743226	1.000	rs6743226	chr2:242236972	T/C	cg10021735	chr2:242295487	FARP2	0.51	9.45	0.4	1.65e-19	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs7939886	0.920	rs7934132	chr11:55942463	T/A	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg21475434	chr5:93447410	FAM172A	0.71	7.24	0.32	1.9e-12	Diabetic retinopathy;
LGG	cis	rs539514	0.587	rs7320216	chr13:76332689	A/G	cg04757411	chr13:76259545	LMO7	-0.28	-7.07	-0.31	5.7e-12	Type 1 diabetes;
LGG	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg23324259	chr8:82754387	SNX16	0.44	7.01	0.31	8.69e-12	Diastolic blood pressure;
LGG	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2413583	0.591	rs115263847	chr22:39729777	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.65	0.33	1.2e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1152591	0.811	rs1255986	chr14:64655161	A/G	cg23250157	chr14:64679961	SYNE2	-0.46	-8.67	-0.37	7.54e-17	Atrial fibrillation;
LGG	cis	rs8067545	0.586	rs2703819	chr17:20121401	A/G	cg13482628	chr17:19912719	NA	-0.53	-10.19	-0.43	3.88e-22	Schizophrenia;
LGG	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg08461772	chr7:95026248	PON3	0.39	8.22	0.36	2.05e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg00825309	chr19:58991885	ZNF446	-0.46	-9.44	-0.4	1.84e-19	Uric acid clearance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12868349	chr11:71639594	RNF121;LOC100133315	0.43	6.71	0.3	5.69e-11	Gut microbiome composition (summer);
LGG	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg13385794	chr1:248469461	NA	0.45	7.89	0.34	2.21e-14	Common traits (Other);
LGG	cis	rs9303401	0.659	rs17822807	chr17:56687190	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.73	0.56	1.45e-40	Cognitive test performance;
LGG	trans	rs9914544	0.545	rs8077775	chr17:18809543	A/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.74	-0.34	6.16e-14	Educational attainment (years of education);
LGG	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg23601095	chr6:26197514	HIST1H3D	0.69	8.73	0.38	4.72e-17	Gout;Renal underexcretion gout;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg00689492	chr4:1303491	MAEA	0.46	7.79	0.34	4.5e-14	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17058777	chr11:71814579	LRTOMT;C11orf59	0.45	7.36	0.32	8.47e-13	Cognitive performance;
LGG	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg15268244	chr15:77196840	NA	-0.47	-10.03	-0.42	1.54e-21	Blood metabolite levels;
LGG	trans	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg19628046	chr18:33552617	C18orf21	-0.49	-7.12	-0.31	4.2e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg13660082	chr14:53194042	PSMC6	-0.55	-7.69	-0.34	9.04e-14	Alzheimer's disease (late onset);
LGG	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg17330251	chr7:94953956	PON1	-0.44	-8.45	-0.37	3.72e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6912958	0.781	rs13193380	chr6:88297057	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs4900069	0.764	rs7146008	chr14:91593301	C/T	cg12167284	chr14:91592793	SNORA11B;C14orf159	0.43	7.27	0.32	1.55e-12	Resting heart rate;
LGG	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg13385794	chr1:248469461	NA	0.43	7.52	0.33	2.79e-13	Common traits (Other);
LGG	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg15103426	chr22:29168792	CCDC117	0.61	9.41	0.4	2.41e-19	Lymphocyte counts;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13012494	chr21:47604986	C21orf56	0.5	8.55	0.37	1.84e-16	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23062115	chr5:143550050	YIPF5;KCTD16	0.47	7.82	0.34	3.7e-14	Cognitive performance;
LGG	cis	rs2599510	0.748	rs6718214	chr2:32550485	T/C	cg02381751	chr2:32503542	YIPF4	-0.5	-8.16	-0.35	3.09e-15	Interleukin-18 levels;
LGG	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.89	-0.51	1.08e-32	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.6e-32	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.46	-0.37	3.58e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.935	rs980571	chr12:39127532	C/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.2	-0.55	3.05e-38	Heart rate;
LGG	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs926392	1.000	rs926392	chr20:37690464	A/G	cg16355469	chr20:37678765	NA	0.44	7.37	0.32	7.89e-13	Dialysis-related mortality;
LGG	cis	rs283228	0.793	rs435519	chr6:101718433	C/T	cg27451362	chr6:101846650	GRIK2	0.57	8.76	0.38	3.66e-17	Coenzyme Q10 levels;
LGG	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.66e-43	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.591	rs35169013	chr6:25918027	A/C	cg01620082	chr3:125678407	NA	-0.67	-6.69	-0.3	6.37e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs6912958	0.712	rs6454640	chr6:88370352	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.48	8.37	0.36	6.82e-16	Monocyte percentage of white cells;
LGG	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.81	0.41	8.86e-21	Colorectal cancer;
LGG	cis	rs17826219	0.568	rs2626985	chr17:29077437	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.53	-0.44	2.11e-23	Body mass index;
LGG	trans	rs208520	0.633	rs79679034	chr6:66701724	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.01	20.0	0.68	1.33e-64	Exhaled nitric oxide output;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-9.81	-0.41	9.13e-21	Bipolar disorder;
LGG	cis	rs8114671	0.562	rs6087644	chr20:33480917	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.0	0.31	9.21e-12	Height;
LGG	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg06212747	chr3:49208901	KLHDC8B	0.46	7.04	0.31	6.84e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg27297192	chr10:134578999	INPP5A	0.31	7.21	0.32	2.32e-12	Migraine;
LGG	cis	rs12724450	0.793	rs7517003	chr1:150282557	T/G	cg03818307	chr1:150480534	ECM1	0.49	6.86	0.3	2.18e-11	Blood protein levels;
LGG	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs7215564	0.908	rs2315922	chr17:78695127	C/T	cg16980736	chr17:78789706	RPTOR	-0.71	-9.1	-0.39	2.62e-18	Myopia (pathological);
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.36	0.5	1.65e-30	Lung cancer;
LGG	cis	rs2028299	0.919	rs8026131	chr15:90417999	C/G	cg23731826	chr15:90371692	NA	0.36	8.72	0.38	5.15e-17	Type 2 diabetes;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	-0.46	-7.43	-0.33	5.19e-13	Menopause (age at onset);
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.61	-0.44	1.08e-23	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg26384229	chr12:38710491	ALG10B	0.79	17.08	0.62	4.66e-51	Morning vs. evening chronotype;
LGG	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.4	-0.36	5.71e-16	Obesity;
LGG	cis	rs6940638	0.688	rs2022272	chr6:27103580	A/G	cg12826209	chr6:26865740	GUSBL1	0.44	7.51	0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs782590	0.807	rs782642	chr2:55928444	G/T	cg18811423	chr2:55921094	PNPT1	0.95	23.34	0.74	3.39e-80	Metabolic syndrome;
LGG	cis	rs79911532	0.515	rs117982500	chr7:75758907	C/A	cg15148918	chr7:75625777	STYXL1	-0.7	-7.96	-0.35	1.34e-14	Mononucleosis;
LGG	trans	rs2204008	0.805	rs11514348	chr12:38243427	T/C	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs72781680	0.716	rs2675363	chr2:24080003	G/C	cg08917208	chr2:24149416	ATAD2B	0.63	8.25	0.36	1.69e-15	Lymphocyte counts;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg08024992	chr7:2133441	MAD1L1	0.36	7.03	0.31	7.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6976053	0.846	rs314375	chr7:100457344	G/A	cg03098644	chr7:100410630	EPHB4	-0.43	-7.8	-0.34	4.11e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs258892	0.947	rs266435	chr5:72174432	C/G	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs73198271	0.751	rs617813	chr8:8635888	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.74	-0.3	4.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10083830	0.628	rs4925084	chr17:19998958	C/T	cg09818912	chr17:20140352	CYTSB	-0.31	-6.71	-0.3	5.88e-11	Immature fraction of reticulocytes;
LGG	cis	rs61931739	0.649	rs1093031	chr12:33722730	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-7.44	-0.33	4.98e-13	Longevity;
LGG	cis	rs9944715	0.954	rs12607898	chr18:43802778	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.36	-6.73	-0.3	5.02e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.28	-0.55	1.32e-38	Heart rate;
LGG	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg00647317	chr7:50633725	DDC	0.37	8.81	0.38	2.58e-17	Body mass index;
LGG	cis	rs709400	1.000	rs57218990	chr14:104128007	T/A	cg26031613	chr14:104095156	KLC1	1.14	27.59	0.79	8.11e-100	Body mass index;
LGG	cis	rs6489882	0.902	rs3759375	chr12:113373588	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg12310025	chr6:25882481	NA	0.52	9.63	0.41	4.01e-20	Blood metabolite levels;
LGG	cis	rs2072732	0.821	rs10909868	chr1:2962207	A/C	cg08733933	chr1:2954429	NA	-0.41	-8.47	-0.37	3.36e-16	Plateletcrit;
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg08888203	chr3:10149979	C3orf24	-0.54	-9.0	-0.39	5.86e-18	Alzheimer's disease;
LGG	cis	rs67366981	0.720	rs4396457	chr14:77685379	G/A	cg22824376	chr14:77648248	TMEM63C	0.87	11.26	0.46	3.83e-26	Obsessive-compulsive symptoms;
LGG	cis	rs58235267	0.656	rs12713469	chr2:63059927	C/T	cg17519650	chr2:63277830	OTX1	-0.63	-11.63	-0.48	1.37e-27	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs1557765	0.527	rs11024272	chr11:17395760	T/C	cg15432903	chr11:17409602	KCNJ11	0.5	9.2	0.39	1.2e-18	Body mass index;Social communication problems;
LGG	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.74	-0.3	4.83e-11	Alzheimer's disease (survival time);
LGG	cis	rs1691799	0.899	rs1168327	chr12:66728842	G/A	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg03213289	chr20:61660250	NA	0.66	14.46	0.56	2.22e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg07701084	chr6:150067640	NUP43	0.65	12.29	0.5	2.91e-30	Lung cancer;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	8.94	0.38	9.19e-18	Longevity;
LGG	cis	rs7166081	1.000	rs34221449	chr15:67644263	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.71	12.53	0.5	3.2e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg04986931	chr22:39850128	NA	0.35	7.99	0.35	1.04e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs73263776	chr17:29211331	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3768617	0.510	rs10911254	chr1:183088627	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12618769	0.597	rs3754886	chr2:99107677	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-12.27	-0.5	3.63e-30	Vitiligo;
LGG	cis	rs6882046	0.513	rs187270	chr5:88026870	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.38	-0.43	7.9e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	9.94	0.42	3.19e-21	Iron status biomarkers;
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16447950	chr5:562315	NA	-0.54	-6.7	-0.3	5.96e-11	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.49	0.56	1.6e-39	Oral cavity cancer;
LGG	cis	rs9381040	0.655	rs2268194	chr6:41024447	T/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.32	-0.32	1.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs12210905	0.688	rs78285097	chr6:27374644	G/C	cg15325629	chr6:28072465	NA	0.92	6.95	0.31	1.24e-11	Hip circumference adjusted for BMI;
LGG	cis	rs72827839	0.790	rs116944299	chr17:46267765	C/A	cg02219949	chr17:45927392	SP6	0.54	8.12	0.35	4.34e-15	Ease of getting up in the morning;
LGG	cis	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg26384229	chr12:38710491	ALG10B	1.07	26.35	0.77	3.61e-94	Heart rate;
LGG	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg22482690	chr17:47019901	SNF8	0.35	6.99	0.31	9.37e-12	Type 2 diabetes;
LGG	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.05	-0.35	6.99e-15	Calcium levels;
LGG	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15369054	chr17:80825471	TBCD	0.59	10.99	0.45	3.92e-25	Breast cancer;
LGG	cis	rs6088580	0.634	rs6058041	chr20:33018008	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	9.2	0.39	1.21e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.38	0.36	6.51e-16	Bipolar disorder;
LGG	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.61	17.27	0.63	6.15e-52	Oropharynx cancer;
LGG	cis	rs9916302	0.904	rs650106	chr17:37451559	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.0	0.6	3.49e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg21948465	chr5:131705150	SLC22A5	0.64	7.29	0.32	1.31e-12	Rheumatoid arthritis;
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.65	-0.41	3.35e-20	Aortic root size;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg13880726	chr7:1868755	MAD1L1	0.41	7.23	0.32	2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg01145232	chr6:150245071	RAET1G	-0.41	-7.38	-0.32	7.51e-13	Lung cancer;
LGG	cis	rs9863	0.828	rs71458830	chr12:124476561	C/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.08	-0.31	5.48e-12	White blood cell count;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg27467005	chr19:17622279	PGLS	0.4	7.23	0.32	2.04e-12	Obesity-related traits;
LGG	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg17211192	chr8:82754475	SNX16	0.77	11.96	0.49	6.33e-29	Diastolic blood pressure;
LGG	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg06238570	chr21:40685208	BRWD1	0.44	6.79	0.3	3.37e-11	Cognitive function;
LGG	cis	rs3816183	0.626	rs4953564	chr2:42912493	A/G	cg14631114	chr2:43023945	NA	0.35	6.93	0.31	1.42e-11	Hypospadias;
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs735396	0.627	rs2264778	chr12:121450354	C/A	cg14101638	chr12:121416612	HNF1A	0.36	7.33	0.32	1.01e-12	N-glycan levels;
LGG	cis	rs910316	1.000	rs3742778	chr14:75538217	A/C	cg08847533	chr14:75593920	NEK9	-0.61	-11.91	-0.48	1.05e-28	Height;
LGG	cis	rs5756391	0.546	rs4821566	chr22:37314507	C/G	cg21209356	chr22:37319042	CSF2RB	0.41	9.28	0.4	6.73e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11644478	chr21:40555479	PSMG1	0.92	18.08	0.64	1.08e-55	Cognitive function;
LGG	trans	rs11875185	0.915	rs72937690	chr18:55617932	T/C	cg15513957	chr14:69354734	ACTN1	-0.69	-7.51	-0.33	3.07e-13	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11764590	0.694	rs10235664	chr7:2086814	T/C	cg23422044	chr7:1970798	MAD1L1	-0.47	-8.8	-0.38	2.64e-17	Neuroticism;
LGG	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg20503657	chr10:835505	NA	0.63	9.43	0.4	2.06e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg11766577	chr21:47581405	C21orf56	0.59	10.93	0.45	6.5e-25	Testicular germ cell tumor;
LGG	cis	rs9868809	0.772	rs9809222	chr3:48714411	C/T	cg00383909	chr3:49044727	WDR6	0.81	10.14	0.43	5.95e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4604732	0.631	rs4411161	chr1:247632374	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.16	0.39	1.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.86	-0.42	5.82e-21	Retinal vascular caliber;
LGG	cis	rs12893668	0.628	rs57072546	chr14:104063723	T/C	cg26031613	chr14:104095156	KLC1	-0.63	-9.89	-0.42	4.77e-21	Reticulocyte count;
LGG	trans	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg24247370	chr13:99142703	STK24	-0.39	-6.92	-0.31	1.54e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg11494091	chr17:61959527	GH2	0.51	8.12	0.35	4.37e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg22044901	chr15:68126292	NA	-0.4	-6.86	-0.3	2.18e-11	Restless legs syndrome;
LGG	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg10253484	chr15:75165896	SCAMP2	-0.61	-9.15	-0.39	1.78e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.72	-0.34	7.15e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs57590327	0.555	rs3772884	chr3:81802720	G/T	cg07356753	chr3:81810745	GBE1	-0.51	-8.32	-0.36	1e-15	Extraversion;
LGG	cis	rs3862030	0.720	rs7081110	chr10:104231651	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.22	-0.39	1.07e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg20608306	chr11:116969690	SIK3	-0.32	-8.31	-0.36	1.05e-15	Blood protein levels;
LGG	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg20003494	chr4:90757398	SNCA	-0.36	-7.18	-0.32	2.78e-12	Dementia with Lewy bodies;
LGG	trans	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg11887960	chr12:57824829	NA	-0.57	-6.93	-0.31	1.45e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs7944735	0.517	rs1827503	chr11:48225115	G/T	cg15704280	chr7:45808275	SEPT13	0.72	7.8	0.34	4.03e-14	Intraocular pressure;
LGG	cis	rs9616064	0.506	rs2073275	chr22:47070432	G/C	cg05621596	chr22:47072043	GRAMD4	-0.37	-7.49	-0.33	3.46e-13	Urate levels in obese individuals;
LGG	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.82	0.51	2.01e-32	Hip circumference adjusted for BMI;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg04861929	chr11:109293070	C11orf87	0.55	9.83	0.42	7.94e-21	Schizophrenia;
LGG	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg03605463	chr16:89740564	NA	0.62	11.27	0.46	3.3e-26	Vitiligo;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.5	7.35	0.32	8.96e-13	Renal function-related traits (BUN);
LGG	cis	rs897080	0.515	rs786617	chr2:44593158	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.67	-0.3	7.53e-11	Height;
LGG	cis	rs9747201	1.000	rs4347682	chr17:80175591	A/G	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11649743	0.957	rs12951345	chr17:36077863	A/C	cg21250756	chr17:36077300	HNF1B	0.36	10.57	0.44	1.6e-23	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12464559	0.522	rs6715027	chr2:152626657	T/C	cg01189475	chr2:152685088	ARL5A	0.74	7.52	0.33	2.92e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs17445240	0.515	rs6760466	chr2:3707136	T/C	cg14882966	chr2:3699353	NA	0.63	8.66	0.37	8.21e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10744625	0.891	rs11062799	chr12:3867263	A/G	cg22221074	chr12:3862810	EFCAB4B	0.35	7.71	0.34	7.92e-14	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg04617936	chr2:214353	NA	-0.39	-7.26	-0.32	1.64e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg19168338	chr16:4465731	CORO7	-0.97	-17.47	-0.63	7.52e-53	Schizophrenia;
LGG	cis	rs1577917	0.874	rs1838954	chr6:86565478	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.09	-0.49	1.88e-29	Response to antipsychotic treatment;
LGG	cis	rs2762353	0.935	rs1185567	chr6:25818588	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.62	-0.41	4.2e-20	Blood metabolite levels;
LGG	cis	rs8133932	0.598	rs753092	chr21:47293521	C/A	cg11214348	chr21:47283868	PCBP3	0.45	8.16	0.35	3.26e-15	Schizophrenia;
LGG	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.59e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg11584989	chr19:19387371	SF4	0.4	7.34	0.32	9.36e-13	Tonsillectomy;
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.7e-12	Height;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs10883506	chr10:102289743	C/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg22307297	chr20:60903441	LAMA5	0.44	8.55	0.37	1.85e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg04691961	chr3:161091175	C3orf57	-0.61	-14.48	-0.56	1.93e-39	Morning vs. evening chronotype;
LGG	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg03160526	chr17:80928410	B3GNTL1	0.49	7.84	0.34	3.05e-14	Glycated hemoglobin levels;
LGG	cis	rs2916247	0.954	rs6992101	chr8:93152048	C/A	cg10183463	chr8:93005414	RUNX1T1	0.39	8.16	0.35	3.18e-15	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg11764359	chr7:65958608	NA	-0.8	-14.97	-0.57	1.36e-41	Aortic root size;
LGG	cis	rs953387	0.866	rs4954577	chr2:136948711	A/G	cg07169764	chr2:136633963	MCM6	0.53	8.8	0.38	2.63e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs56176327	0.600	rs7628207	chr3:49754970	T/C	cg13072238	chr3:49761600	GMPPB	-0.54	-7.4	-0.33	6.57e-13	Intelligence (multi-trait analysis);
LGG	trans	rs9929218	0.954	rs1981871	chr16:68819007	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.57	-0.5	2.18e-31	Colorectal cancer;
LGG	trans	rs6787172	0.702	rs827154	chr3:157907712	C/T	cg23275840	chr4:47708675	CORIN	-0.41	-8.47	-0.37	3.25e-16	Subjective well-being;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg25703541	chr22:24373054	LOC391322	-0.87	-17.0	-0.62	9.92e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg19673125	chr6:150240577	RAET1G	0.37	8.89	0.38	1.37e-17	Testicular germ cell tumor;
LGG	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-13.8	-0.54	1.65e-36	Coronary artery disease;
LGG	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Myopia (pathological);
LGG	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg01246520	chr17:17644344	RAI1	-0.35	-8.13	-0.35	4.05e-15	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs317689	0.690	rs570256	chr12:69662929	A/T	cg20891283	chr12:69753455	YEATS4	0.46	7.0	0.31	9.02e-12	Response to diuretic therapy;
LGG	trans	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg24247370	chr13:99142703	STK24	-0.37	-6.79	-0.3	3.5e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs3106136	0.967	rs17310526	chr4:95222227	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.18	-0.36	2.74e-15	Capecitabine sensitivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26097504	chr15:40857435	C15orf57	0.45	7.07	0.31	5.73e-12	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg03806693	chr22:41940476	POLR3H	1.08	19.55	0.67	1.75e-62	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01726103	chr6:24911615	FAM65B	0.46	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs2072499	0.750	rs55675376	chr1:156165881	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	18.85	0.66	3.14e-59	Testicular germ cell tumor;
LGG	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.62	-12.52	-0.5	3.44e-31	Colorectal cancer;
LGG	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg25358565	chr5:93447407	FAM172A	1.34	16.44	0.61	3.58e-48	Diabetic retinopathy;
LGG	trans	rs6011368	0.749	rs4809418	chr20:62915231	G/A	cg13869341	chr1:15865	WASH5P	-0.61	-10.75	-0.45	3.37e-24	Clozapine-induced cytotoxicity;
LGG	cis	rs61931739	0.500	rs11053166	chr12:34385898	A/C	cg06521331	chr12:34319734	NA	0.58	9.97	0.42	2.35e-21	Morning vs. evening chronotype;
LGG	cis	rs926938	0.527	rs360684	chr1:115499001	A/G	cg12756093	chr1:115239321	AMPD1	0.41	7.84	0.34	3.09e-14	Autism;
LGG	cis	rs7095944	0.584	rs10901814	chr10:126431281	G/C	cg08799069	chr10:126477246	METTL10	-0.45	-9.78	-0.41	1.15e-20	Asthma;
LGG	cis	rs34929064	0.881	rs2961310	chr7:22724407	A/T	cg18045685	chr7:22629474	NA	0.52	9.35	0.4	3.82e-19	Major depression and alcohol dependence;
LGG	cis	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.64	-0.37	9.39e-17	Joint mobility (Beighton score);
LGG	cis	rs7717393	0.786	rs6866394	chr5:155797257	C/T	cg12904904	chr5:155754151	SGCD	-0.68	-7.64	-0.33	1.23e-13	Egg allergy;
LGG	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.1	-0.35	4.82e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6815814	0.950	rs66819621	chr4:38819403	A/G	cg06935464	chr4:38784597	TLR10	0.6	8.07	0.35	5.92e-15	Breast cancer;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs10504229	0.636	rs72649123	chr8:58045789	A/T	cg26174226	chr8:58114915	NA	-0.51	-7.27	-0.32	1.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg00405596	chr8:11794950	NA	-0.43	-6.9	-0.31	1.72e-11	Neuroticism;
LGG	cis	rs11771526	0.579	rs77818421	chr7:32375129	G/T	cg27532318	chr7:32358331	NA	0.85	7.43	0.33	5.17e-13	Body mass index;
LGG	cis	rs2131877	0.871	rs28569214	chr3:194871488	A/G	cg07250128	chr3:194833983	C3orf21	0.41	7.68	0.34	9.47e-14	Non-small cell lung cancer;
LGG	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg16512390	chr1:228756714	NA	0.43	6.73	0.3	4.97e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1401999	1.000	rs6805913	chr3:183662924	T/G	cg20387954	chr3:183756860	HTR3D	0.65	13.17	0.52	7.04e-34	Anterior chamber depth;
LGG	cis	rs17767294	0.611	rs66487884	chr6:28202912	C/G	cg00426182	chr6:28072559	NA	0.71	6.69	0.3	6.26e-11	Parkinson's disease;
LGG	cis	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19171272	chr22:38449367	NA	-0.55	-10.75	-0.45	3.21e-24	Glioblastoma;Glioma;
LGG	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg25173405	chr17:45401733	C17orf57	0.52	8.72	0.38	4.98e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2133450	0.935	rs2136149	chr3:7353966	G/A	cg19930620	chr3:7340148	GRM7	-0.36	-7.76	-0.34	5.67e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.58	10.1	0.42	8.27e-22	Birth weight;
LGG	trans	rs11039798	0.660	rs717897	chr11:48375604	A/G	cg15704280	chr7:45808275	SEPT13	-0.7	-9.76	-0.41	1.43e-20	Axial length;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.37	-0.36	6.83e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs12477438	0.520	rs2632277	chr2:99778985	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	35.78	0.86	2.13e-135	Chronic sinus infection;
LGG	cis	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg00745463	chr17:30367425	LRRC37B	0.58	7.08	0.31	5.22e-12	Hip circumference adjusted for BMI;
LGG	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg14227996	chr4:17616232	MED28	0.72	8.83	0.38	2.25e-17	Opioid sensitivity;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg18926786	chr6:150244388	RAET1G	0.31	6.67	0.3	7.13e-11	Testicular germ cell tumor;
LGG	cis	rs6456042	1.000	rs3099293	chr6:166530658	A/C	cg11088901	chr6:166572345	T	-0.35	-7.18	-0.32	2.73e-12	Asthma;
LGG	cis	rs7681440	0.967	rs920624	chr4:90748195	T/A	cg20003494	chr4:90757398	SNCA	-0.39	-7.86	-0.34	2.66e-14	Dementia with Lewy bodies;
LGG	cis	rs6960043	0.818	rs10238625	chr7:15054232	A/G	cg19272540	chr7:15055459	NA	0.37	8.34	0.36	8.39e-16	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs58616815	0.857	rs4933586	chr10:92163220	T/C	cg17905462	chr10:92153495	NA	-0.26	-6.8	-0.3	3.2e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg11473876	chr11:109292803	C11orf87	0.49	9.21	0.39	1.15e-18	Schizophrenia;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg15948088	chr11:109293068	C11orf87	0.46	8.32	0.36	9.59e-16	Schizophrenia;
LGG	cis	rs350251	0.934	rs1641855	chr16:12214171	G/C	cg02910054	chr16:12241554	SNX29	0.46	8.35	0.36	7.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4820539	0.966	rs2267000	chr22:23455366	A/G	cg21100191	chr22:23484243	RTDR1	0.94	21.42	0.71	3.02e-71	Bone mineral density;
LGG	cis	rs10751667	0.666	rs12295141	chr11:947065	G/A	cg22143635	chr11:980567	AP2A2	0.43	7.94	0.35	1.5e-14	Alzheimer's disease (late onset);
LGG	cis	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.77	-0.34	5.15e-14	Neuroticism;
LGG	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg09201001	chr11:18656081	SPTY2D1	0.99	20.76	0.69	3.83e-68	Breast cancer;
LGG	trans	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.22	0.46	5.07e-26	Corneal astigmatism;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11124360	chr2:11750780	GREB1	0.39	7.06	0.31	5.97e-12	Electrocardiographic conduction measures;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.7	-12.87	-0.51	1.29e-32	Obesity-related traits;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.61	10.09	0.42	9.06e-22	Obesity-related traits;
LGG	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-10.56	-0.44	1.68e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.81	0.3	2.98e-11	Bladder cancer;
LGG	trans	rs1994135	0.617	rs1384590	chr12:33734271	C/T	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.12e-16	Resting heart rate;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg20607798	chr8:58055168	NA	0.69	7.43	0.33	5.37e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs877282	0.898	rs11253348	chr10:765852	C/T	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.05e-11	Uric acid levels;
LGG	cis	rs7826238	0.566	rs2945886	chr8:8148270	C/G	cg08975724	chr8:8085496	FLJ10661	0.51	10.08	0.42	9.48e-22	Systolic blood pressure;
LGG	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg08344181	chr3:125677491	NA	-0.81	-8.03	-0.35	8.13e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.96	0.35	1.34e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg12070911	chr6:150209640	RAET1E	-0.29	-6.91	-0.31	1.64e-11	Lung cancer;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg15971980	chr6:150254442	NA	0.43	8.23	0.36	1.87e-15	Lung cancer;
LGG	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Bone mineral density;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	cis	rs7177699	0.557	rs7403728	chr15:79112016	T/G	cg00540400	chr15:79124168	NA	-0.54	-11.46	-0.47	6.32e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg11584989	chr19:19387371	SF4	0.39	7.14	0.31	3.64e-12	Tonsillectomy;
LGG	cis	rs4891159	0.790	rs11150953	chr18:74145491	G/A	cg24786174	chr18:74118243	ZNF516	-0.57	-13.18	-0.52	6.45e-34	Longevity;
LGG	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.24	-0.32	1.83e-12	Coronary artery disease;
LGG	cis	rs35110281	0.840	rs7276633	chr21:45078800	C/T	cg04455712	chr21:45112962	RRP1B	0.53	10.26	0.43	2.21e-22	Mean corpuscular volume;
LGG	trans	rs1814175	0.817	rs11493756	chr11:50017885	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.85	-0.48	1.75e-28	Height;
LGG	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg25566285	chr7:158114605	PTPRN2	0.89	20.21	0.68	1.36e-65	Calcium levels;
LGG	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	trans	rs3812049	0.826	rs2409110	chr5:127433047	A/T	cg16011800	chr17:1958478	HIC1	-0.66	-9.99	-0.42	2.13e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs965513	1.000	rs10983761	chr9:100553957	A/C	cg13688889	chr9:100608707	NA	-0.54	-9.85	-0.42	6.79e-21	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	8.33	0.36	9.46e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6963495	0.585	rs1706923	chr7:105221097	A/G	cg19920283	chr7:105172520	RINT1	0.44	6.77	0.3	3.94e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs6547741	1.000	rs1919126	chr2:27801418	C/A	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs7666738	0.830	rs1426663	chr4:98990092	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4356932	1.000	rs7665152	chr4:76960205	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg22857025	chr5:266934	NA	-1.57	-24.36	-0.75	5.69e-85	Breast cancer;
LGG	cis	rs7568458	0.663	rs699664	chr2:85780536	A/G	cg02493740	chr2:85810744	VAMP5	0.42	7.13	0.31	3.77e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg05793240	chr7:2802953	GNA12	-0.28	-6.94	-0.31	1.33e-11	Height;
LGG	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg22920501	chr2:26401640	FAM59B	0.41	8.16	0.35	3.19e-15	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg13047869	chr3:10149882	C3orf24	0.59	8.56	0.37	1.64e-16	Alzheimer's disease;
LGG	cis	rs2276314	0.857	rs56230698	chr18:33628885	A/G	cg19628046	chr18:33552617	C18orf21	0.53	7.78	0.34	4.87e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs36051895	0.589	rs7848312	chr9:5237442	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-12.86	-0.51	1.46e-32	Pediatric autoimmune diseases;
LGG	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.92	-0.35	1.8e-14	Retinal vascular caliber;
LGG	cis	rs11700980	0.551	rs2832044	chr21:30116713	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs7586879	0.681	rs6752483	chr2:25120086	C/T	cg04586622	chr2:25135609	ADCY3	0.47	12.77	0.51	3.32e-32	Body mass index;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg01238044	chr22:24384105	GSTT1	-0.4	-6.7	-0.3	5.98e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9814567	0.806	rs9857242	chr3:134316378	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.8	0.45	2.14e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2486288	0.656	rs12908818	chr15:45571668	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.99	-0.45	4.05e-25	Glomerular filtration rate;
LGG	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg06241208	chr11:30344200	C11orf46	0.51	6.75	0.3	4.52e-11	Morning vs. evening chronotype;
LGG	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg06241208	chr11:30344200	C11orf46	0.51	6.68	0.3	7.01e-11	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.92e-43	Prudent dietary pattern;
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg08355456	chr11:67383691	NA	-0.49	-7.94	-0.35	1.5e-14	Mean corpuscular volume;
LGG	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4330281	0.647	rs4909009	chr3:17720104	C/A	cg20981856	chr3:17787350	NA	-0.4	-7.58	-0.33	1.95e-13	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04139300	chr20:40247070	CHD6	-0.41	-7.01	-0.31	8.34e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9354308	0.789	rs13437412	chr6:66611926	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs709400	0.663	rs3783402	chr14:103967929	C/G	cg26031613	chr14:104095156	KLC1	0.77	13.42	0.53	6.6e-35	Body mass index;
LGG	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg24110177	chr3:50126178	RBM5	-0.57	-10.44	-0.44	4.54e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs11191205	0.686	rs11191091	chr10:103448649	C/A	cg15320455	chr10:103880129	LDB1	0.53	7.71	0.34	7.8500000000000006e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg19168338	chr16:4465731	CORO7	-0.92	-17.66	-0.63	9.67e-54	Schizophrenia;
LGG	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg03929089	chr4:120376271	NA	0.45	7.26	0.32	1.61e-12	HDL cholesterol;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.14	0.46	1.03e-25	Obesity-related traits;
LGG	cis	rs7648466	0.592	rs2087726	chr3:46208310	G/A	cg12441928	chr3:46249985	CCR1	-0.45	-8.81	-0.38	2.58e-17	Eotaxin levels;
LGG	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg03929089	chr4:120376271	NA	0.85	13.29	0.53	2.32e-34	Coronary artery disease;
LGG	cis	rs3936840	1.000	rs3936840	chr14:102984274	G/C	cg18135206	chr14:102964638	TECPR2	0.48	8.23	0.36	1.93e-15	Plateletcrit;
LGG	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.56	0.79	1.16e-99	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16041611	chr6:43139680	SRF	0.55	9.46	0.4	1.59e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs9581857	0.685	rs9319369	chr13:28042323	A/T	cg01674679	chr13:27998804	GTF3A	-0.69	-7.97	-0.35	1.21e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs5758511	0.633	rs5758689	chr22:42664972	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.43	0.33	5.45e-13	Birth weight;
LGG	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg03929089	chr4:120376271	NA	-0.85	-16.48	-0.61	2.28e-48	Height;
LGG	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg26384229	chr12:38710491	ALG10B	0.95	23.72	0.74	5.49e-82	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg01221209	chr5:554886	NA	-0.5	-8.13	-0.35	3.9e-15	Obesity-related traits;
LGG	cis	rs3849570	1.000	rs7638516	chr3:81826249	A/C	cg07356753	chr3:81810745	GBE1	-0.41	-7.13	-0.31	3.94e-12	Waist circumference;Body mass index;
LGG	cis	rs6120849	0.707	rs3746444	chr20:33578251	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	6.71	0.3	5.83e-11	Protein C levels;
LGG	cis	rs12949688	0.967	rs7220397	chr17:55823522	C/G	cg12582317	chr17:55822272	NA	0.7	20.23	0.68	1.17e-65	Schizophrenia;
LGG	cis	rs4776059	0.916	rs2414161	chr15:52883285	T/C	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.06	-0.35	6.6e-15	Schizophrenia;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg26783146	chr16:4423632	VASN;CORO7	-0.34	-6.76	-0.3	4.08e-11	Schizophrenia;
LGG	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	3.92e-34	Bladder cancer;
LGG	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg14893161	chr1:205819251	PM20D1	-0.45	-7.26	-0.32	1.64e-12	Parkinson's disease;
LGG	cis	rs4561483	0.583	rs10852344	chr16:12016919	C/T	cg08843971	chr16:11963173	GSPT1	0.59	14.23	0.55	2.32e-38	Testicular germ cell tumor;
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs6577655	0.517	rs6996991	chr8:135589255	G/A	cg17885191	chr8:135476712	NA	0.58	8.64	0.37	9.31e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg23594656	chr7:65796392	TPST1	-0.41	-8.94	-0.38	9.07e-18	Aortic root size;
LGG	cis	rs7044106	0.578	rs4837788	chr9:123396801	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	7.11	0.31	4.37e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12677663	0.935	rs10107863	chr8:74000257	C/T	cg19518093	chr8:74006994	C8orf84	-0.5	-9.64	-0.41	3.55e-20	Crohn's disease;
LGG	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg20607798	chr8:58055168	NA	0.7	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg11062466	chr8:58055876	NA	0.48	8.31	0.36	1.05e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg13010199	chr12:38710504	ALG10B	-0.46	-8.96	-0.38	7.87e-18	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	12.01	0.49	3.96e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg03343631	chr13:114764489	RASA3	-0.58	-8.03	-0.35	8.39e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs16867321	0.639	rs12466864	chr2:181441417	C/G	cg23363182	chr2:181467187	NA	0.43	8.52	0.37	2.23e-16	Obesity;
LGG	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg08305652	chr11:111469057	NA	0.42	8.45	0.37	3.82e-16	Primary sclerosing cholangitis;
LGG	cis	rs477895	0.653	rs7102327	chr11:63908720	C/T	cg04317338	chr11:64019027	PLCB3	0.65	8.02	0.35	8.94e-15	Mean platelet volume;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.85	-0.34	2.88e-14	Schizophrenia;
LGG	cis	rs6430585	0.591	rs75223002	chr2:136525309	G/T	cg07169764	chr2:136633963	MCM6	1.27	24.09	0.75	1e-83	Corneal structure;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg14926445	chr8:58193284	C8orf71	-0.82	-10.62	-0.44	9.66e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7226408	0.857	rs56133445	chr18:34491392	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	6.78	0.3	3.6e-11	Height;
LGG	trans	rs826838	0.935	rs1684406	chr12:39127265	A/G	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs4509693	0.943	rs6584393	chr10:102497206	C/G	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08533424	chr17:37009973	RPL23;SNORA21	0.5	8.25	0.36	1.64e-15	Cognitive performance;
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg13047869	chr3:10149882	C3orf24	0.44	7.01	0.31	8.52e-12	Alzheimer's disease;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs965469	0.603	rs6115892	chr20:3411569	C/T	cg25506879	chr20:3388711	C20orf194	-0.5	-7.88	-0.34	2.28e-14	IFN-related cytopenia;
LGG	cis	rs3806843	0.932	rs2563256	chr5:140141779	G/T	cg19875535	chr5:140030758	IK	-0.52	-10.78	-0.45	2.51e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg04608330	chr12:45269318	NELL2	-0.63	-11.26	-0.46	3.67e-26	Gut microbiome composition (summer);
LGG	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg06532163	chr17:45867833	NA	0.55	9.15	0.39	1.88e-18	IgG glycosylation;
LGG	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg00700412	chr12:58011837	NA	-0.5	-10.54	-0.44	1.99e-23	Multiple sclerosis;
LGG	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9400467	0.506	rs76813116	chr6:111690733	T/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7000551	0.663	rs7827118	chr8:22334669	T/G	cg12081754	chr8:22256438	SLC39A14	0.69	13.34	0.53	1.42e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1878931	0.535	rs55732163	chr16:3411518	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.7	-10.9	-0.45	8.88e-25	Body mass index (adult);
LGG	trans	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg25214090	chr10:38739885	LOC399744	0.65	11.53	0.47	3.28e-27	Corneal astigmatism;
LGG	cis	rs4671458	1.000	rs4671458	chr2:63374063	C/T	cg17519650	chr2:63277830	OTX1	-0.62	-7.83	-0.34	3.31e-14	Subjective well-being;
LGG	cis	rs3087591	0.708	rs9894648	chr17:29653293	T/C	cg24425628	chr17:29625626	OMG;NF1	0.58	11.73	0.48	5.45e-28	Hip circumference;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.43	-0.4	2.01e-19	Lung cancer;
LGG	cis	rs10744422	1.000	rs1532835	chr12:123330665	G/A	cg25930673	chr12:123319894	HIP1R	-0.77	-9.86	-0.42	5.83e-21	Schizophrenia;
LGG	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg27165867	chr14:105738592	BRF1	-0.45	-7.71	-0.34	7.51e-14	Platelet count;
LGG	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg05535760	chr7:792225	HEATR2	0.76	12.14	0.49	1.24e-29	Cerebrospinal P-tau181p levels;
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg11211951	chr8:145729740	GPT	-0.52	-12.09	-0.49	1.9e-29	Age at first birth;
LGG	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.11e-15	Monocyte count;
LGG	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg00409905	chr10:38381863	ZNF37A	0.47	7.02	0.31	7.88e-12	Obesity (extreme);
LGG	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg12636538	chr11:118901039	SLC37A4	-0.65	-13.73	-0.54	3.17e-36	Coronary artery disease;
LGG	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg01191920	chr7:158217561	PTPRN2	0.69	14.97	0.57	1.32e-41	Obesity-related traits;
LGG	cis	rs9443645	0.901	rs1538233	chr6:79743735	G/T	cg18132916	chr6:79620363	NA	-0.3	-8.46	-0.37	3.67e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg03452623	chr4:187889614	NA	-1.05	-29.85	-0.81	6.02e-110	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg08645402	chr16:4508243	NA	0.49	9.08	0.39	3.13e-18	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01046104	chr19:58095588	ZIK1	0.57	9.33	0.4	4.32e-19	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs9915657	0.966	rs8071717	chr17:70128705	C/T	cg09344028	chr17:70110421	NA	0.49	11.28	0.46	2.96e-26	Thyroid hormone levels;
LGG	cis	rs7584330	0.826	rs7604315	chr2:238381729	C/G	cg16989719	chr2:238392110	NA	-0.34	-6.82	-0.3	2.78e-11	Prostate cancer;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg21724239	chr8:58056113	NA	0.63	9.35	0.4	3.88e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg16606324	chr3:10149918	C3orf24	0.54	7.05	0.31	6.48e-12	Alzheimer's disease;
LGG	cis	rs473651	0.935	rs474478	chr2:239335473	C/T	cg18131467	chr2:239335373	ASB1	1.02	23.73	0.74	4.92e-82	Multiple system atrophy;
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg07870213	chr5:140052090	DND1	0.93	17.48	0.63	6.68e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9487094	0.553	rs13191995	chr6:109966460	C/A	cg01125227	chr6:109776195	MICAL1	0.46	7.28	0.32	1.41e-12	Height;
LGG	cis	rs4148087	0.790	rs4148099	chr21:43639591	A/C	cg10192877	chr21:43641690	ABCG1	-0.4	-6.98	-0.31	1e-11	Eating disorder in bipolar disorder;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.69	-0.34	8.86e-14	Testicular germ cell tumor;
LGG	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs12753569	0.748	rs1013630	chr1:76513819	G/T	cg00791851	chr1:76518896	NA	0.43	10.17	0.43	4.48e-22	Personality dimensions;
LGG	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	1e-15	Response to antipsychotic treatment;
LGG	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg15128208	chr22:42549153	NA	0.74	11.33	0.47	1.93e-26	Birth weight;
LGG	cis	rs13420028	0.585	rs2241764	chr2:133174764	C/T	cg02570563	chr2:133174168	GPR39	0.39	6.75	0.3	4.54e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs7264396	0.622	rs3787165	chr20:34228946	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.67	-0.34	1.05e-13	Total cholesterol levels;
LGG	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19524238	chr7:2802976	GNA12	0.33	8.07	0.35	6.29e-15	Height;
LGG	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg11266682	chr4:10021025	SLC2A9	0.41	7.74	0.34	6.31e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg15485101	chr11:133734466	NA	0.6	10.45	0.44	4.18e-23	Childhood ear infection;
LGG	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg03733263	chr8:22462867	KIAA1967	1.02	25.0	0.76	6.21e-88	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6866344	0.601	rs12187838	chr5:178099833	T/C	cg10224037	chr5:178157518	ZNF354A	0.55	7.91	0.34	1.93e-14	Neutrophil percentage of white cells;
LGG	cis	rs3813359	0.545	rs76605355	chr6:130553734	A/G	cg23281432	chr6:130554730	NA	0.5	6.93	0.31	1.43e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1691799	0.899	rs1168318	chr12:66745269	A/G	cg16791601	chr12:66731901	HELB	0.67	15.83	0.59	1.97e-45	White blood cell count (basophil);
LGG	cis	rs1018836	0.923	rs2213886	chr8:91554163	G/C	cg16814680	chr8:91681699	NA	-0.82	-15.46	-0.58	9.2e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs888194	0.763	rs10744826	chr12:109965512	C/G	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-6.68	-0.3	7.02e-11	Neuroticism;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.02	0.39	5.16e-18	Platelet count;
LGG	trans	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.73	-0.3	5.08e-11	Pancreatic cancer;
LGG	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg19441908	chr8:41529140	ANK1	0.42	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.96	-14.72	-0.56	1.68e-40	Chronic sinus infection;
LGG	cis	rs9596863	0.898	rs67601073	chr13:54322196	A/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.19	0.32	2.55e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9463078	0.845	rs9349303	chr6:44792579	C/T	cg25276700	chr6:44698697	NA	0.38	8.16	0.35	3.2e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs854765	0.647	rs854814	chr17:18003648	G/A	cg04398451	chr17:18023971	MYO15A	-0.86	-19.32	-0.67	2e-61	Total body bone mineral density;
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.59	-0.37	1.31e-16	Neuroticism;
LGG	cis	rs7829975	0.511	rs2955578	chr8:8137083	T/C	cg15556689	chr8:8085844	FLJ10661	0.5	9.2	0.39	1.27e-18	Mood instability;
LGG	cis	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg06521331	chr12:34319734	NA	-0.58	-10.1	-0.42	8.28e-22	Morning vs. evening chronotype;
LGG	cis	rs12153243	0.714	rs6580286	chr5:142905354	T/C	cg13907255	chr5:142895549	NA	-0.51	-8.92	-0.38	1.11e-17	Migraine;
LGG	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg07615347	chr10:60278583	BICC1	-0.64	-18.63	-0.65	3.18e-58	Refractive error;
LGG	cis	rs2066819	1.000	rs118130855	chr12:56677979	T/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg27124370	chr19:33622961	WDR88	-0.52	-9.07	-0.39	3.27e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg14092988	chr3:52407081	DNAH1	-0.28	-7.44	-0.33	4.92e-13	Bipolar disorder;
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg15722372	chr19:38865020	PSMD8	-0.39	-6.78	-0.3	3.61e-11	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9916302	0.706	rs11655972	chr17:37407072	C/T	cg07936489	chr17:37558343	FBXL20	-0.99	-15.47	-0.58	8.25e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs7619833	0.592	rs4973756	chr3:27248190	C/T	cg02860705	chr3:27208620	NA	0.4	7.88	0.34	2.36e-14	Breast cancer;
LGG	cis	rs2455799	0.613	rs1393969	chr3:15730257	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.14e-14	Mean platelet volume;
LGG	cis	rs892961	0.932	rs11657961	chr17:75405407	C/T	cg05865280	chr17:75406074	SEPT9	0.42	9.61	0.41	4.6e-20	Airflow obstruction;
LGG	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.17	0.32	3.06e-12	Total cholesterol levels;
LGG	cis	rs11711311	0.955	rs34048496	chr3:113414121	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.33	-0.32	1.03e-12	IgG glycosylation;
LGG	cis	rs13082711	0.911	rs13100751	chr3:27454964	A/G	cg02860705	chr3:27208620	NA	0.81	14.63	0.56	3.99e-40	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7659604	0.502	rs10212738	chr4:122675724	G/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00068621	chr5:150080765	RBM22	0.43	7.01	0.31	8.45e-12	Cognitive performance;
LGG	cis	rs757081	0.637	rs586785	chr11:17208714	T/C	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.98	-0.39	6.77e-18	Systolic blood pressure;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01458961	chr4:102269425	PPP3CA	-0.41	-6.75	-0.3	4.44e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.54	-0.33	2.44e-13	Mood instability;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg04267008	chr7:1944627	MAD1L1	0.63	10.75	0.45	3.39e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs72781680	0.898	rs116113042	chr2:23960194	G/T	cg08917208	chr2:24149416	ATAD2B	0.79	8.95	0.38	8.91e-18	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.77	0.41	1.3e-20	Prudent dietary pattern;
LGG	cis	rs9747201	0.926	rs8065606	chr17:80063526	G/A	cg21453758	chr17:80185943	SLC16A3	-0.32	-6.67	-0.3	7.38e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19942237	chr7:29603211	PRR15	-0.28	-6.72	-0.3	5.47e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg19507638	chr5:93509721	C5orf36	0.42	6.93	0.31	1.42e-11	Diabetic retinopathy;
LGG	cis	rs6684428	0.536	rs4468206	chr1:56397362	A/T	cg11651538	chr1:56320950	NA	-0.4	-7.74	-0.34	6.43e-14	Airflow obstruction;
LGG	cis	rs6500395	0.890	rs9936271	chr16:48601291	A/G	cg16662043	chr16:48846231	NA	0.35	6.91	0.31	1.63e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2191566	1.000	rs2191566	chr19:44511389	A/C	cg20607764	chr19:44506953	ZNF230	0.44	8.25	0.36	1.7e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9399137	0.507	rs12663810	chr6:135289782	G/C	cg24558204	chr6:135376177	HBS1L	0.61	10.39	0.43	7.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.73	0.34	6.66e-14	Coronary artery disease;
LGG	cis	rs4363385	0.693	rs6690549	chr1:152930426	C/T	cg13444842	chr1:152974279	SPRR3	-0.4	-7.43	-0.33	5.25e-13	Inflammatory skin disease;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg09060608	chr5:178986726	RUFY1	0.52	9.17	0.39	1.61e-18	Lung cancer;
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg18402987	chr7:1209562	NA	0.67	7.36	0.32	8.52e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1953600	0.837	rs2573352	chr10:81939813	T/C	cg04850286	chr10:81895943	PLAC9	0.44	9.81	0.41	8.85e-21	Sarcoidosis;
LGG	trans	rs73191547	0.898	rs28570266	chr8:10035827	C/T	cg06636001	chr8:8085503	FLJ10661	0.4	6.97	0.31	1.1e-11	Schizophrenia;
LGG	cis	rs77372450	0.636	rs6876128	chr5:156994437	A/G	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg18404041	chr3:52824283	ITIH1	-0.6	-11.64	-0.48	1.18e-27	Bipolar disorder;
LGG	cis	rs9487094	0.885	rs12524273	chr6:109716964	T/C	cg01125227	chr6:109776195	MICAL1	0.52	8.94	0.38	9.57e-18	Height;
LGG	cis	rs2820315	1.000	rs1517810	chr1:201850057	T/C	cg10061532	chr1:201886748	LMOD1	0.33	6.87	0.3	2.06e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg20607798	chr8:58055168	NA	0.59	7.08	0.31	5.26e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs999796	chr17:29159404	G/C	cg19761014	chr17:28927070	LRRC37B2	0.55	6.95	0.31	1.23e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2404602	0.618	rs12442266	chr15:76567142	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.01	-0.31	8.22e-12	Blood metabolite levels;
LGG	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.08	0.31	5.39e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.04	-0.62	6.86e-51	Response to antipsychotic treatment;
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg13264159	chr8:625131	ERICH1	-1.05	-12.4	-0.5	1.1e-30	IgG glycosylation;
LGG	cis	rs7843479	0.965	rs733543	chr8:21835465	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.08	0.42	9.71e-22	Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.51	0.37	2.35e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs209489	0.892	rs9463892	chr6:53111597	A/T	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg05025164	chr4:1340916	KIAA1530	0.67	12.84	0.51	1.76e-32	Longevity;
LGG	cis	rs56235845	0.694	rs11749830	chr5:176766547	G/A	cg17509989	chr5:176798049	RGS14	0.65	10.73	0.45	3.84e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg04287289	chr16:89883240	FANCA	-0.45	-7.94	-0.35	1.56e-14	Vitiligo;
LGG	cis	rs11190604	1.000	rs10883511	chr10:102299407	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.23	0.32	1.95e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7215564	0.908	rs74000899	chr17:78653542	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs3806843	0.548	rs246057	chr5:140325583	A/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.87e-20	Life satisfaction;
LGG	trans	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg24247370	chr13:99142703	STK24	-0.38	-6.92	-0.31	1.53e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg01200585	chr1:228362443	C1orf69	0.46	7.98	0.35	1.19e-14	Diastolic blood pressure;
LGG	trans	rs208520	0.955	rs208538	chr6:66964492	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.19	-0.55	3.28e-38	Exhaled nitric oxide output;
LGG	cis	rs11098499	0.954	rs10518328	chr4:120401779	G/A	cg24375607	chr4:120327624	NA	0.68	11.19	0.46	7.14e-26	Corneal astigmatism;
LGG	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.45	-0.61	3.27e-48	Skin colour saturation;
LGG	cis	rs7975161	0.520	rs9739833	chr12:104737430	A/T	cg25273343	chr12:104657179	TXNRD1	-0.78	-7.5	-0.33	3.39e-13	Toenail selenium levels;
LGG	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.96	-0.35	1.33e-14	Neuroticism;
LGG	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg06481639	chr22:41940642	POLR3H	0.56	7.88	0.34	2.3e-14	Vitiligo;
LGG	cis	rs763121	0.814	rs5757212	chr22:39053757	G/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.44	0.65	2.56e-57	Menopause (age at onset);
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.22	-0.39	1.02e-18	Obesity-related traits;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.35	-0.32	9.18e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11190604	1.000	rs11190597	chr10:102293676	A/T	cg07570687	chr10:102243282	WNT8B	0.44	7.42	0.33	5.83e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1256531	0.661	rs6573620	chr14:66063395	A/G	cg15999311	chr14:65749247	NA	0.79	6.7	0.3	5.96e-11	Conduct disorder (symptom count);
LGG	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.89	-0.3	1.84e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs4330281	0.678	rs4908939	chr3:17793850	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.06	-0.31	6.01e-12	Schizophrenia;
LGG	cis	rs317689	0.559	rs710794	chr12:69747177	C/T	cg20891283	chr12:69753455	YEATS4	0.67	7.68	0.34	9.46e-14	Response to diuretic therapy;
LGG	cis	rs35306767	0.951	rs12777021	chr10:967270	T/C	cg25019033	chr10:957182	NA	-0.62	-12.08	-0.49	2.2e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs4319547	0.619	rs7973869	chr12:122874284	G/C	cg05707623	chr12:122985044	ZCCHC8	-0.61	-9.03	-0.39	4.66e-18	Body mass index;
LGG	cis	rs709400	1.000	rs8018979	chr14:104109087	G/A	cg26031613	chr14:104095156	KLC1	1.15	28.15	0.79	2.5e-102	Body mass index;
LGG	cis	rs1421811	0.606	rs981001	chr5:32721545	G/A	cg16267343	chr5:32710456	NPR3	0.65	8.98	0.39	6.77e-18	Blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03041860	chr2:208489911	FAM119A	0.46	7.41	0.33	6.06e-13	Gut microbiome composition (summer);
LGG	cis	rs9309473	1.000	rs7558944	chr2:73810909	T/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.31	-0.32	1.21e-12	Metabolite levels;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.36	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs875971	0.545	rs6950988	chr7:65976415	C/T	cg11764359	chr7:65958608	NA	0.64	9.87	0.42	5.45e-21	Aortic root size;
LGG	cis	rs7928758	1.000	rs7108503	chr11:134280766	A/G	cg25213107	chr11:134282864	B3GAT1	0.98	12.36	0.5	1.54e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg19539972	chr4:7069911	GRPEL1	0.68	10.12	0.43	7.01e-22	Monocyte percentage of white cells;
LGG	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg13010199	chr12:38710504	ALG10B	0.66	13.35	0.53	1.28e-34	Bladder cancer;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.23	-0.43	2.74e-22	Lymphocyte counts;
LGG	cis	rs4731207	0.698	rs6963177	chr7:124444604	T/A	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg02018176	chr4:1364513	KIAA1530	0.39	8.72	0.38	4.87e-17	Obesity-related traits;
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg20102877	chr2:27665638	KRTCAP3	-0.29	-6.75	-0.3	4.38e-11	Total body bone mineral density;
LGG	cis	rs6694672	0.867	rs4915378	chr1:197161212	T/G	cg13682187	chr1:196946512	CFHR5	0.48	6.77	0.3	3.85e-11	Asthma;
LGG	cis	rs9358372	0.711	rs6915746	chr6:20879333	A/G	cg13405222	chr6:20811065	CDKAL1	-0.57	-11.95	-0.49	7.24e-29	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs638893	0.527	rs7933859	chr11:118662045	T/C	cg13782932	chr11:118662891	DDX6	0.38	6.93	0.31	1.41e-11	Vitiligo;
LGG	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg18225595	chr11:63971243	STIP1	0.61	11.8	0.48	2.81e-28	Platelet count;
LGG	cis	rs4595586	0.545	rs12814188	chr12:39380853	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs870825	0.550	rs28525282	chr4:185631468	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs11105298	0.891	rs12369685	chr12:89928905	A/G	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg27476859	chr7:2772710	GNA12	0.53	10.24	0.43	2.66e-22	Height;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.34	-6.71	-0.3	5.69e-11	Longevity;Endometriosis;
LGG	cis	rs9314323	0.729	rs7823021	chr8:26224958	G/T	cg11498726	chr8:26250323	BNIP3L	-0.53	-11.01	-0.46	3.38e-25	Red cell distribution width;
LGG	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs9815354	1.000	rs9866759	chr3:41758418	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.54	0.33	2.51e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7833790	0.553	rs9693128	chr8:82706128	A/G	cg06027949	chr8:82754900	SNX16	-0.6	-10.36	-0.43	9.6e-23	Diastolic blood pressure;
LGG	cis	rs7011049	1.000	rs72640863	chr8:53841706	A/T	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg12856521	chr11:46389249	DGKZ	-0.42	-7.18	-0.32	2.88e-12	Leprosy;
LGG	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg24503407	chr1:205819492	PM20D1	0.47	7.95	0.35	1.4e-14	Parkinson's disease;
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.61	-11.13	-0.46	1.13e-25	Total body bone mineral density;
LGG	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Vitiligo;
LGG	trans	rs826838	1.000	rs11183469	chr12:38752311	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.71	-0.34	7.97e-14	Heart rate;
LGG	cis	rs7011049	1.000	rs72648409	chr8:53857307	T/C	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	trans	rs6787172	0.702	rs1730059	chr3:157953375	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.76	0.38	3.73e-17	Subjective well-being;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg21548813	chr6:291882	DUSP22	-0.53	-9.31	-0.4	4.98e-19	Menopause (age at onset);
LGG	cis	rs4750440	0.702	rs11258775	chr10:14029742	T/C	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.89	-0.54	6.78e-37	Adiponectin levels;
LGG	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs7444	0.825	rs131664	chr22:21920403	G/A	cg05046821	chr22:21984468	YDJC	-0.39	-7.08	-0.31	5.48e-12	Systemic lupus erythematosus;
LGG	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg06453172	chr10:134556979	INPP5A	-0.48	-7.39	-0.32	7.01e-13	Migraine;
LGG	cis	rs11190604	0.767	rs7392696	chr10:102182141	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.25	0.32	1.78e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9831754	0.756	rs9817660	chr3:78426373	T/C	cg06138941	chr3:78371609	NA	-0.79	-15.58	-0.59	2.6e-44	Calcium levels;
LGG	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg23057051	chr16:89984268	MC1R	-0.4	-7.66	-0.34	1.08e-13	Vitiligo;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg19168338	chr16:4465731	CORO7	-1.16	-27.22	-0.78	3.99e-98	Schizophrenia;
LGG	cis	rs9357271	0.955	rs9366957	chr6:38327713	T/C	cg07362130	chr6:38359646	BTBD9	-0.44	-9.15	-0.39	1.78e-18	Restless legs syndrome;
LGG	cis	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	10.03	0.42	1.48e-21	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27305525	chr1:154955752	FLAD1	0.49	7.9	0.34	2.04e-14	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.85	-17.72	-0.64	5.23e-54	Personality dimensions;
LGG	cis	rs981844	0.601	rs62323856	chr4:154623149	T/C	cg14289246	chr4:154710475	SFRP2	0.62	9.2	0.39	1.19e-18	Response to statins (LDL cholesterol change);
LGG	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg11764359	chr7:65958608	NA	-0.79	-14.76	-0.57	1.1e-40	Aortic root size;
LGG	cis	rs721399	0.752	rs4921913	chr8:18272377	C/T	cg18736775	chr8:18248649	NAT2	0.49	8.31	0.36	1.06e-15	Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.95	0.52	6.06e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg10840412	chr1:235813424	GNG4	0.67	9.21	0.39	1.13e-18	Bipolar disorder;
LGG	cis	rs75920871	0.920	rs61907605	chr11:116820071	T/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.66e-12	Subjective well-being;
LGG	cis	rs4363385	0.643	rs12734348	chr1:152924650	A/G	cg07796016	chr1:152779584	LCE1C	-0.47	-7.67	-0.34	1.01e-13	Inflammatory skin disease;
LGG	cis	rs7503807	0.935	rs9910745	chr17:78610543	C/T	cg09596252	chr17:78655493	RPTOR	0.45	8.03	0.35	7.96e-15	Obesity;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg05665937	chr4:1216051	CTBP1	0.54	9.91	0.42	3.88e-21	Obesity-related traits;
LGG	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg10845886	chr2:3471009	TTC15	-0.45	-8.4	-0.36	5.34e-16	Neurofibrillary tangles;
LGG	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	8.99	0.39	6.38e-18	Myopia (pathological);
LGG	trans	rs1941687	0.797	rs9953948	chr18:31399399	G/A	cg27147174	chr7:100797783	AP1S1	-0.53	-8.78	-0.38	3.17e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.77e-14	Menopause (age at onset);
LGG	cis	rs17286411	0.750	rs4788450	chr16:71955400	T/G	cg06353428	chr16:71660113	MARVELD3	0.39	6.76	0.3	4.14e-11	Blood protein levels;
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg23730037	chr7:158596552	ESYT2	-0.43	-7.38	-0.32	7.28e-13	Height;
LGG	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg07541023	chr7:19748670	TWISTNB	0.44	7.01	0.31	8.59e-12	Thyroid stimulating hormone;
LGG	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.09	0.46	1.71e-25	Response to antipsychotic treatment;
LGG	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1707322	1.000	rs4074225	chr1:46392364	G/C	cg03146154	chr1:46216737	IPP	0.54	10.06	0.42	1.2e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4819052	0.851	rs7275468	chr21:46656499	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	11.98	0.49	5.45e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9878978	0.964	rs62233799	chr3:2465761	G/T	cg21928760	chr3:2462534	CNTN4	0.4	8.82	0.38	2.32e-17	Blood pressure (smoking interaction);
LGG	cis	rs10489202	0.686	rs11585936	chr1:167847069	G/T	cg24449463	chr1:168025552	DCAF6	-0.55	-7.39	-0.32	6.72e-13	Schizophrenia;
LGG	cis	rs7666738	0.830	rs7659420	chr4:98878714	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.3	0.36	1.19e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg15017067	chr4:17643749	FAM184B	0.3	6.91	0.31	1.65e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.92	0.31	1.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg15971980	chr6:150254442	NA	0.44	8.23	0.36	1.91e-15	Lung cancer;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg09177884	chr7:1199841	ZFAND2A	0.64	11.13	0.46	1.17e-25	Longevity;Endometriosis;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.39	-0.43	7.21e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs12724450	0.793	rs74922169	chr1:150364958	G/T	cg03818307	chr1:150480534	ECM1	0.49	7.15	0.32	3.51e-12	Blood protein levels;
LGG	cis	rs2075371	0.897	rs1646733	chr7:134002228	C/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.23	0.52	4.13e-34	Mean platelet volume;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg09426994	chr11:118478258	PHLDB1	0.44	7.55	0.33	2.3e-13	Cholesterol, total;
LGG	cis	rs774359	1.000	rs774356	chr9:27559721	T/C	cg14173147	chr9:27528300	MOBKL2B	0.42	7.9	0.34	2.11e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs651907	0.557	rs1031710	chr3:101463895	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.42e-12	Colorectal cancer;
LGG	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg18252515	chr7:66147081	NA	-1.35	-18.53	-0.65	9.63e-58	Diabetic kidney disease;
LGG	cis	rs10189230	0.935	rs3755029	chr2:222345820	T/C	cg14652038	chr2:222343519	EPHA4	0.59	12.23	0.49	5.31e-30	Urate levels in lean individuals;
LGG	cis	rs7932354	0.528	rs7931260	chr11:47088303	T/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.98	-0.42	2.23e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg04863758	chr4:1303710	MAEA	0.42	7.32	0.32	1.13e-12	Obesity-related traits;
LGG	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.55	-0.41	7.33e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11700980	0.551	rs2832016	chr21:30111397	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg12658982	chr7:29603541	PRR15	-0.4	-8.39	-0.36	5.72e-16	Facial emotion recognition (angry faces);
LGG	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg00376283	chr12:123451042	ABCB9	0.63	9.67	0.41	2.94e-20	Neutrophil percentage of white cells;
LGG	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg08000102	chr2:233561755	GIGYF2	-0.44	-7.28	-0.32	1.45e-12	Coronary artery disease;
LGG	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs7949030	0.626	rs35587183	chr11:62318656	C/T	cg22862634	chr11:62369728	EML3;MTA2	0.56	11.66	0.48	1.05e-27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg20991723	chr1:152506922	NA	-0.71	-14.38	-0.56	4.83e-39	Hair morphology;
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg18446336	chr7:2847575	GNA12	-0.32	-8.5	-0.37	2.63e-16	Height;
LGG	cis	rs7147624	0.938	rs7147231	chr14:66212371	A/G	cg03016385	chr14:66212404	NA	-0.79	-9.3	-0.4	5.54e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs9479482	0.935	rs9479513	chr6:150367320	G/T	cg07549998	chr6:150325970	RAET1K	-0.35	-6.68	-0.3	6.9e-11	Alopecia areata;
LGG	cis	rs1801251	0.727	rs6437071	chr2:233568793	G/A	cg08000102	chr2:233561755	GIGYF2	0.56	9.66	0.41	3.04e-20	Coronary artery disease;
LGG	cis	rs36715	0.909	rs152906	chr5:127551840	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.54	0.33	2.49e-13	Breast cancer;
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg08888203	chr3:10149979	C3orf24	0.52	8.85	0.38	1.87e-17	Alzheimer's disease;
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg14893161	chr1:205819251	PM20D1	0.5	9.13	0.39	2.08e-18	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.58	-10.17	-0.43	4.42e-22	Prudent dietary pattern;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.67	-0.54	5.86e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg07148914	chr20:33460835	GGT7	0.49	8.21	0.36	2.29e-15	Height;
LGG	cis	rs2180341	0.960	rs9375503	chr6:127677071	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg03469862	chr11:68924853	NA	0.44	6.79	0.3	3.39e-11	Blond vs. brown hair color;
LGG	cis	rs7267979	1.000	rs447722	chr20:25443510	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1008375	0.897	rs3733577	chr4:17649233	T/G	cg15017067	chr4:17643749	FAM184B	0.31	6.97	0.31	1.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9354308	0.868	rs6923994	chr6:66555665	C/T	cg07460842	chr6:66804631	NA	-0.48	-8.12	-0.35	4.16e-15	Metabolite levels;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg14664628	chr15:75095509	CSK	0.47	8.9	0.38	1.26e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs8067545	0.604	rs55705283	chr17:20027138	G/A	cg13482628	chr17:19912719	NA	0.55	10.48	0.44	3.45e-23	Schizophrenia;
LGG	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.58	-0.33	1.94e-13	Neuroticism;
LGG	trans	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg11441553	chr12:57614120	NXPH4	-0.51	-8.06	-0.35	6.46e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs698813	0.604	rs2340813	chr2:44487398	T/C	cg00619915	chr2:44497795	NA	-0.6	-8.82	-0.38	2.36e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg01221209	chr5:554886	NA	-0.51	-8.18	-0.36	2.75e-15	Ulcerative colitis;
LGG	cis	rs9359856	0.600	rs11961825	chr6:90482250	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.14	-0.43	5.91e-22	Bipolar disorder;
LGG	cis	rs13266463	1.000	rs13266463	chr8:143403693	A/G	cg16886403	chr8:143471632	TSNARE1	-0.49	-7.79	-0.34	4.44e-14	Schizophrenia;
LGG	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg08975724	chr8:8085496	FLJ10661	0.57	11.62	0.48	1.51e-27	Neuroticism;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.44	-0.5	7.76e-31	Lymphocyte counts;
LGG	cis	rs7659604	0.540	rs11734075	chr4:122695685	C/T	cg20573242	chr4:122745356	CCNA2	-0.46	-7.84	-0.34	3.12e-14	Type 2 diabetes;
LGG	trans	rs877282	0.755	rs1769242	chr10:787896	T/C	cg22713356	chr15:30763199	NA	0.5	7.83	0.34	3.32e-14	Uric acid levels;
LGG	cis	rs2046867	0.568	rs1553376	chr3:72828151	T/C	cg26655873	chr3:72818019	SHQ1	0.35	6.99	0.31	9.92e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs2602381	0.605	rs2741048	chr2:234581748	C/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.65e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs3857067	1.000	rs6532462	chr4:95026833	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.81	-0.34	3.75e-14	QT interval;
LGG	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.55	10.4	0.44	6.69e-23	Rheumatoid arthritis;
LGG	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg27476859	chr7:2772710	GNA12	0.54	10.58	0.44	1.39e-23	Height;
LGG	cis	rs2236267	0.726	rs6574994	chr14:88614541	A/G	cg18078958	chr14:88630771	NA	-0.32	-7.43	-0.33	5.33e-13	Food antigen IgG levels;
LGG	trans	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg02811702	chr13:24901961	NA	0.41	7.34	0.32	9.81e-13	Obesity-related traits;
LGG	cis	rs10276381	0.579	rs9648026	chr7:28161983	A/G	cg23620719	chr7:28220237	JAZF1	-0.67	-7.25	-0.32	1.75e-12	Crohn's disease;
LGG	cis	rs2274273	0.870	rs11625423	chr14:55795913	G/A	cg04306507	chr14:55594613	LGALS3	0.62	17.23	0.63	9e-52	Protein biomarker;
LGG	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg25457927	chr22:38595422	NA	-0.44	-11.3	-0.46	2.62e-26	Cutaneous nevi;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7523273	0.606	rs2796268	chr1:207925192	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	12.03	0.49	3.34e-29	Schizophrenia;
LGG	cis	rs28595532	0.920	rs17323877	chr4:119671188	A/G	cg21605333	chr4:119757512	SEC24D	1.25	11.25	0.46	3.85e-26	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg16920238	chr17:80076378	CCDC57	0.31	7.01	0.31	8.53e-12	Life satisfaction;
LGG	cis	rs41271473	1.000	rs72751929	chr1:228884358	A/G	cg00850481	chr1:228891306	NA	-0.52	-8.86	-0.38	1.78e-17	Chronic lymphocytic leukemia;
LGG	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.82	0.34	3.64e-14	Platelet count;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs8073060	0.586	rs8077826	chr17:34001139	G/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs1997103	1.000	rs6593237	chr7:55411015	T/C	cg20935933	chr6:143382018	AIG1	0.54	8.46	0.37	3.47e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1659258	0.667	rs1713943	chr2:88599766	G/A	cg00685853	chr2:88648947	NA	-0.45	-6.73	-0.3	4.91e-11	Visceral fat;
LGG	cis	rs1318772	0.932	rs34870059	chr5:112907437	A/C	cg12552261	chr5:112820674	MCC	0.68	7.7	0.34	8.16e-14	F-cell distribution;
LGG	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg14088196	chr11:70211408	PPFIA1	0.96	13.2	0.52	5.26e-34	Coronary artery disease;
LGG	cis	rs4906332	1.000	rs35344594	chr14:103955792	A/G	cg26031613	chr14:104095156	KLC1	-0.5	-7.61	-0.33	1.6e-13	Coronary artery disease;
LGG	cis	rs9649465	0.967	rs1005568	chr7:123306470	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs7584262	0.513	rs34163130	chr2:42263449	A/C	cg19376973	chr2:42229025	NA	0.51	9.33	0.4	4.38e-19	Bone mineral density;
LGG	cis	rs787274	0.867	rs786983	chr9:115458629	T/C	cg13803584	chr9:115635662	SNX30	0.5	7.14	0.31	3.61e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg17376030	chr22:41985996	PMM1	0.4	6.65	0.3	8.18e-11	Vitiligo;
LGG	cis	rs17453880	0.591	rs2961762	chr5:151924158	G/T	cg12297329	chr5:152029980	NA	-0.57	-11.63	-0.48	1.28e-27	Subjective well-being;
LGG	cis	rs9640161	0.830	rs11768108	chr7:150064150	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.94	-0.42	3.16e-21	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1707322	0.752	rs28545085	chr1:46201950	G/A	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg08048268	chr3:133502702	NA	-0.38	-7.09	-0.31	5.15e-12	Ankle injury;
LGG	cis	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg13443165	chr9:33130375	B4GALT1	-0.55	-8.53	-0.37	2.1e-16	IgG glycosylation;
LGG	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg04317338	chr11:64019027	PLCB3	0.66	8.21	0.36	2.15e-15	Mean platelet volume;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg09699651	chr6:150184138	LRP11	0.55	10.58	0.44	1.39e-23	Testicular germ cell tumor;
LGG	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg03929089	chr4:120376271	NA	-0.98	-21.25	-0.7	1.95e-70	Coronary artery disease;
LGG	cis	rs1927790	0.759	rs4771935	chr13:96996902	A/C	cg02571835	chr13:96230311	CLDN10	-0.34	-6.82	-0.3	2.9e-11	Body mass index;
LGG	cis	rs975722	0.543	rs39317	chr7:116966304	G/A	cg10524701	chr7:117356490	CTTNBP2	0.36	7.71	0.34	7.57e-14	Coronary artery disease;
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg27400746	chr16:89904261	SPIRE2	-0.79	-12.71	-0.51	5.74e-32	Skin colour saturation;
LGG	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg20387954	chr3:183756860	HTR3D	-0.47	-9.11	-0.39	2.55e-18	Anterior chamber depth;
LGG	cis	rs368123	1.000	rs384156	chr6:160745751	A/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.04	-0.31	6.92e-12	Waist circumference;
LGG	cis	rs644799	1.000	rs586238	chr11:95560371	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4700695	0.719	rs36922	chr5:65464856	C/T	cg21114390	chr5:65439923	SFRS12	-0.72	-10.57	-0.44	1.61e-23	Facial morphology (factor 19);
LGG	cis	rs2836974	0.897	rs7280375	chr21:40552408	C/T	cg11644478	chr21:40555479	PSMG1	-0.92	-17.52	-0.63	4.37e-53	Cognitive function;
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs801193	0.660	rs2659914	chr7:66156914	C/T	cg11764359	chr7:65958608	NA	0.78	14.6	0.56	5.64e-40	Aortic root size;
LGG	cis	rs2658782	0.789	rs2658776	chr11:93147927	A/G	cg15737290	chr11:93063684	CCDC67	0.52	7.84	0.34	3.05e-14	Pulmonary function decline;
LGG	cis	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.86	-0.45	1.29e-24	Resting heart rate;
LGG	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg12591125	chr7:1885375	MAD1L1	0.47	6.91	0.31	1.63e-11	Bipolar disorder;
LGG	cis	rs6496044	0.526	rs4291869	chr15:86054523	G/A	cg17133734	chr15:86042851	AKAP13	-0.29	-6.89	-0.31	1.79e-11	Interstitial lung disease;
LGG	cis	rs368123	1.000	rs401882	chr6:160723541	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.25e-12	Waist circumference;
LGG	cis	rs9557207	0.950	rs9300538	chr13:100005113	C/T	cg24509225	chr13:100037070	UBAC2	0.68	12.52	0.5	3.69e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg07303275	chr16:75499416	TMEM170A	0.45	7.93	0.35	1.64e-14	Dupuytren's disease;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.57e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg00149659	chr3:10157352	C3orf10	0.88	11.35	0.47	1.66e-26	Alzheimer's disease;
LGG	cis	rs9768139	0.935	rs7782393	chr7:158120486	G/A	cg25566285	chr7:158114605	PTPRN2	-0.96	-25.34	-0.76	1.63e-89	Calcium levels;
LGG	cis	rs2668423	0.959	rs2526134	chr19:1365620	A/T	cg02639931	chr19:1387894	NDUFS7	-0.83	-14.09	-0.55	9.07e-38	Nonalcoholic fatty liver disease;
LGG	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg24812749	chr6:127587940	RNF146	0.66	11.19	0.46	6.62e-26	Breast cancer;
LGG	cis	rs7408868	0.908	rs757474	chr19:15273624	T/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs3833788	1	rs3833788	chr12:121151062	CTCTCTTG/C	cg21892295	chr12:121157589	UNC119B	-0.47	-8.94	-0.38	9.26e-18	Mean corpuscular hemoglobin;
LGG	cis	rs10791097	0.694	rs1054869	chr11:130742630	G/A	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	21.06	0.7	1.41e-69	Homoarginine levels;
LGG	cis	rs6752107	1.000	rs34123137	chr2:234167881	T/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	8.04	0.35	7.81e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.52	7.62	0.33	1.44e-13	Renal function-related traits (BUN);
LGG	cis	rs10504130	0.666	rs7819892	chr8:52845476	A/C	cg13492337	chr8:52722140	PXDNL	0.51	7.71	0.34	7.53e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs12190007	0.508	rs6605539	chr6:169731997	A/T	cg16388071	chr6:169726476	NA	0.54	11.36	0.47	1.55e-26	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs77669868	0.866	rs2735195	chr11:114051192	A/G	cg01914181	chr11:114070210	ZBTB16	-0.54	-6.82	-0.3	2.78e-11	Monocyte percentage of white cells;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.41	-0.33	6.04e-13	Lung cancer;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.59	-0.41	5.4e-20	Lung cancer;
LGG	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-9.11	-0.39	2.51e-18	Kawasaki disease;
LGG	cis	rs7432375	1.000	rs940174	chr3:136309710	T/C	cg21827317	chr3:136751795	NA	0.48	8.59	0.37	1.38e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs253959	0.545	rs6896147	chr5:115425396	A/G	cg22012333	chr11:118888997	RPS25;TRAPPC4	-0.42	-6.82	-0.3	2.9100000000000002e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08677398	chr8:58056175	NA	0.56	8.65	0.37	8.8e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6466055	0.777	rs2299319	chr7:104877916	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.12	-0.31	4.18e-12	Schizophrenia;
LGG	cis	rs11168618	0.605	rs2731102	chr12:48884535	G/C	cg24011408	chr12:48396354	COL2A1	-0.45	-7.37	-0.32	8.16e-13	Adiponectin levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11488569	chr9:130186546	ZNF79	0.38	6.75	0.3	4.47e-11	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.684	rs274567	chr5:131714409	C/T	cg24060327	chr5:131705240	SLC22A5	0.48	8.43	0.36	4.4e-16	Blood metabolite levels;
LGG	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.22	-0.32	2.13e-12	Triglycerides;
LGG	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg13271783	chr10:134563150	INPP5A	-0.59	-8.88	-0.38	1.52e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07677032	chr17:61819896	STRADA	0.66	12.07	0.49	2.29e-29	Prudent dietary pattern;
LGG	cis	rs2964802	0.505	rs7717266	chr5:10832134	C/G	cg14521931	chr5:10832172	NA	-0.76	-16.6	-0.61	6.53e-49	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg24812749	chr6:127587940	RNF146	0.87	13.3	0.53	2.15e-34	Breast cancer;
LGG	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg18200150	chr17:30822561	MYO1D	0.48	9.15	0.39	1.76e-18	Schizophrenia;
LGG	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg19784903	chr17:45786737	TBKBP1	0.36	8.0	0.35	1.02e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs116095464	0.558	rs62347677	chr5:227453	A/G	cg09048205	chr5:1608656	LOC728613	-0.47	-8.04	-0.35	7.37e-15	Breast cancer;
LGG	cis	rs10911251	0.528	rs10911255	chr1:183088868	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	8.03e-17	Lung cancer;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg20309703	chr11:118481025	PHLDB1	-0.56	-10.36	-0.43	9.01e-23	Cholesterol, total;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.27	0.46	3.48e-26	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	5.99e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3093024	0.935	rs10946216	chr6:167538897	T/C	cg07741184	chr6:167504864	NA	-0.36	-7.95	-0.35	1.42e-14	Rheumatoid arthritis;
LGG	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.19	-0.32	2.66e-12	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.86	-0.34	2.76e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg15971980	chr6:150254442	NA	0.45	8.38	0.36	6.31e-16	Lung cancer;
LGG	cis	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	4.82e-55	Exhaled nitric oxide output;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12564650	chr5:179050814	HNRNPH1	0.45	7.35	0.32	9.26e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg04490037	chr7:50633773	DDC	0.31	6.88	0.3	1.96e-11	Body mass index;
LGG	cis	rs7615952	0.515	rs4441610	chr3:125681307	C/G	cg05084668	chr3:125655381	ALG1L	-0.71	-10.18	-0.43	4.18e-22	Blood pressure (smoking interaction);
LGG	cis	rs75920871	1.000	rs7934763	chr11:116792357	T/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.36e-12	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27565719	chr19:52490069	ZNF350	0.45	7.38	0.32	7.22e-13	Cognitive performance;
LGG	cis	rs9358372	0.574	rs9348448	chr6:20830665	A/G	cg13405222	chr6:20811065	CDKAL1	0.45	9.14	0.39	1.94e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs975739	0.902	rs1668632	chr13:78372330	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.73e-11	Hair color;
LGG	cis	rs3784262	0.934	rs4646611	chr15:58265083	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.06	-0.35	6.45e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.66	-0.34	1.12e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1497828	0.956	rs2646839	chr1:217553421	G/A	cg04411442	chr1:217543379	NA	0.47	7.97	0.35	1.22e-14	Dialysis-related mortality;
LGG	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg04568710	chr12:38710424	ALG10B	0.34	7.17	0.32	2.9e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.45	0.58	1.05e-43	Lung cancer;
LGG	cis	rs2302729	0.625	rs1592573	chr12:2831556	A/T	cg19945202	chr12:2788847	CACNA1C	-0.71	-9.47	-0.4	1.38e-19	Sleep quality;
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.64	7.58	0.33	1.95e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs72772090	0.539	rs11135480	chr5:96110582	T/G	cg00188032	chr5:96141721	ERAP1	0.53	7.01	0.31	8.23e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3857067	0.806	rs17302300	chr4:95109177	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.34	1.96e-14	QT interval;
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg08742575	chr21:47604166	C21orf56	0.4	6.89	0.3	1.85e-11	Testicular germ cell tumor;
LGG	trans	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg25214090	chr10:38739885	LOC399744	0.38	6.97	0.31	1.09e-11	Diastolic blood pressure;
LGG	cis	rs7619833	0.506	rs1851366	chr3:27194844	T/C	cg02860705	chr3:27208620	NA	-0.42	-8.07	-0.35	5.89e-15	Breast cancer;
LGG	cis	rs4740619	0.819	rs7875367	chr9:15568230	C/T	cg14451791	chr9:16040625	NA	0.32	8.33	0.36	8.93e-16	Body mass index;
LGG	cis	rs617791	0.508	rs747526	chr11:65776071	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	8.97	0.38	7.61e-18	Breast cancer;
LGG	cis	rs10267417	0.603	rs10263119	chr7:19872844	C/G	cg07541023	chr7:19748670	TWISTNB	0.5	6.76	0.3	4.19e-11	Night sleep phenotypes;
LGG	trans	rs9409565	0.516	rs114766729	chr9:97069901	C/T	cg05679027	chr9:99775184	HIATL2	0.5	8.34	0.36	8.32e-16	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.62	12.47	0.5	5.73e-31	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs115154263	chr4:119765307	G/A	cg21605333	chr4:119757512	SEC24D	1.5	15.1	0.57	3.56e-42	Cannabis dependence symptom count;
LGG	cis	rs7619833	0.692	rs616820	chr3:27356779	C/G	cg02860705	chr3:27208620	NA	0.39	7.47	0.33	4.07e-13	Breast cancer;
LGG	cis	rs1983891	0.826	rs4714476	chr6:41513740	T/C	cg20194872	chr6:41519635	FOXP4	0.59	10.22	0.43	3.13e-22	Prostate cancer;
LGG	cis	rs1595825	0.891	rs77706948	chr2:198608441	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.3	6.85e-11	Ulcerative colitis;
LGG	cis	rs922107	0.846	rs424350	chr1:90006544	G/A	cg01128109	chr1:89989507	LRRC8B	-0.35	-7.86	-0.34	2.74e-14	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg13385521	chr17:29058706	SUZ12P	0.77	8.7	0.37	5.79e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.1	0.39	2.79e-18	Alzheimer's disease;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg11905131	chr22:24372483	LOC391322	-0.42	-7.12	-0.31	4.15e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	24.59	0.75	5.12e-86	IgG glycosylation;
LGG	trans	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg10756647	chr7:56101905	PSPH	0.82	9.55	0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.78	-0.3	3.68e-11	Blood metabolite levels;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.71e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg27411982	chr8:10470053	RP1L1	0.39	6.83	0.3	2.75e-11	Mood instability;
LGG	cis	rs7084402	0.967	rs1658421	chr10:60331928	A/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.33	-0.32	1.02e-12	Refractive error;
LGG	cis	rs62400317	0.821	rs62400269	chr6:45200634	C/T	cg18551225	chr6:44695536	NA	-0.63	-9.94	-0.42	3.23e-21	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg04450456	chr4:17643702	FAM184B	0.3	6.73	0.3	4.98e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3008870	0.920	rs975452	chr1:67480190	A/T	cg08660285	chr1:67390436	MIER1;WDR78	0.99	23.16	0.73	2.23e-79	Lymphocyte percentage of white cells;
LGG	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg12310025	chr6:25882481	NA	-0.37	-6.68	-0.3	6.83e-11	Height;
LGG	cis	rs787274	0.850	rs10759604	chr9:115639748	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-8.93	-0.38	1.03e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs3733585	0.631	rs4697925	chr4:10124330	G/C	cg08250081	chr4:10125330	NA	-0.49	-9.54	-0.41	8.35e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12579753	0.597	rs2244802	chr12:82153749	C/G	cg07988820	chr12:82153109	PPFIA2	0.54	8.41	0.36	5.19e-16	Resting heart rate;
LGG	cis	rs12142240	0.698	rs66575205	chr1:46814092	T/G	cg00530320	chr1:46809349	NSUN4	0.45	8.29	0.36	1.27e-15	Menopause (age at onset);
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.57	9.36	0.4	3.59e-19	Longevity;
LGG	cis	rs12476592	0.602	rs1348803	chr2:63895617	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	cis	rs11122272	0.735	rs2486737	chr1:231520523	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs28830936	1.000	rs4924570	chr15:41974660	A/G	cg17847044	chr15:42102381	MAPKBP1	-0.5	-11.22	-0.46	5.15e-26	Diastolic blood pressure;
LGG	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.43	7.06	0.31	6.1e-12	Carotid intima media thickness;
LGG	cis	rs4731207	0.561	rs6975148	chr7:124686508	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs4671458	0.626	rs72806004	chr2:63729432	A/G	cg17519650	chr2:63277830	OTX1	-0.54	-7.24	-0.32	1.87e-12	Subjective well-being;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19971804	chr2:39102883	MORN2;DHX57	0.45	7.14	0.31	3.73e-12	Cognitive performance;
LGG	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.88	-0.3	1.91e-11	Neuroticism;
LGG	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg25173405	chr17:45401733	C17orf57	-0.47	-8.21	-0.36	2.23e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg15105011	chr4:940614	TMEM175	0.4	7.56	0.33	2.16e-13	Sjögren's syndrome;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-14.66	-0.56	3.05e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12681287	0.547	rs9297921	chr8:87542286	C/T	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.16	-0.39	1.66e-18	Type 2 diabetes;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.01	0.46	3.25e-25	Personality dimensions;
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg27476859	chr7:2772710	GNA12	0.53	10.35	0.43	1.01e-22	Height;
LGG	trans	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg06521331	chr12:34319734	NA	0.45	7.75	0.34	5.97e-14	Bladder cancer;
LGG	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg03929089	chr4:120376271	NA	0.45	7.24	0.32	1.92e-12	HDL cholesterol;
LGG	cis	rs6547631	0.682	rs4832187	chr2:85929675	A/G	cg24620635	chr2:85921963	GNLY	0.58	11.67	0.48	9.19e-28	Blood protein levels;
LGG	cis	rs9325144	0.647	rs34311455	chr12:39060889	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.32	-0.32	1.08e-12	Morning vs. evening chronotype;
LGG	cis	rs240764	0.717	rs180963	chr6:101127213	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.85	0.34	2.83e-14	Neuroticism;
LGG	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.33	0.36	9.42e-16	Joint mobility (Beighton score);
LGG	trans	rs629535	0.814	rs62513373	chr8:70080753	C/T	cg21567404	chr3:27674614	NA	-0.4	-6.7	-0.3	6.22e-11	Dupuytren's disease;
LGG	cis	rs4363385	0.510	rs61815707	chr1:152909018	T/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.41	-0.4	2.33e-19	Inflammatory skin disease;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg27400746	chr16:89904261	SPIRE2	-1.11	-15.64	-0.59	1.37e-44	Skin colour saturation;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs4819052	0.851	rs10470247	chr21:46659018	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.75	0.38	3.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7552404	0.727	rs7547508	chr1:76327958	A/G	cg10523679	chr1:76189770	ACADM	-0.69	-11.02	-0.46	3.2e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs72772090	1.000	rs72772090	chr5:96036311	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.44	-7.05	-0.31	6.5e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs61990749	0.597	rs8003691	chr14:78211225	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	trans	rs9929218	0.906	rs9933844	chr16:68747001	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.57	-0.59	2.91e-44	Colorectal cancer;
LGG	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.15	0.52	8.75e-34	Colorectal cancer;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.61	10.34	0.43	1.13e-22	Obesity-related traits;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg06475006	chr16:89985975	MC1R	-0.61	-7.18	-0.32	2.84e-12	Skin colour saturation;
LGG	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.45	0.5	6.54e-31	Colorectal cancer;
LGG	cis	rs12200782	1.000	rs41267923	chr6:26452947	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-7.21	-0.32	2.23e-12	Small cell lung carcinoma;
LGG	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg14762896	chr20:61691785	NA	0.27	7.2	0.32	2.43e-12	Body mass index;
LGG	trans	rs66887589	0.627	rs3872807	chr4:120360251	T/A	cg25214090	chr10:38739885	LOC399744	0.38	7.01	0.31	8.7e-12	Diastolic blood pressure;
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg08888203	chr3:10149979	C3orf24	0.57	9.54	0.41	8.44e-20	Alzheimer's disease;
LGG	cis	rs6499255	1.000	rs12446201	chr16:69815586	T/C	cg00738113	chr16:70207722	CLEC18C	-0.3	-6.79	-0.3	3.38e-11	IgE levels;
LGG	cis	rs17376456	1.000	rs17323433	chr5:93551028	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.07	0.39	3.36e-18	Diabetic retinopathy;
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg05868516	chr6:26286170	HIST1H4H	0.46	7.98	0.35	1.17e-14	Educational attainment;
LGG	cis	rs2635047	0.967	rs1355593	chr18:44746460	A/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.5	-0.33	3.37e-13	Educational attainment;
LGG	cis	rs67460515	0.892	rs4856757	chr3:160999418	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.58	-0.41	5.94e-20	Parkinson's disease;
LGG	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg04287289	chr16:89883240	FANCA	0.49	8.53	0.37	2.02e-16	Vitiligo;
LGG	trans	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.02	-0.31	7.92e-12	Joint mobility (Beighton score);
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg11494091	chr17:61959527	GH2	0.52	8.11	0.35	4.49e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9398803	0.835	rs1602278	chr6:126838605	A/C	cg19875578	chr6:126661172	C6orf173	0.55	9.99	0.42	2.13e-21	Male-pattern baldness;
LGG	cis	rs1129187	1.000	rs1129187	chr6:42932200	G/T	cg14338887	chr6:42928500	GNMT	0.29	9.44	0.4	1.82e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg08807101	chr21:30365312	RNF160	-0.88	-17.81	-0.64	1.9e-54	Dental caries;
LGG	cis	rs61931739	0.517	rs11611190	chr12:34015697	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg01557791	chr16:72042693	DHODH	-0.56	-10.11	-0.43	7.56e-22	Fibrinogen levels;
LGG	cis	rs2481665	0.806	rs55725347	chr1:62538252	G/A	cg18591186	chr1:62594603	INADL	-0.52	-10.42	-0.44	5.62e-23	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg06558623	chr16:89946397	TCF25	1.1	12.09	0.49	1.98e-29	Skin colour saturation;
LGG	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg11752832	chr7:134001865	SLC35B4	0.59	10.83	0.45	1.61e-24	Mean platelet volume;
LGG	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg20587970	chr11:113659929	NA	-1.35	-24.03	-0.74	1.91e-83	Hip circumference adjusted for BMI;
LGG	cis	rs2201728	0.702	rs114296289	chr4:100180500	A/C	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.89	-0.38	1.39e-17	HDL cholesterol;
LGG	cis	rs7503807	0.664	rs9902390	chr17:78574387	G/A	cg18469159	chr17:78755841	RPTOR	-0.41	-7.78	-0.34	4.83e-14	Obesity;
LGG	cis	rs1008375	0.966	rs4698621	chr4:17587565	C/T	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.84e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8077889	0.956	rs116979403	chr17:41849105	G/A	cg26893861	chr17:41843967	DUSP3	0.97	16.7	0.61	2.32e-49	Triglycerides;
LGG	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg26597838	chr10:835615	NA	0.75	10.36	0.43	9.45e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs2842992	0.750	rs2758354	chr6:160125854	A/G	cg27624424	chr6:160112604	SOD2	0.67	9.74	0.41	1.67e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg11584989	chr19:19387371	SF4	0.4	7.2	0.32	2.4e-12	Tonsillectomy;
LGG	cis	rs990171	0.955	rs6761825	chr2:103075561	T/C	cg05295703	chr2:102895712	NA	-0.51	-8.93	-0.38	1.04e-17	Lymphocyte counts;
LGG	cis	rs9467773	0.869	rs9295689	chr6:26455811	T/C	cg09904177	chr6:26538194	HMGN4	0.64	12.85	0.51	1.54e-32	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	0.562	rs12112698	chr7:19781431	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	9.41	0.4	2.42e-19	Thyroid stimulating hormone;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21585733	chr11:107799660	RAB39	0.44	7.24	0.32	1.87e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.64	0.33	1.23e-13	Morning vs. evening chronotype;
LGG	cis	rs787274	1.000	rs7038684	chr9:115601431	A/G	cg13803584	chr9:115635662	SNX30	-0.59	-7.43	-0.33	5.41e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10220309	0.501	rs2216086	chr14:80642320	C/T	cg08183125	chr14:80678293	DIO2	-0.43	-6.85	-0.3	2.33e-11	Lung function (FEV1);
LGG	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg12310025	chr6:25882481	NA	0.48	8.95	0.38	8.54e-18	Blood metabolite levels;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg01145232	chr6:150245071	RAET1G	0.47	8.51	0.37	2.42e-16	Lung cancer;
LGG	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg12386194	chr3:101231763	SENP7	0.45	7.97	0.35	1.27e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg21724239	chr8:58056113	NA	0.59	8.61	0.37	1.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.59	-0.37	1.37e-16	Aortic root size;
LGG	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg22705602	chr4:152727874	NA	-0.32	-7.35	-0.32	8.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg08621203	chr6:150244597	RAET1G	0.51	9.46	0.4	1.54e-19	Lung cancer;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg13395646	chr4:1353034	KIAA1530	0.48	8.13	0.35	3.86e-15	Obesity-related traits;
LGG	cis	rs7727544	0.581	rs10075801	chr5:131677642	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.88	-0.3	1.93e-11	Blood metabolite levels;
LGG	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg25566285	chr7:158114605	PTPRN2	0.77	16.57	0.61	9.75e-49	Calcium levels;
LGG	cis	rs12477438	0.501	rs6727749	chr2:99793590	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.42	0.58	1.38e-43	Chronic sinus infection;
LGG	cis	rs9549367	0.713	rs9549357	chr13:113860121	C/T	cg00898013	chr13:113819073	PROZ	-0.48	-9.67	-0.41	2.8e-20	Platelet distribution width;
LGG	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.61	0.33	1.6e-13	Electroencephalogram traits;
LGG	cis	rs4774830	0.744	rs62045236	chr15:56291171	A/G	cg05129572	chr15:56138634	NEDD4	0.73	6.81	0.3	3.1e-11	Delta-5 desaturase activity;
LGG	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-10.82	-0.45	1.79e-24	Morning vs. evening chronotype;
LGG	cis	rs9287719	0.967	rs6761678	chr2:10746341	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.43	-0.44	5.25e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs7560272	0.723	rs1320374	chr2:73828310	T/C	cg23020402	chr6:24666573	ACOT13;TTRAP	-0.42	-6.69	-0.3	6.6e-11	Schizophrenia;
LGG	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.59	9.54	0.41	8.39e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4771450	0.962	rs1360341	chr13:103972053	T/A	cg02987523	chr13:103978230	NA	-0.32	-6.82	-0.3	2.86e-11	Uric acid levels;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.25	-0.49	4.27e-30	Obesity-related traits;
LGG	trans	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg14196790	chr5:131705035	SLC22A5	0.6	7.62	0.33	1.42e-13	Rheumatoid arthritis;
LGG	cis	rs6901004	0.803	rs354529	chr6:111504655	G/A	cg15721981	chr6:111408429	SLC16A10	-0.4	-7.11	-0.31	4.37e-12	Blood metabolite levels;
LGG	cis	rs9815354	1.000	rs1716987	chr3:41970516	A/G	cg03022575	chr3:42003672	ULK4	-0.68	-8.74	-0.38	4.19e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg16434002	chr17:42200994	HDAC5	0.52	9.78	0.41	1.18e-20	Total body bone mineral density;
LGG	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.5	-0.63	5.15e-53	Breast cancer;
LGG	cis	rs6433857	0.657	rs6756509	chr2:181500273	T/C	cg23363182	chr2:181467187	NA	-0.36	-7.13	-0.31	3.94e-12	Body mass index;
LGG	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg12623918	chr2:306882	NA	0.51	9.47	0.4	1.5e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs41278232	0.925	rs73916684	chr20:62661274	T/C	cg03065311	chr20:62601662	ZNF512B	0.65	9.14	0.39	2e-18	Tonsillectomy;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.96	0.31	1.17e-11	Vitiligo;
LGG	cis	rs9796	0.870	rs2412574	chr15:41259707	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.21	-0.36	2.27e-15	Menopause (age at onset);
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.76e-12	Height;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.33	-0.47	2.03e-26	Obesity-related traits;
LGG	cis	rs11630290	0.592	rs12232261	chr15:64153302	A/G	cg12036633	chr15:63758958	NA	0.5	7.19	0.32	2.6e-12	Iris characteristics;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.29	-0.32	1.36e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.46	-0.37	3.63e-16	Mean corpuscular volume;
LGG	cis	rs11785693	0.866	rs11782170	chr8:4976942	A/G	cg26367366	chr8:4980734	NA	-0.98	-14.82	-0.57	6.06e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.74	-0.38	4.48e-17	Eosinophil percentage of white cells;
LGG	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg15522984	chr1:182991683	LAMC1	0.47	9.31	0.4	5.11e-19	Colorectal cancer;
LGG	cis	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg06521331	chr12:34319734	NA	-0.63	-11.43	-0.47	7.74e-27	Morning vs. evening chronotype;
LGG	cis	rs9399135	0.933	rs41294852	chr6:135376379	T/G	cg24558204	chr6:135376177	HBS1L	0.52	9.59	0.41	5.66e-20	Red blood cell count;
LGG	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	trans	rs9467711	0.539	rs34436535	chr6:26370365	G/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg22875332	chr1:76189707	ACADM	-0.59	-9.43	-0.4	1.97e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.07	-0.42	1.06e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	1.000	rs12077546	chr1:46431806	C/T	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg22916017	chr11:64110731	CCDC88B	0.5	10.24	0.43	2.59e-22	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg15268244	chr15:77196840	NA	-0.35	-7.91	-0.34	1.93e-14	Blood metabolite levels;
LGG	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg24690094	chr11:67383802	NA	-0.4	-6.89	-0.31	1.79e-11	Mean corpuscular volume;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.31	0.4	5.12e-19	Life satisfaction;
LGG	cis	rs12908161	1.000	rs34570071	chr15:85280212	T/A	cg24253500	chr15:84953950	NA	0.42	6.92	0.31	1.53e-11	Schizophrenia;
LGG	cis	rs2276314	1.000	rs16967317	chr18:33573400	A/G	cg19628046	chr18:33552617	C18orf21	0.53	7.72	0.34	7.18e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	3.2e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4919694	1.000	rs77827514	chr10:104822009	C/T	cg04362960	chr10:104952993	NT5C2	1.07	15.54	0.59	3.95e-44	Arsenic metabolism;
LGG	cis	rs73198271	0.563	rs3748143	chr8:8655237	A/G	cg01851573	chr8:8652454	MFHAS1	-0.45	-7.36	-0.32	8.4e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg07460842	chr6:66804631	NA	0.57	9.52	0.4	1e-19	Metabolite levels;
LGG	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg06637938	chr14:75390232	RPS6KL1	-1.06	-25.3	-0.76	2.45e-89	Caffeine consumption;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.36	-0.5	1.54e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.32	0.36	1.02e-15	Response to antipsychotic treatment;
LGG	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	12.73	0.51	4.66e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg26597838	chr10:835615	NA	0.95	13.04	0.52	2.46e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg16950941	chr11:66035639	RAB1B	0.55	10.23	0.43	2.75e-22	Gout;
LGG	cis	rs295140	0.506	rs4673854	chr2:201134736	G/A	cg17644776	chr2:200775616	C2orf69	-0.47	-7.91	-0.35	1.91e-14	QT interval;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg08677398	chr8:58056175	NA	-0.46	-7.27	-0.32	1.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.657	rs35788195	chr3:143739311	C/T	cg06585982	chr3:143692056	C3orf58	0.56	9.6	0.41	5.16e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs7219021	0.739	rs3760451	chr17:46969177	G/A	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.8	-0.3	3.17e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21747090	chr2:27597821	SNX17	-0.38	-6.75	-0.3	4.49e-11	Total body bone mineral density;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs12477438	0.765	rs1054042	chr2:99614396	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs17221829	0.932	rs7924841	chr11:89460284	C/A	cg02982614	chr11:89391479	FOLH1B	-0.36	-7.67	-0.34	9.93e-14	Anxiety in major depressive disorder;
LGG	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.82e-13	Restless legs syndrome;
LGG	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg04731861	chr2:219085781	ARPC2	-0.49	-12.54	-0.5	2.87e-31	Colorectal cancer;
LGG	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.13e-31	Motion sickness;
LGG	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	cis	rs2905347	0.755	rs2961288	chr7:22665129	T/A	cg18045685	chr7:22629474	NA	-0.72	-15.41	-0.58	1.44e-43	Major depression and alcohol dependence;
LGG	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg22654517	chr2:96458247	NA	0.34	6.73	0.3	4.94e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.73e-13	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg19318889	chr4:1322082	MAEA	0.46	7.96	0.35	1.31e-14	Longevity;
LGG	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.52	-0.4	9.33e-20	Height;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.1	0.31	4.81e-12	Longevity;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.79	-0.34	4.45e-14	Obesity-related traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05587030	chr6:151773450	C6orf211;RMND1	0.58	6.76	0.3	4.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.13	0.75	7.06e-84	Chronic sinus infection;
LGG	cis	rs2408955	0.715	rs1793957	chr12:48392824	C/G	cg24011408	chr12:48396354	COL2A1	0.48	7.65	0.33	1.17e-13	Glycated hemoglobin levels;
LGG	cis	rs1497828	1.000	rs2810765	chr1:217565100	T/C	cg04411442	chr1:217543379	NA	0.46	7.96	0.35	1.33e-14	Dialysis-related mortality;
LGG	cis	rs2718058	0.630	rs2722292	chr7:37824581	A/G	cg24998770	chr7:37888106	TXNDC3	0.47	7.54	0.33	2.58e-13	Alzheimer's disease (late onset);
LGG	cis	rs1318772	1.000	rs13162970	chr5:112733357	T/G	cg12552261	chr5:112820674	MCC	0.69	7.93	0.35	1.62e-14	F-cell distribution;
LGG	cis	rs13217239	0.646	rs6937880	chr6:27000236	C/T	cg12292205	chr6:26970375	C6orf41	0.55	10.82	0.45	1.7e-24	Schizophrenia;
LGG	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04530015	chr2:215796436	ABCA12	-0.41	-7.11	-0.31	4.3e-12	Neuroblastoma;
LGG	cis	rs4635969	0.718	rs27071	chr5:1346081	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.52	-7.88	-0.34	2.43e-14	Testicular germ cell tumor;Testicular germ cell cancer;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.597	rs11763224	chr7:65983615	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.21	0.43	3.35e-22	Aortic root size;
LGG	cis	rs62238980	0.522	rs117307005	chr22:32367511	C/G	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs870825	0.550	rs35981185	chr4:185639720	A/C	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs883115	0.748	rs969026	chr1:224766842	A/T	cg01808320	chr1:224927238	CNIH3	-0.42	-7.74	-0.34	6.14e-14	Cancer;
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg11494091	chr17:61959527	GH2	0.55	9.0	0.39	6.09e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7824557	0.628	rs11994376	chr8:11202960	G/A	cg15596359	chr8:11213517	TDH	-0.41	-8.33	-0.36	8.93e-16	Retinal vascular caliber;
LGG	cis	rs367943	1.000	rs2248930	chr5:112811119	G/T	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.56	-0.53	1.69e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7202877	0.706	rs37602	chr16:75505046	C/T	cg03315344	chr16:75512273	CHST6	-0.52	-7.26	-0.32	1.67e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9972944	0.729	rs10083872	chr17:63773474	A/G	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	trans	rs2727020	0.894	rs1917328	chr11:49359606	G/A	cg03929089	chr4:120376271	NA	-0.8	-13.26	-0.52	2.95e-34	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.17	-0.32	3.06e-12	Lung cancer;
LGG	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg05555928	chr11:63887634	MACROD1	-0.39	-7.05	-0.31	6.51e-12	Platelet count;
LGG	trans	rs3857536	0.813	rs7771569	chr6:66946717	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	trans	rs66573146	0.572	rs67750430	chr4:6957266	T/G	cg07817883	chr1:32538562	TMEM39B	1.13	11.91	0.48	1e-28	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg09264619	chr17:80180166	NA	0.52	9.99	0.42	2.09e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs362296	0.661	rs3095079	chr4:3265414	A/G	cg06533319	chr4:3265114	C4orf44	-0.53	-11.01	-0.46	3.42e-25	Parental longevity (mother's age at death);
LGG	cis	rs68170813	0.617	rs117884147	chr7:107177593	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.34	-0.36	8.83e-16	Coronary artery disease;
LGG	cis	rs2694528	0.858	rs6863749	chr5:60457627	C/T	cg11474532	chr5:59995715	DEPDC1B	0.67	7.11	0.31	4.51e-12	Parkinson's disease;
LGG	cis	rs1882538	0.506	rs7805858	chr7:133126589	G/T	cg10665199	chr7:133106180	EXOC4	0.57	9.75	0.41	1.48e-20	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg26441486	chr22:50317300	CRELD2	0.4	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.2	-0.32	2.49e-12	Diastolic blood pressure;
LGG	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.11	-0.35	4.68e-15	Bipolar disorder;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.09e-13	Tonsillectomy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15698851	chr8:29940391	TMEM66	0.4	6.65	0.3	8.1e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8064299	0.597	rs3785539	chr17:72775099	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.59	0.72	1.01e-76	Monocyte count;
LGG	cis	rs6541297	0.887	rs4846906	chr1:230284257	C/A	cg20703242	chr1:230279135	GALNT2	0.4	7.5	0.33	3.29e-13	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.65	-0.3	8.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12667521	chr19:29218732	NA	0.62	9.39	0.4	2.77e-19	Methadone dose in opioid dependence;
LGG	cis	rs60180747	1.000	rs16953563	chr15:66686770	A/G	cg07575407	chr15:66541975	MEGF11	-0.36	-7.16	-0.32	3.16e-12	Testicular germ cell tumor;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg08742575	chr21:47604166	C21orf56	0.52	9.12	0.39	2.39e-18	Testicular germ cell tumor;
LGG	cis	rs11874712	0.527	rs6507664	chr18:43693615	T/G	cg26436583	chr18:43649176	PSTPIP2	-0.46	-9.22	-0.39	1.03e-18	Migraine - clinic-based;
LGG	cis	rs4481887	0.679	rs4466692	chr1:248423174	C/G	cg00666640	chr1:248458726	OR2T12	0.55	8.65	0.37	8.52e-17	Common traits (Other);
LGG	cis	rs2084898	0.550	rs470411	chr11:120012390	G/C	cg24611264	chr11:120008944	TRIM29	0.39	9.8	0.41	9.68e-21	Stroke (pediatric);
LGG	trans	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg27297192	chr10:134578999	INPP5A	0.33	7.45	0.33	4.67e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1355223	0.872	rs1258466	chr11:34730066	T/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.03	-0.31	7.53e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.11	0.35	4.6e-15	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg24112000	chr20:60950667	NA	-0.38	-9.07	-0.39	3.41e-18	Colorectal cancer;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.56	-10.14	-0.43	5.96e-22	Longevity;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.94	-0.31	1.36e-11	Depression;
LGG	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	8.28	0.36	1.34e-15	Neuroticism;
LGG	cis	rs3784262	0.669	rs3742959	chr15:58249113	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.34	-0.32	9.37e-13	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1620921	0.533	rs11753560	chr6:161267122	T/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs6831256	0.550	rs9993109	chr4:3473659	A/G	cg00887848	chr4:3482507	DOK7	-0.45	-7.82	-0.34	3.49e-14	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.6e-35	Resting heart rate;
LGG	cis	rs4262150	0.883	rs55918828	chr5:152187782	C/T	cg12297329	chr5:152029980	NA	-0.69	-12.88	-0.51	1.13e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25427524	chr10:38739819	LOC399744	-0.66	-12.44	-0.5	7.64e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg12458913	chr13:53173898	NA	0.63	12.36	0.5	1.55e-30	Lewy body disease;
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg08645402	chr16:4508243	NA	0.45	7.63	0.33	1.32e-13	Schizophrenia;
LGG	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg08305652	chr11:111469057	NA	-0.43	-8.55	-0.37	1.81e-16	Primary sclerosing cholangitis;
LGG	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs10915437	0.516	rs10915445	chr1:4197642	G/A	cg27165836	chr1:4193882	NA	0.48	9.81	0.41	9.3e-21	Migraine - clinic-based;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.33	0.4	4.57e-19	Alzheimer's disease;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	15.25	0.58	7.48e-43	Age at first birth;
LGG	cis	rs1577917	1.000	rs1857965	chr6:86630776	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.41e-11	Aortic root size;
LGG	cis	rs981844	0.683	rs1105496	chr4:154756755	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.76	-0.41	1.37e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs7954584	0.813	rs11043288	chr12:122451187	C/T	cg10207240	chr12:122356781	WDR66	-0.23	-7.1	-0.31	4.84e-12	Mean corpuscular volume;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.81	-0.48	2.46e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2282300	0.702	rs4379811	chr11:30294760	C/T	cg25418670	chr11:30344373	C11orf46	0.55	7.75	0.34	5.91e-14	Morning vs. evening chronotype;
LGG	cis	rs7312933	0.558	rs4768399	chr12:42742696	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-7.69	-0.34	9.11e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs963731	0.522	rs10169337	chr2:39284662	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-7.66	-0.34	1.1e-13	Corticobasal degeneration;
LGG	trans	rs7769051	0.808	rs1467403	chr6:133089952	T/A	cg27275811	chr11:74457193	NA	-0.58	-6.66	-0.3	7.56e-11	Type 2 diabetes nephropathy;
LGG	cis	rs35306767	0.714	rs67696450	chr10:1090684	C/T	cg25019033	chr10:957182	NA	-0.52	-9.55	-0.41	7.31e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs17767392	0.846	rs68073803	chr14:71757679	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.09	-0.39	2.92e-18	Mitral valve prolapse;
LGG	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.3	-0.32	1.29e-12	HDL cholesterol;
LGG	cis	rs2836974	0.897	rs34394827	chr21:40528087	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.93	0.35	1.62e-14	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg03517284	chr6:25882590	NA	-0.67	-12.62	-0.51	1.43e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg11859384	chr17:80120422	CCDC57	0.4	6.76	0.3	4.27e-11	Life satisfaction;
LGG	cis	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs67460515	0.596	rs35127376	chr3:160927289	T/C	cg04691961	chr3:161091175	C3orf57	-0.46	-8.93	-0.38	1.04e-17	Parkinson's disease;
LGG	cis	rs10267417	0.556	rs34292170	chr7:19969325	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.96	0.31	1.2e-11	Night sleep phenotypes;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.02	-0.31	7.96e-12	Neuroticism;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs185694	0.947	rs595451	chr13:30896848	T/C	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.66	-0.3	7.6e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9460578	0.537	rs7747989	chr6:20813375	C/G	cg13405222	chr6:20811065	CDKAL1	0.77	17.63	0.63	1.38e-53	Breast cancer;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs4302748	0.862	rs11971724	chr7:36184708	T/C	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs73086581	0.680	rs11908158	chr20:3936672	G/T	cg02187196	chr20:3869020	PANK2	0.75	10.55	0.44	1.76e-23	Response to antidepressants in depression;
LGG	trans	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.61	10.05	0.42	1.25e-21	Metabolite levels;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.84	-0.54	1.06e-36	Tonsillectomy;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg16507663	chr6:150244633	RAET1G	0.43	7.94	0.35	1.57e-14	Lung cancer;
LGG	cis	rs4700695	0.841	rs448454	chr5:65293462	G/A	cg21114390	chr5:65439923	SFRS12	0.59	7.55	0.33	2.31e-13	Facial morphology (factor 19);
LGG	cis	rs11997175	0.784	rs36083407	chr8:33812930	G/T	ch.8.33884649F	chr8:33765107	NA	0.41	7.81	0.34	3.85e-14	Body mass index;
LGG	cis	rs17376456	1.000	rs13154249	chr5:93550508	C/T	cg25358565	chr5:93447407	FAM172A	1.34	16.44	0.61	3.58e-48	Diabetic retinopathy;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg13628971	chr7:2884303	GNA12	0.49	9.56	0.41	7.11e-20	Height;
LGG	cis	rs2688608	0.592	rs12253429	chr10:75496161	C/G	cg19442545	chr10:75533431	FUT11	-0.43	-7.0	-0.31	9.21e-12	Inflammatory bowel disease;
LGG	cis	rs4423214	0.625	rs78685409	chr11:71137383	T/C	cg10847948	chr11:71163743	NADSYN1	0.66	11.71	0.48	6.63e-28	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09882587	chr5:96143769	ERAP1	0.48	7.06	0.31	6.28e-12	Gut microbiome composition (summer);
LGG	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.94	0.52	6.37e-33	Cognitive test performance;
LGG	cis	rs9611565	0.525	rs9611549	chr22:41705909	C/G	cg03806693	chr22:41940476	POLR3H	-0.76	-12.76	-0.51	3.8e-32	Vitiligo;
LGG	cis	rs9902453	0.845	rs2628165	chr17:28121166	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.98	0.54	2.73e-37	Coffee consumption (cups per day);
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.6	10.55	0.44	1.8e-23	Obesity-related traits;
LGG	cis	rs8072100	0.701	rs10163469	chr17:45687767	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.56	-10.29	-0.43	1.7e-22	Rheumatoid arthritis;
LGG	cis	rs9394152	0.781	rs9380362	chr6:33467734	T/C	cg13560919	chr6:33536144	NA	0.68	12.49	0.5	4.68e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9487094	0.744	rs2275652	chr6:109703683	G/C	cg16315928	chr6:109776240	MICAL1	0.54	9.05	0.39	4.13e-18	Height;
LGG	cis	rs2559856	0.935	rs2695287	chr12:102088361	T/C	cg15068132	chr12:102092402	CHPT1	-0.36	-6.69	-0.3	6.53e-11	Blood protein levels;
LGG	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg20302533	chr7:39170763	POU6F2	0.55	13.58	0.53	1.39e-35	IgG glycosylation;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg05863683	chr7:1912471	MAD1L1	0.45	9.06	0.39	3.57e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg19824325	chr16:58548873	SETD6	1.21	11.07	0.46	1.93e-25	Schizophrenia;
LGG	cis	rs12681287	0.608	rs13272148	chr8:87481853	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs769267	1.000	rs769267	chr19:19446936	A/G	cg03709012	chr19:19516395	GATAD2A	0.82	15.88	0.59	1.25e-45	Tonsillectomy;
LGG	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg27279351	chr12:120934652	DYNLL1	0.76	11.86	0.48	1.7e-28	High light scatter reticulocyte count;
LGG	cis	rs13191362	0.935	rs34063386	chr6:163041271	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.13	0.31	3.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6960043	1.000	rs12113083	chr7:15051943	G/C	cg19272540	chr7:15055459	NA	-0.35	-7.75	-0.34	5.71e-14	Type 2 diabetes;
LGG	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.2	0.39	1.24e-18	Rheumatoid arthritis;
LGG	cis	rs6598955	0.724	rs12757113	chr1:26597144	C/T	cg04990556	chr1:26633338	UBXN11	-0.66	-13.55	-0.53	1.86e-35	Obesity-related traits;
LGG	cis	rs7226408	0.901	rs11081991	chr18:34743948	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21014159	chr11:117668035	DSCAML1	0.47	7.17	0.32	2.93e-12	Myopia;
LGG	trans	rs1032833	0.558	rs79605876	chr2:179895287	A/G	cg23654767	chr2:101192981	PDCL3	0.98	10.15	0.43	5.43e-22	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.48e-23	Prudent dietary pattern;
LGG	cis	rs73416724	1.000	rs17209379	chr6:43265231	A/C	cg26312998	chr6:43337775	ZNF318	0.59	7.99	0.35	1.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3789045	0.729	rs12039968	chr1:204490674	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.7	-0.37	5.94e-17	Educational attainment (college completion);
LGG	cis	rs7666738	0.830	rs6532724	chr4:99060993	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2274273	0.875	rs2075602	chr14:55609774	A/G	cg04306507	chr14:55594613	LGALS3	0.65	18.42	0.65	2.94e-57	Protein biomarker;
LGG	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg26441486	chr22:50317300	CRELD2	0.4	6.87	0.3	2.07e-11	Schizophrenia;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg02002194	chr4:3960332	NA	0.43	7.92	0.35	1.8e-14	Neuroticism;
LGG	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg07599136	chr5:415885	AHRR	0.84	11.51	0.47	3.82e-27	Fat distribution (HIV);
LGG	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	trans	rs7395662	0.927	rs117030714	chr11:48760511	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.17	0.35	3.05e-15	HDL cholesterol;
LGG	cis	rs6547631	0.622	rs2118402	chr2:85931078	A/G	cg24620635	chr2:85921963	GNLY	0.52	10.47	0.44	3.56e-23	Blood protein levels;
LGG	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg25019033	chr10:957182	NA	-0.56	-10.26	-0.43	2.19e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21582582	chr3:182698605	DCUN1D1	0.52	9.65	0.41	3.37e-20	Intelligence (multi-trait analysis);
LGG	cis	rs654950	0.783	rs668359	chr1:42003425	A/C	cg16096631	chr1:42092165	HIVEP3	-0.35	-7.17	-0.32	2.98e-12	Airway imaging phenotypes;
LGG	cis	rs3857067	1.000	rs115969971	chr4:95023550	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs8133932	0.701	rs2183599	chr21:47288873	C/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.35	-0.32	9.23e-13	Schizophrenia;
LGG	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg03264133	chr6:25882463	NA	-0.49	-7.93	-0.35	1.68e-14	Iron status biomarkers;
LGG	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg08704250	chr15:31115839	NA	-0.5	-8.94	-0.38	9.65e-18	Huntington's disease progression;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs2832191	0.740	rs6516890	chr21:30476812	T/A	cg08807101	chr21:30365312	RNF160	0.85	17.39	0.63	1.72e-52	Dental caries;
LGG	cis	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg07460842	chr6:66804631	NA	0.89	14.69	0.56	2.35e-40	Exhaled nitric oxide output;
LGG	cis	rs2276314	1.000	rs2298716	chr18:33552598	C/T	cg19628046	chr18:33552617	C18orf21	0.55	7.95	0.35	1.42e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg06238570	chr21:40685208	BRWD1	0.44	6.8	0.3	3.26e-11	Cognitive function;
LGG	cis	rs7582180	0.764	rs1967341	chr2:100924559	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.41	-0.36	5.24e-16	Monocyte count;
LGG	cis	rs61931739	0.620	rs7297316	chr12:33702261	G/A	cg06521331	chr12:34319734	NA	0.4	6.89	0.3	1.82e-11	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg09699651	chr6:150184138	LRP11	0.54	9.7	0.41	2.27e-20	Lung cancer;
LGG	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.61	0.33	1.54e-13	Homoarginine levels;
LGG	cis	rs2976388	0.578	rs13254358	chr8:143823876	G/A	cg06565975	chr8:143823917	SLURP1	-0.57	-13.86	-0.54	8.33e-37	Urinary tract infection frequency;
LGG	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg24189917	chr7:1970923	MAD1L1	-0.59	-8.87	-0.38	1.65e-17	Bipolar disorder;
LGG	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg07882059	chr11:68924751	NA	0.41	7.34	0.32	9.65e-13	Blond vs. brown hair color;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03456512	chr7:107531689	DLD	0.43	7.07	0.31	5.56e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg19748678	chr4:122722346	EXOSC9	0.65	13.29	0.53	2.28e-34	Type 2 diabetes;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg03709012	chr19:19516395	GATAD2A	0.79	15.07	0.57	4.66e-42	Tonsillectomy;
LGG	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg12573674	chr2:1569213	NA	-0.65	-10.01	-0.42	1.69e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg04503457	chr17:41445688	NA	-0.39	-8.16	-0.35	3.19e-15	Menopause (age at onset);
LGG	cis	rs853679	0.517	rs9366715	chr6:28064633	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg01673284	chr16:4527211	HMOX2	0.33	6.65	0.3	8.26e-11	Schizophrenia;
LGG	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg18876405	chr7:65276391	NA	-0.49	-8.69	-0.37	6.15e-17	Aortic root size;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs1862618	0.853	rs252922	chr5:56136343	G/T	cg17809284	chr5:56205270	C5orf35	-0.53	-8.85	-0.38	1.81e-17	Initial pursuit acceleration;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.37	0.47	1.41e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.03e-19	Obesity-related traits;
LGG	cis	rs1021993	0.545	rs55684110	chr1:209541832	A/T	cg24446417	chr1:209558027	NA	-0.72	-10.79	-0.45	2.39e-24	Gut microbiome composition (winter);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18766912	chr15:25683909	UBE3A	0.41	6.85	0.3	2.43e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.26	-0.78	2.5e-98	Height;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg11878867	chr6:150167359	LRP11	-0.58	-12.4	-0.5	1.04e-30	Lung cancer;
LGG	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg26441486	chr22:50317300	CRELD2	0.42	7.1	0.31	4.66e-12	Schizophrenia;
LGG	cis	rs6912958	0.525	rs242262	chr6:88018057	A/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.32	6.69	0.3	6.53e-11	Monocyte percentage of white cells;
LGG	cis	rs2028299	1.000	rs6496609	chr15:90379632	C/A	cg23731826	chr15:90371692	NA	0.37	8.69	0.37	6.37e-17	Type 2 diabetes;
LGG	cis	rs10463554	0.963	rs17154959	chr5:102356291	G/A	cg23492399	chr5:102201601	PAM	-0.51	-7.5	-0.33	3.37e-13	Parkinson's disease;
LGG	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.39	-0.32	7.13e-13	Neuroticism;
LGG	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.4	-7.79	-0.34	4.31e-14	Educational attainment;
LGG	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg06637938	chr14:75390232	RPS6KL1	0.57	10.49	0.44	3.19e-23	Height;
LGG	trans	rs9951602	0.512	rs4799249	chr18:76654370	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg25242756	chr11:120207979	ARHGEF12	0.57	7.34	0.32	9.85e-13	Colorectal cancer;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg05313129	chr8:58192883	C8orf71	-0.6	-8.46	-0.37	3.58e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6032067	1.000	rs6017526	chr20:43871555	A/T	cg10761708	chr20:43804764	PI3	0.76	11.82	0.48	2.36e-28	Blood protein levels;
LGG	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg24130564	chr14:104152367	KLC1	-0.39	-7.16	-0.32	3.23e-12	Reticulocyte count;
LGG	cis	rs4936891	0.645	rs74858431	chr11:123902862	T/C	cg22125253	chr11:123886957	OR10G4	0.71	14.02	0.55	1.88e-37	Male fertility;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25624328	chr15:63334706	TPM1	0.46	6.82	0.3	2.77e-11	Hip circumference;
LGG	cis	rs516946	0.797	rs13266210	chr8:41533514	A/G	cg21772509	chr8:41503840	NKX6-3	-0.72	-11.05	-0.46	2.34e-25	Type 2 diabetes;
LGG	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg12463550	chr7:65579703	CRCP	0.76	8.3	0.36	1.12e-15	Diabetic kidney disease;
LGG	cis	rs1018697	1.000	rs7080587	chr10:104545274	C/T	cg04362960	chr10:104952993	NT5C2	0.5	9.05	0.39	4.08e-18	Colorectal adenoma (advanced);
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg00933542	chr6:150070202	PCMT1	0.36	6.67	0.3	7.09e-11	Lung cancer;
LGG	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-9.76	-0.41	1.38e-20	Chronic sinus infection;
LGG	cis	rs35176054	0.730	rs35696766	chr10:105536662	G/T	cg00730670	chr10:105510713	SH3PXD2A	-0.5	-6.83	-0.3	2.71e-11	Atrial fibrillation;
LGG	cis	rs35740288	0.929	rs11556865	chr15:86303180	C/G	cg04173714	chr15:86211321	AKAP13	0.41	7.1	0.31	4.77e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg19338460	chr6:170058176	WDR27	-0.61	-8.37	-0.36	7.05e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10979	0.597	rs9403516	chr6:143908139	A/T	cg25407410	chr6:143891975	LOC285740	0.48	6.9	0.31	1.66e-11	Hypospadias;
LGG	cis	rs12220238	1.000	rs4320897	chr10:76017732	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.85	11.98	0.49	5.47e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1023500	0.573	rs1807494	chr22:42474138	C/G	cg05082376	chr22:42548792	NA	0.36	7.66	0.34	1.09e-13	Schizophrenia;
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.88	0.42	5.27e-21	Tonsillectomy;
LGG	cis	rs6669919	0.901	rs7527396	chr1:211667857	C/T	cg10512769	chr1:211675356	NA	-0.69	-15.22	-0.58	1.08e-42	Intelligence (multi-trait analysis);
LGG	cis	rs13401104	0.716	rs28821203	chr2:237140475	T/C	cg15742758	chr2:237126235	ASB18	0.49	7.89	0.34	2.26e-14	Educational attainment;
LGG	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg08198773	chr8:1697536	NA	0.36	7.0	0.31	9.02e-12	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18538332	chr22:24372958	LOC391322	0.41	6.9	0.31	1.74e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12431410	0.550	rs10147934	chr14:60210582	G/A	cg07950296	chr14:60194823	RTN1	-0.36	-6.95	-0.31	1.24e-11	Schizophrenia;
LGG	cis	rs4144027	0.869	rs55924227	chr14:104361350	G/C	cg26031613	chr14:104095156	KLC1	-0.44	-7.14	-0.31	3.68e-12	Blood metabolite levels;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	16.48	0.61	2.3e-48	Personality dimensions;
LGG	cis	rs861020	0.604	rs3766612	chr1:210020013	G/T	cg05527609	chr1:210001259	C1orf107	-0.68	-10.04	-0.42	1.38e-21	Orofacial clefts;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg08280861	chr8:58055591	NA	0.63	7.79	0.34	4.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs721917	0.506	rs2254025	chr10:81658213	C/T	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.5	-0.5	4.44e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7274811	0.779	rs34145153	chr20:32159067	C/T	cg21523528	chr20:32077966	CBFA2T2	0.4	6.67	0.3	7.13e-11	Height;
LGG	cis	rs17122278	0.613	rs573971	chr11:118393396	A/G	cg27286069	chr11:118481882	PHLDB1	0.47	6.73	0.3	5.04e-11	Total cholesterol levels;
LGG	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02251663	chr11:14281053	SPON1	0.31	7.41	0.33	5.96e-13	Mitochondrial DNA levels;
LGG	cis	rs2421770	0.532	rs4756215	chr11:35365963	A/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.56	-0.33	2.11e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	9.98	0.42	2.29e-21	Longevity;
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg00405596	chr8:11794950	NA	-0.39	-6.77	-0.3	4e-11	Neuroticism;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg21724239	chr8:58056113	NA	0.47	7.07	0.31	5.88e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7794364	0.658	rs12154872	chr7:117512932	A/G	cg21880328	chr7:117514017	CTTNBP2	-0.35	-7.31	-0.32	1.18e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.34	-0.32	9.62e-13	Triglycerides;
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg17971929	chr21:40555470	PSMG1	0.87	17.32	0.63	3.49e-52	Cognitive function;
LGG	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs710865	0.627	rs10799710	chr1:19483209	A/G	cg13387374	chr1:19411106	UBR4	0.53	11.2	0.46	6.52e-26	Brain structure;
LGG	cis	rs58616815	0.857	rs11186161	chr10:92161642	A/C	cg17905462	chr10:92153495	NA	-0.25	-6.71	-0.3	5.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg03160526	chr17:80928410	B3GNTL1	0.52	8.35	0.36	7.99e-16	Glycated hemoglobin levels;
LGG	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.89	-0.38	1.4e-17	Response to antipsychotic treatment;
LGG	cis	rs4243830	0.737	rs925744	chr1:6615695	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.77	-11.63	-0.48	1.32e-27	Body mass index;
LGG	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7119	0.717	rs12916822	chr15:77818548	G/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg02187348	chr16:89574699	SPG7	0.47	7.78	0.34	4.62e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-10.33	-0.43	1.24e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4680	0.737	rs4646312	chr22:19948337	C/T	cg23601416	chr22:19950040	COMT	0.43	10.98	0.45	4.39e-25	Blood metabolite levels;
LGG	cis	rs912057	0.833	rs1024245	chr6:6743319	A/G	cg06612196	chr6:6737390	NA	0.46	9.39	0.4	2.8e-19	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs2764208	0.576	rs6939345	chr6:34736134	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.46	-8.07	-0.35	5.98e-15	Systemic lupus erythematosus;
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	10.27	0.43	2.03e-22	Eye color traits;
LGG	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	7.75	0.34	5.85e-14	Bone mineral density;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16524936	chr4:1340807	KIAA1530	-0.49	-8.2	-0.36	2.35e-15	Longevity;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg11494091	chr17:61959527	GH2	1.0	24.6	0.75	4.2e-86	Prudent dietary pattern;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg15242686	chr22:24348715	GSTTP1	0.45	8.36	0.36	7.18e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3806843	1.000	rs7732179	chr5:140199039	G/A	cg19875535	chr5:140030758	IK	0.47	9.62	0.41	4.23e-20	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg06108461	chr20:60628389	TAF4	-1.01	-19.57	-0.67	1.43e-62	Body mass index;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.46	0.4	1.52e-19	Obesity-related traits;
LGG	cis	rs4538187	1.000	rs6546029	chr2:64069732	G/A	cg02541582	chr2:64069798	UGP2	0.6	13.97	0.54	2.8e-37	Systolic blood pressure;
LGG	cis	rs3008870	0.917	rs12044492	chr1:67461667	T/C	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs3820928	1.000	rs10204368	chr2:227774244	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.72e-12	Pulmonary function;
LGG	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.22	-0.36	2.11e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.08e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg15971980	chr6:150254442	NA	0.46	8.34	0.36	8.58e-16	Lung cancer;
LGG	cis	rs1577917	0.740	rs7775864	chr6:86247759	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	12.94	0.52	6.32e-33	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.87	-0.34	2.5e-14	IgG glycosylation;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21862992	chr11:68658383	NA	0.49	8.4	0.36	5.52e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7394190	0.935	rs12570126	chr10:75416789	C/T	cg07699608	chr10:75541558	CHCHD1	-0.54	-7.89	-0.34	2.2e-14	Incident atrial fibrillation;
LGG	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg16141378	chr3:129829833	LOC729375	-0.4	-9.16	-0.39	1.65e-18	Joint mobility (Beighton score);
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg14668821	chr17:77704760	ENPP7	0.33	6.66	0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs9341808	0.718	rs10943699	chr6:80940541	G/A	cg08355045	chr6:80787529	NA	0.4	7.7	0.34	8.06e-14	Sitting height ratio;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg05665937	chr4:1216051	CTBP1	0.54	9.97	0.42	2.37e-21	Obesity-related traits;
LGG	cis	rs9357271	1.000	rs9380742	chr6:38357932	T/C	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	trans	rs1814175	0.645	rs1721997	chr11:49916653	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg01620082	chr3:125678407	NA	-0.69	-7.7	-0.34	8.39e-14	Depression;
LGG	cis	rs4262150	0.883	rs113790150	chr5:152272524	T/C	cg12297329	chr5:152029980	NA	-0.65	-12.33	-0.5	2.09e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs1532331	0.548	rs6894506	chr5:43169096	C/T	cg09164108	chr5:43007320	NA	0.36	6.84	0.3	2.5e-11	Menarche (age at onset);
LGG	cis	rs13421350	0.579	rs1574259	chr2:173313453	A/G	cg15021238	chr2:173305865	ITGA6	0.62	7.56	0.33	2.19e-13	Diabetic kidney disease;
LGG	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg13798912	chr7:905769	UNC84A	-0.52	-6.71	-0.3	5.54e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg24692254	chr21:30365293	RNF160	0.71	13.27	0.53	2.64e-34	Cognitive test performance;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06028808	chr11:68637592	NA	0.74	12.29	0.5	3.14e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7727544	1.000	rs7727038	chr5:131590257	C/T	cg07395648	chr5:131743802	NA	-0.5	-11.76	-0.48	3.9e-28	Blood metabolite levels;
LGG	trans	rs73198271	0.729	rs67653033	chr8:8605044	G/C	cg16141378	chr3:129829833	LOC729375	0.38	6.72	0.3	5.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6696846	0.765	rs61822567	chr1:205078725	T/C	cg00857998	chr1:205179979	DSTYK	0.56	9.04	0.39	4.32e-18	Red blood cell count;
LGG	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg00578828	chr5:131826934	IRF1	0.41	7.48	0.33	3.64e-13	Asthma (sex interaction);
LGG	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg24375607	chr4:120327624	NA	0.66	10.9	0.45	8.58e-25	Corneal astigmatism;
LGG	cis	rs2415984	0.622	rs55833034	chr14:46825055	C/A	cg14871534	chr14:47121158	RPL10L	-0.55	-9.25	-0.39	8.33e-19	Number of children ever born;
LGG	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg26248373	chr2:1572462	NA	-0.88	-14.95	-0.57	1.55e-41	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs7762018	1.000	rs6942332	chr6:170131934	A/G	cg06875740	chr19:51307921	C19orf48	-0.64	-7.84	-0.34	3.23e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3820068	0.655	rs59605679	chr1:15863796	T/G	cg05660106	chr1:15850417	CASP9	1.14	27.01	0.78	3.54e-97	Systolic blood pressure;
LGG	cis	rs11159840	0.609	rs6574995	chr14:88618902	T/C	cg18078958	chr14:88630771	NA	-0.3	-7.09	-0.31	5.14e-12	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs4820294	0.516	rs12627973	chr22:38096697	A/G	cg26138144	chr22:38071188	LGALS1	0.68	12.67	0.51	8.79e-32	Fat distribution (HIV);
LGG	cis	rs4843747	0.671	rs4075598	chr16:88107512	T/C	cg06374794	chr16:88002281	BANP	0.44	8.1	0.35	5.08e-15	Menopause (age at onset);
LGG	cis	rs4363385	0.510	rs11812015	chr1:153045584	G/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.33	-0.4	4.43e-19	Inflammatory skin disease;
LGG	cis	rs7590368	0.673	rs72779425	chr2:10940601	C/G	cg15705551	chr2:10952987	PDIA6	0.57	7.38	0.32	7.38e-13	Educational attainment (years of education);
LGG	cis	rs4481887	1.000	rs7511706	chr1:248467360	G/A	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg08085267	chr17:45401833	C17orf57	-0.57	-11.35	-0.47	1.63e-26	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00684032	chr4:1343700	KIAA1530	0.68	14.03	0.55	1.65e-37	Obesity-related traits;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg27606397	chr2:173244251	NA	0.34	6.74	0.3	4.59e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs7267979	1.000	rs6050547	chr20:25326012	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.48	-0.44	3.36e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2273669	0.667	rs12200531	chr6:109320441	T/C	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg25173464	chr15:68126554	NA	0.34	7.15	0.32	3.48e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-11.3	-0.46	2.62e-26	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg20887711	chr4:1340912	KIAA1530	-0.6	-11.29	-0.46	2.77e-26	Obesity-related traits;
LGG	cis	rs4774899	1.000	rs62022988	chr15:57325187	G/A	cg08128148	chr15:57256372	TCF12	-0.33	-7.84	-0.34	3.03e-14	Urinary tract infection frequency;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg23129478	chr18:44337922	ST8SIA5	-0.42	-8.07	-0.35	6.3e-15	Personality dimensions;
LGG	cis	rs787274	0.718	rs2185768	chr9:115462645	C/T	cg13803584	chr9:115635662	SNX30	0.51	7.38	0.32	7.39e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9790314	0.687	rs1037888	chr3:160775251	A/T	cg03342759	chr3:160939853	NMD3	-0.5	-8.4	-0.36	5.54e-16	Morning vs. evening chronotype;
LGG	cis	rs12618769	0.625	rs61180742	chr2:99148078	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs6142618	0.562	rs6142620	chr20:30734994	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.88	0.34	2.44e-14	Inflammatory bowel disease;
LGG	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg03806693	chr22:41940476	POLR3H	1.02	16.72	0.61	2.02e-49	Vitiligo;
LGG	cis	rs67311347	0.577	rs11129870	chr3:40260406	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-14.99	-0.57	1.06e-41	Renal cell carcinoma;
LGG	cis	rs2797160	0.967	rs4897151	chr6:125993202	T/G	cg05901451	chr6:126070800	HEY2	-0.41	-6.95	-0.31	1.24e-11	Endometrial cancer;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.29	-0.36	1.2e-15	Total body bone mineral density;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg15596359	chr8:11213517	TDH	-0.41	-8.37	-0.36	7.11e-16	Retinal vascular caliber;
LGG	cis	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.16	-0.32	3.17e-12	Small cell lung carcinoma;
LGG	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.73	-0.3	4.98e-11	Renal cell carcinoma;
LGG	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg20368463	chr18:77673604	PQLC1	0.57	7.48	0.33	3.79e-13	Opioid sensitivity;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.42	-6.96	-0.31	1.18e-11	Longevity;Endometriosis;
LGG	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs7949030	0.653	rs2516634	chr11:62367186	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.62	-14.12	-0.55	6.72e-38	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9354308	0.738	rs4235976	chr6:66593762	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.8	-0.3	3.24e-11	Metabolite levels;
LGG	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg02187348	chr16:89574699	SPG7	0.65	11.05	0.46	2.45e-25	Multiple myeloma (IgH translocation);
LGG	cis	rs6772849	0.775	rs9828414	chr3:128412717	C/T	cg08795948	chr3:128337044	NA	0.62	9.69	0.41	2.38e-20	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg14159672	chr1:205819179	PM20D1	-0.43	-7.09	-0.31	4.98e-12	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.97	-0.31	1.12e-11	Bipolar disorder;
LGG	cis	rs4845570	0.920	rs11810571	chr1:151762308	C/G	cg07092448	chr1:151763213	TDRKH	1.16	24.71	0.75	1.43e-86	Coronary artery disease;
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg13397359	chr6:42928475	GNMT	0.57	16.03	0.6	2.53e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.9	0.48	1.1e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17504614	0.591	rs72889466	chr2:51056712	C/A	cg23851515	chr2:51057218	NRXN1	0.49	8.04	0.35	7.68e-15	Educational attainment (years of education);
LGG	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg13114125	chr14:105738426	BRF1	0.84	17.64	0.63	1.26e-53	Mean platelet volume;Platelet distribution width;
LGG	cis	rs62400317	0.859	rs17288257	chr6:45193076	T/C	cg18551225	chr6:44695536	NA	-0.63	-9.84	-0.42	7.37e-21	Total body bone mineral density;
LGG	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.18	-0.39	1.4e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs1949733	0.701	rs2688222	chr4:8473735	C/A	cg11789530	chr4:8429930	ACOX3	0.71	13.59	0.53	1.2e-35	Response to antineoplastic agents;
LGG	cis	rs6582630	0.519	rs1607882	chr12:38361657	G/A	cg13010199	chr12:38710504	ALG10B	0.64	13.5	0.53	2.83e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72781680	0.898	rs17763224	chr2:24213776	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.51	0.4	1.03e-19	Lymphocyte counts;
LGG	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.26	-0.32	1.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10267417	0.603	rs10243346	chr7:19862365	G/A	cg05791153	chr7:19748676	TWISTNB	0.62	8.05	0.35	6.94e-15	Night sleep phenotypes;
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg15971980	chr6:150254442	NA	0.42	6.77	0.3	3.99e-11	Lung cancer;
LGG	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-13.56	-0.53	1.64e-35	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21871735	chr16:2015157	SNHG9;RPS2;SNORA78	0.48	7.24	0.32	1.89e-12	Gut microbiome composition (summer);
LGG	cis	rs12367572	0.663	rs1857926	chr12:45344524	C/T	cg04608330	chr12:45269318	NELL2	-0.44	-7.22	-0.32	2.08e-12	Gut microbiome composition (summer);
LGG	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg09904177	chr6:26538194	HMGN4	0.77	17.28	0.63	5.41e-52	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg23625390	chr15:77176239	SCAPER	-0.72	-14.29	-0.55	1.18e-38	Blood metabolite levels;
LGG	trans	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-12.22	-0.49	5.8e-30	Mood instability;
LGG	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs571497	0.583	rs62128261	chr19:7837989	G/C	cg00970558	chr19:7854469	CLEC4GP1	0.7	7.78	0.34	4.9e-14	Monocyte count;
LGG	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg00129232	chr17:37814104	STARD3	-0.6	-11.0	-0.46	3.81e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs17767392	0.747	rs61989240	chr14:71708610	T/C	cg02058870	chr14:72053146	SIPA1L1	0.36	7.19	0.32	2.63e-12	Mitral valve prolapse;
LGG	cis	rs4665809	1.000	rs750450	chr2:26324631	A/G	cg08470875	chr2:26401718	FAM59B	-0.36	-6.67	-0.3	7.22e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.44	-0.33	4.83e-13	Lung cancer;
LGG	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg11764359	chr7:65958608	NA	0.8	14.7	0.56	1.96e-40	Aortic root size;
LGG	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	8.03	0.35	7.84e-15	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg11814155	chr7:99998594	ZCWPW1	0.64	9.84	0.42	7.1e-21	Platelet count;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-6.99	-0.31	9.48e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs60843830	1.000	rs7566279	chr2:281178	C/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.25	0.36	1.67e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00166722	chr3:10149974	C3orf24	0.57	8.06	0.35	6.69e-15	Alzheimer's disease;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.05	-0.31	6.42e-12	Triglycerides;
LGG	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs721917	0.506	rs7088752	chr10:81646460	T/C	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg21775007	chr8:11205619	TDH	-0.8	-13.86	-0.54	9.1e-37	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg13628971	chr7:2884303	GNA12	0.52	10.68	0.44	5.95e-24	Height;
LGG	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg07541023	chr7:19748670	TWISTNB	0.78	10.55	0.44	1.86e-23	Thyroid stimulating hormone;
LGG	cis	rs4148087	1.000	rs9984673	chr21:43615709	T/C	cg08841829	chr21:43638893	ABCG1	-0.6	-7.83	-0.34	3.4e-14	Eating disorder in bipolar disorder;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-11.42	-0.47	8.57e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.54	9.34	0.4	3.96e-19	Birth weight;
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg14675211	chr2:100938903	LONRF2	0.67	11.93	0.48	8.64e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs7010267	0.570	rs7838083	chr8:120016805	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.51	0.37	2.52e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs9886651	0.776	rs4733560	chr8:128779001	G/A	cg24514600	chr8:128805414	PVT1	-0.51	-11.26	-0.46	3.63e-26	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	trans	rs7507204	0.906	rs62125968	chr19:3422261	G/A	cg08382705	chr11:45687319	CHST1	-0.51	-7.1	-0.31	4.81e-12	Height;
LGG	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.15	-0.32	3.49e-12	Sudden cardiac arrest;
LGG	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.67	11.49	0.47	4.56e-27	Chronic sinus infection;
LGG	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg04989706	chr14:50066350	PPIL5	0.52	8.23	0.36	1.91e-15	Carotid intima media thickness;
LGG	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg08400814	chr5:56204995	C5orf35	-0.45	-7.34	-0.32	9.62e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg02725872	chr8:58115012	NA	-0.86	-11.26	-0.46	3.58e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg05775895	chr3:12838266	CAND2	0.65	11.52	0.47	3.58e-27	QRS complex (12-leadsum);
LGG	cis	rs8058578	1.000	rs8048448	chr16:30692208	T/C	cg00531865	chr16:30841666	NA	-0.56	-11.36	-0.47	1.47e-26	Multiple myeloma;
LGG	cis	rs5762813	0.510	rs1222	chr22:29185113	G/T	cg15103426	chr22:29168792	CCDC117	-0.67	-7.21	-0.32	2.33e-12	Hematocrit;Hemoglobin concentration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07498778	chr8:38325092	FGFR1	0.48	7.69	0.34	8.95e-14	Cognitive performance;
LGG	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08045932	chr20:61659980	NA	0.6	12.93	0.52	7.24e-33	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs17685	0.702	rs6960598	chr7:75772991	T/C	cg19862616	chr7:65841803	NCRNA00174	1.06	24.81	0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs757278	0.618	rs6973257	chr7:117364998	G/A	cg10524701	chr7:117356490	CTTNBP2	0.43	7.92	0.35	1.73e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg23461800	chr14:103021989	NA	-0.45	-7.57	-0.33	2.09e-13	Platelet count;
LGG	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg00717180	chr2:96193071	NA	0.42	7.37	0.32	8.02e-13	HDL cholesterol;
LGG	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.85	0.82	2.18e-114	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11638880	chr6:166755991	SFT2D1	0.48	7.22	0.32	2.22e-12	Gut microbiome composition (summer);
LGG	cis	rs6988985	0.703	rs10097914	chr8:143949515	T/A	cg10324643	chr8:143916377	GML	0.39	7.74	0.34	6.28e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.38	0.36	6.59e-16	Obesity-related traits;
LGG	cis	rs4423214	0.959	rs11233747	chr11:71171642	G/A	cg05163923	chr11:71159392	DHCR7	0.72	14.04	0.55	1.46e-37	Vitamin D levels;
LGG	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.75	12.95	0.52	6.15e-33	Alzheimer's disease;
LGG	cis	rs2688608	0.592	rs10824031	chr10:75509273	C/T	cg19442545	chr10:75533431	FUT11	-0.45	-7.49	-0.33	3.57e-13	Inflammatory bowel disease;
LGG	cis	rs6694672	0.850	rs6428387	chr1:197061557	A/G	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs4538187	0.951	rs13018690	chr2:64151381	A/C	cg19915305	chr2:64069682	UGP2	-0.67	-14.96	-0.57	1.44e-41	Systolic blood pressure;
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg26554054	chr8:600488	NA	0.95	9.66	0.41	3.13e-20	IgG glycosylation;
LGG	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg13770153	chr20:60521292	NA	-0.46	-7.55	-0.33	2.29e-13	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27539627	chr3:122513065	DIRC2;HSPBAP1	0.45	6.87	0.3	2.05e-11	Gut microbiome composition (summer);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg12986271	chr19:31841559	TSHZ3	0.58	7.22	0.32	2.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4478858	0.735	rs11582342	chr1:31810681	A/G	cg19084893	chr1:31688959	NA	0.32	6.85	0.3	2.33e-11	Alcohol dependence;
LGG	cis	rs7193541	0.684	rs4887783	chr16:74700743	G/C	cg01733217	chr16:74700730	RFWD3	1.12	35.96	0.86	4.15e-136	Multiple myeloma;
LGG	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Myopia (pathological);
LGG	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg17971929	chr21:40555470	PSMG1	0.79	14.25	0.55	1.9e-38	Cognitive function;
LGG	trans	rs9944715	1.000	rs9963843	chr18:43842618	C/A	cg01718231	chr17:29326311	RNF135	-0.42	-6.8	-0.3	3.23e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg17050807	chr22:42548356	NA	-0.38	-7.22	-0.32	2.14e-12	Schizophrenia;
LGG	cis	rs13314892	0.728	rs62250982	chr3:69844845	C/T	cg17445875	chr3:69859618	MITF	-0.4	-7.76	-0.34	5.46e-14	QRS complex (12-leadsum);
LGG	cis	rs2282300	0.739	rs1222210	chr11:30362125	A/G	cg06241208	chr11:30344200	C11orf46	0.51	6.74	0.3	4.58e-11	Morning vs. evening chronotype;
LGG	cis	rs1559088	0.803	rs10411529	chr19:33616256	A/C	cg27124370	chr19:33622961	WDR88	0.46	8.33	0.36	9.53e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg01262667	chr19:19385393	TM6SF2	0.35	6.96	0.31	1.16e-11	Bipolar disorder;
LGG	cis	rs3820928	0.874	rs4234066	chr2:227882180	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.54	-0.33	2.46e-13	Pulmonary function;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.08	0.35	5.56e-15	Lung cancer;
LGG	cis	rs9394152	0.810	rs9380364	chr6:33471721	T/C	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.75e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.57	-0.47	2.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4356932	1.000	rs4859600	chr4:76959967	C/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg02002194	chr4:3960332	NA	0.39	7.04	0.31	6.98e-12	Joint mobility (Beighton score);
LGG	cis	rs722599	0.715	rs11851433	chr14:75339450	C/T	cg06637938	chr14:75390232	RPS6KL1	0.53	8.87	0.38	1.6e-17	IgG glycosylation;
LGG	cis	rs6121246	0.559	rs10439608	chr20:30258814	T/C	cg13852791	chr20:30311386	BCL2L1	0.94	18.52	0.65	1.08e-57	Mean corpuscular hemoglobin;
LGG	trans	rs7613875	0.620	rs17657664	chr3:50032008	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	6.77	0.3	4e-11	Body mass index;
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg23985595	chr17:80112537	CCDC57	0.38	7.47	0.33	4.09e-13	Life satisfaction;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2635047	0.638	rs12953864	chr18:44625245	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.91	0.31	1.63e-11	Educational attainment;
LGG	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.94	-0.31	1.36e-11	Blood metabolite levels;
LGG	cis	rs758324	0.588	rs426991	chr5:131327345	T/C	cg06307176	chr5:131281290	NA	0.47	7.11	0.31	4.51e-12	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg11752103	chr21:47878969	DIP2A	-0.4	-6.85	-0.3	2.33e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg18335740	chr13:41363409	SLC25A15	0.61	12.14	0.49	1.19e-29	Lewy body disease;
LGG	trans	rs208520	0.837	rs208489	chr6:66927584	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.21	-0.58	1.12e-42	Exhaled nitric oxide output;
LGG	cis	rs72781680	0.898	rs12622290	chr2:23979894	C/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.01	0.39	5.52e-18	Lymphocyte counts;
LGG	cis	rs4713118	0.513	rs149958	chr6:28013617	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.95	-0.31	1.26e-11	Parkinson's disease;
LGG	trans	rs11098499	0.691	rs10010355	chr4:120261043	A/G	cg25214090	chr10:38739885	LOC399744	0.55	10.24	0.43	2.58e-22	Corneal astigmatism;
LGG	cis	rs526231	0.511	rs3756582	chr5:102339552	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.43	-0.36	4.44e-16	Primary biliary cholangitis;
LGG	cis	rs9660992	0.573	rs1172161	chr1:205206495	C/T	cg21545522	chr1:205238299	TMCC2	0.41	7.83	0.34	3.39e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs17221829	0.703	rs75183199	chr11:89356987	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.14	-0.39	1.94e-18	Anxiety in major depressive disorder;
LGG	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg07274523	chr3:49395745	GPX1	0.58	9.82	0.42	8.35e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg09165964	chr15:75287851	SCAMP5	1.07	22.92	0.73	3.08e-78	Blood trace element (Zn levels);
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.8	-12.87	-0.51	1.29e-32	Alzheimer's disease;
LGG	cis	rs5769765	0.671	rs138817	chr22:50163058	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.56	-7.95	-0.35	1.42e-14	Schizophrenia;
LGG	cis	rs6809651	0.524	rs10937240	chr3:185802823	C/T	cg00760338	chr3:185826511	ETV5	-0.91	-15.26	-0.58	7.23e-43	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06481639	chr22:41940642	POLR3H	0.5	7.53	0.33	2.6e-13	Vitiligo;
LGG	cis	rs7216064	1.000	rs2365764	chr17:65857714	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11673344	0.704	rs484001	chr19:37422222	C/T	cg04415599	chr19:37464508	NA	-0.37	-6.95	-0.31	1.21e-11	Obesity-related traits;
LGG	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg00857998	chr1:205179979	DSTYK	0.5	8.03	0.35	7.91e-15	Red blood cell count;
LGG	cis	rs2377585	0.524	rs35146959	chr12:8847546	C/T	cg03761649	chr12:8850719	RIMKLB	0.47	7.98	0.35	1.19e-14	Reticulocyte fraction of red cells;
LGG	cis	rs80282103	0.867	rs13377037	chr10:1068639	C/T	cg08668510	chr10:1095578	IDI1	0.76	7.9	0.34	2.07e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs9351532	chr6:66591290	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg16400903	chr5:693638	TPPP	0.44	6.72	0.3	5.19e-11	Obesity-related traits;
LGG	cis	rs6546537	0.550	rs4852272	chr2:69776730	C/T	cg10773587	chr2:69614142	GFPT1	-0.46	-8.09	-0.35	5.4e-15	Serum thyroid-stimulating hormone levels;
LGG	cis	rs1595825	1.000	rs61605589	chr2:198876532	T/C	cg00982548	chr2:198649783	BOLL	-0.5	-6.86	-0.3	2.19e-11	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.19e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	0.525	rs4316329	chr1:178509333	C/T	cg12486710	chr1:178512616	C1orf220	0.51	10.77	0.45	2.68e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg17058777	chr11:71814579	LRTOMT;C11orf59	0.44	7.63	0.33	1.39e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16405210	chr4:1374714	KIAA1530	0.67	12.33	0.5	2.04e-30	Obesity-related traits;
LGG	cis	rs2802728	0.881	rs72759861	chr1:243567609	G/A	cg05593162	chr1:243577377	SDCCAG8	0.49	6.79	0.3	3.39e-11	Toenail selenium levels;
LGG	trans	rs13128441	1.000	rs13128441	chr4:5162389	C/T	cg26099876	chr8:141644609	EIF2C2	-0.52	-8.19	-0.36	2.58e-15	Celiac disease;
LGG	cis	rs870825	0.616	rs6844588	chr4:185644517	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs11122272	0.735	rs1076804	chr1:231498460	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.3	-0.32	1.26e-12	Hemoglobin concentration;
LGG	cis	rs9611565	0.546	rs5758426	chr22:42098763	T/G	cg06481639	chr22:41940642	POLR3H	0.48	6.82	0.3	2.9e-11	Vitiligo;
LGG	cis	rs7582180	0.700	rs2309852	chr2:100982527	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.62	-0.48	1.49e-27	Intelligence (multi-trait analysis);
LGG	cis	rs16937	0.711	rs3851284	chr1:205156080	A/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.5e-13	Schizophrenia;
LGG	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-9.76	-0.41	1.35e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6694672	1.000	rs9427661	chr1:196946546	T/C	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.8e-11	Asthma;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg09307838	chr4:120376055	NA	0.79	13.09	0.52	1.62e-33	Corneal astigmatism;
LGG	cis	rs1568889	0.838	rs6484359	chr11:28262328	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	18.97	0.66	8.58e-60	Bipolar disorder;
LGG	trans	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.29	-0.36	1.2e-15	Retinal vascular caliber;
LGG	cis	rs35883536	0.967	rs1055044	chr1:101171354	A/G	cg06223162	chr1:101003688	GPR88	0.28	6.85	0.3	2.35e-11	Monocyte count;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg14773178	chr5:1868261	NA	0.36	7.97	0.35	1.23e-14	Cardiovascular disease risk factors;
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg10207240	chr12:122356781	WDR66	0.27	8.07	0.35	5.91e-15	Mean corpuscular volume;
LGG	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg11584989	chr19:19387371	SF4	-0.42	-7.55	-0.33	2.42e-13	Tonsillectomy;
LGG	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.45	0.44	4.28e-23	Arsenic metabolism;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg08621203	chr6:150244597	RAET1G	0.44	7.45	0.33	4.52e-13	Lung cancer;
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg14137381	chr5:502291	SLC9A3	-0.33	-6.75	-0.3	4.39e-11	Cystic fibrosis severity;
LGG	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg22875332	chr1:76189707	ACADM	0.63	11.31	0.47	2.41e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs994014	0.572	rs11736471	chr4:82322918	A/C	cg07938847	chr4:82126349	PRKG2	-0.28	-6.67	-0.3	7.34e-11	Height;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.19	-0.43	3.86e-22	Neuroticism;
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg14541582	chr5:601475	NA	-0.7	-10.42	-0.44	5.38e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs9595066	0.564	rs12869383	chr13:44705441	G/A	cg04068111	chr13:44716778	NA	0.4	6.97	0.31	1.11e-11	Schizophrenia;
LGG	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg22044901	chr15:68126292	NA	-0.41	-6.94	-0.31	1.34e-11	Restless legs syndrome;
LGG	cis	rs7188861	0.626	rs7193871	chr16:11455606	C/G	cg00044050	chr16:11439710	C16orf75	0.47	7.23	0.32	2.04e-12	HDL cholesterol;
LGG	cis	rs7917772	0.503	rs11191320	chr10:104293394	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6580649	0.941	rs17122611	chr12:48458149	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.2	-0.32	2.52e-12	Menarche (age at onset);
LGG	trans	rs75804782	0.521	rs55690022	chr2:239407783	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.73	0.38	4.54e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6815814	0.861	rs28690449	chr4:38789132	C/T	cg06935464	chr4:38784597	TLR10	0.54	8.89	0.38	1.32e-17	Breast cancer;
LGG	trans	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg25214090	chr10:38739885	LOC399744	0.63	10.92	0.45	7.42e-25	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg11584989	chr19:19387371	SF4	0.4	7.22	0.32	2.09e-12	Tonsillectomy;
LGG	cis	rs7681423	1.000	rs2066865	chr4:155525276	G/A	cg20735720	chr4:155535218	FGG	-0.58	-10.4	-0.44	6.81e-23	Fibrinogen;
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg10189774	chr4:17578691	LAP3	0.42	7.57	0.33	2.1e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.874	rs28452522	chr4:120110784	A/G	cg09307838	chr4:120376055	NA	0.65	10.39	0.43	7.31e-23	Corneal astigmatism;
LGG	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg20891283	chr12:69753455	YEATS4	-0.5	-7.94	-0.35	1.53e-14	Response to diuretic therapy;
LGG	trans	rs2727020	0.796	rs7131672	chr11:49274421	A/C	cg15704280	chr7:45808275	SEPT13	0.79	12.6	0.51	1.73e-31	Coronary artery disease;
LGG	cis	rs61931739	0.500	rs11053218	chr12:34474792	A/C	cg06521331	chr12:34319734	NA	0.46	7.45	0.33	4.51e-13	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	9.28	0.4	6.74e-19	Longevity;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.62	0.41	4.41e-20	Schizophrenia;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg24846343	chr22:24311635	DDTL	0.62	12.86	0.51	1.43e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.65	-0.41	3.45e-20	Retinal vascular caliber;
LGG	cis	rs4363385	0.667	rs2050674	chr1:152913356	C/G	cg13444842	chr1:152974279	SPRR3	0.39	7.38	0.32	7.21e-13	Inflammatory skin disease;
LGG	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg14132834	chr19:41945861	ATP5SL	-0.5	-9.58	-0.41	5.95e-20	Height;
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg12463550	chr7:65579703	CRCP	0.49	8.15	0.35	3.45e-15	Aortic root size;
LGG	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.1	-0.42	8.21e-22	Educational attainment;
LGG	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg17971929	chr21:40555470	PSMG1	-0.53	-8.95	-0.38	8.55e-18	Menarche (age at onset);
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.16	0.58	2.02e-42	Platelet count;
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.49	0.69	7.06e-67	Alzheimer's disease;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg05863683	chr7:1912471	MAD1L1	0.48	9.19	0.39	1.3e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg12454169	chr2:30669597	LCLAT1	0.63	8.63	0.37	9.77e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs12431410	0.892	rs1957991	chr14:60167110	A/G	cg07950296	chr14:60194823	RTN1	0.37	6.88	0.3	1.99e-11	Schizophrenia;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.57e-13	Menopause (age at onset);
LGG	cis	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg12297329	chr5:152029980	NA	0.84	19.64	0.67	6.32e-63	Subjective well-being;
LGG	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg21459583	chr1:227974177	NA	0.7	10.76	0.45	3.02e-24	Major depressive disorder;
LGG	cis	rs6496932	0.663	rs7182814	chr15:85906071	C/T	cg19183879	chr15:85880815	NA	-0.42	-7.04	-0.31	7.02e-12	Central corneal thickness;Corneal structure;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg00689492	chr4:1303491	MAEA	0.48	8.33	0.36	9.22e-16	Obesity-related traits;
LGG	cis	rs8067545	0.611	rs2526465	chr17:20167611	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.06	-0.42	1.11e-21	Schizophrenia;
LGG	cis	rs10979	0.965	rs9390109	chr6:143892806	T/C	cg25407410	chr6:143891975	LOC285740	-0.71	-12.24	-0.49	4.7e-30	Hypospadias;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg18350739	chr11:68623251	NA	0.81	20.3	0.69	5.42e-66	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7223966	1.000	rs8069687	chr17:61883023	C/T	cg05941027	chr17:61774174	LIMD2	-0.38	-9.85	-0.42	6.67e-21	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs458649	0.947	rs457961	chr5:4277869	A/G	cg10952591	chr14:67827467	EIF2S1;ATP6V1D	-0.46	-7.01	-0.31	8.45e-12	Endometriosis;
LGG	cis	rs6840360	0.533	rs13139327	chr4:152728590	A/C	cg22705602	chr4:152727874	NA	-0.35	-8.53	-0.37	2.14e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2562456	0.583	rs4809144	chr19:21772730	C/T	cg00806126	chr19:22604979	ZNF98	-0.63	-8.67	-0.37	7.58e-17	Pain;
LGG	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg06634786	chr22:41940651	POLR3H	-0.74	-12.11	-0.49	1.7e-29	Vitiligo;
LGG	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg02725872	chr8:58115012	NA	-0.7	-10.52	-0.44	2.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1697139	1.000	rs1697139	chr5:66511535	A/G	cg11553311	chr5:66541588	NA	0.4	9.05	0.39	4.04e-18	Breast cancer;
LGG	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08109568	chr15:31115862	NA	-0.59	-9.98	-0.42	2.21e-21	Huntington's disease progression;
LGG	cis	rs1577917	0.687	rs13197828	chr6:86805630	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-11.39	-0.47	1.16e-26	Response to antipsychotic treatment;
LGG	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg00990874	chr7:1149470	C7orf50	-0.83	-15.06	-0.57	5.52e-42	Bronchopulmonary dysplasia;
LGG	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg21644426	chr2:191273491	MFSD6	-0.59	-10.23	-0.43	2.76e-22	Pulse pressure;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.14e-34	Skin colour saturation;
LGG	cis	rs7208859	0.673	rs9899349	chr17:29200122	C/T	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg14159672	chr1:205819179	PM20D1	0.42	6.69	0.3	6.44e-11	Parkinson's disease;
LGG	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs975722	0.543	rs10248393	chr7:116998176	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.39	-8.52	-0.37	2.28e-16	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.580	rs17598114	chr15:85171317	C/T	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.35e-12	Schizophrenia;
LGG	cis	rs68170813	0.559	rs17429118	chr7:106964052	C/T	cg02696742	chr7:106810147	HBP1	-0.71	-10.09	-0.42	9.18e-22	Coronary artery disease;
LGG	cis	rs1707322	1.000	rs11211248	chr1:46476844	A/G	cg03146154	chr1:46216737	IPP	0.55	10.23	0.43	2.68e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4631830	0.863	rs2843550	chr10:51521452	C/T	cg16070123	chr10:51489643	NA	-0.4	-7.25	-0.32	1.71e-12	Prostate-specific antigen levels;
LGG	cis	rs9902453	0.808	rs78154346	chr17:28169493	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.85	0.54	9.72e-37	Coffee consumption (cups per day);
LGG	cis	rs7552404	0.696	rs12140121	chr1:76455001	A/G	cg03433033	chr1:76189801	ACADM	0.65	9.06	0.39	3.58e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10895140	0.756	rs1938861	chr11:101497396	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs2455799	0.613	rs12491914	chr3:15808672	A/C	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.89e-15	Mean platelet volume;
LGG	cis	rs4718428	0.960	rs6460317	chr7:66390255	A/G	cg18252515	chr7:66147081	NA	-0.58	-9.29	-0.4	6.2e-19	Corneal structure;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg01673284	chr16:4527211	HMOX2	0.33	6.89	0.3	1.82e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg07460842	chr6:66804631	NA	0.9	14.77	0.57	9.71e-41	Exhaled nitric oxide output;
LGG	cis	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.47e-14	Blood pressure (smoking interaction);
LGG	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg21459583	chr1:227974177	NA	0.58	8.43	0.36	4.3e-16	Major depressive disorder;
LGG	cis	rs1816752	0.748	rs6490912	chr13:24983079	G/A	cg02811702	chr13:24901961	NA	0.39	7.22	0.32	2.16e-12	Obesity-related traits;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.0	-0.31	9.21e-12	Longevity;Endometriosis;
LGG	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg25019033	chr10:957182	NA	-0.57	-10.57	-0.44	1.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs240764	0.658	rs9322213	chr6:101248480	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.78	-0.34	4.7e-14	Neuroticism;
LGG	cis	rs2180341	0.576	rs2057224	chr6:127624414	C/G	cg27446573	chr6:127587934	RNF146	0.73	13.36	0.53	1.18e-34	Breast cancer;
LGG	cis	rs2862064	0.872	rs6555822	chr5:156473185	A/G	cg12943317	chr5:156479607	HAVCR1	-0.89	-11.05	-0.46	2.34e-25	Platelet count;
LGG	cis	rs988958	0.917	rs13401037	chr2:42282632	A/T	cg27428208	chr2:42229179	NA	0.39	6.92	0.31	1.48e-11	Hypospadias;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16175911	chr12:26985133	ITPR2	0.46	7.07	0.31	5.75e-12	Gut microbiome composition (summer);
LGG	cis	rs7659604	0.540	rs10020581	chr4:122676559	A/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.22	-0.46	5.33e-26	IgG glycosylation;
LGG	cis	rs4727027	0.899	rs11771339	chr7:148854132	A/T	cg23583168	chr7:148888333	NA	-0.87	-17.04	-0.62	7.07e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03264133	chr6:25882463	NA	-0.61	-11.23	-0.46	4.73e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1385374	0.858	rs3741615	chr12:129298848	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.8	0.3	3.2e-11	Systemic lupus erythematosus;
LGG	cis	rs317689	0.690	rs10878947	chr12:69642683	A/T	cg20891283	chr12:69753455	YEATS4	0.44	6.71	0.3	5.65e-11	Response to diuretic therapy;
LGG	cis	rs9660992	0.710	rs1668873	chr1:205235990	G/A	cg21545522	chr1:205238299	TMCC2	0.49	9.02	0.39	5.05e-18	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs4942242	1.000	rs1105856	chr13:44227067	G/T	cg19169023	chr15:41853346	TYRO3	0.33	6.9	0.31	1.69e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.74	0.41	1.59e-20	Neuroticism;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs9287719	0.967	rs2287061	chr2:10743153	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg15971980	chr6:150254442	NA	0.43	8.23	0.36	1.87e-15	Lung cancer;
LGG	cis	rs6912958	0.712	rs6908386	chr6:88354746	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.83	-0.38	2.13e-17	Monocyte percentage of white cells;
LGG	cis	rs3087591	1.000	rs4795577	chr17:29456879	T/G	cg24425628	chr17:29625626	OMG;NF1	0.72	14.12	0.55	6.44e-38	Hip circumference;
LGG	trans	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.74	0.48	4.73e-28	Resting heart rate;
LGG	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.07	0.35	5.96e-15	Neuroticism;
LGG	cis	rs1408224	0.607	rs9534448	chr13:47212961	G/A	cg24453118	chr13:47229927	LRCH1	-0.3	-6.92	-0.31	1.5e-11	QRS complex (12-leadsum);
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11245990	chr11:68621969	NA	0.42	9.0	0.39	5.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7617773	0.780	rs36121690	chr3:48345511	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs9944715	0.859	rs73425119	chr18:43753831	G/C	cg26436583	chr18:43649176	PSTPIP2	0.38	6.87	0.3	2.05e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2273669	0.667	rs76201299	chr6:109344975	T/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg02725872	chr8:58115012	NA	-0.88	-11.42	-0.47	8.52e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-7.02	-0.31	7.99e-12	Longevity;
LGG	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.0	-0.39	5.73e-18	Morning vs. evening chronotype;
LGG	cis	rs4919694	1.000	rs11191545	chr10:104829793	C/T	cg04362960	chr10:104952993	NT5C2	1.07	15.62	0.59	1.68e-44	Arsenic metabolism;
LGG	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	Neuroticism;
LGG	cis	rs1018836	0.544	rs2142145	chr8:91460670	A/G	cg16814680	chr8:91681699	NA	-0.5	-8.11	-0.35	4.71e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-8.53	-0.37	2.07e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.620	rs7313483	chr12:123726834	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.58	0.33	1.9e-13	Neutrophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08169394	chr17:11143830	SHISA6	0.42	6.9	0.31	1.7e-11	Cognitive performance;
LGG	cis	rs9818758	0.607	rs12185979	chr3:49651970	C/G	cg00383909	chr3:49044727	WDR6	1.09	11.55	0.47	2.63e-27	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg04248312	chr19:17393744	ANKLE1	-0.68	-11.28	-0.46	3.13e-26	Systemic lupus erythematosus;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg22907277	chr7:1156413	C7orf50	0.45	7.55	0.33	2.38e-13	Longevity;Endometriosis;
LGG	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.22e-12	Neuroticism;
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.72	13.77	0.54	2.06e-36	Personality dimensions;
LGG	cis	rs539514	0.664	rs1323712	chr13:76300085	C/G	cg04757411	chr13:76259545	LMO7	-0.27	-7.11	-0.31	4.48e-12	Type 1 diabetes;
LGG	cis	rs2735413	0.918	rs4888728	chr16:78077199	C/G	cg04733911	chr16:78082701	NA	-0.78	-18.83	-0.66	3.67e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs10463554	0.892	rs158408	chr5:102407374	G/A	cg23492399	chr5:102201601	PAM	-0.49	-7.4	-0.33	6.47e-13	Parkinson's disease;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.57	-0.5	2.19e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs713587	0.563	rs1529897	chr2:25086827	T/G	cg04586622	chr2:25135609	ADCY3	0.42	11.16	0.46	8.61e-26	Body mass index in non-asthmatics;
LGG	cis	rs7077164	1.000	rs7077164	chr10:71583198	C/T	cg20696214	chr10:71583771	COL13A1	0.4	7.57	0.33	2.05e-13	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.23	0.32	2.02e-12	Schizophrenia;
LGG	cis	rs911263	0.561	rs8003738	chr14:68776208	A/G	cg18825221	chr14:68749962	RAD51L1	0.45	7.41	0.33	5.86e-13	Primary biliary cholangitis;
LGG	cis	rs17227506	0.704	rs13263028	chr8:13453490	C/A	cg03566418	chr8:13424080	C8orf48	0.63	9.96	0.42	2.63e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.28	-0.36	1.32e-15	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11582133	chr15:41576691	LOC729082	0.44	6.66	0.3	7.6e-11	Gut microbiome composition (summer);
LGG	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	6.66	0.3	8e-11	Neuroticism;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.55	9.37	0.4	3.11e-19	Obesity-related traits;
LGG	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg16584290	chr5:462447	EXOC3	0.45	9.37	0.4	3.09e-19	Cystic fibrosis severity;
LGG	cis	rs2549003	0.811	rs10035166	chr5:131823927	C/T	cg21138405	chr5:131827807	IRF1	-0.35	-8.74	-0.38	4.23e-17	Asthma (sex interaction);
LGG	cis	rs6831352	0.734	rs12502237	chr4:100015675	G/A	cg12011299	chr4:100065546	ADH4	0.4	8.05	0.35	6.82e-15	Alcohol dependence;
LGG	cis	rs981844	0.775	rs17371261	chr4:154738479	G/T	cg14289246	chr4:154710475	SFRP2	-0.68	-11.25	-0.46	4.18e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs317689	0.819	rs317664	chr12:69704747	C/A	cg11871910	chr12:69753446	YEATS4	0.47	7.63	0.33	1.32e-13	Response to diuretic therapy;
LGG	cis	rs4919044	0.808	rs835280	chr10:94811786	A/G	cg05127821	chr10:94822908	CYP26C1	-0.45	-7.78	-0.34	4.93e-14	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs700651	0.789	rs1813106	chr2:198880589	A/G	cg00792783	chr2:198669748	PLCL1	0.64	10.37	0.43	8.32e-23	Intracranial aneurysm;
LGG	cis	rs8180040	0.800	rs2088135	chr3:47280018	T/C	cg27129171	chr3:47204927	SETD2	-0.81	-14.55	-0.56	9.12e-40	Colorectal cancer;
LGG	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg27121462	chr16:89883253	FANCA	0.62	11.4	0.47	1.1e-26	Vitiligo;
LGG	cis	rs1816752	1.000	rs7999554	chr13:25009769	C/A	cg22771759	chr13:24902376	NA	0.46	7.75	0.34	5.69e-14	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.22	-0.39	1.01e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11920090	0.858	rs10513688	chr3:170727218	G/A	cg09710316	chr3:170744871	SLC2A2	0.67	8.89	0.38	1.32e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg16405210	chr4:1374714	KIAA1530	-0.87	-15.84	-0.59	1.84e-45	Longevity;
LGG	cis	rs1933488	0.562	rs1281967	chr6:153446191	A/T	cg17707550	chr6:153380415	RGS17	0.35	7.5	0.33	3.34e-13	Prostate cancer;
LGG	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg07423050	chr13:99094983	FARP1	-0.56	-10.83	-0.45	1.68e-24	Longevity;
LGG	trans	rs1997103	0.822	rs10273426	chr7:55417857	G/A	cg20935933	chr6:143382018	AIG1	0.54	7.94	0.35	1.54e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7098414	0.511	rs4934134	chr10:82160582	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	12.55	0.5	2.58e-31	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg09699651	chr6:150184138	LRP11	0.51	8.45	0.37	3.72e-16	Lung cancer;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4077515	0.504	rs10870164	chr9:139315682	C/T	cg14169450	chr9:139327907	INPP5E	-0.36	-6.8	-0.3	3.23e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg15028436	chr7:37888078	TXNDC3	0.9	16.42	0.61	4.37e-48	Alzheimer's disease (late onset);
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.75	0.38	3.91e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs73787773	0.866	rs60370278	chr5:111484212	T/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.68	-8.4	-0.36	5.58e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7953508	0.506	rs10859532	chr12:93960917	G/C	cg18151635	chr12:93972918	NA	-0.56	-10.53	-0.44	2.11e-23	Pubertal anthropometrics;
LGG	cis	rs6088580	0.634	rs6059829	chr20:33017074	G/A	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs12579753	0.917	rs10862360	chr12:82187411	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.95	-0.35	1.39e-14	Resting heart rate;
LGG	cis	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-6.7	-0.3	5.91e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.79	0.38	3.01e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06850241	chr22:41845214	NA	0.45	6.85	0.3	2.3e-11	Vitiligo;
LGG	cis	rs5769765	0.773	rs9616395	chr22:50317803	A/G	cg02269571	chr22:50332266	NA	-0.7	-10.37	-0.43	8.18e-23	Schizophrenia;
LGG	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg22044901	chr15:68126292	NA	-0.42	-6.94	-0.31	1.29e-11	Restless legs syndrome;
LGG	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg00857998	chr1:205179979	DSTYK	0.56	8.99	0.39	6.28e-18	Red blood cell count;
LGG	cis	rs2153535	0.580	rs7743995	chr6:8496212	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs10876993	0.890	rs774888	chr12:58036506	A/G	cg18357645	chr12:58087776	OS9	0.67	12.18	0.49	8.48e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs4262150	0.726	rs6884556	chr5:152013316	G/C	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs7246760	0.867	rs2336089	chr19:9849972	C/T	cg16876255	chr19:9731953	ZNF561	0.79	7.29	0.32	1.31e-12	Pursuit maintenance gain;
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg26513180	chr16:89883248	FANCA	0.68	7.56	0.33	2.17e-13	Skin colour saturation;
LGG	cis	rs3087591	1.000	rs2905884	chr17:29512476	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	14.41	0.56	3.69e-39	Hip circumference;
LGG	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.51	-0.33	3.04e-13	Mood instability;
LGG	cis	rs738322	0.533	rs5756934	chr22:38547279	G/A	cg25457927	chr22:38595422	NA	-0.45	-11.06	-0.46	2.08e-25	Cutaneous nevi;
LGG	cis	rs1348850	0.668	rs6734426	chr2:178493770	C/T	cg23306229	chr2:178417860	TTC30B	0.61	7.86	0.34	2.68e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8141529	0.732	rs5752798	chr22:29181868	A/G	cg02153584	chr22:29168773	CCDC117	0.7	11.86	0.48	1.58e-28	Lymphocyte counts;
LGG	cis	rs2531992	1.000	rs2531992	chr16:4021734	A/G	cg05927578	chr16:4029543	ADCY9	0.67	9.23	0.39	9.64e-19	Waist circumference;
LGG	cis	rs638893	0.578	rs5006102	chr11:118662340	A/T	cg22253036	chr11:118662786	DDX6	0.49	7.35	0.32	8.79e-13	Vitiligo;
LGG	cis	rs806215	0.590	rs712715	chr7:127333136	C/T	cg25922125	chr7:127225783	GCC1	-0.5	-7.22	-0.32	2.15e-12	Type 2 diabetes;
LGG	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg20573242	chr4:122745356	CCNA2	0.54	10.1	0.42	8.39e-22	Type 2 diabetes;
LGG	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.29	0.5	3.12e-30	Colorectal cancer;
LGG	cis	rs10811516	0.501	rs10757194	chr9:21162415	G/A	cg23029519	chr9:21187344	IFNA4	-0.45	-7.56	-0.33	2.18e-13	Response to mepolizumab in severe asthma;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs365132	0.875	rs4490607	chr5:176349386	T/C	cg16309518	chr5:176445507	NA	-0.51	-11.2	-0.46	6.3e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs1003719	0.788	rs2835589	chr21:38463342	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2274273	1.000	rs8011834	chr14:55625977	A/C	cg04306507	chr14:55594613	LGALS3	0.61	17.12	0.62	2.79e-51	Protein biomarker;
LGG	trans	rs11098499	0.954	rs11940028	chr4:120411907	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	trans	rs2574985	0.813	rs1203409	chr10:52197195	C/G	cg18558237	chr10:81444220	LOC650623	0.43	6.67	0.3	7.14e-11	Subjective well-being;
LGG	cis	rs17125944	0.615	rs1886785	chr14:53312106	A/C	cg00686598	chr14:53173677	PSMC6	-0.7	-7.29	-0.32	1.31e-12	Alzheimer's disease (late onset);
LGG	cis	rs6495367	1.000	rs1007365	chr15:79379492	T/G	cg17916960	chr15:79447300	NA	0.51	9.05	0.39	3.99e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.82	0.3	2.81e-11	Longevity;
LGG	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs3796727	0.721	rs4696868	chr4:8618920	T/G	cg05284713	chr4:8621361	CPZ	-0.34	-6.89	-0.3	1.89e-11	Sporadic neuroblastoma;
LGG	cis	rs12738007	0.935	rs4654391	chr1:29493866	T/C	cg01115565	chr1:29584222	PTPRU	-0.28	-7.37	-0.32	7.88e-13	Schizophrenia;
LGG	cis	rs28735056	1.000	rs28735056	chr18:77622879	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-9.32	-0.4	4.94e-19	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs17824933	1.000	rs916813	chr11:60764028	A/G	cg16817237	chr11:60793675	NA	0.39	7.47	0.33	4.13e-13	Multiple sclerosis;
LGG	cis	rs7851660	0.714	rs723227	chr9:100669073	G/A	cg13688889	chr9:100608707	NA	-0.51	-9.72	-0.41	1.88e-20	Strep throat;
LGG	cis	rs2439831	0.850	rs56909447	chr15:44137618	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.75	0.38	4.14e-17	Lung cancer in ever smokers;
LGG	cis	rs7635838	0.617	rs346085	chr3:11282724	T/C	cg00170343	chr3:11313890	ATG7	0.56	9.78	0.41	1.18e-20	HDL cholesterol;
LGG	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg19455335	chr8:22457658	C8orf58	0.43	8.8	0.38	2.74e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg00701064	chr4:6280414	WFS1	0.72	15.99	0.6	4.01e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg18681998	chr4:17616180	MED28	-0.86	-19.41	-0.67	7.45e-62	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3008870	1.000	rs12117131	chr1:67451922	C/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs7945718	0.905	rs7949728	chr11:12728595	C/G	cg25843174	chr11:12811716	TEAD1	0.42	8.49	0.37	2.91e-16	Educational attainment (years of education);
LGG	cis	rs10832963	1.000	rs2084220	chr11:18656932	C/T	cg20219074	chr11:18656078	SPTY2D1	0.83	15.18	0.58	1.55e-42	Breast cancer;
LGG	cis	rs35160687	0.644	rs28488524	chr2:86511144	G/A	cg10973622	chr2:86423274	IMMT	-0.4	-7.22	-0.32	2.1e-12	Night sleep phenotypes;
LGG	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21659725	chr3:3221576	CRBN	-0.64	-11.89	-0.48	1.26e-28	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg04568710	chr12:38710424	ALG10B	0.35	7.1	0.31	4.81e-12	Heart rate;
LGG	cis	rs12282928	0.743	rs2202249	chr11:48200586	C/T	cg26585981	chr11:48327164	OR4S1	-0.41	-7.18	-0.32	2.8e-12	Migraine - clinic-based;
LGG	cis	rs7572644	0.699	rs10177845	chr2:28124171	G/A	cg27432699	chr2:27873401	GPN1	-0.45	-6.84	-0.3	2.57e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs910187	0.641	rs3818011	chr20:45816566	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.05	-0.39	4.09e-18	Migraine;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg25986240	chr4:9926439	SLC2A9	-0.45	-9.62	-0.41	4.44e-20	Bone mineral density;
LGG	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04850017	chr11:63683019	RCOR2	0.31	7.92	0.35	1.75e-14	Pulse pressure;
LGG	cis	rs2862064	1.000	rs1501910	chr5:156418790	A/G	cg12943317	chr5:156479607	HAVCR1	-0.83	-10.44	-0.44	4.7e-23	Platelet count;
LGG	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg11040518	chr10:102331378	NA	-0.41	-7.38	-0.32	7.52e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs34929064	0.536	rs2905307	chr7:22638963	A/G	cg23521230	chr7:22704884	NA	-0.43	-7.76	-0.34	5.59e-14	Major depression and alcohol dependence;
LGG	cis	rs2013441	1.000	rs2703774	chr17:20133538	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.49e-19	Obesity-related traits;
LGG	cis	rs62400317	0.859	rs10948226	chr6:45299174	G/C	cg18551225	chr6:44695536	NA	-0.61	-10.06	-0.42	1.18e-21	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs3008870	1.000	rs3008870	chr1:67418027	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.35	0.74	2.84e-80	Lymphocyte percentage of white cells;
LGG	cis	rs1023500	0.505	rs134901	chr22:42683520	C/T	cg04733989	chr22:42467013	NAGA	0.54	9.55	0.41	7.52e-20	Schizophrenia;
LGG	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.16	-0.49	9.84e-30	Bladder cancer;
LGG	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.94	-0.54	4.09e-37	Alzheimer's disease;
LGG	cis	rs6904897	0.563	rs6569976	chr6:135224753	A/C	cg24558204	chr6:135376177	HBS1L	0.5	8.65	0.37	8.82e-17	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.92	-0.62	2.51e-50	Height;
LGG	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg01028140	chr2:1542097	TPO	-0.55	-8.29	-0.36	1.22e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8031584	0.958	rs8034856	chr15:31240957	T/C	cg14829155	chr15:31115871	NA	-0.58	-10.13	-0.43	6.47e-22	Huntington's disease progression;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.21e-25	Aortic root size;
LGG	cis	rs9287719	0.967	rs11687023	chr2:10741412	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	trans	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg06521331	chr12:34319734	NA	0.45	8.04	0.35	7.66e-15	Bladder cancer;
LGG	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-12.1	-0.49	1.85e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs367943	0.666	rs6594703	chr5:112691999	A/G	cg12552261	chr5:112820674	MCC	0.57	10.14	0.43	6.03e-22	Type 2 diabetes;
LGG	trans	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg13010199	chr12:38710504	ALG10B	0.47	8.47	0.37	3.32e-16	Resting heart rate;
LGG	cis	rs9814567	1.000	rs13090969	chr3:134307257	C/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	trans	rs11039798	1.000	rs9667626	chr11:48485877	T/C	cg03929089	chr4:120376271	NA	0.74	8.52	0.37	2.32e-16	Axial length;
LGG	cis	rs4731207	0.596	rs6963594	chr7:124609233	C/T	cg05630886	chr7:124431682	NA	-0.29	-6.76	-0.3	4.15e-11	Cutaneous malignant melanoma;
LGG	cis	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg21453758	chr17:80185943	SLC16A3	0.33	7.05	0.31	6.35e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg00814883	chr7:100076585	TSC22D4	0.69	9.86	0.42	5.94e-21	Platelet count;
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-15.77	-0.59	3.64e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg23173402	chr1:227635558	NA	0.7	11.29	0.46	2.9e-26	Major depressive disorder;
LGG	cis	rs1401999	0.510	rs12634398	chr3:183708405	A/G	cg05044414	chr3:183734942	ABCC5	0.56	11.07	0.46	2.01e-25	Anterior chamber depth;
LGG	cis	rs4315565	0.764	rs4594480	chr2:69287998	G/A	cg13358873	chr2:69271042	ANTXR1	0.54	8.72	0.38	5.06e-17	Height;
LGG	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg13334819	chr7:99746414	C7orf59	-0.48	-7.22	-0.32	2.08e-12	Coronary artery disease;
LGG	cis	rs4631830	0.720	rs12763717	chr10:51500874	C/G	cg10326726	chr10:51549505	MSMB	0.64	12.91	0.51	9.09e-33	Prostate-specific antigen levels;
LGG	cis	rs12618769	0.625	rs4850878	chr2:99112180	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs34929064	0.781	rs2905324	chr7:22709003	A/C	cg18045685	chr7:22629474	NA	0.54	9.98	0.42	2.22e-21	Major depression and alcohol dependence;
LGG	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg25986240	chr4:9926439	SLC2A9	0.76	17.2	0.62	1.23e-51	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg24247370	chr13:99142703	STK24	-0.37	-6.87	-0.3	2.11e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.19	-0.46	6.87e-26	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	1.96e-17	Alzheimer's disease;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg02158880	chr13:53174818	NA	-0.41	-8.1	-0.35	4.85e-15	Lewy body disease;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.45	8.24	0.36	1.83e-15	Longevity;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.09	-0.35	5.3e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6477694	0.651	rs2417998	chr9:111958746	C/G	cg14171727	chr9:111936775	EPB41L4B	-0.34	-7.37	-0.32	8.12e-13	Body mass index;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs972578	0.765	rs2267461	chr22:43269547	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.93	-0.31	1.45e-11	Mean platelet volume;
LGG	cis	rs3796352	1.000	rs11720191	chr3:53013839	T/C	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10895140	0.665	rs12365805	chr11:101503132	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs4363385	0.693	rs56347903	chr1:152932175	T/G	cg13444842	chr1:152974279	SPRR3	-0.4	-7.56	-0.33	2.14e-13	Inflammatory skin disease;
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.559	rs17428126	chr7:106897037	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.77	-0.45	2.82e-24	Coronary artery disease;
LGG	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg19455335	chr8:22457658	C8orf58	-0.45	-9.28	-0.4	6.47e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg13147721	chr7:65941812	NA	-0.84	-10.16	-0.43	4.94e-22	Diabetic kidney disease;
LGG	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.66e-18	Alzheimer's disease;
LGG	cis	rs870825	0.616	rs4616798	chr4:185634144	C/T	cg04058563	chr4:185651563	MLF1IP	-1.02	-22.63	-0.72	6.64e-77	Blood protein levels;
LGG	cis	rs7741085	0.967	rs4711794	chr6:44635852	C/A	cg18551225	chr6:44695536	NA	0.44	7.4	0.33	6.2800000000000005e-13	Total body bone mineral density;
LGG	cis	rs7444	0.941	rs1034329	chr22:21943938	T/C	cg05046821	chr22:21984468	YDJC	-0.38	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg26513180	chr16:89883248	FANCA	0.95	20.36	0.69	2.89e-66	Schizophrenia;
LGG	cis	rs1322639	0.614	rs6925188	chr6:169563337	T/C	cg03254818	chr6:169586852	NA	0.5	7.79	0.34	4.38e-14	Pulse pressure;
LGG	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg27572855	chr1:25598939	RHD	-0.5	-11.2	-0.46	6.23e-26	Erythrocyte sedimentation rate;
LGG	cis	rs10979	0.679	rs9496680	chr6:143896915	G/A	cg25407410	chr6:143891975	LOC285740	-0.64	-10.21	-0.43	3.32e-22	Hypospadias;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg14338887	chr6:42928500	GNMT	0.27	8.75	0.38	3.96e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11874712	0.505	rs12961167	chr18:43635780	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.66	-15.5	-0.58	6.21e-44	Migraine - clinic-based;
LGG	cis	rs4595586	0.545	rs3914596	chr12:39388538	T/C	cg13010199	chr12:38710504	ALG10B	0.42	7.48	0.33	3.79e-13	Morning vs. evening chronotype;
LGG	cis	rs13031619	0.660	rs35668314	chr2:3702673	C/T	cg01268866	chr2:3683757	COLEC11	0.43	6.71	0.3	5.65e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.54	-9.46	-0.4	1.58e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9303401	0.614	rs56284918	chr17:57178838	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.58	0.53	1.38e-35	Cognitive test performance;
LGG	trans	rs11875185	0.510	rs75921686	chr18:55598249	A/G	cg15513957	chr14:69354734	ACTN1	-0.91	-8.62	-0.37	1.05e-16	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3733585	0.673	rs9994937	chr4:9964799	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.48e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg05025164	chr4:1340916	KIAA1530	0.45	7.66	0.34	1.08e-13	Obesity-related traits;
LGG	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg21926883	chr2:100939477	LONRF2	0.53	10.23	0.43	2.77e-22	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.56	-0.33	2.19e-13	Obesity-related traits;
LGG	cis	rs9303401	0.614	rs34678056	chr17:57177549	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.58	0.53	1.38e-35	Cognitive test performance;
LGG	cis	rs7582720	1.000	rs114079739	chr2:203825106	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs3733585	0.577	rs5014939	chr4:9953253	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs970548	0.779	rs11239532	chr10:45964505	C/T	cg14222797	chr10:16859974	RSU1	-0.64	-7.5	-0.33	3.26e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg05861140	chr6:150128134	PCMT1	-0.45	-10.4	-0.44	6.66e-23	Lung cancer;
LGG	cis	rs7106204	0.534	rs1443050	chr11:24275162	C/T	ch.11.24196551F	chr11:24239977	NA	0.84	8.62	0.37	1.06e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg02297831	chr4:17616191	MED28	0.5	9.53	0.41	8.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.54	-0.44	1.93e-23	Lung cancer;
LGG	cis	rs832540	0.656	rs832573	chr5:56159578	T/C	cg12654349	chr5:56205094	C5orf35	-0.39	-6.93	-0.31	1.43e-11	Coronary artery disease;
LGG	cis	rs2011503	1.000	rs2965181	chr19:19512317	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.65	0.3	8.05e-11	Bipolar disorder;
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg22398616	chr13:53314203	LECT1	-0.49	-9.88	-0.42	4.93e-21	Lewy body disease;
LGG	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg22232500	chr2:134024266	NCKAP5	0.67	9.21	0.39	1.13e-18	Bipolar disorder;
LGG	cis	rs17818399	0.547	rs4952833	chr2:46762034	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.56	8.45	0.37	3.8e-16	Height;
LGG	cis	rs4481887	0.708	rs6696691	chr1:248539720	T/C	cg00666640	chr1:248458726	OR2T12	0.54	9.1	0.39	2.79e-18	Common traits (Other);
LGG	cis	rs13421350	0.579	rs6730284	chr2:173401666	C/T	cg15021238	chr2:173305865	ITGA6	-0.75	-8.23	-0.36	1.87e-15	Diabetic kidney disease;
LGG	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.92	-0.38	1.13e-17	Aortic root size;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	7.42	0.33	5.47e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs12220238	1.000	rs10824083	chr10:75911342	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.75	0.48	4.56e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg14664628	chr15:75095509	CSK	-0.54	-10.35	-0.43	1.03e-22	Breast cancer;
LGG	cis	rs477895	1.000	rs66968227	chr11:64070930	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.72	8.24	0.36	1.78e-15	Mean platelet volume;
LGG	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.67	-0.34	1e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.65e-14	Resting heart rate;
LGG	cis	rs4700695	0.614	rs371246	chr5:65209126	G/A	cg21114390	chr5:65439923	SFRS12	0.62	7.0	0.31	9.06e-12	Facial morphology (factor 19);
LGG	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg16339924	chr4:17578868	LAP3	0.6	10.51	0.44	2.67e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.4	0.61	5.6e-48	Lymphocyte counts;
LGG	trans	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg01134436	chr17:81009848	B3GNTL1	0.83	8.68	0.37	7.01e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs62400317	0.859	rs12206561	chr6:45182809	C/T	cg18551225	chr6:44695536	NA	-0.63	-9.97	-0.42	2.39e-21	Total body bone mineral density;
LGG	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.66	0.63	9.9e-54	Vitiligo;
LGG	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.39	0.36	6.1e-16	Fuchs's corneal dystrophy;
LGG	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg23933602	chr10:16859644	RSU1	0.84	16.03	0.6	2.64e-46	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg11673840	chr17:47092156	IGF2BP1	-0.39	-6.82	-0.3	2.78e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25804072	chr2:10829725	NOL10	0.43	6.7	0.3	6.19e-11	Gut microbiome composition (summer);
LGG	cis	rs2013441	1.000	rs2120282	chr17:20209474	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg09021430	chr5:549028	NA	-0.87	-21.08	-0.7	1.19e-69	Obesity-related traits;
LGG	cis	rs7267979	0.816	rs6037158	chr20:25595466	C/A	cg06421707	chr20:25228305	PYGB	0.44	9.21	0.39	1.18e-18	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08366952	chr3:101293020	PCNP	-0.37	-6.72	-0.3	5.38e-11	Brain structure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17059624	chr11:85358760	TMEM126A	0.39	6.9	0.31	1.74e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.15	0.46	9.68e-26	Corneal astigmatism;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.23	-0.32	2.07e-12	Lung cancer;
LGG	cis	rs988958	0.600	rs34917148	chr2:42217721	G/T	cg19376973	chr2:42229025	NA	0.63	9.54	0.41	8.25e-20	Hypospadias;
LGG	trans	rs62458065	0.640	rs10241303	chr7:32534203	T/G	cg00845942	chr12:64062724	DPY19L2	-0.61	-7.65	-0.33	1.19e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.19	0.36	2.59e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1797081	0.811	rs1797076	chr10:16853076	A/G	cg23933602	chr10:16859644	RSU1	0.94	23.22	0.73	1.19e-79	Platelet distribution width;
LGG	cis	rs9910055	0.529	rs190144	chr17:42164584	A/G	cg16434002	chr17:42200994	HDAC5	0.45	7.97	0.35	1.22e-14	Total body bone mineral density;
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.91	-0.31	1.61e-11	Triglycerides;
LGG	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg23933602	chr10:16859644	RSU1	0.74	12.38	0.5	1.26e-30	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2404602	0.692	rs7163397	chr15:76940315	A/G	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs12681288	0.862	rs2701898	chr8:1020812	C/T	cg04851639	chr8:1020857	NA	-0.46	-9.94	-0.42	3.03e-21	Schizophrenia;
LGG	trans	rs853679	1.000	rs1679732	chr6:28221264	G/A	cg08344181	chr3:125677491	NA	0.56	7.28	0.32	1.45e-12	Depression;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00149659	chr3:10157352	C3orf10	1.2	13.85	0.54	9.54e-37	Alzheimer's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17310611	chr1:113615709	LRIG2	0.38	7.1	0.31	4.7e-12	Obesity-related traits;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.32	-0.5	2.34e-30	Lymphocyte counts;
LGG	cis	rs939658	0.805	rs34222382	chr15:79440748	C/T	cg17916960	chr15:79447300	NA	-0.66	-12.92	-0.51	8.17e-33	Refractive error;
LGG	cis	rs4075765	0.764	rs56321250	chr11:26264859	C/T	cg19182008	chr11:26298241	NA	0.99	8.79	0.38	3e-17	Cannabis dependence symptom count;
LGG	cis	rs9287719	0.967	rs7600820	chr2:10740044	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg09904177	chr6:26538194	HMGN4	0.63	11.98	0.49	5.59e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6834538	0.597	rs13146963	chr4:113558602	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.37	0.36	7.13e-16	Free thyroxine concentration;
LGG	cis	rs1816752	0.905	rs9511260	chr13:25011176	T/C	cg02811702	chr13:24901961	NA	0.41	7.69	0.34	8.76e-14	Obesity-related traits;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg17178900	chr1:205818956	PM20D1	0.69	16.54	0.61	1.22e-48	Menarche (age at onset);
LGG	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg02733842	chr7:1102375	C7orf50	-0.47	-7.72	-0.34	7.24e-14	Bronchopulmonary dysplasia;
LGG	cis	rs1942	1.000	rs1942	chr15:41774423	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.53	-9.24	-0.39	9.14e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs1595825	1.000	rs1304165	chr2:198877300	G/A	cg00982548	chr2:198649783	BOLL	-0.48	-6.68	-0.3	7e-11	Ulcerative colitis;
LGG	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs9868809	0.505	rs13063223	chr3:48750340	G/A	cg00383909	chr3:49044727	WDR6	0.92	11.51	0.47	3.81e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs506338	0.517	rs1207179	chr11:64450795	C/T	cg19395706	chr11:64412079	NRXN2	0.41	8.02	0.35	8.77e-15	Body mass index;Urate levels;
LGG	cis	rs367943	1.000	rs348948	chr5:112822452	A/C	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.83	-0.3	2.69e-11	Aortic root size;
LGG	cis	rs1348850	0.558	rs4337505	chr2:178529714	A/T	cg27490568	chr2:178487706	NA	0.51	10.13	0.43	6.52e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2236267	0.726	rs4904428	chr14:88610516	T/C	cg02175263	chr14:88627849	NA	0.33	7.33	0.32	1.04e-12	Food antigen IgG levels;
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg02002194	chr4:3960332	NA	0.46	8.83	0.38	2.19e-17	Mood instability;
LGG	cis	rs2916247	1.000	rs4734170	chr8:93051254	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.31	-0.36	1.09e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7589342	0.831	rs11124062	chr2:106455967	G/A	cg14210321	chr2:106509881	NCK2	-0.52	-9.08	-0.39	3.24e-18	Addiction;
LGG	cis	rs11585357	0.895	rs2977305	chr1:17613737	A/T	cg08277548	chr1:17600880	PADI3	0.69	7.86	0.34	2.63e-14	Hair shape;
LGG	cis	rs2133450	0.836	rs9833636	chr3:7316928	C/G	cg19930620	chr3:7340148	GRM7	-0.37	-8.08	-0.35	5.72e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs41278232	1.000	rs67080992	chr20:62676243	A/G	cg03065311	chr20:62601662	ZNF512B	0.61	8.97	0.38	7.56e-18	Tonsillectomy;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.32	0.47	2.07e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11245990	chr11:68621969	NA	0.44	9.12	0.39	2.37e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18145393	chr4:520203	PIGG	0.39	6.73	0.3	4.91e-11	Menarche (age at onset);
LGG	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg06606381	chr12:133084897	FBRSL1	0.97	10.49	0.44	3.14e-23	Depression;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg14500267	chr11:67383377	NA	0.41	7.82	0.34	3.52e-14	Mean corpuscular volume;
LGG	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg11502198	chr6:26597334	ABT1	0.58	10.02	0.42	1.67e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9595066	1.000	rs66786230	chr13:44711625	T/C	cg04068111	chr13:44716778	NA	-0.57	-7.9	-0.34	2.11e-14	Schizophrenia;
LGG	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg24375607	chr4:120327624	NA	0.64	10.55	0.44	1.9e-23	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg13699009	chr12:122356056	WDR66	0.57	15.89	0.59	1.1e-45	Mean corpuscular volume;
LGG	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg02002194	chr4:3960332	NA	-0.47	-8.35	-0.36	8.08e-16	Systolic blood pressure;
LGG	cis	rs3849570	1.000	rs9818006	chr3:81828230	A/C	cg07356753	chr3:81810745	GBE1	-0.42	-7.26	-0.32	1.65e-12	Waist circumference;Body mass index;
LGG	cis	rs1620921	0.505	rs1991598	chr6:161204488	G/A	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg07303275	chr16:75499416	TMEM170A	0.38	6.94	0.31	1.34e-11	Dupuytren's disease;
LGG	cis	rs9486719	1.000	rs2499809	chr6:96870110	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs4650994	0.623	rs12121188	chr1:178622499	G/A	cg19399532	chr1:178512495	C1orf220	-0.37	-6.86	-0.3	2.25e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.66	-0.54	6.05e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs10851411	0.697	rs8039240	chr15:42817577	A/C	cg21293051	chr15:42870591	STARD9	0.48	6.93	0.31	1.39e-11	Glucose homeostasis traits;
LGG	cis	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.47e-12	Retinal vascular caliber;
LGG	cis	rs1465370	0.720	rs5011387	chr7:130017149	C/T	cg06917763	chr7:130033247	NA	0.33	7.23	0.32	2.02e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06656553	chr16:89960601	TCF25	-0.73	-7.12	-0.31	4.14e-12	Skin colour saturation;
LGG	trans	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.33	-0.36	9.36e-16	Bone mineral density;
LGG	cis	rs8017423	0.967	rs11624725	chr14:90713609	G/T	cg04374321	chr14:90722782	PSMC1	-0.87	-18.09	-0.64	9.85e-56	Mortality in heart failure;
LGG	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg26384229	chr12:38710491	ALG10B	0.56	10.17	0.43	4.62e-22	Morning vs. evening chronotype;
LGG	cis	rs2573652	0.674	rs11630583	chr15:100543355	G/A	cg14911520	chr15:100542628	ADAMTS17	-0.29	-7.11	-0.31	4.46e-12	Height;
LGG	cis	rs10540	1.000	rs12801148	chr11:511707	T/G	cg19913688	chr11:428466	ANO9	-0.68	-8.31	-0.36	1.1e-15	Body mass index;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg05025164	chr4:1340916	KIAA1530	-0.57	-10.11	-0.43	7.79e-22	Obesity-related traits;
LGG	cis	rs8177253	0.507	rs4241357	chr3:133475563	A/C	cg16414030	chr3:133502952	NA	0.45	7.66	0.34	1.09e-13	Iron status biomarkers;
LGG	cis	rs12681366	0.620	rs2930968	chr8:95462695	C/T	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg02158880	chr13:53174818	NA	0.47	9.58	0.41	5.88e-20	Lewy body disease;
LGG	trans	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.61	-10.55	-0.44	1.79e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7572733	0.935	rs700669	chr2:198684467	G/A	cg00792783	chr2:198669748	PLCL1	0.48	8.24	0.36	1.84e-15	Dermatomyositis;
LGG	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg00711542	chr16:29343894	RUNDC2C	-0.42	-7.08	-0.31	5.48e-12	Menopause (age at onset);
LGG	cis	rs1046896	0.594	rs8070403	chr17:80865404	A/G	cg02711726	chr17:80685570	FN3KRP	-0.56	-9.78	-0.41	1.12e-20	Glycated hemoglobin levels;
LGG	cis	rs7614311	0.681	rs60505027	chr3:63844966	T/A	cg22134162	chr3:63841271	THOC7	-0.36	-7.11	-0.31	4.49e-12	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs9649213	0.559	rs56997921	chr7:98009224	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.34	-0.36	8.84e-16	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg13010199	chr12:38710504	ALG10B	0.46	8.89	0.38	1.39e-17	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg17294928	chr15:75287854	SCAMP5	0.66	12.0	0.49	4.42e-29	Caffeine consumption;
LGG	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg08807101	chr21:30365312	RNF160	-0.68	-11.67	-0.48	8.89e-28	Cognitive test performance;
LGG	cis	rs4237845	0.537	rs9645819	chr12:58270063	T/C	cg00677455	chr12:58241039	CTDSP2	0.41	7.6	0.33	1.69e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.37	-0.32	7.73e-13	Mood instability;
LGG	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg01221209	chr5:554886	NA	-0.45	-6.68	-0.3	6.72e-11	Obesity-related traits;
LGG	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg25706281	chr1:46860511	FAAH	-0.29	-7.14	-0.32	3.53e-12	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs2461702	chr15:45647427	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.33	-0.32	1.05e-12	Testicular germ cell tumor;
LGG	trans	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg02002194	chr4:3960332	NA	0.38	6.79	0.3	3.44e-11	Mood instability;
LGG	cis	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg02951883	chr7:2050386	MAD1L1	0.66	12.8	0.51	2.52e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg26441486	chr22:50317300	CRELD2	-0.42	-7.65	-0.33	1.19e-13	Schizophrenia;
LGG	cis	rs1348850	0.837	rs4243388	chr2:178284604	T/G	cg27490568	chr2:178487706	NA	0.51	10.16	0.43	5.15e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2404602	0.735	rs11857015	chr15:76649390	T/C	cg23625390	chr15:77176239	SCAPER	-0.65	-12.99	-0.52	3.91e-33	Blood metabolite levels;
LGG	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg06848047	chr4:90757629	SNCA	0.35	6.65	0.3	8.51e-11	Dementia with Lewy bodies;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.58	9.69	0.41	2.35e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs1371867	0.846	rs1788180	chr8:101333368	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg27165867	chr14:105738592	BRF1	0.46	8.18	0.36	2.72e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.88e-13	Menopause (age at onset);
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg13126279	chr21:47581558	C21orf56	-0.52	-9.44	-0.4	1.76e-19	Testicular germ cell tumor;
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.93e-31	Lymphocyte counts;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg02158880	chr13:53174818	NA	0.4	7.74	0.34	6.43e-14	Lewy body disease;
LGG	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg24006582	chr15:45444508	DUOX1	-0.71	-13.64	-0.54	7.67e-36	Uric acid levels;
LGG	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg26924012	chr15:45694286	SPATA5L1	1.06	23.09	0.73	4.66e-79	Homoarginine levels;
LGG	cis	rs1878931	0.507	rs8054222	chr16:3413477	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.68	-10.32	-0.43	1.27e-22	Body mass index (adult);
LGG	cis	rs806215	0.901	rs989100	chr7:127220918	T/C	cg25922125	chr7:127225783	GCC1	-0.81	-10.9	-0.45	9.12e-25	Type 2 diabetes;
LGG	cis	rs2427308	0.607	rs1741635	chr20:60938197	C/G	cg06026331	chr20:60912101	LAMA5	-0.71	-12.29	-0.5	3.15e-30	Colorectal cancer;
LGG	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.74	0.38	4.16e-17	Systemic lupus erythematosus;
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg24397884	chr7:158709396	WDR60	0.89	18.38	0.65	4.56e-57	Height;
LGG	trans	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg08344181	chr3:125677491	NA	-0.52	-6.65	-0.3	8.49e-11	Lung cancer in ever smokers;
LGG	trans	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg23484912	chr5:273055	PDCD6	-0.39	-7.73	-0.34	6.68e-14	Mean corpuscular volume;
LGG	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg10760299	chr15:45669010	GATM	0.41	8.1	0.35	4.85e-15	Homoarginine levels;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.08	0.35	5.85e-15	Longevity;
LGG	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg12856521	chr11:46389249	DGKZ	-0.5	-9.07	-0.39	3.43e-18	Leprosy;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.09e-19	Obesity-related traits;
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg17554472	chr22:41940697	POLR3H	0.47	7.0	0.31	9.17e-12	Vitiligo;
LGG	cis	rs1371867	0.513	rs1542812	chr8:101207064	G/A	cg06636551	chr8:101224915	SPAG1	0.6	11.82	0.48	2.31e-28	Atrioventricular conduction;
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.45	0.4	1.64e-19	Bipolar disorder;
LGG	trans	rs3758785	0.512	rs79702466	chr11:94101196	C/T	cg14656441	chr1:39500070	NDUFS5	-0.3	-6.8	-0.3	3.33e-11	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LGG	cis	rs28374715	0.662	rs691906	chr15:41474636	T/A	cg18705301	chr15:41695430	NDUFAF1	1.0	17.93	0.64	5.47e-55	Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01272081	chr9:32551527	TOPORS	0.45	7.84	0.34	3.04e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg15704280	chr7:45808275	SEPT13	-0.7	-11.0	-0.46	3.53e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg15971980	chr6:150254442	NA	-0.45	-7.15	-0.32	3.46e-12	Lung cancer;
LGG	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.66	-0.48	1.02e-27	Schizophrenia;
LGG	cis	rs9549367	0.826	rs2302755	chr13:113898418	C/T	cg00898013	chr13:113819073	PROZ	-0.41	-8.48	-0.37	2.96e-16	Platelet distribution width;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.84	-0.38	1.95e-17	Neuroticism;
LGG	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.0	11.19	0.46	6.79e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7939886	0.920	rs7934132	chr11:55942463	T/A	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs9790314	1.000	rs163328	chr3:161073599	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-11.11	-0.46	1.35e-25	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs9677476	0.863	rs11558174	chr2:232072912	T/C	cg14237567	chr2:232057245	NA	-0.33	-6.81	-0.3	3e-11	Food antigen IgG levels;
LGG	cis	rs7192750	0.539	rs7193731	chr16:71897399	T/C	cg06353428	chr16:71660113	MARVELD3	0.66	10.46	0.44	4.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs992157	0.560	rs12992937	chr2:219087072	A/T	cg00012203	chr2:219082015	ARPC2	-0.76	-14.58	-0.56	7.05e-40	Colorectal cancer;
LGG	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.91	-0.35	1.88e-14	Myopia (pathological);
LGG	cis	rs13102973	0.640	rs11722290	chr4:135832268	C/T	cg14419869	chr4:135874104	NA	0.51	9.46	0.4	1.54e-19	Subjective well-being;
LGG	trans	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.53	9.62	0.41	4.17e-20	Brugada syndrome;
LGG	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg09165964	chr15:75287851	SCAMP5	-1.02	-19.87	-0.68	5.35e-64	Blood trace element (Zn levels);
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.69	-11.94	-0.49	7.91e-29	Longevity;Endometriosis;
LGG	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg18245976	chr7:158708271	WDR60	0.44	7.47	0.33	4.04e-13	Height;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg00405596	chr8:11794950	NA	-0.43	-7.21	-0.32	2.32e-12	Neuroticism;
LGG	cis	rs870825	0.585	rs2696039	chr4:185610899	T/C	cg04058563	chr4:185651563	MLF1IP	-0.99	-19.93	-0.68	2.75e-64	Blood protein levels;
LGG	cis	rs7044106	0.537	rs10739573	chr9:123489818	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.46	6.92	0.31	1.52e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg21775007	chr8:11205619	TDH	0.44	7.22	0.32	2.19e-12	Mood instability;
LGG	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg19992207	chr2:111874495	ACOXL	-0.38	-6.94	-0.31	1.35e-11	Chronic lymphocytic leukemia;
LGG	cis	rs193541	0.530	rs9327272	chr5:122073548	T/C	cg19412675	chr5:122181750	SNX24	0.49	7.87	0.34	2.53e-14	Glucose homeostasis traits;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.04	-0.46	2.56e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs3815700	0.920	rs10426856	chr19:33096406	A/G	cg02997394	chr19:33096574	ANKRD27	0.85	13.56	0.53	1.6e-35	Eosinophilic esophagitis;
LGG	trans	rs3858145	0.588	rs731063	chr10:70043190	A/G	cg04882175	chr6:131122610	NA	0.57	8.19	0.36	2.51e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs4268898	0.662	rs35624938	chr2:24576651	T/C	cg06627628	chr2:24431161	ITSN2	-0.78	-12.56	-0.5	2.41e-31	Asthma;
LGG	trans	rs9329221	0.618	rs73197281	chr8:10263282	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.49	-0.37	2.74e-16	Neuroticism;
LGG	cis	rs734999	0.572	rs2985857	chr1:2532624	C/T	cg18854424	chr1:2615690	NA	-0.35	-7.13	-0.31	3.79e-12	Ulcerative colitis;
LGG	cis	rs757978	0.733	rs11689496	chr2:242426399	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.62	-7.15	-0.32	3.39e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg05692746	chr2:100937584	LONRF2	-0.49	-8.32	-0.36	9.69e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6668534	0.679	rs10753610	chr1:161663823	C/G	cg26156167	chr1:161582651	NA	0.39	6.71	0.3	5.7e-11	Blood protein levels;
LGG	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg25427524	chr10:38739819	LOC399744	-0.63	-12.9	-0.51	9.34e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.48	-8.31	-0.36	1.1e-15	Longevity;Endometriosis;
LGG	cis	rs58688157	0.774	rs59115876	chr11:613757	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.5	-0.4	1.17e-19	Systemic lupus erythematosus;
LGG	cis	rs6500395	1.000	rs1558817	chr16:48730722	G/A	cg16662043	chr16:48846231	NA	0.38	7.39	0.32	6.71e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg01472538	chr16:58549086	SETD6	0.98	8.84	0.38	2.07e-17	Schizophrenia;
LGG	cis	rs2282802	0.685	rs6889283	chr5:139653439	G/T	cg26211634	chr5:139558579	C5orf32	0.34	7.57	0.33	1.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7717393	0.786	rs10038418	chr5:155792943	T/C	cg04435420	chr5:155754009	SGCD	0.71	9.15	0.39	1.83e-18	Egg allergy;
LGG	cis	rs4950322	0.542	rs1932977	chr1:146688941	A/G	cg22381352	chr1:146742008	CHD1L	-0.43	-7.34	-0.32	9.92e-13	Protein quantitative trait loci;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.38	0.43	7.5e-23	Mean platelet volume;
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg12432903	chr7:1882776	MAD1L1	0.45	7.03	0.31	7.54e-12	Bipolar disorder;
LGG	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Myopia (pathological);
LGG	cis	rs5995756	0.666	rs926231	chr22:40006986	C/G	cg21377881	chr22:40064566	CACNA1I	-0.33	-6.82	-0.3	2.8e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	13.77	0.54	2.14e-36	Platelet count;
LGG	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.65	-0.41	3.51e-20	Aortic root size;
LGG	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg02297831	chr4:17616191	MED28	0.5	9.44	0.4	1.88e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.71	12.19	0.49	7.75e-30	Response to antipsychotic treatment;
LGG	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs36051895	0.559	rs72701680	chr9:5207294	A/T	cg02405213	chr9:5042618	JAK2	-0.62	-11.0	-0.46	3.53e-25	Pediatric autoimmune diseases;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg27400746	chr16:89904261	SPIRE2	-0.92	-14.08	-0.55	1.01e-37	Skin colour saturation;
LGG	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-9.78	-0.41	1.13e-20	Menarche (age at onset);
LGG	cis	rs9916302	0.904	rs7223438	chr17:37521355	T/C	cg07936489	chr17:37558343	FBXL20	0.84	15.6	0.59	2.08e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1030877	1.000	rs2241797	chr2:105885961	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.74	14.83	0.57	5.61e-41	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg06634786	chr22:41940651	POLR3H	0.79	12.43	0.5	8.24e-31	Vitiligo;
LGG	cis	rs4819052	1.000	rs9984901	chr21:46663952	C/T	cg06618935	chr21:46677482	NA	-0.52	-9.33	-0.4	4.41e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4789452	0.655	rs2001613	chr17:75383679	C/T	cg06761530	chr17:75373219	SEPT9	-0.38	-7.3	-0.32	1.25e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	trans	rs34421088	0.623	rs4841515	chr8:11097166	C/T	cg02002194	chr4:3960332	NA	0.44	7.59	0.33	1.72e-13	Neuroticism;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg08888203	chr3:10149979	C3orf24	-0.53	-8.95	-0.38	8.53e-18	Alzheimer's disease;
LGG	cis	rs713587	0.525	rs1541984	chr2:25082414	G/A	cg04586622	chr2:25135609	ADCY3	0.41	10.99	0.46	3.84e-25	Body mass index in non-asthmatics;
LGG	trans	rs7939886	0.920	rs11227434	chr11:55945251	G/T	cg03929089	chr4:120376271	NA	0.74	6.8	0.3	3.15e-11	Myopia (pathological);
LGG	cis	rs1953600	0.687	rs3851054	chr10:81933306	A/G	cg04850286	chr10:81895943	PLAC9	0.33	7.25	0.32	1.8e-12	Sarcoidosis;
LGG	cis	rs10791097	0.739	rs12279359	chr11:130730544	G/A	cg12179176	chr11:130786555	SNX19	0.77	14.74	0.57	1.36e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg19524238	chr7:2802976	GNA12	0.37	8.21	0.36	2.18e-15	Height;
LGG	cis	rs757278	0.564	rs2079178	chr7:117363795	G/C	cg10524701	chr7:117356490	CTTNBP2	0.44	7.31	0.32	1.16e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.39	0.43	7.23e-23	Mood instability;
LGG	cis	rs2073300	1.000	rs6137983	chr20:23469465	C/A	cg12062639	chr20:23401060	NAPB	0.89	7.19	0.32	2.62e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs60180747	0.909	rs11629783	chr15:66741387	C/G	cg07575407	chr15:66541975	MEGF11	-0.38	-7.41	-0.33	6.1e-13	Testicular germ cell tumor;
LGG	cis	rs9811920	0.683	rs4928230	chr3:99661963	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-7.47	-0.33	4.04e-13	Axial length;
LGG	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg06138931	chr13:21896616	NA	-0.43	-7.15	-0.32	3.42e-12	White matter hyperintensity burden;
LGG	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg24812749	chr6:127587940	RNF146	0.59	10.06	0.42	1.13e-21	Breast cancer;
LGG	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.21	-0.32	2.35e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	1e-35	Lung cancer;
LGG	cis	rs2304069	0.954	rs9324640	chr5:149413186	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.85	-12.91	-0.51	8.71e-33	HIV-1 control;
LGG	cis	rs9393813	1.000	rs12663650	chr6:27366821	C/A	cg18711553	chr6:27366782	ZNF391	-0.53	-10.41	-0.44	6e-23	Bipolar disorder;
LGG	cis	rs9397585	0.676	rs9479496	chr6:153398110	T/C	cg17707550	chr6:153380415	RGS17	-0.45	-9.7	-0.41	2.31e-20	Body mass index;
LGG	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.57	10.82	0.45	1.84e-24	Aortic root size;
LGG	cis	rs4787491	0.765	rs4788216	chr16:30048077	C/G	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	2.97e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg17054900	chr3:154042577	DHX36	0.49	7.44	0.33	4.82e-13	Coronary artery disease;
LGG	trans	rs1814175	0.935	rs11040462	chr11:49683158	G/A	cg15704280	chr7:45808275	SEPT13	-1.04	-23.67	-0.74	8.93e-82	Height;
LGG	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg23752985	chr2:85803571	VAMP8	0.44	8.76	0.38	3.57e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.38e-12	Aortic root size;
LGG	cis	rs6142618	0.562	rs1321415	chr20:30744218	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg20494108	chr6:42981763	MEA1;KLHDC3	-0.41	-6.98	-0.31	1.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4851254	0.660	rs10209201	chr2:100672808	C/T	cg17356467	chr2:100759845	AFF3	0.46	7.41	0.33	6.01e-13	Intelligence (multi-trait analysis);
LGG	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg20744362	chr22:50050164	C22orf34	0.4	7.09	0.31	5.07e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg05025159	chr2:241905733	NA	0.46	9.46	0.4	1.6e-19	Joint mobility (Beighton score);
LGG	cis	rs644799	0.965	rs11021310	chr11:95502106	A/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg10523679	chr1:76189770	ACADM	0.8	13.82	0.54	1.35e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg09163369	chr1:210001066	C1orf107	-0.41	-7.13	-0.31	3.9e-12	Orofacial clefts;
LGG	trans	rs7647973	0.588	rs62262675	chr3:49673662	A/G	cg21659725	chr3:3221576	CRBN	0.56	7.02	0.31	7.89e-12	Menarche (age at onset);
LGG	trans	rs11976180	1.000	rs1533267	chr7:143766440	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.85	-0.3	2.4e-11	Obesity-related traits;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg04025307	chr7:1156635	C7orf50	-0.84	-17.54	-0.63	3.38e-53	Longevity;Endometriosis;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg26174226	chr8:58114915	NA	-0.53	-7.9	-0.34	2.03e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1256061	0.603	rs1152579	chr14:64695087	A/G	cg23250157	chr14:64679961	SYNE2	0.4	7.22	0.32	2.11e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22857025	chr5:266934	NA	-1.52	-26.72	-0.78	7.32e-96	Breast cancer;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.35	-0.47	1.58e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-11.08	-0.46	1.78e-25	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.890	rs1197560	chr12:34121447	G/C	cg06521331	chr12:34319734	NA	-0.42	-7.75	-0.34	5.77e-14	Morning vs. evening chronotype;
LGG	cis	rs6500637	0.580	rs2660243	chr16:4941397	A/G	cg04440724	chr16:4920505	UBN1	0.66	12.64	0.51	1.13e-31	Cancer;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg06112835	chr11:68658793	MRPL21	0.63	10.3	0.43	1.5e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.82	0.3	2.81e-11	Parkinson's disease;
LGG	cis	rs10463554	0.927	rs257311	chr5:102419098	C/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs754205	0.561	rs9515116	chr13:110397663	C/T	cg05430997	chr13:110397189	NA	-0.47	-8.22	-0.36	2.06e-15	Reticulocyte fraction of red cells;
LGG	cis	rs17767392	0.846	rs12127	chr14:71956270	T/C	cg02058870	chr14:72053146	SIPA1L1	0.39	8.14	0.35	3.67e-15	Mitral valve prolapse;
LGG	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg08085267	chr17:45401833	C17orf57	0.52	9.7	0.41	2.21e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs28595532	0.920	rs114639588	chr4:119736176	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs77741769	0.529	rs12579868	chr12:121207147	C/T	cg02419362	chr12:121203948	SPPL3	0.56	9.67	0.41	2.83e-20	Mean corpuscular volume;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg12419862	chr22:24373484	LOC391322	-0.99	-21.14	-0.7	5.96e-70	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	0.39	6.67	0.3	7.32e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.55	-0.33	2.29e-13	Neuroticism;
LGG	cis	rs4423214	0.959	rs12800438	chr11:71171003	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.06	-0.52	2.09e-33	Vitamin D levels;
LGG	cis	rs4684776	1.000	rs12107920	chr3:11540486	G/A	cg24705426	chr3:11550659	ATG7	-0.47	-8.41	-0.36	4.97e-16	Small vessel stroke;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11037719	chr6:2999695	NQO2	0.51	8.56	0.37	1.66e-16	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg10505658	chr17:80084571	CCDC57	-0.4	-8.15	-0.35	3.53e-15	Life satisfaction;
LGG	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg23205692	chr1:25664452	TMEM50A	0.49	10.25	0.43	2.27e-22	Erythrocyte sedimentation rate;
LGG	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg01017244	chr2:74357527	NA	0.47	9.0	0.39	5.7e-18	Gestational age at birth (maternal effect);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16604136	chr1:163291493	NUF2	0.43	7.23	0.32	2.05e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs35306767	0.715	rs1871622	chr10:1049309	T/G	cg25019033	chr10:957182	NA	-0.56	-10.28	-0.43	1.88e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1620921	0.565	rs66542006	chr6:161273252	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.19	-0.32	2.58e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7818345	0.845	rs7821446	chr8:19268822	A/G	cg11303988	chr8:19266685	CSGALNACT1	-0.41	-7.02	-0.31	7.86e-12	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	0.602	rs4897150	chr6:125985540	C/T	cg05901451	chr6:126070800	HEY2	-0.51	-8.71	-0.38	5.33e-17	Endometrial cancer;
LGG	cis	rs4077515	1.000	rs4077515	chr9:139266496	C/T	cg21253087	chr9:139290292	SNAPC4	0.35	7.0	0.31	8.95e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs189798	0.807	rs12785	chr8:8994936	A/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.15	0.32	3.51e-12	Myopia (pathological);
LGG	cis	rs7264396	0.790	rs6060516	chr20:34214368	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.22	0.32	2.17e-12	Total cholesterol levels;
LGG	cis	rs9644630	0.897	rs13266857	chr8:19364515	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.48	11.2	0.46	6.44e-26	Oropharynx cancer;
LGG	cis	rs17102423	0.685	rs4899161	chr14:65540901	G/A	cg16583315	chr14:65563665	MAX	-0.35	-6.88	-0.3	2e-11	Obesity-related traits;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs910316	0.763	rs12588981	chr14:75460561	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	9.26	0.4	7.66e-19	Height;
LGG	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18252515	chr7:66147081	NA	-0.4	-6.82	-0.3	2.94e-11	Aortic root size;
LGG	cis	rs9467773	0.967	rs9467775	chr6:26513435	G/A	cg09904177	chr6:26538194	HMGN4	0.78	18.1	0.64	9.33e-56	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.65	-11.55	-0.47	2.63e-27	Longevity;Endometriosis;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.72e-18	Life satisfaction;
LGG	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.57	-0.33	2.06e-13	Schizophrenia;
LGG	cis	rs11190604	0.767	rs4919458	chr10:102177728	G/A	cg07570687	chr10:102243282	WNT8B	-0.41	-7.41	-0.33	5.93e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12540874	1.000	rs12540874	chr7:50664922	A/G	cg04490037	chr7:50633773	DDC	0.31	6.77	0.3	3.98e-11	Systemic sclerosis;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg02574844	chr11:5959923	NA	-0.56	-8.72	-0.38	4.87e-17	DNA methylation (variation);
LGG	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.82	0.38	2.37e-17	Motion sickness;
LGG	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg10494973	chr17:80897199	TBCD	-0.42	-7.45	-0.33	4.57e-13	Breast cancer;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.72	0.41	1.91e-20	Prudent dietary pattern;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg08645402	chr16:4508243	NA	0.51	9.67	0.41	2.89e-20	Schizophrenia;
LGG	cis	rs4595586	0.545	rs61939643	chr12:39378460	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	trans	rs7615952	0.688	rs17334074	chr3:125540460	A/G	cg07211511	chr3:129823064	LOC729375	0.95	13.92	0.54	4.83e-37	Blood pressure (smoking interaction);
LGG	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg14835575	chr10:16859367	RSU1	0.44	8.93	0.38	9.85e-18	Platelet distribution width;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg25358565	chr5:93447407	FAM172A	1.39	17.22	0.62	1.03e-51	Diabetic retinopathy;
LGG	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg03929089	chr4:120376271	NA	-0.57	-9.92	-0.42	3.56e-21	HDL cholesterol;
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00149659	chr3:10157352	C3orf10	1.13	14.09	0.55	9.08e-38	Alzheimer's disease;
LGG	cis	rs7192380	0.964	rs11075729	chr16:69620278	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.73	-0.34	6.76e-14	Sjögren's syndrome;
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg21782813	chr7:2030301	MAD1L1	0.39	8.96	0.38	8.04e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6688613	0.694	rs1476347	chr1:166815587	G/T	ch.1.3259774R	chr1:166827647	TADA1	0.55	8.53	0.37	2.15e-16	Refractive astigmatism;
LGG	cis	rs10504073	0.626	rs9298106	chr8:50007508	T/G	cg00325661	chr8:49890786	NA	0.69	13.56	0.53	1.68e-35	Blood metabolite ratios;
LGG	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.8	-0.34	4.19e-14	Systolic blood pressure;
LGG	cis	rs17767392	0.645	rs17767296	chr14:71686784	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.95	-0.31	1.27e-11	Mitral valve prolapse;
LGG	trans	rs6825911	0.700	rs4834529	chr4:111368823	T/G	cg10580549	chr19:53101634	ZNF137	0.47	7.31	0.32	1.14e-12	Blood pressure;
LGG	cis	rs7553864	0.667	rs7512650	chr1:87609076	T/C	cg17420885	chr1:87600446	LOC339524	-0.36	-6.88	-0.3	1.96e-11	Smoking behavior;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.27	-0.4	7.34e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.7	12.59	0.5	1.91e-31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1577917	0.740	rs2475792	chr6:86392102	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.14	0.35	3.68e-15	Response to antipsychotic treatment;
LGG	cis	rs908922	0.676	rs1970283	chr1:152495619	G/C	cg20991723	chr1:152506922	NA	-0.7	-14.11	-0.55	7.02e-38	Hair morphology;
LGG	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg24675658	chr1:53192096	ZYG11B	0.63	12.23	0.49	5.16e-30	Monocyte count;
LGG	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg01028140	chr2:1542097	TPO	-0.56	-9.69	-0.41	2.5e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.967	rs4356528	chr17:28489670	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.26	0.52	2.99e-34	Coffee consumption (cups per day);
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.74	0.34	6.34e-14	Renal function-related traits (BUN);
LGG	cis	rs1843834	0.611	rs1058360	chr2:225449242	A/T	cg22455342	chr2:225449267	CUL3	0.86	15.13	0.58	2.64e-42	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2952156	0.920	rs2952152	chr17:37832735	T/C	cg07936489	chr17:37558343	FBXL20	-0.47	-7.93	-0.35	1.64e-14	Asthma;
LGG	cis	rs11696845	0.896	rs61356009	chr20:43372391	T/C	cg25301532	chr20:43378953	KCNK15	0.36	7.85	0.34	2.86e-14	Obesity-related traits;
LGG	cis	rs3008870	0.755	rs2208577	chr1:67513574	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.69	13.49	0.53	3.24e-35	Lymphocyte percentage of white cells;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.62	-0.51	1.42e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg03060546	chr3:49711283	APEH	-0.62	-8.56	-0.37	1.62e-16	Menarche (age at onset);
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg22105103	chr4:187893119	NA	0.46	8.59	0.37	1.29e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs981844	1.000	rs62325105	chr4:154673846	T/C	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.25e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs4713118	0.512	rs2622319	chr6:28120401	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.5	-7.23	-0.32	2.02e-12	Parkinson's disease;
LGG	cis	rs9815354	1.000	rs1717017	chr3:41915616	A/C	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7939886	0.920	rs60087290	chr11:55983527	C/G	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg08344181	chr3:125677491	NA	-0.91	-9.0	-0.39	5.72e-18	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19899065	chr1:52344247	NRD1	0.52	7.64	0.33	1.24e-13	Gut microbiome composition (summer);
LGG	cis	rs7166081	1.000	rs2289789	chr15:67532383	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.8	-0.3	3.15e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.67	9.16	0.39	1.73e-18	Diabetic retinopathy;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.62	0.33	1.41e-13	Rheumatoid arthritis;
LGG	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.6	0.41	4.92e-20	Menopause (age at onset);
LGG	cis	rs9534288	0.699	rs2897028	chr13:46656915	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-14.4	-0.56	4.09e-39	Blood protein levels;
LGG	trans	rs853679	0.546	rs35656932	chr6:28191288	G/T	cg01620082	chr3:125678407	NA	-1.08	-10.57	-0.44	1.5e-23	Depression;
LGG	cis	rs9486719	1.000	rs2472889	chr6:96866803	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs2304069	0.954	rs10045945	chr5:149419297	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.58	7.7	0.34	8.28e-14	HIV-1 control;
LGG	cis	rs36051895	0.695	rs7045000	chr9:5015143	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.69	-0.59	8.86e-45	Pediatric autoimmune diseases;
LGG	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.48	-0.4	1.37e-19	Height;
LGG	cis	rs9303401	0.527	rs12939313	chr17:56755616	A/T	cg25039879	chr17:56429692	SUPT4H1	0.58	7.56	0.33	2.13e-13	Cognitive test performance;
LGG	cis	rs12135191	0.771	rs12749874	chr1:236503856	A/G	cg21399712	chr1:236511386	NA	-0.41	-7.69	-0.34	8.84e-14	Urate levels (BMI interaction);
LGG	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg02023728	chr11:77925099	USP35	0.44	7.6	0.33	1.69e-13	Testicular germ cell tumor;
LGG	cis	rs6964587	0.900	rs6972027	chr7:91781380	T/C	cg17063962	chr7:91808500	NA	0.53	9.85	0.42	6.47e-21	Breast cancer;
LGG	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17818308	chr2:107502146	ST6GAL2	0.44	6.72	0.3	5.45e-11	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.645	rs10128731	chr11:50023554	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.09	-0.6	1.37e-46	Height;
LGG	cis	rs113835537	0.529	rs7928882	chr11:66234765	C/T	cg24851651	chr11:66362959	CCS	0.43	7.58	0.33	1.97e-13	Airway imaging phenotypes;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs72781680	0.752	rs56152044	chr2:23927680	A/G	cg08917208	chr2:24149416	ATAD2B	0.85	8.97	0.38	7.22e-18	Lymphocyte counts;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05923184	chr19:38878861	GGN	-0.44	-7.5	-0.33	3.31e-13	Liver disease severity in Alagille syndrome;
LGG	cis	rs61931739	0.500	rs11053280	chr12:34559297	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg09033563	chr22:24373618	LOC391322	-0.5	-8.22	-0.36	2.02e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg25358565	chr5:93447407	FAM172A	-0.85	-11.7	-0.48	7.13e-28	Diabetic retinopathy;
LGG	cis	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg08250081	chr4:10125330	NA	0.67	12.14	0.49	1.28e-29	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg23188684	chr11:67383651	NA	0.48	7.86	0.34	2.7e-14	Mean corpuscular volume;
LGG	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg16006841	chr5:176797999	RGS14	0.61	9.1	0.39	2.71e-18	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs2976388	0.632	rs2585139	chr8:143808175	C/G	cg06565975	chr8:143823917	SLURP1	0.36	9.12	0.39	2.28e-18	Urinary tract infection frequency;
LGG	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg21427119	chr20:30132790	HM13	-0.37	-6.68	-0.3	6.7e-11	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06850241	chr22:41845214	NA	0.46	7.23	0.32	1.96e-12	Vitiligo;
LGG	cis	rs10851411	0.697	rs11630625	chr15:42819175	A/T	cg21293051	chr15:42870591	STARD9	0.49	6.94	0.31	1.33e-11	Glucose homeostasis traits;
LGG	cis	rs17023223	0.537	rs12097967	chr1:119702913	A/G	cg05756136	chr1:119680316	WARS2	-0.41	-8.53	-0.37	2.11e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs7246657	0.606	rs2972439	chr19:38212581	T/C	cg14683738	chr19:37701593	ZNF585B	-0.45	-7.22	-0.32	2.21e-12	Coronary artery calcification;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	3.82e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2737618	0.651	rs2816974	chr1:200082686	C/G	cg21825944	chr1:200113062	NR5A2	0.59	11.58	0.47	2.09e-27	Uric acid levels;
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.58	-0.33	1.87e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1372520	0.684	rs356191	chr4:90688120	G/A	cg15133208	chr4:90757351	SNCA	0.38	7.57	0.33	2.11e-13	Neuroticism;
LGG	cis	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.42	-0.4	2.14e-19	Morning vs. evening chronotype;
LGG	cis	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg19399532	chr1:178512495	C1orf220	0.42	8.25	0.36	1.66e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs977987	0.586	rs12920883	chr16:75432681	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.69	0.3	6.4e-11	Dupuytren's disease;
LGG	cis	rs883565	0.740	rs6763016	chr3:39098964	G/A	cg01426195	chr3:39028469	NA	-0.7	-15.55	-0.59	3.52e-44	Handedness;
LGG	cis	rs6920372	0.708	rs13198852	chr6:110068322	C/T	cg01125227	chr6:109776195	MICAL1	0.43	7.53	0.33	2.69e-13	Height;
LGG	trans	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg01620082	chr3:125678407	NA	-0.68	-7.09	-0.31	4.98e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg09307838	chr4:120376055	NA	0.72	12.32	0.5	2.27e-30	Corneal astigmatism;
LGG	cis	rs755249	0.567	rs112672438	chr1:39646787	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.16	0.32	3.16e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs79518236	1	rs79518236	chr7:98026554	ACT/A	cg09267113	chr7:98030324	BAIAP2L1	-0.48	-8.14	-0.35	3.69e-15	Breast cancer;
LGG	cis	rs6694672	1.000	rs1412639	chr1:197003593	G/A	cg13682187	chr1:196946512	CFHR5	0.51	6.99	0.31	9.8e-12	Asthma;
LGG	cis	rs7412746	0.658	rs12097963	chr1:150870450	T/C	cg15448220	chr1:150897856	SETDB1	0.4	7.28	0.32	1.4e-12	Melanoma;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg05868516	chr6:26286170	HIST1H4H	0.46	7.89	0.34	2.17e-14	Educational attainment;
LGG	trans	rs1941687	0.765	rs11874521	chr18:31391966	G/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12960782	chr5:59996455	DEPDC1B	0.41	6.91	0.31	1.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.54	0.41	8.28e-20	Lung cancer in ever smokers;
LGG	cis	rs9388451	1.000	rs9388451	chr6:126090377	A/G	cg05901451	chr6:126070800	HEY2	-0.83	-17.51	-0.63	5e-53	Brugada syndrome;
LGG	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg08847335	chr10:891726	LARP4B	-0.36	-6.97	-0.31	1.07e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs10267417	0.603	rs10245287	chr7:19938738	C/G	cg05791153	chr7:19748676	TWISTNB	-0.51	-6.97	-0.31	1.12e-11	Night sleep phenotypes;
LGG	cis	rs4750440	0.706	rs11258770	chr10:14018910	G/T	cg00551146	chr10:14014579	FRMD4A	0.3	7.19	0.32	2.64e-12	Adiponectin levels;
LGG	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg00543991	chr22:32367038	NA	0.76	8.36	0.36	7.18e-16	Childhood ear infection;
LGG	cis	rs911555	0.755	rs4906329	chr14:103942669	A/G	cg24130564	chr14:104152367	KLC1	0.4	7.32	0.32	1.08e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs60719662	chr6:163006643	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.41	-0.47	9.74e-27	Morning vs. evening chronotype;
LGG	cis	rs9527	0.614	rs4919691	chr10:104624475	A/C	cg04362960	chr10:104952993	NT5C2	0.52	9.57	0.41	6.5e-20	Arsenic metabolism;
LGG	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg12458913	chr13:53173898	NA	0.88	20.53	0.69	4.59e-67	Lewy body disease;
LGG	cis	rs28595532	0.688	rs116580819	chr4:119767362	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs62238980	0.522	rs2413065	chr22:32458608	C/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.59	-0.61	7.81e-49	Height;
LGG	cis	rs6831352	0.734	rs3018046	chr4:100030388	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-13.87	-0.54	7.64e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2742417	0.967	rs9877499	chr3:45734404	G/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.74	-0.34	6.32e-14	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg17470184	chr11:118478236	PHLDB1	-0.42	-7.22	-0.32	2.14e-12	Cholesterol, total;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg07701084	chr6:150067640	NUP43	0.71	13.6	0.53	1.1e-35	Lung cancer;
LGG	cis	rs8141529	0.702	rs132536	chr22:29302906	A/G	cg15103426	chr22:29168792	CCDC117	-0.6	-9.16	-0.39	1.68e-18	Lymphocyte counts;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.24	-0.39	9.15e-19	Neuroticism;
LGG	cis	rs1620921	0.625	rs28698869	chr6:161265892	C/T	cg01280913	chr6:161186852	NA	-0.37	-7.44	-0.33	5.01e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7615952	0.932	rs11922218	chr3:125631289	C/T	cg05084668	chr3:125655381	ALG1L	-0.85	-10.49	-0.44	3.17e-23	Blood pressure (smoking interaction);
LGG	trans	rs7939886	0.841	rs10501349	chr11:56021284	G/A	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.4	-7.73	-0.34	6.93e-14	Schizophrenia;
LGG	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg00405596	chr8:11794950	NA	0.65	11.49	0.47	4.81e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.58	-9.61	-0.41	4.74e-20	Height;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.13	-0.35	4e-15	IgG glycosylation;
LGG	cis	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg10596483	chr8:143751796	JRK	0.52	8.14	0.35	3.74e-15	Schizophrenia;
LGG	cis	rs6988985	0.703	rs7833723	chr8:143925666	A/G	cg10324643	chr8:143916377	GML	0.4	7.94	0.35	1.57e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.43	-0.5	8.13e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs12580194	0.593	rs11171416	chr12:55731490	A/G	cg19537932	chr12:55886519	OR6C68	-0.52	-9.35	-0.4	3.68e-19	Cancer;
LGG	cis	rs758324	0.812	rs519240	chr5:131269453	G/A	cg06307176	chr5:131281290	NA	-0.52	-8.51	-0.37	2.37e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg07959490	chr17:80112427	CCDC57	-0.4	-7.92	-0.35	1.8e-14	Life satisfaction;
LGG	cis	rs2731664	0.792	rs465670	chr5:176877624	C/T	cg23176889	chr5:176863531	GRK6	-0.66	-13.08	-0.52	1.68e-33	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	1.000	rs10851631	chr15:58242193	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.42	-0.36	4.69e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7582720	1.000	rs72934537	chr2:203969504	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.4	0.4	2.58e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs208520	1.000	rs12190316	chr6:66973365	T/C	cg07460842	chr6:66804631	NA	0.9	14.76	0.57	1.14e-40	Exhaled nitric oxide output;
LGG	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg26924012	chr15:45694286	SPATA5L1	0.99	19.04	0.66	3.91e-60	Homoarginine levels;
LGG	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.83	-0.42	7.76e-21	Aortic root size;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg05368731	chr17:41323189	NBR1	0.97	19.0	0.66	5.92e-60	Menopause (age at onset);
LGG	cis	rs35740288	0.587	rs4843089	chr15:86176136	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.44	0.37	4.15e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs4714291	0.832	rs761798	chr6:40087514	C/T	cg02267698	chr19:7991119	CTXN1	0.63	10.41	0.44	6.31e-23	Strep throat;
LGG	cis	rs35306767	0.761	rs11253557	chr10:1043667	C/T	cg20503657	chr10:835505	NA	0.56	7.26	0.32	1.69e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg19717773	chr7:2847554	GNA12	-0.34	-7.08	-0.31	5.45e-12	Height;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg21948465	chr5:131705150	SLC22A5	0.68	7.57	0.33	2.02e-13	Rheumatoid arthritis;
LGG	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-16.96	-0.62	1.64e-50	Vitiligo;
LGG	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg26655873	chr3:72818019	SHQ1	0.37	7.47	0.33	3.9e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg03929089	chr4:120376271	NA	-0.43	-6.86	-0.3	2.2e-11	HDL cholesterol;
LGG	cis	rs6088765	0.606	rs2425024	chr20:33844938	G/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.81	-0.3	2.98e-11	Ulcerative colitis;
LGG	trans	rs11875185	0.510	rs35841397	chr18:55634533	C/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg26655873	chr3:72818019	SHQ1	0.37	7.62	0.33	1.43e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1707322	1.000	rs10890355	chr1:46317348	G/A	cg03146154	chr1:46216737	IPP	0.54	10.34	0.43	1.1e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.88	0.42	5.21e-21	Tonsillectomy;
LGG	cis	rs7095944	0.614	rs4962697	chr10:126447545	G/C	cg08799069	chr10:126477246	METTL10	-0.47	-10.73	-0.45	3.81e-24	Asthma;
LGG	cis	rs888194	0.738	rs2241208	chr12:109962795	G/C	cg19025524	chr12:109796872	NA	-0.36	-7.25	-0.32	1.74e-12	Neuroticism;
LGG	cis	rs7769051	0.522	rs6934190	chr6:133116664	G/A	cg07930552	chr6:133119739	C6orf192	1.12	9.71	0.41	2.15e-20	Type 2 diabetes nephropathy;
LGG	cis	rs2242194	0.816	rs6671688	chr1:154994265	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.71	16.26	0.6	2.28e-47	Schizophrenia;
LGG	cis	rs735860	0.572	rs186003	chr6:53185124	A/C	cg10236188	chr6:53219634	NA	0.37	7.1	0.31	4.87e-12	Glaucoma;
LGG	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.21	-0.32	2.27e-12	Bipolar disorder;
LGG	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg18876405	chr7:65276391	NA	0.53	9.42	0.4	2.23e-19	Aortic root size;
LGG	cis	rs2718058	0.704	rs2722295	chr7:37834426	C/T	cg15028436	chr7:37888078	TXNDC3	0.48	8.14	0.35	3.56e-15	Alzheimer's disease (late onset);
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg11878867	chr6:150167359	LRP11	-0.54	-11.02	-0.46	2.98e-25	Lung cancer;
LGG	cis	rs9314323	0.501	rs6557911	chr8:26189230	G/T	cg11498726	chr8:26250323	BNIP3L	-0.44	-9.45	-0.4	1.7e-19	Red cell distribution width;
LGG	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg00666640	chr1:248458726	OR2T12	0.58	9.23	0.39	9.7e-19	Common traits (Other);
LGG	cis	rs10492096	0.853	rs7300092	chr12:6607364	T/C	cg13857086	chr12:6580257	VAMP1	0.48	7.08	0.31	5.41e-12	Hip geometry;
LGG	cis	rs1865760	0.865	rs9467651	chr6:25958257	C/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.86	0.42	6.03e-21	Height;
LGG	cis	rs17270561	0.609	rs17267614	chr6:25730027	A/C	cg03517284	chr6:25882590	NA	-0.43	-7.01	-0.31	8.62e-12	Iron status biomarkers;
LGG	cis	rs2073499	1.000	rs76846888	chr3:50406058	C/T	cg03645007	chr3:50255295	SLC38A3	0.61	6.69	0.3	6.52e-11	Schizophrenia;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.0	0.42	1.91e-21	Height;
LGG	cis	rs9486719	0.857	rs4839833	chr6:96882069	T/C	cg18709589	chr6:96969512	KIAA0776	0.43	7.11	0.31	4.57e-12	Migraine;Coronary artery disease;
LGG	cis	rs12410462	0.591	rs903695	chr1:227733069	A/G	cg23173402	chr1:227635558	NA	0.35	6.7	0.3	6e-11	Major depressive disorder;
LGG	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	10.86	0.45	1.27e-24	Hip circumference adjusted for BMI;
LGG	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg02574844	chr11:5959923	NA	0.56	8.57	0.37	1.59e-16	DNA methylation (variation);
LGG	cis	rs13217239	0.646	rs9393789	chr6:27067028	G/T	cg12292205	chr6:26970375	C6orf41	-0.55	-10.7	-0.45	5.1e-24	Schizophrenia;
LGG	cis	rs6988985	0.765	rs6433	chr8:143993640	C/T	cg10324643	chr8:143916377	GML	0.38	7.62	0.33	1.41e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs2204008	0.837	rs12366727	chr12:38365748	A/C	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.29e-18	Bladder cancer;
LGG	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.55	-0.41	7.7e-20	Triglycerides;
LGG	cis	rs929596	0.517	rs3806592	chr2:234625936	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.55	-0.41	7.71e-20	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg21153622	chr11:89784906	NA	-0.41	-7.0	-0.31	9.2e-12	HDL cholesterol;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-13.51	-0.53	2.64e-35	Presence of antiphospholipid antibodies;
LGG	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg00717180	chr2:96193071	NA	-0.45	-8.08	-0.35	5.68e-15	HDL cholesterol;
LGG	cis	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg05863683	chr7:1912471	MAD1L1	0.45	8.86	0.38	1.68e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg27189623	chr16:705930	WDR90	0.41	7.84	0.34	3.03e-14	Height;
LGG	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg11878867	chr6:150167359	LRP11	-0.39	-8.1	-0.35	4.75e-15	Testicular germ cell tumor;
LGG	cis	rs4356975	0.563	rs4694177	chr4:69975859	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.68	0.3	6.67e-11	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg14689365	chr7:158441557	NCAPG2	0.6	10.33	0.43	1.15e-22	Height;
LGG	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.74	-0.48	5.04e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	0.935	rs1187529	chr6:167376693	T/A	cg07741184	chr6:167504864	NA	-0.31	-6.69	-0.3	6.5500000000000006e-11	Crohn's disease;
LGG	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-10.43	-0.44	5.09e-23	Bronchopulmonary dysplasia;
LGG	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg13852791	chr20:30311386	BCL2L1	-0.8	-12.47	-0.5	5.82e-31	Mean corpuscular hemoglobin;
LGG	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21659725	chr3:3221576	CRBN	0.92	20.51	0.69	5.5e-67	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs114611353	chr4:119736607	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg00204512	chr16:28754710	NA	0.24	6.66	0.3	7.62e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10107145	0.509	rs73209954	chr8:10760667	G/C	cg21775007	chr8:11205619	TDH	-0.45	-6.69	-0.3	6.63e-11	Systolic blood pressure;
LGG	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg18854424	chr1:2615690	NA	0.33	7.15	0.32	3.35e-12	Ulcerative colitis;
LGG	cis	rs8064024	0.676	rs2075467	chr16:4873242	A/G	cg04440724	chr16:4920505	UBN1	0.44	9.2	0.39	1.26e-18	Cancer;
LGG	cis	rs41317993	1	rs41317993	chr1:207961732	G/A	cg22525895	chr1:207977042	MIR29B2	-0.63	-7.32	-0.32	1.09e-12	Resting heart rate;
LGG	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg23324259	chr8:82754387	SNX16	0.45	7.19	0.32	2.55e-12	Diastolic blood pressure;
LGG	cis	rs2133450	0.508	rs7653020	chr3:7335201	G/A	cg19930620	chr3:7340148	GRM7	-0.47	-10.17	-0.43	4.49e-22	Early response to risperidone in schizophrenia;
LGG	cis	rs7937890	0.559	rs2575836	chr11:14497864	T/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs6908034	0.546	rs73376662	chr6:19806340	G/A	cg02682789	chr6:19804855	NA	0.91	8.61	0.37	1.19e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	trans	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.56	-0.37	1.62e-16	Triglycerides;
LGG	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.77	-0.34	5.07e-14	Neuroticism;
LGG	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg13334819	chr7:99746414	C7orf59	0.47	7.4	0.33	6.65e-13	Coronary artery disease;
LGG	cis	rs79349575	0.749	rs2546491	chr17:46977916	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg06374794	chr16:88002281	BANP	-0.44	-8.43	-0.36	4.35e-16	Menopause (age at onset);
LGG	trans	rs7395662	1.000	rs7481880	chr11:48609347	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.19e-13	HDL cholesterol;
LGG	cis	rs4849975	0.510	rs13431927	chr2:3713706	G/C	cg20720597	chr2:3699334	NA	0.59	6.9	0.31	1.67e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg06848047	chr4:90757629	SNCA	-0.43	-8.13	-0.35	3.9e-15	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.69	12.59	0.51	1.77e-31	Obesity-related traits;
LGG	cis	rs11971779	0.618	rs3778931	chr7:139102490	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.34e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs477692	0.569	rs10764882	chr10:131306496	C/G	cg05714579	chr10:131428358	MGMT	0.51	10.03	0.42	1.5e-21	Response to temozolomide;
LGG	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg08847533	chr14:75593920	NEK9	-0.57	-10.61	-0.44	1.06e-23	Height;
LGG	cis	rs8010715	0.848	rs8009511	chr14:24593980	G/A	cg06429887	chr14:24600500	FITM1	0.36	7.47	0.33	3.94e-13	IgG glycosylation;
LGG	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg11890956	chr21:40555474	PSMG1	1.05	21.1	0.7	9.49e-70	Cognitive function;
LGG	cis	rs17376456	0.877	rs35747258	chr5:93310129	C/T	cg19507638	chr5:93509721	C5orf36	-0.69	-9.64	-0.41	3.66e-20	Diabetic retinopathy;
LGG	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.16	0.39	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.79	-0.3	3.38e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.82	-0.34	3.53e-14	Morning vs. evening chronotype;
LGG	cis	rs638893	0.853	rs4938549	chr11:118701597	T/C	cg22253036	chr11:118662786	DDX6	0.42	7.11	0.31	4.52e-12	Vitiligo;
LGG	cis	rs67460515	0.563	rs4679672	chr3:160901020	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-11.84	-0.48	1.99e-28	Parkinson's disease;
LGG	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg01557791	chr16:72042693	DHODH	-0.46	-7.41	-0.33	6.12e-13	Blood protein levels;
LGG	cis	rs12042938	0.507	rs1655301	chr1:231731730	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.76	-14.94	-0.57	1.81e-41	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs7301826	0.934	rs10773826	chr12:131321174	C/G	cg11011512	chr12:131303247	STX2	0.33	7.31	0.32	1.19e-12	Plasma plasminogen activator levels;
LGG	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.2	-0.39	1.19e-18	Gut microbiome composition (summer);
LGG	cis	rs11719291	0.833	rs34037363	chr3:48821036	C/T	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	Cognitive function;
LGG	trans	rs3206736	0.548	rs1637675	chr7:35000492	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.91e-12	Diastolic blood pressure;
LGG	cis	rs9457247	0.765	rs9459838	chr6:167426599	C/G	cg07741184	chr6:167504864	NA	0.42	9.39	0.4	2.73e-19	Crohn's disease;
LGG	cis	rs7786808	0.707	rs62479983	chr7:158227613	G/A	cg01191920	chr7:158217561	PTPRN2	-0.91	-23.78	-0.74	2.83e-82	Obesity-related traits;
LGG	cis	rs988958	0.565	rs6753186	chr2:42235998	C/T	cg27252766	chr2:42229092	NA	0.52	7.48	0.33	3.73e-13	Hypospadias;
LGG	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.41	-7.37	-0.32	8.13e-13	Colorectal cancer;
LGG	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg03433033	chr1:76189801	ACADM	0.8	13.96	0.54	3.38e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs7107174	1.000	rs2450128	chr11:77940075	G/A	cg27205649	chr11:78285834	NARS2	-0.43	-7.09	-0.31	5.18e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs4917300	0.739	rs10875478	chr8:143098247	T/C	cg06573787	chr8:143070187	NA	0.63	11.5	0.47	4.31e-27	Amyotrophic lateral sclerosis;
LGG	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4481887	0.760	rs4559544	chr1:248412507	T/G	cg13385794	chr1:248469461	NA	0.41	6.84	0.3	2.5e-11	Common traits (Other);
LGG	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg04731861	chr2:219085781	ARPC2	-0.44	-10.73	-0.45	3.99e-24	Colorectal cancer;
LGG	trans	rs7746199	0.736	rs34105070	chr6:27560805	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4901869	0.966	rs431343	chr14:59345530	C/T	cg02291164	chr14:59296302	NA	0.28	7.2	0.32	2.39e-12	Panic disorder;
LGG	cis	rs12765878	0.812	rs10786776	chr10:105662994	A/G	cg11005552	chr10:105648138	OBFC1	-0.82	-16.42	-0.61	4.56e-48	Coronary artery disease;
LGG	cis	rs6909430	0.808	rs2029240	chr6:98588028	G/C	cg12860156	chr6:98744658	NA	-0.44	-7.56	-0.33	2.23e-13	Quantitative traits;
LGG	cis	rs7928758	0.767	rs1866768	chr11:134274710	A/G	cg22777979	chr11:134283252	B3GAT1	0.55	8.43	0.36	4.26e-16	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7072216	0.763	rs7909822	chr10:100172035	A/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.2	-0.32	2.42e-12	Metabolite levels;
LGG	trans	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg18335740	chr13:41363409	SLC25A15	0.53	9.48	0.4	1.36e-19	Lewy body disease;
LGG	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg22862634	chr11:62369728	EML3;MTA2	0.56	11.57	0.47	2.28e-27	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs1691799	0.899	rs1168329	chr12:66731864	C/A	cg16791601	chr12:66731901	HELB	-0.66	-15.82	-0.59	2.27e-45	White blood cell count (basophil);
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.68	0.37	6.81e-17	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04309227	chr1:26561027	CCDC21	0.5	7.8	0.34	4.23e-14	Gut microbiome composition (summer);
LGG	cis	rs55794721	0.509	rs6699113	chr1:25777743	C/T	cg09222892	chr1:25734099	RHCE	0.45	9.31	0.4	5.17e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs5758511	0.680	rs17002902	chr22:42625509	C/G	cg15128208	chr22:42549153	NA	0.74	11.45	0.47	6.98e-27	Birth weight;
LGG	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.49	-0.4	1.2e-19	Height;
LGG	cis	rs2952156	0.959	rs2934952	chr17:37832366	G/A	cg07936489	chr17:37558343	FBXL20	-0.41	-6.67	-0.3	7.47e-11	Asthma;
LGG	cis	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg06521331	chr12:34319734	NA	0.41	6.87	0.3	2.08e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.49	0.33	3.41e-13	Retinal vascular caliber;
LGG	cis	rs4950322	1.000	rs72694720	chr1:146843654	C/T	cg22381352	chr1:146742008	CHD1L	-0.45	-7.04	-0.31	6.82e-12	Protein quantitative trait loci;
LGG	cis	rs55871839	0.708	rs6651298	chr8:59808307	C/G	cg07426533	chr8:59803705	TOX	-0.57	-12.9	-0.51	9.69e-33	Pneumonia;
LGG	cis	rs1707322	0.717	rs11211161	chr1:46148138	A/C	cg03146154	chr1:46216737	IPP	0.55	10.45	0.44	4.35e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10193935	0.901	rs12620021	chr2:42477034	T/C	cg27598129	chr2:42591480	NA	-0.65	-9.71	-0.41	2.1e-20	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9388451	0.587	rs1739385	chr6:126099939	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-11.09	-0.46	1.66e-25	Brugada syndrome;
LGG	cis	rs12791968	1.000	rs11038237	chr11:45001880	C/T	cg11846598	chr11:44996168	LOC221122	-0.68	-12.88	-0.51	1.13e-32	Inhibitory control;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.68	12.15	0.49	1.12e-29	Obesity-related traits;
LGG	cis	rs2046867	0.774	rs1393585	chr3:72886722	A/G	cg01043669	chr3:72786069	NA	0.43	6.84	0.3	2.51e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs62380364	0.602	rs588282	chr5:88032651	G/T	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg21775007	chr8:11205619	TDH	0.44	7.32	0.32	1.08e-12	Mood instability;
LGG	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg14689365	chr7:158441557	NCAPG2	0.56	6.75	0.3	4.31e-11	Height;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00166722	chr3:10149974	C3orf24	0.54	9.09	0.39	2.91e-18	Alzheimer's disease;
LGG	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg22349387	chr12:9600060	DDX12	-0.28	-6.97	-0.31	1.13e-11	Breast size;
LGG	cis	rs12493885	0.725	rs11707232	chr3:153742077	T/A	cg17054900	chr3:154042577	DHX36	-0.72	-8.85	-0.38	1.82e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg13880726	chr7:1868755	MAD1L1	-0.38	-6.78	-0.3	3.65e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.644	rs7595785	chr2:86556405	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.85	0.3	2.36e-11	Night sleep phenotypes;
LGG	cis	rs910316	0.763	rs2080201	chr14:75629972	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.51	-0.4	1.01e-19	Height;
LGG	trans	rs11088226	0.709	rs55860967	chr21:33880018	G/A	cg09050820	chr6:167586206	TCP10L2	0.61	9.0	0.39	5.86e-18	Gastritis;
LGG	cis	rs2576037	0.901	rs2571021	chr18:44583498	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.55	-0.53	1.79e-35	Personality dimensions;
LGG	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg01631408	chr1:248437212	OR2T33	0.38	6.88	0.3	1.97e-11	Common traits (Other);
LGG	trans	rs11098499	0.691	rs17009144	chr4:120270795	C/T	cg25214090	chr10:38739885	LOC399744	-0.56	-10.3	-0.43	1.59e-22	Corneal astigmatism;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-6.9	-0.31	1.71e-11	Bipolar disorder;
LGG	cis	rs6750047	0.605	rs2121260	chr2:38268763	T/G	cg07380506	chr2:38303506	CYP1B1	0.44	7.26	0.32	1.68e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs9964724	0.892	rs11877758	chr18:35138110	T/G	cg27332583	chr18:35150602	NA	0.48	9.94	0.42	3.02e-21	Educational attainment (years of education);
LGG	cis	rs9894429	0.966	rs7405901	chr17:79587813	T/C	cg10661904	chr17:79619235	PDE6G	-0.42	-8.51	-0.37	2.4e-16	Eye color traits;
LGG	cis	rs75059851	0.756	rs11223649	chr11:133840471	T/C	cg20042908	chr11:133852938	NA	-0.77	-14.33	-0.55	8.49e-39	Schizophrenia;
LGG	cis	rs2153535	0.580	rs1335637	chr6:8465101	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.91	0.64	6.87e-55	Cognitive function;
LGG	cis	rs8114671	0.805	rs6060168	chr20:33621017	C/T	cg24642439	chr20:33292090	TP53INP2	0.51	8.38	0.36	6.52e-16	Height;
LGG	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg06212747	chr3:49208901	KLHDC8B	0.43	6.89	0.31	1.78e-11	Resting heart rate;
LGG	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.94	0.35	1.56e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg08085267	chr17:45401833	C17orf57	-0.65	-13.02	-0.52	3.06e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg15921436	chr17:44337874	NA	0.58	12.39	0.5	1.17e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg02030672	chr11:45687055	CHST1	0.51	9.2	0.39	1.24e-18	Obesity-related traits;
LGG	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs4740619	0.502	rs9407658	chr9:15834607	G/A	cg14451791	chr9:16040625	NA	0.32	7.61	0.33	1.55e-13	Body mass index;
LGG	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg17376030	chr22:41985996	PMM1	0.5	8.19	0.36	2.58e-15	Vitiligo;
LGG	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.68	-0.3	6.69e-11	Iron status biomarkers;
LGG	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg02825527	chr7:2087843	MAD1L1	-0.34	-6.7	-0.3	5.94e-11	Bipolar disorder;
LGG	cis	rs77972916	0.561	rs72788900	chr2:43559087	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.06	-0.31	6.04e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg13264159	chr8:625131	ERICH1	0.89	10.44	0.44	4.7e-23	IgG glycosylation;
LGG	cis	rs2635047	0.542	rs11082567	chr18:44769820	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.87	0.3	2.09e-11	Educational attainment;
LGG	cis	rs26232	0.521	rs3776855	chr5:102358815	A/C	cg23492399	chr5:102201601	PAM	-0.57	-8.31	-0.36	1.05e-15	Rheumatoid arthritis;
LGG	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06634786	chr22:41940651	POLR3H	0.78	12.78	0.51	2.99e-32	Vitiligo;
LGG	trans	rs61931739	0.534	rs7965503	chr12:34199349	A/G	cg13010199	chr12:38710504	ALG10B	0.58	11.07	0.46	2.02e-25	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg23978390	chr7:1156363	C7orf50	0.49	8.54	0.37	1.98e-16	Longevity;Endometriosis;
LGG	cis	rs283228	0.535	rs2518181	chr6:101835744	G/A	cg02011392	chr6:101847541	GRIK2	0.51	7.18	0.32	2.71e-12	Coenzyme Q10 levels;
LGG	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.93	0.35	1.63e-14	Lung cancer;
LGG	cis	rs6964587	0.692	rs2027950	chr7:91863700	C/G	cg17063962	chr7:91808500	NA	-0.52	-10.06	-0.42	1.16e-21	Breast cancer;
LGG	cis	rs1062177	1.000	rs41494545	chr5:151235094	A/G	cg00977110	chr5:151150581	G3BP1	-0.5	-7.88	-0.34	2.35e-14	Preschool internalizing problems;
LGG	cis	rs300774	0.841	rs453447	chr2:205446	G/T	cg21211680	chr2:198530	NA	0.52	6.79	0.3	3.5e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs1372520	0.684	rs1442144	chr4:90736113	T/C	cg15133208	chr4:90757351	SNCA	-0.4	-8.13	-0.35	3.97e-15	Neuroticism;
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg11494091	chr17:61959527	GH2	0.56	9.01	0.39	5.48e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1670533	1.000	rs12645644	chr4:1054159	C/T	cg27284194	chr4:1044797	NA	0.52	9.39	0.4	2.74e-19	Recombination rate (females);
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg08875078	chr22:50639485	SELO	0.45	7.28	0.32	1.47e-12	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.46	0.37	3.42e-16	Obesity-related traits;
LGG	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs8031584	0.672	rs17227989	chr15:31293774	T/C	cg08704250	chr15:31115839	NA	-0.44	-7.17	-0.32	3.05e-12	Huntington's disease progression;
LGG	cis	rs4595586	0.545	rs1156707	chr12:39372451	G/T	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg25019033	chr10:957182	NA	-0.52	-8.85	-0.38	1.93e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs5015933	1.000	rs2841329	chr9:128134332	G/A	cg14078157	chr9:128172775	NA	-0.36	-6.71	-0.3	5.72e-11	Body mass index;
LGG	cis	rs12912251	1.000	rs35102843	chr15:38988107	C/A	cg01338139	chr15:38987640	C15orf53	-0.55	-8.69	-0.37	6.31e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.59	-0.33	1.72e-13	Neuroticism;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.65	0.59	1.27e-44	Platelet count;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	0.541	rs2955777	chr15:31219788	A/C	cg14829155	chr15:31115871	NA	0.49	8.52	0.37	2.2e-16	Huntington's disease progression;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24465118	chr20:47895107	C20orf199;SNORD12C;ZNFX1	-0.49	-7.29	-0.32	1.38e-12	Systemic lupus erythematosus;
LGG	trans	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17712092	chr4:129076599	LARP1B	0.72	13.75	0.54	2.68e-36	Eosinophil percentage of white cells;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs250677	1.000	rs40525	chr5:148432932	G/T	cg18129178	chr5:148520854	ABLIM3	0.45	7.87	0.34	2.49e-14	Breast cancer;
LGG	cis	rs6840360	0.550	rs6816471	chr4:152494869	A/G	cg25486957	chr4:152246857	NA	-0.51	-8.52	-0.37	2.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg11645453	chr3:52864694	ITIH4	0.39	6.74	0.3	4.84e-11	Bipolar disorder;
LGG	cis	rs12949688	1.000	rs4793566	chr17:55815469	T/C	cg12582317	chr17:55822272	NA	0.64	17.35	0.63	2.48e-52	Schizophrenia;
LGG	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7072216	0.763	rs2274243	chr10:100175267	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.09	-0.31	5.04e-12	Metabolite levels;
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.63	0.37	9.6e-17	Bipolar disorder;
LGG	trans	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.56	0.63	2.86e-53	Exhaled nitric oxide output;
LGG	cis	rs79839061	0.610	rs3736089	chr4:870118	G/A	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg02836325	chr17:76403955	PGS1	-0.72	-14.45	-0.56	2.45e-39	HDL cholesterol levels;
LGG	cis	rs936229	0.749	rs8031937	chr15:75181121	A/G	cg14664628	chr15:75095509	CSK	-0.89	-18.1	-0.64	9.26e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs16944613	0.541	rs7183319	chr15:91095032	A/T	cg26821196	chr15:91095069	CRTC3	0.57	8.38	0.36	6.28e-16	Colorectal cancer;
LGG	cis	rs7582720	1.000	rs72926767	chr2:203796814	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-16.86	-0.62	4.26e-50	Exhaled nitric oxide output;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg11814155	chr7:99998594	ZCWPW1	0.6	8.94	0.38	9.04e-18	Platelet count;
LGG	cis	rs2070488	0.965	rs6599206	chr3:38545349	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-18.29	-0.65	1.2e-56	Electrocardiographic conduction measures;
LGG	cis	rs1497828	0.956	rs2646821	chr1:217528236	C/T	cg04411442	chr1:217543379	NA	-0.47	-8.02	-0.35	8.51e-15	Dialysis-related mortality;
LGG	cis	rs548181	0.536	rs503287	chr11:125461788	C/T	cg03464685	chr11:125439445	EI24	1.26	19.22	0.67	6.18e-61	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20689859	chr2:62933102	EHBP1	0.44	6.78	0.3	3.59e-11	Gut microbiome composition (summer);
LGG	cis	rs283228	0.569	rs626262	chr6:101729772	A/G	cg27451362	chr6:101846650	GRIK2	0.89	13.22	0.52	4.3e-34	Coenzyme Q10 levels;
LGG	cis	rs12496230	1.000	rs62258957	chr3:66864153	G/T	cg04995300	chr3:66848608	NA	0.53	7.92	0.35	1.72e-14	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09137423	chr10:51827642	FAM21A	0.53	7.99	0.35	1.05e-14	Gut microbiome composition (summer);
LGG	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.13	-0.31	3.89e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.21	0.39	1.11e-18	Gout;Renal underexcretion gout;
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg15105011	chr4:940614	TMEM175	0.39	6.79	0.3	3.44e-11	Sjögren's syndrome;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	7.28	0.32	1.49e-12	Schizophrenia;
LGG	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg27490568	chr2:178487706	NA	0.53	10.23	0.43	2.7e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg08109568	chr15:31115862	NA	0.59	10.25	0.43	2.44e-22	Huntington's disease progression;
LGG	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.82	0.42	8.71e-21	Ovarian reserve;
LGG	cis	rs2117029	0.586	rs11168874	chr12:49527536	C/T	cg24176009	chr12:49580217	TUBA1A	0.63	12.23	0.49	5.56e-30	Intelligence (multi-trait analysis);
LGG	trans	rs783540	0.900	rs12916980	chr15:83306447	C/G	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.74	-0.3	4.73e-11	Schizophrenia;
LGG	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg24851651	chr11:66362959	CCS	-0.35	-6.67	-0.3	7.22e-11	HIV-1 susceptibility;
LGG	cis	rs2247341	0.965	rs2236787	chr4:1718883	A/T	cg05026014	chr4:1749153	NA	-0.33	-9.2	-0.39	1.18e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1322639	0.614	rs6925201	chr6:169563357	C/T	cg03254818	chr6:169586852	NA	-0.44	-6.7	-0.3	6.08e-11	Pulse pressure;
LGG	cis	rs911186	0.947	rs9379962	chr6:27145311	C/T	cg12826209	chr6:26865740	GUSBL1	0.6	8.98	0.39	7.04e-18	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	trans	rs61931739	0.517	rs10844727	chr12:34017435	C/T	cg26384229	chr12:38710491	ALG10B	0.74	15.04	0.57	6.31e-42	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg13206674	chr6:150067644	NUP43	-0.42	-9.05	-0.39	4.13e-18	Testicular germ cell tumor;
LGG	cis	rs7192750	0.586	rs2335714	chr16:71897926	A/G	cg06353428	chr16:71660113	MARVELD3	0.65	9.88	0.42	5.22e-21	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11645453	chr3:52864694	ITIH4	0.41	6.81	0.3	3.1e-11	Bipolar disorder;
LGG	cis	rs2694528	0.858	rs80113651	chr5:60394706	T/A	cg11474532	chr5:59995715	DEPDC1B	0.69	7.4	0.33	6.31e-13	Parkinson's disease;
LGG	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.95	0.42	2.89e-21	Common traits (Other);
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.87e-12	Prudent dietary pattern;
LGG	cis	rs1124376	0.882	rs7618597	chr3:20134588	C/A	cg05072819	chr3:20081367	KAT2B	0.62	8.3	0.36	1.12e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	trans	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.52	9.7	0.41	2.18e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7712401	0.691	rs62377436	chr5:122353702	C/G	cg19412675	chr5:122181750	SNX24	-0.42	-6.85	-0.3	2.34e-11	Mean platelet volume;
LGG	cis	rs6694672	0.510	rs1412638	chr1:196995638	T/C	cg13682187	chr1:196946512	CFHR5	0.51	7.09	0.31	5.1e-12	Asthma;
LGG	cis	rs9878978	0.963	rs115249125	chr3:2470154	G/A	cg21928760	chr3:2462534	CNTN4	0.4	8.77	0.38	3.39e-17	Blood pressure (smoking interaction);
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs10464366	0.544	rs12701697	chr7:39182165	C/T	cg18850127	chr7:39170497	POU6F2	0.65	16.33	0.6	1.11e-47	IgG glycosylation;
LGG	cis	rs3743102	0.591	rs17841171	chr15:83358388	C/T	cg00614314	chr15:82944287	LOC80154	0.75	7.9	0.34	2.02e-14	Colorectal adenoma (advanced);
LGG	trans	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg25214090	chr10:38739885	LOC399744	0.67	11.47	0.47	5.51e-27	Corneal astigmatism;
LGG	cis	rs2046867	0.628	rs61159664	chr3:72916958	C/G	cg26655873	chr3:72818019	SHQ1	0.33	7.12	0.31	4.17e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3812831	0.695	rs8000778	chr13:114944310	T/C	cg22348356	chr13:114891224	RASA3	0.39	7.6	0.33	1.7e-13	Schizophrenia;
LGG	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg25986240	chr4:9926439	SLC2A9	0.39	8.05	0.35	6.81e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4243830	0.850	rs7536908	chr1:6607814	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.49	-6.79	-0.3	3.45e-11	Body mass index;
LGG	cis	rs4737010	0.501	rs990174	chr8:41632230	A/G	cg08923054	chr8:41654455	ANK1	0.77	12.88	0.51	1.15e-32	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.46	-0.71	1.9e-71	Coronary artery disease;
LGG	cis	rs7084402	1.000	rs7910442	chr10:60270260	T/G	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05787120	chr3:50365854	TUSC2	0.37	6.65	0.3	8.28e-11	Obesity-related traits;
LGG	cis	rs7827545	0.545	rs16905172	chr8:135556373	A/G	cg17885191	chr8:135476712	NA	0.6	8.92	0.38	1.05e-17	Hypertension (SNP x SNP interaction);
LGG	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg21132104	chr15:45694354	SPATA5L1	0.67	9.83	0.42	7.8e-21	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.61	-0.44	1.13e-23	Lung cancer;
LGG	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg13902645	chr11:5959945	NA	-0.68	-11.83	-0.48	2.04e-28	DNA methylation (variation);
LGG	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg03929089	chr4:120376271	NA	0.72	9.95	0.42	2.98e-21	Axial length;
LGG	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg06636001	chr8:8085503	FLJ10661	0.39	6.7	0.3	6.01e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7444	0.941	rs4820091	chr22:21940189	T/G	cg15846791	chr22:21984385	YDJC	-0.44	-6.83	-0.3	2.76e-11	Systemic lupus erythematosus;
LGG	trans	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg16141378	chr3:129829833	LOC729375	0.34	7.55	0.33	2.32e-13	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07650554	chr16:30457408	SEPHS2	0.53	8.18	0.36	2.69e-15	Gut microbiome composition (summer);
LGG	cis	rs10893109	0.517	rs1377604	chr11:123775759	A/C	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2354432	0.607	rs68080346	chr1:146708484	T/C	cg25205988	chr1:146714368	CHD1L	-1.42	-13.9	-0.54	5.82e-37	Mitochondrial DNA levels;
LGG	cis	rs12477438	0.501	rs17759607	chr2:99737005	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	trans	rs8073060	0.586	rs225264	chr17:33961335	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs988958	0.526	rs10084239	chr2:42253746	G/T	cg27428208	chr2:42229179	NA	-0.52	-7.86	-0.34	2.75e-14	Hypospadias;
LGG	cis	rs28830936	0.966	rs62002090	chr15:42092326	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.02	-0.52	3.12e-33	Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.8	0.59	2.6e-45	Lung cancer;
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.4	0.33	6.26e-13	Tonsillectomy;
LGG	cis	rs9790314	0.723	rs10936223	chr3:160884313	C/A	cg03342759	chr3:160939853	NMD3	-0.62	-11.09	-0.46	1.65e-25	Morning vs. evening chronotype;
LGG	cis	rs3741404	0.512	rs4980504	chr11:63873083	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.35	-7.02	-0.31	7.72e-12	Platelet count;
LGG	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg03735888	chr19:58951602	ZNF132	0.41	8.1	0.35	4.78e-15	Uric acid clearance;
LGG	cis	rs921968	0.541	rs2710246	chr2:219533894	C/T	cg01130898	chr2:219473002	PLCD4	-0.47	-7.94	-0.35	1.53e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7811142	0.830	rs73401450	chr7:99981859	G/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.92	-0.42	3.72e-21	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13321609	chr19:36119900	RBM42	0.47	6.9	0.31	1.67e-11	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.06	0.39	3.82e-18	Fuchs's corneal dystrophy;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs11122272	0.735	rs722302	chr1:231480152	A/C	cg10503236	chr1:231470652	EXOC8	-0.35	-6.71	-0.3	5.7e-11	Hemoglobin concentration;
LGG	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.39	0.32	7.07e-13	Monocyte count;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg23758822	chr17:41437982	NA	0.87	15.47	0.58	7.84e-44	Menopause (age at onset);
LGG	cis	rs10793273	1	rs10793273	chr11:77742595	T/C	cg09721595	chr11:77773924	THRSP	-0.57	-14.0	-0.55	2.23e-37	Pelvic organ prolapse;
LGG	cis	rs6868223	0.617	rs10050883	chr5:33643078	G/A	cg10594543	chr5:33649717	ADAMTS12	0.67	15.89	0.59	1.08e-45	Mortality in heart failure;
LGG	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	cis	rs4950322	0.570	rs72691090	chr1:146769569	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.12	-0.35	4.18e-15	Protein quantitative trait loci;
LGG	cis	rs17001868	0.568	rs9611329	chr22:40792038	G/T	cg07138101	chr22:40742427	ADSL	0.65	8.57	0.37	1.52e-16	Mammographic density (dense area);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08661693	chr20:49574504	DPM1;MOCS3	0.48	7.76	0.34	5.49e-14	Cognitive performance;
LGG	cis	rs7191439	0.657	rs3826076	chr16:88780518	C/T	cg02389323	chr16:88786976	FAM38A	-1.08	-13.43	-0.53	5.72e-35	Plateletcrit;
LGG	cis	rs11864453	0.647	rs9941346	chr16:72135707	C/G	cg01557791	chr16:72042693	DHODH	-0.46	-8.4	-0.36	5.51e-16	Fibrinogen levels;
LGG	trans	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg24247370	chr13:99142703	STK24	-0.43	-7.91	-0.35	1.86e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg09307838	chr4:120376055	NA	0.81	13.59	0.53	1.19e-35	Corneal astigmatism;
LGG	cis	rs61897795	0.657	rs174589	chr11:61615803	C/G	cg19610905	chr11:61596333	FADS2	0.62	8.93	0.38	1.02e-17	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs977987	0.806	rs4888411	chr16:75443183	T/A	cg03315344	chr16:75512273	CHST6	0.51	10.23	0.43	2.89e-22	Dupuytren's disease;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs56283067	0.887	rs9472365	chr6:44770214	C/G	cg20913747	chr6:44695427	NA	0.62	10.53	0.44	2.23e-23	Total body bone mineral density;
LGG	cis	rs11874712	0.931	rs8095608	chr18:43678911	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.59	-0.44	1.35e-23	Migraine - clinic-based;
LGG	trans	rs853679	0.556	rs13200214	chr6:28017250	C/T	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.85	-0.48	1.82e-28	Depression;
LGG	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg04691961	chr3:161091175	C3orf57	0.44	9.29	0.4	6.26e-19	Morning vs. evening chronotype;
LGG	cis	rs9527	0.615	rs36045108	chr10:104697929	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	cis	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg07460842	chr6:66804631	NA	0.83	13.45	0.53	4.6e-35	Exhaled nitric oxide output;
LGG	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.31	6.92	0.31	1.5e-11	Coronary artery disease;
LGG	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.29	0.7	1.29e-70	Chronic sinus infection;
LGG	cis	rs7924176	0.580	rs12360119	chr10:76015316	G/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.96	-0.31	1.13e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg09177884	chr7:1199841	ZFAND2A	0.48	8.13	0.35	4.04e-15	Longevity;Endometriosis;
LGG	cis	rs7084402	0.967	rs1365741	chr10:60277489	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs12893668	0.572	rs4900591	chr14:104154878	G/A	cg23335576	chr14:104009727	NA	0.42	7.12	0.31	4.21e-12	Reticulocyte count;
LGG	cis	rs17169635	0.642	rs4732064	chr7:134552146	T/G	cg02516134	chr7:134575187	CALD1	-0.4	-7.93	-0.35	1.67e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg04845077	chr9:34126958	DCAF12	0.4	6.65	0.3	8.51e-11	Prudent dietary pattern;
LGG	cis	rs68170813	0.605	rs2299428	chr7:107134384	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.09	-0.42	9.08e-22	Coronary artery disease;
LGG	cis	rs4665809	0.618	rs7579199	chr2:26266496	G/A	cg22920501	chr2:26401640	FAM59B	-0.39	-7.8	-0.34	4.04e-14	Gut microbiome composition (summer);
LGG	cis	rs4315565	0.688	rs6546477	chr2:69281345	G/T	cg13358873	chr2:69271042	ANTXR1	0.48	7.27	0.32	1.57e-12	Height;
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.21	-0.32	2.36e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg24375607	chr4:120327624	NA	0.54	9.27	0.4	7.02e-19	Corneal astigmatism;
LGG	cis	rs523522	0.962	rs4767903	chr12:120930046	G/A	cg27279351	chr12:120934652	DYNLL1	0.79	12.69	0.51	6.82e-32	High light scatter reticulocyte count;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-10.4	-0.44	6.57e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21482837	chr2:85581528	ELMOD3;RETSAT	0.42	6.77	0.3	3.89e-11	Cognitive performance;
LGG	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9487051	1.000	rs9400273	chr6:109632799	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.18	-0.36	2.75e-15	Reticulocyte fraction of red cells;
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg16141378	chr3:129829833	LOC729375	0.43	10.0	0.42	1.86e-21	Neuroticism;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.69	-0.37	6.11e-17	Obesity-related traits;
LGG	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg00864171	chr11:67383662	NA	-0.43	-6.94	-0.31	1.37e-11	Mean corpuscular volume;
LGG	cis	rs8141529	0.636	rs5762813	chr22:29203314	C/T	cg02153584	chr22:29168773	CCDC117	0.58	8.21	0.36	2.21e-15	Lymphocyte counts;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	18.71	0.66	1.42e-58	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07880005	chr17:34842371	ZNHIT3	0.43	6.99	0.31	9.54e-12	Gut microbiome composition (summer);
LGG	trans	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-8.45	-0.37	3.68e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs2120243	0.508	rs4435581	chr3:157096217	G/A	cg24825693	chr3:157122686	VEPH1	-0.57	-12.94	-0.52	6.44e-33	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs12738007	0.967	rs4654393	chr1:29534437	G/A	cg01115565	chr1:29584222	PTPRU	-0.27	-7.39	-0.32	6.7e-13	Schizophrenia;
LGG	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.97	0.42	2.39e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2730245	0.569	rs1188955	chr7:158690866	A/G	cg14689365	chr7:158441557	NCAPG2	0.6	10.2	0.43	3.72e-22	Height;
LGG	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-14.32	-0.55	8.94e-39	Colorectal cancer;
LGG	cis	rs2276314	0.762	rs3826600	chr18:33609053	A/G	cg19628046	chr18:33552617	C18orf21	0.52	7.51	0.33	2.99e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs12497850	0.864	rs4279134	chr3:49156676	A/G	cg07636037	chr3:49044803	WDR6	1.11	26.73	0.78	6.59e-96	Parkinson's disease;
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg08888203	chr3:10149979	C3orf24	0.55	9.41	0.4	2.35e-19	Alzheimer's disease;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg10295955	chr4:187884368	NA	-1.13	-31.33	-0.82	1.79e-116	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13266463	0.898	rs13267784	chr8:143394915	C/T	cg16886403	chr8:143471632	TSNARE1	0.48	7.71	0.34	7.93e-14	Schizophrenia;
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg02297831	chr4:17616191	MED28	0.51	9.28	0.4	6.31e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg12654349	chr5:56205094	C5orf35	0.57	9.82	0.42	8.45e-21	Initial pursuit acceleration;
LGG	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg13902645	chr11:5959945	NA	-0.64	-11.25	-0.46	4.08e-26	DNA methylation (variation);
LGG	cis	rs4262150	0.726	rs10515676	chr5:152013887	G/A	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs6466055	0.720	rs4730080	chr7:105001133	T/C	cg04380332	chr7:105027541	SRPK2	-0.38	-7.1	-0.31	4.79e-12	Schizophrenia;
LGG	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.71	13.26	0.52	3.14e-34	Personality dimensions;
LGG	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs8180040	0.966	rs34634681	chr3:47579102	G/A	cg16586182	chr3:47516702	SCAP	0.77	14.85	0.57	4.44e-41	Colorectal cancer;
LGG	cis	rs3735485	0.678	rs2083366	chr7:45137850	G/A	cg03440944	chr7:45023329	C7orf40	-0.55	-9.04	-0.39	4.34e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs881375	0.678	rs3761846	chr9:123689597	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.06	0.49	2.69e-29	Rheumatoid arthritis;
LGG	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.12e-18	Fuchs's corneal dystrophy;
LGG	cis	rs55823223	0.648	rs11867560	chr17:73857206	A/G	cg14829360	chr17:73884958	NA	-0.78	-12.91	-0.51	8.63e-33	Psoriasis;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg06916706	chr16:4465613	CORO7	-0.72	-12.64	-0.51	1.1e-31	Schizophrenia;
LGG	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.9	0.38	1.24e-17	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09295382	chr4:106068032	TET2	0.43	7.07	0.31	5.73e-12	Cognitive performance;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.38	0.43	7.82e-23	Personality dimensions;
LGG	cis	rs972578	0.765	rs7285844	chr22:43297680	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.82	-0.3	2.87e-11	Mean platelet volume;
LGG	cis	rs56775891	0.527	rs71367545	chr18:77576337	G/A	cg13263691	chr18:77568018	NA	0.55	7.24	0.32	1.83e-12	Schizophrenia;
LGG	cis	rs7927771	0.832	rs7924485	chr11:47419129	A/G	cg20307385	chr11:47447363	PSMC3	0.58	10.54	0.44	1.95e-23	Subjective well-being;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg24829409	chr8:58192753	C8orf71	-0.65	-8.45	-0.37	3.68e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2933343	1.000	rs2929859	chr3:128608341	T/G	cg25356066	chr3:128598488	ACAD9	0.46	6.85	0.3	2.39e-11	IgG glycosylation;
LGG	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg22903471	chr2:27725779	GCKR	-0.54	-12.16	-0.49	1.07e-29	Total body bone mineral density;
LGG	cis	rs116095464	0.558	rs12173244	chr5:269524	G/A	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs17453880	0.929	rs4612055	chr5:151963332	C/T	cg12297329	chr5:152029980	NA	0.86	21.98	0.71	7.27e-74	Subjective well-being;
LGG	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9354308	0.727	rs2351718	chr6:66597295	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs11098499	1.000	rs58601355	chr4:120186367	T/C	cg24375607	chr4:120327624	NA	0.61	9.87	0.42	5.77e-21	Corneal astigmatism;
LGG	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg06951627	chr6:26196580	NA	0.49	7.74	0.34	6.21e-14	Gout;Renal underexcretion gout;
LGG	cis	rs2952156	0.916	rs903506	chr17:37879762	G/A	cg00129232	chr17:37814104	STARD3	-0.73	-15.18	-0.58	1.58e-42	Asthma;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg05368731	chr17:41323189	NBR1	-0.88	-17.26	-0.63	6.81e-52	Menopause (age at onset);
LGG	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg03342759	chr3:160939853	NMD3	0.44	7.47	0.33	4.09e-13	Morning vs. evening chronotype;
LGG	cis	rs7529073	0.740	rs340883	chr1:214145706	A/G	cg05052969	chr1:214156842	NA	0.42	7.89	0.34	2.16e-14	Schizophrenia;
LGG	cis	rs7103648	0.630	rs7934481	chr11:47883337	C/T	cg20307385	chr11:47447363	PSMC3	0.81	16.33	0.6	1.15e-47	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs8114671	0.967	rs6088747	chr20:33754604	G/T	cg07148914	chr20:33460835	GGT7	0.42	6.66	0.3	7.96e-11	Height;
LGG	cis	rs1018697	1.000	rs7092346	chr10:104559764	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.0	0.39	5.81e-18	Colorectal adenoma (advanced);
LGG	cis	rs9611565	0.649	rs2413659	chr22:42164862	A/G	cg17376030	chr22:41985996	PMM1	-0.55	-9.05	-0.39	4e-18	Vitiligo;
LGG	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.42	0.53	6.19e-35	Colorectal cancer;
LGG	cis	rs9972944	0.729	rs2024275	chr17:63768913	C/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs10754283	0.967	rs2390763	chr1:90105688	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.36	-0.32	8.73e-13	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs10463316	0.817	rs7713109	chr5:150789284	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.13	-0.43	6.41e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg07395648	chr5:131743802	NA	0.56	13.17	0.52	7.52e-34	Blood metabolite levels;
LGG	trans	rs61931739	0.534	rs2087128	chr12:34000173	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.84	0.42	6.98e-21	Morning vs. evening chronotype;
LGG	trans	rs208520	0.874	rs208473	chr6:66917265	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.58	-0.59	2.52e-44	Exhaled nitric oxide output;
LGG	cis	rs6540556	0.723	rs12090931	chr1:209889601	A/G	cg23920097	chr1:209922102	NA	-0.43	-6.92	-0.31	1.52e-11	Red blood cell count;
LGG	cis	rs11920090	0.800	rs60120444	chr3:170747667	G/A	cg09710316	chr3:170744871	SLC2A2	0.63	8.04	0.35	7.75e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs11209002	0.567	rs983111	chr1:67539356	T/C	cg02640540	chr1:67518911	SLC35D1	0.39	6.65	0.3	8.13e-11	Crohn's disease;
LGG	cis	rs3741404	0.672	rs4980524	chr11:63959259	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	14.54	0.56	1.03e-39	Platelet count;
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.32	0.4	4.66e-19	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04024692	chr11:16760046	C11orf58	0.45	7.48	0.33	3.73e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	1.01e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	8.49	0.37	2.84e-16	Coronary artery disease;
LGG	cis	rs1386478	0.853	rs7631864	chr3:113795834	A/G	cg14431476	chr3:113822413	NA	0.44	6.95	0.31	1.21e-11	Crohn's disease and psoriasis;
LGG	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg02487422	chr3:49467188	NICN1	0.58	10.73	0.45	3.81e-24	Resting heart rate;
LGG	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg17911788	chr17:44343683	NA	0.53	8.23	0.36	1.96e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1387259	0.931	rs1107654	chr12:48681097	T/G	cg24011408	chr12:48396354	COL2A1	0.49	7.7	0.34	8.04e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs17253792	0.822	rs17683728	chr14:56060389	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	trans	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.43	-0.4	1.98e-19	Diabetic kidney disease;
LGG	cis	rs7474896	0.583	rs10827818	chr10:38000856	T/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.62	-0.33	1.43e-13	Obesity (extreme);
LGG	cis	rs1799949	1.000	rs67060599	chr17:41255102	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.31	0.32	1.15e-12	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs9895920	chr17:61852719	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.23	0.32	1.95e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.11	0.31	4.47e-12	Lung cancer;
LGG	cis	rs7143963	0.945	rs2295402	chr14:103338324	T/A	cg23020514	chr14:103360112	TRAF3	0.5	9.83	0.42	7.91e-21	Body mass index;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs9549260	0.755	rs17061450	chr13:41183716	G/A	cg21288729	chr13:41239152	FOXO1	0.33	6.7	0.3	5.99e-11	Red blood cell count;
LGG	cis	rs7192750	0.583	rs2550043	chr16:72067491	T/C	cg06353428	chr16:71660113	MARVELD3	0.9	8.29	0.36	1.2e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg02002194	chr4:3960332	NA	0.45	8.3	0.36	1.12e-15	Monocyte count;
LGG	cis	rs1182180	0.538	rs4722006	chr7:2765723	A/G	cg05793240	chr7:2802953	GNA12	0.31	7.62	0.33	1.48e-13	Platelet count;
LGG	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-10.16	-0.43	5.18e-22	Hepatocellular carcinoma;
LGG	cis	rs5742933	0.744	rs12693557	chr2:190590937	G/A	cg10453823	chr2:190539512	ANKAR	-0.46	-6.88	-0.3	1.9e-11	Ferritin levels;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg09699651	chr6:150184138	LRP11	0.53	9.49	0.4	1.2e-19	Lung cancer;
LGG	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg00689492	chr4:1303491	MAEA	0.45	7.77	0.34	4.96e-14	Obesity-related traits;
LGG	cis	rs2797369	0.583	rs7740295	chr6:101549059	T/G	cg27451362	chr6:101846650	GRIK2	-0.85	-11.52	-0.47	3.65e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg21605333	chr4:119757512	SEC24D	1.45	14.6	0.56	5.32e-40	Cannabis dependence symptom count;
LGG	cis	rs975722	0.615	rs12534210	chr7:117322403	G/T	cg10524701	chr7:117356490	CTTNBP2	0.5	10.29	0.43	1.61e-22	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs77741769	0.571	rs12822123	chr12:121298644	C/T	cg02419362	chr12:121203948	SPPL3	0.52	9.07	0.39	3.47e-18	Mean corpuscular volume;
LGG	cis	rs2952156	0.920	rs2934951	chr17:37833328	A/G	cg00129232	chr17:37814104	STARD3	-0.75	-16.29	-0.6	1.72e-47	Asthma;
LGG	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.52	0.37	2.33e-16	Alzheimer's disease (survival time);
LGG	cis	rs10782582	0.593	rs17848068	chr1:76190216	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-6.74	-0.3	4.63e-11	Daytime sleep phenotypes;
LGG	cis	rs10426930	0.714	rs858422	chr19:5049483	T/C	cg15621731	chr19:5074616	KDM4B	0.33	7.95	0.35	1.4e-14	Monocyte percentage of white cells;
LGG	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg20040747	chr15:74715105	SEMA7A	0.45	9.94	0.42	3.18e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs6942756	0.840	rs963465	chr7:128875612	C/G	cg02491457	chr7:128862824	NA	0.66	12.5	0.5	4.11e-31	White matter hyperintensity burden;
LGG	cis	rs4299518	0.504	rs2673052	chr3:45733827	A/T	cg04837898	chr3:45731254	SACM1L	-0.38	-7.58	-0.33	1.89e-13	Hirschsprung disease;
LGG	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03264133	chr6:25882463	NA	0.54	9.87	0.42	5.53e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6982240	0.514	rs7002268	chr8:142277340	A/G	cg20799268	chr8:142275649	NA	-0.24	-6.66	-0.3	7.83e-11	Tonsillectomy;
LGG	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg10503236	chr1:231470652	EXOC8	0.36	7.01	0.31	8.62e-12	Hemoglobin concentration;
LGG	cis	rs2153535	0.541	rs6938688	chr6:8521629	G/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.17e-18	Motion sickness;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.72	-0.41	1.96e-20	Lewy body disease;
LGG	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg13271783	chr10:134563150	INPP5A	-0.45	-7.03	-0.31	7.23e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs953387	1.000	rs12473760	chr2:136905697	C/A	cg07169764	chr2:136633963	MCM6	0.53	8.91	0.38	1.15e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs7949030	0.523	rs12223627	chr11:62368557	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.6	12.92	0.51	8.23e-33	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg13207630	chr7:32358064	NA	0.69	7.47	0.33	4.11e-13	Body mass index;
LGG	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg00325661	chr8:49890786	NA	0.5	8.93	0.38	1.02e-17	Sudden cardiac arrest;
LGG	cis	rs1355223	0.902	rs34875830	chr11:34722205	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.77	-0.3	4e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9948	0.521	rs62156207	chr2:97359236	C/A	cg01990225	chr2:97406019	LMAN2L	-0.7	-7.02	-0.31	7.79e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg05335186	chr13:53173507	NA	0.42	8.37	0.36	6.83e-16	Lewy body disease;
LGG	cis	rs17221829	0.733	rs12363392	chr11:89370598	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs4077515	0.839	rs10781518	chr9:139300547	C/T	cg21253087	chr9:139290292	SNAPC4	-0.35	-7.08	-0.31	5.44e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.12	0.66	1.69e-60	Personality dimensions;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg08277100	chr3:109115356	NA	0.36	6.82	0.3	2.8e-11	Parkinson's disease (motor and cognition);
LGG	cis	rs6988985	0.728	rs5303	chr8:143955095	A/G	cg10324643	chr8:143916377	GML	0.4	8.01	0.35	9.2e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11967485	0.609	rs72998904	chr6:157164875	C/T	cg23222435	chr6:157204239	ARID1B	-0.81	-7.43	-0.33	5.22e-13	Calcium levels;
LGG	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Metabolite levels (small molecules and protein measures);
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg13736514	chr6:26305472	NA	-0.46	-9.62	-0.41	4.33e-20	Educational attainment;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs4713118	0.513	rs156738	chr6:28014025	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.48	-6.95	-0.31	1.26e-11	Parkinson's disease;
LGG	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg21475434	chr5:93447410	FAM172A	0.69	6.99	0.31	9.64e-12	Diabetic retinopathy;
LGG	cis	rs4906332	1.000	rs12885234	chr14:103889181	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.94	-0.35	1.53e-14	Coronary artery disease;
LGG	cis	rs9487051	0.676	rs9374077	chr6:109600194	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.31e-14	Reticulocyte fraction of red cells;
LGG	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg05890377	chr2:74357713	NA	0.49	9.82	0.42	8.31e-21	Gestational age at birth (maternal effect);
LGG	trans	rs1941687	0.563	rs7238931	chr18:31334993	G/A	cg27147174	chr7:100797783	AP1S1	-0.67	-12.69	-0.51	6.95e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs769267	0.929	rs34538000	chr19:19481379	G/T	cg03709012	chr19:19516395	GATAD2A	-0.84	-17.06	-0.62	5.5e-51	Tonsillectomy;
LGG	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.08e-14	Vitiligo;
LGG	cis	rs709400	0.859	rs7154948	chr14:104022944	C/T	cg26031613	chr14:104095156	KLC1	1.14	25.69	0.77	4.12e-91	Body mass index;
LGG	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg02023728	chr11:77925099	USP35	0.46	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs785830	0.717	rs542669	chr9:224367	G/C	cg14500300	chr9:211689	NA	0.31	7.72	0.34	7.42e-14	Platelet distribution width;
LGG	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg08999081	chr20:33150536	PIGU	0.39	9.72	0.41	1.91e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Myopia (pathological);
LGG	cis	rs2180341	0.889	rs9321074	chr6:127618019	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.44	0.72	4.93e-76	Breast cancer;
LGG	trans	rs7404843	0.925	rs7404803	chr16:15530454	T/C	cg02716450	chr16:28638775	NA	-0.72	-7.55	-0.33	2.31e-13	Testicular germ cell tumor;
LGG	cis	rs9419702	0.614	rs4897816	chr10:133533646	G/A	cg04492858	chr10:133558786	NA	0.43	8.59	0.37	1.36e-16	Survival in rectal cancer;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.4	0.33	6.47e-13	Schizophrenia;
LGG	cis	rs3806843	0.648	rs702399	chr5:140024432	C/T	cg19875535	chr5:140030758	IK	-0.58	-12.3	-0.5	2.81e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg11965913	chr1:205819406	PM20D1	0.84	18.42	0.65	2.93e-57	Menarche (age at onset);
LGG	cis	rs13177718	0.908	rs7713158	chr5:108179300	G/A	cg20423064	chr5:108166851	FER	-0.82	-8.94	-0.38	9.27e-18	Height;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg05896524	chr21:47604654	C21orf56	0.64	10.79	0.45	2.39e-24	Testicular germ cell tumor;
LGG	trans	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.53	-0.37	2.09e-16	Neuroticism;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg00713939	chr8:144660590	NAPRT1	0.9	7.09	0.31	5.19e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs826838	1.000	rs1393537	chr12:38920961	C/T	cg13010199	chr12:38710504	ALG10B	0.76	16.28	0.6	1.88e-47	Heart rate;
LGG	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.45e-20	Life satisfaction;
LGG	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg16141378	chr3:129829833	LOC729375	0.31	6.93	0.31	1.46e-11	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.12	0.55	6.83e-38	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg00717180	chr2:96193071	NA	-0.44	-7.64	-0.33	1.23e-13	HDL cholesterol;
LGG	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg23583168	chr7:148888333	NA	-0.88	-17.21	-0.62	1.16e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg04568710	chr12:38710424	ALG10B	0.34	7.09	0.31	4.98e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg25114630	chr15:101792522	CHSY1	0.56	9.51	0.4	1.04e-19	Corneal structure;
LGG	trans	rs3857536	0.776	rs4710583	chr6:66940101	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs2731664	0.792	rs335467	chr5:176890642	A/G	cg23176889	chr5:176863531	GRK6	-0.63	-12.51	-0.5	4.05e-31	Intelligence (multi-trait analysis);
LGG	cis	rs1497828	1.000	rs1391285	chr1:217561468	C/T	cg04411442	chr1:217543379	NA	0.46	7.89	0.34	2.13e-14	Dialysis-related mortality;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg19077165	chr18:44547161	KATNAL2	0.59	11.0	0.46	3.83e-25	Personality dimensions;
LGG	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.11	-0.43	7.56e-22	Mood instability;
LGG	cis	rs1003719	0.680	rs1034357	chr21:38571482	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	cis	rs9419702	0.639	rs9419624	chr10:133534822	G/A	cg04492858	chr10:133558786	NA	0.43	8.75	0.38	4.02e-17	Survival in rectal cancer;
LGG	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.94e-11	Aortic root size;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.67e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.582	rs4917973	chr10:104333700	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10799590	0.861	rs61676104	chr1:224835021	T/C	cg21444086	chr1:224821584	CNIH3	-0.34	-6.72	-0.3	5.37e-11	Opioid dependence;
LGG	cis	rs3768617	0.706	rs9943067	chr1:182975102	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.36	7.07	0.31	5.72e-12	Fuchs's corneal dystrophy;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22633769	chr20:60982531	CABLES2	0.53	8.17	0.36	2.88e-15	Colorectal cancer;
LGG	trans	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg02002194	chr4:3960332	NA	0.49	9.33	0.4	4.54e-19	Mood instability;
LGG	cis	rs9902453	0.904	rs7225686	chr17:28356744	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs4595586	0.545	rs67985200	chr12:39386891	C/T	cg26384229	chr12:38710491	ALG10B	0.65	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs523522	0.962	rs10744752	chr12:120900554	T/G	cg12219531	chr12:120966889	COQ5	0.62	10.0	0.42	1.85e-21	High light scatter reticulocyte count;
LGG	cis	rs4474465	0.850	rs4482052	chr11:78263331	A/G	cg02023728	chr11:77925099	USP35	-0.39	-6.82	-0.3	2.9100000000000002e-11	Alzheimer's disease (survival time);
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.72	0.38	5.15e-17	Schizophrenia;
LGG	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg12046867	chr14:103022105	NA	-0.7	-13.48	-0.53	3.53e-35	Platelet count;
LGG	cis	rs11608355	0.846	rs4766472	chr12:109853602	C/G	cg19025524	chr12:109796872	NA	-0.4	-6.84	-0.3	2.5e-11	Neuroticism;
LGG	cis	rs3736594	0.759	rs6753736	chr2:27958855	C/G	cg27432699	chr2:27873401	GPN1	-0.58	-9.19	-0.39	1.37e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06481639	chr22:41940642	POLR3H	0.55	7.77	0.34	4.95e-14	Vitiligo;
LGG	cis	rs10089	0.953	rs6887674	chr5:127531183	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.13	0.46	1.15e-25	Ileal carcinoids;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg16301924	chr13:53314226	LECT1	-0.44	-8.86	-0.38	1.66e-17	Lewy body disease;
LGG	cis	rs7769051	0.711	rs6569847	chr6:133083187	C/A	cg07930552	chr6:133119739	C6orf192	0.88	11.31	0.47	2.3e-26	Type 2 diabetes nephropathy;
LGG	cis	rs2933343	0.951	rs9871612	chr3:128570402	C/T	cg25356066	chr3:128598488	ACAD9	0.48	7.02	0.31	7.82e-12	IgG glycosylation;
LGG	cis	rs6089584	0.546	rs6061978	chr20:60615604	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-13.27	-0.52	2.87e-34	Body mass index;
LGG	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg17646820	chr3:66848679	NA	0.51	7.82	0.34	3.49e-14	Type 2 diabetes;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg11062466	chr8:58055876	NA	0.6	10.01	0.42	1.74e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7044106	0.791	rs2416798	chr9:123480603	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.16	0.32	3.29e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs5758511	0.573	rs738248	chr22:42196467	A/G	cg15128208	chr22:42549153	NA	-0.42	-7.27	-0.32	1.53e-12	Birth weight;
LGG	cis	rs2617583	0.904	rs2937639	chr5:1443728	A/G	cg07151155	chr5:1473589	LPCAT1	-0.37	-7.31	-0.32	1.18e-12	Breast cancer;
LGG	trans	rs17685	0.712	rs9800948	chr7:75810473	A/G	cg19862616	chr7:65841803	NCRNA00174	1.0	22.18	0.72	8.27e-75	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg09699651	chr6:150184138	LRP11	0.54	9.33	0.4	4.31e-19	Lung cancer;
LGG	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg17749961	chr2:30669863	LCLAT1	0.72	10.13	0.43	6.48e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg08807101	chr21:30365312	RNF160	-0.62	-10.56	-0.44	1.74e-23	Dental caries;
LGG	cis	rs7523273	0.565	rs2796234	chr1:207900695	T/A	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.75	-0.38	4.07e-17	Schizophrenia;
LGG	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg14541582	chr5:601475	NA	-0.68	-10.2	-0.43	3.68e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs7586879	0.639	rs6545776	chr2:25099357	A/C	cg04586622	chr2:25135609	ADCY3	0.44	11.76	0.48	4.12e-28	Body mass index;
LGG	cis	rs7523273	0.606	rs2724387	chr1:207932617	T/G	cg22525895	chr1:207977042	MIR29B2	0.6	11.9	0.48	1.1e-28	Schizophrenia;
LGG	cis	rs17376456	0.569	rs11135394	chr5:93187135	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.96	-0.35	1.34e-14	Diabetic retinopathy;
LGG	cis	rs9640161	0.711	rs55881542	chr7:150025734	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.81	-17.12	-0.62	2.77e-51	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs11039798	0.528	rs10839208	chr11:49030456	C/T	cg15704280	chr7:45808275	SEPT13	0.77	10.83	0.45	1.61e-24	Axial length;
LGG	cis	rs7937890	0.559	rs2597219	chr11:14530866	C/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.47	0.33	4.1e-13	Colorectal cancer;
LGG	trans	rs7939886	0.920	rs11227449	chr11:55949409	A/G	cg03929089	chr4:120376271	NA	0.72	6.65	0.3	8.46e-11	Myopia (pathological);
LGG	trans	rs61931739	0.534	rs11053047	chr12:34161084	C/T	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.3e-49	Morning vs. evening chronotype;
LGG	cis	rs6748734	0.894	rs4675869	chr2:241827696	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.09	-0.46	1.6e-25	Urinary metabolites;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg27219399	chr15:67835830	MAP2K5	0.32	7.01	0.31	8.21e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs1577917	0.958	rs72907388	chr6:86440207	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.79	-0.45	2.33e-24	Response to antipsychotic treatment;
LGG	cis	rs4959677	0.725	rs1680832	chr6:2504051	G/C	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.6e-15	Orthostatic hypotension;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.17	0.39	1.62e-18	Bipolar disorder;
LGG	cis	rs7904985	1.000	rs12777097	chr10:88115638	G/A	cg07322936	chr10:88137208	NA	-0.48	-7.27	-0.32	1.5e-12	Barrett's esophagus;
LGG	cis	rs4919044	0.808	rs835271	chr10:94791678	C/T	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs854037	0.630	rs12659683	chr5:57129898	A/G	cg08523694	chr5:57076192	NA	0.55	8.05	0.35	7.14e-15	Birth weight;
LGG	cis	rs9534288	0.830	rs1126363	chr13:46633459	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs1408799	0.732	rs10960778	chr9:12756528	G/A	cg05274944	chr9:12693694	TYRP1	0.34	8.15	0.35	3.5e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.25	-0.49	4.36e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7843479	0.582	rs11135743	chr8:21803008	A/G	cg17168535	chr8:21777572	XPO7	0.83	16.42	0.61	4.51e-48	Mean corpuscular volume;
LGG	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.98	0.31	1e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2290159	0.800	rs3730269	chr3:12653233	G/T	cg23032965	chr3:12705835	RAF1	0.66	9.64	0.41	3.61e-20	Cholesterol, total;
LGG	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg00204512	chr16:28754710	NA	0.25	7.29	0.32	1.39e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1847505	0.520	rs79998091	chr13:61483843	C/G	cg25164009	chr13:61490935	NA	0.56	9.74	0.41	1.58e-20	Polychlorinated biphenyl levels;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg12379764	chr21:47803548	PCNT	-0.51	-8.04	-0.35	7.44e-15	Testicular germ cell tumor;
LGG	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg00647317	chr7:50633725	DDC	-0.36	-8.22	-0.36	2.08e-15	Malaria;
LGG	cis	rs62238980	0.614	rs118010731	chr22:32376308	G/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs7945705	0.747	rs10840158	chr11:9020897	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.72	-0.48	5.64e-28	Hemoglobin concentration;
LGG	cis	rs6977660	0.882	rs7781975	chr7:19849629	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	8.03	0.35	8.39e-15	Thyroid stimulating hormone;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.18	0.36	2.69e-15	Longevity;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.13	-33.08	-0.84	4.79e-124	Prudent dietary pattern;
LGG	cis	rs12497850	0.931	rs6442130	chr3:48778027	A/G	cg06212747	chr3:49208901	KLHDC8B	0.61	9.98	0.42	2.18e-21	Parkinson's disease;
LGG	cis	rs7129556	0.702	rs7123080	chr11:77499387	C/T	cg12586386	chr11:77299805	AQP11	0.44	7.33	0.32	1.06e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs2470578	0.792	rs2733517	chr3:17323763	G/A	cg20981856	chr3:17787350	NA	0.35	6.73	0.3	5.05e-11	Schizophrenia;
LGG	cis	rs10851411	0.697	rs62022316	chr15:42770362	T/C	cg21293051	chr15:42870591	STARD9	0.49	7.17	0.32	2.95e-12	Glucose homeostasis traits;
LGG	cis	rs9443645	0.803	rs12195716	chr6:79535412	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.48	-0.37	3.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7646881	1.000	rs59217052	chr3:158452456	C/T	cg19483011	chr3:158453295	NA	-0.66	-9.92	-0.42	3.55e-21	Tetralogy of Fallot;
LGG	cis	rs6502050	0.835	rs67106357	chr17:80116826	T/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg13647721	chr17:30228624	UTP6	0.6	7.84	0.34	3.11e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6594713	0.566	rs35093510	chr5:112925555	A/G	cg12552261	chr5:112820674	MCC	0.61	7.62	0.33	1.44e-13	Brain cytoarchitecture;
LGG	cis	rs9952991	0.941	rs2542149	chr18:12779018	G/A	cg23544223	chr18:12777786	NA	0.62	9.35	0.4	3.76e-19	Inflammatory skin disease;
LGG	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg26384229	chr12:38710491	ALG10B	0.75	14.97	0.57	1.39e-41	Morning vs. evening chronotype;
LGG	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg24623649	chr8:11872141	NA	-0.31	-7.23	-0.32	1.95e-12	Triglycerides;
LGG	cis	rs3733585	0.673	rs4292332	chr4:9953830	C/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06873684	chr19:4472059	HDGF2	0.4	7.19	0.32	2.68e-12	Obesity-related traits;
LGG	cis	rs1957429	0.614	rs76809238	chr14:65380579	C/T	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs1620921	0.774	rs2565721	chr6:161235098	A/G	cg01280913	chr6:161186852	NA	-0.34	-7.05	-0.31	6.56e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.55	8.69	0.37	6.32e-17	Renal function-related traits (BUN);
LGG	cis	rs10463554	0.889	rs34775	chr5:102451276	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.71	-0.34	7.75e-14	Parkinson's disease;
LGG	cis	rs8072100	0.967	rs4794001	chr17:45720849	T/C	cg19784903	chr17:45786737	TBKBP1	-0.35	-7.76	-0.34	5.47e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.73	-0.38	4.81e-17	Retinal vascular caliber;
LGG	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs6601327	0.607	rs35316422	chr8:9575129	G/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.79	-0.34	4.58e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.24	0.49	4.82e-30	Obesity-related traits;
LGG	cis	rs854765	0.964	rs2230316	chr17:17997209	C/T	cg05444541	chr17:17804740	TOM1L2	0.58	13.28	0.53	2.57e-34	Total body bone mineral density;
LGG	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg04226714	chr8:49833948	SNAI2	-0.43	-7.49	-0.33	3.42e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg16950941	chr11:66035639	RAB1B	0.55	10.23	0.43	2.78e-22	Gout;
LGG	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg02297831	chr4:17616191	MED28	0.47	8.38	0.36	6.48e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg16486109	chr11:613632	IRF7	0.41	7.34	0.32	9.65e-13	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs7084402	0.967	rs7087998	chr10:60271531	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.56e-55	Refractive error;
LGG	cis	rs6964587	1.000	rs10228334	chr7:91713972	C/T	cg17063962	chr7:91808500	NA	0.47	8.41	0.36	5.21e-16	Breast cancer;
LGG	cis	rs4774899	0.966	rs7161965	chr15:57485620	G/A	cg08128148	chr15:57256372	TCF12	-0.3	-6.99	-0.31	9.42e-12	Urinary tract infection frequency;
LGG	cis	rs490234	0.702	rs13284572	chr9:128258270	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.31	-0.43	1.46e-22	Mean arterial pressure;
LGG	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg24631222	chr15:78858424	CHRNA5	0.47	7.24	0.32	1.87e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs62458065	0.640	rs10274556	chr7:32513947	A/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.25	-0.32	1.71e-12	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.69	12.07	0.49	2.38e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2071403	1.000	rs2071399	chr2:1416528	A/G	cg06500727	chr2:1417164	TPO	-0.52	-9.89	-0.42	4.61e-21	Thyroid peroxidase antibody positivity;
LGG	cis	rs72945132	0.607	rs67767222	chr11:70121610	T/A	cg14088196	chr11:70211408	PPFIA1	0.91	12.68	0.51	7.8e-32	Coronary artery disease;
LGG	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg06238570	chr21:40685208	BRWD1	-0.54	-8.97	-0.38	7.64e-18	Cognitive function;
LGG	trans	rs9650657	0.836	rs6601523	chr8:10635141	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.48	-0.33	3.68e-13	Neuroticism;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00290607	chr11:67383545	NA	-0.62	-10.26	-0.43	2.2e-22	Mean corpuscular volume;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg21782813	chr7:2030301	MAD1L1	0.45	10.84	0.45	1.54e-24	Bipolar disorder and schizophrenia;
LGG	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg21051086	chr3:73046214	PPP4R2	-0.39	-6.84	-0.3	2.48e-11	Pancreatic cancer;
LGG	cis	rs9911578	0.967	rs57869245	chr17:57106630	A/G	cg12560992	chr17:57184187	TRIM37	-0.89	-15.92	-0.59	7.99e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs9379222	chr6:8514788	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs870825	0.860	rs61165411	chr4:185604461	G/A	cg04058563	chr4:185651563	MLF1IP	1.08	20.11	0.68	4.33e-65	Blood protein levels;
LGG	trans	rs9650657	0.770	rs9969626	chr8:10670801	A/C	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.9	-0.31	1.7e-11	Neuroticism;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.22	0.32	2.1e-12	Height;
LGG	cis	rs225245	0.791	rs2285742	chr17:34018682	C/T	cg05299278	chr17:33885742	SLFN14	0.42	8.04	0.35	7.52e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg15103426	chr22:29168792	CCDC117	0.62	9.5	0.4	1.18e-19	Lymphocyte counts;
LGG	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-7.47	-0.33	3.91e-13	Pulmonary function;
LGG	trans	rs3206736	0.548	rs328896	chr7:35017222	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.21	0.32	2.27e-12	Diastolic blood pressure;
LGG	cis	rs2921073	0.509	rs2976931	chr8:8257317	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.32	0.36	1.01e-15	Parkinson's disease;
LGG	cis	rs1865760	0.613	rs9379801	chr6:25901711	T/C	cg12310025	chr6:25882481	NA	-0.52	-10.1	-0.42	8.44e-22	Height;
LGG	cis	rs2201728	0.967	rs17584051	chr4:100193652	C/T	cg07219303	chr4:100140905	ADH6	-0.4	-8.02	-0.35	8.68e-15	Cardiac Troponin-T levels;
LGG	cis	rs1003719	0.680	rs7276569	chr21:38578207	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg04617936	chr2:214353	NA	-0.39	-7.04	-0.31	6.84e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6868223	0.617	rs4866412	chr5:33647284	G/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.55	0.59	3.4e-44	Mortality in heart failure;
LGG	cis	rs17270561	0.609	rs7754296	chr6:25744878	A/G	cg17691542	chr6:26056736	HIST1H1C	0.6	9.71	0.41	2.03e-20	Iron status biomarkers;
LGG	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs4988958	0.565	rs3755265	chr2:103052816	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.66	0.41	3.15e-20	Asthma (childhood onset);
LGG	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg13147721	chr7:65941812	NA	-0.82	-10.15	-0.43	5.5e-22	Gout;
LGG	cis	rs9325144	0.723	rs11169482	chr12:39164327	A/T	cg13010199	chr12:38710504	ALG10B	0.49	9.13	0.39	2.13e-18	Morning vs. evening chronotype;
LGG	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg18654377	chr3:49208889	KLHDC8B	0.44	6.89	0.3	1.89e-11	Resting heart rate;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.73	-0.3	5.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.03e-12	Bipolar disorder;
LGG	cis	rs4748857	0.947	rs4748855	chr10:23599075	G/A	cg18853376	chr10:23633759	C10orf67	0.37	7.03	0.31	7.24e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.92	-0.38	1.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3126085	0.935	rs2338430	chr1:152214420	C/T	cg26876637	chr1:152193138	HRNR	-0.56	-9.04	-0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13126279	chr21:47581558	C21orf56	-0.47	-8.24	-0.36	1.83e-15	Testicular germ cell tumor;
LGG	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.52	0.4	9.26e-20	Coronary artery disease;
LGG	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg00599393	chr8:22457479	C8orf58	-0.44	-8.23	-0.36	1.9e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9583531	0.760	rs9521916	chr13:111385509	A/G	cg24331049	chr13:111365604	ING1	-0.88	-13.19	-0.52	5.89e-34	Coronary artery disease;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27423411	chr19:6424990	KHSRP	0.52	7.8	0.34	4.09e-14	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	cis	rs9788721	0.836	rs17484524	chr15:78772676	A/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-6.99	-0.31	9.94e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs7301826	0.651	rs10848206	chr12:131281471	G/C	cg11011512	chr12:131303247	STX2	0.41	8.89	0.38	1.33e-17	Plasma plasminogen activator levels;
LGG	trans	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.65	0.41	3.3e-20	Morning vs. evening chronotype;
LGG	cis	rs17092148	1.000	rs2425003	chr20:33403584	G/T	cg12302830	chr20:33297742	TP53INP2	0.47	7.84	0.34	3.2e-14	Neuroticism;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg14541582	chr5:601475	NA	-0.71	-10.98	-0.45	4.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs7614311	0.636	rs57112859	chr3:63842221	A/T	cg22134162	chr3:63841271	THOC7	-0.36	-7.1	-0.31	4.82e-12	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs7666738	0.830	rs11727653	chr4:99001774	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20317180	chr19:56111252	FIZ1;ZNF524	0.38	6.65	0.3	8.32e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs10802346	0.545	rs4478780	chr1:246372241	T/C	cg13514129	chr1:39547527	MACF1	0.68	12.68	0.51	7.76e-32	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07989796	chr19:41082579	SHKBP1	-0.43	-6.81	-0.3	3.01e-11	Pancreatic cancer;
LGG	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg08885076	chr2:99613938	TSGA10	-0.37	-6.86	-0.3	2.26e-11	Chronic sinus infection;
LGG	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.64	-12.82	-0.51	1.97e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6142618	0.523	rs6141651	chr20:30851321	A/G	cg00028034	chr20:30779307	TSPYL3	0.34	7.22	0.32	2.09e-12	Inflammatory bowel disease;
LGG	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg00990874	chr7:1149470	C7orf50	-0.72	-11.8	-0.48	2.9e-28	Bronchopulmonary dysplasia;
LGG	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg20891283	chr12:69753455	YEATS4	0.76	14.84	0.57	4.91e-41	Blood protein levels;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.94	-0.38	9.24e-18	Life satisfaction;
LGG	trans	rs800082	0.507	rs2717379	chr3:144256805	G/A	cg24215973	chr2:240111563	HDAC4	0.37	6.77	0.3	3.97e-11	Smoking behavior;
LGG	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg21452805	chr1:244014465	NA	0.62	7.5	0.33	3.19e-13	RR interval (heart rate);
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg01341218	chr17:43662625	NA	0.96	17.02	0.62	8.42e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg12070911	chr6:150209640	RAET1E	0.31	6.66	0.3	8.01e-11	Lung cancer;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg04287289	chr16:89883240	FANCA	0.72	7.71	0.34	7.69e-14	Skin colour saturation;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg04267008	chr7:1944627	MAD1L1	-0.72	-12.5	-0.5	4.25e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9388451	0.807	rs1268065	chr6:126042783	G/A	cg10911889	chr6:126070802	HEY2	-0.42	-6.98	-0.31	1.01e-11	Brugada syndrome;
LGG	cis	rs7589342	0.895	rs2033008	chr2:106502585	T/A	cg14210321	chr2:106509881	NCK2	-0.57	-9.98	-0.42	2.31e-21	Addiction;
LGG	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	cis	rs1707322	1.000	rs10789486	chr1:46408667	A/G	cg03146154	chr1:46216737	IPP	0.53	10.14	0.43	6.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg14298792	chr15:30685198	CHRFAM7A	-0.53	-7.98	-0.35	1.16e-14	Huntington's disease progression;
LGG	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15128208	chr22:42549153	NA	-0.41	-8.02	-0.35	8.63e-15	Cognitive function;
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg11965913	chr1:205819406	PM20D1	0.76	16.35	0.61	8.76e-48	Menarche (age at onset);
LGG	cis	rs2862064	0.929	rs2862062	chr5:156445677	C/T	cg12943317	chr5:156479607	HAVCR1	-0.8	-10.24	-0.43	2.63e-22	Platelet count;
LGG	cis	rs1318772	0.932	rs2910017	chr5:112863960	G/A	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.53e-13	F-cell distribution;
LGG	cis	rs6546550	0.901	rs6546556	chr2:70139001	A/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg09021430	chr5:549028	NA	-0.69	-9.48	-0.4	1.38e-19	Obesity-related traits;
LGG	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg27490568	chr2:178487706	NA	0.49	10.04	0.42	1.39e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.55	0.37	1.82e-16	Prudent dietary pattern;
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.04	0.31	6.86e-12	Cystic fibrosis severity;
LGG	cis	rs6723108	0.694	rs666614	chr2:135290453	C/G	cg20854539	chr2:135475426	TMEM163	0.41	6.66	0.3	8.01e-11	Type 2 diabetes;
LGG	trans	rs7395662	0.963	rs7120743	chr11:48922645	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.61	-0.33	1.56e-13	HDL cholesterol;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	9.0	0.39	5.89e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs3741798	1.000	rs78028836	chr12:12485448	G/A	cg08615371	chr12:12503544	MANSC1	0.6	6.82	0.3	2.93e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg00908189	chr16:619842	PIGQ	0.84	15.6	0.59	2.12e-44	Height;
LGG	cis	rs7937612	0.965	rs10892563	chr11:120224544	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.51	-12.23	-0.49	5.3e-30	Intraocular pressure;
LGG	cis	rs2133450	0.545	rs12492204	chr3:7350481	T/C	cg19930620	chr3:7340148	GRM7	-0.42	-9.4	-0.4	2.51e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg11766577	chr21:47581405	C21orf56	-0.49	-8.56	-0.37	1.74e-16	Testicular germ cell tumor;
LGG	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.23	-0.43	2.78e-22	Chronic sinus infection;
LGG	cis	rs6942756	1.000	rs7803052	chr7:128959427	A/G	cg02491457	chr7:128862824	NA	-0.74	-13.48	-0.53	3.47e-35	White matter hyperintensity burden;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	trans	rs1814175	0.645	rs1874969	chr11:49826700	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.55	-0.71	7.16e-72	Height;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg13206674	chr6:150067644	NUP43	0.68	16.08	0.6	1.45e-46	Lung cancer;
LGG	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg14664628	chr15:75095509	CSK	0.46	8.63	0.37	9.96e-17	Systemic lupus erythematosus;
LGG	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9303401	0.632	rs9915267	chr17:57244907	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	7.9	0.34	2.09e-14	Cognitive test performance;
LGG	trans	rs11875185	0.510	rs17754717	chr18:55620105	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg21475434	chr5:93447410	FAM172A	0.66	6.77	0.3	3.92e-11	Diabetic retinopathy;
LGG	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg00717180	chr2:96193071	NA	-0.44	-7.76	-0.34	5.4e-14	HDL cholesterol;
LGG	cis	rs10895140	0.756	rs2508255	chr11:101494474	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.02	-0.42	1.57e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9318086	0.578	rs2077709	chr13:24476073	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.45	-8.48	-0.37	3.09e-16	Myopia (pathological);
LGG	cis	rs2594989	0.780	rs2454477	chr3:11555842	G/A	cg01796438	chr3:11312864	ATG7	-0.52	-7.23	-0.32	1.95e-12	Circulating chemerin levels;
LGG	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.18	-0.52	6.86e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs477692	0.544	rs12251589	chr10:131417354	C/A	cg05714579	chr10:131428358	MGMT	-0.88	-22.1	-0.72	2.03e-74	Response to temozolomide;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02228635	chr1:93298093	RPL5	0.41	6.95	0.31	1.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg20607798	chr8:58055168	NA	0.57	6.64	0.3	8.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs735539	0.645	rs9552253	chr13:21202350	T/C	cg04906043	chr13:21280425	IL17D	-0.52	-8.48	-0.37	3.01e-16	Dental caries;
LGG	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.47	-8.23	-0.36	1.93e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7250872	0.568	rs10409758	chr19:1835952	A/C	cg18850929	chr19:1828978	REXO1	0.49	7.83	0.34	3.4e-14	Bipolar disorder;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07274776	chr2:203241322	BMPR2	-0.42	-6.96	-0.31	1.18e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7666738	0.800	rs12163918	chr4:98835794	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.79	0.34	4.37e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8180040	0.620	rs9858443	chr3:47086048	G/A	cg16586182	chr3:47516702	SCAP	-0.73	-13.35	-0.53	1.28e-34	Colorectal cancer;
LGG	cis	rs56399783	0.901	rs757788	chr7:2836433	A/G	cg19731401	chr7:2775893	GNA12	0.35	7.23	0.32	2.06e-12	Childhood ear infection;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg13903179	chr13:21900392	NA	0.41	7.12	0.31	4.1e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg05444541	chr17:17804740	TOM1L2	0.42	9.13	0.39	2.16e-18	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.72	-0.38	5.1e-17	Personality dimensions;
LGG	cis	rs3126085	0.877	rs3120672	chr1:152255575	A/G	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg16145915	chr7:1198662	ZFAND2A	-0.52	-8.83	-0.38	2.23e-17	Longevity;Endometriosis;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	7.18	0.32	2.88e-12	Prudent dietary pattern;
LGG	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg09845145	chr15:78292470	TBC1D2B	-0.58	-10.71	-0.45	4.5e-24	Coronary artery disease or large artery stroke;
LGG	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27297192	chr10:134578999	INPP5A	0.33	7.14	0.31	3.7e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06634786	chr22:41940651	POLR3H	0.75	11.91	0.48	1.03e-28	Vitiligo;
LGG	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg26384229	chr12:38710491	ALG10B	0.92	20.59	0.69	2.48e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg01028140	chr2:1542097	TPO	-0.41	-6.78	-0.3	3.62e-11	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.02	-0.31	7.95e-12	Bipolar disorder;
LGG	cis	rs11096990	0.855	rs2566179	chr4:39158033	C/G	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs12493885	0.818	rs61791543	chr3:153766797	C/G	cg17054900	chr3:154042577	DHX36	-0.76	-8.99	-0.39	6.26e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg01765077	chr12:122356316	WDR66	0.29	7.91	0.35	1.91e-14	Mean corpuscular volume;
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.99	-0.31	9.82e-12	Neuroticism;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg18032289	chr17:61959525	GH2	-0.39	-6.86	-0.3	2.18e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg24110177	chr3:50126178	RBM5	0.58	10.42	0.44	5.5e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9868809	0.881	rs6773261	chr3:48675064	A/G	cg00383909	chr3:49044727	WDR6	0.81	9.34	0.4	4.12e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1669338	1.000	rs1669338	chr3:3199635	A/C	cg16797762	chr3:3221439	CRBN	0.82	11.93	0.48	8.54e-29	White matter integrity;
LGG	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg20891283	chr12:69753455	YEATS4	0.96	21.69	0.71	1.63e-72	Blood protein levels;
LGG	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8072100	0.967	rs8072644	chr17:45653364	A/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.14	0.35	3.59e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs972578	0.715	rs2899364	chr22:43248411	T/G	cg01576275	chr22:43409880	NA	-0.23	-6.8	-0.3	3.3e-11	Mean platelet volume;
LGG	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg06145435	chr7:1022769	CYP2W1	0.39	6.91	0.31	1.62e-11	Bronchopulmonary dysplasia;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg02127607	chr17:61920694	SMARCD2	-0.44	-7.83	-0.34	3.29e-14	Prudent dietary pattern;
LGG	cis	rs7824557	0.815	rs958648	chr8:11103895	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.7	-0.37	5.97e-17	Retinal vascular caliber;
LGG	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg07382826	chr16:28625726	SULT1A1	0.39	8.21	0.36	2.2e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs738321	0.757	rs5750546	chr22:38542499	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.5	-0.4	1.09e-19	Breast cancer;
LGG	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.75	-0.3	4.56e-11	Mean platelet volume;
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.08	-0.52	1.78e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.860	rs72689297	chr4:185600957	A/T	cg04058563	chr4:185651563	MLF1IP	1.08	20.51	0.69	5.61e-67	Blood protein levels;
LGG	cis	rs7072216	0.763	rs7923729	chr10:100169465	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.83e-12	Metabolite levels;
LGG	trans	rs7395662	0.929	rs10838934	chr11:48547072	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.15e-14	HDL cholesterol;
LGG	trans	rs7812879	0.636	rs2618455	chr8:11370878	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-6.8	-0.3	3.24e-11	Systemic lupus erythematosus;
LGG	cis	rs35146811	0.586	rs6946168	chr7:99598286	C/T	cg22906224	chr7:99728672	NA	0.55	8.63	0.37	9.95e-17	Coronary artery disease;
LGG	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg18478394	chr8:109455254	TTC35	0.43	8.64	0.37	9.52e-17	Dupuytren's disease;
LGG	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg12219531	chr12:120966889	COQ5	0.65	10.77	0.45	2.73e-24	High light scatter reticulocyte count;
LGG	cis	rs6500395	1.000	rs12934126	chr16:48705951	C/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1555322	0.872	rs6579227	chr20:33879206	C/T	cg17927777	chr20:33865990	NA	0.78	8.4	0.36	5.56e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs2241210	0.550	rs7486178	chr12:109980266	G/A	cg08884029	chr12:110012500	MVK;MMAB	-0.54	-11.58	-0.47	2.06e-27	HDL cholesterol levels;
LGG	cis	rs2050392	0.929	rs10826798	chr10:30700904	G/A	cg25182066	chr10:30743637	MAP3K8	0.52	10.81	0.45	2.01e-24	Inflammatory bowel disease;
LGG	cis	rs3741151	0.773	rs73544783	chr11:73221256	C/G	cg17517138	chr11:73019481	ARHGEF17	0.83	7.9	0.34	2.02e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.74	0.34	6.52e-14	Cannabis dependence symptom count;
LGG	cis	rs7301826	0.651	rs10744485	chr12:131298550	A/G	cg11011512	chr12:131303247	STX2	0.41	8.87	0.38	1.61e-17	Plasma plasminogen activator levels;
LGG	cis	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg22496380	chr5:211416	CCDC127	-1.17	-16.92	-0.62	2.36e-50	Breast cancer;
LGG	cis	rs981844	0.714	rs2405204	chr4:154705248	A/G	cg14289246	chr4:154710475	SFRP2	-0.59	-10.47	-0.44	3.49e-23	Response to statins (LDL cholesterol change);
LGG	trans	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg14791747	chr16:20752902	THUMPD1	0.5	8.86	0.38	1.67e-17	Cognitive test performance;
LGG	cis	rs6772849	0.708	rs12491942	chr3:128421469	C/G	cg08795948	chr3:128337044	NA	0.65	10.09	0.42	8.94e-22	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs975739	0.902	rs977883	chr13:78372568	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.84e-11	Hair color;
LGG	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg15704280	chr7:45808275	SEPT13	0.49	7.91	0.35	1.93e-14	HDL cholesterol;
LGG	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg18876405	chr7:65276391	NA	-0.55	-9.94	-0.42	3.23e-21	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06734816	chr6:116422381	NT5DC1	0.49	7.8	0.34	4.12e-14	Gut microbiome composition (summer);
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.18	-0.32	2.75e-12	Bipolar disorder;
LGG	cis	rs36051895	0.664	rs62541915	chr9:5151275	A/T	cg02405213	chr9:5042618	JAK2	-0.77	-13.82	-0.54	1.27e-36	Pediatric autoimmune diseases;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg24846343	chr22:24311635	DDTL	0.6	12.07	0.49	2.36e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg08508325	chr11:3079039	CARS	0.42	8.14	0.35	3.64e-15	Calcium levels;
LGG	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.29	0.65	1.25e-56	Refractive error;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg20978937	chr14:105399321	PLD4	0.5	11.39	0.47	1.19e-26	Rheumatoid arthritis;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg19318889	chr4:1322082	MAEA	0.41	7.26	0.32	1.6e-12	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03211173	chr20:61427693	C20orf20	0.44	7.02	0.31	8.09e-12	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg06766960	chr11:133703094	NA	-0.56	-11.27	-0.46	3.3e-26	Childhood ear infection;
LGG	cis	rs7590368	0.673	rs56147885	chr2:10937095	T/A	cg15705551	chr2:10952987	PDIA6	0.58	7.5	0.33	3.35e-13	Educational attainment (years of education);
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-9.62	-0.41	4.28e-20	Prostate cancer;
LGG	cis	rs9560113	1.000	rs9555812	chr13:112181535	A/G	cg14952266	chr13:112191215	NA	-0.42	-7.58	-0.33	1.92e-13	Menarche (age at onset);
LGG	cis	rs7666738	0.822	rs6815312	chr4:99058220	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.83	-0.48	2.07e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1059312	0.808	rs4482069	chr12:129294252	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.88	-20.92	-0.7	6.39e-69	Systemic lupus erythematosus;
LGG	cis	rs1451375	0.572	rs66792686	chr7:50651239	T/C	cg14593290	chr7:50529359	DDC	0.48	8.56	0.37	1.67e-16	Malaria;
LGG	trans	rs877282	0.733	rs7092976	chr10:756358	G/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24308560	chr3:49941425	MST1R	0.22	6.77	0.3	3.9e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	3.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7572733	0.555	rs2342558	chr2:198920142	T/C	cg00792783	chr2:198669748	PLCL1	0.61	9.74	0.41	1.67e-20	Dermatomyositis;
LGG	cis	rs8179	0.645	rs6960181	chr7:92277477	C/T	cg15732164	chr7:92237376	CDK6	-0.52	-9.81	-0.41	8.92e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7617773	0.709	rs4404473	chr3:48353626	A/G	cg11946769	chr3:48343235	NME6	0.72	11.87	0.48	1.47e-28	Coronary artery disease;
LGG	cis	rs3087591	0.615	rs12943365	chr17:29680526	C/G	cg24425628	chr17:29625626	OMG;NF1	0.58	11.5	0.47	4.29e-27	Hip circumference;
LGG	trans	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg13010199	chr12:38710504	ALG10B	0.59	11.2	0.46	6.32e-26	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.721	rs28817701	chr1:46186050	C/T	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs911263	0.603	rs12890124	chr14:68781614	A/C	cg18825221	chr14:68749962	RAD51L1	-0.39	-8.25	-0.36	1.64e-15	Primary biliary cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07256006	chr1:156182774	PMF1	0.53	8.47	0.37	3.36e-16	Gut microbiome composition (summer);
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.06	0.57	5.58e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10893109	0.517	rs1377602	chr11:123775491	C/T	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.45	-0.5	7.11e-31	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01896926	chr17:685509	GLOD4;RNMTL1	0.42	6.87	0.3	2.04e-11	Cognitive performance;
LGG	cis	rs113835537	0.569	rs17496586	chr11:66315512	G/C	cg24851651	chr11:66362959	CCS	0.45	7.69	0.34	8.68e-14	Airway imaging phenotypes;
LGG	trans	rs10506458	1.000	rs1009539	chr12:63414655	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.24	19.46	0.67	4.25e-62	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.39	-0.36	5.8e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4474465	1.000	rs7106080	chr11:78150592	G/A	cg02023728	chr11:77925099	USP35	0.4	7.1	0.31	4.63e-12	Alzheimer's disease (survival time);
LGG	cis	rs1620921	0.563	rs2465848	chr6:161280023	C/T	cg01280913	chr6:161186852	NA	-0.37	-7.42	-0.33	5.47e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs6582630	0.502	rs1607876	chr12:38355750	T/C	cg26384229	chr12:38710491	ALG10B	0.92	19.86	0.68	6e-64	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg11912956	chr7:73588697	EIF4H	0.45	6.92	0.31	1.48e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg02549819	chr16:58548995	SETD6	1.43	13.68	0.54	4.86e-36	Schizophrenia;
LGG	cis	rs4740619	0.544	rs9406535	chr9:15813148	T/C	cg14451791	chr9:16040625	NA	0.3	7.5	0.33	3.38e-13	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22344139	chr1:44435583	DPH2	0.41	6.72	0.3	5.24e-11	Gut microbiome composition (summer);
LGG	cis	rs919433	0.963	rs12618612	chr2:198171058	G/T	cg00792783	chr2:198669748	PLCL1	-0.45	-7.04	-0.31	7.18e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg19673125	chr6:150240577	RAET1G	0.36	8.72	0.38	4.96e-17	Lung cancer;
LGG	cis	rs2280018	0.526	rs1510148	chr16:15167379	T/A	cg27102117	chr16:15229624	NA	0.59	11.14	0.46	1.11e-25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6725041	0.819	rs1521661	chr2:213083104	T/A	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs11676348	0.772	rs7422358	chr2:218952778	C/T	cg00012203	chr2:219082015	ARPC2	-0.44	-7.82	-0.34	3.52e-14	Ulcerative colitis;
LGG	cis	rs6502050	0.835	rs35857672	chr17:80078303	G/A	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs300703	0.935	rs12714403	chr2:273070	A/G	cg21211680	chr2:198530	NA	1.28	15.96	0.6	5.23e-46	Blood protein levels;
LGG	cis	rs16854884	0.586	rs4616638	chr3:143735423	A/T	cg06585982	chr3:143692056	C3orf58	-0.66	-11.74	-0.48	5.01e-28	Economic and political preferences (feminism/equality);
LGG	cis	rs2439831	1.000	rs2254321	chr15:43707542	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	10.77	0.45	2.64e-24	Lung cancer in ever smokers;
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg11645453	chr3:52864694	ITIH4	0.41	6.89	0.31	1.79e-11	Bipolar disorder;
LGG	cis	rs12928939	0.517	rs11865456	chr16:71969497	C/T	cg03805757	chr16:71968109	PKD1L3	-0.66	-13.35	-0.53	1.25e-34	Post bronchodilator FEV1;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25172604	chr17:41446521	NA	-0.3	-6.68	-0.3	6.79e-11	Menopause (age at onset);
LGG	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg08824895	chr13:115047677	UPF3A	0.42	7.19	0.32	2.55e-12	Schizophrenia;
LGG	cis	rs7289126	1.000	rs7290309	chr22:38630287	C/T	cg03162506	chr22:38580953	NA	0.28	6.9	0.31	1.74e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg18898632	chr2:242989856	NA	-0.81	-10.02	-0.42	1.66e-21	Obesity-related traits;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg24690094	chr11:67383802	NA	-0.41	-7.54	-0.33	2.44e-13	Mean corpuscular volume;
LGG	trans	rs11098499	0.955	rs13114751	chr4:120156617	G/A	cg25214090	chr10:38739885	LOC399744	0.62	11.06	0.46	2.16e-25	Corneal astigmatism;
LGG	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg17644776	chr2:200775616	C2orf69	0.54	8.63	0.37	9.59e-17	Osteoporosis;
LGG	cis	rs11229555	0.609	rs7128459	chr11:58179291	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7928758	0.725	rs78751202	chr11:134286609	T/C	cg25213107	chr11:134282864	B3GAT1	1.31	13.99	0.55	2.41e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg02002194	chr4:3960332	NA	0.41	7.09	0.31	4.96e-12	Triglycerides;
LGG	cis	rs427394	0.802	rs274692	chr5:6734625	C/T	cg15145174	chr5:6755386	POLS	-0.4	-7.63	-0.33	1.34e-13	Menopause (age at onset);
LGG	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg18854424	chr1:2615690	NA	-0.35	-7.16	-0.32	3.2e-12	Ulcerative colitis;
LGG	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.03	-0.39	4.5e-18	Joint mobility (Beighton score);
LGG	cis	rs3099143	1.000	rs1913001	chr15:77179408	A/C	cg21673338	chr15:77095150	SCAPER	0.65	10.34	0.43	1.09e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg17691542	chr6:26056736	HIST1H1C	0.58	10.19	0.43	3.78e-22	Height;
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.76	-0.41	1.39e-20	Menarche (age at onset);
LGG	cis	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg07460842	chr6:66804631	NA	0.74	12.73	0.51	5.04e-32	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg18963800	chr10:38644991	HSD17B7P2	-0.51	-8.13	-0.35	4.04e-15	Extrinsic epigenetic age acceleration;
LGG	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg16141378	chr3:129829833	LOC729375	-0.44	-10.64	-0.44	8.18e-24	Mood instability;
LGG	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg13852791	chr20:30311386	BCL2L1	0.73	11.61	0.47	1.61e-27	Mean corpuscular volume;
LGG	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg03806693	chr22:41940476	POLR3H	-1.05	-18.56	-0.65	6.58e-58	Vitiligo;
LGG	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg16512390	chr1:228756714	NA	0.61	8.07	0.35	6.21e-15	Chronic lymphocytic leukemia;
LGG	cis	rs34172651	0.917	rs200532	chr16:24756148	C/T	cg02428538	chr16:24856791	SLC5A11	0.43	7.45	0.33	4.53e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	1.000	rs11211232	chr1:46411146	C/T	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.61e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.82	-0.38	2.27e-17	Eosinophil percentage of white cells;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.43	0.33	5.44e-13	Schizophrenia;
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg11878867	chr6:150167359	LRP11	0.47	8.21	0.36	2.2e-15	Lung cancer;
LGG	cis	rs12478296	0.892	rs60042638	chr2:243038707	G/A	cg06360820	chr2:242988706	NA	-0.89	-11.52	-0.47	3.66e-27	Obesity-related traits;
LGG	cis	rs17824933	1.000	rs12791045	chr11:60767964	C/T	cg16817237	chr11:60793675	NA	0.36	6.77	0.3	3.84e-11	Multiple sclerosis;
LGG	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg13010199	chr12:38710504	ALG10B	0.48	8.67	0.37	7.59e-17	Morning vs. evening chronotype;
LGG	cis	rs16854884	0.657	rs6766685	chr3:143736916	C/T	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs9972944	0.729	rs7224482	chr17:63777949	C/A	cg07283582	chr17:63770753	CCDC46	0.4	7.74	0.34	6.14e-14	Total body bone mineral density;
LGG	cis	rs4731207	0.698	rs7782340	chr7:124506025	A/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.46	-8.3	-0.36	1.15e-15	Height;
LGG	cis	rs796364	0.806	rs74938253	chr2:201008386	T/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.24	-0.36	1.75e-15	Schizophrenia;
LGG	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg00677455	chr12:58241039	CTDSP2	0.39	7.13	0.31	3.81e-12	Intelligence (multi-trait analysis);
LGG	cis	rs25645	0.502	rs7207600	chr17:38091660	G/A	cg17467752	chr17:38218738	THRA	0.46	7.18	0.32	2.83e-12	Myeloid white cell count;
LGG	cis	rs4689642	0.709	rs4689656	chr4:7225745	A/G	cg21353189	chr4:7228343	SORCS2	0.38	8.81	0.38	2.61e-17	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg10523679	chr1:76189770	ACADM	-0.8	-15.13	-0.58	2.59e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-11.01	-0.46	3.5e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2274273	0.870	rs10134339	chr14:55814380	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.96	0.64	4.02e-55	Protein biomarker;
LGG	trans	rs826838	1.000	rs826888	chr12:39104719	C/G	cg06521331	chr12:34319734	NA	0.4	7.21	0.32	2.36e-12	Heart rate;
LGG	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg11317459	chr13:21872234	NA	1.33	25.21	0.76	6.39e-89	White matter hyperintensity burden;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg15383120	chr6:291909	DUSP22	-0.54	-8.9	-0.38	1.29e-17	Menopause (age at onset);
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg26354017	chr1:205819088	PM20D1	0.54	10.59	0.44	1.3e-23	Menarche (age at onset);
LGG	cis	rs787274	1.000	rs7868830	chr9:115577125	G/A	cg13803584	chr9:115635662	SNX30	-0.57	-7.97	-0.35	1.21e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13841901	chr1:45805975	MUTYH;TOE1	0.45	7.37	0.32	7.65e-13	Cognitive performance;
LGG	cis	rs4363385	0.747	rs4845504	chr1:152960043	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.91	-0.38	1.21e-17	Inflammatory skin disease;
LGG	cis	rs1707322	0.655	rs3014240	chr1:46089225	C/G	cg03146154	chr1:46216737	IPP	-0.56	-10.77	-0.45	2.85e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.505	rs200939	chr10:38139483	T/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.36	-0.53	1.13e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs2070488	0.932	rs4678604	chr3:38444273	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.38	0.63	1.83e-52	Electrocardiographic conduction measures;
LGG	cis	rs933688	0.509	rs7731341	chr5:90524105	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.42	-6.69	-0.3	6.54e-11	Smoking behavior;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs763121	0.853	rs2413546	chr22:39107001	G/A	cg06022373	chr22:39101656	GTPBP1	0.91	18.53	0.65	9.68e-58	Menopause (age at onset);
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.25	-0.36	1.64e-15	Neuroticism;
LGG	cis	rs698813	0.674	rs713447	chr2:44505185	T/G	cg00619915	chr2:44497795	NA	-0.65	-9.08	-0.39	3.04e-18	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs6459788	0.585	rs6950818	chr7:157235364	C/G	cg04198125	chr7:157211777	NA	0.42	8.09	0.35	5.12e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.5	-0.61	2.03e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.75	0.34	6.05e-14	Monocyte count;
LGG	cis	rs3096299	0.719	rs2911265	chr16:89511328	G/A	cg05484508	chr16:89589025	SPG7	0.44	7.01	0.31	8.74e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs10840133	1	rs10840133	chr11:8846369	G/A	cg00186954	chr11:8933980	ST5;C11orf17	0.38	7.82	0.34	3.49e-14	Reticulocyte fraction of red cells;
LGG	cis	rs7100689	0.784	rs7081903	chr10:82162509	T/C	cg01528321	chr10:82214614	TSPAN14	1.02	19.43	0.67	5.98e-62	Post bronchodilator FEV1;
LGG	cis	rs11587400	0.656	rs6689415	chr1:115107469	G/T	cg12756093	chr1:115239321	AMPD1	0.38	6.99	0.31	9.7e-12	Autism;
LGG	trans	rs2270927	0.510	rs4566771	chr5:75576522	C/T	cg13563193	chr19:33072644	PDCD5	0.85	10.14	0.43	5.8e-22	Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.07	0.49	2.45e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.63	10.45	0.44	4.48e-23	Longevity;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.61	-0.53	9.78e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs972578	0.765	rs2267473	chr22:43311010	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.12e-11	Mean platelet volume;
LGG	cis	rs9549367	0.713	rs1323315	chr13:113859658	T/C	cg00898013	chr13:113819073	PROZ	0.47	9.68	0.41	2.67e-20	Platelet distribution width;
LGG	cis	rs4538187	1.000	rs35002211	chr2:64152855	A/G	cg19915305	chr2:64069682	UGP2	-0.68	-15.14	-0.58	2.3e-42	Systolic blood pressure;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg04166393	chr7:2884313	GNA12	0.42	7.86	0.34	2.73e-14	Height;
LGG	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.47e-25	Corneal astigmatism;
LGG	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg24879335	chr3:133465180	TF	-0.44	-7.35	-0.32	8.94e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs4731207	0.591	rs12535300	chr7:124613907	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.6	-0.37	1.24e-16	Retinal vascular caliber;
LGG	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg07835443	chr16:89734986	C16orf55	-0.39	-6.88	-0.3	1.98e-11	Hemoglobin concentration;
LGG	cis	rs3820928	0.874	rs10178731	chr2:227874232	C/T	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.44	-0.33	4.78e-13	Pulmonary function;
LGG	cis	rs12618769	0.597	rs4599165	chr2:99144483	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs11583043	0.668	rs6681915	chr1:101558521	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.25	0.36	1.62e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	10.12	0.43	7.09e-22	Mood instability;
LGG	cis	rs1577917	0.696	rs2842617	chr6:86309698	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.43	-0.36	4.31e-16	Response to antipsychotic treatment;
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg23302884	chr18:44338147	ST8SIA5	0.36	7.07	0.31	5.78e-12	Personality dimensions;
LGG	cis	rs2415984	0.583	rs2642090	chr14:46968788	C/T	cg14871534	chr14:47121158	RPL10L	0.58	10.22	0.43	2.93e-22	Number of children ever born;
LGG	trans	rs7819412	0.558	rs11777486	chr8:10908287	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	8.84	0.38	2.01e-17	Triglycerides;
LGG	cis	rs7143963	0.636	rs7154305	chr14:103348743	C/G	cg23020514	chr14:103360112	TRAF3	0.4	8.35	0.36	8.14e-16	Body mass index;
LGG	trans	rs1814175	0.565	rs4881721	chr11:49761851	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-17.16	-0.62	1.9e-51	Height;
LGG	cis	rs6743376	0.556	rs6748448	chr2:113819419	A/G	cg05949173	chr2:113825882	IL1F10	0.48	9.13	0.39	2.16e-18	Inflammatory biomarkers;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.56	-0.37	1.72e-16	Personality dimensions;
LGG	cis	rs17270561	0.583	rs6926425	chr6:25785304	T/C	cg17691542	chr6:26056736	HIST1H1C	0.59	9.78	0.41	1.12e-20	Iron status biomarkers;
LGG	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.34	-0.32	9.51e-13	Monocyte count;
LGG	cis	rs921968	0.643	rs508157	chr2:219435288	G/A	cg01130898	chr2:219473002	PLCD4	-0.41	-7.04	-0.31	6.78e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1505368	0.532	rs2888093	chr2:213328348	G/A	cg20637307	chr2:213403960	ERBB4	0.54	10.65	0.44	7.99e-24	Symmetrical dimethylarginine levels;
LGG	cis	rs228437	0.802	rs228447	chr6:134902903	C/T	cg24504307	chr6:134963096	NA	0.35	6.75	0.3	4.51e-11	Melanoma;
LGG	cis	rs3857067	0.680	rs1509946	chr4:95109078	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.76	-0.34	5.45e-14	QT interval;
LGG	cis	rs340849	0.703	rs17762150	chr1:214124818	C/T	cg05052969	chr1:214156842	NA	0.37	6.84	0.3	2.5e-11	Alzheimer's disease;
LGG	cis	rs6840360	0.550	rs62327349	chr4:152627230	G/C	cg22705602	chr4:152727874	NA	-0.32	-7.45	-0.33	4.66e-13	Intelligence (multi-trait analysis);
LGG	trans	rs9354308	0.764	rs4327677	chr6:66594700	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs2030746	1.000	rs2030746	chr2:121309488	C/T	cg03661458	chr2:121334411	NA	-0.29	-6.92	-0.31	1.54e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs4889855	0.614	rs9892081	chr17:78484484	A/C	cg16591659	chr17:78472290	NA	0.4	9.19	0.39	1.36e-18	Fractional excretion of uric acid;
LGG	cis	rs745821	0.701	rs77310792	chr18:48101746	A/G	cg18923635	chr18:48083994	NA	0.43	7.68	0.34	9.54e-14	Diastolic blood pressure;
LGG	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-9.86	-0.42	5.87e-21	Schizophrenia;
LGG	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	11.27	0.46	3.45e-26	Emphysema distribution in smoking;
LGG	trans	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.43e-16	Total body bone mineral density;
LGG	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg11707556	chr5:10655725	ANKRD33B	0.51	9.78	0.41	1.13e-20	Coronary artery disease;
LGG	cis	rs975739	0.872	rs977884	chr13:78372462	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.84e-11	Hair color;
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.89e-21	Lung cancer;
LGG	cis	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg26384229	chr12:38710491	ALG10B	1.05	28.05	0.79	6.65e-102	Heart rate;
LGG	cis	rs428668	0.523	rs6898671	chr5:150677643	A/T	cg11125805	chr5:150678162	SLC36A3	0.33	6.96	0.31	1.14e-11	Skin aging (microtopography measurement);
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.5	0.4	1.12e-19	Renal function-related traits (BUN);
LGG	cis	rs357618	0.965	rs187180	chr5:150847995	G/A	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.78	-0.3	3.74e-11	Basophil percentage of white cells;
LGG	cis	rs950169	1.000	rs62026530	chr15:84775840	G/T	cg03959625	chr15:84868606	LOC388152	0.55	8.76	0.38	3.59e-17	Schizophrenia;
LGG	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg16506815	chr2:162101123	NA	0.27	6.8	0.3	3.23e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs7147624	1.000	rs10873192	chr14:66110653	A/G	cg03016385	chr14:66212404	NA	-0.81	-9.98	-0.42	2.17e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7953249	0.807	rs2393775	chr12:121424574	G/A	cg14101638	chr12:121416612	HNF1A	-0.36	-8.17	-0.35	3.06e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9811920	0.898	rs7636776	chr3:99840446	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.24	0.36	1.75e-15	Axial length;
LGG	cis	rs7216064	1.000	rs62085993	chr17:65923152	T/C	cg12091567	chr17:66097778	LOC651250	-0.61	-9.03	-0.39	4.63e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2133450	0.712	rs1546238	chr3:7366551	T/C	cg19930620	chr3:7340148	GRM7	-0.37	-7.99	-0.35	1.1e-14	Early response to risperidone in schizophrenia;
LGG	trans	rs330048	0.509	rs36111783	chr8:9145588	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	8.42	0.36	4.84e-16	Systemic lupus erythematosus;
LGG	cis	rs11064837	0.504	rs11064850	chr12:120055786	C/T	cg25937854	chr12:120150414	CIT	-0.59	-10.44	-0.44	4.64e-23	Schizophrenia;
LGG	cis	rs6688613	0.694	rs3820387	chr1:166820284	A/T	ch.1.3259774R	chr1:166827647	TADA1	0.54	8.36	0.36	7.6e-16	Refractive astigmatism;
LGG	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg04691961	chr3:161091175	C3orf57	0.43	9.22	0.39	1.05e-18	Morning vs. evening chronotype;
LGG	cis	rs11771526	0.901	rs17161123	chr7:32305426	G/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg19847130	chr8:10466454	RP1L1	0.31	6.9	0.31	1.74e-11	Neuroticism;
LGG	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg20110707	chr11:118481992	PHLDB1	-0.48	-9.21	-0.39	1.13e-18	Cholesterol, total;
LGG	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs3845702	0.736	rs12693214	chr2:180825685	G/A	cg01881094	chr2:180872142	CWC22	-1.26	-16.57	-0.61	9.27e-49	Schizophrenia;
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.65	0.44	8.06e-24	Total body bone mineral density;
LGG	cis	rs9467773	0.935	rs4573	chr6:26546808	A/G	cg11502198	chr6:26597334	ABT1	0.53	8.9	0.38	1.32e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg23815491	chr16:72088622	HP	0.4	7.03	0.31	7.49e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs67478160	0.608	rs34066659	chr14:104263427	A/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	ch.8.2353618R	chr8:119282796	SAMD12	0.64	7.52	0.33	2.85e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.655	rs9896476	chr17:61629692	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-7.93	-0.35	1.63e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4948102	0.599	rs2230197	chr7:56126360	T/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.4	7.15	0.32	3.33e-12	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg11693508	chr17:37793320	STARD3	0.73	10.66	0.44	6.89e-24	Bipolar disorder;
LGG	cis	rs7226408	0.857	rs7234586	chr18:34434634	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Bone mineral density;
LGG	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs7301826	0.651	rs2277336	chr12:131286119	A/G	cg11011512	chr12:131303247	STX2	-0.4	-8.49	-0.37	2.92e-16	Plasma plasminogen activator levels;
LGG	cis	rs9894429	1.000	rs7209180	chr17:79581519	C/A	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs140330585	1	rs140330585	chr15:78866445	G/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.43	-0.33	5.24e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4731207	0.564	rs12531996	chr7:124619460	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs3106136	0.967	rs12643901	chr4:95145132	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.98	-0.35	1.17e-14	Capecitabine sensitivity;
LGG	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-9.93	-0.42	3.53e-21	Diabetic retinopathy;
LGG	cis	rs12048904	0.964	rs17123467	chr1:101331760	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	9.49	0.4	1.26e-19	Multiple sclerosis;
LGG	cis	rs7215564	0.908	rs8080789	chr17:78735202	A/G	cg16980736	chr17:78789706	RPTOR	0.59	8.09	0.35	5.23e-15	Myopia (pathological);
LGG	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg04000281	chr11:63949212	NA	0.34	6.86	0.3	2.26e-11	Platelet count;
LGG	cis	rs9547996	0.879	rs7985686	chr13:38128643	C/T	cg13634560	chr13:38173852	POSTN	0.34	6.87	0.3	2.12e-11	Diastolic blood pressure;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.47	-0.37	3.18e-16	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg17376030	chr22:41985996	PMM1	0.55	8.7	0.37	5.68e-17	Vitiligo;
LGG	cis	rs1570884	0.516	rs9316462	chr13:50176321	A/G	cg08779649	chr13:50194554	NA	0.37	9.27	0.4	7e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg08875078	chr22:50639485	SELO	-0.48	-7.24	-0.32	1.92e-12	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.85	0.51	1.52e-32	Bladder cancer;
LGG	cis	rs870825	0.616	rs28497285	chr4:185629169	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg24375607	chr4:120327624	NA	0.65	10.73	0.45	3.82e-24	Corneal astigmatism;
LGG	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg26384229	chr12:38710491	ALG10B	0.94	21.95	0.71	1.02e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7106204	0.858	rs2403889	chr11:24210226	T/C	ch.11.24196551F	chr11:24239977	NA	1.04	16.47	0.61	2.78e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-8.22	-0.36	2.07e-15	Schizophrenia;
LGG	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.28	0.43	1.81e-22	Height;
LGG	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg06885757	chr1:42089581	HIVEP3	0.51	11.26	0.46	3.84e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05901451	chr6:126070800	HEY2	0.6	11.02	0.46	3.17e-25	Brugada syndrome;
LGG	trans	rs2018683	0.707	rs4719961	chr7:28969513	C/T	cg19402173	chr7:128379420	CALU	-0.53	-9.25	-0.39	8.3e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg02725872	chr8:58115012	NA	0.91	12.42	0.5	9.38e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.79	-0.41	1.1e-20	Lung cancer;
LGG	cis	rs9398803	0.865	rs4559102	chr6:126773580	G/A	cg19875578	chr6:126661172	C6orf173	0.57	10.34	0.43	1.14e-22	Male-pattern baldness;
LGG	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg24803719	chr17:45855879	NA	-0.3	-8.67	-0.37	7.53e-17	IgG glycosylation;
LGG	cis	rs7598759	0.548	rs1823328	chr2:232355184	G/A	cg19187155	chr2:232395269	NMUR1	0.53	9.93	0.42	3.45e-21	Noise-induced hearing loss;
LGG	cis	rs9487094	0.922	rs13204500	chr6:109961885	G/A	cg16315928	chr6:109776240	MICAL1	0.54	9.19	0.39	1.31e-18	Height;
LGG	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.27	-0.36	1.47e-15	Retinal vascular caliber;
LGG	cis	rs116095464	0.558	rs13356367	chr5:242395	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	cis	rs6840360	0.642	rs6845648	chr4:152376050	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	3.08e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.865	rs6058421	chr20:30295013	G/C	cg13852791	chr20:30311386	BCL2L1	0.78	12.58	0.5	2.05e-31	Mean corpuscular hemoglobin;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01726854	chr17:56429881	SUPT4H1	0.45	6.73	0.3	5.18e-11	Gut microbiome composition (summer);
LGG	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.77	0.3	3.9e-11	Glycated hemoglobin levels;
LGG	cis	rs60180747	0.632	rs8042593	chr15:66630569	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	-0.44	-8.48	-0.37	2.98e-16	Testicular germ cell tumor;
LGG	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg12310025	chr6:25882481	NA	0.51	9.5	0.4	1.15e-19	Blood metabolite levels;
LGG	cis	rs10463316	0.928	rs4958451	chr5:150740007	T/C	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.49	-0.44	2.94e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs12476592	0.602	rs6546019	chr2:63817440	A/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.18	-0.7	3.95e-70	Gut microbiome composition (summer);
LGG	cis	rs1505368	0.505	rs6760554	chr2:213255417	C/T	cg16329650	chr2:213403929	ERBB4	0.44	7.74	0.34	6.42e-14	Symmetrical dimethylarginine levels;
LGG	cis	rs9611565	0.659	rs202653	chr22:41840158	C/T	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Vitiligo;
LGG	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg01200585	chr1:228362443	C1orf69	-0.45	-7.98	-0.35	1.13e-14	Diastolic blood pressure;
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.65	8.69	0.37	6.45e-17	Lung function (FEV1/FVC);
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg05091796	chr16:4465799	CORO7	-0.78	-12.89	-0.51	1.05e-32	Schizophrenia;
LGG	cis	rs926938	0.552	rs360613	chr1:115394864	C/G	cg12756093	chr1:115239321	AMPD1	0.47	9.0	0.39	6e-18	Autism;
LGG	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg24642439	chr20:33292090	TP53INP2	0.55	9.29	0.4	5.85e-19	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg04450456	chr4:17643702	FAM184B	0.32	6.87	0.3	2.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17604090	0.701	rs60930239	chr7:29688544	A/G	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs8072100	0.713	rs1912486	chr17:45515167	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1499614	1.000	rs2659913	chr7:66157336	T/A	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs778371	0.723	rs1022329	chr2:233591239	T/C	cg08000102	chr2:233561755	GIGYF2	0.7	11.98	0.49	5.21e-29	Schizophrenia;
LGG	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.94	9.89	0.42	4.84e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2708240	0.875	rs759177	chr7:147575230	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	3.04e-11	QT interval (drug interaction);
LGG	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs78456975	0.550	rs111467480	chr2:1569154	A/G	cg12573674	chr2:1569213	NA	-0.6	-9.09	-0.39	2.82e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs6582630	0.638	rs12424222	chr12:38548273	C/T	cg06521331	chr12:34319734	NA	0.42	7.68	0.34	9.7e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg13939156	chr17:80058883	NA	0.51	10.08	0.42	9.55e-22	Life satisfaction;
LGG	cis	rs722599	0.748	rs731165	chr14:75352555	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.23	-0.43	2.81e-22	IgG glycosylation;
LGG	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg12560992	chr17:57184187	TRIM37	-0.85	-13.66	-0.54	5.97e-36	Intelligence (multi-trait analysis);
LGG	cis	rs5769707	0.874	rs9616714	chr22:50050859	G/A	cg20744362	chr22:50050164	C22orf34	0.41	7.96	0.35	1.33e-14	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26260386	chr4:140477698	SETD7	0.49	8.0	0.35	1.02e-14	Cognitive performance;
LGG	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.12	11.93	0.48	8.86e-29	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg05182265	chr7:156933206	UBE3C	0.33	6.72	0.3	5.51e-11	Body mass index;
LGG	cis	rs12190007	1.000	rs12190007	chr6:169727601	C/T	cg16388071	chr6:169726476	NA	-0.36	-6.87	-0.3	2.11e-11	Obesity-related traits;
LGG	cis	rs2597513	0.860	rs2630452	chr3:13571228	C/T	cg24006715	chr3:13568212	NA	0.58	9.56	0.41	6.97e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs2985684	1.000	rs3007031	chr14:50102269	G/C	cg02151108	chr14:50098012	C14orf104	-0.47	-10.18	-0.43	4.23e-22	Carotid intima media thickness;
LGG	cis	rs1801251	0.896	rs6719061	chr2:233695885	C/T	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.74	-0.38	4.16e-17	Coronary artery disease;
LGG	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg13395646	chr4:1353034	KIAA1530	-0.62	-10.94	-0.45	6.3e-25	Obesity-related traits;
LGG	cis	rs7089973	0.584	rs4752347	chr10:116646860	T/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.23	0.32	1.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg05973401	chr12:123451056	ABCB9	0.5	7.61	0.33	1.54e-13	Neutrophil percentage of white cells;
LGG	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.58	-0.37	1.42e-16	Schizophrenia;
LGG	cis	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg09307838	chr4:120376055	NA	0.8	13.64	0.54	7.39e-36	Corneal astigmatism;
LGG	cis	rs11920090	0.789	rs68189454	chr3:170755992	A/G	cg09710316	chr3:170744871	SLC2A2	0.69	8.67	0.37	7.52e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1408799	0.732	rs7035500	chr9:12750095	G/T	cg05274944	chr9:12693694	TYRP1	0.35	8.26	0.36	1.54e-15	Eye color;Blue vs. green eyes;
LGG	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.14e-11	Retinal vascular caliber;
LGG	cis	rs2050392	0.965	rs1543725	chr10:30698873	A/G	cg25182066	chr10:30743637	MAP3K8	-0.51	-10.69	-0.44	5.47e-24	Inflammatory bowel disease;
LGG	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.58e-14	Cannabis dependence symptom count;
LGG	cis	rs921968	0.643	rs645796	chr2:219389236	A/G	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg04503457	chr17:41445688	NA	-0.39	-9.39	-0.4	2.82e-19	Menopause (age at onset);
LGG	cis	rs12612619	0.579	rs6756245	chr2:27083489	C/T	cg12045002	chr2:27069975	DPYSL5	0.32	6.88	0.3	2e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	trans	rs9354308	0.764	rs9345708	chr6:66587096	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg25173405	chr17:45401733	C17orf57	-0.46	-7.98	-0.35	1.19e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1829883	0.931	rs7720138	chr5:98879849	G/C	cg08333243	chr5:99726346	NA	0.4	7.8	0.34	4.23e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6840360	0.642	rs11729923	chr4:152392036	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.91e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.938	rs35760705	chr6:163020637	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.73	0.34	6.71e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg16434002	chr17:42200994	HDAC5	-0.43	-8.33	-0.36	9.53e-16	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs78487399	0.808	rs77791126	chr2:43744050	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.77	-0.3	3.94e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg13206674	chr6:150067644	NUP43	-0.68	-15.83	-0.59	2.11e-45	Lung cancer;
LGG	trans	rs1728785	0.901	rs1631910	chr16:68603335	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.35e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg25214090	chr10:38739885	LOC399744	0.6	10.94	0.45	6.04e-25	Corneal astigmatism;
LGG	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg13010199	chr12:38710504	ALG10B	0.63	13.06	0.52	2.18e-33	Bladder cancer;
LGG	cis	rs9326248	0.539	rs518181	chr11:116772787	C/A	cg20608306	chr11:116969690	SIK3	0.41	13.19	0.52	5.97e-34	Blood protein levels;
LGG	cis	rs4788570	0.615	rs1423983	chr16:71701248	G/A	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Intelligence (multi-trait analysis);
LGG	trans	rs1459104	1.000	rs66510003	chr11:55160196	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.8	0.3	3.23e-11	Body mass index;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.9	-17.22	-0.62	9.91e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg20607798	chr8:58055168	NA	0.64	7.12	0.31	4.17e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs611744	0.647	rs1584373	chr8:109263399	C/A	cg18478394	chr8:109455254	TTC35	0.41	8.22	0.36	2.14e-15	Dupuytren's disease;
LGG	cis	rs4563143	0.514	rs73030738	chr19:29312328	G/A	cg03161606	chr19:29218774	NA	0.65	8.35	0.36	8.26e-16	Methadone dose in opioid dependence;
LGG	cis	rs7577696	0.568	rs7562653	chr2:32478629	T/C	cg02381751	chr2:32503542	YIPF4	0.47	6.87	0.3	2.09e-11	Inflammatory biomarkers;
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg06719900	chr11:109292894	C11orf87	-0.51	-9.57	-0.41	6.37e-20	Schizophrenia;
LGG	cis	rs7106204	0.534	rs16912379	chr11:24309053	T/C	ch.11.24196551F	chr11:24239977	NA	0.86	9.17	0.39	1.55e-18	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7208859	0.673	rs28588622	chr17:29245699	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.91	0.38	1.2e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg16482183	chr6:26056742	HIST1H1C	0.61	9.65	0.41	3.39e-20	Iron status biomarkers;
LGG	cis	rs721399	0.752	rs4921915	chr8:18272466	G/A	cg18736775	chr8:18248649	NAT2	0.49	8.38	0.36	6.4e-16	Blood metabolite levels;
LGG	cis	rs17376456	0.877	rs12716456	chr5:93397557	A/G	cg25358565	chr5:93447407	FAM172A	1.32	16.4	0.61	5.75e-48	Diabetic retinopathy;
LGG	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg25174290	chr11:3078921	CARS	-0.47	-8.09	-0.35	5.25e-15	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24859228	chr10:12391835	CAMK1D	0.46	7.06	0.31	6.04e-12	Gut microbiome composition (summer);
LGG	trans	rs7618501	0.932	rs4855850	chr3:49761571	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.908	rs9627800	chr22:50319351	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.73	-0.41	1.76e-20	Schizophrenia;
LGG	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg13206674	chr6:150067644	NUP43	0.63	12.51	0.5	3.83e-31	Lung cancer;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg00166722	chr3:10149974	C3orf24	0.39	7.08	0.31	5.26e-12	Alzheimer's disease;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.41	0.63	1.42e-52	Obesity-related traits;
LGG	cis	rs5758511	0.680	rs5758657	chr22:42618669	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.92	0.35	1.76e-14	Birth weight;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04453241	chr17:76374567	PGS1	0.41	7.28	0.32	1.44e-12	Obesity-related traits;
LGG	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg22630939	chr7:1135958	C7orf50	0.33	6.75	0.3	4.53e-11	Bronchopulmonary dysplasia;
LGG	cis	rs11645898	0.935	rs11641721	chr16:72155241	G/A	cg14768367	chr16:72042858	DHODH	-0.82	-11.34	-0.47	1.77e-26	Blood protein levels;
LGG	cis	rs17125944	0.505	rs76219229	chr14:53178346	G/A	cg00686598	chr14:53173677	PSMC6	1.36	14.87	0.57	3.8e-41	Alzheimer's disease (late onset);
LGG	cis	rs11764590	0.715	rs55770986	chr7:2087823	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-6.77	-0.3	3.84e-11	Neuroticism;
LGG	cis	rs2273669	0.588	rs11153151	chr6:109316754	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs10267417	0.603	rs10216149	chr7:19909093	A/T	cg05791153	chr7:19748676	TWISTNB	0.57	7.49	0.33	3.55e-13	Night sleep phenotypes;
LGG	cis	rs2299587	0.643	rs6586680	chr8:17891178	C/T	cg18067069	chr8:17937731	ASAH1	-0.33	-7.72	-0.34	7.13e-14	Economic and political preferences;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02461956	chr11:134093940	NCAPD3;VPS26B	-0.49	-7.21	-0.32	2.23e-12	Systemic lupus erythematosus;
LGG	cis	rs6964587	1.000	rs10263309	chr7:91645265	A/G	cg17063962	chr7:91808500	NA	0.48	8.59	0.37	1.32e-16	Breast cancer;
LGG	cis	rs6089584	0.893	rs6089305	chr20:60571817	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-16.59	-0.61	7.42e-49	Body mass index;
LGG	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.43	0.44	5.22e-23	Lung cancer in ever smokers;
LGG	cis	rs7000551	0.581	rs11787182	chr8:22256727	T/C	cg12081754	chr8:22256438	SLC39A14	1.19	27.21	0.78	4.36e-98	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11874712	1.000	rs9944637	chr18:43655239	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.77	-0.48	3.56e-28	Migraine - clinic-based;
LGG	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.83	0.34	3.41e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3820068	0.581	rs6692489	chr1:15928517	A/G	cg05660106	chr1:15850417	CASP9	0.83	16.87	0.62	4.12e-50	Systolic blood pressure;
LGG	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg11161011	chr14:65562177	MAX	-0.64	-12.35	-0.5	1.71e-30	Obesity-related traits;
LGG	cis	rs13191362	0.810	rs13200053	chr6:163011443	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg26769984	chr7:1090371	C7orf50	0.44	7.74	0.34	6.37e-14	Bronchopulmonary dysplasia;
LGG	cis	rs4474465	0.688	rs4945300	chr11:78282632	T/C	cg27205649	chr11:78285834	NARS2	0.61	11.49	0.47	4.48e-27	Alzheimer's disease (survival time);
LGG	cis	rs2777491	0.957	rs7163788	chr15:41704789	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.29	-0.69	6.2e-66	Ulcerative colitis;
LGG	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg15736062	chr7:158136485	PTPRN2	-0.38	-7.18	-0.32	2.74e-12	Calcium levels;
LGG	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg27478167	chr7:817139	HEATR2	-0.48	-6.94	-0.31	1.33e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg03264133	chr6:25882463	NA	-0.4	-6.99	-0.31	9.91e-12	Height;
LGG	cis	rs35306767	0.903	rs11253458	chr10:882843	T/C	cg08847335	chr10:891726	LARP4B	-0.5	-9.0	-0.39	5.94e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2832191	0.933	rs2832236	chr21:30547602	C/T	cg08807101	chr21:30365312	RNF160	-0.76	-14.43	-0.56	3.02e-39	Dental caries;
LGG	cis	rs17021463	0.645	rs7664215	chr4:95329157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.48	7.49	0.33	3.55e-13	Testicular germ cell tumor;
LGG	cis	rs977987	0.806	rs11640473	chr16:75403289	C/A	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg24634471	chr8:143751801	JRK	0.5	7.83	0.34	3.27e-14	Schizophrenia;
LGG	cis	rs2011503	0.739	rs10412176	chr19:19689164	T/C	cg11584989	chr19:19387371	SF4	-0.64	-10.11	-0.43	7.8e-22	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14932684	chr12:42632001	YAF2	0.5	8.43	0.36	4.38e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg21132104	chr15:45694354	SPATA5L1	0.72	10.93	0.45	7.06e-25	Homoarginine levels;
LGG	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.03	-0.35	8.22e-15	Initial pursuit acceleration;
LGG	cis	rs7647973	1.000	rs3870341	chr3:49584745	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.26	0.36	1.54e-15	Menarche (age at onset);
LGG	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg18850127	chr7:39170497	POU6F2	0.51	11.57	0.47	2.31e-27	IgG glycosylation;
LGG	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-8.57	-0.37	1.56e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg08508337	chr8:144660607	NAPRT1	0.9	7.25	0.32	1.72e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.68	0.3	6.67e-11	Homoarginine levels;
LGG	cis	rs6735179	0.565	rs736869	chr2:1748463	G/A	cg08534653	chr2:1747700	PXDN	0.49	7.46	0.33	4.37e-13	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs7659604	0.846	rs35986491	chr4:122664528	A/T	cg20573242	chr4:122745356	CCNA2	0.42	7.74	0.34	6.34e-14	Type 2 diabetes;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg05335186	chr13:53173507	NA	-0.44	-8.97	-0.38	7.41e-18	Lewy body disease;
LGG	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg22563815	chr15:78856949	CHRNA5	-0.26	-6.65	-0.3	8.28e-11	Sudden cardiac arrest;
LGG	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg16797656	chr11:68205561	LRP5	0.52	10.0	0.42	1.9e-21	Total body bone mineral density;
LGG	cis	rs6598163	0.517	rs10902453	chr12:132297091	G/T	cg15284433	chr12:132323321	MMP17	0.37	7.04	0.31	6.83e-12	Migraine;
LGG	trans	rs3857536	0.813	rs6903411	chr6:66938288	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	trans	rs7404843	0.789	rs222909	chr16:15499289	A/G	cg02716450	chr16:28638775	NA	0.59	6.66	0.3	7.78e-11	Testicular germ cell tumor;
LGG	cis	rs1691799	0.899	rs1168305	chr12:66738714	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.53	-0.59	4.4e-44	White blood cell count (basophil);
LGG	cis	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg24375607	chr4:120327624	NA	0.6	10.19	0.43	3.96e-22	Corneal astigmatism;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs4478858	0.684	rs4949374	chr1:31754511	G/C	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.26e-11	Alcohol dependence;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10489202	1.000	rs718885	chr1:167954659	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.59	-0.33	1.73e-13	Colorectal cancer;
LGG	cis	rs3796352	1.000	rs4478072	chr3:53106125	G/T	cg12962167	chr3:53033115	SFMBT1	0.65	7.07	0.31	5.64e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg12070911	chr6:150209640	RAET1E	-0.29	-7.15	-0.32	3.46e-12	Lung cancer;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs1707322	0.691	rs61784799	chr1:46177748	A/G	cg03146154	chr1:46216737	IPP	-0.56	-10.7	-0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1125355	0.622	rs1515921	chr2:159615668	A/G	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs13082711	0.911	rs6789539	chr3:27444076	T/A	cg02860705	chr3:27208620	NA	0.72	13.38	0.53	9.7e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg07538946	chr5:131705188	SLC22A5	0.61	7.25	0.32	1.73e-12	Rheumatoid arthritis;
LGG	cis	rs7264396	0.790	rs2207889	chr20:34224898	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.6	-0.33	1.66e-13	Total cholesterol levels;
LGG	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg11764359	chr7:65958608	NA	0.57	9.58	0.41	5.89e-20	Aortic root size;
LGG	cis	rs757081	0.667	rs12577388	chr11:17101155	C/T	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.81	-0.38	2.6e-17	Systolic blood pressure;
LGG	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs3858526	0.584	rs10769274	chr11:5866925	T/C	cg05234568	chr11:5960015	NA	-0.66	-11.6	-0.47	1.78e-27	DNA methylation (variation);
LGG	cis	rs8012	0.517	rs17706531	chr19:13015530	A/G	cg23899408	chr19:12877188	HOOK2	-0.49	-7.91	-0.35	1.87e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.54	0.33	2.48e-13	Schizophrenia;
LGG	cis	rs12348691	0.503	rs10739513	chr9:100592705	C/T	cg13688889	chr9:100608707	NA	-0.83	-16.27	-0.6	2.15e-47	Alopecia areata;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg13736514	chr6:26305472	NA	-0.42	-8.91	-0.38	1.17e-17	Educational attainment;
LGG	cis	rs4481887	0.861	rs10888345	chr1:248447533	A/G	cg01631408	chr1:248437212	OR2T33	-0.55	-10.11	-0.43	7.88e-22	Common traits (Other);
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.5	-9.24	-0.39	8.66e-19	Lymphocyte counts;
LGG	cis	rs2652834	0.696	rs34317102	chr15:63414083	A/C	cg05507819	chr15:63340323	TPM1	0.5	7.06	0.31	5.99e-12	HDL cholesterol;
LGG	cis	rs4629710	0.568	rs9492883	chr6:131573872	A/T	cg12606694	chr6:131520996	AKAP7	0.51	8.28	0.36	1.35e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs3806843	0.547	rs246048	chr5:140327900	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs17039065	0.920	rs1017431	chr4:109474091	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.5	0.33	3.28e-13	Gut microbiome composition (summer);
LGG	cis	rs4356203	0.905	rs7123301	chr11:17163427	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.28	-0.32	1.49e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.42	-0.33	5.78e-13	Menopause (age at onset);
LGG	cis	rs2073300	0.609	rs6137917	chr20:23360369	G/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.59e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg18240062	chr17:79603768	NPLOC4	0.75	13.96	0.54	3.28e-37	Eye color traits;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	11.27	0.46	3.41e-26	Personality dimensions;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg13395646	chr4:1353034	KIAA1530	-0.61	-10.45	-0.44	4.33e-23	Obesity-related traits;
LGG	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12826209	chr6:26865740	GUSBL1	0.57	7.32	0.32	1.11e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg26384229	chr12:38710491	ALG10B	0.58	10.91	0.45	7.89e-25	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.777	rs6582664	chr12:37947022	A/G	cg04568710	chr12:38710424	ALG10B	-0.34	-7.34	-0.32	9.85e-13	Bladder cancer;
LGG	cis	rs1982963	1.000	rs10139288	chr14:52506486	T/C	cg05884192	chr14:52515736	NID2	-0.34	-7.57	-0.33	2.01e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg03060546	chr3:49711283	APEH	-0.67	-11.13	-0.46	1.12e-25	Educational attainment;
LGG	cis	rs56283067	0.847	rs12198153	chr6:44691878	T/C	cg18551225	chr6:44695536	NA	-0.7	-12.4	-0.5	1.11e-30	Total body bone mineral density;
LGG	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.39	7.51	0.33	3.06e-13	Colorectal cancer;
LGG	cis	rs9547692	0.938	rs9547689	chr13:37451861	G/A	cg02985381	chr13:37494744	SMAD9	0.71	12.21	0.49	6.5e-30	Coronary artery disease;
LGG	trans	rs877282	0.891	rs11253393	chr10:788824	G/T	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg19717773	chr7:2847554	GNA12	-0.32	-7.05	-0.31	6.72e-12	Height;
LGG	cis	rs2011503	1.000	rs61744761	chr19:19656615	C/T	cg11584989	chr19:19387371	SF4	0.74	12.0	0.49	4.52e-29	Bipolar disorder;
LGG	cis	rs6500395	0.775	rs4277341	chr16:48664387	T/G	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7512552	0.839	rs17597088	chr1:150475772	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.25	0.39	8.34e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.42	-0.53	6.52e-35	Alzheimer's disease;
LGG	cis	rs2916247	0.908	rs7016890	chr8:93176856	T/C	cg10183463	chr8:93005414	RUNX1T1	0.35	6.96	0.31	1.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.82	-0.38	2.34e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs990171	1.000	rs7561487	chr2:103077894	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs4417704	0.525	rs7585348	chr2:241893716	T/C	cg14055004	chr2:241860995	NA	0.28	7.35	0.32	9.34e-13	Joint mobility (Beighton score);
LGG	cis	rs2204008	0.571	rs8175738	chr12:38311234	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.21	-0.39	1.1e-18	Bladder cancer;
LGG	trans	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg18335740	chr13:41363409	SLC25A15	0.62	12.28	0.5	3.25e-30	Lewy body disease;
LGG	cis	rs10927875	1.000	rs4307563	chr1:16313788	C/T	cg21385522	chr1:16154831	NA	-0.8	-14.27	-0.55	1.57e-38	Dilated cardiomyopathy;
LGG	trans	rs17685	0.712	rs56965035	chr7:75795670	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg03609598	chr5:56110824	MAP3K1	0.53	8.0	0.35	9.77e-15	Initial pursuit acceleration;
LGG	trans	rs6601327	1.000	rs6601327	chr8:9395532	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.41	0.36	5.13e-16	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9291683	0.546	rs6829727	chr4:10051672	A/C	cg11266682	chr4:10021025	SLC2A9	0.5	9.48	0.4	1.34e-19	Bone mineral density;
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.788	rs35176994	chr14:65596004	T/C	cg16583315	chr14:65563665	MAX	-0.36	-6.81	-0.3	3.03e-11	Obesity-related traits;
LGG	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	12.96	0.52	5.7e-33	Colorectal cancer;
LGG	cis	rs2847297	1.000	rs2847297	chr18:12797694	A/G	cg23598886	chr18:12777645	NA	-0.38	-6.74	-0.3	4.69e-11	Rheumatoid arthritis;
LGG	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg16096631	chr1:42092165	HIVEP3	-0.43	-9.29	-0.4	6.23e-19	Airway imaging phenotypes;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01171360	chr6:293285	DUSP22	-0.58	-9.48	-0.4	1.34e-19	Menopause (age at onset);
LGG	cis	rs4731207	0.564	rs1471569	chr7:124650721	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.91	10.47	0.44	3.7e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg19812747	chr11:111475976	SIK2	-0.49	-10.3	-0.43	1.49e-22	Primary sclerosing cholangitis;
LGG	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.18	-0.36	2.72e-15	Neuroticism;
LGG	cis	rs12153243	1.000	rs12153243	chr5:142899801	A/T	cg13907255	chr5:142895549	NA	-0.4	-7.59	-0.33	1.73e-13	Migraine;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg06719900	chr11:109292894	C11orf87	0.45	8.37	0.36	7.11e-16	Schizophrenia;
LGG	cis	rs10884984	0.739	rs3829192	chr10:112269486	G/C	cg18756771	chr10:112261994	DUSP5	-0.68	-13.04	-0.52	2.6e-33	Facial morphology (factor 22);
LGG	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg24642439	chr20:33292090	TP53INP2	-0.83	-15.25	-0.58	7.4e-43	Coronary artery disease;
LGG	cis	rs2404602	0.647	rs10851889	chr15:77023336	C/T	cg15268244	chr15:77196840	NA	0.48	10.3	0.43	1.53e-22	Blood metabolite levels;
LGG	cis	rs73416724	1.000	rs112336903	chr6:43338115	T/C	cg26312998	chr6:43337775	ZNF318	0.61	8.57	0.37	1.59e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.74	-0.34	6.17e-14	Initial pursuit acceleration;
LGG	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	cis	rs2067615	0.524	rs10861646	chr12:107071182	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.87	0.51	1.24e-32	Heart rate;
LGG	trans	rs1728785	0.681	rs4783647	chr16:68558048	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.11	-0.39	2.42e-18	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs116095464	0.867	rs10074958	chr5:230828	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	cis	rs1125355	0.690	rs1356173	chr2:159651973	G/A	cg02251393	chr2:159651559	DAPL1	0.44	8.93	0.38	1e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg24110177	chr3:50126178	RBM5	0.4	6.89	0.3	1.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17826219	0.714	rs11650821	chr17:28968150	T/C	cg19761014	chr17:28927070	LRRC37B2	0.68	7.9	0.34	2.08e-14	Body mass index;
LGG	cis	rs4332037	0.802	rs73048106	chr7:1929019	G/T	cg23422044	chr7:1970798	MAD1L1	-0.76	-13.12	-0.52	1.18e-33	Bipolar disorder;
LGG	cis	rs1978968	0.913	rs12158823	chr22:18439420	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.2	-0.49	6.82e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9487094	0.677	rs4428538	chr6:109730848	C/T	cg16315928	chr6:109776240	MICAL1	0.52	7.88	0.34	2.43e-14	Height;
LGG	trans	rs1997103	1.000	rs6593233	chr7:55406200	C/T	cg20935933	chr6:143382018	AIG1	-0.52	-8.28	-0.36	1.3e-15	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.91	-19.61	-0.67	8.84e-63	Personality dimensions;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.13	-0.31	3.81e-12	Lung cancer;
LGG	cis	rs10927875	0.619	rs28537253	chr1:16148600	A/C	cg21385522	chr1:16154831	NA	-0.73	-14.76	-0.57	1.14e-40	Dilated cardiomyopathy;
LGG	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg16850897	chr7:100343110	ZAN	-0.55	-7.52	-0.33	2.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17125944	0.505	rs118053951	chr14:53259829	G/A	cg00686598	chr14:53173677	PSMC6	1.35	14.4	0.56	4.22e-39	Alzheimer's disease (late onset);
LGG	cis	rs1670533	1.000	rs10902752	chr4:1056199	C/T	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.47e-12	HDL cholesterol;
LGG	trans	rs72991	0.520	rs1560405	chr11:121238594	T/C	cg27192990	chr6:129479024	LAMA2	-0.47	-7.54	-0.33	2.56e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg00490583	chr16:1843685	IGFALS	0.49	8.44	0.37	4.21e-16	Insulin-like growth factors;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26020585	chr1:235491765	GGPS1;ARID4B	0.42	6.89	0.3	1.83e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg26655873	chr3:72818019	SHQ1	-0.36	-7.32	-0.32	1.14e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg26076054	chr5:421317	AHRR	0.46	8.32	0.36	9.63e-16	Cystic fibrosis severity;
LGG	cis	rs2120019	0.938	rs2289582	chr15:75310394	T/C	cg09165964	chr15:75287851	SCAMP5	-1.06	-22.52	-0.72	2.13e-76	Blood trace element (Zn levels);
LGG	cis	rs1790761	0.772	rs36089024	chr11:67244644	C/T	cg00864171	chr11:67383662	NA	-0.43	-6.87	-0.3	2.1e-11	Mean corpuscular volume;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.71	-13.3	-0.53	2.12e-34	Longevity;Endometriosis;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	4.08e-20	Schizophrenia;
LGG	cis	rs7172689	0.529	rs17875494	chr15:81587527	C/A	cg19620333	chr15:81596332	IL16	0.62	9.39	0.4	2.67e-19	Inattentive symptoms;
LGG	cis	rs644799	1.000	rs680134	chr11:95559517	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.93	0.54	4.34e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg27490568	chr2:178487706	NA	0.49	9.91	0.42	4.09e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs526231	0.667	rs187580	chr5:102627355	T/G	cg23492399	chr5:102201601	PAM	-0.57	-7.27	-0.32	1.51e-12	Primary biliary cholangitis;
LGG	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.94	-0.35	1.51e-14	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs6537837	0.517	rs559479	chr1:110138536	A/T	cg08367326	chr1:110052010	AMIGO1	-0.43	-7.22	-0.32	2.21e-12	Major depressive disorder;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07791516	chr6:150247246	NA	0.32	6.65	0.3	8.41e-11	Lung cancer;
LGG	trans	rs1005277	0.540	rs7903942	chr10:37929276	C/T	cg17830980	chr10:43048298	ZNF37B	0.41	9.18	0.39	1.43e-18	Extrinsic epigenetic age acceleration;
LGG	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg05555928	chr11:63887634	MACROD1	-0.78	-10.43	-0.44	4.9e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7209395	1.000	rs62063579	chr17:64139109	A/G	cg19474267	chr17:64306194	PRKCA	0.51	7.84	0.34	3.11e-14	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	trans	rs459571	0.959	rs378740	chr9:136890876	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.71	-0.48	6.48e-28	Platelet distribution width;
LGG	cis	rs7587476	0.599	rs61073893	chr2:215744814	C/T	cg04004882	chr2:215674386	BARD1	0.53	6.89	0.3	1.82e-11	Neuroblastoma;
LGG	cis	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg00086871	chr4:6988644	TBC1D14	0.85	8.39	0.36	6.06e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.87	9.31	0.4	5.29e-19	Lung cancer in ever smokers;
LGG	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.22	-0.32	2.13e-12	Calcium levels;
LGG	cis	rs6062302	0.522	rs3787112	chr20:62222411	G/A	cg16989086	chr20:62203971	PRIC285	0.48	7.02	0.31	7.77e-12	Glioblastoma;
LGG	cis	rs804280	0.662	rs804283	chr8:11611043	G/A	cg12395012	chr8:11607386	GATA4	-0.67	-11.06	-0.46	2.17e-25	Myopia (pathological);
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg21775007	chr8:11205619	TDH	-0.49	-7.38	-0.32	7.48e-13	Neuroticism;
LGG	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg21100191	chr22:23484243	RTDR1	0.97	21.44	0.71	2.52e-71	Bone mineral density;
LGG	cis	rs9398803	0.931	rs2045258	chr6:126674354	A/G	cg19875578	chr6:126661172	C6orf173	0.57	10.37	0.43	8.27e-23	Male-pattern baldness;
LGG	cis	rs10949834	0.878	rs2855727	chr7:73517852	T/G	cg07137043	chr7:73588983	EIF4H	-0.65	-7.31	-0.32	1.21e-12	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.3	-0.58	4.57e-43	Platelet count;
LGG	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg19913688	chr11:428466	ANO9	-0.7	-8.86	-0.38	1.78e-17	Body mass index;
LGG	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg22681709	chr2:178499509	PDE11A	-0.42	-7.62	-0.33	1.45e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg09085632	chr11:111637200	PPP2R1B	1.02	21.2	0.7	3.3e-70	Primary sclerosing cholangitis;
LGG	cis	rs16837677	1.000	rs76207714	chr1:156734657	G/A	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs2011503	0.941	rs56044734	chr19:19366927	G/A	cg01262667	chr19:19385393	TM6SF2	0.36	7.28	0.32	1.42e-12	Bipolar disorder;
LGG	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7666738	0.830	rs969048	chr4:98988921	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg06654118	chr4:1303317	MAEA	0.45	7.74	0.34	6.49e-14	Obesity-related traits;
LGG	cis	rs7918232	0.556	rs788209	chr10:27434716	G/T	cg14240646	chr10:27532245	ACBD5	-0.74	-8.82	-0.38	2.3e-17	Breast cancer;
LGG	cis	rs2274273	0.743	rs13379159	chr14:55540801	C/T	cg04306507	chr14:55594613	LGALS3	0.44	10.92	0.45	7.31e-25	Protein biomarker;
LGG	cis	rs8114671	0.562	rs4911447	chr20:33479445	T/A	cg07148914	chr20:33460835	GGT7	0.55	9.1	0.39	2.73e-18	Height;
LGG	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg01411142	chr8:19674711	INTS10	0.46	7.31	0.32	1.2e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2718058	0.519	rs2598071	chr7:37875347	G/A	cg24998770	chr7:37888106	TXNDC3	0.65	11.12	0.46	1.25e-25	Alzheimer's disease (late onset);
LGG	cis	rs2576037	0.899	rs12955429	chr18:44585484	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.29	-0.53	2.37e-34	Personality dimensions;
LGG	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.94	-0.38	9.26e-18	Triglycerides;
LGG	cis	rs10463316	0.817	rs13355052	chr5:150802003	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.2	-0.43	3.54e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7129556	0.954	rs11823651	chr11:77253879	G/A	cg12586386	chr11:77299805	AQP11	0.5	8.46	0.37	3.66e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg27624424	chr6:160112604	SOD2	0.65	9.72	0.41	1.83e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg13010199	chr12:38710504	ALG10B	-0.75	-15.91	-0.59	8.77e-46	Heart rate;
LGG	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.9	-0.31	1.71e-11	Triglycerides;
LGG	trans	rs12517041	1.000	rs1820748	chr5:23323355	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.18	-0.46	7.53e-26	Calcium levels;
LGG	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg01191920	chr7:158217561	PTPRN2	-0.92	-24.83	-0.76	3.6e-87	Obesity-related traits;
LGG	cis	rs9557207	1.000	rs9557176	chr13:99851804	G/C	cg24509225	chr13:100037070	UBAC2	0.71	12.78	0.51	2.97e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs11039798	0.841	rs11039783	chr11:48526828	G/C	cg15704280	chr7:45808275	SEPT13	0.77	8.9	0.38	1.25e-17	Axial length;
LGG	cis	rs11190604	0.767	rs12360395	chr10:102194074	A/T	cg07570687	chr10:102243282	WNT8B	0.42	7.48	0.33	3.71e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs16976116	0.806	rs28466870	chr15:55495113	C/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12775980	0.737	rs74129724	chr10:29850238	A/G	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs757278	0.591	rs1800136	chr7:117307108	G/A	cg10524701	chr7:117356490	CTTNBP2	0.43	7.63	0.33	1.36e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.73	-0.38	4.81e-17	Obesity-related traits;
LGG	cis	rs4262150	0.672	rs6864972	chr5:152347463	C/T	cg12297329	chr5:152029980	NA	0.56	8.91	0.38	1.15e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	13.77	0.54	2.04e-36	Response to antipsychotic treatment;
LGG	cis	rs11169552	0.510	rs10459235	chr12:51096183	G/A	cg12884762	chr12:50931848	DIP2B	-0.42	-7.99	-0.35	1.08e-14	Colorectal cancer;
LGG	cis	rs12153243	1.000	rs59514002	chr5:142901014	T/A	cg13907255	chr5:142895549	NA	-0.4	-7.59	-0.33	1.73e-13	Migraine;
LGG	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.41	-0.36	5.13e-16	Neuroticism;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.41	0.61	4.94e-48	Platelet count;
LGG	cis	rs9399137	0.507	rs6923512	chr6:135335268	A/G	cg24558204	chr6:135376177	HBS1L	-0.63	-10.81	-0.45	1.89e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg03538708	chr1:25844672	NA	-0.36	-6.85	-0.3	2.37e-11	Erythrocyte sedimentation rate;
LGG	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg26446133	chr18:72167187	CNDP2	-0.69	-13.86	-0.54	8.65e-37	Refractive error;
LGG	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg22437258	chr11:111473054	SIK2	-0.58	-9.6	-0.41	5.13e-20	Primary sclerosing cholangitis;
LGG	cis	rs6743376	0.556	rs2515396	chr2:113819175	G/A	cg05949173	chr2:113825882	IL1F10	0.48	9.07	0.39	3.42e-18	Inflammatory biomarkers;
LGG	cis	rs737693	1.000	rs72981680	chr11:102721859	C/A	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs240764	0.817	rs240145	chr6:101079610	A/C	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs3087591	0.708	rs2525563	chr17:29647908	T/G	cg24425628	chr17:29625626	OMG;NF1	0.6	12.37	0.5	1.48e-30	Hip circumference;
LGG	cis	rs17253792	0.822	rs80174205	chr14:56058694	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg08859206	chr1:53392774	SCP2	-0.42	-8.46	-0.37	3.45e-16	Monocyte count;
LGG	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg05985134	chr18:33552581	C18orf21	0.65	10.25	0.43	2.27e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg10664184	chr19:17420304	DDA1	0.54	8.28	0.36	1.36e-15	Systemic lupus erythematosus;
LGG	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg05585630	chr7:157510462	PTPRN2	-0.61	-10.96	-0.45	5.04e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.37e-11	Aortic root size;
LGG	trans	rs2727020	0.894	rs10839265	chr11:49369733	C/T	cg03929089	chr4:120376271	NA	-0.8	-13.32	-0.53	1.68e-34	Coronary artery disease;
LGG	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg25173405	chr17:45401733	C17orf57	0.48	8.18	0.36	2.77e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.07	0.75	1.32e-83	Chronic sinus infection;
LGG	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.22	0.36	2.06e-15	Retinal vascular caliber;
LGG	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.34	0.4	3.96e-19	Neuroticism;
LGG	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg24375607	chr4:120327624	NA	-0.52	-8.97	-0.38	7.5e-18	Corneal astigmatism;
LGG	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg20578329	chr17:80767326	TBCD	0.39	6.88	0.3	1.93e-11	Breast cancer;
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	2.97e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-10.01	-0.42	1.75e-21	Tonsillectomy;
LGG	cis	rs7917772	0.636	rs7069489	chr10:104525371	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-7.89	-0.34	2.13e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3741151	1.000	rs76764824	chr11:73073580	C/T	cg17517138	chr11:73019481	ARHGEF17	1.03	10.37	0.43	8.17e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg13256891	chr4:100009986	ADH5	0.55	9.71	0.41	2.15e-20	Alcohol dependence;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	7.83	0.34	3.41e-14	Renal function-related traits (BUN);
LGG	cis	rs13082711	0.522	rs653076	chr3:27343691	T/C	cg02860705	chr3:27208620	NA	0.59	11.15	0.46	9.6e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg06028605	chr16:24865363	SLC5A11	-0.47	-7.7	-0.34	8.32e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2239547	0.522	rs2336162	chr3:52951519	C/T	cg11645453	chr3:52864694	ITIH4	-0.68	-10.66	-0.44	6.88e-24	Schizophrenia;
LGG	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg25811766	chr13:21894605	NA	0.65	8.87	0.38	1.63e-17	White matter hyperintensity burden;
LGG	cis	rs2046867	0.866	rs2244246	chr3:72789191	G/A	cg26655873	chr3:72818019	SHQ1	-0.34	-6.93	-0.31	1.42e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg04025307	chr7:1156635	C7orf50	0.56	9.35	0.4	3.65e-19	Bronchopulmonary dysplasia;
LGG	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg18171855	chr10:2543474	NA	0.37	7.22	0.32	2.11e-12	Age-related hearing impairment;
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	16.02	0.6	2.7e-46	Personality dimensions;
LGG	cis	rs3857536	0.730	rs2157962	chr6:66966203	C/T	cg07460842	chr6:66804631	NA	-0.43	-7.2	-0.32	2.49e-12	Blood trace element (Cu levels);
LGG	cis	rs514406	0.708	rs536621	chr1:53309097	A/G	cg16325326	chr1:53192061	ZYG11B	0.63	13.54	0.53	2.08e-35	Monocyte count;
LGG	cis	rs12282928	0.851	rs4980421	chr11:48301482	G/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.24	-0.32	1.82e-12	Migraine - clinic-based;
LGG	cis	rs963731	0.649	rs6725356	chr2:39238395	C/G	cg04010122	chr2:39346883	SOS1	0.75	6.84	0.3	2.46e-11	Corticobasal degeneration;
LGG	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17209837	1.000	rs4148808	chr7:87105795	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.06	-0.49	2.69e-29	Gallbladder cancer;
LGG	cis	rs950169	0.800	rs4099846	chr15:84956894	C/G	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg16473166	chr22:50639996	SELO	0.58	9.7	0.41	2.3e-20	Obesity-related traits;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg07511668	chr11:68622177	NA	0.48	9.09	0.39	2.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs68170813	0.559	rs6951639	chr7:106817639	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg05082376	chr22:42548792	NA	-0.41	-8.67	-0.37	7.37e-17	Schizophrenia;
LGG	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg06481639	chr22:41940642	POLR3H	-0.55	-7.97	-0.35	1.29e-14	Vitiligo;
LGG	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg00864171	chr11:67383662	NA	-0.41	-6.68	-0.3	7.08e-11	Mean corpuscular volume;
LGG	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg14829155	chr15:31115871	NA	0.67	11.31	0.47	2.4e-26	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03067068	chr16:19729774	C16orf88;IQCK	0.49	7.24	0.32	1.9e-12	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg15485101	chr11:133734466	NA	0.52	9.2	0.39	1.23e-18	Childhood ear infection;
LGG	cis	rs11039131	0.929	rs1685404	chr11:47243665	C/G	cg20307385	chr11:47447363	PSMC3	-0.45	-7.44	-0.33	5.03e-13	Schizophrenia;
LGG	cis	rs131777	0.575	rs963980	chr22:51022117	C/A	cg05418105	chr22:50981406	NA	-0.62	-10.59	-0.44	1.31e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs10463554	0.889	rs34822	chr5:102437711	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.61	-0.33	1.5700000000000001e-13	Parkinson's disease;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	15.56	0.59	3.27e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.25	0.32	1.76e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9296092	0.517	rs6911036	chr6:33471652	C/G	cg13560919	chr6:33536144	NA	-0.92	-16.58	-0.61	8.08e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg14416269	chr4:6271139	WFS1	0.51	9.4	0.4	2.61e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg02297831	chr4:17616191	MED28	0.48	8.71	0.38	5.38e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs477895	0.652	rs72920332	chr11:63947071	G/T	cg04317338	chr11:64019027	PLCB3	0.66	8.09	0.35	5.33e-15	Mean platelet volume;
LGG	cis	rs10214930	0.697	rs12665991	chr7:27659771	A/G	cg22168087	chr7:27702803	HIBADH	0.45	6.72	0.3	5.48e-11	Hypospadias;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg12070911	chr6:150209640	RAET1E	0.27	6.98	0.31	1.05e-11	Testicular germ cell tumor;
LGG	cis	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg24110177	chr3:50126178	RBM5	-0.53	-9.29	-0.4	6.16e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.682	rs2320517	chr12:38259239	A/T	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.24	0.39	8.88e-19	Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg16507663	chr6:150244633	RAET1G	0.45	8.54	0.37	1.88e-16	Lung cancer;
LGG	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.15	-0.49	1.11e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg11520003	chr13:113540631	ATP11A	-0.37	-7.73	-0.34	6.63e-14	Interstitial lung disease;
LGG	cis	rs2270450	0.650	rs9381476	chr6:46701733	C/T	cg10156739	chr6:46714674	LOC100287718	-0.47	-10.36	-0.43	9.06e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.21	0.39	1.16e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.17	0.58	1.75e-42	Alzheimer's disease;
LGG	cis	rs758324	0.898	rs7725041	chr5:131188503	C/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs12549902	0.871	rs4736819	chr8:41509915	C/T	cg25883020	chr8:41504993	NKX6-3	0.31	6.72	0.3	5.21e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg05335186	chr13:53173507	NA	0.39	7.33	0.32	1.04e-12	Lewy body disease;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01171360	chr6:293285	DUSP22	-0.58	-9.56	-0.41	6.98e-20	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs1531718	chr7:124644777	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.79	-0.3	3.52e-11	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg12070911	chr6:150209640	RAET1E	0.32	7.65	0.34	1.15e-13	Lung cancer;
LGG	cis	rs7236492	0.515	rs76804350	chr18:77180607	C/T	cg05753993	chr18:77199432	NFATC1	0.41	6.77	0.3	4.01e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7100689	0.577	rs10749551	chr10:82054001	A/C	cg01528321	chr10:82214614	TSPAN14	0.83	14.44	0.56	2.89e-39	Post bronchodilator FEV1;
LGG	cis	rs2204008	0.538	rs61931093	chr12:38242911	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-9.95	-0.42	2.93e-21	Bladder cancer;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs2285947	1.000	rs2285949	chr7:21584243	G/A	cg03697024	chr7:21583438	DNAH11	0.35	8.62	0.37	1.06e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg15556689	chr8:8085844	FLJ10661	0.48	8.86	0.38	1.72e-17	Mood instability;
LGG	cis	rs2075466	0.514	rs17770918	chr16:4909623	A/G	cg04440724	chr16:4920505	UBN1	-0.62	-9.06	-0.39	3.62e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg12419862	chr22:24373484	LOC391322	0.92	19.11	0.66	1.84e-60	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg08847335	chr10:891726	LARP4B	-0.37	-6.82	-0.3	2.8e-11	Eosinophil percentage of granulocytes;
LGG	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg13010199	chr12:38710504	ALG10B	0.46	8.22	0.36	2.13e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7572733	0.935	rs2060489	chr2:198752286	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.99	0.35	1.06e-14	Dermatomyositis;
LGG	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs735539	0.521	rs1966190	chr13:21409137	A/C	cg04906043	chr13:21280425	IL17D	-0.47	-7.35	-0.32	8.8e-13	Dental caries;
LGG	cis	rs4819052	0.851	rs34101026	chr21:46662200	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4665809	0.627	rs35461456	chr2:26482361	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03434872	chr3:186524395	RFC4	-0.46	-7.32	-0.32	1.14e-12	Pancreatic cancer;
LGG	cis	rs4748857	0.947	rs7089898	chr10:23591365	C/T	cg18853376	chr10:23633759	C10orf67	0.36	6.91	0.31	1.62e-11	Systemic lupus erythematosus;
LGG	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg16400903	chr5:693638	TPPP	0.45	6.88	0.3	1.97e-11	Obesity-related traits;
LGG	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg16414030	chr3:133502952	NA	-0.59	-10.16	-0.43	5.09e-22	Iron status biomarkers;
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg16885296	chr6:26284938	NA	0.38	8.4	0.36	5.53e-16	Educational attainment;
LGG	cis	rs4764124	0.615	rs1012683	chr12:14951050	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.55	10.1	0.43	8.01e-22	Pubertal anthropometrics;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg20887711	chr4:1340912	KIAA1530	-0.76	-16.09	-0.6	1.4e-46	Obesity-related traits;
LGG	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.57	-6.82	-0.3	2.9e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10743315	0.732	rs73331849	chr12:19439619	G/C	cg02471346	chr12:19282374	PLEKHA5	0.58	6.78	0.3	3.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.58	-10.3	-0.43	1.49e-22	Total body bone mineral density;
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg03264133	chr6:25882463	NA	-0.5	-9.15	-0.39	1.86e-18	Height;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg27532560	chr4:187881888	NA	-0.6	-13.67	-0.54	5.38e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg13047869	chr3:10149882	C3orf24	-0.63	-9.31	-0.4	5.29e-19	Alzheimer's disease;
LGG	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg21798802	chr22:38057573	PDXP	0.39	8.57	0.37	1.51e-16	Fat distribution (HIV);
LGG	cis	rs4973397	0.765	rs10445830	chr2:232263973	C/T	cg11378575	chr2:232265004	B3GNT7	0.62	11.22	0.46	5.08e-26	Anti-saccade response;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg24777868	chr17:61699845	MAP3K3	-0.4	-6.88	-0.3	2e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs6028335	0.674	rs57993460	chr20:37662068	C/A	cg16355469	chr20:37678765	NA	0.62	8.33	0.36	9.29e-16	Alcohol and nicotine co-dependence;
LGG	cis	rs6908034	0.660	rs111231540	chr6:19802226	A/C	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2153535	0.580	rs9406167	chr6:8502852	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.48e-31	Motion sickness;
LGG	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg08250081	chr4:10125330	NA	0.41	8.1	0.35	4.99e-15	Bone mineral density;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.05	0.52	2.31e-33	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.67	0.61	3.36e-49	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16650099	chr1:114471848	HIPK1	0.49	7.54	0.33	2.55e-13	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg02002194	chr4:3960332	NA	0.42	7.68	0.34	9.7e-14	Retinal vascular caliber;
LGG	cis	rs12711979	0.509	rs10195488	chr2:3824135	T/C	cg17052675	chr2:3827356	NA	-0.49	-9.7	-0.41	2.29e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs7980799	0.682	rs1601007	chr12:33609675	C/G	cg26384229	chr12:38710491	ALG10B	0.64	11.92	0.48	9.33e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs68170813	0.559	rs2023892	chr7:106847686	C/T	cg02696742	chr7:106810147	HBP1	0.71	10.21	0.43	3.17e-22	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.4e-16	Obesity-related traits;
LGG	trans	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg27661571	chr11:113659931	NA	-0.57	-7.89	-0.34	2.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs367943	0.688	rs10063452	chr5:112734165	C/T	cg12552261	chr5:112820674	MCC	0.57	10.3	0.43	1.57e-22	Type 2 diabetes;
LGG	cis	rs12586317	0.586	rs2295103	chr14:35515920	C/G	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.25	-0.32	1.75e-12	Psoriasis;
LGG	cis	rs9341835	0.518	rs9350929	chr6:64175668	A/G	cg00787780	chr6:64151745	NA	0.4	7.06	0.31	6.14e-12	Schizophrenia;
LGG	trans	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	2.11e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg07636037	chr3:49044803	WDR6	0.78	14.0	0.55	2.16e-37	Menarche (age at onset);
LGG	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.38	-0.53	9.47e-35	Life satisfaction;
LGG	cis	rs2273669	0.667	rs77002235	chr6:109321497	G/A	cg05315195	chr6:109294784	ARMC2	-0.67	-8.77	-0.38	3.32e-17	Prostate cancer;
LGG	cis	rs8141529	0.644	rs5752795	chr22:29178820	T/C	cg02153584	chr22:29168773	CCDC117	0.7	11.91	0.48	1e-28	Lymphocyte counts;
LGG	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-9.01	-0.39	5.57e-18	Aortic root size;
LGG	cis	rs3857067	0.506	rs282450	chr4:95139598	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.86	-0.45	1.27e-24	QT interval;
LGG	cis	rs11645898	0.872	rs7206422	chr16:72152652	C/T	cg14768367	chr16:72042858	DHODH	-0.77	-9.97	-0.42	2.48e-21	Blood protein levels;
LGG	cis	rs3204270	0.759	rs8065104	chr17:79672605	G/A	cg18367735	chr17:79674897	NA	0.62	7.86	0.34	2.7e-14	Dental caries;
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs240764	0.578	rs11155613	chr6:101176642	T/C	cg09795085	chr6:101329169	ASCC3	0.48	8.34	0.36	8.28e-16	Neuroticism;
LGG	cis	rs55665837	1.000	rs7121171	chr11:14446420	A/G	cg19336497	chr11:14380999	RRAS2	-0.43	-8.35	-0.36	7.78e-16	Vitamin D levels;
LGG	cis	rs7100689	0.890	rs4934169	chr10:82203663	A/G	cg00277334	chr10:82204260	NA	-0.41	-7.72	-0.34	7.18e-14	Post bronchodilator FEV1;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20431080	chr7:149158239	ZNF777	0.42	6.96	0.31	1.14e-11	Cognitive performance;
LGG	cis	rs6598955	0.671	rs6658935	chr1:26568912	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.09	0.35	5.17e-15	Obesity-related traits;
LGG	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.33	0.4	4.56e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10779751	0.762	rs6671083	chr1:11325910	A/G	cg08854313	chr1:11322531	MTOR	-0.7	-14.26	-0.55	1.71e-38	Body mass index;
LGG	cis	rs4734806	1.000	rs4734806	chr8:105700680	A/G	cg01675814	chr8:105601641	LRP12	0.57	7.68	0.34	9.88e-14	Periodontitis (DPAL);
LGG	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.86	-0.3	2.19e-11	Fear of minor pain;
LGG	cis	rs4595586	0.545	rs2388174	chr12:39389237	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.29e-13	Morning vs. evening chronotype;
LGG	cis	rs7236492	0.748	rs79548165	chr18:77183529	C/T	cg05753993	chr18:77199432	NFATC1	0.4	7.38	0.32	7.23e-13	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7819412	0.818	rs11989439	chr8:11055597	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.59	-0.37	1.36e-16	Triglycerides;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg19168338	chr16:4465731	CORO7	-0.94	-18.33	-0.65	8.06e-57	Schizophrenia;
LGG	cis	rs1408799	0.579	rs1326779	chr9:12737581	T/C	cg05274944	chr9:12693694	TYRP1	-0.31	-6.87	-0.3	2.03e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs9875589	0.509	rs6783645	chr3:14024542	T/C	cg19554555	chr3:13937349	NA	-0.55	-9.85	-0.42	6.49e-21	Ovarian reserve;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg07701084	chr6:150067640	NUP43	0.68	12.69	0.51	7.29e-32	Lung cancer;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.76	-0.38	3.72e-17	IgG glycosylation;
LGG	cis	rs2124969	0.506	rs10497210	chr2:160985549	G/A	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.32	-0.4	4.7e-19	Waist circumference adjusted for body mass index;
LGG	cis	rs847577	0.677	rs1495525	chr7:97826232	G/A	cg13397024	chr7:97797637	LMTK2	0.42	7.44	0.33	5.02e-13	Breast cancer;
LGG	cis	rs2836974	0.931	rs2836972	chr21:40652142	G/A	cg11890956	chr21:40555474	PSMG1	1.17	30.07	0.81	6.31e-111	Cognitive function;
LGG	cis	rs795544	0.580	rs7709692	chr5:13789420	T/C	cg07548982	chr5:13769939	DNAH5	-0.4	-7.58	-0.33	1.93e-13	Corneal astigmatism;
LGG	cis	rs72843166	0.545	rs72839491	chr17:61029908	A/G	cg27279583	chr17:61514753	CYB561	0.41	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3020736	0.500	rs7292241	chr22:42492063	G/A	cg04733989	chr22:42467013	NAGA	-0.58	-10.32	-0.43	1.31e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg04733989	chr22:42467013	NAGA	0.58	10.36	0.43	9.08e-23	Schizophrenia;
LGG	trans	rs1997103	1.000	rs4947504	chr7:55409428	T/C	cg20935933	chr6:143382018	AIG1	0.5	7.82	0.34	3.63e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	1.000	rs2500418	chr20:25382268	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.19	-0.43	3.97e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6500395	1.000	rs8058362	chr16:48645316	T/C	cg04672837	chr16:48644449	N4BP1	0.55	9.07	0.39	3.5e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7742824	1.000	rs57576544	chr6:44072726	T/C	cg04074908	chr6:44101190	TMEM63B	0.68	13.15	0.52	8.43e-34	Major depressive disorder;
LGG	cis	rs9807841	0.670	rs8099926	chr19:10778647	A/G	cg17710535	chr19:10819994	QTRT1	0.44	6.84	0.3	2.57e-11	Inflammatory skin disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21144673	chr22:42017783	PPPDE2;XRCC6	-0.5	-7.33	-0.32	1.02e-12	Systemic lupus erythematosus;
LGG	cis	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg06521331	chr12:34319734	NA	-0.52	-8.86	-0.38	1.71e-17	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16556906	chr6:71666682	B3GAT2	0.44	6.68	0.3	6.84e-11	Gut microbiome composition (summer);
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg05863683	chr7:1912471	MAD1L1	0.44	8.77	0.38	3.45e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg18357526	chr6:26021779	HIST1H4A	0.9	17.48	0.63	6.44e-53	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg27432699	chr2:27873401	GPN1	-0.76	-15.88	-0.59	1.21e-45	Oral cavity cancer;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.6	-0.33	1.68e-13	Personality dimensions;
LGG	cis	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.62	-0.33	1.49e-13	Morning vs. evening chronotype;
LGG	trans	rs1422110	0.641	rs12514639	chr5:85523929	C/T	cg01787110	chr1:109008453	NBPF6	-0.83	-13.55	-0.53	1.81e-35	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.31	-0.32	1.16e-12	Coronary artery disease;
LGG	cis	rs9309473	1.000	rs6546837	chr2:73677898	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.5	-0.33	3.22e-13	Metabolite levels;
LGG	cis	rs67385638	0.855	rs3759074	chr11:5257778	C/T	cg12559170	chr11:5275217	HBG2	0.52	11.15	0.46	9.36e-26	Hemoglobin levels;
LGG	cis	rs9549367	0.789	rs34989271	chr13:113894766	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.07e-16	Platelet distribution width;
LGG	cis	rs9487051	1.000	rs1008084	chr6:109626965	G/A	cg21918786	chr6:109611834	NA	-0.44	-8.16	-0.35	3.26e-15	Reticulocyte fraction of red cells;
LGG	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg25358565	chr5:93447407	FAM172A	1.37	17.05	0.62	6.38e-51	Diabetic retinopathy;
LGG	cis	rs2652822	1.000	rs1126308	chr15:63429086	G/T	cg02713581	chr15:63449717	RPS27L	-0.49	-8.37	-0.36	6.92e-16	Metabolic traits;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.3	0.5	2.77e-30	Prudent dietary pattern;
LGG	cis	rs9467773	0.549	rs9461273	chr6:26584526	A/G	cg09904177	chr6:26538194	HMGN4	-0.63	-12.64	-0.51	1.16e-31	Intelligence (multi-trait analysis);
LGG	cis	rs1595825	0.891	rs59990242	chr2:198895868	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-14.4	-0.56	4.01e-39	Headache;
LGG	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg22681709	chr2:178499509	PDE11A	-0.42	-7.57	-0.33	2.05e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg18446336	chr7:2847575	GNA12	-0.29	-7.41	-0.33	6.07e-13	Height;
LGG	cis	rs6089584	0.528	rs4925334	chr20:60626769	C/T	cg13770153	chr20:60521292	NA	-0.49	-8.11	-0.35	4.47e-15	Body mass index;
LGG	cis	rs7089973	0.624	rs10885613	chr10:116589400	G/A	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg24247370	chr13:99142703	STK24	-0.38	-6.82	-0.3	2.89e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg02002194	chr4:3960332	NA	-0.46	-8.86	-0.38	1.77e-17	Systolic blood pressure;
LGG	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.91	-0.51	8.67e-33	Blood protein levels;
LGG	cis	rs4595586	0.545	rs6580896	chr12:39372223	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs4704187	0.687	rs1345705	chr5:74507007	C/A	cg03227963	chr5:74354835	NA	0.31	6.68	0.3	6.71e-11	Response to amphetamines;
LGG	cis	rs6964587	1.000	rs11982047	chr7:91705274	G/A	cg17063962	chr7:91808500	NA	0.49	8.6	0.37	1.25e-16	Breast cancer;
LGG	trans	rs6561151	0.681	rs61209988	chr13:44416335	G/C	cg17145862	chr1:211918768	LPGAT1	0.68	10.67	0.44	6.3e-24	Crohn's disease;
LGG	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg00531865	chr16:30841666	NA	0.39	7.99	0.35	1.08e-14	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.65	0.37	8.34e-17	Renal function-related traits (BUN);
LGG	cis	rs1949733	1.000	rs2631740	chr4:8484106	C/A	cg13073564	chr4:8508604	NA	0.59	11.75	0.48	4.37e-28	Response to antineoplastic agents;
LGG	cis	rs3733585	0.578	rs6837224	chr4:9955255	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg00149659	chr3:10157352	C3orf10	1.18	13.59	0.53	1.29e-35	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg08621203	chr6:150244597	RAET1G	0.44	7.42	0.33	5.77e-13	Lung cancer;
LGG	trans	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.39	8.25	0.36	1.67e-15	Obesity-related traits;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15806518	chr9:127177817	PSMB7	-0.4	-6.72	-0.3	5.42e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2430307	0.518	rs67763033	chr7:76517677	A/G	cg15770687	chr7:76625569	PMS2L11	0.53	7.17	0.32	3.05e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs10991814	0.557	rs773519	chr9:93944244	C/T	cg14446406	chr9:93919335	NA	0.7	10.37	0.43	8.39e-23	Neutrophil percentage of granulocytes;
LGG	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg24503407	chr1:205819492	PM20D1	0.46	6.85	0.3	2.31e-11	Prostate-specific antigen levels;
LGG	cis	rs7193541	0.965	rs8050262	chr16:74661159	T/C	cg01733217	chr16:74700730	RFWD3	0.9	20.83	0.7	1.74e-68	Multiple myeloma;
LGG	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg01324343	chr3:183735012	ABCC5	0.87	18.69	0.66	1.7e-58	Anterior chamber depth;
LGG	cis	rs7666738	0.645	rs10013290	chr4:99082799	G/A	cg05340658	chr4:99064831	C4orf37	0.44	7.12	0.31	4.03e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4474465	1.000	rs7925034	chr11:78193242	A/G	cg02023728	chr11:77925099	USP35	0.39	6.82	0.3	2.84e-11	Alzheimer's disease (survival time);
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.58e-12	Life satisfaction;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg12432903	chr7:1882776	MAD1L1	0.41	6.94	0.31	1.32e-11	Neuroticism;
LGG	trans	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg16141378	chr3:129829833	LOC729375	-0.46	-11.07	-0.46	2.06e-25	Mood instability;
LGG	cis	rs7572733	0.935	rs771010	chr2:198691006	C/G	cg00792783	chr2:198669748	PLCL1	-0.49	-8.24	-0.36	1.73e-15	Dermatomyositis;
LGG	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.87	0.59	1.29e-45	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.967	rs4899545	chr14:75568138	A/G	cg08847533	chr14:75593920	NEK9	0.63	12.27	0.5	3.84e-30	Height;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.49	9.76	0.41	1.43e-20	Prostate cancer;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.0	-0.35	1.04e-14	Longevity;Endometriosis;
LGG	cis	rs9788721	0.902	rs7180002	chr15:78873993	A/T	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.48	-0.33	3.66e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7143963	1.000	rs76327888	chr14:103380403	G/T	cg23020514	chr14:103360112	TRAF3	0.48	9.19	0.39	1.33e-18	Body mass index;
LGG	cis	rs36229146	1	rs36229146	chr7:22784486	TTATATATAAATATATATATATATATA/T	cg05265849	chr7:22767390	IL6	0.42	7.78	0.34	4.73e-14	Eosinophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LGG	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg16586182	chr3:47516702	SCAP	-0.58	-9.81	-0.41	9.28e-21	Birth weight;
LGG	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg18681998	chr4:17616180	MED28	0.86	19.88	0.68	4.8e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2289583	0.573	rs8025880	chr15:75394881	G/C	cg14664628	chr15:75095509	CSK	0.51	9.09	0.39	3e-18	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4253772	0.513	rs6008700	chr22:46722560	C/T	cg24881330	chr22:46731750	TRMU	0.85	10.7	0.45	5.02e-24	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg23782820	chr8:58130467	NA	0.46	7.03	0.31	7.41e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs6930083	0.605	rs3829964	chr6:36644498	T/C	cg08179530	chr6:36648295	CDKN1A	0.76	14.46	0.56	2.15e-39	Coronary artery disease;
LGG	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	13.03	0.52	2.75e-33	Cognitive test performance;
LGG	cis	rs7666738	0.830	rs79075162	chr4:98960674	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3126085	0.935	rs12746239	chr1:152246726	G/A	cg26876637	chr1:152193138	HRNR	-0.54	-8.53	-0.37	2.03e-16	Atopic dermatitis;
LGG	cis	rs883115	1.000	rs4654058	chr1:224806174	C/G	cg01808320	chr1:224927238	CNIH3	-0.37	-6.72	-0.3	5.29e-11	Cancer;
LGG	cis	rs7267979	0.740	rs2259961	chr20:25282626	T/G	cg06421707	chr20:25228305	PYGB	0.43	9.0	0.39	5.82e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28595532	0.841	rs114107504	chr4:119771080	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.18	0.36	2.75e-15	Mood instability;
LGG	cis	rs738322	1.000	rs133012	chr22:38570721	G/A	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg11987759	chr7:65425863	GUSB	0.4	7.56	0.33	2.22e-13	Aortic root size;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg09699651	chr6:150184138	LRP11	0.51	9.07	0.39	3.38e-18	Lung cancer;
LGG	cis	rs1385374	0.858	rs34888374	chr12:129296536	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs9557207	1.000	rs9585030	chr13:99932359	C/T	cg24509225	chr13:100037070	UBAC2	0.68	12.32	0.5	2.28e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg05665937	chr4:1216051	CTBP1	0.57	10.53	0.44	2.09e-23	Obesity-related traits;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07659893	chr17:61819838	STRADA	-0.41	-6.71	-0.3	5.83e-11	Prudent dietary pattern;
LGG	cis	rs6868223	1.000	rs4076944	chr5:33638224	A/G	cg10594543	chr5:33649717	ADAMTS12	0.54	11.79	0.48	3.22e-28	Mortality in heart failure;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg02462569	chr6:150064036	NUP43	0.36	7.72	0.34	7e-14	Lung cancer;
LGG	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg17201900	chr20:34330562	RBM39	0.53	7.13	0.31	3.9e-12	Total cholesterol levels;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg16885296	chr6:26284938	NA	0.39	8.51	0.37	2.35e-16	Educational attainment;
LGG	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg06713675	chr4:122721982	EXOSC9	-0.6	-10.07	-0.42	1.09e-21	Type 2 diabetes;
LGG	cis	rs67133203	0.579	rs2640527	chr12:51536914	C/G	cg14688905	chr12:51403056	SLC11A2	-0.6	-9.95	-0.42	2.8e-21	Urinary tract infection frequency;
LGG	cis	rs2273669	0.667	rs11153148	chr6:109304084	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.48	-0.37	3.07e-16	Prostate cancer;
LGG	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg15556689	chr8:8085844	FLJ10661	0.46	8.03	0.35	8.13e-15	Retinal vascular caliber;
LGG	cis	rs929354	0.772	rs3802123	chr7:156970641	G/A	cg17757837	chr7:157058334	UBE3C	0.8	16.33	0.6	1.1e-47	Body mass index;
LGG	cis	rs10197940	0.710	rs4500942	chr2:152334580	A/G	cg06191203	chr2:152266755	RIF1	-0.51	-9.38	-0.4	3.02e-19	Lung cancer;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg00495681	chr13:53174319	NA	0.67	12.86	0.51	1.47e-32	Lewy body disease;
LGG	trans	rs3960554	0.808	rs111714534	chr7:75748896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.32	0.5	2.39e-30	Eotaxin levels;
LGG	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg05234568	chr11:5960015	NA	-0.74	-12.1	-0.49	1.75e-29	DNA methylation (variation);
LGG	cis	rs1109114	0.816	rs2918272	chr5:148604456	A/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.68	-0.59	9.51e-45	Body mass index;
LGG	cis	rs9810089	0.708	rs619605	chr3:136087012	G/C	cg21827317	chr3:136751795	NA	0.43	7.29	0.32	1.36e-12	Gestational age at birth (child effect);
LGG	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.57	-0.37	1.53e-16	Bone mineral density;
LGG	cis	rs7582720	1.000	rs79642273	chr2:203830851	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9788682	0.747	rs2568497	chr15:78721397	G/T	cg06917634	chr15:78832804	PSMA4	0.54	8.08	0.35	5.66e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7917772	0.560	rs35095897	chr10:104377759	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-11.22	-0.46	5.11e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs400736	0.655	rs11121086	chr1:8151224	C/T	cg25007680	chr1:8021821	PARK7	-0.37	-6.73	-0.3	5.11e-11	Response to antidepressants and depression;
LGG	cis	rs11877825	0.737	rs6505572	chr18:10579366	T/C	cg07277756	chr18:10589357	NA	0.57	10.19	0.43	4.05e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg04008888	chr11:68622739	NA	-0.55	-11.8	-0.48	2.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6976053	0.804	rs314371	chr7:100455700	C/T	cg03098644	chr7:100410630	EPHB4	-0.4	-7.15	-0.32	3.31e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs3741404	0.574	rs616563	chr11:63877501	G/C	cg18225595	chr11:63971243	STIP1	0.48	9.24	0.39	8.81e-19	Platelet count;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.57	9.59	0.41	5.65e-20	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11699826	chr1:26438425	PDIK1L	0.45	7.63	0.33	1.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4363385	0.693	rs402153	chr1:153054212	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-8.04	-0.35	7.32e-15	Inflammatory skin disease;
LGG	cis	rs9788682	0.747	rs2938674	chr15:78757913	C/A	cg06917634	chr15:78832804	PSMA4	-0.53	-8.13	-0.35	4.01e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1568889	1.000	rs12797712	chr11:28290890	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.34	0.53	1.34e-34	Bipolar disorder;
LGG	cis	rs7192750	0.562	rs4788566	chr16:71893470	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.72	0.45	4.4e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs3824344	0.531	rs7870336	chr9:37007769	C/G	cg14294708	chr9:37120828	ZCCHC7	-0.47	-8.02	-0.35	8.78e-15	Intelligence;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs2898857	0.504	rs7214496	chr17:47384611	C/G	cg11430096	chr6:110968061	CDK19	0.49	8.44	0.37	4.1e-16	Cancer;
LGG	cis	rs28595532	0.641	rs116674223	chr4:119371479	G/C	cg21605333	chr4:119757512	SEC24D	0.99	9.13	0.39	2.12e-18	Cannabis dependence symptom count;
LGG	cis	rs2732480	0.577	rs1489109	chr12:48738780	C/A	cg21466736	chr12:48725269	NA	-0.39	-7.74	-0.34	6.5e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs13314892	0.726	rs78094954	chr3:69881136	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.44e-14	QRS complex (12-leadsum);
LGG	cis	rs6840360	0.515	rs11099811	chr4:152320532	C/A	cg17217059	chr4:152329364	FAM160A1	0.2	6.96	0.31	1.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6120849	0.663	rs13041792	chr20:33545055	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	6.9	0.31	1.69e-11	Protein C levels;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.82	-0.42	8.43e-21	Tonsillectomy;
LGG	cis	rs11914070	0.928	rs13054104	chr22:18961405	A/G	cg14259594	chr22:18958660	DGCR5	-0.58	-9.2	-0.39	1.21e-18	Gait variability;
LGG	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg10857441	chr5:6722123	POLS	-0.27	-6.7	-0.3	6.2e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2288073	0.965	rs13387930	chr2:24414400	A/G	cg06627628	chr2:24431161	ITSN2	-0.66	-10.74	-0.45	3.58e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11626933	1.000	rs6575122	chr14:90753556	A/G	cg14092571	chr14:90743983	NA	-0.81	-16.42	-0.61	4.62e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs1506636	0.889	rs619075	chr7:123426317	A/T	cg03229431	chr7:123269106	ASB15	0.73	17.96	0.64	4.02e-55	Plateletcrit;Platelet count;
LGG	cis	rs9886651	0.905	rs10110243	chr8:128805020	A/G	cg24514600	chr8:128805414	PVT1	-0.56	-12.9	-0.51	1e-32	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.45	-0.33	4.57e-13	Iron status biomarkers;
LGG	cis	rs4774899	0.932	rs12915489	chr15:57551596	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.15	-0.32	3.44e-12	Urinary tract infection frequency;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.61	0.37	1.17e-16	Schizophrenia;
LGG	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg13385521	chr17:29058706	SUZ12P	0.68	8.16	0.35	3.13e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9291683	0.595	rs11731110	chr4:10037346	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.52	0.4	9.82e-20	Bone mineral density;
LGG	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.97	-0.31	1.08e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2952156	0.834	rs903503	chr17:37829571	C/A	cg07936489	chr17:37558343	FBXL20	-0.5	-8.36	-0.36	7.58e-16	Asthma;
LGG	cis	rs539514	0.587	rs9530466	chr13:76323774	T/C	cg04757411	chr13:76259545	LMO7	-0.29	-7.41	-0.33	6.12e-13	Type 1 diabetes;
LGG	cis	rs9300255	0.544	rs1790123	chr12:123659542	C/T	cg00376283	chr12:123451042	ABCB9	0.56	8.17	0.36	2.9e-15	Neutrophil percentage of white cells;
LGG	cis	rs6504108	0.624	rs2041572	chr17:46205273	T/C	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg04935121	chr11:63775413	MACROD1	0.39	9.41	0.4	2.3e-19	Schizophrenia;
LGG	cis	rs2111398	0.689	rs1148732	chr12:13068291	C/G	cg03534847	chr12:13053055	GPRC5A	0.37	7.33	0.32	1.01e-12	Cutaneous malignant melanoma;
LGG	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	5.9e-15	Retinal vascular caliber;
LGG	cis	rs61931739	0.592	rs61927750	chr12:33696070	T/C	cg06521331	chr12:34319734	NA	0.4	6.92	0.31	1.48e-11	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.43	-0.33	5.42e-13	Menopause (age at onset);
LGG	cis	rs10193935	1.000	rs57883795	chr2:42387926	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.0	-0.39	5.77e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2735413	0.881	rs12919672	chr16:78082760	C/G	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs11169552	0.510	rs4768893	chr12:50960480	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.46	-0.33	4.39e-13	Colorectal cancer;
LGG	cis	rs17039065	0.920	rs11730289	chr4:109468100	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs3087591	0.922	rs757383	chr17:29596045	C/G	cg24425628	chr17:29625626	OMG;NF1	0.71	14.7	0.56	1.99e-40	Hip circumference;
LGG	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg17644776	chr2:200775616	C2orf69	0.57	7.13	0.31	3.81e-12	Schizophrenia;
LGG	cis	rs6594499	0.872	rs10051830	chr5:110452845	G/A	cg04022379	chr5:110408740	TSLP	0.4	7.31	0.32	1.17e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg11707556	chr5:10655725	ANKRD33B	0.51	9.71	0.41	2.1e-20	Coronary artery disease;
LGG	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	7.01e-22	Motion sickness;
LGG	cis	rs2562456	0.755	rs2562421	chr19:21631304	T/G	cg00806126	chr19:22604979	ZNF98	0.57	8.03	0.35	8.21e-15	Pain;
LGG	cis	rs7814319	0.933	rs7002575	chr8:97242124	G/A	cg20787634	chr8:97240163	UQCRB	-0.78	-18.34	-0.65	7.11e-57	Lung function (FVC);
LGG	cis	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg04568710	chr12:38710424	ALG10B	0.34	6.71	0.3	5.67e-11	Bladder cancer;
LGG	cis	rs4743820	0.620	rs7046632	chr9:93919341	C/T	cg14446406	chr9:93919335	NA	-0.9	-15.29	-0.58	4.91e-43	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg22916017	chr11:64110731	CCDC88B	0.46	6.78	0.3	3.66e-11	Mean platelet volume;
LGG	cis	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs12410462	0.688	rs35582095	chr1:227959206	A/G	cg23173402	chr1:227635558	NA	0.37	6.87	0.3	2.08e-11	Major depressive disorder;
LGG	cis	rs7264396	0.790	rs12480622	chr20:34234620	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.03	-0.31	7.29e-12	Total cholesterol levels;
LGG	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg20673091	chr1:2541236	MMEL1	0.77	18.34	0.65	7.12e-57	Ulcerative colitis;
LGG	cis	rs12949688	0.935	rs9893344	chr17:55826114	G/A	cg12229367	chr17:55822335	NA	0.43	8.04	0.35	7.39e-15	Schizophrenia;
LGG	cis	rs7737355	0.947	rs2108869	chr5:131086880	A/G	cg06307176	chr5:131281290	NA	0.56	9.27	0.4	6.99e-19	Life satisfaction;
LGG	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.74	0.34	6.27e-14	Homoarginine levels;
LGG	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg09173681	chr1:183549694	NCF2	-0.38	-8.62	-0.37	1.03e-16	Systemic lupus erythematosus;
LGG	cis	rs9462027	0.651	rs9469870	chr6:34744349	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.46	-0.47	5.98e-27	Systemic lupus erythematosus;
LGG	cis	rs6831352	0.918	rs1042364	chr4:100045574	T/C	cg12011299	chr4:100065546	ADH4	0.43	8.61	0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs4780401	0.703	rs12921129	chr16:11769176	C/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.29	-0.32	1.36e-12	Rheumatoid arthritis;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9398803	0.584	rs3850234	chr6:127001534	T/G	cg19875578	chr6:126661172	C6orf173	0.52	9.59	0.41	5.29e-20	Male-pattern baldness;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg13395646	chr4:1353034	KIAA1530	-0.43	-7.46	-0.33	4.44e-13	Longevity;
LGG	cis	rs10504130	0.569	rs9650179	chr8:52824687	G/T	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.09e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1894633	0.547	rs6674018	chr1:172340661	T/A	cg01573306	chr1:172330400	DNM3	-0.43	-7.42	-0.33	5.79e-13	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7223966	1.000	rs8064261	chr17:61705212	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.41	-0.33	5.88e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3733585	0.579	rs4235353	chr4:10122934	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.2	-0.36	2.3e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg00012203	chr2:219082015	ARPC2	-0.49	-8.57	-0.37	1.6e-16	Ulcerative colitis;
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg08355456	chr11:67383691	NA	-0.51	-7.78	-0.34	4.7e-14	Mean corpuscular volume;
LGG	cis	rs9811920	0.893	rs9814549	chr3:99892190	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-8.07	-0.35	5.92e-15	Axial length;
LGG	cis	rs2880765	0.566	rs11630381	chr15:86012503	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-6.93	-0.31	1.45e-11	Coronary artery disease;
LGG	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.86	-0.3	2.28e-11	Neuroticism;
LGG	cis	rs9309711	0.772	rs9309714	chr2:3491830	G/C	cg10845886	chr2:3471009	TTC15	-0.69	-13.45	-0.53	4.81e-35	Neurofibrillary tangles;
LGG	cis	rs9783347	1.000	rs4150562	chr11:18354995	A/G	cg03595886	chr11:18357587	GTF2H1	-0.38	-7.78	-0.34	4.63e-14	Pancreatic cancer;
LGG	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg27129171	chr3:47204927	SETD2	0.79	15.3	0.58	4.51e-43	Colorectal cancer;
LGG	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg03929089	chr4:120376271	NA	0.71	9.85	0.42	6.78e-21	Axial length;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-10.88	-0.45	1.05e-24	Bipolar disorder;
LGG	cis	rs10504073	0.584	rs74457150	chr8:49890753	C/G	cg00325661	chr8:49890786	NA	0.82	16.48	0.61	2.3e-48	Blood metabolite ratios;
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg08888203	chr3:10149979	C3orf24	0.52	8.83	0.38	2.14e-17	Alzheimer's disease;
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-8.91	-0.38	1.16e-17	Triglycerides;
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg00149659	chr3:10157352	C3orf10	0.76	10.6	0.44	1.17e-23	Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.71	-0.3	5.87e-11	Lung cancer;
LGG	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg08305652	chr11:111469057	NA	-0.44	-9.09	-0.39	2.89e-18	Primary sclerosing cholangitis;
LGG	cis	rs9815354	1.000	rs1716693	chr3:41985600	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10173297	0.686	rs62108696	chr2:3707852	T/C	cg17046650	chr2:3699563	NA	0.68	9.43	0.4	1.97e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs61931739	0.583	rs7965929	chr12:33685875	A/C	cg26384229	chr12:38710491	ALG10B	-0.46	-7.88	-0.34	2.35e-14	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.67	-0.41	2.88e-20	Life satisfaction;
LGG	cis	rs889398	0.617	rs11648348	chr16:69890722	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.65	-0.33	1.19e-13	Body mass index;
LGG	cis	rs1476670	0.683	rs2057967	chr1:44515446	T/C	cg09470012	chr1:44509516	NA	0.4	8.15	0.35	3.41e-15	Eotaxin levels;
LGG	cis	rs4731207	0.698	rs10272583	chr7:124509451	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	trans	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg26043149	chr18:55253948	FECH	0.95	16.39	0.61	5.89e-48	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg13512537	chr8:22265999	SLC39A14	0.37	6.72	0.3	5.29e-11	Verbal declarative memory;
LGG	cis	rs514406	0.505	rs6688064	chr1:53165609	C/T	cg24675658	chr1:53192096	ZYG11B	-0.6	-12.88	-0.51	1.2e-32	Monocyte count;
LGG	cis	rs4731207	0.596	rs9332427	chr7:124576958	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.67	0.37	7.22e-17	Colorectal cancer;
LGG	cis	rs9486719	1.000	rs11153023	chr6:96968525	C/T	cg18709589	chr6:96969512	KIAA0776	-0.46	-6.87	-0.3	2.08e-11	Migraine;Coronary artery disease;
LGG	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg11965913	chr1:205819406	PM20D1	-0.41	-6.82	-0.3	2.85e-11	Menarche (age at onset);
LGG	cis	rs17021463	0.872	rs34181160	chr4:95275157	T/G	cg11021082	chr4:95130006	SMARCAD1	0.48	8.7	0.37	5.94e-17	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.54	0.44	1.95e-23	Prudent dietary pattern;
LGG	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs7089973	0.584	rs7908665	chr10:116611337	G/A	cg08188268	chr10:116634841	FAM160B1	0.31	7.02	0.31	8.15e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg17971929	chr21:40555470	PSMG1	0.59	10.2	0.43	3.65e-22	Cognitive function;
LGG	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs10861661	0.963	rs10861662	chr12:107178653	A/C	cg15890332	chr12:107067104	RFX4	0.29	6.69	0.3	6.46e-11	Triglyceride levels;
LGG	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg12438819	chr7:158236134	PTPRN2	0.32	8.21	0.36	2.3e-15	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs11761253	chr7:99939321	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.49	0.67	3.32e-62	Platelet count;
LGG	cis	rs2153535	0.580	rs4960422	chr6:8459309	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.28	0.63	5.65e-52	Response to antipsychotic treatment;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11245990	chr11:68621969	NA	0.42	8.96	0.38	8.27e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs701145	0.938	rs357504	chr3:153956857	A/C	cg17054900	chr3:154042577	DHX36	0.96	11.95	0.49	6.81e-29	Coronary artery disease;
LGG	cis	rs16854884	0.683	rs920968	chr3:143770698	C/G	cg06585982	chr3:143692056	C3orf58	0.56	9.39	0.4	2.75e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.67e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg05025164	chr4:1340916	KIAA1530	0.46	7.97	0.35	1.21e-14	Obesity-related traits;
LGG	cis	rs2624839	0.704	rs1046956	chr3:50222926	T/A	cg24110177	chr3:50126178	RBM5	0.54	8.66	0.37	7.67e-17	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg17830980	chr10:43048298	ZNF37B	0.45	9.88	0.42	5.09e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467773	0.529	rs7356988	chr6:26396727	G/T	cg09904177	chr6:26538194	HMGN4	-0.42	-7.36	-0.32	8.3e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs1957429	0.808	rs9783609	chr14:65352282	A/G	cg23373153	chr14:65346875	NA	1.14	15.7	0.59	7.59e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.51	0.56	1.35e-39	Obesity-related traits;
LGG	cis	rs12367572	0.620	rs2731040	chr12:45416383	G/A	cg03114573	chr12:45410052	DBX2	-0.72	-13.3	-0.53	2.01e-34	Gut microbiome composition (summer);
LGG	cis	rs11920090	0.932	rs12487486	chr3:170718131	C/T	cg09710316	chr3:170744871	SLC2A2	0.6	8.47	0.37	3.2e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.09e-17	Common traits (Other);
LGG	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg01221209	chr5:554886	NA	0.46	6.69	0.3	6.42e-11	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	trans	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg23762105	chr12:34175262	ALG10	-0.33	-6.77	-0.3	3.92e-11	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg08499158	chr17:42289980	UBTF	0.55	10.29	0.43	1.7e-22	Total body bone mineral density;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg20887711	chr4:1340912	KIAA1530	0.93	20.93	0.7	6.04e-69	Longevity;
LGG	cis	rs7666738	0.830	rs34135615	chr4:99001325	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06634786	chr22:41940651	POLR3H	0.73	11.78	0.48	3.43e-28	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs3960554	0.673	rs57358338	chr7:75732923	T/C	cg19862616	chr7:65841803	NCRNA00174	0.85	12.8	0.51	2.48e-32	Eotaxin levels;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg04267008	chr7:1944627	MAD1L1	0.76	14.06	0.55	1.2e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500395	0.962	rs9923371	chr16:48628015	C/T	cg04672837	chr16:48644449	N4BP1	0.57	9.33	0.4	4.53e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg16141378	chr3:129829833	LOC729375	0.54	14.18	0.55	3.6e-38	Neuroticism;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg21095983	chr6:86352623	SYNCRIP	0.59	10.79	0.45	2.26e-24	Smooth-surface caries;
LGG	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg11707556	chr5:10655725	ANKRD33B	0.49	7.19	0.32	2.63e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2224391	0.628	rs2773313	chr6:5252213	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.33	-0.32	1.01e-12	Height;
LGG	cis	rs4988958	0.565	rs1035125	chr2:103033839	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs36051895	0.664	rs10117459	chr9:5094034	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.51	-0.56	1.32e-39	Pediatric autoimmune diseases;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22301261	chr13:50655392	DLEU1;DLEU2	0.43	6.87	0.3	2.05e-11	Cognitive performance;
LGG	cis	rs9964724	0.826	rs12962050	chr18:35179808	C/T	cg27332583	chr18:35150602	NA	-0.42	-9.13	-0.39	2.06e-18	Educational attainment (years of education);
LGG	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.91	0.38	1.16e-17	Cognitive test performance;
LGG	cis	rs2953174	1.000	rs1133353	chr2:241522267	A/T	cg07929629	chr2:241523174	NA	-0.54	-6.67	-0.3	7.12e-11	Bipolar disorder;
LGG	cis	rs12249377	0.519	rs12259060	chr10:92579949	A/G	cg14313238	chr10:92632228	RPP30	0.38	6.77	0.3	3.98e-11	White matter microstructure (global fractional anisotropy);
LGG	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg00383909	chr3:49044727	WDR6	0.44	7.34	0.32	9.43e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1577917	0.958	rs2225754	chr6:86449698	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-10.51	-0.44	2.62e-23	Response to antipsychotic treatment;
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg19901468	chr14:105411992	AHNAK2	-0.95	-21.44	-0.71	2.38e-71	Rheumatoid arthritis;
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.24	-0.39	8.7e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.56e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg06470251	chr20:60548479	NA	0.54	9.45	0.4	1.64e-19	Body mass index;
LGG	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg18551225	chr6:44695536	NA	-0.63	-10.2	-0.43	3.57e-22	Total body bone mineral density;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23350838	chr19:44259495	C19orf61	-0.38	-6.75	-0.3	4.38e-11	Pancreatic cancer;
LGG	cis	rs72949976	0.584	rs12471432	chr2:214022893	A/T	cg08319019	chr2:214017104	IKZF2	0.67	12.89	0.51	1.1e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs7717393	1.000	rs1857769	chr5:155769363	A/G	cg19569526	chr5:155754265	SGCD	0.83	7.89	0.34	2.24e-14	Egg allergy;
LGG	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.98	0.35	1.13e-14	Vitiligo;
LGG	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg02466173	chr16:30829666	NA	-0.56	-10.07	-0.42	1.03e-21	Multiple myeloma;
LGG	cis	rs9354308	0.714	rs9453467	chr6:66592836	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	trans	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg11441553	chr12:57614120	NXPH4	-0.62	-7.77	-0.34	5.22e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4132509	1.000	rs4132509	chr1:243943084	A/C	cg21452805	chr1:244014465	NA	-0.67	-8.22	-0.36	2.11e-15	RR interval (heart rate);
LGG	cis	rs478222	0.866	rs11684464	chr2:25340610	A/G	cg04586622	chr2:25135609	ADCY3	-0.29	-7.02	-0.31	8.14e-12	Type 1 diabetes;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg14926445	chr8:58193284	C8orf71	-0.63	-7.89	-0.34	2.21e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	5.04e-24	Aortic root size;
LGG	cis	rs9964724	0.929	rs12954661	chr18:35160655	C/T	cg27332583	chr18:35150602	NA	-0.47	-10.22	-0.43	2.93e-22	Educational attainment (years of education);
LGG	cis	rs11711311	0.824	rs35089588	chr3:113352580	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.39	-6.84	-0.3	2.5e-11	IgG glycosylation;
LGG	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.67e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg04369109	chr6:150039330	LATS1	-0.4	-6.69	-0.3	6.65e-11	Lung cancer;
LGG	cis	rs1707322	0.964	rs10890358	chr1:46319025	T/A	cg03146154	chr1:46216737	IPP	0.55	10.41	0.44	5.83e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg27490568	chr2:178487706	NA	0.65	11.96	0.49	6.3e-29	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9914988	0.887	rs4795464	chr17:27146497	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03517284	chr6:25882590	NA	0.7	13.54	0.53	1.94e-35	Blood metabolite levels;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.03	-0.31	7.28e-12	Lung cancer;
LGG	cis	rs2832191	0.646	rs2832214	chr21:30517127	C/T	cg08807101	chr21:30365312	RNF160	-0.62	-10.59	-0.44	1.31e-23	Dental caries;
LGG	cis	rs10266483	0.739	rs55747800	chr7:63870483	C/A	cg24201672	chr7:64023550	ZNF680	0.46	6.92	0.31	1.5e-11	Response to statin therapy;
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg16359550	chr11:109292809	C11orf87	-0.48	-9.21	-0.39	1.14e-18	Schizophrenia;
LGG	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.71	0.34	7.63e-14	Cannabis dependence symptom count;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg17219203	chr10:38645113	HSD17B7P2	0.5	8.52	0.37	2.28e-16	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg11494091	chr17:61959527	GH2	0.51	8.19	0.36	2.58e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs2795502	1.000	rs2795508	chr10:43353555	G/T	cg20628663	chr10:43360327	NA	0.41	8.3	0.36	1.17e-15	Blood protein levels;
LGG	cis	rs6430585	0.583	rs730005	chr2:136582694	T/C	cg07169764	chr2:136633963	MCM6	1.31	26.51	0.78	7.2e-95	Corneal structure;
LGG	cis	rs34599045	0.522	rs35686780	chr1:152898182	T/A	cg07796016	chr1:152779584	LCE1C	-0.8	-7.47	-0.33	3.95e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9815354	0.951	rs7626217	chr3:41842415	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.29	0.36	1.24e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs742614	1.000	rs742614	chr20:32482632	A/G	cg06304546	chr20:32448765	NA	-0.47	-8.51	-0.37	2.52e-16	Stearic acid (18:0) levels;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.49	-10.0	-0.42	1.86e-21	Personality dimensions;
LGG	cis	rs67311347	0.955	rs73080163	chr3:40533061	G/T	cg24209194	chr3:40518798	ZNF619	0.47	7.37	0.32	8.1e-13	Renal cell carcinoma;
LGG	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg16339924	chr4:17578868	LAP3	0.67	11.23	0.46	4.86e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1372520	0.623	rs2583975	chr4:90748488	T/C	cg15133208	chr4:90757351	SNCA	-0.4	-7.79	-0.34	4.58e-14	Neuroticism;
LGG	cis	rs60180747	0.865	rs11639144	chr15:66600096	G/A	cg07575407	chr15:66541975	MEGF11	0.4	7.74	0.34	6.19e-14	Testicular germ cell tumor;
LGG	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.32	-0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.91	-0.45	8.35e-25	Resting heart rate;
LGG	cis	rs6087771	0.851	rs6087775	chr20:30325765	G/A	cg13852791	chr20:30311386	BCL2L1	0.93	17.86	0.64	1.13e-54	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2120243	0.647	rs9289983	chr3:157146005	G/A	cg24825693	chr3:157122686	VEPH1	-0.38	-7.7	-0.34	8.46e-14	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg11502198	chr6:26597334	ABT1	0.52	8.78	0.38	3.3e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg03060546	chr3:49711283	APEH	0.75	13.26	0.52	3.07e-34	Resting heart rate;
LGG	cis	rs6976053	0.846	rs4729615	chr7:100462332	A/G	cg03098644	chr7:100410630	EPHB4	-0.43	-7.73	-0.34	6.55e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10540	1.000	rs12421457	chr11:505780	T/C	cg19913688	chr11:428466	ANO9	-0.64	-8.05	-0.35	7.05e-15	Body mass index;
LGG	cis	rs34172651	0.917	rs2059134	chr16:24816492	C/T	cg02428538	chr16:24856791	SLC5A11	0.48	8.14	0.35	3.76e-15	Intelligence (multi-trait analysis);
LGG	cis	rs8020289	0.560	rs8012119	chr14:77260702	G/T	cg23436960	chr14:77239540	VASH1	-0.38	-11.13	-0.46	1.19e-25	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs35110281	0.776	rs2838316	chr21:44990036	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.4	-0.4	2.55e-19	Mean corpuscular volume;
LGG	trans	rs1728785	1.000	rs1170428	chr16:68603988	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs2273669	0.667	rs12374658	chr6:109345930	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs1461503	0.966	rs7113725	chr11:122843511	G/T	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	trans	rs2562456	0.833	rs57250002	chr19:21526850	T/C	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs13177180	0.777	rs13357862	chr5:114882453	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.39	-8.34	-0.36	8.31e-16	Conotruncal heart defects (inherited effects);
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.38	-0.43	7.69e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg04025307	chr7:1156635	C7orf50	0.8	16.78	0.61	1.04e-49	Longevity;Endometriosis;
LGG	cis	rs372883	0.530	rs2832305	chr21:30752964	G/A	cg08807101	chr21:30365312	RNF160	0.53	8.55	0.37	1.83e-16	Pancreatic cancer;
LGG	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg03606772	chr1:152487856	CRCT1	0.31	7.37	0.32	8.07e-13	Hair morphology;
LGG	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	1.0	12.79	0.51	2.72e-32	Lung cancer in ever smokers;
LGG	cis	rs7975161	0.572	rs4614534	chr12:104597917	C/T	cg25273343	chr12:104657179	TXNRD1	0.75	8.45	0.37	3.89e-16	Toenail selenium levels;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg22535103	chr8:58192502	C8orf71	-0.97	-13.36	-0.53	1.1e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs10089	0.552	rs56718459	chr5:127546214	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.56	8.08	0.35	5.82e-15	Ileal carcinoids;
LGG	cis	rs13191362	0.507	rs1079020	chr6:163066596	C/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.57	-7.96	-0.35	1.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	9.07	0.39	3.35e-18	Bipolar disorder;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.05	-0.31	6.38e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg17202724	chr17:61916730	SMARCD2	-0.41	-8.27	-0.36	1.46e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1200821	0.529	rs4934856	chr10:37807847	T/C	cg00409905	chr10:38381863	ZNF37A	0.44	8.5	0.37	2.7e-16	Hemostatic factors and hematological phenotypes;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg24235997	chr7:105264584	ATXN7L1	0.39	6.93	0.31	1.39e-11	Electrocardiographic conduction measures;
LGG	cis	rs6546550	0.935	rs11673826	chr2:70041033	G/A	cg02498382	chr2:70120550	SNRNP27	-0.38	-7.07	-0.31	5.66e-12	Prevalent atrial fibrillation;
LGG	cis	rs735539	0.556	rs9552277	chr13:21352287	T/A	cg04906043	chr13:21280425	IL17D	-0.46	-7.35	-0.32	8.86e-13	Dental caries;
LGG	cis	rs503734	0.818	rs2627546	chr3:100926225	C/T	cg27318481	chr3:100970896	IMPG2	-0.43	-9.63	-0.41	4.07e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17767392	1.000	rs725673	chr14:71878468	A/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs780094	0.500	rs12478841	chr2:27811722	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.3	5.3e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg20368463	chr18:77673604	PQLC1	0.43	7.79	0.34	4.46e-14	Schizophrenia;
LGG	cis	rs4363385	0.747	rs9919276	chr1:152968654	A/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.13	-0.39	2.06e-18	Inflammatory skin disease;
LGG	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg23887609	chr12:130822674	PIWIL1	-0.55	-9.76	-0.41	1.33e-20	Menopause (age at onset);
LGG	cis	rs57024841	0.562	rs7862602	chr9:139840471	G/T	cg00693599	chr9:139836323	FBXW5	0.42	7.49	0.33	3.6e-13	Beta-trace protein levels;
LGG	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg05016508	chr11:63871570	FLRT1;MACROD1	0.38	7.21	0.32	2.37e-12	Platelet count;
LGG	cis	rs11608355	0.538	rs10850074	chr12:109800531	T/C	cg19025524	chr12:109796872	NA	-0.59	-12.84	-0.51	1.69e-32	Neuroticism;
LGG	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs4141404	0.851	rs5997893	chr22:31556103	A/G	cg22777020	chr22:31556080	RNF185	-0.43	-6.72	-0.3	5.27e-11	Paclitaxel-induced neuropathy;
LGG	cis	rs8180040	0.966	rs7649234	chr3:47494380	G/C	cg27129171	chr3:47204927	SETD2	0.8	15.65	0.59	1.22e-44	Colorectal cancer;
LGG	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg19774624	chr17:42201019	HDAC5	-0.58	-10.37	-0.43	8.66e-23	Total body bone mineral density;
LGG	cis	rs7647973	0.626	rs11709734	chr3:49745235	G/A	cg03060546	chr3:49711283	APEH	0.59	8.35	0.36	7.71e-16	Menarche (age at onset);
LGG	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg06634786	chr22:41940651	POLR3H	-0.55	-9.2	-0.39	1.22e-18	Vitiligo;
LGG	cis	rs6977660	0.619	rs10950752	chr7:19781531	A/G	cg07541023	chr7:19748670	TWISTNB	0.51	7.72	0.34	7.38e-14	Thyroid stimulating hormone;
LGG	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.65	-0.3	8.05e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs6059897	chr20:33113224	A/G	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	8.92e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg22916017	chr11:64110731	CCDC88B	0.47	9.42	0.4	2.22e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2693698	0.550	rs2614457	chr14:99686533	A/G	cg07440398	chr14:99712966	BCL11B	0.51	10.76	0.45	2.99e-24	Schizophrenia;
LGG	cis	rs2040771	0.872	rs12485084	chr22:19162326	A/G	cg02655711	chr22:19163373	SLC25A1	0.53	9.43	0.4	1.93e-19	Metabolite levels (small molecules and protein measures);
LGG	trans	rs1941687	0.509	rs7230319	chr18:31321289	A/T	cg04226714	chr8:49833948	SNAI2	-0.47	-8.27	-0.36	1.48e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	7.74	0.34	6.1e-14	Retinal vascular caliber;
LGG	cis	rs2540226	0.539	rs10170462	chr2:39911538	A/G	cg18968196	chr2:39892502	TMEM178	0.3	8.33	0.36	9.38e-16	Personality dimensions;
LGG	cis	rs9398803	0.865	rs1361108	chr6:126767600	C/T	cg19875578	chr6:126661172	C6orf173	0.57	10.34	0.43	1.14e-22	Male-pattern baldness;
LGG	cis	rs7843479	0.601	rs7220	chr8:21863290	G/A	cg17168535	chr8:21777572	XPO7	0.79	15.51	0.58	5.46e-44	Mean corpuscular volume;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.61e-12	Life satisfaction;
LGG	cis	rs854765	0.583	rs9890341	chr17:17823175	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	trans	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg02900749	chr2:68251473	NA	-1.01	-10.31	-0.43	1.47e-22	Pursuit maintenance gain;
LGG	cis	rs3008870	0.583	rs2815369	chr1:67500894	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	17.96	0.64	3.9e-55	Lymphocyte percentage of white cells;
LGG	cis	rs593531	0.571	rs11236087	chr11:74094138	C/T	cg18195628	chr11:73498948	MRPL48	0.39	6.66	0.3	7.73e-11	Neuroticism;
LGG	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	10.99	0.45	4.14e-25	Parkinson's disease;
LGG	cis	rs9287719	0.934	rs10181806	chr2:10741141	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.52	0.33	2.93e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.57	-0.37	1.59e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.54	-9.41	-0.4	2.33e-19	Electroencephalogram traits;
LGG	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg10326726	chr10:51549505	MSMB	-0.61	-12.35	-0.5	1.69e-30	Prostate-specific antigen levels;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg08888203	chr3:10149979	C3orf24	0.54	8.93	0.38	1e-17	Alzheimer's disease;
LGG	cis	rs79349575	0.783	rs903567	chr17:46980318	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.8e-16	Type 2 diabetes;
LGG	cis	rs1023500	0.573	rs133374	chr22:42465941	G/A	cg05082376	chr22:42548792	NA	-0.36	-7.63	-0.33	1.35e-13	Schizophrenia;
LGG	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg00761968	chr13:53314142	LECT1	-0.35	-7.55	-0.33	2.35e-13	Lewy body disease;
LGG	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.51	-0.33	3.05e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.45	0.44	4.15e-23	Diabetic retinopathy;
LGG	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg21862992	chr11:68658383	NA	0.51	8.64	0.37	9.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4731207	0.698	rs16871295	chr7:124461288	C/G	cg05630886	chr7:124431682	NA	0.32	7.52	0.33	2.93e-13	Cutaneous malignant melanoma;
LGG	cis	rs919433	0.680	rs67580728	chr2:198431258	C/T	cg00792783	chr2:198669748	PLCL1	0.5	7.87	0.34	2.55e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9815354	1.000	rs1629460	chr3:41927449	T/G	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg15704280	chr7:45808275	SEPT13	-0.72	-9.88	-0.42	4.96e-21	Axial length;
LGG	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-10.69	-0.44	5.33e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7717393	1.000	rs17053447	chr5:155769694	A/T	cg19569526	chr5:155754265	SGCD	-0.85	-7.98	-0.35	1.2e-14	Egg allergy;
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.87	-0.38	1.59e-17	Life satisfaction;
LGG	cis	rs8133932	0.736	rs11089025	chr21:47281579	C/A	cg13695288	chr21:47294981	PCBP3	-0.36	-7.25	-0.32	1.73e-12	Schizophrenia;
LGG	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg11812906	chr14:75593930	NEK9	0.54	10.11	0.43	7.77e-22	Height;
LGG	cis	rs7216064	1.000	rs11869819	chr17:65868669	A/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg05091796	chr16:4465799	CORO7	-0.6	-9.9	-0.42	4.27e-21	Schizophrenia;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.48	7.65	0.34	1.16e-13	Longevity;
LGG	cis	rs7301826	1.000	rs1106369	chr12:131300095	G/T	cg11011512	chr12:131303247	STX2	0.34	7.45	0.33	4.75e-13	Plasma plasminogen activator levels;
LGG	cis	rs80282103	0.618	rs59377495	chr10:1157019	C/T	cg08668510	chr10:1095578	IDI1	0.77	7.57	0.33	2.06e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs3008870	0.755	rs2815363	chr1:67497221	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-0.7	-15.05	-0.57	5.93e-42	Lymphocyte percentage of white cells;
LGG	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.56	-0.37	1.72e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7129556	0.863	rs11237225	chr11:77283561	A/T	cg12586386	chr11:77299805	AQP11	0.5	8.2	0.36	2.41e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs17453880	0.853	rs6885419	chr5:152027678	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg00830817	chr11:109293614	C11orf87	0.42	6.84	0.3	2.53e-11	Schizophrenia;
LGG	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg09085632	chr11:111637200	PPP2R1B	0.98	18.98	0.66	7.35e-60	Primary sclerosing cholangitis;
LGG	cis	rs8114671	0.967	rs4911472	chr20:33775377	T/A	cg24642439	chr20:33292090	TP53INP2	0.46	7.38	0.32	7.55e-13	Height;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg05863683	chr7:1912471	MAD1L1	0.46	8.86	0.38	1.66e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.780	rs12504773	chr4:120562149	G/C	cg24375607	chr4:120327624	NA	0.65	10.8	0.45	2.11e-24	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg07440826	chr16:89882328	FANCA	-0.26	-6.77	-0.3	3.84e-11	Vitiligo;
LGG	cis	rs1475911	0.507	rs11702347	chr21:43526454	C/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.57	-8.18	-0.36	2.81e-15	IgG glycosylation;
LGG	cis	rs10193935	0.901	rs13384404	chr2:42601147	G/T	cg27598129	chr2:42591480	NA	-0.64	-9.66	-0.41	3.05e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.25e-26	Tonsillectomy;
LGG	cis	rs1185460	1.000	rs15818	chr11:118952173	A/G	cg23280166	chr11:118938394	VPS11	0.51	8.88	0.38	1.53e-17	Coronary artery disease;
LGG	cis	rs908922	0.651	rs1337341	chr1:152508259	A/C	cg20991723	chr1:152506922	NA	-0.7	-13.87	-0.54	7.56e-37	Hair morphology;
LGG	cis	rs59197085	0.636	rs61012549	chr7:128442897	G/A	cg00734629	chr7:128471146	FLNC	0.34	6.98	0.31	1.03e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs17767392	0.718	rs61989206	chr14:71686049	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.33	-6.79	-0.3	3.44e-11	Mitral valve prolapse;
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.49	-0.4	1.23e-19	IgG glycosylation;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.47	-0.37	3.24e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.95e-17	Menopause (age at onset);
LGG	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg00666640	chr1:248458726	OR2T12	-0.6	-9.79	-0.41	1.07e-20	Common traits (Other);
LGG	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg04117972	chr1:227635322	NA	0.57	9.37	0.4	3.1e-19	Major depressive disorder;
LGG	cis	rs4566357	1.000	rs1317770	chr2:227911725	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.85	-0.3	2.39e-11	Coronary artery disease;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg04025307	chr7:1156635	C7orf50	0.83	14.98	0.57	1.15e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.63	0.44	8.95e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs41271473	0.687	rs4388674	chr1:228878563	A/G	cg16512390	chr1:228756714	NA	0.44	7.0	0.31	8.81e-12	Chronic lymphocytic leukemia;
LGG	trans	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.61	0.47	1.52e-27	Corneal astigmatism;
LGG	cis	rs5758659	0.700	rs739294	chr22:42381726	T/C	cg15557168	chr22:42548783	NA	-0.35	-7.32	-0.32	1.08e-12	Cognitive function;
LGG	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.77	-0.34	4.93e-14	Breast cancer;
LGG	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg26384229	chr12:38710491	ALG10B	0.67	13.06	0.52	2.09e-33	Morning vs. evening chronotype;
LGG	cis	rs2251260	0.717	rs2184633	chr14:62014289	A/T	cg23386212	chr14:62041363	NA	0.56	9.41	0.4	2.37e-19	Yeast infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11518257	chr1:1310775	AURKAIP1	0.36	6.88	0.3	1.96e-11	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.850	rs8023458	chr15:44080939	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.62	0.44	1e-23	Lung cancer in ever smokers;
LGG	trans	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg26384229	chr12:38710491	ALG10B	0.63	12.41	0.5	9.49e-31	Morning vs. evening chronotype;
LGG	cis	rs459571	1.000	rs456207	chr9:136911140	G/A	cg13789015	chr9:136890014	NCRNA00094	0.54	10.15	0.43	5.29e-22	Platelet distribution width;
LGG	cis	rs12681288	0.862	rs7814070	chr8:1020991	A/G	cg04851639	chr8:1020857	NA	-0.43	-9.52	-0.4	9.48e-20	Schizophrenia;
LGG	cis	rs10865541	0.902	rs4476382	chr2:3393288	A/G	cg13173536	chr2:3403300	TTC15	-0.33	-6.78	-0.3	3.75e-11	Obesity-related traits;
LGG	cis	rs9880211	0.752	rs9820717	chr3:136346613	C/A	cg21827317	chr3:136751795	NA	-0.47	-6.78	-0.3	3.61e-11	Body mass index;Height;
LGG	cis	rs17125944	0.505	rs75661138	chr14:53259262	G/A	cg00686598	chr14:53173677	PSMC6	1.38	14.84	0.57	5.06e-41	Alzheimer's disease (late onset);
LGG	cis	rs7552404	0.696	rs10518521	chr1:76461214	G/A	cg10523679	chr1:76189770	ACADM	0.7	9.84	0.42	7.34e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-13.24	-0.52	3.57e-34	Menarche (age at onset);
LGG	cis	rs3857067	1.000	rs1904094	chr4:95012459	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg23939001	chr4:940644	TMEM175	0.61	12.21	0.49	6.14e-30	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs3087591	0.708	rs7350943	chr17:29684553	C/T	cg24425628	chr17:29625626	OMG;NF1	0.6	12.59	0.5	1.87e-31	Hip circumference;
LGG	cis	rs3087591	0.708	rs2854319	chr17:29694054	G/C	cg24425628	chr17:29625626	OMG;NF1	0.6	12.53	0.5	3.18e-31	Hip circumference;
LGG	cis	rs477692	1.000	rs508303	chr10:131424996	A/T	cg05714579	chr10:131428358	MGMT	-0.54	-10.98	-0.45	4.46e-25	Response to temozolomide;
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg20453264	chr5:131705742	SLC22A5	-0.64	-8.21	-0.36	2.22e-15	Rheumatoid arthritis;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.56	-9.71	-0.41	2.02e-20	Obesity-related traits;
LGG	trans	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	Neuroticism;
LGG	cis	rs1497828	1.000	rs2815246	chr1:217560463	T/C	cg04411442	chr1:217543379	NA	0.46	8.04	0.35	7.6e-15	Dialysis-related mortality;
LGG	cis	rs7215564	0.818	rs4890055	chr17:78587225	A/C	cg16980736	chr17:78789706	RPTOR	-0.54	-7.21	-0.32	2.29e-12	Myopia (pathological);
LGG	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg20488157	chr14:104394430	TDRD9	0.55	9.15	0.39	1.82e-18	Bipolar disorder;
LGG	trans	rs62103177	0.733	rs62096748	chr18:77619699	T/C	cg14227996	chr4:17616232	MED28	0.75	9.21	0.39	1.1e-18	Opioid sensitivity;
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg20608306	chr11:116969690	SIK3	0.34	8.85	0.38	1.81e-17	Blood protein levels;
LGG	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.01	0.31	8.45e-12	Height;
LGG	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg05425664	chr17:57184151	TRIM37	0.62	9.85	0.42	6.66e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10901296	0.660	rs11789055	chr9:133766295	T/C	cg13397898	chr9:133768931	QRFP	0.41	7.93	0.35	1.7e-14	Bilirubin levels;
LGG	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg22437258	chr11:111473054	SIK2	-0.57	-9.83	-0.42	7.87e-21	Primary sclerosing cholangitis;
LGG	cis	rs735396	1.000	rs735396	chr12:121438844	T/C	cg02403541	chr12:121454288	C12orf43	0.53	8.68	0.37	7.06e-17	N-glycan levels;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg09033563	chr22:24373618	LOC391322	-0.52	-8.51	-0.37	2.46e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07988820	chr12:82153109	PPFIA2	0.39	6.67	0.3	7.16e-11	Bipolar disorder;
LGG	cis	rs4732038	0.510	rs10258909	chr7:134269893	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs8051149	0.625	rs876985	chr16:87882124	T/C	cg01412419	chr16:87856264	NA	0.44	8.49	0.37	2.87e-16	Blood metabolite levels;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg13126279	chr21:47581558	C21orf56	-0.47	-8.0	-0.35	9.96e-15	Testicular germ cell tumor;
LGG	trans	rs28735056	0.967	rs498541	chr18:77589655	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-7.6	-0.33	1.68e-13	Schizophrenia;
LGG	cis	rs988958	0.565	rs6753173	chr2:42235975	C/T	cg19376973	chr2:42229025	NA	0.63	9.27	0.4	7.36e-19	Hypospadias;
LGG	cis	rs11122272	0.735	rs2790886	chr1:231529491	A/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs7091068	0.518	rs1572772	chr10:95432862	A/G	cg20715218	chr10:95462985	C10orf4	-0.66	-11.88	-0.48	1.37e-28	Urinary tract infection frequency;
LGG	cis	rs10214930	0.697	rs1052724	chr7:27565206	A/T	cg22168087	chr7:27702803	HIBADH	0.46	6.92	0.31	1.53e-11	Hypospadias;
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.37	-0.58	2.32e-43	Height;
LGG	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs9948	0.786	rs62156231	chr2:97425603	G/A	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.91e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4975616	0.869	rs466502	chr5:1325767	C/T	cg07493874	chr5:1342172	CLPTM1L	0.88	17.83	0.64	1.64e-54	Lung cancer;
LGG	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.65	11.49	0.47	4.82e-27	Menarche (age at onset);
LGG	cis	rs4262150	0.883	rs72804766	chr5:152273887	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.03	-0.49	3.55e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-10.18	-0.43	4.12e-22	Personality dimensions;
LGG	cis	rs3106136	0.903	rs67552174	chr4:95203097	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	3.98e-15	Capecitabine sensitivity;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.42	-0.53	6.47e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg14789911	chr21:47582049	C21orf56	-0.49	-8.68	-0.37	6.95e-17	Testicular germ cell tumor;
LGG	cis	rs1865760	0.566	rs3752420	chr6:26027135	G/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.66e-21	Height;
LGG	cis	rs1018697	0.518	rs284843	chr10:104553566	C/T	cg04362960	chr10:104952993	NT5C2	-0.63	-10.04	-0.42	1.31e-21	Colorectal adenoma (advanced);
LGG	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg08344181	chr3:125677491	NA	-0.63	-7.2	-0.32	2.41e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6594499	0.872	rs7732974	chr5:110455381	T/C	cg04022379	chr5:110408740	TSLP	0.41	7.58	0.33	1.94e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg08677398	chr8:58056175	NA	0.44	7.4	0.33	6.46e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg03160526	chr17:80928410	B3GNTL1	0.48	7.68	0.34	9.41e-14	Glycated hemoglobin levels;
LGG	cis	rs11608355	0.545	rs12823587	chr12:109896390	A/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg25208724	chr1:156163844	SLC25A44	1.09	22.53	0.72	2.05e-76	Testicular germ cell tumor;
LGG	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg13010199	chr12:38710504	ALG10B	0.46	8.11	0.35	4.46e-15	Morning vs. evening chronotype;
LGG	cis	rs1577917	1.000	rs10455449	chr6:86592226	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.95	-0.42	2.93e-21	Response to antipsychotic treatment;
LGG	cis	rs4974559	0.739	rs10032327	chr4:1323537	C/T	cg02980000	chr4:1222292	CTBP1	0.81	8.99	0.39	6.54e-18	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25486979	chr13:50510739	C13orf1	0.42	7.09	0.31	4.9e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs735860	0.726	rs209507	chr6:53194768	T/A	cg10236188	chr6:53219634	NA	0.36	6.93	0.31	1.37e-11	Glaucoma;
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.81	-15.79	-0.59	2.9e-45	Age at first birth;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.31	0.36	1.08e-15	Lung cancer;
LGG	cis	rs2635047	0.638	rs13381713	chr18:44669499	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.31	0.36	1.1e-15	Educational attainment;
LGG	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg04691961	chr3:161091175	C3orf57	0.41	8.61	0.37	1.12e-16	Morning vs. evening chronotype;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.52e-21	Lymphocyte counts;
LGG	cis	rs9905704	0.624	rs4932691	chr17:57094617	T/C	cg12560992	chr17:57184187	TRIM37	-0.53	-8.58	-0.37	1.47e-16	Testicular germ cell tumor;
LGG	cis	rs9611565	0.921	rs5758297	chr22:41720697	A/G	cg06481639	chr22:41940642	POLR3H	-0.45	-6.83	-0.3	2.68e-11	Vitiligo;
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg03709012	chr19:19516395	GATAD2A	0.85	17.04	0.62	7.1e-51	Tonsillectomy;
LGG	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.79	-0.38	2.9e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2857078	0.720	rs9901595	chr17:42305699	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.39	6.85	0.3	2.34e-11	Red cell distribution width;Reticulocyte count;
LGG	cis	rs6694672	1.000	rs9427662	chr1:196946775	T/C	cg13682187	chr1:196946512	CFHR5	-0.49	-6.74	-0.3	4.8e-11	Asthma;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.3	-0.55	1.1e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.67	-0.41	2.9e-20	Schizophrenia;
LGG	cis	rs926938	0.527	rs58658580	chr1:115539726	A/G	cg12756093	chr1:115239321	AMPD1	0.42	7.97	0.35	1.27e-14	Autism;
LGG	cis	rs4906332	0.811	rs2296487	chr14:103996205	T/C	cg23335576	chr14:104009727	NA	0.49	7.79	0.34	4.56e-14	Coronary artery disease;
LGG	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.14e-21	Hypertriglyceridemia;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg02002194	chr4:3960332	NA	0.42	7.65	0.33	1.21e-13	Neuroticism;
LGG	cis	rs12220238	0.908	rs73284278	chr10:76011751	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.33	0.47	1.99e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg07005078	chr4:17578674	LAP3	0.38	6.84	0.3	2.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4595586	0.525	rs11611705	chr12:39426828	C/T	cg13010199	chr12:38710504	ALG10B	0.48	8.57	0.37	1.6e-16	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.59	0.53	1.21e-35	Lung cancer;
LGG	cis	rs2404602	1.000	rs2404740	chr15:76852143	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-6.74	-0.3	4.75e-11	Blood metabolite levels;
LGG	cis	rs2204008	0.522	rs117743143	chr12:38030824	C/T	cg13010199	chr12:38710504	ALG10B	0.61	12.81	0.51	2.23e-32	Bladder cancer;
LGG	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.44	0.44	4.76e-23	Cognitive test performance;
LGG	cis	rs7927592	0.956	rs7106259	chr11:68298512	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.35	-0.36	8.03e-16	Total body bone mineral density;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg09327250	chr3:195381832	NA	-0.45	-7.48	-0.33	3.68e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Myopia (pathological);
LGG	cis	rs7084402	0.967	rs1365740	chr10:60277549	A/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs7646881	1.000	rs59918529	chr3:158452705	T/C	cg19483011	chr3:158453295	NA	-0.63	-9.41	-0.4	2.28e-19	Tetralogy of Fallot;
LGG	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.55	0.79	1.3e-99	Height;
LGG	cis	rs3806843	1.000	rs2879089	chr5:140191893	A/T	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg11693508	chr17:37793320	STARD3	0.63	9.41	0.4	2.41e-19	Bipolar disorder;
LGG	cis	rs9457247	0.967	rs2149083	chr6:167370971	G/C	cg07741184	chr6:167504864	NA	-0.32	-7.09	-0.31	4.89e-12	Crohn's disease;
LGG	cis	rs9902453	0.967	rs4994355	chr17:28386284	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.22	-0.52	4.37e-34	Coffee consumption (cups per day);
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg00933542	chr6:150070202	PCMT1	0.38	6.92	0.31	1.49e-11	Lung cancer;
LGG	cis	rs972578	0.967	rs738391	chr22:43339878	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.7	-0.3	5.9e-11	Mean platelet volume;
LGG	trans	rs826838	0.616	rs10880754	chr12:38628154	C/T	cg06521331	chr12:34319734	NA	0.42	7.56	0.33	2.11e-13	Heart rate;
LGG	cis	rs12476592	0.602	rs262484	chr2:63878015	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.89	-0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs10789491	1.000	rs4553120	chr1:47165729	C/T	cg15501359	chr1:47185051	KIAA0494	0.74	14.19	0.55	3.17e-38	Response to hepatitis C treatment;
LGG	trans	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.43	-0.4	1.98e-19	Diabetic kidney disease;
LGG	cis	rs9902453	1.000	rs55971458	chr17:28427016	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.13	0.52	1.09e-33	Coffee consumption (cups per day);
LGG	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg08305652	chr11:111469057	NA	0.39	7.52	0.33	2.91e-13	Primary sclerosing cholangitis;
LGG	cis	rs2816316	1.000	rs1547624	chr1:192543837	A/T	cg10861751	chr1:192544716	RGS1	0.34	6.97	0.31	1.07e-11	Celiac disease;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg11235426	chr6:292522	DUSP22	-0.61	-10.17	-0.43	4.6e-22	Menopause (age at onset);
LGG	cis	rs6692729	0.933	rs1046240	chr1:227071525	C/T	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs7849585	0.792	rs4842133	chr9:139127566	C/A	cg14094347	chr9:139131620	QSOX2	-0.48	-8.95	-0.38	8.68e-18	Height;
LGG	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06108461	chr20:60628389	TAF4	-0.63	-10.96	-0.45	5.32e-25	Body mass index;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-14.44	-0.56	2.84e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.02	-0.78	3.19e-97	Schizophrenia;
LGG	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg08250081	chr4:10125330	NA	0.41	8.16	0.35	3.1e-15	Bone mineral density;
LGG	cis	rs4330281	0.647	rs6797952	chr3:17735318	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.55	-0.33	2.32e-13	Schizophrenia;
LGG	cis	rs2559856	1.000	rs2695286	chr12:102088507	T/C	cg15068132	chr12:102092402	CHPT1	-0.36	-6.69	-0.3	6.53e-11	Blood protein levels;
LGG	trans	rs2736345	0.502	rs34801597	chr8:11326493	G/A	cg06636001	chr8:8085503	FLJ10661	0.44	6.96	0.31	1.19e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.79e-21	Diabetic retinopathy;
LGG	cis	rs271738	0.640	rs271772	chr1:234679850	C/T	cg05133706	chr1:234667230	NA	0.33	7.5	0.33	3.28e-13	Bipolar disorder;
LGG	cis	rs867371	1.000	rs6495642	chr15:82457497	G/C	cg00614314	chr15:82944287	LOC80154	0.57	9.38	0.4	2.86e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs3806843	0.576	rs246030	chr5:140333154	C/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.13	0.55	6.05e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.53	-8.78	-0.38	3.15e-17	Height;
LGG	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg02002194	chr4:3960332	NA	0.38	7.0	0.31	9.08e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7940866	0.809	rs2324317	chr11:130877142	T/C	cg12179176	chr11:130786555	SNX19	0.71	13.24	0.52	3.59e-34	Schizophrenia;
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06481639	chr22:41940642	POLR3H	-0.63	-9.05	-0.39	4.08e-18	Vitiligo;
LGG	cis	rs9640161	0.830	rs1051764	chr7:150070663	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.13	-0.43	6.62e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4954585	0.708	rs6430612	chr2:137006198	C/T	cg07169764	chr2:136633963	MCM6	-0.45	-7.24	-0.32	1.92e-12	Colorectal cancer;
LGG	cis	rs3617	0.539	rs11130331	chr3:52956918	G/A	cg11645453	chr3:52864694	ITIH4	-0.47	-7.8	-0.34	4.09e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6466055	0.777	rs10487150	chr7:104797450	A/C	cg04380332	chr7:105027541	SRPK2	-0.37	-7.01	-0.31	8.67e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.34	-0.32	9.46e-13	Life satisfaction;
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.24	0.32	1.92e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg02725872	chr8:58115012	NA	-0.78	-11.07	-0.46	1.99e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg09238746	chr17:78121135	EIF4A3	-0.55	-10.19	-0.43	3.85e-22	Yeast infection;
LGG	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03576123	chr11:487126	PTDSS2	-1.23	-16.4	-0.61	5.62e-48	Body mass index;
LGG	cis	rs9911578	0.813	rs12452313	chr17:57129882	C/A	cg12560992	chr17:57184187	TRIM37	-0.9	-14.75	-0.57	1.28e-40	Intelligence (multi-trait analysis);
LGG	cis	rs6868223	0.651	rs12153197	chr5:33645804	T/A	cg10594543	chr5:33649717	ADAMTS12	0.67	15.48	0.58	7.11e-44	Mortality in heart failure;
LGG	cis	rs317689	0.690	rs317646	chr12:69657145	A/G	cg20891283	chr12:69753455	YEATS4	-0.44	-6.69	-0.3	6.27e-11	Response to diuretic therapy;
LGG	cis	rs709400	0.628	rs4906321	chr14:103878882	C/T	cg12935359	chr14:103987150	CKB	-0.41	-6.72	-0.3	5.47e-11	Body mass index;
LGG	trans	rs7944735	0.508	rs57436966	chr11:47759541	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.82	0.3	2.81e-11	Intraocular pressure;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	29.77	0.81	1.31e-109	Prudent dietary pattern;
LGG	trans	rs7939886	0.920	rs11227507	chr11:55972274	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs1707322	1.000	rs10890380	chr1:46449469	A/G	cg03146154	chr1:46216737	IPP	0.53	9.91	0.42	3.97e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs113835537	0.660	rs7116940	chr11:66303895	T/C	cg24851651	chr11:66362959	CCS	0.46	7.88	0.34	2.43e-14	Airway imaging phenotypes;
LGG	cis	rs62025270	0.547	rs8035496	chr15:86134332	T/C	cg25843651	chr15:86329602	KLHL25	0.55	9.21	0.39	1.17e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg00031303	chr3:195681400	NA	0.52	8.21	0.36	2.28e-15	Pancreatic cancer;
LGG	cis	rs12711979	0.584	rs11694096	chr2:3868113	G/A	cg17052675	chr2:3827356	NA	-0.42	-8.09	-0.35	5.4e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.89	0.31	1.79e-11	Carotid intima media thickness;
LGG	cis	rs3793683	0.597	rs2182620	chr10:134590715	C/T	cg27286337	chr10:134555280	INPP5A	0.87	13.67	0.54	5.61e-36	Migraine;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.57	-10.01	-0.42	1.82e-21	Lymphocyte counts;
LGG	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg27366882	chr3:133540807	NA	0.48	9.85	0.42	6.33e-21	Alcohol consumption (transferrin glycosylation);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14825221	chr4:83720052	SCD5	0.62	7.07	0.31	5.84e-12	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs6488213	chr12:34393319	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.12e-12	Morning vs. evening chronotype;
LGG	cis	rs2072732	0.644	rs75787210	chr1:2942465	A/G	cg22517653	chr1:2918612	NA	-0.5	-7.1	-0.31	4.85e-12	Plateletcrit;
LGG	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg26597838	chr10:835615	NA	0.63	9.25	0.4	8.1e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs36051895	0.589	rs10491650	chr9:5203054	C/T	cg02405213	chr9:5042618	JAK2	0.72	13.16	0.52	8.22e-34	Pediatric autoimmune diseases;
LGG	cis	rs972578	0.715	rs4822246	chr22:43403024	C/T	cg01576275	chr22:43409880	NA	0.24	6.99	0.31	9.57e-12	Mean platelet volume;
LGG	cis	rs7914558	0.966	rs7085598	chr10:104650128	T/C	cg04362960	chr10:104952993	NT5C2	0.52	9.87	0.42	5.71e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg26174226	chr8:58114915	NA	-0.52	-7.34	-0.32	9.74e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2456568	0.570	rs1518579	chr11:93656821	A/G	cg17595323	chr11:93583763	C11orf90	-0.44	-7.83	-0.34	3.29e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17691542	chr6:26056736	HIST1H1C	1.11	18.01	0.64	2.33e-55	Iron status biomarkers;
LGG	cis	rs1719271	0.831	rs1684053	chr15:65191448	G/T	cg11671771	chr15:65133392	PLEKHO2	-0.5	-6.95	-0.31	1.27e-11	Platelet count;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg08770590	chr10:112064742	SMNDC1	0.41	6.79	0.3	3.44e-11	Corneal astigmatism;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg19147804	chr7:1989927	MAD1L1	0.52	10.22	0.43	2.95e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7940866	0.770	rs10750456	chr11:130819634	A/G	cg12179176	chr11:130786555	SNX19	0.76	14.45	0.56	2.5e-39	Schizophrenia;
LGG	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.4	0.4	2.54e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs2131877	0.868	rs12633566	chr3:194880989	A/G	cg07250128	chr3:194833983	C3orf21	0.38	7.4	0.33	6.41e-13	Non-small cell lung cancer;
LGG	trans	rs10838801	1	rs10838801	chr11:48098280	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.99	-0.45	3.88e-25	Height;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.2	-0.36	2.41e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg17133734	chr15:86042851	AKAP13	-0.28	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg09699651	chr6:150184138	LRP11	0.51	8.85	0.38	1.83e-17	Lung cancer;
LGG	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs12410462	0.636	rs2814085	chr1:227705476	T/C	cg04117972	chr1:227635322	NA	0.46	8.37	0.36	6.88e-16	Major depressive disorder;
LGG	cis	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg06609049	chr19:2785107	THOP1	0.62	9.65	0.41	3.5e-20	Total cholesterol levels;
LGG	trans	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs151997	0.962	rs28676922	chr5:50247221	C/T	cg06027927	chr5:50259733	NA	0.65	10.67	0.44	6.64e-24	Callous-unemotional behaviour;
LGG	cis	rs3857067	1.000	rs6532454	chr4:95019067	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.46	-0.33	4.31e-13	QT interval;
LGG	cis	rs9682041	0.740	rs2111826	chr3:170140846	A/G	cg11886554	chr3:170076028	SKIL	1.06	10.45	0.44	4.15e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-6.8	-0.3	3.23e-11	Tonsillectomy;
LGG	cis	rs75920871	0.528	rs723955	chr11:116925042	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.46	-0.33	4.4e-13	Subjective well-being;
LGG	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.74	-0.3	4.77e-11	Blood metabolite levels;
LGG	cis	rs111577701	1	rs111577701	chr3:167861408	C/T	cg03996677	chr3:167817329	NA	-0.49	-7.1	-0.31	4.68e-12	Epilepsy;
LGG	cis	rs2302729	0.578	rs11062299	chr12:2771738	T/C	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.58	-0.5	2.08e-31	Sleep quality;
LGG	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg07923794	chr17:77834237	NA	-0.77	-11.57	-0.47	2.29e-27	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg02711726	chr17:80685570	FN3KRP	-0.59	-11.01	-0.46	3.31e-25	Glycated hemoglobin levels;
LGG	cis	rs1577917	0.518	rs6454482	chr6:86418188	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.41	7.11	0.31	4.48e-12	Response to antipsychotic treatment;
LGG	cis	rs2820315	1.000	rs2494115	chr1:201832864	G/C	cg10061532	chr1:201886748	LMOD1	0.32	6.7	0.3	6.13e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.71	0.38	5.22e-17	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7100689	0.646	rs1538823	chr10:82088040	C/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.65	0.56	3.21e-40	Post bronchodilator FEV1;
LGG	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg11266682	chr4:10021025	SLC2A9	0.54	10.83	0.45	1.62e-24	Bone mineral density;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg09699651	chr6:150184138	LRP11	0.52	9.19	0.39	1.33e-18	Lung cancer;
LGG	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg16797656	chr11:68205561	LRP5	0.57	10.94	0.45	6.29e-25	Total body bone mineral density;
LGG	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg09060608	chr5:178986726	RUFY1	0.44	6.91	0.31	1.6e-11	Lung cancer;
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg25811766	chr13:21894605	NA	0.7	9.45	0.4	1.63e-19	White matter hyperintensity burden;
LGG	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg02574844	chr11:5959923	NA	-0.6	-10.45	-0.44	4.19e-23	DNA methylation (variation);
LGG	trans	rs9929218	1.000	rs11865026	chr16:68774283	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.66	-0.56	3.1e-40	Colorectal cancer;
LGG	cis	rs4073221	0.520	rs13067391	chr3:18191929	C/T	cg07694806	chr3:18168406	NA	-0.67	-8.09	-0.35	5.14e-15	Parkinson's disease;
LGG	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14159747	chr11:113255604	NA	0.3	8.34	0.36	8.59e-16	Neuroticism;
LGG	cis	rs7666738	0.830	rs1111541	chr4:99033860	A/G	cg05340658	chr4:99064831	C4orf37	-0.49	-8.01	-0.35	9.31e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9815354	0.812	rs73069357	chr3:41753319	T/G	cg03022575	chr3:42003672	ULK4	0.8	8.96	0.38	8.12e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4740619	0.967	rs7025669	chr9:15654254	T/A	cg14451791	chr9:16040625	NA	-0.4	-10.56	-0.44	1.74e-23	Body mass index;
LGG	cis	rs35306767	0.807	rs12768348	chr10:899224	T/G	cg26597838	chr10:835615	NA	0.94	12.72	0.51	5.47e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs1461503	0.900	rs7110039	chr11:122834001	C/T	cg27398637	chr11:122830231	C11orf63	0.72	14.8	0.57	7.55e-41	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg23782820	chr8:58130467	NA	0.54	7.5	0.33	3.18e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.748	rs2282579	chr11:130735482	C/T	cg09137382	chr11:130731461	NA	0.36	6.96	0.31	1.17e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs12580194	0.593	rs61957887	chr12:55721734	C/T	cg19537932	chr12:55886519	OR6C68	-0.53	-9.46	-0.4	1.61e-19	Cancer;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg00800038	chr16:89945340	TCF25	-0.6	-8.48	-0.37	2.95e-16	Skin colour saturation;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg03804240	chr11:118481350	PHLDB1	0.41	8.53	0.37	2.14e-16	Cholesterol, total;
LGG	cis	rs240764	0.555	rs11967951	chr6:101231905	G/A	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs11651000	0.654	rs12451801	chr17:45820975	T/C	cg24803719	chr17:45855879	NA	-0.26	-6.66	-0.3	7.73e-11	IgG glycosylation;
LGG	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg10483660	chr13:112241077	NA	0.34	6.76	0.3	4.27e-11	Menarche (age at onset);
LGG	cis	rs7617773	0.747	rs34076262	chr3:48370416	C/T	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs7582720	0.943	rs115628302	chr2:203690047	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.74	0.41	1.65e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg06766960	chr11:133703094	NA	-0.5	-9.97	-0.42	2.39e-21	Childhood ear infection;
LGG	cis	rs2535633	0.631	rs2581803	chr3:52994981	G/A	cg11645453	chr3:52864694	ITIH4	-0.49	-8.33	-0.36	9.24e-16	Body mass index;
LGG	cis	rs7635838	0.718	rs2249051	chr3:11403234	G/A	cg00170343	chr3:11313890	ATG7	0.46	7.92	0.35	1.82e-14	HDL cholesterol;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg07701084	chr6:150067640	NUP43	0.69	13.27	0.52	2.81e-34	Lung cancer;
LGG	cis	rs2439831	0.850	rs28564774	chr15:44125475	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.71	0.45	4.8e-24	Lung cancer in ever smokers;
LGG	cis	rs9880211	0.800	rs34324561	chr3:136101242	T/G	cg21827317	chr3:136751795	NA	-0.47	-6.97	-0.31	1.07e-11	Body mass index;Height;
LGG	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg11584989	chr19:19387371	SF4	-0.49	-8.31	-0.36	1.1e-15	Perceived unattractiveness to mosquitoes;
LGG	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg17182837	chr8:41585554	ANK1	-0.55	-7.85	-0.34	2.92e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs17767392	1.000	rs17767523	chr14:71880739	G/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg07005078	chr4:17578674	LAP3	0.39	6.84	0.3	2.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg12708336	chr17:41446283	NA	-0.32	-7.75	-0.34	5.71e-14	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.27	0.32	1.58e-12	Homoarginine levels;
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg06916706	chr16:4465613	CORO7	-1.07	-20.49	-0.69	7.11e-67	Schizophrenia;
LGG	cis	rs2088885	1.000	rs2088885	chr3:170971291	C/A	cg18052528	chr3:170975382	TNIK	-0.28	-6.85	-0.3	2.41e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs11229555	0.609	rs7928676	chr11:58188022	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00933542	chr6:150070202	PCMT1	0.4	7.23	0.32	2.06e-12	Lung cancer;
LGG	cis	rs274567	0.501	rs581968	chr5:131710202	G/A	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Blood metabolite levels;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg23730037	chr7:158596552	ESYT2	-0.47	-8.51	-0.37	2.38e-16	Height;
LGG	cis	rs7208859	0.623	rs9896603	chr17:29078512	C/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	8.82	0.38	2.43e-17	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.22e-31	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs7672127	chr4:98938477	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.44	0.37	4.08e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.840	rs34634551	chr4:100067362	C/A	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg21226059	chr5:178986404	RUFY1	0.46	8.26	0.36	1.49e-15	Lung cancer;
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg13628971	chr7:2884303	GNA12	0.52	9.97	0.42	2.36e-21	Height;
LGG	trans	rs11039798	0.588	rs7946443	chr11:48545504	G/A	cg15704280	chr7:45808275	SEPT13	0.72	9.97	0.42	2.47e-21	Axial length;
LGG	cis	rs2985684	0.779	rs12160	chr14:50091932	T/A	cg04989706	chr14:50066350	PPIL5	-0.52	-8.23	-0.36	1.97e-15	Carotid intima media thickness;
LGG	cis	rs916888	0.610	rs199444	chr17:44818276	T/C	cg26656751	chr17:43910226	CRHR1	0.35	7.05	0.31	6.63e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10791097	0.739	rs4936120	chr11:130723452	G/A	cg09137382	chr11:130731461	NA	0.4	7.41	0.33	6.1e-13	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs36093844	0.699	rs4015260	chr11:85558887	T/C	cg16165120	chr11:85566439	CCDC83	-0.45	-7.05	-0.31	6.59e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6444746	0.866	rs73207484	chr3:193489403	C/T	cg22553634	chr3:193489233	NA	0.84	9.36	0.4	3.35e-19	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg24642439	chr20:33292090	TP53INP2	0.56	9.4	0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	trans	rs9784649	0.891	rs57355285	chr5:25016384	C/G	cg11038491	chr20:34638489	LOC647979	-0.6	-7.72	-0.34	7.41e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.81	-14.34	-0.55	7.57e-39	Response to antipsychotic treatment;
LGG	trans	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.74	-0.41	1.65e-20	Retinal vascular caliber;
LGG	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.29	0.63	4.85e-52	Cognitive function;
LGG	cis	rs7173389	1.000	rs8035896	chr15:73664310	T/G	cg01796676	chr15:73680284	NA	0.51	8.66	0.37	7.93e-17	Resting heart rate;
LGG	cis	rs1799949	1.000	rs4793191	chr17:41204377	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg15971980	chr6:150254442	NA	0.45	8.3	0.36	1.19e-15	Lung cancer;
LGG	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs2836974	0.931	rs2836968	chr21:40642386	A/G	cg06238570	chr21:40685208	BRWD1	0.43	6.73	0.3	5.15e-11	Cognitive function;
LGG	cis	rs3736594	0.513	rs6751087	chr2:27778016	T/C	cg27432699	chr2:27873401	GPN1	0.57	8.52	0.37	2.26e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2797369	0.629	rs9390728	chr6:101540875	A/C	cg27451362	chr6:101846650	GRIK2	-0.68	-10.11	-0.43	7.84e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg20573242	chr4:122745356	CCNA2	-0.46	-7.89	-0.34	2.18e-14	Type 2 diabetes;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	trans	rs2574985	0.667	rs3011782	chr10:52290002	C/T	cg18558237	chr10:81444220	LOC650623	0.44	6.89	0.3	1.79e-11	Subjective well-being;
LGG	cis	rs897984	0.568	rs67456613	chr16:30888295	G/A	cg00531865	chr16:30841666	NA	-0.55	-10.26	-0.43	2.1e-22	Dementia with Lewy bodies;
LGG	cis	rs1497828	0.956	rs2815222	chr1:217522229	T/A	cg04411442	chr1:217543379	NA	-0.48	-8.03	-0.35	8.06e-15	Dialysis-related mortality;
LGG	cis	rs981844	1.000	rs2579917	chr4:154652648	T/G	cg14289246	chr4:154710475	SFRP2	0.69	11.13	0.46	1.19e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs11098499	0.955	rs6815725	chr4:120158410	C/A	cg25214090	chr10:38739885	LOC399744	0.62	11.21	0.46	5.99e-26	Corneal astigmatism;
LGG	cis	rs9547996	0.879	rs9547940	chr13:38129403	A/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.85	-0.3	2.38e-11	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	3.97e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg08400814	chr5:56204995	C5orf35	-0.49	-7.56	-0.33	2.19e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg08219700	chr8:58056026	NA	0.47	7.16	0.32	3.21e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg00495681	chr13:53174319	NA	0.84	18.45	0.65	2.2e-57	Lewy body disease;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg02127607	chr17:61920694	SMARCD2	-0.48	-8.67	-0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg08835221	chr22:38071607	LGALS1	0.28	7.7	0.34	8.18e-14	Fat distribution (HIV);
LGG	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg06636001	chr8:8085503	FLJ10661	0.46	8.26	0.36	1.51e-15	Neuroticism;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.02	-0.57	8.06e-42	Prudent dietary pattern;
LGG	cis	rs7607369	0.791	rs12468043	chr2:219354197	C/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg20240347	chr1:204465584	NA	0.51	10.27	0.43	1.94e-22	Schizophrenia;
LGG	trans	rs3206736	0.548	rs10265125	chr7:35061136	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.13	0.31	3.86e-12	Diastolic blood pressure;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg12039286	chr8:143533193	NA	-0.42	-7.03	-0.31	7.44e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg25554036	chr4:6271136	WFS1	0.52	8.39	0.36	5.89e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7953508	0.506	rs2053196	chr12:93962959	T/C	cg18151635	chr12:93972918	NA	-0.56	-10.49	-0.44	2.99e-23	Pubertal anthropometrics;
LGG	trans	rs1728785	1.000	rs4783653	chr16:68562815	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.4	0.44	6.64e-23	Ulcerative colitis;
LGG	cis	rs2635047	0.684	rs7236105	chr18:44757226	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.29	0.36	1.28e-15	Educational attainment;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08280861	chr8:58055591	NA	0.64	7.85	0.34	2.97e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg09754948	chr16:28834200	ATXN2L	0.47	7.35	0.32	8.83e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.15	0.35	3.49e-15	Obesity-related traits;
LGG	cis	rs4917300	0.606	rs1388797	chr8:143096908	G/C	cg06573787	chr8:143070187	NA	0.58	9.63	0.41	4.04e-20	Amyotrophic lateral sclerosis;
LGG	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.1	-0.31	4.62e-12	Total cholesterol levels;
LGG	cis	rs477895	0.941	rs71456309	chr11:64108262	T/G	cg22916017	chr11:64110731	CCDC88B	-0.54	-7.08	-0.31	5.42e-12	Mean platelet volume;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.36	0.4	3.51e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg00830817	chr11:109293614	C11orf87	0.41	7.0	0.31	9.08e-12	Schizophrenia;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg26150922	chr2:100937072	LONRF2	-0.58	-11.13	-0.46	1.19e-25	Intelligence (multi-trait analysis);
LGG	cis	rs787274	0.543	rs4978509	chr9:115635641	C/G	cg13803584	chr9:115635662	SNX30	-0.65	-9.95	-0.42	2.85e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7250872	0.568	rs749109	chr19:1819736	G/A	cg18850929	chr19:1828978	REXO1	0.48	7.8	0.34	4.17e-14	Bipolar disorder;
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.43	6.93	0.31	1.46e-11	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.95	0.38	8.39e-18	Motion sickness;
LGG	cis	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.75	-0.3	4.5e-11	Recombination measurement;
LGG	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	cg15522984	chr1:182991683	LAMC1	0.43	8.71	0.38	5.44e-17	Colorectal cancer;
LGG	cis	rs9522267	0.502	rs9522297	chr13:112234419	C/T	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs524281	0.861	rs7929909	chr11:65951698	C/T	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs638893	0.636	rs6589687	chr11:118615660	T/A	cg13782932	chr11:118662891	DDX6	0.37	6.76	0.3	4.13e-11	Vitiligo;
LGG	cis	rs2599510	0.693	rs2754514	chr2:32788836	T/A	cg02381751	chr2:32503542	YIPF4	0.43	6.99	0.31	9.79e-12	Interleukin-18 levels;
LGG	cis	rs1008375	0.966	rs2159582	chr4:17695655	T/C	cg02297831	chr4:17616191	MED28	0.44	8.14	0.35	3.66e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35110281	0.782	rs2838329	chr21:45023329	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.09e-17	Mean corpuscular volume;
LGG	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-12.96	-0.52	5.54e-33	Chronic sinus infection;
LGG	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg04362960	chr10:104952993	NT5C2	0.57	10.63	0.44	9.14e-24	Arsenic metabolism;
LGG	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.9	-0.31	1.75e-11	Iron status biomarkers;
LGG	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg12623918	chr2:306882	NA	0.51	9.5	0.4	1.1e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2860975	1.000	rs2226070	chr10:96776721	C/T	cg09036531	chr10:96991505	NA	-0.48	-8.74	-0.38	4.43e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg11878867	chr6:150167359	LRP11	-0.53	-10.87	-0.45	1.17e-24	Lung cancer;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs910187	0.678	rs3818008	chr20:45816488	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-9.03	-0.39	4.51e-18	Migraine;
LGG	cis	rs4926611	0.736	rs4927023	chr1:54121458	C/T	cg23596471	chr1:54105337	GLIS1	0.33	6.9	0.31	1.75e-11	Hand grip strength;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg00830817	chr11:109293614	C11orf87	-0.6	-9.76	-0.41	1.37e-20	Schizophrenia;
LGG	cis	rs911555	0.755	rs9671414	chr14:103967299	C/T	cg24130564	chr14:104152367	KLC1	0.39	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs754205	0.672	rs2289046	chr13:110407906	A/G	cg05430997	chr13:110397189	NA	-0.38	-6.72	-0.3	5.3e-11	Reticulocyte fraction of red cells;
LGG	cis	rs7751419	0.651	rs10947779	chr6:39093617	A/G	cg08089693	chr6:39098871	NA	-0.44	-7.91	-0.35	1.85e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.16	0.32	3.17e-12	Educational attainment;
LGG	cis	rs2013441	0.670	rs12937327	chr17:19978984	C/T	cg13482628	chr17:19912719	NA	0.52	8.73	0.38	4.81e-17	Obesity-related traits;
LGG	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg21827317	chr3:136751795	NA	0.51	9.4	0.4	2.62e-19	Gestational age at birth (child effect);
LGG	cis	rs59197085	0.591	rs73238120	chr7:128432108	C/T	cg00734629	chr7:128471146	FLNC	0.37	7.11	0.31	4.41e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs10463554	0.892	rs10434791	chr5:102389472	C/G	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg06558623	chr16:89946397	TCF25	1.13	12.32	0.5	2.25e-30	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2289583	0.642	rs8034281	chr15:75384227	A/G	cg10253484	chr15:75165896	SCAMP2	-0.44	-6.96	-0.31	1.18e-11	Systemic lupus erythematosus;
LGG	cis	rs6541297	0.555	rs910502	chr1:230294185	A/T	cg05784532	chr1:230284198	GALNT2	0.52	7.09	0.31	4.94e-12	Coronary artery disease;
LGG	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.41	0.33	6.24e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	1.000	rs12537846	chr7:91721581	C/T	cg17063962	chr7:91808500	NA	-0.46	-8.27	-0.36	1.48e-15	Breast cancer;
LGG	cis	rs75229567	0.717	rs17107156	chr12:70234066	A/G	cg10114359	chr12:70132523	RAB3IP	-1.04	-9.86	-0.42	6.04e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs58235267	0.543	rs2539990	chr2:63170185	C/T	cg17519650	chr2:63277830	OTX1	0.61	11.45	0.47	6.5e-27	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg07061783	chr6:25882402	NA	-0.57	-10.07	-0.42	1.04e-21	Uric acid levels;
LGG	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.98	-0.45	4.36e-25	DNA methylation (variation);
LGG	cis	rs2070488	1.000	rs7373816	chr3:38490443	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.03	0.64	1.83e-55	Electrocardiographic conduction measures;
LGG	cis	rs758324	0.648	rs31473	chr5:131404446	A/T	cg06307176	chr5:131281290	NA	-0.42	-6.82	-0.3	2.81e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6762644	0.573	rs55963864	chr3:4743816	G/T	cg11584376	chr3:4789075	ITPR1	-0.35	-7.23	-0.32	2.01e-12	Breast cancer;
LGG	cis	rs11690935	0.921	rs908670	chr2:172690180	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-25.78	-0.77	1.6e-91	Schizophrenia;
LGG	cis	rs751728	0.689	rs3763257	chr6:33773696	T/A	cg25922239	chr6:33757077	LEMD2	0.65	9.97	0.42	2.42e-21	Crohn's disease;
LGG	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs9911578	1.000	rs9907499	chr17:56949044	A/G	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9581943	0.967	rs7993114	chr13:28476277	A/G	cg16302790	chr13:28498334	PDX1	0.48	8.15	0.35	3.45e-15	Pancreatic cancer;
LGG	cis	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg19338460	chr6:170058176	WDR27	-0.61	-8.35	-0.36	8.23e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg21017887	chr14:105400489	NA	0.43	8.46	0.37	3.46e-16	Rheumatoid arthritis;
LGG	cis	rs17253792	0.822	rs77741349	chr14:56097462	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs344364	0.602	rs7188401	chr16:1876949	G/C	cg08610935	chr16:1836813	NUBP2	-0.44	-6.72	-0.3	5.51e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg26605046	chr4:2439731	NA	-0.39	-7.49	-0.33	3.59e-13	Cognitive function;
LGG	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg10523679	chr1:76189770	ACADM	0.82	15.75	0.59	4.7e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	8.67	0.37	7.41e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs36051895	0.554	rs11789744	chr9:5134213	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.65	-0.56	3.25e-40	Pediatric autoimmune diseases;
LGG	trans	rs7178375	1.000	rs7176351	chr15:31208727	G/A	cg04373760	chr16:53404718	NA	0.56	8.27	0.36	1.44e-15	Hypertriglyceridemia;
LGG	cis	rs8072100	0.713	rs2292346	chr17:45455473	G/A	cg08085267	chr17:45401833	C17orf57	-0.5	-9.23	-0.39	9.57e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg16141378	chr3:129829833	LOC729375	-0.56	-14.71	-0.56	1.9e-40	Mood instability;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10493773	0.609	rs2389972	chr1:86190666	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.73	-16.19	-0.6	4.95e-47	Urate levels in overweight individuals;
LGG	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg27541892	chr1:1571801	CDK11B	-0.6	-10.4	-0.44	6.32e-23	Body mass index;
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.34	-0.36	8.62e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00006032	chr14:66974439	GPHN	0.5	8.0	0.35	9.88e-15	Gut microbiome composition (summer);
LGG	cis	rs524281	0.861	rs10896087	chr11:65924549	A/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.65	-0.3	8.3e-11	Electroencephalogram traits;
LGG	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg22676075	chr6:135203613	NA	0.37	6.69	0.3	6.52e-11	Red blood cell count;
LGG	cis	rs2114646	0.731	rs6732226	chr2:170636738	A/G	cg17598339	chr2:170624727	NA	0.35	6.73	0.3	5.15e-11	Obesity-related traits;
LGG	cis	rs11605924	0.868	rs34043764	chr11:45837457	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.48	-8.13	-0.35	3.92e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs7666738	0.830	rs1365458	chr4:98950961	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.37	0.36	6.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11992162	0.507	rs60902764	chr8:11784991	A/T	cg00405596	chr8:11794950	NA	-0.6	-10.37	-0.43	8.31e-23	Monocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25632114	chr8:95732714	DPY19L4	0.49	8.07	0.35	6.02e-15	Cognitive performance;
LGG	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.49e-24	Schizophrenia;
LGG	trans	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg16724585	chr3:197361211	NA	-0.42	-7.58	-0.33	1.96e-13	Bronchopulmonary dysplasia;
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg14298792	chr15:30685198	CHRFAM7A	0.54	8.1	0.35	5.06e-15	Huntington's disease progression;
LGG	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg10636054	chr15:40330586	SRP14	1.23	14.15	0.55	4.93e-38	Corneal curvature;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg16507663	chr6:150244633	RAET1G	0.42	7.79	0.34	4.37e-14	Lung cancer;
LGG	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.99	19.68	0.67	4.14e-63	Platelet count;
LGG	cis	rs3204270	0.759	rs8066217	chr17:79672615	C/G	cg18367735	chr17:79674897	NA	0.64	8.35	0.36	7.88e-16	Dental caries;
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg14338887	chr6:42928500	GNMT	0.27	8.58	0.37	1.42e-16	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg06640241	chr16:89574553	SPG7	0.71	12.36	0.5	1.53e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg25664220	chr3:72788482	NA	-0.34	-9.28	-0.4	6.53e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4776059	1.000	rs4776059	chr15:52886962	C/T	cg22715398	chr15:52968154	KIAA1370	-0.49	-8.06	-0.35	6.41e-15	Schizophrenia;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg14338887	chr6:42928500	GNMT	0.3	9.72	0.41	1.93e-20	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4481887	0.573	rs10888329	chr1:248404654	C/T	cg01631408	chr1:248437212	OR2T33	0.4	6.81	0.3	3.02e-11	Common traits (Other);
LGG	cis	rs12282928	1.000	rs7129742	chr11:48326592	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs12618769	0.543	rs4851132	chr2:99042782	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	1.97e-16	Bipolar disorder;
LGG	cis	rs6964587	0.967	rs6465341	chr7:91596121	G/C	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs77633900	0.892	rs4886490	chr15:76628440	A/G	cg21673338	chr15:77095150	SCAPER	0.45	6.74	0.3	4.81e-11	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9849248	0.627	rs55883959	chr3:88116071	G/C	cg14530983	chr3:88190749	ZNF654	0.56	7.81	0.34	3.74e-14	Menarche (age at onset);
LGG	cis	rs7683537	0.692	rs56317358	chr4:185659470	G/A	cg04058563	chr4:185651563	MLF1IP	1.01	16.33	0.6	1.14e-47	Systemic lupus erythematosus;
LGG	cis	rs4788570	0.566	rs72795864	chr16:71483497	C/G	cg06353428	chr16:71660113	MARVELD3	-1.0	-13.57	-0.53	1.43e-35	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	1.000	rs7406983	chr17:29703374	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.47	-0.56	2.09e-39	Hip circumference;
LGG	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg11644478	chr21:40555479	PSMG1	-0.54	-8.45	-0.37	3.74e-16	Menarche (age at onset);
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg08645402	chr16:4508243	NA	0.46	7.85	0.34	3e-14	Schizophrenia;
LGG	trans	rs853679	0.546	rs34371502	chr6:28081758	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs35740288	0.787	rs727379	chr15:86229890	A/G	cg07943548	chr15:86304357	KLHL25	-0.35	-6.94	-0.31	1.29e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs3820881	0.628	rs6722649	chr2:201312663	C/T	cg23516759	chr2:201153734	NA	-0.44	-7.22	-0.32	2.1e-12	Chickenpox;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.57	-9.64	-0.41	3.57e-20	Obesity-related traits;
LGG	cis	rs4148660	0.719	rs10770872	chr12:22094815	C/T	cg14669847	chr12:22099120	NA	0.4	7.25	0.32	1.77e-12	Gout;
LGG	cis	rs721399	1.000	rs4646248	chr8:18260355	C/T	cg18736775	chr8:18248649	NAT2	0.51	8.99	0.39	6.48e-18	Blood metabolite levels;
LGG	cis	rs300774	0.925	rs300710	chr2:139574	C/T	cg04617936	chr2:214353	NA	0.5	7.62	0.33	1.48e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.78	-15.57	-0.59	3.03e-44	Longevity;Endometriosis;
LGG	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg24250549	chr1:154909240	PMVK	0.53	9.5	0.4	1.09e-19	Prostate cancer;
LGG	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.21	0.32	2.27e-12	Retinal vascular caliber;
LGG	cis	rs12230513	0.732	rs4356858	chr12:55867290	A/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.98	-0.45	4.45e-25	Contrast sensitivity;
LGG	cis	rs2073300	1.000	rs6137982	chr20:23468892	T/A	cg12062639	chr20:23401060	NAPB	0.89	7.18	0.32	2.86e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3931	0.607	rs11676084	chr2:169703974	C/T	cg13605690	chr2:169746671	SPC25	0.5	6.97	0.31	1.08e-11	Monocyte count;
LGG	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15664640	chr17:80829946	TBCD	-0.81	-15.93	-0.59	7.53e-46	Breast cancer;
LGG	cis	rs9443189	0.570	rs7765254	chr6:76398143	T/C	cg01950844	chr6:76311363	SENP6	0.76	9.74	0.41	1.6e-20	Prostate cancer;
LGG	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.88	0.38	1.54e-17	Fuchs's corneal dystrophy;
LGG	cis	rs7215564	0.643	rs59992540	chr17:78658265	G/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.32	-0.36	9.89e-16	Myopia (pathological);
LGG	cis	rs9457247	1.000	rs393727	chr6:167398632	T/A	cg07741184	chr6:167504864	NA	0.32	7.03	0.31	7.34e-12	Crohn's disease;
LGG	trans	rs853679	0.546	rs13213986	chr6:28358009	T/A	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs4595586	0.644	rs10437944	chr12:39308786	A/C	cg26384229	chr12:38710491	ALG10B	0.48	8.84	0.38	1.99e-17	Morning vs. evening chronotype;
LGG	cis	rs861020	1.000	rs630984	chr1:209982293	C/T	cg05527609	chr1:210001259	C1orf107	0.71	9.8	0.41	1.03e-20	Orofacial clefts;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.88e-21	Lung cancer;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.65	-0.33	1.18e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7027203	0.828	rs4743934	chr9:96581893	A/G	cg13679303	chr9:96623674	NA	-0.37	-6.69	-0.3	6.63e-11	DNA methylation (variation);
LGG	cis	rs7917772	0.560	rs3862030	chr10:104327584	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg11789530	chr4:8429930	ACOX3	0.74	14.54	0.56	9.84e-40	Response to antineoplastic agents;
LGG	cis	rs12144309	0.554	rs1970559	chr1:114377148	T/C	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.34	6.69	0.3	6.53e-11	Coronary artery disease;
LGG	cis	rs9916302	0.904	rs2338755	chr17:37419317	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.71e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.63	0.33	1.36e-13	Joint mobility (Beighton score);
LGG	trans	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	6.75	0.3	4.37e-11	Aortic root size;
LGG	cis	rs897984	0.647	rs8060857	chr16:31002720	G/A	cg02466173	chr16:30829666	NA	0.47	8.45	0.37	3.94e-16	Dementia with Lewy bodies;
LGG	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg00278107	chr5:1061253	SLC12A7	0.66	12.7	0.51	6.22e-32	QT interval;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg11764359	chr7:65958608	NA	0.77	13.93	0.54	4.39e-37	Aortic root size;
LGG	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg22705602	chr4:152727874	NA	-0.33	-7.91	-0.34	1.95e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7512552	0.803	rs3738487	chr1:150477061	C/T	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	9.55e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs2727020	0.521	rs7930855	chr11:49521660	C/T	cg03929089	chr4:120376271	NA	0.84	13.21	0.52	4.73e-34	Coronary artery disease;
LGG	cis	rs11190604	1.000	rs11190602	chr10:102297256	T/C	cg07570687	chr10:102243282	WNT8B	0.44	7.39	0.32	6.72e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg13565492	chr6:43139072	SRF	-0.9	-15.64	-0.59	1.42e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500395	1.000	rs7206647	chr16:48709220	G/C	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7412746	0.611	rs2280627	chr1:150935872	A/G	cg15448220	chr1:150897856	SETDB1	0.36	6.68	0.3	7.05e-11	Melanoma;
LGG	cis	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.47e-25	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25072359	chr17:41440525	NA	0.53	9.97	0.42	2.52e-21	Menopause (age at onset);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19078520	chr2:135676222	CCNT2	0.44	6.78	0.3	3.59e-11	Hip circumference;
LGG	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg06153925	chr17:78755379	RPTOR	0.4	6.91	0.31	1.61e-11	Myopia (pathological);
LGG	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg02389323	chr16:88786976	FAM38A	1.08	13.25	0.52	3.37e-34	Plateletcrit;
LGG	cis	rs9355814	0.508	rs1864449	chr6:161122763	T/C	cg04181478	chr6:161122748	PLG	-0.48	-9.9	-0.42	4.4e-21	Lipoprotein (a) levels;
LGG	cis	rs7226408	0.857	rs8098708	chr18:34563373	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg03517284	chr6:25882590	NA	-0.38	-6.85	-0.3	2.34e-11	Height;
LGG	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg12193833	chr17:30244370	NA	-0.27	-7.26	-0.32	1.6e-12	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05351940	chr2:219081877	ARPC2	0.46	7.04	0.31	7.01e-12	Gut microbiome composition (summer);
LGG	cis	rs11864453	0.927	rs1035560	chr16:72032730	T/C	cg01557791	chr16:72042693	DHODH	-0.61	-11.32	-0.47	2.21e-26	Fibrinogen levels;
LGG	trans	rs6601327	0.613	rs12547642	chr8:9493927	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.37	-0.32	8.15e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs12249377	0.519	rs11599902	chr10:92598823	A/G	cg14313238	chr10:92632228	RPP30	0.41	7.43	0.33	5.36e-13	White matter microstructure (global fractional anisotropy);
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.46	-0.37	3.49e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9462027	0.606	rs2235569	chr6:34570070	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.33	-0.43	1.24e-22	Systemic lupus erythematosus;
LGG	cis	rs2742417	0.603	rs2742448	chr3:45764246	C/T	cg04837898	chr3:45731254	SACM1L	0.42	7.6	0.33	1.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs5758659	0.967	rs5758670	chr22:42636687	T/C	cg15557168	chr22:42548783	NA	-0.4	-8.99	-0.39	6.39e-18	Cognitive function;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs2066819	1.000	rs17118403	chr12:56630067	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	trans	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17712092	chr4:129076599	LARP1B	0.74	13.94	0.54	4.06e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs4731207	0.596	rs1994024	chr7:124660845	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.58	-0.33	1.92e-13	Cutaneous malignant melanoma;
LGG	trans	rs6598955	0.671	rs11247914	chr1:26648838	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.75	-0.51	4.03e-32	Obesity-related traits;
LGG	cis	rs735396	0.770	rs1169301	chr12:121431300	C/T	cg14101638	chr12:121416612	HNF1A	0.4	7.92	0.35	1.78e-14	N-glycan levels;
LGG	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg00343986	chr7:65444356	GUSB	-0.41	-6.68	-0.3	6.95e-11	Aortic root size;
LGG	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.27e-12	Morning vs. evening chronotype;
LGG	cis	rs2692947	0.673	rs2917662	chr2:96794957	G/A	cg22654517	chr2:96458247	NA	0.36	7.41	0.33	6.15e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4845570	0.831	rs11588258	chr1:151780728	A/T	cg07092448	chr1:151763213	TDRKH	-1.07	-15.42	-0.58	1.37e-43	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9557207	1.000	rs9557207	chr13:100036418	A/G	cg24509225	chr13:100037070	UBAC2	0.7	12.67	0.51	8.46e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	Neuroticism;
LGG	cis	rs2836974	0.965	rs7354783	chr21:40652992	G/A	cg11890956	chr21:40555474	PSMG1	1.17	30.07	0.81	6.31e-111	Cognitive function;
LGG	cis	rs1555895	0.656	rs10752020	chr10:840608	G/T	cg10556349	chr10:835070	NA	0.32	8.12	0.35	4.25e-15	Survival in rectal cancer;
LGG	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.88	0.3	2e-11	Neuroticism;
LGG	trans	rs9657904	0.813	rs2197209	chr3:105568165	C/A	cg14088669	chr1:158435396	OR10K1	-0.41	-6.95	-0.31	1.28e-11	Multiple sclerosis;
LGG	cis	rs7727544	0.901	rs55633655	chr5:131598756	T/G	cg24060327	chr5:131705240	SLC22A5	-0.4	-6.77	-0.3	3.89e-11	Blood metabolite levels;
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg03709012	chr19:19516395	GATAD2A	0.78	14.6	0.56	5.78e-40	Tonsillectomy;
LGG	cis	rs8044868	0.586	rs7188962	chr16:72098962	A/G	cg23815491	chr16:72088622	HP	0.39	8.26	0.36	1.56e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2070488	1.000	rs34258593	chr3:38464565	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	17.97	0.64	3.55e-55	Electrocardiographic conduction measures;
LGG	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg07005078	chr4:17578674	LAP3	0.38	7.12	0.31	4.12e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09507928	chr5:140027484	IK;NDUFA2	-0.41	-6.78	-0.3	3.69e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.09	0.52	1.52e-33	Colorectal cancer;
LGG	cis	rs787274	1.000	rs787292	chr9:115508529	A/G	cg13803584	chr9:115635662	SNX30	0.58	7.82	0.34	3.72e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg23202291	chr11:1979235	NA	0.37	7.16	0.32	3.13e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	trans	rs2235573	0.527	rs139886	chr22:38371328	C/T	cg19894588	chr14:64061835	NA	0.63	10.62	0.44	1.04e-23	Glioblastoma;Glioma;
LGG	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg16102102	chr5:83017553	HAPLN1	0.57	10.89	0.45	9.31e-25	Prostate cancer;
LGG	cis	rs7651190	1	rs7651190	chr3:41765955	A/G	cg03022575	chr3:42003672	ULK4	0.6	7.74	0.34	6.27e-14	Diastolic blood pressure;Blood pressure traits (multi-trait analysis);
LGG	cis	rs12908161	0.920	rs35758837	chr15:85311382	C/T	cg03959625	chr15:84868606	LOC388152	0.49	7.22	0.32	2.14e-12	Schizophrenia;
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	7.23	0.32	2.06e-12	Bipolar disorder;
LGG	cis	rs853679	0.517	rs9368550	chr6:28051803	T/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs8064029	1.000	rs17631487	chr16:4906999	A/G	cg04440724	chr16:4920505	UBN1	-0.61	-7.42	-0.33	5.81e-13	Cancer;
LGG	cis	rs10489202	0.634	rs6427119	chr1:168074145	A/G	cg24449463	chr1:168025552	DCAF6	0.56	10.04	0.42	1.41e-21	Schizophrenia;
LGG	cis	rs10465746	0.967	rs1570690	chr1:84377515	G/T	cg10977910	chr1:84465055	TTLL7	0.5	9.24	0.39	9.29e-19	Obesity-related traits;
LGG	cis	rs2652834	0.851	rs2729778	chr15:63407332	T/G	cg05507819	chr15:63340323	TPM1	0.5	7.11	0.31	4.32e-12	HDL cholesterol;
LGG	cis	rs12971120	1.000	rs2278162	chr18:72175814	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-13.68	-0.54	5.27e-36	Refractive error;
LGG	cis	rs6665290	0.901	rs7535826	chr1:227213968	A/C	cg10327440	chr1:227177885	CDC42BPA	1.23	38.26	0.87	1.8e-145	Myeloid white cell count;
LGG	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.27	-0.46	3.5e-26	Vitiligo;
LGG	cis	rs11169552	0.510	rs10876072	chr12:51013559	G/C	cg12884762	chr12:50931848	DIP2B	-0.41	-7.73	-0.34	6.86e-14	Colorectal cancer;
LGG	cis	rs2486288	0.656	rs11637364	chr15:45579238	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.73	-0.45	4.02e-24	Glomerular filtration rate;
LGG	cis	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.0	-0.35	1.01e-14	Ulcerative colitis;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg01570551	chr7:23719851	C7orf46	0.37	8.1	0.35	4.84e-15	Schizophrenia;
LGG	cis	rs11098499	0.820	rs28394116	chr4:120524283	T/G	cg01244601	chr4:120671846	NA	-0.36	-6.84	-0.3	2.45e-11	Corneal astigmatism;
LGG	cis	rs9309711	0.621	rs12993215	chr2:3473727	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.14	-0.35	3.8e-15	Neurofibrillary tangles;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg02018176	chr4:1364513	KIAA1530	0.39	8.65	0.37	8.7e-17	Obesity-related traits;
LGG	cis	rs35110281	0.600	rs914198	chr21:45117456	A/C	cg04455712	chr21:45112962	RRP1B	0.55	10.08	0.42	9.95e-22	Mean corpuscular volume;
LGG	cis	rs7169223	0.653	rs2904228	chr15:79086099	G/A	cg03762349	chr15:79060523	ADAMTS7	0.37	7.22	0.32	2.13e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs4788815	1.000	rs4788815	chr16:71634811	A/T	cg06353428	chr16:71660113	MARVELD3	0.44	6.86	0.3	2.17e-11	Metabolite levels;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg07701084	chr6:150067640	NUP43	0.42	7.83	0.34	3.36e-14	Testicular germ cell tumor;
LGG	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg18252515	chr7:66147081	NA	0.41	6.91	0.31	1.6e-11	Aortic root size;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06850241	chr22:41845214	NA	-0.44	-6.77	-0.3	3.87e-11	Vitiligo;
LGG	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.76	0.45	3.08e-24	Diabetic retinopathy;
LGG	cis	rs262150	0.644	rs2730228	chr7:158789361	T/C	cg09640425	chr7:158790006	NA	-0.39	-7.07	-0.31	5.71e-12	Facial morphology (factor 20);
LGG	cis	rs1497828	0.956	rs1497833	chr1:217535580	T/G	cg04411442	chr1:217543379	NA	-0.48	-8.11	-0.35	4.55e-15	Dialysis-related mortality;
LGG	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg14541582	chr5:601475	NA	-0.65	-10.08	-0.42	9.79e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg07621104	chr11:117668040	DSCAML1	0.62	8.84	0.38	2.01e-17	Myopia;
LGG	cis	rs13260300	0.526	rs1425773	chr8:75536772	A/G	cg22993706	chr8:75542856	NA	0.45	9.58	0.41	6.12e-20	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg01631408	chr1:248437212	OR2T33	-0.53	-9.64	-0.41	3.61e-20	Common traits (Other);
LGG	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg05308233	chr10:104796373	CNNM2	0.35	7.5	0.33	3.35e-13	Arsenic metabolism;
LGG	cis	rs4919087	1.000	rs4919089	chr10:99087905	G/A	cg25902810	chr10:99078978	FRAT1	-0.5	-9.07	-0.39	3.41e-18	Monocyte count;
LGG	cis	rs4713118	0.621	rs9295756	chr6:28033396	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.52	-6.7	-0.3	6.09e-11	Parkinson's disease;
LGG	cis	rs1577917	0.771	rs9362230	chr6:86305013	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.06	-0.49	2.48e-29	Response to antipsychotic treatment;
LGG	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg08305652	chr11:111469057	NA	-0.44	-8.61	-0.37	1.18e-16	Primary sclerosing cholangitis;
LGG	trans	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.0	0.42	1.83e-21	Metabolite levels;
LGG	cis	rs12493885	0.818	rs61791544	chr3:153767504	T/A	cg12800244	chr3:153838788	SGEF	-0.78	-9.35	-0.4	3.61e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7192750	0.517	rs152827	chr16:72126753	C/G	cg14768367	chr16:72042858	DHODH	0.78	8.01	0.35	9.36e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg14675211	chr2:100938903	LONRF2	0.61	10.88	0.45	1.1e-24	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.57	-0.37	1.55e-16	Prudent dietary pattern;
LGG	cis	rs11203032	0.831	rs10887932	chr10:90966996	C/G	cg16672925	chr10:90967113	CH25H	0.86	12.3	0.5	2.84e-30	Heart failure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25306584	chr1:156823940	NTRK1;INSRR	0.4	7.11	0.31	4.5e-12	Pancreatic cancer;
LGG	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg03806693	chr22:41940476	POLR3H	0.93	15.83	0.59	1.94e-45	Vitiligo;
LGG	cis	rs2455601	0.935	rs12049908	chr11:8919309	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-11.44	-0.47	7.28e-27	Schizophrenia;
LGG	cis	rs490234	0.812	rs12351825	chr9:128265736	T/C	cg14078157	chr9:128172775	NA	-0.48	-9.04	-0.39	4.36e-18	Mean arterial pressure;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg09264619	chr17:80180166	NA	0.34	6.7	0.3	6.19e-11	Life satisfaction;
LGG	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg26248373	chr2:1572462	NA	-0.71	-9.19	-0.39	1.33e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg04703951	chr17:43578652	NA	-0.29	-6.67	-0.3	7.24e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.05e-54	Refractive error;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.41	0.53	7.43e-35	Lung cancer;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10053473	chr17:62856997	LRRC37A3	0.89	14.0	0.55	2.23e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2481665	0.608	rs2476194	chr1:62594593	C/T	cg18591186	chr1:62594603	INADL	-0.69	-16.49	-0.61	2.21e-48	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg14689365	chr7:158441557	NCAPG2	-0.56	-9.23	-0.39	9.67e-19	Height;
LGG	cis	rs6445975	0.572	rs12485999	chr3:58409763	C/T	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs972578	0.601	rs4820498	chr22:43327581	T/G	cg01576275	chr22:43409880	NA	-0.23	-7.16	-0.32	3.1e-12	Mean platelet volume;
LGG	cis	rs1003719	0.788	rs2835584	chr21:38460338	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.83	17.0	0.62	1.08e-50	Eye color traits;
LGG	cis	rs11157436	0.602	rs1894370	chr14:22634660	A/G	cg00994629	chr14:22694547	NA	0.33	7.2	0.32	2.52e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2274273	0.624	rs10146637	chr14:55744810	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.66	0.51	9.57e-32	Protein biomarker;
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg21775007	chr8:11205619	TDH	-0.45	-7.54	-0.33	2.45e-13	Neuroticism;
LGG	trans	rs9784649	1.000	rs3933895	chr5:25004929	A/T	cg08600765	chr20:34638493	LOC647979	-0.61	-7.66	-0.34	1.12e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7826238	0.720	rs12546760	chr8:8374836	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.22	-0.39	1.04e-18	Systolic blood pressure;
LGG	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	10.45	0.44	4.21e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6725041	0.547	rs17419211	chr2:213207921	C/T	cg20637307	chr2:213403960	ERBB4	-0.45	-8.65	-0.37	8.53e-17	QT interval (ambient particulate matter interaction);
LGG	cis	rs6714710	0.603	rs34503448	chr2:98587288	A/G	cg26665480	chr2:98280029	ACTR1B	0.64	10.37	0.43	8.86e-23	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs11190604	0.943	rs7900678	chr10:102229016	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	11.01	0.46	3.37e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg13482628	chr17:19912719	NA	0.53	9.74	0.41	1.68e-20	Schizophrenia;
LGG	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg18404041	chr3:52824283	ITIH1	-0.44	-7.77	-0.34	4.99e-14	Bipolar disorder;
LGG	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.98	-0.31	1.01e-11	Neuroticism;
LGG	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	trans	rs9914544	0.545	rs3826380	chr17:18793225	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs9527	0.568	rs1926036	chr10:104883812	C/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs4851254	0.961	rs13011181	chr2:100732446	T/C	cg17356467	chr2:100759845	AFF3	0.4	6.69	0.3	6.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.686	rs708145	chr12:33731580	G/A	cg06521331	chr12:34319734	NA	-0.4	-7.02	-0.31	7.97e-12	Morning vs. evening chronotype;
LGG	cis	rs950776	0.518	rs4886572	chr15:78837452	A/G	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.41	-0.4	2.26e-19	Sudden cardiac arrest;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg20308403	chr7:2120281	MAD1L1	0.33	6.9	0.31	1.72e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg03342759	chr3:160939853	NMD3	-0.76	-13.57	-0.53	1.53e-35	Parkinson's disease;
LGG	cis	rs11169225	0.906	rs3782319	chr12:50345079	G/A	cg04450003	chr12:50355995	AQP5	0.37	7.25	0.32	1.74e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg08949735	chr16:89699720	DPEP1	-0.45	-9.02	-0.39	4.93e-18	Vitiligo;
LGG	cis	rs6665290	0.904	rs3738729	chr1:227191227	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg02002194	chr4:3960332	NA	0.41	7.5	0.33	3.29e-13	Neuroticism;
LGG	cis	rs11724804	0.532	rs62295557	chr4:855708	G/A	cg20916646	chr4:852691	GAK	0.75	12.91	0.51	8.92e-33	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	trans	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	trans	rs6787172	0.622	rs9847045	chr3:158129803	T/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs9309473	0.948	rs6719753	chr2:73749054	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.9	-0.34	2.03e-14	Metabolite levels;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.42	7.32	0.32	1.07e-12	Bilirubin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20591408	chr2:241516333	RNPEPL1	0.46	8.57	0.37	1.54e-16	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.1	-0.39	2.64e-18	Blood metabolite levels;
LGG	cis	rs78456975	0.527	rs4073862	chr2:1563433	A/G	cg26248373	chr2:1572462	NA	-0.87	-14.59	-0.56	5.98e-40	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16448126	chr12:123921461	RILPL2	0.38	6.9	0.31	1.74e-11	Obesity-related traits;
LGG	trans	rs61931739	0.649	rs12424056	chr12:33714314	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-8.61	-0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.75	0.34	5.96e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs559928	0.847	rs11601738	chr11:64159307	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.54	6.72	0.3	5.29e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17665859	0.844	rs17738513	chr8:446359	G/T	cg17960703	chr8:356704	FBXO25	-0.85	-7.85	-0.34	2.96e-14	Bilirubin levels;
LGG	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15369054	chr17:80825471	TBCD	0.57	10.2	0.43	3.45e-22	Breast cancer;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg05313129	chr8:58192883	C8orf71	-0.47	-8.06	-0.35	6.68e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2013441	0.634	rs4925076	chr17:19978292	T/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.73e-15	Obesity-related traits;
LGG	cis	rs6500395	0.925	rs16946342	chr16:48668542	G/A	cg04672837	chr16:48644449	N4BP1	0.52	8.52	0.37	2.23e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg24642439	chr20:33292090	TP53INP2	0.46	7.12	0.31	4.27e-12	Height;
LGG	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg08648136	chr8:956695	NA	0.34	7.29	0.32	1.34e-12	Schizophrenia;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs644799	0.648	rs1255182	chr11:95472391	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.36	6.68	0.3	7.02e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6764363	0.654	rs455187	chr3:298355	T/C	cg02057681	chr3:285234	CHL1	0.38	6.89	0.3	1.86e-11	Sudden cardiac arrest;
LGG	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg26879891	chr1:152191343	HRNR	-0.32	-6.67	-0.3	7.44e-11	Inflammatory skin disease;
LGG	cis	rs4665809	0.938	rs35844686	chr2:26304949	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.88	13.34	0.53	1.37e-34	Gut microbiome composition (summer);
LGG	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	4.06e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.853	rs246902	chr5:102589254	C/T	cg23492399	chr5:102201601	PAM	-0.44	-6.68	-0.3	6.71e-11	Parkinson's disease;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21862992	chr11:68658383	NA	0.49	8.43	0.36	4.27e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2066819	1.000	rs1802236	chr12:56679751	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs2304069	0.545	rs9686746	chr5:149399968	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.15	0.35	3.33e-15	HIV-1 control;
LGG	cis	rs537930	0.560	rs2431151	chr5:134348225	G/T	cg24576358	chr5:134350122	NA	0.45	10.09	0.42	9.2e-22	Height;
LGG	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.38	0.32	7.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.21	0.36	2.26e-15	Longevity;
LGG	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.03e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs2668423	0.502	rs2074898	chr19:1391361	A/G	cg02639931	chr19:1387894	NDUFS7	-0.98	-23.84	-0.74	1.45e-82	Nonalcoholic fatty liver disease;
LGG	cis	rs2456568	0.771	rs8181530	chr11:93638678	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	8.87	0.38	1.61e-17	Cognitive test performance;
LGG	trans	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg13565492	chr6:43139072	SRF	-0.91	-15.7	-0.59	7.81e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg01528321	chr10:82214614	TSPAN14	0.65	11.69	0.48	7.67e-28	Post bronchodilator FEV1;
LGG	cis	rs1395	0.710	rs1992291	chr2:27504312	A/G	cg22903471	chr2:27725779	GCKR	-0.42	-7.22	-0.32	2.19e-12	Blood metabolite levels;
LGG	cis	rs1506636	0.962	rs629474	chr7:123399684	C/T	cg03229431	chr7:123269106	ASB15	0.73	18.17	0.65	4.25e-56	Plateletcrit;Platelet count;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg09699651	chr6:150184138	LRP11	0.52	9.29	0.4	6.2800000000000005e-19	Lung cancer;
LGG	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg26617929	chr16:1858877	NA	0.56	7.63	0.33	1.35e-13	Insulin-like growth factors;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27272293	chr12:76531007	NA	-0.57	-6.86	-0.3	2.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.45	-0.33	4.59e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3820928	0.839	rs13413292	chr2:227893747	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.46e-13	Pulmonary function;
LGG	cis	rs1577917	0.958	rs34622605	chr6:86456519	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.75	-0.45	3.26e-24	Response to antipsychotic treatment;
LGG	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3784262	0.740	rs8032572	chr15:58311280	A/G	cg12031962	chr15:58353849	ALDH1A2	0.33	7.08	0.31	5.35e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.66	-0.37	7.68e-17	Self-reported allergy;
LGG	cis	rs17039065	1.000	rs59029263	chr4:109403907	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	6.99	0.31	9.36e-12	Gut microbiome composition (summer);
LGG	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.86	-0.38	1.74e-17	Self-reported allergy;
LGG	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.53	-0.33	2.59e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg13206674	chr6:150067644	NUP43	-0.67	-15.44	-0.58	1.07e-43	Lung cancer;
LGG	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.92	0.42	3.7e-21	Motion sickness;
LGG	cis	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg00405596	chr8:11794950	NA	0.42	7.08	0.31	5.27e-12	Retinal vascular caliber;
LGG	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg01191920	chr7:158217561	PTPRN2	0.74	16.96	0.62	1.57e-50	Obesity-related traits;
LGG	cis	rs1670533	1.000	rs6822863	chr4:1055606	G/A	cg27284194	chr4:1044797	NA	0.55	9.67	0.41	2.81e-20	Recombination rate (females);
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.99	-12.83	-0.51	1.81e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg08198773	chr8:1697536	NA	0.45	7.89	0.34	2.12e-14	Systolic blood pressure;
LGG	trans	rs1945213	0.694	rs7129022	chr11:55876132	A/G	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.62e-20	Calcium levels;
LGG	cis	rs6964587	1.000	rs28927678	chr7:91715662	C/T	cg17063962	chr7:91808500	NA	0.49	8.53	0.37	2.02e-16	Breast cancer;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	6.98	0.31	1.06e-11	Menopause (age at onset);
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-6.98	-0.31	1e-11	Height;
LGG	cis	rs67311347	1.000	rs73080138	chr3:40516417	A/G	cg24209194	chr3:40518798	ZNF619	0.45	7.11	0.31	4.41e-12	Renal cell carcinoma;
LGG	cis	rs12493885	0.628	rs11925052	chr3:153645195	A/C	cg12800244	chr3:153838788	SGEF	0.58	7.03	0.31	7.47e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.88	-0.34	2.34e-14	Personality dimensions;
LGG	cis	rs755249	0.567	rs905381	chr1:39688552	T/G	cg18385671	chr1:39797026	MACF1	0.43	7.13	0.31	3.84e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3857536	0.776	rs9294687	chr6:66942919	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17154022	chr1:26798964	HMGN2	0.45	8.03	0.35	7.88e-15	Gut microbiome composition (summer);
LGG	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.04	-0.31	6.85e-12	Neuroticism;
LGG	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.6	0.33	1.71e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.67	0.59	1e-44	Platelet count;
LGG	cis	rs283228	0.798	rs283221	chr6:101759528	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.38e-23	Coenzyme Q10 levels;
LGG	cis	rs13088318	0.521	rs2553415	chr3:101095630	T/A	cg11279151	chr3:101281821	RG9MTD1	0.39	7.48	0.33	3.72e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg02187348	chr16:89574699	SPG7	0.44	7.05	0.31	6.54e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.87	0.38	1.63e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg00364696	chr7:1142433	C7orf50	-0.39	-7.57	-0.33	2.05e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6772849	0.805	rs61159406	chr3:128336009	G/A	cg08795948	chr3:128337044	NA	0.6	10.48	0.44	3.29e-23	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6456042	1.000	rs6456041	chr6:166534679	G/A	cg11088901	chr6:166572345	T	-0.36	-7.48	-0.33	3.75e-13	Asthma;
LGG	cis	rs4363385	0.693	rs1933384	chr1:152959488	A/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.91	-0.38	1.21e-17	Inflammatory skin disease;
LGG	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg11693508	chr17:37793320	STARD3	0.53	7.69	0.34	8.9e-14	Bipolar disorder;
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg23985595	chr17:80112537	CCDC57	0.48	9.66	0.41	3.04e-20	Life satisfaction;
LGG	cis	rs3857067	1.000	rs28840089	chr4:95000403	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.53	-0.33	2.67e-13	QT interval;
LGG	cis	rs7666738	0.861	rs10018654	chr4:99002226	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.817	rs1794162	chr11:49899506	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.29	-0.5	3.11e-30	Height;
LGG	cis	rs736801	0.808	rs4705950	chr5:131793286	C/T	cg21138405	chr5:131827807	IRF1	-0.29	-6.96	-0.31	1.15e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs68170813	0.559	rs76933738	chr7:106814574	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-11.06	-0.46	2.18e-25	Coronary artery disease;
LGG	cis	rs2084898	1.000	rs79007113	chr11:120039835	G/A	cg13907859	chr11:120009124	TRIM29	0.93	11.44	0.47	7.22e-27	Stroke (pediatric);
LGG	cis	rs1719271	0.831	rs1719272	chr15:65184200	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.51	-7.18	-0.32	2.72e-12	Platelet count;
LGG	cis	rs9487094	1.000	rs10080429	chr6:109738106	C/T	cg16315928	chr6:109776240	MICAL1	0.47	7.97	0.35	1.26e-14	Height;
LGG	cis	rs2797369	0.574	rs2852548	chr6:101682729	G/T	cg27451362	chr6:101846650	GRIK2	0.49	7.59	0.33	1.75e-13	Renal function-related traits (eGRFcrea);
LGG	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	8.26	0.36	1.52e-15	Neuroticism;
LGG	cis	rs6998277	1.000	rs62523306	chr8:103640752	C/A	cg10187029	chr8:103597600	NA	0.81	11.79	0.48	2.99e-28	Migraine;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4764124	0.652	rs6488712	chr12:14939332	G/A	cg19759883	chr12:14956454	WBP11;C12orf60	0.53	9.81	0.41	9.35e-21	Pubertal anthropometrics;
LGG	cis	rs1577917	0.958	rs12198876	chr6:86525476	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.54	-0.44	1.99e-23	Response to antipsychotic treatment;
LGG	cis	rs2273669	0.667	rs76367548	chr6:109356589	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs58616815	0.857	rs1341824	chr10:92160604	G/A	cg17905462	chr10:92153495	NA	-0.25	-6.65	-0.3	8.51e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6088580	0.634	rs7271970	chr20:32987666	A/G	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.07	-0.35	6.17e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9296249	0.514	rs3923809	chr6:38440970	A/G	cg07362130	chr6:38359646	BTBD9	-0.31	-6.79	-0.3	3.4e-11	Restless legs syndrome;
LGG	cis	rs12220238	1.000	rs10824090	chr10:75923446	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.5	0.47	4.45e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2242116	0.592	rs6442039	chr3:46960797	C/G	cg16586182	chr3:47516702	SCAP	-0.56	-8.62	-0.37	1.1e-16	Birth weight;
LGG	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg03258749	chr1:151040405	MLLT11	-0.45	-8.04	-0.35	7.6e-15	Childhood ear infection;
LGG	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.48	0.5	5.26e-31	Motion sickness;
LGG	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg26656751	chr17:43910226	CRHR1	0.48	8.99	0.39	6.5e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11229555	0.574	rs66573492	chr11:58183797	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg07677032	chr17:61819896	STRADA	-0.67	-12.54	-0.5	2.92e-31	Prudent dietary pattern;
LGG	cis	rs7633770	0.786	rs9845998	chr3:46683710	G/A	cg11219411	chr3:46661640	NA	0.59	14.09	0.55	9.38e-38	Coronary artery disease;
LGG	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.37	0.32	7.67e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2033732	0.955	rs2033731	chr8:85079720	T/G	cg05716166	chr8:85095498	RALYL	0.52	7.98	0.35	1.14e-14	Body mass index;
LGG	cis	rs17253792	0.822	rs78395034	chr14:56069783	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1348850	0.539	rs1453371	chr2:178227862	T/G	cg22681709	chr2:178499509	PDE11A	-0.39	-7.35	-0.32	9.1e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7635838	0.596	rs443503	chr3:11261912	A/T	cg00170343	chr3:11313890	ATG7	-0.43	-7.45	-0.33	4.53e-13	HDL cholesterol;
LGG	cis	rs4888262	0.545	rs7184754	chr16:74667864	C/T	cg01733217	chr16:74700730	RFWD3	0.91	18.98	0.66	7.66e-60	Testicular germ cell tumor;
LGG	cis	rs4474465	0.688	rs4457782	chr11:78284733	A/G	cg27205649	chr11:78285834	NARS2	0.58	10.77	0.45	2.68e-24	Alzheimer's disease (survival time);
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs8028182	0.577	rs8023268	chr15:75814672	A/T	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg07701084	chr6:150067640	NUP43	0.69	13.25	0.52	3.41e-34	Lung cancer;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg26513180	chr16:89883248	FANCA	0.83	8.63	0.37	9.61e-17	Skin colour saturation;
LGG	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg27490568	chr2:178487706	NA	0.47	9.21	0.39	1.15e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10267417	0.603	rs10273885	chr7:19911992	T/C	cg05791153	chr7:19748676	TWISTNB	0.56	7.46	0.33	4.27e-13	Night sleep phenotypes;
LGG	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg03805757	chr16:71968109	PKD1L3	-0.61	-7.5	-0.33	3.33e-13	Post bronchodilator FEV1;
LGG	trans	rs6582630	0.502	rs11614397	chr12:38328163	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.5	-0.4	1.12e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17445240	0.901	rs6754703	chr2:3707646	C/A	cg14882966	chr2:3699353	NA	0.79	8.52	0.37	2.21e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg07061783	chr6:25882402	NA	0.45	7.93	0.35	1.63e-14	Blood metabolite levels;
LGG	cis	rs6565180	0.507	rs4471699	chr16:30320307	G/T	cg17640201	chr16:30407289	ZNF48	-0.6	-10.91	-0.45	8.27e-25	Tonsillectomy;
LGG	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg18129748	chr3:49941408	MST1R	-0.22	-6.94	-0.31	1.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs7508	0.668	rs10087428	chr8:17918454	G/T	cg18067069	chr8:17937731	ASAH1	-0.36	-8.26	-0.36	1.51e-15	Atrial fibrillation;
LGG	cis	rs11252926	0.583	rs4881333	chr10:519164	G/C	cg16386425	chr10:429943	DIP2C	-0.45	-8.92	-0.38	1.08e-17	Psychosis in Alzheimer's disease;
LGG	cis	rs8180040	0.726	rs1869871	chr3:47023948	C/T	cg27129171	chr3:47204927	SETD2	0.81	14.87	0.57	3.75e-41	Colorectal cancer;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.47	10.06	0.42	1.2e-21	Schizophrenia;
LGG	cis	rs3741404	0.537	rs1123251	chr11:63917601	G/T	cg26318627	chr11:63887540	MACROD1	0.38	7.74	0.34	6.5e-14	Platelet count;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.2	-0.36	2.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.2e-15	Bipolar disorder;
LGG	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-8.81	-0.38	2.53e-17	Schizophrenia;
LGG	cis	rs11229555	0.645	rs4594017	chr11:58194788	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg00409905	chr10:38381863	ZNF37A	0.65	12.64	0.51	1.11e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs67460515	0.630	rs7638370	chr3:160921793	G/T	cg03342759	chr3:160939853	NMD3	-0.73	-12.17	-0.49	9.69e-30	Parkinson's disease;
LGG	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg03929089	chr4:120376271	NA	-0.68	-9.45	-0.4	1.71e-19	Axial length;
LGG	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-15.69	-0.59	8.14e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10791323	0.569	rs11223609	chr11:133741766	C/T	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs7647973	0.961	rs56324858	chr3:49544229	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-7.37	-0.32	7.86e-13	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.48	-0.5	4.96e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.595	rs1039033	chr6:101191397	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.37	-0.32	7.91e-13	Neuroticism;
LGG	cis	rs4237845	0.537	rs10877031	chr12:58266695	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	7.18	0.32	2.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg02725872	chr8:58115012	NA	-0.76	-11.34	-0.47	1.8e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7566780	0.631	rs7576783	chr2:16703441	C/T	cg09580478	chr2:16689509	NA	0.45	6.81	0.3	3.08e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs9354308	0.667	rs9294660	chr6:66585334	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs735539	0.521	rs1570672	chr13:21408818	C/T	cg04906043	chr13:21280425	IL17D	-0.47	-7.35	-0.32	8.8e-13	Dental caries;
LGG	cis	rs1368882	1.000	rs1368882	chr1:55107019	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.4	-7.68	-0.34	9.49e-14	Non-substance related behavioral disinhibition;
LGG	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg27398817	chr8:82754497	SNX16	-0.66	-10.38	-0.43	7.81e-23	Diastolic blood pressure;
LGG	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs4764124	0.646	rs2075268	chr12:14956476	A/G	cg19759883	chr12:14956454	WBP11;C12orf60	0.55	10.18	0.43	4.14e-22	Pubertal anthropometrics;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg03709012	chr19:19516395	GATAD2A	-0.84	-16.75	-0.61	1.47e-49	Tonsillectomy;
LGG	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs7953249	0.564	rs11065385	chr12:121423386	A/G	cg02403541	chr12:121454288	C12orf43	-0.5	-8.13	-0.35	3.98e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg11360546	chr7:1094263	C7orf50	-0.41	-7.27	-0.32	1.58e-12	Longevity;Endometriosis;
LGG	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg11764359	chr7:65958608	NA	0.79	14.76	0.57	1.07e-40	Aortic root size;
LGG	cis	rs72781680	1.000	rs72781654	chr2:24218099	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	8.17	0.35	3.05e-15	Lymphocyte counts;
LGG	cis	rs4595586	0.545	rs12819907	chr12:39356906	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.97	0.45	4.82e-25	Morning vs. evening chronotype;
LGG	cis	rs16973500	0.764	rs16973477	chr16:71887381	A/G	cg00732059	chr16:71740210	PHLPP2	-0.56	-9.54	-0.41	7.97e-20	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs9309473	0.950	rs13391258	chr2:73848933	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-7.25	-0.32	1.81e-12	Metabolite levels;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg00364696	chr7:1142433	C7orf50	-0.39	-7.65	-0.34	1.14e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12541335	0.639	rs35068739	chr8:22201719	T/C	cg18135555	chr8:22132992	PIWIL2	0.39	10.41	0.44	6.29e-23	Hypertriglyceridemia;
LGG	cis	rs4650994	0.593	rs2811297	chr1:178551472	C/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.5	-0.33	3.32e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg25703541	chr22:24373054	LOC391322	-0.87	-17.27	-0.63	6.18e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2247341	0.965	rs11736125	chr4:1744939	C/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.83	-0.51	1.81e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs3767633	0.925	rs10733044	chr1:161903534	A/G	cg09175582	chr1:161736000	ATF6	-0.73	-8.88	-0.38	1.52e-17	IgG glycosylation;
LGG	cis	rs9790314	0.779	rs1609688	chr3:160877096	T/G	cg04691961	chr3:161091175	C3orf57	-0.59	-12.9	-0.51	9.24e-33	Morning vs. evening chronotype;
LGG	cis	rs6547631	0.622	rs1561284	chr2:85924295	C/A	cg19805943	chr2:85933069	NA	0.32	6.69	0.3	6.34e-11	Blood protein levels;
LGG	cis	rs12200560	0.505	rs1334321	chr6:97079571	C/T	cg06623918	chr6:96969491	KIAA0776	-0.44	-7.39	-0.33	6.69e-13	Coronary heart disease;
LGG	cis	rs2073300	0.609	rs3827086	chr20:23357331	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01680999	chr16:18801770	RPS15A	0.43	6.77	0.3	3.86e-11	Cognitive performance;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.56	0.53	1.7000000000000001e-35	Lung cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13390998	chr8:145670370	NFKBIL2	-0.52	-7.8	-0.34	4.26e-14	Systemic lupus erythematosus;
LGG	cis	rs15676	1.000	rs10988125	chr9:131572903	A/G	cg04621255	chr9:131581398	ENDOG	-0.39	-7.06	-0.31	6.2e-12	Blood metabolite levels;
LGG	cis	rs12210905	1.000	rs72843608	chr6:27122750	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-7.86	-0.34	2.8e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2976388	0.967	rs2976395	chr8:143763750	G/A	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs2072732	0.861	rs72629497	chr1:2954123	T/C	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs769267	0.895	rs2965183	chr19:19545696	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.43	0.33	5.13e-13	Tonsillectomy;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.7	-0.34	8.36e-14	Menopause (age at onset);
LGG	cis	rs8013055	0.796	rs28662250	chr14:105996341	C/G	cg19700328	chr14:106028568	NA	-0.64	-10.21	-0.43	3.35e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs8028313	0.630	rs28418298	chr15:67935745	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.4	-7.64	-0.33	1.24e-13	Obesity;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.83	0.59	2.09e-45	Lung cancer;
LGG	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg27411982	chr8:10470053	RP1L1	0.48	8.25	0.36	1.62e-15	Joint mobility (Beighton score);
LGG	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg15823100	chr22:32027580	PISD	-0.72	-8.23	-0.36	1.89e-15	Age-related hearing impairment;
LGG	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg27471124	chr11:109292789	C11orf87	0.48	9.59	0.41	5.27e-20	Schizophrenia;
LGG	cis	rs17039065	0.920	rs11725920	chr4:109467939	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.19	0.32	2.55e-12	Gut microbiome composition (summer);
LGG	cis	rs10875595	0.691	rs1076361	chr5:140674609	C/T	cg24830062	chr5:140700576	TAF7	-0.57	-7.24	-0.32	1.91e-12	Pulmonary function decline;
LGG	cis	rs4689642	0.507	rs4689648	chr4:7221647	T/G	cg21353189	chr4:7228343	SORCS2	0.32	6.72	0.3	5.31e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs7192380	0.965	rs3848278	chr16:69640867	T/C	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.71	-0.34	7.8e-14	Sjögren's syndrome;
LGG	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg00571178	chr13:114841904	RASA3	-0.55	-9.92	-0.42	3.67e-21	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg18335740	chr13:41363409	SLC25A15	0.57	10.53	0.44	2.09e-23	Lewy body disease;
LGG	cis	rs3096299	0.838	rs2035481	chr16:89420356	A/C	cg02187348	chr16:89574699	SPG7	0.42	6.84	0.3	2.59e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs1008375	0.900	rs1003413	chr4:17582442	C/T	cg18681998	chr4:17616180	MED28	-0.8	-16.13	-0.6	9.17e-47	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg13607699	chr17:42295918	UBTF	-0.42	-6.69	-0.3	6.33e-11	Total body bone mineral density;
LGG	cis	rs972578	0.740	rs9611969	chr22:43336685	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.14	-0.32	3.6e-12	Mean platelet volume;
LGG	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg03959625	chr15:84868606	LOC388152	0.58	9.03	0.39	4.71e-18	Schizophrenia;
LGG	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg08975724	chr8:8085496	FLJ10661	0.35	6.65	0.3	8.22e-11	Joint mobility (Beighton score);
LGG	trans	rs8002861	0.870	rs2875541	chr13:44417441	G/T	cg17145862	chr1:211918768	LPGAT1	0.96	24.55	0.75	7.48e-86	Leprosy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00995327	chr3:142838847	CHST2	0.44	6.98	0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs6696846	0.765	rs2836	chr1:205111761	G/T	cg00857998	chr1:205179979	DSTYK	-0.58	-9.47	-0.4	1.47e-19	Red blood cell count;
LGG	cis	rs1580019	0.961	rs3801328	chr7:32496930	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs1982963	0.950	rs2645749	chr14:52502795	C/A	cg05884192	chr14:52515736	NID2	-0.34	-7.29	-0.32	1.37e-12	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3106136	0.967	rs2632399	chr4:95153741	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	3.84e-15	Capecitabine sensitivity;
LGG	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg16482183	chr6:26056742	HIST1H1C	0.75	12.69	0.51	6.95e-32	Height;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg08645402	chr16:4508243	NA	0.5	8.94	0.38	9.27e-18	Schizophrenia;
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.69	-0.34	8.84e-14	Schizophrenia;
LGG	cis	rs17767392	0.595	rs17109116	chr14:71651393	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.94	-0.31	1.32e-11	Mitral valve prolapse;
LGG	cis	rs6964587	0.773	rs17757926	chr7:91987702	T/C	cg17063962	chr7:91808500	NA	0.49	8.3	0.36	1.17e-15	Breast cancer;
LGG	cis	rs2153535	0.580	rs6937186	chr6:8494493	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.99	-0.42	2.07e-21	Morning vs. evening chronotype;
LGG	cis	rs7587476	1.000	rs3768707	chr2:215645135	C/T	cg04004882	chr2:215674386	BARD1	0.5	7.48	0.33	3.82e-13	Neuroblastoma;
LGG	cis	rs283228	0.605	rs1222265	chr6:101716901	A/G	cg27451362	chr6:101846650	GRIK2	0.92	13.13	0.52	1.1e-33	Coenzyme Q10 levels;
LGG	cis	rs9457247	1.000	rs413232	chr6:167400972	G/A	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg24441899	chr7:4244372	SDK1	-0.4	-8.24	-0.36	1.83e-15	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LGG	cis	rs4891159	0.757	rs11665018	chr18:74123589	C/T	cg24786174	chr18:74118243	ZNF516	-0.58	-13.52	-0.53	2.43e-35	Longevity;
LGG	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg00340584	chr1:149512963	NA	0.28	8.14	0.35	3.8e-15	Hip geometry;
LGG	cis	rs1801251	1.000	rs13035829	chr2:233604487	A/T	cg08000102	chr2:233561755	GIGYF2	0.56	9.16	0.39	1.67e-18	Coronary artery disease;
LGG	cis	rs910316	0.737	rs175045	chr14:75475275	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.41	-6.98	-0.31	1.06e-11	Height;
LGG	cis	rs2933343	0.729	rs789231	chr3:128602847	A/G	cg25356066	chr3:128598488	ACAD9	0.47	7.22	0.32	2.15e-12	IgG glycosylation;
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg04013166	chr16:89971882	TCF25	0.55	7.36	0.32	8.23e-13	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.67	0.54	5.62e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.76	0.3	4.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs283228	0.793	rs1231906	chr6:101717231	G/C	cg27451362	chr6:101846650	GRIK2	0.57	8.76	0.38	3.66e-17	Coenzyme Q10 levels;
LGG	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg27476859	chr7:2772710	GNA12	0.54	10.61	0.44	1.05e-23	Height;
LGG	cis	rs79839061	0.562	rs62294484	chr4:935571	A/G	cg07828340	chr4:882639	GAK	0.92	9.7	0.41	2.32e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs2279817	0.743	rs3766309	chr1:17977378	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.48	-8.49	-0.37	2.83e-16	Neuroticism;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-9.43	-0.4	1.96e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.65	0.37	8.76e-17	Obesity-related traits;
LGG	cis	rs17401966	1.000	rs17401966	chr1:10385471	C/T	cg15208524	chr1:10270712	KIF1B	-0.42	-7.11	-0.31	4.46e-12	Hepatocellular carcinoma;
LGG	cis	rs283228	0.798	rs283229	chr6:101754901	G/A	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.38e-23	Coenzyme Q10 levels;
LGG	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs4820539	1.000	rs3827316	chr22:23468538	T/C	cg14186256	chr22:23484241	RTDR1	1.0	25.33	0.76	1.85e-89	Bone mineral density;
LGG	cis	rs4319547	0.695	rs55834409	chr12:122862560	C/G	cg23029597	chr12:123009494	RSRC2	0.93	17.24	0.63	8.17e-52	Body mass index;
LGG	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg19524238	chr7:2802976	GNA12	0.33	8.07	0.35	6.29e-15	Height;
LGG	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg01557791	chr16:72042693	DHODH	0.57	10.42	0.44	5.38e-23	Fibrinogen levels;
LGG	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11764359	chr7:65958608	NA	0.56	9.57	0.41	6.56e-20	Aortic root size;
LGG	cis	rs6800768	0.633	rs6769403	chr3:24148622	T/C	cg10674438	chr3:24145617	LOC152024	-0.54	-9.56	-0.41	6.89e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6582630	0.502	rs1607867	chr12:38385463	C/T	cg13010199	chr12:38710504	ALG10B	0.69	14.13	0.55	6.05e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs240764	0.604	rs9404016	chr6:101177728	G/A	cg09795085	chr6:101329169	ASCC3	0.48	8.32	0.36	9.68e-16	Neuroticism;
LGG	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg18538332	chr22:24372958	LOC391322	0.45	7.48	0.33	3.88e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.42	-0.4	2.12e-19	Mood instability;
LGG	cis	rs10078	0.515	rs6872510	chr5:481610	T/C	cg07599136	chr5:415885	AHRR	0.84	11.27	0.46	3.49e-26	Fat distribution (HIV);
LGG	cis	rs11711311	0.869	rs12493635	chr3:113373019	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.44	0.5	7.46e-31	IgG glycosylation;
LGG	cis	rs888194	0.686	rs11067376	chr12:110027795	A/G	cg11367159	chr12:110044531	NA	0.27	6.77	0.3	3.83e-11	Neuroticism;
LGG	cis	rs67460515	0.529	rs6795586	chr3:160897701	A/C	cg03342759	chr3:160939853	NMD3	-0.58	-9.37	-0.4	3.15e-19	Parkinson's disease;
LGG	cis	rs11718455	0.960	rs13059547	chr3:44004492	G/A	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.63e-11	Coronary artery disease;
LGG	cis	rs4731207	0.698	rs6949341	chr7:124564176	C/A	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg05941027	chr17:61774174	LIMD2	0.34	8.31	0.36	1.04e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2180341	0.814	rs9401959	chr6:127736464	T/C	cg24812749	chr6:127587940	RNF146	0.7	11.18	0.46	7.77e-26	Breast cancer;
LGG	cis	rs9443645	0.901	rs4565265	chr6:79741958	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.5	-0.37	2.62e-16	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs56176527	chr11:70162513	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs68170813	0.559	rs76167266	chr7:106900664	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.63	-0.44	9.08e-24	Coronary artery disease;
LGG	cis	rs78456975	1.000	rs10177095	chr2:1570976	C/A	cg01028140	chr2:1542097	TPO	-0.52	-8.13	-0.35	3.86e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	cis	rs10929925	0.902	rs60358769	chr2:6156881	T/A	cg00493617	chr2:6141445	NA	0.32	7.36	0.32	8.63e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs8072100	0.576	rs12948299	chr17:45403057	T/C	cg08085267	chr17:45401833	C17orf57	-0.7	-13.04	-0.52	2.58e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg21775007	chr8:11205619	TDH	0.57	9.42	0.4	2.08e-19	Neuroticism;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg02158880	chr13:53174818	NA	0.43	8.55	0.37	1.84e-16	Lewy body disease;
LGG	cis	rs2708377	0.790	rs73051387	chr12:11314463	A/T	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.31	0.32	1.16e-12	Bitter taste perception;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg05665937	chr4:1216051	CTBP1	0.48	8.28	0.36	1.33e-15	Obesity-related traits;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg05335186	chr13:53173507	NA	0.43	8.56	0.37	1.73e-16	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07262328	chr11:35160709	CD44	0.48	7.92	0.35	1.72e-14	Cognitive performance;
LGG	cis	rs9948	1.000	rs62152794	chr2:97485110	T/C	cg01990225	chr2:97406019	LMAN2L	-0.61	-6.87	-0.3	2.02e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4474465	1.000	rs10751290	chr11:78192707	G/A	cg02023728	chr11:77925099	USP35	0.4	7.12	0.31	4.13e-12	Alzheimer's disease (survival time);
LGG	cis	rs754466	0.580	rs10762765	chr10:79566407	T/C	cg17075019	chr10:79541650	NA	-0.93	-19.77	-0.68	1.65e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7917772	0.582	rs7899004	chr10:104341435	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-10.32	-0.43	1.34e-22	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs62400317	0.859	rs12211519	chr6:45160530	C/A	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg15971980	chr6:150254442	NA	-0.45	-8.52	-0.37	2.27e-16	Lung cancer;
LGG	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.2	0.43	3.66e-22	Thyroid stimulating hormone;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.38e-12	Aortic root size;
LGG	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.67	-8.43	-0.36	4.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg26384229	chr12:38710491	ALG10B	0.6	11.22	0.46	5.38e-26	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs6669919	0.647	rs894985	chr1:211673760	A/G	cg10512769	chr1:211675356	NA	-0.57	-12.01	-0.49	4.21e-29	Intelligence (multi-trait analysis);
LGG	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14829155	chr15:31115871	NA	-0.67	-11.29	-0.46	2.74e-26	Huntington's disease progression;
LGG	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg24623649	chr8:11872141	NA	0.3	6.82	0.3	2.79e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg17178900	chr1:205818956	PM20D1	0.36	7.29	0.32	1.31e-12	Menarche (age at onset);
LGG	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg20283391	chr11:68216788	NA	-0.49	-8.13	-0.35	4.01e-15	Total body bone mineral density;
LGG	trans	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg24247370	chr13:99142703	STK24	-0.36	-6.65	-0.3	8.09e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6598955	0.724	rs884533	chr1:26585657	G/T	cg04990556	chr1:26633338	UBXN11	-0.68	-14.04	-0.55	1.49e-37	Obesity-related traits;
LGG	cis	rs8005677	0.798	rs4982711	chr14:23398990	T/G	cg25600027	chr14:23388339	RBM23	-0.43	-7.25	-0.32	1.72e-12	Cognitive ability (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06730340	chr3:9811714	CAMK1	0.49	7.39	0.32	7.01e-13	Gut microbiome composition (summer);
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg13628971	chr7:2884303	GNA12	-0.52	-10.7	-0.45	4.87e-24	Height;
LGG	cis	rs2124969	0.506	rs10497209	chr2:160985586	A/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-9.32	-0.4	4.7e-19	Waist circumference adjusted for body mass index;
LGG	cis	rs6450176	1.000	rs4588541	chr5:53300640	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.48	-0.47	5.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25072359	chr17:41440525	NA	0.53	10.2	0.43	3.57e-22	Menopause (age at onset);
LGG	cis	rs7241530	0.560	rs12956768	chr18:75890937	G/A	cg14642773	chr18:75888474	NA	0.45	8.94	0.38	9.4e-18	Educational attainment (years of education);
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	cis	rs4740619	0.525	rs10962171	chr9:15812829	G/A	cg14451791	chr9:16040625	NA	0.32	7.85	0.34	2.89e-14	Body mass index;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg12708336	chr17:41446283	NA	-0.32	-7.45	-0.33	4.59e-13	Menopause (age at onset);
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.78	0.45	2.45e-24	Personality dimensions;
LGG	cis	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg06481639	chr22:41940642	POLR3H	0.49	7.39	0.32	6.74e-13	Vitiligo;
LGG	cis	rs7444	0.941	rs5754344	chr22:21963786	A/G	cg11654148	chr22:21984483	YDJC	-0.4	-7.73	-0.34	6.79e-14	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.83	-0.51	1.9e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg25486957	chr4:152246857	NA	-0.52	-8.64	-0.37	9.02e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg15704280	chr7:45808275	SEPT13	-0.53	-8.91	-0.38	1.2e-17	HDL cholesterol;
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg10295955	chr4:187884368	NA	-1.12	-28.81	-0.8	2.7e-105	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs3942852	0.550	rs1113480	chr11:48058313	G/T	cg03929089	chr4:120376271	NA	-0.68	-9.83	-0.42	7.81e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg16850897	chr7:100343110	ZAN	-0.7	-10.39	-0.43	6.88e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4750440	0.540	rs11258766	chr10:14016196	G/A	cg27542038	chr10:14027202	FRMD4A	-0.74	-13.97	-0.54	3.03e-37	Adiponectin levels;
LGG	cis	rs9399137	0.507	rs13214669	chr6:135299959	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.47	0.44	3.51e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg11062466	chr8:58055876	NA	0.49	8.38	0.36	6.4e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04008888	chr11:68622739	NA	-0.55	-11.84	-0.48	1.87e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1595825	0.891	rs10497810	chr2:198895732	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs4595586	0.545	rs12823487	chr12:39391286	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs2976388	0.578	rs34956412	chr8:143822028	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-13.92	-0.54	4.98e-37	Urinary tract infection frequency;
LGG	cis	rs4689388	0.926	rs4458523	chr4:6289986	G/T	cg25554036	chr4:6271136	WFS1	-0.6	-11.3	-0.47	2.47e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9462027	0.628	rs2814968	chr6:34713138	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.2	-0.46	6.53e-26	Systemic lupus erythematosus;
LGG	cis	rs2239547	0.618	rs3733047	chr3:52871929	A/G	cg11645453	chr3:52864694	ITIH4	-0.73	-11.28	-0.46	3.03e-26	Schizophrenia;
LGG	trans	rs8002861	0.905	rs12874535	chr13:44433565	A/G	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.28	-0.7	1.45e-70	Leprosy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27524515	chr8:38239417	WHSC1L1	-0.49	-7.28	-0.32	1.42e-12	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.539	rs4843101	chr15:86339661	G/T	cg04173714	chr15:86211321	AKAP13	0.42	6.95	0.31	1.21e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20887711	chr4:1340912	KIAA1530	0.9	19.9	0.68	4.07e-64	Longevity;
LGG	trans	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg04568710	chr12:38710424	ALG10B	0.35	7.23	0.32	2.05e-12	Morning vs. evening chronotype;
LGG	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg19524238	chr7:2802976	GNA12	0.32	7.67	0.34	1.03e-13	Height;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.79	-0.34	4.41e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4780401	0.546	rs3743588	chr16:11836508	G/A	cg01061890	chr16:11836724	TXNDC11	0.71	11.37	0.47	1.37e-26	Rheumatoid arthritis;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.79	0.45	2.31e-24	Personality dimensions;
LGG	cis	rs13082711	0.522	rs515402	chr3:27331022	G/T	cg02860705	chr3:27208620	NA	0.6	11.39	0.47	1.11e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.39	7.06	0.31	6.2e-12	Longevity;
LGG	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg00204512	chr16:28754710	NA	0.25	7.01	0.31	8.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	12.51	0.5	3.97e-31	Obesity-related traits;
LGG	cis	rs4919694	0.572	rs12240508	chr10:104939232	G/A	cg04362960	chr10:104952993	NT5C2	0.89	13.75	0.54	2.69e-36	Arsenic metabolism;
LGG	cis	rs17767392	0.670	rs17767386	chr14:71748353	T/C	cg02058870	chr14:72053146	SIPA1L1	0.38	7.82	0.34	3.66e-14	Mitral valve prolapse;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg07414643	chr4:187882934	NA	0.5	9.76	0.41	1.34e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9952991	0.941	rs2014857	chr18:12774326	C/T	cg23598886	chr18:12777645	NA	0.74	10.39	0.43	7.14e-23	Inflammatory skin disease;
LGG	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg19980929	chr12:42632907	YAF2	0.36	7.99	0.35	1.11e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.75	-0.41	1.44e-20	Life satisfaction;
LGG	cis	rs2013441	1.000	rs2703810	chr17:20113715	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs782590	0.557	rs7592219	chr2:55887176	T/C	cg18811423	chr2:55921094	PNPT1	-0.66	-11.06	-0.46	2.16e-25	Metabolic syndrome;
LGG	cis	rs11583043	0.918	rs56402739	chr1:101397133	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	9.0	0.39	5.9e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs17209837	1.000	rs45546132	chr7:87086140	C/T	cg00919237	chr7:87102261	ABCB4	-0.73	-12.64	-0.51	1.16e-31	Gallbladder cancer;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg27524515	chr8:38239417	WHSC1L1	-0.43	-6.94	-0.31	1.3e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18252515	chr7:66147081	NA	-0.41	-6.9	-0.31	1.67e-11	Aortic root size;
LGG	cis	rs4696584	0.877	rs1907156	chr4:155384995	C/T	cg04517429	chr4:155413618	DCHS2	-0.34	-7.26	-0.32	1.68e-12	Folding of antihelix;
LGG	cis	rs4973397	0.765	rs2290130	chr2:232263127	G/A	cg11378575	chr2:232265004	B3GNT7	0.63	11.28	0.46	3.07e-26	Anti-saccade response;
LGG	cis	rs16854884	0.673	rs34379944	chr3:143785766	G/A	cg06585982	chr3:143692056	C3orf58	0.63	10.61	0.44	1.11e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs6429082	0.755	rs291370	chr1:235693041	A/G	cg26050004	chr1:235667680	B3GALNT2	0.7	12.12	0.49	1.54e-29	Adiposity;
LGG	cis	rs2084898	0.882	rs60336713	chr11:120054885	C/T	cg07435449	chr11:120005650	TRIM29	-0.66	-7.47	-0.33	4.08e-13	Stroke (pediatric);
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.88	0.42	5.07e-21	Prudent dietary pattern;
LGG	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.15	0.43	5.34e-22	Dupuytren's disease;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg19410845	chr2:84686791	SUCLG1	-0.41	-6.74	-0.3	4.69e-11	Height;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	14.46	0.56	2.2e-39	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg24247370	chr13:99142703	STK24	-0.38	-7.04	-0.31	7.07e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs41563	0.609	rs4727614	chr7:104600854	C/A	cg03782966	chr7:104585482	NA	0.32	7.12	0.31	4.17e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6838801	0.823	rs7677054	chr4:77594463	A/C	cg17476223	chr4:77663285	SHROOM3	0.37	6.7	0.3	5.99e-11	Cleft lip with or without cleft palate;
LGG	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.87	19.39	0.67	9.64e-62	Chronic sinus infection;
LGG	cis	rs9560113	0.724	rs4771755	chr13:112170900	G/A	cg14154082	chr13:112174009	NA	-0.37	-7.83	-0.34	3.45e-14	Menarche (age at onset);
LGG	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.68	0.41	2.73e-20	Blood metabolite levels;
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.13	-0.31	3.96e-12	Menopause (age at onset);
LGG	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg02711726	chr17:80685570	FN3KRP	-0.42	-8.34	-0.36	8.51e-16	Breast cancer;
LGG	trans	rs7762018	1.000	rs60253563	chr6:170083019	T/C	cg06875740	chr19:51307921	C19orf48	-0.69	-8.58	-0.37	1.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs209489	1.000	rs209513	chr6:53204727	C/T	cg15607103	chr6:53167650	ELOVL5	0.51	6.76	0.3	4.22e-11	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4740619	0.619	rs1359957	chr9:16044182	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.45	-0.47	6.65e-27	Body mass index;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.85	-8.64	-0.37	9.21e-17	Lung cancer in ever smokers;
LGG	cis	rs12210905	0.920	rs72839451	chr6:27265437	G/C	cg15325629	chr6:28072465	NA	0.85	6.73	0.3	5.1e-11	Hip circumference adjusted for BMI;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13097342	chr7:38217509	STARD3NL	0.4	6.85	0.3	2.32e-11	Bilirubin levels;
LGG	cis	rs4727027	0.933	rs6961605	chr7:148870108	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.77	0.3	4e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9916302	0.904	rs2024073	chr17:37471330	T/G	cg00129232	chr17:37814104	STARD3	0.61	11.55	0.47	2.7e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2594989	0.943	rs62245869	chr3:11439820	G/A	cg01796438	chr3:11312864	ATG7	-0.55	-7.4	-0.33	6.45e-13	Circulating chemerin levels;
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg08975724	chr8:8085496	FLJ10661	0.42	8.14	0.35	3.59e-15	Monocyte count;
LGG	trans	rs1814175	0.817	rs7946556	chr11:49944874	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.85	-0.78	1.84e-96	Height;
LGG	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg21479132	chr6:26055353	NA	0.77	7.14	0.31	3.6e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg05793240	chr7:2802953	GNA12	0.35	7.96	0.35	1.29e-14	Height;
LGG	cis	rs55665837	0.540	rs4144487	chr11:14750451	C/G	cg18937875	chr11:14930189	NA	-0.48	-7.83	-0.34	3.31e-14	Vitamin D levels;
LGG	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg00832555	chr3:169529716	LRRC34	-0.35	-7.3	-0.32	1.23e-12	Renal cell carcinoma;
LGG	cis	rs4901847	0.967	rs7492608	chr14:58554401	T/C	cg15908186	chr14:58618357	C14orf37	0.53	9.39	0.4	2.74e-19	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.55	-0.41	7.73e-20	Diabetic retinopathy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25161386	chr17:27621177	NUFIP2	0.41	7.36	0.32	8.47e-13	Obesity-related traits;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg01988459	chr11:68622903	NA	-0.62	-12.43	-0.5	8.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg18856731	chr12:58011764	NA	-0.35	-7.07	-0.31	5.81e-12	Multiple sclerosis;
LGG	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.25	0.43	2.33e-22	Cannabis dependence symptom count;
LGG	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg22681709	chr2:178499509	PDE11A	-0.52	-7.53	-0.33	2.59e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.41	-7.05	-0.31	6.39e-12	Menarche (age at onset);
LGG	cis	rs60180747	0.909	rs112095287	chr15:66792087	C/T	cg07575407	chr15:66541975	MEGF11	0.39	7.29	0.32	1.33e-12	Testicular germ cell tumor;
LGG	cis	rs8048589	0.515	rs12443524	chr16:12239979	A/G	cg02910054	chr16:12241554	SNX29	-0.67	-10.7	-0.45	5.17e-24	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg18402987	chr7:1209562	NA	0.65	9.09	0.39	2.87e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.94	-0.31	1.36e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg07274523	chr3:49395745	GPX1	0.57	9.66	0.41	3.08e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-8.0	-0.35	1e-14	Skin colour saturation;
LGG	cis	rs7178909	0.902	rs28372736	chr15:90437858	T/C	cg19708238	chr15:90437601	AP3S2	0.4	6.68	0.3	6.99e-11	Common traits (Other);
LGG	cis	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.4	-0.36	5.63e-16	Retinal vascular caliber;
LGG	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg21138405	chr5:131827807	IRF1	-0.39	-10.34	-0.43	1.05e-22	Asthma (sex interaction);
LGG	cis	rs9300255	0.602	rs1716177	chr12:123655457	C/T	cg05973401	chr12:123451056	ABCB9	0.51	7.38	0.32	7.45e-13	Neutrophil percentage of white cells;
LGG	cis	rs4740619	0.619	rs1410453	chr9:16042191	T/A	cg14451791	chr9:16040625	NA	-0.41	-10.96	-0.45	5.03e-25	Body mass index;
LGG	cis	rs10193935	0.901	rs997288	chr2:42525582	C/G	cg27598129	chr2:42591480	NA	-0.59	-8.86	-0.38	1.77e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4132509	1.000	rs7514984	chr1:243965623	C/T	cg21452805	chr1:244014465	NA	0.66	8.08	0.35	5.56e-15	RR interval (heart rate);
LGG	cis	rs1018836	0.798	rs4735295	chr8:91671608	C/A	cg16814680	chr8:91681699	NA	-1.01	-21.0	-0.7	2.71e-69	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.817	rs11833948	chr12:34276942	G/T	cg26384229	chr12:38710491	ALG10B	0.66	12.75	0.51	4.05e-32	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.5e-14	Bipolar disorder;
LGG	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg01620082	chr3:125678407	NA	-1.03	-9.58	-0.41	6e-20	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9921222	0.500	rs11645742	chr16:367516	C/T	cg07915516	chr16:377344	AXIN1	0.27	6.89	0.3	1.85e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg03806693	chr22:41940476	POLR3H	-0.79	-13.41	-0.53	7.43e-35	Vitiligo;
LGG	cis	rs12615966	1.000	rs9941579	chr2:105384506	C/T	cg16465502	chr2:105461796	NA	0.88	10.6	0.44	1.16e-23	Pancreatic cancer;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs17102884	0.506	rs887746	chr14:75403817	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.63	-11.6	-0.47	1.73e-27	Neuroticism;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg15971980	chr6:150254442	NA	0.46	8.53	0.37	2.11e-16	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06820286	chr22:29664179	EWSR1;RHBDD3	0.43	6.8	0.3	3.33e-11	Cognitive performance;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg02018176	chr4:1364513	KIAA1530	0.37	8.18	0.36	2.84e-15	Obesity-related traits;
LGG	cis	rs3206736	0.548	rs1186716	chr7:34970685	C/G	cg13400248	chr7:35225412	NA	0.53	9.25	0.39	8.18e-19	Diastolic blood pressure;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02470625	chr7:39453784	POU6F2	0.39	6.94	0.31	1.32e-11	Obesity-related traits;
LGG	cis	rs8017423	0.967	rs2277515	chr14:90723000	A/G	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.91	0.35	1.89e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2594989	0.943	rs9830784	chr3:11434605	A/G	cg01796438	chr3:11312864	ATG7	-0.55	-7.4	-0.33	6.2800000000000005e-13	Circulating chemerin levels;
LGG	cis	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10193935	1.000	rs10171023	chr2:42407093	G/C	cg27598129	chr2:42591480	NA	-0.62	-9.14	-0.39	1.92e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04735594	chr11:72853087	FCHSD2	0.59	6.67	0.3	7.25e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7215564	0.818	rs35929483	chr17:78635944	C/A	cg06153925	chr17:78755379	RPTOR	0.4	6.79	0.3	3.51e-11	Myopia (pathological);
LGG	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg06241208	chr11:30344200	C11orf46	-0.51	-6.79	-0.3	3.48e-11	Morning vs. evening chronotype;
LGG	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.2	-0.58	1.31e-42	Colorectal cancer;
LGG	cis	rs8133932	0.690	rs432338	chr21:47347757	C/T	cg11214348	chr21:47283868	PCBP3	-0.45	-7.88	-0.34	2.34e-14	Schizophrenia;
LGG	cis	rs4732038	0.510	rs28589907	chr7:134270567	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18876405	chr7:65276391	NA	0.55	9.78	0.41	1.19e-20	Aortic root size;
LGG	cis	rs2235642	0.671	rs2235641	chr16:1608177	A/G	cg04525384	chr16:1557733	TELO2	0.49	8.45	0.37	3.87e-16	Coronary artery disease;
LGG	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.65	-0.3	8.5e-11	Parkinson's disease;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8068544	0.818	rs8079958	chr17:40155467	C/T	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.99	-0.57	1.05e-41	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs9547692	0.878	rs9531990	chr13:37449605	T/C	cg02985381	chr13:37494744	SMAD9	0.7	12.05	0.49	2.79e-29	Coronary artery disease;
LGG	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg20503657	chr10:835505	NA	0.58	7.57	0.33	2.07e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg02836325	chr17:76403955	PGS1	-0.71	-14.52	-0.56	1.2e-39	HDL cholesterol levels;
LGG	cis	rs11630290	0.736	rs4777239	chr15:64148098	T/A	cg12036633	chr15:63758958	NA	0.55	6.75	0.3	4.36e-11	Iris characteristics;
LGG	cis	rs4901869	0.932	rs12878445	chr14:59339361	A/G	cg02291164	chr14:59296302	NA	0.27	6.79	0.3	3.37e-11	Panic disorder;
LGG	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg26769984	chr7:1090371	C7orf50	0.45	7.14	0.32	3.56e-12	Bronchopulmonary dysplasia;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg03806693	chr22:41940476	POLR3H	-1.04	-18.79	-0.66	5.86e-59	Vitiligo;
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.22	-0.32	2.11e-12	Bipolar disorder;
LGG	cis	rs9487051	1.000	rs9487048	chr6:109615603	G/T	cg21918786	chr6:109611834	NA	-0.44	-8.29	-0.36	1.2e-15	Reticulocyte fraction of red cells;
LGG	cis	rs7773004	0.936	rs6917995	chr6:26327814	T/C	cg00631329	chr6:26305371	NA	-0.39	-6.76	-0.3	4.06e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.92e-19	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10937275	0.793	rs35376159	chr3:186648929	T/A	cg13419791	chr3:186648285	ST6GAL1	0.79	8.09	0.35	5.38e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs236352	0.576	rs9380618	chr6:36853543	A/G	cg03410223	chr6:36853544	C6orf89	0.44	8.35	0.36	7.82e-16	Heart rate;
LGG	cis	rs611744	0.647	rs615233	chr8:109254262	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	cis	rs11748327	0.580	rs10064084	chr5:4012245	T/C	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.27e-12	Myocardial infarction;
LGG	cis	rs1978968	1.000	rs4410378	chr22:18451391	G/A	cg03078520	chr22:18463400	MICAL3	-0.63	-12.78	-0.51	3.09e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg13010199	chr12:38710504	ALG10B	0.57	10.97	0.45	4.83e-25	Morning vs. evening chronotype;
LGG	cis	rs1062753	0.922	rs9611712	chr22:42410993	T/C	cg15128208	chr22:42549153	NA	0.42	7.14	0.31	3.69e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs35771425	0.626	rs55761812	chr1:211653935	C/T	cg10512769	chr1:211675356	NA	-0.9	-18.69	-0.66	1.74e-58	Educational attainment (years of education);
LGG	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.5	9.56	0.41	7.12e-20	IgG glycosylation;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.91	19.35	0.67	1.51e-61	Personality dimensions;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg26656751	chr17:43910226	CRHR1	0.49	9.17	0.39	1.55e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.45	-0.37	3.71e-16	Mean corpuscular volume;
LGG	cis	rs6735179	0.565	rs73182756	chr2:1747826	A/G	cg10160682	chr2:1713001	PXDN	-0.55	-9.56	-0.41	7.02e-20	Response to antipsychotic treatment;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg15921436	chr17:44337874	NA	0.59	12.73	0.51	4.98e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg13206674	chr6:150067644	NUP43	0.69	15.99	0.6	3.82e-46	Lung cancer;
LGG	cis	rs9467160	0.765	rs793717	chr6:24444534	A/C	cg20631270	chr6:24437470	GPLD1	-0.52	-8.01	-0.35	9.49e-15	Liver enzyme levels;
LGG	cis	rs926938	0.501	rs360686	chr1:115502524	C/T	cg12756093	chr1:115239321	AMPD1	0.41	7.68	0.34	9.83e-14	Autism;
LGG	cis	rs2594989	0.943	rs2442785	chr3:11521828	C/T	cg01796438	chr3:11312864	ATG7	-0.55	-7.61	-0.33	1.6e-13	Circulating chemerin levels;
LGG	cis	rs929596	0.563	rs1105879	chr2:234602202	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.55	-9.25	-0.39	8.21e-19	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4566357	0.615	rs3769645	chr2:227913717	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.09	-0.39	2.85e-18	Coronary artery disease;
LGG	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11644478	chr21:40555479	PSMG1	0.93	17.8	0.64	2.24e-54	Cognitive function;
LGG	cis	rs8077889	0.763	rs4792913	chr17:41854497	T/C	cg26893861	chr17:41843967	DUSP3	1.06	24.3	0.75	1.13e-84	Triglycerides;
LGG	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg06623630	chr22:50017776	C22orf34	-0.36	-7.65	-0.33	1.18e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs3126085	0.935	rs1390485	chr1:152182168	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-8.38	-0.36	6.47e-16	Atopic dermatitis;
LGG	cis	rs12600053	0.687	rs8063190	chr16:84849280	C/T	cg09249803	chr16:84846936	NA	0.34	7.38	0.32	7.58e-13	Asthma (childhood onset);
LGG	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.42	-0.33	5.7e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1003719	0.591	rs2018521	chr21:38517264	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.65	-11.73	-0.48	5.22e-28	Eye color traits;
LGG	cis	rs4819852	0.752	rs2012714	chr22:19977647	C/T	cg07821417	chr22:19972146	ARVCF	0.53	11.29	0.46	2.93e-26	Pulse pressure;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.39e-13	Lung cancer;
LGG	cis	rs2046867	0.818	rs17010204	chr3:72879099	G/A	cg25664220	chr3:72788482	NA	-0.33	-9.25	-0.4	8.17e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs5015933	1.000	rs5015933	chr9:128137418	T/C	cg14078157	chr9:128172775	NA	-0.36	-6.79	-0.3	3.41e-11	Body mass index;
LGG	cis	rs7017914	0.967	rs7001162	chr8:71587470	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg17971929	chr21:40555470	PSMG1	0.85	16.26	0.6	2.34e-47	Cognitive function;
LGG	trans	rs116095464	0.558	rs73029475	chr5:206969	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	12.33	0.5	2.01e-30	Breast cancer;
LGG	cis	rs11711311	1.000	rs7622515	chr3:113472538	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.88	-0.34	2.32e-14	IgG glycosylation;
LGG	cis	rs6840360	0.554	rs61308159	chr4:152728941	G/A	cg22705602	chr4:152727874	NA	0.35	8.5	0.37	2.71e-16	Intelligence (multi-trait analysis);
LGG	trans	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.86	-0.42	6.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg04450456	chr4:17643702	FAM184B	0.32	6.87	0.3	2.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs701145	0.730	rs701141	chr3:154061053	G/A	cg17054900	chr3:154042577	DHX36	0.99	12.35	0.5	1.7e-30	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	1.000	rs8072225	chr17:65912960	A/G	cg12091567	chr17:66097778	LOC651250	-0.63	-9.15	-0.39	1.87e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs72781680	1.000	rs72798408	chr2:24181845	G/C	cg08917208	chr2:24149416	ATAD2B	0.93	10.17	0.43	4.43e-22	Lymphocyte counts;
LGG	cis	rs4517514	0.509	rs11018894	chr11:89904238	C/A	cg14505434	chr11:89522851	NA	0.61	7.84	0.34	3.2e-14	Trans fatty acid levels;
LGG	cis	rs1707322	0.686	rs2230658	chr1:46078854	A/G	cg03146154	chr1:46216737	IPP	-0.57	-10.96	-0.45	5.4e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs853679	0.517	rs56364346	chr6:28050762	T/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs11105298	0.891	rs10506972	chr12:89861529	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12130219	0.500	rs4845737	chr1:152177539	G/A	cg17718321	chr1:152188247	HRNR	-0.42	-8.71	-0.38	5.51e-17	Inflammatory skin disease;
LGG	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg12419862	chr22:24373484	LOC391322	0.88	13.34	0.53	1.42e-34	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2562456	0.917	rs6511256	chr19:21693315	G/T	cg00806126	chr19:22604979	ZNF98	0.63	9.4	0.4	2.48e-19	Pain;
LGG	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.73e-25	Hepatitis;
LGG	cis	rs2976388	0.507	rs7813604	chr8:143838062	G/A	cg07661805	chr8:143867942	LY6D	0.27	7.22	0.32	2.1e-12	Urinary tract infection frequency;
LGG	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.58	-9.19	-0.39	1.36e-18	Yeast infection;
LGG	cis	rs62238980	0.614	rs5998256	chr22:32549246	A/T	cg00543991	chr22:32367038	NA	0.72	8.41	0.36	5.21e-16	Childhood ear infection;
LGG	cis	rs12753569	0.748	rs6668566	chr1:76507675	C/G	cg00791851	chr1:76518896	NA	0.4	9.29	0.4	6.18e-19	Personality dimensions;
LGG	cis	rs919433	0.680	rs7582536	chr2:198436103	C/T	cg00792783	chr2:198669748	PLCL1	-0.5	-7.89	-0.34	2.26e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10791097	0.720	rs6590515	chr11:130733365	A/G	cg12179176	chr11:130786555	SNX19	-0.8	-16.24	-0.6	2.98e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg06889755	chr6:150326021	RAET1K	-0.4	-8.34	-0.36	8.67e-16	Alopecia areata;
LGG	cis	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg24189917	chr7:1970923	MAD1L1	-0.41	-6.66	-0.3	7.6e-11	Neuroticism;
LGG	cis	rs2236918	0.710	rs1635510	chr1:242027500	G/T	cg17736920	chr1:242011382	EXO1	0.39	7.1	0.31	4.81e-12	Menopause (age at onset);
LGG	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-10.0	-0.42	1.88e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	0.845	rs7501472	chr17:28010628	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.98	0.54	2.72e-37	Coffee consumption (cups per day);
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.32	0.47	2.09e-26	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16693212	chr11:108093249	ATM;NPAT	0.42	6.74	0.3	4.69e-11	Gut microbiome composition (summer);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg08808811	chr3:184079573	CLCN2	-0.4	-6.77	-0.3	3.95e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs644799	0.965	rs566877	chr11:95528045	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs61884328	0.777	rs17790342	chr11:47127706	G/A	cg03339077	chr11:47165057	C11orf49	0.63	6.85	0.3	2.32e-11	Total body bone mineral density (age over 60);
LGG	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg10911889	chr6:126070802	HEY2	0.44	7.58	0.33	1.86e-13	Brugada syndrome;
LGG	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.45	-0.44	4.43e-23	Chronic sinus infection;
LGG	cis	rs2084898	0.506	rs531260	chr11:120050515	C/T	cg07435449	chr11:120005650	TRIM29	0.74	14.02	0.55	1.84e-37	Stroke (pediatric);
LGG	trans	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg06521331	chr12:34319734	NA	-0.54	-9.43	-0.4	1.93e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg03264133	chr6:25882463	NA	-0.48	-7.73	-0.34	6.64e-14	Iron status biomarkers;
LGG	cis	rs9649465	1.000	rs627689	chr7:123400543	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.77	-0.38	3.45e-17	Migraine;
LGG	cis	rs4253772	0.550	rs6008600	chr22:46704676	A/G	cg24881330	chr22:46731750	TRMU	0.7	7.2	0.32	2.39e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs882632	0.668	rs35904647	chr2:29289703	G/A	cg23429306	chr2:29287725	C2orf71	0.41	8.37	0.36	6.95e-16	Major depressive disorder;
LGG	cis	rs17092148	1.000	rs1884432	chr20:33342439	A/G	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.72	-0.34	7.14e-14	Neuroticism;
LGG	cis	rs13314892	0.764	rs62251026	chr3:69862376	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.48	-7.81	-0.34	3.94e-14	Mean platelet volume;
LGG	cis	rs9549260	0.755	rs2721067	chr13:41156708	C/T	cg21288729	chr13:41239152	FOXO1	0.33	6.75	0.3	4.56e-11	Red blood cell count;
LGG	cis	rs17604090	0.793	rs17150665	chr7:29688860	T/G	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg21775007	chr8:11205619	TDH	0.5	8.35	0.36	7.79e-16	Mood instability;
LGG	cis	rs4689592	0.587	rs6825954	chr4:7074226	T/C	cg19539972	chr4:7069911	GRPEL1	0.77	10.79	0.45	2.27e-24	Monocyte percentage of white cells;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13169525	chr11:126081998	RPUSD4;FAM118B	-0.4	-6.68	-0.3	7.04e-11	Pancreatic cancer;
LGG	cis	rs9522267	0.535	rs7323631	chr13:112232269	A/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.98e-25	Hepatitis;
LGG	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.17	0.39	1.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2617583	0.967	rs2937640	chr5:1443604	C/T	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.13	-0.31	3.76e-12	Breast cancer;
LGG	cis	rs1153858	1.000	rs2461701	chr15:45703391	G/A	cg10760299	chr15:45669010	GATM	0.41	7.98	0.35	1.15e-14	Homoarginine levels;
LGG	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.07	-0.31	5.59e-12	Iron status biomarkers;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.25	-0.36	1.62e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10818894	0.772	rs10120705	chr9:126692600	T/G	cg16191174	chr9:126692580	DENND1A	0.62	8.95	0.38	8.31e-18	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LGG	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg03453431	chr7:157225567	NA	0.5	8.58	0.37	1.5e-16	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7914558	0.966	rs10883805	chr10:104708251	T/C	cg04362960	chr10:104952993	NT5C2	0.54	10.24	0.43	2.46e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4969178	0.965	rs11077362	chr17:76397219	A/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs7084402	0.967	rs1303968	chr10:60298941	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.7e-13	Refractive error;
LGG	cis	rs4076764	1.000	rs7525643	chr1:163426283	G/A	cg06092702	chr1:163392909	NA	-0.46	-8.29	-0.36	1.23e-15	Motion sickness;
LGG	cis	rs10046574	0.519	rs112479683	chr7:135203288	G/A	cg27474649	chr7:135195673	CNOT4	0.73	9.11	0.39	2.56e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9325144	0.555	rs1813392	chr12:38692203	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.05	-0.39	4.01e-18	Morning vs. evening chronotype;
LGG	cis	rs1003719	0.680	rs2154537	chr21:38502012	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.75	-14.21	-0.55	2.85e-38	Eye color traits;
LGG	cis	rs4363385	0.510	rs61811886	chr1:153035743	G/A	cg13444842	chr1:152974279	SPRR3	-0.47	-9.21	-0.39	1.11e-18	Inflammatory skin disease;
LGG	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	9.04	0.39	4.29e-18	Colorectal cancer;
LGG	cis	rs11809207	0.523	rs2186232	chr1:26502676	T/A	cg26412358	chr1:26503933	CNKSR1	0.29	7.36	0.32	8.46e-13	Height;
LGG	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs4742903	0.935	rs7872034	chr9:106896809	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.2	0.36	2.31e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	3.05e-31	Motion sickness;
LGG	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1983891	1.000	rs4714486	chr6:41542417	C/T	cg20194872	chr6:41519635	FOXP4	0.6	10.3	0.43	1.58e-22	Prostate cancer;
LGG	cis	rs6541297	1.000	rs6681042	chr1:230278979	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg03806693	chr22:41940476	POLR3H	0.93	16.89	0.62	3.26e-50	Vitiligo;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07699235	chr13:39260309	FREM2	-0.45	-6.66	-0.3	7.81e-11	Systemic lupus erythematosus;
LGG	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg00898013	chr13:113819073	PROZ	0.42	8.49	0.37	2.77e-16	Platelet distribution width;
LGG	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs4665809	1.000	rs6546768	chr2:26328800	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg07395648	chr5:131743802	NA	-0.55	-13.18	-0.52	6.52e-34	Blood metabolite levels;
LGG	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.68	-0.37	7e-17	Mean corpuscular volume;
LGG	trans	rs9354308	0.764	rs9342506	chr6:66581774	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.09	-0.31	5.16e-12	Metabolite levels;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg04248157	chr5:169930938	KCNIP1	-0.42	-6.69	-0.3	6.44e-11	Alzheimer's disease (survival time);
LGG	cis	rs7945718	0.621	rs4370915	chr11:12664998	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.26	0.32	1.7e-12	Educational attainment (years of education);
LGG	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.2e-18	Myopia (pathological);
LGG	cis	rs28735056	0.967	rs56328473	chr18:77636101	C/T	cg20368463	chr18:77673604	PQLC1	-0.49	-8.27	-0.36	1.47e-15	Schizophrenia;
LGG	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs7715806	0.500	rs17649248	chr5:74998426	C/T	cg19683494	chr5:74908142	NA	0.51	6.85	0.3	2.38e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg04861929	chr11:109293070	C11orf87	0.52	9.08	0.39	3.23e-18	Schizophrenia;
LGG	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg12386194	chr3:101231763	SENP7	0.43	7.55	0.33	2.42e-13	Colorectal cancer;
LGG	cis	rs9486719	1.000	rs3798295	chr6:97052164	C/T	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.8	-0.3	3.2e-11	Migraine;Coronary artery disease;
LGG	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg05444541	chr17:17804740	TOM1L2	-0.42	-9.02	-0.39	5.11e-18	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	11.08	0.46	1.78e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7737355	0.812	rs6881486	chr5:130793836	C/T	cg06307176	chr5:131281290	NA	-0.51	-8.51	-0.37	2.42e-16	Life satisfaction;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.44	-9.43	-0.4	2.06e-19	Schizophrenia;
LGG	cis	rs3857067	0.869	rs6837655	chr4:95051742	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.65	-0.33	1.18e-13	QT interval;
LGG	cis	rs5758511	0.773	rs7288749	chr22:42356430	C/T	cg15128208	chr22:42549153	NA	0.61	9.92	0.42	3.55e-21	Birth weight;
LGG	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg14228332	chr4:119757509	SEC24D	0.97	10.1	0.42	8.57e-22	Cannabis dependence symptom count;
LGG	cis	rs2075371	0.897	rs1646743	chr7:134003451	C/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.02	0.52	3.04e-33	Mean platelet volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24452005	chr18:9913478	VAPA	0.44	7.05	0.31	6.51e-12	Cognitive performance;
LGG	cis	rs6489785	0.522	rs2701177	chr12:121344490	G/T	cg02419362	chr12:121203948	SPPL3	-0.5	-8.72	-0.38	5.03e-17	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1059312	1.000	rs7135854	chr12:129279988	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.8	-18.12	-0.64	7.21e-56	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs3743104	1.000	rs17816260	chr15:33023685	A/C	cg07179000	chr15:33023586	GREM1	-0.5	-9.73	-0.41	1.75e-20	Hypospadias;
LGG	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.8	-0.38	2.67e-17	Response to antipsychotic treatment;
LGG	cis	rs35306767	0.903	rs61830933	chr10:934195	G/A	cg25019033	chr10:957182	NA	-0.55	-9.11	-0.39	2.42e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2235573	0.662	rs2018980	chr22:38450620	A/G	cg19171272	chr22:38449367	NA	-0.63	-12.92	-0.51	7.63e-33	Glioblastoma;Glioma;
LGG	trans	rs3960554	0.569	rs10464565	chr7:75869526	T/G	cg19862616	chr7:65841803	NCRNA00174	0.62	10.13	0.43	6.36e-22	Eotaxin levels;
LGG	cis	rs314370	1.000	rs10278546	chr7:100516003	G/T	cg10426581	chr7:100472382	SRRT	-0.48	-6.88	-0.3	1.96e-11	Resting heart rate;
LGG	cis	rs17376456	1.000	rs12188453	chr5:93560807	G/T	cg25358565	chr5:93447407	FAM172A	-1.36	-16.52	-0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs10927875	0.557	rs1572381	chr1:16344494	G/A	cg21385522	chr1:16154831	NA	0.44	7.14	0.31	3.75e-12	Dilated cardiomyopathy;
LGG	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	10.98	0.45	4.24e-25	Response to antipsychotic treatment;
LGG	cis	rs1784581	0.569	rs9364629	chr6:162416831	T/G	cg17173639	chr6:162384350	PARK2	0.64	13.44	0.53	5.4e-35	Itch intensity from mosquito bite;
LGG	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.59	0.33	1.72e-13	Joint mobility (Beighton score);
LGG	cis	rs75920871	0.800	rs6589595	chr11:116981335	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-6.74	-0.3	4.77e-11	Subjective well-being;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10041390	chr10:89623018	PTEN;KILLIN	-0.4	-6.7	-0.3	6.18e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.42	6.97	0.31	1.08e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7119	0.717	rs12910512	chr15:77817253	C/A	cg10437265	chr15:77819839	NA	0.26	7.38	0.32	7.16e-13	Type 2 diabetes;
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00292662	chr22:38071168	LGALS1	0.89	24.24	0.75	2.1e-84	Fat distribution (HIV);
LGG	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg07061783	chr6:25882402	NA	-0.44	-7.52	-0.33	2.9e-13	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg16141378	chr3:129829833	LOC729375	0.39	8.98	0.39	6.59e-18	Neuroticism;
LGG	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.4	0.33	6.33e-13	Hair morphology;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg06916706	chr16:4465613	CORO7	-0.71	-12.24	-0.49	4.9e-30	Schizophrenia;
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg06558623	chr16:89946397	TCF25	1.04	13.26	0.52	3.07e-34	Skin colour saturation;
LGG	cis	rs888194	0.714	rs7308864	chr12:109871179	A/G	cg19025524	chr12:109796872	NA	-0.37	-7.33	-0.32	1.01e-12	Neuroticism;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.54e-12	Lung cancer;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.57	0.37	1.54e-16	Alzheimer's disease;
LGG	cis	rs503734	0.521	rs348884	chr3:100975293	C/G	cg27318481	chr3:100970896	IMPG2	-0.57	-13.13	-0.52	1.09e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs71403859	0.803	rs34381861	chr16:71640230	T/C	cg08717414	chr16:71523259	ZNF19	-1.15	-14.83	-0.57	5.23e-41	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg16507663	chr6:150244633	RAET1G	0.44	7.15	0.32	3.49e-12	Lung cancer;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35740288	0.787	rs35250181	chr15:86242662	T/G	cg04173714	chr15:86211321	AKAP13	0.46	7.85	0.34	2.85e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4889911	1.000	rs4889910	chr17:77839795	C/T	cg07923794	chr17:77834237	NA	-0.58	-7.41	-0.33	5.84e-13	Electroencephalogram traits;
LGG	cis	rs8078723	0.714	rs8070444	chr17:38151960	A/G	cg17467752	chr17:38218738	THRA	-0.61	-11.06	-0.46	2.09e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg09307838	chr4:120376055	NA	0.7	11.28	0.46	2.99e-26	Corneal astigmatism;
LGG	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs2916247	0.954	rs7839381	chr8:93158296	T/C	cg10183463	chr8:93005414	RUNX1T1	0.38	7.92	0.35	1.84e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Schizophrenia;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	0.657	rs116217838	chr2:1569173	T/C	cg12573674	chr2:1569213	NA	-0.64	-10.0	-0.42	1.97e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg00149659	chr3:10157352	C3orf10	0.85	10.83	0.45	1.7e-24	Alzheimer's disease;
LGG	cis	rs1670533	1.000	rs2290408	chr4:1067267	A/C	cg27284194	chr4:1044797	NA	-0.55	-9.89	-0.42	4.55e-21	Recombination rate (females);
LGG	cis	rs7188861	0.592	rs1794022	chr16:11376446	A/G	cg01510278	chr16:11456238	NA	0.28	6.77	0.3	3.79e-11	HDL cholesterol;
LGG	cis	rs7100689	0.622	rs2342816	chr10:82086546	G/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.65	0.56	3.21e-40	Post bronchodilator FEV1;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02083259	chr16:57220135	RSPRY1;FAM192A	-0.41	-6.83	-0.3	2.72e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.76	-0.34	5.5e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg10840412	chr1:235813424	GNG4	0.5	6.73	0.3	5.14e-11	Bipolar disorder;
LGG	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg05425664	chr17:57184151	TRIM37	-0.45	-7.11	-0.31	4.37e-12	Testicular germ cell tumor;
LGG	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg01493522	chr13:37497338	NA	0.53	9.31	0.4	5.26e-19	Coronary artery disease;
LGG	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg13628971	chr7:2884303	GNA12	-0.33	-7.04	-0.31	7.04e-12	Plateletcrit;
LGG	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17376030	chr22:41985996	PMM1	-0.56	-8.97	-0.38	7.17e-18	Vitiligo;
LGG	cis	rs459571	0.959	rs392134	chr9:136909008	G/A	cg13789015	chr9:136890014	NCRNA00094	0.58	10.93	0.45	6.91e-25	Platelet distribution width;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00018557	chr17:43238884	HEXIM2	-0.44	-7.1	-0.31	4.64e-12	Pancreatic cancer;
LGG	cis	rs11190604	1.000	rs2495732	chr10:102357780	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.61	0.47	1.58e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9916302	0.706	rs8073907	chr17:37424149	C/T	cg00129232	chr17:37814104	STARD3	-0.56	-8.44	-0.37	4.22e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg18681998	chr4:17616180	MED28	0.85	18.9	0.66	1.81e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6840360	0.573	rs4696250	chr4:152266321	T/C	cg25486957	chr4:152246857	NA	-0.41	-7.26	-0.32	1.61e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13012494	chr21:47604986	C21orf56	0.5	8.55	0.37	1.84e-16	Testicular germ cell tumor;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00752047	chr12:110785080	ATP2A2	0.41	6.98	0.31	1.02e-11	Pancreatic cancer;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg06221963	chr1:154839813	KCNN3	-0.49	-9.88	-0.42	5.27e-21	Prostate cancer;
LGG	trans	rs73191547	0.782	rs59255182	chr8:10040205	T/C	cg16141378	chr3:129829833	LOC729375	-0.3	-6.65	-0.3	8.17e-11	Schizophrenia;
LGG	cis	rs11758351	0.500	rs74660303	chr6:26183710	C/T	cg02612650	chr6:26195910	NA	0.88	6.84	0.3	2.54e-11	Gout;Renal underexcretion gout;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg15556689	chr8:8085844	FLJ10661	0.41	7.24	0.32	1.92e-12	Neuroticism;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-7.31	-0.32	1.19e-12	Obesity-related traits;
LGG	cis	rs35306767	0.714	rs12777800	chr10:1070361	G/A	cg20503657	chr10:835505	NA	0.52	6.91	0.31	1.6e-11	Eosinophil percentage of granulocytes;
LGG	trans	rs11976180	1.000	rs13226728	chr7:143746578	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.9	-0.31	1.7e-11	Obesity-related traits;
LGG	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg25664220	chr3:72788482	NA	-0.33	-8.99	-0.39	6.23e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.97	0.52	4.72e-33	Prudent dietary pattern;
LGG	cis	rs7226408	0.857	rs11664211	chr18:34461496	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6840360	0.571	rs62327270	chr4:152533618	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2463822	0.669	rs72919493	chr11:62049651	C/A	cg06239285	chr11:62104954	ASRGL1	-1.12	-13.53	-0.53	2.16e-35	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2952156	0.920	rs2934953	chr17:37832315	T/A	cg00129232	chr17:37814104	STARD3	-0.7	-14.12	-0.55	6.97e-38	Asthma;
LGG	cis	rs600231	0.706	rs10896016	chr11:65335705	C/T	cg17120908	chr11:65337727	SSSCA1	0.62	11.17	0.46	8.14e-26	Bone mineral density;
LGG	cis	rs13190036	1.000	rs71601343	chr5:176632107	G/A	cg06733329	chr5:176740039	MXD3	0.48	6.72	0.3	5.4e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs4909189	0.957	rs71547529	chr7:158135469	G/T	cg25566285	chr7:158114605	PTPRN2	0.69	11.55	0.47	2.83e-27	Response to amphetamines;
LGG	cis	rs4478858	0.735	rs7547897	chr1:31797593	G/A	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.23e-11	Alcohol dependence;
LGG	cis	rs283228	0.958	rs2787583	chr6:101814411	A/G	cg27451362	chr6:101846650	GRIK2	0.54	9.04	0.39	4.2e-18	Coenzyme Q10 levels;
LGG	cis	rs12188164	0.686	rs11741946	chr5:421403	G/A	cg26076054	chr5:421317	AHRR	-0.52	-8.23	-0.36	1.91e-15	Cystic fibrosis severity;
LGG	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg12193833	chr17:30244370	NA	-0.29	-6.94	-0.31	1.31e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.14e-12	Electroencephalogram traits;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg01673284	chr16:4527211	HMOX2	0.35	7.09	0.31	4.99e-12	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	trans	rs61931739	0.513	rs10743833	chr12:33897481	C/T	cg13010199	chr12:38710504	ALG10B	0.46	8.45	0.37	3.78e-16	Morning vs. evening chronotype;
LGG	cis	rs3806843	0.966	rs2337516	chr5:140140853	A/G	cg19875535	chr5:140030758	IK	-0.53	-10.93	-0.45	6.93e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.84	-16.47	-0.61	2.54e-48	Hip circumference adjusted for BMI;
LGG	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg18854424	chr1:2615690	NA	0.32	6.7	0.3	6.25e-11	Ulcerative colitis;
LGG	cis	rs208520	0.874	rs208485	chr6:66925654	T/C	cg07460842	chr6:66804631	NA	-0.94	-16.15	-0.6	7.64e-47	Exhaled nitric oxide output;
LGG	cis	rs308971	0.563	rs217049	chr3:12060917	C/T	cg15873301	chr3:12045459	SYN2	0.55	7.13	0.31	3.95e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg12458913	chr13:53173898	NA	0.56	10.02	0.42	1.55e-21	Lewy body disease;
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg02002194	chr4:3960332	NA	-0.39	-6.69	-0.3	6.6e-11	Neuroticism;
LGG	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	trans	rs12517041	0.935	rs1835047	chr5:23296627	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.03e-25	Calcium levels;
LGG	cis	rs6809651	0.524	rs56940353	chr3:185798296	T/C	cg00760338	chr3:185826511	ETV5	-0.92	-15.29	-0.58	5.03e-43	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs526231	0.543	rs4386712	chr5:102369234	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	trans	rs6582630	0.555	rs2387598	chr12:38510472	G/A	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.25e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg03060546	chr3:49711283	APEH	-0.54	-7.11	-0.31	4.31e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg06916706	chr16:4465613	CORO7	-0.71	-12.36	-0.5	1.63e-30	Schizophrenia;
LGG	cis	rs4969178	0.896	rs11077361	chr17:76397128	A/G	cg05887092	chr17:76393375	PGS1	0.72	15.81	0.59	2.51e-45	HDL cholesterol levels;
LGG	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.99	0.39	6.3e-18	Systolic blood pressure;
LGG	cis	rs870825	0.616	rs7658186	chr4:185622509	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.71	0.73	2.88e-77	Blood protein levels;
LGG	cis	rs35306767	0.714	rs12767171	chr10:1084491	A/G	cg25019033	chr10:957182	NA	-0.45	-8.83	-0.38	2.16e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg00343986	chr7:65444356	GUSB	0.39	6.69	0.3	6.5e-11	Aortic root size;
LGG	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.52	0.56	1.19e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9811920	0.809	rs6440967	chr3:99722396	G/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	8.6	0.37	1.24e-16	Axial length;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg02951883	chr7:2050386	MAD1L1	-0.66	-13.03	-0.52	2.7e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs4655582	0.510	rs11208700	chr1:66133443	A/T	cg04111102	chr1:66153794	NA	0.26	6.78	0.3	3.65e-11	Fibrinogen levels;
LGG	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg06766960	chr11:133703094	NA	-0.58	-11.53	-0.47	3.19e-27	Childhood ear infection;
LGG	cis	rs2635047	0.615	rs1512238	chr18:44748467	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.61	0.33	1.53e-13	Educational attainment;
LGG	cis	rs11967485	0.609	rs73007008	chr6:157222269	A/T	cg23222435	chr6:157204239	ARID1B	-0.86	-7.2	-0.32	2.48e-12	Calcium levels;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.71e-15	Obesity-related traits;
LGG	cis	rs2404602	0.684	rs2047504	chr15:76883516	A/T	cg23625390	chr15:77176239	SCAPER	-0.71	-13.91	-0.54	5.35e-37	Blood metabolite levels;
LGG	cis	rs11711311	1.000	rs9863050	chr3:113508888	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.17e-34	IgG glycosylation;
LGG	cis	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg04568710	chr12:38710424	ALG10B	0.38	8.22	0.36	2.1e-15	Heart rate;
LGG	cis	rs250677	1.000	rs250677	chr5:148433549	T/C	cg18129178	chr5:148520854	ABLIM3	-0.43	-7.8	-0.34	4.21e-14	Breast cancer;
LGG	cis	rs77372450	0.636	rs10072471	chr5:157022207	G/C	cg25387487	chr5:157003181	ADAM19	-0.56	-6.98	-0.31	1.01e-11	Bipolar disorder (body mass index interaction);
LGG	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs17767392	0.958	rs4899398	chr14:72083441	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.48	-0.4	1.37e-19	Mitral valve prolapse;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.967	rs9656003	chr7:91766322	A/C	cg17063962	chr7:91808500	NA	0.53	9.76	0.41	1.38e-20	Breast cancer;
LGG	cis	rs10861342	1.000	rs73395802	chr12:105588718	T/C	cg23923672	chr12:105501055	KIAA1033	0.8	7.23	0.32	1.95e-12	IgG glycosylation;
LGG	cis	rs7773004	1.000	rs1155207	chr6:26328365	A/G	cg13736514	chr6:26305472	NA	-0.42	-8.52	-0.37	2.21e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs1978968	0.556	rs5992962	chr22:18486282	A/G	cg03078520	chr22:18463400	MICAL3	-0.49	-10.42	-0.44	5.57e-23	Presence of antiphospholipid antibodies;
LGG	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22857025	chr5:266934	NA	-1.49	-26.19	-0.77	2.12e-93	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00020052	chr2:68546899	CNRIP1	0.47	7.4	0.33	6.39e-13	Gut microbiome composition (summer);
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.21	-0.36	2.28e-15	Testicular germ cell tumor;
LGG	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.22	-0.46	5.34e-26	Morning vs. evening chronotype;
LGG	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	trans	rs7937682	0.855	rs490897	chr11:111487914	A/G	cg18187862	chr3:45730750	SACM1L	0.58	9.49	0.4	1.27e-19	Primary sclerosing cholangitis;
LGG	cis	rs10865541	0.902	rs12474836	chr2:3418874	A/G	cg11642891	chr2:3452563	TTC15	-0.47	-9.48	-0.4	1.37e-19	Obesity-related traits;
LGG	cis	rs7851660	0.809	rs12004762	chr9:100652755	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.76	-0.51	3.55e-32	Strep throat;
LGG	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.39e-13	Uric acid levels;
LGG	cis	rs1971762	0.563	rs4759279	chr12:54064888	C/T	cg06632207	chr12:54070931	ATP5G2	0.24	7.42	0.33	5.73e-13	Height;
LGG	cis	rs11169552	0.580	rs4768913	chr12:51135956	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.47	-0.33	4.06e-13	Colorectal cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg25450986	chr17:38574356	TOP2A	0.4	6.72	0.3	5.39e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.13	0.31	3.9e-12	Schizophrenia;
LGG	cis	rs7818345	0.967	rs11787230	chr8:19280982	C/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.72	0.3	5.26e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg10756647	chr7:56101905	PSPH	0.82	10.17	0.43	4.7e-22	Diabetic kidney disease;
LGG	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	12.93	0.52	7.12e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10782582	0.593	rs11164042	chr1:76178440	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-7.05	-0.31	6.52e-12	Daytime sleep phenotypes;
LGG	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.3	0.4	5.73e-19	Gout;Renal underexcretion gout;
LGG	trans	rs11098499	0.954	rs10006877	chr4:120242793	C/T	cg25214090	chr10:38739885	LOC399744	0.68	12.03	0.49	3.38e-29	Corneal astigmatism;
LGG	cis	rs3008870	1.000	rs1137656	chr1:67451602	A/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs11190604	1.000	rs10883497	chr10:102228519	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	10.91	0.45	7.8e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.6	-0.44	1.23e-23	Pancreatic cancer;
LGG	trans	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.53	9.84	0.42	6.99e-21	Brugada syndrome;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2249625	0.545	rs2249021	chr6:72889472	A/G	cg27608224	chr6:72922399	RIMS1	0.32	7.21	0.32	2.35e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs1620921	0.840	rs783178	chr6:161169739	C/T	cg01280913	chr6:161186852	NA	-0.35	-7.2	-0.32	2.48e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg05863683	chr7:1912471	MAD1L1	0.39	7.67	0.34	1.06e-13	Schizophrenia;
LGG	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27297192	chr10:134578999	INPP5A	0.26	6.66	0.3	7.79e-11	Migraine;
LGG	cis	rs3735485	0.760	rs28700899	chr7:45083065	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9964724	0.559	rs72893190	chr18:35174815	A/G	cg27332583	chr18:35150602	NA	0.62	11.93	0.48	8.51e-29	Educational attainment (years of education);
LGG	cis	rs8030485	1.000	rs28652642	chr15:79411180	G/A	cg17916960	chr15:79447300	NA	0.41	6.99	0.31	9.35e-12	Left ventricle wall thickness;
LGG	cis	rs283228	0.617	rs542820	chr6:101740930	G/A	cg27451362	chr6:101846650	GRIK2	0.84	13.15	0.52	8.66e-34	Coenzyme Q10 levels;
LGG	cis	rs4794202	0.579	rs9896712	chr17:45884543	G/A	cg02219949	chr17:45927392	SP6	0.53	7.4	0.33	6.5e-13	Alzheimer's disease (cognitive decline);
LGG	cis	rs2030746	0.521	rs2311598	chr2:121331102	A/G	cg03661458	chr2:121334411	NA	-0.42	-10.81	-0.45	1.96e-24	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06028808	chr11:68637592	NA	0.74	12.29	0.5	3.14e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12586317	0.547	rs116499019	chr14:35441931	T/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.63	-0.33	1.33e-13	Psoriasis;
LGG	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.54	-0.37	1.91e-16	Retinal vascular caliber;
LGG	cis	rs612683	0.517	rs3767832	chr1:100943100	A/G	cg09408571	chr1:101003634	GPR88	-0.3	-7.63	-0.33	1.39e-13	Breast cancer;
LGG	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg08807101	chr21:30365312	RNF160	-0.8	-15.72	-0.59	6.07e-45	Dental caries;
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg22968622	chr17:43663579	NA	1.07	20.67	0.69	9.64e-68	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3793683	0.520	rs12769959	chr10:134579026	A/C	cg13271783	chr10:134563150	INPP5A	-0.53	-8.21	-0.36	2.22e-15	Migraine;
LGG	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg20703242	chr1:230279135	GALNT2	0.37	7.55	0.33	2.31e-13	Coronary artery disease;
LGG	cis	rs1062746	0.582	rs8050303	chr16:87375753	T/C	cg02258303	chr16:87377426	FBXO31	-0.59	-11.45	-0.47	6.89e-27	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs7737355	0.812	rs6891387	chr5:130765917	G/C	cg06307176	chr5:131281290	NA	-0.52	-8.82	-0.38	2.28e-17	Life satisfaction;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	7.07	0.31	5.72e-12	Aortic root size;
LGG	cis	rs11874712	1.000	rs7244950	chr18:43676523	G/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.41	-0.4	2.26e-19	Morning vs. evening chronotype;
LGG	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg10327440	chr1:227177885	CDC42BPA	-1.25	-38.64	-0.87	5.49e-147	Myeloid white cell count;
LGG	cis	rs7172689	1.000	rs7180245	chr15:81535149	G/A	cg11808699	chr15:81528661	IL16	-0.49	-10.22	-0.43	3.08e-22	Inattentive symptoms;
LGG	cis	rs5762813	0.524	rs5752815	chr22:29230733	C/A	cg15103426	chr22:29168792	CCDC117	0.66	7.75	0.34	5.83e-14	Hematocrit;Hemoglobin concentration;
LGG	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg26769984	chr7:1090371	C7orf50	0.53	9.52	0.4	9.85e-20	Bronchopulmonary dysplasia;
LGG	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.55	0.41	7.83e-20	Joint mobility (Beighton score);
LGG	cis	rs311392	1.000	rs311392	chr8:55084782	A/G	cg11783602	chr8:55087084	NA	-0.3	-6.86	-0.3	2.22e-11	Pelvic organ prolapse (moderate/severe);
LGG	trans	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.67	-0.34	1.04e-13	Heart rate;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs7208859	0.673	rs3816780	chr17:29161358	C/T	cg13385521	chr17:29058706	SUZ12P	0.71	8.04	0.35	7.54e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4253772	0.591	rs11704614	chr22:46691936	A/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.09	-0.31	4.96e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12893668	0.572	rs35011804	chr14:104151400	C/T	cg26031613	chr14:104095156	KLC1	-0.67	-10.8	-0.45	2.14e-24	Reticulocyte count;
LGG	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.5	0.44	2.84e-23	Diabetic retinopathy;
LGG	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg16486109	chr11:613632	IRF7	0.42	7.51	0.33	3.02e-13	Systemic lupus erythematosus;
LGG	cis	rs77633900	0.892	rs2469552	chr15:76615481	G/C	cg21673338	chr15:77095150	SCAPER	-0.46	-6.76	-0.3	4.09e-11	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4417704	0.551	rs4334491	chr2:241892478	G/A	cg26818257	chr2:241905806	NA	0.5	11.07	0.46	2.05e-25	Joint mobility (Beighton score);
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg19077165	chr18:44547161	KATNAL2	-0.59	-10.95	-0.45	5.59e-25	Personality dimensions;
LGG	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-16.09	-0.6	1.38e-46	Calcium levels;
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.64	0.37	9.49e-17	Bipolar disorder;
LGG	cis	rs55665837	0.540	rs12416696	chr11:14790889	G/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.54	-0.33	2.46e-13	Vitamin D levels;
LGG	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg19678392	chr7:94953810	PON1	0.43	10.54	0.44	2.08e-23	Paraoxonase activity;
LGG	cis	rs9486715	0.964	rs6921480	chr6:97066329	C/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.36	-0.4	3.41e-19	Headache;
LGG	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg15325629	chr6:28072465	NA	0.95	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	cis	rs12753569	0.934	rs6593523	chr1:76486908	C/T	cg00791851	chr1:76518896	NA	-0.43	-9.62	-0.41	4.23e-20	Personality dimensions;
LGG	cis	rs4851254	0.660	rs13430705	chr2:100690616	G/A	cg17356467	chr2:100759845	AFF3	0.45	7.31	0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.919	rs2012581	chr17:29560800	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.51	-0.56	1.41e-39	Hip circumference;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs9308731	1.000	rs13396983	chr2:111900598	A/G	cg19992207	chr2:111874495	ACOXL	-0.4	-7.36	-0.32	8.7e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9309473	0.950	rs10207264	chr2:73714097	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.33	-0.32	1e-12	Metabolite levels;
LGG	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg24642439	chr20:33292090	TP53INP2	0.82	14.47	0.56	2.01e-39	Coronary artery disease;
LGG	cis	rs8062405	1.000	rs12325113	chr16:28848668	T/C	cg07382826	chr16:28625726	SULT1A1	0.37	7.65	0.34	1.16e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg19399532	chr1:178512495	C1orf220	0.57	11.25	0.46	3.92e-26	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10791323	0.604	rs2723615	chr11:133704567	C/T	cg06766960	chr11:133703094	NA	-0.57	-11.07	-0.46	2.07e-25	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg13939156	chr17:80058883	NA	-0.48	-9.21	-0.39	1.1e-18	Life satisfaction;
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.57	-0.33	2.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15369054	chr17:80825471	TBCD	0.38	7.46	0.33	4.42e-13	Breast cancer;
LGG	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg05623727	chr3:50126028	RBM5	0.42	9.23	0.39	9.64e-19	Body mass index;
LGG	trans	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg06521331	chr12:34319734	NA	-0.5	-8.74	-0.38	4.47e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12500482	1.000	rs12500482	chr4:2430235	A/G	cg08330972	chr4:2403930	ZFYVE28	-0.48	-8.02	-0.35	9e-15	Cognitive function;
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg15971980	chr6:150254442	NA	-0.45	-7.22	-0.32	2.15e-12	Lung cancer;
LGG	cis	rs7192750	0.562	rs9302631	chr16:71943414	C/T	cg06353428	chr16:71660113	MARVELD3	0.69	10.8	0.45	2.09e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07080220	chr10:102295463	HIF1AN	-0.62	-10.89	-0.45	9.93e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg21724239	chr8:58056113	NA	0.7	15.65	0.59	1.28e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs11700980	0.636	rs114711857	chr21:30260199	T/C	cg08807101	chr21:30365312	RNF160	-0.68	-7.56	-0.33	2.2e-13	QRS complex (12-leadsum);
LGG	cis	rs4845570	0.834	rs13376155	chr1:151721270	A/G	cg07092448	chr1:151763213	TDRKH	-1.07	-15.39	-0.58	1.93e-43	Coronary artery disease;
LGG	cis	rs898097	0.841	rs4986122	chr17:80825500	C/T	cg15664640	chr17:80829946	TBCD	-0.79	-15.71	-0.59	7.24e-45	Breast cancer;
LGG	cis	rs2832077	0.506	rs2832081	chr21:30152992	A/C	cg03476357	chr21:30257390	N6AMT1	0.42	7.01	0.31	8.45e-12	Cognitive test performance;
LGG	cis	rs67133203	0.904	rs2285230	chr12:51381750	T/C	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs78545713	0.649	rs41266811	chr6:26216656	T/C	cg01420254	chr6:26195488	NA	0.78	7.45	0.33	4.59e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs13191362	0.507	rs2023036	chr6:163122736	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	6.93	0.31	1.4e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs151349	1.000	rs151346	chr20:57587040	C/A	cg23907860	chr20:57583709	CTSZ	-0.46	-9.39	-0.4	2.78e-19	Platelet distribution width;
LGG	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg27478167	chr7:817139	HEATR2	-0.43	-6.97	-0.31	1.11e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7551222	0.752	rs10900599	chr1:204541943	T/C	cg20240347	chr1:204465584	NA	-0.53	-10.61	-0.44	1.08e-23	Schizophrenia;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg02733842	chr7:1102375	C7orf50	0.74	8.46	0.37	3.54e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.61e-11	Total body bone mineral density;
LGG	cis	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg19847130	chr8:10466454	RP1L1	0.32	6.82	0.3	2.84e-11	Neuroticism;
LGG	cis	rs6541297	0.699	rs4846915	chr1:230296470	C/A	cg05784532	chr1:230284198	GALNT2	0.46	6.68	0.3	6.98e-11	Coronary artery disease;
LGG	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.9	0.34	2.01e-14	Retinal vascular caliber;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27144592	chr16:783916	NARFL	0.41	6.85	0.3	2.4e-11	Height;
LGG	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.43	0.47	8.06e-27	Mood instability;
LGG	cis	rs9463078	0.764	rs6923519	chr6:44864152	A/G	cg25276700	chr6:44698697	NA	-0.39	-8.41	-0.36	5.03e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1451375	0.617	rs2329371	chr7:50615440	G/A	cg14593290	chr7:50529359	DDC	0.6	10.93	0.45	6.63e-25	Malaria;
LGG	cis	rs2221894	0.506	rs77417969	chr8:28844934	C/T	cg07962641	chr8:28805897	HMBOX1	-0.54	-7.85	-0.34	2.87e-14	Obesity-related traits;
LGG	cis	rs734999	0.505	rs10910107	chr1:2539181	C/T	cg15627072	chr1:2432621	PLCH2	0.32	7.03	0.31	7.42e-12	Ulcerative colitis;
LGG	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg11161011	chr14:65562177	MAX	-0.78	-15.87	-0.59	1.37e-45	Obesity-related traits;
LGG	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg08305652	chr11:111469057	NA	0.43	8.62	0.37	1.07e-16	Primary sclerosing cholangitis;
LGG	cis	rs7805747	1.000	rs56012466	chr7:151406788	G/A	cg17611936	chr7:151411526	PRKAG2	0.54	7.72	0.34	7.4e-14	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg15454534	chr1:248569605	OR2T1	-0.39	-7.12	-0.31	4.22e-12	Common traits (Other);
LGG	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.61	0.33	1.5700000000000001e-13	Schizophrenia;
LGG	cis	rs4888262	0.526	rs4887772	chr16:74537591	C/T	cg01733217	chr16:74700730	RFWD3	0.83	16.46	0.61	2.95e-48	Testicular germ cell tumor;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.2	-0.43	3.62e-22	Longevity;Endometriosis;
LGG	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg06360820	chr2:242988706	NA	0.82	10.63	0.44	9.14e-24	Obesity-related traits;
LGG	cis	rs72960926	1.000	rs72956962	chr6:75100904	T/C	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs12928939	0.637	rs8046629	chr16:71643116	G/A	cg03805757	chr16:71968109	PKD1L3	-0.47	-8.43	-0.36	4.49e-16	Post bronchodilator FEV1;
LGG	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg18963800	chr10:38644991	HSD17B7P2	0.42	7.03	0.31	7.64e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7937612	0.965	rs9633919	chr11:120249493	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.66	-0.51	9.65e-32	Intraocular pressure;
LGG	trans	rs7944735	0.817	rs6485788	chr11:47873883	C/T	cg03929089	chr4:120376271	NA	-0.57	-7.13	-0.31	3.82e-12	Intraocular pressure;
LGG	cis	rs61990749	0.544	rs11628888	chr14:78161506	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.54	-6.74	-0.3	4.86e-11	Fibroblast growth factor basic levels;
LGG	cis	rs8051149	0.652	rs4843719	chr16:87882695	C/A	cg02614661	chr16:87878292	SLC7A5	-0.37	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs11645898	1.000	rs72791115	chr16:72207315	T/C	cg14768367	chr16:72042858	DHODH	-0.74	-10.04	-0.42	1.38e-21	Blood protein levels;
LGG	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg18477163	chr1:228402036	OBSCN	-0.26	-6.99	-0.31	9.41e-12	Diastolic blood pressure;
LGG	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.52	-6.93	-0.31	1.43e-11	Subjective well-being;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg24371152	chr4:159592377	C4orf46;ETFDH	-0.51	-7.38	-0.32	7.44e-13	Beard thickness;
LGG	cis	rs12765878	0.580	rs55983834	chr10:105601210	C/T	cg11005552	chr10:105648138	OBFC1	-0.7	-11.96	-0.49	6.69e-29	Coronary artery disease;
LGG	cis	rs28588043	0.877	rs72710581	chr1:170999936	A/G	cg03458344	chr1:170964477	C1orf129	-0.54	-7.25	-0.32	1.78e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7666738	0.830	rs7664305	chr4:99037691	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937890	0.559	rs2034480	chr11:14466923	G/A	cg02886208	chr11:14281011	SPON1	-0.4	-7.77	-0.34	5.18e-14	Mitochondrial DNA levels;
LGG	cis	rs7945705	0.935	rs11042102	chr11:8882164	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.54	11.47	0.47	5.5e-27	Hemoglobin concentration;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg10053473	chr17:62856997	LRRC37A3	-0.79	-13.89	-0.54	6.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15208284	chr3:107242730	BBX	0.41	6.74	0.3	4.59e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg05973401	chr12:123451056	ABCB9	0.51	7.58	0.33	1.97e-13	Neutrophil percentage of white cells;
LGG	cis	rs77106637	0.860	rs11603334	chr11:72432985	G/A	cg03713592	chr11:72463424	ARAP1	0.44	7.82	0.34	3.71e-14	Type 2 diabetes;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	1.02e-16	Lung cancer;
LGG	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg22437258	chr11:111473054	SIK2	-0.51	-8.72	-0.38	4.99e-17	Primary sclerosing cholangitis;
LGG	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg00701064	chr4:6280414	WFS1	0.72	15.97	0.6	4.67e-46	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg22852734	chr6:133119734	C6orf192	1.3	10.19	0.43	3.86e-22	Type 2 diabetes nephropathy;
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg14675211	chr2:100938903	LONRF2	0.62	11.04	0.46	2.57e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.867	rs2470134	chr15:43849886	A/G	cg15269541	chr15:43626905	ADAL	0.43	6.84	0.3	2.5e-11	Lung cancer in ever smokers;
LGG	cis	rs244731	0.959	rs10037110	chr5:176658066	A/T	cg17509989	chr5:176798049	RGS14	-0.58	-8.28	-0.36	1.35e-15	Urate levels in lean individuals;
LGG	cis	rs2764208	0.576	rs6457791	chr6:34759954	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs6547631	0.622	rs2118402	chr2:85931078	A/G	cg19805943	chr2:85933069	NA	0.33	7.03	0.31	7.49e-12	Blood protein levels;
LGG	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg08297393	chr2:100937505	LONRF2	0.57	9.82	0.42	8.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-8.76	-0.38	3.83e-17	Chronic sinus infection;
LGG	cis	rs9354308	0.738	rs1353873	chr6:66610049	A/T	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs11214589	0.774	rs10891544	chr11:113256152	A/C	cg14159747	chr11:113255604	NA	-0.32	-8.66	-0.37	8.16e-17	Neuroticism;
LGG	cis	rs12282928	0.918	rs7948903	chr11:48247305	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.13	-0.31	3.88e-12	Migraine - clinic-based;
LGG	cis	rs67311347	0.577	rs2371129	chr3:40248393	C/T	cg13683864	chr3:40499215	RPL14	0.77	14.74	0.57	1.33e-40	Renal cell carcinoma;
LGG	cis	rs62238980	0.614	rs75840726	chr22:32425834	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg02297831	chr4:17616191	MED28	0.51	9.5	0.4	1.12e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg20308403	chr7:2120281	MAD1L1	0.32	6.94	0.31	1.31e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.09	0.62	3.96e-51	Alzheimer's disease;
LGG	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg06889755	chr6:150326021	RAET1K	0.39	7.98	0.35	1.13e-14	Alopecia areata;
LGG	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg00579200	chr11:133705235	NA	-0.6	-11.66	-0.48	9.89e-28	Childhood ear infection;
LGG	cis	rs2354432	0.825	rs10900347	chr1:146800107	G/C	cg25205988	chr1:146714368	CHD1L	1.27	17.3	0.63	4.41e-52	Mitochondrial DNA levels;
LGG	cis	rs9486719	0.948	rs11152970	chr6:96909077	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs8017423	0.967	rs11844225	chr14:90726676	G/A	cg04374321	chr14:90722782	PSMC1	0.9	19.63	0.67	7.26e-63	Mortality in heart failure;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.23e-17	Response to antipsychotic treatment;
LGG	cis	rs78456975	1.000	rs72776252	chr2:1525599	G/A	cg01028140	chr2:1542097	TPO	-0.56	-8.4	-0.36	5.54e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7098414	0.511	rs10749592	chr10:82150891	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	11.77	0.48	3.62e-28	Post bronchodilator FEV1;
LGG	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06481639	chr22:41940642	POLR3H	-0.54	-8.12	-0.35	4.16e-15	Vitiligo;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.55	-0.44	1.88e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg23782820	chr8:58130467	NA	0.43	6.64	0.3	8.62e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3845702	0.733	rs12693217	chr2:180841914	T/G	cg01881094	chr2:180872142	CWC22	-1.26	-16.57	-0.61	9.27e-49	Schizophrenia;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.73	-0.3	5.18e-11	Aortic root size;
LGG	cis	rs7666738	0.791	rs13128640	chr4:99003918	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3741151	1.000	rs112840535	chr11:73066771	G/A	cg17517138	chr11:73019481	ARHGEF17	1.03	10.37	0.43	8.61e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs6601327	0.641	rs12542457	chr8:9564600	A/G	cg02002194	chr4:3960332	NA	0.37	6.66	0.3	7.74e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg03806693	chr22:41940476	POLR3H	0.96	16.97	0.62	1.38e-50	Vitiligo;
LGG	cis	rs11190604	0.806	rs76835764	chr10:102193612	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.5	0.33	3.36e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7647973	0.771	rs9865051	chr3:49166069	C/T	cg06212747	chr3:49208901	KLHDC8B	0.54	7.79	0.34	4.52e-14	Menarche (age at onset);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02018176	chr4:1364513	KIAA1530	0.65	16.05	0.6	2.11e-46	Longevity;
LGG	cis	rs4700695	0.668	rs153393	chr5:65428707	A/G	cg21114390	chr5:65439923	SFRS12	-0.69	-9.83	-0.42	7.96e-21	Facial morphology (factor 19);
LGG	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.04	0.31	7.13e-12	Resting heart rate;
LGG	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.88	-0.3	1.99e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs10206020	0.921	rs10177509	chr2:1568536	T/C	cg12573674	chr2:1569213	NA	-0.65	-10.01	-0.42	1.74e-21	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	8.23	0.36	1.96e-15	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2599510	0.783	rs2038534	chr2:32659489	G/A	cg02381751	chr2:32503542	YIPF4	0.53	8.49	0.37	2.87e-16	Interleukin-18 levels;
LGG	cis	rs7296418	0.961	rs4275659	chr12:123447928	C/T	cg00376283	chr12:123451042	ABCB9	-0.7	-13.03	-0.52	2.8e-33	Platelet count;
LGG	cis	rs4075765	0.881	rs72887688	chr11:26224232	G/T	cg19182008	chr11:26298241	NA	0.85	8.13	0.35	3.87e-15	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.73e-31	Motion sickness;
LGG	cis	rs826838	1.000	rs826891	chr12:39100824	A/G	cg13010199	chr12:38710504	ALG10B	-0.62	-13.29	-0.53	2.38e-34	Heart rate;
LGG	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.15	-0.32	3.4e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1459104	0.706	rs35264107	chr11:55038574	T/C	cg15704280	chr7:45808275	SEPT13	0.76	7.07	0.31	5.63e-12	Body mass index;
LGG	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg06618935	chr21:46677482	NA	-0.48	-9.4	-0.4	2.54e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.7	0.45	5.01e-24	Morning vs. evening chronotype;
LGG	cis	rs2916247	1.000	rs1838181	chr8:92993679	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.65	-0.37	8.85e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6445975	0.666	rs57621305	chr3:58346744	C/T	cg24175188	chr3:58374923	PXK	0.54	8.79	0.38	2.93e-17	Systemic lupus erythematosus;
LGG	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg10661904	chr17:79619235	PDE6G	0.4	8.11	0.35	4.7e-15	Eye color traits;
LGG	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	8.87	0.38	1.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs60843830	1.000	rs10193373	chr2:281886	T/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.3	0.36	1.19e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7666738	0.800	rs11941885	chr4:99072921	A/C	cg05340658	chr4:99064831	C4orf37	0.51	8.52	0.37	2.22e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs55871839	0.708	rs12115074	chr8:59817473	C/T	cg07426533	chr8:59803705	TOX	-0.49	-10.39	-0.43	7.34e-23	Pneumonia;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg26174226	chr8:58114915	NA	-0.53	-7.34	-0.32	9.91e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	9.28	0.4	6.67e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg02811702	chr13:24901961	NA	0.42	7.66	0.34	1.09e-13	Obesity-related traits;
LGG	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg06481639	chr22:41940642	POLR3H	0.56	7.88	0.34	2.3e-14	Vitiligo;
LGG	cis	rs4665809	0.549	rs62130460	chr2:26472718	T/C	cg08470875	chr2:26401718	FAM59B	0.41	7.68	0.34	9.36e-14	Gut microbiome composition (summer);
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg02002194	chr4:3960332	NA	-0.46	-8.83	-0.38	2.11e-17	Monocyte count;
LGG	cis	rs28595532	0.920	rs114390336	chr4:119771452	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs78456975	0.739	rs11896906	chr2:1519550	A/G	cg01028140	chr2:1542097	TPO	-0.51	-8.16	-0.35	3.25e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg19143629	chr17:61920732	SMARCD2	0.4	6.82	0.3	2.94e-11	Prudent dietary pattern;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs6831352	0.879	rs29001212	chr4:100051877	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.74	-0.41	1.59e-20	Alcohol dependence;
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06481639	chr22:41940642	POLR3H	0.59	8.65	0.37	8.46e-17	Vitiligo;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.59	11.48	0.47	5.01e-27	Obesity-related traits;
LGG	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.9	-0.31	1.73e-11	Blood metabolite levels;
LGG	cis	rs6750795	0.870	rs6754952	chr2:232381245	G/T	cg19187155	chr2:232395269	NMUR1	-0.61	-11.77	-0.48	3.76e-28	Height;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg00933542	chr6:150070202	PCMT1	0.37	6.86	0.3	2.26e-11	Lung cancer;
LGG	cis	rs75059851	0.756	rs11223658	chr11:133843216	G/A	cg17703048	chr11:133852993	NA	-0.88	-15.97	-0.6	4.93e-46	Schizophrenia;
LGG	cis	rs9815354	0.951	rs4616614	chr3:41753648	T/G	cg03022575	chr3:42003672	ULK4	0.63	7.78	0.34	4.85e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.03	-0.42	1.54e-21	Lung cancer;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg19635926	chr16:89946313	TCF25	0.69	8.11	0.35	4.59e-15	Skin colour saturation;
LGG	trans	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg00701064	chr4:6280414	WFS1	0.68	13.34	0.53	1.3600000000000001e-34	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg08017634	chr8:144659831	NAPRT1	-0.58	-8.44	-0.37	4.07e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs2070997	0.702	rs3780284	chr9:133733961	A/G	cg03924115	chr9:133768966	QRFP	0.43	7.05	0.31	6.54e-12	Response to amphetamines;
LGG	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.66	0.41	3.06e-20	Lung cancer in ever smokers;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18588052	chr6:111408752	SLC16A10	-0.42	-6.73	-0.3	5.01e-11	Pancreatic cancer;
LGG	cis	rs12190007	0.547	rs3006181	chr6:169809117	T/A	cg15038512	chr6:170123185	PHF10	-0.44	-8.54	-0.37	2.01e-16	Obesity-related traits;
LGG	cis	rs2273669	0.748	rs114830980	chr6:109297857	A/T	cg05315195	chr6:109294784	ARMC2	-0.52	-7.34	-0.32	9.41e-13	Prostate cancer;
LGG	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg06637938	chr14:75390232	RPS6KL1	0.59	10.87	0.45	1.19e-24	Height;
LGG	trans	rs561341	1.000	rs521919	chr17:30298039	G/T	cg20587970	chr11:113659929	NA	-1.29	-24.07	-0.75	1.33e-83	Hip circumference adjusted for BMI;
LGG	cis	rs4363385	0.818	rs10888526	chr1:153000311	G/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.9	-0.38	1.23e-17	Inflammatory skin disease;
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.02	-0.52	3.13e-33	Aortic root size;
LGG	cis	rs28830936	0.510	rs11858843	chr15:42092915	C/A	cg17847044	chr15:42102381	MAPKBP1	-0.78	-25.78	-0.77	1.51e-91	Diastolic blood pressure;
LGG	cis	rs11264213	0.901	rs72661623	chr1:36398368	G/A	cg27506609	chr1:36549197	TEKT2	0.77	7.64	0.33	1.3e-13	Schizophrenia;
LGG	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs8114671	0.562	rs725521	chr20:33516071	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.05	0.31	6.67e-12	Height;
LGG	cis	rs2120243	0.539	rs2168431	chr3:157120029	A/T	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-7.95	-0.35	1.48e-14	IgG glycosylation;
LGG	cis	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-8.32	-0.36	9.76e-16	Cognitive test performance;
LGG	cis	rs7512552	0.839	rs12042229	chr1:150447398	A/G	cg15654264	chr1:150340011	RPRD2	0.46	9.37	0.4	3.26e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8028313	0.630	rs8035989	chr15:67965620	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.51	-0.33	2.98e-13	Obesity;
LGG	cis	rs3749237	0.615	rs6792911	chr3:49429856	C/T	cg07636037	chr3:49044803	WDR6	0.59	10.29	0.43	1.62e-22	Resting heart rate;
LGG	cis	rs10089	1.000	rs6595806	chr5:127499764	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	12.03	0.49	3.33e-29	Ileal carcinoids;
LGG	trans	rs6089829	0.962	rs2314130	chr20:61665129	G/T	cg23505145	chr19:12996616	KLF1	0.4	7.1	0.31	4.86e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6089829	0.855	rs6090205	chr20:61665269	A/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17818399	0.533	rs13420857	chr2:46798005	C/G	cg02822958	chr2:46747628	ATP6V1E2	-0.42	-7.08	-0.31	5.34e-12	Height;
LGG	cis	rs6495122	0.699	rs2168518	chr15:75081078	G/A	cg17294928	chr15:75287854	SCAMP5	0.41	6.72	0.3	5.21e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06634786	chr22:41940651	POLR3H	-0.73	-12.07	-0.49	2.32e-29	Vitiligo;
LGG	cis	rs7769051	0.522	rs56908272	chr6:133102165	G/C	cg22852734	chr6:133119734	C6orf192	1.28	9.97	0.42	2.41e-21	Type 2 diabetes nephropathy;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.29	0.6	1.79e-47	Lymphocyte counts;
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.08	-0.31	5.53e-12	Bipolar disorder;
LGG	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg09545109	chr3:50388910	TUSC4;CYB561D2	0.47	6.72	0.3	5.36e-11	Schizophrenia;
LGG	cis	rs17767392	0.958	rs10483836	chr14:72001614	A/C	cg02058870	chr14:72053146	SIPA1L1	0.45	8.79	0.38	2.92e-17	Mitral valve prolapse;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16119134	chr17:19281001	MAPK7	0.46	7.04	0.31	7.12e-12	Gut microbiome composition (summer);
LGG	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.99	-0.35	1.09e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg18402987	chr7:1209562	NA	0.68	9.02	0.39	4.89e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg26513180	chr16:89883248	FANCA	0.93	9.9	0.42	4.19e-21	Skin colour saturation;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.79e-31	Lymphocyte counts;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg24829409	chr8:58192753	C8orf71	-0.7	-9.21	-0.39	1.14e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg21926883	chr2:100939477	LONRF2	0.67	15.75	0.59	4.61e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4808199	0.948	rs2074300	chr19:19380996	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.12	0.31	4.22e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs17373728	0.739	rs7835101	chr8:76169185	T/C	cg07016329	chr8:76221503	NA	-0.61	-11.39	-0.47	1.18e-26	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7937890	0.904	rs11023169	chr11:14290985	C/A	cg02251663	chr11:14281053	SPON1	0.33	8.23	0.36	1.94e-15	Mitochondrial DNA levels;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg08621203	chr6:150244597	RAET1G	0.48	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs2028299	1.000	rs35608327	chr15:90369204	C/T	cg23731826	chr15:90371692	NA	0.38	8.91	0.38	1.2e-17	Type 2 diabetes;
LGG	trans	rs35110281	0.782	rs6518302	chr21:45018478	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	11.8	0.48	2.73e-28	Mean corpuscular volume;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12586317	0.547	rs112510746	chr14:35491833	T/G	cg16230307	chr14:35515116	FAM177A1	0.92	13.57	0.53	1.55e-35	Psoriasis;
LGG	trans	rs8002861	0.967	rs7983109	chr13:44484351	C/A	cg12856521	chr11:46389249	DGKZ	0.43	7.51	0.33	3.01e-13	Leprosy;
LGG	cis	rs2011503	0.941	rs55762233	chr19:19367319	C/G	cg01262667	chr19:19385393	TM6SF2	0.36	7.28	0.32	1.42e-12	Bipolar disorder;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.02	-0.39	5.07e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8054556	0.647	rs4788211	chr16:30015565	C/T	cg06326092	chr16:30034487	C16orf92	0.35	7.05	0.31	6.7e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.09e-19	Common traits (Other);
LGG	cis	rs9557207	0.789	rs9557173	chr13:99825512	C/T	cg24509225	chr13:100037070	UBAC2	0.58	10.68	0.44	5.74e-24	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7681440	0.904	rs28777703	chr4:90769924	A/G	cg15133208	chr4:90757351	SNCA	0.37	8.66	0.37	8.13e-17	Dementia with Lewy bodies;
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.54	-0.33	2.48e-13	Height;
LGG	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg21926883	chr2:100939477	LONRF2	0.7	16.34	0.6	1.05e-47	Intelligence (multi-trait analysis);
LGG	cis	rs4704187	0.687	rs6862740	chr5:74405749	A/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs7927771	0.524	rs4752796	chr11:47841862	A/G	cg20307385	chr11:47447363	PSMC3	-0.55	-10.84	-0.45	1.55e-24	Subjective well-being;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03178232	chr16:984175	LMF1	-0.35	-6.85	-0.3	2.42e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg03929089	chr4:120376271	NA	0.74	8.51	0.37	2.35e-16	Axial length;
LGG	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.74e-12	Aortic root size;
LGG	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.32	-0.32	1.1e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.03	-0.31	7.45e-12	Bipolar disorder;
LGG	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs4330281	0.608	rs28454413	chr3:17383964	C/T	cg20981856	chr3:17787350	NA	0.36	6.91	0.31	1.59e-11	Schizophrenia;
LGG	cis	rs10186029	0.676	rs10932465	chr2:213968389	T/C	cg08319019	chr2:214017104	IKZF2	0.48	8.35	0.36	7.83e-16	Systemic sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07698384	chr15:25684465	UBE3A	0.45	6.86	0.3	2.19e-11	Gut microbiome composition (summer);
LGG	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9815354	0.556	rs113213296	chr3:41873097	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24721750	chr14:101348446	MIR127;RTL1	0.37	7.59	0.33	1.77e-13	Menarche (age at onset);
LGG	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Bone mineral density;
LGG	cis	rs6071166	0.838	rs6027258	chr20:37314674	G/A	cg10737118	chr20:37354790	SLC32A1	-0.39	-6.77	-0.3	3.8e-11	circulating leptin levels adjusted for BMI;circulating leptin levels;
LGG	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg03806693	chr22:41940476	POLR3H	0.92	15.84	0.59	1.76e-45	Vitiligo;
LGG	cis	rs7659604	0.540	rs4455438	chr4:122669550	G/A	cg19671926	chr4:122722719	EXOSC9	0.46	7.12	0.31	4.2e-12	Type 2 diabetes;
LGG	cis	rs11190604	1.000	rs10883499	chr10:102232188	T/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.96	0.45	5.38e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs138880	0.580	rs28562884	chr22:50312869	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-10.28	-0.43	1.81e-22	Schizophrenia;
LGG	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg01043669	chr3:72786069	NA	0.39	6.8	0.3	3.32e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4819052	0.851	rs13052344	chr21:46676101	C/T	cg06618935	chr21:46677482	NA	-0.48	-9.35	-0.4	3.66e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7129556	0.954	rs10899386	chr11:77246426	T/C	cg12586386	chr11:77299805	AQP11	0.5	8.39	0.36	6.16e-16	Weight loss (gastric bypass surgery);
LGG	trans	rs2727020	0.688	rs4929894	chr11:49196333	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.52	-10.23	-0.43	2.83e-22	Coronary artery disease;
LGG	trans	rs66573146	0.572	rs67922134	chr4:6955772	G/A	cg07817883	chr1:32538562	TMEM39B	1.15	12.07	0.49	2.45e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9815354	0.951	rs9849393	chr3:41875369	G/C	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2071403	0.527	rs11211645	chr2:1412581	C/T	cg06500727	chr2:1417164	TPO	0.58	11.79	0.48	3.13e-28	Thyroid peroxidase antibody positivity;
LGG	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg03929089	chr4:120376271	NA	0.83	8.66	0.37	7.74e-17	Myopia (pathological);
LGG	cis	rs17021463	0.676	rs13124715	chr4:95313382	C/T	cg11021082	chr4:95130006	SMARCAD1	0.42	7.07	0.31	5.83e-12	Testicular germ cell tumor;
LGG	cis	rs9303401	0.659	rs35564417	chr17:56718286	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.94	15.25	0.58	7.89e-43	Cognitive test performance;
LGG	cis	rs9287719	1.000	rs9679122	chr2:10751710	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg21724239	chr8:58056113	NA	0.46	7.15	0.32	3.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg11494091	chr17:61959527	GH2	1.01	24.64	0.75	2.89e-86	Prudent dietary pattern;
LGG	cis	rs9878978	0.722	rs62233819	chr3:2504229	C/T	cg21928760	chr3:2462534	CNTN4	0.38	7.53	0.33	2.77e-13	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg23782820	chr8:58130467	NA	0.54	7.46	0.33	4.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.740	rs12212560	chr6:86342679	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.05	-0.35	7e-15	Response to antipsychotic treatment;
LGG	cis	rs1153858	1.000	rs12440038	chr15:45706739	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	1.01e-25	Homoarginine levels;
LGG	cis	rs7615952	0.641	rs61048217	chr3:125807905	G/T	cg18479299	chr3:125709523	NA	-0.57	-7.15	-0.32	3.48e-12	Blood pressure (smoking interaction);
LGG	trans	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg11441553	chr12:57614120	NXPH4	-0.63	-7.85	-0.34	2.89e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4936894	0.500	rs4556547	chr11:124124775	C/T	cg27160556	chr11:124181099	OR8D1	0.47	10.83	0.45	1.61e-24	Aging (time to death);
LGG	cis	rs422249	0.512	rs174554	chr11:61579463	A/G	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	Trans fatty acid levels;
LGG	cis	rs735539	1.000	rs735539	chr13:21280034	A/G	cg04906043	chr13:21280425	IL17D	0.62	10.66	0.44	7.25e-24	Dental caries;
LGG	cis	rs2905347	0.757	rs2905318	chr7:22696653	A/C	cg23521230	chr7:22704884	NA	-0.38	-7.01	-0.31	8.69e-12	Major depression and alcohol dependence;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg15947599	chr18:9478638	RALBP1	0.42	6.82	0.3	2.81e-11	Pancreatic cancer;
LGG	cis	rs3736594	0.546	rs965813	chr2:27789861	T/A	cg27432699	chr2:27873401	GPN1	0.57	8.55	0.37	1.78e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.91	0.35	1.88e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.69	-13.19	-0.52	5.73e-34	Personality dimensions;
LGG	trans	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.86	-0.42	6.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs185694	1.000	rs202099	chr13:30896874	C/T	cg07600127	chr13:30881527	KATNAL1	-0.51	-6.73	-0.3	5.12e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-17.54	-0.63	3.44e-53	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg22105103	chr4:187893119	NA	0.56	10.43	0.44	5.31e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2013441	0.786	rs4003797	chr17:20288900	T/C	cg13482628	chr17:19912719	NA	-0.5	-9.1	-0.39	2.59e-18	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg11062466	chr8:58055876	NA	0.61	9.69	0.41	2.43e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4969178	0.965	rs4969186	chr17:76398404	C/G	cg20026190	chr17:76395443	PGS1	0.57	10.18	0.43	4.23e-22	HDL cholesterol levels;
LGG	cis	rs6754311	0.731	rs309134	chr2:136755684	A/G	cg07169764	chr2:136633963	MCM6	-0.83	-14.01	-0.55	1.92e-37	Mosquito bite size;
LGG	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg03806693	chr22:41940476	POLR3H	1.05	17.65	0.63	1.14e-53	Vitiligo;
LGG	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs2227564	0.672	rs2459449	chr10:75669013	T/C	cg00564723	chr10:75632066	CAMK2G	-0.43	-8.77	-0.38	3.33e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.01	-19.7	-0.68	3.32e-63	Primary sclerosing cholangitis;
LGG	cis	rs7914558	0.966	rs11191438	chr10:104637864	C/G	cg04362960	chr10:104952993	NT5C2	0.56	10.86	0.45	1.21e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs832540	0.669	rs832538	chr5:56200016	C/T	cg12654349	chr5:56205094	C5orf35	-0.51	-8.57	-0.37	1.55e-16	Coronary artery disease;
LGG	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg03517284	chr6:25882590	NA	-0.54	-10.28	-0.43	1.85e-22	Blood metabolite levels;
LGG	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg04989706	chr14:50066350	PPIL5	-0.62	-10.18	-0.43	4.41e-22	Carotid intima media thickness;
LGG	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg18876405	chr7:65276391	NA	-0.55	-9.83	-0.42	7.76e-21	Aortic root size;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg13047869	chr3:10149882	C3orf24	0.59	8.97	0.38	7.19e-18	Alzheimer's disease;
LGG	cis	rs73416724	1.000	rs74690967	chr6:43370915	C/T	cg26312998	chr6:43337775	ZNF318	0.6	8.43	0.36	4.31e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg17133734	chr15:86042851	AKAP13	-0.3	-7.16	-0.32	3.2e-12	Coronary artery disease;
LGG	cis	rs12282928	0.959	rs2007961	chr11:48273208	G/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.64e-12	Migraine - clinic-based;
LGG	cis	rs2742417	0.935	rs2742442	chr3:45748599	T/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2033711	0.870	rs11084545	chr19:58951693	G/C	cg26874164	chr19:58962979	ZNF324B	0.4	7.89	0.34	2.23e-14	Uric acid clearance;
LGG	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg25427524	chr10:38739819	LOC399744	0.36	6.68	0.3	6.99e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.71	-13.2	-0.52	5.19e-34	Colorectal cancer;
LGG	trans	rs826838	0.967	rs7965656	chr12:38807244	G/A	cg06521331	chr12:34319734	NA	-0.42	-6.91	-0.31	1.61e-11	Heart rate;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.3	0.36	1.17e-15	Platelet count;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg20746552	chr10:63809108	ARID5B	-0.36	-6.98	-0.31	9.99e-12	Systemic lupus erythematosus;
LGG	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.28	-0.4	6.73e-19	Mean corpuscular volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17606287	chr9:99776144	HIATL2	0.41	6.87	0.3	2.06e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg15208524	chr1:10270712	KIF1B	0.47	8.1	0.35	5e-15	Hepatocellular carcinoma;
LGG	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg27661571	chr11:113659931	NA	0.58	7.87	0.34	2.57e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4774899	0.932	rs1037958	chr15:57523542	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.17e-12	Urinary tract infection frequency;
LGG	cis	rs2635047	0.542	rs1512236	chr18:44768493	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-7.37	-0.32	7.68e-13	Educational attainment;
LGG	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.53	-0.33	2.67e-13	IgG glycosylation;
LGG	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg18479299	chr3:125709523	NA	-0.57	-7.35	-0.32	8.95e-13	Blood pressure (smoking interaction);
LGG	cis	rs3768617	0.510	rs2093985	chr1:183094322	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.94	0.38	9.44e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11690935	0.655	rs17614941	chr2:172541378	A/G	cg13550731	chr2:172543902	DYNC1I2	0.54	10.66	0.44	7.06e-24	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.56	-0.37	1.63e-16	Lung cancer;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg21724239	chr8:58056113	NA	0.45	7.07	0.31	5.88e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9513627	0.588	rs9585073	chr13:100128516	A/G	cg15490075	chr13:100150979	NA	-0.69	-7.22	-0.32	2.17e-12	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs9364536	chr6:160225559	G/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	7.52	0.33	2.88e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg26338869	chr17:61819248	STRADA	0.55	9.29	0.4	6.14e-19	Prudent dietary pattern;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.5	0.37	2.66e-16	Obesity-related traits;
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg12458913	chr13:53173898	NA	0.55	10.15	0.43	5.65e-22	Lewy body disease;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.38	-0.5	1.36e-30	Colorectal cancer;
LGG	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg16950941	chr11:66035639	RAB1B	0.56	10.49	0.44	2.95e-23	Gout;
LGG	cis	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg15596359	chr8:11213517	TDH	-0.34	-6.87	-0.3	2.14e-11	Retinal vascular caliber;
LGG	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg00701064	chr4:6280414	WFS1	0.73	16.73	0.61	1.73e-49	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17286411	0.750	rs4788450	chr16:71955400	T/G	cg03805757	chr16:71968109	PKD1L3	0.34	6.98	0.31	1.05e-11	Blood protein levels;
LGG	cis	rs6444746	0.800	rs61019814	chr3:193486902	A/C	cg22553634	chr3:193489233	NA	0.82	8.75	0.38	3.99e-17	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs17428076	0.872	rs72892835	chr2:172894614	G/A	cg21435375	chr2:172878103	MAP1D	0.47	9.94	0.42	3.06e-21	Myopia;
LGG	trans	rs11976180	1.000	rs2951360	chr7:143757349	C/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.93	-0.31	1.39e-11	Obesity-related traits;
LGG	cis	rs7098414	0.511	rs7899513	chr10:82150559	G/A	cg01528321	chr10:82214614	TSPAN14	0.65	11.64	0.48	1.16e-27	Post bronchodilator FEV1;
LGG	trans	rs941408	1.000	rs1736181	chr19:2797703	C/T	cg19676328	chr12:49525230	TUBA1B	-0.61	-9.9	-0.42	4.25e-21	Total cholesterol levels;
LGG	cis	rs7635838	0.785	rs7427412	chr3:11535020	G/A	cg00170343	chr3:11313890	ATG7	0.41	6.77	0.3	3.95e-11	HDL cholesterol;
LGG	cis	rs7928758	0.945	rs55986667	chr11:134280126	A/C	cg25213107	chr11:134282864	B3GAT1	0.99	11.76	0.48	4.08e-28	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg00579200	chr11:133705235	NA	0.55	10.75	0.45	3.21e-24	Childhood ear infection;
LGG	cis	rs4650994	0.571	rs11588907	chr1:178509462	C/T	cg19399532	chr1:178512495	C1orf220	-0.4	-7.71	-0.34	8.02e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg15242686	chr22:24348715	GSTTP1	0.36	6.66	0.3	7.62e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs6547631	0.622	rs34943381	chr2:85923997	A/G	cg19805943	chr2:85933069	NA	0.32	6.69	0.3	6.34e-11	Blood protein levels;
LGG	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.61	-13.84	-0.54	1.04e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg22232500	chr2:134024266	NCKAP5	0.52	7.31	0.32	1.18e-12	Bipolar disorder;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.86	-0.3	2.22e-11	Personality dimensions;
LGG	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg11941060	chr3:133502564	NA	-0.54	-9.22	-0.39	1.08e-18	Iron status biomarkers;
LGG	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg26384229	chr12:38710491	ALG10B	-1.06	-28.51	-0.8	5.66e-104	Heart rate;
LGG	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg01191920	chr7:158217561	PTPRN2	0.72	16.28	0.6	1.84e-47	Obesity-related traits;
LGG	cis	rs11190604	1.000	rs57025426	chr10:102205868	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg05535760	chr7:792225	HEATR2	-0.39	-6.68	-0.3	6.76e-11	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg08621203	chr6:150244597	RAET1G	0.48	8.21	0.36	2.24e-15	Lung cancer;
LGG	cis	rs8177179	0.565	rs4355280	chr3:133468425	A/G	cg08048268	chr3:133502702	NA	-0.44	-7.74	-0.34	6.3e-14	Iron status biomarkers (transferrin levels);
LGG	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.44	-0.4	1.85e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs8114671	0.562	rs3746450	chr20:33508588	G/T	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.12e-12	Height;
LGG	cis	rs752010	0.695	rs10890155	chr1:42107843	C/T	cg16096631	chr1:42092165	HIVEP3	0.53	12.64	0.51	1.16e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1461503	0.934	rs11605693	chr11:122837037	T/C	cg27398637	chr11:122830231	C11orf63	-0.68	-13.91	-0.54	5.46e-37	Menarche (age at onset);
LGG	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15664640	chr17:80829946	TBCD	-0.66	-9.02	-0.39	5.22e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs548181	0.545	rs1054997	chr11:125618813	G/A	cg03464685	chr11:125439445	EI24	-1.2	-16.6	-0.61	7.11e-49	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11608355	0.515	rs7136048	chr12:109903926	A/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs657075	0.697	rs71583481	chr5:131696551	G/A	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs2404618	0.506	rs12156177	chr8:1493684	C/T	cg02903104	chr8:1507517	DLGAP2	0.4	8.49	0.37	2.89e-16	Lung cancer;
LGG	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.64e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.48	-0.33	3.69e-13	Height;
LGG	cis	rs9399135	0.967	rs10872427	chr6:135353452	T/C	cg24558204	chr6:135376177	HBS1L	0.53	9.63	0.41	3.82e-20	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09682251	chr3:50654786	MAPKAPK3	0.45	6.68	0.3	6.73e-11	Gut microbiome composition (summer);
LGG	cis	rs27434	0.583	rs26653	chr5:96139250	C/G	cg16492584	chr5:96139282	ERAP1	-0.35	-6.84	-0.3	2.47e-11	Ankylosing spondylitis;
LGG	cis	rs12519773	0.526	rs6897863	chr5:92512481	A/C	cg18783429	chr5:92414398	NA	0.31	7.58	0.33	1.91e-13	Migraine;
LGG	cis	rs922692	0.715	rs2277546	chr15:79083376	C/A	cg00540400	chr15:79124168	NA	-0.39	-7.58	-0.33	1.9e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.08	-0.31	5.41e-12	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23077509	chr3:142166793	XRN1	-0.43	-7.07	-0.31	5.64e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs950169	0.614	rs12903883	chr15:84680553	A/G	cg24253500	chr15:84953950	NA	0.46	7.49	0.33	3.57e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26462404	chr19:2270807	OAZ1	0.51	7.99	0.35	1.08e-14	Gut microbiome composition (summer);
LGG	cis	rs9303280	0.870	rs1011082	chr17:38068514	T/C	cg00129232	chr17:37814104	STARD3	0.44	8.23	0.36	1.95e-15	Self-reported allergy;
LGG	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg18357526	chr6:26021779	HIST1H4A	0.93	17.51	0.63	4.91e-53	Intelligence (multi-trait analysis);
LGG	trans	rs17685	0.753	rs10264760	chr7:75749694	A/G	cg19862616	chr7:65841803	NCRNA00174	1.08	25.91	0.77	4e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.86	-0.45	1.31e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12190007	0.517	rs3006210	chr6:169828915	C/T	cg15038512	chr6:170123185	PHF10	-0.45	-8.51	-0.37	2.51e-16	Obesity-related traits;
LGG	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-11.75	-0.48	4.6e-28	Mood instability;
LGG	cis	rs58616815	0.857	rs1935254	chr10:92162463	A/G	cg17905462	chr10:92153495	NA	-0.25	-6.71	-0.3	5.63e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs3087591	1.000	rs2854332	chr17:29712378	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.71	-0.56	1.85e-40	Hip circumference;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg14675211	chr2:100938903	LONRF2	0.61	10.69	0.45	5.36e-24	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	1.000	rs3999221	chr6:26959322	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.65	-0.33	1.18e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg10760299	chr15:45669010	GATM	0.39	7.41	0.33	5.85e-13	Homoarginine levels;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg09303159	chr6:26284866	NA	0.34	7.91	0.34	1.93e-14	Educational attainment;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.12	-0.35	4.23e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05491587	chr18:77659695	KCNG2	-0.52	-7.02	-0.31	8.06e-12	Opioid sensitivity;
LGG	cis	rs933688	1.000	rs1541674	chr5:90660447	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.76	0.64	3.49e-54	Smoking behavior;
LGG	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.29	-0.63	5.05e-52	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.800	rs35463363	chr4:17613423	G/T	cg18681998	chr4:17616180	MED28	0.85	17.37	0.63	2.1e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs887829	0.570	rs10445704	chr2:234600274	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.46	-7.94	-0.35	1.51e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs7267979	1.000	rs2258884	chr20:25279539	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg07027305	chr7:2059796	MAD1L1	-0.31	-6.75	-0.3	4.45e-11	Bipolar disorder;
LGG	cis	rs4356203	0.870	rs214916	chr11:17241649	A/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.29	-0.32	1.39e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg25072359	chr17:41440525	NA	0.5	9.71	0.41	1.99e-20	Menopause (age at onset);
LGG	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg00092383	chr7:157075207	NA	-0.38	-6.68	-0.3	6.69e-11	Body mass index;
LGG	cis	rs861020	0.630	rs9308411	chr1:210005713	C/T	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15351736	chr11:111808104	DIXDC1	0.47	7.83	0.34	3.45e-14	Gut microbiome composition (summer);
LGG	cis	rs919433	0.889	rs787995	chr2:198216853	T/G	cg00792783	chr2:198669748	PLCL1	0.44	6.99	0.31	9.57e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg22907277	chr7:1156413	C7orf50	0.69	8.9	0.38	1.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2011503	1.000	rs55927782	chr19:19642032	T/C	cg11584989	chr19:19387371	SF4	0.73	11.63	0.48	1.31e-27	Bipolar disorder;
LGG	cis	rs72781680	0.950	rs72798404	chr2:24180125	C/T	cg08917208	chr2:24149416	ATAD2B	0.93	10.13	0.43	6.7e-22	Lymphocyte counts;
LGG	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg18825076	chr15:78729989	IREB2	-0.55	-9.19	-0.39	1.36e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs751728	0.717	rs3763260	chr6:33774070	C/T	cg25922239	chr6:33757077	LEMD2	0.65	9.97	0.42	2.42e-21	Crohn's disease;
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.35	-0.43	1.02e-22	Bipolar disorder;
LGG	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.28	-0.32	1.4e-12	Height;
LGG	cis	rs2688608	0.869	rs2633308	chr10:75653904	A/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-6.78	-0.3	3.7e-11	Inflammatory bowel disease;
LGG	cis	rs62238980	0.614	rs111301871	chr22:32540006	A/C	cg02631450	chr22:32366979	NA	0.99	9.34	0.4	4.17e-19	Childhood ear infection;
LGG	cis	rs4919087	0.884	rs4917762	chr10:98976471	G/T	cg25902810	chr10:99078978	FRAT1	0.52	9.76	0.41	1.35e-20	Monocyte count;
LGG	cis	rs1620921	0.505	rs4708886	chr6:161206350	G/T	cg01280913	chr6:161186852	NA	-0.53	-10.92	-0.45	7.68e-25	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9914988	1.000	rs6803	chr17:27187789	C/T	cg20469991	chr17:27169893	C17orf63	0.55	6.95	0.31	1.24e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs17067123	0.614	rs55983301	chr4:180070495	A/G	cg26610307	chr4:180072759	NA	-0.49	-7.02	-0.31	7.98e-12	Response to hepatitis C treatment;
LGG	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg07148914	chr20:33460835	GGT7	0.54	9.0	0.39	5.9e-18	Height;
LGG	cis	rs13424612	1.000	rs4149556	chr2:240915307	C/T	cg01812947	chr2:240904978	NDUFA10	0.42	7.01	0.31	8.53e-12	Odorant perception (isobutyraldehyde);
LGG	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.79	-0.41	1.05e-20	Coronary artery disease;
LGG	cis	rs3740540	0.507	rs897293	chr10:126290050	T/G	cg04949429	chr10:126290192	LHPP	0.61	11.84	0.48	1.96e-28	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg21948465	chr5:131705150	SLC22A5	-0.65	-7.32	-0.32	1.1e-12	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08501054	chr8:9413133	TNKS	-0.39	-6.66	-0.3	7.59e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.45	-0.33	4.64e-13	Mean corpuscular volume;
LGG	cis	rs4665809	0.590	rs1056389	chr2:26502875	T/C	cg22920501	chr2:26401640	FAM59B	0.46	9.48	0.4	1.38e-19	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.715	rs11525003	chr12:38332359	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.67	0.3	7.41e-11	Bladder cancer;
LGG	cis	rs10083830	0.628	rs4925084	chr17:19998958	C/T	cg13482628	chr17:19912719	NA	0.43	7.34	0.32	9.97e-13	Immature fraction of reticulocytes;
LGG	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg01262667	chr19:19385393	TM6SF2	0.43	10.79	0.45	2.23e-24	Tonsillectomy;
LGG	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg01200585	chr1:228362443	C1orf69	-0.45	-8.0	-0.35	1.04e-14	Diastolic blood pressure;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-7.37	-0.32	7.97e-13	Lung cancer;
LGG	cis	rs2153535	0.623	rs2152346	chr6:8454652	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.82e-22	Motion sickness;
LGG	cis	rs754423	0.515	rs8020227	chr14:52545391	C/G	cg12071775	chr14:52591786	NA	0.41	6.85	0.3	2.36e-11	Craniofacial microsomia;
LGG	cis	rs1003719	0.788	rs2835600	chr21:38468958	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08280861	chr8:58055591	NA	0.63	7.76	0.34	5.62e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2860975	0.967	rs11188134	chr10:96774255	G/C	cg09036531	chr10:96991505	NA	-0.49	-8.82	-0.38	2.26e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg01221209	chr5:554886	NA	-0.38	-7.01	-0.31	8.54e-12	Obesity-related traits;
LGG	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.19	0.36	2.51e-15	Mood instability;
LGG	cis	rs2470578	0.792	rs2167119	chr3:17262139	A/G	cg20981856	chr3:17787350	NA	0.35	6.7	0.3	6.04e-11	Schizophrenia;
LGG	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	32.16	0.83	4.36e-120	Chronic sinus infection;
LGG	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.28	-0.32	1.46e-12	Systemic lupus erythematosus;
LGG	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-9.93	-0.42	3.52e-21	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg01346077	chr3:125931526	NA	-0.59	-14.31	-0.55	9.72e-39	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs6120849	0.754	rs6120790	chr20:33599090	A/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.35e-11	Protein C levels;
LGG	cis	rs6546537	0.840	rs34743816	chr2:69813345	A/C	cg10773587	chr2:69614142	GFPT1	-0.43	-7.37	-0.32	7.71e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs6456156	0.774	rs2022001	chr6:167529509	C/T	cg07741184	chr6:167504864	NA	-0.3	-6.71	-0.3	5.71e-11	Primary biliary cholangitis;
LGG	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg24596788	chr1:163392923	NA	0.63	11.86	0.48	1.66e-28	Motion sickness;
LGG	cis	rs1697139	0.583	rs1428475	chr5:66543954	G/T	cg11553311	chr5:66541588	NA	0.45	10.15	0.43	5.56e-22	Breast cancer;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg18402987	chr7:1209562	NA	0.67	9.13	0.39	2.15e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4731207	0.698	rs10252039	chr7:124539537	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.72	-0.34	7.35e-14	Cutaneous malignant melanoma;
LGG	cis	rs7444	0.941	rs140489	chr22:21921294	G/A	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.85e-11	Systemic lupus erythematosus;
LGG	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.42	-0.36	4.64e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9341835	0.772	rs9449233	chr6:64138234	G/T	cg00787780	chr6:64151745	NA	0.42	7.68	0.34	9.46e-14	Schizophrenia;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs2354432	0.607	rs1890039	chr1:146681951	T/C	cg25205988	chr1:146714368	CHD1L	1.09	9.39	0.4	2.82e-19	Mitochondrial DNA levels;
LGG	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg04455712	chr21:45112962	RRP1B	0.51	9.71	0.41	2.02e-20	Mean corpuscular volume;
LGG	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.94	-0.38	9.3e-18	Colorectal cancer;
LGG	cis	rs9487094	0.626	rs12192776	chr6:109955353	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.79	0.34	4.45e-14	Height;
LGG	cis	rs6032067	0.641	rs62206437	chr20:43759316	T/C	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.18	-0.32	2.79e-12	Calcium levels;
LGG	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.3	0.4	5.58e-19	Height;
LGG	cis	rs523522	0.962	rs11065145	chr12:120947419	A/G	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg22903471	chr2:27725779	GCKR	-0.57	-12.93	-0.51	7.57e-33	Total body bone mineral density;
LGG	cis	rs11098499	0.697	rs10016448	chr4:120298845	A/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg06916706	chr16:4465613	CORO7	-0.9	-16.1	-0.6	1.17e-46	Schizophrenia;
LGG	cis	rs2133450	0.712	rs1508708	chr3:7364572	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.12	-0.35	4.24e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs977987	0.778	rs4888426	chr16:75476451	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.22	0.43	3e-22	Dupuytren's disease;
LGG	cis	rs67478160	0.619	rs12886363	chr14:104273786	T/C	cg26031613	chr14:104095156	KLC1	-0.47	-7.65	-0.34	1.16e-13	Schizophrenia;
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.78	-0.34	4.67e-14	Dementia with Lewy bodies;
LGG	cis	rs10744422	1.000	rs897385	chr12:123341297	A/G	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	5.35e-19	Schizophrenia;
LGG	cis	rs11074306	0.561	rs9806708	chr15:28073079	G/A	cg26402630	chr15:28053930	OCA2	0.36	7.28	0.32	1.42e-12	Uveal melanoma;
LGG	cis	rs9807989	0.507	rs3213732	chr2:102998279	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs9815354	1.000	rs73079321	chr3:41863910	C/T	cg03022575	chr3:42003672	ULK4	0.67	8.59	0.37	1.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg07414643	chr4:187882934	NA	0.44	8.9	0.38	1.25e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.64	0.33	1.3e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs8177253	0.763	rs6797713	chr3:133474832	T/C	cg11941060	chr3:133502564	NA	-0.46	-7.21	-0.32	2.31e-12	Iron status biomarkers;
LGG	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg11166453	chr1:247681781	NA	0.63	10.23	0.43	2.7e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8179	0.553	rs42377	chr7:92243672	G/A	cg15732164	chr7:92237376	CDK6	-0.51	-10.53	-0.44	2.12e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg18451016	chr1:38461880	NA	-0.49	-8.45	-0.37	3.93e-16	Coronary artery disease;
LGG	cis	rs6694672	1.000	rs4915313	chr1:197049355	G/T	cg13682187	chr1:196946512	CFHR5	0.51	7.17	0.32	2.95e-12	Asthma;
LGG	cis	rs7819412	0.521	rs2409720	chr8:11037903	A/C	cg21775007	chr8:11205619	TDH	-0.51	-8.06	-0.35	6.52e-15	Triglycerides;
LGG	trans	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7819412	0.540	rs2409725	chr8:11041661	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.11	-0.35	4.53e-15	Triglycerides;
LGG	cis	rs7918232	0.941	rs1753415	chr10:27395102	T/C	cg14442939	chr10:27389572	ANKRD26	0.75	11.11	0.46	1.35e-25	Breast cancer;
LGG	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg24189917	chr7:1970923	MAD1L1	-0.47	-7.93	-0.35	1.62e-14	Bipolar disorder;
LGG	cis	rs9303401	0.659	rs17222621	chr17:56695923	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs2072438	0.503	rs1323474	chr9:123852859	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.5	9.13	0.39	2.09e-18	Rheumatoid arthritis;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16680214	chr1:154839983	KCNN3	-0.5	-9.89	-0.42	4.61e-21	Prostate cancer;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.22	0.32	2.1e-12	Height;
LGG	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg16301924	chr13:53314226	LECT1	0.37	7.02	0.31	8.11e-12	Lewy body disease;
LGG	cis	rs1552244	0.554	rs6762594	chr3:9995516	G/A	cg08888203	chr3:10149979	C3orf24	0.34	6.7	0.3	6.05e-11	Alzheimer's disease;
LGG	cis	rs2294693	0.945	rs11756893	chr6:41010058	A/C	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.74	-0.3	4.62e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg16386425	chr10:429943	DIP2C	-0.37	-7.23	-0.32	2.01e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19748678	chr4:122722346	EXOSC9	0.44	7.87	0.34	2.62e-14	Type 2 diabetes;
LGG	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs7765175	1.000	rs7765175	chr6:113665327	C/T	cg26552650	chr6:113682475	NA	-0.31	-6.79	-0.3	3.36e-11	Coronary artery calcification;
LGG	cis	rs11690935	0.632	rs34242651	chr2:172553999	G/A	cg13550731	chr2:172543902	DYNC1I2	0.71	14.56	0.56	8.24e-40	Schizophrenia;
LGG	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04935121	chr11:63775413	MACROD1	0.3	7.17	0.32	3.02e-12	Pulse pressure;
LGG	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg20573242	chr4:122745356	CCNA2	0.6	11.8	0.48	2.93e-28	Type 2 diabetes;
LGG	cis	rs514406	0.861	rs2065477	chr1:53250213	C/T	cg16325326	chr1:53192061	ZYG11B	0.82	17.94	0.64	5.23e-55	Monocyte count;
LGG	cis	rs2694528	0.844	rs1563522	chr5:60057932	A/G	cg11474532	chr5:59995715	DEPDC1B	0.72	7.65	0.34	1.17e-13	Parkinson's disease;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.31	-0.36	1.08e-15	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg17852997	chr13:21100460	CRYL1	0.42	6.8	0.3	3.17e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7717393	1.000	rs17053447	chr5:155769694	A/T	cg01474424	chr5:155754231	SGCD	-0.82	-7.82	-0.34	3.6e-14	Egg allergy;
LGG	cis	rs877426	0.634	rs7329801	chr13:114824560	G/A	cg27119904	chr13:114814333	RASA3	0.35	7.17	0.32	2.91e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs12477438	0.798	rs10202452	chr2:99569409	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.97	0.42	2.47e-21	Schizophrenia;
LGG	cis	rs2204008	0.627	rs11176531	chr12:38152166	T/G	cg13010199	chr12:38710504	ALG10B	0.68	13.12	0.52	1.13e-33	Bladder cancer;
LGG	cis	rs6502050	0.799	rs6416859	chr17:80111442	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg08200770	chr17:80723486	TBCD	0.46	8.32	0.36	1.01e-15	Glycated hemoglobin levels;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.46	-7.76	-0.34	5.65e-14	Renal function-related traits (BUN);
LGG	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg03351412	chr1:154909251	PMVK	0.65	12.2	0.49	7.12e-30	Prostate cancer;
LGG	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg06219351	chr7:158114137	PTPRN2	-0.69	-13.59	-0.53	1.28e-35	Calcium levels;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.644	rs4832264	chr2:86486834	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.9	0.31	1.74e-11	Night sleep phenotypes;
LGG	cis	rs10489202	0.608	rs6657019	chr1:168079669	T/C	cg24449463	chr1:168025552	DCAF6	-0.56	-10.03	-0.42	1.47e-21	Schizophrenia;
LGG	cis	rs3617	0.625	rs2239548	chr3:52854186	A/C	cg11645453	chr3:52864694	ITIH4	0.43	7.27	0.32	1.58e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6977660	0.660	rs12531296	chr7:19816450	A/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs12701220	0.894	rs12701406	chr7:1050283	G/A	cg20821713	chr7:1055600	C7orf50	-0.51	-8.04	-0.35	7.56e-15	Bronchopulmonary dysplasia;
LGG	cis	rs1008375	0.618	rs6842764	chr4:17568420	C/T	cg18681998	chr4:17616180	MED28	-0.82	-15.68	-0.59	9.43e-45	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg22358067	chr17:16797159	NA	-0.5	-6.8	-0.3	3.19e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6784615	0.744	rs4312651	chr3:52506282	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs1267303	0.682	rs1998545	chr1:46954587	C/T	cg22795216	chr1:47078649	MOBKL2C	-0.39	-7.17	-0.32	3e-12	Monobrow;
LGG	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg08344181	chr3:125677491	NA	-0.64	-7.48	-0.33	3.64e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.66	0.54	6.45e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10895140	0.756	rs2508729	chr11:101491051	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs2228479	0.681	rs8044906	chr16:89969603	T/C	cg04287289	chr16:89883240	FANCA	0.6	6.8	0.3	3.29e-11	Skin colour saturation;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2648832	1.000	rs2648832	chr8:129150668	A/C	cg27509867	chr8:129165585	NA	0.36	7.96	0.35	1.29e-14	Tonsillectomy;
LGG	cis	rs963731	0.522	rs1037495	chr2:39209426	A/G	cg04010122	chr2:39346883	SOS1	-0.67	-6.77	-0.3	4.02e-11	Corticobasal degeneration;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	6.93	0.31	1.4e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1401999	0.898	rs4148564	chr3:183725982	C/T	cg01324343	chr3:183735012	ABCC5	0.9	18.88	0.66	2.22e-59	Anterior chamber depth;
LGG	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg20818283	chr2:191399100	TMEM194B	0.3	7.1	0.31	4.79e-12	Pulse pressure;
LGG	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.36e-18	Motion sickness;
LGG	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.4	-0.36	5.66e-16	Depression;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg04166393	chr7:2884313	GNA12	0.45	8.45	0.37	3.82e-16	Height;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg07701084	chr6:150067640	NUP43	0.5	7.49	0.33	3.54e-13	Lung cancer;
LGG	cis	rs939658	0.935	rs12903747	chr15:79449627	A/C	cg17916960	chr15:79447300	NA	0.62	12.28	0.5	3.4e-30	Refractive error;
LGG	cis	rs9972944	0.756	rs7218844	chr17:63768289	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg25358565	chr5:93447407	FAM172A	1.28	15.96	0.6	5.5e-46	Diabetic retinopathy;
LGG	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.32	-0.32	1.07e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3857067	1.000	rs4693364	chr4:95012284	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.5	-0.33	3.38e-13	QT interval;
LGG	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	trans	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.67	-0.34	9.94e-14	Triglycerides;
LGG	cis	rs9815354	0.812	rs11129932	chr3:41838767	C/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg05368731	chr17:41323189	NBR1	0.97	19.12	0.66	1.65e-60	Menopause (age at onset);
LGG	trans	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg25214090	chr10:38739885	LOC399744	-0.58	-10.61	-0.44	1.05e-23	Corneal astigmatism;
LGG	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg25174290	chr11:3078921	CARS	0.74	15.83	0.59	2.06e-45	Longevity;
LGG	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg14664628	chr15:75095509	CSK	0.6	9.94	0.42	3.03e-21	Systemic lupus erythematosus;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg04008888	chr11:68622739	NA	-0.54	-11.61	-0.47	1.64e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.65	-0.48	1.1e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs11676348	0.772	rs10932745	chr2:218942976	T/C	cg04731861	chr2:219085781	ARPC2	0.28	6.73	0.3	4.89e-11	Ulcerative colitis;
LGG	cis	rs9470366	0.805	rs1321313	chr6:36618821	C/T	cg08179530	chr6:36648295	CDKN1A	0.6	8.31	0.36	1.04e-15	QRS duration;
LGG	cis	rs600231	0.683	rs588298	chr11:65253574	A/G	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.11	-0.39	2.52e-18	Bone mineral density;
LGG	cis	rs7267979	1.000	rs6050559	chr20:25329915	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs6684428	1.000	rs12141873	chr1:56374311	G/T	cg11651538	chr1:56320950	NA	-0.75	-13.09	-0.52	1.63e-33	Airflow obstruction;
LGG	cis	rs4072980	0.545	rs7528185	chr1:38452059	C/T	cg26528311	chr1:38462546	FHL3	-0.31	-7.05	-0.31	6.66e-12	Coronary artery disease;
LGG	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg21918786	chr6:109611834	NA	0.48	8.94	0.38	9.34e-18	Reticulocyte fraction of red cells;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.07	0.35	6.16e-15	Obesity-related traits;
LGG	cis	rs6445975	0.666	rs11710823	chr3:58396493	A/G	cg24175188	chr3:58374923	PXK	-0.55	-8.93	-0.38	9.96e-18	Systemic lupus erythematosus;
LGG	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg19077165	chr18:44547161	KATNAL2	-0.51	-9.0	-0.39	6.03e-18	Educational attainment;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.9	-0.42	4.41e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7264396	0.635	rs6058366	chr20:34512172	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.4e-12	Total cholesterol levels;
LGG	cis	rs283228	0.605	rs659271	chr6:101733189	A/C	cg27451362	chr6:101846650	GRIK2	0.9	13.19	0.52	6.18e-34	Coenzyme Q10 levels;
LGG	cis	rs8017423	0.607	rs12885664	chr14:90845697	T/C	cg04374321	chr14:90722782	PSMC1	-0.61	-11.28	-0.46	3.01e-26	Mortality in heart failure;
LGG	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg12310025	chr6:25882481	NA	-0.47	-7.47	-0.33	4.01e-13	Height;
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26897989	chr16:1907736	C16orf73	0.84	14.04	0.55	1.53e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2073300	0.609	rs6132609	chr20:23400412	A/C	cg12062639	chr20:23401060	NAPB	0.93	9.05	0.39	3.99e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg04503457	chr17:41445688	NA	0.38	9.16	0.39	1.69e-18	Menopause (age at onset);
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14159672	chr1:205819179	PM20D1	0.9	21.79	0.71	5.65e-73	Menarche (age at onset);
LGG	cis	rs9547996	0.879	rs73184517	chr13:38194023	G/A	cg17979426	chr13:38220150	TRPC4	-0.37	-7.08	-0.31	5.44e-12	Diastolic blood pressure;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg14675211	chr2:100938903	LONRF2	0.65	11.42	0.47	8.57e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs427394	0.802	rs274712	chr5:6723950	G/A	cg10857441	chr5:6722123	POLS	-0.27	-6.7	-0.3	6.2e-11	Menopause (age at onset);
LGG	cis	rs7614311	0.636	rs66818634	chr3:63913222	G/A	cg22134162	chr3:63841271	THOC7	-0.44	-7.78	-0.34	4.7e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.69	-13.23	-0.52	3.95e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs638893	0.578	rs580079	chr11:118625609	C/T	cg13782932	chr11:118662891	DDX6	0.38	6.82	0.3	2.82e-11	Vitiligo;
LGG	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg08999081	chr20:33150536	PIGU	0.44	11.44	0.47	7.45e-27	Coronary artery disease;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10464366	0.957	rs12667577	chr7:39095133	T/G	cg20302533	chr7:39170763	POU6F2	0.5	11.49	0.47	4.72e-27	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	0.941	rs112569713	chr17:30271738	C/T	cg13647721	chr17:30228624	UTP6	0.6	7.78	0.34	4.83e-14	Hip circumference adjusted for BMI;
LGG	cis	rs897984	0.542	rs6565217	chr16:31083324	C/T	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.41e-14	Dementia with Lewy bodies;
LGG	cis	rs9796	0.804	rs28688742	chr15:41403638	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.69	-0.41	2.49e-20	Menopause (age at onset);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg15692687	chr8:27950300	ELP3	-0.42	-6.75	-0.3	4.46e-11	Body fat percentage;
LGG	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.591	rs903692	chr1:227732721	A/G	cg04117972	chr1:227635322	NA	0.46	8.62	0.37	1.04e-16	Major depressive disorder;
LGG	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08109568	chr15:31115862	NA	0.6	10.21	0.43	3.38e-22	Huntington's disease progression;
LGG	cis	rs7927771	0.800	rs12146565	chr11:47398963	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.28	-0.43	1.8e-22	Subjective well-being;
LGG	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg07636037	chr3:49044803	WDR6	1.02	23.25	0.73	8.44e-80	Parkinson's disease;
LGG	cis	rs9910055	0.529	rs228746	chr17:42173752	T/C	cg16434002	chr17:42200994	HDAC5	0.45	8.13	0.35	3.89e-15	Total body bone mineral density;
LGG	cis	rs17767392	0.767	rs61989382	chr14:71983638	T/C	cg02058870	chr14:72053146	SIPA1L1	0.4	8.37	0.36	6.75e-16	Mitral valve prolapse;
LGG	trans	rs2243480	1.000	rs2243480	chr7:65599196	C/T	cg10756647	chr7:56101905	PSPH	0.75	8.38	0.36	6.5e-16	Diabetic kidney disease;
LGG	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg19784903	chr17:45786737	TBKBP1	0.33	7.06	0.31	6.32e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg18379455	chr17:41446167	NA	-0.34	-7.69	-0.34	8.81e-14	Menopause (age at onset);
LGG	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg15704280	chr7:45808275	SEPT13	-0.86	-13.76	-0.54	2.3e-36	Coronary artery disease;
LGG	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.94	-0.31	1.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg21782813	chr7:2030301	MAD1L1	0.47	10.99	0.46	3.84e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9868809	0.881	rs3821876	chr3:48668394	G/T	cg00383909	chr3:49044727	WDR6	0.83	9.59	0.41	5.61e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs308971	0.563	rs307611	chr3:12063344	G/C	cg15873301	chr3:12045459	SYN2	0.56	7.25	0.32	1.77e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs3735485	0.738	rs10279523	chr7:45101645	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.58	-0.41	6.12e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs4740619	0.619	rs752490	chr9:16032570	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.35	-0.47	1.6e-26	Body mass index;
LGG	cis	rs28595532	0.920	rs115437723	chr4:119741828	C/T	cg14228332	chr4:119757509	SEC24D	1.0	10.35	0.43	1.05e-22	Cannabis dependence symptom count;
LGG	cis	rs42648	0.564	rs6465248	chr7:89824740	C/T	cg04070188	chr7:89809444	NA	-0.28	-6.69	-0.3	6.32e-11	Homocysteine levels;
LGG	cis	rs11676348	0.774	rs4672870	chr2:218941916	C/T	cg00012203	chr2:219082015	ARPC2	-0.49	-8.56	-0.37	1.74e-16	Ulcerative colitis;
LGG	cis	rs1927790	0.697	rs7981931	chr13:96934176	C/T	cg02571835	chr13:96230311	CLDN10	-0.36	-7.31	-0.32	1.18e-12	Body mass index;
LGG	trans	rs4942242	0.663	rs7319346	chr13:44218201	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-8.82	-0.38	2.31e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3857067	0.806	rs11943926	chr4:95136512	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.58	-0.37	1.4e-16	QT interval;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg04503457	chr17:41445688	NA	-0.39	-9.23	-0.39	9.78e-19	Menopause (age at onset);
LGG	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs7904368	0.806	rs45495501	chr10:16861476	G/A	cg23933602	chr10:16859644	RSU1	0.64	9.4	0.4	2.44e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06894651	chr1:151689203	TNRC4	0.6	7.08	0.31	5.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4740619	0.740	rs1539173	chr9:15784865	C/T	cg14451791	chr9:16040625	NA	0.32	8.2	0.36	2.32e-15	Body mass index;
LGG	cis	rs6868223	0.585	rs10065767	chr5:33643085	A/G	cg10594543	chr5:33649717	ADAMTS12	0.67	15.87	0.59	1.3e-45	Mortality in heart failure;
LGG	cis	rs11608355	0.552	rs2304549	chr12:109794875	A/G	cg19025524	chr12:109796872	NA	-0.6	-13.09	-0.52	1.55e-33	Neuroticism;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg13903179	chr13:21900392	NA	0.41	7.12	0.31	4.1e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg14346243	chr4:90757452	SNCA	-0.41	-8.39	-0.36	6.15e-16	Dementia with Lewy bodies;
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.67	-0.37	7.44e-17	Retinal vascular caliber;
LGG	cis	rs7107174	1.000	rs72931690	chr11:78073192	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg27189623	chr16:705930	WDR90	0.41	7.84	0.34	3.03e-14	Height;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg25300318	chr2:200527297	NA	0.68	7.3	0.32	1.26e-12	Airflow obstruction;
LGG	cis	rs3820068	0.581	rs6666373	chr1:15939884	A/T	cg05660106	chr1:15850417	CASP9	0.86	17.39	0.63	1.68e-52	Systolic blood pressure;
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs2280018	0.526	rs2966129	chr16:15152927	A/C	cg07549590	chr16:15018862	NA	0.58	9.89	0.42	4.75e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg05234568	chr11:5960015	NA	-0.67	-11.15	-0.46	9.58e-26	DNA methylation (variation);
LGG	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg23601095	chr6:26197514	HIST1H3D	0.69	8.75	0.38	3.85e-17	Gout;Renal underexcretion gout;
LGG	cis	rs2797369	0.656	rs846796	chr6:101364363	G/T	cg27451362	chr6:101846650	GRIK2	0.77	10.53	0.44	2.11e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs10870270	1.000	rs6560695	chr10:133774986	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.67	-0.54	5.36e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.72	-0.34	7.24e-14	Joint mobility (Beighton score);
LGG	cis	rs3790455	0.560	rs1171557	chr1:156451264	C/T	cg14087168	chr1:156450669	MEF2D	-0.65	-9.42	-0.4	2.13e-19	Migraine;
LGG	cis	rs28489187	0.683	rs1498373	chr1:85790633	G/A	cg16011679	chr1:85725395	C1orf52	0.35	6.7	0.3	6.01e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs888194	0.690	rs877710	chr12:109993976	C/G	cg19025524	chr12:109796872	NA	-0.35	-7.11	-0.31	4.29e-12	Neuroticism;
LGG	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg20503657	chr10:835505	NA	0.76	10.49	0.44	3.18e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs4665809	0.531	rs12990692	chr2:26464939	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	trans	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg25214090	chr10:38739885	LOC399744	-0.57	-10.22	-0.43	2.95e-22	Corneal astigmatism;
LGG	cis	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg12826209	chr6:26865740	GUSBL1	0.73	7.92	0.35	1.82e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.05	18.89	0.66	1.92e-59	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.78	0.41	1.13e-20	Neuroticism;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg14675211	chr2:100938903	LONRF2	0.61	10.71	0.45	4.73e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2201728	0.652	rs66715038	chr4:100173052	C/G	cg07219303	chr4:100140905	ADH6	-0.38	-6.94	-0.31	1.31e-11	Cardiac Troponin-T levels;
LGG	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg02175503	chr12:58329896	NA	0.55	9.01	0.39	5.44e-18	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.87	0.3	2.1e-11	Retinal vascular caliber;
LGG	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg08250081	chr4:10125330	NA	0.61	11.45	0.47	6.66e-27	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg21053147	chr12:120880522	NA	0.53	7.75	0.34	5.77e-14	Type 1 diabetes nephropathy;
LGG	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.54	7.57	0.33	1.99e-13	Schizophrenia;
LGG	trans	rs6076960	0.744	rs6516125	chr20:6165320	G/C	cg21095983	chr6:86352623	SYNCRIP	0.54	9.74	0.41	1.67e-20	Smooth-surface caries;
LGG	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg18876405	chr7:65276391	NA	0.59	10.82	0.45	1.72e-24	Aortic root size;
LGG	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg22681709	chr2:178499509	PDE11A	-0.52	-7.59	-0.33	1.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1552244	0.832	rs61056817	chr3:10027641	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.14	0.31	3.68e-12	Alzheimer's disease;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21963583	chr11:68658836	MRPL21	0.61	10.38	0.43	7.53e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.23	-0.49	5.23e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.06	-0.31	5.93e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs10504073	0.669	rs341802	chr8:50039313	C/T	cg00325661	chr8:49890786	NA	0.68	13.3	0.53	2.11e-34	Blood metabolite ratios;
LGG	cis	rs714515	0.934	rs1011731	chr1:172346548	A/G	cg01573306	chr1:172330400	DNM3	-0.33	-7.03	-0.31	7.47e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9660992	0.573	rs12125276	chr1:205199440	C/T	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg03078520	chr22:18463400	MICAL3	0.66	13.66	0.54	5.95e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.88	0.3	1.96e-11	Educational attainment;
LGG	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg19303637	chr13:24153954	TNFRSF19	0.4	7.31	0.32	1.18e-12	Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22337169	chr7:100218717	TFR2	0.42	6.89	0.3	1.84e-11	Pancreatic cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00821051	chr10:131592591	NA	0.35	6.92	0.31	1.56e-11	Electrocardiographic conduction measures;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg04080417	chr5:1859792	NA	-0.48	-7.48	-0.33	3.68e-13	Cardiovascular disease risk factors;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-9.0	-0.39	5.94e-18	Lung cancer;
LGG	trans	rs2018683	0.677	rs55718000	chr7:28975625	T/C	cg19402173	chr7:128379420	CALU	-0.53	-9.27	-0.4	7.23e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	cis	rs3789045	0.866	rs11584700	chr1:204576983	C/T	cg17419461	chr1:204415978	PIK3C2B	0.41	8.0	0.35	1.01e-14	Educational attainment (college completion);
LGG	cis	rs2777491	0.707	rs1757456	chr15:41793494	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.84	-15.57	-0.59	2.88e-44	Ulcerative colitis;
LGG	cis	rs1015291	0.836	rs1352902	chr12:19990847	A/G	cg25401612	chr12:20009446	NA	-0.32	-6.96	-0.31	1.18e-11	Diastolic blood pressure;
LGG	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.05	23.36	0.74	2.68e-80	Height;
LGG	cis	rs7712401	0.601	rs30055	chr5:122301079	T/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg26150922	chr2:100937072	LONRF2	-0.57	-10.87	-0.45	1.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg00684032	chr4:1343700	KIAA1530	0.5	9.85	0.42	6.4e-21	Obesity-related traits;
LGG	cis	rs908922	0.676	rs7550769	chr1:152531213	G/A	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs12478296	0.792	rs57482298	chr2:243011148	C/A	cg06360820	chr2:242988706	NA	-0.96	-11.28	-0.46	3.05e-26	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs11735193	chr4:98761900	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7939886	0.920	rs78769647	chr11:55965527	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.78	0.34	4.68e-14	Myopia (pathological);
LGG	cis	rs10463316	0.823	rs7700342	chr5:150776323	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.48	-0.44	3.46e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs9398803	0.865	rs9385401	chr6:126789472	C/T	cg19875578	chr6:126661172	C6orf173	0.58	10.51	0.44	2.48e-23	Male-pattern baldness;
LGG	cis	rs6754311	0.731	rs6719488	chr2:136575199	G/T	cg07169764	chr2:136633963	MCM6	-0.75	-12.8	-0.51	2.44e-32	Mosquito bite size;
LGG	cis	rs35306767	0.953	rs1106064	chr10:957211	G/A	cg08847335	chr10:891726	LARP4B	-0.37	-7.04	-0.31	7.18e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.05	0.31	6.7e-12	Aortic root size;
LGG	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.89	-0.51	1.08e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg14343214	chr6:133562056	EYA4	0.32	7.52	0.33	2.92e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs1927702	0.706	rs7031725	chr9:16011898	C/T	cg14451791	chr9:16040625	NA	0.28	6.87	0.3	2.14e-11	Body mass index;
LGG	trans	rs11875185	0.510	rs78073450	chr18:55648678	G/A	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg20891283	chr12:69753455	YEATS4	0.8	16.24	0.6	2.99e-47	Blood protein levels;
LGG	cis	rs6500395	0.928	rs12934788	chr16:48706343	C/A	cg04672837	chr16:48644449	N4BP1	-0.53	-8.82	-0.38	2.26e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg02002194	chr4:3960332	NA	-0.46	-8.74	-0.38	4.45e-17	Mood instability;
LGG	cis	rs8072100	0.967	rs4239163	chr17:45755954	C/T	cg19784903	chr17:45786737	TBKBP1	-0.35	-7.73	-0.34	6.7e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs67460515	0.892	rs34016896	chr3:160992864	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-9.99	-0.42	2.07e-21	Parkinson's disease;
LGG	cis	rs3770081	1.000	rs3770087	chr2:86267068	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.93	-0.31	1.38e-11	Facial emotion recognition (sad faces);
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.01e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs2159584	chr4:17620568	G/A	cg04450456	chr4:17643702	FAM184B	0.32	7.12	0.31	4.04e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9467773	1.000	rs9393732	chr6:26530898	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg05468064	chr22:46423449	NA	0.39	6.99	0.31	9.43e-12	Dupuytren's disease;
LGG	trans	rs853679	0.556	rs13197633	chr6:28174757	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.39	-0.43	7.22e-23	Depression;
LGG	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg18357526	chr6:26021779	HIST1H4A	0.49	8.14	0.35	3.73e-15	Height;
LGG	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg22437258	chr11:111473054	SIK2	-0.51	-8.72	-0.38	4.99e-17	Primary sclerosing cholangitis;
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	10.92	0.45	7.33e-25	Total body bone mineral density;
LGG	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg13397359	chr6:42928475	GNMT	-0.45	-9.68	-0.41	2.56e-20	Blood protein levels;
LGG	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.99	0.39	6.18e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg16141378	chr3:129829833	LOC729375	0.48	12.31	0.5	2.52e-30	Mood instability;
LGG	cis	rs2439831	1.000	rs471229	chr15:43733994	G/A	cg15269541	chr15:43626905	ADAL	-0.42	-7.02	-0.31	7.73e-12	Lung cancer in ever smokers;
LGG	trans	rs6598955	0.616	rs11247890	chr1:26590182	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-13.04	-0.52	2.54e-33	Obesity-related traits;
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.97	-0.42	2.45e-21	Bipolar disorder;
LGG	cis	rs4650994	0.816	rs2209169	chr1:178601492	C/T	cg19399532	chr1:178512495	C1orf220	-0.37	-7.01	-0.31	8.38e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.49	-0.56	1.7e-39	Tonsillectomy;
LGG	cis	rs367943	0.712	rs9326888	chr5:112731133	A/C	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.29e-23	Type 2 diabetes;
LGG	cis	rs7765175	0.698	rs2029555	chr6:113671846	C/T	cg26552650	chr6:113682475	NA	0.34	7.66	0.34	1.11e-13	Coronary artery calcification;
LGG	cis	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg19413766	chr7:29689036	LOC646762	-0.52	-7.42	-0.33	5.71e-13	Facial emotion recognition (angry faces);
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.62	-0.33	1.43e-13	Personality dimensions;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg17178900	chr1:205818956	PM20D1	0.69	16.54	0.61	1.22e-48	Menarche (age at onset);
LGG	cis	rs7226408	0.600	rs9954330	chr18:34648977	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.18	-0.39	1.4e-18	Obesity-related traits;
LGG	cis	rs1790761	0.505	rs7927657	chr11:67346988	T/C	cg09038676	chr11:67351608	GSTP1	0.36	7.06	0.31	5.97e-12	Mean corpuscular volume;
LGG	cis	rs3796352	1.000	rs13072395	chr3:52980573	T/C	cg12962167	chr3:53033115	SFMBT1	0.78	8.25	0.36	1.61e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg05791153	chr7:19748676	TWISTNB	0.74	10.41	0.44	5.96e-23	Thyroid stimulating hormone;
LGG	cis	rs11122272	0.735	rs2790873	chr1:231539685	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.85	-0.45	1.42e-24	Hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.63	-0.41	3.85e-20	Lung cancer;
LGG	cis	rs911555	0.755	rs7148567	chr14:103882234	C/T	cg24130564	chr14:104152367	KLC1	-0.38	-7.1	-0.31	4.76e-12	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.737	rs175065	chr14:75494983	T/C	cg08847533	chr14:75593920	NEK9	-0.53	-9.89	-0.42	4.62e-21	Height;
LGG	trans	rs931812	0.825	rs35515344	chr8:101896769	C/G	cg20993868	chr7:22813445	NA	0.7	13.02	0.52	3.15e-33	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg14675211	chr2:100938903	LONRF2	0.64	11.24	0.46	4.5e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2133450	0.526	rs62234954	chr3:7342912	A/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.5	-0.4	1.13e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs10936602	0.500	rs10049456	chr3:169563523	T/G	cg08193579	chr3:169529701	LRRC34	0.39	7.8	0.34	4.04e-14	Renal cell carcinoma;
LGG	cis	rs6032067	0.636	rs6104092	chr20:43906730	A/G	cg10761708	chr20:43804764	PI3	-0.58	-8.88	-0.38	1.47e-17	Blood protein levels;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04008888	chr11:68622739	NA	-0.55	-11.97	-0.49	6.06e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504130	0.666	rs7819892	chr8:52845476	A/C	cg22653915	chr8:52722023	PXDNL	0.49	8.25	0.36	1.61e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg15532942	chr18:77220712	NFATC1	0.51	7.37	0.32	7.93e-13	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.534	rs4931775	chr12:34050729	G/A	cg13010199	chr12:38710504	ALG10B	0.56	10.44	0.44	4.76e-23	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg01879757	chr17:41196368	BRCA1	-0.4	-8.2	-0.36	2.39e-15	Menopause (age at onset);
LGG	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg25986240	chr4:9926439	SLC2A9	0.37	7.57	0.33	2.02e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs78049276	0.688	rs56024659	chr4:148378604	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.77	-0.34	5.16e-14	Pulse pressure;
LGG	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg19913688	chr11:428466	ANO9	-0.69	-8.31	-0.36	1.04e-15	Body mass index;
LGG	cis	rs3862030	0.594	rs7923675	chr10:104235809	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	9.08	0.39	3.18e-18	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7084783	0.538	rs1077016	chr10:105333242	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.47	8.14	0.35	3.72e-15	Fear of pain;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs1461503	0.512	rs4259833	chr11:122809205	G/A	cg27398637	chr11:122830231	C11orf63	-0.67	-13.06	-0.52	2.06e-33	Menarche (age at onset);
LGG	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	cis	rs212524	0.623	rs212534	chr1:21590754	C/T	cg02994246	chr1:21587174	ECE1	-0.29	-6.94	-0.31	1.35e-11	Height;
LGG	cis	rs17253792	0.822	rs78429067	chr14:56092551	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.06	-0.31	5.96e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs13082711	0.911	rs13077400	chr3:27473066	A/G	cg02860705	chr3:27208620	NA	0.69	12.53	0.5	3.11e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.3	0.36	1.18e-15	Retinal vascular caliber;
LGG	cis	rs11971779	0.523	rs10234578	chr7:139037988	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg05194412	chr2:137003533	NA	0.38	8.1	0.35	4.8e-15	Colorectal cancer;
LGG	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg12395012	chr8:11607386	GATA4	-0.39	-7.13	-0.31	3.95e-12	Monocyte count;
LGG	cis	rs1801251	1.000	rs3817311	chr2:233612557	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	6.91e-32	Coronary artery disease;
LGG	trans	rs34421088	0.623	rs4841515	chr8:11097166	C/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.62	-0.33	1.42e-13	Neuroticism;
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.74e-12	Tonsillectomy;
LGG	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg20283391	chr11:68216788	NA	-0.49	-8.06	-0.35	6.49e-15	Total body bone mineral density;
LGG	cis	rs236352	0.521	rs58214515	chr6:36827416	T/C	cg03410223	chr6:36853544	C6orf89	0.43	7.91	0.35	1.87e-14	Heart rate;
LGG	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg23335576	chr14:104009727	NA	0.47	8.17	0.36	2.88e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35740288	0.770	rs12898597	chr15:86189919	T/C	cg04173714	chr15:86211321	AKAP13	0.47	8.6	0.37	1.26e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	trans	rs34421088	0.506	rs2409755	chr8:11169983	G/A	cg06636001	chr8:8085503	FLJ10661	0.38	6.72	0.3	5.23e-11	Neuroticism;
LGG	cis	rs7539542	0.536	rs12091234	chr1:202855508	C/T	cg19681188	chr1:202830198	LOC148709	0.53	8.94	0.38	9.3e-18	Mean platelet volume;
LGG	cis	rs7565124	1.000	rs7565124	chr2:20261685	G/A	cg24657347	chr2:20261756	NA	-0.76	-15.04	-0.57	6.27e-42	Major depressive disorder;
LGG	cis	rs2439831	0.850	rs7174208	chr15:44052682	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.64	0.44	8.61e-24	Lung cancer in ever smokers;
LGG	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg09238746	chr17:78121135	EIF4A3	-0.71	-12.79	-0.51	2.76e-32	Yeast infection;
LGG	cis	rs7226408	0.553	rs322655	chr18:34620011	C/T	cg15022739	chr18:34823045	BRUNOL4	0.39	8.65	0.37	8.51e-17	Obesity-related traits;
LGG	trans	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.64	-0.33	1.22e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs6748734	0.516	rs4605365	chr2:241892009	G/A	cg14055004	chr2:241860995	NA	0.29	7.74	0.34	6.49e-14	Urinary metabolites;
LGG	cis	rs7100689	0.646	rs1538819	chr10:82122523	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg06394585	chr2:148777915	ORC4L	0.44	6.76	0.3	4.28e-11	Breast cancer;
LGG	cis	rs4595586	0.525	rs12818844	chr12:39423806	A/G	cg13010199	chr12:38710504	ALG10B	0.44	7.91	0.34	1.93e-14	Morning vs. evening chronotype;
LGG	trans	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg25214090	chr10:38739885	LOC399744	0.56	10.25	0.43	2.27e-22	Corneal astigmatism;
LGG	trans	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.68	-0.34	9.58e-14	Depression;
LGG	cis	rs12476592	0.602	rs262495	chr2:63848607	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.73	-0.3	4.91e-11	Childhood ear infection;
LGG	cis	rs62025270	0.688	rs55957626	chr15:86316717	G/A	cg25843651	chr15:86329602	KLHL25	0.63	10.15	0.43	5.53e-22	Idiopathic pulmonary fibrosis;
LGG	cis	rs12738007	0.901	rs61783694	chr1:29510934	C/T	cg11747820	chr1:29584023	PTPRU	-0.33	-7.61	-0.33	1.52e-13	Schizophrenia;
LGG	cis	rs754466	0.651	rs11002316	chr10:79617511	C/G	cg17075019	chr10:79541650	NA	-0.94	-19.99	-0.68	1.47e-64	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg09461388	chr22:46763229	CELSR1	-0.7	-7.14	-0.32	3.52e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg06636001	chr8:8085503	FLJ10661	0.57	10.91	0.45	8.31e-25	Triglycerides;
LGG	cis	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.46e-15	Ulcerative colitis;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.58e-16	Obesity-related traits;
LGG	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg13010199	chr12:38710504	ALG10B	0.67	13.34	0.53	1.45e-34	Bladder cancer;
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg16434002	chr17:42200994	HDAC5	-0.55	-10.33	-0.43	1.23e-22	Total body bone mineral density;
LGG	trans	rs941408	1.000	rs1736179	chr19:2795516	T/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.45	-0.44	4.46e-23	Total cholesterol levels;
LGG	cis	rs2124969	0.562	rs6750639	chr2:161066862	T/C	cg03641300	chr2:160917029	PLA2R1	-0.63	-11.8	-0.48	2.94e-28	Waist circumference adjusted for body mass index;
LGG	cis	rs68170813	0.559	rs77150993	chr7:106817100	G/T	cg02696742	chr7:106810147	HBP1	-0.77	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	cis	rs9972944	0.691	rs7225471	chr17:63777913	T/C	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg08603382	chr10:743973	NA	0.39	7.19	0.32	2.64e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs137603	0.966	rs126228	chr22:39681436	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.48	8.06	0.35	6.34e-15	Primary biliary cholangitis;
LGG	cis	rs620875	0.925	rs634571	chr11:126858322	C/G	cg06504925	chr11:126872760	NA	-0.53	-7.41	-0.33	5.9e-13	Response to antipsychotic treatment;
LGG	cis	rs2000999	0.691	rs11648003	chr16:72052348	A/G	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.4	-7.04	-0.31	6.94e-12	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg18681998	chr4:17616180	MED28	-0.75	-15.26	-0.58	6.73e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6062788	0.524	rs6122362	chr20:61701245	C/T	cg04970637	chr20:61718950	NA	-0.27	-7.1	-0.31	4.68e-12	Body mass index;
LGG	cis	rs6088590	0.502	rs6059861	chr20:33068563	A/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.31	0.36	1.05e-15	Coronary artery disease;
LGG	cis	rs35740288	0.731	rs12898964	chr15:86161277	G/A	cg07943548	chr15:86304357	KLHL25	-0.32	-6.66	-0.3	7.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6582630	0.502	rs11520234	chr12:38255005	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	10.37	0.43	8.52e-23	Lung cancer in ever smokers;
LGG	cis	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.9	-0.48	1.09e-28	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.55	-9.06	-0.39	3.78e-18	Longevity;Endometriosis;
LGG	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg10636054	chr15:40330586	SRP14	0.63	6.77	0.3	3.85e-11	Response to haloperidol in psychosis;
LGG	trans	rs7178375	1.000	rs12907055	chr15:31204294	C/G	cg04373760	chr16:53404718	NA	0.55	8.37	0.36	6.98e-16	Hypertriglyceridemia;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06112835	chr11:68658793	MRPL21	-0.63	-10.42	-0.44	5.37e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg12395012	chr8:11607386	GATA4	-0.37	-6.77	-0.3	3.91e-11	Neuroticism;
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg14689365	chr7:158441557	NCAPG2	0.6	10.46	0.44	3.93e-23	Height;
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg05313129	chr8:58192883	C8orf71	-0.84	-12.5	-0.5	4.31e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.22	-0.32	2.15e-12	Cognitive ability;
LGG	cis	rs568617	0.716	rs77779142	chr11:65599656	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.73	9.03	0.39	4.7e-18	Crohn's disease;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg18379455	chr17:41446167	NA	-0.32	-7.27	-0.32	1.56e-12	Menopause (age at onset);
LGG	cis	rs9810089	0.843	rs650326	chr3:136037707	G/A	cg12473912	chr3:136751656	NA	0.41	6.89	0.3	1.86e-11	Gestational age at birth (child effect);
LGG	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg19445457	chr11:5799446	OR52N5	-0.41	-6.83	-0.3	2.7e-11	DNA methylation (variation);
LGG	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	24.5	0.75	1.3e-85	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.72e-17	Lung cancer;
LGG	cis	rs57502260	0.704	rs60538784	chr11:68386735	G/A	cg01657329	chr11:68192670	LRP5	-0.57	-7.4	-0.33	6.26e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs12505749	0.542	rs17086794	chr4:57334752	C/T	cg07846311	chr4:57371927	ARL9	-0.31	-7.55	-0.33	2.38e-13	Airflow obstruction;
LGG	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg19761014	chr17:28927070	LRRC37B2	0.69	8.65	0.37	8.26e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.66	0.34	1.13e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg00129232	chr17:37814104	STARD3	-0.59	-11.03	-0.46	2.85e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs273218	0.694	rs274369	chr5:53379987	G/C	ch.5.1024479R	chr5:53302184	ARL15	0.5	7.75	0.34	5.93e-14	Migraine;
LGG	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg01864069	chr14:103024347	NA	-0.7	-10.73	-0.45	3.83e-24	Platelet count;
LGG	cis	rs9329289	0.926	rs9329290	chr10:2542751	G/T	cg15533453	chr10:2542242	NA	0.28	6.65	0.3	8.33e-11	Age-related hearing impairment;
LGG	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg06606381	chr12:133084897	FBRSL1	-1.05	-8.52	-0.37	2.34e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9905704	0.647	rs11650809	chr17:56972741	A/G	cg05425664	chr17:57184151	TRIM37	-0.43	-6.75	-0.3	4.44e-11	Testicular germ cell tumor;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.78e-21	Lung cancer;
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg18963800	chr10:38644991	HSD17B7P2	-0.45	-7.31	-0.32	1.21e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4356932	1.000	rs6811301	chr4:76970579	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.55e-11	Blood protein levels;
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs2742417	0.603	rs2742370	chr3:45782098	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.3	-0.4	5.65e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.56	-8.37	-0.36	6.74e-16	Huntington's disease progression;
LGG	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg12011299	chr4:100065546	ADH4	0.42	8.51	0.37	2.4e-16	Alcohol dependence;
LGG	cis	rs2952156	0.883	rs907089	chr17:37833600	C/T	cg07936489	chr17:37558343	FBXL20	-0.49	-8.38	-0.36	6.31e-16	Asthma;
LGG	cis	rs4664308	0.935	rs4520994	chr2:160937750	G/A	cg03641300	chr2:160917029	PLA2R1	-0.87	-17.95	-0.64	4.34e-55	Idiopathic membranous nephropathy;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg00035636	chr13:21900591	NA	0.34	7.08	0.31	5.23e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9443645	0.810	rs9361482	chr6:79750385	T/C	cg18132916	chr6:79620363	NA	-0.26	-6.91	-0.31	1.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.824	rs577044	chr11:111490420	G/T	cg19812747	chr11:111475976	SIK2	-0.49	-10.25	-0.43	2.3e-22	Primary sclerosing cholangitis;
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	9.47	0.4	1.44e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg06606381	chr12:133084897	FBRSL1	-0.91	-9.48	-0.4	1.34e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg11494091	chr17:61959527	GH2	0.54	8.74	0.38	4.35e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.48	-0.33	3.84e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4666002	0.789	rs6727215	chr2:27934731	G/A	cg27432699	chr2:27873401	GPN1	0.55	7.63	0.33	1.32e-13	Phospholipid levels (plasma);
LGG	trans	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg11693508	chr17:37793320	STARD3	0.43	6.7	0.3	6.17e-11	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19978540	chr12:3409405	NA	0.42	6.79	0.3	3.44e-11	Gut microbiome composition (summer);
LGG	cis	rs12474201	0.928	rs17822019	chr2:46934505	T/C	cg06386533	chr2:46925753	SOCS5	0.79	14.71	0.56	1.75e-40	Height;
LGG	cis	rs4631830	0.896	rs7088225	chr10:51522120	T/C	cg10326726	chr10:51549505	MSMB	0.7	14.89	0.57	3.13e-41	Prostate-specific antigen levels;
LGG	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.13	-0.31	4e-12	Blood metabolite levels;
LGG	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg08250081	chr4:10125330	NA	-0.35	-6.7	-0.3	6.01e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs801193	0.569	rs35070132	chr7:66238083	C/T	cg11764359	chr7:65958608	NA	0.69	12.18	0.49	8.82e-30	Aortic root size;
LGG	cis	rs12928939	0.815	rs8049163	chr16:71719353	C/T	cg08717414	chr16:71523259	ZNF19	-0.47	-7.17	-0.32	2.95e-12	Post bronchodilator FEV1;
LGG	cis	rs7633770	0.664	rs7373994	chr3:46701114	C/G	cg11219411	chr3:46661640	NA	-0.54	-12.47	-0.5	5.41e-31	Coronary artery disease;
LGG	cis	rs2074193	0.569	rs12371209	chr12:47768668	A/C	cg02516419	chr12:47771422	NA	0.57	8.67	0.37	7.23e-17	Migraine with aura;
LGG	cis	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg06521331	chr12:34319734	NA	-0.41	-7.14	-0.32	3.57e-12	Morning vs. evening chronotype;
LGG	cis	rs28374715	0.528	rs7181982	chr15:41623020	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.68	-0.84	1.36e-126	Ulcerative colitis;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg05280133	chr15:45670068	GATM;LOC145663	-0.42	-7.27	-0.32	1.55e-12	Homoarginine levels;
LGG	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg22974920	chr21:40686053	BRWD1	-0.41	-6.65	-0.3	8.54e-11	Cognitive function;
LGG	trans	rs75804782	0.521	rs55713398	chr2:239419933	A/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.6	0.37	1.27e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs757110	0.526	rs757081	chr11:17351683	C/G	cg15432903	chr11:17409602	KCNJ11	-0.64	-11.52	-0.47	3.47e-27	Type 2 diabetes;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg16680214	chr1:154839983	KCNN3	0.46	9.09	0.39	2.92e-18	Prostate cancer;
LGG	cis	rs10861342	0.892	rs74971338	chr12:105499757	C/A	cg23923672	chr12:105501055	KIAA1033	0.79	7.01	0.31	8.49e-12	IgG glycosylation;
LGG	cis	rs1385374	0.858	rs11059926	chr12:129294244	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg04267008	chr7:1944627	MAD1L1	0.67	11.81	0.48	2.64e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.11e-13	Tonsillectomy;
LGG	cis	rs2051211	0.744	rs62241772	chr3:38551125	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-7.04	-0.31	6.9e-12	QRS duration;
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.04	-0.35	7.69e-15	HDL cholesterol;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg02725872	chr8:58115012	NA	-1.03	-14.63	-0.56	4e-40	Developmental language disorder (linguistic errors);
LGG	cis	rs950776	0.518	rs4243083	chr15:78833830	C/G	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.45	-0.4	1.67e-19	Sudden cardiac arrest;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.21	-0.32	2.23e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03264133	chr6:25882463	NA	-0.72	-13.76	-0.54	2.38e-36	Blood metabolite levels;
LGG	cis	rs7216064	1.000	rs2365468	chr17:65841318	C/T	cg12091567	chr17:66097778	LOC651250	-0.63	-9.33	-0.4	4.48e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.3	-0.46	2.6e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.882	rs13075842	chr3:10055813	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.67	0.63	9.03e-54	Alzheimer's disease;
LGG	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg11764359	chr7:65958608	NA	-0.77	-14.3	-0.55	1.12e-38	Aortic root size;
LGG	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.44	-0.33	4.84e-13	Iron status biomarkers;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17030434	0.784	rs10032475	chr4:154674748	C/T	cg14289246	chr4:154710475	SFRP2	-0.56	-9.65	-0.41	3.3e-20	Electrocardiographic conduction measures;
LGG	cis	rs7011049	1.000	rs72648413	chr8:53860576	C/T	cg26025543	chr8:53854495	NA	0.64	8.96	0.38	8.06e-18	Systolic blood pressure;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20887711	chr4:1340912	KIAA1530	-0.75	-15.49	-0.58	6.92e-44	Obesity-related traits;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg01765077	chr12:122356316	WDR66	0.28	7.74	0.34	6.1e-14	Mean corpuscular volume;
LGG	cis	rs35883536	0.611	rs72977390	chr1:101107147	C/T	cg06223162	chr1:101003688	GPR88	0.34	7.86	0.34	2.76e-14	Monocyte count;
LGG	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-6.85	-0.3	2.32e-11	Body mass index;
LGG	cis	rs61884328	0.733	rs61897843	chr11:47187549	G/A	cg03339077	chr11:47165057	C11orf49	0.68	6.68	0.3	6.99e-11	Total body bone mineral density (age over 60);
LGG	cis	rs950776	0.518	rs12594391	chr15:78816240	A/G	cg06917634	chr15:78832804	PSMA4	0.83	17.29	0.63	5.01e-52	Sudden cardiac arrest;
LGG	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg04986931	chr22:39850128	NA	0.33	7.52	0.33	2.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg15557168	chr22:42548783	NA	0.4	8.56	0.37	1.71e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500395	0.962	rs9972682	chr16:48686644	T/G	cg04672837	chr16:48644449	N4BP1	0.51	8.37	0.36	6.99e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.86	-0.38	1.74e-17	Reticulocyte fraction of red cells;
LGG	cis	rs854765	0.547	rs2955378	chr17:17930253	G/A	cg05444541	chr17:17804740	TOM1L2	-0.68	-16.36	-0.61	8.36e-48	Total body bone mineral density;
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg23758822	chr17:41437982	NA	0.87	15.47	0.58	7.84e-44	Menopause (age at onset);
LGG	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg04568710	chr12:38710424	ALG10B	0.36	7.72	0.34	7.31e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19743759	chr9:35072884	VCP	0.49	8.23	0.36	1.98e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs11158198	0.738	rs910880	chr14:58571274	G/A	cg15908186	chr14:58618357	C14orf37	0.52	8.96	0.38	7.77e-18	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs4474465	0.850	rs4944205	chr11:78227790	T/A	cg27205649	chr11:78285834	NARS2	0.49	8.34	0.36	8.51e-16	Alzheimer's disease (survival time);
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg18621852	chr3:10150065	C3orf24	-0.4	-6.78	-0.3	3.62e-11	Alzheimer's disease;
LGG	cis	rs10929925	0.933	rs4670028	chr2:6156766	T/C	cg00493617	chr2:6141445	NA	0.32	7.36	0.32	8.61e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs6768930	0.509	rs6787090	chr3:57751032	A/G	cg01571842	chr3:57934672	NA	0.3	6.65	0.3	8.22e-11	Obesity-related traits;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.59	-0.37	1.36e-16	Obesity-related traits;
LGG	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg00564723	chr10:75632066	CAMK2G	0.33	7.44	0.33	5.05e-13	Inflammatory bowel disease;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg11062466	chr8:58055876	NA	0.47	7.94	0.35	1.51e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.53	0.44	2.24e-23	Iron status biomarkers;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg05556477	chr5:131705319	SLC22A5	0.82	9.79	0.41	1.03e-20	Rheumatoid arthritis;
LGG	cis	rs1185460	0.967	rs1307145	chr11:118950217	C/G	cg23280166	chr11:118938394	VPS11	0.59	10.67	0.44	6.42e-24	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg21483842	chr13:49821938	CDADC1	0.38	6.73	0.3	5.15e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9309473	0.950	rs11689588	chr2:73773691	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.67	-0.34	1.03e-13	Metabolite levels;
LGG	cis	rs7927592	0.913	rs7104345	chr11:68316772	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg08621203	chr6:150244597	RAET1G	0.52	9.72	0.41	1.84e-20	Testicular germ cell tumor;
LGG	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg23920097	chr1:209922102	NA	-0.5	-8.82	-0.38	2.34e-17	Red blood cell count;
LGG	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg19980929	chr12:42632907	YAF2	0.38	8.56	0.37	1.72e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.12	-0.46	1.24e-25	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.56	-0.37	1.68e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg08807101	chr21:30365312	RNF160	0.68	11.4	0.47	1.01e-26	Cognitive test performance;
LGG	cis	rs7572644	0.699	rs1395324	chr2:28276643	C/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.69	-0.3	6.54e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg26384229	chr12:38710491	ALG10B	0.97	22.06	0.72	3.15e-74	Bladder cancer;
LGG	trans	rs9467711	0.591	rs9467622	chr6:25854644	C/A	cg06606381	chr12:133084897	FBRSL1	-0.74	-6.79	-0.3	3.38e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs75804782	0.625	rs10929281	chr2:239468938	G/A	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7917772	0.503	rs2031602	chr10:104307955	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.77e-43	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.27	-0.32	1.58e-12	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.53e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.79	-0.38	3.01e-17	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.7	-0.34	8.06e-14	Initial pursuit acceleration;
LGG	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg24253500	chr15:84953950	NA	0.61	11.39	0.47	1.13e-26	Schizophrenia;
LGG	cis	rs12282928	0.788	rs753095	chr11:48328644	C/T	cg20307385	chr11:47447363	PSMC3	0.43	6.92	0.31	1.51e-11	Migraine - clinic-based;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.53	-0.37	2.17e-16	Body mass index;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.5700000000000001e-13	Personality dimensions;
LGG	trans	rs116095464	0.850	rs10057272	chr5:340188	T/C	cg00938859	chr5:1591904	SDHAP3	0.81	7.06	0.31	6.23e-12	Breast cancer;
LGG	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg19748678	chr4:122722346	EXOSC9	0.69	13.79	0.54	1.81e-36	Type 2 diabetes;
LGG	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg08999081	chr20:33150536	PIGU	0.41	10.18	0.43	4.41e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7546668	1.000	rs6695562	chr1:15842842	C/T	cg21858823	chr1:15850916	CASP9	0.38	6.94	0.31	1.3e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs2797160	0.651	rs1343121	chr6:126036184	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.48	8.4	0.36	5.71e-16	Endometrial cancer;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2154319	0.887	rs61780439	chr1:41490177	G/A	cg02290550	chr1:41487317	SLFNL1	0.49	8.66	0.37	8.18e-17	Height;
LGG	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg03733263	chr8:22462867	KIAA1967	1.05	26.91	0.78	1.05e-96	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs8073060	0.586	rs8064895	chr17:34001121	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2304069	0.909	rs10038824	chr5:149369776	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.56	-7.59	-0.33	1.8e-13	HIV-1 control;
LGG	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg19628046	chr18:33552617	C18orf21	0.51	7.35	0.32	9.13e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08677398	chr8:58056175	NA	0.5	7.93	0.35	1.64e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.515	rs6768768	chr3:10177653	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.7	-10.4	-0.44	6.42e-23	Alzheimer's disease;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg10056627	chr6:42928773	GNMT	0.26	7.15	0.32	3.43e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10499694	0.933	rs12718583	chr7:50582631	T/C	cg00647317	chr7:50633725	DDC	0.35	8.39	0.36	5.85e-16	Body mass index;
LGG	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg03733263	chr8:22462867	KIAA1967	1.07	26.89	0.78	1.31e-96	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27415899	chr3:196438768	PIGX;C3orf34	-0.47	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	cis	rs9325144	1.000	rs7963123	chr12:38976617	C/T	cg13010199	chr12:38710504	ALG10B	-0.48	-7.99	-0.35	1.11e-14	Morning vs. evening chronotype;
LGG	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.27	-0.36	1.39e-15	Myopia;Myopia (pathological);
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.73	0.38	4.69e-17	Personality dimensions;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	9.47	0.4	1.42e-19	Schizophrenia;
LGG	cis	rs6976053	0.846	rs6465776	chr7:100462004	A/G	cg03098644	chr7:100410630	EPHB4	-0.43	-7.74	-0.34	6.4e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs4704187	0.687	rs10462512	chr5:74387317	C/G	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs2018055	0.618	rs6568976	chr6:117792176	A/G	cg14611402	chr6:117803162	DCBLD1	0.3	8.63	0.37	9.81e-17	Diastolic blood pressure;
LGG	cis	rs7937682	0.924	rs875257	chr11:111530453	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.63	-0.37	1.02e-16	Primary sclerosing cholangitis;
LGG	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-12.59	-0.51	1.82e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg21775007	chr8:11205619	TDH	0.47	7.46	0.33	4.17e-13	Neuroticism;
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10179964	chr12:2113874	DCP1B	0.45	7.3	0.32	1.24e-12	Cognitive performance;
LGG	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg26850624	chr5:429559	AHRR	-0.38	-8.43	-0.36	4.44e-16	Cystic fibrosis severity;
LGG	cis	rs17428076	0.718	rs17499544	chr2:172640734	A/G	cg21435375	chr2:172878103	MAP1D	-0.36	-6.69	-0.3	6.39e-11	Myopia;
LGG	cis	rs7715806	0.500	rs17649362	chr5:75008958	C/T	cg19683494	chr5:74908142	NA	0.52	6.87	0.3	2.02e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg25809561	chr17:30822961	MYO1D	0.38	8.96	0.38	7.74e-18	Schizophrenia;
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.68	-0.34	9.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg13009111	chr11:71350975	NA	-0.32	-7.02	-0.31	8.04e-12	Systolic blood pressure;
LGG	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.64	0.41	3.61e-20	Coronary artery disease;
LGG	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg26769984	chr7:1090371	C7orf50	0.55	9.88	0.42	5.06e-21	Bronchopulmonary dysplasia;
LGG	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg04673462	chr1:38461896	NA	-0.55	-11.79	-0.48	3.04e-28	Coronary artery disease;
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg04911050	chr16:677664	RAB40C	0.35	6.94	0.31	1.33e-11	Height;
LGG	cis	rs7615952	0.800	rs11915699	chr3:125632684	A/G	cg05084668	chr3:125655381	ALG1L	-0.86	-10.61	-0.44	1.11e-23	Blood pressure (smoking interaction);
LGG	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg06636001	chr8:8085503	FLJ10661	0.58	11.68	0.48	8.65e-28	Mood instability;
LGG	trans	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.28	-0.4	6.31e-19	Brugada syndrome;
LGG	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg27624424	chr6:160112604	SOD2	0.68	10.0	0.42	1.85e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs367615	0.659	rs13435970	chr5:108884660	C/T	cg17395555	chr5:108820864	NA	0.67	9.56	0.41	6.76e-20	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg20283391	chr11:68216788	NA	-0.49	-8.05	-0.35	7.28e-15	Total body bone mineral density;
LGG	cis	rs9612	1.000	rs346544	chr19:44256205	A/G	cg08581076	chr19:44259116	C19orf61	0.48	8.33	0.36	8.94e-16	Exhaled nitric oxide output;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01976176	chr14:20922685	APEX1;OSGEP	-0.42	-6.84	-0.3	2.54e-11	Body fat percentage;
LGG	trans	rs7944735	0.671	rs7106731	chr11:48003392	T/G	cg03929089	chr4:120376271	NA	0.63	8.78	0.38	3.25e-17	Intraocular pressure;
LGG	cis	rs67460515	0.892	rs6780536	chr3:161058726	T/C	cg04691961	chr3:161091175	C3orf57	-0.48	-9.85	-0.42	6.58e-21	Parkinson's disease;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	trans	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg14227996	chr4:17616232	MED28	-0.53	-7.51	-0.33	3.1e-13	Opioid sensitivity;
LGG	cis	rs34172651	0.517	rs7204288	chr16:24784531	A/G	cg02428538	chr16:24856791	SLC5A11	-0.71	-10.96	-0.45	5.34e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.723	rs1586373	chr12:39181582	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.11	-0.49	1.59e-29	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.03	0.35	8.05e-15	Lung cancer;
LGG	trans	rs61931739	1.000	rs11052989	chr12:34057614	G/A	cg26384229	chr12:38710491	ALG10B	-0.6	-10.8	-0.45	2.15e-24	Morning vs. evening chronotype;
LGG	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	cis	rs4919694	0.611	rs77328741	chr10:105066314	T/C	cg04362960	chr10:104952993	NT5C2	0.92	11.87	0.48	1.51e-28	Arsenic metabolism;
LGG	cis	rs17767392	0.846	rs2332576	chr14:71765507	T/A	cg02058870	chr14:72053146	SIPA1L1	0.4	8.53	0.37	2.11e-16	Mitral valve prolapse;
LGG	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg08000102	chr2:233561755	GIGYF2	0.56	9.09	0.39	2.97e-18	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14711201	chr5:36152436	SKP2;LMBRD2	0.42	7.14	0.31	3.74e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs963731	0.522	rs10206751	chr2:39289004	C/G	cg04010122	chr2:39346883	SOS1	-0.67	-7.34	-0.32	9.41e-13	Corticobasal degeneration;
LGG	cis	rs7107174	0.681	rs3102742	chr11:77949334	G/T	cg02023728	chr11:77925099	USP35	0.45	7.72	0.34	7.18e-14	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06481639	chr22:41940642	POLR3H	0.52	7.54	0.33	2.48e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg14191688	chr11:70257035	CTTN	0.59	8.6	0.37	1.23e-16	Coronary artery disease;
LGG	trans	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg18187862	chr3:45730750	SACM1L	-0.6	-9.68	-0.41	2.75e-20	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13955347	chr12:9106586	NA	0.33	6.73	0.3	4.93e-11	Gut microbiome composition (summer);
LGG	cis	rs7635838	0.718	rs2594973	chr3:11395821	C/G	cg00170343	chr3:11313890	ATG7	0.49	8.41	0.36	5.1e-16	HDL cholesterol;
LGG	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.55	0.47	2.7e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg03213289	chr20:61660250	NA	0.59	11.08	0.46	1.77e-25	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10908458	0.808	rs10908456	chr1:155086148	A/G	cg13808842	chr1:155066096	NA	0.32	8.08	0.35	5.7e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6580649	0.783	rs1635526	chr12:48396785	C/T	cg24011408	chr12:48396354	COL2A1	0.68	8.51	0.37	2.37e-16	Lung cancer;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg00012203	chr2:219082015	ARPC2	-0.75	-14.46	-0.56	2.32e-39	Colorectal cancer;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg20790798	chr5:1857306	NA	-0.41	-6.67	-0.3	7.16e-11	Cardiovascular disease risk factors;
LGG	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg01448562	chr3:133502909	NA	-0.51	-8.51	-0.37	2.35e-16	Iron status biomarkers;
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg04287289	chr16:89883240	FANCA	0.81	16.88	0.62	3.65e-50	Vitiligo;
LGG	cis	rs72945132	1.000	rs72945129	chr11:70110808	C/T	cg14088196	chr11:70211408	PPFIA1	0.86	11.11	0.46	1.4e-25	Coronary artery disease;
LGG	cis	rs6942756	0.806	rs2566877	chr7:128897317	G/A	cg02491457	chr7:128862824	NA	0.65	12.29	0.5	3.08e-30	White matter hyperintensity burden;
LGG	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg04287289	chr16:89883240	FANCA	-0.45	-8.06	-0.35	6.7e-15	Vitiligo;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.91	-0.38	1.14e-17	Menopause (age at onset);
LGG	cis	rs10791323	0.569	rs2257004	chr11:133712473	C/T	cg00579200	chr11:133705235	NA	-0.59	-11.29	-0.46	2.89e-26	Childhood ear infection;
LGG	cis	rs9487051	0.714	rs13209277	chr6:109624963	T/A	cg21918786	chr6:109611834	NA	-0.47	-8.88	-0.38	1.5e-17	Reticulocyte fraction of red cells;
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19524238	chr7:2802976	GNA12	0.3	7.16	0.32	3.22e-12	Height;
LGG	cis	rs2916247	1.000	rs10441534	chr8:93056692	A/G	cg10183463	chr8:93005414	RUNX1T1	0.39	8.24	0.36	1.85e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1062746	0.502	rs76128303	chr16:87339236	T/C	cg02258303	chr16:87377426	FBXO31	-0.42	-7.86	-0.34	2.69e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs2797160	0.935	rs926855	chr6:126021782	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.66	0.34	1.11e-13	Endometrial cancer;
LGG	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg04503457	chr17:41445688	NA	-0.4	-9.53	-0.4	8.88e-20	Menopause (age at onset);
LGG	cis	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg13789015	chr9:136890014	NCRNA00094	0.47	7.07	0.31	5.61e-12	Mosquito bite size;
LGG	cis	rs28595532	0.920	rs116612909	chr4:119749823	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg16270222	chr17:41446396	NA	-0.3	-7.17	-0.32	2.91e-12	Menopause (age at onset);
LGG	cis	rs8177253	0.901	rs9843728	chr3:133501407	C/T	cg08048268	chr3:133502702	NA	-0.61	-11.62	-0.48	1.46e-27	Iron status biomarkers;
LGG	cis	rs9381040	0.655	rs879491	chr6:41026953	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.32	-0.32	1.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs17428076	0.874	rs62182373	chr2:172685555	C/T	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg01557791	chr16:72042693	DHODH	-0.46	-8.36	-0.36	7.58e-16	Fibrinogen levels;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.11	0.31	4.55e-12	Schizophrenia;
LGG	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs7523273	1.000	rs1142469	chr1:207965427	G/A	cg22525895	chr1:207977042	MIR29B2	-0.63	-11.7	-0.48	6.82e-28	Schizophrenia;
LGG	cis	rs4665809	0.590	rs6716858	chr2:26423414	G/A	cg22920501	chr2:26401640	FAM59B	-0.43	-9.02	-0.39	5.13e-18	Gut microbiome composition (summer);
LGG	cis	rs6920965	0.507	rs12203025	chr6:126192034	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-8.79	-0.38	3.05e-17	High light scatter reticulocyte count;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.85	-0.34	2.85e-14	Diabetic retinopathy;
LGG	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs1865760	0.532	rs2006736	chr6:26086017	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg26597838	chr10:835615	NA	0.95	13.06	0.52	2.04e-33	Eosinophil percentage of granulocytes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05797656	chr17:61851352	DDX42;CCDC47	0.45	7.22	0.32	2.15e-12	Cognitive performance;
LGG	cis	rs2439831	0.571	rs2470121	chr15:43937618	G/C	cg15269541	chr15:43626905	ADAL	-0.43	-6.83	-0.3	2.65e-11	Lung cancer in ever smokers;
LGG	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg20891558	chr2:74357851	NA	0.51	9.58	0.41	5.94e-20	Gestational age at birth (maternal effect);
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg16507663	chr6:150244633	RAET1G	-0.44	-8.37	-0.36	6.85e-16	Lung cancer;
LGG	cis	rs17854409	0.803	rs1063246	chr20:61472116	G/A	cg05147244	chr20:61493195	TCFL5	0.78	7.45	0.33	4.73e-13	Obesity-related traits;
LGG	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21582582	chr3:182698605	DCUN1D1	0.39	6.8	0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8056064	0.793	rs34735041	chr16:82781755	G/A	cg08271366	chr16:82816457	CDH13	-0.42	-6.96	-0.31	1.14e-11	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.85	0.34	3e-14	Restless legs syndrome;
LGG	cis	rs7301016	1.000	rs73141014	chr12:62891412	T/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg05791153	chr7:19748676	TWISTNB	0.94	12.32	0.5	2.32e-30	Thyroid stimulating hormone;
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18252515	chr7:66147081	NA	0.42	7.1	0.31	4.59e-12	Aortic root size;
LGG	cis	rs7267979	1.000	rs4813562	chr20:25352588	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs73001065	0.901	rs10401969	chr19:19407718	A/G	cg03709012	chr19:19516395	GATAD2A	0.88	8.07	0.35	5.89e-15	LDL cholesterol;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg18252515	chr7:66147081	NA	-0.42	-6.95	-0.31	1.27e-11	Aortic root size;
LGG	cis	rs4740619	0.525	rs10962170	chr9:15812665	A/G	cg14451791	chr9:16040625	NA	0.32	7.91	0.35	1.92e-14	Body mass index;
LGG	cis	rs12928939	0.911	rs12919271	chr16:71792696	C/A	cg03805757	chr16:71968109	PKD1L3	-0.54	-10.49	-0.44	2.99e-23	Post bronchodilator FEV1;
LGG	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg08344181	chr3:125677491	NA	-0.64	-7.6	-0.33	1.69e-13	Depression;
LGG	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08109568	chr15:31115862	NA	-0.53	-9.19	-0.39	1.32e-18	Huntington's disease progression;
LGG	cis	rs4478858	0.684	rs16865957	chr1:31753353	G/A	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.54e-11	Alcohol dependence;
LGG	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg24375607	chr4:120327624	NA	0.67	11.16	0.46	9.18e-26	Corneal astigmatism;
LGG	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg13385521	chr17:29058706	SUZ12P	-0.81	-9.68	-0.41	2.61e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1109114	0.844	rs4490572	chr5:148612322	G/A	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.86	-0.59	1.5e-45	Body mass index;
LGG	trans	rs7824557	0.602	rs1435273	chr8:11209499	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.81	0.3	2.95e-11	Retinal vascular caliber;
LGG	trans	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.06	0.46	2.16e-25	Corneal astigmatism;
LGG	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.78	-0.3	3.61e-11	Response to amphetamines;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.89	-0.38	1.42e-17	Life satisfaction;
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.05	-0.31	6.48e-12	Aortic root size;
LGG	cis	rs27434	0.607	rs34753	chr5:96150911	C/T	cg16492584	chr5:96139282	ERAP1	-0.34	-6.73	-0.3	5.05e-11	Ankylosing spondylitis;
LGG	cis	rs7819412	0.502	rs4840548	chr8:10992883	C/T	cg21775007	chr8:11205619	TDH	-0.51	-7.65	-0.33	1.19e-13	Triglycerides;
LGG	cis	rs4132509	0.793	rs9428579	chr1:243690034	C/T	cg21452805	chr1:244014465	NA	0.75	7.6	0.33	1.64e-13	RR interval (heart rate);
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.78	-0.34	4.64e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.36e-20	Calcium levels;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04772025	chr11:68637568	NA	0.75	13.01	0.52	3.25e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7193541	0.684	rs4888264	chr16:74681632	T/G	cg01733217	chr16:74700730	RFWD3	1.1	34.98	0.85	4.78e-132	Multiple myeloma;
LGG	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.85	-0.34	2.84e-14	Morning vs. evening chronotype;
LGG	cis	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg23422044	chr7:1970798	MAD1L1	-0.69	-11.56	-0.47	2.5e-27	Bipolar disorder;
LGG	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs5769707	0.632	rs5770601	chr22:50021903	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.38	-0.4	2.9e-19	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs3960554	0.808	rs11983987	chr7:75657850	A/G	cg19862616	chr7:65841803	NCRNA00174	0.77	11.36	0.47	1.46e-26	Eotaxin levels;
LGG	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg21772509	chr8:41503840	NKX6-3	0.86	18.99	0.66	7.03e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg25319279	chr11:5960081	NA	-0.53	-8.57	-0.37	1.57e-16	DNA methylation (variation);
LGG	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.9	-11.95	-0.49	6.87e-29	Body mass index;
LGG	cis	rs881375	0.678	rs10760125	chr9:123662590	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.83	0.45	1.64e-24	Rheumatoid arthritis;
LGG	cis	rs6815814	0.950	rs73236617	chr4:38793860	C/G	cg06935464	chr4:38784597	TLR10	0.61	8.32	0.36	9.79e-16	Breast cancer;
LGG	cis	rs12148488	0.966	rs1867148	chr15:75339985	T/C	cg17294928	chr15:75287854	SCAMP5	-0.56	-10.46	-0.44	3.93e-23	Caffeine consumption;
LGG	cis	rs2522056	1.000	rs1003533	chr5:131755651	C/T	cg07395648	chr5:131743802	NA	0.41	7.05	0.31	6.51e-12	Lymphocyte counts;Fibrinogen;
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg19168338	chr16:4465731	CORO7	-0.89	-16.68	-0.61	2.8e-49	Schizophrenia;
LGG	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg26384229	chr12:38710491	ALG10B	0.94	21.29	0.7	1.2e-70	Bladder cancer;
LGG	cis	rs1538970	1.000	rs11211101	chr1:45849311	C/G	cg05343316	chr1:45956843	TESK2	0.7	11.97	0.49	6.19e-29	Platelet count;
LGG	cis	rs12479064	0.703	rs28382977	chr2:100018304	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-9.01	-0.39	5.46e-18	Chronic sinus infection;
LGG	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.51	0.69	5.58e-67	Calcium levels;
LGG	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg09873164	chr1:152488093	CRCT1	0.56	11.52	0.47	3.45e-27	Hair morphology;
LGG	cis	rs9557207	1.000	rs9557195	chr13:99956622	T/C	cg24509225	chr13:100037070	UBAC2	0.7	12.58	0.5	1.92e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2371030	0.930	rs2371029	chr2:211568889	T/C	cg18417063	chr2:211583084	NA	-0.63	-12.17	-0.49	9.57e-30	Non-small cell lung cancer;
LGG	cis	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.78	-0.38	3.29e-17	Mood instability;
LGG	trans	rs1005277	0.522	rs1208681	chr10:38092975	C/T	cg27523141	chr10:43048294	ZNF37B	0.36	7.47	0.33	4.05e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg02772935	chr3:125709198	NA	-0.51	-7.26	-0.32	1.7e-12	Blood pressure (smoking interaction);
LGG	cis	rs4566357	0.576	rs10187255	chr2:227913442	T/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.05	-0.39	3.88e-18	Coronary artery disease;
LGG	cis	rs6088580	0.505	rs6141503	chr20:33274469	G/A	cg24642439	chr20:33292090	TP53INP2	-0.43	-6.8	-0.3	3.32e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg19147804	chr7:1989927	MAD1L1	-0.63	-12.74	-0.51	4.43e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs9880211	0.898	rs34031772	chr3:136018141	T/C	cg21827317	chr3:136751795	NA	-0.47	-6.85	-0.3	2.3e-11	Body mass index;Height;
LGG	cis	rs12367572	0.501	rs2897857	chr12:45481949	A/G	cg03114573	chr12:45410052	DBX2	-0.52	-8.8	-0.38	2.65e-17	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.867	rs28729853	chr15:43673680	A/C	cg15269541	chr15:43626905	ADAL	-0.46	-7.94	-0.35	1.53e-14	Lung cancer in ever smokers;
LGG	trans	rs1681630	0.848	rs1631174	chr11:47974373	A/C	cg15704280	chr7:45808275	SEPT13	-0.44	-6.72	-0.3	5.36e-11	Height;
LGG	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-14.83	-0.57	5.61e-41	Colorectal cancer;
LGG	cis	rs8141529	0.778	rs9625566	chr22:29162506	G/A	cg15103426	chr22:29168792	CCDC117	0.71	11.32	0.47	2.16e-26	Lymphocyte counts;
LGG	cis	rs2652834	1.000	rs2729780	chr15:63404639	C/G	cg05507819	chr15:63340323	TPM1	0.61	8.25	0.36	1.61e-15	HDL cholesterol;
LGG	trans	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg20290983	chr6:43655470	MRPS18A	-0.81	-15.9	-0.59	9.95e-46	IgG glycosylation;
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.77	14.12	0.55	6.72e-38	Blood protein levels;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.5	-0.33	3.37e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg03517284	chr6:25882590	NA	0.55	10.35	0.43	1.05e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2201728	0.677	rs13123099	chr4:100194517	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.95	-0.31	1.27e-11	Cardiac Troponin-T levels;
LGG	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg16339924	chr4:17578868	LAP3	0.64	10.85	0.45	1.4e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg11887960	chr12:57824829	NA	0.6	7.42	0.33	5.73e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg03352830	chr11:487213	PTDSS2	0.86	10.87	0.45	1.14e-24	Body mass index;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.32	0.4	4.92e-19	Bipolar disorder;
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Electroencephalogram traits;
LGG	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg13385521	chr17:29058706	SUZ12P	-0.91	-10.76	-0.45	2.96e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2764208	0.576	rs2064253	chr6:34645322	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-7.68	-0.34	9.86e-14	Systemic lupus erythematosus;
LGG	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.3	-0.36	1.12e-15	Life satisfaction;
LGG	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.96	0.42	2.72e-21	Height;
LGG	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	trans	rs7826238	0.502	rs10503377	chr8:8378422	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.35	-0.32	9e-13	Systolic blood pressure;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg13732083	chr21:47605072	C21orf56	0.55	9.69	0.41	2.4e-20	Testicular germ cell tumor;
LGG	cis	rs758324	0.797	rs253948	chr5:131322026	C/T	cg06307176	chr5:131281290	NA	-0.45	-6.72	-0.3	5.38e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs889398	0.741	rs7193038	chr16:69926134	T/G	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.98	-0.31	1.05e-11	Body mass index;
LGG	cis	rs240764	0.659	rs1006398	chr6:101037718	T/A	cg09795085	chr6:101329169	ASCC3	0.4	6.69	0.3	6.63e-11	Neuroticism;
LGG	cis	rs798554	0.704	rs2527684	chr7:2825922	G/T	cg19717773	chr7:2847554	GNA12	-0.35	-8.31	-0.36	1.11e-15	Height;
LGG	cis	rs9815354	1.000	rs1716690	chr3:41922102	T/G	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.05e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9341835	0.584	rs2096346	chr6:64153014	T/C	cg00787780	chr6:64151745	NA	0.44	8.12	0.35	4.32e-15	Schizophrenia;
LGG	cis	rs2249694	1.000	rs2480258	chr10:135352100	T/C	cg20169779	chr10:135381914	SYCE1	0.49	7.54	0.33	2.42e-13	Obesity-related traits;
LGG	cis	rs701145	0.938	rs355752	chr3:153970796	A/G	cg17054900	chr3:154042577	DHX36	0.97	11.98	0.49	5.54e-29	Coronary artery disease;
LGG	cis	rs12200782	0.799	rs72845515	chr6:26646871	A/G	cg11502198	chr6:26597334	ABT1	-0.92	-7.87	-0.34	2.46e-14	Small cell lung carcinoma;
LGG	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg11887960	chr12:57824829	NA	0.56	6.89	0.3	1.79e-11	Obesity-related traits;
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg00290607	chr11:67383545	NA	-0.63	-11.46	-0.47	6.21e-27	Mean corpuscular volume;
LGG	cis	rs12926788	0.640	rs73551577	chr16:24845143	G/A	cg00339695	chr16:24857497	SLC5A11	0.42	7.37	0.32	7.95e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs8072100	1.000	rs3809868	chr17:45750596	G/A	cg25173405	chr17:45401733	C17orf57	0.49	8.48	0.37	2.94e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg22968622	chr17:43663579	NA	1.09	21.76	0.71	7.6499999999999994e-73	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg16797656	chr11:68205561	LRP5	0.51	10.05	0.42	1.29e-21	Total body bone mineral density;
LGG	cis	rs11792861	0.816	rs7021366	chr9:111727670	C/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.27	0.43	1.97e-22	Menarche (age at onset);
LGG	cis	rs9902453	0.900	rs12451122	chr17:28486376	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	12.34	0.5	1.91e-30	Coffee consumption (cups per day);
LGG	cis	rs477692	1.000	rs548390	chr10:131417427	G/A	cg05714579	chr10:131428358	MGMT	0.56	11.45	0.47	6.8e-27	Response to temozolomide;
LGG	cis	rs4891159	0.790	rs56077581	chr18:74116865	T/G	cg24786174	chr18:74118243	ZNF516	-0.58	-13.33	-0.53	1.62e-34	Longevity;
LGG	cis	rs300703	0.810	rs72772835	chr2:134554	C/T	cg21211680	chr2:198530	NA	-1.24	-12.21	-0.49	6.21e-30	Blood protein levels;
LGG	cis	rs6840360	0.516	rs6535794	chr4:152302783	G/T	cg25486957	chr4:152246857	NA	-0.4	-7.2	-0.32	2.48e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9818758	0.556	rs9835439	chr3:49220330	G/C	cg00383909	chr3:49044727	WDR6	0.97	12.25	0.49	4.24e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.99e-19	Gout;Renal underexcretion gout;
LGG	cis	rs17286411	0.814	rs12708918	chr16:71984941	C/G	cg03805757	chr16:71968109	PKD1L3	0.35	7.26	0.32	1.69e-12	Blood protein levels;
LGG	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg20891558	chr2:74357851	NA	0.47	9.08	0.39	3.18e-18	Gestational age at birth (maternal effect);
LGG	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	13.99	0.54	2.53e-37	Cognitive test performance;
LGG	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.64	-0.41	3.52e-20	Aortic root size;
LGG	cis	rs2290159	0.800	rs5746214	chr3:12644753	A/G	cg23032965	chr3:12705835	RAF1	0.68	9.85	0.42	6.56e-21	Cholesterol, total;
LGG	cis	rs344364	0.636	rs344363	chr16:1972548	C/T	cg26617929	chr16:1858877	NA	-0.6	-8.23	-0.36	1.97e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs8062405	0.721	rs151181	chr16:28490517	A/G	cg00204512	chr16:28754710	NA	0.27	7.33	0.32	1.03e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.31	0.43	1.46e-22	Aortic root size;
LGG	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg03538708	chr1:25844672	NA	-0.35	-6.77	-0.3	3.94e-11	Erythrocyte sedimentation rate;
LGG	cis	rs11700980	0.551	rs2832027	chr21:30114365	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs7011049	0.778	rs73603203	chr8:53871618	C/T	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg02631450	chr22:32366979	NA	0.98	9.32	0.4	4.9e-19	Childhood ear infection;
LGG	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg05163923	chr11:71159392	DHCR7	0.73	14.42	0.56	3.53e-39	Vitamin D levels;
LGG	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg16096631	chr1:42092165	HIVEP3	0.81	24.92	0.76	1.52e-87	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4332037	0.510	rs11764040	chr7:1884830	G/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.93	-0.38	1.02e-17	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs7219361	chr17:29080393	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.76	0.45	2.88e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7582720	0.943	rs72934546	chr2:203980033	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.4	0.4	2.58e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg00071950	chr4:10020882	SLC2A9	0.37	7.43	0.33	5.14e-13	Bone mineral density;
LGG	cis	rs1008375	0.966	rs12503540	chr4:17698781	C/G	cg16339924	chr4:17578868	LAP3	-0.47	-7.74	-0.34	6.13e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3820928	0.874	rs4234062	chr2:227819050	C/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.82	-0.34	3.65e-14	Pulmonary function;
LGG	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15369054	chr17:80825471	TBCD	0.48	6.75	0.3	4.43e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06634786	chr22:41940651	POLR3H	-0.8	-13.29	-0.53	2.29e-34	Vitiligo;
LGG	cis	rs2587949	0.615	rs1444059	chr3:4228369	C/G	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.93	-12.36	-0.5	1.57e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11960470	1.000	rs11960470	chr5:50328257	A/C	cg06027927	chr5:50259733	NA	0.58	9.68	0.41	2.66e-20	Breast cancer;
LGG	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg14829155	chr15:31115871	NA	0.47	8.36	0.36	7.64e-16	Huntington's disease progression;
LGG	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs11866815	0.602	rs55705600	chr16:373001	A/C	cg07915516	chr16:377344	AXIN1	-0.5	-11.2	-0.46	6e-26	Body mass index;
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.9	-0.48	1.16e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs561341	0.941	rs501773	chr17:30314435	T/G	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.61e-81	Hip circumference adjusted for BMI;
LGG	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg08885076	chr2:99613938	TSGA10	-0.54	-9.64	-0.41	3.59e-20	Chronic sinus infection;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg11494091	chr17:61959527	GH2	1.03	26.01	0.77	1.34e-92	Prudent dietary pattern;
LGG	trans	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg21775007	chr8:11205619	TDH	0.45	7.21	0.32	2.31e-12	Mood instability;
LGG	trans	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.58	-0.37	1.41e-16	Mood instability;
LGG	trans	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.93	0.35	1.61e-14	Intelligence (multi-trait analysis);
LGG	trans	rs75804782	0.630	rs80271258	chr2:239311505	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	6.77	0.3	4.03e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg18621852	chr3:10150065	C3orf24	0.39	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.87	-0.34	2.6e-14	Testicular germ cell tumor;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg04287289	chr16:89883240	FANCA	0.81	17.41	0.63	1.38e-52	Vitiligo;
LGG	cis	rs3617	0.591	rs2276823	chr3:52869263	C/A	cg11645453	chr3:52864694	ITIH4	-0.43	-7.27	-0.32	1.5e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3849046	0.846	rs256007	chr5:137897589	A/C	cg10920316	chr5:137946599	NA	0.47	7.68	0.34	9.45e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15235832	chr2:65455536	ACTR2	0.42	6.93	0.31	1.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg12454169	chr2:30669597	LCLAT1	0.54	7.68	0.34	9.32e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs758324	0.947	rs10054618	chr5:131195002	C/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs7939886	0.920	rs11227434	chr11:55945251	G/T	cg15704280	chr7:45808275	SEPT13	0.84	7.78	0.34	4.8e-14	Myopia (pathological);
LGG	cis	rs9972944	0.651	rs7222415	chr17:63765137	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	6.69e-16	Total body bone mineral density;
LGG	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	6.72e-22	Axial length;
LGG	cis	rs9463078	0.774	rs4373351	chr6:45276324	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.46	-0.37	3.62e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs73086581	1.000	rs56141565	chr20:3998603	G/A	cg02187196	chr20:3869020	PANK2	0.79	10.89	0.45	9.45e-25	Response to antidepressants in depression;
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg01494348	chr8:144660395	NAPRT1	0.89	7.34	0.32	9.86e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg11878867	chr6:150167359	LRP11	0.44	8.92	0.38	1.05e-17	Lung cancer;
LGG	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg20290983	chr6:43655470	MRPS18A	0.82	12.22	0.49	5.68e-30	IgG glycosylation;
LGG	cis	rs17683430	0.718	rs117277832	chr22:32369667	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg11494091	chr17:61959527	GH2	0.51	8.22	0.36	2.1e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg06453172	chr10:134556979	INPP5A	-0.57	-8.59	-0.37	1.33e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg13013644	chr5:502571	SLC9A3	-0.35	-6.84	-0.3	2.46e-11	Cystic fibrosis severity;
LGG	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12292205	chr6:26970375	C6orf41	0.4	6.97	0.31	1.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25172604	chr17:41446521	NA	0.31	7.15	0.32	3.51e-12	Menopause (age at onset);
LGG	cis	rs13031619	0.650	rs6542617	chr2:3694932	C/T	cg01268866	chr2:3683757	COLEC11	-0.4	-7.01	-0.31	8.67e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg27446573	chr6:127587934	RNF146	0.9	17.11	0.62	3.38e-51	Breast cancer;
LGG	cis	rs6032067	0.866	rs1007137	chr20:43816593	T/C	cg10761708	chr20:43804764	PI3	0.62	9.39	0.4	2.71e-19	Blood protein levels;
LGG	cis	rs4330281	0.608	rs12488093	chr3:17388506	T/C	cg20981856	chr3:17787350	NA	0.35	6.8	0.3	3.21e-11	Schizophrenia;
LGG	cis	rs9303401	0.564	rs4968396	chr17:57247805	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.49	7.9	0.34	2.11e-14	Cognitive test performance;
LGG	cis	rs1961637	0.514	rs6436369	chr2:223897917	A/G	cg02552189	chr2:223891284	NA	-0.48	-8.8	-0.38	2.76e-17	Oropharynx cancer;
LGG	cis	rs1978968	0.763	rs9605475	chr22:18463306	T/C	cg03078520	chr22:18463400	MICAL3	-0.68	-14.82	-0.57	6.07e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg14088196	chr11:70211408	PPFIA1	0.94	13.16	0.52	7.85e-34	Coronary artery disease;
LGG	cis	rs9549367	0.713	rs2476319	chr13:113836519	C/T	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg16680214	chr1:154839983	KCNN3	-0.5	-9.53	-0.41	8.58e-20	Prostate cancer;
LGG	cis	rs858239	0.699	rs1881200	chr7:23201637	T/C	cg23682824	chr7:23144976	KLHL7	-0.41	-6.91	-0.31	1.62e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4919694	1.000	rs12246689	chr10:104817031	C/T	cg04362960	chr10:104952993	NT5C2	1.07	15.29	0.58	5.26e-43	Arsenic metabolism;
LGG	cis	rs2050392	0.965	rs2265368	chr10:30690289	G/C	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.66	-0.44	7.1e-24	Inflammatory bowel disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14395634	chr11:65626208	CFL1	-0.49	-7.24	-0.32	1.93e-12	Systemic lupus erythematosus;
LGG	cis	rs8114671	0.836	rs6060165	chr20:33619480	A/C	cg07148914	chr20:33460835	GGT7	-0.47	-7.83	-0.34	3.33e-14	Height;
LGG	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg19812747	chr11:111475976	SIK2	0.48	9.47	0.4	1.38e-19	Primary sclerosing cholangitis;
LGG	cis	rs4819388	0.751	rs2838532	chr21:45639866	G/T	cg01992765	chr21:45622493	NA	0.47	8.99	0.39	6.57e-18	Celiac disease;
LGG	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	9.78e-21	Common traits (Other);
LGG	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.42e-22	Blood metabolite levels;
LGG	cis	rs78545713	0.649	rs16891464	chr6:26235300	A/G	cg01420254	chr6:26195488	NA	0.71	7.39	0.32	6.72e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs9911578	1.000	rs6503870	chr17:56659018	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.85	0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6835098	0.962	rs6851632	chr4:174109611	A/G	cg08422745	chr4:174089978	GALNT7	-0.85	-15.05	-0.57	5.98e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs9457247	0.765	rs3752520	chr6:167436159	T/C	cg07741184	chr6:167504864	NA	0.41	9.21	0.39	1.11e-18	Crohn's disease;
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg10295955	chr4:187884368	NA	-1.15	-31.51	-0.83	2.97e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06850241	chr22:41845214	NA	-0.43	-6.89	-0.31	1.79e-11	Vitiligo;
LGG	cis	rs611744	0.517	rs62537573	chr8:109269281	C/T	cg18478394	chr8:109455254	TTC35	0.49	10.07	0.42	1.07e-21	Dupuytren's disease;
LGG	cis	rs2050392	0.624	rs303450	chr10:30725337	C/A	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.43	-0.5	8.04e-31	Inflammatory bowel disease;
LGG	cis	rs12200782	0.872	rs59438701	chr6:26412527	C/T	cg27193005	chr6:26382695	BTN2A2	-0.59	-6.69	-0.3	6.31e-11	Small cell lung carcinoma;
LGG	cis	rs4595586	0.566	rs7307174	chr12:39368862	A/G	cg26384229	chr12:38710491	ALG10B	0.53	9.4	0.4	2.48e-19	Morning vs. evening chronotype;
LGG	cis	rs11874712	1.000	rs28757346	chr18:43696540	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.53	-11.44	-0.47	7.49e-27	Migraine - clinic-based;
LGG	cis	rs7666738	0.830	rs34244876	chr4:99031336	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4888262	0.508	rs4462623	chr16:74692426	C/T	cg01733217	chr16:74700730	RFWD3	0.93	19.59	0.67	1.06e-62	Testicular germ cell tumor;
LGG	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg24006582	chr15:45444508	DUOX1	-0.66	-12.49	-0.5	4.87e-31	Uric acid levels;
LGG	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg13852791	chr20:30311386	BCL2L1	0.92	17.76	0.64	3.55e-54	Mean corpuscular hemoglobin;
LGG	cis	rs7666738	0.830	rs11723283	chr4:99001617	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-8.98	-0.39	6.75e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08564027	chr20:61660810	NA	1.02	25.62	0.77	8.76e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs721399	0.962	rs1495746	chr8:18262842	C/T	cg18736775	chr8:18248649	NAT2	0.49	8.53	0.37	2.15e-16	Blood metabolite levels;
LGG	cis	rs55788414	1.000	rs9921827	chr16:81181869	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs921968	0.643	rs539451	chr2:219426972	T/C	cg01130898	chr2:219473002	PLCD4	-0.39	-6.68	-0.3	6.98e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6580649	1.000	rs7132668	chr12:48405860	C/T	cg24011408	chr12:48396354	COL2A1	0.62	7.59	0.33	1.77e-13	Lung cancer;
LGG	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg11644478	chr21:40555479	PSMG1	-0.71	-12.61	-0.51	1.46e-31	Cognitive function;
LGG	cis	rs6743376	0.556	rs2441376	chr2:113817755	T/C	cg05949173	chr2:113825882	IL1F10	0.48	9.17	0.39	1.57e-18	Inflammatory biomarkers;
LGG	cis	rs4789693	0.679	rs7217570	chr17:80379332	G/T	cg19579500	chr17:80346614	NA	-0.51	-8.93	-0.38	1e-17	Glucocorticoid-induced osteonecrosis;
LGG	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg01620082	chr3:125678407	NA	-1.01	-9.68	-0.41	2.75e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07262328	chr11:35160709	CD44	-0.43	-7.24	-0.32	1.89e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27180365	chr19:30432806	C19orf2	0.34	7.17	0.32	2.93e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs965513	1.000	rs10983700	chr9:100537455	T/C	cg13688889	chr9:100608707	NA	-0.52	-9.5	-0.4	1.15e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs68170813	0.562	rs11770061	chr7:107071310	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg04832318	chr3:185303823	SENP2	-0.38	-6.83	-0.3	2.67e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs7084402	0.967	rs6481404	chr10:60286071	C/G	cg09696939	chr10:60272079	BICC1	0.36	6.92	0.31	1.49e-11	Refractive error;
LGG	cis	rs9341808	0.718	rs9361584	chr6:80819946	G/C	cg08355045	chr6:80787529	NA	0.42	8.11	0.35	4.49e-15	Sitting height ratio;
LGG	cis	rs6430585	0.528	rs309154	chr2:136726567	C/T	cg07169764	chr2:136633963	MCM6	1.21	22.21	0.72	6.34e-75	Corneal structure;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.8e-21	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09360321	chr11:129939700	APLP2	0.45	7.01	0.31	8.21e-12	Gut microbiome composition (summer);
LGG	cis	rs910316	1.000	rs10143132	chr14:75525850	G/A	cg11812906	chr14:75593930	NEK9	0.53	9.89	0.42	4.78e-21	Height;
LGG	cis	rs2635047	0.967	rs2668786	chr18:44708472	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.15	0.39	1.75e-18	Educational attainment;
LGG	cis	rs858239	0.539	rs2178139	chr7:23191636	A/G	cg23682824	chr7:23144976	KLHL7	0.42	6.88	0.3	1.98e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7937682	0.562	rs527847	chr11:111369132	A/C	cg09085632	chr11:111637200	PPP2R1B	0.74	13.6	0.53	1.06e-35	Primary sclerosing cholangitis;
LGG	cis	rs2718058	0.519	rs2598047	chr7:37888488	G/T	cg02531859	chr7:37888154	TXNDC3	-0.46	-7.07	-0.31	5.81e-12	Alzheimer's disease (late onset);
LGG	cis	rs968567	0.559	rs174548	chr11:61571348	C/G	cg19610905	chr11:61596333	FADS2	-0.74	-12.7	-0.51	6.39e-32	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04080417	chr5:1859792	NA	-0.52	-8.71	-0.38	5.33e-17	Cardiovascular disease risk factors;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg07701084	chr6:150067640	NUP43	0.65	12.34	0.5	1.9e-30	Lung cancer;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	trans	rs7507204	0.906	rs11671513	chr19:3429937	C/T	cg08382705	chr11:45687319	CHST1	-0.53	-7.55	-0.33	2.35e-13	Height;
LGG	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg06558623	chr16:89946397	TCF25	-0.87	-11.5	-0.47	4.41e-27	Skin colour saturation;
LGG	cis	rs4771450	0.962	rs4771451	chr13:103976005	G/A	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg17376030	chr22:41985996	PMM1	-0.55	-8.78	-0.38	3.18e-17	Vitiligo;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg04025307	chr7:1156635	C7orf50	0.84	17.06	0.62	5.63e-51	Longevity;Endometriosis;
LGG	cis	rs7173743	0.784	rs11072810	chr15:79132206	C/T	cg00540400	chr15:79124168	NA	-0.41	-8.15	-0.35	3.41e-15	Coronary artery disease;
LGG	cis	rs9354308	0.727	rs9354309	chr6:66566694	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.75	-0.3	4.54e-11	Metabolite levels;
LGG	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11758351	0.715	rs76130408	chr6:26208962	A/G	cg06951627	chr6:26196580	NA	0.48	7.21	0.32	2.22e-12	Gout;Renal underexcretion gout;
LGG	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg01324343	chr3:183735012	ABCC5	0.73	14.36	0.56	6.07e-39	Anterior chamber depth;
LGG	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg15556689	chr8:8085844	FLJ10661	0.5	9.27	0.4	7.18e-19	Mood instability;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg02725872	chr8:58115012	NA	-0.76	-10.91	-0.45	8.07e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6087990	0.842	rs6119279	chr20:31330612	A/G	cg13636640	chr20:31349939	DNMT3B	0.89	18.78	0.66	6.28e-59	Ulcerative colitis;
LGG	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17691542	chr6:26056736	HIST1H1C	1.09	17.7	0.64	6.44e-54	Iron status biomarkers;
LGG	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.0	-0.31	8.88e-12	Uric acid levels;
LGG	cis	rs8038465	0.615	rs4075802	chr15:73963239	A/G	cg15420318	chr15:73925796	NPTN	0.44	7.54	0.33	2.48e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11209002	0.614	rs12140736	chr1:67586671	T/C	cg02640540	chr1:67518911	SLC35D1	0.4	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.96	0.38	7.97e-18	Renal function-related traits (BUN);
LGG	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg16339924	chr4:17578868	LAP3	0.59	10.35	0.43	9.72e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg15395560	chr15:45543142	SLC28A2	0.42	6.92	0.31	1.51e-11	Glomerular filtration rate;
LGG	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg23306229	chr2:178417860	TTC30B	0.76	9.98	0.42	2.18e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-9.67	-0.41	2.82e-20	Cognitive test performance;
LGG	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.82e-22	Motion sickness;
LGG	cis	rs4727443	0.866	rs2897075	chr7:99630342	C/T	cg12813108	chr7:99719912	CNPY4	-0.58	-11.41	-0.47	9.58e-27	Interstitial lung disease;
LGG	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg08773314	chr2:239334832	ASB1	0.41	7.87	0.34	2.47e-14	Multiple system atrophy;
LGG	trans	rs61931739	0.500	rs12371415	chr12:34521362	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.33	0.53	1.61e-34	Morning vs. evening chronotype;
LGG	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.67	0.79	3.48e-100	Cognitive ability;
LGG	cis	rs3219090	0.962	rs3219119	chr1:226556443	A/T	cg17127702	chr1:226594323	PARP1	-0.38	-12.16	-0.49	9.8e-30	Melanoma;
LGG	cis	rs11098499	0.575	rs907204	chr4:120238654	G/A	cg24375607	chr4:120327624	NA	0.6	10.03	0.42	1.47e-21	Corneal astigmatism;
LGG	cis	rs11098499	0.863	rs3775844	chr4:120428033	G/A	cg09307838	chr4:120376055	NA	0.8	13.42	0.53	6.32e-35	Corneal astigmatism;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.69	-0.3	6.32e-11	Lung cancer;
LGG	trans	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg11887960	chr12:57824829	NA	0.57	6.93	0.31	1.45e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg06885757	chr1:42089581	HIVEP3	0.57	11.74	0.48	5.08e-28	Airway imaging phenotypes;
LGG	cis	rs7712401	0.601	rs30026	chr5:122284568	T/C	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs1816752	0.905	rs9511266	chr13:25012504	C/G	cg02811702	chr13:24901961	NA	0.4	7.68	0.34	9.81e-14	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs9968749	chr5:93509559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.33	0.43	1.21e-22	Diabetic retinopathy;
LGG	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.5	-0.44	2.85e-23	Total body bone mineral density;
LGG	cis	rs9309473	0.950	rs7596773	chr2:73846000	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.62	-0.33	1.49e-13	Metabolite levels;
LGG	cis	rs709400	0.628	rs2010281	chr14:103862322	G/A	cg26031613	chr14:104095156	KLC1	0.8	13.68	0.54	4.86e-36	Body mass index;
LGG	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg02034447	chr16:89574710	SPG7	0.43	6.65	0.3	8.04e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg25811766	chr13:21894605	NA	-0.58	-7.66	-0.34	1.09e-13	White matter hyperintensity burden;
LGG	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg15309053	chr8:964076	NA	0.37	7.4	0.33	6.68e-13	Schizophrenia;
LGG	cis	rs7568458	0.905	rs10172544	chr2:85788270	C/A	cg17127132	chr2:85788382	GGCX	0.45	7.79	0.34	4.3e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg13628971	chr7:2884303	GNA12	0.48	9.63	0.41	4.06e-20	Height;
LGG	trans	rs8002861	0.967	rs9525871	chr13:44477712	A/T	cg17145862	chr1:211918768	LPGAT1	0.95	24.16	0.75	4.69e-84	Leprosy;
LGG	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg05775895	chr3:12838266	CAND2	0.8	16.28	0.6	1.89e-47	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg05313129	chr8:58192883	C8orf71	0.74	9.83	0.42	7.92e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-8.02	-0.35	8.76e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9487094	0.644	rs9791241	chr6:109792103	A/G	cg01125227	chr6:109776195	MICAL1	0.39	6.7	0.3	6e-11	Height;
LGG	cis	rs7829975	0.840	rs555617	chr8:8592845	C/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.74	-0.34	6.37e-14	Mood instability;
LGG	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg07636037	chr3:49044803	WDR6	1.09	27.8	0.79	9.23e-101	Parkinson's disease;
LGG	cis	rs6456156	0.792	rs10946214	chr6:167516122	G/A	cg07741184	chr6:167504864	NA	0.4	8.92	0.38	1.08e-17	Primary biliary cholangitis;
LGG	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.61	0.51	1.55e-31	Mean corpuscular hemoglobin;
LGG	cis	rs308971	0.656	rs307610	chr3:12064555	C/T	cg02700894	chr3:12045449	SYN2	0.48	6.97	0.31	1.12e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg21775007	chr8:11205619	TDH	0.62	10.19	0.43	3.83e-22	Retinal vascular caliber;
LGG	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg15704280	chr7:45808275	SEPT13	-0.69	-12.54	-0.5	2.87e-31	Coronary artery disease;
LGG	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg06606381	chr12:133084897	FBRSL1	-0.94	-10.31	-0.43	1.47e-22	Depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10625266	chr1:87169752	SH3GLB1	0.42	6.99	0.31	9.79e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20149998	chr11:73587608	CHCHD8;PAAF1	0.46	6.69	0.3	6.57e-11	Gut microbiome composition (summer);
LGG	cis	rs6445975	0.666	rs4613423	chr3:58341568	C/T	cg24175188	chr3:58374923	PXK	0.54	8.79	0.38	2.93e-17	Systemic lupus erythematosus;
LGG	cis	rs7917772	0.582	rs10786684	chr10:104323028	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.46	-0.47	5.94e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9354308	0.868	rs9453450	chr6:66545431	T/A	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.33	0.43	1.21e-22	Diabetic retinopathy;
LGG	cis	rs9547996	0.842	rs11147662	chr13:38213816	T/C	cg17979426	chr13:38220150	TRPC4	-0.39	-7.56	-0.33	2.23e-13	Diastolic blood pressure;
LGG	cis	rs6456042	0.756	rs2197450	chr6:166585112	C/T	cg11088901	chr6:166572345	T	-0.34	-6.92	-0.31	1.54e-11	Asthma;
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg11584989	chr19:19387371	SF4	-0.39	-6.98	-0.31	1.05e-11	Tonsillectomy;
LGG	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg00666640	chr1:248458726	OR2T12	0.55	8.85	0.38	1.81e-17	Common traits (Other);
LGG	cis	rs490234	0.783	rs7852065	chr9:128462023	T/C	cg14078157	chr9:128172775	NA	-0.42	-7.55	-0.33	2.41e-13	Mean arterial pressure;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-11.11	-0.46	1.37e-25	Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.17	-0.39	1.52e-18	Life satisfaction;
LGG	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.48	-0.4	1.31e-19	Common traits (Other);
LGG	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg02023728	chr11:77925099	USP35	0.44	7.72	0.34	7.36e-14	Testicular germ cell tumor;
LGG	cis	rs876084	0.505	rs9297614	chr8:121105444	C/T	cg06265175	chr8:121136014	COL14A1	0.47	9.64	0.41	3.74e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2224391	1.000	rs9504370	chr6:5261601	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.11	-0.35	4.58e-15	Height;
LGG	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.14	-0.46	1.04e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg01864069	chr14:103024347	NA	-0.73	-12.16	-0.49	1.02e-29	Platelet count;
LGG	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg16576597	chr16:28551801	NUPR1	-0.33	-7.08	-0.31	5.26e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.89	-0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg03909863	chr11:638404	DRD4	-0.4	-6.74	-0.3	4.68e-11	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg11890956	chr21:40555474	PSMG1	0.9	16.49	0.61	2.12e-48	Cognitive function;
LGG	cis	rs6750047	0.605	rs59501228	chr2:38261972	A/C	cg07380506	chr2:38303506	CYP1B1	-0.43	-7.11	-0.31	4.36e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg02725872	chr8:58115012	NA	-0.89	-12.11	-0.49	1.56e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.83	-0.3	2.75e-11	Arsenic metabolism;
LGG	cis	rs6942756	0.876	rs2303303	chr7:129019736	G/A	cg02491457	chr7:128862824	NA	-0.66	-12.01	-0.49	3.97e-29	White matter hyperintensity burden;
LGG	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.57	9.08	0.39	3.1e-18	Height;
LGG	cis	rs611744	0.647	rs1379336	chr8:109276606	G/T	cg21045802	chr8:109455806	TTC35	0.53	9.94	0.42	3.1e-21	Dupuytren's disease;
LGG	cis	rs4077515	0.806	rs11145839	chr9:139285137	A/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.25	0.32	1.78e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4308124	0.708	rs6716091	chr2:111991133	C/T	cg04571233	chr2:111982156	NA	-0.6	-9.92	-0.42	3.69e-21	Vitiligo;
LGG	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg07928641	chr1:182991847	LAMC1	0.47	9.33	0.4	4.52e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg18129748	chr3:49941408	MST1R	0.22	6.95	0.31	1.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10463316	0.894	rs11167542	chr5:150760282	A/G	cg03212797	chr5:150827313	SLC36A1	0.59	10.2	0.43	3.48e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.29	-0.55	1.2e-38	Alzheimer's disease;
LGG	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.89	-0.34	2.26e-14	IgG glycosylation;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.7	-0.34	8.22e-14	Morning vs. evening chronotype;
LGG	trans	rs6601327	0.585	rs1394	chr8:9511654	G/A	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.03	-0.31	7.6e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg19700328	chr14:106028568	NA	-0.6	-10.06	-0.42	1.18e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg08250081	chr4:10125330	NA	0.38	7.25	0.32	1.75e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg27411982	chr8:10470053	RP1L1	-0.47	-7.78	-0.34	4.76e-14	Triglycerides;
LGG	cis	rs9362426	0.551	rs6912282	chr6:88103000	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.4	7.92	0.35	1.82e-14	Depressive episodes in bipolar disorder;
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg18479299	chr3:125709523	NA	-0.61	-7.81	-0.34	3.75e-14	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg05861140	chr6:150128134	PCMT1	-0.41	-9.04	-0.39	4.46e-18	Lung cancer;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.55	0.37	1.76e-16	Alzheimer's disease;
LGG	cis	rs10267417	0.603	rs4721835	chr7:19910273	C/T	cg05791153	chr7:19748676	TWISTNB	0.56	7.27	0.32	1.56e-12	Night sleep phenotypes;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.87	0.34	2.54e-14	Longevity;
LGG	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	Neuroticism;
LGG	cis	rs9611565	0.659	rs12484228	chr22:41939739	A/G	cg03806693	chr22:41940476	POLR3H	-1.14	-21.82	-0.71	3.92e-73	Vitiligo;
LGG	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	12.93	0.52	7.12e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2114646	0.652	rs56995534	chr2:170635495	G/T	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg06606381	chr12:133084897	FBRSL1	-0.93	-9.87	-0.42	5.38e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4253772	0.530	rs55653327	chr22:46682976	C/T	cg09461388	chr22:46763229	CELSR1	-0.7	-6.9	-0.31	1.75e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg06197492	chr11:2016605	H19	0.5	10.29	0.43	1.6400000000000001e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.17	0.35	3.02e-15	Bipolar disorder;
LGG	cis	rs758324	0.947	rs687816	chr5:131262077	C/T	cg06307176	chr5:131281290	NA	-0.57	-9.23	-0.39	9.57e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2599510	0.811	rs176413	chr2:32646847	G/A	cg02381751	chr2:32503542	YIPF4	-0.5	-8.16	-0.35	3.2e-15	Interleukin-18 levels;
LGG	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg14673194	chr17:80132900	CCDC57	-0.46	-8.36	-0.36	7.59e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11165623	0.564	rs9887897	chr1:96996671	T/C	cg10631902	chr5:14652156	NA	-0.44	-9.25	-0.39	8.01e-19	Hip circumference;Waist circumference;
LGG	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg21775007	chr8:11205619	TDH	0.43	7.18	0.32	2.84e-12	Neuroticism;
LGG	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg20578329	chr17:80767326	TBCD	-0.79	-11.69	-0.48	7.72e-28	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs17818399	0.926	rs35682608	chr2:46836542	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-10.46	-0.44	4.06e-23	Height;
LGG	cis	rs1062177	0.855	rs919262	chr5:151266084	C/T	cg00977110	chr5:151150581	G3BP1	-0.43	-6.78	-0.3	3.73e-11	Preschool internalizing problems;
LGG	cis	rs950027	0.620	rs1145077	chr15:45683795	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.68	-12.03	-0.49	3.53e-29	Response to fenofibrate (adiponectin levels);
LGG	cis	rs9811920	0.809	rs766778	chr3:99751480	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.33	-0.36	9.32e-16	Axial length;
LGG	cis	rs774359	0.744	rs895022	chr9:27484371	G/C	cg22262168	chr9:27528999	MOBKL2B	0.45	6.77	0.3	3.94e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2274273	0.624	rs8014477	chr14:55841477	A/G	cg04306507	chr14:55594613	LGALS3	-0.5	-12.07	-0.49	2.28e-29	Protein biomarker;
LGG	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg06618935	chr21:46677482	NA	-0.52	-9.05	-0.39	4e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg12798564	chr3:75263641	NA	0.66	6.94	0.31	1.33e-11	Airflow obstruction;
LGG	cis	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg06521331	chr12:34319734	NA	-0.43	-7.59	-0.33	1.76e-13	Morning vs. evening chronotype;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg01114163	chr5:1856713	NA	-0.41	-7.1	-0.31	4.76e-12	Cardiovascular disease risk factors;
LGG	cis	rs1927790	0.727	rs6491285	chr13:96944930	T/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.97	-0.31	1.11e-11	Body mass index;
LGG	cis	rs10504073	0.584	rs11776843	chr8:49928449	C/T	cg00325661	chr8:49890786	NA	0.8	16.25	0.6	2.62e-47	Blood metabolite ratios;
LGG	cis	rs9911578	1.000	rs7207693	chr17:57016525	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	cis	rs12579753	1.000	rs10862372	chr12:82249804	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.01	-0.46	3.4e-25	Resting heart rate;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs4474465	1.000	rs4945282	chr11:78188795	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.64	-0.33	1.24e-13	Alzheimer's disease (survival time);
LGG	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg26384229	chr12:38710491	ALG10B	0.6	11.73	0.48	5.43e-28	Morning vs. evening chronotype;
LGG	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg17911788	chr17:44343683	NA	0.46	7.78	0.34	4.73e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg07659893	chr17:61819838	STRADA	-0.43	-6.89	-0.3	1.86e-11	Prudent dietary pattern;
LGG	cis	rs6430585	0.528	rs309122	chr2:136761853	A/G	cg07169764	chr2:136633963	MCM6	1.16	21.91	0.71	1.52e-73	Corneal structure;
LGG	cis	rs7113874	0.550	rs10840085	chr11:8613949	A/G	cg23764900	chr11:8616102	STK33	0.39	6.9	0.31	1.67e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6450176	0.909	rs6884936	chr5:53293198	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.06	-0.46	2.23e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs61931739	0.534	rs7313137	chr12:34010231	T/G	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs9487051	0.837	rs4403290	chr6:109611583	A/T	cg21918786	chr6:109611834	NA	-0.48	-8.85	-0.38	1.89e-17	Reticulocyte fraction of red cells;
LGG	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg10760299	chr15:45669010	GATM	0.4	8.0	0.35	9.82e-15	Homoarginine levels;
LGG	cis	rs9303401	0.659	rs62081316	chr17:56781499	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs4443100	0.631	rs13054904	chr22:23410918	A/T	cg14186256	chr22:23484241	RTDR1	-0.54	-8.48	-0.37	3.12e-16	Serum parathyroid hormone levels;
LGG	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.15	0.7	5.84e-70	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg06481639	chr22:41940642	POLR3H	0.5	7.07	0.31	5.9e-12	Vitiligo;
LGG	trans	rs7944735	0.567	rs7946766	chr11:48004369	C/T	cg15704280	chr7:45808275	SEPT13	0.69	7.28	0.32	1.42e-12	Intraocular pressure;
LGG	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs4731207	0.698	rs886704	chr7:124422266	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.92	-0.35	1.77e-14	Cutaneous malignant melanoma;
LGG	cis	rs6840360	1.000	rs6535818	chr4:152650882	T/G	cg22705602	chr4:152727874	NA	-0.27	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg11890956	chr21:40555474	PSMG1	-0.95	-19.6	-0.67	1.01e-62	Cognitive function;
LGG	trans	rs826838	0.967	rs1352122	chr12:39130885	G/A	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs4689642	0.756	rs4689089	chr4:7225587	C/G	cg21353189	chr4:7228343	SORCS2	0.38	9.02	0.39	4.98e-18	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs11875185	0.510	rs56732657	chr18:55620077	A/G	cg15513957	chr14:69354734	ACTN1	-0.89	-9.04	-0.39	4.15e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9768139	1.000	rs9768139	chr7:158120731	G/A	cg15736062	chr7:158136485	PTPRN2	0.38	7.47	0.33	3.96e-13	Calcium levels;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.23	0.32	2.04e-12	Lung cancer;
LGG	cis	rs11098499	0.754	rs12507565	chr4:120251121	G/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg10760299	chr15:45669010	GATM	-0.4	-7.78	-0.34	4.91e-14	Homoarginine levels;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.09	-0.42	8.96e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs35740288	0.545	rs12916187	chr15:86326124	A/C	cg04173714	chr15:86211321	AKAP13	0.45	7.27	0.32	1.57e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.47	0.33	4.15e-13	Triglycerides;
LGG	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.14	0.31	3.64e-12	Refractive error;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06183820	chr6:2972097	SERPINB6	0.35	6.75	0.3	4.46e-11	Cognitive performance;
LGG	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	cis	rs897984	0.645	rs9938550	chr16:30999142	A/G	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs2455799	0.613	rs13096622	chr3:15837656	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-7.88	-0.34	2.44e-14	Mean platelet volume;
LGG	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg02002194	chr4:3960332	NA	0.52	10.52	0.44	2.38e-23	Neuroticism;
LGG	cis	rs2253017	0.723	rs2818989	chr13:21386851	A/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.27	-0.32	1.55e-12	PR segment;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.56e-23	Lung cancer;
LGG	cis	rs9649465	0.967	rs1005567	chr7:123305836	A/T	cg03229431	chr7:123269106	ASB15	0.4	8.94	0.38	9.59e-18	Migraine;
LGG	cis	rs926938	0.505	rs360593	chr1:115472265	T/G	cg12756093	chr1:115239321	AMPD1	0.43	8.01	0.35	9.25e-15	Autism;
LGG	cis	rs368123	0.961	rs384071	chr6:160731201	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.28	-0.32	1.44e-12	Waist circumference;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg14789911	chr21:47582049	C21orf56	-0.52	-9.19	-0.39	1.37e-18	Testicular germ cell tumor;
LGG	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg07978099	chr16:83986941	OSGIN1	-0.6	-9.31	-0.4	5.02e-19	Pursuit maintenance gain;
LGG	trans	rs2243480	1.000	rs316315	chr7:65591205	C/T	cg10756647	chr7:56101905	PSPH	-0.7	-9.06	-0.39	3.6e-18	Diabetic kidney disease;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg17911788	chr17:44343683	NA	0.57	8.96	0.38	8.04e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7219021	0.739	rs1973404	chr17:46967892	G/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.95	-0.31	1.28e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs35740288	0.770	rs67253156	chr15:86105045	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.6	0.37	1.23e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6558530	0.965	rs6558529	chr8:1706206	C/T	cg19131313	chr8:1704013	NA	-0.3	-6.72	-0.3	5.35e-11	Systolic blood pressure;
LGG	cis	rs11676348	0.808	rs1008563	chr2:219026888	G/A	cg00012203	chr2:219082015	ARPC2	-0.48	-8.48	-0.37	2.97e-16	Ulcerative colitis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03244616	chr12:130935837	RIMBP2	0.37	7.06	0.31	6.2e-12	Electrocardiographic conduction measures;
LGG	cis	rs7523273	0.606	rs2796271	chr1:207941927	A/G	cg22525895	chr1:207977042	MIR29B2	0.61	12.06	0.49	2.52e-29	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11976233	chr4:56719715	EXOC1	0.63	7.5	0.33	3.25e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.690	rs7640397	chr3:46989828	C/T	cg16586182	chr3:47516702	SCAP	-0.74	-13.38	-0.53	9.14e-35	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06476805	chr3:123304425	PTPLB	0.44	7.18	0.32	2.72e-12	Cognitive performance;
LGG	cis	rs7444	0.941	rs5754426	chr22:21980638	T/C	cg05046821	chr22:21984468	YDJC	-0.37	-6.67	-0.3	7.45e-11	Systemic lupus erythematosus;
LGG	cis	rs6728642	0.708	rs115507803	chr2:97752054	T/C	cg26665480	chr2:98280029	ACTR1B	-0.68	-6.76	-0.3	4.08e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2299587	0.604	rs11203933	chr8:17901910	G/T	cg18067069	chr8:17937731	ASAH1	-0.32	-7.6	-0.33	1.7e-13	Economic and political preferences;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07097722	chr20:43247325	PKIG	0.42	7.79	0.34	4.54e-14	Electrocardiographic conduction measures;
LGG	cis	rs8016982	0.662	rs1951616	chr14:81671752	T/C	cg01989461	chr14:81687754	GTF2A1	0.58	9.07	0.39	3.31e-18	Schizophrenia;
LGG	cis	rs7587476	0.682	rs13009646	chr2:215691259	T/A	cg04530015	chr2:215796436	ABCA12	-0.45	-7.71	-0.34	8.02e-14	Neuroblastoma;
LGG	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.75	0.3	4.47e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs939317	0.678	rs843372	chr3:183996213	C/T	cg09405238	chr3:183994500	ECE2	0.57	10.78	0.45	2.61e-24	Menarche (age at onset);
LGG	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg10167378	chr1:228756711	NA	0.71	9.48	0.4	1.35e-19	Chronic lymphocytic leukemia;
LGG	trans	rs6787172	0.622	rs9853566	chr3:158093870	C/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs2916247	0.954	rs13267490	chr8:93137598	A/G	cg10183463	chr8:93005414	RUNX1T1	0.36	7.47	0.33	4.01e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg11871910	chr12:69753446	YEATS4	0.7	13.57	0.53	1.54e-35	Blood protein levels;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs10883723	0.810	rs7094751	chr10:104274818	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.96e-43	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg03929089	chr4:120376271	NA	-0.69	-9.54	-0.41	8.25e-20	Axial length;
LGG	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg04450456	chr4:17643702	FAM184B	0.34	7.55	0.33	2.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg19168338	chr16:4465731	CORO7	-0.77	-14.39	-0.56	4.52e-39	Schizophrenia;
LGG	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8028182	0.549	rs56395816	chr15:75664571	A/T	cg20655648	chr15:75932815	IMP3	-0.44	-7.36	-0.32	8.62e-13	Sudden cardiac arrest;
LGG	cis	rs2120019	0.938	rs2120020	chr15:75316845	T/C	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.88	-0.66	2.14e-59	Blood trace element (Zn levels);
LGG	cis	rs888194	0.601	rs918106	chr12:109904318	C/T	cg19025524	chr12:109796872	NA	-0.36	-7.2	-0.32	2.4e-12	Neuroticism;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	7.95	0.35	1.44e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg17971929	chr21:40555470	PSMG1	-0.71	-13.6	-0.53	1.1e-35	Cognitive function;
LGG	cis	rs858239	0.600	rs10256359	chr7:23123877	C/T	cg23682824	chr7:23144976	KLHL7	0.44	7.57	0.33	2.02e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10936602	0.527	rs7628572	chr3:169539649	T/A	cg00832555	chr3:169529716	LRRC34	0.35	7.26	0.32	1.66e-12	Renal cell carcinoma;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	0.3	7.8	0.34	4.18e-14	IgG glycosylation;
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs12282928	0.959	rs871249	chr11:48284477	G/A	cg26585981	chr11:48327164	OR4S1	0.44	7.12	0.31	4.22e-12	Migraine - clinic-based;
LGG	trans	rs561341	1.000	rs542132	chr17:30307193	A/T	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg00745463	chr17:30367425	LRRC37B	-0.79	-11.0	-0.46	3.69e-25	Hip circumference adjusted for BMI;
LGG	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg07636037	chr3:49044803	WDR6	1.12	28.72	0.8	6.63e-105	Parkinson's disease;
LGG	cis	rs1419980	0.673	rs12146828	chr12:7739341	C/G	cg10578777	chr12:7781093	NA	-0.62	-8.48	-0.37	2.97e-16	HDL cholesterol levels;
LGG	cis	rs4566357	1.000	rs7567789	chr2:227922104	T/C	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.87	0.3	2.11e-11	Glycated hemoglobin levels;
LGG	cis	rs7666738	0.791	rs28579101	chr4:98843203	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.69	0.34	9.14e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.04	0.52	2.5e-33	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.655	rs9638973	chr7:1133678	A/G	cg00990874	chr7:1149470	C7orf50	-0.82	-14.41	-0.56	3.89e-39	Bronchopulmonary dysplasia;
LGG	cis	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-6.78	-0.3	3.68e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7412746	0.611	rs4970931	chr1:150910727	G/A	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Melanoma;
LGG	cis	rs2652834	1.000	rs7182618	chr15:63398622	T/C	cg05507819	chr15:63340323	TPM1	0.57	7.64	0.33	1.28e-13	HDL cholesterol;
LGG	cis	rs1348850	0.757	rs4893954	chr2:178340520	T/G	cg22681709	chr2:178499509	PDE11A	-0.44	-8.1	-0.35	4.98e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4363385	0.553	rs41263664	chr1:152974063	G/A	cg13444842	chr1:152974279	SPRR3	-0.51	-10.28	-0.43	1.78e-22	Inflammatory skin disease;
LGG	trans	rs72991	1.000	rs72991	chr11:121243716	A/G	cg27192990	chr6:129479024	LAMA2	0.49	7.95	0.35	1.42e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg00830817	chr11:109293614	C11orf87	0.44	6.97	0.31	1.1e-11	Schizophrenia;
LGG	cis	rs11969893	0.649	rs9498408	chr6:101292340	C/T	cg12253828	chr6:101329408	ASCC3	0.8	7.56	0.33	2.22e-13	Economic and political preferences (immigration/crime);
LGG	cis	rs926392	0.932	rs6124105	chr20:37686081	G/A	cg16355469	chr20:37678765	NA	0.43	7.06	0.31	6.17e-12	Dialysis-related mortality;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08677398	chr8:58056175	NA	0.5	7.91	0.34	1.97e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19550313	chr11:85359017	TMEM126A	0.46	6.65	0.3	8.22e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26222042	chr5:31532200	RNASEN;C5orf22	0.46	7.05	0.31	6.42e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg11062466	chr8:58055876	NA	0.48	8.32	0.36	1.01e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg19645103	chr12:69753606	YEATS4	-0.51	-7.44	-0.33	4.88e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7647973	0.626	rs4855882	chr3:49715354	G/T	cg03060546	chr3:49711283	APEH	0.63	8.54	0.37	2.01e-16	Menarche (age at onset);
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs3733585	0.638	rs6414766	chr4:9956474	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.93	-0.31	1.46e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg02023728	chr11:77925099	USP35	0.43	7.72	0.34	7.19e-14	Testicular germ cell tumor;
LGG	cis	rs10193935	0.901	rs2286702	chr2:42555473	C/T	cg27598129	chr2:42591480	NA	-0.65	-9.79	-0.41	1.06e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62400317	0.821	rs72857080	chr6:45198373	G/A	cg18551225	chr6:44695536	NA	-0.62	-9.82	-0.42	8.27e-21	Total body bone mineral density;
LGG	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.64	-0.41	3.67e-20	Height;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg18402987	chr7:1209562	NA	0.73	11.14	0.46	1.07e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.52	-0.44	2.27e-23	Bipolar disorder;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg15763984	chr4:1342303	KIAA1530	0.38	6.8	0.3	3.19e-11	Obesity-related traits;
LGG	cis	rs4660306	0.677	rs10493120	chr1:45903488	C/T	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.46	6.8	0.3	3.19e-11	Homocysteine levels;
LGG	cis	rs12282928	0.743	rs10769323	chr11:48213453	C/T	cg26585981	chr11:48327164	OR4S1	-0.39	-6.83	-0.3	2.63e-11	Migraine - clinic-based;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs6868223	1.000	rs35529483	chr5:33637243	A/G	cg10594543	chr5:33649717	ADAMTS12	0.57	12.57	0.5	2.13e-31	Mortality in heart failure;
LGG	cis	rs9287719	0.810	rs1990612	chr2:10781944	A/G	cg02196655	chr2:10830764	NOL10	-0.47	-8.23	-0.36	1.98e-15	Prostate cancer;
LGG	cis	rs9987353	0.566	rs34491841	chr8:9065510	C/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.87	-0.3	2.11e-11	Recombination measurement;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg05863683	chr7:1912471	MAD1L1	0.47	9.17	0.39	1.54e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg02574844	chr11:5959923	NA	-0.58	-8.95	-0.38	8.74e-18	DNA methylation (variation);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs11098499	0.954	rs11935596	chr4:120412457	G/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.63e-14	Cystic fibrosis severity;
LGG	cis	rs7927771	1.000	rs34128973	chr11:47851376	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg15704280	chr7:45808275	SEPT13	0.77	8.93	0.38	9.88e-18	Axial length;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.01e-17	Menopause (age at onset);
LGG	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg16850897	chr7:100343110	ZAN	0.66	9.74	0.41	1.63e-20	Other erythrocyte phenotypes;
LGG	cis	rs2270450	0.614	rs9395209	chr6:46709014	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.67	-0.44	6.69e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs78456975	0.527	rs10203194	chr2:1558021	A/G	cg12573674	chr2:1569213	NA	-0.63	-9.7	-0.41	2.23e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs12478296	0.901	rs9653611	chr2:243006956	C/G	cg06360820	chr2:242988706	NA	-0.93	-12.25	-0.49	4.61e-30	Obesity-related traits;
LGG	trans	rs2840044	1.000	rs225295	chr17:33925755	A/G	cg19694781	chr19:47549865	TMEM160	-0.55	-9.19	-0.39	1.36e-18	Response to radiotherapy in cancer (late toxicity);
LGG	trans	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.57	-10.07	-0.42	1.08e-21	Mean corpuscular volume;
LGG	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg10596483	chr8:143751796	JRK	0.58	9.58	0.41	5.99e-20	Schizophrenia;
LGG	cis	rs710865	0.519	rs10753518	chr1:19483593	T/C	cg13387374	chr1:19411106	UBR4	0.52	11.0	0.46	3.63e-25	Brain structure;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs11148252	0.634	rs66849828	chr13:52714837	C/A	cg00761968	chr13:53314142	LECT1	-0.35	-7.17	-0.32	3.02e-12	Lewy body disease;
LGG	cis	rs755249	0.567	rs2018212	chr1:39905588	T/C	cg18385671	chr1:39797026	MACF1	0.45	7.47	0.33	3.91e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4713118	0.587	rs9393899	chr6:28133528	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Parkinson's disease;
LGG	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg09307838	chr4:120376055	NA	0.78	11.85	0.48	1.74e-28	Corneal astigmatism;
LGG	cis	rs763121	0.853	rs6001175	chr22:39018334	T/C	cg21395723	chr22:39101663	GTPBP1	0.37	6.67	0.3	7.36e-11	Menopause (age at onset);
LGG	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.09	0.52	1.52e-33	Colorectal cancer;
LGG	cis	rs9486715	1.000	rs9486725	chr6:97061159	C/T	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.42	-0.4	2.07e-19	Headache;
LGG	cis	rs2742417	1.000	rs2245705	chr3:45749722	A/G	cg04837898	chr3:45731254	SACM1L	-0.38	-7.5	-0.33	3.24e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs892961	0.932	rs3987886	chr17:75414980	A/G	cg05865280	chr17:75406074	SEPT9	0.42	9.89	0.42	4.68e-21	Airflow obstruction;
LGG	cis	rs1014246	0.826	rs11197801	chr10:118471693	C/T	cg14919929	chr10:118506882	NA	-0.62	-12.42	-0.5	8.74e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2115630	0.967	rs7171167	chr15:85239123	A/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.87	-0.3	2.12e-11	P wave terminal force;
LGG	cis	rs4671458	0.948	rs72813478	chr2:63526869	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-7.84	-0.34	3.13e-14	Subjective well-being;
LGG	cis	rs35771425	0.529	rs60096533	chr1:211377218	G/A	cg10512769	chr1:211675356	NA	-0.65	-8.17	-0.35	3.06e-15	Educational attainment (years of education);
LGG	cis	rs12410462	0.681	rs76705164	chr1:227615570	G/A	cg04117972	chr1:227635322	NA	0.84	13.38	0.53	9.41e-35	Major depressive disorder;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.3	-0.43	1.56e-22	Platelet count;
LGG	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.87	-0.34	2.52e-14	HDL cholesterol;
LGG	cis	rs7666738	0.830	rs7673385	chr4:99024922	T/G	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.39e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg05163923	chr11:71159392	DHCR7	0.72	14.01	0.55	2.03e-37	Vitamin D levels;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00130309	chr20:25677623	ZNF337	0.53	8.28	0.36	1.29e-15	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.817	rs10839358	chr11:49770972	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.19	-0.49	7.9e-30	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06295404	chr16:11350337	SOCS1	-0.43	-6.73	-0.3	5.09e-11	Pancreatic cancer;
LGG	cis	rs4780401	0.729	rs8045300	chr16:11769266	C/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.27	-0.32	1.55e-12	Rheumatoid arthritis;
LGG	cis	rs9858542	1.000	rs11709525	chr3:49690496	C/T	cg03060546	chr3:49711283	APEH	-0.69	-11.45	-0.47	6.47e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.14e-34	Skin colour saturation;
LGG	cis	rs1348850	0.574	rs2365617	chr2:178421934	C/A	cg23306229	chr2:178417860	TTC30B	0.74	8.78	0.38	3.17e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg24642844	chr7:1081250	C7orf50	-0.84	-13.95	-0.54	3.69e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg00938859	chr5:1591904	SDHAP3	0.81	8.55	0.37	1.75e-16	Breast cancer;
LGG	cis	rs926938	0.618	rs360587	chr1:115467553	A/G	cg12756093	chr1:115239321	AMPD1	0.49	9.34	0.4	4.09e-19	Autism;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	8.53	0.37	2.18e-16	Lung function (FEV1/FVC);
LGG	trans	rs3857536	0.654	rs9342541	chr6:66977595	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.08	-0.31	5.39e-12	Blood trace element (Cu levels);
LGG	cis	rs561341	1.000	rs530715	chr17:30320544	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.21	-0.43	3.17e-22	Hip circumference adjusted for BMI;
LGG	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.04	-0.39	4.23e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs2074193	0.569	rs215377	chr12:47752171	T/G	cg02516419	chr12:47771422	NA	-0.54	-7.86	-0.34	2.63e-14	Migraine with aura;
LGG	cis	rs1577917	0.876	rs12212808	chr6:86533972	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs6807915	0.541	rs310757	chr3:12281063	C/T	cg02700894	chr3:12045449	SYN2	0.39	6.76	0.3	4.22e-11	Leprosy;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.11	24.93	0.76	1.32e-87	Height;
LGG	cis	rs2587949	0.615	rs2629241	chr3:4208798	A/G	cg16519197	chr3:4211558	NA	-0.33	-6.79	-0.3	3.44e-11	Periodontitis (DPAL);
LGG	cis	rs9916302	0.904	rs3964723	chr17:37403979	C/T	cg07936489	chr17:37558343	FBXL20	-0.83	-15.07	-0.57	4.93e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs4538187	0.906	rs17619753	chr2:63943616	G/A	cg02541582	chr2:64069798	UGP2	-0.56	-13.02	-0.52	2.98e-33	Systolic blood pressure;
LGG	cis	rs10911251	0.546	rs2274984	chr1:183107446	A/C	cg07928641	chr1:182991847	LAMC1	-0.4	-7.98	-0.35	1.19e-14	Colorectal cancer;
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.2	0.36	2.43e-15	Lung cancer;
LGG	cis	rs6580649	0.882	rs7133249	chr12:48456823	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs7582720	1.000	rs6705330	chr2:203662197	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2832191	0.671	rs2832212	chr21:30511417	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-10.6	-0.44	1.18e-23	Dental caries;
LGG	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg18240062	chr17:79603768	NPLOC4	0.61	10.07	0.42	1.06e-21	Eye color traits;
LGG	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg06713675	chr4:122721982	EXOSC9	0.48	6.95	0.31	1.23e-11	Type 2 diabetes;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.47	7.86	0.34	2.71e-14	Longevity;
LGG	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-6.7	-0.3	6.1e-11	Morning vs. evening chronotype;
LGG	cis	rs9771228	0.515	rs415820	chr7:32359277	T/C	cg27532318	chr7:32358331	NA	-0.54	-7.7	-0.34	8.45e-14	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg18854424	chr1:2615690	NA	0.34	6.9	0.31	1.72e-11	Ulcerative colitis;
LGG	cis	rs2439831	1.000	rs2584726	chr15:43715382	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.36	0.5	1.54e-30	Lung cancer in ever smokers;
LGG	cis	rs7336332	0.547	rs9581859	chr13:28035147	A/T	cg01674679	chr13:27998804	GTF3A	-0.64	-7.29	-0.32	1.35e-12	Weight;
LGG	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.17	-0.39	1.59e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1538970	0.924	rs1006216	chr1:45909994	A/G	cg05343316	chr1:45956843	TESK2	0.72	11.83	0.48	2.23e-28	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20261243	chr20:44718728	NCOA5	0.5	7.65	0.33	1.22e-13	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg15268244	chr15:77196840	NA	-0.32	-7.2	-0.32	2.45e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08284180	chr1:160232170	DCAF8	0.51	7.5	0.33	3.25e-13	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg05863683	chr7:1912471	MAD1L1	0.44	8.47	0.37	3.32e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg25457927	chr22:38595422	NA	-0.38	-9.02	-0.39	5.09e-18	Breast cancer;
LGG	cis	rs883565	0.610	rs4676600	chr3:39157011	A/G	cg01426195	chr3:39028469	NA	-0.6	-11.54	-0.47	2.89e-27	Handedness;
LGG	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.76	0.84	1.2e-122	Chronic sinus infection;
LGG	cis	rs17270561	0.609	rs9358876	chr6:25738956	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs7208859	0.573	rs58920731	chr17:29191746	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6815814	0.851	rs73235002	chr4:38769018	A/G	cg06935464	chr4:38784597	TLR10	0.53	7.16	0.32	3.28e-12	Breast cancer;
LGG	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg00071950	chr4:10020882	SLC2A9	0.43	8.96	0.38	8.06e-18	Bone mineral density;
LGG	cis	rs7927771	0.801	rs12798028	chr11:47604639	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-7.54	-0.33	2.48e-13	Subjective well-being;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.6	-0.37	1.27e-16	Personality dimensions;
LGG	cis	rs7617773	0.817	rs9311421	chr3:48293078	G/A	cg11946769	chr3:48343235	NME6	0.63	10.39	0.43	7.32e-23	Coronary artery disease;
LGG	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg12463550	chr7:65579703	CRCP	-0.53	-8.55	-0.37	1.79e-16	Aortic root size;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg22398616	chr13:53314203	LECT1	-0.42	-8.66	-0.37	8.09e-17	Lewy body disease;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05025164	chr4:1340916	KIAA1530	0.65	12.24	0.49	5.02e-30	Longevity;
LGG	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.27	-0.4	7.36e-19	Neuroticism;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	8.17	0.35	3.02e-15	Obesity-related traits;
LGG	cis	rs6964587	0.621	rs39744	chr7:92043016	A/G	cg17063962	chr7:91808500	NA	0.44	8.01	0.35	9.3e-15	Breast cancer;
LGG	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg25922239	chr6:33757077	LEMD2	0.42	7.32	0.32	1.12e-12	Crohn's disease;
LGG	cis	rs8133932	0.701	rs3788228	chr21:47307669	G/A	cg11214348	chr21:47283868	PCBP3	0.44	7.96	0.35	1.35e-14	Schizophrenia;
LGG	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.49	-0.47	4.62e-27	Height;
LGG	cis	rs208520	0.754	rs851592	chr6:66875175	G/T	cg07460842	chr6:66804631	NA	-0.96	-17.65	-0.63	1.1e-53	Exhaled nitric oxide output;
LGG	cis	rs1665650	1.000	rs1665650	chr10:118487100	A/G	cg14919929	chr10:118506882	NA	0.47	8.19	0.36	2.58e-15	Colorectal cancer;
LGG	trans	rs6601327	0.736	rs4840426	chr8:9408978	G/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.26	-0.32	1.65e-12	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg16141378	chr3:129829833	LOC729375	0.4	9.05	0.39	4.02e-18	Retinal vascular caliber;
LGG	cis	rs6089829	0.926	rs1060489	chr20:61665921	C/T	cg03213289	chr20:61660250	NA	0.66	14.37	0.56	5.53e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg01262667	chr19:19385393	TM6SF2	0.48	11.98	0.49	5.65e-29	Tonsillectomy;
LGG	cis	rs7542091	0.579	rs34638782	chr1:210032055	C/G	cg05527609	chr1:210001259	C1orf107	-0.44	-7.27	-0.32	1.58e-12	Monobrow;
LGG	cis	rs889398	0.510	rs11646575	chr16:69567781	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.66	-0.34	1.1e-13	Body mass index;
LGG	cis	rs4268898	0.760	rs4665675	chr2:24468132	C/T	cg06627628	chr2:24431161	ITSN2	-0.43	-7.35	-0.32	9e-13	Asthma;
LGG	cis	rs9948	1.000	rs9948	chr2:97500800	C/G	cg01990225	chr2:97406019	LMAN2L	0.67	7.49	0.33	3.45e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2241941	0.840	rs10500882	chr11:20629837	A/G	cg05572763	chr11:20631898	SLC6A5	0.47	8.86	0.38	1.74e-17	Obesity-related traits;
LGG	cis	rs741702	0.819	rs62108438	chr19:13000247	T/C	cg04657146	chr19:12876947	HOOK2	-0.44	-7.34	-0.32	9.42e-13	Red blood cell traits;
LGG	cis	rs972578	0.765	rs5751378	chr22:43219836	C/G	cg01576275	chr22:43409880	NA	-0.23	-6.97	-0.31	1.11e-11	Mean platelet volume;
LGG	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.75	-0.3	4.46e-11	Menarche (age at onset);
LGG	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.22	-0.36	2.14e-15	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs10004184	chr4:119486801	G/T	cg14228332	chr4:119757509	SEC24D	0.92	9.41	0.4	2.34e-19	Cannabis dependence symptom count;
LGG	cis	rs12188164	0.965	rs11743639	chr5:450710	C/T	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14276619	chr12:117319577	HRK	0.39	6.75	0.3	4.46e-11	Cognitive performance;
LGG	trans	rs2736345	0.535	rs4366049	chr8:11398504	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.18	-0.32	2.78e-12	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs66561647	0.634	rs7821856	chr8:128939499	A/G	cg05480350	chr8:128972681	MIR1205;PVT1	0.39	6.65	0.3	8.3e-11	Hemoglobin concentration;
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg24623649	chr8:11872141	NA	-0.29	-7.09	-0.31	4.97e-12	Neuroticism;
LGG	cis	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg00086871	chr4:6988644	TBC1D14	0.85	8.39	0.36	6.06e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg18551225	chr6:44695536	NA	-0.69	-11.46	-0.47	6.04e-27	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.41	-0.33	6.05e-13	Lung cancer;
LGG	cis	rs60843830	0.662	rs6721594	chr2:305203	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	-0.68	-11.89	-0.48	1.21e-28	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs75804782	0.520	rs72987319	chr2:239351143	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.74	0.38	4.33e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9303280	0.517	rs12939566	chr17:38038390	A/T	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.43e-12	Self-reported allergy;
LGG	cis	rs593982	1.000	rs593982	chr11:65513107	T/C	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	cis	rs350251	0.868	rs350278	chr16:12232402	T/C	cg02910054	chr16:12241554	SNX29	0.48	8.96	0.38	7.73e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	1.000	rs7935180	chr11:78169785	C/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs1847202	0.826	rs11922892	chr3:72952186	T/G	cg25664220	chr3:72788482	NA	-0.24	-7.22	-0.32	2.11e-12	Motion sickness;
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.94	-0.38	9.42e-18	Height;
LGG	cis	rs7552404	0.727	rs5745427	chr1:76332637	C/A	cg03433033	chr1:76189801	ACADM	-0.63	-9.64	-0.41	3.71e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4716602	0.596	rs10261230	chr7:156159632	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.58	-0.41	5.92e-20	Anti-saccade response;
LGG	cis	rs7086627	0.515	rs11202960	chr10:82209807	G/A	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.06e-11	Total body bone mineral density;
LGG	cis	rs17428076	0.872	rs17500114	chr2:172896587	A/C	cg21435375	chr2:172878103	MAP1D	0.46	9.72	0.41	1.9e-20	Myopia;
LGG	trans	rs9914544	0.545	rs34417974	chr17:18773636	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.86	-0.34	2.69e-14	Educational attainment (years of education);
LGG	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.22e-12	Neuroticism;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg09699651	chr6:150184138	LRP11	0.56	10.62	0.44	9.7e-24	Testicular germ cell tumor;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg12708336	chr17:41446283	NA	0.31	7.47	0.33	3.9e-13	Menopause (age at onset);
LGG	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	13.09	0.52	1.52e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg24503407	chr1:205819492	PM20D1	0.83	19.99	0.68	1.55e-64	Menarche (age at onset);
LGG	cis	rs9325144	0.600	rs1825807	chr12:38737007	T/C	cg13010199	chr12:38710504	ALG10B	0.56	10.9	0.45	9.04e-25	Morning vs. evening chronotype;
LGG	cis	rs13424612	0.896	rs12467120	chr2:240894275	A/G	cg01812947	chr2:240904978	NDUFA10	-0.4	-6.8	-0.3	3.25e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg17108064	chr15:78857060	CHRNA5	0.45	9.64	0.41	3.6e-20	Sudden cardiac arrest;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs7301826	0.651	rs4759794	chr12:131297348	T/G	cg11011512	chr12:131303247	STX2	0.41	8.87	0.38	1.61e-17	Plasma plasminogen activator levels;
LGG	cis	rs8067545	0.750	rs11868084	chr17:19992717	A/G	cg13482628	chr17:19912719	NA	0.63	12.61	0.51	1.57e-31	Schizophrenia;
LGG	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg02931644	chr1:25747376	RHCE	0.44	9.56	0.41	7.26e-20	Plateletcrit;Mean corpuscular volume;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg21775007	chr8:11205619	TDH	-0.56	-9.16	-0.39	1.73e-18	Neuroticism;
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg15971980	chr6:150254442	NA	0.44	8.26	0.36	1.51e-15	Lung cancer;
LGG	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.71	12.56	0.5	2.49e-31	Body mass index;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	10.72	0.45	4.26e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg07928641	chr1:182991847	LAMC1	0.45	8.78	0.38	3.06e-17	Fuchs's corneal dystrophy;
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg14675211	chr2:100938903	LONRF2	0.69	12.26	0.5	4.01e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4689642	0.507	rs12646898	chr4:7221071	A/G	cg21353189	chr4:7228343	SORCS2	0.32	6.84	0.3	2.5e-11	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.9	0.42	4.27e-21	Morning vs. evening chronotype;
LGG	cis	rs7247513	0.964	rs1007352	chr19:12722545	G/C	cg01871581	chr19:12707946	ZNF490	-0.43	-8.61	-0.37	1.19e-16	Bipolar disorder;
LGG	cis	rs7209395	0.959	rs8078801	chr17:64132745	C/T	cg19474267	chr17:64306194	PRKCA	0.53	8.47	0.37	3.28e-16	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs7582720	0.887	rs72934591	chr2:204019762	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.29	0.4	6.08e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs911555	0.570	rs11625397	chr14:104027557	A/G	cg23335576	chr14:104009727	NA	-0.39	-6.77	-0.3	4.02e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.864	rs7482764	chr11:48625858	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg12432903	chr7:1882776	MAD1L1	0.54	8.76	0.38	3.6e-17	Bipolar disorder;
LGG	cis	rs2870946	1.000	rs2870946	chr12:68596661	C/T	cg01673780	chr12:68619593	IL26	0.8	7.67	0.34	1.05e-13	Ulcerative colitis;
LGG	cis	rs8012	0.517	rs9384	chr19:13010643	G/T	cg04657146	chr19:12876947	HOOK2	-0.45	-7.38	-0.32	7.5e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.56	-0.5	2.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg03342759	chr3:160939853	NMD3	-0.59	-10.22	-0.43	3.1e-22	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.8	0.38	2.76e-17	Hypertriglyceridemia;
LGG	cis	rs9486719	0.901	rs13206547	chr6:97006942	T/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.79	-0.45	2.24e-24	Migraine;Coronary artery disease;
LGG	cis	rs7666738	0.830	rs4699598	chr4:99019158	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.9e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4363385	0.574	rs6683514	chr1:152984397	A/G	cg13444842	chr1:152974279	SPRR3	-0.51	-10.25	-0.43	2.37e-22	Inflammatory skin disease;
LGG	cis	rs3213545	0.659	rs2259693	chr12:121457995	G/A	cg02403541	chr12:121454288	C12orf43	0.54	9.29	0.4	5.96e-19	Subjective well-being;Cardiovascular disease risk factors;
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg26513180	chr16:89883248	FANCA	0.88	8.66	0.37	8.19e-17	Skin colour saturation;
LGG	cis	rs2717559	0.503	rs62523781	chr8:143870981	A/G	cg07661805	chr8:143867942	LY6D	0.26	6.9	0.31	1.71e-11	Urinary tract infection frequency;
LGG	cis	rs1816752	0.905	rs8002309	chr13:24976355	C/T	cg22771759	chr13:24902376	NA	0.43	6.95	0.31	1.25e-11	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg08888203	chr3:10149979	C3orf24	0.54	8.99	0.39	6.15e-18	Alzheimer's disease;
LGG	cis	rs7000551	0.715	rs7839577	chr8:22307325	T/A	cg12081754	chr8:22256438	SLC39A14	0.7	13.91	0.54	5.15e-37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg19901956	chr11:77921274	USP35	-0.4	-6.65	-0.3	8.25e-11	Testicular germ cell tumor;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg25407064	chr15:40226267	EIF2AK4	0.63	9.49	0.4	1.2e-19	Response to haloperidol in psychosis;
LGG	cis	rs34783982	0.510	rs12911953	chr15:89529439	C/T	cg09489435	chr15:89561491	NA	0.36	6.99	0.31	9.82e-12	Squamous cell lung carcinoma;
LGG	cis	rs9788682	0.747	rs2656069	chr15:78745707	C/T	cg06917634	chr15:78832804	PSMA4	0.53	8.15	0.35	3.31e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg12253571	chr8:8283032	NA	-0.3	-6.64	-0.3	8.61e-11	Mood instability;
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg22433210	chr17:43662623	NA	0.91	15.09	0.57	3.88e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs926938	0.527	rs360679	chr1:115494121	G/T	cg12756093	chr1:115239321	AMPD1	0.45	8.49	0.37	2.85e-16	Autism;
LGG	cis	rs1665650	0.957	rs1638418	chr10:118493758	T/C	cg14919929	chr10:118506882	NA	0.49	8.59	0.37	1.36e-16	Colorectal cancer;
LGG	cis	rs473651	0.904	rs10929275	chr2:239323169	A/G	cg08773314	chr2:239334832	ASB1	0.41	7.84	0.34	3.02e-14	Multiple system atrophy;
LGG	cis	rs80282103	0.867	rs11819178	chr10:1098417	A/G	cg08668510	chr10:1095578	IDI1	0.79	8.23	0.36	1.95e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.98	0.54	2.68e-37	Colorectal cancer;
LGG	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	cis	rs7582180	0.715	rs1866198	chr2:100917739	C/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.15	-0.46	9.44e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9287719	0.625	rs7567304	chr2:10790029	T/C	cg02196655	chr2:10830764	NOL10	0.53	9.21	0.39	1.14e-18	Prostate cancer;
LGG	cis	rs1580019	0.587	rs7805311	chr7:32558302	A/G	cg06133097	chr7:32552212	AVL9	0.38	6.98	0.31	1.02e-11	Cognitive ability;
LGG	cis	rs735539	0.521	rs513795	chr13:21427448	T/C	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs7927592	0.913	rs55883802	chr11:68278829	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs432925	0.600	rs385862	chr16:344659	A/G	cg06233593	chr16:337645	AXIN1	0.42	7.68	0.34	9.25e-14	Morning vs. evening chronotype;
LGG	cis	rs6988985	0.617	rs7016924	chr8:144006073	A/G	cg10324643	chr8:143916377	GML	-0.39	-7.76	-0.34	5.4e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg24247370	chr13:99142703	STK24	-0.36	-6.84	-0.3	2.52e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1044826	0.619	rs7375091	chr3:139090389	T/A	cg15131784	chr3:139108705	COPB2	-0.42	-6.9	-0.31	1.71e-11	Obesity-related traits;
LGG	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg05444541	chr17:17804740	TOM1L2	0.6	13.98	0.54	2.77e-37	Total body bone mineral density;
LGG	cis	rs283228	0.883	rs1338161	chr6:101835116	T/C	cg27451362	chr6:101846650	GRIK2	0.56	9.56	0.41	7.09e-20	Coenzyme Q10 levels;
LGG	cis	rs2242116	0.761	rs6780601	chr3:46965856	A/G	cg27129171	chr3:47204927	SETD2	0.72	12.49	0.5	4.62e-31	Birth weight;
LGG	cis	rs6582630	0.555	rs11610015	chr12:38508856	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.22	0.32	2.21e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg22920501	chr2:26401640	FAM59B	-0.39	-7.87	-0.34	2.46e-14	Gut microbiome composition (summer);
LGG	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.8	-0.45	2.03e-24	Hemoglobin concentration;
LGG	cis	rs727505	1.000	rs10226033	chr7:124521430	C/A	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24229701	chr12:130821962	PIWIL1	0.43	7.38	0.32	7.23e-13	Menopause (age at onset);
LGG	cis	rs11700980	0.551	rs2832040	chr21:30115840	C/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg26174226	chr8:58114915	NA	-0.44	-6.89	-0.3	1.88e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.638	rs4882309	chr12:38448595	A/G	cg13010199	chr12:38710504	ALG10B	-0.53	-10.42	-0.44	5.73e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg11764359	chr7:65958608	NA	0.73	13.21	0.52	5.02e-34	Aortic root size;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg06916706	chr16:4465613	CORO7	-0.88	-15.54	-0.59	4.03e-44	Schizophrenia;
LGG	cis	rs3820068	0.581	rs16851819	chr1:15918739	C/T	cg05660106	chr1:15850417	CASP9	-0.85	-16.85	-0.62	4.83e-50	Systolic blood pressure;
LGG	cis	rs4434138	0.533	rs11130324	chr3:52770310	T/G	cg18404041	chr3:52824283	ITIH1	-0.4	-7.76	-0.34	5.32e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.595	rs3733585	chr4:10036339	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	9.44	0.4	1.85e-19	Bone mineral density;
LGG	cis	rs62238980	0.614	rs80321137	chr22:32460767	C/T	cg02631450	chr22:32366979	NA	0.98	9.34	0.4	4e-19	Childhood ear infection;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.56	0.56	8.55e-40	Obesity-related traits;
LGG	cis	rs208520	1.000	rs208536	chr6:66963440	T/C	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	trans	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.72	-12.13	-0.49	1.29e-29	Obesity-related traits;
LGG	cis	rs892961	1.000	rs11077909	chr17:75403480	T/C	cg05865280	chr17:75406074	SEPT9	0.41	9.73	0.41	1.8e-20	Airflow obstruction;
LGG	cis	rs6840360	0.606	rs2709813	chr4:152357444	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	trans	rs12579753	0.869	rs17692407	chr12:82171369	G/C	cg07923666	chr12:49932857	KCNH3	-0.5	-7.48	-0.33	3.84e-13	Resting heart rate;
LGG	cis	rs8180040	0.553	rs7620997	chr3:47214122	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-14.25	-0.55	1.87e-38	Colorectal cancer;
LGG	cis	rs858239	0.601	rs1034963	chr7:23148473	T/C	cg23682824	chr7:23144976	KLHL7	0.43	7.39	0.32	7.15e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg06634786	chr22:41940651	POLR3H	0.65	10.34	0.43	1.14e-22	Vitiligo;
LGG	cis	rs2832191	0.636	rs8131295	chr21:30516819	A/T	cg24692254	chr21:30365293	RNF160	-0.73	-14.26	-0.55	1.61e-38	Dental caries;
LGG	cis	rs757278	0.552	rs6943317	chr7:117313645	C/T	cg10524701	chr7:117356490	CTTNBP2	0.42	7.45	0.33	4.5e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg15485101	chr11:133734466	NA	0.56	10.14	0.43	6e-22	Childhood ear infection;
LGG	cis	rs4731207	0.672	rs2286174	chr7:124465876	C/G	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg05665937	chr4:1216051	CTBP1	-0.49	-8.81	-0.38	2.63e-17	Obesity-related traits;
LGG	cis	rs8067545	0.611	rs2526486	chr17:20101626	T/G	cg09818912	chr17:20140352	CYTSB	0.31	7.32	0.32	1.1e-12	Schizophrenia;
LGG	cis	rs7481584	0.646	rs434114	chr11:3050210	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	cis	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.08	-0.35	5.58e-15	Subjective well-being;
LGG	cis	rs7572733	0.534	rs700681	chr2:198711502	C/A	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg00294572	chr6:26285232	NA	0.43	7.78	0.34	4.71e-14	Educational attainment;
LGG	cis	rs548181	0.673	rs12288034	chr11:125570941	A/T	cg03464685	chr11:125439445	EI24	-1.29	-17.98	-0.64	3.17e-55	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs4148087	1.000	rs9981390	chr21:43634081	G/A	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.8	0.38	2.75e-17	Neuroticism;
LGG	cis	rs17253792	0.818	rs78393484	chr14:56065802	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs11792861	0.926	rs12686736	chr9:111888739	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.07	0.39	3.3e-18	Menarche (age at onset);
LGG	cis	rs7084402	0.967	rs1427200	chr10:60274928	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.05e-54	Refractive error;
LGG	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.82	-16.88	-0.62	3.49e-50	Longevity;Endometriosis;
LGG	cis	rs365132	0.875	rs691141	chr5:176323298	A/G	cg16309518	chr5:176445507	NA	0.49	10.91	0.45	8.38e-25	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.58	-0.44	1.42e-23	Chronic sinus infection;
LGG	trans	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg10840412	chr1:235813424	GNG4	-0.49	-6.82	-0.3	2.77e-11	Bipolar disorder;
LGG	cis	rs7937682	0.883	rs631490	chr11:111452040	G/C	cg19812747	chr11:111475976	SIK2	-0.49	-10.34	-0.43	1.09e-22	Primary sclerosing cholangitis;
LGG	cis	rs941873	0.838	rs2233713	chr10:81107135	A/C	cg09469691	chr10:81107165	PPIF	0.65	11.61	0.47	1.6e-27	Height;
LGG	cis	rs8053891	0.756	rs9930930	chr16:72001971	A/G	cg09427745	chr16:71932006	KIAA0174	-0.37	-6.74	-0.3	4.7e-11	Coronary artery disease;
LGG	trans	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08382705	chr11:45687319	CHST1	-0.66	-11.62	-0.48	1.51e-27	Height;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg23531748	chr20:60969906	CABLES2	-0.43	-7.69	-0.34	9.22e-14	Colorectal cancer;
LGG	cis	rs564799	0.931	rs6808518	chr3:159730738	T/A	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs11877825	0.826	rs3748425	chr18:10581762	A/C	cg25239095	chr18:10589360	NA	0.48	8.71	0.38	5.33e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.95	0.38	8.74e-18	Obesity-related traits;
LGG	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg26446133	chr18:72167187	CNDP2	-0.69	-14.67	-0.56	2.84e-40	Refractive error;
LGG	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg04455712	chr21:45112962	RRP1B	0.52	9.84	0.42	7.01e-21	Mean corpuscular volume;
LGG	cis	rs367943	0.698	rs2900074	chr5:113000374	A/C	cg12552261	chr5:112820674	MCC	0.55	9.86	0.42	5.94e-21	Type 2 diabetes;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg02018176	chr4:1364513	KIAA1530	0.43	9.87	0.42	5.74e-21	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg10756647	chr7:56101905	PSPH	0.83	9.9	0.42	4.47e-21	Diabetic kidney disease;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg11878867	chr6:150167359	LRP11	-0.38	-7.83	-0.34	3.33e-14	Testicular germ cell tumor;
LGG	cis	rs4774899	1.000	rs3803454	chr15:57241042	T/C	cg08128148	chr15:57256372	TCF12	-0.33	-7.89	-0.34	2.14e-14	Urinary tract infection frequency;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg27185819	chr4:73434820	ADAMTS3	0.38	6.65	0.3	8.4e-11	Body mass index;
LGG	trans	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg25482853	chr8:67687455	SGK3	1.03	13.44	0.53	5.36e-35	Lung disease severity in cystic fibrosis;
LGG	cis	rs4478858	0.735	rs12126725	chr1:31805853	G/T	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs951366	0.649	rs7522056	chr1:205735891	A/G	cg07157834	chr1:205819609	PM20D1	0.39	7.34	0.32	9.92e-13	Menarche (age at onset);
LGG	trans	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg08975724	chr8:8085496	FLJ10661	0.37	6.73	0.3	5.11e-11	Retinal vascular caliber;
LGG	trans	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg27053975	chr1:166958233	MAEL	-0.48	-6.67	-0.3	7.1e-11	Obesity-related traits;
LGG	trans	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-7.28	-0.32	1.44e-12	Body mass index;
LGG	cis	rs7666738	0.830	rs11731478	chr4:99001686	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6909430	1.000	rs9491071	chr6:98688123	C/T	cg12860156	chr6:98744658	NA	-0.46	-7.53	-0.33	2.65e-13	Quantitative traits;
LGG	cis	rs1065852	0.526	rs11090066	chr22:42398195	A/G	cg15128208	chr22:42549153	NA	0.39	6.67	0.3	7.53e-11	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs2133450	0.683	rs9812421	chr3:7298180	A/G	cg19930620	chr3:7340148	GRM7	-0.35	-7.62	-0.33	1.43e-13	Early response to risperidone in schizophrenia;
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg17691542	chr6:26056736	HIST1H1C	0.59	10.48	0.44	3.43e-23	Height;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.82	-0.54	1.33e-36	Schizophrenia;
LGG	trans	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-12.58	-0.5	2.09e-31	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9341808	0.621	rs2322627	chr6:80806341	T/A	cg08355045	chr6:80787529	NA	0.49	9.8	0.41	1.03e-20	Sitting height ratio;
LGG	cis	rs4764487	0.735	rs3782717	chr12:6332310	C/G	cg08284733	chr12:6341482	CD9	0.37	9.98	0.42	2.27e-21	Mean platelet volume;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg03929089	chr4:120376271	NA	0.7	8.43	0.36	4.4e-16	Intraocular pressure;
LGG	cis	rs11585357	0.947	rs72646789	chr1:17610030	C/T	cg08277548	chr1:17600880	PADI3	-0.77	-8.86	-0.38	1.74e-17	Hair shape;
LGG	cis	rs4363385	0.818	rs1415965	chr1:153002750	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-16.34	-0.6	9.86e-48	Morning vs. evening chronotype;
LGG	cis	rs9487094	0.778	rs61318425	chr6:109748506	T/C	cg16315928	chr6:109776240	MICAL1	0.55	8.97	0.38	7.25e-18	Height;
LGG	cis	rs1847202	1.000	rs7651022	chr3:72924564	T/C	cg25664220	chr3:72788482	NA	-0.25	-7.63	-0.33	1.37e-13	Motion sickness;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06741594	chr7:132260475	PLXNA4	-0.5	-7.5	-0.33	3.39e-13	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.48	-0.53	3.76e-35	Personality dimensions;
LGG	cis	rs5753037	0.702	rs36576	chr22:30206291	C/A	cg01021169	chr22:30184971	ASCC2	-0.36	-7.14	-0.32	3.55e-12	Type 1 diabetes;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg21724239	chr8:58056113	NA	0.53	7.59	0.33	1.81e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.954	rs7681544	chr4:120411255	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs7106204	0.620	rs12805125	chr11:24258967	A/T	ch.11.24196551F	chr11:24239977	NA	-0.85	-9.55	-0.41	7.7e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2455601	0.786	rs10279	chr11:8969309	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.58	-10.19	-0.43	3.79e-22	Schizophrenia;
LGG	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg06637938	chr14:75390232	RPS6KL1	0.59	10.81	0.45	1.93e-24	Height;
LGG	cis	rs6688613	0.685	rs2235184	chr1:166870528	A/G	ch.1.3259774R	chr1:166827647	TADA1	-0.46	-7.03	-0.31	7.63e-12	Refractive astigmatism;
LGG	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg15704280	chr7:45808275	SEPT13	-0.8	-11.82	-0.48	2.29e-28	Coronary artery disease;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02711726	chr17:80685570	FN3KRP	-0.45	-8.5	-0.37	2.65e-16	Glycated hemoglobin levels;
LGG	cis	rs11764590	0.715	rs55810445	chr7:2103739	C/T	cg02825527	chr7:2087843	MAD1L1	-0.54	-9.12	-0.39	2.33e-18	Neuroticism;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg05863683	chr7:1912471	MAD1L1	0.37	7.3	0.32	1.3e-12	Schizophrenia;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg20887711	chr4:1340912	KIAA1530	0.61	12.08	0.49	2.09e-29	Longevity;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg13607699	chr17:42295918	UBTF	-0.63	-10.88	-0.45	1.09e-24	Total body bone mineral density;
LGG	trans	rs6601327	0.613	rs4612345	chr8:9580001	A/G	cg02002194	chr4:3960332	NA	0.38	6.91	0.31	1.6e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs1478898	0.569	rs2249260	chr8:11388714	T/C	cg02002194	chr4:3960332	NA	0.45	7.35	0.32	9.06e-13	Morning vs. evening chronotype;
LGG	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg26818257	chr2:241905806	NA	0.38	7.18	0.32	2.85e-12	Urinary metabolites;
LGG	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg16339924	chr4:17578868	LAP3	0.59	10.2	0.43	3.47e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg13628971	chr7:2884303	GNA12	-0.52	-11.25	-0.46	4.19e-26	Height;
LGG	cis	rs3857747	0.861	rs7779860	chr7:40421458	T/G	cg00420559	chr7:40367873	C7orf10	0.36	7.31	0.32	1.19e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09854775	chr9:137029881	RNU6ATAC	-0.46	-6.95	-0.31	1.28e-11	Pancreatic cancer;
LGG	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg03264133	chr6:25882463	NA	0.46	7.41	0.33	5.85e-13	Iron status biomarkers;
LGG	trans	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg26043149	chr18:55253948	FECH	0.4	6.69	0.3	6.35e-11	Bone mineral density;
LGG	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.19	-0.32	2.61e-12	Colorectal cancer;
LGG	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg19729930	chr2:74357872	NA	0.58	11.86	0.48	1.7e-28	Gestational age at birth (maternal effect);
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07677032	chr17:61819896	STRADA	-0.68	-12.62	-0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs6121246	0.559	rs1062794	chr20:30381758	G/C	cg13852791	chr20:30311386	BCL2L1	0.95	18.99	0.66	6.64e-60	Mean corpuscular hemoglobin;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs7766436	0.885	rs10946567	chr6:22581302	T/C	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	trans	rs6089829	0.962	rs6122347	chr20:61661866	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4642101	0.561	rs7638333	chr3:12806142	T/C	cg05775895	chr3:12838266	CAND2	0.57	9.57	0.41	6.45e-20	QRS complex (12-leadsum);
LGG	cis	rs7241530	0.662	rs55634452	chr18:75902067	A/G	cg14642773	chr18:75888474	NA	0.48	9.3	0.4	5.46e-19	Educational attainment (years of education);
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-10.05	-0.42	1.31e-21	Tonsillectomy;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.28e-19	Life satisfaction;
LGG	cis	rs2276314	1.000	rs2298715	chr18:33552425	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.82	0.34	3.57e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs79349575	0.749	rs519537	chr17:46971140	G/A	cg22482690	chr17:47019901	SNF8	0.34	6.67	0.3	7.3e-11	Type 2 diabetes;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	cis	rs79149102	0.579	rs61166993	chr15:75306644	C/A	cg09165964	chr15:75287851	SCAMP5	-0.8	-9.2	-0.39	1.22e-18	Lung cancer;
LGG	trans	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-8.85	-0.38	1.87e-17	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.813	rs35831373	chr14:71918421	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.84	-0.38	1.95e-17	Mitral valve prolapse;
LGG	cis	rs2180341	0.961	rs9375501	chr6:127652539	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs36051895	0.632	rs10974979	chr9:5131731	C/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.59	-0.56	6.11e-40	Pediatric autoimmune diseases;
LGG	cis	rs4474465	0.646	rs10793334	chr11:78278792	C/T	cg27205649	chr11:78285834	NARS2	-0.6	-11.31	-0.47	2.38e-26	Alzheimer's disease (survival time);
LGG	cis	rs7937612	0.965	rs4938801	chr11:120223399	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.51	-0.5	3.92e-31	Intraocular pressure;
LGG	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-8.02	-0.35	8.64e-15	Aortic root size;
LGG	cis	rs2735413	0.709	rs4395084	chr16:78088011	C/G	cg04733911	chr16:78082701	NA	-0.74	-16.15	-0.6	7.7e-47	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg18252515	chr7:66147081	NA	1.44	20.8	0.7	2.34e-68	Diabetic kidney disease;
LGG	trans	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg24829409	chr8:58192753	C8orf71	-0.48	-8.33	-0.36	9.34e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs60695258	0.550	rs4693798	chr4:87914288	G/C	cg11209507	chr4:87813803	C4orf36	-0.48	-8.08	-0.35	5.51e-15	Hematocrit;
LGG	cis	rs9467773	1.000	rs6925895	chr6:26572165	G/T	cg11502198	chr6:26597334	ABT1	0.58	10.05	0.42	1.3e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg06219351	chr7:158114137	PTPRN2	-0.76	-14.97	-0.57	1.26e-41	Calcium levels;
LGG	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.49	-0.33	3.4e-13	Testicular germ cell tumor;
LGG	cis	rs8064024	0.680	rs3747613	chr16:4908504	C/G	cg04440724	chr16:4920505	UBN1	0.57	12.97	0.52	4.95e-33	Cancer;
LGG	cis	rs2587949	0.593	rs1444052	chr3:4197000	T/C	cg16519197	chr3:4211558	NA	-0.38	-7.68	-0.34	9.8e-14	Periodontitis (DPAL);
LGG	cis	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.77	0.3	3.86e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs9944715	1.000	rs12605945	chr18:43834118	A/G	cg01718231	chr17:29326311	RNF135	-0.41	-6.66	-0.3	7.56e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs1961456	0.542	rs10095159	chr8:18244684	G/A	cg18736775	chr8:18248649	NAT2	-0.73	-12.01	-0.49	3.95e-29	Total cholesterol levels;
LGG	cis	rs6977660	0.714	rs4719587	chr7:19828174	C/G	cg05791153	chr7:19748676	TWISTNB	0.71	9.56	0.41	6.8e-20	Thyroid stimulating hormone;
LGG	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.59	-0.37	1.32e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10064886	chr14:58764945	FLJ31306;ARID4A	0.45	7.31	0.32	1.19e-12	Cognitive performance;
LGG	cis	rs12549902	0.966	rs17659386	chr8:41513531	T/C	cg21772509	chr8:41503840	NKX6-3	0.86	18.96	0.66	9.65e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs4704846	0.904	rs431620	chr5:156546628	C/G	cg12943317	chr5:156479607	HAVCR1	-0.51	-6.68	-0.3	6.76e-11	Blood protein levels;
LGG	cis	rs7582720	1.000	rs77268589	chr2:203751981	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.06	-0.31	6.16e-12	Bipolar disorder;
LGG	cis	rs6516091	0.640	rs6117070	chr20:6061606	A/G	cg25325723	chr20:6104886	FERMT1	-0.59	-6.76	-0.3	4.27e-11	Abdominal aortic aneurysm;
LGG	cis	rs3735485	0.678	rs62457083	chr7:45152192	T/G	cg03440944	chr7:45023329	C7orf40	-0.51	-8.78	-0.38	3.28e-17	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs981844	1.000	rs2606325	chr4:154652681	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.13	0.46	1.19e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs7107174	1.000	rs11237462	chr11:78058812	C/A	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs4853012	0.941	rs78128123	chr2:74347525	C/T	cg20891558	chr2:74357851	NA	0.49	8.6	0.37	1.25e-16	Gestational age at birth (maternal effect);
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg22535103	chr8:58192502	C8orf71	-1.0	-13.57	-0.53	1.52e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.774	rs11098505	chr4:120284627	C/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs7666738	0.753	rs13137152	chr4:98938044	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	7.07	0.31	5.72e-12	Retinal vascular caliber;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02475777	chr4:1388615	CRIPAK	-0.52	-9.15	-0.39	1.79e-18	Longevity;
LGG	cis	rs4262150	0.883	rs55752608	chr5:152138775	T/A	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg03528353	chr17:61819722	STRADA	0.44	7.28	0.32	1.45e-12	Prudent dietary pattern;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg08807101	chr21:30365312	RNF160	-0.59	-8.27	-0.36	1.46e-15	Cognitive test performance;
LGG	cis	rs758324	0.773	rs40819	chr5:131305384	G/T	cg06307176	chr5:131281290	NA	-0.55	-8.96	-0.38	7.71e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs703842	0.532	rs238516	chr12:58117355	T/C	cg18357645	chr12:58087776	OS9	0.53	9.54	0.41	8.29e-20	Multiple sclerosis;
LGG	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg17718321	chr1:152188247	HRNR	-0.41	-8.69	-0.37	6.12e-17	Inflammatory skin disease;
LGG	trans	rs2727020	0.729	rs2299650	chr11:49174007	A/C	cg15704280	chr7:45808275	SEPT13	-0.91	-18.93	-0.66	1.33e-59	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.51e-33	Obesity-related traits;
LGG	cis	rs12545109	0.800	rs1467126	chr8:57418452	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.31	0.36	1.08e-15	Morning vs. evening chronotype;
LGG	cis	rs12282928	0.959	rs1566736	chr11:48238179	A/G	cg26585981	chr11:48327164	OR4S1	0.46	7.52	0.33	2.96e-13	Migraine - clinic-based;
LGG	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg14784868	chr12:69753453	YEATS4	1.0	24.04	0.75	1.77e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg14773178	chr5:1868261	NA	0.38	8.08	0.35	5.5e-15	Cardiovascular disease risk factors;
LGG	cis	rs1348850	0.537	rs3770010	chr2:178537796	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-8.61	-0.37	1.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.36	0.32	8.42e-13	Neuroticism;
LGG	cis	rs870825	0.616	rs6552806	chr4:185638231	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs1035144	0.785	rs4903962	chr14:81464486	A/G	cg06600135	chr14:81408086	NA	0.37	7.02	0.31	8.12e-12	Male sexual orientation;
LGG	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg00405596	chr8:11794950	NA	-0.63	-11.05	-0.46	2.41e-25	Monocyte count;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg02018176	chr4:1364513	KIAA1530	0.46	10.85	0.45	1.4e-24	Obesity-related traits;
LGG	cis	rs6060960	0.537	rs75351461	chr20:30458612	C/T	cg13852791	chr20:30311386	BCL2L1	0.54	6.93	0.31	1.46e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.49	0.71	1.49e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg08188268	chr10:116634841	FAM160B1	0.32	6.84	0.3	2.56e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs3099143	1.000	rs4541044	chr15:77173193	C/T	cg21673338	chr15:77095150	SCAPER	0.66	10.46	0.44	4.08e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs35740288	0.822	rs1961601	chr15:86229606	T/C	cg07943548	chr15:86304357	KLHL25	-0.35	-6.94	-0.31	1.29e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg05623727	chr3:50126028	RBM5	0.34	7.4	0.33	6.54e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.37	-0.47	1.34e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg25237894	chr2:233734115	C2orf82	-0.46	-7.84	-0.34	3.15e-14	Schizophrenia;
LGG	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.88	-0.57	3.28e-41	Aortic root size;
LGG	cis	rs3206736	0.529	rs1649225	chr7:34991676	C/A	cg13400248	chr7:35225412	NA	0.53	9.3	0.4	5.54e-19	Diastolic blood pressure;
LGG	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.58	-0.41	6.03e-20	Depression;
LGG	cis	rs11190604	0.767	rs7085426	chr10:102163640	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.99	0.42	1.99e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17508449	0.602	rs3789608	chr1:114397788	C/T	cg26035817	chr1:114414802	PTPN22	-0.46	-6.75	-0.3	4.33e-11	Leprosy;
LGG	cis	rs3784262	1.000	rs7178497	chr15:58240333	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.24	-0.36	1.82e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.08	0.55	9.52e-38	Tonsillectomy;
LGG	cis	rs2386661	0.826	rs10905519	chr10:5672483	C/A	cg26603656	chr10:5671107	NA	0.38	7.69	0.34	8.83e-14	Breast cancer;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg23758822	chr17:41437982	NA	0.9	15.35	0.58	2.68e-43	Menopause (age at onset);
LGG	cis	rs13191362	0.935	rs34009353	chr6:163007668	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.68	7.64	0.33	1.29e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-8.82	-0.38	2.36e-17	Blood protein levels;
LGG	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.38	0.43	7.99e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg11965913	chr1:205819406	PM20D1	-0.41	-6.66	-0.3	8.03e-11	Menarche (age at onset);
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg11494091	chr17:61959527	GH2	0.56	9.16	0.39	1.68e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.46	0.37	3.48e-16	Obesity-related traits;
LGG	cis	rs1018836	0.923	rs2023626	chr8:91619264	G/T	cg16814680	chr8:91681699	NA	0.82	14.98	0.57	1.14e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg13010199	chr12:38710504	ALG10B	0.68	14.16	0.55	4.29e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg17971929	chr21:40555470	PSMG1	-0.53	-8.95	-0.38	8.55e-18	Menarche (age at onset);
LGG	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.72e-21	HDL cholesterol;
LGG	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg21972741	chr5:435613	AHRR	0.45	7.79	0.34	4.43e-14	Cystic fibrosis severity;
LGG	cis	rs17039065	0.920	rs57594448	chr4:109461514	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	7.68	0.34	9.77e-14	Gut microbiome composition (summer);
LGG	cis	rs11191205	0.601	rs3730477	chr10:103340056	G/A	cg15320455	chr10:103880129	LDB1	0.49	7.11	0.31	4.37e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg11859384	chr17:80120422	CCDC57	0.46	8.02	0.35	8.59e-15	Life satisfaction;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00495681	chr13:53174319	NA	0.57	10.19	0.43	3.89e-22	Lewy body disease;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.21	0.43	3.2800000000000002e-22	Height;
LGG	cis	rs4474465	0.920	rs4474466	chr11:78204406	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.92e-11	Alzheimer's disease (survival time);
LGG	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.27e-25	Obesity-related traits;
LGG	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg00071950	chr4:10020882	SLC2A9	0.36	7.58	0.33	1.94e-13	Bone mineral density;
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg18963800	chr10:38644991	HSD17B7P2	-0.45	-7.2	-0.32	2.47e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg16301924	chr13:53314226	LECT1	-0.57	-12.07	-0.49	2.44e-29	Lewy body disease;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg07142201	chr11:109293216	C11orf87	0.51	9.25	0.39	8.44e-19	Schizophrenia;
LGG	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.11	-0.39	2.57e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.7	-0.34	8.07e-14	Bipolar disorder;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.89	-0.38	1.38e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3806843	0.766	rs2251860	chr5:140048209	T/C	cg19875535	chr5:140030758	IK	-0.54	-10.99	-0.45	4.02e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.69	0.41	2.53e-20	Height;
LGG	trans	rs7944735	0.508	rs77073917	chr11:47854975	C/T	cg15704280	chr7:45808275	SEPT13	0.63	6.88	0.3	1.98e-11	Intraocular pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22605179	chr22:29664171	EWSR1;RHBDD3	0.43	7.09	0.31	4.88e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6445975	0.666	rs4553989	chr3:58381120	T/A	cg24175188	chr3:58374923	PXK	-0.54	-8.86	-0.38	1.79e-17	Systemic lupus erythematosus;
LGG	cis	rs7444	0.941	rs131665	chr22:21920903	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	cis	rs9790314	0.613	rs1447619	chr3:160616077	A/T	cg03342759	chr3:160939853	NMD3	0.44	7.43	0.33	5.33e-13	Morning vs. evening chronotype;
LGG	cis	rs7937612	1.000	rs10892574	chr11:120288944	G/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.04	-0.52	2.46e-33	Intraocular pressure;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.29	-0.32	1.31e-12	Menopause (age at onset);
LGG	cis	rs61931739	0.620	rs1482981	chr12:33691763	C/G	cg06521331	chr12:34319734	NA	0.4	6.87	0.3	2.1e-11	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.77	-0.38	3.37e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9399135	0.967	rs12527707	chr6:135324511	G/A	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Red blood cell count;
LGG	cis	rs7208859	0.623	rs73269945	chr17:29108759	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs870825	0.929	rs72689278	chr4:185593718	C/T	cg04058563	chr4:185651563	MLF1IP	1.06	19.7	0.68	3.51e-63	Blood protein levels;
LGG	cis	rs4253772	0.637	rs11703173	chr22:46660367	G/A	cg00784671	chr22:46762841	CELSR1	-0.56	-6.77	-0.3	3.93e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg07636037	chr3:49044803	WDR6	0.6	10.33	0.43	1.22e-22	Resting heart rate;
LGG	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg13010199	chr12:38710504	ALG10B	0.42	7.5	0.33	3.38e-13	Morning vs. evening chronotype;
LGG	trans	rs1463132	0.553	rs55905124	chr16:10215934	G/A	cg08466385	chr6:18368294	NA	0.32	6.78	0.3	3.79e-11	HIV-1 control;
LGG	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.73	0.3	5.02e-11	Homoarginine levels;
LGG	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.96	-0.49	6.76e-29	Depression;
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg10852096	chr15:79043040	NA	-0.26	-7.24	-0.32	1.86e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg18032289	chr17:61959525	GH2	-0.42	-6.93	-0.31	1.38e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9788682	0.747	rs2656071	chr15:78745343	A/T	cg06917634	chr15:78832804	PSMA4	0.53	8.1	0.35	4.91e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg03264133	chr6:25882463	NA	-0.49	-7.86	-0.34	2.78e-14	Iron status biomarkers;
LGG	cis	rs4727027	0.704	rs4727031	chr7:148908305	T/C	cg23583168	chr7:148888333	NA	-0.9	-18.01	-0.64	2.42e-55	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg06875740	chr19:51307921	C19orf48	-0.69	-8.6	-0.37	1.23e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs727505	0.866	rs73227503	chr7:124721044	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05191792	chr6:2765113	WRNIP1	0.43	6.84	0.3	2.47e-11	Cognitive performance;
LGG	cis	rs28595532	0.582	rs71608361	chr4:119224081	T/C	cg21605333	chr4:119757512	SEC24D	0.88	9.54	0.41	8.08e-20	Cannabis dependence symptom count;
LGG	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs4561483	0.551	rs1126889	chr16:12061910	C/G	cg08843971	chr16:11963173	GSPT1	-0.51	-11.53	-0.47	3.35e-27	Testicular germ cell tumor;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.22	-0.39	1.05e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6977660	0.714	rs12536561	chr7:19816659	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg07005078	chr4:17578674	LAP3	0.39	7.08	0.31	5.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.36	-0.36	7.67e-16	Systolic blood pressure;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg01879757	chr17:41196368	BRCA1	0.41	8.34	0.36	8.44e-16	Menopause (age at onset);
LGG	cis	rs67478160	0.595	rs67768834	chr14:104221085	C/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.4	-0.33	6.64e-13	Schizophrenia;
LGG	cis	rs11711311	1.000	rs13073843	chr3:113449150	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.44e-13	IgG glycosylation;
LGG	cis	rs9894429	0.608	rs7406382	chr17:79597786	T/C	cg18240062	chr17:79603768	NPLOC4	0.61	10.27	0.43	2.03e-22	Eye color traits;
LGG	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg16096631	chr1:42092165	HIVEP3	-0.41	-9.3	-0.4	5.78e-19	Airway imaging phenotypes;
LGG	trans	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.2	0.55	3.13e-38	Exhaled nitric oxide output;
LGG	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.24	-0.36	1.83e-15	IgG glycosylation;
LGG	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.44	0.37	3.96e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.84	-0.45	1.43e-24	Lung cancer;
LGG	cis	rs9650657	0.836	rs6601523	chr8:10635141	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.07	-0.31	5.7e-12	Neuroticism;
LGG	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg15162869	chr22:32027605	PISD	-0.75	-7.74	-0.34	6.25e-14	Age-related hearing impairment;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	trans	rs5756813	0.715	rs5756825	chr22:38199950	T/C	cg19894588	chr14:64061835	NA	0.79	15.33	0.58	3.23e-43	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9460578	0.673	rs4712561	chr6:20878282	A/G	cg13405222	chr6:20811065	CDKAL1	0.67	11.87	0.48	1.5e-28	Breast cancer;
LGG	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.47	0.37	3.28e-16	Retinal vascular caliber;
LGG	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.48e-14	Bone mineral density;
LGG	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.58	0.33	1.91e-13	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7980799	0.711	rs1482993	chr12:33594515	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-7.83	-0.34	3.28e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs911555	0.504	rs4906340	chr14:104076645	G/A	cg23335576	chr14:104009727	NA	-0.41	-6.97	-0.31	1.13e-11	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.38	-0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs6138458	1.000	rs7268095	chr20:24972333	C/T	cg26195577	chr20:24973756	C20orf3	1.25	26.44	0.78	1.45e-94	Blood protein levels;
LGG	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg27572855	chr1:25598939	RHD	0.48	10.91	0.45	8.03e-25	Erythrocyte sedimentation rate;
LGG	cis	rs2153535	0.580	rs7341382	chr6:8470549	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.0	0.39	6e-18	Motion sickness;
LGG	cis	rs2486288	0.656	rs9920290	chr15:45548035	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.9	-0.42	4.31e-21	Glomerular filtration rate;
LGG	cis	rs9947295	0.649	rs8099026	chr18:11775468	G/A	cg14735704	chr18:11749182	GNAL	0.48	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.36	-0.47	1.49e-26	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2599510	0.783	rs2568464	chr2:32848658	C/T	cg02381751	chr2:32503542	YIPF4	-0.47	-7.82	-0.34	3.55e-14	Interleukin-18 levels;
LGG	cis	rs17818399	0.781	rs34449783	chr2:46863555	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.74	0.3	4.65e-11	Height;
LGG	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg04450456	chr4:17643702	FAM184B	0.32	6.81	0.3	3.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12952552	chr14:68283333	ZFYVE26	-0.44	-6.82	-0.3	2.9e-11	Systemic lupus erythematosus;
LGG	cis	rs9660992	0.710	rs1768586	chr1:205238275	A/G	cg21545522	chr1:205238299	TMCC2	0.49	9.02	0.39	5.05e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7044106	0.762	rs1158553	chr9:123400974	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.24	0.6	2.79e-47	Hip circumference adjusted for BMI;
LGG	cis	rs10791097	0.694	rs4459316	chr11:130756176	T/C	cg09137382	chr11:130731461	NA	0.35	6.77	0.3	3.87e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4253772	0.530	rs9615933	chr22:46677298	G/A	cg00784671	chr22:46762841	CELSR1	-0.61	-7.01	-0.31	8.44e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6831352	0.918	rs29001194	chr4:100054844	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs3816183	0.616	rs62144828	chr2:42761930	T/C	cg14631114	chr2:43023945	NA	0.44	8.16	0.35	3.16e-15	Hypospadias;
LGG	cis	rs9325144	0.560	rs11182930	chr12:38633693	A/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.49e-18	Morning vs. evening chronotype;
LGG	cis	rs9596863	0.750	rs1545660	chr13:54451624	A/G	ch.13.53330881F	chr13:54432880	NA	-0.49	-7.61	-0.33	1.51e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7666738	0.830	rs6854919	chr4:98947326	C/T	cg05340658	chr4:99064831	C4orf37	0.49	7.92	0.35	1.76e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-12.11	-0.49	1.58e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg19223190	chr17:80058835	NA	0.44	8.44	0.37	4.03e-16	Life satisfaction;
LGG	cis	rs7143963	0.636	rs2403103	chr14:103309622	G/A	cg23020514	chr14:103360112	TRAF3	0.4	8.42	0.36	4.7e-16	Body mass index;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg16359550	chr11:109292809	C11orf87	0.42	8.23	0.36	1.9e-15	Schizophrenia;
LGG	cis	rs6732160	0.613	rs59979991	chr2:73384422	G/A	cg01422370	chr2:73384389	NA	0.57	9.91	0.42	3.92e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg13385521	chr17:29058706	SUZ12P	0.84	9.63	0.41	3.81e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7084402	0.967	rs1649034	chr10:60279324	G/A	cg09696939	chr10:60272079	BICC1	0.36	7.01	0.31	8.69e-12	Refractive error;
LGG	cis	rs4865875	1.000	rs9292074	chr5:54115322	G/A	cg22421804	chr5:54100067	NA	0.51	7.66	0.34	1.07e-13	Sense of smell;
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.85	0.38	1.86e-17	Aortic root size;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.11	0.46	1.35e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06028808	chr11:68637592	NA	0.7	12.02	0.49	3.88e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17125944	0.615	rs7146915	chr14:53316039	C/T	cg00686598	chr14:53173677	PSMC6	-0.66	-7.25	-0.32	1.73e-12	Alzheimer's disease (late onset);
LGG	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04530015	chr2:215796436	ABCA12	0.42	7.34	0.32	9.68e-13	Neuroblastoma;
LGG	cis	rs3818285	0.679	rs612155	chr10:111630731	C/G	cg00817464	chr10:111662876	XPNPEP1	0.47	9.88	0.42	5.08e-21	Superior crus of antihelix expression;
LGG	cis	rs4566357	0.615	rs2272202	chr2:227914625	C/T	cg11843606	chr2:227700838	RHBDD1	0.5	8.97	0.38	7.45e-18	Coronary artery disease;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.67	0.37	7.58e-17	Schizophrenia;
LGG	cis	rs3219090	0.586	rs10915986	chr1:226543113	C/T	cg17127702	chr1:226594323	PARP1	-0.31	-9.73	-0.41	1.79e-20	Melanoma;
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg02725872	chr8:58115012	NA	-0.84	-12.11	-0.49	1.61e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs7971957	chr12:34477558	C/T	cg26384229	chr12:38710491	ALG10B	0.85	18.51	0.65	1.17e-57	Morning vs. evening chronotype;
LGG	cis	rs9309473	0.583	rs6713196	chr2:73576405	T/C	cg20560298	chr2:73613845	ALMS1	-0.5	-9.14	-0.39	2.04e-18	Metabolite levels;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.81	-0.57	6.5e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg07120314	chr15:79043507	NA	-0.38	-7.49	-0.33	3.45e-13	Sudden cardiac arrest;
LGG	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.3	-0.4	5.46e-19	Intelligence (multi-trait analysis);
LGG	trans	rs62103177	0.584	rs9956207	chr18:77968392	A/G	cg05926928	chr17:57297772	GDPD1	-0.74	-8.68	-0.37	6.67e-17	Opioid sensitivity;
LGG	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11719291	0.651	rs1134043	chr3:49200137	G/T	cg00383909	chr3:49044727	WDR6	0.75	9.86	0.42	6.15e-21	Cognitive function;
LGG	cis	rs7712401	0.601	rs442427	chr5:122322265	T/C	cg19412675	chr5:122181750	SNX24	-0.4	-6.64	-0.3	8.6e-11	Mean platelet volume;
LGG	cis	rs2549003	1.000	rs2549004	chr5:131827825	C/G	cg00578828	chr5:131826934	IRF1	-0.39	-6.82	-0.3	2.9e-11	Asthma (sex interaction);
LGG	cis	rs7937682	0.632	rs4936834	chr11:111764017	T/A	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg04568710	chr12:38710424	ALG10B	0.35	7.58	0.33	1.84e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1927790	0.727	rs9556550	chr13:96947034	A/C	cg02571835	chr13:96230311	CLDN10	-0.34	-7.01	-0.31	8.62e-12	Body mass index;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg11473876	chr11:109292803	C11orf87	0.45	9.13	0.39	2.14e-18	Schizophrenia;
LGG	cis	rs5756391	0.782	rs5756384	chr22:37282093	C/T	cg21209356	chr22:37319042	CSF2RB	-0.35	-8.19	-0.36	2.5e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg20587970	chr11:113659929	NA	1.1	14.11	0.55	7.35e-38	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.88	-0.45	1.1e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-8.95	-0.38	8.55e-18	Bladder cancer;
LGG	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg05555928	chr11:63887634	MACROD1	-0.59	-9.92	-0.42	3.82e-21	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs514406	0.621	rs1930306	chr1:53195686	C/G	cg16325326	chr1:53192061	ZYG11B	-0.9	-25.64	-0.77	7.2e-91	Monocyte count;
LGG	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12477438	0.520	rs4851188	chr2:99745898	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg13206674	chr6:150067644	NUP43	0.62	13.94	0.54	3.84e-37	Lung cancer;
LGG	cis	rs9790314	0.838	rs4414866	chr3:160928709	C/T	cg04691961	chr3:161091175	C3orf57	-0.61	-13.35	-0.53	1.31e-34	Morning vs. evening chronotype;
LGG	cis	rs1335587	0.580	rs9518400	chr13:102078212	G/A	cg13538571	chr13:102108074	ITGBL1	0.36	6.69	0.3	6.32e-11	Obesity-related traits;
LGG	cis	rs4917300	0.606	rs6583567	chr8:143114617	A/G	cg26003909	chr8:143102224	NA	-0.33	-6.69	-0.3	6.6e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10089	0.953	rs6595807	chr5:127531603	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.13	0.46	1.12e-25	Ileal carcinoids;
LGG	cis	rs9479482	0.935	rs5017315	chr6:150333574	C/T	cg06889755	chr6:150326021	RAET1K	-0.4	-8.26	-0.36	1.5e-15	Alopecia areata;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg24397884	chr7:158709396	WDR60	0.92	19.55	0.67	1.77e-62	Height;
LGG	cis	rs17366136	1.000	rs17366136	chr7:22601127	A/C	cg23261107	chr7:22602895	NA	0.46	8.89	0.38	1.37e-17	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
LGG	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg15596359	chr8:11213517	TDH	-0.35	-7.35	-0.32	8.82e-13	Retinal vascular caliber;
LGG	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.42	0.33	5.59e-13	Total cholesterol levels;
LGG	cis	rs7100689	0.646	rs10736346	chr10:82134281	A/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	trans	rs61931739	0.927	rs1906135	chr12:34038103	C/A	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.898	rs61047804	chr4:17593965	G/A	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.47	12.08	0.49	2.08e-29	Oropharynx cancer;
LGG	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.9	0.38	1.23e-17	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00140910	chr6:131384370	EPB41L2	0.53	7.86	0.34	2.81e-14	Gut microbiome composition (summer);
LGG	cis	rs4700695	0.841	rs251300	chr5:65299715	C/G	cg21114390	chr5:65439923	SFRS12	-0.59	-7.35	-0.32	8.86e-13	Facial morphology (factor 19);
LGG	cis	rs17665859	0.844	rs6980614	chr8:447844	G/A	cg17960703	chr8:356704	FBXO25	0.95	8.5	0.37	2.57e-16	Bilirubin levels;
LGG	trans	rs783540	0.967	rs783529	chr15:83267981	A/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.36	0.32	8.19e-13	Schizophrenia;
LGG	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg09307838	chr4:120376055	NA	0.81	13.38	0.53	9.71e-35	Corneal astigmatism;
LGG	cis	rs877282	0.533	rs10904565	chr10:819991	G/T	cg01169559	chr10:831247	NA	0.54	9.36	0.4	3.48e-19	Uric acid levels;
LGG	cis	rs1568889	0.838	rs7131379	chr11:28085789	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.63e-61	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.89	-0.54	6.22e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg13576294	chr9:131124572	NA	0.42	6.89	0.3	1.85e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs2153535	0.546	rs9378559	chr6:8539058	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.26e-18	Motion sickness;
LGG	cis	rs11148252	0.595	rs4885325	chr13:53171317	C/T	cg12458913	chr13:53173898	NA	0.87	19.7	0.68	3.37e-63	Lewy body disease;
LGG	cis	rs4144743	1.000	rs61312893	chr17:45325023	C/G	cg18085866	chr17:45331354	ITGB3	-0.76	-9.37	-0.4	3.09e-19	Body mass index;
LGG	trans	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg25214090	chr10:38739885	LOC399744	0.39	7.08	0.31	5.39e-12	Educational attainment;
LGG	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.37	-0.32	7.75e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg21775007	chr8:11205619	TDH	-0.48	-7.8	-0.34	4.17e-14	Neuroticism;
LGG	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.28	0.4	6.75e-19	Diabetic retinopathy;
LGG	cis	rs9783347	1.000	rs4150566	chr11:18355599	C/G	cg15585147	chr11:18324498	HPS5	0.43	9.02	0.39	5e-18	Pancreatic cancer;
LGG	cis	rs7851660	0.870	rs1867278	chr9:100615949	C/A	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs308971	0.563	rs2618403	chr3:12039463	C/T	cg15873301	chr3:12045459	SYN2	0.5	6.67	0.3	7.15e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs4253772	0.591	rs6008595	chr22:46703860	A/T	cg24881330	chr22:46731750	TRMU	0.7	7.2	0.32	2.39e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg24692254	chr21:30365293	RNF160	-0.64	-11.51	-0.47	4.05e-27	Pancreatic cancer;
LGG	cis	rs7215564	0.908	rs4243241	chr17:78660502	A/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.9	-0.45	8.57e-25	Coronary artery disease;
LGG	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg00686598	chr14:53173677	PSMC6	1.32	14.54	0.56	1.03e-39	Alzheimer's disease (late onset);
LGG	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg00857998	chr1:205179979	DSTYK	0.47	7.26	0.32	1.66e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg02466173	chr16:30829666	NA	0.46	8.24	0.36	1.79e-15	Dementia with Lewy bodies;
LGG	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-6.7	-0.3	6.09e-11	Ulcerative colitis;
LGG	cis	rs757081	0.648	rs11024231	chr11:17287250	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.63	-0.33	1.33e-13	Systolic blood pressure;
LGG	cis	rs10781543	0.839	rs1127152	chr9:139335599	A/G	cg14019695	chr9:139328340	INPP5E	0.4	6.81	0.3	3.01e-11	Monocyte percentage of white cells;
LGG	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs10206020	0.885	rs11887527	chr2:1578080	A/G	cg26248373	chr2:1572462	NA	-0.88	-15.35	-0.58	2.81e-43	IgG glycosylation;
LGG	cis	rs9878978	0.927	rs62245752	chr3:2462485	A/C	cg21928760	chr3:2462534	CNTN4	0.47	10.3	0.43	1.57e-22	Blood pressure (smoking interaction);
LGG	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4731207	0.505	rs7795233	chr7:124578468	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs28374715	0.635	rs112547435	chr15:41648737	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.25	-29.67	-0.81	3.81e-109	Ulcerative colitis;
LGG	cis	rs7223966	1.000	rs7223412	chr17:61808172	T/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11886014	chr5:41904500	C5orf51	0.4	6.84	0.3	2.59e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg08847533	chr14:75593920	NEK9	-0.61	-11.77	-0.48	3.64e-28	Height;
LGG	trans	rs9929218	0.520	rs1078621	chr16:68778996	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.82	16.45	0.61	3.34e-48	Colorectal cancer;
LGG	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.78	-0.48	3.43e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.02e-24	Bladder cancer;
LGG	trans	rs7944735	0.567	rs79837139	chr11:48000780	T/C	cg15704280	chr7:45808275	SEPT13	0.71	7.18	0.32	2.77e-12	Intraocular pressure;
LGG	cis	rs745080	1.000	rs1902865	chr14:52934139	T/A	cg23333723	chr14:53022898	GPR137C	-0.33	-7.17	-0.32	3.07e-12	Orofacial clefts;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.1	-0.31	4.87e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11039808	chr5:77591002	AP3B1	0.44	7.02	0.31	7.71e-12	Cognitive performance;
LGG	trans	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg21775007	chr8:11205619	TDH	0.44	6.94	0.31	1.31e-11	Joint mobility (Beighton score);
LGG	cis	rs2072732	0.861	rs2993510	chr1:2956666	C/T	cg08733933	chr1:2954429	NA	0.33	7.4	0.33	6.26e-13	Plateletcrit;
LGG	cis	rs67311347	1.000	rs56291770	chr3:40515370	T/C	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs9807989	0.524	rs7591246	chr2:102999403	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs35160687	0.871	rs11127028	chr2:86537509	A/T	cg10973622	chr2:86423274	IMMT	0.39	6.64	0.3	8.59e-11	Night sleep phenotypes;
LGG	trans	rs116095464	0.558	rs34629844	chr5:200829	A/G	cg09048205	chr5:1608656	LOC728613	-0.51	-8.34	-0.36	8.45e-16	Breast cancer;
LGG	cis	rs3816183	0.616	rs10190727	chr2:42710569	T/C	cg14631114	chr2:43023945	NA	0.42	7.54	0.33	2.52e-13	Hypospadias;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg10950524	chr7:2139216	MAD1L1	0.33	7.0	0.31	8.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.06	-0.39	3.57e-18	Life satisfaction;
LGG	cis	rs7586879	0.681	rs6705446	chr2:25118608	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.86	0.51	1.4e-32	Body mass index;
LGG	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.72	-13.44	-0.53	5.2e-35	Colorectal cancer;
LGG	cis	rs77741769	0.529	rs1467283	chr12:121210220	G/C	cg02419362	chr12:121203948	SPPL3	0.58	9.94	0.42	3.07e-21	Mean corpuscular volume;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.45	-7.44	-0.33	4.97e-13	Prudent dietary pattern;
LGG	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	9.2e-12	Schizophrenia;
LGG	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg02002194	chr4:3960332	NA	-0.45	-8.19	-0.36	2.65e-15	Neuroticism;
LGG	trans	rs73191547	0.501	rs6986885	chr8:9978471	G/A	cg15556689	chr8:8085844	FLJ10661	0.41	7.36	0.32	8.29e-13	Schizophrenia;
LGG	cis	rs6450176	0.909	rs11742688	chr5:53291081	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.06	-0.46	2.19e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs8180040	0.593	rs10433549	chr3:47031433	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-14.36	-0.56	6.08e-39	Colorectal cancer;
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg01494348	chr8:144660395	NAPRT1	0.92	7.36	0.32	8.54e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs11168854	0.656	rs7969963	chr12:49512005	C/G	cg24176009	chr12:49580217	TUBA1A	0.61	11.81	0.48	2.68e-28	Body mass index;
LGG	cis	rs9863	0.896	rs4765148	chr12:124478637	G/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.02	-0.31	8.06e-12	White blood cell count;
LGG	cis	rs7129556	0.775	rs12286317	chr11:77389020	T/C	cg12586386	chr11:77299805	AQP11	0.44	7.22	0.32	2.17e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs2587949	0.615	rs2686719	chr3:4217326	T/C	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg14154082	chr13:112174009	NA	0.36	7.9	0.34	1.99e-14	Menarche (age at onset);
LGG	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	0.74	9.06	0.39	3.6e-18	Yeast infection;
LGG	cis	rs4595586	0.525	rs4511319	chr12:39340457	T/C	cg13010199	chr12:38710504	ALG10B	0.39	7.13	0.31	3.91e-12	Morning vs. evening chronotype;
LGG	cis	rs2976388	1.000	rs2920297	chr8:143763083	A/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs4242434	0.927	rs2291232	chr8:22464064	A/G	cg19455335	chr8:22457658	C8orf58	-0.45	-9.27	-0.4	7.29e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg05059571	chr16:84539110	KIAA1609	0.57	10.85	0.45	1.39e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs4714291	1.000	rs9380924	chr6:39994175	G/C	cg02267698	chr19:7991119	CTXN1	0.51	7.63	0.33	1.3e-13	Strep throat;
LGG	trans	rs10842750	1.000	rs10842750	chr12:26690565	G/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.63	6.81	0.3	3.05e-11	Kashin-Beck disease;
LGG	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg12011299	chr4:100065546	ADH4	0.4	7.9	0.34	2.06e-14	Smoking initiation;
LGG	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg00898013	chr13:113819073	PROZ	0.42	8.57	0.37	1.5e-16	Platelet distribution width;
LGG	cis	rs2597513	1.000	rs2630445	chr3:13554886	G/T	cg24006715	chr3:13568212	NA	-0.62	-10.45	-0.44	4.19e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1062177	0.826	rs2915873	chr5:151156658	G/A	cg00977110	chr5:151150581	G3BP1	0.48	7.65	0.33	1.18e-13	Preschool internalizing problems;
LGG	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg18446336	chr7:2847575	GNA12	-0.3	-7.82	-0.34	3.48e-14	Height;
LGG	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg24083324	chr1:214162604	PROX1	0.45	8.1	0.35	5.02e-15	Schizophrenia;
LGG	cis	rs7166081	0.951	rs67872952	chr15:67561598	C/T	cg05925327	chr15:68127851	NA	-0.31	-6.66	-0.3	7.58e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4689642	0.507	rs12649616	chr4:7220975	G/A	cg21353189	chr4:7228343	SORCS2	0.32	6.84	0.3	2.5e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.66e-28	Obesity-related traits;
LGG	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.52	8.76	0.38	3.62e-17	Menarche (age at onset);
LGG	cis	rs13191362	1.000	rs13215491	chr6:163010325	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg19338460	chr6:170058176	WDR27	-0.82	-9.3	-0.4	5.79e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.23	-0.32	2.01e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs992157	0.835	rs34353396	chr2:219153982	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.26	-0.43	2.24e-22	Colorectal cancer;
LGG	cis	rs7727544	0.647	rs72793280	chr5:131562900	C/T	cg07395648	chr5:131743802	NA	-0.41	-8.87	-0.38	1.56e-17	Blood metabolite levels;
LGG	cis	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg07777115	chr5:623756	CEP72	-0.63	-8.21	-0.36	2.16e-15	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.03	-0.35	8.35e-15	Initial pursuit acceleration;
LGG	trans	rs2727020	0.688	rs2734002	chr11:49234162	A/G	cg03929089	chr4:120376271	NA	0.86	17.2	0.62	1.3e-51	Coronary artery disease;
LGG	cis	rs62103177	1.000	rs62103177	chr18:77624479	G/A	cg20368463	chr18:77673604	PQLC1	0.57	7.49	0.33	3.55e-13	Opioid sensitivity;
LGG	trans	rs1941687	0.505	rs1389534	chr18:31311161	C/G	cg04226714	chr8:49833948	SNAI2	0.4	6.95	0.31	1.22e-11	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.38	-0.36	6.34e-16	Diabetic kidney disease;
LGG	trans	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg02030672	chr11:45687055	CHST1	0.49	8.68	0.37	6.88e-17	Obesity-related traits;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.77	0.57	1.03e-40	Platelet count;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.22e-19	Bipolar disorder;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg13047869	chr3:10149882	C3orf24	0.52	8.44	0.37	4.17e-16	Alzheimer's disease;
LGG	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01570182	chr17:44337453	NA	0.51	9.31	0.4	5.23e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs6582630	0.638	rs10880644	chr12:38554959	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.99	-0.31	9.84e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg26384229	chr12:38710491	ALG10B	0.94	20.24	0.69	1.05e-65	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg17376030	chr22:41985996	PMM1	-0.59	-9.78	-0.41	1.15e-20	Vitiligo;
LGG	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg10840412	chr1:235813424	GNG4	0.6	8.18	0.36	2.75e-15	Bipolar disorder;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.09	-0.42	8.78e-22	Obesity-related traits;
LGG	cis	rs16976116	0.851	rs28889339	chr15:55503205	T/G	cg11288833	chr15:55489084	RSL24D1	0.56	7.51	0.33	3.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs473651	0.935	rs477041	chr2:239355995	C/G	cg18131467	chr2:239335373	ASB1	-1.02	-23.65	-0.74	1.21e-81	Multiple system atrophy;
LGG	trans	rs7786808	0.564	rs10267128	chr7:158198490	G/A	cg02030672	chr11:45687055	CHST1	-0.5	-9.11	-0.39	2.5e-18	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.27	-0.36	1.43e-15	Breast cancer;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs2760061	0.626	rs2527614	chr1:228126470	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-7.07	-0.31	5.92e-12	Diastolic blood pressure;
LGG	cis	rs2797160	1.000	rs78602343	chr6:126019768	T/C	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.41e-13	Endometrial cancer;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.65	-0.44	8.06e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.37	0.43	8.2000000000000006e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg04450456	chr4:17643702	FAM184B	0.32	6.94	0.31	1.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg20673091	chr1:2541236	MMEL1	0.78	20.27	0.69	7.1e-66	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs4650994	0.967	rs4650998	chr1:178531850	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.45	0.37	3.69e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.47e-14	Obesity-related traits;
LGG	trans	rs853679	0.607	rs13197574	chr6:28060239	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	trans	rs208520	0.690	rs207107	chr6:66794385	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs17767392	0.788	rs7156194	chr14:71698616	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.15	-0.32	3.33e-12	Mitral valve prolapse;
LGG	cis	rs6450176	0.638	rs16881969	chr5:53300748	A/G	ch.5.1024479R	chr5:53302184	ARL15	1.03	15.74	0.59	5.25e-45	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs4731207	0.596	rs10280341	chr7:124583935	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs11758351	0.517	rs79958315	chr6:26221826	C/T	cg01420254	chr6:26195488	NA	0.84	10.97	0.45	4.74e-25	Gout;Renal underexcretion gout;
LGG	cis	rs2404602	0.647	rs12910081	chr15:77022959	G/C	cg23625390	chr15:77176239	SCAPER	-0.71	-13.91	-0.54	5.16e-37	Blood metabolite levels;
LGG	cis	rs1707322	0.963	rs4630155	chr1:46257110	G/C	cg03146154	chr1:46216737	IPP	0.57	10.51	0.44	2.49e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7570971	1.000	rs6730157	chr2:135907088	C/T	cg07169764	chr2:136633963	MCM6	-0.58	-9.16	-0.39	1.64e-18	Blood metabolite levels;Body mass index;Cholesterol, total;
LGG	cis	rs6982240	0.514	rs892362	chr8:142269214	A/G	cg20799268	chr8:142275649	NA	0.25	6.87	0.3	2.04e-11	Tonsillectomy;
LGG	cis	rs10883723	0.810	rs10883729	chr10:104273943	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.36	0.55	6.39e-39	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7944584	0.552	rs12361415	chr11:47474146	T/G	cg20307385	chr11:47447363	PSMC3	0.83	16.57	0.61	9.31e-49	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg04731861	chr2:219085781	ARPC2	-0.43	-10.5	-0.44	2.8e-23	Colorectal cancer;
LGG	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-10.32	-0.43	1.31e-22	Hepatocellular carcinoma;
LGG	cis	rs4789452	0.902	rs4789454	chr17:75375199	C/T	cg06761530	chr17:75373219	SEPT9	-0.38	-7.3	-0.32	1.23e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs785830	0.717	rs602742	chr9:224338	A/T	cg14500300	chr9:211689	NA	0.31	7.73	0.34	6.89e-14	Platelet distribution width;
LGG	cis	rs68170813	0.559	rs77641084	chr7:106970522	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-10.16	-0.43	5.16e-22	Coronary artery disease;
LGG	cis	rs3820928	1.000	rs61067328	chr2:227761256	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.46	-0.33	4.45e-13	Pulmonary function;
LGG	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg03352830	chr11:487213	PTDSS2	0.83	10.12	0.43	7.05e-22	Body mass index;
LGG	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg00666640	chr1:248458726	OR2T12	0.5	8.75	0.38	3.92e-17	Common traits (Other);
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.39	-0.36	6.08e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4919087	0.715	rs793520	chr10:99032375	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.35	-0.32	9.19e-13	Monocyte count;
LGG	trans	rs7647973	0.626	rs1463728	chr3:49647404	T/A	cg21659725	chr3:3221576	CRBN	-0.59	-7.54	-0.33	2.51e-13	Menarche (age at onset);
LGG	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg08305652	chr11:111469057	NA	-0.43	-8.63	-0.37	1.02e-16	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg25072359	chr17:41440525	NA	0.52	10.33	0.43	1.16e-22	Menopause (age at onset);
LGG	cis	rs755249	0.567	rs41270799	chr1:39748662	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.36	0.32	8.29e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs35740288	0.685	rs12899481	chr15:86308970	C/T	cg07943548	chr15:86304357	KLHL25	-0.36	-7.26	-0.32	1.69e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7635838	0.617	rs346075	chr3:11294027	T/G	cg00170343	chr3:11313890	ATG7	0.55	9.52	0.4	9.35e-20	HDL cholesterol;
LGG	cis	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg06521331	chr12:34319734	NA	0.41	7.26	0.32	1.69e-12	Morning vs. evening chronotype;
LGG	cis	rs2916247	0.909	rs13259499	chr8:93057823	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.39	-7.89	-0.34	2.2e-14	Intelligence (multi-trait analysis);
LGG	cis	rs41271951	0.622	rs77018356	chr1:151134961	G/C	cg11822372	chr1:151115635	SEMA6C	-0.74	-7.26	-0.32	1.7e-12	Blood protein levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01733783	chr9:128003852	HSPA5	0.38	6.68	0.3	6.76e-11	Body mass index;
LGG	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg13512537	chr8:22265999	SLC39A14	-0.44	-6.66	-0.3	7.87e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.06	-0.39	3.81e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg21775007	chr8:11205619	TDH	-0.49	-7.95	-0.35	1.47e-14	Triglycerides;
LGG	cis	rs8048589	1.000	rs12596549	chr16:12183500	C/A	cg02910054	chr16:12241554	SNX29	0.42	6.73	0.3	5.01e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.91	0.31	1.58e-11	Cystic fibrosis severity;
LGG	cis	rs778371	0.649	rs283465	chr2:233666787	G/A	cg08000102	chr2:233561755	GIGYF2	0.72	11.6	0.47	1.73e-27	Schizophrenia;
LGG	cis	rs9399135	0.935	rs11760000	chr6:135370496	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.47	0.4	1.46e-19	Red blood cell count;
LGG	cis	rs1044826	0.642	rs1080371	chr3:139210894	C/T	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs9393692	0.627	rs2179517	chr6:26198845	G/C	cg16885296	chr6:26284938	NA	0.34	7.45	0.33	4.51e-13	Educational attainment;
LGG	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.83	15.6	0.59	2.11e-44	Subjective well-being;
LGG	trans	rs9467711	0.591	rs36109883	chr6:26133070	G/A	cg08344181	chr3:125677491	NA	-0.76	-6.83	-0.3	2.7e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3820928	0.874	rs59630650	chr2:227786514	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.61	-0.33	1.55e-13	Pulmonary function;
LGG	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-10.9	-0.45	8.56e-25	Total body bone mineral density;
LGG	cis	rs10274279	1.000	rs73163816	chr7:157388126	C/G	cg09270525	chr7:157391030	PTPRN2	0.74	9.53	0.4	9.22e-20	Myopia (pathological);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02005336	chr11:61560123	MIR611;C11orf10;FEN1	0.44	7.05	0.31	6.39e-12	Cognitive performance;
LGG	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg01181863	chr3:195395398	SDHAP2	-0.65	-10.28	-0.43	1.79e-22	Pancreatic cancer;
LGG	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1163251	0.902	rs627707	chr1:120217133	C/G	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs2075371	0.796	rs7780583	chr7:133960716	C/G	cg11752832	chr7:134001865	SLC35B4	0.57	10.2	0.43	3.67e-22	Mean platelet volume;
LGG	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs6554196	0.525	rs3819391	chr4:55526702	A/G	cg18836493	chr4:55524333	KIT	-0.44	-8.14	-0.35	3.62e-15	Monocyte count;
LGG	cis	rs4319547	0.620	rs12372756	chr12:122815130	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.56	-0.41	6.71e-20	Body mass index;
LGG	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg07382826	chr16:28625726	SULT1A1	0.42	8.99	0.39	6.44e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.93	0.31	1.43e-11	Neuroticism;
LGG	cis	rs1707322	0.721	rs6699418	chr1:46100181	G/A	cg03146154	chr1:46216737	IPP	0.57	11.01	0.46	3.42e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14664575	chr19:40476624	PSMC4	0.42	7.04	0.31	6.98e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg09324608	chr17:30823087	MYO1D	0.31	7.35	0.32	8.94e-13	Schizophrenia;
LGG	trans	rs1997103	1.000	rs10249105	chr7:55412405	A/G	cg20935933	chr6:143382018	AIG1	-0.47	-7.75	-0.34	5.84e-14	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs10191773	0.589	rs72831641	chr2:112955815	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.6	-9.05	-0.39	4.12e-18	Yeast infection;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg20913747	chr6:44695427	NA	-0.61	-10.16	-0.43	4.88e-22	Total body bone mineral density;
LGG	cis	rs35110281	0.627	rs1595167	chr21:44965874	T/G	cg04455712	chr21:45112962	RRP1B	0.49	9.07	0.39	3.34e-18	Mean corpuscular volume;
LGG	trans	rs6076960	0.684	rs3852949	chr20:6264758	T/A	cg17788362	chr6:86352627	SYNCRIP	0.55	9.74	0.41	1.69e-20	Smooth-surface caries;
LGG	cis	rs62103177	0.673	rs55852342	chr18:77594109	G/C	cg20368463	chr18:77673604	PQLC1	0.48	7.32	0.32	1.13e-12	Opioid sensitivity;
LGG	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs317689	0.513	rs317678	chr12:69692166	C/G	cg20891283	chr12:69753455	YEATS4	0.7	12.96	0.52	5.47e-33	Response to diuretic therapy;
LGG	cis	rs741702	0.928	rs2974750	chr19:13044544	C/A	cg06417478	chr19:12876846	HOOK2	0.41	6.86	0.3	2.16e-11	Red blood cell traits;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.66e-21	Bipolar disorder;
LGG	cis	rs3540	0.618	rs2301832	chr15:91040725	A/T	cg22089800	chr15:90895588	ZNF774	-0.67	-12.16	-0.49	9.82e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs4789668	chr17:80161990	C/T	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.31e-16	Life satisfaction;
LGG	cis	rs8049634	0.732	rs2875860	chr16:84231580	G/A	cg26466773	chr16:84211947	TAF1C	0.42	6.98	0.31	1.04e-11	Small cell lung carcinoma;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg24829409	chr8:58192753	C8orf71	-0.66	-8.81	-0.38	2.45e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-9.1	-0.39	2.6e-18	Triglycerides;
LGG	cis	rs2559856	0.935	rs2559864	chr12:102084710	C/G	cg12924262	chr12:102091054	CHPT1	0.65	12.82	0.51	2.15e-32	Blood protein levels;
LGG	cis	rs16867321	0.588	rs1919156	chr2:181456978	C/T	cg23363182	chr2:181467187	NA	-0.42	-8.46	-0.37	3.66e-16	Obesity;
LGG	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	4.01e-13	Schizophrenia;
LGG	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg06634786	chr22:41940651	POLR3H	0.72	12.03	0.49	3.29e-29	Vitiligo;
LGG	cis	rs4481887	1.000	rs4916125	chr1:248466583	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs8133932	0.555	rs374331	chr21:47338218	A/G	cg11214348	chr21:47283868	PCBP3	-0.45	-7.98	-0.35	1.17e-14	Schizophrenia;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg05210886	chr1:245133216	EFCAB2	-0.38	-6.74	-0.3	4.74e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	trans	rs17685	0.535	rs6953065	chr7:75601169	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.54	-9.21	-0.39	1.13e-18	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1109114	0.816	rs748066	chr5:148620535	G/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.23	-0.58	9.4e-43	Body mass index;
LGG	trans	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg06521331	chr12:34319734	NA	0.51	9.48	0.4	1.35e-19	Bladder cancer;
LGG	cis	rs10979	0.782	rs9390108	chr6:143892722	A/T	cg25407410	chr6:143891975	LOC285740	-0.7	-12.02	-0.49	3.89e-29	Hypospadias;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.37e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	0.647	rs12905181	chr15:77098431	A/G	cg23625390	chr15:77176239	SCAPER	-0.73	-14.6	-0.56	5.38e-40	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.14	-0.31	3.68e-12	Menopause (age at onset);
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.49	-0.61	2.05e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg26554054	chr8:600488	NA	0.89	8.64	0.37	9.42e-17	IgG glycosylation;
LGG	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg11752832	chr7:134001865	SLC35B4	0.61	10.95	0.45	5.65e-25	Mean platelet volume;
LGG	cis	rs6815814	0.950	rs5743794	chr4:38832727	C/T	cg06935464	chr4:38784597	TLR10	0.58	7.92	0.35	1.78e-14	Breast cancer;
LGG	cis	rs17030434	1.000	rs75418383	chr4:154719084	A/G	cg14289246	chr4:154710475	SFRP2	-0.72	-11.0	-0.46	3.77e-25	Electrocardiographic conduction measures;
LGG	cis	rs9290877	0.667	rs9864167	chr3:188456896	T/C	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs2274273	1.000	rs66871576	chr14:55629050	C/T	cg04306507	chr14:55594613	LGALS3	0.62	16.88	0.62	3.73e-50	Protein biomarker;
LGG	cis	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.91	-0.35	1.9e-14	Mood instability;
LGG	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg09137382	chr11:130731461	NA	-0.35	-6.77	-0.3	3.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg06873352	chr17:61820015	STRADA	0.72	13.17	0.52	6.91e-34	Prudent dietary pattern;
LGG	cis	rs17125944	0.505	rs74642116	chr14:53213507	A/G	cg00686598	chr14:53173677	PSMC6	1.35	14.8	0.57	7.62e-41	Alzheimer's disease (late onset);
LGG	cis	rs9937943	0.720	rs112685216	chr16:74609517	G/A	cg01733217	chr16:74700730	RFWD3	0.66	9.31	0.4	5.34e-19	Neutrophil percentage of white cells;
LGG	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.75	-0.3	4.33e-11	Restless legs syndrome;
LGG	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.71	-0.3	5.65e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs79349575	0.783	rs4794000	chr17:47022755	C/G	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs6583826	0.538	rs11187076	chr10:94336963	G/A	cg25093409	chr10:94429542	NA	0.42	8.6	0.37	1.25e-16	Type 2 diabetes;
LGG	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.22	-0.39	1.07e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12200782	0.505	rs9295696	chr6:26550288	C/T	cg11502198	chr6:26597334	ABT1	0.89	13.09	0.52	1.59e-33	Small cell lung carcinoma;
LGG	cis	rs9467773	0.620	rs2130657	chr6:26650826	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg22968622	chr17:43663579	NA	0.8	15.54	0.59	4.03e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1010254	0.510	rs72806379	chr5:151701942	C/T	cg12297329	chr5:152029980	NA	-0.47	-6.89	-0.3	1.82e-11	Optic nerve measurement (cup area);
LGG	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.94	-0.35	1.55e-14	HDL cholesterol;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg07747251	chr5:1868357	NA	0.46	8.88	0.38	1.46e-17	Cardiovascular disease risk factors;
LGG	cis	rs10781543	0.845	rs10735662	chr9:139327869	A/T	cg14169450	chr9:139327907	INPP5E	0.41	7.44	0.33	5.05e-13	Monocyte percentage of white cells;
LGG	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs6693567	0.565	rs1262432	chr1:150371839	C/A	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs10937275	0.826	rs13061952	chr3:186658866	C/G	cg24050613	chr3:186648279	ST6GAL1	0.76	8.12	0.35	4.37e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.95e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg19168338	chr16:4465731	CORO7	-0.93	-19.28	-0.67	3.02e-61	Schizophrenia;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg07332563	chr6:291687	DUSP22	-0.58	-9.47	-0.4	1.43e-19	Menopause (age at onset);
LGG	cis	rs6089829	0.962	rs2314131	chr20:61665225	A/G	cg08045932	chr20:61659980	NA	0.46	8.22	0.36	2.08e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10080237	0.564	rs2490232	chr6:80814802	C/T	cg08355045	chr6:80787529	NA	-0.39	-7.9	-0.34	2.1e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	9.01	0.39	5.41e-18	Mood instability;
LGG	cis	rs490234	0.867	rs829181	chr9:128288002	A/G	cg14078157	chr9:128172775	NA	0.4	7.55	0.33	2.31e-13	Mean arterial pressure;
LGG	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg18252515	chr7:66147081	NA	-0.75	-11.99	-0.49	5.08e-29	Corneal structure;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg11645453	chr3:52864694	ITIH4	0.39	6.69	0.3	6.57e-11	Electroencephalogram traits;
LGG	cis	rs9457247	1.000	rs2757047	chr6:167374489	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs6496044	0.591	rs979825	chr15:86080625	A/T	cg13263323	chr15:86062960	AKAP13	-0.36	-7.77	-0.34	5.01e-14	Interstitial lung disease;
LGG	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg09904177	chr6:26538194	HMGN4	0.78	18.03	0.64	1.96e-55	Intelligence (multi-trait analysis);
LGG	cis	rs1566085	0.676	rs11786990	chr8:142652379	G/A	cg26331504	chr8:142652174	NA	0.31	7.35	0.32	9.34e-13	Intelligence (multi-trait analysis);
LGG	cis	rs526231	0.543	rs246915	chr5:102558044	G/A	cg23492399	chr5:102201601	PAM	-0.57	-8.25	-0.36	1.64e-15	Primary biliary cholangitis;
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg13397359	chr6:42928475	GNMT	0.68	20.87	0.7	1.12e-68	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9815354	0.951	rs9831404	chr3:41871825	T/G	cg03022575	chr3:42003672	ULK4	0.68	8.67	0.37	7.32e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952809	0.532	rs2057840	chr7:2432797	C/G	cg23289794	chr7:2394357	EIF3B	-0.73	-9.65	-0.41	3.34e-20	Multiple sclerosis;
LGG	cis	rs77972916	0.536	rs6751209	chr2:43588302	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.53	-7.96	-0.35	1.38e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg05084668	chr3:125655381	ALG1L	-0.54	-7.34	-0.32	9.49e-13	Blood pressure (smoking interaction);
LGG	cis	rs4566357	0.615	rs2272204	chr2:227915601	G/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.97e-18	Coronary artery disease;
LGG	cis	rs765787	0.530	rs2899378	chr15:45537584	C/T	cg25801113	chr15:45476975	SHF	-0.88	-18.85	-0.66	3.19e-59	Uric acid levels;
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg09303159	chr6:26284866	NA	-0.31	-6.96	-0.31	1.18e-11	Educational attainment;
LGG	cis	rs2249694	0.520	rs7095996	chr10:135328948	G/A	cg20169779	chr10:135381914	SYCE1	-0.54	-7.32	-0.32	1.1e-12	Obesity-related traits;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg18279126	chr7:2041391	MAD1L1	0.33	7.07	0.31	5.84e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9581943	0.901	rs9579127	chr13:28477268	A/G	cg16302790	chr13:28498334	PDX1	0.5	8.51	0.37	2.45e-16	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10225491	chr17:3571916	TMEM93;TAX1BP3	0.47	6.82	0.3	2.9100000000000002e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs7648952	chr3:40457038	C/T	cg13683864	chr3:40499215	RPL14	0.98	20.14	0.68	2.94e-65	Renal cell carcinoma;
LGG	cis	rs2282300	0.739	rs67670125	chr11:30214914	C/T	cg25418670	chr11:30344373	C11orf46	-0.57	-7.9	-0.34	2.03e-14	Morning vs. evening chronotype;
LGG	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.65	8.51	0.37	2.51e-16	Crohn's disease;
LGG	cis	rs2180341	0.814	rs7768435	chr6:127737038	A/C	cg27446573	chr6:127587934	RNF146	0.93	17.37	0.63	2.21e-52	Breast cancer;
LGG	trans	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-11.67	-0.48	8.85e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs7412746	0.611	rs10888398	chr1:150886782	A/G	cg15448220	chr1:150897856	SETDB1	-0.36	-6.71	-0.3	5.67e-11	Melanoma;
LGG	trans	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg13009111	chr11:71350975	NA	-0.34	-7.67	-0.34	1.02e-13	Neuroticism;
LGG	trans	rs61931739	0.500	rs10844789	chr12:34202279	C/G	cg13010199	chr12:38710504	ALG10B	0.57	10.85	0.45	1.41e-24	Morning vs. evening chronotype;
LGG	cis	rs34599045	0.522	rs79520860	chr1:152895586	G/A	cg07796016	chr1:152779584	LCE1C	-0.82	-7.49	-0.33	3.4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs908922	0.887	rs1415432	chr1:152480654	G/A	cg20991723	chr1:152506922	NA	-0.58	-9.7	-0.41	2.31e-20	Hair morphology;
LGG	cis	rs3096299	0.503	rs9925045	chr16:89556476	T/C	cg08392591	chr16:89556376	ANKRD11	0.63	10.23	0.43	2.85e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24110177	chr3:50126178	RBM5	0.58	10.6	0.44	1.23e-23	Intelligence (multi-trait analysis);
LGG	cis	rs868036	0.609	rs3784707	chr15:68043878	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.32	-6.85	-0.3	2.39e-11	Restless legs syndrome;
LGG	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg17108064	chr15:78857060	CHRNA5	-0.44	-9.44	-0.4	1.9e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs17125944	0.615	rs12589020	chr14:53312002	C/T	cg00686598	chr14:53173677	PSMC6	0.83	8.33	0.36	9.57e-16	Alzheimer's disease (late onset);
LGG	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg25554036	chr4:6271136	WFS1	0.62	11.58	0.47	2.02e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs61884328	0.852	rs61896132	chr11:47113303	C/T	cg03339077	chr11:47165057	C11orf49	0.63	6.85	0.3	2.32e-11	Total body bone mineral density (age over 60);
LGG	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg11621586	chr10:70884670	VPS26A	1.16	21.37	0.7	5.44e-71	Left atrial antero-posterior diameter;
LGG	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.33	-0.5	2.03e-30	Height;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg04863758	chr4:1303710	MAEA	0.46	7.77	0.34	5.16e-14	Obesity-related traits;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg05368731	chr17:41323189	NBR1	-0.9	-17.62	-0.63	1.56e-53	Menopause (age at onset);
LGG	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg01028140	chr2:1542097	TPO	-0.43	-8.13	-0.35	3.91e-15	IgG glycosylation;
LGG	cis	rs13314892	0.728	rs62252234	chr3:69890474	T/G	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg27476859	chr7:2772710	GNA12	0.41	7.05	0.31	6.46e-12	Height;
LGG	trans	rs800082	1.000	rs9849975	chr3:144294530	A/G	cg24215973	chr2:240111563	HDAC4	-0.49	-8.57	-0.37	1.56e-16	Smoking behavior;
LGG	cis	rs1801251	1.000	rs283475	chr2:233654381	A/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-9.98	-0.42	2.19e-21	Coronary artery disease;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg27121462	chr16:89883253	FANCA	0.63	11.78	0.48	3.25e-28	Vitiligo;
LGG	cis	rs300774	0.925	rs435919	chr2:128890	T/G	cg04617936	chr2:214353	NA	-0.5	-7.64	-0.33	1.24e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs7572733	0.555	rs11889006	chr2:198928647	A/G	cg00792783	chr2:198669748	PLCL1	0.56	8.76	0.38	3.77e-17	Dermatomyositis;
LGG	cis	rs9790314	0.875	rs336580	chr3:161082982	A/T	cg04691961	chr3:161091175	C3orf57	-0.67	-16.18	-0.6	5.55e-47	Morning vs. evening chronotype;
LGG	cis	rs503734	0.666	rs2317745	chr3:101111312	C/T	cg27318481	chr3:100970896	IMPG2	-0.35	-7.16	-0.32	3.2e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg13010199	chr12:38710504	ALG10B	0.63	13.21	0.52	4.85e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs10274279	0.614	rs12669550	chr7:157403743	G/A	cg09270525	chr7:157391030	PTPRN2	0.84	10.98	0.45	4.2e-25	Myopia (pathological);
LGG	cis	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	trans	rs6601327	0.663	rs12543346	chr8:9655823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.95	-0.31	1.22e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs883565	0.502	rs11129810	chr3:38946064	C/T	cg01426195	chr3:39028469	NA	-0.58	-12.24	-0.49	4.97e-30	Handedness;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00551387	chr10:24874291	ARHGAP21	0.34	6.86	0.3	2.17e-11	Electrocardiographic conduction measures;
LGG	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.42	-0.4	2.15e-19	Systemic lupus erythematosus;
LGG	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg17545662	chr6:170176663	C6orf70	0.69	8.78	0.38	3.2e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4731207	0.564	rs12531311	chr7:124625546	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.87	-0.3	2.14e-11	Cutaneous malignant melanoma;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.84	17.2	0.62	1.21e-51	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10089	1.000	rs10089	chr5:127522543	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	10.99	0.45	3.96e-25	Ileal carcinoids;
LGG	cis	rs2613964	0.504	rs9838215	chr3:112850463	A/G	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	5.83e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs9560113	1.000	rs11069895	chr13:112178824	C/T	cg10483660	chr13:112241077	NA	0.36	7.08	0.31	5.52e-12	Menarche (age at onset);
LGG	cis	rs4650994	0.593	rs12735140	chr1:178544218	C/A	cg12486710	chr1:178512616	C1orf220	-0.35	-6.88	-0.3	1.93e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6466055	0.720	rs2040914	chr7:104972174	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.36	0.32	8.39e-13	Schizophrenia;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	8.64	0.37	9.4e-17	Lung function (FEV1/FVC);
LGG	cis	rs963731	0.579	rs2060987	chr2:39282079	A/G	cg04010122	chr2:39346883	SOS1	-0.79	-7.7	-0.34	8.13e-14	Corticobasal degeneration;
LGG	cis	rs2274273	0.662	rs2147970	chr14:55660217	C/T	cg04306507	chr14:55594613	LGALS3	0.51	11.86	0.48	1.69e-28	Protein biomarker;
LGG	cis	rs8005677	1.000	rs2295685	chr14:23398153	A/G	cg01529538	chr14:23388837	RBM23	0.36	6.68	0.3	6.9e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs11645898	0.748	rs11647889	chr16:72052034	C/G	cg14768367	chr16:72042858	DHODH	-0.9	-11.84	-0.48	1.87e-28	Blood protein levels;
LGG	cis	rs4700695	0.841	rs152933	chr5:65359530	A/G	cg21114390	chr5:65439923	SFRS12	-0.58	-7.09	-0.31	5.1e-12	Facial morphology (factor 19);
LGG	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg13010199	chr12:38710504	ALG10B	0.73	14.89	0.57	2.91e-41	Bladder cancer;
LGG	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	19.11	0.66	1.93e-60	Smoking behavior;
LGG	cis	rs4731207	0.698	rs4728011	chr7:124481712	C/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg15971980	chr6:150254442	NA	0.46	8.68	0.37	6.86e-17	Lung cancer;
LGG	cis	rs735860	0.726	rs209490	chr6:53179047	C/T	cg10236188	chr6:53219634	NA	0.35	6.76	0.3	4.11e-11	Glaucoma;
LGG	cis	rs1577917	1.000	rs13199006	chr6:86608708	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.2e-16	Response to antipsychotic treatment;
LGG	cis	rs2905347	0.520	rs1858936	chr7:22647553	G/C	cg18045685	chr7:22629474	NA	-0.73	-15.15	-0.58	2.17e-42	Major depression and alcohol dependence;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg22398616	chr13:53314203	LECT1	0.45	9.3	0.4	5.5e-19	Lewy body disease;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.47	-0.37	3.22e-16	Obesity-related traits;
LGG	cis	rs62400317	0.762	rs10456120	chr6:44900107	C/T	cg18551225	chr6:44695536	NA	-0.68	-11.36	-0.47	1.51e-26	Total body bone mineral density;
LGG	cis	rs12893668	0.663	rs12889731	chr14:104087482	C/T	cg23335576	chr14:104009727	NA	0.48	8.34	0.36	8.54e-16	Reticulocyte count;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17604090	0.793	rs10226095	chr7:29690059	A/G	cg19413766	chr7:29689036	LOC646762	0.54	7.41	0.33	6.14e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19524238	chr7:2802976	GNA12	0.34	8.13	0.35	4.06e-15	Height;
LGG	cis	rs8032158	0.929	rs1509406	chr15:56229760	A/G	cg02198044	chr15:56286336	NEDD4	-0.74	-12.82	-0.51	1.98e-32	Keloid;
LGG	cis	rs10979	0.557	rs9390117	chr6:143907590	C/T	cg25407410	chr6:143891975	LOC285740	-0.54	-8.07	-0.35	6.26e-15	Hypospadias;
LGG	cis	rs7312933	0.933	rs4534650	chr12:42444222	A/G	cg19980929	chr12:42632907	YAF2	0.35	7.62	0.33	1.42e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6964587	0.967	rs17164315	chr7:91659150	C/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs75059851	0.756	rs7127156	chr11:133839857	T/C	cg20042908	chr11:133852938	NA	-0.77	-14.33	-0.55	8.49e-39	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21227347	chr9:117374170	C9orf91	0.51	8.27	0.36	1.39e-15	Gut microbiome composition (summer);
LGG	cis	rs4642101	0.611	rs6442331	chr3:12820636	T/G	cg05775895	chr3:12838266	CAND2	0.63	11.05	0.46	2.47e-25	QRS complex (12-leadsum);
LGG	cis	rs875971	1.000	rs778706	chr7:65860424	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs9330264	0.508	rs7364869	chr1:155087188	A/G	cg13808842	chr1:155066096	NA	-0.29	-6.98	-0.31	1.04e-11	1,5-anhydroglucitol levels;
LGG	cis	rs2760061	0.603	rs697761	chr1:228192397	G/A	cg01200585	chr1:228362443	C1orf69	0.48	8.06	0.35	6.76e-15	Diastolic blood pressure;
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.44e-24	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15556689	chr8:8085844	FLJ10661	0.49	8.62	0.37	1.06e-16	Retinal vascular caliber;
LGG	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg25019033	chr10:957182	NA	-0.46	-8.82	-0.38	2.32e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.0	-0.52	3.76e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs894344	0.812	rs11166612	chr8:135600954	A/G	cg17885191	chr8:135476712	NA	0.39	6.66	0.3	7.56e-11	Systolic blood pressure;
LGG	cis	rs7828089	1.000	rs7838127	chr8:22264561	G/A	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.79	-0.3	3.43e-11	Verbal declarative memory;
LGG	cis	rs6772849	0.930	rs1962040	chr3:128324161	G/A	cg08795948	chr3:128337044	NA	0.66	10.87	0.45	1.19e-24	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs12681287	0.640	rs12549332	chr8:87353392	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.53	-0.33	2.72e-13	Caudate activity during reward;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg09264619	chr17:80180166	NA	0.34	6.84	0.3	2.46e-11	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18455653	chr20:17662865	RRBP1	0.42	6.89	0.3	1.79e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg06636001	chr8:8085503	FLJ10661	0.48	8.63	0.37	9.85e-17	Myopia (pathological);
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.85e-13	Retinal vascular caliber;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17554472	chr22:41940697	POLR3H	0.45	7.0	0.31	9.21e-12	Vitiligo;
LGG	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg18551225	chr6:44695536	NA	-0.62	-9.93	-0.42	3.38e-21	Total body bone mineral density;
LGG	cis	rs9486719	1.000	rs2499804	chr6:96861216	A/G	cg06623918	chr6:96969491	KIAA0776	0.74	10.37	0.43	8.62e-23	Migraine;Coronary artery disease;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg07167872	chr1:205819463	PM20D1	0.55	11.03	0.46	2.77e-25	Menarche (age at onset);
LGG	cis	rs4731207	0.671	rs10085867	chr7:124486168	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg27478167	chr7:817139	HEATR2	-0.44	-7.08	-0.31	5.22e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs853679	0.517	rs56310871	chr6:28044482	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg26769984	chr7:1090371	C7orf50	0.42	7.61	0.33	1.5700000000000001e-13	Bronchopulmonary dysplasia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21618713	chr4:153701330	ARFIP1;TIGD4	0.43	6.88	0.3	2e-11	Cognitive performance;
LGG	cis	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg25358565	chr5:93447407	FAM172A	1.37	17.02	0.62	8.51e-51	Diabetic retinopathy;
LGG	cis	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg13010199	chr12:38710504	ALG10B	0.68	13.76	0.54	2.29e-36	Bladder cancer;
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7760949	0.889	rs9396264	chr6:13930342	T/A	cg27413430	chr6:13925136	RNF182	0.48	7.29	0.32	1.36e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9399137	0.507	rs4289677	chr6:135275485	A/G	cg24558204	chr6:135376177	HBS1L	0.6	10.41	0.44	6.16e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.98	-0.31	1.04e-11	Mood instability;
LGG	cis	rs7010267	0.570	rs4305930	chr8:120058021	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.79	0.38	2.96e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs3733585	0.605	rs4235354	chr4:10122942	C/A	cg26043149	chr18:55253948	FECH	-0.5	-8.1	-0.35	5.05e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs653465	0.621	rs11719250	chr3:27174261	G/T	cg02860705	chr3:27208620	NA	-0.41	-7.92	-0.35	1.8e-14	Breast cancer (early onset);
LGG	cis	rs6547631	0.594	rs7908	chr2:85925756	C/G	cg19805943	chr2:85933069	NA	0.32	6.8	0.3	3.3e-11	Blood protein levels;
LGG	trans	rs3206736	0.548	rs1649238	chr7:35004517	C/T	cg14337134	chr7:102920323	DPY19L2P2	-0.4	-7.24	-0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs9443645	0.901	rs12193319	chr6:79583437	C/A	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11608355	0.545	rs11066782	chr12:109910552	C/T	cg05360138	chr12:110035743	NA	0.84	12.02	0.49	3.87e-29	Neuroticism;
LGG	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg14416269	chr4:6271139	WFS1	0.46	7.7	0.34	8.61e-14	Cisplatin-induced ototoxicity;
LGG	cis	rs3099143	1.000	rs3110378	chr15:77127983	G/A	cg21673338	chr15:77095150	SCAPER	-0.66	-10.64	-0.44	8.28e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.81e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4356203	0.870	rs7949699	chr11:17247708	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs208520	0.954	rs12190073	chr6:66983740	T/C	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs9302635	0.626	rs34508528	chr16:72215115	C/T	cg23815491	chr16:72088622	HP	0.41	7.31	0.32	1.18e-12	Blood protein levels;
LGG	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg02536541	chr18:77568900	NA	-0.59	-9.63	-0.41	3.84e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6504108	0.624	rs8075270	chr17:46275010	T/C	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.64e-15	Body mass index;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.9	0.48	1.13e-28	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.63e-12	Lung cancer;
LGG	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg25358565	chr5:93447407	FAM172A	-0.83	-11.48	-0.47	4.98e-27	Diabetic retinopathy;
LGG	cis	rs12200560	0.505	rs211174	chr6:97071120	C/T	cg06623918	chr6:96969491	KIAA0776	0.46	7.82	0.34	3.5e-14	Coronary heart disease;
LGG	cis	rs7113850	0.541	rs74832028	chr11:24232359	A/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.45	0.44	4.3e-23	Bone fracture in osteoporosis;
LGG	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.27	-0.36	1.39e-15	Joint mobility (Beighton score);
LGG	cis	rs2455799	0.573	rs2062824	chr3:15757901	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-8.01	-0.35	9.24e-15	Mean platelet volume;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg13880726	chr7:1868755	MAD1L1	0.45	7.81	0.34	3.9e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6815814	0.847	rs11725309	chr4:38783848	T/C	cg06935464	chr4:38784597	TLR10	0.61	8.25	0.36	1.7e-15	Breast cancer;
LGG	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7107174	1.000	rs2256187	chr11:77919768	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.1	-0.31	4.8e-12	Testicular germ cell tumor;
LGG	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg13607699	chr17:42295918	UBTF	0.91	18.72	0.66	1.28e-58	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.84e-13	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.32	0.63	3.56e-52	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg06873352	chr17:61820015	STRADA	0.75	14.23	0.55	2.19e-38	Prudent dietary pattern;
LGG	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg26769984	chr7:1090371	C7orf50	0.43	7.22	0.32	2.16e-12	Bronchopulmonary dysplasia;
LGG	cis	rs10929925	0.897	rs2609184	chr2:6160923	G/C	cg00493617	chr2:6141445	NA	0.33	7.45	0.33	4.49e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs698833	0.605	rs13403127	chr2:44717071	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	7.19	0.32	2.7e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1697139	0.583	rs6895853	chr5:66541427	T/C	cg11553311	chr5:66541588	NA	0.45	10.05	0.42	1.23e-21	Breast cancer;
LGG	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11890956	chr21:40555474	PSMG1	0.98	14.67	0.56	2.85e-40	Cognitive function;
LGG	cis	rs2576037	0.796	rs2576034	chr18:44588548	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-7.95	-0.35	1.45e-14	Personality dimensions;
LGG	cis	rs11209002	0.592	rs4655672	chr1:67553543	C/T	cg02640540	chr1:67518911	SLC35D1	0.41	7.14	0.32	3.56e-12	Crohn's disease;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.89	18.75	0.66	8.55e-59	Personality dimensions;
LGG	cis	rs763121	0.853	rs2413547	chr22:39107338	A/G	cg06022373	chr22:39101656	GTPBP1	0.91	18.53	0.65	9.68e-58	Menopause (age at onset);
LGG	trans	rs35110281	0.782	rs1454650	chr21:45012353	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.07	0.46	2e-25	Mean corpuscular volume;
LGG	cis	rs1707322	0.717	rs1135850	chr1:46093692	G/A	cg03146154	chr1:46216737	IPP	0.56	10.84	0.45	1.43e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9790314	1.000	rs6441373	chr3:161026717	T/G	cg04691961	chr3:161091175	C3orf57	-0.63	-14.74	-0.57	1.33e-40	Morning vs. evening chronotype;
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.09e-21	Bipolar disorder;
LGG	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg05623727	chr3:50126028	RBM5	-0.38	-8.44	-0.37	4.15e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg15556689	chr8:8085844	FLJ10661	0.54	10.2	0.43	3.56e-22	Systolic blood pressure;
LGG	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg25174290	chr11:3078921	CARS	-0.49	-8.52	-0.37	2.25e-16	Calcium levels;
LGG	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.53	0.53	2.19e-35	Bladder cancer;
LGG	cis	rs28830936	0.535	rs2289743	chr15:41860698	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.38	-7.7	-0.34	8.05e-14	Diastolic blood pressure;
LGG	cis	rs9318086	0.673	rs7981928	chr13:24435180	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	9.75	0.41	1.45e-20	Myopia (pathological);
LGG	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg10760299	chr15:45669010	GATM	0.41	8.05	0.35	7.26e-15	Homoarginine levels;
LGG	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.3	-0.53	1.98e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg09264619	chr17:80180166	NA	0.34	6.77	0.3	3.88e-11	Life satisfaction;
LGG	cis	rs12479064	0.724	rs62153852	chr2:99934713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-10.15	-0.43	5.42e-22	Chronic sinus infection;
LGG	cis	rs17739167	0.569	rs6493015	chr15:42225260	G/T	cg20935245	chr15:42234343	EHD4	0.45	8.81	0.38	2.52e-17	Monocyte count;
LGG	cis	rs17445240	0.901	rs6754703	chr2:3707646	C/A	cg20720597	chr2:3699334	NA	0.8	8.82	0.38	2.33e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6445975	0.667	rs6772264	chr3:58232941	G/A	cg24175188	chr3:58374923	PXK	0.39	7.35	0.32	8.75e-13	Systemic lupus erythematosus;
LGG	cis	rs7851660	0.839	rs10818213	chr9:100648631	T/C	cg13688889	chr9:100608707	NA	-0.63	-12.54	-0.5	3.07e-31	Strep throat;
LGG	cis	rs7044106	0.734	rs10491784	chr9:123432289	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.36	0.32	8.38e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.52	-0.44	2.4e-23	Prostate cancer;
LGG	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.79	-0.3	3.5e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg15596359	chr8:11213517	TDH	-0.38	-7.64	-0.33	1.23e-13	Retinal vascular caliber;
LGG	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg15971980	chr6:150254442	NA	0.45	8.23	0.36	1.92e-15	Lung cancer;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg14346243	chr4:90757452	SNCA	0.38	7.64	0.33	1.27e-13	Dementia with Lewy bodies;
LGG	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg24253500	chr15:84953950	NA	0.6	10.97	0.45	4.59e-25	Schizophrenia;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	11.13	0.46	1.16e-25	Schizophrenia;
LGG	cis	rs6867032	1.000	rs6867032	chr5:2015103	G/T	cg26168224	chr5:2018326	NA	-1.29	-32.42	-0.83	3.34e-121	Gut microbiome composition (winter);
LGG	cis	rs752010	0.523	rs10890160	chr1:42120011	A/G	cg06885757	chr1:42089581	HIVEP3	0.55	12.48	0.5	5.05e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	8.49	0.37	2.9e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6430585	0.583	rs4594504	chr2:136625113	A/C	cg07169764	chr2:136633963	MCM6	1.29	26.41	0.78	2.07e-94	Corneal structure;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs950169	0.922	rs12906983	chr15:84931022	G/A	cg24253500	chr15:84953950	NA	0.58	10.33	0.43	1.22e-22	Schizophrenia;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg14343214	chr6:133562056	EYA4	0.31	7.32	0.32	1.1e-12	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	4.95e-43	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.32	0.32	1.09e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9660992	0.573	rs12144980	chr1:205185104	C/T	cg00857998	chr1:205179979	DSTYK	0.49	7.7	0.34	8.6e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7727544	0.606	rs17622208	chr5:131717050	G/A	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.81	-0.3	3.01e-11	Blood metabolite levels;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg18350739	chr11:68623251	NA	0.82	20.87	0.7	1.14e-68	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28735056	0.904	rs35201860	chr18:77628719	T/C	cg23825213	chr18:77623475	KCNG2	-0.4	-7.14	-0.31	3.74e-12	Schizophrenia;
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg02002194	chr4:3960332	NA	0.43	7.96	0.35	1.36e-14	Triglycerides;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg08621203	chr6:150244597	RAET1G	0.46	8.01	0.35	9.64e-15	Lung cancer;
LGG	cis	rs67366981	1.000	rs67130018	chr14:77703280	C/T	cg22824376	chr14:77648248	TMEM63C	0.71	7.5	0.33	3.33e-13	Obsessive-compulsive symptoms;
LGG	cis	rs787274	0.557	rs1570754	chr9:115669284	C/A	cg13803584	chr9:115635662	SNX30	-0.68	-7.48	-0.33	3.8e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4740619	0.525	rs2382553	chr9:15814455	A/G	cg14451791	chr9:16040625	NA	0.32	8.01	0.35	9.48e-15	Body mass index;
LGG	cis	rs6963495	0.818	rs73190186	chr7:105164368	G/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs79349575	0.783	rs12602746	chr17:47031741	A/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs9549367	0.789	rs3850451	chr13:113905812	C/G	cg18105134	chr13:113819100	PROZ	-0.7	-14.32	-0.55	8.99e-39	Platelet distribution width;
LGG	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg11871910	chr12:69753446	YEATS4	0.72	14.48	0.56	1.76e-39	Blood protein levels;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg11584989	chr19:19387371	SF4	0.45	8.02	0.35	8.97e-15	Tonsillectomy;
LGG	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg00376283	chr12:123451042	ABCB9	-0.57	-8.56	-0.37	1.62e-16	Neutrophil percentage of white cells;
LGG	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	8.67	0.37	7.43e-17	Thyroid stimulating hormone;
LGG	cis	rs12143943	0.934	rs4951406	chr1:204554603	A/G	cg20240347	chr1:204465584	NA	-0.33	-7.19	-0.32	2.69e-12	Cognitive performance;
LGG	cis	rs7493	1.000	rs6961773	chr7:95037718	T/G	cg08461772	chr7:95026248	PON3	0.37	8.04	0.35	7.59e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4262150	0.567	rs2964224	chr5:151938802	G/A	cg12297329	chr5:152029980	NA	-0.58	-11.14	-0.46	1.03e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6547631	0.622	rs10180445	chr2:85926218	C/G	cg24620635	chr2:85921963	GNLY	-0.51	-10.26	-0.43	2.23e-22	Blood protein levels;
LGG	cis	rs875971	0.545	rs1796222	chr7:66057154	T/C	cg11764359	chr7:65958608	NA	-0.62	-9.42	-0.4	2.18e-19	Aortic root size;
LGG	cis	rs7633770	0.643	rs11130102	chr3:46689567	G/C	cg11219411	chr3:46661640	NA	-0.51	-10.99	-0.45	3.97e-25	Coronary artery disease;
LGG	cis	rs8112449	0.930	rs8112675	chr19:10538719	C/T	cg21868191	chr19:10515988	NA	-0.47	-7.9	-0.34	1.98e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs2953145	0.568	rs2975752	chr2:241521327	A/G	cg07929629	chr2:241523174	NA	0.59	9.83	0.42	7.87e-21	Bipolar disorder;
LGG	cis	rs9527	0.830	rs11191440	chr10:104641511	G/A	cg04362960	chr10:104952993	NT5C2	0.58	10.16	0.43	4.97e-22	Arsenic metabolism;
LGG	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	8.35	0.36	8.01e-16	Menarche (age at onset);
LGG	cis	rs4474465	1.000	rs11604969	chr11:78179293	C/T	cg27205649	chr11:78285834	NARS2	0.51	8.58	0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs975722	0.638	rs213964	chr7:117229336	A/G	cg10524701	chr7:117356490	CTTNBP2	0.47	10.44	0.44	4.61e-23	Coronary artery disease;
LGG	cis	rs10435719	0.902	rs6601633	chr8:11805173	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.85	-0.3	2.34e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2013441	0.508	rs35770292	chr17:19973539	A/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	trans	rs208520	0.690	rs866452	chr6:66849936	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.52	-0.63	4.33e-53	Exhaled nitric oxide output;
LGG	cis	rs17767392	1.000	rs34873919	chr14:71780741	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.34e-18	Mitral valve prolapse;
LGG	cis	rs4727027	0.933	rs4725800	chr7:148862516	C/G	cg23583168	chr7:148888333	NA	-0.84	-16.33	-0.6	1.14e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg06221963	chr1:154839813	KCNN3	-0.51	-9.65	-0.41	3.36e-20	Prostate cancer;
LGG	cis	rs12477438	0.798	rs4850894	chr2:99629396	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg05925327	chr15:68127851	NA	-0.32	-6.71	-0.3	5.84e-11	Obesity;
LGG	cis	rs1371867	0.817	rs1788185	chr8:101335529	T/C	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs4262150	0.672	rs72806775	chr5:152345941	C/T	cg12297329	chr5:152029980	NA	-0.55	-8.76	-0.38	3.82e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9796	0.636	rs1983400	chr15:41373029	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.88	-0.42	4.99e-21	Menopause (age at onset);
LGG	cis	rs6831352	0.879	rs1984362	chr4:100070973	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.45	-0.37	3.84e-16	Alcohol dependence;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25072359	chr17:41440525	NA	0.54	10.17	0.43	4.73e-22	Menopause (age at onset);
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg04703951	chr17:43578652	NA	0.38	7.6	0.33	1.71e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11190604	0.943	rs3750632	chr10:102279295	G/C	cg07570687	chr10:102243282	WNT8B	0.44	7.34	0.32	9.85e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.01e-23	Lymphocyte counts;
LGG	cis	rs12545109	0.800	rs2670055	chr8:57421575	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.93	-0.31	1.38e-11	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.05	-0.46	2.39e-25	Hemoglobin concentration;
LGG	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs72945132	0.678	rs12786421	chr11:70235314	G/C	cg14191688	chr11:70257035	CTTN	0.55	8.31	0.36	1.07e-15	Coronary artery disease;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg02002194	chr4:3960332	NA	0.5	9.61	0.41	4.66e-20	Neuroticism;
LGG	cis	rs11170468	0.697	rs7972884	chr12:39433338	G/A	cg26384229	chr12:38710491	ALG10B	-0.43	-6.84	-0.3	2.44e-11	Body mass index;
LGG	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.58	0.59	2.62e-44	Body mass index;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.8	0.34	4.18e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.61	-0.37	1.13e-16	Hemoglobin concentration;
LGG	cis	rs36051895	0.659	rs12349508	chr9:5184222	T/G	cg02405213	chr9:5042618	JAK2	-0.82	-14.45	-0.56	2.62e-39	Pediatric autoimmune diseases;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00166722	chr3:10149974	C3orf24	0.55	8.91	0.38	1.16e-17	Alzheimer's disease;
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg00294572	chr6:26285232	NA	0.42	7.57	0.33	2.11e-13	Educational attainment;
LGG	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg16414030	chr3:133502952	NA	-0.64	-11.41	-0.47	9.59e-27	Iron status biomarkers;
LGG	cis	rs56235845	0.964	rs11746443	chr5:176798306	G/A	cg06060754	chr5:176797920	RGS14	0.47	7.54	0.33	2.48e-13	Hemoglobin concentration;Hematocrit;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg20295408	chr7:1910781	MAD1L1	-0.4	-7.07	-0.31	5.73e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.01	0.52	3.3e-33	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs10055993	chr5:264296	A/C	cg22857025	chr5:266934	NA	-1.57	-25.04	-0.76	4.15e-88	Breast cancer;
LGG	cis	rs12497850	0.931	rs7643368	chr3:48992855	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.83	0.3	2.74e-11	Parkinson's disease;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.72	0.38	4.85e-17	Bipolar disorder;
LGG	trans	rs2562456	0.833	rs62107547	chr19:21524047	A/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg05973401	chr12:123451056	ABCB9	0.48	6.8	0.3	3.24e-11	Platelet count;
LGG	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.56	0.33	2.17e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg27336068	chr10:1336103	ADARB2	-0.41	-9.24	-0.39	8.81e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.0	-0.52	3.62e-33	Alzheimer's disease;
LGG	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.13	-0.55	6.07e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg21775007	chr8:11205619	TDH	0.41	6.91	0.31	1.63e-11	Mood instability;
LGG	cis	rs4700695	0.841	rs706679	chr5:65317181	A/G	cg21114390	chr5:65439923	SFRS12	-0.57	-7.19	-0.32	2.69e-12	Facial morphology (factor 19);
LGG	cis	rs503734	0.620	rs2682383	chr3:101110145	T/A	cg27318481	chr3:100970896	IMPG2	-0.36	-7.24	-0.32	1.88e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg15017067	chr4:17643749	FAM184B	0.3	6.85	0.3	2.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg07148914	chr20:33460835	GGT7	-0.51	-8.4	-0.36	5.45e-16	Height;
LGG	cis	rs7851660	0.874	rs2417576	chr9:100628707	C/T	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs7727544	1.000	rs7727544	chr5:131590534	C/T	cg24060327	chr5:131705240	SLC22A5	-0.41	-7.0	-0.31	8.75e-12	Blood metabolite levels;
LGG	cis	rs6977660	0.652	rs10254427	chr7:19816240	C/T	cg07541023	chr7:19748670	TWISTNB	0.54	8.0	0.35	9.89e-15	Thyroid stimulating hormone;
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.36	0.4	3.42e-19	Monocyte count;
LGG	cis	rs11867479	0.600	rs72856781	chr17:68060451	A/T	cg02868298	chr17:68066712	NA	0.35	7.0	0.31	9.01e-12	Height;
LGG	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg07636037	chr3:49044803	WDR6	1.11	28.45	0.8	1.07e-103	Parkinson's disease;
LGG	cis	rs4731207	0.698	rs10954045	chr7:124498155	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs9900972	0.549	rs11077399	chr17:76864175	C/T	cg00961940	chr17:76876995	TIMP2	-0.29	-6.65	-0.3	8.48e-11	Obesity-related traits;
LGG	trans	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs7760949	0.889	rs9396262	chr6:13927418	C/T	cg27413430	chr6:13925136	RNF182	0.49	7.38	0.32	7.42e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs11758351	0.500	rs16891404	chr6:26203970	G/A	cg01420254	chr6:26195488	NA	0.98	7.4	0.33	6.45e-13	Gout;Renal underexcretion gout;
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg16141378	chr3:129829833	LOC729375	0.45	10.76	0.45	3.07e-24	Mood instability;
LGG	trans	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg23484912	chr5:273055	PDCD6	0.47	9.29	0.4	6.09e-19	Pancreatic cancer;
LGG	cis	rs751728	1.000	rs747695	chr6:33736672	G/A	cg25922239	chr6:33757077	LEMD2	0.67	11.51	0.47	4.07e-27	Crohn's disease;
LGG	cis	rs4731207	0.565	rs7777126	chr7:124599742	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.13	0.39	2.13e-18	Blood metabolite levels;
LGG	cis	rs11190604	0.767	rs10883481	chr10:102165021	G/A	cg07080220	chr10:102295463	HIF1AN	0.58	10.07	0.42	1.04e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3812831	0.669	rs382913	chr13:114928255	G/T	cg06611532	chr13:114900021	NA	0.29	7.24	0.32	1.91e-12	Schizophrenia;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.15e-11	Life satisfaction;
LGG	cis	rs11627756	0.846	rs1190336	chr14:103108478	A/G	cg12046867	chr14:103022105	NA	0.38	7.15	0.32	3.4e-12	Mean platelet volume;
LGG	cis	rs12367572	0.620	rs1857924	chr12:45344212	T/G	cg04608330	chr12:45269318	NELL2	-0.41	-6.68	-0.3	7e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg12310025	chr6:25882481	NA	-0.41	-7.35	-0.32	8.94e-13	Height;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg13009111	chr11:71350975	NA	-0.31	-6.68	-0.3	6.9e-11	Triglycerides;
LGG	cis	rs5758511	0.680	rs5758686	chr22:42655377	G/T	cg15128208	chr22:42549153	NA	0.75	11.62	0.48	1.47e-27	Birth weight;
LGG	cis	rs7432375	0.899	rs6439655	chr3:136466599	A/G	cg21827317	chr3:136751795	NA	-0.42	-7.52	-0.33	2.93e-13	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs12493885	0.818	rs6800048	chr3:153766181	T/C	cg12800244	chr3:153838788	SGEF	-0.77	-9.28	-0.4	6.7e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs55692411	0.537	rs35375092	chr3:50065274	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-8.13	-0.35	3.84e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg06074448	chr4:187884817	NA	-0.58	-12.75	-0.51	4.11e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1577917	1.000	rs10455456	chr6:86670322	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.34	-0.43	1.07e-22	Hip circumference adjusted for BMI;
LGG	cis	rs1620921	0.595	rs9458048	chr6:161272317	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs8073060	0.586	rs72828038	chr17:33893908	C/A	cg19694781	chr19:47549865	TMEM160	1.11	16.51	0.61	1.67e-48	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3857536	0.740	rs7763555	chr6:66889930	C/T	cg07460842	chr6:66804631	NA	-0.48	-8.39	-0.36	6.13e-16	Blood trace element (Cu levels);
LGG	cis	rs17597773	0.674	rs903319	chr1:220985811	A/G	cg15450098	chr1:221057561	HLX	-0.38	-6.78	-0.3	3.63e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7236492	0.688	rs73494217	chr18:77186200	G/A	cg15644404	chr18:77186268	NFATC1	-0.8	-9.78	-0.41	1.17e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2084898	0.550	rs470941	chr11:119999755	C/T	cg13907859	chr11:120009124	TRIM29	-0.45	-7.69	-0.34	9.05e-14	Stroke (pediatric);
LGG	cis	rs62400317	0.859	rs56357385	chr6:45203591	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.21	-0.43	3.37e-22	Total body bone mineral density;
LGG	cis	rs5015933	1.000	rs10760397	chr9:128133207	T/C	cg14078157	chr9:128172775	NA	-0.36	-6.81	-0.3	3.02e-11	Body mass index;
LGG	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg26384229	chr12:38710491	ALG10B	0.55	10.06	0.42	1.13e-21	Morning vs. evening chronotype;
LGG	cis	rs72781680	0.799	rs17508218	chr2:23976536	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	8.95	0.38	8.91e-18	Lymphocyte counts;
LGG	cis	rs9911578	0.867	rs72628394	chr17:57121313	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.92	-0.59	7.99e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2470578	0.755	rs2470586	chr3:17297663	C/T	cg20981856	chr3:17787350	NA	-0.36	-6.8	-0.3	3.15e-11	Schizophrenia;
LGG	cis	rs11608355	0.515	rs12822282	chr12:109923207	G/A	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs1010254	0.510	rs72808303	chr5:151718049	C/T	cg12297329	chr5:152029980	NA	-0.5	-7.19	-0.32	2.6e-12	Optic nerve measurement (cup area);
LGG	trans	rs9650657	0.613	rs877116	chr8:10712945	G/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.0	-0.31	8.79e-12	Neuroticism;
LGG	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.98	0.54	2.68e-37	Colorectal cancer;
LGG	trans	rs7824557	0.564	rs2736302	chr8:11236419	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.73	0.34	6.73e-14	Retinal vascular caliber;
LGG	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg18551225	chr6:44695536	NA	-0.69	-11.22	-0.46	5.26e-26	Total body bone mineral density;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg05896524	chr21:47604654	C21orf56	-0.65	-10.97	-0.45	4.58e-25	Testicular germ cell tumor;
LGG	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs4242434	0.699	rs878051	chr8:22483836	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.8	-0.34	4.18e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11166927	0.562	rs4736095	chr8:140802744	T/C	cg16909799	chr8:140841666	TRAPPC9	0.4	7.32	0.32	1.09e-12	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.8	-0.41	1e-20	Alcohol dependence;
LGG	cis	rs2119480	0.927	rs11069863	chr13:111329665	T/C	cg24331049	chr13:111365604	ING1	0.63	9.44	0.4	1.78e-19	Diastolic blood pressure;
LGG	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs3857067	0.934	rs2865336	chr4:95029357	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.85	-0.34	2.84e-14	QT interval;
LGG	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.42	0.4	2.18e-19	Aortic root size;
LGG	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.93	-0.45	7.06e-25	Neuroticism;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-15.42	-0.58	1.39e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.57e-15	Bone mineral density;
LGG	cis	rs10028773	0.666	rs12498657	chr4:120262866	G/C	cg09307838	chr4:120376055	NA	0.68	11.79	0.48	3.13e-28	Educational attainment;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs3768617	0.510	rs10797838	chr1:183077020	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.1	0.39	2.72e-18	Fuchs's corneal dystrophy;
LGG	cis	rs17270561	0.609	rs1408271	chr6:25859621	T/A	cg17691542	chr6:26056736	HIST1H1C	0.69	11.24	0.46	4.42e-26	Iron status biomarkers;
LGG	trans	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.14	0.31	3.74e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg21926883	chr2:100939477	LONRF2	-0.66	-15.22	-0.58	1.09e-42	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.37	-0.32	7.87e-13	Bladder cancer;
LGG	cis	rs9354308	0.764	rs4334963	chr6:66606476	A/C	cg07460842	chr6:66804631	NA	-0.4	-6.78	-0.3	3.65e-11	Metabolite levels;
LGG	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21659725	chr3:3221576	CRBN	0.93	20.77	0.69	3.33e-68	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg03709012	chr19:19516395	GATAD2A	-0.84	-17.01	-0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg07362569	chr17:61921086	SMARCD2	0.49	9.4	0.4	2.52e-19	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.29e-23	Prudent dietary pattern;
LGG	cis	rs6964587	0.626	rs404	chr7:91544316	G/T	cg17063962	chr7:91808500	NA	-0.45	-8.15	-0.35	3.54e-15	Breast cancer;
LGG	cis	rs10911232	0.507	rs10752891	chr1:183023283	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.66	-0.3	7.62e-11	Coronary artery disease;
LGG	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg26818010	chr10:134567672	INPP5A	-0.71	-11.09	-0.46	1.68e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2692947	0.526	rs58719199	chr2:96578247	G/A	cg22654517	chr2:96458247	NA	0.38	7.59	0.33	1.74e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs72991	0.639	rs297528	chr11:121243423	A/G	cg27192990	chr6:129479024	LAMA2	-0.52	-7.51	-0.33	3.06e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs5769765	0.908	rs138866	chr22:50205903	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.68	9.86	0.42	5.99e-21	Schizophrenia;
LGG	cis	rs6500395	1.000	rs7196823	chr16:48616278	G/A	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02071572	chr4:1403502	NA	0.41	7.11	0.31	4.41e-12	Longevity;
LGG	cis	rs2963155	0.518	rs2963151	chr5:142734151	T/C	cg17617527	chr5:142782415	NR3C1	0.98	12.99	0.52	4.2e-33	Breast cancer;
LGG	cis	rs9911578	0.785	rs10853008	chr17:56993407	T/C	cg05425664	chr17:57184151	TRIM37	0.67	10.12	0.43	6.94e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4819852	0.752	rs2238783	chr22:19972452	C/G	cg07821417	chr22:19972146	ARVCF	0.49	10.58	0.44	1.44e-23	Pulse pressure;
LGG	trans	rs9354308	0.868	rs9363460	chr6:66557539	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.49	-8.29	-0.36	1.21e-15	Metabolite levels;
LGG	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.29	-0.32	1.38e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs858239	0.600	rs2072368	chr7:23146112	C/T	cg23682824	chr7:23144976	KLHL7	0.44	7.46	0.33	4.21e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.26	-0.32	1.69e-12	Total cholesterol levels;
LGG	cis	rs4891159	0.527	rs34956524	chr18:74130480	A/G	cg24786174	chr18:74118243	ZNF516	0.68	17.49	0.63	6.01e-53	Longevity;
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	0.3	7.84	0.34	3.23e-14	IgG glycosylation;
LGG	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg27165867	chr14:105738592	BRF1	-0.46	-7.35	-0.32	9.16e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs561341	0.883	rs1034627	chr17:30219569	C/T	cg13647721	chr17:30228624	UTP6	0.65	8.6	0.37	1.22e-16	Hip circumference adjusted for BMI;
LGG	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg17294928	chr15:75287854	SCAMP5	-0.59	-10.94	-0.45	6.15e-25	Breast cancer;
LGG	cis	rs55665837	0.540	rs10832294	chr11:14747427	C/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.42	-0.33	5.56e-13	Vitamin D levels;
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.6	-0.33	1.63e-13	Retinal vascular caliber;
LGG	cis	rs8114671	0.562	rs34837802	chr20:33424908	C/G	cg24642439	chr20:33292090	TP53INP2	0.43	6.74	0.3	4.69e-11	Height;
LGG	cis	rs75059851	0.756	rs55747998	chr11:133840793	C/T	cg17703048	chr11:133852993	NA	-0.86	-15.79	-0.59	3.08e-45	Schizophrenia;
LGG	trans	rs2204008	0.805	rs3863360	chr12:37966432	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.14e-20	Bladder cancer;
LGG	cis	rs115344852	0.598	rs2191035	chr6:28434943	A/G	cg13525197	chr6:28411240	ZSCAN23	-0.49	-7.44	-0.33	5e-13	Epithelial ovarian cancer;
LGG	cis	rs2046867	0.862	rs62251646	chr3:72805787	T/C	cg25664220	chr3:72788482	NA	-0.31	-8.81	-0.38	2.58e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs989128	0.600	rs8082568	chr17:48629312	G/C	cg20467136	chr17:48638190	CACNA1G	0.47	7.01	0.31	8.42e-12	Type 2 diabetes;
LGG	cis	rs1707322	0.963	rs4508055	chr1:46257731	A/T	cg03146154	chr1:46216737	IPP	0.57	10.51	0.44	2.57e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.78	0.3	3.65e-11	Menopause (age at onset);
LGG	trans	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg24247370	chr13:99142703	STK24	-0.43	-7.54	-0.33	2.54e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg02959939	chr21:47813025	PCNT	-0.3	-6.84	-0.3	2.46e-11	Testicular germ cell tumor;
LGG	cis	rs7712401	0.601	rs34707663	chr5:122320463	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.78	-0.3	3.73e-11	Mean platelet volume;
LGG	cis	rs3857747	0.931	rs4360204	chr7:40387459	T/C	cg00420559	chr7:40367873	C7orf10	0.42	8.16	0.35	3.22e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs56283067	0.810	rs10948155	chr6:44687957	T/C	cg18551225	chr6:44695536	NA	-0.68	-12.27	-0.5	3.78e-30	Total body bone mineral density;
LGG	trans	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg06521331	chr12:34319734	NA	0.42	7.03	0.31	7.45e-12	Morning vs. evening chronotype;
LGG	cis	rs3096299	0.933	rs2965824	chr16:89455306	A/G	cg06640241	chr16:89574553	SPG7	0.68	11.5	0.47	4.26e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs2842992	0.915	rs2758321	chr6:160071611	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.66	10.68	0.44	5.92e-24	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13424612	0.965	rs58652766	chr2:240904884	G/A	cg01812947	chr2:240904978	NDUFA10	0.43	7.16	0.32	3.29e-12	Odorant perception (isobutyraldehyde);
LGG	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs755249	0.567	rs2036463	chr1:39688075	G/A	cg18385671	chr1:39797026	MACF1	0.43	7.13	0.31	3.84e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg03528353	chr17:61819722	STRADA	0.44	7.54	0.33	2.46e-13	Prudent dietary pattern;
LGG	cis	rs854037	0.759	rs34275130	chr5:57086338	T/C	cg08523694	chr5:57076192	NA	0.6	7.26	0.32	1.63e-12	Birth weight;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg13384949	chr1:2383501	NA	-0.61	-13.44	-0.53	5.19e-35	Non-obstructive azoospermia;
LGG	cis	rs7727544	0.582	rs3749756	chr5:131534499	C/T	cg07395648	chr5:131743802	NA	-0.4	-8.68	-0.37	6.71e-17	Blood metabolite levels;
LGG	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg06431347	chr2:235935754	SH3BP4	-0.41	-8.98	-0.38	7.07e-18	Dialysis-related mortality;
LGG	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs826838	0.967	rs980572	chr12:39127673	A/C	cg06521331	chr12:34319734	NA	-0.43	-7.72	-0.34	7.43e-14	Heart rate;
LGG	trans	rs1478897	0.510	rs11786148	chr8:11423781	C/G	cg02002194	chr4:3960332	NA	0.41	7.01	0.31	8.39e-12	Systemic lupus erythematosus;
LGG	cis	rs988958	0.527	rs1440098	chr2:42291028	A/G	cg27252766	chr2:42229092	NA	0.37	6.9	0.31	1.7e-11	Hypospadias;
LGG	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg13560919	chr6:33536144	NA	-0.42	-7.45	-0.33	4.65e-13	Crohn's disease;
LGG	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.17	-0.32	2.92e-12	Blood metabolite levels;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs7662987	0.540	rs2851257	chr4:100039499	G/C	cg13256891	chr4:100009986	ADH5	0.56	9.59	0.41	5.47e-20	Smoking initiation;
LGG	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg23335576	chr14:104009727	NA	0.51	8.95	0.38	8.4e-18	Reticulocyte count;
LGG	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	13.77	0.54	2.07e-36	Subjective well-being;
LGG	trans	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.37	0.4	3.17e-19	Diabetic kidney disease;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.56	10.24	0.43	2.59e-22	Longevity;
LGG	cis	rs10489202	1.000	rs11587594	chr1:167989180	A/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.24	-0.43	2.62e-22	Schizophrenia;
LGG	cis	rs3820068	0.581	rs72645877	chr1:15928106	G/T	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs6988985	0.703	rs10098023	chr8:143949604	T/C	cg10324643	chr8:143916377	GML	0.38	7.56	0.33	2.12e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg06640241	chr16:89574553	SPG7	0.93	17.77	0.64	2.92e-54	Multiple myeloma (IgH translocation);
LGG	cis	rs9309711	0.961	rs11678655	chr2:3476234	T/G	cg10845886	chr2:3471009	TTC15	-0.74	-14.88	-0.57	3.22e-41	Neurofibrillary tangles;
LGG	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs721399	0.752	rs35246381	chr8:18272535	C/T	cg18736775	chr8:18248649	NAT2	0.49	8.33	0.36	9.5e-16	Blood metabolite levels;
LGG	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.95	0.31	1.27e-11	Parkinson's disease;
LGG	cis	rs1816752	0.819	rs6490917	chr13:24997257	G/T	cg22771759	chr13:24902376	NA	0.39	6.66	0.3	7.74e-11	Obesity-related traits;
LGG	cis	rs7084402	0.935	rs11006192	chr10:60343638	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.17	-0.32	2.93e-12	Refractive error;
LGG	cis	rs1949733	0.598	rs869602	chr4:8535371	G/T	cg13073564	chr4:8508604	NA	0.42	7.4	0.33	6.48e-13	Response to antineoplastic agents;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19524238	chr7:2802976	GNA12	0.38	8.7	0.37	5.82e-17	Height;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs919433	1.000	rs7422899	chr2:198163527	G/C	cg00792783	chr2:198669748	PLCL1	-0.43	-6.75	-0.3	4.44e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.52	-0.53	2.51e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-9.86	-0.42	5.89e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9807989	0.507	rs1420096	chr2:103010912	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.77	-0.48	3.61e-28	Obesity-related traits;
LGG	cis	rs11577318	0.853	rs1071849	chr1:26646726	A/G	cg04990556	chr1:26633338	UBXN11	-0.49	-7.62	-0.33	1.46e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg05985134	chr18:33552581	C18orf21	0.64	10.16	0.43	4.92e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.39	0.32	6.93e-13	Menopause (age at onset);
LGG	cis	rs11748327	0.580	rs10079900	chr5:4009402	C/G	cg01025095	chr5:4101132	NA	-0.42	-6.83	-0.3	2.72e-11	Myocardial infarction;
LGG	cis	rs2797160	1.000	rs1832980	chr6:125997444	T/G	cg05901451	chr6:126070800	HEY2	-0.42	-7.03	-0.31	7.56e-12	Endometrial cancer;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs1021993	0.545	rs4844809	chr1:209519772	G/C	cg24446417	chr1:209558027	NA	-0.67	-9.8	-0.41	9.84e-21	Gut microbiome composition (winter);
LGG	cis	rs1008375	1.000	rs11722037	chr4:17683811	G/A	cg18681998	chr4:17616180	MED28	0.82	18.25	0.65	1.86e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28830936	0.966	rs1918310	chr15:42065253	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.12	-0.52	1.23e-33	Diastolic blood pressure;
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg05793240	chr7:2802953	GNA12	0.33	8.09	0.35	5.45e-15	Height;
LGG	cis	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs4356203	0.870	rs214910	chr11:17242789	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs4780401	0.609	rs4781142	chr16:11808806	T/C	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.91	-0.51	8.9e-33	Rheumatoid arthritis;
LGG	cis	rs2463822	0.583	rs7129536	chr11:62030829	C/T	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.17	-0.49	9.17e-30	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg23188684	chr11:67383651	NA	-0.58	-10.17	-0.43	4.58e-22	Mean corpuscular volume;
LGG	cis	rs17301259	0.548	rs2519944	chr7:88329995	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-6.88	-0.3	1.9e-11	Heschl's gyrus morphology;
LGG	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg08250081	chr4:10125330	NA	-0.48	-9.4	-0.4	2.51e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs61931739	0.546	rs61927758	chr12:33712017	T/C	cg06521331	chr12:34319734	NA	0.39	6.76	0.3	4.06e-11	Morning vs. evening chronotype;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.27	0.46	3.22e-26	Tonsillectomy;
LGG	cis	rs12780845	0.540	rs2273734	chr10:17216556	C/T	cg01003015	chr10:17271136	VIM	0.43	7.28	0.32	1.48e-12	Homocysteine levels;
LGG	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg06917634	chr15:78832804	PSMA4	-0.61	-10.96	-0.45	5.34e-25	Sudden cardiac arrest;
LGG	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-9.81	-0.41	8.9e-21	Pancreatic cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27134659	chr14:94640653	PPP4R4	0.6	6.92	0.31	1.55e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg04226714	chr8:49833948	SNAI2	-0.49	-8.91	-0.38	1.2e-17	Life satisfaction;
LGG	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08109568	chr15:31115862	NA	-0.54	-9.53	-0.41	8.56e-20	Huntington's disease progression;
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.14	-0.43	5.95e-22	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs2274273	0.870	rs2016931	chr14:55842332	C/G	cg04306507	chr14:55594613	LGALS3	0.61	17.12	0.62	2.91e-51	Protein biomarker;
LGG	cis	rs7208859	0.673	rs3764420	chr17:29164154	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8067287	0.595	rs62065423	chr17:16828571	C/T	cg26910001	chr17:16838321	NA	-0.47	-8.76	-0.38	3.79e-17	Diabetic kidney disease;
LGG	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg23564243	chr22:46441127	LOC100271722	-0.44	-7.61	-0.33	1.51e-13	Dupuytren's disease;
LGG	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-10.99	-0.45	3.93e-25	Platelet distribution width;
LGG	cis	rs3820928	0.605	rs4675124	chr2:227802354	G/A	cg11843606	chr2:227700838	RHBDD1	-0.58	-10.95	-0.45	5.82e-25	Pulmonary function;
LGG	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.31	-0.32	1.19e-12	Triglycerides;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.2e-20	Tonsillectomy;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	0.716	rs76313799	chr3:41931751	A/C	cg03022575	chr3:42003672	ULK4	0.82	9.5	0.4	1.11e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11229555	1.000	rs11229545	chr11:58386650	A/G	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg03351412	chr1:154909251	PMVK	0.66	12.74	0.51	4.56e-32	Prostate cancer;
LGG	cis	rs7100689	0.784	rs4934153	chr10:82191255	T/C	cg01528321	chr10:82214614	TSPAN14	1.07	21.13	0.7	7.35e-70	Post bronchodilator FEV1;
LGG	cis	rs8141529	0.600	rs916332	chr22:29308414	C/T	cg15103426	chr22:29168792	CCDC117	0.62	7.11	0.31	4.32e-12	Lymphocyte counts;
LGG	cis	rs77633900	0.772	rs2469554	chr15:76642700	G/C	cg21673338	chr15:77095150	SCAPER	-0.62	-8.03	-0.35	8.2e-15	Non-glioblastoma glioma;Glioma;
LGG	trans	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg21775007	chr8:11205619	TDH	0.51	8.47	0.37	3.29e-16	Mood instability;
LGG	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg12165864	chr7:66369176	NA	0.58	9.49	0.4	1.26e-19	Corneal structure;
LGG	cis	rs12477438	0.501	rs6761390	chr2:100106797	C/A	cg23527387	chr2:100056660	REV1	0.42	9.33	0.4	4.39e-19	Chronic sinus infection;
LGG	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.96	0.31	1.17e-11	Resting heart rate;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg04267008	chr7:1944627	MAD1L1	0.45	7.62	0.33	1.41e-13	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs1707322	0.721	rs12037803	chr1:46156492	A/G	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9937943	0.673	rs12922972	chr16:74494522	T/A	cg01733217	chr16:74700730	RFWD3	0.67	9.18	0.39	1.42e-18	Neutrophil percentage of white cells;
LGG	trans	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg20290983	chr6:43655470	MRPS18A	-1.1	-24.61	-0.75	4.11e-86	IgG glycosylation;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.36	4.24e-16	Bipolar disorder;
LGG	cis	rs1862618	0.802	rs2591949	chr5:56132627	T/C	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	cis	rs1881797	1.000	rs66845073	chr1:247688010	C/T	cg18198730	chr1:247681584	NA	0.73	12.28	0.5	3.21e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg00579200	chr11:133705235	NA	0.59	11.38	0.47	1.31e-26	Childhood ear infection;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	trans	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg02002194	chr4:3960332	NA	-0.38	-7.07	-0.31	5.75e-12	Joint mobility (Beighton score);
LGG	cis	rs2976388	0.507	rs2572874	chr8:143837219	C/T	cg06565975	chr8:143823917	SLURP1	0.35	8.78	0.38	3.11e-17	Urinary tract infection frequency;
LGG	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg12046867	chr14:103022105	NA	-0.67	-11.76	-0.48	4.03e-28	Platelet count;
LGG	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg25214090	chr10:38739885	LOC399744	0.64	11.25	0.46	3.85e-26	Corneal astigmatism;
LGG	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.14	-0.58	2.4e-42	Chronic sinus infection;
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-9.38	-0.4	2.95e-19	Schizophrenia;
LGG	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg18252515	chr7:66147081	NA	-0.75	-12.01	-0.49	4.22e-29	Corneal structure;
LGG	cis	rs7666738	0.791	rs1967978	chr4:98966152	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1459104	1.000	rs116220196	chr11:55293221	C/T	cg15704280	chr7:45808275	SEPT13	0.67	6.67	0.3	7.25e-11	Body mass index;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.62e-18	Menopause (age at onset);
LGG	cis	rs8054556	0.669	rs4787491	chr16:30015337	A/G	cg06326092	chr16:30034487	C16orf92	0.34	6.82	0.3	2.82e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg02524346	chr8:600233	NA	1.24	11.31	0.47	2.29e-26	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs67852463	chr3:10157205	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-13.93	-0.54	4.2e-37	Alzheimer's disease;
LGG	cis	rs3820928	1.000	rs12615988	chr2:227769000	A/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.38	-0.32	7.37e-13	Pulmonary function;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg18245976	chr7:158708271	WDR60	0.46	7.72	0.34	7.41e-14	Height;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.68	0.37	6.98e-17	Lung cancer;
LGG	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.2	-0.39	1.26e-18	Triglycerides;
LGG	cis	rs4950322	0.570	rs17356233	chr1:146740502	C/G	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs2463822	0.925	rs6863	chr11:62160725	G/T	cg06239285	chr11:62104954	ASRGL1	-1.12	-14.93	-0.57	1.99e-41	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs10937275	0.624	rs17774519	chr3:186665247	G/A	cg24050613	chr3:186648279	ST6GAL1	0.84	8.72	0.38	5.06e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg03788504	chr6:150331562	NA	-0.62	-14.01	-0.55	1.96e-37	Alopecia areata;
LGG	trans	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.78	0.38	3.21e-17	Mood instability;
LGG	cis	rs4974559	0.895	rs57037487	chr4:1386652	A/G	cg02980000	chr4:1222292	CTBP1	0.68	10.36	0.43	9.13e-23	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25733915	chr17:40829168	PLEKHH3	0.56	8.73	0.38	4.5e-17	Gut microbiome composition (summer);
LGG	cis	rs7493	0.755	rs17886036	chr7:94987727	C/A	cg17330251	chr7:94953956	PON1	-0.43	-8.52	-0.37	2.24e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg16885296	chr6:26284938	NA	0.41	8.79	0.38	3.01e-17	Educational attainment;
LGG	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.08	-0.42	9.65e-22	Type 2 diabetes;
LGG	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs910187	0.597	rs1883885	chr20:45795456	T/C	cg27589058	chr20:45804311	EYA2	-0.3	-7.61	-0.33	1.53e-13	Migraine;
LGG	cis	rs8180040	0.676	rs11130114	chr3:47154651	T/G	cg27129171	chr3:47204927	SETD2	0.86	16.7	0.61	2.45e-49	Colorectal cancer;
LGG	cis	rs9814567	1.000	rs6790466	chr3:134197740	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.6	-0.51	1.62e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	cis	rs73416724	1.000	rs80193186	chr6:43362324	G/T	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.84e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7408868	1.000	rs7250232	chr19:15277199	C/T	cg14696996	chr19:15285081	NOTCH3	1.02	12.74	0.51	4.36e-32	Pulse pressure;
LGG	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg18709589	chr6:96969512	KIAA0776	0.45	7.52	0.33	2.83e-13	Migraine;Coronary artery disease;
LGG	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg27624424	chr6:160112604	SOD2	0.65	9.51	0.4	1.08e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs79839061	0.666	rs62297063	chr4:869708	G/A	cg07828340	chr4:882639	GAK	0.86	9.13	0.39	2.1e-18	Intelligence (multi-trait analysis);
LGG	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg25457927	chr22:38595422	NA	0.43	10.92	0.45	7.33e-25	Cutaneous nevi;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.45	-0.37	3.75e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg07636037	chr3:49044803	WDR6	0.44	6.77	0.3	4e-11	Resting heart rate;
LGG	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg21775007	chr8:11205619	TDH	-0.47	-7.43	-0.33	5.15e-13	Morning vs. evening chronotype;
LGG	cis	rs6586163	1.000	rs1324551	chr10:90751516	C/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.87	-0.3	2.07e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4774899	0.752	rs2951901	chr15:57336750	A/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.83	-0.3	2.69e-11	Urinary tract infection frequency;
LGG	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg14673194	chr17:80132900	CCDC57	-0.46	-8.39	-0.36	5.82e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7582720	1.000	rs115400054	chr2:203676105	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.05	0.39	3.89e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1408799	0.678	rs7021368	chr9:12757832	T/C	cg05274944	chr9:12693694	TYRP1	0.35	8.43	0.36	4.36e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs1385374	1.000	rs1385374	chr12:129300694	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	6.8	0.3	3.26e-11	Systemic lupus erythematosus;
LGG	cis	rs1577917	0.958	rs12207374	chr6:86656645	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2e-33	Response to antipsychotic treatment;
LGG	cis	rs950169	0.512	rs4374136	chr15:84645007	C/G	cg24253500	chr15:84953950	NA	0.44	7.05	0.31	6.66e-12	Schizophrenia;
LGG	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg08847533	chr14:75593920	NEK9	-0.47	-8.55	-0.37	1.83e-16	Height;
LGG	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-11.08	-0.46	1.75e-25	Body mass index;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02569437	chr6:42947051	PEX6	-0.42	-7.11	-0.31	4.54e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs858239	0.600	rs10237755	chr7:23131564	A/G	cg23682824	chr7:23144976	KLHL7	0.44	7.66	0.34	1.08e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg09044154	chr16:88155775	NA	-0.5	-7.56	-0.33	2.13e-13	Menopause (age at onset);
LGG	cis	rs10936602	0.527	rs6793160	chr3:169535266	A/C	cg17737146	chr3:169530037	LRRC34	-0.36	-6.8	-0.3	3.14e-11	Renal cell carcinoma;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.38	0.36	6.39e-16	Platelet count;
LGG	cis	rs7444	0.941	rs5749485	chr22:21938224	A/C	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs7503807	0.515	rs12453034	chr17:78682756	G/A	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	cis	rs12049351	0.665	rs7534252	chr1:229569592	C/T	cg13547644	chr1:229569608	ACTA1	0.32	6.99	0.31	9.77e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs9326248	0.590	rs2542063	chr11:116684767	C/T	cg20608306	chr11:116969690	SIK3	0.29	7.87	0.34	2.6e-14	Blood protein levels;
LGG	cis	rs7166081	1.000	rs4776908	chr15:67540087	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.0	-0.31	9.19e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg00142150	chr22:38071001	LGALS1	0.92	19.76	0.68	1.8e-63	Fat distribution (HIV);
LGG	cis	rs6546550	0.935	rs2872075	chr2:70068635	G/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.05	-0.35	7.15e-15	Prevalent atrial fibrillation;
LGG	cis	rs6558530	0.666	rs6558523	chr8:1702504	T/C	cg08198773	chr8:1697536	NA	0.44	7.82	0.34	3.62e-14	Systolic blood pressure;
LGG	cis	rs2742417	1.000	rs2249357	chr3:45758381	C/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2.07e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs8078723	1.000	rs4795412	chr17:38150604	C/T	cg17467752	chr17:38218738	THRA	0.74	13.96	0.54	3.36e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs1707322	0.752	rs11211146	chr1:46109794	T/C	cg03146154	chr1:46216737	IPP	0.57	10.83	0.45	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7226408	0.857	rs72888916	chr18:34521336	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs13102973	0.899	rs10212820	chr4:135899842	G/T	cg14419869	chr4:135874104	NA	-0.45	-8.18	-0.36	2.69e-15	Subjective well-being;
LGG	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg04617936	chr2:214353	NA	-0.4	-7.31	-0.32	1.21e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg18876405	chr7:65276391	NA	-0.64	-11.94	-0.49	7.46e-29	Aortic root size;
LGG	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.41	-0.44	6.08e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6032067	0.929	rs2233895	chr20:43850143	T/A	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs2836974	0.867	rs77959119	chr21:40542768	G/A	cg17971929	chr21:40555470	PSMG1	0.89	17.2	0.62	1.22e-51	Cognitive function;
LGG	cis	rs2075064	0.900	rs10760309	chr9:126792005	A/G	cg14112217	chr9:126806003	NA	0.37	7.4	0.33	6.55e-13	Waist circumference;
LGG	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.49	-0.33	3.46e-13	Triglycerides;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.51e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs13421350	0.579	rs12621278	chr2:173311553	A/G	cg15021238	chr2:173305865	ITGA6	-0.84	-9.6	-0.41	5.12e-20	Diabetic kidney disease;
LGG	cis	rs61931739	0.817	rs2203086	chr12:34232590	T/C	cg06521331	chr12:34319734	NA	-0.4	-6.97	-0.31	1.11e-11	Morning vs. evening chronotype;
LGG	trans	rs7746199	0.673	rs72845046	chr6:27575268	T/A	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg05863683	chr7:1912471	MAD1L1	0.46	9.08	0.39	3.12e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4731207	0.698	rs7799938	chr7:124521391	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg10189774	chr4:17578691	LAP3	0.41	7.23	0.32	2.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9341835	0.518	rs2758237	chr6:64218297	G/A	cg00787780	chr6:64151745	NA	-0.39	-6.97	-0.31	1.11e-11	Schizophrenia;
LGG	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg06494592	chr3:125709126	NA	-0.52	-6.7	-0.3	5.91e-11	Blood pressure (smoking interaction);
LGG	cis	rs2153535	0.580	rs7767780	chr6:8453462	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs11920090	0.722	rs16855567	chr3:170670279	C/T	cg09710316	chr3:170744871	SLC2A2	0.65	7.68	0.34	9.61e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg00405596	chr8:11794950	NA	-0.46	-7.12	-0.31	4.23e-12	Neuroticism;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg26513180	chr16:89883248	FANCA	1.02	9.73	0.41	1.71e-20	Skin colour saturation;
LGG	cis	rs1107366	0.618	rs1447657	chr3:125929471	A/G	cg17230874	chr3:125932073	NA	0.74	15.91	0.59	8.69e-46	Metabolite levels;
LGG	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	trans	rs4332037	0.624	rs73046339	chr7:1889300	G/A	cg22232500	chr2:134024266	NCKAP5	0.55	7.94	0.35	1.56e-14	Bipolar disorder;
LGG	cis	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg15145296	chr3:125709740	NA	-0.59	-7.71	-0.34	7.57e-14	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg15971980	chr6:150254442	NA	0.42	6.72	0.3	5.38e-11	Lung cancer;
LGG	cis	rs9522267	1.000	rs9522265	chr13:112195182	A/G	cg14952266	chr13:112191215	NA	0.37	6.96	0.31	1.14e-11	Hepatitis;
LGG	cis	rs7617773	0.817	rs3937	chr3:48312402	T/C	cg11946769	chr3:48343235	NME6	0.63	10.58	0.44	1.43e-23	Coronary artery disease;
LGG	cis	rs3008870	0.727	rs2755270	chr1:67474503	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.89	0.59	1.07e-45	Lymphocyte percentage of white cells;
LGG	cis	rs3741404	0.609	rs635139	chr11:63872210	A/G	cg18225595	chr11:63971243	STIP1	0.48	9.31	0.4	5.27e-19	Platelet count;
LGG	trans	rs11875185	0.510	rs80239651	chr18:55619275	G/A	cg15513957	chr14:69354734	ACTN1	-0.9	-9.04	-0.39	4.41e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6500395	1.000	rs6500395	chr16:48621402	T/C	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.02	-0.42	1.67e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs8065981	chr17:80091393	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.91	-0.35	1.88e-14	Life satisfaction;
LGG	cis	rs9815354	0.812	rs17215988	chr3:41851320	A/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	9.98e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg04617936	chr2:214353	NA	-0.4	-7.28	-0.32	1.46e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2050392	0.517	rs2480299	chr10:30743197	G/A	cg25182066	chr10:30743637	MAP3K8	-0.68	-14.71	-0.56	1.87e-40	Inflammatory bowel disease;
LGG	cis	rs4642101	0.793	rs6799179	chr3:12829095	A/C	cg05775895	chr3:12838266	CAND2	0.62	11.09	0.46	1.72e-25	QRS complex (12-leadsum);
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.46	7.13	0.31	4.01e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2404602	0.647	rs62026889	chr15:76917885	C/T	cg15268244	chr15:77196840	NA	0.49	10.47	0.44	3.57e-23	Blood metabolite levels;
LGG	cis	rs62238980	0.614	rs77099614	chr22:32452759	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg26031613	chr14:104095156	KLC1	-0.61	-9.66	-0.41	3.2e-20	Reticulocyte count;
LGG	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg18876405	chr7:65276391	NA	-0.65	-11.6	-0.47	1.76e-27	Aortic root size;
LGG	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg06606381	chr12:133084897	FBRSL1	0.83	8.57	0.37	1.61e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg08975724	chr8:8085496	FLJ10661	0.41	7.63	0.33	1.38e-13	Neuroticism;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21963583	chr11:68658836	MRPL21	0.61	10.57	0.44	1.55e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-13.27	-0.53	2.64e-34	Chronic sinus infection;
LGG	cis	rs11997175	0.550	rs7464954	chr8:33832202	A/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.39	0.32	7.1e-13	Body mass index;
LGG	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg04990556	chr1:26633338	UBXN11	-0.71	-13.95	-0.54	3.75e-37	Obesity-related traits;
LGG	cis	rs933688	1.000	rs332529	chr5:90789470	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	16.54	0.61	1.23e-48	Smoking behavior;
LGG	cis	rs9902453	1.000	rs9890886	chr17:28391076	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	8.1e-35	Coffee consumption (cups per day);
LGG	cis	rs3741151	0.656	rs11544311	chr11:73106237	A/C	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.55e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26245302	chr6:163148501	PACRG;PARK2	0.6	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9807841	0.727	rs12463204	chr19:10855781	A/C	cg17710535	chr19:10819994	QTRT1	0.41	7.26	0.32	1.61e-12	Inflammatory skin disease;
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.56e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.19	-0.36	2.57e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12618769	0.520	rs4851135	chr2:99050705	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg08677398	chr8:58056175	NA	0.47	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg15133208	chr4:90757351	SNCA	-0.39	-8.94	-0.38	9.28e-18	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.84	-0.42	7.33e-21	Lung cancer;
LGG	cis	rs975722	0.638	rs7796211	chr7:117327325	G/T	cg10524701	chr7:117356490	CTTNBP2	0.48	9.71	0.41	2.1e-20	Coronary artery disease;
LGG	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg18876405	chr7:65276391	NA	0.59	10.87	0.45	1.19e-24	Aortic root size;
LGG	trans	rs7615952	0.688	rs7624806	chr3:125599074	G/A	cg07211511	chr3:129823064	LOC729375	-1.41	-22.12	-0.72	1.7e-74	Blood pressure (smoking interaction);
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.5	-0.53	3.03e-35	Total body bone mineral density;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.17	0.58	1.81e-42	Platelet count;
LGG	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg05096777	chr10:104283225	SUFU	0.32	6.83	0.3	2.6e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg23815491	chr16:72088622	HP	0.53	11.71	0.48	6.46e-28	Fibrinogen levels;
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.52e-23	Bipolar disorder;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20887711	chr4:1340912	KIAA1530	-0.91	-20.08	-0.68	5.95e-65	Longevity;
LGG	cis	rs868036	0.645	rs28539889	chr15:68121428	T/A	cg18567174	chr15:68126065	LBXCOR1	-0.37	-6.75	-0.3	4.5e-11	Restless legs syndrome;
LGG	cis	rs2708240	1.000	rs2538986	chr7:147580726	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.92	-0.31	1.48e-11	QT interval (drug interaction);
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg18681998	chr4:17616180	MED28	0.86	18.79	0.66	5.77e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13004237	1	rs13004237	chr2:172833139	A/G	cg13550731	chr2:172543902	DYNC1I2	-0.89	-19.64	-0.67	6.36e-63	Schizophrenia;
LGG	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg00990874	chr7:1149470	C7orf50	-0.82	-14.51	-0.56	1.33e-39	Bronchopulmonary dysplasia;
LGG	cis	rs7503807	1.000	rs901064	chr17:78596040	C/T	cg09596252	chr17:78655493	RPTOR	-0.42	-7.48	-0.33	3.88e-13	Obesity;
LGG	cis	rs9362426	0.708	rs7753821	chr6:88100010	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.42	8.21	0.36	2.17e-15	Depressive episodes in bipolar disorder;
LGG	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs6964587	1.000	rs56072181	chr7:91690457	A/G	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	cis	rs2629540	0.889	rs4962696	chr10:126445630	A/G	cg08799069	chr10:126477246	METTL10	-0.68	-14.39	-0.56	4.69e-39	Cocaine dependence;
LGG	cis	rs16912285	0.585	rs11027807	chr11:24346556	G/T	ch.11.24196551F	chr11:24239977	NA	0.92	12.69	0.51	7.24e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg05973401	chr12:123451056	ABCB9	0.49	7.03	0.31	7.23e-12	Neutrophil percentage of white cells;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.59	11.16	0.46	9.23e-26	Obesity-related traits;
LGG	cis	rs7572733	0.935	rs696814	chr2:198687899	C/G	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.63e-16	Dermatomyositis;
LGG	cis	rs2013441	0.804	rs1811453	chr17:20232193	A/C	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6.06e-11	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs4432221	chr15:67634862	C/T	cg24231037	chr15:68117551	LBXCOR1	0.33	7.39	0.32	7.11e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3219090	0.861	rs2695239	chr1:226605227	T/C	cg17127702	chr1:226594323	PARP1	0.38	12.33	0.5	2.01e-30	Melanoma;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01412450	chr3:132441373	NCRNA00119;NPHP3	0.68	7.6	0.33	1.61e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg18105134	chr13:113819100	PROZ	-0.77	-15.97	-0.6	4.94e-46	Platelet distribution width;
LGG	cis	rs1045714	0.895	rs4721867	chr7:2643352	A/G	cg20813462	chr7:2646259	IQCE	-0.54	-6.99	-0.31	9.6e-12	Urate levels in lean individuals;
LGG	cis	rs9303401	0.580	rs12946396	chr17:57164195	T/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	13.87	0.54	7.53e-37	Cognitive test performance;
LGG	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg24060327	chr5:131705240	SLC22A5	0.5	8.67	0.37	7.4e-17	Blood metabolite levels;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg18402987	chr7:1209562	NA	0.39	7.17	0.32	3.01e-12	Longevity;Endometriosis;
LGG	cis	rs929596	0.585	rs2018985	chr2:234648860	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.57	-10.16	-0.43	4.93e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg21724239	chr8:58056113	NA	0.46	7.15	0.32	3.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3816183	0.716	rs7582737	chr2:43082899	G/A	cg14631114	chr2:43023945	NA	0.45	8.09	0.35	5.26e-15	Hypospadias;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg02297831	chr4:17616191	MED28	0.48	8.92	0.38	1.12e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1519814	0.736	rs7822384	chr8:121071789	A/G	cg22335954	chr8:121166405	COL14A1	-0.51	-9.63	-0.41	4.12e-20	Breast cancer;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg06916706	chr16:4465613	CORO7	-0.72	-12.22	-0.49	5.89e-30	Schizophrenia;
LGG	cis	rs916888	0.821	rs199507	chr17:44858855	A/G	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg15145174	chr5:6755386	POLS	-0.4	-7.6	-0.33	1.67e-13	Menopause (age at onset);
LGG	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.78	-16.84	-0.62	5.37e-50	Systemic lupus erythematosus;
LGG	cis	rs7301016	0.846	rs7296573	chr12:63033041	A/C	cg11441379	chr12:63026424	NA	0.69	9.61	0.41	4.83e-20	IgG glycosylation;
LGG	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	7.6	0.33	1.62e-13	Obesity (extreme);
LGG	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg07150166	chr2:30669952	LCLAT1	0.57	7.75	0.34	5.99e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs7577696	0.539	rs13010405	chr2:32338204	A/T	cg02381751	chr2:32503542	YIPF4	-0.46	-6.76	-0.3	4.16e-11	Inflammatory biomarkers;
LGG	cis	rs9649465	0.967	rs2299986	chr7:123369539	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	cis	rs1869026	1.000	rs1880542	chr2:121338584	C/T	cg03661458	chr2:121334411	NA	0.31	7.16	0.32	3.28e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4132509	0.793	rs10927046	chr1:243801190	T/C	cg21452805	chr1:244014465	NA	0.85	8.45	0.37	3.68e-16	RR interval (heart rate);
LGG	cis	rs12210905	1.000	rs12196084	chr6:27198204	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.28	-0.32	1.45e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12210905	1.000	rs12214930	chr6:27093715	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg27400746	chr16:89904261	SPIRE2	-1.12	-16.26	-0.6	2.37e-47	Skin colour saturation;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg23985595	chr17:80112537	CCDC57	0.47	9.36	0.4	3.33e-19	Life satisfaction;
LGG	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.13	0.31	3.8e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.82	-0.34	3.53e-14	Menopause (age at onset);
LGG	cis	rs4975709	0.838	rs4975752	chr5:1880588	A/C	cg15595755	chr5:1867978	NA	0.44	7.75	0.34	5.74e-14	Cardiovascular disease risk factors;
LGG	cis	rs9300255	0.544	rs1727310	chr12:123660510	A/G	cg00376283	chr12:123451042	ABCB9	0.61	8.76	0.38	3.73e-17	Neutrophil percentage of white cells;
LGG	cis	rs2836974	0.897	rs13339986	chr21:40605982	T/C	cg11644478	chr21:40555479	PSMG1	0.89	16.7	0.61	2.32e-49	Cognitive function;
LGG	cis	rs9290877	0.667	rs17615154	chr3:188450757	A/G	cg17392043	chr3:188495102	LPP	-0.43	-7.37	-0.32	7.97e-13	IgE levels;
LGG	cis	rs11966931	0.948	rs9486686	chr6:108089545	T/C	cg04749840	chr6:108095067	SCML4	0.44	7.51	0.33	3.01e-13	Neutrophil percentage of white cells;
LGG	cis	rs17102423	0.623	rs4902368	chr14:65612048	A/G	cg11161011	chr14:65562177	MAX	0.65	11.86	0.48	1.61e-28	Obesity-related traits;
LGG	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7615952	0.611	rs35321002	chr3:125612065	G/C	cg07211511	chr3:129823064	LOC729375	-1.32	-16.86	-0.62	4.69e-50	Blood pressure (smoking interaction);
LGG	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg12654349	chr5:56205094	C5orf35	-0.66	-10.36	-0.43	9.44e-23	Initial pursuit acceleration;
LGG	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg06360820	chr2:242988706	NA	-0.91	-11.66	-0.48	1.05e-27	Obesity-related traits;
LGG	cis	rs10463316	0.855	rs352701	chr5:150736474	A/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.47	-0.44	3.63e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg14893161	chr1:205819251	PM20D1	0.5	8.0	0.35	1e-14	Parkinson's disease;
LGG	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9902453	0.780	rs3115093	chr17:28039755	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.6	0.56	5.33e-40	Coffee consumption (cups per day);
LGG	cis	rs4664308	0.692	rs4233681	chr2:160960058	T/C	cg03641300	chr2:160917029	PLA2R1	-0.71	-13.64	-0.54	7.2e-36	Idiopathic membranous nephropathy;
LGG	cis	rs9905704	0.801	rs302847	chr17:56687481	C/T	cg12560992	chr17:57184187	TRIM37	0.45	6.7	0.3	5.95e-11	Testicular germ cell tumor;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04529582	chr20:30697510	TM9SF4	0.38	6.69	0.3	6.26e-11	Bilirubin levels;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg11494091	chr17:61959527	GH2	1.01	25.12	0.76	1.69e-88	Prudent dietary pattern;
LGG	cis	rs10760123	1	rs10760123	chr9:123650534	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.3	0.4	5.52e-19	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs56283067	0.578	rs62400353	chr6:45387899	G/A	cg18551225	chr6:44695536	NA	-0.55	-7.97	-0.35	1.29e-14	Total body bone mineral density;
LGG	cis	rs2066819	1.000	rs2306693	chr12:56680531	T/C	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs7010267	0.596	rs1905777	chr8:120021840	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.96	0.38	7.84e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs933688	1.000	rs10059163	chr5:90742444	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	19.16	0.67	1.07e-60	Smoking behavior;
LGG	cis	rs912057	0.582	rs1294412	chr6:6739854	A/G	cg06612196	chr6:6737390	NA	0.52	11.83	0.48	2.08e-28	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs5758511	0.514	rs9607882	chr22:42567451	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.42	0.33	5.78e-13	Birth weight;
LGG	cis	rs4148883	0.651	rs4147547	chr4:100127311	G/T	cg12011299	chr4:100065546	ADH4	0.37	7.8	0.34	4.2e-14	Alcohol dependence;
LGG	cis	rs745080	1.000	rs745080	chr14:52989228	A/G	cg23333723	chr14:53022898	GPR137C	0.31	6.73	0.3	4.95e-11	Orofacial clefts;
LGG	cis	rs546131	0.642	rs568529	chr11:34842506	C/A	cg06937548	chr11:34938143	PDHX;APIP	0.46	7.44	0.33	4.84e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs1682825	0.585	rs13091714	chr3:10768096	A/G	cg25137700	chr3:10780651	NA	0.48	6.66	0.3	7.87e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs28830936	0.966	rs2303516	chr15:42128568	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.77	-0.51	3.24e-32	Diastolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07192821	chr15:45003560	B2M	0.42	7.38	0.32	7.45e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Vitiligo;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.53e-21	Prudent dietary pattern;
LGG	cis	rs17818399	0.510	rs12105801	chr2:46799343	C/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-9.85	-0.42	6.62e-21	Height;
LGG	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.94	0.31	1.3e-11	Bipolar disorder;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.77	0.38	3.44e-17	Aortic root size;
LGG	cis	rs4924935	1.000	rs4924935	chr17:18753870	C/T	cg26378065	chr17:18585709	ZNF286B	0.49	8.01	0.35	9.17e-15	Pancreatic cancer;
LGG	trans	rs804280	0.662	rs804283	chr8:11611043	G/A	cg02002194	chr4:3960332	NA	-0.49	-7.77	-0.34	5.22e-14	Myopia (pathological);
LGG	cis	rs12291225	0.585	rs11023194	chr11:14369769	T/C	cg19336497	chr11:14380999	RRAS2	-0.63	-13.48	-0.53	3.43e-35	Sense of smell;
LGG	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg17691542	chr6:26056736	HIST1H1C	-0.5	-8.53	-0.37	2.09e-16	Blood metabolite levels;
LGG	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.7	0.37	5.67e-17	Colorectal cancer;
LGG	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg14092988	chr3:52407081	DNAH1	0.31	7.86	0.34	2.63e-14	Electroencephalogram traits;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg15971980	chr6:150254442	NA	0.45	8.48	0.37	3.14e-16	Lung cancer;
LGG	cis	rs952623	0.622	rs12667652	chr7:39074572	C/G	cg20302533	chr7:39170763	POU6F2	0.32	7.75	0.34	6.08e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.557	rs13000904	chr2:42863642	G/A	cg14631114	chr2:43023945	NA	0.34	6.68	0.3	6.88e-11	Hypospadias;
LGG	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.94e-13	Neuroticism;
LGG	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg00024416	chr22:24240387	NA	-0.44	-7.21	-0.32	2.33e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.19	0.43	3.79e-22	Dupuytren's disease;
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.51	0.37	2.45e-16	Triglycerides;
LGG	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg20703242	chr1:230279135	GALNT2	-0.37	-7.7	-0.34	8.36e-14	Coronary artery disease;
LGG	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.91	0.42	4.13e-21	Mean corpuscular volume;
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg01069141	chr11:67398826	TBX10;NUDT8	-0.4	-6.93	-0.31	1.38e-11	Mean corpuscular volume;
LGG	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-12.37	-0.5	1.47e-30	Menarche (age at onset);
LGG	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg24375607	chr4:120327624	NA	0.68	11.08	0.46	1.78e-25	Corneal astigmatism;
LGG	cis	rs7605378	0.658	rs4673507	chr2:200710167	G/C	cg17644776	chr2:200775616	C2orf69	0.63	10.68	0.44	6.21e-24	Osteoporosis;
LGG	cis	rs7666738	0.791	rs11730069	chr4:98945772	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	1.000	rs17063599	chr3:41861676	C/T	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7917772	0.503	rs11191321	chr10:104293412	C/T	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg03161606	chr19:29218774	NA	0.69	10.64	0.44	8.63e-24	Methadone dose in opioid dependence;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg03528353	chr17:61819722	STRADA	-0.47	-7.77	-0.34	5.13e-14	Prudent dietary pattern;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg06221963	chr1:154839813	KCNN3	0.48	9.69	0.41	2.41e-20	Prostate cancer;
LGG	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg04568710	chr12:38710424	ALG10B	-0.41	-9.19	-0.39	1.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1978968	0.707	rs13058527	chr22:18412929	G/A	cg03078520	chr22:18463400	MICAL3	-0.5	-9.7	-0.41	2.29e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg06212747	chr3:49208901	KLHDC8B	0.45	6.66	0.3	7.56e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4979906	1.000	rs4325263	chr10:79444236	A/G	cg07817648	chr10:79422355	NA	-0.5	-7.98	-0.35	1.13e-14	Mortality in heart failure;
LGG	cis	rs7444	0.941	rs5749502	chr22:21945096	T/A	cg05046821	chr22:21984468	YDJC	-0.39	-7.1	-0.31	4.65e-12	Systemic lupus erythematosus;
LGG	cis	rs2718058	0.769	rs12155159	chr7:37800529	G/A	cg24998770	chr7:37888106	TXNDC3	-0.46	-8.64	-0.37	8.91e-17	Alzheimer's disease (late onset);
LGG	cis	rs12477438	0.520	rs2516835	chr2:99779131	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg22875332	chr1:76189707	ACADM	0.59	10.37	0.43	8.57e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00090767	chr14:65569376	MAX	-0.5	-7.23	-0.32	1.99e-12	Systemic lupus erythematosus;
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg11984989	chr7:158649758	WDR60	1.04	22.61	0.72	8.65e-77	Height;
LGG	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg12751644	chr20:60527061	NA	-0.31	-6.93	-0.31	1.4e-11	Body mass index;
LGG	cis	rs7945718	0.621	rs10831895	chr11:12683327	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.57e-12	Educational attainment (years of education);
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg05665937	chr4:1216051	CTBP1	0.57	10.57	0.44	1.6e-23	Obesity-related traits;
LGG	cis	rs7129220	0.512	rs12279871	chr11:10228196	G/A	cg01453529	chr11:10209919	SBF2	-0.47	-7.68	-0.34	9.48e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs1032833	0.557	rs74550225	chr2:179968346	C/A	cg23654767	chr2:101192981	PDCL3	0.71	8.51	0.37	2.42e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg23422044	chr7:1970798	MAD1L1	0.76	13.01	0.52	3.35e-33	Bipolar disorder;
LGG	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.82	-16.67	-0.61	3.28e-49	Caffeine consumption;
LGG	cis	rs1408799	0.704	rs10960781	chr9:12762374	C/T	cg05274944	chr9:12693694	TYRP1	0.34	7.89	0.34	2.27e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs7659604	0.521	rs4833773	chr4:122689245	C/T	cg19671926	chr4:122722719	EXOSC9	0.52	8.08	0.35	5.71e-15	Type 2 diabetes;
LGG	cis	rs804280	0.593	rs2645396	chr8:11608126	C/A	cg12395012	chr8:11607386	GATA4	-0.68	-10.68	-0.44	5.83e-24	Myopia (pathological);
LGG	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg23594656	chr7:65796392	TPST1	-0.34	-7.41	-0.33	5.9e-13	Aortic root size;
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.08	-0.35	5.73e-15	Lewy body disease;
LGG	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.03	0.55	1.67e-37	Cognitive test performance;
LGG	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg24812749	chr6:127587940	RNF146	0.7	11.15	0.46	9.69e-26	Breast cancer;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	7.89	0.34	2.19e-14	Menarche (age at onset);
LGG	cis	rs4740619	0.935	rs7032877	chr9:15640047	C/T	cg14451791	chr9:16040625	NA	-0.38	-9.8	-0.41	1.01e-20	Body mass index;
LGG	cis	rs11753937	0.774	rs569833	chr6:133527935	T/C	cg14343214	chr6:133562056	EYA4	0.33	7.67	0.34	1.05e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs12282928	0.921	rs7108931	chr11:48288626	C/T	cg26585981	chr11:48327164	OR4S1	-0.45	-7.31	-0.32	1.21e-12	Migraine - clinic-based;
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.02e-34	Skin colour saturation;
LGG	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	cis	rs36093844	0.752	rs78820266	chr11:85558257	T/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.37	-0.32	7.89e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg25986240	chr4:9926439	SLC2A9	0.32	6.72	0.3	5.47e-11	Bone mineral density;
LGG	trans	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg02002194	chr4:3960332	NA	-0.5	-9.34	-0.4	4.1e-19	Myopia (pathological);
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	cis	rs17818399	0.597	rs13385693	chr2:46867158	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-8.0	-0.35	1.01e-14	Height;
LGG	cis	rs17030434	0.954	rs6847810	chr4:154752789	C/T	cg14289246	chr4:154710475	SFRP2	-0.71	-11.25	-0.46	3.85e-26	Electrocardiographic conduction measures;
LGG	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg07928641	chr1:182991847	LAMC1	0.45	8.78	0.38	3.06e-17	Fuchs's corneal dystrophy;
LGG	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg15485101	chr11:133734466	NA	-0.59	-10.48	-0.44	3.2e-23	Childhood ear infection;
LGG	cis	rs16937	0.662	rs10900472	chr1:205181526	A/G	cg00889227	chr1:205173544	DSTYK	-0.28	-7.03	-0.31	7.64e-12	Schizophrenia;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.23	-0.52	3.99e-34	Personality dimensions;
LGG	cis	rs1056053	0.514	rs3099268	chr6:166572826	T/C	cg11088901	chr6:166572345	T	-0.52	-9.87	-0.42	5.39e-21	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9308731	0.966	rs6753785	chr2:111923630	T/G	cg19992207	chr2:111874495	ACOXL	-0.42	-7.74	-0.34	6.43e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg15269541	chr15:43626905	ADAL	-0.42	-7.18	-0.32	2.77e-12	Lung cancer in ever smokers;
LGG	cis	rs701145	0.585	rs1727954	chr3:153871272	T/A	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs9831754	0.906	rs7611939	chr3:78392751	A/C	cg06138941	chr3:78371609	NA	-0.9	-18.74	-0.66	1.02e-58	Calcium levels;
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs3087591	0.960	rs2905794	chr17:29470002	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.34	0.55	7.39e-39	Hip circumference;
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg16141378	chr3:129829833	LOC729375	0.41	9.49	0.4	1.27e-19	Neuroticism;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	12.19	0.49	7.55e-30	Total body bone mineral density;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs6894268	0.722	rs6601058	chr5:179032187	A/G	cg22014891	chr5:179071901	C5orf60	-0.37	-7.36	-0.32	8.23e-13	Eating disorders;
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg11584989	chr19:19387371	SF4	-0.42	-7.67	-0.34	1.02e-13	Tonsillectomy;
LGG	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.3	-0.43	1.59e-22	Aortic root size;
LGG	cis	rs77741769	0.571	rs11065283	chr12:121266453	A/G	cg02419362	chr12:121203948	SPPL3	0.53	9.29	0.4	5.91e-19	Mean corpuscular volume;
LGG	cis	rs10883723	0.810	rs10748824	chr10:104274466	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.96e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs745821	0.701	rs17718537	chr18:48099345	G/T	cg18923635	chr18:48083994	NA	0.42	7.52	0.33	2.81e-13	Diastolic blood pressure;
LGG	cis	rs2070677	1.000	rs743534	chr10:135349226	G/T	cg20169779	chr10:135381914	SYCE1	0.92	12.06	0.49	2.61e-29	Gout;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12579753	0.667	rs7484495	chr12:82301834	T/C	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.3	-0.32	1.29e-12	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03947513	chr1:112298101	DDX20;C1orf183	0.5	9.41	0.4	2.29e-19	Gut microbiome composition (summer);
LGG	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg17127132	chr2:85788382	GGCX	0.47	8.02	0.35	8.55e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9644630	0.870	rs10888165	chr8:19358961	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.57	-0.47	2.26e-27	Oropharynx cancer;
LGG	cis	rs6732160	0.838	rs13411380	chr2:73382846	G/C	cg01422370	chr2:73384389	NA	0.54	10.48	0.44	3.19e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9443645	0.527	rs949846	chr6:79817596	C/T	cg18132916	chr6:79620363	NA	-0.28	-7.21	-0.32	2.34e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.96	0.42	2.58e-21	Motion sickness;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs888194	0.966	rs7313797	chr12:109896165	A/G	cg19025524	chr12:109796872	NA	-0.39	-7.86	-0.34	2.66e-14	Neuroticism;
LGG	cis	rs7546668	1.000	rs4661640	chr1:15854882	T/G	cg21858823	chr1:15850916	CASP9	0.38	7.0	0.31	9.03e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs11168618	0.626	rs2731091	chr12:48880381	A/G	cg24011408	chr12:48396354	COL2A1	-0.44	-7.02	-0.31	8.18e-12	Adiponectin levels;
LGG	cis	rs7551222	0.752	rs4951398	chr1:204531876	T/C	cg18851795	chr1:204543875	NA	-0.36	-6.91	-0.31	1.59e-11	Schizophrenia;
LGG	cis	rs11122272	0.735	rs2808596	chr1:231530723	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.85	-0.45	1.37e-24	Hemoglobin concentration;
LGG	trans	rs3858145	0.588	rs61854831	chr10:70035837	C/T	cg04882175	chr6:131122610	NA	-0.56	-8.0	-0.35	1.04e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs1552244	0.572	rs6797536	chr3:10168802	C/T	cg00166722	chr3:10149974	C3orf24	-0.56	-8.27	-0.36	1.4e-15	Alzheimer's disease;
LGG	cis	rs7937682	0.632	rs11603779	chr11:111781047	A/C	cg22437258	chr11:111473054	SIK2	-0.42	-6.92	-0.31	1.46e-11	Primary sclerosing cholangitis;
LGG	trans	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg12045294	chr17:78518616	RPTOR	-0.47	-7.31	-0.32	1.15e-12	Glycated hemoglobin levels;
LGG	cis	rs9359856	0.517	rs17506515	chr6:90507332	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.81	-10.43	-0.44	5.2e-23	Bipolar disorder;
LGG	cis	rs240764	0.658	rs7768210	chr6:101261494	C/T	cg09795085	chr6:101329169	ASCC3	0.47	8.0	0.35	1.02e-14	Neuroticism;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	17.46	0.63	8.32e-53	Tonsillectomy;
LGG	cis	rs8141529	0.748	rs1318026	chr22:29283518	A/G	cg02153584	chr22:29168773	CCDC117	0.6	9.75	0.41	1.52e-20	Lymphocyte counts;
LGG	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg17133734	chr15:86042851	AKAP13	-0.28	-6.87	-0.3	2.1e-11	Coronary artery disease;
LGG	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg08344181	chr3:125677491	NA	-0.91	-8.65	-0.37	8.37e-17	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs1727884	chr3:153838368	A/C	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs9814567	1.000	rs17694011	chr3:134213981	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.3	-0.53	2.07e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4919044	0.599	rs11187215	chr10:94670849	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.22	-0.32	2.2e-12	Coronary artery disease;
LGG	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg23594656	chr7:65796392	TPST1	0.38	8.32	0.36	9.6e-16	Aortic root size;
LGG	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg26838691	chr2:24397539	C2orf84	-0.48	-6.79	-0.3	3.4e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2797369	0.541	rs2749131	chr6:101482033	C/T	cg27451362	chr6:101846650	GRIK2	0.74	10.69	0.44	5.39e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs1949733	0.628	rs1543246	chr4:8504909	A/T	cg11789530	chr4:8429930	ACOX3	0.73	13.96	0.54	3.12e-37	Response to antineoplastic agents;
LGG	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg02269571	chr22:50332266	NA	-0.64	-10.2	-0.43	3.67e-22	Schizophrenia;
LGG	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.13	0.31	3.79e-12	Educational attainment;
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00142150	chr22:38071001	LGALS1	-0.93	-20.07	-0.68	6.63e-65	Fat distribution (HIV);
LGG	cis	rs3096299	0.596	rs889573	chr16:89437560	C/T	cg06640241	chr16:89574553	SPG7	0.65	10.63	0.44	9.23e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg23649088	chr2:200775458	C2orf69	-0.58	-6.98	-0.31	9.97e-12	Schizophrenia;
LGG	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg13385794	chr1:248469461	NA	0.47	7.89	0.34	2.23e-14	Common traits (Other);
LGG	cis	rs4493873	1.000	rs10090581	chr8:92070160	G/C	cg16814680	chr8:91681699	NA	0.48	7.24	0.32	1.83e-12	Migraine - clinic-based;
LGG	cis	rs4820294	1.000	rs78974622	chr22:38059925	A/C	cg10587741	chr22:38071170	LGALS1	0.83	22.14	0.72	1.32e-74	Fat distribution (HIV);
LGG	cis	rs12220238	0.730	rs4746177	chr10:75913033	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.47	0.47	5.71e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs988958	0.958	rs35771566	chr2:42280358	C/T	cg19376973	chr2:42229025	NA	0.48	8.05	0.35	6.96e-15	Hypospadias;
LGG	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg19524238	chr7:2802976	GNA12	0.31	7.35	0.32	8.94e-13	Height;
LGG	cis	rs950169	1.000	rs12902672	chr15:84716986	G/A	cg24253500	chr15:84953950	NA	0.59	10.79	0.45	2.24e-24	Schizophrenia;
LGG	cis	rs4481887	0.927	rs4244185	chr1:248486913	A/G	cg00666640	chr1:248458726	OR2T12	0.56	8.95	0.38	8.55e-18	Common traits (Other);
LGG	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg21545522	chr1:205238299	TMCC2	0.41	7.85	0.34	2.91e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg06917634	chr15:78832804	PSMA4	-0.64	-11.56	-0.47	2.4e-27	Sudden cardiac arrest;
LGG	cis	rs4684776	0.867	rs11706990	chr3:11343663	G/A	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	trans	rs12310956	0.532	rs1906134	chr12:33957135	A/C	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs17445240	1.000	rs17445240	chr2:3703041	C/T	cg14882966	chr2:3699353	NA	-0.88	-9.39	-0.4	2.84e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg16339924	chr4:17578868	LAP3	0.66	11.51	0.47	3.85e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.67	-12.11	-0.49	1.6e-29	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg24375607	chr4:120327624	NA	0.67	10.99	0.45	4.06e-25	Corneal astigmatism;
LGG	cis	rs11105298	0.685	rs117578503	chr12:89836672	G/C	cg00757033	chr12:89920650	WDR51B	0.65	9.22	0.39	1.03e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs67133203	0.768	rs3890212	chr12:51533557	T/C	cg14688905	chr12:51403056	SLC11A2	0.72	10.85	0.45	1.38e-24	Urinary tract infection frequency;
LGG	trans	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg07211511	chr3:129823064	LOC729375	-0.66	-9.1	-0.39	2.77e-18	Blood pressure (smoking interaction);
LGG	trans	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs1371867	0.875	rs1788169	chr8:101326314	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs12220238	0.722	rs10762635	chr10:76403131	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.53	6.96	0.31	1.15e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4356203	0.933	rs12801545	chr11:17266176	C/A	cg15432903	chr11:17409602	KCNJ11	0.41	7.21	0.32	2.35e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs8078723	1.000	rs4795418	chr17:38164851	T/C	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs4650994	0.593	rs6700266	chr1:178508930	A/G	cg19399532	chr1:178512495	C1orf220	0.41	7.94	0.35	1.57e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs637571	0.522	rs550435	chr11:65732651	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.44	7.58	0.33	1.89e-13	Eosinophil percentage of white cells;
LGG	cis	rs12210905	0.925	rs72838236	chr6:26971202	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.73	0.34	6.88e-14	Homoarginine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09311052	chr1:154531418	UBE2Q1	0.53	8.3	0.36	1.12e-15	Gut microbiome composition (summer);
LGG	cis	rs7089973	0.624	rs11196930	chr10:116583596	C/T	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg09873164	chr1:152488093	CRCT1	0.64	16.11	0.6	1.06e-46	Hair morphology;
LGG	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.5	0.37	2.69e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.748	rs4851185	chr2:99666497	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00198680	chr16:28758506	NA	0.28	6.77	0.3	4.02e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg06766960	chr11:133703094	NA	-0.59	-11.65	-0.48	1.1e-27	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18876405	chr7:65276391	NA	-0.54	-9.74	-0.41	1.61e-20	Aortic root size;
LGG	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg04025307	chr7:1156635	C7orf50	0.43	7.62	0.33	1.43e-13	Longevity;Endometriosis;
LGG	cis	rs11169552	0.510	rs10876058	chr12:50956266	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.68e-14	Colorectal cancer;
LGG	cis	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg09307838	chr4:120376055	NA	0.48	8.29	0.36	1.23e-15	Diastolic blood pressure;
LGG	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg26655873	chr3:72818019	SHQ1	0.35	7.04	0.31	7.2e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg27121462	chr16:89883253	FANCA	0.62	11.57	0.47	2.31e-27	Vitiligo;
LGG	cis	rs4478137	0.501	rs4146926	chr4:164230788	C/G	cg06758707	chr4:164254230	NPY1R	-0.54	-7.92	-0.35	1.75e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21659725	chr3:3221576	CRBN	-0.93	-20.85	-0.7	1.43e-68	Intelligence (multi-trait analysis);
LGG	cis	rs3857067	0.806	rs722486	chr4:95092315	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.81	-0.34	3.84e-14	QT interval;
LGG	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs12949688	0.654	rs4793914	chr17:55834581	T/G	cg12582317	chr17:55822272	NA	0.46	10.61	0.44	1.06e-23	Schizophrenia;
LGG	cis	rs13191362	0.507	rs2849534	chr6:163144657	T/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.5	-6.67	-0.3	7.26e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9902453	0.933	rs8074028	chr17:28461687	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.84	0.51	1.79e-32	Coffee consumption (cups per day);
LGG	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg11634705	chr7:873449	UNC84A	0.43	7.62	0.33	1.44e-13	Subjective well-being;
LGG	cis	rs9914544	0.628	rs4630608	chr17:18678548	C/T	cg26306683	chr17:18585705	ZNF286B	0.39	7.63	0.33	1.32e-13	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25846339	chr11:85359022	TMEM126A	0.5	7.93	0.35	1.68e-14	Gut microbiome composition (summer);
LGG	cis	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6831352	0.918	rs13127153	chr4:100058121	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg14926445	chr8:58193284	C8orf71	-0.84	-10.42	-0.44	5.64e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs921318	chr3:153856775	T/G	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	cis	rs67460515	0.563	rs1599375	chr3:160897771	C/T	cg04691961	chr3:161091175	C3orf57	0.45	8.69	0.37	6.2e-17	Parkinson's disease;
LGG	cis	rs7428	0.545	rs1053561	chr2:85546052	A/G	cg24342717	chr2:85555507	TGOLN2	-0.72	-13.73	-0.54	3.08e-36	Ear protrusion;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20296188	chr17:77397067	HRNBP3	0.49	7.82	0.34	3.58e-14	Cognitive performance;
LGG	cis	rs8044868	0.530	rs7185840	chr16:72102112	A/G	cg23815491	chr16:72088622	HP	0.39	8.28	0.36	1.36e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs4700695	0.545	rs29441	chr5:65509116	G/T	cg21114390	chr5:65439923	SFRS12	-0.57	-8.23	-0.36	1.97e-15	Facial morphology (factor 19);
LGG	cis	rs6489785	0.737	rs487912	chr12:121214723	G/T	cg02419362	chr12:121203948	SPPL3	0.43	6.7	0.3	6e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs10506458	0.834	rs73125186	chr12:63373400	C/T	cg22491629	chr6:157744540	C6orf35	-0.98	-13.66	-0.54	6.26e-36	Hemostatic factors and hematological phenotypes;
LGG	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg27411982	chr8:10470053	RP1L1	0.43	7.64	0.33	1.22e-13	Mood instability;
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.4e-21	Lymphocyte counts;
LGG	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg26076054	chr5:421317	AHRR	0.52	7.72	0.34	7.13e-14	Cystic fibrosis severity;
LGG	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg21775007	chr8:11205619	TDH	-0.44	-6.85	-0.3	2.3e-11	Neuroticism;
LGG	cis	rs1682825	1.000	rs58688912	chr3:10775517	G/A	cg23512531	chr3:10780469	NA	0.59	8.22	0.36	2.12e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs2173063	1.000	rs80024331	chr15:93135669	G/A	cg07052004	chr15:93132129	NA	0.69	7.16	0.32	3.1e-12	Subcutaneous adipose tissue;
LGG	cis	rs4740619	0.846	rs10733295	chr9:15681901	A/G	cg14451791	chr9:16040625	NA	-0.33	-8.25	-0.36	1.68e-15	Body mass index;
LGG	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.39	-0.32	7.15e-13	Retinal vascular caliber;
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.1	30.19	0.81	1.9e-111	Birth weight;
LGG	trans	rs61931739	0.635	rs10772123	chr12:33975557	C/T	cg26384229	chr12:38710491	ALG10B	0.6	11.23	0.46	4.65e-26	Morning vs. evening chronotype;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.51e-13	IgG glycosylation;
LGG	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg21401794	chr1:90099060	LRRC8C	-0.55	-11.41	-0.47	9.61e-27	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06915872	chr16:87998081	BANP	0.46	6.89	0.31	1.81e-11	Menopause (age at onset);
LGG	cis	rs12926788	0.640	rs12924246	chr16:24844629	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	7.4	0.33	6.64e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9814567	0.806	rs9839705	chr3:134323819	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2354432	0.556	rs2353975	chr1:146837703	C/A	cg25205988	chr1:146714368	CHD1L	1.19	11.62	0.48	1.48e-27	Mitochondrial DNA levels;
LGG	cis	rs67311347	1.000	rs73078158	chr3:40472567	G/C	cg13683864	chr3:40499215	RPL14	-1.13	-26.58	-0.78	3.22e-95	Renal cell carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02461956	chr11:134093940	NCAPD3;VPS26B	0.49	8.31	0.36	1.06e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs9916302	0.904	rs9904334	chr17:37468336	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.55	0.47	2.7e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg25986240	chr4:9926439	SLC2A9	0.33	6.68	0.3	7.06e-11	Bone mineral density;
LGG	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9487051	0.872	rs9372211	chr6:109609648	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs12282928	0.670	rs12576395	chr11:48355132	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.26	-0.32	1.66e-12	Migraine - clinic-based;
LGG	cis	rs546131	0.928	rs547504	chr11:34847225	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.6	10.77	0.45	2.78e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs1417569	1.000	rs1417569	chr10:31101743	C/T	cg00428179	chr10:31322131	ZNF438	0.35	8.03	0.35	8.34e-15	Tuberculosis;
LGG	cis	rs11966931	0.744	rs6924554	chr6:108141706	A/G	cg04749840	chr6:108095067	SCML4	0.45	8.94	0.38	9.17e-18	Neutrophil percentage of white cells;
LGG	cis	rs6141769	0.542	rs6058846	chr20:31324035	A/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.82	-0.3	2.9e-11	Subjective well-being;
LGG	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs123509	0.731	rs73087348	chr3:42811571	C/T	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.8	-0.3	3.31e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21219744	chr4:44680344	GUF1	0.45	7.35	0.32	8.88e-13	Gut microbiome composition (summer);
LGG	trans	rs10838798	0.523	rs4752907	chr11:48170581	G/A	cg00717180	chr2:96193071	NA	-0.4	-6.98	-0.31	1e-11	Height;
LGG	cis	rs3087591	0.708	rs3785956	chr17:29647707	C/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.34	0.5	1.99e-30	Hip circumference;
LGG	trans	rs877282	0.838	rs11253374	chr10:774961	C/T	cg22713356	chr15:30763199	NA	0.55	8.31	0.36	1.03e-15	Uric acid levels;
LGG	cis	rs875971	0.508	rs10950045	chr7:66066373	T/C	cg18252515	chr7:66147081	NA	0.41	7.07	0.31	5.71e-12	Aortic root size;
LGG	cis	rs571497	0.756	rs557094	chr19:7832286	C/G	cg00371453	chr19:7854482	CLEC4GP1	-0.63	-7.33	-0.32	1.03e-12	Monocyte count;
LGG	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.95	0.35	1.47e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01341218	chr17:43662625	NA	0.96	17.09	0.62	3.91e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.58	-0.37	1.49e-16	Resting heart rate;
LGG	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg02297831	chr4:17616191	MED28	0.5	9.32	0.4	4.68e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs752010	0.695	rs10890156	chr1:42108090	T/C	cg16096631	chr1:42092165	HIVEP3	0.53	12.63	0.51	1.23e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg18165381	chr3:44552316	NA	-0.41	-6.76	-0.3	4.05e-11	Depressive symptoms;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.27	0.32	1.59e-12	Lung cancer;
LGG	cis	rs992157	0.661	rs17653757	chr2:219109364	G/C	cg00012203	chr2:219082015	ARPC2	0.84	17.03	0.62	7.21e-51	Colorectal cancer;
LGG	cis	rs6456156	0.774	rs6456158	chr6:167528032	A/C	cg07741184	chr6:167504864	NA	0.32	7.06	0.31	6.31e-12	Primary biliary cholangitis;
LGG	cis	rs2836974	0.583	rs9636957	chr21:40705847	G/A	cg11644478	chr21:40555479	PSMG1	-0.71	-12.5	-0.5	4.17e-31	Cognitive function;
LGG	cis	rs765787	0.530	rs2413786	chr15:45525394	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.73	-0.51	4.89e-32	Uric acid levels;
LGG	cis	rs4595586	0.545	rs2388176	chr12:39372357	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs3106136	0.609	rs28696050	chr4:95136630	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-6.76	-0.3	4.16e-11	Capecitabine sensitivity;
LGG	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg12654349	chr5:56205094	C5orf35	-0.64	-9.68	-0.41	2.73e-20	Initial pursuit acceleration;
LGG	cis	rs10991814	0.688	rs76530346	chr9:94010298	G/A	cg14446406	chr9:93919335	NA	-0.82	-8.22	-0.36	2.12e-15	Neutrophil percentage of granulocytes;
LGG	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.7	0.3	5.91e-11	Myopia (pathological);
LGG	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg08733933	chr1:2954429	NA	-0.41	-8.66	-0.37	7.94e-17	Plateletcrit;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg14789911	chr21:47582049	C21orf56	-0.5	-8.77	-0.38	3.54e-17	Testicular germ cell tumor;
LGG	cis	rs7586879	0.616	rs6722587	chr2:25132192	C/A	cg04586622	chr2:25135609	ADCY3	0.48	13.13	0.52	1.08e-33	Body mass index;
LGG	cis	rs7927592	0.956	rs10896348	chr11:68357368	T/C	cg20283391	chr11:68216788	NA	-0.51	-8.36	-0.36	7.29e-16	Total body bone mineral density;
LGG	cis	rs4969178	0.965	rs2292642	chr17:76395430	C/T	cg20026190	chr17:76395443	PGS1	0.57	10.11	0.43	7.86e-22	HDL cholesterol levels;
LGG	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg05793240	chr7:2802953	GNA12	0.32	7.96	0.35	1.38e-14	Height;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg02405530	chr4:926135	TMEM175;GAK	0.41	6.71	0.3	5.68e-11	Corneal astigmatism;
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg00405596	chr8:11794950	NA	-0.43	-7.2	-0.32	2.39e-12	Neuroticism;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	trans	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.31	0.47	2.39e-26	Corneal astigmatism;
LGG	cis	rs10927875	0.541	rs1763607	chr1:16337509	G/A	cg22431228	chr1:16359049	CLCNKA	-0.48	-8.44	-0.37	4.17e-16	Dilated cardiomyopathy;
LGG	cis	rs1577917	0.916	rs12206726	chr6:86499716	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.23	-0.49	5.58e-30	Response to antipsychotic treatment;
LGG	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg06028605	chr16:24865363	SLC5A11	0.47	7.77	0.34	5e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg22907277	chr7:1156413	C7orf50	0.85	14.88	0.57	3.24e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Hypertriglyceridemia;
LGG	trans	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg13565492	chr6:43139072	SRF	-0.72	-8.78	-0.38	3.25e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg22676075	chr6:135203613	NA	-0.49	-8.63	-0.37	9.73e-17	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs3733585	0.736	rs4543113	chr4:10008305	G/A	cg11266682	chr4:10021025	SLC2A9	0.47	8.87	0.38	1.63e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9393777	0.513	rs9379905	chr6:26630990	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	12.12	0.49	1.53e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1065656	0.619	rs2492883	chr16:1902105	C/T	cg26897989	chr16:1907736	C16orf73	-0.52	-9.88	-0.42	4.98e-21	Insulin-like growth factors;
LGG	cis	rs4743820	0.651	rs4237213	chr9:93932708	A/T	cg14446406	chr9:93919335	NA	0.88	14.87	0.57	3.55e-41	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2070677	1.000	rs2070677	chr10:135351174	A/T	cg20169779	chr10:135381914	SYCE1	-0.93	-12.45	-0.5	6.87e-31	Gout;
LGG	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.39	-0.43	6.91e-23	Initial pursuit acceleration;
LGG	cis	rs9504361	0.838	rs3757114	chr6:559576	A/C	cg13471009	chr6:564609	EXOC2	-0.39	-8.38	-0.36	6.33e-16	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LGG	cis	rs2153535	0.580	rs962590	chr6:8450899	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg23978390	chr7:1156363	C7orf50	0.45	7.75	0.34	5.82e-14	Longevity;Endometriosis;
LGG	cis	rs4363385	0.667	rs2050674	chr1:152913356	C/G	cg07796016	chr1:152779584	LCE1C	0.44	7.05	0.31	6.58e-12	Inflammatory skin disease;
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.33	-0.36	9.51e-16	Personality dimensions;
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.53	-8.67	-0.37	7.24e-17	Longevity;Endometriosis;
LGG	cis	rs6450176	0.951	rs5013866	chr5:53300947	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs9914544	0.545	rs4924944	chr17:18810002	C/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.62	-0.33	1.46e-13	Educational attainment (years of education);
LGG	cis	rs9296092	0.538	rs112113649	chr6:33524529	A/G	cg13560919	chr6:33536144	NA	-1.05	-21.95	-0.71	1e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.24	0.32	1.93e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs4740619	0.592	rs7034388	chr9:15901289	A/G	cg14451791	chr9:16040625	NA	-0.28	-6.91	-0.31	1.56e-11	Body mass index;
LGG	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.09	-0.31	5.09e-12	Arsenic metabolism;
LGG	cis	rs1577917	0.655	rs9342045	chr6:86425148	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.0	0.46	3.51e-25	Response to antipsychotic treatment;
LGG	cis	rs35425515	0.706	rs2279510	chr10:98863189	C/T	cg09122387	chr10:98855762	SLIT1	0.7	9.24	0.39	9.26e-19	Bipolar disorder;
LGG	cis	rs3747547	1.000	rs17418324	chr9:37921712	G/A	cg13774184	chr9:37916125	SHB	-0.69	-6.71	-0.3	5.76e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs9457247	0.756	rs2345572	chr6:167403441	A/T	cg07741184	chr6:167504864	NA	0.31	6.84	0.3	2.53e-11	Crohn's disease;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10239941	chr2:27545751	MPV17	0.47	6.81	0.3	3.09e-11	Gut microbiome composition (summer);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	ch.11.1835930F	chr11:85826417	NA	-0.33	-6.85	-0.3	2.41e-11	Iris color (L* coordinate);
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg23594656	chr7:65796392	TPST1	0.42	9.22	0.39	1.04e-18	Aortic root size;
LGG	cis	rs17001868	0.568	rs73167007	chr22:40734241	G/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs11785693	0.862	rs11782556	chr8:5002389	C/G	cg26367366	chr8:4980734	NA	1.0	14.92	0.57	2.29e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs6772849	0.930	rs68090762	chr3:128343907	C/T	cg08795948	chr3:128337044	NA	0.67	11.36	0.47	1.57e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs593982	0.920	rs563427	chr11:65484569	A/G	cg08755490	chr11:65554678	OVOL1	0.7	8.62	0.37	1.11e-16	Atopic dermatitis;
LGG	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg00319359	chr11:70116639	PPFIA1	0.74	7.75	0.34	5.94e-14	Coronary artery disease;
LGG	cis	rs12477438	0.666	rs10179910	chr2:99658503	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.53	-9.11	-0.39	2.43e-18	Chronic sinus infection;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg01059449	chr18:44338099	ST8SIA5	0.35	7.6	0.33	1.64e-13	Personality dimensions;
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.62	0.37	1.07e-16	Bipolar disorder;
LGG	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg26597838	chr10:835615	NA	0.75	10.26	0.43	2.09e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs2797160	0.651	rs6569436	chr6:126032104	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.45	7.85	0.34	2.91e-14	Endometrial cancer;
LGG	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg22437258	chr11:111473054	SIK2	-0.48	-8.11	-0.35	4.62e-15	Primary sclerosing cholangitis;
LGG	cis	rs7301826	1.000	rs10773819	chr12:131279022	G/A	cg11011512	chr12:131303247	STX2	0.35	7.5	0.33	3.37e-13	Plasma plasminogen activator levels;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.2	-0.7	3.43e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs34172651	0.917	rs1465422	chr16:24772486	C/T	cg02428538	chr16:24856791	SLC5A11	-0.43	-7.45	-0.33	4.65e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11250098	0.526	rs116793410	chr8:10770255	G/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.05	-0.31	6.75e-12	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.501	rs9941561	chr2:99753829	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.38	0.63	1.9e-52	Chronic sinus infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25478109	chr3:179322476	NDUFB5;MRPL47	0.47	7.62	0.33	1.46e-13	Cognitive performance;
LGG	cis	rs2070997	0.618	rs3780282	chr9:133743654	G/A	cg01000188	chr9:133769184	QRFP	0.29	6.78	0.3	3.72e-11	Response to amphetamines;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg06654118	chr4:1303317	MAEA	0.49	8.61	0.37	1.13e-16	Obesity-related traits;
LGG	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg20913747	chr6:44695427	NA	-0.69	-12.35	-0.5	1.69e-30	Total body bone mineral density;
LGG	cis	rs763121	0.524	rs760645	chr22:39032270	C/T	cg06022373	chr22:39101656	GTPBP1	0.61	10.63	0.44	9.08e-24	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs1658494	chr10:60280323	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs735539	0.645	rs9552251	chr13:21180247	A/G	cg04906043	chr13:21280425	IL17D	0.52	8.46	0.37	3.52e-16	Dental caries;
LGG	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs12724450	0.793	rs34001546	chr1:150459715	T/C	cg03818307	chr1:150480534	ECM1	0.51	7.39	0.32	6.83e-13	Blood protein levels;
LGG	cis	rs9393777	0.588	rs6456727	chr6:26471155	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	12.15	0.49	1.14e-29	Intelligence (multi-trait analysis);
LGG	trans	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.62	-0.33	1.41e-13	Body mass index;
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg26138144	chr22:38071188	LGALS1	0.91	24.34	0.75	7.06e-85	Fat distribution (HIV);
LGG	trans	rs3206736	0.548	rs10243141	chr7:35062566	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.3	0.32	1.24e-12	Diastolic blood pressure;
LGG	cis	rs36051895	0.664	rs10815154	chr9:5095538	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.19	-0.6	4.62e-47	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.52e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.918	rs3784062	chr14:72090505	T/G	cg13720639	chr14:72061746	SIPA1L1	0.39	7.97	0.35	1.23e-14	Mitral valve prolapse;
LGG	cis	rs528418	0.592	rs4895673	chr6:145715652	A/T	cg03642472	chr6:145670687	NA	0.56	7.29	0.32	1.36e-12	Methadone dose in opioid dependence;
LGG	trans	rs75804782	0.630	rs56108200	chr2:239276888	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg23933602	chr10:16859644	RSU1	0.99	25.73	0.77	2.75e-91	Platelet distribution width;
LGG	cis	rs3740909	1.000	rs7942816	chr11:125882750	A/G	cg24940576	chr11:125904314	CDON	-0.46	-7.08	-0.31	5.53e-12	Blood protein levels;
LGG	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs4144743	0.528	rs2292866	chr17:45356782	T/C	cg18085866	chr17:45331354	ITGB3	-0.74	-7.62	-0.33	1.41e-13	Body mass index;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg18252515	chr7:66147081	NA	-0.42	-6.98	-0.31	1.04e-11	Aortic root size;
LGG	cis	rs701145	0.617	rs355775	chr3:154036129	A/G	cg12800244	chr3:153838788	SGEF	0.54	7.41	0.33	6.17e-13	Coronary artery disease;
LGG	cis	rs2354432	0.607	rs2353999	chr1:146830686	T/C	cg25205988	chr1:146714368	CHD1L	-1.28	-12.95	-0.52	6.23e-33	Mitochondrial DNA levels;
LGG	cis	rs6743376	0.556	rs1530551	chr2:113817566	C/T	cg05949173	chr2:113825882	IL1F10	-0.48	-9.3	-0.4	5.63e-19	Inflammatory biomarkers;
LGG	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg05234568	chr11:5960015	NA	-0.66	-11.8	-0.48	2.8e-28	DNA methylation (variation);
LGG	cis	rs10191773	0.589	rs72833410	chr2:113054119	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.77	10.02	0.42	1.66e-21	Yeast infection;
LGG	cis	rs611744	0.839	rs672552	chr8:109164223	A/G	cg21045802	chr8:109455806	TTC35	0.39	6.96	0.31	1.15e-11	Dupuytren's disease;
LGG	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg24112000	chr20:60950667	NA	-0.35	-8.33	-0.36	9.55e-16	Colorectal cancer;
LGG	cis	rs67311347	0.866	rs3214006	chr3:40352134	C/T	cg13683864	chr3:40499215	RPL14	-0.86	-16.8	-0.62	8.55e-50	Renal cell carcinoma;
LGG	cis	rs17102423	0.964	rs8015330	chr14:65602183	C/T	cg16583315	chr14:65563665	MAX	-0.35	-6.66	-0.3	7.96e-11	Obesity-related traits;
LGG	trans	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg06521331	chr12:34319734	NA	-0.52	-9.09	-0.39	2.97e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg09640425	chr7:158790006	NA	-0.38	-6.99	-0.31	9.81e-12	Facial morphology (factor 20);
LGG	cis	rs877426	0.681	rs41291225	chr13:114839462	T/C	cg00571178	chr13:114841904	RASA3	-0.54	-9.41	-0.4	2.33e-19	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg03909863	chr11:638404	DRD4	-0.41	-6.75	-0.3	4.42e-11	Systemic lupus erythematosus;
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9814567	1.000	rs7432268	chr3:134242051	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	4.08e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg13802316	chr11:70253460	CTTN	-0.72	-9.87	-0.42	5.53e-21	Coronary artery disease;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg07944736	chr1:28908226	SNHG12;SNORA44;SNORA16A	0.38	6.65	0.3	8.35e-11	Corneal astigmatism;
LGG	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.31	0.43	1.44e-22	Height;
LGG	cis	rs7666738	0.830	rs13144564	chr4:98939276	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs11608355	0.515	rs35691047	chr12:109932585	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs12493885	0.725	rs11718315	chr3:153724197	A/G	cg17054900	chr3:154042577	DHX36	-0.59	-7.69	-0.34	8.88e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.0	0.6	3.35e-46	Obesity-related traits;
LGG	cis	rs11098499	0.863	rs7678400	chr4:120461957	G/A	cg09307838	chr4:120376055	NA	0.8	13.38	0.53	9.47e-35	Corneal astigmatism;
LGG	cis	rs283228	0.617	rs505963	chr6:101781684	A/G	cg27451362	chr6:101846650	GRIK2	-0.86	-13.3	-0.53	2.06e-34	Coenzyme Q10 levels;
LGG	cis	rs7264396	0.790	rs2425097	chr20:34308926	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.34	0.32	9.37e-13	Total cholesterol levels;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg13206674	chr6:150067644	NUP43	0.63	12.98	0.52	4.61e-33	Lung cancer;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg14004847	chr7:1930337	MAD1L1	-0.46	-8.24	-0.36	1.76e-15	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg25026715	chr17:26989248	SUPT6H;SDF2	0.56	6.78	0.3	3.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.65	-0.3	8.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7143963	0.580	rs10148367	chr14:103357310	C/T	cg23020514	chr14:103360112	TRAF3	0.39	8.21	0.36	2.18e-15	Body mass index;
LGG	cis	rs79911532	0.515	rs113056502	chr7:75667901	G/A	cg15148918	chr7:75625777	STYXL1	-0.7	-8.01	-0.35	9.67e-15	Mononucleosis;
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.26	-0.46	3.73e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg08975724	chr8:8085496	FLJ10661	0.53	10.45	0.44	4.43e-23	Systolic blood pressure;
LGG	cis	rs7010267	0.596	rs4354338	chr8:120016060	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.59	0.37	1.3e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg04166393	chr7:2884313	GNA12	-0.48	-9.34	-0.4	3.95e-19	Height;
LGG	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9914988	0.943	rs7215000	chr17:27088436	C/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs13191362	0.935	rs7767254	chr6:162954674	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.26	0.4	7.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4851254	0.618	rs13033732	chr2:100644797	A/G	cg17356467	chr2:100759845	AFF3	0.47	7.62	0.33	1.44e-13	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26279152	chr13:20356101	PSPC1	0.47	7.71	0.34	8.01e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs78487399	0.808	rs79955955	chr2:43686985	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.85	-0.3	2.31e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs2898290	0.622	rs1478890	chr8:11355602	C/G	cg16141378	chr3:129829833	LOC729375	0.39	9.07	0.39	3.51e-18	Systolic blood pressure;
LGG	cis	rs372883	0.613	rs1153290	chr21:30687404	G/T	cg24692254	chr21:30365293	RNF160	-0.61	-11.37	-0.47	1.32e-26	Pancreatic cancer;
LGG	cis	rs4788570	0.584	rs6499529	chr16:71715378	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Intelligence (multi-trait analysis);
LGG	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.44	0.67	5.82e-62	Breast cancer;
LGG	cis	rs17818399	0.547	rs7607308	chr2:46759104	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.53	8.14	0.35	3.66e-15	Height;
LGG	cis	rs11887277	0.900	rs1434058	chr2:27073853	T/C	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.94	-0.31	1.33e-11	Obesity-related traits;
LGG	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg21399703	chr1:247681439	NA	0.58	7.1	0.31	4.85e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3781913	0.845	rs2037030	chr11:72370200	C/T	cg02728101	chr11:72386540	PDE2A	0.32	7.01	0.31	8.73e-12	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg11317459	chr13:21872234	NA	-1.18	-19.46	-0.67	4.49e-62	White matter hyperintensity burden;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg16103275	chr6:290800	DUSP22	0.49	8.09	0.35	5.35e-15	Menopause (age at onset);
LGG	cis	rs2242116	0.727	rs6442040	chr3:46963035	C/A	cg27129171	chr3:47204927	SETD2	0.64	10.85	0.45	1.43e-24	Birth weight;
LGG	cis	rs79349575	0.783	rs62075839	chr17:46996434	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.93	0.31	1.38e-11	Type 2 diabetes;
LGG	cis	rs6964587	0.967	rs7801058	chr7:91784381	C/T	cg17063962	chr7:91808500	NA	0.55	10.22	0.43	2.99e-22	Breast cancer;
LGG	trans	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg06875740	chr19:51307921	C19orf48	-0.62	-7.97	-0.35	1.29e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2075671	0.903	rs11973874	chr7:100263272	T/C	cg21055462	chr7:100276975	NA	0.45	9.56	0.41	7.03e-20	Other erythrocyte phenotypes;
LGG	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg26396452	chr14:65542826	MAX	0.43	8.35	0.36	8.19e-16	Obesity-related traits;
LGG	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	10.07	0.42	1.07e-21	Post bronchodilator FEV1;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.42	-6.8	-0.3	3.19e-11	Longevity;Endometriosis;
LGG	cis	rs11190604	1.000	rs3793706	chr10:102269085	A/C	cg11040518	chr10:102331378	NA	0.35	6.66	0.3	7.56e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs870825	0.616	rs14969	chr4:185615764	C/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs2013441	0.508	rs12947713	chr17:19974002	G/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.73	-0.45	3.73e-24	Cannabis dependence symptom count;
LGG	cis	rs6696846	0.777	rs6664397	chr1:205051871	C/T	cg00857998	chr1:205179979	DSTYK	0.48	7.8	0.34	4.29e-14	Red blood cell count;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.33	-0.32	1.06e-12	Lung cancer;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07791516	chr6:150247246	NA	0.32	7.01	0.31	8.72e-12	Lung cancer;
LGG	cis	rs1577917	1.000	rs34281561	chr6:86701872	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.3	-0.53	2.07e-34	Response to antipsychotic treatment;
LGG	cis	rs977987	0.843	rs10459859	chr16:75381950	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.37	0.43	8.61e-23	Dupuytren's disease;
LGG	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg10057126	chr4:77819792	ANKRD56	0.36	6.95	0.31	1.26e-11	Emphysema distribution in smoking;
LGG	cis	rs344364	0.511	rs2906912	chr16:1953151	G/A	cg26897989	chr16:1907736	C16orf73	-0.82	-13.71	-0.54	3.67e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9311474	0.607	rs4234633	chr3:52557038	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.74	-0.3	4.73e-11	Electroencephalogram traits;
LGG	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg23625390	chr15:77176239	SCAPER	0.47	9.13	0.39	2.13e-18	Blood metabolite levels;
LGG	cis	rs875971	0.895	rs1833495	chr7:65921595	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs1577917	0.654	rs9450284	chr6:86199329	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	10.24	0.43	2.46e-22	Response to antipsychotic treatment;
LGG	cis	rs7607369	0.648	rs17470271	chr2:219651995	A/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.14	-0.32	3.54e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs6840360	0.615	rs12641433	chr4:152607548	A/C	cg22705602	chr4:152727874	NA	-0.37	-8.98	-0.39	6.97e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10819861	0.645	rs10819810	chr9:98849911	C/T	cg14508093	chr9:98862825	NA	0.3	7.09	0.31	5.16e-12	Electrocardiographic traits;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09742170	chr7:25021208	OSBPL3	0.39	7.09	0.31	4.89e-12	Obesity-related traits;
LGG	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs368123	1.000	rs410118	chr6:160728440	T/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs2421770	0.601	rs3843609	chr11:35331173	T/C	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.78	-0.34	4.73e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg03806693	chr22:41940476	POLR3H	-0.99	-17.76	-0.64	3.33e-54	Vitiligo;
LGG	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg02227867	chr8:22457446	C8orf58	0.43	8.27	0.36	1.47e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-7.56	-0.33	2.23e-13	Platelet distribution width;
LGG	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg01879757	chr17:41196368	BRCA1	-0.45	-9.01	-0.39	5.39e-18	Menopause (age at onset);
LGG	cis	rs1003719	0.751	rs56268364	chr21:38542765	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.26	-0.58	6.85e-43	Eye color traits;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.23e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.778	rs780094	chr2:27741237	C/T	cg22903471	chr2:27725779	GCKR	0.36	7.14	0.32	3.58e-12	Total body bone mineral density;
LGG	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.89	0.3	1.87e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.19	0.43	3.77e-22	Iron status biomarkers;
LGG	trans	rs2727020	0.530	rs7113153	chr11:49457957	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.66	-10.7	-0.45	4.86e-24	Coronary artery disease;
LGG	trans	rs7762018	0.891	rs1981069	chr6:170148837	G/A	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg02158880	chr13:53174818	NA	0.4	7.94	0.35	1.49e-14	Lewy body disease;
LGG	cis	rs765787	0.530	rs28524974	chr15:45543528	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-7.02	-0.31	8.19e-12	Uric acid levels;
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg06719900	chr11:109292894	C11orf87	0.51	9.25	0.4	8.05e-19	Schizophrenia;
LGG	trans	rs6828577	0.732	rs60711916	chr4:119461284	G/T	cg26518628	chr1:97050305	NA	-0.54	-8.56	-0.37	1.65e-16	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	trans	rs2898290	0.540	rs12677146	chr8:11450737	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.6	-0.37	1.25e-16	Systolic blood pressure;
LGG	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	31.32	0.82	1.99e-116	Chronic sinus infection;
LGG	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg22681709	chr2:178499509	PDE11A	-0.38	-7.32	-0.32	1.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs907683	0.584	rs2070927	chr2:220282955	C/T	cg15015639	chr2:220282977	DES	0.36	10.11	0.43	7.72e-22	Resting heart rate;
LGG	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.24	-0.46	4.33e-26	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.78	0.59	3.33e-45	Lung cancer;
LGG	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.53	0.37	2.15e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg16103275	chr6:290800	DUSP22	-0.5	-8.23	-0.36	1.94e-15	Menopause (age at onset);
LGG	cis	rs755249	0.567	rs76111861	chr1:39842690	G/T	cg18385671	chr1:39797026	MACF1	0.44	7.65	0.34	1.17e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.51e-14	Lung cancer;
LGG	trans	rs2243480	0.615	rs34363376	chr7:65939536	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.32	0.4	4.73e-19	Diabetic kidney disease;
LGG	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg17809284	chr5:56205270	C5orf35	-0.54	-10.17	-0.43	4.66e-22	Initial pursuit acceleration;
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.87	-0.51	1.3e-32	Alzheimer's disease;
LGG	cis	rs17376456	0.877	rs10064520	chr5:93427358	T/C	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.27e-12	Diabetic retinopathy;
LGG	cis	rs4936894	0.500	rs11599947	chr11:124124483	A/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.94	-0.45	6.38e-25	Aging (time to death);
LGG	cis	rs10991814	0.920	rs75120664	chr9:94117275	A/C	cg14446406	chr9:93919335	NA	-0.74	-8.29	-0.36	1.21e-15	Neutrophil percentage of granulocytes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10905876	chr6:56716656	DST	-0.48	-6.96	-0.31	1.17e-11	Systemic lupus erythematosus;
LGG	cis	rs6586163	0.967	rs10887877	chr10:90753038	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.92	-0.31	1.49e-11	Chronic lymphocytic leukemia;
LGG	cis	rs225245	0.817	rs225299	chr17:33922742	T/C	cg05299278	chr17:33885742	SLFN14	0.41	7.75	0.34	6.05e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.05e-13	Rheumatoid arthritis;
LGG	cis	rs12478296	0.685	rs67829386	chr2:242992276	T/A	cg06360820	chr2:242988706	NA	-1.0	-12.66	-0.51	9.89e-32	Obesity-related traits;
LGG	cis	rs45544231	0.569	rs1420530	chr16:52558729	C/T	cg09051775	chr16:52580266	TOX3	-0.41	-6.82	-0.3	2.83e-11	Restless legs syndrome;
LGG	trans	rs7726839	0.507	rs111707179	chr5:593308	T/A	cg25482853	chr8:67687455	SGK3	0.95	11.98	0.49	5.36e-29	Obesity-related traits;
LGG	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs7572733	0.840	rs4286272	chr2:198535678	T/C	cg00792783	chr2:198669748	PLCL1	-0.42	-7.1	-0.31	4.86e-12	Dermatomyositis;
LGG	cis	rs727505	0.954	rs989177	chr7:124412886	A/G	cg23710748	chr7:124431027	NA	-0.54	-9.97	-0.42	2.35e-21	Lewy body disease;
LGG	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	trans	rs9858542	0.953	rs9827708	chr3:49649989	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.58	-0.33	1.92e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg18196295	chr10:418757	DIP2C	-0.56	-10.22	-0.43	3.1e-22	Psychosis in Alzheimer's disease;
LGG	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	trans	rs11976180	0.953	rs2961127	chr7:143762737	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs887829	0.694	rs6725478	chr2:234615400	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.45	-0.37	3.75e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg05734866	chr2:234756087	HJURP	-0.39	-7.17	-0.32	3.07e-12	Liver disease severity in Alagille syndrome;
LGG	trans	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg25214090	chr10:38739885	LOC399744	0.57	10.39	0.43	7.47e-23	Corneal astigmatism;
LGG	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs5015933	0.902	rs2270746	chr9:128121592	C/T	cg14078157	chr9:128172775	NA	0.38	7.21	0.32	2.36e-12	Body mass index;
LGG	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg23815491	chr16:72088622	HP	0.5	11.09	0.46	1.7e-25	Fibrinogen levels;
LGG	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	8.2	0.36	2.31e-15	Mood instability;
LGG	cis	rs12791968	0.659	rs12808379	chr11:45009273	C/G	cg11846598	chr11:44996168	LOC221122	-0.55	-9.14	-0.39	1.98e-18	Inhibitory control;
LGG	trans	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.96	-0.38	7.99e-18	Bladder cancer;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10892173	0.765	rs7125693	chr11:117670651	C/T	cg21640587	chr11:117668038	DSCAML1	0.46	7.67	0.34	1.01e-13	Myopia;
LGG	cis	rs2243480	1.000	rs2257790	chr7:65600450	C/T	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	trans	rs7395662	0.622	rs2865620	chr11:48807911	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.36	-0.32	8.33e-13	HDL cholesterol;
LGG	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.25	-0.32	1.76e-12	Common traits (Other);
LGG	cis	rs9611519	0.590	rs4821980	chr22:41415479	C/G	cg03806693	chr22:41940476	POLR3H	-0.46	-7.63	-0.33	1.36e-13	Neuroticism;
LGG	cis	rs10426930	0.752	rs10401934	chr19:5038715	C/T	cg18473234	chr19:5097819	KDM4B	0.42	7.15	0.32	3.51e-12	Monocyte percentage of white cells;
LGG	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg03264133	chr6:25882463	NA	-0.66	-11.85	-0.48	1.84e-28	Intelligence (multi-trait analysis);
LGG	cis	rs16912285	0.748	rs7952223	chr11:24256443	G/C	ch.11.24196551F	chr11:24239977	NA	0.93	13.32	0.53	1.68e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2742417	0.967	rs2742439	chr3:45744248	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs950776	0.642	rs12905641	chr15:78964362	A/G	cg03762349	chr15:79060523	ADAMTS7	-0.37	-7.97	-0.35	1.26e-14	Sudden cardiac arrest;
LGG	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-8.07	-0.35	6.09e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs735539	0.598	rs2149769	chr13:21266227	C/T	cg04906043	chr13:21280425	IL17D	0.45	7.47	0.33	4.09e-13	Dental caries;
LGG	cis	rs853679	0.517	rs9368553	chr6:28082265	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs2562456	0.682	rs11085464	chr19:21751778	C/G	cg00806126	chr19:22604979	ZNF98	-0.64	-9.62	-0.41	4.47e-20	Pain;
LGG	cis	rs7412746	0.524	rs58304714	chr1:150831561	T/A	cg15448220	chr1:150897856	SETDB1	0.39	7.18	0.32	2.77e-12	Melanoma;
LGG	cis	rs11671005	0.735	rs11878198	chr19:58920302	A/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs9487094	1.000	rs17070580	chr6:109738714	C/T	cg16315928	chr6:109776240	MICAL1	-0.48	-8.02	-0.35	8.43e-15	Height;
LGG	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg14191688	chr11:70257035	CTTN	0.5	7.16	0.32	3.22e-12	Coronary artery disease;
LGG	cis	rs13082711	0.558	rs1844983	chr3:27370203	C/T	cg02860705	chr3:27208620	NA	-0.65	-12.46	-0.5	6.5e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs62238980	0.614	rs4821005	chr22:32369804	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs1335587	0.679	rs2297699	chr13:102106193	C/T	cg13538571	chr13:102108074	ITGBL1	0.41	7.84	0.34	3.18e-14	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs4919694	0.908	rs11191523	chr10:104792400	A/G	cg04362960	chr10:104952993	NT5C2	1.07	14.76	0.57	1.09e-40	Arsenic metabolism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06434972	chr7:44122219	POLM	0.47	7.63	0.33	1.35e-13	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.4	-0.4	2.5e-19	Triglycerides;
LGG	trans	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg18187862	chr3:45730750	SACM1L	-0.57	-8.95	-0.38	8.78e-18	Primary sclerosing cholangitis;
LGG	cis	rs4472734	0.606	rs9728667	chr1:214632474	A/G	cg17492795	chr1:214637903	PTPN14	-0.33	-8.81	-0.38	2.44e-17	Height;
LGG	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.08	0.49	2.09e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7635838	0.587	rs1992910	chr3:11311942	C/T	cg00170343	chr3:11313890	ATG7	0.55	9.47	0.4	1.4e-19	HDL cholesterol;
LGG	cis	rs10256972	0.900	rs7812072	chr7:1053862	A/G	cg20821713	chr7:1055600	C7orf50	-0.42	-8.07	-0.35	6.13e-15	Longevity;Endometriosis;
LGG	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.37	-7.33	-0.32	1.06e-12	Insulin-like growth factors;
LGG	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg03929089	chr4:120376271	NA	-0.52	-8.73	-0.38	4.67e-17	HDL cholesterol;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg08677398	chr8:58056175	NA	0.44	7.09	0.31	5.03e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg12438819	chr7:158236134	PTPRN2	0.33	8.59	0.37	1.34e-16	Obesity-related traits;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg16339924	chr4:17578868	LAP3	0.63	10.76	0.45	2.91e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8077889	0.917	rs8081646	chr17:41893360	T/C	cg26893861	chr17:41843967	DUSP3	0.92	15.77	0.59	3.57e-45	Triglycerides;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg19147804	chr7:1989927	MAD1L1	-0.63	-12.65	-0.51	1.02e-31	Bipolar disorder and schizophrenia;
LGG	trans	rs877282	0.853	rs12777155	chr10:754731	G/C	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg13263691	chr18:77568018	NA	0.82	14.6	0.56	5.6e-40	Schizophrenia;
LGG	trans	rs459571	0.959	rs392134	chr9:136909008	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.84	-0.48	1.99e-28	Platelet distribution width;
LGG	cis	rs2587949	0.509	rs2120509	chr3:4208591	G/A	cg16519197	chr3:4211558	NA	-0.36	-7.3	-0.32	1.24e-12	Periodontitis (DPAL);
LGG	cis	rs2735413	0.564	rs2222897	chr16:78092035	G/A	cg04733911	chr16:78082701	NA	0.62	8.73	0.38	4.6e-17	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg27523141	chr10:43048294	ZNF37B	0.37	7.53	0.33	2.73e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9911578	1.000	rs2270097	chr17:56572070	G/A	cg05425664	chr17:57184151	TRIM37	0.61	9.78	0.41	1.14e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.74	-0.34	6.24e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs883115	1.000	rs883115	chr1:224807561	T/C	cg01808320	chr1:224927238	CNIH3	-0.39	-7.08	-0.31	5.34e-12	Cancer;
LGG	cis	rs870825	0.616	rs28558715	chr4:185627761	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06475006	chr16:89985975	MC1R	-0.59	-6.81	-0.3	2.98e-11	Skin colour saturation;
LGG	cis	rs4774899	0.800	rs2733341	chr15:57466232	T/A	cg08128148	chr15:57256372	TCF12	-0.3	-7.28	-0.32	1.41e-12	Urinary tract infection frequency;
LGG	cis	rs9649465	0.967	rs13230230	chr7:123329603	G/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg13010199	chr12:38710504	ALG10B	0.76	16.28	0.6	1.88e-47	Heart rate;
LGG	cis	rs1957429	0.614	rs66883381	chr14:65334773	C/T	cg23373153	chr14:65346875	NA	-1.02	-10.84	-0.45	1.48e-24	Pediatric areal bone mineral density (radius);
LGG	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.09	-0.31	4.93e-12	Iron status biomarkers;
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg26513180	chr16:89883248	FANCA	0.81	8.82	0.38	2.38e-17	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs634534	0.622	rs531612	chr11:65705432	C/T	cg17712092	chr4:129076599	LARP1B	-0.71	-13.45	-0.53	5.04e-35	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg06634786	chr22:41940651	POLR3H	0.76	12.14	0.49	1.25e-29	Vitiligo;
LGG	cis	rs9943753	0.508	rs7138357	chr12:109832303	A/G	cg19025524	chr12:109796872	NA	-0.54	-11.68	-0.48	8.04e-28	HDL cholesterol;
LGG	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg24634471	chr8:143751801	JRK	0.53	8.38	0.36	6.52e-16	Schizophrenia;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg23825981	chr20:60982038	CABLES2	-0.44	-7.51	-0.33	3.13e-13	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg13699009	chr12:122356056	WDR66	0.53	14.03	0.55	1.69e-37	Mean platelet volume;
LGG	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Gut microbiome composition (summer);
LGG	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg11502198	chr6:26597334	ABT1	0.7	12.68	0.51	7.88e-32	Intelligence (multi-trait analysis);
LGG	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg21385522	chr1:16154831	NA	-1.04	-26.19	-0.77	1.99e-93	Dilated cardiomyopathy;
LGG	cis	rs4073582	1.000	rs801732	chr11:65935502	T/A	cg16950941	chr11:66035639	RAB1B	0.41	7.02	0.31	7.92e-12	Gout;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13126279	chr21:47581558	C21orf56	-0.54	-9.8	-0.41	1e-20	Testicular germ cell tumor;
LGG	cis	rs7602441	0.521	rs77940955	chr2:14767411	T/C	cg06545361	chr2:14773388	FAM84A	0.82	7.61	0.33	1.54e-13	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs60871478	0.730	rs73042471	chr7:927762	G/A	cg22643751	chr7:855365	UNC84A	-0.43	-6.93	-0.31	1.43e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7617773	0.780	rs34523942	chr3:48342669	C/T	cg11946769	chr3:48343235	NME6	0.66	11.0	0.46	3.66e-25	Coronary artery disease;
LGG	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg01280390	chr8:19363452	CSGALNACT1	-0.6	-17.31	-0.63	3.91e-52	Oropharynx cancer;
LGG	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.72	-11.05	-0.46	2.29e-25	Homoarginine levels;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg20607798	chr8:58055168	NA	0.68	7.67	0.34	1.02e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9715521	0.868	rs6848053	chr4:59839309	T/C	cg11281224	chr4:60001000	NA	-0.45	-7.45	-0.33	4.6e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs5771225	0.544	rs13055135	chr22:50672479	A/G	cg16473166	chr22:50639996	SELO	0.7	10.93	0.45	6.54e-25	Late-onset Alzheimer's disease;
LGG	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.91	0.35	1.91e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.42e-27	Rheumatoid arthritis;
LGG	trans	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg13565492	chr6:43139072	SRF	-0.79	-10.12	-0.43	6.75e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7173743	0.756	rs11852830	chr15:79125429	A/T	cg00540400	chr15:79124168	NA	0.43	9.1	0.39	2.64e-18	Coronary artery disease;
LGG	cis	rs7255436	0.965	rs12981318	chr19:8451430	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.74	-0.3	4.67e-11	HDL cholesterol;
LGG	cis	rs2862064	1.000	rs7706978	chr5:156432566	T/C	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.8	-0.45	2.05e-24	Platelet count;
LGG	trans	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs67311347	0.822	rs9826847	chr3:40345312	A/T	cg13683864	chr3:40499215	RPL14	-0.87	-17.24	-0.63	8.42e-52	Renal cell carcinoma;
LGG	cis	rs6088619	1.000	rs6088619	chr20:33411871	A/G	cg06115741	chr20:33292138	TP53INP2	0.65	6.72	0.3	5.31e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.23	-0.32	1.99e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg00490583	chr16:1843685	IGFALS	0.47	10.26	0.43	2.09e-22	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg04673462	chr1:38461896	NA	0.55	11.84	0.48	1.9e-28	Coronary artery disease;
LGG	cis	rs1010254	0.559	rs72808320	chr5:151741858	G/C	cg12297329	chr5:152029980	NA	-0.5	-7.17	-0.32	2.93e-12	Optic nerve measurement (cup area);
LGG	cis	rs11664298	0.606	rs11081564	chr18:77551586	A/G	cg13263691	chr18:77568018	NA	0.51	7.79	0.34	4.55e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9682041	0.660	rs13089256	chr3:170113601	G/A	cg11886554	chr3:170076028	SKIL	0.65	8.42	0.36	4.65e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs2197308	0.765	rs7295711	chr12:37903631	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14042131	chr11:48003169	PTPRJ	0.41	6.74	0.3	4.64e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg03517284	chr6:25882590	NA	-0.41	-7.41	-0.33	6.01e-13	Height;
LGG	cis	rs427394	0.796	rs274683	chr5:6747950	T/A	cg15145174	chr5:6755386	POLS	-0.39	-7.31	-0.32	1.19e-12	Menopause (age at onset);
LGG	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg21385522	chr1:16154831	NA	1.08	25.49	0.76	3.2e-90	Dilated cardiomyopathy;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.3	0.32	1.25e-12	Lung cancer;
LGG	cis	rs6594713	0.642	rs6867579	chr5:112899573	T/C	cg12552261	chr5:112820674	MCC	0.64	7.87	0.34	2.54e-14	Brain cytoarchitecture;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg12070911	chr6:150209640	RAET1E	0.28	6.76	0.3	4.11e-11	Lung cancer;
LGG	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg01620082	chr3:125678407	NA	0.58	7.48	0.33	3.87e-13	Depression;
LGG	cis	rs5756391	0.546	rs4239882	chr22:37314008	A/G	cg21209356	chr22:37319042	CSF2RB	0.39	8.97	0.38	7.4e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs3741151	0.773	rs7950375	chr11:73281345	G/A	cg17517138	chr11:73019481	ARHGEF17	0.83	7.9	0.34	2.04e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.94	-0.31	1.35e-11	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs55788414	0.932	rs9936302	chr16:81190790	C/T	cg06400318	chr16:81190750	PKD1L2	-1.1	-13.04	-0.52	2.51e-33	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg02297831	chr4:17616191	MED28	0.42	7.83	0.34	3.39e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.571	rs7683769	chr4:99091742	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.93	0.31	1.4e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1023500	0.551	rs2301521	chr22:42423110	G/C	cg04733989	chr22:42467013	NAGA	0.6	10.28	0.43	1.87e-22	Schizophrenia;
LGG	cis	rs7107174	1.000	rs4945268	chr11:78037936	T/C	cg02023728	chr11:77925099	USP35	0.46	7.88	0.34	2.31e-14	Testicular germ cell tumor;
LGG	cis	rs498872	0.507	rs10892247	chr11:118490076	G/A	cg19182353	chr11:118479428	PHLDB1	0.41	7.34	0.32	9.37e-13	Glioma;
LGG	cis	rs7084402	0.967	rs1427197	chr10:60275150	A/G	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.71e-12	Refractive error;
LGG	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg27129171	chr3:47204927	SETD2	-0.8	-14.8	-0.57	7.26e-41	Colorectal cancer;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg05863683	chr7:1912471	MAD1L1	0.41	7.93	0.35	1.68e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg13147721	chr7:65941812	NA	0.73	8.88	0.38	1.47e-17	Diabetic kidney disease;
LGG	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg09222892	chr1:25734099	RHCE	0.46	9.63	0.41	3.96e-20	Erythrocyte sedimentation rate;
LGG	cis	rs6121246	0.559	rs6060919	chr20:30331922	A/T	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg08847533	chr14:75593920	NEK9	0.61	11.68	0.48	8.08e-28	Height;
LGG	cis	rs9393813	0.805	rs2205829	chr6:27480227	A/G	cg18711553	chr6:27366782	ZNF391	0.47	8.93	0.38	9.95e-18	Bipolar disorder;
LGG	cis	rs2742417	0.587	rs2742375	chr3:45784602	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-9.08	-0.39	3.06e-18	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7091068	0.518	rs1543580	chr10:95446811	C/T	cg20715218	chr10:95462985	C10orf4	0.67	12.01	0.49	4.02e-29	Urinary tract infection frequency;
LGG	cis	rs4664308	1.000	rs10929966	chr2:160908341	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg18252515	chr7:66147081	NA	-0.41	-6.87	-0.3	2.12e-11	Aortic root size;
LGG	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg08975724	chr8:8085496	FLJ10661	0.47	9.15	0.39	1.89e-18	Joint mobility (Beighton score);
LGG	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-11.92	-0.48	9.26e-29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.06	-0.35	6.55e-15	Skin colour saturation;
LGG	cis	rs7666738	0.830	rs6829567	chr4:99047340	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg07414643	chr4:187882934	NA	0.55	11.41	0.47	1e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.58	0.41	5.95e-20	Obesity-related traits;
LGG	cis	rs2290405	0.593	rs12499663	chr4:888170	G/A	cg20916646	chr4:852691	GAK	0.42	7.61	0.33	1.6e-13	Systemic sclerosis;
LGG	cis	rs9393777	0.513	rs3999471	chr6:26650306	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.961	rs35067331	chr2:3474085	C/T	cg10845886	chr2:3471009	TTC15	-0.76	-15.05	-0.57	6.08e-42	Neurofibrillary tangles;
LGG	cis	rs9581857	0.579	rs3759433	chr13:27997999	C/T	cg01674679	chr13:27998804	GTF3A	-0.71	-9.05	-0.39	3.97e-18	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs10766533	1.000	rs10766533	chr11:19224677	A/T	cg14704941	chr11:19224659	CSRP3	0.52	9.49	0.4	1.24e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.53	0.5	3.16e-31	Lung cancer in ever smokers;
LGG	trans	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.87	0.48	1.5e-28	Lewy body disease;
LGG	cis	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg13010199	chr12:38710504	ALG10B	-0.72	-15.14	-0.58	2.3e-42	Heart rate;
LGG	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg22705602	chr4:152727874	NA	0.32	7.86	0.34	2.74e-14	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.737	rs11861132	chr16:28871860	A/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg02002194	chr4:3960332	NA	-0.5	-9.36	-0.4	3.49e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9674544	0.757	rs11871214	chr17:47124902	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.49	-9.55	-0.41	7.84e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs981844	0.712	rs4434231	chr4:154746293	G/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.9	-0.42	4.38e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.7	0.56	2.02e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg01765077	chr12:122356316	WDR66	-0.28	-7.7	-0.34	8.25e-14	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.3	-0.43	1.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg06719900	chr11:109292894	C11orf87	-0.44	-8.44	-0.37	4.17e-16	Schizophrenia;
LGG	cis	rs2066819	1.000	rs57870697	chr12:56752874	A/G	cg26714650	chr12:56694279	CS	-1.58	-15.14	-0.58	2.42e-42	Psoriasis vulgaris;
LGG	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg03060546	chr3:49711283	APEH	-0.7	-11.73	-0.48	5.11e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7932354	0.528	rs7108902	chr11:47091571	C/T	cg03339077	chr11:47165057	C11orf49	-0.53	-9.96	-0.42	2.63e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs7712401	0.601	rs246321	chr5:122308299	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.88	-0.3	1.98e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg07511668	chr11:68622177	NA	0.51	9.79	0.41	1.1e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8114671	0.585	rs2236271	chr20:33523840	G/T	cg07148914	chr20:33460835	GGT7	-0.47	-7.78	-0.34	4.85e-14	Height;
LGG	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.35	0.43	1.03e-22	Aortic root size;
LGG	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs1109114	0.816	rs2918270	chr5:148604904	C/T	cg06539116	chr5:148597365	ABLIM3	-0.61	-16.07	-0.6	1.66e-46	Body mass index;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.21	-0.32	2.34e-12	Menopause (age at onset);
LGG	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.47	-0.4	1.43e-19	Mean corpuscular volume;
LGG	cis	rs1691799	0.867	rs1168333	chr12:66761377	G/A	cg16791601	chr12:66731901	HELB	-0.63	-14.56	-0.56	8.4e-40	White blood cell count (basophil);
LGG	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-12.37	-0.5	1.49e-30	Cognitive function;
LGG	cis	rs362272	0.505	rs2857854	chr4:3043184	G/T	cg02566259	chr4:3043199	NA	0.35	8.77	0.38	3.53e-17	Serum sulfate level;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15738916	chr2:102314495	MAP4K4	0.5	7.64	0.33	1.27e-13	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs9920506	0.536	rs11636605	chr15:78928878	A/G	cg07120314	chr15:79043507	NA	-0.49	-8.94	-0.38	9.45e-18	Post bronchodilator FEV1;
LGG	cis	rs4732038	1.000	rs782876	chr7:134240770	C/G	cg06906464	chr7:134288099	NA	-0.51	-12.69	-0.51	7.12e-32	Longevity;
LGG	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg13385521	chr17:29058706	SUZ12P	-0.69	-8.13	-0.35	4.06e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2180341	1.000	rs4897207	chr6:127605898	C/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	5.85e-47	Breast cancer;
LGG	cis	rs2117029	0.898	rs10875914	chr12:49422094	A/G	cg24176009	chr12:49580217	TUBA1A	0.45	8.12	0.35	4.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.62	0.41	4.34e-20	Educational attainment;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg26150922	chr2:100937072	LONRF2	-0.57	-10.85	-0.45	1.35e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs17445240	0.901	rs13418767	chr2:3704830	G/T	cg17046650	chr2:3699563	NA	0.83	10.02	0.42	1.64e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7769051	0.522	rs7775241	chr6:133109022	T/C	cg22852734	chr6:133119734	C6orf192	1.39	11.7	0.48	7.25e-28	Type 2 diabetes nephropathy;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	9.01	0.39	5.42e-18	Schizophrenia;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg18538332	chr22:24372958	LOC391322	-0.41	-6.81	-0.3	3e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg11693508	chr17:37793320	STARD3	0.51	7.35	0.32	8.75e-13	Bipolar disorder;
LGG	cis	rs2797369	0.570	rs2813639	chr6:101571764	T/A	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.89e-15	Renal function-related traits (eGRFcrea);
LGG	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.2	0.39	1.25e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.14	-0.52	9.48e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs1620712	chr3:153790050	C/G	cg17054900	chr3:154042577	DHX36	0.7	8.66	0.37	7.8e-17	Coronary artery disease;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.45	-0.61	3.24e-48	Skin colour saturation;
LGG	cis	rs847649	0.692	rs1541519	chr7:102466741	G/T	cg18108683	chr7:102477205	FBXL13	-0.71	-15.86	-0.59	1.4e-45	Morning vs. evening chronotype;
LGG	cis	rs7192750	0.562	rs9889011	chr16:71987816	T/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.29e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.33	-0.5	2.1000000000000002e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.17e-18	Motion sickness;
LGG	cis	rs61931739	0.929	rs2389274	chr12:34075149	T/C	cg06521331	chr12:34319734	NA	0.41	7.49	0.33	3.63e-13	Morning vs. evening chronotype;
LGG	cis	rs4926611	0.830	rs4926604	chr1:54051924	T/C	cg23596471	chr1:54105337	GLIS1	0.38	7.86	0.34	2.73e-14	Hand grip strength;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.73	-0.38	4.66e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7551222	0.646	rs7556371	chr1:204457336	A/G	cg20240347	chr1:204465584	NA	0.51	9.63	0.41	4e-20	Schizophrenia;
LGG	cis	rs3096299	0.933	rs28608022	chr16:89454292	C/T	cg06640241	chr16:89574553	SPG7	0.71	12.32	0.5	2.31e-30	Multiple myeloma (IgH translocation);
LGG	cis	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg24623649	chr8:11872141	NA	-0.31	-6.77	-0.3	3.96e-11	Systemic lupus erythematosus;
LGG	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg11166453	chr1:247681781	NA	0.66	10.33	0.43	1.21e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4356932	1.000	rs7377856	chr4:76964096	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	5.07e-11	Blood protein levels;
LGG	trans	rs1962073	0.623	rs7459532	chr8:10261068	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.38	0.32	7.26e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	trans	rs941408	1.000	rs1736183	chr19:2809672	A/G	cg22153745	chr1:153894579	GATAD2B	-0.63	-10.23	-0.43	2.8e-22	Total cholesterol levels;
LGG	cis	rs9788721	0.836	rs17483686	chr15:78733390	A/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.46	-0.4	1.61e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9543976	1.000	rs2296146	chr13:76143572	T/C	cg01531495	chr13:76123901	UCHL3	-0.62	-7.39	-0.32	7.1e-13	Diabetic retinopathy;
LGG	cis	rs2304069	0.565	rs13183261	chr5:149421847	T/G	cg12661370	chr5:149340060	SLC26A2	0.48	8.03	0.35	8.39e-15	HIV-1 control;
LGG	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg20283391	chr11:68216788	NA	-0.49	-8.03	-0.35	8.02e-15	Total body bone mineral density;
LGG	cis	rs34599045	0.522	rs34889136	chr1:152923124	A/G	cg07796016	chr1:152779584	LCE1C	-0.87	-8.05	-0.35	6.84e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs79911532	0.515	rs79663210	chr7:75684326	G/A	cg19862616	chr7:65841803	NCRNA00174	0.76	8.02	0.35	8.59e-15	Mononucleosis;
LGG	cis	rs1620921	0.595	rs2465862	chr6:161261198	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg00383909	chr3:49044727	WDR6	0.98	12.38	0.5	1.33e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6817170	0.577	rs12644734	chr4:154385594	A/G	cg24020152	chr4:154419554	KIAA0922	0.33	7.09	0.31	4.97e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs12586317	0.547	rs2273154	chr14:35433187	C/T	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.64	-0.33	1.29e-13	Psoriasis;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	5.19e-31	Lung cancer;
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.26	-0.32	1.7e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs8072100	0.817	rs9912101	chr17:45547078	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.44	-0.44	4.83e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg27211696	chr2:191398769	TMEM194B	0.4	9.34	0.4	4.07e-19	Pulse pressure;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25172604	chr17:41446521	NA	-0.31	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14437634	chr14:67879385	PLEK2	0.34	6.66	0.3	7.78e-11	Electrocardiographic conduction measures;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg11211951	chr8:145729740	GPT	0.52	12.37	0.5	1.48e-30	Age at first birth;
LGG	cis	rs7927771	0.524	rs7122182	chr11:47843133	A/C	cg20307385	chr11:47447363	PSMC3	-0.56	-11.02	-0.46	3.09e-25	Subjective well-being;
LGG	cis	rs9341808	0.718	rs910266	chr6:80921170	A/T	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.43	-0.44	5.13e-23	Longevity;Endometriosis;
LGG	cis	rs11734570	0.581	rs73811714	chr4:38588327	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.6	8.22	0.36	2.02e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1582827	chr10:60297102	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs4948102	0.595	rs7793921	chr7:56120881	G/A	cg17215666	chr7:56131930	SUMF2	0.5	8.42	0.36	4.7e-16	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg14541582	chr5:601475	NA	-0.57	-9.14	-0.39	2.03e-18	Obesity-related traits;
LGG	cis	rs1355223	1.000	rs11604069	chr11:34764251	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-6.84	-0.3	2.52e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1847505	0.501	rs3119871	chr13:61407658	C/T	cg25164009	chr13:61490935	NA	0.47	7.97	0.35	1.28e-14	Polychlorinated biphenyl levels;
LGG	trans	rs916888	0.610	rs199446	chr17:44813169	G/A	cg22968622	chr17:43663579	NA	-0.78	-15.24	-0.58	8.43e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35740288	0.895	rs3743332	chr15:86303751	T/C	cg07943548	chr15:86304357	KLHL25	-0.37	-7.43	-0.33	5.24e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.24	0.43	2.59e-22	Colorectal cancer;
LGG	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg03264133	chr6:25882463	NA	0.54	9.84	0.42	7.26e-21	Blood metabolite levels;
LGG	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg26384229	chr12:38710491	ALG10B	0.76	15.7	0.59	7.73e-45	Morning vs. evening chronotype;
LGG	cis	rs6831352	0.918	rs28987097	chr4:100049579	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs4268898	0.662	rs72795824	chr2:24435837	T/C	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg04831495	chr15:85060580	GOLGA6L5	0.34	6.85	0.3	2.37e-11	Bulimia nervosa;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg20308403	chr7:2120281	MAD1L1	0.33	7.19	0.32	2.68e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.58	-7.66	-0.34	1.1e-13	Smoking behavior;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg18350739	chr11:68623251	NA	-0.89	-21.45	-0.71	2.16e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg17691542	chr6:26056736	HIST1H1C	0.46	8.29	0.36	1.25e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.967	rs6428559	chr1:90099036	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.1	-0.31	4.59e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg16387850	chr1:46982889	NA	0.34	8.62	0.37	1.09e-16	Monobrow;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05025164	chr4:1340916	KIAA1530	0.65	11.97	0.49	6.08e-29	Obesity-related traits;
LGG	cis	rs2865126	0.818	rs8088701	chr18:10764365	T/A	cg21165219	chr18:10698044	FAM38B	-0.45	-7.3	-0.32	1.23e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg24503407	chr1:205819492	PM20D1	-0.4	-7.2	-0.32	2.45e-12	Menarche (age at onset);
LGG	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg08250081	chr4:10125330	NA	0.42	8.32	0.36	9.94e-16	Bone mineral density;
LGG	cis	rs17504614	0.591	rs9645152	chr2:51064402	C/T	cg23851515	chr2:51057218	NRXN1	0.48	7.83	0.34	3.43e-14	Educational attainment (years of education);
LGG	cis	rs4664308	1.000	rs17341301	chr2:160902420	G/A	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.14	-0.62	2.25e-51	Idiopathic membranous nephropathy;
LGG	cis	rs7769051	1.000	rs10484629	chr6:133117870	A/C	cg22852734	chr6:133119734	C6orf192	1.17	14.84	0.57	5.06e-41	Type 2 diabetes nephropathy;
LGG	cis	rs67133203	0.904	rs7306293	chr12:51364349	A/G	cg14688905	chr12:51403056	SLC11A2	0.79	12.17	0.49	9.48e-30	Urinary tract infection frequency;
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg18357526	chr6:26021779	HIST1H4A	0.42	6.85	0.3	2.41e-11	Height;
LGG	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg07061783	chr6:25882402	NA	-0.39	-7.05	-0.31	6.38e-12	Blood metabolite levels;
LGG	cis	rs2067615	0.524	rs10778499	chr12:107068387	C/T	cg15890332	chr12:107067104	RFX4	0.43	12.34	0.5	1.84e-30	Heart rate;
LGG	cis	rs6547631	0.622	rs10180547	chr2:85926305	G/A	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	trans	rs208520	1.000	rs72882102	chr6:66983408	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23214285	chr7:16685646	BZW2;ANKMY2	0.4	6.67	0.3	7.27e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	0.824	rs12785858	chr11:48778806	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.47	-0.33	4.12e-13	HDL cholesterol;
LGG	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18876405	chr7:65276391	NA	0.55	9.78	0.41	1.14e-20	Aortic root size;
LGG	cis	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	8.77e-26	Morning vs. evening chronotype;
LGG	cis	rs11671005	0.735	rs11671591	chr19:58918337	A/G	cg13877915	chr19:58951672	ZNF132	-0.59	-8.56	-0.37	1.63e-16	Mean platelet volume;
LGG	cis	rs28595532	0.920	rs56212415	chr4:119737731	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.11	0.8	1.18e-106	Chronic sinus infection;
LGG	cis	rs7681440	0.647	rs1372508	chr4:90819786	C/G	cg20003494	chr4:90757398	SNCA	0.35	6.72	0.3	5.23e-11	Dementia with Lewy bodies;
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg16141378	chr3:129829833	LOC729375	0.39	8.9	0.38	1.23e-17	Neuroticism;
LGG	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08564027	chr20:61660810	NA	1.02	25.19	0.76	7.89e-89	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.63	0.61	5.11e-49	Platelet count;
LGG	cis	rs7215564	0.818	rs1471790	chr17:78670565	C/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.14e-15	Myopia (pathological);
LGG	cis	rs1153858	0.723	rs4580098	chr15:45596909	T/A	cg26924012	chr15:45694286	SPATA5L1	0.97	18.05	0.64	1.64e-55	Homoarginine levels;
LGG	trans	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-10.01	-0.42	1.74e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs7084402	0.967	rs1649018	chr10:60288150	T/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs3741404	0.609	rs687581	chr11:63871533	G/T	cg04000281	chr11:63949212	NA	0.37	7.27	0.32	1.52e-12	Platelet count;
LGG	cis	rs4268898	0.697	rs10445892	chr2:24406958	T/C	cg06627628	chr2:24431161	ITSN2	0.47	7.74	0.34	6.19e-14	Asthma;
LGG	cis	rs6940638	0.956	rs10946899	chr6:27023694	T/A	cg09904177	chr6:26538194	HMGN4	-0.49	-7.29	-0.32	1.39e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg25319279	chr11:5960081	NA	-0.57	-8.76	-0.38	3.57e-17	DNA methylation (variation);
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.74e-12	Lung cancer;
LGG	cis	rs3762637	1.000	rs13321097	chr3:122162007	C/T	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg13114125	chr14:105738426	BRF1	-0.84	-17.0	-0.62	1.05e-50	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12447804	0.645	rs12599249	chr16:58118226	T/C	cg03859792	chr16:58121049	NA	0.61	9.2	0.39	1.25e-18	Pulmonary function;Pulmonary function (smoking interaction);
LGG	trans	rs1032833	0.732	rs78519350	chr2:180126611	A/T	cg23654767	chr2:101192981	PDCL3	0.72	8.39	0.36	5.92e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9486719	0.843	rs3860230	chr6:97036560	T/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-12.17	-0.49	9.37e-30	Migraine;Coronary artery disease;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg14092988	chr3:52407081	DNAH1	0.3	8.05	0.35	6.9e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2153904	0.793	rs12564209	chr1:205720212	C/G	cg26354017	chr1:205819088	PM20D1	-0.52	-6.71	-0.3	5.7e-11	Prostate-specific antigen levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17323045	chr14:58764804	FLJ31306;ARID4A	0.46	7.38	0.32	7.16e-13	Cognitive performance;
LGG	cis	rs7326068	0.595	rs2762988	chr13:21370780	T/A	cg04906043	chr13:21280425	IL17D	-0.45	-7.08	-0.31	5.29e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.67	-0.3	7.42e-11	Height;
LGG	cis	rs208515	0.525	rs10755508	chr6:66675790	T/C	cg07460842	chr6:66804631	NA	0.93	17.02	0.62	8.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-7.34	-0.32	9.84e-13	Schizophrenia;
LGG	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg13010199	chr12:38710504	ALG10B	0.73	14.89	0.57	2.91e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs58235267	0.544	rs12478556	chr2:63341711	T/A	cg17519650	chr2:63277830	OTX1	0.55	10.0	0.42	1.87e-21	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs56077333	1	rs56077333	chr15:78899003	C/A	cg18825076	chr15:78729989	IREB2	-0.44	-7.04	-0.31	6.96e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09285771	chr14:35761165	PSMA6	0.43	7.36	0.32	8.36e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.45	-0.33	4.74e-13	Colorectal cancer;
LGG	cis	rs11971779	0.680	rs6949599	chr7:139054188	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs9398803	0.865	rs1907067	chr6:126837663	A/C	cg19875578	chr6:126661172	C6orf173	0.57	10.45	0.44	4.48e-23	Male-pattern baldness;
LGG	cis	rs2153535	0.542	rs9393012	chr6:8439809	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.27e-18	Motion sickness;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs12893597	0.704	rs34065247	chr14:76834029	A/C	cg20290672	chr14:76816747	NA	-0.48	-7.3	-0.32	1.3e-12	Maximal oxygen uptake response;
LGG	trans	rs637571	0.522	rs649000	chr11:65742933	T/C	cg17712092	chr4:129076599	LARP1B	0.72	13.78	0.54	1.87e-36	Eosinophil percentage of white cells;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22968622	chr17:43663579	NA	1.1	21.79	0.71	5.72e-73	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg22535103	chr8:58192502	C8orf71	-1.0	-15.88	-0.59	1.14e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs4702718	0.519	rs2918391	chr5:10705486	C/T	cg18867653	chr5:10760375	DAP	0.3	7.5	0.33	3.24e-13	Obesity-related traits;
LGG	cis	rs6489882	0.934	rs1859330	chr12:113376388	G/A	cg25319449	chr12:113376135	OAS3	-0.38	-7.13	-0.31	3.8e-12	Chronic lymphocytic leukemia;
LGG	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.09	-0.35	5.43e-15	IgG glycosylation;
LGG	cis	rs801193	0.569	rs2707847	chr7:66202871	C/G	cg11764359	chr7:65958608	NA	0.71	12.88	0.51	1.16e-32	Aortic root size;
LGG	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg27539214	chr16:67997921	SLC12A4	-0.51	-7.76	-0.34	5.39e-14	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2795502	0.882	rs2744087	chr10:43340270	A/C	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg27286069	chr11:118481882	PHLDB1	0.55	10.53	0.44	2.11e-23	Cholesterol, total;
LGG	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.65	-0.41	3.33e-20	Diabetic retinopathy;
LGG	cis	rs6732160	1.000	rs6732160	chr2:73387228	A/G	cg01422370	chr2:73384389	NA	0.53	10.26	0.43	2.1e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.54	0.71	8.24e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4665809	0.590	rs35532350	chr2:26441605	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs9399135	0.967	rs11756988	chr6:135347595	A/G	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg05425664	chr17:57184151	TRIM37	0.59	9.4	0.4	2.61e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	1.000	rs28558133	chr6:26531433	G/C	cg09904177	chr6:26538194	HMGN4	0.78	18.09	0.64	9.87e-56	Intelligence (multi-trait analysis);
LGG	cis	rs2227564	0.597	rs2271271	chr10:75558867	G/A	cg00564723	chr10:75632066	CAMK2G	-0.47	-10.0	-0.42	1.84e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2760061	0.583	rs708121	chr1:228208257	A/G	cg01200585	chr1:228362443	C1orf69	0.47	7.98	0.35	1.14e-14	Diastolic blood pressure;
LGG	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2120243	0.647	rs7632702	chr3:157145903	C/T	cg24825693	chr3:157122686	VEPH1	-0.37	-7.55	-0.33	2.28e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg06634786	chr22:41940651	POLR3H	-0.76	-12.09	-0.49	1.99e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs61931739	0.620	rs708141	chr12:33719664	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.21	0.43	3.34e-22	Tonsillectomy;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.36	-0.32	8.72e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.25	-0.32	1.76e-12	Lung cancer;
LGG	cis	rs6539267	0.741	rs2279759	chr12:106694988	T/C	cg02476566	chr12:106696527	TCP11L2	0.5	7.13	0.31	3.92e-12	Tourette syndrome;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg13012494	chr21:47604986	C21orf56	0.49	8.18	0.36	2.73e-15	Testicular germ cell tumor;
LGG	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg09596252	chr17:78655493	RPTOR	0.44	7.98	0.35	1.17e-14	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01166180	chr19:36606541	POLR2I;TBCB	0.46	6.71	0.3	5.57e-11	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs8067545	0.611	rs2703805	chr17:20107773	T/C	cg09818912	chr17:20140352	CYTSB	0.31	7.18	0.32	2.76e-12	Schizophrenia;
LGG	cis	rs1816752	0.870	rs2033955	chr13:25010544	T/C	cg22771759	chr13:24902376	NA	0.42	7.13	0.31	3.86e-12	Obesity-related traits;
LGG	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg15704280	chr7:45808275	SEPT13	-0.57	-9.59	-0.41	5.7e-20	HDL cholesterol;
LGG	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.69	-0.34	9.01e-14	Cognitive test performance;
LGG	cis	rs2204008	0.683	rs7305703	chr12:38138381	T/C	cg26384229	chr12:38710491	ALG10B	0.89	20.02	0.68	1.09e-64	Bladder cancer;
LGG	cis	rs17321999	0.904	rs906865	chr2:30478173	C/T	cg05247661	chr2:30472410	LBH	0.53	8.78	0.38	3.07e-17	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg22105103	chr4:187893119	NA	-0.56	-10.55	-0.44	1.86e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs62238980	0.614	rs117960638	chr22:32417569	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg04166393	chr7:2884313	GNA12	0.48	9.16	0.39	1.7e-18	Height;
LGG	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.5	-0.33	3.33e-13	Testicular germ cell tumor;
LGG	cis	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.38	0.53	9.09e-35	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg12591125	chr7:1885375	MAD1L1	0.46	7.12	0.31	4.03e-12	Bipolar disorder;
LGG	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg08344181	chr3:125677491	NA	-0.63	-7.44	-0.33	5e-13	Depression;
LGG	cis	rs6141769	0.569	rs6057616	chr20:31259279	A/T	cg13636640	chr20:31349939	DNMT3B	-0.48	-7.24	-0.32	1.89e-12	Subjective well-being;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg15575017	chr2:237010430	AGAP1	0.38	6.95	0.31	1.22e-11	Electrocardiographic conduction measures;
LGG	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.94e-13	Neuroticism;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg03115019	chr17:80708279	FN3K	0.37	7.06	0.31	6.16e-12	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.96	-0.42	2.6e-21	Lung cancer;
LGG	trans	rs853679	0.546	rs17695758	chr6:27837183	T/C	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	cis	rs2658782	0.950	rs2446061	chr11:93149277	C/T	cg15737290	chr11:93063684	CCDC67	0.58	8.54	0.37	1.89e-16	Pulmonary function decline;
LGG	cis	rs36071027	0.615	rs13189454	chr5:158410515	C/T	cg23468002	chr5:158532401	NA	0.41	6.92	0.31	1.47e-11	Carotid intima media thickness;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg04008888	chr11:68622739	NA	0.53	11.51	0.47	3.89e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4740619	0.803	rs6474931	chr9:15617677	G/T	cg14451791	chr9:16040625	NA	-0.38	-9.77	-0.41	1.29e-20	Body mass index;
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs7584330	0.910	rs880930	chr2:238396872	G/C	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.24e-11	Prostate cancer;
LGG	cis	rs2742417	0.603	rs2673075	chr3:45778288	C/A	cg04837898	chr3:45731254	SACM1L	-0.48	-9.5	-0.4	1.12e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs62238980	0.614	rs79022443	chr22:32456717	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs9660992	0.736	rs55673946	chr1:205250475	T/C	cg21545522	chr1:205238299	TMCC2	0.46	8.28	0.36	1.32e-15	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg18187862	chr3:45730750	SACM1L	0.55	9.0	0.39	5.89e-18	Primary sclerosing cholangitis;
LGG	cis	rs6728642	0.614	rs113485946	chr2:97866442	T/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.74	-0.3	4.67e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs2688608	0.672	rs2633321	chr10:75693695	C/T	cg10168709	chr10:75599394	CAMK2G	-0.35	-7.05	-0.31	6.46e-12	Inflammatory bowel disease;
LGG	cis	rs4918072	0.793	rs7905046	chr10:105697934	T/G	cg11005552	chr10:105648138	OBFC1	0.43	6.98	0.31	1.01e-11	Coronary artery disease;
LGG	cis	rs6800768	0.636	rs11129133	chr3:24092176	C/T	cg10674438	chr3:24145617	LOC152024	-0.33	-6.73	-0.3	5.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4750440	0.585	rs10508470	chr10:14021822	G/A	cg00551146	chr10:14014579	FRMD4A	0.34	7.75	0.34	6.06e-14	Adiponectin levels;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.71	0.38	5.32e-17	Lung cancer;
LGG	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.68	0.37	6.79e-17	Aortic root size;
LGG	cis	rs6952808	0.531	rs3779002	chr7:2183219	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.23	-0.32	2.04e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg26818010	chr10:134567672	INPP5A	-0.57	-9.12	-0.39	2.25e-18	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg01324343	chr3:183735012	ABCC5	0.84	17.93	0.64	5.61e-55	Anterior chamber depth;
LGG	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg16797656	chr11:68205561	LRP5	-0.39	-6.87	-0.3	2.14e-11	Total body bone mineral density;
LGG	cis	rs694739	0.857	rs574835	chr11:64110668	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.83	16.37	0.61	7.47e-48	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg21479132	chr6:26055353	NA	0.8	7.76	0.34	5.29e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg06634786	chr22:41940651	POLR3H	-0.73	-12.12	-0.49	1.47e-29	Vitiligo;
LGG	cis	rs763121	0.853	rs3747174	chr22:39069181	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	trans	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg01620082	chr3:125678407	NA	-0.78	-7.96	-0.35	1.37e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2227564	0.830	rs2633322	chr10:75693932	T/C	cg00564723	chr10:75632066	CAMK2G	-0.43	-8.81	-0.38	2.48e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9902453	1.000	rs7223786	chr17:28332107	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.7	0.3	5.94e-11	Alzheimer's disease;
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03891330	chr8:27491259	SCARA3	0.45	6.69	0.3	6.59e-11	Gut microbiome composition (summer);
LGG	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.47	0.47	5.71e-27	Bone mineral density;
LGG	cis	rs9309473	0.898	rs10209517	chr2:73845392	C/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.61	-0.33	1.5e-13	Metabolite levels;
LGG	trans	rs9467603	1.000	rs9467606	chr6:25809218	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.82	-0.3	2.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg12773197	chr13:112238673	NA	-0.36	-7.35	-0.32	9.18e-13	Hepatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13099106	chr12:120525172	CCDC64	0.57	9.23	0.39	9.83e-19	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.8	-0.34	4.05e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg08975724	chr8:8085496	FLJ10661	0.45	8.82	0.38	2.35e-17	Mood instability;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-16.1	-0.6	1.27e-46	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.21	-0.32	2.23e-12	Skin colour saturation;
LGG	cis	rs4716602	0.898	rs10242177	chr7:156162350	C/A	cg16983916	chr7:156159713	NA	-0.38	-6.83	-0.3	2.74e-11	Anti-saccade response;
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs4443100	0.670	rs8139280	chr22:23405957	G/A	cg21100191	chr22:23484243	RTDR1	0.54	7.97	0.35	1.23e-14	Serum parathyroid hormone levels;
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.88	-0.38	1.44e-17	Neuroticism;
LGG	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7166081	1.000	rs35011221	chr15:67645013	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg25019033	chr10:957182	NA	-0.55	-10.05	-0.42	1.25e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg02836325	chr17:76403955	PGS1	-0.71	-14.51	-0.56	1.34e-39	HDL cholesterol levels;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg11494091	chr17:61959527	GH2	1.11	34.35	0.85	2e-129	Prudent dietary pattern;
LGG	cis	rs12477438	0.520	rs12475639	chr2:99930910	A/G	cg23527387	chr2:100056660	REV1	0.44	9.83	0.42	7.62e-21	Chronic sinus infection;
LGG	cis	rs240764	0.817	rs11155610	chr6:101170233	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.68	-0.34	9.68e-14	Neuroticism;
LGG	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.41	0.4	2.35e-19	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg06481639	chr22:41940642	POLR3H	0.54	7.57	0.33	2.05e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.11	0.43	7.84e-22	Prudent dietary pattern;
LGG	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg01620082	chr3:125678407	NA	-0.63	-6.96	-0.31	1.15e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg27624424	chr6:160112604	SOD2	0.59	9.28	0.4	6.51e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1577917	0.727	rs9351065	chr6:86360428	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.14	-0.62	2.27e-51	Response to antipsychotic treatment;
LGG	trans	rs11875185	0.510	rs112571615	chr18:55609380	A/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg08392591	chr16:89556376	ANKRD11	0.48	7.64	0.33	1.25e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs8077059	1.000	rs8075326	chr17:55813869	G/T	cg12582317	chr17:55822272	NA	0.39	7.04	0.31	6.78e-12	Sex hormone-binding globulin levels;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg13880726	chr7:1868755	MAD1L1	0.44	7.54	0.33	2.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-6.9	-0.31	1.67e-11	Height;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22168489	chr12:122356033	WDR66	0.43	10.28	0.43	1.85e-22	Mean corpuscular volume;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.96	0.42	2.71e-21	Tonsillectomy;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg14675211	chr2:100938903	LONRF2	-0.69	-12.41	-0.5	9.76e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7683537	0.673	rs1401363	chr4:185643862	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.16	0.72	1.03e-74	Systemic lupus erythematosus;
LGG	cis	rs7301016	0.846	rs11174568	chr12:63021157	T/C	cg01804193	chr12:63026212	NA	0.54	7.06	0.31	6.2e-12	IgG glycosylation;
LGG	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.95	0.45	5.53e-25	Diabetic retinopathy;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg27532560	chr4:187881888	NA	-0.61	-13.82	-0.54	1.24e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg11905131	chr22:24372483	LOC391322	-0.4	-7.01	-0.31	8.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13421350	0.579	rs78534109	chr2:173374424	C/G	cg15021238	chr2:173305865	ITGA6	-0.76	-8.33	-0.36	9.48e-16	Diabetic kidney disease;
LGG	cis	rs1891275	0.515	rs10881957	chr10:93501876	C/T	cg07889827	chr10:93443413	NA	-0.25	-6.68	-0.3	6.94e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7827545	1.000	rs7008158	chr8:135565982	T/C	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg07541023	chr7:19748670	TWISTNB	0.49	6.99	0.31	9.57e-12	Night sleep phenotypes;
LGG	trans	rs8073060	0.927	rs7502331	chr17:33868858	A/G	cg19694781	chr19:47549865	TMEM160	0.64	10.31	0.43	1.41e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.24	-0.32	1.93e-12	Joint mobility (Beighton score);
LGG	cis	rs9682041	0.877	rs12489967	chr3:170073339	A/C	cg11886554	chr3:170076028	SKIL	0.77	9.44	0.4	1.91e-19	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg15325629	chr6:28072465	NA	1.07	8.1	0.35	5.02e-15	Hip circumference adjusted for BMI;
LGG	cis	rs41271473	0.898	rs55730631	chr1:228865663	C/A	cg16512390	chr1:228756714	NA	0.49	6.84	0.3	2.52e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10463554	0.963	rs1552916	chr5:102337740	A/G	cg23492399	chr5:102201601	PAM	-0.52	-8.1	-0.35	5.07e-15	Parkinson's disease;
LGG	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.46	-0.37	3.45e-16	Schizophrenia;
LGG	cis	rs7927771	0.965	rs4752845	chr11:47539697	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.73	-0.38	4.72e-17	Subjective well-being;
LGG	cis	rs1878931	0.501	rs42329	chr16:3425524	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.8	-13.91	-0.54	5.58e-37	Body mass index (adult);
LGG	cis	rs4639966	0.836	rs7130875	chr11:118613674	T/C	cg20309703	chr11:118481025	PHLDB1	-0.48	-7.21	-0.32	2.33e-12	Systemic lupus erythematosus;
LGG	cis	rs504918	0.676	rs1838473	chr3:124051830	A/G	cg05766129	chr3:123988013	KALRN	-0.42	-7.33	-0.32	1.01e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07315521	chr16:71929403	KIAA0174	0.44	7.01	0.31	8.55e-12	Cognitive performance;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.07	0.31	5.86e-12	Neuroticism;
LGG	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-9.09	-0.39	2.87e-18	Depression;
LGG	cis	rs975739	0.872	rs1144387	chr13:78365190	G/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.8	0.3	3.26e-11	Hair color;
LGG	cis	rs2320614	0.679	rs10001148	chr4:164101614	G/A	cg15586945	chr4:164088095	NAF1	-0.49	-8.58	-0.37	1.49e-16	Lung adenocarcinoma;
LGG	cis	rs11018874	0.709	rs10830428	chr11:89894294	C/G	cg14505434	chr11:89522851	NA	-0.55	-6.97	-0.31	1.11e-11	White blood cell types;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg11809123	chr19:1584870	MBD3	0.39	6.73	0.3	4.89e-11	Menarche (age at onset);
LGG	cis	rs2694528	0.858	rs16878548	chr5:60367626	T/C	cg11474532	chr5:59995715	DEPDC1B	0.67	7.25	0.32	1.8e-12	Parkinson's disease;
LGG	trans	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs41271473	0.687	rs13349	chr1:228881129	A/G	cg00850481	chr1:228891306	NA	-0.56	-11.3	-0.46	2.61e-26	Chronic lymphocytic leukemia;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-8.0	-0.35	1.01e-14	Personality dimensions;
LGG	cis	rs9399135	0.660	rs4440481	chr6:135276696	A/G	cg22676075	chr6:135203613	NA	0.39	6.9	0.31	1.71e-11	Red blood cell count;
LGG	cis	rs72781680	0.848	rs6754694	chr2:24155448	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.34	0.4	4.04e-19	Lymphocyte counts;
LGG	cis	rs4924590	0.531	rs2114477	chr15:42227441	C/T	cg20935245	chr15:42234343	EHD4	-0.42	-8.37	-0.36	6.69e-16	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LGG	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.76	0.59	4.13e-45	Headache;
LGG	cis	rs7928758	0.887	rs78642342	chr11:134269120	G/A	cg15243474	chr11:134282918	B3GAT1	1.24	16.09	0.6	1.37e-46	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.46	-0.33	4.4e-13	Blood pressure (smoking interaction);
LGG	cis	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs9354308	0.764	rs9345714	chr6:66596523	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg03653399	chr8:142233436	SLC45A4	0.37	6.86	0.3	2.15e-11	Immature fraction of reticulocytes;
LGG	cis	rs1577917	0.740	rs9344533	chr6:86236188	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	12.9	0.51	9.73e-33	Response to antipsychotic treatment;
LGG	cis	rs4642101	0.662	rs9840766	chr3:12821870	G/A	cg24848339	chr3:12840334	CAND2	0.45	10.52	0.44	2.41e-23	QRS complex (12-leadsum);
LGG	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg19507638	chr5:93509721	C5orf36	0.4	7.18	0.32	2.79e-12	Diabetic retinopathy;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.59	0.33	1.72e-13	Myopia (pathological);
LGG	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg03733263	chr8:22462867	KIAA1967	1.12	32.59	0.83	6.45e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7215564	0.818	rs76704328	chr17:78585954	T/G	cg16980736	chr17:78789706	RPTOR	-0.64	-8.35	-0.36	8.17e-16	Myopia (pathological);
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg08645402	chr16:4508243	NA	0.52	9.98	0.42	2.32e-21	Schizophrenia;
LGG	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs6834538	0.895	rs4488991	chr4:113391982	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.49	7.18	0.32	2.81e-12	Free thyroxine concentration;
LGG	cis	rs2439831	1.000	rs2251538	chr15:43767209	G/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.37	-0.32	8.05e-13	Lung cancer in ever smokers;
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.33e-13	Educational attainment;
LGG	cis	rs6993813	0.843	rs10098408	chr8:120039721	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg21171335	chr12:122356390	WDR66	0.25	7.19	0.32	2.63e-12	Mean corpuscular volume;
LGG	cis	rs10782582	0.593	rs4638068	chr1:76161663	G/A	cg10523679	chr1:76189770	ACADM	-0.43	-6.92	-0.31	1.55e-11	Daytime sleep phenotypes;
LGG	trans	rs826838	1.000	rs10880826	chr12:38672787	G/C	cg06521331	chr12:34319734	NA	-0.46	-8.0	-0.35	1.02e-14	Heart rate;
LGG	cis	rs13191362	0.810	rs35509380	chr6:163053028	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.78	0.3	3.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg02733842	chr7:1102375	C7orf50	0.67	7.95	0.35	1.39e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6693567	0.545	rs6664703	chr1:150459087	G/C	cg15654264	chr1:150340011	RPRD2	0.33	6.76	0.3	4.17e-11	Migraine;
LGG	trans	rs61931739	0.578	rs726748	chr12:33624416	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-8.24	-0.36	1.79e-15	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.64	0.41	3.61e-20	Life satisfaction;
LGG	cis	rs7582720	1.000	rs72934514	chr2:203933339	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.09	0.39	2.83e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg06872548	chr17:78716983	RPTOR	0.45	11.1	0.46	1.48e-25	Obesity;
LGG	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg08807101	chr21:30365312	RNF160	-0.84	-17.03	-0.62	7.5400000000000006e-51	Dental caries;
LGG	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg21775007	chr8:11205619	TDH	-0.46	-7.33	-0.32	1.02e-12	Systolic blood pressure;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08280861	chr8:58055591	NA	0.6	7.76	0.34	5.37e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs988958	0.526	rs7592119	chr2:42243667	T/A	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Hypospadias;
LGG	cis	rs2046867	0.818	rs11928620	chr3:72863209	A/C	cg01043669	chr3:72786069	NA	0.43	6.98	0.31	1.05e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2153535	0.541	rs6908504	chr6:8456778	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.51	-0.33	2.97e-13	Personality dimensions;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07362569	chr17:61921086	SMARCD2	0.48	9.29	0.4	6.18e-19	Prudent dietary pattern;
LGG	cis	rs3762637	0.943	rs9289196	chr3:122268506	T/C	cg24169773	chr3:122142474	KPNA1	-0.5	-8.96	-0.38	7.76e-18	LDL cholesterol levels;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8113308	0.752	rs8113758	chr19:52493307	C/T	cg25782003	chr19:52490127	ZNF350	0.56	8.81	0.38	2.49e-17	Survival in endocrine treated breast cancer (estrogen-receptor positive);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23077509	chr3:142166793	XRN1	0.5	8.15	0.35	3.43e-15	Cognitive performance;
LGG	cis	rs62344088	0.590	rs6882234	chr5:177389	C/G	cg22857025	chr5:266934	NA	-1.13	-9.18	-0.39	1.48e-18	Asthma (childhood onset);
LGG	cis	rs13160562	0.527	rs152479	chr5:96105043	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.12	0.31	4.02e-12	Alcohol dependence;
LGG	cis	rs17401966	1.000	rs12136376	chr1:10296452	C/T	cg15208524	chr1:10270712	KIF1B	0.47	7.87	0.34	2.45e-14	Hepatocellular carcinoma;
LGG	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg27286337	chr10:134555280	INPP5A	0.87	13.86	0.54	8.55e-37	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg00761968	chr13:53314142	LECT1	-0.38	-8.03	-0.35	8.13e-15	Lewy body disease;
LGG	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg11247378	chr22:39784982	NA	0.3	7.9	0.34	2.1e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs9443189	0.723	rs2748947	chr6:76437921	C/T	cg01950844	chr6:76311363	SENP6	-0.56	-7.37	-0.32	7.71e-13	Prostate cancer;
LGG	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg15506890	chr2:3487001	NA	-0.59	-11.03	-0.46	2.92e-25	Neurofibrillary tangles;
LGG	cis	rs9290065	0.558	rs9846254	chr3:160770370	C/T	cg03342759	chr3:160939853	NMD3	-0.57	-9.7	-0.41	2.2e-20	Kawasaki disease;
LGG	cis	rs2115630	0.902	rs8023276	chr15:85219638	C/T	cg12501888	chr15:85177176	SCAND2	-0.44	-7.28	-0.32	1.49e-12	P wave terminal force;
LGG	cis	rs6496667	0.557	rs2601203	chr15:90958129	T/G	cg22089800	chr15:90895588	ZNF774	0.52	8.4	0.36	5.49e-16	Rheumatoid arthritis;
LGG	cis	rs1451882	0.800	rs12547408	chr8:1054205	G/A	cg07395941	chr8:1078200	NA	0.5	6.94	0.31	1.29e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10875746	0.669	rs11168496	chr12:48650855	G/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.45	-0.33	4.59e-13	Longevity (90 years and older);
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg08888203	chr3:10149979	C3orf24	0.56	9.43	0.4	2.04e-19	Alzheimer's disease;
LGG	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.36e-18	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg14092988	chr3:52407081	DNAH1	0.28	7.58	0.33	1.9e-13	Electroencephalogram traits;
LGG	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg16586182	chr3:47516702	SCAP	0.73	13.18	0.52	6.48e-34	Colorectal cancer;
LGG	cis	rs7923609	0.967	rs10761766	chr10:65190327	G/A	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2066819	1.000	rs2066819	chr12:56750204	C/T	cg26714650	chr12:56694279	CS	-1.58	-15.14	-0.58	2.42e-42	Psoriasis vulgaris;
LGG	cis	rs7226408	0.857	rs72887032	chr18:34473233	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs80035296	chr22:32387536	C/T	cg00543991	chr22:32367038	NA	0.81	8.95	0.38	8.83e-18	Childhood ear infection;
LGG	cis	rs73787773	0.668	rs73227490	chr5:111473340	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.61	-7.79	-0.34	4.32e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4846580	0.660	rs12048860	chr1:219886534	T/C	cg08034750	chr1:219919793	NA	0.42	7.4	0.33	6.35e-13	Total body bone mineral density;
LGG	cis	rs7493	0.755	rs34774523	chr7:94962142	G/A	cg08461772	chr7:95026248	PON3	0.38	8.22	0.36	2.01e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs11098499	0.615	rs28850368	chr4:120554313	G/A	cg09307838	chr4:120376055	NA	0.73	12.56	0.5	2.47e-31	Corneal astigmatism;
LGG	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.38	0.43	7.88e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9467773	1.000	rs10214634	chr6:26564582	T/A	cg09904177	chr6:26538194	HMGN4	0.77	17.17	0.62	1.64e-51	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg13324934	chr2:97779433	ANKRD36	0.4	7.19	0.32	2.67e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg01557791	chr16:72042693	DHODH	0.56	10.2	0.43	3.63e-22	Fibrinogen levels;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.37	0.32	7.82e-13	Schizophrenia;
LGG	cis	rs597583	0.951	rs579239	chr11:117425009	T/C	cg27161313	chr11:117392002	DSCAML1	-0.41	-6.96	-0.31	1.15e-11	Putamen volume;
LGG	cis	rs1953600	0.837	rs2236556	chr10:81932790	T/C	cg04850286	chr10:81895943	PLAC9	0.44	9.77	0.41	1.3e-20	Sarcoidosis;
LGG	cis	rs10927875	0.501	rs9660676	chr1:16279041	C/T	cg21385522	chr1:16154831	NA	-0.93	-14.7	-0.56	2.08e-40	Dilated cardiomyopathy;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg07142201	chr11:109293216	C11orf87	0.5	8.74	0.38	4.42e-17	Schizophrenia;
LGG	cis	rs3617	0.539	rs9880619	chr3:52953055	G/A	cg11645453	chr3:52864694	ITIH4	-0.47	-7.8	-0.34	4.09e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg02466173	chr16:30829666	NA	-0.44	-7.84	-0.34	3.2e-14	Dementia with Lewy bodies;
LGG	cis	rs35110281	0.633	rs4819289	chr21:45120237	A/G	cg04455712	chr21:45112962	RRP1B	0.53	9.85	0.42	6.62e-21	Mean corpuscular volume;
LGG	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg15325629	chr6:28072465	NA	1.01	7.69	0.34	9.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg03894339	chr8:19674705	INTS10	-0.53	-8.35	-0.36	7.74e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs4919694	0.611	rs75182663	chr10:105058104	A/G	cg04362960	chr10:104952993	NT5C2	0.92	11.87	0.48	1.51e-28	Arsenic metabolism;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg25172604	chr17:41446521	NA	-0.31	-7.14	-0.31	3.62e-12	Menopause (age at onset);
LGG	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg22916017	chr11:64110731	CCDC88B	0.43	8.86	0.38	1.68e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7113850	0.541	rs78363992	chr11:24232126	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.45	0.44	4.3e-23	Bone fracture in osteoporosis;
LGG	cis	rs701145	0.585	rs4680125	chr3:153784698	G/A	cg12800244	chr3:153838788	SGEF	-0.81	-9.0	-0.39	6.07e-18	Coronary artery disease;
LGG	cis	rs7107174	0.792	rs10899488	chr11:78088754	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.45	-0.33	4.76e-13	Testicular germ cell tumor;
LGG	trans	rs1814175	0.587	rs7937757	chr11:49978342	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.29	-0.32	1.32e-12	Bone mineral density;
LGG	cis	rs2213920	0.522	rs7847118	chr9:118199763	T/C	cg13918206	chr9:118159781	DEC1	0.63	8.93	0.38	1.01e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg11941060	chr3:133502564	NA	-0.48	-8.24	-0.36	1.81e-15	Iron status biomarkers;
LGG	cis	rs11920090	0.790	rs16855617	chr3:170713522	G/T	cg09710316	chr3:170744871	SLC2A2	0.6	8.46	0.37	3.59e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs7937890	0.593	rs2597189	chr11:14512060	C/T	cg02886208	chr11:14281011	SPON1	-0.42	-7.71	-0.34	7.51e-14	Mitochondrial DNA levels;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.48	-0.44	3.36e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg18875453	chr22:50517795	MLC1	0.29	6.75	0.3	4.48e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06481639	chr22:41940642	POLR3H	-0.49	-7.04	-0.31	7.15e-12	Vitiligo;
LGG	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.71	-0.41	1.99e-20	Mean corpuscular volume;
LGG	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.32	-0.36	1.03e-15	Triglycerides;
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg27144592	chr16:783916	NARFL	0.41	6.72	0.3	5.26e-11	Height;
LGG	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg15557168	chr22:42548783	NA	-0.34	-7.52	-0.33	2.79e-13	Cognitive function;
LGG	cis	rs709400	0.770	rs7142883	chr14:104066645	G/A	cg26031613	chr14:104095156	KLC1	1.18	29.68	0.81	3.29e-109	Body mass index;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg11062466	chr8:58055876	NA	0.47	8.18	0.36	2.78e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs365132	0.934	rs149307	chr5:176471591	C/T	cg16309518	chr5:176445507	NA	-0.55	-12.14	-0.49	1.23e-29	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs9640161	0.789	rs1464753	chr7:150021350	G/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.77	-16.07	-0.6	1.77e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.4	-0.53	8.17e-35	Personality dimensions;
LGG	cis	rs266717	0.904	rs843991	chr3:186516428	A/G	cg00373256	chr3:186519153	RFC4	-0.42	-8.83	-0.38	2.1e-17	Adiponectin levels;
LGG	cis	rs79349575	0.715	rs1058018	chr17:47000251	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.68	0.37	7.02e-17	Type 2 diabetes;
LGG	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.6	0.37	1.22e-16	Joint mobility (Beighton score);
LGG	cis	rs9467711	0.591	rs13220488	chr6:25896907	A/G	cg21479132	chr6:26055353	NA	0.83	7.44	0.33	4.97e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1401999	0.966	rs4148585	chr3:183670642	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.75	0.61	1.45e-49	Anterior chamber depth;
LGG	cis	rs10089	1.000	rs4835943	chr5:127457569	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs3789045	0.560	rs1002779	chr1:204405098	T/A	cg17419461	chr1:204415978	PIK3C2B	-0.57	-10.48	-0.44	3.23e-23	Educational attainment (college completion);
LGG	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg25110126	chr1:46999211	NA	-0.57	-8.55	-0.37	1.84e-16	Monobrow;
LGG	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg00938859	chr5:1591904	SDHAP3	0.86	11.87	0.48	1.47e-28	Breast cancer;
LGG	cis	rs7147624	1.000	rs11848209	chr14:66022832	T/A	cg03016385	chr14:66212404	NA	-0.78	-9.58	-0.41	5.78e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.58	-10.06	-0.42	1.15e-21	Obesity-related traits;
LGG	cis	rs7633770	0.710	rs4683259	chr3:46698538	A/G	cg11219411	chr3:46661640	NA	-0.54	-12.25	-0.49	4.33e-30	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg12395012	chr8:11607386	GATA4	0.41	7.39	0.32	6.93e-13	Monocyte count;
LGG	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs4262150	0.774	rs12188960	chr5:152214214	C/G	cg12297329	chr5:152029980	NA	-0.67	-12.19	-0.49	7.87e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2806561	0.704	rs2806570	chr1:23527005	C/T	cg19743168	chr1:23544995	NA	-0.38	-7.68	-0.34	9.4e-14	Height;
LGG	cis	rs453301	0.506	rs476845	chr8:8622877	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.74	-0.3	4.74e-11	Joint mobility (Beighton score);
LGG	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg14993813	chr1:46806288	NSUN4	-0.55	-9.05	-0.39	4.02e-18	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	2.08e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs870825	0.616	rs4386643	chr4:185624281	A/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg18876405	chr7:65276391	NA	0.61	10.92	0.45	7.29e-25	Aortic root size;
LGG	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.67	-0.51	8.5e-32	Uric acid levels;
LGG	trans	rs4942242	0.663	rs1390371	chr13:44211727	A/G	cg19169023	chr15:41853346	TYRO3	0.44	8.89	0.38	1.34e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9807989	0.501	rs11903946	chr2:103005330	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg17809284	chr5:56205270	C5orf35	-0.52	-8.6	-0.37	1.22e-16	Initial pursuit acceleration;
LGG	cis	rs1372520	0.532	rs2583972	chr4:90747411	T/G	cg15133208	chr4:90757351	SNCA	-0.42	-8.5	-0.37	2.7e-16	Neuroticism;
LGG	cis	rs9397585	0.599	rs9322409	chr6:153405793	G/A	cg17707550	chr6:153380415	RGS17	-0.44	-9.94	-0.42	3.01e-21	Body mass index;
LGG	cis	rs17321999	1.000	rs1001204	chr2:30478779	A/G	cg05247661	chr2:30472410	LBH	0.55	8.93	0.38	1.01e-17	Systemic lupus erythematosus;
LGG	cis	rs2820315	0.838	rs2819347	chr1:201884288	C/G	cg10061532	chr1:201886748	LMOD1	0.33	6.88	0.3	1.92e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs11168618	0.904	rs12371700	chr12:48919213	G/T	cg24011408	chr12:48396354	COL2A1	-0.45	-7.18	-0.32	2.83e-12	Adiponectin levels;
LGG	cis	rs113835537	0.529	rs116867234	chr11:66209024	C/T	cg24851651	chr11:66362959	CCS	0.43	7.36	0.32	8.6e-13	Airway imaging phenotypes;
LGG	cis	rs2197308	0.765	rs11182481	chr12:37926019	T/C	cg26384229	chr12:38710491	ALG10B	0.91	20.7	0.69	7.08e-68	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08280861	chr8:58055591	NA	0.61	7.66	0.34	1.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg12555334	chr7:56120290	CCT6A;PSPH	-0.4	-7.25	-0.32	1.78e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg08888203	chr3:10149979	C3orf24	0.54	8.68	0.37	6.98e-17	Alzheimer's disease;
LGG	cis	rs6868223	0.617	rs6869719	chr5:33645354	T/C	cg10594543	chr5:33649717	ADAMTS12	0.67	15.82	0.59	2.27e-45	Mortality in heart failure;
LGG	cis	rs11628318	0.515	rs4906245	chr14:103088182	G/C	cg12046867	chr14:103022105	NA	-0.4	-7.56	-0.33	2.2e-13	Platelet count;
LGG	cis	rs7444	0.825	rs738129	chr22:21971041	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs9354308	0.770	rs2802048	chr6:66525044	C/G	cg07460842	chr6:66804631	NA	0.54	8.72	0.38	4.94e-17	Metabolite levels;
LGG	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.75	0.38	4.01e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1682825	1.000	rs73812284	chr3:10766043	G/A	cg23512531	chr3:10780469	NA	0.56	7.73	0.34	6.79e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs4631830	0.896	rs7077830	chr10:51522276	C/G	cg16070123	chr10:51489643	NA	0.39	7.12	0.31	4.02e-12	Prostate-specific antigen levels;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg26174226	chr8:58114915	NA	-0.46	-6.9	-0.31	1.67e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.0	0.35	1.03e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9650657	0.871	rs7814142	chr8:10637552	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.49	-0.33	3.45e-13	Neuroticism;
LGG	cis	rs6426558	0.502	rs10916080	chr1:227232040	A/G	cg10327440	chr1:227177885	CDC42BPA	0.64	10.74	0.45	3.52e-24	Neutrophil percentage of white cells;
LGG	cis	rs74781061	0.722	rs4073149	chr15:74898419	A/G	cg02384859	chr15:74862662	ARID3B	0.38	6.76	0.3	4.13e-11	Endometriosis;
LGG	cis	rs2481665	0.740	rs2457831	chr1:62633581	C/T	cg18591186	chr1:62594603	INADL	0.47	10.22	0.43	2.93e-22	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2797369	0.570	rs2770335	chr6:101576169	A/C	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.86e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg19847130	chr8:10466454	RP1L1	0.37	7.65	0.33	1.2e-13	Neuroticism;
LGG	cis	rs72827839	0.846	rs72823530	chr17:46109371	G/A	cg02219949	chr17:45927392	SP6	0.52	7.93	0.35	1.71e-14	Ease of getting up in the morning;
LGG	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.42e-21	HDL cholesterol;
LGG	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg09904177	chr6:26538194	HMGN4	0.68	14.02	0.55	1.8e-37	Intelligence (multi-trait analysis);
LGG	cis	rs709400	1.000	rs55885592	chr14:104126024	C/T	cg24130564	chr14:104152367	KLC1	-0.44	-8.54	-0.37	2.02e-16	Body mass index;
LGG	cis	rs7769051	1.000	rs9399041	chr6:133096233	T/G	cg07930552	chr6:133119739	C6orf192	0.87	11.55	0.47	2.65e-27	Type 2 diabetes nephropathy;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.43	-0.33	5.13e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1555895	0.576	rs4362075	chr10:865476	A/G	cg09361094	chr10:834503	NA	-0.29	-7.9	-0.34	1.99e-14	Survival in rectal cancer;
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs13202913	0.652	rs9371528	chr6:151832668	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.54	7.34	0.32	9.9e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs2108225	0.934	rs2301989	chr7:107443871	G/A	cg18560240	chr7:107437656	SLC26A3	-0.55	-9.76	-0.41	1.33e-20	Ulcerative colitis;
LGG	trans	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg24888170	chr7:55808739	NA	0.56	8.87	0.38	1.57e-17	Subjective response to lithium treatment in bipolar disorder;
LGG	cis	rs11112613	0.713	rs12307351	chr12:105955634	T/A	cg03607813	chr12:105948248	NA	0.56	9.66	0.41	3.14e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.83	0.38	2.16e-17	Lung cancer;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg06028808	chr11:68637592	NA	0.69	11.81	0.48	2.51e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg13770153	chr20:60521292	NA	-0.44	-7.23	-0.32	2.05e-12	Body mass index;
LGG	trans	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg25482853	chr8:67687455	SGK3	0.85	11.15	0.46	9.37e-26	Obesity-related traits;
LGG	cis	rs2180341	0.814	rs6940933	chr6:127732740	C/G	cg27446573	chr6:127587934	RNF146	0.92	17.09	0.62	3.91e-51	Breast cancer;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg25703541	chr22:24373054	LOC391322	-0.86	-16.91	-0.62	2.77e-50	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.63	7.01	0.31	8.2e-12	Initial pursuit acceleration;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg19774624	chr17:42201019	HDAC5	0.56	9.78	0.41	1.2e-20	Red cell distribution width;Reticulocyte count;
LGG	cis	rs7666738	0.791	rs2081622	chr4:98927369	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs283228	0.583	rs504324	chr6:101772092	A/T	cg27451362	chr6:101846650	GRIK2	1.01	15.33	0.58	3.42e-43	Coenzyme Q10 levels;
LGG	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg15890332	chr12:107067104	RFX4	0.32	8.44	0.37	4.09e-16	Total body bone mineral density;
LGG	cis	rs7523273	0.565	rs34355011	chr1:207887322	T/G	cg22525895	chr1:207977042	MIR29B2	0.45	8.57	0.37	1.58e-16	Schizophrenia;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04025590	chr1:26560450	CCDC21	0.41	6.85	0.3	2.3e-11	Body mass index;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	17.88	0.64	9.05e-55	Personality dimensions;
LGG	cis	rs1008375	0.900	rs13144986	chr4:17675019	C/A	cg18681998	chr4:17616180	MED28	-0.84	-17.49	-0.63	6.01e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg01620082	chr3:125678407	NA	-1.02	-9.5	-0.4	1.16e-19	Depression;
LGG	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8180040	0.764	rs11718795	chr3:47218727	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg08700190	chr5:6636046	SRD5A1	-0.36	-7.63	-0.33	1.31e-13	Response to amphetamines;
LGG	trans	rs1814175	0.502	rs12365889	chr11:49623034	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.67	-11.72	-0.48	5.73e-28	Height;
LGG	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9547692	0.938	rs17217404	chr13:37466215	C/T	cg02985381	chr13:37494744	SMAD9	0.73	12.79	0.51	2.63e-32	Coronary artery disease;
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg15394860	chr11:2017084	H19	0.62	13.0	0.52	3.58e-33	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg14416269	chr4:6271139	WFS1	0.46	8.41	0.36	5.07e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6831352	0.918	rs35784540	chr4:100061692	T/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.6	-0.37	1.26e-16	Alcohol dependence;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.58	-0.53	1.29e-35	Alzheimer's disease;
LGG	cis	rs1595825	0.891	rs58409972	chr2:198897061	A/T	cg00982548	chr2:198649783	BOLL	-0.52	-6.75	-0.3	4.32e-11	Ulcerative colitis;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg20887711	chr4:1340912	KIAA1530	0.76	15.68	0.59	9.53e-45	Longevity;
LGG	cis	rs1497406	0.744	rs7538216	chr1:16509671	T/C	cg20430773	chr1:16534157	ARHGEF19	0.29	8.05	0.35	6.85e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2032447	0.765	rs1935235	chr6:26067782	C/G	cg03517284	chr6:25882590	NA	-0.63	-12.13	-0.49	1.31e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg19223190	chr17:80058835	NA	0.44	8.33	0.36	8.94e-16	Life satisfaction;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.32	-0.36	9.83e-16	Neuroticism;
LGG	cis	rs7122539	0.646	rs4930390	chr11:66560023	C/T	cg01599099	chr11:66649832	PC	-0.49	-9.95	-0.42	2.78e-21	HIV-1 susceptibility;
LGG	cis	rs9462027	0.540	rs2814951	chr6:34695081	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.74	-0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs7638995	0.941	rs1995663	chr3:69182974	G/A	cg26574240	chr3:69171822	LMOD3	-0.58	-9.3	-0.4	5.51e-19	Alzheimer's disease (late onset);
LGG	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg11266682	chr4:10021025	SLC2A9	0.42	7.89	0.34	2.22e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9790314	0.580	rs10936227	chr3:161043869	A/C	cg04691961	chr3:161091175	C3orf57	-0.52	-11.03	-0.46	2.76e-25	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg02733842	chr7:1102375	C7orf50	0.4	7.1	0.31	4.63e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs62400317	0.859	rs12205905	chr6:45178498	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.06	-0.42	1.2e-21	Total body bone mineral density;
LGG	cis	rs2320614	0.648	rs1382661	chr4:164104090	C/T	cg15586945	chr4:164088095	NAF1	-0.48	-8.49	-0.37	2.78e-16	Lung adenocarcinoma;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.41	0.33	5.94e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg02725872	chr8:58115012	NA	-0.84	-16.2	-0.6	4.53e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.740	rs10962153	chr9:15776638	G/A	cg14451791	chr9:16040625	NA	0.35	8.88	0.38	1.49e-17	Body mass index;
LGG	cis	rs74781061	0.929	rs55662551	chr15:74781086	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17321999	0.516	rs60827632	chr2:30504629	A/T	cg05247661	chr2:30472410	LBH	0.66	8.02	0.35	8.96e-15	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17319849	chr1:155214564	GBA	0.47	7.02	0.31	7.8e-12	Gut microbiome composition (summer);
LGG	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.45	8.58	0.37	1.48e-16	Multiple sclerosis;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	5.27e-55	Exhaled nitric oxide output;
LGG	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.9	-0.34	1.99e-14	Blood metabolite levels;
LGG	cis	rs3733585	0.673	rs4407505	chr4:9953367	T/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs5758511	0.573	rs1883205	chr22:42243020	A/G	cg15128208	chr22:42549153	NA	-0.44	-7.52	-0.33	2.84e-13	Birth weight;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg24829409	chr8:58192753	C8orf71	-0.82	-13.18	-0.52	6.61e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4319547	0.915	rs10734924	chr12:123018894	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.56	-0.41	6.7e-20	Body mass index;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs968451	0.951	rs12627838	chr22:39733521	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	11.43	0.47	8.06e-27	Primary biliary cholangitis;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg05335186	chr13:53173507	NA	0.61	13.33	0.53	1.58e-34	Lewy body disease;
LGG	cis	rs975722	0.638	rs117243	chr7:117234537	A/G	cg10524701	chr7:117356490	CTTNBP2	0.48	10.64	0.44	8.35e-24	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23883989	chr14:105886026	MTA1	0.46	6.7	0.3	6.17e-11	Gut microbiome composition (summer);
LGG	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg00701064	chr4:6280414	WFS1	0.73	16.75	0.61	1.48e-49	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.9	0.54	6.01e-37	Cognitive test performance;
LGG	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg00666640	chr1:248458726	OR2T12	0.63	10.16	0.43	4.95e-22	Common traits (Other);
LGG	cis	rs1949733	0.701	rs940134	chr4:8454870	C/T	cg13073564	chr4:8508604	NA	-0.53	-10.92	-0.45	7.56e-25	Response to antineoplastic agents;
LGG	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg15979348	chr13:112237479	NA	-0.47	-8.06	-0.35	6.52e-15	Menarche (age at onset);
LGG	cis	rs4919087	0.923	rs11189038	chr10:98974765	A/T	cg25902810	chr10:99078978	FRAT1	0.52	9.68	0.41	2.54e-20	Monocyte count;
LGG	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.71e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.06	-0.31	6.2e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg00647317	chr7:50633725	DDC	0.34	7.64	0.33	1.27e-13	Malaria;
LGG	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg20578329	chr17:80767326	TBCD	-0.46	-7.95	-0.35	1.46e-14	Breast cancer;
LGG	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg19773385	chr1:10388646	KIF1B	-0.48	-10.3	-0.43	1.51e-22	Hepatocellular carcinoma;
LGG	cis	rs62025270	0.632	rs111906684	chr15:86221936	A/G	cg25843651	chr15:86329602	KLHL25	0.56	8.48	0.37	3.04e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg11764359	chr7:65958608	NA	0.63	10.92	0.45	7.5e-25	Aortic root size;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	15.19	0.58	1.47e-42	Platelet count;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs963731	0.579	rs11692687	chr2:39265428	A/G	cg04010122	chr2:39346883	SOS1	-0.86	-7.52	-0.33	2.96e-13	Corticobasal degeneration;
LGG	cis	rs981844	0.857	rs72731698	chr4:154716353	T/C	cg14289246	chr4:154710475	SFRP2	0.72	12.1	0.49	1.73e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs3784262	0.669	rs1061278	chr15:58246029	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.01	-0.31	8.41e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs17376456	0.825	rs6877030	chr5:93201841	C/A	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs4692589	0.865	rs6553486	chr4:170984825	C/G	cg14155976	chr2:132124748	NA	-0.51	-7.25	-0.32	1.8e-12	Anxiety disorder;
LGG	cis	rs1829883	1.000	rs1523381	chr5:98773754	T/C	cg08333243	chr5:99726346	NA	-0.39	-7.69	-0.34	8.98e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7666738	0.830	rs10034330	chr4:99064849	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.52e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06165179	chr7:39990544	CDK13	0.44	6.66	0.3	7.61e-11	Gut microbiome composition (summer);
LGG	cis	rs701145	0.640	rs357506	chr3:153932403	A/C	cg12800244	chr3:153838788	SGEF	0.84	8.33	0.36	9.55e-16	Coronary artery disease;
LGG	cis	rs910187	0.605	rs6063080	chr20:45805091	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-9.4	-0.4	2.58e-19	Migraine;
LGG	cis	rs3816183	0.716	rs11890952	chr2:43077743	G/C	cg14631114	chr2:43023945	NA	0.45	8.02	0.35	8.74e-15	Hypospadias;
LGG	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg19774624	chr17:42201019	HDAC5	-0.59	-10.43	-0.44	5.24e-23	Total body bone mineral density;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg22398616	chr13:53314203	LECT1	-0.53	-11.61	-0.47	1.61e-27	Lewy body disease;
LGG	trans	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg22358067	chr17:16797159	NA	-0.5	-6.99	-0.31	9.87e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs932287	0.505	rs2742536	chr11:8909816	G/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.45	-9.8	-0.41	9.52e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg13206674	chr6:150067644	NUP43	0.64	14.41	0.56	3.77e-39	Lung cancer;
LGG	cis	rs4950322	0.542	rs115179956	chr1:146644199	C/A	cg22381352	chr1:146742008	CHD1L	-0.45	-7.62	-0.33	1.42e-13	Protein quantitative trait loci;
LGG	cis	rs11750568	0.967	rs890699	chr5:178511846	A/G	cg10208897	chr5:178548229	ADAMTS2	-0.41	-6.77	-0.3	3.87e-11	Height;
LGG	cis	rs3206736	0.548	rs1637675	chr7:35000492	C/T	cg13400248	chr7:35225412	NA	0.53	9.42	0.4	2.2e-19	Diastolic blood pressure;
LGG	cis	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.22	0.36	2.1e-15	Mood instability;
LGG	cis	rs9398803	0.897	rs9398804	chr6:126703390	T/A	cg19875578	chr6:126661172	C6orf173	0.57	10.15	0.43	5.38e-22	Male-pattern baldness;
LGG	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg08461772	chr7:95026248	PON3	0.37	8.01	0.35	9.32e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg00405596	chr8:11794950	NA	-0.44	-7.35	-0.32	9.09e-13	Neuroticism;
LGG	cis	rs72634258	0.796	rs10746475	chr1:8168261	T/A	cg00042356	chr1:8021962	PARK7	-0.54	-7.64	-0.33	1.26e-13	Inflammatory bowel disease;
LGG	cis	rs564799	0.966	rs491966	chr3:159733692	T/C	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs7587476	0.954	rs3768708	chr2:215645046	C/T	cg04004882	chr2:215674386	BARD1	-0.51	-7.68	-0.34	9.78e-14	Neuroblastoma;
LGG	cis	rs7582720	1.000	rs72932776	chr2:203688300	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.68	0.41	2.7e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg26354017	chr1:205819088	PM20D1	-0.42	-7.44	-0.33	4.95e-13	Menarche (age at onset);
LGG	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.36	-0.36	7.6e-16	Triglycerides;
LGG	trans	rs9650657	0.771	rs4240670	chr8:10665848	T/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.06	-0.31	6.23e-12	Neuroticism;
LGG	cis	rs4808199	1.000	rs12977524	chr19:19568244	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.55	0.63	3.13e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	0.767	rs11190519	chr10:102175133	C/T	cg07570687	chr10:102243282	WNT8B	0.4	7.07	0.31	5.79e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2032447	0.899	rs1090947	chr6:26076642	T/C	cg03517284	chr6:25882590	NA	-0.58	-11.19	-0.46	6.8e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.92	0.35	1.8e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6708331	0.938	rs13000514	chr2:70395016	G/A	cg01613454	chr2:70366299	NA	0.54	9.39	0.4	2.74e-19	Obesity-related traits;
LGG	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.88	-0.34	2.3e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4664308	1.000	rs56297666	chr2:160902023	G/C	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.22	-0.62	1.05e-51	Idiopathic membranous nephropathy;
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg20003494	chr4:90757398	SNCA	0.42	8.01	0.35	9.32e-15	Dementia with Lewy bodies;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg16301924	chr13:53314226	LECT1	-0.45	-9.26	-0.4	7.6e-19	Lewy body disease;
LGG	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-14.18	-0.55	3.77e-38	Headache;
LGG	trans	rs1814175	0.817	rs1621090	chr11:49895868	C/A	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs240764	0.658	rs11155659	chr6:101222568	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.9	-0.34	2.11e-14	Neuroticism;
LGG	cis	rs3735485	0.800	rs1294962	chr7:45067017	A/G	cg03440944	chr7:45023329	C7orf40	0.55	9.4	0.4	2.62e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9818758	0.607	rs13068038	chr3:49294250	C/A	cg00383909	chr3:49044727	WDR6	1.01	12.56	0.5	2.38e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7084402	0.967	rs12261597	chr10:60297662	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.56	-0.63	2.91e-53	Refractive error;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg07005078	chr4:17578674	LAP3	-0.38	-7.11	-0.31	4.51e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27650175	chr9:124461640	DAB2IP	0.44	6.73	0.3	5.11e-11	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	trans	rs7618501	0.633	rs9814664	chr3:50078541	C/T	cg21659725	chr3:3221576	CRBN	-0.64	-11.83	-0.48	2.13e-28	Intelligence (multi-trait analysis);
LGG	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.83	-0.34	3.39e-14	Restless legs syndrome;
LGG	cis	rs11864453	0.647	rs2550035	chr16:72113416	C/G	cg01557791	chr16:72042693	DHODH	-0.46	-8.39	-0.36	6.1e-16	Fibrinogen levels;
LGG	cis	rs35160687	0.644	rs1863058	chr2:86509267	G/A	cg10973622	chr2:86423274	IMMT	-0.41	-7.24	-0.32	1.83e-12	Night sleep phenotypes;
LGG	cis	rs4774899	0.966	rs12910556	chr15:57493210	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.86	-0.3	2.2e-11	Urinary tract infection frequency;
LGG	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg18681998	chr4:17616180	MED28	0.86	19.73	0.68	2.51e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9815354	0.857	rs794902	chr3:42025939	T/C	cg03022575	chr3:42003672	ULK4	-0.61	-7.57	-0.33	2.01e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg17108064	chr15:78857060	CHRNA5	0.38	7.52	0.33	2.8e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg16270222	chr17:41446396	NA	-0.3	-7.23	-0.32	2.05e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg05665937	chr4:1216051	CTBP1	0.56	10.49	0.44	2.98e-23	Obesity-related traits;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg03188948	chr7:1209495	NA	0.4	7.04	0.31	7.02e-12	Longevity;Endometriosis;
LGG	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.86	0.38	1.77e-17	Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24743778	chr2:220379058	ACCN4	0.47	7.4	0.33	6.66e-13	Gut microbiome composition (summer);
LGG	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.41	0.33	5.9e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg25237894	chr2:233734115	C2orf82	0.46	7.97	0.35	1.24e-14	Schizophrenia;
LGG	cis	rs7412746	0.611	rs11204748	chr1:150927369	G/T	cg15448220	chr1:150897856	SETDB1	0.36	6.65	0.3	8.54e-11	Melanoma;
LGG	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg00383909	chr3:49044727	WDR6	0.58	8.15	0.35	3.44e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-10.95	-0.45	5.46e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg24503407	chr1:205819492	PM20D1	0.84	20.3	0.69	5.64e-66	Menarche (age at onset);
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg16434002	chr17:42200994	HDAC5	-0.52	-9.58	-0.41	6.18e-20	Total body bone mineral density;
LGG	cis	rs751728	0.664	rs4711349	chr6:33740592	C/T	cg07519485	chr6:33762594	MLN	-0.3	-6.7	-0.3	6.2e-11	Crohn's disease;
LGG	cis	rs2290159	0.800	rs73812836	chr3:12655149	T/G	cg23032965	chr3:12705835	RAF1	0.67	9.79	0.41	1.05e-20	Cholesterol, total;
LGG	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs701145	0.585	rs17766586	chr3:153778918	C/T	cg17054900	chr3:154042577	DHX36	-0.61	-7.65	-0.34	1.14e-13	Coronary artery disease;
LGG	cis	rs6586163	1.000	rs7097572	chr10:90753260	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-7.08	-0.31	5.45e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2013441	1.000	rs34644796	chr17:20064128	C/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs17209837	1.000	rs60123540	chr7:87085182	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.78	-0.51	3.16e-32	Gallbladder cancer;
LGG	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg24596788	chr1:163392923	NA	-0.68	-12.79	-0.51	2.7e-32	Motion sickness;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	13.99	0.55	2.3e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.83	0.34	3.47e-14	Mean corpuscular volume;
LGG	cis	rs7523050	0.643	rs34367763	chr1:109400805	C/T	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs2354432	0.505	rs4424556	chr1:146863973	G/C	cg25205988	chr1:146714368	CHD1L	1.19	11.65	0.48	1.13e-27	Mitochondrial DNA levels;
LGG	cis	rs7149337	0.836	rs35345236	chr14:51671817	T/C	cg23942311	chr14:51606299	NA	0.33	7.23	0.32	1.97e-12	Cancer;
LGG	cis	rs1015291	0.708	rs1466686	chr12:19996232	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs911555	0.755	rs11627446	chr14:103946450	G/C	cg24130564	chr14:104152367	KLC1	-0.39	-7.28	-0.32	1.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.04	-18.43	-0.65	2.75e-57	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10937275	1.000	rs35923019	chr3:186651388	C/T	cg13419791	chr3:186648285	ST6GAL1	0.79	8.13	0.35	3.83e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs67478160	0.619	rs1040813	chr14:104306696	T/C	cg26031613	chr14:104095156	KLC1	-0.41	-6.75	-0.3	4.47e-11	Schizophrenia;
LGG	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs7133214	0.771	rs11049139	chr12:27927144	G/T	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.9	-0.31	1.72e-11	Gut microbiota (functional units);
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg02158880	chr13:53174818	NA	0.38	7.17	0.32	2.95e-12	Lewy body disease;
LGG	cis	rs17227506	0.502	rs7846043	chr8:13412918	A/G	cg03566418	chr8:13424080	C8orf48	0.54	8.49	0.37	2.87e-16	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg13010199	chr12:38710504	ALG10B	0.55	9.81	0.41	9.3e-21	Resting heart rate;
LGG	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.39	-0.4	2.67e-19	Educational attainment;
LGG	cis	rs11630290	0.806	rs10519220	chr15:64047120	C/T	cg12036633	chr15:63758958	NA	0.57	7.82	0.34	3.56e-14	Iris characteristics;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.31	0.63	3.75e-52	Obesity-related traits;
LGG	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg04691961	chr3:161091175	C3orf57	-0.6	-13.54	-0.53	1.99e-35	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	trans	rs3780486	0.881	rs10738906	chr9:33135634	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	24.77	0.75	7.15e-87	IgG glycosylation;
LGG	cis	rs151997	0.538	rs62367392	chr5:50270298	T/C	cg06027927	chr5:50259733	NA	0.65	10.26	0.43	2.17e-22	Callous-unemotional behaviour;
LGG	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg06713675	chr4:122721982	EXOSC9	-0.44	-6.99	-0.31	9.74e-12	Type 2 diabetes;
LGG	cis	rs7927771	1.000	rs11605774	chr11:47832793	G/A	cg20307385	chr11:47447363	PSMC3	-0.48	-8.55	-0.37	1.84e-16	Subjective well-being;
LGG	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg16482183	chr6:26056742	HIST1H1C	0.49	8.26	0.36	1.57e-15	Height;
LGG	cis	rs9557207	0.901	rs9557210	chr13:100047504	C/T	cg24509225	chr13:100037070	UBAC2	0.58	10.03	0.42	1.46e-21	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg10563352	chr2:228028774	COL4A3;COL4A4	-0.38	-6.97	-0.31	1.12e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7246865	0.859	rs11086052	chr19:17169081	G/A	cg19418318	chr19:17219073	MYO9B	0.29	7.69	0.34	8.88e-14	Reticulocyte fraction of red cells;
LGG	cis	rs2816316	1.000	rs1323297	chr1:192537400	T/C	cg02586212	chr1:192544902	RGS1	0.46	9.28	0.4	6.52e-19	Celiac disease;
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg06221963	chr1:154839813	KCNN3	-0.52	-10.74	-0.45	3.56e-24	Prostate cancer;
LGG	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.22	-0.49	5.62e-30	Height;
LGG	cis	rs3540	0.597	rs10152221	chr15:91047664	A/G	cg22089800	chr15:90895588	ZNF774	-0.68	-12.59	-0.51	1.77e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.14	-0.35	3.59e-15	HDL cholesterol;
LGG	cis	rs6450176	1.000	rs3776706	chr5:53304933	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs1422110	0.543	rs888804	chr5:85411181	G/A	cg01787110	chr1:109008453	NBPF6	0.79	13.55	0.53	1.75e-35	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs3733585	0.699	rs6449178	chr4:9968684	A/G	cg08250081	chr4:10125330	NA	0.36	6.84	0.3	2.56e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7106204	0.514	rs7935857	chr11:24252420	C/T	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg05064044	chr6:292385	DUSP22	-0.64	-10.84	-0.45	1.46e-24	Menopause (age at onset);
LGG	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg24692254	chr21:30365293	RNF160	-0.58	-10.76	-0.45	2.9e-24	Pancreatic cancer;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg18402987	chr7:1209562	NA	0.5	8.43	0.36	4.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10911232	0.507	rs4652762	chr1:182993960	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs3742264	0.656	rs1041166	chr13:46555220	T/A	cg15192986	chr13:46630673	CPB2	-0.37	-7.12	-0.31	4.25e-12	Blood protein levels;
LGG	trans	rs7618501	1.000	rs9855505	chr3:49792158	T/G	cg21659725	chr3:3221576	CRBN	-0.92	-20.41	-0.69	1.63e-66	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.633	rs762400	chr21:45113629	C/G	cg01579765	chr21:45077557	HSF2BP	0.39	8.88	0.38	1.48e-17	Mean corpuscular volume;
LGG	cis	rs6430585	0.646	rs12468768	chr2:136494985	C/T	cg07169764	chr2:136633963	MCM6	1.25	20.62	0.69	1.68e-67	Corneal structure;
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg06558623	chr16:89946397	TCF25	1.1	12.09	0.49	1.98e-29	Skin colour saturation;
LGG	cis	rs6993813	0.807	rs4424296	chr8:120013276	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.28	6.91	0.31	1.59e-11	Bone mineral density (hip);
LGG	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs62400317	0.859	rs72858511	chr6:45218119	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.48e-22	Total body bone mineral density;
LGG	cis	rs62238980	0.614	rs80148383	chr22:32513717	A/C	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs2439831	0.850	rs8032649	chr15:44134922	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.99	-10.72	-0.45	4.27e-24	Lung cancer in ever smokers;
LGG	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.47	-7.49	-0.33	3.42e-13	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.74	0.34	6.28e-14	Homoarginine levels;
LGG	trans	rs6993244	1	rs6993244	chr8:8863059	C/G	cg21775007	chr8:11205619	TDH	0.44	7.01	0.31	8.26e-12	Mean corpuscular hemoglobin;
LGG	cis	rs877282	0.898	rs11253347	chr10:765769	A/G	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.11e-11	Uric acid levels;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg09448879	chr15:79043637	NA	-0.51	-12.75	-0.51	4.11e-32	Coronary artery disease or large artery stroke;
LGG	cis	rs72781680	1.000	rs72796316	chr2:24132272	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.49	0.4	1.23e-19	Lymphocyte counts;
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg16141378	chr3:129829833	LOC729375	-0.48	-11.9	-0.48	1.09e-28	Neuroticism;
LGG	cis	rs7715811	1.000	rs6554813	chr5:13763039	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.82	-0.42	8.08e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs2346177	0.542	rs1900591	chr2:46697968	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.14	0.39	1.93e-18	HDL cholesterol;
LGG	cis	rs11074306	0.561	rs55800284	chr15:28068301	G/C	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	trans	rs7395662	0.864	rs11039872	chr11:48629533	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.34e-13	HDL cholesterol;
LGG	trans	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg18335740	chr13:41363409	SLC25A15	-0.59	-11.33	-0.47	2.05e-26	Lewy body disease;
LGG	cis	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg13443165	chr9:33130375	B4GALT1	0.61	9.26	0.4	7.57e-19	IgG glycosylation;
LGG	cis	rs910316	0.875	rs12588099	chr14:75594462	A/T	cg11812906	chr14:75593930	NEK9	0.53	9.91	0.42	4.04e-21	Height;
LGG	cis	rs116095464	0.718	rs62331563	chr5:355286	T/C	cg22496380	chr5:211416	CCDC127	-1.16	-10.03	-0.42	1.52e-21	Breast cancer;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07234876	chr8:600039	NA	1.16	11.48	0.47	4.91e-27	IgG glycosylation;
LGG	cis	rs4748857	0.891	rs4747456	chr10:23571136	A/T	cg18853376	chr10:23633759	C10orf67	0.36	6.82	0.3	2.77e-11	Systemic lupus erythematosus;
LGG	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg01448562	chr3:133502909	NA	0.42	7.36	0.32	8.54e-13	Alcohol consumption (transferrin glycosylation);
LGG	trans	rs6582630	0.502	rs2387603	chr12:38353389	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3816183	0.656	rs4953583	chr2:42940859	G/T	cg14631114	chr2:43023945	NA	0.39	7.59	0.33	1.81e-13	Hypospadias;
LGG	cis	rs4650994	0.544	rs11579513	chr1:178496092	T/C	cg12486710	chr1:178512616	C1orf220	0.5	10.56	0.44	1.67e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg10661904	chr17:79619235	PDE6G	-0.42	-8.51	-0.37	2.4e-16	Eye color traits;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.83	-0.42	7.44e-21	Response to antipsychotic treatment;
LGG	cis	rs7582720	1.000	rs72936856	chr2:203775712	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg26924012	chr15:45694286	SPATA5L1	1.03	21.03	0.7	2.02e-69	Homoarginine levels;
LGG	trans	rs7980799	0.935	rs10844580	chr12:33553867	G/A	cg26384229	chr12:38710491	ALG10B	-0.51	-8.69	-0.37	6.46e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg25019033	chr10:957182	NA	0.35	7.25	0.32	1.78e-12	Response to angiotensin II receptor blocker therapy;
LGG	trans	rs8073060	0.516	rs2376177	chr17:33938089	T/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.3	-0.65	1.09e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03437731	chr2:198570720	MARS2	0.43	7.07	0.31	5.86e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs57502260	0.915	rs7106320	chr11:68210118	C/T	cg01657329	chr11:68192670	LRP5	-0.59	-7.49	-0.33	3.54e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	cis	rs1816752	0.905	rs7339140	chr13:25011902	A/G	cg02811702	chr13:24901961	NA	0.41	7.69	0.34	8.87e-14	Obesity-related traits;
LGG	cis	rs12580194	0.593	rs115471673	chr12:55766516	A/G	cg19537932	chr12:55886519	OR6C68	-0.56	-10.21	-0.43	3.35e-22	Cancer;
LGG	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg25801113	chr15:45476975	SHF	-0.88	-18.87	-0.66	2.58e-59	Uric acid levels;
LGG	cis	rs6912958	0.500	rs9342104	chr6:87798512	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-9.85	-0.42	6.53e-21	Monocyte percentage of white cells;
LGG	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg10253484	chr15:75165896	SCAMP2	0.44	7.06	0.31	6.08e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.76	-0.41	1.39e-20	Platelet count;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.95	-0.35	1.42e-14	Monocyte count;
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg27432699	chr2:27873401	GPN1	-0.53	-9.28	-0.4	6.54e-19	Total body bone mineral density;
LGG	cis	rs12478296	1.000	rs12474070	chr2:243039738	C/T	cg18898632	chr2:242989856	NA	-0.8	-9.89	-0.42	4.89e-21	Obesity-related traits;
LGG	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	19.77	0.68	1.61e-63	Smoking behavior;
LGG	cis	rs9393692	0.905	rs6940237	chr6:26282322	T/C	cg15665833	chr6:26285013	NA	0.39	7.69	0.34	8.63e-14	Educational attainment;
LGG	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg19524238	chr7:2802976	GNA12	0.32	7.58	0.33	1.96e-13	Height;
LGG	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg02574844	chr11:5959923	NA	0.39	6.96	0.31	1.17e-11	DNA methylation (variation);
LGG	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Colorectal cancer;
LGG	cis	rs2180341	0.960	rs9401953	chr6:127687574	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.85	0.59	1.57e-45	Breast cancer;
LGG	cis	rs4622507	0.618	rs34045213	chr16:55063749	T/C	cg09947736	chr16:55091198	NA	0.77	11.31	0.47	2.44e-26	Social communication problems;
LGG	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg05082376	chr22:42548792	NA	-0.37	-7.37	-0.32	7.84e-13	Schizophrenia;
LGG	cis	rs74781061	0.929	rs8041030	chr15:74818067	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg00012203	chr2:219082015	ARPC2	-0.69	-12.75	-0.51	4.19e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs9354308	0.764	rs9354334	chr6:66607770	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.65	-0.3	8.26e-11	Metabolite levels;
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	cis	rs774359	0.750	rs2477521	chr9:27509945	A/G	cg21249376	chr9:27528432	MOBKL2B	0.45	8.63	0.37	9.69e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs1814175	0.645	rs10128563	chr11:50023681	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg16576083	chr14:105354267	KIAA0284	0.6	10.22	0.43	3.09e-22	IgG glycosylation;
LGG	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs8056893	0.513	rs3743742	chr16:68345036	G/T	cg07273125	chr16:68295692	NA	0.47	10.8	0.45	2.04e-24	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16546432	chr1:234350263	SLC35F3	0.42	6.83	0.3	2.63e-11	Gut microbiome composition (summer);
LGG	cis	rs5839475	1	rs5839475	chr2:234188015	A/AG	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.44	6.96	0.31	1.13e-11	Strep throat;
LGG	cis	rs17376456	0.757	rs10066431	chr5:93198204	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs26868	0.766	rs26867	chr16:2249410	T/C	cg02248941	chr16:2239361	CASKIN1	0.47	9.51	0.4	1.09e-19	Height;
LGG	cis	rs58649573	0.509	rs10739635	chr9:126792086	A/G	cg14112217	chr9:126806003	NA	0.39	7.57	0.33	2.03e-13	Post-traumatic stress disorder;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs2652834	0.808	rs966331	chr15:63411927	T/C	cg05507819	chr15:63340323	TPM1	0.5	7.0	0.31	9.2e-12	HDL cholesterol;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22627940	chr8:49390241	NA	0.42	8.01	0.35	9.29e-15	Menarche (age at onset);
LGG	cis	rs9796	0.653	rs28516683	chr15:41446645	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.61	-0.41	4.52e-20	Menopause (age at onset);
LGG	cis	rs4363385	0.747	rs4314835	chr1:152984901	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.07	-0.39	3.34e-18	Inflammatory skin disease;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04772025	chr11:68637568	NA	0.75	13.12	0.52	1.17e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.89	-0.31	1.78e-11	Lung cancer;
LGG	trans	rs2018683	0.707	rs917219	chr7:28975343	A/G	cg19402173	chr7:128379420	CALU	-0.54	-9.37	-0.4	3.32e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs367615	0.918	rs4270746	chr5:108876839	T/C	cg17395555	chr5:108820864	NA	0.66	9.19	0.39	1.29e-18	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg24642844	chr7:1081250	C7orf50	-0.71	-9.02	-0.39	4.94e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11608355	0.521	rs4766595	chr12:109846998	A/T	cg19025524	chr12:109796872	NA	-0.56	-11.99	-0.49	4.88e-29	Neuroticism;
LGG	cis	rs6089584	0.816	rs4925336	chr20:60627180	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.8	-0.38	2.81e-17	Body mass index;
LGG	cis	rs35110281	0.776	rs62226866	chr21:45024186	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.59	0.41	5.26e-20	Mean corpuscular volume;
LGG	cis	rs8180040	0.967	rs807935	chr3:47321669	A/G	cg27129171	chr3:47204927	SETD2	0.79	15.3	0.58	4.51e-43	Colorectal cancer;
LGG	trans	rs9944715	0.871	rs4890632	chr18:43826293	G/A	cg01718231	chr17:29326311	RNF135	-0.41	-6.66	-0.3	7.56e-11	Red cell distribution width;Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08267701	chr19:45393621	TOMM40	0.43	6.99	0.31	9.64e-12	Cognitive performance;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg08645402	chr16:4508243	NA	0.52	9.49	0.4	1.24e-19	Schizophrenia;
LGG	cis	rs3923380	0.585	rs7659268	chr4:77466254	T/C	cg07933720	chr4:77468187	SHROOM3	0.35	7.43	0.33	5.31e-13	Craniofacial microsomia;
LGG	cis	rs9309473	0.687	rs6748040	chr2:73609928	A/G	cg20560298	chr2:73613845	ALMS1	0.48	8.64	0.37	9.46e-17	Metabolite levels;
LGG	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg18404041	chr3:52824283	ITIH1	-0.49	-9.25	-0.39	8.24e-19	Electroencephalogram traits;
LGG	cis	rs11157436	0.509	rs12589104	chr14:22635650	T/G	cg00994629	chr14:22694547	NA	0.33	7.19	0.32	2.69e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	7.43	0.33	5.21e-13	Renal function-related traits (BUN);
LGG	cis	rs4919694	1.000	rs77505796	chr10:104647774	A/T	cg04362960	chr10:104952993	NT5C2	1.1	13.82	0.54	1.27e-36	Arsenic metabolism;
LGG	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.94	0.82	8.7e-115	Cognitive function;
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg26513180	chr16:89883248	FANCA	-0.92	-20.52	-0.69	5.01e-67	Vitiligo;
LGG	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg05941027	chr17:61774174	LIMD2	0.37	9.48	0.4	1.32e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs853679	0.607	rs34878803	chr6:28250179	T/C	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22825116	chr2:88991018	RPIA	-0.47	-6.82	-0.3	2.8e-11	Systemic lupus erythematosus;
LGG	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2133450	0.780	rs2030155	chr3:7361473	C/T	cg19930620	chr3:7340148	GRM7	-0.37	-7.88	-0.34	2.4e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg16511985	chr3:153974050	SGEF	0.49	8.31	0.36	1.08e-15	Coronary artery disease;
LGG	cis	rs737693	0.527	rs72983552	chr11:102764093	T/G	cg14995062	chr11:102826570	MMP13	0.48	7.11	0.31	4.5e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs8067545	0.636	rs11204300	chr17:20195438	C/T	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.42e-22	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06995565	chr16:75590339	TMEM231	0.44	7.03	0.31	7.23e-12	Cognitive performance;
LGG	cis	rs7582720	1.000	rs72932557	chr2:203846817	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg26384229	chr12:38710491	ALG10B	0.76	15.66	0.59	1.11e-44	Morning vs. evening chronotype;
LGG	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.52	0.53	2.46e-35	Colorectal cancer;
LGG	cis	rs12893597	0.580	rs2278687	chr14:76838336	G/C	cg20290672	chr14:76816747	NA	-0.41	-6.84	-0.3	2.54e-11	Maximal oxygen uptake response;
LGG	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.41	-6.72	-0.3	5.49e-11	Ulcerative colitis;
LGG	cis	rs4538187	0.806	rs34777730	chr2:64250804	T/C	cg14150252	chr2:64069583	UGP2	-0.47	-9.35	-0.4	3.79e-19	Systolic blood pressure;
LGG	cis	rs12701220	0.744	rs35588238	chr7:1012006	G/A	cg00990874	chr7:1149470	C7orf50	-0.52	-7.88	-0.34	2.36e-14	Bronchopulmonary dysplasia;
LGG	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg06028605	chr16:24865363	SLC5A11	-0.48	-7.88	-0.34	2.39e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg10587741	chr22:38071170	LGALS1	0.66	12.82	0.51	2.08e-32	Fat distribution (HIV);
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.81	-0.41	9.14e-21	Life satisfaction;
LGG	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg17145862	chr1:211918768	LPGAT1	0.8	17.21	0.62	1.1e-51	Leprosy;
LGG	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg24112000	chr20:60950667	NA	0.35	7.96	0.35	1.37e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.82	-0.3	2.9e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg06138931	chr13:21896616	NA	-0.44	-7.19	-0.32	2.64e-12	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26614578	chr12:113623930	C12orf52;DDX54	0.49	7.74	0.34	6.44e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.538	rs4523214	chr8:10970773	T/A	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.3	-0.4	5.52e-19	Triglycerides;
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.87	-0.3	2.12e-11	Neuroticism;
LGG	cis	rs17767392	1.000	rs35260692	chr14:71831665	T/C	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.59e-18	Mitral valve prolapse;
LGG	cis	rs7917772	0.582	rs10786698	chr10:104378750	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.34	0.47	1.77e-26	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg06637938	chr14:75390232	RPS6KL1	0.59	10.99	0.45	3.89e-25	Height;
LGG	cis	rs736408	0.812	rs2270197	chr3:52824095	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	7.95	0.35	1.46e-14	Bipolar disorder;
LGG	cis	rs774359	0.797	rs774354	chr9:27515967	A/G	cg21249376	chr9:27528432	MOBKL2B	0.43	8.94	0.38	9.62e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.28	0.55	1.37e-38	Platelet count;
LGG	cis	rs4689642	1.000	rs13144864	chr4:7215224	C/T	cg21353189	chr4:7228343	SORCS2	0.3	7.38	0.32	7.53e-13	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11098499	0.821	rs10032151	chr4:120391628	C/T	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs9788721	0.836	rs2568494	chr15:78740964	G/A	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.83	-0.3	2.67e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs12496230	1.000	rs12495879	chr3:66861656	A/G	cg17646820	chr3:66848679	NA	-0.52	-8.14	-0.35	3.62e-15	Type 2 diabetes;
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs11864453	1.000	rs11864453	chr16:72050480	C/T	cg23815491	chr16:72088622	HP	0.53	11.73	0.48	5.27e-28	Fibrinogen levels;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg00761968	chr13:53314142	LECT1	-0.37	-7.98	-0.35	1.18e-14	Lewy body disease;
LGG	trans	rs4714291	0.802	rs2983140	chr6:40017224	A/G	cg02267698	chr19:7991119	CTXN1	-0.61	-9.8	-0.41	9.96e-21	Strep throat;
LGG	cis	rs798554	0.591	rs757791	chr7:2867296	A/G	cg05793240	chr7:2802953	GNA12	0.28	6.89	0.3	1.83e-11	Height;
LGG	cis	rs12282928	0.959	rs1393791	chr11:48264183	T/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.2	-0.32	2.45e-12	Migraine - clinic-based;
LGG	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs4356975	0.583	rs62296935	chr4:69948596	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.67	0.3	7.23e-11	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs4517800	chr16:48677404	T/A	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2777491	1.000	rs66538814	chr15:41685917	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.95	-18.97	-0.66	8.57e-60	Ulcerative colitis;
LGG	cis	rs11634851	0.844	rs4778849	chr15:81026226	C/T	cg03950166	chr15:80988613	FAM108C1	-0.4	-7.33	-0.32	1.03e-12	Systolic blood pressure;
LGG	cis	rs921968	0.519	rs72966020	chr2:219642620	C/G	cg01130898	chr2:219473002	PLCD4	0.42	7.04	0.31	6.89e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.98	-0.39	6.95e-18	Cutaneous nevi;
LGG	cis	rs7737355	0.773	rs32111	chr5:131046708	T/C	cg06307176	chr5:131281290	NA	0.52	8.6	0.37	1.22e-16	Life satisfaction;
LGG	cis	rs5758511	0.689	rs45441993	chr22:42471738	C/A	cg15128208	chr22:42549153	NA	0.77	10.96	0.45	5.3e-25	Birth weight;
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.31	0.47	2.29e-26	Tonsillectomy;
LGG	cis	rs7582720	1.000	rs114395475	chr2:203769112	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg03060546	chr3:49711283	APEH	0.55	8.43	0.36	4.47e-16	Resting heart rate;
LGG	cis	rs870825	0.616	rs67409049	chr4:185623989	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs72781680	1.000	rs72781679	chr2:24237712	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.62	0.41	4.16e-20	Lymphocyte counts;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.23	0.55	2.25e-38	Morning vs. evening chronotype;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg18446336	chr7:2847575	GNA12	-0.28	-7.13	-0.31	3.98e-12	Height;
LGG	cis	rs1318772	1.000	rs185336	chr5:112739836	T/C	cg12552261	chr5:112820674	MCC	0.7	7.98	0.35	1.13e-14	F-cell distribution;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3206736	0.514	rs1637679	chr7:35001022	C/A	cg13400248	chr7:35225412	NA	0.53	9.42	0.4	2.2e-19	Diastolic blood pressure;
LGG	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg08885076	chr2:99613938	TSGA10	-0.57	-11.62	-0.48	1.5e-27	Chronic sinus infection;
LGG	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg01420254	chr6:26195488	NA	0.85	10.96	0.45	5.09e-25	Gout;Renal underexcretion gout;
LGG	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg23894439	chr1:183413866	NA	0.49	9.11	0.39	2.5e-18	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs6496044	0.568	rs1351196	chr15:86077404	T/C	cg13263323	chr15:86062960	AKAP13	-0.39	-8.33	-0.36	9.1e-16	Interstitial lung disease;
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg22398616	chr13:53314203	LECT1	-0.4	-7.58	-0.33	1.96e-13	Lewy body disease;
LGG	cis	rs561341	1.000	rs548957	chr17:30302411	G/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg27189623	chr16:705930	WDR90	0.4	7.65	0.33	1.19e-13	Height;
LGG	cis	rs12618769	0.597	rs3769734	chr2:99096149	A/T	cg18455616	chr2:99124870	INPP4A	0.29	8.53	0.37	2.15e-16	Bipolar disorder;
LGG	cis	rs36093844	0.752	rs7931698	chr11:85549926	A/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs3858526	0.584	rs10769270	chr11:5860563	T/C	cg25319279	chr11:5960081	NA	-0.45	-7.27	-0.32	1.5e-12	DNA methylation (variation);
LGG	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.59	0.44	1.29e-23	Lung cancer in ever smokers;
LGG	cis	rs6942756	0.774	rs2566876	chr7:128890055	A/G	cg02491457	chr7:128862824	NA	0.65	12.27	0.5	3.53e-30	White matter hyperintensity burden;
LGG	cis	rs4642101	0.855	rs9873475	chr3:12845422	A/G	cg24848339	chr3:12840334	CAND2	0.38	8.67	0.37	7.33e-17	QRS complex (12-leadsum);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24308307	chr19:10676765	KRI1	-0.48	-7.76	-0.34	5.67e-14	Pancreatic cancer;
LGG	cis	rs72781680	0.950	rs72796402	chr2:24180104	A/G	cg08917208	chr2:24149416	ATAD2B	0.93	10.13	0.43	6.7e-22	Lymphocyte counts;
LGG	cis	rs2117029	0.555	rs9788139	chr12:49520669	C/T	cg24176009	chr12:49580217	TUBA1A	0.62	12.13	0.49	1.3e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg05623727	chr3:50126028	RBM5	-0.32	-6.93	-0.31	1.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9487051	0.799	rs351724	chr6:109546577	T/C	cg21918786	chr6:109611834	NA	-0.4	-7.06	-0.31	6.21e-12	Reticulocyte fraction of red cells;
LGG	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg16141378	chr3:129829833	LOC729375	0.37	7.92	0.35	1.77e-14	Retinal vascular caliber;
LGG	cis	rs2652834	1.000	rs11637852	chr15:63397151	G/A	cg05507819	chr15:63340323	TPM1	0.59	7.96	0.35	1.37e-14	HDL cholesterol;
LGG	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg06637938	chr14:75390232	RPS6KL1	0.62	10.14	0.43	6.01e-22	Height;
LGG	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-25.91	-0.77	3.96e-92	Height;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06339248	chr11:57435803	ZDHHC5	0.44	7.0	0.31	9.19e-12	Cognitive performance;
LGG	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg07930552	chr6:133119739	C6orf192	1.11	9.67	0.41	2.76e-20	Type 2 diabetes nephropathy;
LGG	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7954584	0.567	rs1720033	chr12:122384344	C/T	cg10207240	chr12:122356781	WDR66	-0.26	-8.03	-0.35	7.9e-15	Mean corpuscular volume;
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg05793240	chr7:2802953	GNA12	0.33	7.47	0.33	3.9e-13	Height;
LGG	cis	rs17767392	0.958	rs8010616	chr14:72019108	A/G	cg13720639	chr14:72061746	SIPA1L1	0.4	8.77	0.38	3.35e-17	Mitral valve prolapse;
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg04287289	chr16:89883240	FANCA	0.83	7.33	0.32	1.02e-12	Skin colour saturation;
LGG	cis	rs929354	0.742	rs2107863	chr7:156963731	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.26	0.69	7.94e-66	Alzheimer's disease;
LGG	cis	rs6541297	1.000	rs6658942	chr1:230287517	A/C	cg20703242	chr1:230279135	GALNT2	0.37	7.82	0.34	3.48e-14	Coronary artery disease;
LGG	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg11890956	chr21:40555474	PSMG1	-0.72	-12.37	-0.5	1.47e-30	Menarche (age at onset);
LGG	cis	rs7975161	1.000	rs4964728	chr12:104649733	G/A	cg25273343	chr12:104657179	TXNRD1	-0.74	-10.59	-0.44	1.26e-23	Toenail selenium levels;
LGG	cis	rs1555133	0.610	rs6141706	chr20:30992894	C/T	cg00028034	chr20:30779307	TSPYL3	0.35	6.95	0.31	1.27e-11	Monocyte count;
LGG	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg21466736	chr12:48725269	NA	0.38	7.74	0.34	6.22e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg00106254	chr7:1943704	MAD1L1	0.4	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs7107174	0.786	rs2450134	chr11:77925778	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.42	-0.33	5.83e-13	Testicular germ cell tumor;
LGG	cis	rs4731207	0.596	rs6971413	chr7:124592668	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.52	0.4	9.63e-20	Diabetic retinopathy;
LGG	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg23649088	chr2:200775458	C2orf69	-0.61	-8.12	-0.35	4.26e-15	Schizophrenia;
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg06697600	chr4:7070879	GRPEL1	0.52	9.08	0.39	3.06e-18	Monocyte percentage of white cells;
LGG	cis	rs2274273	0.934	rs2341621	chr14:55726425	C/T	cg04306507	chr14:55594613	LGALS3	0.63	17.39	0.63	1.74e-52	Protein biomarker;
LGG	cis	rs8072100	0.764	rs4794371	chr17:45627693	G/C	cg08085267	chr17:45401833	C17orf57	0.61	12.28	0.5	3.5e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11608355	0.521	rs10850131	chr12:109837052	A/G	cg19025524	chr12:109796872	NA	0.58	12.87	0.51	1.31e-32	Neuroticism;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg19077165	chr18:44547161	KATNAL2	0.59	11.09	0.46	1.67e-25	Personality dimensions;
LGG	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg07959490	chr17:80112427	CCDC57	0.39	7.49	0.33	3.51e-13	Life satisfaction;
LGG	cis	rs11096990	0.855	rs2711989	chr4:39152036	A/G	cg24403649	chr4:39172243	NA	-0.48	-7.75	-0.34	5.89e-14	Cognitive function;
LGG	cis	rs67385638	1.000	rs2855039	chr11:5271671	C/T	cg12559170	chr11:5275217	HBG2	0.57	13.36	0.53	1.14e-34	Hemoglobin levels;
LGG	cis	rs2404602	0.647	rs12898810	chr15:76904738	T/C	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.22e-22	Blood metabolite levels;
LGG	cis	rs258892	0.895	rs16901131	chr5:72054836	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg04287289	chr16:89883240	FANCA	-0.54	-9.98	-0.42	2.18e-21	Vitiligo;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27373220	chr10:465035	DIP2C	0.39	6.9	0.31	1.69e-11	Pancreatic cancer;
LGG	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.69	-0.44	5.67e-24	Vitiligo;
LGG	cis	rs1461503	0.934	rs7115679	chr11:122831963	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-14.41	-0.56	3.81e-39	Menarche (age at onset);
LGG	trans	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs3749237	0.555	rs2117939	chr3:49415179	C/A	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.26e-23	Resting heart rate;
LGG	cis	rs36715	0.953	rs36700	chr5:127551273	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.45	0.33	4.56e-13	Breast cancer;
LGG	cis	rs868036	0.681	rs28670272	chr15:68109907	C/T	cg05925327	chr15:68127851	NA	0.36	7.42	0.33	5.58e-13	Restless legs syndrome;
LGG	cis	rs7267979	0.844	rs6050477	chr20:25221547	C/T	cg06421707	chr20:25228305	PYGB	-0.41	-8.72	-0.38	5.01e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs600550	0.588	rs2304936	chr11:60102156	T/C	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.83	-0.34	3.47e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg18357526	chr6:26021779	HIST1H4A	0.93	18.5	0.65	1.32e-57	Intelligence (multi-trait analysis);
LGG	cis	rs9309473	0.607	rs7560272	chr2:73561485	A/T	cg20560298	chr2:73613845	ALMS1	-0.47	-8.51	-0.37	2.39e-16	Metabolite levels;
LGG	cis	rs240764	0.817	rs58266877	chr6:101156284	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.62	-0.33	1.47e-13	Neuroticism;
LGG	cis	rs9326248	0.515	rs2727793	chr11:116683374	C/T	cg20608306	chr11:116969690	SIK3	0.29	7.7	0.34	8.51e-14	Blood protein levels;
LGG	cis	rs9611565	0.605	rs202638	chr22:41855458	A/G	cg17376030	chr22:41985996	PMM1	-0.46	-7.35	-0.32	8.89e-13	Vitiligo;
LGG	cis	rs9733	0.818	rs12403609	chr1:150676485	T/C	cg13175981	chr1:150552382	MCL1	0.54	9.12	0.39	2.24e-18	Tonsillectomy;
LGG	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.79	-0.59	3.01e-45	Height;
LGG	cis	rs561341	1.000	rs498391	chr17:30328704	G/A	cg12193833	chr17:30244370	NA	-0.27	-6.79	-0.3	3.46e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11096990	0.613	rs6829660	chr4:39282563	A/C	cg24403649	chr4:39172243	NA	0.41	7.26	0.32	1.61e-12	Cognitive function;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg05665937	chr4:1216051	CTBP1	0.48	8.31	0.36	1.09e-15	Obesity-related traits;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg09201001	chr11:18656081	SPTY2D1	0.96	20.73	0.69	5.46e-68	Breast cancer;
LGG	trans	rs7395662	0.963	rs2865923	chr11:48724955	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs737693	0.834	rs1940938	chr11:102774844	G/A	cg19620758	chr11:102826565	MMP13	0.56	6.76	0.3	4.06e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs28595532	0.641	rs116674223	chr4:119371479	G/C	cg26518628	chr1:97050305	NA	-0.82	-6.86	-0.3	2.29e-11	Cannabis dependence symptom count;
LGG	cis	rs7107174	0.901	rs2512525	chr11:77923019	T/C	cg02023728	chr11:77925099	USP35	0.45	7.79	0.34	4.44e-14	Testicular germ cell tumor;
LGG	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg19077165	chr18:44547161	KATNAL2	0.41	6.71	0.3	5.79e-11	Educational attainment;
LGG	trans	rs7939886	0.920	rs11227850	chr11:56081507	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg08677398	chr8:58056175	NA	0.48	7.05	0.31	6.44e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs8010715	0.804	rs1134334	chr14:24594114	A/G	cg06429887	chr14:24600500	FITM1	0.36	7.47	0.33	3.94e-13	IgG glycosylation;
LGG	cis	rs1691799	0.899	rs1185244	chr12:66725160	C/T	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs17208368	0.628	rs12446032	chr16:55097648	A/C	cg11181171	chr16:55090946	NA	0.46	7.76	0.34	5.44e-14	Hypospadias;
LGG	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg05623727	chr3:50126028	RBM5	0.34	7.36	0.32	8.38e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6909430	1.000	rs9490948	chr6:98655178	A/G	cg12860156	chr6:98744658	NA	-0.44	-7.42	-0.33	5.48e-13	Quantitative traits;
LGG	cis	rs7551222	0.691	rs11240760	chr1:204547268	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.45	-0.47	6.52e-27	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.62	-0.44	1.01e-23	Lung cancer;
LGG	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg26597838	chr10:835615	NA	0.73	9.95	0.42	3e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg08603382	chr10:743973	NA	0.38	6.92	0.31	1.52e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs709400	0.832	rs10145755	chr14:104121984	C/T	cg26031613	chr14:104095156	KLC1	1.15	27.87	0.79	4.31e-101	Body mass index;
LGG	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs11671005	0.735	rs34511020	chr19:58921296	A/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs4356203	0.905	rs662711	chr11:17206188	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg25208724	chr1:156163844	SLC25A44	1.19	25.38	0.76	1.13e-89	Testicular germ cell tumor;
LGG	cis	rs11722228	0.522	rs1109472	chr4:10134448	C/G	cg08250081	chr4:10125330	NA	0.58	10.6	0.44	1.18e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs12681287	0.547	rs7465511	chr8:87521481	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.1e-13	Caudate activity during reward;
LGG	cis	rs6450176	1.000	rs12654393	chr5:53302620	A/C	ch.5.1024479R	chr5:53302184	ARL15	0.7	11.61	0.47	1.55e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs3780486	1.000	rs3780480	chr9:33163486	G/T	cg13443165	chr9:33130375	B4GALT1	-0.69	-11.24	-0.46	4.36e-26	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg16606324	chr3:10149918	C3orf24	0.54	7.26	0.32	1.68e-12	Alzheimer's disease;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg05863683	chr7:1912471	MAD1L1	0.43	8.37	0.36	6.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6840360	0.582	rs11733820	chr4:152316139	T/C	cg25486957	chr4:152246857	NA	-0.37	-6.67	-0.3	7.45e-11	Intelligence (multi-trait analysis);
LGG	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15128208	chr22:42549153	NA	0.49	10.06	0.42	1.12e-21	Cognitive function;
LGG	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	7.81	0.34	3.84e-14	Educational attainment;
LGG	cis	rs4356203	0.905	rs10832733	chr11:17111272	A/G	cg15432903	chr11:17409602	KCNJ11	-0.4	-7.37	-0.32	7.93e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg15522984	chr1:182991683	LAMC1	-0.48	-9.93	-0.42	3.26e-21	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs115860303	chr4:119734526	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs561341	0.556	rs41290963	chr17:30396390	C/T	cg20587970	chr11:113659929	NA	-1.4	-18.5	-0.65	1.24e-57	Hip circumference adjusted for BMI;
LGG	cis	rs6450176	0.830	rs7718193	chr5:53291591	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.06	-0.46	2.19e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.53	-0.33	2.74e-13	Total cholesterol levels;
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.9	0.42	4.41e-21	Electroencephalogram traits;
LGG	cis	rs847577	0.832	rs1799068	chr7:97707069	G/T	cg13397024	chr7:97797637	LMTK2	0.39	7.14	0.31	3.7e-12	Breast cancer;
LGG	trans	rs11134654	0.935	rs1895410	chr5:170241306	C/T	cg20034712	chr19:52675470	ZNF836	-0.46	-7.63	-0.33	1.31e-13	Smooth-surface caries;
LGG	cis	rs16937	0.711	rs4333898	chr1:205169613	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg13206674	chr6:150067644	NUP43	0.67	14.85	0.57	4.67e-41	Lung cancer;
LGG	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg21475434	chr5:93447410	FAM172A	0.69	7.13	0.31	3.99e-12	Diabetic retinopathy;
LGG	cis	rs12681288	0.576	rs6990403	chr8:963471	C/A	cg15309053	chr8:964076	NA	0.43	9.19	0.39	1.37e-18	Schizophrenia;
LGG	cis	rs1153858	1.000	rs11070456	chr15:45686835	G/A	cg10760299	chr15:45669010	GATM	0.41	8.05	0.35	7.26e-15	Homoarginine levels;
LGG	cis	rs926938	0.527	rs360681	chr1:115496741	C/G	cg12756093	chr1:115239321	AMPD1	0.42	7.98	0.35	1.13e-14	Autism;
LGG	cis	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.81	0.38	2.59e-17	Neuroticism;
LGG	trans	rs561341	1.000	rs530209	chr17:30315287	A/G	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs13403149	0.695	rs10202957	chr2:2844858	A/T	cg02105481	chr2:2853515	NA	0.32	7.08	0.31	5.39e-12	Smoking initiation;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg07538946	chr5:131705188	SLC22A5	0.68	7.7	0.34	8.17e-14	Rheumatoid arthritis;
LGG	cis	rs539514	0.587	rs7320602	chr13:76332868	A/G	cg04757411	chr13:76259545	LMO7	-0.28	-7.06	-0.31	5.96e-12	Type 1 diabetes;
LGG	cis	rs7149337	0.836	rs34953083	chr14:51672432	A/G	cg23942311	chr14:51606299	NA	0.34	7.38	0.32	7.58e-13	Cancer;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.47	-0.5	5.92e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.589	rs2285428	chr17:30820176	C/T	cg25809561	chr17:30822961	MYO1D	-0.39	-8.99	-0.39	6.57e-18	Schizophrenia;
LGG	trans	rs1945213	0.694	rs7131381	chr11:55858158	T/G	cg03929089	chr4:120376271	NA	0.81	11.12	0.46	1.23e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9291683	0.546	rs4575994	chr4:9997979	G/A	cg08250081	chr4:10125330	NA	0.4	7.61	0.33	1.56e-13	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25817788	chr6:21589024	NA	0.48	7.24	0.32	1.89e-12	Gut microbiome composition (summer);
LGG	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg07117364	chr1:16154769	NA	-0.5	-9.46	-0.4	1.55e-19	Dilated cardiomyopathy;
LGG	cis	rs818427	1.000	rs514763	chr5:112215156	C/T	cg07820702	chr5:112228657	REEP5	-0.36	-6.69	-0.3	6.43e-11	Total body bone mineral density;
LGG	cis	rs9527	0.615	rs4919685	chr10:104587362	G/T	cg04362960	chr10:104952993	NT5C2	0.52	9.38	0.4	3.01e-19	Arsenic metabolism;
LGG	cis	rs2860975	0.905	rs10786182	chr10:96789775	C/T	cg09036531	chr10:96991505	NA	-0.52	-9.52	-0.4	9.49e-20	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs9487051	0.872	rs4601178	chr6:109611246	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.52e-12	Reticulocyte fraction of red cells;
LGG	cis	rs7914558	0.505	rs12260436	chr10:104741114	A/C	cg04362960	chr10:104952993	NT5C2	0.64	11.12	0.46	1.31e-25	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11920090	0.858	rs7620985	chr3:170675588	G/A	cg09710316	chr3:170744871	SLC2A2	0.66	8.61	0.37	1.17e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.77	-0.38	3.56e-17	Bone mineral density;
LGG	cis	rs2120019	0.938	rs5020842	chr15:75322310	T/C	cg09165964	chr15:75287851	SCAMP5	-1.09	-24.12	-0.75	7.53e-84	Blood trace element (Zn levels);
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg15948088	chr11:109293068	C11orf87	0.46	8.22	0.36	1.99e-15	Schizophrenia;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg08621203	chr6:150244597	RAET1G	0.53	9.98	0.42	2.16e-21	Testicular germ cell tumor;
LGG	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.82	0.34	3.64e-14	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg01200585	chr1:228362443	C1orf69	0.47	7.96	0.35	1.32e-14	Diastolic blood pressure;
LGG	cis	rs6754311	0.731	rs3754686	chr2:136603276	T/C	cg07169764	chr2:136633963	MCM6	-0.76	-12.98	-0.52	4.59e-33	Mosquito bite size;
LGG	cis	rs42648	0.935	rs42624	chr7:89957541	C/G	cg25739043	chr7:89950458	NA	-0.42	-8.88	-0.38	1.47e-17	Homocysteine levels;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.43	-0.36	4.45e-16	Life satisfaction;
LGG	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14159747	chr11:113255604	NA	0.31	8.45	0.37	3.86e-16	Neuroticism;
LGG	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg11161011	chr14:65562177	MAX	-0.77	-15.54	-0.59	3.87e-44	Obesity-related traits;
LGG	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.54	-0.37	2.01e-16	Menarche (age at onset);
LGG	cis	rs875971	0.545	rs4718325	chr7:65680310	G/A	cg11764359	chr7:65958608	NA	0.62	9.29	0.4	6.07e-19	Aortic root size;
LGG	cis	rs941873	0.868	rs10740497	chr10:81126380	T/C	cg09469691	chr10:81107165	PPIF	0.63	11.21	0.46	5.85e-26	Height;
LGG	trans	rs9467603	1.000	rs9467609	chr6:25809751	A/G	cg01620082	chr3:125678407	NA	-0.69	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8054556	0.692	rs4788199	chr16:29970857	C/G	cg06326092	chr16:30034487	C16orf92	0.35	7.0	0.31	9.24e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9796	0.870	rs72737704	chr15:41323575	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.12	-0.35	4.12e-15	Menopause (age at onset);
LGG	cis	rs7717393	0.582	rs17556534	chr5:155809735	C/G	cg04435420	chr5:155754009	SGCD	0.86	9.41	0.4	2.31e-19	Egg allergy;
LGG	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.91	-0.45	7.8e-25	Coronary artery disease;
LGG	cis	rs796364	0.806	rs35200468	chr2:201110368	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-8.13	-0.35	3.92e-15	Schizophrenia;
LGG	cis	rs7226408	0.901	rs17652935	chr18:34756530	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg07636037	chr3:49044803	WDR6	1.08	26.45	0.78	1.31e-94	Parkinson's disease;
LGG	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg04181038	chr4:183730758	NA	0.56	7.68	0.34	9.51e-14	Pediatric autoimmune diseases;
LGG	trans	rs7395662	1.000	rs34636547	chr11:48590103	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs1862618	0.853	rs33322	chr5:56175226	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs1878931	0.624	rs28089	chr16:3446937	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-11.54	-0.47	2.85e-27	Body mass index (adult);
LGG	cis	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg15596359	chr8:11213517	TDH	0.33	6.7	0.3	6.03e-11	Neuroticism;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg01145232	chr6:150245071	RAET1G	-0.5	-9.23	-0.39	9.81e-19	Lung cancer;
LGG	cis	rs7091068	0.616	rs7084701	chr10:95482249	A/G	cg20715218	chr10:95462985	C10orf4	0.71	11.08	0.46	1.78e-25	Urinary tract infection frequency;
LGG	cis	rs757110	0.902	rs2074310	chr11:17421886	T/C	cg04705435	chr11:17411270	KCNJ11	0.5	9.3	0.4	5.79e-19	Type 2 diabetes;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg12288994	chr5:1860383	NA	0.79	16.07	0.6	1.63e-46	Cardiovascular disease risk factors;
LGG	cis	rs1552244	0.554	rs6443275	chr3:10008819	G/A	cg00149659	chr3:10157352	C3orf10	0.56	8.05	0.35	7.29e-15	Alzheimer's disease;
LGG	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg14893161	chr1:205819251	PM20D1	-0.44	-7.57	-0.33	2.06e-13	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23043968	chr1:119682730	WARS2	0.49	7.99	0.35	1.05e-14	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.649	rs815046	chr12:33720602	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.66	0.37	7.8e-17	Morning vs. evening chronotype;
LGG	cis	rs7617773	0.817	rs11130162	chr3:48297611	A/G	cg11946769	chr3:48343235	NME6	0.58	9.76	0.41	1.36e-20	Coronary artery disease;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.58	-0.47	1.99e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.5	-0.61	2.03e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6815814	0.799	rs11466640	chr4:38778903	A/G	cg06935464	chr4:38784597	TLR10	-0.53	-7.27	-0.32	1.52e-12	Breast cancer;
LGG	trans	rs2243480	1.000	rs6964245	chr7:65718717	G/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs17162190	0.698	rs6693662	chr1:26821230	A/G	cg23229016	chr1:26872525	RPS6KA1	0.25	6.77	0.3	3.98e-11	Mean corpuscular volume;
LGG	cis	rs2832191	0.671	rs68101501	chr21:30513229	G/T	cg08807101	chr21:30365312	RNF160	-0.62	-10.6	-0.44	1.18e-23	Dental caries;
LGG	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg14088196	chr11:70211408	PPFIA1	0.93	13.08	0.52	1.74e-33	Coronary artery disease;
LGG	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg03959625	chr15:84868606	LOC388152	0.55	8.45	0.37	3.83e-16	Schizophrenia;
LGG	cis	rs12134245	0.776	rs13447526	chr1:91983174	A/G	cg02896835	chr1:92012615	NA	0.45	9.0	0.39	5.72e-18	Breast cancer;
LGG	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	8.1	0.35	4.99e-15	Coronary artery disease;
LGG	cis	rs6725041	0.819	rs11677095	chr2:213092080	A/G	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg26668828	chr6:292823	DUSP22	-0.69	-11.99	-0.49	4.82e-29	Menopause (age at onset);
LGG	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg07936489	chr17:37558343	FBXL20	-0.51	-8.57	-0.37	1.54e-16	Asthma;
LGG	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg12623918	chr2:306882	NA	0.51	9.56	0.41	6.79e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs711245	0.573	rs7570763	chr2:36800589	A/C	cg15105969	chr2:36825350	FEZ2	-0.5	-7.81	-0.34	3.79e-14	Height;
LGG	cis	rs2213920	0.679	rs7862261	chr9:118187677	A/G	cg13918206	chr9:118159781	DEC1	0.63	8.89	0.38	1.42e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs896854	0.818	rs896855	chr8:95959808	A/G	cg16049864	chr8:95962084	TP53INP1	-0.41	-9.0	-0.39	5.8e-18	Type 2 diabetes;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg14159672	chr1:205819179	PM20D1	0.77	16.56	0.61	1.03e-48	Menarche (age at onset);
LGG	cis	rs8133932	0.736	rs4818804	chr21:47282631	T/C	cg11214348	chr21:47283868	PCBP3	0.45	8.13	0.35	3.98e-15	Schizophrenia;
LGG	cis	rs7523273	0.565	rs2025374	chr1:207887536	A/G	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.64	-0.37	9.48e-17	Schizophrenia;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.11	-0.35	4.58e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs4363385	0.588	rs1577960	chr1:153025687	G/A	cg13444842	chr1:152974279	SPRR3	-0.48	-9.85	-0.42	6.84e-21	Inflammatory skin disease;
LGG	cis	rs9807989	0.507	rs10203558	chr2:103027640	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.4e-19	Asthma;
LGG	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	trans	rs853679	0.607	rs66886492	chr6:28089731	C/T	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	trans	rs2270927	0.510	rs35966882	chr5:75577716	A/G	cg13563193	chr19:33072644	PDCD5	0.88	10.51	0.44	2.65e-23	Mean corpuscular volume;
LGG	cis	rs2797369	0.570	rs2813652	chr6:101584342	C/T	cg27451362	chr6:101846650	GRIK2	0.54	7.96	0.35	1.35e-14	Renal function-related traits (eGRFcrea);
LGG	cis	rs17125944	0.505	rs2295827	chr14:53174981	C/T	cg00686598	chr14:53173677	PSMC6	1.43	15.78	0.59	3.36e-45	Alzheimer's disease (late onset);
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.98e-11	Menopause (age at onset);
LGG	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg01411142	chr8:19674711	INTS10	0.47	7.26	0.32	1.65e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs10877945	0.967	rs1495032	chr12:63433836	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.37	7.19	0.32	2.62e-12	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs1577917	1.000	rs34622557	chr6:86630852	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.36	-0.4	3.45e-19	Response to antipsychotic treatment;
LGG	cis	rs950169	0.922	rs12912934	chr15:85114447	C/T	cg03959625	chr15:84868606	LOC388152	0.57	9.02	0.39	5.13e-18	Schizophrenia;
LGG	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.88	-0.34	2.28e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg09307838	chr4:120376055	NA	0.72	12.29	0.5	3.19e-30	Corneal astigmatism;
LGG	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs71636778	0.543	rs10493037	chr1:27248645	A/G	cg12203394	chr1:27248618	NUDC	0.5	6.65	0.3	8.25e-11	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LGG	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg09165964	chr15:75287851	SCAMP5	-0.81	-8.62	-0.37	1.06e-16	Lung cancer;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg23782820	chr8:58130467	NA	0.5	7.67	0.34	1.05e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6795744	1.000	rs6795744	chr3:13906850	G/A	cg19554555	chr3:13937349	NA	0.57	6.84	0.3	2.49e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs10895140	0.756	rs2513185	chr11:101494659	T/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg09173681	chr1:183549694	NCF2	0.37	8.36	0.36	7.52e-16	Systemic lupus erythematosus;
LGG	trans	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.43	-0.44	5.16e-23	Total cholesterol levels;
LGG	cis	rs4538187	0.502	rs11683408	chr2:64193684	C/T	cg19915305	chr2:64069682	UGP2	-0.63	-9.71	-0.41	2.06e-20	Systolic blood pressure;
LGG	cis	rs1639906	0.895	rs62443039	chr7:2209354	C/T	cg02951883	chr7:2050386	MAD1L1	0.45	7.75	0.34	5.99e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.86	0.34	2.75e-14	Lung cancer;
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs12893597	1.000	rs12893597	chr14:76812695	C/T	cg20290672	chr14:76816747	NA	-0.44	-6.65	-0.3	8.39e-11	Maximal oxygen uptake response;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg00071950	chr4:10020882	SLC2A9	0.43	8.89	0.38	1.32e-17	Bone mineral density;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-7.71	-0.34	7.73e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg25019033	chr10:957182	NA	-0.52	-9.55	-0.41	7.31e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.48	-0.33	3.88e-13	Tonsillectomy;
LGG	cis	rs7911264	0.703	rs7894183	chr10:94382040	G/A	cg25093409	chr10:94429542	NA	0.49	9.56	0.41	7.18e-20	Inflammatory bowel disease;
LGG	cis	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg25019033	chr10:957182	NA	-0.52	-9.55	-0.41	7.31e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs367615	0.552	rs2963010	chr5:108737043	T/C	cg17395555	chr5:108820864	NA	-0.75	-12.2	-0.49	7.06e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9341835	0.583	rs2753062	chr6:64131810	G/T	cg00787780	chr6:64151745	NA	0.44	7.97	0.35	1.25e-14	Schizophrenia;
LGG	cis	rs2573652	0.722	rs12898366	chr15:100543067	C/T	cg14911520	chr15:100542628	ADAMTS17	-0.31	-7.63	-0.33	1.33e-13	Height;
LGG	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg06627557	chr7:32535165	LSM5;AVL9	1.01	21.43	0.71	2.8e-71	Cognitive ability;
LGG	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg08885076	chr2:99613938	TSGA10	0.42	8.96	0.38	8.3e-18	Chronic sinus infection;
LGG	cis	rs7717393	1.000	rs72798937	chr5:155796766	T/C	cg04435420	chr5:155754009	SGCD	1.02	11.21	0.46	5.65e-26	Egg allergy;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.64	0.37	9.19e-17	Obesity-related traits;
LGG	cis	rs921968	0.541	rs588770	chr2:219494638	T/C	cg01130898	chr2:219473002	PLCD4	-0.45	-7.87	-0.34	2.51e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4481887	0.893	rs10888355	chr1:248457180	G/A	cg00666640	chr1:248458726	OR2T12	0.6	9.72	0.41	1.8899999999999998e-20	Common traits (Other);
LGG	cis	rs367943	0.688	rs255877	chr5:112753584	A/G	cg12552261	chr5:112820674	MCC	0.57	10.4	0.44	6.41e-23	Type 2 diabetes;
LGG	cis	rs10484885	0.690	rs292236	chr6:90528422	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.9	-13.67	-0.54	5.87e-36	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs9393777	0.623	rs3734544	chr6:26468660	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.74	-0.3	4.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9296092	0.538	rs56199698	chr6:33534505	G/C	cg13560919	chr6:33536144	NA	-1.04	-21.43	-0.71	2.78e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs738322	0.533	rs2284064	chr22:38547395	A/C	cg03162506	chr22:38580953	NA	0.39	9.64	0.41	3.7e-20	Cutaneous nevi;
LGG	cis	rs2976388	0.904	rs2920281	chr8:143760444	C/T	cg06565975	chr8:143823917	SLURP1	-0.42	-10.43	-0.44	5.24e-23	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07254608	chr8:41997973	NA	0.52	8.39	0.36	5.97e-16	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg12395012	chr8:11607386	GATA4	-0.38	-6.9	-0.31	1.75e-11	Neuroticism;
LGG	cis	rs7084402	0.935	rs10763558	chr10:60341934	A/C	cg07615347	chr10:60278583	BICC1	-0.59	-16.29	-0.6	1.79e-47	Refractive error;
LGG	cis	rs10819861	0.645	rs7045648	chr9:98855039	G/T	cg14508093	chr9:98862825	NA	0.3	7.19	0.32	2.68e-12	Electrocardiographic traits;
LGG	cis	rs9549367	0.789	rs34448227	chr13:113884754	A/C	cg00898013	chr13:113819073	PROZ	-0.44	-8.59	-0.37	1.37e-16	Platelet distribution width;
LGG	cis	rs9400467	0.537	rs3218591	chr6:111696129	T/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21582582	chr3:182698605	DCUN1D1	0.51	9.34	0.4	4.01e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg12310025	chr6:25882481	NA	-0.39	-7.14	-0.32	3.58e-12	Height;
LGG	cis	rs4727027	0.866	rs7778766	chr7:148806729	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.86	0.3	2.16e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9354308	0.933	rs55672811	chr6:66571730	G/A	cg07460842	chr6:66804631	NA	0.57	9.5	0.4	1.17e-19	Metabolite levels;
LGG	cis	rs9517320	0.534	rs9554477	chr13:99160379	C/T	cg03701759	chr13:99174930	STK24	-0.35	-6.7	-0.3	6.23e-11	Longevity;
LGG	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.51	8.79	0.38	2.85e-17	Menarche (age at onset);
LGG	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6582630	0.574	rs12146797	chr12:38436499	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.25	0.32	1.74e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7940866	0.834	rs10791105	chr11:130839161	A/G	cg12179176	chr11:130786555	SNX19	0.72	13.42	0.53	6.51e-35	Schizophrenia;
LGG	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs7191700	0.712	rs7187741	chr16:11433103	C/G	cg00044050	chr16:11439710	C16orf75	-0.63	-11.18	-0.46	7.36e-26	Multiple sclerosis;
LGG	cis	rs3796352	0.881	rs11710394	chr3:53015839	A/G	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7017914	0.967	rs12680988	chr8:71695890	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.69e-11	Menopause (age at onset);
LGG	cis	rs1018836	0.818	rs2285232	chr8:91546162	C/G	cg16814680	chr8:91681699	NA	-0.72	-12.94	-0.52	6.78e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg22842854	chr12:123319900	HIP1R	-0.53	-6.67	-0.3	7.35e-11	Schizophrenia;
LGG	cis	rs9649465	1.000	rs7803287	chr7:123354807	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-9.04	-0.39	4.45e-18	Migraine;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.38	-0.32	7.32e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.79	0.54	1.72e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs950169	1.000	rs35297609	chr15:84772896	A/G	cg03959625	chr15:84868606	LOC388152	0.55	8.76	0.38	3.59e-17	Schizophrenia;
LGG	cis	rs11628318	0.515	rs8009257	chr14:103155594	A/G	cg12046867	chr14:103022105	NA	0.46	8.37	0.36	6.87e-16	Platelet count;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.95	-0.31	1.22e-11	Neuroticism;
LGG	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-10.02	-0.42	1.63e-21	Chronic sinus infection;
LGG	cis	rs787274	1.000	rs4979165	chr9:115609539	T/C	cg13803584	chr9:115635662	SNX30	-0.61	-7.55	-0.33	2.38e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7216064	1.000	rs6504542	chr17:65836642	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.91	-0.38	1.22e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26122402	chr14:23938846	NGDN	0.52	7.92	0.35	1.74e-14	Gut microbiome composition (summer);
LGG	cis	rs7193541	0.550	rs28607667	chr16:74476015	C/T	cg01733217	chr16:74700730	RFWD3	-0.83	-18.1	-0.64	8.98e-56	Multiple myeloma;
LGG	cis	rs2916247	0.954	rs1552314	chr8:93104805	C/T	cg10183463	chr8:93005414	RUNX1T1	0.36	7.71	0.34	7.99e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6704644	0.584	rs72980318	chr2:234296221	C/T	cg27060346	chr2:234359958	DGKD	-0.58	-6.86	-0.3	2.18e-11	Bilirubin levels;
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11716531	0.537	rs7626646	chr3:27268316	G/T	cg02860705	chr3:27208620	NA	0.81	14.93	0.57	2.08e-41	Diastolic blood pressure;
LGG	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.29	0.36	1.23e-15	Retinal vascular caliber;
LGG	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg08250081	chr4:10125330	NA	-0.39	-7.74	-0.34	6.49e-14	Bone mineral density;
LGG	cis	rs9768139	0.903	rs10262701	chr7:158114591	G/A	cg06219351	chr7:158114137	PTPRN2	0.75	15.15	0.58	2.15e-42	Calcium levels;
LGG	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg11845111	chr2:191398756	TMEM194B	0.36	7.96	0.35	1.39e-14	Pulse pressure;
LGG	trans	rs61931739	0.534	rs10844729	chr12:34022919	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.68	0.44	6.14e-24	Morning vs. evening chronotype;
LGG	cis	rs2415984	0.579	rs8010773	chr14:46956863	T/C	cg14871534	chr14:47121158	RPL10L	-0.57	-10.03	-0.42	1.47e-21	Number of children ever born;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.54e-21	Lung cancer;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg12458913	chr13:53173898	NA	0.56	9.97	0.42	2.48e-21	Lewy body disease;
LGG	cis	rs11644362	1.000	rs3843707	chr16:12996788	G/A	cg06890432	chr16:12997467	SHISA9	-0.33	-7.14	-0.31	3.73e-12	Positive affect;Subjective well-being;
LGG	cis	rs2274273	0.870	rs10139000	chr14:55849876	G/T	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	5.09e-51	Protein biomarker;
LGG	cis	rs992157	0.560	rs4674274	chr2:219089131	A/T	cg00012203	chr2:219082015	ARPC2	-0.75	-14.37	-0.56	5.66e-39	Colorectal cancer;
LGG	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg02023728	chr11:77925099	USP35	0.47	8.29	0.36	1.27e-15	Testicular germ cell tumor;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg11295777	chr19:6110313	RFX2	-0.38	-6.81	-0.3	3.04e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg21475434	chr5:93447410	FAM172A	0.73	7.32	0.32	1.09e-12	Diabetic retinopathy;
LGG	cis	rs34172651	0.917	rs17771137	chr16:24792242	G/A	cg02428538	chr16:24856791	SLC5A11	-0.47	-7.97	-0.35	1.26e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7586879	0.828	rs1865688	chr2:25108245	C/G	cg04586622	chr2:25135609	ADCY3	0.35	8.58	0.37	1.48e-16	Body mass index;
LGG	cis	rs1728785	1.000	rs821167	chr16:68577222	T/G	cg02972257	chr16:68554789	NA	-0.56	-8.39	-0.36	6.04e-16	Ulcerative colitis;
LGG	cis	rs1816752	0.792	rs7330956	chr13:24987312	A/G	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	cis	rs3617	0.573	rs3821873	chr3:52913006	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-7.74	-0.34	6.25e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs367943	0.665	rs4705560	chr5:112977073	T/G	cg12552261	chr5:112820674	MCC	0.53	9.35	0.4	3.64e-19	Type 2 diabetes;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14159672	chr1:205819179	PM20D1	0.9	21.57	0.71	6.21e-72	Menarche (age at onset);
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.42	0.44	5.36e-23	Obesity-related traits;
LGG	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.79	-0.34	4.48e-14	Obesity;
LGG	cis	rs9811920	0.683	rs1718235	chr3:99583484	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.44	-7.79	-0.34	4.47e-14	Axial length;
LGG	trans	rs2727020	0.638	rs1164668	chr11:49330627	A/C	cg15704280	chr7:45808275	SEPT13	0.94	19.19	0.67	7.73e-61	Coronary artery disease;
LGG	cis	rs12893668	0.703	rs7148456	chr14:104028270	C/T	cg23335576	chr14:104009727	NA	-0.51	-9.0	-0.39	6.02e-18	Reticulocyte count;
LGG	cis	rs7524258	0.835	rs7521425	chr1:7306543	C/T	cg07173049	chr1:7289937	CAMTA1	0.72	16.36	0.61	8.41e-48	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg16606324	chr3:10149918	C3orf24	0.53	7.04	0.31	7.13e-12	Alzheimer's disease;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg26513180	chr16:89883248	FANCA	0.81	8.38	0.36	6.21e-16	Skin colour saturation;
LGG	cis	rs10937275	0.826	rs62294593	chr3:186642111	T/G	cg16751732	chr3:186648392	ST6GAL1	0.7	7.04	0.31	6.95e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9894429	0.634	rs9709130	chr17:79583948	C/T	cg18240062	chr17:79603768	NPLOC4	0.61	10.23	0.43	2.79e-22	Eye color traits;
LGG	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.33	-0.36	9.02e-16	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	2.06e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10979	0.964	rs12526234	chr6:143898680	A/T	cg25407410	chr6:143891975	LOC285740	-0.71	-12.09	-0.49	1.89e-29	Hypospadias;
LGG	cis	rs4650994	0.623	rs35854525	chr1:178618604	C/T	cg12486710	chr1:178512616	C1orf220	-0.36	-7.09	-0.31	5.11e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7959452	0.535	rs11177577	chr12:69671791	C/T	cg20891283	chr12:69753455	YEATS4	0.72	13.67	0.54	5.55e-36	Blood protein levels;
LGG	cis	rs6752107	0.936	rs10192702	chr2:234206750	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	12.01	0.49	4.04e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00490583	chr16:1843685	IGFALS	-0.42	-7.07	-0.31	5.65e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7769051	0.522	rs62424539	chr6:133173272	C/T	cg07930552	chr6:133119739	C6orf192	0.68	7.45	0.33	4.6e-13	Type 2 diabetes nephropathy;
LGG	cis	rs17270561	0.609	rs2000351	chr6:25759783	T/C	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs7226408	0.600	rs2629958	chr18:34603781	A/G	cg15022739	chr18:34823045	BRUNOL4	0.43	9.31	0.4	5.15e-19	Obesity-related traits;
LGG	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg21095983	chr6:86352623	SYNCRIP	0.6	11.21	0.46	5.98e-26	Smooth-surface caries;
LGG	cis	rs9788721	0.967	rs72740955	chr15:78849779	C/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.49	-0.33	3.4e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs10791323	0.569	rs546381	chr11:133760651	T/G	cg06766960	chr11:133703094	NA	-0.5	-10.02	-0.42	1.62e-21	Childhood ear infection;
LGG	cis	rs1375194	0.606	rs10188817	chr2:33815471	A/G	cg04131969	chr2:33951647	MYADML	-0.58	-10.27	-0.43	2.02e-22	Response to antidepressants in depression;
LGG	cis	rs138249	0.898	rs138227	chr22:50556815	A/G	cg18875453	chr22:50517795	MLC1	0.26	6.67	0.3	7.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg24375607	chr4:120327624	NA	0.63	10.61	0.44	1.11e-23	Corneal astigmatism;
LGG	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.07	0.35	5.99e-15	Iron status biomarkers;
LGG	cis	rs2201728	0.690	rs7655945	chr4:100152429	A/G	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg21862992	chr11:68658383	NA	0.47	7.66	0.34	1.13e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.78	-0.34	4.85e-14	HDL cholesterol;
LGG	cis	rs887829	0.507	rs10929301	chr2:234663649	C/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.82	-0.34	3.62e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11112613	0.609	rs6539218	chr12:105934875	C/T	cg03607813	chr12:105948248	NA	0.61	10.03	0.42	1.53e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs116095464	1.000	rs6879758	chr5:350277	G/C	cg00938859	chr5:1591904	SDHAP3	0.72	6.96	0.31	1.16e-11	Breast cancer;
LGG	cis	rs735539	0.521	rs9552281	chr13:21365407	A/G	cg04906043	chr13:21280425	IL17D	-0.5	-7.84	-0.34	3.13e-14	Dental caries;
LGG	cis	rs9649465	1.000	rs11770041	chr7:123365788	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.9	-0.38	1.26e-17	Migraine;
LGG	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg24675658	chr1:53192096	ZYG11B	-0.61	-13.48	-0.53	3.54e-35	Monocyte count;
LGG	cis	rs526231	0.511	rs55741939	chr5:102372688	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.83e-12	Bipolar disorder;
LGG	cis	rs9790314	0.846	rs12495310	chr3:160970956	T/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg02002194	chr4:3960332	NA	0.5	9.61	0.41	4.85e-20	Systolic blood pressure;
LGG	trans	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.47	1.91e-27	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9790314	0.613	rs13092102	chr3:160598093	C/G	cg03342759	chr3:160939853	NMD3	0.46	7.61	0.33	1.5700000000000001e-13	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.5	-0.4	1.15e-19	Diabetic retinopathy;
LGG	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03517284	chr6:25882590	NA	-0.51	-9.62	-0.41	4.2e-20	Blood metabolite levels;
LGG	cis	rs1682825	1.000	rs73812286	chr3:10769921	C/G	cg23512531	chr3:10780469	NA	0.6	7.95	0.35	1.39e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs881375	0.967	rs7034492	chr9:123687211	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.99	0.49	5.14e-29	Rheumatoid arthritis;
LGG	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs10463554	0.927	rs34810	chr5:102430749	A/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04553410	chr7:150864885	GBX1	0.44	7.47	0.33	4.02e-13	Cognitive performance;
LGG	cis	rs698833	0.926	rs1067353	chr2:44666626	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.45	6.95	0.31	1.21e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg11062466	chr8:58055876	NA	0.61	10.15	0.43	5.49e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7089973	0.604	rs2420065	chr10:116583753	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00689492	chr4:1303491	MAEA	0.48	8.35	0.36	7.68e-16	Obesity-related traits;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg10360139	chr7:1886902	MAD1L1	-0.46	-8.15	-0.35	3.33e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7615952	0.641	rs7640158	chr3:125808011	G/A	cg18479299	chr3:125709523	NA	-0.57	-7.15	-0.32	3.48e-12	Blood pressure (smoking interaction);
LGG	cis	rs3796352	1.000	rs34121720	chr3:53072167	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	7.16	0.32	3.09e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10949834	0.877	rs34325097	chr7:73492990	G/A	cg07137043	chr7:73588983	EIF4H	-0.64	-7.28	-0.32	1.46e-12	Verbal memory performance (residualized delayed recall change);
LGG	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.35e-16	Retinal vascular caliber;
LGG	cis	rs7143963	0.666	rs7161606	chr14:103307110	A/C	cg23020514	chr14:103360112	TRAF3	0.43	8.69	0.37	6.31e-17	Body mass index;
LGG	cis	rs10262624	0.935	rs10487596	chr7:23917077	A/G	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs4589502	0.502	rs2169460	chr15:67197240	A/G	cg09911534	chr15:67153556	NA	0.46	7.06	0.31	6.03e-12	Lung cancer (smoking interaction);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00495681	chr13:53174319	NA	0.58	10.4	0.44	6.39e-23	Lewy body disease;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs4795384	chr17:37716771	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-15.23	-0.58	9.67e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7727544	0.507	rs11741341	chr5:131570218	A/G	cg07395648	chr5:131743802	NA	-0.36	-7.21	-0.32	2.31e-12	Blood metabolite levels;
LGG	cis	rs2535633	0.631	rs2581819	chr3:53016552	C/A	cg11645453	chr3:52864694	ITIH4	-0.49	-8.13	-0.35	3.91e-15	Body mass index;
LGG	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg26818010	chr10:134567672	INPP5A	-0.72	-10.93	-0.45	6.5e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.11e-12	Bipolar disorder;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.89	0.3	1.89e-11	Prudent dietary pattern;
LGG	cis	rs2361718	0.501	rs8065486	chr17:78138196	A/G	cg21238619	chr17:78079768	GAA	0.42	7.9	0.34	2.01e-14	Yeast infection;
LGG	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.19	-0.43	4.05e-22	Diabetic kidney disease;
LGG	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.7	-0.3	6.02e-11	Menarche (age at onset);
LGG	cis	rs3087591	0.959	rs8076441	chr17:29405878	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.63	-10.63	-0.44	9.37e-24	Hip circumference;
LGG	cis	rs7086627	0.515	rs12245180	chr10:82211897	C/G	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg06219351	chr7:158114137	PTPRN2	-0.82	-14.12	-0.55	6.71e-38	Response to amphetamines;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg24829409	chr8:58192753	C8orf71	-0.89	-13.51	-0.53	2.58e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4742903	0.904	rs10121829	chr9:106993996	A/G	cg14250997	chr9:106856677	SMC2	0.37	7.78	0.34	4.62e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs490234	0.841	rs512445	chr9:128329179	T/C	cg14078157	chr9:128172775	NA	0.42	7.81	0.34	3.8e-14	Mean arterial pressure;
LGG	cis	rs2120243	0.591	rs9871290	chr3:157099591	A/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.7	-0.54	4.01e-36	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2694528	0.858	rs4235484	chr5:60216633	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.58	-0.33	1.96e-13	Parkinson's disease;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs1941687	0.509	rs2282632	chr18:31320229	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.24	-0.36	1.83e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21219203	chr4:103748293	UBE2D3	0.44	6.68	0.3	6.82e-11	Gut microbiome composition (summer);
LGG	cis	rs12410462	0.636	rs114870233	chr1:227764842	G/A	cg23173402	chr1:227635558	NA	0.39	7.26	0.32	1.69e-12	Major depressive disorder;
LGG	cis	rs765787	0.530	rs2668737	chr15:45522799	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.22e-32	Uric acid levels;
LGG	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.17	0.58	1.72e-42	Cognitive test performance;
LGG	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.69	-0.41	2.43e-20	Neuroticism;
LGG	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg16141378	chr3:129829833	LOC729375	-0.37	-8.34	-0.36	8.48e-16	Neuroticism;
LGG	cis	rs6964587	0.626	rs12704631	chr7:91523525	T/C	cg17063962	chr7:91808500	NA	-0.44	-7.98	-0.35	1.14e-14	Breast cancer;
LGG	cis	rs9309473	0.950	rs6705977	chr2:73849170	C/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.21	-0.32	2.3e-12	Metabolite levels;
LGG	cis	rs4927850	1.000	rs6799572	chr3:195740408	C/T	cg12923728	chr3:195709715	SDHAP1	-0.8	-14.68	-0.56	2.36e-40	Pancreatic cancer;
LGG	cis	rs2153535	0.580	rs1932276	chr6:8442593	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	trans	rs12517041	0.938	rs35504874	chr5:23271073	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.62	-9.11	-0.39	2.56e-18	Calcium levels;
LGG	cis	rs5758659	0.714	rs6002607	chr22:42496506	C/T	cg15557168	chr22:42548783	NA	0.36	8.11	0.35	4.69e-15	Cognitive function;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.11	0.35	4.67e-15	Prudent dietary pattern;
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg05896524	chr21:47604654	C21orf56	0.54	9.32	0.4	4.92e-19	Testicular germ cell tumor;
LGG	cis	rs798766	1.000	rs798756	chr4:1707447	T/C	cg00006948	chr4:1768889	NA	-0.49	-6.7	-0.3	5.9e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs80064395	0.850	rs12152276	chr3:196368501	A/G	cg20534585	chr3:196373598	LRRC33	0.63	7.05	0.31	6.7e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg15979348	chr13:112237479	NA	0.47	8.0	0.35	9.83e-15	Menarche (age at onset);
LGG	cis	rs16976116	0.901	rs8031949	chr15:55492724	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.22	0.32	2.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs74781061	0.790	rs6495105	chr15:74772853	C/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs7267979	0.966	rs6107031	chr20:25350677	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg12438819	chr7:158236134	PTPRN2	0.34	8.62	0.37	1.1e-16	Obesity-related traits;
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.91	0.31	1.58e-11	Cystic fibrosis severity;
LGG	cis	rs2952156	0.959	rs1565922	chr17:37831035	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-13.96	-0.54	3.15e-37	Asthma;
LGG	cis	rs4253772	0.591	rs6007727	chr22:46650959	G/A	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4493873	0.702	rs7016960	chr8:92051053	A/G	cg16814680	chr8:91681699	NA	0.49	7.97	0.35	1.24e-14	Migraine - clinic-based;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg19223190	chr17:80058835	NA	0.44	8.55	0.37	1.77e-16	Life satisfaction;
LGG	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg16414030	chr3:133502952	NA	-0.59	-10.2	-0.43	3.48e-22	Iron status biomarkers;
LGG	cis	rs11734570	0.581	rs4461531	chr4:38603576	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.61	8.63	0.37	1.02e-16	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs920590	0.918	rs11777075	chr8:19655666	G/A	cg03894339	chr8:19674705	INTS10	0.55	9.08	0.39	3.16e-18	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg18335740	chr13:41363409	SLC25A15	0.51	9.07	0.39	3.38e-18	Lewy body disease;
LGG	cis	rs988958	0.567	rs6719975	chr2:42271646	G/A	cg19376973	chr2:42229025	NA	0.58	9.28	0.4	6.58e-19	Hypospadias;
LGG	cis	rs9309711	0.772	rs9752251	chr2:3489869	C/T	cg10845886	chr2:3471009	TTC15	-0.68	-13.1	-0.52	1.47e-33	Neurofibrillary tangles;
LGG	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.13	0.31	3.8e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3785574	0.962	rs62077483	chr17:61806380	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.52	0.79	1.67e-99	Height;
LGG	cis	rs651907	0.640	rs1091664	chr3:101618690	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.43	6.84	0.3	2.57e-11	Colorectal cancer;
LGG	cis	rs7247513	0.701	rs8107642	chr19:12766370	C/T	cg01871581	chr19:12707946	ZNF490	-0.36	-7.15	-0.32	3.45e-12	Bipolar disorder;
LGG	cis	rs6665290	0.935	rs12403236	chr1:227196502	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-46.08	-0.91	4.61e-175	Myeloid white cell count;
LGG	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg06115741	chr20:33292138	TP53INP2	-0.59	-9.77	-0.41	1.3e-20	Coronary artery disease;
LGG	cis	rs7072216	0.763	rs6584204	chr10:100173580	C/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.31e-12	Metabolite levels;
LGG	cis	rs13202913	0.837	rs6906667	chr6:151772569	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	7.04	0.31	7.03e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.12e-14	IgG glycosylation;
LGG	cis	rs9815354	0.680	rs73073292	chr3:42028023	C/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg17809284	chr5:56205270	C5orf35	-0.49	-8.08	-0.35	5.65e-15	Initial pursuit acceleration;
LGG	cis	rs7551222	0.752	rs10900594	chr1:204470129	C/G	cg20240347	chr1:204465584	NA	-0.54	-10.68	-0.44	6.18e-24	Schizophrenia;
LGG	cis	rs2439831	0.850	rs10438303	chr15:44016417	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.59	0.44	1.32e-23	Lung cancer in ever smokers;
LGG	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.65	-0.51	1.01e-31	Total body bone mineral density;
LGG	cis	rs4665809	0.590	rs6730317	chr2:26419482	C/T	cg22920501	chr2:26401640	FAM59B	-0.46	-9.51	-0.4	1.08e-19	Gut microbiome composition (summer);
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.74	-0.34	6.33e-14	Systolic blood pressure;
LGG	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg21518248	chr2:162101506	NA	0.24	7.4	0.33	6.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg18225595	chr11:63971243	STIP1	0.5	6.88	0.3	2.01e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg02975922	chr3:195473998	MUC4	-0.54	-8.98	-0.39	6.82e-18	Pancreatic cancer;
LGG	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11644478	chr21:40555479	PSMG1	0.88	16.26	0.6	2.44e-47	Cognitive function;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg17734273	chr15:78292508	TBC1D2B	-0.31	-7.09	-0.31	5.12e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs2153535	0.580	rs6912374	chr6:8456423	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.82e-22	Motion sickness;
LGG	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.03	-0.35	8.1e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13191362	0.938	rs59067610	chr6:163030440	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.43	7.04	0.31	6.86e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg06521331	chr12:34319734	NA	0.41	6.99	0.31	9.72e-12	Morning vs. evening chronotype;
LGG	cis	rs1595825	0.945	rs61184128	chr2:198843659	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.89	-0.3	1.89e-11	Ulcerative colitis;
LGG	cis	rs79149102	0.579	rs74023936	chr15:75362084	C/T	cg17294928	chr15:75287854	SCAMP5	-0.71	-7.96	-0.35	1.33e-14	Lung cancer;
LGG	cis	rs5758659	0.652	rs133324	chr22:42406371	C/A	cg15128208	chr22:42549153	NA	-0.37	-7.31	-0.32	1.17e-12	Cognitive function;
LGG	cis	rs10262624	0.967	rs13235406	chr7:23918831	T/C	cg09690326	chr7:23720549	C7orf46	-0.32	-6.68	-0.3	6.8e-11	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.35	0.43	9.83e-23	Iron status biomarkers;
LGG	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg02711726	chr17:80685570	FN3KRP	0.65	13.44	0.53	5.11e-35	Glycated hemoglobin levels;
LGG	cis	rs7010267	0.773	rs10101385	chr8:119923850	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.81	-0.41	8.96e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs738322	0.839	rs9607517	chr22:38596100	G/A	cg25457927	chr22:38595422	NA	0.46	11.59	0.47	1.83e-27	Cutaneous nevi;
LGG	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.7	-0.3	6.02e-11	Arsenic metabolism;
LGG	cis	rs9463078	0.683	rs1342640	chr6:44743516	T/C	cg25276700	chr6:44698697	NA	0.44	9.03	0.39	4.53e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg06521331	chr12:34319734	NA	0.46	7.91	0.35	1.88e-14	Heart rate;
LGG	cis	rs9300255	0.602	rs2695479	chr12:123689386	T/C	cg05973401	chr12:123451056	ABCB9	0.48	7.0	0.31	8.89e-12	Neutrophil percentage of white cells;
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg13009111	chr11:71350975	NA	-0.31	-6.67	-0.3	7.47e-11	Triglycerides;
LGG	cis	rs1506636	1.000	rs2429619	chr7:123425599	C/G	cg03229431	chr7:123269106	ASB15	0.73	17.81	0.64	1.93e-54	Plateletcrit;Platelet count;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.87	-0.34	2.61e-14	Bladder cancer;
LGG	cis	rs7959452	0.640	rs1598543	chr12:69688757	G/T	cg14784868	chr12:69753453	YEATS4	0.73	13.81	0.54	1.36e-36	Blood protein levels;
LGG	cis	rs10207628	1.000	rs76168490	chr2:127850618	C/G	cg06223080	chr2:127868745	NA	-0.76	-14.71	-0.56	1.81e-40	Psychosis and Alzheimer's disease;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.83	-0.3	2.75e-11	Obesity-related traits;
LGG	cis	rs951366	0.617	rs708727	chr1:205767885	G/A	cg17178900	chr1:205818956	PM20D1	0.68	16.36	0.61	8.52e-48	Menarche (age at onset);
LGG	cis	rs6754311	0.731	rs2164210	chr2:136580287	T/C	cg07169764	chr2:136633963	MCM6	-0.75	-12.8	-0.51	2.44e-32	Mosquito bite size;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg13206674	chr6:150067644	NUP43	0.66	14.76	0.57	1.16e-40	Lung cancer;
LGG	cis	rs498079	0.544	rs509685	chr6:133517005	A/G	cg14343214	chr6:133562056	EYA4	0.31	7.49	0.33	3.47e-13	Total body bone mineral density;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.34	0.4	4.21e-19	Electroencephalogram traits;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.28	-0.32	1.49e-12	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg01420254	chr6:26195488	NA	0.88	11.57	0.47	2.33e-27	Gout;Renal underexcretion gout;
LGG	cis	rs7000551	0.689	rs6984908	chr8:22316901	A/G	cg12081754	chr8:22256438	SLC39A14	-0.68	-13.25	-0.52	3.5e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9811920	0.638	rs1688782	chr3:99630527	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-8.8	-0.38	2.72e-17	Axial length;
LGG	cis	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg04455712	chr21:45112962	RRP1B	0.52	9.16	0.39	1.7e-18	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.38	0.4	2.97e-19	Bipolar disorder;
LGG	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs698833	0.605	rs6728449	chr2:44702785	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	6.7	0.3	5.88e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs300703	0.935	rs10193882	chr2:246301	A/T	cg24565620	chr2:194026	NA	0.66	8.52	0.37	2.27e-16	Blood protein levels;
LGG	cis	rs921968	0.643	rs62191565	chr2:219482017	C/T	cg01130898	chr2:219473002	PLCD4	-0.39	-6.8	-0.3	3.21e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4356932	0.967	rs6835736	chr4:76962494	A/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg15147215	chr3:52552868	STAB1	-0.35	-6.71	-0.3	5.57e-11	Electroencephalogram traits;
LGG	cis	rs2708240	0.967	rs2708239	chr7:147575961	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs368123	1.000	rs368123	chr6:160719593	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19504496	chr19:36119917	RBM42	0.51	7.74	0.34	6.12e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg04166393	chr7:2884313	GNA12	0.45	8.46	0.37	3.45e-16	Height;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.89e-12	Bipolar disorder;
LGG	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg04317338	chr11:64019027	PLCB3	0.66	8.2	0.36	2.4e-15	Mean platelet volume;
LGG	cis	rs1620921	0.594	rs2489930	chr6:161271311	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.85	0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11229555	0.574	rs11229454	chr11:58203682	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35306767	0.903	rs12778891	chr10:950130	T/A	cg08847335	chr10:891726	LARP4B	-0.49	-8.65	-0.37	8.44e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs11169552	0.543	rs10876051	chr12:50932336	A/G	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.63e-14	Colorectal cancer;
LGG	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-7.86	-0.34	2.77e-14	Menopause (age at onset);
LGG	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg25706281	chr1:46860511	FAAH	-0.28	-6.71	-0.3	5.55e-11	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23797439	chr20:8113355	PLCB1	0.45	6.93	0.31	1.46e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	9.49	0.4	1.21e-19	Height;
LGG	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.14e-28	Dupuytren's disease;
LGG	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.13	-0.43	6.65e-22	Obesity-related traits;
LGG	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg14703610	chr5:56206110	C5orf35	0.43	7.51	0.33	2.98e-13	Breast cancer;Breast cancer (early onset);
LGG	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg14893161	chr1:205819251	PM20D1	-0.44	-7.57	-0.33	1.97e-13	Menarche (age at onset);
LGG	cis	rs2562152	0.744	rs216597	chr16:106777	G/C	cg02949481	chr16:131562	MPG	0.56	8.44	0.37	4.04e-16	Glioblastoma;
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.95e-12	Electroencephalogram traits;
LGG	cis	rs9905704	0.647	rs2036730	chr17:57038282	A/G	cg12560992	chr17:57184187	TRIM37	0.53	8.57	0.37	1.51e-16	Testicular germ cell tumor;
LGG	cis	rs11690935	0.550	rs6718013	chr2:172869185	A/G	cg13550731	chr2:172543902	DYNC1I2	0.63	12.0	0.49	4.59e-29	Schizophrenia;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02767633	chr5:2253242	NA	0.33	6.72	0.3	5.39e-11	Menarche (age at onset);
LGG	cis	rs887829	0.588	rs4663971	chr2:234674252	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.51	-9.13	-0.39	2.09e-18	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4622507	0.618	rs34676379	chr16:55070317	G/A	cg09947736	chr16:55091198	NA	0.76	11.12	0.46	1.29e-25	Social communication problems;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.17	-0.39	1.54e-18	Obesity-related traits;
LGG	cis	rs5758659	0.569	rs133293	chr22:42382797	G/A	cg15128208	chr22:42549153	NA	-0.37	-7.39	-0.32	6.9e-13	Cognitive function;
LGG	cis	rs561341	1.000	rs508192	chr17:30315147	C/T	cg13647721	chr17:30228624	UTP6	-0.66	-8.02	-0.35	8.91e-15	Hip circumference adjusted for BMI;
LGG	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.11	-0.49	1.67e-29	Corneal structure;
LGG	cis	rs8067545	0.532	rs12449914	chr17:20003969	T/C	cg13482628	chr17:19912719	NA	0.52	8.67	0.37	7.34e-17	Schizophrenia;
LGG	cis	rs68170813	0.559	rs79978998	chr7:106845482	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.99	-0.45	3.96e-25	Coronary artery disease;
LGG	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg21132104	chr15:45694354	SPATA5L1	0.64	9.19	0.39	1.3e-18	Homoarginine levels;
LGG	cis	rs1005224	0.853	rs9323616	chr14:76151697	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.74	-0.3	4.8e-11	Large artery stroke;
LGG	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.46	-0.4	1.62e-19	Mood instability;
LGG	cis	rs8141529	0.748	rs5752826	chr22:29269808	A/G	cg15103426	chr22:29168792	CCDC117	0.62	9.63	0.41	3.92e-20	Lymphocyte counts;
LGG	cis	rs921968	0.541	rs561570	chr2:219379348	T/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs10506458	0.834	rs73127067	chr12:63390333	G/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.36	-0.53	1.2e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg18876405	chr7:65276391	NA	-0.64	-11.46	-0.47	6.14e-27	Aortic root size;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg00319157	chr22:47052970	GRAMD4	0.37	7.13	0.31	3.89e-12	Menarche (age at onset);
LGG	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg02574844	chr11:5959923	NA	-0.54	-8.72	-0.38	5.2e-17	DNA methylation (variation);
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg24690094	chr11:67383802	NA	0.59	10.94	0.45	6.44e-25	Mean corpuscular volume;
LGG	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg12310025	chr6:25882481	NA	-0.7	-13.27	-0.52	2.76e-34	Intelligence (multi-trait analysis);
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg19357499	chr8:144660631	NAPRT1	0.87	6.72	0.3	5.39e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs12474201	0.822	rs897530	chr2:46948150	C/G	cg06386533	chr2:46925753	SOCS5	0.79	14.62	0.56	4.75e-40	Height;
LGG	trans	rs7395662	0.736	rs4882036	chr11:48749384	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.72	-0.34	7.35e-14	HDL cholesterol;
LGG	cis	rs79349575	0.783	rs62075838	chr17:46996432	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.93	0.31	1.38e-11	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14035771	chr1:98515272	NA	0.4	6.8	0.3	3.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11648796	0.718	rs62032512	chr16:764826	C/T	cg27144592	chr16:783916	NARFL	0.82	14.25	0.55	1.92e-38	Height;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg11494091	chr17:61959527	GH2	-1.0	-24.58	-0.75	5.69e-86	Prudent dietary pattern;
LGG	cis	rs6956675	0.874	rs6968344	chr7:62574533	A/G	cg08930214	chr7:62859557	LOC100287834	0.45	7.28	0.32	1.48e-12	Obesity-related traits;
LGG	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.52	-0.4	9.61e-20	Schizophrenia;
LGG	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg01864069	chr14:103024347	NA	-0.68	-9.87	-0.42	5.39e-21	Platelet count;
LGG	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.82	-0.42	8.3e-21	Response to antipsychotic treatment;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	18.77	0.66	7.08e-59	Platelet count;
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.69	-0.37	6.11e-17	Life satisfaction;
LGG	trans	rs34421088	0.506	rs4841518	chr8:11145963	G/C	cg02002194	chr4:3960332	NA	-0.38	-6.78	-0.3	3.57e-11	Neuroticism;
LGG	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg11839771	chr15:80205821	ST20	-0.35	-7.39	-0.32	6.89e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg03653399	chr8:142233436	SLC45A4	0.44	8.59	0.37	1.35e-16	Immature fraction of reticulocytes;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg11493924	chr5:55008521	SLC38A9	0.44	6.69	0.3	6.29e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs765787	0.530	rs10851423	chr15:45515950	G/A	cg24006582	chr15:45444508	DUOX1	0.66	12.05	0.49	2.95e-29	Uric acid levels;
LGG	cis	rs6489882	0.966	rs4238033	chr12:113378081	T/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7998202	0.567	rs914019	chr13:113352911	A/G	cg02820901	chr13:113351484	ATP11A	0.57	7.06	0.31	6.04e-12	Glycated hemoglobin levels;
LGG	cis	rs8180040	0.966	rs1872164	chr3:47415100	G/A	cg16586182	chr3:47516702	SCAP	0.79	15.96	0.6	5.19e-46	Colorectal cancer;
LGG	trans	rs826838	0.967	rs826879	chr12:39088999	A/C	cg06521331	chr12:34319734	NA	0.42	7.49	0.33	3.56e-13	Heart rate;
LGG	cis	rs9487094	0.961	rs1040284	chr6:109673933	T/C	cg16315928	chr6:109776240	MICAL1	0.54	9.18	0.39	1.4e-18	Height;
LGG	cis	rs73227498	0.590	rs7713216	chr5:111495381	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.49	-6.78	-0.3	3.71e-11	Thyroid cancer;
LGG	cis	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.92	-0.31	1.5e-11	Morning vs. evening chronotype;
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg13384949	chr1:2383501	NA	-0.51	-13.63	-0.54	8.37e-36	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.816	rs8115257	chr20:25207931	A/G	cg08601574	chr20:25228251	PYGB	0.4	7.95	0.35	1.45e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05666372	chr16:28857989	TUFM	0.49	7.5	0.33	3.4e-13	Gut microbiome composition (summer);
LGG	cis	rs10911363	0.592	rs10797886	chr1:183479090	T/C	cg09173681	chr1:183549694	NCF2	0.37	8.35	0.36	8.25e-16	Systemic lupus erythematosus;
LGG	cis	rs7617480	0.616	rs9873227	chr3:48773108	G/C	cg07636037	chr3:49044803	WDR6	0.9	16.17	0.6	5.95e-47	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00761968	chr13:53314142	LECT1	-0.39	-8.13	-0.35	3.84e-15	Lewy body disease;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.24	-0.32	1.91e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1355223	0.583	rs1549789	chr11:34867947	G/A	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-7.2	-0.32	2.42e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg03929089	chr4:120376271	NA	0.69	9.87	0.42	5.76e-21	Intraocular pressure;
LGG	cis	rs1867631	0.958	rs7520226	chr1:67080995	T/G	cg13052034	chr1:66999238	SGIP1	0.47	9.06	0.39	3.59e-18	Menopause (age at onset);
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg23978390	chr7:1156363	C7orf50	0.43	7.15	0.32	3.51e-12	Longevity;Endometriosis;
LGG	cis	rs834603	0.575	rs1799370	chr7:47467864	C/T	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs10905065	0.735	rs10795347	chr10:5742077	C/G	cg11519256	chr10:5708881	ASB13	-0.41	-6.95	-0.31	1.22e-11	Menopause (age at onset);
LGG	cis	rs3087591	0.683	rs17826544	chr17:29640225	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.32	0.5	2.22e-30	Hip circumference;
LGG	trans	rs6601327	0.602	rs7820917	chr8:9647868	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.88	-0.34	2.39e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs656319	0.580	rs17690549	chr8:9998538	C/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.91	-0.35	1.86e-14	Myopia (pathological);
LGG	cis	rs9682041	0.696	rs11927807	chr3:170096623	A/G	cg11886554	chr3:170076028	SKIL	0.64	8.36	0.36	7.55e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	trans	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.42	-0.4	2.21e-19	Retinal vascular caliber;
LGG	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.61	-0.59	1.91e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs4919694	0.572	rs12255989	chr10:104867206	C/T	cg04362960	chr10:104952993	NT5C2	0.87	13.37	0.53	1.1e-34	Arsenic metabolism;
LGG	cis	rs858239	0.539	rs2103281	chr7:23194231	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.09	0.31	4.94e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg06221963	chr1:154839813	KCNN3	-0.51	-10.05	-0.42	1.28e-21	Prostate cancer;
LGG	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.59	0.44	1.32e-23	Iron status biomarkers;
LGG	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg11502198	chr6:26597334	ABT1	0.54	9.46	0.4	1.58e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7106204	0.514	rs2083753	chr11:24255896	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	14.0	0.55	2.28e-37	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7928758	0.945	rs11223787	chr11:134277978	G/A	cg15243474	chr11:134282918	B3GAT1	0.98	13.87	0.54	7.84e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.42	0.36	4.82e-16	Neuroticism;
LGG	cis	rs4132509	0.739	rs79367267	chr1:243689543	C/A	cg21452805	chr1:244014465	NA	0.82	7.96	0.35	1.35e-14	RR interval (heart rate);
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs3812831	0.695	rs423237	chr13:114930955	C/T	cg06611532	chr13:114900021	NA	0.28	7.21	0.32	2.34e-12	Schizophrenia;
LGG	trans	rs8073060	0.586	rs9649	chr17:34050934	C/T	cg19694781	chr19:47549865	TMEM160	1.16	17.64	0.63	1.17e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.36	-0.4	3.49e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12477438	0.520	rs58086269	chr2:99945794	A/C	cg23527387	chr2:100056660	REV1	0.44	9.7	0.41	2.25e-20	Chronic sinus infection;
LGG	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg03733263	chr8:22462867	KIAA1967	1.09	29.22	0.81	3.83e-107	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7255045	0.752	rs2242512	chr19:12975599	G/A	cg07955356	chr19:12992479	DNASE2	0.42	7.09	0.31	5.05e-12	Mean corpuscular volume;
LGG	cis	rs2236267	0.726	rs2093317	chr14:88609578	T/C	cg18078958	chr14:88630771	NA	-0.33	-7.74	-0.34	6.1e-14	Food antigen IgG levels;
LGG	cis	rs758324	0.947	rs4493667	chr5:131247218	G/T	cg06307176	chr5:131281290	NA	-0.57	-9.47	-0.4	1.44e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9807989	0.507	rs6743516	chr2:103036335	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg20608306	chr11:116969690	SIK3	0.34	8.84	0.38	2.01e-17	Blood protein levels;
LGG	cis	rs7843479	1.000	rs7821592	chr8:21811530	C/G	cg17168535	chr8:21777572	XPO7	0.6	9.84	0.42	7.27e-21	Mean corpuscular volume;
LGG	cis	rs10752881	0.775	rs2147585	chr1:183074875	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Colorectal cancer;
LGG	cis	rs975739	0.695	rs1924916	chr13:78514568	C/A	cg07847733	chr13:78271382	SLAIN1	0.4	6.9	0.31	1.73e-11	Hair color;
LGG	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.5	-0.33	3.32e-13	Coronary artery disease;
LGG	cis	rs67460515	0.563	rs11717272	chr3:160810355	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-7.85	-0.34	2.97e-14	Parkinson's disease;
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.42	-0.4	2.16e-19	Neuroticism;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3768617	0.510	rs10911243	chr1:183075415	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12220238	0.730	rs10740421	chr10:75941002	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.3e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1707322	1.000	rs6661500	chr1:46465662	T/C	cg03146154	chr1:46216737	IPP	0.55	10.26	0.43	2.09e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1497828	0.956	rs2646834	chr1:217545202	G/C	cg04411442	chr1:217543379	NA	0.47	8.01	0.35	9.43e-15	Dialysis-related mortality;
LGG	cis	rs9467160	0.644	rs62400468	chr6:24457358	C/T	cg20631270	chr6:24437470	GPLD1	0.52	7.37	0.32	8.09e-13	Liver enzyme levels;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg03528353	chr17:61819722	STRADA	-0.44	-7.56	-0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs7226408	0.857	rs72888992	chr18:34572381	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs2836974	0.583	rs2735307	chr21:40713358	C/T	cg11890956	chr21:40555474	PSMG1	0.76	12.99	0.52	4e-33	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16618003	chr1:65432492	JAK1	0.51	7.73	0.34	6.84e-14	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06496078	chr12:107350075	C12orf23	0.47	8.01	0.35	9.24e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg22546130	chr22:19950026	COMT	0.37	8.92	0.38	1.09e-17	Blood metabolite levels;
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs1577917	0.958	rs13219504	chr6:86556917	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.69	-0.45	5.27e-24	Response to antipsychotic treatment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08730330	chr17:61904790	PSMC5;FTSJ3	0.42	6.69	0.3	6.48e-11	Cognitive performance;
LGG	cis	rs6541297	0.699	rs4846916	chr1:230296492	G/A	cg05784532	chr1:230284198	GALNT2	0.46	6.68	0.3	6.98e-11	Coronary artery disease;
LGG	cis	rs79349575	0.783	rs58591767	chr17:47026076	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs2307022	0.586	rs3785125	chr16:68388392	T/A	cg07273125	chr16:68295692	NA	0.45	10.07	0.42	1.04e-21	Body mass index;
LGG	cis	rs28595532	0.764	rs116788606	chr4:119748849	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.85e-22	Cannabis dependence symptom count;
LGG	cis	rs4662750	0.580	rs7558838	chr2:128351346	T/C	cg10021288	chr2:128175891	PROC	0.38	7.04	0.31	7.15e-12	Renal cell carcinoma;
LGG	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs1577917	1.000	rs36096931	chr6:86693134	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs7565124	0.955	rs11096638	chr2:20266386	G/T	cg24657347	chr2:20261756	NA	-0.76	-14.85	-0.57	4.47e-41	Major depressive disorder;
LGG	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg26150922	chr2:100937072	LONRF2	-0.53	-9.67	-0.41	2.77e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10463316	0.894	rs7729438	chr5:150762197	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs7819412	0.669	rs28630509	chr8:10997039	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.73	0.34	6.54e-14	Triglycerides;
LGG	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg25706281	chr1:46860511	FAAH	-0.28	-6.71	-0.3	5.55e-11	Menopause (age at onset);
LGG	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg09060608	chr5:178986726	RUFY1	0.45	8.16	0.35	3.12e-15	Lung cancer;
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg09359103	chr1:154839909	KCNN3	0.51	10.53	0.44	2.09e-23	Prostate cancer;
LGG	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	trans	rs4332037	0.538	rs6951956	chr7:1934131	C/T	cg11693508	chr17:37793320	STARD3	0.55	8.22	0.36	2e-15	Bipolar disorder;
LGG	cis	rs4650994	0.525	rs10913567	chr1:178511941	A/C	cg12486710	chr1:178512616	C1orf220	0.52	10.63	0.44	9.59e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7666738	0.753	rs11932536	chr4:98930105	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11867479	0.611	rs12940346	chr17:68075324	T/C	cg02868298	chr17:68066712	NA	0.35	6.97	0.31	1.09e-11	Height;
LGG	cis	rs16866061	0.515	rs3738951	chr2:225368321	A/G	cg22455342	chr2:225449267	CUL3	0.45	7.47	0.33	4.14e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.52	0.37	2.31e-16	Iron status biomarkers;
LGG	cis	rs17826219	0.706	rs609472	chr17:28951427	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.71	-8.96	-0.38	8e-18	Body mass index;
LGG	cis	rs10227331	0.846	rs12673606	chr7:157297518	C/G	cg04156418	chr7:157293606	NA	0.61	13.73	0.54	3.13e-36	Inattentive symptoms;
LGG	cis	rs9916302	0.904	rs8081338	chr17:37406139	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.61	-0.59	1.91e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs2354432	0.607	rs6677679	chr1:146803630	C/T	cg25205988	chr1:146714368	CHD1L	-1.43	-14.5	-0.56	1.55e-39	Mitochondrial DNA levels;
LGG	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg20503657	chr10:835505	NA	-0.72	-9.84	-0.42	7.2e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg17219203	chr10:38645113	HSD17B7P2	0.43	7.1	0.31	4.6e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1816752	0.749	rs77832754	chr13:24990154	G/A	cg22771759	chr13:24902376	NA	0.4	6.77	0.3	3.84e-11	Obesity-related traits;
LGG	cis	rs12210905	0.843	rs12208039	chr6:26984004	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg02462569	chr6:150064036	NUP43	-0.42	-9.0	-0.39	6.09e-18	Lung cancer;
LGG	cis	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.44	-7.16	-0.32	3.27e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs13040088	1.000	rs12480117	chr20:61558274	G/A	cg23096297	chr20:61557774	DIDO1	0.87	11.87	0.48	1.42e-28	Menopause (age at onset);
LGG	cis	rs2229238	0.911	rs58881140	chr1:154515193	C/T	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg26338869	chr17:61819248	STRADA	-0.59	-9.95	-0.42	2.78e-21	Prudent dietary pattern;
LGG	cis	rs9733	0.791	rs11800059	chr1:150651175	C/T	cg13175981	chr1:150552382	MCL1	0.54	9.14	0.39	1.9e-18	Tonsillectomy;
LGG	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	8.53	0.37	2.09e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg02269571	chr22:50332266	NA	-0.65	-9.77	-0.41	1.26e-20	Schizophrenia;
LGG	cis	rs11931598	0.783	rs870660	chr4:7052182	T/C	cg26116260	chr4:7069785	GRPEL1	0.56	10.01	0.42	1.79e-21	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs12410462	0.551	rs66938123	chr1:227808231	G/A	cg04117972	chr1:227635322	NA	0.43	7.9	0.34	2.01e-14	Major depressive disorder;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg14926445	chr8:58193284	C8orf71	-0.67	-8.44	-0.37	4.12e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	0.964	rs11864107	chr16:28885931	T/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06873352	chr17:61820015	STRADA	0.46	7.16	0.32	3.09e-12	Height;
LGG	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.31	-0.32	1.19e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00435006	chr16:1877199	HAGH;FAHD1	0.47	6.92	0.31	1.55e-11	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.822	rs56322219	chr15:86276340	A/T	cg07943548	chr15:86304357	KLHL25	-0.36	-6.99	-0.31	9.73e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4774830	0.590	rs62045217	chr15:56260773	T/C	cg05129572	chr15:56138634	NEDD4	0.87	7.99	0.35	1.11e-14	Delta-5 desaturase activity;
LGG	trans	rs61931739	0.613	rs7971612	chr12:33644835	C/T	cg26384229	chr12:38710491	ALG10B	-0.47	-8.14	-0.35	3.67e-15	Morning vs. evening chronotype;
LGG	cis	rs10416265	0.528	rs3826906	chr19:33620897	C/T	cg03563238	chr19:33554763	RHPN2	-0.38	-6.7	-0.3	5.94e-11	Bone properties (heel);
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.38	0.56	4.93e-39	Lung cancer;
LGG	cis	rs17428076	0.874	rs72885529	chr2:172684032	C/T	cg21435375	chr2:172878103	MAP1D	0.4	8.65	0.37	8.23e-17	Myopia;
LGG	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg24011408	chr12:48396354	COL2A1	-0.51	-8.05	-0.35	7.12e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16025584	chr9:139887217	C9orf142	0.46	7.03	0.31	7.44e-12	Gut microbiome composition (summer);
LGG	cis	rs5769765	0.817	rs11912619	chr22:50317401	G/A	cg02269571	chr22:50332266	NA	-0.65	-9.74	-0.41	1.63e-20	Schizophrenia;
LGG	cis	rs4951018	0.887	rs3761916	chr1:205630893	A/G	cg24503407	chr1:205819492	PM20D1	-0.37	-7.15	-0.32	3.32e-12	Prostate-specific antigen levels;
LGG	cis	rs62400317	0.859	rs58769170	chr6:45298531	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.51	-0.44	2.64e-23	Total body bone mineral density;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg21862992	chr11:68658383	NA	0.5	8.36	0.36	7.28e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.04	0.39	4.14e-18	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01212965	chr4:106630041	GSTCD;INTS12	0.42	6.99	0.31	9.72e-12	Cognitive performance;
LGG	cis	rs7208859	0.524	rs11653098	chr17:29122501	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.61	-0.44	1.05e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs656319	0.669	rs56279061	chr8:9873980	T/C	cg16141378	chr3:129829833	LOC729375	0.34	7.34	0.32	9.5e-13	Myopia (pathological);
LGG	cis	rs7737355	0.773	rs32112	chr5:131048122	G/A	cg06307176	chr5:131281290	NA	0.52	8.64	0.37	8.88e-17	Life satisfaction;
LGG	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg04935436	chr20:30431758	NA	0.41	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin;
LGG	cis	rs11122272	0.735	rs2790889	chr1:231520240	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7659604	0.540	rs10012775	chr4:122676878	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg24642439	chr20:33292090	TP53INP2	0.44	6.95	0.31	1.24e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs7648466	0.513	rs2201150	chr3:46258902	T/C	cg13144783	chr3:46249795	CCR1	-0.67	-14.55	-0.56	8.76e-40	Eotaxin levels;
LGG	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.58	10.28	0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs9326248	0.559	rs573549	chr11:116736679	A/G	cg20608306	chr11:116969690	SIK3	0.39	12.48	0.5	4.93e-31	Blood protein levels;
LGG	cis	rs889398	0.771	rs1566454	chr16:69900083	C/T	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.87	-0.3	2.04e-11	Body mass index;
LGG	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs11969893	0.649	rs12527901	chr6:101280435	G/A	cg12253828	chr6:101329408	ASCC3	0.76	7.16	0.32	3.24e-12	Economic and political preferences (immigration/crime);
LGG	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg15704280	chr7:45808275	SEPT13	-0.85	-16.98	-0.62	1.26e-50	Height;
LGG	cis	rs2832077	0.527	rs1048546	chr21:30244877	G/T	cg08807101	chr21:30365312	RNF160	-0.67	-11.25	-0.46	4.18e-26	Cognitive test performance;
LGG	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00405596	chr8:11794950	NA	0.63	11.19	0.46	6.76e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg22044901	chr15:68126292	NA	-0.4	-7.14	-0.31	3.65e-12	Obesity;
LGG	cis	rs4319547	0.656	rs10744209	chr12:122931568	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.24	-0.43	2.63e-22	Body mass index;
LGG	cis	rs4148087	1.000	rs4148101	chr21:43640183	G/A	cg15319517	chr21:43638949	ABCG1	-0.49	-6.65	-0.3	8.29e-11	Eating disorder in bipolar disorder;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00495681	chr13:53174319	NA	0.56	10.41	0.44	6.3e-23	Lewy body disease;
LGG	cis	rs4732038	0.546	rs59085389	chr7:134279285	A/G	cg06906464	chr7:134288099	NA	-0.72	-20.96	-0.7	4.28e-69	Longevity;
LGG	cis	rs7927771	0.542	rs3886262	chr11:47817010	T/G	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.52e-25	Subjective well-being;
LGG	trans	rs1032833	0.732	rs17453976	chr2:179970978	C/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs4665809	1.000	rs1371553	chr2:26262948	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.26e-14	Gut microbiome composition (summer);
LGG	cis	rs79057730	0.599	rs4721086	chr7:821123	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.67	7.54	0.33	2.44e-13	Initial pursuit acceleration;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg15971980	chr6:150254442	NA	0.45	7.1	0.31	4.82e-12	Lung cancer;
LGG	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg08888203	chr3:10149979	C3orf24	0.34	6.7	0.3	6.05e-11	Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg25072359	chr17:41440525	NA	-0.49	-9.62	-0.41	4.13e-20	Menopause (age at onset);
LGG	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04529582	chr20:30697510	TM9SF4	0.44	7.46	0.33	4.45e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7226408	0.600	rs8097677	chr18:34501310	G/T	cg15022739	chr18:34823045	BRUNOL4	0.41	8.84	0.38	2.06e-17	Obesity-related traits;
LGG	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.82e-14	Hepatitis;
LGG	cis	rs240764	0.567	rs12528607	chr6:101260131	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.94	0.35	1.53e-14	Neuroticism;
LGG	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg00717180	chr2:96193071	NA	-0.46	-8.31	-0.36	1.05e-15	HDL cholesterol;
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.71	0.68	3.06e-63	Platelet count;
LGG	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg27523141	chr10:43048294	ZNF37B	0.39	7.53	0.33	2.66e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg07157834	chr1:205819609	PM20D1	-0.39	-8.06	-0.35	6.34e-15	Prostate-specific antigen levels;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.48	9.06	0.39	3.76e-18	Longevity;
LGG	cis	rs7512552	0.839	rs1097070	chr1:150332955	A/T	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg18252515	chr7:66147081	NA	-1.41	-20.28	-0.69	6.73e-66	Diabetic kidney disease;
LGG	cis	rs28655083	0.828	rs9938028	chr16:77127830	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.55	9.16	0.39	1.69e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4771450	0.886	rs9300808	chr13:103986519	T/G	cg02987523	chr13:103978230	NA	-0.33	-7.17	-0.32	2.93e-12	Uric acid levels;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg17328964	chr8:145687451	CYHR1	0.62	11.26	0.46	3.54e-26	Age at first birth;
LGG	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg05973401	chr12:123451056	ABCB9	-0.5	-7.1	-0.31	4.81e-12	Neutrophil percentage of white cells;
LGG	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg03605463	chr16:89740564	NA	-0.39	-6.77	-0.3	3.97e-11	Vitiligo;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs3762637	1.000	rs7626861	chr3:122155196	T/C	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs2798269	0.668	rs1199950	chr13:22091153	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.5	-8.87	-0.38	1.61e-17	PR segment;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	-0.48	-7.14	-0.31	3.62e-12	Systemic lupus erythematosus;
LGG	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg13010199	chr12:38710504	ALG10B	0.78	16.95	0.62	1.72e-50	Heart rate;
LGG	trans	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	24.59	0.75	5.12e-86	IgG glycosylation;
LGG	cis	rs10883723	0.810	rs12265877	chr10:104247247	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.99	0.57	1.07e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.77	-0.41	1.3e-20	Common traits (Other);
LGG	cis	rs832540	0.931	rs832535	chr5:56213334	C/T	cg14703610	chr5:56206110	C5orf35	0.45	7.77	0.34	5.17e-14	Coronary artery disease;
LGG	cis	rs7538876	0.903	rs6688886	chr1:17753639	G/A	cg10329579	chr1:17754830	RCC2	-0.54	-10.24	-0.43	2.47e-22	Basal cell carcinoma;
LGG	cis	rs36051895	0.695	rs10974915	chr9:5016818	A/G	cg02405213	chr9:5042618	JAK2	-0.83	-16.0	-0.6	3.6e-46	Pediatric autoimmune diseases;
LGG	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg12800244	chr3:153838788	SGEF	0.58	8.31	0.36	1.07e-15	Coronary artery disease;
LGG	cis	rs873946	0.586	rs2001426	chr10:134563871	G/A	cg26818010	chr10:134567672	INPP5A	-0.75	-11.61	-0.47	1.59e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6121246	0.567	rs6058197	chr20:30194899	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.918	rs6002351	chr22:41757223	C/T	cg06481639	chr22:41940642	POLR3H	-0.48	-7.24	-0.32	1.89e-12	Vitiligo;
LGG	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg17108064	chr15:78857060	CHRNA5	0.46	9.89	0.42	4.75e-21	Sudden cardiac arrest;
LGG	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg03929089	chr4:120376271	NA	-0.65	-8.12	-0.35	4.13e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6800768	0.633	rs826375	chr3:24163964	A/G	cg10674438	chr3:24145617	LOC152024	-0.51	-9.25	-0.4	7.98e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-10.12	-0.43	7.25e-22	IgG glycosylation;
LGG	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg00631329	chr6:26305371	NA	-0.46	-7.72	-0.34	7.35e-14	Educational attainment;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.35e-12	Lung cancer;
LGG	cis	rs12410462	0.581	rs35141785	chr1:227553496	G/C	cg04117972	chr1:227635322	NA	0.57	9.44	0.4	1.9e-19	Major depressive disorder;
LGG	cis	rs4740619	0.619	rs10810522	chr9:16031644	C/A	cg14451791	chr9:16040625	NA	-0.42	-11.2	-0.46	6.18e-26	Body mass index;
LGG	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg25554036	chr4:6271136	WFS1	0.61	11.18	0.46	7.59e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs854765	0.575	rs7207821	chr17:17891781	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.36	0.58	2.52e-43	Total body bone mineral density;
LGG	cis	rs12908161	0.959	rs11637728	chr15:85203392	A/T	cg24253500	chr15:84953950	NA	0.42	6.93	0.31	1.4e-11	Schizophrenia;
LGG	cis	rs6665290	0.935	rs17600627	chr1:227201449	A/G	cg05696931	chr1:227175867	NA	-0.4	-7.86	-0.34	2.73e-14	Myeloid white cell count;
LGG	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg26150922	chr2:100937072	LONRF2	-0.56	-9.84	-0.42	7.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12478296	1.000	rs6743297	chr2:243013814	A/G	cg18898632	chr2:242989856	NA	-0.73	-8.6	-0.37	1.21e-16	Obesity-related traits;
LGG	trans	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg26043149	chr18:55253948	FECH	0.95	16.33	0.6	1.08e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2836974	0.602	rs2037925	chr21:40699931	C/T	cg06238570	chr21:40685208	BRWD1	-0.51	-8.38	-0.36	6.5e-16	Cognitive function;
LGG	cis	rs7085104	0.700	rs10786712	chr10:104596396	A/G	cg04362960	chr10:104952993	NT5C2	-0.5	-9.31	-0.4	5.33e-19	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg06889755	chr6:150326021	RAET1K	-0.39	-8.13	-0.35	3.93e-15	Alopecia areata;
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	cis	rs3206736	0.548	rs328929	chr7:35040038	A/G	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg04986931	chr22:39850128	NA	0.34	7.68	0.34	9.8e-14	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg13010199	chr12:38710504	ALG10B	0.51	9.94	0.42	3.08e-21	Morning vs. evening chronotype;
LGG	trans	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.1e-17	Aortic root size;
LGG	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs3762637	0.943	rs7629285	chr3:122265739	A/G	cg24169773	chr3:122142474	KPNA1	0.59	10.14	0.43	6.16e-22	LDL cholesterol levels;
LGG	cis	rs283228	0.550	rs503387	chr6:101805331	C/T	cg02011392	chr6:101847541	GRIK2	0.53	7.29	0.32	1.39e-12	Coenzyme Q10 levels;
LGG	cis	rs11585357	0.895	rs2501795	chr1:17633499	A/G	cg08277548	chr1:17600880	PADI3	-0.72	-8.23	-0.36	1.97e-15	Hair shape;
LGG	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg03433033	chr1:76189801	ACADM	0.76	12.74	0.51	4.32e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2290159	0.948	rs11711270	chr3:12639596	C/T	cg23032965	chr3:12705835	RAF1	0.56	8.45	0.37	3.82e-16	Cholesterol, total;
LGG	cis	rs7192380	0.630	rs2965749	chr16:69771914	C/T	cg00738113	chr16:70207722	CLEC18C	0.35	9.99	0.42	2.14e-21	Sjögren's syndrome;
LGG	cis	rs4148087	1.000	rs9981390	chr21:43634081	G/A	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs35160687	0.623	rs35408390	chr2:86471782	C/T	cg10973622	chr2:86423274	IMMT	-0.41	-7.32	-0.32	1.12e-12	Night sleep phenotypes;
LGG	cis	rs2386661	0.547	rs4747358	chr10:5650193	A/G	cg17085576	chr10:5658249	NA	0.42	7.86	0.34	2.73e-14	Breast cancer;
LGG	cis	rs9733	0.635	rs486836	chr1:150875967	A/T	cg13175981	chr1:150552382	MCL1	0.55	8.81	0.38	2.49e-17	Tonsillectomy;
LGG	cis	rs7222240	1.000	rs877599	chr17:43176622	G/A	cg24806326	chr17:43207588	PLCD3	0.45	7.79	0.34	4.32e-14	Craniofacial microsomia;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg14215459	chr19:10764813	ILF3;LOC147727	-0.36	-7.04	-0.31	7.19e-12	Iris color (L* coordinate);
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.86	-0.3	2.21e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs12519773	0.562	rs6557066	chr5:92499467	T/A	cg18783429	chr5:92414398	NA	0.31	7.49	0.33	3.4e-13	Migraine;
LGG	trans	rs8073060	0.544	rs225258	chr17:33956883	C/T	cg19694781	chr19:47549865	TMEM160	-1.14	-18.02	-0.64	2.05e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg21775007	chr8:11205619	TDH	-0.46	-7.32	-0.32	1.11e-12	Neuroticism;
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs2180341	0.538	rs4392733	chr6:127712603	T/C	cg27446573	chr6:127587934	RNF146	0.66	11.9	0.48	1.16e-28	Breast cancer;
LGG	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg04362960	chr10:104952993	NT5C2	0.47	7.84	0.34	3.1e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs916888	0.773	rs199533	chr17:44828931	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.12	-0.57	2.75e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.58	-9.32	-0.4	4.84e-19	Blood metabolite levels;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-6.97	-0.31	1.1e-11	Longevity;Endometriosis;
LGG	cis	rs2180341	0.782	rs6912196	chr6:127722732	C/G	cg27446573	chr6:127587934	RNF146	0.89	16.98	0.62	1.33e-50	Breast cancer;
LGG	cis	rs3862030	0.836	rs12771867	chr10:104246691	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-10.81	-0.45	1.98e-24	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs12200782	0.649	rs9467744	chr6:26386711	T/C	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg11050988	chr7:1952600	MAD1L1	-0.4	-9.81	-0.41	9.14e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs490234	0.676	rs12202	chr9:128200299	C/G	cg14078157	chr9:128172775	NA	-0.48	-8.84	-0.38	2.08e-17	Mean arterial pressure;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg08677398	chr8:58056175	NA	0.44	7.54	0.33	2.55e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-11.79	-0.48	3.11e-28	Personality dimensions;
LGG	cis	rs6088580	0.524	rs4911437	chr20:33266149	G/T	cg07148914	chr20:33460835	GGT7	-0.51	-8.05	-0.35	6.81e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs1124376	1.000	rs9828701	chr3:20149203	A/G	cg05072819	chr3:20081367	KAT2B	0.63	8.42	0.36	4.65e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.5	-0.4	1.13e-19	Neuroticism;
LGG	cis	rs8077889	0.672	rs15359	chr17:41843979	C/G	cg26893861	chr17:41843967	DUSP3	-1.11	-26.21	-0.77	1.56e-93	Triglycerides;
LGG	cis	rs7927592	0.913	rs10896330	chr11:68254998	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.36	-0.36	7.3e-16	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04772025	chr11:68637568	NA	0.75	13.23	0.52	4.25e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs17767392	0.834	rs61991191	chr14:71739204	T/C	cg02058870	chr14:72053146	SIPA1L1	0.41	7.96	0.35	1.38e-14	Mitral valve prolapse;
LGG	cis	rs2694528	0.844	rs16878373	chr5:60058987	A/G	cg11474532	chr5:59995715	DEPDC1B	0.73	7.81	0.34	3.74e-14	Parkinson's disease;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs193541	0.502	rs2061511	chr5:122056727	A/G	cg19412675	chr5:122181750	SNX24	0.5	7.75	0.34	5.79e-14	Glucose homeostasis traits;
LGG	cis	rs75920871	0.920	rs61907594	chr11:116801811	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.0	-0.31	8.94e-12	Subjective well-being;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg15242686	chr22:24348715	GSTTP1	0.39	7.25	0.32	1.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4911259	0.552	rs11697394	chr20:31460076	G/A	cg13636640	chr20:31349939	DNMT3B	-0.64	-11.61	-0.47	1.65e-27	Inflammatory bowel disease;
LGG	cis	rs9790314	0.628	rs1599381	chr3:160867680	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-10.28	-0.43	1.84e-22	Morning vs. evening chronotype;
LGG	cis	rs155076	1.000	rs155076	chr13:21870114	A/G	cg11317459	chr13:21872234	NA	-1.24	-20.8	-0.7	2.36e-68	White matter hyperintensity burden;
LGG	trans	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	trans	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg17712092	chr4:129076599	LARP1B	-0.73	-13.86	-0.54	8.55e-37	Eosinophil percentage of white cells;
LGG	cis	rs9815354	1.000	rs1717009	chr3:41946308	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg13628971	chr7:2884303	GNA12	0.54	10.97	0.45	4.75e-25	Height;
LGG	cis	rs6840360	0.642	rs2724571	chr4:152376795	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10751667	0.621	rs10794348	chr11:939941	G/A	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.6e-14	Alzheimer's disease (late onset);
LGG	cis	rs6558530	0.666	rs4242538	chr8:1694010	G/C	cg25947184	chr8:1697459	NA	0.44	7.74	0.34	6.15e-14	Systolic blood pressure;
LGG	cis	rs10824796	0.584	rs34297717	chr10:54505446	T/G	cg27418851	chr10:54531653	MBL2	-0.41	-7.08	-0.31	5.31e-12	Blood protein levels;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg06197492	chr11:2016605	H19	0.5	10.28	0.43	1.85e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs8060686	0.641	rs113258243	chr16:68086656	C/T	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.6	-0.33	1.67e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.0	-0.31	8.98e-12	Intelligence (multi-trait analysis);
LGG	cis	rs883115	0.782	rs1499292	chr1:224763594	C/T	cg01808320	chr1:224927238	CNIH3	-0.4	-7.19	-0.32	2.69e-12	Cancer;
LGG	cis	rs4664308	0.618	rs3749117	chr2:160885442	T/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.66	-0.48	1e-27	Idiopathic membranous nephropathy;
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg18681998	chr4:17616180	MED28	0.86	18.39	0.65	4.19e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.909	rs1546504	chr4:120241179	C/T	cg24375607	chr4:120327624	NA	0.65	10.52	0.44	2.36e-23	Corneal astigmatism;
LGG	cis	rs2816316	1.000	rs2816316	chr1:192536813	C/A	cg10861751	chr1:192544716	RGS1	0.34	6.85	0.3	2.41e-11	Celiac disease;
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.7	0.34	8.11e-14	Rheumatoid arthritis;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg21911579	chr5:131705225	SLC22A5	0.67	7.44	0.33	4.97e-13	Rheumatoid arthritis;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	7.67	0.34	1.05e-13	Schizophrenia;
LGG	cis	rs539514	0.637	rs2025354	chr13:76275577	T/C	cg04757411	chr13:76259545	LMO7	-0.27	-6.82	-0.3	2.92e-11	Type 1 diabetes;
LGG	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18876405	chr7:65276391	NA	0.59	10.87	0.45	1.19e-24	Aortic root size;
LGG	cis	rs9503598	0.605	rs9968900	chr6:3457687	C/T	cg00476032	chr6:3446245	SLC22A23	0.52	10.42	0.44	5.73e-23	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	trans	rs8073060	0.586	rs225278	chr17:33974170	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-18.0	-0.64	2.54e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs11074306	0.561	rs2311468	chr15:28069041	G/A	cg26402630	chr15:28053930	OCA2	0.36	7.29	0.32	1.36e-12	Uveal melanoma;
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.65	-0.41	3.35e-20	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08741578	chr4:4250464	TMEM128	0.43	7.22	0.32	2.18e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg20578329	chr17:80767326	TBCD	0.46	8.02	0.35	8.61e-15	Breast cancer;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.14	-0.31	3.67e-12	Obesity-related traits;
LGG	cis	rs17818399	0.547	rs35178974	chr2:46763898	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-11.17	-0.46	8.43e-26	Height;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg05313129	chr8:58192883	C8orf71	-0.82	-10.96	-0.45	5.33e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9796	0.866	rs692155	chr15:41407061	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.51	-8.62	-0.37	1.03e-16	Menopause (age at onset);
LGG	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.98	-21.73	-0.71	1.07e-72	Schizophrenia;
LGG	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg13147721	chr7:65941812	NA	0.84	10.13	0.43	6.44e-22	Diabetic kidney disease;
LGG	cis	rs68170813	0.652	rs6957186	chr7:107200592	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.42	-0.36	4.92e-16	Coronary artery disease;
LGG	cis	rs12410462	0.591	rs2819498	chr1:227724401	G/T	cg23173402	chr1:227635558	NA	0.38	7.27	0.32	1.54e-12	Major depressive disorder;
LGG	trans	rs9914544	0.545	rs9903574	chr17:18768582	C/T	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.2e-13	Educational attainment (years of education);
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.31	0.69	4.95e-66	Alzheimer's disease;
LGG	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.12	0.43	6.94e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7119	0.717	rs7181283	chr15:77814544	G/A	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs4006360	0.546	rs1848812	chr17:39235917	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.53	-0.47	3.16e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.92	-0.42	3.62e-21	Bipolar disorder;
LGG	cis	rs4132509	0.895	rs7556516	chr1:243782009	G/A	cg21452805	chr1:244014465	NA	0.62	7.4	0.33	6.42e-13	RR interval (heart rate);
LGG	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg24642439	chr20:33292090	TP53INP2	-0.76	-12.76	-0.51	3.55e-32	Coronary artery disease;
LGG	cis	rs9815354	0.556	rs116717051	chr3:42027411	G/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg19774624	chr17:42201019	HDAC5	0.55	9.59	0.41	5.29e-20	Red cell distribution width;Reticulocyte count;
LGG	cis	rs798554	0.797	rs798487	chr7:2802943	G/A	cg13628971	chr7:2884303	GNA12	0.51	10.08	0.42	9.66e-22	Height;
LGG	trans	rs3942852	0.868	rs7118226	chr11:48106267	T/G	cg15704280	chr7:45808275	SEPT13	-0.67	-8.36	-0.36	7.27e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4974559	0.739	rs3817604	chr4:1291337	C/T	cg02980000	chr4:1222292	CTBP1	0.82	9.26	0.4	7.88e-19	Systolic blood pressure;
LGG	cis	rs11214589	0.719	rs10891535	chr11:113201280	C/G	cg14373873	chr11:113211441	TTC12	0.53	11.65	0.48	1.15e-27	Neuroticism;
LGG	cis	rs17102423	0.731	rs10143198	chr14:65555471	C/T	cg16583315	chr14:65563665	MAX	-0.4	-8.13	-0.35	3.97e-15	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07085476	chr11:82867879	PCF11	0.45	7.42	0.33	5.77e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg17951613	chr5:131705445	SLC22A5	0.69	7.59	0.33	1.72e-13	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg12070911	chr6:150209640	RAET1E	0.3	7.22	0.32	2.18e-12	Lung cancer;
LGG	cis	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Bladder cancer;
LGG	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg02903104	chr8:1507517	DLGAP2	0.38	7.93	0.35	1.69e-14	Lung cancer;
LGG	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg27490568	chr2:178487706	NA	0.82	14.3	0.55	1.13e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg03733263	chr8:22462867	KIAA1967	0.97	23.37	0.74	2.29e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.2	-0.32	2.53e-12	Mood instability;
LGG	cis	rs3806843	1.000	rs4404730	chr5:140162610	G/A	cg19875535	chr5:140030758	IK	0.5	10.18	0.43	4.24e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs1426670	chr4:98923572	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.09e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7681423	1.000	rs2066861	chr4:155527436	C/T	cg20735720	chr4:155535218	FGG	-0.59	-10.67	-0.44	6.32e-24	Fibrinogen;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg09033563	chr22:24373618	LOC391322	0.5	8.41	0.36	5.31e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9902453	0.967	rs34323226	chr17:28517454	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	13.19	0.52	6.09e-34	Coffee consumption (cups per day);
LGG	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.81	-0.3	2.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg11366901	chr6:160182831	ACAT2	1.07	16.33	0.6	1.1e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs34599045	0.522	rs71626747	chr1:153019217	A/T	cg07796016	chr1:152779584	LCE1C	-0.9	-8.02	-0.35	8.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs360798	0.512	rs2539978	chr2:63195179	T/C	cg17519650	chr2:63277830	OTX1	0.52	8.46	0.37	3.41e-16	Coronary artery disease;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg02725872	chr8:58115012	NA	-0.86	-11.4	-0.47	1.03e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.12	-0.35	4.12e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6912958	0.754	rs10755484	chr6:88244648	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.44	-0.37	4.17e-16	Monocyte percentage of white cells;
LGG	cis	rs6088580	0.634	rs2424992	chr20:33012060	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs11190604	1.000	rs2495758	chr10:102321900	C/G	cg07080220	chr10:102295463	HIF1AN	0.73	12.03	0.49	3.3e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9303280	0.806	rs4795399	chr17:38061439	T/C	cg19468946	chr17:37922297	IKZF3	-0.44	-7.86	-0.34	2.63e-14	Self-reported allergy;
LGG	trans	rs7980799	0.649	rs2220059	chr12:33648630	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-7.99	-0.35	1.1e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12893668	0.703	rs4906336	chr14:104033265	C/G	cg23335576	chr14:104009727	NA	0.47	8.03	0.35	7.94e-15	Reticulocyte count;
LGG	cis	rs12724450	0.546	rs71622689	chr1:150279603	G/C	cg03818307	chr1:150480534	ECM1	0.49	6.86	0.3	2.18e-11	Blood protein levels;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg18402987	chr7:1209562	NA	0.53	7.67	0.34	1.02e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.55	-10.61	-0.44	1.1e-23	Prudent dietary pattern;
LGG	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.84	0.34	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg19445457	chr11:5799446	OR52N5	-0.42	-6.88	-0.3	1.92e-11	DNA methylation (variation);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18917495	chr2:74006961	DUSP11	0.42	6.84	0.3	2.52e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6540556	0.608	rs7548781	chr1:209915795	A/G	cg23920097	chr1:209922102	NA	0.4	7.21	0.32	2.27e-12	Red blood cell count;
LGG	cis	rs5769707	0.592	rs6009783	chr22:50011001	C/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.76	-0.41	1.43e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6909430	0.901	rs9372740	chr6:98598340	C/T	cg12860156	chr6:98744658	NA	-0.45	-7.56	-0.33	2.15e-13	Quantitative traits;
LGG	cis	rs2046867	0.908	rs68142603	chr3:72790220	A/C	cg26655873	chr3:72818019	SHQ1	0.34	6.69	0.3	6.31e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.23	0.39	9.96e-19	Bipolar disorder;
LGG	cis	rs77633900	0.772	rs284904	chr15:76744302	A/C	cg21673338	chr15:77095150	SCAPER	0.62	7.87	0.34	2.52e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1816752	0.719	rs11843470	chr13:24997699	A/C	cg02811702	chr13:24901961	NA	0.38	7.09	0.31	4.95e-12	Obesity-related traits;
LGG	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg08305652	chr11:111469057	NA	-0.44	-8.88	-0.38	1.53e-17	Primary sclerosing cholangitis;
LGG	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.46	-8.05	-0.35	6.94e-15	Response to antipsychotic treatment;
LGG	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg00405596	chr8:11794950	NA	-0.44	-7.37	-0.32	7.65e-13	Neuroticism;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg07870213	chr5:140052090	DND1	0.72	12.73	0.51	5.09e-32	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17270561	0.609	rs1937132	chr6:25757017	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.31	-0.32	1.16e-12	Iron status biomarkers;
LGG	cis	rs4595586	0.563	rs2388178	chr12:39364366	T/G	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs977987	0.806	rs6564258	chr16:75447363	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg24623649	chr8:11872141	NA	0.3	7.04	0.31	6.91e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9427116	0.702	rs9427108	chr1:154607914	G/A	cg11650704	chr1:154556575	ADAR	-0.44	-8.47	-0.37	3.24e-16	Blood protein levels;
LGG	cis	rs4684776	1.000	rs4684774	chr3:11426086	T/C	cg24705426	chr3:11550659	ATG7	-0.41	-7.5	-0.33	3.34e-13	Small vessel stroke;
LGG	cis	rs11645898	0.625	rs8047930	chr16:72106024	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-8.98	-0.39	7.01e-18	Blood protein levels;
LGG	cis	rs10791323	0.569	rs10750552	chr11:133740141	A/C	cg15485101	chr11:133734466	NA	-0.52	-9.23	-0.39	9.79e-19	Childhood ear infection;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg14926445	chr8:58193284	C8orf71	-0.74	-9.38	-0.4	3.07e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2201728	0.905	rs7662955	chr4:100217128	G/A	cg07219303	chr4:100140905	ADH6	-0.4	-8.08	-0.35	5.74e-15	Cardiac Troponin-T levels;
LGG	cis	rs6882716	0.636	rs1470023	chr5:10800150	A/G	cg14521931	chr5:10832172	NA	-0.99	-16.84	-0.62	5.5e-50	Alcohol consumption (maxi-drinks);
LGG	trans	rs11099942	0.737	rs9994741	chr4:155120463	C/T	cg25074170	chr4:187088169	FAM149A	-0.44	-6.66	-0.3	8e-11	Type 2 diabetes (age of onset);
LGG	cis	rs12971120	0.891	rs11151960	chr18:72177232	G/A	cg25817165	chr18:72167213	CNDP2	-0.64	-12.84	-0.51	1.64e-32	Refractive error;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg17034360	chr1:68629032	GPR177	0.36	7.07	0.31	5.68e-12	Parkinson's disease (motor and cognition);
LGG	cis	rs1788820	1.000	rs1788820	chr18:21101944	A/G	cg14672496	chr18:21087552	C18orf8	0.38	7.05	0.31	6.4e-12	Body mass index;
LGG	cis	rs13314892	0.764	rs62252182	chr3:69881433	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.44e-14	QRS complex (12-leadsum);
LGG	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg26384229	chr12:38710491	ALG10B	0.72	14.43	0.56	3.09e-39	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.810	rs72797211	chr5:151959517	T/A	cg12297329	chr5:152029980	NA	-0.8	-15.36	-0.58	2.47e-43	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.92	-0.62	2.51e-50	Height;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg22398616	chr13:53314203	LECT1	-0.45	-9.44	-0.4	1.78e-19	Lewy body disease;
LGG	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04530015	chr2:215796436	ABCA12	0.52	10.34	0.43	1.11e-22	Neuroblastoma (high-risk);
LGG	cis	rs4242434	0.854	rs11782130	chr8:22452357	G/T	cg19455335	chr8:22457658	C8orf58	-0.43	-8.84	-0.38	2.07e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2278491	0.557	rs4876680	chr8:117777914	C/G	cg23513447	chr8:117778558	UTP23	-0.51	-6.83	-0.3	2.63e-11	Body mass index;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg09359103	chr1:154839909	KCNN3	-0.53	-10.94	-0.45	6.17e-25	Prostate cancer;
LGG	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg03959625	chr15:84868606	LOC388152	-0.49	-8.24	-0.36	1.72e-15	Schizophrenia;
LGG	cis	rs620875	0.660	rs682033	chr11:126862644	T/C	cg06504925	chr11:126872760	NA	-0.49	-7.08	-0.31	5.51e-12	Response to antipsychotic treatment;
LGG	cis	rs2836974	0.897	rs8128102	chr21:40606414	G/A	cg11890956	chr21:40555474	PSMG1	1.19	29.85	0.81	5.65e-110	Cognitive function;
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg11301795	chr4:187892539	NA	-0.95	-24.61	-0.75	3.83e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1505368	0.505	rs6760554	chr2:213255417	C/T	cg20637307	chr2:213403960	ERBB4	0.48	9.25	0.4	8.13e-19	Symmetrical dimethylarginine levels;
LGG	cis	rs2274273	0.662	rs4040064	chr14:55678088	G/T	cg04306507	chr14:55594613	LGALS3	0.51	11.83	0.48	2.21e-28	Protein biomarker;
LGG	cis	rs6831352	0.918	rs17817359	chr4:100054197	G/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.12e-34	Heart rate;
LGG	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.86	-0.38	1.78e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.22	-0.43	3.04e-22	Hemoglobin concentration;
LGG	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg19455335	chr8:22457658	C8orf58	0.45	9.07	0.39	3.28e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11696845	0.626	rs6073537	chr20:43378270	A/G	cg25301532	chr20:43378953	KCNK15	-0.48	-12.04	-0.49	3.09e-29	Obesity-related traits;
LGG	cis	rs8056893	0.550	rs9923188	chr16:68311867	G/T	cg07273125	chr16:68295692	NA	0.46	10.3	0.43	1.51e-22	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs3741404	0.665	rs12418535	chr11:63910980	A/G	cg18225595	chr11:63971243	STIP1	0.64	12.69	0.51	7.28e-32	Platelet count;
LGG	cis	rs12579753	0.913	rs7965664	chr12:82237340	G/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs9309473	0.898	rs10185080	chr2:73797507	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs6694672	0.717	rs10801588	chr1:197062923	T/C	cg13682187	chr1:196946512	CFHR5	0.51	7.15	0.32	3.41e-12	Asthma;
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.67	12.58	0.5	2.01e-31	Total body bone mineral density;
LGG	cis	rs2933343	0.649	rs728839	chr3:128589359	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-6.83	-0.3	2.73e-11	IgG glycosylation;
LGG	cis	rs9513627	0.510	rs4365162	chr13:100212614	G/C	cg15490075	chr13:100150979	NA	0.63	6.7	0.3	6.25e-11	Obesity-related traits;
LGG	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.22	-0.52	4.36e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs10262624	1.000	rs17347733	chr7:23918510	G/C	cg09690326	chr7:23720549	C7orf46	-0.33	-6.78	-0.3	3.7e-11	Schizophrenia;
LGG	cis	rs9880211	1.000	rs9878078	chr3:136237573	C/T	cg21827317	chr3:136751795	NA	-0.49	-7.3	-0.32	1.24e-12	Body mass index;Height;
LGG	cis	rs7072216	0.763	rs2274246	chr10:100175060	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.6e-12	Metabolite levels;
LGG	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg20503657	chr10:835505	NA	0.73	10.13	0.43	6.33e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs704	0.790	rs4795434	chr17:26716917	G/T	cg10342447	chr17:26645325	TMEM97	-0.38	-6.88	-0.3	2.01e-11	Osteoprotegerin levels;
LGG	cis	rs9325144	0.647	rs11169189	chr12:39097078	A/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.17	-0.32	3.04e-12	Morning vs. evening chronotype;
LGG	trans	rs11165623	0.564	rs6669908	chr1:96998261	G/A	cg10631902	chr5:14652156	NA	-0.45	-9.38	-0.4	2.86e-19	Hip circumference;Waist circumference;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.42	0.53	6.62e-35	Lung cancer;
LGG	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg02733842	chr7:1102375	C7orf50	-0.56	-8.38	-0.36	6.61e-16	Bronchopulmonary dysplasia;
LGG	cis	rs8114671	0.562	rs6120758	chr20:33492523	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.93	0.31	1.4e-11	Height;
LGG	cis	rs11608355	1.000	rs7969719	chr12:109883577	C/T	cg19025524	chr12:109796872	NA	-0.49	-9.21	-0.39	1.12e-18	Neuroticism;
LGG	cis	rs3091242	0.933	rs61775167	chr1:25780893	A/G	cg09222892	chr1:25734099	RHCE	-0.46	-9.63	-0.41	4.03e-20	Erythrocyte sedimentation rate;
LGG	cis	rs8063761	0.640	rs4785760	chr16:90051438	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.72	13.14	0.52	9.42e-34	Squamous cell carcinoma;
LGG	cis	rs55788414	0.651	rs2317121	chr16:81182826	T/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	6.07e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.86	-0.34	2.68e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg21724239	chr8:58056113	NA	0.59	8.58	0.37	1.47e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.57	0.33	2.05e-13	Electroencephalogram traits;
LGG	cis	rs55665837	1.000	rs11023224	chr11:14457739	G/A	cg19336497	chr11:14380999	RRAS2	-0.44	-8.68	-0.37	6.59e-17	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11970301	chr16:30087888	PPP4C	0.45	6.66	0.3	7.95e-11	Gut microbiome composition (summer);
LGG	cis	rs1941023	0.584	rs10897057	chr11:60172273	A/T	cg08716584	chr11:60157161	MS4A7	-0.43	-8.58	-0.37	1.46e-16	Congenital heart disease (maternal effect);
LGG	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg13852791	chr20:30311386	BCL2L1	-0.79	-12.79	-0.51	2.88e-32	Mean corpuscular hemoglobin;
LGG	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg08000102	chr2:233561755	GIGYF2	-0.44	-7.18	-0.32	2.78e-12	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.1	-0.31	4.84e-12	Menopause (age at onset);
LGG	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg03342759	chr3:160939853	NMD3	-0.61	-10.47	-0.44	3.7e-23	Morning vs. evening chronotype;
LGG	cis	rs2880765	0.835	rs4340287	chr15:86043737	A/G	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.56e-11	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs11190604	1.000	rs2298074	chr10:102247526	G/C	cg07570687	chr10:102243282	WNT8B	0.45	7.75	0.34	5.94e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg03517284	chr6:25882590	NA	-0.41	-7.46	-0.33	4.34e-13	Height;
LGG	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg00857998	chr1:205179979	DSTYK	0.55	8.96	0.38	7.8e-18	Red blood cell count;
LGG	cis	rs75229567	0.618	rs35394896	chr12:70188346	T/A	cg10114359	chr12:70132523	RAB3IP	1.1	9.96	0.42	2.58e-21	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.85	0.38	1.81e-17	Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	32.79	0.84	8.22e-123	Chronic sinus infection;
LGG	cis	rs17125944	0.686	rs9646151	chr14:53354464	C/G	cg00686598	chr14:53173677	PSMC6	-0.62	-6.95	-0.31	1.27e-11	Alzheimer's disease (late onset);
LGG	cis	rs9640161	0.830	rs3757425	chr7:150067640	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.22	-0.43	3.05e-22	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs7210837	0.591	rs10432025	chr17:16803779	A/G	cg11294312	chr17:28900046	NA	-0.7	-8.48	-0.37	3.14e-16	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs13132184	0.507	rs35266215	chr4:38048878	C/T	cg24826020	chr4:38070998	TBC1D1	0.5	8.5	0.37	2.54e-16	Verbal declarative memory;
LGG	cis	rs2274273	0.588	rs2880103	chr14:55737832	A/C	cg04306507	chr14:55594613	LGALS3	0.54	12.72	0.51	5.47e-32	Protein biomarker;
LGG	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg11644478	chr21:40555479	PSMG1	-0.72	-12.73	-0.51	4.99e-32	Cognitive function;
LGG	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.62	0.33	1.43e-13	Bipolar disorder;
LGG	cis	rs679087	0.932	rs7312697	chr12:29933069	T/C	cg14258853	chr12:29935411	TMTC1	0.41	8.41	0.36	4.99e-16	Schizophrenia;
LGG	cis	rs7119	0.689	rs12901765	chr15:77819103	C/A	cg10437265	chr15:77819839	NA	0.25	6.94	0.31	1.37e-11	Type 2 diabetes;
LGG	cis	rs806215	0.547	rs12667197	chr7:127369147	A/T	cg25922125	chr7:127225783	GCC1	-0.5	-7.35	-0.32	9.05e-13	Type 2 diabetes;
LGG	cis	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2018683	0.834	rs2012754	chr7:29026257	G/A	cg19402173	chr7:128379420	CALU	-0.68	-12.33	-0.5	2.17e-30	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9583531	0.527	rs9515274	chr13:111390429	A/G	cg24331049	chr13:111365604	ING1	0.85	15.06	0.57	5.44e-42	Coronary artery disease;
LGG	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-6.83	-0.3	2.65e-11	Lung cancer in ever smokers;
LGG	cis	rs7208859	0.673	rs4131618	chr17:29204801	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4731207	0.596	rs10252072	chr7:124578636	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9560113	1.000	rs9560106	chr13:112179605	A/G	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs9549367	0.789	rs2287247	chr13:113889212	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.72	-0.38	4.94e-17	Platelet distribution width;
LGG	cis	rs4148087	0.530	rs221953	chr21:43608656	A/G	cg08841829	chr21:43638893	ABCG1	0.39	6.71	0.3	5.58e-11	Eating disorder in bipolar disorder;
LGG	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.27e-17	Lung cancer;
LGG	cis	rs6763768	1.000	rs6763768	chr3:53537879	C/T	cg16894138	chr3:53270350	TKT	-0.36	-6.9	-0.31	1.72e-11	Bacterial meningitis;
LGG	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg03929089	chr4:120376271	NA	-0.87	-17.67	-0.63	9.22e-54	Coronary artery disease;
LGG	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg19680485	chr15:31195859	MTMR15	-0.51	-8.94	-0.38	9.14e-18	Huntington's disease progression;
LGG	cis	rs7247513	0.866	rs2861405	chr19:12722332	A/C	cg01871581	chr19:12707946	ZNF490	-0.42	-8.45	-0.37	3.88e-16	Bipolar disorder;
LGG	cis	rs9303401	0.659	rs35539277	chr17:56853833	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.73	0.56	1.45e-40	Cognitive test performance;
LGG	cis	rs10186029	0.680	rs12694293	chr2:213937221	T/C	cg08319019	chr2:214017104	IKZF2	0.45	8.07	0.35	6.07e-15	Systemic sclerosis;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg04025307	chr7:1156635	C7orf50	0.63	11.82	0.48	2.3e-28	Longevity;Endometriosis;
LGG	cis	rs1014246	0.848	rs11197798	chr10:118457277	C/T	cg14919929	chr10:118506882	NA	0.62	11.72	0.48	5.95e-28	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs970548	0.685	rs1487562	chr10:45928822	C/T	cg14222797	chr10:16859974	RSU1	-0.62	-7.48	-0.33	3.69e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	11.2	0.46	6.41e-26	Obesity-related traits;
LGG	cis	rs13082711	0.911	rs34307140	chr3:27467875	A/C	cg02860705	chr3:27208620	NA	0.69	12.53	0.5	3.33e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.31	7.04e-12	Bipolar disorder;
LGG	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.75	0.3	4.47e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.87	-0.3	2.02e-11	Lung cancer;
LGG	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg12623918	chr2:306882	NA	0.52	9.7	0.41	2.19e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg05418105	chr22:50981406	NA	0.43	7.84	0.34	3.13e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7589342	0.831	rs13429270	chr2:106453060	C/T	cg14210321	chr2:106509881	NCK2	-0.53	-9.1	-0.39	2.78e-18	Addiction;
LGG	cis	rs4330281	0.669	rs4908963	chr3:17758260	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.1e-13	Schizophrenia;
LGG	cis	rs7523273	0.565	rs2104303	chr1:207886684	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.69	-0.37	6.1e-17	Schizophrenia;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.2	0.39	1.22e-18	Electroencephalogram traits;
LGG	cis	rs72634258	0.945	rs12757968	chr1:8106201	A/G	cg00042356	chr1:8021962	PARK7	0.84	10.98	0.45	4.32e-25	Inflammatory bowel disease;
LGG	cis	rs3824867	0.920	rs7948705	chr11:47447955	C/G	cg20307385	chr11:47447363	PSMC3	-0.46	-7.31	-0.32	1.18e-12	Mean corpuscular hemoglobin;
LGG	cis	rs589448	0.902	rs315134	chr12:69762713	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.34e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg13047869	chr3:10149882	C3orf24	0.55	9.41	0.4	2.3e-19	Alzheimer's disease;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4696584	0.816	rs1388081	chr4:155405579	A/G	cg04517429	chr4:155413618	DCHS2	-0.31	-7.42	-0.33	5.83e-13	Folding of antihelix;
LGG	cis	rs357618	0.965	rs357621	chr5:150847554	T/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs2011503	0.941	rs7257875	chr19:19372150	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	7.33	0.32	1.06e-12	Bipolar disorder;
LGG	cis	rs209489	0.892	rs17544464	chr6:53148019	T/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs10267417	0.603	rs4721836	chr7:19910497	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	7.89	0.34	2.19e-14	Night sleep phenotypes;
LGG	cis	rs5769707	0.656	rs135875	chr22:50012419	T/G	cg06623630	chr22:50017776	C22orf34	-0.47	-9.57	-0.41	6.62e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7267979	0.903	rs6050481	chr20:25224580	C/T	cg08601574	chr20:25228251	PYGB	0.33	6.71	0.3	5.85e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9486719	1.000	rs11153070	chr6:97039720	C/G	cg06623918	chr6:96969491	KIAA0776	-0.73	-9.7	-0.41	2.29e-20	Migraine;Coronary artery disease;
LGG	cis	rs2652834	0.507	rs7175973	chr15:63425027	T/A	cg05507819	chr15:63340323	TPM1	0.52	7.29	0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs8067545	0.750	rs918228	chr17:20002012	C/T	cg09818912	chr17:20140352	CYTSB	-0.3	-6.93	-0.31	1.43e-11	Schizophrenia;
LGG	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.74	-0.38	4.27e-17	Aortic root size;
LGG	cis	rs858239	0.601	rs10255228	chr7:23158863	G/T	cg23682824	chr7:23144976	KLHL7	0.45	7.53	0.33	2.75e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6032067	0.561	rs2741502	chr20:43936265	C/T	cg10761708	chr20:43804764	PI3	0.53	8.23	0.36	1.98e-15	Blood protein levels;
LGG	cis	rs1865760	0.516	rs9393683	chr6:26066198	A/G	cg12310025	chr6:25882481	NA	-0.38	-6.74	-0.3	4.72e-11	Height;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg11473876	chr11:109292803	C11orf87	0.48	9.59	0.41	5.46e-20	Schizophrenia;
LGG	cis	rs4819052	0.851	rs8126930	chr21:46671715	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.68	12.18	0.49	8.51e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs6088590	0.561	rs3891369	chr20:33161127	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.6	0.37	1.27e-16	Coronary artery disease;
LGG	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.62e-14	Testicular germ cell tumor;
LGG	cis	rs10540	0.908	rs1044707	chr11:491334	G/T	cg03352830	chr11:487213	PTDSS2	-0.87	-11.74	-0.48	4.97e-28	Body mass index;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.16	-0.7	5.18e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg21775007	chr8:11205619	TDH	-0.45	-7.48	-0.33	3.69e-13	Neuroticism;
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.95	-0.31	1.21e-11	Height;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg07701084	chr6:150067640	NUP43	0.68	13.1	0.52	1.4e-33	Lung cancer;
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg24687543	chr11:63912206	MACROD1	0.63	8.84	0.38	2.07e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21517261	chr7:38217791	STARD3NL	0.49	7.93	0.35	1.66e-14	Gut microbiome composition (summer);
LGG	cis	rs11245387	0.564	rs7915429	chr10:126510089	T/C	cg08799069	chr10:126477246	METTL10	-0.63	-11.91	-0.48	1.07e-28	Response to bronchodilator in chronic obstructive pulmonary disease (change in FEV1);
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.51	-7.03	-0.31	7.46e-12	Response to haloperidol in psychosis;
LGG	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg16586182	chr3:47516702	SCAP	0.73	13.09	0.52	1.6e-33	Colorectal cancer;
LGG	cis	rs1461503	0.966	rs10790547	chr11:122842110	T/A	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs4975616	0.714	rs37007	chr5:1352372	G/C	cg06550200	chr5:1325588	CLPTM1L	-0.54	-9.21	-0.39	1.15e-18	Lung cancer;
LGG	cis	rs7843479	0.582	rs7009693	chr8:21775314	C/T	cg17168535	chr8:21777572	XPO7	0.75	14.73	0.56	1.53e-40	Mean corpuscular volume;
LGG	cis	rs4604732	0.536	rs4433437	chr1:247636580	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	10.5	0.44	2.91e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs8067545	0.641	rs203455	chr17:19821185	A/G	cg13482628	chr17:19912719	NA	0.52	9.53	0.4	8.89e-20	Schizophrenia;
LGG	cis	rs4330281	0.647	rs17043541	chr3:17426846	T/C	cg20981856	chr3:17787350	NA	0.36	6.77	0.3	3.93e-11	Schizophrenia;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg15971980	chr6:150254442	NA	0.46	8.74	0.38	4.34e-17	Lung cancer;
LGG	cis	rs1451375	0.617	rs10277662	chr7:50594836	C/T	cg14593290	chr7:50529359	DDC	0.64	11.7	0.48	6.84e-28	Malaria;
LGG	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg03264133	chr6:25882463	NA	-0.47	-7.45	-0.33	4.54e-13	Iron status biomarkers;
LGG	cis	rs17253792	0.822	rs80328469	chr14:56067701	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs9815354	0.812	rs73069203	chr3:41938767	T/C	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.11e-49	Obesity-related traits;
LGG	cis	rs9858542	0.537	rs9873994	chr3:49359943	T/C	cg03060546	chr3:49711283	APEH	-0.53	-7.07	-0.31	5.6e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4132509	0.739	rs10927033	chr1:243695539	C/A	cg21452805	chr1:244014465	NA	0.86	8.12	0.35	4.36e-15	RR interval (heart rate);
LGG	cis	rs3785574	0.962	rs2584623	chr17:61906679	G/A	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg20003494	chr4:90757398	SNCA	-0.44	-8.77	-0.38	3.47e-17	Dementia with Lewy bodies;
LGG	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg19338460	chr6:170058176	WDR27	-0.6	-8.11	-0.35	4.59e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg06606381	chr12:133084897	FBRSL1	-0.95	-9.3	-0.4	5.38e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12999616	1.000	rs12999616	chr2:98324381	C/T	cg26665480	chr2:98280029	ACTR1B	0.68	9.64	0.41	3.8e-20	Colorectal cancer;
LGG	cis	rs8060686	0.641	rs113704872	chr16:68032598	G/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-6.92	-0.31	1.51e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs75920871	0.588	rs7119185	chr11:116886096	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-8.34	-0.36	8.4e-16	Subjective well-being;
LGG	cis	rs17428076	0.709	rs55791993	chr2:172911712	A/G	cg21435375	chr2:172878103	MAP1D	0.46	9.74	0.41	1.66e-20	Myopia;
LGG	cis	rs7508	0.618	rs13266287	chr8:17871598	T/A	cg18067069	chr8:17937731	ASAH1	-0.3	-6.69	-0.3	6.57e-11	Atrial fibrillation;
LGG	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg08305652	chr11:111469057	NA	-0.45	-8.92	-0.38	1.08e-17	Primary sclerosing cholangitis;
LGG	cis	rs1570884	0.516	rs9535268	chr13:50175478	C/A	cg03651054	chr13:50194643	NA	0.3	6.75	0.3	4.31e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs55665837	1.000	rs10832269	chr11:14465069	C/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.74	-0.38	4.34e-17	Vitamin D levels;
LGG	cis	rs9397585	0.857	rs9397579	chr6:153368062	G/T	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs13191362	0.935	rs34709632	chr6:163048380	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.15	0.32	3.39e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg06636001	chr8:8085503	FLJ10661	0.43	7.43	0.33	5.29e-13	Neuroticism;
LGG	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg21095983	chr6:86352623	SYNCRIP	0.58	10.77	0.45	2.65e-24	Smooth-surface caries;
LGG	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.22e-18	Blood metabolite levels;
LGG	cis	rs7973719	0.899	rs12424618	chr12:7344802	A/G	cg07052231	chr12:7363540	PEX5	0.38	6.7	0.3	6.07e-11	IgG glycosylation;
LGG	cis	rs4478858	0.735	rs7526095	chr1:31797581	C/T	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg13395646	chr4:1353034	KIAA1530	-0.63	-11.06	-0.46	2.21e-25	Obesity-related traits;
LGG	trans	rs9929218	0.551	rs2296409	chr16:68713730	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.13	31.44	0.83	6.03e-117	Colorectal cancer;
LGG	cis	rs12220238	1.000	rs1908331	chr10:75885817	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.72	0.48	6.04e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg04455712	chr21:45112962	RRP1B	0.5	9.42	0.4	2.18e-19	Mean corpuscular volume;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.09	-0.39	2.92e-18	Prostate cancer;
LGG	cis	rs9650657	0.590	rs10096777	chr8:10518500	G/A	cg21775007	chr8:11205619	TDH	-0.42	-6.78	-0.3	3.73e-11	Neuroticism;
LGG	cis	rs2842992	0.747	rs733319	chr6:160221475	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.83	0.34	3.41e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs75920871	0.925	rs61903417	chr11:116956157	T/G	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs57920188	0.584	rs12080516	chr1:4089613	C/T	cg20703997	chr1:4087676	NA	0.49	7.21	0.32	2.33e-12	Interleukin-17 levels;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg23939001	chr4:940644	TMEM175	0.72	18.27	0.65	1.53e-56	Sjögren's syndrome;
LGG	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg14088196	chr11:70211408	PPFIA1	0.94	13.16	0.52	7.85e-34	Coronary artery disease;
LGG	cis	rs61931739	0.500	rs56404399	chr12:34543101	A/G	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs7241530	0.610	rs7235050	chr18:75893094	A/C	cg14642773	chr18:75888474	NA	0.49	9.17	0.39	1.5e-18	Educational attainment (years of education);
LGG	cis	rs3008870	0.727	rs4582760	chr1:67464394	G/A	cg02640540	chr1:67518911	SLC35D1	-0.39	-7.79	-0.34	4.51e-14	Lymphocyte percentage of white cells;
LGG	cis	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg07636037	chr3:49044803	WDR6	-0.54	-7.23	-0.32	2.06e-12	Menarche (age at onset);
LGG	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-10.98	-0.45	4.32e-25	Bronchopulmonary dysplasia;
LGG	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg07080220	chr10:102295463	HIF1AN	-0.72	-12.04	-0.49	3.22e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4740619	0.819	rs954663	chr9:15695533	C/G	cg14451791	chr9:16040625	NA	0.33	8.32	0.36	1.03e-15	Body mass index;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg00684032	chr4:1343700	KIAA1530	0.65	13.35	0.53	1.29e-34	Obesity-related traits;
LGG	cis	rs4321325	0.733	rs79995601	chr2:127947452	T/C	cg11380483	chr2:127933992	NA	0.63	8.89	0.38	1.35e-17	Protein C levels;
LGG	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	9.63	0.41	3.82e-20	Menarche (age at onset);
LGG	cis	rs6088580	0.524	rs6087616	chr20:33263033	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.06	-0.31	6.11e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs17776563	0.853	rs72763825	chr15:89149872	A/G	cg05013243	chr15:89149849	MIR1179	-0.51	-10.53	-0.44	2.13e-23	Thyroid hormone levels;
LGG	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.33	-0.4	4.42e-19	Triglycerides;
LGG	cis	rs889398	0.802	rs12925700	chr16:69793463	C/A	cg00738113	chr16:70207722	CLEC18C	0.25	6.98	0.31	1.03e-11	Body mass index;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.79e-31	Lymphocyte counts;
LGG	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	8.01	0.35	9.54e-15	Mood instability;
LGG	cis	rs1949733	0.675	rs2688219	chr4:8444631	T/C	cg11789530	chr4:8429930	ACOX3	0.73	14.53	0.56	1.16e-39	Response to antineoplastic agents;
LGG	cis	rs16912285	0.688	rs12277966	chr11:24286633	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	12.66	0.51	9.47e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg11814155	chr7:99998594	ZCWPW1	0.62	9.49	0.4	1.22e-19	Platelet count;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	trans	rs1422110	0.879	rs1363268	chr5:85469695	C/T	cg01787110	chr1:109008453	NBPF6	-0.68	-11.06	-0.46	2.22e-25	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs798554	0.704	rs798513	chr7:2782493	C/T	cg27476859	chr7:2772710	GNA12	0.53	10.4	0.44	6.52e-23	Height;
LGG	cis	rs6456156	0.586	rs6456149	chr6:167463902	T/C	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg10621924	chr7:39171070	POU6F2	0.48	9.92	0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.0	-0.31	8.82e-12	Prostate cancer;
LGG	trans	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg26043149	chr18:55253948	FECH	0.95	16.63	0.61	5.01e-49	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.31	-0.36	1.06e-15	Lymphocyte counts;
LGG	cis	rs6580649	0.882	rs2286022	chr12:48436647	G/A	cg24011408	chr12:48396354	COL2A1	-0.57	-6.92	-0.31	1.49e-11	Lung cancer;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg19147804	chr7:1989927	MAD1L1	-0.61	-12.26	-0.5	4.07e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg25319279	chr11:5960081	NA	-0.48	-8.05	-0.35	6.99e-15	DNA methylation (variation);
LGG	cis	rs209489	0.681	rs1469475	chr6:53114498	C/T	cg15607103	chr6:53167650	ELOVL5	-0.59	-7.31	-0.32	1.21e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg00666640	chr1:248458726	OR2T12	0.54	8.7	0.37	5.81e-17	Common traits (Other);
LGG	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg02574844	chr11:5959923	NA	0.48	7.76	0.34	5.46e-14	DNA methylation (variation);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18106800	chr5:94890715	ARSK;TTC37	0.5	8.03	0.35	8.05e-15	Cognitive performance;
LGG	cis	rs9463078	0.605	rs9472416	chr6:44950963	T/C	cg25276700	chr6:44698697	NA	0.35	7.19	0.32	2.58e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2749592	0.550	rs7917262	chr10:37874602	A/C	cg25427524	chr10:38739819	LOC399744	0.46	8.82	0.38	2.3e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs9951602	0.512	rs8089247	chr18:76651467	C/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs752010	0.808	rs7529858	chr1:42086606	G/C	cg16096631	chr1:42092165	HIVEP3	0.76	22.31	0.72	2.03e-75	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21659725	chr3:3221576	CRBN	-0.66	-10.7	-0.45	4.92e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg16301924	chr13:53314226	LECT1	-0.44	-8.42	-0.36	4.71e-16	Lewy body disease;
LGG	cis	rs72634258	0.554	rs12061787	chr1:7888730	G/C	cg26816564	chr1:7831052	VAMP3	0.79	11.5	0.47	4.1e-27	Inflammatory bowel disease;
LGG	cis	rs926392	0.965	rs6129166	chr20:37688825	T/C	cg16355469	chr20:37678765	NA	0.41	6.74	0.3	4.72e-11	Dialysis-related mortality;
LGG	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.15	0.52	9.13e-34	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.7	-0.34	8.52e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.05	0.39	4.03e-18	Motion sickness;
LGG	cis	rs787274	0.850	rs4978510	chr9:115643795	C/G	cg13803584	chr9:115635662	SNX30	0.57	6.67	0.3	7.25e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg13264159	chr8:625131	ERICH1	0.97	11.09	0.46	1.65e-25	IgG glycosylation;
LGG	cis	rs8064024	0.604	rs1049212	chr16:4932929	A/G	cg04440724	chr16:4920505	UBN1	0.56	12.03	0.49	3.31e-29	Cancer;
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg17376030	chr22:41985996	PMM1	0.53	8.35	0.36	7.94e-16	Vitiligo;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.35	-0.43	1.03e-22	Tonsillectomy;
LGG	cis	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg21775007	chr8:11205619	TDH	0.83	15.09	0.57	3.75e-42	Retinal vascular caliber;
LGG	cis	rs9462027	0.675	rs9296132	chr6:34777531	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.3	-0.46	2.64e-26	Systemic lupus erythematosus;
LGG	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg03162506	chr22:38580953	NA	-0.35	-8.39	-0.36	6.06e-16	Cutaneous nevi;
LGG	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg02187348	chr16:89574699	SPG7	0.57	9.62	0.41	4.37e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs3008870	1.000	rs12041926	chr1:67434602	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.96	23.22	0.73	1.11e-79	Lymphocyte percentage of white cells;
LGG	cis	rs752010	0.841	rs17363834	chr1:42076607	C/T	cg16096631	chr1:42092165	HIVEP3	0.71	19.11	0.66	1.86e-60	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05013783	chr12:56652058	ANKRD52	0.53	8.34	0.36	8.56e-16	Gut microbiome composition (summer);
LGG	cis	rs10779751	0.922	rs4845985	chr1:11288618	G/A	cg08854313	chr1:11322531	MTOR	0.73	16.07	0.6	1.7e-46	Body mass index;
LGG	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg07777115	chr5:623756	CEP72	-0.61	-7.68	-0.34	9.76e-14	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs7185899	chr16:48714101	A/G	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.82	13.38	0.53	9.6e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg26384229	chr12:38710491	ALG10B	0.79	16.37	0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg27490568	chr2:178487706	NA	0.54	10.75	0.45	3.33e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs853679	0.607	rs66868086	chr6:27865902	A/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.59	-0.47	1.84e-27	Depression;
LGG	cis	rs1555322	0.530	rs2250205	chr20:33867924	C/T	cg03689076	chr20:33865952	NA	0.61	8.21	0.36	2.3e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs2669010	1.000	rs1512501	chr12:76964435	A/T	cg14998926	chr12:77026162	NA	0.39	7.02	0.31	8.05e-12	Systemic lupus erythematosus;
LGG	trans	rs7208859	0.673	rs216440	chr17:28928309	A/T	cg22358067	chr17:16797159	NA	-0.51	-7.22	-0.32	2.14e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg08508325	chr11:3079039	CARS	0.44	9.11	0.39	2.44e-18	Calcium levels;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs4950322	0.542	rs4950384	chr1:146648889	G/C	cg22381352	chr1:146742008	CHD1L	-0.46	-7.7	-0.34	8.07e-14	Protein quantitative trait loci;
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.34	-0.36	8.8e-16	Myopia (pathological);
LGG	trans	rs7395662	1.000	rs10838971	chr11:48606624	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.02e-12	HDL cholesterol;
LGG	cis	rs908922	0.651	rs1572534	chr1:152509689	G/A	cg09873164	chr1:152488093	CRCT1	0.64	16.05	0.6	2.1e-46	Hair morphology;
LGG	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg17145862	chr1:211918768	LPGAT1	0.8	17.3	0.63	4.62e-52	Leprosy;
LGG	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg13798912	chr7:905769	UNC84A	0.57	7.08	0.31	5.51e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs1552244	0.572	rs59074548	chr3:10164347	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.03	0.57	7.39e-42	Alzheimer's disease;
LGG	cis	rs4959677	0.725	rs1772976	chr6:2503335	C/T	cg20147862	chr6:2634573	C6orf195	-0.38	-8.42	-0.36	4.69e-16	Orthostatic hypotension;
LGG	cis	rs1915146	0.901	rs6597884	chr10:126851174	T/C	cg23000734	chr10:126850823	CTBP2	0.31	9.38	0.4	2.95e-19	Menarche (age at onset);
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06850241	chr22:41845214	NA	-0.44	-6.79	-0.3	3.55e-11	Vitiligo;
LGG	cis	rs2204008	0.774	rs7305085	chr12:38263511	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs908922	0.676	rs4845788	chr1:152519496	T/C	cg03606772	chr1:152487856	CRCT1	0.3	7.11	0.31	4.39e-12	Hair morphology;
LGG	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2658782	0.724	rs2658770	chr11:93261886	A/G	cg15737290	chr11:93063684	CCDC67	0.47	6.88	0.3	1.99e-11	Pulmonary function decline;
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs854765	0.964	rs854764	chr17:18011750	A/G	cg04398451	chr17:18023971	MYO15A	0.66	13.77	0.54	2.21e-36	Total body bone mineral density;
LGG	cis	rs12908161	1.000	rs58416181	chr15:85264461	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.22	0.32	2.15e-12	Schizophrenia;
LGG	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg18198730	chr1:247681584	NA	0.72	12.1	0.49	1.84e-29	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2011503	1.000	rs8105642	chr19:19558468	G/A	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.58e-12	Life satisfaction;
LGG	cis	rs4821897	0.514	rs739141	chr22:39824450	A/G	cg04986931	chr22:39850128	NA	-0.32	-7.45	-0.33	4.61e-13	IgG glycosylation;
LGG	cis	rs4509693	0.843	rs4403743	chr10:102496740	A/C	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.2e-31	Prostate cancer;
LGG	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg00149659	chr3:10157352	C3orf10	-0.57	-8.18	-0.36	2.78e-15	Alzheimer's disease;
LGG	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08045932	chr20:61659980	NA	0.6	13.07	0.52	1.92e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg15485101	chr11:133734466	NA	0.46	7.91	0.34	1.98e-14	Childhood ear infection;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22068764	chr1:170501645	GORAB	0.39	6.83	0.3	2.69e-11	Body mass index;
LGG	cis	rs4742903	0.935	rs1507507	chr9:106949429	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.05	0.35	7.19e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4819388	0.915	rs4818892	chr21:45650085	A/G	cg01992765	chr21:45622493	NA	-0.44	-8.38	-0.36	6.27e-16	Celiac disease;
LGG	cis	rs7827545	1.000	rs6578235	chr8:135568022	C/T	cg17885191	chr8:135476712	NA	0.42	6.67	0.3	7.13e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs593982	0.858	rs537385	chr11:65504900	G/A	cg08755490	chr11:65554678	OVOL1	0.76	11.96	0.49	6.34e-29	Atopic dermatitis;
LGG	trans	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg06875740	chr19:51307921	C19orf48	-0.67	-8.34	-0.36	8.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2373794	0.614	rs400673	chr2:40379276	T/C	cg17740179	chr2:40377776	SLC8A1	0.76	9.62	0.41	4.33e-20	Asthma;
LGG	cis	rs861020	0.677	rs12723578	chr1:210032392	G/A	cg05527609	chr1:210001259	C1orf107	-0.71	-10.32	-0.43	1.33e-22	Orofacial clefts;
LGG	cis	rs666930	1.000	rs666930	chr1:120258970	A/G	cg19096424	chr1:120255104	PHGDH	0.49	9.08	0.39	3.17e-18	Breast cancer;
LGG	trans	rs9467711	0.606	rs12174623	chr6:26373086	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20824237	chr3:99979579	TBC1D23	0.48	7.64	0.33	1.27e-13	Gut microbiome composition (summer);
LGG	cis	rs6466055	0.777	rs3801278	chr7:104907017	C/T	cg04380332	chr7:105027541	SRPK2	0.37	6.98	0.31	1.05e-11	Schizophrenia;
LGG	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg06212747	chr3:49208901	KLHDC8B	0.72	12.37	0.5	1.4e-30	Parkinson's disease;
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.36e-26	Personality dimensions;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg05863683	chr7:1912471	MAD1L1	-0.43	-8.79	-0.38	3.01e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg22875332	chr1:76189707	ACADM	0.57	9.4	0.4	2.43e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs713587	0.520	rs512419	chr2:25310155	G/T	cg04586622	chr2:25135609	ADCY3	-0.31	-7.9	-0.34	2.03e-14	Body mass index in non-asthmatics;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.05	0.52	2.31e-33	Obesity-related traits;
LGG	cis	rs142518269	1	rs142518269	chr2:24087095	G/A	cg08917208	chr2:24149416	ATAD2B	0.91	9.66	0.41	3.05e-20	Mean corpuscular hemoglobin;
LGG	trans	rs57046232	0.552	rs2009127	chr20:6341680	C/T	cg21095983	chr6:86352623	SYNCRIP	0.41	6.92	0.31	1.51e-11	Colorectal cancer;
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9649465	0.967	rs12531955	chr7:123377066	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.92	-0.38	1.09e-17	Migraine;
LGG	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg05692746	chr2:100937584	LONRF2	0.45	7.59	0.33	1.72e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs9309711	0.544	rs9309712	chr2:3491327	G/T	cg15506890	chr2:3487001	NA	-0.55	-10.74	-0.45	3.43e-24	Neurofibrillary tangles;
LGG	cis	rs977987	0.815	rs11861810	chr16:75461829	A/G	cg03315344	chr16:75512273	CHST6	0.5	9.93	0.42	3.42e-21	Dupuytren's disease;
LGG	cis	rs8114671	0.662	rs6058146	chr20:33540529	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	7.45	0.33	4.76e-13	Height;
LGG	cis	rs933688	0.938	rs10063683	chr5:90714595	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.0	-0.35	1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9878978	0.964	rs79638226	chr3:2493146	G/C	cg21928760	chr3:2462534	CNTN4	0.4	8.91	0.38	1.18e-17	Blood pressure (smoking interaction);
LGG	cis	rs1707322	0.896	rs946528	chr1:46485562	C/T	cg03146154	chr1:46216737	IPP	-0.53	-9.96	-0.42	2.56e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1997103	1.000	rs4590393	chr7:55408990	C/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg27661571	chr11:113659931	NA	-0.69	-9.57	-0.41	6.32e-20	Hip circumference adjusted for BMI;
LGG	cis	rs10654220	1	rs10654220	chr12:123703422	A/AGTT	cg00376283	chr12:123451042	ABCB9	0.62	9.45	0.4	1.73e-19	Platelet count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01010781	chr7:44622047	TMED4	-0.48	-7.27	-0.32	1.52e-12	Systemic lupus erythematosus;
LGG	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg26384229	chr12:38710491	ALG10B	0.99	23.11	0.73	3.83e-79	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2635047	0.615	rs2576052	chr18:44690107	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-6.9	-0.31	1.69e-11	Educational attainment;
LGG	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg20821713	chr7:1055600	C7orf50	-0.54	-8.17	-0.36	2.89e-15	Bronchopulmonary dysplasia;
LGG	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg16096631	chr1:42092165	HIVEP3	0.55	12.47	0.5	5.77e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6831352	0.918	rs2602893	chr4:100044095	G/T	cg13256891	chr4:100009986	ADH5	0.57	9.72	0.41	1.87e-20	Alcohol dependence;
LGG	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13191362	1.000	rs34918316	chr6:163005386	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10193935	0.901	rs10174872	chr2:42459807	T/G	cg27598129	chr2:42591480	NA	-0.64	-9.53	-0.41	8.55e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.13	-0.55	6.27e-38	Alzheimer's disease;
LGG	cis	rs7524258	0.868	rs2412152	chr1:7303213	C/T	cg07173049	chr1:7289937	CAMTA1	0.79	18.68	0.66	1.81e-58	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg27476859	chr7:2772710	GNA12	0.51	10.13	0.43	6.19e-22	Height;
LGG	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02251663	chr11:14281053	SPON1	0.33	8.29	0.36	1.23e-15	Mitochondrial DNA levels;
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18252515	chr7:66147081	NA	0.42	7.03	0.31	7.26e-12	Aortic root size;
LGG	cis	rs1461503	0.868	rs10790543	chr11:122838311	A/C	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.87e-16	Lung cancer;
LGG	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.95	-16.61	-0.61	6.02e-49	Chronic sinus infection;
LGG	cis	rs12738007	0.840	rs1565714	chr1:29574363	C/T	cg11747820	chr1:29584023	PTPRU	-0.4	-9.01	-0.39	5.28e-18	Schizophrenia;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg11301795	chr4:187892539	NA	-0.94	-24.15	-0.75	5.55e-84	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10876993	0.928	rs2640631	chr12:58067532	A/T	cg18357645	chr12:58087776	OS9	0.67	12.34	0.5	1.98e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs4742903	0.967	rs4743690	chr9:106909577	T/C	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.18e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg20848291	chr7:100343083	ZAN	-0.69	-10.19	-0.43	3.83e-22	Other erythrocyte phenotypes;
LGG	cis	rs9583531	0.600	rs9555726	chr13:111368316	C/T	cg24331049	chr13:111365604	ING1	0.82	14.77	0.57	9.98e-41	Coronary artery disease;
LGG	trans	rs7395662	0.929	rs10838956	chr11:48581765	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs4664304	0.900	rs3828327	chr2:160742095	G/A	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.21	-0.32	2.3e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs300774	0.925	rs300735	chr2:167739	C/G	cg04617936	chr2:214353	NA	-0.44	-6.73	-0.3	5.11e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs72781680	1.000	rs72781658	chr2:24220141	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.73	0.41	1.74e-20	Lymphocyte counts;
LGG	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.91e-11	Aortic root size;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg14004847	chr7:1930337	MAD1L1	0.52	8.99	0.39	6.23e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.33	0.43	1.19e-22	Diabetic retinopathy;
LGG	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg13482628	chr17:19912719	NA	0.53	10.1	0.42	8.58e-22	Schizophrenia;
LGG	cis	rs10463554	0.926	rs5855	chr5:102365186	G/A	cg23492399	chr5:102201601	PAM	0.46	6.91	0.31	1.6e-11	Parkinson's disease;
LGG	cis	rs28655083	0.509	rs285024	chr16:77099844	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.93	0.31	1.39e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.58	9.94	0.42	3.05e-21	Bipolar disorder;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.2	-0.52	5.62e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs763121	0.853	rs4821798	chr22:39021165	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.71	0.3	5.79e-11	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg12708336	chr17:41446283	NA	-0.31	-7.01	-0.31	8.39e-12	Menopause (age at onset);
LGG	cis	rs3820068	0.581	rs74054797	chr1:15926217	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs9309473	0.950	rs73947808	chr2:73721250	A/C	cg20560298	chr2:73613845	ALMS1	-0.49	-8.05	-0.35	7.16e-15	Metabolite levels;
LGG	cis	rs6460942	1.000	rs111761262	chr7:12415916	T/C	cg06484146	chr7:12443880	VWDE	-0.39	-6.77	-0.3	3.97e-11	Coronary artery disease;
LGG	cis	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg21775007	chr8:11205619	TDH	-0.6	-9.94	-0.42	3.18e-21	Retinal vascular caliber;
LGG	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg02002194	chr4:3960332	NA	0.38	6.83	0.3	2.69e-11	Triglycerides;
LGG	cis	rs2070488	0.965	rs13093640	chr3:38487176	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.03	0.64	1.83e-55	Electrocardiographic conduction measures;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg03709012	chr19:19516395	GATAD2A	0.82	15.85	0.59	1.59e-45	Tonsillectomy;
LGG	cis	rs2298450	0.550	rs2156416	chr21:37661913	A/G	cg02919814	chr21:37666008	DOPEY2	-0.45	-9.02	-0.39	5.05e-18	Schizophrenia;
LGG	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.97	-0.7	3.95e-69	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.673	rs11654331	chr17:29165017	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.11	-0.31	4.44e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7558370	0.737	rs112914737	chr2:3713431	G/A	cg17046650	chr2:3699563	NA	0.91	8.84	0.38	2.04e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg23758822	chr17:41437982	NA	0.88	15.69	0.59	8.2e-45	Menopause (age at onset);
LGG	cis	rs9467773	1.000	rs6903973	chr6:26499942	C/A	cg09904177	chr6:26538194	HMGN4	0.77	17.32	0.63	3.55e-52	Intelligence (multi-trait analysis);
LGG	cis	rs6580649	0.825	rs4760611	chr12:48421449	A/G	cg24011408	chr12:48396354	COL2A1	0.56	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs7762018	0.891	rs73242950	chr6:170144737	C/T	cg17545662	chr6:170176663	C6orf70	0.67	8.7	0.37	5.76e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg07332563	chr6:291687	DUSP22	-0.6	-9.92	-0.42	3.77e-21	Menopause (age at onset);
LGG	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.83	0.54	1.14e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.962	rs5009868	chr1:248474495	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.81	-0.41	9.34e-21	Common traits (Other);
LGG	cis	rs4356203	0.905	rs214937	chr11:17189552	T/C	cg15432903	chr11:17409602	KCNJ11	0.38	7.18	0.32	2.73e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg07519485	chr6:33762594	MLN	0.3	6.85	0.3	2.4e-11	Crohn's disease;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.53	-0.53	2.13e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1669338	0.588	rs3864049	chr3:3186719	T/G	cg16797762	chr3:3221439	CRBN	-0.98	-13.07	-0.52	1.89e-33	White matter integrity;
LGG	cis	rs17102423	0.530	rs4902359	chr14:65542790	G/A	cg11161011	chr14:65562177	MAX	-0.63	-12.33	-0.5	2.02e-30	Obesity-related traits;
LGG	cis	rs977987	0.864	rs37595	chr16:75496963	G/C	cg03315344	chr16:75512273	CHST6	-0.57	-11.16	-0.46	8.79e-26	Dupuytren's disease;
LGG	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg20991723	chr1:152506922	NA	-0.7	-14.12	-0.55	6.56e-38	Hair morphology;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs4917300	0.606	rs5003835	chr8:143103240	C/G	cg26003909	chr8:143102224	NA	-0.34	-6.76	-0.3	4.07e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs9914988	0.887	rs2070265	chr17:27075423	A/G	cg20469991	chr17:27169893	C17orf63	0.59	7.28	0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs12286929	0.515	rs6589486	chr11:115084297	T/C	cg04055981	chr11:115044050	NA	0.37	6.89	0.31	1.79e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg27119904	chr13:114814333	RASA3	0.36	7.57	0.33	2.04e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs7582180	0.903	rs2309821	chr2:100900304	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-9.34	-0.4	3.96e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6568686	0.679	rs7776184	chr6:111809918	G/A	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs7524258	0.900	rs12035586	chr1:7273020	C/T	cg07173049	chr1:7289937	CAMTA1	-0.66	-16.16	-0.6	6.47e-47	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg05535760	chr7:792225	HEATR2	0.79	12.69	0.51	6.94e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg12395012	chr8:11607386	GATA4	0.41	7.39	0.32	6.93e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4936894	0.500	rs7931968	chr11:124134686	C/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.43	-0.44	5.1e-23	Aging (time to death);
LGG	cis	rs72781680	0.784	rs12616678	chr2:24181159	G/T	cg08917208	chr2:24149416	ATAD2B	0.65	8.67	0.37	7.24e-17	Lymphocyte counts;
LGG	cis	rs9473924	0.542	rs9473922	chr6:50831792	C/T	cg14470998	chr6:50812995	TFAP2B	0.68	8.13	0.35	3.95e-15	Body mass index;
LGG	cis	rs924607	1.000	rs924607	chr5:610093	C/T	cg09021430	chr5:549028	NA	0.54	10.41	0.44	6.24e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs9910055	0.529	rs2523161	chr17:42179405	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.47	-0.33	4.11e-13	Total body bone mineral density;
LGG	cis	rs11650494	0.710	rs8065814	chr17:47470720	T/C	cg08112188	chr17:47440006	ZNF652	1.2	13.15	0.52	8.93e-34	Prostate cancer;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg12708336	chr17:41446283	NA	-0.33	-8.06	-0.35	6.35e-15	Menopause (age at onset);
LGG	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg22563815	chr15:78856949	CHRNA5	0.28	6.88	0.3	1.94e-11	Sudden cardiac arrest;
LGG	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.34	0.55	7.36e-39	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg07677032	chr17:61819896	STRADA	0.66	12.2	0.49	7.3e-30	Prudent dietary pattern;
LGG	cis	rs12447804	0.863	rs12597233	chr16:58100208	A/G	cg03859792	chr16:58121049	NA	-0.49	-7.51	-0.33	2.97e-13	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9487094	0.666	rs9480958	chr6:109754171	A/G	cg01125227	chr6:109776195	MICAL1	-0.39	-6.89	-0.3	1.87e-11	Height;
LGG	cis	rs35110281	0.776	rs9306159	chr21:45061839	G/T	cg04455712	chr21:45112962	RRP1B	0.51	9.6	0.41	5.25e-20	Mean corpuscular volume;
LGG	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.19e-13	HDL cholesterol;
LGG	trans	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg02002194	chr4:3960332	NA	-0.38	-6.81	-0.3	2.98e-11	Retinal vascular caliber;
LGG	cis	rs7851660	0.809	rs12550872	chr9:100653128	G/A	cg13688889	chr9:100608707	NA	-0.64	-12.76	-0.51	3.55e-32	Strep throat;
LGG	cis	rs1862618	0.853	rs252887	chr5:56166188	A/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.55	-0.5	2.69e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.53	-0.44	2.19e-23	IgG glycosylation;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg08219700	chr8:58056026	NA	-0.44	-6.98	-0.31	1.03e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2421770	0.532	rs10768128	chr11:35361518	C/T	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.66	-0.34	1.1e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs17453880	0.929	rs4958570	chr5:152022254	C/G	cg10931792	chr5:152022470	NA	0.4	8.82	0.38	2.41e-17	Subjective well-being;
LGG	trans	rs7618501	1.000	rs1049256	chr3:49763338	T/C	cg21659725	chr3:3221576	CRBN	-0.91	-20.26	-0.69	8.57e-66	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.48	-0.33	3.82e-13	Lung cancer;
LGG	cis	rs9915657	0.773	rs9912974	chr17:70095963	C/T	cg09344028	chr17:70110421	NA	0.59	14.06	0.55	1.25e-37	Thyroid hormone levels;
LGG	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg17376030	chr22:41985996	PMM1	0.54	8.68	0.37	7.01e-17	Vitiligo;
LGG	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg08250081	chr4:10125330	NA	0.65	12.19	0.49	7.96e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg02493740	chr2:85810744	VAMP5	-0.4	-7.26	-0.32	1.6e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-8.02	-0.35	8.47e-15	Subjective well-being;
LGG	cis	rs36051895	0.664	rs3824433	chr9:5113577	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.28	-0.58	5.95e-43	Pediatric autoimmune diseases;
LGG	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg12386194	chr3:101231763	SENP7	0.44	7.8	0.34	4.11e-14	Colorectal cancer;
LGG	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.47	-7.88	-0.34	2.38e-14	Osteoporosis;
LGG	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.4e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg10505658	chr17:80084571	CCDC57	-0.4	-8.1	-0.35	4.77e-15	Life satisfaction;
LGG	cis	rs3096299	0.719	rs2965817	chr16:89513234	C/T	cg06640241	chr16:89574553	SPG7	0.86	16.09	0.6	1.3e-46	Multiple myeloma (IgH translocation);
LGG	cis	rs4566357	0.964	rs2396443	chr2:227921208	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	trans	rs35110281	0.666	rs9977076	chr21:45085829	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.76	0.41	1.37e-20	Mean corpuscular volume;
LGG	cis	rs7932354	0.528	rs11039107	chr11:47157866	G/A	cg03339077	chr11:47165057	C11orf49	0.54	10.3	0.43	1.6e-22	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg13565492	chr6:43139072	SRF	-0.69	-8.52	-0.37	2.22e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs3796352	0.892	rs35076015	chr3:53026366	C/T	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.43e-59	Diabetic kidney disease;
LGG	cis	rs7192750	0.586	rs2018384	chr16:71940825	T/C	cg06353428	chr16:71660113	MARVELD3	0.66	10.57	0.44	1.61e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4888262	0.526	rs4888253	chr16:74583146	C/T	cg01733217	chr16:74700730	RFWD3	0.82	16.38	0.61	6.42e-48	Testicular germ cell tumor;
LGG	cis	rs11758351	1.000	rs75921373	chr6:26191843	C/T	cg06951627	chr6:26196580	NA	0.53	8.06	0.35	6.43e-15	Gout;Renal underexcretion gout;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4262150	0.508	rs2961741	chr5:151919607	T/C	cg12297329	chr5:152029980	NA	-0.65	-11.69	-0.48	7.99e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg03469862	chr11:68924853	NA	0.44	6.79	0.3	3.39e-11	Blond vs. brown hair color;
LGG	cis	rs4077515	0.967	rs3812558	chr9:139269135	A/G	cg21253087	chr9:139290292	SNAPC4	0.35	6.94	0.31	1.3e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg26578617	chr4:90757533	SNCA	-0.47	-9.55	-0.41	7.27e-20	Dementia with Lewy bodies;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg18350739	chr11:68623251	NA	0.54	12.07	0.49	2.27e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.39	-7.0	-0.31	8.76e-12	Schizophrenia;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs603424	0.509	rs598133	chr10:102082245	A/G	cg10365880	chr10:102089681	PKD2L1	0.48	7.09	0.31	5.19e-12	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LGG	trans	rs1459104	0.714	rs67321261	chr11:54911368	A/G	cg03929089	chr4:120376271	NA	0.71	6.96	0.31	1.16e-11	Body mass index;
LGG	cis	rs7633857	0.512	rs745707	chr3:160652672	G/T	cg04691961	chr3:161091175	C3orf57	-0.39	-7.87	-0.34	2.47e-14	Educational attainment (years of education);
LGG	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg18876405	chr7:65276391	NA	-0.65	-11.74	-0.48	4.99e-28	Aortic root size;
LGG	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs4478037	0.822	rs9863331	chr3:33123235	G/T	cg19404215	chr3:33155277	CRTAP	0.74	9.24	0.39	9.27e-19	Major depressive disorder;
LGG	cis	rs2637030	0.559	rs2637024	chr5:52993453	A/G	cg06476337	chr5:52856530	NDUFS4	0.44	6.9	0.31	1.66e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg10664184	chr19:17420304	DDA1	0.55	8.58	0.37	1.48e-16	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25707994	chr7:157129685	DNAJB6	0.47	8.19	0.36	2.54e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs68170813	0.559	rs76208112	chr7:106964222	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.4	-0.44	6.5e-23	Coronary artery disease;
LGG	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.63e-22	Schizophrenia;
LGG	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg12011299	chr4:100065546	ADH4	-0.43	-8.61	-0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs12348691	0.503	rs10983975	chr9:100614188	A/C	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs751728	1.000	rs2395449	chr6:33728755	T/A	cg25922239	chr6:33757077	LEMD2	0.66	11.3	0.46	2.64e-26	Crohn's disease;
LGG	cis	rs7474896	0.537	rs1779068	chr10:38250785	G/A	cg00409905	chr10:38381863	ZNF37A	0.46	6.73	0.3	5.18e-11	Obesity (extreme);
LGG	cis	rs989128	0.600	rs2240218	chr17:48630580	A/T	cg20467136	chr17:48638190	CACNA1G	0.46	6.92	0.31	1.48e-11	Type 2 diabetes;
LGG	cis	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	10.05	0.42	1.25e-21	Joint mobility (Beighton score);
LGG	cis	rs11605924	0.934	rs7945565	chr11:45878992	A/G	ch.11.939596F	chr11:45881766	CRY2	-0.53	-8.77	-0.38	3.46e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6582630	0.555	rs10880421	chr12:38423015	C/T	cg13010199	chr12:38710504	ALG10B	0.72	14.74	0.57	1.32e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg00490583	chr16:1843685	IGFALS	0.41	7.13	0.31	3.86e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs57221529	0.766	rs17497684	chr5:558307	T/C	cg11887960	chr12:57824829	NA	0.58	7.02	0.31	8.03e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9463078	0.817	rs3799967	chr6:44798701	A/G	cg25276700	chr6:44698697	NA	-0.41	-8.71	-0.38	5.35e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg16141378	chr3:129829833	LOC729375	-0.5	-12.16	-0.49	1.07e-29	Systolic blood pressure;
LGG	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	trans	rs7980799	0.649	rs11559754	chr12:33649229	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-7.99	-0.35	1.1e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg11360546	chr7:1094263	C7orf50	-0.38	-6.82	-0.3	2.85e-11	Longevity;Endometriosis;
LGG	cis	rs9326248	0.581	rs10892048	chr11:116814596	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.73	0.45	3.76e-24	Blood protein levels;
LGG	cis	rs11250098	0.583	rs66724331	chr8:10789345	C/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.01	-0.31	8.47e-12	Morning vs. evening chronotype;
LGG	cis	rs12482904	0.836	rs9981704	chr21:43831955	C/T	cg23042151	chr21:43824109	UBASH3A	-0.42	-7.19	-0.32	2.57e-12	Vitiligo;
LGG	cis	rs72772090	0.539	rs17405676	chr5:96182615	C/T	cg00188032	chr5:96141721	ERAP1	0.56	7.29	0.32	1.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg05484376	chr2:27715224	FNDC4	0.43	9.43	0.4	1.99e-19	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.48	0.4	1.28e-19	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10387901	chr3:15106641	MRPS25	0.48	7.33	0.32	1.03e-12	Gut microbiome composition (summer);
LGG	cis	rs4356932	1.000	rs6532142	chr4:76970905	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	7.05e-11	Blood protein levels;
LGG	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg05234568	chr11:5960015	NA	-0.62	-10.06	-0.42	1.17e-21	DNA methylation (variation);
LGG	trans	rs17685	0.753	rs7788763	chr7:75651665	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.04	-24.0	-0.74	2.61e-83	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17284200	chr6:20837097	CDKAL1	0.33	6.81	0.3	3.13e-11	Menarche (age at onset);
LGG	cis	rs1109114	0.844	rs1438688	chr5:148639062	C/T	cg06539116	chr5:148597365	ABLIM3	-0.49	-11.66	-0.48	9.89e-28	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06564818	chr18:33162094	NA	0.45	7.11	0.31	4.52e-12	Cognitive performance;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg02002194	chr4:3960332	NA	0.44	8.44	0.37	4.14e-16	Monocyte count;
LGG	cis	rs4665809	0.590	rs4665321	chr2:26433801	A/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-13.68	-0.54	4.87e-36	Platelet count;
LGG	trans	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg26043149	chr18:55253948	FECH	0.44	7.65	0.33	1.2e-13	Bone mineral density;
LGG	trans	rs6598955	0.671	rs11247884	chr1:26577338	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg16230307	chr14:35515116	FAM177A1	0.58	9.17	0.39	1.51e-18	Psoriasis;
LGG	cis	rs4926611	1.000	rs6685730	chr1:54116788	C/T	cg23596471	chr1:54105337	GLIS1	0.41	8.48	0.37	2.98e-16	Hand grip strength;
LGG	cis	rs2285947	0.967	rs2285944	chr7:21582964	A/T	cg03697024	chr7:21583438	DNAH11	0.34	8.39	0.36	5.76e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.85	-0.3	2.4e-11	Lung cancer;
LGG	cis	rs8180040	1.000	rs807931	chr3:47389317	C/T	cg27129171	chr3:47204927	SETD2	0.8	15.43	0.58	1.24e-43	Colorectal cancer;
LGG	cis	rs10463316	0.779	rs6861968	chr5:150817725	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.06	-0.42	1.15e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg24829409	chr8:58192753	C8orf71	-0.84	-12.98	-0.52	4.58e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg06609049	chr19:2785107	THOP1	-0.94	-15.89	-0.59	1.07e-45	Total cholesterol levels;
LGG	cis	rs8112449	1.000	rs8112449	chr19:10520064	C/T	cg21868191	chr19:10515988	NA	-0.47	-8.21	-0.36	2.2e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs8062405	0.690	rs62034351	chr16:28565489	G/A	cg16576597	chr16:28551801	NUPR1	0.43	10.08	0.42	9.91e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg25482853	chr8:67687455	SGK3	0.84	11.26	0.46	3.79e-26	Obesity-related traits;
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.13	-0.31	3.77e-12	Height;
LGG	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg23752985	chr2:85803571	VAMP8	0.43	8.5	0.37	2.67e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg13607699	chr17:42295918	UBTF	0.64	10.43	0.44	4.94e-23	Total body bone mineral density;
LGG	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23633679	chr1:173793655	CENPL;DARS2	0.36	6.73	0.3	4.93e-11	Obesity-related traits;
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg00761968	chr13:53314142	LECT1	-0.39	-8.57	-0.37	1.54e-16	Lewy body disease;
LGG	cis	rs5750830	0.645	rs4821890	chr22:39777523	G/A	cg11247378	chr22:39784982	NA	-0.31	-8.77	-0.38	3.56e-17	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.623	rs12354710	chr10:1114020	C/T	cg25019033	chr10:957182	NA	-0.51	-8.73	-0.38	4.49e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs12738007	0.967	rs34380016	chr1:29558230	A/G	cg01115565	chr1:29584222	PTPRU	-0.28	-7.44	-0.33	4.8e-13	Schizophrenia;
LGG	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.65	0.3	8.36e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg19399532	chr1:178512495	C1orf220	0.55	10.95	0.45	5.71e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg03188948	chr7:1209495	NA	0.64	8.47	0.37	3.28e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2067615	0.579	rs11113119	chr12:107200056	C/A	cg15890332	chr12:107067104	RFX4	0.4	11.69	0.48	7.89e-28	Heart rate;
LGG	cis	rs7954584	0.635	rs7309024	chr12:122338334	C/T	cg10207240	chr12:122356781	WDR66	0.27	8.26	0.36	1.5e-15	Mean corpuscular volume;
LGG	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs7241530	0.662	rs11081528	chr18:75902453	G/A	cg14642773	chr18:75888474	NA	0.47	9.33	0.4	4.32e-19	Educational attainment (years of education);
LGG	cis	rs910316	1.000	rs3742773	chr14:75579643	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	10.77	0.45	2.69e-24	Height;
LGG	trans	rs2727020	0.755	rs652655	chr11:49251293	G/A	cg00717180	chr2:96193071	NA	0.38	6.68	0.3	6.78e-11	Coronary artery disease;
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.61	-0.47	1.53e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.529	rs7912116	chr10:60335389	G/C	cg07615347	chr10:60278583	BICC1	0.5	12.27	0.5	3.74e-30	Refractive error;
LGG	trans	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.18	-0.62	1.54e-51	Exhaled nitric oxide output;
LGG	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg20913747	chr6:44695427	NA	-0.61	-10.16	-0.43	5.16e-22	Total body bone mineral density;
LGG	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg03806693	chr22:41940476	POLR3H	-1.03	-17.42	-0.63	1.25e-52	Vitiligo;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg01966878	chr4:90757139	SNCA	0.34	7.07	0.31	5.81e-12	Dementia with Lewy bodies;
LGG	cis	rs1318772	1.000	rs34539248	chr5:112697365	T/C	cg12552261	chr5:112820674	MCC	0.71	8.14	0.35	3.63e-15	F-cell distribution;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg05025164	chr4:1340916	KIAA1530	0.66	12.41	0.5	9.5e-31	Longevity;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg04772025	chr11:68637568	NA	0.76	12.97	0.52	4.8e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1451375	0.698	rs11489734	chr7:50635730	A/T	cg00647317	chr7:50633725	DDC	-0.32	-7.32	-0.32	1.08e-12	Malaria;
LGG	cis	rs3206736	0.548	rs73110545	chr7:35063794	G/A	cg13400248	chr7:35225412	NA	0.55	9.5	0.4	1.16e-19	Diastolic blood pressure;
LGG	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.85	0.34	3e-14	Cannabis dependence symptom count;
LGG	trans	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg16141378	chr3:129829833	LOC729375	0.4	9.43	0.4	1.99e-19	Neuroticism;
LGG	cis	rs13132184	0.507	rs933818	chr4:38079294	A/G	cg24826020	chr4:38070998	TBC1D1	0.49	8.26	0.36	1.52e-15	Verbal declarative memory;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06702721	chr11:77899898	KCTD21;USP35	-0.41	-6.93	-0.31	1.42e-11	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25998860	chr5:126853954	PRRC1	0.53	8.62	0.37	1.06e-16	Gut microbiome composition (summer);
LGG	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.94	-0.35	1.53e-14	IgG glycosylation;
LGG	cis	rs11098499	0.954	rs59394118	chr4:120295551	A/G	cg24375607	chr4:120327624	NA	0.66	10.64	0.44	8.18e-24	Corneal astigmatism;
LGG	cis	rs12681287	0.517	rs34367154	chr8:87508749	A/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs714031	0.867	rs5750868	chr22:40063012	G/A	cg21377881	chr22:40064566	CACNA1I	-0.62	-14.5	-0.56	1.5e-39	Schizophrenia;
LGG	cis	rs6558530	0.692	rs10105317	chr8:1701432	G/A	cg25947184	chr8:1697459	NA	0.44	7.61	0.33	1.54e-13	Systolic blood pressure;
LGG	cis	rs2404602	0.735	rs2461870	chr15:76813920	T/G	cg23625390	chr15:77176239	SCAPER	-0.61	-12.02	-0.49	3.74e-29	Blood metabolite levels;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	8.42	0.36	4.88e-16	Longevity;
LGG	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg14683738	chr19:37701593	ZNF585B	-0.45	-7.22	-0.32	2.21e-12	Coronary artery calcification;
LGG	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg08125733	chr17:73851984	WBP2	0.7	10.79	0.45	2.33e-24	Psoriasis;
LGG	cis	rs892085	0.559	rs11670097	chr19:10877127	T/C	cg17710535	chr19:10819994	QTRT1	-0.48	-8.47	-0.37	3.32e-16	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg14835575	chr10:16859367	RSU1	0.73	13.46	0.53	4.44e-35	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2153535	0.580	rs7775909	chr6:8477778	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.19	0.39	1.31e-18	Motion sickness;
LGG	cis	rs11711311	1.000	rs921741	chr3:113444051	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.61	0.51	1.56e-31	IgG glycosylation;
LGG	cis	rs1497406	0.744	rs1007887	chr1:16509029	C/T	cg20430773	chr1:16534157	ARHGEF19	0.28	8.06	0.35	6.78e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg04979063	chr2:113191202	RGPD5;RGPD8	0.78	9.91	0.42	3.98e-21	Yeast infection;
LGG	cis	rs11785400	0.963	rs6990126	chr8:143728387	T/C	cg24634471	chr8:143751801	JRK	0.53	8.4	0.36	5.56e-16	Schizophrenia;
LGG	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg05729581	chr11:3078854	CARS	-0.54	-9.1	-0.39	2.77e-18	Longevity;
LGG	cis	rs9302635	0.688	rs763665	chr16:72078043	C/T	cg01557791	chr16:72042693	DHODH	-0.54	-7.13	-0.31	3.81e-12	Blood protein levels;
LGG	cis	rs2985684	0.841	rs7158577	chr14:50058633	C/T	cg04989706	chr14:50066350	PPIL5	-0.57	-9.06	-0.39	3.55e-18	Carotid intima media thickness;
LGG	cis	rs6910233	1.000	rs6910233	chr6:33534726	A/C	cg13560919	chr6:33536144	NA	0.44	7.43	0.33	5.14e-13	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;
LGG	trans	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg20587970	chr11:113659929	NA	-1.34	-23.57	-0.74	2.63e-81	Hip circumference adjusted for BMI;
LGG	cis	rs6840360	0.582	rs2709826	chr4:152332120	G/T	cg17217059	chr4:152329364	FAM160A1	0.19	6.69	0.3	6.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs834603	0.611	rs2692540	chr7:47465325	C/G	cg23694490	chr7:47445681	TNS3	-0.43	-12.26	-0.5	4.06e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs4380275	0.782	rs11691064	chr2:755718	T/G	cg02758766	chr2:740531	NA	-0.39	-6.77	-0.3	4.03e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7089973	0.872	rs7072356	chr10:116634651	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.56	0.33	2.19e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg08885076	chr2:99613938	TSGA10	0.43	9.23	0.39	9.84e-19	Chronic sinus infection;
LGG	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg02151108	chr14:50098012	C14orf104	-0.47	-9.97	-0.42	2.52e-21	Carotid intima media thickness;
LGG	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg20290983	chr6:43655470	MRPS18A	1.09	24.05	0.75	1.54e-83	IgG glycosylation;
LGG	cis	rs2074193	0.627	rs215387	chr12:47763673	A/G	cg02516419	chr12:47771422	NA	-0.71	-10.52	-0.44	2.47e-23	Migraine with aura;
LGG	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.46	7.6	0.33	1.71e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6087990	0.735	rs2424922	chr20:31386449	T/C	cg13636640	chr20:31349939	DNMT3B	0.82	16.83	0.62	5.9e-50	Ulcerative colitis;
LGG	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7264396	0.790	rs3787168	chr20:34233278	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.67	-0.34	1.04e-13	Total cholesterol levels;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7767084	0.611	rs10945673	chr6:160910899	C/T	cg04181478	chr6:161122748	PLG	0.47	6.8	0.3	3.26e-11	Coronary heart disease;
LGG	cis	rs6598955	0.670	rs6676619	chr1:26539035	T/G	cg04990556	chr1:26633338	UBXN11	-0.69	-13.78	-0.54	1.9e-36	Obesity-related traits;
LGG	trans	rs853679	0.599	rs156743	chr6:27967089	T/C	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.93	-0.38	1.03e-17	Depression;
LGG	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg04568710	chr12:38710424	ALG10B	0.33	6.74	0.3	4.86e-11	Bladder cancer;
LGG	cis	rs4430311	0.622	rs10927060	chr1:243875989	A/G	cg25706552	chr1:244017396	NA	-0.63	-15.56	-0.59	3.1e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1707322	0.963	rs12076580	chr1:46258159	G/A	cg03146154	chr1:46216737	IPP	0.57	10.57	0.44	1.59e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12402800	chr5:56204917	C5orf35	0.46	7.06	0.31	6.28e-12	Initial pursuit acceleration;
LGG	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.71	0.45	4.42e-24	Mean platelet volume;
LGG	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.37	-0.32	8.11e-13	Triglycerides;
LGG	cis	rs2013441	1.000	rs2526484	chr17:20103760	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.65	-0.37	8.36e-17	Triglycerides;
LGG	cis	rs7827545	1.000	rs6578229	chr8:135562453	T/G	cg17885191	chr8:135476712	NA	0.44	7.03	0.31	7.27e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs11098499	0.909	rs10026736	chr4:120384322	G/C	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.87e-26	Corneal astigmatism;
LGG	cis	rs143283559	1	rs143283559	chr18:77567761	T/G	cg19746982	chr18:77552568	NA	0.32	6.79	0.3	3.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11105298	0.891	rs3741899	chr12:89933931	G/A	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg20040747	chr15:74715105	SEMA7A	0.75	21.86	0.71	2.53e-73	Airflow obstruction;
LGG	cis	rs9467773	0.967	rs7753565	chr6:26560012	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.06	0.62	5.39e-51	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.25e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs870825	0.616	rs7667409	chr4:185650941	C/T	cg04058563	chr4:185651563	MLF1IP	-1.03	-22.82	-0.73	8.54e-78	Blood protein levels;
LGG	trans	rs783540	0.835	rs8030185	chr15:83391537	G/A	cg16105309	chr15:79090380	ADAMTS7	-0.46	-7.92	-0.35	1.76e-14	Schizophrenia;
LGG	cis	rs2286885	1.000	rs10733679	chr9:129242416	C/T	cg14319473	chr9:129242481	FAM125B	0.45	8.49	0.37	2.76e-16	Intraocular pressure;
LGG	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg08807101	chr21:30365312	RNF160	0.77	14.64	0.56	3.61e-40	Dental caries;
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs2228479	0.681	rs7199685	chr16:89959805	G/C	cg27400746	chr16:89904261	SPIRE2	-0.88	-15.14	-0.58	2.28e-42	Skin colour saturation;
LGG	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.91	-0.31	1.57e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg27532318	chr7:32358331	NA	0.73	7.43	0.33	5.29e-13	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18493069	chr6:108582623	SNX3	0.43	7.15	0.32	3.5e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1577917	1.000	rs1999852	chr6:86705738	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.66	-0.41	3.18e-20	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-12.94	-0.52	6.86e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg05692746	chr2:100937584	LONRF2	-0.64	-11.75	-0.48	4.36e-28	Intelligence (multi-trait analysis);
LGG	cis	rs60695258	1.000	rs2035403	chr4:88018991	A/G	cg11209507	chr4:87813803	C4orf36	0.43	6.86	0.3	2.27e-11	Hematocrit;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg21226059	chr5:178986404	RUFY1	-0.49	-8.8	-0.38	2.73e-17	Lung cancer;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg27471124	chr11:109292789	C11orf87	0.47	9.35	0.4	3.75e-19	Schizophrenia;
LGG	cis	rs3857067	1.000	rs2199603	chr4:95016174	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs11758351	1.000	rs16891378	chr6:26188864	A/G	cg23601095	chr6:26197514	HIST1H3D	0.71	9.25	0.39	8.37e-19	Gout;Renal underexcretion gout;
LGG	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg10818794	chr15:86012489	AKAP13	-0.37	-7.97	-0.35	1.21e-14	Coronary artery disease;
LGG	cis	rs6708331	0.540	rs28623550	chr2:70366392	T/C	cg01613454	chr2:70366299	NA	0.55	11.02	0.46	3.03e-25	Obesity-related traits;
LGG	cis	rs6977660	0.943	rs10270447	chr7:19849823	C/G	cg07541023	chr7:19748670	TWISTNB	-0.47	-7.28	-0.32	1.48e-12	Thyroid stimulating hormone;
LGG	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg14582100	chr15:45693742	SPATA5L1	0.4	6.68	0.3	6.67e-11	Homoarginine levels;
LGG	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs8114671	0.967	rs6142324	chr20:33789043	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.48	-0.33	3.76e-13	Height;
LGG	cis	rs7808935	0.914	rs67746093	chr7:27985524	C/G	cg22168087	chr7:27702803	HIBADH	0.65	8.93	0.38	1.01e-17	Prostate cancer;
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg11764359	chr7:65958608	NA	-0.57	-9.64	-0.41	3.77e-20	Corneal structure;
LGG	cis	rs977987	0.898	rs12918974	chr16:75493943	T/A	cg03315344	chr16:75512273	CHST6	0.59	11.8	0.48	2.72e-28	Dupuytren's disease;
LGG	cis	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg26384229	chr12:38710491	ALG10B	0.95	21.64	0.71	3e-72	Morning vs. evening chronotype;
LGG	cis	rs739401	0.611	rs2239899	chr11:3024624	A/G	cg05729581	chr11:3078854	CARS	0.51	8.69	0.37	6.47e-17	Longevity;
LGG	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11644478	chr21:40555479	PSMG1	0.92	17.46	0.63	7.88e-53	Cognitive function;
LGG	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg06026331	chr20:60912101	LAMA5	-0.7	-12.77	-0.51	3.41e-32	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6489785	0.775	rs1151852	chr12:121340068	T/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.76	-0.3	4.28e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	12.37	0.5	1.43e-30	Neutrophil percentage of white cells;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06108461	chr20:60628389	TAF4	-0.9	-17.0	-0.62	1.02e-50	Body mass index;
LGG	cis	rs9467773	1.000	rs9393728	chr6:26509330	C/G	cg09904177	chr6:26538194	HMGN4	0.77	17.45	0.63	9.21e-53	Intelligence (multi-trait analysis);
LGG	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg08975724	chr8:8085496	FLJ10661	0.57	11.21	0.46	5.81e-26	Neuroticism;
LGG	cis	rs12410462	0.581	rs6675521	chr1:227544702	C/T	cg23173402	chr1:227635558	NA	0.5	8.44	0.37	3.99e-16	Major depressive disorder;
LGG	cis	rs763121	0.853	rs3747172	chr22:39067524	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs42648	0.869	rs42613	chr7:89950303	C/T	cg25739043	chr7:89950458	NA	-0.44	-9.35	-0.4	3.73e-19	Homocysteine levels;
LGG	cis	rs9487051	0.844	rs9386792	chr6:109609975	G/A	cg12927641	chr6:109611667	NA	-0.36	-6.91	-0.31	1.65e-11	Reticulocyte fraction of red cells;
LGG	cis	rs7712401	0.601	rs35699701	chr5:122333756	G/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.79	-0.34	4.5e-14	Height;
LGG	cis	rs7772486	0.625	rs2050027	chr6:146116113	C/G	cg23711669	chr6:146136114	FBXO30	-0.4	-6.72	-0.3	5.23e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs36071027	0.577	rs12109219	chr5:158393842	T/G	cg04248271	chr5:158524404	EBF1	0.41	7.24	0.32	1.89e-12	Carotid intima media thickness;
LGG	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg13147721	chr7:65941812	NA	-0.76	-8.98	-0.38	7.09e-18	Diabetic kidney disease;
LGG	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg09307838	chr4:120376055	NA	0.71	11.78	0.48	3.39e-28	Corneal astigmatism;
LGG	cis	rs4319547	1.000	rs6489156	chr12:123100397	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.61	-9.47	-0.4	1.43e-19	Body mass index;
LGG	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.31	-0.55	1e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs3008870	0.701	rs2815358	chr1:67493778	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.71	15.16	0.58	1.84e-42	Lymphocyte percentage of white cells;
LGG	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg04684003	chr14:76127793	TTLL5;C14orf1	-0.42	-6.95	-0.31	1.25e-11	Large artery stroke;
LGG	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	9.6	0.41	4.97e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs916888	0.779	rs199498	chr17:44865603	A/G	cg01570182	chr17:44337453	NA	0.56	9.23	0.39	9.75e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg27129171	chr3:47204927	SETD2	-0.8	-14.32	-0.55	9.05e-39	Colorectal cancer;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg11494091	chr17:61959527	GH2	-1.11	-32.33	-0.83	7.91e-121	Prudent dietary pattern;
LGG	cis	rs6871536	1.000	rs3798134	chr5:131965179	C/T	cg04303330	chr5:131992430	IL13	0.28	6.76	0.3	4.22e-11	Asthma (childhood onset);
LGG	cis	rs2070997	0.617	rs7848941	chr9:133744672	G/A	cg13397898	chr9:133768931	QRFP	0.32	6.69	0.3	6.65e-11	Response to amphetamines;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10185311	chr6:26124167	HIST1H2AC;HIST1H2BC	0.41	6.91	0.31	1.59e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg22105103	chr4:187893119	NA	0.53	10.2	0.43	3.53e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg11789530	chr4:8429930	ACOX3	-0.76	-13.83	-0.54	1.19e-36	Response to antineoplastic agents;
LGG	cis	rs34172651	0.517	rs11647120	chr16:24819806	A/G	cg06028605	chr16:24865363	SLC5A11	0.5	8.18	0.36	2.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.67	-0.37	7.1e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs3762318	0.624	rs2064691	chr1:67607963	T/C	cg17031739	chr1:67600172	NA	0.53	7.34	0.32	9.81e-13	Leprosy;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg05313129	chr8:58192883	C8orf71	-0.81	-12.3	-0.5	2.74e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7539542	0.556	rs6427979	chr1:202869503	T/C	cg19681188	chr1:202830198	LOC148709	0.53	8.96	0.38	8.29e-18	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19235966	chr1:16173721	SPEN;FLJ37453	-0.45	-6.89	-0.3	1.88e-11	Gut microbiome composition (summer);
LGG	cis	rs9834373	0.853	rs6797869	chr3:78495322	C/T	cg06138941	chr3:78371609	NA	-0.49	-8.92	-0.38	1.06e-17	Protein quantitative trait loci;
LGG	cis	rs806215	0.526	rs712707	chr7:127322614	C/T	cg25922125	chr7:127225783	GCC1	-0.51	-7.42	-0.33	5.55e-13	Type 2 diabetes;
LGG	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.78	0.45	2.58e-24	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs4821124	chr22:21979289	T/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.43	-0.33	5.31e-13	Systemic lupus erythematosus;
LGG	cis	rs933688	0.532	rs10072084	chr5:90539203	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	0.52	6.77	0.3	4e-11	Smoking behavior;
LGG	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.54	-8.57	-0.37	1.61e-16	Tonsillectomy;
LGG	cis	rs6456042	1.000	rs3127408	chr6:166530659	T/A	cg11088901	chr6:166572345	T	-0.35	-7.18	-0.32	2.73e-12	Asthma;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.01	0.35	9.07e-15	Colorectal cancer;
LGG	cis	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.75	-13.48	-0.53	3.69e-35	Primary sclerosing cholangitis;
LGG	cis	rs35306767	0.953	rs34405399	chr10:981015	G/A	cg08847335	chr10:891726	LARP4B	-0.37	-6.83	-0.3	2.69e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.36	2.92e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs67311347	0.826	rs9863679	chr3:40439614	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.73	0.3	4.9e-11	Renal cell carcinoma;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9625935	0.518	rs245008	chr22:30315736	T/C	cg01021169	chr22:30184971	ASCC2	-0.35	-6.75	-0.3	4.49e-11	Tonsillectomy;
LGG	cis	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg19847130	chr8:10466454	RP1L1	0.35	7.31	0.32	1.16e-12	Neuroticism;
LGG	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg09165964	chr15:75287851	SCAMP5	-0.64	-7.34	-0.32	9.5e-13	Lung cancer;
LGG	cis	rs950169	0.656	rs11632395	chr15:85145793	C/A	cg24253500	chr15:84953950	NA	0.51	8.9	0.38	1.27e-17	Schizophrenia;
LGG	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs12410462	0.591	rs72748074	chr1:227763286	G/A	cg04117972	chr1:227635322	NA	0.48	8.65	0.37	8.52e-17	Major depressive disorder;
LGG	cis	rs9534288	0.797	rs9526134	chr13:46618046	G/T	cg15192986	chr13:46630673	CPB2	-0.59	-13.12	-0.52	1.18e-33	Blood protein levels;
LGG	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg12623918	chr2:306882	NA	0.51	9.53	0.4	9.15e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.58	-0.33	1.87e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg03733263	chr8:22462867	KIAA1967	-1.01	-22.94	-0.73	2.48e-78	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-12.61	-0.51	1.46e-31	Intelligence (multi-trait analysis);
LGG	trans	rs78049276	0.688	rs73855809	chr4:148380348	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.56	-0.33	2.21e-13	Pulse pressure;
LGG	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg25019033	chr10:957182	NA	-0.59	-12.59	-0.5	1.91e-31	Eosinophil percentage of granulocytes;
LGG	trans	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg01134436	chr17:81009848	B3GNTL1	0.64	7.53	0.33	2.75e-13	Lung function (FEV1/FVC);
LGG	cis	rs4262150	0.774	rs17565727	chr5:152081338	C/T	cg12297329	chr5:152029980	NA	-0.75	-13.98	-0.54	2.73e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.38	0.32	7.34e-13	Tonsillectomy;
LGG	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg02297831	chr4:17616191	MED28	0.46	8.43	0.36	4.56e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg18200150	chr17:30822561	MYO1D	0.5	9.62	0.41	4.43e-20	Schizophrenia;
LGG	trans	rs9409565	0.559	rs11788395	chr9:97251382	T/C	cg05679027	chr9:99775184	HIATL2	-0.47	-7.01	-0.31	8.25e-12	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg07061783	chr6:25882402	NA	-0.64	-10.5	-0.44	2.85e-23	Intelligence (multi-trait analysis);
LGG	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg12573674	chr2:1569213	NA	-0.5	-6.83	-0.3	2.68e-11	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7949566	0.535	rs4935965	chr11:126278522	C/T	cg05055844	chr11:126275997	ST3GAL4	0.39	7.79	0.34	4.59e-14	Platelet distribution width;Mean platelet volume;
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg00908189	chr16:619842	PIGQ	0.85	15.64	0.59	1.38e-44	Height;
LGG	trans	rs79976124	0.797	rs77895756	chr6:66626782	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.29	0.5	3.13e-30	Type 2 diabetes;
LGG	cis	rs7524258	0.900	rs4908611	chr1:7313861	G/A	cg07173049	chr1:7289937	CAMTA1	0.68	15.87	0.59	1.33e-45	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs7100689	0.784	rs7078075	chr10:82162768	A/G	cg01528321	chr10:82214614	TSPAN14	1.02	19.43	0.67	5.98e-62	Post bronchodilator FEV1;
LGG	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.06	0.35	6.44e-15	Retinal vascular caliber;
LGG	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.19	-0.75	3.35e-84	Height;
LGG	cis	rs3742264	0.656	rs9534284	chr13:46591061	T/C	cg15192986	chr13:46630673	CPB2	-0.37	-7.14	-0.31	3.63e-12	Blood protein levels;
LGG	cis	rs12476592	0.602	rs187801	chr2:63867446	A/C	cg17519650	chr2:63277830	OTX1	0.44	6.88	0.3	1.93e-11	Childhood ear infection;
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs2273669	0.915	rs1080945	chr6:109304694	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-7.46	-0.33	4.38e-13	Prostate cancer;
LGG	cis	rs1408799	0.607	rs7025678	chr9:12760788	A/G	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	4.99e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs977987	0.806	rs2285225	chr16:75429252	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19405965	chr11:129872790	NCRNA00167;PRDM10	0.5	7.21	0.32	2.25e-12	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07659893	chr17:61819838	STRADA	0.49	8.24	0.36	1.73e-15	Prudent dietary pattern;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.37	0.82	2.92e-112	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.19	-0.43	3.81e-22	Lung cancer;
LGG	cis	rs1566085	0.674	rs57800269	chr8:142660505	C/G	cg26331504	chr8:142652174	NA	-0.3	-7.11	-0.31	4.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg03342759	chr3:160939853	NMD3	-0.76	-13.57	-0.53	1.53e-35	Parkinson's disease;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg02187348	chr16:89574699	SPG7	0.44	7.2	0.32	2.51e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs9894429	0.621	rs7502337	chr17:79588470	T/C	cg18240062	chr17:79603768	NPLOC4	0.61	10.29	0.43	1.71e-22	Eye color traits;
LGG	cis	rs9399135	0.622	rs3817776	chr6:135256756	C/T	cg22676075	chr6:135203613	NA	-0.4	-7.14	-0.31	3.65e-12	Red blood cell count;
LGG	trans	rs7923837	0.687	rs1111875	chr10:94462882	C/T	cg27639046	chr2:171608303	NA	-0.36	-7.33	-0.32	1.03e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs4959677	0.901	rs7776061	chr6:2487061	G/T	cg20147862	chr6:2634573	C6orf195	-0.4	-8.75	-0.38	4.14e-17	Orthostatic hypotension;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg23782820	chr8:58130467	NA	0.53	7.42	0.33	5.78e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg07460842	chr6:66804631	NA	0.91	14.88	0.57	3.41e-41	Exhaled nitric oxide output;
LGG	cis	rs1943345	0.519	rs11233504	chr11:82886525	A/G	cg07047830	chr11:82868014	PCF11	0.61	11.73	0.48	5.47e-28	Obesity-related traits;
LGG	cis	rs1348850	1.000	rs3927978	chr2:178443854	A/G	cg22681709	chr2:178499509	PDE11A	0.43	7.93	0.35	1.67e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16854524	chr4:83931902	LIN54	0.39	7.07	0.31	5.61e-12	Obesity-related traits;
LGG	cis	rs2236521	0.659	rs72487383	chr20:60889313	A/C	cg06026331	chr20:60912101	LAMA5	0.41	7.82	0.34	3.54e-14	Pelvic organ prolapse;
LGG	cis	rs11096990	0.855	rs6855008	chr4:39173626	A/G	cg24403649	chr4:39172243	NA	-0.49	-7.77	-0.34	5.13e-14	Cognitive function;
LGG	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg12654349	chr5:56205094	C5orf35	-0.4	-7.05	-0.31	6.48e-12	Coronary artery disease;
LGG	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg07777115	chr5:623756	CEP72	-0.56	-7.12	-0.31	4.26e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg07701084	chr6:150067640	NUP43	0.71	13.9	0.54	5.92e-37	Lung cancer;
LGG	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.49e-15	Bone mineral density;
LGG	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.82	-0.51	2.06e-32	Response to antipsychotic treatment;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.1e-21	Rheumatoid arthritis;
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.6	10.56	0.44	1.7e-23	Lymphocyte counts;
LGG	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg19812747	chr11:111475976	SIK2	-0.42	-8.65	-0.37	8.83e-17	Primary sclerosing cholangitis;
LGG	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.45e-13	HDL cholesterol;
LGG	cis	rs2221894	0.506	rs78029870	chr8:28963659	A/G	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.81	-0.34	3.74e-14	Obesity-related traits;
LGG	cis	rs2354432	0.607	rs4950385	chr1:146656292	A/G	cg25205988	chr1:146714368	CHD1L	1.07	9.34	0.4	4e-19	Mitochondrial DNA levels;
LGG	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg06640241	chr16:89574553	SPG7	0.93	17.49	0.63	5.91e-53	Multiple myeloma (IgH translocation);
LGG	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1847505	0.716	rs7321236	chr13:61516730	C/T	cg25164009	chr13:61490935	NA	-0.63	-11.51	-0.47	4e-27	Polychlorinated biphenyl levels;
LGG	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg24848339	chr3:12840334	CAND2	0.38	8.67	0.37	7.33e-17	QRS complex (12-leadsum);
LGG	cis	rs727563	0.636	rs2413653	chr22:42106996	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.58	0.63	2.26e-53	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg25811766	chr13:21894605	NA	0.8	16.13	0.6	8.94e-47	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-7.92	-0.35	1.8e-14	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18525740	chr5:176449647	ZNF346	0.43	6.68	0.3	7.05e-11	Gut microbiome composition (summer);
LGG	cis	rs56235845	0.665	rs4976685	chr5:176766177	C/T	cg17509989	chr5:176798049	RGS14	-0.65	-10.74	-0.45	3.46e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs753778	0.570	rs10875465	chr8:142210500	A/G	cg18755752	chr8:142205143	DENND3	-0.45	-9.26	-0.4	7.75e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.45	-0.4	1.72e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg21948465	chr5:131705150	SLC22A5	0.7	7.53	0.33	2.73e-13	Rheumatoid arthritis;
LGG	cis	rs7927592	0.763	rs10896326	chr11:68234571	T/C	cg01657329	chr11:68192670	LRP5	-0.56	-10.48	-0.44	3.37e-23	Total body bone mineral density;
LGG	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.74	-0.3	4.62e-11	Parkinson's disease;
LGG	cis	rs7143963	0.666	rs7145509	chr14:103329430	A/C	cg23020514	chr14:103360112	TRAF3	-0.4	-8.33	-0.36	8.97e-16	Body mass index;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.59	0.41	5.27e-20	Prudent dietary pattern;
LGG	cis	rs7326068	0.595	rs2477164	chr13:21402388	A/C	cg04906043	chr13:21280425	IL17D	-0.51	-8.03	-0.35	8.05e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs7507204	1.000	rs7507204	chr19:3428834	G/C	cg08382705	chr11:45687319	CHST1	-0.51	-7.23	-0.32	2.03e-12	Height;
LGG	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4639966	0.836	rs10892282	chr11:118627778	C/G	cg20110707	chr11:118481992	PHLDB1	0.43	6.9	0.31	1.75e-11	Systemic lupus erythematosus;
LGG	cis	rs72781680	0.948	rs72781652	chr2:24213754	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	9.51	0.4	1.03e-19	Lymphocyte counts;
LGG	cis	rs4363385	0.693	rs7556517	chr1:152925755	G/T	cg07796016	chr1:152779584	LCE1C	0.46	7.26	0.32	1.6e-12	Inflammatory skin disease;
LGG	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	14.14	0.55	5.29e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09299307	chr5:86709023	CCNH	0.5	8.13	0.35	3.83e-15	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.28	0.36	1.33e-15	Bipolar disorder;
LGG	cis	rs10876993	0.928	rs1628552	chr12:58082142	C/T	cg18357645	chr12:58087776	OS9	0.69	12.36	0.5	1.59e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg27165867	chr14:105738592	BRF1	-0.46	-7.33	-0.32	1.03e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg08470875	chr2:26401718	FAM59B	0.42	8.2	0.36	2.44e-15	Gut microbiome composition (summer);
LGG	trans	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg12395012	chr8:11607386	GATA4	-0.39	-6.74	-0.3	4.73e-11	Myopia (pathological);
LGG	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg20744362	chr22:50050164	C22orf34	0.39	7.52	0.33	2.86e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs972578	0.668	rs4820489	chr22:43241003	C/G	cg01576275	chr22:43409880	NA	-0.23	-6.78	-0.3	3.56e-11	Mean platelet volume;
LGG	trans	rs11098499	0.739	rs9996382	chr4:120151012	C/T	cg25214090	chr10:38739885	LOC399744	0.55	9.84	0.42	7.11e-21	Corneal astigmatism;
LGG	cis	rs868036	1.000	rs1471460	chr15:68089299	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.44	-0.33	4.84e-13	Restless legs syndrome;
LGG	cis	rs11758351	0.500	rs74974409	chr6:26194402	A/G	cg23601095	chr6:26197514	HIST1H3D	0.89	6.73	0.3	5.12e-11	Gout;Renal underexcretion gout;
LGG	cis	rs664172	1	rs664172	chr15:78862762	G/A	cg06917634	chr15:78832804	PSMA4	-0.51	-7.86	-0.34	2.7e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg00405596	chr8:11794950	NA	-0.44	-7.28	-0.32	1.43e-12	Neuroticism;
LGG	cis	rs8005677	0.770	rs56180741	chr14:23377246	T/C	cg01529538	chr14:23388837	RBM23	0.36	6.66	0.3	7.63e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs17401966	0.931	rs3748577	chr1:10357406	C/T	cg15208524	chr1:10270712	KIF1B	-0.44	-7.62	-0.33	1.44e-13	Hepatocellular carcinoma;
LGG	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg25208724	chr1:156163844	SLC25A44	-1.16	-26.34	-0.77	4.04e-94	Testicular germ cell tumor;
LGG	cis	rs6088590	0.561	rs6059918	chr20:33150503	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.74	0.38	4.36e-17	Coronary artery disease;
LGG	cis	rs875971	0.505	rs1723275	chr7:65504633	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.6	-0.44	1.22e-23	Aortic root size;
LGG	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg18681998	chr4:17616180	MED28	0.75	15.38	0.58	2.02e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.92	20.25	0.69	9.48e-66	Prudent dietary pattern;
LGG	cis	rs4604732	0.642	rs10925047	chr1:247640143	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.36	0.36	7.24e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9926296	0.656	rs2376884	chr16:89826922	C/T	cg04287289	chr16:89883240	FANCA	0.52	9.28	0.4	6.39e-19	Vitiligo;
LGG	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg03894339	chr8:19674705	INTS10	0.63	10.21	0.43	3.26e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg23782820	chr8:58130467	NA	0.51	7.21	0.32	2.24e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg02549819	chr16:58548995	SETD6	1.43	13.68	0.54	5.3e-36	Schizophrenia;
LGG	cis	rs7929679	0.551	rs11032840	chr11:34779464	G/T	cg06937548	chr11:34938143	PDHX;APIP	0.43	7.34	0.32	9.47e-13	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.31e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.965	rs10222474	chr3:99862551	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	8.05	0.35	7.27e-15	Axial length;
LGG	cis	rs208520	0.802	rs208499	chr6:66932146	C/T	cg07460842	chr6:66804631	NA	-0.9	-15.57	-0.59	2.94e-44	Exhaled nitric oxide output;
LGG	cis	rs6912958	0.781	rs3934838	chr6:88284699	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs6686643	1.000	rs6686643	chr1:165616588	T/C	cg19407955	chr1:165599744	MGST3	-0.59	-8.83	-0.38	2.22e-17	Total ventricular volume;
LGG	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg11247378	chr22:39784982	NA	-0.31	-8.64	-0.37	8.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.765	rs132905	chr22:41799106	C/A	cg17376030	chr22:41985996	PMM1	-0.5	-8.18	-0.36	2.84e-15	Vitiligo;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg11814155	chr7:99998594	ZCWPW1	0.64	9.8	0.41	9.72e-21	Platelet count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17019866	chr8:121457656	MTBP;MRPL13	-0.53	-7.85	-0.34	2.94e-14	Systemic lupus erythematosus;
LGG	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg15832292	chr6:96025679	MANEA	0.51	7.02	0.31	7.78e-12	Behavioural disinhibition (generation interaction);
LGG	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg02153584	chr22:29168773	CCDC117	0.62	10.16	0.43	4.97e-22	Lymphocyte counts;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg05368731	chr17:41323189	NBR1	0.97	19.12	0.66	1.65e-60	Menopause (age at onset);
LGG	cis	rs975210	1.000	rs975210	chr15:70364352	G/A	cg01666796	chr15:70364327	TLE3	-0.53	-7.3	-0.32	1.24e-12	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.37	-0.32	8.11e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg19913688	chr11:428466	ANO9	-0.67	-8.6	-0.37	1.26e-16	Body mass index;
LGG	cis	rs2836974	0.932	rs6517526	chr21:40581530	T/C	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	cis	rs9427116	0.840	rs9427114	chr1:154626705	T/C	cg11650704	chr1:154556575	ADAR	-0.41	-7.9	-0.34	2.03e-14	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07080177	chr17:75243417	NA	0.42	6.71	0.3	5.67e-11	Cognitive performance;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.74	-0.41	1.58e-20	Lung cancer;
LGG	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs11235843	0.636	rs2140892	chr11:73422879	A/G	cg18195628	chr11:73498948	MRPL48	-0.52	-7.24	-0.32	1.82e-12	Hand grip strength;
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg11764359	chr7:65958608	NA	-0.72	-12.89	-0.51	1.09e-32	Aortic root size;
LGG	cis	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05901451	chr6:126070800	HEY2	0.6	10.89	0.45	1.01e-24	Endometrial cancer;
LGG	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg00012203	chr2:219082015	ARPC2	0.66	12.01	0.49	4.19e-29	Colorectal cancer;
LGG	cis	rs6032067	0.714	rs35770435	chr20:43788804	C/T	cg10761708	chr20:43804764	PI3	0.75	11.88	0.48	1.41e-28	Blood protein levels;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg24623649	chr8:11872141	NA	-0.31	-7.22	-0.32	2.2e-12	Triglycerides;
LGG	cis	rs4423214	0.879	rs4945008	chr11:71221248	A/G	cg05163923	chr11:71159392	DHCR7	0.69	13.51	0.53	2.68e-35	Vitamin D levels;
LGG	cis	rs908922	0.676	rs539393	chr1:152518896	C/T	cg03606772	chr1:152487856	CRCT1	0.28	6.69	0.3	6.5e-11	Hair morphology;
LGG	cis	rs2486288	0.656	rs8039138	chr15:45551592	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg00717180	chr2:96193071	NA	-0.45	-8.32	-0.36	9.75e-16	HDL cholesterol;
LGG	cis	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg19847130	chr8:10466454	RP1L1	-0.33	-6.91	-0.31	1.65e-11	Neuroticism;
LGG	cis	rs3857536	0.740	rs9360191	chr6:66942454	A/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.13	0.39	2.15e-18	Bipolar disorder;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg07511668	chr11:68622177	NA	0.51	9.59	0.41	5.38e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6942756	1.000	rs6467235	chr7:128939150	A/G	cg02491457	chr7:128862824	NA	0.7	12.97	0.52	4.91e-33	White matter hyperintensity burden;
LGG	cis	rs590121	0.876	rs6704	chr11:75283653	C/A	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.57	-0.37	1.51e-16	Coronary artery disease;
LGG	cis	rs539514	0.690	rs1092601	chr13:76309746	C/T	cg04757411	chr13:76259545	LMO7	-0.27	-7.04	-0.31	7.08e-12	Type 1 diabetes;
LGG	cis	rs295140	0.605	rs34693942	chr2:201184348	T/C	cg17644776	chr2:200775616	C2orf69	-0.44	-7.29	-0.32	1.35e-12	QT interval;
LGG	trans	rs1941687	0.797	rs12963804	chr18:31391208	T/C	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1552244	0.882	rs55840655	chr3:10042690	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs745821	0.701	rs3853681	chr18:48100771	G/A	cg18923635	chr18:48083994	NA	0.42	7.57	0.33	2.02e-13	Diastolic blood pressure;
LGG	cis	rs2274273	0.870	rs28716725	chr14:55816610	T/C	cg04306507	chr14:55594613	LGALS3	0.63	18.13	0.64	6.9e-56	Protein biomarker;
LGG	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.54	-8.51	-0.37	2.4e-16	Menarche (age at onset);
LGG	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.57	7.37	0.32	7.88e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6066825	0.644	rs1040559	chr20:47314445	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.17	0.36	2.89e-15	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.83	0.3	2.67e-11	Homoarginine levels;
LGG	trans	rs800082	0.839	rs62275528	chr3:144293687	T/C	cg24215973	chr2:240111563	HDAC4	-0.48	-8.14	-0.35	3.65e-15	Smoking behavior;
LGG	cis	rs11064837	0.511	rs278154	chr12:120121050	G/A	cg25937854	chr12:120150414	CIT	-0.73	-12.33	-0.5	2.16e-30	Schizophrenia;
LGG	cis	rs2334880	0.602	rs12444212	chr16:71437689	T/C	cg06353428	chr16:71660113	MARVELD3	-0.69	-9.61	-0.41	4.57e-20	Malaria;
LGG	cis	rs3857747	0.827	rs4134194	chr7:40440560	A/G	cg00420559	chr7:40367873	C7orf10	0.39	7.89	0.34	2.17e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7208859	0.673	rs11080135	chr17:29176481	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4363385	0.510	rs11205182	chr1:153045748	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.38	-0.4	3.06e-19	Inflammatory skin disease;
LGG	cis	rs798554	0.759	rs2644291	chr7:2890456	T/C	cg14668632	chr7:2872130	GNA12	-0.34	-7.12	-0.31	4.05e-12	Height;
LGG	cis	rs7765175	0.651	rs1074618	chr6:113667638	C/T	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.41e-13	Coronary artery calcification;
LGG	cis	rs72781680	0.898	rs718139	chr2:23975911	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.41	0.4	2.29e-19	Lymphocyte counts;
LGG	cis	rs2241941	0.802	rs72927524	chr11:20629584	C/T	cg05572763	chr11:20631898	SLC6A5	-0.48	-8.7	-0.37	5.79e-17	Obesity-related traits;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg16507663	chr6:150244633	RAET1G	-0.41	-7.56	-0.33	2.19e-13	Lung cancer;
LGG	cis	rs17453880	0.929	rs4391148	chr5:152026986	T/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs8112449	0.964	rs6417247	chr19:10522597	G/A	cg21868191	chr19:10515988	NA	-0.47	-8.26	-0.36	1.54e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs36051895	0.623	rs2381215	chr9:5262607	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-13.82	-0.54	1.32e-36	Pediatric autoimmune diseases;
LGG	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.27e-12	Cystic fibrosis severity;
LGG	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.47	-8.04	-0.35	7.66e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17641971	0.662	rs10435575	chr8:49996107	C/T	cg00325661	chr8:49890786	NA	0.57	10.75	0.45	3.26e-24	Blood metabolite levels;
LGG	cis	rs977987	0.843	rs10431974	chr16:75435461	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.82	0.3	2.81e-11	Dupuytren's disease;
LGG	cis	rs754466	0.580	rs2289311	chr10:79565655	G/A	cg17075019	chr10:79541650	NA	-0.93	-19.77	-0.68	1.65e-63	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17221829	0.965	rs10830364	chr11:89458632	T/G	cg02982614	chr11:89391479	FOLH1B	-0.36	-7.92	-0.35	1.81e-14	Anxiety in major depressive disorder;
LGG	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg17145862	chr1:211918768	LPGAT1	0.8	17.36	0.63	2.34e-52	Leprosy;
LGG	cis	rs13082711	0.863	rs35998108	chr3:27423427	G/A	cg02860705	chr3:27208620	NA	0.73	13.5	0.53	2.83e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs55871839	0.643	rs7004274	chr8:59810378	T/A	cg07426533	chr8:59803705	TOX	-0.55	-12.32	-0.5	2.35e-30	Pneumonia;
LGG	cis	rs2180341	1.000	rs3798850	chr6:127613966	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.44	0.72	4.93e-76	Breast cancer;
LGG	cis	rs12153243	0.802	rs12153151	chr5:142897834	T/A	cg13907255	chr5:142895549	NA	-0.42	-7.71	-0.34	7.55e-14	Migraine;
LGG	cis	rs6504108	0.624	rs4794505	chr17:46283306	A/G	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.62e-15	Body mass index;
LGG	cis	rs9399135	0.933	rs7755680	chr6:135294259	A/G	cg22676075	chr6:135203613	NA	0.37	6.69	0.3	6.52e-11	Red blood cell count;
LGG	cis	rs2693698	0.679	rs4905808	chr14:99692271	T/C	cg07440398	chr14:99712966	BCL11B	0.57	12.09	0.49	1.95e-29	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10390922	chr17:58755255	BCAS3	0.5	7.23	0.32	1.98e-12	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs709609	chr7:65560561	A/G	cg11764359	chr7:65958608	NA	-0.7	-12.06	-0.49	2.57e-29	Aortic root size;
LGG	cis	rs35123781	0.696	rs4912755	chr5:139070651	A/G	cg10513866	chr5:139070639	NA	0.4	7.81	0.34	4e-14	Schizophrenia;
LGG	cis	rs28830936	0.934	rs2412641	chr15:42124399	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.93	-0.52	7.23e-33	Diastolic blood pressure;
LGG	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4302748	0.817	rs11773129	chr7:36186670	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg13647721	chr17:30228624	UTP6	-0.76	-9.87	-0.42	5.36e-21	Hip circumference adjusted for BMI;
LGG	cis	rs6988985	0.728	rs5299	chr8:143955471	T/C	cg10324643	chr8:143916377	GML	0.38	7.63	0.33	1.31e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7226408	0.600	rs323319	chr18:34674412	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.16	-0.39	1.75e-18	Obesity-related traits;
LGG	cis	rs12580194	0.593	rs61957941	chr12:55748058	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-20.82	-0.7	2.02e-68	Vitiligo;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.29	-0.32	1.34e-12	Lung cancer;
LGG	cis	rs4936891	0.577	rs7945483	chr11:123903709	T/A	cg22125253	chr11:123886957	OR10G4	-0.54	-9.14	-0.39	2.04e-18	Male fertility;
LGG	cis	rs11098499	0.754	rs2964	chr4:120240131	T/C	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	cis	rs765787	0.530	rs2899379	chr15:45534799	C/T	cg25801113	chr15:45476975	SHF	-0.87	-18.68	-0.66	1.96e-58	Uric acid levels;
LGG	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg13385794	chr1:248469461	NA	0.44	8.05	0.35	7.28e-15	Common traits (Other);
LGG	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg26408565	chr15:76604113	ETFA	-0.38	-6.64	-0.3	8.61e-11	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20743544	chr7:32982957	RP9P	0.47	7.56	0.33	2.21e-13	Gut microbiome composition (summer);
LGG	cis	rs620875	1.000	rs600903	chr11:126847667	T/C	cg06504925	chr11:126872760	NA	-0.55	-7.7	-0.34	8.53e-14	Response to antipsychotic treatment;
LGG	trans	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg21238619	chr17:78079768	GAA	0.37	7.78	0.34	4.74e-14	Yeast infection;
LGG	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg01017244	chr2:74357527	NA	0.47	8.82	0.38	2.33e-17	Gestational age at birth (maternal effect);
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg17470184	chr11:118478236	PHLDB1	-0.43	-7.52	-0.33	2.8e-13	Cholesterol, total;
LGG	cis	rs757978	0.777	rs11693232	chr2:242362240	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.57	-0.37	1.61e-16	Chronic lymphocytic leukemia;
LGG	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg20821713	chr7:1055600	C7orf50	-0.46	-6.65	-0.3	8.13e-11	Bronchopulmonary dysplasia;
LGG	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Vitiligo;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.65	0.34	1.14e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09454676	chr2:207307732	ADAM23	0.48	7.33	0.32	1e-12	Gut microbiome composition (summer);
LGG	cis	rs6712932	1.000	rs6746579	chr2:105843223	G/T	cg27422857	chr2:105853526	NA	-0.38	-7.03	-0.31	7.5e-12	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.4	-0.56	4.17e-39	Platelet count;
LGG	cis	rs12431410	0.584	rs6573284	chr14:60247162	A/G	cg07950296	chr14:60194823	RTN1	-0.38	-7.13	-0.31	3.94e-12	Schizophrenia;
LGG	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg18225595	chr11:63971243	STIP1	0.47	6.78	0.3	3.69e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg00405596	chr8:11794950	NA	-0.41	-6.91	-0.31	1.65e-11	Mood instability;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.43	0.33	5.34e-13	Prudent dietary pattern;
LGG	cis	rs10883723	0.962	rs11191294	chr10:104225837	T/G	cg05096777	chr10:104283225	SUFU	0.31	6.69	0.3	6.59e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg24375607	chr4:120327624	NA	0.66	10.86	0.45	1.24e-24	Corneal astigmatism;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs367943	0.966	rs348947	chr5:112822795	C/G	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg19143629	chr17:61920732	SMARCD2	0.41	7.1	0.31	4.77e-12	Prudent dietary pattern;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.91	-0.31	1.59e-11	Total body bone mineral density;
LGG	cis	rs3087591	0.708	rs2525569	chr17:29675971	T/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.59	0.51	1.82e-31	Hip circumference;
LGG	trans	rs62103177	0.673	rs62096717	chr18:77616819	C/T	cg05926928	chr17:57297772	GDPD1	0.97	15.57	0.59	2.97e-44	Opioid sensitivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14283194	chr7:91763737	CYP51A1	0.51	8.74	0.38	4.39e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	8.17	0.36	2.88e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.57	-0.37	1.55e-16	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13196826	chr10:98945664	SLIT1	-0.46	-6.71	-0.3	5.56e-11	Systemic lupus erythematosus;
LGG	cis	rs727505	0.908	rs56155943	chr7:124606346	T/G	cg23710748	chr7:124431027	NA	-0.52	-9.6	-0.41	5e-20	Lewy body disease;
LGG	cis	rs4787491	0.704	rs9928448	chr16:30072530	T/C	cg06326092	chr16:30034487	C16orf92	0.43	8.5	0.37	2.68e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6988985	0.765	rs7824229	chr8:143984064	A/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.75	-0.51	3.89e-32	Total body bone mineral density;
LGG	cis	rs4253772	0.637	rs7284687	chr22:46690321	T/C	cg18190219	chr22:46762943	CELSR1	-0.59	-6.66	-0.3	7.71e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.95e-42	Prudent dietary pattern;
LGG	cis	rs9771228	0.931	rs215639	chr7:32373639	C/T	cg27532318	chr7:32358331	NA	-0.43	-6.79	-0.3	3.49e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	trans	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.05	0.31	6.66e-12	Retinal vascular caliber;
LGG	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg00700412	chr12:58011837	NA	0.47	9.5	0.4	1.11e-19	Multiple sclerosis;
LGG	cis	rs4474465	0.850	rs10899528	chr11:78207686	T/C	cg02023728	chr11:77925099	USP35	-0.39	-7.05	-0.31	6.46e-12	Alzheimer's disease (survival time);
LGG	cis	rs8038465	0.594	rs55816897	chr15:73869767	G/T	cg15420318	chr15:73925796	NPTN	0.51	8.87	0.38	1.58e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg22857025	chr5:266934	NA	-1.15	-9.46	-0.4	1.58e-19	Asthma (childhood onset);
LGG	cis	rs889398	0.594	rs8047194	chr16:69891510	G/T	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.43	-0.33	5.31e-13	Body mass index;
LGG	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg14416269	chr4:6271139	WFS1	0.47	8.39	0.36	5.73e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-8.96	-0.38	7.95e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs1941687	0.524	rs6507062	chr18:31374197	G/C	cg04226714	chr8:49833948	SNAI2	-0.48	-8.71	-0.38	5.24e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg18252515	chr7:66147081	NA	-1.42	-19.98	-0.68	1.74e-64	Diabetic kidney disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02580404	chr16:19729857	C16orf88;IQCK	0.57	6.73	0.3	4.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs524281	0.861	rs10896094	chr11:65959206	C/T	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg07930552	chr6:133119739	C6orf192	1.13	9.84	0.42	7.36e-21	Type 2 diabetes nephropathy;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs2273669	0.667	rs76732622	chr6:109318280	A/T	cg05315195	chr6:109294784	ARMC2	-0.69	-8.39	-0.36	5.83e-16	Prostate cancer;
LGG	cis	rs6032067	0.641	rs761500	chr20:43772272	A/G	cg10761708	chr20:43804764	PI3	-0.69	-9.99	-0.42	2.04e-21	Blood protein levels;
LGG	cis	rs7017914	0.934	rs62530772	chr8:71601541	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs6011674	1.000	rs1555337	chr20:61863641	A/G	cg14895298	chr20:61867178	BIRC7	0.43	6.91	0.31	1.65e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs2224391	0.578	rs766339	chr6:5243506	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.16	-0.32	3.18e-12	Height;
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.27	-0.46	3.28e-26	Personality dimensions;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg08677398	chr8:58056175	NA	0.45	7.41	0.33	5.87e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg13628971	chr7:2884303	GNA12	0.51	10.53	0.44	2.23e-23	Height;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00684032	chr4:1343700	KIAA1530	0.68	14.03	0.55	1.65e-37	Obesity-related traits;
LGG	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.42	0.58	1.38e-43	Chronic sinus infection;
LGG	cis	rs11711311	1.000	rs9865435	chr3:113450046	G/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.44e-13	IgG glycosylation;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12741488	chr16:2933841	FLYWCH2	0.38	6.97	0.31	1.06e-11	Obesity-related traits;
LGG	cis	rs593531	0.571	rs11236088	chr11:74094343	A/G	cg18195628	chr11:73498948	MRPL48	-0.4	-6.82	-0.3	2.93e-11	Neuroticism;
LGG	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg21100191	chr22:23484243	RTDR1	0.98	22.33	0.72	1.61e-75	Bone mineral density;
LGG	cis	rs36051895	0.587	rs11999802	chr9:5189773	T/G	cg02405213	chr9:5042618	JAK2	-0.75	-13.3	-0.53	2.12e-34	Pediatric autoimmune diseases;
LGG	cis	rs74781061	0.929	rs1821848	chr15:74833784	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg26248373	chr2:1572462	NA	-0.69	-8.88	-0.38	1.51e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9487094	0.885	rs13212766	chr6:109705431	C/A	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.75e-18	Height;
LGG	cis	rs4740619	0.766	rs36013000	chr9:15751913	T/C	cg14451791	chr9:16040625	NA	0.33	8.33	0.36	9.21e-16	Body mass index;
LGG	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg20891283	chr12:69753455	YEATS4	0.76	14.63	0.56	4.14e-40	Blood protein levels;
LGG	cis	rs4748857	0.947	rs4748856	chr10:23599342	C/T	cg12804278	chr10:23633326	C10orf67	-0.39	-6.72	-0.3	5.35e-11	Systemic lupus erythematosus;
LGG	cis	rs1124376	0.816	rs1061636	chr3:20190727	G/C	cg05072819	chr3:20081367	KAT2B	0.51	7.09	0.31	5.03e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.500	rs2878762	chr3:52919002	T/C	cg11645453	chr3:52864694	ITIH4	0.62	9.81	0.41	9.4499999999999992e-21	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.82	0.3	2.89e-11	Bladder cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07924874	chr19:58609793	ZSCAN18	0.36	6.69	0.3	6.4e-11	Obesity-related traits;
LGG	cis	rs2718058	0.836	rs4723711	chr7:37844263	T/A	cg15028436	chr7:37888078	TXNDC3	-0.51	-9.31	-0.4	5.14e-19	Alzheimer's disease (late onset);
LGG	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg07549998	chr6:150325970	RAET1K	-0.36	-6.92	-0.31	1.54e-11	Alopecia areata;
LGG	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg22875332	chr1:76189707	ACADM	0.55	7.9	0.34	1.99e-14	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs56399783	0.901	rs73049380	chr7:2832845	C/T	cg19731401	chr7:2775893	GNA12	0.35	7.23	0.32	1.98e-12	Childhood ear infection;
LGG	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg01017244	chr2:74357527	NA	0.47	8.9	0.38	1.29e-17	Gestational age at birth (maternal effect);
LGG	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.64	-0.37	9.38e-17	Lung cancer in ever smokers;
LGG	cis	rs9354308	0.738	rs1938115	chr6:66593165	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs4986172	0.655	rs1044977	chr17:43227214	T/C	cg10701640	chr17:43249399	NA	0.43	7.49	0.33	3.48e-13	Height;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.9	9.39	0.4	2.66e-19	Diabetic retinopathy;
LGG	cis	rs2832077	0.943	rs2832091	chr21:30162855	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-8.12	-0.35	4.25e-15	Cognitive test performance;
LGG	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-7.2	-0.32	2.47e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs3206736	0.636	rs6950920	chr7:35221053	A/G	cg13400248	chr7:35225412	NA	0.44	7.99	0.35	1.08e-14	Diastolic blood pressure;
LGG	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Myopia (pathological);
LGG	cis	rs796364	0.951	rs12620298	chr2:201047184	C/T	cg23649088	chr2:200775458	C2orf69	-0.61	-8.56	-0.37	1.7e-16	Schizophrenia;
LGG	cis	rs77633900	0.614	rs203753	chr15:76946195	A/T	cg21673338	chr15:77095150	SCAPER	-0.65	-10.17	-0.43	4.62e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg08392591	chr16:89556376	ANKRD11	0.62	10.0	0.42	1.97e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.64	-0.48	1.17e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01423820	chr14:77228690	VASH1	0.52	8.57	0.37	1.6e-16	Cognitive performance;
LGG	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg15627072	chr1:2432621	PLCH2	0.36	8.13	0.35	4.05e-15	Ulcerative colitis;
LGG	cis	rs7587476	0.906	rs17487792	chr2:215643500	A/G	cg04530015	chr2:215796436	ABCA12	0.44	6.89	0.3	1.84e-11	Neuroblastoma;
LGG	cis	rs66887589	0.807	rs9799664	chr4:120326678	C/T	cg09307838	chr4:120376055	NA	0.5	8.56	0.37	1.66e-16	Diastolic blood pressure;
LGG	cis	rs3793683	0.556	rs2803989	chr10:134560596	C/T	cg27286337	chr10:134555280	INPP5A	0.82	14.23	0.55	2.19e-38	Migraine;
LGG	cis	rs7715806	0.500	rs4704233	chr5:75000792	G/A	cg19683494	chr5:74908142	NA	0.5	6.68	0.3	6.95e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11877825	0.826	rs9676161	chr18:10571439	G/A	cg07277756	chr18:10589357	NA	0.58	10.36	0.43	9.13e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs2120243	0.845	rs2316710	chr3:157150180	G/T	cg24825693	chr3:157122686	VEPH1	-0.36	-7.67	-0.34	1.02e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg05863683	chr7:1912471	MAD1L1	0.44	8.83	0.38	2.23e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.48	-0.33	3.88e-13	Life satisfaction;
LGG	cis	rs801193	1.000	rs2659909	chr7:66160279	G/A	cg00343986	chr7:65444356	GUSB	0.39	6.77	0.3	3.89e-11	Aortic root size;
LGG	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg00531865	chr16:30841666	NA	-0.54	-10.87	-0.45	1.11e-24	Multiple myeloma;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg00933542	chr6:150070202	PCMT1	0.4	7.04	0.31	7.15e-12	Lung cancer;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.1	-0.35	4.96e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10791097	0.720	rs6590518	chr11:130733530	C/T	cg12179176	chr11:130786555	SNX19	0.8	16.21	0.6	4.13e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2439831	1.000	rs9920763	chr15:43760508	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.44	0.44	4.71e-23	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.74	0.3	4.83e-11	Schizophrenia;
LGG	cis	rs754423	0.515	rs35800326	chr14:52549984	T/C	cg12071775	chr14:52591786	NA	-0.43	-7.05	-0.31	6.65e-12	Craniofacial microsomia;
LGG	cis	rs2075466	0.588	rs111581085	chr16:4868293	C/G	cg04440724	chr16:4920505	UBN1	-0.57	-8.34	-0.36	8.27e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	cg07928641	chr1:182991847	LAMC1	0.45	8.73	0.38	4.77e-17	Fuchs's corneal dystrophy;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg21226059	chr5:178986404	RUFY1	0.51	9.27	0.4	7.07e-19	Lung cancer;
LGG	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg11887960	chr12:57824829	NA	0.58	7.15	0.32	3.31e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09217309	chr6:150244204	RAET1G	0.42	7.66	0.34	1.1e-13	Lung cancer;
LGG	cis	rs17604090	0.793	rs10241305	chr7:29689929	T/C	cg12658982	chr7:29603541	PRR15	-0.36	-6.93	-0.31	1.44e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs924607	0.931	rs1709556	chr5:637058	A/G	cg09021430	chr5:549028	NA	-0.52	-10.15	-0.43	5.34e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs8017423	0.935	rs4643251	chr14:90669256	C/T	cg04374321	chr14:90722782	PSMC1	-0.89	-18.47	-0.65	1.77e-57	Mortality in heart failure;
LGG	trans	rs7762018	0.769	rs7766146	chr6:170070135	A/T	cg06875740	chr19:51307921	C19orf48	-0.72	-8.51	-0.37	2.39e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6456156	0.586	rs4710176	chr6:167491639	T/C	cg07741184	chr6:167504864	NA	0.41	9.01	0.39	5.33e-18	Primary biliary cholangitis;
LGG	cis	rs4700695	1.000	rs111338	chr5:65420393	G/A	cg21114390	chr5:65439923	SFRS12	-0.56	-6.89	-0.3	1.86e-11	Facial morphology (factor 19);
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg26174226	chr8:58114915	NA	-0.54	-8.0	-0.35	1.02e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg07936489	chr17:37558343	FBXL20	-0.49	-8.29	-0.36	1.28e-15	Asthma;
LGG	cis	rs6708331	0.517	rs6546570	chr2:70350033	G/C	cg01613454	chr2:70366299	NA	0.54	10.99	0.45	3.91e-25	Obesity-related traits;
LGG	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	15.45	0.58	9.99e-44	Mean platelet volume;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg22682162	chr6:97731065	MIR548H3;C6orf167	0.39	6.65	0.3	8.08e-11	Lung adenocarcinoma;
LGG	cis	rs6879260	1.000	rs888922	chr5:179731635	C/G	cg02891314	chr5:179741120	GFPT2	-0.62	-11.58	-0.47	2.12e-27	Height;
LGG	trans	rs7395662	0.782	rs4882064	chr11:48455757	C/T	cg00717180	chr2:96193071	NA	0.43	7.69	0.34	8.8e-14	HDL cholesterol;
LGG	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.19e-18	Neuroticism;
LGG	cis	rs988958	0.958	rs2425	chr2:42285642	G/A	cg27252766	chr2:42229092	NA	0.46	7.42	0.33	5.79e-13	Hypospadias;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg24503407	chr1:205819492	PM20D1	0.85	21.15	0.7	5.85e-70	Menarche (age at onset);
LGG	cis	rs806215	0.526	rs62481450	chr7:127568983	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	7.12e-12	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg26174226	chr8:58114915	NA	-0.45	-6.73	-0.3	5.11e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs5753037	0.702	rs81800	chr22:30200362	C/G	cg01021169	chr22:30184971	ASCC2	0.36	7.22	0.32	2.09e-12	Type 1 diabetes;
LGG	cis	rs9393692	0.557	rs17608582	chr6:26318799	C/A	cg13736514	chr6:26305472	NA	-0.48	-9.44	-0.4	1.78e-19	Educational attainment;
LGG	cis	rs875971	0.825	rs66981195	chr7:66079035	C/A	cg11764359	chr7:65958608	NA	-0.74	-13.34	-0.53	1.41e-34	Aortic root size;
LGG	cis	rs12980942	0.810	rs35812313	chr19:41789178	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.6	7.68	0.34	9.62e-14	Coronary artery disease;
LGG	cis	rs7246865	0.906	rs11666569	chr19:17214073	A/G	cg19418318	chr19:17219073	MYO9B	-0.34	-9.25	-0.39	8.29e-19	Reticulocyte fraction of red cells;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg10189774	chr4:17578691	LAP3	0.38	6.67	0.3	7.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.08	-0.31	5.47e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4789452	1.000	rs35971812	chr17:75373362	C/A	cg06761530	chr17:75373219	SEPT9	-0.39	-7.53	-0.33	2.63e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs9308433	0.529	rs17022608	chr1:214500907	A/C	cg06198575	chr1:214491504	SMYD2	0.51	7.73	0.34	6.8e-14	IgG glycosylation;
LGG	trans	rs28595532	0.660	rs11933762	chr4:119307126	A/G	cg26518628	chr1:97050305	NA	-0.91	-12.39	-0.5	1.24e-30	Cannabis dependence symptom count;
LGG	cis	rs896854	0.684	rs2340534	chr8:95992330	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.42	-0.36	4.59e-16	Type 2 diabetes;
LGG	trans	rs1941687	0.797	rs9954214	chr18:31390754	T/C	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10254118	0.757	rs7788086	chr7:133135206	C/T	cg10665199	chr7:133106180	EXOC4	0.57	9.45	0.4	1.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg16359550	chr11:109292809	C11orf87	0.54	10.18	0.43	4.16e-22	Schizophrenia;
LGG	cis	rs2287838	0.668	rs12979274	chr19:10000925	A/G	cg00846166	chr19:10022875	OLFM2	-0.32	-7.34	-0.32	9.46e-13	Sleep duration;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.6e-22	Menopause (age at onset);
LGG	cis	rs17767392	0.834	rs11626886	chr14:71727155	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.84	-0.38	1.94e-17	Mitral valve prolapse;
LGG	cis	rs4629180	0.586	rs290773	chr2:102125930	G/A	cg16435561	chr2:102091048	RFX8	-0.46	-8.44	-0.36	4.24e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs4700695	0.719	rs27078	chr5:65445331	G/C	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs2013441	0.613	rs7215803	chr17:19998377	C/T	cg13482628	chr17:19912719	NA	0.52	9.73	0.41	1.77e-20	Obesity-related traits;
LGG	cis	rs9783347	1.000	rs9988866	chr11:18392983	A/T	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.41	-0.33	6.06e-13	Pancreatic cancer;
LGG	trans	rs61931739	0.817	rs10743841	chr12:34252870	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.42	0.36	4.67e-16	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs11053194	chr12:34440841	A/G	cg26384229	chr12:38710491	ALG10B	0.86	18.75	0.66	9.13e-59	Morning vs. evening chronotype;
LGG	cis	rs35771425	0.956	rs12758491	chr1:211589572	C/T	cg10512769	chr1:211675356	NA	-0.74	-11.97	-0.49	5.93e-29	Educational attainment (years of education);
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs8077889	0.956	rs55768269	chr17:41888997	C/T	cg26893861	chr17:41843967	DUSP3	0.92	15.49	0.58	6.49e-44	Triglycerides;
LGG	cis	rs4917300	0.650	rs4917268	chr8:143072510	G/A	cg06573787	chr8:143070187	NA	0.76	16.0	0.6	3.58e-46	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg24058013	chr18:77568902	NA	-0.43	-6.92	-0.31	1.54e-11	Schizophrenia;
LGG	cis	rs7546668	1.000	rs4233537	chr1:15849700	T/A	cg21858823	chr1:15850916	CASP9	0.37	6.87	0.3	2.03e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg06916706	chr16:4465613	CORO7	-0.87	-15.12	-0.57	2.94e-42	Schizophrenia;
LGG	cis	rs944722	1.000	rs1060822	chr17:26092631	A/G	cg07704981	chr17:26127537	NOS2	-0.49	-8.5	-0.37	2.7e-16	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs17270561	0.583	rs7749149	chr6:25781139	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.18	-0.32	2.84e-12	Iron status biomarkers;
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg12463550	chr7:65579703	CRCP	0.5	8.25	0.36	1.63e-15	Aortic root size;
LGG	cis	rs78456975	0.527	rs7590743	chr2:1575048	A/G	cg01028140	chr2:1542097	TPO	-0.43	-8.17	-0.35	3.01e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10791323	0.660	rs10791332	chr11:133732150	A/G	cg00579200	chr11:133705235	NA	-0.54	-10.45	-0.44	4.26e-23	Childhood ear infection;
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg19774624	chr17:42201019	HDAC5	-0.81	-14.66	-0.56	2.98e-40	Total body bone mineral density;
LGG	trans	rs1814175	0.647	rs1404157	chr11:49917301	G/C	cg15704280	chr7:45808275	SEPT13	-0.86	-17.07	-0.62	4.69e-51	Height;
LGG	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg25025879	chr12:53359317	NA	-0.48	-8.62	-0.37	1.08e-16	Cancer (pleiotropy);
LGG	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg00666640	chr1:248458726	OR2T12	0.58	9.31	0.4	4.99e-19	Common traits (Other);
LGG	cis	rs7241530	0.662	rs2898715	chr18:75906351	T/C	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs6500602	0.893	rs6500598	chr16:4470964	G/T	cg08645402	chr16:4508243	NA	0.51	8.86	0.38	1.73e-17	Schizophrenia;
LGG	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.18	0.43	4.24e-22	Height;
LGG	cis	rs9486719	1.000	rs4078038	chr6:96904366	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.46	-0.44	3.99e-23	Migraine;Coronary artery disease;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg23978390	chr7:1156363	C7orf50	0.46	7.69	0.34	9.22e-14	Longevity;Endometriosis;
LGG	cis	rs778371	0.723	rs1973675	chr2:233636450	C/T	cg08000102	chr2:233561755	GIGYF2	-0.74	-12.47	-0.5	5.62e-31	Schizophrenia;
LGG	cis	rs7914558	1.000	rs11191539	chr10:104819770	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.69	0.44	5.43e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6693295	0.536	rs2788013	chr1:246241892	C/T	cg11798871	chr1:246315928	SMYD3	-0.61	-8.13	-0.35	3.98e-15	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.25	0.83	1.76e-120	Chronic sinus infection;
LGG	cis	rs11885103	0.543	rs2724926	chr2:562776	T/C	cg21195176	chr2:593345	NA	0.4	7.45	0.33	4.63e-13	Heschl's gyrus morphology;
LGG	cis	rs4664308	0.618	rs4665139	chr2:160890692	G/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.65	-0.48	1.1e-27	Idiopathic membranous nephropathy;
LGG	cis	rs28595532	0.920	rs55640619	chr4:119761999	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.88e-12	Tonsillectomy;
LGG	cis	rs2594989	0.943	rs6442251	chr3:11417477	A/G	cg01796438	chr3:11312864	ATG7	-0.51	-6.77	-0.3	3.84e-11	Circulating chemerin levels;
LGG	cis	rs35522438	1	rs35522438	chr7:91872872	A/AT	cg17063962	chr7:91808500	NA	0.52	9.58	0.41	5.94e-20	Breast cancer;
LGG	cis	rs870825	0.616	rs55685500	chr4:185614810	G/A	cg04058563	chr4:185651563	MLF1IP	1.08	22.03	0.72	4.11e-74	Blood protein levels;
LGG	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.25	-0.49	4.57e-30	Depression;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.32	0.32	1.12e-12	Tonsillectomy;
LGG	cis	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg00405596	chr8:11794950	NA	0.65	11.61	0.47	1.55e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg14101638	chr12:121416612	HNF1A	-0.44	-9.56	-0.41	6.8e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg19077165	chr18:44547161	KATNAL2	0.55	9.85	0.42	6.69e-21	Personality dimensions;
LGG	cis	rs4788815	0.533	rs12102548	chr16:71929763	C/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	Metabolite levels;
LGG	cis	rs2694528	0.686	rs7729781	chr5:59872406	C/T	cg11474532	chr5:59995715	DEPDC1B	0.92	8.84	0.38	1.99e-17	Parkinson's disease;
LGG	cis	rs9517320	0.935	rs1886089	chr13:99124356	C/T	cg07423050	chr13:99094983	FARP1	0.4	8.12	0.35	4.16e-15	Longevity;
LGG	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.57e-22	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19932523	chr11:72145623	CLPB	0.46	6.93	0.31	1.41e-11	Gut microbiome composition (summer);
LGG	cis	rs231513	1.000	rs231526	chr17:41951277	T/C	cg26893861	chr17:41843967	DUSP3	-0.57	-6.69	-0.3	6.5e-11	Cognitive function;
LGG	cis	rs10186029	0.657	rs11689895	chr2:213938553	G/T	cg08319019	chr2:214017104	IKZF2	0.47	8.24	0.36	1.77e-15	Systemic sclerosis;
LGG	cis	rs1015291	0.748	rs941233	chr12:19993676	C/T	cg25401612	chr12:20009446	NA	0.35	7.59	0.33	1.78e-13	Diastolic blood pressure;
LGG	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg27432699	chr2:27873401	GPN1	-0.42	-6.98	-0.31	9.97e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs8048589	1.000	rs16958964	chr16:12186586	T/C	cg02910054	chr16:12241554	SNX29	0.42	6.73	0.3	5.14e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg01879757	chr17:41196368	BRCA1	0.4	8.22	0.36	2e-15	Menopause (age at onset);
LGG	cis	rs6831352	0.879	rs1230154	chr4:99988659	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.05	0.35	7.18e-15	Alcohol dependence;
LGG	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.82	-0.42	8.23e-21	Educational attainment;
LGG	cis	rs1059312	1.000	rs9738216	chr12:129281788	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.22	0.32	2.08e-12	Systemic lupus erythematosus;
LGG	cis	rs8017423	0.647	rs1958345	chr14:90823770	T/C	cg04374321	chr14:90722782	PSMC1	-0.64	-12.83	-0.51	1.91e-32	Mortality in heart failure;
LGG	cis	rs412000	0.598	rs8263	chr17:56423114	C/T	cg12560992	chr17:57184187	TRIM37	0.52	8.23	0.36	1.97e-15	Primary tooth development (time to first tooth eruption);
LGG	cis	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg10911889	chr6:126070802	HEY2	0.41	6.94	0.31	1.35e-11	Brugada syndrome;
LGG	cis	rs2073300	0.609	rs56334525	chr20:23365812	A/G	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs800082	1.000	rs12637885	chr3:144291254	G/T	cg24215973	chr2:240111563	HDAC4	-0.48	-8.46	-0.37	3.43e-16	Smoking behavior;
LGG	cis	rs1249910	0.744	rs12054416	chr3:112390975	C/G	cg02954903	chr3:112359935	CCDC80	0.4	6.99	0.31	9.43e-12	Diabetic kidney disease;
LGG	cis	rs9512730	0.553	rs6491212	chr13:28049631	T/C	cg04070771	chr13:27998621	GTF3A	0.47	7.14	0.31	3.66e-12	Schizophrenia;
LGG	trans	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg17712092	chr4:129076599	LARP1B	0.75	14.49	0.56	1.71e-39	Eosinophil percentage of white cells;
LGG	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	cg07928641	chr1:182991847	LAMC1	-0.45	-9.03	-0.39	4.78e-18	Colorectal cancer;
LGG	cis	rs7312933	0.558	rs1669936	chr12:42813509	C/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.23	-0.36	1.87e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12618769	0.570	rs17032866	chr2:99132415	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1577917	0.958	rs12196230	chr6:86519960	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.58	-0.37	1.43e-16	Response to antipsychotic treatment;
LGG	cis	rs9394438	0.628	rs4714079	chr6:37544439	C/T	cg00985040	chr6:37553208	NA	-0.37	-8.3	-0.36	1.18e-15	IgG glycosylation;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16524936	chr4:1340807	KIAA1530	-0.49	-8.31	-0.36	1.05e-15	Longevity;
LGG	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg15627072	chr1:2432621	PLCH2	0.36	8.06	0.35	6.62e-15	Ulcerative colitis;
LGG	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg21238619	chr17:78079768	GAA	-0.38	-7.8	-0.34	4.13e-14	Yeast infection;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.61	11.43	0.47	8.17e-27	Obesity-related traits;
LGG	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg24998770	chr7:37888106	TXNDC3	0.68	11.86	0.48	1.68e-28	Alzheimer's disease (late onset);
LGG	cis	rs17102423	0.964	rs11623603	chr14:65602287	T/A	cg11161011	chr14:65562177	MAX	-0.61	-11.5	-0.47	4.25e-27	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg18032289	chr17:61959525	GH2	-0.41	-7.06	-0.31	5.97e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg09764611	chr12:132620959	NA	-0.58	-8.79	-0.38	2.95e-17	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.63e-19	Neuroticism;
LGG	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg13385794	chr1:248469461	NA	0.49	8.14	0.35	3.63e-15	Common traits (Other);
LGG	trans	rs1814175	0.791	rs10839468	chr11:49986288	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs7177699	0.557	rs4073322	chr15:79122541	G/C	cg00540400	chr15:79124168	NA	0.54	11.53	0.47	3.39e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7208859	0.673	rs9889755	chr17:29234505	A/G	cg01831904	chr17:28903510	LRRC37B2	0.6	7.3	0.32	1.23e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg17054900	chr3:154042577	DHX36	0.46	7.12	0.31	4.17e-12	Coronary artery disease;
LGG	cis	rs919433	0.648	rs6434933	chr2:198426960	G/A	cg00792783	chr2:198669748	PLCL1	0.5	7.83	0.34	3.43e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7011049	1.000	rs72643600	chr8:53854530	T/G	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.44	7.4	0.33	6.53e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs61935443	0.832	rs11107771	chr12:95276844	A/G	cg21533806	chr12:95267307	NA	0.5	6.87	0.3	2.09e-11	Schizophrenia;
LGG	cis	rs2842992	0.872	rs2758330	chr6:160104844	G/T	cg27624424	chr6:160112604	SOD2	0.69	10.26	0.43	2.14e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	trans	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg19894588	chr14:64061835	NA	-0.56	-8.74	-0.38	4.32e-17	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9549367	1.000	rs9549367	chr13:113911532	C/G	cg00898013	chr13:113819073	PROZ	-0.41	-8.21	-0.36	2.21e-15	Platelet distribution width;
LGG	cis	rs8005677	0.798	rs35615180	chr14:23404389	T/C	cg25600027	chr14:23388339	RBM23	-0.43	-7.2	-0.32	2.38e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9828933	0.752	rs17069507	chr3:63924956	A/G	cg17941049	chr3:63904683	ATXN7	0.71	7.26	0.32	1.67e-12	Type 2 diabetes;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg25811766	chr13:21894605	NA	0.75	13.76	0.54	2.32e-36	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs867371	0.762	rs12905578	chr15:82581264	T/G	cg00614314	chr15:82944287	LOC80154	-0.64	-10.57	-0.44	1.57e-23	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.921	rs2281332	chr22:41746212	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-7.25	-0.32	1.72e-12	Vitiligo;
LGG	cis	rs9487094	1.000	rs12197114	chr6:109735498	T/C	cg01125227	chr6:109776195	MICAL1	0.53	9.1	0.39	2.65e-18	Height;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg11062466	chr8:58055876	NA	0.44	7.3	0.32	1.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17672112	0.834	rs612117	chr6:101344511	A/C	cg27451362	chr6:101846650	GRIK2	0.8	10.52	0.44	2.38e-23	Putamen volume;
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16318349	chr1:154917307	PBXIP1	0.29	7.91	0.35	1.89e-14	Prostate cancer;
LGG	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg23625390	chr15:77176239	SCAPER	-0.66	-13.46	-0.53	4.58e-35	Blood metabolite levels;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.88	-0.54	7.37e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.71	0.66	1.43e-58	Menopause (age at onset);
LGG	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.95	16.61	0.61	6.02e-49	Chronic sinus infection;
LGG	trans	rs7395662	1.000	rs12806328	chr11:48647971	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.35	-0.32	8.9e-13	HDL cholesterol;
LGG	cis	rs7712401	0.623	rs30032	chr5:122238387	G/T	cg19412675	chr5:122181750	SNX24	0.42	6.99	0.31	9.76e-12	Mean platelet volume;
LGG	cis	rs367943	1.000	rs348929	chr5:112814883	T/A	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.84	18.46	0.65	1.94e-57	Menarche (age at onset);
LGG	cis	rs4959677	0.586	rs55732532	chr6:2474874	A/G	cg23817096	chr6:1620687	NA	-0.31	-7.43	-0.33	5.32e-13	Orthostatic hypotension;
LGG	trans	rs853679	0.585	rs201000	chr6:27809159	C/T	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.41	-0.33	6.21e-13	Depression;
LGG	cis	rs17253792	0.545	rs35230683	chr14:56012493	G/T	cg01858014	chr14:56050164	KTN1	-0.73	-8.53	-0.37	2.04e-16	Putamen volume;
LGG	cis	rs755249	0.501	rs1889830	chr1:39730172	A/G	cg18385671	chr1:39797026	MACF1	-0.49	-9.61	-0.41	4.81e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02037503	chr14:23540729	ACIN1	0.52	8.22	0.36	2.11e-15	Gut microbiome composition (summer);
LGG	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	11.68	0.48	8.19e-28	Hemoglobin concentration;
LGG	cis	rs1408799	0.542	rs10756402	chr9:12739948	A/T	cg05274944	chr9:12693694	TYRP1	-0.31	-6.85	-0.3	2.41e-11	Eye color;Blue vs. green eyes;
LGG	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg13009111	chr11:71350975	NA	0.35	7.8	0.34	4.1e-14	Myopia (pathological);
LGG	cis	rs4740619	0.810	rs10810430	chr9:15704211	C/G	cg14451791	chr9:16040625	NA	0.32	8.26	0.36	1.57e-15	Body mass index;
LGG	cis	rs6681460	0.625	rs12138066	chr1:67103816	C/T	cg13052034	chr1:66999238	SGIP1	0.36	7.01	0.31	8.68e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs11098499	0.675	rs11098534	chr4:120556772	T/G	cg24375607	chr4:120327624	NA	0.59	10.1	0.42	8.21e-22	Corneal astigmatism;
LGG	cis	rs773506	0.565	rs4354431	chr9:94109406	T/A	cg14446406	chr9:93919335	NA	0.44	7.23	0.32	1.97e-12	Type 2 diabetes nephropathy;
LGG	cis	rs11122272	0.735	rs2244986	chr1:231537452	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.51	-12.03	-0.49	3.42e-29	Oropharynx cancer;
LGG	cis	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg21775007	chr8:11205619	TDH	-0.52	-8.15	-0.35	3.52e-15	Triglycerides;
LGG	cis	rs2120019	0.567	rs28844983	chr15:75178088	T/A	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.06	-0.46	2.12e-25	Blood trace element (Zn levels);
LGG	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg09303159	chr6:26284866	NA	0.32	6.85	0.3	2.41e-11	Mosquito bite size;
LGG	cis	rs7927592	0.956	rs11228258	chr11:68254328	A/C	cg20283391	chr11:68216788	NA	0.49	7.98	0.35	1.14e-14	Total body bone mineral density;
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg07061783	chr6:25882402	NA	0.4	7.04	0.31	7.05e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.34	-0.32	9.99e-13	Uric acid levels;
LGG	cis	rs12681288	0.676	rs1562921	chr8:1021986	G/T	cg15309053	chr8:964076	NA	0.36	7.08	0.31	5.26e-12	Schizophrenia;
LGG	cis	rs9894429	0.646	rs7220310	chr17:79606056	C/A	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg27165867	chr14:105738592	BRF1	-0.47	-7.77	-0.34	5.27e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.58	10.03	0.42	1.49e-21	Obesity-related traits;
LGG	cis	rs8064299	0.655	rs2305214	chr17:72768970	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.53	9.25	0.39	8.28e-19	Monocyte count;
LGG	cis	rs17504614	0.678	rs66848903	chr2:51092593	T/C	cg23851515	chr2:51057218	NRXN1	0.41	6.7	0.3	6.19e-11	Educational attainment (years of education);
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs6088580	0.624	rs6120645	chr20:33025171	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs4417704	0.551	rs7585067	chr2:241893465	T/C	cg05025159	chr2:241905733	NA	0.51	10.52	0.44	2.32e-23	Joint mobility (Beighton score);
LGG	cis	rs7737355	0.842	rs7731001	chr5:130781338	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.51	-0.37	2.42e-16	Life satisfaction;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg14893161	chr1:205819251	PM20D1	1.0	27.09	0.78	1.58e-97	Menarche (age at onset);
LGG	cis	rs1152591	0.562	rs1262242	chr14:64653869	C/T	cg21174375	chr14:64681225	SYNE2	0.42	7.86	0.34	2.72e-14	Atrial fibrillation;
LGG	cis	rs9357271	0.955	rs6923701	chr6:38374722	C/A	cg07362130	chr6:38359646	BTBD9	-0.44	-10.06	-0.42	1.2e-21	Restless legs syndrome;
LGG	cis	rs4423214	1.000	rs12792306	chr11:71166992	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.05	-0.52	2.27e-33	Vitamin D levels;
LGG	cis	rs4689388	0.819	rs12649341	chr4:6294759	G/A	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1144	0.537	rs2470949	chr7:104590780	C/T	cg03782966	chr7:104585482	NA	0.34	7.91	0.35	1.85e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs11105298	0.891	rs10777185	chr12:89921275	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs1941687	0.797	rs12963024	chr18:31389547	A/G	cg27147174	chr7:100797783	AP1S1	-0.54	-8.92	-0.38	1.06e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	9.44	0.4	1.9e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6601327	0.775	rs12156017	chr8:9406837	C/G	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.71e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1707322	1.000	rs11211244	chr1:46456673	G/A	cg03146154	chr1:46216737	IPP	0.53	9.95	0.42	2.96e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg27411982	chr8:10470053	RP1L1	0.4	6.71	0.3	5.8e-11	Morning vs. evening chronotype;
LGG	cis	rs2832191	0.791	rs2832202	chr21:30501342	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-23.81	-0.74	2.16e-82	Dental caries;
LGG	cis	rs11096990	0.821	rs2711991	chr4:39151353	G/A	cg24403649	chr4:39172243	NA	-0.49	-7.93	-0.35	1.63e-14	Cognitive function;
LGG	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	17.76	0.64	3.46e-54	Smoking behavior;
LGG	cis	rs11628318	0.803	rs10138267	chr14:103035432	C/T	cg01864069	chr14:103024347	NA	-0.73	-12.25	-0.49	4.58e-30	Platelet count;
LGG	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg00864171	chr11:67383662	NA	-0.45	-7.47	-0.33	4.05e-13	Mean corpuscular volume;
LGG	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	9.28	0.4	6.71e-19	Cognitive test performance;
LGG	cis	rs2413583	0.591	rs17000981	chr22:39708017	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.66	7.57	0.33	2.03e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11874712	0.965	rs28694780	chr18:43665338	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.78e-12	Blood metabolite levels;
LGG	cis	rs1348850	0.750	rs12997716	chr2:178494629	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-9.65	-0.41	3.3e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9549328	0.756	rs2993291	chr13:113653846	C/T	cg08528486	chr13:113648767	MCF2L	-0.33	-6.91	-0.31	1.58e-11	Systolic blood pressure;
LGG	cis	rs10771431	0.597	rs10771412	chr12:9354353	A/C	cg08997352	chr12:9597637	DDX12	-0.75	-13.72	-0.54	3.57e-36	Breast size;
LGG	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.73	-0.45	3.89e-24	Neuroticism;
LGG	cis	rs9916302	0.904	rs8076546	chr17:37555403	G/A	cg07936489	chr17:37558343	FBXL20	0.85	15.85	0.59	1.72e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06481639	chr22:41940642	POLR3H	-0.63	-9.13	-0.39	2.06e-18	Vitiligo;
LGG	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	trans	rs2018683	0.899	rs10479817	chr7:28978148	A/C	cg19402173	chr7:128379420	CALU	-0.65	-11.76	-0.48	3.98e-28	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs6840360	0.571	rs2406976	chr4:152541056	G/C	cg22705602	chr4:152727874	NA	-0.33	-7.95	-0.35	1.39e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg10253484	chr15:75165896	SCAMP2	0.51	7.53	0.33	2.72e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs35146811	0.657	rs36019559	chr7:99814586	A/G	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.39e-13	Coronary artery disease;
LGG	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9399135	0.967	rs1023179	chr6:135343829	T/A	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.71e-11	Red blood cell count;
LGG	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg21385522	chr1:16154831	NA	-1.04	-26.01	-0.77	1.42e-92	Dilated cardiomyopathy;
LGG	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Vitiligo;
LGG	cis	rs9291683	0.546	rs13139055	chr4:10038924	G/T	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg08048268	chr3:133502702	NA	-0.49	-8.42	-0.36	4.74e-16	Iron status biomarkers;
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg16318349	chr1:154917307	PBXIP1	0.26	7.03	0.31	7.51e-12	Prostate cancer;
LGG	cis	rs1035144	0.546	rs2215981	chr14:81444967	G/A	cg06600135	chr14:81408086	NA	-0.48	-9.28	-0.4	6.5e-19	Male sexual orientation;
LGG	cis	rs738322	0.511	rs5756947	chr22:38573230	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.77	-0.38	3.33e-17	Cutaneous nevi;
LGG	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-8.21	-0.36	2.24e-15	Height;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00166722	chr3:10149974	C3orf24	0.54	8.92	0.38	1.05e-17	Alzheimer's disease;
LGG	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg15268244	chr15:77196840	NA	-0.43	-9.48	-0.4	1.3e-19	Blood metabolite levels;
LGG	cis	rs10276381	1.000	rs10280937	chr7:28182306	T/C	cg23620719	chr7:28220237	JAZF1	0.81	10.4	0.44	6.67e-23	Crohn's disease;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg10505658	chr17:80084571	CCDC57	0.42	8.54	0.37	1.9e-16	Life satisfaction;
LGG	cis	rs3733585	0.673	rs4312757	chr4:9956145	T/A	cg08250081	chr4:10125330	NA	-0.37	-7.06	-0.31	6.2e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg19635926	chr16:89946313	TCF25	0.72	7.09	0.31	5.12e-12	Skin colour saturation;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg27532560	chr4:187881888	NA	-0.59	-12.92	-0.51	8.02e-33	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	cis	rs10875746	0.669	rs10875779	chr12:48629869	G/A	cg24011408	chr12:48396354	COL2A1	-0.58	-7.54	-0.33	2.56e-13	Longevity (90 years and older);
LGG	cis	rs1978968	0.700	rs10854521	chr22:18482600	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-12.55	-0.5	2.74e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07405021	chr5:115152019	CDO1	0.43	6.93	0.31	1.4e-11	Cognitive performance;
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs12220238	1.000	rs73284257	chr10:76000710	T/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.33	0.47	1.99e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1843834	0.721	rs6715655	chr2:225582284	C/T	cg22455342	chr2:225449267	CUL3	-0.46	-7.95	-0.35	1.46e-14	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs9914544	0.545	rs68046274	chr17:18785126	G/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs4595586	0.545	rs12812262	chr12:39392567	T/A	cg13010199	chr12:38710504	ALG10B	0.41	7.39	0.32	6.84e-13	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.52	10.01	0.42	1.71e-21	Longevity;
LGG	cis	rs2404602	0.669	rs12148877	chr15:76919959	T/G	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.49e-11	Blood metabolite levels;
LGG	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg04607235	chr12:12878440	APOLD1	-0.53	-7.64	-0.33	1.27e-13	Systemic lupus erythematosus;
LGG	cis	rs12681287	0.547	rs9297922	chr8:87542317	A/G	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs78456975	1.000	rs72776251	chr2:1525097	G/A	cg26248373	chr2:1572462	NA	-0.71	-8.56	-0.37	1.69e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg13647721	chr17:30228624	UTP6	0.6	7.72	0.34	7.01e-14	Hip circumference adjusted for BMI;
LGG	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg18196295	chr10:418757	DIP2C	-0.51	-8.76	-0.38	3.83e-17	Psychosis in Alzheimer's disease;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg12419862	chr22:24373484	LOC391322	-0.88	-17.94	-0.64	5.08e-55	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12477438	0.520	rs7606977	chr2:99991481	A/G	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.09	0.52	1.52e-33	Colorectal cancer;
LGG	cis	rs11096990	0.855	rs2566180	chr4:39159001	A/G	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs17401966	0.838	rs11580854	chr1:10293565	G/A	cg19773385	chr1:10388646	KIF1B	-0.5	-10.6	-0.44	1.22e-23	Hepatocellular carcinoma;
LGG	cis	rs3741151	0.881	rs12099129	chr11:73091318	T/G	cg17517138	chr11:73019481	ARHGEF17	0.97	9.36	0.4	3.51e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs908922	0.676	rs4845780	chr1:152488846	T/G	cg20991723	chr1:152506922	NA	-0.73	-14.96	-0.57	1.54e-41	Hair morphology;
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg00405596	chr8:11794950	NA	-0.39	-6.76	-0.3	4.04e-11	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01186835	chr6:26569014	NA	0.38	6.75	0.3	4.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg18351406	chr4:77819688	ANKRD56	0.43	7.2	0.32	2.52e-12	Emphysema distribution in smoking;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.98	0.35	1.15e-14	Bipolar disorder;
LGG	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.39	-0.32	7.15e-13	Retinal vascular caliber;
LGG	cis	rs41271473	0.526	rs942852	chr1:228730748	A/G	cg16512390	chr1:228756714	NA	0.61	8.07	0.35	6.21e-15	Chronic lymphocytic leukemia;
LGG	cis	rs2377585	0.898	rs73053848	chr12:8837330	C/T	cg03761649	chr12:8850719	RIMKLB	0.45	7.31	0.32	1.19e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg03605463	chr16:89740564	NA	0.41	6.9	0.31	1.7e-11	Vitiligo;
LGG	cis	rs11683229	0.598	rs13023873	chr2:64039567	C/T	cg02541582	chr2:64069798	UGP2	-0.51	-10.02	-0.42	1.55e-21	Protein quantitative trait loci;
LGG	cis	rs1009647	0.529	rs56098354	chr14:55668170	G/T	cg04306507	chr14:55594613	LGALS3	0.46	7.79	0.34	4.3e-14	Testicular germ cell tumor;
LGG	cis	rs10883723	0.810	rs7079810	chr10:104243883	C/T	cg05096777	chr10:104283225	SUFU	0.32	6.87	0.3	2.14e-11	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg11693508	chr17:37793320	STARD3	0.58	9.07	0.39	3.44e-18	Bipolar disorder;
LGG	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg01620082	chr3:125678407	NA	-0.63	-6.88	-0.3	1.99e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.42e-12	Colorectal cancer;
LGG	cis	rs12618769	0.597	rs3769727	chr2:99103318	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19422253	chr3:149212391	TM4SF4	0.42	6.86	0.3	2.19e-11	Pancreatic cancer;
LGG	cis	rs7166081	1.000	rs4352000	chr15:67643705	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg24690094	chr11:67383802	NA	0.5	9.14	0.39	1.96e-18	Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs466983	chr7:65520496	T/G	cg18252515	chr7:66147081	NA	-1.38	-19.15	-0.66	1.3e-60	Diabetic kidney disease;
LGG	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg06026331	chr20:60912101	LAMA5	-0.5	-9.49	-0.4	1.19e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs644799	0.710	rs12273579	chr11:95524421	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.44	0.58	1.11e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs35883536	1.000	rs4908087	chr1:101088594	C/T	cg06223162	chr1:101003688	GPR88	0.29	6.88	0.3	1.98e-11	Monocyte count;
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg03264133	chr6:25882463	NA	-0.5	-9.28	-0.4	6.59e-19	Height;
LGG	cis	rs793571	0.566	rs1648532	chr15:59076778	G/C	cg05156742	chr15:59063176	FAM63B	0.6	10.28	0.43	1.78e-22	Schizophrenia;
LGG	cis	rs12286929	0.609	rs45614535	chr11:115090866	G/A	cg04055981	chr11:115044050	NA	0.36	6.71	0.3	5.69e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6032067	0.929	rs17424723	chr20:43814520	G/T	cg10761708	chr20:43804764	PI3	-0.76	-12.01	-0.49	3.93e-29	Blood protein levels;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.13	-0.31	3.83e-12	Neuroticism;
LGG	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.73	-8.61	-0.37	1.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2404602	0.684	rs8029283	chr15:76837140	A/G	cg15268244	chr15:77196840	NA	0.46	9.79	0.41	1.11e-20	Blood metabolite levels;
LGG	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg19847130	chr8:10466454	RP1L1	0.31	6.8	0.3	3.33e-11	Neuroticism;
LGG	cis	rs9807841	0.670	rs2738039	chr19:10793749	A/G	cg17710535	chr19:10819994	QTRT1	0.45	6.94	0.31	1.35e-11	Inflammatory skin disease;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg02951883	chr7:2050386	MAD1L1	-0.58	-10.36	-0.43	9.13e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs73086581	1.000	rs3746665	chr20:3910406	C/T	cg02187196	chr20:3869020	PANK2	-0.74	-10.53	-0.44	2.22e-23	Response to antidepressants in depression;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg13047869	chr3:10149882	C3orf24	0.47	7.89	0.34	2.2e-14	Alzheimer's disease;
LGG	cis	rs6735179	0.958	rs7577768	chr2:1772552	T/C	cg20570797	chr2:1712800	PXDN	-0.4	-6.65	-0.3	8.31e-11	Response to antipsychotic treatment;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg03188948	chr7:1209495	NA	0.43	7.71	0.34	7.91e-14	Longevity;Endometriosis;
LGG	cis	rs2708377	0.789	rs3911150	chr12:11202248	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	-0.45	-7.12	-0.31	4.05e-12	Bitter taste perception;
LGG	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.14	-0.35	3.67e-15	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs9397585	0.599	rs639475	chr6:153407709	C/T	cg17707550	chr6:153380415	RGS17	-0.45	-9.83	-0.42	7.61e-21	Body mass index;
LGG	cis	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg15556689	chr8:8085844	FLJ10661	0.57	10.72	0.45	4.27e-24	Neuroticism;
LGG	cis	rs4926611	0.871	rs10888799	chr1:54100737	T/G	cg23596471	chr1:54105337	GLIS1	0.4	8.2	0.36	2.33e-15	Hand grip strength;
LGG	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9467773	0.620	rs6925087	chr6:26592853	T/A	cg09904177	chr6:26538194	HMGN4	0.69	14.15	0.55	4.91e-38	Intelligence (multi-trait analysis);
LGG	cis	rs10227331	0.846	rs10237006	chr7:157298250	A/G	cg06076350	chr7:157294107	NA	0.37	7.04	0.31	6.78e-12	Inattentive symptoms;
LGG	cis	rs12493885	0.729	rs10513452	chr3:153640429	A/C	cg17054900	chr3:154042577	DHX36	-0.58	-7.04	-0.31	6.9e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.32	6.7	0.3	6.07e-11	Schizophrenia;
LGG	cis	rs861020	1.000	rs622832	chr1:209974232	A/C	cg05527609	chr1:210001259	C1orf107	0.68	9.36	0.4	3.51e-19	Orofacial clefts;
LGG	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-8.44	-0.37	3.98e-16	Schizophrenia;
LGG	cis	rs4961252	0.505	rs12680168	chr8:142102522	A/T	cg17960426	chr8:142067321	NA	-0.38	-7.38	-0.32	7.33e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-20.7	-0.69	7.38e-68	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.27e-16	Obesity-related traits;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg16507663	chr6:150244633	RAET1G	0.41	7.58	0.33	1.86e-13	Lung cancer;
LGG	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs7586879	0.752	rs11683748	chr2:25130434	C/T	cg04586622	chr2:25135609	ADCY3	0.4	9.82	0.42	8.58e-21	Body mass index;
LGG	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-9.82	-0.42	8.53e-21	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.12e-24	Corneal astigmatism;
LGG	cis	rs172166	0.694	rs203876	chr6:28046673	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.11	-0.31	4.43e-12	Cardiac Troponin-T levels;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.69	-0.34	8.92e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg13010199	chr12:38710504	ALG10B	-0.68	-13.45	-0.53	4.69e-35	Morning vs. evening chronotype;
LGG	cis	rs826838	0.967	rs2892410	chr12:38990282	A/G	cg26384229	chr12:38710491	ALG10B	-1.05	-27.17	-0.78	6.66e-98	Heart rate;
LGG	cis	rs1348850	0.651	rs4893821	chr2:178229352	A/G	cg22681709	chr2:178499509	PDE11A	0.38	7.37	0.32	7.88e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg14137381	chr5:502291	SLC9A3	-0.33	-6.84	-0.3	2.52e-11	Cystic fibrosis severity;
LGG	cis	rs1620921	0.505	rs13196324	chr6:161201842	A/T	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1348850	0.914	rs11893448	chr2:178280013	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.39	-0.36	5.86e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs853679	0.517	rs1340004	chr6:28103691	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.58	-0.33	1.91e-13	Depression;
LGG	cis	rs9649465	0.561	rs2429621	chr7:123430316	A/G	cg03229431	chr7:123269106	ASB15	0.59	13.66	0.54	6.14e-36	Migraine;
LGG	cis	rs7143963	1.000	rs3783384	chr14:103351830	C/T	cg23020514	chr14:103360112	TRAF3	0.51	9.77	0.41	1.32e-20	Body mass index;
LGG	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg13770153	chr20:60521292	NA	-0.48	-7.64	-0.33	1.28e-13	Body mass index;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg17470184	chr11:118478236	PHLDB1	0.43	7.85	0.34	2.97e-14	Systemic lupus erythematosus;
LGG	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.45	-0.58	1.01e-43	Colorectal cancer;
LGG	trans	rs11875185	0.510	rs112969015	chr18:55634013	G/A	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.49	-0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2180341	0.855	rs9385422	chr6:127716457	C/T	cg24812749	chr6:127587940	RNF146	0.72	11.7	0.48	7.1e-28	Breast cancer;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.17	-0.39	1.55e-18	Obesity-related traits;
LGG	trans	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg13565492	chr6:43139072	SRF	-0.75	-9.06	-0.39	3.76e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg08847335	chr10:891726	LARP4B	-0.36	-7.03	-0.31	7.53e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.88	-0.3	1.92e-11	Type 2 diabetes;
LGG	cis	rs10267417	0.603	rs13245108	chr7:19910053	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	7.49	0.33	3.55e-13	Night sleep phenotypes;
LGG	cis	rs9649213	0.614	rs4236537	chr7:97996593	T/C	cg09267113	chr7:98030324	BAIAP2L1	-0.48	-8.35	-0.36	7.75e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs72945132	0.882	rs3133179	chr11:70187574	T/G	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.37	-0.32	7.96e-13	Mood instability;
LGG	cis	rs7927592	0.513	rs7950129	chr11:68202903	A/G	cg16797656	chr11:68205561	LRP5	0.57	10.98	0.45	4.43e-25	Total body bone mineral density;
LGG	trans	rs7829975	0.564	rs2976855	chr8:8301794	G/A	cg02002194	chr4:3960332	NA	-0.5	-9.7	-0.41	2.22e-20	Mood instability;
LGG	cis	rs1669338	0.588	rs3864050	chr3:3186769	T/C	cg16797762	chr3:3221439	CRBN	-0.98	-13.06	-0.52	2.12e-33	White matter integrity;
LGG	cis	rs3213545	0.659	rs2259690	chr12:121457914	T/G	cg02403541	chr12:121454288	C12orf43	0.54	9.29	0.4	5.96e-19	Subjective well-being;Cardiovascular disease risk factors;
LGG	trans	rs116095464	0.558	rs62347678	chr5:227496	A/G	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs2133450	0.933	rs41412146	chr3:7341024	A/G	cg19930620	chr3:7340148	GRM7	-0.38	-8.4	-0.36	5.62e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg21427119	chr20:30132790	HM13	-0.58	-8.9	-0.38	1.32e-17	Mean corpuscular hemoglobin;
LGG	cis	rs3020736	0.500	rs6002597	chr22:42488160	C/A	cg04733989	chr22:42467013	NAGA	-0.58	-10.27	-0.43	2.01e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs35110281	0.594	rs230641	chr21:44915441	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-9.26	-0.4	7.89e-19	Mean corpuscular volume;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg11360546	chr7:1094263	C7orf50	-0.42	-7.59	-0.33	1.83e-13	Longevity;Endometriosis;
LGG	trans	rs11088226	0.681	rs4547609	chr21:33953542	G/A	cg09050820	chr6:167586206	TCP10L2	0.95	13.67	0.54	5.72e-36	Gastritis;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.46	0.37	3.62e-16	Lung cancer;
LGG	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg18240062	chr17:79603768	NPLOC4	0.62	10.0	0.42	1.97e-21	Eye color traits;
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg14338887	chr6:42928500	GNMT	0.29	9.36	0.4	3.54e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12347191	0.500	rs907582	chr9:100621926	T/C	cg13688889	chr9:100608707	NA	-0.83	-15.94	-0.6	6.5e-46	Orofacial clefts;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	10.65	0.44	7.45e-24	Height;
LGG	trans	rs3206736	0.521	rs329232	chr7:35054951	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.27	0.32	1.53e-12	Diastolic blood pressure;
LGG	cis	rs8180040	0.967	rs17411375	chr3:47395135	C/T	cg16586182	chr3:47516702	SCAP	0.77	15.23	0.58	9.26e-43	Colorectal cancer;
LGG	cis	rs3540	0.574	rs2526000	chr15:90962626	C/T	cg22089800	chr15:90895588	ZNF774	0.68	12.35	0.5	1.79e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg01419164	chr10:131742167	EBF3	0.32	6.75	0.3	4.52e-11	Electrocardiographic conduction measures;
LGG	cis	rs6500602	0.929	rs9926114	chr16:4478322	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.35	7.2	0.32	2.49e-12	Schizophrenia;
LGG	cis	rs2086824	0.702	rs3114896	chr16:89393562	C/T	cg06640241	chr16:89574553	SPG7	-0.56	-9.48	-0.4	1.3e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.4	-0.5	1.1e-30	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26897989	chr16:1907736	C16orf73	0.83	13.92	0.54	4.67e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4566357	0.930	rs13424003	chr2:227926860	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.06	-0.31	6.07e-12	Coronary artery disease;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.2	-0.39	1.19e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.04	-0.31	7.03e-12	Aortic root size;
LGG	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18876405	chr7:65276391	NA	0.49	8.62	0.37	1.07e-16	Aortic root size;
LGG	cis	rs9790314	1.000	rs7653361	chr3:160992291	C/T	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.592	rs4822046	chr22:41987543	G/A	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Vitiligo;
LGG	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg03806693	chr22:41940476	POLR3H	1.09	19.86	0.68	5.84e-64	Vitiligo;
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.45	-0.33	4.72e-13	Menopause (age at onset);
LGG	cis	rs2046867	0.818	rs6808341	chr3:72914847	A/G	cg26655873	chr3:72818019	SHQ1	0.35	7.23	0.32	2.02e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg03929089	chr4:120376271	NA	0.79	8.14	0.35	3.74e-15	Myopia (pathological);
LGG	cis	rs12780845	0.505	rs10795460	chr10:17244253	A/G	cg01003015	chr10:17271136	VIM	-0.44	-7.63	-0.33	1.36e-13	Homocysteine levels;
LGG	cis	rs4838594	0.563	rs730509	chr10:49679153	C/A	cg17291251	chr10:49678358	ARHGAP22	0.55	11.43	0.47	8.02e-27	Daytime sleep phenotypes;
LGG	cis	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.23	-0.46	4.79e-26	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08253463	chr7:65579941	CRCP	0.46	7.21	0.32	2.31e-12	Gut microbiome composition (summer);
LGG	cis	rs7172689	1.000	rs28648707	chr15:81534034	G/A	cg11808699	chr15:81528661	IL16	-0.48	-9.92	-0.42	3.77e-21	Inattentive symptoms;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs2708240	1.000	rs759179	chr7:147574914	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs6582630	0.598	rs12823134	chr12:38514347	T/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.6	-0.41	4.92e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10028187	0.745	rs713247	chr4:154408360	A/C	cg24020152	chr4:154419554	KIAA0922	0.47	10.53	0.44	2.12e-23	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs2290416	0.681	rs3793371	chr8:144664299	C/T	cg00713939	chr8:144660590	NAPRT1	0.86	7.27	0.32	1.58e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs11771526	0.901	rs10264625	chr7:32304205	T/C	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.34	-7.43	-0.33	5.36e-13	Schizophrenia;
LGG	cis	rs12474201	0.894	rs34401107	chr2:46972768	A/C	cg06386533	chr2:46925753	SOCS5	0.79	14.78	0.57	9.28e-41	Height;
LGG	cis	rs62400317	0.762	rs12198308	chr6:44911886	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.46	2.55e-26	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15123824	chr2:85581917	ELMOD3;RETSAT	0.48	7.68	0.34	9.81e-14	Cognitive performance;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg13047869	chr3:10149882	C3orf24	0.57	9.6	0.41	4.98e-20	Alzheimer's disease;
LGG	cis	rs6840360	0.762	rs62327352	chr4:152670780	C/A	cg22705602	chr4:152727874	NA	-0.27	-6.83	-0.3	2.7e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg26043149	chr18:55253948	FECH	0.43	7.3	0.32	1.28e-12	Bone mineral density;
LGG	cis	rs2404602	0.583	rs12438741	chr15:76542114	C/A	cg23625390	chr15:77176239	SCAPER	0.41	7.72	0.34	7.18e-14	Blood metabolite levels;
LGG	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg07936489	chr17:37558343	FBXL20	-0.99	-15.36	-0.58	2.56e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.37	0.47	1.41e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg02002194	chr4:3960332	NA	0.47	9.14	0.39	1.96e-18	Joint mobility (Beighton score);
LGG	trans	rs9354308	0.738	rs4235976	chr6:66593762	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.85	-0.3	2.41e-11	Metabolite levels;
LGG	cis	rs2806561	1.000	rs2806563	chr1:23506625	C/T	cg19743168	chr1:23544995	NA	-0.32	-6.73	-0.3	5.11e-11	Height;
LGG	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg07120314	chr15:79043507	NA	-0.35	-6.96	-0.31	1.16e-11	Sudden cardiac arrest;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.16	0.39	1.63e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg21453758	chr17:80185943	SLC16A3	0.34	7.48	0.33	3.73e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2070488	0.965	rs35091896	chr3:38443320	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.88	18.7	0.66	1.57e-58	Electrocardiographic conduction measures;
LGG	cis	rs875971	0.895	rs778700	chr7:65866450	C/T	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs7647973	0.826	rs9834535	chr3:49378797	A/T	cg06212747	chr3:49208901	KLHDC8B	0.5	7.61	0.33	1.51e-13	Menarche (age at onset);
LGG	cis	rs35146811	0.844	rs59261051	chr7:99650429	C/T	cg13334819	chr7:99746414	C7orf59	-0.51	-7.63	-0.33	1.37e-13	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09578018	chr15:60883649	RORA	0.45	6.9	0.31	1.77e-11	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00808053	chr12:6125746	VWF	-0.44	-6.7	-0.3	6.19e-11	Systemic lupus erythematosus;
LGG	cis	rs10744422	0.800	rs6489240	chr12:123275030	T/C	cg25930673	chr12:123319894	HIP1R	-0.67	-8.04	-0.35	7.75e-15	Schizophrenia;
LGG	cis	rs10193935	0.892	rs12612372	chr2:42414035	A/G	cg27598129	chr2:42591480	NA	-0.64	-9.41	-0.4	2.35e-19	Colonoscopy-negative controls vs population controls;
LGG	trans	rs10964378	0.527	rs9407954	chr9:19995019	G/A	cg22081558	chr11:34380598	NA	0.34	6.79	0.3	3.47e-11	Asthma;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.51	-0.37	2.4e-16	Neuroticism;
LGG	cis	rs283228	0.570	rs532796	chr6:101727112	A/G	cg02011392	chr6:101847541	GRIK2	0.51	7.01	0.31	8.28e-12	Coenzyme Q10 levels;
LGG	cis	rs35306767	1.000	rs35306767	chr10:989437	A/T	cg26597838	chr10:835615	NA	0.67	9.21	0.39	1.14e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2032447	0.736	rs115810	chr6:25975883	G/C	cg07061783	chr6:25882402	NA	-0.45	-7.55	-0.33	2.38e-13	Intelligence (multi-trait analysis);
LGG	trans	rs12517041	1.000	rs6875447	chr5:23305303	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs6429082	0.585	rs7524848	chr1:235711688	G/C	cg26050004	chr1:235667680	B3GALNT2	-0.51	-7.72	-0.34	7.49e-14	Adiposity;
LGG	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg03605463	chr16:89740564	NA	-0.43	-7.12	-0.31	4.08e-12	Vitiligo;
LGG	trans	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg25214090	chr10:38739885	LOC399744	0.4	7.36	0.32	8.24e-13	Diastolic blood pressure;
LGG	cis	rs2795502	1.000	rs1852959	chr10:43359636	T/C	cg20628663	chr10:43360327	NA	0.42	8.62	0.37	1.04e-16	Blood protein levels;
LGG	cis	rs10871290	0.881	rs7498574	chr16:74472661	A/G	cg01733217	chr16:74700730	RFWD3	-0.74	-14.22	-0.55	2.56e-38	Breast cancer;
LGG	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg00012203	chr2:219082015	ARPC2	-0.49	-8.65	-0.37	8.74e-17	Ulcerative colitis;
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-9.3	-0.4	5.64e-19	Neuroticism;
LGG	cis	rs12318506	1.000	rs35635311	chr12:75712220	C/T	cg04728562	chr12:75699417	CAPS2	-1.32	-11.25	-0.46	4e-26	Coronary artery calcification;
LGG	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.46e-13	White matter hyperintensity burden;
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg10652674	chr10:62023665	ANK3	-0.32	-6.83	-0.3	2.71e-11	Select biomarker traits;
LGG	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.24	0.52	3.71e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs4363385	0.818	rs11205164	chr1:152986023	A/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.62	-0.37	1.11e-16	Inflammatory skin disease;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-6.83	-0.3	2.64e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs561341	1.000	rs527256	chr17:30321293	C/G	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4631830	0.900	rs7914347	chr10:51537431	C/T	cg16070123	chr10:51489643	NA	-0.39	-7.17	-0.32	3.03e-12	Prostate-specific antigen levels;
LGG	cis	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg00405596	chr8:11794950	NA	0.64	11.13	0.46	1.13e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg08305652	chr11:111469057	NA	-0.39	-7.83	-0.34	3.38e-14	Primary sclerosing cholangitis;
LGG	trans	rs17685	0.712	rs59659102	chr7:75710114	G/A	cg19862616	chr7:65841803	NCRNA00174	1.08	26.08	0.77	6.23e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4727443	0.932	rs7803714	chr7:99585150	G/T	cg12813108	chr7:99719912	CNPY4	-0.47	-8.84	-0.38	1.96e-17	Interstitial lung disease;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3126085	1.000	rs2338556	chr1:152309427	T/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.95	-0.35	1.47e-14	Atopic dermatitis;
LGG	cis	rs9300255	0.782	rs12809602	chr12:123768916	T/G	cg00376283	chr12:123451042	ABCB9	-0.58	-8.7	-0.37	5.75e-17	Neutrophil percentage of white cells;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg18926786	chr6:150244388	RAET1G	0.31	6.74	0.3	4.79e-11	Testicular germ cell tumor;
LGG	cis	rs9393692	0.905	rs6908328	chr6:26292855	C/A	cg16885296	chr6:26284938	NA	0.4	8.71	0.38	5.39e-17	Educational attainment;
LGG	cis	rs208520	0.526	rs9354366	chr6:66788559	C/T	cg07460842	chr6:66804631	NA	-1.13	-30.96	-0.82	7.58e-115	Exhaled nitric oxide output;
LGG	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg23815491	chr16:72088622	HP	0.52	11.78	0.48	3.41e-28	Fibrinogen levels;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.78	-0.34	4.64e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg13293535	chr8:11597251	GATA4	0.35	8.61	0.37	1.14e-16	Neuroticism;
LGG	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.64	-8.9	-0.38	1.28e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2832077	0.943	rs4816336	chr21:30193519	C/T	cg08807101	chr21:30365312	RNF160	-0.58	-7.98	-0.35	1.16e-14	Cognitive test performance;
LGG	cis	rs17125944	0.686	rs76673112	chr14:53366692	T/C	cg00686598	chr14:53173677	PSMC6	0.79	8.02	0.35	8.9e-15	Alzheimer's disease (late onset);
LGG	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06481639	chr22:41940642	POLR3H	-0.57	-8.42	-0.36	4.63e-16	Vitiligo;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.51	0.33	3.07e-13	Lung cancer;
LGG	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.1	-0.55	8.33e-38	Hair morphology;
LGG	cis	rs9354308	0.867	rs2802051	chr6:66536403	C/T	cg07460842	chr6:66804631	NA	0.57	9.67	0.41	2.77e-20	Metabolite levels;
LGG	cis	rs1506636	1.000	rs12706545	chr7:123348744	C/T	cg03229431	chr7:123269106	ASB15	-0.73	-19.64	-0.67	6.18e-63	Plateletcrit;Platelet count;
LGG	cis	rs10089	1.000	rs2409109	chr5:127461471	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg05091796	chr16:4465799	CORO7	-0.97	-16.9	-0.62	2.92e-50	Schizophrenia;
LGG	cis	rs10911232	0.507	rs4642853	chr1:182996242	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.77	0.41	1.24e-20	Hypertriglyceridemia;
LGG	cis	rs13102973	0.720	rs13122251	chr4:135887466	C/T	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs1555133	0.694	rs6141680	chr20:30929192	C/T	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.54e-11	Monocyte count;
LGG	cis	rs8062405	1.000	rs7498555	chr16:28893571	T/C	cg07382826	chr16:28625726	SULT1A1	0.38	7.74	0.34	6.29e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4308124	0.708	rs28871990	chr2:111962441	G/A	cg04571233	chr2:111982156	NA	-0.6	-9.9	-0.42	4.32e-21	Vitiligo;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg03647317	chr4:187891568	NA	0.41	8.58	0.37	1.42e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs2171564	0.557	rs3846043	chr3:112436847	A/C	cg06685282	chr3:112453648	NA	-0.62	-11.58	-0.47	1.99e-27	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1218582	0.772	rs12095061	chr1:154912968	A/T	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.37	2.51e-16	Prostate cancer;
LGG	cis	rs79146658	0.749	rs10166147	chr2:179780624	G/T	cg17765952	chr2:179737173	CCDC141	0.59	8.33	0.36	9.37e-16	Diastolic blood pressure;
LGG	cis	rs10791097	0.703	rs11222360	chr11:130730871	C/T	cg12179176	chr11:130786555	SNX19	0.76	14.67	0.56	2.61e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg23758822	chr17:41437982	NA	0.87	15.57	0.59	2.99e-44	Menopause (age at onset);
LGG	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg15128208	chr22:42549153	NA	0.74	11.45	0.47	6.88e-27	Birth weight;
LGG	trans	rs656319	0.605	rs4840467	chr8:10079637	A/G	cg08975724	chr8:8085496	FLJ10661	0.39	6.91	0.31	1.6e-11	Myopia (pathological);
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg25019033	chr10:957182	NA	-0.56	-10.28	-0.43	1.88e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs4731207	0.596	rs12055904	chr7:124662864	C/T	cg05630886	chr7:124431682	NA	-0.31	-7.08	-0.31	5.26e-12	Cutaneous malignant melanoma;
LGG	cis	rs910187	0.678	rs3818014	chr20:45816649	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-9.05	-0.39	4.09e-18	Migraine;
LGG	cis	rs9325144	0.671	rs7486919	chr12:38767997	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-10.68	-0.44	6.18e-24	Morning vs. evening chronotype;
LGG	cis	rs2274273	0.622	rs11846809	chr14:55401782	T/C	cg04306507	chr14:55594613	LGALS3	0.33	7.88	0.34	2.39e-14	Protein biomarker;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg02158880	chr13:53174818	NA	0.38	7.17	0.32	3.06e-12	Lewy body disease;
LGG	cis	rs4820539	1.000	rs4820539	chr22:23477970	C/T	cg21100191	chr22:23484243	RTDR1	-0.97	-22.08	-0.72	2.58e-74	Bone mineral density;
LGG	cis	rs6772849	1.000	rs6798431	chr3:128303373	C/T	cg08795948	chr3:128337044	NA	0.53	8.71	0.38	5.27e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs17767392	0.788	rs61989239	chr14:71705928	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.21	-0.32	2.26e-12	Mitral valve prolapse;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.79	0.51	2.8099999999999997e-32	Obesity-related traits;
LGG	cis	rs758324	0.561	rs253946	chr5:131330461	G/A	cg06307176	chr5:131281290	NA	0.44	6.7	0.3	5.92e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.33	-0.43	1.23e-22	Total body bone mineral density;
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.81	-0.41	9.35e-21	Systolic blood pressure;
LGG	cis	rs2635047	0.777	rs9944807	chr18:44788908	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.7e-11	Educational attainment;
LGG	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs2033732	0.706	rs10958211	chr8:85074884	G/C	cg05716166	chr8:85095498	RALYL	0.46	7.33	0.32	1.06e-12	Body mass index;
LGG	cis	rs62025270	0.688	rs10163064	chr15:86277520	A/G	cg25843651	chr15:86329602	KLHL25	0.57	8.97	0.38	7.48e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg10792982	chr14:105748885	BRF1	0.66	13.37	0.53	1.03e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11644478	chr21:40555479	PSMG1	-0.59	-9.79	-0.41	1.09e-20	Menarche (age at onset);
LGG	cis	rs9487094	0.670	rs12194061	chr6:109867642	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs16912285	0.584	rs7131124	chr11:24249455	A/G	ch.11.24196551F	chr11:24239977	NA	0.97	15.24	0.58	8.8e-43	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs10193935	1.000	rs12622910	chr2:42398918	C/A	cg27598129	chr2:42591480	NA	-0.62	-9.17	-0.39	1.57e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg02725872	chr8:58115012	NA	-0.84	-11.73	-0.48	5.55e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs5995756	0.666	rs3788566	chr22:40006024	G/T	cg21377881	chr22:40064566	CACNA1I	-0.35	-7.3	-0.32	1.26e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg03929089	chr4:120376271	NA	-0.81	-15.5	-0.58	5.87e-44	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.47	7.05	0.31	6.71e-12	Gut microbiome composition (summer);
LGG	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg24253500	chr15:84953950	NA	-0.53	-9.46	-0.4	1.51e-19	Schizophrenia;
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	2.99e-27	Intelligence (multi-trait analysis);
LGG	trans	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg20290983	chr6:43655470	MRPS18A	0.8	15.16	0.58	1.84e-42	IgG glycosylation;
LGG	cis	rs9527	0.544	rs1572578	chr10:104822431	C/G	cg05308233	chr10:104796373	CNNM2	-0.32	-7.23	-0.32	2.04e-12	Arsenic metabolism;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg24829409	chr8:58192753	C8orf71	-0.8	-11.33	-0.47	2.02e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs564799	0.966	rs484600	chr3:159729961	A/C	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs7107174	1.000	rs2511158	chr11:77973980	C/T	cg02023728	chr11:77925099	USP35	0.44	7.52	0.33	2.95e-13	Testicular germ cell tumor;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.82	0.66	4.09e-59	Platelet count;
LGG	cis	rs7582720	1.000	rs72932741	chr2:203661048	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.34	-0.4	4.17e-19	Lung cancer;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg03709012	chr19:19516395	GATAD2A	0.84	17.02	0.62	7.97e-51	Tonsillectomy;
LGG	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	trans	rs6582630	0.502	rs11504451	chr12:38425294	G/A	cg06521331	chr12:34319734	NA	-0.49	-8.48	-0.37	2.97e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs8114671	0.869	rs66535333	chr20:33656666	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs73227498	0.590	rs61482608	chr5:111490633	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.49	-6.68	-0.3	6.66e-11	Thyroid cancer;
LGG	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg06121193	chr1:90282411	NA	-0.41	-7.6	-0.33	1.62e-13	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21815083	chr11:69458002	CCND1	-0.44	-6.9	-0.31	1.73e-11	Pancreatic cancer;
LGG	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg26384229	chr12:38710491	ALG10B	0.88	19.86	0.68	6.06e-64	Bladder cancer;
LGG	cis	rs6908034	0.607	rs80355837	chr6:19808343	C/G	cg02682789	chr6:19804855	NA	0.92	8.74	0.38	4.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6723226	0.766	rs455737	chr2:32528234	A/G	cg02381751	chr2:32503542	YIPF4	0.73	11.85	0.48	1.83e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7580658	0.750	rs4497825	chr2:128061053	A/G	cg10021288	chr2:128175891	PROC	-0.61	-12.55	-0.5	2.69e-31	Protein C levels;
LGG	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg02811702	chr13:24901961	NA	0.4	7.45	0.33	4.54e-13	Obesity-related traits;
LGG	cis	rs7202877	0.656	rs3851736	chr16:75387332	T/C	cg03315344	chr16:75512273	CHST6	0.53	7.19	0.32	2.64e-12	Type 2 diabetes;Type 1 diabetes;
LGG	trans	rs2749592	0.513	rs9417249	chr10:37837155	C/T	cg17830980	chr10:43048298	ZNF37B	0.31	6.76	0.3	4.08e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4950322	0.570	rs72691098	chr1:146771840	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg16586182	chr3:47516702	SCAP	0.73	12.97	0.52	4.94e-33	Colorectal cancer;
LGG	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg23625390	chr15:77176239	SCAPER	0.72	14.46	0.56	2.36e-39	Blood metabolite levels;
LGG	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg00579200	chr11:133705235	NA	-0.59	-11.26	-0.46	3.58e-26	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20786246	chr2:72377174	NA	0.48	7.39	0.32	6.95e-13	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg17133734	chr15:86042851	AKAP13	0.28	6.68	0.3	6.94e-11	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.7	0.45	5.14e-24	Lung cancer in ever smokers;
LGG	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg24642844	chr7:1081250	C7orf50	-0.65	-8.5	-0.37	2.57e-16	Longevity;Endometriosis;
LGG	cis	rs9916302	0.904	rs2061338	chr17:37421767	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7766436	0.848	rs66989470	chr6:22598707	G/C	cg13666174	chr6:22585274	NA	-0.51	-11.61	-0.47	1.52e-27	Coronary artery disease;
LGG	cis	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg26384229	chr12:38710491	ALG10B	0.92	21.34	0.7	7.28e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7814319	1.000	rs6468495	chr8:97259953	C/A	cg20787634	chr8:97240163	UQCRB	-0.75	-17.84	-0.64	1.5e-54	Lung function (FVC);
LGG	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg22760086	chr17:21116917	TMEM11	-0.46	-6.65	-0.3	8.31e-11	Beard thickness;
LGG	cis	rs4919044	0.756	rs2486686	chr10:94778511	G/T	cg05127821	chr10:94822908	CYP26C1	-0.42	-7.07	-0.31	5.73e-12	Coronary artery disease;
LGG	trans	rs7939886	0.844	rs7106504	chr11:55932827	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs753778	0.628	rs1045248	chr8:142204326	C/G	cg18755752	chr8:142205143	DENND3	-0.51	-10.35	-0.43	1.02e-22	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.2e-28	Tonsillectomy;
LGG	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg06713675	chr4:122721982	EXOSC9	-0.58	-9.57	-0.41	6.27e-20	Type 2 diabetes;
LGG	cis	rs11657217	0.502	rs4442854	chr17:77698224	C/T	cg06901238	chr17:77706717	ENPP7	0.48	10.09	0.42	8.84e-22	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs422249	0.512	rs174568	chr11:61593816	C/T	cg19610905	chr11:61596333	FADS2	-0.8	-14.49	-0.56	1.62e-39	Trans fatty acid levels;
LGG	cis	rs7765175	0.698	rs9488153	chr6:113664384	C/T	cg26552650	chr6:113682475	NA	-0.34	-7.69	-0.34	8.85e-14	Coronary artery calcification;
LGG	cis	rs875971	0.545	rs2279757	chr7:65828663	T/C	cg11764359	chr7:65958608	NA	0.63	9.54	0.41	8.53e-20	Aortic root size;
LGG	cis	rs11764590	0.715	rs9639202	chr7:2087315	G/A	cg07027305	chr7:2059796	MAD1L1	-0.34	-6.85	-0.3	2.3e-11	Neuroticism;
LGG	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs8072100	0.817	rs9905581	chr17:45547185	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-10.41	-0.44	6.12e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg13256891	chr4:100009986	ADH5	0.54	9.72	0.41	1.8899999999999998e-20	Alcohol dependence;
LGG	cis	rs17209837	0.607	rs60040620	chr7:87085379	C/A	cg25823085	chr7:87105416	ABCB4	0.3	7.34	0.32	9.79e-13	Gallbladder cancer;
LGG	cis	rs9611565	0.918	rs9611566	chr22:41768625	A/G	cg17376030	chr22:41985996	PMM1	-0.52	-8.45	-0.37	3.72e-16	Vitiligo;
LGG	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg08392591	chr16:89556376	ANKRD11	0.6	9.75	0.41	1.47e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg13206674	chr6:150067644	NUP43	0.67	15.47	0.58	8.48e-44	Lung cancer;
LGG	trans	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.91	-0.31	1.58e-11	Heart rate;
LGG	cis	rs6815814	0.950	rs66922907	chr4:38812537	A/G	cg06935464	chr4:38784597	TLR10	0.6	8.2	0.36	2.47e-15	Breast cancer;
LGG	cis	rs807669	0.868	rs2800973	chr22:19168616	A/G	cg02655711	chr22:19163373	SLC25A1	0.78	15.66	0.59	1.17e-44	Metabolite levels;
LGG	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg19147804	chr7:1989927	MAD1L1	-0.47	-9.25	-0.39	8.39e-19	Schizophrenia;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.87	-0.3	2.02e-11	Bipolar disorder;
LGG	cis	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg26384229	chr12:38710491	ALG10B	0.99	24.5	0.75	1.23e-85	Heart rate;
LGG	cis	rs4580814	0.869	rs4535497	chr5:1107428	G/T	cg17733824	chr5:1099592	SLC12A7	0.34	6.92	0.31	1.55e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.42	-0.33	5.54e-13	Personality dimensions;
LGG	cis	rs11785400	0.963	rs9771845	chr8:143726577	C/G	cg10596483	chr8:143751796	JRK	0.59	9.61	0.41	4.8e-20	Schizophrenia;
LGG	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg17215666	chr7:56131930	SUMF2	0.47	7.61	0.33	1.51e-13	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.29	0.4	6.01e-19	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg00149659	chr3:10157352	C3orf10	0.89	11.43	0.47	8.07e-27	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19763735	chr2:170550826	C2orf77;PHOSPHO2;KLHL23	0.39	6.83	0.3	2.76e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12928939	1.000	rs12928939	chr16:71800045	G/A	cg03805757	chr16:71968109	PKD1L3	-0.53	-9.98	-0.42	2.22e-21	Post bronchodilator FEV1;
LGG	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	9.99	0.42	2.08e-21	Neuroticism;
LGG	cis	rs62103177	0.535	rs62101568	chr18:77934671	G/A	cg20368463	chr18:77673604	PQLC1	0.53	6.83	0.3	2.71e-11	Opioid sensitivity;
LGG	cis	rs72945132	0.882	rs60780459	chr11:70162468	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	trans	rs75804782	0.625	rs10929278	chr2:239468643	A/G	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs4478037	1.000	rs4074418	chr3:33161165	G/T	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs801193	1.000	rs7788576	chr7:66148302	G/A	cg18252515	chr7:66147081	NA	0.41	6.87	0.3	2.12e-11	Aortic root size;
LGG	cis	rs6988985	0.678	rs6651273	chr8:143986500	G/A	cg10324643	chr8:143916377	GML	0.4	7.85	0.34	2.9e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs244731	0.959	rs7724098	chr5:176659570	G/A	cg17509989	chr5:176798049	RGS14	-0.58	-8.28	-0.36	1.35e-15	Urate levels in lean individuals;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07080177	chr17:75243417	NA	0.38	6.71	0.3	5.58e-11	Obesity-related traits;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14893161	chr1:205819251	PM20D1	0.87	19.94	0.68	2.53e-64	Menarche (age at onset);
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-10.34	-0.43	1.14e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2180341	0.804	rs6902233	chr6:127555963	A/G	cg24812749	chr6:127587940	RNF146	0.89	13.58	0.53	1.37e-35	Breast cancer;
LGG	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg09307838	chr4:120376055	NA	0.81	13.56	0.53	1.66e-35	Corneal astigmatism;
LGG	cis	rs7980799	0.711	rs12319055	chr12:33626509	C/T	cg06521331	chr12:34319734	NA	0.41	6.86	0.3	2.25e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs3741151	0.686	rs7935948	chr11:73219118	A/G	cg17517138	chr11:73019481	ARHGEF17	-0.65	-6.89	-0.31	1.78e-11	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9419702	0.568	rs7920966	chr10:133555185	G/T	cg20568497	chr10:133558893	NA	0.34	7.7	0.34	8.12e-14	Survival in rectal cancer;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg16301924	chr13:53314226	LECT1	0.44	9.04	0.39	4.34e-18	Lewy body disease;
LGG	cis	rs875971	0.862	rs6460282	chr7:65691246	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.47	-0.4	1.38e-19	Aortic root size;
LGG	cis	rs2046867	0.862	rs57396880	chr3:72844785	G/A	cg25664220	chr3:72788482	NA	-0.34	-9.29	-0.4	5.82e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2050392	0.517	rs589980	chr10:30756385	T/A	cg25182066	chr10:30743637	MAP3K8	-0.67	-14.38	-0.56	4.96e-39	Inflammatory bowel disease;
LGG	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg00319359	chr11:70116639	PPFIA1	0.71	7.77	0.34	5.26e-14	Coronary artery disease;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.19	0.52	6.04e-34	Obesity-related traits;
LGG	cis	rs35771425	0.529	rs35228985	chr1:211418760	C/T	cg10512769	chr1:211675356	NA	-0.6	-8.02	-0.35	8.69e-15	Educational attainment (years of education);
LGG	cis	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.87	-0.3	2.08e-11	Neuroticism;
LGG	cis	rs1784581	0.802	rs7768986	chr6:162427890	G/C	cg17173639	chr6:162384350	PARK2	0.76	17.84	0.64	1.49e-54	Itch intensity from mosquito bite;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg21302120	chr4:24585281	DHX15	-0.43	-6.67	-0.3	7.42e-11	Alzheimer's disease (survival time);
LGG	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	9.35	0.4	3.66e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9486715	0.838	rs9400034	chr6:96954566	C/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.2	0.36	2.3e-15	Headache;
LGG	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg12560992	chr17:57184187	TRIM37	0.47	7.02	0.31	7.73e-12	Cognitive test performance;
LGG	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.69	12.34	0.5	1.9e-30	Hip circumference adjusted for BMI;
LGG	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg23285774	chr14:45431188	KLHL28;FAM179B	0.5	7.0	0.31	8.91e-12	QT interval;
LGG	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg09021430	chr5:549028	NA	-0.8	-17.3	-0.63	4.32e-52	Ulcerative colitis;
LGG	cis	rs2297440	0.527	rs4809318	chr20:62264760	G/A	cg16989086	chr20:62203971	PRIC285	0.49	7.08	0.31	5.44e-12	Glioma;Non-glioblastoma glioma;Glioblastoma;
LGG	cis	rs4474465	1.000	rs4945281	chr11:78188627	C/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.62	-0.37	1.03e-16	Alzheimer's disease (survival time);
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs77216612	0.874	rs11055034	chr12:12890626	C/A	cg04607235	chr12:12878440	APOLD1	-1.0	-19.93	-0.68	2.9e-64	Lymphocyte counts;
LGG	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-11.63	-0.48	1.31e-27	Chronic sinus infection;
LGG	cis	rs236352	0.521	rs6910832	chr6:36856739	C/T	cg03410223	chr6:36853544	C6orf89	0.42	7.5	0.33	3.35e-13	Heart rate;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg23131131	chr22:24373011	LOC391322	-0.5	-8.19	-0.36	2.6e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg26031613	chr14:104095156	KLC1	1.14	27.35	0.79	9.62e-99	Body mass index;
LGG	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg01403660	chr11:68851641	TPCN2	0.5	7.01	0.31	8.6e-12	Blond vs. brown hair color;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01148728	chr11:117198424	CEP164	0.39	6.7	0.3	5.91e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2204008	0.870	rs12369578	chr12:38444227	C/T	cg26384229	chr12:38710491	ALG10B	0.91	20.46	0.69	9.46e-67	Bladder cancer;
LGG	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg17108064	chr15:78857060	CHRNA5	0.44	9.61	0.41	4.8e-20	Sudden cardiac arrest;
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg27400746	chr16:89904261	SPIRE2	-0.97	-15.57	-0.59	3.02e-44	Skin colour saturation;
LGG	cis	rs62400317	0.859	rs11965520	chr6:45259431	T/A	cg18551225	chr6:44695536	NA	-0.62	-10.27	-0.43	2.03e-22	Total body bone mineral density;
LGG	cis	rs10752881	0.967	rs4652757	chr1:182974750	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4774899	0.752	rs28648502	chr15:57400749	T/C	cg08128148	chr15:57256372	TCF12	0.28	6.85	0.3	2.39e-11	Urinary tract infection frequency;
LGG	cis	rs9649465	0.551	rs10255400	chr7:123388036	G/A	cg03229431	chr7:123269106	ASB15	-0.61	-14.44	-0.56	2.64e-39	Migraine;
LGG	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06634786	chr22:41940651	POLR3H	0.71	11.8	0.48	2.92e-28	Vitiligo;
LGG	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg00204512	chr16:28754710	NA	0.25	7.03	0.31	7.61e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7580658	0.545	rs12477559	chr2:127951797	C/T	cg10021288	chr2:128175891	PROC	-0.45	-8.61	-0.37	1.11e-16	Protein C levels;
LGG	trans	rs826838	1.000	rs6582619	chr12:38729904	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.64	-0.33	1.24e-13	Heart rate;
LGG	cis	rs12893668	0.637	rs4525427	chr14:104072793	C/A	cg26031613	chr14:104095156	KLC1	-0.63	-10.03	-0.42	1.47e-21	Reticulocyte count;
LGG	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg21775007	chr8:11205619	TDH	0.5	8.08	0.35	5.58e-15	Joint mobility (Beighton score);
LGG	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.33e-26	Colorectal cancer;
LGG	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg14703610	chr5:56206110	C5orf35	-0.46	-7.99	-0.35	1.05e-14	Coronary artery disease;
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg13009111	chr11:71350975	NA	-0.31	-6.94	-0.31	1.3e-11	Neuroticism;
LGG	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg25019033	chr10:957182	NA	-0.6	-12.55	-0.5	2.79e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs6977660	1.000	rs6973890	chr7:19820497	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg06212747	chr3:49208901	KLHDC8B	0.43	6.88	0.3	1.9e-11	Resting heart rate;
LGG	cis	rs988958	0.526	rs60056083	chr2:42242928	A/T	cg27428208	chr2:42229179	NA	0.5	7.65	0.33	1.2e-13	Hypospadias;
LGG	cis	rs2247341	0.893	rs743569	chr4:1719620	T/G	cg08629884	chr4:1719983	TMEM129	-0.57	-11.08	-0.46	1.81e-25	Hip circumference adjusted for BMI;Height;
LGG	cis	rs3733585	0.673	rs4627861	chr4:9954238	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg07061783	chr6:25882402	NA	-0.39	-7.01	-0.31	8.29e-12	Blood metabolite levels;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg05091796	chr16:4465799	CORO7	0.78	12.58	0.5	2.1e-31	Schizophrenia;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg13903179	chr13:21900392	NA	0.45	8.3	0.36	1.18e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs782590	0.721	rs1084525	chr2:55929430	C/T	cg18811423	chr2:55921094	PNPT1	0.93	22.02	0.72	4.85e-74	Metabolic syndrome;
LGG	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg02297831	chr4:17616191	MED28	-0.39	-6.77	-0.3	3.99e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs503734	0.846	rs6795427	chr3:100913241	T/G	cg27318481	chr3:100970896	IMPG2	-0.44	-9.79	-0.41	1.06e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg08305652	chr11:111469057	NA	-0.43	-8.63	-0.37	1.02e-16	Primary sclerosing cholangitis;
LGG	trans	rs7746199	0.736	rs35037868	chr6:27759115	G/C	cg08344181	chr3:125677491	NA	-0.88	-8.7	-0.37	5.83e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6121246	0.567	rs2889488	chr20:30185758	G/A	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.36	0.32	8.2e-13	Neuroticism;
LGG	cis	rs698833	0.788	rs1142523	chr2:44545576	T/C	cg00619915	chr2:44497795	NA	-0.47	-7.07	-0.31	5.8e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs10464366	0.544	rs6952466	chr7:39155032	A/T	cg18850127	chr7:39170497	POU6F2	0.62	15.74	0.59	4.84e-45	IgG glycosylation;
LGG	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.9	-0.34	2.02e-14	Neuroticism;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.97	0.66	8.72e-60	Menopause (age at onset);
LGG	cis	rs9398803	0.687	rs4629706	chr6:126888331	A/T	cg19875578	chr6:126661172	C6orf173	0.52	9.58	0.41	5.79e-20	Male-pattern baldness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06420324	chr11:73309256	FAM168A	-0.45	-6.88	-0.3	1.91e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg09998033	chr7:158218633	PTPRN2	0.56	10.42	0.44	5.72e-23	Obesity-related traits;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg06916706	chr16:4465613	CORO7	-0.71	-12.35	-0.5	1.68e-30	Schizophrenia;
LGG	cis	rs4356975	0.563	rs6851533	chr4:69978750	T/C	cg27372994	chr4:70080453	UGT2B11	0.37	6.77	0.3	3.85e-11	Obesity-related traits;
LGG	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.25	-0.36	1.62e-15	Morning vs. evening chronotype;
LGG	cis	rs2239547	0.522	rs2581780	chr3:53058960	C/T	cg11645453	chr3:52864694	ITIH4	-0.67	-10.39	-0.43	7.22e-23	Schizophrenia;
LGG	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg26874229	chr2:105853672	NA	-0.32	-6.96	-0.31	1.2e-11	Type 2 diabetes;
LGG	cis	rs2301436	0.512	rs6925969	chr6:167501738	C/A	cg07741184	chr6:167504864	NA	0.41	9.2	0.39	1.21e-18	Crohn's disease;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.66	-12.04	-0.49	3.16e-29	Prudent dietary pattern;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg10360139	chr7:1886902	MAD1L1	-0.42	-7.39	-0.32	6.82e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg07541023	chr7:19748670	TWISTNB	0.58	7.94	0.35	1.56e-14	Thyroid stimulating hormone;
LGG	cis	rs9460578	0.537	rs9465907	chr6:20822887	A/G	cg13405222	chr6:20811065	CDKAL1	0.76	17.27	0.63	5.76e-52	Breast cancer;
LGG	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg23609528	chr2:113191194	RGPD5;RGPD8	0.56	6.87	0.3	2.12e-11	Yeast infection;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.79e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00495681	chr13:53174319	NA	0.46	7.65	0.33	1.21e-13	Lewy body disease;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.16	-0.32	3.09e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20878095	chr19:49298744	BCAT2	0.41	6.69	0.3	6.62e-11	Cognitive performance;
LGG	cis	rs7589342	0.929	rs13024715	chr2:106433950	A/G	cg14210321	chr2:106509881	NCK2	-0.51	-8.81	-0.38	2.47e-17	Addiction;
LGG	cis	rs17767392	0.746	rs72728403	chr14:71733375	G/A	cg02058870	chr14:72053146	SIPA1L1	0.36	7.71	0.34	7.5e-14	Mitral valve prolapse;
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg23730037	chr7:158596552	ESYT2	-0.4	-6.92	-0.31	1.5e-11	Height;
LGG	cis	rs643506	1.000	rs4936675	chr11:111623088	T/A	cg09085632	chr11:111637200	PPP2R1B	0.59	9.47	0.4	1.44e-19	Breast cancer;
LGG	cis	rs9905704	0.647	rs7221274	chr17:57008128	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.0	-0.31	8.92e-12	Testicular germ cell tumor;
LGG	cis	rs921968	0.541	rs593888	chr2:219427597	A/G	cg01130898	chr2:219473002	PLCD4	-0.41	-7.14	-0.31	3.68e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg16141378	chr3:129829833	LOC729375	0.36	8.16	0.35	3.17e-15	Neuroticism;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg04772025	chr11:68637568	NA	0.74	13.0	0.52	3.53e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.32	0.32	1.1e-12	Joint mobility (Beighton score);
LGG	cis	rs7408868	0.764	rs12610803	chr19:15260682	A/C	cg14696996	chr19:15285081	NOTCH3	1.06	12.57	0.5	2.24e-31	Pulse pressure;
LGG	cis	rs4732038	0.565	rs1708406	chr7:134276365	T/C	cg06906464	chr7:134288099	NA	-0.72	-20.85	-0.7	1.38e-68	Longevity;
LGG	cis	rs11605275	1.000	rs76735151	chr11:20026419	G/A	cg14835545	chr11:20032148	NAV2	-0.9	-10.81	-0.45	1.96e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10819861	0.645	rs10819835	chr9:98858665	C/T	cg14508093	chr9:98862825	NA	0.3	6.95	0.31	1.26e-11	Electrocardiographic traits;
LGG	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg12751644	chr20:60527061	NA	-0.29	-6.96	-0.31	1.14e-11	Body mass index;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs713587	0.713	rs11125884	chr2:25239264	C/T	cg04586622	chr2:25135609	ADCY3	0.36	9.38	0.4	2.94e-19	Body mass index in non-asthmatics;
LGG	cis	rs4936894	0.500	rs10893166	chr11:124077445	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-10.16	-0.43	4.81e-22	Aging (time to death);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg04229928	chr11:119303807	NA	-0.36	-6.81	-0.3	3.06e-11	Iris color (L* coordinate);
LGG	trans	rs826838	0.935	rs10875816	chr12:38955014	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.6	-0.33	1.66e-13	Heart rate;
LGG	cis	rs9300255	0.510	rs1727323	chr12:123698790	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9677476	0.779	rs12612219	chr2:232107363	G/T	cg23338755	chr2:231921595	PSMD1	0.49	6.71	0.3	5.71e-11	Food antigen IgG levels;
LGG	cis	rs6763768	0.888	rs1264098	chr3:53522314	T/G	cg16894138	chr3:53270350	TKT	0.38	7.45	0.33	4.6e-13	Bacterial meningitis;
LGG	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg06470251	chr20:60548479	NA	0.4	6.89	0.31	1.78e-11	Body mass index;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg11360546	chr7:1094263	C7orf50	-0.42	-7.67	-0.34	1.06e-13	Longevity;Endometriosis;
LGG	cis	rs8014204	0.816	rs10083386	chr14:75347585	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.69	-12.91	-0.51	9.06e-33	Caffeine consumption;
LGG	cis	rs2070488	0.965	rs3762788	chr3:38493852	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.19	0.65	3.66e-56	Electrocardiographic conduction measures;
LGG	trans	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg06521331	chr12:34319734	NA	0.41	7.35	0.32	8.99e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.74	0.38	4.37e-17	Lung cancer;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.97	-0.35	1.28e-14	Neuroticism;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg11050988	chr7:1952600	MAD1L1	-0.29	-6.83	-0.3	2.7e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg15541040	chr2:3486749	NA	-0.46	-8.22	-0.36	2.06e-15	Neurofibrillary tangles;
LGG	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.97	0.42	2.53e-21	Dupuytren's disease;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg13206674	chr6:150067644	NUP43	-0.62	-13.8	-0.54	1.64e-36	Lung cancer;
LGG	trans	rs9914544	0.545	rs8071458	chr17:18790840	C/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	trans	rs1941687	0.505	rs9956918	chr18:31315878	C/G	cg04226714	chr8:49833948	SNAI2	0.44	7.67	0.34	1.05e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg04990556	chr1:26633338	UBXN11	0.59	7.95	0.35	1.48e-14	Obesity-related traits;
LGG	cis	rs9399135	0.816	rs4134030	chr6:135354094	G/T	cg24558204	chr6:135376177	HBS1L	0.53	9.75	0.41	1.45e-20	Red blood cell count;
LGG	cis	rs6831352	0.879	rs4699717	chr4:100066137	C/T	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg21314978	chr2:96191015	NA	0.63	6.67	0.3	7.41e-11	Airflow obstruction;
LGG	cis	rs35264875	1.000	rs72919432	chr11:68829954	C/T	cg01403660	chr11:68851641	TPCN2	0.53	7.36	0.32	8.49e-13	Blond vs. brown hair color;
LGG	cis	rs7100689	0.784	rs4934083	chr10:82116501	G/C	cg01528321	chr10:82214614	TSPAN14	0.94	16.76	0.61	1.23e-49	Post bronchodilator FEV1;
LGG	trans	rs9409565	0.826	rs639276	chr9:97206737	G/T	cg05679027	chr9:99775184	HIATL2	-0.49	-8.15	-0.35	3.39e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.48	-0.63	6.6e-53	Bladder cancer;
LGG	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg20302533	chr7:39170763	POU6F2	0.35	8.21	0.36	2.29e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	trans	rs459571	0.916	rs467303	chr9:136904835	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.76	-0.48	4.23e-28	Platelet distribution width;
LGG	trans	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.7	-0.34	8.32e-14	Heart rate;
LGG	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg24375607	chr4:120327624	NA	0.67	11.11	0.46	1.39e-25	Corneal astigmatism;
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.7	-0.37	5.76e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs3784262	0.740	rs4646600	chr15:58295616	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.95	-0.31	1.26e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs8056893	0.837	rs9888796	chr16:68297589	T/C	cg07273125	chr16:68295692	NA	0.37	6.88	0.3	2e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4851254	0.961	rs11691486	chr2:100796182	T/C	cg17356467	chr2:100759845	AFF3	0.4	7.05	0.31	6.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.571	rs718801	chr4:152549247	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.63	-0.33	1.39e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.52	-0.44	2.41e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs6601327	0.665	rs12543369	chr8:9655915	C/A	cg16141378	chr3:129829833	LOC729375	0.35	7.94	0.35	1.54e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg02733842	chr7:1102375	C7orf50	0.62	9.74	0.41	1.6e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg03929089	chr4:120376271	NA	-0.98	-20.65	-0.69	1.24e-67	Coronary artery disease;
LGG	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.47	0.33	3.97e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs78456975	1.000	rs11884854	chr2:1566154	A/G	cg01028140	chr2:1542097	TPO	-0.53	-8.43	-0.36	4.33e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg14664628	chr15:75095509	CSK	-0.78	-16.0	-0.6	3.5e-46	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs4650994	0.525	rs4457535	chr1:178497186	C/T	cg19399532	chr1:178512495	C1orf220	-0.55	-11.54	-0.47	2.99e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs367615	0.513	rs11741087	chr5:108807760	G/A	cg17395555	chr5:108820864	NA	0.89	15.59	0.59	2.48e-44	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs8141529	0.748	rs5762874	chr22:29269658	C/G	cg15103426	chr22:29168792	CCDC117	0.63	9.74	0.41	1.6e-20	Lymphocyte counts;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg07362569	chr17:61921086	SMARCD2	0.49	9.38	0.4	2.91e-19	Prudent dietary pattern;
LGG	cis	rs883565	0.569	rs2949565	chr3:39163425	G/A	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg00149659	chr3:10157352	C3orf10	0.55	8.12	0.35	4.29e-15	Alzheimer's disease;
LGG	cis	rs9324022	0.929	rs72698718	chr14:101178555	G/A	cg01194073	chr14:101175302	NA	0.44	7.02	0.31	8.08e-12	Plateletcrit;
LGG	cis	rs546131	0.642	rs2956073	chr11:34842883	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.45	7.13	0.31	3.8e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg05091796	chr16:4465799	CORO7	-0.6	-9.86	-0.42	5.91e-21	Schizophrenia;
LGG	cis	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg21775007	chr8:11205619	TDH	0.45	7.12	0.31	4.24e-12	Morning vs. evening chronotype;
LGG	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-9.75	-0.41	1.49e-20	Menarche (age at onset);
LGG	cis	rs7503807	1.000	rs4889775	chr17:78592287	A/G	cg09596252	chr17:78655493	RPTOR	0.42	7.49	0.33	3.53e-13	Obesity;
LGG	cis	rs4330281	0.935	rs11921152	chr3:17812688	A/C	cg20981856	chr3:17787350	NA	0.37	6.66	0.3	8.02e-11	Schizophrenia;
LGG	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.45	-0.4	1.71e-19	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.28e-12	Menopause (age at onset);
LGG	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg00543991	chr22:32367038	NA	0.81	8.95	0.38	8.83e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs17376456	0.877	rs7736620	chr5:93305762	C/T	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg05082376	chr22:42548792	NA	-0.39	-8.12	-0.35	4.34e-15	Schizophrenia;
LGG	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg17347104	chr14:75034677	LTBP2	-0.4	-7.29	-0.32	1.38e-12	Caffeine consumption;
LGG	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg03929089	chr4:120376271	NA	-0.96	-20.23	-0.68	1.15e-65	Coronary artery disease;
LGG	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.88	-18.36	-0.65	6.08e-57	Lung cancer;
LGG	trans	rs72766638	0.895	rs11795079	chr9:136930134	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.58	-7.81	-0.34	3.98e-14	Mosquito bite size;
LGG	cis	rs7568458	0.905	rs10198569	chr2:85794415	C/T	cg17127132	chr2:85788382	GGCX	-0.47	-8.25	-0.36	1.61e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.86	-0.34	2.66e-14	HDL cholesterol;
LGG	cis	rs9911578	1.000	rs437732	chr17:56675861	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8044868	0.530	rs2550870	chr16:72070129	C/T	cg23815491	chr16:72088622	HP	0.35	7.23	0.32	1.97e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs2117029	0.619	rs2753	chr12:49521672	C/T	cg24176009	chr12:49580217	TUBA1A	0.65	12.73	0.51	4.93e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7630877	0.719	rs73057366	chr3:179672470	C/G	cg18765712	chr3:179670323	PEX5L	0.44	7.06	0.31	6.06e-12	Type 2 diabetes;
LGG	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	1.000	rs6460295	chr7:65882728	T/C	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs6076065	0.548	rs1112818	chr20:23323936	G/A	cg11657817	chr20:23433608	CST11	0.38	7.26	0.32	1.64e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6684428	0.505	rs4927274	chr1:56396501	A/G	cg11651538	chr1:56320950	NA	0.39	7.61	0.33	1.55e-13	Airflow obstruction;
LGG	cis	rs2303745	0.544	rs6512181	chr19:17399213	T/G	cg04248312	chr19:17393744	ANKLE1	-0.65	-10.61	-0.44	1.09e-23	Systemic lupus erythematosus;
LGG	cis	rs3008870	1.000	rs2009319	chr1:67481070	G/T	cg08660285	chr1:67390436	MIER1;WDR78	1.01	23.3	0.73	4.86e-80	Lymphocyte percentage of white cells;
LGG	trans	rs3942852	0.868	rs7122335	chr11:48106486	C/T	cg03929089	chr4:120376271	NA	-0.59	-7.42	-0.33	5.79e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	11.56	0.47	2.52e-27	Lymphocyte counts;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.11	-0.43	7.67e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs738322	0.804	rs2076116	chr22:38517405	A/G	cg03162506	chr22:38580953	NA	0.31	7.54	0.33	2.49e-13	Cutaneous nevi;
LGG	cis	rs4356203	0.870	rs214921	chr11:17237461	C/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs651907	0.557	rs2318090	chr3:101474933	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.49	0.53	3.24e-35	Colorectal cancer;
LGG	cis	rs17767392	0.914	rs7147668	chr14:71857427	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.13	0.39	2.14e-18	Mitral valve prolapse;
LGG	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.94	0.35	1.56e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2032447	0.575	rs198847	chr6:26106619	C/A	cg03264133	chr6:25882463	NA	0.48	8.56	0.37	1.62e-16	Intelligence (multi-trait analysis);
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-8.03	-0.35	7.93e-15	Bipolar disorder;
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs780096	0.546	rs2293572	chr2:27728777	C/G	cg20102877	chr2:27665638	KRTCAP3	0.3	6.93	0.31	1.38e-11	Total body bone mineral density;
LGG	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg23324259	chr8:82754387	SNX16	-0.39	-6.72	-0.3	5.38e-11	Diastolic blood pressure;
LGG	cis	rs4917300	0.904	rs13257943	chr8:143122836	A/G	cg06573787	chr8:143070187	NA	0.49	9.06	0.39	3.69e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg24575275	chr7:1094737	C7orf50	-0.39	-7.43	-0.33	5.27e-13	Longevity;Endometriosis;
LGG	cis	rs11764590	0.543	rs55893771	chr7:2096255	C/T	cg02825527	chr7:2087843	MAD1L1	-0.54	-9.17	-0.39	1.5e-18	Neuroticism;
LGG	cis	rs6430585	0.583	rs2839740	chr2:136648883	G/T	cg07169764	chr2:136633963	MCM6	1.26	23.34	0.74	3.11e-80	Corneal structure;
LGG	cis	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg05091796	chr16:4465799	CORO7	0.59	9.61	0.41	4.65e-20	Schizophrenia;
LGG	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg16325326	chr1:53192061	ZYG11B	-0.61	-12.36	-0.5	1.61e-30	Monocyte count;
LGG	cis	rs55665837	1.000	rs12792120	chr11:14469443	G/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.8	-0.38	2.65e-17	Vitamin D levels;
LGG	cis	rs2404602	0.692	rs35395069	chr15:76986334	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.22e-18	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.18	-0.43	4.15e-22	Lung cancer;
LGG	cis	rs7192750	0.586	rs2335713	chr16:71904291	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.59	0.44	1.27e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg21775007	chr8:11205619	TDH	0.58	9.08	0.39	3.22e-18	Retinal vascular caliber;
LGG	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Body mass index;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.94e-11	Aortic root size;
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg22398616	chr13:53314203	LECT1	-0.47	-9.71	-0.41	2.08e-20	Lewy body disease;
LGG	cis	rs765787	0.530	rs1648286	chr15:45517386	G/C	cg25801113	chr15:45476975	SHF	0.87	20.0	0.68	1.34e-64	Uric acid levels;
LGG	cis	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg17545662	chr6:170176663	C6orf70	0.66	8.0	0.35	1.04e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg08975724	chr8:8085496	FLJ10661	0.56	11.59	0.47	1.94e-27	Systolic blood pressure;
LGG	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg23894439	chr1:183413866	NA	0.49	9.19	0.39	1.38e-18	Systemic lupus erythematosus;
LGG	cis	rs1966248	0.656	rs4895387	chr6:134123317	A/T	cg25632230	chr6:134101081	NA	-0.32	-6.77	-0.3	3.88e-11	Coronary artery disease;
LGG	cis	rs2404602	0.716	rs12440815	chr15:76627328	C/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.96	-0.31	1.17e-11	Blood metabolite levels;
LGG	cis	rs3813359	0.545	rs6927875	chr6:130551190	C/T	cg23281432	chr6:130554730	NA	0.52	7.41	0.33	6.04e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09823679	chr13:53425813	NA	0.41	6.97	0.31	1.08e-11	Bipolar disorder;
LGG	cis	rs68170813	0.527	rs78133594	chr7:107025260	T/C	cg02696742	chr7:106810147	HBP1	-0.71	-9.89	-0.42	4.72e-21	Coronary artery disease;
LGG	cis	rs1577917	0.771	rs6454486	chr6:86433587	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.55	9.67	0.41	2.8e-20	Response to antipsychotic treatment;
LGG	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21582582	chr3:182698605	DCUN1D1	0.52	9.65	0.41	3.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg12070911	chr6:150209640	RAET1E	0.29	7.1	0.31	4.65e-12	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15574263	chr11:911693	CHID1	0.4	6.71	0.3	5.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6976053	0.846	rs12672665	chr7:100483731	A/G	cg03098644	chr7:100410630	EPHB4	-0.43	-7.59	-0.33	1.83e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg21775007	chr8:11205619	TDH	0.83	14.76	0.57	1.07e-40	Retinal vascular caliber;
LGG	cis	rs6083	0.549	rs11858020	chr15:58852422	A/T	cg05156742	chr15:59063176	FAM63B	0.44	8.03	0.35	7.84e-15	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.08e-23	Prudent dietary pattern;
LGG	cis	rs9300255	0.664	rs12316131	chr12:123817796	T/C	cg00376283	chr12:123451042	ABCB9	-0.56	-8.67	-0.37	7.06e-17	Neutrophil percentage of white cells;
LGG	trans	rs1864585	0.520	rs714370	chr8:10665847	C/T	cg26278703	chr11:58910052	FAM111A	0.52	6.81	0.3	3.11e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs4918072	0.834	rs12413741	chr10:105711283	C/G	cg11005552	chr10:105648138	OBFC1	0.43	7.43	0.33	5.29e-13	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.49	0.47	4.55e-27	Bone mineral density;
LGG	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.73	-0.38	4.7e-17	Plateletcrit;
LGG	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg18105134	chr13:113819100	PROZ	-0.68	-13.73	-0.54	3.13e-36	Platelet distribution width;
LGG	cis	rs7945718	0.811	rs7104832	chr11:12786489	A/G	cg25843174	chr11:12811716	TEAD1	0.39	8.13	0.35	4.05e-15	Educational attainment (years of education);
LGG	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.33	6.7e-13	Schizophrenia;
LGG	cis	rs7267979	0.932	rs6115200	chr20:25487377	G/T	cg06421707	chr20:25228305	PYGB	0.47	9.96	0.42	2.58e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2303759	0.551	rs7249040	chr19:49790602	C/T	cg22307029	chr19:49891270	CCDC155	0.4	7.58	0.33	1.94e-13	Multiple sclerosis;
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg13009111	chr11:71350975	NA	-0.32	-6.84	-0.3	2.57e-11	Triglycerides;
LGG	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg15556689	chr8:8085844	FLJ10661	0.41	7.17	0.32	2.94e-12	Retinal vascular caliber;
LGG	cis	rs9815354	1.000	rs9818169	chr3:41860599	A/G	cg03022575	chr3:42003672	ULK4	0.66	8.49	0.37	2.93e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg25566285	chr7:158114605	PTPRN2	0.7	11.74	0.48	4.91e-28	Response to amphetamines;
LGG	cis	rs1358748	0.573	rs7529446	chr1:67581576	A/C	cg02640540	chr1:67518911	SLC35D1	0.55	6.75	0.3	4.41e-11	Tuberculosis;
LGG	cis	rs1125355	0.622	rs62183014	chr2:159615541	C/T	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.98e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11105298	0.891	rs11105312	chr12:89920733	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12190007	0.547	rs2981945	chr6:169819839	G/A	cg15038512	chr6:170123185	PHF10	-0.44	-8.45	-0.37	3.77e-16	Obesity-related traits;
LGG	cis	rs77633900	0.892	rs874224	chr15:76631797	C/G	cg21673338	chr15:77095150	SCAPER	-0.46	-6.77	-0.3	3.99e-11	Non-glioblastoma glioma;Glioma;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg02725872	chr8:58115012	NA	-0.85	-11.51	-0.47	4.09e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg18681998	chr4:17616180	MED28	0.89	19.82	0.68	9.4e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13421350	0.892	rs16860416	chr2:173316788	G/A	cg15021238	chr2:173305865	ITGA6	-0.45	-7.36	-0.32	8.37e-13	Diabetic kidney disease;
LGG	cis	rs7508	1.000	rs7508	chr8:17913970	G/A	cg18067069	chr8:17937731	ASAH1	-0.33	-6.87	-0.3	2.11e-11	Atrial fibrillation;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.46	-0.37	3.44e-16	Aortic root size;
LGG	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg01152986	chr16:58549298	SETD6	0.84	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.07	-0.39	3.45e-18	Systemic lupus erythematosus;
LGG	cis	rs1975974	0.549	rs4889746	chr17:21745187	T/C	cg18423549	chr17:21743878	NA	-0.53	-8.09	-0.35	5.35e-15	Psoriasis;
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg18252515	chr7:66147081	NA	-0.42	-6.98	-0.31	1.04e-11	Aortic root size;
LGG	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.86e-11	Bone mineral density;
LGG	cis	rs16912285	0.786	rs112633506	chr11:24250766	G/A	ch.11.24196551F	chr11:24239977	NA	0.86	8.77	0.38	3.54e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2282032	0.527	rs60971518	chr14:90765745	A/G	cg14092571	chr14:90743983	NA	0.43	7.59	0.33	1.72e-13	Longevity;
LGG	cis	rs1062177	1.000	rs6890099	chr5:151151962	A/G	cg00977110	chr5:151150581	G3BP1	0.5	8.11	0.35	4.52e-15	Preschool internalizing problems;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs929354	0.772	rs1182444	chr7:157024510	A/G	cg17757837	chr7:157058334	UBE3C	-0.78	-15.94	-0.6	6.35e-46	Body mass index;
LGG	cis	rs368123	1.000	rs409610	chr6:160718264	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.1	0.35	4.88e-15	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.819	rs5757169	chr22:39003495	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.24	0.65	2.17e-56	Menopause (age at onset);
LGG	cis	rs9358372	0.574	rs6456379	chr6:20893247	G/T	cg13405222	chr6:20811065	CDKAL1	-0.43	-8.63	-0.37	1.03e-16	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7659604	0.502	rs4516738	chr4:122669177	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	7.08	0.31	5.39e-12	Type 2 diabetes;
LGG	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg02187348	chr16:89574699	SPG7	-0.45	-7.45	-0.33	4.63e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13732083	chr21:47605072	C21orf56	0.47	7.94	0.35	1.59e-14	Testicular germ cell tumor;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.2	-0.36	2.43e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12745769	chr19:21579993	ZNF493	0.46	7.49	0.33	3.46e-13	Cognitive performance;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg27476859	chr7:2772710	GNA12	0.43	7.34	0.32	9.72e-13	Height;
LGG	cis	rs2354432	0.556	rs2883319	chr1:146838177	A/G	cg25205988	chr1:146714368	CHD1L	-1.24	-11.77	-0.48	3.71e-28	Mitochondrial DNA levels;
LGG	cis	rs12950390	0.893	rs4794110	chr17:45847230	A/G	cg03474202	chr17:45855739	NA	-0.27	-8.09	-0.35	5.13e-15	IgG glycosylation;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.14	-0.35	3.81e-15	IgG glycosylation;
LGG	cis	rs7659604	1.000	rs7660078	chr4:122665577	G/T	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.04	-0.31	7.01e-12	Type 2 diabetes;
LGG	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg16950941	chr11:66035639	RAB1B	0.47	7.37	0.32	8.09e-13	Electroencephalogram traits;
LGG	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg10483660	chr13:112241077	NA	-0.36	-7.91	-0.35	1.86e-14	Hepatitis;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.86e-13	Life satisfaction;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	7.76	0.34	5.62e-14	Obesity-related traits;
LGG	cis	rs7493	0.755	rs13228784	chr7:94960825	A/G	cg17330251	chr7:94953956	PON1	-0.44	-8.45	-0.37	3.72e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.57e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.502	rs2296584	chr10:104244323	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.02	0.57	8.36e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs36051895	0.659	rs12343065	chr9:5083533	C/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.19	-0.58	1.46e-42	Pediatric autoimmune diseases;
LGG	trans	rs28595532	0.516	rs28552458	chr4:119288363	T/C	cg26518628	chr1:97050305	NA	-0.85	-8.83	-0.38	2.18e-17	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.601	rs7738877	chr6:8542230	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.77e-18	Motion sickness;
LGG	cis	rs2455601	1.000	rs56336128	chr11:8908299	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-10.14	-0.43	5.81e-22	Schizophrenia;
LGG	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.39e-16	Restless legs syndrome;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.87	0.54	7.86e-37	Obesity-related traits;
LGG	cis	rs3540	0.533	rs2352601	chr15:91053125	G/A	cg18942110	chr15:91072797	CRTC3	-0.29	-6.66	-0.3	8e-11	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs11671005	0.779	rs55875034	chr19:58983558	T/G	cg13877915	chr19:58951672	ZNF132	0.61	7.8	0.34	4.28e-14	Mean platelet volume;
LGG	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.68	0.56	2.38e-40	Cognitive test performance;
LGG	cis	rs2467099	0.786	rs1463486	chr17:73943942	G/A	cg23806715	chr17:73775811	H3F3B	0.49	7.3	0.32	1.24e-12	Systolic blood pressure;
LGG	cis	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg21775007	chr8:11205619	TDH	-0.48	-7.59	-0.33	1.72e-13	Neuroticism;
LGG	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg26441486	chr22:50317300	CRELD2	0.4	7.35	0.32	9.11e-13	Schizophrenia;
LGG	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs2075371	0.829	rs9641970	chr7:134004887	C/A	cg11752832	chr7:134001865	SLC35B4	0.64	11.58	0.47	2.07e-27	Mean platelet volume;
LGG	cis	rs2836974	0.897	rs2836932	chr21:40546717	G/A	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.2e-54	Cognitive function;
LGG	cis	rs4417704	0.551	rs10179839	chr2:241898947	G/T	cg05025159	chr2:241905733	NA	0.49	9.97	0.42	2.35e-21	Joint mobility (Beighton score);
LGG	trans	rs1997103	1.000	rs2877284	chr7:55408778	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg08000102	chr2:233561755	GIGYF2	0.6	9.73	0.41	1.78e-20	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg18402987	chr7:1209562	NA	0.67	9.06	0.39	3.69e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7100689	0.615	rs10788639	chr10:82233225	C/G	cg00277334	chr10:82204260	NA	-0.37	-7.16	-0.32	3.14e-12	Post bronchodilator FEV1;
LGG	cis	rs17253792	0.822	rs17746106	chr14:56069168	C/T	cg01858014	chr14:56050164	KTN1	-0.89	-13.28	-0.53	2.58e-34	Putamen volume;
LGG	cis	rs4595586	0.679	rs7131749	chr12:39405462	A/G	cg26384229	chr12:38710491	ALG10B	-0.46	-8.38	-0.36	6.5e-16	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11877577	chr6:133135687	RPS12;SNORD101	-0.49	-7.27	-0.32	1.56e-12	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg10505658	chr17:80084571	CCDC57	0.34	6.76	0.3	4.11e-11	Life satisfaction;
LGG	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.94	-0.42	3.03e-21	Multiple myeloma;
LGG	cis	rs3106136	0.872	rs13130583	chr4:95245543	T/C	cg11021082	chr4:95130006	SMARCAD1	0.43	7.28	0.32	1.4e-12	Capecitabine sensitivity;
LGG	cis	rs920590	0.684	rs7461774	chr8:19666645	G/A	cg03894339	chr8:19674705	INTS10	0.66	10.65	0.44	8.02e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg24229701	chr12:130821962	PIWIL1	0.45	7.83	0.34	3.39e-14	Menopause (age at onset);
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg09033563	chr22:24373618	LOC391322	-0.5	-8.47	-0.37	3.28e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg16141378	chr3:129829833	LOC729375	0.36	7.93	0.35	1.63e-14	Retinal vascular caliber;
LGG	cis	rs926938	0.618	rs360624	chr1:115409476	A/C	cg12756093	chr1:115239321	AMPD1	0.48	9.17	0.39	1.6e-18	Autism;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg00689492	chr4:1303491	MAEA	0.52	8.63	0.37	9.83e-17	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg02462569	chr6:150064036	NUP43	-0.35	-7.47	-0.33	4.14e-13	Lung cancer;
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg08499158	chr17:42289980	UBTF	-0.54	-10.04	-0.42	1.34e-21	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs1119691	chr6:8460452	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.21	0.43	3.36e-22	Motion sickness;
LGG	cis	rs1572438	0.811	rs9379179	chr6:879853	A/C	cg21062780	chr6:887772	NA	0.4	7.69	0.34	8.86e-14	Aging;
LGG	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.33	0.43	1.17e-22	Aortic root size;
LGG	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.5e-12	Height;
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.41	8.69e-20	Bipolar disorder;
LGG	cis	rs9290877	0.667	rs9821679	chr3:188463443	T/C	cg17392043	chr3:188495102	LPP	-0.46	-8.09	-0.35	5.35e-15	IgE levels;
LGG	cis	rs2470578	0.792	rs2733498	chr3:17276455	T/C	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.13e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2587949	0.615	rs1385487	chr3:4228738	G/A	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs6076065	0.748	rs1016628	chr20:23398738	C/G	cg11657817	chr20:23433608	CST11	-0.41	-8.32	-0.36	9.770000000000001e-16	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6977940	0.512	rs11765726	chr7:2850878	A/G	cg19731401	chr7:2775893	GNA12	0.34	6.94	0.31	1.34e-11	White matter integrity;
LGG	cis	rs7408868	0.764	rs62113791	chr19:15277009	C/T	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs2066819	1.000	rs116535779	chr12:56739261	A/G	cg26714650	chr12:56694279	CS	-1.49	-17.81	-0.64	2.1e-54	Psoriasis vulgaris;
LGG	cis	rs11690935	0.655	rs1028127	chr2:172530036	T/C	cg13550731	chr2:172543902	DYNC1I2	0.7	14.28	0.55	1.41e-38	Schizophrenia;
LGG	cis	rs12643440	0.538	rs2041442	chr4:17137895	C/T	cg22650099	chr4:17144496	NA	-0.51	-8.71	-0.38	5.47e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	cis	rs17286411	0.750	rs12444594	chr16:71941912	A/T	cg03805757	chr16:71968109	PKD1L3	0.34	7.04	0.31	6.93e-12	Blood protein levels;
LGG	cis	rs921968	0.573	rs684776	chr2:219324016	T/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.25	-0.32	1.72e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4474465	1.000	rs952605	chr11:78200427	A/T	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.53e-11	Alzheimer's disease (survival time);
LGG	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	trans	rs12439619	0.921	rs4778672	chr15:82537354	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.46	8.9	0.38	1.25e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs2010834	chr18:44560875	C/A	cg23302884	chr18:44338147	ST8SIA5	0.38	7.7	0.34	8.46e-14	Personality dimensions;
LGG	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg17644776	chr2:200775616	C2orf69	-0.6	-6.87	-0.3	2.03e-11	Schizophrenia;
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg23958373	chr8:599963	NA	0.98	9.91	0.42	3.98e-21	IgG glycosylation;
LGG	cis	rs478607	0.510	rs61884411	chr11:64437714	A/C	cg19395706	chr11:64412079	NRXN2	0.44	6.81	0.3	2.95e-11	Urate levels;
LGG	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg14683738	chr19:37701593	ZNF585B	-0.43	-6.91	-0.31	1.58e-11	Coronary artery calcification;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg06558623	chr16:89946397	TCF25	1.16	13.23	0.52	3.92e-34	Skin colour saturation;
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg02002194	chr4:3960332	NA	-0.46	-8.77	-0.38	3.5e-17	Mood instability;
LGG	cis	rs9875589	0.509	rs4684174	chr3:14048375	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs9472414	0.510	rs227844	chr6:44692212	A/C	cg20913747	chr6:44695427	NA	0.49	8.06	0.35	6.49e-15	Height;
LGG	cis	rs9948	0.655	rs62156216	chr2:97405127	C/T	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs3771570	1.000	rs6752050	chr2:242228780	T/C	cg21155796	chr2:242212141	HDLBP	0.73	9.13	0.39	2.15e-18	Prostate cancer;
LGG	cis	rs13095912	0.785	rs62291882	chr3:185313278	T/C	cg11274856	chr3:185301563	NA	0.49	7.92	0.35	1.74e-14	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg08621203	chr6:150244597	RAET1G	0.46	8.04	0.35	7.56e-15	Lung cancer;
LGG	cis	rs6582630	0.519	rs11495724	chr12:38337507	T/C	cg26384229	chr12:38710491	ALG10B	0.92	20.42	0.69	1.42e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1200821	0.535	rs1208784	chr10:37768433	A/G	cg00409905	chr10:38381863	ZNF37A	-0.44	-8.16	-0.35	3.25e-15	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6681460	0.604	rs11208920	chr1:67075312	C/A	cg20812318	chr1:67072952	SGIP1	-0.32	-7.55	-0.33	2.29e-13	Presence of antiphospholipid antibodies;
LGG	cis	rs28595532	0.920	rs115986613	chr4:119752156	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs6988985	0.678	rs10110732	chr8:143995994	C/T	cg10324643	chr8:143916377	GML	-0.4	-7.98	-0.35	1.14e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1408799	0.679	rs1326791	chr9:12761300	T/C	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	5.28e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg22875332	chr1:76189707	ACADM	0.62	11.0	0.46	3.75e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg19717773	chr7:2847554	GNA12	0.35	7.17	0.32	2.92e-12	Height;
LGG	trans	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg07211511	chr3:129823064	LOC729375	-0.67	-9.25	-0.39	8.45e-19	Blood pressure (smoking interaction);
LGG	cis	rs4696584	0.816	rs4150	chr4:155405919	C/T	cg04517429	chr4:155413618	DCHS2	0.32	7.66	0.34	1.09e-13	Folding of antihelix;
LGG	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.5	-0.33	3.39e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg02725872	chr8:58115012	NA	-1.04	-14.01	-0.55	2.01e-37	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg13010199	chr12:38710504	ALG10B	0.63	12.65	0.51	1.06e-31	Bladder cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09454676	chr2:207307732	ADAM23	0.4	6.74	0.3	4.66e-11	Menarche (age at onset);
LGG	cis	rs10911232	0.507	rs3934578	chr1:183027216	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs1957429	0.614	rs72625640	chr14:65333231	G/A	cg23373153	chr14:65346875	NA	-1.04	-9.94	-0.42	3.2e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs55665837	1.000	rs10832256	chr11:14442875	G/A	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.86e-17	Vitamin D levels;
LGG	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.91	-0.35	1.9e-14	Height;
LGG	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg12773197	chr13:112238673	NA	-0.34	-6.82	-0.3	2.81e-11	Hepatitis;
LGG	cis	rs17453880	0.929	rs10071370	chr5:152048813	T/G	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg08250081	chr4:10125330	NA	-0.5	-9.88	-0.42	5.08e-21	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs2373794	0.583	rs7570501	chr2:40386285	A/T	cg17740179	chr2:40377776	SLC8A1	-0.81	-10.02	-0.42	1.66e-21	Asthma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13173848	chr9:16870893	BNC2	0.49	7.48	0.33	3.88e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7737355	0.812	rs31241	chr5:130808198	T/C	cg06307176	chr5:131281290	NA	0.51	8.54	0.37	1.93e-16	Life satisfaction;
LGG	cis	rs17102423	0.623	rs2093989	chr14:65553939	C/T	cg16583315	chr14:65563665	MAX	-0.37	-7.38	-0.32	7.44e-13	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg02631450	chr22:32366979	NA	-0.97	-9.23	-0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs2235573	0.625	rs139905	chr22:38409596	C/T	cg19171272	chr22:38449367	NA	0.55	10.68	0.44	5.81e-24	Glioblastoma;Glioma;
LGG	cis	rs9814567	1.000	rs1863913	chr3:134200205	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.18	-0.52	6.87e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7911264	0.628	rs7078243	chr10:94414263	A/C	cg25093409	chr10:94429542	NA	0.42	8.66	0.37	8.13e-17	Inflammatory bowel disease;
LGG	cis	rs4363385	0.818	rs1334849	chr1:153004652	A/G	cg13444842	chr1:152974279	SPRR3	0.4	8.33	0.36	9.4e-16	Inflammatory skin disease;
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs911263	0.581	rs12890110	chr14:68781595	C/T	cg18825221	chr14:68749962	RAD51L1	0.39	8.5	0.37	2.68e-16	Primary biliary cholangitis;
LGG	cis	rs7089973	0.604	rs35319791	chr10:116602296	C/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.39	-0.32	6.84e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2249694	0.572	rs9418984	chr10:135322356	C/G	cg20169779	chr10:135381914	SYCE1	-0.6	-8.55	-0.37	1.82e-16	Obesity-related traits;
LGG	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.74	0.38	4.4e-17	Vitiligo;
LGG	cis	rs2055942	0.599	rs2229940	chr4:46995366	G/T	cg09812070	chr4:46995689	GABRA4	0.48	8.92	0.38	1.11e-17	Type 2 diabetes;
LGG	trans	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.94	-0.31	1.37e-11	Triglycerides;
LGG	cis	rs8010715	0.636	rs2277480	chr14:24587515	G/A	cg06429887	chr14:24600500	FITM1	0.36	7.29	0.32	1.33e-12	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs56399783	0.901	rs6964740	chr7:2819656	C/G	cg23009067	chr7:2775923	GNA12	0.35	6.67	0.3	7.44e-11	Childhood ear infection;
LGG	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	cis	rs899997	0.773	rs11072783	chr15:78965966	G/A	cg07120314	chr15:79043507	NA	-0.68	-12.48	-0.5	5.1e-31	Coronary artery disease or large artery stroke;
LGG	cis	rs2985684	0.948	rs2985685	chr14:50101370	G/A	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	cis	rs3796619	1.000	rs4974638	chr4:1099201	G/A	cg27284194	chr4:1044797	NA	0.57	11.68	0.48	8.78e-28	Recombination rate (males);
LGG	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg21466736	chr12:48725269	NA	-0.36	-7.32	-0.32	1.13e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs524281	0.648	rs10896089	chr11:65936292	A/G	cg16950941	chr11:66035639	RAB1B	-0.46	-6.7	-0.3	5.99e-11	Electroencephalogram traits;
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg27219399	chr15:67835830	MAP2K5	-0.31	-6.91	-0.31	1.61e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-8.87	-0.38	1.58e-17	Ulcerative colitis;
LGG	cis	rs774359	0.797	rs10738774	chr9:27506051	G/A	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.4	-0.36	5.33e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg11494091	chr17:61959527	GH2	-1.11	-31.95	-0.83	3.64e-119	Prudent dietary pattern;
LGG	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg03517284	chr6:25882590	NA	0.5	9.4	0.4	2.6e-19	Blood metabolite levels;
LGG	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg12756686	chr19:29218302	NA	0.7	11.4	0.47	1.09e-26	Methadone dose in opioid dependence;
LGG	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg14829360	chr17:73884958	NA	-0.81	-14.98	-0.57	1.17e-41	Psoriasis;
LGG	cis	rs986417	0.818	rs8008804	chr14:61082357	A/T	cg27398547	chr14:60952738	C14orf39	0.76	7.08	0.31	5.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg15595755	chr5:1867978	NA	0.51	10.39	0.43	7.12e-23	Cardiovascular disease risk factors;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00107682	chr15:96888959	NA	0.46	6.87	0.3	2.09e-11	Gut microbiome composition (summer);
LGG	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.6	0.33	1.67e-13	Neuroticism;
LGG	trans	rs2736345	0.755	rs2061831	chr8:11339882	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.67	0.3	7.25e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs17253792	0.822	rs111467375	chr14:56046159	T/G	cg01858014	chr14:56050164	KTN1	-0.89	-11.99	-0.49	5.08e-29	Putamen volume;
LGG	cis	rs7246657	0.722	rs2909093	chr19:38199462	T/C	cg18154014	chr19:37997991	ZNF793	-0.43	-7.77	-0.34	5.07e-14	Coronary artery calcification;
LGG	cis	rs12541335	0.603	rs9792127	chr8:22180334	G/A	cg26039829	chr8:22132926	PIWIL2	0.54	12.43	0.5	7.96e-31	Hypertriglyceridemia;
LGG	cis	rs1065852	0.526	rs1062753	chr22:42392811	G/A	cg15128208	chr22:42549153	NA	0.41	7.13	0.31	3.77e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs56399783	0.808	rs73049331	chr7:2799911	C/T	cg19731401	chr7:2775893	GNA12	0.36	7.55	0.33	2.29e-13	Childhood ear infection;
LGG	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg06421707	chr20:25228305	PYGB	0.54	11.79	0.48	3.03e-28	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg14829155	chr15:31115871	NA	-0.56	-9.68	-0.41	2.62e-20	Huntington's disease progression;
LGG	cis	rs67311347	0.577	rs1317217	chr3:40271697	T/G	cg13683864	chr3:40499215	RPL14	-0.78	-14.83	-0.57	5.74e-41	Renal cell carcinoma;
LGG	trans	rs6787172	0.840	rs1656376	chr3:158284681	C/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.53	-0.33	2.59e-13	Subjective well-being;
LGG	cis	rs7666738	0.830	rs13144771	chr4:99026935	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.97	0.35	1.29e-14	Homoarginine levels;
LGG	cis	rs6964587	1.000	rs2285333	chr7:91667692	T/G	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.77e-16	Breast cancer;
LGG	cis	rs6582630	0.634	rs10748443	chr12:38734062	G/T	cg04568710	chr12:38710424	ALG10B	0.4	8.46	0.37	3.65e-16	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs253959	0.502	rs10478275	chr5:115428096	G/T	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.78	0.3	3.56e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-15.56	-0.59	3.1e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs344364	0.511	rs56077812	chr16:1948870	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs459571	1.000	rs2810489	chr9:136922700	C/T	cg13789015	chr9:136890014	NCRNA00094	0.59	10.68	0.44	6.06e-24	Platelet distribution width;
LGG	cis	rs9815354	1.000	rs7372217	chr3:41990122	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2404602	1.000	rs2896954	chr15:76851692	C/A	cg26408565	chr15:76604113	ETFA	-0.4	-6.88	-0.3	1.92e-11	Blood metabolite levels;
LGG	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg01236616	chr12:121019343	POP5	-1.24	-22.83	-0.73	8.12e-78	Type 1 diabetes nephropathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09507928	chr5:140027484	IK;NDUFA2	0.5	8.46	0.37	3.62e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7412746	0.566	rs2864871	chr1:150766964	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.04	0.31	7.02e-12	Melanoma;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6088580	0.524	rs6088575	chr20:33273403	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	6.96	0.31	1.15e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9788682	0.748	rs569207	chr15:78873119	A/G	cg06917634	chr15:78832804	PSMA4	0.5	7.82	0.34	3.51e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2439831	0.850	rs3742982	chr15:44176681	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	10.1	0.42	8.57e-22	Lung cancer in ever smokers;
LGG	cis	rs6784615	0.744	rs2109558	chr3:52501616	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.61	7.44	0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs11690935	0.959	rs6722757	chr2:172591963	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.33	-0.77	4.73e-94	Schizophrenia;
LGG	cis	rs2073499	1.000	rs2236948	chr3:50409826	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.75	9.71	0.41	2.11e-20	Schizophrenia;
LGG	cis	rs4731207	0.596	rs10270055	chr7:124649406	T/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs796364	0.951	rs971232	chr2:200792881	C/T	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg23306229	chr2:178417860	TTC30B	0.77	10.07	0.42	1.08e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg05926928	chr17:57297772	GDPD1	-0.51	-7.87	-0.34	2.49e-14	Schizophrenia;
LGG	cis	rs870825	0.616	rs7680779	chr4:185652830	G/C	cg04058563	chr4:185651563	MLF1IP	-1.0	-22.1	-0.72	2.05e-74	Blood protein levels;
LGG	trans	rs61931739	0.546	rs7297354	chr12:33700556	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.58	-0.37	1.4e-16	Morning vs. evening chronotype;
LGG	cis	rs883115	0.743	rs1002130	chr1:224800929	C/T	cg01808320	chr1:224927238	CNIH3	-0.44	-8.13	-0.35	3.98e-15	Cancer;
LGG	cis	rs933688	1.000	rs6452953	chr5:90723034	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.9	17.67	0.63	9.07e-54	Smoking behavior;
LGG	trans	rs6787172	0.677	rs844119	chr3:158013223	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.81	0.38	2.6e-17	Subjective well-being;
LGG	cis	rs6430585	0.583	rs9636213	chr2:136589278	G/A	cg07169764	chr2:136633963	MCM6	-1.23	-24.29	-0.75	1.18e-84	Corneal structure;
LGG	cis	rs67366981	1.000	rs425310	chr14:77711497	C/T	cg22824376	chr14:77648248	TMEM63C	0.63	7.12	0.31	4.14e-12	Obsessive-compulsive symptoms;
LGG	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg13010199	chr12:38710504	ALG10B	-0.38	-6.7	-0.3	6.12e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs13190036	1.000	rs13157667	chr5:176613877	C/T	cg06733329	chr5:176740039	MXD3	0.48	6.74	0.3	4.77e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs4740619	0.619	rs10738423	chr9:16027329	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.28	-0.46	3.17e-26	Body mass index;
LGG	cis	rs2718058	0.519	rs2598072	chr7:37875319	A/C	cg02531859	chr7:37888154	TXNDC3	-0.45	-6.82	-0.3	2.79e-11	Alzheimer's disease (late onset);
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg07142201	chr11:109293216	C11orf87	0.83	16.27	0.6	2.15e-47	Schizophrenia;
LGG	cis	rs6121246	0.529	rs41310803	chr20:30452709	A/G	cg13852791	chr20:30311386	BCL2L1	0.52	6.69	0.3	6.37e-11	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.97	-0.42	2.45e-21	Lung cancer;
LGG	cis	rs17776563	0.887	rs8030854	chr15:89133549	C/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.4	-0.44	6.52e-23	Thyroid hormone levels;
LGG	cis	rs17102423	0.826	rs12887607	chr14:65596887	G/A	cg11161011	chr14:65562177	MAX	-0.72	-13.51	-0.53	2.77e-35	Obesity-related traits;
LGG	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.65	-0.48	1.1e-27	Schizophrenia;
LGG	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.85	0.38	1.91e-17	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs41271473	0.898	rs17352535	chr1:228822284	C/G	cg10167378	chr1:228756711	NA	0.56	7.58	0.33	1.88e-13	Chronic lymphocytic leukemia;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00684032	chr4:1343700	KIAA1530	-0.47	-9.15	-0.39	1.76e-18	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs12592400	chr15:67558010	C/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.65	-0.3	8.46e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.87	-0.3	2.06e-11	Bipolar disorder;
LGG	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg22437258	chr11:111473054	SIK2	0.57	9.83	0.42	7.57e-21	Primary sclerosing cholangitis;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg14159672	chr1:205819179	PM20D1	0.76	16.14	0.6	8.04e-47	Menarche (age at onset);
LGG	cis	rs17270561	0.583	rs6908407	chr6:25703656	A/T	cg03264133	chr6:25882463	NA	0.46	7.41	0.33	5.85e-13	Iron status biomarkers;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.46	-0.37	3.41e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1372520	0.808	rs1372518	chr4:90757294	A/C	cg15133208	chr4:90757351	SNCA	-0.42	-8.48	-0.37	3.07e-16	Neuroticism;
LGG	cis	rs34929064	1.000	rs2097677	chr7:22732839	G/A	cg18045685	chr7:22629474	NA	0.56	8.79	0.38	3.04e-17	Major depression and alcohol dependence;
LGG	cis	rs7193541	0.508	rs7188581	chr16:74672901	T/A	cg01733217	chr16:74700730	RFWD3	1.09	32.54	0.83	1.06e-121	Multiple myeloma;
LGG	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.12	-0.35	4.37e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.97	-0.42	2.43e-21	Educational attainment;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg21399703	chr1:247681439	NA	0.65	11.54	0.47	3.11e-27	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	9.51	0.4	1.07e-19	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg26174226	chr8:58114915	NA	-0.54	-7.4	-0.33	6.68e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8072100	0.875	rs12451409	chr17:45544856	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.21	-0.39	1.12e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4862750	0.914	rs1346126	chr4:187876404	T/C	cg27532560	chr4:187881888	NA	-0.59	-12.88	-0.51	1.15e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7084402	0.967	rs1658454	chr10:60306770	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs9479482	0.967	rs9479478	chr6:150354608	T/G	cg16395133	chr6:150326394	RAET1K	0.28	7.0	0.31	9.12e-12	Alopecia areata;
LGG	cis	rs4851254	0.660	rs1821830	chr2:100680279	C/T	cg17356467	chr2:100759845	AFF3	0.46	7.39	0.32	6.75e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg25214090	chr10:38739885	LOC399744	0.64	11.47	0.47	5.55e-27	Corneal astigmatism;
LGG	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg16486109	chr11:613632	IRF7	0.41	7.34	0.32	9.65e-13	Systemic lupus erythematosus;
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg04503457	chr17:41445688	NA	-0.39	-9.39	-0.4	2.82e-19	Menopause (age at onset);
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg14912033	chr15:79043428	NA	0.37	7.94	0.35	1.52e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs6982240	0.514	rs10481391	chr8:142277149	A/G	cg20799268	chr8:142275649	NA	-0.25	-6.85	-0.3	2.39e-11	Tonsillectomy;
LGG	cis	rs875971	0.862	rs4718377	chr7:66049678	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs757081	0.648	rs214102	chr11:17288298	G/A	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.72	-0.34	7.03e-14	Systolic blood pressure;
LGG	cis	rs28595532	0.920	rs114462478	chr4:119752656	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs1322639	0.657	rs9355135	chr6:169573006	C/T	cg04662567	chr6:169592167	NA	-0.89	-12.29	-0.5	3.1e-30	Pulse pressure;
LGG	cis	rs11877825	0.826	rs9675768	chr18:10571709	T/C	cg07277756	chr18:10589357	NA	0.58	10.45	0.44	4.26e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg00405596	chr8:11794950	NA	0.61	10.55	0.44	1.84e-23	Monocyte count;
LGG	cis	rs1003719	0.788	rs2835582	chr21:38458773	C/G	cg10648535	chr21:38446584	PIGP;TTC3	0.84	17.09	0.62	4.13e-51	Eye color traits;
LGG	cis	rs2070433	1.000	rs2839302	chr21:47952364	G/A	cg12379764	chr21:47803548	PCNT	0.58	8.32	0.36	1.03e-15	Lymphocyte counts;
LGG	trans	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs2153535	0.601	rs2327091	chr6:8540369	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.35	0.43	9.9e-23	Motion sickness;
LGG	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg18129748	chr3:49941408	MST1R	0.22	7.12	0.31	4.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs13315711	chr3:48986399	A/T	cg07636037	chr3:49044803	WDR6	1.1	28.13	0.79	3.05e-102	Parkinson's disease;
LGG	cis	rs2455601	0.671	rs2568091	chr11:8986048	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-11.25	-0.46	4.04e-26	Schizophrenia;
LGG	cis	rs9902453	0.817	rs1842026	chr17:28188111	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs72781680	1.000	rs72781683	chr2:24247423	T/C	cg08917208	chr2:24149416	ATAD2B	0.92	9.8	0.41	9.85e-21	Lymphocyte counts;
LGG	cis	rs17612678	0.934	rs1122702	chr15:93819593	A/G	cg19550034	chr15:93814737	NA	0.34	6.76	0.3	4.07e-11	Obesity-related traits;
LGG	cis	rs9400467	0.537	rs12215291	chr6:111463520	A/G	cg15721981	chr6:111408429	SLC16A10	0.56	6.84	0.3	2.48e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.98	-0.35	1.2e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs67311347	1.000	rs1454497	chr3:40496326	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.03	-0.31	7.3e-12	Renal cell carcinoma;
LGG	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.35	-7.66	-0.34	1.12e-13	Restless legs syndrome;
LGG	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.7	-0.51	6.21e-32	Diastolic blood pressure;
LGG	cis	rs7107174	1.000	rs10793297	chr11:78009660	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.45	0.58	9.89e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2267681	0.565	rs6464800	chr7:139518480	A/G	cg14116596	chr7:139528673	TBXAS1	0.32	7.06	0.31	6.18e-12	Cervical cancer;
LGG	cis	rs28830936	0.934	rs4923915	chr15:42119606	C/T	cg17847044	chr15:42102381	MAPKBP1	-0.56	-12.68	-0.51	7.65e-32	Diastolic blood pressure;
LGG	cis	rs2110001	1	rs2110001	chr7:150517022	C/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.27	6.92	0.31	1.47e-11	Height;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.52e-13	Personality dimensions;
LGG	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs9916302	0.821	rs412430	chr17:37737094	C/G	cg07936489	chr17:37558343	FBXL20	-0.83	-15.04	-0.57	6.46e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs1107366	0.722	rs35331719	chr3:125907392	C/A	cg11252792	chr3:125932053	NA	0.6	12.04	0.49	3.21e-29	Metabolite levels;
LGG	trans	rs11782517	1.000	rs12547261	chr8:10114107	A/T	cg02002194	chr4:3960332	NA	-0.45	-6.78	-0.3	3.76e-11	Nose size;
LGG	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg05973401	chr12:123451056	ABCB9	0.47	7.85	0.34	2.9e-14	Platelet count;
LGG	trans	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.41e-11	Depression;
LGG	trans	rs826838	0.967	rs7970069	chr12:38810631	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.66	-0.34	1.1e-13	Heart rate;
LGG	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.12e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7980799	0.905	rs4244866	chr12:33511983	G/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.27	-0.36	1.4e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10197940	0.753	rs2290368	chr2:152266473	T/C	cg19508488	chr2:152266495	RIF1	0.71	13.71	0.54	3.9e-36	Lung cancer;
LGG	trans	rs61931739	0.592	rs61927750	chr12:33696070	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.7	-0.37	5.96e-17	Morning vs. evening chronotype;
LGG	cis	rs9487094	0.744	rs12661287	chr6:110053250	A/T	cg16315928	chr6:109776240	MICAL1	0.48	7.67	0.34	1.04e-13	Height;
LGG	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.65	0.41	3.32e-20	Height;
LGG	cis	rs172166	0.611	rs203883	chr6:28078356	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.13	-0.31	3.98e-12	Cardiac Troponin-T levels;
LGG	trans	rs2727020	0.538	rs61885230	chr11:49128958	T/C	cg21153622	chr11:89784906	NA	-0.4	-7.2	-0.32	2.46e-12	Coronary artery disease;
LGG	cis	rs34599045	0.522	rs71626740	chr1:152920663	A/G	cg07796016	chr1:152779584	LCE1C	-0.87	-8.05	-0.35	6.84e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.69	-0.41	2.36e-20	Height;
LGG	cis	rs1419980	0.630	rs2080126	chr12:7774524	A/C	cg10578777	chr12:7781093	NA	0.63	8.58	0.37	1.42e-16	HDL cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24229819	chr17:41856238	DUSP3	0.54	8.15	0.35	3.39e-15	Gut microbiome composition (summer);
LGG	cis	rs4742903	1.000	rs10761010	chr9:106858788	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.25	0.36	1.66e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg17108064	chr15:78857060	CHRNA5	0.47	10.07	0.42	1.07e-21	Sudden cardiac arrest;
LGG	cis	rs774359	0.789	rs12554036	chr9:27509211	G/T	cg21249376	chr9:27528432	MOBKL2B	0.43	7.92	0.35	1.76e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.79	16.03	0.6	2.6e-46	Personality dimensions;
LGG	cis	rs4740619	0.653	rs7860024	chr9:15740673	G/T	cg14451791	chr9:16040625	NA	0.34	8.67	0.37	7.41e-17	Body mass index;
LGG	cis	rs4253772	0.591	rs6008361	chr22:46652372	A/G	cg24881330	chr22:46731750	TRMU	-0.72	-8.91	-0.38	1.16e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.73e-19	Menopause (age at onset);
LGG	cis	rs752010	0.746	rs11210499	chr1:42089703	C/T	cg16096631	chr1:42092165	HIVEP3	-0.77	-23.11	-0.73	3.75e-79	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg26318627	chr11:63887540	MACROD1	-0.46	-6.67	-0.3	7.22e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs2197308	0.728	rs7304305	chr12:37932990	T/C	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.26e-19	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.87	-0.38	1.56e-17	Menopause (age at onset);
LGG	cis	rs8017423	0.935	rs2149653	chr14:90669333	G/A	cg04374321	chr14:90722782	PSMC1	0.86	18.29	0.65	1.26e-56	Mortality in heart failure;
LGG	cis	rs8064299	0.574	rs1879455	chr17:72774738	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.07	0.72	2.75e-74	Monocyte count;
LGG	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs8060686	0.641	rs2418737	chr16:68122726	T/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.03	-0.31	7.37e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg25801113	chr15:45476975	SHF	-0.88	-18.87	-0.66	2.58e-59	Uric acid levels;
LGG	cis	rs7904368	1.000	rs7904368	chr10:16858587	C/T	cg22980697	chr10:16874865	CUBN	0.54	8.8	0.38	2.79e-17	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg12395012	chr8:11607386	GATA4	0.37	6.69	0.3	6.27e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10267417	0.603	rs10229973	chr7:19894778	G/A	cg05791153	chr7:19748676	TWISTNB	0.63	8.21	0.36	2.28e-15	Night sleep phenotypes;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg05552183	chr6:42928497	GNMT	0.43	12.33	0.5	2.15e-30	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4819052	0.851	rs2236445	chr21:46678453	T/C	cg06618935	chr21:46677482	NA	-0.46	-8.81	-0.38	2.57e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3008870	1.000	rs2815348	chr1:67472165	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.0	23.53	0.74	4.24e-81	Lymphocyte percentage of white cells;
LGG	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs757978	0.733	rs41342147	chr2:242407588	C/T	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.63	-7.13	-0.31	3.94e-12	Chronic lymphocytic leukemia;
LGG	cis	rs41271473	0.526	rs2182202	chr1:228733959	G/C	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.18e-19	Chronic lymphocytic leukemia;
LGG	cis	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.82	-0.34	3.54e-14	Neuroticism;
LGG	cis	rs34467563	0.721	rs2640806	chr8:97369634	C/A	cg22138393	chr8:97340270	PTDSS1	0.29	7.18	0.32	2.8e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4742903	1.000	rs4743687	chr9:106856910	C/T	cg14250997	chr9:106856677	SMC2	0.41	8.49	0.37	2.83e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-12.55	-0.5	2.68e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.36e-31	Educational attainment;
LGG	cis	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg00031303	chr3:195681400	NA	-0.45	-6.94	-0.31	1.33e-11	Mean corpuscular volume;
LGG	cis	rs11239187	0.512	rs10900072	chr10:45066922	T/G	cg03916630	chr10:45065415	NA	0.34	8.36	0.36	7.53e-16	Body mass index;
LGG	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg16141378	chr3:129829833	LOC729375	0.32	7.29	0.32	1.38e-12	Monocyte count;
LGG	cis	rs7737355	0.947	rs13163091	chr5:130836041	A/G	cg06307176	chr5:131281290	NA	-0.55	-9.23	-0.39	9.87e-19	Life satisfaction;
LGG	cis	rs3617	0.573	rs62253582	chr3:52928333	G/A	cg11645453	chr3:52864694	ITIH4	-0.46	-7.78	-0.34	4.82e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07132326	chr6:150258058	NA	0.37	8.08	0.35	5.53e-15	Testicular germ cell tumor;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.35	-0.43	1.02e-22	Bipolar disorder;
LGG	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg21132104	chr15:45694354	SPATA5L1	0.69	10.14	0.43	6.01e-22	Homoarginine levels;
LGG	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg07005078	chr4:17578674	LAP3	0.36	6.77	0.3	3.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg01200585	chr1:228362443	C1orf69	0.47	8.14	0.35	3.72e-15	Diastolic blood pressure;
LGG	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg03929089	chr4:120376271	NA	0.9	18.18	0.65	3.72e-56	Coronary artery disease;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg16524936	chr4:1340807	KIAA1530	-0.49	-7.59	-0.33	1.73e-13	Obesity-related traits;
LGG	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg13560919	chr6:33536144	NA	-0.4	-7.29	-0.32	1.32e-12	Crohn's disease;
LGG	cis	rs4356203	0.905	rs7939750	chr11:17079755	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.32	-0.32	1.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.19	-0.43	3.86e-22	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03226425	chr6:170151538	C6orf70;TCTE3	0.44	7.97	0.35	1.27e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs62238980	0.614	rs743764	chr22:32459217	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg19131313	chr8:1704013	NA	-0.3	-6.69	-0.3	6.52e-11	Systolic blood pressure;
LGG	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg07157834	chr1:205819609	PM20D1	0.41	7.05	0.31	6.54e-12	Parkinson's disease;
LGG	cis	rs2075371	1.000	rs2598288	chr7:133977304	A/T	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs11098499	0.909	rs78332141	chr4:120375782	C/T	cg24375607	chr4:120327624	NA	0.69	11.16	0.46	9.17e-26	Corneal astigmatism;
LGG	cis	rs75920871	0.623	rs7928320	chr11:116942753	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-8.07	-0.35	6.21e-15	Subjective well-being;
LGG	cis	rs7586879	0.598	rs6545806	chr2:25124348	G/A	cg04586622	chr2:25135609	ADCY3	0.47	12.67	0.51	8.29e-32	Body mass index;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.48e-20	Prudent dietary pattern;
LGG	cis	rs1256061	0.603	rs1256044	chr14:64734027	G/A	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.13	0.35	3.91e-15	Neuroticism;
LGG	cis	rs4253772	0.637	rs9627295	chr22:46650100	C/T	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	trans	rs9467711	0.651	rs17528178	chr6:25983777	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-8.14	-0.35	3.69e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg05926928	chr17:57297772	GDPD1	1.36	21.78	0.71	6.66e-73	Opioid sensitivity;
LGG	cis	rs2762353	0.935	rs1165153	chr6:25817789	A/G	cg03264133	chr6:25882463	NA	-0.53	-9.99	-0.42	2.04e-21	Blood metabolite levels;
LGG	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg04617936	chr2:214353	NA	-0.4	-7.25	-0.32	1.82e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg16141378	chr3:129829833	LOC729375	0.37	8.43	0.36	4.37e-16	Mood instability;
LGG	cis	rs2404602	0.619	rs7342603	chr15:76982625	C/T	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.79e-12	Blood metabolite levels;
LGG	cis	rs76070545	0.551	rs10104097	chr8:104207451	A/G	cg03923813	chr8:104230441	BAALC	-1.18	-13.02	-0.52	3.08e-33	Alzheimer disease and age of onset;
LGG	cis	rs6558530	0.932	rs10102731	chr8:1709020	A/G	cg08198773	chr8:1697536	NA	0.35	6.76	0.3	4.17e-11	Systolic blood pressure;
LGG	cis	rs4538187	0.951	rs13018690	chr2:64151381	A/C	cg14150252	chr2:64069583	UGP2	-0.48	-9.34	-0.4	3.96e-19	Systolic blood pressure;
LGG	cis	rs12220238	1.000	rs10824110	chr10:75968098	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.61	0.47	1.62e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs896543	0.702	rs6711119	chr2:237494334	C/T	cg25295825	chr2:237489920	CXCR7	0.9	13.95	0.54	3.77e-37	Alcohol dependence (age at onset);
LGG	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg11366901	chr6:160182831	ACAT2	0.93	13.92	0.54	4.7e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6665290	0.904	rs2297418	chr1:227192579	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs138880	0.542	rs9616210	chr22:50317346	C/T	cg02269571	chr22:50332266	NA	-0.8	-9.44	-0.4	1.83e-19	Schizophrenia;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01171360	chr6:293285	DUSP22	-0.58	-9.61	-0.41	4.6e-20	Menopause (age at onset);
LGG	cis	rs13314892	0.770	rs79502300	chr3:69856753	C/T	cg17445875	chr3:69859618	MITF	-0.38	-7.16	-0.32	3.1e-12	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg21724239	chr8:58056113	NA	0.43	6.79	0.3	3.5e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg18180673	chr5:137827632	NA	-0.44	-6.9	-0.31	1.72e-11	Coronary artery disease;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.67e-16	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg13047869	chr3:10149882	C3orf24	-0.55	-9.44	-0.4	1.84e-19	Alzheimer's disease;
LGG	cis	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg26384229	chr12:38710491	ALG10B	0.93	21.26	0.7	1.72e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4144027	0.904	rs35551424	chr14:104341669	A/G	cg26031613	chr14:104095156	KLC1	0.44	7.02	0.31	8.2e-12	Blood metabolite levels;
LGG	cis	rs701145	0.585	rs1727949	chr3:153875713	A/G	cg12800244	chr3:153838788	SGEF	0.76	8.96	0.38	8.2e-18	Coronary artery disease;
LGG	cis	rs7572263	0.652	rs34575089	chr2:209047368	G/A	cg00164906	chr2:209055251	C2orf80	0.69	9.27	0.4	7.07e-19	Glioma;Non-glioblastoma glioma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10069734	chr2:120124354	DBI;C2orf76	0.47	7.08	0.31	5.41e-12	Gut microbiome composition (summer);
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg00800038	chr16:89945340	TCF25	-0.71	-8.62	-0.37	1.05e-16	Skin colour saturation;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs12936587	0.536	rs8075153	chr17:17622666	C/T	cg01246520	chr17:17644344	RAI1	0.37	8.68	0.37	6.75e-17	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.2	0.36	2.47e-15	Lung cancer;
LGG	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg04989706	chr14:50066350	PPIL5	-0.61	-9.87	-0.42	5.57e-21	Carotid intima media thickness;
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg23730037	chr7:158596552	ESYT2	-0.42	-7.24	-0.32	1.88e-12	Height;
LGG	cis	rs9649465	1.000	rs56396297	chr7:123350535	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.88	-0.38	1.45e-17	Migraine;
LGG	cis	rs6831352	0.918	rs29001201	chr4:100053861	T/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.76	-0.38	3.78e-17	Alcohol dependence;
LGG	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg14983838	chr19:29218262	NA	0.72	11.8	0.48	2.78e-28	Methadone dose in opioid dependence;
LGG	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg00677455	chr12:58241039	CTDSP2	0.4	7.33	0.32	1.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs826838	1.000	rs11183160	chr12:38676702	T/C	cg26384229	chr12:38710491	ALG10B	1.06	28.48	0.8	7.91e-104	Heart rate;
LGG	cis	rs870825	0.616	rs9715644	chr4:185632965	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs7301016	0.846	rs73126024	chr12:63027764	C/T	cg01804193	chr12:63026212	NA	0.55	7.15	0.32	3.3e-12	IgG glycosylation;
LGG	cis	rs9816226	1.000	rs55835921	chr3:185831474	T/C	cg00760338	chr3:185826511	ETV5	-0.84	-12.55	-0.5	2.78e-31	Obesity;Body mass index;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.39	8.0	0.35	9.99e-15	Prostate cancer;
LGG	cis	rs4969178	0.896	rs12602206	chr17:76397133	A/G	cg05887092	chr17:76393375	PGS1	0.72	15.81	0.59	2.51e-45	HDL cholesterol levels;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg00149659	chr3:10157352	C3orf10	0.85	11.13	0.46	1.19e-25	Alzheimer's disease;
LGG	trans	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	cis	rs3816183	0.585	rs9973454	chr2:42885611	C/T	cg14631114	chr2:43023945	NA	0.35	6.92	0.31	1.47e-11	Hypospadias;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.71	13.13	0.52	1.11e-33	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.37	0.36	6.67e-16	Obesity-related traits;
LGG	cis	rs273218	1.000	rs156442	chr5:53373029	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.66	9.41	0.4	2.37e-19	Migraine;
LGG	cis	rs4466137	0.953	rs1420654	chr5:82975793	G/A	cg16102102	chr5:83017553	HAPLN1	-0.62	-11.35	-0.47	1.58e-26	Prostate cancer;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.36	-0.53	1.13e-34	Aortic root size;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg18479299	chr3:125709523	NA	-0.61	-7.81	-0.34	3.75e-14	Blood pressure (smoking interaction);
LGG	cis	rs6464772	0.540	rs10952668	chr7:140143520	C/T	cg17228231	chr7:140178305	MKRN1	0.38	6.79	0.3	3.36e-11	Creatinine levels in ischemic stroke;
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg16920238	chr17:80076378	CCDC57	0.34	7.81	0.34	3.92e-14	Life satisfaction;
LGG	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.59	0.33	1.8e-13	Electroencephalogram traits;
LGG	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg08862035	chr2:2617432	NA	0.42	6.8	0.3	3.31e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3857536	0.740	rs4710572	chr6:66890361	C/A	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs6121246	0.609	rs6089075	chr20:30392884	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	17.93	0.64	5.8e-55	Mean corpuscular hemoglobin;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06789412	chr3:101405552	RPL24	0.4	6.73	0.3	5.15e-11	Bipolar disorder;
LGG	cis	rs9487094	0.504	rs71541003	chr6:109973897	C/G	cg01125227	chr6:109776195	MICAL1	0.44	7.74	0.34	6.26e-14	Height;
LGG	cis	rs9398803	0.687	rs4629707	chr6:126937890	T/C	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.92e-19	Male-pattern baldness;
LGG	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg08885076	chr2:99613938	TSGA10	0.43	9.16	0.39	1.65e-18	Chronic sinus infection;
LGG	cis	rs921968	0.643	rs832806	chr2:219473914	A/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.11	-0.31	4.46e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1945213	0.694	rs1384088	chr11:55848713	G/C	cg03929089	chr4:120376271	NA	-0.81	-11.16	-0.46	9.31e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg08999081	chr20:33150536	PIGU	0.44	11.39	0.47	1.16e-26	Coronary artery disease;
LGG	cis	rs12464559	0.522	rs7424335	chr2:152593741	C/T	cg01189475	chr2:152685088	ARL5A	0.69	7.31	0.32	1.16e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg09165964	chr15:75287851	SCAMP5	-0.57	-10.61	-0.44	1.09e-23	Breast cancer;
LGG	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25072359	chr17:41440525	NA	0.52	9.88	0.42	5.15e-21	Menopause (age at onset);
LGG	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg00504896	chr12:9437009	LOC642846	-0.45	-8.1	-0.35	4.95e-15	Breast size;
LGG	cis	rs7241530	0.662	rs4799009	chr18:75910320	C/G	cg14642773	chr18:75888474	NA	0.45	8.64	0.37	9.5e-17	Educational attainment (years of education);
LGG	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg23057051	chr16:89984268	MC1R	-0.36	-6.98	-0.31	1.01e-11	Vitiligo;
LGG	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	cis	rs4538187	0.826	rs1440002	chr2:64147834	G/A	cg02541582	chr2:64069798	UGP2	-0.54	-13.12	-0.52	1.15e-33	Systolic blood pressure;
LGG	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg11494091	chr17:61959527	GH2	0.63	10.89	0.45	9.69e-25	Height;
LGG	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg17294928	chr15:75287854	SCAMP5	0.41	6.69	0.3	6.45e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg25019033	chr10:957182	NA	-0.55	-10.08	-0.42	9.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.63	0.44	9.14e-24	Arsenic metabolism;
LGG	cis	rs11239187	0.530	rs10793545	chr10:45063071	T/A	cg03916630	chr10:45065415	NA	0.37	8.98	0.39	6.66e-18	Body mass index;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03221778	chr16:89284213	ZNF778	0.58	6.71	0.3	5.8200000000000003e-11	Intelligence (multi-trait analysis);
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg26318627	chr11:63887540	MACROD1	-0.47	-6.74	-0.3	4.65e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg23815491	chr16:72088622	HP	0.54	11.92	0.48	9.41e-29	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs367943	0.799	rs2115209	chr5:112973494	A/G	cg12552261	chr5:112820674	MCC	0.58	10.04	0.42	1.36e-21	Type 2 diabetes;
LGG	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08704250	chr15:31115839	NA	-0.45	-8.17	-0.36	2.86e-15	Huntington's disease progression;
LGG	cis	rs736408	0.609	rs2230535	chr3:52800284	T/C	cg18099408	chr3:52552593	STAB1	-0.34	-6.75	-0.3	4.52e-11	Bipolar disorder;
LGG	cis	rs9547692	1.000	rs2147167	chr13:37467404	G/A	cg01493522	chr13:37497338	NA	-0.5	-8.61	-0.37	1.16e-16	Coronary artery disease;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg16680214	chr1:154839983	KCNN3	-0.51	-9.98	-0.42	2.16e-21	Prostate cancer;
LGG	trans	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.76	-0.34	5.47e-14	Mood instability;
LGG	cis	rs2932538	0.614	rs6537741	chr1:113085175	A/C	cg22162597	chr1:113214053	CAPZA1	-0.6	-9.82	-0.42	8.61e-21	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	trans	rs11782517	1.000	rs12547261	chr8:10114107	A/T	cg16141378	chr3:129829833	LOC729375	-0.39	-7.32	-0.32	1.11e-12	Nose size;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.22	0.39	1.06e-18	Life satisfaction;
LGG	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg10513866	chr5:139070639	NA	0.41	7.99	0.35	1.05e-14	Schizophrenia;
LGG	cis	rs11252926	0.545	rs10466270	chr10:556129	A/G	cg08603382	chr10:743973	NA	0.38	6.95	0.31	1.25e-11	Psychosis in Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14868726	chr18:2571660	METTL4;NDC80	0.5	7.59	0.33	1.74e-13	Gut microbiome composition (summer);
LGG	cis	rs8114671	0.562	rs6119536	chr20:33450041	A/G	cg07148914	chr20:33460835	GGT7	-0.49	-8.28	-0.36	1.37e-15	Height;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg03351412	chr1:154909251	PMVK	0.63	11.84	0.48	2.04e-28	Prostate cancer;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.11	-0.35	4.54e-15	Personality dimensions;
LGG	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.2	0.39	1.25e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs72634258	0.945	rs4908724	chr1:8119251	G/T	cg00042356	chr1:8021962	PARK7	0.83	10.81	0.45	1.91e-24	Inflammatory bowel disease;
LGG	cis	rs9660992	0.573	rs12140703	chr1:205182865	G/C	cg00857998	chr1:205179979	DSTYK	0.51	7.98	0.35	1.13e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs908922	0.676	rs10888494	chr1:152514709	T/C	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.47	0.63	7.66e-53	Alzheimer's disease;
LGG	cis	rs9359856	0.564	rs56224741	chr6:90475231	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.14	-0.43	5.91e-22	Bipolar disorder;
LGG	cis	rs56283067	0.577	rs114009236	chr6:44897517	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.32	-0.47	2.11e-26	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21037892	chr2:96874728	STARD7	0.55	8.42	0.36	4.78e-16	Gut microbiome composition (summer);
LGG	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg05802129	chr4:122689817	NA	-0.41	-6.95	-0.31	1.22e-11	Type 2 diabetes;
LGG	cis	rs2576037	0.901	rs6507719	chr18:44581310	A/T	cg23302884	chr18:44338147	ST8SIA5	0.36	7.01	0.31	8.55e-12	Personality dimensions;
LGG	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg23461800	chr14:103021989	NA	-0.58	-9.95	-0.42	2.78e-21	Platelet count;
LGG	cis	rs10789491	1.000	rs10749863	chr1:47174328	C/T	cg15501359	chr1:47185051	KIAA0494	0.76	14.87	0.57	3.73e-41	Response to hepatitis C treatment;
LGG	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.64	0.48	1.25e-27	Rheumatoid arthritis;
LGG	cis	rs12580194	0.593	rs74844018	chr12:55766871	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.21	-0.43	3.35e-22	Cancer;
LGG	cis	rs67460515	0.926	rs13062740	chr3:161024208	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-13.27	-0.52	2.73e-34	Parkinson's disease;
LGG	cis	rs2839186	0.814	rs2276257	chr21:47711229	A/G	cg08742575	chr21:47604166	C21orf56	0.49	8.34	0.36	8.28e-16	Testicular germ cell tumor;
LGG	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.37e-19	Height;
LGG	cis	rs6445975	0.715	rs6809809	chr3:58267950	A/G	cg24175188	chr3:58374923	PXK	0.4	7.4	0.33	6.65e-13	Systemic lupus erythematosus;
LGG	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg03894339	chr8:19674705	INTS10	0.63	10.17	0.43	4.62e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs6787172	0.622	rs4679827	chr3:158124543	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs7072216	0.763	rs12763044	chr10:100167451	C/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.21	-0.32	2.33e-12	Metabolite levels;
LGG	cis	rs7662987	0.517	rs1311615	chr4:100012261	G/A	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.8e-20	Smoking initiation;
LGG	cis	rs2777491	0.574	rs72739644	chr15:41719706	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.66	-0.84	1.63e-126	Ulcerative colitis;
LGG	trans	rs826838	0.616	rs2200605	chr12:38624088	G/A	cg06521331	chr12:34319734	NA	-0.39	-6.96	-0.31	1.16e-11	Heart rate;
LGG	cis	rs593982	0.920	rs4930298	chr11:65448108	T/A	cg08755490	chr11:65554678	OVOL1	-0.63	-7.21	-0.32	2.33e-12	Atopic dermatitis;
LGG	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg24642439	chr20:33292090	TP53INP2	-0.45	-7.17	-0.32	2.97e-12	Height;
LGG	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg25019033	chr10:957182	NA	-0.6	-11.7	-0.48	7.09e-28	Eosinophil percentage of granulocytes;
LGG	cis	rs11792861	0.619	rs2289481	chr9:111712924	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.66	11.68	0.48	8.59e-28	Menarche (age at onset);
LGG	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.74	12.86	0.51	1.4e-32	Response to antipsychotic treatment;
LGG	cis	rs4936891	0.520	rs61908592	chr11:123871602	G/T	cg22125253	chr11:123886957	OR10G4	-0.47	-7.92	-0.35	1.75e-14	Male fertility;
LGG	trans	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg24247370	chr13:99142703	STK24	-0.36	-6.65	-0.3	8.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs787274	1.000	rs787285	chr9:115536743	A/G	cg13803584	chr9:115635662	SNX30	-0.59	-7.31	-0.32	1.16e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2243480	1.000	rs67536397	chr7:65947917	G/A	cg18252515	chr7:66147081	NA	-1.43	-20.27	-0.69	7.69e-66	Diabetic kidney disease;
LGG	cis	rs6586163	0.546	rs12359362	chr10:90753145	G/C	cg03111039	chr10:90751583	FAS;ACTA2	0.76	14.98	0.57	1.21e-41	Chronic lymphocytic leukemia;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.29	0.69	6.25e-66	Platelet count;
LGG	cis	rs9549367	0.826	rs9549710	chr13:113898064	A/C	cg18105134	chr13:113819100	PROZ	-0.69	-14.18	-0.55	3.6e-38	Platelet distribution width;
LGG	cis	rs9790314	0.846	rs7627528	chr3:160990878	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.26	-0.49	4.21e-30	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.967	rs61014003	chr17:28485233	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.26	0.52	2.95e-34	Coffee consumption (cups per day);
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg04772025	chr11:68637568	NA	-0.74	-12.96	-0.52	5.59e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1784581	0.588	rs9355971	chr6:162421242	A/G	cg17173639	chr6:162384350	PARK2	0.64	13.58	0.53	1.41e-35	Itch intensity from mosquito bite;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg21144673	chr22:42017783	PPPDE2;XRCC6	0.39	6.88	0.3	1.9e-11	Bilirubin levels;
LGG	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.88	-0.38	1.44e-17	Body mass index;
LGG	cis	rs11229555	0.574	rs12272096	chr11:58186118	A/G	cg15696309	chr11:58395628	NA	-0.94	-15.28	-0.58	5.53e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6502050	0.765	rs4789671	chr17:80129970	C/T	cg13939156	chr17:80058883	NA	-0.44	-8.37	-0.36	6.77e-16	Life satisfaction;
LGG	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	9.5	0.4	1.11e-19	Retinal vascular caliber;
LGG	cis	rs4613509	1	rs4613509	chr3:160728059	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-9.38	-0.4	2.84e-19	Morning vs. evening chronotype;
LGG	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	cg15522984	chr1:182991683	LAMC1	0.45	8.78	0.38	3.12e-17	Colorectal cancer;
LGG	cis	rs806215	0.526	rs882694	chr7:127496768	A/G	cg25922125	chr7:127225783	GCC1	-0.49	-7.13	-0.31	3.95e-12	Type 2 diabetes;
LGG	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.11	0.31	4.31e-12	Bladder cancer;
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs3806843	0.966	rs2240693	chr5:140183325	G/C	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.23	-0.58	8.97e-43	Chronic sinus infection;
LGG	trans	rs6575793	0.532	rs11849489	chr14:101037762	C/G	cg09399377	chr6:136611038	BCLAF1	0.48	7.28	0.32	1.45e-12	Menarche (age at onset);
LGG	cis	rs6540556	0.682	rs667681	chr1:209914449	A/G	cg23920097	chr1:209922102	NA	0.46	7.72	0.34	7.18e-14	Red blood cell count;
LGG	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg25174290	chr11:3078921	CARS	0.75	16.17	0.6	5.99e-47	Longevity;
LGG	cis	rs1577917	0.917	rs1838959	chr6:86556804	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.52	0.44	2.28e-23	Prudent dietary pattern;
LGG	cis	rs4356203	0.905	rs2052188	chr11:17126670	C/T	cg15432903	chr11:17409602	KCNJ11	0.38	7.26	0.32	1.65e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7267979	0.816	rs3746337	chr20:25208272	C/T	cg06421707	chr20:25228305	PYGB	0.52	11.45	0.47	6.66e-27	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9911578	1.000	rs302840	chr17:56673079	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.87	-0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1788820	0.917	rs1788760	chr18:21137442	A/G	cg14672496	chr18:21087552	C18orf8	0.38	6.93	0.31	1.46e-11	Body mass index;
LGG	cis	rs7843479	0.931	rs1031883	chr8:21788936	G/A	cg17168535	chr8:21777572	XPO7	0.6	9.68	0.41	2.73e-20	Mean corpuscular volume;
LGG	trans	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	cis	rs4595586	0.545	rs12826080	chr12:39387772	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.77	0.45	2.65e-24	Morning vs. evening chronotype;
LGG	cis	rs9513627	0.915	rs4539436	chr13:100122802	C/G	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs11105298	0.891	rs4842662	chr12:89933446	T/C	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1729951	0.575	rs2163896	chr3:136691177	G/A	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg23594656	chr7:65796392	TPST1	0.41	9.03	0.39	4.65e-18	Aortic root size;
LGG	cis	rs12464559	0.649	rs2030588	chr2:152668750	C/A	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11645453	chr3:52864694	ITIH4	0.42	6.89	0.31	1.82e-11	Bipolar disorder;
LGG	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg24189917	chr7:1970923	MAD1L1	-0.48	-7.84	-0.34	3.18e-14	Bipolar disorder;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg09845145	chr15:78292470	TBC1D2B	-0.6	-10.56	-0.44	1.7e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs12200782	1.000	rs72843802	chr6:26517515	C/T	cg11502198	chr6:26597334	ABT1	-0.86	-7.4	-0.33	6.52e-13	Small cell lung carcinoma;
LGG	cis	rs2247341	0.965	rs2854921	chr4:1715250	C/T	cg08446824	chr4:1720184	TMEM129	-0.67	-12.93	-0.51	7.49e-33	Hip circumference adjusted for BMI;Height;
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg16141378	chr3:129829833	LOC729375	0.41	9.47	0.4	1.42e-19	Neuroticism;
LGG	trans	rs877282	1.000	rs11253367	chr10:773389	G/A	cg22713356	chr15:30763199	NA	0.57	8.78	0.38	3.21e-17	Uric acid levels;
LGG	cis	rs13314892	0.881	rs17043851	chr3:69825970	T/G	cg17445875	chr3:69859618	MITF	-0.36	-7.25	-0.32	1.73e-12	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs4148883	0.713	rs3828541	chr4:100042262	A/G	cg12011299	chr4:100065546	ADH4	0.4	8.78	0.38	3.14e-17	Alcohol dependence;
LGG	cis	rs17030434	0.906	rs57446135	chr4:154679331	A/G	cg14289246	chr4:154710475	SFRP2	-0.72	-11.06	-0.46	2.08e-25	Electrocardiographic conduction measures;
LGG	cis	rs9583531	0.629	rs7991766	chr13:111380684	A/G	cg24331049	chr13:111365604	ING1	0.84	14.73	0.56	1.56e-40	Coronary artery disease;
LGG	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg00086871	chr4:6988644	TBC1D14	1.09	9.94	0.42	3.16e-21	Granulocyte percentage of myeloid white cells;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg07167872	chr1:205819463	PM20D1	0.56	11.32	0.47	2.08e-26	Menarche (age at onset);
LGG	cis	rs10865541	0.967	rs6755327	chr2:3397281	T/C	cg13173536	chr2:3403300	TTC15	-0.37	-7.83	-0.34	3.37e-14	Obesity-related traits;
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg09359103	chr1:154839909	KCNN3	-0.48	-9.47	-0.4	1.47e-19	Prostate cancer;
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg03351412	chr1:154909251	PMVK	0.67	12.94	0.52	6.49e-33	Prostate cancer;
LGG	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg17201900	chr20:34330562	RBM39	-0.49	-6.79	-0.3	3.38e-11	Total cholesterol levels;
LGG	cis	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.01	0.31	8.42e-12	Lung cancer;
LGG	cis	rs6840360	0.615	rs1962910	chr4:152479392	T/A	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	1.000	rs11607300	chr11:34759319	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.36	-0.32	8.58e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs988958	0.567	rs11894613	chr2:42268392	T/C	cg27428208	chr2:42229179	NA	0.5	8.78	0.38	3.29e-17	Hypospadias;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00689492	chr4:1303491	MAEA	0.5	8.5	0.37	2.68e-16	Obesity-related traits;
LGG	cis	rs3096299	0.781	rs2170839	chr16:89409452	C/G	cg02187348	chr16:89574699	SPG7	0.42	6.84	0.3	2.48e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs4819052	0.851	rs13047598	chr21:46660777	G/T	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs5756813	0.661	rs2285177	chr22:38205894	A/G	cg19894588	chr14:64061835	NA	-0.59	-9.79	-0.41	1.07e-20	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs722599	0.748	rs20578	chr14:75367807	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.6	-10.03	-0.42	1.52e-21	IgG glycosylation;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.28	0.79	2.13e-98	Height;
LGG	cis	rs910316	0.934	rs8006587	chr14:75664939	A/G	cg08847533	chr14:75593920	NEK9	0.59	11.35	0.47	1.65e-26	Height;
LGG	cis	rs10781543	0.839	rs4379550	chr9:139376426	C/T	cg14019695	chr9:139328340	INPP5E	-0.4	-7.18	-0.32	2.83e-12	Monocyte percentage of white cells;
LGG	cis	rs35740288	0.787	rs2008916	chr15:86221190	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.09	0.35	5.21e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg26597838	chr10:835615	NA	0.53	6.87	0.3	2.05e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs16912285	0.579	rs73438263	chr11:24265205	C/T	ch.11.24196551F	chr11:24239977	NA	0.78	8.22	0.36	2.01e-15	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4730250	0.634	rs11767623	chr7:106792332	C/T	cg02696742	chr7:106810147	HBP1	0.79	11.12	0.46	1.24e-25	Osteoarthritis;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.846	rs17767398	chr14:71770485	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.31	-0.36	1.06e-15	Mitral valve prolapse;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.45e-22	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03157738	chr19:11308118	KANK2	0.53	8.85	0.38	1.85e-17	Gut microbiome composition (summer);
LGG	trans	rs1493916	0.748	rs1845386	chr18:31318256	C/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.56	-0.47	2.57e-27	Life satisfaction;
LGG	cis	rs12586317	0.586	rs74243590	chr14:35513246	G/A	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.9	-0.34	2.04e-14	Psoriasis;
LGG	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg15704280	chr7:45808275	SEPT13	-1.09	-26.76	-0.78	5.2e-96	Height;
LGG	cis	rs7481584	1.000	rs2239898	chr11:3024462	G/A	cg08468577	chr11:2973342	NAP1L4	-0.39	-8.01	-0.35	9.44e-15	Calcium levels;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04156016	chr5:1868137	NA	0.31	6.95	0.31	1.28e-11	Cardiovascular disease risk factors;
LGG	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.65	-0.33	1.21e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs870825	0.587	rs35377170	chr4:185639728	T/C	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.61	-0.41	4.49e-20	Response to antipsychotic treatment;
LGG	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg14088196	chr11:70211408	PPFIA1	0.96	13.28	0.53	2.43e-34	Coronary artery disease;
LGG	cis	rs4740619	0.711	rs4740629	chr9:15981633	T/G	cg14451791	chr9:16040625	NA	-0.4	-10.41	-0.44	5.86e-23	Body mass index;
LGG	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.49	0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs2587949	0.615	rs2629242	chr3:4225060	T/C	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.77e-11	Periodontitis (DPAL);
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg09264619	chr17:80180166	NA	0.35	7.01	0.31	8.23e-12	Life satisfaction;
LGG	trans	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.48	-0.4	1.37e-19	Brugada syndrome;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.54	0.37	1.97e-16	Personality dimensions;
LGG	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.69	-0.3	6.66e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs898097	0.585	rs9892342	chr17:80893029	C/T	cg10494973	chr17:80897199	TBCD	-0.42	-7.41	-0.33	5.99e-13	Breast cancer;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg04080417	chr5:1859792	NA	-0.52	-8.55	-0.37	1.79e-16	Cardiovascular disease risk factors;
LGG	cis	rs929596	0.793	rs2602376	chr2:234582051	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.64	-10.27	-0.43	1.98e-22	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg06521331	chr12:34319734	NA	0.45	7.93	0.35	1.7e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg22535103	chr8:58192502	C8orf71	-0.69	-9.05	-0.39	4.09e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.553	rs10839295	chr11:49527345	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.33	-0.7	7.74e-71	Coronary artery disease;
LGG	cis	rs2306032	0.669	rs10838622	chr11:46856536	T/C	cg03339077	chr11:47165057	C11orf49	-0.45	-8.18	-0.36	2.71e-15	Total body bone mineral density;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.71	13.13	0.52	1.11e-33	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04728121	chr14:89883534	FOXN3	-0.45	-6.69	-0.3	6.52e-11	Pancreatic cancer;
LGG	cis	rs4950322	0.570	rs72692951	chr1:146792269	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs300774	0.925	rs375613	chr2:130618	C/G	cg04617936	chr2:214353	NA	0.5	7.63	0.33	1.39e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12949296	chr6:107077437	RTN4IP1;QRSL1	0.46	7.49	0.33	3.46e-13	Cognitive performance;
LGG	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.35	0.43	1.02e-22	Iron status biomarkers;
LGG	cis	rs4901847	0.967	rs7143063	chr14:58549178	A/G	cg15908186	chr14:58618357	C14orf37	-0.57	-10.15	-0.43	5.46e-22	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.71	-0.38	5.32e-17	Personality dimensions;
LGG	cis	rs13082711	0.595	rs7615321	chr3:27368010	A/G	cg02860705	chr3:27208620	NA	0.9	16.36	0.61	8.46e-48	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg03517284	chr6:25882590	NA	-0.4	-7.26	-0.32	1.66e-12	Height;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs3847687	1.000	rs78233646	chr12:131520170	G/T	cg06093039	chr12:131527216	GPR133	0.28	6.96	0.31	1.19e-11	Longevity;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg10360139	chr7:1886902	MAD1L1	-0.38	-6.87	-0.3	2.06e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs34638952	0.577	rs877492	chr17:27449059	C/A	cg27392559	chr17:27410759	MYO18A	-0.37	-7.08	-0.31	5.41e-12	Sitting height ratio;
LGG	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg12591125	chr7:1885375	MAD1L1	0.48	7.44	0.33	5.05e-13	Bipolar disorder;
LGG	cis	rs1348850	0.750	rs13031008	chr2:178477114	G/A	cg27490568	chr2:178487706	NA	0.53	10.45	0.44	4.2e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.81	0.41	9.35e-21	Diabetic kidney disease;
LGG	cis	rs10540	1.000	rs12418639	chr11:473300	A/C	cg19913688	chr11:428466	ANO9	0.68	8.74	0.38	4.21e-17	Body mass index;
LGG	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.37	0.4	3.21e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg01620082	chr3:125678407	NA	-1.02	-9.52	-0.4	9.65e-20	Depression;
LGG	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg02297831	chr4:17616191	MED28	0.46	8.32	0.36	9.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg13628971	chr7:2884303	GNA12	0.34	6.98	0.31	1.03e-11	Height;
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	0.3	8.07	0.35	6.25e-15	IgG glycosylation;
LGG	cis	rs17539620	0.624	rs4566892	chr6:154837346	C/T	cg17771515	chr6:154831774	CNKSR3	0.61	7.54	0.33	2.44e-13	Lipoprotein (a) levels;
LGG	cis	rs4563143	0.675	rs112383987	chr19:29261081	C/T	cg03161606	chr19:29218774	NA	0.69	10.53	0.44	2.18e-23	Methadone dose in opioid dependence;
LGG	trans	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.49	8.1	0.35	5.06e-15	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg19635926	chr16:89946313	TCF25	0.75	7.28	0.32	1.42e-12	Skin colour saturation;
LGG	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg22153745	chr1:153894579	GATAD2B	-0.58	-8.65	-0.37	8.41e-17	Total cholesterol levels;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg04897188	chr1:1363291	NA	-0.35	-6.75	-0.3	4.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.532	rs1589394	chr12:38419700	A/C	cg13010199	chr12:38710504	ALG10B	0.53	10.41	0.44	5.97e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg06609049	chr19:2785107	THOP1	0.96	16.49	0.61	2.11e-48	Total cholesterol levels;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05961935	chr2:145274125	ZEB2	0.47	7.24	0.32	1.83e-12	Gut microbiome composition (summer);
LGG	cis	rs3741151	0.773	rs73544711	chr11:73164870	T/A	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs526231	0.578	rs35100629	chr5:102246085	C/G	cg23492399	chr5:102201601	PAM	-0.61	-9.33	-0.4	4.51e-19	Primary biliary cholangitis;
LGG	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs988958	0.601	rs11887745	chr2:42238054	C/T	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs9462027	0.628	rs2814991	chr6:34615443	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.72	-0.45	4.13e-24	Systemic lupus erythematosus;
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.63e-12	Height;
LGG	cis	rs11098499	0.954	rs10024844	chr4:120311528	A/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs1021993	0.545	rs17014395	chr1:209548807	T/G	cg24446417	chr1:209558027	NA	-0.76	-11.42	-0.47	9.06e-27	Gut microbiome composition (winter);
LGG	cis	rs870825	0.549	rs7656993	chr4:185635159	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs4731207	0.698	rs10243736	chr7:124458966	A/G	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs644799	0.965	rs1944080	chr11:95503636	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs7395662	0.824	rs4882180	chr11:48749357	C/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.92	-0.35	1.83e-14	HDL cholesterol;
LGG	cis	rs7917772	0.636	rs7079231	chr10:104527341	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.51	8.4	0.36	5.44e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg15352829	chr14:105391018	PLD4	0.42	9.98	0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	0.897	rs2026267	chr21:40711477	C/A	cg11890956	chr21:40555474	PSMG1	1.07	21.96	0.71	8.92e-74	Cognitive function;
LGG	cis	rs644799	0.544	rs1727165	chr11:95521648	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	10.97	0.45	4.96e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg18225595	chr11:63971243	STIP1	-0.53	-10.55	-0.44	1.83e-23	Platelet count;
LGG	cis	rs7666738	0.830	rs28729647	chr4:99059552	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg13385521	chr17:29058706	SUZ12P	0.93	10.68	0.44	6.02e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg00938859	chr5:1591904	SDHAP3	0.9	13.0	0.52	3.59e-33	Breast cancer;
LGG	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg15269541	chr15:43626905	ADAL	-0.43	-6.83	-0.3	2.65e-11	Lung cancer in ever smokers;
LGG	trans	rs1814175	0.817	rs4881648	chr11:49812901	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.8e-30	Height;
LGG	cis	rs10504073	0.669	rs12548464	chr8:50023867	C/T	cg00325661	chr8:49890786	NA	0.7	13.64	0.54	7.48e-36	Blood metabolite ratios;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.02	0.39	5.16e-18	Platelet count;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg01262667	chr19:19385393	TM6SF2	0.45	11.37	0.47	1.42e-26	Tonsillectomy;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg05863683	chr7:1912471	MAD1L1	0.46	8.81	0.38	2.45e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4851254	0.961	rs13000759	chr2:100753903	A/T	cg17356467	chr2:100759845	AFF3	-0.4	-6.97	-0.31	1.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6489785	0.737	rs566994	chr12:121213591	C/T	cg02419362	chr12:121203948	SPPL3	0.43	6.77	0.3	3.87e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8060686	0.641	rs7199588	chr16:68224582	C/T	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.23	-0.32	1.97e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs67460515	0.563	rs1585481	chr3:160901481	C/T	cg03342759	chr3:160939853	NMD3	-0.71	-11.84	-0.48	1.99e-28	Parkinson's disease;
LGG	trans	rs9944715	1.000	rs4890628	chr18:43788045	T/C	cg01718231	chr17:29326311	RNF135	-0.41	-6.7	-0.3	6.25e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2224391	0.628	rs2773304	chr6:5242602	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.28	-0.32	1.49e-12	Height;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg12016809	chr21:47604291	C21orf56	0.58	10.28	0.43	1.79e-22	Testicular germ cell tumor;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.49	7.89	0.34	2.2e-14	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01363902	chr12:121022439	NA	0.5	7.82	0.34	3.6e-14	Gut microbiome composition (summer);
LGG	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.61	-9.09	-0.39	3.02e-18	Systemic lupus erythematosus;
LGG	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg06360820	chr2:242988706	NA	-1.0	-12.79	-0.51	2.68e-32	Obesity-related traits;
LGG	cis	rs17092148	0.887	rs2068474	chr20:33231079	A/G	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.32	-0.32	1.09e-12	Neuroticism;
LGG	cis	rs16854884	0.632	rs4446205	chr3:143682607	A/G	cg06585982	chr3:143692056	C3orf58	0.62	10.63	0.44	9.45e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs9547996	1.000	rs9547992	chr13:38218191	C/T	cg17979426	chr13:38220150	TRPC4	-0.44	-8.34	-0.36	8.78e-16	Diastolic blood pressure;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg07027305	chr7:2059796	MAD1L1	-0.31	-6.88	-0.3	1.93e-11	Bipolar disorder;
LGG	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.2	-0.39	1.2e-18	Sudden cardiac arrest;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26595336	chr15:82338380	MEX3B	0.61	7.11	0.31	4.49e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3219090	0.861	rs2695238	chr1:226604519	C/G	cg17127702	chr1:226594323	PARP1	-0.38	-12.35	-0.5	1.78e-30	Melanoma;
LGG	cis	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg21775007	chr8:11205619	TDH	-0.59	-9.45	-0.4	1.72e-19	Retinal vascular caliber;
LGG	trans	rs2797160	0.714	rs1777220	chr6:126022602	G/T	cg05039488	chr6:79577232	IRAK1BP1	0.45	7.63	0.33	1.4e-13	Endometrial cancer;
LGG	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg00599393	chr8:22457479	C8orf58	-0.47	-8.4	-0.36	5.32e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7584262	0.695	rs12712824	chr2:42244325	T/C	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Bone mineral density;
LGG	trans	rs8073060	0.586	rs225296	chr17:33924847	C/G	cg19694781	chr19:47549865	TMEM160	-1.14	-18.03	-0.64	1.99e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs10193935	0.901	rs10169411	chr2:42637749	G/A	cg27598129	chr2:42591480	NA	-0.64	-9.81	-0.41	9.29e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9443645	0.545	rs10755377	chr6:79637925	T/C	cg18132916	chr6:79620363	NA	-0.28	-7.29	-0.32	1.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9467711	0.538	rs36012762	chr6:25980523	A/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.38	0.32	7.3e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg22437258	chr11:111473054	SIK2	-0.53	-8.87	-0.38	1.66e-17	Primary sclerosing cholangitis;
LGG	cis	rs12220238	1.000	rs10824076	chr10:75886956	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.82	0.48	2.39e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs7618501	0.933	rs6809431	chr3:49804119	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	8.85e-33	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg21132104	chr15:45694354	SPATA5L1	0.72	11.04	0.46	2.5e-25	Homoarginine levels;
LGG	cis	rs7027203	0.797	rs3996254	chr9:96591239	A/G	cg14598338	chr9:96623480	NA	-0.54	-9.63	-0.41	4e-20	DNA methylation (variation);
LGG	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg23933602	chr10:16859644	RSU1	0.66	9.64	0.41	3.66e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs236352	0.576	rs3756905	chr6:36843777	C/T	cg03410223	chr6:36853544	C6orf89	0.44	8.4	0.36	5.69e-16	Heart rate;
LGG	cis	rs72634258	0.554	rs17374781	chr1:7919363	A/G	cg00042356	chr1:8021962	PARK7	-0.67	-9.67	-0.41	2.76e-20	Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.07	-0.31	5.6e-12	Retinal vascular caliber;
LGG	cis	rs36051895	0.695	rs10974916	chr9:5017350	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-15.92	-0.59	8.09e-46	Pediatric autoimmune diseases;
LGG	cis	rs3740540	0.507	rs897292	chr10:126290035	A/G	cg04949429	chr10:126290192	LHPP	0.61	11.84	0.48	1.96e-28	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10905065	1.000	rs10737013	chr10:5746772	C/G	cg11519256	chr10:5708881	ASB13	0.42	7.32	0.32	1.13e-12	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs6997458	0.785	rs931505	chr8:86348243	A/G	cg02393479	chr8:86352350	CA3	-0.32	-6.98	-0.31	1.01e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg00383909	chr3:49044727	WDR6	0.47	7.67	0.34	1.03e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9467773	0.967	rs9461267	chr6:26525455	T/G	cg09904177	chr6:26538194	HMGN4	0.79	18.43	0.65	2.75e-57	Intelligence (multi-trait analysis);
LGG	cis	rs4919087	0.923	rs11189037	chr10:98974707	C/G	cg25902810	chr10:99078978	FRAT1	0.52	9.68	0.41	2.54e-20	Monocyte count;
LGG	cis	rs7586879	1.000	rs7608185	chr2:25115432	G/C	cg04586622	chr2:25135609	ADCY3	0.39	9.89	0.42	4.71e-21	Body mass index;
LGG	cis	rs35740288	0.770	rs35348278	chr15:86200340	G/A	cg04173714	chr15:86211321	AKAP13	0.47	8.64	0.37	9.4e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs72717009	0.825	rs12722986	chr1:161465420	A/G	cg23840854	chr1:161414152	NA	-0.73	-8.85	-0.38	1.85e-17	Rheumatoid arthritis;
LGG	cis	rs6763768	0.565	rs11714096	chr3:53396145	G/C	cg16894138	chr3:53270350	TKT	0.42	8.08	0.35	5.75e-15	Bacterial meningitis;
LGG	cis	rs72925845	0.519	rs589582	chr17:76427732	C/A	cg03830375	chr17:76426088	DNAH17	0.53	7.48	0.33	3.77e-13	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18094330	chr7:100136910	AGFG2	0.44	7.02	0.31	8.05e-12	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg18681998	chr4:17616180	MED28	0.88	18.8	0.66	5.5099999999999996e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.76	0.3	4.21e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11209002	0.614	rs7519768	chr1:67555522	C/T	cg02640540	chr1:67518911	SLC35D1	0.42	7.4	0.33	6.4e-13	Crohn's disease;
LGG	cis	rs9377188	0.593	rs7738162	chr6:149376102	T/C	cg21368479	chr6:149415018	NA	0.27	6.89	0.3	1.85e-11	Cancer;
LGG	cis	rs61925898	1	rs61925898	chr12:66779537	A/G	cg16791601	chr12:66731901	HELB	-0.63	-14.57	-0.56	7.28e-40	Basophil percentage of granulocytes;Basophil percentage of white cells;
LGG	cis	rs6489785	0.745	rs491602	chr12:121312331	G/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.7	-0.3	5.97e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs11711311	0.824	rs35089588	chr3:113352580	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.36	0.5	1.53e-30	IgG glycosylation;
LGG	cis	rs4356203	0.811	rs214920	chr11:17237949	A/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs919433	0.679	rs61155920	chr2:198528881	C/T	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs61931739	0.649	rs815046	chr12:33720602	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.87	-0.3	2.02e-11	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs876084	0.505	rs9969584	chr8:121104786	G/A	cg06265175	chr8:121136014	COL14A1	0.47	9.63	0.41	4.01e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1345301	0.518	rs1558623	chr2:102862402	T/A	cg05295703	chr2:102895712	NA	0.48	9.62	0.41	4.32e-20	Waist circumference;
LGG	cis	rs6594499	0.872	rs10055177	chr5:110450584	T/G	cg04022379	chr5:110408740	TSLP	0.4	7.38	0.32	7.42e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17125944	0.505	rs3783447	chr14:53191647	G/A	cg13660082	chr14:53194042	PSMC6	-0.56	-7.89	-0.34	2.22e-14	Alzheimer's disease (late onset);
LGG	cis	rs2479724	0.901	rs6458244	chr6:41790455	C/T	cg17623882	chr6:41773611	USP49	0.53	9.48	0.4	1.35e-19	Menarche (age at onset);
LGG	cis	rs4660306	0.677	rs1691216	chr1:45899416	A/G	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.45	6.77	0.3	4e-11	Homocysteine levels;
LGG	cis	rs11971779	0.878	rs4732378	chr7:139120395	C/T	cg07862535	chr7:139043722	LUC7L2	0.66	9.93	0.42	3.42e-21	Diisocyanate-induced asthma;
LGG	cis	rs992157	0.764	rs4672886	chr2:219185545	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-8.57	-0.37	1.51e-16	Colorectal cancer;
LGG	cis	rs5756813	0.754	rs11705616	chr22:38180487	G/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.22	0.32	2.12e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7617773	0.817	rs13094727	chr3:48323489	G/A	cg11946769	chr3:48343235	NME6	0.7	11.61	0.47	1.52e-27	Coronary artery disease;
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg14338887	chr6:42928500	GNMT	0.28	9.2	0.39	1.25e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg08344181	chr3:125677491	NA	-0.51	-6.68	-0.3	7.04e-11	Depression;
LGG	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg26116260	chr4:7069785	GRPEL1	-0.81	-7.8	-0.34	4.18e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17767392	0.813	rs61989386	chr14:71986545	T/C	cg02058870	chr14:72053146	SIPA1L1	0.41	8.53	0.37	2.05e-16	Mitral valve prolapse;
LGG	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.89	-10.97	-0.45	4.96e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.09	0.39	2.91e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg00495681	chr13:53174319	NA	0.46	7.53	0.33	2.68e-13	Lewy body disease;
LGG	cis	rs2832191	0.967	rs1999321	chr21:30530233	A/C	cg24692254	chr21:30365293	RNF160	0.85	19.15	0.66	1.23e-60	Dental caries;
LGG	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg06212747	chr3:49208901	KLHDC8B	0.53	8.18	0.36	2.71e-15	Menarche (age at onset);
LGG	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg26924012	chr15:45694286	SPATA5L1	1.04	22.42	0.72	6.52e-76	Homoarginine levels;
LGG	cis	rs9463078	0.683	rs227851	chr6:44699209	A/C	cg25276700	chr6:44698697	NA	0.41	8.64	0.37	9.06e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs10870270	0.956	rs67378218	chr10:133752420	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.38	-0.5	1.3e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs58106596	0.800	rs28883318	chr2:232562935	G/A	cg01370599	chr3:116745421	NA	0.65	9.94	0.42	3.15e-21	White blood cell count;Lymphocyte counts;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg15383120	chr6:291909	DUSP22	-0.55	-9.17	-0.39	1.55e-18	Menopause (age at onset);
LGG	cis	rs2404602	0.598	rs11634019	chr15:76634680	A/G	cg15268244	chr15:77196840	NA	0.41	8.05	0.35	7.13e-15	Blood metabolite levels;
LGG	cis	rs7508	0.521	rs4377998	chr8:17923339	C/T	cg18067069	chr8:17937731	ASAH1	-0.39	-9.62	-0.41	4.43e-20	Atrial fibrillation;
LGG	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25517755	chr10:38738941	LOC399744	0.35	6.71	0.3	5.8e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs8050260	0.500	rs4783650	chr16:68558528	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.62	-9.07	-0.39	3.53e-18	Plateletcrit;
LGG	cis	rs4919694	0.536	rs12414777	chr10:104697781	C/T	cg04362960	chr10:104952993	NT5C2	0.79	12.53	0.5	3.09e-31	Arsenic metabolism;
LGG	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg03606772	chr1:152487856	CRCT1	0.31	7.34	0.32	9.75e-13	Hair morphology;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.71e-12	Lung cancer;
LGG	cis	rs6964587	1.000	rs13231578	chr7:91663266	C/T	cg17063962	chr7:91808500	NA	0.48	8.63	0.37	1.01e-16	Breast cancer;
LGG	cis	rs9287719	0.967	rs9679581	chr2:10751736	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.3	-0.36	1.18e-15	Obesity-related traits;
LGG	cis	rs9309473	0.898	rs7580750	chr2:73788126	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.77	-0.34	5.25e-14	Metabolite levels;
LGG	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.27	-0.32	1.54e-12	Coronary artery disease;
LGG	cis	rs992157	0.717	rs3817266	chr2:219142594	C/T	cg00012203	chr2:219082015	ARPC2	-0.68	-12.25	-0.49	4.24e-30	Colorectal cancer;
LGG	cis	rs35306767	0.953	rs35693858	chr10:979813	C/T	cg20503657	chr10:835505	NA	0.63	9.11	0.39	2.49e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs1620921	0.622	rs12153973	chr6:161273891	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.36	-0.32	8.33e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	trans	rs6787172	0.677	rs2698322	chr3:157992636	G/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04935121	chr11:63775413	MACROD1	0.5	12.87	0.51	1.3e-32	Pulse pressure;
LGG	cis	rs7927592	0.956	rs7944870	chr11:68309108	C/G	cg16797656	chr11:68205561	LRP5	0.38	6.68	0.3	6.97e-11	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg08677398	chr8:58056175	NA	0.56	8.67	0.37	7.16e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02629319	chr4:83821365	THAP9	-0.39	-6.75	-0.3	4.52e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs2455799	0.573	rs2654648	chr3:15775425	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-8.04	-0.35	7.34e-15	Mean platelet volume;
LGG	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg21665744	chr7:39171113	POU6F2	0.39	7.97	0.35	1.23e-14	IgG glycosylation;
LGG	cis	rs10870270	1.000	rs72636963	chr10:133771271	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.5	-0.5	4.09e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.15	-0.43	5.34e-22	IgG glycosylation;
LGG	cis	rs17270561	0.609	rs1165181	chr6:25825390	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.78	0.38	3.18e-17	Iron status biomarkers;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg02023728	chr11:77925099	USP35	0.44	7.56	0.33	2.22e-13	Testicular germ cell tumor;
LGG	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.94e-46	Morning vs. evening chronotype;
LGG	cis	rs6868223	1.000	rs12110037	chr5:33635395	C/T	cg10594543	chr5:33649717	ADAMTS12	0.55	12.04	0.49	2.97e-29	Mortality in heart failure;
LGG	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	15.23	0.58	9.68e-43	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.6	0.65	4.5e-58	Menopause (age at onset);
LGG	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg20913747	chr6:44695427	NA	-0.52	-7.59	-0.33	1.8e-13	Total body bone mineral density;
LGG	trans	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg07393940	chr7:158741817	NA	0.59	10.78	0.45	2.5300000000000002e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg14338887	chr6:42928500	GNMT	0.23	7.6	0.33	1.7e-13	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs7737355	0.947	rs4996522	chr5:130761470	G/A	cg06307176	chr5:131281290	NA	-0.56	-9.25	-0.4	8.06e-19	Life satisfaction;
LGG	cis	rs2762353	0.935	rs1165209	chr6:25801319	G/A	cg03264133	chr6:25882463	NA	-0.53	-10.0	-0.42	1.85e-21	Blood metabolite levels;
LGG	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	7.76e-13	Monocyte count;
LGG	cis	rs4740619	0.935	rs7874533	chr9:15573582	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.43	-0.44	5.24e-23	Body mass index;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13981804	chr4:87797509	C4orf36	0.35	6.66	0.3	7.64e-11	Electrocardiographic conduction measures;
LGG	trans	rs7819412	0.502	rs4840548	chr8:10992883	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.35	-0.32	9e-13	Triglycerides;
LGG	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg21775007	chr8:11205619	TDH	-0.52	-8.35	-0.36	8.27e-16	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04661721	chr11:122311749	NA	0.45	6.9	0.31	1.71e-11	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.724	rs6656716	chr1:26563105	G/A	cg10402321	chr1:26617780	UBXN11	-0.36	-7.01	-0.31	8.47e-12	Obesity-related traits;
LGG	cis	rs9815354	1.000	rs1716692	chr3:41983786	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11690935	0.959	rs76324055	chr2:172620150	T/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.41	-0.78	2.02e-94	Schizophrenia;
LGG	cis	rs7089973	0.604	rs11196936	chr10:116588630	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.49	8.25	0.36	1.61e-15	Longevity;
LGG	cis	rs2236293	0.789	rs10972581	chr9:35779571	A/G	cg12876594	chr9:35791798	NPR2	-0.43	-8.16	-0.35	3.3e-15	Blood protein levels;
LGG	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg26039829	chr8:22132926	PIWIL2	0.54	12.38	0.5	1.31e-30	Hypertriglyceridemia;
LGG	cis	rs4268898	0.722	rs11691212	chr2:24404733	A/G	cg06627628	chr2:24431161	ITSN2	0.46	7.6	0.33	1.71e-13	Asthma;
LGG	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg19812747	chr11:111475976	SIK2	0.48	9.51	0.4	1.01e-19	Primary sclerosing cholangitis;
LGG	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.94	-0.35	1.58e-14	Hemoglobin concentration;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.39	0.4	2.78e-19	Obesity-related traits;
LGG	cis	rs6732160	0.574	rs12465780	chr2:73472012	A/G	cg01422370	chr2:73384389	NA	-0.48	-9.04	-0.39	4.31e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	1.000	rs1716997	chr3:41924333	A/G	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.05e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg13010199	chr12:38710504	ALG10B	0.53	10.27	0.43	1.94e-22	Morning vs. evening chronotype;
LGG	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg20608306	chr11:116969690	SIK3	-0.38	-10.39	-0.43	7.4e-23	Subjective well-being;
LGG	cis	rs11098499	0.618	rs35265692	chr4:120325135	T/C	cg09307838	chr4:120376055	NA	0.82	13.33	0.53	1.47e-34	Corneal astigmatism;
LGG	trans	rs61931739	0.500	rs11053260	chr12:34530215	T/G	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs7747724	0.715	rs4478387	chr6:20782893	A/G	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.41	-0.4	2.35e-19	Bladder cancer;
LGG	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg21452805	chr1:244014465	NA	0.93	10.12	0.43	6.74e-22	RR interval (heart rate);
LGG	trans	rs4689592	0.546	rs10937782	chr4:7057106	G/C	cg07817883	chr1:32538562	TMEM39B	-0.66	-9.38	-0.4	2.87e-19	Monocyte percentage of white cells;
LGG	cis	rs1014246	0.807	rs10886003	chr10:118461226	G/A	cg14919929	chr10:118506882	NA	0.63	11.81	0.48	2.48e-28	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs28719689	0.730	rs62483953	chr8:1260558	A/C	cg22761795	chr8:1265118	NA	0.8	7.74	0.34	6.19e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg23840854	chr1:161414152	NA	-0.74	-8.87	-0.38	1.61e-17	Rheumatoid arthritis;
LGG	cis	rs2470578	0.792	rs2733500	chr3:17276149	A/G	cg20981856	chr3:17787350	NA	-0.35	-6.68	-0.3	6.68e-11	Schizophrenia;
LGG	cis	rs709400	0.628	rs72708854	chr14:103864885	T/C	cg26031613	chr14:104095156	KLC1	0.79	13.61	0.53	9.77e-36	Body mass index;
LGG	cis	rs919433	0.963	rs10166569	chr2:198183439	G/A	cg00792783	chr2:198669748	PLCL1	-0.45	-7.03	-0.31	7.33e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4481887	1.000	rs4489592	chr1:248470697	A/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.71	-0.41	2.01e-20	Common traits (Other);
LGG	cis	rs7084783	0.532	rs4918040	chr10:105423908	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.4	7.33	0.32	1.03e-12	Fear of pain;
LGG	cis	rs62238980	0.614	rs4821003	chr22:32362709	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.39	-0.32	6.77e-13	Coronary artery disease;
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg18252515	chr7:66147081	NA	-0.41	-6.91	-0.31	1.62e-11	Aortic root size;
LGG	cis	rs10046574	0.519	rs11505985	chr7:135210197	G/T	cg27474649	chr7:135195673	CNOT4	0.73	9.2	0.39	1.21e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg21724239	chr8:58056113	NA	0.43	6.74	0.3	4.67e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7747724	0.692	rs9350281	chr6:20771960	T/C	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Bladder cancer;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.17	0.39	1.58e-18	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.57	-0.33	2.01e-13	Initial pursuit acceleration;
LGG	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg08847335	chr10:891726	LARP4B	-0.37	-7.04	-0.31	7.18e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.72	-0.38	4.88e-17	Schizophrenia;
LGG	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg17691542	chr6:26056736	HIST1H1C	0.73	12.01	0.49	4.26e-29	Height;
LGG	cis	rs62400317	0.859	rs12193812	chr6:45140761	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.37	-0.43	8.34e-23	Total body bone mineral density;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10789808	chr5:6633262	NSUN2;SRD5A1	-0.41	-6.74	-0.3	4.68e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs12681287	0.570	rs4961188	chr8:87383033	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.92	-11.9	-0.48	1.1e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4680	0.737	rs4818	chr22:19951207	C/G	cg06346307	chr22:19949965	COMT	-0.47	-12.3	-0.5	2.71e-30	Blood metabolite levels;
LGG	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg08250081	chr4:10125330	NA	0.62	11.18	0.46	7.25e-26	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg26617929	chr16:1858877	NA	-0.61	-8.58	-0.37	1.4e-16	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10055227	chr16:58768320	GOT2	0.39	6.87	0.3	2.03e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06481639	chr22:41940642	POLR3H	-0.55	-8.01	-0.35	9.65e-15	Vitiligo;
LGG	cis	rs12701220	0.689	rs12701824	chr7:1102364	G/A	cg00990874	chr7:1149470	C7orf50	-0.64	-9.26	-0.4	7.77e-19	Bronchopulmonary dysplasia;
LGG	cis	rs4774899	1.000	rs12914182	chr15:57424454	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.44	-0.33	5.05e-13	Urinary tract infection frequency;
LGG	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-10.28	-0.43	1.85e-22	Schizophrenia;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg25172604	chr17:41446521	NA	0.31	7.28	0.32	1.4e-12	Menopause (age at onset);
LGG	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg03264133	chr6:25882463	NA	-0.57	-10.66	-0.44	7.26e-24	Blood metabolite levels;
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-7.82	-0.34	3.64e-14	Neuroticism;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs7580658	0.864	rs4150454	chr2:128038544	T/C	cg10021288	chr2:128175891	PROC	-0.62	-12.84	-0.51	1.72e-32	Protein C levels;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg20978937	chr14:105399321	PLD4	0.49	11.19	0.46	6.96e-26	Rheumatoid arthritis;
LGG	cis	rs7959452	0.640	rs12370042	chr12:69692420	C/G	cg14784868	chr12:69753453	YEATS4	0.73	13.96	0.54	3.37e-37	Blood protein levels;
LGG	cis	rs4268898	0.560	rs2384007	chr2:24514841	A/G	cg06627628	chr2:24431161	ITSN2	-0.72	-11.23	-0.46	5.01e-26	Asthma;
LGG	cis	rs76419734	0.558	rs7696836	chr4:106583826	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	0.64	10.02	0.42	1.63e-21	Post bronchodilator FEV1;
LGG	cis	rs2540226	0.655	rs2160199	chr2:39930191	A/G	cg02886589	chr2:39892450	TMEM178	0.26	6.85	0.3	2.42e-11	Personality dimensions;
LGG	cis	rs7928758	0.767	rs10894810	chr11:134273559	C/T	cg25213107	chr11:134282864	B3GAT1	0.75	10.86	0.45	1.26e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1957429	0.520	rs230723	chr14:65316017	C/T	cg23373153	chr14:65346875	NA	-1.03	-10.94	-0.45	5.95e-25	Pediatric areal bone mineral density (radius);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25628481	chr11:19368112	NA	0.41	6.94	0.31	1.34e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2766692	0.956	rs35696661	chr14:100742355	G/C	cg14866419	chr14:100704911	YY1	0.61	9.6	0.41	5.05e-20	Electroencephalographic traits in alcoholism;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg12070911	chr6:150209640	RAET1E	0.32	7.66	0.34	1.14e-13	Lung cancer;
LGG	cis	rs10979	1.000	rs9390113	chr6:143896205	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs6696846	0.765	rs11577406	chr1:205065733	G/T	cg00857998	chr1:205179979	DSTYK	0.57	9.42	0.4	2.16e-19	Red blood cell count;
LGG	cis	rs7408868	0.656	rs1043997	chr19:15292437	T/C	cg14696996	chr19:15285081	NOTCH3	0.77	10.49	0.44	3.07e-23	Pulse pressure;
LGG	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg03576123	chr11:487126	PTDSS2	-1.22	-16.26	-0.6	2.38e-47	Body mass index;
LGG	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg21772509	chr8:41503840	NKX6-3	0.54	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs919433	0.889	rs787998	chr2:198216092	A/G	cg00792783	chr2:198669748	PLCL1	0.43	6.86	0.3	2.23e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg13880726	chr7:1868755	MAD1L1	0.41	7.32	0.32	1.12e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6988985	0.765	rs28753687	chr8:143988377	T/C	cg10324643	chr8:143916377	GML	0.4	7.84	0.34	3.15e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4430311	0.723	rs12119594	chr1:243743379	C/G	cg25706552	chr1:244017396	NA	-0.64	-15.53	-0.59	4.44e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9462027	0.585	rs188190	chr6:34551086	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.54	-0.44	2.03e-23	Systemic lupus erythematosus;
LGG	trans	rs826838	0.838	rs11183646	chr12:38799846	A/T	cg06521331	chr12:34319734	NA	-0.44	-7.64	-0.33	1.24e-13	Heart rate;
LGG	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg12463550	chr7:65579703	CRCP	0.51	8.6	0.37	1.27e-16	Aortic root size;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13418804	chr10:134593418	INPP5A	0.36	7.12	0.31	4.19e-12	Electrocardiographic conduction measures;
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg16524936	chr4:1340807	KIAA1530	-0.45	-7.5	-0.33	3.31e-13	Longevity;
LGG	cis	rs10267417	0.603	rs4721831	chr7:19876769	T/C	cg07541023	chr7:19748670	TWISTNB	0.5	6.76	0.3	4.19e-11	Night sleep phenotypes;
LGG	cis	rs36051895	0.664	rs10115518	chr9:5094559	T/C	cg02405213	chr9:5042618	JAK2	-0.79	-14.53	-0.56	1.16e-39	Pediatric autoimmune diseases;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	9.45	0.4	1.74e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs12928939	0.815	rs10500560	chr16:71681153	G/A	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.09	-0.39	2.98e-18	Post bronchodilator FEV1;
LGG	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.51	-0.53	2.59e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg20302533	chr7:39170763	POU6F2	0.58	14.82	0.57	6.22e-41	IgG glycosylation;
LGG	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.62	-0.33	1.49e-13	Triglycerides;
LGG	cis	rs4730250	0.707	rs1981696	chr7:106794100	C/T	cg02696742	chr7:106810147	HBP1	0.73	10.28	0.43	1.76e-22	Osteoarthritis;
LGG	cis	rs2276314	1.000	rs8086395	chr18:33564592	C/G	cg19628046	chr18:33552617	C18orf21	0.52	7.6	0.33	1.66e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2028299	0.920	rs12594774	chr15:90406884	A/G	cg23731826	chr15:90371692	NA	0.36	8.01	0.35	9.52e-15	Type 2 diabetes;
LGG	cis	rs13102973	0.965	rs13106621	chr4:135854975	A/T	cg14419869	chr4:135874104	NA	0.57	10.87	0.45	1.11e-24	Subjective well-being;
LGG	cis	rs4774830	0.744	rs73420376	chr15:56283648	T/C	cg05129572	chr15:56138634	NEDD4	0.7	6.8	0.3	3.27e-11	Delta-5 desaturase activity;
LGG	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.32	-0.36	1.01e-15	Joint mobility (Beighton score);
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.72	0.41	1.88e-20	Schizophrenia;
LGG	cis	rs57502260	0.680	rs55654976	chr11:68393541	C/T	cg01657329	chr11:68192670	LRP5	-0.56	-7.18	-0.32	2.86e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.88	-0.34	2.4e-14	Mood instability;
LGG	cis	rs9397585	0.637	rs9478385	chr6:153402477	C/T	cg17707550	chr6:153380415	RGS17	-0.47	-10.11	-0.43	7.44e-22	Body mass index;
LGG	cis	rs9902453	0.845	rs3115099	chr17:28019293	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs2415984	0.579	rs113349829	chr14:46973973	C/A	cg14871534	chr14:47121158	RPL10L	-0.56	-9.96	-0.42	2.7e-21	Number of children ever born;
LGG	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.49	0.37	2.91e-16	Aortic root size;
LGG	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.0	-0.31	9.02e-12	HDL cholesterol;
LGG	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg08822215	chr16:89438651	ANKRD11	-0.4	-7.81	-0.34	3.94e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs8053891	0.585	rs12926804	chr16:71994932	A/G	cg04254540	chr16:71951199	KIAA0174	-0.77	-9.85	-0.42	6.54e-21	Coronary artery disease;
LGG	cis	rs2862064	1.000	rs6896499	chr5:156431325	A/G	cg12943317	chr5:156479607	HAVCR1	-0.84	-10.59	-0.44	1.33e-23	Platelet count;
LGG	cis	rs16976116	0.901	rs11852763	chr15:55494606	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.22	0.32	2.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28588043	1.000	rs28715204	chr1:170964065	A/C	cg03458344	chr1:170964477	C1orf129	-0.51	-7.45	-0.33	4.55e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg06138931	chr13:21896616	NA	0.53	8.89	0.38	1.39e-17	White matter hyperintensity burden;
LGG	cis	rs9309473	0.950	rs6735946	chr2:73790058	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg05707623	chr12:122985044	ZCCHC8	0.63	9.25	0.39	8.59e-19	Body mass index;
LGG	cis	rs62238980	0.614	rs117358438	chr22:32374532	A/G	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs7246657	0.639	rs3112434	chr19:38198148	G/T	cg18154014	chr19:37997991	ZNF793	-0.44	-7.91	-0.34	1.97e-14	Coronary artery calcification;
LGG	cis	rs1003719	0.715	rs2835639	chr21:38537016	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.17	-0.58	1.75e-42	Eye color traits;
LGG	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg25173405	chr17:45401733	C17orf57	-0.51	-8.49	-0.37	2.73e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8017423	0.669	rs7153190	chr14:90703904	T/G	cg04374321	chr14:90722782	PSMC1	0.87	18.25	0.65	1.78e-56	Mortality in heart failure;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg02353165	chr6:42928485	GNMT	-0.4	-11.52	-0.47	3.47e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2997447	0.655	rs1317709	chr1:26384690	A/C	cg19633962	chr1:26362018	EXTL1	-0.54	-8.26	-0.36	1.54e-15	QRS complex (12-leadsum);
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg15665833	chr6:26285013	NA	0.38	7.26	0.32	1.64e-12	Educational attainment;
LGG	cis	rs7336332	0.527	rs1475219	chr13:28037415	A/G	cg01674679	chr13:27998804	GTF3A	-0.56	-7.66	-0.34	1.07e-13	Weight;
LGG	cis	rs12493885	0.872	rs9840371	chr3:153796829	C/T	cg17054900	chr3:154042577	DHX36	0.79	9.38	0.4	3.07e-19	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg03929089	chr4:120376271	NA	-0.96	-20.28	-0.69	6.67e-66	Coronary artery disease;
LGG	cis	rs2213920	1.000	rs9299227	chr9:118263508	A/G	cg13918206	chr9:118159781	DEC1	0.49	6.68	0.3	6.9e-11	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.88	-0.3	1.9e-11	Longevity;Endometriosis;
LGG	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg18196295	chr10:418757	DIP2C	0.51	9.78	0.41	1.21e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs7215564	0.908	rs2340773	chr17:78744395	T/C	cg16980736	chr17:78789706	RPTOR	0.59	7.79	0.34	4.55e-14	Myopia (pathological);
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg00933542	chr6:150070202	PCMT1	0.37	6.8	0.3	3.16e-11	Lung cancer;
LGG	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg26441486	chr22:50317300	CRELD2	0.39	7.18	0.32	2.75e-12	Schizophrenia;
LGG	cis	rs1278769	0.735	rs9577395	chr13:113534984	C/G	cg00823993	chr13:113535758	ATP11A	0.65	9.8	0.41	9.92e-21	Interstitial lung disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg11252953	chr17:80358829	C17orf101	0.3	7.55	0.33	2.35e-13	Menarche (age at onset);
LGG	trans	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.76	-0.51	3.65e-32	Obesity-related traits;
LGG	cis	rs10174077	0.874	rs6750342	chr2:152485754	A/G	cg06191203	chr2:152266755	RIF1	-0.42	-7.26	-0.32	1.67e-12	Squamous cell lung carcinoma;
LGG	trans	rs1493916	0.870	rs7239173	chr18:31395534	A/T	cg04226714	chr8:49833948	SNAI2	-0.49	-8.98	-0.39	6.65e-18	Life satisfaction;
LGG	cis	rs6430585	0.583	rs3769013	chr2:136556182	C/T	cg07169764	chr2:136633963	MCM6	1.25	24.85	0.76	3.12e-87	Corneal structure;
LGG	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.34	-0.32	9.48e-13	Total cholesterol levels;
LGG	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg05234568	chr11:5960015	NA	-0.66	-10.57	-0.44	1.51e-23	DNA methylation (variation);
LGG	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg14227996	chr4:17616232	MED28	0.72	8.83	0.38	2.25e-17	Opioid sensitivity;
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.46	0.37	3.44e-16	Aortic root size;
LGG	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg27398817	chr8:82754497	SNX16	-0.7	-10.87	-0.45	1.17e-24	Diastolic blood pressure;
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg19077165	chr18:44547161	KATNAL2	0.59	10.91	0.45	8.33e-25	Personality dimensions;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6696846	0.749	rs11578293	chr1:205070178	T/C	cg00857998	chr1:205179979	DSTYK	0.47	7.6	0.33	1.69e-13	Red blood cell count;
LGG	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg16141378	chr3:129829833	LOC729375	-0.46	-11.28	-0.46	3.16e-26	Mood instability;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg25623174	chr19:1487019	PCSK4	0.37	6.82	0.3	2.88e-11	Electrocardiographic conduction measures;
LGG	cis	rs150641967	1	rs150641967	chr19:19370340	TGACA/T	cg03709012	chr19:19516395	GATAD2A	0.97	8.17	0.35	3.02e-15	Triglyceride levels;Very low density lipoprotein cholesterol levels;Low density lipoprotein cholesterol;Total cholesterol levels;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.19	0.32	2.62e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.99	-0.31	9.8e-12	Total body bone mineral density;
LGG	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.79	-0.3	3.54e-11	Coronary artery disease;
LGG	cis	rs9815354	0.812	rs17214987	chr3:41810481	C/T	cg03022575	chr3:42003672	ULK4	-0.8	-9.18	-0.39	1.41e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2898857	0.504	rs12937923	chr17:47408475	G/A	cg08112188	chr17:47440006	ZNF652	-0.41	-6.73	-0.3	5.16e-11	Cancer;
LGG	cis	rs1408799	0.711	rs10809808	chr9:12624463	T/G	cg05274944	chr9:12693694	TYRP1	0.32	7.4	0.33	6.39e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg08888203	chr3:10149979	C3orf24	0.53	8.99	0.39	6.18e-18	Alzheimer's disease;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.89	0.38	1.34e-17	Platelet count;
LGG	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.18	-0.46	7.74e-26	Mean platelet volume;
LGG	trans	rs7395662	0.963	rs6485906	chr11:48651661	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.36	-0.32	8.57e-13	HDL cholesterol;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg16301924	chr13:53314226	LECT1	-0.48	-9.95	-0.42	2.82e-21	Lewy body disease;
LGG	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg27297192	chr10:134578999	INPP5A	0.31	6.81	0.3	3e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs514406	0.607	rs11206000	chr1:53205923	A/C	cg24675658	chr1:53192096	ZYG11B	0.6	13.11	0.52	1.35e-33	Monocyte count;
LGG	cis	rs8141529	0.529	rs2269578	chr22:29196843	G/C	cg15103426	chr22:29168792	CCDC117	0.66	6.91	0.31	1.59e-11	Lymphocyte counts;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.57	5.65e-42	Platelet count;
LGG	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.37e-12	Blood metabolite levels;
LGG	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg17182837	chr8:41585554	ANK1	-0.55	-8.04	-0.35	7.56e-15	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs259282	0.692	rs17693106	chr19:33125055	C/T	cg02997394	chr19:33096574	ANKRD27	0.38	7.4	0.33	6.6e-13	Schizophrenia;
LGG	cis	rs9880211	0.948	rs9820621	chr3:136110513	G/A	cg21827317	chr3:136751795	NA	-0.48	-6.97	-0.31	1.07e-11	Body mass index;Height;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	8.2	0.36	2.41e-15	Bipolar disorder;
LGG	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	9.89	0.42	4.86e-21	Aortic root size;
LGG	cis	rs7615952	0.932	rs9841157	chr3:125635655	C/A	cg05084668	chr3:125655381	ALG1L	-0.91	-11.1	-0.46	1.47e-25	Blood pressure (smoking interaction);
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.1e-21	Rheumatoid arthritis;
LGG	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1806153	0.605	rs61879810	chr11:31821467	A/G	cg11990419	chr11:31841155	NA	-0.36	-7.51	-0.33	3.1e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.12	-0.35	4.17e-15	Huntington's disease progression;
LGG	cis	rs283228	0.550	rs555909	chr6:101770304	A/G	cg27451362	chr6:101846650	GRIK2	0.99	15.09	0.57	4.03e-42	Coenzyme Q10 levels;
LGG	cis	rs4924935	1.000	rs6502674	chr17:18776897	A/G	cg26378065	chr17:18585709	ZNF286B	0.47	7.88	0.34	2.34e-14	Pancreatic cancer;
LGG	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg06481639	chr22:41940642	POLR3H	0.47	6.79	0.3	3.55e-11	Vitiligo;
LGG	cis	rs1878931	0.624	rs1149492	chr16:3445239	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.75	-11.78	-0.48	3.38e-28	Body mass index (adult);
LGG	cis	rs2033732	0.706	rs1437509	chr8:85065342	G/T	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs1005224	0.654	rs8005753	chr14:76136086	A/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-6.88	-0.3	1.94e-11	Large artery stroke;
LGG	cis	rs6668534	0.904	rs1340976	chr1:161661489	C/A	cg01550473	chr1:161493932	HSPA6	0.5	6.96	0.31	1.18e-11	Blood protein levels;
LGG	cis	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg12432903	chr7:1882776	MAD1L1	0.54	8.81	0.38	2.53e-17	Bipolar disorder;
LGG	cis	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg24375607	chr4:120327624	NA	0.61	10.07	0.42	1.06e-21	Corneal astigmatism;
LGG	cis	rs9479482	1.000	rs11155696	chr6:150357283	G/A	cg07549998	chr6:150325970	RAET1K	-0.38	-7.28	-0.32	1.46e-12	Alopecia areata;
LGG	cis	rs2274273	0.588	rs7155054	chr14:55750662	A/G	cg04306507	chr14:55594613	LGALS3	0.54	12.65	0.51	9.95e-32	Protein biomarker;
LGG	cis	rs1345301	0.518	rs17689452	chr2:102864681	A/G	cg05295703	chr2:102895712	NA	0.5	9.93	0.42	3.27e-21	Waist circumference;
LGG	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg06421707	chr20:25228305	PYGB	0.52	11.48	0.47	5.24e-27	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg08085267	chr17:45401833	C17orf57	0.63	13.03	0.52	2.84e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2404602	0.709	rs11072591	chr15:76649562	A/G	cg23625390	chr15:77176239	SCAPER	0.68	14.0	0.55	2.3e-37	Blood metabolite levels;
LGG	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.14	-0.32	3.53e-12	Pancreatic cancer;
LGG	cis	rs8050755	0.649	rs1800720	chr16:2105400	C/T	cg04515572	chr16:2107413	TSC2	-0.85	-10.94	-0.45	6e-25	Major depressive disorder;
LGG	trans	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg07211511	chr3:129823064	LOC729375	-0.69	-9.73	-0.41	1.69e-20	Blood pressure (smoking interaction);
LGG	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg21827317	chr3:136751795	NA	0.51	9.43	0.4	2.02e-19	Gestational age at birth (child effect);
LGG	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg10189774	chr4:17578691	LAP3	0.39	6.87	0.3	2.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20089077	chr19:37569736	ZNF420	-0.48	-6.96	-0.31	1.15e-11	Systemic lupus erythematosus;
LGG	trans	rs11644601	1	rs11644601	chr16:15172118	T/C	cg04146151	chr16:2155961	PKD1	-0.5	-8.68	-0.37	7.02e-17	Metabolite levels (lipid measures);
LGG	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg01221209	chr5:554886	NA	-0.47	-7.02	-0.31	7.85e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg16724585	chr3:197361211	NA	-0.48	-8.22	-0.36	1.99e-15	Pancreatic cancer;
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg14092988	chr3:52407081	DNAH1	0.25	6.69	0.3	6.62e-11	Bipolar disorder;
LGG	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.71	-14.97	-0.57	1.35e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs11864453	0.713	rs7190995	chr16:72124157	A/G	cg23815491	chr16:72088622	HP	0.52	11.78	0.48	3.41e-28	Fibrinogen levels;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg13443165	chr9:33130375	B4GALT1	-0.59	-11.42	-0.47	8.54e-27	IgG glycosylation;
LGG	trans	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg11887960	chr12:57824829	NA	0.59	6.88	0.3	1.96e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg11301795	chr4:187892539	NA	0.95	24.58	0.75	5.33e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6032067	0.538	rs6017488	chr20:43731022	A/G	cg10761708	chr20:43804764	PI3	0.66	9.81	0.41	9.25e-21	Blood protein levels;
LGG	cis	rs10771431	0.597	rs10771413	chr12:9354413	C/T	cg08997352	chr12:9597637	DDX12	-0.75	-13.72	-0.54	3.57e-36	Breast size;
LGG	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg18681998	chr4:17616180	MED28	0.8	16.63	0.61	5.19e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11711311	0.747	rs9882193	chr3:113349451	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.43	7.81	0.34	3.75e-14	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00149659	chr3:10157352	C3orf10	0.77	9.64	0.41	3.72e-20	Alzheimer's disease;
LGG	cis	rs4690686	0.964	rs1840270	chr4:177246288	G/C	cg17059388	chr4:177262070	NA	0.75	16.18	0.6	5.57e-47	Essential tremor;
LGG	trans	rs7246760	0.881	rs68018725	chr19:9855919	C/T	cg02900749	chr2:68251473	NA	-1.02	-11.21	-0.46	5.85e-26	Pursuit maintenance gain;
LGG	cis	rs7107174	0.786	rs4945269	chr11:78047077	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.71	-0.34	7.64e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2692947	0.599	rs7561198	chr2:96774981	C/G	cg22654517	chr2:96458247	NA	-0.38	-7.76	-0.34	5.44e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4774899	0.752	rs2962990	chr15:57350965	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-7.1	-0.31	4.77e-12	Urinary tract infection frequency;
LGG	cis	rs11166927	0.548	rs28366721	chr8:140827797	C/G	cg16909799	chr8:140841666	TRAPPC9	-0.64	-13.92	-0.54	4.66e-37	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs883565	0.792	rs784492	chr3:39175576	A/C	cg01426195	chr3:39028469	NA	-0.62	-11.44	-0.47	7.62e-27	Handedness;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.32	3.56e-12	Life satisfaction;
LGG	cis	rs4917300	0.606	rs6583569	chr8:143115609	G/A	cg06573787	chr8:143070187	NA	0.6	9.85	0.42	6.33e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg13939156	chr17:80058883	NA	-0.46	-8.96	-0.38	7.78e-18	Life satisfaction;
LGG	cis	rs988958	0.675	rs111621311	chr2:42219214	T/G	cg19376973	chr2:42229025	NA	0.6	9.83	0.42	7.71e-21	Hypospadias;
LGG	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg09818912	chr17:20140352	CYTSB	0.32	7.39	0.33	6.7e-13	Schizophrenia;
LGG	cis	rs6669384	0.547	rs2745979	chr1:208018219	G/C	cg22525895	chr1:207977042	MIR29B2	-0.42	-6.76	-0.3	4.28e-11	Immune response to measles vaccine (measles-specific neutralising antibody titre);
LGG	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2797369	0.713	rs4429955	chr6:101569106	T/C	cg27451362	chr6:101846650	GRIK2	-0.84	-11.2	-0.46	6.29e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	11.21	0.46	5.51e-26	Breast cancer;
LGG	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg24623649	chr8:11872141	NA	-0.32	-7.82	-0.34	3.5e-14	Neuroticism;
LGG	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	0.898	rs72796152	chr2:23933626	G/A	cg08917208	chr2:24149416	ATAD2B	0.78	8.83	0.38	2.16e-17	Lymphocyte counts;
LGG	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.74	0.71	9.56e-73	Bladder cancer;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.77	0.38	3.49e-17	Bipolar disorder;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg04696559	chr5:36152378	SKP2;LMBRD2	-0.4	-6.89	-0.3	1.79e-11	Platelet count;
LGG	cis	rs6582630	0.555	rs7965311	chr12:38513307	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-13.87	-0.54	7.74e-37	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1941687	0.797	rs8096533	chr18:31383889	A/C	cg27147174	chr7:100797783	AP1S1	-0.53	-8.84	-0.38	2.07e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg02733842	chr7:1102375	C7orf50	0.52	9.02	0.39	5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg03188948	chr7:1209495	NA	0.72	9.95	0.42	2.87e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.41	8.69e-20	Bipolar disorder;
LGG	cis	rs6088590	0.965	rs6120730	chr20:33385102	G/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.53	0.59	4.22e-44	Coronary artery disease;
LGG	cis	rs12681287	0.640	rs7833049	chr8:87445898	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs17854409	0.803	rs1048109	chr20:61472120	G/A	cg05147244	chr20:61493195	TCFL5	0.78	7.45	0.33	4.73e-13	Obesity-related traits;
LGG	cis	rs11885103	0.754	rs6712881	chr2:584745	G/A	cg21195176	chr2:593345	NA	0.39	7.41	0.33	6e-13	Heschl's gyrus morphology;
LGG	cis	rs2688608	0.620	rs7098444	chr10:75580042	C/T	cg19442545	chr10:75533431	FUT11	-0.43	-7.3	-0.32	1.27e-12	Inflammatory bowel disease;
LGG	cis	rs9467160	0.834	rs10946701	chr6:24453878	T/A	cg20631270	chr6:24437470	GPLD1	0.55	8.08	0.35	5.57e-15	Liver enzyme levels;
LGG	cis	rs10463316	0.894	rs6579862	chr5:150761717	T/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.25	-0.43	2.32e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.76	-0.41	1.36e-20	Personality dimensions;
LGG	cis	rs6582630	0.502	rs4379906	chr12:38295673	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.57	0.33	2.11e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7633787	0.556	rs9821146	chr3:23126440	A/C	cg00327796	chr3:23032191	NA	-0.39	-7.19	-0.32	2.63e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs3849570	1.000	rs11915016	chr3:81833966	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.86	-0.34	2.67e-14	Waist circumference;Body mass index;
LGG	cis	rs861020	0.630	rs599649	chr1:210003402	T/C	cg23166289	chr1:210001082	C1orf107	0.32	6.7	0.3	5.91e-11	Orofacial clefts;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg07701084	chr6:150067640	NUP43	0.67	12.64	0.51	1.15e-31	Lung cancer;
LGG	cis	rs3816183	0.793	rs1347930	chr2:43050468	A/G	cg14631114	chr2:43023945	NA	0.46	8.48	0.37	3.02e-16	Hypospadias;
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg14541582	chr5:601475	NA	-0.71	-10.86	-0.45	1.29e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.94	-0.38	9.22e-18	Neuroticism;
LGG	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg03030879	chr14:75389066	RPS6KL1	0.39	7.18	0.32	2.76e-12	Caffeine consumption;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg24503407	chr1:205819492	PM20D1	0.83	20.16	0.68	2.41e-65	Menarche (age at onset);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs8064299	0.597	rs6501737	chr17:72780830	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.96	-22.22	-0.72	5.24e-75	Monocyte count;
LGG	cis	rs10851411	0.657	rs12440118	chr15:42744094	A/G	cg21293051	chr15:42870591	STARD9	0.51	7.07	0.31	5.89e-12	Glucose homeostasis traits;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg16268157	chr7:99778414	STAG3	-0.47	-7.32	-0.32	1.13e-12	Lung function (FEV1/FVC);
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.63	11.07	0.46	1.92e-25	Obesity-related traits;
LGG	cis	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg06521331	chr12:34319734	NA	-0.57	-10.23	-0.43	2.7e-22	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.87	-0.45	1.17e-24	Migraine;Coronary artery disease;
LGG	trans	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg00101895	chr6:108279135	SEC63	0.39	6.73	0.3	4.93e-11	Dupuytren's disease;
LGG	cis	rs3740909	1.000	rs79442208	chr11:125885791	C/T	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.22	-0.52	4.54e-34	Vitamin D levels;
LGG	cis	rs6964587	0.967	rs10279943	chr7:91587477	G/C	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.32	0.72	1.9e-75	Homoarginine levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24591563	chr3:40498842	RPL14	0.45	7.22	0.32	2.12e-12	Cognitive performance;
LGG	cis	rs10791097	0.694	rs10791103	chr11:130757161	G/A	cg09137382	chr11:130731461	NA	0.36	6.83	0.3	2.65e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1707322	1.000	rs12077974	chr1:46384141	G/A	cg03146154	chr1:46216737	IPP	0.56	10.17	0.43	4.79e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg16141378	chr3:129829833	LOC729375	0.4	9.45	0.4	1.73e-19	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.36	-0.58	2.61e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg12437481	chr16:420112	MRPL28	-0.46	-7.43	-0.33	5.17e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg14703610	chr5:56206110	C5orf35	-0.45	-8.01	-0.35	9.3e-15	Coronary artery disease;
LGG	cis	rs7173389	0.867	rs74022964	chr15:73677264	C/T	cg01796676	chr15:73680284	NA	0.52	8.73	0.38	4.51e-17	Resting heart rate;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg03930948	chr17:5322888	RPAIN;NUP88	0.45	7.23	0.32	1.99e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg15208524	chr1:10270712	KIF1B	0.43	7.7	0.34	8.53e-14	Hepatocellular carcinoma;
LGG	cis	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-6.7	-0.3	5.94e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg09085632	chr11:111637200	PPP2R1B	1.17	25.61	0.77	9.01e-91	Primary sclerosing cholangitis;
LGG	cis	rs7104764	0.507	rs7111364	chr11:258542	G/C	cg00562011	chr11:252351	PSMD13	-0.44	-6.65	-0.3	8.42e-11	Menarche (age at onset);
LGG	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg02269571	chr22:50332266	NA	0.65	8.63	0.37	1.02e-16	Schizophrenia;
LGG	trans	rs61931739	0.500	rs11053235	chr12:34507899	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.46	0.53	4.41e-35	Morning vs. evening chronotype;
LGG	cis	rs3820928	0.874	rs4234063	chr2:227828335	A/T	cg11843606	chr2:227700838	RHBDD1	0.46	7.91	0.35	1.91e-14	Pulmonary function;
LGG	cis	rs7011049	1.000	rs74457055	chr8:53842669	T/G	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs4819052	0.851	rs8134392	chr21:46663790	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.56	-9.12	-0.39	2.35e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg04568710	chr12:38710424	ALG10B	0.38	8.03	0.35	8.07e-15	Bladder cancer;
LGG	cis	rs112591243	0.685	rs117450955	chr21:47990916	T/A	cg10657630	chr21:48055338	PRMT2	0.88	7.18	0.32	2.79e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-8.27	-0.36	1.47e-15	Colorectal cancer;
LGG	cis	rs9290877	0.704	rs7356019	chr3:188459597	C/T	cg17392043	chr3:188495102	LPP	-0.42	-7.31	-0.32	1.22e-12	IgE levels;
LGG	cis	rs8072100	0.875	rs7208530	chr17:45544107	C/T	cg08085267	chr17:45401833	C17orf57	-0.53	-10.35	-0.43	1e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs832540	0.656	rs6862118	chr5:56106474	G/A	cg12654349	chr5:56205094	C5orf35	-0.42	-7.4	-0.33	6.62e-13	Coronary artery disease;
LGG	cis	rs9487094	0.813	rs34131679	chr6:109697051	C/A	cg01125227	chr6:109776195	MICAL1	0.5	8.49	0.37	2.81e-16	Height;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg21724239	chr8:58056113	NA	0.56	8.19	0.36	2.52e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7523273	0.606	rs2724380	chr1:207949682	C/T	cg22525895	chr1:207977042	MIR29B2	0.62	12.1	0.49	1.8e-29	Schizophrenia;
LGG	trans	rs9657904	0.901	rs58340800	chr3:105566676	A/G	cg14088669	chr1:158435396	OR10K1	-0.39	-6.72	-0.3	5.32e-11	Multiple sclerosis;
LGG	cis	rs11700980	0.551	rs2832037	chr21:30115246	A/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05025164	chr4:1340916	KIAA1530	0.42	7.09	0.31	5.15e-12	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22683035	chr19:3035674	TLE2	-0.48	-7.47	-0.33	4.11e-13	Pancreatic cancer;
LGG	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.83	0.45	1.62e-24	Bone mineral density;
LGG	cis	rs4595586	0.505	rs76485055	chr12:39358294	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.64	0.33	1.23e-13	Morning vs. evening chronotype;
LGG	trans	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.66	0.54	6.3e-36	Obesity-related traits;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	17.84	0.64	1.47e-54	Personality dimensions;
LGG	cis	rs951366	0.576	rs7513645	chr1:205698026	A/G	cg24503407	chr1:205819492	PM20D1	0.4	7.16	0.32	3.15e-12	Menarche (age at onset);
LGG	cis	rs7241530	0.610	rs12966809	chr18:75894211	A/C	cg14642773	chr18:75888474	NA	0.48	9.17	0.39	1.58e-18	Educational attainment (years of education);
LGG	cis	rs3126085	0.935	rs12726613	chr1:152185500	C/G	cg26876637	chr1:152193138	HRNR	-0.51	-8.13	-0.35	3.84e-15	Atopic dermatitis;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg02462569	chr6:150064036	NUP43	-0.39	-8.25	-0.36	1.68e-15	Lung cancer;
LGG	trans	rs7395662	0.963	rs10769389	chr11:48618011	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs727505	1.000	rs6971909	chr7:124525517	C/T	cg23710748	chr7:124431027	NA	-0.47	-8.94	-0.38	9.36e-18	Lewy body disease;
LGG	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg12310025	chr6:25882481	NA	-0.44	-7.16	-0.32	3.26e-12	Iron status biomarkers;
LGG	cis	rs36093844	0.752	rs77497327	chr11:85586941	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs801193	1.000	rs2659906	chr7:66165310	T/C	cg00343986	chr7:65444356	GUSB	0.39	6.72	0.3	5.27e-11	Aortic root size;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	1.000	rs12427391	chr12:34022891	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-8.08	-0.35	5.83e-15	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg21775007	chr8:11205619	TDH	-0.6	-9.95	-0.42	2.83e-21	Retinal vascular caliber;
LGG	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg05091796	chr16:4465799	CORO7	-0.83	-13.65	-0.54	6.78e-36	Schizophrenia;
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg08461457	chr11:2027003	NA	0.39	7.62	0.33	1.46e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7937612	1.000	rs10750174	chr11:120292097	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.05	-0.52	2.31e-33	Intraocular pressure;
LGG	cis	rs1465370	0.720	rs7811463	chr7:130017488	G/A	cg25718383	chr7:130020096	CPA1	0.32	8.32	0.36	9.81e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.86	0.3	2.25e-11	Lung cancer;
LGG	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg06026331	chr20:60912101	LAMA5	0.57	9.8	0.41	9.66e-21	Colorectal cancer;
LGG	cis	rs7851660	0.844	rs4743139	chr9:100638420	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.65	-0.51	1.07e-31	Strep throat;
LGG	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.46	0.33	4.2e-13	Retinal vascular caliber;
LGG	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg02811702	chr13:24901961	NA	-0.43	-7.98	-0.35	1.19e-14	Obesity-related traits;
LGG	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg15595755	chr5:1867978	NA	0.5	8.55	0.37	1.87e-16	Cardiovascular disease risk factors;
LGG	cis	rs11255291	1.000	rs10905219	chr10:7738411	C/T	cg13340899	chr10:7670827	ITIH5	0.4	6.88	0.3	1.98e-11	Ovarian reserve;
LGG	cis	rs9527	0.637	rs7096169	chr10:104618695	A/G	cg04362960	chr10:104952993	NT5C2	0.52	9.17	0.39	1.58e-18	Arsenic metabolism;
LGG	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg08999081	chr20:33150536	PIGU	-0.39	-9.84	-0.42	7.36e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.31	0.58	4.19e-43	Platelet count;
LGG	cis	rs3087591	0.960	rs4795575	chr17:29452625	A/G	cg24425628	chr17:29625626	OMG;NF1	0.72	14.15	0.55	4.88e-38	Hip circumference;
LGG	cis	rs9831754	0.756	rs1512476	chr3:78434219	G/A	cg06138941	chr3:78371609	NA	-0.78	-15.26	-0.58	7.14e-43	Calcium levels;
LGG	cis	rs240764	0.711	rs240148	chr6:101076767	C/T	cg09795085	chr6:101329169	ASCC3	0.47	7.72	0.34	7.02e-14	Neuroticism;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg22771759	chr13:24902376	NA	0.43	7.25	0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs2380220	0.606	rs7747776	chr6:96005852	C/T	cg23517279	chr6:96025343	MANEA	0.5	6.86	0.3	2.23e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg22968622	chr17:43663579	NA	-0.96	-17.66	-0.63	9.39e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg13010199	chr12:38710504	ALG10B	-0.58	-11.03	-0.46	2.74e-25	Morning vs. evening chronotype;
LGG	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg08885076	chr2:99613938	TSGA10	-0.45	-8.18	-0.36	2.81e-15	Chronic sinus infection;
LGG	trans	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg25482853	chr8:67687455	SGK3	1.01	12.47	0.5	5.67e-31	Lung disease severity in cystic fibrosis;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs6466055	0.748	rs10266871	chr7:104812129	G/A	cg04380332	chr7:105027541	SRPK2	-0.37	-6.99	-0.31	9.49e-12	Schizophrenia;
LGG	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs8031584	0.918	rs35396566	chr15:31263057	T/C	cg08704250	chr15:31115839	NA	-0.43	-7.58	-0.33	1.97e-13	Huntington's disease progression;
LGG	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.33	-0.47	1.99e-26	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg18379455	chr17:41446167	NA	-0.33	-7.58	-0.33	1.84e-13	Menopause (age at onset);
LGG	cis	rs9549260	0.755	rs3892360	chr13:41184078	C/G	cg21288729	chr13:41239152	FOXO1	0.33	6.66	0.3	7.73e-11	Red blood cell count;
LGG	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs7914558	1.000	rs7920251	chr10:104950197	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.62	0.44	9.64e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg08885076	chr2:99613938	TSGA10	0.44	9.53	0.41	8.79e-20	Chronic sinus infection;
LGG	cis	rs3008870	1.000	rs3008854	chr1:67385951	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg18479299	chr3:125709523	NA	-0.55	-7.78	-0.34	4.75e-14	Blood pressure (smoking interaction);
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg21948465	chr5:131705150	SLC22A5	0.68	7.53	0.33	2.7e-13	Rheumatoid arthritis;
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg21775007	chr8:11205619	TDH	-0.51	-7.87	-0.34	2.61e-14	Neuroticism;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs2011503	0.943	rs8100927	chr19:19643636	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.65	-0.56	3.48e-40	Prudent dietary pattern;
LGG	cis	rs4906332	1.000	rs11625172	chr14:103944912	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-7.78	-0.34	4.75e-14	Coronary artery disease;
LGG	cis	rs62400317	0.859	rs12191262	chr6:45227016	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.29	-0.43	1.74e-22	Total body bone mineral density;
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg02353165	chr6:42928485	GNMT	0.47	14.04	0.55	1.42e-37	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9486715	0.867	rs9373833	chr6:96904998	A/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-8.67	-0.37	7.45e-17	Headache;
LGG	cis	rs12928939	0.769	rs1056303	chr16:71670066	C/T	cg08717414	chr16:71523259	ZNF19	-0.49	-7.48	-0.33	3.79e-13	Post bronchodilator FEV1;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.99	-0.31	9.51e-12	Lung cancer;
LGG	cis	rs4595586	0.545	rs7136002	chr12:39369168	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg02023728	chr11:77925099	USP35	0.44	7.58	0.33	1.96e-13	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg11494091	chr17:61959527	GH2	0.51	8.19	0.36	2.58e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg14926445	chr8:58193284	C8orf71	-0.68	-9.02	-0.39	4.92e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg04450456	chr4:17643702	FAM184B	0.33	7.23	0.32	2e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.863	rs9997631	chr4:120469995	C/G	cg09307838	chr4:120376055	NA	0.79	13.28	0.53	2.56e-34	Corneal astigmatism;
LGG	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg19442545	chr10:75533431	FUT11	0.44	7.33	0.32	1.05e-12	Inflammatory bowel disease;
LGG	cis	rs554111	0.963	rs666371	chr1:21041555	A/G	cg15613048	chr1:21044031	KIF17	-0.37	-7.66	-0.34	1.13e-13	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs929354	0.742	rs7807556	chr7:156934329	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.17	0.58	1.78e-42	Body mass index;
LGG	cis	rs67478160	0.634	rs941473	chr14:104201869	C/G	cg26031613	chr14:104095156	KLC1	-0.42	-6.75	-0.3	4.38e-11	Schizophrenia;
LGG	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg14092988	chr3:52407081	DNAH1	0.25	6.88	0.3	1.9e-11	Electroencephalogram traits;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg02158880	chr13:53174818	NA	-0.4	-7.98	-0.35	1.19e-14	Lewy body disease;
LGG	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg02023728	chr11:77925099	USP35	-0.39	-6.85	-0.3	2.41e-11	Alzheimer's disease (survival time);
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.6	7.95	0.35	1.47e-14	Lung function (FEV1/FVC);
LGG	cis	rs9583531	0.660	rs61971610	chr13:111330476	T/C	cg24331049	chr13:111365604	ING1	-0.74	-7.47	-0.33	4.13e-13	Coronary artery disease;
LGG	cis	rs7000551	0.725	rs2469756	chr8:22360423	G/A	cg12081754	chr8:22256438	SLC39A14	0.68	13.19	0.52	5.87e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg10587741	chr22:38071170	LGALS1	0.83	22.16	0.72	1.03e-74	Fat distribution (HIV);
LGG	trans	rs7395662	1.000	rs7478900	chr11:48544003	T/C	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	6e-13	HDL cholesterol;
LGG	cis	rs528418	0.592	rs4896792	chr6:145685869	A/T	cg03642472	chr6:145670687	NA	-0.53	-7.44	-0.33	5.07e-13	Methadone dose in opioid dependence;
LGG	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg21453758	chr17:80185943	SLC16A3	0.34	7.48	0.33	3.73e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs75920871	0.660	rs12271161	chr11:116979911	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.08	-0.35	5.88e-15	Subjective well-being;
LGG	trans	rs3206736	0.548	rs328936	chr7:35047579	T/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11699374	chr1:27114614	PIGV	0.38	6.77	0.3	3.87e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.17	-20.2	-0.68	1.52e-65	Alzheimer's disease;
LGG	cis	rs4936894	0.500	rs10790660	chr11:124146135	A/G	cg27160556	chr11:124181099	OR8D1	-0.48	-11.13	-0.46	1.19e-25	Aging (time to death);
LGG	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg08975724	chr8:8085496	FLJ10661	0.47	9.18	0.39	1.39e-18	Joint mobility (Beighton score);
LGG	cis	rs7412746	0.658	rs59024312	chr1:150909005	T/G	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	trans	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg06521331	chr12:34319734	NA	-0.51	-8.91	-0.38	1.14e-17	Bladder cancer;
LGG	cis	rs910316	0.737	rs175077	chr14:75506875	G/A	cg11812906	chr14:75593930	NEK9	-0.46	-8.54	-0.37	1.9e-16	Height;
LGG	cis	rs6568686	0.786	rs4145457	chr6:111821182	T/C	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs3617	0.625	rs7612624	chr3:52893426	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-7.53	-0.33	2.63e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7444	0.825	rs131664	chr22:21920403	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.55e-14	Systemic lupus erythematosus;
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	13.29	0.53	2.33e-34	Total body bone mineral density;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-8.11	-0.35	4.6e-15	Life satisfaction;
LGG	cis	rs4478858	0.684	rs7544946	chr1:31749736	T/C	cg19084893	chr1:31688959	NA	0.32	6.88	0.3	2e-11	Alcohol dependence;
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg16301924	chr13:53314226	LECT1	0.41	8.29	0.36	1.25e-15	Lewy body disease;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg06558623	chr16:89946397	TCF25	1.21	13.31	0.53	1.9e-34	Skin colour saturation;
LGG	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.74	-0.34	6.19e-14	Bone mineral density;
LGG	cis	rs28735056	0.904	rs9967107	chr18:77633343	C/T	cg23825213	chr18:77623475	KCNG2	-0.42	-7.26	-0.32	1.63e-12	Schizophrenia;
LGG	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg15704280	chr7:45808275	SEPT13	-0.47	-7.71	-0.34	7.65e-14	HDL cholesterol;
LGG	cis	rs6764363	0.733	rs193071	chr3:294358	A/C	cg02057681	chr3:285234	CHL1	0.37	6.95	0.31	1.24e-11	Sudden cardiac arrest;
LGG	cis	rs911263	0.603	rs11158729	chr14:68776060	T/C	cg18825221	chr14:68749962	RAD51L1	0.38	8.3	0.36	1.14e-15	Primary biliary cholangitis;
LGG	cis	rs35264875	0.808	rs2305498	chr11:68866914	G/A	cg23845249	chr11:68861649	NA	0.37	7.04	0.31	7.16e-12	Blond vs. brown hair color;
LGG	cis	rs6834538	0.597	rs6822451	chr4:113463265	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.78	0.38	3.1e-17	Free thyroxine concentration;
LGG	cis	rs1816752	0.819	rs7317504	chr13:24985425	C/T	cg22771759	chr13:24902376	NA	0.42	7.0	0.31	8.93e-12	Obesity-related traits;
LGG	cis	rs2235642	0.785	rs1057983	chr16:1660274	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	9.19	0.39	1.33e-18	Coronary artery disease;
LGG	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.13	-0.31	3.77e-12	IgG glycosylation;
LGG	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.33	0.65	8.02e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs8014204	0.935	rs3742786	chr14:75373011	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.86	-18.38	-0.65	4.85e-57	Caffeine consumption;
LGG	cis	rs7953508	0.659	rs1316739	chr12:93968256	G/A	cg18151635	chr12:93972918	NA	-0.59	-11.4	-0.47	1.01e-26	Pubertal anthropometrics;
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.27	0.46	3.43e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg19913688	chr11:428466	ANO9	-0.68	-8.31	-0.36	1.1e-15	Body mass index;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.47	2.48e-26	Bipolar disorder;
LGG	cis	rs10875746	0.669	rs10875772	chr12:48609553	C/T	cg24011408	chr12:48396354	COL2A1	-0.57	-7.33	-0.32	1.01e-12	Longevity (90 years and older);
LGG	cis	rs3796352	0.881	rs35384050	chr3:53008769	G/T	cg12962167	chr3:53033115	SFMBT1	0.72	7.8	0.34	4.19e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg09127314	chr1:152161683	NA	0.42	6.93	0.31	1.44e-11	Inflammatory skin disease;
LGG	cis	rs2072499	0.750	rs72708291	chr1:156177285	A/T	cg24450063	chr1:156163899	SLC25A44	1.03	17.99	0.64	2.98e-55	Testicular germ cell tumor;
LGG	cis	rs11157436	0.602	rs928954	chr14:22634026	G/A	cg00994629	chr14:22694547	NA	0.34	7.18	0.32	2.86e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.11	0.46	1.38e-25	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs3960554	0.808	rs78478514	chr7:75655896	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	12.26	0.5	4.05e-30	Eotaxin levels;
LGG	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg21452805	chr1:244014465	NA	0.64	7.61	0.33	1.52e-13	RR interval (heart rate);
LGG	cis	rs701145	0.585	rs12497267	chr3:153839960	T/C	cg17054900	chr3:154042577	DHX36	0.76	8.85	0.38	1.83e-17	Coronary artery disease;
LGG	cis	rs78456975	1.000	rs10192959	chr2:1553393	G/T	cg26248373	chr2:1572462	NA	-0.71	-8.73	-0.38	4.8e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.16	-0.35	3.17e-15	Retinal vascular caliber;
LGG	cis	rs9964724	0.559	rs12959642	chr18:35154480	A/G	cg27332583	chr18:35150602	NA	-0.63	-12.86	-0.51	1.45e-32	Educational attainment (years of education);
LGG	trans	rs10802346	0.524	rs10802356	chr1:246385857	T/C	cg13514129	chr1:39547527	MACF1	0.68	12.69	0.51	7.17e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg18402987	chr7:1209562	NA	0.5	8.33	0.36	8.92e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg23302884	chr18:44338147	ST8SIA5	0.39	7.8	0.34	4.08e-14	Personality dimensions;
LGG	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.62e-13	Prudent dietary pattern;
LGG	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg16141378	chr3:129829833	LOC729375	0.4	8.94	0.38	9.26e-18	Retinal vascular caliber;
LGG	cis	rs6500395	1.000	rs8059819	chr16:48682834	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg18279126	chr7:2041391	MAD1L1	-0.32	-6.75	-0.3	4.41e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2050392	0.928	rs6481677	chr10:30701816	A/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-11.02	-0.46	3e-25	Inflammatory bowel disease;
LGG	cis	rs68170813	0.617	rs7797791	chr7:107197222	T/C	cg02696742	chr7:106810147	HBP1	-0.64	-7.9	-0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs4740619	0.661	rs13297383	chr9:15944400	T/C	cg14451791	chr9:16040625	NA	-0.41	-10.2	-0.43	3.45e-22	Body mass index;
LGG	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg18681998	chr4:17616180	MED28	0.87	20.09	0.68	4.92e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.45e-19	Red blood cell count;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11295801	chr6:150039190	LATS1	0.46	7.09	0.31	5.01e-12	Hip circumference;
LGG	cis	rs11608355	0.515	rs61941631	chr12:109935475	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg25338242	chr13:114786047	RASA3	0.41	7.39	0.32	6.85e-13	Schizophrenia;
LGG	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	trans	rs1814175	0.616	rs1851848	chr11:49992254	G/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs240764	0.659	rs240766	chr6:100954036	G/A	cg21058520	chr6:100914733	NA	0.4	6.98	0.31	1.03e-11	Neuroticism;
LGG	cis	rs6088580	0.634	rs6142153	chr20:32968747	C/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.26	-0.4	7.61e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs7044106	0.791	rs10985008	chr9:123492960	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	18.39	0.65	4.39e-57	Hip circumference adjusted for BMI;
LGG	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg02002194	chr4:3960332	NA	-0.52	-9.8	-0.41	1.01e-20	Retinal vascular caliber;
LGG	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.46	-0.58	9.39e-44	Chronic sinus infection;
LGG	cis	rs9397585	0.857	rs7750523	chr6:153390453	A/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs17321999	0.516	rs13396720	chr2:30502938	C/T	cg05247661	chr2:30472410	LBH	0.65	8.07	0.35	6e-15	Systemic lupus erythematosus;
LGG	cis	rs7173743	0.756	rs4551997	chr15:79130433	G/A	cg00540400	chr15:79124168	NA	0.42	8.6	0.37	1.28e-16	Coronary artery disease;
LGG	cis	rs4555082	0.874	rs2735828	chr14:105710486	C/A	cg13114125	chr14:105738426	BRF1	-0.87	-17.82	-0.64	1.77e-54	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9362426	0.672	rs12663865	chr6:88103149	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	0.41	7.98	0.35	1.12e-14	Depressive episodes in bipolar disorder;
LGG	cis	rs295140	1.000	rs12618057	chr2:201171355	T/C	cg25099087	chr2:201172481	SPATS2L	0.27	6.74	0.3	4.66e-11	QT interval;
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg04553112	chr3:125709451	NA	-0.54	-6.92	-0.31	1.5e-11	Blood pressure (smoking interaction);
LGG	cis	rs7301826	1.000	rs4619189	chr12:131313797	A/G	cg11011512	chr12:131303247	STX2	0.32	6.9	0.31	1.68e-11	Plasma plasminogen activator levels;
LGG	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.17	0.46	8e-26	Mean platelet volume;
LGG	cis	rs171408	0.895	rs164966	chr3:8615277	C/T	cg03557445	chr3:8615444	LOH3CR2A	-0.5	-9.2	-0.39	1.28e-18	Mitral valve prolapse;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg04369109	chr6:150039330	LATS1	-0.4	-6.73	-0.3	4.98e-11	Lung cancer;
LGG	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs7100689	0.598	rs35353819	chr10:82135737	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.3	0.58	4.78e-43	Post bronchodilator FEV1;
LGG	cis	rs6460942	1.000	rs6460935	chr7:12401317	A/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.87	-0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg01028140	chr2:1542097	TPO	-0.42	-8.08	-0.35	5.62e-15	IgG glycosylation;
LGG	cis	rs2652834	1.000	rs36116701	chr15:63397494	T/C	cg05507819	chr15:63340323	TPM1	0.58	7.83	0.34	3.45e-14	HDL cholesterol;
LGG	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs9944715	0.954	rs62096523	chr18:43737966	T/A	cg26436583	chr18:43649176	PSTPIP2	0.4	7.41	0.33	5.91e-13	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg05585630	chr7:157510462	PTPRN2	-0.65	-13.73	-0.54	3e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs1023500	0.552	rs5758566	chr22:42454354	G/A	cg04733989	chr22:42467013	NAGA	0.58	10.18	0.43	4.34e-22	Schizophrenia;
LGG	cis	rs67478160	0.595	rs1475007	chr14:104297147	A/G	cg26031613	chr14:104095156	KLC1	-0.42	-6.95	-0.31	1.25e-11	Schizophrenia;
LGG	cis	rs10743315	0.732	rs6486947	chr12:19455924	C/T	cg02471346	chr12:19282374	PLEKHA5	0.62	7.07	0.31	5.86e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6032067	0.683	rs6032029	chr20:43786064	A/G	cg10761708	chr20:43804764	PI3	0.59	9.06	0.39	3.81e-18	Blood protein levels;
LGG	trans	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.99e-30	Corneal astigmatism;
LGG	cis	rs62238980	0.522	rs75380258	chr22:32413280	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg09307838	chr4:120376055	NA	0.8	13.29	0.53	2.21e-34	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21606777	chr7:100806772	VGF	0.5	7.66	0.34	1.08e-13	Gut microbiome composition (summer);
LGG	cis	rs1784581	0.507	rs1790020	chr6:162366266	C/T	cg17173639	chr6:162384350	PARK2	-0.65	-13.51	-0.53	2.71e-35	Itch intensity from mosquito bite;
LGG	cis	rs870825	0.860	rs72703518	chr4:185602109	T/C	cg04058563	chr4:185651563	MLF1IP	1.08	20.11	0.68	4.33e-65	Blood protein levels;
LGG	trans	rs877282	0.945	rs11253391	chr10:788752	G/A	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.43	-0.58	1.2e-43	Total body bone mineral density;
LGG	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.66e-13	Retinal vascular caliber;
LGG	cis	rs250677	0.687	rs250673	chr5:148445798	C/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.16	-0.32	3.14e-12	Breast cancer;
LGG	trans	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.36	-0.36	7.47e-16	Bladder cancer;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg11062466	chr8:58055876	NA	0.58	9.07	0.39	3.47e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg20637307	chr2:213403960	ERBB4	0.74	16.85	0.62	4.76e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10865541	0.902	rs4476382	chr2:3393288	A/G	cg11642891	chr2:3452563	TTC15	-0.39	-7.47	-0.33	4.02e-13	Obesity-related traits;
LGG	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.89	10.64	0.44	8.45e-24	Lung cancer in ever smokers;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg10950524	chr7:2139216	MAD1L1	0.35	7.61	0.33	1.52e-13	Schizophrenia;
LGG	cis	rs3829251	0.786	rs7103591	chr11:71237619	T/C	cg10847948	chr11:71163743	NADSYN1	0.58	8.75	0.38	3.94e-17	Vitamin D levels;
LGG	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	trans	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04565464	chr8:145669602	NFKBIL2	0.39	6.68	0.3	7.06e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4690686	0.538	rs6855882	chr4:177261061	T/G	cg17059388	chr4:177262070	NA	0.97	21.51	0.71	1.13e-71	Essential tremor;
LGG	cis	rs68170813	0.523	rs3757713	chr7:107042750	A/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg03161606	chr19:29218774	NA	0.69	10.65	0.44	7.89e-24	Methadone dose in opioid dependence;
LGG	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg17330251	chr7:94953956	PON1	-0.44	-8.62	-0.37	1.05e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2075371	0.863	rs12707139	chr7:133954153	A/G	cg20476274	chr7:133979776	SLC35B4	0.72	13.73	0.54	3.05e-36	Mean platelet volume;
LGG	trans	rs11088226	0.681	rs2833906	chr21:33945521	G/T	cg09050820	chr6:167586206	TCP10L2	0.92	13.08	0.52	1.73e-33	Gastritis;
LGG	cis	rs4737010	0.630	rs569451	chr8:41623001	G/A	cg17182837	chr8:41585554	ANK1	0.51	7.99	0.35	1.1e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs4555082	0.915	rs28594491	chr14:105758018	G/A	cg27165867	chr14:105738592	BRF1	-0.43	-6.99	-0.31	9.77e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2916247	0.954	rs1160821	chr8:93105771	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.67	-0.34	9.96e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4742903	0.935	rs7872170	chr9:106957103	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.15	0.35	3.34e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4731207	0.596	rs7794538	chr7:124648850	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11890956	chr21:40555474	PSMG1	-0.73	-12.83	-0.51	1.87e-32	Menarche (age at onset);
LGG	cis	rs344364	0.511	rs911391	chr16:1947016	C/A	cg26897989	chr16:1907736	C16orf73	-0.85	-14.04	-0.55	1.54e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2836974	0.831	rs4375956	chr21:40521788	G/A	cg17971929	chr21:40555470	PSMG1	0.89	16.58	0.61	8.78e-49	Cognitive function;
LGG	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg02940042	chr14:96000874	GLRX5;SNHG10;SCARNA13	0.79	9.89	0.42	4.92e-21	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs6912958	0.684	rs4707382	chr6:88320641	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.63	-0.37	1.03e-16	Monocyte percentage of white cells;
LGG	cis	rs774359	0.789	rs2764332	chr9:27492522	T/A	cg14173147	chr9:27528300	MOBKL2B	0.46	8.81	0.38	2.44e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs6909430	0.731	rs6928671	chr6:98620633	T/C	cg12860156	chr6:98744658	NA	-0.39	-6.89	-0.31	1.82e-11	Quantitative traits;
LGG	cis	rs1971762	0.545	rs10747675	chr12:54000031	A/G	cg06632207	chr12:54070931	ATP5G2	-0.23	-7.08	-0.31	5.34e-12	Height;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg22907277	chr7:1156413	C7orf50	0.85	15.16	0.58	1.94e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03276167	chr6:86388360	SNHG5;SNORD50B;SNORD50A	0.39	6.65	0.3	8.09e-11	Cognitive performance;
LGG	cis	rs734999	0.566	rs4648658	chr1:2560882	G/A	cg15627072	chr1:2432621	PLCH2	-0.33	-7.67	-0.34	1.01e-13	Ulcerative colitis;
LGG	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg18105134	chr13:113819100	PROZ	-0.7	-14.18	-0.55	3.73e-38	Platelet distribution width;
LGG	trans	rs6601327	0.635	rs34782826	chr8:9663630	G/T	cg16141378	chr3:129829833	LOC729375	0.35	7.88	0.34	2.34e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg12373951	chr3:133503437	NA	0.4	6.98	0.31	1.03e-11	Iron status biomarkers;
LGG	cis	rs4474465	0.850	rs4565922	chr11:78260699	A/G	cg02023728	chr11:77925099	USP35	-0.38	-6.84	-0.3	2.58e-11	Alzheimer's disease (survival time);
LGG	cis	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg24375607	chr4:120327624	NA	0.58	9.62	0.41	4.37e-20	Corneal astigmatism;
LGG	cis	rs17321999	0.904	rs59693338	chr2:30473177	T/C	cg05247661	chr2:30472410	LBH	0.61	9.55	0.41	7.68e-20	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg16141378	chr3:129829833	LOC729375	-0.4	-9.45	-0.4	1.69e-19	Retinal vascular caliber;
LGG	cis	rs2273669	0.667	rs3734649	chr6:109294752	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.31	-0.36	1.05e-15	Prostate cancer;
LGG	cis	rs2204008	0.748	rs7312204	chr12:38334909	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.54	0.33	2.43e-13	Bladder cancer;
LGG	trans	rs116095464	0.558	rs28418643	chr5:240859	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg13736514	chr6:26305472	NA	0.35	7.16	0.32	3.24e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg26554054	chr8:600488	NA	1.18	11.98	0.49	5.52e-29	IgG glycosylation;
LGG	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg06917634	chr15:78832804	PSMA4	-0.83	-17.61	-0.63	1.71e-53	Sudden cardiac arrest;
LGG	trans	rs7944735	0.508	rs4752877	chr11:47886165	C/A	cg15704280	chr7:45808275	SEPT13	0.64	6.9	0.31	1.75e-11	Intraocular pressure;
LGG	cis	rs7208859	0.673	rs11080138	chr17:29224542	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7829975	0.846	rs7005216	chr8:8547110	C/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.09	-0.35	5.18e-15	Mood instability;
LGG	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg18876405	chr7:65276391	NA	-0.59	-10.41	-0.44	5.84e-23	Aortic root size;
LGG	cis	rs12477438	0.765	rs7571390	chr2:99626593	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.22	-0.43	3.04e-22	Chronic sinus infection;
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.15	0.32	3.44e-12	Lung cancer;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg26253258	chr20:60697513	LSM14B	0.4	6.7	0.3	6.17e-11	Corneal astigmatism;
LGG	cis	rs10464366	0.560	rs12672089	chr7:39132816	G/A	cg10621924	chr7:39171070	POU6F2	0.41	8.32	0.36	1.01e-15	IgG glycosylation;
LGG	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg27572855	chr1:25598939	RHD	-0.49	-11.05	-0.46	2.41e-25	Erythrocyte sedimentation rate;
LGG	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.57	-0.33	2.07e-13	Psoriasis;
LGG	cis	rs4481887	0.861	rs6676064	chr1:248443890	G/C	cg01631408	chr1:248437212	OR2T33	-0.55	-9.88	-0.42	5.26e-21	Common traits (Other);
LGG	cis	rs7617480	0.648	rs9284885	chr3:48883100	A/C	cg06212747	chr3:49208901	KLHDC8B	0.47	7.14	0.31	3.72e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6908034	0.660	rs7746588	chr6:19804640	C/T	cg02682789	chr6:19804855	NA	0.84	9.58	0.41	5.94e-20	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg11360546	chr7:1094263	C7orf50	-0.39	-6.83	-0.3	2.66e-11	Longevity;Endometriosis;
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.77e-13	Bipolar disorder;
LGG	cis	rs6500395	1.000	rs3743779	chr16:48574040	T/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.26e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs8077889	0.672	rs3785810	chr17:41850689	C/G	cg26893861	chr17:41843967	DUSP3	1.08	25.63	0.77	7.89e-91	Triglycerides;
LGG	cis	rs9309473	1.000	rs2901438	chr2:73665656	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.42	-0.33	5.54e-13	Metabolite levels;
LGG	cis	rs2742417	0.904	rs2373047	chr3:45747497	C/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.98e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6912958	0.500	rs3828759	chr6:87806640	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.57	-9.96	-0.42	2.75e-21	Monocyte percentage of white cells;
LGG	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	12.66	0.51	9.68e-32	Cognitive test performance;
LGG	trans	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg16724585	chr3:197361211	NA	-0.47	-8.23	-0.36	1.96e-15	Pancreatic cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15765896	chr12:53472985	SPRYD3	0.42	6.98	0.31	1.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2766692	0.810	rs7151517	chr14:100767044	C/G	cg14866419	chr14:100704911	YY1	-0.56	-8.73	-0.38	4.67e-17	Electroencephalographic traits in alcoholism;
LGG	trans	rs208515	0.525	rs12193560	chr6:66690457	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.11	0.62	3.22e-51	Exhaled nitric oxide levels;
LGG	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.87	0.3	2.11e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62400317	0.762	rs756	chr6:44795772	C/T	cg20913747	chr6:44695427	NA	-0.68	-11.38	-0.47	1.28e-26	Total body bone mineral density;
LGG	cis	rs2718058	0.630	rs2718045	chr7:37795438	C/G	cg24998770	chr7:37888106	TXNDC3	-0.42	-7.1	-0.31	4.78e-12	Alzheimer's disease (late onset);
LGG	cis	rs2117029	0.554	rs7954530	chr12:49573525	A/G	cg24176009	chr12:49580217	TUBA1A	0.66	12.79	0.51	2.83e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg04374321	chr14:90722782	PSMC1	0.48	7.97	0.35	1.22e-14	Longevity;
LGG	cis	rs457717	0.706	rs456708	chr5:75947013	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg17644776	chr2:200775616	C2orf69	-0.66	-8.89	-0.38	1.34e-17	Schizophrenia;
LGG	cis	rs1408224	0.688	rs7318773	chr13:47208947	G/T	cg24453118	chr13:47229927	LRCH1	-0.29	-6.82	-0.3	2.79e-11	QRS complex (12-leadsum);
LGG	cis	rs9811920	0.609	rs7636447	chr3:99612677	G/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg19812747	chr11:111475976	SIK2	0.48	9.5	0.4	1.13e-19	Primary sclerosing cholangitis;
LGG	cis	rs977987	0.872	rs4888422	chr16:75470576	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.16	0.43	4.84e-22	Dupuytren's disease;
LGG	cis	rs6539288	0.674	rs989560	chr12:107285751	T/C	cg15890332	chr12:107067104	RFX4	0.36	10.29	0.43	1.62e-22	Total body bone mineral density;
LGG	cis	rs10779751	0.770	rs10864490	chr1:11236410	A/C	cg08854313	chr1:11322531	MTOR	0.72	14.73	0.56	1.54e-40	Body mass index;
LGG	cis	rs7326068	0.595	rs9552284	chr13:21378344	A/G	cg04906043	chr13:21280425	IL17D	-0.51	-8.01	-0.35	9.44e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg21100191	chr22:23484243	RTDR1	0.99	22.51	0.72	2.33e-76	Bone mineral density;
LGG	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.48	-0.37	3.12e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs796364	0.901	rs13030683	chr2:201061535	C/T	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.26e-17	Schizophrenia;
LGG	cis	rs986417	0.748	rs1955700	chr14:61046481	A/G	cg27398547	chr14:60952738	C14orf39	0.65	6.86	0.3	2.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg02725872	chr8:58115012	NA	-0.86	-11.91	-0.48	1.04e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.2	-0.46	6.11e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2458413	0.563	rs2458422	chr8:105332817	C/T	cg23108931	chr8:105342351	NA	-0.28	-7.31	-0.32	1.2e-12	Paget's disease;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg11878867	chr6:150167359	LRP11	0.52	10.75	0.45	3.23e-24	Lung cancer;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg01059449	chr18:44338099	ST8SIA5	0.32	7.06	0.31	5.95e-12	Personality dimensions;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg06916706	chr16:4465613	CORO7	-0.73	-12.69	-0.51	7.25e-32	Schizophrenia;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs6426558	0.537	rs498020	chr1:227304180	G/A	cg10327440	chr1:227177885	CDC42BPA	0.61	10.26	0.43	2.07e-22	Neutrophil percentage of white cells;
LGG	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg10224037	chr5:178157518	ZNF354A	0.77	12.7	0.51	6.29e-32	Neutrophil percentage of white cells;
LGG	cis	rs4720575	1.000	rs7791050	chr7:47086452	T/C	cg00036614	chr7:47093842	NA	-0.49	-9.89	-0.42	4.7e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs9467711	0.559	rs2295593	chr6:26501768	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	8.94	0.38	8.99e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.61	-0.33	1.56e-13	Longevity;Endometriosis;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17219203	chr10:38645113	HSD17B7P2	0.43	7.01	0.31	8.39e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs78487399	0.808	rs74600494	chr2:43743491	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.77	-0.3	3.94e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg05234568	chr11:5960015	NA	-0.64	-10.72	-0.45	4.28e-24	DNA methylation (variation);
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg03517284	chr6:25882590	NA	0.51	9.68	0.41	2.63e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg24134504	chr18:76639479	NA	-0.46	-8.08	-0.35	5.84e-15	Obesity-related traits;
LGG	cis	rs826838	0.616	rs9668847	chr12:38614669	C/T	cg04568710	chr12:38710424	ALG10B	0.38	8.26	0.36	1.6e-15	Heart rate;
LGG	cis	rs1003719	0.715	rs2835646	chr21:38546574	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.31	-0.58	4.35e-43	Eye color traits;
LGG	cis	rs11168187	0.843	rs7306556	chr12:48119997	C/G	cg12761788	chr12:48120090	P11	0.51	8.88	0.38	1.43e-17	Vertical cup-disc ratio;
LGG	cis	rs11877825	0.826	rs1893228	chr18:10578872	C/T	cg25239095	chr18:10589360	NA	0.48	8.71	0.38	5.33e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg24642844	chr7:1081250	C7orf50	-0.47	-9.14	-0.39	1.97e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.39	-8.02	-0.35	8.84e-15	Schizophrenia;
LGG	trans	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg25554036	chr4:6271136	WFS1	0.62	11.56	0.47	2.48e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg19812747	chr11:111475976	SIK2	0.48	9.45	0.4	1.72e-19	Primary sclerosing cholangitis;
LGG	cis	rs7924176	0.601	rs7089391	chr10:75937520	T/A	cg19889307	chr10:75911429	ADK;AP3M1	-0.4	-6.87	-0.3	2.06e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.11	0.52	1.35e-33	Coronary artery disease;
LGG	cis	rs1577917	1.000	rs12205548	chr6:86759770	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.47	-0.53	3.81e-35	Response to antipsychotic treatment;
LGG	cis	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg19399532	chr1:178512495	C1orf220	-0.54	-10.76	-0.45	2.9e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.63	-0.33	1.31e-13	Sudden cardiac arrest;
LGG	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.6	0.56	5.3e-40	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00389420	chr1:32254320	NA	0.48	7.4	0.33	6.38e-13	Gut microbiome composition (summer);
LGG	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs988958	0.526	rs34006080	chr2:42239736	T/C	cg27428208	chr2:42229179	NA	0.47	7.45	0.33	4.73e-13	Hypospadias;
LGG	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg00209037	chr22:46443395	NA	0.29	7.92	0.35	1.77e-14	Dupuytren's disease;
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg18681998	chr4:17616180	MED28	0.84	18.72	0.66	1.24e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs42648	0.564	rs13224065	chr7:89802363	G/A	cg04070188	chr7:89809444	NA	-0.27	-6.66	-0.3	7.93e-11	Homocysteine levels;
LGG	cis	rs75920871	0.660	rs12271161	chr11:116979911	C/T	cg20608306	chr11:116969690	SIK3	-0.36	-9.12	-0.39	2.27e-18	Subjective well-being;
LGG	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.69	8.95	0.38	8.63e-18	Schizophrenia;
LGG	cis	rs2712184	0.873	rs1548945	chr2:217665788	T/C	cg05032264	chr2:217675019	NA	-0.52	-12.09	-0.49	1.88e-29	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg18404041	chr3:52824283	ITIH1	-0.61	-11.94	-0.49	7.68e-29	Bipolar disorder;
LGG	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.64	-0.44	8.52e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.69	-12.65	-0.51	1.08e-31	Personality dimensions;
LGG	cis	rs2268241	0.938	rs11088251	chr21:34770810	A/C	cg14850771	chr21:34775459	IFNGR2	0.66	8.47	0.37	3.21e-16	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs12213343	chr6:86443019	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.21	-0.49	6.14e-30	Response to antipsychotic treatment;
LGG	cis	rs9906944	0.641	rs11655587	chr17:47140794	C/T	cg09029085	chr17:47094198	IGF2BP1	0.29	7.73	0.34	6.95e-14	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs826838	1.000	rs826851	chr12:39112639	A/G	cg26384229	chr12:38710491	ALG10B	-0.9	-21.33	-0.7	8.4e-71	Heart rate;
LGG	cis	rs9783347	1.000	rs4150651	chr11:18374425	T/C	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.56	-0.33	2.17e-13	Pancreatic cancer;
LGG	cis	rs2415984	0.579	rs2255935	chr14:46964271	A/G	cg14871534	chr14:47121158	RPL10L	0.58	10.26	0.43	2.2e-22	Number of children ever born;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs9296092	0.521	rs9461886	chr6:33526770	T/C	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg17971929	chr21:40555470	PSMG1	0.88	16.45	0.61	3.25e-48	Cognitive function;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs7746199	0.736	rs13212093	chr6:27606716	C/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1348850	0.837	rs12619074	chr2:178472336	G/A	cg27490568	chr2:178487706	NA	0.54	10.47	0.44	3.68e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg05926928	chr17:57297772	GDPD1	1.4	23.08	0.73	5.18e-79	Opioid sensitivity;
LGG	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.06e-19	Obesity-related traits;
LGG	cis	rs4774899	0.902	rs2414491	chr15:57465775	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.32	-0.32	1.13e-12	Urinary tract infection frequency;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg04772025	chr11:68637568	NA	0.72	12.53	0.5	3.25e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4774899	1.000	rs17239040	chr15:57299119	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.12	-0.35	4.3e-15	Urinary tract infection frequency;
LGG	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.33	-0.43	1.23e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4605213	0.686	rs9896627	chr17:49328705	A/G	cg00965052	chr17:49230932	NME1;NME1-NME2	-0.42	-6.92	-0.31	1.49e-11	Height;
LGG	cis	rs62400317	0.859	rs17209741	chr6:45292438	A/T	cg18551225	chr6:44695536	NA	-0.6	-10.13	-0.43	6.44e-22	Total body bone mineral density;
LGG	cis	rs4969178	0.965	rs11653305	chr17:76386918	T/C	cg02836325	chr17:76403955	PGS1	-0.71	-14.17	-0.55	3.97e-38	HDL cholesterol levels;
LGG	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg08975724	chr8:8085496	FLJ10661	0.38	6.92	0.31	1.55e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg16387850	chr1:46982889	NA	-0.31	-7.29	-0.32	1.35e-12	Monobrow;
LGG	cis	rs10791323	0.602	rs7946895	chr11:133733893	T/C	cg00579200	chr11:133705235	NA	-0.54	-10.31	-0.43	1.39e-22	Childhood ear infection;
LGG	cis	rs112908525	1	rs112908525	chr7:80305278	T/TGAGGGTTGA	cg21369886	chr7:80305251	CD36	-0.5	-11.38	-0.47	1.3e-26	Mean corpuscular volume;
LGG	cis	rs9394159	0.583	rs4713650	chr6:33616828	C/T	cg14003231	chr6:33640908	ITPR3	-0.4	-9.7	-0.41	2.23e-20	Graves' disease;
LGG	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.27	-0.4	7.08e-19	Neuroticism;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9296092	0.517	rs62405895	chr6:33471969	G/T	cg13560919	chr6:33536144	NA	-0.97	-17.75	-0.64	3.84e-54	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs12476592	0.602	rs1348806	chr2:63895884	A/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	0.714	rs6902892	chr6:109627601	G/T	cg21918786	chr6:109611834	NA	-0.49	-9.08	-0.39	3.27e-18	Reticulocyte fraction of red cells;
LGG	cis	rs6088580	0.634	rs11700221	chr20:32940320	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.11	-0.43	7.52e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.63	-0.37	9.78e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs950169	0.580	rs11630887	chr15:85193015	A/T	cg24253500	chr15:84953950	NA	0.42	7.11	0.31	4.49e-12	Schizophrenia;
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg20978937	chr14:105399321	PLD4	0.46	10.06	0.42	1.18e-21	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg18252515	chr7:66147081	NA	1.43	20.52	0.69	5e-67	Diabetic kidney disease;
LGG	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg08297393	chr2:100937505	LONRF2	-0.54	-10.35	-0.43	1.02e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg07493874	chr5:1342172	CLPTM1L	-0.87	-17.74	-0.64	4.26e-54	Lung cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg09700990	chr6:90122154	RRAGD	-0.37	-6.92	-0.31	1.53e-11	Iris color (L* coordinate);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg24684576	chr17:42883379	GJC1	-0.41	-6.8	-0.3	3.24e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg26578617	chr4:90757533	SNCA	0.44	8.87	0.38	1.61e-17	Dementia with Lewy bodies;
LGG	cis	rs10895140	0.709	rs1938863	chr11:101497627	A/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7647973	0.925	rs4955423	chr3:49220448	G/A	cg07636037	chr3:49044803	WDR6	0.78	13.89	0.54	6.59e-37	Menarche (age at onset);
LGG	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11890956	chr21:40555474	PSMG1	-0.75	-12.91	-0.51	8.95e-33	Menarche (age at onset);
LGG	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg08508325	chr11:3079039	CARS	0.39	7.35	0.32	9.28e-13	Calcium levels;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg24250549	chr1:154909240	PMVK	0.7	13.55	0.53	1.82e-35	Prostate cancer;
LGG	cis	rs9584850	0.522	rs9517299	chr13:99095031	C/T	cg07423050	chr13:99094983	FARP1	0.41	7.77	0.34	5.02e-14	Neuroticism;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.04	15.62	0.59	1.74e-44	Chronic sinus infection;
LGG	cis	rs6725041	0.819	rs4563169	chr2:213090274	G/A	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg13939156	chr17:80058883	NA	-0.46	-9.02	-0.39	5.15e-18	Blood metabolite levels;
LGG	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs6750047	0.771	rs1056836	chr2:38298203	C/G	cg07380506	chr2:38303506	CYP1B1	-0.44	-7.88	-0.34	2.35e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs7191439	0.858	rs7205626	chr16:88780472	T/C	cg02389323	chr16:88786976	FAM38A	1.08	13.2	0.52	5.2e-34	Plateletcrit;
LGG	trans	rs61931739	0.629	rs708146	chr12:33731808	C/G	cg26384229	chr12:38710491	ALG10B	0.49	8.73	0.38	4.69e-17	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg00761968	chr13:53314142	LECT1	-0.35	-7.49	-0.33	3.54e-13	Lewy body disease;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg05863683	chr7:1912471	MAD1L1	0.46	8.95	0.38	8.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1497828	0.956	rs2810784	chr1:217546406	A/T	cg04411442	chr1:217543379	NA	0.48	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	cis	rs2739330	0.587	rs4820571	chr22:24242973	A/G	cg25703541	chr22:24373054	LOC391322	-0.82	-14.26	-0.55	1.65e-38	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg23743428	chr13:21893420	NA	-0.47	-10.81	-0.45	1.86e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17039065	1.000	rs72889382	chr4:109391564	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.86	0.3	2.25e-11	Gut microbiome composition (summer);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08866814	chr16:89351500	ANKRD11	0.4	7.04	0.31	7.02e-12	Pancreatic cancer;
LGG	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg25809561	chr17:30822961	MYO1D	0.4	9.63	0.41	3.94e-20	Schizophrenia;
LGG	cis	rs68170813	0.559	rs78267892	chr7:106823734	C/T	cg02696742	chr7:106810147	HBP1	-0.77	-11.12	-0.46	1.31e-25	Coronary artery disease;
LGG	cis	rs7236492	0.872	rs78536295	chr18:77229738	G/A	cg15644404	chr18:77186268	NFATC1	-0.84	-10.16	-0.43	5.04e-22	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg26811252	chr16:29126840	RRN3P2	0.63	9.98	0.42	2.29e-21	Menopause (age at onset);
LGG	trans	rs17685	0.753	rs869804	chr7:75688954	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	26.1	0.77	5.15e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6831352	0.734	rs2602856	chr4:100029145	C/A	cg13256891	chr4:100009986	ADH5	0.53	9.51	0.4	1.08e-19	Alcohol dependence;
LGG	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	trans	rs459571	0.920	rs455073	chr9:136909141	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.84	-0.48	1.99e-28	Platelet distribution width;
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.35	-8.71	-0.38	5.27e-17	IgG glycosylation;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22168489	chr12:122356033	WDR66	0.44	10.55	0.44	1.83e-23	Mean corpuscular volume;
LGG	trans	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.71	-0.38	5.53e-17	Bladder cancer;
LGG	cis	rs2270450	0.650	rs9381474	chr6:46697380	G/T	cg10156739	chr6:46714674	LOC100287718	-0.45	-9.59	-0.41	5.39e-20	Hashimoto thyroiditis versus Graves' disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15112032	chr13:58204365	PCDH17	0.44	7.3	0.32	1.24e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	trans	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg25214090	chr10:38739885	LOC399744	-0.56	-10.07	-0.42	1.07e-21	Corneal astigmatism;
LGG	cis	rs11971779	0.680	rs7805824	chr7:139111169	C/G	cg07862535	chr7:139043722	LUC7L2	-0.42	-7.1	-0.31	4.61e-12	Diisocyanate-induced asthma;
LGG	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg05444541	chr17:17804740	TOM1L2	-0.61	-13.18	-0.52	6.32e-34	Total body bone mineral density;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11645821	chr10:93557994	TNKS2	-0.44	-6.94	-0.31	1.37e-11	Pancreatic cancer;
LGG	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs883565	0.792	rs784491	chr3:39174462	T/C	cg01426195	chr3:39028469	NA	0.61	10.99	0.45	3.99e-25	Handedness;
LGG	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg18567174	chr15:68126065	LBXCOR1	-0.4	-7.56	-0.33	2.2e-13	Obesity;
LGG	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg04374321	chr14:90722782	PSMC1	-0.45	-7.2	-0.32	2.38e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1620921	0.625	rs66940842	chr6:161265190	C/G	cg01280913	chr6:161186852	NA	-0.36	-7.31	-0.32	1.19e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.2	0.32	2.45e-12	Lung cancer;
LGG	cis	rs526231	0.511	rs27896	chr5:102488571	T/C	cg23492399	chr5:102201601	PAM	-0.58	-8.58	-0.37	1.43e-16	Primary biliary cholangitis;
LGG	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.62	0.41	4.43e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs12579753	0.957	rs35001833	chr12:82188510	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.71	-0.34	7.6e-14	Resting heart rate;
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.34	0.5	1.98e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg01324343	chr3:183735012	ABCC5	0.87	18.39	0.65	4.17e-57	Anterior chamber depth;
LGG	cis	rs6028335	0.867	rs66465343	chr20:37699436	T/G	cg16355469	chr20:37678765	NA	0.56	7.04	0.31	7.2e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs2916247	0.954	rs7839095	chr8:93158052	T/C	cg10183463	chr8:93005414	RUNX1T1	0.4	8.07	0.35	6.19e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.840	rs11547116	chr14:55738165	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.72	0.64	5.44e-54	Protein biomarker;
LGG	cis	rs1497828	1.000	rs2646845	chr1:217559136	G/A	cg04411442	chr1:217543379	NA	0.47	7.91	0.34	1.95e-14	Dialysis-related mortality;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg16103275	chr6:290800	DUSP22	0.49	7.84	0.34	3.2e-14	Menopause (age at onset);
LGG	cis	rs807669	0.524	rs11089258	chr22:19162276	C/T	cg02655711	chr22:19163373	SLC25A1	0.54	9.99	0.42	2.04e-21	Metabolite levels;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	cis	rs7766436	0.885	rs13198355	chr6:22577119	C/G	cg13666174	chr6:22585274	NA	-0.51	-11.62	-0.48	1.43e-27	Coronary artery disease;
LGG	cis	rs1691799	0.867	rs1168332	chr12:66761548	C/T	cg16791601	chr12:66731901	HELB	-0.65	-15.17	-0.58	1.72e-42	White blood cell count (basophil);
LGG	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.42e-16	Life satisfaction;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07132326	chr6:150258058	NA	0.38	8.08	0.35	5.65e-15	Testicular germ cell tumor;
LGG	cis	rs10155981	0.510	rs28673155	chr7:22593935	C/T	cg05062323	chr7:22590069	NA	-0.79	-9.84	-0.42	7.42e-21	Bilirubin levels;
LGG	cis	rs5756391	0.748	rs2413429	chr22:37289869	A/G	cg21209356	chr22:37319042	CSF2RB	0.36	8.25	0.36	1.68e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs7395662	1.000	rs4881994	chr11:48498139	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.58	-0.33	1.89e-13	HDL cholesterol;
LGG	cis	rs7177699	0.550	rs4468572	chr15:79124475	C/T	cg00540400	chr15:79124168	NA	-0.52	-11.09	-0.46	1.6e-25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7660883	0.897	rs3775214	chr4:88023299	A/G	cg21988461	chr4:88008667	AFF1	-0.35	-10.11	-0.43	7.71e-22	HDL cholesterol levels;
LGG	cis	rs6912958	0.559	rs183599	chr6:88061024	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	12.9	0.51	9.9e-33	Monocyte percentage of white cells;
LGG	cis	rs8014204	0.816	rs4903262	chr14:75340818	A/G	cg06637938	chr14:75390232	RPS6KL1	0.67	12.43	0.5	8.03e-31	Caffeine consumption;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg01570182	chr17:44337453	NA	0.73	12.12	0.49	1.51e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs12517041	1.000	rs1593967	chr5:23313900	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.69	-9.49	-0.4	1.26e-19	Calcium levels;
LGG	trans	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg21659725	chr3:3221576	CRBN	0.54	8.0	0.35	1.01e-14	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.53	-0.47	3.27e-27	Schizophrenia;
LGG	cis	rs9467711	0.606	rs9379871	chr6:26375854	C/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.0	0.35	1.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs5758659	1.000	rs134902	chr22:42683997	C/T	cg15557168	chr22:42548783	NA	-0.38	-8.63	-0.37	9.9900000000000006e-17	Cognitive function;
LGG	cis	rs7264396	0.690	rs2425164	chr20:34434916	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.39	-0.32	6.94e-13	Total cholesterol levels;
LGG	cis	rs6598955	0.670	rs6663950	chr1:26560131	T/C	cg04990556	chr1:26633338	UBXN11	-0.69	-13.98	-0.54	2.75e-37	Obesity-related traits;
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.97	-0.31	1.08e-11	Bipolar disorder;
LGG	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg25664220	chr3:72788482	NA	-0.33	-9.01	-0.39	5.45e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2816316	0.697	rs9803778	chr1:192523556	T/C	cg02586212	chr1:192544902	RGS1	0.42	8.4	0.36	5.59e-16	Celiac disease;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.42	0.5	8.69e-31	Lymphocyte counts;
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.27	-0.4	6.95e-19	Life satisfaction;
LGG	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg10057126	chr4:77819792	ANKRD56	0.36	6.79	0.3	3.51e-11	Emphysema distribution in smoking;
LGG	cis	rs3789045	1.000	rs11588857	chr1:204587047	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.44	-8.62	-0.37	1.03e-16	Educational attainment (college completion);
LGG	cis	rs823143	0.570	rs823084	chr1:205798313	G/T	cg07157834	chr1:205819609	PM20D1	0.61	13.64	0.54	7.69e-36	Monocyte percentage of white cells;
LGG	cis	rs4901847	0.740	rs10132600	chr14:58560625	G/A	cg15908186	chr14:58618357	C14orf37	0.4	6.93	0.31	1.44e-11	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs774359	0.797	rs2492817	chr9:27511151	A/G	cg14173147	chr9:27528300	MOBKL2B	0.42	8.73	0.38	4.69e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs8072100	0.807	rs4561509	chr17:45781799	G/A	cg19784903	chr17:45786737	TBKBP1	-0.34	-7.35	-0.32	9.06e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4862750	0.872	rs9998172	chr4:187898773	T/C	cg06074448	chr4:187884817	NA	-0.59	-13.16	-0.52	8.26e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6537837	0.838	rs71657105	chr1:110114122	G/A	cg05049280	chr1:110155535	GNAT2	0.33	6.95	0.31	1.27e-11	Major depressive disorder;
LGG	cis	rs2479724	0.846	rs2488338	chr6:41808351	A/G	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	cis	rs751728	1.000	rs9394166	chr6:33751122	G/C	cg25922239	chr6:33757077	LEMD2	0.69	12.27	0.5	3.61e-30	Crohn's disease;
LGG	cis	rs1957429	0.901	rs1957427	chr14:65354085	A/G	cg23373153	chr14:65346875	NA	0.86	10.89	0.45	9.65e-25	Pediatric areal bone mineral density (radius);
LGG	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg26444097	chr4:2432313	NA	-0.4	-10.25	-0.43	2.45e-22	Cognitive function;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg16405210	chr4:1374714	KIAA1530	-0.86	-16.3	-0.6	1.49e-47	Longevity;
LGG	cis	rs4631830	0.863	rs2611507	chr10:51518673	T/C	cg10326726	chr10:51549505	MSMB	-0.68	-14.2	-0.55	2.98e-38	Prostate-specific antigen levels;
LGG	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.71e-22	Motion sickness;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.85	-0.62	4.94e-50	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs4712957	chr6:25719814	C/T	cg16482183	chr6:26056742	HIST1H1C	0.5	7.96	0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs8067545	0.641	rs203462	chr17:19812541	T/C	cg04132472	chr17:19861366	AKAP10	0.26	7.28	0.32	1.45e-12	Schizophrenia;
LGG	cis	rs2204008	0.837	rs73112346	chr12:38357606	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.09	0.55	9.43e-38	Bladder cancer;
LGG	cis	rs6138458	0.626	rs6132789	chr20:25012809	C/T	cg26195577	chr20:24973756	C20orf3	-0.89	-15.86	-0.59	1.5e-45	Blood protein levels;
LGG	cis	rs8114671	0.562	rs6087649	chr20:33510662	A/G	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.12e-12	Height;
LGG	cis	rs1476679	0.927	rs2405442	chr7:99971313	T/C	cg22906224	chr7:99728672	NA	-0.44	-7.04	-0.31	6.98e-12	Alzheimer's disease (late onset);
LGG	cis	rs66887589	0.934	rs12648182	chr4:120503891	T/A	cg09307838	chr4:120376055	NA	-0.47	-8.13	-0.35	3.87e-15	Diastolic blood pressure;
LGG	cis	rs10857712	0.950	rs10857711	chr10:135224059	G/A	cg00491522	chr10:135256596	NA	0.46	7.41	0.33	5.88e-13	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.501	rs13033012	chr2:99795149	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.18	0.7	4.2e-70	Chronic sinus infection;
LGG	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg19171272	chr22:38449367	NA	-0.62	-12.29	-0.5	3e-30	Glioblastoma;Glioma;
LGG	cis	rs2976388	0.590	rs3758082	chr8:143824483	A/G	cg06565975	chr8:143823917	SLURP1	-0.53	-13.45	-0.53	4.75e-35	Urinary tract infection frequency;
LGG	cis	rs10779751	1.000	rs11121702	chr1:11293147	C/T	cg08854313	chr1:11322531	MTOR	0.73	16.1	0.6	1.18e-46	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02399570	chr3:156877196	CCNL1	0.42	6.77	0.3	3.97e-11	Cognitive performance;
LGG	cis	rs727505	0.954	rs58618031	chr7:124583896	T/C	cg23710748	chr7:124431027	NA	-0.48	-8.94	-0.38	9.39e-18	Lewy body disease;
LGG	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg15268244	chr15:77196840	NA	-0.32	-6.94	-0.31	1.35e-11	Blood metabolite levels;
LGG	cis	rs2635047	0.601	rs2635052	chr18:44650607	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.4	0.36	5.43e-16	Educational attainment;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.47e-12	Menopause (age at onset);
LGG	cis	rs283228	0.502	rs2852506	chr6:101843916	T/A	cg27451362	chr6:101846650	GRIK2	0.98	15.39	0.58	1.76e-43	Coenzyme Q10 levels;
LGG	cis	rs72634501	0.542	rs2134472	chr1:39603214	T/G	cg18385671	chr1:39797026	MACF1	-0.44	-9.62	-0.41	4.41e-20	HDL cholesterol;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.64	0.37	9.44e-17	Lung cancer;
LGG	cis	rs2067615	0.507	rs10746064	chr12:107086245	G/T	cg15890332	chr12:107067104	RFX4	0.44	12.87	0.51	1.28e-32	Heart rate;
LGG	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.34	-0.36	8.73e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9616064	0.506	rs2542038	chr22:47059282	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	8.91	0.38	1.13e-17	Urate levels in obese individuals;
LGG	trans	rs1997103	1.000	rs4947501	chr7:55407342	C/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.52	-0.37	2.24e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7267979	0.714	rs2474763	chr20:25241295	A/G	cg08601574	chr20:25228251	PYGB	0.37	7.54	0.33	2.43e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18876405	chr7:65276391	NA	0.49	8.82	0.38	2.41e-17	Aortic root size;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg06873352	chr17:61820015	STRADA	0.72	13.38	0.53	9.12e-35	Prudent dietary pattern;
LGG	cis	rs4926611	1.000	rs4926609	chr1:54110911	T/C	cg23596471	chr1:54105337	GLIS1	0.41	8.58	0.37	1.49e-16	Hand grip strength;
LGG	cis	rs2072732	0.861	rs67872056	chr1:2954165	C/T	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs12949688	0.845	rs740439	chr17:55804463	G/C	cg12229367	chr17:55822335	NA	0.42	7.95	0.35	1.41e-14	Schizophrenia;
LGG	cis	rs4742903	0.868	rs4743684	chr9:106852385	A/C	cg14250997	chr9:106856677	SMC2	0.39	8.15	0.35	3.55e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.2	0.32	2.48e-12	Height;
LGG	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg27476859	chr7:2772710	GNA12	0.52	10.13	0.43	6.62e-22	Height;
LGG	cis	rs35264875	1.000	rs72917389	chr11:68822831	C/T	cg03469862	chr11:68924853	NA	0.44	6.79	0.3	3.44e-11	Blond vs. brown hair color;
LGG	cis	rs644799	0.509	rs561635	chr11:95634232	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.49	-8.22	-0.36	2.11e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.68	-0.34	9.38e-14	Neuroticism;
LGG	cis	rs6450176	1.000	rs7707547	chr5:53295737	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.13	-0.46	1.21e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg08280861	chr8:58055591	NA	0.54	6.89	0.3	1.87e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17767294	0.612	rs9461425	chr6:27919688	G/A	cg15325629	chr6:28072465	NA	0.69	6.96	0.31	1.19e-11	Parkinson's disease;
LGG	cis	rs9547996	0.959	rs28646275	chr13:38248037	A/G	cg17979426	chr13:38220150	TRPC4	-0.4	-7.84	-0.34	3.18e-14	Diastolic blood pressure;
LGG	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg24596788	chr1:163392923	NA	-0.7	-13.39	-0.53	8.69e-35	Motion sickness;
LGG	cis	rs7294478	0.510	rs7297327	chr12:7266580	C/T	cg01074767	chr12:7262137	C1RL;LOC283314	0.35	9.06	0.39	3.59e-18	Neuritic plaque;
LGG	cis	rs10811516	0.520	rs4568676	chr9:21184475	C/G	cg23029519	chr9:21187344	IFNA4	0.47	8.28	0.36	1.36e-15	Response to mepolizumab in severe asthma;
LGG	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.95	0.31	1.23e-11	Sjögren's syndrome;
LGG	cis	rs17030434	0.911	rs115948674	chr4:154742052	G/T	cg14289246	chr4:154710475	SFRP2	-0.69	-10.87	-0.45	1.14e-24	Electrocardiographic conduction measures;
LGG	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.96	0.45	5.34e-25	Diabetic retinopathy;
LGG	cis	rs709400	0.567	rs11624343	chr14:103859156	T/A	cg26031613	chr14:104095156	KLC1	0.79	13.26	0.52	3.1e-34	Body mass index;
LGG	cis	rs2075371	0.829	rs11770764	chr7:134003308	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	13.12	0.52	1.12e-33	Mean platelet volume;
LGG	cis	rs8064024	0.650	rs8056889	chr16:4903243	C/T	cg08329684	chr16:4932620	PPL	0.53	11.94	0.49	7.46e-29	Cancer;
LGG	trans	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.7	-0.37	5.64e-17	Lung cancer in ever smokers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23620279	chr10:79793495	RPS24	-0.43	-7.16	-0.32	3.17e-12	Gut microbiome composition (summer);
LGG	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.28	-0.36	1.36e-15	Neuroticism;
LGG	cis	rs55728055	0.661	rs62237791	chr22:31973124	A/G	cg01338084	chr22:32026380	PISD	1.45	11.76	0.48	3.94e-28	Age-related hearing impairment;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04772025	chr11:68637568	NA	0.71	12.72	0.51	5.3e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs16966142	0.681	rs56244407	chr16:90049622	G/A	cg08854185	chr16:90077956	DBNDD1	-0.65	-7.77	-0.34	5.01e-14	Caffeine consumption;
LGG	cis	rs17433780	0.964	rs12121223	chr1:89481583	C/T	cg09516651	chr1:89888402	LOC400759	0.74	16.85	0.62	5.22e-50	Carotid intima media thickness;
LGG	cis	rs975739	0.657	rs4482161	chr13:78589295	A/C	cg07847733	chr13:78271382	SLAIN1	0.45	7.86	0.34	2.69e-14	Hair color;
LGG	cis	rs2901331	0.533	rs62171285	chr2:125415182	A/T	cg07771321	chr2:125368595	CNTNAP5	-0.46	-8.17	-0.36	2.93e-15	Response to statin therapy;
LGG	cis	rs4743820	0.535	rs13289294	chr9:94124414	T/C	cg14446406	chr9:93919335	NA	0.45	7.26	0.32	1.67e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7267979	1.000	rs2482943	chr20:25380593	G/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.14	-0.43	5.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs62344088	0.590	rs62329989	chr5:300141	A/G	cg22857025	chr5:266934	NA	-1.42	-22.93	-0.73	2.56e-78	Asthma (childhood onset);
LGG	cis	rs7582720	1.000	rs72932573	chr2:203861113	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2304069	0.819	rs10875553	chr5:149374932	T/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	13.44	0.53	5.52e-35	HIV-1 control;
LGG	cis	rs1010254	0.510	rs957211	chr5:151757858	T/A	cg12297329	chr5:152029980	NA	-0.51	-7.23	-0.32	1.99e-12	Optic nerve measurement (cup area);
LGG	cis	rs6879260	1.000	rs7706951	chr5:179733407	C/T	cg23248424	chr5:179741104	GFPT2	-0.6	-10.9	-0.45	8.59e-25	Height;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.19	-0.46	7.12e-26	IgG glycosylation;
LGG	cis	rs9899728	0.572	rs4365317	chr17:73059820	C/G	cg27626185	chr17:73056755	KCTD2	-0.61	-8.96	-0.38	8.03e-18	Alzheimer's disease or small vessel stroke;
LGG	cis	rs2073499	0.935	rs74398439	chr3:50331927	C/T	cg03645007	chr3:50255295	SLC38A3	0.61	6.69	0.3	6.45e-11	Schizophrenia;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.79	0.62	9.23e-50	Obesity-related traits;
LGG	cis	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09964705	chr19:19030333	DDX49;COPE	0.44	7.4	0.33	6.45e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.39	9.22	0.39	1.06e-18	Schizophrenia;
LGG	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg16386425	chr10:429943	DIP2C	0.38	7.08	0.31	5.53e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs10911198	chr1:182997318	G/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.55e-20	Depression;
LGG	cis	rs7927771	0.524	rs4752865	chr11:47759841	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-10.92	-0.45	7.23e-25	Subjective well-being;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.41	0.65	3.48e-57	Personality dimensions;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg27471124	chr11:109292789	C11orf87	0.5	9.61	0.41	4.81e-20	Schizophrenia;
LGG	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg07615347	chr10:60278583	BICC1	0.64	18.47	0.65	1.78e-57	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03382304	chr21:27012176	JAM2	0.47	6.89	0.3	1.78e-11	Gut microbiome composition (summer);
LGG	trans	rs4942242	0.663	rs34978818	chr13:44214096	T/C	cg19169023	chr15:41853346	TYRO3	-0.44	-8.88	-0.38	1.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	cis	rs2839186	0.559	rs2277826	chr21:47639492	C/G	cg12379764	chr21:47803548	PCNT	0.47	7.98	0.35	1.18e-14	Testicular germ cell tumor;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.44	-0.61	3.72e-48	Skin colour saturation;
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.57	-0.44	1.51e-23	IgG glycosylation;
LGG	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg13514129	chr1:39547527	MACF1	0.68	12.68	0.51	7.76e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs7503807	0.664	rs35524093	chr17:78574246	A/G	cg06872548	chr17:78716983	RPTOR	0.41	9.12	0.39	2.28e-18	Obesity;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12579753	1.000	rs7306395	chr12:82175867	A/G	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.26	-0.46	3.83e-26	Resting heart rate;
LGG	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	-0.72	-15.34	-0.58	3.1e-43	Menarche (age at onset);
LGG	cis	rs2439831	0.681	rs825740	chr15:43592408	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.0	13.05	0.52	2.26e-33	Lung cancer in ever smokers;
LGG	cis	rs1878931	0.507	rs35214904	chr16:3410017	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.69	-10.71	-0.45	4.49e-24	Body mass index (adult);
LGG	cis	rs12615966	1.000	rs6543268	chr2:105370105	G/C	cg16465502	chr2:105461796	NA	0.92	10.66	0.44	6.97e-24	Pancreatic cancer;
LGG	cis	rs1707322	0.963	rs4660900	chr1:46419605	T/C	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.4	0.4	2.56e-19	Mood instability;
LGG	cis	rs3126085	1.000	rs72698906	chr1:152307184	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.16	-0.32	3.23e-12	Atopic dermatitis;
LGG	cis	rs7219021	0.705	rs9904288	chr17:47031973	T/C	cg09029085	chr17:47094198	IGF2BP1	0.28	7.02	0.31	7.83e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs7551222	0.752	rs4328119	chr1:204564986	C/T	cg20240347	chr1:204465584	NA	-0.47	-9.17	-0.39	1.6e-18	Schizophrenia;
LGG	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg19824325	chr16:58548873	SETD6	1.23	11.21	0.46	5.86e-26	Schizophrenia;
LGG	cis	rs875971	1.000	rs11971949	chr7:65626014	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.39e-16	Aortic root size;
LGG	cis	rs9303280	0.806	rs12941333	chr17:38040534	C/T	cg17467752	chr17:38218738	THRA	-0.44	-7.09	-0.31	5.04e-12	Self-reported allergy;
LGG	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg07928641	chr1:182991847	LAMC1	-0.48	-9.89	-0.42	4.62e-21	Colorectal cancer;
LGG	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg11861562	chr11:117069780	TAGLN	0.26	6.92	0.31	1.5e-11	Blood protein levels;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-12.82	-0.51	2.02e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg06873352	chr17:61820015	STRADA	-0.74	-13.67	-0.54	5.36e-36	Prudent dietary pattern;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg13607699	chr17:42295918	UBTF	0.64	11.11	0.46	1.4e-25	Total body bone mineral density;
LGG	cis	rs17453880	0.890	rs28749810	chr5:152048630	C/A	cg12297329	chr5:152029980	NA	-0.9	-23.18	-0.73	1.8e-79	Subjective well-being;
LGG	cis	rs1816752	0.740	rs6490924	chr13:25007052	G/A	cg22771759	chr13:24902376	NA	-0.4	-6.73	-0.3	5.1e-11	Obesity-related traits;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg19635926	chr16:89946313	TCF25	0.82	8.39	0.36	5.89e-16	Skin colour saturation;
LGG	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg13010199	chr12:38710504	ALG10B	0.47	9.34	0.4	4.05e-19	Morning vs. evening chronotype;
LGG	cis	rs17776563	0.959	rs13329353	chr15:89113877	A/G	cg05013243	chr15:89149849	MIR1179	-0.48	-9.73	-0.41	1.83e-20	Thyroid hormone levels;
LGG	cis	rs1966248	0.543	rs4895994	chr6:134120826	G/A	cg25632230	chr6:134101081	NA	-0.34	-7.28	-0.32	1.4e-12	Coronary artery disease;
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg00290607	chr11:67383545	NA	-0.57	-11.08	-0.46	1.75e-25	Mean corpuscular volume;
LGG	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.79	0.34	4.39e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6032067	1.000	rs62205501	chr20:43864089	G/A	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs138229	0.506	rs138233	chr22:50559953	G/A	cg16473166	chr22:50639996	SELO	0.52	7.91	0.34	1.97e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg00290607	chr11:67383545	NA	-0.5	-8.89	-0.38	1.33e-17	Mean corpuscular volume;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.66	-0.54	6.05e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs73191547	1.000	rs11993663	chr8:10032894	C/A	cg06636001	chr8:8085503	FLJ10661	0.39	6.83	0.3	2.75e-11	Schizophrenia;
LGG	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg24642844	chr7:1081250	C7orf50	-0.77	-9.98	-0.42	2.22e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg02725872	chr8:58115012	NA	-0.86	-11.91	-0.48	1.04e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs10489202	0.686	rs11590282	chr1:167848231	C/T	cg24449463	chr1:168025552	DCAF6	-0.55	-7.5	-0.33	3.29e-13	Schizophrenia;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.27	-0.43	2.04e-22	Bipolar disorder;
LGG	cis	rs7945705	0.869	rs2742471	chr11:9003953	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-11.98	-0.49	5.38e-29	Hemoglobin concentration;
LGG	cis	rs10089	1.000	rs10478798	chr5:127442394	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs3784262	0.669	rs12915821	chr15:58315685	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.99	-0.31	9.93e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1451375	0.657	rs12672526	chr7:50657695	C/T	cg20336341	chr7:50628841	DDC	0.37	7.16	0.32	3.25e-12	Malaria;
LGG	cis	rs12701220	0.689	rs6973645	chr7:1112246	C/T	cg00990874	chr7:1149470	C7orf50	-0.64	-9.07	-0.39	3.51e-18	Bronchopulmonary dysplasia;
LGG	cis	rs4478137	0.824	rs4691907	chr4:164223658	G/T	cg06758707	chr4:164254230	NPY1R	0.71	12.83	0.51	1.9e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg13647721	chr17:30228624	UTP6	-0.67	-8.0	-0.35	1e-14	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-7.02	-0.31	8.2e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.0	-0.6	3.35e-46	Longevity;
LGG	cis	rs754466	0.914	rs4595491	chr10:79685833	G/A	cg17075019	chr10:79541650	NA	-0.8	-13.42	-0.53	6.66e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.09	-0.31	5.13e-12	Lung cancer;
LGG	cis	rs8017423	0.529	rs12898020	chr14:90835752	A/G	cg04374321	chr14:90722782	PSMC1	-0.57	-9.87	-0.42	5.66e-21	Mortality in heart failure;
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.4	-0.36	5.46e-16	Total body bone mineral density;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg06848047	chr4:90757629	SNCA	0.4	7.63	0.33	1.34e-13	Dementia with Lewy bodies;
LGG	cis	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg07460842	chr6:66804631	NA	0.57	9.51	0.4	1.05e-19	Metabolite levels;
LGG	cis	rs4006360	0.505	rs9916287	chr17:39286884	T/G	cg16985667	chr17:39306289	KRTAP4-5	-0.47	-9.41	-0.4	2.38e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	1.000	rs7513161	chr1:248453422	A/T	cg00666640	chr1:248458726	OR2T12	0.6	9.69	0.41	2.5e-20	Common traits (Other);
LGG	trans	rs7395662	1.000	rs11039745	chr11:48463811	G/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.93	-0.35	1.69e-14	HDL cholesterol;
LGG	cis	rs3820928	0.874	rs10166456	chr2:227900113	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.3	-0.32	1.3e-12	Pulmonary function;
LGG	cis	rs988958	1.000	rs988959	chr2:42287389	C/T	cg27252766	chr2:42229092	NA	0.43	6.87	0.3	2.02e-11	Hypospadias;
LGG	cis	rs12493885	0.818	rs73158489	chr3:153757862	C/T	cg12800244	chr3:153838788	SGEF	-0.74	-9.06	-0.39	3.6e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10208940	0.502	rs10203846	chr2:68670921	G/A	cg12452813	chr2:68675892	NA	-0.88	-12.98	-0.52	4.29e-33	Urate levels in lean individuals;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg12070911	chr6:150209640	RAET1E	0.26	6.79	0.3	3.46e-11	Lung cancer;
LGG	cis	rs9467711	0.790	rs13220495	chr6:26441640	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	6.88	0.3	2e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs952623	0.501	rs11973171	chr7:39086521	A/G	cg15212455	chr7:39170539	POU6F2	0.3	6.89	0.31	1.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.76	-0.57	1.13e-40	IgG glycosylation;
LGG	cis	rs607541	0.764	rs629880	chr15:45934810	A/T	cg26924012	chr15:45694286	SPATA5L1	0.54	7.59	0.33	1.8e-13	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg18404041	chr3:52824283	ITIH1	-0.51	-9.95	-0.42	2.99e-21	Bipolar disorder;
LGG	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.17	-0.52	6.92e-34	Gut microbiome composition (summer);
LGG	cis	rs4689388	0.926	rs5018647	chr4:6292799	A/C	cg14416269	chr4:6271139	WFS1	0.51	9.2	0.39	1.2e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2120243	0.539	rs7617727	chr3:157105558	A/C	cg24825693	chr3:157122686	VEPH1	0.58	13.48	0.53	3.45e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg09462578	chr12:12878428	APOLD1	-0.54	-7.56	-0.33	2.14e-13	Systemic lupus erythematosus;
LGG	trans	rs634534	0.622	rs501353	chr11:65739549	T/G	cg17712092	chr4:129076599	LARP1B	0.71	13.64	0.54	7.85e-36	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs12600053	0.554	rs4783077	chr16:84848221	A/G	cg09249803	chr16:84846936	NA	0.37	7.95	0.35	1.46e-14	Asthma (childhood onset);
LGG	cis	rs138549714	1	rs138549714	chr18:3220755	G/GT	cg14944538	chr18:3220532	MYOM1	-0.74	-7.65	-0.34	1.14e-13	Brain volume in infants (white matter);
LGG	cis	rs6500637	0.659	rs10500326	chr16:4918326	G/T	cg08329684	chr16:4932620	PPL	0.47	8.41	0.36	5.21e-16	Cancer;
LGG	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg00717180	chr2:96193071	NA	-0.46	-8.31	-0.36	1.05e-15	HDL cholesterol;
LGG	cis	rs734999	0.588	rs3748818	chr1:2525660	G/A	cg20673091	chr1:2541236	MMEL1	0.8	18.38	0.65	4.56e-57	Ulcerative colitis;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg03452623	chr4:187889614	NA	-1.04	-30.04	-0.81	8.44e-111	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg13009111	chr11:71350975	NA	-0.33	-7.54	-0.33	2.48e-13	Neuroticism;
LGG	trans	rs61931739	0.507	rs4638394	chr12:33813585	C/T	cg26384229	chr12:38710491	ALG10B	0.46	8.25	0.36	1.7e-15	Morning vs. evening chronotype;
LGG	cis	rs13177180	0.673	rs2546484	chr5:114844882	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	0.34	7.49	0.33	3.44e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs938554	0.513	rs3775948	chr4:9995182	G/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-7.09	-0.31	5.04e-12	Blood metabolite levels;
LGG	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg25517755	chr10:38738941	LOC399744	0.35	6.76	0.3	4.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg25338242	chr13:114786047	RASA3	0.45	6.92	0.31	1.53e-11	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs763121	0.853	rs2281020	chr22:39064406	A/G	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs6582630	0.555	rs10880624	chr12:38526316	C/T	cg26384229	chr12:38710491	ALG10B	0.93	21.87	0.71	2.52e-73	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11310629	chr13:45991975	SLC25A30	0.41	7.15	0.32	3.33e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.81	-0.51	2.22e-32	Chronic sinus infection;
LGG	cis	rs28595532	0.541	rs114463740	chr4:119763329	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs11920090	0.858	rs6808595	chr3:170674678	A/G	cg09710316	chr3:170744871	SLC2A2	0.68	8.97	0.38	7.24e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs8062405	0.723	rs4788077	chr16:28569764	G/C	cg07382826	chr16:28625726	SULT1A1	0.43	8.96	0.38	7.69e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8180040	0.654	rs6773521	chr3:47234419	A/G	cg27129171	chr3:47204927	SETD2	-0.81	-14.81	-0.57	6.69e-41	Colorectal cancer;
LGG	cis	rs1577917	0.682	rs6909767	chr6:86228109	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.59	0.37	1.3e-16	Response to antipsychotic treatment;
LGG	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.58	0.41	6.08e-20	Blood protein levels;
LGG	cis	rs6665290	0.904	rs10495273	chr1:227183359	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs60180747	1.000	rs11630608	chr15:66745137	T/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.59	10.52	0.44	2.35e-23	Testicular germ cell tumor;
LGG	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg02002194	chr4:3960332	NA	0.45	8.26	0.36	1.51e-15	Retinal vascular caliber;
LGG	cis	rs4702718	0.632	rs11133623	chr5:10692082	T/C	cg18867653	chr5:10760375	DAP	0.31	7.54	0.33	2.43e-13	Obesity-related traits;
LGG	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg08779649	chr13:50194554	NA	-0.37	-9.43	-0.4	1.91e-19	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16341592	chr3:112931182	BOC	0.41	6.79	0.3	3.48e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2404602	0.716	rs12917430	chr15:76674360	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.49	0.4	1.2e-19	Blood metabolite levels;
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10802521	chr3:52805072	NEK4	0.42	6.99	0.31	9.79e-12	Bipolar disorder;
LGG	cis	rs7843479	0.601	rs727693	chr8:21850116	A/G	cg17168535	chr8:21777572	XPO7	0.79	15.54	0.59	4.11e-44	Mean corpuscular volume;
LGG	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg13385521	chr17:29058706	SUZ12P	0.72	8.78	0.38	3.15e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg26384229	chr12:38710491	ALG10B	-0.58	-10.58	-0.44	1.45e-23	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.591	rs2814060	chr1:227722228	A/G	cg23173402	chr1:227635558	NA	0.39	7.33	0.32	1.04e-12	Major depressive disorder;
LGG	cis	rs10463316	0.817	rs12653378	chr5:150802366	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.2	-0.43	3.54e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4919694	1.000	rs11191473	chr10:104710710	C/G	cg04362960	chr10:104952993	NT5C2	1.06	15.11	0.57	3.18e-42	Arsenic metabolism;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21425332	chr2:70485145	PCYOX1	0.56	8.42	0.36	4.85e-16	Gut microbiome composition (summer);
LGG	cis	rs6740322	0.895	rs6711966	chr2:43561989	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.77	-0.38	3.39e-17	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.31e-13	Lung cancer;
LGG	cis	rs6583826	0.712	rs6583823	chr10:94344415	C/T	cg25093409	chr10:94429542	NA	0.34	6.7	0.3	6.06e-11	Type 2 diabetes;
LGG	cis	rs9811920	0.609	rs6440938	chr3:99652092	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.07	-0.39	3.44e-18	Axial length;
LGG	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg22517653	chr1:2918612	NA	-0.51	-7.27	-0.32	1.52e-12	Plateletcrit;
LGG	cis	rs4595586	0.545	rs6580889	chr12:39369742	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.4e-13	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18621852	chr3:10150065	C3orf24	0.4	6.74	0.3	4.67e-11	Alzheimer's disease;
LGG	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg23205692	chr1:25664452	TMEM50A	0.46	9.85	0.42	6.74e-21	Erythrocyte sedimentation rate;
LGG	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg04248312	chr19:17393744	ANKLE1	0.64	10.55	0.44	1.85e-23	Systemic lupus erythematosus;
LGG	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg23205692	chr1:25664452	TMEM50A	0.49	10.4	0.44	6.61e-23	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.89	0.38	1.41e-17	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04761648	chr13:26829199	CDK8	0.46	7.75	0.34	5.94e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27498675	chr19:41945691	ATP5SL	0.43	7.4	0.33	6.65e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg25319279	chr11:5960081	NA	-0.49	-8.21	-0.36	2.28e-15	DNA methylation (variation);
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg03847636	chr4:7070632	GRPEL1	0.51	7.27	0.32	1.58e-12	Monocyte percentage of white cells;
LGG	cis	rs10924309	0.889	rs10802246	chr1:245858493	T/G	cg00036263	chr1:245852353	KIF26B	-0.46	-6.78	-0.3	3.56e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs12643440	0.538	rs2041443	chr4:17137996	G/A	cg22650099	chr4:17144496	NA	-0.51	-8.68	-0.37	6.69e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs1005224	0.963	rs11623813	chr14:76138194	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.87	-0.3	2.06e-11	Large artery stroke;
LGG	cis	rs1062753	0.961	rs9620007	chr22:42405657	C/G	cg15128208	chr22:42549153	NA	0.41	7.09	0.31	5.14e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25365783	chr7:108166722	PNPLA8	0.45	7.15	0.32	3.42e-12	Cognitive performance;
LGG	trans	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg27349345	chr7:35225932	NA	-0.52	-7.49	-0.33	3.61e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2624839	0.602	rs2526390	chr3:50192760	C/T	cg14019146	chr3:50243930	SLC38A3	-0.52	-10.42	-0.44	5.69e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg15268244	chr15:77196840	NA	-0.32	-7.12	-0.31	4.06e-12	Blood metabolite levels;
LGG	cis	rs1961637	0.642	rs10206046	chr2:223887697	G/A	cg02552189	chr2:223891284	NA	-0.38	-7.49	-0.33	3.53e-13	Oropharynx cancer;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg21963583	chr11:68658836	MRPL21	0.58	9.9	0.42	4.38e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	1.000	rs1402003	chr3:183642879	C/T	cg05044414	chr3:183734942	ABCC5	0.77	17.13	0.62	2.75e-51	Anterior chamber depth;
LGG	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg08999081	chr20:33150536	PIGU	0.32	7.47	0.33	3.98e-13	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs1978968	0.956	rs7291304	chr22:18421821	C/A	cg03078520	chr22:18463400	MICAL3	-0.59	-11.19	-0.46	6.71e-26	Presence of antiphospholipid antibodies;
LGG	cis	rs8067287	0.597	rs4985725	chr17:16863477	T/A	cg26910001	chr17:16838321	NA	0.38	7.5	0.33	3.21e-13	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs742320	0.756	rs4984925	chr16:839996	T/C	cg03433313	chr16:819064	MIR662	-0.58	-10.24	-0.43	2.55e-22	Mean corpuscular volume;
LGG	trans	rs3942852	0.568	rs4412719	chr11:48101660	T/A	cg03929089	chr4:120376271	NA	-0.69	-10.78	-0.45	2.5300000000000002e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs796364	0.662	rs11687313	chr2:201146399	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-7.02	-0.31	7.73e-12	Schizophrenia;
LGG	cis	rs75804782	0.641	rs11902599	chr2:239348400	C/T	cg18131467	chr2:239335373	ASB1	-0.67	-6.72	-0.3	5.43e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs1620921	0.682	rs66561051	chr6:161265144	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.31	-0.32	1.15e-12	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs34421088	0.540	rs4841517	chr8:11132007	C/G	cg16141378	chr3:129829833	LOC729375	0.32	6.78	0.3	3.56e-11	Neuroticism;
LGG	cis	rs4851250	0.518	rs34490534	chr2:100616060	T/G	cg17356467	chr2:100759845	AFF3	0.44	6.94	0.31	1.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg24623649	chr8:11872141	NA	0.3	7.21	0.32	2.26e-12	Monocyte count;
LGG	trans	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.37	0.53	1.06e-34	Breast cancer;
LGG	cis	rs6964587	1.000	rs34548928	chr7:91668365	G/A	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.77e-16	Breast cancer;
LGG	cis	rs16912285	0.688	rs7128680	chr11:24338796	C/T	ch.11.24196551F	chr11:24239977	NA	0.93	12.88	0.51	1.13e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03699307	chr16:75600014	GABARAPL2	-0.51	-7.4	-0.33	6.68e-13	Systemic lupus erythematosus;
LGG	cis	rs4936891	0.563	rs78158860	chr11:123890220	A/G	cg22125253	chr11:123886957	OR10G4	0.7	13.69	0.54	4.82e-36	Male fertility;
LGG	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.16	-0.49	1.05e-29	Corneal structure;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg16405210	chr4:1374714	KIAA1530	0.5	8.43	0.36	4.26e-16	Obesity-related traits;
LGG	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg15485101	chr11:133734466	NA	0.61	10.69	0.44	5.71e-24	Childhood ear infection;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.49	8.77	0.38	3.35e-17	Longevity;
LGG	cis	rs9811920	0.638	rs796978	chr3:99564321	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.54	-0.37	1.93e-16	Axial length;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg09739081	chr7:23719861	C7orf46	0.36	7.98	0.35	1.14e-14	Schizophrenia;
LGG	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.56	-0.33	2.17e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2075466	0.514	rs76407180	chr16:4898529	C/T	cg04440724	chr16:4920505	UBN1	-0.6	-8.78	-0.38	3.29e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9814567	1.000	rs10935120	chr3:134233092	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.48	0.53	3.74e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg14004847	chr7:1930337	MAD1L1	0.49	8.4	0.36	5.5e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7267979	1.000	rs2257982	chr20:25269630	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs876084	0.527	rs7460965	chr8:121164389	C/T	cg06265175	chr8:121136014	COL14A1	0.45	8.74	0.38	4.26e-17	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg26174226	chr8:58114915	NA	-0.56	-7.56	-0.33	2.23e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg08847533	chr14:75593920	NEK9	0.62	12.04	0.49	2.97e-29	Height;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg01244601	chr4:120671846	NA	-0.35	-6.67	-0.3	7.49e-11	Corneal astigmatism;
LGG	cis	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg27411982	chr8:10470053	RP1L1	0.41	6.76	0.3	4.28e-11	Triglycerides;
LGG	cis	rs4974559	0.594	rs11946384	chr4:1313566	T/C	cg02980000	chr4:1222292	CTBP1	0.68	9.66	0.41	3.02e-20	Systolic blood pressure;
LGG	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.65	-0.37	8.32e-17	Retinal vascular caliber;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg21724239	chr8:58056113	NA	0.45	6.97	0.31	1.1e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.65	-11.36	-0.47	1.51e-26	Mean corpuscular volume;
LGG	cis	rs17221829	0.626	rs10830340	chr11:89413850	C/T	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.71	-0.38	5.47e-17	Anxiety in major depressive disorder;
LGG	cis	rs11651000	0.761	rs11657388	chr17:45820707	C/G	cg06532163	chr17:45867833	NA	0.51	7.88	0.34	2.39e-14	IgG glycosylation;
LGG	cis	rs7100689	0.784	rs10736341	chr10:82061206	C/G	cg01528321	chr10:82214614	TSPAN14	0.88	15.9	0.59	9.5e-46	Post bronchodilator FEV1;
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11912956	chr7:73588697	EIF4H	0.51	7.55	0.33	2.29e-13	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg26384229	chr12:38710491	ALG10B	0.61	11.87	0.48	1.52e-28	Morning vs. evening chronotype;
LGG	cis	rs368123	1.000	rs422973	chr6:160717911	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.13e-12	Waist circumference;
LGG	cis	rs8062405	0.755	rs56209193	chr16:28585636	C/T	cg00204512	chr16:28754710	NA	0.25	6.93	0.31	1.38e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9341808	0.727	rs1324120	chr6:80976125	G/C	cg08355045	chr6:80787529	NA	0.39	7.52	0.33	2.87e-13	Sitting height ratio;
LGG	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00933542	chr6:150070202	PCMT1	0.38	6.87	0.3	2.13e-11	Lung cancer;
LGG	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.75	0.45	3.37e-24	Systolic blood pressure;
LGG	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03576123	chr11:487126	PTDSS2	-1.25	-16.84	-0.62	5.48e-50	Body mass index;
LGG	cis	rs77633900	0.772	rs284903	chr15:76744813	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4006360	0.525	rs72625956	chr17:39237517	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.52	-0.47	3.57e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg27532560	chr4:187881888	NA	-0.6	-13.18	-0.52	6.52e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06634786	chr22:41940651	POLR3H	-0.74	-12.47	-0.5	5.49e-31	Vitiligo;
LGG	cis	rs9815354	1.000	rs61744385	chr3:41756986	A/T	cg03022575	chr3:42003672	ULK4	0.61	7.61	0.33	1.5e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.59	-0.47	1.93e-27	Height;
LGG	trans	rs7395662	1.000	rs7945192	chr11:48580737	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs965513	1.000	rs7030241	chr9:100550375	T/A	cg13688889	chr9:100608707	NA	-0.53	-9.64	-0.41	3.68e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs5769765	0.908	rs9627788	chr22:50300438	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.51	-0.47	4.02e-27	Schizophrenia;
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.59	0.44	1.33e-23	Lung function (FEV1/FVC);
LGG	cis	rs7236492	0.872	rs78226032	chr18:77230822	G/A	cg15644404	chr18:77186268	NFATC1	-0.81	-9.9	-0.42	4.35e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10892173	0.545	rs115865940	chr11:117666711	C/T	cg21640587	chr11:117668038	DSCAML1	0.92	15.31	0.58	4.36e-43	Myopia;
LGG	cis	rs36051895	0.553	rs12338854	chr9:5057568	G/C	cg02405213	chr9:5042618	JAK2	-0.83	-16.19	-0.6	4.61e-47	Pediatric autoimmune diseases;
LGG	cis	rs11514810	1.000	rs9648620	chr7:1427980	T/C	cg24899294	chr7:1481343	MICALL2	-0.69	-8.42	-0.36	4.73e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg18538332	chr22:24372958	LOC391322	0.47	7.62	0.33	1.42e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg24253500	chr15:84953950	NA	0.61	11.54	0.47	2.97e-27	Schizophrenia;
LGG	cis	rs778371	0.748	rs1878287	chr2:233790649	G/T	cg08000102	chr2:233561755	GIGYF2	-0.57	-8.16	-0.35	3.11e-15	Schizophrenia;
LGG	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg05793240	chr7:2802953	GNA12	0.32	7.86	0.34	2.65e-14	Height;
LGG	cis	rs12220238	0.722	rs7894466	chr10:76401365	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.51	6.75	0.3	4.52e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.83e-15	Diabetic kidney disease;
LGG	cis	rs4851266	1.000	rs7566527	chr2:100811970	C/T	cg21926883	chr2:100939477	LONRF2	-0.43	-7.75	-0.34	5.87e-14	Educational attainment;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.75	-0.34	5.91e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg01191920	chr7:158217561	PTPRN2	0.72	16.01	0.6	3.14e-46	Obesity-related traits;
LGG	cis	rs6964587	0.692	rs17672805	chr7:91573466	A/G	cg17063962	chr7:91808500	NA	-0.5	-9.39	-0.4	2.79e-19	Breast cancer;
LGG	cis	rs6138458	0.828	rs6132785	chr20:24993414	T/C	cg26195577	chr20:24973756	C20orf3	1.02	19.85	0.68	6.7e-64	Blood protein levels;
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg08742575	chr21:47604166	C21orf56	0.48	8.42	0.36	4.65e-16	Testicular germ cell tumor;
LGG	cis	rs1881797	0.527	rs1852908	chr1:247678260	C/T	cg18198730	chr1:247681584	NA	0.67	7.5	0.33	3.18e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13102973	0.645	rs11734870	chr4:135885118	T/A	cg14419869	chr4:135874104	NA	0.47	7.96	0.35	1.37e-14	Subjective well-being;
LGG	cis	rs4356203	0.905	rs7107283	chr11:17089403	A/G	cg15432903	chr11:17409602	KCNJ11	0.4	7.5	0.33	3.34e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs3820068	0.581	rs16851841	chr1:15922713	A/G	cg05660106	chr1:15850417	CASP9	0.86	17.7	0.64	6.49e-54	Systolic blood pressure;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19027619	chr1:6674655	PHF13	0.56	7.02	0.31	8.1e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6835098	0.816	rs13111572	chr4:174159788	G/A	cg08422745	chr4:174089978	GALNT7	0.83	14.1	0.55	8.5e-38	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs2133450	0.526	rs12489404	chr3:7346698	C/T	cg19930620	chr3:7340148	GRM7	-0.42	-9.34	-0.4	4.04e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg15323506	chr17:19619410	SLC47A2	-0.48	-8.54	-0.37	1.99e-16	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.78e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs787274	0.850	rs10759603	chr9:115639581	C/G	cg13803584	chr9:115635662	SNX30	-0.64	-8.93	-0.38	1.03e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1008375	0.966	rs1476836	chr4:17585014	G/C	cg07005078	chr4:17578674	LAP3	0.38	6.97	0.31	1.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4787491	0.704	rs66467443	chr16:30050494	G/A	cg06326092	chr16:30034487	C16orf92	0.41	8.23	0.36	1.97e-15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17711722	0.740	rs7809991	chr7:65406218	A/G	cg18876405	chr7:65276391	NA	0.68	13.01	0.52	3.33e-33	Calcium levels;
LGG	cis	rs7267979	0.966	rs6083817	chr20:25343998	G/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28595532	0.920	rs116149978	chr4:119761069	A/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg04772025	chr11:68637568	NA	0.77	13.8	0.54	1.59e-36	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.74	-0.41	1.61e-20	Personality dimensions;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg18350739	chr11:68623251	NA	-0.85	-21.97	-0.71	8.56e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg18867708	chr6:26865862	GUSBL1	-0.44	-7.32	-0.32	1.11e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19942237	chr7:29603211	PRR15	0.28	6.69	0.3	6.26e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs10214930	0.671	rs9639553	chr7:27578167	C/G	cg22168087	chr7:27702803	HIBADH	-0.45	-6.95	-0.31	1.24e-11	Hypospadias;
LGG	cis	rs523522	0.962	rs12371550	chr12:120987643	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.89	0.51	1.02e-32	High light scatter reticulocyte count;
LGG	cis	rs4731207	0.596	rs6948283	chr7:124679523	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg19980929	chr12:42632907	YAF2	0.37	8.16	0.35	3.14e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2247341	0.928	rs2290011	chr4:1746229	G/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.8	-0.45	2.14e-24	Hip circumference adjusted for BMI;Height;
LGG	trans	rs1814175	0.935	rs28586931	chr11:49693872	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-24.09	-0.75	9.8e-84	Height;
LGG	cis	rs12681366	0.734	rs4735292	chr8:95408731	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.67	0.3	7.24e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6500395	0.928	rs4553627	chr16:48708801	A/T	cg16662043	chr16:48846231	NA	-0.36	-7.13	-0.31	3.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2734839	0.964	rs12798900	chr11:113298996	G/T	cg14159747	chr11:113255604	NA	0.26	7.02	0.31	7.94e-12	Information processing speed;
LGG	cis	rs17376456	0.569	rs12653528	chr5:93212833	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.68	-9.19	-0.39	1.35e-18	Diabetic retinopathy;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.74	0.41	1.66e-20	Obesity-related traits;
LGG	trans	rs62103177	0.714	rs12607447	chr18:77605212	A/G	cg14227996	chr4:17616232	MED28	0.54	7.57	0.33	2.04e-13	Opioid sensitivity;
LGG	cis	rs920590	0.643	rs6982084	chr8:19669333	G/A	cg03894339	chr8:19674705	INTS10	-0.51	-8.66	-0.37	7.88e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6121246	0.909	rs1994249	chr20:30287593	C/T	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.65e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.23e-16	Personality dimensions;
LGG	trans	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.57	-0.37	1.52e-16	Bladder cancer;
LGG	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs2290159	0.800	rs11709504	chr3:12674199	T/C	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.03e-20	Cholesterol, total;
LGG	cis	rs9868809	0.772	rs73078349	chr3:48688114	G/A	cg07636037	chr3:49044803	WDR6	-0.67	-6.89	-0.3	1.87e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg05665937	chr4:1216051	CTBP1	0.54	9.91	0.42	3.88e-21	Obesity-related traits;
LGG	cis	rs36051895	0.594	rs10115464	chr9:5144268	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-15.05	-0.57	6.05e-42	Pediatric autoimmune diseases;
LGG	cis	rs6784615	0.744	rs929529	chr3:52505525	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.44	-0.33	4.94e-13	Waist-hip ratio;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs868036	1.000	rs1026733	chr15:68095122	G/A	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25214090	chr10:38739885	LOC399744	0.65	11.32	0.47	2.23e-26	Corneal astigmatism;
LGG	trans	rs1032833	0.732	rs17454192	chr2:180000816	C/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.7	0.34	8.6e-14	Schizophrenia;
LGG	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg21926883	chr2:100939477	LONRF2	-0.49	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7937612	1.000	rs6589812	chr11:120278359	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.0	-0.52	3.78e-33	Intraocular pressure;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.45	0.33	4.7e-13	Schizophrenia;
LGG	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00049323	chr5:472564	LOC25845	0.4	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.21	-0.32	2.3e-12	Triglycerides;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg03036210	chr16:89904091	SPIRE2	-0.49	-7.04	-0.31	7.12e-12	Skin colour saturation;
LGG	cis	rs796364	0.806	rs10445792	chr2:201078821	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	cis	rs17092148	0.887	rs6058077	chr20:33140999	G/A	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.78	-0.3	3.76e-11	Neuroticism;
LGG	cis	rs2131877	0.830	rs62290344	chr3:194849620	T/C	cg07250128	chr3:194833983	C3orf21	0.41	6.73	0.3	4.9e-11	Non-small cell lung cancer;
LGG	cis	rs67460515	0.892	rs4856769	chr3:161004549	C/A	cg03342759	chr3:160939853	NMD3	-0.75	-13.14	-0.52	9.45e-34	Parkinson's disease;
LGG	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg25237894	chr2:233734115	C2orf82	-0.66	-12.53	-0.5	3.35e-31	Coronary artery disease;
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.45e-29	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg18032289	chr17:61959525	GH2	-0.39	-6.76	-0.3	4.21e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7619833	0.653	rs2370942	chr3:27286810	G/C	cg02860705	chr3:27208620	NA	0.4	7.65	0.33	1.19e-13	Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23400208	chr10:60936031	PHYHIPL	0.4	6.94	0.31	1.36e-11	Bipolar disorder;
LGG	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.11	-0.49	1.55e-29	Chronic sinus infection;
LGG	cis	rs7106204	0.590	rs28864378	chr11:24206582	C/A	ch.11.24196551F	chr11:24239977	NA	0.97	14.42	0.56	3.52e-39	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs17767392	0.794	rs17767362	chr14:71733790	G/A	cg02058870	chr14:72053146	SIPA1L1	0.41	8.17	0.36	2.89e-15	Mitral valve prolapse;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs763121	0.853	rs1056610	chr22:39080078	C/T	cg06022373	chr22:39101656	GTPBP1	-0.91	-18.91	-0.66	1.68e-59	Menopause (age at onset);
LGG	cis	rs8095374	1.000	rs8095374	chr18:43793488	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.38	-8.14	-0.35	3.57e-15	Clinical laboratory measurements;
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg03452623	chr4:187889614	NA	-1.03	-30.46	-0.82	1.18e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.97	0.35	1.24e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4243830	0.850	rs908273	chr1:6588604	G/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-12.3	-0.5	2.87e-30	Body mass index;
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.72	0.45	4.35e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg03433033	chr1:76189801	ACADM	0.83	15.59	0.59	2.27e-44	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.39	-0.32	6.74e-13	Electroencephalogram traits;
LGG	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.74	-0.38	4.38e-17	Bone mineral density;
LGG	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg00405596	chr8:11794950	NA	-0.44	-7.28	-0.32	1.43e-12	Neuroticism;
LGG	cis	rs17767392	0.836	rs2332640	chr14:72044547	C/T	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.42	-0.4	2.07e-19	Mitral valve prolapse;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg06521331	chr12:34319734	NA	0.44	7.9	0.34	2.09e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg19223190	chr17:80058835	NA	0.44	8.48	0.37	3.07e-16	Life satisfaction;
LGG	cis	rs2549003	1.000	rs9282763	chr5:131822133	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg20913747	chr6:44695427	NA	-0.68	-11.51	-0.47	3.77e-27	Total body bone mineral density;
LGG	cis	rs4819052	0.765	rs2838854	chr21:46680364	A/G	cg06618935	chr21:46677482	NA	-0.49	-9.65	-0.41	3.38e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg13647721	chr17:30228624	UTP6	0.67	9.17	0.39	1.52e-18	Hip circumference adjusted for BMI;
LGG	cis	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg07636037	chr3:49044803	WDR6	0.45	6.82	0.3	2.85e-11	Resting heart rate;
LGG	cis	rs4478858	0.735	rs10914368	chr1:31847937	A/G	cg19084893	chr1:31688959	NA	0.32	6.69	0.3	6.4e-11	Alcohol dependence;
LGG	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg10760299	chr15:45669010	GATM	0.39	7.48	0.33	3.76e-13	Homoarginine levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01162436	chr10:15902292	FAM188A	0.47	8.2	0.36	2.43e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2075371	0.933	rs2544182	chr7:133949793	C/T	cg11752832	chr7:134001865	SLC35B4	0.58	10.45	0.44	4.33e-23	Mean platelet volume;
LGG	cis	rs6963495	0.818	rs6956234	chr7:105149707	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.85	0.34	2.86e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg04731861	chr2:219085781	ARPC2	-0.43	-10.31	-0.43	1.39e-22	Colorectal cancer;
LGG	trans	rs9747201	0.890	rs12946944	chr17:80061748	C/T	cg07393940	chr7:158741817	NA	-0.59	-10.17	-0.43	4.44e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs12517041	1.000	rs10079487	chr5:23294939	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs367943	0.667	rs13173069	chr5:113011778	T/G	cg12552261	chr5:112820674	MCC	0.5	8.02	0.35	8.81e-15	Type 2 diabetes;
LGG	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg03929089	chr4:120376271	NA	-0.43	-6.71	-0.3	5.77e-11	Height;
LGG	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg04608330	chr12:45269318	NELL2	-0.63	-11.15	-0.46	9.41e-26	Gut microbiome composition (summer);
LGG	cis	rs561341	0.739	rs6505267	chr17:30225950	A/C	cg00745463	chr17:30367425	LRRC37B	-0.49	-7.14	-0.32	3.57e-12	Hip circumference adjusted for BMI;
LGG	cis	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg09307838	chr4:120376055	NA	0.48	8.13	0.35	3.95e-15	Diastolic blood pressure;
LGG	cis	rs9560113	0.556	rs9560128	chr13:112221924	A/G	cg15979348	chr13:112237479	NA	0.45	7.74	0.34	6.37e-14	Menarche (age at onset);
LGG	cis	rs2836974	0.899	rs8127087	chr21:40544502	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.92	0.82	1.09e-114	Cognitive function;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20349687	chr2:88927127	EIF2AK3	-0.47	-6.77	-0.3	3.95e-11	Systemic lupus erythematosus;
LGG	cis	rs3096299	0.503	rs9940093	chr16:89558705	G/A	cg08392591	chr16:89556376	ANKRD11	0.64	10.29	0.43	1.7e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs17102423	0.660	rs7152277	chr14:65535391	G/C	cg11161011	chr14:65562177	MAX	-0.57	-10.77	-0.45	2.82e-24	Obesity-related traits;
LGG	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg18129748	chr3:49941408	MST1R	-0.21	-6.75	-0.3	4.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7124681	0.565	rs2904127	chr11:47817290	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg24690094	chr11:67383802	NA	-0.56	-9.3	-0.4	5.65e-19	Mean corpuscular volume;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg14092988	chr3:52407081	DNAH1	0.31	8.04	0.35	7.42e-15	Bipolar disorder;
LGG	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs737693	1.000	rs17361668	chr11:102720344	A/T	cg14995062	chr11:102826570	MMP13	0.49	6.67	0.3	7.33e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.17	0.52	6.96e-34	Bladder cancer;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg06656553	chr16:89960601	TCF25	-0.71	-6.98	-0.31	1.02e-11	Skin colour saturation;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg00149659	chr3:10157352	C3orf10	0.87	11.3	0.47	2.47e-26	Alzheimer's disease;
LGG	trans	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg19862616	chr7:65841803	NCRNA00174	0.69	7.6	0.33	1.68e-13	Mononucleosis;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07659893	chr17:61819838	STRADA	0.47	7.93	0.35	1.62e-14	Prudent dietary pattern;
LGG	cis	rs8180040	0.932	rs1038394	chr3:47464122	A/G	cg27129171	chr3:47204927	SETD2	0.78	15.08	0.57	4.31e-42	Colorectal cancer;
LGG	trans	rs1032833	0.732	rs17454150	chr2:179994361	C/T	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg20703242	chr1:230279135	GALNT2	0.36	7.48	0.33	3.7e-13	Coronary artery disease;
LGG	cis	rs4704846	1.000	rs10515746	chr5:156536568	A/C	cg12943317	chr5:156479607	HAVCR1	-0.58	-7.63	-0.33	1.37e-13	Blood protein levels;
LGG	cis	rs6496667	0.509	rs6496677	chr15:90990358	A/G	cg22089800	chr15:90895588	ZNF774	0.52	8.62	0.37	1.1e-16	Rheumatoid arthritis;
LGG	cis	rs10540	0.915	rs12419209	chr11:494510	T/C	cg03352830	chr11:487213	PTDSS2	0.87	11.24	0.46	4.51e-26	Body mass index;
LGG	cis	rs2652834	0.851	rs2652819	chr15:63431175	A/G	cg05507819	chr15:63340323	TPM1	0.52	7.36	0.32	8.38e-13	HDL cholesterol;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.06	-0.46	2.17e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs6800768	0.636	rs11916435	chr3:24092346	A/T	cg10674438	chr3:24145617	LOC152024	-0.33	-6.84	-0.3	2.55e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs71403859	0.570	rs76231867	chr16:71449926	G/A	cg08717414	chr16:71523259	ZNF19	-1.15	-13.7	-0.54	4.34e-36	Post bronchodilator FEV1;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14370961	chr14:105767520	BRF1	0.58	6.72	0.3	5.32e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg11062466	chr8:58055876	NA	0.6	9.91	0.42	3.86e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.580	rs2964249	chr5:151916766	G/T	cg12297329	chr5:152029980	NA	-0.61	-11.09	-0.46	1.68e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs11645898	0.935	rs72787094	chr16:72192613	C/A	cg14768367	chr16:72042858	DHODH	-0.8	-10.99	-0.45	4.14e-25	Blood protein levels;
LGG	cis	rs367943	0.666	rs7700413	chr5:112704435	T/C	cg12552261	chr5:112820674	MCC	0.57	10.27	0.43	1.94e-22	Type 2 diabetes;
LGG	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg20533982	chr7:158533927	ESYT2	0.62	7.78	0.34	4.75e-14	Hippocampal volume;
LGG	cis	rs4974559	0.948	rs3856982	chr4:1328863	C/T	cg02980000	chr4:1222292	CTBP1	-0.67	-10.02	-0.42	1.55e-21	Systolic blood pressure;
LGG	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.18	-0.39	1.42e-18	Vitiligo;
LGG	cis	rs9790314	0.967	rs6762645	chr3:160948349	T/G	cg04691961	chr3:161091175	C3orf57	-0.64	-15.12	-0.57	2.9e-42	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.38	-7.27	-0.32	1.55e-12	Personality dimensions;
LGG	cis	rs7666738	0.830	rs4699590	chr4:98974030	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.17e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs35110281	0.837	rs2838336	chr21:45071741	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.56	-10.05	-0.42	1.21e-21	Mean corpuscular volume;
LGG	cis	rs11252926	0.537	rs61836851	chr10:447231	T/C	cg16346588	chr10:242978	ZMYND11	0.4	6.91	0.31	1.66e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs1799949	0.965	rs11650913	chr17:41331597	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.25e-11	Menopause (age at onset);
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.58	0.41	6.04e-20	Lung cancer;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg07636037	chr3:49044803	WDR6	1.1	28.22	0.8	1.19e-102	Parkinson's disease;
LGG	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg00071950	chr4:10020882	SLC2A9	0.44	9.3	0.4	5.8e-19	Bone mineral density;
LGG	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.4e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg04455712	chr21:45112962	RRP1B	0.53	9.89	0.42	4.9e-21	Mean corpuscular volume;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.17	0.6	6.04e-47	Obesity-related traits;
LGG	cis	rs6840360	0.642	rs2709842	chr4:152370637	C/T	cg17217059	chr4:152329364	FAM160A1	-0.21	-7.25	-0.32	1.81e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3740909	1.000	rs77634170	chr11:125885731	C/T	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg04568710	chr12:38710424	ALG10B	-0.35	-7.38	-0.32	7.32e-13	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs7424096	0.613	rs111805423	chr2:37248924	G/T	cg14987922	chr2:37194071	STRN	0.45	6.67	0.3	7.18e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs10870270	0.956	rs10870293	chr10:133771413	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.51	-0.53	2.59e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs4731207	0.698	rs720615	chr7:124452706	C/T	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs875971	0.522	rs2949690	chr7:65483242	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-8.47	-0.37	3.27e-16	Aortic root size;
LGG	cis	rs1046896	0.594	rs9914570	chr17:80783721	C/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.26	-0.36	1.57e-15	Glycated hemoglobin levels;
LGG	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg12011299	chr4:100065546	ADH4	0.42	8.47	0.37	3.38e-16	Alcohol dependence;
LGG	cis	rs3733585	0.699	rs4408959	chr4:9948868	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.91	0.34	1.96e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2840044	1.000	rs225243	chr17:33947212	A/G	cg19694781	chr19:47549865	TMEM160	-0.55	-9.15	-0.39	1.89e-18	Response to radiotherapy in cancer (late toxicity);
LGG	trans	rs877282	0.945	rs34367686	chr10:791868	G/C	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs4474465	0.915	rs12794810	chr11:78212743	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.9	-0.31	1.68e-11	Alzheimer's disease (survival time);
LGG	cis	rs4720575	1.000	rs1074575	chr7:47090545	A/C	cg00036614	chr7:47093842	NA	-0.5	-9.91	-0.42	3.87e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs782590	0.608	rs10207590	chr2:55921782	G/C	cg18811423	chr2:55921094	PNPT1	-0.78	-16.41	-0.61	4.89e-48	Metabolic syndrome;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.33	0.32	1.03e-12	Prudent dietary pattern;
LGG	cis	rs2276314	1.000	rs1789513	chr18:33545630	A/G	cg05985134	chr18:33552581	C18orf21	-0.64	-10.06	-0.42	1.19e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg07549998	chr6:150325970	RAET1K	-0.35	-6.86	-0.3	2.16e-11	Alopecia areata;
LGG	cis	rs9768139	0.596	rs7812034	chr7:158115222	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.63	-0.33	1.35e-13	Calcium levels;
LGG	trans	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg26043149	chr18:55253948	FECH	0.99	17.64	0.63	1.26e-53	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg19077165	chr18:44547161	KATNAL2	0.54	9.72	0.41	1.94e-20	Personality dimensions;
LGG	cis	rs929354	0.566	rs6979947	chr7:157005863	C/T	cg17757837	chr7:157058334	UBE3C	-0.76	-13.61	-0.53	1.01e-35	Body mass index;
LGG	cis	rs5758511	0.634	rs1001587	chr22:42670111	C/T	cg15128208	chr22:42549153	NA	0.75	11.8	0.48	2.89e-28	Birth weight;
LGG	cis	rs17125944	0.615	rs2025633	chr14:53317340	C/T	cg00686598	chr14:53173677	PSMC6	-0.74	-7.75	-0.34	6.07e-14	Alzheimer's disease (late onset);
LGG	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg25885449	chr18:77638415	KCNG2	-0.34	-6.75	-0.3	4.53e-11	Schizophrenia;
LGG	cis	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg12568669	chr8:11666485	FDFT1	-0.34	-6.67	-0.3	7.11e-11	Myopia (pathological);
LGG	cis	rs4732038	0.510	rs4345502	chr7:134271015	G/C	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs1920116	0.778	rs4352416	chr3:169554084	G/A	cg00832555	chr3:169529716	LRRC34	0.38	6.68	0.3	6.97e-11	Glioma (high-grade);
LGG	cis	rs3741151	1.000	rs78433080	chr11:73067565	G/A	cg17517138	chr11:73019481	ARHGEF17	1.03	10.37	0.43	8.61e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00761968	chr13:53314142	LECT1	0.41	9.07	0.39	3.28e-18	Lewy body disease;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg05234568	chr11:5960015	NA	-0.68	-11.45	-0.47	6.9e-27	DNA methylation (variation);
LGG	cis	rs847649	0.924	rs6960428	chr7:102589706	C/G	cg18108683	chr7:102477205	FBXL13	0.62	13.5	0.53	2.99e-35	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.662	rs13108589	chr4:120268102	G/C	cg09307838	chr4:120376055	NA	0.73	12.51	0.5	3.81e-31	Corneal astigmatism;
LGG	cis	rs9513627	0.833	rs4605005	chr13:100132471	T/C	cg25919922	chr13:100150906	NA	0.82	10.35	0.43	1.01e-22	Obesity-related traits;
LGG	cis	rs2439831	0.702	rs8033995	chr15:44013509	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.51	0.4	1.04e-19	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.03	-0.6	2.48e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2905347	0.560	rs2905312	chr7:22682942	T/C	cg23521230	chr7:22704884	NA	0.4	7.14	0.31	3.71e-12	Major depression and alcohol dependence;
LGG	cis	rs6988636	1.000	rs16898095	chr8:124193523	T/C	cg23067535	chr8:124195133	FAM83A	-0.57	-6.94	-0.31	1.35e-11	Urinary uromodulin levels;
LGG	cis	rs881375	0.933	rs1548784	chr9:123685280	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.18	0.49	8.85e-30	Rheumatoid arthritis;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	17.41	0.63	1.43e-52	Platelet count;
LGG	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg06481639	chr22:41940642	POLR3H	-0.56	-7.68	-0.34	9.51e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg27411982	chr8:10470053	RP1L1	0.42	7.36	0.32	8.72e-13	Mood instability;
LGG	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-12.27	-0.5	3.79e-30	Migraine;Coronary artery disease;
LGG	cis	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg16386425	chr10:429943	DIP2C	0.46	9.07	0.39	3.46e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg12463550	chr7:65579703	CRCP	0.73	8.32	0.36	9.79e-16	Diabetic kidney disease;
LGG	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.37	-0.32	8e-13	HDL cholesterol;
LGG	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.35	-0.47	1.59e-26	Vitamin D levels;
LGG	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg15309053	chr8:964076	NA	0.34	6.86	0.3	2.19e-11	Schizophrenia;
LGG	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.16	0.39	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.27	-0.32	1.5e-12	HDL cholesterol;
LGG	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.79e-30	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg01673284	chr16:4527211	HMOX2	0.33	6.78	0.3	3.73e-11	Schizophrenia;
LGG	trans	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs34333482	1	rs34333482	chr6:116855952	A/AG	cg23085344	chr6:116937351	RSPH4A	-0.39	-6.94	-0.31	1.33e-11	Pelvic organ prolapse (moderate/severe);
LGG	cis	rs873946	0.504	rs12254034	chr10:134571007	T/C	cg27297192	chr10:134578999	INPP5A	0.32	7.63	0.33	1.39e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4891159	0.790	rs1787448	chr18:74113179	T/C	cg24786174	chr18:74118243	ZNF516	0.57	13.34	0.53	1.38e-34	Longevity;
LGG	cis	rs9611565	0.559	rs5758397	chr22:42019251	C/T	cg06634786	chr22:41940651	POLR3H	0.79	12.54	0.5	2.95e-31	Vitiligo;
LGG	cis	rs2370759	1.000	rs79442609	chr10:32608749	C/T	cg01819863	chr10:32635814	EPC1	1.11	15.48	0.58	7.4e-44	Sexual dysfunction (female);
LGG	cis	rs7617773	0.925	rs7374376	chr3:48172687	T/C	cg11946769	chr3:48343235	NME6	-0.51	-8.27	-0.36	1.38e-15	Coronary artery disease;
LGG	cis	rs7615952	0.546	rs2976733	chr3:125414138	T/C	cg21696256	chr3:125484277	NA	-0.45	-7.62	-0.33	1.49e-13	Blood pressure (smoking interaction);
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs798554	1.000	rs798544	chr7:2763102	A/G	cg27476859	chr7:2772710	GNA12	-0.42	-7.18	-0.32	2.73e-12	Height;
LGG	cis	rs28829049	0.597	rs12740975	chr1:19437923	G/A	cg13387374	chr1:19411106	UBR4	0.38	6.82	0.3	2.94e-11	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs963731	0.579	rs10177250	chr2:39334488	G/A	cg04010122	chr2:39346883	SOS1	0.76	7.84	0.34	3.14e-14	Corticobasal degeneration;
LGG	trans	rs3206736	0.575	rs75847838	chr7:35106396	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.09	0.31	5.07e-12	Diastolic blood pressure;
LGG	cis	rs28595532	0.920	rs116108618	chr4:119763585	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2798269	1.000	rs7990030	chr13:22123819	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.86e-11	PR segment;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg13395646	chr4:1353034	KIAA1530	-0.58	-9.92	-0.42	3.76e-21	Obesity-related traits;
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg17376030	chr22:41985996	PMM1	-0.47	-7.67	-0.34	1.03e-13	Vitiligo;
LGG	cis	rs9875589	0.509	rs56071023	chr3:14075920	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	9.75	0.41	1.55e-20	Ovarian reserve;
LGG	cis	rs1003719	0.788	rs4817843	chr21:38447040	C/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg26174226	chr8:58114915	NA	-0.51	-6.91	-0.31	1.61e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9467773	0.935	rs11752946	chr6:26560364	C/A	cg11502198	chr6:26597334	ABT1	0.56	9.33	0.4	4.31e-19	Intelligence (multi-trait analysis);
LGG	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg15704280	chr7:45808275	SEPT13	0.74	8.05	0.35	7.1e-15	Intraocular pressure;
LGG	cis	rs273218	0.573	rs16882051	chr5:53342979	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.96	-14.35	-0.55	6.95e-39	Migraine;
LGG	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg09818912	chr17:20140352	CYTSB	0.33	7.64	0.33	1.27e-13	Schizophrenia;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-10.06	-0.42	1.11e-21	IgG glycosylation;
LGG	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	-0.51	-8.85	-0.38	1.83e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05827058	chr17:7620372	NA	-0.41	-6.98	-0.31	1.03e-11	Pancreatic cancer;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-8.57	-0.37	1.6e-16	Menopause (age at onset);
LGG	cis	rs11771526	0.792	rs17161104	chr7:32298582	C/T	cg13207630	chr7:32358064	NA	0.58	6.64	0.3	8.54e-11	Body mass index;
LGG	cis	rs17221829	0.673	rs12364712	chr11:89373847	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.29	0.55	1.29e-38	Platelet count;
LGG	cis	rs4262150	0.672	rs1438934	chr5:152360494	C/T	cg12297329	chr5:152029980	NA	-0.55	-8.22	-0.36	2.09e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6674970	1.000	rs6676190	chr1:151079317	C/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.47	-7.09	-0.31	4.96e-12	Childhood ear infection;
LGG	cis	rs17102423	0.731	rs1957949	chr14:65542607	C/T	cg26396452	chr14:65542826	MAX	0.55	11.98	0.49	5.29e-29	Obesity-related traits;
LGG	trans	rs3779273	0.740	rs4727630	chr7:77834201	A/G	cg05596911	chr5:118502651	DMXL1	-0.49	-10.75	-0.45	3.39e-24	Body mass index;
LGG	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg21589460	chr7:45850481	NA	-0.51	-6.66	-0.3	7.73e-11	Subjective response to lithium treatment in bipolar disorder;
LGG	cis	rs9912468	0.738	rs12945884	chr17:64300281	T/C	cg19474267	chr17:64306194	PRKCA	-0.78	-17.81	-0.64	2.04e-54	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg23758822	chr17:41437982	NA	0.9	15.97	0.6	4.7e-46	Menopause (age at onset);
LGG	cis	rs2120243	0.782	rs7609926	chr3:157149160	T/C	cg01018701	chr3:157155998	VEPH1;PTX3	0.32	6.89	0.31	1.79e-11	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2377585	0.653	rs7299203	chr12:8849161	G/A	cg03761649	chr12:8850719	RIMKLB	0.46	7.78	0.34	4.84e-14	Reticulocyte fraction of red cells;
LGG	cis	rs368123	0.961	rs370413	chr6:160731321	C/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.95e-12	Waist circumference;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.67e-12	Menopause (age at onset);
LGG	cis	rs4853012	0.793	rs6723185	chr2:74344884	T/A	cg05890377	chr2:74357713	NA	0.49	9.77	0.41	1.22e-20	Gestational age at birth (maternal effect);
LGG	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg25986240	chr4:9926439	SLC2A9	-0.49	-10.56	-0.44	1.7e-23	Bone mineral density;
LGG	cis	rs490234	0.651	rs13291556	chr9:128240922	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.14	-0.43	6e-22	Mean arterial pressure;
LGG	cis	rs1801251	0.896	rs79793315	chr2:233690864	C/T	cg08000102	chr2:233561755	GIGYF2	-0.53	-8.8	-0.38	2.75e-17	Coronary artery disease;
LGG	trans	rs4924935	0.509	rs28540773	chr17:18761754	T/C	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.57	-0.33	2.01e-13	Pancreatic cancer;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.9	-0.31	1.77e-11	Lung cancer;
LGG	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.29	-0.36	1.28e-15	Total body bone mineral density;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20887711	chr4:1340912	KIAA1530	0.6	11.48	0.47	5.16e-27	Obesity-related traits;
LGG	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.78	-0.3	3.78e-11	Fear of minor pain;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg00933542	chr6:150070202	PCMT1	0.36	6.68	0.3	7.03e-11	Lung cancer;
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg03235661	chr20:60525775	NA	-0.31	-7.07	-0.31	5.59e-12	Obesity-related traits;
LGG	cis	rs745080	0.519	rs12717423	chr14:52940827	A/G	cg23333723	chr14:53022898	GPR137C	-0.41	-8.37	-0.36	6.82e-16	Orofacial clefts;
LGG	cis	rs4595586	0.545	rs12831116	chr12:39401456	C/T	cg26384229	chr12:38710491	ALG10B	0.66	11.78	0.48	3.29e-28	Morning vs. evening chronotype;
LGG	cis	rs2502399	0.898	rs774573	chr6:113512663	G/A	cg20413948	chr6:113544930	NA	0.29	6.85	0.3	2.4e-11	Plasma clusterin levels;
LGG	cis	rs12621278	0.655	rs16860643	chr2:173371278	A/G	cg15021238	chr2:173305865	ITGA6	-0.77	-8.34	-0.36	8.4e-16	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg14829155	chr15:31115871	NA	-0.67	-11.29	-0.46	2.74e-26	Huntington's disease progression;
LGG	cis	rs9463078	0.774	rs1321081	chr6:45355609	T/C	cg25276700	chr6:44698697	NA	0.38	7.67	0.34	1.05e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs614226	0.935	rs17431717	chr12:120912210	G/A	cg21053147	chr12:120880522	NA	0.59	9.01	0.39	5.58e-18	Type 1 diabetes nephropathy;
LGG	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg23029597	chr12:123009494	RSRC2	-0.93	-17.32	-0.63	3.56e-52	Body mass index;
LGG	cis	rs79349575	0.783	rs62075818	chr17:46982327	T/A	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.28	-0.32	1.42e-12	Bipolar disorder;
LGG	cis	rs17428076	0.715	rs788164	chr2:172913390	C/G	cg21435375	chr2:172878103	MAP1D	-0.41	-8.89	-0.38	1.33e-17	Myopia;
LGG	cis	rs504918	0.967	rs7634929	chr3:124076011	T/C	cg05766129	chr3:123988013	KALRN	0.38	7.08	0.31	5.48e-12	Schizophrenia;
LGG	cis	rs6088590	1.000	rs1998028	chr20:33344595	A/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.29	0.58	5.33e-43	Coronary artery disease;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.39	-0.61	5.9e-48	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-7.84	-0.34	3.11e-14	Life satisfaction;
LGG	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.41	-0.36	5.22e-16	Life satisfaction;
LGG	trans	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.68	-0.44	5.73e-24	Pursuit maintenance gain;
LGG	cis	rs28595532	0.702	rs55981733	chr4:119306600	G/A	cg21605333	chr4:119757512	SEC24D	0.78	8.51	0.37	2.37e-16	Cannabis dependence symptom count;
LGG	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg27572855	chr1:25598939	RHD	0.49	10.84	0.45	1.53e-24	Erythrocyte sedimentation rate;
LGG	cis	rs1976403	0.510	rs1697421	chr1:21823292	C/T	cg02390115	chr1:21767211	NBPF3	0.5	9.66	0.41	3.18e-20	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4639966	0.836	rs73001486	chr11:118629364	G/A	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.93	-0.31	1.4e-11	Systemic lupus erythematosus;
LGG	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg21095983	chr6:86352623	SYNCRIP	0.58	10.46	0.44	3.79e-23	Smooth-surface caries;
LGG	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg16339924	chr4:17578868	LAP3	0.61	10.63	0.44	9.08e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	trans	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg19676328	chr12:49525230	TUBA1B	-0.62	-8.21	-0.36	2.19e-15	Total cholesterol levels;
LGG	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg19784903	chr17:45786737	TBKBP1	0.34	7.13	0.31	4e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg24642439	chr20:33292090	TP53INP2	0.83	15.15	0.58	2.07e-42	Coronary artery disease;
LGG	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	Neuroticism;
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.21	-0.43	3.25e-22	Lymphocyte counts;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.74	0.57	1.32e-40	Platelet count;
LGG	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg17294928	chr15:75287854	SCAMP5	-0.56	-10.42	-0.44	5.73e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.66	0.51	9.77e-32	Motion sickness;
LGG	cis	rs17301259	0.548	rs2718339	chr7:88321687	G/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.82	-0.3	2.9e-11	Heschl's gyrus morphology;
LGG	cis	rs28735056	0.591	rs62101204	chr18:77712832	G/A	cg20368463	chr18:77673604	PQLC1	0.55	10.58	0.44	1.44e-23	Schizophrenia;
LGG	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg06360820	chr2:242988706	NA	-0.89	-11.47	-0.47	5.41e-27	Obesity-related traits;
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.27	-0.32	1.52e-12	Electroencephalogram traits;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg24503272	chr6:160210831	MRPL18;TCP1	0.4	6.75	0.3	4.32e-11	Bipolar disorder;
LGG	cis	rs4330281	0.669	rs9839588	chr3:17667278	T/C	cg20981856	chr3:17787350	NA	0.39	7.28	0.32	1.41e-12	Schizophrenia;
LGG	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1278769	1.000	rs1278769	chr13:113536627	C/T	cg00823993	chr13:113535758	ATP11A	0.58	9.18	0.39	1.48e-18	Interstitial lung disease;
LGG	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs11229555	0.645	rs7930547	chr11:58197616	A/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg23484912	chr5:273055	PDCD6	0.4	7.84	0.34	3.15e-14	Mean corpuscular volume;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg20308403	chr7:2120281	MAD1L1	0.34	7.37	0.32	7.72e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	cis	rs2274273	0.624	rs10129505	chr14:55776375	C/T	cg04306507	chr14:55594613	LGALS3	0.53	12.43	0.5	7.87e-31	Protein biomarker;
LGG	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.25	0.7	1.9e-70	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.817	rs10769598	chr11:49669326	C/G	cg15704280	chr7:45808275	SEPT13	-1.07	-25.4	-0.76	8.36e-90	Height;
LGG	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg11764359	chr7:65958608	NA	0.62	9.68	0.41	2.7e-20	Aortic root size;
LGG	cis	rs10895140	0.718	rs4636632	chr11:101516812	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs1983891	0.909	rs4714482	chr6:41528199	G/A	cg20194872	chr6:41519635	FOXP4	0.58	9.88	0.42	5.35e-21	Prostate cancer;
LGG	cis	rs4865875	1.000	rs12522199	chr5:54120218	A/C	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs1401999	0.546	rs56889301	chr3:183675315	T/C	cg01324343	chr3:183735012	ABCC5	0.85	17.44	0.63	9.97e-53	Anterior chamber depth;
LGG	cis	rs9362426	0.524	rs2296133	chr6:88032332	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	-1.09	-17.04	-0.62	6.72e-51	Depressive episodes in bipolar disorder;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.39	-7.04	-0.31	7.15e-12	Longevity;Endometriosis;
LGG	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg05484508	chr16:89589025	SPG7	0.42	6.66	0.3	7.97e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs12210905	0.920	rs9368500	chr6:27290981	A/C	cg15325629	chr6:28072465	NA	0.84	6.73	0.3	4.88e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs1566085	0.704	rs10088430	chr8:142661456	A/G	cg26331504	chr8:142652174	NA	0.29	6.98	0.31	1.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.24	-0.32	1.91e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.638	rs9973536	chr2:100942243	C/T	cg14675211	chr2:100938903	LONRF2	0.63	11.28	0.46	3.08e-26	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.0	0.35	1.03e-14	Retinal vascular caliber;
LGG	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.54	-0.44	1.94e-23	Pancreatic cancer;
LGG	cis	rs10170846	0.893	rs1447108	chr2:223542231	A/G	cg25565276	chr2:223520875	FARSB	0.65	11.02	0.46	3.05e-25	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg04861929	chr11:109293070	C11orf87	-0.49	-8.17	-0.35	2.98e-15	Schizophrenia;
LGG	trans	rs2562456	0.752	rs7258562	chr19:21514564	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.38	-0.32	7.54e-13	Pain;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg00149659	chr3:10157352	C3orf10	0.9	11.43	0.47	7.92e-27	Alzheimer's disease;
LGG	cis	rs55665837	0.540	rs4757261	chr11:14669802	C/A	cg19336497	chr11:14380999	RRAS2	-0.39	-7.42	-0.33	5.71e-13	Vitamin D levels;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.83	-0.45	1.6e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.54	-0.47	3.03e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.13	-0.31	3.86e-12	Total body bone mineral density;
LGG	cis	rs7208859	0.623	rs78071511	chr17:29128154	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35079168	0.923	rs11103473	chr9:137287629	A/T	cg00753924	chr9:137298813	RXRA	0.38	7.26	0.32	1.62e-12	Intelligence;
LGG	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2133450	0.712	rs1546237	chr3:7366674	T/C	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.64e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs875971	0.638	rs6460305	chr7:66060408	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.7	-0.45	5e-24	Aortic root size;
LGG	cis	rs2204008	0.807	rs12816136	chr12:38456037	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-8.06	-0.35	6.63e-15	Bladder cancer;
LGG	cis	rs2073499	0.935	rs2624837	chr3:50205962	A/G	cg03645007	chr3:50255295	SLC38A3	-0.63	-6.97	-0.31	1.07e-11	Schizophrenia;
LGG	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg25319279	chr11:5960081	NA	-0.55	-8.58	-0.37	1.43e-16	DNA methylation (variation);
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg02158880	chr13:53174818	NA	0.47	9.57	0.41	6.38e-20	Lewy body disease;
LGG	cis	rs9916302	0.629	rs9972882	chr17:37807698	A/C	cg00129232	chr17:37814104	STARD3	-0.73	-14.57	-0.56	7.21e-40	Glomerular filtration rate (creatinine);
LGG	cis	rs2836974	0.836	rs8129355	chr21:40579869	A/G	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08747777	chr16:65156158	CDH11	0.59	6.81	0.3	3.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg06238570	chr21:40685208	BRWD1	0.43	6.66	0.3	7.81e-11	Cognitive function;
LGG	trans	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.52	0.33	2.86e-13	Retinal vascular caliber;
LGG	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg23594656	chr7:65796392	TPST1	-0.32	-6.84	-0.3	2.49e-11	Aortic root size;
LGG	cis	rs7617773	0.815	rs9825637	chr3:48372282	T/C	cg11946769	chr3:48343235	NME6	0.64	10.68	0.44	5.98e-24	Coronary artery disease;
LGG	cis	rs11920090	0.932	rs11709140	chr3:170694497	T/C	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg14582100	chr15:45693742	SPATA5L1	0.4	6.72	0.3	5.48e-11	Homoarginine levels;
LGG	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.79	-8.91	-0.38	1.17e-17	Lung cancer in ever smokers;
LGG	cis	rs9557207	1.000	rs9582290	chr13:99936460	A/G	cg24509225	chr13:100037070	UBAC2	0.68	12.18	0.49	8.7e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	trans	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg14227996	chr4:17616232	MED28	0.75	9.21	0.39	1.1e-18	Opioid sensitivity;
LGG	trans	rs7618501	0.521	rs11130222	chr3:49901060	A/T	cg21659725	chr3:3221576	CRBN	0.6	10.54	0.44	2.03e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.46	0.33	4.46e-13	Schizophrenia;
LGG	cis	rs3806843	1.000	rs6898906	chr5:140169299	C/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs2238531	chr16:89856217	C/G	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	cis	rs7928758	0.725	rs78751202	chr11:134286609	T/C	cg22777979	chr11:134283252	B3GAT1	1.09	12.54	0.5	2.8e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.57e-22	Menopause (age at onset);
LGG	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg06521331	chr12:34319734	NA	0.52	9.55	0.41	7.28e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11792861	0.926	rs1333344	chr9:111776224	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.49	0.4	1.27e-19	Menarche (age at onset);
LGG	cis	rs897984	0.542	rs73530203	chr16:31099859	G/A	cg00531865	chr16:30841666	NA	-0.48	-9.65	-0.41	3.3e-20	Dementia with Lewy bodies;
LGG	cis	rs68170813	0.523	rs7777976	chr7:106888594	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.77	-0.45	2.82e-24	Coronary artery disease;
LGG	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.57	-0.33	2.11e-13	Total cholesterol levels;
LGG	trans	rs7618501	0.521	rs11709573	chr3:49956628	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	6.73	0.3	5.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg01631408	chr1:248437212	OR2T33	-0.55	-9.93	-0.42	3.45e-21	Common traits (Other);
LGG	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-11.98	-0.49	5.38e-29	Hemoglobin concentration;
LGG	cis	rs897984	0.609	rs732173	chr16:31050023	C/A	cg02466173	chr16:30829666	NA	-0.41	-7.09	-0.31	5.03e-12	Dementia with Lewy bodies;
LGG	cis	rs75059851	0.756	rs7106715	chr11:133838905	A/G	cg17703048	chr11:133852993	NA	0.87	16.02	0.6	2.76e-46	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15893127	chr1:153756397	NA	0.46	6.77	0.3	3.96e-11	Gut microbiome composition (summer);
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.08	-0.42	1.01e-21	Electroencephalogram traits;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg27471124	chr11:109292789	C11orf87	0.48	9.59	0.41	5.27e-20	Schizophrenia;
LGG	cis	rs67311347	1.000	rs11539046	chr3:40503809	G/A	cg24209194	chr3:40518798	ZNF619	-0.44	-6.99	-0.31	9.66e-12	Renal cell carcinoma;
LGG	cis	rs4665809	0.590	rs6749046	chr2:26429451	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.01	-0.35	9.44e-15	Neuroticism;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	11.33	0.47	2.01e-26	Obesity-related traits;
LGG	cis	rs41005	0.597	rs62104919	chr2:8101999	C/T	cg03155496	chr2:8117019	LOC339788	-0.54	-9.42	-0.4	2.2e-19	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24051152	chr8:145133159	EXOSC4	0.47	6.89	0.3	1.8e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg11062466	chr8:58055876	NA	0.43	7.04	0.31	7.15e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.663	rs9467656	chr6:25993559	G/A	cg18357526	chr6:26021779	HIST1H4A	0.49	8.15	0.35	3.43e-15	Height;
LGG	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg26248373	chr2:1572462	NA	-0.86	-14.1	-0.55	7.93e-38	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs500492	0.542	rs416055	chr16:1074931	G/A	cg08273874	chr16:1060765	NA	-0.59	-8.37	-0.36	6.67e-16	Polycystic ovary syndrome;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs2404602	0.583	rs12898415	chr15:76574232	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.01	-0.31	8.56e-12	Blood metabolite levels;
LGG	cis	rs6964587	0.869	rs6964050	chr7:91482418	C/T	cg17063962	chr7:91808500	NA	-0.4	-7.03	-0.31	7.38e-12	Breast cancer;
LGG	trans	rs9467711	0.790	rs13195401	chr6:26463574	G/T	cg01620082	chr3:125678407	NA	-0.96	-8.96	-0.38	8.02e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg18335740	chr13:41363409	SLC25A15	0.6	11.83	0.48	2.1e-28	Lewy body disease;
LGG	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg14191688	chr11:70257035	CTTN	0.55	8.04	0.35	7.81e-15	Coronary artery disease;
LGG	cis	rs13177180	0.671	rs10069695	chr5:114960963	G/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-9.64	-0.41	3.56e-20	Conotruncal heart defects (inherited effects);
LGG	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg27490568	chr2:178487706	NA	0.5	10.0	0.42	1.87e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3750082	0.754	rs35110377	chr7:32971770	C/G	cg08946731	chr7:32981826	RP9P	-0.42	-7.09	-0.31	4.9e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.46e-15	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg17971929	chr21:40555470	PSMG1	0.71	13.41	0.53	6.98e-35	Cognitive function;
LGG	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14159747	chr11:113255604	NA	0.28	7.49	0.33	3.62e-13	Neuroticism;
LGG	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg27219399	chr15:67835830	MAP2K5	0.32	7.1	0.31	4.84e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg08847335	chr10:891726	LARP4B	-0.53	-8.99	-0.39	6.21e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs10789491	1.000	rs1371834	chr1:47176894	G/A	cg15501359	chr1:47185051	KIAA0494	0.77	14.5	0.56	1.56e-39	Response to hepatitis C treatment;
LGG	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.83	-0.3	2.63e-11	Parkinson's disease;
LGG	cis	rs1355223	0.902	rs448016	chr11:34706593	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	7.1	0.31	4.8e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7493	0.901	rs2237586	chr7:95051052	G/T	cg08461772	chr7:95026248	PON3	0.36	7.63	0.33	1.39e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg25703541	chr22:24373054	LOC391322	0.94	14.21	0.55	2.82e-38	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs12422267	0.536	rs12423631	chr12:132606886	C/T	cg09764611	chr12:132620959	NA	-0.54	-7.63	-0.33	1.35e-13	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.81	-0.45	1.89e-24	Response to antipsychotic treatment;
LGG	cis	rs9398803	0.865	rs2326451	chr6:126811928	A/T	cg19875578	chr6:126661172	C6orf173	0.56	10.11	0.43	7.91e-22	Male-pattern baldness;
LGG	cis	rs2228479	0.702	rs11649501	chr16:89850957	A/T	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg26396452	chr14:65542826	MAX	0.45	8.95	0.38	8.88e-18	Obesity-related traits;
LGG	cis	rs6565180	0.962	rs6565183	chr16:30382755	T/C	cg17640201	chr16:30407289	ZNF48	-0.87	-17.75	-0.64	3.84e-54	Tonsillectomy;
LGG	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg14456004	chr13:21872349	NA	-1.13	-17.87	-0.64	1.05e-54	White matter hyperintensity burden;
LGG	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg03060546	chr3:49711283	APEH	-0.6	-8.45	-0.37	3.91e-16	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg13047869	chr3:10149882	C3orf24	0.54	8.98	0.39	6.63e-18	Alzheimer's disease;
LGG	trans	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.74	10.9	0.45	9.06e-25	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs28735056	0.904	rs12953738	chr18:77627877	A/G	cg05926928	chr17:57297772	GDPD1	0.58	9.45	0.4	1.7e-19	Schizophrenia;
LGG	cis	rs1318772	0.932	rs3763141	chr5:112896576	C/G	cg12552261	chr5:112820674	MCC	0.67	7.56	0.33	2.25e-13	F-cell distribution;
LGG	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.48	-0.33	3.74e-13	Psoriasis;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg23782820	chr8:58130467	NA	0.49	7.58	0.33	1.94e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4319547	0.695	rs6489002	chr12:122929822	T/C	cg23029597	chr12:123009494	RSRC2	-0.94	-17.17	-0.62	1.76e-51	Body mass index;
LGG	cis	rs9291683	0.509	rs10939671	chr4:10050815	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	10.06	0.42	1.12e-21	Bone mineral density;
LGG	cis	rs11191205	0.644	rs11191069	chr10:103388129	A/C	cg15320455	chr10:103880129	LDB1	-0.48	-6.9	-0.31	1.76e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13917004	chr19:42462874	RABAC1	0.51	7.77	0.34	5.18e-14	Gut microbiome composition (summer);
LGG	cis	rs748404	0.578	rs552701	chr15:43613810	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.53	7.86	0.34	2.76e-14	Lung cancer;
LGG	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs8067545	0.641	rs203457	chr17:19818338	A/C	cg13482628	chr17:19912719	NA	-0.52	-9.56	-0.41	6.9e-20	Schizophrenia;
LGG	cis	rs4720575	0.931	rs10242850	chr7:47099868	A/C	cg00036614	chr7:47093842	NA	-0.5	-9.84	-0.42	6.86e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs6754311	0.861	rs12475139	chr2:136786651	A/T	cg07169764	chr2:136633963	MCM6	0.74	12.48	0.5	5.3e-31	Mosquito bite size;
LGG	cis	rs472402	0.560	rs6874005	chr5:6624371	C/T	cg08700190	chr5:6636046	SRD5A1	-0.32	-6.88	-0.3	1.95e-11	Response to amphetamines;
LGG	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg16586182	chr3:47516702	SCAP	0.74	13.37	0.53	1.05e-34	Colorectal cancer;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.73e-21	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00040380	chr1:153963107	RPS27	0.44	7.45	0.33	4.59e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12731740	1.000	rs12404817	chr1:208004531	A/G	cg22525895	chr1:207977042	MIR29B2	-0.66	-7.48	-0.33	3.74e-13	Biomedical quantitative traits;
LGG	cis	rs7727544	0.684	rs2516788	chr5:131715565	G/C	cg24060327	chr5:131705240	SLC22A5	0.48	8.21	0.36	2.25e-15	Blood metabolite levels;
LGG	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.0	-17.13	-0.62	2.54e-51	Chronic sinus infection;
LGG	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-12.73	-0.51	5.04e-32	Extrinsic epigenetic age acceleration;
LGG	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.1	-0.39	2.77e-18	Myopia (pathological);
LGG	cis	rs367615	0.704	rs7704824	chr5:108850278	A/G	cg17395555	chr5:108820864	NA	0.81	14.8	0.57	7.24e-41	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10504130	0.569	rs71513549	chr8:52682886	C/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08280861	chr8:58055591	NA	0.61	7.76	0.34	5.32e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11134654	0.627	rs4868033	chr5:170234264	A/T	cg02091185	chr5:170288766	RANBP17	0.39	7.58	0.33	1.85e-13	Smooth-surface caries;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg09264619	chr17:80180166	NA	0.33	6.65	0.3	8.05e-11	Life satisfaction;
LGG	cis	rs10489202	1.000	rs7538581	chr1:167979347	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs67311347	0.544	rs7644181	chr3:40355665	A/G	cg13683864	chr3:40499215	RPL14	0.83	16.88	0.62	3.67e-50	Renal cell carcinoma;
LGG	trans	rs12517041	1.000	rs12519798	chr5:23290006	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs6496044	0.568	rs12708554	chr15:86074297	C/G	cg13263323	chr15:86062960	AKAP13	-0.38	-8.37	-0.36	6.68e-16	Interstitial lung disease;
LGG	cis	rs1018836	0.923	rs7840846	chr8:91565501	T/A	cg16814680	chr8:91681699	NA	-0.8	-14.73	-0.56	1.52e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg26031613	chr14:104095156	KLC1	0.59	9.4	0.4	2.62e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.647	rs61081795	chr3:17709275	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs6088580	0.634	rs6059875	chr20:33086090	T/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.6e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4737010	0.570	rs10112594	chr8:41645565	C/T	cg08923054	chr8:41654455	ANK1	0.78	13.57	0.53	1.48e-35	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg01516881	chr6:292596	DUSP22	-0.7	-11.84	-0.48	1.88e-28	Menopause (age at onset);
LGG	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg22563815	chr15:78856949	CHRNA5	-0.28	-7.15	-0.32	3.3e-12	Sudden cardiac arrest;
LGG	cis	rs9583531	0.891	rs9515270	chr13:111352073	C/T	cg24331049	chr13:111365604	ING1	-0.84	-11.43	-0.47	7.87e-27	Coronary artery disease;
LGG	cis	rs7932354	0.528	rs10769234	chr11:47084061	G/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.98	-0.42	2.23e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs2120243	0.510	rs7623173	chr3:157119949	A/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg20587970	chr11:113659929	NA	1.13	15.09	0.57	3.82e-42	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	0.965	rs8176310	chr17:41199913	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.79	-0.41	1.09e-20	Menopause (age at onset);
LGG	cis	rs17376456	0.825	rs10078941	chr5:93279029	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.32	0.4	4.59e-19	Diabetic retinopathy;
LGG	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.64	9.54	0.41	8.24e-20	Blood protein levels;
LGG	cis	rs9318086	0.578	rs75752641	chr13:24473240	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.49	9.15	0.39	1.78e-18	Myopia (pathological);
LGG	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg13385794	chr1:248469461	NA	0.43	7.55	0.33	2.41e-13	Common traits (Other);
LGG	cis	rs7086627	0.515	rs10887896	chr10:82210144	A/C	cg00277334	chr10:82204260	NA	-0.52	-12.52	-0.5	3.49e-31	Post bronchodilator FEV1;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg10053473	chr17:62856997	LRRC37A3	-0.93	-15.31	-0.58	4.27e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg06046430	chr4:77819534	ANKRD56	0.55	11.33	0.47	1.95e-26	Emphysema distribution in smoking;
LGG	cis	rs10895140	0.756	rs1939452	chr11:101506720	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	trans	rs9393777	0.720	rs35212793	chr6:26998693	T/C	cg08344181	chr3:125677491	NA	-0.58	-7.18	-0.32	2.77e-12	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.34	0.32	9.85e-13	Tonsillectomy;
LGG	trans	rs116095464	0.558	rs9312957	chr5:202194	C/T	cg09048205	chr5:1608656	LOC728613	-0.52	-8.41	-0.36	5.06e-16	Breast cancer;
LGG	cis	rs2235642	0.701	rs2281230	chr16:1601767	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.43	0.33	5.2e-13	Coronary artery disease;
LGG	cis	rs1559088	0.744	rs12972060	chr19:33537096	C/T	cg27124370	chr19:33622961	WDR88	-0.44	-6.7	-0.3	6.07e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs8030485	0.728	rs4778886	chr15:79389019	T/C	cg17916960	chr15:79447300	NA	0.51	8.43	0.36	4.4e-16	Left ventricle wall thickness;
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.59	9.83	0.42	7.45e-21	Obesity-related traits;
LGG	cis	rs4356975	0.563	rs4327554	chr4:69986408	C/T	cg27372994	chr4:70080453	UGT2B11	-0.38	-6.98	-0.31	1.02e-11	Obesity-related traits;
LGG	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.55	-10.69	-0.44	5.7e-24	Coronary artery disease;
LGG	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	8.14	0.35	3.67e-15	Cognitive test performance;
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.63	11.6	0.47	1.68e-27	Personality dimensions;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg00684032	chr4:1343700	KIAA1530	-0.5	-9.92	-0.42	3.66e-21	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg19717773	chr7:2847554	GNA12	-0.33	-6.83	-0.3	2.65e-11	Height;
LGG	trans	rs208520	0.690	rs3846808	chr6:66818604	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.97	-18.33	-0.65	8.08e-57	Exhaled nitric oxide output;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.32e-11	Lung cancer;
LGG	cis	rs7659604	0.540	rs9995322	chr4:122675642	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.08	-0.31	5.4e-12	Bipolar disorder;
LGG	cis	rs13260300	0.516	rs1834449	chr8:75552733	G/A	cg22993706	chr8:75542856	NA	0.52	11.18	0.46	7.72e-26	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs9354308	0.866	rs2814095	chr6:66535706	C/G	cg07460842	chr6:66804631	NA	0.57	9.67	0.41	2.77e-20	Metabolite levels;
LGG	cis	rs477692	0.685	rs3852507	chr10:131399616	G/T	cg05714579	chr10:131428358	MGMT	-0.62	-12.78	-0.51	2.95e-32	Response to temozolomide;
LGG	cis	rs17102423	0.594	rs942626	chr14:65550082	C/T	cg26396452	chr14:65542826	MAX	0.48	10.0	0.42	1.85e-21	Obesity-related traits;
LGG	cis	rs3790455	1.000	rs2274316	chr1:156446242	C/A	cg14087168	chr1:156450669	MEF2D	0.48	7.84	0.34	3.05e-14	Migraine;
LGG	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	trans	rs6787172	0.728	rs2362969	chr3:158128357	G/C	cg23275840	chr4:47708675	CORIN	-0.4	-8.53	-0.37	2.07e-16	Subjective well-being;
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg22168489	chr12:122356033	WDR66	0.43	9.97	0.42	2.54e-21	Mean corpuscular volume;
LGG	cis	rs7224668	0.647	rs7219382	chr17:79241097	A/G	cg03823431	chr17:79229385	SLC38A10	0.35	7.51	0.33	3.01e-13	IgG glycosylation;
LGG	cis	rs62244186	0.593	rs9814298	chr3:44871899	T/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.8	0.34	4.24e-14	Depressive symptoms;
LGG	cis	rs9487094	0.922	rs6916579	chr6:109851638	A/G	cg16315928	chr6:109776240	MICAL1	0.54	9.09	0.39	2.85e-18	Height;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.52	-9.82	-0.42	8.35e-21	Prudent dietary pattern;
LGG	cis	rs11671005	0.736	rs11668201	chr19:59003632	A/T	cg13877915	chr19:58951672	ZNF132	0.55	7.63	0.33	1.33e-13	Mean platelet volume;
LGG	cis	rs1505368	1.000	rs1505368	chr2:213297253	G/A	cg20637307	chr2:213403960	ERBB4	0.44	8.02	0.35	8.5e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs193541	0.593	rs30042	chr5:122272641	A/G	cg19412675	chr5:122181750	SNX24	0.55	8.82	0.38	2.27e-17	Glucose homeostasis traits;
LGG	cis	rs4665809	0.590	rs13019536	chr2:26526978	C/A	cg22920501	chr2:26401640	FAM59B	-0.37	-7.7	-0.34	8.34e-14	Gut microbiome composition (summer);
LGG	cis	rs4262150	0.883	rs72799150	chr5:152110686	G/A	cg12297329	chr5:152029980	NA	-0.7	-12.9	-0.51	9.38e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02645353	chr3:171393941	PLD1	-0.54	-6.7	-0.3	5.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg10845886	chr2:3471009	TTC15	0.5	9.93	0.42	3.4e-21	Neurofibrillary tangles;
LGG	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.57	0.59	2.98e-44	Total body bone mineral density;
LGG	cis	rs9358372	1.000	rs9348447	chr6:20827828	G/A	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.35	-0.58	2.8e-43	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11239187	0.530	rs11239147	chr10:45064917	T/G	cg03916630	chr10:45065415	NA	0.37	8.92	0.38	1.05e-17	Body mass index;
LGG	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs62027291	0.605	rs62030413	chr15:76878201	A/G	cg23625390	chr15:77176239	SCAPER	-0.61	-6.84	-0.3	2.57e-11	Plateletcrit;
LGG	cis	rs4660306	0.677	rs1691217	chr1:45900190	T/C	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.45	6.79	0.3	3.43e-11	Homocysteine levels;
LGG	cis	rs6430585	0.528	rs75524146	chr2:136725459	C/T	cg07169764	chr2:136633963	MCM6	1.23	22.62	0.72	7.26e-77	Corneal structure;
LGG	cis	rs853679	0.517	rs7755442	chr6:28039015	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	9.99e-14	Depression;
LGG	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg10122326	chr6:28072925	NA	0.94	7.23	0.32	1.96e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg11062466	chr8:58055876	NA	0.63	9.8	0.41	1.03e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg13010199	chr12:38710504	ALG10B	0.57	10.62	0.44	9.9899999999999993e-24	Morning vs. evening chronotype;
LGG	cis	rs2688608	0.592	rs7076585	chr10:75503692	T/C	cg19442545	chr10:75533431	FUT11	-0.44	-7.24	-0.32	1.83e-12	Inflammatory bowel disease;
LGG	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg02153584	chr22:29168773	CCDC117	0.62	8.82	0.38	2.4e-17	Lymphocyte counts;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg05602212	chr5:79703393	ZFYVE16	0.4	7.37	0.32	7.8e-13	Body mass index;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.74	0.38	4.19e-17	Rheumatoid arthritis;
LGG	cis	rs9463078	0.838	rs9395066	chr6:45095163	A/C	cg25276700	chr6:44698697	NA	-0.38	-7.86	-0.34	2.73e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg01966878	chr4:90757139	SNCA	-0.36	-7.45	-0.33	4.72e-13	Dementia with Lewy bodies;
LGG	cis	rs912057	0.671	rs1294427	chr6:6744546	T/G	cg06612196	chr6:6737390	NA	0.5	10.77	0.45	2.8e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs9858542	1.000	rs11130213	chr3:49712297	C/T	cg07274523	chr3:49395745	GPX1	0.55	8.99	0.39	6.16e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs61931739	0.782	rs451940	chr12:34196005	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.53	0.37	2.15e-16	Morning vs. evening chronotype;
LGG	cis	rs7523273	0.606	rs1474742	chr1:207976666	A/C	cg22525895	chr1:207977042	MIR29B2	0.63	12.23	0.49	5.42e-30	Schizophrenia;
LGG	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.72	0.38	5.02e-17	Neuroticism;
LGG	cis	rs870825	0.616	rs6552802	chr4:185620751	C/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg11965913	chr1:205819406	PM20D1	0.47	7.23	0.32	1.99e-12	Parkinson's disease;
LGG	cis	rs12549902	0.800	rs7825337	chr8:41507237	C/T	cg21772509	chr8:41503840	NKX6-3	0.8	16.84	0.62	5.25e-50	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.49	-8.26	-0.36	1.54e-15	Blood metabolite levels;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.22	-0.32	2.12e-12	Morning vs. evening chronotype;
LGG	cis	rs9818758	0.607	rs11706052	chr3:49064110	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs8180040	0.966	rs7651762	chr3:47470484	G/A	cg27129171	chr3:47204927	SETD2	-0.79	-15.36	-0.58	2.63e-43	Colorectal cancer;
LGG	cis	rs2404602	0.679	rs12908421	chr15:76881794	T/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.1	-0.31	4.7e-12	Blood metabolite levels;
LGG	cis	rs55883249	1.000	rs10495573	chr2:9712160	T/G	cg23886495	chr2:9695866	ADAM17	0.67	9.51	0.4	1.02e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs1493916	0.748	rs1941684	chr18:31304421	C/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.42	-0.36	4.88e-16	Life satisfaction;
LGG	cis	rs2836974	0.897	rs36113648	chr21:40555497	G/A	cg11890956	chr21:40555474	PSMG1	1.21	30.64	0.82	1.91e-113	Cognitive function;
LGG	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg00646200	chr1:148855367	NA	-0.53	-10.12	-0.43	7.29e-22	Hip geometry;
LGG	cis	rs10048158	0.530	rs8178870	chr17:64206696	T/A	cg19474267	chr17:64306194	PRKCA	0.62	12.33	0.5	2.03e-30	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs9948	0.708	rs116121826	chr2:97441914	A/G	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs910316	0.673	rs2012627	chr14:75443103	C/T	cg06637938	chr14:75390232	RPS6KL1	0.51	9.26	0.4	7.54e-19	Height;
LGG	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg05677249	chr15:77158041	SCAPER	-0.32	-6.85	-0.3	2.29e-11	Blood metabolite levels;
LGG	cis	rs2735413	0.563	rs11640933	chr16:78065607	C/T	cg04733911	chr16:78082701	NA	0.57	7.76	0.34	5.35e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3768617	0.510	rs7525917	chr1:183065406	A/G	cg15522984	chr1:182991683	LAMC1	0.45	8.91	0.38	1.21e-17	Fuchs's corneal dystrophy;
LGG	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19748678	chr4:122722346	EXOSC9	-0.55	-9.98	-0.42	2.29e-21	Type 2 diabetes;
LGG	cis	rs5769707	0.656	rs135878	chr22:50014369	T/A	cg06623630	chr22:50017776	C22orf34	-0.49	-9.84	-0.42	7.17e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	0.951	rs11680258	chr2:200996976	T/C	cg23649088	chr2:200775458	C2orf69	-0.65	-9.17	-0.39	1.53e-18	Schizophrenia;
LGG	cis	rs11098499	0.866	rs12499602	chr4:120284387	T/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs2235642	0.859	rs12599207	chr16:1606445	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	9.08	0.39	3.16e-18	Coronary artery disease;
LGG	cis	rs2742540	0.503	rs982273	chr11:8906862	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.54	-12.03	-0.49	3.55e-29	Hematocrit;
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.23e-15	Rheumatoid arthritis;
LGG	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.3	0.5	2.68e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7084402	0.967	rs1658419	chr10:60332812	A/C	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	1.9e-54	Refractive error;
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	2.03e-57	Platelet count;
LGG	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.43	7.79	0.34	4.52e-14	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.63	0.33	1.34e-13	Schizophrenia;
LGG	cis	rs1420338	0.933	rs10253869	chr7:34149922	A/G	cg01275685	chr7:34179230	BMPER	-0.46	-8.23	-0.36	1.97e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg02127607	chr17:61920694	SMARCD2	-0.46	-8.1	-0.35	4.77e-15	Prudent dietary pattern;
LGG	cis	rs10911232	0.507	rs7547953	chr1:183031641	T/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs10791097	0.608	rs12363140	chr11:130744268	A/C	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2075371	0.932	rs2598290	chr7:133987736	C/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.47	-0.37	3.27e-16	Systolic blood pressure;
LGG	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg02390115	chr1:21767211	NBPF3	0.59	11.22	0.46	5.04e-26	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.16	0.52	8.28e-34	Prudent dietary pattern;
LGG	cis	rs4538187	0.906	rs6546035	chr2:64092331	C/T	cg02541582	chr2:64069798	UGP2	0.59	14.12	0.55	6.58e-38	Systolic blood pressure;
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg17554472	chr22:41940697	POLR3H	0.47	6.95	0.31	1.21e-11	Vitiligo;
LGG	cis	rs2671245	1.000	rs2671242	chr1:56163388	A/G	cg11523071	chr1:56160889	NA	0.29	6.69	0.3	6.48e-11	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg07817883	chr1:32538562	TMEM39B	1.15	12.08	0.49	2.08e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg12708336	chr17:41446283	NA	-0.33	-7.94	-0.35	1.51e-14	Menopause (age at onset);
LGG	cis	rs2249625	0.523	rs2496501	chr6:72885364	A/G	cg27608224	chr6:72922399	RIMS1	0.32	7.23	0.32	2.05e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg27471124	chr11:109292789	C11orf87	0.48	9.04	0.39	4.18e-18	Schizophrenia;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25172604	chr17:41446521	NA	-0.29	-6.66	-0.3	7.72e-11	Menopause (age at onset);
LGG	cis	rs283228	0.605	rs673464	chr6:101728256	A/G	cg02011392	chr6:101847541	GRIK2	0.49	6.66	0.3	7.78e-11	Coenzyme Q10 levels;
LGG	cis	rs714515	0.934	rs10797996	chr1:172353311	C/T	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6489785	0.662	rs631168	chr12:121291497	T/C	cg02419362	chr12:121203948	SPPL3	-0.44	-6.85	-0.3	2.42e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.62	-0.33	1.41e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9300255	0.602	rs11057192	chr12:123693420	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	trans	rs12579753	1.000	rs12811607	chr12:82233619	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1620921	0.594	rs12176296	chr6:161266407	C/G	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.01e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg16507663	chr6:150244633	RAET1G	0.41	7.72	0.34	7e-14	Lung cancer;
LGG	cis	rs7662987	0.517	rs2602877	chr4:100039847	T/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.31e-20	Smoking initiation;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13129888	chr1:28415099	EYA3	-0.43	-7.14	-0.31	3.58e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs2303319	1.000	rs10490568	chr2:162252421	C/T	cg13806767	chr2:162164127	PSMD14	0.69	8.02	0.35	8.78e-15	Cognitive function;
LGG	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.36e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg17201900	chr20:34330562	RBM39	0.5	6.75	0.3	4.45e-11	Total cholesterol levels;
LGG	cis	rs9463078	0.874	rs2093901	chr6:45177315	C/G	cg25276700	chr6:44698697	NA	-0.39	-8.05	-0.35	6.98e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg17467752	chr17:38218738	THRA	-0.44	-7.07	-0.31	5.87e-12	Eosinophil percentage of white cells;
LGG	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg15627072	chr1:2432621	PLCH2	0.33	7.34	0.32	9.65e-13	Inflammatory bowel disease;Ulcerative colitis;
LGG	trans	rs208520	0.690	rs12198297	chr6:66714665	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.71	0.64	5.77e-54	Exhaled nitric oxide output;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23088989	chr10:38301786	ZNF33A	-0.59	-7.12	-0.31	4.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	1.000	rs116005859	chr6:27155485	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.46	-0.33	4.21e-13	Hip circumference adjusted for BMI;
LGG	cis	rs8133932	0.813	rs75761084	chr21:47057422	C/A	cg11214348	chr21:47283868	PCBP3	-0.41	-6.78	-0.3	3.6e-11	Schizophrenia;
LGG	cis	rs4891159	0.790	rs4891161	chr18:74142683	A/G	cg24786174	chr18:74118243	ZNF516	-0.64	-15.34	-0.58	3.07e-43	Longevity;
LGG	cis	rs7648466	0.551	rs12631342	chr3:46338435	G/C	cg13144783	chr3:46249795	CCR1	0.42	7.27	0.32	1.55e-12	Eotaxin levels;
LGG	cis	rs9914544	1.000	rs59682951	chr17:18800766	G/T	cg26378065	chr17:18585709	ZNF286B	0.51	9.41	0.4	2.4e-19	Educational attainment (years of education);
LGG	cis	rs2916247	0.954	rs7011377	chr8:93020588	A/C	cg10183463	chr8:93005414	RUNX1T1	0.41	8.41	0.36	5.23e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17665859	0.925	rs35475931	chr8:481500	C/G	cg17960703	chr8:356704	FBXO25	0.87	8.11	0.35	4.56e-15	Bilirubin levels;
LGG	cis	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg08250081	chr4:10125330	NA	0.67	12.3	0.5	2.7e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4849845	0.637	rs4849851	chr2:121055910	A/C	cg15425061	chr2:121036351	RALB	0.37	6.86	0.3	2.16e-11	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg08305652	chr11:111469057	NA	0.42	8.45	0.37	3.82e-16	Primary sclerosing cholangitis;
LGG	trans	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg27523141	chr10:43048294	ZNF37B	0.32	6.75	0.3	4.39e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg04025307	chr7:1156635	C7orf50	0.56	10.5	0.44	2.79e-23	Longevity;Endometriosis;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg04008888	chr11:68622739	NA	-0.55	-11.73	-0.48	5.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs988958	0.958	rs13419617	chr2:42280854	C/T	cg27428208	chr2:42229179	NA	0.39	7.05	0.31	6.51e-12	Hypospadias;
LGG	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg12856521	chr11:46389249	DGKZ	-0.41	-7.04	-0.31	7.02e-12	Leprosy;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg16606324	chr3:10149918	C3orf24	-0.53	-6.89	-0.3	1.85e-11	Alzheimer's disease;
LGG	cis	rs1577917	1.000	rs6454513	chr6:86720049	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.66	11.52	0.47	3.6e-27	Response to antipsychotic treatment;
LGG	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg12395012	chr8:11607386	GATA4	0.56	8.0	0.35	1.01e-14	Alcohol dependence;Nicotine use;
LGG	cis	rs2456568	0.548	rs7113080	chr11:93657520	G/A	cg17595323	chr11:93583763	C11orf90	-0.44	-7.83	-0.34	3.29e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg05665937	chr4:1216051	CTBP1	0.59	10.97	0.45	4.92e-25	Obesity-related traits;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.46	-0.4	1.62e-19	Neuroticism;
LGG	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg17646820	chr3:66848679	NA	-0.52	-8.23	-0.36	1.85e-15	Type 2 diabetes;
LGG	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg17809284	chr5:56205270	C5orf35	0.67	10.05	0.42	1.28e-21	Initial pursuit acceleration;
LGG	cis	rs2415984	0.500	rs12323609	chr14:46976023	C/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.0	-0.42	1.84e-21	Number of children ever born;
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs68170813	0.559	rs12536603	chr7:107002573	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.33	-0.43	1.19e-22	Coronary artery disease;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.36	0.32	8.32e-13	Schizophrenia;
LGG	cis	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg12486710	chr1:178512616	C1orf220	-0.42	-8.39	-0.36	5.99e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17554472	chr22:41940697	POLR3H	-0.47	-6.67	-0.3	7.28e-11	Vitiligo;
LGG	cis	rs2153535	0.563	rs6942177	chr6:8534460	A/G	cg23788917	chr6:8435910	SLC35B3	-0.51	-8.52	-0.37	2.24e-16	Motion sickness;
LGG	cis	rs6952808	0.500	rs3778996	chr7:2177190	G/A	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.7	-0.41	2.3e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs1775715	0.737	rs2151047	chr10:32102110	G/A	cg14930904	chr10:32216787	ARHGAP12	0.35	6.77	0.3	3.8e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg25072359	chr17:41440525	NA	-0.5	-9.96	-0.42	2.56e-21	Menopause (age at onset);
LGG	cis	rs12476592	0.571	rs7606045	chr2:63826528	T/G	cg17519650	chr2:63277830	OTX1	-0.43	-6.88	-0.3	1.93e-11	Childhood ear infection;
LGG	trans	rs11098499	1.000	rs28419773	chr4:120211061	T/C	cg25214090	chr10:38739885	LOC399744	0.65	11.65	0.48	1.09e-27	Corneal astigmatism;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs7095944	0.583	rs12218394	chr10:126480591	G/C	cg08799069	chr10:126477246	METTL10	-0.48	-10.78	-0.45	2.44e-24	Asthma;
LGG	cis	rs9300255	0.537	rs2682429	chr12:123642955	C/G	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs765787	0.530	rs11636440	chr15:45535982	C/T	cg25801113	chr15:45476975	SHF	0.87	19.83	0.68	8.06e-64	Uric acid levels;
LGG	cis	rs36051895	0.623	rs7043634	chr9:5263146	G/A	cg02405213	chr9:5042618	JAK2	-0.75	-13.69	-0.54	4.61e-36	Pediatric autoimmune diseases;
LGG	cis	rs9902453	0.904	rs7218379	chr17:28402737	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.7	-13.81	-0.54	1.44e-36	Coffee consumption (cups per day);
LGG	cis	rs2115630	1.000	rs7183401	chr15:85371944	G/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.78	-0.3	3.67e-11	P wave terminal force;
LGG	cis	rs599083	0.793	rs314750	chr11:68182028	G/A	cg16797656	chr11:68205561	LRP5	-0.52	-9.52	-0.4	9.66e-20	Bone mineral density (spine);
LGG	cis	rs2708977	0.965	rs13019986	chr2:97243058	C/T	cg01950434	chr2:97203154	ARID5A	0.57	9.22	0.39	1.04e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12681288	0.723	rs12545453	chr8:970582	C/T	cg15309053	chr8:964076	NA	0.39	8.31	0.36	1.09e-15	Schizophrenia;
LGG	cis	rs875971	0.830	rs28714531	chr7:65968237	G/A	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.2e-20	Aortic root size;
LGG	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9443645	0.901	rs9361480	chr6:79724429	C/T	cg18132916	chr6:79620363	NA	-0.26	-7.22	-0.32	2.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg03806693	chr22:41940476	POLR3H	-0.98	-17.44	-0.63	1.01e-52	Vitiligo;
LGG	cis	rs377457	0.718	rs4843588	chr16:85742699	G/A	cg08768472	chr16:85689701	KIAA0182	0.43	8.02	0.35	8.86e-15	Type 2 diabetes;
LGG	trans	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg05059571	chr16:84539110	KIAA1609	0.53	10.02	0.42	1.61e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9467773	1.000	rs6926629	chr6:26499903	T/C	cg09904177	chr6:26538194	HMGN4	0.77	17.32	0.63	3.61e-52	Intelligence (multi-trait analysis);
LGG	cis	rs1927702	0.577	rs7849380	chr9:15811980	T/G	cg14451791	chr9:16040625	NA	0.31	7.66	0.34	1.13e-13	Body mass index;
LGG	cis	rs9400467	0.537	rs12210707	chr6:111538387	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.14	0.31	3.67e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs12410462	0.551	rs1923821	chr1:227862055	G/T	cg23173402	chr1:227635558	NA	0.35	6.8	0.3	3.19e-11	Major depressive disorder;
LGG	cis	rs12310956	0.532	rs1352209	chr12:33983408	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.23	-0.46	4.79e-26	Morning vs. evening chronotype;
LGG	cis	rs9309473	1.000	rs3813227	chr2:73651967	A/G	cg20560298	chr2:73613845	ALMS1	0.45	7.49	0.33	3.5e-13	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06555490	chr5:148931367	CSNK1A1	0.51	7.42	0.33	5.69e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg00919237	chr7:87102261	ABCB4	-0.79	-15.94	-0.6	6.7e-46	Gallbladder cancer;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs4788570	0.566	rs16972808	chr16:71478717	A/G	cg06353428	chr16:71660113	MARVELD3	-1.01	-13.65	-0.54	7.09e-36	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg19761014	chr17:28927070	LRRC37B2	-0.65	-8.11	-0.35	4.42e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2180341	0.920	rs9401951	chr6:127671632	A/C	cg24812749	chr6:127587940	RNF146	0.99	16.3	0.6	1.56e-47	Breast cancer;
LGG	cis	rs209489	1.000	rs209489	chr6:53177678	A/C	cg15607103	chr6:53167650	ELOVL5	0.53	7.54	0.33	2.48e-13	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg03733263	chr8:22462867	KIAA1967	-0.93	-20.61	-0.69	1.96e-67	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg06640241	chr16:89574553	SPG7	0.94	18.09	0.64	1.07e-55	Multiple myeloma (IgH translocation);
LGG	cis	rs8180040	0.629	rs7426969	chr3:47091355	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.32e-42	Colorectal cancer;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg02275930	chr1:2372054	NA	-0.86	-17.0	-0.62	1.06e-50	Non-obstructive azoospermia;
LGG	cis	rs714515	0.900	rs4916252	chr1:172354017	T/C	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4595586	0.566	rs11615585	chr12:39409351	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.49	0.33	3.42e-13	Morning vs. evening chronotype;
LGG	cis	rs7191439	0.518	rs4238679	chr16:88742688	G/C	cg27087555	chr16:88793112	FAM38A	-1.23	-11.72	-0.48	6.1e-28	Plateletcrit;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg23188684	chr11:67383651	NA	0.51	8.6	0.37	1.25e-16	Mean corpuscular volume;
LGG	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg07435449	chr11:120005650	TRIM29	0.71	13.24	0.52	3.78e-34	Stroke (pediatric);
LGG	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.33	-0.36	9.5e-16	Aortic root size;
LGG	trans	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.38	0.36	6.53e-16	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg27532560	chr4:187881888	NA	-0.61	-12.84	-0.51	1.74e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6032067	0.866	rs6104054	chr20:43822771	C/T	cg10761708	chr20:43804764	PI3	0.57	8.8	0.38	2.79e-17	Blood protein levels;
LGG	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg07382826	chr16:28625726	SULT1A1	-0.4	-8.15	-0.35	3.51e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9287719	0.967	rs7563894	chr2:10754649	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg09830162	chr16:1889614	FAHD1;C16orf73	0.51	7.65	0.34	1.16e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg05973401	chr12:123451056	ABCB9	0.5	7.54	0.33	2.57e-13	Neutrophil percentage of white cells;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs3749237	0.964	rs2352967	chr3:49871641	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.2	0.39	1.26e-18	Resting heart rate;
LGG	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg18876405	chr7:65276391	NA	-0.6	-11.4	-0.47	1.01e-26	Aortic root size;
LGG	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.96	-0.38	7.75e-18	Mood instability;
LGG	cis	rs7659604	0.702	rs6815790	chr4:122695385	A/C	cg05802129	chr4:122689817	NA	-0.4	-6.87	-0.3	2.09e-11	Type 2 diabetes;
LGG	cis	rs4917300	0.606	rs5003835	chr8:143103240	C/G	cg06573787	chr8:143070187	NA	0.59	9.96	0.42	2.7e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs4889911	0.544	rs2650254	chr17:77833655	A/G	cg07923794	chr17:77834237	NA	-0.84	-12.35	-0.5	1.68e-30	Electroencephalogram traits;
LGG	cis	rs11229555	0.645	rs12290089	chr11:58176849	A/G	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg18876405	chr7:65276391	NA	0.55	9.84	0.42	7.35e-21	Aortic root size;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg01114163	chr5:1856713	NA	-0.41	-7.16	-0.32	3.15e-12	Cardiovascular disease risk factors;
LGG	cis	rs3540	0.533	rs937793	chr15:91053583	A/G	cg22089800	chr15:90895588	ZNF774	-0.67	-11.64	-0.48	1.19e-27	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs7267979	0.844	rs6115188	chr20:25432170	G/T	cg06421707	chr20:25228305	PYGB	0.43	9.06	0.39	3.77e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg13010199	chr12:38710504	ALG10B	0.69	13.78	0.54	1.94e-36	Bladder cancer;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.44	0.33	4.97e-13	Schizophrenia;
LGG	cis	rs7928758	0.708	rs11223785	chr11:134275986	G/A	cg15243474	chr11:134282918	B3GAT1	0.86	12.61	0.51	1.51e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs710216	0.571	rs11210772	chr1:43448499	A/G	cg03128534	chr1:43423976	SLC2A1	-0.41	-7.06	-0.31	6.16e-12	Red cell distribution width;
LGG	cis	rs17253792	0.915	rs76957332	chr14:56195370	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-9.95	-0.42	2.81e-21	Putamen volume;
LGG	cis	rs929354	0.772	rs3802124	chr7:156970609	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.08e-13	Prudent dietary pattern;
LGG	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg23173402	chr1:227635558	NA	0.68	10.02	0.42	1.55e-21	Major depressive disorder;
LGG	cis	rs2470578	0.792	rs2470577	chr3:17313311	A/G	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg12016809	chr21:47604291	C21orf56	0.6	10.01	0.42	1.78e-21	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs4651140	chr1:183096952	G/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg12623918	chr2:306882	NA	0.53	9.93	0.42	3.28e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg16141378	chr3:129829833	LOC729375	-0.39	-9.02	-0.39	5.21e-18	Neuroticism;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg12070911	chr6:150209640	RAET1E	0.28	6.9	0.31	1.7e-11	Lung cancer;
LGG	cis	rs62238980	0.614	rs12160688	chr22:32554996	C/T	cg00543991	chr22:32367038	NA	0.75	8.27	0.36	1.42e-15	Childhood ear infection;
LGG	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.94e-18	Fuchs's corneal dystrophy;
LGG	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.02	0.35	8.99e-15	Coronary artery disease;
LGG	cis	rs1707322	0.721	rs10430124	chr1:46221617	C/T	cg03146154	chr1:46216737	IPP	0.58	11.22	0.46	5.38e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04573475	chr1:227127449	CABC1	0.4	7.17	0.32	3e-12	Obesity-related traits;
LGG	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg16141378	chr3:129829833	LOC729375	-0.44	-10.75	-0.45	3.31e-24	Mood instability;
LGG	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-11.05	-0.46	2.39e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs796364	0.951	rs7565005	chr2:201013277	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.63	-8.31	-0.36	1.1e-15	Schizophrenia;
LGG	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg16339924	chr4:17578868	LAP3	-0.53	-8.82	-0.38	2.29e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15139222	chr18:34409401	KIAA1328;C18orf10	0.4	6.81	0.3	2.97e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg26384229	chr12:38710491	ALG10B	0.67	12.11	0.49	1.57e-29	Resting heart rate;
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs7928758	0.887	rs75474440	chr11:134267092	C/T	cg15243474	chr11:134282918	B3GAT1	1.25	16.27	0.6	2.09e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg05313129	chr8:58192883	C8orf71	-0.83	-12.35	-0.5	1.81e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8077889	1.000	rs2880329	chr17:41866168	T/A	cg26893861	chr17:41843967	DUSP3	0.96	16.42	0.61	4.22e-48	Triglycerides;
LGG	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-12.12	-0.49	1.44e-29	Morning vs. evening chronotype;
LGG	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.88	-16.64	-0.61	4.5e-49	Height;
LGG	trans	rs9291683	0.526	rs6827785	chr4:10018205	C/T	cg26043149	chr18:55253948	FECH	0.41	6.72	0.3	5.42e-11	Bone mineral density;
LGG	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg13902645	chr11:5959945	NA	0.73	12.92	0.51	7.75e-33	DNA methylation (variation);
LGG	cis	rs17376456	0.877	rs9314095	chr5:93425495	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-10.08	-0.42	9.4e-22	Diabetic retinopathy;
LGG	cis	rs2133450	0.745	rs9311986	chr3:7369342	C/G	cg19930620	chr3:7340148	GRM7	0.35	7.64	0.33	1.26e-13	Early response to risperidone in schizophrenia;
LGG	cis	rs4789452	1.000	rs11658815	chr17:75375881	G/A	cg06761530	chr17:75373219	SEPT9	-0.38	-7.3	-0.32	1.23e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs4474465	0.790	rs4945293	chr11:78254554	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.13e-11	Alzheimer's disease (survival time);
LGG	cis	rs6540556	0.724	rs6679631	chr1:209935491	C/A	cg23920097	chr1:209922102	NA	-0.45	-8.0	-0.35	1.01e-14	Red blood cell count;
LGG	cis	rs1978968	0.957	rs2053601	chr22:18448605	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs3806843	0.735	rs801167	chr5:140081423	A/G	cg19875535	chr5:140030758	IK	0.57	11.87	0.48	1.5e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg26378065	chr17:18585709	ZNF286B	0.4	7.53	0.33	2.75e-13	Educational attainment (years of education);
LGG	cis	rs2242116	0.727	rs7635480	chr3:46968227	T/C	cg27129171	chr3:47204927	SETD2	0.63	10.62	0.44	1.01e-23	Birth weight;
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs3806843	0.576	rs155359	chr5:140315425	G/T	cg19875535	chr5:140030758	IK	0.38	7.49	0.33	3.41e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9682041	0.932	rs1525362	chr3:170070702	C/T	cg11886554	chr3:170076028	SKIL	0.84	10.87	0.45	1.11e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs72945132	0.882	rs12099016	chr11:70195161	C/G	cg13802316	chr11:70253460	CTTN	-0.57	-7.39	-0.32	6.77e-13	Coronary artery disease;
LGG	cis	rs35740288	0.731	rs2344440	chr15:86161565	T/C	cg07943548	chr15:86304357	KLHL25	-0.32	-6.66	-0.3	7.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs644799	0.601	rs7902	chr11:95565288	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.71	12.78	0.51	2.9e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9487051	0.735	rs419106	chr6:109520067	C/G	cg21918786	chr6:109611834	NA	-0.41	-7.59	-0.33	1.82e-13	Reticulocyte fraction of red cells;
LGG	cis	rs2243480	1.000	rs34529418	chr7:65403209	A/G	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs6714710	0.580	rs57681139	chr2:98454473	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg00800038	chr16:89945340	TCF25	-0.67	-8.87	-0.38	1.55e-17	Skin colour saturation;
LGG	cis	rs9906944	0.707	rs8068981	chr17:47122525	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.95	-0.31	1.29e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs503734	0.666	rs2553416	chr3:101095727	C/G	cg27318481	chr3:100970896	IMPG2	-0.36	-7.22	-0.32	2.11e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg11812906	chr14:75593930	NEK9	-0.47	-8.63	-0.37	1.01e-16	Height;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg06719900	chr11:109292894	C11orf87	-0.76	-15.48	-0.58	7.57e-44	Schizophrenia;
LGG	cis	rs9976767	0.932	rs28371062	chr21:43828267	C/T	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.88	-0.42	5.02e-21	Type 1 diabetes;
LGG	cis	rs4474465	0.850	rs7111004	chr11:78269961	G/A	cg27205649	chr11:78285834	NARS2	0.51	8.81	0.38	2.62e-17	Alzheimer's disease (survival time);
LGG	cis	rs9783347	1.000	rs9783386	chr11:18386625	G/A	cg03595886	chr11:18357587	GTF2H1	-0.35	-6.89	-0.3	1.82e-11	Pancreatic cancer;
LGG	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs9976767	0.637	rs11909930	chr21:43822200	C/A	cg23042151	chr21:43824109	UBASH3A	-0.62	-13.04	-0.52	2.42e-33	Type 1 diabetes;
LGG	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg00198680	chr16:28758506	NA	0.3	7.4	0.33	6.68e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11239187	0.523	rs994179	chr10:45103362	A/G	cg03916630	chr10:45065415	NA	0.42	7.71	0.34	7.93e-14	Body mass index;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11162385	chr20:25604740	NANP	0.39	7.16	0.32	3.22e-12	Obesity-related traits;
LGG	cis	rs9814567	1.000	rs9826496	chr3:134224437	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.29	-0.53	2.3e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs992157	0.731	rs1399132	chr2:219159770	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.15	0.43	5.22e-22	Colorectal cancer;
LGG	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg05985134	chr18:33552581	C18orf21	0.64	10.18	0.43	4.15e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg08621203	chr6:150244597	RAET1G	-0.42	-7.15	-0.32	3.49e-12	Lung cancer;
LGG	trans	rs17685	0.753	rs4732542	chr7:75663203	A/G	cg19862616	chr7:65841803	NCRNA00174	1.05	25.18	0.76	8.84e-89	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4788570	0.655	rs2133773	chr16:71812296	A/G	cg06353428	chr16:71660113	MARVELD3	1.27	19.29	0.67	2.8e-61	Intelligence (multi-trait analysis);
LGG	cis	rs7463659	0.935	rs7844624	chr8:135433894	T/C	cg17885191	chr8:135476712	NA	-0.42	-7.29	-0.32	1.33e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8078723	0.677	rs11658328	chr17:38149236	T/C	cg17467752	chr17:38218738	THRA	-0.62	-11.2	-0.46	6e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs4865875	0.901	rs10073721	chr5:54097575	C/T	cg22421804	chr5:54100067	NA	0.5	7.28	0.32	1.45e-12	Sense of smell;
LGG	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg01194073	chr14:101175302	NA	0.44	6.8	0.3	3.19e-11	Plateletcrit;
LGG	cis	rs9547996	0.879	rs9547986	chr13:38203982	C/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.86	-0.3	2.21e-11	Diastolic blood pressure;
LGG	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22857025	chr5:266934	NA	-1.54	-25.08	-0.76	2.55e-88	Breast cancer;
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.06	-0.31	6.2e-12	Life satisfaction;
LGG	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg21427119	chr20:30132790	HM13	-0.59	-9.12	-0.39	2.33e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.81	-0.41	8.85e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs4538187	1.000	rs6546030	chr2:64071651	G/A	cg19915305	chr2:64069682	UGP2	0.68	15.12	0.57	3e-42	Systolic blood pressure;
LGG	trans	rs1814175	0.817	rs28525029	chr11:50045815	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.85	-0.48	1.77e-28	Height;
LGG	cis	rs17221829	0.932	rs10830358	chr11:89452943	T/A	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.55	-0.33	2.38e-13	Anxiety in major depressive disorder;
LGG	cis	rs11997175	0.520	rs6994803	chr8:33817796	A/G	ch.8.33884649F	chr8:33765107	NA	0.37	7.02	0.31	8.07e-12	Body mass index;
LGG	cis	rs67478160	0.643	rs11847468	chr14:104220295	G/A	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.8e-13	Schizophrenia;
LGG	cis	rs7172689	0.908	rs7175701	chr15:81558623	T/C	cg11808699	chr15:81528661	IL16	-0.47	-9.87	-0.42	5.44e-21	Inattentive symptoms;
LGG	cis	rs62025270	0.632	rs62023935	chr15:86148835	G/A	cg25843651	chr15:86329602	KLHL25	0.54	8.14	0.35	3.78e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs28830936	1.000	rs17678138	chr15:42043067	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.94	-0.52	6.71e-33	Diastolic blood pressure;
LGG	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg08847533	chr14:75593920	NEK9	-0.54	-9.98	-0.42	2.27e-21	Height;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg19223190	chr17:80058835	NA	0.44	8.47	0.37	3.16e-16	Life satisfaction;
LGG	cis	rs1801251	0.727	rs35853577	chr2:233558879	T/C	cg25237894	chr2:233734115	C2orf82	0.51	9.41	0.4	2.28e-19	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.42	0.56	3.26e-39	Lung cancer;
LGG	cis	rs782590	0.533	rs2008040	chr2:55687290	G/C	cg18811423	chr2:55921094	PNPT1	0.67	12.61	0.51	1.51e-31	Metabolic syndrome;
LGG	cis	rs2731664	0.819	rs449351	chr5:176872591	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-12.78	-0.51	3.08e-32	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.75	0.41	1.46e-20	Obesity-related traits;
LGG	cis	rs7474896	0.583	rs11011341	chr10:37998500	G/A	cg25427524	chr10:38739819	LOC399744	-0.46	-7.18	-0.32	2.8e-12	Obesity (extreme);
LGG	cis	rs1620921	0.505	rs66496533	chr6:161210741	T/C	cg01280913	chr6:161186852	NA	-0.49	-9.91	-0.42	4.13e-21	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7215564	0.908	rs35884143	chr17:78656043	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.21	-0.36	2.15e-15	Myopia (pathological);
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.88	-0.34	2.3e-14	Height;
LGG	cis	rs367943	0.965	rs458044	chr5:112797779	A/G	cg27587195	chr5:112824172	MCC	-0.46	-7.42	-0.33	5.55e-13	Type 2 diabetes;
LGG	cis	rs10949834	1.000	rs11760714	chr7:73482701	A/G	cg07137043	chr7:73588983	EIF4H	-0.67	-7.37	-0.32	7.67e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs7166081	1.000	rs12911370	chr15:67546321	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.11	-0.31	4.39e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6860806	0.531	rs272887	chr5:131665713	A/G	cg07395648	chr5:131743802	NA	-0.48	-9.87	-0.42	5.44e-21	Breast cancer;
LGG	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg09165964	chr15:75287851	SCAMP5	0.52	9.51	0.4	1.05e-19	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg09085632	chr11:111637200	PPP2R1B	1.03	19.94	0.68	2.51e-64	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg08862035	chr2:2617432	NA	0.42	6.91	0.31	1.62e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16405210	chr4:1374714	KIAA1530	-0.54	-9.32	-0.4	4.95e-19	Obesity-related traits;
LGG	cis	rs2549003	0.966	rs2070730	chr5:131819800	G/A	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs3845702	0.736	rs3845701	chr2:180826781	A/G	cg01881094	chr2:180872142	CWC22	-1.25	-16.82	-0.62	7.03e-50	Schizophrenia;
LGG	trans	rs7944735	0.507	rs10838802	chr11:48102478	A/G	cg03929089	chr4:120376271	NA	0.67	9.7	0.41	2.27e-20	Intraocular pressure;
LGG	cis	rs2251381	0.750	rs8129616	chr21:30520085	C/T	cg24692254	chr21:30365293	RNF160	-0.81	-16.74	-0.61	1.58e-49	Selective IgA deficiency;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg25172604	chr17:41446521	NA	-0.31	-6.96	-0.31	1.16e-11	Menopause (age at onset);
LGG	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg02297831	chr4:17616191	MED28	0.47	8.27	0.36	1.43e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	trans	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg25214090	chr10:38739885	LOC399744	-0.51	-9.39	-0.4	2.69e-19	Corneal astigmatism;
LGG	cis	rs7927592	0.645	rs7950900	chr11:68293545	G/A	cg20283391	chr11:68216788	NA	-0.4	-6.83	-0.3	2.69e-11	Total body bone mineral density;
LGG	cis	rs936229	0.749	rs6495126	chr15:75175026	C/T	cg14664628	chr15:75095509	CSK	0.88	17.81	0.64	2e-54	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2905347	0.757	rs2961295	chr7:22696272	C/T	cg18045685	chr7:22629474	NA	0.65	13.72	0.54	3.58e-36	Major depression and alcohol dependence;
LGG	cis	rs365132	1.000	rs353493	chr5:176432585	T/C	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	trans	rs2282526	0.615	rs463738	chr21:44921166	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.61	-10.03	-0.42	1.43e-21	Mean corpuscular hemoglobin;
LGG	cis	rs1790761	0.868	rs872375	chr11:67205978	G/A	cg14500267	chr11:67383377	NA	-0.38	-6.91	-0.31	1.61e-11	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs6489785	0.710	rs2393717	chr12:121220375	G/C	cg02419362	chr12:121203948	SPPL3	0.58	9.95	0.42	2.99e-21	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504073	0.631	rs341813	chr8:50039916	T/C	cg00325661	chr8:49890786	NA	0.68	13.29	0.53	2.28e-34	Blood metabolite ratios;
LGG	cis	rs12908161	0.920	rs12904605	chr15:85201419	T/C	cg24253500	chr15:84953950	NA	0.42	7.07	0.31	5.92e-12	Schizophrenia;
LGG	cis	rs12479254	0.537	rs7572476	chr2:242496325	C/T	cg24828208	chr2:242500484	BOK	-0.35	-8.73	-0.38	4.52e-17	Brain structure;
LGG	cis	rs3820928	0.904	rs2894623	chr2:227766112	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.29	-0.32	1.36e-12	Pulmonary function;
LGG	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg24189917	chr7:1970923	MAD1L1	-0.54	-8.11	-0.35	4.63e-15	Bipolar disorder;
LGG	cis	rs2404602	1.000	rs11072603	chr15:76881138	G/T	cg26408565	chr15:76604113	ETFA	-0.38	-6.68	-0.3	6.76e-11	Blood metabolite levels;
LGG	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg22633769	chr20:60982531	CABLES2	0.5	6.89	0.3	1.83e-11	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg14926445	chr8:58193284	C8orf71	-0.82	-10.29	-0.43	1.71e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs116927879	1.000	rs116927879	chr7:45864727	G/A	cg26437564	chr7:45808727	SEPT13	0.73	9.26	0.4	7.5e-19	Subjective response to lithium treatment in bipolar disorder;
LGG	cis	rs7551222	0.752	rs885012	chr1:204544001	C/A	cg20240347	chr1:204465584	NA	-0.56	-11.18	-0.46	7.16e-26	Schizophrenia;
LGG	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6594499	0.872	rs6880351	chr5:110451664	C/G	cg04022379	chr5:110408740	TSLP	0.39	7.23	0.32	2.07e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10089	1.000	rs10060390	chr5:127452947	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs13082711	0.911	rs74279676	chr3:27512944	G/A	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.22e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9596863	0.808	rs9596844	chr13:54302585	G/A	ch.13.53330881F	chr13:54432880	NA	0.5	6.71	0.3	5.62e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg02269571	chr22:50332266	NA	-0.65	-9.71	-0.41	2.12e-20	Schizophrenia;
LGG	cis	rs11690935	0.569	rs62183770	chr2:172838117	C/G	cg13550731	chr2:172543902	DYNC1I2	0.63	12.18	0.49	8.16e-30	Schizophrenia;
LGG	cis	rs7923609	1.000	rs4310508	chr10:65138573	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.98e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2224391	0.628	rs2753232	chr6:5250765	G/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-7.46	-0.33	4.35e-13	Height;
LGG	trans	rs7395662	1.000	rs11039821	chr11:48562875	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.28e-13	HDL cholesterol;
LGG	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg08344181	chr3:125677491	NA	-0.84	-8.16	-0.35	3.28e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.59	-0.41	5.41e-20	Neuroticism;
LGG	cis	rs7166081	1.000	rs4776917	chr15:67600344	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.22	-0.32	2.1e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg08125733	chr17:73851984	WBP2	0.96	15.6	0.59	2.25e-44	Psoriasis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06399148	chr8:104153148	BAALC;C8orf56	0.63	7.33	0.32	1.05e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg07085476	chr11:82867879	PCF11	0.4	6.87	0.3	2.09e-11	Bilirubin levels;
LGG	cis	rs10504073	0.584	rs10504070	chr8:49978554	A/G	cg00325661	chr8:49890786	NA	-0.76	-14.85	-0.57	4.63e-41	Blood metabolite ratios;
LGG	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg11764359	chr7:65958608	NA	0.63	10.95	0.45	5.58e-25	Aortic root size;
LGG	trans	rs1493916	0.748	rs2040203	chr18:31307420	G/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.47	-0.47	5.84e-27	Life satisfaction;
LGG	cis	rs9633740	1.000	rs6586028	chr10:82253984	C/T	cg01528321	chr10:82214614	TSPAN14	1.05	16.47	0.61	2.74e-48	Post bronchodilator FEV1;
LGG	cis	rs778371	0.697	rs2344611	chr2:233581937	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	10.56	0.44	1.74e-23	Schizophrenia;
LGG	cis	rs13040088	1.000	rs12480870	chr20:61543606	A/C	cg23096297	chr20:61557774	DIDO1	0.88	12.4	0.5	1.14e-30	Menopause (age at onset);
LGG	cis	rs7223966	0.921	rs6504186	chr17:61863932	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.68	-0.34	9.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs11690935	0.632	rs2292816	chr2:172586714	G/C	cg13550731	chr2:172543902	DYNC1I2	0.71	14.53	0.56	1.17e-39	Schizophrenia;
LGG	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	cis	rs12912251	1.000	rs2172835	chr15:38990171	C/T	cg01338139	chr15:38987640	C15orf53	-0.52	-7.8	-0.34	4.25e-14	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs2439831	0.618	rs8023508	chr15:44176103	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.67	-8.24	-0.36	1.83e-15	Lung cancer in ever smokers;
LGG	cis	rs60180747	0.909	rs79981875	chr15:66801662	T/C	cg07575407	chr15:66541975	MEGF11	0.39	7.29	0.32	1.33e-12	Testicular germ cell tumor;
LGG	trans	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08862035	chr2:2617432	NA	0.43	6.97	0.31	1.12e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs62244186	0.748	rs13319803	chr3:44635461	G/A	cg02073558	chr3:44770973	ZNF501	0.7	13.01	0.52	3.28e-33	Depressive symptoms;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-8.79	-0.38	2.99e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs300703	0.542	rs300697	chr2:184496	C/T	cg21211680	chr2:198530	NA	-1.16	-18.8	-0.66	5.27e-59	Blood protein levels;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.58e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.830	rs28515641	chr4:98726419	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6568686	0.786	rs4458728	chr6:111840562	A/C	cg21044968	chr6:111895086	TRAF3IP2	0.47	7.8	0.34	4.23e-14	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs847577	0.630	rs11764933	chr7:97825188	G/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.71	-0.3	5.83e-11	Breast cancer;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.72	-0.3	5.2e-11	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05663655	chr7:107532014	DLD	0.45	6.96	0.31	1.2e-11	Gut microbiome composition (summer);
LGG	cis	rs10484885	0.878	rs72921916	chr6:90555990	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.6	-0.44	1.22e-23	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6840360	0.571	rs55808836	chr4:152554991	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2992756	0.562	rs11261022	chr1:18807953	C/A	cg04846421	chr1:18800208	NA	-0.43	-7.7	-0.34	8.53e-14	Breast cancer;
LGG	trans	rs78049276	0.512	rs6855875	chr4:148402737	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.63	-9.77	-0.41	1.23e-20	Pulse pressure;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs12478296	0.581	rs56142391	chr2:242992248	C/T	cg06360820	chr2:242988706	NA	-0.94	-12.27	-0.5	3.77e-30	Obesity-related traits;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.5	0.4	1.11e-19	Longevity;
LGG	cis	rs9326248	0.559	rs484646	chr11:116732856	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.56	0.44	1.67e-23	Blood protein levels;
LGG	cis	rs4595586	0.545	rs2218762	chr12:39397762	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg22535103	chr8:58192502	C8orf71	-1.03	-16.37	-0.61	7.35e-48	Developmental language disorder (linguistic errors);
LGG	cis	rs6087990	1.000	rs2424900	chr20:31344342	G/C	cg13636640	chr20:31349939	DNMT3B	1.01	21.89	0.71	1.96e-73	Ulcerative colitis;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.42e-50	Skin colour saturation;
LGG	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.09	-0.64	1.01e-55	Refractive error;
LGG	cis	rs4302748	0.862	rs60346569	chr7:36184201	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	trans	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.47	8.38	0.36	6.22e-16	Mean corpuscular volume;
LGG	cis	rs3768617	0.510	rs3768621	chr1:183090057	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.81	-0.3	3.05e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	16.1	0.6	1.3e-46	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs2280018	0.963	rs4985147	chr16:15168760	T/C	cg27102117	chr16:15229624	NA	0.5	9.75	0.41	1.53e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs12579753	0.917	rs6539580	chr12:82184765	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.65e-14	Resting heart rate;
LGG	cis	rs6714710	0.603	rs1875699	chr2:98580724	G/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.48	0.4	1.31e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg16141378	chr3:129829833	LOC729375	0.42	9.81	0.41	8.9e-21	Neuroticism;
LGG	cis	rs6450176	0.564	rs31228	chr5:53325994	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.51	-0.47	3.99e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg06521331	chr12:34319734	NA	0.51	9.42	0.4	2.22e-19	Bladder cancer;
LGG	cis	rs7647973	0.506	rs11920251	chr3:49356671	C/T	cg07636037	chr3:49044803	WDR6	0.78	15.69	0.59	8.61e-45	Menarche (age at onset);
LGG	cis	rs7712401	0.580	rs30041	chr5:122275353	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg20814179	chr4:940893	TMEM175	0.42	6.83	0.3	2.65e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg26513180	chr16:89883248	FANCA	-0.52	-8.89	-0.38	1.4e-17	Vitiligo;
LGG	cis	rs55940034	0.523	rs2149067	chr13:111062324	G/A	cg06243866	chr13:111019493	COL4A2	-0.41	-7.6	-0.33	1.63e-13	Myocardial infarction;
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg05692746	chr2:100937584	LONRF2	-0.6	-10.75	-0.45	3.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg12310025	chr6:25882481	NA	-0.4	-7.23	-0.32	2.06e-12	Height;
LGG	cis	rs16866061	1.000	rs72974238	chr2:225432470	C/A	cg12698349	chr2:225449008	CUL3	0.93	19.26	0.67	3.86e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs8180040	0.620	rs4683322	chr3:47093189	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.32e-42	Colorectal cancer;
LGG	cis	rs10950821	0.770	rs7792341	chr7:20702201	C/G	cg21202529	chr7:20656503	ABCB5	-0.39	-6.72	-0.3	5.28e-11	Response to statin therapy;
LGG	cis	rs3106136	0.967	rs2306803	chr4:95161996	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.77	-0.34	5.22e-14	Capecitabine sensitivity;
LGG	cis	rs3774854	1.000	rs9790440	chr4:5711334	A/G	cg09558315	chr4:5711301	EVC2	-0.31	-6.98	-0.31	1.04e-11	Body mass index (change over time) in gastrointestinal cancer or chronic obstructive pulmonary disease;
LGG	trans	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.59	9.22	0.39	1.07e-18	Resting heart rate;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg05001715	chr5:92956474	FAM172A;MIR2277	0.69	6.82	0.3	2.84e-11	Diabetic retinopathy;
LGG	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	13.63	0.54	8.3e-36	Birth weight;
LGG	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg02187348	chr16:89574699	SPG7	0.62	10.45	0.44	4.16e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs10464366	0.879	rs1527952	chr7:39119320	A/C	cg21665744	chr7:39171113	POU6F2	0.34	6.82	0.3	2.78e-11	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.57	0.37	1.53e-16	Lung cancer;
LGG	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.42	0.36	4.92e-16	Neuroticism;
LGG	cis	rs7474896	0.583	rs12776092	chr10:38015795	G/C	cg25427524	chr10:38739819	LOC399744	-0.5	-7.47	-0.33	4.05e-13	Obesity (extreme);
LGG	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg06153925	chr17:78755379	RPTOR	-0.41	-7.3	-0.32	1.26e-12	Myopia (pathological);
LGG	cis	rs6787391	0.933	rs9880424	chr3:4746886	G/A	cg11584376	chr3:4789075	ITPR1	-0.34	-7.01	-0.31	8.52e-12	Breast cancer;
LGG	cis	rs4664304	1.000	rs3806603	chr2:160761808	T/C	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.36	-0.32	8.32e-13	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7395662	0.895	rs8186350	chr11:48739261	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.4e-14	HDL cholesterol;
LGG	cis	rs7712401	0.580	rs4288111	chr5:122388182	A/G	cg19412675	chr5:122181750	SNX24	-0.43	-7.11	-0.31	4.51e-12	Mean platelet volume;
LGG	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.57	-0.33	2.04e-13	Gut microbiome composition (summer);
LGG	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg00012203	chr2:219082015	ARPC2	0.65	11.5	0.47	4.45e-27	Colorectal cancer;
LGG	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg08392591	chr16:89556376	ANKRD11	0.59	9.4	0.4	2.55e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs28830936	1.000	rs17734856	chr15:42045160	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.56	-12.78	-0.51	3e-32	Diastolic blood pressure;
LGG	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.06	-0.31	6.18e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs45544231	0.544	rs1362547	chr16:52563883	T/C	cg09051775	chr16:52580266	TOX3	-0.43	-7.21	-0.32	2.37e-12	Restless legs syndrome;
LGG	cis	rs12476592	0.602	rs1867849	chr2:63726932	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	cis	rs12282928	0.959	rs4980426	chr11:48296019	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.52e-12	Migraine - clinic-based;
LGG	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg04772025	chr11:68637568	NA	0.74	13.09	0.52	1.51e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs758324	0.812	rs3756287	chr5:131135478	A/G	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.41e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs7712401	0.601	rs30028	chr5:122283269	G/T	cg19412675	chr5:122181750	SNX24	0.41	6.82	0.3	2.94e-11	Mean platelet volume;
LGG	cis	rs6558530	0.932	rs7842425	chr8:1706041	G/T	cg08198773	chr8:1697536	NA	0.36	7.03	0.31	7.58e-12	Systolic blood pressure;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.37	0.47	1.33e-26	Electroencephalogram traits;
LGG	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg17376030	chr22:41985996	PMM1	0.66	10.66	0.44	7.15e-24	Vitiligo;
LGG	cis	rs4356203	0.678	rs1125737	chr11:17263933	T/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-7.51	-0.33	2.97e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.22	-0.32	2.21e-12	Mood instability;
LGG	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg22852734	chr6:133119734	C6orf192	1.16	14.75	0.57	1.23e-40	Type 2 diabetes nephropathy;
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.22	-0.32	2.21e-12	Bipolar disorder;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg27286069	chr11:118481882	PHLDB1	-0.55	-10.14	-0.43	6.16e-22	Cholesterol, total;
LGG	cis	rs8180040	0.966	rs922957	chr3:47422152	G/C	cg27129171	chr3:47204927	SETD2	-0.78	-15.2	-0.58	1.34e-42	Colorectal cancer;
LGG	cis	rs2011503	0.943	rs4239639	chr19:19435876	G/A	cg11584989	chr19:19387371	SF4	-0.77	-12.91	-0.51	8.88e-33	Bipolar disorder;
LGG	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.5	8.16	0.35	3.09e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs909674	0.865	rs5757683	chr22:39850174	G/A	cg11247378	chr22:39784982	NA	-0.31	-8.59	-0.37	1.32e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs4789693	0.518	rs6502108	chr17:80374899	A/C	cg04308225	chr17:80449738	NA	-0.51	-8.11	-0.35	4.67e-15	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs2795502	0.873	rs2077626	chr10:43410962	A/G	cg20628663	chr10:43360327	NA	0.37	7.35	0.32	9.28e-13	Blood protein levels;
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg23958373	chr8:599963	NA	1.37	13.07	0.52	1.87e-33	IgG glycosylation;
LGG	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg06634786	chr22:41940651	POLR3H	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs11098499	0.954	rs35063680	chr4:120387102	T/C	cg09307838	chr4:120376055	NA	0.81	13.55	0.53	1.76e-35	Corneal astigmatism;
LGG	cis	rs6594713	0.921	rs34316732	chr5:112699627	T/C	cg12552261	chr5:112820674	MCC	0.5	6.93	0.31	1.38e-11	Brain cytoarchitecture;
LGG	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg13385794	chr1:248469461	NA	0.48	7.87	0.34	2.45e-14	Common traits (Other);
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg02002194	chr4:3960332	NA	0.42	7.68	0.34	9.31e-14	Triglycerides;
LGG	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg03929089	chr4:120376271	NA	0.45	7.38	0.32	7.59e-13	HDL cholesterol;
LGG	cis	rs7737355	0.673	rs26006	chr5:130982768	A/G	cg06307176	chr5:131281290	NA	0.52	8.63	0.37	9.7e-17	Life satisfaction;
LGG	cis	rs28595532	0.920	rs114916728	chr4:119776886	G/A	cg21605333	chr4:119757512	SEC24D	1.47	13.64	0.54	7.78e-36	Cannabis dependence symptom count;
LGG	cis	rs526231	0.543	rs42431	chr5:102400063	C/T	cg23492399	chr5:102201601	PAM	0.57	8.32	0.36	9.63e-16	Primary biliary cholangitis;
LGG	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.96	-0.52	5.67e-33	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg15863547	chr2:96987704	NA	-0.4	-6.96	-0.31	1.17e-11	Brain structure;
LGG	cis	rs209489	0.892	rs59737379	chr6:53115621	A/G	cg15607103	chr6:53167650	ELOVL5	0.68	8.02	0.35	8.74e-15	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9457247	0.765	rs9457249	chr6:167426438	A/G	cg07741184	chr6:167504864	NA	0.42	9.26	0.4	7.94e-19	Crohn's disease;
LGG	cis	rs898097	0.841	rs2271918	chr17:80861206	A/G	cg15369054	chr17:80825471	TBCD	0.58	10.38	0.43	7.78e-23	Breast cancer;
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg11984989	chr7:158649758	WDR60	0.96	21.1	0.7	9.72e-70	Height;
LGG	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.65	0.69	1.25e-67	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg00149659	chr3:10157352	C3orf10	0.85	11.03	0.46	2.89e-25	Alzheimer's disease;
LGG	cis	rs4774899	0.767	rs13329616	chr15:57430242	A/T	cg08128148	chr15:57256372	TCF12	0.3	7.33	0.32	1.05e-12	Urinary tract infection frequency;
LGG	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg09307838	chr4:120376055	NA	0.79	13.06	0.52	2.04e-33	Corneal astigmatism;
LGG	cis	rs7647973	1.000	rs7644148	chr3:49545241	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.5	-7.82	-0.34	3.6e-14	Menarche (age at onset);
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.6	-0.33	1.6e-13	Rheumatoid arthritis;
LGG	cis	rs7572733	0.773	rs7588831	chr2:198508016	A/G	cg00792783	chr2:198669748	PLCL1	0.4	6.65	0.3	8.46e-11	Dermatomyositis;
LGG	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.19	-0.36	2.59e-15	Neuroticism;
LGG	cis	rs80033912	0.713	rs7629936	chr3:49836707	G/A	cg03060546	chr3:49711283	APEH	0.48	6.72	0.3	5.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg11757124	chr7:157526947	PTPRN2	-0.53	-9.76	-0.41	1.41e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg19635926	chr16:89946313	TCF25	0.77	7.69	0.34	8.82e-14	Skin colour saturation;
LGG	cis	rs4481887	0.830	rs1538703	chr1:248519821	T/G	cg13385794	chr1:248469461	NA	0.44	7.9	0.34	2.04e-14	Common traits (Other);
LGG	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs7949030	0.591	rs12049914	chr11:62369436	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.21	0.6	3.98e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg18876405	chr7:65276391	NA	-0.62	-11.59	-0.47	1.99e-27	Aortic root size;
LGG	cis	rs2274273	0.686	rs2296489	chr14:55624977	T/C	cg04306507	chr14:55594613	LGALS3	0.52	11.98	0.49	5.45e-29	Protein biomarker;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg07511668	chr11:68622177	NA	-0.49	-9.43	-0.4	2.02e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg00666640	chr1:248458726	OR2T12	-0.53	-8.88	-0.38	1.43e-17	Common traits (Other);
LGG	cis	rs858239	0.539	rs4365988	chr7:23190871	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.85	0.3	2.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg06640241	chr16:89574553	SPG7	-0.7	-11.99	-0.49	5.05e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs9902453	0.689	rs7216948	chr17:28203173	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.89	0.54	6.47e-37	Coffee consumption (cups per day);
LGG	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg16576597	chr16:28551801	NUPR1	0.31	7.03	0.31	7.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4851254	0.618	rs7572939	chr2:100654914	A/G	cg17356467	chr2:100759845	AFF3	0.47	7.57	0.33	1.97e-13	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.578	rs11052720	chr12:33623126	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.94	-0.35	1.55e-14	Morning vs. evening chronotype;
LGG	cis	rs701145	0.938	rs242117	chr3:154026467	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs7727544	0.584	rs7714191	chr5:131341541	C/G	cg07395648	chr5:131743802	NA	-0.42	-9.11	-0.39	2.55e-18	Blood metabolite levels;
LGG	cis	rs2836974	0.899	rs34176878	chr21:40548855	C/A	cg11890956	chr21:40555474	PSMG1	1.2	30.0	0.81	1.27e-110	Cognitive function;
LGG	cis	rs4363385	0.747	rs1577963	chr1:152961882	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-9.0	-0.39	5.91e-18	Inflammatory skin disease;
LGG	cis	rs2916247	0.908	rs2996057	chr8:93179864	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.35	-7.27	-0.32	1.56e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.676	rs778591	chr5:140025484	G/A	cg19875535	chr5:140030758	IK	-0.59	-12.4	-0.5	1.06e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6714710	0.603	rs34502870	chr2:98405929	A/G	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.27	0.32	1.59e-12	Schizophrenia;
LGG	cis	rs2011503	1.000	rs77427798	chr19:19652982	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.82	0.3	2.84e-11	Bipolar disorder;
LGG	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg08048268	chr3:133502702	NA	0.6	11.2	0.46	6.1e-26	Iron status biomarkers;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	9.07	0.39	3.4e-18	Bipolar disorder;
LGG	cis	rs4774899	0.934	rs11071309	chr15:57482877	G/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.29	-0.32	1.36e-12	Urinary tract infection frequency;
LGG	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.81	0.54	1.37e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.09	0.35	5.35e-15	Prostate cancer;
LGG	cis	rs7949566	0.676	rs752807	chr11:126293202	A/G	cg05055844	chr11:126275997	ST3GAL4	0.33	6.89	0.3	1.83e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs4639966	0.797	rs11217021	chr11:118640828	T/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.45	-0.33	4.73e-13	Systemic lupus erythematosus;
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg09359103	chr1:154839909	KCNN3	-0.54	-11.21	-0.46	5.63e-26	Prostate cancer;
LGG	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-7.34	-0.32	9.89e-13	Bipolar disorder;
LGG	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06481639	chr22:41940642	POLR3H	0.54	7.61	0.33	1.55e-13	Vitiligo;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg09699651	chr6:150184138	LRP11	0.47	8.36	0.36	7.26e-16	Lung cancer;
LGG	cis	rs1519814	0.616	rs2326428	chr8:121011363	A/G	cg22335954	chr8:121166405	COL14A1	-0.45	-8.06	-0.35	6.62e-15	Breast cancer;
LGG	cis	rs138249	1.000	rs138252	chr22:50570873	G/T	cg07310406	chr22:50524374	MLC1	0.45	9.08	0.39	3.09e-18	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg02461776	chr11:598696	PHRF1	0.48	7.02	0.31	8e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg06889755	chr6:150326021	RAET1K	-0.4	-8.18	-0.36	2.72e-15	Alopecia areata;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg15971980	chr6:150254442	NA	0.45	8.39	0.36	6.08e-16	Lung cancer;
LGG	trans	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg23762105	chr12:34175262	ALG10	0.34	6.83	0.3	2.72e-11	Morning vs. evening chronotype;
LGG	cis	rs62380364	0.565	rs40504	chr5:88011139	G/C	cg22951263	chr5:87985283	NA	-0.57	-10.55	-0.44	1.85e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg12486710	chr1:178512616	C1orf220	-0.51	-10.54	-0.44	2.08e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg09845145	chr15:78292470	TBC1D2B	0.66	12.96	0.52	5.29e-33	Coronary artery disease or large artery stroke;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg24101359	chr6:42928495	GNMT	0.52	14.6	0.56	5.64e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs919433	0.680	rs6434930	chr2:198369370	A/G	cg00792783	chr2:198669748	PLCL1	0.49	7.79	0.34	4.48e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	0.532	rs4916851	chr5:90536300	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.59	-7.7	-0.34	8.09e-14	Smoking behavior;
LGG	cis	rs4819052	0.851	rs2838828	chr21:46663423	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.79	-0.34	4.5e-14	Height;
LGG	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs735539	0.521	rs2763001	chr13:21378018	A/C	cg04906043	chr13:21280425	IL17D	-0.51	-7.99	-0.35	1.05e-14	Dental caries;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.78	-0.3	3.73e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9296092	0.538	rs9461881	chr6:33520041	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg01244601	chr4:120671846	NA	-0.41	-7.81	-0.34	3.92e-14	Corneal astigmatism;
LGG	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9815354	0.951	rs17060938	chr3:41759191	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.59	0.33	1.76e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1355223	0.902	rs7102625	chr11:34739717	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.42	7.05	0.31	6.5e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg19399532	chr1:178512495	C1orf220	0.54	10.89	0.45	9.86e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7301826	0.932	rs1007246	chr12:131280130	T/A	cg11011512	chr12:131303247	STX2	0.35	7.57	0.33	2.09e-13	Plasma plasminogen activator levels;
LGG	cis	rs4820294	0.669	rs9622678	chr22:38057338	A/G	cg00142150	chr22:38071001	LGALS1	0.67	13.13	0.52	1.02e-33	Fat distribution (HIV);
LGG	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg26384229	chr12:38710491	ALG10B	0.81	16.35	0.61	9.5e-48	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.29	-0.55	1.2e-38	Alzheimer's disease;
LGG	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg17971929	chr21:40555470	PSMG1	0.73	13.69	0.54	4.8e-36	Cognitive function;
LGG	cis	rs17253792	0.732	rs28380739	chr14:56088402	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-8.41	-0.36	5.15e-16	Menopause (age at onset);
LGG	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.55	-0.33	2.41e-13	Mood instability;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg02725872	chr8:58115012	NA	-0.86	-12.41	-0.5	9.62e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.59	-9.85	-0.42	6.46e-21	Colorectal cancer;
LGG	cis	rs62025270	0.580	rs62022938	chr15:86247995	G/T	cg25843651	chr15:86329602	KLHL25	0.55	8.46	0.37	3.55e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs17428076	0.710	rs17499593	chr2:172649755	C/G	cg21435375	chr2:172878103	MAP1D	0.4	7.32	0.32	1.1e-12	Myopia;
LGG	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg06453172	chr10:134556979	INPP5A	-0.57	-8.38	-0.36	6.34e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs5758511	0.680	rs739147	chr22:42671066	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.43	0.33	5.2e-13	Birth weight;
LGG	cis	rs861020	1.000	rs7555285	chr1:209970355	C/G	cg05527609	chr1:210001259	C1orf107	-0.64	-8.63	-0.37	9.8e-17	Orofacial clefts;
LGG	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg00495681	chr13:53174319	NA	0.42	6.96	0.31	1.17e-11	Lewy body disease;
LGG	cis	rs9747201	0.963	rs11077982	chr17:80147377	G/C	cg09264619	chr17:80180166	NA	-0.5	-10.05	-0.42	1.28e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17227506	0.730	rs35380952	chr8:13457292	G/A	cg03566418	chr8:13424080	C8orf48	0.63	9.97	0.42	2.45e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs11700980	0.636	rs2832138	chr21:30284123	G/A	cg24692254	chr21:30365293	RNF160	-0.57	-6.8	-0.3	3.33e-11	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg05861140	chr6:150128134	PCMT1	-0.38	-8.33	-0.36	9.22e-16	Lung cancer;
LGG	trans	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg06636001	chr8:8085503	FLJ10661	0.41	7.12	0.31	4.23e-12	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3733418	0.860	rs13141887	chr4:165950921	C/T	cg10852876	chr4:165953100	TRIM60	-0.52	-7.18	-0.32	2.85e-12	Obesity-related traits;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.66e-13	Rheumatoid arthritis;
LGG	cis	rs1639906	0.893	rs13233298	chr7:2227707	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.82	-0.34	3.61e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9880211	0.800	rs9858560	chr3:136517154	C/T	cg21827317	chr3:136751795	NA	-0.49	-7.13	-0.31	3.79e-12	Body mass index;Height;
LGG	cis	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg13443165	chr9:33130375	B4GALT1	-0.7	-11.82	-0.48	2.39e-28	IgG glycosylation;
LGG	cis	rs7928758	1.000	rs58475265	chr11:134264142	T/C	cg22777979	chr11:134283252	B3GAT1	0.77	10.67	0.44	6.77e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1003719	0.715	rs7282195	chr21:38508619	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg12773197	chr13:112238673	NA	-0.36	-7.29	-0.32	1.36e-12	Hepatitis;
LGG	cis	rs17270561	0.636	rs7453371	chr6:25719256	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.26	0.43	2.07e-22	Iron status biomarkers;
LGG	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.65	-0.41	3.33e-20	Diabetic retinopathy;
LGG	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.2	-0.32	2.51e-12	Mood instability;
LGG	cis	rs7326068	0.504	rs7983020	chr13:21239941	C/T	cg04906043	chr13:21280425	IL17D	0.42	7.39	0.32	6.73e-13	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg03709012	chr19:19516395	GATAD2A	0.8	15.24	0.58	8.5e-43	Tonsillectomy;
LGG	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08045932	chr20:61659980	NA	0.6	12.98	0.52	4.3e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg06654118	chr4:1303317	MAEA	0.48	8.09	0.35	5.25e-15	Obesity-related traits;
LGG	trans	rs1814175	0.607	rs11493324	chr11:50011304	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-17.55	-0.63	3.21e-53	Height;
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg23202291	chr11:1979235	NA	0.41	7.79	0.34	4.35e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.65	-0.37	8.63e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs735539	1.000	rs9579929	chr13:21282724	C/T	cg04906043	chr13:21280425	IL17D	0.6	10.4	0.44	6.69e-23	Dental caries;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg18000306	chr6:288505	NA	0.59	10.56	0.44	1.66e-23	Menopause (age at onset);
LGG	cis	rs7503807	1.000	rs12939613	chr17:78588202	A/G	cg06872548	chr17:78716983	RPTOR	0.45	10.77	0.45	2.82e-24	Obesity;
LGG	cis	rs13191362	0.808	rs13217502	chr6:163231414	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.82	9.29	0.4	6.27e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.66	-13.89	-0.54	6.25e-37	Colorectal cancer;
LGG	trans	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.42	-7.55	-0.33	2.27e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3741151	0.773	rs7951072	chr11:73221721	G/A	cg17517138	chr11:73019481	ARHGEF17	0.83	7.9	0.34	2.02e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6840360	0.615	rs6858483	chr4:152465509	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.5	-0.37	2.63e-16	Intelligence (multi-trait analysis);
LGG	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.74	-0.3	4.81e-11	Crohn's disease;
LGG	trans	rs6582630	0.555	rs7133706	chr12:38475465	G/A	cg06521331	chr12:34319734	NA	0.52	9.61	0.41	4.49e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9393692	0.627	rs1059486	chr6:26200083	A/G	cg09303159	chr6:26284866	NA	0.31	7.06	0.31	5.93e-12	Educational attainment;
LGG	trans	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.44	-0.33	4.88e-13	Retinal vascular caliber;
LGG	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg12463550	chr7:65579703	CRCP	-0.52	-8.69	-0.37	6.19e-17	Aortic root size;
LGG	cis	rs28735056	0.587	rs8093548	chr18:77636451	G/A	cg20368463	chr18:77673604	PQLC1	-0.69	-14.29	-0.55	1.17e-38	Schizophrenia;
LGG	cis	rs5769765	0.862	rs9616392	chr22:50314705	G/A	cg02269571	chr22:50332266	NA	-0.7	-10.39	-0.43	7.02e-23	Schizophrenia;
LGG	cis	rs10193935	0.901	rs10169971	chr2:42602189	G/A	cg27598129	chr2:42591480	NA	-0.66	-9.75	-0.41	1.49e-20	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21158896	chr11:17099219	RPS13	-0.5	-7.37	-0.32	7.68e-13	Systemic lupus erythematosus;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.45	-0.37	3.83e-16	Renal function-related traits (BUN);
LGG	cis	rs7949030	0.591	rs35880596	chr11:62369884	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	15.85	0.59	1.66e-45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3888647	0.561	rs4758617	chr11:2995185	T/A	cg05729581	chr11:3078854	CARS	-0.5	-8.44	-0.37	4.17e-16	Type 2 diabetes;
LGG	cis	rs765787	0.530	rs12909987	chr15:45512207	C/T	cg25801113	chr15:45476975	SHF	0.86	18.82	0.66	4.38e-59	Uric acid levels;
LGG	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.27	0.32	1.53e-12	Hair morphology;
LGG	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	cis	rs4330281	0.608	rs7630286	chr3:17371566	C/T	cg20981856	chr3:17787350	NA	0.36	6.89	0.31	1.81e-11	Schizophrenia;
LGG	cis	rs774359	0.789	rs868857	chr9:27488906	G/A	cg21249376	chr9:27528432	MOBKL2B	0.45	8.49	0.37	2.78e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg22535103	chr8:58192502	C8orf71	-0.96	-12.63	-0.51	1.26e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.09	0.35	5.23e-15	Longevity;
LGG	cis	rs1552244	0.543	rs28719585	chr3:10050813	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.58	-0.44	1.47e-23	Alzheimer's disease;
LGG	trans	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg27523141	chr10:43048294	ZNF37B	0.38	7.49	0.33	3.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9636252	0.847	rs6743232	chr2:9269387	A/G	cg20341998	chr2:9276514	NA	0.39	7.47	0.33	3.91e-13	IgG glycosylation;
LGG	cis	rs11096990	0.855	rs2566173	chr4:39152731	G/C	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs741702	0.819	rs62108438	chr19:13000247	T/C	cg11738485	chr19:12877000	HOOK2	-0.46	-7.46	-0.33	4.25e-13	Red blood cell traits;
LGG	cis	rs975722	0.622	rs13438309	chr7:117158642	A/G	cg10524701	chr7:117356490	CTTNBP2	0.43	9.59	0.41	5.47e-20	Coronary artery disease;
LGG	cis	rs11718455	1.000	rs9858826	chr3:44031412	C/T	cg21419209	chr3:44054225	NA	0.42	6.8	0.3	3.19e-11	Coronary artery disease;
LGG	cis	rs1867631	0.585	rs6670827	chr1:67127006	C/T	cg13052034	chr1:66999238	SGIP1	0.34	6.87	0.3	2.09e-11	Menopause (age at onset);
LGG	cis	rs4965869	0.866	rs4965866	chr15:101975931	C/T	cg12371147	chr15:101978424	PCSK6	-0.42	-7.69	-0.34	9.03e-14	Platelet-derived growth factor BB levels;
LGG	cis	rs6696846	0.749	rs7553876	chr1:205079915	A/G	cg21545522	chr1:205238299	TMCC2	0.37	7.26	0.32	1.7e-12	Red blood cell count;
LGG	cis	rs9788721	1.000	rs8031948	chr15:78816057	G/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.45	-0.33	4.49e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11890956	chr21:40555474	PSMG1	-0.71	-12.29	-0.5	3.03e-30	Menarche (age at onset);
LGG	cis	rs7084783	0.532	rs11191759	chr10:105419028	A/C	cg00126946	chr10:105363258	SH3PXD2A	0.39	7.41	0.33	6.24e-13	Fear of pain;
LGG	cis	rs919433	0.680	rs7605813	chr2:198375329	C/G	cg00792783	chr2:198669748	PLCL1	0.51	7.96	0.35	1.38e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs910316	1.000	rs4903279	chr14:75546583	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	10.83	0.45	1.7e-24	Height;
LGG	trans	rs57046232	0.552	rs6038449	chr20:6337980	C/T	cg21095983	chr6:86352623	SYNCRIP	0.43	7.17	0.32	3.03e-12	Colorectal cancer;
LGG	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg11887960	chr12:57824829	NA	0.56	6.91	0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg23029597	chr12:123009494	RSRC2	-0.98	-19.05	-0.66	3.75e-60	Body mass index;
LGG	cis	rs2613964	0.504	rs12695288	chr3:112851515	G/A	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	5.83e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs6840360	0.571	rs11944139	chr4:152505291	T/C	cg25486957	chr4:152246857	NA	-0.53	-8.66	-0.37	7.73e-17	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.613	rs556497	chr2:219446477	G/A	cg01130898	chr2:219473002	PLCD4	-0.39	-6.69	-0.3	6.41e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7172677	0.501	rs8040061	chr15:75393720	C/A	cg14664628	chr15:75095509	CSK	0.52	9.1	0.39	2.78e-18	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.06	0.72	3.06e-74	Morning vs. evening chronotype;
LGG	cis	rs9430161	0.579	rs9659356	chr1:11034817	A/G	cg27631724	chr1:11040367	C1orf127	0.44	9.07	0.39	3.44e-18	Ewing sarcoma;
LGG	cis	rs9309711	0.922	rs13385119	chr2:3484521	G/A	cg10845886	chr2:3471009	TTC15	-0.73	-14.37	-0.56	5.3e-39	Neurofibrillary tangles;
LGG	cis	rs17767392	0.958	rs17767553	chr14:71910587	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.6	-0.37	1.22e-16	Mitral valve prolapse;
LGG	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg05444541	chr17:17804740	TOM1L2	0.41	8.91	0.38	1.14e-17	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg04111992	chr7:158790115	NA	-0.36	-7.31	-0.32	1.2e-12	Facial morphology (factor 20);
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg04861929	chr11:109293070	C11orf87	0.56	10.09	0.42	8.66e-22	Schizophrenia;
LGG	cis	rs9487094	0.504	rs71541003	chr6:109973897	C/G	cg16315928	chr6:109776240	MICAL1	0.46	8.15	0.35	3.52e-15	Height;
LGG	cis	rs963731	0.649	rs297137	chr2:39305721	T/C	cg04010122	chr2:39346883	SOS1	-0.81	-7.2	-0.32	2.38e-12	Corticobasal degeneration;
LGG	cis	rs986417	0.748	rs4381505	chr14:61035968	C/T	cg27398547	chr14:60952738	C14orf39	0.65	6.86	0.3	2.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg12708336	chr17:41446283	NA	-0.31	-7.37	-0.32	7.92e-13	Menopause (age at onset);
LGG	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	trans	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg21659725	chr3:3221576	CRBN	-0.57	-9.9	-0.42	4.23e-21	Body mass index;
LGG	trans	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg21659725	chr3:3221576	CRBN	0.62	10.05	0.42	1.29e-21	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.92	0.42	3.83e-21	Prudent dietary pattern;
LGG	trans	rs1814175	0.817	rs10839351	chr11:49758153	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.49e-30	Height;
LGG	cis	rs4665809	1.000	rs6546728	chr2:26276531	G/C	cg08470875	chr2:26401718	FAM59B	-0.36	-6.71	-0.3	5.72e-11	Gut microbiome composition (summer);
LGG	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.17e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg05308233	chr10:104796373	CNNM2	-0.31	-6.99	-0.31	9.61e-12	Arsenic metabolism;
LGG	trans	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg18335740	chr13:41363409	SLC25A15	-0.64	-12.54	-0.5	2.88e-31	Lewy body disease;
LGG	cis	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.4	-0.33	6.63e-13	Morning vs. evening chronotype;
LGG	cis	rs2430307	0.556	rs3930019	chr7:76541610	C/T	cg15770687	chr7:76625569	PMS2L11	0.55	7.59	0.33	1.78e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg26384229	chr12:38710491	ALG10B	0.76	14.12	0.55	6.89e-38	Resting heart rate;
LGG	cis	rs2953174	0.507	rs2953172	chr2:241525316	C/T	cg07929629	chr2:241523174	NA	0.64	10.16	0.43	5.14e-22	Bipolar disorder;
LGG	cis	rs9513627	0.510	rs4365162	chr13:100212614	G/C	cg25919922	chr13:100150906	NA	0.69	7.15	0.32	3.35e-12	Obesity-related traits;
LGG	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg20891283	chr12:69753455	YEATS4	0.76	14.64	0.56	3.65e-40	Blood protein levels;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03647317	chr4:187891568	NA	0.42	9.05	0.39	4.06e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg02725872	chr8:58115012	NA	-0.76	-10.89	-0.45	9.61e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg17809284	chr5:56205270	C5orf35	-0.54	-9.98	-0.42	2.24e-21	Initial pursuit acceleration;
LGG	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.517	rs7139189	chr12:34319757	T/C	cg13010199	chr12:38710504	ALG10B	0.53	10.54	0.44	1.95e-23	Morning vs. evening chronotype;
LGG	cis	rs10771431	0.782	rs10771415	chr12:9358223	C/T	cg00504896	chr12:9437009	LOC642846	-0.5	-9.86	-0.42	5.86e-21	Breast size;
LGG	cis	rs2559856	1.000	rs2695296	chr12:102085487	T/C	cg12924262	chr12:102091054	CHPT1	0.65	13.0	0.52	3.87e-33	Blood protein levels;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.59	-0.44	1.32e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg06558623	chr16:89946397	TCF25	1.19	12.93	0.52	7.08e-33	Skin colour saturation;
LGG	cis	rs12681366	0.683	rs2450572	chr8:95424335	A/G	cg13257157	chr8:95487014	RAD54B	-0.36	-6.68	-0.3	7.09e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg16329197	chr12:53359506	NA	-0.65	-11.38	-0.47	1.27e-26	Cancer (pleiotropy);
LGG	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11764359	chr7:65958608	NA	-0.59	-9.87	-0.42	5.46e-21	Aortic root size;
LGG	cis	rs7106204	0.609	rs16912371	chr11:24298455	A/G	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg05335186	chr13:53173507	NA	0.43	8.52	0.37	2.28e-16	Lewy body disease;
LGG	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.24	0.39	8.77e-19	Diabetic retinopathy;
LGG	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg19539972	chr4:7069911	GRPEL1	-0.67	-9.3	-0.4	5.38e-19	Monocyte percentage of white cells;
LGG	cis	rs11096990	0.634	rs2381372	chr4:39273091	A/C	cg24403649	chr4:39172243	NA	0.38	6.69	0.3	6.33e-11	Cognitive function;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg03188948	chr7:1209495	NA	0.43	7.68	0.34	9.76e-14	Longevity;Endometriosis;
LGG	cis	rs9834373	0.853	rs3923272	chr3:78488245	A/G	cg06138941	chr3:78371609	NA	-0.52	-9.25	-0.4	8.04e-19	Protein quantitative trait loci;
LGG	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg21055462	chr7:100276975	NA	0.45	9.46	0.4	1.6e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9650657	0.682	rs6989160	chr8:10705360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.6	-0.33	1.72e-13	Neuroticism;
LGG	cis	rs9463078	0.605	rs1578676	chr6:44906861	G/A	cg25276700	chr6:44698697	NA	0.34	7.04	0.31	6.76e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs561341	1.000	rs576985	chr17:30323323	C/T	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7267979	1.000	rs398036	chr20:25439850	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.08	0.42	9.9e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13191362	0.507	rs2803083	chr6:163111199	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.6	8.21	0.36	2.25e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6976053	0.518	rs144173	chr7:100416250	A/G	cg03098644	chr7:100410630	EPHB4	-0.59	-11.14	-0.46	1.08e-25	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg25214090	chr10:38739885	LOC399744	0.69	12.25	0.49	4.32e-30	Corneal astigmatism;
LGG	cis	rs3784262	0.740	rs12898976	chr15:58276358	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.26e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11608355	0.515	rs12818537	chr12:109902150	C/T	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs9810259	0.525	rs310749	chr3:12273768	A/C	cg15873301	chr3:12045459	SYN2	-0.44	-7.48	-0.33	3.84e-13	Platelet count;
LGG	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7077164	1.000	rs1227764	chr10:71583223	G/A	cg20696214	chr10:71583771	COL13A1	-0.4	-7.75	-0.34	5.71e-14	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs2153535	0.580	rs9405390	chr6:8466209	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.9	0.51	9.48e-33	Obesity-related traits;
LGG	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg08994789	chr17:28903642	LRRC37B2	0.62	7.59	0.33	1.76e-13	Body mass index;
LGG	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg03605463	chr16:89740564	NA	0.61	11.13	0.46	1.16e-25	Vitiligo;
LGG	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.63	0.79	5.57e-100	Cognitive ability;
LGG	cis	rs10463316	0.894	rs13361316	chr5:150765593	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.2	-0.43	3.51e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg13206674	chr6:150067644	NUP43	0.6	13.53	0.53	2.27e-35	Lung cancer;
LGG	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg06766960	chr11:133703094	NA	-0.59	-12.03	-0.49	3.35e-29	Childhood ear infection;
LGG	cis	rs854765	0.583	rs5002487	chr17:17832460	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.63	12.24	0.49	4.75e-30	Total body bone mineral density;
LGG	cis	rs10950821	0.843	rs73684577	chr7:20665781	A/G	cg22066521	chr7:20687223	ABCB5	-0.32	-6.75	-0.3	4.42e-11	Response to statin therapy;
LGG	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg09998033	chr7:158218633	PTPRN2	-0.5	-9.0	-0.39	5.99e-18	Obesity-related traits;
LGG	cis	rs11588062	0.703	rs11589812	chr1:46858748	C/T	cg08947153	chr1:46664340	POMGNT1	0.43	7.71	0.34	7.74e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4846580	0.513	rs4072500	chr1:219975817	G/A	cg07216884	chr1:219964455	NA	0.39	6.83	0.3	2.74e-11	Total body bone mineral density;
LGG	cis	rs9807989	0.507	rs11465721	chr2:103063240	T/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.66	0.41	3.15e-20	Asthma;
LGG	cis	rs4330281	0.669	rs6804837	chr3:17787399	G/A	cg20981856	chr3:17787350	NA	-0.41	-7.46	-0.33	4.19e-13	Schizophrenia;
LGG	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-7.81	-0.34	3.76e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	cis	rs11971779	0.680	rs6467837	chr7:139023575	A/G	cg07862535	chr7:139043722	LUC7L2	0.41	6.73	0.3	5.17e-11	Diisocyanate-induced asthma;
LGG	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg10847948	chr11:71163743	NADSYN1	-0.51	-9.11	-0.39	2.45e-18	Vitamin D levels;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.41	0.36	5.18e-16	Skin colour saturation;
LGG	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.51	0.58	5.22e-44	Total body bone mineral density;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.88	-0.34	2.34e-14	Personality dimensions;
LGG	cis	rs1371867	0.846	rs1660346	chr8:101312497	A/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs10911232	0.520	rs10797831	chr1:183036816	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.7	0.41	2.2e-20	Hypertriglyceridemia;
LGG	cis	rs883565	0.543	rs784496	chr3:39179536	A/G	cg01426195	chr3:39028469	NA	0.64	13.43	0.53	5.66e-35	Handedness;
LGG	cis	rs742614	0.935	rs6057930	chr20:32477972	C/T	cg06304546	chr20:32448765	NA	-0.48	-8.65	-0.37	8.84e-17	Stearic acid (18:0) levels;
LGG	cis	rs11711311	1.000	rs12736	chr3:113530211	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.73	-0.34	6.66e-14	IgG glycosylation;
LGG	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.37	-0.43	8.16e-23	Triglycerides;
LGG	cis	rs7582180	0.817	rs7559464	chr2:100906323	A/G	cg21926883	chr2:100939477	LONRF2	-0.5	-9.57	-0.41	6.53e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg04935436	chr20:30431758	NA	-0.4	-7.07	-0.31	5.68e-12	Mean corpuscular hemoglobin;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg21548813	chr6:291882	DUSP22	-0.73	-12.84	-0.51	1.64e-32	Menopause (age at onset);
LGG	trans	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg25482853	chr8:67687455	SGK3	0.67	9.45	0.4	1.7e-19	Obesity-related traits;
LGG	cis	rs367943	0.712	rs10035686	chr5:112683357	C/T	cg12552261	chr5:112820674	MCC	0.54	9.78	0.41	1.17e-20	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11971779	0.616	rs7784192	chr7:139039649	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	1.000	rs28360546	chr6:163210973	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.95	9.71	0.41	2.14e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937612	0.965	rs10750172	chr11:120270253	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-13.02	-0.52	3.04e-33	Intraocular pressure;
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg16268157	chr7:99778414	STAG3	-0.49	-8.27	-0.36	1.47e-15	Lung function (FEV1/FVC);
LGG	cis	rs6121246	0.954	rs6060992	chr20:30431255	G/T	cg21427119	chr20:30132790	HM13	-0.43	-7.35	-0.32	8.88e-13	Mean corpuscular hemoglobin;
LGG	cis	rs892961	0.932	rs11658267	chr17:75411884	C/T	cg05865280	chr17:75406074	SEPT9	-0.42	-10.07	-0.42	1.1e-21	Airflow obstruction;
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.16	-20.49	-0.69	7.22e-67	Alzheimer's disease;
LGG	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.98	-0.45	4.2e-25	Triglycerides;
LGG	cis	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg09699651	chr6:150184138	LRP11	0.53	9.37	0.4	3.28e-19	Lung cancer;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.7e-21	Bipolar disorder;
LGG	cis	rs9487094	0.665	rs13207864	chr6:110029730	C/T	cg01125227	chr6:109776195	MICAL1	0.51	8.36	0.36	7.15e-16	Height;
LGG	cis	rs12477438	0.798	rs10196680	chr2:99628617	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.49	-0.5	4.71e-31	Chronic sinus infection;
LGG	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.58	-11.35	-0.47	1.69e-26	IgG glycosylation;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg03575189	chr17:44344142	NA	0.49	7.16	0.32	3.19e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.31e-19	Lung cancer;
LGG	cis	rs9914988	0.887	rs12451790	chr17:27112000	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.69	12.94	0.52	6.81e-33	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.61e-23	Aortic root size;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg11062466	chr8:58055876	NA	0.48	7.9	0.34	2.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.17	0.83	4.07e-120	Prudent dietary pattern;
LGG	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg08188268	chr10:116634841	FAM160B1	0.32	6.98	0.31	1.03e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs9329221	0.563	rs4841317	chr8:10186135	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.93	-0.38	1.03e-17	Neuroticism;
LGG	cis	rs7580658	0.864	rs4150441	chr2:128040915	T/C	cg10021288	chr2:128175891	PROC	-0.61	-12.79	-0.51	2.76e-32	Protein C levels;
LGG	cis	rs7503807	0.664	rs8068637	chr17:78614470	C/T	cg18469159	chr17:78755841	RPTOR	-0.37	-6.91	-0.31	1.64e-11	Obesity;
LGG	cis	rs2117029	0.553	rs11168909	chr12:49576875	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.8	0.51	2.61e-32	Intelligence (multi-trait analysis);
LGG	trans	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg07817883	chr1:32538562	TMEM39B	0.67	8.3	0.36	1.18e-15	Monocyte percentage of white cells;
LGG	cis	rs11971779	0.793	rs9632774	chr7:139137562	C/T	cg07862535	chr7:139043722	LUC7L2	0.52	8.11	0.35	4.71e-15	Diisocyanate-induced asthma;
LGG	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg12386194	chr3:101231763	SENP7	0.69	11.61	0.47	1.62e-27	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7169223	0.653	rs8029039	chr15:79100871	G/C	cg03762349	chr15:79060523	ADAMTS7	-0.4	-7.52	-0.33	2.85e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11644478	chr21:40555479	PSMG1	-0.59	-9.87	-0.42	5.78e-21	Menarche (age at onset);
LGG	cis	rs7107174	1.000	rs2510035	chr11:77953175	A/C	cg02023728	chr11:77925099	USP35	0.44	7.61	0.33	1.58e-13	Testicular germ cell tumor;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg13628971	chr7:2884303	GNA12	0.33	6.85	0.3	2.29e-11	Height;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.941	rs11126336	chr2:26245931	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-13.21	-0.52	4.78e-34	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	cis	rs10426930	0.738	rs2613757	chr19:5062405	T/C	cg15621731	chr19:5074616	KDM4B	0.26	6.77	0.3	4e-11	Monocyte percentage of white cells;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs611744	0.781	rs656406	chr8:109173843	G/A	cg21045802	chr8:109455806	TTC35	0.4	7.01	0.31	8.69e-12	Dupuytren's disease;
LGG	cis	rs1728785	1.000	rs1645923	chr16:68581051	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg16301924	chr13:53314226	LECT1	-0.48	-9.98	-0.42	2.2e-21	Lewy body disease;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.79e-31	Lymphocyte counts;
LGG	cis	rs981844	0.857	rs56198877	chr4:154718970	A/G	cg14289246	chr4:154710475	SFRP2	0.72	11.9	0.48	1.16e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg16751781	chr15:78858589	CHRNA5	-0.41	-8.0	-0.35	1e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg12855166	chr17:30846586	MYO1D	0.38	6.64	0.3	8.59e-11	Schizophrenia;
LGG	cis	rs4332037	0.906	rs6461009	chr7:1952139	T/C	cg12432903	chr7:1882776	MAD1L1	-0.52	-8.01	-0.35	9.71e-15	Bipolar disorder;
LGG	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.71	-0.45	4.46e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11203032	0.831	rs10887925	chr10:90938902	G/T	cg16672925	chr10:90967113	CH25H	0.77	11.02	0.46	3.11e-25	Heart failure;
LGG	cis	rs4919087	0.715	rs34787876	chr10:98999213	T/C	cg25902810	chr10:99078978	FRAT1	-0.44	-7.45	-0.33	4.62e-13	Monocyte count;
LGG	cis	rs1371867	0.846	rs1660349	chr8:101319326	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	trans	rs9467711	0.538	rs13191445	chr6:26015489	G/A	cg01620082	chr3:125678407	NA	-0.87	-7.54	-0.33	2.57e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg26513180	chr16:89883248	FANCA	0.98	9.07	0.39	3.38e-18	Skin colour saturation;
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	1.96e-17	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs10934753	0.632	rs13070856	chr3:125909415	A/G	cg06827562	chr3:125932279	NA	-0.75	-17.86	-0.64	1.19e-54	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs8114671	0.662	rs6088664	chr20:33551100	G/A	cg24642439	chr20:33292090	TP53INP2	0.48	7.78	0.34	4.77e-14	Height;
LGG	trans	rs62103177	0.608	rs34383580	chr18:77833263	A/G	cg05926928	chr17:57297772	GDPD1	-0.93	-11.95	-0.49	7.44e-29	Opioid sensitivity;
LGG	trans	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg26043149	chr18:55253948	FECH	-0.67	-11.2	-0.46	6.3e-26	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1927790	0.727	rs7991843	chr13:96970986	C/T	cg02571835	chr13:96230311	CLDN10	-0.35	-7.12	-0.31	4.11e-12	Body mass index;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg24846343	chr22:24311635	DDTL	-0.62	-12.45	-0.5	6.78e-31	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7572263	0.724	rs6705133	chr2:209054422	G/A	cg00164906	chr2:209055251	C2orf80	0.73	9.78	0.41	1.15e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs12220238	1.000	rs10824129	chr10:76008855	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.85	12.01	0.49	3.96e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11785400	0.793	rs4587307	chr8:143738529	G/A	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.6e-22	Total body bone mineral density;
LGG	cis	rs7523273	0.564	rs7543097	chr1:207882592	T/G	cg22525895	chr1:207977042	MIR29B2	0.46	8.7	0.37	5.98e-17	Schizophrenia;
LGG	cis	rs2239547	0.657	rs2072391	chr3:52862200	C/T	cg11645453	chr3:52864694	ITIH4	0.72	11.24	0.46	4.56e-26	Schizophrenia;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.29	0.32	1.33e-12	Alzheimer's disease;
LGG	cis	rs17376456	0.877	rs12153501	chr5:93360866	T/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.55	-0.41	7.52e-20	Diabetic retinopathy;
LGG	cis	rs7084402	0.967	rs1649085	chr10:60292042	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.97e-13	Refractive error;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg04496899	chr1:70820341	HHLA3;ANKRD13C	0.4	7.16	0.32	3.18e-12	Bilirubin levels;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg11062466	chr8:58055876	NA	0.62	9.84	0.42	7.26e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	27.32	0.79	1.44e-98	Cognitive ability;
LGG	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg03343631	chr13:114764489	RASA3	-0.6	-8.78	-0.38	3.21e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	trans	rs7474896	0.561	rs2474603	chr10:38445682	C/T	cg17830980	chr10:43048298	ZNF37B	-0.46	-7.09	-0.31	5.02e-12	Obesity (extreme);
LGG	cis	rs2404602	0.716	rs4886817	chr15:76877702	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.74	-0.3	4.69e-11	Blood metabolite levels;
LGG	cis	rs7178909	0.866	rs3784388	chr15:90437301	C/T	cg19708238	chr15:90437601	AP3S2	0.41	6.82	0.3	2.92e-11	Common traits (Other);
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.84	0.42	7.41e-21	Menarche (age at onset);
LGG	cis	rs9910055	0.530	rs8072954	chr17:42294722	G/A	cg19774624	chr17:42201019	HDAC5	-0.58	-10.35	-0.43	1e-22	Total body bone mineral density;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg00684032	chr4:1343700	KIAA1530	0.45	9.03	0.39	4.54e-18	Longevity;
LGG	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg08807101	chr21:30365312	RNF160	-0.9	-19.1	-0.66	2.06e-60	Dental caries;
LGG	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs240764	0.658	rs1336251	chr6:101247698	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.06	-0.35	6.53e-15	Neuroticism;
LGG	cis	rs12893597	0.715	rs12896100	chr14:76825064	C/T	cg20290672	chr14:76816747	NA	-0.5	-7.53	-0.33	2.72e-13	Maximal oxygen uptake response;
LGG	cis	rs6032067	0.925	rs35875037	chr20:43859921	A/G	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs362272	0.525	rs2798286	chr4:3046173	A/G	cg13731523	chr4:3047190	NA	-0.42	-9.81	-0.41	9.16e-21	Serum sulfate level;
LGG	trans	rs2727020	0.533	rs10839195	chr11:48973460	C/T	cg03929089	chr4:120376271	NA	-0.56	-9.79	-0.41	1.08e-20	Coronary artery disease;
LGG	cis	rs9398803	0.678	rs9401892	chr6:126895368	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.96e-19	Male-pattern baldness;
LGG	cis	rs1185460	0.967	rs1177562	chr11:118949331	C/T	cg23280166	chr11:118938394	VPS11	0.58	10.57	0.44	1.56e-23	Coronary artery disease;
LGG	cis	rs2439831	0.681	rs524527	chr15:43599116	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.95	-12.79	-0.51	2.74e-32	Lung cancer in ever smokers;
LGG	cis	rs7216064	0.532	rs8065296	chr17:66018562	T/A	cg02705964	chr17:66097276	LOC651250	-0.47	-8.27	-0.36	1.45e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg16606324	chr3:10149918	C3orf24	0.53	7.09	0.31	5.01e-12	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs13088318	0.504	rs2553419	chr3:101068620	C/T	cg11279151	chr3:101281821	RG9MTD1	0.38	7.21	0.32	2.24e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs910316	0.763	rs175036	chr14:75464295	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.14	-0.39	2.05e-18	Height;
LGG	cis	rs9902453	0.967	rs4493117	chr17:28489770	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.02	0.52	2.95e-33	Coffee consumption (cups per day);
LGG	cis	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.28	0.32	1.42e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg16141378	chr3:129829833	LOC729375	0.4	8.8	0.38	2.72e-17	Triglycerides;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.01	-0.42	1.78e-21	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.46	-0.37	3.58e-16	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg08888203	chr3:10149979	C3orf24	-0.55	-9.4	-0.4	2.58e-19	Alzheimer's disease;
LGG	cis	rs13177180	0.723	rs10038493	chr5:114890712	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.39	-8.58	-0.37	1.42e-16	Conotruncal heart defects (inherited effects);
LGG	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg26384229	chr12:38710491	ALG10B	0.61	11.87	0.48	1.52e-28	Morning vs. evening chronotype;
LGG	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg04181038	chr4:183730758	NA	0.55	7.61	0.33	1.54e-13	Pediatric autoimmune diseases;
LGG	cis	rs8067545	0.611	rs11868116	chr17:20029593	T/C	cg13482628	chr17:19912719	NA	0.54	10.26	0.43	2.19e-22	Schizophrenia;
LGG	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14952266	chr13:112191215	NA	-0.41	-7.39	-0.32	6.78e-13	Menarche (age at onset);
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs6083862	chr20:25411086	A/T	cg06421707	chr20:25228305	PYGB	-0.44	-9.2	-0.39	1.23e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1865760	0.566	rs9467672	chr6:26083904	C/T	cg12310025	chr6:25882481	NA	-0.37	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.34	0.32	9.4e-13	Lung cancer;
LGG	cis	rs10904908	0.733	rs7080366	chr10:17254832	C/T	cg01003015	chr10:17271136	VIM	-0.46	-7.73	-0.34	6.85e-14	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg17644776	chr2:200775616	C2orf69	0.47	7.79	0.34	4.41e-14	QT interval;
LGG	cis	rs6459788	0.720	rs6965466	chr7:157250749	G/T	cg04198125	chr7:157211777	NA	0.39	7.37	0.32	7.68e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs68170813	0.559	rs12538090	chr7:106974647	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-9.94	-0.42	3.12e-21	Coronary artery disease;
LGG	cis	rs12042938	0.507	rs1655303	chr1:231731439	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.78	-15.32	-0.58	3.79e-43	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs1697139	0.563	rs6859520	chr5:66529020	C/T	cg11553311	chr5:66541588	NA	0.46	10.3	0.43	1.57e-22	Breast cancer;
LGG	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg22307297	chr20:60903441	LAMA5	0.44	8.44	0.37	3.99e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6750047	0.868	rs1431332	chr2:38280253	G/A	cg07380506	chr2:38303506	CYP1B1	0.44	7.46	0.33	4.25e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg08250081	chr4:10125330	NA	0.6	11.11	0.46	1.34e-25	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg02002194	chr4:3960332	NA	-0.43	-7.98	-0.35	1.13e-14	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18350792	chr12:112563442	TRAFD1	0.43	7.04	0.31	6.86e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.71	-0.34	7.74e-14	Lung cancer;
LGG	cis	rs7937890	0.559	rs2575852	chr11:14533368	G/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs9815354	0.812	rs61661916	chr3:41921915	T/C	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6912958	0.712	rs4706294	chr6:88317675	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.62	-0.37	1.07e-16	Monocyte percentage of white cells;
LGG	cis	rs9303401	0.614	rs3887355	chr17:56538639	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.36	0.56	5.99e-39	Cognitive test performance;
LGG	cis	rs11122272	0.735	rs2790884	chr1:231531932	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg23730037	chr7:158596552	ESYT2	-0.45	-8.01	-0.35	9.18e-15	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13620921	chr11:3400587	ZNF195	0.51	7.93	0.35	1.63e-14	Gut microbiome composition (summer);
LGG	cis	rs11971779	0.588	rs2003531	chr7:139126578	A/G	cg07862535	chr7:139043722	LUC7L2	0.46	7.59	0.33	1.8e-13	Diisocyanate-induced asthma;
LGG	cis	rs6960043	1.000	rs62448644	chr7:15053485	C/T	cg19272540	chr7:15055459	NA	-0.35	-7.88	-0.34	2.42e-14	Type 2 diabetes;
LGG	cis	rs17208368	0.657	rs16954195	chr16:55093432	C/T	cg11181171	chr16:55090946	NA	0.46	7.59	0.33	1.77e-13	Hypospadias;
LGG	cis	rs2836974	0.897	rs2836927	chr21:40543216	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.92	0.82	1.09e-114	Cognitive function;
LGG	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg17330251	chr7:94953956	PON1	-0.43	-8.33	-0.36	9.21e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg23166289	chr1:210001082	C1orf107	0.36	7.1	0.31	4.73e-12	Orofacial clefts;
LGG	cis	rs4803468	1.000	rs3810174	chr19:41904165	C/T	cg14132834	chr19:41945861	ATP5SL	-0.48	-9.55	-0.41	7.44e-20	Height;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg13395646	chr4:1353034	KIAA1530	-0.46	-7.89	-0.34	2.24e-14	Obesity-related traits;
LGG	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg04455712	chr21:45112962	RRP1B	0.51	10.03	0.42	1.47e-21	Mean corpuscular volume;
LGG	cis	rs36071027	0.615	rs56176059	chr5:158414823	T/C	cg23468002	chr5:158532401	NA	0.43	7.19	0.32	2.6e-12	Carotid intima media thickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25377726	chr2:45838438	SRBD1	0.5	7.38	0.32	7.62e-13	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.97	-0.38	7.65e-18	Menopause (age at onset);
LGG	cis	rs7814319	0.646	rs938828	chr8:97316821	A/C	cg20787634	chr8:97240163	UQCRB	-0.6	-12.8	-0.51	2.53e-32	Lung function (FVC);
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6754311	0.512	rs12998387	chr2:136507039	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-13.65	-0.54	6.64e-36	Mosquito bite size;
LGG	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.24	-0.39	9.21e-19	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.04	-0.42	1.35e-21	Lung cancer;
LGG	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.3e-14	Schizophrenia;
LGG	trans	rs1997103	0.834	rs10274457	chr7:55390199	G/A	cg20935933	chr6:143382018	AIG1	0.58	9.07	0.39	3.38e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg07659893	chr17:61819838	STRADA	0.5	8.32	0.36	1e-15	Prudent dietary pattern;
LGG	trans	rs12517041	1.000	rs35411935	chr5:23282784	T/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.4	6.73	0.3	4.95e-11	Prudent dietary pattern;
LGG	cis	rs4430311	0.723	rs2345994	chr1:243932275	T/C	cg25706552	chr1:244017396	NA	-0.65	-16.12	-0.6	1.01e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.75	-0.38	4.08e-17	Initial pursuit acceleration;
LGG	cis	rs1109114	0.934	rs1011399	chr5:148612061	A/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.57	-0.59	2.99e-44	Body mass index;
LGG	trans	rs9951602	0.512	rs73494176	chr18:76644895	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	13.18	0.52	6.56e-34	Obesity-related traits;
LGG	cis	rs6582630	0.519	rs8189599	chr12:38280748	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.18	0.52	6.87e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	16.49	0.61	2.23e-48	Personality dimensions;
LGG	cis	rs9296095	0.747	rs12206050	chr6:33564296	A/T	cg14003231	chr6:33640908	ITPR3	0.42	8.22	0.36	2.03e-15	Platelet count;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.44	0.53	5.49e-35	Lung cancer;
LGG	trans	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg21659725	chr3:3221576	CRBN	0.55	7.47	0.33	3.9e-13	Menarche (age at onset);
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg04166393	chr7:2884313	GNA12	0.47	9.09	0.39	2.92e-18	Height;
LGG	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg02811702	chr13:24901961	NA	0.39	7.42	0.33	5.56e-13	Obesity-related traits;
LGG	cis	rs1949733	0.585	rs2631768	chr4:8473050	A/G	cg13073564	chr4:8508604	NA	0.47	9.6	0.41	5.24e-20	Response to antineoplastic agents;
LGG	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs67460515	0.892	rs7610985	chr3:161062848	G/A	cg03342759	chr3:160939853	NMD3	-0.74	-12.93	-0.52	7e-33	Parkinson's disease;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.33	-0.47	2.03e-26	Personality dimensions;
LGG	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg19847130	chr8:10466454	RP1L1	0.32	6.94	0.31	1.34e-11	Neuroticism;
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg18681998	chr4:17616180	MED28	0.85	18.31	0.65	1.03e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.43	-0.61	4.03e-48	Skin colour saturation;
LGG	cis	rs1978968	0.957	rs34486385	chr22:18444290	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg16662043	chr16:48846231	NA	0.36	7.13	0.31	3.94e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1978968	0.956	rs7290762	chr22:18449130	C/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2952156	0.883	rs907088	chr17:37833567	G/C	cg07936489	chr17:37558343	FBXL20	-0.49	-8.38	-0.36	6.21e-16	Asthma;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.66e-12	Lung cancer;
LGG	cis	rs9715521	0.718	rs7441564	chr4:59845405	A/T	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08677398	chr8:58056175	NA	0.56	8.67	0.37	7.16e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.708	rs10839464	chr11:49981386	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.68e-54	Menopause (age at onset);
LGG	cis	rs34734847	0.787	rs695948	chr12:121149596	A/G	cg21892295	chr12:121157589	UNC119B	-0.39	-7.23	-0.32	2e-12	Mean corpuscular volume;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg19223190	chr17:80058835	NA	0.44	8.58	0.37	1.46e-16	Life satisfaction;
LGG	trans	rs7944735	0.575	rs34972471	chr11:48050391	G/A	cg15704280	chr7:45808275	SEPT13	0.69	9.43	0.4	1.97e-19	Intraocular pressure;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg05335186	chr13:53173507	NA	-0.52	-10.93	-0.45	6.81e-25	Lewy body disease;
LGG	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg16434002	chr17:42200994	HDAC5	0.43	7.62	0.33	1.44e-13	Total body bone mineral density;
LGG	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.84	0.54	1.01e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2842992	0.830	rs1535475	chr6:160148935	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	12.33	0.5	2.07e-30	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs17060993	0.618	rs9801891	chr8:26868846	C/T	cg19071002	chr6:63940486	NA	-0.5	-7.11	-0.31	4.52e-12	Musician's dystonia;
LGG	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg25358565	chr5:93447407	FAM172A	1.27	15.43	0.58	1.18e-43	Diabetic retinopathy;
LGG	cis	rs3126085	1.000	rs3126092	chr1:152307955	T/A	cg26876637	chr1:152193138	HRNR	-0.52	-7.95	-0.35	1.4e-14	Atopic dermatitis;
LGG	trans	rs6787172	0.702	rs1526192	chr3:158018030	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs240764	0.619	rs7452753	chr6:101053726	C/T	cg09795085	chr6:101329169	ASCC3	0.39	6.66	0.3	7.9e-11	Neuroticism;
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg08742575	chr21:47604166	C21orf56	0.55	9.87	0.42	5.51e-21	Testicular germ cell tumor;
LGG	trans	rs7939886	0.841	rs11227583	chr11:55995737	C/A	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	trans	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg13009111	chr11:71350975	NA	0.29	6.66	0.3	7.86e-11	Systolic blood pressure;
LGG	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg18252515	chr7:66147081	NA	1.34	18.11	0.64	7.91e-56	Diabetic kidney disease;
LGG	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.32	0.36	9.7e-16	Monocyte count;
LGG	cis	rs12493885	0.769	rs61791504	chr3:153745537	C/G	cg17054900	chr3:154042577	DHX36	-0.65	-8.41	-0.36	5.18e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7927771	0.524	rs7933896	chr11:47882782	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.14	0.46	1.05e-25	Subjective well-being;
LGG	cis	rs6582630	0.594	rs7308707	chr12:38450428	G/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.43	-0.4	2.04e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11890956	chr21:40555474	PSMG1	-1.17	-29.05	-0.8	2.07e-106	Cognitive function;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.49e-20	Bipolar disorder;
LGG	cis	rs7647973	1.000	rs4241407	chr3:49600319	C/T	cg06212747	chr3:49208901	KLHDC8B	0.48	7.56	0.33	2.11e-13	Menarche (age at onset);
LGG	cis	rs4750440	0.614	rs4750446	chr10:14030319	T/G	cg00551146	chr10:14014579	FRMD4A	0.31	7.37	0.32	7.76e-13	Adiponectin levels;
LGG	cis	rs7666738	0.830	rs59751489	chr4:98933802	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9921222	0.502	rs28461430	chr16:369562	G/A	cg07915516	chr16:377344	AXIN1	0.27	6.7	0.3	5.98e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4517514	0.509	rs10830417	chr11:89871940	A/G	cg14505434	chr11:89522851	NA	0.64	8.07	0.35	6.3e-15	Trans fatty acid levels;
LGG	cis	rs56283067	0.887	rs9463043	chr6:44771114	T/C	cg18551225	chr6:44695536	NA	-0.65	-10.81	-0.45	1.95e-24	Total body bone mineral density;
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.04	-0.31	6.77e-12	Aortic root size;
LGG	cis	rs4774899	0.932	rs4774251	chr15:57582269	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs6088580	0.634	rs1205345	chr20:32914699	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.21	-0.39	1.15e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs6088590	0.550	rs12624640	chr20:32952125	G/A	cg24642439	chr20:33292090	TP53INP2	0.69	11.61	0.47	1.56e-27	Coronary artery disease;
LGG	cis	rs7582180	0.903	rs13031493	chr2:100896376	G/C	cg26150922	chr2:100937072	LONRF2	-0.55	-9.66	-0.41	3.01e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs4948102	0.642	rs4948104	chr7:56142519	A/G	cg17215666	chr7:56131930	SUMF2	0.44	7.16	0.32	3.24e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg25019033	chr10:957182	NA	-0.56	-10.11	-0.43	7.88e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7712401	0.601	rs454617	chr5:122321927	A/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.55	-8.18	-0.36	2.73e-15	Body mass index;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.35	0.36	8.2e-16	Bipolar disorder;
LGG	trans	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.02e-30	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.64e-11	Lung cancer;
LGG	cis	rs875971	0.895	rs10755833	chr7:65913917	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs7474896	0.526	rs1742235	chr10:38052256	T/C	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.91	-0.35	1.85e-14	Obesity (extreme);
LGG	cis	rs2290402	0.536	rs7684266	chr4:856609	T/C	cg09237302	chr4:906077	GAK	-0.44	-7.43	-0.33	5.17e-13	Type 2 diabetes;
LGG	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.77	0.59	3.78e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2559856	1.000	rs2559855	chr12:102090080	A/G	cg12924262	chr12:102091054	CHPT1	-0.61	-10.89	-0.45	9.48e-25	Blood protein levels;
LGG	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg09448879	chr15:79043637	NA	0.42	7.34	0.32	9.52e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs7944735	0.567	rs7111404	chr11:48011283	C/G	cg15704280	chr7:45808275	SEPT13	0.72	7.58	0.33	1.93e-13	Intraocular pressure;
LGG	cis	rs9596863	0.898	rs9568917	chr13:54351040	G/A	ch.13.53330881F	chr13:54432880	NA	0.53	7.2	0.32	2.49e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2334880	0.836	rs9934715	chr16:71757387	C/G	cg06353428	chr16:71660113	MARVELD3	1.26	21.53	0.71	9.43e-72	Malaria;
LGG	cis	rs4654899	0.865	rs10916910	chr1:21283192	G/T	cg05370193	chr1:21551575	ECE1	0.3	6.86	0.3	2.21e-11	Superior frontal gyrus grey matter volume;
LGG	cis	rs10905065	0.804	rs2380203	chr10:5810897	A/G	cg11519256	chr10:5708881	ASB13	0.41	7.12	0.31	4.2e-12	Menopause (age at onset);
LGG	cis	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg00383909	chr3:49044727	WDR6	0.96	12.34	0.5	1.9e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.83	17.12	0.62	2.85e-51	Personality dimensions;
LGG	trans	rs6598955	0.671	rs12090258	chr1:26644698	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-12.73	-0.51	4.67e-32	Obesity-related traits;
LGG	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.93	0.35	1.62e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3762637	0.941	rs9837149	chr3:122230845	G/C	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	cis	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg21775007	chr8:11205619	TDH	-0.49	-7.53	-0.33	2.7e-13	Triglycerides;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06642177	chr6:134496341	SGK1	0.51	8.75	0.38	3.94e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	8.88	0.38	1.45e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.6	-0.37	1.28e-16	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.12	-0.43	6.99e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg14926445	chr8:58193284	C8orf71	-0.87	-11.64	-0.48	1.16e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.45	-0.37	3.88e-16	Aortic root size;
LGG	cis	rs3764563	0.877	rs4646526	chr19:15729773	A/G	cg20725493	chr19:15740067	CYP4F8	-0.66	-8.35	-0.36	7.72e-16	Inflammatory biomarkers;
LGG	cis	rs427394	0.802	rs274698	chr5:6730957	T/G	cg15145174	chr5:6755386	POLS	-0.4	-7.6	-0.33	1.65e-13	Menopause (age at onset);
LGG	cis	rs2153535	0.526	rs9406179	chr6:8538224	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.15	0.39	1.83e-18	Motion sickness;
LGG	cis	rs708547	0.836	rs1315005	chr4:57858237	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	12.0	0.49	4.48e-29	Response to bleomycin (chromatid breaks);
LGG	cis	rs9747201	1.000	rs4506966	chr17:80175421	T/C	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7772486	0.875	rs9399573	chr6:146403255	A/T	cg23711669	chr6:146136114	FBXO30	0.39	6.77	0.3	3.87e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11634851	0.565	rs972481	chr15:81026925	A/G	cg03950166	chr15:80988613	FAM108C1	0.43	7.71	0.34	7.67e-14	Systolic blood pressure;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg04287289	chr16:89883240	FANCA	0.75	7.24	0.32	1.86e-12	Skin colour saturation;
LGG	cis	rs258892	0.843	rs34455289	chr5:72053282	G/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.71	-0.3	5.71e-11	Small cell lung carcinoma;
LGG	cis	rs155076	0.711	rs4770131	chr13:21897468	A/G	cg14456004	chr13:21872349	NA	1.32	23.92	0.74	6.46e-83	White matter hyperintensity burden;
LGG	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs6784615	0.744	rs419050	chr3:52426884	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.88	0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.55	-0.44	1.77e-23	Alzheimer's disease;
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg14912033	chr15:79043428	NA	-0.41	-10.39	-0.43	7.02e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs4731207	0.698	rs7794710	chr7:124561115	C/G	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs9636252	0.605	rs12622209	chr2:9274692	A/C	cg20341998	chr2:9276514	NA	-0.41	-8.2	-0.36	2.3e-15	IgG glycosylation;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.03	0.42	1.46e-21	Tonsillectomy;
LGG	cis	rs9381040	0.610	rs2235679	chr6:41020577	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.72	-0.3	5.34e-11	Alzheimer's disease (late onset);
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs58688157	0.705	rs936469	chr11:606749	G/A	cg16486109	chr11:613632	IRF7	0.43	7.21	0.32	2.27e-12	Systemic lupus erythematosus;
LGG	cis	rs1018836	0.828	rs7006279	chr8:91605364	A/G	cg16814680	chr8:91681699	NA	-0.76	-14.01	-0.55	1.93e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.02	0.31	8.15e-12	Parkinson's disease;
LGG	cis	rs240110	0.570	rs966741	chr6:101218375	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.7	-0.3	6.08e-11	Arsenic metabolism;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.05e-21	Electroencephalogram traits;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.73	-0.3	5.04e-11	Personality dimensions;
LGG	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15541040	chr2:3486749	NA	-0.46	-8.37	-0.36	6.76e-16	Neurofibrillary tangles;
LGG	cis	rs9976767	0.714	rs35269816	chr21:43835087	A/G	cg23042151	chr21:43824109	UBASH3A	-0.49	-9.42	-0.4	2.13e-19	Type 1 diabetes;
LGG	cis	rs4319547	0.656	rs7975747	chr12:122816995	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.63	-0.41	4.09e-20	Body mass index;
LGG	cis	rs3784262	0.669	rs2197092	chr15:58247781	C/T	cg12031962	chr15:58353849	ALDH1A2	0.33	7.19	0.32	2.55e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg07382826	chr16:28625726	SULT1A1	-0.35	-6.87	-0.3	2.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2976388	0.967	rs2976397	chr8:143764613	G/T	cg06565975	chr8:143823917	SLURP1	-0.4	-10.04	-0.42	1.39e-21	Urinary tract infection frequency;
LGG	cis	rs6800768	0.633	rs12498129	chr3:24120454	A/G	cg10674438	chr3:24145617	LOC152024	-0.51	-9.09	-0.39	2.96e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.11	-0.31	4.45e-12	Mood instability;
LGG	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.64	0.37	9.05e-17	Colorectal cancer;
LGG	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.56e-35	Anterior chamber depth;
LGG	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg02487422	chr3:49467188	NICN1	0.58	10.72	0.45	4.19e-24	Resting heart rate;
LGG	cis	rs9911578	1.000	rs12602346	chr17:56901713	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	trans	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs2285947	1.000	rs2285947	chr7:21584088	A/G	cg04471919	chr7:21584483	DNAH11	-0.49	-13.86	-0.54	8.68e-37	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs9329221	0.662	rs35472251	chr8:10246669	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.7	0.3	5.97e-11	Neuroticism;
LGG	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg26897989	chr16:1907736	C16orf73	-0.63	-9.97	-0.42	2.4e-21	Insulin-like growth factors;
LGG	trans	rs36715	1.000	rs251213	chr5:127545605	C/T	cg16011800	chr17:1958478	HIC1	-0.46	-6.72	-0.3	5.38e-11	Breast cancer;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg05064044	chr6:292385	DUSP22	-0.49	-8.58	-0.37	1.43e-16	Menopause (age at onset);
LGG	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg09754948	chr16:28834200	ATXN2L	0.5	7.93	0.35	1.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs2072732	0.756	rs55949537	chr1:2936746	A/T	cg22517653	chr1:2918612	NA	-0.52	-7.29	-0.32	1.35e-12	Plateletcrit;
LGG	cis	rs1915146	0.935	rs1057234	chr10:126850793	C/G	cg03862225	chr10:126850454	CTBP2	0.25	6.98	0.31	9.97e-12	Menarche (age at onset);
LGG	cis	rs2559856	1.000	rs2695299	chr12:102082664	G/A	cg15068132	chr12:102092402	CHPT1	-0.36	-6.66	-0.3	7.88e-11	Blood protein levels;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.41	2.67e-20	Bipolar disorder;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg26174226	chr8:58114915	NA	-0.53	-7.9	-0.34	2.03e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs72781680	0.898	rs72782137	chr2:24047805	C/T	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.71e-18	Lymphocyte counts;
LGG	cis	rs537930	0.925	rs503035	chr5:134353734	A/G	cg24576358	chr5:134350122	NA	0.43	8.94	0.38	9.53e-18	Height;
LGG	cis	rs35123781	1.000	rs601324	chr5:139057179	C/G	cg21230503	chr5:139085173	NA	0.31	7.41	0.33	5.92e-13	Schizophrenia;
LGG	cis	rs36093844	0.752	rs17817343	chr11:85598312	C/T	cg16165120	chr11:85566439	CCDC83	-0.43	-6.73	-0.3	4.96e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6909430	0.731	rs2450510	chr6:98612792	G/A	cg12860156	chr6:98744658	NA	-0.39	-6.95	-0.31	1.23e-11	Quantitative traits;
LGG	trans	rs61931739	0.578	rs61927759	chr12:33713297	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.61	-0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs5742933	0.779	rs1899025	chr2:190649582	C/T	cg04003228	chr2:190539410	ANKAR	-0.46	-6.78	-0.3	3.64e-11	Ferritin levels;
LGG	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.79	14.33	0.55	8.65e-39	Menarche (age at onset);
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg02002194	chr4:3960332	NA	0.43	7.87	0.34	2.61e-14	Triglycerides;
LGG	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-7.88	-0.34	2.28e-14	Schizophrenia;
LGG	cis	rs4077515	0.839	rs3812570	chr9:139275204	A/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.42	0.33	5.58e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3087591	1.000	rs2952982	chr17:29470646	A/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.55	0.56	9.18e-40	Hip circumference;
LGG	trans	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.42	0.4	2.15e-19	Aortic root size;
LGG	cis	rs709400	1.000	rs3915733	chr14:104147353	G/A	cg26031613	chr14:104095156	KLC1	1.14	27.5	0.79	2.2e-99	Body mass index;
LGG	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg04117972	chr1:227635322	NA	-0.6	-10.08	-0.42	9.87e-22	Major depressive disorder;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.89	-0.3	1.83e-11	Joint mobility (Beighton score);
LGG	cis	rs9527	0.590	rs10883839	chr10:104920341	A/G	cg04362960	chr10:104952993	NT5C2	0.54	9.63	0.41	4.08e-20	Arsenic metabolism;
LGG	trans	rs79911532	0.515	rs77381667	chr7:75663126	C/T	cg19862616	chr7:65841803	NCRNA00174	0.73	7.64	0.33	1.27e-13	Mononucleosis;
LGG	cis	rs12704876	0.509	rs1464808	chr7:96363633	A/T	cg03808172	chr7:96339361	SHFM1	0.56	10.2	0.43	3.55e-22	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-9.41	-0.4	2.3e-19	Coronary artery disease;
LGG	trans	rs2624839	0.602	rs2526398	chr3:50187596	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	6.72	0.3	5.37e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7717393	0.786	rs72798948	chr5:155800893	G/A	cg12904904	chr5:155754151	SGCD	0.7	7.63	0.33	1.31e-13	Egg allergy;
LGG	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg09307838	chr4:120376055	NA	-0.68	-11.97	-0.49	5.72e-29	Corneal astigmatism;
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg16301924	chr13:53314226	LECT1	0.41	8.2	0.36	2.32e-15	Lewy body disease;
LGG	cis	rs2180341	0.883	rs7760748	chr6:127690062	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.21	0.72	6.23e-75	Breast cancer;
LGG	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg04691961	chr3:161091175	C3orf57	-0.39	-7.83	-0.34	3.3e-14	Educational attainment (years of education);
LGG	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.19	-0.39	1.33e-18	Systemic lupus erythematosus;
LGG	cis	rs7264396	0.677	rs6060553	chr20:34267386	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.29	0.32	1.31e-12	Total cholesterol levels;
LGG	cis	rs6708331	0.941	rs10173330	chr2:70367113	G/T	cg01613454	chr2:70366299	NA	0.51	9.04	0.39	4.4e-18	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs61990749	0.544	rs1477259	chr14:78256138	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	6.99	0.31	9.84e-12	Fibroblast growth factor basic levels;
LGG	cis	rs10089	1.000	rs1864922	chr5:127420700	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.97	0.49	5.84e-29	Ileal carcinoids;
LGG	cis	rs7267979	0.816	rs409853	chr20:25506067	T/C	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.68e-17	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21008684	chr2:157198370	NA	0.43	6.94	0.31	1.35e-11	Cognitive performance;
LGG	cis	rs75059851	1.000	rs73036064	chr11:133829442	G/A	cg20042908	chr11:133852938	NA	-0.69	-12.5	-0.5	4.09e-31	Schizophrenia;
LGG	trans	rs7618501	0.571	rs2240329	chr3:50107512	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.9	-0.34	2e-14	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs62276839	chr3:153780407	C/T	cg12800244	chr3:153838788	SGEF	-0.76	-8.56	-0.37	1.65e-16	Coronary artery disease;
LGG	cis	rs4819052	0.851	rs13050359	chr21:46672671	T/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.65	0.51	1.04e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6754311	0.773	rs309178	chr2:136611624	C/T	cg07169764	chr2:136633963	MCM6	-0.77	-13.08	-0.52	1.77e-33	Mosquito bite size;
LGG	trans	rs2727020	0.729	rs588458	chr11:49214048	C/A	cg00717180	chr2:96193071	NA	0.4	7.18	0.32	2.82e-12	Coronary artery disease;
LGG	cis	rs881375	0.631	rs10739577	chr9:123668854	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.05	0.52	2.4e-33	Rheumatoid arthritis;
LGG	cis	rs11785400	0.793	rs750530	chr8:143744931	G/A	cg24634471	chr8:143751801	JRK	0.5	7.66	0.34	1.09e-13	Schizophrenia;
LGG	cis	rs10911251	0.528	rs4652777	chr1:183091992	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	cis	rs7666738	0.791	rs1830231	chr4:99026185	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.45	0.37	3.78e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.65	0.3	8.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.31	-0.36	1.07e-15	Tonsillectomy;
LGG	cis	rs7617773	0.780	rs3731550	chr3:48206583	A/C	cg11946769	chr3:48343235	NME6	0.69	11.3	0.46	2.69e-26	Coronary artery disease;
LGG	cis	rs6460942	1.000	rs6970095	chr7:12403840	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.77	-0.3	3.81e-11	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs7444	0.941	rs2266961	chr22:21928597	C/G	cg05046821	chr22:21984468	YDJC	-0.4	-7.12	-0.31	4.1e-12	Systemic lupus erythematosus;
LGG	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.81	-16.16	-0.6	6.65e-47	Lung cancer;
LGG	cis	rs7587476	1.000	rs7587476	chr2:215653887	T/C	cg04004882	chr2:215674386	BARD1	-0.55	-7.83	-0.34	3.34e-14	Neuroblastoma;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg07701084	chr6:150067640	NUP43	0.68	12.4	0.5	1.09e-30	Lung cancer;
LGG	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg26513180	chr16:89883248	FANCA	0.95	21.84	0.71	3.23e-73	Vitiligo;
LGG	trans	rs6561151	0.681	rs17653353	chr13:44421746	A/G	cg12856521	chr11:46389249	DGKZ	0.91	14.49	0.56	1.61e-39	Crohn's disease;
LGG	cis	rs4774899	1.000	rs1430823	chr15:57323279	T/G	cg08128148	chr15:57256372	TCF12	-0.33	-7.85	-0.34	3.02e-14	Urinary tract infection frequency;
LGG	cis	rs644799	0.511	rs11021302	chr11:95485768	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	9.31	0.4	4.97e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9400467	0.537	rs12196955	chr6:111442937	A/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.72	0.3	5.49e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4742903	0.935	rs10119876	chr9:106961080	T/G	cg14250997	chr9:106856677	SMC2	0.39	8.1	0.35	4.87e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.88e-11	Aortic root size;
LGG	cis	rs7017914	0.967	rs13257800	chr8:71714133	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.39	-7.05	-0.31	6.68e-12	Bone mineral density;
LGG	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	cg07928641	chr1:182991847	LAMC1	0.45	9.04	0.39	4.44e-18	Colorectal cancer;
LGG	cis	rs1670533	1.000	rs2045066	chr4:1052401	C/T	cg27284194	chr4:1044797	NA	0.53	9.65	0.41	3.3e-20	Recombination rate (females);
LGG	trans	rs637571	0.528	rs566266	chr11:65573587	A/C	cg17712092	chr4:129076599	LARP1B	-0.67	-12.25	-0.49	4.3e-30	Eosinophil percentage of white cells;
LGG	trans	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.78	-0.34	4.74e-14	Joint mobility (Beighton score);
LGG	cis	rs12477438	1.000	rs995617	chr2:99857904	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.84	13.2	0.52	5.52e-34	Chronic sinus infection;
LGG	trans	rs11875185	0.510	rs17692919	chr18:55618315	A/C	cg15513957	chr14:69354734	ACTN1	-0.87	-8.77	-0.38	3.42e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6952808	0.756	rs12537348	chr7:1948172	C/G	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.97	-0.49	5.84e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs11644362	0.966	rs11645507	chr16:12992570	C/A	cg08528231	chr16:12997261	SHISA9	-0.37	-7.3	-0.32	1.23e-12	Positive affect;Subjective well-being;
LGG	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg15309053	chr8:964076	NA	0.43	9.09	0.39	2.86e-18	Schizophrenia;
LGG	cis	rs7945705	0.846	rs905290	chr11:8753729	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.45	9.04	0.39	4.19e-18	Hemoglobin concentration;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02972793	chr2:3322136	TSSC1	0.37	7.41	0.33	5.92e-13	Electrocardiographic conduction measures;
LGG	cis	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg06521331	chr12:34319734	NA	-0.4	-7.13	-0.31	3.84e-12	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25517755	chr10:38738941	LOC399744	-0.38	-6.86	-0.3	2.24e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8114671	0.562	rs2273683	chr20:33509523	C/T	cg07148914	chr20:33460835	GGT7	0.58	9.66	0.41	3.18e-20	Height;
LGG	trans	rs61931739	0.534	rs7138522	chr12:34039762	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.84e-46	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg08888203	chr3:10149979	C3orf24	0.41	7.54	0.33	2.48e-13	Alzheimer's disease;
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs17767392	0.958	rs12896986	chr14:71922893	T/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.57	-0.37	1.57e-16	Lung cancer;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg21302120	chr4:24585281	DHX15	-0.43	-7.18	-0.32	2.84e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11088226	0.538	rs4816436	chr21:33880251	A/G	cg09050820	chr6:167586206	TCP10L2	0.49	7.95	0.35	1.46e-14	Gastritis;
LGG	cis	rs2153535	0.560	rs9379214	chr6:8480870	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.06	0.42	1.14e-21	Motion sickness;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23213688	chr1:231473791	C1orf124;EXOC8	-0.43	-7.12	-0.31	4.18e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs8049040	0.586	rs8060176	chr16:71456757	T/C	cg06353428	chr16:71660113	MARVELD3	-0.46	-7.35	-0.32	9.03e-13	Blood protein levels;
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg11984989	chr7:158649758	WDR60	1.06	24.56	0.75	7.03e-86	Height;
LGG	cis	rs8062405	0.540	rs151226	chr16:28549823	A/C	cg00198680	chr16:28758506	NA	0.29	7.44	0.33	4.9e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg17202724	chr17:61916730	SMARCD2	0.49	10.86	0.45	1.26e-24	Prudent dietary pattern;
LGG	cis	rs977747	0.872	rs743270	chr1:47675536	G/C	cg03885399	chr1:47691550	TAL1	-0.36	-7.74	-0.34	6.31e-14	Body mass index;
LGG	cis	rs2120019	0.935	rs8042409	chr15:75350433	G/A	cg17294928	chr15:75287854	SCAMP5	-0.95	-17.03	-0.62	7.19e-51	Blood trace element (Zn levels);
LGG	cis	rs2694528	0.858	rs113306887	chr5:60392766	G/A	cg11474532	chr5:59995715	DEPDC1B	0.67	7.17	0.32	2.99e-12	Parkinson's disease;
LGG	cis	rs79349575	0.715	rs55724082	chr17:47017879	G/A	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	trans	rs6582630	0.576	rs4403871	chr12:38292193	G/A	cg06521331	chr12:34319734	NA	0.45	7.92	0.35	1.74e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg21827317	chr3:136751795	NA	0.53	9.91	0.42	3.86e-21	Neuroticism;
LGG	cis	rs9462027	0.628	rs7776219	chr6:34784667	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg24130564	chr14:104152367	KLC1	-0.42	-8.04	-0.35	7.69e-15	Body mass index;
LGG	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg05491587	chr18:77659695	KCNG2	-0.41	-7.41	-0.33	5.96e-13	Schizophrenia;
LGG	cis	rs3206736	0.548	rs73110562	chr7:35069923	G/A	cg13400248	chr7:35225412	NA	0.55	9.51	0.4	1.07e-19	Diastolic blood pressure;
LGG	cis	rs2549003	1.000	rs2549003	chr5:131829297	A/G	cg21138405	chr5:131827807	IRF1	0.39	10.36	0.43	9.43e-23	Asthma (sex interaction);
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.49e-13	IgG glycosylation;
LGG	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg04111992	chr7:158790115	NA	-0.38	-7.68	-0.34	9.73e-14	Facial morphology (factor 20);
LGG	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg19980929	chr12:42632907	YAF2	0.35	7.71	0.34	7.69e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10170846	0.800	rs10180462	chr2:223526385	C/T	cg25565276	chr2:223520875	FARSB	0.64	11.26	0.46	3.69e-26	Schizophrenia (inflammation and infection response interaction);
LGG	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Aortic root size;
LGG	cis	rs8180040	1.000	rs1076394	chr3:47322781	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-15.85	-0.59	1.67e-45	Colorectal cancer;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg12458913	chr13:53173898	NA	-0.67	-12.97	-0.52	4.71e-33	Lewy body disease;
LGG	cis	rs17604090	0.775	rs73090343	chr7:29688768	T/C	cg19413766	chr7:29689036	LOC646762	-0.54	-6.85	-0.3	2.33e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs17253792	0.822	rs12100753	chr14:56042870	G/A	cg01858014	chr14:56050164	KTN1	-0.88	-11.5	-0.47	4.36e-27	Putamen volume;
LGG	cis	rs3747547	1.000	rs72724195	chr9:37948063	C/T	cg13774184	chr9:37916125	SHB	-0.73	-6.91	-0.31	1.58e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.45	0.33	4.61e-13	Menopause (age at onset);
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg00761968	chr13:53314142	LECT1	-0.39	-7.86	-0.34	2.81e-14	Lewy body disease;
LGG	cis	rs2282032	1.000	rs115667214	chr14:90733890	A/G	cg04374321	chr14:90722782	PSMC1	0.5	6.86	0.3	2.15e-11	Longevity;
LGG	cis	rs868036	0.681	rs4776977	chr15:68108219	C/T	cg22044901	chr15:68126292	NA	-0.4	-6.86	-0.3	2.18e-11	Restless legs syndrome;
LGG	trans	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.76	13.95	0.54	3.7e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg09699651	chr6:150184138	LRP11	0.5	8.67	0.37	7.07e-17	Lung cancer;
LGG	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg07061783	chr6:25882402	NA	-0.46	-7.91	-0.34	1.94e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4073582	0.595	rs801737	chr11:65928193	T/C	cg14036092	chr11:66035641	RAB1B	0.44	7.77	0.34	5.16e-14	Gout;
LGG	cis	rs4481887	0.861	rs4575112	chr1:248473534	A/G	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	0.34	8.82	0.38	2.27e-17	IgG glycosylation;
LGG	cis	rs7937612	1.000	rs10892567	chr11:120244192	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.1	-0.52	1.45e-33	Intraocular pressure;
LGG	cis	rs3806933	0.522	rs11241100	chr5:110460958	C/T	cg04022379	chr5:110408740	TSLP	0.49	8.2	0.36	2.35e-15	Eosinophilic esophagitis;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.77	0.45	2.82e-24	Personality dimensions;
LGG	cis	rs2816316	0.636	rs1323299	chr1:192510030	T/G	cg02586212	chr1:192544902	RGS1	0.31	6.81	0.3	3.1e-11	Celiac disease;
LGG	cis	rs9534288	0.797	rs7990095	chr13:46587262	G/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg07511668	chr11:68622177	NA	0.48	9.24	0.39	9.28e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4262150	0.544	rs2961745	chr5:151916826	C/T	cg12297329	chr5:152029980	NA	-0.61	-11.11	-0.46	1.41e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	6.96	0.31	1.17e-11	Schizophrenia;
LGG	cis	rs911555	0.755	rs1138400	chr14:103956833	A/G	cg24130564	chr14:104152367	KLC1	-0.39	-7.19	-0.32	2.59e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg02030672	chr11:45687055	CHST1	-0.5	-8.9	-0.38	1.24e-17	Obesity-related traits;
LGG	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg03929089	chr4:120376271	NA	-1.03	-22.63	-0.72	6.82e-77	Height;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.65	0.33	1.18e-13	Lung cancer;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg18165381	chr3:44552316	NA	-0.41	-6.88	-0.3	2e-11	Depressive symptoms;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.87	-0.42	5.56e-21	Lung cancer;
LGG	trans	rs9302065	0.681	rs9524902	chr13:95963518	C/T	cg19955956	chr7:72299837	SBDSP;TYW1B	0.41	7.51	0.33	3.03e-13	Blood metabolite levels;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg20607798	chr8:58055168	NA	0.69	7.72	0.34	7.06e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.522	rs79152613	chr22:32413707	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21553154	chr22:36784489	MYH9	0.49	7.47	0.33	4.14e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg03188948	chr7:1209495	NA	0.67	8.66	0.37	8.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg11245990	chr11:68621969	NA	0.42	8.85	0.38	1.8e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13202913	0.733	rs13215869	chr6:151803659	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.59	7.51	0.33	3.12e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7166081	1.000	rs9806590	chr15:67516341	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.67	0.3	7.26e-11	Retinal vascular caliber;
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg11965913	chr1:205819406	PM20D1	-0.52	-8.41	-0.36	5e-16	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs308971	0.520	rs373827	chr3:12076475	C/T	cg15873301	chr3:12045459	SYN2	0.54	6.94	0.31	1.37e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	1.0	14.8	0.57	7.77e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.95	0.54	3.53e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6817170	0.692	rs11099882	chr4:154371971	T/C	cg07229402	chr4:154369277	NA	0.34	6.66	0.3	7.81e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs4727027	0.901	rs7794500	chr7:148819519	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.44	-6.75	-0.3	4.31e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9911578	0.805	rs1811202	chr17:56454435	T/G	cg12560992	chr17:57184187	TRIM37	-0.73	-12.08	-0.49	2.2e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.546	rs683978	chr11:68192421	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-10.73	-0.45	3.95e-24	Total body bone mineral density;
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg12751644	chr20:60527061	NA	0.44	9.55	0.41	7.66e-20	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs490234	0.841	rs13285366	chr9:128375047	G/A	cg14078157	chr9:128172775	NA	-0.48	-8.9	-0.38	1.25e-17	Mean arterial pressure;
LGG	trans	rs9329221	0.725	rs11250001	chr8:10255901	G/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.85	-0.3	2.29e-11	Neuroticism;
LGG	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.49	-0.44	3.05e-23	Total body bone mineral density;
LGG	cis	rs12618769	0.543	rs56357378	chr2:99032455	T/G	cg18455616	chr2:99124870	INPP4A	0.3	8.77	0.38	3.42e-17	Bipolar disorder;
LGG	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg07636037	chr3:49044803	WDR6	0.82	14.39	0.56	4.52e-39	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.64	-0.37	8.9e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs35164067	1.000	rs35164067	chr19:10525181	G/A	cg21868191	chr19:10515988	NA	-0.52	-7.61	-0.33	1.56e-13	Inflammatory bowel disease;
LGG	cis	rs17253792	0.822	rs9972180	chr14:56073732	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Calcium levels;
LGG	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.82	-17.47	-0.63	7.39e-53	Chronic sinus infection;
LGG	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.25	-0.32	1.73e-12	Mood instability;
LGG	cis	rs56399783	0.901	rs17300022	chr7:2808517	C/T	cg19731401	chr7:2775893	GNA12	-0.37	-7.3	-0.32	1.25e-12	Childhood ear infection;
LGG	cis	rs2070997	0.756	rs7872328	chr9:133727453	T/A	cg13397898	chr9:133768931	QRFP	0.38	7.69	0.34	9.11e-14	Response to amphetamines;
LGG	cis	rs11190604	0.945	rs2495746	chr10:102328270	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	11.81	0.48	2.62e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6089584	0.545	rs6089578	chr20:60554636	G/T	cg13770153	chr20:60521292	NA	-0.42	-6.88	-0.3	1.9e-11	Body mass index;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.13	-0.49	1.34e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs2721811	0.738	rs2521757	chr7:24761669	C/T	cg06301139	chr7:24798175	DFNA5	0.4	7.4	0.33	6.64e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6772849	0.775	rs12486377	chr3:128414853	G/C	cg08795948	chr3:128337044	NA	0.63	9.82	0.42	8.69e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs509477	1.000	rs7240845	chr18:32574960	G/C	cg23791764	chr18:32556832	MAPRE2	-0.51	-8.63	-0.37	1.02e-16	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs11785693	0.862	rs11781233	chr8:4993653	C/G	cg26367366	chr8:4980734	NA	-1.03	-16.52	-0.61	1.63e-48	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.25	-0.32	1.8e-12	Triglycerides;
LGG	cis	rs3540	0.513	rs2589962	chr15:90921636	G/A	cg22089800	chr15:90895588	ZNF774	0.73	13.55	0.53	1.81e-35	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2797369	0.600	rs11155726	chr6:101315102	C/A	cg27451362	chr6:101846650	GRIK2	0.68	9.19	0.39	1.38e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19524238	chr7:2802976	GNA12	0.39	8.9	0.38	1.24e-17	Height;
LGG	cis	rs62238980	0.614	rs116982428	chr22:32381272	G/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs28595532	0.841	rs114465037	chr4:119778165	A/G	cg21605333	chr4:119757512	SEC24D	1.47	13.64	0.54	7.78e-36	Cannabis dependence symptom count;
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	1.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12618769	0.625	rs3769736	chr2:99089119	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.4	-0.33	6.52e-13	Initial pursuit acceleration;
LGG	cis	rs10504130	0.569	rs35032384	chr8:52823084	T/A	cg24946253	chr8:52722146	PXDNL	-0.46	-6.78	-0.3	3.79e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs908922	0.676	rs7529136	chr1:152516389	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.1	-0.55	8.33e-38	Hair morphology;
LGG	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg18245976	chr7:158708271	WDR60	-0.62	-8.18	-0.36	2.7e-15	Height;
LGG	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04530015	chr2:215796436	ABCA12	-0.45	-7.72	-0.34	7.2e-14	Neuroblastoma;
LGG	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.03	-0.49	3.37e-29	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.963	rs12310956	chr12:33970682	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-10.28	-0.43	1.77e-22	Morning vs. evening chronotype;
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.78	15.43	0.58	1.2e-43	Age at first birth;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.62	0.37	1.05e-16	Obesity-related traits;
LGG	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg26248373	chr2:1572462	NA	-0.85	-14.21	-0.55	2.66e-38	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6964587	0.626	rs4729011	chr7:91515419	G/A	cg17063962	chr7:91808500	NA	-0.44	-7.94	-0.35	1.57e-14	Breast cancer;
LGG	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg14541582	chr5:601475	NA	-0.68	-10.65	-0.44	7.51e-24	Obesity-related traits;
LGG	cis	rs12479064	0.694	rs4341989	chr2:100046783	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-11.31	-0.47	2.4e-26	Chronic sinus infection;
LGG	cis	rs1552244	0.938	rs56274701	chr3:10167790	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.01	0.31	8.34e-12	Alzheimer's disease;
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg11984989	chr7:158649758	WDR60	1.04	23.94	0.74	5.34e-83	Height;
LGG	cis	rs60180747	1.000	rs76428668	chr15:66839282	T/G	cg07575407	chr15:66541975	MEGF11	0.35	6.85	0.3	2.36e-11	Testicular germ cell tumor;
LGG	cis	rs2070488	0.965	rs2154778	chr3:38553639	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.53	-0.63	3.95e-53	Electrocardiographic conduction measures;
LGG	cis	rs7106204	0.702	rs11826172	chr11:24233998	G/A	ch.11.24196551F	chr11:24239977	NA	1.02	16.24	0.6	3.03e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1348850	0.668	rs4893972	chr2:178496874	T/C	cg27490568	chr2:178487706	NA	0.69	13.05	0.52	2.2e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13113963	chr6:170863576	PSMB1;TBP	0.5	7.75	0.34	6.03e-14	Gut microbiome composition (summer);
LGG	cis	rs9487051	0.676	rs6933326	chr6:109601333	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.97	-0.35	1.29e-14	Reticulocyte fraction of red cells;
LGG	cis	rs12188164	0.812	rs9313065	chr5:423426	T/C	cg21972741	chr5:435613	AHRR	0.39	7.13	0.31	3.82e-12	Cystic fibrosis severity;
LGG	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs7929679	0.521	rs11499809	chr11:34790743	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg07747251	chr5:1868357	NA	0.47	9.52	0.4	9.27e-20	Cardiovascular disease risk factors;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg03929089	chr4:120376271	NA	-1.03	-23.79	-0.74	2.53e-82	Height;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.4	-0.47	1.01e-26	Neuroticism;
LGG	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg01448562	chr3:133502909	NA	-0.73	-13.28	-0.53	2.52e-34	Iron status biomarkers;
LGG	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg05535760	chr7:792225	HEATR2	-0.41	-7.0	-0.31	9.19e-12	Perceived unattractiveness to mosquitoes;
LGG	cis	rs4262150	0.846	rs72799161	chr5:152129607	T/C	cg12297329	chr5:152029980	NA	-0.7	-12.92	-0.51	7.93e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs4423214	1.000	rs11606612	chr11:71164047	C/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05665937	chr4:1216051	CTBP1	0.54	9.97	0.42	2.35e-21	Obesity-related traits;
LGG	cis	rs7618501	0.635	rs34080578	chr3:50026029	A/C	cg05623727	chr3:50126028	RBM5	0.32	7.05	0.31	6.66e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg14541582	chr5:601475	NA	-0.68	-10.66	-0.44	7.01e-24	Obesity-related traits;
LGG	trans	rs9329221	0.686	rs13264580	chr8:10250699	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	6.9	0.31	1.73e-11	Neuroticism;
LGG	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.36	7.22	0.32	2.18e-12	Hemoglobin concentration;
LGG	cis	rs6500395	1.000	rs11076578	chr16:48714520	C/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4478037	0.732	rs12490111	chr3:33103007	G/A	cg19404215	chr3:33155277	CRTAP	0.78	8.89	0.38	1.34e-17	Major depressive disorder;
LGG	trans	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.67	-12.0	-0.49	4.69e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1957429	0.614	rs61012404	chr14:65347649	C/T	cg23373153	chr14:65346875	NA	-1.08	-12.1	-0.49	1.76e-29	Pediatric areal bone mineral density (radius);
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg14092988	chr3:52407081	DNAH1	0.33	8.48	0.37	2.96e-16	Bipolar disorder;
LGG	cis	rs2708240	0.577	rs2373270	chr7:147567042	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-7.85	-0.34	2.96e-14	QT interval (drug interaction);
LGG	cis	rs7660883	0.897	rs342437	chr4:88040909	A/G	cg21988461	chr4:88008667	AFF1	0.35	10.2	0.43	3.59e-22	HDL cholesterol levels;
LGG	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg08975724	chr8:8085496	FLJ10661	0.49	9.31	0.4	5.11e-19	Joint mobility (Beighton score);
LGG	cis	rs6993813	0.872	rs10091277	chr8:120034387	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.91	0.31	1.66e-11	Bone mineral density (hip);
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg17911788	chr17:44343683	NA	-0.6	-9.18	-0.39	1.4e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12477438	0.520	rs61103312	chr2:100005612	T/A	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.26e-23	Resting heart rate;
LGG	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg26396452	chr14:65542826	MAX	0.49	10.21	0.43	3.37e-22	Obesity-related traits;
LGG	cis	rs16837677	0.826	rs76114442	chr1:156699977	G/A	cg14991358	chr1:156767203	PRCC	0.73	8.01	0.35	9.09e-15	Sjögren's syndrome;
LGG	cis	rs6743226	0.603	rs55659209	chr2:242254317	A/G	cg10021735	chr2:242295487	FARP2	0.41	7.06	0.31	6.23e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs12410462	0.591	rs2644144	chr1:227731867	C/G	cg04117972	chr1:227635322	NA	0.46	8.42	0.36	4.66e-16	Major depressive disorder;
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg03806693	chr22:41940476	POLR3H	-1.16	-20.61	-0.69	2e-67	Vitiligo;
LGG	cis	rs921968	0.541	rs523305	chr2:219402691	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg23743428	chr13:21893420	NA	-0.49	-10.8	-0.45	2.13e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9902453	1.000	rs7222308	chr17:28277041	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.6	0.53	1.17e-35	Coffee consumption (cups per day);
LGG	trans	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg23762105	chr12:34175262	ALG10	-0.34	-6.92	-0.31	1.53e-11	Morning vs. evening chronotype;
LGG	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg11995313	chr8:8860691	ERI1	0.43	7.21	0.32	2.3e-12	Joint mobility (Beighton score);
LGG	cis	rs9814567	0.679	rs1880379	chr3:134330612	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.96	-0.52	5.42e-33	Intelligence (multi-trait analysis);
LGG	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.17	0.39	1.59e-18	Height;
LGG	cis	rs7103648	1.000	rs7947450	chr11:47429904	G/A	cg20307385	chr11:47447363	PSMC3	0.97	23.83	0.74	1.65e-82	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg07615347	chr10:60278583	BICC1	0.64	18.52	0.65	1.09e-57	Refractive error;
LGG	cis	rs9487051	0.768	rs437779	chr6:109527691	T/G	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.58e-11	Reticulocyte fraction of red cells;
LGG	cis	rs854765	0.547	rs28537385	chr17:17902135	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-15.56	-0.59	3.33e-44	Total body bone mineral density;
LGG	cis	rs8180040	0.654	rs1466740	chr3:47245883	C/T	cg16586182	chr3:47516702	SCAP	0.74	13.5	0.53	2.84e-35	Colorectal cancer;
LGG	cis	rs4919044	0.808	rs835279	chr10:94809809	A/T	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.2	-0.36	2.42e-15	Coronary artery disease;
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.56	0.37	1.67e-16	Rheumatoid arthritis;
LGG	cis	rs55871839	0.708	rs1562612	chr8:59817068	A/G	cg07426533	chr8:59803705	TOX	-0.57	-12.71	-0.51	5.61e-32	Pneumonia;
LGG	cis	rs6121246	0.909	rs6089070	chr20:30377773	A/G	cg04935436	chr20:30431758	NA	-0.43	-7.33	-0.32	1.04e-12	Mean corpuscular hemoglobin;
LGG	cis	rs3106136	0.934	rs2902979	chr4:95177874	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.21	-0.36	2.25e-15	Capecitabine sensitivity;
LGG	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-13.76	-0.54	2.26e-36	Cognitive function;
LGG	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg15664640	chr17:80829946	TBCD	-0.48	-9.46	-0.4	1.5700000000000001e-19	Breast cancer;
LGG	cis	rs9527	0.590	rs1935323	chr10:104877035	T/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.87	-0.3	2.14e-11	Arsenic metabolism;
LGG	trans	rs11976180	1.000	rs2961117	chr7:143755253	C/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.98	-0.31	1.04e-11	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11529614	chr17:59941050	BRIP1	-0.48	-7.07	-0.31	5.73e-12	Systemic lupus erythematosus;
LGG	trans	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg07817883	chr1:32538562	TMEM39B	0.67	8.32	0.36	9.97e-16	Monocyte percentage of white cells;
LGG	cis	rs1550582	0.662	rs6981748	chr8:135501309	A/C	cg17885191	chr8:135476712	NA	-0.94	-16.5	-0.61	1.87e-48	Educational attainment;
LGG	cis	rs6964587	1.000	rs6950470	chr7:91680641	G/A	cg17063962	chr7:91808500	NA	0.49	8.7	0.37	6.06e-17	Breast cancer;
LGG	trans	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.26	-0.32	1.64e-12	Triglycerides;
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.4	-0.44	6.33e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7818345	1.000	rs4379462	chr8:19311496	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	6.92	0.31	1.49e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs8072100	0.790	rs11656856	chr17:45714671	C/T	cg08085267	chr17:45401833	C17orf57	0.52	9.64	0.41	3.58e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs367943	1.000	rs348944	chr5:112822925	C/T	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs10046574	0.561	rs10214966	chr7:135196642	A/G	cg27474649	chr7:135195673	CNOT4	0.75	8.93	0.38	9.73e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.9	-11.05	-0.46	2.32e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14593314	chr6:44191312	SLC29A1	0.45	6.76	0.3	4.19e-11	Hip circumference;
LGG	cis	rs11945232	1.000	rs28630962	chr4:88336386	C/T	cg23841344	chr4:88312519	HSD17B11	-0.52	-9.35	-0.4	3.88e-19	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.94	-15.1	-0.57	3.54e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7937612	0.965	rs4539328	chr11:120218243	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.51	-0.5	3.92e-31	Intraocular pressure;
LGG	cis	rs2708240	0.577	rs2888536	chr7:147566862	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.33	-7.85	-0.34	2.96e-14	QT interval (drug interaction);
LGG	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15557168	chr22:42548783	NA	0.35	8.01	0.35	9.55e-15	Cognitive function;
LGG	cis	rs714515	0.546	rs57668887	chr1:172327399	T/C	cg01573306	chr1:172330400	DNM3	-0.47	-10.66	-0.44	6.89e-24	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs7833790	0.700	rs7825180	chr8:82723991	T/A	cg17211192	chr8:82754475	SNX16	-0.72	-11.96	-0.49	6.46e-29	Diastolic blood pressure;
LGG	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21659725	chr3:3221576	CRBN	0.74	14.12	0.55	6.9e-38	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08589270	chr7:150949204	SMARCD3	0.49	7.27	0.32	1.56e-12	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs4538187	1.000	rs6732746	chr2:64089748	C/A	cg19915305	chr2:64069682	UGP2	0.69	15.81	0.59	2.51e-45	Systolic blood pressure;
LGG	cis	rs757278	0.513	rs2518879	chr7:117241508	A/G	cg10524701	chr7:117356490	CTTNBP2	0.44	7.41	0.33	6.25e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs12586317	0.582	rs731906	chr14:35604543	C/T	cg16230307	chr14:35515116	FAM177A1	0.89	12.74	0.51	4.37e-32	Psoriasis;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg10911889	chr6:126070802	HEY2	0.44	7.44	0.33	4.96e-13	Brugada syndrome;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg09699651	chr6:150184138	LRP11	0.54	9.71	0.41	2.11e-20	Lung cancer;
LGG	trans	rs208520	1.000	rs12212063	chr6:66985148	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.22	0.55	2.56e-38	Exhaled nitric oxide output;
LGG	cis	rs9487094	0.600	rs1885690	chr6:109672998	C/A	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.32e-11	Height;
LGG	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg05294307	chr14:35346193	BAZ1A	-0.49	-6.88	-0.3	1.92e-11	Psoriasis;
LGG	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.86	-0.3	2.24e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs4808199	0.947	rs7250658	chr19:19571100	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.56	0.63	2.72e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs62064224	0.714	rs62064225	chr17:30635429	C/T	cg18200150	chr17:30822561	MYO1D	0.5	9.62	0.41	4.43e-20	Schizophrenia;
LGG	cis	rs8017423	0.967	rs61996919	chr14:90701803	A/C	cg04374321	chr14:90722782	PSMC1	0.87	18.35	0.65	6.72e-57	Mortality in heart failure;
LGG	trans	rs7830939	0.586	rs9918737	chr8:9321543	T/A	cg06636001	chr8:8085503	FLJ10661	0.41	6.82	0.3	2.88e-11	Neuroticism;
LGG	cis	rs17666538	0.585	rs4333567	chr8:636611	C/T	cg07234876	chr8:600039	NA	1.14	10.41	0.44	5.82e-23	IgG glycosylation;
LGG	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs372883	0.935	rs379592	chr21:30706470	A/G	cg24692254	chr21:30365293	RNF160	-0.42	-7.41	-0.33	6.22e-13	Pancreatic cancer;
LGG	cis	rs10492096	1.000	rs12422771	chr12:6580273	G/T	cg13857086	chr12:6580257	VAMP1	0.64	9.22	0.39	1.02e-18	Hip geometry;
LGG	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg21605333	chr4:119757512	SEC24D	1.47	13.64	0.54	7.78e-36	Cannabis dependence symptom count;
LGG	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg13402656	chr8:1511478	DLGAP2	0.77	14.75	0.57	1.23e-40	Lung cancer;
LGG	cis	rs2204008	0.749	rs4579984	chr12:38166266	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.68e-35	Bladder cancer;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg13882712	chr2:27603741	ZNF513	-0.4	-7.04	-0.31	6.92e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2712184	0.729	rs2541390	chr2:217664020	A/G	cg05032264	chr2:217675019	NA	-0.43	-9.5	-0.4	1.13e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.74	0.45	3.65e-24	Lung cancer in ever smokers;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg24575275	chr7:1094737	C7orf50	-0.39	-7.28	-0.32	1.42e-12	Longevity;Endometriosis;
LGG	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg12042659	chr19:58951599	ZNF132	0.35	7.11	0.31	4.56e-12	Uric acid clearance;
LGG	cis	rs701145	0.585	rs1624917	chr3:153827300	T/A	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs2213920	0.516	rs6415818	chr9:118210588	A/G	cg13918206	chr9:118159781	DEC1	0.62	8.73	0.38	4.5e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg19338460	chr6:170058176	WDR27	-0.73	-9.5	-0.4	1.11e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg13010199	chr12:38710504	ALG10B	0.36	6.79	0.3	3.35e-11	Morning vs. evening chronotype;
LGG	trans	rs17685	0.753	rs869806	chr7:75688623	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.1e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6901004	0.803	rs402014	chr6:111527696	C/T	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.43	-0.33	5.11e-13	Blood metabolite levels;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.61	-0.61	6.28e-49	Intelligence (multi-trait analysis);
LGG	trans	rs10506458	0.915	rs17763441	chr12:63418335	T/C	cg22491629	chr6:157744540	C6orf35	-0.92	-13.2	-0.52	5.28e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2289583	0.642	rs12148697	chr15:75384375	G/T	cg10253484	chr15:75165896	SCAMP2	-0.44	-6.88	-0.3	1.92e-11	Systemic lupus erythematosus;
LGG	cis	rs2629540	0.824	rs10901809	chr10:126410804	C/T	cg08799069	chr10:126477246	METTL10	0.57	11.75	0.48	4.26e-28	Cocaine dependence;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg04861929	chr11:109293070	C11orf87	-0.86	-17.32	-0.63	3.47e-52	Schizophrenia;
LGG	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg27205649	chr11:78285834	NARS2	0.48	8.23	0.36	1.87e-15	Alzheimer's disease (survival time);
LGG	cis	rs62064224	0.553	rs9915115	chr17:30684858	A/G	cg18200150	chr17:30822561	MYO1D	0.48	9.24	0.39	9.19e-19	Schizophrenia;
LGG	cis	rs1062753	0.771	rs5751245	chr22:42620940	T/C	cg15128208	chr22:42549153	NA	0.5	8.27	0.36	1.39e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg27211696	chr2:191398769	TMEM194B	-0.4	-9.53	-0.4	9.18e-20	Pulse pressure;
LGG	cis	rs986417	0.901	rs2351171	chr14:61000322	T/C	cg27398547	chr14:60952738	C14orf39	0.71	6.82	0.3	2.81e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	8.84e-76	Homoarginine levels;
LGG	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg06697600	chr4:7070879	GRPEL1	-0.53	-9.17	-0.39	1.56e-18	Monocyte percentage of white cells;
LGG	cis	rs4356932	1.000	rs10025102	chr4:76955358	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg23782820	chr8:58130467	NA	0.51	7.83	0.34	3.43e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg14132834	chr19:41945861	ATP5SL	-0.51	-9.98	-0.42	2.24e-21	Height;
LGG	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.6	-0.44	1.23e-23	Pancreatic cancer;
LGG	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.93	19.76	0.68	1.79e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9863	0.828	rs75989601	chr12:124466723	C/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.08	-0.31	5.27e-12	White blood cell count;
LGG	cis	rs1927790	0.727	rs16953068	chr13:96949327	C/G	cg02571835	chr13:96230311	CLDN10	-0.33	-6.79	-0.3	3.55e-11	Body mass index;
LGG	cis	rs9916302	0.706	rs4488484	chr17:37717377	A/T	cg07936489	chr17:37558343	FBXL20	0.97	15.1	0.57	3.64e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.52	0.4	9.82e-20	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03699307	chr16:75600014	GABARAPL2	0.47	7.45	0.33	4.63e-13	Cognitive performance;
LGG	cis	rs17039065	1.000	rs76088375	chr4:109393181	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.88	0.3	1.96e-11	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.770	rs11630112	chr15:86120246	T/C	cg04173714	chr15:86211321	AKAP13	0.49	8.94	0.38	9.06e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs561341	0.714	rs547473	chr17:30297560	T/G	cg20587970	chr11:113659929	NA	-1.3	-24.25	-0.75	1.8e-84	Hip circumference adjusted for BMI;
LGG	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.87	-0.45	1.17e-24	Hemoglobin concentration;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13126279	chr21:47581558	C21orf56	0.45	7.41	0.33	6.18e-13	Testicular germ cell tumor;
LGG	trans	rs561341	1.000	rs546748	chr17:30324293	A/C	cg20587970	chr11:113659929	NA	-1.21	-21.75	-0.71	8.76e-73	Hip circumference adjusted for BMI;
LGG	cis	rs2117029	0.555	rs3741621	chr12:49494025	T/C	cg24176009	chr12:49580217	TUBA1A	0.55	10.19	0.43	3.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7937890	0.559	rs1116739	chr11:14489182	G/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.85	-0.34	2.89e-14	Mitochondrial DNA levels;
LGG	cis	rs988958	0.567	rs6719975	chr2:42271646	G/A	cg27428208	chr2:42229179	NA	0.49	8.57	0.37	1.56e-16	Hypospadias;
LGG	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4474465	1.000	rs7929712	chr11:78158542	T/C	cg27205649	chr11:78285834	NARS2	-0.51	-8.6	-0.37	1.24e-16	Alzheimer's disease (survival time);
LGG	cis	rs8177179	0.967	rs9820225	chr3:133449189	A/G	cg24879335	chr3:133465180	TF	0.44	7.36	0.32	8.52e-13	Iron status biomarkers (transferrin levels);
LGG	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg17145862	chr1:211918768	LPGAT1	0.99	24.96	0.76	9.05e-88	Leprosy;
LGG	cis	rs2777491	0.507	rs11854081	chr15:41646398	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.34	-34.65	-0.85	1.17e-130	Ulcerative colitis;
LGG	cis	rs5769707	0.846	rs5770610	chr22:50036897	A/C	cg20744362	chr22:50050164	C22orf34	0.39	7.73	0.34	6.77e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg12438819	chr7:158236134	PTPRN2	-0.31	-7.99	-0.35	1.11e-14	Obesity-related traits;
LGG	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg20476274	chr7:133979776	SLC35B4	0.65	11.26	0.46	3.55e-26	Mean platelet volume;
LGG	cis	rs10895140	0.756	rs2508254	chr11:101489573	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg21775007	chr8:11205619	TDH	0.62	10.34	0.43	1.08e-22	Retinal vascular caliber;
LGG	cis	rs3768617	0.510	rs1547712	chr1:183088013	T/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg18252515	chr7:66147081	NA	-0.41	-6.87	-0.3	2.12e-11	Aortic root size;
LGG	cis	rs6582630	0.502	rs11520278	chr12:38359642	T/A	cg13010199	chr12:38710504	ALG10B	0.71	14.09	0.55	9.43e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7512552	0.839	rs12046446	chr1:150460855	T/G	cg15654264	chr1:150340011	RPRD2	0.45	9.25	0.39	8.33e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-7.13	-0.31	3.98e-12	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15376229	chr11:592496	PHRF1	-0.39	-7.1	-0.31	4.67e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs36051895	0.626	rs10283564	chr9:5075628	C/G	cg02405213	chr9:5042618	JAK2	-0.82	-14.92	-0.57	2.1e-41	Pediatric autoimmune diseases;
LGG	cis	rs9303401	0.614	rs3803752	chr17:56540267	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	14.0	0.55	2.13e-37	Cognitive test performance;
LGG	cis	rs6735179	0.565	rs733376	chr2:1751958	C/A	cg10160682	chr2:1713001	PXDN	-0.56	-9.51	-0.4	1.01e-19	Response to antipsychotic treatment;
LGG	cis	rs17270561	0.609	rs4464787	chr6:25733558	G/C	cg03517284	chr6:25882590	NA	-0.43	-7.0	-0.31	9.29e-12	Iron status biomarkers;
LGG	cis	rs2247341	0.965	rs11248073	chr4:1737502	C/T	cg05026014	chr4:1749153	NA	-0.34	-9.38	-0.4	2.97e-19	Hip circumference adjusted for BMI;Height;
LGG	trans	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg27661571	chr11:113659931	NA	-0.65	-9.08	-0.39	3.26e-18	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg12419862	chr22:24373484	LOC391322	0.9	18.12	0.64	7.76e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.19	-0.55	3.29e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg06719900	chr11:109292894	C11orf87	0.45	8.43	0.36	4.29e-16	Schizophrenia;
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4268898	0.965	rs4665673	chr2:24459737	A/T	cg06627628	chr2:24431161	ITSN2	0.52	8.72	0.38	5.02e-17	Asthma;
LGG	cis	rs72781680	0.699	rs72794291	chr2:23897935	C/T	cg08917208	chr2:24149416	ATAD2B	0.84	8.79	0.38	3.01e-17	Lymphocyte counts;
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg08856697	chr17:61627902	DCAF7	0.51	7.01	0.31	8.71e-12	Leprosy;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.84e-17	Bipolar disorder;
LGG	cis	rs2153535	0.580	rs2152348	chr6:8474301	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs2273669	0.667	rs2003315	chr6:109367169	C/T	cg05315195	chr6:109294784	ARMC2	-0.62	-8.37	-0.36	6.92e-16	Prostate cancer;
LGG	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13710703	chr15:43415332	NA	0.5	7.68	0.34	9.54e-14	Gut microbiome composition (summer);
LGG	cis	rs3816183	1.000	rs3772062	chr2:43017045	T/C	cg14631114	chr2:43023945	NA	0.51	9.48	0.4	1.37e-19	Hypospadias;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg00830817	chr11:109293614	C11orf87	0.42	6.93	0.31	1.45e-11	Schizophrenia;
LGG	cis	rs806215	0.547	rs712718	chr7:127346950	C/G	cg25922125	chr7:127225783	GCC1	-0.51	-7.36	-0.32	8.43e-13	Type 2 diabetes;
LGG	cis	rs3816183	1.000	rs7422835	chr2:43016007	A/G	cg27299406	chr2:43020013	HAAO	-0.27	-6.66	-0.3	7.55e-11	Hypospadias;
LGG	cis	rs79911532	0.551	rs11553096	chr7:75677216	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-8.01	-0.35	9.67e-15	Mononucleosis;
LGG	cis	rs6582630	0.502	rs11520276	chr12:38359216	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.42e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2470578	0.792	rs283927	chr3:17358421	G/A	cg20981856	chr3:17787350	NA	0.36	6.9	0.31	1.71e-11	Schizophrenia;
LGG	cis	rs2594989	0.943	rs9836824	chr3:11463517	G/A	cg01796438	chr3:11312864	ATG7	-0.53	-7.09	-0.31	5.16e-12	Circulating chemerin levels;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg22963979	chr7:1858916	MAD1L1	-0.46	-8.97	-0.38	7.44e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs3087591	0.683	rs2854303	chr17:29716342	C/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.19	0.49	7.56e-30	Hip circumference;
LGG	cis	rs8079658	1.000	rs62065084	chr17:63822357	T/C	cg18091269	chr17:63822838	CCDC46	-0.41	-6.92	-0.31	1.56e-11	Post bronchodilator FEV1;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18751588	chr12:51566859	TFCP2	-0.48	-7.05	-0.31	6.34e-12	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.79	15.76	0.59	4.25e-45	Obesity-related traits;
LGG	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg06766960	chr11:133703094	NA	0.51	9.82	0.42	8.76e-21	Childhood ear infection;
LGG	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg13385794	chr1:248469461	NA	0.5	8.31	0.36	1.11e-15	Common traits (Other);
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.79	0.3	3.51e-11	Schizophrenia;
LGG	cis	rs11148252	0.875	rs4884452	chr13:52949784	C/T	cg12458913	chr13:53173898	NA	-0.56	-10.47	-0.44	3.49e-23	Lewy body disease;
LGG	cis	rs10799590	0.866	rs7511897	chr1:224892969	G/C	cg01808320	chr1:224927238	CNIH3	0.37	6.78	0.3	3.6e-11	Opioid dependence;
LGG	cis	rs7129556	0.728	rs628668	chr11:77577494	C/T	cg12586386	chr11:77299805	AQP11	0.45	7.34	0.32	9.5e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs12517041	1.000	rs71611220	chr5:23281005	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.21e-25	Calcium levels;
LGG	cis	rs796364	0.806	rs115717210	chr2:201006247	T/C	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs9633740	0.842	rs1870140	chr10:82246749	A/G	cg01528321	chr10:82214614	TSPAN14	0.97	12.81	0.51	2.36e-32	Post bronchodilator FEV1;
LGG	cis	rs10771431	0.738	rs11049697	chr12:9385339	T/C	cg08997352	chr12:9597637	DDX12	-0.79	-15.21	-0.58	1.21e-42	Breast size;
LGG	trans	rs225245	0.791	rs4796103	chr17:34025182	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.14	-0.31	3.63e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs35740288	0.929	rs11630585	chr15:86306004	C/A	cg04173714	chr15:86211321	AKAP13	0.41	7.11	0.31	4.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4642101	0.561	rs7641959	chr3:12810755	G/C	cg24848339	chr3:12840334	CAND2	0.36	8.06	0.35	6.61e-15	QRS complex (12-leadsum);
LGG	cis	rs939658	0.805	rs8035606	chr15:79420245	C/T	cg17916960	chr15:79447300	NA	-0.67	-13.29	-0.53	2.22e-34	Refractive error;
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.69	-0.3	6.45e-11	Menopause (age at onset);
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg10189774	chr4:17578691	LAP3	0.41	7.46	0.33	4.38e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.53	0.33	2.62e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg22676075	chr6:135203613	NA	0.36	6.66	0.3	7.66e-11	Red blood cell count;
LGG	cis	rs963731	0.649	rs4670901	chr2:39199271	T/C	cg04010122	chr2:39346883	SOS1	-0.81	-7.19	-0.32	2.56e-12	Corticobasal degeneration;
LGG	cis	rs12887734	0.566	rs8548	chr14:104199580	A/C	cg26031613	chr14:104095156	KLC1	-0.57	-8.97	-0.38	7.64e-18	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2153535	0.580	rs6938071	chr6:8464845	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg00825309	chr19:58991885	ZNF446	-0.46	-9.35	-0.4	3.64e-19	Uric acid clearance;
LGG	cis	rs6688613	0.694	rs2075946	chr1:166818566	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.54	8.43	0.36	4.33e-16	Refractive astigmatism;
LGG	cis	rs4740619	0.810	rs36086644	chr9:15713413	A/G	cg14451791	chr9:16040625	NA	0.33	8.37	0.36	6.81e-16	Body mass index;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.29	0.36	1.27e-15	Schizophrenia;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs763121	0.853	rs5750621	chr22:38956166	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	16.95	0.62	1.83e-50	Menopause (age at onset);
LGG	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg03315344	chr16:75512273	CHST6	0.5	9.87	0.42	5.59e-21	Dupuytren's disease;
LGG	cis	rs116095464	0.558	rs10043002	chr5:226753	G/A	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	trans	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg10756647	chr7:56101905	PSPH	0.83	9.5	0.4	1.11e-19	Diabetic kidney disease;
LGG	cis	rs9326248	1.000	rs4938354	chr11:117051165	A/G	cg11861562	chr11:117069780	TAGLN	0.26	6.87	0.3	2.02e-11	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02952686	chr15:99791546	LRRC28	0.46	7.38	0.32	7.58e-13	Cognitive performance;
LGG	cis	rs9427116	0.967	rs7547072	chr1:154639255	A/G	cg11650704	chr1:154556575	ADAR	0.37	7.28	0.32	1.48e-12	Blood protein levels;
LGG	cis	rs9300255	0.544	rs10772995	chr12:123671761	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.33	0.32	1.02e-12	Neutrophil percentage of white cells;
LGG	cis	rs4788570	0.697	rs4788559	chr16:71848959	T/C	cg06353428	chr16:71660113	MARVELD3	1.24	19.03	0.66	4.63e-60	Intelligence (multi-trait analysis);
LGG	cis	rs7010267	0.593	rs2055101	chr8:119886923	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.32	8.05	0.35	6.98e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs3099143	1.000	rs3110379	chr15:77095175	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-10.26	-0.43	2.24e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg03188948	chr7:1209495	NA	0.49	7.93	0.35	1.66e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9527	0.590	rs7088200	chr10:104793235	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.57	0.44	1.53e-23	Arsenic metabolism;
LGG	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg01043669	chr3:72786069	NA	0.43	6.9	0.31	1.71e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.72	0.48	5.77e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11039798	0.588	rs12284168	chr11:48555627	C/T	cg03929089	chr4:120376271	NA	0.69	9.48	0.4	1.33e-19	Axial length;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	9.08	0.39	3.27e-18	Obesity-related traits;
LGG	cis	rs774359	0.744	rs2484319	chr9:27563755	A/C	cg21249376	chr9:27528432	MOBKL2B	0.42	7.6	0.33	1.64e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs6840360	0.571	rs1473305	chr4:152511721	T/G	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.958	rs10873246	chr14:72153693	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.46	-0.4	1.55e-19	Mitral valve prolapse;
LGG	cis	rs3761847	0.500	rs10760132	chr9:123739993	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.47	8.41	0.36	5.11e-16	Rheumatoid arthritis;
LGG	cis	rs3768617	0.510	rs12078729	chr1:183060072	T/A	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.97	-0.35	1.21e-14	Menopause (age at onset);
LGG	cis	rs7208859	0.573	rs56031503	chr17:29075665	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7552404	0.731	rs5745445	chr1:76344332	G/A	cg10523679	chr1:76189770	ACADM	0.73	11.17	0.46	8.25e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3824867	0.920	rs4752836	chr11:47465095	T/C	cg20307385	chr11:47447363	PSMC3	0.47	7.55	0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs6868223	0.617	rs4337860	chr5:33648271	A/G	cg10594543	chr5:33649717	ADAMTS12	0.66	15.51	0.58	5.52e-44	Mortality in heart failure;
LGG	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg10523679	chr1:76189770	ACADM	0.81	15.17	0.58	1.67e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.73	0.34	6.92e-14	Eosinophil percentage of white cells;
LGG	trans	rs11039798	0.591	rs74992349	chr11:49019252	G/A	cg03929089	chr4:120376271	NA	0.71	9.88	0.42	5.02e-21	Axial length;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg04166393	chr7:2884313	GNA12	0.47	9.01	0.39	5.4e-18	Height;
LGG	cis	rs11098499	0.863	rs3822192	chr4:120445720	A/C	cg09307838	chr4:120376055	NA	0.78	12.64	0.51	1.13e-31	Corneal astigmatism;
LGG	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.51	-9.4	-0.4	2.6e-19	Chronic sinus infection;
LGG	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs9972944	0.729	rs10512505	chr17:63776696	A/G	cg07283582	chr17:63770753	CCDC46	0.4	7.73	0.34	6.95e-14	Total body bone mineral density;
LGG	cis	rs55823223	0.564	rs936391	chr17:73847799	A/G	cg08125733	chr17:73851984	WBP2	-0.62	-10.25	-0.43	2.35e-22	Psoriasis;
LGG	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg15269541	chr15:43626905	ADAL	0.42	6.8	0.3	3.33e-11	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg22535103	chr8:58192502	C8orf71	-0.96	-15.6	-0.59	2.11e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg07511668	chr11:68622177	NA	-0.35	-7.08	-0.31	5.48e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.830	rs10470893	chr4:99038756	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21961512	chr4:8692854	NA	0.39	7.4	0.33	6.56e-13	Menarche (age at onset);
LGG	cis	rs2201728	0.967	rs3749550	chr4:100221503	C/T	cg07219303	chr4:100140905	ADH6	-0.4	-8.22	-0.36	1.99e-15	Cardiac Troponin-T levels;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07157834	chr1:205819609	PM20D1	0.74	16.58	0.61	8.19e-49	Menarche (age at onset);
LGG	cis	rs12893668	0.703	rs4906338	chr14:104050357	A/G	cg26031613	chr14:104095156	KLC1	-0.61	-9.71	-0.41	2.05e-20	Reticulocyte count;
LGG	cis	rs6735179	0.607	rs10202812	chr2:1746468	A/T	cg10160682	chr2:1713001	PXDN	-0.58	-9.79	-0.41	1.09e-20	Response to antipsychotic treatment;
LGG	cis	rs4774899	0.866	rs2431023	chr15:57553832	A/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.26	-0.32	1.65e-12	Urinary tract infection frequency;
LGG	trans	rs116095464	1.000	rs28416084	chr5:217640	G/A	cg00938859	chr5:1591904	SDHAP3	0.88	12.01	0.49	4.25e-29	Breast cancer;
LGG	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs9911578	1.000	rs4398153	chr17:56968181	T/C	cg05425664	chr17:57184151	TRIM37	0.63	10.01	0.42	1.71e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7177699	0.534	rs56683682	chr15:79112524	G/T	cg00540400	chr15:79124168	NA	-0.54	-11.15	-0.46	9.49e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs4740619	0.619	rs10756739	chr9:16036716	G/C	cg14451791	chr9:16040625	NA	-0.44	-11.72	-0.48	5.73e-28	Body mass index;
LGG	trans	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg26043149	chr18:55253948	FECH	-0.41	-6.67	-0.3	7.28e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.43	-9.16	-0.39	1.66e-18	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08494150	chr16:26044201	HS3ST4	0.35	6.66	0.3	8e-11	Gut microbiome composition (summer);
LGG	cis	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.29	-0.4	5.88e-19	Hip circumference adjusted for BMI;
LGG	cis	rs9926296	0.542	rs12599531	chr16:89909401	C/T	cg26513180	chr16:89883248	FANCA	-0.62	-11.05	-0.46	2.3e-25	Vitiligo;
LGG	cis	rs4380275	0.782	rs4854369	chr2:752530	G/A	cg14072418	chr2:740025	NA	-0.35	-6.97	-0.31	1.13e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg23958373	chr8:599963	NA	-1.35	-11.52	-0.47	3.6e-27	IgG glycosylation;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03983713	chr5:172744704	STC2	0.35	7.03	0.31	7.57e-12	Menarche (age at onset);
LGG	cis	rs477692	0.905	rs489966	chr10:131422115	C/G	cg05714579	chr10:131428358	MGMT	-0.63	-13.01	-0.52	3.29e-33	Response to temozolomide;
LGG	cis	rs782590	0.869	rs782599	chr2:55847423	C/T	cg18811423	chr2:55921094	PNPT1	0.86	19.75	0.68	2.03e-63	Metabolic syndrome;
LGG	cis	rs7923837	0.963	rs11187141	chr10:94467145	A/T	cg25093409	chr10:94429542	NA	0.41	7.41	0.33	5.85e-13	Body mass index;Multiple sclerosis;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11245990	chr11:68621969	NA	0.42	9.0	0.39	5.82e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs990171	0.913	rs4851587	chr2:103073474	C/T	cg05295703	chr2:102895712	NA	-0.51	-8.92	-0.38	1.1e-17	Lymphocyte counts;
LGG	cis	rs12493885	0.769	rs11710560	chr3:153777276	A/G	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12586317	1.000	rs12586317	chr14:35682172	T/C	cg05294307	chr14:35346193	BAZ1A	-0.47	-7.41	-0.33	5.96e-13	Psoriasis;
LGG	cis	rs1018836	0.663	rs56784954	chr8:91505094	C/T	cg16814680	chr8:91681699	NA	-0.7	-11.92	-0.48	9.32e-29	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg08112188	chr17:47440006	ZNF652	1.33	15.72	0.59	6.2e-45	Prostate cancer;
LGG	cis	rs6882046	0.513	rs34320	chr5:88021527	T/G	cg22951263	chr5:87985283	NA	-0.57	-10.49	-0.44	3.17e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs1322639	0.614	rs6900964	chr6:169566763	A/G	cg03254818	chr6:169586852	NA	0.54	8.24	0.36	1.82e-15	Pulse pressure;
LGG	cis	rs10751667	0.621	rs7396107	chr11:970029	C/T	cg22143635	chr11:980567	AP2A2	0.45	8.28	0.36	1.35e-15	Alzheimer's disease (late onset);
LGG	cis	rs7619833	0.512	rs9858306	chr3:27222542	T/G	cg02860705	chr3:27208620	NA	0.42	8.12	0.35	4.32e-15	Breast cancer;
LGG	cis	rs7215564	0.818	rs4889881	chr17:78664157	T/C	cg06153925	chr17:78755379	RPTOR	0.39	6.7	0.3	6.14e-11	Myopia (pathological);
LGG	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.57	13.27	0.52	2.75e-34	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2862064	0.649	rs1995377	chr5:156436679	T/A	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.84	-0.45	1.52e-24	Platelet count;
LGG	cis	rs727505	1.000	rs10464529	chr7:124520308	G/A	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs9354308	0.738	rs1818051	chr6:66569582	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11632617	chr15:75315747	PPCDC	0.46	7.42	0.33	5.48e-13	Gut microbiome composition (summer);
LGG	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg08250081	chr4:10125330	NA	-0.37	-7.15	-0.32	3.47e-12	Bone mineral density;
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg21782813	chr7:2030301	MAD1L1	0.47	10.9	0.45	8.49e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg08250081	chr4:10125330	NA	0.41	8.02	0.35	8.59e-15	Bone mineral density;
LGG	cis	rs7674212	0.541	rs2623070	chr4:104037388	A/G	cg16532752	chr4:104119610	CENPE	0.4	6.98	0.31	1.03e-11	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg04450456	chr4:17643702	FAM184B	-0.3	-6.74	-0.3	4.78e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1862618	0.671	rs28397234	chr5:56248428	T/G	cg08400814	chr5:56204995	C5orf35	0.4	7.12	0.31	4.19e-12	Initial pursuit acceleration;
LGG	cis	rs12048904	0.964	rs8888	chr1:101338324	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	9.87	0.42	5.8e-21	Multiple sclerosis;
LGG	cis	rs11674184	0.714	rs16857668	chr2:11723110	G/A	cg07314298	chr2:11723111	GREB1	-0.83	-19.96	-0.68	2.1e-64	Endometriosis;
LGG	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg23280166	chr11:118938394	VPS11	-0.52	-9.15	-0.39	1.89e-18	Coronary artery disease;
LGG	cis	rs894734	0.535	rs3847783	chr12:54320692	C/T	cg12374095	chr12:54320830	NA	-0.42	-7.5	-0.33	3.33e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg24375607	chr4:120327624	NA	0.68	11.16	0.46	8.92e-26	Corneal astigmatism;
LGG	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg07928641	chr1:182991847	LAMC1	0.49	10.04	0.42	1.36e-21	Colorectal cancer;
LGG	trans	rs2898857	0.545	rs12602382	chr17:47356805	C/A	cg11430096	chr6:110968061	CDK19	0.48	8.38	0.36	6.55e-16	Cancer;
LGG	cis	rs6977660	0.714	rs10224920	chr7:19816173	A/T	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs7027203	0.828	rs10761287	chr9:96609150	A/G	cg14598338	chr9:96623480	NA	-0.54	-9.64	-0.41	3.65e-20	DNA methylation (variation);
LGG	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26850624	chr5:429559	AHRR	-0.33	-7.22	-0.32	2.14e-12	Cystic fibrosis severity;
LGG	cis	rs4727027	0.716	rs4727020	chr7:148837317	C/T	cg23583168	chr7:148888333	NA	-0.71	-11.27	-0.46	3.47e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7805747	0.885	rs55791829	chr7:151407429	C/G	cg17611936	chr7:151411526	PRKAG2	0.5	7.29	0.32	1.34e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	trans	rs1459104	0.714	rs35789111	chr11:54926634	C/G	cg15704280	chr7:45808275	SEPT13	0.77	7.68	0.34	9.23e-14	Body mass index;
LGG	trans	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Bladder cancer;
LGG	cis	rs1577917	0.771	rs4441928	chr6:86241894	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	16.34	0.6	1.04e-47	Response to antipsychotic treatment;
LGG	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.4	0.33	6.65e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1467026	0.563	rs58674721	chr3:12811233	G/A	cg24848339	chr3:12840334	CAND2	0.36	8.13	0.35	3.87e-15	P wave duration;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg05863683	chr7:1912471	MAD1L1	0.44	9.04	0.39	4.17e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7219021	1.000	rs11657371	chr17:46843873	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.78	-0.3	3.68e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg07308232	chr7:1071921	C7orf50	-0.72	-14.35	-0.55	6.99e-39	Longevity;Endometriosis;
LGG	cis	rs9462027	0.628	rs9296127	chr6:34719628	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs597583	0.806	rs11603340	chr11:117396527	C/G	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.27	-0.36	1.4e-15	Putamen volume;
LGG	cis	rs7765175	0.598	rs2130849	chr6:113624121	T/C	cg26552650	chr6:113682475	NA	0.33	7.14	0.31	3.66e-12	Coronary artery calcification;
LGG	cis	rs754466	0.580	rs11002293	chr10:79537965	C/T	cg17075019	chr10:79541650	NA	-0.98	-21.63	-0.71	3.09e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14893161	chr1:205819251	PM20D1	0.51	8.29	0.36	1.25e-15	Prostate-specific antigen levels;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7241530	0.662	rs924890	chr18:75900657	C/T	cg14642773	chr18:75888474	NA	0.47	9.2	0.39	1.25e-18	Educational attainment (years of education);
LGG	cis	rs2718058	0.613	rs2709115	chr7:37790325	C/T	cg15028436	chr7:37888078	TXNDC3	-0.44	-8.05	-0.35	6.86e-15	Alzheimer's disease (late onset);
LGG	cis	rs6489785	0.775	rs1151850	chr12:121340363	T/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.76	-0.3	4.28e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7241530	0.560	rs8094722	chr18:75904415	C/A	cg14642773	chr18:75888474	NA	0.47	9.28	0.4	6.6e-19	Educational attainment (years of education);
LGG	cis	rs17067123	0.614	rs72712852	chr4:180066270	T/C	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs3789045	0.774	rs4252697	chr1:204501383	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.7	-0.37	5.71e-17	Educational attainment (college completion);
LGG	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs537626	0.667	rs625668	chr11:69308369	G/A	cg08353955	chr11:69289746	NA	-0.65	-7.81	-0.34	3.77e-14	Breast cancer (early onset);
LGG	cis	rs7072216	0.763	rs1061437	chr10:100176154	C/T	cg26618903	chr10:100175079	PYROXD2	-0.28	-7.13	-0.31	3.95e-12	Metabolite levels;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg01988459	chr11:68622903	NA	-0.63	-12.68	-0.51	8.08e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6138458	1.000	rs227616	chr20:24908811	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg03806693	chr22:41940476	POLR3H	1.04	17.6	0.63	1.87e-53	Vitiligo;
LGG	cis	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	trans	rs9467603	0.547	rs9295661	chr6:25450026	A/C	cg06606381	chr12:133084897	FBRSL1	-0.79	-6.75	-0.3	4.32e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.841	rs11231800	chr11:55770930	A/G	cg15704280	chr7:45808275	SEPT13	0.88	9.18	0.39	1.45e-18	Myopia (pathological);
LGG	cis	rs7851660	0.933	rs13302470	chr9:100615553	A/G	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs8072100	0.934	rs8067286	chr17:45594590	A/G	cg19784903	chr17:45786737	TBKBP1	0.33	7.32	0.32	1.09e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.22	0.39	1.06e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg06951627	chr6:26196580	NA	0.49	7.37	0.32	8.14e-13	Gout;Renal underexcretion gout;
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.564	rs4938723	chr11:111382565	T/C	cg09085632	chr11:111637200	PPP2R1B	0.66	11.06	0.46	2.26e-25	Primary sclerosing cholangitis;
LGG	cis	rs1048238	0.846	rs945420	chr1:16345208	G/A	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.37	-0.4	3.3e-19	Systolic blood pressure;
LGG	cis	rs1577917	1.000	rs1018184	chr6:86648475	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.53	8.85	0.38	1.84e-17	Response to antipsychotic treatment;
LGG	cis	rs2153535	0.606	rs11243253	chr6:8380193	T/C	cg21535247	chr6:8435926	SLC35B3	-0.53	-8.72	-0.38	5.12e-17	Motion sickness;
LGG	cis	rs4430311	0.723	rs11589907	chr1:243818260	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.49	-0.58	6.43e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs66716358	0.800	rs4755809	chr11:44323193	A/G	cg16977035	chr11:44330474	ALX4	-0.31	-7.83	-0.34	3.38e-14	Monobrow;
LGG	cis	rs7561149	0.534	rs12477346	chr2:179737610	A/G	cg17765952	chr2:179737173	CCDC141	0.32	6.67	0.3	7.2e-11	QT interval;
LGG	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg23752985	chr2:85803571	VAMP8	0.4	7.68	0.34	9.79e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.85e-16	Tonsillectomy;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg20607798	chr8:58055168	NA	0.65	7.53	0.33	2.62e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg08847533	chr14:75593920	NEK9	0.63	12.1	0.49	1.71e-29	Height;
LGG	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg11871910	chr12:69753446	YEATS4	0.83	15.58	0.59	2.54e-44	Response to diuretic therapy;
LGG	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.87	-13.79	-0.54	1.76e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.13	0.31	3.82e-12	Height;
LGG	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg06917634	chr15:78832804	PSMA4	0.69	12.82	0.51	2.04e-32	Sudden cardiac arrest;
LGG	cis	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg08112188	chr17:47440006	ZNF652	1.3	15.35	0.58	2.73e-43	Prostate cancer;
LGG	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg04469686	chr1:162760199	HSD17B7	0.43	6.97	0.31	1.06e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg10818794	chr15:86012489	AKAP13	0.36	7.38	0.32	7.47e-13	Bulimia nervosa;
LGG	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.17	0.46	8.25e-26	Homoarginine levels;
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.8	-0.3	3.28e-11	Aortic root size;
LGG	cis	rs7432375	0.901	rs1729951	chr3:136500733	T/G	cg21827317	chr3:136751795	NA	-0.48	-8.46	-0.37	3.42e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs5769765	0.542	rs738707	chr22:50250827	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.6	7.14	0.31	3.67e-12	Schizophrenia;
LGG	cis	rs9815354	0.812	rs55682201	chr3:41848497	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6977660	0.714	rs6945533	chr7:19813913	G/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.48	0.44	3.31e-23	Thyroid stimulating hormone;
LGG	cis	rs16912285	0.892	rs75859717	chr11:24346313	G/A	ch.11.24196551F	chr11:24239977	NA	0.86	8.85	0.38	1.93e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs10463316	0.894	rs12652733	chr5:150753999	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.24	-0.43	2.51e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs1941687	0.797	rs6507071	chr18:31393333	C/T	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.87	17.37	0.63	2.21e-52	Hip circumference adjusted for BMI;
LGG	cis	rs1983891	1.000	rs4714483	chr6:41528214	G/A	cg20194872	chr6:41519635	FOXP4	0.58	9.88	0.42	5.35e-21	Prostate cancer;
LGG	cis	rs9354308	1.000	rs9360161	chr6:66565457	C/T	cg07460842	chr6:66804631	NA	0.52	9.16	0.39	1.73e-18	Metabolite levels;
LGG	cis	rs3126085	0.735	rs4845744	chr1:152185095	T/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	trans	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg02002194	chr4:3960332	NA	0.5	9.35	0.4	3.63e-19	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07483432	chr12:72079704	TMEM19	0.45	6.68	0.3	6.73e-11	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.21	-0.39	1.16e-18	Menopause (age at onset);
LGG	cis	rs9462027	0.583	rs6937784	chr6:34644276	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.67	-0.44	6.33e-24	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.64	0.54	7.91e-36	Bladder cancer;
LGG	cis	rs1048238	0.506	rs56352596	chr1:16297592	G/A	cg21385522	chr1:16154831	NA	0.56	10.27	0.43	2.04e-22	Systolic blood pressure;
LGG	cis	rs735860	0.718	rs209488	chr6:53177540	A/T	cg10236188	chr6:53219634	NA	0.35	6.76	0.3	4.11e-11	Glaucoma;
LGG	cis	rs12367572	0.965	rs7952764	chr12:45246211	C/A	cg03114573	chr12:45410052	DBX2	-0.52	-9.01	-0.39	5.42e-18	Gut microbiome composition (summer);
LGG	trans	rs3206736	0.593	rs328923	chr7:35035695	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.0	0.31	8.84e-12	Diastolic blood pressure;
LGG	cis	rs62238980	0.614	rs78818509	chr22:32447582	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08628584	chr6:118228382	SLC35F1	0.63	7.07	0.31	5.56e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg06417478	chr19:12876846	HOOK2	0.42	7.08	0.31	5.33e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	trans	rs2204008	0.774	rs4534658	chr12:38246783	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg00092383	chr7:157075207	NA	0.4	6.94	0.31	1.32e-11	Body mass index;
LGG	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.62	-8.31	-0.36	1.06e-15	Schizophrenia;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg10295955	chr4:187884368	NA	-1.14	-29.66	-0.81	4.11e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.72	0.54	3.4e-36	Bladder cancer;
LGG	cis	rs1707322	0.752	rs8179402	chr1:46142466	C/A	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs975722	0.638	rs17550204	chr7:117329324	T/C	cg10524701	chr7:117356490	CTTNBP2	0.49	10.08	0.42	1.01e-21	Coronary artery disease;
LGG	cis	rs10499694	0.933	rs11575352	chr7:50594982	A/G	cg04490037	chr7:50633773	DDC	0.32	7.02	0.31	7.81e-12	Body mass index;
LGG	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.71	0.41	1.99e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4006360	0.505	rs8067313	chr17:39290306	G/T	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-8.53	-0.37	2.13e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.46	-0.33	4.26e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs611744	0.529	rs13282825	chr8:109263237	T/C	cg18478394	chr8:109455254	TTC35	0.41	8.22	0.36	2.14e-15	Dupuytren's disease;
LGG	cis	rs804292	0.695	rs804279	chr8:11623889	A/T	cg26752888	chr8:11627280	NEIL2	0.7	11.4	0.47	1.09e-26	Alcohol dependence;Nicotine use;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.74	0.59	5.02e-45	Lung cancer;
LGG	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg08629884	chr4:1719983	TMEM129	-0.56	-10.52	-0.44	2.35e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg00761968	chr13:53314142	LECT1	-0.34	-6.68	-0.3	6.98e-11	Lewy body disease;
LGG	cis	rs11785693	0.730	rs62489552	chr8:4956801	T/C	cg26367366	chr8:4980734	NA	0.78	10.34	0.43	1.07e-22	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7267979	0.966	rs2257233	chr20:25265984	A/C	cg06421707	chr20:25228305	PYGB	-0.5	-10.75	-0.45	3.21e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.1	-0.35	4.9e-15	IgG glycosylation;
LGG	cis	rs9815354	0.761	rs12186051	chr3:41836919	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7928758	0.887	rs75474440	chr11:134267092	C/T	cg22777979	chr11:134283252	B3GAT1	1.01	12.81	0.51	2.18e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg16576597	chr16:28551801	NUPR1	0.29	6.68	0.3	6.75e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg21782813	chr7:2030301	MAD1L1	0.56	14.39	0.56	4.35e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg01631408	chr1:248437212	OR2T33	0.53	9.61	0.41	4.7e-20	Common traits (Other);
LGG	cis	rs9467773	1.000	rs6924838	chr6:26571756	C/T	cg09904177	chr6:26538194	HMGN4	0.77	16.91	0.62	2.6e-50	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01979511	chr1:185126431	C1orf25;C1orf26	0.45	6.72	0.3	5.47e-11	Gut microbiome composition (summer);
LGG	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg05425664	chr17:57184151	TRIM37	-0.61	-9.57	-0.41	6.37e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg09818912	chr17:20140352	CYTSB	0.32	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs1506636	0.854	rs6466879	chr7:123276197	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.35	-0.65	6.66e-57	Plateletcrit;Platelet count;
LGG	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg25358565	chr5:93447407	FAM172A	-1.33	-16.27	-0.6	2.17e-47	Diabetic retinopathy;
LGG	cis	rs368123	0.961	rs415934	chr6:160717292	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.27	-0.32	1.57e-12	Waist circumference;
LGG	cis	rs4684776	0.800	rs11128554	chr3:11621441	G/A	cg24705426	chr3:11550659	ATG7	-0.41	-7.08	-0.31	5.35e-12	Small vessel stroke;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg12813108	chr7:99719912	CNPY4	-0.58	-9.03	-0.39	4.76e-18	Lung function (FEV1/FVC);
LGG	cis	rs4684776	0.676	rs35975472	chr3:11292653	T/G	cg24705426	chr3:11550659	ATG7	-0.4	-7.22	-0.32	2.09e-12	Small vessel stroke;
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.13	-0.35	3.92e-15	IgG glycosylation;
LGG	cis	rs858239	0.600	rs28483572	chr7:23131785	A/G	cg23682824	chr7:23144976	KLHL7	0.42	7.35	0.32	9.24e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg08461772	chr7:95026248	PON3	0.38	8.11	0.35	4.71e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg23131131	chr22:24373011	LOC391322	-0.41	-6.7	-0.3	5.96e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs11785400	0.762	rs4401833	chr8:143739731	A/T	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs2635047	0.811	rs12962421	chr18:44787498	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.76e-11	Educational attainment;
LGG	cis	rs6456042	1.000	rs6456042	chr6:166534742	G/T	cg11088901	chr6:166572345	T	0.34	7.17	0.32	3.06e-12	Asthma;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.817	rs240164	chr6:101044487	T/A	cg21058520	chr6:100914733	NA	-0.4	-6.95	-0.31	1.21e-11	Neuroticism;
LGG	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg08949735	chr16:89699720	DPEP1	-0.5	-10.22	-0.43	3.15e-22	Vitiligo;
LGG	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg03517284	chr6:25882590	NA	0.45	7.65	0.33	1.2e-13	Iron status biomarkers;
LGG	cis	rs4901847	0.716	rs10144575	chr14:58560531	A/G	cg15908186	chr14:58618357	C14orf37	0.41	7.13	0.31	3.82e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs16937	0.662	rs11240376	chr1:205146460	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.56	-0.33	2.17e-13	Schizophrenia;
LGG	trans	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg06875740	chr19:51307921	C19orf48	-0.67	-8.34	-0.36	8.47e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs888194	0.714	rs2338104	chr12:109895168	C/G	cg19025524	chr12:109796872	NA	-0.36	-7.22	-0.32	2.18e-12	Neuroticism;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07157834	chr1:205819609	PM20D1	0.73	16.66	0.61	3.66e-49	Menarche (age at onset);
LGG	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.83	-0.51	1.8e-32	Chronic sinus infection;
LGG	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs1218582	0.774	rs2335409	chr1:154916106	G/A	cg03351412	chr1:154909251	PMVK	0.64	11.51	0.47	3.97e-27	Prostate cancer;
LGG	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg22643751	chr7:855365	UNC84A	0.37	7.09	0.31	4.97e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs7481584	0.624	rs421196	chr11:3048582	T/G	cg25174290	chr11:3078921	CARS	-0.51	-9.35	-0.4	3.74e-19	Calcium levels;
LGG	cis	rs7945718	0.967	rs12291695	chr11:12795662	A/G	cg25843174	chr11:12811716	TEAD1	-0.43	-8.71	-0.38	5.53e-17	Educational attainment (years of education);
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00149659	chr3:10157352	C3orf10	1.19	13.97	0.54	2.89e-37	Alzheimer's disease;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg07747251	chr5:1868357	NA	0.46	9.31	0.4	5.33e-19	Cardiovascular disease risk factors;
LGG	cis	rs1318772	0.932	rs348921	chr5:112837207	T/C	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.05	-0.31	6.38e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs17102423	0.731	rs7145112	chr14:65534084	A/C	cg16583315	chr14:65563665	MAX	-0.4	-8.16	-0.35	3.12e-15	Obesity-related traits;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs72781680	0.821	rs12616257	chr2:24135034	A/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.7	0.37	5.76e-17	Lymphocyte counts;
LGG	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03264133	chr6:25882463	NA	-0.49	-9.19	-0.39	1.33e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9878978	1.000	rs17194392	chr3:2487275	A/G	cg21928760	chr3:2462534	CNTN4	0.4	8.8	0.38	2.82e-17	Blood pressure (smoking interaction);
LGG	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1682825	1.000	rs1682825	chr3:10774759	C/T	cg23512531	chr3:10780469	NA	-0.57	-8.03	-0.35	8.1e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg24764310	chr7:157512201	PTPRN2	-0.46	-8.83	-0.38	2.2e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs17345786	0.520	rs13062677	chr3:101305078	G/A	cg27318481	chr3:100970896	IMPG2	0.34	7.04	0.31	6.79e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg00035636	chr13:21900591	NA	0.35	7.14	0.31	3.63e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs3857067	1.000	rs7694631	chr4:95016931	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02018176	chr4:1364513	KIAA1530	0.57	14.08	0.55	1e-37	Longevity;
LGG	cis	rs7520050	0.645	rs1768809	chr1:46502836	A/C	cg03146154	chr1:46216737	IPP	-0.35	-7.03	-0.31	7.54e-12	Red blood cell count;Reticulocyte count;
LGG	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg00204512	chr16:28754710	NA	0.25	7.15	0.32	3.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg21479132	chr6:26055353	NA	0.72	7.03	0.31	7.64e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9291683	0.509	rs998676	chr4:9948564	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.38	-0.4	2.9e-19	Bone mineral density;
LGG	cis	rs2880765	0.631	rs55767890	chr15:86004142	C/G	cg10818794	chr15:86012489	AKAP13	-0.55	-12.3	-0.5	2.78e-30	Coronary artery disease;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg16284684	chr7:1164063	C7orf50	0.35	6.68	0.3	6.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1814175	0.817	rs10769613	chr11:49769692	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.43	-0.75	2.68e-85	Height;
LGG	cis	rs9487051	1.000	rs11757567	chr6:109614713	G/A	cg21918786	chr6:109611834	NA	-0.44	-8.19	-0.36	2.65e-15	Reticulocyte fraction of red cells;
LGG	cis	rs7712401	0.601	rs438196	chr5:122263063	T/G	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs9457247	0.846	rs2757052	chr6:167380174	T/C	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-10.77	-0.45	2.74e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	6.83e-37	Prudent dietary pattern;
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg01943577	chr7:158741284	NA	-0.45	-7.91	-0.34	1.94e-14	Height;
LGG	cis	rs1045714	0.836	rs56246161	chr7:2644679	G/A	cg14042143	chr7:2646782	IQCE	0.78	11.99	0.49	4.87e-29	Urate levels in lean individuals;
LGG	cis	rs68170813	0.559	rs4730239	chr7:107056960	A/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.18	-0.43	4.3e-22	Coronary artery disease;
LGG	cis	rs7666738	0.753	rs10029372	chr4:98859002	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4730779	0.819	rs6977665	chr7:116976830	A/G	cg10524701	chr7:117356490	CTTNBP2	0.34	7.04	0.31	6.79e-12	Waist circumference;
LGG	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.08	-0.39	3.06e-18	Eosinophil percentage of white cells;
LGG	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg12856521	chr11:46389249	DGKZ	0.39	6.65	0.3	8.27e-11	Leprosy;
LGG	cis	rs9462027	0.651	rs2395599	chr6:34641415	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.67e-24	Systemic lupus erythematosus;
LGG	cis	rs9811920	0.715	rs1017967	chr3:99905803	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.38	6.66	0.3	7.78e-11	Axial length;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03552156	chr3:187463844	BCL6	-0.4	-6.66	-0.3	8.02e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg14789911	chr21:47582049	C21orf56	-0.44	-6.79	-0.3	3.41e-11	Testicular germ cell tumor;
LGG	cis	rs2204008	0.774	rs11616004	chr12:38278822	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	trans	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-9.35	-0.4	3.7e-19	Brugada syndrome;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25742201	chr17:35306863	AATF	0.5	8.17	0.35	2.89e-15	Cognitive performance;
LGG	cis	rs12200782	1.000	rs72845509	chr6:26639865	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.16	-0.35	3.25e-15	Small cell lung carcinoma;
LGG	cis	rs62025270	0.632	rs8029034	chr15:86125728	T/G	cg25843651	chr15:86329602	KLHL25	0.54	8.05	0.35	7.29e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.95	-0.42	2.94e-21	Platelet count;
LGG	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg03929089	chr4:120376271	NA	0.8	14.23	0.55	2.14e-38	Coronary artery disease;
LGG	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg04727924	chr7:799746	HEATR2	-0.48	-7.65	-0.33	1.18e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs17376456	0.778	rs72786662	chr5:93137630	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-9.34	-0.4	4.07e-19	Diabetic retinopathy;
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.21	-0.36	2.26e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9325144	0.581	rs2653758	chr12:38946233	G/T	cg26384229	chr12:38710491	ALG10B	-0.79	-16.26	-0.6	2.37e-47	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05970398	chr4:95129288	SMARCAD1	0.43	6.66	0.3	7.87e-11	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.7	-0.37	5.88e-17	Neuroticism;
LGG	cis	rs12579753	1.000	rs12366580	chr12:82222784	G/A	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.07e-25	Resting heart rate;
LGG	cis	rs7819412	0.807	rs4840542	chr8:10944809	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.43	-0.33	5.24e-13	Triglycerides;
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs12210905	0.925	rs114172511	chr6:26964301	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs61931739	0.517	rs7975714	chr12:34055611	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.11e-25	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11890956	chr21:40555474	PSMG1	-0.96	-19.63	-0.67	7.05e-63	Cognitive function;
LGG	cis	rs896854	0.596	rs7823059	chr8:95974961	T/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs4843185	0.667	rs4143865	chr16:85716612	T/A	cg26571870	chr16:85723150	GINS2	-0.42	-7.53	-0.33	2.74e-13	Platelet distribution width;
LGG	cis	rs1707322	0.752	rs11211171	chr1:46168642	A/G	cg03146154	chr1:46216737	IPP	0.56	10.67	0.44	6.72e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.5	-0.33	3.26e-13	Lung cancer in ever smokers;
LGG	cis	rs9368481	0.761	rs12661756	chr6:27003483	A/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	0.41	6.88	0.3	1.98e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72781680	0.898	rs72780123	chr2:23996009	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	Schizophrenia;
LGG	trans	rs7812879	0.543	rs2736356	chr8:11370451	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.08	-0.31	5.27e-12	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg17691542	chr6:26056736	HIST1H1C	0.65	10.92	0.45	7.31e-25	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.19	0.32	2.61e-12	Lung cancer;
LGG	trans	rs1459104	0.714	rs35789111	chr11:54926634	C/G	cg03929089	chr4:120376271	NA	0.7	6.92	0.31	1.54e-11	Body mass index;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	1.02e-16	Lung cancer;
LGG	cis	rs28595532	0.920	rs56303276	chr4:119723514	C/T	cg14228332	chr4:119757509	SEC24D	1.04	10.51	0.44	2.51e-23	Cannabis dependence symptom count;
LGG	cis	rs7264396	0.676	rs6060730	chr20:34558503	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs4073582	0.516	rs1151539	chr11:66031660	C/T	cg14036092	chr11:66035641	RAB1B	0.46	7.97	0.35	1.23e-14	Gout;
LGG	cis	rs4919087	0.962	rs10748691	chr10:98983955	C/T	cg25902810	chr10:99078978	FRAT1	0.53	9.53	0.41	8.55e-20	Monocyte count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17123534	chr6:26204773	HIST1H4E	-0.5	-7.27	-0.32	1.55e-12	Systemic lupus erythematosus;
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg20916646	chr4:852691	GAK	0.5	8.83	0.38	2.25e-17	Sjögren's syndrome;
LGG	cis	rs920590	0.796	rs10788700	chr8:19635098	T/C	cg01411142	chr8:19674711	INTS10	0.44	6.89	0.31	1.8e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.71e-14	Testicular germ cell tumor;
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg18252515	chr7:66147081	NA	0.42	7.0	0.31	9.23e-12	Aortic root size;
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg00490583	chr16:1843685	IGFALS	-0.42	-7.07	-0.31	5.65e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg14787155	chr3:108308533	DZIP3;KIAA1524	0.35	6.66	0.3	7.79e-11	Blood protein levels;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg15242686	chr22:24348715	GSTTP1	0.41	7.38	0.32	7.34e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg18721089	chr20:30220636	NA	-0.51	-7.75	-0.34	5.72e-14	Mean corpuscular hemoglobin;
LGG	cis	rs17270561	0.609	rs9358878	chr6:25740273	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.72	-0.34	7.11e-14	Iron status biomarkers;
LGG	cis	rs4595586	0.756	rs1400283	chr12:39364596	G/C	cg26384229	chr12:38710491	ALG10B	0.51	9.47	0.4	1.42e-19	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.57	-0.44	1.56e-23	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.43e-44	Obesity-related traits;
LGG	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg15133208	chr4:90757351	SNCA	-0.32	-7.16	-0.32	3.18e-12	Dementia with Lewy bodies;
LGG	cis	rs7193541	0.646	rs4888267	chr16:74687906	A/G	cg01733217	chr16:74700730	RFWD3	1.1	35.02	0.85	3.28e-132	Multiple myeloma;
LGG	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs881375	0.501	rs10156413	chr9:123867782	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.4	6.67	0.3	7.42e-11	Rheumatoid arthritis;
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg02002194	chr4:3960332	NA	0.52	10.22	0.43	2.91e-22	Neuroticism;
LGG	cis	rs7742824	1.000	rs56168551	chr6:44104306	G/A	cg04074908	chr6:44101190	TMEM63B	0.69	13.32	0.53	1.64e-34	Major depressive disorder;
LGG	cis	rs4700695	0.511	rs29443	chr5:65504927	G/A	cg21114390	chr5:65439923	SFRS12	-0.57	-8.32	-0.36	1.02e-15	Facial morphology (factor 19);
LGG	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.07	-0.31	5.69e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7799006	0.895	rs3757437	chr7:2271980	C/T	cg02951883	chr7:2050386	MAD1L1	-0.43	-7.4	-0.33	6.6e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs870825	0.616	rs57316663	chr4:185630011	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs3206736	0.548	rs1186721	chr7:34974602	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.11	0.31	4.48e-12	Diastolic blood pressure;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg11494091	chr17:61959527	GH2	0.56	9.0	0.39	5.69e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs952623	0.649	rs17171519	chr7:39060312	T/C	cg18850127	chr7:39170497	POU6F2	0.35	8.19	0.36	2.62e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.34	-0.36	8.63e-16	Triglycerides;
LGG	cis	rs9818758	0.545	rs11717978	chr3:48969036	T/A	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4356203	0.870	rs10832751	chr11:17274016	T/C	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.75	-0.34	5.76e-14	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2836974	0.526	rs1888488	chr21:40686521	C/T	cg17971929	chr21:40555470	PSMG1	-0.66	-12.04	-0.49	3.01e-29	Cognitive function;
LGG	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.37	0.32	7.76e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17253792	0.822	rs12323476	chr14:56172722	C/T	cg01858014	chr14:56050164	KTN1	0.89	13.0	0.52	3.56e-33	Putamen volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21735648	chr20:46130382	NCOA3	0.44	7.37	0.32	8.04e-13	Cognitive performance;
LGG	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.79	-0.34	4.37e-14	Mood instability;
LGG	cis	rs6704644	0.932	rs72980402	chr2:234392743	G/A	cg27060346	chr2:234359958	DGKD	-0.57	-6.67	-0.3	7.15e-11	Bilirubin levels;
LGG	cis	rs769267	0.965	rs2905426	chr19:19478022	G/T	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.17	-0.46	7.85e-26	Tonsillectomy;
LGG	cis	rs6748734	1.000	rs6751693	chr2:241837332	T/C	cg26818257	chr2:241905806	NA	0.37	7.03	0.31	7.6e-12	Urinary metabolites;
LGG	cis	rs713587	0.967	rs10182181	chr2:25150296	C/T	cg04586622	chr2:25135609	ADCY3	-0.44	-11.97	-0.49	5.84e-29	Body mass index in non-asthmatics;
LGG	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg04990556	chr1:26633338	UBXN11	-0.69	-14.13	-0.55	5.76e-38	Obesity-related traits;
LGG	cis	rs4253772	0.515	rs8142080	chr22:46647429	G/T	cg24881330	chr22:46731750	TRMU	0.71	6.66	0.3	7.98e-11	LDL cholesterol;Cholesterol, total;
LGG	trans	rs208520	0.706	rs851601	chr6:66893853	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-16.9	-0.62	2.99e-50	Exhaled nitric oxide output;
LGG	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg02487422	chr3:49467188	NICN1	0.58	10.71	0.45	4.79e-24	Resting heart rate;
LGG	cis	rs994014	0.534	rs6831114	chr4:82205016	G/A	cg07938847	chr4:82126349	PRKG2	-0.3	-7.22	-0.32	2.2e-12	Height;
LGG	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.76	-0.45	3.05e-24	Migraine;Coronary artery disease;
LGG	trans	rs11875185	0.510	rs17754723	chr18:55620396	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3784262	0.692	rs4646581	chr15:58307898	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.76	-0.3	4.15e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.47	-0.44	3.59e-23	Lung cancer;
LGG	cis	rs7226408	0.600	rs8089495	chr18:34464502	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.42	-8.89	-0.38	1.39e-17	Obesity-related traits;
LGG	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg19773385	chr1:10388646	KIF1B	-0.49	-10.38	-0.43	8e-23	Hepatocellular carcinoma;
LGG	trans	rs6787172	0.702	rs1193507	chr3:157993404	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	trans	rs10506458	0.834	rs12426860	chr12:63387948	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-21.4	-0.71	3.74e-71	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7647973	0.961	rs7619016	chr3:49272589	C/T	cg07636037	chr3:49044803	WDR6	0.76	13.1	0.52	1.47e-33	Menarche (age at onset);
LGG	cis	rs12220238	0.722	rs7901055	chr10:76415029	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.53	-6.8	-0.3	3.21e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg15017067	chr4:17643749	FAM184B	0.3	6.8	0.3	3.31e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.962	rs2342861	chr6:150098697	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.83	0.42	7.61e-21	Schizophrenia;
LGG	cis	rs7223966	1.000	rs9912201	chr17:61763208	A/G	cg05941027	chr17:61774174	LIMD2	0.36	8.94	0.38	9.5e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3806843	0.966	rs2563255	chr5:140142547	T/C	cg19875535	chr5:140030758	IK	-0.52	-10.78	-0.45	2.51e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7215564	0.908	rs2316060	chr17:78663728	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs6930083	0.737	rs13196885	chr6:36632688	C/T	cg08179530	chr6:36648295	CDKN1A	-0.71	-12.88	-0.51	1.12e-32	Coronary artery disease;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg02562052	chr2:202508330	ALS2CR4	-0.42	-7.06	-0.31	6.14e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg12463550	chr7:65579703	CRCP	0.79	8.53	0.37	2.03e-16	Diabetic kidney disease;
LGG	cis	rs2840044	0.534	rs321596	chr17:33885736	C/T	cg05299278	chr17:33885742	SLFN14	-0.45	-8.96	-0.38	7.74e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2777491	1.000	rs2730057	chr15:41736275	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.35	-0.69	3.04e-66	Ulcerative colitis;
LGG	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs4793233	chr17:41435437	G/C	cg05368731	chr17:41323189	NBR1	0.93	18.23	0.65	2.41e-56	Menopause (age at onset);
LGG	trans	rs9784649	0.760	rs72755820	chr5:25066181	G/A	cg11038491	chr20:34638489	LOC647979	-0.7	-10.3	-0.43	1.52e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg25319279	chr11:5960081	NA	-0.55	-8.57	-0.37	1.6e-16	DNA methylation (variation);
LGG	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg07150166	chr2:30669952	LCLAT1	0.69	9.33	0.4	4.4e-19	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg06197492	chr11:2016605	H19	0.5	10.05	0.42	1.25e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1801251	1.000	rs2674839	chr2:233669040	G/C	cg08000102	chr2:233561755	GIGYF2	0.59	9.56	0.41	6.85e-20	Coronary artery disease;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg19077165	chr18:44547161	KATNAL2	-0.69	-13.34	-0.53	1.41e-34	Personality dimensions;
LGG	cis	rs12738007	1.000	rs34921636	chr1:29558281	A/G	cg11747820	chr1:29584023	PTPRU	-0.33	-7.64	-0.33	1.3e-13	Schizophrenia;
LGG	cis	rs17221829	0.599	rs7112871	chr11:89404829	G/A	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.69	-0.37	6.17e-17	Anxiety in major depressive disorder;
LGG	cis	rs9902453	0.935	rs4310926	chr17:28433275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	13.99	0.54	2.52e-37	Coffee consumption (cups per day);
LGG	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.53	-0.33	2.73e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs9911578	1.000	rs1267545	chr17:56646909	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.9	-0.42	4.52e-21	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg06521331	chr12:34319734	NA	0.43	7.64	0.33	1.22e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg19847130	chr8:10466454	RP1L1	0.31	6.81	0.3	3.13e-11	Neuroticism;
LGG	cis	rs12135191	0.771	rs12134040	chr1:236490678	A/G	cg21399712	chr1:236511386	NA	-0.42	-7.99	-0.35	1.05e-14	Urate levels (BMI interaction);
LGG	cis	rs911555	0.755	rs10148970	chr14:103892000	G/A	cg24130564	chr14:104152367	KLC1	-0.38	-7.14	-0.32	3.57e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3857536	0.842	rs2188591	chr6:66939511	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs13082711	0.911	rs11717669	chr3:27458484	C/T	cg02860705	chr3:27208620	NA	0.81	14.58	0.56	6.79e-40	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.07	-0.31	5.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11864453	0.826	rs9941087	chr16:72118324	G/A	cg23815491	chr16:72088622	HP	0.56	12.26	0.5	3.88e-30	Fibrinogen levels;
LGG	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg26384229	chr12:38710491	ALG10B	1.0	24.3	0.75	1.08e-84	Heart rate;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.59	0.51	1.76e-31	Prudent dietary pattern;
LGG	cis	rs10463554	0.963	rs11242483	chr5:102323766	C/T	cg23492399	chr5:102201601	PAM	-0.53	-8.19	-0.36	2.64e-15	Parkinson's disease;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.64	0.65	2.85e-58	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg13206674	chr6:150067644	NUP43	0.61	13.74	0.54	2.94e-36	Lung cancer;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg18426345	chr19:19516893	GATAD2A	-0.4	-6.79	-0.3	3.39e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs741702	0.928	rs2293683	chr19:13039284	A/G	cg23899408	chr19:12877188	HOOK2	0.48	7.68	0.34	9.27e-14	Red blood cell traits;
LGG	cis	rs10464366	0.957	rs6979210	chr7:39104119	C/G	cg10621924	chr7:39171070	POU6F2	0.44	8.55	0.37	1.75e-16	IgG glycosylation;
LGG	cis	rs611744	0.647	rs6981420	chr8:109266694	T/G	cg18478394	chr8:109455254	TTC35	0.43	8.5	0.37	2.57e-16	Dupuytren's disease;
LGG	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.61e-12	Blood metabolite levels;
LGG	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14829155	chr15:31115871	NA	-0.58	-10.18	-0.43	4.21e-22	Huntington's disease progression;
LGG	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.5	0.5	4.28e-31	Coronary artery disease;
LGG	cis	rs7769051	0.522	rs34688576	chr6:133118214	C/T	cg22852734	chr6:133119734	C6orf192	1.31	10.21	0.43	3.38e-22	Type 2 diabetes nephropathy;
LGG	trans	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg01620082	chr3:125678407	NA	-0.96	-8.96	-0.38	8.02e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg19717773	chr7:2847554	GNA12	-0.32	-6.77	-0.3	3.84e-11	Height;
LGG	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg18876405	chr7:65276391	NA	0.66	12.81	0.51	2.19e-32	Aortic root size;
LGG	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg12419862	chr22:24373484	LOC391322	0.88	13.3	0.53	2.05e-34	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs67311347	0.955	rs6773383	chr3:40377412	A/T	cg13683864	chr3:40499215	RPL14	-0.97	-19.92	-0.68	3.14e-64	Renal cell carcinoma;
LGG	cis	rs875971	0.862	rs880166	chr7:65670762	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.71	-0.3	5.53e-11	Aortic root size;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg07440826	chr16:89882328	FANCA	-0.26	-7.01	-0.31	8.34e-12	Vitiligo;
LGG	cis	rs1003719	0.788	rs3787783	chr21:38462959	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs12101261	0.580	rs4411444	chr14:81445108	A/G	cg06600135	chr14:81408086	NA	0.39	7.43	0.33	5.23e-13	Graves' disease;
LGG	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.96	0.49	6.29e-29	Hip circumference adjusted for BMI;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg17178900	chr1:205818956	PM20D1	0.67	15.65	0.59	1.33e-44	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg00933542	chr6:150070202	PCMT1	0.37	6.65	0.3	8.45e-11	Lung cancer;
LGG	trans	rs10838798	0.504	rs1483123	chr11:48326773	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.72	-0.3	5.33e-11	Height;
LGG	cis	rs9894429	0.966	rs6565604	chr17:79589242	G/A	cg10661904	chr17:79619235	PDE6G	-0.42	-8.51	-0.37	2.5e-16	Eye color traits;
LGG	cis	rs8180040	0.874	rs11130123	chr3:47285912	A/G	cg16586182	chr3:47516702	SCAP	-0.78	-15.27	-0.58	6.04e-43	Colorectal cancer;
LGG	cis	rs835154	0.817	rs835157	chr5:14874533	T/C	cg18064842	chr5:14874549	NA	-0.51	-11.79	-0.48	3.07e-28	Blood metabolite levels;
LGG	cis	rs9902453	0.934	rs34433787	chr17:28496780	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.52	0.53	2.49e-35	Coffee consumption (cups per day);
LGG	cis	rs7589342	0.745	rs11124066	chr2:106516925	T/A	cg14210321	chr2:106509881	NCK2	-0.51	-9.06	-0.39	3.82e-18	Addiction;
LGG	cis	rs9513627	1.000	rs4466950	chr13:100166875	G/T	cg15490075	chr13:100150979	NA	0.63	6.76	0.3	4.23e-11	Obesity-related traits;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg00684032	chr4:1343700	KIAA1530	0.4	7.15	0.32	3.37e-12	Obesity-related traits;
LGG	cis	rs892961	0.932	rs12453822	chr17:75416792	G/A	cg05865280	chr17:75406074	SEPT9	0.42	9.66	0.41	3.15e-20	Airflow obstruction;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg06112835	chr11:68658793	MRPL21	0.61	10.39	0.43	7.37e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7769051	0.522	rs60631157	chr6:133094817	G/A	cg07930552	chr6:133119739	C6orf192	1.16	10.58	0.44	1.46e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7666738	0.830	rs10007872	chr4:99001904	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.89	0.34	2.26e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs308971	0.563	rs394945	chr3:12075117	T/C	cg15873301	chr3:12045459	SYN2	0.56	7.25	0.32	1.74e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs2243480	1.000	rs2177703	chr7:65391717	C/A	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs644799	0.930	rs2186782	chr11:95649543	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.73	12.32	0.5	2.33e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.69	0.3	6.5500000000000006e-11	Height;
LGG	cis	rs4665809	0.590	rs4665318	chr2:26424517	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.05	0.39	3.92e-18	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4788570	0.538	rs72797728	chr16:71552789	C/T	cg06353428	chr16:71660113	MARVELD3	-1.03	-13.85	-0.54	9.66e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg04234412	chr22:24373322	LOC391322	-0.88	-18.83	-0.66	3.77e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg22907277	chr7:1156413	C7orf50	0.49	8.66	0.37	7.82e-17	Longevity;Endometriosis;
LGG	cis	rs7084402	0.967	rs1649065	chr10:60306386	T/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg05925327	chr15:68127851	NA	0.35	8.39	0.36	5.81e-16	Restless legs syndrome;
LGG	cis	rs4918072	0.917	rs35041090	chr10:105648686	G/A	cg11005552	chr10:105648138	OBFC1	0.72	12.28	0.5	3.5e-30	Coronary artery disease;
LGG	cis	rs7607369	0.617	rs12987009	chr2:219658170	A/T	cg01130898	chr2:219473002	PLCD4	0.4	6.69	0.3	6.5500000000000006e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs35110281	0.591	rs189094	chr21:44932017	A/G	cg04455712	chr21:45112962	RRP1B	0.42	7.45	0.33	4.72e-13	Mean corpuscular volume;
LGG	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg07148914	chr20:33460835	GGT7	0.53	9.01	0.39	5.26e-18	Height;
LGG	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg17788362	chr6:86352627	SYNCRIP	0.56	9.82	0.42	8.74e-21	Smooth-surface caries;
LGG	cis	rs7524258	0.868	rs11120885	chr1:7306755	C/G	cg07173049	chr1:7289937	CAMTA1	0.74	17.3	0.63	4.43e-52	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2762353	0.574	rs16890999	chr6:25755583	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.54	-8.89	-0.38	1.33e-17	Blood metabolite levels;
LGG	trans	rs7939886	0.920	rs7946368	chr11:55804219	C/T	cg03929089	chr4:120376271	NA	0.82	8.62	0.37	1.05e-16	Myopia (pathological);
LGG	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.96	0.57	1.46e-41	Morning vs. evening chronotype;
LGG	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg08807101	chr21:30365312	RNF160	0.75	13.39	0.53	8.57e-35	Selective IgA deficiency;
LGG	cis	rs6120849	0.754	rs7268266	chr20:33581889	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.71	0.3	5.69e-11	Protein C levels;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.38	-0.36	6.32e-16	Total body bone mineral density;
LGG	cis	rs73787773	0.866	rs79092804	chr5:111478820	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.11	-0.35	4.56e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs10267417	0.603	rs2214318	chr7:19899150	G/A	cg05791153	chr7:19748676	TWISTNB	0.54	7.1	0.31	4.85e-12	Night sleep phenotypes;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.36	0.5	1.59e-30	Obesity-related traits;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg05552183	chr6:42928497	GNMT	-0.38	-11.15	-0.46	9.45e-26	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg26384229	chr12:38710491	ALG10B	0.88	19.75	0.68	2.06e-63	Bladder cancer;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00495681	chr13:53174319	NA	0.74	15.07	0.57	4.96e-42	Lewy body disease;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.93	-0.31	1.4e-11	Obesity-related traits;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs2172802	0.693	rs1497919	chr4:62482227	G/A	cg04118610	chr4:62707027	LPHN3	-0.5	-7.85	-0.34	2.87e-14	Partial epilepsies;
LGG	cis	rs372883	0.648	rs2832297	chr21:30742996	A/C	cg24692254	chr21:30365293	RNF160	0.65	11.75	0.48	4.57e-28	Pancreatic cancer;
LGG	cis	rs4689388	0.727	rs1801213	chr4:6293696	C/G	cg25554036	chr4:6271136	WFS1	0.57	10.09	0.42	9.14e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.43	-0.44	5.21e-23	Bipolar disorder;
LGG	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg13647721	chr17:30228624	UTP6	-0.76	-10.05	-0.42	1.21e-21	Hip circumference adjusted for BMI;
LGG	trans	rs2197308	0.610	rs10880837	chr12:37864924	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.16	-0.39	1.66e-18	Morning vs. evening chronotype;
LGG	cis	rs422249	0.512	rs99780	chr11:61596633	C/T	cg19610905	chr11:61596333	FADS2	-0.76	-13.9	-0.54	5.81e-37	Trans fatty acid levels;
LGG	cis	rs7255045	0.711	rs2077544	chr19:12963285	C/T	cg07955356	chr19:12992479	DNASE2	0.45	6.81	0.3	3.01e-11	Mean corpuscular volume;
LGG	cis	rs9486715	1.000	rs9486715	chr6:97059769	A/C	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.25	-0.39	8.24e-19	Headache;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.99	0.35	1.05e-14	Bipolar disorder;
LGG	cis	rs1978968	0.784	rs71328248	chr22:18452501	C/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.69	-13.67	-0.54	5.55e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs877282	0.629	rs78997110	chr10:764388	A/G	cg17470449	chr10:769945	NA	0.57	6.75	0.3	4.43e-11	Uric acid levels;
LGG	cis	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg21401794	chr1:90099060	LRRC8C	0.44	8.06	0.35	6.66e-15	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12220238	1.000	rs4745740	chr10:75942469	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.57	0.47	2.34e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs78456975	0.941	rs6755875	chr2:1557109	T/C	cg01028140	chr2:1542097	TPO	-0.55	-8.55	-0.37	1.81e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8016982	0.674	rs1957549	chr14:81706179	G/A	cg01989461	chr14:81687754	GTF2A1	0.81	19.97	0.68	1.84e-64	Schizophrenia;
LGG	cis	rs6502050	0.712	rs8077079	chr17:80059011	C/T	cg13939156	chr17:80058883	NA	0.54	10.99	0.45	4.04e-25	Life satisfaction;
LGG	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg04990556	chr1:26633338	UBXN11	-0.48	-7.54	-0.33	2.57e-13	Granulocyte percentage of myeloid white cells;
LGG	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-9.03	-0.39	4.5e-18	Joint mobility (Beighton score);
LGG	cis	rs7044106	0.762	rs4837790	chr9:123446325	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.49e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10231759	0.617	rs11982695	chr7:150512100	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.36	0.36	7.34e-16	Height;
LGG	cis	rs11122272	0.735	rs10489610	chr1:231517765	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs9796	0.689	rs576336	chr15:41452771	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.53	-0.4	8.86e-20	Menopause (age at onset);
LGG	cis	rs4919087	0.810	rs10786321	chr10:99026112	T/C	cg25902810	chr10:99078978	FRAT1	0.48	8.66	0.37	7.79e-17	Monocyte count;
LGG	cis	rs1348850	0.958	rs11684320	chr2:178456346	T/C	cg27490568	chr2:178487706	NA	0.47	9.02	0.39	4.93e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg20978937	chr14:105399321	PLD4	-0.47	-10.57	-0.44	1.53e-23	Rheumatoid arthritis;
LGG	cis	rs804292	0.724	rs8191518	chr8:11627261	C/G	cg12395012	chr8:11607386	GATA4	0.53	7.4	0.33	6.38e-13	Alcohol dependence;Nicotine use;
LGG	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg00701064	chr4:6280414	WFS1	0.75	16.6	0.61	7.04e-49	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs60515486	0.646	rs753812	chr11:47431529	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.84	0.3	2.5e-11	Lymphocyte counts;
LGG	cis	rs240764	0.764	rs2213594	chr6:100931400	G/A	cg21058520	chr6:100914733	NA	0.52	9.16	0.39	1.64e-18	Neuroticism;
LGG	cis	rs62238980	0.614	rs117827593	chr22:32501199	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16405210	chr4:1374714	KIAA1530	-0.56	-10.06	-0.42	1.15e-21	Longevity;
LGG	cis	rs2404602	0.647	rs3812908	chr15:77176158	C/T	cg15268244	chr15:77196840	NA	-0.47	-10.11	-0.43	7.31e-22	Blood metabolite levels;
LGG	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	19.16	0.67	1.07e-60	Smoking behavior;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.69	-0.34	8.68e-14	Neuroticism;
LGG	cis	rs7613875	0.521	rs4688754	chr3:50074641	G/T	cg24110177	chr3:50126178	RBM5	0.61	11.07	0.46	2.02e-25	Body mass index;
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.56	-0.37	1.72e-16	Personality dimensions;
LGG	cis	rs889398	0.617	rs1566456	chr16:69900226	G/C	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.54	-0.33	2.54e-13	Body mass index;
LGG	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg10760299	chr15:45669010	GATM	0.41	7.88	0.34	2.37e-14	Homoarginine levels;
LGG	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	cis	rs870825	0.616	rs4444872	chr4:185628405	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.45	0.72	4.4e-76	Blood protein levels;
LGG	cis	rs815815	0.608	rs6751198	chr2:47396274	C/T	cg27223769	chr2:47403360	CALM2	-0.55	-8.18	-0.36	2.75e-15	Dialysis-related mortality;
LGG	cis	rs6723226	0.679	rs116617324	chr2:32622709	C/T	cg02381751	chr2:32503542	YIPF4	-0.62	-10.7	-0.45	5.15e-24	Intelligence (multi-trait analysis);
LGG	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg18654377	chr3:49208889	KLHDC8B	0.44	6.88	0.3	1.93e-11	Resting heart rate;
LGG	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.5	8.1	0.35	4.76e-15	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06850241	chr22:41845214	NA	-0.44	-6.76	-0.3	4.17e-11	Vitiligo;
LGG	cis	rs11800820	0.517	rs12022808	chr1:246659163	C/A	cg16700716	chr1:246684329	NA	0.42	7.36	0.32	8.65e-13	Obesity-related traits;
LGG	cis	rs7681423	1.000	rs2066864	chr4:155525695	G/A	cg20735720	chr4:155535218	FGG	-0.58	-10.38	-0.43	7.88e-23	Fibrinogen;
LGG	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg11584989	chr19:19387371	SF4	0.68	11.32	0.47	2.25e-26	Bipolar disorder;
LGG	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.83	0.38	2.13e-17	Parkinson's disease;
LGG	cis	rs1023500	0.505	rs134874	chr22:42661144	A/G	cg04733989	chr22:42467013	NAGA	0.5	8.66	0.37	7.67e-17	Schizophrenia;
LGG	cis	rs7503807	0.664	rs8068637	chr17:78614470	C/T	cg06872548	chr17:78716983	RPTOR	0.39	8.62	0.37	1.06e-16	Obesity;
LGG	cis	rs13191362	1.000	rs36107456	chr6:162997399	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.25	0.43	2.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09063977	chr22:24200205	SLC2A11	0.46	6.71	0.3	5.55e-11	Gut microbiome composition (summer);
LGG	cis	rs988958	0.958	rs34482969	chr2:42280300	G/A	cg27252766	chr2:42229092	NA	0.47	7.85	0.34	3.01e-14	Hypospadias;
LGG	cis	rs62025270	0.522	rs338519	chr15:86214879	T/C	cg25843651	chr15:86329602	KLHL25	0.52	8.72	0.38	4.94e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs11168618	0.686	rs11168574	chr12:48838969	T/A	cg24011408	chr12:48396354	COL2A1	0.49	7.98	0.35	1.16e-14	Adiponectin levels;
LGG	cis	rs2933343	0.729	rs1683780	chr3:128640239	C/T	cg25356066	chr3:128598488	ACAD9	0.45	6.83	0.3	2.73e-11	IgG glycosylation;
LGG	cis	rs11158559	0.865	rs1695778	chr14:65243476	C/T	cg22797773	chr14:65239943	SPTB	-0.42	-7.02	-0.31	7.99e-12	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25016364	chr7:152457024	ACTR3B	0.45	6.8	0.3	3.18e-11	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.99	-0.49	4.92e-29	Alzheimer's disease;
LGG	cis	rs9325144	0.554	rs7960616	chr12:39096664	T/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.43	-0.33	5.45e-13	Morning vs. evening chronotype;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03324837	chr17:61044407	NA	-0.41	-6.9	-0.31	1.71e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9462027	0.628	rs9469894	chr6:34774725	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.7	-0.51	6.53e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs208520	0.661	rs207090	chr6:66783963	T/A	cg07460842	chr6:66804631	NA	-0.98	-18.31	-0.65	9.41e-57	Exhaled nitric oxide output;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg04025307	chr7:1156635	C7orf50	0.6	11.11	0.46	1.41e-25	Longevity;Endometriosis;
LGG	cis	rs9398803	0.713	rs1490385	chr6:126875521	C/T	cg19875578	chr6:126661172	C6orf173	0.51	9.32	0.4	4.79e-19	Male-pattern baldness;
LGG	cis	rs1018836	0.505	rs7015030	chr8:91460331	T/C	cg16814680	chr8:91681699	NA	-0.5	-8.11	-0.35	4.71e-15	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg02725872	chr8:58115012	NA	-0.97	-12.73	-0.51	4.94e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg24250549	chr1:154909240	PMVK	0.66	12.06	0.49	2.51e-29	Prostate cancer;
LGG	cis	rs741702	0.928	rs2293683	chr19:13039284	A/G	cg04657146	chr19:12876947	HOOK2	0.44	7.15	0.32	3.36e-12	Red blood cell traits;
LGG	trans	rs6956675	1.000	rs6968327	chr7:62574489	A/G	cg01314568	chr7:57830625	NA	-0.51	-8.05	-0.35	7.02e-15	Obesity-related traits;
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg07440826	chr16:89882328	FANCA	-0.26	-6.75	-0.3	4.37e-11	Vitiligo;
LGG	cis	rs9649465	1.000	rs9641715	chr7:123348623	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs2470578	0.792	rs283949	chr3:17355801	G/C	cg20981856	chr3:17787350	NA	0.35	6.72	0.3	5.42e-11	Schizophrenia;
LGG	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg13114125	chr14:105738426	BRF1	-0.85	-17.22	-0.62	1.06e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2120243	1.000	rs9289982	chr3:157144444	G/C	cg24825693	chr3:157122686	VEPH1	-0.41	-8.63	-0.37	1.01e-16	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg19147804	chr7:1989927	MAD1L1	0.51	10.1	0.42	8.58e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs474442	chr11:95583995	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.95	0.35	1.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg09085632	chr11:111637200	PPP2R1B	0.73	13.32	0.53	1.7e-34	Primary sclerosing cholangitis;
LGG	trans	rs11875185	0.510	rs17754517	chr18:55595465	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg02018176	chr4:1364513	KIAA1530	-0.64	-15.73	-0.59	5.42e-45	Longevity;
LGG	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg15704280	chr7:45808275	SEPT13	0.91	17.49	0.63	6.08e-53	Coronary artery disease;
LGG	cis	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	8.1	0.35	4.92e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1065852	0.526	rs9607869	chr22:42418110	T/A	cg15128208	chr22:42549153	NA	0.41	7.13	0.31	3.78e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs17125944	0.686	rs6572869	chr14:53353454	C/T	cg00686598	chr14:53173677	PSMC6	0.67	7.15	0.32	3.32e-12	Alzheimer's disease (late onset);
LGG	cis	rs738322	0.726	rs5750561	chr22:38595260	A/T	cg25457927	chr22:38595422	NA	0.5	13.41	0.53	6.86e-35	Cutaneous nevi;
LGG	cis	rs7582720	1.000	rs72926793	chr2:203826396	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg15242686	chr22:24348715	GSTTP1	0.37	6.78	0.3	3.6e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.71	-0.3	5.81e-11	Schizophrenia;
LGG	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.8	-0.3	3.3e-11	Blood metabolite levels;
LGG	cis	rs62400317	0.762	rs12215263	chr6:44831364	C/A	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9810089	0.934	rs10935184	chr3:136153468	T/C	cg21827317	chr3:136751795	NA	0.44	7.74	0.34	6.19e-14	Gestational age at birth (child effect);
LGG	cis	rs11630290	0.592	rs1039817	chr15:64155367	T/A	cg12036633	chr15:63758958	NA	0.49	7.11	0.31	4.37e-12	Iris characteristics;
LGG	cis	rs2044029	0.504	rs1441363	chr15:71699681	G/C	cg19634315	chr15:71679485	THSD4	0.47	9.02	0.39	4.84e-18	Airflow obstruction;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg13903179	chr13:21900392	NA	0.39	6.79	0.3	3.45e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2075371	1.000	rs2505	chr7:133979552	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.52	0.58	5.06e-44	Mean platelet volume;
LGG	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg24634471	chr8:143751801	JRK	0.5	7.62	0.33	1.48e-13	Schizophrenia;
LGG	cis	rs6696846	0.515	rs6593924	chr1:205110452	A/G	cg00889227	chr1:205173544	DSTYK	-0.32	-7.83	-0.34	3.33e-14	Red blood cell count;
LGG	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg08997352	chr12:9597637	DDX12	-0.69	-13.58	-0.53	1.34e-35	Breast size;
LGG	cis	rs10751667	0.580	rs10751664	chr11:927077	T/G	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	trans	rs75804782	0.521	rs72982590	chr2:239451826	T/C	cg01134436	chr17:81009848	B3GNTL1	0.77	8.56	0.37	1.62e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg08677398	chr8:58056175	NA	0.42	6.71	0.3	5.79e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.641	rs203479	chr17:19829311	T/C	cg04132472	chr17:19861366	AKAP10	0.26	7.2	0.32	2.46e-12	Schizophrenia;
LGG	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg08975724	chr8:8085496	FLJ10661	0.46	8.35	0.36	7.7e-16	Neuroticism;
LGG	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.05	-0.35	7.28e-15	Educational attainment;
LGG	cis	rs1263173	0.566	rs4225	chr11:116703671	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.57	9.53	0.41	8.63e-20	HDL cholesterol;
LGG	cis	rs8072100	0.840	rs11079774	chr17:45479706	C/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.5	-0.37	2.63e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7011049	1.000	rs11997775	chr8:53833571	C/T	cg26025543	chr8:53854495	NA	-0.73	-9.73	-0.41	1.82e-20	Systolic blood pressure;
LGG	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg01270228	chr10:1369114	ADARB2	0.51	9.49	0.4	1.22e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3820068	0.581	rs111699992	chr1:15927158	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs8141529	0.664	rs5762862	chr22:29252732	C/T	cg02153584	chr22:29168773	CCDC117	0.59	8.43	0.36	4.26e-16	Lymphocyte counts;
LGG	cis	rs9549367	0.664	rs9549689	chr13:113848387	G/A	cg00898013	chr13:113819073	PROZ	-0.51	-10.02	-0.42	1.55e-21	Platelet distribution width;
LGG	cis	rs7582720	1.000	rs72934704	chr2:203706433	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs6787172	0.702	rs1095637	chr3:157968802	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs11229555	0.609	rs12291791	chr11:58186290	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.47	-0.4	1.43e-19	Mean corpuscular volume;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg18316613	chr7:23719636	C7orf46	-0.38	-8.89	-0.38	1.42e-17	Schizophrenia;
LGG	cis	rs2455799	0.613	rs4467435	chr3:15791671	A/G	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs1570884	0.539	rs7983291	chr13:50111931	G/C	cg11801959	chr13:50123613	RCBTB1	-0.39	-6.87	-0.3	2.05e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1577917	1.000	rs10944169	chr6:86683036	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.88	-0.51	1.14e-32	Response to antipsychotic treatment;
LGG	cis	rs7737355	0.947	rs6596007	chr5:130588550	A/G	cg06307176	chr5:131281290	NA	-0.49	-8.2	-0.36	2.37e-15	Life satisfaction;
LGG	trans	rs116095464	0.558	rs10079760	chr5:230778	A/G	cg09048205	chr5:1608656	LOC728613	-0.47	-8.2	-0.36	2.31e-15	Breast cancer;
LGG	cis	rs4851254	0.920	rs4850920	chr2:100757308	C/A	cg17356467	chr2:100759845	AFF3	0.41	7.14	0.31	3.63e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg11752832	chr7:134001865	SLC35B4	-0.5	-8.53	-0.37	2.14e-16	Mean platelet volume;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs17253792	0.822	rs13379353	chr14:56050478	G/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.62	-0.51	1.41e-31	Putamen volume;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12731740	1.000	rs12731740	chr1:208024820	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.45	-0.33	4.67e-13	Biomedical quantitative traits;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.43	-0.36	4.45e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.98	-14.69	-0.56	2.29e-40	Platelet count;
LGG	cis	rs807029	0.533	rs3740486	chr10:102750623	T/C	cg04662943	chr10:102668895	NA	0.47	6.92	0.31	1.52e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg26666090	chr16:58549219	SETD6	1.13	10.05	0.42	1.3e-21	Schizophrenia;
LGG	cis	rs8062405	0.754	rs28410083	chr16:28631360	A/T	cg07382826	chr16:28625726	SULT1A1	-0.4	-8.1	-0.35	4.8e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs67478160	0.654	rs1997913	chr14:104213960	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.27	-0.32	1.55e-12	Schizophrenia;
LGG	cis	rs5769707	0.777	rs739243	chr22:50057211	C/T	cg06623630	chr22:50017776	C22orf34	-0.34	-7.23	-0.32	2.01e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6121246	0.954	rs6121245	chr20:30432060	G/A	cg13852791	chr20:30311386	BCL2L1	0.71	11.13	0.46	1.2e-25	Mean corpuscular hemoglobin;
LGG	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg03877680	chr5:178157825	ZNF354A	0.83	14.17	0.55	4.19e-38	Neutrophil percentage of white cells;
LGG	cis	rs35306767	0.953	rs11253520	chr10:975961	C/G	cg08847335	chr10:891726	LARP4B	0.32	6.87	0.3	2.13e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs28595532	0.841	rs10019311	chr4:119785458	G/A	cg11846333	chr4:119757529	SEC24D	0.84	7.81	0.34	3.87e-14	Cannabis dependence symptom count;
LGG	trans	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg20587970	chr11:113659929	NA	0.93	12.77	0.51	3.41e-32	Hip circumference adjusted for BMI;
LGG	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg06951627	chr6:26196580	NA	0.53	8.06	0.35	6.43e-15	Gout;Renal underexcretion gout;
LGG	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg21775007	chr8:11205619	TDH	-0.44	-7.3	-0.32	1.28e-12	Neuroticism;
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	8.03	0.35	8.33e-15	Renal function-related traits (BUN);
LGG	cis	rs896854	0.684	rs10099941	chr8:95987008	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.5	-0.37	2.56e-16	Type 2 diabetes;
LGG	cis	rs2066819	1.000	rs2020854	chr12:56743367	T/C	cg26714650	chr12:56694279	CS	-1.45	-16.54	-0.61	1.23e-48	Psoriasis vulgaris;
LGG	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.82	-0.3	2.9100000000000002e-11	Myopia (pathological);
LGG	cis	rs4740619	0.836	rs10962158	chr9:15786902	T/A	cg14451791	chr9:16040625	NA	-0.4	-10.4	-0.44	6.5e-23	Body mass index;
LGG	cis	rs9527	0.590	rs1475642	chr10:104546183	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-7.08	-0.31	5.38e-12	Arsenic metabolism;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg21862992	chr11:68658383	NA	0.49	7.92	0.35	1.82e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg00012203	chr2:219082015	ARPC2	0.78	14.85	0.57	4.56e-41	Colorectal cancer;
LGG	trans	rs61931739	0.578	rs1384597	chr12:33604164	A/T	cg26384229	chr12:38710491	ALG10B	-0.46	-8.07	-0.35	6.13e-15	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg00631329	chr6:26305371	NA	-0.54	-9.69	-0.41	2.34e-20	Educational attainment;
LGG	cis	rs6142618	0.562	rs2235902	chr20:30721350	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs36051895	0.659	rs62541538	chr9:5038164	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-15.69	-0.59	8.92e-45	Pediatric autoimmune diseases;
LGG	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg14593290	chr7:50529359	DDC	-0.48	-8.42	-0.36	4.85e-16	Malaria;
LGG	cis	rs9534288	0.797	rs7998854	chr13:46592174	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg27286337	chr10:134555280	INPP5A	0.51	6.88	0.3	1.93e-11	Primary sclerosing cholangitis;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg25358565	chr5:93447407	FAM172A	1.27	15.62	0.59	1.67e-44	Diabetic retinopathy;
LGG	cis	rs425535	0.757	rs1898002	chr4:74807490	G/A	cg01447579	chr4:74847100	PF4	0.53	6.68	0.3	6.88e-11	Blood protein levels;
LGG	cis	rs614226	1.000	rs12310837	chr12:120880572	C/T	cg01236616	chr12:121019343	POP5	1.15	19.97	0.68	1.78e-64	Type 1 diabetes nephropathy;
LGG	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg03929089	chr4:120376271	NA	0.76	12.18	0.49	8.46e-30	Coronary artery disease;
LGG	cis	rs9549367	0.737	rs11619691	chr13:113904636	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg18681998	chr4:17616180	MED28	0.85	18.14	0.64	6.1e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg21926883	chr2:100939477	LONRF2	-0.66	-15.14	-0.58	2.3e-42	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.78	0.59	3.33e-45	Lung cancer;
LGG	cis	rs9534288	0.619	rs6561290	chr13:46682460	A/G	cg15192986	chr13:46630673	CPB2	-0.7	-14.26	-0.55	1.7e-38	Blood protein levels;
LGG	trans	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg20587970	chr11:113659929	NA	-1.38	-17.83	-0.64	1.7e-54	Hip circumference adjusted for BMI;
LGG	cis	rs977747	1.000	rs7534271	chr1:47693981	C/G	cg03885399	chr1:47691550	TAL1	0.33	7.12	0.31	4.13e-12	Body mass index;
LGG	cis	rs9311474	0.508	rs12637627	chr3:52619962	G/T	cg18404041	chr3:52824283	ITIH1	-0.51	-10.02	-0.42	1.57e-21	Electroencephalogram traits;
LGG	cis	rs9443189	0.865	rs2133190	chr6:76443493	A/G	cg01950844	chr6:76311363	SENP6	-0.56	-7.52	-0.33	2.87e-13	Prostate cancer;
LGG	cis	rs7927771	0.524	rs11039419	chr11:47851354	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs6977660	1.000	rs714239	chr7:19803944	C/T	cg05791153	chr7:19748676	TWISTNB	0.57	8.56	0.37	1.74e-16	Thyroid stimulating hormone;
LGG	cis	rs933688	0.938	rs1477348	chr5:90707823	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs1451375	0.741	rs55738142	chr7:50632326	T/C	cg00647317	chr7:50633725	DDC	-0.33	-7.48	-0.33	3.76e-13	Malaria;
LGG	cis	rs66887589	0.934	rs41464847	chr4:120532401	A/G	cg09307838	chr4:120376055	NA	-0.49	-8.55	-0.37	1.84e-16	Diastolic blood pressure;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg20308403	chr7:2120281	MAD1L1	0.32	6.9	0.31	1.74e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg21724239	chr8:58056113	NA	0.63	9.29	0.4	5.82e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg23231163	chr10:75533350	FUT11	-0.42	-7.27	-0.32	1.56e-12	Inflammatory bowel disease;
LGG	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.38	-0.36	6.37e-16	Blood metabolite levels;
LGG	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.37	-0.43	8.36e-23	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs367943	0.608	rs4705463	chr5:112980273	C/G	cg12552261	chr5:112820674	MCC	0.51	8.89	0.38	1.4e-17	Type 2 diabetes;
LGG	cis	rs9517320	0.534	rs9554474	chr13:99140871	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.85	-0.45	1.4e-24	Longevity;
LGG	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg18681998	chr4:17616180	MED28	0.86	19.69	0.68	3.72e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg09448879	chr15:79043637	NA	0.44	8.66	0.37	7.63e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs11585357	0.895	rs72633803	chr1:17616758	G/A	cg08277548	chr1:17600880	PADI3	-0.73	-8.15	-0.35	3.4e-15	Hair shape;
LGG	cis	rs7635838	0.819	rs904474	chr3:11524648	C/G	cg00170343	chr3:11313890	ATG7	0.4	6.79	0.3	3.46e-11	HDL cholesterol;
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg22398616	chr13:53314203	LECT1	-0.43	-8.26	-0.36	1.55e-15	Lewy body disease;
LGG	trans	rs7939886	0.920	rs7112964	chr11:55866408	T/C	cg02254774	chr11:50257496	LOC441601	0.57	6.76	0.3	4.15e-11	Myopia (pathological);
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11166927	0.703	rs2126128	chr8:140788299	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.45	-9.12	-0.39	2.23e-18	Pediatric non-alcoholic fatty liver disease activity score;
LGG	trans	rs783540	0.632	rs17356528	chr15:83305550	A/G	cg16105309	chr15:79090380	ADAMTS7	0.49	8.29	0.36	1.26e-15	Schizophrenia;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg08742575	chr21:47604166	C21orf56	0.57	10.38	0.43	7.95e-23	Testicular germ cell tumor;
LGG	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.78	-0.41	1.18e-20	Morning vs. evening chronotype;
LGG	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg12395012	chr8:11607386	GATA4	0.41	7.49	0.33	3.57e-13	Myopia (pathological);
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.66	-0.37	7.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs483180	0.512	rs677277	chr1:120202298	C/T	cg19096424	chr1:120255104	PHGDH	-0.63	-11.38	-0.47	1.23e-26	Macular telangiectasia type 2;
LGG	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg02466173	chr16:30829666	NA	-0.43	-7.74	-0.34	6.28e-14	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.76	13.53	0.53	2.19e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9783347	1.000	rs1520884	chr11:18309700	C/T	cg15585147	chr11:18324498	HPS5	-0.43	-8.83	-0.38	2.18e-17	Pancreatic cancer;
LGG	cis	rs919433	0.679	rs13000656	chr2:198522126	T/C	cg00792783	chr2:198669748	PLCL1	-0.58	-9.21	-0.39	1.11e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6681460	0.625	rs6680364	chr1:67104834	G/A	cg20812318	chr1:67072952	SGIP1	-0.31	-7.22	-0.32	2.13e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg24623649	chr8:11872141	NA	-0.29	-7.09	-0.31	5.08e-12	Neuroticism;
LGG	cis	rs6840360	0.615	rs10001603	chr4:152647577	T/A	cg22705602	chr4:152727874	NA	-0.4	-9.95	-0.42	2.9e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2559856	1.000	rs2695284	chr12:102089318	A/G	cg12924262	chr12:102091054	CHPT1	-0.66	-13.09	-0.52	1.62e-33	Blood protein levels;
LGG	cis	rs6964587	0.934	rs73226382	chr7:91692760	T/C	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	trans	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg25214090	chr10:38739885	LOC399744	-0.65	-11.51	-0.47	4.07e-27	Corneal astigmatism;
LGG	trans	rs2204008	0.806	rs11525001	chr12:38234397	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.53	-0.4	9.08e-20	Bladder cancer;
LGG	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	22.29	0.72	2.71e-75	Homoarginine levels;
LGG	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg20302533	chr7:39170763	POU6F2	0.58	14.95	0.57	1.7e-41	IgG glycosylation;
LGG	cis	rs2268667	0.511	rs1874807	chr1:85779393	A/G	cg02862864	chr1:85742044	BCL10	0.43	8.03	0.35	8.28e-15	Asymmetrical dimethylarginine levels;
LGG	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11096990	0.855	rs2566184	chr4:39164320	T/C	cg24403649	chr4:39172243	NA	-0.48	-7.79	-0.34	4.42e-14	Cognitive function;
LGG	cis	rs9393777	0.513	rs9348728	chr6:26634436	G/A	cg12826209	chr6:26865740	GUSBL1	0.82	12.12	0.49	1.53e-29	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.881	rs34061264	chr14:71785276	A/G	cg02058870	chr14:72053146	SIPA1L1	0.4	8.34	0.36	8.28e-16	Mitral valve prolapse;
LGG	cis	rs9814567	1.000	rs4498009	chr3:134198008	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.6	-0.51	1.62e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6909430	0.908	rs289764	chr6:98660208	A/G	cg12860156	chr6:98744658	NA	-0.42	-7.28	-0.32	1.49e-12	Quantitative traits;
LGG	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.5	-0.37	2.63e-16	Retinal vascular caliber;
LGG	cis	rs9811920	0.609	rs10936005	chr3:99674093	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-9.03	-0.39	4.72e-18	Axial length;
LGG	trans	rs7395662	1.000	rs10838975	chr11:48617615	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06873684	chr19:4472059	HDGF2	0.51	8.68	0.37	6.72e-17	Gut microbiota (bacterial taxa);
LGG	trans	rs7615952	0.673	rs34209763	chr3:125599595	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-16.95	-0.62	1.69e-50	Blood pressure (smoking interaction);
LGG	cis	rs7829975	0.501	rs4840353	chr8:8580570	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.89	-0.3	1.88e-11	Mood instability;
LGG	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg19729930	chr2:74357872	NA	0.49	10.54	0.44	1.95e-23	Gestational age at birth (maternal effect);
LGG	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg26248373	chr2:1572462	NA	-0.88	-14.38	-0.56	5.06e-39	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs981844	0.857	rs41320045	chr4:154720615	A/T	cg14289246	chr4:154710475	SFRP2	-0.68	-11.14	-0.46	1.08e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs1941687	0.831	rs1353168	chr18:31359762	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.65	-0.37	8.33e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.84	0.48	1.95e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs858239	0.571	rs2390755	chr7:23190716	A/T	cg23682824	chr7:23144976	KLHL7	0.42	6.85	0.3	2.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.71	14.49	0.56	1.71e-39	Obesity-related traits;
LGG	trans	rs28595532	0.623	rs56324414	chr4:119274655	A/C	cg26518628	chr1:97050305	NA	-0.85	-8.7	-0.37	5.78e-17	Cannabis dependence symptom count;
LGG	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg26597838	chr10:835615	NA	0.48	6.65	0.3	8.15e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs757081	0.671	rs214070	chr11:17305317	T/A	cg15432903	chr11:17409602	KCNJ11	-0.56	-8.49	-0.37	2.85e-16	Systolic blood pressure;
LGG	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg15557168	chr22:42548783	NA	-0.39	-8.5	-0.37	2.66e-16	Schizophrenia;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs28588043	0.702	rs55847906	chr1:170986416	C/T	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg03929089	chr4:120376271	NA	-1.03	-24.68	-0.75	1.83e-86	Height;
LGG	cis	rs72781680	0.898	rs12623079	chr2:24103749	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.06	0.39	3.8e-18	Lymphocyte counts;
LGG	cis	rs13102973	0.965	rs6853276	chr4:135881445	A/T	cg14419869	chr4:135874104	NA	0.57	10.82	0.45	1.72e-24	Subjective well-being;
LGG	cis	rs490234	0.812	rs12553699	chr9:128294526	C/G	cg14078157	chr9:128172775	NA	-0.48	-9.15	-0.39	1.83e-18	Mean arterial pressure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11786005	chr6:170863399	PSMB1;TBP	0.41	6.94	0.31	1.29e-11	Bipolar disorder;
LGG	cis	rs12209877	0.929	rs4710961	chr6:21031079	A/G	cg13405222	chr6:20811065	CDKAL1	0.38	7.07	0.31	5.64e-12	Cognitive function;
LGG	cis	rs4789378	1.000	rs7217999	chr17:74930674	T/C	cg02841895	chr17:74942714	MGAT5B	-0.35	-7.28	-0.32	1.49e-12	Colorectal or endometrial cancer;
LGG	cis	rs8056893	0.879	rs3961282	chr16:68365157	A/G	cg07273125	chr16:68295692	NA	0.36	6.69	0.3	6.54e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg02297831	chr4:17616191	MED28	0.49	9.27	0.4	7.22e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7119	0.717	rs12901732	chr15:77818933	G/T	cg10437265	chr15:77819839	NA	0.25	7.01	0.31	8.27e-12	Type 2 diabetes;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg18379455	chr17:41446167	NA	-0.3	-6.9	-0.31	1.73e-11	Menopause (age at onset);
LGG	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg01028140	chr2:1542097	TPO	0.55	8.68	0.37	7.05e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8005745	0.522	rs2301109	chr14:62197596	G/A	cg01748970	chr14:62088363	NA	-0.84	-9.95	-0.42	2.85e-21	Select biomarker traits;
LGG	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg11984989	chr7:158649758	WDR60	-1.04	-15.1	-0.57	3.46e-42	Height;
LGG	cis	rs1878931	0.501	rs9635547	chr16:3416664	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.82	14.16	0.55	4.29e-38	Body mass index (adult);
LGG	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg09873164	chr1:152488093	CRCT1	0.62	15.33	0.58	3.48e-43	Hair morphology;
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg19223190	chr17:80058835	NA	-0.49	-9.67	-0.41	2.9e-20	Life satisfaction;
LGG	cis	rs11885103	0.775	rs11127480	chr2:592469	G/T	cg21195176	chr2:593345	NA	0.41	7.62	0.33	1.47e-13	Heschl's gyrus morphology;
LGG	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg25019033	chr10:957182	NA	-0.54	-9.86	-0.42	5.98e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs13314892	0.764	rs62251030	chr3:69864948	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs62400317	0.859	rs55779653	chr6:45265960	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.26	-0.43	2.12e-22	Total body bone mineral density;
LGG	cis	rs6725041	0.792	rs11676942	chr2:213091716	A/T	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs9807841	0.592	rs1053007	chr19:10754400	A/G	cg17710535	chr19:10819994	QTRT1	0.45	7.31	0.32	1.18e-12	Inflammatory skin disease;
LGG	trans	rs7923837	1.000	rs1112718	chr10:94479107	A/G	cg27639046	chr2:171608303	NA	-0.34	-6.75	-0.3	4.37e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs2797369	0.600	rs72947091	chr6:101288400	T/C	cg27451362	chr6:101846650	GRIK2	0.67	9.21	0.39	1.14e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	13.33	0.53	1.6e-34	Prudent dietary pattern;
LGG	cis	rs9361491	0.621	rs12196457	chr6:79627743	A/T	cg18132916	chr6:79620363	NA	-0.28	-7.29	-0.32	1.38e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.41	-10.34	-0.43	1.05e-22	IgG glycosylation;
LGG	cis	rs637571	0.544	rs617791	chr11:65702523	C/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.41	6.73	0.3	5.07e-11	Eosinophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	trans	rs9944715	1.000	rs9959813	chr18:43841082	C/T	cg01718231	chr17:29326311	RNF135	0.42	6.74	0.3	4.74e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg22980697	chr10:16874865	CUBN	0.58	9.48	0.4	1.36e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs9409565	0.762	rs55877910	chr9:97234213	G/C	cg05679027	chr9:99775184	HIATL2	-0.49	-8.08	-0.35	5.77e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.28e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467773	0.596	rs3001369	chr6:26670969	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.75	0.54	2.52e-36	Intelligence (multi-trait analysis);
LGG	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.71e-11	Reticulocyte count;High light scatter reticulocyte count;
LGG	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-10.1	-0.43	8.03e-22	Diabetic retinopathy;
LGG	cis	rs11168187	0.843	rs7967546	chr12:48119049	G/A	cg12761788	chr12:48120090	P11	0.51	8.86	0.38	1.77e-17	Vertical cup-disc ratio;
LGG	cis	rs11098499	0.954	rs878373	chr4:120237484	A/T	cg24375607	chr4:120327624	NA	0.65	10.65	0.44	7.6e-24	Corneal astigmatism;
LGG	trans	rs1941687	0.702	rs9956636	chr18:31304974	C/T	cg27147174	chr7:100797783	AP1S1	-0.53	-8.63	-0.37	9.86e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11971779	0.648	rs6467849	chr7:139080512	C/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9814567	1.000	rs7611828	chr3:134250325	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg27129171	chr3:47204927	SETD2	-0.8	-15.63	-0.59	1.52e-44	Colorectal cancer;
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.93	0.31	1.41e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6964587	1.000	rs3753109	chr7:91630001	G/C	cg17063962	chr7:91808500	NA	0.47	8.51	0.37	2.45e-16	Breast cancer;
LGG	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg16339924	chr4:17578868	LAP3	0.6	10.4	0.44	6.67e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1665650	0.957	rs1665644	chr10:118488038	C/T	cg14919929	chr10:118506882	NA	0.48	8.45	0.37	3.75e-16	Colorectal cancer;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.2	-0.52	5.46e-34	Alzheimer's disease;
LGG	cis	rs2439831	1.000	rs2584725	chr15:43793135	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.79	-0.34	4.32e-14	Systemic lupus erythematosus;
LGG	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg22681709	chr2:178499509	PDE11A	-0.52	-7.76	-0.34	5.37e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04856096	chr8:68255097	ARFGEF1	0.47	8.22	0.36	2.1e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7481584	0.581	rs406598	chr11:3076285	G/A	cg25174290	chr11:3078921	CARS	-0.51	-9.07	-0.39	3.36e-18	Calcium levels;
LGG	cis	rs2274273	0.624	rs7157308	chr14:55782043	A/G	cg04306507	chr14:55594613	LGALS3	0.53	12.46	0.5	5.98e-31	Protein biomarker;
LGG	cis	rs1691799	0.867	rs1168343	chr12:66758581	C/T	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	cis	rs3733585	0.762	rs6449217	chr4:10009151	T/A	cg08250081	chr4:10125330	NA	0.39	7.46	0.33	4.4e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs941873	0.835	rs4246944	chr10:81105684	C/T	cg09469691	chr10:81107165	PPIF	0.63	11.42	0.47	8.46e-27	Height;
LGG	cis	rs9479482	1.000	rs9478380	chr6:150354665	A/G	cg03788504	chr6:150331562	NA	0.58	13.15	0.52	8.85e-34	Alopecia areata;
LGG	cis	rs9811920	0.809	rs4928150	chr3:99685991	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.49	8.68	0.37	6.79e-17	Axial length;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.27	-0.43	2.03e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.954	rs72884027	chr6:66995044	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.24	0.55	2.01e-38	Exhaled nitric oxide output;
LGG	cis	rs2439831	0.867	rs2412779	chr15:43655927	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	11.31	0.47	2.43e-26	Lung cancer in ever smokers;
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.81	0.41	8.88e-21	Height;
LGG	cis	rs1552244	0.572	rs41464050	chr3:10158393	A/G	cg00166722	chr3:10149974	C3orf24	0.52	7.64	0.33	1.25e-13	Alzheimer's disease;
LGG	trans	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg20325293	chr4:54244256	FIP1L1	-0.77	-8.14	-0.35	3.78e-15	IgG glycosylation;
LGG	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg24692254	chr21:30365293	RNF160	0.64	11.58	0.47	2.02e-27	Pancreatic cancer;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg13206674	chr6:150067644	NUP43	0.41	8.69	0.37	6.44e-17	Testicular germ cell tumor;
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg05091796	chr16:4465799	CORO7	-1.01	-17.65	-0.63	1.06e-53	Schizophrenia;
LGG	cis	rs1595825	0.891	rs112898725	chr2:198650006	C/T	cg00982548	chr2:198649783	BOLL	-0.52	-7.06	-0.31	6.01e-12	Ulcerative colitis;
LGG	cis	rs12325245	0.536	rs35432891	chr16:58561966	G/A	cg02549819	chr16:58548995	SETD6	1.45	13.97	0.54	2.81e-37	Schizophrenia;
LGG	cis	rs6724607	1.000	rs13410230	chr2:191446252	A/G	cg21644426	chr2:191273491	MFSD6	0.58	10.0	0.42	1.89e-21	Pulse pressure;
LGG	trans	rs6582630	0.502	rs1115515	chr12:38279830	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.91	-0.38	1.14e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg13010199	chr12:38710504	ALG10B	0.68	14.4	0.56	4.19e-39	Heart rate;
LGG	cis	rs490234	0.616	rs2648318	chr9:128163447	T/C	cg14078157	chr9:128172775	NA	-0.5	-9.44	-0.4	1.82e-19	Mean arterial pressure;
LGG	cis	rs1497828	0.871	rs2815248	chr1:217572871	C/T	cg04411442	chr1:217543379	NA	0.46	7.75	0.34	5.72e-14	Dialysis-related mortality;
LGG	trans	rs1814175	0.791	rs10839395	chr11:49846274	G/T	cg03929089	chr4:120376271	NA	-1.04	-24.48	-0.75	1.63e-85	Height;
LGG	cis	rs1003719	0.715	rs8128387	chr21:38556787	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.08	-0.57	4.13e-42	Eye color traits;
LGG	cis	rs6496932	0.802	rs12442399	chr15:85854850	T/A	cg19183879	chr15:85880815	NA	0.42	6.74	0.3	4.76e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg03060546	chr3:49711283	APEH	0.74	13.44	0.53	5.21e-35	Resting heart rate;
LGG	cis	rs858239	0.636	rs28706766	chr7:23169834	T/A	cg23682824	chr7:23144976	KLHL7	0.42	7.1	0.31	4.58e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.23	-0.36	1.94e-15	Prudent dietary pattern;
LGG	cis	rs11874712	1.000	rs1800639	chr18:43671240	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.68	-0.44	6.04e-24	Migraine - clinic-based;
LGG	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg12667521	chr19:29218732	NA	0.63	9.53	0.4	8.8e-20	Methadone dose in opioid dependence;
LGG	cis	rs4662750	0.859	rs2245297	chr2:128382859	C/T	cg10021288	chr2:128175891	PROC	0.38	7.01	0.31	8.74e-12	Renal cell carcinoma;
LGG	cis	rs11764590	0.694	rs3996323	chr7:2079428	G/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.31	-0.36	1.07e-15	Neuroticism;
LGG	cis	rs7072216	0.763	rs8181292	chr10:100175477	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.18	-0.32	2.73e-12	Metabolite levels;
LGG	cis	rs10421328	0.950	rs55831814	chr19:19777644	C/T	cg11584989	chr19:19387371	SF4	0.44	6.76	0.3	4.12e-11	Parental longevity (combined parental age at death);
LGG	cis	rs668210	0.739	rs543952	chr11:65744275	T/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.71	9.68	0.41	2.58e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.33	-0.43	1.22e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00933542	chr6:150070202	PCMT1	0.37	6.66	0.3	7.8e-11	Lung cancer;
LGG	cis	rs17221829	0.699	rs7129641	chr11:89383706	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.21	-0.39	1.13e-18	Anxiety in major depressive disorder;
LGG	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg01403660	chr11:68851641	TPCN2	0.5	7.01	0.31	8.6e-12	Blond vs. brown hair color;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.2	-0.36	2.41e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06339248	chr11:57435803	ZDHHC5	0.37	6.65	0.3	8.07e-11	Obesity-related traits;
LGG	cis	rs975722	0.543	rs6466611	chr7:117029737	C/T	cg10524701	chr7:117356490	CTTNBP2	0.41	8.66	0.37	7.74e-17	Coronary artery disease;
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg11211951	chr8:145729740	GPT	0.53	12.7	0.51	6.55e-32	Age at first birth;
LGG	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs11864453	0.826	rs12708928	chr16:72137227	C/A	cg23815491	chr16:72088622	HP	0.51	11.37	0.47	1.37e-26	Fibrinogen levels;
LGG	cis	rs4268898	0.760	rs7597919	chr2:24563646	A/G	cg06627628	chr2:24431161	ITSN2	0.42	7.1	0.31	4.69e-12	Asthma;
LGG	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg09818912	chr17:20140352	CYTSB	0.33	7.66	0.34	1.08e-13	Schizophrenia;
LGG	trans	rs7939886	0.920	rs57730678	chr11:56005204	C/T	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg19748678	chr4:122722346	EXOSC9	0.49	9.19	0.39	1.37e-18	Type 2 diabetes;
LGG	cis	rs2522056	1.000	rs6874639	chr5:131778716	C/T	cg07395648	chr5:131743802	NA	-0.4	-6.95	-0.31	1.28e-11	Lymphocyte counts;Fibrinogen;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg11984989	chr7:158649758	WDR60	1.01	14.02	0.55	1.78e-37	Height;
LGG	cis	rs10197940	0.662	rs1047957	chr2:152333773	C/T	cg06191203	chr2:152266755	RIF1	-0.42	-7.41	-0.33	6.15e-13	Lung cancer;
LGG	cis	rs7020830	0.931	rs7034554	chr9:37081301	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	34.01	0.85	5.51e-128	Schizophrenia;
LGG	cis	rs61931739	0.635	rs3937819	chr12:33942715	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.15	-0.32	3.52e-12	Morning vs. evening chronotype;
LGG	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs35661897	0.920	rs62190909	chr2:227294858	C/G	cg03426602	chr2:227312417	NA	-0.43	-6.75	-0.3	4.52e-11	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs239198	0.602	rs17672397	chr6:101288160	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.3	0.32	1.25e-12	Menarche (age at onset);
LGG	cis	rs9611565	0.512	rs9607842	chr22:42192722	G/A	cg17376030	chr22:41985996	PMM1	0.66	10.69	0.44	5.7e-24	Vitiligo;
LGG	cis	rs9341808	0.727	rs10943697	chr6:80931506	A/C	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.83e-14	Sitting height ratio;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.85	-0.45	1.42e-24	Lung cancer;
LGG	cis	rs10197940	0.624	rs17270233	chr2:152372420	A/G	cg06191203	chr2:152266755	RIF1	-0.47	-8.1	-0.35	4.87e-15	Lung cancer;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.23	-0.49	5.17e-30	Alzheimer's disease;
LGG	cis	rs2213920	0.679	rs6415819	chr9:118212492	A/C	cg13918206	chr9:118159781	DEC1	0.62	8.76	0.38	3.62e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg14169450	chr9:139327907	INPP5E	0.36	6.69	0.3	6.57e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17345786	0.520	rs12638134	chr3:101334609	G/T	cg27318481	chr3:100970896	IMPG2	0.34	6.97	0.31	1.12e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.6	-0.37	1.25e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4936894	0.500	rs10893207	chr11:124178236	C/T	cg27160556	chr11:124181099	OR8D1	-0.47	-10.81	-0.45	1.86e-24	Aging (time to death);
LGG	cis	rs8044868	0.530	rs3890860	chr16:72103409	A/G	cg23815491	chr16:72088622	HP	0.38	8.1	0.35	4.82e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.7	-12.86	-0.51	1.37e-32	Longevity;Endometriosis;
LGG	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.37	-0.36	6.66e-16	Mean corpuscular volume;
LGG	cis	rs5758659	1.000	rs134873	chr22:42657566	T/G	cg15557168	chr22:42548783	NA	-0.39	-8.77	-0.38	3.55e-17	Cognitive function;
LGG	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg18252515	chr7:66147081	NA	1.4	19.85	0.68	6.67e-64	Diabetic kidney disease;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs17428076	0.872	rs6761111	chr2:172883568	G/C	cg21435375	chr2:172878103	MAP1D	0.46	9.93	0.42	3.35e-21	Myopia;
LGG	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-8.65	-0.37	8.61e-17	Height;
LGG	cis	rs796364	0.760	rs56225698	chr2:200910653	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	trans	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg00711542	chr16:29343894	RUNDC2C	0.4	6.82	0.3	2.81e-11	Menopause (age at onset);
LGG	cis	rs9397585	0.857	rs9322408	chr6:153375888	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.54	0.56	1.04e-39	Body mass index;
LGG	trans	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg21775007	chr8:11205619	TDH	0.45	7.21	0.32	2.34e-12	Mood instability;
LGG	cis	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg07460842	chr6:66804631	NA	0.58	9.65	0.41	3.35e-20	Metabolite levels;
LGG	trans	rs7615952	0.932	rs13321217	chr3:125631771	G/A	cg07211511	chr3:129823064	LOC729375	-1.38	-22.45	-0.72	4.83e-76	Blood pressure (smoking interaction);
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.8	0.48	2.89e-28	Prudent dietary pattern;
LGG	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs9549260	0.755	rs9532579	chr13:41243458	T/C	cg21288729	chr13:41239152	FOXO1	0.33	6.72	0.3	5.46e-11	Red blood cell count;
LGG	cis	rs921968	0.541	rs585185	chr2:219457741	G/A	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg06916706	chr16:4465613	CORO7	-0.85	-14.8	-0.57	7.61e-41	Schizophrenia;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.43	-0.33	5.13e-13	Height;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.64	0.41	3.53e-20	Prudent dietary pattern;
LGG	cis	rs514024	0.519	rs550045	chr9:130477160	G/A	cg13643465	chr9:130375613	STXBP1	0.53	9.56	0.41	6.81e-20	Eating disorders (purging via substances);
LGG	cis	rs1318772	0.932	rs68131815	chr5:112886693	G/A	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg22643751	chr7:855365	UNC84A	0.4	6.94	0.31	1.36e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs9354308	0.764	rs9363477	chr6:66594243	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.8	-0.3	3.24e-11	Metabolite levels;
LGG	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.32	0.36	9.65e-16	Monocyte count;
LGG	cis	rs12893668	0.703	rs2403197	chr14:104053764	C/T	cg23335576	chr14:104009727	NA	0.48	8.46	0.37	3.43e-16	Reticulocyte count;
LGG	cis	rs3820068	0.608	rs12091750	chr1:16042766	T/C	cg05660106	chr1:15850417	CASP9	0.75	13.95	0.54	3.62e-37	Systolic blood pressure;
LGG	trans	rs3942852	0.774	rs10838814	chr11:48187178	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.88	-0.42	5.31e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12367572	0.663	rs1118481	chr12:45354469	C/G	cg03114573	chr12:45410052	DBX2	-0.67	-12.14	-0.49	1.2e-29	Gut microbiome composition (summer);
LGG	cis	rs1218582	0.710	rs9794000	chr1:154878876	T/A	cg16680214	chr1:154839983	KCNN3	-0.45	-8.92	-0.38	1.08e-17	Prostate cancer;
LGG	cis	rs2228479	0.717	rs1800358	chr16:89809319	T/C	cg06558623	chr16:89946397	TCF25	1.02	12.76	0.51	3.69e-32	Skin colour saturation;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21963583	chr11:68658836	MRPL21	0.55	9.54	0.41	8.07e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-12.63	-0.51	1.24e-31	Vitiligo;
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg02524346	chr8:600233	NA	1.16	11.5	0.47	4.36e-27	IgG glycosylation;
LGG	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg12463550	chr7:65579703	CRCP	-0.72	-7.65	-0.33	1.18e-13	Diabetic kidney disease;
LGG	cis	rs6138458	1.000	rs227618	chr20:24909472	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.53	0.76	2.29e-90	Blood protein levels;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	8.33	0.36	9.22e-16	Longevity;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg02462569	chr6:150064036	NUP43	-0.37	-7.81	-0.34	3.95e-14	Lung cancer;
LGG	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.95	0.49	6.99e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg14541582	chr5:601475	NA	-0.56	-9.01	-0.39	5.62e-18	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.95	0.45	5.91e-25	Personality dimensions;
LGG	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg19507638	chr5:93509721	C5orf36	-0.73	-10.09	-0.42	9.28e-22	Diabetic retinopathy;
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.02	-0.39	4.95e-18	Neuroticism;
LGG	trans	rs9747201	1.000	rs3922470	chr17:80110159	C/T	cg07393940	chr7:158741817	NA	-0.58	-10.76	-0.45	2.98e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7647973	0.516	rs4308307	chr3:49193216	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.51	-7.95	-0.35	1.4e-14	Menarche (age at onset);
LGG	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.83	13.58	0.53	1.38e-35	Cognitive test performance;
LGG	cis	rs7208859	0.573	rs4055105	chr17:29102550	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.66	0.44	6.92e-24	Neuroticism;
LGG	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg03709012	chr19:19516395	GATAD2A	0.96	15.26	0.58	6.75e-43	Nonalcoholic fatty liver disease;
LGG	cis	rs262150	0.544	rs2428780	chr7:158812471	T/A	cg19418458	chr7:158789849	NA	-0.52	-10.93	-0.45	6.88e-25	Facial morphology (factor 20);
LGG	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg02297831	chr4:17616191	MED28	-0.46	-7.7	-0.34	8.18e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs244899	0.967	rs244898	chr5:167918926	T/C	cg06604206	chr5:167912465	RARS	-0.53	-11.65	-0.48	1.06e-27	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs7503807	0.515	rs12452916	chr17:78664655	C/T	cg22878693	chr17:78755604	RPTOR	-0.56	-9.16	-0.39	1.63e-18	Obesity;
LGG	trans	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg00405596	chr8:11794950	NA	0.43	7.39	0.32	6.76e-13	Mood instability;
LGG	cis	rs4474465	1.000	rs873311	chr11:78145886	G/C	cg02023728	chr11:77925099	USP35	0.4	6.88	0.3	1.91e-11	Alzheimer's disease (survival time);
LGG	cis	rs7582720	1.000	rs72936353	chr2:204070956	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.51	0.4	1.02e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11203032	0.831	rs7091822	chr10:90957403	G/T	cg16672925	chr10:90967113	CH25H	0.51	7.95	0.35	1.47e-14	Heart failure;
LGG	cis	rs12586317	0.547	rs28395170	chr14:35506988	C/T	cg16230307	chr14:35515116	FAM177A1	0.9	13.09	0.52	1.51e-33	Psoriasis;
LGG	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg15704280	chr7:45808275	SEPT13	0.85	8.88	0.38	1.53e-17	Myopia (pathological);
LGG	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg11890956	chr21:40555474	PSMG1	1.18	28.65	0.8	1.29e-104	Cognitive function;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg26897989	chr16:1907736	C16orf73	0.52	9.81	0.41	9.08e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4665809	0.590	rs62130493	chr2:26516418	C/T	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Gut microbiome composition (summer);
LGG	cis	rs240764	0.817	rs12201852	chr6:101149576	T/C	cg09795085	chr6:101329169	ASCC3	-0.45	-7.48	-0.33	3.72e-13	Neuroticism;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15408407	chr19:1438438	RPS15	0.39	6.67	0.3	7.26e-11	Bipolar disorder;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.94	0.35	1.57e-14	Schizophrenia;
LGG	cis	rs6708331	0.517	rs7579922	chr2:70361913	A/G	cg01613454	chr2:70366299	NA	0.54	11.02	0.46	3.03e-25	Obesity-related traits;
LGG	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.78	-0.64	2.87e-54	Breast cancer;
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.5e-11	Glomerular filtration rate;
LGG	cis	rs10484885	0.824	rs72919954	chr6:90515665	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.85	-10.77	-0.45	2.75e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.52e-16	Obesity-related traits;
LGG	cis	rs9513627	0.915	rs73556177	chr13:100121840	G/A	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs7681440	0.775	rs6848181	chr4:90807252	T/C	cg06848047	chr4:90757629	SNCA	-0.4	-7.52	-0.33	2.85e-13	Dementia with Lewy bodies;
LGG	cis	rs7546668	0.744	rs1800615	chr1:15832281	C/T	cg21858823	chr1:15850916	CASP9	0.37	6.98	0.31	1.04e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg07930552	chr6:133119739	C6orf192	0.77	9.57	0.41	6.52e-20	Type 2 diabetes nephropathy;
LGG	cis	rs11758351	1.000	rs76722536	chr6:26192946	C/G	cg06951627	chr6:26196580	NA	0.52	7.83	0.34	3.47e-14	Gout;Renal underexcretion gout;
LGG	cis	rs883565	0.655	rs7633233	chr3:39146724	G/T	cg01426195	chr3:39028469	NA	-0.74	-17.39	-0.63	1.76e-52	Handedness;
LGG	cis	rs2933343	0.649	rs789214	chr3:128594995	A/G	cg11901034	chr3:128598214	ACAD9	-0.46	-6.95	-0.31	1.25e-11	IgG glycosylation;
LGG	cis	rs10791097	0.690	rs12286234	chr11:130730528	T/C	cg09137382	chr11:130731461	NA	0.42	8.01	0.35	9.65e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10463554	1.000	rs56372231	chr5:102321905	C/T	cg23492399	chr5:102201601	PAM	-0.53	-8.2	-0.36	2.38e-15	Parkinson's disease;
LGG	cis	rs7523273	0.565	rs2761422	chr1:207893266	A/T	cg22525895	chr1:207977042	MIR29B2	0.45	8.55	0.37	1.76e-16	Schizophrenia;
LGG	cis	rs4319547	0.737	rs10846921	chr12:122943376	G/T	cg23029597	chr12:123009494	RSRC2	0.86	16.6	0.61	6.96e-49	Body mass index;
LGG	cis	rs1552244	0.554	rs59465469	chr3:9990800	G/C	cg00149659	chr3:10157352	C3orf10	0.55	8.06	0.35	6.59e-15	Alzheimer's disease;
LGG	cis	rs7551222	0.749	rs6682208	chr1:204566183	T/C	cg20240347	chr1:204465584	NA	-0.47	-9.17	-0.39	1.6e-18	Schizophrenia;
LGG	cis	rs6460942	1.000	rs2053382	chr7:12400587	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.87	-0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.7	-0.3	6.09e-11	Menopause (age at onset);
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.65	0.44	7.94e-24	Lung function (FEV1/FVC);
LGG	cis	rs7208859	0.673	rs9898858	chr17:29156211	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.13	-0.39	2.11e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4975616	0.869	rs31490	chr5:1344458	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.62	-10.77	-0.45	2.69e-24	Lung cancer;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg27532560	chr4:187881888	NA	0.6	13.33	0.53	1.57e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9886651	0.869	rs4074703	chr8:128786990	C/T	cg24514600	chr8:128805414	PVT1	-0.54	-12.18	-0.49	8.45e-30	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03352830	chr11:487213	PTDSS2	0.87	11.33	0.47	1.9e-26	Body mass index;
LGG	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9512730	0.553	rs6491213	chr13:28049822	T/C	cg04070771	chr13:27998621	GTF3A	0.48	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs7928758	0.887	rs111711955	chr11:134264529	A/G	cg25213107	chr11:134282864	B3GAT1	1.26	14.99	0.57	1.14e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7084402	0.967	rs1649022	chr10:60285867	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.57e-13	Refractive error;
LGG	cis	rs769267	0.831	rs2872878	chr19:19480521	G/C	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.13	-0.46	1.14e-25	Tonsillectomy;
LGG	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.8	-0.45	2.1e-24	Migraine;Coronary artery disease;
LGG	cis	rs1670533	1.000	rs4690215	chr4:1054619	G/C	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	trans	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.16e-14	Bladder cancer;
LGG	cis	rs7666738	0.830	rs1967977	chr4:98966141	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg27572855	chr1:25598939	RHD	0.5	11.55	0.47	2.61e-27	Erythrocyte sedimentation rate;
LGG	cis	rs7255045	0.788	rs8110185	chr19:12959827	T/A	cg07955356	chr19:12992479	DNASE2	0.42	7.14	0.31	3.69e-12	Mean corpuscular volume;
LGG	cis	rs9790314	0.586	rs1811483	chr3:161130900	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.19	-0.46	6.81e-26	Morning vs. evening chronotype;
LGG	cis	rs1124376	0.816	rs62243131	chr3:20141308	A/G	cg05072819	chr3:20081367	KAT2B	0.61	8.19	0.36	2.53e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6028335	0.610	rs67743908	chr20:37572643	G/A	cg16355469	chr20:37678765	NA	0.55	7.34	0.32	9.59e-13	Alcohol and nicotine co-dependence;
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg05084668	chr3:125655381	ALG1L	0.57	7.71	0.34	7.88e-14	Blood pressure (smoking interaction);
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg19774624	chr17:42201019	HDAC5	-0.57	-10.13	-0.43	6.24e-22	Total body bone mineral density;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg00830817	chr11:109293614	C11orf87	0.42	6.88	0.3	1.9e-11	Schizophrenia;
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	cg07245641	chr1:182991651	LAMC1	0.4	8.99	0.39	6.22e-18	Colorectal cancer;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg05313129	chr8:58192883	C8orf71	-0.61	-8.33	-0.36	9.49e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2952156	0.883	rs2517960	chr17:37846521	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-15.94	-0.6	6.77e-46	Asthma;
LGG	cis	rs992157	0.767	rs2382822	chr2:219173327	T/C	cg00012203	chr2:219082015	ARPC2	-0.65	-11.54	-0.47	3e-27	Colorectal cancer;
LGG	cis	rs2795502	0.882	rs2744093	chr10:43339243	A/G	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Vitiligo;
LGG	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg12486710	chr1:178512616	C1orf220	0.51	10.51	0.44	2.47e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11098499	0.779	rs10011097	chr4:120310359	T/G	cg24375607	chr4:120327624	NA	0.67	10.97	0.45	4.71e-25	Corneal astigmatism;
LGG	cis	rs981844	0.816	rs62325147	chr4:154727568	G/A	cg14289246	chr4:154710475	SFRP2	0.73	11.92	0.48	9.78e-29	Response to statins (LDL cholesterol change);
LGG	trans	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg07393940	chr7:158741817	NA	0.57	10.57	0.44	1.53e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg07599136	chr5:415885	AHRR	0.84	11.51	0.47	3.82e-27	Fat distribution (HIV);
LGG	cis	rs9815354	0.812	rs73081392	chr3:41923009	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06481639	chr22:41940642	POLR3H	0.55	8.14	0.35	3.6e-15	Vitiligo;
LGG	cis	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg24623649	chr8:11872141	NA	0.33	7.88	0.34	2.33e-14	Neuroticism;
LGG	cis	rs600231	0.613	rs12803915	chr11:65211979	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.35	-0.36	8.03e-16	Bone mineral density;
LGG	cis	rs2901460	0.509	rs12465313	chr2:62078301	G/A	cg02183531	chr2:62113199	CCT4	-0.47	-8.24	-0.36	1.85e-15	Mean corpuscular volume;
LGG	trans	rs826838	0.967	rs826855	chr12:39114888	T/C	cg06521331	chr12:34319734	NA	0.42	7.56	0.33	2.14e-13	Heart rate;
LGG	trans	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	cis	rs17453880	0.929	rs10056328	chr5:152024369	C/G	cg12297329	chr5:152029980	NA	0.9	23.9	0.74	7.92e-83	Subjective well-being;
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	9.24	0.39	8.77e-19	Height;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg01966878	chr4:90757139	SNCA	-0.33	-6.91	-0.31	1.6e-11	Dementia with Lewy bodies;
LGG	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-9.16	-0.39	1.63e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs3849570	0.925	rs6765917	chr3:81891116	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-6.97	-0.31	1.11e-11	Waist circumference;Body mass index;
LGG	cis	rs2276314	1.000	rs4799835	chr18:33571268	G/A	cg05985134	chr18:33552581	C18orf21	0.65	10.14	0.43	5.88e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9916302	0.904	rs8079560	chr17:37497661	C/T	cg07936489	chr17:37558343	FBXL20	0.85	16.07	0.6	1.68e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs2067615	0.560	rs10467028	chr12:107076405	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.05	0.49	2.79e-29	Heart rate;
LGG	cis	rs4566357	0.615	rs4350744	chr2:227918146	A/T	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.06	-0.39	3.56e-18	Coronary artery disease;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18252515	chr7:66147081	NA	0.41	6.93	0.31	1.44e-11	Aortic root size;
LGG	cis	rs7208859	0.673	rs2269915	chr17:29233344	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs738322	0.967	rs133021	chr22:38573338	T/C	cg03162506	chr22:38580953	NA	0.37	9.52	0.4	9.62e-20	Cutaneous nevi;
LGG	cis	rs10504229	0.639	rs56066782	chr8:58105857	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4268898	0.722	rs7563958	chr2:24422381	C/A	cg06627628	chr2:24431161	ITSN2	0.49	8.02	0.35	8.52e-15	Asthma;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.6	0.53	1.12e-35	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs10018977	chr4:119785229	C/T	cg11846333	chr4:119757529	SEC24D	0.84	7.8	0.34	4.07e-14	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.53	0.37	2.04e-16	Lung cancer;
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.43	-0.33	5.24e-13	Prostate cancer;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	10.05	0.42	1.31e-21	Tonsillectomy;
LGG	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11890956	chr21:40555474	PSMG1	1.18	28.61	0.8	1.98e-104	Cognitive function;
LGG	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg18165381	chr3:44552316	NA	-0.41	-6.88	-0.3	2e-11	Depressive symptoms;
LGG	trans	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.27	0.32	1.56e-12	Myopia (pathological);
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg11168104	chr5:1857477	NA	-0.4	-7.1	-0.31	4.85e-12	Cardiovascular disease risk factors;
LGG	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg02002194	chr4:3960332	NA	0.42	7.47	0.33	3.94e-13	Triglycerides;
LGG	cis	rs4740619	0.525	rs1341737	chr9:15808216	A/G	cg14451791	chr9:16040625	NA	0.3	7.54	0.33	2.48e-13	Body mass index;
LGG	trans	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg02002194	chr4:3960332	NA	-0.47	-8.76	-0.38	3.73e-17	Joint mobility (Beighton score);
LGG	cis	rs6120849	0.901	rs11696967	chr20:33743609	A/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.66	0.3	7.7e-11	Protein C levels;
LGG	cis	rs7188861	0.813	rs1794021	chr16:11377234	G/A	cg01510278	chr16:11456238	NA	0.29	7.11	0.31	4.55e-12	HDL cholesterol;
LGG	cis	rs763121	1.000	rs1946990	chr22:38912771	C/T	cg06022373	chr22:39101656	GTPBP1	-0.8	-16.13	-0.6	8.73e-47	Menopause (age at onset);
LGG	cis	rs7408868	1.000	rs4809029	chr19:15273248	A/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.03	0.52	2.68e-33	Pulse pressure;
LGG	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg10792982	chr14:105748885	BRF1	0.67	13.36	0.53	1.14e-34	Mean platelet volume;Platelet distribution width;
LGG	trans	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.3e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs4843747	0.519	rs12599755	chr16:88107006	A/G	cg26811252	chr16:29126840	RRN3P2	0.69	10.84	0.45	1.5e-24	Menopause (age at onset);
LGG	cis	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg21775007	chr8:11205619	TDH	-0.51	-8.2	-0.36	2.47e-15	Triglycerides;
LGG	cis	rs4566357	0.595	rs6707286	chr2:227911400	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.11	-0.39	2.48e-18	Coronary artery disease;
LGG	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg23057051	chr16:89984268	MC1R	-0.36	-6.81	-0.3	3.06e-11	Vitiligo;
LGG	cis	rs4911259	0.552	rs2014837	chr20:31461082	C/T	cg13636640	chr20:31349939	DNMT3B	0.65	11.8	0.48	2.94e-28	Inflammatory bowel disease;
LGG	cis	rs4731207	0.598	rs2301930	chr7:124465097	A/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	trans	rs853679	1.000	rs9986596	chr6:28219661	G/A	cg01620082	chr3:125678407	NA	-0.6	-7.45	-0.33	4.49e-13	Depression;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.8e-21	Prudent dietary pattern;
LGG	cis	rs12282928	0.743	rs1393794	chr11:48232853	T/C	cg26585981	chr11:48327164	OR4S1	-0.39	-6.8	-0.3	3.3e-11	Migraine - clinic-based;
LGG	cis	rs9640161	0.789	rs10248490	chr7:150051418	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-11.42	-0.47	8.87e-27	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9358372	1.000	rs10946412	chr6:20817623	C/T	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.47	-0.58	7.84e-44	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2710642	0.861	rs2710644	chr2:63248968	A/C	cg17519650	chr2:63277830	OTX1	0.52	8.3	0.36	1.16e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs2281845	0.929	rs6704363	chr1:201096383	A/G	cg22815214	chr1:201083145	CACNA1S	0.36	6.77	0.3	3.81e-11	Permanent tooth development;
LGG	trans	rs916888	0.821	rs199512	chr17:44857352	T/C	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg18681998	chr4:17616180	MED28	0.87	18.84	0.66	3.56e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg03627896	chr16:30934334	NCRNA00095	0.45	6.77	0.3	4.02e-11	Glomerular filtration rate (creatinine);
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.59	0.37	1.34e-16	Triglycerides;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg06719900	chr11:109292894	C11orf87	0.44	8.3	0.36	1.16e-15	Schizophrenia;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg21724239	chr8:58056113	NA	0.49	7.43	0.33	5.23e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11122272	0.735	rs2486735	chr1:231521778	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7851660	0.844	rs13287360	chr9:100637681	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.68	-0.51	8.14e-32	Strep throat;
LGG	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-10.94	-0.45	6.46e-25	Chronic sinus infection;
LGG	cis	rs116095464	0.558	rs62347683	chr5:230331	C/T	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs11239187	0.530	rs10047392	chr10:45061068	G/A	cg03916630	chr10:45065415	NA	0.37	9.03	0.39	4.5e-18	Body mass index;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg00495681	chr13:53174319	NA	0.59	10.81	0.45	1.93e-24	Lewy body disease;
LGG	cis	rs7617773	0.539	rs13087050	chr3:48392800	C/T	cg11946769	chr3:48343235	NME6	0.52	8.83	0.38	2.22e-17	Coronary artery disease;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg15665833	chr6:26285013	NA	0.39	7.66	0.34	1.07e-13	Educational attainment;
LGG	cis	rs2228479	0.850	rs62054610	chr16:89816920	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg21775007	chr8:11205619	TDH	-0.47	-7.57	-0.33	2e-13	Neuroticism;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg00166722	chr3:10149974	C3orf24	0.58	8.1	0.35	4.94e-15	Alzheimer's disease;
LGG	cis	rs9309473	0.950	rs6745480	chr2:73840055	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.66	-0.34	1.11e-13	Metabolite levels;
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22618164	chr12:122356400	WDR66	0.4	12.51	0.5	3.88e-31	Mean corpuscular volume;
LGG	cis	rs2070488	0.965	rs1870915	chr3:38494228	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.9	19.64	0.67	6.28e-63	Electrocardiographic conduction measures;
LGG	cis	rs9807841	0.592	rs2043304	chr19:10772112	T/C	cg17710535	chr19:10819994	QTRT1	0.49	7.9	0.34	2.01e-14	Inflammatory skin disease;
LGG	cis	rs12618769	0.597	rs3769724	chr2:99105981	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.68	0.37	6.69e-17	Bipolar disorder;
LGG	trans	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg11608241	chr8:8085544	FLJ10661	0.32	7.31	0.32	1.18e-12	Neuroticism;
LGG	cis	rs2290159	0.800	rs9817675	chr3:12676113	C/T	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.03e-20	Cholesterol, total;
LGG	cis	rs4919087	0.545	rs793531	chr10:99041167	G/T	cg25902810	chr10:99078978	FRAT1	-0.43	-7.07	-0.31	5.86e-12	Monocyte count;
LGG	cis	rs2730245	0.569	rs842692	chr7:158657228	T/C	cg01943577	chr7:158741284	NA	-0.47	-8.49	-0.37	2.9e-16	Height;
LGG	cis	rs3762637	1.000	rs3762637	chr3:122145324	C/T	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.89e-23	LDL cholesterol levels;
LGG	cis	rs17253792	0.731	rs74829671	chr14:56112759	G/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.78e-31	Putamen volume;
LGG	cis	rs7444	0.941	rs4821116	chr22:21973319	A/G	cg15846791	chr22:21984385	YDJC	0.46	6.97	0.31	1.12e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg21171335	chr12:122356390	WDR66	0.29	8.05	0.35	7.25e-15	Mean corpuscular volume;
LGG	cis	rs3820928	0.605	rs4281898	chr2:227855493	A/C	cg11843606	chr2:227700838	RHBDD1	-0.58	-10.61	-0.44	1.06e-23	Pulmonary function;
LGG	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg26384229	chr12:38710491	ALG10B	0.84	18.59	0.65	4.84e-58	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.932	rs6844593	chr4:17659039	T/C	cg02297831	chr4:17616191	MED28	0.46	8.32	0.36	9.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17125944	0.615	rs7150808	chr14:53304871	C/T	cg00686598	chr14:53173677	PSMC6	-0.81	-8.32	-0.36	9.9e-16	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs741702	0.892	rs11085824	chr19:13001547	A/G	cg23899408	chr19:12877188	HOOK2	-0.49	-7.84	-0.34	3.22e-14	Red blood cell traits;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.62	-0.37	1.09e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg17757837	chr7:157058334	UBE3C	0.76	15.29	0.58	5.26e-43	Body mass index;
LGG	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.66e-12	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg07061783	chr6:25882402	NA	-0.46	-7.86	-0.34	2.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg05887092	chr17:76393375	PGS1	0.72	16.0	0.6	3.37e-46	HDL cholesterol levels;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	cis	rs9487094	0.626	rs10457192	chr6:109828474	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.09	0.35	5.17e-15	Height;
LGG	cis	rs944722	0.935	rs2314809	chr17:26095378	C/T	cg07704981	chr17:26127537	NOS2	-0.43	-7.39	-0.32	6.79e-13	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1467026	0.691	rs9985266	chr3:12803162	C/T	cg05775895	chr3:12838266	CAND2	-0.66	-11.73	-0.48	5.42e-28	P wave duration;
LGG	cis	rs742614	0.533	rs736953	chr20:32415089	G/T	cg06304546	chr20:32448765	NA	-0.69	-13.89	-0.54	6.49e-37	Stearic acid (18:0) levels;
LGG	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-13.85	-0.54	1.01e-36	Body mass index;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg22398616	chr13:53314203	LECT1	0.5	9.92	0.42	3.62e-21	Lewy body disease;
LGG	cis	rs4650994	0.593	rs12096732	chr1:178523164	C/T	cg19399532	chr1:178512495	C1orf220	-0.38	-7.31	-0.32	1.22e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs898097	0.841	rs55810435	chr17:80836722	G/C	cg22432760	chr17:80829718	TBCD	0.4	7.09	0.31	4.89e-12	Breast cancer;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.6	-0.59	2.23e-44	Rheumatoid arthritis;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs7618915	0.773	rs10510760	chr3:52650348	G/A	cg14092988	chr3:52407081	DNAH1	0.38	9.87	0.42	5.67e-21	Bipolar disorder;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-14.66	-0.56	3.05e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.34	0.4	4.21e-19	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21139845	chr12:7053993	C12orf57	0.48	7.81	0.34	3.74e-14	Cognitive performance;
LGG	trans	rs6076960	0.684	rs3852947	chr20:6255341	A/G	cg17788362	chr6:86352627	SYNCRIP	0.55	9.74	0.41	1.69e-20	Smooth-surface caries;
LGG	cis	rs12477438	0.520	rs7597141	chr2:100034331	A/G	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs9916302	0.706	rs7208252	chr17:37584368	A/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.36	-0.58	2.56e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572733	0.935	rs11692344	chr2:198795863	T/G	cg00792783	chr2:198669748	PLCL1	0.47	8.0	0.35	1.02e-14	Dermatomyositis;
LGG	cis	rs4820294	0.516	rs12627943	chr22:38096334	C/G	cg26138144	chr22:38071188	LGALS1	0.67	12.42	0.5	8.94e-31	Fat distribution (HIV);
LGG	cis	rs8177179	0.967	rs10935085	chr3:133459735	C/T	cg16262614	chr3:133464971	TF	0.48	8.74	0.38	4.16e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs2613964	0.504	rs9288972	chr3:112850269	A/T	cg16248390	chr3:112854924	NA	0.51	10.68	0.44	5.83e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg24634471	chr8:143751801	JRK	0.49	7.46	0.33	4.23e-13	Schizophrenia;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg16706629	chr5:93954361	ANKRD32;C5orf36	0.73	6.87	0.3	2.06e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg14993813	chr1:46806288	NSUN4	-0.55	-9.12	-0.39	2.39e-18	Menopause (age at onset);
LGG	cis	rs977987	0.806	rs8051407	chr16:75448659	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs1007190	0.881	rs9914884	chr17:42955589	T/C	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	trans	rs9354308	0.899	rs2802058	chr6:66550787	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	9.94	0.42	3.07e-21	Metabolite levels;
LGG	cis	rs9649465	0.967	rs2402666	chr7:123285478	A/T	cg03229431	chr7:123269106	ASB15	-0.39	-8.63	-0.37	1.01e-16	Migraine;
LGG	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.09	0.35	5.11e-15	Chronic sinus infection;
LGG	cis	rs4650994	0.593	rs7540745	chr1:178529757	C/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.37	-0.32	8.04e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2859741	0.546	rs2134846	chr1:37500723	G/A	cg09363841	chr1:37513479	NA	-0.56	-11.58	-0.47	2.16e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	trans	rs11875185	0.588	rs74458528	chr18:55645662	T/G	cg15513957	chr14:69354734	ACTN1	-0.95	-9.27	-0.4	6.88e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3784262	0.564	rs34958088	chr15:58328332	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.97	-0.31	1.1e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11690935	0.959	rs75922913	chr2:172620152	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.41	-0.78	2.02e-94	Schizophrenia;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg11301795	chr4:187892539	NA	-0.95	-23.84	-0.74	1.44e-82	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2273669	0.588	rs6568555	chr6:109331777	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs55665837	0.524	rs61884009	chr11:14426462	C/T	cg19336497	chr11:14380999	RRAS2	-0.54	-10.74	-0.45	3.64e-24	Vitamin D levels;
LGG	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg26513180	chr16:89883248	FANCA	0.94	21.56	0.71	6.54e-72	Vitiligo;
LGG	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg19812747	chr11:111475976	SIK2	0.46	9.5	0.4	1.12e-19	Primary sclerosing cholangitis;
LGG	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg03929089	chr4:120376271	NA	-0.95	-20.3	-0.69	5.39e-66	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00633736	chr17:15164050	PMP22	0.45	6.75	0.3	4.52e-11	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.68	0.56	2.49e-40	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg19077165	chr18:44547161	KATNAL2	-0.72	-13.75	-0.54	2.5e-36	Personality dimensions;
LGG	cis	rs1953600	0.870	rs2245168	chr10:81921918	T/C	cg04850286	chr10:81895943	PLAC9	-0.43	-9.6	-0.41	4.87e-20	Sarcoidosis;
LGG	cis	rs9880211	0.752	rs9847427	chr3:136351550	C/A	cg21827317	chr3:136751795	NA	-0.48	-6.93	-0.31	1.46e-11	Body mass index;Height;
LGG	cis	rs950776	0.642	rs34694149	chr15:78965917	C/T	cg06917634	chr15:78832804	PSMA4	0.43	7.09	0.31	5.04e-12	Sudden cardiac arrest;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg10295955	chr4:187884368	NA	-1.16	-30.98	-0.82	6.29e-115	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17453880	0.929	rs12517092	chr5:152054744	A/C	cg12297329	chr5:152029980	NA	-0.89	-23.44	-0.74	1.08e-80	Subjective well-being;
LGG	cis	rs6456042	0.893	rs3127440	chr6:166558950	C/T	cg11088901	chr6:166572345	T	-0.37	-7.72	-0.34	7.46e-14	Asthma;
LGG	cis	rs17401966	0.838	rs946503	chr1:10308631	C/G	cg19773385	chr1:10388646	KIF1B	0.44	9.56	0.41	7.18e-20	Hepatocellular carcinoma;
LGG	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg02002194	chr4:3960332	NA	0.41	7.73	0.34	6.95e-14	Neuroticism;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg05091796	chr16:4465799	CORO7	-0.61	-9.96	-0.42	2.7e-21	Schizophrenia;
LGG	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg24623649	chr8:11872141	NA	-0.29	-6.82	-0.3	2.78e-11	Systolic blood pressure;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg14926445	chr8:58193284	C8orf71	-0.68	-8.34	-0.36	8.81e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs5771225	0.544	rs67157296	chr22:50672877	T/C	cg08875078	chr22:50639485	SELO	0.52	7.57	0.33	2e-13	Late-onset Alzheimer's disease;
LGG	cis	rs10088262	0.629	rs7833650	chr8:124822969	C/T	cg02993010	chr8:124780839	FAM91A1	-0.67	-10.09	-0.42	8.84e-22	Pancreatic cancer;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1977876	0.929	rs11119763	chr1:211705734	G/A	cg01575408	chr1:211752895	SLC30A1	0.49	6.97	0.31	1.08e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg11965913	chr1:205819406	PM20D1	0.9	20.92	0.7	6.46e-69	Menarche (age at onset);
LGG	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.46	-0.33	4.4e-13	Restless legs syndrome;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.37	2.51e-16	Prostate cancer;
LGG	cis	rs11190604	1.000	rs11190570	chr10:102227702	G/C	cg07570687	chr10:102243282	WNT8B	0.45	7.9	0.34	2.09e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11167764	1.000	rs6887599	chr5:141484349	G/A	cg08523384	chr5:141488047	NDFIP1	-0.37	-7.0	-0.31	8.75e-12	Crohn's disease;
LGG	cis	rs4671458	1.000	rs72813408	chr2:63363242	G/T	cg17519650	chr2:63277830	OTX1	-0.63	-7.81	-0.34	3.78e-14	Subjective well-being;
LGG	cis	rs4262150	0.883	rs12153328	chr5:152247221	T/C	cg12297329	chr5:152029980	NA	-0.65	-12.09	-0.49	1.96e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.6	-11.77	-0.48	3.86e-28	Lymphocyte counts;
LGG	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.61	-12.58	-0.5	1.94e-31	Height;
LGG	cis	rs12220238	0.841	rs7919010	chr10:76111137	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.93	0.38	9.91e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs62380364	0.602	rs591228	chr5:88064809	G/A	cg22951263	chr5:87985283	NA	-0.54	-10.0	-0.42	1.95e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg05368731	chr17:41323189	NBR1	0.94	18.31	0.65	9.51e-57	Menopause (age at onset);
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.52	0.4	9.51e-20	Obesity-related traits;
LGG	cis	rs981844	0.712	rs1456398	chr4:154738266	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs11112613	0.775	rs10778413	chr12:105962118	G/A	cg03607813	chr12:105948248	NA	0.55	9.38	0.4	2.95e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.6	0.41	5e-20	Renal function-related traits (BUN);
LGG	cis	rs657075	0.511	rs4705943	chr5:131755004	A/G	cg05556477	chr5:131705319	SLC22A5	0.55	7.34	0.32	9.47e-13	Rheumatoid arthritis;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg22907277	chr7:1156413	C7orf50	0.53	9.44	0.4	1.9e-19	Longevity;Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26431298	chr1:156737036	PRCC	-0.45	-6.66	-0.3	7.73e-11	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg15596359	chr8:11213517	TDH	-0.42	-8.78	-0.38	3.3e-17	Retinal vascular caliber;
LGG	cis	rs6792151	0.652	rs3914273	chr3:171557597	T/A	cg26441893	chr3:171559851	TMEM212	-0.45	-7.97	-0.35	1.22e-14	Red cell distribution width;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg19478983	chr7:120590592	ING3	-0.41	-6.86	-0.3	2.24e-11	Platelet count;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs17799476	0.938	rs72808770	chr2:46361322	G/A	cg12428440	chr2:46370979	PRKCE	0.43	6.74	0.3	4.75e-11	Hemoglobin concentration;Hematocrit;
LGG	cis	rs11239177	0.626	rs10160051	chr10:45061922	A/T	cg03916630	chr10:45065415	NA	0.37	8.91	0.38	1.15e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.41	-0.33	6.19e-13	Menopause (age at onset);
LGG	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg19455335	chr8:22457658	C8orf58	0.42	8.23	0.36	1.97e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg26043149	chr18:55253948	FECH	0.43	7.18	0.32	2.88e-12	Bone mineral density;
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg08888203	chr3:10149979	C3orf24	0.54	8.68	0.37	6.98e-17	Alzheimer's disease;
LGG	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	trans	rs826838	0.616	rs1601746	chr12:38626195	G/T	cg06521331	chr12:34319734	NA	0.39	6.87	0.3	2.11e-11	Heart rate;
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.81	-0.38	2.51e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.958	rs2660576	chr6:86651603	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs1865760	0.573	rs7450342	chr6:25919480	T/C	cg16482183	chr6:26056742	HIST1H1C	0.39	6.71	0.3	5.55e-11	Height;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs9878978	1.000	rs11711499	chr3:2472345	C/T	cg21928760	chr3:2462534	CNTN4	0.4	8.76	0.38	3.71e-17	Blood pressure (smoking interaction);
LGG	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg12179176	chr11:130786555	SNX19	0.84	17.53	0.63	3.88e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1122900	1.000	rs56039629	chr5:36683903	C/T	cg24186104	chr5:36689192	NA	-0.49	-11.18	-0.46	7.2e-26	Aggressive periodontitis;
LGG	cis	rs12367572	0.965	rs10880696	chr12:45234989	A/G	cg03114573	chr12:45410052	DBX2	0.52	8.95	0.38	8.84e-18	Gut microbiome composition (summer);
LGG	cis	rs7584330	0.826	rs72620824	chr2:238381083	G/A	cg16989719	chr2:238392110	NA	-0.36	-7.21	-0.32	2.36e-12	Prostate cancer;
LGG	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg21479132	chr6:26055353	NA	0.74	6.76	0.3	4.04e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1843834	0.898	rs2015099	chr2:225519915	T/C	cg22455342	chr2:225449267	CUL3	0.59	10.08	0.42	9.47e-22	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.07e-12	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6728642	0.808	rs114192053	chr2:97871906	G/A	cg26665480	chr2:98280029	ACTR1B	-0.67	-6.74	-0.3	4.67e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08496016	chr9:99181722	ZNF367	0.46	7.11	0.31	4.48e-12	Gut microbiome composition (summer);
LGG	cis	rs6831352	0.703	rs2602854	chr4:100028651	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.9e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.06	0.35	6.47e-15	Dupuytren's disease;
LGG	cis	rs4077515	0.839	rs4307445	chr9:139279776	C/G	cg21253087	chr9:139290292	SNAPC4	0.36	7.18	0.32	2.72e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs5742933	0.857	rs12471217	chr2:190572063	G/A	cg10453823	chr2:190539512	ANKAR	-0.46	-6.79	-0.3	3.41e-11	Ferritin levels;
LGG	cis	rs5758511	0.773	rs62241023	chr22:42385429	G/A	cg15128208	chr22:42549153	NA	0.59	9.32	0.4	4.79e-19	Birth weight;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-7.12	-0.31	4.2e-12	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	trans	rs459571	0.920	rs460154	chr9:136909309	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.64	-10.93	-0.45	6.97e-25	Platelet distribution width;
LGG	trans	rs11039798	0.588	rs1847640	chr11:49004025	C/T	cg03929089	chr4:120376271	NA	0.68	9.57	0.41	6.34e-20	Axial length;
LGG	cis	rs7119	0.717	rs12904348	chr15:77815738	G/C	cg10437265	chr15:77819839	NA	0.25	7.08	0.31	5.23e-12	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.69e-18	Life satisfaction;
LGG	cis	rs6963495	0.519	rs3892297	chr7:105152173	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.83	0.34	3.37e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg17376030	chr22:41985996	PMM1	0.65	10.63	0.44	9.09e-24	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs11098499	0.955	rs35434465	chr4:120169378	C/G	cg25214090	chr10:38739885	LOC399744	0.64	11.63	0.48	1.31e-27	Corneal astigmatism;
LGG	cis	rs4363385	0.747	rs9919333	chr1:152968744	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.15	-0.39	1.87e-18	Inflammatory skin disease;
LGG	cis	rs4684776	1.000	rs57092749	chr3:11542137	C/T	cg24705426	chr3:11550659	ATG7	-0.48	-8.64	-0.37	8.92e-17	Small vessel stroke;
LGG	trans	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg16141378	chr3:129829833	LOC729375	-0.41	-9.36	-0.4	3.53e-19	Neuroticism;
LGG	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg21775007	chr8:11205619	TDH	0.44	7.0	0.31	9e-12	Myopia (pathological);
LGG	cis	rs314370	0.521	rs314308	chr7:100420878	C/T	cg03098644	chr7:100410630	EPHB4	-0.42	-6.84	-0.3	2.53e-11	Resting heart rate;
LGG	cis	rs708547	0.599	rs1718864	chr4:57887471	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.52	8.53	0.37	2.1e-16	Response to bleomycin (chromatid breaks);
LGG	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.29e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.66	12.51	0.5	4e-31	Obesity-related traits;
LGG	cis	rs8017423	0.935	rs7158410	chr14:90704370	T/C	cg04374321	chr14:90722782	PSMC1	0.89	18.87	0.66	2.57e-59	Mortality in heart failure;
LGG	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg05484508	chr16:89589025	SPG7	0.43	6.94	0.31	1.31e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs1729951	0.575	rs361248	chr3:136709066	G/A	cg21827317	chr3:136751795	NA	0.53	9.84	0.42	7.25e-21	Neuroticism;
LGG	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg05425664	chr17:57184151	TRIM37	0.62	9.84	0.42	7.41e-21	Intelligence (multi-trait analysis);
LGG	cis	rs123509	0.874	rs339683	chr3:42788511	G/T	cg10144569	chr3:42726640	KBTBD5	0.51	7.4	0.33	6.53e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.2	-0.36	2.39e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs4727027	0.933	rs28767030	chr7:148825918	T/G	cg23583168	chr7:148888333	NA	-0.87	-16.93	-0.62	2.2e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs56307353	0.652	rs4807191	chr19:1990309	C/T	cg07946961	chr19:1955956	C19orf34;CSNK1G2	0.3	6.7	0.3	6.15e-11	Coronary artery disease;
LGG	cis	rs911555	0.723	rs4906324	chr14:103923099	A/G	cg24130564	chr14:104152367	KLC1	0.37	6.95	0.31	1.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7918232	0.627	rs6482588	chr10:27308307	G/C	cg14442939	chr10:27389572	ANKRD26	0.53	8.42	0.36	4.63e-16	Breast cancer;
LGG	cis	rs4319547	0.695	rs7969429	chr12:122875606	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.52	-0.4	9.46e-20	Body mass index;
LGG	cis	rs11785400	0.793	rs4581034	chr8:143736968	G/A	cg24634471	chr8:143751801	JRK	0.5	7.72	0.34	7.06e-14	Schizophrenia;
LGG	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.93	-0.57	2.07e-41	Aortic root size;
LGG	trans	rs1814175	0.645	rs10742953	chr11:49807491	C/G	cg03929089	chr4:120376271	NA	0.93	18.86	0.66	2.79e-59	Height;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs10773046	0.740	rs10846567	chr12:124360117	A/C	cg18594669	chr12:124364423	DNAH10	-0.34	-6.83	-0.3	2.67e-11	Osteoarthritis (hip);
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg12070911	chr6:150209640	RAET1E	-0.32	-7.94	-0.35	1.53e-14	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08905496	chr1:165414332	RXRG	0.44	6.97	0.31	1.11e-11	Gut microbiome composition (summer);
LGG	cis	rs28374715	0.580	rs8030228	chr15:41636867	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.22	-28.27	-0.8	6.75e-103	Ulcerative colitis;
LGG	cis	rs8077889	0.672	rs2106764	chr17:41852717	T/A	cg26893861	chr17:41843967	DUSP3	1.06	24.64	0.75	2.86e-86	Triglycerides;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs4788815	0.552	rs7187129	chr16:71861444	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	Metabolite levels;
LGG	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg13010199	chr12:38710504	ALG10B	0.6	11.86	0.48	1.57e-28	Morning vs. evening chronotype;
LGG	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg05623727	chr3:50126028	RBM5	-0.4	-8.66	-0.37	8.21e-17	Body mass index;
LGG	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg19507638	chr5:93509721	C5orf36	-0.43	-7.07	-0.31	5.68e-12	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13193757	chr20:48552853	RNF114	0.46	6.98	0.31	1.02e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.513	rs739135	chr22:42090069	A/C	cg17376030	chr22:41985996	PMM1	-0.67	-10.7	-0.45	4.9e-24	Vitiligo;
LGG	cis	rs12476592	0.543	rs12713494	chr2:63698162	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.97	-0.31	1.06e-11	Childhood ear infection;
LGG	cis	rs2408955	0.541	rs11168428	chr12:48547128	A/G	cg24011408	chr12:48396354	COL2A1	-0.56	-9.32	-0.4	4.6e-19	Glycated hemoglobin levels;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.96	-0.42	2.66e-21	Bipolar disorder;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.48	-0.4	1.31e-19	Lung cancer;
LGG	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg22842854	chr12:123319900	HIP1R	-0.53	-6.65	-0.3	8.37e-11	Schizophrenia;
LGG	cis	rs11967485	0.688	rs62434286	chr6:157226683	G/A	cg23222435	chr6:157204239	ARID1B	-0.85	-7.06	-0.31	6.01e-12	Calcium levels;
LGG	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.13	0.43	6.18e-22	Red cell distribution width;
LGG	cis	rs950169	0.686	rs12906474	chr15:85109237	A/G	cg03959625	chr15:84868606	LOC388152	0.58	9.32	0.4	4.85e-19	Schizophrenia;
LGG	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg00850481	chr1:228891306	NA	-0.52	-10.89	-0.45	9.37e-25	Chronic lymphocytic leukemia;
LGG	cis	rs6500395	0.888	rs8057165	chr16:48563467	A/C	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.82e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs832540	0.618	rs41106	chr5:56145057	G/T	cg12654349	chr5:56205094	C5orf35	-0.42	-7.37	-0.32	8.13e-13	Coronary artery disease;
LGG	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6815814	0.731	rs28532329	chr4:38771368	C/T	cg06935464	chr4:38784597	TLR10	0.44	6.8	0.3	3.31e-11	Breast cancer;
LGG	cis	rs12310956	0.515	rs1830086	chr12:33958874	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.534	rs72834629	chr6:26023032	C/T	cg17691542	chr6:26056736	HIST1H1C	0.75	12.77	0.51	3.48e-32	Height;
LGG	cis	rs7582720	1.000	rs115654617	chr2:203893999	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.39	0.4	2.76e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg03188948	chr7:1209495	NA	0.49	7.78	0.34	4.69e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4774899	0.752	rs2470079	chr15:57322099	G/C	cg08128148	chr15:57256372	TCF12	0.28	6.76	0.3	4.25e-11	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13836627	chr15:30113723	TJP1	0.47	6.83	0.3	2.62e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg09739081	chr7:23719861	C7orf46	0.35	7.63	0.33	1.32e-13	Schizophrenia;
LGG	cis	rs796364	0.806	rs74266490	chr2:201005995	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.77e-15	Obesity-related traits;
LGG	cis	rs7192380	0.893	rs1469908	chr16:69764412	C/T	cg00738113	chr16:70207722	CLEC18C	0.3	8.58	0.37	1.42e-16	Sjögren's syndrome;
LGG	cis	rs6500637	0.558	rs11076856	chr16:4949815	A/G	cg04440724	chr16:4920505	UBN1	0.54	11.83	0.48	2.13e-28	Cancer;
LGG	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg02297831	chr4:17616191	MED28	0.5	9.42	0.4	2.17e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs77106637	0.556	rs7123876	chr11:72444583	T/C	cg04827223	chr11:72435913	ARAP1	-0.44	-7.59	-0.33	1.79e-13	Type 2 diabetes;
LGG	cis	rs9790314	0.601	rs1450519	chr3:161094930	A/G	cg03342759	chr3:160939853	NMD3	-0.59	-10.27	-0.43	1.96e-22	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.765	rs727563	chr22:41867377	C/T	cg17376030	chr22:41985996	PMM1	-0.42	-6.86	-0.3	2.27e-11	Vitiligo;
LGG	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.827	rs6683274	chr1:46241638	T/G	cg03146154	chr1:46216737	IPP	0.58	10.45	0.44	4.49e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11971779	0.938	rs28477480	chr7:139036058	C/T	cg07862535	chr7:139043722	LUC7L2	-0.6	-8.92	-0.38	1.07e-17	Diisocyanate-induced asthma;
LGG	cis	rs4330281	0.967	rs11128857	chr3:17814553	C/T	cg20981856	chr3:17787350	NA	-0.37	-6.69	-0.3	6.51e-11	Schizophrenia;
LGG	cis	rs6684428	0.706	rs12118218	chr1:56320445	C/T	cg11651538	chr1:56320950	NA	-0.71	-12.74	-0.51	4.39e-32	Airflow obstruction;
LGG	cis	rs4319547	0.508	rs10846826	chr12:122894987	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.61	-0.41	4.69e-20	Body mass index;
LGG	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg14191688	chr11:70257035	CTTN	0.6	8.51	0.37	2.41e-16	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg13206674	chr6:150067644	NUP43	0.63	14.3	0.55	1.12e-38	Lung cancer;
LGG	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg03477792	chr4:77819574	ANKRD56	0.53	9.3	0.4	5.59e-19	Emphysema distribution in smoking;
LGG	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.71	0.34	7.84e-14	Colorectal cancer;
LGG	cis	rs2204008	0.805	rs11169513	chr12:37988640	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.23	0.7	2.27e-70	Bladder cancer;
LGG	cis	rs7932354	0.528	rs4752957	chr11:47125632	T/G	cg03339077	chr11:47165057	C11orf49	-0.53	-9.97	-0.42	2.42e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.61	7.44	0.33	4.94e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6840360	0.582	rs2724555	chr4:152341878	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	8.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.21	0.39	1.17e-18	Alzheimer's disease;
LGG	cis	rs2836950	0.501	rs2056844	chr21:40670460	G/C	cg17971929	chr21:40555470	PSMG1	-0.52	-8.92	-0.38	1.06e-17	Menarche (age at onset);
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.16e-12	Bipolar disorder;
LGG	cis	rs35160687	0.623	rs11127019	chr2:86467618	G/A	cg10973622	chr2:86423274	IMMT	-0.41	-7.31	-0.32	1.22e-12	Night sleep phenotypes;
LGG	cis	rs12310956	0.515	rs1852221	chr12:33945489	G/T	cg06521331	chr12:34319734	NA	-0.6	-11.16	-0.46	8.82e-26	Morning vs. evening chronotype;
LGG	cis	rs75059851	1.000	rs3802924	chr11:133827733	A/C	cg17703048	chr11:133852993	NA	-0.81	-13.86	-0.54	8.56e-37	Schizophrenia;
LGG	cis	rs7560272	0.723	rs1052161	chr2:73828538	A/G	cg20560298	chr2:73613845	ALMS1	-0.36	-6.72	-0.3	5.35e-11	Schizophrenia;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.69	0.3	6.29e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3789045	0.774	rs898388	chr1:204500257	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.46	-9.26	-0.4	7.86e-19	Educational attainment (college completion);
LGG	cis	rs9487094	0.626	rs1322124	chr6:110062873	A/C	cg16315928	chr6:109776240	MICAL1	0.43	7.51	0.33	3.1400000000000003e-13	Height;
LGG	cis	rs4076764	0.846	rs12035840	chr1:163419177	G/C	cg24596788	chr1:163392923	NA	-0.62	-11.71	-0.48	6.26e-28	Motion sickness;
LGG	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.15	0.43	5.36e-22	Diabetic retinopathy;
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.28	-0.32	1.48e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs25645	0.502	rs8065126	chr17:38099035	C/T	cg17467752	chr17:38218738	THRA	-0.47	-7.28	-0.32	1.46e-12	Myeloid white cell count;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg12692727	chr7:1102344	C7orf50	0.48	6.72	0.3	5.37e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1620921	0.967	rs1247556	chr6:161189595	G/C	cg01280913	chr6:161186852	NA	-0.33	-6.85	-0.3	2.3e-11	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.42	-0.33	5.71e-13	Neuroticism;
LGG	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.81	0.34	3.73e-14	Birth weight;
LGG	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg18404041	chr3:52824283	ITIH1	-0.48	-8.54	-0.37	1.96e-16	Bipolar disorder;
LGG	cis	rs2032447	0.714	rs199725	chr6:25953684	A/G	cg03517284	chr6:25882590	NA	-0.66	-12.35	-0.5	1.69e-30	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.35	-0.32	9.22e-13	Obesity-related traits;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg26354017	chr1:205819088	PM20D1	0.87	20.75	0.69	4.06e-68	Menarche (age at onset);
LGG	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg17545662	chr6:170176663	C6orf70	0.73	6.95	0.31	1.29e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs889312	0.500	rs33323	chr5:56175566	C/G	cg12654349	chr5:56205094	C5orf35	-0.38	-6.86	-0.3	2.19e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs11877825	0.826	rs1893879	chr18:10583247	G/A	cg25239095	chr18:10589360	NA	0.48	8.66	0.37	7.92e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg07382826	chr16:28625726	SULT1A1	0.38	7.81	0.34	3.96e-14	Tonsillectomy;Mean corpuscular volume;
LGG	cis	rs654950	0.505	rs2475839	chr1:42006005	A/G	cg06885757	chr1:42089581	HIVEP3	-0.35	-6.93	-0.31	1.44e-11	Airway imaging phenotypes;
LGG	cis	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.866	rs4795529	chr17:28443549	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.35	0.53	1.31e-34	Coffee consumption (cups per day);
LGG	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.65e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	trans	rs11039798	0.588	rs7479642	chr11:48553808	G/T	cg03929089	chr4:120376271	NA	0.69	9.42	0.4	2.15e-19	Axial length;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	7.84	0.34	3.14e-14	Lung function (FEV1/FVC);
LGG	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01570182	chr17:44337453	NA	0.51	9.32	0.4	4.74e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3733585	0.673	rs10000983	chr4:9951606	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.33	-0.36	9.48e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9815354	1.000	rs73081364	chr3:41913616	G/C	cg03022575	chr3:42003672	ULK4	0.74	9.27	0.4	6.95e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.46	0.33	4.28e-13	Neuroticism;
LGG	cis	rs787274	1.000	rs7041965	chr9:115598341	T/G	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10754283	0.557	rs1215511	chr1:90087543	C/A	cg21401794	chr1:90099060	LRRC8C	0.39	7.37	0.32	7.76e-13	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs60843830	1.000	rs3791224	chr2:221981	C/T	cg12623918	chr2:306882	NA	0.5	9.49	0.4	1.21e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.97	0.38	7.65e-18	Lung cancer;
LGG	cis	rs1816854	0.938	rs11182280	chr12:44209584	T/C	cg20956634	chr12:44200518	TWF1	0.46	6.77	0.3	3.86e-11	Inflammatory bowel disease;
LGG	cis	rs300774	0.925	rs6735974	chr2:179581	A/G	cg04617936	chr2:214353	NA	-0.54	-7.93	-0.35	1.64e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs4731207	0.561	rs12706631	chr7:124586580	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.91	-0.31	1.66e-11	Cutaneous malignant melanoma;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg01673284	chr16:4527211	HMOX2	0.36	7.29	0.32	1.32e-12	Schizophrenia;
LGG	cis	rs10752881	0.839	rs2093983	chr1:183094210	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	trans	rs6787172	0.702	rs827095	chr3:157984210	A/T	cg23275840	chr4:47708675	CORIN	0.42	8.93	0.38	9.98e-18	Subjective well-being;
LGG	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg24812749	chr6:127587940	RNF146	0.97	16.04	0.6	2.2e-46	Breast cancer;
LGG	cis	rs9596863	0.634	rs2806738	chr13:54298306	G/A	ch.13.53330881F	chr13:54432880	NA	-0.45	-7.13	-0.31	3.77e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9682041	0.660	rs13089074	chr3:170113481	G/A	cg11886554	chr3:170076028	SKIL	0.65	8.43	0.36	4.56e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.56	-0.33	2.22e-13	Mood instability;
LGG	cis	rs3816183	0.602	rs58585549	chr2:43117246	A/G	cg14631114	chr2:43023945	NA	0.42	7.6	0.33	1.71e-13	Hypospadias;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg02158880	chr13:53174818	NA	-0.43	-8.41	-0.36	5e-16	Lewy body disease;
LGG	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg08499158	chr17:42289980	UBTF	0.44	7.97	0.35	1.21e-14	Total body bone mineral density;
LGG	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg02002194	chr4:3960332	NA	0.46	8.71	0.38	5.53e-17	Neuroticism;
LGG	cis	rs6754311	0.731	rs687670	chr2:136740900	T/C	cg07169764	chr2:136633963	MCM6	0.76	12.58	0.5	2.05e-31	Mosquito bite size;
LGG	cis	rs6831352	0.760	rs1311616	chr4:100012303	T/G	cg12011299	chr4:100065546	ADH4	0.41	8.02	0.35	8.94e-15	Alcohol dependence;
LGG	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg05623727	chr3:50126028	RBM5	0.32	6.9	0.31	1.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7481584	0.624	rs438384	chr11:3045651	A/G	cg25174290	chr11:3078921	CARS	-0.46	-7.97	-0.35	1.25e-14	Calcium levels;
LGG	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg13385794	chr1:248469461	NA	0.5	8.52	0.37	2.29e-16	Common traits (Other);
LGG	cis	rs9325144	0.647	rs17518186	chr12:38883665	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-13.94	-0.54	4.12e-37	Morning vs. evening chronotype;
LGG	cis	rs9796	0.561	rs7173086	chr15:41509288	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.55	-9.48	-0.4	1.38e-19	Menopause (age at onset);
LGG	cis	rs34929064	0.672	rs2961298	chr7:22708091	A/C	cg18045685	chr7:22629474	NA	-0.56	-10.5	-0.44	2.8e-23	Major depression and alcohol dependence;
LGG	cis	rs2635047	0.638	rs2317324	chr18:44628687	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.84	0.3	2.52e-11	Educational attainment;
LGG	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg20283391	chr11:68216788	NA	-0.5	-8.28	-0.36	1.36e-15	Total body bone mineral density;
LGG	cis	rs2629540	0.737	rs10901821	chr10:126480556	T/C	cg08799069	chr10:126477246	METTL10	-0.63	-13.69	-0.54	4.46e-36	Cocaine dependence;
LGG	cis	rs10463316	0.894	rs869198	chr5:150745893	G/T	cg03212797	chr5:150827313	SLC36A1	0.6	10.57	0.44	1.57e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg27426351	chr10:43362370	NA	0.55	7.75	0.34	5.89e-14	Blood protein levels;
LGG	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg13010199	chr12:38710504	ALG10B	-0.49	-9.21	-0.39	1.17e-18	Morning vs. evening chronotype;
LGG	trans	rs1493916	0.905	rs9956315	chr18:31405546	G/C	cg04226714	chr8:49833948	SNAI2	-0.49	-8.98	-0.39	6.63e-18	Life satisfaction;
LGG	cis	rs4696584	0.877	rs4696582	chr4:155396138	C/T	cg13738195	chr4:155413469	DCHS2	0.36	7.69	0.34	8.84e-14	Folding of antihelix;
LGG	cis	rs45544231	0.521	rs1477074	chr16:52578548	T/C	cg09051775	chr16:52580266	TOX3	-0.44	-7.48	-0.33	3.68e-13	Restless legs syndrome;
LGG	cis	rs10884984	0.739	rs915216	chr10:112271467	A/G	cg18756771	chr10:112261994	DUSP5	0.72	13.63	0.54	8.51e-36	Facial morphology (factor 22);
LGG	cis	rs881375	1.000	rs10818480	chr9:123643170	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.69	0.48	7.78e-28	Rheumatoid arthritis;
LGG	cis	rs17767392	0.958	rs12894478	chr14:71825113	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.25	-0.39	8.45e-19	Mitral valve prolapse;
LGG	cis	rs8064024	0.513	rs1049208	chr16:4934549	G/A	cg04440724	chr16:4920505	UBN1	0.56	11.67	0.48	9.07e-28	Cancer;
LGG	cis	rs9911578	0.967	rs8072712	chr17:57162464	A/T	cg05425664	chr17:57184151	TRIM37	-0.71	-11.65	-0.48	1.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9660992	0.674	rs1151785	chr1:205232299	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.88	0.3	2e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs138857	0.515	rs9616375	chr22:50310600	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-10.28	-0.43	1.81e-22	Mean platelet volume;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg02725872	chr8:58115012	NA	-0.81	-11.96	-0.49	6.63e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs2288073	0.965	rs10173173	chr2:24415461	G/T	cg06627628	chr2:24431161	ITSN2	0.65	10.54	0.44	1.94e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4731207	0.564	rs10954057	chr7:124613938	T/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs11190604	1.000	rs4919465	chr10:102221703	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.57	0.33	2.01e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg24308560	chr3:49941425	MST1R	0.22	6.89	0.3	1.87e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	1.000	rs2395077	chr10:75932001	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.24	0.46	4.5e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg13385521	chr17:29058706	SUZ12P	-0.8	-8.78	-0.38	3.28e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg02428538	chr16:24856791	SLC5A11	0.72	10.96	0.45	5.17e-25	Intelligence (multi-trait analysis);
LGG	cis	rs3816183	0.959	rs3772061	chr2:43016941	A/G	cg27299406	chr2:43020013	HAAO	-0.27	-6.66	-0.3	7.95e-11	Hypospadias;
LGG	cis	rs889312	0.500	rs832580	chr5:56172646	T/C	cg12654349	chr5:56205094	C5orf35	-0.37	-6.67	-0.3	7.39e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	9.29e-26	Colorectal cancer;
LGG	cis	rs7098414	0.530	rs10749572	chr10:82136664	G/T	cg00277334	chr10:82204260	NA	-0.35	-7.32	-0.32	1.07e-12	Post bronchodilator FEV1;
LGG	cis	rs35160687	0.862	rs17737955	chr2:86508014	C/T	cg10973622	chr2:86423274	IMMT	0.45	7.64	0.33	1.22e-13	Night sleep phenotypes;
LGG	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg27426351	chr10:43362370	NA	-0.55	-7.8	-0.34	4.28e-14	Blood protein levels;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07659893	chr17:61819838	STRADA	0.49	8.24	0.36	1.73e-15	Prudent dietary pattern;
LGG	cis	rs919433	0.680	rs2565163	chr2:198354414	T/C	cg00792783	chr2:198669748	PLCL1	0.51	8.0	0.35	9.92e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.6	-0.44	1.17e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11098499	0.913	rs13126596	chr4:120140729	A/G	cg24375607	chr4:120327624	NA	0.59	9.75	0.41	1.54e-20	Corneal astigmatism;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.36	-0.32	8.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg19318889	chr4:1322082	MAEA	-0.42	-7.19	-0.32	2.63e-12	Longevity;
LGG	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.43	-0.36	4.34e-16	Diabetic retinopathy;
LGG	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg04198125	chr7:157211777	NA	0.4	7.28	0.32	1.4e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg25072359	chr17:41440525	NA	0.5	9.77	0.41	1.3e-20	Menopause (age at onset);
LGG	cis	rs7503807	0.688	rs901061	chr17:78595328	G/C	cg18469159	chr17:78755841	RPTOR	-0.37	-6.91	-0.31	1.61e-11	Obesity;
LGG	cis	rs7937890	1.000	rs2970335	chr11:14325401	A/C	cg22961513	chr11:14280813	SPON1	-0.35	-8.44	-0.37	4.06e-16	Mitochondrial DNA levels;
LGG	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs1372356	0.780	rs11159840	chr14:88556525	G/T	cg18078958	chr14:88630771	NA	0.28	6.85	0.3	2.3e-11	Food antigen IgG levels;
LGG	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.79	-0.38	2.93e-17	Lung cancer;
LGG	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg16797656	chr11:68205561	LRP5	-0.51	-10.03	-0.42	1.5e-21	Total body bone mineral density;
LGG	cis	rs7659604	0.539	rs7660548	chr4:122730821	G/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.27e-27	Type 2 diabetes;
LGG	trans	rs1814175	0.645	rs11040661	chr11:49952146	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.74	-0.68	2.16e-63	Height;
LGG	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.75	-0.34	6.07e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2153535	0.541	rs1414353	chr6:8485642	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg10253484	chr15:75165896	SCAMP2	-0.49	-8.02	-0.35	8.76e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs6835098	1.000	rs28477433	chr4:174085820	T/C	cg08422745	chr4:174089978	GALNT7	-0.85	-15.17	-0.58	1.81e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg15921436	chr17:44337874	NA	-0.45	-10.54	-0.44	2.03e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.87	-0.34	2.57e-14	Life satisfaction;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs16854884	0.606	rs60676654	chr3:143734937	A/G	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg05555928	chr11:63887634	MACROD1	-0.64	-9.13	-0.39	2.16e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg07636037	chr3:49044803	WDR6	0.68	11.97	0.49	5.89e-29	Red cell distribution width;
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg13607699	chr17:42295918	UBTF	-0.56	-9.32	-0.4	4.87e-19	Total body bone mineral density;
LGG	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg22963979	chr7:1858916	MAD1L1	-0.48	-9.24	-0.39	9.06e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.538	rs1684260	chr11:49224231	G/A	cg11707556	chr5:10655725	ANKRD33B	0.49	9.56	0.41	6.92e-20	Height;
LGG	cis	rs6693567	0.545	rs1566225	chr1:150415990	G/C	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg17470184	chr11:118478236	PHLDB1	0.43	7.37	0.32	8.07e-13	Cholesterol, total;
LGG	cis	rs6752107	1.000	rs2241879	chr2:234183468	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.03e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.92	-0.45	7.5e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.623	rs12103440	chr17:29086657	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3749237	0.595	rs3870338	chr3:49557051	A/G	cg02487422	chr3:49467188	NICN1	0.57	10.44	0.44	4.77e-23	Resting heart rate;
LGG	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg15395560	chr15:45543142	SLC28A2	0.42	6.92	0.31	1.51e-11	Glomerular filtration rate;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg05861140	chr6:150128134	PCMT1	-0.45	-10.26	-0.43	2.18e-22	Lung cancer;
LGG	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-8.1	-0.35	4.79e-15	Menarche (age at onset);
LGG	cis	rs2708240	1.000	rs2538991	chr7:147579619	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.8	-0.3	3.2e-11	QT interval (drug interaction);
LGG	cis	rs8114671	0.562	rs4911161	chr20:33402231	C/T	cg07148914	chr20:33460835	GGT7	0.55	9.29	0.4	6.27e-19	Height;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.33	-0.4	4.56e-19	Life satisfaction;
LGG	cis	rs2153535	0.601	rs9502715	chr6:8455709	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.12	0.43	6.82e-22	Motion sickness;
LGG	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1920116	0.661	rs13062210	chr3:169549773	A/T	cg08193579	chr3:169529701	LRRC34	0.41	6.66	0.3	7.6e-11	Glioma (high-grade);
LGG	cis	rs7666738	0.830	rs13140676	chr4:98804978	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.74	0.34	6.35e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.791	rs34152299	chr4:98929862	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.06	-0.31	6.06e-12	Life satisfaction;
LGG	cis	rs240764	0.658	rs1039030	chr6:101198707	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.26	-0.36	1.56e-15	Neuroticism;
LGG	cis	rs7582180	0.715	rs7571306	chr2:100906084	G/C	cg14675211	chr2:100938903	LONRF2	0.53	8.79	0.38	2.86e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.647	rs1386018	chr12:39104360	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-13.4	-0.53	7.62e-35	Morning vs. evening chronotype;
LGG	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg02733842	chr7:1102375	C7orf50	-0.44	-7.15	-0.32	3.5e-12	Bronchopulmonary dysplasia;
LGG	cis	rs4330281	0.630	rs34487714	chr3:17763899	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.42	-0.33	5.83e-13	Schizophrenia;
LGG	cis	rs9549367	0.707	rs9549353	chr13:113843427	G/A	cg00898013	chr13:113819073	PROZ	-0.51	-10.09	-0.42	9.06e-22	Platelet distribution width;
LGG	cis	rs7301016	0.948	rs73141045	chr12:62931083	C/G	cg11441379	chr12:63026424	NA	0.65	8.72	0.38	5.01e-17	IgG glycosylation;
LGG	trans	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg16141378	chr3:129829833	LOC729375	-0.48	-12.41	-0.5	9.59e-31	Mood instability;
LGG	cis	rs4975616	0.804	rs31489	chr5:1342714	C/A	cg06550200	chr5:1325588	CLPTM1L	-0.61	-10.8	-0.45	2.13e-24	Lung cancer;
LGG	cis	rs4639966	0.797	rs68097885	chr11:118596444	G/A	cg19182353	chr11:118479428	PHLDB1	-0.57	-9.15	-0.39	1.85e-18	Systemic lupus erythematosus;
LGG	cis	rs4740619	0.619	rs10810526	chr9:16041399	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.51	-0.47	3.97e-27	Body mass index;
LGG	cis	rs2075371	0.966	rs2544223	chr7:133995787	A/G	cg20476274	chr7:133979776	SLC35B4	0.77	15.22	0.58	1.06e-42	Mean platelet volume;
LGG	cis	rs2764208	0.535	rs2744966	chr6:34585931	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.43	-7.32	-0.32	1.11e-12	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00239003	chr19:45458398	CLPTM1	0.4	6.68	0.3	7.06e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-8.04	-0.35	7.48e-15	Diabetic kidney disease;
LGG	cis	rs490647	0.652	rs510159	chr1:37253488	T/C	cg24672014	chr1:37203461	NA	0.36	7.55	0.33	2.35e-13	Neuroticism;
LGG	cis	rs774359	0.789	rs12554036	chr9:27509211	G/T	cg14173147	chr9:27528300	MOBKL2B	0.43	8.22	0.36	2.05e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs365132	0.840	rs58400555	chr5:176454081	A/T	cg16309518	chr5:176445507	NA	-0.55	-12.27	-0.5	3.81e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs4363385	0.550	rs6661932	chr1:152896734	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.46	-0.37	3.46e-16	Inflammatory skin disease;
LGG	cis	rs4474465	1.000	rs1567889	chr11:78147055	A/G	cg02023728	chr11:77925099	USP35	0.39	6.67	0.3	7.18e-11	Alzheimer's disease (survival time);
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg19635926	chr16:89946313	TCF25	0.7	8.36	0.36	7.5e-16	Skin colour saturation;
LGG	cis	rs2549003	0.966	rs10213701	chr5:131824064	T/A	cg00578828	chr5:131826934	IRF1	0.39	7.01	0.31	8.48e-12	Asthma (sex interaction);
LGG	cis	rs910316	0.789	rs4899552	chr14:75667921	C/A	cg11812906	chr14:75593930	NEK9	-0.47	-8.65	-0.37	8.67e-17	Height;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12016809	chr21:47604291	C21orf56	-0.46	-7.5	-0.33	3.29e-13	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05926043	chr19:18059042	NA	0.53	8.15	0.35	3.31e-15	Gut microbiome composition (summer);
LGG	cis	rs9399135	0.967	rs4896121	chr6:135293645	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.49	0.4	1.21e-19	Red blood cell count;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09742170	chr7:25021208	OSBPL3	0.44	7.85	0.34	3.02e-14	Bipolar disorder;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg12419862	chr22:24373484	LOC391322	-0.93	-18.82	-0.66	4.04e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8077889	0.750	rs231539	chr17:41942109	T/C	cg26893861	chr17:41843967	DUSP3	-0.92	-12.44	-0.5	7.84e-31	Triglycerides;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.18e-31	Prudent dietary pattern;
LGG	cis	rs4819052	0.679	rs4819053	chr21:46711357	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.6	-10.82	-0.45	1.74e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1420338	0.967	rs10224203	chr7:34149593	C/T	cg01275685	chr7:34179230	BMPER	-0.45	-8.03	-0.35	8.36e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg11062466	chr8:58055876	NA	0.53	8.75	0.38	4.03e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs457717	0.660	rs461475	chr5:75947198	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.3	6.71	0.3	5.67e-11	Hearing impairment;
LGG	cis	rs8032158	1.000	rs7162435	chr15:56121334	C/T	cg02198044	chr15:56286336	NEDD4	0.69	12.22	0.49	5.96e-30	Keloid;
LGG	cis	rs10743315	0.547	rs7310796	chr12:19362390	C/T	cg02471346	chr12:19282374	PLEKHA5	-0.57	-7.92	-0.35	1.72e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs503734	0.666	rs12496260	chr3:101221703	C/T	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs36093844	0.698	rs79435802	chr11:85585206	T/C	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs4639966	0.836	rs3825057	chr11:118622985	T/C	cg20309703	chr11:118481025	PHLDB1	-0.48	-7.3	-0.32	1.27e-12	Systemic lupus erythematosus;
LGG	cis	rs72799341	1.000	rs35675346	chr16:30936081	G/A	cg00531865	chr16:30841666	NA	-0.48	-8.52	-0.37	2.31e-16	Diastolic blood pressure;
LGG	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg22920501	chr2:26401640	FAM59B	0.46	9.05	0.39	3.9e-18	Gut microbiome composition (summer);
LGG	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg16576597	chr16:28551801	NUPR1	0.36	7.91	0.34	1.94e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.38	6.68	0.3	6.82e-11	Glycated hemoglobin levels;
LGG	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg00376283	chr12:123451042	ABCB9	0.62	11.45	0.47	6.84e-27	Platelet count;
LGG	cis	rs6964587	0.626	rs34404183	chr7:91551249	T/C	cg17063962	chr7:91808500	NA	-0.47	-8.76	-0.38	3.66e-17	Breast cancer;
LGG	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	7.64	0.33	1.29e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs78487399	0.614	rs77389971	chr2:43718084	G/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.82	-0.3	2.93e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs9894429	0.966	rs10871499	chr17:79589006	G/A	cg18240062	chr17:79603768	NPLOC4	0.75	13.9	0.54	5.8e-37	Eye color traits;
LGG	cis	rs4243830	0.850	rs2274553	chr1:6586553	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.76	-12.34	-0.5	1.91e-30	Body mass index;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg02733842	chr7:1102375	C7orf50	0.72	8.34	0.36	8.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7998202	0.561	rs442098	chr13:113353032	C/A	cg02820901	chr13:113351484	ATP11A	0.59	7.13	0.31	3.86e-12	Glycated hemoglobin levels;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.56e-21	Prudent dietary pattern;
LGG	cis	rs6500395	1.000	rs9931123	chr16:48614293	G/T	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05409276	chr17:73400549	GRB2	0.42	6.87	0.3	2.04e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs896854	0.902	rs726816	chr8:95968413	T/G	cg16049864	chr8:95962084	TP53INP1	-0.45	-9.86	-0.42	6.19e-21	Type 2 diabetes;
LGG	cis	rs2073300	0.609	rs56094936	chr20:23401586	G/A	cg12062639	chr20:23401060	NAPB	0.92	8.93	0.38	9.82e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.54	-0.53	2.06e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03264133	chr6:25882463	NA	-0.57	-10.44	-0.44	4.6e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.735	rs11635463	chr15:76762986	C/T	cg15268244	chr15:77196840	NA	0.43	9.36	0.4	3.41e-19	Blood metabolite levels;
LGG	cis	rs2072732	0.821	rs12034766	chr1:2944038	A/G	cg22517653	chr1:2918612	NA	-0.5	-7.01	-0.31	8.74e-12	Plateletcrit;
LGG	cis	rs1003719	0.645	rs8131944	chr21:38547215	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs2708377	0.858	rs117212341	chr12:11282556	C/G	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.78	-0.3	3.77e-11	Bitter taste perception;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg11766577	chr21:47581405	C21orf56	0.49	8.14	0.35	3.72e-15	Testicular germ cell tumor;
LGG	cis	rs17767392	0.756	rs61989256	chr14:71729964	C/T	cg02058870	chr14:72053146	SIPA1L1	0.41	8.08	0.35	5.6e-15	Mitral valve prolapse;
LGG	trans	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.68	-0.3	6.71e-11	Neuroticism;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4927850	1.000	rs7614767	chr3:195753451	C/T	cg01181863	chr3:195395398	SDHAP2	-0.6	-9.54	-0.41	8.48e-20	Pancreatic cancer;
LGG	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs8180040	0.966	rs11130129	chr3:47489885	G/C	cg16586182	chr3:47516702	SCAP	0.77	15.39	0.58	1.91e-43	Colorectal cancer;
LGG	cis	rs4959677	0.558	rs4959671	chr6:2472911	C/G	cg20147862	chr6:2634573	C6orf195	-0.33	-7.04	-0.31	7.14e-12	Orthostatic hypotension;
LGG	cis	rs2862064	0.745	rs4704733	chr5:156480104	T/G	cg12943317	chr5:156479607	HAVCR1	-0.78	-10.53	-0.44	2.22e-23	Platelet count;
LGG	cis	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg20368463	chr18:77673604	PQLC1	0.54	6.88	0.3	1.99e-11	Opioid sensitivity;
LGG	cis	rs7666738	0.791	rs2081621	chr4:98926753	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.05e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9467773	0.595	rs6907924	chr6:26438817	T/G	cg09904177	chr6:26538194	HMGN4	-0.43	-7.72	-0.34	7.24e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7975161	0.671	rs7314893	chr12:104597769	C/T	cg25273343	chr12:104657179	TXNRD1	-0.59	-9.75	-0.41	1.54e-20	Toenail selenium levels;
LGG	cis	rs360798	0.512	rs6545973	chr2:63089434	C/T	cg17519650	chr2:63277830	OTX1	0.46	7.49	0.33	3.48e-13	Coronary artery disease;
LGG	trans	rs9650657	0.623	rs7004066	chr8:10600743	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.34	-0.32	9.85e-13	Neuroticism;
LGG	cis	rs62400317	0.701	rs12195339	chr6:44796179	T/C	cg18551225	chr6:44695536	NA	-0.67	-10.19	-0.43	3.95e-22	Total body bone mineral density;
LGG	cis	rs3790455	1.000	rs2274319	chr1:156450873	T/C	cg14087168	chr1:156450669	MEF2D	0.5	8.15	0.35	3.42e-15	Migraine;
LGG	cis	rs62238980	0.614	rs78078590	chr22:32370487	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	trans	rs2048656	0.508	rs7387886	chr8:9676575	T/G	cg16141378	chr3:129829833	LOC729375	0.33	6.85	0.3	2.36e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07151830	chr6:160211006	TCP1;MRPL18	0.45	7.01	0.31	8.52e-12	Gut microbiome composition (summer);
LGG	cis	rs3816183	0.598	rs6749160	chr2:42892590	T/C	cg14631114	chr2:43023945	NA	0.36	6.98	0.31	1.05e-11	Hypospadias;
LGG	cis	rs35740288	0.929	rs11630684	chr15:86306256	C/A	cg04173714	chr15:86211321	AKAP13	0.41	7.11	0.31	4.52e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg12395012	chr8:11607386	GATA4	0.39	6.88	0.3	1.92e-11	Schizophrenia;
LGG	cis	rs2880765	0.835	rs11856869	chr15:86029097	C/G	cg13263323	chr15:86062960	AKAP13	-0.36	-7.37	-0.32	8.03e-13	Coronary artery disease;
LGG	cis	rs8067545	0.574	rs62067483	chr17:19948394	C/T	cg13482628	chr17:19912719	NA	0.51	8.33	0.36	9.17e-16	Schizophrenia;
LGG	cis	rs11758351	0.588	rs2050948	chr6:26234952	A/G	cg01420254	chr6:26195488	NA	0.82	10.63	0.44	9.03e-24	Gout;Renal underexcretion gout;
LGG	cis	rs2304069	0.644	rs216131	chr5:149431223	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	9.86	0.42	6.14e-21	HIV-1 control;
LGG	cis	rs2115536	1.000	rs2903105	chr15:80189523	C/G	cg11839771	chr15:80205821	ST20	-0.34	-7.23	-0.32	1.96e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg02886208	chr11:14281011	SPON1	0.47	9.52	0.4	9.66e-20	Mitochondrial DNA levels;
LGG	trans	rs1997103	1.000	rs6968966	chr7:55411356	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.53	0.37	2.03e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs3806843	0.576	rs246003	chr5:140340865	C/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg27286337	chr10:134555280	INPP5A	0.82	12.89	0.51	1.1e-32	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.84	-0.51	1.67e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7215564	0.749	rs7217825	chr17:78733901	C/T	cg16980736	chr17:78789706	RPTOR	0.59	7.99	0.35	1.05e-14	Myopia (pathological);
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.29	-0.58	5.3800000000000004e-43	Height;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.79	-0.38	2.92e-17	Lung cancer;
LGG	cis	rs17321999	0.516	rs72787730	chr2:30497632	T/C	cg05247661	chr2:30472410	LBH	0.64	7.91	0.35	1.88e-14	Systemic lupus erythematosus;
LGG	cis	rs2635047	0.783	rs8084241	chr18:44798139	A/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.85	-0.3	2.32e-11	Educational attainment;
LGG	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs911555	0.755	rs8014013	chr14:103937372	A/G	cg24130564	chr14:104152367	KLC1	0.41	7.41	0.33	6.04e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.16	-0.35	3.25e-15	Obesity;
LGG	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg08975724	chr8:8085496	FLJ10661	0.38	7.08	0.31	5.51e-12	Retinal vascular caliber;
LGG	cis	rs8062405	0.691	rs743590	chr16:28608230	G/A	cg07382826	chr16:28625726	SULT1A1	0.4	8.1	0.35	4.79e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21659725	chr3:3221576	CRBN	-0.58	-9.89	-0.42	4.9e-21	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg16141378	chr3:129829833	LOC729375	-0.5	-12.68	-0.51	8.19e-32	Mood instability;
LGG	cis	rs208520	0.874	rs208515	chr6:66945749	A/G	cg07460842	chr6:66804631	NA	-0.92	-15.89	-0.59	1.11e-45	Exhaled nitric oxide output;
LGG	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.95	-0.31	1.24e-11	Blood metabolite levels;
LGG	cis	rs6997458	0.904	rs1532424	chr8:86268192	G/T	cg02393479	chr8:86352350	CA3	-0.3	-6.66	-0.3	7.77e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs3784262	0.669	rs12595180	chr15:58332541	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.83	-0.3	2.62e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2562456	0.917	rs2681389	chr19:21692575	G/A	cg00806126	chr19:22604979	ZNF98	0.63	9.4	0.4	2.48e-19	Pain;
LGG	cis	rs7926971	0.756	rs11826266	chr11:12659535	T/C	cg25843174	chr11:12811716	TEAD1	0.32	6.86	0.3	2.24e-11	Height;
LGG	cis	rs6061231	0.505	rs13037253	chr20:60928724	G/A	cg06026331	chr20:60912101	LAMA5	0.72	12.73	0.51	5.05e-32	Colorectal cancer;
LGG	cis	rs5771242	0.776	rs6010198	chr22:50610628	A/G	cg16473166	chr22:50639996	SELO	-0.67	-10.71	-0.45	4.58e-24	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs888194	0.649	rs10774697	chr12:109875981	A/G	cg19025524	chr12:109796872	NA	-0.47	-9.39	-0.4	2.71e-19	Neuroticism;
LGG	cis	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg27411982	chr8:10470053	RP1L1	0.44	7.65	0.33	1.2e-13	Neuroticism;
LGG	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.64	-0.33	1.23e-13	Colorectal cancer;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg14490972	chr6:43484812	POLR1C;YIPF3	0.42	7.04	0.31	7.19e-12	Prudent dietary pattern;
LGG	cis	rs2764980	1.000	rs11251794	chr10:3283931	C/T	cg11630169	chr10:3283847	NA	-0.44	-10.57	-0.44	1.57e-23	Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs2562456	0.833	rs2358993	chr19:21558169	G/A	cg00806126	chr19:22604979	ZNF98	-0.58	-7.75	-0.34	5.85e-14	Pain;
LGG	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	cis	rs6032067	0.777	rs56063128	chr20:43783210	G/A	cg10761708	chr20:43804764	PI3	0.74	11.58	0.47	2.01e-27	Blood protein levels;
LGG	cis	rs11229555	0.609	rs4519113	chr11:58216825	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg10523679	chr1:76189770	ACADM	0.75	13.92	0.54	4.85e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg14338887	chr6:42928500	GNMT	0.29	9.49	0.4	1.27e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.02	-17.36	-0.63	2.22e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg02975922	chr3:195473998	MUC4	0.46	7.34	0.32	9.97e-13	Mean corpuscular volume;
LGG	cis	rs6748734	0.843	rs6749674	chr2:241834501	G/C	cg26818257	chr2:241905806	NA	0.36	6.98	0.31	1.02e-11	Urinary metabolites;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg08621203	chr6:150244597	RAET1G	0.44	7.44	0.33	4.82e-13	Lung cancer;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg19524238	chr7:2802976	GNA12	0.38	8.56	0.37	1.66e-16	Height;
LGG	cis	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17833341	chr1:154947313	SHC1;CKS1B	0.41	6.93	0.31	1.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs240764	0.658	rs9399685	chr6:101204318	C/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.07	-0.35	6.09e-15	Neuroticism;
LGG	cis	rs910187	0.678	rs6124967	chr20:45813624	T/C	cg27589058	chr20:45804311	EYA2	-0.35	-9.14	-0.39	2e-18	Migraine;
LGG	cis	rs1659258	0.527	rs1258404	chr2:88620216	C/T	cg00685853	chr2:88648947	NA	-0.44	-6.74	-0.3	4.82e-11	Visceral fat;
LGG	cis	rs9359856	0.564	rs34766278	chr6:90397132	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.75	-0.41	1.46e-20	Bipolar disorder;
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg23531748	chr20:60969906	CABLES2	0.41	7.07	0.31	5.83e-12	Colorectal cancer;
LGG	cis	rs7113850	0.541	rs11819948	chr11:24231257	A/C	ch.11.24196551F	chr11:24239977	NA	0.89	10.14	0.43	5.8e-22	Bone fracture in osteoporosis;
LGG	cis	rs4900538	0.963	rs1190553	chr14:102915331	G/T	cg18135206	chr14:102964638	TECPR2	-0.81	-16.19	-0.6	4.69e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2718058	0.630	rs2722363	chr7:37835603	A/G	cg15028436	chr7:37888078	TXNDC3	0.53	8.32	0.36	9.76e-16	Alzheimer's disease (late onset);
LGG	cis	rs137603	0.644	rs137621	chr22:39710244	G/A	cg01093212	chr22:39715156	SNORD43;RPL3	-0.39	-6.72	-0.3	5.52e-11	Primary biliary cholangitis;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg09699651	chr6:150184138	LRP11	0.56	10.65	0.44	7.85e-24	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs34703416	chr7:65300642	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.25	-0.39	8.36e-19	Diabetic kidney disease;
LGG	cis	rs2180341	1.000	rs2180341	chr6:127600630	C/T	cg27446573	chr6:127587934	RNF146	1.06	20.07	0.68	6.34e-65	Breast cancer;
LGG	cis	rs7666738	0.753	rs7657644	chr4:99057734	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs826838	1.000	rs7315028	chr12:38710523	G/A	cg26384229	chr12:38710491	ALG10B	1.08	29.82	0.81	8.13e-110	Heart rate;
LGG	cis	rs10895140	0.625	rs1892873	chr11:101472862	T/G	cg04553838	chr11:101454733	TRPC6	-0.41	-6.67	-0.3	7.18e-11	Menarche (age at onset);
LGG	cis	rs6912958	1.000	rs2223880	chr6:88167897	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.65	-0.44	7.43e-24	Monocyte percentage of white cells;
LGG	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg17691542	chr6:26056736	HIST1H1C	0.67	11.11	0.46	1.34e-25	Iron status biomarkers;
LGG	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg03264133	chr6:25882463	NA	-0.48	-7.73	-0.34	6.64e-14	Iron status biomarkers;
LGG	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg13072238	chr3:49761600	GMPPB	-0.53	-6.81	-0.3	2.98e-11	Menarche (age at onset);
LGG	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg25600027	chr14:23388339	RBM23	-0.44	-7.23	-0.32	2.07e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg07636037	chr3:49044803	WDR6	0.59	10.28	0.43	1.77e-22	Resting heart rate;
LGG	cis	rs4819052	0.885	rs28576202	chr21:46674684	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.89	0.38	1.39e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2836974	0.627	rs8127986	chr21:40687211	A/T	cg06238570	chr21:40685208	BRWD1	-0.52	-8.47	-0.37	3.35e-16	Cognitive function;
LGG	cis	rs2075371	1.000	rs2058976	chr7:133981379	G/T	cg11752832	chr7:134001865	SLC35B4	0.61	11.03	0.46	2.77e-25	Mean platelet volume;
LGG	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs2249694	0.960	rs7075572	chr10:135404358	T/C	cg20169779	chr10:135381914	SYCE1	-0.5	-7.79	-0.34	4.35e-14	Obesity-related traits;
LGG	cis	rs7143963	0.887	rs11552464	chr14:103377354	T/G	cg23020514	chr14:103360112	TRAF3	0.53	9.73	0.41	1.8e-20	Body mass index;
LGG	trans	rs7618501	1.000	rs7374277	chr3:49784777	T/C	cg21659725	chr3:3221576	CRBN	-0.92	-20.41	-0.69	1.63e-66	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs729354	chr11:77962453	T/A	cg02023728	chr11:77925099	USP35	0.42	7.45	0.33	4.63e-13	Testicular germ cell tumor;
LGG	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-10.21	-0.43	3.18e-22	Hepatocellular carcinoma;
LGG	cis	rs2404602	1.000	rs12148786	chr15:76800362	A/G	cg22467129	chr15:76604101	ETFA	-0.46	-7.75	-0.34	5.94e-14	Blood metabolite levels;
LGG	cis	rs79349575	0.715	rs9894220	chr17:46989154	C/T	cg22482690	chr17:47019901	SNF8	0.34	6.77	0.3	3.99e-11	Type 2 diabetes;
LGG	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7444	0.941	rs878825	chr22:21982249	A/G	cg22858872	chr22:21984481	YDJC	-0.35	-6.72	-0.3	5.32e-11	Systemic lupus erythematosus;
LGG	cis	rs12738007	0.745	rs6702335	chr1:29411250	A/G	cg01115565	chr1:29584222	PTPRU	-0.25	-6.85	-0.3	2.39e-11	Schizophrenia;
LGG	cis	rs41271473	0.607	rs6692032	chr1:228853984	G/C	cg16512390	chr1:228756714	NA	0.42	6.95	0.31	1.21e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.93	-0.54	4.39e-37	Alzheimer's disease;
LGG	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1983170	1.000	rs597288	chr1:91999296	C/T	cg25838465	chr1:92012736	NA	0.46	7.28	0.32	1.44e-12	Eosinophil percentage of white cells;
LGG	cis	rs9790314	1.000	rs1600209	chr3:161038217	A/T	cg04691961	chr3:161091175	C3orf57	-0.63	-14.84	-0.57	4.79e-41	Morning vs. evening chronotype;
LGG	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg04317338	chr11:64019027	PLCB3	0.66	8.19	0.36	2.57e-15	Mean platelet volume;
LGG	cis	rs7937890	0.559	rs2597208	chr11:14472329	A/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.93	-0.35	1.64e-14	Mitochondrial DNA levels;
LGG	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.2	0.36	2.46e-15	Retinal vascular caliber;
LGG	cis	rs8133932	0.668	rs3788226	chr21:47300115	A/G	cg13695288	chr21:47294981	PCBP3	0.36	7.01	0.31	8.27e-12	Schizophrenia;
LGG	cis	rs17818399	0.815	rs17768132	chr2:46863249	G/T	cg26688816	chr2:46740690	ATP6V1E2	0.56	9.62	0.41	4.17e-20	Height;
LGG	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg23029597	chr12:123009494	RSRC2	0.79	7.19	0.32	2.67e-12	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LGG	cis	rs2865126	0.743	rs1941551	chr18:10744620	G/T	cg21165219	chr18:10698044	FAM38B	-0.46	-7.49	-0.33	3.43e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs611744	0.647	rs4735053	chr8:109260776	A/G	cg18478394	chr8:109455254	TTC35	0.41	8.19	0.36	2.5e-15	Dupuytren's disease;
LGG	cis	rs9427116	1.000	rs9427117	chr1:154632231	C/G	cg11650704	chr1:154556575	ADAR	-0.38	-7.33	-0.32	1.03e-12	Blood protein levels;
LGG	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg25008857	chr14:105974488	NA	0.58	10.16	0.43	4.9e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6121246	0.559	rs6060950	chr20:30378031	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs9810089	1.000	rs9810089	chr3:135807609	G/T	cg21827317	chr3:136751795	NA	-0.39	-6.86	-0.3	2.15e-11	Gestational age at birth (child effect);
LGG	trans	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10851478	0.529	rs12901929	chr15:49675308	T/C	cg08060515	chr15:49448048	GALK2;COPS2	0.43	7.78	0.34	4.93e-14	Oral cavity cancer;
LGG	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg12654349	chr5:56205094	C5orf35	-0.69	-10.67	-0.44	6.49e-24	Initial pursuit acceleration;
LGG	cis	rs963731	0.649	rs2373495	chr2:39254627	C/G	cg04010122	chr2:39346883	SOS1	-0.79	-7.04	-0.31	7.15e-12	Corticobasal degeneration;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg16590910	chr6:42928470	GNMT	0.41	11.55	0.47	2.65e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9815354	1.000	rs6599176	chr3:41788492	G/T	cg03022575	chr3:42003672	ULK4	-0.59	-7.47	-0.33	4e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12220238	0.915	rs11001021	chr10:76139657	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.74	0.38	4.23e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.6e-12	Bipolar disorder;
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg27471124	chr11:109292789	C11orf87	0.82	18.23	0.65	2.2e-56	Schizophrenia;
LGG	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs2797160	0.967	rs1739368	chr6:126011079	C/T	cg05901451	chr6:126070800	HEY2	0.46	7.77	0.34	5.06e-14	Endometrial cancer;
LGG	cis	rs1878931	0.543	rs1129568	chr16:3483475	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.92	18.3	0.65	1.09e-56	Body mass index (adult);
LGG	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-9.73	-0.41	1.8e-20	Coronary artery disease;
LGG	cis	rs1210638	1.000	rs2518806	chr22:18976603	A/G	cg14259594	chr22:18958660	DGCR5	-0.58	-9.34	-0.4	4.07e-19	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg12708336	chr17:41446283	NA	-0.33	-7.94	-0.35	1.51e-14	Menopause (age at onset);
LGG	cis	rs2289583	0.503	rs113742359	chr15:75261643	A/G	cg10253484	chr15:75165896	SCAMP2	0.48	7.44	0.33	4.78e-13	Systemic lupus erythematosus;
LGG	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	3.94e-11	Parkinson's disease;
LGG	cis	rs12681287	0.511	rs9297923	chr8:87548989	T/C	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	trans	rs9354308	0.764	rs9345703	chr6:66583609	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.11	-0.31	4.4e-12	Metabolite levels;
LGG	cis	rs7659604	0.702	rs61217486	chr4:122693973	T/C	cg20573242	chr4:122745356	CCNA2	0.51	9.24	0.39	8.76e-19	Type 2 diabetes;
LGG	cis	rs36051895	0.658	rs11999928	chr9:5006743	T/G	cg02405213	chr9:5042618	JAK2	-0.8	-15.32	-0.58	3.71e-43	Pediatric autoimmune diseases;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.44	-9.01	-0.39	5.23e-18	Schizophrenia;
LGG	cis	rs17767392	0.881	rs10138557	chr14:72061718	C/T	cg13720639	chr14:72061746	SIPA1L1	0.38	8.26	0.36	1.54e-15	Mitral valve prolapse;
LGG	cis	rs4742903	0.967	rs10820601	chr9:106861281	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.25	0.36	1.66e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4072980	0.545	rs12120737	chr1:38422544	C/T	cg26528311	chr1:38462546	FHL3	0.33	8.39	0.36	6e-16	Coronary artery disease;
LGG	cis	rs2075371	0.547	rs12666682	chr7:134021784	C/A	cg11752832	chr7:134001865	SLC35B4	0.49	8.03	0.35	8.18e-15	Mean platelet volume;
LGG	cis	rs2153535	0.580	rs6900007	chr6:8474035	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.08	0.31	5.36e-12	Prudent dietary pattern;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01458961	chr4:102269425	PPP3CA	-0.47	-6.9	-0.31	1.71e-11	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg08621203	chr6:150244597	RAET1G	0.44	7.46	0.33	4.21e-13	Lung cancer;
LGG	cis	rs16837677	1.000	rs80278884	chr1:156754099	C/G	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	trans	rs4714291	0.963	rs1721412	chr6:40100606	T/G	cg02267698	chr19:7991119	CTXN1	0.62	9.78	0.41	1.2e-20	Strep throat;
LGG	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs9920506	0.536	rs12441998	chr15:78929372	G/A	cg09448879	chr15:79043637	NA	-0.34	-7.09	-0.31	5.19e-12	Post bronchodilator FEV1;
LGG	trans	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg02002194	chr4:3960332	NA	0.4	7.37	0.32	8.03e-13	Joint mobility (Beighton score);
LGG	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.34	0.32	9.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	6.9299999999999992e-21	Aortic root size;
LGG	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.79	-0.51	2.78e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs10937275	1.000	rs35923019	chr3:186651388	C/T	cg26193484	chr3:186648175	ST6GAL1	0.89	9.26	0.4	7.56e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg18335740	chr13:41363409	SLC25A15	0.8	18.79	0.66	5.87e-59	Lewy body disease;
LGG	cis	rs8180040	0.764	rs11130115	chr3:47181661	C/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.42e-47	Colorectal cancer;
LGG	cis	rs3091242	0.836	rs34997029	chr1:25783823	A/G	cg27572855	chr1:25598939	RHD	-0.49	-11.1	-0.46	1.56e-25	Erythrocyte sedimentation rate;
LGG	trans	rs9393777	0.778	rs35608615	chr6:27040402	G/C	cg08344181	chr3:125677491	NA	-0.65	-7.55	-0.33	2.41e-13	Intelligence (multi-trait analysis);
LGG	cis	rs826838	0.967	rs980572	chr12:39127673	A/C	cg13010199	chr12:38710504	ALG10B	0.67	14.11	0.55	7.11e-38	Heart rate;
LGG	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg04568710	chr12:38710424	ALG10B	0.34	6.95	0.31	1.21e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg13206674	chr6:150067644	NUP43	0.62	14.03	0.55	1.66e-37	Lung cancer;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs4423214	0.879	rs1792284	chr11:71134966	A/G	cg05163923	chr11:71159392	DHCR7	0.63	10.97	0.45	4.93e-25	Vitamin D levels;
LGG	cis	rs7582180	0.629	rs4851298	chr2:100949827	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9309711	0.698	rs9750503	chr2:3491772	A/G	cg10845886	chr2:3471009	TTC15	0.7	13.51	0.53	2.73e-35	Neurofibrillary tangles;
LGG	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-7.86	-0.34	2.63e-14	Self-reported allergy;
LGG	cis	rs2282032	0.527	rs8004573	chr14:90765743	C/T	cg14092571	chr14:90743983	NA	0.43	7.59	0.33	1.72e-13	Longevity;
LGG	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg19468946	chr17:37922297	IKZF3	-0.43	-7.73	-0.34	6.88e-14	Self-reported allergy;
LGG	cis	rs6964587	1.000	rs417	chr7:91581121	C/A	cg17063962	chr7:91808500	NA	-0.5	-8.76	-0.38	3.6e-17	Breast cancer;
LGG	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs561341	0.602	rs114562703	chr17:30233899	G/T	cg00745463	chr17:30367425	LRRC37B	-0.48	-7.05	-0.31	6.43e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs2067615	0.579	rs10861657	chr12:107131314	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.19	0.49	7.94e-30	Heart rate;
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs17208368	0.628	rs2397357	chr16:55099215	T/C	cg11181171	chr16:55090946	NA	0.46	7.67	0.34	1.05e-13	Hypospadias;
LGG	cis	rs4474465	1.000	rs7102316	chr11:78149365	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.56	-0.37	1.65e-16	Alzheimer's disease (survival time);
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg24450063	chr1:156163899	SLC25A44	1.22	31.01	0.82	4.57e-115	Testicular germ cell tumor;
LGG	cis	rs1707322	0.721	rs61784796	chr1:46163256	A/G	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg26769984	chr7:1090371	C7orf50	0.53	9.33	0.4	4.24e-19	Bronchopulmonary dysplasia;
LGG	cis	rs10267417	0.603	rs6976553	chr7:19869113	T/C	cg05791153	chr7:19748676	TWISTNB	0.63	8.09	0.35	5.17e-15	Night sleep phenotypes;
LGG	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg21724239	chr8:58056113	NA	0.51	7.74	0.34	6.12e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs758324	0.773	rs13174385	chr5:131160187	T/G	cg06307176	chr5:131281290	NA	0.53	8.74	0.38	4.48e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs61931739	0.500	rs7488438	chr12:34531359	G/T	cg13010199	chr12:38710504	ALG10B	0.68	13.09	0.52	1.49e-33	Morning vs. evening chronotype;
LGG	cis	rs41278232	1.000	rs73153160	chr20:62675410	G/A	cg03065311	chr20:62601662	ZNF512B	0.67	8.82	0.38	2.3e-17	Tonsillectomy;
LGG	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg13010199	chr12:38710504	ALG10B	0.5	9.65	0.41	3.49e-20	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	cis	rs9902453	0.933	rs60694493	chr17:28473256	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.82e-34	Coffee consumption (cups per day);
LGG	trans	rs7395662	0.963	rs4882112	chr11:48561083	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs733592	0.965	rs1978161	chr12:48467721	A/G	cg24011408	chr12:48396354	COL2A1	-0.65	-10.95	-0.45	5.82e-25	Plateletcrit;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.21	0.43	3.32e-22	Prudent dietary pattern;
LGG	cis	rs7590368	0.673	rs56264212	chr2:10931435	A/C	cg15705551	chr2:10952987	PDIA6	0.58	7.51	0.33	3.12e-13	Educational attainment (years of education);
LGG	cis	rs2120019	0.567	rs8037152	chr15:75156996	A/T	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.84	-0.51	1.64e-32	Blood trace element (Zn levels);
LGG	cis	rs721399	1.000	rs4646249	chr8:18260431	T/G	cg18736775	chr8:18248649	NAT2	0.51	8.99	0.39	6.48e-18	Blood metabolite levels;
LGG	cis	rs56399783	0.708	rs56208415	chr7:2813806	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.33	0.32	1.01e-12	Childhood ear infection;
LGG	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg21605333	chr4:119757512	SEC24D	1.33	12.6	0.51	1.65e-31	Cannabis dependence symptom count;
LGG	cis	rs9595066	0.941	rs9533777	chr13:44708720	C/T	cg04068111	chr13:44716778	NA	0.48	7.63	0.33	1.33e-13	Schizophrenia;
LGG	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2652834	0.519	rs4075584	chr15:63340292	C/T	cg05507819	chr15:63340323	TPM1	0.75	9.69	0.41	2.43e-20	HDL cholesterol;
LGG	cis	rs3740540	0.761	rs34496154	chr10:126284336	C/T	cg04949429	chr10:126290192	LHPP	-0.43	-6.77	-0.3	3.86e-11	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11098499	0.865	rs9996417	chr4:120295862	T/C	cg09307838	chr4:120376055	NA	0.81	13.38	0.53	9.71e-35	Corneal astigmatism;
LGG	cis	rs11675119	0.501	rs13003003	chr2:3493560	A/G	cg15541040	chr2:3486749	NA	-0.41	-7.08	-0.31	5.25e-12	Neurofibrillary tangles;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg05091796	chr16:4465799	CORO7	-0.77	-12.47	-0.5	5.92e-31	Schizophrenia;
LGG	cis	rs12464483	0.591	rs2602775	chr2:30883012	C/T	cg17749961	chr2:30669863	LCLAT1	0.74	10.55	0.44	1.8e-23	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs3925075	0.934	rs9673522	chr16:31347648	T/C	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs9810089	0.802	rs73222302	chr3:136098085	A/G	cg21827317	chr3:136751795	NA	0.43	7.51	0.33	3.09e-13	Gestational age at birth (child effect);
LGG	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg16583315	chr14:65563665	MAX	0.39	7.7	0.34	8.04e-14	Obesity-related traits;
LGG	cis	rs9796	0.689	rs28409432	chr15:41447454	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.61	-0.41	4.83e-20	Menopause (age at onset);
LGG	cis	rs4687717	0.636	rs12494824	chr3:53279525	C/T	cg16894138	chr3:53270350	TKT	0.43	8.27	0.36	1.4e-15	Blood metabolite levels;Blood metabolite ratios;
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs62103177	0.525	rs4283293	chr18:77759582	A/G	cg20368463	chr18:77673604	PQLC1	-0.55	-7.9	-0.34	1.98e-14	Opioid sensitivity;
LGG	cis	rs7267979	1.000	rs910997	chr20:25267301	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6504108	0.560	rs2072441	chr17:46185014	C/G	cg02219949	chr17:45927392	SP6	0.4	7.6	0.33	1.64e-13	Body mass index;
LGG	cis	rs4242434	0.757	rs7005025	chr8:22519815	G/T	cg02227867	chr8:22457446	C8orf58	-0.44	-8.52	-0.37	2.3e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.4	-0.44	6.84e-23	Aortic root size;
LGG	cis	rs6141769	0.542	rs28730896	chr20:31295844	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.74	-0.3	4.61e-11	Subjective well-being;
LGG	cis	rs2963155	0.518	rs864355	chr5:142633229	A/G	cg17617527	chr5:142782415	NR3C1	0.97	13.26	0.52	2.93e-34	Breast cancer;
LGG	cis	rs10771431	0.597	rs10843142	chr12:9357502	A/G	cg08997352	chr12:9597637	DDX12	-0.76	-14.2	-0.55	3e-38	Breast size;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg17911788	chr17:44343683	NA	0.61	9.35	0.4	3.63e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7747724	0.715	rs6941727	chr6:20772574	T/C	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.48	-0.4	1.38e-19	Bladder cancer;
LGG	cis	rs8112449	0.719	rs7249459	chr19:10537092	C/T	cg21868191	chr19:10515988	NA	-0.47	-7.88	-0.34	2.29e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs992157	0.735	rs12990082	chr2:219102332	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.29	0.43	1.71e-22	Colorectal cancer;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg17470184	chr11:118478236	PHLDB1	0.43	7.74	0.34	6.17e-14	Cholesterol, total;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg20363904	chr8:22552821	NA	0.41	6.76	0.3	4.11e-11	Hip circumference;
LGG	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg22920501	chr2:26401640	FAM59B	-0.43	-9.05	-0.39	4.1e-18	Gut microbiome composition (summer);
LGG	cis	rs909674	0.818	rs8137426	chr22:39844350	T/G	cg04986931	chr22:39850128	NA	0.4	8.69	0.37	6.34e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.23	0.32	1.96e-12	Menopause (age at onset);
LGG	cis	rs4740619	0.933	rs10738404	chr9:15704715	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.19	-0.43	3.92e-22	Body mass index;
LGG	cis	rs4684776	0.935	rs13086126	chr3:11547936	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.23	-0.36	1.91e-15	Small vessel stroke;
LGG	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs887829	0.570	rs4553819	chr2:234594083	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.14	-0.35	3.77e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs1008375	1.000	rs1558377	chr4:17650758	A/G	cg18681998	chr4:17616180	MED28	0.87	20.33	0.69	3.74e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3087591	0.960	rs9903754	chr17:29634468	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.47	-0.56	2.05e-39	Hip circumference;
LGG	cis	rs9513627	1.000	rs6491511	chr13:100198717	C/A	cg15490075	chr13:100150979	NA	0.63	6.65	0.3	8.4e-11	Obesity-related traits;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9296092	0.522	rs62405955	chr6:33527176	T/C	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.0	-0.31	9.11e-12	Life satisfaction;
LGG	cis	rs9290065	0.519	rs7635796	chr3:160674689	G/C	cg04691961	chr3:161091175	C3orf57	-0.43	-9.01	-0.39	5.26e-18	Kawasaki disease;
LGG	cis	rs17021463	0.615	rs4626213	chr4:95297241	G/A	cg11021082	chr4:95130006	SMARCAD1	0.41	7.09	0.31	4.95e-12	Testicular germ cell tumor;
LGG	cis	rs6988985	0.533	rs6391	chr8:143956965	A/G	cg10324643	chr8:143916377	GML	0.4	8.07	0.35	6.03e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7937890	0.559	rs2597221	chr11:14527075	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg02187348	chr16:89574699	SPG7	0.59	9.79	0.41	1.06e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs910187	0.678	rs6122563	chr20:45813885	C/T	cg27589058	chr20:45804311	EYA2	-0.35	-9.14	-0.39	2e-18	Migraine;
LGG	cis	rs7929679	0.521	rs10768097	chr11:34792902	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.93	-0.31	1.45e-11	Schizophrenia;
LGG	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs4774899	0.966	rs11856073	chr15:57556261	T/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.15	-0.32	3.44e-12	Urinary tract infection frequency;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.7	-0.3	6.23e-11	Lung cancer;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs17428076	0.681	rs788163	chr2:172931559	A/C	cg21435375	chr2:172878103	MAP1D	0.38	8.41	0.36	5e-16	Myopia;
LGG	cis	rs6496044	0.611	rs8026938	chr15:86069118	G/T	cg13263323	chr15:86062960	AKAP13	0.38	8.3	0.36	1.16e-15	Interstitial lung disease;
LGG	cis	rs4919694	1.000	rs10509758	chr10:104681710	T/C	cg04362960	chr10:104952993	NT5C2	1.05	14.68	0.56	2.58e-40	Arsenic metabolism;
LGG	cis	rs8082590	1	rs8082590	chr17:17958402	G/A	cg05444541	chr17:17804740	TOM1L2	0.69	16.47	0.61	2.76e-48	Schizophrenia;
LGG	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.02	-0.52	3.11e-33	Schizophrenia;
LGG	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg07599136	chr5:415885	AHRR	0.77	10.54	0.44	2.03e-23	Fat distribution (HIV);
LGG	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg26354017	chr1:205819088	PM20D1	-0.45	-7.33	-0.32	1.07e-12	Parkinson's disease;
LGG	trans	rs7824557	0.872	rs2572431	chr8:11105077	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.09	-0.42	9e-22	Retinal vascular caliber;
LGG	cis	rs13202913	0.652	rs9383578	chr6:151838192	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.56	7.45	0.33	4.48e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.07	0.39	3.36e-18	Diabetic retinopathy;
LGG	cis	rs35110281	0.693	rs2251253	chr21:45092257	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.49	-0.4	1.2e-19	Mean corpuscular volume;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg23131131	chr22:24373011	LOC391322	-0.49	-8.19	-0.36	2.59e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.63	-0.67	7.28e-63	Height;
LGG	cis	rs7584262	0.737	rs7578091	chr2:42243480	G/C	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Bone mineral density;
LGG	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.3	-0.5	2.67e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg06848047	chr4:90757629	SNCA	-0.42	-7.95	-0.35	1.44e-14	Dementia with Lewy bodies;
LGG	cis	rs7084402	1.000	rs1427201	chr10:60269755	G/T	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	cis	rs8072100	0.840	rs56952963	chr17:45493826	T/C	cg25173405	chr17:45401733	C17orf57	-0.49	-8.5	-0.37	2.54e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12824058	0.831	rs12829373	chr12:130814114	G/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.33e-20	Menopause (age at onset);
LGG	cis	rs140839642	1	rs140839642	chr11:102728812	T/A	cg14995062	chr11:102826570	MMP13	0.48	6.89	0.3	1.89e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9894429	0.621	rs9747119	chr17:79607017	A/G	cg10661904	chr17:79619235	PDE6G	-0.51	-10.42	-0.44	5.68e-23	Eye color traits;
LGG	cis	rs10791323	0.517	rs1120247	chr11:133745180	T/G	cg00579200	chr11:133705235	NA	-0.51	-9.78	-0.41	1.15e-20	Childhood ear infection;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg03351412	chr1:154909251	PMVK	0.65	12.53	0.5	3.3e-31	Prostate cancer;
LGG	cis	rs963731	0.649	rs297147	chr2:39322942	C/T	cg04010122	chr2:39346883	SOS1	-0.77	-7.84	-0.34	3.13e-14	Corticobasal degeneration;
LGG	cis	rs2153535	0.580	rs6597325	chr6:8461053	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.51e-22	Motion sickness;
LGG	cis	rs10876993	0.890	rs774891	chr12:58068571	G/A	cg18357645	chr12:58087776	OS9	0.68	12.43	0.5	8.57e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9398803	0.613	rs6918725	chr6:126990392	T/G	cg19875578	chr6:126661172	C6orf173	0.47	8.5	0.37	2.57e-16	Male-pattern baldness;
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.17	0.55	4.21e-38	Tonsillectomy;
LGG	cis	rs965513	1.000	rs7027030	chr9:100550455	A/C	cg13688889	chr9:100608707	NA	-0.53	-9.7	-0.41	2.26e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs4919087	1.000	rs11189127	chr10:99079023	G/A	cg25902810	chr10:99078978	FRAT1	0.52	9.68	0.41	2.68e-20	Monocyte count;
LGG	cis	rs2953174	0.938	rs2953166	chr2:241539863	G/C	cg07929629	chr2:241523174	NA	0.56	6.7	0.3	6.02e-11	Bipolar disorder;
LGG	cis	rs55665837	1.000	rs12804549	chr11:14437758	A/T	cg19336497	chr11:14380999	RRAS2	-0.43	-8.4	-0.36	5.48e-16	Vitamin D levels;
LGG	cis	rs763121	0.925	rs1043312	chr22:39131727	T/G	cg06022373	chr22:39101656	GTPBP1	0.81	16.52	0.61	1.55e-48	Menopause (age at onset);
LGG	trans	rs3942852	0.606	rs10734561	chr11:48097480	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.47	-7.37	-0.32	7.72e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03685910	chr17:39844834	EIF1	0.55	8.59	0.37	1.35e-16	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg10760299	chr15:45669010	GATM	0.41	7.96	0.35	1.34e-14	Homoarginine levels;
LGG	cis	rs73086581	0.645	rs2103659	chr20:3982572	C/T	cg02187196	chr20:3869020	PANK2	-0.46	-7.03	-0.31	7.59e-12	Response to antidepressants in depression;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.58	-0.47	1.99e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs62045849	0.557	rs6500534	chr16:89190313	C/T	cg08015503	chr16:89190385	ACSF3	-0.65	-7.61	-0.33	1.5e-13	Red blood cell count;
LGG	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg02623684	chr3:5229378	EDEM1	0.41	6.79	0.3	3.38e-11	Response to antipsychotic treatment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21139845	chr12:7053993	C12orf57	0.44	7.47	0.33	4.09e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg20309703	chr11:118481025	PHLDB1	0.55	10.66	0.44	6.95e-24	Systemic lupus erythematosus;
LGG	cis	rs8077889	0.956	rs4793026	chr17:41850508	A/G	cg26893861	chr17:41843967	DUSP3	0.96	16.96	0.62	1.56e-50	Triglycerides;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1658489	chr10:60285924	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.81e-56	Refractive error;
LGG	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg08250081	chr4:10125330	NA	0.46	9.25	0.39	8.46e-19	Bone mineral density;
LGG	cis	rs6964587	0.692	rs6970629	chr7:91846599	T/C	cg17063962	chr7:91808500	NA	0.53	10.37	0.43	8.72e-23	Breast cancer;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.04	-0.31	6.97e-12	Electroencephalogram traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08330117	chr8:90770456	RIPK2	0.51	7.97	0.35	1.22e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg22535103	chr8:58192502	C8orf71	-0.79	-10.53	-0.44	2.25e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6547631	0.622	rs4240200	chr2:85925529	A/G	cg24620635	chr2:85921963	GNLY	0.51	10.16	0.43	5.16e-22	Blood protein levels;
LGG	cis	rs4959677	0.662	rs4959186	chr6:2477763	T/G	cg23817096	chr6:1620687	NA	-0.35	-8.58	-0.37	1.42e-16	Orthostatic hypotension;
LGG	cis	rs4917300	0.606	rs4917291	chr8:143115093	A/G	cg26003909	chr8:143102224	NA	-0.34	-7.0	-0.31	9.18e-12	Amyotrophic lateral sclerosis;
LGG	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06470251	chr20:60548479	NA	0.48	8.21	0.36	2.26e-15	Body mass index;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.25	-7.04	-0.31	6.98e-12	IgG glycosylation;
LGG	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	trans	rs459571	0.839	rs2519831	chr9:136886257	T/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.15	-0.49	1.15e-29	Platelet distribution width;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg03806693	chr22:41940476	POLR3H	-1.13	-20.48	-0.69	7.95e-67	Vitiligo;
LGG	cis	rs12971120	0.947	rs4891559	chr18:72170397	C/T	cg26446133	chr18:72167187	CNDP2	-0.75	-17.35	-0.63	2.63e-52	Refractive error;
LGG	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg02023728	chr11:77925099	USP35	0.44	7.66	0.34	1.13e-13	Testicular germ cell tumor;
LGG	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg09264619	chr17:80180166	NA	0.5	9.6	0.41	4.95e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg03538708	chr1:25844672	NA	0.35	6.7	0.3	6.09e-11	Erythrocyte sedimentation rate;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25467855	chr5:96271197	LNPEP	-0.39	-6.7	-0.3	6.03e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg20887711	chr4:1340912	KIAA1530	0.71	14.51	0.56	1.41e-39	Longevity;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.65	-11.48	-0.47	5.05e-27	Longevity;Endometriosis;
LGG	cis	rs7412746	0.658	rs10305714	chr1:150800655	C/T	cg15448220	chr1:150897856	SETDB1	-0.38	-7.07	-0.31	5.76e-12	Melanoma;
LGG	cis	rs6430585	0.528	rs79826902	chr2:136670419	G/A	cg07169764	chr2:136633963	MCM6	1.22	22.34	0.72	1.46e-75	Corneal structure;
LGG	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.45	-0.47	7e-27	Type 2 diabetes;
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs7017914	0.967	rs13271442	chr8:71585169	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.41e-11	Bone mineral density;
LGG	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg04492858	chr10:133558786	NA	0.43	8.75	0.38	4.02e-17	Survival in rectal cancer;
LGG	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.92	10.9	0.45	9.15e-25	Lung cancer in ever smokers;
LGG	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.34	-0.32	9.4e-13	Mood instability;
LGG	cis	rs35883536	0.647	rs7524322	chr1:101047730	C/G	cg06223162	chr1:101003688	GPR88	0.43	10.49	0.44	3.17e-23	Monocyte count;
LGG	trans	rs11098499	0.754	rs10213267	chr4:120239074	A/G	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.1e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24054938	chr1:153651301	NPR1	0.46	6.86	0.3	2.2e-11	Gut microbiome composition (summer);
LGG	cis	rs9560113	1.000	rs4773386	chr13:112180896	C/G	cg14154082	chr13:112174009	NA	0.42	9.24	0.39	9.01e-19	Menarche (age at onset);
LGG	cis	rs4006360	0.575	rs447608	chr17:39308497	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.62	-13.97	-0.54	2.82e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg08508325	chr11:3079039	CARS	-0.58	-12.06	-0.49	2.63e-29	Type 2 diabetes;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg08521684	chr3:195488725	MUC4	0.53	7.05	0.31	6.43e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs3096299	0.738	rs9929606	chr16:89527537	C/T	cg08392591	chr16:89556376	ANKRD11	0.51	7.97	0.35	1.26e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4696584	0.816	rs4696588	chr4:155405717	C/T	cg13738195	chr4:155413469	DCHS2	0.4	8.34	0.36	8.83e-16	Folding of antihelix;
LGG	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.7	-0.3	6.02e-11	Arsenic metabolism;
LGG	cis	rs9357271	0.736	rs4714160	chr6:38404140	C/T	cg07362130	chr6:38359646	BTBD9	-0.4	-8.23	-0.36	1.93e-15	Restless legs syndrome;
LGG	cis	rs738321	0.757	rs12329956	chr22:38535946	G/A	cg03162506	chr22:38580953	NA	0.4	9.7	0.41	2.25e-20	Breast cancer;
LGG	cis	rs6942756	1.000	rs73472312	chr7:128925217	T/C	cg02491457	chr7:128862824	NA	-0.76	-13.64	-0.54	7.26e-36	White matter hyperintensity burden;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg08677398	chr8:58056175	NA	0.51	7.81	0.34	3.73e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1497828	0.956	rs2646819	chr1:217525691	T/G	cg04411442	chr1:217543379	NA	-0.48	-8.2	-0.36	2.43e-15	Dialysis-related mortality;
LGG	cis	rs7177699	0.557	rs9920493	chr15:79113846	A/C	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs12681287	0.571	rs10097450	chr8:87358677	G/A	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs3206736	0.521	rs2057819	chr7:34944871	C/T	cg13400248	chr7:35225412	NA	0.52	8.93	0.38	1.04e-17	Diastolic blood pressure;
LGG	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg23461800	chr14:103021989	NA	-0.6	-10.73	-0.45	3.78e-24	Platelet count;
LGG	cis	rs2658782	0.789	rs3020076	chr11:93141058	C/T	cg15737290	chr11:93063684	CCDC67	0.51	7.7	0.34	8.6e-14	Pulmonary function decline;
LGG	cis	rs9878978	0.691	rs11716315	chr3:2502255	T/C	cg21928760	chr3:2462534	CNTN4	0.38	7.54	0.33	2.57e-13	Blood pressure (smoking interaction);
LGG	cis	rs8018808	0.875	rs11159258	chr14:77880593	T/C	cg20045696	chr14:77926864	AHSA1	0.42	7.05	0.31	6.61e-12	Myeloid white cell count;
LGG	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6089584	0.888	rs6142927	chr20:60605848	A/G	cg13770153	chr20:60521292	NA	-0.6	-9.25	-0.39	8.5e-19	Body mass index;
LGG	cis	rs2070488	0.804	rs13092164	chr3:38458533	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.69	0.56	2.14e-40	Electrocardiographic conduction measures;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg13047869	chr3:10149882	C3orf24	0.5	7.27	0.32	1.56e-12	Alzheimer's disease;
LGG	cis	rs1010254	0.510	rs72806396	chr5:151708325	G/A	cg12297329	chr5:152029980	NA	-0.51	-7.3	-0.32	1.3e-12	Optic nerve measurement (cup area);
LGG	cis	rs11098499	1.000	rs13116504	chr4:120209412	A/C	cg24375607	chr4:120327624	NA	0.62	10.17	0.43	4.78e-22	Corneal astigmatism;
LGG	trans	rs561341	1.000	rs7214017	chr17:30332220	T/C	cg27661571	chr11:113659931	NA	-0.66	-9.42	-0.4	2.17e-19	Hip circumference adjusted for BMI;
LGG	cis	rs6840360	0.606	rs10028035	chr4:152347825	T/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.06	0.31	6.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs877282	0.786	rs10904558	chr10:797509	C/T	cg17470449	chr10:769945	NA	0.6	7.68	0.34	9.37e-14	Uric acid levels;
LGG	trans	rs3857536	0.813	rs6931701	chr6:66940905	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs4936891	0.563	rs78294880	chr11:123890006	C/T	cg22125253	chr11:123886957	OR10G4	0.7	13.69	0.54	4.82e-36	Male fertility;
LGG	cis	rs875971	0.895	rs12698520	chr7:65918707	C/A	cg11764359	chr7:65958608	NA	0.8	14.92	0.57	2.17e-41	Aortic root size;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04836154	chr11:62439314	C11orf83;C11orf48	0.42	6.88	0.3	1.94e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs240764	0.507	rs9377193	chr6:101188198	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.42	0.33	5.62e-13	Neuroticism;
LGG	cis	rs8067545	0.611	rs2703781	chr17:20144714	A/G	cg13482628	chr17:19912719	NA	-0.53	-10.21	-0.43	3.24e-22	Schizophrenia;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs711245	0.699	rs3770818	chr2:36769497	T/G	cg10546459	chr2:36825355	FEZ2	0.46	6.67	0.3	7.25e-11	Height;
LGG	cis	rs2074193	0.627	rs215391	chr12:47765057	A/G	cg02516419	chr12:47771422	NA	-0.72	-10.6	-0.44	1.16e-23	Migraine with aura;
LGG	cis	rs2798269	0.966	rs35067197	chr13:22169323	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.43	-7.39	-0.32	6.97e-13	PR segment;
LGG	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.66e-11	Inflammatory skin disease;
LGG	cis	rs13191362	0.810	rs28360533	chr6:162996742	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.85	0.34	2.82e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7647973	0.593	rs58339610	chr3:49845006	T/A	cg13072238	chr3:49761600	GMPPB	0.52	7.02	0.31	7.95e-12	Menarche (age at onset);
LGG	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.27	-0.43	1.96e-22	Intelligence (multi-trait analysis);
LGG	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.2	0.32	2.48e-12	Schizophrenia;
LGG	cis	rs7814319	0.600	rs111300519	chr8:97262939	G/A	cg20787634	chr8:97240163	UQCRB	-0.67	-13.62	-0.53	9.54e-36	Lung function (FVC);
LGG	cis	rs6489882	0.867	rs7305035	chr12:113365803	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.39	-0.32	6.81e-13	Chronic lymphocytic leukemia;
LGG	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg05234568	chr11:5960015	NA	-0.71	-11.68	-0.48	8.08e-28	DNA methylation (variation);
LGG	cis	rs4076764	1.000	rs7528020	chr1:163426537	G/A	cg06092702	chr1:163392909	NA	-0.47	-8.39	-0.36	5.85e-16	Motion sickness;
LGG	cis	rs116095464	0.558	rs10065584	chr5:253997	G/A	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	cis	rs916888	0.821	rs70602	chr17:44859715	T/C	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28588043	0.877	rs114765529	chr1:170997401	G/T	cg03458344	chr1:170964477	C1orf129	-0.54	-7.25	-0.32	1.78e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs6988985	0.703	rs4736312	chr8:143953937	A/C	cg10324643	chr8:143916377	GML	0.38	7.73	0.34	6.81e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs727505	1.000	rs10264060	chr7:124486413	C/A	cg23710748	chr7:124431027	NA	-0.52	-9.88	-0.42	5.03e-21	Lewy body disease;
LGG	cis	rs6754311	0.731	rs13404551	chr2:136721995	T/C	cg07169764	chr2:136633963	MCM6	0.76	12.66	0.51	9.66e-32	Mosquito bite size;
LGG	cis	rs11018904	0.906	rs10501713	chr11:89953013	G/A	cg16176437	chr11:89678848	NA	0.41	6.94	0.31	1.36e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg03188948	chr7:1209495	NA	0.65	8.47	0.37	3.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7954584	0.546	rs10840630	chr12:122352445	C/T	cg13699009	chr12:122356056	WDR66	0.56	14.89	0.57	2.88e-41	Mean corpuscular volume;
LGG	cis	rs9814567	1.000	rs11919350	chr3:134235970	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.93	0.51	7.45e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg15395560	chr15:45543142	SLC28A2	0.42	6.81	0.3	2.98e-11	Glomerular filtration rate;
LGG	trans	rs12517041	0.935	rs10053181	chr5:23293265	A/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg06360820	chr2:242988706	NA	-0.91	-11.8	-0.48	2.78e-28	Obesity-related traits;
LGG	cis	rs61884328	0.852	rs17790390	chr11:47151897	A/G	cg03339077	chr11:47165057	C11orf49	-0.64	-7.04	-0.31	7.09e-12	Total body bone mineral density (age over 60);
LGG	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.45	-0.63	9.34e-53	Chronic sinus infection;
LGG	cis	rs35306767	0.903	rs11253467	chr10:901244	A/G	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.9e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7216064	0.906	rs1976052	chr17:65830578	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.32e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	cis	rs6692729	0.933	rs1295640	chr1:227070378	C/T	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.47	-0.37	3.18e-16	Obesity-related traits;
LGG	cis	rs113835537	0.735	rs519380	chr11:66409409	G/A	cg24851651	chr11:66362959	CCS	0.48	7.77	0.34	5.19e-14	Airway imaging phenotypes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg02182114	chr7:139876578	LOC100134229;JHDM1D	0.4	6.99	0.31	9.75e-12	Body mass index;
LGG	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg25883020	chr8:41504993	NKX6-3	0.31	6.79	0.3	3.45e-11	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs17102423	0.559	rs7160037	chr14:65490948	T/C	cg11161011	chr14:65562177	MAX	-0.77	-12.67	-0.51	8.5e-32	Obesity-related traits;
LGG	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg05527609	chr1:210001259	C1orf107	-0.58	-8.54	-0.37	1.95e-16	Orofacial clefts;
LGG	cis	rs6489785	0.547	rs625228	chr12:121278266	G/A	cg02419362	chr12:121203948	SPPL3	-0.51	-8.88	-0.38	1.51e-17	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg01324343	chr3:183735012	ABCC5	-0.65	-12.63	-0.51	1.23e-31	Anterior chamber depth;
LGG	trans	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.52e-28	Corneal astigmatism;
LGG	trans	rs2243480	1.000	rs160643	chr7:65558222	C/T	cg10756647	chr7:56101905	PSPH	0.7	9.2	0.39	1.22e-18	Diabetic kidney disease;
LGG	cis	rs4430311	0.723	rs6672195	chr1:243959543	T/C	cg25706552	chr1:244017396	NA	-0.65	-16.06	-0.6	1.8e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs7103648	0.742	rs34937994	chr11:47389638	C/T	cg20307385	chr11:47447363	PSMC3	0.92	20.5	0.69	5.92e-67	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg03342759	chr3:160939853	NMD3	0.69	11.49	0.47	4.69e-27	Parkinson's disease;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg16606324	chr3:10149918	C3orf24	0.65	7.34	0.32	9.83e-13	Alzheimer's disease;
LGG	cis	rs1125355	0.622	rs62183665	chr2:159646375	G/A	cg02251393	chr2:159651559	DAPL1	0.4	7.89	0.34	2.21e-14	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11966931	0.948	rs1607399	chr6:108089007	A/G	cg04749840	chr6:108095067	SCML4	-0.44	-7.49	-0.33	3.46e-13	Neutrophil percentage of white cells;
LGG	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	11.19	0.46	6.66e-26	Diabetic retinopathy;
LGG	cis	rs7072216	0.763	rs10883092	chr10:100167276	A/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.23	-0.32	1.97e-12	Metabolite levels;
LGG	cis	rs12210905	0.858	rs72838249	chr6:26998489	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs477895	0.838	rs72922039	chr11:64013116	A/C	cg04317338	chr11:64019027	PLCB3	0.66	7.94	0.35	1.56e-14	Mean platelet volume;
LGG	cis	rs4727027	0.933	rs1058059	chr7:148879134	A/T	cg23583168	chr7:148888333	NA	-0.88	-17.15	-0.62	2.17e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6502050	0.698	rs6502076	chr17:80121978	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9467711	0.591	rs28360595	chr6:26030044	A/G	cg21479132	chr6:26055353	NA	0.8	7.21	0.32	2.22e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg03452623	chr4:187889614	NA	-1.04	-30.53	-0.82	5.62e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7659604	0.539	rs2063165	chr4:122750005	A/G	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.49	-0.47	4.8400000000000004e-27	Type 2 diabetes;
LGG	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg19748678	chr4:122722346	EXOSC9	0.49	9.3	0.4	5.71e-19	Type 2 diabetes;
LGG	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg03264133	chr6:25882463	NA	-0.56	-10.33	-0.43	1.18e-22	Intelligence (multi-trait analysis);
LGG	cis	rs236352	0.576	rs3778017	chr6:36842183	C/T	cg03410223	chr6:36853544	C6orf89	0.44	8.44	0.37	4.1e-16	Heart rate;
LGG	cis	rs4975616	0.869	rs452384	chr5:1330840	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.39	-0.65	3.99e-57	Lung cancer;
LGG	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg17201900	chr20:34330562	RBM39	0.51	6.94	0.31	1.31e-11	Total cholesterol levels;
LGG	cis	rs853679	0.517	rs4713145	chr6:28106827	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.75	-0.34	5.82e-14	Depression;
LGG	cis	rs2865126	0.779	rs4516291	chr18:10758988	A/G	cg21165219	chr18:10698044	FAM38B	-0.45	-7.27	-0.32	1.51e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs7819412	0.558	rs4841483	chr8:10908354	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.33	-0.32	1.06e-12	Triglycerides;
LGG	cis	rs11264213	0.901	rs72661616	chr1:36370512	G/A	cg27506609	chr1:36549197	TEKT2	0.72	7.52	0.33	2.89e-13	Schizophrenia;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.46	8.72	0.38	5.13e-17	Obesity-related traits;
LGG	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06481639	chr22:41940642	POLR3H	-0.53	-7.9	-0.34	1.98e-14	Vitiligo;
LGG	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg13383153	chr19:36980459	ZNF566	-0.42	-7.02	-0.31	8.07e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg17830980	chr10:43048298	ZNF37B	-0.58	-13.04	-0.52	2.44e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs4716602	0.596	rs34977094	chr7:156160864	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.51	-0.4	1.04e-19	Anti-saccade response;
LGG	cis	rs9875589	0.509	rs2607761	chr3:14091428	A/G	cg19554555	chr3:13937349	NA	-0.56	-10.13	-0.43	6.55e-22	Ovarian reserve;
LGG	cis	rs2486288	0.656	rs62026703	chr15:45569929	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.91	-0.45	8.14e-25	Glomerular filtration rate;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg08888203	chr3:10149979	C3orf24	0.5	8.4	0.36	5.44e-16	Alzheimer's disease;
LGG	cis	rs11676348	0.776	rs11690316	chr2:219017462	A/G	cg00012203	chr2:219082015	ARPC2	-0.56	-10.03	-0.42	1.53e-21	Ulcerative colitis;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.71	0.54	3.71e-36	Obesity-related traits;
LGG	cis	rs7010267	0.740	rs1485289	chr8:119954279	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.33	-8.15	-0.35	3.32e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs6496044	0.568	rs6496066	chr15:86075462	A/C	cg10818794	chr15:86012489	AKAP13	-0.31	-6.7	-0.3	6.2e-11	Interstitial lung disease;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg16606324	chr3:10149918	C3orf24	0.54	7.05	0.31	6.48e-12	Alzheimer's disease;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg23034840	chr1:205782522	SLC41A1	0.56	9.09	0.39	2.82e-18	Menarche (age at onset);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg24583940	chr2:15507542	NBAS	-0.4	-6.74	-0.3	4.6e-11	Apolipoprotein A-IV levels;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.42e-16	Life satisfaction;
LGG	cis	rs17376456	0.877	rs10062711	chr5:93348659	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.23e-22	Diabetic retinopathy;
LGG	cis	rs11920090	0.932	rs5406	chr3:170723276	A/G	cg09710316	chr3:170744871	SLC2A2	-0.59	-8.43	-0.36	4.46e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.07	-0.31	5.71e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs975739	0.872	rs1279667	chr13:78364838	T/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.8	0.3	3.26e-11	Hair color;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs45544231	0.536	rs7190749	chr16:52544078	A/G	cg09051775	chr16:52580266	TOX3	-0.42	-6.83	-0.3	2.66e-11	Restless legs syndrome;
LGG	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg04727924	chr7:799746	HEATR2	-0.49	-7.2	-0.32	2.53e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10893109	0.517	rs6590017	chr11:123781044	G/A	cg12387464	chr11:123775935	OR8D4	0.39	8.44	0.37	4.06e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2832191	0.692	rs2776240	chr21:30310639	C/T	cg08807101	chr21:30365312	RNF160	0.89	18.94	0.66	1.16e-59	Dental caries;
LGG	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg11764359	chr7:65958608	NA	0.48	7.98	0.35	1.19e-14	Aortic root size;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg03576123	chr11:487126	PTDSS2	-1.22	-15.75	-0.59	4.41e-45	Body mass index;
LGG	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.04	0.31	7.15e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.04	-18.55	-0.65	7.84e-58	Chronic sinus infection;
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.85	-0.42	6.83e-21	Personality dimensions;
LGG	cis	rs9911578	0.967	rs11079368	chr17:57086473	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-16.43	-0.61	4.21e-48	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.618	rs6943788	chr7:139087697	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs11168618	0.810	rs6580671	chr12:48841057	G/A	cg24011408	chr12:48396354	COL2A1	0.49	7.96	0.35	1.37e-14	Adiponectin levels;
LGG	cis	rs7904368	0.754	rs7076955	chr10:16852781	G/A	cg14835575	chr10:16859367	RSU1	0.8	15.14	0.58	2.36e-42	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.49	-0.4	1.23e-19	Brugada syndrome;
LGG	cis	rs8114671	0.551	rs4911162	chr20:33411425	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.13	0.31	3.83e-12	Height;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg11245990	chr11:68621969	NA	0.41	8.74	0.38	4.35e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	7.87	0.34	2.58e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.72e-13	Aortic root size;
LGG	cis	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg18129748	chr3:49941408	MST1R	0.22	6.71	0.3	5.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	1.000	rs9306123	chr21:46709922	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.02	0.55	1.74e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg11878867	chr6:150167359	LRP11	-0.53	-10.89	-0.45	9.54e-25	Lung cancer;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18402987	chr7:1209562	NA	0.4	7.34	0.32	9.59e-13	Longevity;Endometriosis;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.77	-0.3	3.98e-11	Lung cancer;
LGG	cis	rs2836974	0.897	rs8132419	chr21:40527827	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs9354308	0.764	rs9345715	chr6:66603371	G/C	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs709400	0.628	rs6575984	chr14:103876454	A/G	cg12935359	chr14:103987150	CKB	0.4	6.67	0.3	7.33e-11	Body mass index;
LGG	cis	rs7580658	0.545	rs59318157	chr2:127950074	G/C	cg10021288	chr2:128175891	PROC	-0.45	-8.46	-0.37	3.44e-16	Protein C levels;
LGG	trans	rs6076960	0.684	rs6054058	chr20:6262187	T/C	cg17788362	chr6:86352627	SYNCRIP	0.55	9.77	0.41	1.27e-20	Smooth-surface caries;
LGG	cis	rs1982963	1.000	rs2749876	chr14:52504397	T/G	cg05884192	chr14:52515736	NID2	-0.34	-7.54	-0.33	2.56e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg20476274	chr7:133979776	SLC35B4	0.71	13.66	0.54	5.95e-36	Mean platelet volume;
LGG	cis	rs7474896	0.515	rs2738208	chr10:38306128	A/G	cg25427524	chr10:38739819	LOC399744	0.52	7.68	0.34	9.5e-14	Obesity (extreme);
LGG	cis	rs13082711	0.595	rs6783818	chr3:27361988	C/G	cg02860705	chr3:27208620	NA	0.92	16.92	0.62	2.34e-50	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.69	-0.44	5.58e-24	Height;
LGG	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg26818010	chr10:134567672	INPP5A	-0.77	-11.99	-0.49	5.15e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6743226	0.870	rs12624197	chr2:242254737	G/C	cg10021735	chr2:242295487	FARP2	0.54	9.78	0.41	1.14e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs7772486	0.875	rs9322048	chr6:146400439	A/G	cg23711669	chr6:146136114	FBXO30	0.38	6.68	0.3	6.81e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg19913688	chr11:428466	ANO9	-0.67	-8.23	-0.36	1.98e-15	Body mass index;
LGG	trans	rs75804782	0.625	rs10202089	chr2:239464695	G/A	cg01134436	chr17:81009848	B3GNTL1	0.67	7.19	0.32	2.6e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7107174	0.748	rs11237458	chr11:78050849	A/T	cg02023728	chr11:77925099	USP35	0.48	8.41	0.36	5.24e-16	Testicular germ cell tumor;
LGG	cis	rs1538970	0.781	rs10890330	chr1:45920406	G/A	cg05343316	chr1:45956843	TESK2	0.77	12.7	0.51	6.75e-32	Platelet count;
LGG	cis	rs889398	0.741	rs4146819	chr16:69923563	C/A	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.83	-0.3	2.72e-11	Body mass index;
LGG	trans	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg06521331	chr12:34319734	NA	-0.56	-9.61	-0.41	4.78e-20	Bladder cancer;
LGG	cis	rs13064447	0.845	rs11128610	chr3:12761123	G/T	cg23032965	chr3:12705835	RAF1	-0.5	-7.53	-0.33	2.62e-13	Major depression and alcohol dependence;
LGG	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg08885076	chr2:99613938	TSGA10	0.42	8.87	0.38	1.62e-17	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.91	0.59	8.93e-46	Lung cancer;
LGG	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg11693508	chr17:37793320	STARD3	0.63	9.04	0.39	4.28e-18	Bipolar disorder;
LGG	cis	rs7737355	0.812	rs12513768	chr5:130616792	G/A	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs911263	0.603	rs1956532	chr14:68783274	A/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.2	0.36	2.37e-15	Primary biliary cholangitis;
LGG	cis	rs7503807	0.688	rs12600403	chr17:78602477	A/T	cg18469159	chr17:78755841	RPTOR	-0.37	-6.87	-0.3	2.07e-11	Obesity;
LGG	cis	rs36071027	0.615	rs13189454	chr5:158410515	C/T	cg18496440	chr5:158532302	NA	0.41	6.94	0.31	1.31e-11	Carotid intima media thickness;
LGG	trans	rs1994135	0.669	rs11052746	chr12:33697473	A/C	cg26384229	chr12:38710491	ALG10B	-0.69	-12.79	-0.51	2.85e-32	Resting heart rate;
LGG	cis	rs9640161	0.830	rs17173682	chr7:150059602	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-10.55	-0.44	1.88e-23	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs774359	0.744	rs895022	chr9:27484371	G/C	cg14173147	chr9:27528300	MOBKL2B	0.47	8.76	0.38	3.72e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	12.21	0.49	6.45e-30	Rheumatoid arthritis;
LGG	cis	rs13314892	0.764	rs56764448	chr3:69860504	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.01	-0.31	8.3e-12	IgG glycosylation;
LGG	cis	rs1010254	0.559	rs114309942	chr5:151743915	G/A	cg12297329	chr5:152029980	NA	-0.47	-6.8	-0.3	3.34e-11	Optic nerve measurement (cup area);
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.602	rs6488864	chr12:123618362	G/C	cg05973401	chr12:123451056	ABCB9	0.46	6.78	0.3	3.62e-11	Neutrophil percentage of white cells;
LGG	cis	rs11674184	0.743	rs12470971	chr2:11725241	A/G	cg07314298	chr2:11723111	GREB1	0.86	20.96	0.7	4.44e-69	Endometriosis;
LGG	cis	rs9733	0.744	rs12568757	chr1:150729793	C/T	cg13175981	chr1:150552382	MCL1	0.53	8.72	0.38	4.85e-17	Tonsillectomy;
LGG	cis	rs9394438	0.628	rs2153947	chr6:37544930	A/G	cg00985040	chr6:37553208	NA	-0.35	-7.63	-0.33	1.39e-13	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11477847	chr17:4693856	NA	0.41	6.68	0.3	6.68e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1620921	0.625	rs12189741	chr6:161263528	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg15556689	chr8:8085844	FLJ10661	0.52	9.61	0.41	4.51e-20	Retinal vascular caliber;
LGG	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg06637938	chr14:75390232	RPS6KL1	0.57	10.53	0.44	2.14e-23	Height;
LGG	cis	rs4478858	0.595	rs4949387	chr1:31803440	T/A	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs4481887	0.508	rs6666148	chr1:248402758	C/T	cg00666640	chr1:248458726	OR2T12	0.46	6.97	0.31	1.08e-11	Common traits (Other);
LGG	cis	rs9815354	1.000	rs1716651	chr3:41975099	A/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.61e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.49e-14	Coronary artery disease;
LGG	cis	rs2836950	0.545	rs2836952	chr21:40616651	G/C	cg11644478	chr21:40555479	PSMG1	-0.6	-9.98	-0.42	2.17e-21	Menarche (age at onset);
LGG	cis	rs6831352	0.918	rs13112733	chr4:100050319	A/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs919433	0.783	rs788014	chr2:198228997	G/A	cg00792783	chr2:198669748	PLCL1	0.46	7.27	0.32	1.56e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs59918340	0.764	rs10107024	chr8:142227592	T/C	cg23750338	chr8:142222470	SLC45A4	0.58	11.86	0.48	1.65e-28	Immature fraction of reticulocytes;
LGG	cis	rs73787773	0.690	rs55641410	chr5:111478211	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.18	-0.32	2.71e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg12292205	chr6:26970375	C6orf41	0.51	9.74	0.41	1.56e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg03264133	chr6:25882463	NA	-0.72	-13.43	-0.53	5.71e-35	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg10483660	chr13:112241077	NA	-0.34	-6.86	-0.3	2.16e-11	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.33	-0.6	1.15e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2735413	0.918	rs7197254	chr16:78063353	C/G	cg04733911	chr16:78082701	NA	-0.77	-17.95	-0.64	4.75e-55	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs1814175	0.904	rs7924371	chr11:49620595	C/T	cg15704280	chr7:45808275	SEPT13	-1.06	-23.95	-0.74	4.64e-83	Height;
LGG	cis	rs11785693	0.865	rs11784227	chr8:4970485	A/C	cg26367366	chr8:4980734	NA	0.99	15.22	0.58	1.05e-42	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs72781680	0.898	rs72782106	chr2:24022009	A/G	cg08917208	chr2:24149416	ATAD2B	0.89	9.35	0.4	3.69e-19	Lymphocyte counts;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg05025164	chr4:1340916	KIAA1530	0.54	9.87	0.42	5.42e-21	Longevity;
LGG	cis	rs2404602	0.552	rs4886823	chr15:76965402	A/G	cg15268244	chr15:77196840	NA	0.43	8.33	0.36	9.53e-16	Blood metabolite levels;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg21782813	chr7:2030301	MAD1L1	0.53	13.81	0.54	1.43e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs4843185	0.669	rs889502	chr16:85716832	A/G	cg26571870	chr16:85723150	GINS2	-0.42	-7.56	-0.33	2.15e-13	Platelet distribution width;
LGG	cis	rs2916247	0.954	rs923041	chr8:93165420	C/T	cg10183463	chr8:93005414	RUNX1T1	0.35	7.05	0.31	6.74e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg26384229	chr12:38710491	ALG10B	0.67	13.4	0.53	7.46e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4481887	0.893	rs11204632	chr1:248479532	G/A	cg13385794	chr1:248469461	NA	0.5	8.3	0.36	1.14e-15	Common traits (Other);
LGG	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg06115741	chr20:33292138	TP53INP2	0.58	9.35	0.4	3.78e-19	Coronary artery disease;
LGG	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.35e-11	Cognitive ability;
LGG	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg17644776	chr2:200775616	C2orf69	0.59	6.76	0.3	4.2e-11	Schizophrenia;
LGG	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22857025	chr5:266934	NA	-1.42	-12.36	-0.5	1.65e-30	Asthma (childhood onset);
LGG	cis	rs6997458	0.967	rs13273654	chr8:86286557	A/G	cg02393479	chr8:86352350	CA3	-0.31	-6.78	-0.3	3.67e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Myopia (pathological);
LGG	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	11.27	0.46	3.45e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2236267	0.726	rs6574991	chr14:88603502	T/C	cg02175263	chr14:88627849	NA	0.32	7.32	0.32	1.09e-12	Food antigen IgG levels;
LGG	cis	rs711245	0.732	rs848643	chr2:36782387	G/A	cg09467607	chr2:36825704	FEZ2	0.44	8.55	0.37	1.76e-16	Height;
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg13047869	chr3:10149882	C3orf24	0.58	8.43	0.36	4.31e-16	Alzheimer's disease;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg19635926	chr16:89946313	TCF25	0.75	7.36	0.32	8.74e-13	Skin colour saturation;
LGG	cis	rs877426	0.681	rs113130895	chr13:114806184	C/T	cg27119904	chr13:114814333	RASA3	0.36	7.68	0.34	9.52e-14	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs3780486	0.713	rs3780489	chr9:33129844	G/T	cg20290983	chr6:43655470	MRPS18A	1.12	24.98	0.76	7.49e-88	IgG glycosylation;
LGG	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.87	-0.34	2.47e-14	Initial pursuit acceleration;
LGG	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg10792982	chr14:105748885	BRF1	0.56	11.12	0.46	1.23e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg14186256	chr22:23484241	RTDR1	1.0	25.79	0.77	1.36e-91	Bone mineral density;
LGG	cis	rs3219090	0.886	rs2793654	chr1:226601706	T/A	cg17127702	chr1:226594323	PARP1	0.38	12.34	0.5	1.85e-30	Melanoma;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	18.31	0.65	9.43e-57	Alzheimer's disease;
LGG	cis	rs3857536	0.704	rs7753493	chr6:66963871	A/G	cg07460842	chr6:66804631	NA	-0.43	-7.2	-0.32	2.49e-12	Blood trace element (Cu levels);
LGG	cis	rs4774899	0.752	rs2962991	chr15:57348776	A/G	cg08128148	chr15:57256372	TCF12	-0.29	-7.08	-0.31	5.41e-12	Urinary tract infection frequency;
LGG	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg21479132	chr6:26055353	NA	0.71	6.89	0.3	1.85e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1962073	0.528	rs4582610	chr8:10318343	T/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.93	-0.35	1.64e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs981844	0.689	rs6835372	chr4:154682056	T/C	cg14289246	chr4:154710475	SFRP2	-0.6	-10.49	-0.44	2.94e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg06917634	chr15:78832804	PSMA4	-0.64	-9.74	-0.41	1.67e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4356203	0.905	rs214939	chr11:17187539	A/G	cg15432903	chr11:17409602	KCNJ11	0.39	7.27	0.32	1.55e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs13031619	0.660	rs34855424	chr2:3702780	C/A	cg01268866	chr2:3683757	COLEC11	0.43	6.71	0.3	5.65e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg22907277	chr7:1156413	C7orf50	0.7	12.84	0.51	1.65e-32	Longevity;Endometriosis;
LGG	cis	rs478607	0.831	rs3825074	chr11:64415767	G/A	cg19395706	chr11:64412079	NRXN2	0.43	7.15	0.32	3.48e-12	Urate levels;
LGG	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg02269571	chr22:50332266	NA	-0.64	-10.2	-0.43	3.67e-22	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.85	0.34	2.86e-14	Lung cancer;
LGG	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	trans	rs6598955	0.671	rs11247909	chr1:26640135	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.63	-0.51	1.25e-31	Obesity-related traits;
LGG	cis	rs6489785	0.775	rs10774577	chr12:121364324	T/C	cg02419362	chr12:121203948	SPPL3	0.44	6.96	0.31	1.17e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.43	-0.33	5.28e-13	Height;
LGG	cis	rs7781557	1.000	rs11496066	chr7:102486254	T/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.56	-0.37	1.62e-16	Colorectal adenoma (advanced);
LGG	trans	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs9486715	0.838	rs6928442	chr6:96870118	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs10782582	0.593	rs12132750	chr1:76136222	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-6.9	-0.31	1.69e-11	Daytime sleep phenotypes;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg11766577	chr21:47581405	C21orf56	-0.5	-8.64	-0.37	9.27e-17	Testicular germ cell tumor;
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg13047869	chr3:10149882	C3orf24	0.4	7.15	0.32	3.3e-12	Alzheimer's disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23271606	chr7:92464891	CDK6	-0.39	-7.23	-0.32	1.95e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2251381	0.722	rs2776252	chr21:30531705	G/A	cg24692254	chr21:30365293	RNF160	0.82	16.64	0.61	4.58e-49	Selective IgA deficiency;
LGG	trans	rs5744897	0.867	rs5744773	chr12:133250550	C/T	cg04991071	chr3:71615924	FOXP1	0.66	7.25	0.32	1.75e-12	Urate levels in overweight individuals;
LGG	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg00646200	chr1:148855367	NA	-0.52	-10.28	-0.43	1.75e-22	Hip geometry;
LGG	cis	rs9397585	0.626	rs13215045	chr6:153447516	C/T	cg12989544	chr6:153429875	RGS17	0.3	6.83	0.3	2.61e-11	Body mass index;
LGG	cis	rs1983891	0.774	rs6935446	chr6:41514372	A/G	cg20194872	chr6:41519635	FOXP4	0.58	10.03	0.42	1.45e-21	Prostate cancer;
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	9.66	0.41	3.03e-20	Triglycerides;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07362569	chr17:61921086	SMARCD2	0.49	9.4	0.4	2.52e-19	Prudent dietary pattern;
LGG	cis	rs8032158	0.702	rs2288345	chr15:56122461	T/C	cg05129572	chr15:56138634	NEDD4	-0.4	-6.89	-0.3	1.87e-11	Keloid;
LGG	cis	rs1552244	0.554	rs2272121	chr3:10047680	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.42	0.5	8.89e-31	Alzheimer's disease;
LGG	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.55	0.37	1.82e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10895140	0.756	rs2508252	chr11:101486989	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs6061231	1.000	rs67941642	chr20:60958108	C/T	cg24112000	chr20:60950667	NA	-0.36	-7.83	-0.34	3.33e-14	Colorectal cancer;
LGG	cis	rs6495367	0.966	rs745029	chr15:79381779	C/T	cg17916960	chr15:79447300	NA	0.53	9.42	0.4	2.12e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9878978	0.722	rs35472449	chr3:2437323	C/T	cg21928760	chr3:2462534	CNTN4	0.39	7.79	0.34	4.44e-14	Blood pressure (smoking interaction);
LGG	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.53	-7.42	-0.33	5.75e-13	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.41	6.98	0.31	1.02e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.16	0.35	3.14e-15	Retinal vascular caliber;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg21641552	chr12:88535903	TMTC3;CEP290	0.42	6.93	0.31	1.39e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg25319279	chr11:5960081	NA	-0.56	-8.68	-0.37	7e-17	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03828693	chr10:63661686	ARID5B	0.39	6.75	0.3	4.55e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.12e-25	Homoarginine levels;
LGG	cis	rs7711186	0.655	rs75315590	chr5:178020818	A/T	cg17371294	chr5:178012716	COL23A1	-0.78	-7.66	-0.34	1.1e-13	Urate levels in obese individuals;
LGG	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.08	-0.35	5.68e-15	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12970008	chr11:3186095	OSBPL5	0.48	7.3	0.32	1.27e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03205495	chr19:14640249	TECR;MIR639	0.55	8.46	0.37	3.66e-16	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.966	rs11707895	chr3:47574937	G/A	cg27129171	chr3:47204927	SETD2	-0.78	-14.66	-0.56	2.92e-40	Colorectal cancer;
LGG	cis	rs1577917	1.000	rs35385043	chr6:86648546	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg09044154	chr16:88155775	NA	-0.5	-7.32	-0.32	1.14e-12	Menopause (age at onset);
LGG	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg17077180	chr1:38461687	NA	0.4	8.61	0.37	1.14e-16	Coronary artery disease;
LGG	cis	rs714031	0.934	rs4820387	chr22:40070446	A/G	cg21377881	chr22:40064566	CACNA1I	-0.6	-14.4	-0.56	4.21e-39	Schizophrenia;
LGG	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg26384229	chr12:38710491	ALG10B	0.91	20.4	0.69	1.74e-66	Bladder cancer;
LGG	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg08468577	chr11:2973342	NAP1L4	-0.41	-8.45	-0.37	3.71e-16	Calcium levels;
LGG	cis	rs2494938	0.730	rs1737679	chr6:40527525	G/A	cg14084896	chr6:40530702	LRFN2	-0.31	-6.74	-0.3	4.6e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg21782813	chr7:2030301	MAD1L1	0.47	10.99	0.46	3.84e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2694528	0.686	rs6885703	chr5:59862790	T/C	cg11474532	chr5:59995715	DEPDC1B	0.92	8.82	0.38	2.43e-17	Parkinson's disease;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg07701084	chr6:150067640	NUP43	0.66	12.34	0.5	2e-30	Lung cancer;
LGG	cis	rs7777754	0.512	rs11238131	chr7:50538589	T/C	cg14593290	chr7:50529359	DDC	-0.45	-8.47	-0.37	3.3e-16	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs2731664	0.792	rs2630765	chr5:176876825	T/C	cg23176889	chr5:176863531	GRK6	-0.65	-12.98	-0.52	4.59e-33	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs1856120	chr1:152512441	G/A	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs7618915	0.547	rs11709448	chr3:52647449	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.7e-12	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23503864	chr12:64616369	C12orf66	0.52	7.77	0.34	5.28e-14	Gut microbiome composition (summer);
LGG	cis	rs875971	0.545	rs4718348	chr7:65906576	A/G	cg11764359	chr7:65958608	NA	0.64	9.58	0.41	5.95e-20	Aortic root size;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg09699651	chr6:150184138	LRP11	0.51	8.85	0.38	1.86e-17	Lung cancer;
LGG	cis	rs11722228	0.549	rs55848383	chr4:10081117	C/A	cg08250081	chr4:10125330	NA	0.67	12.24	0.49	5.09e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg04156016	chr5:1868137	NA	0.32	7.11	0.31	4.39e-12	Cardiovascular disease risk factors;
LGG	trans	rs9325144	0.555	rs7960411	chr12:38703019	A/G	cg23762105	chr12:34175262	ALG10	0.34	6.88	0.3	1.95e-11	Morning vs. evening chronotype;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.79	-13.89	-0.54	6.29e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7829975	0.577	rs79495969	chr8:8545250	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.34	-0.32	9.38e-13	Mood instability;
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg22535103	chr8:58192502	C8orf71	-0.79	-9.86	-0.42	5.89e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs3741798	0.901	rs61922024	chr12:12485881	C/A	cg08615371	chr12:12503544	MANSC1	0.6	6.86	0.3	2.28e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25437947	chr8:17941982	ASAH1	-0.51	-8.18	-0.36	2.73e-15	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02786417	chr19:15218144	SYDE1	0.47	7.01	0.31	8.57e-12	Gut microbiome composition (summer);
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg00960700	chr17:80709150	TBCD	0.39	6.69	0.3	6.38e-11	Glycated hemoglobin levels;
LGG	cis	rs10927875	1.000	rs3979179	chr1:16306846	A/G	cg21385522	chr1:16154831	NA	0.82	14.75	0.57	1.22e-40	Dilated cardiomyopathy;
LGG	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg14882966	chr2:3699353	NA	0.89	9.15	0.39	1.78e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg01017244	chr2:74357527	NA	0.46	8.58	0.37	1.4e-16	Gestational age at birth (maternal effect);
LGG	cis	rs2302729	0.790	rs10505724	chr12:2782070	C/T	cg19945202	chr12:2788847	CACNA1C	-0.82	-10.01	-0.42	1.75e-21	Sleep quality;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg07308232	chr7:1071921	C7orf50	-0.57	-10.45	-0.44	4.42e-23	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg26338869	chr17:61819248	STRADA	0.59	9.86	0.42	6.16e-21	Prudent dietary pattern;
LGG	cis	rs6541297	0.645	rs2296065	chr1:230301776	G/A	cg05784532	chr1:230284198	GALNT2	0.47	7.2	0.32	2.51e-12	Coronary artery disease;
LGG	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg09307838	chr4:120376055	NA	0.79	13.09	0.52	1.52e-33	Corneal astigmatism;
LGG	cis	rs11170631	0.504	rs10128880	chr12:53927783	T/C	cg06632207	chr12:54070931	ATP5G2	0.22	6.81	0.3	3.09e-11	Height;
LGG	cis	rs7666738	0.830	rs28878289	chr4:98855181	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22455342	chr2:225449267	CUL3	0.85	14.86	0.57	3.87e-41	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.12	-0.35	4.21e-15	IgG glycosylation;
LGG	cis	rs7267979	1.000	rs4815424	chr20:25390284	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs68170813	0.652	rs6947674	chr7:107193504	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.49	-0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs17767392	0.958	rs12894478	chr14:71825113	T/C	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.59e-18	Mitral valve prolapse;
LGG	cis	rs9611565	0.649	rs5758434	chr22:42116163	G/A	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.89e-41	Vitiligo;
LGG	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg24308560	chr3:49941425	MST1R	0.22	6.84	0.3	2.51e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg22903471	chr2:27725779	GCKR	-0.58	-13.19	-0.52	5.77e-34	Total body bone mineral density;
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg16680214	chr1:154839983	KCNN3	-0.47	-9.24	-0.39	9.02e-19	Prostate cancer;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.41	-0.47	9.92e-27	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15806518	chr9:127177817	PSMB7	0.43	6.91	0.31	1.59e-11	Cognitive performance;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg18621852	chr3:10150065	C3orf24	0.39	6.65	0.3	8.04e-11	Alzheimer's disease;
LGG	cis	rs2576037	0.583	rs11660085	chr18:44529603	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.52	8.87	0.38	1.65e-17	Personality dimensions;
LGG	cis	rs4919087	0.590	rs1253396	chr10:99045230	C/T	cg25902810	chr10:99078978	FRAT1	-0.43	-7.07	-0.31	5.63e-12	Monocyte count;
LGG	cis	rs1707322	1.000	rs785506	chr1:46540652	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.81	-0.41	9.31e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs757081	0.606	rs679201	chr11:17200891	T/C	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.0	-0.39	5.95e-18	Systolic blood pressure;
LGG	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03264133	chr6:25882463	NA	0.54	9.92	0.42	3.68e-21	Blood metabolite levels;
LGG	cis	rs2235642	0.533	rs2667679	chr16:1654946	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.21	0.32	2.24e-12	Coronary artery disease;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs4930561	0.765	rs1894204	chr11:67929671	C/T	cg16338278	chr11:67432957	ALDH3B2	0.42	7.91	0.35	1.91e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs17014483	0.749	rs3017899	chr4:89643997	C/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.58	6.65	0.3	8.44e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs975722	0.638	rs1429563	chr7:117322912	C/T	cg10524701	chr7:117356490	CTTNBP2	0.48	9.74	0.41	1.63e-20	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08179428	chr15:75745131	SIN3A	0.5	7.32	0.32	1.08e-12	Gut microbiome composition (summer);
LGG	cis	rs7503807	0.515	rs12948040	chr17:78678434	A/G	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	trans	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg05059571	chr16:84539110	KIAA1609	0.53	9.96	0.42	2.7e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3741151	0.773	rs58334887	chr11:73171510	A/C	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	trans	rs7812879	0.636	rs2618458	chr8:11369068	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-7.3	-0.32	1.23e-12	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.42	-0.36	4.92e-16	Retinal vascular caliber;
LGG	cis	rs2120243	0.504	rs1824058	chr3:157124780	C/A	cg24825693	chr3:157122686	VEPH1	-0.58	-13.38	-0.53	9.11e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6665290	0.904	rs1343743	chr1:227183125	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.96	-0.91	1.19e-174	Myeloid white cell count;
LGG	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	7.67	0.34	1.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.34	0.4	4.21e-19	Bipolar disorder;
LGG	cis	rs1816752	0.776	rs7998843	chr13:25017285	T/C	cg22771759	chr13:24902376	NA	0.41	7.04	0.31	6.92e-12	Obesity-related traits;
LGG	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg16751781	chr15:78858589	CHRNA5	-0.45	-8.87	-0.38	1.64e-17	Sudden cardiac arrest;
LGG	cis	rs9318086	0.712	rs9510917	chr13:24442846	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.48	9.33	0.4	4.45e-19	Myopia (pathological);
LGG	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.83e-22	Axial length;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.94	0.35	1.5e-14	Prudent dietary pattern;
LGG	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.88	0.3	1.97e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7681440	0.904	rs2301134	chr4:90758945	A/G	cg20003494	chr4:90757398	SNCA	-0.44	-8.8	-0.38	2.82e-17	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.851	rs4819049	chr21:46673086	C/G	cg06618935	chr21:46677482	NA	-0.48	-9.47	-0.4	1.4e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7727544	0.660	rs274563	chr5:131717859	C/A	cg24060327	chr5:131705240	SLC22A5	0.48	8.21	0.36	2.25e-15	Blood metabolite levels;
LGG	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.35e-17	Hypertriglyceridemia;
LGG	cis	rs10754283	0.870	rs2390764	chr1:90112827	T/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	7.72	0.34	7.07e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg13010199	chr12:38710504	ALG10B	-0.51	-10.08	-0.42	9.81e-22	Bladder cancer;
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg03665457	chr10:38645376	HSD17B7P2	0.47	7.44	0.33	4.81e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs654950	0.901	rs594656	chr1:41999873	C/T	cg16096631	chr1:42092165	HIVEP3	-0.45	-9.37	-0.4	3.09e-19	Airway imaging phenotypes;
LGG	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	4.06e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg16576597	chr16:28551801	NUPR1	-0.33	-7.26	-0.32	1.7e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs16944613	0.541	rs10852135	chr15:91106412	T/C	cg22089800	chr15:90895588	ZNF774	-0.58	-7.05	-0.31	6.63e-12	Colorectal cancer;
LGG	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg04986931	chr22:39850128	NA	0.32	7.3	0.32	1.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg27432699	chr2:27873401	GPN1	-0.5	-8.58	-0.37	1.5e-16	Menopause (age at onset);
LGG	cis	rs7267979	1.000	rs6050562	chr20:25336186	C/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.86e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs8060686	0.545	rs3815173	chr16:68160289	T/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7227917	0.536	rs72916012	chr18:45510910	C/T	cg22195133	chr18:45534586	NA	0.77	7.0	0.31	9.3e-12	Lung cancer in ever smokers;
LGG	cis	rs77633900	0.614	rs280024	chr15:77034518	A/C	cg21673338	chr15:77095150	SCAPER	-0.67	-10.39	-0.43	7.04e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg04568710	chr12:38710424	ALG10B	0.37	7.92	0.35	1.78e-14	Morning vs. evening chronotype;
LGG	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg20578329	chr17:80767326	TBCD	-0.45	-7.94	-0.35	1.57e-14	Breast cancer;
LGG	cis	rs7617773	0.815	rs6793150	chr3:48351560	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.58	-9.11	-0.39	2.49e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg27286337	chr10:134555280	INPP5A	0.87	12.92	0.51	8.06e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9400467	0.506	rs12190135	chr6:111698204	T/C	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs736801	0.808	rs72797303	chr5:131796163	T/C	cg21138405	chr5:131827807	IRF1	-0.28	-6.76	-0.3	4.18e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs9677476	0.644	rs12470661	chr2:232060050	A/G	cg14237567	chr2:232057245	NA	-0.33	-6.76	-0.3	4.29e-11	Food antigen IgG levels;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg16339924	chr4:17578868	LAP3	0.64	10.94	0.45	6.06e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7264396	0.635	rs6060675	chr20:34493614	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.16	-0.32	3.29e-12	Total cholesterol levels;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.96e-13	Life satisfaction;
LGG	cis	rs12618769	0.597	rs1961651	chr2:99049674	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.49	0.37	2.79e-16	Bipolar disorder;
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.67	-0.3	7.33e-11	Aortic root size;
LGG	cis	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.74	-0.38	4.42e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg14222797	chr10:16859974	RSU1	-0.7	-7.82	-0.34	3.48e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.43	7.23	0.32	2.03e-12	Longevity;
LGG	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.85	13.67	0.54	5.77e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9443645	0.869	rs4706080	chr6:79760997	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.46	-0.37	3.58e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg17809284	chr5:56205270	C5orf35	-0.55	-8.94	-0.38	9.18e-18	Initial pursuit acceleration;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg23302884	chr18:44338147	ST8SIA5	0.46	9.15	0.39	1.82e-18	Personality dimensions;
LGG	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs2985684	0.894	rs6572585	chr14:50021075	A/G	cg02151108	chr14:50098012	C14orf104	-0.41	-8.84	-0.38	1.97e-17	Carotid intima media thickness;
LGG	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg08847335	chr10:891726	LARP4B	-0.47	-8.55	-0.37	1.8e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs9309473	0.607	rs7574291	chr2:73594941	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-8.47	-0.37	3.23e-16	Metabolite levels;
LGG	cis	rs9796	0.689	rs9888718	chr15:41446254	T/G	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.63	-0.41	4e-20	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-8.02	-0.35	8.99e-15	Skin colour saturation;
LGG	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg08344181	chr3:125677491	NA	-0.64	-7.65	-0.33	1.16e-13	Depression;
LGG	cis	rs509477	1.000	rs505763	chr18:32558879	G/A	cg23791764	chr18:32556832	MAPRE2	0.51	8.46	0.37	3.45e-16	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7647973	0.626	rs62260720	chr3:49853796	T/A	cg03060546	chr3:49711283	APEH	-0.6	-8.17	-0.36	2.9e-15	Menarche (age at onset);
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.2	0.46	6.09e-26	Personality dimensions;
LGG	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.91	-0.31	1.64e-11	Neuroticism;
LGG	cis	rs9513627	0.920	rs7984052	chr13:100177225	G/A	cg15490075	chr13:100150979	NA	0.64	6.8	0.3	3.19e-11	Obesity-related traits;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg05941027	chr17:61774174	LIMD2	0.35	8.92	0.38	1.1e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25946869	chr12:113796432	PLBD2	0.47	7.13	0.31	3.78e-12	Gut microbiome composition (summer);
LGG	cis	rs62400317	0.859	rs12205905	chr6:45178498	T/C	cg18551225	chr6:44695536	NA	-0.62	-9.9	-0.42	4.37e-21	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08667777	chr3:51422532	MANF	0.45	6.76	0.3	4.09e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-15.17	-0.58	1.69e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01395402	chr3:63898123	ATXN7	0.45	6.65	0.3	8.2e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.61	-0.33	1.56e-13	Prudent dietary pattern;
LGG	cis	rs372883	0.648	rs1153288	chr21:30686091	A/G	cg24692254	chr21:30365293	RNF160	0.64	11.56	0.47	2.51e-27	Pancreatic cancer;
LGG	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg20587970	chr11:113659929	NA	-1.31	-24.43	-0.75	2.59e-85	Hip circumference adjusted for BMI;
LGG	cis	rs774359	0.711	rs10967965	chr9:27497988	A/T	cg14173147	chr9:27528300	MOBKL2B	0.52	9.47	0.4	1.5e-19	Amyotrophic lateral sclerosis;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg16268157	chr7:99778414	STAG3	-0.48	-8.11	-0.35	4.45e-15	Lung function (FEV1/FVC);
LGG	cis	rs10905065	0.965	rs10795541	chr10:5811954	A/G	cg11519256	chr10:5708881	ASB13	-0.4	-7.02	-0.31	8.11e-12	Menopause (age at onset);
LGG	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.46	-0.47	5.93e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs7100689	0.725	rs10749574	chr10:82136856	T/C	cg01528321	chr10:82214614	TSPAN14	0.96	17.02	0.62	7.94e-51	Post bronchodilator FEV1;
LGG	cis	rs11158026	0.757	rs9285583	chr14:55431435	T/C	cg04306507	chr14:55594613	LGALS3	0.31	6.82	0.3	2.92e-11	Parkinson's disease;
LGG	cis	rs12765878	0.580	rs2295786	chr10:105616482	A/T	cg11005552	chr10:105648138	OBFC1	-0.71	-12.35	-0.5	1.79e-30	Coronary artery disease;
LGG	cis	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg16400903	chr5:693638	TPPP	0.45	6.8	0.3	3.23e-11	Obesity-related traits;
LGG	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	7.86e-13	Platelet count;
LGG	cis	rs2404602	0.647	rs10152247	chr15:76942252	T/G	cg23625390	chr15:77176239	SCAPER	-0.72	-14.49	-0.56	1.75e-39	Blood metabolite levels;
LGG	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg07005078	chr4:17578674	LAP3	0.36	6.75	0.3	4.5e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg18755752	chr8:142205143	DENND3	-0.49	-9.98	-0.42	2.31e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg15596359	chr8:11213517	TDH	-0.35	-7.1	-0.31	4.65e-12	Retinal vascular caliber;
LGG	cis	rs6735179	0.579	rs13396623	chr2:1758481	T/C	cg10160682	chr2:1713001	PXDN	-0.54	-9.59	-0.41	5.55e-20	Response to antipsychotic treatment;
LGG	trans	rs800082	0.668	rs9821986	chr3:144292701	T/G	cg24215973	chr2:240111563	HDAC4	-0.64	-12.6	-0.51	1.61e-31	Smoking behavior;
LGG	cis	rs7551222	0.752	rs16853865	chr1:204465659	A/G	cg20240347	chr1:204465584	NA	-0.58	-11.43	-0.47	8.25e-27	Schizophrenia;
LGG	cis	rs7143963	1.000	rs72704731	chr14:103358070	A/C	cg23020514	chr14:103360112	TRAF3	0.51	9.74	0.41	1.65e-20	Body mass index;
LGG	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg20336341	chr7:50628841	DDC	-0.44	-7.74	-0.34	6.39e-14	Malaria;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.88	-0.42	5.1e-21	Lung cancer;
LGG	cis	rs11169225	0.724	rs7305290	chr12:50341465	A/G	cg09002919	chr12:50339186	NA	0.4	7.12	0.31	4.21e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg15971980	chr6:150254442	NA	0.45	8.46	0.37	3.52e-16	Lung cancer;
LGG	cis	rs754466	0.606	rs11002310	chr10:79596030	A/C	cg17075019	chr10:79541650	NA	-0.97	-20.68	-0.69	8.5e-68	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.74	12.89	0.51	1.11e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs72772090	1.000	rs72772092	chr5:96046912	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.44	-7.05	-0.31	6.64e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs889398	0.771	rs1566453	chr16:69899787	C/T	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.85	-0.3	2.34e-11	Body mass index;
LGG	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg05696931	chr1:227175867	NA	-0.39	-7.69	-0.34	8.92e-14	Myeloid white cell count;
LGG	cis	rs4356932	1.000	rs6840980	chr4:76985331	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs2071426	0.755	rs1934952	chr10:96797500	A/G	cg09036531	chr10:96991505	NA	0.43	7.15	0.32	3.4e-12	Blood metabolite levels;
LGG	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.07e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7635838	0.750	rs2648463	chr3:11403857	G/A	cg00170343	chr3:11313890	ATG7	0.46	7.92	0.35	1.82e-14	HDL cholesterol;
LGG	cis	rs11630290	0.736	rs7177695	chr15:64140228	C/T	cg12036633	chr15:63758958	NA	-0.6	-7.02	-0.31	8.15e-12	Iris characteristics;
LGG	trans	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.7	-0.64	6.43e-54	Exhaled nitric oxide output;
LGG	cis	rs1953600	0.870	rs2788296	chr10:81937889	G/A	cg04850286	chr10:81895943	PLAC9	0.44	9.81	0.41	8.85e-21	Sarcoidosis;
LGG	cis	rs2976388	0.692	rs1435453	chr8:143780775	C/T	cg06565975	chr8:143823917	SLURP1	0.35	8.85	0.38	1.9e-17	Urinary tract infection frequency;
LGG	trans	rs7395662	0.500	rs1304199	chr11:48699032	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-10.92	-0.45	7.63e-25	HDL cholesterol;
LGG	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.14e-20	Mean corpuscular volume;
LGG	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg01324343	chr3:183735012	ABCC5	0.59	11.14	0.46	1.04e-25	Anterior chamber depth;
LGG	cis	rs2594989	0.943	rs346072	chr3:11306851	A/G	cg01796438	chr3:11312864	ATG7	0.62	8.41	0.36	5.29e-16	Circulating chemerin levels;
LGG	cis	rs34172651	0.917	rs2112786	chr16:24778944	C/T	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.5	-0.33	3.21e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7715806	0.500	rs10515213	chr5:74980572	C/T	cg19683494	chr5:74908142	NA	-0.51	-6.84	-0.3	2.5e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9457247	0.967	rs86755	chr6:167403108	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs12586317	0.620	rs12437439	chr14:35585669	C/A	cg16230307	chr14:35515116	FAM177A1	0.91	13.53	0.53	2.16e-35	Psoriasis;
LGG	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12923728	chr3:195709715	SDHAP1	-0.73	-12.43	-0.5	8.46e-31	Pancreatic cancer;
LGG	cis	rs9309473	0.950	rs2947860	chr2:73855386	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-6.98	-0.31	1.04e-11	Metabolite levels;
LGG	cis	rs1008375	1.000	rs10939746	chr4:17684951	A/G	cg18681998	chr4:17616180	MED28	-0.82	-18.24	-0.65	2.08e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg10207240	chr12:122356781	WDR66	-0.24	-7.46	-0.33	4.29e-13	Mean corpuscular volume;
LGG	cis	rs6920372	0.748	rs12528392	chr6:110068614	G/A	cg16315928	chr6:109776240	MICAL1	0.43	7.46	0.33	4.41e-13	Height;
LGG	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	14.5	0.56	1.44e-39	Platelet count;
LGG	cis	rs3008870	1.000	rs2815370	chr1:67503727	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.05	-21.39	-0.71	4.08e-71	Lymphocyte percentage of white cells;
LGG	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg11843606	chr2:227700838	RHBDD1	-0.56	-10.23	-0.43	2.7e-22	Pulmonary function;
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs10267417	0.603	rs10950762	chr7:19912203	A/G	cg05791153	chr7:19748676	TWISTNB	0.54	7.05	0.31	6.67e-12	Night sleep phenotypes;
LGG	cis	rs36051895	0.632	rs7032616	chr9:5180996	T/C	cg02405213	chr9:5042618	JAK2	-0.79	-15.5	-0.58	5.89e-44	Pediatric autoimmune diseases;
LGG	cis	rs7954584	0.626	rs12809676	chr12:122442381	C/A	cg22168489	chr12:122356033	WDR66	0.41	9.27	0.4	6.97e-19	Mean corpuscular volume;
LGG	cis	rs4423214	1.000	rs12808368	chr11:71170817	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.13	-0.52	1.09e-33	Vitamin D levels;
LGG	cis	rs6489785	0.775	rs683091	chr12:121294744	T/C	cg02419362	chr12:121203948	SPPL3	-0.44	-6.85	-0.3	2.42e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11971779	0.584	rs6942519	chr7:139070090	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg27532560	chr4:187881888	NA	-0.6	-13.56	-0.53	1.57e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6466055	0.777	rs6466053	chr7:104923929	C/T	cg04380332	chr7:105027541	SRPK2	0.38	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.53	0.4	9.11e-20	Fuchs's corneal dystrophy;
LGG	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg18357526	chr6:26021779	HIST1H4A	0.63	11.32	0.47	2.21e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11683229	0.852	rs11685079	chr2:63374600	C/T	cg19915305	chr2:64069682	UGP2	-0.48	-7.25	-0.32	1.72e-12	Protein quantitative trait loci;
LGG	trans	rs7395662	0.658	rs8189235	chr11:48740064	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.09	0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs908922	0.742	rs499913	chr1:152476743	T/A	cg20991723	chr1:152506922	NA	-0.58	-9.54	-0.41	7.99e-20	Hair morphology;
LGG	cis	rs9296092	0.500	rs9469503	chr6:33527234	G/T	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs16937	0.574	rs10900455	chr1:205123534	T/C	cg00889227	chr1:205173544	DSTYK	-0.3	-7.62	-0.33	1.46e-13	Schizophrenia;
LGG	cis	rs2153535	0.580	rs9505446	chr6:8448691	T/C	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs71403859	0.502	rs34015581	chr16:71508229	T/A	cg08717414	chr16:71523259	ZNF19	-1.35	-18.84	-0.66	3.57e-59	Post bronchodilator FEV1;
LGG	cis	rs9814567	1.000	rs2370641	chr3:134222161	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.29	-0.53	2.3e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8016982	0.634	rs1035948	chr14:81682392	C/T	cg01989461	chr14:81687754	GTF2A1	0.79	19.67	0.67	4.46e-63	Schizophrenia;
LGG	cis	rs5750830	0.594	rs5757647	chr22:39775047	C/A	cg04986931	chr22:39850128	NA	0.35	7.68	0.34	9.57e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17598690	chr6:40555076	LRFN2	0.43	6.7	0.3	6.02e-11	Gut microbiome composition (summer);
LGG	cis	rs1534166	1.000	rs1534166	chr3:133537067	C/T	cg27366882	chr3:133540807	NA	0.49	9.23	0.39	9.87e-19	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs853679	0.517	rs12174753	chr6:28042465	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.72	-0.34	7.22e-14	Depression;
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg26354017	chr1:205819088	PM20D1	-0.73	-17.05	-0.62	5.92e-51	Monocyte percentage of white cells;
LGG	cis	rs1650123	1.000	rs1650123	chr12:104034319	C/T	cg23227824	chr12:103980017	STAB2	0.33	7.4	0.33	6.32e-13	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs2272123	chr3:10140115	G/A	cg13047869	chr3:10149882	C3orf24	0.56	9.37	0.4	3.28e-19	Alzheimer's disease;
LGG	cis	rs6594713	0.684	rs1816062	chr5:112856023	A/C	cg12552261	chr5:112820674	MCC	0.63	7.79	0.34	4.35e-14	Brain cytoarchitecture;
LGG	cis	rs7100689	0.646	rs1572819	chr10:82112488	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	13.9	0.54	5.95e-37	Post bronchodilator FEV1;
LGG	cis	rs7208859	0.673	rs36056619	chr17:29172284	T/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.76	0.3	4.22e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9487094	0.670	rs11752791	chr6:109885646	G/T	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.6	0.69	2.1e-67	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25612183	chr2:39893438	TMEM178	0.47	7.02	0.31	7.72e-12	Gut microbiome composition (summer);
LGG	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	cis	rs796364	1.000	rs11680723	chr2:200810957	C/G	cg23649088	chr2:200775458	C2orf69	-0.59	-7.22	-0.32	2.16e-12	Schizophrenia;
LGG	cis	rs5995756	0.666	rs3788567	chr22:40006035	G/T	cg21377881	chr22:40064566	CACNA1I	-0.33	-6.86	-0.3	2.18e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs804280	1.000	rs804281	chr8:11611865	A/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.84	-0.3	2.48e-11	Myopia (pathological);
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.6	-10.16	-0.43	5.1e-22	Longevity;Endometriosis;
LGG	cis	rs922692	0.715	rs11632102	chr15:79086057	G/A	cg00540400	chr15:79124168	NA	-0.4	-7.69	-0.34	8.65e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs35538253	0.522	rs12934297	chr16:72022821	A/G	cg03805757	chr16:71968109	PKD1L3	-0.7	-9.27	-0.4	6.84e-19	Post bronchodilator FEV1;
LGG	cis	rs1843834	0.931	rs10170573	chr2:225552916	A/G	cg22455342	chr2:225449267	CUL3	0.57	9.65	0.41	3.44e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg08125733	chr17:73851984	WBP2	0.43	7.19	0.32	2.67e-12	White matter hyperintensity burden;
LGG	cis	rs17445240	0.901	rs13418767	chr2:3704830	G/T	cg14882966	chr2:3699353	NA	0.71	7.71	0.34	7.94e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-8.17	-0.35	3.04e-15	Lung cancer;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg18099408	chr3:52552593	STAB1	-0.33	-6.83	-0.3	2.73e-11	Bipolar disorder;
LGG	cis	rs7444	0.941	rs5998599	chr22:21941981	A/G	cg22858872	chr22:21984481	YDJC	-0.36	-6.67	-0.3	7.47e-11	Systemic lupus erythematosus;
LGG	cis	rs3816788	0.774	rs11784816	chr8:21773500	C/T	cg17168535	chr8:21777572	XPO7	-0.72	-13.69	-0.54	4.51e-36	Lung cancer in ever smokers;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg06558623	chr16:89946397	TCF25	1.13	12.3	0.5	2.8e-30	Skin colour saturation;
LGG	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.07	-0.42	1.06e-21	Neuroticism;
LGG	cis	rs10046574	0.519	rs9656456	chr7:135202208	G/A	cg27474649	chr7:135195673	CNOT4	0.75	9.07	0.39	3.46e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs2242663	0.531	rs2511225	chr11:66248431	A/C	cg01599099	chr11:66649832	PC	0.34	7.08	0.31	5.51e-12	Bipolar disorder;
LGG	cis	rs11227306	0.934	rs10896056	chr11:65587905	A/G	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.57	-0.33	2.11e-13	DNA methylation (variation);
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	cis	rs7584262	0.695	rs12712824	chr2:42244325	T/C	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Bone mineral density;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg05804949	chr7:23719620	C7orf46	0.32	7.26	0.32	1.67e-12	Schizophrenia;
LGG	cis	rs113835537	0.529	rs11550299	chr11:66254085	G/T	cg24851651	chr11:66362959	CCS	0.43	7.59	0.33	1.75e-13	Airway imaging phenotypes;
LGG	cis	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg21775007	chr8:11205619	TDH	-0.48	-7.73	-0.34	6.6e-14	Triglycerides;
LGG	cis	rs7927592	0.956	rs7124078	chr11:68298633	G/T	cg20283391	chr11:68216788	NA	-0.49	-8.09	-0.35	5.28e-15	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3e-13	Schizophrenia;
LGG	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs2640806	0.525	rs2280264	chr8:97342090	C/T	cg22138393	chr8:97340270	PTDSS1	0.26	6.87	0.3	2.12e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12933314	chr7:4815160	KIAA0415	0.52	8.1	0.35	4.88e-15	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.64	0.37	9.35e-17	Bipolar disorder;
LGG	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs7193541	0.510	rs79473128	chr16:74589192	G/A	cg01733217	chr16:74700730	RFWD3	0.73	13.41	0.53	6.79e-35	Multiple myeloma;
LGG	cis	rs10499694	0.933	rs7778349	chr7:50593157	C/T	cg04490037	chr7:50633773	DDC	0.32	6.96	0.31	1.18e-11	Body mass index;
LGG	cis	rs17345786	0.906	rs12638137	chr3:101150964	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.55	7.97	0.35	1.22e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11096990	0.593	rs1026235	chr4:39228249	G/A	cg24403649	chr4:39172243	NA	0.4	7.24	0.32	1.93e-12	Cognitive function;
LGG	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs523522	0.962	rs10849758	chr12:120971149	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg18196295	chr10:418757	DIP2C	-0.62	-12.48	-0.5	5.07e-31	Psychosis in Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg18252515	chr7:66147081	NA	-1.21	-18.34	-0.65	7.3e-57	Diabetic kidney disease;
LGG	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg01620082	chr3:125678407	NA	-0.64	-6.95	-0.31	1.26e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28374715	0.532	rs316607	chr15:41772693	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.34	-32.55	-0.83	9.45e-122	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7172677	1.000	rs2029520	chr15:75415768	A/G	cg14664628	chr15:75095509	CSK	-0.46	-7.01	-0.31	8.42e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7937890	0.810	rs10734224	chr11:14424124	G/T	cg02251663	chr11:14281053	SPON1	-0.3	-7.03	-0.31	7.27e-12	Mitochondrial DNA levels;
LGG	cis	rs11098499	0.863	rs3736115	chr4:120488703	A/G	cg09307838	chr4:120376055	NA	-0.82	-13.53	-0.53	2.25e-35	Corneal astigmatism;
LGG	cis	rs8054556	0.647	rs11649149	chr16:30008644	C/T	cg06326092	chr16:30034487	C16orf92	0.35	6.95	0.31	1.24e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg01236616	chr12:121019343	POP5	1.27	23.06	0.73	6.22e-79	Type 1 diabetes nephropathy;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.29	0.6	1.69e-47	Obesity-related traits;
LGG	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs1483121	0.808	rs11039482	chr11:48009074	C/T	cg20307385	chr11:47447363	PSMC3	0.54	6.83	0.3	2.61e-11	Fasting blood glucose (BMI interaction);Fasting blood glucose;
LGG	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.6e-19	Red blood cell count;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs868036	0.958	rs4261478	chr15:68074084	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.5	-0.33	3.35e-13	Restless legs syndrome;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs910316	0.737	rs175043	chr14:75471803	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-9.82	-0.42	8.74e-21	Height;
LGG	cis	rs9549367	0.724	rs7985335	chr13:113869244	G/T	cg18105134	chr13:113819100	PROZ	0.65	13.26	0.52	3.15e-34	Platelet distribution width;
LGG	cis	rs34172651	0.517	rs35560136	chr16:24788915	T/A	cg06028605	chr16:24865363	SLC5A11	0.47	7.69	0.34	9.01e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg03433033	chr1:76189801	ACADM	0.72	12.61	0.51	1.5e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4604732	0.631	rs12039642	chr1:247624898	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.8	-0.38	2.83e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2013441	0.866	rs17686622	chr17:20020364	C/G	cg09818912	chr17:20140352	CYTSB	0.32	7.04	0.31	6.78e-12	Obesity-related traits;
LGG	cis	rs8133932	0.564	rs452797	chr21:47348455	C/G	cg11214348	chr21:47283868	PCBP3	-0.45	-7.88	-0.34	2.34e-14	Schizophrenia;
LGG	cis	rs35306767	0.951	rs11253530	chr10:993729	T/C	cg20503657	chr10:835505	NA	0.64	8.68	0.37	6.81e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-7.83	-0.34	3.47e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs155076	1.000	rs2478824	chr13:21844144	G/C	cg14456004	chr13:21872349	NA	-1.16	-18.27	-0.65	1.52e-56	White matter hyperintensity burden;
LGG	cis	rs61192259	1.000	rs6933268	chr6:38446350	A/G	cg07362130	chr6:38359646	BTBD9	0.3	7.07	0.31	5.67e-12	Restless legs syndrome;
LGG	cis	rs509477	0.718	rs273353	chr18:32599361	G/A	cg23791764	chr18:32556832	MAPRE2	0.44	7.44	0.33	4.98e-13	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs11771526	0.892	rs1376282	chr7:32370492	A/G	cg27532318	chr7:32358331	NA	0.87	8.49	0.37	2.82e-16	Body mass index;
LGG	cis	rs10949834	1.000	rs11770302	chr7:73485252	G/C	cg07137043	chr7:73588983	EIF4H	-0.67	-7.6	-0.33	1.61e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg03847636	chr4:7070632	GRPEL1	-0.53	-7.33	-0.32	1.06e-12	Monocyte percentage of white cells;
LGG	cis	rs4820539	0.966	rs3788350	chr22:23468468	C/T	cg14186256	chr22:23484241	RTDR1	0.97	23.34	0.74	3.23e-80	Bone mineral density;
LGG	cis	rs1475911	0.656	rs9980065	chr21:43528072	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.75	13.95	0.54	3.54e-37	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg03351412	chr1:154909251	PMVK	0.65	12.17	0.49	9.21e-30	Prostate cancer;
LGG	cis	rs1784581	0.651	rs1784593	chr6:162386096	A/T	cg17173639	chr6:162384350	PARK2	-0.76	-17.19	-0.62	1.4e-51	Itch intensity from mosquito bite;
LGG	cis	rs6963495	0.769	rs117986187	chr7:105167311	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.94	0.35	1.51e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2019137	0.936	rs12620738	chr2:113963739	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.96	-0.42	2.73e-21	Lymphocyte counts;
LGG	cis	rs7027203	0.797	rs4744294	chr9:96612114	C/G	cg13679303	chr9:96623674	NA	-0.39	-6.88	-0.3	1.9e-11	DNA methylation (variation);
LGG	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg08645402	chr16:4508243	NA	0.54	9.79	0.41	1.07e-20	Schizophrenia;
LGG	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg26116260	chr4:7069785	GRPEL1	-1.06	-15.63	-0.59	1.65e-44	Monocyte percentage of white cells;
LGG	trans	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg10756647	chr7:56101905	PSPH	0.84	9.93	0.42	3.53e-21	Diabetic kidney disease;
LGG	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg22437258	chr11:111473054	SIK2	-0.4	-6.69	-0.3	6.28e-11	Primary sclerosing cholangitis;
LGG	cis	rs1557765	0.527	rs10832782	chr11:17397273	G/C	cg15432903	chr11:17409602	KCNJ11	0.5	9.2	0.39	1.21e-18	Body mass index;Social communication problems;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg08888203	chr3:10149979	C3orf24	0.54	9.24	0.39	9.2e-19	Alzheimer's disease;
LGG	cis	rs4950322	0.542	rs2883434	chr1:146649084	A/C	cg22381352	chr1:146742008	CHD1L	-0.45	-7.65	-0.34	1.14e-13	Protein quantitative trait loci;
LGG	cis	rs283228	0.550	rs570556	chr6:101741702	A/G	cg27451362	chr6:101846650	GRIK2	0.99	15.09	0.57	4.03e-42	Coenzyme Q10 levels;
LGG	cis	rs6735179	0.958	rs1424921	chr2:1771874	A/G	cg20570797	chr2:1712800	PXDN	-0.41	-6.82	-0.3	2.87e-11	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	8.63	0.37	9.76e-17	Cognitive test performance;
LGG	cis	rs9814567	0.762	rs13070654	chr3:134219348	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.01	0.46	3.46e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.85e-13	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09581281	chr1:15853227	DNAJC16	0.46	7.54	0.33	2.57e-13	Gut microbiome composition (summer);
LGG	cis	rs9768139	0.733	rs13225172	chr7:158120334	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.06	0.68	7.26e-65	Calcium levels;
LGG	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.39	0.36	5.94e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.09e-35	Alzheimer's disease;
LGG	cis	rs12497850	0.931	rs9311430	chr3:48845251	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs3816183	1.000	rs3816181	chr2:43015612	G/T	cg14631114	chr2:43023945	NA	0.51	9.68	0.41	2.68e-20	Hypospadias;
LGG	cis	rs758324	0.812	rs4705839	chr5:131175258	G/A	cg06307176	chr5:131281290	NA	0.53	8.66	0.37	7.9e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs16854884	0.609	rs9872126	chr3:143683851	G/A	cg06585982	chr3:143692056	C3orf58	0.66	11.52	0.47	3.64e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs1395	0.744	rs11126935	chr2:27476740	G/T	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg02158880	chr13:53174818	NA	0.47	9.56	0.41	7.25e-20	Lewy body disease;
LGG	cis	rs10895140	0.756	rs1938860	chr11:101497285	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7191439	0.522	rs8060640	chr16:88744430	G/C	cg02389323	chr16:88786976	FAM38A	0.85	7.98	0.35	1.2e-14	Plateletcrit;
LGG	trans	rs9354308	0.764	rs9345705	chr6:66586504	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs10870270	1.000	rs4880250	chr10:133773919	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.58	-0.53	1.4e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.05	-0.49	2.85e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg15971980	chr6:150254442	NA	0.45	8.93	0.38	1.01e-17	Testicular germ cell tumor;
LGG	cis	rs6542838	0.641	rs6724477	chr2:99537074	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.4	6.9	0.31	1.68e-11	Fear of minor pain;
LGG	cis	rs35110281	0.616	rs2236666	chr21:45109856	T/C	cg04455712	chr21:45112962	RRP1B	0.54	9.98	0.42	2.23e-21	Mean corpuscular volume;
LGG	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg06636001	chr8:8085503	FLJ10661	0.57	11.34	0.47	1.73e-26	Mood instability;
LGG	cis	rs8064024	0.599	rs882235	chr16:4931651	C/T	cg04440724	chr16:4920505	UBN1	-0.51	-10.18	-0.43	4.19e-22	Cancer;
LGG	cis	rs5758511	0.680	rs5758667	chr22:42633204	G/A	cg15128208	chr22:42549153	NA	0.75	11.57	0.47	2.34e-27	Birth weight;
LGG	cis	rs9393692	0.557	rs7755741	chr6:26337264	G/A	cg13736514	chr6:26305472	NA	-0.47	-8.83	-0.38	2.13e-17	Educational attainment;
LGG	cis	rs6065	0.618	rs16942630	chr17:4878437	C/G	cg16045459	chr17:4872488	CAMTA2;SPAG7	-0.53	-7.18	-0.32	2.77e-12	Platelet count;
LGG	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.85	0.48	1.76e-28	Rheumatoid arthritis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21160151	chr5:131131930	FNIP1	0.41	6.83	0.3	2.61e-11	Cognitive performance;
LGG	cis	rs936229	0.784	rs12906946	chr15:75153140	A/G	cg14664628	chr15:75095509	CSK	-0.92	-18.35	-0.65	6.33e-57	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs7192380	1.000	rs8049728	chr16:69654790	G/T	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.77	-0.34	4.94e-14	Sjögren's syndrome;
LGG	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg00717180	chr2:96193071	NA	-0.39	-6.83	-0.3	2.74e-11	Coronary artery disease;
LGG	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg10792982	chr14:105748885	BRF1	0.55	10.81	0.45	1.86e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4665809	0.590	rs13016807	chr2:26496186	G/C	cg22920501	chr2:26401640	FAM59B	0.45	9.22	0.39	1.04e-18	Gut microbiome composition (summer);
LGG	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg16511985	chr3:153974050	SGEF	0.5	8.4	0.36	5.52e-16	Coronary artery disease;
LGG	cis	rs9341808	0.530	rs3805876	chr6:81031539	C/A	cg08355045	chr6:80787529	NA	0.36	7.04	0.31	6.99e-12	Sitting height ratio;
LGG	cis	rs2463822	0.844	rs2513737	chr11:62119495	G/C	cg06239285	chr11:62104954	ASRGL1	1.15	15.87	0.59	1.39e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs477895	0.838	rs11607007	chr11:64007976	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	10.36	0.43	9.42e-23	Mean platelet volume;
LGG	cis	rs3857536	0.706	rs7749120	chr6:66889832	T/G	cg07460842	chr6:66804631	NA	-0.48	-8.39	-0.36	6.13e-16	Blood trace element (Cu levels);
LGG	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg15327641	chr2:3715039	ALLC	0.34	7.39	0.32	7.09e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs9462027	0.562	rs2814946	chr6:34651180	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.25e-24	Systemic lupus erythematosus;
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.79	10.98	0.45	4.48e-25	Lung function (FEV1/FVC);
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.1	-0.42	8.47e-22	Lung cancer;
LGG	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.8	0.54	1.64e-36	Colorectal cancer;
LGG	trans	rs7819412	0.654	rs6987059	chr8:11071057	A/G	cg16141378	chr3:129829833	LOC729375	0.37	7.97	0.35	1.26e-14	Triglycerides;
LGG	trans	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg16141378	chr3:129829833	LOC729375	0.32	7.15	0.32	3.38e-12	Mood instability;
LGG	cis	rs17818399	0.749	rs13000560	chr2:46790997	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.33	0.32	1.04e-12	Height;
LGG	cis	rs11885103	0.692	rs2724916	chr2:566419	A/G	cg21195176	chr2:593345	NA	0.41	7.6	0.33	1.72e-13	Heschl's gyrus morphology;
LGG	cis	rs6061231	0.561	rs67072353	chr20:60940702	G/A	cg22307297	chr20:60903441	LAMA5	0.39	7.2	0.32	2.5e-12	Colorectal cancer;
LGG	cis	rs11239177	0.772	rs11239137	chr10:45062330	T/C	cg03916630	chr10:45065415	NA	0.35	8.51	0.37	2.49e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg00784671	chr22:46762841	CELSR1	-0.59	-7.13	-0.31	3.95e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs921968	0.541	rs490483	chr2:219429052	A/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.14	-0.31	3.68e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7781557	1.000	rs727175	chr7:102471780	T/C	cg18108683	chr7:102477205	FBXL13	-0.55	-8.54	-0.37	1.94e-16	Colorectal adenoma (advanced);
LGG	cis	rs9487094	0.689	rs9480936	chr6:109679430	G/T	cg16315928	chr6:109776240	MICAL1	0.39	6.81	0.3	3.07e-11	Height;
LGG	cis	rs11578119	0.836	rs12130520	chr1:170539500	G/A	cg09767346	chr1:170501363	GORAB	0.37	6.74	0.3	4.71e-11	Male-pattern baldness;
LGG	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg05082376	chr22:42548792	NA	-0.4	-8.48	-0.37	2.94e-16	Schizophrenia;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.44	-0.37	4.17e-16	Lung cancer;
LGG	cis	rs62238980	0.614	rs78593283	chr22:32365433	C/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg26039829	chr8:22132926	PIWIL2	0.53	12.24	0.49	4.94e-30	Hypertriglyceridemia;
LGG	cis	rs2303319	1.000	rs74733151	chr2:162251856	C/G	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.5	-0.33	3.3e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs4714291	0.832	rs9471244	chr6:40092331	A/G	cg02267698	chr19:7991119	CTXN1	0.61	10.06	0.42	1.2e-21	Strep throat;
LGG	cis	rs2860975	1.000	rs7070074	chr10:96786886	T/C	cg09036531	chr10:96991505	NA	-0.47	-8.56	-0.37	1.73e-16	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg21775007	chr8:11205619	TDH	0.43	6.92	0.31	1.5e-11	Mood instability;
LGG	cis	rs12701220	0.689	rs12530960	chr7:1095471	G/A	cg02733842	chr7:1102375	C7orf50	-0.56	-8.27	-0.36	1.47e-15	Bronchopulmonary dysplasia;
LGG	cis	rs10484885	0.553	rs17707975	chr6:90622318	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.66	-8.32	-0.36	9.770000000000001e-16	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs10838798	0.523	rs11039543	chr11:48168103	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.38	-0.32	7.18e-13	Height;
LGG	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg27124370	chr19:33622961	WDR88	0.46	8.31	0.36	1.06e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.02	-0.42	1.61e-21	Triglycerides;
LGG	trans	rs853679	0.882	rs3757188	chr6:28107357	T/C	cg01620082	chr3:125678407	NA	-0.65	-7.33	-0.32	1.01e-12	Depression;
LGG	cis	rs189218934	1	rs189218934	chr15:78903987	T/C	cg06917634	chr15:78832804	PSMA4	0.5	7.83	0.34	3.25e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4363385	0.747	rs946098	chr1:152975038	A/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.39	-0.4	2.63e-19	Inflammatory skin disease;
LGG	cis	rs4936894	0.500	rs12282624	chr11:124164611	C/T	cg27160556	chr11:124181099	OR8D1	-0.46	-10.74	-0.45	3.4e-24	Aging (time to death);
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23556447	chr6:90529595	MDN1	0.42	7.29	0.32	1.35e-12	Bipolar disorder;
LGG	cis	rs6784615	0.744	rs34385735	chr3:52299737	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.67	7.4	0.33	6.56e-13	Waist-hip ratio;
LGG	cis	rs28530618	0.515	rs6579027	chr20:31239025	G/T	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.7	-0.3	6.09e-11	Birth weight;
LGG	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg03961551	chr1:25251730	RUNX3	0.47	12.11	0.49	1.62e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1975974	0.511	rs112710683	chr17:21741695	C/A	cg18423549	chr17:21743878	NA	-0.54	-8.23	-0.36	1.89e-15	Psoriasis;
LGG	cis	rs10857712	0.551	rs12252576	chr10:135227244	T/C	cg00491522	chr10:135256596	NA	0.59	10.87	0.45	1.1e-24	Systemic lupus erythematosus;
LGG	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg18876405	chr7:65276391	NA	0.66	12.8	0.51	2.57e-32	Aortic root size;
LGG	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg08610935	chr16:1836813	NUBP2	0.44	6.9	0.31	1.69e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11168187	0.891	rs867143	chr12:47982336	C/T	cg12761788	chr12:48120090	P11	0.48	7.48	0.33	3.71e-13	Vertical cup-disc ratio;
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg04267008	chr7:1944627	MAD1L1	-0.54	-9.05	-0.39	3.93e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1728785	0.901	rs1728797	chr16:68570989	A/T	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs12580194	0.593	rs61556775	chr12:55745640	A/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs9796	0.870	rs28581803	chr15:41326513	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.47	-8.11	-0.35	4.69e-15	Menopause (age at onset);
LGG	cis	rs514406	0.825	rs9661082	chr1:53245472	A/T	cg24675658	chr1:53192096	ZYG11B	0.49	9.75	0.41	1.44e-20	Monocyte count;
LGG	cis	rs35264875	0.851	rs72930621	chr11:68866745	C/T	cg23845249	chr11:68861649	NA	0.43	7.92	0.35	1.81e-14	Blond vs. brown hair color;
LGG	cis	rs7241530	0.585	rs35084996	chr18:75912243	T/A	cg14642773	chr18:75888474	NA	0.44	8.4	0.36	5.7e-16	Educational attainment (years of education);
LGG	cis	rs9814567	1.000	rs13081177	chr3:134289860	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	13.04	0.52	2.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4356932	1.000	rs4859587	chr4:76943296	A/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs9811920	0.609	rs793447	chr3:99598278	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.19	-0.46	6.6e-26	Personality dimensions;
LGG	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg26116260	chr4:7069785	GRPEL1	-0.82	-7.4	-0.33	6.52e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg18963800	chr10:38644991	HSD17B7P2	0.49	8.32	0.36	1.02e-15	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7666738	0.830	rs13112037	chr4:98976986	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.932	rs6814465	chr4:17659034	C/T	cg16339924	chr4:17578868	LAP3	0.62	10.53	0.44	2.13e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs74417235	0.684	rs13179754	chr5:154059845	C/T	cg08754654	chr5:154026448	NA	0.52	10.8	0.45	2.16e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	trans	rs8002861	0.905	rs6561149	chr13:44456782	T/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-22.07	-0.72	2.7e-74	Leprosy;
LGG	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg11266682	chr4:10021025	SLC2A9	0.43	8.09	0.35	5.36e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8081692	1	rs8081692	chr17:38154595	A/G	cg17467752	chr17:38218738	THRA	0.74	13.81	0.54	1.49e-36	Neutrophil count;
LGG	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg23649088	chr2:200775458	C2orf69	0.46	8.04	0.35	7.43e-15	Asthma (bronchodilator response);
LGG	cis	rs6502050	0.835	rs6502077	chr17:80122966	G/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.31	0.5	2.5e-30	Corneal astigmatism;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs6456156	0.806	rs11967165	chr6:167529936	T/C	cg07741184	chr6:167504864	NA	-0.3	-6.67	-0.3	7.33e-11	Primary biliary cholangitis;
LGG	cis	rs4481887	1.000	rs6683717	chr1:248476792	A/G	cg13385794	chr1:248469461	NA	0.48	8.12	0.35	4.39e-15	Common traits (Other);
LGG	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.42	0.33	5.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg26695010	chr11:65641043	EFEMP2	0.47	7.41	0.33	6.19e-13	Breast cancer;
LGG	cis	rs6594499	0.872	rs13161853	chr5:110446741	C/A	cg04022379	chr5:110408740	TSLP	0.4	7.34	0.32	9.39e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.77	-0.41	1.25e-20	Menopause (age at onset);
LGG	trans	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg25214090	chr10:38739885	LOC399744	-0.62	-11.03	-0.46	2.71e-25	Corneal astigmatism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20498895	chr3:12883366	SNORA7A;RPL32	0.4	6.79	0.3	3.35e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs13421350	0.579	rs79481012	chr2:173401264	T/G	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.41e-12	Schizophrenia;
LGG	cis	rs12360000	0.864	rs12767731	chr10:1907712	T/C	cg26364871	chr10:1889757	NA	-0.71	-13.66	-0.54	6.48e-36	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs6696846	0.715	rs61822659	chr1:205142847	G/A	cg00857998	chr1:205179979	DSTYK	0.56	8.89	0.38	1.39e-17	Red blood cell count;
LGG	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.68	-0.37	6.61e-17	Neuroticism;
LGG	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg18245976	chr7:158708271	WDR60	-0.59	-7.73	-0.34	6.58e-14	Height;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	0.919	rs9913470	chr17:29566575	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.73	-0.56	1.55e-40	Hip circumference;
LGG	cis	rs1577917	0.570	rs114854865	chr6:86554236	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.24	-0.49	4.88e-30	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs151997	0.925	rs26087	chr5:50172911	G/A	cg06027927	chr5:50259733	NA	0.67	11.09	0.46	1.7e-25	Callous-unemotional behaviour;
LGG	cis	rs9341808	0.754	rs9352817	chr6:81025879	T/G	cg08355045	chr6:80787529	NA	0.41	8.12	0.35	4.29e-15	Sitting height ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20503117	chr3:5164013	ARL8B	0.47	7.28	0.32	1.43e-12	Gut microbiome composition (summer);
LGG	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg00531865	chr16:30841666	NA	-0.57	-11.73	-0.48	5.42e-28	Multiple myeloma;
LGG	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg27490568	chr2:178487706	NA	0.52	10.05	0.42	1.31e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg17911788	chr17:44343683	NA	-0.47	-7.98	-0.35	1.13e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14078059	chr12:65174660	NA	0.36	6.68	0.3	6.7e-11	Cognitive performance;
LGG	cis	rs7172689	0.862	rs11853837	chr15:81563913	G/A	cg11808699	chr15:81528661	IL16	-0.46	-9.37	-0.4	3.24e-19	Inattentive symptoms;
LGG	cis	rs10771431	0.967	rs7137443	chr12:9372029	C/T	cg08997352	chr12:9597637	DDX12	-0.67	-13.03	-0.52	2.73e-33	Breast size;
LGG	cis	rs7264396	0.790	rs2425096	chr20:34308588	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.92	-0.35	1.77e-14	Total cholesterol levels;
LGG	trans	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg07461501	chr17:79650226	HGS;ARL16	0.39	8.21	0.36	2.19e-15	Obesity-related traits;
LGG	cis	rs78366141	0.649	rs61737091	chr4:89671721	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.83	7.9	0.34	1.99e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg12270520	chr8:146023939	ZNF517	0.41	6.84	0.3	2.52e-11	Age at first birth;
LGG	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg03477792	chr4:77819574	ANKRD56	0.52	9.38	0.4	3.03e-19	Emphysema distribution in smoking;
LGG	cis	rs12681287	0.640	rs7461413	chr8:87470978	C/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs12478296	0.591	rs7573042	chr2:242996589	A/G	cg01596870	chr19:55963115	NA	-0.45	-7.26	-0.32	1.68e-12	Obesity-related traits;
LGG	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg14541582	chr5:601475	NA	-0.71	-11.1	-0.46	1.54e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs745570	0.833	rs1696757	chr17:77800743	C/T	cg25456068	chr17:77800718	NA	0.57	12.67	0.51	8.72e-32	Breast cancer;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg22105103	chr4:187893119	NA	0.58	11.26	0.46	3.66e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs861020	0.630	rs686582	chr1:210008673	A/C	cg05527609	chr1:210001259	C1orf107	0.59	9.56	0.41	7.1e-20	Orofacial clefts;
LGG	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg19748678	chr4:122722346	EXOSC9	0.51	9.69	0.41	2.42e-20	Type 2 diabetes;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03738868	chr7:100281714	GIGYF1	0.44	7.24	0.32	1.92e-12	Pancreatic cancer;
LGG	cis	rs950169	0.580	rs11636189	chr15:85193554	G/A	cg03959625	chr15:84868606	LOC388152	0.48	7.13	0.31	3.77e-12	Schizophrenia;
LGG	cis	rs131777	0.526	rs86337	chr22:51020668	C/A	cg25309564	chr22:51001381	C22orf41	0.45	7.45	0.33	4.51e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg21665744	chr7:39171113	POU6F2	0.39	7.97	0.35	1.23e-14	IgG glycosylation;
LGG	cis	rs4906332	1.000	rs78316803	chr14:103942863	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.87	-0.34	2.46e-14	Coronary artery disease;
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg03929089	chr4:120376271	NA	-0.65	-11.55	-0.47	2.74e-27	Coronary artery disease;
LGG	cis	rs9398803	0.741	rs9388501	chr6:126903011	T/C	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.92e-19	Male-pattern baldness;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg09978734	chr17:74330308	PRPSAP1	-0.39	-6.76	-0.3	4.06e-11	Apolipoprotein A-IV levels;
LGG	cis	rs12926788	0.546	rs200531	chr16:24756172	G/A	cg00339695	chr16:24857497	SLC5A11	-0.4	-6.87	-0.3	2.05e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.13	-0.39	2.16e-18	Breast cancer;
LGG	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg19847130	chr8:10466454	RP1L1	0.32	7.17	0.32	3.05e-12	Mood instability;
LGG	cis	rs4595586	0.545	rs4623945	chr12:39364572	A/T	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs75920871	0.528	rs1531707	chr11:116944712	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.52	-0.33	2.92e-13	Subjective well-being;
LGG	cis	rs6582630	0.500	rs35251810	chr12:38577666	T/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.47	-0.4	1.5e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg00106254	chr7:1943704	MAD1L1	0.47	8.08	0.35	5.68e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg07636037	chr3:49044803	WDR6	0.78	13.95	0.54	3.41e-37	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06622379	chr4:66536309	EPHA5	0.48	7.07	0.31	5.64e-12	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg12751644	chr20:60527061	NA	-0.32	-7.43	-0.33	5.32e-13	Body mass index;
LGG	cis	rs62238980	0.614	rs2899174	chr22:32458789	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.29	-0.36	1.2e-15	Tonsillectomy;
LGG	cis	rs7975161	0.572	rs4964228	chr12:104572759	T/C	cg25273343	chr12:104657179	TXNRD1	-0.8	-7.45	-0.33	4.55e-13	Toenail selenium levels;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.08	-0.42	1.01e-21	Electroencephalogram traits;
LGG	cis	rs6879260	1.000	rs6879260	chr5:179731014	A/G	cg13944838	chr5:179740914	GFPT2	-0.67	-12.41	-0.5	1.01e-30	Height;
LGG	trans	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19894588	chr14:64061835	NA	0.59	9.9	0.42	4.45e-21	Glioblastoma;Glioma;
LGG	cis	rs701145	0.585	rs4680125	chr3:153784698	G/A	cg17054900	chr3:154042577	DHX36	-0.77	-9.28	-0.4	6.3e-19	Coronary artery disease;
LGG	cis	rs7717393	1.000	rs1857769	chr5:155769363	A/G	cg12904904	chr5:155754151	SGCD	0.89	8.53	0.37	2.18e-16	Egg allergy;
LGG	trans	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg01314568	chr7:57830625	NA	-0.49	-7.64	-0.33	1.22e-13	Obesity-related traits;
LGG	cis	rs6665290	0.566	rs1513617	chr1:227447213	C/T	cg10327440	chr1:227177885	CDC42BPA	0.96	17.82	0.64	1.82e-54	Myeloid white cell count;
LGG	cis	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.82	-0.34	3.69e-14	Mood instability;
LGG	cis	rs317689	0.718	rs315130	chr12:69761444	T/C	cg14784868	chr12:69753453	YEATS4	0.7	11.09	0.46	1.72e-25	Response to diuretic therapy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18975462	chr8:119123269	EXT1	0.44	7.16	0.32	3.13e-12	Cognitive performance;
LGG	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.4	-0.33	6.55e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.6e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.671	rs2591970	chr5:56232595	T/C	cg08400814	chr5:56204995	C5orf35	0.41	7.3	0.32	1.26e-12	Initial pursuit acceleration;
LGG	cis	rs10870270	1.000	rs3935905	chr10:133758262	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.67	-0.54	5.64e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg06640241	chr16:89574553	SPG7	0.91	17.31	0.63	3.89e-52	Multiple myeloma (IgH translocation);
LGG	trans	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs372883	0.600	rs1312254	chr21:30695401	A/G	cg08807101	chr21:30365312	RNF160	-0.61	-10.29	-0.43	1.69e-22	Pancreatic cancer;
LGG	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.48	7.59	0.33	1.74e-13	Hip circumference adjusted for BMI;
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07234876	chr8:600039	NA	1.19	11.76	0.48	3.92e-28	IgG glycosylation;
LGG	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg23978390	chr7:1156363	C7orf50	0.44	6.67	0.3	7.21e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7226408	0.857	rs17652769	chr18:34731828	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	trans	rs2574985	0.702	rs3011780	chr10:52287792	A/C	cg18558237	chr10:81444220	LOC650623	0.45	6.91	0.31	1.57e-11	Subjective well-being;
LGG	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg24812749	chr6:127587940	RNF146	0.66	11.19	0.46	6.62e-26	Breast cancer;
LGG	cis	rs6840360	0.571	rs1822347	chr4:152525319	A/G	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	0.626	rs409	chr7:91556355	C/T	cg17063962	chr7:91808500	NA	0.46	8.44	0.37	4.16e-16	Breast cancer;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg19168338	chr16:4465731	CORO7	-0.92	-17.75	-0.64	3.79e-54	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12979743	chr3:179322479	NDUFB5;MRPL47	0.42	6.84	0.3	2.46e-11	Cognitive performance;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.27	0.36	1.43e-15	Obesity-related traits;
LGG	trans	rs7980799	0.935	rs10844582	chr12:33560873	A/G	cg26384229	chr12:38710491	ALG10B	-0.52	-8.86	-0.38	1.69e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg20673091	chr1:2541236	MMEL1	0.78	19.04	0.66	3.89e-60	Ulcerative colitis;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.82	-0.54	1.35e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg06808227	chr14:105710500	BRF1	-0.63	-11.34	-0.47	1.79e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg23601095	chr6:26197514	HIST1H3D	0.69	8.75	0.38	3.85e-17	Gout;Renal underexcretion gout;
LGG	cis	rs8133932	0.608	rs382195	chr21:47339222	G/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.98	-0.35	1.17e-14	Schizophrenia;
LGG	cis	rs9399135	0.967	rs4388304	chr6:135309597	T/A	cg22676075	chr6:135203613	NA	0.36	6.66	0.3	7.78e-11	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27649522	chr12:12877729	APOLD1	0.55	8.87	0.38	1.62e-17	Gut microbiome composition (summer);
LGG	cis	rs13421350	0.579	rs115160117	chr2:173411004	G/C	cg15021238	chr2:173305865	ITGA6	-0.79	-8.46	-0.37	3.57e-16	Diabetic kidney disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05591758	chr2:74685531	WBP1	0.39	6.83	0.3	2.7e-11	Obesity-related traits;
LGG	cis	rs9463078	0.691	rs9296458	chr6:45267183	T/C	cg25276700	chr6:44698697	NA	-0.32	-6.74	-0.3	4.87e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs7246760	0.867	rs889177	chr19:9846225	C/T	cg02900749	chr2:68251473	NA	-1.0	-11.07	-0.46	1.95e-25	Pursuit maintenance gain;
LGG	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.75	-0.3	4.36e-11	Schizophrenia;
LGG	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	7.45	0.33	4.49e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg14004847	chr7:1930337	MAD1L1	0.55	9.67	0.41	2.88e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs4925386	0.840	rs6143035	chr20:60920700	C/T	cg24112000	chr20:60950667	NA	0.37	7.47	0.33	3.89e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs910187	0.678	rs6122562	chr20:45813847	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.47	-0.4	1.43e-19	Migraine;
LGG	cis	rs12451471	0.637	rs7567	chr17:78093549	G/T	cg06718696	chr17:78121285	EIF4A3	0.92	14.97	0.57	1.36e-41	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7000551	0.527	rs12677619	chr8:22243326	G/A	cg12081754	chr8:22256438	SLC39A14	1.18	24.49	0.75	1.45e-85	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg06532163	chr17:45867833	NA	0.56	9.26	0.4	7.4e-19	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg13207630	chr7:32358064	NA	0.65	7.06	0.31	6.03e-12	Body mass index;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs17504614	0.634	rs12233045	chr2:51044913	T/A	cg23851515	chr2:51057218	NRXN1	0.51	8.24	0.36	1.77e-15	Educational attainment (years of education);
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.08	-0.31	5.28e-12	Iron status biomarkers;
LGG	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg11871910	chr12:69753446	YEATS4	1.06	28.69	0.8	9.09e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13102973	0.720	rs13122447	chr4:135887524	C/T	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.37	0.32	7.78e-13	Tonsillectomy;
LGG	cis	rs1372520	0.684	rs2583968	chr4:90745395	C/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.21	-0.36	2.25e-15	Neuroticism;
LGG	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg12458913	chr13:53173898	NA	0.86	19.65	0.67	5.73e-63	Lewy body disease;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05165339	chr4:1420672	NA	0.31	8.05	0.35	7.18e-15	Obesity-related traits;
LGG	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg12633918	chr20:23549525	CST9L	-0.34	-7.02	-0.31	8.04e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.3	-0.32	1.24e-12	Joint mobility (Beighton score);
LGG	trans	rs629535	0.814	rs62513371	chr8:70077779	T/A	cg21567404	chr3:27674614	NA	-0.4	-6.7	-0.3	6.22e-11	Dupuytren's disease;
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.46	0.33	4.23e-13	Tonsillectomy;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.12e-12	Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.56	-0.37	1.68e-16	Diabetic kidney disease;
LGG	cis	rs7917772	0.582	rs729024	chr10:104341975	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.59e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14009749	chr11:17098715	RPS13	0.39	6.87	0.3	2.07e-11	Bilirubin levels;
LGG	cis	rs694739	0.595	rs11542299	chr11:64138805	T/C	cg22916017	chr11:64110731	CCDC88B	0.47	9.53	0.4	9.01e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7215564	0.908	rs34785514	chr17:78661166	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	cis	rs7954584	0.567	rs11612028	chr12:122387872	C/G	cg22168489	chr12:122356033	WDR66	0.42	9.65	0.41	3.47e-20	Mean corpuscular volume;
LGG	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg17644776	chr2:200775616	C2orf69	0.62	9.8	0.41	9.54e-21	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs5758511	0.514	rs5758586	chr22:42517471	A/T	cg15128208	chr22:42549153	NA	0.79	12.63	0.51	1.2e-31	Birth weight;
LGG	cis	rs17767392	0.846	rs34281934	chr14:71979756	C/T	cg02058870	chr14:72053146	SIPA1L1	0.4	8.37	0.36	6.75e-16	Mitral valve prolapse;
LGG	cis	rs75920871	0.660	rs4938330	chr11:116928514	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.48	-6.75	-0.3	4.52e-11	Subjective well-being;
LGG	cis	rs8070128	0.583	rs7406982	chr17:17942613	C/T	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.53	-0.61	1.44e-48	Total body bone mineral density;
LGG	trans	rs6601327	0.641	rs7462070	chr8:9571364	C/T	cg02002194	chr4:3960332	NA	0.39	7.0	0.31	8.91e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg26554054	chr8:600488	NA	-1.13	-10.18	-0.43	4.34e-22	IgG glycosylation;
LGG	cis	rs7980687	0.574	rs10744149	chr12:123708490	T/A	cg05973401	chr12:123451056	ABCB9	0.49	7.49	0.33	3.58e-13	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg21775007	chr8:11205619	TDH	0.83	14.76	0.57	1.07e-40	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	12.95	0.52	6.16e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1594829	0.535	rs1434022	chr8:26153222	G/A	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg04080417	chr5:1859792	NA	-0.54	-8.97	-0.38	7.47e-18	Cardiovascular disease risk factors;
LGG	cis	rs4742903	0.935	rs10116938	chr9:106977255	T/G	cg14250997	chr9:106856677	SMC2	0.4	8.31	0.36	1.05e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7143963	0.666	rs2092973	chr14:103320961	G/A	cg23020514	chr14:103360112	TRAF3	0.41	8.67	0.37	7.57e-17	Body mass index;
LGG	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg09165964	chr15:75287851	SCAMP5	-1.08	-23.44	-0.74	1.1e-80	Blood trace element (Zn levels);
LGG	cis	rs13082711	0.595	rs62255583	chr3:27309704	G/T	cg02860705	chr3:27208620	NA	0.92	17.08	0.62	4.23e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg12310025	chr6:25882481	NA	0.46	8.15	0.35	3.55e-15	Blood metabolite levels;
LGG	cis	rs721048	1.000	rs721048	chr2:63131731	G/A	cg17519650	chr2:63277830	OTX1	0.55	6.95	0.31	1.24e-11	Prostate cancer;
LGG	cis	rs6998277	1.000	rs16869658	chr8:103633762	C/T	cg10187029	chr8:103597600	NA	0.81	11.98	0.49	5.52e-29	Migraine;
LGG	cis	rs10850519	0.744	rs10850529	chr12:115949875	C/G	cg18639984	chr12:115943877	NA	-0.4	-8.78	-0.38	3.11e-17	Diastolic blood pressure;
LGG	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg09307838	chr4:120376055	NA	0.73	12.56	0.5	2.47e-31	Corneal astigmatism;
LGG	cis	rs853679	0.517	rs9393884	chr6:28046789	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.74	0.3	4.83e-11	Depression;
LGG	cis	rs2242116	0.796	rs9852082	chr3:46972377	T/C	cg02527881	chr3:46936655	PTH1R	-0.33	-7.78	-0.34	4.69e-14	Birth weight;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.97	0.38	7.5e-18	Alzheimer's disease;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg02353165	chr6:42928485	GNMT	0.48	14.49	0.56	1.61e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.22	0.39	1.03e-18	Schizophrenia;
LGG	trans	rs7762018	0.891	rs4716343	chr6:170143817	C/G	cg06875740	chr19:51307921	C19orf48	-0.62	-7.99	-0.35	1.11e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.16	0.52	7.64e-34	Prudent dietary pattern;
LGG	cis	rs422249	0.511	rs102274	chr11:61557826	T/C	cg19610905	chr11:61596333	FADS2	-0.81	-14.84	-0.57	5.18e-41	Trans fatty acid levels;
LGG	cis	rs72772090	0.634	rs72773912	chr5:96107801	A/G	cg00188032	chr5:96141721	ERAP1	0.53	7.23	0.32	2.02e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9880211	0.800	rs9871184	chr3:136514310	G/A	cg21827317	chr3:136751795	NA	-0.49	-7.13	-0.31	3.79e-12	Body mass index;Height;
LGG	cis	rs9611565	0.559	rs12483860	chr22:41961916	C/T	cg17376030	chr22:41985996	PMM1	0.54	8.68	0.37	7.01e-17	Vitiligo;
LGG	cis	rs128738	0.500	rs6875603	chr5:131565390	A/C	cg05556477	chr5:131705319	SLC22A5	0.45	6.71	0.3	5.83e-11	Giant cell arteritis;
LGG	cis	rs7255045	0.702	rs2293682	chr19:12989560	G/A	cg07955356	chr19:12992479	DNASE2	0.45	7.02	0.31	8.18e-12	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24996263	chr1:31297444	NA	0.41	6.74	0.3	4.84e-11	Cognitive performance;
LGG	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg02227867	chr8:22457446	C8orf58	-0.43	-8.33	-0.36	9.24e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg19680485	chr15:31195859	MTMR15	-0.47	-7.74	-0.34	6.23e-14	Huntington's disease progression;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs9912468	0.534	rs4791076	chr17:64237889	C/A	cg19474267	chr17:64306194	PRKCA	-0.7	-14.33	-0.55	8.57e-39	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-6.64	-0.3	8.61e-11	Skin colour saturation;
LGG	cis	rs11410354	1	rs11410354	chr11:442472	C/CT	cg19913688	chr11:428466	ANO9	0.71	10.64	0.44	8.32e-24	Breast cancer;
LGG	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg12856521	chr11:46389249	DGKZ	-0.89	-14.1	-0.55	7.87e-38	Crohn's disease;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-8.99	-0.39	6.23e-18	Personality dimensions;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg18350739	chr11:68623251	NA	-0.87	-22.23	-0.72	5.2e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7662987	0.517	rs1453873	chr4:100022571	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs1552244	0.554	rs6796411	chr3:10010681	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.36	-0.43	9.22e-23	Alzheimer's disease;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg00495681	chr13:53174319	NA	0.86	19.31	0.67	2.25e-61	Lewy body disease;
LGG	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg14088196	chr11:70211408	PPFIA1	0.83	11.66	0.48	1.04e-27	Coronary artery disease;
LGG	cis	rs523522	0.962	rs55848094	chr12:120966659	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.11	-0.35	4.43e-15	Morning vs. evening chronotype;
LGG	cis	rs514406	0.505	rs436363	chr1:53172163	T/C	cg16325326	chr1:53192061	ZYG11B	0.84	23.21	0.73	1.26e-79	Monocyte count;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg20790798	chr5:1857306	NA	-0.43	-7.1	-0.31	4.79e-12	Cardiovascular disease risk factors;
LGG	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg26924012	chr15:45694286	SPATA5L1	1.04	21.52	0.71	1.06e-71	Homoarginine levels;
LGG	cis	rs892961	0.932	rs7216909	chr17:75405234	A/G	cg05865280	chr17:75406074	SEPT9	0.42	9.86	0.42	6.07e-21	Airflow obstruction;
LGG	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg02002194	chr4:3960332	NA	0.38	7.06	0.31	6.04e-12	Triglycerides;
LGG	cis	rs6763768	0.606	rs4687576	chr3:53385418	T/C	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs7666738	0.830	rs1426668	chr4:98945585	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4663969	0.839	rs7572563	chr2:234617236	G/A	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.46	-8.49	-0.37	2.83e-16	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs3741151	0.773	rs73542990	chr11:73134398	C/T	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs911186	0.740	rs6938200	chr6:27231150	A/G	cg12292205	chr6:26970375	C6orf41	-0.58	-8.54	-0.37	1.9e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.72	-0.3	5.36e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.41	-0.4	2.31e-19	Personality dimensions;
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg00149659	chr3:10157352	C3orf10	0.85	11.13	0.46	1.19e-25	Alzheimer's disease;
LGG	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg24848339	chr3:12840334	CAND2	0.37	8.07	0.35	6.29e-15	QRS complex (12-leadsum);
LGG	cis	rs7928758	0.945	rs113328990	chr11:134278010	G/T	cg22777979	chr11:134283252	B3GAT1	0.86	11.1	0.46	1.57e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7666738	0.830	rs10856936	chr4:99011319	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.91	0.35	1.87e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05025164	chr4:1340916	KIAA1530	0.54	9.82	0.42	8.67e-21	Longevity;
LGG	cis	rs9992101	0.636	rs72657813	chr4:77258307	G/T	cg17010112	chr4:77227123	STBD1	-0.48	-9.91	-0.42	4.1e-21	Creatinine levels;
LGG	cis	rs7143963	0.945	rs56083744	chr14:103292191	G/A	cg23020514	chr14:103360112	TRAF3	0.55	10.42	0.44	5.56e-23	Body mass index;
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg19635926	chr16:89946313	TCF25	0.82	9.24	0.39	8.87e-19	Skin colour saturation;
LGG	cis	rs12282928	0.918	rs1503173	chr11:48246297	A/T	cg26585981	chr11:48327164	OR4S1	-0.43	-6.88	-0.3	1.99e-11	Migraine - clinic-based;
LGG	cis	rs17301259	0.602	rs2538921	chr7:88314970	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-7.2	-0.32	2.51e-12	Heschl's gyrus morphology;
LGG	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	11.08	0.46	1.74e-25	Neuroticism;
LGG	cis	rs4321325	0.733	rs4284778	chr2:127946326	A/G	cg11380483	chr2:127933992	NA	0.63	8.92	0.38	1.09e-17	Protein C levels;
LGG	cis	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19743759	chr9:35072884	VCP	0.42	6.74	0.3	4.73e-11	Cognitive performance;
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Electroencephalogram traits;
LGG	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2613964	0.504	rs7617193	chr3:112848851	T/C	cg16248390	chr3:112854924	NA	0.51	10.73	0.45	3.82e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs2415984	0.520	rs60342772	chr14:46935394	C/A	cg14871534	chr14:47121158	RPL10L	0.44	7.46	0.33	4.29e-13	Number of children ever born;
LGG	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg06968155	chr5:131705112	SLC22A5	0.69	8.08	0.35	5.52e-15	Rheumatoid arthritis;
LGG	cis	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.28	-0.4	6.43e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg18379455	chr17:41446167	NA	0.31	7.27	0.32	1.53e-12	Menopause (age at onset);
LGG	cis	rs61990749	0.597	rs4903643	chr14:78254791	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	6.75	0.3	4.44e-11	Fibroblast growth factor basic levels;
LGG	cis	rs7444	0.556	rs5754100	chr22:21916166	T/C	cg15846791	chr22:21984385	YDJC	-0.47	-6.78	-0.3	3.64e-11	Systemic lupus erythematosus;
LGG	cis	rs9462027	0.606	rs2815001	chr6:34634353	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.22e-24	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11890956	chr21:40555474	PSMG1	1.2	28.67	0.8	1.05e-104	Cognitive function;
LGG	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg14829155	chr15:31115871	NA	-0.56	-8.99	-0.39	6.28e-18	Huntington's disease progression;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	trans	rs8073060	0.561	rs225260	chr17:33958422	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.45	-0.63	9.3e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	cg07928641	chr1:182991847	LAMC1	0.45	9.1	0.39	2.68e-18	Colorectal cancer;
LGG	trans	rs3206736	0.520	rs1637674	chr7:34998087	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.01	0.31	8.63e-12	Diastolic blood pressure;
LGG	cis	rs526231	0.578	rs6867392	chr5:102281887	C/G	cg23492399	chr5:102201601	PAM	-0.6	-9.22	-0.39	1.06e-18	Primary biliary cholangitis;
LGG	cis	rs2204008	0.775	rs11514370	chr12:38305566	G/A	cg26384229	chr12:38710491	ALG10B	0.91	20.39	0.69	1.94e-66	Bladder cancer;
LGG	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.17	-0.32	2.96e-12	Calcium levels;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg09699651	chr6:150184138	LRP11	0.53	9.33	0.4	4.53e-19	Lung cancer;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.37	-0.43	8.28e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.15	0.32	3.34e-12	Obesity-related traits;
LGG	cis	rs7011049	0.687	rs6473770	chr8:53869554	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg24253500	chr15:84953950	NA	0.44	7.37	0.32	8.01e-13	Schizophrenia;
LGG	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg27624424	chr6:160112604	SOD2	0.66	9.91	0.42	4.12e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs477895	0.713	rs7952318	chr11:63961242	G/A	cg18225595	chr11:63971243	STIP1	0.5	7.18	0.32	2.8e-12	Mean platelet volume;
LGG	cis	rs1015291	0.708	rs1352900	chr12:20005490	C/T	cg25401612	chr12:20009446	NA	-0.34	-7.26	-0.32	1.67e-12	Diastolic blood pressure;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.49	-0.37	2.89e-16	Life satisfaction;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12136530	0.774	rs4911995	chr1:19765004	C/G	cg17081867	chr1:19768096	CAPZB	0.35	8.14	0.35	3.81e-15	Lead levels in blood;
LGG	cis	rs12210905	0.920	rs72839468	chr6:27301734	A/G	cg15325629	chr6:28072465	NA	0.9	6.99	0.31	9.71e-12	Hip circumference adjusted for BMI;
LGG	cis	rs992157	0.735	rs13392177	chr2:219112956	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.21	-0.43	3.33e-22	Colorectal cancer;
LGG	cis	rs4750440	0.702	rs4750444	chr10:14029068	C/T	cg27542038	chr10:14027202	FRMD4A	-0.71	-14.18	-0.55	3.53e-38	Adiponectin levels;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg19168338	chr16:4465731	CORO7	-0.86	-16.07	-0.6	1.62e-46	Schizophrenia;
LGG	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg21475434	chr5:93447410	FAM172A	0.66	6.71	0.3	5.68e-11	Diabetic retinopathy;
LGG	cis	rs17767392	0.918	rs35094946	chr14:71752790	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.04	-0.39	4.33e-18	Mitral valve prolapse;
LGG	cis	rs73787773	0.644	rs17134154	chr5:111480534	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.55	-7.05	-0.31	6.36e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs209489	0.892	rs79738227	chr6:53148251	T/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4917300	0.650	rs4917218	chr8:143072470	G/A	cg06573787	chr8:143070187	NA	0.76	16.0	0.6	3.58e-46	Amyotrophic lateral sclerosis;
LGG	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg19077165	chr18:44547161	KATNAL2	-0.51	-9.11	-0.39	2.4e-18	Personality dimensions;
LGG	cis	rs910187	0.605	rs6018324	chr20:45810181	G/C	cg27589058	chr20:45804311	EYA2	-0.36	-9.22	-0.39	1.09e-18	Migraine;
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg27411982	chr8:10470053	RP1L1	0.43	7.51	0.33	2.98e-13	Mood instability;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg03528353	chr17:61819722	STRADA	0.41	6.81	0.3	3.05e-11	Prudent dietary pattern;
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg14092988	chr3:52407081	DNAH1	0.31	8.08	0.35	5.6e-15	Bipolar disorder;
LGG	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg00405596	chr8:11794950	NA	-0.45	-7.54	-0.33	2.44e-13	Triglycerides;
LGG	cis	rs2797160	1.000	rs2747714	chr6:126007620	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.38	0.32	7.45e-13	Endometrial cancer;
LGG	cis	rs9287719	0.934	rs6432110	chr2:10738018	T/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs4356932	0.967	rs4859591	chr4:76948578	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg21775007	chr8:11205619	TDH	-0.43	-6.99	-0.31	9.93e-12	Systolic blood pressure;
LGG	cis	rs546131	0.600	rs502857	chr11:34854662	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	7.27	0.32	1.57e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.65	-0.48	1.1e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg12708336	chr17:41446283	NA	0.31	7.56	0.33	2.15e-13	Menopause (age at onset);
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg06719900	chr11:109292894	C11orf87	0.45	8.44	0.37	3.99e-16	Schizophrenia;
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.47	-0.33	4.13e-13	Obesity-related traits;
LGG	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg07930552	chr6:133119739	C6orf192	0.85	11.31	0.47	2.38e-26	Type 2 diabetes nephropathy;
LGG	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.64e-20	Hypertriglyceridemia;
LGG	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg18129748	chr3:49941408	MST1R	0.21	6.86	0.3	2.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs6964587	1.000	rs35317449	chr7:91637010	G/A	cg17063962	chr7:91808500	NA	0.47	8.49	0.37	2.77e-16	Breast cancer;
LGG	cis	rs17321999	1.000	rs10171305	chr2:30481343	A/T	cg05247661	chr2:30472410	LBH	0.53	8.35	0.36	8.11e-16	Systemic lupus erythematosus;
LGG	cis	rs8067545	0.611	rs12938355	chr17:20195217	A/G	cg13482628	chr17:19912719	NA	-0.55	-10.48	-0.44	3.44e-23	Schizophrenia;
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	cis	rs139156536	1	rs139156536	chr17:38164432	TTTTA/T	cg17467752	chr17:38218738	THRA	0.62	11.27	0.46	3.23e-26	Lymphocyte percentage of white cells;
LGG	cis	rs9326248	0.569	rs11216161	chr11:116721201	T/C	cg20608306	chr11:116969690	SIK3	0.33	7.17	0.32	3.01e-12	Blood protein levels;
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg16141378	chr3:129829833	LOC729375	0.36	8.41	0.36	5.23e-16	Neuroticism;
LGG	cis	rs3784262	1.000	rs11071356	chr15:58240518	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.2	-0.36	2.38e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs2548003	1.000	rs1423287	chr5:28762202	A/G	cg12623145	chr2:97778927	ANKRD36	0.45	6.91	0.31	1.65e-11	Hip geometry;
LGG	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.39	8.5e-19	Diabetic retinopathy;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00689492	chr4:1303491	MAEA	0.5	8.35	0.36	7.81e-16	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs35560973	chr21:46662573	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.2	0.36	2.37e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6708331	1.000	rs13000817	chr2:70273707	C/T	cg01613454	chr2:70366299	NA	0.53	9.01	0.39	5.27e-18	Obesity-related traits;
LGG	cis	rs4740619	0.846	rs10810429	chr9:15701074	C/T	cg14451791	chr9:16040625	NA	0.33	8.44	0.37	3.98e-16	Body mass index;
LGG	cis	rs1949733	0.656	rs6845969	chr4:8402465	A/T	cg11789530	chr4:8429930	ACOX3	0.74	14.45	0.56	2.38e-39	Response to antineoplastic agents;
LGG	cis	rs72949976	0.966	rs6752061	chr2:214027818	C/T	cg08319019	chr2:214017104	IKZF2	-0.59	-10.0	-0.42	1.95e-21	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs6163	0.727	rs284862	chr10:104572081	C/T	cg04362960	chr10:104952993	NT5C2	-0.44	-7.78	-0.34	4.69e-14	Waist circumference;Hip circumference;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.49	-0.37	2.74e-16	Personality dimensions;
LGG	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg03733263	chr8:22462867	KIAA1967	-0.94	-21.31	-0.7	9.85e-71	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.71e-12	Aortic root size;
LGG	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.46	0.33	4.35e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9372253	1.000	rs11153232	chr6:110716252	G/T	cg01119278	chr6:110721349	DDO	0.28	6.83	0.3	2.65e-11	Platelet distribution width;
LGG	cis	rs7582720	1.000	rs72926781	chr2:203808835	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs17453880	0.709	rs73284889	chr5:151928731	G/A	cg12297329	chr5:152029980	NA	-0.64	-13.48	-0.53	3.76e-35	Subjective well-being;
LGG	cis	rs6840360	0.593	rs59350867	chr4:152695935	G/A	cg22705602	chr4:152727874	NA	-0.4	-10.26	-0.43	2.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg17749961	chr2:30669863	LCLAT1	-0.68	-9.58	-0.41	5.83e-20	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07498778	chr8:38325092	FGFR1	-0.41	-6.7	-0.3	5.91e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg15352829	chr14:105391018	PLD4	0.48	11.42	0.47	8.61e-27	Rheumatoid arthritis;
LGG	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg23825213	chr18:77623475	KCNG2	-0.4	-7.01	-0.31	8.2e-12	Schizophrenia;
LGG	cis	rs62025270	0.632	rs17637411	chr15:86246447	C/G	cg25843651	chr15:86329602	KLHL25	0.55	8.46	0.37	3.55e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs4430311	0.566	rs10927035	chr1:243703982	C/T	cg25706552	chr1:244017396	NA	-0.58	-13.5	-0.53	2.94e-35	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs965513	1.000	rs10983701	chr9:100537577	G/A	cg13688889	chr9:100608707	NA	-0.52	-9.5	-0.4	1.15e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs7647973	0.922	rs56049603	chr3:49585243	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	-0.46	-7.24	-0.32	1.88e-12	Menarche (age at onset);
LGG	cis	rs300774	0.925	rs397911	chr2:147317	A/G	cg04617936	chr2:214353	NA	-0.5	-7.49	-0.33	3.48e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11106794	chr5:134241538	PCBD2	-0.4	-6.94	-0.31	1.3e-11	Pancreatic cancer;
LGG	cis	rs2562152	0.530	rs216604	chr16:112513	T/C	cg02949481	chr16:131562	MPG	0.65	9.01	0.39	5.51e-18	Glioblastoma;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.06e-43	Menopause (age at onset);
LGG	cis	rs478607	1.000	rs551890	chr11:64477999	C/T	cg19395706	chr11:64412079	NRXN2	-0.38	-6.73	-0.3	5.15e-11	Urate levels;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6546550	0.935	rs2168115	chr2:70034793	A/G	cg02498382	chr2:70120550	SNRNP27	-0.39	-7.16	-0.32	3.14e-12	Prevalent atrial fibrillation;
LGG	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg25947184	chr8:1697459	NA	0.42	7.34	0.32	9.66e-13	Systolic blood pressure;
LGG	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.95	18.9	0.66	1.73e-59	Platelet count;
LGG	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	cis	rs785830	0.655	rs588412	chr9:249391	A/C	cg14500300	chr9:211689	NA	-0.32	-7.92	-0.35	1.82e-14	Platelet distribution width;
LGG	cis	rs10791097	0.694	rs1893017	chr11:130756253	C/T	cg09137382	chr11:130731461	NA	0.35	6.79	0.3	3.49e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.42	-0.33	5.57e-13	Menopause (age at onset);
LGG	cis	rs3849570	0.695	rs6792696	chr3:81874009	G/A	cg07356753	chr3:81810745	GBE1	-0.47	-7.62	-0.33	1.49e-13	Waist circumference;Body mass index;
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg05091796	chr16:4465799	CORO7	-0.9	-14.44	-0.56	2.64e-39	Schizophrenia;
LGG	cis	rs59197085	0.636	rs9791702	chr7:128440185	T/C	cg00734629	chr7:128471146	FLNC	0.33	6.75	0.3	4.55e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs17376456	0.877	rs35075119	chr5:93385457	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.9e-22	Diabetic retinopathy;
LGG	cis	rs17125944	0.505	rs75296244	chr14:53233218	G/A	cg00686598	chr14:53173677	PSMC6	1.39	15.5	0.58	5.73e-44	Alzheimer's disease (late onset);
LGG	cis	rs1816752	0.905	rs7991450	chr13:25000036	T/G	cg22771759	chr13:24902376	NA	0.42	7.09	0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg20607798	chr8:58055168	NA	0.64	7.43	0.33	5.38e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg08677398	chr8:58056175	NA	0.55	8.32	0.36	9.65e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11674184	0.686	rs2358039	chr2:11729606	A/G	cg07314298	chr2:11723111	GREB1	-0.8	-16.55	-0.61	1.2e-48	Endometriosis;
LGG	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg09517075	chr8:22133004	PIWIL2	0.42	9.02	0.39	4.9e-18	Hypertriglyceridemia;
LGG	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg03469862	chr11:68924853	NA	0.47	7.12	0.31	4.13e-12	Blond vs. brown hair color;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg08677398	chr8:58056175	NA	0.55	8.32	0.36	9.65e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg13385794	chr1:248469461	NA	-0.48	-7.99	-0.35	1.05e-14	Common traits (Other);
LGG	cis	rs4727027	0.745	rs10952801	chr7:148864757	T/C	cg23583168	chr7:148888333	NA	-0.87	-16.88	-0.62	3.72e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2071403	0.933	rs1567920	chr2:1413226	A/G	cg06500727	chr2:1417164	TPO	-0.51	-9.63	-0.41	4.02e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.8	0.66	5.12e-59	Smoking behavior;
LGG	cis	rs11122272	0.735	rs2246645	chr1:231497393	T/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.36	-0.32	8.6e-13	Hemoglobin concentration;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.72	0.38	4.93e-17	Bipolar disorder;
LGG	cis	rs981844	0.753	rs1105491	chr4:154726634	A/C	cg14289246	chr4:154710475	SFRP2	0.6	10.14	0.43	5.84e-22	Response to statins (LDL cholesterol change);
LGG	cis	rs2836974	0.897	rs35386515	chr21:40532047	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs17376456	0.825	rs17314797	chr5:93234845	T/A	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17996757	chr7:131013207	MKLN1	0.39	7.17	0.32	3.08e-12	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.19	-0.36	2.51e-15	HDL cholesterol;
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-10.88	-0.45	1.08e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg00254258	chr1:3105189	PRDM16	-0.69	-13.5	-0.53	3.04e-35	Migraine;
LGG	cis	rs1185460	0.547	rs667584	chr11:118911544	C/T	cg23280166	chr11:118938394	VPS11	-0.44	-7.63	-0.33	1.38e-13	Coronary artery disease;
LGG	cis	rs1003719	0.680	rs3992	chr21:38505969	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs7122539	0.734	rs10750790	chr11:66582210	A/G	cg01599099	chr11:66649832	PC	0.48	9.79	0.41	1.09e-20	HIV-1 susceptibility;
LGG	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg19812747	chr11:111475976	SIK2	0.48	9.44	0.4	1.85e-19	Primary sclerosing cholangitis;
LGG	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg19418458	chr7:158789849	NA	-0.52	-10.94	-0.45	6.45e-25	Facial morphology (factor 20);
LGG	cis	rs9354308	0.764	rs9351538	chr6:66607743	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.72	-0.3	5.34e-11	Metabolite levels;
LGG	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg17077180	chr1:38461687	NA	0.41	9.41	0.4	2.36e-19	Coronary artery disease;
LGG	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg15485101	chr11:133734466	NA	0.6	10.71	0.45	4.6e-24	Childhood ear infection;
LGG	cis	rs6964587	0.692	rs2158138	chr7:91700879	A/G	cg17063962	chr7:91808500	NA	0.48	8.92	0.38	1.12e-17	Breast cancer;
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg01765077	chr12:122356316	WDR66	0.26	7.09	0.31	5.13e-12	Mean platelet volume;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs988958	0.565	rs6758382	chr2:42231733	G/A	cg27428208	chr2:42229179	NA	0.48	7.56	0.33	2.15e-13	Hypospadias;
LGG	cis	rs9547692	0.938	rs4520715	chr13:37459113	C/T	cg01493522	chr13:37497338	NA	-0.53	-8.85	-0.38	1.9e-17	Coronary artery disease;
LGG	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg09998033	chr7:158218633	PTPRN2	0.54	10.15	0.43	5.67e-22	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03746823	chr10:61122100	FAM13C	0.51	8.14	0.35	3.58e-15	Gut microbiome composition (summer);
LGG	cis	rs10752881	1.000	rs4304541	chr1:182970238	G/T	cg15522984	chr1:182991683	LAMC1	0.48	9.92	0.42	3.7e-21	Colorectal cancer;
LGG	cis	rs7936323	1	rs7936323	chr11:76293758	G/A	cg17647271	chr11:76299819	NA	-0.43	-7.51	-0.33	3.16e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil counts;Eosinophil percentage of white cells;Allergy;Allergic disease (asthma, hay fever or eczema);Asthma;
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg13628971	chr7:2884303	GNA12	0.52	10.67	0.44	6.57e-24	Height;
LGG	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg20019365	chr2:219134978	PNKD;AAMP	0.69	12.07	0.49	2.32e-29	Colorectal cancer;
LGG	cis	rs9611565	0.559	rs5758412	chr22:42080803	T/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Vitiligo;
LGG	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	11.94	0.49	7.55e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs75920871	0.925	rs17120237	chr11:116891046	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.98e-12	Subjective well-being;
LGG	cis	rs9611565	0.512	rs5751147	chr22:42139054	G/A	cg17376030	chr22:41985996	PMM1	-0.66	-10.77	-0.45	2.64e-24	Vitiligo;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg23730037	chr7:158596552	ESYT2	-0.41	-6.93	-0.31	1.38e-11	Height;
LGG	cis	rs2274273	0.868	rs9919926	chr14:55813890	G/C	cg04306507	chr14:55594613	LGALS3	0.61	16.67	0.61	3.25e-49	Protein biomarker;
LGG	cis	rs6088580	0.634	rs4911423	chr20:32999386	T/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.21	-0.43	3.32e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20646995	chr7:102105124	LRWD1;ALKBH4	0.45	6.67	0.3	7.53e-11	Gut microbiome composition (summer);
LGG	cis	rs7589342	0.628	rs11886675	chr2:106409118	G/T	cg16077055	chr2:106428750	NCK2	0.3	7.2	0.32	2.49e-12	Addiction;
LGG	cis	rs2587949	0.615	rs2600120	chr3:4222395	G/A	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02990094	chr3:12526312	TSEN2	0.5	7.35	0.32	9.2e-13	Gut microbiome composition (summer);
LGG	cis	rs4954585	0.683	rs13024450	chr2:137014611	C/T	cg07169764	chr2:136633963	MCM6	-0.46	-7.34	-0.32	9.96e-13	Colorectal cancer;
LGG	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg08344181	chr3:125677491	NA	-0.92	-8.64	-0.37	9.01e-17	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg03264133	chr6:25882463	NA	0.46	7.45	0.33	4.75e-13	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24113505	chr7:92861286	CCDC132	0.43	7.4	0.33	6.55e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.762	rs6909047	chr6:44998915	C/G	cg20913747	chr6:44695427	NA	-0.51	-7.93	-0.35	1.71e-14	Total body bone mineral density;
LGG	cis	rs56235845	0.964	rs11741640	chr5:176792743	G/A	cg06060754	chr5:176797920	RGS14	0.46	7.61	0.33	1.5e-13	Hemoglobin concentration;Hematocrit;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.03	-0.68	9.6e-65	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	9.91	0.42	3.89e-21	Prudent dietary pattern;
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg27400746	chr16:89904261	SPIRE2	-1.14	-17.01	-0.62	9.12e-51	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02754722	chr6:2766192	WRNIP1	0.44	6.66	0.3	8.02e-11	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.569	rs1119851	chr11:133742842	T/C	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs2976388	0.565	rs2572905	chr8:143797104	C/T	cg06565975	chr8:143823917	SLURP1	0.37	9.4	0.4	2.6e-19	Urinary tract infection frequency;
LGG	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.19	-0.36	2.6e-15	Mood instability;
LGG	cis	rs10883723	0.669	rs2001595	chr10:104395085	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	11.42	0.47	8.9e-27	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg06437703	chr8:37914619	EIF4EBP1	0.75	10.99	0.45	4.06e-25	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2692947	0.726	rs13009727	chr2:96769883	C/G	cg22654517	chr2:96458247	NA	-0.39	-8.47	-0.37	3.27e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg04568710	chr12:38710424	ALG10B	-0.4	-8.59	-0.37	1.29e-16	Morning vs. evening chronotype;
LGG	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.1	0.57	3.66e-42	Cognitive test performance;
LGG	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2652822	0.935	rs2292038	chr15:63449680	C/G	cg02713581	chr15:63449717	RPS27L	-0.5	-8.53	-0.37	2.09e-16	Metabolic traits;
LGG	cis	rs9527	0.615	rs7080462	chr10:104736699	T/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.83	-0.3	2.75e-11	Arsenic metabolism;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-9.87	-0.42	5.43e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg25019033	chr10:957182	NA	-0.53	-9.64	-0.41	3.62e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg11859384	chr17:80120422	CCDC57	-0.47	-8.24	-0.36	1.8e-15	Life satisfaction;
LGG	cis	rs10924309	0.889	rs10802248	chr1:245858554	A/C	cg00036263	chr1:245852353	KIF26B	-0.46	-6.88	-0.3	1.91e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs1318772	1.000	rs255859	chr5:112743480	C/T	cg12552261	chr5:112820674	MCC	0.7	7.99	0.35	1.11e-14	F-cell distribution;
LGG	cis	rs3849046	0.781	rs11745933	chr5:137940165	C/T	cg10920316	chr5:137946599	NA	-0.45	-7.19	-0.32	2.59e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3768617	0.510	rs10911249	chr1:183080690	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2072438	0.505	rs7034074	chr9:123923029	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	9.21	0.39	1.17e-18	Rheumatoid arthritis;
LGG	cis	rs1978968	0.763	rs5992137	chr22:18457986	T/C	cg03078520	chr22:18463400	MICAL3	-0.67	-14.62	-0.56	4.33e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.19	0.32	2.6e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs968451	0.865	rs2007418	chr22:39712394	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	12.02	0.49	3.57e-29	Primary biliary cholangitis;
LGG	trans	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg26384229	chr12:38710491	ALG10B	0.82	16.51	0.61	1.77e-48	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg05941027	chr17:61774174	LIMD2	0.38	9.79	0.41	1.04e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12912251	0.591	rs10520103	chr15:39006243	C/G	cg10631289	chr15:39006617	NA	0.42	7.1	0.31	4.82e-12	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26900616	chr4:159593389	ETFDH;C4orf46	0.42	7.0	0.31	8.94e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg06374794	chr16:88002281	BANP	0.49	8.96	0.38	8.19e-18	Menopause (age at onset);
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.09	0.42	8.99e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6547631	0.527	rs55665393	chr2:85927727	T/C	cg24620635	chr2:85921963	GNLY	0.5	9.89	0.42	4.77e-21	Blood protein levels;
LGG	cis	rs7667	1.000	rs7667	chr1:19718824	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.41	-7.46	-0.33	4.18e-13	Crohn's disease and psoriasis;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.25	0.52	3.37e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08280861	chr8:58055591	NA	0.64	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11203032	0.831	rs11203022	chr10:90954068	G/A	cg16672925	chr10:90967113	CH25H	0.79	11.31	0.47	2.33e-26	Heart failure;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.61e-12	Menopause (age at onset);
LGG	cis	rs10895140	0.665	rs2508251	chr11:101486956	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs9880211	0.948	rs13321721	chr3:136209550	A/G	cg21827317	chr3:136751795	NA	-0.49	-7.18	-0.32	2.79e-12	Body mass index;Height;
LGG	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.57	-0.33	2.07e-13	Testicular germ cell tumor;
LGG	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.8	0.3	3.22e-11	Cognitive function;
LGG	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs10088262	0.629	rs7828192	chr8:124804669	C/T	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.84	-0.34	3.21e-14	Pancreatic cancer;
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-6.94	-0.31	1.36e-11	Bipolar disorder;
LGG	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.12e-25	Corneal astigmatism;
LGG	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.84	-0.34	3.2e-14	Neuroticism;
LGG	cis	rs6964587	1.000	rs7785095	chr7:91640773	A/T	cg17063962	chr7:91808500	NA	-0.48	-8.54	-0.37	1.96e-16	Breast cancer;
LGG	cis	rs1682825	0.929	rs73812285	chr3:10768244	C/A	cg23512531	chr3:10780469	NA	0.58	8.06	0.35	6.5e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs612683	0.764	rs558035	chr1:100939777	T/C	cg09408571	chr1:101003634	GPR88	-0.32	-8.01	-0.35	9.64e-15	Breast cancer;
LGG	cis	rs7712401	0.601	rs386602	chr5:122321957	T/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.51e-11	Mean platelet volume;
LGG	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs7769051	0.522	rs6927991	chr6:133113888	T/G	cg07930552	chr6:133119739	C6orf192	1.13	9.71	0.41	2.01e-20	Type 2 diabetes nephropathy;
LGG	cis	rs5769765	0.862	rs9616384	chr22:50313082	C/T	cg02269571	chr22:50332266	NA	-0.71	-10.9	-0.45	8.73e-25	Schizophrenia;
LGG	trans	rs9354308	0.840	rs17508021	chr6:66569748	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.01	0.42	1.71e-21	Metabolite levels;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.04e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs11858495	chr15:45637662	A/G	cg21132104	chr15:45694354	SPATA5L1	-0.7	-10.72	-0.45	4.34e-24	Homoarginine levels;
LGG	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg11693508	chr17:37793320	STARD3	0.48	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg05707623	chr12:122985044	ZCCHC8	-0.67	-10.09	-0.42	8.82e-22	Body mass index;
LGG	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.65	-0.33	1.19e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.65	0.61	3.95e-49	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.65	-0.61	3.97e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.93	-0.52	7.28e-33	Intelligence (multi-trait analysis);
LGG	cis	rs7945718	0.621	rs7943920	chr11:12695614	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.31	0.32	1.2e-12	Educational attainment (years of education);
LGG	cis	rs12410462	0.636	rs2644154	chr1:227703888	G/A	cg23173402	chr1:227635558	NA	0.38	7.09	0.31	4.99e-12	Major depressive disorder;
LGG	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg09217309	chr6:150244204	RAET1G	0.44	8.11	0.35	4.55e-15	Lung cancer;
LGG	cis	rs8064024	0.599	rs1876359	chr16:4930100	C/T	cg04440724	chr16:4920505	UBN1	-0.5	-10.06	-0.42	1.18e-21	Cancer;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.64	12.67	0.51	8.62e-32	Obesity-related traits;
LGG	cis	rs921968	0.541	rs3770213	chr2:219508372	A/T	cg01130898	chr2:219473002	PLCD4	0.48	8.29	0.36	1.23e-15	Mean corpuscular hemoglobin concentration;
LGG	trans	rs6076960	0.652	rs3905171	chr20:6211177	T/C	cg24759859	chr6:86352639	SYNCRIP	0.44	7.53	0.33	2.64e-13	Smooth-surface caries;
LGG	cis	rs13191362	0.810	rs34714603	chr6:163008078	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg02725872	chr8:58115012	NA	-0.86	-11.73	-0.48	5.27e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg11252792	chr3:125932053	NA	0.55	11.22	0.46	5.35e-26	Metabolite levels;
LGG	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg17299007	chr1:248814626	OR2T27	-0.32	-6.69	-0.3	6.42e-11	Common traits (Other);
LGG	trans	rs4942242	0.512	rs9533551	chr13:44187120	G/C	cg19169023	chr15:41853346	TYRO3	-0.45	-8.67	-0.37	7.25e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs6787172	0.702	rs1193508	chr3:158030350	A/T	cg23275840	chr4:47708675	CORIN	0.4	8.63	0.37	1.01e-16	Subjective well-being;
LGG	cis	rs56235845	0.694	rs11748912	chr5:176765395	G/A	cg17509989	chr5:176798049	RGS14	0.66	10.92	0.45	7.4e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs782590	1.000	rs782594	chr2:55844445	T/C	cg18811423	chr2:55921094	PNPT1	0.89	20.74	0.69	4.89e-68	Metabolic syndrome;
LGG	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg26384229	chr12:38710491	ALG10B	0.85	18.51	0.65	1.17e-57	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.681	rs113316536	chr1:227547033	T/G	cg23173402	chr1:227635558	NA	0.5	8.44	0.37	3.99e-16	Major depressive disorder;
LGG	cis	rs9814567	0.896	rs11915964	chr3:134348930	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.57	0.5	2.17e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27606397	chr2:173244251	NA	0.41	7.41	0.33	5.85e-13	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17554472	chr22:41940697	POLR3H	0.46	6.67	0.3	7.12e-11	Vitiligo;
LGG	cis	rs11628318	0.515	rs1190343	chr14:103100348	G/A	cg12046867	chr14:103022105	NA	-0.4	-7.56	-0.33	2.17e-13	Platelet count;
LGG	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.64	0.41	3.68e-20	Height;
LGG	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg03433033	chr1:76189801	ACADM	0.81	14.25	0.55	1.83e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg12813108	chr7:99719912	CNPY4	-0.52	-7.97	-0.35	1.23e-14	Lung function (FEV1/FVC);
LGG	cis	rs17253792	0.822	rs76264681	chr14:56060447	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg09873164	chr1:152488093	CRCT1	0.64	15.62	0.59	1.68e-44	Hair morphology;
LGG	trans	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg25214090	chr10:38739885	LOC399744	0.6	10.93	0.45	6.66e-25	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03732293	chr1:179335087	C1orf125	0.52	7.86	0.34	2.78e-14	Gut microbiome composition (summer);
LGG	cis	rs1497828	1.000	rs2815237	chr1:217543239	T/C	cg04411442	chr1:217543379	NA	0.48	8.25	0.36	1.66e-15	Dialysis-related mortality;
LGG	cis	rs9300255	0.722	rs10846515	chr12:123801672	T/G	cg00376283	chr12:123451042	ABCB9	0.56	8.74	0.38	4.42e-17	Neutrophil percentage of white cells;
LGG	cis	rs6138458	1.000	rs7269416	chr20:24976196	T/G	cg26195577	chr20:24973756	C20orf3	1.24	25.98	0.77	1.77e-92	Blood protein levels;
LGG	cis	rs6667605	0.527	rs6673993	chr1:2552071	T/C	cg15627072	chr1:2432621	PLCH2	0.33	7.63	0.33	1.33e-13	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs36051895	0.559	rs7850228	chr9:5210671	C/G	cg02405213	chr9:5042618	JAK2	0.63	11.41	0.47	9.46e-27	Pediatric autoimmune diseases;
LGG	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.07	-0.49	2.39e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.96	-0.31	1.14e-11	Vitiligo;
LGG	cis	rs2455601	0.882	rs11042115	chr11:8926679	A/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.49	-0.47	4.7e-27	Schizophrenia;
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.65	0.44	7.81e-24	Total body bone mineral density;
LGG	cis	rs988958	0.675	rs1866669	chr2:42221789	C/T	cg27252766	chr2:42229092	NA	0.56	8.64	0.37	8.95e-17	Hypospadias;
LGG	cis	rs9788721	0.806	rs951985	chr15:78720923	T/G	cg18825076	chr15:78729989	IREB2	-0.57	-8.89	-0.38	1.37e-17	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2249694	0.520	rs7096203	chr10:135324505	A/C	cg20169779	chr10:135381914	SYCE1	-0.54	-7.42	-0.33	5.54e-13	Obesity-related traits;
LGG	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg10523679	chr1:76189770	ACADM	0.82	14.23	0.55	2.2e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.23e-13	Schizophrenia;
LGG	cis	rs6988636	1.000	rs28694222	chr8:124195017	C/T	cg23067535	chr8:124195133	FAM83A	-0.6	-7.17	-0.32	2.95e-12	Urinary uromodulin levels;
LGG	cis	rs8072100	0.790	rs7222225	chr17:45693497	A/G	cg08085267	chr17:45401833	C17orf57	0.52	9.67	0.41	2.95e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7914558	0.966	rs1890185	chr10:104748718	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.45	0.44	4.49e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs13172324	1.000	rs13172324	chr5:7368845	C/T	cg03764088	chr15:23115232	NA	-0.54	-6.65	-0.3	8.48e-11	Myopia (pathological);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20419181	chr4:38063874	TBC1D1	-0.51	-8.53	-0.37	2.07e-16	Body fat percentage;
LGG	cis	rs457717	0.730	rs2431366	chr5:75945393	T/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs870825	0.616	rs28618216	chr4:185648998	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.53e-30	Corneal astigmatism;
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-8.06	-0.35	6.56e-15	Personality dimensions;
LGG	cis	rs3096299	0.900	rs2911258	chr16:89480760	A/G	cg02187348	chr16:89574699	SPG7	0.47	7.67	0.34	1.03e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs4919694	0.808	rs112574306	chr10:104971159	C/T	cg04362960	chr10:104952993	NT5C2	1.01	12.05	0.49	2.75e-29	Arsenic metabolism;
LGG	cis	rs2486288	0.656	rs7162022	chr15:45565253	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.54	-0.44	1.95e-23	Glomerular filtration rate;
LGG	cis	rs4538187	0.662	rs66980330	chr2:64125978	C/G	cg14150252	chr2:64069583	UGP2	-0.46	-8.83	-0.38	2.24e-17	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.39	0.32	6.93e-13	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.86e-13	Life satisfaction;
LGG	cis	rs763121	0.889	rs2267390	chr22:38889657	C/T	cg06022373	chr22:39101656	GTPBP1	0.85	16.97	0.62	1.47e-50	Menopause (age at onset);
LGG	cis	rs9308731	0.623	rs2241841	chr2:111879467	G/A	cg26001287	chr2:111877753	BCL2L11	-0.35	-6.99	-0.31	9.87e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-11.95	-0.49	7.32e-29	Cognitive function;
LGG	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg02187348	chr16:89574699	SPG7	0.47	7.55	0.33	2.31e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs11123694	1.000	rs11123694	chr2:109064563	C/T	cg02082929	chr2:109068933	GCC2	0.44	9.96	0.42	2.6e-21	Mean platelet volume;
LGG	cis	rs6495122	0.501	rs12904227	chr15:75387048	A/C	cg17294928	chr15:75287854	SCAMP5	-0.54	-9.9	-0.42	4.39e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg04863758	chr4:1303710	MAEA	0.43	7.39	0.32	6.88e-13	Obesity-related traits;
LGG	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.69	-0.34	8.77e-14	Menarche (age at onset);
LGG	cis	rs9811920	0.809	rs793443	chr3:99573547	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.36	-0.36	7.61e-16	Axial length;
LGG	cis	rs853679	0.542	rs6934769	chr6:28090931	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6942756	0.806	rs6467237	chr7:128964831	A/G	cg02491457	chr7:128862824	NA	-0.62	-11.62	-0.48	1.45e-27	White matter hyperintensity burden;
LGG	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.65	-0.37	8.43e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg25208724	chr1:156163844	SLC25A44	1.27	31.92	0.83	4.73e-119	Testicular germ cell tumor;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.64	-0.33	1.29e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg26338869	chr17:61819248	STRADA	-0.47	-7.5	-0.33	3.39e-13	Prudent dietary pattern;
LGG	cis	rs10191773	0.535	rs12477879	chr2:112969865	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-9.13	-0.39	2.2e-18	Yeast infection;
LGG	cis	rs2075371	0.796	rs12154724	chr7:133943443	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	9.94	0.42	3.08e-21	Mean platelet volume;
LGG	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg10580341	chr11:889148	CHID1	-0.38	-7.05	-0.31	6.41e-12	Mean platelet volume;
LGG	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.57	7.35	0.32	9.22e-13	Schizophrenia;
LGG	cis	rs7582720	1.000	rs72932752	chr2:203667526	G/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.57	0.41	6.31e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2742417	1.000	rs2742452	chr3:45765708	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.39	-0.32	6.94e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6933660	0.744	rs35143743	chr6:151768532	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.53	-8.18	-0.36	2.7e-15	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24777868	chr17:61699845	MAP3K3	0.43	6.7	0.3	5.98e-11	Gut microbiome composition (summer);
LGG	cis	rs3815700	1.000	rs7248845	chr19:33096718	T/C	cg02997394	chr19:33096574	ANKRD27	0.91	14.42	0.56	3.22e-39	Eosinophilic esophagitis;
LGG	trans	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.16e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17919570	chr2:234763381	HJURP	0.49	7.6	0.33	1.67e-13	Gut microbiome composition (summer);
LGG	cis	rs2470578	0.792	rs2733485	chr3:17318438	A/C	cg20981856	chr3:17787350	NA	0.35	6.7	0.3	5.91e-11	Schizophrenia;
LGG	cis	rs2070433	0.706	rs55696586	chr21:47733918	T/C	cg12379764	chr21:47803548	PCNT	0.68	9.35	0.4	3.76e-19	Lymphocyte counts;
LGG	cis	rs4684776	1.000	rs12107908	chr3:11540083	G/T	cg24705426	chr3:11550659	ATG7	-0.48	-8.46	-0.37	3.59e-16	Small vessel stroke;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.14	0.55	5.7e-38	Obesity-related traits;
LGG	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg02974968	chr1:160236444	NA	-0.61	-12.05	-0.49	2.74e-29	Squamous cell lung carcinoma;
LGG	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg19773385	chr1:10388646	KIF1B	-0.53	-11.35	-0.47	1.69e-26	Hepatocellular carcinoma;
LGG	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg11890956	chr21:40555474	PSMG1	-0.94	-18.78	-0.66	6.67e-59	Cognitive function;
LGG	cis	rs9425766	0.640	rs9660881	chr1:173836516	T/C	cg06124660	chr1:173389066	NA	-0.4	-6.89	-0.3	1.87e-11	Life satisfaction;
LGG	cis	rs7246865	0.768	rs8106184	chr19:17159779	A/C	cg19418318	chr19:17219073	MYO9B	0.27	6.81	0.3	3.05e-11	Reticulocyte fraction of red cells;
LGG	cis	rs10940138	0.501	rs2087621	chr5:67248930	A/T	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.04	-0.35	7.46e-15	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-9.91	-0.42	3.95e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7924005	0.787	rs10905876	chr10:6174601	C/T	cg17191567	chr10:6178319	NA	0.39	7.12	0.31	4.2e-12	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg12386194	chr3:101231763	SENP7	0.44	7.83	0.34	3.33e-14	Colorectal cancer;
LGG	cis	rs4253772	0.513	rs6008597	chr22:46703904	A/C	cg00784671	chr22:46762841	CELSR1	-0.56	-7.31	-0.32	1.18e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs931812	0.895	rs4734493	chr8:101902169	C/T	cg20993868	chr7:22813445	NA	-0.69	-13.0	-0.52	3.68e-33	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs3925075	0.833	rs11641202	chr16:31330161	A/G	cg02846316	chr16:31340340	ITGAM	0.37	7.3	0.32	1.23e-12	IgA nephropathy;
LGG	trans	rs28735056	1.000	rs28865701	chr18:77620911	A/G	cg05926928	chr17:57297772	GDPD1	-0.42	-6.83	-0.3	2.7e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.72e-15	Skin colour saturation;
LGG	cis	rs3806843	0.966	rs7737424	chr5:140146345	C/T	cg19875535	chr5:140030758	IK	0.52	10.78	0.45	2.51e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4363385	0.818	rs684305	chr1:153006242	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.62	-10.39	-0.43	7.41e-23	Renal function-related traits (BUN);
LGG	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg17218041	chr13:113365319	ATP11A	0.43	6.99	0.31	9.38e-12	Glycated hemoglobin levels;
LGG	trans	rs9409565	0.586	rs58057339	chr9:97117788	T/C	cg05679027	chr9:99775184	HIATL2	0.44	6.7	0.3	5.92e-11	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs11583043	0.918	rs3850453	chr1:101408933	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.87	0.38	1.63e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.37	0.32	7.67e-13	Menopause (age at onset);
LGG	cis	rs806215	1.000	rs2106186	chr7:127241352	G/C	cg25922125	chr7:127225783	GCC1	0.74	10.02	0.42	1.55e-21	Type 2 diabetes;
LGG	cis	rs9486719	1.000	rs11153064	chr6:97021959	A/G	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs12497850	0.931	rs13064784	chr3:49135961	C/G	cg07636037	chr3:49044803	WDR6	1.12	28.68	0.8	9.92e-105	Parkinson's disease;
LGG	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.04	0.42	1.41e-21	Motion sickness;
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg27471124	chr11:109292789	C11orf87	0.82	17.81	0.64	2.01e-54	Schizophrenia;
LGG	cis	rs42648	0.738	rs10248104	chr7:89895262	C/T	cg25739043	chr7:89950458	NA	-0.33	-6.75	-0.3	4.55e-11	Homocysteine levels;
LGG	cis	rs8072100	0.544	rs7214993	chr17:45386797	C/G	cg25173405	chr17:45401733	C17orf57	-0.58	-9.92	-0.42	3.77e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6951245	1.000	rs28528096	chr7:1070912	G/C	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3924048	0.574	rs12410270	chr1:12612843	G/A	cg00291366	chr1:12616550	NA	0.36	8.76	0.38	3.6e-17	Optic cup area;
LGG	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.86	0.34	2.69e-14	Neuroticism;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg01879757	chr17:41196368	BRCA1	-0.44	-8.9	-0.38	1.26e-17	Menopause (age at onset);
LGG	cis	rs11190604	0.767	rs10883490	chr10:102194775	C/T	cg07570687	chr10:102243282	WNT8B	0.41	7.32	0.32	1.11e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg04990556	chr1:26633338	UBXN11	0.62	8.15	0.35	3.46e-15	Obesity-related traits;
LGG	cis	rs11874712	1.000	rs8088881	chr18:43664970	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg02733842	chr7:1102375	C7orf50	0.42	7.48	0.33	3.76e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6840360	0.868	rs6823462	chr4:152708740	G/A	cg22705602	chr4:152727874	NA	-0.27	-6.9	-0.31	1.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.16	0.43	4.92e-22	Tonsillectomy;
LGG	cis	rs6977660	0.714	rs6977079	chr7:19818207	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs7927771	0.832	rs55677087	chr11:47397714	C/G	cg20307385	chr11:47447363	PSMC3	-0.57	-10.29	-0.43	1.74e-22	Subjective well-being;
LGG	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg13293535	chr8:11597251	GATA4	0.3	7.15	0.32	3.4e-12	Morning vs. evening chronotype;
LGG	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg16325326	chr1:53192061	ZYG11B	0.74	17.11	0.62	3.09e-51	Monocyte count;
LGG	cis	rs2346177	0.846	rs62138876	chr2:46650672	C/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.2	-0.43	3.54e-22	HDL cholesterol;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.65	-0.3	8.26e-11	Longevity;
LGG	cis	rs11098499	0.909	rs28571712	chr4:120375980	G/A	cg09307838	chr4:120376055	NA	0.81	13.56	0.53	1.66e-35	Corneal astigmatism;
LGG	cis	rs73086581	0.945	rs6052219	chr20:3970307	A/G	cg02187196	chr20:3869020	PANK2	0.81	11.37	0.47	1.32e-26	Response to antidepressants in depression;
LGG	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg16141378	chr3:129829833	LOC729375	0.37	8.16	0.35	3.1e-15	Neuroticism;
LGG	cis	rs924840	0.634	rs2869030	chr15:78711803	A/C	cg06917634	chr15:78832804	PSMA4	-0.44	-6.91	-0.31	1.63e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg15556689	chr8:8085844	FLJ10661	0.44	7.84	0.34	3.08e-14	Mood instability;
LGG	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg02297831	chr4:17616191	MED28	0.49	9.27	0.4	7.22e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.58	0.44	1.4e-23	Diabetic retinopathy;
LGG	cis	rs138249	0.867	rs715616	chr22:50558505	G/A	cg07310406	chr22:50524374	MLC1	0.41	8.09	0.35	5.18e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-7.12	-0.31	4.13e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs12517041	0.872	rs67191421	chr5:23281046	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.21e-25	Calcium levels;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg02158880	chr13:53174818	NA	0.38	7.19	0.32	2.63e-12	Lewy body disease;
LGG	cis	rs881375	0.967	rs1008381	chr9:123681116	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs6956675	0.793	rs6946559	chr7:62660568	A/T	cg08930214	chr7:62859557	LOC100287834	0.47	7.74	0.34	6.36e-14	Obesity-related traits;
LGG	cis	rs7927771	0.965	rs3817335	chr11:47643891	T/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.91	-0.38	1.16e-17	Subjective well-being;
LGG	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg11890956	chr21:40555474	PSMG1	-0.72	-12.39	-0.5	1.15e-30	Menarche (age at onset);
LGG	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg02002194	chr4:3960332	NA	0.46	9.08	0.39	3.16e-18	Joint mobility (Beighton score);
LGG	cis	rs546131	0.928	rs483976	chr11:34840167	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.61	10.95	0.45	5.81e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg11040518	chr10:102331378	NA	-0.37	-6.84	-0.3	2.5e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2354432	0.607	rs6689243	chr1:146710559	A/T	cg25205988	chr1:146714368	CHD1L	-1.42	-13.91	-0.54	5.18e-37	Mitochondrial DNA levels;
LGG	cis	rs5769707	0.967	rs5769698	chr22:49997706	A/G	cg06623630	chr22:50017776	C22orf34	-0.34	-7.24	-0.32	1.82e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg22398616	chr13:53314203	LECT1	0.4	7.83	0.34	3.3e-14	Lewy body disease;
LGG	cis	rs8017423	0.647	rs10132599	chr14:90815342	C/T	cg04374321	chr14:90722782	PSMC1	-0.64	-12.57	-0.5	2.23e-31	Mortality in heart failure;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.1	-0.42	8.43e-22	Lung cancer;
LGG	cis	rs9660992	0.710	rs1668869	chr1:205239779	G/C	cg21545522	chr1:205238299	TMCC2	0.49	9.0	0.39	6.08e-18	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg13565492	chr6:43139072	SRF	-0.78	-10.51	-0.44	2.53e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10089	1.000	rs1559263	chr5:127512873	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.59	0.47	1.88e-27	Ileal carcinoids;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	9.86	0.42	5.83e-21	Schizophrenia;
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg06968155	chr5:131705112	SLC22A5	0.68	7.75	0.34	5.93e-14	Rheumatoid arthritis;
LGG	cis	rs41271473	0.526	rs56043220	chr1:228783474	G/C	cg16512390	chr1:228756714	NA	0.61	7.96	0.35	1.37e-14	Chronic lymphocytic leukemia;
LGG	cis	rs55665837	1.000	rs34980103	chr11:14512885	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.77	-0.38	3.44e-17	Vitamin D levels;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg07142201	chr11:109293216	C11orf87	0.54	9.71	0.41	2.09e-20	Schizophrenia;
LGG	trans	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg00711542	chr16:29343894	RUNDC2C	0.4	6.94	0.31	1.32e-11	Menopause (age at onset);
LGG	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.43	-0.33	5.24e-13	Obesity;
LGG	cis	rs704	0.764	rs3093692	chr17:26670627	G/A	cg10342447	chr17:26645325	TMEM97	-0.38	-7.05	-0.31	6.63e-12	Osteoprotegerin levels;
LGG	cis	rs2976388	0.566	rs2585146	chr8:143798641	A/C	cg06565975	chr8:143823917	SLURP1	0.5	12.4	0.5	1.09e-30	Urinary tract infection frequency;
LGG	cis	rs6500602	0.647	rs4786501	chr16:4536165	G/T	cg19168338	chr16:4465731	CORO7	0.75	14.01	0.55	2.08e-37	Schizophrenia;
LGG	cis	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Vitiligo;
LGG	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg15596359	chr8:11213517	TDH	-0.41	-8.33	-0.36	9.52e-16	Retinal vascular caliber;
LGG	cis	rs7618501	0.633	rs6446193	chr3:50059758	T/C	cg18129748	chr3:49941408	MST1R	-0.22	-7.11	-0.31	4.42e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg00761968	chr13:53314142	LECT1	-0.45	-9.85	-0.42	6.64e-21	Lewy body disease;
LGG	cis	rs2656056	1	rs2656056	chr15:78722519	T/C	cg06917634	chr15:78832804	PSMA4	0.53	7.95	0.35	1.46e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-11.74	-0.48	5.06e-28	Morning vs. evening chronotype;
LGG	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg11366901	chr6:160182831	ACAT2	1.06	16.49	0.61	2.24e-48	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6815814	0.950	rs113465719	chr4:38808045	A/T	cg06935464	chr4:38784597	TLR10	0.6	8.31	0.36	1.08e-15	Breast cancer;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg17178900	chr1:205818956	PM20D1	0.6	13.61	0.53	9.65e-36	Menarche (age at onset);
LGG	cis	rs734999	0.505	rs4073286	chr1:2539901	A/C	cg15627072	chr1:2432621	PLCH2	0.32	7.04	0.31	6.93e-12	Ulcerative colitis;
LGG	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.22	0.32	2.2e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11190604	1.000	rs7099913	chr10:102314777	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.69	0.48	7.5e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs9457247	0.967	rs2769355	chr6:167380493	G/A	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs10504130	0.518	rs6473654	chr8:52671514	C/A	cg22653915	chr8:52722023	PXDNL	0.45	7.21	0.32	2.34e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.58	-0.5	1.92e-31	Bipolar disorder;
LGG	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg18171855	chr10:2543474	NA	0.4	7.7	0.34	8.32e-14	Age-related hearing impairment;
LGG	cis	rs73193808	0.639	rs2832248	chr21:30556981	C/T	cg03476357	chr21:30257390	N6AMT1	0.4	6.72	0.3	5.35e-11	Coronary artery disease;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.27	0.4	6.84e-19	Aortic root size;
LGG	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	trans	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.58	-0.33	1.85e-13	Menarche (age at onset);
LGG	trans	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs7737355	1.000	rs798416	chr5:130693100	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.63	-0.37	1.03e-16	Life satisfaction;
LGG	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg13877915	chr19:58951672	ZNF132	1.0	26.73	0.78	6.54e-96	Uric acid clearance;
LGG	cis	rs17227506	0.679	rs4294186	chr8:13432838	A/G	cg03566418	chr8:13424080	C8orf48	0.63	9.82	0.42	8.3e-21	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs2562456	0.833	rs4644962	chr19:21520927	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04297258	chr16:88772664	RNF166;CTU2	0.56	8.61	0.37	1.2e-16	Gut microbiome composition (summer);
LGG	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg27489772	chr12:121021490	NA	0.59	7.79	0.34	4.39e-14	Type 1 diabetes nephropathy;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-12.99	-0.52	3.92e-33	Obesity-related traits;
LGG	cis	rs9443645	0.810	rs9448610	chr6:79739622	G/A	cg18132916	chr6:79620363	NA	-0.26	-6.91	-0.31	1.58e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4684776	0.935	rs3816380	chr3:11381973	A/C	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg16586182	chr3:47516702	SCAP	-0.73	-13.14	-0.52	9.9e-34	Colorectal cancer;
LGG	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.69	-0.34	8.96e-14	Menarche (age at onset);
LGG	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg25866889	chr13:114914595	NA	-0.35	-7.03	-0.31	7.23e-12	Schizophrenia;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg15537850	chr8:144661051	NAPRT1	-0.8	-8.83	-0.38	2.1e-17	Attention deficit hyperactivity disorder;
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg19212674	chr4:71571625	RUFY3	-0.42	-7.06	-0.31	5.95e-12	Breast cancer;
LGG	cis	rs911263	0.603	rs8017304	chr14:68785077	A/G	cg18825221	chr14:68749962	RAD51L1	-0.36	-7.73	-0.34	6.53e-14	Primary biliary cholangitis;
LGG	cis	rs6539288	0.500	rs11113116	chr12:107195929	C/A	cg15890332	chr12:107067104	RFX4	0.4	11.59	0.47	1.83e-27	Total body bone mineral density;
LGG	cis	rs873946	0.504	rs12775990	chr10:134575836	C/T	cg26818010	chr10:134567672	INPP5A	-0.61	-9.82	-0.42	8.18e-21	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg24101359	chr6:42928495	GNMT	0.52	14.59	0.56	6.02e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7572733	0.515	rs13382697	chr2:198920560	A/C	cg00792783	chr2:198669748	PLCL1	0.61	9.72	0.41	1.93e-20	Dermatomyositis;
LGG	cis	rs6542838	0.641	rs12712042	chr2:99534401	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.41	-0.33	6e-13	Fear of minor pain;
LGG	cis	rs2470578	0.792	rs2596646	chr3:17296401	T/C	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.4e-11	Schizophrenia;
LGG	trans	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.37e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17284969	0.579	rs2371671	chr7:83044481	G/C	cg14519356	chr7:83097669	SEMA3E	-0.27	-7.63	-0.33	1.38e-13	Blood protein levels;
LGG	cis	rs7666738	0.752	rs62318905	chr4:99036103	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.47	0.37	3.33e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg04861929	chr11:109293070	C11orf87	-0.52	-9.6	-0.41	4.87e-20	Schizophrenia;
LGG	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg01864069	chr14:103024347	NA	-0.68	-9.84	-0.42	7.03e-21	Platelet count;
LGG	cis	rs2404602	0.692	rs12910382	chr15:77053442	A/C	cg23625390	chr15:77176239	SCAPER	0.48	9.29	0.4	6.27e-19	Blood metabolite levels;
LGG	cis	rs2153535	0.601	rs1855765	chr6:8444325	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs17767392	1.000	rs61991250	chr14:71869684	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	trans	rs2727020	0.681	rs1976901	chr11:49378697	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.88	-0.42	4.97e-21	Coronary artery disease;
LGG	cis	rs4356932	0.935	rs7677924	chr4:76977023	C/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	6.68e-11	Blood protein levels;
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg02725872	chr8:58115012	NA	-0.74	-10.31	-0.43	1.4e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg00495681	chr13:53174319	NA	0.57	10.22	0.43	2.94e-22	Lewy body disease;
LGG	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-7.93	-0.35	1.67e-14	Height;
LGG	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.63	-10.59	-0.44	1.3e-23	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1371867	0.846	rs1660348	chr8:101315248	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.59	-0.37	1.36e-16	Atrioventricular conduction;
LGG	cis	rs67133203	0.799	rs71445768	chr12:51336376	G/A	cg14688905	chr12:51403056	SLC11A2	0.73	10.8	0.45	2.06e-24	Urinary tract infection frequency;
LGG	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg21466736	chr12:48725269	NA	-0.37	-7.43	-0.33	5.14e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg16325326	chr1:53192061	ZYG11B	0.74	17.11	0.62	3.12e-51	Monocyte count;
LGG	trans	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08862035	chr2:2617432	NA	0.43	6.95	0.31	1.25e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.37	0.36	7.06e-16	Neuroticism;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.87	-0.3	2.02e-11	Lung cancer;
LGG	cis	rs2294693	0.898	rs6458195	chr6:40972498	A/T	cg14769373	chr6:40998127	UNC5CL	0.4	7.0	0.31	9.18e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.32	-0.36	9.83e-16	Neuroticism;
LGG	cis	rs10851478	0.500	rs36023246	chr15:49699311	A/G	cg08060515	chr15:49448048	GALK2;COPS2	0.43	7.82	0.34	3.59e-14	Oral cavity cancer;
LGG	cis	rs1552244	1.000	rs67569278	chr3:10149893	T/C	cg15117754	chr3:10150083	C3orf24	0.5	6.85	0.3	2.35e-11	Alzheimer's disease;
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.28	-0.4	6.64e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg02158880	chr13:53174818	NA	0.41	7.73	0.34	6.96e-14	Lewy body disease;
LGG	cis	rs35740288	0.822	rs2016517	chr15:86229618	C/T	cg04173714	chr15:86211321	AKAP13	0.47	8.14	0.35	3.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.17	-0.35	2.91e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs783147	0.652	rs1782629	chr6:161195866	C/A	cg01280913	chr6:161186852	NA	0.35	7.38	0.32	7.4e-13	Lp (a) levels;
LGG	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg09021430	chr5:549028	NA	-0.69	-9.86	-0.42	6.16e-21	Obesity-related traits;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.2e-19	Bipolar disorder;
LGG	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.2	-0.46	6.14e-26	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.716	rs2164101	chr15:76749117	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.32	1.96e-12	Blood metabolite levels;
LGG	cis	rs6121246	1.000	rs6121246	chr20:30433352	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	11.37	0.47	1.37e-26	Mean corpuscular hemoglobin;
LGG	cis	rs2439831	1.000	rs2444250	chr15:43785051	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.82	-0.34	3.56e-14	Myopia (pathological);
LGG	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg06634786	chr22:41940651	POLR3H	-0.55	-9.09	-0.39	3.02e-18	Vitiligo;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg23188684	chr11:67383651	NA	0.5	8.4	0.36	5.32e-16	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.34	0.58	3.09e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9547996	0.879	rs61957470	chr13:38133049	G/A	cg17979426	chr13:38220150	TRPC4	-0.36	-6.91	-0.31	1.6e-11	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.42	-7.17	-0.32	2.95e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10857712	0.528	rs2265638	chr10:135217175	A/G	cg00491522	chr10:135256596	NA	0.65	12.26	0.5	4.1e-30	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23057284	chr9:131938815	IER5L	0.45	7.04	0.31	7.13e-12	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.0	0.55	2.14e-37	Bladder cancer;
LGG	cis	rs2842992	0.915	rs1322427	chr6:160075454	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.68	0.3	6.97e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg08742575	chr21:47604166	C21orf56	0.54	9.77	0.41	1.26e-20	Testicular germ cell tumor;
LGG	cis	rs9467773	0.595	rs2237236	chr6:26451553	A/G	cg09904177	chr6:26538194	HMGN4	-0.44	-7.73	-0.34	6.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.38	-0.36	6.22e-16	Lung cancer;
LGG	cis	rs28830936	0.966	rs890498	chr15:42111298	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-13.12	-0.52	1.2e-33	Diastolic blood pressure;
LGG	cis	rs1978968	1.000	rs1076543	chr22:18446490	T/C	cg03078520	chr22:18463400	MICAL3	-0.61	-12.36	-0.5	1.56e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs7179456	0.513	rs640704	chr15:59049021	A/G	cg05156742	chr15:59063176	FAM63B	0.6	9.71	0.41	2.06e-20	Asperger disorder;
LGG	cis	rs4901847	0.562	rs4901849	chr14:58614471	G/A	cg15908186	chr14:58618357	C14orf37	0.68	12.59	0.51	1.83e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2562456	0.652	rs62110214	chr19:21775208	G/A	cg00806126	chr19:22604979	ZNF98	-0.63	-8.69	-0.37	6.14e-17	Pain;
LGG	cis	rs2732480	0.577	rs2732457	chr12:48758379	A/G	cg24011408	chr12:48396354	COL2A1	-0.49	-7.79	-0.34	4.54e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7953508	0.711	rs3825199	chr12:93976954	A/G	cg18151635	chr12:93972918	NA	-0.45	-8.03	-0.35	8.08e-15	Pubertal anthropometrics;
LGG	cis	rs638893	0.636	rs526850	chr11:118605127	G/T	cg22253036	chr11:118662786	DDX6	0.44	6.71	0.3	5.81e-11	Vitiligo;
LGG	cis	rs12908161	1.000	rs35316992	chr15:85248133	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.65e-12	Schizophrenia;
LGG	cis	rs10276381	0.786	rs740261	chr7:28241276	A/G	cg23620719	chr7:28220237	JAZF1	0.85	10.4	0.44	6.81e-23	Crohn's disease;
LGG	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg11584989	chr19:19387371	SF4	-0.39	-6.66	-0.3	7.85e-11	Tonsillectomy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19034708	chr8:17780168	PCM1	-0.41	-6.79	-0.3	3.46e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.5	-0.33	3.23e-13	Morning vs. evening chronotype;
LGG	cis	rs6445975	0.666	rs6793328	chr3:58414872	G/A	cg24175188	chr3:58374923	PXK	-0.56	-9.13	-0.39	2.11e-18	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.615	rs216462	chr17:28895897	T/C	cg08994789	chr17:28903642	LRRC37B2	0.7	8.14	0.35	3.72e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6743376	0.533	rs10206428	chr2:113826475	A/G	cg05949173	chr2:113825882	IL1F10	0.51	9.84	0.42	7.08e-21	Inflammatory biomarkers;
LGG	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg20703242	chr1:230279135	GALNT2	0.37	7.56	0.33	2.22e-13	Coronary artery disease;
LGG	cis	rs6831352	0.877	rs28987101	chr4:100049253	T/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs3806843	0.576	rs246037	chr5:140331846	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	trans	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg11441553	chr12:57614120	NXPH4	-0.58	-7.16	-0.32	3.16e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1994135	0.617	rs2200155	chr12:33734935	G/A	cg06521331	chr12:34319734	NA	-0.47	-7.94	-0.35	1.58e-14	Resting heart rate;
LGG	cis	rs11098499	0.909	rs6842762	chr4:120398236	A/T	cg09307838	chr4:120376055	NA	0.82	13.68	0.54	4.88e-36	Corneal astigmatism;
LGG	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg04455712	chr21:45112962	RRP1B	0.55	10.28	0.43	1.87e-22	Mean corpuscular volume;
LGG	cis	rs774359	0.789	rs9969832	chr9:27493063	C/T	cg22262168	chr9:27528999	MOBKL2B	0.47	7.02	0.31	7.8e-12	Amyotrophic lateral sclerosis;
LGG	cis	rs3087591	0.960	rs2905802	chr17:29520084	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.5	0.56	1.49e-39	Hip circumference;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg16885296	chr6:26284938	NA	0.37	7.9	0.34	1.99e-14	Educational attainment;
LGG	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Body mass index;
LGG	cis	rs921968	0.643	rs600057	chr2:219456737	A/G	cg02985541	chr2:219472218	PLCD4	0.28	6.69	0.3	6.5500000000000006e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.63	0.37	9.6e-17	Coronary artery disease;
LGG	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.41	-6.83	-0.3	2.64e-11	Schizophrenia;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg22398616	chr13:53314203	LECT1	-0.49	-9.64	-0.41	3.63e-20	Lewy body disease;
LGG	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg22509189	chr2:225307070	NA	-0.6	-9.78	-0.41	1.18e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1728785	1.000	rs7202306	chr16:68587684	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22656964	chr7:151217277	RHEB	0.48	7.08	0.31	5.25e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs55822690	chr3:10128003	A/G	cg13047869	chr3:10149882	C3orf24	0.56	9.39	0.4	2.65e-19	Alzheimer's disease;
LGG	cis	rs9326248	0.861	rs7120309	chr11:117042816	T/A	cg01368799	chr11:117014884	PAFAH1B2	0.62	7.96	0.35	1.3e-14	Blood protein levels;
LGG	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg00262122	chr8:11665843	FDFT1	0.42	6.67	0.3	7.25e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4689388	0.926	rs10937717	chr4:6295087	T/A	cg00701064	chr4:6280414	WFS1	0.74	16.52	0.61	1.63e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.66	-0.37	8.17e-17	Obesity-related traits;
LGG	cis	rs4742903	0.870	rs10991172	chr9:106976151	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.34	0.36	8.29e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs11711311	1.000	rs2305546	chr3:113503354	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.12e-34	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.8e-43	Prudent dietary pattern;
LGG	cis	rs77216612	0.874	rs11055034	chr12:12890626	C/A	cg09462578	chr12:12878428	APOLD1	-1.04	-20.53	-0.69	4.72e-67	Lymphocyte counts;
LGG	cis	rs6089584	1.000	rs3787424	chr20:60559219	G/A	cg12751644	chr20:60527061	NA	-0.3	-6.94	-0.31	1.29e-11	Body mass index;
LGG	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg16850897	chr7:100343110	ZAN	-0.64	-9.18	-0.39	1.43e-18	Other erythrocyte phenotypes;
LGG	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg00031303	chr3:195681400	NA	-0.45	-6.99	-0.31	9.89e-12	Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg24607181	chr17:41446203	NA	-0.3	-6.92	-0.31	1.49e-11	Menopause (age at onset);
LGG	cis	rs2933343	1.000	rs789213	chr3:128616359	C/G	cg25356066	chr3:128598488	ACAD9	-0.45	-6.69	-0.3	6.53e-11	IgG glycosylation;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-14.84	-0.57	4.78e-41	Platelet count;
LGG	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg06212747	chr3:49208901	KLHDC8B	0.43	6.88	0.3	1.9e-11	Resting heart rate;
LGG	cis	rs9972944	0.639	rs2052153	chr17:63800382	G/T	cg07283582	chr17:63770753	CCDC46	-0.38	-6.91	-0.31	1.57e-11	Total body bone mineral density;
LGG	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg18351406	chr4:77819688	ANKRD56	0.46	7.84	0.34	3.18e-14	Emphysema distribution in smoking;
LGG	cis	rs9399135	0.967	rs9376077	chr6:135299713	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.35	0.4	3.72e-19	Red blood cell count;
LGG	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-9.34	-0.4	3.94e-19	Schizophrenia;
LGG	cis	rs11644362	1.000	rs35972357	chr16:12987664	C/T	cg06890432	chr16:12997467	SHISA9	-0.32	-7.07	-0.31	5.7e-12	Positive affect;Subjective well-being;
LGG	trans	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg24247370	chr13:99142703	STK24	-0.4	-7.27	-0.32	1.56e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	9.35	0.4	3.79e-19	Menarche (age at onset);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg17456636	chr2:12900170	NA	-0.39	-6.67	-0.3	7.12e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7843479	0.930	rs2054713	chr8:21840534	A/G	cg17168535	chr8:21777572	XPO7	0.59	9.68	0.41	2.62e-20	Mean corpuscular volume;
LGG	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08564027	chr20:61660810	NA	1.02	25.72	0.77	3.06e-91	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07560035	chr8:127570383	FAM84B	0.45	6.87	0.3	2.08e-11	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg16141378	chr3:129829833	LOC729375	0.43	9.88	0.42	5.11e-21	Neuroticism;
LGG	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg04617936	chr2:214353	NA	-0.38	-7.24	-0.32	1.85e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs11875185	0.510	rs75960560	chr18:55633064	C/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs283228	0.550	rs962538	chr6:101819995	T/A	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	1e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs2241024	1.000	rs2241024	chr19:28257393	G/A	cg08190545	chr19:28403514	NA	-0.54	-7.68	-0.34	9.35e-14	Testicular germ cell tumor;
LGG	cis	rs3796619	1.000	rs2290409	chr4:1067249	C/T	cg04016957	chr4:1044486	NA	-0.35	-6.7	-0.3	6.16e-11	Recombination rate (males);
LGG	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg12924262	chr12:102091054	CHPT1	0.66	13.31	0.53	1.93e-34	Blood protein levels;
LGG	trans	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg02002194	chr4:3960332	NA	0.39	7.04	0.31	6.98e-12	Joint mobility (Beighton score);
LGG	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg04986931	chr22:39850128	NA	0.35	8.0	0.35	1.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.967	rs783173	chr6:161172942	C/G	cg01280913	chr6:161186852	NA	-0.35	-7.2	-0.32	2.48e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10883723	0.810	rs2296581	chr10:104242886	G/A	cg05096777	chr10:104283225	SUFU	0.31	6.69	0.3	6.45e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4671458	1.000	rs11125949	chr2:63357876	T/C	cg17519650	chr2:63277830	OTX1	-0.61	-7.73	-0.34	6.61e-14	Subjective well-being;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg05665937	chr4:1216051	CTBP1	0.55	10.27	0.43	1.95e-22	Obesity-related traits;
LGG	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.05	0.57	5.76e-42	Cognitive test performance;
LGG	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg13010199	chr12:38710504	ALG10B	0.7	14.16	0.55	4.57e-38	Bladder cancer;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13336428	0.730	rs3946124	chr16:1525779	A/G	cg08008072	chr16:1524255	CLCN7	0.63	11.07	0.46	1.94e-25	Bone mineral density;
LGG	cis	rs12931792	0.687	rs8057425	chr16:30182541	T/C	cg17640201	chr16:30407289	ZNF48	0.53	9.11	0.39	2.42e-18	Tonsillectomy;
LGG	cis	rs7202877	0.610	rs4536500	chr16:75343197	C/G	cg03315344	chr16:75512273	CHST6	-0.51	-6.92	-0.31	1.52e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.87e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs6743355	chr2:99732360	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs1185460	0.565	rs540261	chr11:118947634	C/T	cg23280166	chr11:118938394	VPS11	-0.49	-8.4	-0.36	5.36e-16	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs7113850	0.541	rs114370606	chr11:24232247	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.42	0.44	5.67e-23	Bone fracture in osteoporosis;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg11168104	chr5:1857477	NA	-0.4	-6.99	-0.31	9.92e-12	Cardiovascular disease risk factors;
LGG	cis	rs7172689	0.826	rs67853122	chr15:81577362	G/A	cg11808699	chr15:81528661	IL16	-0.49	-9.8	-0.41	1.03e-20	Inattentive symptoms;
LGG	cis	rs7917772	0.503	rs7068535	chr10:104349127	C/T	cg05096777	chr10:104283225	SUFU	0.31	6.81	0.3	2.95e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg20673091	chr1:2541236	MMEL1	-0.75	-18.21	-0.65	2.77e-56	Ulcerative colitis;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg05025164	chr4:1340916	KIAA1530	-0.71	-13.47	-0.53	4.04e-35	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg24829409	chr8:58192753	C8orf71	-0.66	-8.48	-0.37	3.07e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4268898	0.662	rs2303292	chr2:24432138	C/T	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs910316	0.663	rs175034	chr14:75463687	T/G	cg11812906	chr14:75593930	NEK9	-0.45	-8.15	-0.35	3.37e-15	Height;
LGG	cis	rs12230513	0.732	rs55797706	chr12:55836585	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-11.14	-0.46	1.11e-25	Contrast sensitivity;
LGG	cis	rs9467773	0.620	rs2101582	chr6:26622734	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.56	0.5	2.47e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	1.000	rs1716993	chr3:41974556	G/C	cg03022575	chr3:42003672	ULK4	-0.67	-8.54	-0.37	1.89e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs35306767	0.714	rs17293608	chr10:1056252	C/T	cg25019033	chr10:957182	NA	-0.54	-10.06	-0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs10267417	0.603	rs10276105	chr7:19956497	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.59e-11	Night sleep phenotypes;
LGG	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14240646	chr10:27532245	ACBD5	0.74	10.85	0.45	1.37e-24	Breast cancer;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs12210905	0.610	rs12216370	chr6:26878930	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.54	-7.36	-0.32	8.72e-13	Hip circumference adjusted for BMI;
LGG	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg12373951	chr3:133503437	NA	0.39	6.86	0.3	2.26e-11	Iron status biomarkers;
LGG	cis	rs796364	0.715	rs78988795	chr2:201095739	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.66	-7.47	-0.33	4.03e-13	Schizophrenia;
LGG	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.41	-0.5	1.02e-30	Depression;
LGG	cis	rs2307022	0.671	rs9928605	chr16:68373954	C/T	cg07273125	chr16:68295692	NA	0.46	10.34	0.43	1.14e-22	Body mass index;
LGG	cis	rs6840360	0.571	rs11736116	chr4:152531816	A/G	cg25486957	chr4:152246857	NA	-0.46	-7.75	-0.34	5.83e-14	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg00204512	chr16:28754710	NA	0.24	6.7	0.3	6.23e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8017423	0.967	rs1005788	chr14:90692747	C/T	cg04374321	chr14:90722782	PSMC1	0.87	18.55	0.65	7.97e-58	Mortality in heart failure;
LGG	cis	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg09307838	chr4:120376055	NA	0.78	12.79	0.51	2.66e-32	Corneal astigmatism;
LGG	cis	rs2072499	0.966	rs2253677	chr1:156171296	C/G	cg06970220	chr1:156163860	SLC25A44	-0.46	-6.75	-0.3	4.31e-11	Testicular germ cell tumor;
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs6784615	0.744	rs352141	chr3:52267118	G/C	cg16850945	chr3:52488229	TNNC1;NISCH	0.68	7.38	0.32	7.21e-13	Waist-hip ratio;
LGG	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg15704280	chr7:45808275	SEPT13	-0.94	-19.31	-0.67	2.14e-61	Coronary artery disease;
LGG	cis	rs548181	0.611	rs562599	chr11:125459951	A/C	cg03464685	chr11:125439445	EI24	1.39	20.2	0.68	1.6e-65	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg25703541	chr22:24373054	LOC391322	0.87	16.63	0.61	5.09e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6977660	0.652	rs12673842	chr7:19747437	T/C	cg07541023	chr7:19748670	TWISTNB	0.99	14.06	0.55	1.19e-37	Thyroid stimulating hormone;
LGG	trans	rs73198271	0.729	rs67000451	chr8:8605083	A/G	cg16141378	chr3:129829833	LOC729375	0.38	6.72	0.3	5.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg20790798	chr5:1857306	NA	-0.42	-6.93	-0.31	1.41e-11	Cardiovascular disease risk factors;
LGG	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg20283391	chr11:68216788	NA	-0.51	-8.12	-0.35	4.32e-15	Total body bone mineral density;
LGG	cis	rs17818399	0.788	rs13013245	chr2:46806086	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.67	-11.22	-0.46	5.17e-26	Height;
LGG	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg13010199	chr12:38710504	ALG10B	-0.48	-9.19	-0.39	1.37e-18	Morning vs. evening chronotype;
LGG	cis	rs10911232	0.507	rs6672306	chr1:183058898	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.81	0.41	8.94e-21	Hypertriglyceridemia;
LGG	cis	rs2933343	0.700	rs1680779	chr3:128614770	G/A	cg25356066	chr3:128598488	ACAD9	0.45	6.89	0.3	1.86e-11	IgG glycosylation;
LGG	cis	rs4356975	0.509	rs5014975	chr4:69995962	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	7.03	0.31	7.55e-12	Obesity-related traits;
LGG	cis	rs4851254	0.660	rs4851244	chr2:100671449	C/T	cg17356467	chr2:100759845	AFF3	-0.45	-7.34	-0.32	9.62e-13	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	1.000	rs4855862	chr3:49748833	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs68170813	0.559	rs3801963	chr7:106898036	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.46	-0.44	4.06e-23	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs781156	chr7:65479141	C/A	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg06637938	chr14:75390232	RPS6KL1	0.63	11.78	0.48	3.24e-28	Caffeine consumption;
LGG	cis	rs473651	0.901	rs563282	chr2:239329736	T/C	cg18131467	chr2:239335373	ASB1	0.95	18.84	0.66	3.45e-59	Multiple system atrophy;
LGG	cis	rs6960043	0.875	rs17168594	chr7:15048776	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.95	-0.35	1.46e-14	Type 2 diabetes;
LGG	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.94	-0.31	1.3e-11	Triglycerides;
LGG	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg12395012	chr8:11607386	GATA4	0.43	7.89	0.34	2.2e-14	Neuroticism;
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg01081584	chr15:40268610	EIF2AK4	-0.52	-7.0	-0.31	9.27e-12	Response to haloperidol in psychosis;
LGG	cis	rs7084402	0.967	rs1658443	chr10:60316926	G/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs2204008	0.774	rs8189620	chr12:38241621	A/G	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg07148914	chr20:33460835	GGT7	0.55	9.28	0.4	6.52e-19	Height;
LGG	cis	rs4700695	0.668	rs166180	chr5:65499225	C/T	cg21114390	chr5:65439923	SFRS12	-0.67	-9.77	-0.41	1.25e-20	Facial morphology (factor 19);
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.55	0.41	7.67e-20	Longevity;
LGG	cis	rs7107174	1.000	rs11237469	chr11:78072875	A/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.48	-0.33	3.78e-13	Testicular germ cell tumor;
LGG	cis	rs17286411	0.750	rs12444594	chr16:71941912	A/T	cg06353428	chr16:71660113	MARVELD3	0.4	7.12	0.31	4.12e-12	Blood protein levels;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00933542	chr6:150070202	PCMT1	-0.38	-6.9	-0.31	1.72e-11	Lung cancer;
LGG	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg13385521	chr17:29058706	SUZ12P	0.93	10.83	0.45	1.6e-24	Body mass index;
LGG	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.42	7.36	0.32	8.63e-13	IgG glycosylation;
LGG	cis	rs7552404	0.727	rs7547056	chr1:76279267	C/T	cg22875332	chr1:76189707	ACADM	0.56	8.9	0.38	1.3e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg02297831	chr4:17616191	MED28	0.48	8.9	0.38	1.24e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10754283	0.905	rs7519969	chr1:90108721	G/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs911555	0.539	rs4374097	chr14:104072766	A/C	cg26031613	chr14:104095156	KLC1	0.56	8.83	0.38	2.19e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7511006	0.893	rs5771104	chr22:50651839	C/T	cg16473166	chr22:50639996	SELO	0.65	11.58	0.47	2.08e-27	Obesity-related traits;
LGG	cis	rs12497850	0.897	rs6781790	chr3:49044767	C/T	cg07636037	chr3:49044803	WDR6	1.11	28.49	0.8	7.1e-104	Parkinson's disease;
LGG	cis	rs35714695	0.710	rs34660379	chr17:26710570	G/A	cg10342447	chr17:26645325	TMEM97	0.5	6.69	0.3	6.63e-11	Amyotrophic lateral sclerosis;Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg08885076	chr2:99613938	TSGA10	-0.55	-10.14	-0.43	5.79e-22	Chronic sinus infection;
LGG	cis	rs6500395	1.000	rs12598514	chr16:48689319	T/C	cg04672837	chr16:48644449	N4BP1	-0.53	-8.84	-0.38	2e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg12705353	chr12:122356852	WDR66	0.23	6.65	0.3	8.4e-11	Mean corpuscular volume;
LGG	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.64	-0.33	1.25e-13	Joint mobility (Beighton score);
LGG	cis	rs503734	0.666	rs2141179	chr3:101227639	A/C	cg27318481	chr3:100970896	IMPG2	0.35	7.11	0.31	4.33e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09699651	chr6:150184138	LRP11	0.57	10.9	0.45	8.94e-25	Testicular germ cell tumor;
LGG	cis	rs9354308	0.764	rs6908191	chr6:66613540	T/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.43	0.56	3.1e-39	Colorectal cancer;
LGG	cis	rs8044868	0.530	rs8060770	chr16:72155694	C/A	cg23815491	chr16:72088622	HP	0.37	7.92	0.35	1.77e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg16301924	chr13:53314226	LECT1	-0.4	-7.98	-0.35	1.15e-14	Lewy body disease;
LGG	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35306767	0.623	rs56201968	chr10:1141666	A/G	cg25019033	chr10:957182	NA	-0.42	-8.13	-0.35	4.06e-15	Eosinophil percentage of granulocytes;
LGG	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg19554555	chr3:13937349	NA	-0.55	-10.08	-0.42	9.53e-22	Ovarian reserve;
LGG	trans	rs11039798	1.000	rs10160423	chr11:48457227	G/T	cg15704280	chr7:45808275	SEPT13	0.78	8.95	0.38	8.9e-18	Axial length;
LGG	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.74	-0.41	1.66e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11690935	0.959	rs10166005	chr2:172607294	C/T	cg21435375	chr2:172878103	MAP1D	-0.31	-6.93	-0.31	1.45e-11	Schizophrenia;
LGG	cis	rs13033859	0.526	rs12477065	chr2:292753	C/T	cg04617936	chr2:214353	NA	-0.47	-7.47	-0.33	4.07e-13	Mitochondrial DNA levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23628684	chr21:30446052	CCT8	0.53	8.63	0.37	9.81e-17	Gut microbiome composition (summer);
LGG	cis	rs500492	0.542	rs2744148	chr16:1073552	A/G	cg08273874	chr16:1060765	NA	-0.6	-8.78	-0.38	3.28e-17	Polycystic ovary syndrome;
LGG	trans	rs7824557	0.591	rs2572452	chr8:11228254	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.75	-0.3	4.45e-11	Retinal vascular caliber;
LGG	cis	rs6489882	0.867	rs7132404	chr12:113368605	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.62	-0.33	1.4e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9303401	0.659	rs17822735	chr17:56620167	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.51	7.49	0.33	3.49e-13	Renal function-related traits (BUN);
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16524936	chr4:1340807	KIAA1530	-0.48	-8.02	-0.35	9.05e-15	Longevity;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg17376030	chr22:41985996	PMM1	0.59	9.39	0.4	2.76e-19	Vitiligo;
LGG	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg08824895	chr13:115047677	UPF3A	0.4	6.84	0.3	2.59e-11	Schizophrenia;
LGG	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg09462578	chr12:12878428	APOLD1	-0.56	-7.65	-0.33	1.17e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg09699651	chr6:150184138	LRP11	0.5	8.7	0.38	5.64e-17	Lung cancer;
LGG	cis	rs9487094	0.922	rs9885646	chr6:109742460	C/T	cg01125227	chr6:109776195	MICAL1	0.46	7.93	0.35	1.6e-14	Height;
LGG	cis	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.12	-0.49	1.49e-29	Corneal structure;
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07648498	chr16:89883185	FANCA	-0.4	-6.93	-0.31	1.44e-11	Vitiligo;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9290065	0.519	rs2121721	chr3:160685788	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-8.31	-0.36	1.07e-15	Kawasaki disease;
LGG	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg26656751	chr17:43910226	CRHR1	0.35	7.11	0.31	4.41e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4788570	0.615	rs7193549	chr16:71649416	T/C	cg06353428	chr16:71660113	MARVELD3	1.26	21.54	0.71	8.82e-72	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23558473	chr9:125667702	RC3H2	0.42	6.93	0.31	1.4e-11	Cognitive performance;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00149659	chr3:10157352	C3orf10	1.19	14.13	0.55	6.27e-38	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.73e-33	Prudent dietary pattern;
LGG	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg15268244	chr15:77196840	NA	0.48	10.2	0.43	3.5e-22	Blood metabolite levels;
LGG	trans	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-8.02	-0.35	8.99e-15	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs4718319	chr7:65652784	C/A	cg11764359	chr7:65958608	NA	-0.74	-13.32	-0.53	1.73e-34	Aortic root size;
LGG	cis	rs757978	1.000	rs80085676	chr2:242347907	G/A	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.56	-0.37	1.73e-16	Chronic lymphocytic leukemia;
LGG	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs17253792	0.822	rs13379342	chr14:56050452	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.62	-0.51	1.41e-31	Putamen volume;
LGG	cis	rs7829975	0.684	rs488904	chr8:8587571	T/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.7	-0.34	8.14e-14	Mood instability;
LGG	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg08085267	chr17:45401833	C17orf57	-0.71	-13.88	-0.54	7e-37	Glaucoma (primary open-angle);
LGG	cis	rs9547692	0.938	rs4520715	chr13:37459113	C/T	cg02985381	chr13:37494744	SMAD9	0.71	12.28	0.5	3.32e-30	Coronary artery disease;
LGG	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg18551225	chr6:44695536	NA	-0.68	-11.24	-0.46	4.37e-26	Total body bone mineral density;
LGG	cis	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs950169	0.614	rs765524	chr15:84681782	G/T	cg24253500	chr15:84953950	NA	0.45	7.1	0.31	4.62e-12	Schizophrenia;
LGG	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs8010715	0.636	rs2277482	chr14:24587795	C/T	cg06429887	chr14:24600500	FITM1	0.36	7.32	0.32	1.09e-12	IgG glycosylation;
LGG	cis	rs7666738	0.830	rs7679299	chr4:99057620	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs2463822	0.583	rs7104825	chr11:62026833	C/T	cg06239285	chr11:62104954	ASRGL1	-0.96	-11.68	-0.48	8.37e-28	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs17711722	0.522	rs6957759	chr7:65271785	A/G	cg18876405	chr7:65276391	NA	0.46	8.2	0.36	2.42e-15	Calcium levels;
LGG	cis	rs9916302	0.706	rs7212621	chr17:37527911	T/G	cg07936489	chr17:37558343	FBXL20	1.0	15.49	0.58	6.49e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg18681998	chr4:17616180	MED28	-0.77	-15.15	-0.58	2.17e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs861020	0.630	rs655712	chr1:210006437	G/A	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs9952991	0.941	rs2542150	chr18:12779763	G/C	cg23544223	chr18:12777786	NA	0.62	9.35	0.4	3.76e-19	Inflammatory skin disease;
LGG	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg16851482	chr4:6955953	TBC1D14	0.26	6.67	0.3	7.23e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.75e-25	Prostate cancer;
LGG	cis	rs4595586	0.505	rs6580897	chr12:39372254	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.39	0.32	7.14e-13	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	11.09	0.46	1.73e-25	Obesity-related traits;
LGG	cis	rs2066819	1.000	rs76745316	chr12:56627652	A/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.6	-0.44	1.22e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.812	rs181738	chr5:130820451	T/C	cg06307176	chr5:131281290	NA	0.51	8.51	0.37	2.4e-16	Life satisfaction;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.58	-0.41	5.75e-20	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05264510	chr19:54023915	ZNF331	0.43	7.32	0.32	1.14e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1355223	0.902	rs1453387	chr11:34707898	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.85	-0.3	2.43e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7155454	1.000	rs7155454	chr14:65502239	G/A	cg11161011	chr14:65562177	MAX	-0.44	-7.09	-0.31	4.89e-12	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Body mass index;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.29e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12786942	0.569	rs10082588	chr11:101315000	A/G	cg03942599	chr11:101341554	TRPC6	0.49	7.36	0.32	8.27e-13	Facial depth;
LGG	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg03264133	chr6:25882463	NA	-0.41	-7.19	-0.32	2.67e-12	Height;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs6558530	0.931	rs4639549	chr8:1708044	A/G	cg08198773	chr8:1697536	NA	0.37	7.16	0.32	3.29e-12	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17152465	chr16:30390102	SEPT1	0.47	6.86	0.3	2.15e-11	Gut microbiome composition (summer);
LGG	cis	rs1519814	0.956	rs4133251	chr8:121166993	A/G	cg22335954	chr8:121166405	COL14A1	-0.55	-11.1	-0.46	1.46e-25	Breast cancer;
LGG	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1555322	0.530	rs2425042	chr20:33865895	G/A	cg17927777	chr20:33865990	NA	0.75	10.03	0.42	1.42e-21	Attention deficit hyperactivity disorder;
LGG	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg26769984	chr7:1090371	C7orf50	0.43	7.56	0.33	2.15e-13	Bronchopulmonary dysplasia;
LGG	cis	rs9916302	0.706	rs1874226	chr17:37729031	C/T	cg00129232	chr17:37814104	STARD3	0.58	8.72	0.38	5.13e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs9815354	1.000	rs9847006	chr3:41755359	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.45	0.33	4.48e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7916697	0.520	rs4745957	chr10:70044702	A/G	cg04882175	chr6:131122610	NA	0.48	7.26	0.32	1.65e-12	Optic disc area;
LGG	cis	rs7309	0.810	rs11684253	chr2:162034536	G/T	cg21518248	chr2:162101506	NA	0.23	7.28	0.32	1.44e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg03188948	chr7:1209495	NA	0.45	7.79	0.34	4.47e-14	Longevity;Endometriosis;
LGG	cis	rs7044106	0.791	rs10760116	chr9:123494681	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.74	13.68	0.54	5.23e-36	Hip circumference adjusted for BMI;
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	1.000	rs1615243	chr3:41965234	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs881375	0.678	rs9886724	chr9:123665019	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.83	0.45	1.64e-24	Rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs9669027	chr12:34583528	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.08	-0.31	5.41e-12	Morning vs. evening chronotype;
LGG	trans	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.49	-0.33	3.49e-13	Joint mobility (Beighton score);
LGG	cis	rs72781680	1.000	rs7578969	chr2:24168620	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7927771	0.832	rs11607981	chr11:47401060	T/G	cg20307385	chr11:47447363	PSMC3	-0.58	-10.66	-0.44	7.16e-24	Subjective well-being;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6500395	1.000	rs8044519	chr16:48669081	G/T	cg16662043	chr16:48846231	NA	0.36	7.02	0.31	8.18e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg08461457	chr11:2027003	NA	0.39	7.64	0.33	1.22e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4740619	0.967	rs6474945	chr9:15670492	G/T	cg14451791	chr9:16040625	NA	-0.4	-10.5	-0.44	2.89e-23	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19763735	chr2:170550826	C2orf77;PHOSPHO2;KLHL23	0.5	7.83	0.34	3.48e-14	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg24375607	chr4:120327624	NA	0.58	9.59	0.41	5.55e-20	Corneal astigmatism;
LGG	cis	rs79839061	0.610	rs73207794	chr4:872020	T/C	cg07828340	chr4:882639	GAK	0.87	9.26	0.4	7.37e-19	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20136959	chr13:49821950	CDADC1	0.5	7.73	0.34	6.93e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.88	-0.45	1.02e-24	Lung cancer;
LGG	cis	rs6456156	0.846	rs10946211	chr6:167515489	G/A	cg07741184	chr6:167504864	NA	-0.34	-7.58	-0.33	1.85e-13	Primary biliary cholangitis;
LGG	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	9.98	0.42	2.21e-21	Rheumatoid arthritis;
LGG	cis	rs2730245	0.527	rs2527202	chr7:158738849	T/C	cg18245976	chr7:158708271	WDR60	0.63	7.89	0.34	2.24e-14	Height;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.54	-0.37	1.92e-16	Personality dimensions;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg05896524	chr21:47604654	C21orf56	0.55	9.75	0.41	1.44e-20	Testicular germ cell tumor;
LGG	cis	rs7241530	0.636	rs8099795	chr18:75909874	T/G	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	8.11e-17	Educational attainment (years of education);
LGG	cis	rs3206736	0.548	rs329242	chr7:35059667	T/C	cg13400248	chr7:35225412	NA	0.55	9.49	0.4	1.23e-19	Diastolic blood pressure;
LGG	cis	rs4006360	0.522	rs11871050	chr17:39236997	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.56	-0.47	2.49e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs7181230	0.885	rs35781999	chr15:40355406	G/C	cg22705835	chr10:65332833	REEP3	-0.62	-10.28	-0.43	1.88e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs7246760	0.867	rs59616842	chr19:9792245	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.1	-0.31	4.57e-12	Lung cancer;
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg16434002	chr17:42200994	HDAC5	0.53	9.74	0.41	1.66e-20	Total body bone mineral density;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg20308403	chr7:2120281	MAD1L1	0.32	6.9	0.31	1.73e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	8.3	0.36	1.17e-15	Diabetic retinopathy;
LGG	cis	rs597583	0.715	rs4938399	chr11:117398399	C/T	cg27161313	chr11:117392002	DSCAML1	-0.63	-9.93	-0.42	3.31e-21	Putamen volume;
LGG	cis	rs12291225	0.535	rs16930126	chr11:14404983	C/T	cg19336497	chr11:14380999	RRAS2	0.52	10.33	0.43	1.24e-22	Sense of smell;
LGG	cis	rs4517514	0.509	rs11018870	chr11:89871409	T/G	cg14505434	chr11:89522851	NA	0.56	7.47	0.33	3.91e-13	Trans fatty acid levels;
LGG	cis	rs504918	0.588	rs73188160	chr3:123965749	A/G	cg05766129	chr3:123988013	KALRN	-0.57	-10.17	-0.43	4.71e-22	Schizophrenia;
LGG	cis	rs910316	1.000	rs7142235	chr14:75559963	T/C	cg11812906	chr14:75593930	NEK9	0.54	10.23	0.43	2.75e-22	Height;
LGG	cis	rs8014204	0.935	rs2300596	chr14:75353855	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.28	-0.32	1.43e-12	Caffeine consumption;
LGG	cis	rs2235573	0.710	rs738443	chr22:38458681	G/A	cg19171272	chr22:38449367	NA	-0.62	-12.28	-0.5	3.3e-30	Glioblastoma;Glioma;
LGG	cis	rs6028335	0.674	rs974561	chr20:37591184	G/C	cg16355469	chr20:37678765	NA	0.6	8.03	0.35	8.08e-15	Alcohol and nicotine co-dependence;
LGG	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg24623649	chr8:11872141	NA	0.3	6.99	0.31	9.56e-12	Neuroticism;
LGG	cis	rs2712184	0.875	rs35925637	chr2:217676628	T/A	cg05032264	chr2:217675019	NA	0.43	9.36	0.4	3.43e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg00012203	chr2:219082015	ARPC2	0.75	14.3	0.55	1.09e-38	Colorectal cancer;
LGG	cis	rs4262150	0.660	rs4958599	chr5:152338061	A/G	cg12297329	chr5:152029980	NA	-0.7	-11.63	-0.48	1.33e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg05896524	chr21:47604654	C21orf56	0.64	11.58	0.47	2.07e-27	Testicular germ cell tumor;
LGG	cis	rs2303745	0.589	rs11086065	chr19:17395003	A/G	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.71	-0.45	4.51e-24	Systemic lupus erythematosus;
LGG	cis	rs9911578	1.000	rs11870671	chr17:56605360	A/G	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg13385794	chr1:248469461	NA	0.44	7.49	0.33	3.46e-13	Common traits (Other);
LGG	cis	rs6558530	0.653	rs7001282	chr8:1700188	A/C	cg08198773	chr8:1697536	NA	0.45	8.05	0.35	6.83e-15	Systolic blood pressure;
LGG	cis	rs9309473	0.632	rs7599076	chr2:73585519	G/T	cg20560298	chr2:73613845	ALMS1	-0.48	-8.81	-0.38	2.51e-17	Metabolite levels;
LGG	cis	rs9354308	0.764	rs1938120	chr6:66568919	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.84	-0.3	2.56e-11	Metabolite levels;
LGG	cis	rs4906332	1.000	rs17617935	chr14:103952886	A/T	cg26031613	chr14:104095156	KLC1	-0.51	-7.74	-0.34	6.23e-14	Coronary artery disease;
LGG	cis	rs1577917	0.687	rs34618171	chr6:86811165	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-8.86	-0.38	1.71e-17	Response to antipsychotic treatment;
LGG	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg12386194	chr3:101231763	SENP7	0.75	13.05	0.52	2.33e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.94	0.42	3.03e-21	Lung cancer in ever smokers;
LGG	cis	rs516946	0.797	rs10106563	chr8:41533200	C/A	cg21772509	chr8:41503840	NKX6-3	-0.72	-10.93	-0.45	6.91e-25	Type 2 diabetes;
LGG	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg23625390	chr15:77176239	SCAPER	0.5	10.06	0.42	1.19e-21	Blood metabolite levels;
LGG	cis	rs9549367	0.826	rs9549713	chr13:113905308	G/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg01181863	chr3:195395398	SDHAP2	0.49	7.47	0.33	4.11e-13	Mean corpuscular volume;
LGG	cis	rs75059851	0.756	rs11223656	chr11:133842973	T/A	cg20042908	chr11:133852938	NA	-0.76	-13.92	-0.54	4.8e-37	Schizophrenia;
LGG	cis	rs2280018	0.581	rs7404524	chr16:15129158	A/G	cg07549590	chr16:15018862	NA	-0.45	-7.72	-0.34	7.18e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06347996	chr1:98386915	DPYD	0.44	7.4	0.33	6.2800000000000005e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg11062466	chr8:58055876	NA	0.46	7.77	0.34	5.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11890956	chr21:40555474	PSMG1	0.73	12.45	0.5	6.95e-31	Menarche (age at onset);
LGG	cis	rs6912958	0.754	rs7762864	chr6:88236213	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.79	-0.38	2.93e-17	Monocyte percentage of white cells;
LGG	cis	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.01	0.35	9.34e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs2120019	0.567	rs12385940	chr15:75168162	C/T	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.02	-0.46	3.07e-25	Blood trace element (Zn levels);
LGG	cis	rs11785400	0.793	rs4567014	chr8:143737690	G/C	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs7927592	0.513	rs653056	chr11:68203625	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-11.03	-0.46	2.8e-25	Total body bone mineral density;
LGG	cis	rs9916302	0.904	rs7503705	chr17:37669704	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.07e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9783347	0.714	rs4150628	chr11:18365868	G/A	cg15585147	chr11:18324498	HPS5	0.32	7.54	0.33	2.51e-13	Pancreatic cancer;
LGG	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg12395012	chr8:11607386	GATA4	-0.38	-7.06	-0.31	6.06e-12	Neuroticism;
LGG	cis	rs13314892	0.728	rs74280296	chr3:69889006	T/A	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs12971120	0.838	rs747176	chr18:72154931	G/A	cg25817165	chr18:72167213	CNDP2	-0.63	-13.0	-0.52	3.85e-33	Refractive error;
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.89	0.3	1.87e-11	Vitiligo;
LGG	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	13.97	0.54	2.86e-37	Cognitive test performance;
LGG	cis	rs7577696	0.597	rs6756085	chr2:32336522	A/G	cg02381751	chr2:32503542	YIPF4	-0.47	-6.86	-0.3	2.23e-11	Inflammatory biomarkers;
LGG	cis	rs7762018	1.000	rs6459657	chr6:170136454	A/G	cg17545662	chr6:170176663	C6orf70	0.68	8.7	0.37	6.02e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.48	-0.44	3.25e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg18402987	chr7:1209562	NA	0.43	8.04	0.35	7.36e-15	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08541953	chr1:6259338	RPL22	0.46	6.99	0.31	9.78e-12	Gut microbiome composition (summer);
LGG	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg02002194	chr4:3960332	NA	-0.46	-8.36	-0.36	7.16e-16	Neuroticism;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg02249930	chr10:70166207	RUFY2	-0.43	-6.84	-0.3	2.51e-11	Coronary artery disease;
LGG	cis	rs7937682	1.000	rs2186839	chr11:111534442	T/G	cg22437258	chr11:111473054	SIK2	0.54	9.27	0.4	6.96e-19	Primary sclerosing cholangitis;
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg20814179	chr4:940893	TMEM175	0.49	9.11	0.39	2.54e-18	Sjögren's syndrome;
LGG	cis	rs826838	1.000	rs11183941	chr12:38851692	G/C	cg26384229	chr12:38710491	ALG10B	1.06	28.12	0.79	3.3e-102	Heart rate;
LGG	cis	rs4690686	0.500	rs7667671	chr4:177275599	T/C	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.48e-84	Essential tremor;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg16590910	chr6:42928470	GNMT	0.42	11.79	0.48	3.17e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg08888203	chr3:10149979	C3orf24	0.53	7.91	0.35	1.85e-14	Alzheimer's disease;
LGG	cis	rs8017423	0.647	rs4904680	chr14:90822075	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-12.97	-0.52	5.1e-33	Mortality in heart failure;
LGG	cis	rs9547692	0.877	rs12020203	chr13:37469287	G/A	cg01493522	chr13:37497338	NA	-0.49	-8.48	-0.37	2.98e-16	Coronary artery disease;
LGG	cis	rs11748327	0.806	rs12659815	chr5:4075178	G/A	cg01025095	chr5:4101132	NA	-0.6	-9.66	-0.41	3e-20	Myocardial infarction;
LGG	cis	rs9487051	0.676	rs7753705	chr6:109593302	A/C	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.02e-14	Reticulocyte fraction of red cells;
LGG	cis	rs2404602	0.669	rs12441484	chr15:77109875	G/A	cg05677249	chr15:77158041	SCAPER	-0.32	-6.8	-0.3	3.3e-11	Blood metabolite levels;
LGG	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.09	0.42	9e-22	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.44	0.4	1.89e-19	Mood instability;
LGG	cis	rs2694528	0.844	rs1031745	chr5:60058398	C/T	cg11474532	chr5:59995715	DEPDC1B	0.7	7.4	0.33	6.46e-13	Parkinson's disease;
LGG	cis	rs1348850	0.668	rs13010396	chr2:178492934	T/C	cg22681709	chr2:178499509	PDE11A	-0.47	-7.68	-0.34	9.27e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4819052	0.788	rs9978857	chr21:46705155	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	8.04	0.35	7.47e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10463554	0.963	rs61418746	chr5:102379618	T/A	cg23492399	chr5:102201601	PAM	-0.51	-7.64	-0.33	1.25e-13	Parkinson's disease;
LGG	trans	rs1032833	0.643	rs116230656	chr2:180107139	G/A	cg23654767	chr2:101192981	PDCL3	0.65	7.72	0.34	7.45e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg14784868	chr12:69753453	YEATS4	1.01	24.12	0.75	7.19e-84	Cerebrospinal fluid biomarker levels;
LGG	cis	rs240764	0.619	rs12525128	chr6:101174245	G/A	cg09795085	chr6:101329169	ASCC3	0.41	6.84	0.3	2.52e-11	Neuroticism;
LGG	trans	rs11039798	0.557	rs683180	chr11:48463949	A/G	cg15704280	chr7:45808275	SEPT13	-0.72	-9.89	-0.42	4.71e-21	Axial length;
LGG	cis	rs7727544	0.606	rs200838	chr5:131710399	A/C	cg24060327	chr5:131705240	SLC22A5	0.41	6.94	0.31	1.37e-11	Blood metabolite levels;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.6	0.44	1.21e-23	Lung function (FEV1/FVC);
LGG	cis	rs61931739	0.570	rs7315655	chr12:33912869	G/A	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.521	rs3796386	chr3:49899795	G/A	cg21659725	chr3:3221576	CRBN	0.61	10.77	0.45	2.75e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2945232	1	rs2945232	chr8:8098038	T/C	cg08975724	chr8:8085496	FLJ10661	0.6	12.4	0.5	1.07e-30	Schizophrenia;
LGG	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs3820928	0.874	rs4423583	chr2:227874957	A/G	cg11843606	chr2:227700838	RHBDD1	0.44	7.42	0.33	5.82e-13	Pulmonary function;
LGG	cis	rs2470578	0.792	rs283909	chr3:17333068	A/G	cg20981856	chr3:17787350	NA	0.35	6.74	0.3	4.83e-11	Schizophrenia;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs975722	1.000	rs1208526	chr7:117337484	G/A	cg10524701	chr7:117356490	CTTNBP2	0.51	11.58	0.47	2.16e-27	Coronary artery disease;
LGG	cis	rs1371867	0.641	rs1788209	chr8:101337056	C/T	cg06636551	chr8:101224915	SPAG1	-0.47	-8.83	-0.38	2.1e-17	Atrioventricular conduction;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg00933542	chr6:150070202	PCMT1	0.39	7.12	0.31	4.01e-12	Lung cancer;
LGG	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg05234568	chr11:5960015	NA	0.58	9.62	0.41	4.25e-20	DNA methylation (variation);
LGG	cis	rs2235642	0.893	rs2143285	chr16:1593171	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.42	10.28	0.43	1.81e-22	Coronary artery disease;
LGG	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg21972741	chr5:435613	AHRR	0.5	8.93	0.38	1.01e-17	Cystic fibrosis severity;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.94	0.38	9.19e-18	Schizophrenia;
LGG	cis	rs7647973	1.000	rs11130189	chr3:49347357	C/A	cg07636037	chr3:49044803	WDR6	0.77	13.42	0.53	6.16e-35	Menarche (age at onset);
LGG	cis	rs77633900	0.772	rs506000	chr15:76817788	T/C	cg21673338	chr15:77095150	SCAPER	-0.62	-8.09	-0.35	5.29e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7927771	0.524	rs2170815	chr11:47875910	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.07	0.46	1.92e-25	Subjective well-being;
LGG	cis	rs3768617	0.510	rs4491025	chr1:183065183	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg08125733	chr17:73851984	WBP2	0.87	13.4	0.53	8.02e-35	Psoriasis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16075209	chr5:44808992	MRPS30	0.4	6.73	0.3	5.11e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1994135	0.669	rs11052747	chr12:33697913	C/G	cg13010199	chr12:38710504	ALG10B	0.5	8.89	0.38	1.42e-17	Resting heart rate;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg03188948	chr7:1209495	NA	0.42	7.43	0.33	5.19e-13	Longevity;Endometriosis;
LGG	cis	rs2028299	0.959	rs12912009	chr15:90429148	G/A	cg23731826	chr15:90371692	NA	0.36	8.58	0.37	1.4e-16	Type 2 diabetes;
LGG	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg26150922	chr2:100937072	LONRF2	-0.55	-9.66	-0.41	3.01e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6686643	1.000	rs957644	chr1:165616157	C/T	cg19407955	chr1:165599744	MGST3	-0.59	-8.74	-0.38	4.2e-17	Total ventricular volume;
LGG	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2535633	0.631	rs2245424	chr3:53003021	G/C	cg11645453	chr3:52864694	ITIH4	-0.5	-8.29	-0.36	1.25e-15	Body mass index;
LGG	cis	rs7843479	0.601	rs9969551	chr8:21860007	T/C	cg17168535	chr8:21777572	XPO7	0.79	15.42	0.58	1.3e-43	Mean corpuscular volume;
LGG	cis	rs10489202	0.632	rs275143	chr1:168056724	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-10.64	-0.44	8.36e-24	Schizophrenia;
LGG	trans	rs78049276	0.688	rs1878406	chr4:148393664	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.55	-0.33	2.31e-13	Pulse pressure;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.88	-18.88	-0.66	2.18e-59	Prudent dietary pattern;
LGG	cis	rs12210905	1.000	rs72843613	chr6:27138467	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-7.71	-0.34	7.88e-14	Hip circumference adjusted for BMI;
LGG	cis	rs988958	0.565	rs34629045	chr2:42237224	A/G	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg04450456	chr4:17643702	FAM184B	0.32	7.09	0.31	5.17e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10463554	0.963	rs62364874	chr5:102392179	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.83	-0.34	3.42e-14	Parkinson's disease;
LGG	cis	rs2797369	0.656	rs625745	chr6:101351852	C/T	cg27451362	chr6:101846650	GRIK2	0.77	10.7	0.45	5.02e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs2415984	0.579	rs17740937	chr14:46959273	A/G	cg14871534	chr14:47121158	RPL10L	-0.57	-9.89	-0.42	4.81e-21	Number of children ever born;
LGG	cis	rs6740322	0.748	rs6544636	chr2:43487486	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.71	-11.08	-0.46	1.78e-25	Coronary artery disease;
LGG	cis	rs1577917	1.000	rs12204365	chr6:86700532	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.07e-33	Response to antipsychotic treatment;
LGG	cis	rs35771425	1.000	rs11579557	chr1:211619703	A/G	cg10512769	chr1:211675356	NA	0.72	11.85	0.48	1.85e-28	Educational attainment (years of education);
LGG	trans	rs3780486	0.718	rs3818593	chr9:33120706	A/G	cg04842962	chr6:43655489	MRPS18A	0.84	12.41	0.5	9.7e-31	IgG glycosylation;
LGG	cis	rs4604732	0.631	rs34924545	chr1:247626892	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.84	0.38	1.99e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2932538	0.922	rs6681371	chr1:113101168	A/C	cg22162597	chr1:113214053	CAPZA1	0.57	10.52	0.44	2.42e-23	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs2688608	0.592	rs7909802	chr10:75484186	G/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.32	-0.32	1.13e-12	Inflammatory bowel disease;
LGG	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg25706552	chr1:244017396	NA	0.52	8.45	0.37	3.86e-16	RR interval (heart rate);
LGG	cis	rs4740619	0.509	rs74864879	chr9:15633072	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.41	-0.44	5.98e-23	Body mass index;
LGG	cis	rs9771228	0.585	rs10263673	chr7:32282519	C/T	cg27532318	chr7:32358331	NA	0.53	7.68	0.34	9.62e-14	Cognitive ability;Verbal-numerical reasoning;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19716004	chr3:82857285	NA	0.4	7.52	0.33	2.96e-13	Menarche (age at onset);
LGG	trans	rs6600671	0.934	rs11249429	chr1:121291080	C/T	cg17023122	chr1:144479586	NA	-0.32	-7.37	-0.32	8.1e-13	Hip geometry;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25782835	chr3:101443325	CEP97	-0.47	-6.84	-0.3	2.5e-11	Systemic lupus erythematosus;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg14773178	chr5:1868261	NA	0.41	8.69	0.37	6.12e-17	Cardiovascular disease risk factors;
LGG	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.66	-0.54	6.39e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6467136	0.560	rs12673058	chr7:127083129	T/C	cg25922125	chr7:127225783	GCC1	-0.43	-6.74	-0.3	4.84e-11	Type 2 diabetes;
LGG	cis	rs4924935	0.748	rs9915894	chr17:18752778	T/C	cg26378065	chr17:18585709	ZNF286B	0.53	7.17	0.32	2.93e-12	Pancreatic cancer;
LGG	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg01028140	chr2:1542097	TPO	-0.43	-8.17	-0.35	3.01e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17401966	0.800	rs12122029	chr1:10339822	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.94	0.35	1.54e-14	Hepatocellular carcinoma;
LGG	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg00405596	chr8:11794950	NA	0.64	11.41	0.47	9.3e-27	Neuroticism;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.63	-0.69	1.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3087591	0.960	rs6505232	chr17:29611411	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.57	-0.56	7.8e-40	Hip circumference;
LGG	cis	rs1620921	0.967	rs1247553	chr6:161188103	A/G	cg01280913	chr6:161186852	NA	-0.33	-6.79	-0.3	3.46e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg05585630	chr7:157510462	PTPRN2	-0.62	-11.08	-0.46	1.88e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9379850	0.528	rs67575965	chr6:26196593	A/G	cg06951627	chr6:26196580	NA	0.43	7.41	0.33	6.05e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9362426	0.639	rs35332886	chr6:88141064	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.46	-8.77	-0.38	3.38e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs1185460	0.546	rs589925	chr11:118955679	C/T	cg24687335	chr11:118901407	SLC37A4	-0.58	-10.4	-0.44	6.8e-23	Coronary artery disease;
LGG	cis	rs35264875	0.846	rs72930627	chr11:68867121	C/A	cg01403660	chr11:68851641	TPCN2	0.48	6.74	0.3	4.69e-11	Blond vs. brown hair color;
LGG	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.68e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.52e-17	Prudent dietary pattern;
LGG	cis	rs7937682	0.632	rs11214028	chr11:111761149	T/C	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs7954584	0.520	rs1169094	chr12:122465535	A/G	cg13699009	chr12:122356056	WDR66	-0.43	-10.22	-0.43	3.14e-22	Mean corpuscular volume;
LGG	cis	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg15749322	chr11:82905199	ANKRD42	0.38	6.77	0.3	3.96e-11	Obesity-related traits;
LGG	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg09264619	chr17:80180166	NA	-0.51	-10.04	-0.42	1.37e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6831352	0.918	rs13107558	chr4:100050200	C/A	cg12011299	chr4:100065546	ADH4	-0.42	-8.35	-0.36	8.19e-16	Alcohol dependence;
LGG	cis	rs10861342	1.000	rs10861353	chr12:105515290	T/C	cg23923672	chr12:105501055	KIAA1033	0.78	7.01	0.31	8.28e-12	IgG glycosylation;
LGG	cis	rs17767392	0.834	rs61991190	chr14:71737278	T/C	cg02058870	chr14:72053146	SIPA1L1	0.41	8.09	0.35	5.47e-15	Mitral valve prolapse;
LGG	cis	rs9303280	0.836	rs11557467	chr17:38028634	G/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.76	-0.3	4.21e-11	Self-reported allergy;
LGG	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg12042659	chr19:58951599	ZNF132	0.36	7.36	0.32	8.23e-13	Uric acid clearance;
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.58	-0.33	1.84e-13	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs11169552	0.510	rs11169537	chr12:51126792	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.65	-0.34	1.14e-13	Colorectal cancer;
LGG	cis	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg14541582	chr5:601475	NA	-0.68	-10.87	-0.45	1.16e-24	Obesity-related traits;
LGG	cis	rs6977660	0.607	rs10243965	chr7:19797893	G/A	cg07541023	chr7:19748670	TWISTNB	0.61	8.6	0.37	1.22e-16	Thyroid stimulating hormone;
LGG	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg09021430	chr5:549028	NA	-0.79	-17.19	-0.62	1.34e-51	Ulcerative colitis;
LGG	cis	rs12210905	1.000	rs6917419	chr6:27243480	C/T	cg15325629	chr6:28072465	NA	0.7	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7208859	0.573	rs11656121	chr17:29214043	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs653465	0.739	rs1522151	chr3:27165174	C/T	cg02860705	chr3:27208620	NA	0.39	7.49	0.33	3.59e-13	Breast cancer (early onset);
LGG	cis	rs9388451	0.874	rs7739566	chr6:126094757	A/T	cg10911889	chr6:126070802	HEY2	0.43	7.37	0.32	7.69e-13	Brugada syndrome;
LGG	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Body mass index;
LGG	cis	rs2227564	0.620	rs7098573	chr10:75580014	G/A	cg00564723	chr10:75632066	CAMK2G	-0.47	-10.06	-0.42	1.2e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10884984	0.674	rs10884985	chr10:112273704	A/G	cg18756771	chr10:112261994	DUSP5	0.69	12.32	0.5	2.35e-30	Facial morphology (factor 22);
LGG	cis	rs6988985	0.658	rs28719775	chr8:143938577	G/A	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg24375607	chr4:120327624	NA	0.54	9.18	0.39	1.49e-18	Corneal astigmatism;
LGG	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg11266682	chr4:10021025	SLC2A9	0.57	11.66	0.48	9.85e-28	Bone mineral density;
LGG	trans	rs9944715	1.000	rs7239351	chr18:43851338	A/T	cg01718231	chr17:29326311	RNF135	-0.42	-6.84	-0.3	2.53e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs16854884	0.657	rs6778627	chr3:143720869	G/T	cg06585982	chr3:143692056	C3orf58	0.61	10.61	0.44	1.1e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs9291683	0.530	rs11723591	chr4:9985398	T/A	cg25986240	chr4:9926439	SLC2A9	-0.47	-10.08	-0.42	9.47e-22	Bone mineral density;
LGG	trans	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.58	-0.33	1.94e-13	Joint mobility (Beighton score);
LGG	cis	rs3916	0.955	rs12828810	chr12:121152017	T/G	cg21892295	chr12:121157589	UNC119B	-0.41	-7.26	-0.32	1.6e-12	Urinary metabolites (H-NMR features);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg27498675	chr19:41945691	ATP5SL	0.39	6.69	0.3	6.48e-11	Body mass index;
LGG	trans	rs7395662	0.963	rs6485889	chr11:48608785	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.44	0.33	4.93e-13	Tonsillectomy;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg08888203	chr3:10149979	C3orf24	0.54	9.09	0.39	3.02e-18	Alzheimer's disease;
LGG	cis	rs8072100	0.713	rs8075058	chr17:45482857	A/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.06	-0.39	3.81e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg10950524	chr7:2139216	MAD1L1	0.35	7.58	0.33	1.84e-13	Schizophrenia;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg24503407	chr1:205819492	PM20D1	0.95	26.9	0.78	1.16e-96	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg16141378	chr3:129829833	LOC729375	0.34	7.42	0.33	5.56e-13	Retinal vascular caliber;
LGG	cis	rs2077654	0.908	rs7926934	chr11:17433088	A/C	cg25308976	chr11:17434268	ABCC8	0.84	10.0	0.42	1.9e-21	Gout;
LGG	cis	rs35123781	0.696	rs356429	chr5:139073143	C/T	cg21230503	chr5:139085173	NA	0.37	8.58	0.37	1.5e-16	Schizophrenia;
LGG	trans	rs9467711	0.790	rs17598658	chr6:26175866	A/C	cg06606381	chr12:133084897	FBRSL1	-1.16	-9.94	-0.42	3.24e-21	Autism spectrum disorder or schizophrenia;
LGG	cis	rs765787	0.530	rs2554454	chr15:45521536	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.45	-7.65	-0.34	1.16e-13	Uric acid levels;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg13206674	chr6:150067644	NUP43	0.68	16.02	0.6	2.83e-46	Lung cancer;
LGG	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg10847948	chr11:71163743	NADSYN1	0.66	12.97	0.52	5.02e-33	Vitamin D levels;
LGG	trans	rs7829975	0.777	rs486781	chr8:8639740	A/G	cg12395012	chr8:11607386	GATA4	0.37	6.65	0.3	8.33e-11	Mood instability;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg22903471	chr2:27725779	GCKR	-0.57	-12.92	-0.51	8.19e-33	Total body bone mineral density;
LGG	trans	rs4650994	0.525	rs10913574	chr1:178536482	G/C	cg05059571	chr16:84539110	KIAA1609	-0.57	-10.87	-0.45	1.18e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg11707556	chr5:10655725	ANKRD33B	0.66	11.29	0.46	2.9e-26	Coronary artery disease;
LGG	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg01967586	chr1:228894546	NA	0.4	8.5	0.37	2.57e-16	Chronic lymphocytic leukemia;
LGG	cis	rs933688	1.000	rs10073657	chr5:90689749	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	17.14	0.62	2.27e-51	Smoking behavior;
LGG	cis	rs12472274	0.646	rs10929269	chr2:239097423	A/G	cg17459225	chr2:239074497	NA	0.75	10.83	0.45	1.65e-24	Phospholipid levels (plasma);
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg06654118	chr4:1303317	MAEA	0.44	7.75	0.34	5.77e-14	Obesity-related traits;
LGG	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.66	-0.41	3.07e-20	Height;
LGG	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	19.16	0.67	1.07e-60	Smoking behavior;
LGG	trans	rs7615952	0.551	rs12695470	chr3:125635718	C/A	cg07211511	chr3:129823064	LOC729375	-1.39	-21.25	-0.7	1.96e-70	Blood pressure (smoking interaction);
LGG	cis	rs10193935	0.901	rs10490552	chr2:42559947	C/T	cg27598129	chr2:42591480	NA	0.59	9.03	0.39	4.74e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs79911532	0.515	rs10245109	chr7:75846115	G/T	cg19862616	chr7:65841803	NCRNA00174	0.67	7.39	0.32	6.72e-13	Mononucleosis;
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg00495681	chr13:53174319	NA	0.54	9.25	0.4	8.12e-19	Lewy body disease;
LGG	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13012494	chr21:47604986	C21orf56	0.49	8.13	0.35	3.91e-15	Testicular germ cell tumor;
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg02524346	chr8:600233	NA	1.02	10.31	0.43	1.47e-22	IgG glycosylation;
LGG	cis	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19171272	chr22:38449367	NA	-0.49	-8.99	-0.39	6.12e-18	Glioblastoma;Glioma;
LGG	cis	rs6502050	0.835	rs7219180	chr17:80079968	C/G	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg24675658	chr1:53192096	ZYG11B	0.65	13.57	0.53	1.47e-35	Monocyte count;
LGG	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.94	0.31	1.34e-11	Retinal vascular caliber;
LGG	cis	rs62244186	0.659	rs62251383	chr3:44552421	A/G	cg02073558	chr3:44770973	ZNF501	0.66	11.98	0.49	5.5e-29	Depressive symptoms;
LGG	trans	rs3960554	1.000	rs2079477	chr7:75836549	C/G	cg19862616	chr7:65841803	NCRNA00174	0.84	12.32	0.5	2.35e-30	Eotaxin levels;
LGG	cis	rs877282	0.945	rs71489301	chr10:770191	A/G	cg17470449	chr10:769945	NA	0.65	8.19	0.36	2.49e-15	Uric acid levels;
LGG	cis	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg09044154	chr16:88155775	NA	-0.49	-7.49	-0.33	3.45e-13	Menopause (age at onset);
LGG	cis	rs6541297	1.000	rs6674744	chr1:230279011	C/T	cg05784532	chr1:230284198	GALNT2	0.51	8.94	0.38	9.15e-18	Coronary artery disease;
LGG	cis	rs1577917	0.917	rs35283633	chr6:86690787	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.78	-0.41	1.12e-20	Response to antipsychotic treatment;
LGG	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.34e-18	Rheumatoid arthritis;
LGG	cis	rs9309473	1.000	rs7598396	chr2:73652628	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.6	-0.33	1.62e-13	Metabolite levels;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11608355	0.545	rs35422737	chr12:109911456	A/G	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs8044868	0.530	rs12932845	chr16:72122765	G/A	cg23815491	chr16:72088622	HP	0.39	8.43	0.36	4.27e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs9875589	0.957	rs6778297	chr3:13932143	C/T	cg19554555	chr3:13937349	NA	0.7	13.28	0.53	2.43e-34	Ovarian reserve;
LGG	cis	rs7598759	0.548	rs11693738	chr2:232360484	C/T	cg19187155	chr2:232395269	NMUR1	0.53	9.94	0.42	3.2e-21	Noise-induced hearing loss;
LGG	cis	rs6568686	0.786	rs7776286	chr6:111810216	A/G	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg21435375	chr2:172878103	MAP1D	-0.32	-7.57	-0.33	1.99e-13	Schizophrenia;
LGG	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg06718696	chr17:78121285	EIF4A3	0.89	14.43	0.56	3.19e-39	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs3820068	0.603	rs72647120	chr1:15956769	G/T	cg05660106	chr1:15850417	CASP9	0.86	17.51	0.63	4.96e-53	Systolic blood pressure;
LGG	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22455342	chr2:225449267	CUL3	0.87	15.16	0.58	1.98e-42	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2354432	0.607	rs6683243	chr1:146733422	A/T	cg25205988	chr1:146714368	CHD1L	-1.48	-14.89	-0.57	3.07e-41	Mitochondrial DNA levels;
LGG	cis	rs477895	0.941	rs12808002	chr11:64110932	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	7.68	0.34	9.3e-14	Mean platelet volume;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg20607798	chr8:58055168	NA	0.64	7.46	0.33	4.41e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.66	0.51	9.05e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10484885	0.571	rs56019056	chr6:90630623	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.61	-7.51	-0.33	3.04e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12016809	chr21:47604291	C21orf56	-0.6	-10.07	-0.42	1.04e-21	Testicular germ cell tumor;
LGG	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.93	-0.45	7.06e-25	Neuroticism;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg11965913	chr1:205819406	PM20D1	0.95	23.13	0.73	2.92e-79	Menarche (age at onset);
LGG	cis	rs6088590	0.687	rs8115656	chr20:33282780	G/C	cg24642439	chr20:33292090	TP53INP2	0.65	11.26	0.46	3.72e-26	Coronary artery disease;
LGG	cis	rs75920871	1.000	rs11216221	chr11:116868137	A/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs16910800	0.731	rs16910759	chr11:23192131	C/G	cg20040320	chr11:23191996	NA	-0.6	-6.91	-0.31	1.58e-11	Cancer;
LGG	cis	rs7166081	1.000	rs8038652	chr15:67552064	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.65	-0.3	8.45e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs8180040	0.701	rs34103310	chr3:47073266	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.47	-0.58	8.06e-44	Colorectal cancer;
LGG	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg06219351	chr7:158114137	PTPRN2	0.69	13.74	0.54	2.74e-36	Calcium levels;
LGG	cis	rs9309711	0.736	rs9678647	chr2:3497036	A/G	cg10845886	chr2:3471009	TTC15	0.62	11.68	0.48	8.39e-28	Neurofibrillary tangles;
LGG	cis	rs4509693	0.891	rs10748797	chr10:102502173	A/C	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.28e-11	Alzheimer's disease;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.21	-0.43	3.33e-22	Obesity-related traits;
LGG	cis	rs11771526	0.901	rs10239582	chr7:32298116	T/A	cg13207630	chr7:32358064	NA	0.67	7.24	0.32	1.86e-12	Body mass index;
LGG	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg19524238	chr7:2802976	GNA12	0.37	8.43	0.36	4.52e-16	Height;
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg19901468	chr14:105411992	AHNAK2	-0.89	-19.33	-0.67	1.86e-61	Rheumatoid arthritis;
LGG	cis	rs55863869	0.748	rs74805196	chr2:179619400	T/C	cg02880032	chr2:179629472	TTN	0.47	6.69	0.3	6.28e-11	QT interval;
LGG	cis	rs12220238	1.000	rs7081350	chr10:75990328	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.84	11.85	0.48	1.82e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs8077889	0.917	rs72836556	chr17:41911824	G/T	cg26893861	chr17:41843967	DUSP3	0.93	15.79	0.59	2.96e-45	Triglycerides;
LGG	cis	rs9902453	0.845	rs2321331	chr17:28025528	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg26865084	chr6:169223825	NA	-0.42	-7.83	-0.34	3.32e-14	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
LGG	cis	rs10861342	1.000	rs34705618	chr12:105518611	C/G	cg23923672	chr12:105501055	KIAA1033	0.79	7.03	0.31	7.64e-12	IgG glycosylation;
LGG	cis	rs11225247	0.536	rs12277853	chr11:102257853	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg00689492	chr4:1303491	MAEA	0.48	8.31	0.36	1.08e-15	Obesity-related traits;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg26248373	chr2:1572462	NA	-0.69	-8.3	-0.36	1.16e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7226408	0.625	rs323327	chr18:34722503	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.08	-0.39	3.03e-18	Obesity-related traits;
LGG	cis	rs4819052	1.000	rs2297285	chr21:46705621	A/G	cg06618935	chr21:46677482	NA	0.51	8.71	0.38	5.39e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs2243480	1.000	rs781149	chr7:65481284	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	cis	rs58688157	0.705	rs36060383	chr11:598723	A/C	cg16486109	chr11:613632	IRF7	0.42	7.18	0.32	2.85e-12	Systemic lupus erythematosus;
LGG	cis	rs7241530	0.610	rs8098981	chr18:75896607	C/T	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.35e-18	Educational attainment (years of education);
LGG	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26076054	chr5:421317	AHRR	-0.45	-7.57	-0.33	2.07e-13	Cystic fibrosis severity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02147989	chr7:138794603	ZC3HAV1	0.41	6.69	0.3	6.28e-11	Cognitive performance;
LGG	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg05677249	chr15:77158041	SCAPER	-0.31	-6.67	-0.3	7.47e-11	Blood metabolite levels;
LGG	cis	rs769267	0.965	rs2905427	chr19:19478023	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.43	-6.93	-0.31	1.45e-11	Tonsillectomy;
LGG	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg01620082	chr3:125678407	NA	-0.99	-9.46	-0.4	1.5700000000000001e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	0.767	rs79106148	chr10:102184732	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.65e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs360798	0.512	rs4671050	chr2:62988169	G/T	cg17519650	chr2:63277830	OTX1	-0.49	-7.82	-0.34	3.53e-14	Coronary artery disease;
LGG	cis	rs7523273	1.000	rs12123251	chr1:207992546	G/A	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.42	-0.47	8.79e-27	Schizophrenia;
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg04824913	chr4:887549	GAK	0.55	9.76	0.41	1.41e-20	Sjögren's syndrome;
LGG	cis	rs9926296	0.609	rs4785710	chr16:89796756	C/T	cg23057051	chr16:89984268	MC1R	0.35	6.84	0.3	2.49e-11	Vitiligo;
LGG	cis	rs9633740	1.000	rs1902660	chr10:82263683	G/C	cg01528321	chr10:82214614	TSPAN14	1.06	16.72	0.61	1.94e-49	Post bronchodilator FEV1;
LGG	cis	rs4460629	0.742	rs7548955	chr1:155082298	T/C	cg13808842	chr1:155066096	NA	-0.29	-7.05	-0.31	6.43e-12	Serum magnesium levels;
LGG	cis	rs6963495	0.818	rs73192125	chr7:105175068	A/C	cg21420622	chr7:105162941	PUS7	-0.44	-6.67	-0.3	7.39e-11	Bipolar disorder (body mass index interaction);
LGG	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg13010199	chr12:38710504	ALG10B	0.47	9.01	0.39	5.27e-18	Morning vs. evening chronotype;
LGG	cis	rs6963495	0.818	rs73192145	chr7:105203628	A/C	cg19920283	chr7:105172520	RINT1	0.64	8.37	0.36	6.92e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs12367572	0.580	rs1495034	chr12:45414203	C/T	cg04608330	chr12:45269318	NELL2	-0.4	-6.66	-0.3	7.63e-11	Gut microbiome composition (summer);
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16680214	chr1:154839983	KCNN3	-0.5	-9.86	-0.42	5.95e-21	Prostate cancer;
LGG	cis	rs9457247	0.765	rs9295385	chr6:167448181	A/G	cg07741184	chr6:167504864	NA	0.45	9.33	0.4	4.37e-19	Crohn's disease;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.93	13.95	0.54	3.59e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4595586	0.545	rs4768526	chr12:39402898	A/G	cg13010199	chr12:38710504	ALG10B	0.46	8.17	0.36	2.95e-15	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg01657329	chr11:68192670	LRP5	-0.51	-8.81	-0.38	2.54e-17	Total body bone mineral density;
LGG	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg03806693	chr22:41940476	POLR3H	-1.01	-17.3	-0.63	4.26e-52	Vitiligo;
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs7937890	0.684	rs12799007	chr11:14426484	T/A	cg22961513	chr11:14280813	SPON1	-0.29	-6.88	-0.3	1.99e-11	Mitochondrial DNA levels;
LGG	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg12386194	chr3:101231763	SENP7	0.7	12.14	0.49	1.26e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs283228	0.724	rs1385764	chr6:101815243	G/A	cg27451362	chr6:101846650	GRIK2	0.76	11.78	0.48	3.31e-28	Coenzyme Q10 levels;
LGG	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg26384229	chr12:38710491	ALG10B	0.91	20.4	0.69	1.74e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg12070911	chr6:150209640	RAET1E	0.3	7.33	0.32	1.02e-12	Lung cancer;
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg01673284	chr16:4527211	HMOX2	0.35	7.11	0.31	4.39e-12	Schizophrenia;
LGG	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg15485101	chr11:133734466	NA	-0.59	-10.42	-0.44	5.67e-23	Childhood ear infection;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.69	-0.34	8.92e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg05625103	chr10:2543513	NA	0.5	8.83	0.38	2.18e-17	Age-related hearing impairment;
LGG	cis	rs283228	0.535	rs2852502	chr6:101842178	C/A	cg27451362	chr6:101846650	GRIK2	0.99	15.61	0.59	1.89e-44	Coenzyme Q10 levels;
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg24585782	chr17:78113791	EIF4A3	-0.45	-7.42	-0.33	5.52e-13	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs6489882	0.867	rs6489870	chr12:113363972	G/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.38e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7172689	0.908	rs67396561	chr15:81561124	A/G	cg11808699	chr15:81528661	IL16	-0.46	-9.44	-0.4	1.84e-19	Inattentive symptoms;
LGG	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg13256891	chr4:100009986	ADH5	-0.57	-9.56	-0.41	6.79e-20	Alcohol dependence;
LGG	cis	rs61008539	0.821	rs10950789	chr7:897492	A/G	cg22643751	chr7:855365	UNC84A	-0.51	-12.89	-0.51	1.06e-32	Perceived unattractiveness to mosquitoes;
LGG	cis	rs11650494	0.522	rs117821438	chr17:47325867	A/T	cg08112188	chr17:47440006	ZNF652	1.29	14.96	0.57	1.5e-41	Prostate cancer;
LGG	cis	rs4662750	0.798	rs777435	chr2:128369896	A/G	cg10021288	chr2:128175891	PROC	0.39	7.09	0.31	4.99e-12	Renal cell carcinoma;
LGG	cis	rs6732160	0.691	rs7599223	chr2:73427103	A/G	cg01422370	chr2:73384389	NA	0.48	9.15	0.39	1.81e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9522267	1.000	rs1411628	chr13:112199321	G/A	cg14952266	chr13:112191215	NA	0.38	6.82	0.3	2.94e-11	Hepatitis;
LGG	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06634786	chr22:41940651	POLR3H	-0.77	-12.8	-0.51	2.44e-32	Vitiligo;
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.63	0.37	9.6e-17	Systolic blood pressure;
LGG	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.61	-0.37	1.16e-16	Retinal vascular caliber;
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg12288994	chr5:1860383	NA	0.78	15.59	0.59	2.27e-44	Cardiovascular disease risk factors;
LGG	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg01262667	chr19:19385393	TM6SF2	0.35	7.1	0.31	4.85e-12	Bipolar disorder;
LGG	cis	rs4242434	0.672	rs900267	chr8:22485258	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.13	-0.35	3.89e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1878931	0.582	rs10048083	chr16:3417465	A/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.73	11.52	0.47	3.55e-27	Body mass index (adult);
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	9.54e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.21	-0.49	6.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.65	-0.59	1.31e-44	Skin colour saturation;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.6	8.93	0.38	1.03e-17	Platelet count;
LGG	cis	rs7937890	0.695	rs17557844	chr11:14262559	A/G	cg02886208	chr11:14281011	SPON1	0.44	8.64	0.37	9.19e-17	Mitochondrial DNA levels;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg07747251	chr5:1868357	NA	0.44	8.83	0.38	2.18e-17	Cardiovascular disease risk factors;
LGG	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg02493740	chr2:85810744	VAMP5	-0.39	-6.86	-0.3	2.18e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs35306767	0.903	rs35567307	chr10:915804	G/C	cg26597838	chr10:835615	NA	0.74	10.11	0.43	7.51e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg18681998	chr4:17616180	MED28	0.74	15.24	0.58	8.87e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg22813744	chr11:77899778	KCTD21;USP35	-0.41	-6.94	-0.31	1.36e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9815354	0.812	rs73077358	chr3:41850005	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs66887589	0.967	rs1480933	chr4:120433248	C/T	cg09307838	chr4:120376055	NA	0.48	8.17	0.35	3.01e-15	Diastolic blood pressure;
LGG	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg23583168	chr7:148888333	NA	-0.7	-11.31	-0.47	2.32e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg25718383	chr7:130020096	CPA1	0.32	8.42	0.36	4.83e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs7567389	0.504	rs13030463	chr2:128188871	G/A	cg10021288	chr2:128175891	PROC	0.37	6.74	0.3	4.64e-11	Self-rated health;
LGG	cis	rs806795	0.525	rs12661552	chr6:26265200	G/A	cg13736514	chr6:26305472	NA	-0.47	-9.08	-0.39	3.21e-18	Mosquito bite size;
LGG	cis	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-10.24	-0.43	2.62e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs11088226	0.681	rs2833891	chr21:33928821	A/G	cg09050820	chr6:167586206	TCP10L2	0.88	12.95	0.52	6.19e-33	Gastritis;
LGG	cis	rs12643440	0.718	rs612181	chr4:17143492	A/T	cg22650099	chr4:17144496	NA	0.4	7.45	0.33	4.62e-13	Metabolite levels (Pyroglutamine);
LGG	cis	rs4332037	0.539	rs55993248	chr7:2071132	A/G	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.0	-0.31	8.75e-12	Bipolar disorder;
LGG	cis	rs4684776	1.000	rs6791877	chr3:11474354	A/G	cg24705426	chr3:11550659	ATG7	-0.44	-7.95	-0.35	1.45e-14	Small vessel stroke;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg04691961	chr3:161091175	C3orf57	0.41	8.63	0.37	9.57e-17	Morning vs. evening chronotype;
LGG	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg00405596	chr8:11794950	NA	0.61	10.55	0.44	1.78e-23	Monocyte count;
LGG	cis	rs9807989	0.507	rs10208196	chr2:102996345	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs4849975	0.510	rs13432750	chr2:3708503	G/A	cg16123090	chr2:3699210	NA	0.59	7.93	0.35	1.7e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs367943	0.635	rs2222144	chr5:112712208	G/T	cg12552261	chr5:112820674	MCC	0.57	10.43	0.44	5.2e-23	Type 2 diabetes;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg14500267	chr11:67383377	NA	0.47	8.8	0.38	2.8e-17	Mean corpuscular volume;
LGG	cis	rs7851660	0.935	rs12347191	chr9:100619719	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.65	-0.56	3.22e-40	Strep throat;
LGG	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.61	-0.33	1.58e-13	Height;
LGG	cis	rs3820068	0.734	rs72645830	chr1:15889910	A/G	cg05660106	chr1:15850417	CASP9	1.17	25.13	0.76	1.5e-88	Systolic blood pressure;
LGG	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.97e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2070433	0.749	rs718496	chr21:47904585	A/C	cg12379764	chr21:47803548	PCNT	0.5	7.22	0.32	2.21e-12	Lymphocyte counts;
LGG	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg06153925	chr17:78755379	RPTOR	0.4	6.69	0.3	6.42e-11	Myopia (pathological);
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs11190604	1.000	rs2495745	chr10:102329075	A/G	cg07080220	chr10:102295463	HIF1AN	0.68	11.61	0.47	1.59e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9427116	1.000	rs9330261	chr1:154634998	T/A	cg11650704	chr1:154556575	ADAR	-0.39	-7.43	-0.33	5.41e-13	Blood protein levels;
LGG	cis	rs6763768	0.606	rs9812118	chr3:53380053	T/C	cg16894138	chr3:53270350	TKT	0.42	8.09	0.35	5.35e-15	Bacterial meningitis;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.43	0.33	5.28e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.95	-0.31	1.24e-11	Monocyte count;
LGG	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg17294928	chr15:75287854	SCAMP5	-0.93	-16.87	-0.62	4.24e-50	Blood trace element (Zn levels);
LGG	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.62	-0.44	9.93e-24	Aortic root size;
LGG	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.28	-0.4	6.54e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg09117114	chr16:67998030	SLC12A4	-0.36	-6.64	-0.3	8.54e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg23782820	chr8:58130467	NA	0.43	6.66	0.3	7.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12618769	0.597	rs3754879	chr2:99164541	G/T	cg18455616	chr2:99124870	INPP4A	0.27	7.65	0.33	1.19e-13	Bipolar disorder;
LGG	cis	rs1594829	0.553	rs2046225	chr8:26151802	A/C	cg11498726	chr8:26250323	BNIP3L	0.38	8.52	0.37	2.26e-16	Height;
LGG	cis	rs10895140	0.665	rs1939454	chr11:101520753	G/A	cg23650423	chr11:101454676	TRPC6	-0.4	-6.77	-0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.96	-0.31	1.19e-11	Type 2 diabetes;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04772025	chr11:68637568	NA	-0.74	-13.07	-0.52	1.96e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07555182	chr11:82782896	RAB30	0.45	7.02	0.31	8.06e-12	Gut microbiome composition (summer);
LGG	cis	rs1322639	0.614	rs6940913	chr6:169563666	G/A	cg04662567	chr6:169592167	NA	-0.78	-11.44	-0.47	7.52e-27	Pulse pressure;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7086627	0.515	rs10887900	chr10:82210265	A/G	cg01528321	chr10:82214614	TSPAN14	0.62	10.97	0.45	4.93e-25	Post bronchodilator FEV1;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs2439831	1.000	rs2245054	chr15:43751909	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.53	0.5	3.16e-31	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.71	13.12	0.52	1.21e-33	Obesity-related traits;
LGG	cis	rs2439831	0.571	rs689883	chr15:43812596	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.84	0.42	6.86e-21	Lung cancer in ever smokers;
LGG	cis	rs12200782	1.000	rs72844496	chr6:26611608	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-8.2	-0.36	2.4e-15	Small cell lung carcinoma;
LGG	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs2486288	0.656	rs1706768	chr15:45569443	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.88	-0.45	1.08e-24	Glomerular filtration rate;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.36	-0.36	7.56e-16	Menopause (age at onset);
LGG	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.59	-0.44	1.25e-23	Alzheimer's disease;
LGG	cis	rs8032158	1.000	rs28660477	chr15:56145267	T/C	cg02198044	chr15:56286336	NEDD4	-0.69	-11.88	-0.48	1.32e-28	Keloid;
LGG	cis	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg04568710	chr12:38710424	ALG10B	0.35	7.28	0.32	1.44e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9462027	0.628	rs1543558	chr6:34784371	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	trans	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg10756647	chr7:56101905	PSPH	0.85	10.32	0.43	1.3e-22	Diabetic kidney disease;
LGG	cis	rs6547741	0.904	rs2384659	chr2:27856793	G/A	cg27432699	chr2:27873401	GPN1	0.69	14.0	0.55	2.28e-37	Oral cavity cancer;
LGG	cis	rs9308731	0.863	rs616582	chr2:111941995	T/C	cg26001287	chr2:111877753	BCL2L11	-0.36	-6.99	-0.31	9.66e-12	Chronic lymphocytic leukemia;
LGG	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg11494091	chr17:61959527	GH2	0.6	10.09	0.42	9.35e-22	Height;
LGG	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg12636538	chr11:118901039	SLC37A4	-0.62	-12.75	-0.51	3.94e-32	Coronary artery disease;
LGG	cis	rs765787	0.530	rs11636367	chr15:45535862	A/G	cg25801113	chr15:45476975	SHF	0.87	19.95	0.68	2.21e-64	Uric acid levels;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg02182114	chr7:139876578	LOC100134229;JHDM1D	-0.42	-7.07	-0.31	5.85e-12	Leprosy;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg03036210	chr16:89904091	SPIRE2	-0.58	-8.28	-0.36	1.32e-15	Skin colour saturation;
LGG	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg21401794	chr1:90099060	LRRC8C	0.56	12.08	0.49	2.16e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg06606381	chr12:133084897	FBRSL1	0.71	8.31	0.36	1.06e-15	Depression;
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg22839075	chr3:12045461	SYN2	0.55	9.74	0.41	1.59e-20	Plateletcrit;Lymphocyte counts;White blood cell count;
LGG	cis	rs9309711	0.736	rs13412581	chr2:3497187	G/A	cg10845886	chr2:3471009	TTC15	-0.62	-11.42	-0.47	8.97e-27	Neurofibrillary tangles;
LGG	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.32	0.36	9.97e-16	Retinal vascular caliber;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg21963583	chr11:68658836	MRPL21	0.6	10.06	0.42	1.15e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4363385	0.818	rs4845514	chr1:153000820	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.94	-0.38	9.68e-18	Inflammatory skin disease;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg06028808	chr11:68637592	NA	0.73	12.44	0.5	7.74e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.62	-0.33	1.45e-13	Mean corpuscular volume;
LGG	cis	rs2153535	0.580	rs9392223	chr6:8468650	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.82	0.38	2.37e-17	Motion sickness;
LGG	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg02487422	chr3:49467188	NICN1	0.42	7.09	0.31	5.06e-12	Parkinson's disease;
LGG	cis	rs12497850	0.931	rs9867373	chr3:48960938	A/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.66e-25	Parkinson's disease;
LGG	cis	rs7904368	0.806	rs7900527	chr10:16857992	C/G	cg23933602	chr10:16859644	RSU1	0.63	9.22	0.39	1.03e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg04733989	chr22:42467013	NAGA	0.59	10.75	0.45	3.12e-24	Schizophrenia;
LGG	trans	rs208520	1.000	rs12190773	chr6:66968194	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7017914	0.902	rs34882924	chr8:71566308	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.91	-0.31	1.6e-11	Bone mineral density;
LGG	cis	rs12580194	0.593	rs7313465	chr12:55736863	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-9.38	-0.4	2.85e-19	Cancer;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg03528353	chr17:61819722	STRADA	0.44	7.39	0.32	6.98e-13	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs7477246	chr10:102261538	C/T	cg11040518	chr10:102331378	NA	-0.36	-6.67	-0.3	7.36e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3008870	0.755	rs4655661	chr1:67408828	A/C	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.76e-44	Lymphocyte percentage of white cells;
LGG	cis	rs801193	0.591	rs4506088	chr7:66135457	G/A	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg05896524	chr21:47604654	C21orf56	0.63	10.8	0.45	2.12e-24	Testicular germ cell tumor;
LGG	cis	rs875971	0.660	rs801217	chr7:66010577	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.51e-24	Aortic root size;
LGG	cis	rs2011503	0.714	rs113980591	chr19:19565357	G/A	cg11584989	chr19:19387371	SF4	0.76	12.14	0.49	1.2e-29	Bipolar disorder;
LGG	cis	rs4639966	0.836	rs11217016	chr11:118627149	A/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.45	-0.33	4.5e-13	Systemic lupus erythematosus;
LGG	cis	rs62025270	0.632	rs17636096	chr15:86218734	C/G	cg25843651	chr15:86329602	KLHL25	0.57	8.57	0.37	1.56e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs4243971	0.516	rs14353	chr20:30922398	C/T	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.54e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7215564	0.908	rs61707349	chr17:78665255	T/C	cg16980736	chr17:78789706	RPTOR	-0.61	-8.13	-0.35	4e-15	Myopia (pathological);
LGG	cis	rs2075371	0.501	rs1646652	chr7:134024515	A/T	cg11752832	chr7:134001865	SLC35B4	0.48	8.56	0.37	1.7e-16	Mean platelet volume;
LGG	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.23	-0.32	2.01e-12	Inflammatory bowel disease;
LGG	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg02466173	chr16:30829666	NA	-0.55	-10.09	-0.42	8.84e-22	Multiple myeloma;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg23758822	chr17:41437982	NA	0.9	15.76	0.59	4.33e-45	Menopause (age at onset);
LGG	cis	rs208520	1.000	rs12195505	chr6:66986279	T/A	cg07460842	chr6:66804631	NA	0.9	14.84	0.57	5.02e-41	Exhaled nitric oxide output;
LGG	cis	rs4722585	0.605	rs3753098	chr7:26198040	C/T	cg07876897	chr7:26191696	NFE2L3	-0.36	-7.31	-0.32	1.21e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04362095	chr11:63592001	C11orf84	-0.57	-11.04	-0.46	2.51e-25	Pulse pressure;
LGG	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg26924012	chr15:45694286	SPATA5L1	0.9	16.35	0.61	8.98e-48	Homoarginine levels;
LGG	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg24692254	chr21:30365293	RNF160	0.97	25.2	0.76	7.47e-89	Dental caries;
LGG	cis	rs1555322	0.530	rs932562	chr20:33871310	T/C	cg03689076	chr20:33865952	NA	0.65	9.16	0.39	1.69e-18	Attention deficit hyperactivity disorder;
LGG	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg03188948	chr7:1209495	NA	0.46	8.4	0.36	5.7e-16	Longevity;Endometriosis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25352856	chr1:180472145	ACBD6	0.41	7.24	0.32	1.93e-12	Obesity-related traits;
LGG	cis	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg11764359	chr7:65958608	NA	0.69	12.16	0.49	1.04e-29	Aortic root size;
LGG	cis	rs2841233	0.791	rs2028415	chr14:105349220	T/G	cg16576083	chr14:105354267	KIAA0284	0.41	7.96	0.35	1.32e-14	IgG glycosylation;
LGG	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.05	0.35	7.04e-15	Neuroticism;
LGG	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.33	-0.32	1.05e-12	Coronary artery disease;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19524238	chr7:2802976	GNA12	0.42	9.48	0.4	1.37e-19	Height;
LGG	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg11764359	chr7:65958608	NA	0.8	15.01	0.57	9e-42	Aortic root size;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg08975724	chr8:8085496	FLJ10661	-0.48	-9.1	-0.39	2.65e-18	Triglycerides;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs4740619	0.782	rs276448	chr9:15577004	T/G	cg14451791	chr9:16040625	NA	-0.33	-8.51	-0.37	2.39e-16	Body mass index;
LGG	trans	rs17685	0.753	rs1104879	chr7:75685568	C/T	cg19862616	chr7:65841803	NCRNA00174	1.08	26.08	0.77	6.23e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg02002194	chr4:3960332	NA	-0.45	-8.39	-0.36	5.89e-16	Mood instability;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.07	-0.31	5.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.65	11.68	0.48	8.19e-28	Hemoglobin concentration;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg26897989	chr16:1907736	C16orf73	-0.82	-13.88	-0.54	7.18e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.77	-0.48	3.72e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs8067545	0.611	rs2158472	chr17:20171524	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.15	-0.43	5.66e-22	Schizophrenia;
LGG	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg03538708	chr1:25844672	NA	-0.36	-6.87	-0.3	2.08e-11	Erythrocyte sedimentation rate;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.78	0.38	3.09e-17	Lung cancer;
LGG	cis	rs12999616	0.857	rs34459720	chr2:98325447	T/C	cg26665480	chr2:98280029	ACTR1B	0.54	7.8	0.34	4.04e-14	Colorectal cancer;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.51	-0.4	1.02e-19	Platelet count;
LGG	cis	rs35771425	1.000	rs12733930	chr1:211603026	C/A	cg10512769	chr1:211675356	NA	-0.74	-11.85	-0.48	1.81e-28	Educational attainment (years of education);
LGG	cis	rs4764487	0.622	rs2268014	chr12:6325582	C/G	cg08284733	chr12:6341482	CD9	0.3	8.0	0.35	1.04e-14	Mean platelet volume;
LGG	cis	rs425535	0.702	rs351997	chr4:74834059	A/G	cg01447579	chr4:74847100	PF4	0.57	7.0	0.31	9.27e-12	Blood protein levels;
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.64	-0.41	3.67e-20	Aortic root size;
LGG	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg16325326	chr1:53192061	ZYG11B	-0.92	-26.04	-0.77	1.01e-92	Monocyte count;
LGG	cis	rs7945705	0.782	rs3763918	chr11:8819683	T/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	8.37	0.36	6.71e-16	Hemoglobin concentration;
LGG	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg17376030	chr22:41985996	PMM1	-0.42	-6.86	-0.3	2.2e-11	Vitiligo;
LGG	cis	rs7937890	0.559	rs2597196	chr11:14491601	C/T	cg02886208	chr11:14281011	SPON1	0.38	7.27	0.32	1.59e-12	Mitochondrial DNA levels;
LGG	cis	rs10267417	0.603	rs2214319	chr7:19946286	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg03929089	chr4:120376271	NA	-0.63	-8.79	-0.38	3.02e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8060686	0.641	rs75297764	chr16:68212820	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg14196790	chr5:131705035	SLC22A5	0.61	7.74	0.34	6.12e-14	Rheumatoid arthritis;
LGG	cis	rs2295359	1.000	rs4655683	chr1:67611613	C/T	cg17031739	chr1:67600172	NA	0.36	7.22	0.32	2.1e-12	Psoriasis;
LGG	cis	rs4760636	0.512	rs12229373	chr12:47996868	G/C	cg12761788	chr12:48120090	P11	0.49	7.88	0.34	2.35e-14	Urate levels;
LGG	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg09021430	chr5:549028	NA	-0.74	-10.33	-0.43	1.22e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs7474896	0.583	rs10740950	chr10:38003496	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-8.0	-0.35	1.03e-14	Obesity (extreme);
LGG	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.03	-0.31	7.28e-12	Iron status biomarkers;
LGG	trans	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg18335740	chr13:41363409	SLC25A15	0.61	12.14	0.49	1.26e-29	Lewy body disease;
LGG	cis	rs6089584	0.850	rs6142939	chr20:60627729	A/G	cg06108461	chr20:60628389	TAF4	-1.06	-21.29	-0.7	1.28e-70	Body mass index;
LGG	cis	rs7615952	0.512	rs4234285	chr3:125404477	G/A	cg21696256	chr3:125484277	NA	-0.45	-7.55	-0.33	2.28e-13	Blood pressure (smoking interaction);
LGG	cis	rs847577	0.609	rs6977321	chr7:97774859	A/G	cg13397024	chr7:97797637	LMTK2	-0.37	-6.94	-0.31	1.32e-11	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15228606	chr17:1812096	NA	0.49	7.7	0.34	8.44e-14	Gut microbiome composition (summer);
LGG	cis	rs754466	0.651	rs11818687	chr10:79637709	C/T	cg17075019	chr10:79541650	NA	-0.95	-20.24	-0.69	9.89e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.68	0.54	4.87e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17321999	0.516	rs7579019	chr2:30501989	G/A	cg05247661	chr2:30472410	LBH	0.64	7.99	0.35	1.09e-14	Systemic lupus erythematosus;
LGG	cis	rs924607	0.898	rs905193	chr5:635095	T/C	cg09021430	chr5:549028	NA	-0.53	-10.27	-0.43	2.01e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	trans	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg02002194	chr4:3960332	NA	-0.47	-8.82	-0.38	2.36e-17	Parkinson's disease;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg07701084	chr6:150067640	NUP43	0.49	7.38	0.32	7.63e-13	Lung cancer;
LGG	cis	rs12042938	1.000	rs11122319	chr1:231808282	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.55	-9.62	-0.41	4.17e-20	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg15212455	chr7:39170539	POU6F2	0.48	11.14	0.46	1.05e-25	IgG glycosylation;
LGG	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg03929089	chr4:120376271	NA	-0.68	-9.45	-0.4	1.65e-19	Axial length;
LGG	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg26354017	chr1:205819088	PM20D1	-0.42	-7.44	-0.33	4.95e-13	Menarche (age at onset);
LGG	cis	rs10893109	0.517	rs10750249	chr11:123777049	G/T	cg12387464	chr11:123775935	OR8D4	0.39	8.41	0.36	4.99e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs9297145	0.724	rs6954584	chr7:98766930	G/A	cg05967295	chr7:98741636	SMURF1	0.93	15.57	0.59	2.95e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs8114671	0.836	rs3746432	chr20:33592763	C/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.18	-0.36	2.68e-15	Height;
LGG	cis	rs868036	1.000	rs1026736	chr15:68101813	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00586367	chr8:74790437	UBE2W	-0.41	-7.11	-0.31	4.44e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.61	0.56	5.07e-40	Obesity-related traits;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg09359103	chr1:154839909	KCNN3	0.51	10.52	0.44	2.4e-23	Prostate cancer;
LGG	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg16339924	chr4:17578868	LAP3	0.59	10.23	0.43	2.68e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6540556	0.723	rs1999826	chr1:209919275	C/T	cg05527609	chr1:210001259	C1orf107	-0.5	-6.84	-0.3	2.55e-11	Red blood cell count;
LGG	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1109114	1.000	rs59757169	chr5:148618752	G/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.27	-0.58	6.01e-43	Body mass index;
LGG	cis	rs7267979	0.966	rs6037097	chr20:25347221	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.42	0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7580658	0.676	rs2174270	chr2:128006078	C/T	cg10021288	chr2:128175891	PROC	-0.6	-11.95	-0.49	7.01e-29	Protein C levels;
LGG	cis	rs9649465	1.000	rs12537287	chr7:123364747	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.9	-0.38	1.26e-17	Migraine;
LGG	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg03806693	chr22:41940476	POLR3H	0.99	16.75	0.61	1.45e-49	Vitiligo;
LGG	cis	rs12410462	0.551	rs903694	chr1:227733005	C/G	cg21459583	chr1:227974177	NA	0.36	6.85	0.3	2.31e-11	Major depressive disorder;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg13880726	chr7:1868755	MAD1L1	0.45	7.81	0.34	3.9e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs12310956	0.532	rs1589902	chr12:33989289	G/A	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.53e-21	Morning vs. evening chronotype;
LGG	trans	rs7613875	0.543	rs34034116	chr3:49959156	C/A	cg21659725	chr3:3221576	CRBN	0.55	9.58	0.41	5.87e-20	Body mass index;
LGG	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.69e-22	DNA methylation (variation);
LGG	cis	rs4906332	1.000	rs8012127	chr14:103942762	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-7.87	-0.34	2.46e-14	Coronary artery disease;
LGG	cis	rs7465272	1.000	rs36050651	chr8:143681796	A/G	cg10104451	chr8:143696006	ARC	-0.7	-10.23	-0.43	2.9e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.97	-21.53	-0.71	9.1e-72	Schizophrenia;
LGG	cis	rs7799006	1.000	rs7810970	chr7:2276385	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.68	-0.34	9.23e-14	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9926296	0.744	rs460879	chr16:89712889	C/T	cg26513180	chr16:89883248	FANCA	-0.46	-7.84	-0.34	3.14e-14	Vitiligo;
LGG	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg21055462	chr7:100276975	NA	0.44	9.34	0.4	3.91e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2032447	0.670	rs198801	chr6:26139741	T/C	cg13736514	chr6:26305472	NA	0.36	7.21	0.32	2.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12478296	0.818	rs57194240	chr2:243011545	A/G	cg18898632	chr2:242989856	NA	-0.7	-8.43	-0.36	4.29e-16	Obesity-related traits;
LGG	trans	rs11098499	0.789	rs9991166	chr4:120237851	G/A	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	cis	rs990171	1.000	rs1807782	chr2:103033147	C/T	cg05295703	chr2:102895712	NA	-0.55	-9.69	-0.41	2.53e-20	Lymphocyte counts;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg13047869	chr3:10149882	C3orf24	0.58	8.28	0.36	1.31e-15	Alzheimer's disease;
LGG	cis	rs6547631	0.622	rs1437745	chr2:85928283	A/G	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	cis	rs62238980	0.522	rs118120290	chr22:32399262	T/C	cg00543991	chr22:32367038	NA	0.8	8.88	0.38	1.46e-17	Childhood ear infection;
LGG	cis	rs7937612	0.965	rs11217840	chr11:120238655	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.33e-32	Intraocular pressure;
LGG	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg19875535	chr5:140030758	IK	-0.57	-11.91	-0.48	1.02e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6940638	0.688	rs9379960	chr6:27121325	A/C	cg12826209	chr6:26865740	GUSBL1	0.46	7.57	0.33	1.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06108461	chr20:60628389	TAF4	-1.01	-19.77	-0.68	1.65e-63	Body mass index;
LGG	cis	rs2559856	1.000	rs10778139	chr12:102083202	C/T	cg12924262	chr12:102091054	CHPT1	-0.65	-13.07	-0.52	1.82e-33	Blood protein levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11211259	chr1:155178215	MTX1;THBS3	-0.47	-6.7	-0.3	5.98e-11	Systemic lupus erythematosus;
LGG	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg00012203	chr2:219082015	ARPC2	-0.46	-8.11	-0.35	4.58e-15	Ulcerative colitis;
LGG	trans	rs9914544	0.545	rs8073436	chr17:18801841	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.98	-0.35	1.16e-14	Educational attainment (years of education);
LGG	cis	rs12497850	0.627	rs4974078	chr3:49009386	C/T	cg06212747	chr3:49208901	KLHDC8B	0.47	7.63	0.33	1.32e-13	Parkinson's disease;
LGG	cis	rs17376456	0.877	rs10078194	chr5:93364310	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.91	10.13	0.43	6.33e-22	Diabetic retinopathy;
LGG	cis	rs2587949	0.615	rs1385484	chr3:4231861	G/C	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.57e-11	Periodontitis (DPAL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13872356	chr11:62341519	EEF1G	0.46	7.64	0.33	1.26e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9863	0.861	rs4405410	chr12:124435788	T/A	cg13487667	chr12:124434373	CCDC92	-0.36	-7.29	-0.32	1.32e-12	White blood cell count;
LGG	cis	rs941408	1.000	rs1736177	chr19:2791624	C/T	cg06609049	chr19:2785107	THOP1	0.61	9.6	0.41	4.91e-20	Total cholesterol levels;
LGG	trans	rs3206736	0.556	rs328924	chr7:35035704	T/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs6694672	1.000	rs1759009	chr1:197026672	C/T	cg13682187	chr1:196946512	CFHR5	-0.48	-6.69	-0.3	6.61e-11	Asthma;
LGG	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00820581	chr1:174969299	CACYBP	0.47	7.75	0.34	5.96e-14	Cognitive performance;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	10.11	0.43	7.59e-22	Obesity-related traits;
LGG	cis	rs9916302	0.904	rs7210488	chr17:37539819	T/G	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg14074117	chr16:1909714	C16orf73	-0.54	-8.03	-0.35	8.12e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1577917	0.771	rs10944133	chr6:86358984	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.07	-0.62	4.86e-51	Response to antipsychotic treatment;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.13	-0.35	4.09e-15	Total body bone mineral density;
LGG	cis	rs2243480	1.000	rs316317	chr7:65613637	G/T	cg18252515	chr7:66147081	NA	-1.43	-20.57	-0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs7666738	0.830	rs4401456	chr4:98959902	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs751728	0.664	rs6929696	chr6:33759290	C/T	cg25922239	chr6:33757077	LEMD2	-0.42	-7.27	-0.32	1.59e-12	Crohn's disease;
LGG	cis	rs1595825	0.838	rs16823400	chr2:198603229	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.69	-0.3	6.5e-11	Ulcerative colitis;
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg11766577	chr21:47581405	C21orf56	-0.48	-8.26	-0.36	1.56e-15	Testicular germ cell tumor;
LGG	cis	rs11966931	1.000	rs67958225	chr6:108132458	G/A	cg04749840	chr6:108095067	SCML4	0.45	7.59	0.33	1.8e-13	Neutrophil percentage of white cells;
LGG	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg08297393	chr2:100937505	LONRF2	-0.57	-10.59	-0.44	1.3e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	1.000	rs35568473	chr5:112734881	T/A	cg12552261	chr5:112820674	MCC	0.69	7.93	0.35	1.62e-14	F-cell distribution;
LGG	cis	rs9325144	1.000	rs7963123	chr12:38976617	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-10.19	-0.43	3.85e-22	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.569	rs6895356	chr5:93060781	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.72	9.73	0.41	1.76e-20	Diabetic retinopathy;
LGG	cis	rs57590327	0.583	rs13062245	chr3:81833718	G/T	cg07356753	chr3:81810745	GBE1	-0.5	-8.02	-0.35	8.45e-15	Extraversion;
LGG	trans	rs9354308	0.764	rs1938071	chr6:66583180	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs6502050	0.787	rs11653012	chr17:80058857	C/T	cg11859384	chr17:80120422	CCDC57	0.39	6.82	0.3	2.92e-11	Life satisfaction;
LGG	cis	rs6087990	0.765	rs6058900	chr20:31400673	T/C	cg13636640	chr20:31349939	DNMT3B	0.93	19.32	0.67	1.94e-61	Ulcerative colitis;
LGG	trans	rs9657904	0.774	rs7645021	chr3:105531169	C/A	cg14088669	chr1:158435396	OR10K1	0.42	7.87	0.34	2.58e-14	Multiple sclerosis;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg21782813	chr7:2030301	MAD1L1	0.43	10.39	0.43	6.9e-23	Schizophrenia;
LGG	cis	rs6750047	0.647	rs62136320	chr2:38275953	T/G	cg07380506	chr2:38303506	CYP1B1	0.45	7.47	0.33	3.98e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs593531	0.571	rs10898983	chr11:74093992	C/T	cg18195628	chr11:73498948	MRPL48	-0.4	-6.88	-0.3	2e-11	Neuroticism;
LGG	cis	rs11098499	0.820	rs12503082	chr4:120284317	A/G	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs12493885	0.818	rs73160504	chr3:153773384	C/T	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13424612	0.896	rs878925	chr2:240918502	A/G	cg01812947	chr2:240904978	NDUFA10	0.43	7.14	0.32	3.52e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs62238980	0.614	rs1547411	chr22:32443590	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs10883723	0.962	rs1056738	chr10:104236481	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.67	0.51	8.25e-32	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1372520	0.684	rs2583963	chr4:90727088	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	cis	rs7208859	0.673	rs9896095	chr17:29187497	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.26	0.4	7.56e-19	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07898084	chr13:53029385	CKAP2	0.52	8.25	0.36	1.72e-15	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.73	0.51	5.08e-32	Motion sickness;
LGG	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-6.92	-0.31	1.5e-11	Neuroticism;
LGG	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.35	0.32	8.77e-13	Mood instability;
LGG	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.79	-0.34	4.41e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.55	0.33	2.31e-13	Neuroticism;
LGG	cis	rs7811142	0.943	rs67196635	chr7:100025564	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs17604090	0.775	rs10225523	chr7:29689735	C/A	cg12658982	chr7:29603541	PRR15	-0.36	-6.92	-0.31	1.5e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg05165339	chr4:1420672	NA	-0.36	-9.02	-0.39	4.84e-18	Longevity;
LGG	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg02896835	chr1:92012615	NA	-0.4	-7.21	-0.32	2.35e-12	Eosinophil percentage of white cells;
LGG	trans	rs7939886	0.841	rs79254833	chr11:55986896	T/C	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg01221209	chr5:554886	NA	-0.46	-6.73	-0.3	4.91e-11	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.2	-0.39	1.19e-18	Erythrocyte sedimentation rate;
LGG	cis	rs2274273	1.000	rs72718804	chr14:55630610	G/A	cg04306507	chr14:55594613	LGALS3	0.62	16.82	0.62	6.56e-50	Protein biomarker;
LGG	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg13852791	chr20:30311386	BCL2L1	0.66	8.78	0.38	3.23e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2075371	0.863	rs2075370	chr7:133967812	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	14.68	0.56	2.53e-40	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.75	-9.63	-0.41	4.01e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.699	rs28610447	chr4:9971517	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.63	-0.33	1.31e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg15596359	chr8:11213517	TDH	-0.34	-6.86	-0.3	2.16e-11	Retinal vascular caliber;
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg13282195	chr8:144660772	NAPRT1	0.92	7.36	0.32	8.48e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg15369054	chr17:80825471	TBCD	-0.39	-7.76	-0.34	5.4e-14	Breast cancer;
LGG	trans	rs7395662	1.000	rs11039890	chr11:48653468	C/G	cg00717180	chr2:96193071	NA	-0.42	-7.42	-0.33	5.49e-13	HDL cholesterol;
LGG	cis	rs2063714	0.967	rs9322586	chr6:157195220	T/C	cg23222435	chr6:157204239	ARID1B	-0.63	-12.12	-0.49	1.53e-29	Sitting height ratio;
LGG	trans	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs643506	0.874	rs687152	chr11:111721673	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.86	0.3	2.22e-11	Breast cancer;
LGG	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg07274523	chr3:49395745	GPX1	0.56	9.37	0.4	3.29e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00166722	chr3:10149974	C3orf24	0.5	7.93	0.35	1.65e-14	Alzheimer's disease;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg24642844	chr7:1081250	C7orf50	-0.83	-14.2	-0.55	2.98e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11272475	chr22:41460167	NA	-0.6	-6.94	-0.31	1.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg11245990	chr11:68621969	NA	0.38	8.2	0.36	2.37e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg26384229	chr12:38710491	ALG10B	0.74	15.08	0.57	4.48e-42	Morning vs. evening chronotype;
LGG	cis	rs10267417	0.603	rs10081315	chr7:19934007	T/A	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg23088430	chr8:144679052	EEF1D;TIGD5	0.39	6.68	0.3	6.77e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.31	-0.32	1.19e-12	Life satisfaction;
LGG	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.48	-7.81	-0.34	3.86e-14	Iron status biomarkers;
LGG	cis	rs9783347	1.000	rs4150661	chr11:18379629	C/A	cg15585147	chr11:18324498	HPS5	0.43	9.15	0.39	1.76e-18	Pancreatic cancer;
LGG	trans	rs73191547	0.867	rs1484647	chr8:10056276	G/A	cg16141378	chr3:129829833	LOC729375	-0.3	-6.82	-0.3	2.93e-11	Schizophrenia;
LGG	cis	rs8016982	0.662	rs1957546	chr14:81639984	C/T	cg01989461	chr14:81687754	GTF2A1	0.56	8.62	0.37	1.1e-16	Schizophrenia;
LGG	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.13	0.35	4.04e-15	Retinal vascular caliber;
LGG	cis	rs4732038	0.510	rs67549894	chr7:134271985	C/G	cg06906464	chr7:134288099	NA	-0.66	-17.15	-0.62	2.18e-51	Longevity;
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9549367	0.569	rs3024738	chr13:113819921	T/A	cg00898013	chr13:113819073	PROZ	0.48	9.63	0.41	4.01e-20	Platelet distribution width;
LGG	cis	rs2075371	0.835	rs1646724	chr7:134001875	T/G	cg20476274	chr7:133979776	SLC35B4	0.7	13.06	0.52	2.16e-33	Mean platelet volume;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.73e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.567	rs2964225	chr5:151937982	C/T	cg12297329	chr5:152029980	NA	-0.58	-11.14	-0.46	1.03e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs11122272	0.735	rs2749706	chr1:231527170	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs11588062	0.628	rs11211270	chr1:46838986	C/T	cg08947153	chr1:46664340	POMGNT1	0.41	7.49	0.33	3.57e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg26384229	chr12:38710491	ALG10B	-0.7	-13.01	-0.52	3.26e-33	Morning vs. evening chronotype;
LGG	cis	rs1034435	1.000	rs9680744	chr22:48889547	C/G	cg05992904	chr22:48892994	FAM19A5	-0.78	-15.09	-0.57	3.95e-42	Late-onset Alzheimer's disease;
LGG	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg27624424	chr6:160112604	SOD2	0.66	9.73	0.41	1.82e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg13385521	chr17:29058706	SUZ12P	-0.94	-10.95	-0.45	5.77e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2370759	0.898	rs113412621	chr10:32579306	C/T	cg01819863	chr10:32635814	EPC1	1.13	15.82	0.59	2.29e-45	Sexual dysfunction (female);
LGG	cis	rs739401	0.566	rs7931504	chr11:3026712	C/T	cg25174290	chr11:3078921	CARS	0.74	15.41	0.58	1.49e-43	Longevity;
LGG	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	cg07245641	chr1:182991651	LAMC1	0.4	8.96	0.38	7.72e-18	Colorectal cancer;
LGG	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.76	-0.41	1.33e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7662987	0.517	rs2602881	chr4:100040695	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs56283067	0.887	rs4644056	chr6:44776136	G/T	cg18551225	chr6:44695536	NA	0.7	11.36	0.47	1.5e-26	Total body bone mineral density;
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.99	-0.45	4.02e-25	Neuroticism;
LGG	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg04851639	chr8:1020857	NA	-0.42	-9.21	-0.39	1.14e-18	Schizophrenia;
LGG	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.71	-0.51	5.76e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9354308	0.738	rs4710556	chr6:66614663	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs10779751	1.000	rs10779751	chr1:11284336	A/G	cg08854313	chr1:11322531	MTOR	0.75	16.51	0.61	1.8e-48	Body mass index;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg04861929	chr11:109293070	C11orf87	0.46	7.92	0.35	1.83e-14	Schizophrenia;
LGG	cis	rs12286929	0.600	rs4445669	chr11:115045237	C/T	cg04055981	chr11:115044050	NA	-0.37	-6.88	-0.3	2e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg11360546	chr7:1094263	C7orf50	-0.42	-7.93	-0.35	1.7e-14	Longevity;Endometriosis;
LGG	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg03264133	chr6:25882463	NA	0.53	9.66	0.41	3.06e-20	Blood metabolite levels;
LGG	cis	rs9894429	0.809	rs9889642	chr17:79591762	T/C	cg18240062	chr17:79603768	NPLOC4	0.75	13.92	0.54	4.81e-37	Eye color traits;
LGG	cis	rs9487094	0.670	rs12197950	chr6:109963389	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.69	0.34	8.79e-14	Height;
LGG	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06634786	chr22:41940651	POLR3H	-0.65	-10.96	-0.45	4.99e-25	Vitiligo;
LGG	cis	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg00405596	chr8:11794950	NA	0.44	7.4	0.33	6.64e-13	Monocyte count;
LGG	cis	rs523522	0.962	rs10849754	chr12:120940418	A/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg19980929	chr12:42632907	YAF2	0.35	7.71	0.34	7.54e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2274273	0.624	rs7155954	chr14:55750943	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.52	0.5	3.52e-31	Protein biomarker;
LGG	cis	rs7927771	0.524	rs3758655	chr11:47703943	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.18	0.46	7.26e-26	Subjective well-being;
LGG	cis	rs17014483	0.749	rs3017900	chr4:89639466	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.76	0.3	4.06e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg14101638	chr12:121416612	HNF1A	-0.44	-9.56	-0.41	6.8e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg00745463	chr17:30367425	LRRC37B	0.48	7.07	0.31	5.89e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.516	rs11776524	chr8:57983246	A/G	cg14926445	chr8:58193284	C8orf71	-0.42	-6.77	-0.3	3.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg05368731	chr17:41323189	NBR1	0.92	18.0	0.64	2.76e-55	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs1978968	1.000	rs11704059	chr22:18449543	A/G	cg03078520	chr22:18463400	MICAL3	-0.63	-12.7	-0.51	6.73e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg13009111	chr11:71350975	NA	0.35	7.66	0.34	1.1e-13	Neuroticism;
LGG	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7017914	0.934	rs6987313	chr8:71570989	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06558623	chr16:89946397	TCF25	0.96	12.34	0.5	1.93e-30	Skin colour saturation;
LGG	cis	rs1008375	1.000	rs6854733	chr4:17640526	C/T	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62158211	0.691	rs1964463	chr2:114069021	C/T	cg17784749	chr2:114082611	LOC440839	-0.5	-7.53	-0.33	2.65e-13	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs3857747	0.827	rs7785515	chr7:40477058	T/C	cg00420559	chr7:40367873	C7orf10	0.38	7.86	0.34	2.71e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs3857747	0.895	rs12669999	chr7:40366686	T/C	cg00420559	chr7:40367873	C7orf10	-0.41	-8.4	-0.36	5.54e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs963731	0.522	rs1454222	chr2:39215895	C/A	cg04010122	chr2:39346883	SOS1	-0.76	-6.69	-0.3	6.45e-11	Corticobasal degeneration;
LGG	cis	rs2243480	0.522	rs778717	chr7:65848151	G/C	cg07424592	chr7:64974309	NA	0.71	6.81	0.3	2.99e-11	Diabetic kidney disease;
LGG	cis	rs12220238	1.000	rs7904207	chr10:75884474	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.72	0.48	6.04e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs12496230	0.951	rs34954762	chr3:66853890	A/G	cg04995300	chr3:66848608	NA	0.54	7.82	0.34	3.57e-14	Type 2 diabetes;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg23758822	chr17:41437982	NA	0.9	15.66	0.59	1.2e-44	Menopause (age at onset);
LGG	trans	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg07211511	chr3:129823064	LOC729375	-0.65	-8.9	-0.38	1.3e-17	Blood pressure (smoking interaction);
LGG	cis	rs10875595	0.836	rs12187725	chr5:140662912	A/G	cg19650706	chr5:140594406	PCDHB13	-0.53	-6.86	-0.3	2.19e-11	Pulmonary function decline;
LGG	trans	rs11875185	0.510	rs78470374	chr18:55650637	T/C	cg15513957	chr14:69354734	ACTN1	-1.09	-11.69	-0.48	7.48e-28	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4262150	0.726	rs67979431	chr5:152012437	G/T	cg12297329	chr5:152029980	NA	-0.83	-17.24	-0.63	8.66e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.877	rs10476598	chr5:93367281	C/T	cg25358565	chr5:93447407	FAM172A	-1.32	-16.37	-0.61	7.17e-48	Diabetic retinopathy;
LGG	trans	rs1941687	0.831	rs12957087	chr18:31328519	C/T	cg27147174	chr7:100797783	AP1S1	-0.54	-9.09	-0.39	2.87e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs62238980	0.614	rs76869058	chr22:32561375	C/T	cg00543991	chr22:32367038	NA	0.74	9.19	0.39	1.29e-18	Childhood ear infection;
LGG	cis	rs807669	0.565	rs5746682	chr22:19185526	C/T	cg02655711	chr22:19163373	SLC25A1	0.66	12.91	0.51	8.55e-33	Metabolite levels;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg23978390	chr7:1156363	C7orf50	0.56	9.49	0.4	1.21e-19	Longevity;Endometriosis;
LGG	cis	rs1577917	0.740	rs2842604	chr6:86336300	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-11.61	-0.47	1.58e-27	Response to antipsychotic treatment;
LGG	cis	rs17208368	0.657	rs16954195	chr16:55093432	C/T	cg09947736	chr16:55091198	NA	0.68	12.92	0.51	8.16e-33	Hypospadias;
LGG	cis	rs4820834	0.569	rs740223	chr22:30762140	G/A	cg00101453	chr22:30685584	GATSL3	-0.5	-6.66	-0.3	8.02e-11	Coronary artery calcification;
LGG	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg04398451	chr17:18023971	MYO15A	-0.83	-18.19	-0.65	3.7e-56	Total body bone mineral density;
LGG	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg10223061	chr2:219282414	VIL1	0.3	6.78	0.3	3.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg13073564	chr4:8508604	NA	0.59	11.76	0.48	4.23e-28	Response to antineoplastic agents;
LGG	trans	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg10756647	chr7:56101905	PSPH	0.75	8.59	0.37	1.31e-16	Gout;
LGG	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg02297831	chr4:17616191	MED28	0.43	8.01	0.35	9.18e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg02002194	chr4:3960332	NA	0.43	7.66	0.34	1.1e-13	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs7833790	0.724	rs4739627	chr8:82734657	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-11.05	-0.46	2.38e-25	Diastolic blood pressure;
LGG	cis	rs4671458	0.689	rs114780236	chr2:63789049	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.24	-0.32	1.93e-12	Subjective well-being;
LGG	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg06346307	chr22:19949965	COMT	-0.48	-12.6	-0.51	1.68e-31	Blood metabolite levels;
LGG	cis	rs8058578	0.943	rs35629860	chr16:30671532	G/A	cg00531865	chr16:30841666	NA	-0.52	-10.22	-0.43	2.98e-22	Multiple myeloma;
LGG	cis	rs6882076	1.000	rs12657266	chr5:156396003	C/T	cg12943317	chr5:156479607	HAVCR1	-0.66	-11.68	-0.48	8.34e-28	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs11838776	0.522	rs7318424	chr13:111021623	C/G	cg06243866	chr13:111019493	COL4A2	0.81	16.54	0.61	1.21e-48	Coronary artery disease;
LGG	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg15704280	chr7:45808275	SEPT13	-0.85	-13.57	-0.53	1.55e-35	Coronary artery disease;
LGG	cis	rs11711311	0.955	rs7650764	chr3:113414439	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.79	-0.34	4.48e-14	IgG glycosylation;
LGG	trans	rs6601327	0.613	rs10094989	chr8:9612009	T/C	cg12395012	chr8:11607386	GATA4	-0.38	-6.89	-0.3	1.83e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg27129171	chr3:47204927	SETD2	0.79	15.3	0.58	4.51e-43	Colorectal cancer;
LGG	cis	rs72949976	0.934	rs1441172	chr2:214037703	C/T	cg08319019	chr2:214017104	IKZF2	-0.58	-9.67	-0.41	2.86e-20	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs1461503	0.932	rs10892944	chr11:122843895	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-13.86	-0.54	8.48e-37	Menarche (age at onset);
LGG	cis	rs7737355	1.000	rs27421	chr5:130743771	C/T	cg06307176	chr5:131281290	NA	-0.54	-8.98	-0.39	6.6e-18	Life satisfaction;
LGG	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.79	0.57	8.07e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs963731	0.579	rs388958	chr2:39315586	T/C	cg04010122	chr2:39346883	SOS1	-0.78	-8.1	-0.35	4.82e-15	Corticobasal degeneration;
LGG	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg25019033	chr10:957182	NA	-0.55	-10.07	-0.42	1.07e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs295137	0.752	rs10931892	chr2:201104997	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-7.52	-0.33	2.92e-13	Asthma (bronchodilator response);
LGG	cis	rs11971779	0.616	rs6967932	chr7:139022381	C/T	cg07862535	chr7:139043722	LUC7L2	0.41	6.77	0.3	3.96e-11	Diisocyanate-induced asthma;
LGG	cis	rs9596863	0.898	rs6561746	chr13:54358368	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.11	0.31	4.32e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs7945718	0.875	rs7105783	chr11:12719794	A/G	cg25843174	chr11:12811716	TEAD1	0.4	7.97	0.35	1.21e-14	Educational attainment (years of education);
LGG	cis	rs3806843	1.000	rs6870764	chr5:140171790	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7619833	0.620	rs13085724	chr3:27258758	C/T	cg02860705	chr3:27208620	NA	0.42	8.27	0.36	1.41e-15	Breast cancer;
LGG	cis	rs7572733	0.935	rs6753450	chr2:198735031	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.33	0.36	9.09e-16	Dermatomyositis;
LGG	cis	rs6460942	0.915	rs80345607	chr7:12442249	T/C	cg06484146	chr7:12443880	VWDE	-0.42	-7.29	-0.32	1.31e-12	Coronary artery disease;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg03188948	chr7:1209495	NA	0.41	7.07	0.31	5.63e-12	Longevity;Endometriosis;
LGG	cis	rs9831754	0.704	rs1512491	chr3:78470954	T/C	cg06138941	chr3:78371609	NA	0.78	15.44	0.58	1.1e-43	Calcium levels;
LGG	cis	rs7122539	0.721	rs2077432	chr11:66621383	C/T	cg01599099	chr11:66649832	PC	0.45	8.93	0.38	9.74e-18	HIV-1 susceptibility;
LGG	cis	rs1562975	0.609	rs11932691	chr4:109431283	C/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.45	8.35	0.36	8.15e-16	Height;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.07	0.39	3.38e-18	Lung cancer;
LGG	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg03929089	chr4:120376271	NA	0.66	9.29	0.4	6.04e-19	Intraocular pressure;
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg00908189	chr16:619842	PIGQ	0.85	15.64	0.59	1.38e-44	Height;
LGG	trans	rs7939886	0.920	rs17145425	chr11:55950030	A/G	cg03929089	chr4:120376271	NA	0.73	6.82	0.3	2.84e-11	Myopia (pathological);
LGG	cis	rs17030434	0.906	rs78436201	chr4:154661755	C/A	cg14289246	chr4:154710475	SFRP2	-0.71	-11.36	-0.47	1.47e-26	Electrocardiographic conduction measures;
LGG	trans	rs61931739	0.649	rs815045	chr12:33722057	C/G	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs4268898	0.662	rs9917355	chr2:24433400	C/T	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.67	0.61	3.36e-49	Personality dimensions;
LGG	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg07636037	chr3:49044803	WDR6	0.88	17.09	0.62	3.81e-51	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.956	rs11228256	chr11:68251460	G/A	cg16797656	chr11:68205561	LRP5	0.4	7.08	0.31	5.38e-12	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18942579	chr17:57915773	TMEM49	0.3	6.98	0.31	9.97e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07610776	chr16:1832675	SPSB3;NUBP2	0.47	7.2	0.32	2.46e-12	Gut microbiome composition (summer);
LGG	cis	rs977987	0.835	rs4888379	chr16:75340231	A/T	cg03315344	chr16:75512273	CHST6	0.48	9.69	0.41	2.48e-20	Dupuytren's disease;
LGG	trans	rs3857536	0.730	rs4710584	chr6:66953453	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.74	-0.3	4.65e-11	Blood trace element (Cu levels);
LGG	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg14664628	chr15:75095509	CSK	0.51	9.05	0.39	3.94e-18	Systemic lupus erythematosus;
LGG	trans	rs2048656	0.578	rs925610	chr8:9681836	G/C	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.8	-0.3	3.21e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs13082711	0.522	rs586229	chr3:27354520	A/G	cg02860705	chr3:27208620	NA	0.59	11.02	0.46	3.1e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs8078723	0.668	rs3859192	chr17:38128648	C/T	cg17467752	chr17:38218738	THRA	0.59	10.6	0.44	1.2e-23	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.98	0.42	2.17e-21	Height;
LGG	trans	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.48	-0.37	3.11e-16	Triglycerides;
LGG	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg24642439	chr20:33292090	TP53INP2	0.82	14.0	0.55	2.14e-37	Coronary artery disease;
LGG	cis	rs11671005	0.735	rs11666716	chr19:58920952	A/G	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	cis	rs1707322	1.000	rs1768807	chr1:46510570	A/G	cg03146154	chr1:46216737	IPP	-0.53	-10.17	-0.43	4.6e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7911264	0.905	rs7918084	chr10:94429467	C/T	cg25093409	chr10:94429542	NA	0.57	11.32	0.47	2.14e-26	Inflammatory bowel disease;
LGG	cis	rs10751667	0.600	rs10751672	chr11:948712	T/C	cg22143635	chr11:980567	AP2A2	0.42	7.78	0.34	4.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs27434	0.607	rs695965	chr5:96148366	C/T	cg16492584	chr5:96139282	ERAP1	-0.36	-7.11	-0.31	4.31e-12	Ankylosing spondylitis;
LGG	cis	rs3784262	0.669	rs4646594	chr15:58302386	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.76	-0.3	4.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs897984	0.721	rs28360557	chr16:30983260	A/C	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.15	-0.39	1.86e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6582630	0.555	rs11182422	chr12:38522833	A/G	cg04568710	chr12:38710424	ALG10B	0.33	6.79	0.3	3.5e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.03e-21	HDL cholesterol levels;
LGG	cis	rs6063312	0.518	rs6122718	chr20:47346225	A/G	cg18078177	chr20:47281410	PREX1	-0.87	-14.68	-0.56	2.42e-40	Tonometry;
LGG	cis	rs8141529	0.753	rs5752813	chr22:29226570	T/G	cg15103426	chr22:29168792	CCDC117	0.73	11.78	0.48	3.46e-28	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22237200	chr17:7555298	ATP1B2	0.45	6.78	0.3	3.67e-11	Gut microbiome composition (summer);
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg03188948	chr7:1209495	NA	0.4	6.89	0.3	1.85e-11	Longevity;Endometriosis;
LGG	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg14906510	chr12:7781169	NA	-0.66	-7.04	-0.31	7.1e-12	HDL cholesterol levels;
LGG	cis	rs7660883	0.897	rs236992	chr4:88016739	A/G	cg21988461	chr4:88008667	AFF1	0.34	9.84	0.42	7.37e-21	HDL cholesterol levels;
LGG	cis	rs847649	1.000	rs847648	chr7:102553850	C/T	cg18108683	chr7:102477205	FBXL13	-0.63	-13.71	-0.54	3.84e-36	Morning vs. evening chronotype;
LGG	cis	rs2285947	1.000	rs10229224	chr7:21583921	G/A	cg23045935	chr7:21583304	DNAH11	0.43	9.33	0.4	4.36e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.46	0.33	4.24e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12908161	1.000	rs17600551	chr15:85319258	A/G	cg24253500	chr15:84953950	NA	0.41	6.76	0.3	4.28e-11	Schizophrenia;
LGG	cis	rs787274	1.000	rs2645994	chr9:115483322	C/T	cg13803584	chr9:115635662	SNX30	0.53	6.78	0.3	3.73e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6061231	0.837	rs6121558	chr20:60961365	A/G	cg22601191	chr20:60968625	CABLES2	0.59	10.53	0.44	2.19e-23	Colorectal cancer;
LGG	cis	rs875971	1.000	rs709597	chr7:65825983	A/G	cg18876405	chr7:65276391	NA	-0.52	-9.25	-0.39	8.5e-19	Aortic root size;
LGG	cis	rs2916247	0.954	rs10094140	chr8:93155798	G/C	cg10183463	chr8:93005414	RUNX1T1	0.37	7.7	0.34	8.21e-14	Intelligence (multi-trait analysis);
LGG	trans	rs34421088	0.532	rs1545073	chr8:11167700	C/T	cg02002194	chr4:3960332	NA	-0.42	-7.6	-0.33	1.62e-13	Neuroticism;
LGG	cis	rs9291683	0.588	rs12507330	chr4:10002195	G/A	cg25986240	chr4:9926439	SLC2A9	-0.44	-9.25	-0.4	8.08e-19	Bone mineral density;
LGG	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02886208	chr11:14281011	SPON1	0.5	10.49	0.44	3.16e-23	Mitochondrial DNA levels;
LGG	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.68	-0.3	6.69e-11	Menarche (age at onset);
LGG	cis	rs2643217	0.953	rs2643207	chr15:38999745	G/T	cg10631289	chr15:39006617	NA	-0.44	-7.58	-0.33	1.91e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4731207	0.596	rs1481331	chr7:124577325	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs12431410	0.584	rs7152594	chr14:60240325	A/G	cg07950296	chr14:60194823	RTN1	-0.38	-7.38	-0.32	7.48e-13	Schizophrenia;
LGG	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	24.59	0.75	5.12e-86	IgG glycosylation;
LGG	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.1	0.39	2.73e-18	Blood metabolite levels;
LGG	cis	rs9815354	1.000	rs1716660	chr3:41929960	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7980799	0.649	rs1601003	chr12:33689436	A/T	cg13010199	chr12:38710504	ALG10B	0.46	8.22	0.36	2.13e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1941023	0.503	rs4939348	chr11:60135871	A/C	cg08716584	chr11:60157161	MS4A7	-0.42	-8.39	-0.36	5.92e-16	Congenital heart disease (maternal effect);
LGG	cis	rs7444	0.941	rs5998672	chr22:21966442	G/A	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.58	-0.41	6.15e-20	Triglycerides;
LGG	cis	rs17270561	0.779	rs1165200	chr6:25875212	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.77	-11.86	-0.48	1.6e-28	Iron status biomarkers;
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs11514810	1.000	rs4076699	chr7:1435521	C/T	cg24899294	chr7:1481343	MICALL2	-0.68	-7.68	-0.34	9.87e-14	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs778371	0.958	rs2675968	chr2:233736244	A/G	cg08000102	chr2:233561755	GIGYF2	0.62	9.95	0.42	2.91e-21	Schizophrenia;
LGG	cis	rs6964587	1.000	rs13245393	chr7:91641928	A/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg09021430	chr5:549028	NA	-0.69	-9.44	-0.4	1.8e-19	Obesity-related traits;
LGG	cis	rs10088262	0.629	rs9918907	chr8:124816862	A/G	cg02993010	chr8:124780839	FAM91A1	-0.67	-10.18	-0.43	4.22e-22	Pancreatic cancer;
LGG	cis	rs11122272	0.735	rs10489611	chr1:231517854	A/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.6	-0.33	1.63e-13	Iron status biomarkers;
LGG	cis	rs763121	0.853	rs4821808	chr22:39065739	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	17.67	0.63	8.35e-54	Menopause (age at onset);
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	7.04	0.31	6.96e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs898097	0.756	rs11655103	chr17:80813467	T/C	cg15369054	chr17:80825471	TBCD	0.59	10.78	0.45	2.54e-24	Breast cancer;
LGG	cis	rs2404602	0.632	rs34338978	chr15:77226805	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.11	0.39	2.47e-18	Blood metabolite levels;
LGG	cis	rs13401104	0.796	rs1466205	chr2:237121194	A/G	cg15742758	chr2:237126235	ASB18	0.41	6.67	0.3	7.28e-11	Educational attainment;
LGG	cis	rs7666738	0.830	rs13149779	chr4:99010145	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.34	0.36	8.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12431410	0.550	rs7147135	chr14:60207565	T/C	cg07950296	chr14:60194823	RTN1	-0.39	-7.43	-0.33	5.24e-13	Schizophrenia;
LGG	cis	rs7582720	1.000	rs35212307	chr2:203765756	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2011503	0.882	rs4808958	chr19:19571752	G/A	cg11584989	chr19:19387371	SF4	0.74	11.73	0.48	5.34e-28	Bipolar disorder;
LGG	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.23	0.43	2.84e-22	Diabetic retinopathy;
LGG	cis	rs7247513	0.964	rs4804202	chr19:12718619	T/C	cg01871581	chr19:12707946	ZNF490	-0.44	-9.11	-0.39	2.54e-18	Bipolar disorder;
LGG	cis	rs1497828	0.956	rs2132994	chr1:217548036	A/G	cg04411442	chr1:217543379	NA	-0.47	-8.01	-0.35	9.18e-15	Dialysis-related mortality;
LGG	cis	rs10206020	0.921	rs72776302	chr2:1571383	G/A	cg12573674	chr2:1569213	NA	-0.65	-10.04	-0.42	1.38e-21	IgG glycosylation;
LGG	cis	rs2470578	0.792	rs2596677	chr3:17318844	T/C	cg20981856	chr3:17787350	NA	0.36	6.87	0.3	2.1e-11	Schizophrenia;
LGG	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	5.01e-22	Axial length;
LGG	cis	rs17039065	0.920	rs11097990	chr4:109432223	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.29	0.32	1.38e-12	Gut microbiome composition (summer);
LGG	cis	rs10463554	0.889	rs246899	chr5:102577139	T/A	cg23492399	chr5:102201601	PAM	-0.53	-7.81	-0.34	3.75e-14	Parkinson's disease;
LGG	cis	rs10743315	0.908	rs7312841	chr12:19466749	T/C	cg02471346	chr12:19282374	PLEKHA5	0.62	6.9	0.31	1.75e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10751667	0.643	rs7395613	chr11:933873	C/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.67	-0.44	6.68e-24	Lung cancer;
LGG	cis	rs1719271	0.710	rs2010875	chr15:65157482	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.75	-0.3	4.51e-11	Platelet count;
LGG	cis	rs11025559	0.716	rs1596376	chr11:20454229	T/C	cg19653624	chr11:20408972	PRMT3	-0.51	-8.51	-0.37	2.46e-16	Pursuit maintenance gain;
LGG	cis	rs317689	0.918	rs610192	chr12:69739941	T/C	cg20891283	chr12:69753455	YEATS4	0.78	12.55	0.5	2.74e-31	Response to diuretic therapy;
LGG	cis	rs4819052	1.000	rs733738	chr21:46666396	A/G	cg06618935	chr21:46677482	NA	0.52	9.08	0.39	3.1e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2456568	0.802	rs10765638	chr11:93636171	A/T	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg02158880	chr13:53174818	NA	0.4	7.94	0.35	1.5e-14	Lewy body disease;
LGG	cis	rs4780401	0.933	rs1579258	chr16:11824903	C/G	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.25	-0.32	1.79e-12	Rheumatoid arthritis;
LGG	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs7927771	1.000	rs7120333	chr11:47817441	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg11062466	chr8:58055876	NA	0.51	8.62	0.37	1.04e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13082711	0.516	rs1388786	chr3:27372222	G/A	cg02860705	chr3:27208620	NA	-0.63	-11.98	-0.49	5.38e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg16447950	chr5:562315	NA	0.42	7.2	0.32	2.43e-12	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.48	7.63	0.33	1.38e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.99	0.39	6.47e-18	Lung cancer;
LGG	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6456042	0.756	rs3099266	chr6:166581147	T/C	cg11088901	chr6:166572345	T	-0.35	-7.26	-0.32	1.68e-12	Asthma;
LGG	cis	rs4959677	0.725	rs1680830	chr6:2503734	C/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.42	-0.36	4.72e-16	Orthostatic hypotension;
LGG	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.32	0.36	9.64e-16	Tonsillectomy;
LGG	cis	rs11785400	0.793	rs9297972	chr8:143723660	C/T	cg10596483	chr8:143751796	JRK	0.52	8.02	0.35	8.53e-15	Schizophrenia;
LGG	trans	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg24247370	chr13:99142703	STK24	-0.37	-6.83	-0.3	2.62e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg11878867	chr6:150167359	LRP11	-0.37	-7.69	-0.34	8.77e-14	Testicular germ cell tumor;
LGG	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs9398803	0.723	rs4460221	chr6:127031221	G/A	cg19875578	chr6:126661172	C6orf173	-0.52	-9.64	-0.41	3.57e-20	Male-pattern baldness;
LGG	cis	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg16662043	chr16:48846231	NA	0.38	7.52	0.33	2.96e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7937682	0.883	rs12804962	chr11:111442683	A/T	cg22437258	chr11:111473054	SIK2	-0.52	-9.06	-0.39	3.65e-18	Primary sclerosing cholangitis;
LGG	cis	rs4862750	0.914	rs6553028	chr4:187876046	T/C	cg27532560	chr4:187881888	NA	-0.6	-12.94	-0.52	6.87e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg09448879	chr15:79043637	NA	-0.42	-8.22	-0.36	2.13e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg11812906	chr14:75593930	NEK9	0.54	9.98	0.42	2.33e-21	Height;
LGG	cis	rs11148252	0.532	rs9536190	chr13:53181044	T/C	cg12458913	chr13:53173898	NA	1.04	25.93	0.77	3.08e-92	Lewy body disease;
LGG	cis	rs6450176	0.909	rs1541681	chr5:53304620	G/T	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.26	-0.46	3.72e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs72717009	0.825	rs11810143	chr1:161480649	A/G	cg23840854	chr1:161414152	NA	-0.72	-8.77	-0.38	3.38e-17	Rheumatoid arthritis;
LGG	cis	rs755249	0.567	rs16826038	chr1:39758634	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1009647	0.645	rs67773067	chr14:55697207	G/T	cg04306507	chr14:55594613	LGALS3	0.46	7.77	0.34	5.26e-14	Testicular germ cell tumor;
LGG	trans	rs35110281	0.776	rs1073522	chr21:45009219	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	12.49	0.5	4.7e-31	Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg18926786	chr6:150244388	RAET1G	0.32	6.92	0.31	1.51e-11	Testicular germ cell tumor;
LGG	cis	rs9916302	0.904	rs12450559	chr17:37694709	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.73	-0.59	5.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg15595755	chr5:1867978	NA	0.5	10.05	0.42	1.28e-21	Cardiovascular disease risk factors;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg07701084	chr6:150067640	NUP43	-0.48	-7.38	-0.32	7.57e-13	Lung cancer;
LGG	cis	rs12580194	1.000	rs7968881	chr12:55694434	A/C	cg19537932	chr12:55886519	OR6C68	-0.37	-6.73	-0.3	5.18e-11	Cancer;
LGG	cis	rs12478296	0.901	rs59191623	chr2:243028595	G/A	cg18898632	chr2:242989856	NA	-0.77	-9.76	-0.41	1.4e-20	Obesity-related traits;
LGG	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	cis	rs7587476	0.531	rs35933323	chr2:215674090	T/G	cg04004882	chr2:215674386	BARD1	-0.56	-8.79	-0.38	3.06e-17	Neuroblastoma;
LGG	cis	rs4538187	0.813	rs2302808	chr2:64139834	A/T	cg19915305	chr2:64069682	UGP2	-0.62	-14.14	-0.55	5.69e-38	Systolic blood pressure;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg04863758	chr4:1303710	MAEA	0.42	7.25	0.32	1.81e-12	Obesity-related traits;
LGG	cis	rs6504108	0.624	rs8069263	chr17:46286778	T/G	cg02219949	chr17:45927392	SP6	0.43	8.06	0.35	6.76e-15	Body mass index;
LGG	trans	rs2898290	0.506	rs2736311	chr8:11252170	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.03	-0.31	7.49e-12	Systolic blood pressure;
LGG	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.81	0.48	2.61e-28	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.43	-0.44	4.98e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12893668	0.603	rs12896171	chr14:104135966	A/G	cg26031613	chr14:104095156	KLC1	-0.67	-10.7	-0.45	5.08e-24	Reticulocyte count;
LGG	cis	rs1784581	0.588	rs7765624	chr6:162427462	C/A	cg17173639	chr6:162384350	PARK2	0.65	13.6	0.53	1.17e-35	Itch intensity from mosquito bite;
LGG	cis	rs644799	0.544	rs498553	chr11:95534441	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.25	0.52	3.29e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.22	-0.32	2.21e-12	Bipolar disorder;
LGG	cis	rs28595532	1.000	rs115965820	chr4:119586485	G/A	cg14228332	chr4:119757509	SEC24D	0.98	9.69	0.41	2.42e-20	Cannabis dependence symptom count;
LGG	cis	rs2456568	0.709	rs1354765	chr11:93637776	G/T	cg26875233	chr11:93583750	C11orf90	0.36	7.02	0.31	7.95e-12	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs4660214	0.666	rs7538300	chr1:39652764	C/A	cg18385671	chr1:39797026	MACF1	-0.46	-9.35	-0.4	3.65e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9425766	0.640	rs3791020	chr1:173813197	A/G	cg06124660	chr1:173389066	NA	0.43	7.7	0.34	8.55e-14	Life satisfaction;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg19143629	chr17:61920732	SMARCD2	0.4	6.78	0.3	3.79e-11	Prudent dietary pattern;
LGG	cis	rs2976388	0.524	rs7012804	chr8:143844650	A/G	cg06565975	chr8:143823917	SLURP1	0.34	8.24	0.36	1.79e-15	Urinary tract infection frequency;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.23	0.36	1.97e-15	Longevity;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00689492	chr4:1303491	MAEA	0.44	7.73	0.34	6.61e-14	Obesity-related traits;
LGG	cis	rs7408868	0.611	rs11671336	chr19:15294043	C/T	cg14696996	chr19:15285081	NOTCH3	0.78	10.57	0.44	1.56e-23	Pulse pressure;
LGG	cis	rs677665	0.537	rs72641832	chr1:9336116	C/A	cg25755851	chr1:9335794	NA	0.3	8.93	0.38	1.02e-17	Eosinophil percentage of white cells;
LGG	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg13009111	chr11:71350975	NA	0.35	7.71	0.34	8.03e-14	Neuroticism;
LGG	cis	rs137603	0.644	rs137619	chr22:39706360	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.72	-13.96	-0.54	3.39e-37	Primary biliary cholangitis;
LGG	cis	rs17270561	0.541	rs17586946	chr6:25939053	C/T	cg17691542	chr6:26056736	HIST1H1C	1.09	16.97	0.62	1.42e-50	Iron status biomarkers;
LGG	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg02023728	chr11:77925099	USP35	0.39	6.84	0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg19628046	chr18:33552617	C18orf21	0.54	7.76	0.34	5.59e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs1256531	0.661	rs56158541	chr14:65832530	A/G	cg15999311	chr14:65749247	NA	0.85	6.95	0.31	1.29e-11	Conduct disorder (symptom count);
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg00855466	chr17:19652056	ALDH3A1	-0.63	-12.25	-0.49	4.36e-30	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg14675211	chr2:100938903	LONRF2	0.45	7.06	0.31	6.25e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.13e-23	Migraine;Coronary artery disease;
LGG	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs12188164	0.575	rs112126699	chr5:419462	A/T	cg26850624	chr5:429559	AHRR	-0.33	-7.15	-0.32	3.4e-12	Cystic fibrosis severity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06932451	chr19:36869880	NA	0.41	7.25	0.32	1.8e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	0.862	rs6460293	chr7:65810192	C/A	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs5756931	0.503	rs2076112	chr22:38538822	A/G	cg03162506	chr22:38580953	NA	0.31	7.56	0.33	2.23e-13	Triglycerides;
LGG	cis	rs9911578	1.000	rs304299	chr17:56838472	C/G	cg12560992	chr17:57184187	TRIM37	0.88	15.71	0.59	7.21e-45	Intelligence (multi-trait analysis);
LGG	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg13009111	chr11:71350975	NA	-0.35	-7.66	-0.34	1.12e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs889398	0.741	rs6499270	chr16:69917740	A/G	cg00738113	chr16:70207722	CLEC18C	0.23	6.7	0.3	6.16e-11	Body mass index;
LGG	cis	rs9420907	0.579	rs2475218	chr10:105672015	C/T	cg11005552	chr10:105648138	OBFC1	0.66	7.09	0.31	4.97e-12	Telomere length;
LGG	cis	rs7927997	0.746	rs7126418	chr11:76292573	A/T	cg17647271	chr11:76299819	NA	-0.41	-7.34	-0.32	9.54e-13	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg11814155	chr7:99998594	ZCWPW1	0.56	8.22	0.36	2.14e-15	Platelet count;
LGG	cis	rs4689388	0.926	rs4688987	chr4:6287329	C/T	cg14416269	chr4:6271139	WFS1	0.51	9.56	0.41	7.21e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs9682041	0.877	rs10755126	chr3:170071694	C/G	cg11886554	chr3:170076028	SKIL	-0.64	-8.6	-0.37	1.27e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2439831	0.850	rs12101756	chr15:44053887	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.64	0.44	8.61e-24	Lung cancer in ever smokers;
LGG	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg11984989	chr7:158649758	WDR60	1.01	14.39	0.56	4.67e-39	Height;
LGG	cis	rs11758351	0.587	rs2050950	chr6:26234883	A/G	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2797369	0.600	rs705609	chr6:101326794	G/T	cg27451362	chr6:101846650	GRIK2	0.67	9.11	0.39	2.52e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs12431410	0.550	rs11158269	chr14:60225411	C/T	cg07950296	chr14:60194823	RTN1	-0.36	-6.91	-0.31	1.65e-11	Schizophrenia;
LGG	cis	rs9487094	0.961	rs3778475	chr6:109696206	A/G	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.13e-18	Height;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	5.14e-19	Coronary artery disease;
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg19774624	chr17:42201019	HDAC5	0.75	13.62	0.53	8.92e-36	Total body bone mineral density;
LGG	cis	rs67311347	0.956	rs9817233	chr3:40425618	G/T	cg13683864	chr3:40499215	RPL14	-1.15	-25.96	-0.77	2.38e-92	Renal cell carcinoma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	0.44	7.18	0.32	2.82e-12	Cognitive performance;
LGG	cis	rs6912958	0.781	rs985764	chr6:88215206	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.8e-16	Monocyte percentage of white cells;
LGG	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11987759	chr7:65425863	GUSB	-0.4	-7.82	-0.34	3.52e-14	Calcium levels;
LGG	trans	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	trans	rs7395662	0.889	rs1848158	chr11:48697294	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs7762018	1.000	rs7746598	chr6:170084933	T/A	cg15038512	chr6:170123185	PHF10	0.51	6.67	0.3	7.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.78	-0.45	2.6e-24	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg20160729	chr7:5785550	RNF216	0.37	7.53	0.33	2.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg11764359	chr7:65958608	NA	0.63	10.94	0.45	6.37e-25	Aortic root size;
LGG	trans	rs7939886	0.764	rs79601668	chr11:55753767	G/C	cg15704280	chr7:45808275	SEPT13	0.88	9.21	0.39	1.1e-18	Myopia (pathological);
LGG	cis	rs2288073	0.965	rs6545338	chr2:24422156	C/T	cg06627628	chr2:24431161	ITSN2	-0.66	-10.65	-0.44	7.94e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9911578	0.835	rs58647683	chr17:56483194	T/C	cg12560992	chr17:57184187	TRIM37	-0.8	-13.71	-0.54	3.88e-36	Intelligence (multi-trait analysis);
LGG	trans	rs11250098	0.510	rs4840525	chr8:10765635	C/A	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.74e-15	Morning vs. evening chronotype;
LGG	cis	rs7633857	0.512	rs733948	chr3:160652784	C/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.48	-0.4	1.34e-19	Educational attainment (years of education);
LGG	cis	rs2455601	0.786	rs3751064	chr11:8958903	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.76	-13.33	-0.53	1.6e-34	Schizophrenia;
LGG	trans	rs7618501	1.000	rs2234391	chr3:49842625	A/G	cg21582582	chr3:182698605	DCUN1D1	0.52	9.63	0.41	3.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11605924	0.692	rs877412	chr11:45897651	A/C	ch.11.939596F	chr11:45881766	CRY2	0.75	13.54	0.53	1.96e-35	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6504108	0.624	rs12941830	chr17:46219131	T/C	cg02219949	chr17:45927392	SP6	0.44	8.3	0.36	1.18e-15	Body mass index;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg04013166	chr16:89971882	TCF25	0.54	7.22	0.32	2.12e-12	Skin colour saturation;
LGG	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.7	-0.73	3.19e-77	Schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08808811	chr3:184079573	CLCN2	0.63	7.1	0.31	4.68e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.547	rs9991859	chr4:152265572	T/C	cg25486957	chr4:152246857	NA	-0.42	-7.38	-0.32	7.19e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7617773	0.779	rs11718329	chr3:48309828	C/G	cg11946769	chr3:48343235	NME6	0.63	10.59	0.44	1.31e-23	Coronary artery disease;
LGG	cis	rs1558375	0.679	rs31674	chr7:87068464	T/C	cg00919237	chr7:87102261	ABCB4	0.55	9.74	0.41	1.64e-20	Gallbladder cancer;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.76	-0.3	4.3e-11	Personality dimensions;
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.2	-0.49	6.95e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs11758351	0.500	rs113738935	chr6:26196567	T/A	cg03181300	chr6:26195995	NA	0.87	6.67	0.3	7.09e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg24642439	chr20:33292090	TP53INP2	0.65	11.68	0.48	8.16e-28	Coronary artery disease;
LGG	cis	rs17453880	0.856	rs11953465	chr5:151960536	A/G	cg12297329	chr5:152029980	NA	-0.87	-22.1	-0.72	2.09e-74	Subjective well-being;
LGG	cis	rs950169	0.959	rs12911210	chr15:84792083	A/C	cg03959625	chr15:84868606	LOC388152	0.54	8.57	0.37	1.5e-16	Schizophrenia;
LGG	cis	rs727505	1.000	rs67585224	chr7:124537476	A/C	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	cis	rs4304924	0.500	rs12585725	chr13:79220899	C/A	cg07837209	chr13:79184101	NA	-0.39	-7.05	-0.31	6.35e-12	Large artery stroke;
LGG	cis	rs2274273	0.588	rs9919932	chr14:55814080	A/G	cg04306507	chr14:55594613	LGALS3	0.53	12.49	0.5	4.75e-31	Protein biomarker;
LGG	cis	rs9457247	0.508	rs6918286	chr6:167505829	C/T	cg07741184	chr6:167504864	NA	0.37	8.76	0.38	3.68e-17	Crohn's disease;
LGG	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg15268244	chr15:77196840	NA	0.48	10.24	0.43	2.53e-22	Blood metabolite levels;
LGG	cis	rs6429082	0.755	rs291372	chr1:235694106	G/C	cg26050004	chr1:235667680	B3GALNT2	0.69	11.98	0.49	5.39e-29	Adiposity;
LGG	cis	rs11690935	0.589	rs62183782	chr2:172865009	T/A	cg13550731	chr2:172543902	DYNC1I2	0.63	11.93	0.48	8.81e-29	Schizophrenia;
LGG	cis	rs1506636	0.708	rs7788702	chr7:123237421	C/T	cg03229431	chr7:123269106	ASB15	0.57	12.69	0.51	7.02e-32	Plateletcrit;Platelet count;
LGG	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs6918586	0.658	rs198843	chr6:26110314	A/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.55	-0.41	7.53e-20	Schizophrenia;
LGG	cis	rs6961069	0.745	rs1953298	chr7:80265451	C/T	cg04458919	chr7:80252533	CD36	-0.28	-6.87	-0.3	2.08e-11	Platelet count;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg09060608	chr5:178986726	RUFY1	0.5	8.49	0.37	2.84e-16	Lung cancer;
LGG	cis	rs16867321	0.614	rs10204086	chr2:181449668	G/T	cg23363182	chr2:181467187	NA	-0.43	-8.59	-0.37	1.3e-16	Obesity;
LGG	cis	rs151997	0.962	rs27273	chr5:50181074	G/A	cg06027927	chr5:50259733	NA	0.68	11.19	0.46	7.15e-26	Callous-unemotional behaviour;
LGG	cis	rs10744422	0.920	rs10773657	chr12:123327900	C/A	cg25930673	chr12:123319894	HIP1R	-0.74	-9.4	-0.4	2.62e-19	Schizophrenia;
LGG	cis	rs7113874	0.504	rs10743081	chr11:8624100	T/G	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.71e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4819052	1.000	rs13053002	chr21:46677854	C/T	cg06618935	chr21:46677482	NA	-0.52	-9.2	-0.39	1.26e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7851660	0.809	rs7022148	chr9:100660824	T/C	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs2842992	0.872	rs2758315	chr6:160158640	T/C	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.29	0.32	1.39e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs638893	0.578	rs1790188	chr11:118661055	T/C	cg13782932	chr11:118662891	DDX6	0.37	6.83	0.3	2.64e-11	Vitiligo;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	6.72	0.3	5.27e-11	Menopause (age at onset);
LGG	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7241530	0.636	rs12961788	chr18:75897998	C/T	cg14642773	chr18:75888474	NA	0.47	8.99	0.39	6.4e-18	Educational attainment (years of education);
LGG	cis	rs10231759	0.617	rs13223879	chr7:150502868	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.4	9.3	0.4	5.43e-19	Height;
LGG	cis	rs67311347	1.000	rs12634013	chr3:40452388	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-25.64	-0.77	6.5e-91	Renal cell carcinoma;
LGG	cis	rs1865760	0.964	rs9295677	chr6:25933712	T/C	cg12310025	chr6:25882481	NA	-0.41	-7.35	-0.32	9.03e-13	Height;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20349687	chr2:88927127	EIF2AK3	0.46	7.89	0.34	2.26e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs9291683	0.525	rs12506455	chr4:10031569	T/A	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.37e-14	Bone mineral density;
LGG	cis	rs9463078	0.547	rs9472362	chr6:44751285	C/A	cg25276700	chr6:44698697	NA	0.39	7.88	0.34	2.34e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6951245	0.572	rs75818004	chr7:1047572	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	10.14	0.43	6.11e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.765	rs10181344	chr2:99692829	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs701145	0.529	rs355759	chr3:154008078	G/C	cg17054900	chr3:154042577	DHX36	0.48	7.39	0.32	6.76e-13	Coronary artery disease;
LGG	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg21972741	chr5:435613	AHRR	0.49	8.87	0.38	1.58e-17	Cystic fibrosis severity;
LGG	cis	rs3092073	0.603	rs4810477	chr20:44544654	C/T	cg27529037	chr20:44575021	PCIF1	0.39	7.3	0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.62	-0.51	1.43e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4595586	0.545	rs17546137	chr12:39401124	G/A	cg26384229	chr12:38710491	ALG10B	0.65	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.74	-0.41	1.59e-20	Educational attainment;
LGG	trans	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg13010199	chr12:38710504	ALG10B	0.69	13.51	0.53	2.75e-35	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs1465722	chr18:44564499	C/G	cg19077165	chr18:44547161	KATNAL2	0.69	13.14	0.52	9.86e-34	Personality dimensions;
LGG	cis	rs7731783	1	rs7731783	chr5:177060312	T/C	cg26673648	chr5:177209285	NA	0.6	10.21	0.43	3.17e-22	Methadone dose in opioid dependence;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg11494091	chr17:61959527	GH2	0.98	23.8	0.74	2.24e-82	Prudent dietary pattern;
LGG	cis	rs2439831	0.867	rs4075674	chr15:43650230	A/C	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg16590910	chr6:42928470	GNMT	0.42	11.8	0.48	2.79e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1401999	0.650	rs3749445	chr3:183638506	C/T	cg20387954	chr3:183756860	HTR3D	0.48	9.28	0.4	6.36e-19	Anterior chamber depth;
LGG	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.64	-0.56	3.74e-40	Schizophrenia;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs2180341	1.000	rs3798852	chr6:127636733	A/G	cg27446573	chr6:127587934	RNF146	1.13	22.51	0.72	2.55e-76	Breast cancer;
LGG	cis	rs10463316	1.000	rs10463316	chr5:150746034	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.12	-0.43	7.27e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6089584	0.853	rs1740367	chr20:60574834	C/T	cg13770153	chr20:60521292	NA	-0.61	-9.35	-0.4	3.7e-19	Body mass index;
LGG	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg19507638	chr5:93509721	C5orf36	-0.67	-9.38	-0.4	3.05e-19	Diabetic retinopathy;
LGG	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.65	-0.33	1.17e-13	Systemic lupus erythematosus;
LGG	cis	rs3540	0.512	rs11633872	chr15:91080512	G/A	cg22089800	chr15:90895588	ZNF774	-0.66	-12.36	-0.5	1.56e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.31	0.32	1.19e-12	Skin colour saturation;
LGG	trans	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs11874712	0.966	rs9962380	chr18:43678706	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.57	-0.44	1.55e-23	Migraine - clinic-based;
LGG	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg17467752	chr17:38218738	THRA	-0.45	-7.2	-0.32	2.47e-12	Self-reported allergy;
LGG	cis	rs4555082	0.874	rs113291192	chr14:105738181	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.41	-0.33	5.92e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7208859	0.623	rs1061343	chr17:29114276	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.673	rs4235348	chr4:9951968	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2439831	1.000	rs690002	chr15:43729349	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.62	0.44	1.03e-23	Lung cancer in ever smokers;
LGG	cis	rs745821	0.541	rs2969972	chr18:48108763	A/G	cg18923635	chr18:48083994	NA	-0.4	-7.58	-0.33	1.9e-13	Diastolic blood pressure;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.967	rs62070344	chr17:28476997	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.31	0.53	1.85e-34	Coffee consumption (cups per day);
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg17328964	chr8:145687451	CYHR1	0.67	12.93	0.52	7.33e-33	Age at first birth;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.19	0.36	2.51e-15	Bipolar disorder;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.16	-0.46	8.97e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs11105298	0.891	rs6538189	chr12:89885923	C/A	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12579753	0.667	rs73359938	chr12:82308613	T/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.32	-0.32	1.14e-12	Resting heart rate;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.55	-0.33	2.33e-13	Bipolar disorder;
LGG	trans	rs208515	0.525	rs9453538	chr6:66668508	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	16.96	0.62	1.5e-50	Exhaled nitric oxide levels;
LGG	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-8.09	-0.35	5.38e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13030908	chr1:11741533	MAD2L2	0.53	8.32	0.36	1e-15	Gut microbiome composition (summer);
LGG	cis	rs4302748	0.862	rs12530870	chr7:36181501	A/G	cg24442661	chr7:36192818	EEPD1	0.57	7.37	0.32	8.07e-13	Platelet count;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs35160687	0.644	rs11127024	chr2:86505453	C/T	cg10973622	chr2:86423274	IMMT	-0.4	-7.17	-0.32	2.95e-12	Night sleep phenotypes;
LGG	cis	rs9300255	0.602	rs949142	chr12:123634043	T/C	cg00376283	chr12:123451042	ABCB9	0.65	10.67	0.44	6.51e-24	Neutrophil percentage of white cells;
LGG	cis	rs4731207	0.698	rs10261610	chr7:124450577	G/A	cg05630886	chr7:124431682	NA	0.34	7.93	0.35	1.69e-14	Cutaneous malignant melanoma;
LGG	cis	rs801193	0.660	rs1962050	chr7:66240008	C/T	cg18876405	chr7:65276391	NA	-0.5	-8.93	-0.38	9.74e-18	Aortic root size;
LGG	cis	rs8014204	0.868	rs2230237	chr14:75359670	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.85	-18.14	-0.64	5.8e-56	Caffeine consumption;
LGG	cis	rs7917772	0.503	rs11191347	chr10:104351617	C/T	cg05096777	chr10:104283225	SUFU	0.32	7.0	0.31	9.17e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-8.04	-0.35	7.7e-15	Life satisfaction;
LGG	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg04240660	chr16:89714849	CHMP1A	-0.4	-7.15	-0.32	3.44e-12	Hemoglobin concentration;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.21	-0.49	6.49e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs9443189	0.570	rs72888705	chr6:76403114	A/G	cg01950844	chr6:76311363	SENP6	0.76	10.07	0.42	1.07e-21	Prostate cancer;
LGG	cis	rs3849046	0.846	rs11738995	chr5:137927619	C/G	cg10920316	chr5:137946599	NA	-0.47	-7.61	-0.33	1.52e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1555322	0.530	rs2425043	chr20:33868702	T/C	cg03689076	chr20:33865952	NA	0.64	8.68	0.37	6.75e-17	Attention deficit hyperactivity disorder;
LGG	cis	rs10851478	0.657	rs12916839	chr15:49735665	C/T	cg08060515	chr15:49448048	GALK2;COPS2	0.42	7.32	0.32	1.07e-12	Oral cavity cancer;
LGG	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg12310025	chr6:25882481	NA	0.7	13.93	0.54	4.19e-37	Blood metabolite levels;
LGG	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg19539972	chr4:7069911	GRPEL1	-0.55	-8.22	-0.36	2e-15	Monocyte percentage of white cells;
LGG	cis	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg13147721	chr7:65941812	NA	-0.44	-6.82	-0.3	2.89e-11	Corneal structure;
LGG	cis	rs2832191	0.655	rs2247110	chr21:30323888	G/A	cg08807101	chr21:30365312	RNF160	-0.91	-19.47	-0.67	4.18e-62	Dental caries;
LGG	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg26384229	chr12:38710491	ALG10B	0.99	23.52	0.74	4.63e-81	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg24006582	chr15:45444508	DUOX1	0.68	12.33	0.5	2.04e-30	Uric acid levels;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs11640336	chr16:89941153	T/C	cg19635926	chr16:89946313	TCF25	0.79	8.27	0.36	1.47e-15	Skin colour saturation;
LGG	cis	rs7914558	0.966	rs10748839	chr10:104953547	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.56	0.44	1.63e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.16	0.62	1.99e-51	Obesity-related traits;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg11494091	chr17:61959527	GH2	0.59	9.59	0.41	5.58e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6667605	0.506	rs10797440	chr1:2541269	A/G	cg15627072	chr1:2432621	PLCH2	0.32	7.14	0.31	3.69e-12	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg19626725	chr5:178986131	RUFY1	0.46	7.63	0.33	1.34e-13	Lung cancer;
LGG	cis	rs6977660	1.000	rs5017196	chr7:19819983	T/C	cg05791153	chr7:19748676	TWISTNB	0.58	8.75	0.38	3.9e-17	Thyroid stimulating hormone;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg11645453	chr3:52864694	ITIH4	0.47	7.73	0.34	6.55e-14	Bipolar disorder;
LGG	cis	rs42648	0.837	rs4728879	chr7:89924237	T/G	cg25739043	chr7:89950458	NA	-0.44	-9.46	-0.4	1.59e-19	Homocysteine levels;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.06	0.52	2.18e-33	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg00800038	chr16:89945340	TCF25	-0.68	-7.19	-0.32	2.64e-12	Skin colour saturation;
LGG	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg14835575	chr10:16859367	RSU1	0.63	12.03	0.49	3.41e-29	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs12618769	0.597	rs12619665	chr2:99126551	A/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.41e-16	Bipolar disorder;
LGG	trans	rs961253	0.522	rs2148813	chr20:6352470	T/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.93	0.31	1.43e-11	Colorectal cancer;
LGG	cis	rs6076065	0.748	rs6048779	chr20:23374709	C/G	cg12633918	chr20:23549525	CST9L	-0.33	-6.67	-0.3	7.26e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs1065656	0.553	rs344359	chr16:1838640	T/C	cg26617929	chr16:1858877	NA	0.55	7.66	0.34	1.12e-13	Insulin-like growth factors;
LGG	cis	rs4731207	0.844	rs4731208	chr7:124398196	T/C	cg05630886	chr7:124431682	NA	0.31	6.84	0.3	2.48e-11	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg20607798	chr8:58055168	NA	-0.64	-7.53	-0.33	2.75e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs757110	0.834	rs1002226	chr11:17405617	C/T	cg04705435	chr11:17411270	KCNJ11	0.42	8.55	0.37	1.76e-16	Type 2 diabetes;
LGG	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs12220238	1.000	rs10824101	chr10:75947438	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.07	0.46	1.97e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs6825911	0.723	rs10023175	chr4:111379719	A/G	cg10580549	chr19:53101634	ZNF137	0.55	6.99	0.31	9.67e-12	Blood pressure;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg00166722	chr3:10149974	C3orf24	0.54	7.96	0.35	1.37e-14	Alzheimer's disease;
LGG	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.21	0.32	2.37e-12	Facial emotion recognition (sad faces);
LGG	cis	rs262150	0.672	rs2730230	chr7:158788529	A/G	cg19418458	chr7:158789849	NA	-0.44	-8.69	-0.37	6.3e-17	Facial morphology (factor 20);
LGG	cis	rs6918586	0.658	rs198813	chr6:26128226	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.79	-0.41	1.05e-20	Schizophrenia;
LGG	cis	rs3782089	0.744	rs11545200	chr11:65319751	G/A	cg00206168	chr11:65308501	LTBP3	0.74	8.26	0.36	1.53e-15	Height;
LGG	cis	rs68170813	0.652	rs4730250	chr7:107207695	A/G	cg02696742	chr7:106810147	HBP1	-0.67	-8.5	-0.37	2.72e-16	Coronary artery disease;
LGG	cis	rs2236918	1.000	rs1635515	chr1:242017009	A/G	cg17736920	chr1:242011382	EXO1	0.52	9.42	0.4	2.08e-19	Menopause (age at onset);
LGG	cis	rs11690935	0.885	rs6725388	chr2:172730015	G/C	cg21435375	chr2:172878103	MAP1D	-0.34	-7.7	-0.34	8.48e-14	Schizophrenia;
LGG	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg01270228	chr10:1369114	ADARB2	0.52	9.48	0.4	1.28e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3735485	0.678	rs10233699	chr7:45132710	C/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.13	-0.39	2.16e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg00129232	chr17:37814104	STARD3	0.58	8.65	0.37	8.25e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2073499	1.000	rs1989839	chr3:50378946	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.61	7.04	0.31	7.19e-12	Schizophrenia;
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15094636	chr3:125094397	ZNF148	0.44	7.46	0.33	4.23e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7193541	0.691	rs3851728	chr16:74480660	C/T	cg01733217	chr16:74700730	RFWD3	0.87	19.18	0.67	8.97e-61	Multiple myeloma;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg11235426	chr6:292522	DUSP22	-0.61	-10.18	-0.43	4.11e-22	Menopause (age at onset);
LGG	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg06640241	chr16:89574553	SPG7	0.93	17.56	0.63	2.93e-53	Multiple myeloma (IgH translocation);
LGG	cis	rs4262150	0.810	rs72797237	chr5:151998463	A/C	cg12297329	chr5:152029980	NA	-0.81	-15.95	-0.6	5.57e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs8049634	0.732	rs2303243	chr16:84230500	A/C	cg26466773	chr16:84211947	TAF1C	0.41	6.74	0.3	4.67e-11	Small cell lung carcinoma;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg00717180	chr2:96193071	NA	-0.38	-6.79	-0.3	3.41e-11	Coronary artery disease;
LGG	cis	rs11190604	0.767	rs10883485	chr10:102174805	G/C	cg07570687	chr10:102243282	WNT8B	0.4	7.09	0.31	5.13e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs738322	0.555	rs2284063	chr22:38544298	C/T	cg03162506	chr22:38580953	NA	-0.39	-10.02	-0.42	1.61e-21	Cutaneous nevi;
LGG	cis	rs1728785	1.000	rs1728781	chr16:68567794	A/T	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg06835404	chr16:988973	LMF1	0.49	8.58	0.37	1.48e-16	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg00129232	chr17:37814104	STARD3	0.61	11.53	0.47	3.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs66573146	1.000	rs55672215	chr4:6970529	T/C	cg26116260	chr4:7069785	GRPEL1	-0.75	-6.78	-0.3	3.62e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg07959490	chr17:80112427	CCDC57	0.47	9.28	0.4	6.71e-19	Life satisfaction;
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.34	-0.43	1.07e-22	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02970425	chr20:48552805	RNF114	0.47	7.14	0.31	3.54e-12	Gut microbiome composition (summer);
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg24846343	chr22:24311635	DDTL	-0.56	-10.73	-0.45	4.02e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs981844	0.740	rs6841173	chr4:154682563	A/G	cg14289246	chr4:154710475	SFRP2	-0.6	-10.77	-0.45	2.75e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs4481887	0.927	rs6587445	chr1:248440915	A/G	cg01631408	chr1:248437212	OR2T33	-0.56	-10.03	-0.42	1.52e-21	Common traits (Other);
LGG	cis	rs308971	0.521	rs2600230	chr3:12038629	T/A	cg15873301	chr3:12045459	SYN2	0.52	6.79	0.3	3.39e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs11877825	0.685	rs2099871	chr18:10578676	G/A	cg25239095	chr18:10589360	NA	0.48	8.68	0.37	6.83e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	cis	rs698813	0.774	rs786625	chr2:44604156	C/T	cg00619915	chr2:44497795	NA	-0.48	-6.74	-0.3	4.75e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs10895140	0.756	rs1939449	chr11:101505303	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	trans	rs1728785	0.901	rs1728787	chr16:68593042	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg14782152	chr13:114913410	NA	-0.33	-6.73	-0.3	4.96e-11	Schizophrenia;
LGG	cis	rs4788570	0.615	rs6499531	chr16:71731485	T/C	cg06353428	chr16:71660113	MARVELD3	1.27	19.93	0.68	2.72e-64	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.505	rs1549741	chr6:161204783	G/T	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.65e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg24101359	chr6:42928495	GNMT	0.52	14.5	0.56	1.5e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	8.01e-53	Chronic sinus infection;
LGG	cis	rs10504229	0.906	rs112793785	chr8:58190537	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.72e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2718058	0.589	rs1986618	chr7:37800116	C/G	cg24998770	chr7:37888106	TXNDC3	0.46	7.42	0.33	5.73e-13	Alzheimer's disease (late onset);
LGG	cis	rs35828350	1	rs35828350	chr15:85355841	G/A	cg03959625	chr15:84868606	LOC388152	0.49	7.07	0.31	5.84e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3099143	1.000	rs3106380	chr15:77104377	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-10.11	-0.43	7.87e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg06654118	chr4:1303317	MAEA	-0.44	-7.48	-0.33	3.71e-13	Obesity-related traits;
LGG	cis	rs12155623	1.000	rs12155623	chr8:49812201	A/T	cg22283653	chr8:49824208	NA	-0.56	-10.44	-0.44	4.66e-23	Sudden cardiac arrest;
LGG	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.03	-19.99	-0.68	1.53e-64	Gut microbiome composition (summer);
LGG	cis	rs12048904	0.505	rs6577209	chr1:101255080	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.65	13.95	0.54	3.5e-37	Multiple sclerosis;
LGG	cis	rs2916247	0.954	rs4735107	chr8:93160055	C/T	cg10183463	chr8:93005414	RUNX1T1	0.39	7.77	0.34	5e-14	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.667	rs1912485	chr17:45515678	T/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12188164	0.525	rs2561665	chr5:460135	A/G	cg13013644	chr5:502571	SLC9A3	0.32	7.18	0.32	2.86e-12	Cystic fibrosis severity;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.794	rs4840133	chr6:100914717	C/T	cg21058520	chr6:100914733	NA	0.52	9.01	0.39	5.48e-18	Neuroticism;
LGG	cis	rs883565	0.655	rs6778963	chr3:39091812	T/G	cg01426195	chr3:39028469	NA	-0.73	-17.19	-0.62	1.45e-51	Handedness;
LGG	cis	rs1419980	0.673	rs2377086	chr12:7753798	C/T	cg10578777	chr12:7781093	NA	0.62	8.5	0.37	2.68e-16	HDL cholesterol levels;
LGG	cis	rs7223966	1.000	rs9891018	chr17:61827856	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.56	-0.33	2.14e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7166081	1.000	rs12899051	chr15:67573741	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1391576	1	rs1391576	chr11:51394932	C/T	cg15704280	chr7:45808275	SEPT13	0.78	7.74	0.34	6.29e-14	Body mass index;
LGG	cis	rs7215564	0.908	rs34135683	chr17:78652903	G/T	cg16980736	chr17:78789706	RPTOR	-0.64	-8.41	-0.36	5.04e-16	Myopia (pathological);
LGG	cis	rs6793245	0.810	rs1805126	chr3:38592406	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.49	8.35	0.36	7.86e-16	QT interval;
LGG	cis	rs988958	0.958	rs34482969	chr2:42280300	G/A	cg27428208	chr2:42229179	NA	0.41	7.49	0.33	3.56e-13	Hypospadias;
LGG	cis	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19171272	chr22:38449367	NA	-0.5	-9.21	-0.39	1.18e-18	Glioblastoma;Glioma;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.49	0.4	1.27e-19	Obesity-related traits;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg04267008	chr7:1944627	MAD1L1	0.61	10.35	0.43	1.04e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4948102	0.642	rs6593297	chr7:56122058	A/T	cg17215666	chr7:56131930	SUMF2	-0.48	-8.04	-0.35	7.74e-15	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1816752	0.712	rs2862898	chr13:24988461	A/G	cg22771759	chr13:24902376	NA	0.42	6.96	0.31	1.16e-11	Obesity-related traits;
LGG	cis	rs9875589	0.509	rs2731337	chr3:14091440	G/C	cg19554555	chr3:13937349	NA	-0.57	-10.24	-0.43	2.48e-22	Ovarian reserve;
LGG	cis	rs847851	0.833	rs3817473	chr6:34949451	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.37	6.74	0.3	4.64e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.569	rs10883801	chr10:104677887	A/C	cg04362960	chr10:104952993	NT5C2	0.55	10.03	0.42	1.51e-21	Arsenic metabolism;
LGG	cis	rs6430585	0.583	rs4988145	chr2:136632300	A/C	cg07169764	chr2:136633963	MCM6	1.29	26.47	0.78	1.1e-94	Corneal structure;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25427524	chr10:38739819	LOC399744	-0.67	-12.48	-0.5	5.23e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs4820539	1.000	rs5759595	chr22:23471624	G/A	cg14186256	chr22:23484241	RTDR1	1.0	25.83	0.77	9.48e-92	Bone mineral density;
LGG	cis	rs926392	0.965	rs6124106	chr20:37693042	G/A	cg16355469	chr20:37678765	NA	0.42	6.85	0.3	2.3e-11	Dialysis-related mortality;
LGG	cis	rs1878931	0.545	rs28603	chr16:3449479	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.72	-10.46	-0.44	3.98e-23	Body mass index (adult);
LGG	cis	rs10779751	1.000	rs2253213	chr1:11265785	A/G	cg08854313	chr1:11322531	MTOR	0.74	16.08	0.6	1.47e-46	Body mass index;
LGG	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg18876405	chr7:65276391	NA	-0.62	-10.98	-0.45	4.57e-25	Aortic root size;
LGG	cis	rs6032067	0.929	rs62205504	chr20:43867894	C/G	cg10761708	chr20:43804764	PI3	0.76	11.74	0.48	4.7e-28	Blood protein levels;
LGG	cis	rs1348850	0.567	rs4144276	chr2:178523420	T/C	cg27490568	chr2:178487706	NA	0.51	10.01	0.42	1.79e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs4714291	0.862	rs2984433	chr6:39973445	T/G	cg02267698	chr19:7991119	CTXN1	-0.6	-9.46	-0.4	1.62e-19	Strep throat;
LGG	cis	rs17767392	0.881	rs35625243	chr14:71944937	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.66	-0.37	7.62e-17	Mitral valve prolapse;
LGG	cis	rs7646881	0.951	rs6441222	chr3:158449767	A/G	cg19483011	chr3:158453295	NA	-0.62	-9.22	-0.39	1.07e-18	Tetralogy of Fallot;
LGG	cis	rs834603	0.575	rs834597	chr7:47464488	A/T	cg23694490	chr7:47445681	TNS3	-0.42	-12.06	-0.49	2.69e-29	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.64	0.37	9e-17	Mood instability;
LGG	cis	rs4604732	0.631	rs1106720	chr1:247624681	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg12615879	chr12:58013172	SLC26A10	0.4	9.19	0.39	1.29e-18	Multiple sclerosis;
LGG	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg02158880	chr13:53174818	NA	0.67	15.32	0.58	3.62e-43	Lewy body disease;
LGG	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	11.04	0.46	2.52e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13425677	chr5:56112090	MAP3K1	0.46	7.68	0.34	9.51e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs17021463	0.934	rs28403447	chr4:95257753	G/A	cg11021082	chr4:95130006	SMARCAD1	0.51	9.37	0.4	3.28e-19	Testicular germ cell tumor;
LGG	trans	rs11098499	0.908	rs9995234	chr4:120321827	A/G	cg25214090	chr10:38739885	LOC399744	0.72	12.54	0.5	2.81e-31	Corneal astigmatism;
LGG	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg23166289	chr1:210001082	C1orf107	0.38	7.28	0.32	1.44e-12	Orofacial clefts;
LGG	cis	rs929596	0.561	rs7564935	chr2:234645186	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-10.23	-0.43	2.76e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs2247341	0.965	rs11248074	chr4:1743754	C/T	cg05026014	chr4:1749153	NA	-0.33	-9.26	-0.4	7.46e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.57	0.37	1.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs41271473	0.526	rs1925720	chr1:228728377	G/C	cg16512390	chr1:228756714	NA	0.61	8.06	0.35	6.67e-15	Chronic lymphocytic leukemia;
LGG	cis	rs714031	1.000	rs5757765	chr22:40067840	T/C	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.54	-0.56	1.05e-39	Schizophrenia;
LGG	cis	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg00745463	chr17:30367425	LRRC37B	-0.65	-9.54	-0.41	8.46e-20	Hip circumference adjusted for BMI;
LGG	cis	rs896854	0.654	rs28591375	chr8:95973637	C/G	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs796364	0.806	rs6435040	chr2:200861161	T/G	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.4e-12	Schizophrenia;
LGG	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.94	-0.45	6.31e-25	Neuroticism;
LGG	cis	rs4851266	0.898	rs12994592	chr2:100857984	T/C	cg21926883	chr2:100939477	LONRF2	-0.47	-8.35	-0.36	8.09e-16	Educational attainment;
LGG	cis	rs4684776	0.935	rs13059407	chr3:11377345	G/C	cg24705426	chr3:11550659	ATG7	-0.45	-8.53	-0.37	2.12e-16	Small vessel stroke;
LGG	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg15325629	chr6:28072465	NA	1.01	7.69	0.34	9.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs8141529	0.732	rs2347447	chr22:29179739	C/A	cg15103426	chr22:29168792	CCDC117	0.73	11.82	0.48	2.24e-28	Lymphocyte counts;
LGG	cis	rs10864302	0.525	rs1418491	chr1:7425266	T/C	cg08923594	chr1:7462176	CAMTA1	0.67	8.36	0.36	7.5e-16	Photic sneeze reflex;
LGG	cis	rs240764	0.554	rs723742	chr6:101237174	T/A	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	15.42	0.58	1.34e-43	Menarche (age at onset);
LGG	cis	rs2839186	0.526	rs2839297	chr21:47921839	A/G	cg13126279	chr21:47581558	C21orf56	-0.41	-7.18	-0.32	2.71e-12	Testicular germ cell tumor;
LGG	cis	rs7089973	0.934	rs68085797	chr10:116632130	A/T	cg08188268	chr10:116634841	FAM160B1	0.32	6.75	0.3	4.3e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7647973	0.593	rs59684465	chr3:49874246	C/T	cg21659725	chr3:3221576	CRBN	0.58	7.68	0.34	9.57e-14	Menarche (age at onset);
LGG	cis	rs3816183	1.000	rs3816183	chr2:43015719	C/T	cg27299406	chr2:43020013	HAAO	0.28	6.83	0.3	2.69e-11	Hypospadias;
LGG	cis	rs6964587	1.000	rs416	chr7:91580571	A/G	cg17063962	chr7:91808500	NA	-0.48	-8.56	-0.37	1.71e-16	Breast cancer;
LGG	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg25039879	chr17:56429692	SUPT4H1	0.75	11.0	0.46	3.69e-25	Cognitive test performance;
LGG	cis	rs1659258	0.568	rs1258436	chr2:88608962	G/T	cg00685853	chr2:88648947	NA	-0.45	-6.73	-0.3	4.91e-11	Visceral fat;
LGG	cis	rs7172689	0.908	rs67476632	chr15:81566969	T/C	cg11808699	chr15:81528661	IL16	-0.44	-9.24	-0.39	8.84e-19	Inattentive symptoms;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09435090	chr4:17513980	QDPR	-0.48	-7.03	-0.31	7.37e-12	Systemic lupus erythematosus;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.82	0.34	3.56e-14	Longevity;
LGG	trans	rs12517041	1.000	rs1428625	chr5:23290664	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs926938	0.584	rs2798663	chr1:115363582	G/A	cg12756093	chr1:115239321	AMPD1	0.46	8.57	0.37	1.56e-16	Autism;
LGG	cis	rs7666738	0.830	rs6854902	chr4:99033416	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs2732480	0.500	rs1552550	chr12:48643351	C/A	cg24011408	chr12:48396354	COL2A1	0.5	8.0	0.35	1.02e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7215564	0.908	rs4889879	chr17:78662573	A/T	cg16980736	chr17:78789706	RPTOR	0.6	8.16	0.35	3.2e-15	Myopia (pathological);
LGG	cis	rs7923609	0.756	rs7911761	chr10:65338753	C/G	cg02276361	chr10:65351566	REEP3	-0.31	-6.86	-0.3	2.26e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg14338887	chr6:42928500	GNMT	0.27	8.65	0.37	8.53e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg08975724	chr8:8085496	FLJ10661	0.39	7.43	0.33	5.16e-13	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.27	-0.43	2.03e-22	Bipolar disorder;
LGG	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg00908189	chr16:619842	PIGQ	0.87	16.64	0.61	4.31e-49	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24595957	chr14:20811627	PARP2;RPPH1	0.46	6.73	0.3	5.08e-11	Gut microbiome composition (summer);
LGG	cis	rs17221829	0.521	rs2118022	chr11:89316133	T/C	cg02982614	chr11:89391479	FOLH1B	-0.37	-8.41	-0.36	5.01e-16	Anxiety in major depressive disorder;
LGG	cis	rs7566780	0.602	rs1430056	chr2:16684144	T/C	cg09580478	chr2:16689509	NA	0.49	7.53	0.33	2.73e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs4639966	0.756	rs61219050	chr11:118648624	C/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.61	-0.37	1.16e-16	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg07701084	chr6:150067640	NUP43	0.7	13.49	0.53	3.37e-35	Lung cancer;
LGG	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg21775007	chr8:11205619	TDH	0.44	7.0	0.31	8.81e-12	Mood instability;
LGG	cis	rs3096299	0.746	rs9931120	chr16:89501357	A/G	cg08392591	chr16:89556376	ANKRD11	0.46	7.19	0.32	2.66e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs7186908	0.761	rs34714490	chr16:72177099	G/T	cg23815491	chr16:72088622	HP	0.5	8.9	0.38	1.27e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg11062466	chr8:58055876	NA	0.52	7.95	0.35	1.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg24764310	chr7:157512201	PTPRN2	-0.36	-6.99	-0.31	9.6e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2708377	0.790	rs73051387	chr12:11314463	A/T	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.74	-0.3	4.85e-11	Bitter taste perception;
LGG	cis	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.65	-0.33	1.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12220238	0.554	rs10824192	chr10:76251573	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.74	8.61	0.37	1.11e-16	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11158026	0.757	rs8018800	chr14:55453306	C/T	cg04306507	chr14:55594613	LGALS3	-0.31	-7.17	-0.32	2.95e-12	Parkinson's disease;
LGG	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	9.76	0.41	1.36e-20	Joint mobility (Beighton score);
LGG	cis	rs4731207	0.565	rs998054	chr7:124640487	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.62	-0.33	1.45e-13	Personality dimensions;
LGG	cis	rs6688363	0.887	rs6695366	chr1:160097666	G/A	cg01023271	chr1:160068607	IGSF8	0.55	6.9	0.31	1.72e-11	Response to antipsychotic treatment;
LGG	trans	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.68	-0.34	9.55e-14	Mosquito bite size;
LGG	cis	rs220324	0.954	rs456358	chr21:43583649	C/G	cg15319517	chr21:43638949	ABCG1	0.46	7.37	0.32	7.79e-13	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs6712932	1.000	rs6734358	chr2:105843732	A/C	cg26874229	chr2:105853672	NA	-0.32	-6.98	-0.31	1.03e-11	Type 2 diabetes;
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.51	-0.5	3.75e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.77	0.84	1.05e-122	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg21827317	chr3:136751795	NA	0.85	19.98	0.68	1.63e-64	Schizophrenia;
LGG	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.63	-18.42	-0.65	3.11e-57	Oropharynx cancer;
LGG	cis	rs3857747	0.827	rs10229210	chr7:40440573	G/A	cg00420559	chr7:40367873	C7orf10	-0.39	-8.03	-0.35	8.26e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7973719	1.000	rs12828040	chr12:7326541	T/C	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-8.04	-0.35	7.55e-15	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.08	-0.31	5.41e-12	Menopause (age at onset);
LGG	cis	rs6088590	1.000	rs12626122	chr20:33425800	A/G	cg24642439	chr20:33292090	TP53INP2	0.79	13.27	0.53	2.68e-34	Coronary artery disease;
LGG	trans	rs12339094	1.000	rs9410967	chr9:90411001	C/G	cg24436365	chr6:63940138	NA	0.44	7.35	0.32	8.75e-13	Smoking quantity;
LGG	trans	rs8002861	0.905	rs12853286	chr13:44446817	A/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.49	-0.71	1.43e-71	Leprosy;
LGG	cis	rs1847505	0.693	rs7989616	chr13:61587706	G/A	cg25164009	chr13:61490935	NA	-0.64	-11.46	-0.47	6.35e-27	Polychlorinated biphenyl levels;
LGG	cis	rs7107174	1.000	rs11601590	chr11:78073288	T/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	8.01e-13	Testicular germ cell tumor;
LGG	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg08847533	chr14:75593920	NEK9	0.62	12.08	0.49	2.07e-29	Height;
LGG	cis	rs7726839	0.578	rs10080150	chr5:593160	C/T	cg09021430	chr5:549028	NA	0.84	20.88	0.7	1.04e-68	Obesity-related traits;
LGG	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2439831	0.867	rs12323999	chr15:43683115	T/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	12.99	0.52	4.2e-33	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00933542	chr6:150070202	PCMT1	0.4	7.14	0.31	3.64e-12	Lung cancer;
LGG	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs6912958	0.559	rs373646	chr6:88056896	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	12.93	0.52	7.28e-33	Monocyte percentage of white cells;
LGG	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg21775007	chr8:11205619	TDH	0.43	6.93	0.31	1.41e-11	Mood instability;
LGG	cis	rs75059851	0.756	rs11223655	chr11:133842707	G/A	cg20042908	chr11:133852938	NA	-0.76	-14.2	-0.55	3.1e-38	Schizophrenia;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg03351412	chr1:154909251	PMVK	0.66	12.74	0.51	4.56e-32	Prostate cancer;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3767633	0.925	rs4656339	chr1:161915387	A/T	cg09175582	chr1:161736000	ATF6	0.73	8.93	0.38	1.03e-17	IgG glycosylation;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.34	-0.53	1.41e-34	Aortic root size;
LGG	cis	rs4891159	0.790	rs10514217	chr18:74144939	A/G	cg24786174	chr18:74118243	ZNF516	-0.48	-9.32	-0.4	4.92e-19	Longevity;
LGG	cis	rs2635047	0.542	rs2668764	chr18:44790218	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-7.38	-0.32	7.43e-13	Educational attainment;
LGG	cis	rs6993813	0.620	rs6469802	chr8:120029323	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.81	0.34	3.77e-14	Bone mineral density (hip);
LGG	trans	rs1459104	0.777	rs116287458	chr11:54916623	G/A	cg03929089	chr4:120376271	NA	0.71	6.96	0.31	1.16e-11	Body mass index;
LGG	cis	rs2066819	1.000	rs76430365	chr12:56699993	A/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.18	-0.36	2.67e-15	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs7647973	0.961	rs11130187	chr3:49307872	T/C	cg07636037	chr3:49044803	WDR6	0.76	13.57	0.53	1.44e-35	Menarche (age at onset);
LGG	cis	rs7647973	1.000	rs892974	chr3:49398514	C/A	cg06212747	chr3:49208901	KLHDC8B	0.52	8.08	0.35	5.66e-15	Menarche (age at onset);
LGG	cis	rs9309473	0.607	rs6720094	chr2:73588076	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-8.44	-0.37	4.08e-16	Metabolite levels;
LGG	cis	rs887829	0.570	rs6759892	chr2:234601669	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.45	7.79	0.34	4.49e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs11098499	1.000	rs13435802	chr4:120177960	A/T	cg24375607	chr4:120327624	NA	-0.61	-10.05	-0.42	1.2e-21	Corneal astigmatism;
LGG	cis	rs4474465	0.688	rs7929656	chr11:78276416	T/C	cg27205649	chr11:78285834	NARS2	0.59	10.99	0.45	3.9e-25	Alzheimer's disease (survival time);
LGG	cis	rs9875589	0.533	rs12490233	chr3:13977365	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	9.35	0.4	3.84e-19	Ovarian reserve;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg11062466	chr8:58055876	NA	-0.6	-10.06	-0.42	1.2e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs10462794	0.853	rs62343516	chr5:4495407	G/A	cg18482690	chr5:4511582	NA	-0.43	-7.24	-0.32	1.85e-12	DNA methylation (variation);
LGG	cis	rs504918	1.000	rs492270	chr3:124084974	A/T	cg05766129	chr3:123988013	KALRN	0.37	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs11190604	1.000	rs4917901	chr10:102201773	A/C	cg07570687	chr10:102243282	WNT8B	0.45	7.83	0.34	3.28e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7799006	0.929	rs745566	chr7:2256406	T/C	cg02951883	chr7:2050386	MAD1L1	-0.41	-6.92	-0.31	1.5e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1878931	0.507	rs11648783	chr16:3406626	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.66	10.34	0.43	1.07e-22	Body mass index (adult);
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg05368731	chr17:41323189	NBR1	0.96	18.61	0.65	4.04e-58	Menopause (age at onset);
LGG	cis	rs763121	0.853	rs5995610	chr22:39064681	C/T	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs4689388	0.890	rs6838400	chr4:6295427	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg14983838	chr19:29218262	NA	0.7	11.37	0.47	1.35e-26	Methadone dose in opioid dependence;
LGG	cis	rs6087990	0.735	rs2065576	chr20:31389009	C/T	cg13636640	chr20:31349939	DNMT3B	0.83	17.38	0.63	1.84e-52	Ulcerative colitis;
LGG	trans	rs1814175	0.869	rs10769600	chr11:49681832	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.58	-0.72	1.14e-76	Height;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.54e-21	Lung cancer;
LGG	cis	rs4147929	0.532	rs2242437	chr19:1065563	G/C	cg05372495	chr19:1063624	ABCA7	-0.55	-8.97	-0.38	7.41e-18	Alzheimer's disease (late onset);
LGG	cis	rs1318772	1.000	rs68189049	chr5:112690255	C/T	cg12552261	chr5:112820674	MCC	0.69	8.25	0.36	1.61e-15	F-cell distribution;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.86e-12	Bipolar disorder;
LGG	cis	rs9325144	0.560	rs13377717	chr12:38639474	T/A	cg04568710	chr12:38710424	ALG10B	-0.34	-7.24	-0.32	1.87e-12	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg15485101	chr11:133734466	NA	0.61	10.7	0.45	4.97e-24	Childhood ear infection;
LGG	cis	rs11098499	0.526	rs10026625	chr4:120280136	T/C	cg09307838	chr4:120376055	NA	0.51	8.14	0.35	3.69e-15	Corneal astigmatism;
LGG	cis	rs798554	0.836	rs798526	chr7:2775542	G/C	cg18446336	chr7:2847575	GNA12	-0.3	-7.11	-0.31	4.3e-12	Height;
LGG	cis	rs4776059	0.724	rs11633933	chr15:52948357	T/C	cg22715398	chr15:52968154	KIAA1370	-0.52	-8.0	-0.35	1.03e-14	Schizophrenia;
LGG	cis	rs12906542	0.507	rs4395040	chr15:78282533	G/A	cg04896959	chr15:78267971	NA	-0.49	-7.28	-0.32	1.46e-12	Breast cancer;
LGG	cis	rs7107174	0.901	rs10899473	chr11:78042983	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.56	-0.33	2.13e-13	Testicular germ cell tumor;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.45	0.67	5.08e-62	Personality dimensions;
LGG	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg13902645	chr11:5959945	NA	-0.7	-11.08	-0.46	1.87e-25	DNA methylation (variation);
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.46e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4566357	1.000	rs3820926	chr2:227926621	G/T	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.06	-0.31	6.07e-12	Coronary artery disease;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg13126279	chr21:47581558	C21orf56	-0.48	-8.21	-0.36	2.18e-15	Testicular germ cell tumor;
LGG	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg03924115	chr9:133768966	QRFP	0.45	6.79	0.3	3.37e-11	Bilirubin levels;
LGG	cis	rs8014204	0.804	rs2287403	chr14:75259140	C/T	cg06637938	chr14:75390232	RPS6KL1	0.76	15.24	0.58	8.43e-43	Caffeine consumption;
LGG	cis	rs10851411	0.688	rs62022314	chr15:42754649	T/C	cg21293051	chr15:42870591	STARD9	0.51	7.4	0.33	6.31e-13	Glucose homeostasis traits;
LGG	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg03806693	chr22:41940476	POLR3H	-0.98	-17.43	-0.63	1.14e-52	Vitiligo;
LGG	trans	rs11098499	0.644	rs3806808	chr4:120551085	A/C	cg25214090	chr10:38739885	LOC399744	0.58	10.43	0.44	5.18e-23	Corneal astigmatism;
LGG	cis	rs11967485	0.686	rs72996913	chr6:157135778	G/A	cg23222435	chr6:157204239	ARID1B	-0.78	-7.03	-0.31	7.31e-12	Calcium levels;
LGG	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.68	-0.3	6.88e-11	Crohn's disease;
LGG	cis	rs738322	0.967	rs2092180	chr22:38571563	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs7044106	0.762	rs1324473	chr9:123404610	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.67	-12.02	-0.49	3.83e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7503807	0.515	rs12948040	chr17:78678434	A/G	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg15352829	chr14:105391018	PLD4	-0.47	-11.37	-0.47	1.32e-26	Rheumatoid arthritis;
LGG	cis	rs3785574	0.962	rs2665835	chr17:61903258	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	trans	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.7	0.41	2.32e-20	Mean corpuscular volume;
LGG	cis	rs9487094	0.922	rs10872034	chr6:109807239	A/T	cg01125227	chr6:109776195	MICAL1	0.51	8.41	0.36	5.28e-16	Height;
LGG	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg09461388	chr22:46763229	CELSR1	-0.6	-6.77	-0.3	3.9e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.77	-0.34	5.17e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2273669	0.667	rs2145763	chr6:109306963	C/A	cg05315195	chr6:109294784	ARMC2	-0.67	-8.64	-0.37	9.38e-17	Prostate cancer;
LGG	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg22732515	chr19:44031385	ETHE1	0.54	9.41	0.4	2.33e-19	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs1997103	0.954	rs6593235	chr7:55410986	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.42	0.36	4.62e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7010267	0.935	rs11573824	chr8:119959925	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.43	0.44	5.18e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs17767392	0.781	rs8015644	chr14:71842729	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.79	-0.38	2.91e-17	Mitral valve prolapse;
LGG	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg19748678	chr4:122722346	EXOSC9	0.51	9.69	0.41	2.34e-20	Type 2 diabetes;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.07	-0.49	2.45e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg19875535	chr5:140030758	IK	-0.56	-11.52	-0.47	3.5e-27	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1816752	0.905	rs4769352	chr13:25000375	G/A	cg22771759	chr13:24902376	NA	0.42	7.09	0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.4	-0.44	6.37e-23	Initial pursuit acceleration;
LGG	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg20913747	chr6:44695427	NA	-0.61	-10.31	-0.43	1.42e-22	Total body bone mineral density (age over 60);Total body bone mineral density;
LGG	cis	rs67311347	1.000	rs6762997	chr3:40478151	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-21.27	-0.7	1.56e-70	Renal cell carcinoma;
LGG	cis	rs7107174	1.000	rs10793303	chr11:78060750	G/A	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs7659604	1.000	rs10016433	chr4:122664771	A/G	cg20573242	chr4:122745356	CCNA2	0.41	7.35	0.32	8.75e-13	Type 2 diabetes;
LGG	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.24	0.49	4.69e-30	Cognitive test performance;
LGG	cis	rs3771570	1.000	rs62190367	chr2:242376276	G/A	cg21155796	chr2:242212141	HDLBP	0.75	10.02	0.42	1.68e-21	Prostate cancer;
LGG	cis	rs2243480	1.000	rs160633	chr7:65528228	T/C	cg18252515	chr7:66147081	NA	-1.36	-18.47	-0.65	1.87e-57	Diabetic kidney disease;
LGG	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg14979609	chr8:8086686	FLJ10661	0.33	8.43	0.36	4.37e-16	Neuroticism;
LGG	cis	rs6831352	0.819	rs896992	chr4:100002372	C/T	cg13256891	chr4:100009986	ADH5	0.51	8.94	0.38	9.47e-18	Alcohol dependence;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	4.95e-12	Lung cancer;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.5	0.58	6.01e-44	Platelet count;
LGG	cis	rs12210905	0.688	rs12215289	chr6:27468705	T/C	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.08e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg05335186	chr13:53173507	NA	0.74	18.67	0.66	2.12e-58	Lewy body disease;
LGG	cis	rs472402	0.560	rs2303705	chr5:6622017	A/C	cg08700190	chr5:6636046	SRD5A1	-0.32	-6.95	-0.31	1.28e-11	Response to amphetamines;
LGG	cis	rs6988985	0.693	rs6395	chr8:143956808	A/C	cg10324643	chr8:143916377	GML	0.41	8.48	0.37	3.03e-16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2455799	0.593	rs13085352	chr3:15914845	T/C	cg16303742	chr3:15540471	COLQ	-0.39	-7.74	-0.34	6.29e-14	Mean platelet volume;
LGG	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-8.97	-0.38	7.67e-18	Morning vs. evening chronotype;
LGG	cis	rs2797160	0.967	rs2226158	chr6:125995467	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-7.58	-0.33	1.92e-13	Endometrial cancer;
LGG	cis	rs12704876	0.530	rs2177675	chr7:96342253	A/T	cg03808172	chr7:96339361	SHFM1	0.54	9.56	0.41	6.77e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1639906	0.560	rs1637730	chr7:2260928	T/C	cg08027265	chr7:2291960	NA	-0.55	-10.97	-0.45	4.91e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11683229	0.925	rs12993094	chr2:63475724	G/A	cg19915305	chr2:64069682	UGP2	-0.47	-7.12	-0.31	4.2e-12	Protein quantitative trait loci;
LGG	trans	rs7939886	0.920	rs11227372	chr11:55919682	C/A	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.5	-0.37	2.67e-16	Skin colour saturation;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg00864171	chr11:67383662	NA	0.56	9.62	0.41	4.41e-20	Mean corpuscular volume;
LGG	cis	rs5769765	0.908	rs7410601	chr22:50317187	C/T	cg02269571	chr22:50332266	NA	-0.65	-9.77	-0.41	1.31e-20	Schizophrenia;
LGG	cis	rs4319547	0.741	rs4758663	chr12:122939483	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.69	-0.41	2.47e-20	Body mass index;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg09823679	chr13:53425813	NA	0.41	6.78	0.3	3.65e-11	Prudent dietary pattern;
LGG	cis	rs868036	1.000	rs4776974	chr15:68095927	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg05623727	chr3:50126028	RBM5	0.33	7.14	0.31	3.72e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4073582	0.595	rs9326370	chr11:65992008	A/G	cg16950941	chr11:66035639	RAB1B	0.56	10.32	0.43	1.29e-22	Gout;
LGG	cis	rs1869026	1.000	rs1869026	chr2:121341281	G/T	cg03661458	chr2:121334411	NA	-0.31	-7.28	-0.32	1.44e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.27	0.52	2.64e-34	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.69	-0.44	5.51e-24	Lung cancer;
LGG	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.28	0.36	1.37e-15	Mood instability;
LGG	trans	rs61931739	0.649	rs1068864	chr12:33733119	A/C	cg13010199	chr12:38710504	ALG10B	0.36	6.67	0.3	7.36e-11	Morning vs. evening chronotype;
LGG	cis	rs7635838	0.617	rs346076	chr3:11292682	A/G	cg00170343	chr3:11313890	ATG7	-0.55	-9.58	-0.41	5.83e-20	HDL cholesterol;
LGG	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg14101638	chr12:121416612	HNF1A	0.44	9.8	0.41	9.78e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.14	-0.32	3.52e-12	Hemoglobin concentration;
LGG	cis	rs782590	0.837	rs782573	chr2:55912961	T/C	cg18811423	chr2:55921094	PNPT1	0.94	22.87	0.73	4.85e-78	Metabolic syndrome;
LGG	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.0	-0.39	5.84e-18	Bipolar disorder;
LGG	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg18188782	chr20:61659543	NA	0.42	6.89	0.3	1.83e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg23422044	chr7:1970798	MAD1L1	-0.67	-11.38	-0.47	1.26e-26	Bipolar disorder;
LGG	cis	rs992157	0.835	rs12987180	chr2:219144089	G/A	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.33e-26	Colorectal cancer;
LGG	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.48	0.4	1.35e-19	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg02631450	chr22:32366979	NA	0.99	9.63	0.41	3.91e-20	Childhood ear infection;
LGG	cis	rs8060686	0.545	rs8057119	chr16:68268836	C/T	cg27539214	chr16:67997921	SLC12A4	-0.45	-6.92	-0.31	1.52e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7928758	0.887	rs75373472	chr11:134264506	T/G	cg22777979	chr11:134283252	B3GAT1	1.02	12.74	0.51	4.37e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs17253792	0.822	rs8013714	chr14:56172286	T/C	cg01858014	chr14:56050164	KTN1	-0.89	-12.81	-0.51	2.18e-32	Putamen volume;
LGG	cis	rs36051895	0.659	rs57299248	chr9:5062932	C/G	cg02405213	chr9:5042618	JAK2	-0.82	-15.95	-0.6	5.7e-46	Pediatric autoimmune diseases;
LGG	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg04287289	chr16:89883240	FANCA	-0.53	-9.92	-0.42	3.82e-21	Vitiligo;
LGG	cis	rs367615	0.679	rs4259216	chr5:108841817	A/G	cg17395555	chr5:108820864	NA	0.87	15.86	0.59	1.53e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs41271473	1.000	rs4993975	chr1:228878669	A/C	cg16512390	chr1:228756714	NA	0.48	6.71	0.3	5.63e-11	Chronic lymphocytic leukemia;
LGG	cis	rs4678145	0.563	rs62265637	chr3:124496529	T/C	cg03021329	chr3:124554058	ITGB5	-0.62	-9.49	-0.4	1.24e-19	Coronary artery disease;
LGG	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.65	-0.3	8.05e-11	Myopia (pathological);
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg21775007	chr8:11205619	TDH	-0.44	-6.88	-0.3	1.96e-11	Neuroticism;
LGG	cis	rs59197085	0.636	rs60389668	chr7:128452556	T/G	cg00734629	chr7:128471146	FLNC	0.36	7.27	0.32	1.57e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	9.02	0.39	4.96e-18	Lung function (FEV1/FVC);
LGG	cis	rs12476592	0.571	rs6546005	chr2:63672071	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.96	-0.31	1.15e-11	Childhood ear infection;
LGG	trans	rs1814175	0.645	rs1851845	chr11:49982396	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg12395012	chr8:11607386	GATA4	0.38	6.87	0.3	2.02e-11	Neuroticism;
LGG	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.79	-0.38	2.91e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02650317	chr20:61808888	MIR124-3	0.43	6.78	0.3	3.59e-11	Gut microbiome composition (summer);
LGG	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg26850624	chr5:429559	AHRR	-0.38	-8.28	-0.36	1.33e-15	Cystic fibrosis severity;
LGG	cis	rs11718455	0.960	rs11920021	chr3:44000856	T/C	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.56e-11	Coronary artery disease;
LGG	cis	rs4423214	1.000	rs4944956	chr11:71167765	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.05	-0.52	2.27e-33	Vitamin D levels;
LGG	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.34	-0.4	4.02e-19	Common traits (Other);
LGG	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg22432760	chr17:80829718	TBCD	0.41	7.09	0.31	4.97e-12	Breast cancer;
LGG	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg24375607	chr4:120327624	NA	0.67	11.0	0.46	3.7e-25	Corneal astigmatism;
LGG	cis	rs7818345	1.000	rs4379462	chr8:19311496	T/G	cg01280390	chr8:19363452	CSGALNACT1	0.3	6.73	0.3	4.93e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23598886	chr18:12777645	NA	0.75	10.45	0.44	4.23e-23	Inflammatory skin disease;
LGG	cis	rs9581857	0.685	rs79699519	chr13:28023241	C/T	cg01674679	chr13:27998804	GTF3A	-0.63	-7.49	-0.33	3.41e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2694528	0.686	rs7729652	chr5:59872414	A/G	cg11474532	chr5:59995715	DEPDC1B	0.82	7.95	0.35	1.39e-14	Parkinson's disease;
LGG	cis	rs7727544	0.716	rs10058655	chr5:131570896	A/T	cg07395648	chr5:131743802	NA	-0.42	-8.92	-0.38	1.05e-17	Blood metabolite levels;
LGG	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg25319279	chr11:5960081	NA	-0.52	-8.3	-0.36	1.13e-15	DNA methylation (variation);
LGG	cis	rs7727544	0.513	rs10065787	chr5:131436486	G/T	cg07395648	chr5:131743802	NA	-0.39	-8.31	-0.36	1.08e-15	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs6540556	0.643	rs2282739	chr1:209883001	C/T	cg23920097	chr1:209922102	NA	-0.4	-7.18	-0.32	2.73e-12	Red blood cell count;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg12183522	chr12:57039070	ATP5B;SNORD59A	-0.4	-6.66	-0.3	7.91e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs988958	0.565	rs34629045	chr2:42237224	A/G	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs807669	1.000	rs807669	chr22:19154522	T/C	cg02655711	chr22:19163373	SLC25A1	0.78	16.13	0.6	8.73e-47	Metabolite levels;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.49	7.93	0.35	1.71e-14	Renal function-related traits (BUN);
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg17178900	chr1:205818956	PM20D1	0.58	12.81	0.51	2.37e-32	Menarche (age at onset);
LGG	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg04546413	chr19:29218101	NA	0.73	12.57	0.5	2.23e-31	Methadone dose in opioid dependence;
LGG	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	25.09	0.76	2.4e-88	Height;
LGG	cis	rs4481887	1.000	rs10888352	chr1:248451965	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.63	-0.41	3.89e-20	Common traits (Other);
LGG	cis	rs9543976	1.000	rs9565177	chr13:76195403	T/G	cg01531495	chr13:76123901	UCHL3	-0.64	-7.81	-0.34	3.81e-14	Diabetic retinopathy;
LGG	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg06951627	chr6:26196580	NA	0.51	7.82	0.34	3.53e-14	Gout;Renal underexcretion gout;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg06654118	chr4:1303317	MAEA	0.42	7.27	0.32	1.55e-12	Obesity-related traits;
LGG	cis	rs61008539	0.893	rs11765528	chr7:861952	C/T	cg22643751	chr7:855365	UNC84A	-0.55	-13.92	-0.54	5.02e-37	Perceived unattractiveness to mosquitoes;
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg07061783	chr6:25882402	NA	-0.48	-8.36	-0.36	7.35e-16	Blood metabolite levels;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg11814155	chr7:99998594	ZCWPW1	0.65	9.84	0.42	7.11e-21	Platelet count;
LGG	cis	rs61931739	0.635	rs1601627	chr12:33962420	G/A	cg06521331	chr12:34319734	NA	-0.4	-7.05	-0.31	6.5e-12	Morning vs. evening chronotype;
LGG	cis	rs3733585	0.753	rs12500805	chr4:10017979	C/T	cg08250081	chr4:10125330	NA	0.43	8.45	0.37	3.7e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1878931	0.535	rs7188903	chr16:3412861	A/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.7	11.11	0.46	1.34e-25	Body mass index (adult);
LGG	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.75	0.38	3.96e-17	Mean corpuscular hemoglobin;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg03188948	chr7:1209495	NA	0.43	7.79	0.34	4.56e-14	Longevity;Endometriosis;
LGG	cis	rs3785574	0.962	rs2665799	chr17:61919723	A/G	cg11494091	chr17:61959527	GH2	0.61	10.1	0.43	8.03e-22	Height;
LGG	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg06026331	chr20:60912101	LAMA5	-0.69	-12.19	-0.49	7.81e-30	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs939658	0.805	rs4778924	chr15:79443363	T/C	cg17916960	chr15:79447300	NA	-0.66	-12.79	-0.51	2.73e-32	Refractive error;
LGG	trans	rs2197308	0.655	rs1971964	chr12:37870474	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	1.01e-18	Morning vs. evening chronotype;
LGG	cis	rs4730250	0.707	rs80095766	chr7:106901394	G/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.46	-0.44	4.06e-23	Osteoarthritis;
LGG	cis	rs67460515	0.892	rs11929238	chr3:161045937	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.17e-20	Parkinson's disease;
LGG	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg26578617	chr4:90757533	SNCA	-0.35	-7.02	-0.31	7.82e-12	Dementia with Lewy bodies;
LGG	cis	rs12291225	0.546	rs11023199	chr11:14394258	A/G	cg19336497	chr11:14380999	RRAS2	-0.62	-12.89	-0.51	1.1e-32	Sense of smell;
LGG	cis	rs9894429	0.646	rs8080391	chr17:79566319	A/T	cg18240062	chr17:79603768	NPLOC4	-0.81	-15.07	-0.57	5.04e-42	Eye color traits;
LGG	cis	rs4901847	0.562	rs7142336	chr14:58612539	C/G	cg15908186	chr14:58618357	C14orf37	0.68	12.45	0.5	6.7e-31	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4253772	0.550	rs738444	chr22:46721088	C/T	cg24881330	chr22:46731750	TRMU	0.84	10.21	0.43	3.4e-22	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7255436	0.894	rs10413136	chr19:8452879	T/C	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.68	-0.3	6.78e-11	HDL cholesterol;
LGG	cis	rs2777491	1.000	rs7167729	chr15:41721042	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.09	-0.68	4.87e-65	Ulcerative colitis;
LGG	cis	rs34734847	1.000	rs56179458	chr12:121157535	G/A	cg21892295	chr12:121157589	UNC119B	-0.47	-8.96	-0.38	8.23e-18	Mean corpuscular volume;
LGG	trans	rs853679	0.607	rs35072899	chr6:28281541	C/T	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.4	0.56	4.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12826209	chr6:26865740	GUSBL1	0.62	9.47	0.4	1.41e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	0.550	rs1163633	chr13:112231561	G/T	cg14154082	chr13:112174009	NA	-0.38	-8.3	-0.36	1.17e-15	Menarche (age at onset);
LGG	cis	rs4664308	0.692	rs10497213	chr2:160963603	G/A	cg03641300	chr2:160917029	PLA2R1	-0.7	-13.35	-0.53	1.28e-34	Idiopathic membranous nephropathy;
LGG	cis	rs2204008	0.692	rs11613378	chr12:38213138	T/A	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs9952991	0.943	rs9952753	chr18:12780463	A/C	cg23544223	chr18:12777786	NA	0.62	9.4	0.4	2.49e-19	Inflammatory skin disease;
LGG	cis	rs745821	0.783	rs61148001	chr18:48133241	C/T	cg18923635	chr18:48083994	NA	0.51	8.38	0.36	6.27e-16	Diastolic blood pressure;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.31	-0.4	5.26e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs17253792	0.822	rs77415412	chr14:56154146	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs774359	0.797	rs7864595	chr9:27495572	C/A	cg14173147	chr9:27528300	MOBKL2B	-0.41	-8.61	-0.37	1.12e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs7618915	0.621	rs6788993	chr3:52605136	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.69	0.3	6.32e-11	Bipolar disorder;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07362569	chr17:61921086	SMARCD2	0.49	9.33	0.4	4.36e-19	Prudent dietary pattern;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.48	7.12	0.31	4.14e-12	Renal function-related traits (BUN);
LGG	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg01028140	chr2:1542097	TPO	-0.43	-8.16	-0.35	3.24e-15	IgG glycosylation;
LGG	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg01529538	chr14:23388837	RBM23	0.36	6.7	0.3	5.96e-11	Cognitive ability (multi-trait analysis);
LGG	trans	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-7.6	-0.33	1.68e-13	Schizophrenia;
LGG	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg27490568	chr2:178487706	NA	0.74	13.92	0.54	4.71e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07318088	chr6:90539243	CASP8AP2	-0.51	-7.59	-0.33	1.8e-13	Systemic lupus erythematosus;
LGG	cis	rs7666738	0.830	rs34870112	chr4:99045815	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.83	0.54	1.18e-36	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.59	-0.44	1.28e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg10587741	chr22:38071170	LGALS1	0.6	13.78	0.54	1.92e-36	Fat distribution (HIV);
LGG	cis	rs2380220	0.541	rs9285413	chr6:96023439	G/A	cg23517279	chr6:96025343	MANEA	0.52	6.67	0.3	7.49e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs3768617	0.510	rs3818417	chr1:183079376	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.57	0.41	6.4e-20	Fuchs's corneal dystrophy;
LGG	cis	rs9951602	0.512	rs4799245	chr18:76653397	T/C	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs6840360	0.642	rs2709816	chr4:152380269	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs6519955	0.860	rs8136098	chr22:46425646	A/G	cg00209037	chr22:46443395	NA	-0.23	-6.71	-0.3	5.73e-11	Dupuytren's disease;
LGG	cis	rs763121	0.853	rs5757193	chr22:39034867	A/G	cg06022373	chr22:39101656	GTPBP1	-0.86	-17.23	-0.63	9.34e-52	Menopause (age at onset);
LGG	cis	rs2795502	1.000	rs2185717	chr10:43343875	G/A	cg27426351	chr10:43362370	NA	0.54	7.72	0.34	7.49e-14	Blood protein levels;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	18.52	0.65	1.04e-57	Platelet count;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg11050988	chr7:1952600	MAD1L1	-0.4	-9.79	-0.41	1.11e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg14893161	chr1:205819251	PM20D1	-0.44	-7.47	-0.33	3.89e-13	Menarche (age at onset);
LGG	trans	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25373794	chr1:162760220	HSD17B7	0.44	7.12	0.31	4.09e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg08344181	chr3:125677491	NA	-0.8	-8.05	-0.35	7.11e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.13	0.35	4.09e-15	Triglycerides;
LGG	cis	rs10197940	0.578	rs2432946	chr2:152306897	G/T	cg19508488	chr2:152266495	RIF1	-0.48	-8.64	-0.37	8.95e-17	Lung cancer;
LGG	cis	rs4474465	0.646	rs6592794	chr11:78275743	A/G	cg27205649	chr11:78285834	NARS2	0.6	11.1	0.46	1.52e-25	Alzheimer's disease (survival time);
LGG	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg19145607	chr3:45983792	CXCR6;FYCO1	-0.31	-6.65	-0.3	8.15e-11	Eotaxin levels;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.19	0.49	8.08e-30	Prudent dietary pattern;
LGG	cis	rs2354432	0.556	rs1932979	chr1:146708912	A/G	cg25205988	chr1:146714368	CHD1L	-1.42	-13.9	-0.54	5.82e-37	Mitochondrial DNA levels;
LGG	cis	rs6088580	0.609	rs2378205	chr20:33110803	C/G	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	8.09	0.35	5.15e-15	Mood instability;
LGG	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg03315344	chr16:75512273	CHST6	0.54	10.77	0.45	2.83e-24	Dupuytren's disease;
LGG	cis	rs972578	1.000	rs738378	chr22:43398962	A/G	cg01576275	chr22:43409880	NA	0.24	6.93	0.31	1.42e-11	Mean platelet volume;
LGG	cis	rs607541	1.000	rs607541	chr15:45934869	C/A	cg26924012	chr15:45694286	SPATA5L1	0.54	7.6	0.33	1.68e-13	Obesity-related traits;
LGG	cis	rs1386478	0.711	rs7620955	chr3:113809350	A/C	cg14431476	chr3:113822413	NA	0.48	7.35	0.32	8.75e-13	Crohn's disease and psoriasis;
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg27476859	chr7:2772710	GNA12	0.47	8.91	0.38	1.14e-17	Height;
LGG	cis	rs4356203	0.870	rs10832745	chr11:17249675	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg11366901	chr6:160182831	ACAT2	0.88	14.2	0.55	3.04e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2243480	1.000	rs316312	chr7:65596491	T/G	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.66	-0.61	3.53e-49	Total body bone mineral density;
LGG	trans	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg12045294	chr17:78518616	RPTOR	-0.44	-6.94	-0.31	1.36e-11	Glycated hemoglobin levels;
LGG	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-25.82	-0.77	9.92e-92	Monocyte count;
LGG	trans	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.56	-0.41	7.06e-20	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.41	0.4	2.39e-19	Longevity;
LGG	cis	rs1978968	0.912	rs34156568	chr22:18444261	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs17685	0.671	rs10274404	chr7:75706634	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	25.9	0.77	4.42e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg09359103	chr1:154839909	KCNN3	-0.48	-9.52	-0.4	9.73e-20	Prostate cancer;
LGG	cis	rs10752881	1.000	rs12028740	chr1:182985581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	1.99e-12	Calcium levels;
LGG	cis	rs3096299	0.838	rs3096319	chr16:89402634	C/G	cg06640241	chr16:89574553	SPG7	0.59	9.97	0.42	2.54e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg26174226	chr8:58114915	NA	-0.56	-7.3	-0.32	1.27e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3771570	1.000	rs12619369	chr2:242282957	A/T	cg21155796	chr2:242212141	HDLBP	0.63	8.46	0.37	3.5e-16	Prostate cancer;
LGG	cis	rs736408	0.521	rs13074853	chr3:52779801	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.97e-26	Bipolar disorder;
LGG	cis	rs11239187	0.523	rs12416250	chr10:45078111	A/G	cg03916630	chr10:45065415	NA	-0.4	-7.46	-0.33	4.4e-13	Body mass index;
LGG	cis	rs4718428	1.000	rs12534637	chr7:66327654	G/C	cg12165864	chr7:66369176	NA	-0.46	-7.81	-0.34	3.88e-14	Corneal structure;
LGG	cis	rs9487094	0.689	rs11251	chr6:109689907	G/T	cg01125227	chr6:109776195	MICAL1	0.43	7.77	0.34	5.2e-14	Height;
LGG	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs3942852	1.000	rs3942852	chr11:48115089	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-8.61	-0.37	1.15e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.81	0.57	6.48e-41	Cognitive test performance;
LGG	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18876405	chr7:65276391	NA	0.6	10.99	0.45	4.02e-25	Aortic root size;
LGG	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.16	-0.43	4.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1461503	1.000	rs1461503	chr11:122845075	A/C	cg27398637	chr11:122830231	C11orf63	-0.66	-13.41	-0.53	7.24e-35	Menarche (age at onset);
LGG	cis	rs4704187	0.687	rs4447960	chr5:74361857	C/A	cg03227963	chr5:74354835	NA	0.31	6.69	0.3	6.62e-11	Response to amphetamines;
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.1	-0.31	4.65e-12	Bipolar disorder;
LGG	trans	rs11775334	0.599	rs11774836	chr8:10062543	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.13	-0.31	3.8e-12	Hypertension;
LGG	cis	rs2415984	0.562	rs61991051	chr14:46904538	C/A	cg14871534	chr14:47121158	RPL10L	0.45	7.38	0.32	7.34e-13	Number of children ever born;
LGG	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg09307838	chr4:120376055	NA	0.48	7.87	0.34	2.58e-14	Diastolic blood pressure;
LGG	cis	rs61931739	0.500	rs10772154	chr12:34373271	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.94	-0.42	3.03e-21	Morning vs. evening chronotype;
LGG	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg06766960	chr11:133703094	NA	-0.53	-10.59	-0.44	1.31e-23	Childhood ear infection;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs344364	0.577	rs2745194	chr16:1854038	C/T	cg26897989	chr16:1907736	C16orf73	0.51	9.46	0.4	1.52e-19	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11583043	1.000	rs11584222	chr1:101480110	G/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.07	0.35	6.03e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs3825932	1.000	rs3825932	chr15:79235446	A/G	cg25744700	chr15:79237217	CTSH	0.35	6.78	0.3	3.67e-11	Type 1 diabetes;
LGG	cis	rs7312774	0.618	rs4964503	chr12:107335937	C/G	cg16260113	chr12:107380972	MTERFD3	-0.89	-8.08	-0.35	5.7e-15	Severe influenza A (H1N1) infection;
LGG	cis	rs11711311	1.000	rs9828449	chr3:113518602	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.17	0.55	4.02e-38	IgG glycosylation;
LGG	cis	rs5758659	0.819	rs134871	chr22:42652716	A/G	cg15128208	chr22:42549153	NA	-0.49	-9.73	-0.41	1.73e-20	Cognitive function;
LGG	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg02466173	chr16:30829666	NA	0.44	8.04	0.35	7.51e-15	Dementia with Lewy bodies;
LGG	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.03	0.52	2.68e-33	Colorectal cancer;
LGG	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg08344181	chr3:125677491	NA	-0.66	-7.79	-0.34	4.59e-14	Depression;
LGG	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg16701003	chr16:89028210	CBFA2T3	0.66	10.8	0.45	2.07e-24	Social autistic-like traits;
LGG	cis	rs2594989	1.000	rs2594978	chr3:11383347	C/A	cg01796438	chr3:11312864	ATG7	-0.57	-7.66	-0.34	1.13e-13	Circulating chemerin levels;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs3743347	chr15:67547301	C/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.77	-0.3	3.87e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12802200	0.561	rs7937217	chr11:571967	T/C	cg16486109	chr11:613632	IRF7	0.41	7.47	0.33	4.15e-13	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg06481639	chr22:41940642	POLR3H	0.48	6.86	0.3	2.21e-11	Vitiligo;
LGG	cis	rs2247341	0.894	rs61675353	chr4:1720794	T/G	cg08629884	chr4:1719983	TMEM129	-0.57	-11.14	-0.46	1.09e-25	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.26	-0.43	2.18e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.46e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2421770	0.561	rs11033081	chr11:35363885	C/G	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.45	-0.33	4.54e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg00717180	chr2:96193071	NA	-0.39	-7.07	-0.31	5.84e-12	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs10019856	chr4:17615742	T/A	cg18681998	chr4:17616180	MED28	0.88	19.6	0.67	9.89e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2251381	0.778	rs2245021	chr21:30546841	C/T	cg24692254	chr21:30365293	RNF160	0.83	17.08	0.62	4.32e-51	Selective IgA deficiency;
LGG	cis	rs6977660	1.000	rs7812001	chr7:19803323	A/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-8.27	-0.36	1.43e-15	Thyroid stimulating hormone;
LGG	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg26783146	chr16:4423632	VASN;CORO7	-0.41	-7.55	-0.33	2.35e-13	Schizophrenia;
LGG	cis	rs7717393	0.786	rs10059872	chr5:155779927	G/T	cg12904904	chr5:155754151	SGCD	0.65	7.42	0.33	5.65e-13	Egg allergy;
LGG	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg25817165	chr18:72167213	CNDP2	-0.64	-12.86	-0.51	1.48e-32	Refractive error;
LGG	cis	rs5769707	0.967	rs739248	chr22:50025205	T/C	cg20744362	chr22:50050164	C22orf34	0.4	7.83	0.34	3.25e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4780401	0.609	rs11639945	chr16:11824056	T/G	cg01061890	chr16:11836724	TXNDC11	-0.7	-12.81	-0.51	2.21e-32	Rheumatoid arthritis;
LGG	cis	rs7226408	0.600	rs2654544	chr18:34659837	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.18	-0.39	1.4e-18	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs2159644	chr3:52774530	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.85	-0.3	2.42e-11	Bipolar disorder;
LGG	cis	rs2688608	0.592	rs10762563	chr10:75524802	C/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.09	-0.31	5.02e-12	Inflammatory bowel disease;
LGG	cis	rs2070677	1.000	rs2515641	chr10:135351362	T/C	cg20169779	chr10:135381914	SYCE1	0.96	12.77	0.51	3.32e-32	Gout;
LGG	cis	rs5750830	0.594	rs5757650	chr22:39778419	A/G	cg11247378	chr22:39784982	NA	-0.3	-8.74	-0.38	4.19e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2188554	0.785	rs213938	chr7:117164439	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	6.72	0.3	5.28e-11	Esophageal adenocarcinoma;
LGG	cis	rs1552244	0.572	rs58223482	chr3:10169746	G/C	cg00149659	chr3:10157352	C3orf10	1.19	14.13	0.55	6.27e-38	Alzheimer's disease;
LGG	cis	rs8141529	0.702	rs469992	chr22:29314899	T/C	cg02153584	chr22:29168773	CCDC117	-0.58	-9.18	-0.39	1.44e-18	Lymphocyte counts;
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	12.93	0.52	6.93e-33	Tonsillectomy;
LGG	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-9.69	-0.41	2.35e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.18	0.32	2.76e-12	Retinal vascular caliber;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg12016809	chr21:47604291	C21orf56	0.53	9.21	0.39	1.12e-18	Testicular germ cell tumor;
LGG	cis	rs1728785	1.000	rs698716	chr16:68560296	C/T	cg02972257	chr16:68554789	NA	-0.56	-8.34	-0.36	8.78e-16	Ulcerative colitis;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7828089	0.935	rs4872485	chr8:22255990	G/T	cg12081754	chr8:22256438	SLC39A14	0.72	14.21	0.55	2.67e-38	Verbal declarative memory;
LGG	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.64	0.82	1.91e-113	Cognitive function;
LGG	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg10596483	chr8:143751796	JRK	0.58	9.43	0.4	1.98e-19	Schizophrenia;
LGG	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.38	0.36	6.33e-16	Type 2 diabetes;
LGG	cis	rs60180747	1.000	rs11637556	chr15:66728951	A/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	11.01	0.46	3.44e-25	Testicular germ cell tumor;
LGG	cis	rs8064024	0.560	rs741769	chr16:4936205	G/T	cg08329684	chr16:4932620	PPL	0.44	8.94	0.38	9.45e-18	Cancer;
LGG	cis	rs3857747	0.931	rs11772072	chr7:40386344	G/A	cg00420559	chr7:40367873	C7orf10	-0.41	-8.34	-0.36	8.7e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7824557	0.547	rs4512344	chr8:11078781	A/C	cg24623649	chr8:11872141	NA	-0.29	-6.85	-0.3	2.41e-11	Retinal vascular caliber;
LGG	cis	rs7554547	0.667	rs4846072	chr1:11950391	T/C	cg07603449	chr1:11986842	KIAA2013	-0.31	-8.23	-0.36	1.91e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2274273	0.870	rs8021583	chr14:55749607	G/A	cg04306507	chr14:55594613	LGALS3	0.62	17.01	0.62	9.08e-51	Protein biomarker;
LGG	cis	rs977987	0.750	rs4888414	chr16:75447233	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs3820928	0.874	rs13393902	chr2:227880554	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.65	-0.34	1.16e-13	Pulmonary function;
LGG	cis	rs1497406	0.744	rs4661718	chr1:16505908	C/T	cg20430773	chr1:16534157	ARHGEF19	0.3	8.41	0.36	5.27e-16	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.74	-0.3	4.59e-11	Body mass index;
LGG	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg01657329	chr11:68192670	LRP5	-0.58	-10.76	-0.45	2.9e-24	Bone mineral density (spine);
LGG	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg18105134	chr13:113819100	PROZ	-0.69	-14.15	-0.55	5.16e-38	Platelet distribution width;
LGG	cis	rs2153535	0.580	rs7745043	chr6:8513507	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs2153535	0.580	rs9392220	chr6:8457946	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs58649573	0.552	rs1042486	chr9:126783433	G/C	cg14112217	chr9:126806003	NA	0.38	7.51	0.33	3.12e-13	Post-traumatic stress disorder;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg16270222	chr17:41446396	NA	-0.3	-7.21	-0.32	2.29e-12	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20786221	chr7:65215780	CCT6P1	0.48	7.11	0.31	4.45e-12	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg05091796	chr16:4465799	CORO7	0.71	11.45	0.47	6.76e-27	Schizophrenia;
LGG	cis	rs35740288	0.770	rs11635587	chr15:86173633	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.46	0.37	3.44e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg06521331	chr12:34319734	NA	0.4	6.84	0.3	2.58e-11	Morning vs. evening chronotype;
LGG	cis	rs6669919	0.565	rs10863911	chr1:211686860	C/T	cg10512769	chr1:211675356	NA	-0.58	-10.99	-0.45	4.11e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs7044106	0.791	rs10985001	chr9:123484232	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	17.3	0.63	4.6e-52	Hip circumference adjusted for BMI;
LGG	cis	rs3862435	0.518	rs2601169	chr15:90913890	T/C	cg22089800	chr15:90895588	ZNF774	0.55	7.02	0.31	7.89e-12	Response to exercise (triglyceride level interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02759489	chr4:55098483	PDGFRA	0.43	7.03	0.31	7.6e-12	Cognitive performance;
LGG	cis	rs9790314	0.730	rs4856705	chr3:161100219	T/G	cg03342759	chr3:160939853	NMD3	-0.53	-9.22	-0.39	1.08e-18	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.67	0.34	1.01e-13	Rheumatoid arthritis;
LGG	cis	rs10078	0.515	rs890984	chr5:479540	A/G	cg24955955	chr5:415729	AHRR	0.81	10.77	0.45	2.83e-24	Fat distribution (HIV);
LGG	cis	rs1014246	0.807	rs12771069	chr10:118471676	A/G	cg14919929	chr10:118506882	NA	0.62	11.66	0.48	9.75e-28	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs3219090	0.586	rs12567614	chr1:226544420	T/C	cg17127702	chr1:226594323	PARP1	-0.31	-9.74	-0.41	1.67e-20	Melanoma;
LGG	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-11.04	-0.46	2.56e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.3	0.58	4.47e-43	Platelet count;
LGG	cis	rs1395	0.710	rs11682913	chr2:27473649	G/A	cg23587288	chr2:27483067	SLC30A3	-0.33	-7.41	-0.33	5.97e-13	Blood metabolite levels;
LGG	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg18876405	chr7:65276391	NA	0.59	10.78	0.45	2.41e-24	Aortic root size;
LGG	cis	rs9915657	0.840	rs10512582	chr17:70139393	A/C	cg09344028	chr17:70110421	NA	0.45	9.81	0.41	9.43e-21	Thyroid hormone levels;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.89	11.09	0.46	1.7e-25	Lung cancer in ever smokers;
LGG	cis	rs981844	0.740	rs6858578	chr4:154682058	G/T	cg14289246	chr4:154710475	SFRP2	-0.6	-10.7	-0.45	5.2e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs11250464	0.517	rs2387667	chr10:1430761	T/C	cg08668359	chr10:1443807	ADARB2	0.49	9.1	0.39	2.78e-18	Radiation response;
LGG	cis	rs7937682	0.889	rs567859	chr11:111486738	A/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs6882046	0.513	rs676096	chr5:88035887	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-8.42	-0.36	4.89e-16	Prudent dietary pattern;
LGG	trans	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg25214090	chr10:38739885	LOC399744	-0.63	-11.58	-0.47	2.09e-27	Corneal astigmatism;
LGG	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg09021430	chr5:549028	NA	-0.63	-9.3	-0.4	5.61e-19	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs4821013	chr22:32388224	A/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.4	-0.4	2.61e-19	Life satisfaction;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg06916706	chr16:4465613	CORO7	0.71	12.34	0.5	1.9e-30	Schizophrenia;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-8.24	-0.36	1.83e-15	Renal function-related traits (BUN);
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg11764359	chr7:65958608	NA	-0.73	-13.14	-0.52	9.61e-34	Aortic root size;
LGG	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg06115741	chr20:33292138	TP53INP2	0.5	8.36	0.36	7.67e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg22535103	chr8:58192502	C8orf71	0.74	10.27	0.43	2.02e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs2018683	0.691	rs4722881	chr7:29001560	A/G	cg19402173	chr7:128379420	CALU	0.52	8.77	0.38	3.4e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs1419980	0.556	rs11054516	chr12:7724875	C/T	cg25828445	chr12:7781288	NA	-0.62	-8.14	-0.35	3.71e-15	HDL cholesterol levels;
LGG	cis	rs6547631	0.836	rs4832180	chr2:85911629	A/G	cg24620635	chr2:85921963	GNLY	0.36	6.8	0.3	3.19e-11	Blood protein levels;
LGG	cis	rs765787	0.530	rs4775836	chr15:45537664	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs2978263	0.657	rs17538182	chr8:30311662	G/A	cg05780722	chr8:30327988	RBPMS	-0.33	-6.65	-0.3	8.09e-11	Cognitive performance;
LGG	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.71	0.3	5.81e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7084402	1.000	rs1427202	chr10:60267917	A/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.21	-0.62	1.18e-51	Refractive error;
LGG	cis	rs62064224	0.714	rs8074594	chr17:30632998	G/A	cg18200150	chr17:30822561	MYO1D	0.52	9.98	0.42	2.28e-21	Schizophrenia;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg26203845	chr14:105293866	NA	0.42	6.68	0.3	6.7e-11	IgG glycosylation;
LGG	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-6.8	-0.3	3.32e-11	Cognitive function;
LGG	cis	rs3126085	1.000	rs1858482	chr1:152306921	A/G	cg26876637	chr1:152193138	HRNR	0.51	7.91	0.35	1.91e-14	Atopic dermatitis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08327705	chr5:6756273	POLS	0.37	6.77	0.3	3.92e-11	Menarche (age at onset);
LGG	cis	rs861020	0.959	rs658860	chr1:209990549	C/T	cg05527609	chr1:210001259	C1orf107	0.73	10.1	0.43	8e-22	Orofacial clefts;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg00376283	chr12:123451042	ABCB9	-0.6	-9.13	-0.39	2.07e-18	Neutrophil percentage of white cells;
LGG	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.55	10.08	0.42	9.73e-22	Multiple sclerosis;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.45	0.33	4.5e-13	Lung cancer;
LGG	cis	rs56283067	0.847	rs56172130	chr6:44696262	G/A	cg18551225	chr6:44695536	NA	-0.72	-12.73	-0.51	4.66e-32	Total body bone mineral density;
LGG	cis	rs4481887	0.927	rs10157089	chr1:248488157	A/G	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs2797369	0.824	rs1775642	chr6:101616270	G/T	cg27451362	chr6:101846650	GRIK2	-0.77	-10.33	-0.43	1.15e-22	Renal function-related traits (eGRFcrea);
LGG	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	4.81e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg21548813	chr6:291882	DUSP22	-0.75	-13.41	-0.53	7.05e-35	Menopause (age at onset);
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03264133	chr6:25882463	NA	-0.7	-13.12	-0.52	1.14e-33	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg10189774	chr4:17578691	LAP3	0.4	7.27	0.32	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	trans	rs61931739	0.635	rs1486884	chr12:33908876	A/T	cg26384229	chr12:38710491	ALG10B	-0.6	-11.12	-0.46	1.27e-25	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg03188948	chr7:1209495	NA	0.65	8.19	0.36	2.63e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7647973	0.961	rs4955417	chr3:49298205	T/C	cg06212747	chr3:49208901	KLHDC8B	0.53	8.3	0.36	1.11e-15	Menarche (age at onset);
LGG	cis	rs8180040	0.647	rs57756484	chr3:47239333	A/G	cg27129171	chr3:47204927	SETD2	-0.81	-14.81	-0.57	6.69e-41	Colorectal cancer;
LGG	cis	rs4493873	0.869	rs7815938	chr8:92109673	A/T	cg16814680	chr8:91681699	NA	0.44	6.85	0.3	2.37e-11	Migraine - clinic-based;
LGG	cis	rs12618769	0.597	rs3754893	chr2:99063149	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.65	0.37	8.56e-17	Bipolar disorder;
LGG	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.81	0.3	3.03e-11	Homoarginine levels;
LGG	cis	rs1153858	1.000	rs1049503	chr15:45653707	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg20578329	chr17:80767326	TBCD	-0.77	-11.11	-0.46	1.4e-25	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.14	-0.35	3.77e-15	Total body bone mineral density;
LGG	cis	rs2115630	0.645	rs6496284	chr15:85178270	A/G	cg24253500	chr15:84953950	NA	-0.41	-7.58	-0.33	1.86e-13	P wave terminal force;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.04	0.31	6.95e-12	Lung cancer;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg04863758	chr4:1303710	MAEA	0.42	7.25	0.32	1.81e-12	Obesity-related traits;
LGG	cis	rs56283067	0.847	rs12204270	chr6:44697502	A/T	cg18551225	chr6:44695536	NA	-0.72	-12.78	-0.51	2.98e-32	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg24829409	chr8:58192753	C8orf71	-0.75	-10.51	-0.44	2.63e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4843185	0.763	rs1974868	chr16:85710983	C/T	cg26571870	chr16:85723150	GINS2	-0.4	-7.32	-0.32	1.12e-12	Platelet distribution width;
LGG	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg26031613	chr14:104095156	KLC1	-0.59	-9.33	-0.4	4.28e-19	Reticulocyte count;
LGG	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.51	-9.31	-0.4	5.16e-19	Rheumatoid arthritis;
LGG	cis	rs151997	0.925	rs26090	chr5:50170071	C/T	cg06027927	chr5:50259733	NA	-0.66	-10.89	-0.45	9.7e-25	Callous-unemotional behaviour;
LGG	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg13647721	chr17:30228624	UTP6	-0.76	-9.87	-0.42	5.36e-21	Hip circumference adjusted for BMI;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.52	-0.67	2.31e-62	Rheumatoid arthritis;
LGG	cis	rs933688	1.000	rs6865495	chr5:90746424	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	19.71	0.68	2.91e-63	Smoking behavior;
LGG	cis	rs2153535	0.580	rs1932279	chr6:8473653	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg07777115	chr5:623756	CEP72	-0.5	-6.69	-0.3	6.33e-11	Obesity-related traits;
LGG	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.72	0.45	4.24e-24	Lung cancer in ever smokers;
LGG	cis	rs4975709	0.959	rs9312959	chr5:1877008	G/A	cg15595755	chr5:1867978	NA	0.5	8.67	0.37	7.29e-17	Cardiovascular disease risk factors;
LGG	trans	rs2727020	0.553	rs61904166	chr11:49581461	T/C	cg03929089	chr4:120376271	NA	-0.97	-20.49	-0.69	6.99e-67	Coronary artery disease;
LGG	cis	rs8077889	0.672	rs1234612	chr17:41840802	A/G	cg26893861	chr17:41843967	DUSP3	1.05	24.15	0.75	5.19e-84	Triglycerides;
LGG	cis	rs4595586	0.525	rs7972595	chr12:39338000	G/A	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.11e-16	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15596359	chr8:11213517	TDH	0.42	8.78	0.38	3.29e-17	Retinal vascular caliber;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.97	-21.81	-0.71	4.34e-73	Prudent dietary pattern;
LGG	trans	rs75804782	0.641	rs72983861	chr2:239326126	G/A	cg01134436	chr17:81009848	B3GNTL1	0.86	8.97	0.38	7.26e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06713297	chr1:242011104	EXO1	0.48	8.14	0.35	3.57e-15	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs12927205	0.510	rs7185601	chr16:72035082	A/G	cg06353428	chr16:71660113	MARVELD3	0.84	8.15	0.35	3.54e-15	Cholesterol, total;LDL cholesterol;
LGG	cis	rs7208859	0.673	rs9915139	chr17:29158515	A/G	cg13385521	chr17:29058706	SUZ12P	0.8	9.22	0.39	1.07e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17253792	0.545	rs12894368	chr14:56025178	C/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.56	-0.41	7.14e-20	Putamen volume;
LGG	cis	rs9487094	0.670	rs11755641	chr6:109907936	A/T	cg16315928	chr6:109776240	MICAL1	0.46	7.98	0.35	1.19e-14	Height;
LGG	cis	rs7394190	0.748	rs2075641	chr10:75562108	G/A	cg07699608	chr10:75541558	CHCHD1	0.57	7.62	0.33	1.4e-13	Incident atrial fibrillation;
LGG	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg23609528	chr2:113191194	RGPD5;RGPD8	0.58	6.94	0.31	1.29e-11	Yeast infection;
LGG	cis	rs7208859	0.673	rs73277986	chr17:29196197	C/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg23625390	chr15:77176239	SCAPER	-0.71	-13.86	-0.54	8.42e-37	Blood metabolite levels;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg23202291	chr11:1979235	NA	0.4	7.55	0.33	2.3e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.25e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs7939886	0.920	rs7107736	chr11:55987980	C/G	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs7572733	0.534	rs700667	chr2:198677508	T/C	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Dermatomyositis;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.32	0.47	2.06e-26	Colorectal cancer;
LGG	cis	rs6728642	0.519	rs7589232	chr2:97566148	C/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-8.33	-0.36	9.41e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs4788570	0.566	rs61171207	chr16:71504798	C/T	cg06353428	chr16:71660113	MARVELD3	-0.85	-11.79	-0.48	3.01e-28	Intelligence (multi-trait analysis);
LGG	cis	rs8005677	0.798	rs4536383	chr14:23410926	T/C	cg25600027	chr14:23388339	RBM23	-0.42	-7.15	-0.32	3.34e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg20578329	chr17:80767326	TBCD	-0.8	-12.14	-0.49	1.26e-29	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg00717180	chr2:96193071	NA	0.43	7.61	0.33	1.51e-13	HDL cholesterol;
LGG	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg06026331	chr20:60912101	LAMA5	0.36	6.79	0.3	3.44e-11	Colorectal cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04305134	chr10:75173374	ANXA7	-0.48	-7.24	-0.32	1.9e-12	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.91	0.42	3.91e-21	Height;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.42	7.35	0.32	8.95e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg03477792	chr4:77819574	ANKRD56	0.53	9.23	0.39	9.47e-19	Emphysema distribution in smoking;
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg14403583	chr14:105418241	AHNAK2	-0.8	-16.65	-0.61	4.01e-49	Rheumatoid arthritis;
LGG	trans	rs1728785	1.000	rs1099296	chr16:68588653	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs17767392	0.595	rs8005615	chr14:71661187	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.04	-0.31	6.85e-12	Mitral valve prolapse;
LGG	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg18681998	chr4:17616180	MED28	0.82	18.08	0.64	1.18e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.23	-0.49	5.47e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs3099143	1.000	rs4243043	chr15:77178540	A/G	cg21673338	chr15:77095150	SCAPER	0.65	10.46	0.44	4.02e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg00405596	chr8:11794950	NA	0.39	6.65	0.3	8.31e-11	Neuroticism;
LGG	cis	rs12188164	0.965	rs11739543	chr5:443676	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.69	0.34	8.93e-14	Cystic fibrosis severity;
LGG	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	18.88	0.66	2.32e-59	Smoking behavior;
LGG	cis	rs3820068	0.580	rs12082523	chr1:16005792	A/G	cg05660106	chr1:15850417	CASP9	-0.7	-13.82	-0.54	1.33e-36	Systolic blood pressure;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.65	-0.33	1.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.35e-18	Blood metabolite levels;
LGG	cis	rs7166081	1.000	rs35997299	chr15:67507590	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.45	-0.33	4.69e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg08677398	chr8:58056175	NA	-0.56	-9.14	-0.39	1.98e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.893	rs6702113	chr1:248486151	T/C	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs10865541	1.000	rs11692425	chr2:3395383	A/G	cg13173536	chr2:3403300	TTC15	-0.34	-7.04	-0.31	7.11e-12	Obesity-related traits;
LGG	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg12395012	chr8:11607386	GATA4	0.42	7.58	0.33	1.87e-13	Monocyte count;
LGG	cis	rs62238980	0.614	rs77661816	chr22:32565772	A/G	cg02631450	chr22:32366979	NA	0.8	8.42	0.36	4.64e-16	Childhood ear infection;
LGG	cis	rs11608355	0.538	rs7305165	chr12:109804222	G/A	cg19025524	chr12:109796872	NA	-0.59	-12.78	-0.51	2.9e-32	Neuroticism;
LGG	cis	rs2708977	0.698	rs772159	chr2:97036439	G/A	cg01950434	chr2:97203154	ARID5A	-0.49	-7.51	-0.33	3.16e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg26003909	chr8:143102224	NA	-0.4	-8.78	-0.38	3.18e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg20848291	chr7:100343083	ZAN	-0.6	-8.48	-0.37	3.14e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs72945132	0.714	rs57320340	chr11:70160010	G/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs9472414	0.680	rs9472331	chr6:44699354	C/G	cg20913747	chr6:44695427	NA	0.48	7.3	0.32	1.29e-12	Height;
LGG	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg15557168	chr22:42548783	NA	-0.46	-10.2	-0.43	3.43e-22	Schizophrenia;
LGG	cis	rs67311347	0.524	rs11129869	chr3:40259738	G/A	cg13683864	chr3:40499215	RPL14	-0.78	-14.84	-0.57	5.03e-41	Renal cell carcinoma;
LGG	cis	rs9398803	0.835	rs9321065	chr6:126744087	G/A	cg19875578	chr6:126661172	C6orf173	0.58	10.47	0.44	3.66e-23	Male-pattern baldness;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs9467773	0.511	rs17278688	chr6:26890136	G/C	cg09904177	chr6:26538194	HMGN4	0.44	8.09	0.35	5.29e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3735485	0.843	rs10951785	chr7:45047791	C/G	cg03440944	chr7:45023329	C7orf40	-0.53	-8.9	-0.38	1.25e-17	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs887829	0.569	rs3806596	chr2:234637707	C/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.42	7.74	0.34	6.18e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.67	0.3	7.37e-11	Schizophrenia;
LGG	cis	rs4330281	0.647	rs7644020	chr3:17481548	C/T	cg20981856	chr3:17787350	NA	0.35	6.71	0.3	5.81e-11	Schizophrenia;
LGG	cis	rs3857067	0.836	rs12501138	chr4:95098444	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.9	-0.34	2.09e-14	QT interval;
LGG	cis	rs6089584	0.627	rs35560719	chr20:60561917	A/C	cg13770153	chr20:60521292	NA	-0.43	-7.09	-0.31	5.04e-12	Body mass index;
LGG	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.31	0.58	4.19e-43	Platelet count;
LGG	cis	rs11758351	0.500	rs74974409	chr6:26194402	A/G	cg01420254	chr6:26195488	NA	0.97	7.36	0.32	8.35e-13	Gout;Renal underexcretion gout;
LGG	cis	rs3740909	1.000	rs3740910	chr11:125889673	A/G	cg24940576	chr11:125904314	CDON	-0.49	-7.54	-0.33	2.53e-13	Blood protein levels;
LGG	cis	rs6594713	0.717	rs13436825	chr5:112817687	T/A	cg12552261	chr5:112820674	MCC	0.62	8.71	0.38	5.5e-17	Brain cytoarchitecture;
LGG	trans	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg21775007	chr8:11205619	TDH	0.44	7.34	0.32	9.44e-13	Neuroticism;
LGG	cis	rs17001868	0.614	rs61467436	chr22:40736713	T/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	trans	rs11875185	0.510	rs76942327	chr18:55600615	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11583043	0.918	rs6577216	chr1:101409972	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	9.13	0.39	2.13e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg14675211	chr2:100938903	LONRF2	0.68	12.25	0.49	4.6e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg08280861	chr8:58055591	NA	0.52	6.66	0.3	8.02e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6774721	1.000	rs6774721	chr3:49381898	G/A	cg19401529	chr3:49056140	DALRD3	0.73	8.33	0.36	9.13e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3008870	0.755	rs2755243	chr1:67482783	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.7	0.59	7.76e-45	Lymphocyte percentage of white cells;
LGG	cis	rs867371	1.000	rs11855089	chr15:82447265	T/C	cg00614314	chr15:82944287	LOC80154	0.6	10.14	0.43	5.94e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2456568	0.802	rs1395387	chr11:93639307	A/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.7	-0.3	6.21e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2594989	0.943	rs2454501	chr3:11500089	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.29	-0.32	1.39e-12	Circulating chemerin levels;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg04234412	chr22:24373322	LOC391322	-0.75	-15.45	-0.58	1.02e-43	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4731207	0.596	rs2219953	chr7:124671915	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.95	-0.31	1.23e-11	Cutaneous malignant melanoma;
LGG	cis	rs17125944	0.686	rs73304351	chr14:53375140	G/A	cg00686598	chr14:53173677	PSMC6	0.78	7.87	0.34	2.48e-14	Alzheimer's disease (late onset);
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg16885296	chr6:26284938	NA	0.36	7.65	0.33	1.17e-13	Educational attainment;
LGG	cis	rs11112613	0.938	rs2374513	chr12:106007300	C/T	cg03607813	chr12:105948248	NA	0.48	7.05	0.31	6.54e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs17428076	0.874	rs17581361	chr2:172682612	T/G	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs7236492	0.532	rs3786184	chr18:77195885	A/C	cg15644404	chr18:77186268	NFATC1	-0.54	-8.25	-0.36	1.64e-15	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs34421088	0.532	rs3808515	chr8:11156041	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.49	-0.33	3.58e-13	Neuroticism;
LGG	cis	rs757081	0.676	rs677042	chr11:17207080	A/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.75	-0.34	5.71e-14	Systolic blood pressure;
LGG	trans	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg21659725	chr3:3221576	CRBN	0.55	9.54	0.41	8.04e-20	Body mass index;
LGG	cis	rs9810089	0.903	rs7427564	chr3:136274435	G/A	cg12473912	chr3:136751656	NA	0.39	6.78	0.3	3.71e-11	Gestational age at birth (child effect);
LGG	cis	rs989128	0.600	rs916978	chr17:48630452	T/C	cg20467136	chr17:48638190	CACNA1G	0.47	7.03	0.31	7.25e-12	Type 2 diabetes;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.76	-0.41	1.34e-20	Lung cancer;
LGG	cis	rs2455799	0.613	rs6789076	chr3:15807725	A/T	cg16303742	chr3:15540471	COLQ	0.4	8.13	0.35	3.83e-15	Mean platelet volume;
LGG	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg03060546	chr3:49711283	APEH	0.75	13.46	0.53	4.29e-35	Resting heart rate;
LGG	cis	rs4730250	0.654	rs12705405	chr7:106792517	C/T	cg02696742	chr7:106810147	HBP1	0.79	11.12	0.46	1.24e-25	Osteoarthritis;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-9.73	-0.41	1.75e-20	Longevity;
LGG	cis	rs9796	0.866	rs1678750	chr15:41410705	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.93	-0.38	1.04e-17	Menopause (age at onset);
LGG	cis	rs17453880	0.929	rs7715495	chr5:152048107	T/G	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg07157834	chr1:205819609	PM20D1	-0.6	-13.56	-0.53	1.68e-35	Monocyte percentage of white cells;
LGG	trans	rs7395662	0.591	rs4882093	chr11:48530820	G/A	cg15704280	chr7:45808275	SEPT13	-0.58	-9.86	-0.42	5.99e-21	HDL cholesterol;
LGG	cis	rs4746059	0.714	rs11599210	chr10:72457250	A/G	cg18679544	chr10:72432482	ADAMTS14	0.5	8.66	0.37	7.95e-17	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.06	-0.31	6.2e-12	Retinal vascular caliber;
LGG	cis	rs4481887	1.000	rs4360553	chr1:248467092	A/G	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.73e-16	Common traits (Other);
LGG	cis	rs5769707	0.967	rs1018812	chr22:50010073	C/T	cg20744362	chr22:50050164	C22orf34	0.36	6.99	0.31	9.56e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9902453	0.904	rs12951836	chr17:28410277	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.34	-0.53	1.34e-34	Coffee consumption (cups per day);
LGG	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.18	-0.36	2.72e-15	Neuroticism;
LGG	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.38	0.36	6.53e-16	Red cell distribution width;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16189644	chr5:96271684	LNPEP	0.38	6.67	0.3	7.18e-11	Bilirubin levels;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg00761968	chr13:53314142	LECT1	0.32	6.7	0.3	6.06e-11	Lewy body disease;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2289328	1.000	rs2289328	chr15:40705417	G/A	cg13931752	chr15:40660718	DISP2	0.38	7.65	0.34	1.15e-13	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7241530	0.610	rs59421856	chr18:75891599	A/C	cg14642773	chr18:75888474	NA	0.47	9.01	0.39	5.61e-18	Educational attainment (years of education);
LGG	cis	rs7091068	0.616	rs1890657	chr10:95506087	G/A	cg20715218	chr10:95462985	C10orf4	0.69	9.89	0.42	4.85e-21	Urinary tract infection frequency;
LGG	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg04568710	chr12:38710424	ALG10B	0.36	7.44	0.33	4.79e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4969178	0.965	rs3817294	chr17:76396963	A/G	cg05887092	chr17:76393375	PGS1	0.72	15.84	0.59	1.89e-45	HDL cholesterol levels;
LGG	cis	rs7635838	0.503	rs9853547	chr3:11396101	C/G	cg00170343	chr3:11313890	ATG7	0.5	8.23	0.36	1.95e-15	HDL cholesterol;
LGG	cis	rs7172689	0.908	rs11857325	chr15:81563904	T/C	cg11808699	chr15:81528661	IL16	-0.44	-9.3	-0.4	5.48e-19	Inattentive symptoms;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27326856	chr19:37663410	ZNF585A	0.42	7.06	0.31	6.29e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs262150	0.837	rs2657404	chr7:158783155	C/T	cg19418458	chr7:158789849	NA	-0.46	-9.39	-0.4	2.69e-19	Facial morphology (factor 20);
LGG	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg26441486	chr22:50317300	CRELD2	0.4	7.24	0.32	1.9e-12	Schizophrenia;
LGG	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg15704280	chr7:45808275	SEPT13	-0.52	-8.74	-0.38	4.18e-17	HDL cholesterol;
LGG	cis	rs4253772	0.637	rs9627350	chr22:46663017	A/G	cg24881330	chr22:46731750	TRMU	0.71	8.76	0.38	3.71e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg21775007	chr8:11205619	TDH	0.53	8.3	0.36	1.14e-15	Triglycerides;
LGG	cis	rs477895	0.653	rs11603212	chr11:63927810	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.84	-11.0	-0.46	3.64e-25	Mean platelet volume;
LGG	cis	rs1978968	0.654	rs13056749	chr22:18402924	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.5	-9.57	-0.41	6.42e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.36e-20	Aortic root size;
LGG	cis	rs12765878	1.000	rs1980653	chr10:105654164	A/G	cg11005552	chr10:105648138	OBFC1	1.04	27.32	0.79	1.43e-98	Coronary artery disease;
LGG	cis	rs7851660	0.809	rs7032114	chr9:100656459	T/G	cg13688889	chr9:100608707	NA	-0.64	-12.71	-0.51	5.85e-32	Strep throat;
LGG	cis	rs55692411	0.517	rs13095697	chr3:50136463	G/A	cg24110177	chr3:50126178	RBM5	-0.55	-8.24	-0.36	1.83e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1408799	0.549	rs2209277	chr9:12706236	A/G	cg05274944	chr9:12693694	TYRP1	0.44	11.04	0.46	2.52e-25	Eye color;Blue vs. green eyes;
LGG	cis	rs1978968	0.956	rs35972244	chr22:18434038	C/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-11.11	-0.46	1.35e-25	Presence of antiphospholipid antibodies;
LGG	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg04450456	chr4:17643702	FAM184B	0.3	6.78	0.3	3.77e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs588177	0.919	rs2244625	chr11:64026144	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.46	7.08	0.31	5.45e-12	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs9326248	0.509	rs533556	chr11:116741572	A/C	cg20608306	chr11:116969690	SIK3	0.4	12.65	0.51	1.08e-31	Blood protein levels;
LGG	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg02187348	chr16:89574699	SPG7	0.61	10.34	0.43	1.09e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08045932	chr20:61659980	NA	0.6	13.02	0.52	3.16e-33	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg26043149	chr18:55253948	FECH	-0.45	-7.34	-0.32	9.46e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7216064	1.000	rs7223930	chr17:65842186	G/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg23933602	chr10:16859644	RSU1	0.67	9.8	0.41	1e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04156016	chr5:1868137	NA	0.32	7.07	0.31	5.66e-12	Cardiovascular disease risk factors;
LGG	cis	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg22437258	chr11:111473054	SIK2	0.55	9.6	0.41	5.01e-20	Primary sclerosing cholangitis;
LGG	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg21238619	chr17:78079768	GAA	-0.44	-7.99	-0.35	1.06e-14	Yeast infection;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.7	-0.41	2.29e-20	Aortic root size;
LGG	cis	rs13095912	0.785	rs6800725	chr3:185298156	C/A	cg11274856	chr3:185301563	NA	0.5	8.07	0.35	6.07e-15	Systolic blood pressure;
LGG	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.5	0.33	3.29e-13	Systolic blood pressure;
LGG	cis	rs2797369	0.882	rs4382272	chr6:101614676	T/G	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs8070624	0.574	rs9914127	chr17:17875836	A/T	cg04398451	chr17:18023971	MYO15A	-0.69	-13.77	-0.54	2.1e-36	Total body bone mineral density;
LGG	trans	rs7395662	1.000	rs4882021	chr11:48615966	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.43e-13	HDL cholesterol;
LGG	cis	rs4865875	0.818	rs4362906	chr5:54108386	A/G	cg22421804	chr5:54100067	NA	0.51	7.73	0.34	6.97e-14	Sense of smell;
LGG	trans	rs6601450	0.522	rs10095190	chr8:10239612	C/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.83	0.3	2.63e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs763121	0.744	rs5757140	chr22:38957013	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	16.95	0.62	1.83e-50	Menopause (age at onset);
LGG	cis	rs7789940	0.904	rs56919252	chr7:75937520	T/C	cg10167463	chr7:75959203	YWHAG	-0.44	-7.2	-0.32	2.46e-12	Multiple sclerosis;
LGG	cis	rs815815	0.636	rs815817	chr2:47396558	C/T	cg27223769	chr2:47403360	CALM2	-0.5	-7.71	-0.34	7.5e-14	Dialysis-related mortality;
LGG	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg07061783	chr6:25882402	NA	0.47	8.11	0.35	4.73e-15	Blood metabolite levels;
LGG	cis	rs9443645	0.869	rs9343863	chr6:79752792	T/C	cg18132916	chr6:79620363	NA	-0.3	-8.32	-0.36	9.94e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9472414	0.510	rs227857	chr6:44704392	A/T	cg20913747	chr6:44695427	NA	0.46	7.68	0.34	9.86e-14	Height;
LGG	trans	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.83	-0.3	2.73e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08045932	chr20:61659980	NA	-0.57	-12.01	-0.49	3.97e-29	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7072216	0.763	rs12763326	chr10:100167396	A/G	cg26618903	chr10:100175079	PYROXD2	0.29	7.15	0.32	3.39e-12	Metabolite levels;
LGG	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	11.02	0.46	3.01e-25	Breast cancer;
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg27400746	chr16:89904261	SPIRE2	-0.97	-15.57	-0.59	3.02e-44	Skin colour saturation;
LGG	cis	rs798554	0.679	rs1636254	chr7:2885724	T/C	cg19524238	chr7:2802976	GNA12	0.37	8.76	0.38	3.64e-17	Height;
LGG	cis	rs988958	0.675	rs7583681	chr2:42225701	G/A	cg27428208	chr2:42229179	NA	0.54	9.18	0.39	1.39e-18	Hypospadias;
LGG	cis	rs9788682	0.948	rs59683676	chr15:78833453	T/C	cg24631222	chr15:78858424	CHRNA5	0.46	6.9	0.31	1.69e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1729951	0.575	rs1654926	chr3:136709924	G/A	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	5.85e-21	Neuroticism;
LGG	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg00864171	chr11:67383662	NA	-0.44	-7.21	-0.32	2.3e-12	Mean corpuscular volume;
LGG	cis	rs2084898	1.000	rs2084899	chr11:120026810	A/C	cg07435449	chr11:120005650	TRIM29	-0.64	-7.58	-0.33	1.9e-13	Stroke (pediatric);
LGG	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11644478	chr21:40555479	PSMG1	-0.61	-10.32	-0.43	1.35e-22	Menarche (age at onset);
LGG	cis	rs12476592	0.602	rs11125978	chr2:63809602	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.93	-0.31	1.41e-11	Childhood ear infection;
LGG	trans	rs1814175	0.645	rs10839448	chr11:49938930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.92	-0.62	2.51e-50	Height;
LGG	cis	rs6694672	0.681	rs615647	chr1:197188908	T/C	cg13682187	chr1:196946512	CFHR5	0.48	6.85	0.3	2.37e-11	Asthma;
LGG	cis	rs952623	0.649	rs6462886	chr7:39066567	A/T	cg20302533	chr7:39170763	POU6F2	-0.32	-7.63	-0.33	1.33e-13	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg00689492	chr4:1303491	MAEA	-0.46	-7.73	-0.34	6.56e-14	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23763197	chr11:118965649	H2AFX	0.52	7.81	0.34	3.78e-14	Gut microbiome composition (summer);
LGG	cis	rs67311347	1.000	rs9848083	chr3:40466979	A/G	cg13683864	chr3:40499215	RPL14	1.01	21.44	0.71	2.45e-71	Renal cell carcinoma;
LGG	trans	rs4942242	0.640	rs9533563	chr13:44212127	A/G	cg19169023	chr15:41853346	TYRO3	-0.44	-8.79	-0.38	3.02e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7939886	0.841	rs11227583	chr11:55995737	C/A	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs3780378	0.967	rs10815144	chr9:5010192	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.36	-0.4	3.52e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs8002861	0.555	rs4942245	chr13:44389479	T/G	cg17145862	chr1:211918768	LPGAT1	0.76	14.88	0.57	3.41e-41	Leprosy;
LGG	trans	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg27349345	chr7:35225932	NA	-0.52	-7.49	-0.33	3.61e-13	Facial emotion recognition (angry faces);
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.84e-12	Prudent dietary pattern;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.5	-8.87	-0.38	1.66e-17	Longevity;Endometriosis;
LGG	cis	rs10883723	0.962	rs10883726	chr10:104236276	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.69	12.85	0.51	1.56e-32	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.84	-0.34	3.14e-14	Neuroticism;
LGG	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs17767392	0.705	rs4899393	chr14:71739924	C/T	cg02058870	chr14:72053146	SIPA1L1	0.36	7.12	0.31	4.06e-12	Mitral valve prolapse;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06112835	chr11:68658793	MRPL21	0.6	9.89	0.42	4.7e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7011049	0.841	rs6473775	chr8:53875047	G/A	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs1821002	1	rs1821002	chr8:10640065	C/G	cg27411982	chr8:10470053	RP1L1	-0.4	-6.71	-0.3	5.55e-11	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02711801	chr19:37997798	ZNF793	0.46	7.0	0.31	9.06e-12	Gut microbiome composition (summer);
LGG	cis	rs7312933	0.645	rs11181404	chr12:42683840	T/C	cg19980929	chr12:42632907	YAF2	0.39	8.74	0.38	4.31e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs970548	0.657	rs11239572	chr10:46088061	C/T	cg14222797	chr10:16859974	RSU1	0.64	7.57	0.33	2.1e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3796352	1.000	rs35163227	chr3:53127876	A/G	cg12962167	chr3:53033115	SFMBT1	0.78	8.04	0.35	7.46e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2455799	0.573	rs62243672	chr3:15937200	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.51	-0.33	3.12e-13	Mean platelet volume;
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.44	-0.33	5e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg13482628	chr17:19912719	NA	-0.53	-10.14	-0.43	6.1e-22	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05351302	chr7:87563908	ADAM22	0.43	7.34	0.32	9.49e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2011503	1.000	rs2916075	chr19:19530590	G/C	cg11584989	chr19:19387371	SF4	0.74	12.12	0.49	1.54e-29	Bipolar disorder;
LGG	trans	rs6076960	0.564	rs3844457	chr20:6143379	A/G	cg21095983	chr6:86352623	SYNCRIP	0.53	9.44	0.4	1.86e-19	Smooth-surface caries;
LGG	cis	rs8017423	0.967	rs7158180	chr14:90729117	C/T	cg04374321	chr14:90722782	PSMC1	0.9	19.53	0.67	2.16e-62	Mortality in heart failure;
LGG	cis	rs9549367	0.756	rs9549702	chr13:113881944	T/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.51e-17	Platelet distribution width;
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg20120463	chr17:44301886	NA	0.44	6.74	0.3	4.67e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-9.35	-0.4	3.87e-19	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12406941	chr16:70472589	ST3GAL2	0.5	7.3	0.32	1.26e-12	Gut microbiome composition (summer);
LGG	cis	rs751728	0.965	rs4713681	chr6:33754817	T/C	cg25922239	chr6:33757077	LEMD2	0.69	12.38	0.5	1.27e-30	Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03873659	chr3:123304056	PTPLB	0.47	6.83	0.3	2.64e-11	Gut microbiome composition (summer);
LGG	cis	rs773506	0.965	rs9299391	chr9:94017643	G/A	cg14446406	chr9:93919335	NA	-0.46	-8.31	-0.36	1.05e-15	Type 2 diabetes nephropathy;
LGG	cis	rs4740619	0.525	rs9406542	chr9:15828147	G/T	cg14451791	chr9:16040625	NA	0.32	7.88	0.34	2.36e-14	Body mass index;
LGG	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg08250081	chr4:10125330	NA	-0.38	-7.34	-0.32	9.57e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg13206674	chr6:150067644	NUP43	0.68	15.92	0.59	8.1e-46	Lung cancer;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg13628971	chr7:2884303	GNA12	0.34	6.93	0.31	1.43e-11	Height;
LGG	cis	rs2289583	0.642	rs7162941	chr15:75385622	C/T	cg10253484	chr15:75165896	SCAMP2	0.44	6.98	0.31	1.05e-11	Systemic lupus erythematosus;
LGG	cis	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg11266682	chr4:10021025	SLC2A9	0.57	11.6	0.47	1.71e-27	Bone mineral density;
LGG	cis	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-13.65	-0.54	6.63e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.44	0.5	7.33e-31	Prudent dietary pattern;
LGG	cis	rs72945132	0.882	rs12279046	chr11:70130388	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg02733842	chr7:1102375	C7orf50	0.73	10.93	0.45	6.67e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.613	rs12425430	chr12:33663185	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.34	-0.36	8.66e-16	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg08975724	chr8:8085496	FLJ10661	-0.52	-10.2	-0.43	3.6e-22	Retinal vascular caliber;
LGG	cis	rs9790314	0.613	rs1447620	chr3:160616211	T/C	cg03342759	chr3:160939853	NMD3	0.44	7.43	0.33	5.33e-13	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08396677	chr2:136288699	ZRANB3;R3HDM1	0.41	6.75	0.3	4.37e-11	Cognitive performance;
LGG	trans	rs12517041	0.515	rs13171226	chr5:23334424	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-8.69	-0.37	6.27e-17	Calcium levels;
LGG	trans	rs1941687	0.527	rs2000945	chr18:31365336	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-12.63	-0.51	1.29e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg11584989	chr19:19387371	SF4	-0.42	-7.67	-0.34	1.02e-13	Tonsillectomy;
LGG	cis	rs7572733	0.576	rs6734781	chr2:198759973	G/A	cg00792783	chr2:198669748	PLCL1	0.67	11.06	0.46	2.13e-25	Dermatomyositis;
LGG	cis	rs873946	0.648	rs12782123	chr10:134554662	G/A	cg13271783	chr10:134563150	INPP5A	-0.55	-8.03	-0.35	7.93e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.72	-0.3	5.26e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg23958373	chr8:599963	NA	-1.07	-10.99	-0.45	4.04e-25	IgG glycosylation;
LGG	cis	rs9547996	0.842	rs11843893	chr13:38213738	C/T	cg17979426	chr13:38220150	TRPC4	-0.38	-7.39	-0.32	6.94e-13	Diastolic blood pressure;
LGG	cis	rs7166081	0.951	rs67872952	chr15:67561598	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.68	-0.3	6.85e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg08704250	chr15:31115839	NA	-0.49	-8.76	-0.38	3.75e-17	Huntington's disease progression;
LGG	cis	rs7103648	0.553	rs12803857	chr11:47890172	G/A	cg20307385	chr11:47447363	PSMC3	0.77	14.81	0.57	6.54e-41	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9462027	0.628	rs7741437	chr6:34737553	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	trans	rs453301	0.657	rs36056437	chr8:8792865	T/G	cg16141378	chr3:129829833	LOC729375	0.32	7.08	0.31	5.31e-12	Joint mobility (Beighton score);
LGG	cis	rs2050392	1.000	rs2253585	chr10:30696503	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.59	-0.44	1.25e-23	Inflammatory bowel disease;
LGG	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.04	-0.31	6.77e-12	Hemoglobin concentration;
LGG	cis	rs7555523	0.887	rs4657475	chr1:165687175	T/C	cg24409356	chr1:165738333	TMCO1	0.71	8.71	0.38	5.39e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg13010199	chr12:38710504	ALG10B	0.67	12.96	0.52	5.45e-33	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	8.04	0.35	7.72e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7572644	0.640	rs6547820	chr2:28281545	G/A	cg27432699	chr2:27873401	GPN1	-0.44	-6.67	-0.3	7.25e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs6601327	0.635	rs28828176	chr8:9663453	A/C	cg16141378	chr3:129829833	LOC729375	0.33	7.47	0.33	3.95e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg16434002	chr17:42200994	HDAC5	0.43	7.78	0.34	4.83e-14	Total body bone mineral density;
LGG	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.34	0.36	8.32e-16	Colorectal cancer;
LGG	cis	rs7945705	0.875	rs2653616	chr11:8885892	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.94	-0.35	1.58e-14	Hemoglobin concentration;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg09699651	chr6:150184138	LRP11	0.5	8.82	0.38	2.33e-17	Lung cancer;
LGG	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg08704250	chr15:31115839	NA	-0.42	-7.63	-0.33	1.36e-13	Huntington's disease progression;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs6429082	0.811	rs291348	chr1:235667690	A/G	cg26050004	chr1:235667680	B3GALNT2	0.86	17.87	0.64	1.04e-54	Adiposity;
LGG	cis	rs2242116	0.833	rs6442038	chr3:46960742	A/G	cg16586182	chr3:47516702	SCAP	-0.58	-9.73	-0.41	1.71e-20	Birth weight;
LGG	cis	rs9644630	0.841	rs4922035	chr8:19328174	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.56	14.86	0.57	4.23e-41	Oropharynx cancer;
LGG	cis	rs2243480	1.000	rs937108	chr7:65428452	G/A	cg13147721	chr7:65941812	NA	-0.72	-9.02	-0.39	4.86e-18	Diabetic kidney disease;
LGG	cis	rs9398803	0.865	rs2050644	chr6:126805255	A/G	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg23029597	chr12:123009494	RSRC2	-0.97	-18.8	-0.66	5.08e-59	Body mass index;
LGG	cis	rs9300255	0.602	rs1790116	chr12:123618544	G/T	cg05973401	chr12:123451056	ABCB9	0.5	7.59	0.33	1.76e-13	Neutrophil percentage of white cells;
LGG	cis	rs9783347	0.714	rs10766471	chr11:18367130	C/T	cg15585147	chr11:18324498	HPS5	0.32	7.54	0.33	2.51e-13	Pancreatic cancer;
LGG	cis	rs11700980	0.551	rs2832036	chr21:30115170	T/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.05	-0.35	7.26e-15	Total body bone mineral density;
LGG	trans	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg26384229	chr12:38710491	ALG10B	0.7	13.09	0.52	1.57e-33	Resting heart rate;
LGG	cis	rs9322193	0.516	rs1999632	chr6:150187873	C/T	cg11878867	chr6:150167359	LRP11	-0.49	-8.45	-0.37	3.73e-16	Lung cancer;
LGG	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg12560992	chr17:57184187	TRIM37	0.53	8.56	0.37	1.69e-16	Testicular germ cell tumor;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs870825	0.929	rs72689266	chr4:185591053	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	cis	rs561341	1.000	rs561341	chr17:30316385	T/G	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg21775007	chr8:11205619	TDH	-0.51	-8.19	-0.36	2.55e-15	Triglycerides;
LGG	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs1665650	0.957	rs1665641	chr10:118494937	C/G	cg14919929	chr10:118506882	NA	0.51	8.87	0.38	1.58e-17	Colorectal cancer;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg11905131	chr22:24372483	LOC391322	-0.4	-6.99	-0.31	9.86e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06969527	chr19:14248428	ASF1B	0.54	8.44	0.37	3.97e-16	Gut microbiome composition (summer);
LGG	cis	rs9951602	0.512	rs9958497	chr18:76655296	G/C	cg24134504	chr18:76639479	NA	-0.47	-8.21	-0.36	2.21e-15	Obesity-related traits;
LGG	cis	rs12681366	0.553	rs2930967	chr8:95462599	A/G	cg13257157	chr8:95487014	RAD54B	-0.37	-6.88	-0.3	1.95e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1451375	1.000	rs6949897	chr7:50621920	C/T	cg20336341	chr7:50628841	DDC	0.37	7.18	0.32	2.8e-12	Malaria;
LGG	trans	rs656319	0.513	rs17746245	chr8:9981686	A/C	cg06636001	chr8:8085503	FLJ10661	0.43	7.32	0.32	1.12e-12	Myopia (pathological);
LGG	cis	rs3862030	0.810	rs5870	chr10:104239100	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.57	-10.69	-0.45	5.35e-24	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg11247378	chr22:39784982	NA	-0.3	-8.17	-0.36	2.9e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.97	0.38	7.41e-18	Neuroticism;
LGG	cis	rs12200560	0.505	rs211179	chr6:97074103	A/G	cg06623918	chr6:96969491	KIAA0776	0.45	7.71	0.34	8.02e-14	Coronary heart disease;
LGG	cis	rs34929064	1.000	rs13225099	chr7:22722925	C/T	cg18045685	chr7:22629474	NA	0.55	8.89	0.38	1.42e-17	Major depression and alcohol dependence;
LGG	cis	rs7619833	0.719	rs599298	chr3:27355115	T/C	cg02860705	chr3:27208620	NA	0.39	7.39	0.32	7.04e-13	Breast cancer;
LGG	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg00071950	chr4:10020882	SLC2A9	-0.38	-7.75	-0.34	6e-14	Bone mineral density;
LGG	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.27	-0.52	2.85e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs9972944	0.756	rs6416948	chr17:63767131	T/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.34	-0.36	8.65e-16	Total body bone mineral density;
LGG	cis	rs7681440	0.874	rs1372525	chr4:90776165	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs9596863	1.000	rs9568946	chr13:54430220	T/C	ch.13.53330881F	chr13:54432880	NA	0.51	6.98	0.31	1.03e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg24829409	chr8:58192753	C8orf71	-0.8	-11.39	-0.47	1.18e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg10548669	chr15:37782940	NA	0.64	6.88	0.3	1.91e-11	Airflow obstruction;
LGG	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg13902645	chr11:5959945	NA	-0.67	-10.26	-0.43	2.09e-22	DNA methylation (variation);
LGG	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.69	13.24	0.52	3.75e-34	Lymphocyte percentage of white cells;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.25	0.32	1.81e-12	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19789848	chr17:30454741	NA	-0.47	-6.85	-0.3	2.42e-11	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.73	-0.3	4.9e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7587476	0.689	rs78989396	chr2:215714816	C/T	cg04004882	chr2:215674386	BARD1	0.53	7.45	0.33	4.74e-13	Neuroblastoma;
LGG	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs2703782	chr17:20144799	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.43	-0.4	1.95e-19	Obesity-related traits;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.65	0.37	8.81e-17	Schizophrenia;
LGG	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg04727924	chr7:799746	HEATR2	0.45	6.97	0.31	1.07e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs12410462	0.688	rs35582095	chr1:227959206	A/G	cg04117972	chr1:227635322	NA	0.52	9.43	0.4	1.94e-19	Major depressive disorder;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg16885296	chr6:26284938	NA	0.38	8.24	0.36	1.79e-15	Educational attainment;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	8.16	0.35	3.17e-15	Schizophrenia;
LGG	cis	rs698833	0.926	rs1067406	chr2:44674450	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.88	0.3	1.96e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1784581	0.588	rs6455790	chr6:162418447	C/T	cg17173639	chr6:162384350	PARK2	-0.63	-13.3	-0.53	2.15e-34	Itch intensity from mosquito bite;
LGG	cis	rs6582630	0.555	rs2004152	chr12:38478951	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.57e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02293828	chr1:154946938	SHC1;CKS1B	-0.41	-6.73	-0.3	4.94e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1348850	0.914	rs6761593	chr2:178451600	A/G	cg27490568	chr2:178487706	NA	-0.48	-9.26	-0.4	7.54e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg18898632	chr2:242989856	NA	-0.73	-8.68	-0.37	6.89e-17	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	12.93	0.52	6.92e-33	Menopause (age at onset);
LGG	cis	rs1862618	0.853	rs832554	chr5:56115036	A/G	cg08400814	chr5:56204995	C5orf35	-0.47	-7.62	-0.33	1.4e-13	Initial pursuit acceleration;
LGG	cis	rs2074193	0.627	rs215390	chr12:47765037	T/C	cg02516419	chr12:47771422	NA	-0.72	-10.6	-0.44	1.16e-23	Migraine with aura;
LGG	cis	rs71403859	0.730	rs17355804	chr16:71717214	A/G	cg08717414	chr16:71523259	ZNF19	-1.07	-13.63	-0.54	8.56e-36	Post bronchodilator FEV1;
LGG	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg04287289	chr16:89883240	FANCA	0.79	16.56	0.61	9.99e-49	Vitiligo;
LGG	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg11846333	chr4:119757529	SEC24D	0.85	7.86	0.34	2.73e-14	Cannabis dependence symptom count;
LGG	cis	rs10189230	0.967	rs13002861	chr2:222352859	T/G	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs79349575	0.721	rs3744608	chr17:46993233	C/G	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	trans	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.66	0.48	1.01e-27	Corneal astigmatism;
LGG	cis	rs4740619	0.619	rs943788	chr9:16031886	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.83e-26	Body mass index;
LGG	cis	rs9486715	0.929	rs2025044	chr6:97067028	A/G	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.48	-0.56	1.84e-39	Headache;
LGG	cis	rs7851660	0.967	rs1443434	chr9:100617479	G/T	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs4788570	0.615	rs2052584	chr16:71688977	A/G	cg06353428	chr16:71660113	MARVELD3	-1.25	-21.79	-0.71	5.87e-73	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg15971980	chr6:150254442	NA	0.46	9.2	0.39	1.24e-18	Testicular germ cell tumor;
LGG	cis	rs3096299	0.933	rs2965934	chr16:89481229	C/G	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.93	-0.31	1.4e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs9368481	0.502	rs3933232	chr6:26877446	T/C	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg24692254	chr21:30365293	RNF160	-0.66	-12.09	-0.49	2.02e-29	Pancreatic cancer;
LGG	cis	rs992157	0.687	rs35271699	chr2:219117482	G/A	cg04731861	chr2:219085781	ARPC2	-0.49	-12.35	-0.5	1.75e-30	Colorectal cancer;
LGG	cis	rs7089973	0.872	rs7918253	chr10:116614501	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.68	0.34	9.66e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs16976116	0.901	rs73409853	chr15:55502681	A/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.26	0.32	1.68e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.29	0.6	1.69e-47	Obesity-related traits;
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg26138144	chr22:38071188	LGALS1	-0.91	-24.86	-0.76	2.89e-87	Fat distribution (HIV);
LGG	cis	rs7717393	0.786	rs6872904	chr5:155777713	C/G	cg04435420	chr5:155754009	SGCD	0.73	9.26	0.4	7.58e-19	Egg allergy;
LGG	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg12940439	chr1:67600707	NA	-0.43	-8.79	-0.38	2.96e-17	Psoriasis;
LGG	cis	rs1707322	1.000	rs12133129	chr1:46373348	C/T	cg03146154	chr1:46216737	IPP	0.54	10.31	0.43	1.46e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11098499	0.644	rs34835603	chr4:120553428	C/T	cg24375607	chr4:120327624	NA	0.59	10.12	0.43	7.28e-22	Corneal astigmatism;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg18538332	chr22:24372958	LOC391322	-0.45	-7.6	-0.33	1.72e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs13128441	0.637	rs9291071	chr4:5152981	T/C	cg26099876	chr8:141644609	EIF2C2	-0.54	-8.42	-0.36	4.6e-16	Celiac disease;
LGG	cis	rs929354	0.772	rs1182432	chr7:157029176	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.76	0.59	4.14e-45	Body mass index;
LGG	cis	rs3741151	1.000	rs76887714	chr11:73045500	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	10.13	0.43	6.3e-22	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs10949834	0.878	rs36010170	chr7:73499498	C/A	cg07137043	chr7:73588983	EIF4H	-0.63	-7.25	-0.32	1.71e-12	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg15595755	chr5:1867978	NA	0.5	9.95	0.42	2.77e-21	Cardiovascular disease risk factors;
LGG	cis	rs116139393	0.536	rs13247186	chr7:6769155	A/G	cg09896999	chr7:6746977	ZNF12	-0.53	-7.3	-0.32	1.23e-12	Alzheimer's disease (APOE e4 interaction);
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg21724239	chr8:58056113	NA	0.63	9.24	0.39	8.92e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs17683430	0.614	rs2006253	chr22:32530256	A/C	cg02631450	chr22:32366979	NA	0.64	7.2	0.32	2.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7444	0.941	rs2283790	chr22:21956653	C/T	cg11654148	chr22:21984483	YDJC	0.39	7.57	0.33	2.04e-13	Systemic lupus erythematosus;
LGG	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg00850481	chr1:228891306	NA	0.51	8.76	0.38	3.72e-17	Chronic lymphocytic leukemia;
LGG	trans	rs1032833	0.732	rs115647285	chr2:179950029	G/C	cg23654767	chr2:101192981	PDCL3	0.72	8.52	0.37	2.22e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10463316	0.817	rs10052992	chr5:150788602	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.27	-0.43	1.98e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7777484	0.534	rs2533888	chr7:2831083	T/C	cg27476859	chr7:2772710	GNA12	0.64	13.0	0.52	3.62e-33	Height;
LGG	cis	rs2549003	1.000	rs2070725	chr5:131821788	C/T	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs4764487	0.735	rs3181301	chr12:6345784	G/T	cg08284733	chr12:6341482	CD9	0.38	10.29	0.43	1.65e-22	Mean platelet volume;
LGG	trans	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg00938859	chr5:1591904	SDHAP3	0.77	6.82	0.3	2.8e-11	Asthma (childhood onset);
LGG	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg24812749	chr6:127587940	RNF146	-0.65	-11.1	-0.46	1.51e-25	Breast cancer;
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.51	-0.4	1.02e-19	Neuroticism;
LGG	cis	rs9486715	0.867	rs3860243	chr6:96905303	T/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.65	0.59	1.22e-44	Headache;
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.31	0.32	1.19e-12	Skin colour saturation;
LGG	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-13.77	-0.54	2.11e-36	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04696181	chr5:3386790	NA	0.37	7.28	0.32	1.43e-12	Electrocardiographic conduction measures;
LGG	cis	rs7617773	0.779	rs9833309	chr3:48327450	C/T	cg11946769	chr3:48343235	NME6	0.63	10.57	0.44	1.48e-23	Coronary artery disease;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.37	-0.32	7.9e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg08621203	chr6:150244597	RAET1G	0.42	7.12	0.31	4.06e-12	Lung cancer;
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg08499158	chr17:42289980	UBTF	-0.55	-10.32	-0.43	1.33e-22	Total body bone mineral density;
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs68170813	0.559	rs997311	chr7:106953033	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1e-23	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00503587	chr20:18118441	PET117	-0.43	-6.93	-0.31	1.43e-11	Pancreatic cancer;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg17088814	chr2:12856702	TRIB2	-0.42	-7.2	-0.32	2.37e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs12135191	1.000	rs12135191	chr1:236470734	C/T	cg21399712	chr1:236511386	NA	-0.4	-7.61	-0.33	1.51e-13	Urate levels (BMI interaction);
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg04863758	chr4:1303710	MAEA	0.43	7.35	0.32	9.16e-13	Obesity-related traits;
LGG	cis	rs757278	0.552	rs35292549	chr7:117318803	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	7.81	0.34	3.78e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs881375	0.967	rs7046108	chr9:123660339	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-12.02	-0.49	3.57e-29	Rheumatoid arthritis;
LGG	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs4740619	0.935	rs10810439	chr9:15754393	C/T	cg14451791	chr9:16040625	NA	0.39	10.24	0.43	2.56e-22	Body mass index;
LGG	cis	rs9308731	1.000	rs6746608	chr2:111892984	C/T	cg26001287	chr2:111877753	BCL2L11	0.39	7.76	0.34	5.6e-14	Chronic lymphocytic leukemia;
LGG	cis	rs3735485	0.657	rs10951786	chr7:45047890	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg02002194	chr4:3960332	NA	0.43	7.67	0.34	1.05e-13	Triglycerides;
LGG	cis	rs17208368	0.628	rs4784471	chr16:55092849	G/A	cg09947736	chr16:55091198	NA	0.68	12.85	0.51	1.59e-32	Hypospadias;
LGG	cis	rs5750830	0.621	rs5757665	chr22:39821641	A/G	cg11247378	chr22:39784982	NA	-0.32	-9.02	-0.39	4.83e-18	Intelligence (multi-trait analysis);
LGG	trans	rs12517041	0.938	rs10053581	chr5:23260066	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.76	-0.38	3.81e-17	Calcium levels;
LGG	cis	rs801193	1.000	rs3800812	chr7:66223461	T/C	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.25e-25	Aortic root size;
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs765787	0.530	rs11639403	chr15:45538350	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg13114125	chr14:105738426	BRF1	-0.86	-16.01	-0.6	3.03e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs17711722	0.522	rs4642526	chr7:65216742	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	13.8	0.54	1.52e-36	Calcium levels;
LGG	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg26384229	chr12:38710491	ALG10B	0.6	11.08	0.46	1.86e-25	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.13	0.35	4e-15	Personality dimensions;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17129028	chr17:74304023	QRICH2	0.39	6.78	0.3	3.61e-11	Pancreatic cancer;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs977987	0.736	rs11865296	chr16:75473693	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.95	0.42	2.81e-21	Dupuytren's disease;
LGG	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg15017067	chr4:17643749	FAM184B	0.31	7.22	0.32	2.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg19318889	chr4:1322082	MAEA	0.47	7.82	0.34	3.58e-14	Longevity;
LGG	cis	rs8177253	0.665	rs9869535	chr3:133451581	G/A	cg08048268	chr3:133502702	NA	-0.46	-7.94	-0.35	1.54e-14	Iron status biomarkers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16649755	chr6:88412160	NCRNA00120;AKIRIN2	0.5	8.1	0.35	4.87e-15	Cognitive performance;
LGG	cis	rs9467711	0.591	rs6940007	chr6:25931957	A/C	cg21479132	chr6:26055353	NA	0.74	6.9	0.31	1.69e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg03433033	chr1:76189801	ACADM	0.68	10.16	0.43	5.13e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	14.3	0.55	1.07e-38	Cognitive test performance;
LGG	cis	rs8114671	0.967	rs2378337	chr20:33771435	G/A	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs11190604	1.000	rs2298075	chr10:102247408	C/A	cg07080220	chr10:102295463	HIF1AN	0.64	11.12	0.46	1.31e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg20476274	chr7:133979776	SLC35B4	0.7	13.24	0.52	3.56e-34	Mean platelet volume;
LGG	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg13852791	chr20:30311386	BCL2L1	0.81	12.99	0.52	4.14e-33	Monocyte count;
LGG	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg18721089	chr20:30220636	NA	-0.5	-7.52	-0.33	2.8e-13	Mean corpuscular hemoglobin;
LGG	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg25358565	chr5:93447407	FAM172A	1.39	17.11	0.62	3.18e-51	Diabetic retinopathy;
LGG	cis	rs4906332	0.840	rs34161327	chr14:103857325	G/A	cg26031613	chr14:104095156	KLC1	-0.53	-8.03	-0.35	8.4e-15	Coronary artery disease;
LGG	cis	rs2235573	0.551	rs139891	chr22:38387914	G/T	cg19171272	chr22:38449367	NA	-0.51	-9.56	-0.41	7.13e-20	Glioblastoma;Glioma;
LGG	cis	rs910316	0.591	rs7157158	chr14:75457238	A/G	cg06637938	chr14:75390232	RPS6KL1	0.53	9.36	0.4	3.39e-19	Height;
LGG	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg19524238	chr7:2802976	GNA12	0.29	7.01	0.31	8.41e-12	Height;
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg02158880	chr13:53174818	NA	0.36	6.72	0.3	5.33e-11	Lewy body disease;
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26076054	chr5:421317	AHRR	-0.54	-8.88	-0.38	1.48e-17	Cystic fibrosis severity;
LGG	trans	rs61931739	0.620	rs4323992	chr12:33693639	G/A	cg26384229	chr12:38710491	ALG10B	-0.49	-8.63	-0.37	1.02e-16	Morning vs. evening chronotype;
LGG	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.31	-6.85	-0.3	2.41e-11	Restless legs syndrome;
LGG	cis	rs4803468	1.000	rs3810175	chr19:41904396	C/T	cg14132834	chr19:41945861	ATP5SL	0.47	9.3	0.4	5.74e-19	Height;
LGG	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg23205692	chr1:25664452	TMEM50A	0.54	11.97	0.49	6.04e-29	Erythrocyte sedimentation rate;
LGG	cis	rs7666738	0.800	rs7684523	chr4:98983175	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4622507	0.566	rs17208312	chr16:55071488	C/T	cg09947736	chr16:55091198	NA	0.76	11.5	0.47	4.42e-27	Social communication problems;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg06121193	chr1:90282411	NA	0.39	7.19	0.32	2.69e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3812831	0.599	rs428636	chr13:114927133	T/C	cg25338242	chr13:114786047	RASA3	0.39	7.06	0.31	6.06e-12	Schizophrenia;
LGG	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg18129748	chr3:49941408	MST1R	0.22	7.11	0.31	4.49e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs6466990	chr7:124691512	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.39	-0.32	6.71e-13	Cutaneous malignant melanoma;
LGG	cis	rs1008375	0.900	rs13101742	chr4:17701297	G/A	cg02297831	chr4:17616191	MED28	-0.46	-8.13	-0.35	3.87e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11096990	0.929	rs56037933	chr4:39227273	A/G	cg24403649	chr4:39172243	NA	-0.46	-7.54	-0.33	2.47e-13	Cognitive function;
LGG	cis	rs9547996	0.879	rs61957468	chr13:38132914	G/A	cg13634560	chr13:38173852	POSTN	-0.35	-7.04	-0.31	7.19e-12	Diastolic blood pressure;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	cis	rs9604529	0.759	rs77777032	chr13:114625889	T/C	cg13259177	chr13:114761607	RASA3	-0.65	-8.53	-0.37	2.1e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	7.69	0.34	9.21e-14	Retinal vascular caliber;
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	7.0	0.31	8.89e-12	Renal function-related traits (BUN);
LGG	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg01338084	chr22:32026380	PISD	1.49	12.9	0.51	1.01e-32	Age-related hearing impairment;
LGG	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.69	12.94	0.52	6.32e-33	Response to antipsychotic treatment;
LGG	cis	rs1865760	0.566	rs2032449	chr6:26026599	G/C	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs12681287	0.640	rs13253261	chr8:87458500	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs9815354	1.000	rs1717027	chr3:41987920	T/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.83	-10.06	-0.42	1.17e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7929679	0.602	rs11032872	chr11:34806192	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.41	6.96	0.31	1.17e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.29	0.36	1.23e-15	Tonsillectomy;
LGG	cis	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg21775007	chr8:11205619	TDH	0.46	6.97	0.31	1.06e-11	Triglycerides;
LGG	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg20573242	chr4:122745356	CCNA2	0.52	9.59	0.41	5.57e-20	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg24829409	chr8:58192753	C8orf71	-0.77	-10.43	-0.44	5.01e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg07636037	chr3:49044803	WDR6	-0.8	-13.96	-0.54	3.22e-37	Menarche (age at onset);
LGG	trans	rs9354308	0.714	rs2351714	chr6:66585731	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2797369	0.574	rs1222223	chr6:101610221	T/G	cg27451362	chr6:101846650	GRIK2	-0.46	-7.19	-0.32	2.64e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.14	0.52	9.76e-34	Lung cancer;
LGG	cis	rs17221829	0.739	rs55812948	chr11:89446332	T/C	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.68	-0.34	9.5e-14	Anxiety in major depressive disorder;
LGG	cis	rs951366	0.589	rs823099	chr1:205669322	C/A	cg07157834	chr1:205819609	PM20D1	0.73	16.59	0.61	7.5e-49	Menarche (age at onset);
LGG	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg13939156	chr17:80058883	NA	0.53	10.81	0.45	1.97e-24	Life satisfaction;
LGG	cis	rs2011503	1.000	rs56280531	chr19:19585788	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.79	0.3	3.41e-11	Bipolar disorder;
LGG	cis	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg09998033	chr7:158218633	PTPRN2	-0.61	-11.86	-0.48	1.59e-28	Obesity-related traits;
LGG	cis	rs3806843	0.576	rs246046	chr5:140329264	T/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12681287	0.547	rs10956873	chr8:87547028	T/C	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs3204270	0.684	rs57405099	chr17:79637065	T/C	cg18367735	chr17:79674897	NA	0.57	7.31	0.32	1.15e-12	Dental caries;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	13.9	0.54	6.12e-37	Platelet count;
LGG	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg02711726	chr17:80685570	FN3KRP	0.66	13.53	0.53	2.14e-35	Glycated hemoglobin levels;
LGG	trans	rs7746199	0.736	rs17693963	chr6:27710165	A/C	cg01620082	chr3:125678407	NA	-0.92	-9.17	-0.39	1.55e-18	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4481887	0.790	rs4453078	chr1:248411889	A/G	cg13385794	chr1:248469461	NA	-0.4	-6.79	-0.3	3.34e-11	Common traits (Other);
LGG	cis	rs11250464	1.000	rs11250464	chr10:1406364	A/G	cg08668359	chr10:1443807	ADARB2	0.59	11.29	0.46	2.92e-26	Radiation response;
LGG	cis	rs240764	0.621	rs12175456	chr6:101219511	A/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.2	-0.36	2.36e-15	Neuroticism;
LGG	cis	rs9300255	0.602	rs1716172	chr12:123712712	G/T	cg00376283	chr12:123451042	ABCB9	0.63	10.1	0.42	8.58e-22	Neutrophil percentage of white cells;
LGG	cis	rs72781680	0.846	rs72780198	chr2:24014883	T/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs9790314	0.747	rs4616689	chr3:160856269	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-11.68	-0.48	8.7300000000000009e-28	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg00684032	chr4:1343700	KIAA1530	-0.47	-9.12	-0.39	2.31e-18	Obesity-related traits;
LGG	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.41	-0.36	5.13e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs17253792	0.749	rs45458197	chr14:56145018	A/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	trans	rs9354308	0.702	rs9345713	chr6:66591842	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	trans	rs62458065	0.850	rs10239812	chr7:32460348	A/G	cg00845942	chr12:64062724	DPY19L2	-0.57	-7.09	-0.31	5.08e-12	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.07e-17	Lung cancer;
LGG	cis	rs861020	0.771	rs661849	chr1:210001233	C/T	cg09163369	chr1:210001066	C1orf107	0.39	6.97	0.31	1.1e-11	Orofacial clefts;
LGG	cis	rs34891900	0.507	rs2535707	chr22:18181869	C/T	cg19898043	chr22:18121309	BCL2L13	-0.55	-8.96	-0.38	7.98e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs11252926	0.650	rs4880678	chr10:490472	G/A	cg08603382	chr10:743973	NA	0.43	7.95	0.35	1.47e-14	Psychosis in Alzheimer's disease;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.79	0.38	3.04e-17	Height;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	trans	rs11039798	0.699	rs7120775	chr11:48266736	C/G	cg03929089	chr4:120376271	NA	0.69	8.08	0.35	5.72e-15	Axial length;
LGG	cis	rs240764	0.782	rs395521	chr6:101054999	C/T	cg09795085	chr6:101329169	ASCC3	0.45	7.66	0.34	1.08e-13	Neuroticism;
LGG	cis	rs9560113	0.573	rs9560132	chr13:112237456	C/T	cg15979348	chr13:112237479	NA	0.45	7.82	0.34	3.5e-14	Menarche (age at onset);
LGG	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.06	0.49	2.7e-29	Height;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg06112835	chr11:68658793	MRPL21	0.58	9.61	0.41	4.66e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg02071572	chr4:1403502	NA	0.41	6.99	0.31	9.5e-12	Longevity;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg13012494	chr21:47604986	C21orf56	0.56	9.79	0.41	1.1e-20	Testicular germ cell tumor;
LGG	cis	rs13191362	0.935	rs73037930	chr6:162937146	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.72	0.3	5.31e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.39	-0.36	6.05e-16	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14535006	chr20:18448030	C20orf12;POLR3F	0.47	7.91	0.35	1.86e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs11098499	0.739	rs7441137	chr4:120133221	G/T	cg25214090	chr10:38739885	LOC399744	-0.57	-10.13	-0.43	6.35e-22	Corneal astigmatism;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg00364696	chr7:1142433	C7orf50	-0.39	-7.59	-0.33	1.74e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12580194	1.000	rs61539173	chr12:55703206	C/T	cg19537932	chr12:55886519	OR6C68	-0.37	-6.69	-0.3	6.52e-11	Cancer;
LGG	cis	rs10861661	0.963	rs10444533	chr12:107229705	A/G	cg15890332	chr12:107067104	RFX4	-0.3	-6.86	-0.3	2.28e-11	Triglyceride levels;
LGG	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg03929089	chr4:120376271	NA	0.74	8.6	0.37	1.27e-16	Axial length;
LGG	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.76e-33	Vitamin D levels;
LGG	cis	rs17767392	0.756	rs61991195	chr14:71747223	G/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.63	0.37	1e-16	Mitral valve prolapse;
LGG	cis	rs4363385	0.597	rs6679201	chr1:152976840	C/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.2	-0.39	1.19e-18	Inflammatory skin disease;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs7520050	0.581	rs3855959	chr1:46633874	C/T	cg08947153	chr1:46664340	POMGNT1	0.37	6.69	0.3	6.28e-11	Red blood cell count;Reticulocyte count;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.26	0.4	7.84e-19	Electroencephalogram traits;
LGG	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	4.03e-16	Retinal vascular caliber;
LGG	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.01	-0.6	2.98e-46	Height;
LGG	cis	rs4851250	0.580	rs56909870	chr2:100620017	C/T	cg17356467	chr2:100759845	AFF3	0.45	7.09	0.31	5.05e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4901847	0.901	rs10144315	chr14:58546621	A/T	cg15908186	chr14:58618357	C14orf37	0.54	9.67	0.41	2.91e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg18357526	chr6:26021779	HIST1H4A	0.62	11.06	0.46	2.23e-25	Blood metabolite levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23952643	chr11:8009057	EIF3F	0.37	7.1	0.31	4.61e-12	Menarche (age at onset);
LGG	cis	rs13191362	1.000	rs68144677	chr6:163149024	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.03	0.31	7.63e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7166081	0.950	rs35322464	chr15:67511490	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.0	-0.31	9.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg06521331	chr12:34319734	NA	0.39	6.69	0.3	6.42e-11	Morning vs. evening chronotype;
LGG	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08822215	chr16:89438651	ANKRD11	-0.35	-6.67	-0.3	7.23e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs2540226	0.539	rs2540247	chr2:39909949	C/T	cg02886589	chr2:39892450	TMEM178	0.31	8.56	0.37	1.74e-16	Personality dimensions;
LGG	cis	rs977987	0.806	rs35683383	chr16:75479277	G/T	cg03315344	chr16:75512273	CHST6	0.53	10.64	0.44	8.52e-24	Dupuytren's disease;
LGG	cis	rs9467711	0.606	rs13203358	chr6:26590578	A/T	cg12826209	chr6:26865740	GUSBL1	0.78	8.25	0.36	1.69e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12444795	0.755	rs741692	chr16:4862425	C/T	cg04440724	chr16:4920505	UBN1	-0.57	-8.4	-0.36	5.33e-16	Cancer;
LGG	trans	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg10756647	chr7:56101905	PSPH	-0.82	-9.8	-0.41	9.84e-21	Diabetic kidney disease;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04106633	chr4:1044584	NA	0.37	7.85	0.34	2.89e-14	Recombination rate (males);
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg13047869	chr3:10149882	C3orf24	0.46	7.31	0.32	1.18e-12	Alzheimer's disease;
LGG	trans	rs7939886	0.844	rs17150088	chr11:55894862	T/G	cg15704280	chr7:45808275	SEPT13	0.84	8.83	0.38	2.18e-17	Myopia (pathological);
LGG	trans	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6459788	0.720	rs11768765	chr7:157253133	C/T	cg03453431	chr7:157225567	NA	-0.47	-8.23	-0.36	1.91e-15	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6723108	0.603	rs1947112	chr2:135715957	A/G	cg07169764	chr2:136633963	MCM6	0.43	6.69	0.3	6.41e-11	Type 2 diabetes;
LGG	trans	rs3857536	0.813	rs62415859	chr6:66934278	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.53e-14	Blood trace element (Cu levels);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19057882	chr20:37101373	RALGAPB	0.4	7.07	0.31	5.61e-12	Obesity-related traits;
LGG	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg03929089	chr4:120376271	NA	-0.97	-20.41	-0.69	1.72e-66	Coronary artery disease;
LGG	cis	rs12474201	0.928	rs34186074	chr2:46965010	T/C	cg06386533	chr2:46925753	SOCS5	0.8	15.03	0.57	7.43e-42	Height;
LGG	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg24209194	chr3:40518798	ZNF619	-0.43	-6.82	-0.3	2.86e-11	Renal cell carcinoma;
LGG	cis	rs67478160	0.643	rs8005594	chr14:104279889	T/C	cg26031613	chr14:104095156	KLC1	-0.46	-7.53	-0.33	2.62e-13	Schizophrenia;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg00761968	chr13:53314142	LECT1	-0.36	-7.69	-0.34	9.07e-14	Lewy body disease;
LGG	cis	rs3206736	0.548	rs167893	chr7:35042733	A/T	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.13	-25.3	-0.76	2.43e-89	Primary sclerosing cholangitis;
LGG	cis	rs11741688	0.557	rs6897783	chr5:178330574	G/A	cg09339527	chr5:178322752	ZFP2	-0.41	-7.54	-0.33	2.49e-13	Sleep duration;
LGG	cis	rs883565	0.655	rs7619193	chr3:39044116	T/C	cg01426195	chr3:39028469	NA	-0.74	-17.23	-0.63	8.73e-52	Handedness;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9291683	0.585	rs12648479	chr4:10104571	G/A	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.58	-0.33	1.91e-13	Bone mineral density;
LGG	trans	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg02002194	chr4:3960332	NA	0.45	8.17	0.35	2.93e-15	Monocyte count;
LGG	trans	rs75804782	0.515	rs79557340	chr2:239297952	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	6.9	0.31	1.77e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg24130564	chr14:104152367	KLC1	-0.48	-9.7	-0.41	2.16e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2599510	0.703	rs58852184	chr2:32729763	A/T	cg02381751	chr2:32503542	YIPF4	0.5	8.06	0.35	6.5e-15	Interleukin-18 levels;
LGG	cis	rs28595532	0.920	rs114653217	chr4:119769216	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs9815354	1.000	rs1613759	chr3:41906183	G/A	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17092148	0.887	rs4911430	chr20:33145404	C/G	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.77	-0.3	3.93e-11	Neuroticism;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg19680485	chr15:31195859	MTMR15	0.54	9.38	0.4	2.89e-19	Huntington's disease progression;
LGG	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg24642439	chr20:33292090	TP53INP2	0.56	9.4	0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs4746818	1.000	rs4746817	chr10:70882515	T/C	cg11621586	chr10:70884670	VPS26A	1.15	16.98	0.62	1.31e-50	Left atrial antero-posterior diameter;
LGG	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg22681709	chr2:178499509	PDE11A	-0.53	-9.69	-0.41	2.45e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9467711	0.591	rs13203673	chr6:25979122	T/C	cg21479132	chr6:26055353	NA	0.81	7.1	0.31	4.86e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7529073	0.815	rs1431984	chr1:214148628	A/G	cg05052969	chr1:214156842	NA	0.44	8.56	0.37	1.65e-16	Schizophrenia;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.85	-0.3	2.3e-11	Total body bone mineral density;
LGG	cis	rs60180747	1.000	rs60180747	chr15:66663261	A/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.55	9.84	0.42	7.24e-21	Testicular germ cell tumor;
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg14092988	chr3:52407081	DNAH1	0.34	8.93	0.38	1.04e-17	Bipolar disorder;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg14926445	chr8:58193284	C8orf71	-0.82	-10.6	-0.44	1.17e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs13314892	0.734	rs1549746	chr3:69851350	C/T	cg17445875	chr3:69859618	MITF	-0.38	-7.11	-0.31	4.38e-12	QRS complex (12-leadsum);
LGG	cis	rs1577917	0.655	rs1059307	chr6:86387888	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.58	10.76	0.45	3.11e-24	Response to antipsychotic treatment;
LGG	cis	rs12493885	0.725	rs11717851	chr3:153741735	G/A	cg17054900	chr3:154042577	DHX36	-0.65	-8.39	-0.36	5.88e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9397585	0.857	rs9397127	chr6:153374197	A/G	cg17707550	chr6:153380415	RGS17	0.62	14.47	0.56	2.05e-39	Body mass index;
LGG	cis	rs11700980	0.551	rs2832034	chr21:30114927	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs9388451	0.839	rs11154331	chr6:126111429	A/T	cg10911889	chr6:126070802	HEY2	0.44	7.44	0.33	5.05e-13	Brugada syndrome;
LGG	cis	rs13418410	0.539	rs11695597	chr2:33840024	A/G	cg04131969	chr2:33951647	MYADML	0.68	12.38	0.5	1.34e-30	Non-response to antidepressants and depression;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg24607181	chr17:41446203	NA	0.31	7.27	0.32	1.58e-12	Menopause (age at onset);
LGG	cis	rs2303319	1.000	rs62188140	chr2:162269866	A/G	cg13806767	chr2:162164127	PSMD14	-0.68	-7.87	-0.34	2.55e-14	Cognitive function;
LGG	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs877282	0.853	rs10904544	chr10:756966	A/G	cg22713356	chr15:30763199	NA	0.47	7.12	0.31	4.05e-12	Uric acid levels;
LGG	cis	rs2133450	0.967	rs6766479	chr3:7324186	C/G	cg19930620	chr3:7340148	GRM7	-0.37	-8.22	-0.36	2.08e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs3784262	1.000	rs4646593	chr15:58302467	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.01	-0.35	9.47e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs13191362	1.000	rs55822577	chr6:163069710	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	11.59	0.47	1.93e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9788721	1.000	rs10519203	chr15:78814046	C/T	cg18825076	chr15:78729989	IREB2	0.47	7.69	0.34	8.86e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2502399	0.898	rs774574	chr6:113511051	C/T	cg20413948	chr6:113544930	NA	0.29	6.93	0.31	1.4e-11	Plasma clusterin levels;
LGG	cis	rs12586317	0.620	rs17091786	chr14:35565856	A/T	cg05294307	chr14:35346193	BAZ1A	-0.56	-7.98	-0.35	1.17e-14	Psoriasis;
LGG	trans	rs5756813	1.000	rs1129448	chr22:38170026	G/A	cg19894588	chr14:64061835	NA	0.7	12.12	0.49	1.42e-29	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs2832191	0.740	rs2832175	chr21:30475606	A/G	cg24692254	chr21:30365293	RNF160	-1.04	-29.5	-0.81	2.12e-108	Dental caries;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg08975724	chr8:8085496	FLJ10661	0.45	8.62	0.37	1.04e-16	Neuroticism;
LGG	cis	rs1322639	0.668	rs9766666	chr6:169613541	G/T	cg03254818	chr6:169586852	NA	0.41	7.39	0.32	6.73e-13	Pulse pressure;
LGG	cis	rs9557207	1.000	rs9557202	chr13:99992280	A/G	cg24509225	chr13:100037070	UBAC2	0.71	12.93	0.52	6.96e-33	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs10189230	0.967	rs13012429	chr2:222350788	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs6087990	0.735	rs6087420	chr20:31359391	G/A	cg13636640	chr20:31349939	DNMT3B	0.84	17.71	0.64	5.5e-54	Ulcerative colitis;
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.58	0.37	1.46e-16	Bipolar disorder;
LGG	cis	rs2629540	0.731	rs11245341	chr10:126408777	G/C	cg08799069	chr10:126477246	METTL10	0.65	13.09	0.52	1.64e-33	Cocaine dependence;
LGG	cis	rs4076764	0.801	rs6698738	chr1:163359918	G/A	cg06092702	chr1:163392909	NA	-0.39	-6.86	-0.3	2.18e-11	Motion sickness;
LGG	cis	rs2013441	0.513	rs62067488	chr17:19967281	G/A	cg13482628	chr17:19912719	NA	0.41	7.09	0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs8133932	0.701	rs2183599	chr21:47288873	C/G	cg11214348	chr21:47283868	PCBP3	0.43	7.85	0.34	2.84e-14	Schizophrenia;
LGG	cis	rs10911232	0.507	rs10797833	chr1:183044067	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.11e-22	Height;
LGG	cis	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg05084668	chr3:125655381	ALG1L	0.87	11.08	0.46	1.77e-25	Blood pressure (smoking interaction);
LGG	cis	rs1059312	0.808	rs11059921	chr12:129289919	C/T	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.61	0.37	1.12e-16	Systemic lupus erythematosus;
LGG	cis	rs12476592	0.602	rs262476	chr2:63870607	A/G	cg17519650	chr2:63277830	OTX1	0.43	6.67	0.3	7.3e-11	Childhood ear infection;
LGG	cis	rs137603	0.644	rs137635	chr22:39720656	G/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.71	-13.84	-0.54	1.05e-36	Primary biliary cholangitis;
LGG	cis	rs4474465	1.000	rs7124043	chr11:78205644	G/T	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs1552244	0.744	rs6763366	chr3:10033544	T/C	cg00149659	chr3:10157352	C3orf10	0.76	9.68	0.41	2.63e-20	Alzheimer's disease;
LGG	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg10253484	chr15:75165896	SCAMP2	-0.66	-10.07	-0.42	1.07e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg14773178	chr5:1868261	NA	0.38	8.42	0.36	4.86e-16	Cardiovascular disease risk factors;
LGG	cis	rs34938134	0.686	rs7541633	chr1:245503899	C/G	cg15057323	chr1:245496060	KIF26B	0.52	8.65	0.37	8.31e-17	Daytime sleep phenotypes;
LGG	cis	rs72848980	0.512	rs3781362	chr10:105375601	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.8	12.96	0.52	5.22e-33	White matter hyperintensity burden;
LGG	cis	rs1881797	1.000	rs12061460	chr1:247686787	G/A	cg21399703	chr1:247681439	NA	0.65	11.54	0.47	3.11e-27	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2018055	0.618	rs6568977	chr6:117792460	G/C	cg14611402	chr6:117803162	DCBLD1	0.3	8.63	0.37	9.81e-17	Diastolic blood pressure;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg00789671	chr3:195488493	MUC4	0.59	8.55	0.37	1.75e-16	Lung disease severity in cystic fibrosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02773019	chr3:135684688	PPP2R3A	0.4	7.18	0.32	2.84e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9522267	0.535	rs56330641	chr13:112233538	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs6912958	0.781	rs6454632	chr6:88231824	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.82	-0.38	2.28e-17	Monocyte percentage of white cells;
LGG	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs11227306	0.934	rs11227315	chr11:65590389	C/A	cg17712092	chr4:129076599	LARP1B	0.63	10.71	0.45	4.78e-24	DNA methylation (variation);
LGG	cis	rs7582720	1.000	rs72936846	chr2:203774734	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-15.81	-0.59	2.4e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs72960926	1.000	rs55958316	chr6:75103944	C/T	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs4851266	0.833	rs11685491	chr2:100858122	A/G	cg21926883	chr2:100939477	LONRF2	-0.47	-8.35	-0.36	8.09e-16	Educational attainment;
LGG	cis	rs4954585	0.683	rs13004902	chr2:137027680	A/G	cg05194412	chr2:137003533	NA	0.38	8.28	0.36	1.37e-15	Colorectal cancer;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.73	-14.87	-0.57	3.53e-41	Obesity-related traits;
LGG	cis	rs2742417	1.000	rs2742437	chr3:45743277	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11372422	chr4:115519985	UGT8	0.41	6.65	0.3	8.39e-11	Cognitive performance;
LGG	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.8899999999999998e-20	Retinal vascular caliber;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.13	-0.39	2.16e-18	Life satisfaction;
LGG	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Body mass index;
LGG	cis	rs763121	0.853	rs138706	chr22:39137834	C/G	cg06022373	chr22:39101656	GTPBP1	0.88	17.35	0.63	2.66e-52	Menopause (age at onset);
LGG	cis	rs79349575	0.715	rs999474	chr17:46987665	G/A	cg22482690	chr17:47019901	SNF8	-0.34	-6.77	-0.3	3.99e-11	Type 2 diabetes;
LGG	cis	rs2046867	0.818	rs1502757	chr3:72864161	C/T	cg26655873	chr3:72818019	SHQ1	0.35	7.0	0.31	9.11e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs228437	1.000	rs1474828	chr6:134926962	A/C	cg24504307	chr6:134963096	NA	0.41	7.7	0.34	8.07e-14	Melanoma;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7928758	0.887	rs74639401	chr11:134264213	C/T	cg22777979	chr11:134283252	B3GAT1	1.02	12.85	0.51	1.48e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs757278	0.526	rs10272233	chr7:117309974	G/A	cg10524701	chr7:117356490	CTTNBP2	0.42	7.53	0.33	2.72e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.62	-0.41	4.27e-20	Morning vs. evening chronotype;
LGG	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.07	0.39	3.34e-18	Rheumatoid arthritis;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10979	1.000	rs35354710	chr6:143886454	A/G	cg25407410	chr6:143891975	LOC285740	-0.71	-12.42	-0.5	8.7e-31	Hypospadias;
LGG	cis	rs75920871	0.841	rs7112967	chr11:116831912	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.99e-12	Subjective well-being;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.53	-9.99	-0.42	1.99e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg10840412	chr1:235813424	GNG4	0.5	6.69	0.3	6.27e-11	Bipolar disorder;
LGG	cis	rs6752107	1.000	rs2289472	chr2:234182240	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.03e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4665809	0.590	rs2891496	chr2:26452605	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.14	0.35	3.58e-15	Gut microbiome composition (summer);
LGG	cis	rs1007190	0.881	rs71373521	chr17:42949442	C/T	cg15406952	chr17:42872593	NA	1.05	13.86	0.54	8.36e-37	DNA methylation (variation);
LGG	cis	rs7917772	0.503	rs7915589	chr10:104299264	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7143963	0.636	rs10133709	chr14:103310758	A/T	cg23020514	chr14:103360112	TRAF3	0.4	8.41	0.36	5.31e-16	Body mass index;
LGG	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7551222	0.646	rs1398148	chr1:204458328	C/G	cg20240347	chr1:204465584	NA	-0.51	-9.68	-0.41	2.72e-20	Schizophrenia;
LGG	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg24253500	chr15:84953950	NA	0.61	11.43	0.47	7.91e-27	Schizophrenia;
LGG	cis	rs9300255	0.568	rs1627724	chr12:123638580	T/A	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1.05e-13	Neutrophil percentage of white cells;
LGG	cis	rs9457247	0.935	rs2757046	chr6:167374353	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs6062302	0.548	rs6089940	chr20:62252695	C/T	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	cis	rs4595586	0.545	rs3858554	chr12:39381460	C/T	cg13010199	chr12:38710504	ALG10B	0.4	7.31	0.32	1.2e-12	Morning vs. evening chronotype;
LGG	cis	rs1707322	1.000	rs10890353	chr1:46298383	G/T	cg03146154	chr1:46216737	IPP	0.55	10.47	0.44	3.7e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9863	0.828	rs35099862	chr12:124467204	C/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.08	-0.31	5.27e-12	White blood cell count;
LGG	trans	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.34	-0.65	7.39e-57	Exhaled nitric oxide output;
LGG	cis	rs3206736	0.549	rs10282424	chr7:35211135	A/G	cg13400248	chr7:35225412	NA	-0.53	-9.16	-0.39	1.62e-18	Diastolic blood pressure;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg00142150	chr22:38071001	LGALS1	0.92	19.76	0.68	1.8e-63	Fat distribution (HIV);
LGG	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg02640540	chr1:67518911	SLC35D1	0.58	11.64	0.48	1.24e-27	Lymphocyte percentage of white cells;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg03528353	chr17:61819722	STRADA	0.43	7.38	0.32	7.46e-13	Prudent dietary pattern;
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg14092988	chr3:52407081	DNAH1	0.3	7.95	0.35	1.4e-14	Bipolar disorder;
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg12310025	chr6:25882481	NA	-0.47	-8.7	-0.37	5.9e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.791	rs10010438	chr4:99022177	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs169738	1	rs169738	chr6:33537546	A/G	cg13560919	chr6:33536144	NA	-0.44	-6.95	-0.31	1.26e-11	Platelet count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs9951602	0.512	rs9955812	chr18:76650954	T/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs9358872	chr6:25727517	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	cis	rs6121246	0.821	rs7265413	chr20:30317923	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19237809	chr12:46120899	LOC400027	0.5	7.51	0.33	2.98e-13	Gut microbiome composition (summer);
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg01765077	chr12:122356316	WDR66	0.3	8.2	0.36	2.31e-15	Mean corpuscular volume;
LGG	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg06046430	chr4:77819534	ANKRD56	-0.52	-10.91	-0.45	8.21e-25	Emphysema distribution in smoking;
LGG	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-10.96	-0.45	5.39e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.72e-18	Aortic root size;
LGG	cis	rs8070128	0.637	rs4925133	chr17:17884801	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	12.67	0.51	8.22e-32	Total body bone mineral density;
LGG	trans	rs10028773	0.556	rs4473640	chr4:120260437	G/A	cg25214090	chr10:38739885	LOC399744	0.56	10.24	0.43	2.49e-22	Educational attainment;
LGG	cis	rs6582630	0.539	rs8189604	chr12:38308546	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.13	-0.39	2.2e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg12292205	chr6:26970375	C6orf41	0.56	11.03	0.46	2.87e-25	Schizophrenia;
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.85e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs8077116	chr17:29140162	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2836950	0.520	rs8133927	chr21:40689961	G/T	cg11890956	chr21:40555474	PSMG1	-0.72	-12.37	-0.5	1.47e-30	Menarche (age at onset);
LGG	cis	rs258892	0.895	rs155433	chr5:72139664	G/C	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	cis	rs972578	0.765	rs4822223	chr22:43294744	T/C	cg01576275	chr22:43409880	NA	-0.22	-6.82	-0.3	2.85e-11	Mean platelet volume;
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02825527	chr7:2087843	MAD1L1	-0.44	-7.81	-0.34	3.89e-14	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.32	-0.32	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs721399	0.927	rs1495747	chr8:18262861	T/C	cg18736775	chr8:18248649	NAT2	0.5	8.86	0.38	1.72e-17	Blood metabolite levels;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg10295955	chr4:187884368	NA	1.09	25.45	0.76	5.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7586879	0.765	rs11683429	chr2:25120733	T/A	cg04586622	chr2:25135609	ADCY3	0.37	9.14	0.39	1.93e-18	Body mass index;
LGG	cis	rs12893597	0.715	rs4624098	chr14:76826256	G/A	cg20290672	chr14:76816747	NA	-0.51	-7.69	-0.34	8.98e-14	Maximal oxygen uptake response;
LGG	cis	rs2718058	0.630	rs2722227	chr7:37858610	G/A	cg24998770	chr7:37888106	TXNDC3	0.45	7.25	0.32	1.72e-12	Alzheimer's disease (late onset);
LGG	cis	rs1816752	0.805	rs61614647	chr13:25015967	C/T	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs2645694	0.626	rs2645708	chr4:77822682	G/A	cg10057126	chr4:77819792	ANKRD56	0.36	7.01	0.31	8.53e-12	Emphysema distribution in smoking;
LGG	cis	rs7044106	0.791	rs2416799	chr9:123480866	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.63	0.51	1.3e-31	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg00800038	chr16:89945340	TCF25	-0.62	-8.51	-0.37	2.4e-16	Skin colour saturation;
LGG	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.43e-59	Diabetic kidney disease;
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg05793240	chr7:2802953	GNA12	0.31	7.55	0.33	2.32e-13	Height;
LGG	cis	rs2380220	0.606	rs9488080	chr6:96006973	A/G	cg15832292	chr6:96025679	MANEA	0.5	6.91	0.31	1.6e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs4262150	0.774	rs72799105	chr5:152048633	A/G	cg12297329	chr5:152029980	NA	-0.81	-15.4	-0.58	1.73e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs10861342	1.000	rs11112371	chr12:105499021	T/C	cg23923672	chr12:105501055	KIAA1033	0.82	7.19	0.32	2.6e-12	IgG glycosylation;
LGG	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.48	0.4	1.32e-19	Height;
LGG	cis	rs933688	1.000	rs985434	chr5:90744509	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04455180	chr1:227506639	CDC42BPA	0.47	7.7	0.34	8.45e-14	Cognitive performance;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.96	0.31	1.2e-11	Lung cancer;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.12	-20.93	-0.7	6.35e-69	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7223966	1.000	rs8075422	chr17:61804686	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.19	0.32	2.58e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7107174	0.792	rs12291726	chr11:78088210	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.64	-0.33	1.26e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	1.01e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12586317	0.547	rs4982236	chr14:35468046	C/G	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs2180341	0.960	rs9398842	chr6:127674662	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.03	0.6	2.67e-46	Breast cancer;
LGG	cis	rs1552244	0.938	rs7652951	chr3:10063763	A/C	cg16606324	chr3:10149918	C3orf24	0.58	7.7	0.34	8.38e-14	Alzheimer's disease;
LGG	trans	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.75	0.48	4.39e-28	Mean corpuscular volume;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01788996	chr2:109403045	CCDC138	-0.49	-7.69	-0.34	9.01e-14	Pancreatic cancer;
LGG	cis	rs7851660	0.967	rs10818133	chr9:100610348	C/G	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.58e-40	Strep throat;
LGG	cis	rs738322	0.555	rs731821	chr22:38559448	C/A	cg03162506	chr22:38580953	NA	0.4	10.18	0.43	4.24e-22	Cutaneous nevi;
LGG	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs2012796	0.957	rs8016255	chr14:81816121	C/G	cg02996355	chr14:81879375	NA	0.45	7.16	0.32	3.13e-12	Night sleep phenotypes;
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.68	0.37	6.81e-17	Schizophrenia;
LGG	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11122272	0.668	rs2472261	chr1:231505701	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg11965913	chr1:205819406	PM20D1	-0.42	-6.96	-0.31	1.2e-11	Menarche (age at onset);
LGG	cis	rs4474465	0.920	rs908002	chr11:78144753	T/A	cg27205649	chr11:78285834	NARS2	-0.49	-8.25	-0.36	1.7e-15	Alzheimer's disease (survival time);
LGG	cis	rs12477438	0.798	rs4851179	chr2:99568774	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.55	-0.5	2.58e-31	Chronic sinus infection;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21832731	chr22:42475642	C22orf32	-0.42	-7.11	-0.31	4.44e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11586313	0.507	rs6658967	chr1:152870372	C/G	cg13444842	chr1:152974279	SPRR3	-0.41	-7.92	-0.35	1.78e-14	Vitamin D levels;
LGG	cis	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs6815814	0.950	rs5743580	chr4:38804405	C/T	cg06935464	chr4:38784597	TLR10	0.61	8.39	0.36	5.74e-16	Breast cancer;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg11965913	chr1:205819406	PM20D1	0.95	23.13	0.73	2.92e-79	Menarche (age at onset);
LGG	cis	rs2734839	0.964	rs1116313	chr11:113296107	A/G	cg14159747	chr11:113255604	NA	0.27	7.06	0.31	6.24e-12	Information processing speed;
LGG	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	cis	rs4423214	0.559	rs10898201	chr11:71201527	C/A	cg05163923	chr11:71159392	DHCR7	-0.57	-8.39	-0.36	6.02e-16	Vitamin D levels;
LGG	cis	rs75920871	0.623	rs11823889	chr11:116960403	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-8.0	-0.35	1.04e-14	Subjective well-being;
LGG	cis	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg06521331	chr12:34319734	NA	-0.61	-11.37	-0.47	1.38e-26	Morning vs. evening chronotype;
LGG	cis	rs5758511	0.680	rs5758652	chr22:42612408	T/C	cg15128208	chr22:42549153	NA	0.74	11.31	0.47	2.42e-26	Birth weight;
LGG	cis	rs9487051	0.872	rs9487043	chr6:109610474	C/T	cg21918786	chr6:109611834	NA	-0.49	-9.08	-0.39	3.06e-18	Reticulocyte fraction of red cells;
LGG	cis	rs2013441	1.000	rs2526483	chr17:20112216	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs11785400	1.000	rs10099892	chr8:143734608	C/T	cg10596483	chr8:143751796	JRK	0.59	9.66	0.41	3.01e-20	Schizophrenia;
LGG	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.41	-7.85	-0.34	2.95e-14	Educational attainment;
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg14074117	chr16:1909714	C16orf73	-0.52	-7.58	-0.33	1.87e-13	Ankle injury;
LGG	cis	rs1372520	0.873	rs983361	chr4:90761944	T/G	cg15133208	chr4:90757351	SNCA	-0.41	-8.46	-0.37	3.63e-16	Neuroticism;
LGG	cis	rs62238980	0.522	rs117246042	chr22:32454080	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg08621203	chr6:150244597	RAET1G	0.45	7.84	0.34	3.17e-14	Lung cancer;
LGG	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.08	-0.39	3.06e-18	Systemic lupus erythematosus;
LGG	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg21772509	chr8:41503840	NKX6-3	-0.53	-8.29	-0.36	1.27e-15	Type 2 diabetes;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg11062466	chr8:58055876	NA	0.51	8.71	0.38	5.28e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3099143	0.901	rs78020233	chr15:77107050	T/G	cg21673338	chr15:77095150	SCAPER	-0.66	-9.77	-0.41	1.22e-20	Recalcitrant atopic dermatitis;
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg23188684	chr11:67383651	NA	0.52	8.37	0.36	7.03e-16	Mean corpuscular volume;
LGG	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg06850241	chr22:41845214	NA	0.45	7.17	0.32	2.9e-12	Vitiligo;
LGG	cis	rs7084402	0.967	rs1658424	chr10:60331588	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.85	-0.34	2.88e-14	Blood metabolite levels;
LGG	cis	rs17039065	0.920	rs73838435	chr4:109445261	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.62	7.71	0.34	7.87e-14	Gut microbiome composition (summer);
LGG	cis	rs4808199	0.948	rs7250368	chr19:19452763	G/A	cg03709012	chr19:19516395	GATAD2A	0.96	15.19	0.58	1.35e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs8048589	0.851	rs12918263	chr16:12195123	A/G	cg02910054	chr16:12241554	SNX29	0.44	7.1	0.31	4.84e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg23985595	chr17:80112537	CCDC57	0.39	7.62	0.33	1.48e-13	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05239308	chr15:90793056	TTLL13	0.49	7.83	0.34	3.38e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.8	0.45	2.17e-24	Longevity;
LGG	cis	rs7737355	0.738	rs3776016	chr5:130855352	C/T	cg06307176	chr5:131281290	NA	0.52	8.72	0.38	5.19e-17	Life satisfaction;
LGG	cis	rs1558375	0.679	rs31671	chr7:87059403	C/G	cg00919237	chr7:87102261	ABCB4	-0.54	-9.68	-0.41	2.71e-20	Gallbladder cancer;
LGG	cis	rs78545713	0.649	rs11754368	chr6:26221173	G/A	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg09327250	chr3:195381832	NA	0.44	7.36	0.32	8.47e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs7552404	1.000	rs437298	chr1:76113770	T/C	cg10523679	chr1:76189770	ACADM	-0.83	-14.36	-0.56	6.1e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg12183467	chr14:104352244	NA	-0.43	-7.68	-0.34	9.51e-14	Bipolar disorder;
LGG	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg19847130	chr8:10466454	RP1L1	0.31	6.96	0.31	1.14e-11	Neuroticism;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg04503457	chr17:41445688	NA	-0.39	-8.96	-0.38	7.91e-18	Menopause (age at onset);
LGG	trans	rs1422110	0.519	rs12055343	chr5:85437684	T/C	cg01787110	chr1:109008453	NBPF6	0.68	11.73	0.48	5.28e-28	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg02002194	chr4:3960332	NA	-0.45	-7.98	-0.35	1.16e-14	Retinal vascular caliber;
LGG	cis	rs11758351	0.500	rs75551401	chr6:26185387	T/C	cg02612650	chr6:26195910	NA	0.87	6.82	0.3	2.82e-11	Gout;Renal underexcretion gout;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg04025307	chr7:1156635	C7orf50	0.62	8.27	0.36	1.44e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12701220	0.553	rs7782024	chr7:1157502	G/T	cg00990874	chr7:1149470	C7orf50	-0.82	-15.0	-0.57	9.65e-42	Bronchopulmonary dysplasia;
LGG	cis	rs1595825	0.786	rs73054839	chr2:198671665	C/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.65	-0.3	8.53e-11	Ulcerative colitis;
LGG	cis	rs10421328	0.821	rs4808976	chr19:19759299	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.33	7.14	0.31	3.61e-12	Parental longevity (combined parental age at death);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17324776	chr17:41116197	AARSD1	0.48	7.22	0.32	2.11e-12	Gut microbiome composition (summer);
LGG	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.58	-0.33	1.85e-13	Joint mobility (Beighton score);
LGG	cis	rs2013441	0.866	rs9898295	chr17:20120594	G/T	cg13482628	chr17:19912719	NA	-0.41	-6.97	-0.31	1.11e-11	Obesity-related traits;
LGG	cis	rs12210905	0.925	rs12214640	chr6:26762080	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.74	-0.34	6.33e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4742903	0.875	rs10991141	chr9:106938280	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg20290983	chr6:43655470	MRPS18A	0.82	15.77	0.59	3.61e-45	IgG glycosylation;
LGG	cis	rs74781061	0.872	rs6495106	chr15:74779347	G/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.23	-0.32	2e-12	Endometriosis;
LGG	cis	rs2011503	1.000	rs11669558	chr19:19655670	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.84	0.3	2.45e-11	Bipolar disorder;
LGG	cis	rs9649213	0.614	rs59120980	chr7:98017730	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.34	-0.36	8.84e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg03264133	chr6:25882463	NA	0.47	8.36	0.36	7.33e-16	Height;
LGG	cis	rs208520	0.690	rs12202913	chr6:66734198	C/T	cg07460842	chr6:66804631	NA	0.96	17.92	0.64	5.89e-55	Exhaled nitric oxide output;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg11473876	chr11:109292803	C11orf87	0.49	9.6	0.41	4.88e-20	Schizophrenia;
LGG	cis	rs9354308	0.764	rs9283824	chr6:66597980	G/C	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.7	11.44	0.47	7.23e-27	Iron status biomarkers;
LGG	cis	rs2559856	1.000	rs2559857	chr12:102089399	A/C	cg12924262	chr12:102091054	CHPT1	0.66	13.31	0.53	1.93e-34	Blood protein levels;
LGG	cis	rs7122539	0.722	rs7948839	chr11:66634397	C/T	cg01599099	chr11:66649832	PC	0.45	9.12	0.39	2.37e-18	HIV-1 susceptibility;
LGG	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.81	-0.59	2.42e-45	Tonsillectomy;
LGG	cis	rs12477438	0.520	rs6712704	chr2:99719687	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs2029213	0.523	rs2035450	chr3:53269317	C/T	cg16894138	chr3:53270350	TKT	0.5	10.19	0.43	3.89e-22	Heart rate;
LGG	cis	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.43	-0.33	5.21e-13	Triglycerides;
LGG	cis	rs910316	0.967	rs11159116	chr14:75550584	G/T	cg08847533	chr14:75593920	NEK9	0.63	12.24	0.49	4.78e-30	Height;
LGG	cis	rs920590	0.796	rs7820520	chr8:19634864	A/G	cg01411142	chr8:19674711	INTS10	-0.43	-6.67	-0.3	7.12e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs908922	0.676	rs11205014	chr1:152483634	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.42	0.58	1.38e-43	Hair morphology;
LGG	cis	rs79839061	0.610	rs11248051	chr4:858332	C/T	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.904	rs8068427	chr17:37511517	G/A	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	2.93e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs11039798	0.841	rs10839174	chr11:48931185	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs2228479	0.681	rs2270461	chr16:89972345	C/T	cg03036210	chr16:89904091	SPIRE2	0.47	6.9	0.31	1.68e-11	Skin colour saturation;
LGG	cis	rs12586317	0.534	rs28384418	chr14:35452126	C/A	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.25	-0.43	2.4e-22	Psoriasis;
LGG	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-13.8	-0.54	1.55e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.06e-13	Bipolar disorder;
LGG	cis	rs975722	0.650	rs213985	chr7:117259011	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	9.17	0.39	1.61e-18	Coronary artery disease;
LGG	cis	rs73198271	0.562	rs113730597	chr8:8651573	G/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs503734	0.846	rs2627547	chr3:100921085	T/A	cg27318481	chr3:100970896	IMPG2	-0.43	-9.59	-0.41	5.4e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11245990	chr11:68621969	NA	0.4	8.55	0.37	1.86e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-9.34	-0.4	4.01e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.523	rs10838750	chr11:5886246	C/T	cg02574844	chr11:5959923	NA	0.59	10.11	0.43	7.48e-22	DNA methylation (variation);
LGG	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg18225595	chr11:63971243	STIP1	0.64	12.69	0.51	7.32e-32	Platelet count;
LGG	cis	rs12493885	0.872	rs9840371	chr3:153796829	C/T	cg12800244	chr3:153838788	SGEF	0.81	8.81	0.38	2.52e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13138137	chr18:35146478	BRUNOL4	0.45	6.94	0.31	1.34e-11	Gut microbiome composition (summer);
LGG	cis	rs910316	0.692	rs7156586	chr14:75506230	A/T	cg11812906	chr14:75593930	NEK9	0.48	7.76	0.34	5.47e-14	Height;
LGG	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs4006360	0.604	rs3843964	chr17:39227984	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.46	10.12	0.43	6.81e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg02503808	chr4:7069936	GRPEL1	0.9	14.15	0.55	5.05e-38	Monocyte percentage of white cells;
LGG	cis	rs11967485	0.609	rs62435828	chr6:157193607	C/T	cg23222435	chr6:157204239	ARID1B	-0.8	-7.38	-0.32	7.51e-13	Calcium levels;
LGG	cis	rs7236492	0.683	rs79747802	chr18:77198964	C/T	cg15644404	chr18:77186268	NFATC1	-0.81	-10.11	-0.43	7.74e-22	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg12395012	chr8:11607386	GATA4	-0.39	-7.41	-0.33	6.04e-13	Mood instability;
LGG	cis	rs17039065	0.834	rs12499196	chr4:109425988	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg12458913	chr13:53173898	NA	0.67	13.46	0.53	4.4e-35	Lewy body disease;
LGG	cis	rs3617	0.573	rs9880978	chr3:52923251	C/G	cg11645453	chr3:52864694	ITIH4	0.5	8.48	0.37	3.12e-16	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9522267	0.737	rs9522276	chr13:112220208	C/T	cg14952266	chr13:112191215	NA	0.44	8.5	0.37	2.55e-16	Hepatitis;
LGG	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg26769984	chr7:1090371	C7orf50	0.54	9.8	0.41	9.53e-21	Bronchopulmonary dysplasia;
LGG	cis	rs6032067	0.704	rs2223901	chr20:43789924	C/G	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs801193	0.548	rs2659904	chr7:66178602	C/A	cg18252515	chr7:66147081	NA	-0.42	-7.1	-0.31	4.87e-12	Aortic root size;
LGG	cis	rs9837602	0.507	rs793455	chr3:99526135	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.31	-0.36	1.03e-15	Breast cancer;
LGG	cis	rs9611519	0.780	rs3171692	chr22:41642212	C/T	cg06634786	chr22:41940651	POLR3H	-0.53	-8.68	-0.37	6.79e-17	Neuroticism;
LGG	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.59e-59	Diabetic kidney disease;
LGG	cis	rs57590327	0.503	rs13062741	chr3:81887124	C/T	cg07356753	chr3:81810745	GBE1	-0.45	-7.14	-0.31	3.75e-12	Extraversion;
LGG	cis	rs8077889	0.826	rs60085355	chr17:41847415	T/C	cg26893861	chr17:41843967	DUSP3	0.96	17.03	0.62	7.16e-51	Triglycerides;
LGG	cis	rs9309473	0.607	rs1851546	chr2:73591127	C/A	cg20560298	chr2:73613845	ALMS1	-0.5	-9.11	-0.39	2.49e-18	Metabolite levels;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs10788779	chr1:248481661	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.09e-19	Common traits (Other);
LGG	cis	rs7674212	0.539	rs2866635	chr4:104121576	G/A	cg16532752	chr4:104119610	CENPE	-0.41	-7.14	-0.31	3.65e-12	Type 2 diabetes;
LGG	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg15704280	chr7:45808275	SEPT13	0.9	18.43	0.65	2.6e-57	Coronary artery disease;
LGG	cis	rs11096990	0.656	rs7686161	chr4:39284821	A/G	cg24403649	chr4:39172243	NA	-0.39	-7.07	-0.31	5.67e-12	Cognitive function;
LGG	cis	rs5762813	0.524	rs5762835	chr22:29230754	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.75	0.34	5.83e-14	Hematocrit;Hemoglobin concentration;
LGG	cis	rs7000551	0.700	rs7431	chr8:22398462	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	12.27	0.5	3.75e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg12395012	chr8:11607386	GATA4	0.37	6.96	0.31	1.16e-11	Neuroticism;
LGG	cis	rs36051895	0.632	rs12344116	chr9:5142216	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-15.48	-0.58	7.63e-44	Pediatric autoimmune diseases;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg10150615	chr22:24372951	LOC391322	-0.41	-6.82	-0.3	2.8e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs6981523	0.553	rs2409730	chr8:11060638	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.87	-0.34	2.51e-14	Neuroticism;
LGG	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg26769984	chr7:1090371	C7orf50	0.46	7.48	0.33	3.77e-13	Bronchopulmonary dysplasia;
LGG	cis	rs17376456	0.757	rs1031424	chr5:93139706	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.96	0.45	5.4e-25	Diabetic retinopathy;
LGG	cis	rs644799	0.710	rs523153	chr11:95570961	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.33	0.58	3.49e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs929596	0.517	rs1875263	chr2:234625622	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-9.57	-0.41	6.2e-20	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.08	-0.39	3.26e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.76	-0.34	5.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.62	11.23	0.46	4.67e-26	Lymphocyte counts;
LGG	cis	rs7927592	0.913	rs7106339	chr11:68240241	C/T	cg20283391	chr11:68216788	NA	-0.51	-8.12	-0.35	4.32e-15	Total body bone mineral density;
LGG	cis	rs709400	0.628	rs12889639	chr14:103860206	G/A	cg26031613	chr14:104095156	KLC1	-0.8	-14.33	-0.55	7.86e-39	Body mass index;
LGG	cis	rs2013441	1.000	rs2526475	chr17:20136216	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.89e-11	Obesity-related traits;
LGG	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg02951883	chr7:2050386	MAD1L1	0.44	7.09	0.31	5.1e-12	Neuroticism;
LGG	trans	rs3206736	0.548	rs329243	chr7:35059716	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.34	0.32	9.6e-13	Diastolic blood pressure;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.53	0.33	2.66e-13	Rheumatoid arthritis;
LGG	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08109568	chr15:31115862	NA	-0.61	-10.29	-0.43	1.63e-22	Huntington's disease progression;
LGG	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg16586182	chr3:47516702	SCAP	0.75	13.77	0.54	2.03e-36	Colorectal cancer;
LGG	cis	rs1957429	0.522	rs73279816	chr14:65348375	G/A	cg23373153	chr14:65346875	NA	-1.08	-12.1	-0.49	1.76e-29	Pediatric areal bone mineral density (radius);
LGG	trans	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg01314568	chr7:57830625	NA	0.47	7.53	0.33	2.61e-13	Obesity-related traits;
LGG	cis	rs4808199	0.895	rs8105984	chr19:19374068	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	6.92	0.31	1.55e-11	Nonalcoholic fatty liver disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22799917	chr20:43514951	YWHAB	-0.48	-7.15	-0.32	3.43e-12	Pancreatic cancer;
LGG	cis	rs9768139	0.708	rs36064654	chr7:158116632	C/T	cg06219351	chr7:158114137	PTPRN2	-0.8	-16.09	-0.6	1.38e-46	Calcium levels;
LGG	cis	rs9896933	0.723	rs7224189	chr17:80782227	C/T	cg20578329	chr17:80767326	TBCD	-0.74	-11.6	-0.47	1.67e-27	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05164570	chr5:140071033	HARS;HARS2	0.39	6.69	0.3	6.65e-11	Bipolar disorder;
LGG	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg27661571	chr11:113659931	NA	-0.7	-9.58	-0.41	5.75e-20	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg24829409	chr8:58192753	C8orf71	-0.69	-9.5	-0.4	1.1e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9443645	0.901	rs9352683	chr6:79718795	T/G	cg18132916	chr6:79620363	NA	-0.3	-8.37	-0.36	7.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.599	rs12309369	chr12:38419683	C/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.28	-0.4	6.54e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23875821	chr14:96969303	PAPOLA	0.44	7.36	0.32	8.36e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg07701084	chr6:150067640	NUP43	0.68	12.74	0.51	4.38e-32	Lung cancer;
LGG	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.33	-0.32	1e-12	Mood instability;
LGG	cis	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg00405596	chr8:11794950	NA	0.43	7.28	0.32	1.4e-12	Neuroticism;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.79	-0.34	4.42e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs28498503	1.000	rs9964465	chr18:76662714	A/G	cg00806245	chr18:76673096	NA	0.59	7.25	0.32	1.81e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs963731	0.649	rs297141	chr2:39319382	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-8.03	-0.35	8.34e-15	Corticobasal degeneration;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs10991814	1.000	rs74508579	chr9:93959594	C/T	cg14446406	chr9:93919335	NA	-0.76	-8.37	-0.36	6.82e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.35	-0.5	1.67e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6586163	1.000	rs3824729	chr10:90752616	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.92	-0.31	1.49e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11711311	1.000	rs12636577	chr3:113497507	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.51	-0.33	3.01e-13	IgG glycosylation;
LGG	cis	rs1318772	0.932	rs66838021	chr5:112898834	G/T	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	cis	rs11677416	1.000	rs1516789	chr2:113531024	C/T	cg27083787	chr2:113543245	IL1A	0.53	8.8	0.38	2.73e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.06	0.55	1.18e-37	Prudent dietary pattern;
LGG	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg10818794	chr15:86012489	AKAP13	-0.36	-7.55	-0.33	2.34e-13	Coronary artery disease;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg13628971	chr7:2884303	GNA12	0.34	7.0	0.31	9.16e-12	Height;
LGG	cis	rs11229555	0.645	rs12291551	chr11:58176915	T/A	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11785400	1.000	rs7002932	chr8:143738816	C/A	cg24634471	chr8:143751801	JRK	0.53	8.56	0.37	1.62e-16	Schizophrenia;
LGG	trans	rs9393777	0.778	rs35526527	chr6:27042287	C/A	cg01620082	chr3:125678407	NA	-0.67	-7.33	-0.32	1.07e-12	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg05468351	chr5:21459598	LOC728411	0.41	6.96	0.31	1.2e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.14e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	17.39	0.63	1.64e-52	Obesity-related traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10880995	chr3:57541826	PDE12	-0.47	-6.85	-0.3	2.39e-11	Systemic lupus erythematosus;
LGG	cis	rs41271473	0.607	rs6692032	chr1:228853984	G/C	cg10167378	chr1:228756711	NA	0.47	7.85	0.34	2.96e-14	Chronic lymphocytic leukemia;
LGG	cis	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg06521331	chr12:34319734	NA	0.4	6.75	0.3	4.37e-11	Morning vs. evening chronotype;
LGG	cis	rs12791968	0.765	rs12790121	chr11:45001089	G/A	cg11846598	chr11:44996168	LOC221122	-0.59	-10.06	-0.42	1.17e-21	Inhibitory control;
LGG	cis	rs7106204	0.514	rs11027789	chr11:24260906	T/C	ch.11.24196551F	chr11:24239977	NA	0.91	12.23	0.49	5.41e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.8	-0.38	2.71e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs1595825	0.891	rs57990618	chr2:198660838	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.3	6.85e-11	Ulcerative colitis;
LGG	cis	rs2836974	0.583	rs2410124	chr21:40704760	C/G	cg17971929	chr21:40555470	PSMG1	-0.67	-12.1	-0.49	1.71e-29	Cognitive function;
LGG	cis	rs3087591	0.683	rs2040792	chr17:29628549	G/T	cg24425628	chr17:29625626	OMG;NF1	0.59	12.22	0.49	6.06e-30	Hip circumference;
LGG	cis	rs4253772	0.513	rs6008612	chr22:46707907	G/A	cg24881330	chr22:46731750	TRMU	0.82	9.97	0.42	2.38e-21	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12200782	0.932	rs12212145	chr6:26646418	T/A	cg11502198	chr6:26597334	ABT1	-0.92	-7.87	-0.34	2.46e-14	Small cell lung carcinoma;
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg17691542	chr6:26056736	HIST1H1C	0.49	8.48	0.37	3.1e-16	Height;
LGG	cis	rs7216064	0.953	rs4790981	chr17:65921834	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-8.91	-0.38	1.14e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4891159	0.790	rs11872411	chr18:74132051	C/T	cg24786174	chr18:74118243	ZNF516	-0.59	-13.8	-0.54	1.62e-36	Longevity;
LGG	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14442939	chr10:27389572	ANKRD26	0.92	20.39	0.69	2.09e-66	Breast cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14237749	chr9:136344651	SLC2A6	0.41	7.07	0.31	5.59e-12	Bipolar disorder;
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs911555	0.655	rs10149470	chr14:104017953	A/G	cg24130564	chr14:104152367	KLC1	-0.5	-9.99	-0.42	1.99e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1018836	0.628	rs6471085	chr8:91463783	G/A	cg16814680	chr8:91681699	NA	-0.74	-12.34	-0.5	1.87e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs73416724	1.000	rs77626494	chr6:43286886	C/T	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs80282103	0.867	rs11250242	chr10:1100064	A/C	cg08668510	chr10:1095578	IDI1	-0.73	-7.78	-0.34	4.78e-14	Glomerular filtration rate (creatinine);
LGG	trans	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.16	-0.35	3.17e-15	Retinal vascular caliber;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.4e-16	Obesity-related traits;
LGG	cis	rs6997458	0.867	rs10097917	chr8:86260295	A/T	cg02393479	chr8:86352350	CA3	-0.32	-7.01	-0.31	8.73e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6882046	0.513	rs616391	chr5:88038845	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.37	-0.43	8.63e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg01338084	chr22:32026380	PISD	1.49	12.14	0.49	1.22e-29	Age-related hearing impairment;
LGG	cis	rs9463078	0.746	rs3749863	chr6:45345248	A/C	cg25276700	chr6:44698697	NA	0.38	7.8	0.34	4.12e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg16359550	chr11:109292809	C11orf87	-0.39	-7.19	-0.32	2.66e-12	Schizophrenia;
LGG	cis	rs4732038	0.510	rs12673750	chr7:134276201	T/C	cg06906464	chr7:134288099	NA	-0.66	-17.22	-0.62	1e-51	Longevity;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg21782813	chr7:2030301	MAD1L1	-0.48	-11.62	-0.48	1.44e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7252981	0.632	rs8101679	chr19:19733877	T/C	cg11584989	chr19:19387371	SF4	-0.49	-8.29	-0.36	1.23e-15	Perceived unattractiveness to mosquitoes;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.37	-0.32	8.01e-13	Life satisfaction;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg13732083	chr21:47605072	C21orf56	0.46	7.6	0.33	1.69e-13	Testicular germ cell tumor;
LGG	cis	rs2735413	0.670	rs11861339	chr16:78094390	C/T	cg04733911	chr16:78082701	NA	0.66	10.6	0.44	1.19e-23	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg06219351	chr7:158114137	PTPRN2	-0.76	-14.7	-0.56	2e-40	Calcium levels;
LGG	cis	rs113835537	0.529	rs74869459	chr11:66296569	T/C	cg24851651	chr11:66362959	CCS	0.46	7.96	0.35	1.29e-14	Airway imaging phenotypes;
LGG	cis	rs2075371	1.000	rs2504	chr7:133979545	A/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.52	0.58	5.06e-44	Mean platelet volume;
LGG	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-14.97	-0.57	1.31e-41	Colorectal cancer;
LGG	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.44	-8.39	-0.36	5.97e-16	Coronary artery disease;
LGG	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.0	-0.31	8.79e-12	Neuroticism;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg26338869	chr17:61819248	STRADA	-0.55	-9.04	-0.39	4.41e-18	Prudent dietary pattern;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-8.03	-0.35	7.93e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs3770081	1.000	rs6724025	chr2:86200835	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.63	7.2	0.32	2.45e-12	Facial emotion recognition (sad faces);
LGG	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg25811766	chr13:21894605	NA	-0.56	-7.41	-0.33	6.08e-13	White matter hyperintensity burden;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg02475777	chr4:1388615	CRIPAK	0.59	10.65	0.44	7.83e-24	Longevity;
LGG	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg24955955	chr5:415729	AHRR	0.77	10.42	0.44	5.7e-23	Fat distribution (HIV);
LGG	cis	rs3087591	0.960	rs2905880	chr17:29546175	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs2455799	0.552	rs2470540	chr3:15718652	T/A	cg16303742	chr3:15540471	COLQ	-0.37	-7.12	-0.31	4.25e-12	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07956936	chr16:72127419	TXNL4B;DHX38	0.46	7.01	0.31	8.31e-12	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.729	rs10839283	chr11:49490943	T/C	cg15704280	chr7:45808275	SEPT13	0.91	17.26	0.63	6.83e-52	Coronary artery disease;
LGG	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.85	-0.3	2.4e-11	Blood metabolite levels;
LGG	cis	rs1568889	0.877	rs7933326	chr11:28288416	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	14.6	0.56	5.4e-40	Bipolar disorder;
LGG	cis	rs8056893	0.543	rs12708883	chr16:68382790	T/C	cg07273125	chr16:68295692	NA	0.4	8.73	0.38	4.73e-17	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.62	-0.37	1.07e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg21045802	chr8:109455806	TTC35	0.53	9.94	0.42	3.24e-21	Dupuytren's disease;
LGG	cis	rs9902453	0.933	rs1532042	chr17:28504389	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.72	0.51	5.16e-32	Coffee consumption (cups per day);
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg24846343	chr22:24311635	DDTL	0.54	10.33	0.43	1.24e-22	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2016266	0.819	rs4758965	chr12:53662735	C/T	cg19049858	chr12:53661747	ESPL1	-0.38	-6.88	-0.3	1.95e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs12618769	0.652	rs17513468	chr2:99235169	T/G	cg18455616	chr2:99124870	INPP4A	0.27	7.67	0.34	1.01e-13	Bipolar disorder;
LGG	trans	rs2282526	0.615	rs162377	chr21:44926001	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	9.79	0.41	1.03e-20	Mean corpuscular hemoglobin;
LGG	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg06636001	chr8:8085503	FLJ10661	0.56	10.23	0.43	2.81e-22	Retinal vascular caliber;
LGG	trans	rs453301	0.653	rs1045529	chr8:8890098	A/G	cg02002194	chr4:3960332	NA	0.47	8.89	0.38	1.41e-17	Joint mobility (Beighton score);
LGG	cis	rs13082711	0.522	rs820617	chr3:27335510	T/C	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2073300	1.000	rs6132623	chr20:23442324	T/A	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg13206674	chr6:150067644	NUP43	-0.66	-15.29	-0.58	5.29e-43	Lung cancer;
LGG	cis	rs55692411	0.537	rs13071931	chr3:50062878	G/A	cg24110177	chr3:50126178	RBM5	-0.53	-8.14	-0.35	3.63e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7508	0.512	rs6984498	chr8:17831753	A/T	cg18067069	chr8:17937731	ASAH1	-0.3	-7.07	-0.31	5.57e-12	Atrial fibrillation;
LGG	cis	rs875971	0.522	rs34973832	chr7:65396204	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.62	0.37	1.03e-16	Aortic root size;
LGG	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg03929089	chr4:120376271	NA	-1.04	-24.56	-0.75	6.52e-86	Height;
LGG	cis	rs929596	0.697	rs17863787	chr2:234611094	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.63	-10.77	-0.45	2.81e-24	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs16854884	0.584	rs59768870	chr3:143738366	G/A	cg06585982	chr3:143692056	C3orf58	0.6	10.36	0.43	9.36e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg08975724	chr8:8085496	FLJ10661	0.5	9.35	0.4	3.63e-19	Red cell distribution width;
LGG	cis	rs9910055	0.530	rs2269907	chr17:42294215	G/A	cg13607699	chr17:42295918	UBTF	0.9	18.79	0.66	5.65e-59	Total body bone mineral density;
LGG	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg10621924	chr7:39171070	POU6F2	0.42	8.43	0.36	4.51e-16	IgG glycosylation;
LGG	cis	rs7737355	0.947	rs244739	chr5:130806874	A/C	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.47e-19	Life satisfaction;
LGG	cis	rs1408799	0.678	rs12552462	chr9:12758650	T/G	cg05274944	chr9:12693694	TYRP1	0.34	7.97	0.35	1.26e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs4731207	0.698	rs35184624	chr7:124469587	G/A	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs2760061	0.583	rs1745413	chr1:228212456	A/G	cg01200585	chr1:228362443	C1orf69	0.48	8.17	0.35	3.05e-15	Diastolic blood pressure;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.21e-20	Life satisfaction;
LGG	cis	rs7000551	0.751	rs2449348	chr8:22359572	C/T	cg12081754	chr8:22256438	SLC39A14	0.64	11.64	0.48	1.22e-27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg25319279	chr11:5960081	NA	-0.56	-8.74	-0.38	4.46e-17	DNA methylation (variation);
LGG	cis	rs974417	0.508	rs986066	chr6:97342489	C/T	cg10979063	chr6:97285822	GPR63	0.41	6.87	0.3	2.04e-11	Body mass index;
LGG	cis	rs490234	0.966	rs542974	chr9:128373218	G/A	cg14078157	chr9:128172775	NA	0.39	7.14	0.32	3.57e-12	Mean arterial pressure;
LGG	trans	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg02002194	chr4:3960332	NA	0.49	9.26	0.4	7.8e-19	Mood instability;
LGG	cis	rs10744422	0.925	rs2061098	chr12:123349410	T/C	cg25930673	chr12:123319894	HIP1R	-0.66	-8.0	-0.35	9.94e-15	Schizophrenia;
LGG	cis	rs721399	1.000	rs11784251	chr8:18260013	A/G	cg18736775	chr8:18248649	NAT2	0.52	9.17	0.39	1.51e-18	Blood metabolite levels;
LGG	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg07027305	chr7:2059796	MAD1L1	-0.33	-6.75	-0.3	4.45e-11	Neuroticism;
LGG	cis	rs9911578	1.000	rs9902994	chr17:56948722	T/A	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs807669	0.807	rs807431	chr22:19242361	G/A	cg02655711	chr22:19163373	SLC25A1	0.65	12.87	0.51	1.33e-32	Metabolite levels;
LGG	cis	rs10504130	0.502	rs71513552	chr8:52689222	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.35	0.36	7.75e-16	Tonsillectomy;
LGG	trans	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg18335740	chr13:41363409	SLC25A15	0.83	18.66	0.66	2.39e-58	Lewy body disease;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg23129478	chr18:44337922	ST8SIA5	0.39	7.69	0.34	8.88e-14	Personality dimensions;
LGG	trans	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg12045294	chr17:78518616	RPTOR	-0.47	-7.19	-0.32	2.65e-12	Glycated hemoglobin levels;
LGG	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg16586182	chr3:47516702	SCAP	-0.44	-7.16	-0.32	3.26e-12	Birth weight;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg04025307	chr7:1156635	C7orf50	0.54	9.03	0.39	4.73e-18	Bronchopulmonary dysplasia;
LGG	cis	rs533581	0.866	rs561795	chr16:88970818	A/G	cg16701003	chr16:89028210	CBFA2T3	0.46	7.52	0.33	2.84e-13	Social autistic-like traits;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg04450456	chr4:17643702	FAM184B	0.33	7.19	0.32	2.61e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs36051895	0.554	rs10975027	chr9:5248827	G/A	cg02405213	chr9:5042618	JAK2	-0.73	-12.22	-0.49	5.76e-30	Pediatric autoimmune diseases;
LGG	cis	rs921968	0.643	rs4674321	chr2:219511368	G/A	cg01130898	chr2:219473002	PLCD4	-0.44	-7.58	-0.33	1.87e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs548181	0.621	rs2912098	chr11:125528569	C/T	cg03464685	chr11:125439445	EI24	1.32	19.92	0.68	3.22e-64	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg25358565	chr5:93447407	FAM172A	-0.68	-9.81	-0.41	9.28e-21	Diabetic retinopathy;
LGG	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg21775007	chr8:11205619	TDH	0.45	7.32	0.32	1.11e-12	Systolic blood pressure;
LGG	cis	rs6735179	0.565	rs6726887	chr2:1749257	A/G	cg10160682	chr2:1713001	PXDN	-0.55	-9.39	-0.4	2.67e-19	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.539	rs1839667	chr2:100064264	C/T	cg23527387	chr2:100056660	REV1	0.42	9.46	0.4	1.52e-19	Chronic sinus infection;
LGG	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg18188782	chr20:61659543	NA	0.4	6.82	0.3	2.93e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3750965	0.920	rs11828017	chr11:68818617	A/G	cg23121140	chr11:68816938	TPCN2	0.34	6.66	0.3	7.65e-11	Hair color;
LGG	cis	rs8078723	1.000	rs56922390	chr17:38157021	C/G	cg17467752	chr17:38218738	THRA	0.74	13.9	0.54	6.07e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg22467129	chr15:76604101	ETFA	-0.45	-7.68	-0.34	9.76e-14	Blood metabolite levels;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg11494091	chr17:61959527	GH2	1.0	24.51	0.75	1.11e-85	Prudent dietary pattern;
LGG	cis	rs12540874	0.663	rs1451371	chr7:50553051	T/C	cg00647317	chr7:50633725	DDC	0.38	9.21	0.39	1.1e-18	Systemic sclerosis;
LGG	cis	rs7123876	0.830	rs57614870	chr11:72435983	A/G	cg04827223	chr11:72435913	ARAP1	-0.48	-8.36	-0.36	7.56e-16	Body mass index;
LGG	cis	rs6500395	0.775	rs7191225	chr16:48662675	C/G	cg04672837	chr16:48644449	N4BP1	0.5	8.41	0.36	5.12e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs700641	1	rs700641	chr2:198599233	C/T	cg00792783	chr2:198669748	PLCL1	0.48	8.07	0.35	5.95e-15	Morning vs. evening chronotype;
LGG	cis	rs317689	0.690	rs317656	chr12:69681101	T/A	cg20891283	chr12:69753455	YEATS4	0.45	6.95	0.31	1.22e-11	Response to diuretic therapy;
LGG	cis	rs490234	0.702	rs12553311	chr9:128398996	T/C	cg14078157	chr9:128172775	NA	-0.55	-10.14	-0.43	5.92e-22	Mean arterial pressure;
LGG	cis	rs11696845	0.604	rs1980577	chr20:43382112	A/G	cg25301532	chr20:43378953	KCNK15	0.49	12.03	0.49	3.4e-29	Obesity-related traits;
LGG	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.83	0.34	3.3e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.79	0.3	3.43e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs910316	0.726	rs175040	chr14:75469555	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.14	-0.39	2.04e-18	Height;
LGG	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg11812906	chr14:75593930	NEK9	0.41	7.37	0.32	7.93e-13	Coronary artery disease;
LGG	cis	rs11018904	0.906	rs7925507	chr11:89940146	T/C	cg16176437	chr11:89678848	NA	0.39	6.67	0.3	7.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg16096631	chr1:42092165	HIVEP3	0.75	20.65	0.69	1.22e-67	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs12949688	0.682	rs1476729	chr17:55838708	C/T	cg12582317	chr17:55822272	NA	-0.51	-11.79	-0.48	3.01e-28	Schizophrenia;
LGG	cis	rs9303401	0.659	rs34913878	chr17:56897094	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs7617480	0.648	rs9848268	chr3:48762271	C/T	cg07636037	chr3:49044803	WDR6	0.88	15.36	0.58	2.44e-43	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg24607181	chr17:41446203	NA	-0.3	-7.09	-0.31	5.15e-12	Menopause (age at onset);
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg08621203	chr6:150244597	RAET1G	0.47	7.82	0.34	3.52e-14	Lung cancer;
LGG	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.61	0.53	9.78e-36	Bladder cancer;
LGG	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg07382826	chr16:28625726	SULT1A1	0.42	8.43	0.36	4.35e-16	Body mass index;
LGG	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg05791153	chr7:19748676	TWISTNB	-1.11	-15.69	-0.59	8.29e-45	Thyroid stimulating hormone;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.95	-0.31	1.25e-11	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.11	-0.31	4.35e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11168854	0.620	rs11168888	chr12:49543397	C/A	cg24176009	chr12:49580217	TUBA1A	0.6	11.32	0.47	2.2e-26	Body mass index;
LGG	cis	rs78456975	0.527	rs7590742	chr2:1575049	A/T	cg12573674	chr2:1569213	NA	-0.62	-9.85	-0.42	6.41e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg08677398	chr8:58056175	NA	0.4	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12155623	0.803	rs7011862	chr8:49817333	C/G	cg22283653	chr8:49824208	NA	0.48	8.83	0.38	2.1e-17	Sudden cardiac arrest;
LGG	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg06917634	chr15:78832804	PSMA4	0.69	13.53	0.53	2.2e-35	Sudden cardiac arrest;
LGG	cis	rs7572733	0.515	rs6752458	chr2:198835106	G/T	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs1577917	1.000	rs117907570	chr6:86601283	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs6456042	0.929	rs3127421	chr6:166539059	A/G	cg11088901	chr6:166572345	T	-0.35	-7.37	-0.32	7.87e-13	Asthma;
LGG	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.43	-0.4	1.95e-19	Lung cancer;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25172604	chr17:41446521	NA	-0.31	-6.89	-0.3	1.86e-11	Menopause (age at onset);
LGG	cis	rs4740619	0.846	rs10738411	chr9:15762446	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.93	-0.45	6.63e-25	Body mass index;
LGG	cis	rs4750440	0.702	rs7917296	chr10:14029639	G/A	cg00551146	chr10:14014579	FRMD4A	0.27	6.81	0.3	2.97e-11	Adiponectin levels;
LGG	cis	rs8056893	0.543	rs2290698	chr16:68362809	A/G	cg07273125	chr16:68295692	NA	-0.4	-8.68	-0.37	6.79e-17	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	trans	rs208520	0.955	rs17644076	chr6:67004973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.77	-12.33	-0.5	2.12e-30	Exhaled nitric oxide output;
LGG	cis	rs1348850	0.561	rs1838890	chr2:178410938	C/A	cg22681709	chr2:178499509	PDE11A	-0.52	-7.58	-0.33	1.89e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6001027	0.540	rs1005529	chr22:38541266	T/C	cg03162506	chr22:38580953	NA	0.36	8.79	0.38	2.95e-17	Melanoma;
LGG	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg23625390	chr15:77176239	SCAPER	-0.65	-12.98	-0.52	4.57e-33	Blood metabolite levels;
LGG	cis	rs3762637	1.000	rs7617042	chr3:122190985	C/T	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg15733309	chr7:157513707	PTPRN2	0.66	15.23	0.58	9.74e-43	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg18681998	chr4:17616180	MED28	0.86	19.68	0.67	4.04e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7091068	0.536	rs7893369	chr10:95410147	A/G	cg20715218	chr10:95462985	C10orf4	0.62	9.81	0.41	9.15e-21	Urinary tract infection frequency;
LGG	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg24110177	chr3:50126178	RBM5	-0.55	-10.08	-0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.582	rs10786689	chr10:104356359	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.39e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9287719	0.934	rs6710033	chr2:10757677	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg14668821	chr17:77704760	ENPP7	0.42	8.12	0.35	4.14e-15	Menopause (age at onset);
LGG	trans	rs62103177	0.673	rs4438371	chr18:77615988	C/T	cg14227996	chr4:17616232	MED28	0.56	7.79	0.34	4.35e-14	Opioid sensitivity;
LGG	cis	rs11098499	0.820	rs13128602	chr4:120459366	C/T	cg24375607	chr4:120327624	NA	-0.66	-10.87	-0.45	1.14e-24	Corneal astigmatism;
LGG	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg24045276	chr1:183552095	NCF2	0.29	6.73	0.3	5.18e-11	Lung cancer;
LGG	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.59	-0.33	1.78e-13	Depression;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24483552	chr8:67687060	SGK3	0.38	6.87	0.3	2.05e-11	Obesity-related traits;
LGG	cis	rs10463554	0.963	rs26816	chr5:102540522	C/T	cg23492399	chr5:102201601	PAM	-0.5	-7.56	-0.33	2.21e-13	Parkinson's disease;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.63	12.56	0.5	2.54e-31	Obesity-related traits;
LGG	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.13	-0.35	3.82e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9309473	0.748	rs2421552	chr2:73758803	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.85	-0.34	2.97e-14	Metabolite levels;
LGG	cis	rs10189230	0.935	rs6731133	chr2:222359155	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.53	0.5	3.08e-31	Urate levels in lean individuals;
LGG	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg16339924	chr4:17578868	LAP3	0.5	8.35	0.36	7.91e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg15627072	chr1:2432621	PLCH2	0.33	7.34	0.32	9.65e-13	Ulcerative colitis;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg12310025	chr6:25882481	NA	-0.37	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs9303401	0.580	rs34076823	chr17:57114497	C/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.83	13.39	0.53	8.68e-35	Cognitive test performance;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.46e-16	Testicular germ cell tumor;
LGG	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg09696939	chr10:60272079	BICC1	0.36	7.03	0.31	7.5e-12	Refractive error;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg05484376	chr2:27715224	FNDC4	0.46	9.96	0.42	2.7e-21	Total body bone mineral density;
LGG	cis	rs1124376	1.000	rs1124376	chr3:20108546	A/G	cg05072819	chr3:20081367	KAT2B	-0.65	-8.52	-0.37	2.26e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg13647721	chr17:30228624	UTP6	0.64	7.98	0.35	1.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4665809	0.509	rs62128431	chr2:26398116	C/T	cg08470875	chr2:26401718	FAM59B	0.43	8.06	0.35	6.69e-15	Gut microbiome composition (summer);
LGG	cis	rs7586879	0.719	rs7565468	chr2:25130092	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.6	0.41	5.16e-20	Body mass index;
LGG	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg17691542	chr6:26056736	HIST1H1C	0.65	10.77	0.45	2.75e-24	Iron status biomarkers;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.07	-28.21	-0.8	1.29e-102	Prudent dietary pattern;
LGG	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.52	-0.33	2.9e-13	Personality dimensions;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06481639	chr22:41940642	POLR3H	-0.63	-9.18	-0.39	1.48e-18	Vitiligo;
LGG	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg16141378	chr3:129829833	LOC729375	0.36	7.78	0.34	4.62e-14	Triglycerides;
LGG	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg11887960	chr12:57824829	NA	0.59	7.24	0.32	1.88e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs796364	0.760	rs11690371	chr2:200989616	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.72	-8.41	-0.36	5.2e-16	Schizophrenia;
LGG	cis	rs7432375	0.933	rs6791142	chr3:136377377	C/T	cg21827317	chr3:136751795	NA	0.47	8.48	0.37	3.06e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09031165	chr17:17586474	RAI1	0.46	7.0	0.31	9.08e-12	Gut microbiome composition (summer);
LGG	cis	rs12135191	0.867	rs12068636	chr1:236475592	T/C	cg21399712	chr1:236511386	NA	-0.41	-7.89	-0.34	2.25e-14	Urate levels (BMI interaction);
LGG	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	cis	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.53	0.33	2.69e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07414097	chr2:232646663	PDE6D	0.45	7.56	0.33	2.2e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2933343	0.621	rs789242	chr3:128585707	T/C	cg11901034	chr3:128598214	ACAD9	-0.46	-6.96	-0.31	1.15e-11	IgG glycosylation;
LGG	cis	rs8012	0.537	rs741702	chr19:13024250	A/C	cg23899408	chr19:12877188	HOOK2	0.49	7.93	0.35	1.67e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg00149659	chr3:10157352	C3orf10	1.18	13.99	0.55	2.35e-37	Alzheimer's disease;
LGG	cis	rs7945705	0.837	rs2742474	chr11:9002089	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.36	-7.15	-0.32	3.38e-12	Hemoglobin concentration;
LGG	cis	rs68170813	0.559	rs3779498	chr7:106923158	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.61	-0.44	1.07e-23	Coronary artery disease;
LGG	cis	rs8062405	1.000	rs4788099	chr16:28855727	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.68	0.34	9.83e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2224391	0.628	rs2753223	chr6:5244317	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.3	-0.32	1.3e-12	Height;
LGG	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg19748678	chr4:122722346	EXOSC9	0.66	13.27	0.52	2.86e-34	Type 2 diabetes;
LGG	cis	rs9400467	0.537	rs73528982	chr6:111431638	T/G	cg15721981	chr6:111408429	SLC16A10	0.54	6.67	0.3	7.11e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs11864453	0.749	rs7192730	chr16:72124219	T/C	cg01557791	chr16:72042693	DHODH	-0.51	-9.36	-0.4	3.54e-19	Fibrinogen levels;
LGG	cis	rs75804782	0.641	rs72987321	chr2:239352765	T/G	cg18131467	chr2:239335373	ASB1	-0.66	-6.64	-0.3	8.62e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11098499	0.909	rs9994810	chr4:120381590	A/G	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	cis	rs2153535	0.601	rs969420	chr6:8451966	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs41271951	0.512	rs34761930	chr1:151089523	T/C	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.0	-0.31	8.77e-12	Blood protein levels;
LGG	cis	rs35110281	0.811	rs2838339	chr21:45075750	A/G	cg01579765	chr21:45077557	HSF2BP	0.42	9.67	0.41	2.77e-20	Mean corpuscular volume;
LGG	cis	rs6901004	0.772	rs191632	chr6:111544882	C/T	cg15721981	chr6:111408429	SLC16A10	-0.44	-7.8	-0.34	4.09e-14	Blood metabolite levels;
LGG	trans	rs1814175	0.616	rs1722020	chr11:49904189	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.83	-0.62	6.31e-50	Height;
LGG	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg09443347	chr12:88178374	NA	-0.37	-6.75	-0.3	4.56e-11	Iris color (L* coordinate);
LGG	cis	rs1691799	0.867	rs1168330	chr12:66763167	C/T	cg16791601	chr12:66731901	HELB	0.63	14.49	0.56	1.65e-39	White blood cell count (basophil);
LGG	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg22563815	chr15:78856949	CHRNA5	0.29	7.18	0.32	2.75e-12	Sudden cardiac arrest;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08692423	chr21:45148864	PDXK	0.46	7.15	0.32	3.44e-12	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs4888262	0.526	rs8055803	chr16:74615190	A/G	cg01733217	chr16:74700730	RFWD3	0.86	17.03	0.62	7.18e-51	Testicular germ cell tumor;
LGG	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg12310025	chr6:25882481	NA	0.43	7.89	0.34	2.18e-14	Height;
LGG	cis	rs4423214	1.000	rs12419334	chr11:71139472	T/C	cg05163923	chr11:71159392	DHCR7	0.71	13.69	0.54	4.46e-36	Vitamin D levels;
LGG	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg18225595	chr11:63971243	STIP1	-0.51	-10.03	-0.42	1.54e-21	Platelet count;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02640306	chr2:191745287	GLS	0.42	7.25	0.32	1.73e-12	Bipolar disorder;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs736408	0.561	rs2276815	chr3:52853747	C/G	cg11645453	chr3:52864694	ITIH4	0.64	10.08	0.42	9.95e-22	Bipolar disorder;
LGG	cis	rs12497850	0.864	rs3212	chr3:49145741	T/C	cg06212747	chr3:49208901	KLHDC8B	0.71	12.15	0.49	1.17e-29	Parkinson's disease;
LGG	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg16751781	chr15:78858589	CHRNA5	-0.45	-8.89	-0.38	1.41e-17	Sudden cardiac arrest;
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.77e-11	Total body bone mineral density;
LGG	cis	rs933688	0.775	rs10434640	chr5:90578301	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	-0.47	-7.3	-0.32	1.24e-12	Smoking behavior;
LGG	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg13010199	chr12:38710504	ALG10B	0.71	13.94	0.54	3.86e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9302635	0.513	rs9923575	chr16:72230112	C/T	cg23815491	chr16:72088622	HP	0.4	6.96	0.31	1.15e-11	Blood protein levels;
LGG	cis	rs2290416	0.892	rs59742520	chr8:144676234	G/C	cg08508337	chr8:144660607	NAPRT1	0.86	6.71	0.3	5.83e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs427394	0.593	rs880993	chr5:6732120	C/G	cg15145174	chr5:6755386	POLS	-0.44	-8.07	-0.35	6.01e-15	Menopause (age at onset);
LGG	cis	rs6831352	0.918	rs3919370	chr4:100064326	A/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.51	-0.4	1.01e-19	Alcohol dependence;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	trans	rs853679	0.760	rs967005	chr6:28210688	C/T	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.68e-11	Depression;
LGG	cis	rs1707322	1.000	rs12124847	chr1:46380850	T/A	cg03146154	chr1:46216737	IPP	0.54	10.05	0.42	1.23e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9596863	0.851	rs9568923	chr13:54357573	G/A	ch.13.53330881F	chr13:54432880	NA	0.53	7.21	0.32	2.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7829975	0.606	rs6422352	chr8:8794193	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.18	-0.36	2.72e-15	Mood instability;
LGG	cis	rs1008375	1.000	rs60178264	chr4:17685308	G/T	cg18681998	chr4:17616180	MED28	0.82	18.08	0.64	1.15e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08109568	chr15:31115862	NA	-0.52	-8.6	-0.37	1.27e-16	Huntington's disease progression;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-6.77	-0.3	3.8e-11	Lung cancer;
LGG	cis	rs8133932	0.701	rs2839035	chr21:47308281	A/G	cg11214348	chr21:47283868	PCBP3	0.44	7.92	0.35	1.75e-14	Schizophrenia;
LGG	cis	rs61008539	0.741	rs11767322	chr7:867405	A/G	cg05535760	chr7:792225	HEATR2	-0.44	-7.35	-0.32	8.79e-13	Perceived unattractiveness to mosquitoes;
LGG	cis	rs6582630	0.502	rs11181230	chr12:38300085	A/G	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.65e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.42	0.63	1.29e-52	Obesity-related traits;
LGG	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg21775007	chr8:11205619	TDH	0.81	14.37	0.56	5.73e-39	Retinal vascular caliber;
LGG	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg06636001	chr8:8085503	FLJ10661	0.4	6.82	0.3	2.87e-11	Retinal vascular caliber;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.46	8.41	0.36	4.98e-16	Obesity-related traits;
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.6	0.41	5.14e-20	Height;
LGG	cis	rs2153535	0.580	rs1335641	chr6:8487860	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs9788721	0.640	rs1394371	chr15:78724469	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-6.87	-0.3	2.12e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs988958	0.567	rs6719975	chr2:42271646	G/A	cg27252766	chr2:42229092	NA	0.5	7.78	0.34	4.93e-14	Hypospadias;
LGG	cis	rs977747	0.815	rs11211480	chr1:47693220	A/G	cg03885399	chr1:47691550	TAL1	-0.35	-7.56	-0.33	2.22e-13	Body mass index;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs909674	0.690	rs1972280	chr22:39831986	T/A	cg11247378	chr22:39784982	NA	-0.31	-8.52	-0.37	2.2e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs9660992	0.686	rs1668870	chr1:205239031	C/G	cg21545522	chr1:205238299	TMCC2	0.49	8.98	0.39	6.64e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.07	-0.31	5.62e-12	Iron status biomarkers;
LGG	trans	rs725344	0.881	rs1498825	chr4:54677521	C/A	cg01654820	chr16:10675123	EMP2	-0.54	-6.68	-0.3	6.91e-11	Serum VEGFR2 concentration;
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.65	0.41	3.38e-20	Bipolar disorder;
LGG	cis	rs225245	0.817	rs12150359	chr17:34024584	C/T	cg05299278	chr17:33885742	SLFN14	0.43	8.21	0.36	2.18e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	12.5	0.5	4.39e-31	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1816752	0.819	rs7988388	chr13:24986813	C/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs910316	0.763	rs175435	chr14:75612025	A/G	cg08847533	chr14:75593920	NEK9	0.53	9.73	0.41	1.82e-20	Height;
LGG	cis	rs1003719	0.762	rs2835590	chr21:38463406	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs17683430	0.764	rs117001013	chr22:32348841	C/T	cg00543991	chr22:32367038	NA	0.8	8.78	0.38	3.08e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs67385638	0.925	rs12417960	chr11:5265106	C/A	cg12559170	chr11:5275217	HBG2	0.57	12.98	0.52	4.33e-33	Hemoglobin levels;
LGG	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs12410462	0.681	rs58496521	chr1:227582375	T/C	cg04117972	chr1:227635322	NA	0.7	11.31	0.47	2.35e-26	Major depressive disorder;
LGG	cis	rs2865126	0.868	rs1881090	chr18:10765889	G/A	cg21165219	chr18:10698044	FAM38B	-0.43	-6.98	-0.31	9.98e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.65	-0.37	8.67e-17	Initial pursuit acceleration;
LGG	cis	rs7582180	0.900	rs2309823	chr2:100901557	A/G	cg05692746	chr2:100937584	LONRF2	0.59	9.65	0.41	3.47e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	trans	rs62103177	0.810	rs62103191	chr18:77628769	C/G	cg05926928	chr17:57297772	GDPD1	1.36	21.6	0.71	4.56e-72	Opioid sensitivity;
LGG	cis	rs9549367	0.713	rs9549691	chr13:113861606	A/C	cg18105134	chr13:113819100	PROZ	-0.79	-16.68	-0.61	2.95e-49	Platelet distribution width;
LGG	cis	rs7444	0.941	rs12484550	chr22:21941915	C/T	cg15846791	chr22:21984385	YDJC	-0.47	-7.09	-0.31	5.06e-12	Systemic lupus erythematosus;
LGG	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg20891558	chr2:74357851	NA	0.47	8.55	0.37	1.87e-16	Gestational age at birth (maternal effect);
LGG	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg19507638	chr5:93509721	C5orf36	-0.74	-10.33	-0.43	1.17e-22	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22796393	chr3:50375250	RASSF1	0.41	6.89	0.3	1.79e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7223966	1.000	rs7220821	chr17:61704147	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.58	0.33	1.84e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg14697323	chr12:108955167	ISCU;SART3	0.75	7.01	0.31	8.57e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs6977940	0.818	rs11769302	chr7:2898839	C/T	cg19731401	chr7:2775893	GNA12	0.35	6.91	0.31	1.56e-11	White matter integrity;
LGG	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg06453172	chr10:134556979	INPP5A	-0.58	-8.58	-0.37	1.43e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.6	0.53	1.08e-35	Bladder cancer;
LGG	cis	rs12949688	0.967	rs8081251	chr17:55824033	A/G	cg12229367	chr17:55822335	NA	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs7765175	0.598	rs6905873	chr6:113655606	A/T	cg26552650	chr6:113682475	NA	0.33	7.26	0.32	1.6e-12	Coronary artery calcification;
LGG	cis	rs17641971	0.645	rs341806	chr8:50034028	A/C	cg00325661	chr8:49890786	NA	0.56	10.5	0.44	2.71e-23	Blood metabolite levels;
LGG	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg07936489	chr17:37558343	FBXL20	0.85	15.98	0.6	4.28e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs780096	0.526	rs4582	chr2:27604279	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.62	0.41	4.22e-20	Total body bone mineral density;
LGG	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs11874712	0.527	rs4257298	chr18:43689353	C/A	cg26436583	chr18:43649176	PSTPIP2	-0.46	-9.26	-0.4	7.72e-19	Migraine - clinic-based;
LGG	cis	rs9290877	0.667	rs17671666	chr3:188454664	T/C	cg17392043	chr3:188495102	LPP	-0.42	-7.26	-0.32	1.7e-12	IgE levels;
LGG	cis	rs2901656	0.677	rs2301455	chr1:172418268	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.9	0.31	1.7e-11	Red cell distribution width;Platelet distribution width;
LGG	cis	rs2243480	1.000	rs6958420	chr7:65751171	A/G	cg13147721	chr7:65941812	NA	0.84	10.13	0.43	6.44e-22	Diabetic kidney disease;
LGG	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.98	11.83	0.48	2.15e-28	Lung cancer in ever smokers;
LGG	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00198680	chr16:28758506	NA	0.28	6.77	0.3	4.02e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs637571	0.726	rs526631	chr11:65681965	T/G	cg26695010	chr11:65641043	EFEMP2	0.63	11.5	0.47	4.47e-27	Eosinophil percentage of white cells;
LGG	cis	rs7582720	1.000	rs116678869	chr2:203819471	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-16.03	-0.6	2.63e-46	Platelet count;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg06028808	chr11:68637592	NA	0.73	12.76	0.51	3.76e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs637571	0.780	rs677029	chr11:65683531	A/G	cg17712092	chr4:129076599	LARP1B	0.91	20.66	0.69	1.11e-67	Eosinophil percentage of white cells;
LGG	cis	rs7928758	1.000	rs56134226	chr11:134279882	T/C	cg25213107	chr11:134282864	B3GAT1	0.99	11.76	0.48	4.08e-28	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2153535	0.580	rs1577467	chr6:8444241	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs8114671	0.836	rs13042358	chr20:33634479	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.0	0.39	5.97e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20814179	chr4:940893	TMEM175	0.53	10.81	0.45	2e-24	Sjögren's syndrome;
LGG	trans	rs1814175	0.619	rs10769623	chr11:49865926	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.47	-0.71	1.71e-71	Height;
LGG	cis	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg21775007	chr8:11205619	TDH	-0.75	-13.1	-0.52	1.49e-33	Retinal vascular caliber;
LGG	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11890956	chr21:40555474	PSMG1	1.14	25.27	0.76	3.65e-89	Cognitive function;
LGG	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.92	-0.38	1.13e-17	Aortic root size;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.46	-0.37	3.58e-16	Obesity-related traits;
LGG	cis	rs13421350	0.579	rs59970483	chr2:173378344	G/A	cg15021238	chr2:173305865	ITGA6	-0.8	-8.61	-0.37	1.18e-16	Diabetic kidney disease;
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg12458913	chr13:53173898	NA	0.63	12.28	0.5	3.4e-30	Lewy body disease;
LGG	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg19507638	chr5:93509721	C5orf36	-0.77	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.92e-21	Cannabis dependence symptom count;
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg16141378	chr3:129829833	LOC729375	0.39	9.02	0.39	5.01e-18	Morning vs. evening chronotype;
LGG	cis	rs7216064	0.953	rs11079705	chr17:65835452	A/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.48e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs854037	0.698	rs34645667	chr5:57076044	G/A	cg08523694	chr5:57076192	NA	0.61	7.49	0.33	3.45e-13	Birth weight;
LGG	cis	rs56146971	0.763	rs75059313	chr14:91847559	T/A	cg14409461	chr14:91925021	SMEK1	-0.43	-7.0	-0.31	9.19e-12	Alzheimer disease and age of onset;
LGG	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg19468946	chr17:37922297	IKZF3	-0.44	-7.94	-0.35	1.55e-14	Lymphocyte counts;
LGG	cis	rs73001065	0.818	rs10500212	chr19:19723215	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	7.0	0.31	9.22e-12	LDL cholesterol;
LGG	cis	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg00806126	chr19:22604979	ZNF98	-0.64	-9.46	-0.4	1.61e-19	Pain;
LGG	trans	rs7395662	1.000	rs11039871	chr11:48626620	C/T	cg00717180	chr2:96193071	NA	0.43	7.6	0.33	1.7e-13	HDL cholesterol;
LGG	cis	rs4888262	0.526	rs7193423	chr16:74626340	A/C	cg01733217	chr16:74700730	RFWD3	0.9	17.41	0.63	1.38e-52	Testicular germ cell tumor;
LGG	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.85	17.51	0.63	4.92e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs75920871	0.528	rs10082609	chr11:116949074	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.57	-0.33	2.05e-13	Subjective well-being;
LGG	cis	rs12765878	0.580	rs67764572	chr10:105596007	T/C	cg11005552	chr10:105648138	OBFC1	-0.7	-12.01	-0.49	3.94e-29	Coronary artery disease;
LGG	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg13256891	chr4:100009986	ADH5	-0.6	-9.9	-0.42	4.3e-21	Alcohol dependence;
LGG	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg02228329	chr11:64053129	BAD;GPR137	0.84	16.75	0.61	1.41e-49	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs3747547	0.710	rs7863948	chr9:37949409	A/C	cg13774184	chr9:37916125	SHB	-0.72	-8.02	-0.35	8.98e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg12438819	chr7:158236134	PTPRN2	-0.31	-8.14	-0.35	3.64e-15	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11921908	chr5:153825219	SAP30L	0.45	6.74	0.3	4.83e-11	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg05941027	chr17:61774174	LIMD2	0.34	8.76	0.38	3.74e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg07005078	chr4:17578674	LAP3	0.37	6.91	0.31	1.58e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.7	0.34	8.6e-14	Menopause (age at onset);
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.42	-0.4	2.16e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs988958	0.600	rs7587291	chr2:42247668	T/A	cg19376973	chr2:42229025	NA	0.65	9.82	0.42	8.1899999999999992e-21	Hypospadias;
LGG	cis	rs870825	0.860	rs72689277	chr4:185593699	G/A	cg04058563	chr4:185651563	MLF1IP	1.06	19.7	0.68	3.51e-63	Blood protein levels;
LGG	cis	rs2171564	0.791	rs9852197	chr3:112442538	T/A	cg06685282	chr3:112453648	NA	0.47	8.84	0.38	2.07e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6088580	0.567	rs6088520	chr20:33132364	A/G	cg06115741	chr20:33292138	TP53INP2	-0.48	-7.65	-0.33	1.19e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg07928641	chr1:182991847	LAMC1	0.45	9.14	0.39	1.99e-18	Hypertriglyceridemia;
LGG	cis	rs6684428	0.536	rs4927275	chr1:56396564	A/G	cg11651538	chr1:56320950	NA	0.39	7.5	0.33	3.29e-13	Airflow obstruction;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg16590910	chr6:42928470	GNMT	-0.36	-10.14	-0.43	6.11e-22	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9311474	0.607	rs11711421	chr3:52561779	C/T	cg18404041	chr3:52824283	ITIH1	-0.48	-8.95	-0.38	8.81e-18	Electroencephalogram traits;
LGG	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07080220	chr10:102295463	HIF1AN	0.71	12.12	0.49	1.53e-29	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.64	0.48	1.22e-27	Obesity-related traits;
LGG	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.91	0.35	1.91e-14	Platelet count;
LGG	cis	rs12477438	0.501	rs11899745	chr2:100064072	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.94	-0.31	1.34e-11	Chronic sinus infection;
LGG	cis	rs7717393	0.786	rs10061194	chr5:155763769	A/C	cg04435420	chr5:155754009	SGCD	-0.67	-8.33	-0.36	8.97e-16	Egg allergy;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg19182353	chr11:118479428	PHLDB1	0.55	11.12	0.46	1.26e-25	Cholesterol, total;
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.84	-0.38	2.07e-17	Dementia with Lewy bodies;
LGG	cis	rs6684428	1.000	rs10888947	chr1:56375280	C/T	cg11651538	chr1:56320950	NA	-0.82	-13.46	-0.53	4.34e-35	Airflow obstruction;
LGG	cis	rs7085104	0.700	rs7096183	chr10:104609466	T/C	cg04362960	chr10:104952993	NT5C2	0.48	8.91	0.38	1.16e-17	Immature fraction of reticulocytes;Schizophrenia;
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.09	-0.39	2.97e-18	Triglycerides;
LGG	cis	rs7208859	0.673	rs9913782	chr17:29237384	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.569	rs7735009	chr5:93260865	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.57	-8.05	-0.35	6.89e-15	Diabetic retinopathy;
LGG	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg01420254	chr6:26195488	NA	0.82	10.64	0.44	8.76e-24	Gout;Renal underexcretion gout;
LGG	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg13009111	chr11:71350975	NA	0.36	7.86	0.34	2.8e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.7	-0.34	8.12e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs67460515	0.500	rs9822435	chr3:160748068	A/T	cg04691961	chr3:161091175	C3orf57	-0.4	-7.64	-0.33	1.26e-13	Parkinson's disease;
LGG	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg03929089	chr4:120376271	NA	-0.74	-13.68	-0.54	5.08e-36	Height;
LGG	cis	rs6541297	0.941	rs6541294	chr1:230278826	A/G	cg20703242	chr1:230279135	GALNT2	0.37	7.64	0.33	1.26e-13	Coronary artery disease;
LGG	trans	rs561341	1.000	rs576985	chr17:30323323	C/T	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1059312	0.932	rs7962918	chr12:129288534	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.71	-0.61	2.12e-49	Systemic lupus erythematosus;
LGG	cis	rs8012	0.517	rs1060218	chr19:13008607	G/T	cg11738485	chr19:12877000	HOOK2	-0.42	-6.72	-0.3	5.3e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs6840360	0.573	rs6810430	chr4:152259759	C/T	cg25486957	chr4:152246857	NA	-0.42	-7.53	-0.33	2.68e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs13202675	chr6:97028427	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg00684032	chr4:1343700	KIAA1530	0.46	8.94	0.38	9.17e-18	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg16507663	chr6:150244633	RAET1G	0.47	8.86	0.38	1.79e-17	Lung cancer;
LGG	cis	rs6502050	0.835	rs8066284	chr17:80127825	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	cis	rs7618915	0.547	rs13065019	chr3:52685244	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7.39e-23	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs11645240	chr16:89837326	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs9354352	1.000	rs9354352	chr6:66696272	T/C	cg07460842	chr6:66804631	NA	0.74	13.97	0.54	2.85e-37	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg00319359	chr11:70116639	PPFIA1	0.71	7.48	0.33	3.83e-13	Coronary artery disease;
LGG	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg27129171	chr3:47204927	SETD2	-0.79	-15.46	-0.58	9.42e-44	Colorectal cancer;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg19500098	chr13:21900506	NA	0.48	10.2	0.43	3.69e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.53e-21	Morning vs. evening chronotype;
LGG	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg14541582	chr5:601475	NA	-0.57	-9.14	-0.39	2.03e-18	Obesity-related traits;
LGG	cis	rs892961	0.932	rs11650011	chr17:75412334	A/G	cg05865280	chr17:75406074	SEPT9	0.44	10.49	0.44	3.07e-23	Airflow obstruction;
LGG	cis	rs727563	0.555	rs5751136	chr22:42075581	T/A	cg06634786	chr22:41940651	POLR3H	0.74	11.9	0.48	1.11e-28	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2153535	0.601	rs9328487	chr6:8529378	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-8.06	-0.35	6.55e-15	Personality dimensions;
LGG	cis	rs10949834	1.000	rs117012864	chr7:73486969	G/A	cg07137043	chr7:73588983	EIF4H	-0.69	-7.66	-0.34	1.08e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs17122278	0.613	rs572126	chr11:118359161	C/T	cg20110707	chr11:118481992	PHLDB1	0.45	7.31	0.32	1.17e-12	Total cholesterol levels;
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs60733400	0.818	rs10909839	chr1:2708430	G/A	cg15627072	chr1:2432621	PLCH2	0.38	8.16	0.35	3.12e-15	Multiple sclerosis;
LGG	cis	rs12477438	0.798	rs6716913	chr2:99580641	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg06112835	chr11:68658793	MRPL21	0.61	10.2	0.43	3.5e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg01191920	chr7:158217561	PTPRN2	0.72	16.01	0.6	3.15e-46	Obesity-related traits;
LGG	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg05026014	chr4:1749153	NA	0.3	8.02	0.35	8.58e-15	Hip circumference adjusted for BMI;Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11787828	chr6:97345624	NDUFAF4	-0.43	-6.67	-0.3	7.25e-11	Pancreatic cancer;
LGG	cis	rs9815354	0.638	rs73071259	chr3:42001847	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2075371	0.933	rs1421480	chr7:133958114	A/C	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg24829409	chr8:58192753	C8orf71	-0.65	-9.1	-0.39	2.62e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg16141378	chr3:129829833	LOC729375	0.31	6.77	0.3	4e-11	Myopia (pathological);
LGG	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.92	-0.48	9.5e-29	Response to antipsychotic treatment;
LGG	cis	rs4481887	0.751	rs28607212	chr1:248520358	T/C	cg00666640	chr1:248458726	OR2T12	0.49	8.24	0.36	1.76e-15	Common traits (Other);
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	7.76e-13	Monocyte count;
LGG	cis	rs11885103	0.791	rs12151573	chr2:590801	G/A	cg21195176	chr2:593345	NA	0.39	7.43	0.33	5.14e-13	Heschl's gyrus morphology;
LGG	cis	rs5769707	0.681	rs9616329	chr22:50026314	G/A	cg20744362	chr22:50050164	C22orf34	0.42	7.41	0.33	5.98e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg05729581	chr11:3078854	CARS	-0.55	-9.59	-0.41	5.39e-20	Longevity;
LGG	cis	rs7169223	0.653	rs1994017	chr15:79080306	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.39	-7.58	-0.33	1.9e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19717773	chr7:2847554	GNA12	0.36	8.51	0.37	2.41e-16	Height;
LGG	cis	rs881375	0.933	rs4837804	chr9:123705304	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.71	0.48	6.56e-28	Rheumatoid arthritis;
LGG	cis	rs228437	0.913	rs7763821	chr6:134939618	A/G	cg24504307	chr6:134963096	NA	-0.4	-7.65	-0.33	1.2e-13	Melanoma;
LGG	trans	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg21659725	chr3:3221576	CRBN	-0.63	-6.79	-0.3	3.46e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	15.59	0.59	2.43e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.791	rs11097601	chr4:98960103	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11605275	1.000	rs73434177	chr11:20023995	G/A	cg14835545	chr11:20032148	NAV2	-0.97	-10.75	-0.45	3.38e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs898097	0.625	rs7406464	chr17:80891460	A/G	cg10494973	chr17:80897199	TBCD	0.42	7.43	0.33	5.38e-13	Breast cancer;
LGG	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21582582	chr3:182698605	DCUN1D1	0.51	9.43	0.4	2.05e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg06654118	chr4:1303317	MAEA	0.46	8.15	0.35	3.34e-15	Obesity-related traits;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg25072359	chr17:41440525	NA	0.51	9.93	0.42	3.49e-21	Menopause (age at onset);
LGG	cis	rs12915845	0.584	rs17196732	chr15:89069299	A/C	cg05013243	chr15:89149849	MIR1179	-0.35	-7.32	-0.32	1.11e-12	Menarche (age at onset);
LGG	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs3099143	0.908	rs6495222	chr15:77180015	A/C	cg21673338	chr15:77095150	SCAPER	0.66	10.46	0.44	4.08e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.02	-21.01	-0.7	2.47e-69	Primary sclerosing cholangitis;
LGG	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg02023728	chr11:77925099	USP35	0.39	7.05	0.31	6.66e-12	Alzheimer's disease (survival time);
LGG	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62209	0.800	rs201082	chr10:11005704	G/A	cg26901096	chr10:10994189	LOC254312	0.57	8.81	0.38	2.48e-17	Alzheimer's disease (late onset);
LGG	cis	rs782590	0.902	rs782601	chr2:55848244	T/C	cg18811423	chr2:55921094	PNPT1	0.86	19.75	0.68	2.03e-63	Metabolic syndrome;
LGG	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06481639	chr22:41940642	POLR3H	0.56	7.91	0.35	1.87e-14	Vitiligo;
LGG	cis	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.91	-0.31	1.64e-11	Triglycerides;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg22907277	chr7:1156413	C7orf50	0.5	8.76	0.38	3.7e-17	Longevity;Endometriosis;
LGG	cis	rs10779751	0.960	rs1883964	chr1:11294942	T/A	cg08854313	chr1:11322531	MTOR	0.74	16.13	0.6	9.28e-47	Body mass index;
LGG	cis	rs950169	0.580	rs4603535	chr15:85173872	C/T	cg24253500	chr15:84953950	NA	0.43	7.21	0.32	2.3e-12	Schizophrenia;
LGG	cis	rs9811920	0.893	rs6798114	chr3:99892825	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	8.04	0.35	7.53e-15	Axial length;
LGG	cis	rs4664308	0.905	rs62177860	chr2:160960571	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.72	-0.64	5.09e-54	Idiopathic membranous nephropathy;
LGG	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg19680485	chr15:31195859	MTMR15	-0.46	-7.48	-0.33	3.76e-13	Huntington's disease progression;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg05608128	chr12:12764917	CREBL2	0.39	6.69	0.3	6.29e-11	Eye color traits;
LGG	cis	rs62400317	0.723	rs755	chr6:44795790	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.21	-0.46	5.72e-26	Total body bone mineral density;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.64	11.99	0.49	4.87e-29	Total body bone mineral density;
LGG	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg00717180	chr2:96193071	NA	-0.44	-7.94	-0.35	1.5e-14	HDL cholesterol;
LGG	cis	rs17376456	1.000	rs12187701	chr5:93522290	A/G	cg25358565	chr5:93447407	FAM172A	1.36	16.5	0.61	1.84e-48	Diabetic retinopathy;
LGG	cis	rs9611519	0.580	rs8138349	chr22:41412723	C/T	cg03806693	chr22:41940476	POLR3H	-0.46	-7.49	-0.33	3.54e-13	Neuroticism;
LGG	cis	rs6714710	0.603	rs12995673	chr2:98409046	G/A	cg26665480	chr2:98280029	ACTR1B	0.64	10.39	0.43	7.31e-23	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs9549367	0.713	rs1755690	chr13:113824266	T/C	cg00898013	chr13:113819073	PROZ	0.47	9.68	0.41	2.75e-20	Platelet distribution width;
LGG	cis	rs12615966	0.932	rs17030324	chr2:105403251	A/C	cg16465502	chr2:105461796	NA	0.87	10.48	0.44	3.29e-23	Pancreatic cancer;
LGG	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg12386194	chr3:101231763	SENP7	0.46	8.34	0.36	8.58e-16	Colorectal cancer;
LGG	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.18	-0.32	2.75e-12	Iron status biomarkers;
LGG	cis	rs9354308	0.764	rs9354320	chr6:66583901	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs34172651	0.917	rs1075987	chr16:24794957	G/A	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.66	-0.34	1.08e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.506	rs61388686	chr12:123810873	G/A	cg05973401	chr12:123451056	ABCB9	0.44	7.42	0.33	5.61e-13	Neutrophil percentage of white cells;
LGG	trans	rs1032833	0.732	rs79839178	chr2:180031881	C/T	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21795699	chr17:15903687	ZSWIM7;TTC19	-0.47	-6.84	-0.3	2.47e-11	Systemic lupus erythematosus;
LGG	cis	rs2658782	0.694	rs3019221	chr11:93079700	C/G	cg15737290	chr11:93063684	CCDC67	0.51	7.81	0.34	3.87e-14	Pulmonary function decline;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.21	-0.49	6.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.49	-0.33	3.55e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03352830	chr11:487213	PTDSS2	0.86	10.92	0.45	7.31e-25	Body mass index;
LGG	cis	rs8067545	0.536	rs62067482	chr17:19947275	G/A	cg13482628	chr17:19912719	NA	0.5	8.17	0.36	2.91e-15	Schizophrenia;
LGG	cis	rs1847505	0.563	rs1514171	chr13:61410527	C/G	cg25164009	chr13:61490935	NA	-0.6	-9.93	-0.42	3.32e-21	Polychlorinated biphenyl levels;
LGG	cis	rs283228	0.550	rs1338157	chr6:101822778	G/A	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	trans	rs61931739	0.500	rs6488224	chr12:34537205	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.23	-0.32	2e-12	Prostate cancer;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg05890377	chr2:74357713	NA	0.47	9.08	0.39	3.18e-18	Gestational age at birth (maternal effect);
LGG	cis	rs13191362	0.507	rs2849524	chr6:163127070	C/T	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-6.68	-0.3	7.09e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9354308	0.764	rs6927734	chr6:66613917	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.66	-0.3	7.97e-11	Metabolite levels;
LGG	cis	rs9596863	0.898	rs68056413	chr13:54375907	G/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg00933542	chr6:150070202	PCMT1	0.4	7.19	0.32	2.6e-12	Lung cancer;
LGG	trans	rs1032833	0.732	rs76413813	chr2:179962028	A/T	cg23654767	chr2:101192981	PDCL3	0.6	7.51	0.33	3.15e-13	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9790314	0.747	rs1599386	chr3:160856314	C/T	cg04691961	chr3:161091175	C3orf57	0.54	11.81	0.48	2.46e-28	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg09021430	chr5:549028	NA	-0.68	-9.53	-0.41	8.67e-20	Obesity-related traits;
LGG	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.33	-0.32	1e-12	Testicular germ cell tumor;
LGG	cis	rs6942756	0.531	rs2896415	chr7:128904523	G/A	cg02491457	chr7:128862824	NA	0.51	9.64	0.41	3.54e-20	White matter hyperintensity burden;
LGG	cis	rs7119038	0.509	rs11216964	chr11:118581895	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.81	0.3	3.04e-11	Sjögren's syndrome;
LGG	cis	rs854765	0.647	rs2974999	chr17:17997547	T/G	cg05444541	chr17:17804740	TOM1L2	-0.58	-12.46	-0.5	5.97e-31	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg17202724	chr17:61916730	SMARCD2	-0.46	-8.79	-0.38	3.04e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs67311347	1.000	rs954589	chr3:40444545	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-25.84	-0.77	8.4e-92	Renal cell carcinoma;
LGG	cis	rs977987	0.624	rs59867374	chr16:75432682	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.03	0.42	1.46e-21	Dupuytren's disease;
LGG	cis	rs10927875	0.619	rs2102664	chr1:16130169	A/G	cg21385522	chr1:16154831	NA	-0.74	-15.34	-0.58	3.15e-43	Dilated cardiomyopathy;
LGG	trans	rs12439619	0.921	rs56042848	chr15:82527585	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.47	-9.09	-0.39	2.98e-18	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	1.000	rs11000897	chr10:75911276	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.3	0.46	2.59e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs12325245	0.536	rs35832551	chr16:58591444	G/T	cg01152986	chr16:58549298	SETD6	0.84	7.37	0.32	7.71e-13	Schizophrenia;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg13206674	chr6:150067644	NUP43	0.42	9.06	0.39	3.56e-18	Testicular germ cell tumor;
LGG	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg09307838	chr4:120376055	NA	0.82	13.76	0.54	2.34e-36	Corneal astigmatism;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-11.31	-0.47	2.4e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4417704	0.551	rs4430951	chr2:241894333	G/A	cg26818257	chr2:241905806	NA	0.5	10.98	0.45	4.52e-25	Joint mobility (Beighton score);
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.36	-0.32	8.28e-13	Personality dimensions;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03595861	chr6:26126282	NA	0.4	6.81	0.3	3.04e-11	Bipolar disorder;
LGG	cis	rs3540	0.960	rs8030722	chr15:90974920	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.08	0.35	5.61e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs9303280	0.747	rs1453559	chr17:38020419	T/C	cg19468946	chr17:37922297	IKZF3	-0.38	-6.83	-0.3	2.71e-11	Self-reported allergy;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg04025307	chr7:1156635	C7orf50	0.8	16.69	0.61	2.59e-49	Longevity;Endometriosis;
LGG	cis	rs79349575	0.783	rs9747646	chr17:47016882	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg24829409	chr8:58192753	C8orf71	-0.77	-10.11	-0.43	7.32e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs74781061	0.929	rs11855521	chr15:74780379	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg08888203	chr3:10149979	C3orf24	0.57	7.99	0.35	1.07e-14	Alzheimer's disease;
LGG	cis	rs4926611	0.830	rs2948045	chr1:54051898	C/T	cg23596471	chr1:54105337	GLIS1	0.39	8.16	0.35	3.26e-15	Hand grip strength;
LGG	cis	rs2294693	0.947	rs4714417	chr6:40987782	A/G	cg14769373	chr6:40998127	UNC5CL	-0.43	-7.51	-0.33	2.98e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg02297831	chr4:17616191	MED28	-0.49	-8.23	-0.36	1.9e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs5758511	0.680	rs5758698	chr22:42684818	C/T	cg15128208	chr22:42549153	NA	0.76	12.03	0.49	3.33e-29	Birth weight;
LGG	cis	rs1015291	0.708	rs1352901	chr12:20005347	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.26	-0.32	1.67e-12	Diastolic blood pressure;
LGG	trans	rs6582630	0.548	rs1607870	chr12:38385964	G/T	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.52e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9644630	0.932	rs4922048	chr8:19360814	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.38	-0.47	1.24e-26	Oropharynx cancer;
LGG	cis	rs1014246	0.826	rs1900509	chr10:118470942	T/C	cg14919929	chr10:118506882	NA	-0.62	-12.42	-0.5	8.74e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs8141529	0.732	rs5997408	chr22:29207915	G/A	cg02153584	chr22:29168773	CCDC117	0.69	11.69	0.48	7.37e-28	Lymphocyte counts;
LGG	cis	rs4740619	0.525	rs9407654	chr9:15829263	A/G	cg14451791	chr9:16040625	NA	-0.31	-7.19	-0.32	2.62e-12	Body mass index;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg16507663	chr6:150244633	RAET1G	0.44	8.28	0.36	1.31e-15	Lung cancer;
LGG	cis	rs4538187	0.518	rs781516	chr2:64276576	A/G	cg14150252	chr2:64069583	UGP2	0.39	8.87	0.38	1.63e-17	Systolic blood pressure;
LGG	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg07541023	chr7:19748670	TWISTNB	0.6	8.38	0.36	6.52e-16	Thyroid stimulating hormone;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18317022	chr19:48017995	NAPA	-0.37	-6.69	-0.3	6.51e-11	Pancreatic cancer;
LGG	cis	rs4319547	0.656	rs3817011	chr12:122819566	C/T	cg23029597	chr12:123009494	RSRC2	-0.89	-16.5	-0.61	1.94e-48	Body mass index;
LGG	cis	rs2762353	0.574	rs9461204	chr6:25718466	A/G	cg03264133	chr6:25882463	NA	0.69	13.32	0.53	1.71e-34	Blood metabolite levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24595957	chr14:20811627	PARP2;RPPH1	0.38	6.71	0.3	5.75e-11	Obesity-related traits;
LGG	cis	rs2285947	0.933	rs10275354	chr7:21580599	G/A	cg23045935	chr7:21583304	DNAH11	0.44	9.42	0.4	2.2e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg18188782	chr20:61659543	NA	0.4	6.74	0.3	4.64e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg14159672	chr1:205819179	PM20D1	0.5	8.04	0.35	7.69e-15	Parkinson's disease;
LGG	trans	rs2574985	0.702	rs3011793	chr10:52316472	C/T	cg18558237	chr10:81444220	LOC650623	0.43	6.69	0.3	6.36e-11	Subjective well-being;
LGG	cis	rs7580658	0.817	rs6761447	chr2:128074573	A/T	cg10021288	chr2:128175891	PROC	-0.62	-12.83	-0.51	1.82e-32	Protein C levels;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.3	0.4	5.75e-19	Platelet count;
LGG	cis	rs116095464	0.558	rs7356696	chr5:284251	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.56	-0.33	2.13e-13	Testicular germ cell tumor;
LGG	cis	rs3816183	0.626	rs7578494	chr2:42896255	C/G	cg14631114	chr2:43023945	NA	0.35	6.83	0.3	2.62e-11	Hypospadias;
LGG	cis	rs3816183	0.531	rs7569325	chr2:43124989	C/G	cg14631114	chr2:43023945	NA	-0.42	-7.12	-0.31	4.26e-12	Hypospadias;
LGG	cis	rs741702	0.928	rs10451496	chr19:13017876	C/T	cg04657146	chr19:12876947	HOOK2	-0.44	-7.21	-0.32	2.34e-12	Red blood cell traits;
LGG	cis	rs4481887	0.861	rs6669290	chr1:248476804	G/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs4731207	0.541	rs6960027	chr7:124543011	G/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs561341	1.000	rs501312	chr17:30329066	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	trans	rs877282	0.947	rs7475589	chr10:767479	C/G	cg22713356	chr15:30763199	NA	0.54	8.18	0.36	2.8e-15	Uric acid levels;
LGG	cis	rs17030434	0.728	rs16998891	chr4:154646419	T/G	cg14289246	chr4:154710475	SFRP2	-0.63	-9.7	-0.41	2.27e-20	Electrocardiographic conduction measures;
LGG	trans	rs11098499	0.645	rs78422072	chr4:120281042	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.01	0.46	3.26e-25	Corneal astigmatism;
LGG	cis	rs1348850	0.526	rs7582179	chr2:178370631	A/G	cg27490568	chr2:178487706	NA	0.81	14.31	0.55	1.04e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12210905	0.925	rs858985	chr6:27178028	T/C	cg23155468	chr6:27110703	HIST1H2BK	0.53	6.72	0.3	5.38e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2243480	0.901	rs778730	chr7:65823325	T/A	cg18252515	chr7:66147081	NA	-1.4	-19.73	-0.68	2.36e-63	Diabetic kidney disease;
LGG	trans	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg18187862	chr3:45730750	SACM1L	0.64	10.33	0.43	1.17e-22	Primary sclerosing cholangitis;
LGG	cis	rs6867032	0.917	rs10474734	chr5:2004208	A/G	cg26168224	chr5:2018326	NA	1.02	18.34	0.65	6.88e-57	Gut microbiome composition (winter);
LGG	cis	rs36051895	0.589	rs6476947	chr9:5204279	A/G	cg02405213	chr9:5042618	JAK2	-0.73	-13.3	-0.53	2.07e-34	Pediatric autoimmune diseases;
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.95	-0.45	5.58e-25	Neuroticism;
LGG	cis	rs1538970	0.962	rs9429076	chr1:45819489	A/G	cg05343316	chr1:45956843	TESK2	0.68	9.76	0.41	1.42e-20	Platelet count;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg00800038	chr16:89945340	TCF25	-0.71	-8.45	-0.37	3.74e-16	Skin colour saturation;
LGG	cis	rs477895	0.887	rs12793347	chr11:64117491	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.66	7.19	0.32	2.64e-12	Mean platelet volume;
LGG	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.51	-0.4	1.04e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg22875332	chr1:76189707	ACADM	0.6	10.73	0.45	3.78e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.09	-0.39	2.9e-18	Lewy body disease;
LGG	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg04727924	chr7:799746	HEATR2	-0.48	-7.72	-0.34	7.17e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg25809561	chr17:30822961	MYO1D	0.45	11.12	0.46	1.26e-25	Schizophrenia;
LGG	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg27535305	chr1:53392650	SCP2	-0.31	-7.13	-0.31	3.99e-12	Monocyte count;
LGG	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg18681998	chr4:17616180	MED28	-0.88	-19.25	-0.67	4.31e-61	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs736408	0.609	rs13061423	chr3:52790213	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.48	-0.44	3.31e-23	Bipolar disorder;
LGG	cis	rs1799949	0.526	rs4352088	chr17:41414679	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.67	-0.37	7.45e-17	Menopause (age at onset);
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.65	0.37	8.72e-17	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg21605333	chr4:119757512	SEC24D	1.37	12.93	0.51	7.48e-33	Cannabis dependence symptom count;
LGG	cis	rs10463316	0.894	rs4099171	chr5:150766623	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4330281	0.647	rs7647914	chr3:17742786	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.5	-0.33	3.23e-13	Schizophrenia;
LGG	cis	rs943466	0.537	rs2296329	chr6:33650743	A/G	cg07519485	chr6:33762594	MLN	0.39	6.82	0.3	2.8e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg06475006	chr16:89985975	MC1R	-0.58	-6.78	-0.3	3.67e-11	Skin colour saturation;
LGG	cis	rs12477438	0.520	rs3749087	chr2:100026940	A/G	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	trans	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.0	-0.57	1.02e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2481665	1.000	rs2481665	chr1:62594677	T/C	cg18591186	chr1:62594603	INADL	-0.59	-12.93	-0.51	7.54e-33	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg06917634	chr15:78832804	PSMA4	-0.61	-10.89	-0.45	9.93e-25	Sudden cardiac arrest;
LGG	cis	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs11150038	0.623	rs16946927	chr16:78013386	G/A	cg04733911	chr16:78082701	NA	0.55	7.13	0.31	3.92e-12	Colorectal or endometrial cancer;
LGG	cis	rs950169	1.000	rs35658069	chr15:84780146	C/T	cg24253500	chr15:84953950	NA	0.6	10.95	0.45	5.88e-25	Schizophrenia;
LGG	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.67	-0.3	7.3e-11	Parkinson's disease;
LGG	cis	rs780096	0.565	rs780104	chr2:27677691	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs11864453	0.614	rs12445586	chr16:72126276	C/T	cg01557791	chr16:72042693	DHODH	-0.51	-9.46	-0.4	1.62e-19	Fibrinogen levels;
LGG	cis	rs11608355	0.515	rs2270361	chr12:109935894	G/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs62238980	0.614	rs17744899	chr22:32406766	G/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs28595532	1.000	rs17258106	chr4:119675406	C/T	cg11846333	chr4:119757529	SEC24D	-0.76	-6.81	-0.3	3.06e-11	Cannabis dependence symptom count;
LGG	cis	rs6964587	0.839	rs11767135	chr7:91551245	T/G	cg17063962	chr7:91808500	NA	-0.43	-7.77	-0.34	5.15e-14	Breast cancer;
LGG	cis	rs1348850	0.872	rs4893824	chr2:178298104	G/A	cg22681709	chr2:178499509	PDE11A	-0.47	-8.47	-0.37	3.38e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.55	-0.37	1.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.62	11.01	0.46	3.48e-25	Total body bone mineral density;
LGG	cis	rs7246865	0.859	rs12461874	chr19:17180358	C/A	cg19418318	chr19:17219073	MYO9B	0.3	7.83	0.34	3.43e-14	Reticulocyte fraction of red cells;
LGG	cis	rs13314892	0.692	rs62253174	chr3:69898414	C/T	cg17445875	chr3:69859618	MITF	-0.41	-8.1	-0.35	4.89e-15	QRS complex (12-leadsum);
LGG	cis	rs273218	1.000	rs156440	chr5:53373656	A/T	ch.5.1024479R	chr5:53302184	ARL15	0.65	9.48	0.4	1.29e-19	Migraine;
LGG	cis	rs4740619	0.565	rs10738424	chr9:16032142	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.29	-0.46	2.92e-26	Body mass index;
LGG	trans	rs800082	0.698	rs800073	chr3:144347599	G/A	cg24215973	chr2:240111563	HDAC4	-0.72	-13.28	-0.53	2.41e-34	Smoking behavior;
LGG	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.28	0.4	6.36e-19	Blood metabolite levels;
LGG	cis	rs611744	0.839	rs638238	chr8:109169152	A/G	cg21045802	chr8:109455806	TTC35	0.39	6.99	0.31	9.63e-12	Dupuytren's disease;
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.59	-0.41	5.31e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg14689365	chr7:158441557	NCAPG2	0.61	10.46	0.44	3.87e-23	Height;
LGG	cis	rs3087591	0.960	rs9303642	chr17:29578360	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.71	-0.56	1.8e-40	Hip circumference;
LGG	cis	rs1552244	0.938	rs34750074	chr3:10091740	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.24	0.69	1.04e-65	Alzheimer's disease;
LGG	cis	rs4788570	0.566	rs3886947	chr16:71483958	G/C	cg06353428	chr16:71660113	MARVELD3	-1.03	-13.92	-0.54	4.61e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2028299	1.000	rs9920762	chr15:90368171	T/C	cg23731826	chr15:90371692	NA	0.37	8.75	0.38	3.99e-17	Type 2 diabetes;
LGG	cis	rs10267417	0.603	rs79323924	chr7:19924321	T/G	cg05791153	chr7:19748676	TWISTNB	0.53	6.66	0.3	7.82e-11	Night sleep phenotypes;
LGG	cis	rs6920372	0.748	rs12190372	chr6:110084534	G/A	cg01125227	chr6:109776195	MICAL1	0.43	7.53	0.33	2.64e-13	Height;
LGG	cis	rs7100689	0.577	rs4934038	chr10:82057334	C/A	cg01528321	chr10:82214614	TSPAN14	0.84	14.82	0.57	5.95e-41	Post bronchodilator FEV1;
LGG	trans	rs7395662	1.000	rs7925955	chr11:48647533	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	5e-15	HDL cholesterol;
LGG	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg05623727	chr3:50126028	RBM5	-0.39	-8.37	-0.36	6.91e-16	Menarche (age at onset);
LGG	cis	rs2732480	0.538	rs2468943	chr12:48747249	G/T	cg21466736	chr12:48725269	NA	0.36	7.13	0.31	3.78e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs1881797	0.527	rs74227706	chr1:247638315	A/C	cg18198730	chr1:247681584	NA	0.62	6.67	0.3	7.52e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12615966	1.000	rs17030309	chr2:105391328	G/A	cg16465502	chr2:105461796	NA	0.88	10.77	0.45	2.76e-24	Pancreatic cancer;
LGG	cis	rs1506636	0.511	rs62484466	chr7:123174880	T/A	cg03229431	chr7:123269106	ASB15	0.47	10.17	0.43	4.42e-22	Plateletcrit;Platelet count;
LGG	cis	rs2732480	0.577	rs2732448	chr12:48730600	T/C	cg24011408	chr12:48396354	COL2A1	0.5	7.86	0.34	2.66e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs61931739	0.620	rs708143	chr12:33719962	A/C	cg13010199	chr12:38710504	ALG10B	0.42	7.75	0.34	6.03e-14	Morning vs. evening chronotype;
LGG	trans	rs2161208	1.000	rs2161208	chr5:85389380	C/T	cg01787110	chr1:109008453	NBPF6	-0.54	-7.69	-0.34	8.88e-14	Daytime sleep phenotypes;
LGG	cis	rs12142240	0.698	rs68112720	chr1:46813888	T/C	cg00530320	chr1:46809349	NSUN4	0.45	8.29	0.36	1.23e-15	Menopause (age at onset);
LGG	cis	rs12681287	0.608	rs2953511	chr8:87340870	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.49	-0.33	3.42e-13	Caudate activity during reward;
LGG	cis	rs9788682	1.000	rs34138960	chr15:78831668	A/G	cg24631222	chr15:78858424	CHRNA5	0.46	6.95	0.31	1.25e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg25072359	chr17:41440525	NA	0.46	7.46	0.33	4.42e-13	Menopause (age at onset);
LGG	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg11812906	chr14:75593930	NEK9	-0.45	-8.1	-0.35	4.99e-15	Height;
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg02297831	chr4:17616191	MED28	0.48	8.94	0.38	8.98e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4144743	0.702	rs7208055	chr17:45330827	C/A	cg18085866	chr17:45331354	ITGB3	-0.77	-8.18	-0.36	2.72e-15	Body mass index;
LGG	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg22705602	chr4:152727874	NA	-0.33	-7.91	-0.34	1.95e-14	Intelligence (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03150474	chr6:10695108	C6orf52;PAK1IP1	0.43	7.28	0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.43	0.33	5.4e-13	Schizophrenia;
LGG	cis	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg00409905	chr10:38381863	ZNF37A	-0.63	-11.79	-0.48	2.98e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg15320075	chr8:145703422	NA	0.64	12.74	0.51	4.33e-32	Age at first birth;
LGG	cis	rs9300255	0.568	rs1790108	chr12:123636841	A/G	cg00376283	chr12:123451042	ABCB9	0.64	10.3	0.43	1.5e-22	Neutrophil percentage of white cells;
LGG	cis	rs1124376	1.000	rs17006610	chr3:20152563	G/A	cg05072819	chr3:20081367	KAT2B	0.58	7.86	0.34	2.77e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg13206674	chr6:150067644	NUP43	0.62	14.12	0.55	6.35e-38	Lung cancer;
LGG	cis	rs1030877	1.000	rs1030877	chr2:105910513	G/A	cg02079111	chr2:105885981	TGFBRAP1	0.74	14.6	0.56	5.35e-40	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.27	-8.03	-0.35	7.99e-15	IgG glycosylation;
LGG	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.88e-19	Menarche (age at onset);
LGG	cis	rs12519773	0.597	rs17360518	chr5:92457899	A/C	cg18783429	chr5:92414398	NA	0.33	8.27	0.36	1.39e-15	Migraine;
LGG	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg18200150	chr17:30822561	MYO1D	0.51	9.72	0.41	1.83e-20	Schizophrenia;
LGG	trans	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg27523141	chr10:43048294	ZNF37B	0.32	6.69	0.3	6.3e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.38	0.32	7.4e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.23	-0.49	5.23e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs910316	0.726	rs12882664	chr14:75446778	C/T	cg11812906	chr14:75593930	NEK9	0.46	8.16	0.35	3.12e-15	Height;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.2	0.36	2.34e-15	Obesity-related traits;
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07440826	chr16:89882328	FANCA	-0.26	-6.88	-0.3	1.98e-11	Vitiligo;
LGG	cis	rs9810089	0.934	rs66691851	chr3:136154828	C/T	cg12473912	chr3:136751656	NA	0.39	6.72	0.3	5.38e-11	Gestational age at birth (child effect);
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.2	-0.32	2.41e-12	Life satisfaction;
LGG	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg11502198	chr6:26597334	ABT1	0.71	12.96	0.52	5.27e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2694528	0.858	rs80120114	chr5:60429823	T/A	cg11474532	chr5:59995715	DEPDC1B	0.68	7.29	0.32	1.35e-12	Parkinson's disease;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg21724239	chr8:58056113	NA	0.7	15.94	0.6	6.61e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11239187	0.523	rs12767435	chr10:45088884	A/G	cg03916630	chr10:45065415	NA	0.42	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.57	-0.47	2.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	cis	rs7267979	1.000	rs6115153	chr20:25325567	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.49	-0.44	3.04e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg18402987	chr7:1209562	NA	0.42	7.85	0.34	2.88e-14	Longevity;Endometriosis;
LGG	cis	rs1801251	0.963	rs13424351	chr2:233573629	A/G	cg25237894	chr2:233734115	C2orf82	0.63	12.03	0.49	3.51e-29	Coronary artery disease;
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg27189623	chr16:705930	WDR90	0.41	7.77	0.34	5.14e-14	Height;
LGG	cis	rs35110281	0.627	rs1436291	chr21:44965485	T/C	cg04455712	chr21:45112962	RRP1B	0.49	9.07	0.39	3.3e-18	Mean corpuscular volume;
LGG	cis	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg22232500	chr2:134024266	NCKAP5	0.67	9.2	0.39	1.24e-18	Bipolar disorder;
LGG	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.86	-0.45	1.24e-24	Coronary artery disease;
LGG	cis	rs3206736	0.548	rs2108690	chr7:35082809	C/T	cg13400248	chr7:35225412	NA	0.54	9.45	0.4	1.71e-19	Diastolic blood pressure;
LGG	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg01043669	chr3:72786069	NA	0.44	7.05	0.31	6.61e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs77741769	0.571	rs11065282	chr12:121264415	G/T	cg02419362	chr12:121203948	SPPL3	0.54	9.26	0.4	7.63e-19	Mean corpuscular volume;
LGG	trans	rs7395662	1.000	rs4882130	chr11:48588954	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08086074	chr14:50359443	ARF6	0.48	7.24	0.32	1.94e-12	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg08470875	chr2:26401718	FAM59B	-0.37	-6.84	-0.3	2.59e-11	Gut microbiome composition (summer);
LGG	cis	rs4704187	0.687	rs6872475	chr5:74419793	G/A	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs60180747	0.909	rs28684409	chr15:66794706	T/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.38	0.43	8.13e-23	Testicular germ cell tumor;
LGG	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg16384552	chr7:74938386	SPDYE8P	-0.52	-9.62	-0.41	4.45e-20	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17641971	0.684	rs6984804	chr8:49987910	G/A	cg00325661	chr8:49890786	NA	0.57	10.89	0.45	9.93e-25	Blood metabolite levels;
LGG	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.91	0.54	5.24e-37	Colorectal cancer;
LGG	cis	rs1816752	0.905	rs1050112	chr13:25009297	G/T	cg22771759	chr13:24902376	NA	0.42	7.13	0.31	3.86e-12	Obesity-related traits;
LGG	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg00784671	chr22:46762841	CELSR1	-0.57	-7.2	-0.32	2.47e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg23306229	chr2:178417860	TTC30B	0.6	7.48	0.33	3.82e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg02073558	chr3:44770973	ZNF501	0.7	13.14	0.52	9.63e-34	Depressive symptoms;
LGG	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg09222892	chr1:25734099	RHCE	0.45	9.28	0.4	6.54e-19	Erythrocyte sedimentation rate;
LGG	cis	rs4731207	0.698	rs2896361	chr7:124473825	C/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs354225	0.565	rs2971880	chr2:54885640	A/T	cg26097391	chr2:54893211	SPTBN1	0.3	7.61	0.33	1.54e-13	Schizophrenia;
LGG	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg02476566	chr12:106696527	TCP11L2	0.5	7.11	0.31	4.29e-12	Tourette syndrome;
LGG	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.87	-9.64	-0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs9467160	0.520	rs9356934	chr6:24442171	C/T	cg20631270	chr6:24437470	GPLD1	0.39	6.7	0.3	6.05e-11	Liver enzyme levels;
LGG	cis	rs9815354	0.767	rs73087378	chr3:41936827	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg26783146	chr16:4423632	VASN;CORO7	-0.35	-6.8	-0.3	3.23e-11	Schizophrenia;
LGG	cis	rs9815354	0.597	rs59432762	chr3:41812294	G/C	cg03022575	chr3:42003672	ULK4	0.79	9.14	0.39	1.92e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg07511668	chr11:68622177	NA	-0.5	-9.73	-0.41	1.77e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.83	-0.3	2.67e-11	Mood instability;
LGG	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg04149295	chr10:70884716	VPS26A	0.49	7.44	0.33	4.84e-13	Left atrial antero-posterior diameter;
LGG	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg00012203	chr2:219082015	ARPC2	0.75	14.32	0.55	8.97e-39	Colorectal cancer;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02071572	chr4:1403502	NA	-0.4	-6.79	-0.3	3.4e-11	Longevity;
LGG	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	cis	rs2836974	0.831	rs6517521	chr21:40551588	A/G	cg11890956	chr21:40555474	PSMG1	1.21	31.01	0.82	4.36e-115	Cognitive function;
LGG	cis	rs3741404	0.620	rs2236648	chr11:63964657	C/T	cg18225595	chr11:63971243	STIP1	0.52	10.43	0.44	5.26e-23	Platelet count;
LGG	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg26597838	chr10:835615	NA	0.75	10.43	0.44	5.03e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg08508337	chr8:144660607	NAPRT1	0.89	7.17	0.32	2.92e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs701145	0.585	rs1727947	chr3:153879467	C/T	cg12800244	chr3:153838788	SGEF	0.7	7.84	0.34	3.1e-14	Coronary artery disease;
LGG	cis	rs72827839	0.802	rs16953925	chr17:46294498	C/T	cg02219949	chr17:45927392	SP6	0.52	7.74	0.34	6.08e-14	Ease of getting up in the morning;
LGG	cis	rs9487094	0.670	rs11754455	chr6:109817883	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.51e-16	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.68	0.54	5.1e-36	Lung cancer;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.07	-0.31	5.68e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2290405	0.527	rs935965	chr4:928684	T/C	cg04824913	chr4:887549	GAK	0.83	16.71	0.61	2.21e-49	Systemic sclerosis;
LGG	cis	rs17604090	0.536	rs112165062	chr7:29687592	C/T	cg19413766	chr7:29689036	LOC646762	-0.62	-7.94	-0.35	1.59e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg18187862	chr3:45730750	SACM1L	-0.53	-8.38	-0.36	6.6e-16	Primary sclerosing cholangitis;
LGG	cis	rs7523273	1.000	rs34385765	chr1:207993637	A/G	cg22525895	chr1:207977042	MIR29B2	-0.62	-11.42	-0.47	8.79e-27	Schizophrenia;
LGG	cis	rs7928758	0.943	rs75184941	chr11:134277750	G/A	cg25213107	chr11:134282864	B3GAT1	1.03	12.37	0.5	1.41e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg19468946	chr17:37922297	IKZF3	-0.44	-8.03	-0.35	8.33e-15	Self-reported allergy;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg06028808	chr11:68637592	NA	-0.72	-12.23	-0.49	5.55e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4727027	0.870	rs11524138	chr7:148799125	G/A	cg23583168	chr7:148888333	NA	-0.88	-16.85	-0.62	5.2e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4631830	0.737	rs7071471	chr10:51503335	C/T	cg16070123	chr10:51489643	NA	0.4	7.13	0.31	3.93e-12	Prostate-specific antigen levels;
LGG	trans	rs853679	0.546	rs35883476	chr6:28368508	G/C	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs4478037	0.822	rs9883177	chr3:33123354	T/C	cg19404215	chr3:33155277	CRTAP	0.74	9.24	0.39	9.27e-19	Major depressive disorder;
LGG	cis	rs875971	0.862	rs1612452	chr7:65573896	T/A	cg23594656	chr7:65796392	TPST1	0.39	8.54	0.37	1.97e-16	Aortic root size;
LGG	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg21545522	chr1:205238299	TMCC2	0.48	8.49	0.37	2.86e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg05925327	chr15:68127851	NA	-0.38	-7.97	-0.35	1.24e-14	Restless legs syndrome;
LGG	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg02403541	chr12:121454288	C12orf43	0.54	8.76	0.38	3.74e-17	N-glycan levels;
LGG	cis	rs9815354	0.812	rs55916855	chr3:42002761	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.04e-12	Bipolar disorder;
LGG	cis	rs6120849	0.754	rs1885116	chr20:33600560	A/G	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.39e-11	Protein C levels;
LGG	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg16482183	chr6:26056742	HIST1H1C	-0.5	-7.99	-0.35	1.06e-14	Iron status biomarkers;
LGG	cis	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg07460842	chr6:66804631	NA	-0.97	-18.09	-0.64	9.95e-56	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-12.75	-0.51	3.89e-32	Response to antipsychotic treatment;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg22105103	chr4:187893119	NA	0.57	10.81	0.45	1.99e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.91	-0.31	1.64e-11	Fear of minor pain;
LGG	cis	rs8177253	0.696	rs4459901	chr3:133465699	T/C	cg01448562	chr3:133502909	NA	-0.56	-9.19	-0.39	1.36e-18	Iron status biomarkers;
LGG	cis	rs853679	0.542	rs9380063	chr6:28137853	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs736408	0.583	rs2710323	chr3:52815905	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.73	0.3	4.99e-11	Bipolar disorder;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg14159672	chr1:205819179	PM20D1	0.75	16.27	0.6	2.06e-47	Menarche (age at onset);
LGG	trans	rs526821	0.595	rs565859	chr11:55297367	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg12561776	chr17:30844705	MYO1D	-0.28	-7.04	-0.31	7.19e-12	Schizophrenia;
LGG	cis	rs6430585	1.000	rs6430585	chr2:136506927	A/C	cg07169764	chr2:136633963	MCM6	-0.99	-18.71	-0.66	1.35e-58	Corneal structure;
LGG	cis	rs7089973	0.525	rs11196945	chr10:116600424	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs17321999	1.000	rs13389106	chr2:30480750	T/G	cg05247661	chr2:30472410	LBH	0.56	9.19	0.39	1.37e-18	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg00933542	chr6:150070202	PCMT1	0.37	6.75	0.3	4.31e-11	Lung cancer;
LGG	cis	rs7103648	0.808	rs7103835	chr11:47461693	G/A	cg20307385	chr11:47447363	PSMC3	0.88	18.12	0.64	7.21e-56	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17744375	chr7:4243286	SDK1	0.42	7.88	0.34	2.4e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9467711	0.606	rs9379901	chr6:26603866	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	8.25	0.36	1.69e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg26513180	chr16:89883248	FANCA	0.85	8.08	0.35	5.54e-15	Skin colour saturation;
LGG	cis	rs11239187	0.962	rs34072809	chr10:45108830	G/C	cg03916630	chr10:45065415	NA	0.34	7.56	0.33	2.24e-13	Body mass index;
LGG	cis	rs2693698	0.563	rs36171032	chr14:99683700	T/C	cg07440398	chr14:99712966	BCL11B	0.58	11.84	0.48	1.91e-28	Schizophrenia;
LGG	cis	rs868036	1.000	rs884202	chr15:68054388	G/A	cg05925327	chr15:68127851	NA	0.37	8.55	0.37	1.8e-16	Restless legs syndrome;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg13047869	chr3:10149882	C3orf24	0.52	8.65	0.37	8.64e-17	Alzheimer's disease;
LGG	cis	rs362296	0.698	rs362282	chr4:3259671	G/A	cg06533319	chr4:3265114	C4orf44	0.5	9.76	0.41	1.32e-20	Parental longevity (mother's age at death);
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg08677398	chr8:58056175	NA	0.41	7.0	0.31	9.2e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16245510	chr1:25559209	SYF2	-0.45	-7.12	-0.31	4.28e-12	Systemic lupus erythematosus;
LGG	cis	rs2224391	1.000	rs2224391	chr6:5260936	A/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-8.64	-0.37	9.49e-17	Height;
LGG	cis	rs9649465	0.902	rs10253850	chr7:123273095	T/C	cg03229431	chr7:123269106	ASB15	-0.42	-9.14	-0.39	1.96e-18	Migraine;
LGG	cis	rs7769051	1.000	rs6934161	chr6:133124077	C/T	cg22852734	chr6:133119734	C6orf192	-1.15	-15.59	-0.59	2.42e-44	Type 2 diabetes nephropathy;
LGG	cis	rs875971	0.545	rs316305	chr7:65617971	G/A	cg11764359	chr7:65958608	NA	-0.63	-9.75	-0.41	1.44e-20	Aortic root size;
LGG	trans	rs6787172	0.622	rs10936133	chr3:158089973	C/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs929596	0.531	rs2741022	chr2:234514273	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.54	-8.5	-0.37	2.66e-16	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg04166393	chr7:2884313	GNA12	0.44	8.45	0.37	3.94e-16	Height;
LGG	cis	rs6732160	0.613	rs58317144	chr2:73388153	C/T	cg01422370	chr2:73384389	NA	0.56	9.76	0.41	1.33e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7924176	0.601	rs2131957	chr10:75866929	C/A	cg19889307	chr10:75911429	ADK;AP3M1	-0.39	-6.74	-0.3	4.73e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	9.0	0.39	5.92e-18	Retinal vascular caliber;
LGG	cis	rs7129556	0.690	rs12285765	chr11:77569035	C/T	cg12586386	chr11:77299805	AQP11	0.44	7.33	0.32	1.01e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs75059851	0.756	rs2000852	chr11:133838221	C/T	cg17703048	chr11:133852993	NA	-0.87	-15.97	-0.6	4.75e-46	Schizophrenia;
LGG	cis	rs490234	0.841	rs7044663	chr9:128268263	C/T	cg14078157	chr9:128172775	NA	-0.45	-8.48	-0.37	3.13e-16	Mean arterial pressure;
LGG	cis	rs11122272	0.764	rs4486439	chr1:231477470	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.67	-0.44	6.38e-24	Hemoglobin concentration;
LGG	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg04842962	chr6:43655489	MRPS18A	0.79	14.76	0.57	1.06e-40	IgG glycosylation;
LGG	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg15309053	chr8:964076	NA	0.43	9.05	0.39	4.12e-18	Schizophrenia;
LGG	cis	rs1697139	1.000	rs1705397	chr5:66511062	G/T	cg11553311	chr5:66541588	NA	-0.37	-8.22	-0.36	2.1e-15	Breast cancer;
LGG	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg23939001	chr4:940644	TMEM175	-0.4	-8.7	-0.37	5.96e-17	Systemic sclerosis;
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.37	-0.56	5.71e-39	Tonsillectomy;
LGG	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg24631222	chr15:78858424	CHRNA5	0.46	7.13	0.31	3.76e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg11984989	chr7:158649758	WDR60	1.0	13.79	0.54	1.81e-36	Height;
LGG	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.56	0.33	2.25e-13	Neuroticism;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs1552244	0.572	rs67227131	chr3:10172744	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-10.96	-0.45	5.09e-25	Alzheimer's disease;
LGG	cis	rs947474	0.517	rs4396194	chr10:6401615	G/A	cg19837174	chr10:6389707	NA	0.49	7.47	0.33	4.16e-13	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg02018176	chr4:1364513	KIAA1530	0.64	15.86	0.59	1.55e-45	Longevity;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg26174226	chr8:58114915	NA	-0.52	-7.7	-0.34	8.2e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg05025164	chr4:1340916	KIAA1530	0.56	9.95	0.42	2.81e-21	Obesity-related traits;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24972080	chr11:65154083	FRMD8	-0.4	-7.01	-0.31	8.34e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg07061783	chr6:25882402	NA	-0.56	-9.48	-0.4	1.37e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7247513	1.000	rs7247513	chr19:12691185	C/T	cg01871581	chr19:12707946	ZNF490	-0.45	-9.36	-0.4	3.49e-19	Bipolar disorder;
LGG	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg25237894	chr2:233734115	C2orf82	0.66	12.75	0.51	3.88e-32	Coronary artery disease;
LGG	cis	rs36051895	0.632	rs7850484	chr9:5147817	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.67	-0.56	2.62e-40	Pediatric autoimmune diseases;
LGG	cis	rs6772849	0.930	rs6768344	chr3:128373556	G/A	cg08795948	chr3:128337044	NA	0.66	11.29	0.46	2.88e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.79	0.3	3.54e-11	Cognitive ability;
LGG	cis	rs8112449	0.822	rs2043330	chr19:10553618	C/T	cg21868191	chr19:10515988	NA	-0.45	-7.49	-0.33	3.41e-13	Multiple sclerosis;Gastritis;
LGG	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg04553112	chr3:125709451	NA	-0.53	-7.53	-0.33	2.72e-13	Blood pressure (smoking interaction);
LGG	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg17892150	chr10:133769511	PPP2R2D	-0.63	-12.8	-0.51	2.57e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs597583	0.950	rs473343	chr11:117408156	G/C	cg27161313	chr11:117392002	DSCAML1	-0.41	-6.98	-0.31	1.06e-11	Putamen volume;
LGG	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg21926883	chr2:100939477	LONRF2	-0.54	-10.38	-0.43	7.86e-23	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg18252515	chr7:66147081	NA	0.44	7.32	0.32	1.08e-12	Aortic root size;
LGG	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.47	-0.71	1.71e-71	Height;
LGG	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg13385521	chr17:29058706	SUZ12P	0.84	9.61	0.41	4.53e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg18252515	chr7:66147081	NA	1.43	21.04	0.7	1.78e-69	Diabetic kidney disease;
LGG	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg07541023	chr7:19748670	TWISTNB	0.46	7.24	0.32	1.84e-12	Thyroid stimulating hormone;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg00677455	chr12:58241039	CTDSP2	0.43	7.67	0.34	1.01e-13	Multiple sclerosis;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg07308232	chr7:1071921	C7orf50	-0.54	-9.97	-0.42	2.51e-21	Longevity;Endometriosis;
LGG	cis	rs870825	0.655	rs7683556	chr4:185632019	T/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Blood protein levels;
LGG	cis	rs4740619	0.810	rs7034484	chr9:15665201	G/T	cg14451791	chr9:16040625	NA	0.34	8.82	0.38	2.39e-17	Body mass index;
LGG	cis	rs4538187	0.853	rs6546032	chr2:64075076	A/C	cg02541582	chr2:64069798	UGP2	0.59	12.62	0.51	1.42e-31	Systolic blood pressure;
LGG	trans	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg12045294	chr17:78518616	RPTOR	-0.47	-7.28	-0.32	1.47e-12	Glycated hemoglobin levels;
LGG	cis	rs11716531	0.573	rs642570	chr3:27342595	C/G	cg02860705	chr3:27208620	NA	0.6	11.37	0.47	1.36e-26	Diastolic blood pressure;
LGG	cis	rs6500637	0.580	rs5013674	chr16:4932470	G/A	cg08329684	chr16:4932620	PPL	-0.57	-12.55	-0.5	2.61e-31	Cancer;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg27471124	chr11:109292789	C11orf87	0.45	8.42	0.36	4.65e-16	Schizophrenia;
LGG	cis	rs2239547	0.525	rs2246556	chr3:53027983	T/C	cg11645453	chr3:52864694	ITIH4	-0.53	-8.98	-0.39	6.98e-18	Schizophrenia;
LGG	cis	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg15596359	chr8:11213517	TDH	-0.41	-8.34	-0.36	8.72e-16	Retinal vascular caliber;
LGG	cis	rs6051080	1	rs6051080	chr20:25975674	A/G	cg11521797	chr20:25125784	LOC284798	-0.43	-7.27	-0.32	1.58e-12	Colorectal or endometrial cancer;
LGG	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.65	-11.1	-0.46	1.46e-25	Coronary artery disease;
LGG	cis	rs7267979	0.586	rs6050432	chr20:25184028	T/C	cg06421707	chr20:25228305	PYGB	0.39	7.99	0.35	1.12e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs172166	0.694	rs188105	chr6:28071393	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.12	-0.31	4.2e-12	Cardiac Troponin-T levels;
LGG	cis	rs17376456	0.825	rs13165400	chr5:93091427	G/A	cg19507638	chr5:93509721	C5orf36	-0.66	-9.17	-0.39	1.61e-18	Diabetic retinopathy;
LGG	cis	rs12493885	0.725	rs11707232	chr3:153742077	T/A	cg12800244	chr3:153838788	SGEF	-0.78	-8.78	-0.38	3.27e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg01420254	chr6:26195488	NA	0.91	12.29	0.5	3.19e-30	Gout;Renal underexcretion gout;
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.77	0.41	1.25e-20	Height;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg16405210	chr4:1374714	KIAA1530	0.67	12.06	0.49	2.48e-29	Obesity-related traits;
LGG	cis	rs7503807	0.515	rs34863264	chr17:78655312	C/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.25	-0.39	8.4e-19	Obesity;
LGG	cis	rs773506	0.965	rs298718	chr9:94081674	A/G	cg14446406	chr9:93919335	NA	-0.46	-8.33	-0.36	9.31e-16	Type 2 diabetes nephropathy;
LGG	cis	rs4330281	0.647	rs4909010	chr3:17736023	G/A	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs17453880	0.890	rs12522538	chr5:152002303	A/G	cg12297329	chr5:152029980	NA	-0.86	-22.17	-0.72	9.33e-75	Subjective well-being;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.78	-0.41	1.17e-20	Life satisfaction;
LGG	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg08885076	chr2:99613938	TSGA10	0.43	9.25	0.39	8.23e-19	Chronic sinus infection;
LGG	cis	rs12478296	1.000	rs66612947	chr2:243035962	A/T	cg06360820	chr2:242988706	NA	-0.9	-11.62	-0.48	1.46e-27	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.4	-7.27	-0.32	1.58e-12	Homoarginine levels;
LGG	cis	rs1129187	0.837	rs3763236	chr6:42902508	C/T	cg13397359	chr6:42928475	GNMT	-0.52	-14.14	-0.55	5.21e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.78e-25	Aortic root size;
LGG	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg04568710	chr12:38710424	ALG10B	0.33	6.89	0.3	1.87e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs910316	1.000	rs3742780	chr14:75505008	G/C	cg08847533	chr14:75593920	NEK9	0.61	11.68	0.48	8.49e-28	Height;
LGG	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg10057126	chr4:77819792	ANKRD56	0.35	6.86	0.3	2.17e-11	Emphysema distribution in smoking;
LGG	cis	rs6940638	0.688	rs9461335	chr6:27138529	C/A	cg12826209	chr6:26865740	GUSBL1	0.47	7.71	0.34	7.94e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg09085632	chr11:111637200	PPP2R1B	1.02	19.6	0.67	9.85e-63	Primary sclerosing cholangitis;
LGG	cis	rs2028299	0.881	rs11629791	chr15:90449135	A/G	cg23731826	chr15:90371692	NA	0.37	8.79	0.38	3.04e-17	Type 2 diabetes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10055227	chr16:58768320	GOT2	-0.39	-6.72	-0.3	5.36e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg09462578	chr12:12878428	APOLD1	-0.56	-7.72	-0.34	7.08e-14	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg20607798	chr8:58055168	NA	0.62	7.27	0.32	1.56e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.521	rs2117691	chr2:239414734	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.54	0.37	2e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6121246	0.567	rs6058187	chr20:30190923	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	1.34	21.17	0.7	4.77e-70	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2742417	0.935	rs2673028	chr3:45759654	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2.07e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg02002194	chr4:3960332	NA	0.47	9.19	0.39	1.33e-18	Joint mobility (Beighton score);
LGG	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	cis	rs7904985	1.000	rs10887586	chr10:88113521	G/A	cg07322936	chr10:88137208	NA	-0.49	-7.3	-0.32	1.26e-12	Barrett's esophagus;
LGG	cis	rs10911251	0.546	rs2027081	chr1:183074576	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.38	0.4	2.98e-19	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27570636	chr1:214454189	SMYD2	0.39	6.77	0.3	4e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs7119	0.717	rs11635567	chr15:77819515	A/G	cg10437265	chr15:77819839	NA	0.24	6.77	0.3	3.86e-11	Type 2 diabetes;
LGG	cis	rs1021993	0.545	rs4844815	chr1:209529654	G/A	cg24446417	chr1:209558027	NA	-0.7	-10.16	-0.43	5.1e-22	Gut microbiome composition (winter);
LGG	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg03264133	chr6:25882463	NA	0.48	7.9	0.34	2.08e-14	Iron status biomarkers;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs4356932	0.967	rs5005109	chr4:76986342	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.28	-0.36	1.37e-15	Triglycerides;
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1475911	1.000	rs2839467	chr21:43513200	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.49	8.65	0.37	8.3e-17	IgG glycosylation;
LGG	cis	rs758324	0.891	rs491624	chr5:131270222	A/T	cg06307176	chr5:131281290	NA	-0.56	-9.21	-0.39	1.15e-18	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs459571	0.792	rs55923934	chr9:136888233	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.91	-0.48	9.92e-29	Platelet distribution width;
LGG	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg10523679	chr1:76189770	ACADM	0.73	11.1	0.46	1.48e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg05665937	chr4:1216051	CTBP1	0.57	10.67	0.44	6.39e-24	Obesity-related traits;
LGG	cis	rs4302748	0.862	rs74301277	chr7:36184831	C/G	cg24442661	chr7:36192818	EEPD1	0.55	7.16	0.32	3.17e-12	Platelet count;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg09699651	chr6:150184138	LRP11	0.51	8.84	0.38	1.98e-17	Lung cancer;
LGG	cis	rs7666738	0.830	rs10021709	chr4:99030587	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1348850	0.567	rs2222711	chr2:178534110	G/T	cg27490568	chr2:178487706	NA	0.52	10.12	0.43	6.95e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-10.59	-0.44	1.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.01e-23	Prudent dietary pattern;
LGG	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.04	0.52	2.56e-33	Rheumatoid arthritis;
LGG	cis	rs4330281	0.669	rs4470554	chr3:17671037	T/C	cg20981856	chr3:17787350	NA	-0.39	-7.4	-0.33	6.27e-13	Schizophrenia;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.4	0.56	4.28e-39	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6504108	0.602	rs1452667	chr17:46302415	G/A	cg02219949	chr17:45927392	SP6	0.43	7.99	0.35	1.06e-14	Body mass index;
LGG	cis	rs8016982	0.632	rs8010219	chr14:81696982	A/G	cg01989461	chr14:81687754	GTF2A1	0.58	9.08	0.39	3.27e-18	Schizophrenia;
LGG	cis	rs13065560	0.534	rs4637231	chr3:38909115	T/C	cg01426195	chr3:39028469	NA	-0.43	-8.92	-0.38	1.06e-17	Interleukin-18 levels;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.72	0.38	5.15e-17	Lung cancer;
LGG	cis	rs10791097	0.582	rs2282578	chr11:130735691	A/T	cg12179176	chr11:130786555	SNX19	0.87	17.81	0.64	1.93e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.79e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7172689	0.565	rs4128767	chr15:81543407	A/G	cg11808699	chr15:81528661	IL16	-0.31	-7.04	-0.31	6.79e-12	Inattentive symptoms;
LGG	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs17253792	0.545	rs12893676	chr14:56016159	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-9.29	-0.4	6.07e-19	Putamen volume;
LGG	cis	rs6594713	0.684	rs7708831	chr5:112933202	A/G	cg12552261	chr5:112820674	MCC	0.61	7.76	0.34	5.64e-14	Brain cytoarchitecture;
LGG	cis	rs12980942	0.630	rs7256856	chr19:41788352	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.51	6.97	0.31	1.07e-11	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg20821713	chr7:1055600	C7orf50	-0.41	-8.0	-0.35	1.03e-14	Longevity;Endometriosis;
LGG	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.21	-0.36	2.26e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg12923728	chr3:195709715	SDHAP1	0.57	9.57	0.41	6.37e-20	Mean corpuscular volume;
LGG	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.36	-0.32	8.23e-13	Morning vs. evening chronotype;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg22903471	chr2:27725779	GCKR	-0.57	-12.93	-0.51	7.57e-33	Total body bone mineral density;
LGG	trans	rs10506458	0.915	rs998506	chr12:63400017	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-22.01	-0.72	5.18e-74	Hemostatic factors and hematological phenotypes;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-9.37	-0.4	3.32e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7945705	0.875	rs4929914	chr11:8824388	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-7.21	-0.32	2.36e-12	Hemoglobin concentration;
LGG	cis	rs7928758	0.943	rs7948031	chr11:134269091	T/C	cg15243474	chr11:134282918	B3GAT1	1.15	15.37	0.58	2.34e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg26116260	chr4:7069785	GRPEL1	-1.09	-10.74	-0.45	3.51e-24	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg21926883	chr2:100939477	LONRF2	-0.58	-12.34	-0.5	1.86e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg06481639	chr22:41940642	POLR3H	0.48	6.86	0.3	2.21e-11	Vitiligo;
LGG	cis	rs752010	0.631	rs1073197	chr1:42059822	C/T	cg06885757	chr1:42089581	HIVEP3	-0.79	-20.35	-0.69	3.21e-66	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs35740288	0.577	rs10163090	chr15:86193756	G/A	cg04173714	chr15:86211321	AKAP13	0.39	7.59	0.33	1.81e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.93	-0.31	1.4e-11	Lung cancer;
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg21775007	chr8:11205619	TDH	0.51	8.51	0.37	2.47e-16	Neuroticism;
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg19357499	chr8:144660631	NAPRT1	0.87	6.93	0.31	1.45e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs757081	0.667	rs476890	chr11:17209962	A/G	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.91	-0.38	1.17e-17	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15990800	chr14:55738852	FBXO34	0.51	7.79	0.34	4.47e-14	Gut microbiome composition (summer);
LGG	cis	rs2976388	0.609	rs2717603	chr8:143803193	T/C	cg06565975	chr8:143823917	SLURP1	0.36	9.28	0.4	6.73e-19	Urinary tract infection frequency;
LGG	cis	rs6752107	1.000	rs12994997	chr2:234173503	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.61	0.53	9.86e-36	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs503734	0.666	rs473702	chr3:101045977	C/T	cg27318481	chr3:100970896	IMPG2	0.36	7.38	0.32	7.64e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg16359550	chr11:109292809	C11orf87	0.43	8.22	0.36	2.14e-15	Schizophrenia;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg02733842	chr7:1102375	C7orf50	0.68	10.26	0.43	2.17e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.904	rs4567782	chr17:28268800	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.22	0.55	2.4e-38	Coffee consumption (cups per day);
LGG	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.43	-0.33	5.45e-13	Hepatitis;
LGG	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg20246863	chr2:73402720	NA	-0.27	-6.87	-0.3	2.06e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.25	-0.36	1.63e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs8071789	1.000	rs8071789	chr17:38006333	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-8.64	-0.37	9.53e-17	Selective IgA deficiency;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00586367	chr8:74790437	UBE2W	0.44	7.65	0.33	1.2e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg02931644	chr1:25747376	RHCE	0.41	8.96	0.38	7.93e-18	Erythrocyte sedimentation rate;
LGG	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.24e-12	Iron status biomarkers;
LGG	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs28374715	0.578	rs72739630	chr15:41631064	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.33	-32.9	-0.84	3e-123	Ulcerative colitis;
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.44	8.2e-24	Neuroticism;
LGG	cis	rs4819052	0.851	rs914214	chr21:46697820	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.58	9.42	0.4	2.2e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs939658	0.805	rs35602654	chr15:79417527	T/A	cg17916960	chr15:79447300	NA	-0.67	-13.34	-0.53	1.35e-34	Refractive error;
LGG	cis	rs4642101	0.765	rs9870269	chr3:12853450	T/G	cg24848339	chr3:12840334	CAND2	0.4	8.9	0.38	1.23e-17	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.99	0.35	1.1e-14	Lung cancer;
LGG	cis	rs1707322	0.656	rs9429172	chr1:46092476	C/G	cg03146154	chr1:46216737	IPP	-0.56	-10.84	-0.45	1.43e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.19	0.32	2.7e-12	Lung cancer;
LGG	cis	rs9479482	1.000	rs9479403	chr6:150337746	C/T	cg16395133	chr6:150326394	RAET1K	-0.27	-6.75	-0.3	4.38e-11	Alopecia areata;
LGG	cis	rs644799	0.562	rs654345	chr11:95581865	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.62	10.52	0.44	2.45e-23	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg20978937	chr14:105399321	PLD4	-0.47	-10.4	-0.44	6.64e-23	Rheumatoid arthritis;
LGG	cis	rs61332075	0.531	rs11885695	chr2:239338632	G/A	cg18131467	chr2:239335373	ASB1	-0.72	-10.12	-0.43	7.19e-22	Lung function (FEV1/FVC);
LGG	cis	rs4731207	0.596	rs1871774	chr7:124674898	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.53	-0.33	2.64e-13	Cutaneous malignant melanoma;
LGG	cis	rs870825	0.616	rs56232457	chr4:185628153	T/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.45	0.72	4.4e-76	Blood protein levels;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs4566357	0.930	rs6436647	chr2:227922958	G/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-6.99	-0.31	9.37e-12	Coronary artery disease;
LGG	trans	rs2204008	0.905	rs8189449	chr12:38437377	C/A	cg06521331	chr12:34319734	NA	-0.48	-8.43	-0.36	4.48e-16	Bladder cancer;
LGG	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg24130564	chr14:104152367	KLC1	-0.41	-7.72	-0.34	7.02e-14	Body mass index;
LGG	cis	rs6977660	0.943	rs10227692	chr7:19850199	T/C	cg07541023	chr7:19748670	TWISTNB	0.47	7.41	0.33	6.1e-13	Thyroid stimulating hormone;
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.59e-24	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs28470208	chr7:65584700	A/G	cg11764359	chr7:65958608	NA	-0.72	-12.46	-0.5	6.44e-31	Aortic root size;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.67	-0.44	6.52e-24	Lung cancer;
LGG	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs3126085	1.000	rs72696963	chr1:152181189	T/C	cg26876637	chr1:152193138	HRNR	-0.48	-6.9	-0.31	1.71e-11	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09504352	chr12:58146286	CDK4	0.47	6.87	0.3	2.08e-11	Gut microbiome composition (summer);
LGG	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.41e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg15596359	chr8:11213517	TDH	-0.34	-7.04	-0.31	7.09e-12	Retinal vascular caliber;
LGG	trans	rs2235573	0.673	rs5756894	chr22:38450136	C/A	cg19894588	chr14:64061835	NA	0.46	7.72	0.34	7.28e-14	Glioblastoma;Glioma;
LGG	cis	rs9814567	1.000	rs6782563	chr3:134295959	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.4	0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg12193833	chr17:30244370	NA	-0.28	-7.0	-0.31	8.76e-12	Hip circumference adjusted for BMI;
LGG	cis	rs701145	0.537	rs437396	chr3:153923273	A/G	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs240764	0.853	rs10457808	chr6:100979506	A/T	cg21058520	chr6:100914733	NA	0.42	7.46	0.33	4.45e-13	Neuroticism;
LGG	cis	rs10207628	0.941	rs11887884	chr2:127848041	C/T	cg06223080	chr2:127868745	NA	-0.73	-12.7	-0.51	6.49e-32	Psychosis and Alzheimer's disease;
LGG	cis	rs1594829	0.500	rs4871973	chr8:26199883	A/G	cg11498726	chr8:26250323	BNIP3L	-0.43	-9.28	-0.4	6.77e-19	Height;
LGG	cis	rs12950390	0.853	rs56363619	chr17:45854621	T/C	cg03474202	chr17:45855739	NA	-0.27	-7.95	-0.35	1.45e-14	IgG glycosylation;
LGG	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg15736062	chr7:158136485	PTPRN2	0.36	7.14	0.31	3.74e-12	Calcium levels;
LGG	trans	rs2562456	0.833	rs7258099	chr19:21535743	G/A	cg00806126	chr19:22604979	ZNF98	-0.56	-7.56	-0.33	2.19e-13	Pain;
LGG	cis	rs897984	0.806	rs10782001	chr16:30942625	G/A	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg11878867	chr6:150167359	LRP11	-0.57	-11.77	-0.48	3.83e-28	Lung cancer;
LGG	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.591	rs34525648	chr6:25914853	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.78	-0.3	3.71e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9583531	0.689	rs4773244	chr13:111383937	A/T	cg24331049	chr13:111365604	ING1	-0.89	-15.46	-0.58	8.68e-44	Coronary artery disease;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.48	-0.33	3.7e-13	Skin colour saturation;
LGG	trans	rs7618501	0.521	rs34654589	chr3:49911449	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.44	0.33	5.08e-13	Intelligence (multi-trait analysis);
LGG	cis	rs11229555	1.000	rs1938598	chr11:58413910	T/C	cg15696309	chr11:58395628	NA	-0.98	-17.62	-0.63	1.5e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.5	-0.33	3.33e-13	Schizophrenia;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.54	0.61	1.23e-48	Obesity-related traits;
LGG	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs7928758	0.943	rs77897340	chr11:134265173	C/T	cg25213107	chr11:134282864	B3GAT1	1.19	14.23	0.55	2.21e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs12893668	0.644	rs12890820	chr14:104034849	T/C	cg23335576	chr14:104009727	NA	0.49	8.47	0.37	3.2e-16	Reticulocyte count;
LGG	cis	rs1788820	0.917	rs1788762	chr18:21132571	G/C	cg14672496	chr18:21087552	C18orf8	0.39	7.17	0.32	3.05e-12	Body mass index;
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs7107174	1.000	rs2512546	chr11:77957276	T/C	cg02023728	chr11:77925099	USP35	0.43	7.74	0.34	6.41e-14	Testicular germ cell tumor;
LGG	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg02733842	chr7:1102375	C7orf50	-0.39	-6.87	-0.3	2.11e-11	Bronchopulmonary dysplasia;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg05896524	chr21:47604654	C21orf56	0.55	9.35	0.4	3.61e-19	Testicular germ cell tumor;
LGG	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs17286411	0.750	rs8044335	chr16:71869520	A/C	cg03805757	chr16:71968109	PKD1L3	0.34	6.91	0.31	1.62e-11	Blood protein levels;
LGG	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg17644776	chr2:200775616	C2orf69	0.6	8.49	0.37	2.91e-16	Schizophrenia;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	7.77	0.34	5.25e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2832077	1.000	rs2832065	chr21:30135362	C/T	cg03476357	chr21:30257390	N6AMT1	-0.59	-9.02	-0.39	4.97e-18	Cognitive test performance;
LGG	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg01631408	chr1:248437212	OR2T33	-0.45	-7.84	-0.34	3.05e-14	Common traits (Other);
LGG	cis	rs4731207	0.672	rs62478914	chr7:124456654	G/A	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.64	-7.16	-0.32	3.28e-12	Schizophrenia;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.2	0.36	2.42e-15	Obesity-related traits;
LGG	cis	rs4740619	0.544	rs7853744	chr9:15830018	A/G	cg14451791	chr9:16040625	NA	0.34	8.4	0.36	5.5e-16	Body mass index;
LGG	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg11984989	chr7:158649758	WDR60	1.02	14.2	0.55	3.07e-38	Height;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.49e-12	Prudent dietary pattern;
LGG	cis	rs2072499	0.778	rs2247476	chr1:156190280	C/A	cg25208724	chr1:156163844	SLC25A44	1.07	18.28	0.65	1.39e-56	Testicular germ cell tumor;
LGG	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg26408565	chr15:76604113	ETFA	-0.39	-6.73	-0.3	4.96e-11	Blood metabolite levels;
LGG	cis	rs7267979	1.000	rs13038834	chr20:25441433	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.18	0.43	4.27e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2073499	1.000	rs4141060	chr3:50300117	T/C	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.72	9.08	0.39	3.1e-18	Schizophrenia;
LGG	cis	rs6988985	0.728	rs5017238	chr8:143954769	G/A	cg10324643	chr8:143916377	GML	0.38	7.74	0.34	6.45e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9398803	0.687	rs7738836	chr6:126936235	A/G	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.89e-20	Male-pattern baldness;
LGG	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg23221052	chr5:179740743	GFPT2	-0.62	-11.52	-0.47	3.45e-27	Height;
LGG	trans	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.53	0.37	2.15e-16	Retinal vascular caliber;
LGG	cis	rs8060686	0.641	rs3785109	chr16:68118311	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.73	-0.3	5.09e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs75804782	0.630	rs75651012	chr2:239234396	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.37e-11	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg02002194	chr4:3960332	NA	0.44	8.08	0.35	5.8e-15	Monocyte count;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.05	-0.35	6.88e-15	Neuroticism;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.68	-0.34	9.23e-14	Schizophrenia;
LGG	cis	rs3126085	0.935	rs6587666	chr1:152296863	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-8.1	-0.35	4.76e-15	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07590406	chr3:58292066	RPP14	0.44	6.83	0.3	2.68e-11	Gut microbiome composition (summer);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07831432	chr5:179125659	CANX	-0.46	-6.73	-0.3	5.01e-11	Systemic lupus erythematosus;
LGG	cis	rs3791406	1.000	rs3791406	chr2:240030484	A/G	cg14550559	chr2:240039617	HDAC4	0.44	7.97	0.35	1.27e-14	Skin aging (microtopography measurement);
LGG	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg21427119	chr20:30132790	HM13	-0.43	-7.42	-0.33	5.65e-13	Mean corpuscular volume;
LGG	cis	rs8044868	0.512	rs10048144	chr16:72052891	C/G	cg23815491	chr16:72088622	HP	0.38	8.04	0.35	7.54e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs3741151	1.000	rs7941454	chr11:73085336	C/T	cg17517138	chr11:73019481	ARHGEF17	0.89	9.14	0.39	1.91e-18	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9944715	0.954	rs6507676	chr18:43739730	T/C	cg26436583	chr18:43649176	PSTPIP2	0.41	7.77	0.34	5.18e-14	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs12477438	0.501	rs11123770	chr2:99825102	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.09	26.08	0.77	6.26e-93	Chronic sinus infection;
LGG	cis	rs28595532	0.920	rs115506655	chr4:119757667	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg18567174	chr15:68126065	LBXCOR1	0.38	7.54	0.33	2.52e-13	Motion sickness;
LGG	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg27398817	chr8:82754497	SNX16	0.69	10.6	0.44	1.23e-23	Diastolic blood pressure;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.934	rs4512319	chr7:91733829	G/A	cg17063962	chr7:91808500	NA	0.5	8.76	0.38	3.61e-17	Breast cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14251622	chr14:36003741	INSM2	0.58	6.69	0.3	6.38e-11	Intelligence (multi-trait analysis);
LGG	cis	rs756199	0.848	rs12128716	chr1:183991905	G/A	cg01436608	chr1:184005534	GLT25D2	0.57	8.73	0.38	4.77e-17	Height;
LGG	trans	rs7939886	0.920	rs74707325	chr11:56005562	T/A	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs7236492	0.688	rs77069608	chr18:77186319	C/T	cg15644404	chr18:77186268	NFATC1	-0.8	-9.78	-0.41	1.17e-20	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs9409565	0.660	rs9409510	chr9:97061134	C/T	cg05679027	chr9:99775184	HIATL2	0.43	7.12	0.31	4.2e-12	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs1015291	0.836	rs7297605	chr12:19989121	T/G	cg25401612	chr12:20009446	NA	-0.32	-6.72	-0.3	5.35e-11	Diastolic blood pressure;
LGG	trans	rs7395662	0.926	rs10742848	chr11:48468788	T/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.93	-0.35	1.69e-14	HDL cholesterol;
LGG	cis	rs11608355	0.545	rs6606721	chr12:109891999	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	trans	rs1814175	0.754	rs7103235	chr11:49699191	A/G	cg03929089	chr4:120376271	NA	-0.94	-18.24	-0.65	2.05e-56	Height;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg16405210	chr4:1374714	KIAA1530	-0.64	-11.73	-0.48	5.55e-28	Longevity;
LGG	cis	rs7208859	0.623	rs7503335	chr17:29073962	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4742903	0.935	rs7026246	chr9:106955686	A/C	cg14250997	chr9:106856677	SMC2	0.39	8.17	0.35	2.96e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg04149295	chr10:70884716	VPS26A	0.48	7.39	0.32	6.86e-13	Left atrial antero-posterior diameter;
LGG	cis	rs877282	0.945	rs11599043	chr10:777972	C/T	cg17470449	chr10:769945	NA	0.55	6.86	0.3	2.26e-11	Uric acid levels;
LGG	cis	rs3099143	1.000	rs2046415	chr15:77085253	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-10.24	-0.43	2.45e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	trans	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07923666	chr12:49932857	KCNH3	-0.51	-7.91	-0.35	1.94e-14	Resting heart rate;
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg21926883	chr2:100939477	LONRF2	-0.7	-16.62	-0.61	5.64e-49	Intelligence (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08951907	chr17:18218556	TOP3A;SMCR8	0.38	6.8	0.3	3.32e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs11053236	chr12:34507962	C/G	cg26384229	chr12:38710491	ALG10B	0.97	21.48	0.71	1.58e-71	Morning vs. evening chronotype;
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg19847130	chr8:10466454	RP1L1	0.31	7.09	0.31	4.95e-12	Neuroticism;
LGG	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.55	-0.41	7.52e-20	Diabetic retinopathy;
LGG	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg06026331	chr20:60912101	LAMA5	-0.72	-12.9	-0.51	9.48e-33	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.23	0.43	2.68e-22	Motion sickness;
LGG	trans	rs7819412	0.623	rs7833435	chr8:10801137	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.56	-0.44	1.66e-23	Triglycerides;
LGG	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs12143943	0.866	rs35666383	chr1:204492784	T/C	cg20240347	chr1:204465584	NA	-0.35	-7.54	-0.33	2.51e-13	Cognitive performance;
LGG	cis	rs8072100	0.544	rs9284377	chr17:45386412	C/T	cg08085267	chr17:45401833	C17orf57	-0.52	-9.89	-0.42	4.86e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs870825	0.616	rs10022818	chr4:185619282	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.07	0.72	2.83e-74	Blood protein levels;
LGG	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	20.83	0.7	1.79e-68	Homoarginine levels;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg05025164	chr4:1340916	KIAA1530	-0.57	-9.97	-0.42	2.49e-21	Obesity-related traits;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.45	-0.33	4.6e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs990171	1.000	rs3771170	chr2:102985980	T/A	cg05295703	chr2:102895712	NA	-0.57	-10.0	-0.42	1.98e-21	Lymphocyte counts;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.11	0.35	4.73e-15	Lung cancer;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	7.51e-24	Lung cancer;
LGG	cis	rs9929218	0.906	rs4783565	chr16:68750190	G/A	cg02972257	chr16:68554789	NA	0.44	6.74	0.3	4.79e-11	Colorectal cancer;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg13009111	chr11:71350975	NA	-0.33	-7.15	-0.32	3.4e-12	Neuroticism;
LGG	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg07928641	chr1:182991847	LAMC1	0.47	9.33	0.4	4.52e-19	Fuchs's corneal dystrophy;
LGG	cis	rs796364	0.806	rs34381014	chr2:200916403	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs10178094	0.669	rs7595982	chr2:161332385	T/G	cg03641300	chr2:160917029	PLA2R1	-0.51	-8.99	-0.39	6.45e-18	White blood cell count;
LGG	cis	rs75920871	0.841	rs61905709	chr11:116897834	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.05	-0.31	6.7e-12	Subjective well-being;
LGG	cis	rs2153535	0.580	rs4960423	chr6:8477210	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs62400317	0.762	rs62436376	chr6:44885817	C/T	cg18551225	chr6:44695536	NA	-0.69	-11.41	-0.47	9.5e-27	Total body bone mineral density;
LGG	cis	rs2235642	0.821	rs2281234	chr16:1602938	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.52	0.4	9.48e-20	Coronary artery disease;
LGG	cis	rs774359	0.711	rs10967965	chr9:27497988	A/T	cg22262168	chr9:27528999	MOBKL2B	0.5	7.38	0.32	7.26e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.72	-14.01	-0.55	1.95e-37	Total body bone mineral density;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.36	-0.58	2.39e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.57	-8.27	-0.36	1.44e-15	Subjective well-being;
LGG	cis	rs477895	0.713	rs11601024	chr11:63943074	A/G	cg22916017	chr11:64110731	CCDC88B	-0.45	-6.66	-0.3	7.62e-11	Mean platelet volume;
LGG	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.79	0.73	1.18e-77	Homoarginine levels;
LGG	cis	rs2067615	0.579	rs7297592	chr12:107223969	G/T	cg15890332	chr12:107067104	RFX4	0.41	12.02	0.49	3.78e-29	Heart rate;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg00149659	chr3:10157352	C3orf10	-0.81	-10.44	-0.44	4.76e-23	Alzheimer's disease;
LGG	cis	rs7666738	0.830	rs6833822	chr4:98951354	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs308971	0.656	rs307558	chr3:12095130	G/A	cg02700894	chr3:12045449	SYN2	0.48	6.83	0.3	2.61e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg23594656	chr7:65796392	TPST1	0.42	8.91	0.38	1.15e-17	Aortic root size;
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg11301795	chr4:187892539	NA	-0.94	-24.88	-0.76	2.16e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1190596	0.526	rs1190572	chr14:102634589	A/G	cg23904247	chr14:102554826	HSP90AA1	-0.24	-6.7	-0.3	6.19e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs2204008	0.528	rs11503820	chr12:38395379	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.44	-0.5	7.37e-31	Bladder cancer;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg01262667	chr19:19385393	TM6SF2	0.43	10.92	0.45	7.44e-25	Tonsillectomy;
LGG	cis	rs7765175	0.598	rs2801438	chr6:113631900	A/G	cg26552650	chr6:113682475	NA	0.33	7.14	0.31	3.66e-12	Coronary artery calcification;
LGG	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs763121	0.853	rs2267395	chr22:39113903	C/T	cg06022373	chr22:39101656	GTPBP1	0.91	18.78	0.66	6.84e-59	Menopause (age at onset);
LGG	cis	rs2290402	0.572	rs3775119	chr4:893712	C/T	cg00846425	chr4:957561	DGKQ	-0.47	-7.14	-0.31	3.65e-12	Type 2 diabetes;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.18e-12	Menopause (age at onset);
LGG	cis	rs9911578	1.000	rs7215808	chr17:56940742	G/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.636	rs2482499	chr10:104516246	G/A	cg04362960	chr10:104952993	NT5C2	-0.47	-7.77	-0.34	4.96e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4148087	1.000	rs4148094	chr21:43635381	C/T	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.52e-20	Eating disorder in bipolar disorder;
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.35	0.36	8.12e-16	Aortic root size;
LGG	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.54e-22	Motion sickness;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg11062466	chr8:58055876	NA	0.58	13.2	0.52	5.38e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg04000281	chr11:63949212	NA	-0.37	-7.33	-0.32	1.06e-12	Platelet count;
LGG	cis	rs6558530	0.932	rs7846610	chr8:1706675	C/T	cg19131313	chr8:1704013	NA	-0.31	-6.82	-0.3	2.88e-11	Systolic blood pressure;
LGG	cis	rs9914988	0.943	rs9894335	chr17:27138483	C/A	cg20469991	chr17:27169893	C17orf63	-0.58	-7.23	-0.32	1.99e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs11920090	0.932	rs10513686	chr3:170725542	C/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.37	0.36	7.1e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.13	0.72	1.45e-74	Bladder cancer;
LGG	cis	rs2131877	0.956	rs6775431	chr3:194859194	G/T	cg07250128	chr3:194833983	C3orf21	0.39	7.43	0.33	5.42e-13	Non-small cell lung cancer;
LGG	cis	rs2270450	0.614	rs9395210	chr6:46711962	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.67	-0.44	6.62e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs1816752	0.870	rs7998797	chr13:25014988	A/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs701145	0.585	rs1713813	chr3:153873643	T/G	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs6708331	1.000	rs13429940	chr2:70379868	T/C	cg01613454	chr2:70366299	NA	0.53	9.37	0.4	3.24e-19	Obesity-related traits;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20432589	chr17:77774124	NA	0.35	6.65	0.3	8.36e-11	Bipolar disorder;
LGG	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.08	-0.39	3.14e-18	Common traits (Other);
LGG	cis	rs4771450	0.962	rs7983773	chr13:103975944	G/A	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg25358565	chr5:93447407	FAM172A	1.39	16.85	0.62	5.05e-50	Diabetic retinopathy;
LGG	cis	rs72634258	0.838	rs10489450	chr1:8079301	C/T	cg00042356	chr1:8021962	PARK7	0.84	11.31	0.47	2.27e-26	Inflammatory bowel disease;
LGG	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06108461	chr20:60628389	TAF4	-0.63	-10.96	-0.45	5.32e-25	Body mass index;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg24475210	chr4:6642433	MRFAP1	-0.41	-6.73	-0.3	5.15e-11	Leprosy;
LGG	cis	rs6764363	0.504	rs13077665	chr3:277878	C/G	cg02057681	chr3:285234	CHL1	-0.42	-7.62	-0.33	1.48e-13	Sudden cardiac arrest;
LGG	cis	rs3820068	0.581	rs16851848	chr1:15927698	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.88	-0.38	1.54e-17	Mood instability;
LGG	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg03469862	chr11:68924853	NA	0.47	7.12	0.31	4.13e-12	Blond vs. brown hair color;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg22753661	chr15:79092743	ADAMTS7	0.4	6.84	0.3	2.44e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26306683	chr17:18585705	ZNF286B	-0.47	-9.28	-0.4	6.41e-19	Educational attainment (years of education);
LGG	cis	rs9326248	0.581	rs10892053	chr11:116857003	C/T	cg20608306	chr11:116969690	SIK3	0.42	13.39	0.53	8.46e-35	Blood protein levels;
LGG	cis	rs1355223	0.573	rs1901830	chr11:34725028	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.16	-0.32	3.15e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	-0.57	-11.32	-0.47	2.21e-26	Prudent dietary pattern;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg06916706	chr16:4465613	CORO7	-0.69	-11.85	-0.48	1.74e-28	Schizophrenia;
LGG	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg06637938	chr14:75390232	RPS6KL1	0.58	10.68	0.44	5.92e-24	Height;
LGG	trans	rs2727020	0.612	rs603672	chr11:49234566	T/A	cg03929089	chr4:120376271	NA	0.86	17.2	0.62	1.3e-51	Coronary artery disease;
LGG	cis	rs782590	0.967	rs1084522	chr2:55843294	A/G	cg18811423	chr2:55921094	PNPT1	0.88	20.48	0.69	7.96e-67	Metabolic syndrome;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg13628971	chr7:2884303	GNA12	0.51	10.16	0.43	4.82e-22	Height;
LGG	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg00530320	chr1:46809349	NSUN4	0.45	8.25	0.36	1.63e-15	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.36e-11	Lung cancer;
LGG	cis	rs559928	0.553	rs1320628	chr11:64175986	C/T	cg26318627	chr11:63887540	MACROD1	-0.4	-7.27	-0.32	1.57e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12618769	0.597	rs17033136	chr2:99149404	C/T	cg18455616	chr2:99124870	INPP4A	-0.28	-8.36	-0.36	7.58e-16	Bipolar disorder;
LGG	cis	rs1983891	0.706	rs913077	chr6:41569157	G/A	cg20194872	chr6:41519635	FOXP4	0.48	8.38	0.36	6.32e-16	Prostate cancer;
LGG	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.58	-10.79	-0.45	2.26e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg12756686	chr19:29218302	NA	-0.56	-7.45	-0.33	4.47e-13	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg24623649	chr8:11872141	NA	-0.3	-7.37	-0.32	7.76e-13	Monocyte count;
LGG	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg02151108	chr14:50098012	C14orf104	-0.43	-9.14	-0.39	2e-18	Carotid intima media thickness;
LGG	cis	rs6840360	0.593	rs1877185	chr4:152690348	C/T	cg22705602	chr4:152727874	NA	-0.38	-9.32	-0.4	4.9e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	1.000	rs11130218	chr3:49752372	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.46e-32	Intelligence (multi-trait analysis);
LGG	trans	rs970548	0.779	rs3891524	chr10:45971689	C/A	cg20477318	chr10:51623047	TIMM23	0.58	6.89	0.3	1.8e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs7769051	0.521	rs9321367	chr6:133084359	G/T	cg22852734	chr6:133119734	C6orf192	1.06	11.02	0.46	3.12e-25	Type 2 diabetes nephropathy;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg23782820	chr8:58130467	NA	0.57	8.43	0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25793693	chr2:166810089	TTC21B	-0.41	-6.96	-0.31	1.15e-11	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs1962073	0.667	rs11250004	chr8:10270958	T/G	cg16141378	chr3:129829833	LOC729375	0.34	7.36	0.32	8.51e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs701145	0.585	rs1713846	chr3:153787632	C/T	cg12800244	chr3:153838788	SGEF	0.81	8.82	0.38	2.32e-17	Coronary artery disease;
LGG	cis	rs12681288	0.754	rs4735975	chr8:1000470	T/C	cg08648136	chr8:956695	NA	0.36	7.6	0.33	1.67e-13	Schizophrenia;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg01879757	chr17:41196368	BRCA1	-0.44	-7.74	-0.34	6.41e-14	Menopause (age at onset);
LGG	cis	rs2273669	0.831	rs11153152	chr6:109343340	A/T	cg05315195	chr6:109294784	ARMC2	-0.48	-7.01	-0.31	8.27e-12	Prostate cancer;
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7072216	0.763	rs2274245	chr10:100175082	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.19	-0.32	2.6e-12	Metabolite levels;
LGG	cis	rs703842	1.000	rs10877019	chr12:58172929	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	-0.51	-7.97	-0.35	1.28e-14	Multiple sclerosis;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.37	-0.36	7.12e-16	Neuroticism;
LGG	cis	rs17102423	0.755	rs8009714	chr14:65573446	G/T	cg16583315	chr14:65563665	MAX	-0.36	-6.81	-0.3	2.95e-11	Obesity-related traits;
LGG	cis	rs1754541	1.000	rs499531	chr1:101630828	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-6.99	-0.31	9.77e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs9443645	0.869	rs10943609	chr6:79676328	A/T	cg18132916	chr6:79620363	NA	-0.31	-8.56	-0.37	1.72e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs34192365	chr6:163012382	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	10.47	0.44	3.7e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg08999081	chr20:33150536	PIGU	0.32	7.42	0.33	5.63e-13	Coronary artery disease;
LGG	cis	rs123509	0.687	rs73075297	chr3:42832466	A/G	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.78	-0.3	3.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.12e-14	IgG glycosylation;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg09699651	chr6:150184138	LRP11	0.51	9.01	0.39	5.51e-18	Lung cancer;
LGG	cis	rs4731207	0.596	rs10264210	chr7:124611594	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9788721	0.775	rs12914385	chr15:78898723	C/T	cg17108064	chr15:78857060	CHRNA5	-0.35	-7.19	-0.32	2.66e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.22	-0.36	2.03e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs807029	0.533	rs67692077	chr10:102740271	T/C	cg04662943	chr10:102668895	NA	0.48	7.0	0.31	9.01e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs55665837	0.922	rs12287212	chr11:14449861	C/A	cg19336497	chr11:14380999	RRAS2	-0.44	-8.75	-0.38	4.15e-17	Vitamin D levels;
LGG	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg01169559	chr10:831247	NA	-0.53	-9.43	-0.4	1.93e-19	Uric acid levels;
LGG	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.32	-0.36	9.62e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs789852	0.867	rs708632	chr3:194325325	C/T	cg18000598	chr3:194342907	TMEM44	-0.86	-8.09	-0.35	5.22e-15	QT interval;
LGG	trans	rs561341	1.000	rs537166	chr17:30326827	C/T	cg20587970	chr11:113659929	NA	-1.27	-23.19	-0.73	1.65e-79	Hip circumference adjusted for BMI;
LGG	cis	rs360798	0.532	rs360799	chr2:62953166	G/A	cg17519650	chr2:63277830	OTX1	-0.47	-7.51	-0.33	3.09e-13	Coronary artery disease;
LGG	cis	rs2635047	0.967	rs2571016	chr18:44639175	C/G	cg19077165	chr18:44547161	KATNAL2	0.53	9.56	0.41	7.25e-20	Educational attainment;
LGG	cis	rs457717	0.706	rs457205	chr5:75946543	G/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.76	0.3	4.11e-11	Hearing impairment;
LGG	cis	rs7789940	1.000	rs2072435	chr7:75959188	G/A	cg10167463	chr7:75959203	YWHAG	-0.47	-7.91	-0.35	1.89e-14	Multiple sclerosis;
LGG	cis	rs7707921	0.522	rs10070637	chr5:81490608	A/G	cg15871215	chr5:81402204	ATG10	0.31	6.93	0.31	1.4e-11	Breast cancer;
LGG	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg04842962	chr6:43655489	MRPS18A	1.12	24.45	0.75	2.26e-85	IgG glycosylation;
LGG	cis	rs877282	0.945	rs11253388	chr10:787852	A/G	cg17470449	chr10:769945	NA	0.61	7.58	0.33	1.87e-13	Uric acid levels;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg21948465	chr5:131705150	SLC22A5	0.65	7.32	0.32	1.13e-12	Rheumatoid arthritis;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg22558474	chr17:78388905	FLJ35220;LOC100294362	-0.41	-6.81	-0.3	3.08e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs1018697	0.966	rs6584526	chr10:104566241	G/C	cg04362960	chr10:104952993	NT5C2	0.5	9.07	0.39	3.3e-18	Colorectal adenoma (advanced);
LGG	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs4702718	0.651	rs2930047	chr5:10695526	A/G	cg14521931	chr5:10832172	NA	0.41	7.7	0.34	8.04e-14	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-8.98	-0.39	6.6e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs60843830	1.000	rs9213	chr2:218386	G/A	cg04617936	chr2:214353	NA	-0.38	-7.09	-0.31	5.08e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7617773	0.780	rs35190747	chr3:48343290	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs11690935	0.531	rs62183800	chr2:172867273	C/T	cg13550731	chr2:172543902	DYNC1I2	0.63	12.0	0.49	4.59e-29	Schizophrenia;
LGG	cis	rs875971	0.545	rs6970498	chr7:65740895	A/G	cg11764359	chr7:65958608	NA	0.61	9.15	0.39	1.88e-18	Aortic root size;
LGG	cis	rs4006360	0.575	rs6416909	chr17:39235389	A/G	cg16985667	chr17:39306289	KRTAP4-5	0.51	11.17	0.46	8.15e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs7928758	0.943	rs75184941	chr11:134277750	G/A	cg22777979	chr11:134283252	B3GAT1	0.86	11.07	0.46	1.92e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs11098499	0.863	rs3775854	chr4:120471971	C/T	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.63e-34	Corneal astigmatism;
LGG	cis	rs4727027	0.833	rs2107846	chr7:148832774	G/A	cg23583168	chr7:148888333	NA	-0.89	-17.1	-0.62	3.5e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4409675	0.576	rs6700473	chr1:28236682	C/T	cg23691781	chr1:28212827	C1orf38	0.45	10.15	0.43	5.53e-22	Corneal astigmatism;
LGG	cis	rs62064224	0.714	rs4794917	chr17:30636146	C/G	cg25809561	chr17:30822961	MYO1D	0.34	7.84	0.34	3.09e-14	Schizophrenia;
LGG	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg13852791	chr20:30311386	BCL2L1	0.67	8.89	0.38	1.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.87	0.3	2.04e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9790314	0.612	rs9875200	chr3:160733708	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-8.62	-0.37	1.07e-16	Morning vs. evening chronotype;
LGG	trans	rs11976180	1.000	rs1320894	chr7:143751802	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.91	-0.31	1.63e-11	Obesity-related traits;
LGG	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg20368463	chr18:77673604	PQLC1	-0.61	-11.93	-0.48	8.55e-29	Schizophrenia;
LGG	cis	rs10435719	0.580	rs13260712	chr8:11782570	A/C	cg00405596	chr8:11794950	NA	-0.6	-10.67	-0.44	6.56e-24	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2011503	1.000	rs2060275	chr19:19536208	G/C	cg11584989	chr19:19387371	SF4	0.75	12.34	0.5	1.95e-30	Bipolar disorder;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg26513180	chr16:89883248	FANCA	0.88	9.2	0.39	1.27e-18	Skin colour saturation;
LGG	trans	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg25042112	chr7:64838748	ZNF92	-0.49	-7.02	-0.31	7.77e-12	Pain;
LGG	cis	rs7296418	0.699	rs11057254	chr12:123794581	A/C	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.63e-13	Platelet count;
LGG	cis	rs7582720	1.000	rs72936332	chr2:204056678	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.42	0.4	2.21e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12210905	1.000	rs12192446	chr6:26995638	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg15242686	chr22:24348715	GSTTP1	0.37	6.81	0.3	3.09e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15557168	chr22:42548783	NA	0.35	7.78	0.34	4.83e-14	Cognitive function;
LGG	trans	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg26043149	chr18:55253948	FECH	0.94	16.04	0.6	2.18e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg05313129	chr8:58192883	C8orf71	-0.77	-10.64	-0.44	8.8e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7551222	0.752	rs10793765	chr1:204549375	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.3	-0.46	2.59e-26	Schizophrenia;
LGG	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.43	8.2	0.36	2.3e-15	Educational attainment;
LGG	cis	rs611744	0.523	rs13253581	chr8:109343105	A/G	cg18478394	chr8:109455254	TTC35	0.48	9.35	0.4	3.81e-19	Dupuytren's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03330867	chr16:1543988	TELO2	0.43	6.84	0.3	2.49e-11	Cognitive performance;
LGG	cis	rs4746818	1.000	rs4284308	chr10:70884861	C/T	cg11621586	chr10:70884670	VPS26A	1.16	22.64	0.72	5.83e-77	Left atrial antero-posterior diameter;
LGG	cis	rs13260300	0.516	rs2553712	chr8:75565092	A/G	cg22993706	chr8:75542856	NA	0.51	11.04	0.46	2.56e-25	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg09165964	chr15:75287851	SCAMP5	-1.08	-22.91	-0.73	3.16e-78	Blood trace element (Zn levels);
LGG	cis	rs1015291	0.708	rs1492125	chr12:20007550	T/C	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs9425766	0.640	rs9425756	chr1:173816586	C/T	cg06124660	chr1:173389066	NA	-0.4	-7.08	-0.31	5.25e-12	Life satisfaction;
LGG	cis	rs12971120	0.783	rs7229256	chr18:72169129	T/A	cg25817165	chr18:72167213	CNDP2	-0.68	-15.17	-0.58	1.74e-42	Refractive error;
LGG	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.02	0.35	8.58e-15	Colorectal cancer;
LGG	cis	rs17453880	0.929	rs62398709	chr5:152055235	A/T	cg12297329	chr5:152029980	NA	-0.88	-22.37	-0.72	1.05e-75	Subjective well-being;
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg19223190	chr17:80058835	NA	0.43	8.29	0.36	1.28e-15	Life satisfaction;
LGG	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg22732515	chr19:44031385	ETHE1	0.54	9.41	0.4	2.39e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs10463554	0.889	rs246908	chr5:102564177	G/A	cg23492399	chr5:102201601	PAM	-0.52	-7.62	-0.33	1.43e-13	Parkinson's disease;
LGG	cis	rs611744	0.563	rs7815105	chr8:109298794	C/T	cg21045802	chr8:109455806	TTC35	0.5	9.02	0.39	4.96e-18	Dupuytren's disease;
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.79	0.41	1.04e-20	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.05	0.39	4.12e-18	Alzheimer's disease;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg00864171	chr11:67383662	NA	0.54	9.3	0.4	5.66e-19	Mean corpuscular volume;
LGG	cis	rs8072100	0.934	rs9905583	chr17:45741016	C/T	cg08085267	chr17:45401833	C17orf57	-0.61	-12.64	-0.51	1.1e-31	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.38	-6.66	-0.3	7.55e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg06875740	chr19:51307921	C19orf48	-0.65	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg24623649	chr8:11872141	NA	0.3	7.32	0.32	1.12e-12	Monocyte count;
LGG	cis	rs2114646	0.731	rs60682408	chr2:170636148	T/C	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs6089584	0.927	rs2296083	chr20:60574216	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-16.5	-0.61	1.95e-48	Body mass index;
LGG	cis	rs2070488	0.695	rs6599201	chr3:38476614	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.76	0.57	1.07e-40	Electrocardiographic conduction measures;
LGG	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.64	-0.3	8.55e-11	Parkinson's disease;
LGG	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg15162869	chr22:32027605	PISD	-0.76	-7.84	-0.34	3.21e-14	Age-related hearing impairment;
LGG	cis	rs6558530	0.965	rs7460287	chr8:1708274	G/C	cg08198773	chr8:1697536	NA	0.35	6.74	0.3	4.65e-11	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.47	-0.37	3.28e-16	Restless legs syndrome;
LGG	cis	rs12360000	0.740	rs55679834	chr10:1910856	T/A	cg26364871	chr10:1889757	NA	-0.7	-13.46	-0.53	4.35e-35	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg22963979	chr7:1858916	MAD1L1	-0.35	-6.97	-0.31	1.08e-11	Schizophrenia;
LGG	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg07308232	chr7:1071921	C7orf50	-0.61	-11.72	-0.48	5.74e-28	Longevity;Endometriosis;
LGG	cis	rs13190036	0.901	rs4631	chr5:176733116	A/G	cg06733329	chr5:176740039	MXD3	-0.49	-6.78	-0.3	3.79e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs10540	1.000	rs12417570	chr11:462684	C/T	cg03576123	chr11:487126	PTDSS2	-1.34	-17.19	-0.62	1.37e-51	Body mass index;
LGG	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg14186256	chr22:23484241	RTDR1	0.97	24.26	0.75	1.69e-84	Bone mineral density;
LGG	cis	rs7769051	0.803	rs12193474	chr6:133186168	T/C	cg22852734	chr6:133119734	C6orf192	1.08	12.67	0.51	8.25e-32	Type 2 diabetes nephropathy;
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg08888203	chr3:10149979	C3orf24	0.52	8.78	0.38	3.16e-17	Alzheimer's disease;
LGG	cis	rs6977660	0.943	rs9638765	chr7:19840616	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	8.59	0.37	1.39e-16	Thyroid stimulating hormone;
LGG	cis	rs67311347	1.000	rs9849992	chr3:40402140	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.18	-0.68	1.93e-65	Renal cell carcinoma;
LGG	cis	rs9467711	0.651	rs1045537	chr6:26096748	G/C	cg21479132	chr6:26055353	NA	0.72	7.03	0.31	7.64e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11652947	chr17:80605508	WDR45L	0.43	7.12	0.31	4.1e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3020736	0.500	rs6002601	chr22:42489058	A/T	cg04733989	chr22:42467013	NAGA	-0.57	-10.27	-0.43	2.01e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg19554555	chr3:13937349	NA	0.74	14.04	0.55	1.49e-37	Ovarian reserve;
LGG	cis	rs4356203	0.840	rs7942094	chr11:17259409	A/T	cg15432903	chr11:17409602	KCNJ11	-0.38	-6.98	-0.31	1e-11	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs17608059	0.524	rs9897978	chr17:13900256	G/T	cg11395062	chr17:14139857	CDRT15	-0.49	-8.69	-0.37	6.41e-17	Temperament;
LGG	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg08250081	chr4:10125330	NA	0.45	8.28	0.36	1.3e-15	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs9341808	0.727	rs9361599	chr6:81025242	C/G	cg08355045	chr6:80787529	NA	0.41	8.12	0.35	4.29e-15	Sitting height ratio;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.52	8.79	0.38	2.96e-17	Bipolar disorder;
LGG	cis	rs5756391	0.568	rs11705450	chr22:37317529	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.62	0.41	4.4e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg22535103	chr8:58192502	C8orf71	-0.99	-10.98	-0.45	4.4e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs526231	0.511	rs17154942	chr5:102352718	C/T	cg23492399	chr5:102201601	PAM	0.57	8.39	0.36	6.02e-16	Primary biliary cholangitis;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg04267008	chr7:1944627	MAD1L1	0.66	11.18	0.46	7.75e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00109274	chr13:42623032	DGKH	-0.42	-6.99	-0.31	9.85e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7432375	0.578	rs17366234	chr3:136577085	C/T	cg12473912	chr3:136751656	NA	0.42	6.98	0.31	1.03e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3126085	1.000	rs12405278	chr1:152282267	G/A	cg26876637	chr1:152193138	HRNR	-0.49	-7.11	-0.31	4.29e-12	Atopic dermatitis;
LGG	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg23422044	chr7:1970798	MAD1L1	-0.49	-9.0	-0.39	5.91e-18	Neuroticism;
LGG	cis	rs9560113	0.580	rs9560115	chr13:112193619	G/A	cg10483660	chr13:112241077	NA	0.44	8.81	0.38	2.54e-17	Menarche (age at onset);
LGG	cis	rs55823223	0.564	rs1463485	chr17:73851791	C/G	cg08125733	chr17:73851984	WBP2	0.73	11.46	0.47	6.11e-27	Psoriasis;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.61	0.56	5.07e-40	Obesity-related traits;
LGG	cis	rs1003719	0.743	rs2835615	chr21:38497303	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.8	-15.76	-0.59	4.16e-45	Eye color traits;
LGG	cis	rs9916302	0.904	rs8079355	chr17:37473018	G/A	cg07936489	chr17:37558343	FBXL20	0.85	15.99	0.6	3.77e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs208346	0.612	rs208356	chr7:2775825	A/T	cg16569650	chr7:2773072	GNA12	-0.42	-7.31	-0.32	1.18e-12	Loneliness (linear analysis);
LGG	cis	rs4132509	0.744	rs59953491	chr1:243894953	C/T	cg21452805	chr1:244014465	NA	0.96	10.4	0.44	6.83e-23	RR interval (heart rate);
LGG	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg26597838	chr10:835615	NA	0.78	10.99	0.45	3.9e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs3087591	0.597	rs731759	chr17:29722809	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.55	-11.01	-0.46	3.28e-25	Hip circumference;
LGG	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg13902645	chr11:5959945	NA	-0.7	-12.6	-0.51	1.7e-31	DNA methylation (variation);
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.81	-0.41	9.42e-21	Lung cancer;
LGG	trans	rs11764590	0.671	rs17734969	chr7:2110517	T/C	cg11693508	chr17:37793320	STARD3	0.44	6.77	0.3	3.98e-11	Neuroticism;
LGG	trans	rs2204008	0.571	rs7970136	chr12:38531951	G/C	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Bladder cancer;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs3820928	0.874	rs1996998	chr2:227840294	C/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.52e-14	Pulmonary function;
LGG	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg18252515	chr7:66147081	NA	-1.35	-18.65	-0.65	2.68e-58	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.94	-14.34	-0.55	7.78e-39	Platelet count;
LGG	cis	rs6429082	0.689	rs10925965	chr1:235708443	C/A	cg26050004	chr1:235667680	B3GALNT2	-0.54	-8.48	-0.37	2.99e-16	Adiposity;
LGG	cis	rs11971779	0.680	rs111461944	chr7:139077903	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs12200782	1.000	rs4292511	chr6:26622290	G/T	cg11502198	chr6:26597334	ABT1	-0.92	-7.85	-0.34	2.85e-14	Small cell lung carcinoma;
LGG	cis	rs10937275	0.826	rs62294592	chr3:186635584	C/T	cg26193484	chr3:186648175	ST6GAL1	0.89	9.09	0.39	2.98e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9303401	0.659	rs34351230	chr17:56782555	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg27129171	chr3:47204927	SETD2	0.84	16.39	0.61	5.91e-48	Colorectal cancer;
LGG	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.87e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6460942	1.000	rs2053381	chr7:12400710	C/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.87	-0.3	2.04e-11	Coronary artery disease;
LGG	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.5	-0.33	3.24e-13	Systemic lupus erythematosus;
LGG	cis	rs7928758	0.887	rs7945585	chr11:134272451	G/A	cg25213107	chr11:134282864	B3GAT1	1.12	13.97	0.54	3.08e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.531	rs11205188	chr1:153053645	A/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.26	-0.4	7.74e-19	Inflammatory skin disease;
LGG	cis	rs7089973	0.604	rs7895830	chr10:116625776	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.47	0.33	3.97e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs4589502	1.000	rs8023363	chr15:67154654	G/A	cg09911534	chr15:67153556	NA	-0.57	-7.11	-0.31	4.46e-12	Lung cancer (smoking interaction);
LGG	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs4474465	1.000	rs10899513	chr11:78172353	T/C	cg02023728	chr11:77925099	USP35	0.39	6.77	0.3	4.02e-11	Alzheimer's disease (survival time);
LGG	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.33	-0.32	1.06e-12	Calcium levels;
LGG	trans	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg22358067	chr17:16797159	NA	-0.52	-7.33	-0.32	1.01e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9388451	0.868	rs10457467	chr6:126045148	T/A	cg10911889	chr6:126070802	HEY2	0.45	7.57	0.33	2.04e-13	Brugada syndrome;
LGG	cis	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg24375607	chr4:120327624	NA	0.51	8.68	0.37	7.02e-17	Corneal astigmatism;
LGG	cis	rs368123	1.000	rs402051	chr6:160730132	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs2067615	0.579	rs3910854	chr12:107165669	T/C	cg15890332	chr12:107067104	RFX4	0.4	11.89	0.48	1.18e-28	Heart rate;
LGG	cis	rs7923609	0.967	rs3956912	chr10:65205881	C/T	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2976388	0.507	rs1036385	chr8:143842901	T/C	cg07661805	chr8:143867942	LY6D	0.26	6.9	0.31	1.68e-11	Urinary tract infection frequency;
LGG	cis	rs2018055	0.618	rs7745840	chr6:117795881	T/A	cg14611402	chr6:117803162	DCBLD1	0.31	8.96	0.38	7.77e-18	Diastolic blood pressure;
LGG	cis	rs9302635	0.513	rs8061459	chr16:72156063	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-8.95	-0.38	8.38e-18	Blood protein levels;
LGG	cis	rs1957429	0.901	rs59876171	chr14:65384429	C/T	cg23373153	chr14:65346875	NA	-1.0	-12.91	-0.51	8.85e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg00579200	chr11:133705235	NA	0.59	11.6	0.47	1.66e-27	Childhood ear infection;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.08	0.6	1.45e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4851254	0.961	rs11680485	chr2:100749744	A/G	cg17356467	chr2:100759845	AFF3	0.4	6.97	0.31	1.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7617773	0.780	rs13084616	chr3:48339699	A/G	cg11946769	chr3:48343235	NME6	-0.71	-11.79	-0.48	2.98e-28	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg08621203	chr6:150244597	RAET1G	0.52	9.75	0.41	1.43e-20	Testicular germ cell tumor;
LGG	trans	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.64	-0.33	1.26e-13	Heart rate;
LGG	cis	rs1408799	0.772	rs1074789	chr9:12752340	A/G	cg05274944	chr9:12693694	TYRP1	0.35	8.1	0.35	4.95e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs35146811	0.622	rs6946204	chr7:99589125	T/C	cg22906224	chr7:99728672	NA	0.53	8.48	0.37	2.94e-16	Coronary artery disease;
LGG	cis	rs7762018	0.655	rs2184194	chr6:170148394	C/T	cg17545662	chr6:170176663	C6orf70	0.66	8.59	0.37	1.31e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	11.72	0.48	5.76e-28	Lung cancer in ever smokers;
LGG	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg24642844	chr7:1081250	C7orf50	-0.76	-9.55	-0.41	7.7e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1832871	0.672	rs62437361	chr6:158728759	C/T	cg07215822	chr6:158701037	NA	-0.44	-6.88	-0.3	1.96e-11	Height;
LGG	trans	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.1	-0.35	4.77e-15	Joint mobility (Beighton score);
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg00149659	chr3:10157352	C3orf10	0.76	9.75	0.41	1.48e-20	Alzheimer's disease;
LGG	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg09307838	chr4:120376055	NA	0.81	13.55	0.53	1.76e-35	Corneal astigmatism;
LGG	cis	rs9894429	0.608	rs7406219	chr17:79609410	G/T	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs9906944	0.742	rs4073893	chr17:47118523	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs2494938	0.846	rs11753423	chr6:40531722	T/A	cg14084896	chr6:40530702	LRFN2	-0.3	-7.06	-0.31	6.1e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2645694	0.532	rs2645706	chr4:77829606	A/C	cg10057126	chr4:77819792	ANKRD56	0.36	6.84	0.3	2.5e-11	Emphysema distribution in smoking;
LGG	cis	rs953387	0.910	rs7568884	chr2:136928320	A/G	cg07169764	chr2:136633963	MCM6	-0.53	-8.8	-0.38	2.83e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs1707322	0.721	rs10430123	chr1:46221440	T/C	cg03146154	chr1:46216737	IPP	0.57	11.07	0.46	2.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs208520	1.000	rs72884025	chr6:66994185	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.23	0.55	2.31e-38	Exhaled nitric oxide output;
LGG	cis	rs10540	1.000	rs78520676	chr11:517173	G/A	cg19913688	chr11:428466	ANO9	-0.68	-8.31	-0.36	1.1e-15	Body mass index;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.37	-0.56	5.42e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	1.99e-17	Bipolar disorder;
LGG	cis	rs6840360	1.000	rs9998462	chr4:152646548	T/A	cg22705602	chr4:152727874	NA	-0.27	-6.9	-0.31	1.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9355610	0.727	rs2247315	chr6:167370211	A/C	cg18261144	chr6:167370276	RNASET2	-0.38	-7.79	-0.34	4.53e-14	Graves' disease;
LGG	trans	rs7615952	0.641	rs12495947	chr3:125771698	C/T	cg07211511	chr3:129823064	LOC729375	-0.62	-8.66	-0.37	8.2e-17	Blood pressure (smoking interaction);
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.85	0.38	1.87e-17	Schizophrenia;
LGG	cis	rs17572109	0.666	rs4674297	chr2:219229147	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.48	6.9	0.31	1.69e-11	Platelet count;Platelet distribution width;Mean platelet volume;
LGG	cis	rs1790761	0.667	rs11227837	chr11:67336424	A/T	cg24690094	chr11:67383802	NA	0.51	9.08	0.39	3.05e-18	Mean corpuscular volume;
LGG	cis	rs9486719	0.843	rs2499789	chr6:96844510	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.23e-56	White matter hyperintensity burden;
LGG	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg09307838	chr4:120376055	NA	-0.73	-12.53	-0.5	3.33e-31	Corneal astigmatism;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg20300129	chr6:35058181	ANKS1A	0.4	7.76	0.34	5.52e-14	Body fat percentage;
LGG	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs2019137	0.589	rs7560701	chr2:114026882	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.45	7.59	0.33	1.78e-13	Lymphocyte counts;
LGG	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg17376030	chr22:41985996	PMM1	0.47	7.63	0.33	1.34e-13	Vitiligo;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02475777	chr4:1388615	CRIPAK	0.4	7.17	0.32	2.89e-12	Longevity;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	cis	rs2018055	0.956	rs13210963	chr6:117823289	A/G	cg14611402	chr6:117803162	DCBLD1	-0.28	-7.74	-0.34	6.28e-14	Diastolic blood pressure;
LGG	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg26031613	chr14:104095156	KLC1	-0.67	-11.12	-0.46	1.32e-25	Reticulocyte count;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg15971980	chr6:150254442	NA	0.44	8.32	0.36	9.59e-16	Lung cancer;
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg26513180	chr16:89883248	FANCA	1.02	9.5	0.4	1.16e-19	Skin colour saturation;
LGG	cis	rs9341835	0.772	rs9294196	chr6:64135193	A/G	cg00787780	chr6:64151745	NA	-0.42	-7.67	-0.34	1.02e-13	Schizophrenia;
LGG	cis	rs6456156	0.565	rs2181058	chr6:167465330	A/T	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg00933542	chr6:150070202	PCMT1	0.42	7.48	0.33	3.74e-13	Lung cancer;
LGG	cis	rs13102973	0.965	rs7656209	chr4:135875550	G/A	cg14419869	chr4:135874104	NA	0.58	10.99	0.45	4.16e-25	Subjective well-being;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg24607181	chr17:41446203	NA	-0.3	-7.07	-0.31	5.65e-12	Menopause (age at onset);
LGG	cis	rs12908161	1.000	rs12910012	chr15:85298662	T/C	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg15764593	chr10:829463	NA	-0.68	-10.23	-0.43	2.82e-22	Uric acid levels;
LGG	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.12	0.43	7.03e-22	Height;
LGG	cis	rs9487051	0.676	rs7753697	chr6:109593292	A/G	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.02e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3916	0.910	rs7306541	chr12:121130046	A/G	cg21892295	chr12:121157589	UNC119B	-0.41	-7.14	-0.31	3.75e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs9357271	0.955	rs6903611	chr6:38374709	T/C	cg07362130	chr6:38359646	BTBD9	-0.47	-10.81	-0.45	1.97e-24	Restless legs syndrome;
LGG	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg13147721	chr7:65941812	NA	-0.78	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs4660214	0.724	rs7554301	chr1:39643464	C/T	cg18385671	chr1:39797026	MACF1	-0.46	-9.61	-0.41	4.6e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.48	-0.47	5.04e-27	Personality dimensions;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1.05e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs208520	0.690	rs10455594	chr6:66737894	C/G	cg07460842	chr6:66804631	NA	0.96	17.95	0.64	4.53e-55	Exhaled nitric oxide output;
LGG	cis	rs2404602	0.569	rs2469249	chr15:76772062	C/T	cg15268244	chr15:77196840	NA	0.42	8.48	0.37	2.94e-16	Blood metabolite levels;
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	20.5	0.69	6.19e-67	Alzheimer's disease;
LGG	cis	rs2153535	0.580	rs1832101	chr6:8460177	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg15556689	chr8:8085844	FLJ10661	0.45	7.79	0.34	4.56e-14	Retinal vascular caliber;
LGG	cis	rs9398803	0.723	rs853983	chr6:127046153	G/A	cg19875578	chr6:126661172	C6orf173	-0.51	-9.31	-0.4	5.12e-19	Male-pattern baldness;
LGG	cis	rs4700695	0.764	rs251278	chr5:65381826	G/A	cg21114390	chr5:65439923	SFRS12	-0.57	-7.32	-0.32	1.13e-12	Facial morphology (factor 19);
LGG	cis	rs7246657	0.722	rs2909100	chr19:38212680	C/T	cg23950597	chr19:37808831	NA	0.58	8.29	0.36	1.2e-15	Coronary artery calcification;
LGG	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg05775895	chr3:12838266	CAND2	0.71	12.57	0.5	2.14e-31	P wave duration;
LGG	cis	rs9992101	0.645	rs56367238	chr4:77342159	G/C	cg17010112	chr4:77227123	STBD1	-0.44	-8.93	-0.38	1e-17	Creatinine levels;
LGG	cis	rs3820928	0.934	rs1366756	chr2:227772038	G/A	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.22	-0.32	2.2e-12	Pulmonary function;
LGG	cis	rs9487094	0.670	rs11752791	chr6:109885646	G/T	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs2224391	0.656	rs68007503	chr6:5292616	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.5	-6.99	-0.31	9.44e-12	Height;
LGG	trans	rs853679	0.760	rs9468317	chr6:28198456	A/G	cg01620082	chr3:125678407	NA	-0.49	-6.81	-0.3	3.05e-11	Depression;
LGG	cis	rs1018836	0.892	rs2187981	chr8:91549629	T/C	cg16814680	chr8:91681699	NA	-0.73	-13.14	-0.52	9.63e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs736801	0.808	rs2706396	chr5:131796809	A/C	cg07395648	chr5:131743802	NA	0.51	10.62	0.44	9.72e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg02018176	chr4:1364513	KIAA1530	0.65	16.04	0.6	2.25e-46	Longevity;
LGG	cis	rs694739	0.628	rs475032	chr11:64140737	G/C	cg22916017	chr11:64110731	CCDC88B	-0.46	-9.34	-0.4	3.94e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.71	-0.75	1.3e-86	Height;
LGG	cis	rs10744422	0.858	rs7980541	chr12:123379477	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-9.31	-0.4	5.03e-19	Schizophrenia;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg23306229	chr2:178417860	TTC30B	0.71	8.45	0.37	3.87e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg19847130	chr8:10466454	RP1L1	0.31	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.72	0.34	7.39e-14	Rheumatoid arthritis;
LGG	cis	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg27411982	chr8:10470053	RP1L1	0.45	7.36	0.32	8.74e-13	Neuroticism;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg07308232	chr7:1071921	C7orf50	-0.6	-10.91	-0.45	7.83e-25	Longevity;Endometriosis;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.16	-0.32	3.25e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2274273	0.688	rs6573001	chr14:55556502	A/G	cg04306507	chr14:55594613	LGALS3	0.49	12.51	0.5	3.75e-31	Protein biomarker;
LGG	cis	rs9920506	0.536	rs1316971	chr15:78930510	A/G	cg09448879	chr15:79043637	NA	-0.35	-7.07	-0.31	5.88e-12	Post bronchodilator FEV1;
LGG	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.21	0.39	1.16e-18	Neuroticism;
LGG	trans	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.24	-0.32	1.89e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.862	rs2174062	chr3:72826901	T/C	cg25664220	chr3:72788482	NA	-0.33	-9.19	-0.39	1.33e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg07959490	chr17:80112427	CCDC57	0.39	7.41	0.33	6.21e-13	Life satisfaction;
LGG	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg18252515	chr7:66147081	NA	-1.35	-18.85	-0.66	2.95e-59	Diabetic kidney disease;
LGG	cis	rs798554	0.567	rs1182191	chr7:2869364	A/T	cg05793240	chr7:2802953	GNA12	0.28	6.72	0.3	5.37e-11	Height;
LGG	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	0.36	6.86	0.3	2.17e-11	Alzheimer's disease (late onset);
LGG	trans	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg26043149	chr18:55253948	FECH	0.42	7.14	0.31	3.62e-12	Bone mineral density;
LGG	cis	rs2991971	0.967	rs60608374	chr1:46008913	G/A	cg24296786	chr1:45957014	TESK2	0.39	6.97	0.31	1.1e-11	High light scatter reticulocyte count;
LGG	cis	rs36051895	0.632	rs10116823	chr9:5171944	T/A	cg02405213	chr9:5042618	JAK2	-0.78	-15.43	-0.58	1.21e-43	Pediatric autoimmune diseases;
LGG	cis	rs7107174	0.901	rs10899500	chr11:78125246	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.32	-0.32	1.1e-12	Testicular germ cell tumor;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.95	-0.38	8.6e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs8114671	0.967	rs6142321	chr20:33788474	G/A	cg07148914	chr20:33460835	GGT7	-0.42	-6.75	-0.3	4.47e-11	Height;
LGG	cis	rs12200782	0.649	rs3757146	chr6:26381125	A/T	cg27193005	chr6:26382695	BTN2A2	0.52	7.38	0.32	7.65e-13	Small cell lung carcinoma;
LGG	trans	rs916888	0.821	rs415430	chr17:44859144	C/T	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01570182	chr17:44337453	NA	0.51	9.32	0.4	4.74e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9906944	0.933	rs12945020	chr17:47082775	G/A	cg09029085	chr17:47094198	IGF2BP1	0.32	8.61	0.37	1.17e-16	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2075371	0.932	rs11766132	chr7:133993062	T/C	cg20476274	chr7:133979776	SLC35B4	0.75	14.27	0.55	1.52e-38	Mean platelet volume;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.31	-0.36	1.11e-15	Obesity-related traits;
LGG	cis	rs3540	0.553	rs8042861	chr15:90977333	G/T	cg22089800	chr15:90895588	ZNF774	0.67	12.01	0.49	3.94e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6840360	0.532	rs4235221	chr4:152511193	C/T	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg25986240	chr4:9926439	SLC2A9	-0.55	-10.58	-0.44	1.46e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10751667	0.666	rs7105477	chr11:964271	C/G	cg22143635	chr11:980567	AP2A2	0.44	8.09	0.35	5.41e-15	Alzheimer's disease (late onset);
LGG	cis	rs7975161	0.535	rs6539138	chr12:104735928	G/A	cg25273343	chr12:104657179	TXNRD1	-0.74	-9.62	-0.41	4.13e-20	Toenail selenium levels;
LGG	cis	rs4965869	0.866	rs28521402	chr15:101976951	A/C	cg12371147	chr15:101978424	PCSK6	-0.43	-7.78	-0.34	4.72e-14	Platelet-derived growth factor BB levels;
LGG	cis	rs4959677	0.935	rs7758842	chr6:2496664	A/G	cg23817096	chr6:1620687	NA	0.32	7.52	0.33	2.82e-13	Orthostatic hypotension;
LGG	cis	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg14541582	chr5:601475	NA	-0.71	-11.21	-0.46	5.75e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs11105298	0.891	rs10858852	chr12:89833338	T/C	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.85e-20	Bone mineral density;
LGG	cis	rs738322	0.577	rs6001034	chr22:38558459	A/G	cg25457927	chr22:38595422	NA	-0.41	-10.15	-0.43	5.67e-22	Cutaneous nevi;
LGG	cis	rs7100689	0.646	rs7089003	chr10:82124155	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs10911232	0.507	rs10732271	chr1:183025898	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs9467711	0.517	rs16901784	chr6:26555433	C/A	cg12826209	chr6:26865740	GUSBL1	0.8	9.03	0.39	4.49e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11628318	0.564	rs8013957	chr14:103140254	C/T	cg12046867	chr14:103022105	NA	0.46	8.98	0.38	7.11e-18	Platelet count;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg08470875	chr2:26401718	FAM59B	0.37	7.01	0.31	8.43e-12	Gut microbiome composition (summer);
LGG	cis	rs17504614	0.634	rs72837097	chr2:51051714	T/C	cg23851515	chr2:51057218	NRXN1	0.48	7.86	0.34	2.77e-14	Educational attainment (years of education);
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg06916706	chr16:4465613	CORO7	-1.07	-19.55	-0.67	1.68e-62	Schizophrenia;
LGG	cis	rs11758351	0.660	rs113205297	chr6:26210808	A/C	cg23601095	chr6:26197514	HIST1H3D	0.72	9.16	0.39	1.7e-18	Gout;Renal underexcretion gout;
LGG	cis	rs6693567	0.545	rs6699093	chr1:150440451	A/G	cg15654264	chr1:150340011	RPRD2	-0.32	-6.68	-0.3	6.88e-11	Migraine;
LGG	cis	rs427394	0.802	rs274718	chr5:6720988	G/T	cg10857441	chr5:6722123	POLS	-0.27	-6.65	-0.3	8.46e-11	Menopause (age at onset);
LGG	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg26396452	chr14:65542826	MAX	0.49	10.14	0.43	5.8e-22	Obesity-related traits;
LGG	cis	rs9902453	0.791	rs57719820	chr17:28335088	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs11758351	0.866	rs2069018	chr6:26205718	T/C	cg06951627	chr6:26196580	NA	0.51	7.82	0.34	3.53e-14	Gout;Renal underexcretion gout;
LGG	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg15369054	chr17:80825471	TBCD	0.58	10.61	0.44	1.12e-23	Breast cancer;
LGG	cis	rs6076065	0.683	rs2424556	chr20:23419556	C/T	cg12633918	chr20:23549525	CST9L	-0.36	-6.74	-0.3	4.68e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9460578	0.673	rs12194583	chr6:20878885	C/T	cg13405222	chr6:20811065	CDKAL1	0.67	11.87	0.48	1.5e-28	Breast cancer;
LGG	cis	rs919433	0.680	rs788017	chr2:198265173	T/A	cg00792783	chr2:198669748	PLCL1	0.51	7.98	0.35	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg05025164	chr4:1340916	KIAA1530	0.88	16.68	0.61	3.05e-49	Longevity;
LGG	cis	rs11122272	0.735	rs2749723	chr1:231493302	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.3	-0.32	1.28e-12	Hemoglobin concentration;
LGG	cis	rs7166081	1.000	rs4776913	chr15:67580356	A/C	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.96	0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs62238980	0.522	rs62238977	chr22:32573224	G/C	cg02631450	chr22:32366979	NA	0.81	8.07	0.35	5.93e-15	Childhood ear infection;
LGG	cis	rs240764	0.619	rs9390502	chr6:101057478	G/A	cg09795085	chr6:101329169	ASCC3	0.39	6.65	0.3	8.31e-11	Neuroticism;
LGG	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13445891	chr20:4155144	SMOX	0.43	7.78	0.34	4.75e-14	Menarche (age at onset);
LGG	trans	rs1962073	0.507	rs7460226	chr8:10197718	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	7.48	0.33	3.83e-13	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg07661805	chr8:143867942	LY6D	0.3	8.0	0.35	1.03e-14	Urinary tract infection frequency;
LGG	cis	rs4819852	0.752	rs4819527	chr22:19978022	C/T	cg07821417	chr22:19972146	ARVCF	0.52	11.06	0.46	2.14e-25	Pulse pressure;
LGG	cis	rs367615	0.679	rs11241021	chr5:108812090	T/G	cg17395555	chr5:108820864	NA	0.88	15.95	0.6	5.64e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs919433	0.680	rs3792160	chr2:198403519	G/A	cg00792783	chr2:198669748	PLCL1	0.49	7.79	0.34	4.48e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs17030434	0.815	rs78638854	chr4:154648804	C/T	cg14289246	chr4:154710475	SFRP2	-0.66	-10.02	-0.42	1.64e-21	Electrocardiographic conduction measures;
LGG	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.17	0.75	4.23e-84	Chronic sinus infection;
LGG	cis	rs3091242	0.900	rs669063	chr1:25721154	A/G	cg27572855	chr1:25598939	RHD	0.54	12.5	0.5	4.31e-31	Erythrocyte sedimentation rate;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.99	-0.35	1.1e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4664308	0.618	rs3792192	chr2:160886875	G/A	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.71	-0.48	6.67e-28	Idiopathic membranous nephropathy;
LGG	cis	rs2346177	0.846	rs6714738	chr2:46646164	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-10.38	-0.43	7.95e-23	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24044651	chr1:24105262	C1orf128	0.45	6.89	0.3	1.84e-11	Gut microbiome composition (summer);
LGG	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.76	0.34	5.39e-14	Red cell distribution width;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.67	-0.37	7.1e-17	Longevity;
LGG	cis	rs3858526	0.920	rs11511938	chr11:5928793	A/G	cg25319279	chr11:5960081	NA	-0.55	-8.57	-0.37	1.6e-16	DNA methylation (variation);
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.86	-0.42	6.16e-21	Lung cancer;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg16359550	chr11:109292809	C11orf87	0.42	8.14	0.35	3.56e-15	Schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09155575	chr17:38084037	ORMDL3	0.39	6.72	0.3	5.46e-11	Bipolar disorder;
LGG	cis	rs17767392	0.881	rs1029570	chr14:72043200	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.39	-0.4	2.68e-19	Mitral valve prolapse;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg27194467	chr19:11039319	YIPF2;C19orf52	-0.43	-6.88	-0.3	1.95e-11	Pancreatic cancer;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg02711726	chr17:80685570	FN3KRP	0.46	8.68	0.37	6.85e-17	Glycated hemoglobin levels;
LGG	cis	rs8141529	0.504	rs6005915	chr22:29233262	A/G	cg02153584	chr22:29168773	CCDC117	0.63	9.24	0.39	8.73e-19	Lymphocyte counts;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg13699009	chr12:122356056	WDR66	0.55	15.21	0.58	1.15e-42	Mean corpuscular volume;
LGG	cis	rs7712401	0.580	rs10066632	chr5:122364683	C/A	cg19412675	chr5:122181750	SNX24	0.49	7.83	0.34	3.32e-14	Mean platelet volume;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.97e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4731207	0.596	rs7789392	chr7:124611076	T/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.73e-19	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05835456	chr15:43785425	TP53BP1	0.45	7.14	0.31	3.71e-12	Cognitive performance;
LGG	cis	rs7551222	0.752	rs11240754	chr1:204477977	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.36	-0.47	1.55e-26	Schizophrenia;
LGG	cis	rs4731207	0.596	rs10276834	chr7:124607549	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg06026331	chr20:60912101	LAMA5	0.75	14.0	0.55	2.29e-37	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9547996	0.876	rs9547941	chr13:38130243	C/T	cg13634560	chr13:38173852	POSTN	-0.35	-7.03	-0.31	7.4e-12	Diastolic blood pressure;
LGG	cis	rs7851660	0.967	rs3758251	chr9:100613700	G/C	cg13688889	chr9:100608707	NA	-0.69	-14.71	-0.56	1.9e-40	Strep throat;
LGG	cis	rs2303319	1.000	rs62197070	chr2:162149167	T/C	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.97	-0.52	5.13e-33	Vitiligo;
LGG	cis	rs3761847	0.508	rs4837813	chr9:123934463	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.46	8.06	0.35	6.73e-15	Rheumatoid arthritis;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	11.97	0.49	5.76e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs986417	1.000	rs6573320	chr14:61092022	A/G	cg27398547	chr14:60952738	C14orf39	0.73	7.15	0.32	3.38e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs870825	1.000	rs870823	chr4:185588195	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	18.5	0.65	1.27e-57	Blood protein levels;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06873352	chr17:61820015	STRADA	-0.74	-13.78	-0.54	1.92e-36	Prudent dietary pattern;
LGG	cis	rs17039065	0.920	rs17039099	chr4:109434574	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.62	0.33	1.48e-13	Gut microbiome composition (summer);
LGG	trans	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.43	-0.44	4.89e-23	Total cholesterol levels;
LGG	cis	rs8051431	0.544	rs2878492	chr16:71981113	A/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.71	0.45	4.59e-24	LDL cholesterol levels;
LGG	cis	rs10206020	0.885	rs6720923	chr2:1574197	T/C	cg12573674	chr2:1569213	NA	-0.61	-9.83	-0.42	7.74e-21	IgG glycosylation;
LGG	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.09	-0.35	5.4e-15	Neuroticism;
LGG	cis	rs921968	0.541	rs3821031	chr2:219295249	C/T	cg01130898	chr2:219473002	PLCD4	0.43	7.39	0.32	7.02e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs28595532	1.000	rs41455648	chr4:119718030	A/G	cg11846333	chr4:119757529	SEC24D	0.78	7.46	0.33	4.29e-13	Cannabis dependence symptom count;
LGG	cis	rs477692	0.789	rs507900	chr10:131398144	A/G	cg05714579	chr10:131428358	MGMT	-0.51	-10.33	-0.43	1.22e-22	Response to temozolomide;
LGG	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	10.36	0.43	9.49e-23	Mean platelet volume;
LGG	cis	rs1395	0.626	rs72817537	chr2:27497549	G/A	cg22903471	chr2:27725779	GCKR	-0.41	-6.76	-0.3	4.24e-11	Blood metabolite levels;
LGG	cis	rs2737618	0.674	rs2737684	chr1:200092951	C/T	cg21825944	chr1:200113062	NR5A2	-0.6	-11.6	-0.47	1.81e-27	Uric acid levels;
LGG	cis	rs7932354	0.502	rs57323109	chr11:47193367	T/G	cg03339077	chr11:47165057	C11orf49	0.55	10.48	0.44	3.47e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	8.04	0.35	7.56e-15	Coronary artery disease;
LGG	cis	rs1505368	0.817	rs6435701	chr2:213283512	A/G	cg16329650	chr2:213403929	ERBB4	0.46	7.95	0.35	1.43e-14	Symmetrical dimethylarginine levels;
LGG	cis	rs9341808	0.718	rs6910201	chr6:80904938	G/C	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23280290	chr7:35734964	HERPUD2	0.41	6.72	0.3	5.38e-11	Cognitive performance;
LGG	cis	rs2120243	0.565	rs1500919	chr3:157079048	C/T	cg24825693	chr3:157122686	VEPH1	-0.51	-11.2	-0.46	6.51e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs11039798	0.588	rs61932767	chr11:48704806	C/T	cg03929089	chr4:120376271	NA	0.71	9.88	0.42	5.02e-21	Axial length;
LGG	trans	rs7507204	0.906	rs1860323	chr19:3424799	G/C	cg08382705	chr11:45687319	CHST1	-0.51	-7.14	-0.31	3.69e-12	Height;
LGG	cis	rs7737355	0.947	rs739952	chr5:130796568	A/T	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.9e-19	Life satisfaction;
LGG	cis	rs4253772	0.513	rs9306512	chr22:46716603	T/C	cg24881330	chr22:46731750	TRMU	0.82	9.96	0.42	2.71e-21	LDL cholesterol;Cholesterol, total;
LGG	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.33	0.53	1.55e-34	Colorectal cancer;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.5	8.75	0.38	4.12e-17	Longevity;
LGG	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.86	0.64	1.2e-54	Cognitive function;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.05	0.55	1.3e-37	Obesity-related traits;
LGG	cis	rs2749592	0.550	rs7081464	chr10:37883937	C/T	cg00409905	chr10:38381863	ZNF37A	0.51	10.17	0.43	4.51e-22	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.2	-0.32	2.38e-12	Retinal vascular caliber;
LGG	trans	rs11875185	0.510	rs17064156	chr18:55619878	A/G	cg15513957	chr14:69354734	ACTN1	0.87	8.93	0.38	9.92e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6912958	0.678	rs9450744	chr6:88280529	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	cis	rs7219021	0.705	rs9904288	chr17:47031973	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.99	-0.31	9.69e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs2729354	0.768	rs1001956	chr11:57266949	C/G	cg24343310	chr11:57249947	NA	0.43	8.3	0.36	1.17e-15	Blood protein levels;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.42	6.93	0.31	1.39e-11	Electroencephalogram traits;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg06112835	chr11:68658793	MRPL21	0.64	10.38	0.43	7.51e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.48	-9.3	-0.4	5.38e-19	Height;
LGG	cis	rs144345632	1	rs144345632	chr6:96886894	T/TA	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.51	-0.44	2.67e-23	Facial morphology (factor 17, height of vermillion upper lip);
LGG	cis	rs4771450	0.925	rs7333033	chr13:103978262	G/T	cg02987523	chr13:103978230	NA	0.33	6.96	0.31	1.14e-11	Uric acid levels;
LGG	cis	rs78487399	0.808	rs7599799	chr2:43685493	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.85	-0.3	2.31e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs367615	0.506	rs2914684	chr5:108775110	C/T	cg17395555	chr5:108820864	NA	-0.78	-14.19	-0.55	3.45e-38	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6554196	0.525	rs2192158	chr4:55505360	C/T	cg18836493	chr4:55524333	KIT	0.39	7.28	0.32	1.46e-12	Monocyte count;
LGG	trans	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.31e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg24530489	chr15:56299380	NA	-0.84	-7.73	-0.34	6.56e-14	Delta-5 desaturase activity;
LGG	cis	rs912057	1.000	rs1294414	chr6:6740366	A/G	cg06612196	chr6:6737390	NA	0.46	9.14	0.39	2e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs1163251	0.902	rs839605	chr1:120217524	C/A	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs919433	0.713	rs6719483	chr2:198472886	A/G	cg00792783	chr2:198669748	PLCL1	0.51	8.06	0.35	6.44e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.1	-0.31	4.77e-12	Inflammatory bowel disease;
LGG	cis	rs1862618	0.853	rs33325	chr5:56142547	G/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.89	-0.34	2.2e-14	Initial pursuit acceleration;
LGG	cis	rs61931739	0.533	rs7970871	chr12:33917301	G/A	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2070677	0.935	rs7907312	chr10:135417364	A/G	cg20169779	chr10:135381914	SYCE1	-0.99	-12.87	-0.51	1.34e-32	Gout;
LGG	cis	rs12612619	0.579	rs41448746	chr2:27080706	A/G	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.84	-0.3	2.5e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22753607	chr9:37120306	ZCCHC7	0.5	7.83	0.34	3.29e-14	Gut microbiome composition (summer);
LGG	cis	rs9354308	0.738	rs9294666	chr6:66598420	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs873946	0.517	rs7071784	chr10:134559980	T/C	cg06453172	chr10:134556979	INPP5A	-0.43	-7.03	-0.31	7.38e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7312933	0.558	rs11181507	chr12:42844763	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.11	0.35	4.56e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg08847533	chr14:75593920	NEK9	-0.58	-10.88	-0.45	1.03e-24	Height;
LGG	cis	rs12949688	1.000	rs4793566	chr17:55815469	T/C	cg12229367	chr17:55822335	NA	0.43	8.07	0.35	6.02e-15	Schizophrenia;
LGG	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs9964724	0.796	rs6507216	chr18:35195719	A/C	cg27332583	chr18:35150602	NA	-0.38	-8.25	-0.36	1.64e-15	Educational attainment (years of education);
LGG	cis	rs2404618	0.561	rs4242536	chr8:1477225	A/G	cg13402656	chr8:1511478	DLGAP2	-0.74	-13.8	-0.54	1.63e-36	Lung cancer;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg05025164	chr4:1340916	KIAA1530	0.45	7.47	0.33	3.94e-13	Obesity-related traits;
LGG	cis	rs4642101	0.618	rs9877079	chr3:12821287	A/G	cg24848339	chr3:12840334	CAND2	0.45	10.85	0.45	1.39e-24	QRS complex (12-leadsum);
LGG	trans	rs561341	1.000	rs484175	chr17:30309041	G/A	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Retinal vascular caliber;
LGG	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg10664184	chr19:17420304	DDA1	0.73	10.0	0.42	1.85e-21	Systemic lupus erythematosus;
LGG	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg23815491	chr16:72088622	HP	0.53	11.75	0.48	4.56e-28	Fibrinogen levels;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.06	-0.42	1.15e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg04117972	chr1:227635322	NA	0.87	13.31	0.53	1.89e-34	Major depressive disorder;
LGG	cis	rs6121246	0.559	rs6060599	chr20:30257754	T/G	cg13852791	chr20:30311386	BCL2L1	0.94	18.47	0.65	1.7e-57	Mean corpuscular hemoglobin;
LGG	trans	rs61931739	0.534	rs11052957	chr12:33995354	G/A	cg13010199	chr12:38710504	ALG10B	0.51	9.93	0.42	3.27e-21	Morning vs. evening chronotype;
LGG	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg15145296	chr3:125709740	NA	-0.59	-7.71	-0.34	7.57e-14	Blood pressure (smoking interaction);
LGG	cis	rs889312	0.500	rs1867731	chr5:56132115	C/G	cg12654349	chr5:56205094	C5orf35	-0.37	-6.66	-0.3	7.71e-11	Breast cancer;Breast cancer (early onset);
LGG	trans	rs656319	0.638	rs670044	chr8:9892529	G/T	cg02002194	chr4:3960332	NA	-0.41	-7.05	-0.31	6.75e-12	Myopia (pathological);
LGG	cis	rs1270639	1.000	rs1270639	chr7:157455459	C/T	cg13357408	chr7:157437802	PTPRN2	-0.55	-7.47	-0.33	4.05e-13	Colorectal cancer;
LGG	cis	rs11690935	0.959	rs13419987	chr2:172623914	T/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.93	-0.31	1.45e-11	Schizophrenia;
LGG	cis	rs2273669	0.667	rs74582170	chr6:109312689	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.39	-0.36	5.81e-16	Prostate cancer;
LGG	cis	rs208520	0.690	rs207094	chr6:66799009	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	cis	rs9796	0.835	rs3100807	chr15:41292206	G/A	cg18705301	chr15:41695430	NDUFAF1	0.48	8.2	0.36	2.46e-15	Menopause (age at onset);
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	cis	rs7301826	0.651	rs7132657	chr12:131285187	T/C	cg11011512	chr12:131303247	STX2	0.41	8.89	0.38	1.38e-17	Plasma plasminogen activator levels;
LGG	cis	rs72945132	0.882	rs7121012	chr11:70214421	A/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.22	0.52	4.47e-34	Coronary artery disease;
LGG	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg09467607	chr2:36825704	FEZ2	0.52	9.33	0.4	4.43e-19	Height;
LGG	cis	rs490234	0.812	rs2416971	chr9:128466113	A/G	cg14078157	chr9:128172775	NA	-0.42	-7.65	-0.34	1.15e-13	Mean arterial pressure;
LGG	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.95	-0.45	5.59e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs9296092	0.517	rs76361685	chr6:33536458	G/C	cg13560919	chr6:33536144	NA	-1.04	-21.49	-0.71	1.38e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg11766577	chr21:47581405	C21orf56	-0.46	-7.23	-0.32	2.05e-12	Testicular germ cell tumor;
LGG	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.85	9.83	0.42	8.03e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs704	0.605	rs2071379	chr17:26695832	A/G	cg10342447	chr17:26645325	TMEM97	-0.52	-9.88	-0.42	4.98e-21	Osteoprotegerin levels;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg06654118	chr4:1303317	MAEA	0.5	8.75	0.38	4.05e-17	Obesity-related traits;
LGG	cis	rs1401999	0.606	rs7644687	chr3:183753353	A/G	cg01324343	chr3:183735012	ABCC5	0.78	13.79	0.54	1.72e-36	Anterior chamber depth;
LGG	cis	rs870825	0.616	rs28660669	chr4:185623312	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs801193	1.000	rs2659915	chr7:66153101	A/G	cg18252515	chr7:66147081	NA	-0.41	-7.02	-0.31	8.08e-12	Aortic root size;
LGG	cis	rs2836974	0.932	rs2234543	chr21:40572072	G/A	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	cis	rs4356203	0.870	rs214922	chr11:17237123	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6598163	0.520	rs12813376	chr12:132302324	C/T	cg15284433	chr12:132323321	MMP17	-0.4	-7.68	-0.34	9.52e-14	Migraine;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs2692947	0.644	rs3821051	chr2:96912787	A/G	cg22654517	chr2:96458247	NA	-0.36	-7.42	-0.33	5.83e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-6.85	-0.3	2.38e-11	Height;
LGG	cis	rs7166081	0.950	rs28645602	chr15:67531323	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.98	-0.31	1.04e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg04861929	chr11:109293070	C11orf87	0.56	10.06	0.42	1.12e-21	Schizophrenia;
LGG	cis	rs7666738	0.791	rs1559860	chr4:99024422	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.32	-0.32	1.13e-12	Menarche (age at onset);
LGG	cis	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg07460842	chr6:66804631	NA	-0.95	-17.33	-0.63	3.31e-52	Exhaled nitric oxide output;
LGG	cis	rs12478296	1.000	rs66466023	chr2:243046151	T/G	cg06360820	chr2:242988706	NA	-0.89	-11.48	-0.47	5.3e-27	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg09699651	chr6:150184138	LRP11	0.52	9.36	0.4	3.57e-19	Lung cancer;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg09858108	chr8:58055024	NA	0.42	6.69	0.3	6.64e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4747241	0.662	rs9415068	chr10:74113333	A/G	cg25082487	chr10:74091975	NA	0.39	7.34	0.32	9.95e-13	Heschl's gyrus morphology;
LGG	cis	rs12780845	0.505	rs7085742	chr10:17248828	G/C	cg01003015	chr10:17271136	VIM	-0.44	-7.51	-0.33	2.97e-13	Homocysteine levels;
LGG	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.41	-6.75	-0.3	4.35e-11	Platelet distribution width;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.89	-0.3	1.85e-11	Lung cancer;
LGG	cis	rs10267417	0.657	rs6963367	chr7:19857873	A/C	cg05791153	chr7:19748676	TWISTNB	0.62	7.93	0.35	1.7e-14	Night sleep phenotypes;
LGG	cis	rs3126085	0.935	rs4845423	chr1:152184950	T/G	cg26876637	chr1:152193138	HRNR	0.54	8.97	0.38	7.31e-18	Atopic dermatitis;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs12200782	0.769	rs10456329	chr6:26436399	G/A	cg27193005	chr6:26382695	BTN2A2	-0.59	-6.7	-0.3	5.97e-11	Small cell lung carcinoma;
LGG	cis	rs4423214	0.798	rs1894100	chr11:71130343	G/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.05	-0.46	2.42e-25	Vitamin D levels;
LGG	cis	rs62025270	0.632	rs10520594	chr15:86128641	A/T	cg25843651	chr15:86329602	KLHL25	-0.53	-7.82	-0.34	3.52e-14	Idiopathic pulmonary fibrosis;
LGG	cis	rs7937682	1.000	rs4936661	chr11:111587495	G/A	cg22437258	chr11:111473054	SIK2	-0.59	-9.84	-0.42	7.39e-21	Primary sclerosing cholangitis;
LGG	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg01620082	chr3:125678407	NA	-0.7	-7.12	-0.31	4.12e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.841	rs17258907	chr4:119769905	A/G	cg21605333	chr4:119757512	SEC24D	1.49	13.69	0.54	4.42e-36	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.27	-0.36	1.38e-15	Life satisfaction;
LGG	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg17150306	chr7:855575	UNC84A	-0.34	-6.93	-0.31	1.43e-11	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.87	-0.3	2.06e-11	Urate levels in obese individuals;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg01879757	chr17:41196368	BRCA1	-0.46	-9.14	-0.39	1.99e-18	Menopause (age at onset);
LGG	cis	rs2797160	1.000	rs1739373	chr6:126011509	A/G	cg05901451	chr6:126070800	HEY2	0.46	7.77	0.34	5.06e-14	Endometrial cancer;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.33	-0.32	1.04e-12	Life satisfaction;
LGG	cis	rs877282	1.000	rs12775643	chr10:773242	G/A	cg17470449	chr10:769945	NA	0.66	8.41	0.36	5.15e-16	Uric acid levels;
LGG	cis	rs876084	0.505	rs66488706	chr8:121132894	C/T	cg06265175	chr8:121136014	COL14A1	0.49	9.93	0.42	3.4e-21	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12493885	0.585	rs787811	chr3:153622907	G/T	cg12800244	chr3:153838788	SGEF	-0.65	-7.63	-0.33	1.34e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.44	-0.5	7.76e-31	Lymphocyte counts;
LGG	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg08305652	chr11:111469057	NA	-0.44	-8.73	-0.38	4.6e-17	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01159149	chr11:10830970	EIF4G2	0.5	7.72	0.34	7.12e-14	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg16359550	chr11:109292809	C11orf87	0.4	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg18681998	chr4:17616180	MED28	0.85	18.27	0.65	1.54e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11039798	1.000	rs7104642	chr11:48588534	C/T	cg03929089	chr4:120376271	NA	0.74	8.6	0.37	1.23e-16	Axial length;
LGG	trans	rs2562456	0.754	rs76688173	chr19:21504658	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7781557	0.640	rs2228687	chr7:102616469	G/A	cg18108683	chr7:102477205	FBXL13	0.55	8.39	0.36	5.94e-16	Colorectal adenoma (advanced);
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs35740288	0.770	rs75039806	chr15:86105044	C/T	cg04173714	chr15:86211321	AKAP13	0.47	8.4	0.36	5.68e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12477438	0.501	rs13000731	chr2:99795231	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.42	0.58	1.38e-43	Chronic sinus infection;
LGG	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.14e-27	Height;
LGG	cis	rs17767392	0.794	rs17767362	chr14:71733790	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.61	-0.37	1.19e-16	Mitral valve prolapse;
LGG	cis	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg24110177	chr3:50126178	RBM5	0.41	7.0	0.31	9.17e-12	Blood protein levels;
LGG	cis	rs73086581	0.787	rs68127408	chr20:3868447	T/C	cg02187196	chr20:3869020	PANK2	0.93	13.04	0.52	2.61e-33	Response to antidepressants in depression;
LGG	cis	rs4319547	0.915	rs7316734	chr12:123117425	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.62	-9.48	-0.4	1.35e-19	Body mass index;
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22968622	chr17:43663579	NA	-0.78	-15.24	-0.58	8.43e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	cis	rs3857747	0.861	rs10238411	chr7:40437450	C/A	cg00420559	chr7:40367873	C7orf10	0.36	7.18	0.32	2.71e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs992157	0.735	rs2271541	chr2:219082119	G/T	cg00012203	chr2:219082015	ARPC2	0.84	17.19	0.62	1.46e-51	Colorectal cancer;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs79057730	0.599	rs9458	chr7:825494	A/G	cg05729249	chr7:766119	PRKAR1B;HEATR2	-0.76	-8.32	-0.36	1e-15	Initial pursuit acceleration;
LGG	cis	rs9831754	0.906	rs2314196	chr3:78411050	C/T	cg06138941	chr3:78371609	NA	-0.83	-17.56	-0.63	2.81e-53	Calcium levels;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	19.57	0.67	1.33e-62	Alzheimer's disease;
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg08621203	chr6:150244597	RAET1G	0.46	6.8	0.3	3.3e-11	Lung cancer;
LGG	cis	rs17270561	0.585	rs9393663	chr6:25741033	A/T	cg03517284	chr6:25882590	NA	-0.43	-7.0	-0.31	9.09e-12	Iron status biomarkers;
LGG	cis	rs9814567	0.896	rs7642266	chr3:134346025	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.3	-0.5	2.7e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.68	0.34	9.29e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9788682	0.706	rs2656055	chr15:78720194	C/A	cg06917634	chr15:78832804	PSMA4	0.52	7.75	0.34	5.8e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs1459104	1.000	rs35218816	chr11:55087104	C/A	cg15704280	chr7:45808275	SEPT13	0.72	7.07	0.31	5.77e-12	Body mass index;
LGG	cis	rs5758511	0.514	rs5751211	chr22:42486056	G/A	cg15128208	chr22:42549153	NA	0.78	12.53	0.5	3.08e-31	Birth weight;
LGG	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg10189774	chr4:17578691	LAP3	-0.4	-6.92	-0.31	1.56e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.25	-0.36	1.61e-15	Retinal vascular caliber;
LGG	cis	rs2439831	0.850	rs16965120	chr15:44100342	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	9.42	0.4	2.11e-19	Lung cancer in ever smokers;
LGG	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7769051	1.000	rs7765224	chr6:133101624	T/C	cg07930552	chr6:133119739	C6orf192	0.85	11.23	0.46	4.61e-26	Type 2 diabetes nephropathy;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7188861	0.681	rs34947566	chr16:11412926	C/A	cg01510278	chr16:11456238	NA	0.29	6.65	0.3	8.19e-11	HDL cholesterol;
LGG	cis	rs4293296	0.525	rs1955458	chr14:54827524	A/C	cg11186706	chr14:54815745	NA	-0.58	-8.12	-0.35	4.33e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs4665809	0.887	rs6546716	chr2:26263836	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.87	-0.51	1.31e-32	Gut microbiome composition (summer);
LGG	cis	rs10206020	0.921	rs11884956	chr2:1566426	A/G	cg26248373	chr2:1572462	NA	-0.88	-14.99	-0.57	1.12e-41	IgG glycosylation;
LGG	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg17644776	chr2:200775616	C2orf69	-0.6	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg12373951	chr3:133503437	NA	0.4	7.0	0.31	9.15e-12	Iron status biomarkers;
LGG	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.4	0.4	2.49e-19	Bone mineral density;
LGG	cis	rs10864302	0.747	rs7524314	chr1:7449971	A/G	cg08923594	chr1:7462176	CAMTA1	-0.57	-7.63	-0.33	1.36e-13	Photic sneeze reflex;
LGG	cis	rs67460515	0.926	rs11715591	chr3:161043137	C/T	cg03342759	chr3:160939853	NMD3	-0.75	-13.17	-0.52	6.98e-34	Parkinson's disease;
LGG	cis	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg07460842	chr6:66804631	NA	-0.68	-11.61	-0.47	1.64e-27	Blood trace element (Cu levels);
LGG	cis	rs240764	0.717	rs239236	chr6:101099217	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.49	0.33	3.62e-13	Neuroticism;
LGG	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-11.1	-0.46	1.54e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.37	0.63	2e-52	Vitiligo;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.7	12.17	0.49	9.12e-30	Obesity-related traits;
LGG	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.4	0.44	6.7e-23	Diabetic retinopathy;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg26138144	chr22:38071188	LGALS1	0.91	24.34	0.75	7.06e-85	Fat distribution (HIV);
LGG	trans	rs1994135	0.608	rs1482994	chr12:33713631	T/C	cg13010199	chr12:38710504	ALG10B	0.55	9.75	0.41	1.51e-20	Resting heart rate;
LGG	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg10483660	chr13:112241077	NA	0.45	9.4	0.4	2.54e-19	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs3784262	1.000	rs4646629	chr15:58255215	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.38	-0.36	6.58e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs3742264	0.656	rs9534272	chr13:46566823	G/C	cg15192986	chr13:46630673	CPB2	-0.36	-6.95	-0.31	1.23e-11	Blood protein levels;
LGG	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg07636037	chr3:49044803	WDR6	0.61	10.59	0.44	1.29e-23	Resting heart rate;
LGG	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg24642439	chr20:33292090	TP53INP2	0.82	14.48	0.56	1.82e-39	Coronary artery disease;
LGG	cis	rs17067123	0.614	rs35522192	chr4:180064376	C/A	cg26610307	chr4:180072759	NA	-0.48	-6.84	-0.3	2.48e-11	Response to hepatitis C treatment;
LGG	cis	rs7927771	0.965	rs34958982	chr11:47547046	T/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.73	-0.38	4.72e-17	Subjective well-being;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	trans	rs17685	0.753	rs13240404	chr7:75675719	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.77	-0.77	1.82e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.41	-0.33	6.15e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg09021430	chr5:549028	NA	-0.82	-12.79	-0.51	2.73e-32	Obesity-related traits;
LGG	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.73	-0.34	6.94e-14	Gut microbiome composition (summer);
LGG	cis	rs9486719	0.947	rs12208556	chr6:96903486	C/T	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.62	-0.44	9.63e-24	Migraine;Coronary artery disease;
LGG	cis	rs17401966	1.000	rs12407992	chr1:10311983	A/C	cg15208524	chr1:10270712	KIF1B	0.47	8.11	0.35	4.58e-15	Hepatocellular carcinoma;
LGG	cis	rs1003719	0.788	rs3787782	chr21:38462909	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	trans	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg05926928	chr17:57297772	GDPD1	-0.55	-9.08	-0.39	3.08e-18	Schizophrenia;
LGG	cis	rs504918	1.000	rs552988	chr3:124088449	G/A	cg05766129	chr3:123988013	KALRN	0.37	6.74	0.3	4.69e-11	Schizophrenia;
LGG	cis	rs9398803	0.723	rs1262545	chr6:127074587	C/T	cg19875578	chr6:126661172	C6orf173	-0.51	-9.29	-0.4	6e-19	Male-pattern baldness;
LGG	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.41	-8.13	-0.35	3.83e-15	Ovarian reserve;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.89	-0.34	2.14e-14	Height;
LGG	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg26297688	chr12:107349093	C12orf23	-0.37	-6.96	-0.31	1.17e-11	Total body bone mineral density;
LGG	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs17376456	0.877	rs13185660	chr5:93336500	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.82	-0.42	8.75e-21	Diabetic retinopathy;
LGG	cis	rs992157	0.735	rs13393821	chr2:219076742	C/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.62	-0.51	1.38e-31	Colorectal cancer;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs15676	0.947	rs10988124	chr9:131569345	G/A	cg04621255	chr9:131581398	ENDOG	-0.39	-6.87	-0.3	2.13e-11	Blood metabolite levels;
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg12395012	chr8:11607386	GATA4	-0.37	-6.73	-0.3	4.89e-11	Neuroticism;
LGG	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg13385794	chr1:248469461	NA	0.5	8.35	0.36	8.14e-16	Common traits (Other);
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg16284684	chr7:1164063	C7orf50	0.35	6.72	0.3	5.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8067287	0.546	rs62065425	chr17:16828711	C/T	cg26910001	chr17:16838321	NA	-0.48	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	cis	rs2303319	1.000	rs2303319	chr2:162224664	C/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs1707322	0.789	rs10789473	chr1:46248131	C/T	cg03146154	chr1:46216737	IPP	0.59	10.66	0.44	7.1e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21659725	chr3:3221576	CRBN	-0.65	-10.63	-0.44	9.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6997458	0.785	rs7016369	chr8:86368269	A/G	cg02393479	chr8:86352350	CA3	0.32	6.97	0.31	1.11e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs8031584	0.781	rs4779498	chr15:31177476	C/T	cg08109568	chr15:31115862	NA	-0.53	-9.12	-0.39	2.37e-18	Huntington's disease progression;
LGG	trans	rs637571	0.584	rs659824	chr11:65636509	A/G	cg17712092	chr4:129076599	LARP1B	-0.75	-14.87	-0.57	3.48e-41	Eosinophil percentage of white cells;
LGG	cis	rs2108225	0.900	rs2395930	chr7:107451677	T/C	cg18560240	chr7:107437656	SLC26A3	-0.59	-10.58	-0.44	1.47e-23	Ulcerative colitis;
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg18681998	chr4:17616180	MED28	0.89	19.73	0.68	2.54e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg08885076	chr2:99613938	TSGA10	0.42	8.91	0.38	1.2e-17	Chronic sinus infection;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg25214090	chr10:38739885	LOC399744	0.72	12.6	0.51	1.65e-31	Corneal astigmatism;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg22907277	chr7:1156413	C7orf50	0.4	6.87	0.3	2.06e-11	Longevity;Endometriosis;
LGG	cis	rs377457	0.856	rs11117268	chr16:85738269	A/T	cg08768472	chr16:85689701	KIAA0182	0.43	8.23	0.36	1.96e-15	Type 2 diabetes;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.86	0.3	2.25e-11	Lung cancer;
LGG	cis	rs1793639	0.606	rs11533200	chr11:131955594	C/T	cg13908476	chr11:131942942	NTM	0.68	13.7	0.54	4e-36	Myopia;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg19223190	chr17:80058835	NA	0.45	8.72	0.38	4.97e-17	Life satisfaction;
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.11	-0.68	4e-65	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2594989	0.831	rs7620624	chr3:11476270	C/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.24	-0.32	1.83e-12	Circulating chemerin levels;
LGG	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08704250	chr15:31115839	NA	-0.43	-7.9	-0.34	2.05e-14	Huntington's disease progression;
LGG	cis	rs10752881	1.000	rs10797810	chr1:182980950	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.62	0.41	4.14e-20	Colorectal cancer;
LGG	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-6.87	-0.3	2.06e-11	Huntington's disease progression;
LGG	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04530015	chr2:215796436	ABCA12	-0.46	-7.71	-0.34	7.87e-14	Neuroblastoma;
LGG	cis	rs5769765	0.728	rs6520064	chr22:50294469	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.09	-0.42	8.96e-22	Schizophrenia;
LGG	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg16176437	chr11:89678848	NA	-0.43	-7.21	-0.32	2.24e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.22e-31	Prudent dietary pattern;
LGG	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg06481639	chr22:41940642	POLR3H	-0.47	-7.27	-0.32	1.49e-12	Vitiligo;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.01	-0.42	1.74e-21	Bipolar disorder;
LGG	cis	rs11158026	0.757	rs7153937	chr14:55470875	A/G	cg04306507	chr14:55594613	LGALS3	0.31	7.11	0.31	4.35e-12	Parkinson's disease;
LGG	cis	rs1568889	0.838	rs716366	chr11:28121536	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.27	0.67	3.43e-61	Bipolar disorder;
LGG	cis	rs1577917	0.958	rs6454487	chr6:86446868	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.67	11.81	0.48	2.47e-28	Response to antipsychotic treatment;
LGG	cis	rs847577	0.715	rs4729402	chr7:97707731	A/G	cg13397024	chr7:97797637	LMTK2	-0.37	-6.94	-0.31	1.36e-11	Breast cancer;
LGG	cis	rs11122272	0.668	rs1538664	chr1:231555295	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.58	-10.52	-0.44	2.43e-23	Hemoglobin concentration;
LGG	cis	rs933688	0.941	rs2887007	chr5:90740531	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	17.12	0.62	2.92e-51	Smoking behavior;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg01673284	chr16:4527211	HMOX2	-0.34	-6.99	-0.31	9.56e-12	Schizophrenia;
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs932287	0.536	rs10840160	chr11:9053536	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-10.92	-0.45	7.2e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.5	0.33	3.31e-13	Tonsillectomy;
LGG	trans	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg25214090	chr10:38739885	LOC399744	0.66	11.61	0.47	1.52e-27	Corneal astigmatism;
LGG	cis	rs17401966	0.838	rs4475756	chr1:10387788	A/G	cg15208524	chr1:10270712	KIF1B	0.41	7.05	0.31	6.34e-12	Hepatocellular carcinoma;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.08	-0.42	9.96e-22	Platelet count;
LGG	cis	rs11605275	0.688	rs11601815	chr11:20020564	C/T	cg14835545	chr11:20032148	NAV2	-0.56	-7.67	-0.34	1.02e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs3771570	1.000	rs62193205	chr2:242316512	C/T	cg21155796	chr2:242212141	HDLBP	0.75	9.76	0.41	1.32e-20	Prostate cancer;
LGG	cis	rs7923452	0.507	rs215494	chr10:30776589	T/G	cg25182066	chr10:30743637	MAP3K8	-0.62	-12.54	-0.5	2.86e-31	Itch intensity from mosquito bite;
LGG	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	9.2	0.39	1.21e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs12230513	0.732	rs7980098	chr12:55844694	A/G	cg19537932	chr12:55886519	OR6C68	-0.61	-10.97	-0.45	4.7e-25	Contrast sensitivity;
LGG	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg04731861	chr2:219085781	ARPC2	0.42	10.2	0.43	3.72e-22	Colorectal cancer;
LGG	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg05692746	chr2:100937584	LONRF2	-0.65	-12.09	-0.49	1.98e-29	Intelligence (multi-trait analysis);
LGG	trans	rs11764590	0.950	rs62444919	chr7:2109499	C/T	cg22232500	chr2:134024266	NCKAP5	0.54	7.54	0.33	2.55e-13	Neuroticism;
LGG	cis	rs9902453	0.765	rs8071576	chr17:28188554	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.11	0.55	7.58e-38	Coffee consumption (cups per day);
LGG	cis	rs13395090	0.967	rs12105179	chr2:3721729	C/T	cg20493526	chr2:3714936	ALLC	-0.46	-10.18	-0.43	4.13e-22	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg15921436	chr17:44337874	NA	-0.54	-11.5	-0.47	4.45e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4938330	0.739	rs11216266	chr11:116950150	T/C	cg20608306	chr11:116969690	SIK3	-0.38	-10.44	-0.44	4.77e-23	Blood protein levels;
LGG	cis	rs6964587	0.743	rs33993294	chr7:91998655	A/C	cg17063962	chr7:91808500	NA	0.49	8.36	0.36	7.52e-16	Breast cancer;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.82	-0.34	3.65e-14	Interleukin-17 levels;
LGG	cis	rs9815354	1.000	rs3934103	chr3:41977214	C/T	cg03022575	chr3:42003672	ULK4	-0.68	-8.74	-0.38	4.19e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg13455623	chr4:3480656	DOK7	-0.69	-14.51	-0.56	1.34e-39	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	trans	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg13010199	chr12:38710504	ALG10B	-0.47	-9.04	-0.39	4.42e-18	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg05368731	chr17:41323189	NBR1	0.96	19.1	0.66	2.23e-60	Menopause (age at onset);
LGG	cis	rs497273	0.534	rs608394	chr12:121194053	C/T	cg02419362	chr12:121203948	SPPL3	0.49	8.47	0.37	3.2e-16	Systemic lupus erythematosus;
LGG	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.99	0.31	9.62e-12	Monocyte count;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.31	1.77e-11	Obesity-related traits;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.44	0.33	4.79e-13	Tonsillectomy;
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg06558623	chr16:89946397	TCF25	1.21	13.31	0.53	1.9e-34	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	17.39	0.63	1.64e-52	Obesity-related traits;
LGG	cis	rs11967485	0.614	rs72998928	chr6:157192225	C/T	cg23222435	chr6:157204239	ARID1B	-0.81	-7.28	-0.32	1.42e-12	Calcium levels;
LGG	cis	rs2729354	0.729	rs2258835	chr11:57243588	A/G	cg24343310	chr11:57249947	NA	0.43	8.17	0.36	2.94e-15	Blood protein levels;
LGG	cis	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg06521331	chr12:34319734	NA	-0.62	-10.99	-0.45	4.14e-25	Morning vs. evening chronotype;
LGG	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.39	-0.4	2.71e-19	Aortic root size;
LGG	cis	rs12724450	0.793	rs56214117	chr1:150420625	A/G	cg03818307	chr1:150480534	ECM1	0.51	7.17	0.32	2.94e-12	Blood protein levels;
LGG	cis	rs12612619	0.621	rs4665943	chr2:27295885	C/T	cg12045002	chr2:27069975	DPYSL5	-0.31	-6.67	-0.3	7.15e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg23978390	chr7:1156363	C7orf50	0.5	7.18	0.32	2.81e-12	Bronchopulmonary dysplasia;
LGG	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.61	-0.33	1.5e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1003719	1.000	rs1003719	chr21:38491095	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.79	15.59	0.59	2.42e-44	Eye color traits;
LGG	cis	rs564799	0.966	rs574808	chr3:159732983	T/C	cg04855961	chr3:159719849	NA	-0.28	-7.49	-0.33	3.63e-13	Systemic lupus erythematosus;
LGG	cis	rs7428	0.527	rs7607284	chr2:85547376	C/G	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.74	-0.54	2.91e-36	Ear protrusion;
LGG	trans	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	trans	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg26384229	chr12:38710491	ALG10B	0.77	14.21	0.55	2.81e-38	Resting heart rate;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg00800038	chr16:89945340	TCF25	-0.7	-9.15	-0.39	1.85e-18	Skin colour saturation;
LGG	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs755249	0.567	rs61779284	chr1:39855177	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.41	0.33	6.06e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg12193833	chr17:30244370	NA	-0.29	-6.99	-0.31	9.77e-12	Hip circumference adjusted for BMI;
LGG	trans	rs453301	0.631	rs28572014	chr8:8793607	C/T	cg02002194	chr4:3960332	NA	0.39	7.05	0.31	6.62e-12	Joint mobility (Beighton score);
LGG	cis	rs870825	0.616	rs28620459	chr4:185627132	G/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.05	-0.42	1.24e-21	Depression;
LGG	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.96	-0.31	1.21e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs357618	1.000	rs357628	chr5:150850352	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.77	-0.3	3.81e-11	Basophil percentage of white cells;
LGG	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg26818257	chr2:241905806	NA	0.37	7.09	0.31	4.93e-12	Urinary metabolites;
LGG	cis	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.52	-0.33	2.96e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10751667	0.666	rs7103585	chr11:971166	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg24829409	chr8:58192753	C8orf71	-0.88	-13.63	-0.54	8.11e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21257117	chr11:65029643	POLA2	0.47	7.72	0.34	7.15e-14	Gut microbiome composition (summer);
LGG	cis	rs76288851	0.627	rs9838548	chr3:126747367	T/C	cg00307254	chr3:126706825	PLXNA1	-0.4	-6.66	-0.3	7.64e-11	Alcoholic chronic pancreatitis;
LGG	cis	rs9557207	1.000	rs7332472	chr13:99944381	C/G	cg24509225	chr13:100037070	UBAC2	0.69	12.36	0.5	1.58e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7799006	0.929	rs6461233	chr7:2261468	G/A	cg02951883	chr7:2050386	MAD1L1	-0.42	-7.44	-0.33	4.87e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg18032289	chr17:61959525	GH2	-0.4	-6.79	-0.3	3.37e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17018464	chr11:6411469	SMPD1	0.41	6.94	0.31	1.34e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs643506	0.715	rs11214031	chr11:111766039	C/A	cg09085632	chr11:111637200	PPP2R1B	0.43	6.85	0.3	2.31e-11	Breast cancer;
LGG	cis	rs11608355	0.810	rs12424599	chr12:109866615	A/G	cg05360138	chr12:110035743	NA	0.51	7.12	0.31	4.11e-12	Neuroticism;
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.33	-0.53	1.56e-34	Aortic root size;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.01	-0.31	8.6e-12	Electroencephalogram traits;
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg20308403	chr7:2120281	MAD1L1	0.32	6.84	0.3	2.52e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs778691	chr7:65873092	G/C	cg18252515	chr7:66147081	NA	-1.43	-20.76	-0.69	3.88e-68	Diabetic kidney disease;
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg02002194	chr4:3960332	NA	0.48	9.19	0.39	1.29e-18	Systolic blood pressure;
LGG	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.06	0.42	1.14e-21	Diabetic retinopathy;
LGG	cis	rs8114671	0.967	rs6088753	chr20:33768252	C/T	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs8014204	0.935	rs2853779	chr14:75368508	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.86	-18.21	-0.65	2.75e-56	Caffeine consumption;
LGG	cis	rs9443645	0.527	rs36128361	chr6:79684340	C/G	cg18132916	chr6:79620363	NA	-0.28	-7.3	-0.32	1.26e-12	Intelligence (multi-trait analysis);
LGG	trans	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg24247370	chr13:99142703	STK24	-0.42	-7.56	-0.33	2.11e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.61	-0.44	1.05e-23	Alzheimer's disease;
LGG	cis	rs6977955	0.877	rs9648346	chr7:28160113	C/G	cg23620719	chr7:28220237	JAZF1	0.44	6.81	0.3	2.96e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10267417	0.657	rs16872411	chr7:19913562	T/C	cg05791153	chr7:19748676	TWISTNB	0.54	6.73	0.3	5.02e-11	Night sleep phenotypes;
LGG	cis	rs1059312	1.000	rs7970815	chr12:129288366	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.9	-0.64	7.58e-55	Systemic lupus erythematosus;
LGG	cis	rs12971120	0.947	rs8084410	chr18:72168486	T/C	cg25817165	chr18:72167213	CNDP2	-0.67	-15.11	-0.57	3.33e-42	Refractive error;
LGG	trans	rs3942852	0.955	rs4752897	chr11:48136990	C/T	cg15704280	chr7:45808275	SEPT13	-0.63	-8.13	-0.35	3.92e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7751419	0.651	rs10947778	chr6:39093606	T/C	cg08089693	chr6:39098871	NA	-0.44	-7.92	-0.35	1.73e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg16141378	chr3:129829833	LOC729375	0.4	9.43	0.4	1.99e-19	Neuroticism;
LGG	cis	rs10884984	0.770	rs10509919	chr10:112272043	T/G	cg18756771	chr10:112261994	DUSP5	0.68	12.6	0.51	1.68e-31	Facial morphology (factor 22);
LGG	cis	rs919433	0.783	rs787980	chr2:198239225	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.37	0.32	8.15e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs877282	1.000	rs34257857	chr10:772993	C/A	cg22713356	chr15:30763199	NA	0.56	8.63	0.37	1.02e-16	Uric acid levels;
LGG	cis	rs7660883	0.866	rs342456	chr4:88023870	T/C	cg21988461	chr4:88008667	AFF1	0.34	9.79	0.41	1.09e-20	HDL cholesterol levels;
LGG	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg11630169	chr10:3283847	NA	-0.44	-10.51	-0.44	2.61e-23	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs826838	0.834	rs826874	chr12:39122599	C/A	cg13010199	chr12:38710504	ALG10B	-0.63	-13.59	-0.53	1.24e-35	Heart rate;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6466055	0.639	rs11760317	chr7:104711711	T/C	cg04380332	chr7:105027541	SRPK2	-0.39	-7.38	-0.32	7.32e-13	Schizophrenia;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.53	9.32	0.4	4.66e-19	Longevity;
LGG	cis	rs926938	0.527	rs360672	chr1:115483836	C/T	cg12756093	chr1:115239321	AMPD1	0.43	8.02	0.35	8.63e-15	Autism;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26004664	chr4:183794378	NA	0.36	6.84	0.3	2.58e-11	Menarche (age at onset);
LGG	trans	rs9467711	0.591	rs9467621	chr6:25851338	G/A	cg01620082	chr3:125678407	NA	-0.7	-6.92	-0.31	1.55e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1008375	0.966	rs3775925	chr4:17588437	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.82	0.3	2.89e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg02002194	chr4:3960332	NA	0.52	10.35	0.43	1.05e-22	Neuroticism;
LGG	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg06532163	chr17:45867833	NA	0.4	7.04	0.31	6.85e-12	IgG glycosylation;
LGG	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg11502198	chr6:26597334	ABT1	0.69	12.05	0.49	2.88e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.812	rs26003	chr5:130990384	T/C	cg06307176	chr5:131281290	NA	0.53	8.65	0.37	8.72e-17	Life satisfaction;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs1059312	0.522	rs3825181	chr12:129279264	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	11.1	0.46	1.48e-25	Systemic lupus erythematosus;
LGG	cis	rs2018055	0.618	rs7763979	chr6:117795970	C/T	cg14611402	chr6:117803162	DCBLD1	0.3	8.75	0.38	3.94e-17	Diastolic blood pressure;
LGG	cis	rs9549260	0.727	rs4603422	chr13:41148353	T/C	cg21288729	chr13:41239152	FOXO1	0.33	6.71	0.3	5.84e-11	Red blood cell count;
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg12813108	chr7:99719912	CNPY4	-0.56	-8.29	-0.36	1.2e-15	Lung function (FEV1/FVC);
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.95e-42	Prudent dietary pattern;
LGG	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg16301924	chr13:53314226	LECT1	-0.35	-6.93	-0.31	1.41e-11	Lewy body disease;
LGG	cis	rs3768617	0.811	rs10797828	chr1:183028430	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.83	0.3	2.74e-11	Fuchs's corneal dystrophy;
LGG	cis	rs17125944	0.686	rs7160582	chr14:53341445	G/T	cg00686598	chr14:53173677	PSMC6	0.78	8.18	0.36	2.85e-15	Alzheimer's disease (late onset);
LGG	cis	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg26384229	chr12:38710491	ALG10B	0.72	14.69	0.56	2.34e-40	Bladder cancer;
LGG	cis	rs950027	0.596	rs2467853	chr15:45698793	T/G	cg26924012	chr15:45694286	SPATA5L1	0.66	11.83	0.48	2.21e-28	Response to fenofibrate (adiponectin levels);
LGG	cis	rs10751667	0.643	rs10902237	chr11:944801	C/A	cg22143635	chr11:980567	AP2A2	0.42	7.65	0.33	1.18e-13	Alzheimer's disease (late onset);
LGG	trans	rs17685	0.753	rs3757593	chr7:75678735	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.77	-0.77	1.82e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.77	0.34	4.98e-14	Rheumatoid arthritis;
LGG	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg24450063	chr1:156163899	SLC25A44	0.83	12.72	0.51	5.58e-32	Testicular germ cell tumor;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg18357526	chr6:26021779	HIST1H4A	0.69	11.06	0.46	2.2e-25	Urate levels;
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.11	-0.39	2.48e-18	Retinal vascular caliber;
LGG	cis	rs2112347	0.502	rs34339	chr5:74931333	G/T	cg19683494	chr5:74908142	NA	-0.61	-8.34	-0.36	8.63e-16	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LGG	cis	rs12042938	0.622	rs11122318	chr1:231806852	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.54	8.91	0.38	1.16e-17	Neuranatomic and neurocognitive phenotypes;
LGG	trans	rs13256369	0.865	rs13277708	chr8:8573936	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.71	-0.3	5.8e-11	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-9.34	-0.4	4.14e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs45544231	0.569	rs3095605	chr16:52583847	A/G	cg09051775	chr16:52580266	TOX3	-0.46	-7.84	-0.34	3.16e-14	Restless legs syndrome;
LGG	cis	rs6964587	0.967	rs58673519	chr7:91823887	T/G	cg17063962	chr7:91808500	NA	0.53	9.59	0.41	5.4e-20	Breast cancer;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	9.11	0.39	2.45e-18	Obesity-related traits;
LGG	trans	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg06521331	chr12:34319734	NA	0.5	9.38	0.4	3.07e-19	Bladder cancer;
LGG	trans	rs9291683	0.610	rs993172	chr4:10324361	G/T	cg26043149	chr18:55253948	FECH	0.45	7.53	0.33	2.71e-13	Bone mineral density;
LGG	trans	rs9657904	0.865	rs6437624	chr3:105590427	C/T	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.39e-14	Multiple sclerosis;
LGG	cis	rs1595825	0.891	rs7573687	chr2:198893376	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.82	-0.3	2.77e-11	Ulcerative colitis;
LGG	cis	rs9916302	0.904	rs11078915	chr17:37715426	T/C	cg07936489	chr17:37558343	FBXL20	-0.84	-15.79	-0.59	2.94e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg11532179	chr8:4329150	CSMD1	0.53	6.75	0.3	4.48e-11	QT interval;
LGG	cis	rs9549367	0.789	rs2287248	chr13:113889226	T/C	cg00898013	chr13:113819073	PROZ	-0.44	-8.64	-0.37	9.02e-17	Platelet distribution width;
LGG	cis	rs271738	0.674	rs271771	chr1:234677268	G/C	cg05133706	chr1:234667230	NA	-0.3	-6.82	-0.3	2.9100000000000002e-11	Bipolar disorder;
LGG	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg07777115	chr5:623756	CEP72	-0.57	-7.13	-0.31	3.95e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs741702	0.892	rs1799918	chr19:13002400	G/C	cg04657146	chr19:12876947	HOOK2	-0.44	-7.26	-0.32	1.61e-12	Red blood cell traits;
LGG	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg00531865	chr16:30841666	NA	0.5	10.09	0.42	8.89e-22	Dementia with Lewy bodies;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg04503457	chr17:41445688	NA	-0.39	-8.8	-0.38	2.81e-17	Menopause (age at onset);
LGG	cis	rs6735179	0.688	rs6745142	chr2:1763886	A/G	cg08534653	chr2:1747700	PXDN	0.43	6.77	0.3	4.01e-11	Response to antipsychotic treatment;
LGG	cis	rs7998202	0.667	rs282574	chr13:113361310	C/T	cg02820901	chr13:113351484	ATP11A	0.56	6.73	0.3	5e-11	Glycated hemoglobin levels;
LGG	cis	rs990171	1.000	rs2058622	chr2:102985424	A/G	cg05295703	chr2:102895712	NA	-0.56	-9.84	-0.42	7.4e-21	Lymphocyte counts;
LGG	cis	rs115344852	0.575	rs2531820	chr6:28456719	T/C	cg13525197	chr6:28411240	ZSCAN23	-0.51	-6.76	-0.3	4.18e-11	Epithelial ovarian cancer;
LGG	trans	rs9329221	0.655	rs4292737	chr8:10259115	A/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.72	-0.3	5.47e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.33	0.43	1.18e-22	Prudent dietary pattern;
LGG	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg25019033	chr10:957182	NA	-0.55	-9.96	-0.42	2.75e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.39	0.82	2.3e-112	Prudent dietary pattern;
LGG	cis	rs9549367	0.789	rs2287253	chr13:113891075	G/A	cg18105134	chr13:113819100	PROZ	0.69	13.87	0.54	8.09e-37	Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23330034	chr19:41770021	HNRNPUL1	0.51	8.02	0.35	8.49e-15	Gut microbiome composition (summer);
LGG	cis	rs798554	0.616	rs1713921	chr7:2882262	G/A	cg13628971	chr7:2884303	GNA12	0.38	7.8	0.34	4.09e-14	Height;
LGG	cis	rs11809207	0.723	rs57653638	chr1:26524401	A/G	cg23602478	chr1:26503979	CNKSR1	0.38	7.7	0.34	8.47e-14	Height;
LGG	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.69	-10.31	-0.43	1.36e-22	Body mass index;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg01238044	chr22:24384105	GSTT1	-0.41	-6.98	-0.31	1.02e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4740619	0.933	rs10962124	chr9:15716039	T/C	cg14451791	chr9:16040625	NA	-0.36	-9.02	-0.39	4.91e-18	Body mass index;
LGG	cis	rs2153535	0.580	rs1335628	chr6:8491742	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.95	-0.38	8.69e-18	Neuroticism;
LGG	cis	rs6087990	0.735	rs2424914	chr20:31374520	A/G	cg13636640	chr20:31349939	DNMT3B	0.84	17.24	0.63	8.02e-52	Ulcerative colitis;
LGG	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg08603382	chr10:743973	NA	-0.42	-7.61	-0.33	1.59e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs7607369	0.637	rs3731866	chr2:219288899	C/T	cg10223061	chr2:219282414	VIL1	0.4	8.73	0.38	4.59e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg07777115	chr5:623756	CEP72	-0.58	-7.25	-0.32	1.76e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg22916017	chr11:64110731	CCDC88B	-0.48	-9.83	-0.42	7.93e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg25486957	chr4:152246857	NA	-0.39	-6.93	-0.31	1.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg15038512	chr6:170123185	PHF10	0.53	6.79	0.3	3.41e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1682825	0.858	rs4594599	chr3:10760706	C/G	cg23512531	chr3:10780469	NA	-0.56	-7.47	-0.33	4.09e-13	Economic and political preferences (feminism/equality);
LGG	cis	rs1048238	0.846	rs945419	chr1:16344858	C/T	cg21385522	chr1:16154831	NA	0.42	6.67	0.3	7.23e-11	Systolic blood pressure;
LGG	cis	rs60180747	1.000	rs79065844	chr15:66690111	T/G	cg07575407	chr15:66541975	MEGF11	0.35	7.02	0.31	8.01e-12	Testicular germ cell tumor;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17769463	chr19:37341261	ZNF345	0.44	7.36	0.32	8.67e-13	Menarche (age at onset);
LGG	cis	rs6793245	0.960	rs12053903	chr3:38593393	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.49	-8.27	-0.36	1.47e-15	QT interval;
LGG	cis	rs2188554	0.630	rs39309	chr7:116952304	G/A	cg10524701	chr7:117356490	CTTNBP2	0.35	6.83	0.3	2.72e-11	Esophageal adenocarcinoma;
LGG	cis	rs472402	0.623	rs8192130	chr5:6636450	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.08	-0.31	5.45e-12	Response to amphetamines;
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.1	0.35	5.05e-15	Monocyte count;
LGG	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.41	-0.33	5.99e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs9815354	0.857	rs6796078	chr3:42017820	A/T	cg03022575	chr3:42003672	ULK4	-0.6	-7.43	-0.33	5.31e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.06	-0.39	3.68e-18	Primary sclerosing cholangitis;
LGG	cis	rs597583	0.575	rs35200015	chr11:117383215	G/A	cg27161313	chr11:117392002	DSCAML1	-0.54	-8.43	-0.36	4.49e-16	Putamen volume;
LGG	cis	rs1801251	1.000	rs2592113	chr2:233669553	C/T	cg25237894	chr2:233734115	C2orf82	0.66	12.58	0.5	1.95e-31	Coronary artery disease;
LGG	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg27476859	chr7:2772710	GNA12	0.55	10.61	0.44	1.1e-23	Height;
LGG	cis	rs36071027	0.554	rs34366240	chr5:158425013	C/A	cg00594129	chr5:158524270	EBF1	0.47	8.44	0.37	4.11e-16	Carotid intima media thickness;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg19168338	chr16:4465731	CORO7	-0.73	-13.65	-0.54	6.73e-36	Schizophrenia;
LGG	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg00717180	chr2:96193071	NA	-0.42	-7.38	-0.32	7.26e-13	HDL cholesterol;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11298680	chr1:28559461	DNAJC8	0.43	7.85	0.34	2.91e-14	Obesity-related traits;
LGG	cis	rs9783347	0.621	rs3802967	chr11:18344064	T/C	cg03595886	chr11:18357587	GTF2H1	-0.51	-12.67	-0.51	8.93e-32	Pancreatic cancer;
LGG	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg03469862	chr11:68924853	NA	0.46	7.07	0.31	5.85e-12	Blond vs. brown hair color;
LGG	cis	rs67133203	0.904	rs35037088	chr12:51362756	C/T	cg14688905	chr12:51403056	SLC11A2	0.77	11.61	0.47	1.54e-27	Urinary tract infection frequency;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.36	6.85	0.3	2.37e-11	Longevity;
LGG	cis	rs11649743	0.830	rs17138469	chr17:36080165	C/G	cg21250756	chr17:36077300	HNF1B	0.37	9.62	0.41	4.23e-20	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg22168489	chr12:122356033	WDR66	0.44	10.31	0.43	1.36e-22	Mean corpuscular volume;
LGG	trans	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg23762105	chr12:34175262	ALG10	0.34	7.0	0.31	9.06e-12	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.838	rs6546780	chr2:26352857	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	trans	rs1459104	0.570	rs56152290	chr11:54858073	C/T	cg03929089	chr4:120376271	NA	0.66	6.65	0.3	8.17e-11	Body mass index;
LGG	trans	rs3857536	0.776	rs2040593	chr6:66944076	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.68	-0.34	9.8e-14	Blood trace element (Cu levels);
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg04772025	chr11:68637568	NA	0.76	13.59	0.53	1.23e-35	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7084402	0.967	rs1649032	chr10:60279701	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.3	0.32	1.25e-12	Refractive error;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.640	rs2122365	chr3:153930808	T/G	cg12800244	chr3:153838788	SGEF	0.8	8.17	0.36	2.92e-15	Coronary artery disease;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg08677398	chr8:58056175	NA	0.56	9.0	0.39	5.9e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.9	0.31	1.7e-11	Lung cancer;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg07701084	chr6:150067640	NUP43	0.69	13.41	0.53	6.79e-35	Lung cancer;
LGG	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg11812906	chr14:75593930	NEK9	-0.46	-8.27	-0.36	1.38e-15	Height;
LGG	cis	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg12751644	chr20:60527061	NA	-0.3	-7.05	-0.31	6.71e-12	Body mass index;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.89	-0.31	1.79e-11	Height;
LGG	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.58e-40	Cognitive test performance;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg13752114	chr3:195489708	MUC4	0.63	8.79	0.38	2.98e-17	Lung disease severity in cystic fibrosis;
LGG	cis	rs1408799	0.720	rs35666741	chr9:12747561	T/C	cg05274944	chr9:12693694	TYRP1	0.33	7.86	0.34	2.76e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs826838	0.967	rs826876	chr12:39123843	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.23	-0.55	2.27e-38	Heart rate;
LGG	cis	rs2046867	0.862	rs28632160	chr3:72800690	T/C	cg25664220	chr3:72788482	NA	-0.33	-9.27	-0.4	6.87e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs701145	0.640	rs357497	chr3:153943068	C/A	cg17054900	chr3:154042577	DHX36	0.92	10.12	0.43	7.02e-22	Coronary artery disease;
LGG	cis	rs17227506	0.704	rs13280049	chr8:13460257	A/G	cg03566418	chr8:13424080	C8orf48	0.64	10.15	0.43	5.55e-22	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs7209395	1.000	rs6504401	chr17:64174971	G/A	cg19474267	chr17:64306194	PRKCA	0.52	8.32	0.36	9.69e-16	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs209489	0.901	rs209531	chr6:53221279	T/C	cg15607103	chr6:53167650	ELOVL5	-0.52	-6.81	-0.3	3.01e-11	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1976403	0.659	rs10799701	chr1:21820990	A/G	cg20417195	chr1:21767127	NBPF3	0.41	7.52	0.33	2.94e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg18854424	chr1:2615690	NA	0.35	6.86	0.3	2.28e-11	Ulcerative colitis;
LGG	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg18252515	chr7:66147081	NA	-0.4	-6.78	-0.3	3.58e-11	Aortic root size;
LGG	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg24623649	chr8:11872141	NA	0.33	7.81	0.34	3.91e-14	Monocyte count;
LGG	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg06634786	chr22:41940651	POLR3H	0.73	11.63	0.48	1.37e-27	Vitiligo;
LGG	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg07636037	chr3:49044803	WDR6	0.6	10.5	0.44	2.92e-23	Resting heart rate;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.54e-37	Alzheimer's disease;
LGG	trans	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.81	-0.45	1.94e-24	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg14893161	chr1:205819251	PM20D1	0.88	20.66	0.69	1.1e-67	Menarche (age at onset);
LGG	cis	rs7166081	1.000	rs17526859	chr15:67611066	A/C	cg05925327	chr15:68127851	NA	0.32	6.78	0.3	3.78e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg17830980	chr10:43048298	ZNF37B	0.39	8.92	0.38	1.12e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg04111992	chr7:158790115	NA	-0.39	-7.69	-0.34	8.66e-14	Facial morphology (factor 20);
LGG	cis	rs11072805	1	rs11072805	chr15:79078518	T/C	cg00540400	chr15:79124168	NA	-0.37	-7.11	-0.31	4.45e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg18876405	chr7:65276391	NA	0.55	9.88	0.42	5.09e-21	Aortic root size;
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.74	-0.41	1.64e-20	Life satisfaction;
LGG	cis	rs10231759	0.617	rs4725947	chr7:150514529	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.39	8.85	0.38	1.9e-17	Height;
LGG	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.62	-0.41	4.33e-20	Response to antipsychotic treatment;
LGG	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22022881	chr2:105853494	NA	-0.38	-7.88	-0.34	2.28e-14	Type 2 diabetes;
LGG	cis	rs4740619	0.819	rs432452	chr9:15602068	A/T	cg14451791	chr9:16040625	NA	-0.33	-8.33	-0.36	9.37e-16	Body mass index;
LGG	cis	rs10911232	0.507	rs4652764	chr1:182994115	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs35306767	0.903	rs12763396	chr10:927357	C/A	cg25019033	chr10:957182	NA	-0.55	-10.15	-0.43	5.54e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs11785400	0.793	rs4430070	chr8:143729184	G/C	cg10596483	chr8:143751796	JRK	0.52	8.02	0.35	8.94e-15	Schizophrenia;
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.59	-0.33	1.78e-13	Menopause (age at onset);
LGG	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg15133208	chr4:90757351	SNCA	-0.37	-8.62	-0.37	1.05e-16	Dementia with Lewy bodies;
LGG	cis	rs11971779	0.648	rs6467852	chr7:139112591	A/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg07679836	chr6:33548423	BAK1	0.62	10.04	0.42	1.38e-21	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LGG	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg24634471	chr8:143751801	JRK	-0.5	-7.63	-0.33	1.38e-13	Schizophrenia;
LGG	cis	rs4731207	0.967	rs2267708	chr7:124392512	C/T	cg05630886	chr7:124431682	NA	0.31	7.4	0.33	6.46e-13	Cutaneous malignant melanoma;
LGG	cis	rs2213920	0.619	rs7870511	chr9:118196904	A/G	cg13918206	chr9:118159781	DEC1	0.63	8.93	0.38	1e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs4684776	0.932	rs4684786	chr3:11559087	T/C	cg24705426	chr3:11550659	ATG7	-0.47	-8.47	-0.37	3.37e-16	Small vessel stroke;
LGG	cis	rs6088590	0.687	rs6088580	chr20:33285053	G/C	cg24642439	chr20:33292090	TP53INP2	0.64	11.3	0.46	2.59e-26	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg07959490	chr17:80112427	CCDC57	-0.48	-9.31	-0.4	5.03e-19	Life satisfaction;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg14004847	chr7:1930337	MAD1L1	-0.57	-9.97	-0.42	2.51e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs9768139	0.733	rs56205111	chr7:158121055	T/C	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.33	-0.32	1.03e-12	Calcium levels;
LGG	cis	rs2985684	0.894	rs2883436	chr14:50013822	T/C	cg02151108	chr14:50098012	C14orf104	-0.39	-7.81	-0.34	3.84e-14	Carotid intima media thickness;
LGG	cis	rs3126085	0.877	rs4845742	chr1:152183949	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs1829883	0.931	rs7713876	chr5:98878187	C/G	cg08333243	chr5:99726346	NA	-0.4	-7.98	-0.35	1.16e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	16.54	0.61	1.25e-48	Obesity-related traits;
LGG	cis	rs526231	0.578	rs6876278	chr5:102249546	A/G	cg23492399	chr5:102201601	PAM	-0.61	-9.33	-0.4	4.51e-19	Primary biliary cholangitis;
LGG	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18876405	chr7:65276391	NA	0.49	8.78	0.38	3.14e-17	Aortic root size;
LGG	cis	rs9303401	0.659	rs34878689	chr17:56694330	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.64	0.56	3.84e-40	Cognitive test performance;
LGG	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg03929089	chr4:120376271	NA	-0.64	-8.07	-0.35	6.06e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.44	-0.33	4.98e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs9388451	0.874	rs13209968	chr6:126089285	G/C	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.61	-0.41	4.56e-20	Brugada syndrome;
LGG	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.18	0.36	2.83e-15	Aortic root size;
LGG	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg21775007	chr8:11205619	TDH	-0.47	-7.71	-0.34	7.65e-14	Morning vs. evening chronotype;
LGG	cis	rs4700695	0.719	rs27084	chr5:65435286	G/A	cg21114390	chr5:65439923	SFRS12	-0.72	-10.49	-0.44	3.15e-23	Facial morphology (factor 19);
LGG	cis	rs7215564	0.908	rs35821645	chr17:78652479	G/A	cg16980736	chr17:78789706	RPTOR	-0.63	-8.42	-0.36	4.75e-16	Myopia (pathological);
LGG	cis	rs509477	0.718	rs273363	chr18:32594703	A/G	cg23791764	chr18:32556832	MAPRE2	0.43	7.05	0.31	6.41e-12	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7582180	0.591	rs11674569	chr2:101010860	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.16	-0.49	1.03e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	0.790	rs4945290	chr11:78252249	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.13e-11	Alzheimer's disease (survival time);
LGG	cis	rs1109114	0.691	rs3887874	chr5:148621452	G/T	cg06539116	chr5:148597365	ABLIM3	-0.52	-12.53	-0.5	3.22e-31	Body mass index;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg26897989	chr16:1907736	C16orf73	-0.82	-13.84	-0.54	1.11e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg23894439	chr1:183413866	NA	-0.49	-9.14	-0.39	1.93e-18	Systemic lupus erythematosus;
LGG	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg21453758	chr17:80185943	SLC16A3	0.34	7.2	0.32	2.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs67133203	0.555	rs11169752	chr12:51580707	C/A	cg14688905	chr12:51403056	SLC11A2	0.57	8.29	0.36	1.23e-15	Urinary tract infection frequency;
LGG	cis	rs3096299	0.685	rs4785568	chr16:89553707	A/G	cg05484508	chr16:89589025	SPG7	0.46	7.32	0.32	1.12e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg11764359	chr7:65958608	NA	0.68	12.48	0.5	5.26e-31	Aortic root size;
LGG	cis	rs9549367	0.789	rs9549718	chr13:113909822	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-13.85	-0.54	9.16e-37	Platelet distribution width;
LGG	trans	rs1814175	0.645	rs7119101	chr11:49955665	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs514024	0.672	rs482095	chr9:130493513	A/G	cg13643465	chr9:130375613	STXBP1	0.6	11.13	0.46	1.14e-25	Eating disorders (purging via substances);
LGG	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg08392591	chr16:89556376	ANKRD11	0.6	9.66	0.41	3.05e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.72e-20	Aortic root size;
LGG	cis	rs34602589	0.778	rs62206432	chr20:43748038	A/G	cg10761708	chr20:43804764	PI3	0.73	10.69	0.44	5.53e-24	Parental longevity (mother's age at death);
LGG	cis	rs9951602	0.541	rs7243702	chr18:76645637	G/A	cg24134504	chr18:76639479	NA	-0.47	-8.31	-0.36	1.09e-15	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg02297831	chr4:17616191	MED28	0.5	9.42	0.4	2.12e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2455799	0.594	rs11128769	chr3:15926230	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-7.35	-0.32	9.13e-13	Mean platelet volume;
LGG	cis	rs6942756	0.747	rs692697	chr7:129112576	C/T	cg02491457	chr7:128862824	NA	0.61	11.2	0.46	6.46e-26	White matter hyperintensity burden;
LGG	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Calcium levels;
LGG	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg16141378	chr3:129829833	LOC729375	0.34	7.49	0.33	3.5e-13	Monocyte count;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	0.959	rs10497374	chr2:172640623	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.19	-0.78	5.4e-98	Schizophrenia;
LGG	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg18240062	chr17:79603768	NPLOC4	-0.75	-13.86	-0.54	8.37e-37	Eye color traits;
LGG	cis	rs7662987	0.517	rs2851286	chr4:100014976	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.49	-0.4	1.21e-19	Smoking initiation;
LGG	cis	rs4665809	1.000	rs4233708	chr2:26291345	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.81	-13.13	-0.52	1.02e-33	Gut microbiome composition (summer);
LGG	cis	rs787274	0.543	rs1324930	chr9:115634639	A/G	cg13803584	chr9:115635662	SNX30	0.66	10.1	0.42	8.21e-22	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7084402	0.935	rs10763559	chr10:60347410	C/T	cg07615347	chr10:60278583	BICC1	0.62	17.28	0.63	5.15e-52	Refractive error;
LGG	cis	rs8067287	0.688	rs58928848	chr17:16844876	G/A	cg26910001	chr17:16838321	NA	-0.4	-7.92	-0.35	1.74e-14	Diabetic kidney disease;
LGG	cis	rs975739	1.000	rs1766347	chr13:78387963	C/G	cg07847733	chr13:78271382	SLAIN1	-0.39	-6.9	-0.31	1.76e-11	Hair color;
LGG	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg26384229	chr12:38710491	ALG10B	0.93	23.26	0.73	7.69e-80	Heart rate;
LGG	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg08885076	chr2:99613938	TSGA10	-0.45	-8.29	-0.36	1.26e-15	Chronic sinus infection;
LGG	trans	rs7939886	0.920	rs11227868	chr11:56083905	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg27432699	chr2:27873401	GPN1	0.7	14.12	0.55	6.41e-38	Oral cavity cancer;
LGG	trans	rs5756813	1.000	rs5756813	chr22:38175477	A/C	cg19894588	chr14:64061835	NA	-0.68	-11.85	-0.48	1.78e-28	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07080220	chr10:102295463	HIF1AN	0.69	11.78	0.48	3.23e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg03877680	chr5:178157825	ZNF354A	-0.81	-13.03	-0.52	2.83e-33	Neutrophil percentage of white cells;
LGG	cis	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs67311347	1.000	rs73076035	chr3:40439881	G/C	cg13683864	chr3:40499215	RPL14	-1.13	-25.7	-0.77	3.65e-91	Renal cell carcinoma;
LGG	cis	rs11191205	0.645	rs11498776	chr10:103458566	A/G	cg15320455	chr10:103880129	LDB1	0.5	7.36	0.32	8.6e-13	Intelligence (multi-trait analysis);
LGG	cis	rs300774	0.925	rs300723	chr2:134131	C/T	cg04617936	chr2:214353	NA	-0.5	-7.67	-0.34	1.01e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs524281	1.000	rs475805	chr11:65848738	G/A	cg16950941	chr11:66035639	RAB1B	0.48	7.55	0.33	2.4e-13	Electroencephalogram traits;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg05861140	chr6:150128134	PCMT1	-0.35	-6.72	-0.3	5.24e-11	Lung cancer;
LGG	cis	rs7432375	0.901	rs7618518	chr3:136370092	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.55	-0.37	1.76e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg26513180	chr16:89883248	FANCA	1.02	9.81	0.41	8.98e-21	Skin colour saturation;
LGG	cis	rs7572733	0.555	rs7590828	chr2:198940251	A/G	cg00792783	chr2:198669748	PLCL1	-0.6	-9.76	-0.41	1.38e-20	Dermatomyositis;
LGG	trans	rs9693857	0.553	rs10100760	chr8:9370559	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.32	0.32	1.14e-12	Systolic blood pressure;
LGG	cis	rs9948	1.000	rs1320149	chr2:97493877	T/C	cg26665480	chr2:98280029	ACTR1B	-0.7	-7.48	-0.33	3.87e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg19168338	chr16:4465731	CORO7	-0.92	-17.75	-0.64	3.77e-54	Schizophrenia;
LGG	cis	rs10876993	0.821	rs1629032	chr12:58038686	C/T	cg18357645	chr12:58087776	OS9	0.67	12.08	0.49	2.09e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg00666640	chr1:248458726	OR2T12	-0.54	-9.04	-0.39	4.45e-18	Common traits (Other);
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.93	-0.45	6.77e-25	Lung cancer;
LGG	cis	rs35123781	0.654	rs356486	chr5:139085103	C/G	cg21230503	chr5:139085173	NA	-0.37	-8.37	-0.36	7.11e-16	Schizophrenia;
LGG	cis	rs8051149	0.625	rs876985	chr16:87882124	T/C	cg02614661	chr16:87878292	SLC7A5	-0.38	-7.16	-0.32	3.29e-12	Blood metabolite levels;
LGG	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg05527609	chr1:210001259	C1orf107	0.73	11.03	0.46	2.78e-25	Orofacial clefts;
LGG	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.99	-0.49	4.85e-29	Height;
LGG	cis	rs7077256	0.564	rs34204266	chr10:65110040	T/C	cg02276361	chr10:65351566	REEP3	-0.34	-6.91	-0.31	1.58e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	trans	rs6787172	0.702	rs1095635	chr3:157968239	C/A	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg11494091	chr17:61959527	GH2	0.99	24.14	0.75	6.1e-84	Prudent dietary pattern;
LGG	cis	rs137603	1.000	rs137603	chr22:39694225	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	-0.44	-7.44	-0.33	4.91e-13	Primary biliary cholangitis;
LGG	trans	rs7824557	0.767	rs10104728	chr8:11171300	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.61	-0.37	1.15e-16	Retinal vascular caliber;
LGG	cis	rs477895	0.653	rs7939784	chr11:63910153	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.17	0.46	8e-26	Mean platelet volume;
LGG	cis	rs4330281	0.647	rs4602424	chr3:17722619	A/T	cg20981856	chr3:17787350	NA	-0.4	-7.58	-0.33	1.95e-13	Schizophrenia;
LGG	cis	rs9487094	0.885	rs1590306	chr6:109680950	G/A	cg16315928	chr6:109776240	MICAL1	0.53	9.04	0.39	4.27e-18	Height;
LGG	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg25706552	chr1:244017396	NA	0.48	6.76	0.3	4.16e-11	RR interval (heart rate);
LGG	cis	rs17767392	1.000	rs61991205	chr14:71771921	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs9611565	0.559	rs739136	chr22:42100275	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-7.61	-0.33	1.53e-13	Vitiligo;
LGG	trans	rs7939886	0.841	rs79902631	chr11:55995241	A/C	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs12477438	0.520	rs7572660	chr2:99788582	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.1	0.62	3.51e-51	Chronic sinus infection;
LGG	cis	rs870825	0.616	rs57086463	chr4:185639525	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg21132104	chr15:45694354	SPATA5L1	0.71	10.48	0.44	3.26e-23	Homoarginine levels;
LGG	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.03	-0.35	8.03e-15	Total body bone mineral density;
LGG	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.83	0.38	2.12e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.98	0.42	2.17e-21	Height;
LGG	cis	rs6489785	0.775	rs1732405	chr12:121325031	G/A	cg02419362	chr12:121203948	SPPL3	-0.43	-6.79	-0.3	3.53e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9297145	0.509	rs13222381	chr7:98785024	T/G	cg05967295	chr7:98741636	SMURF1	-0.63	-11.17	-0.46	7.93e-26	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs11864453	0.786	rs1050362	chr16:72130815	C/A	cg01557791	chr16:72042693	DHODH	-0.56	-10.1	-0.42	8.38e-22	Fibrinogen levels;
LGG	cis	rs35306767	0.761	rs11253559	chr10:1044809	T/C	cg20503657	chr10:835505	NA	0.56	7.26	0.32	1.69e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs1814175	0.935	rs10839329	chr11:49694206	G/A	cg15704280	chr7:45808275	SEPT13	-1.05	-24.09	-0.75	9.8e-84	Height;
LGG	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg00294572	chr6:26285232	NA	0.39	6.8	0.3	3.32e-11	Educational attainment;
LGG	cis	rs9875589	0.509	rs1488377	chr3:14073178	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	10.51	0.44	2.61e-23	Ovarian reserve;
LGG	cis	rs62064224	0.791	rs11654833	chr17:30667728	C/T	cg12561776	chr17:30844705	MYO1D	-0.27	-6.85	-0.3	2.4e-11	Schizophrenia;
LGG	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg09461388	chr22:46763229	CELSR1	-0.71	-7.28	-0.32	1.47e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs73198271	0.562	rs76702427	chr8:8660141	G/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.36	0.36	7.34e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs694739	0.628	rs617051	chr11:64133638	C/A	cg02228329	chr11:64053129	BAD;GPR137	0.79	15.1	0.57	3.55e-42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.56	0.47	2.52e-27	Mean corpuscular volume;
LGG	cis	rs1577917	0.655	rs9444351	chr6:86247799	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.86	0.34	2.76e-14	Response to antipsychotic treatment;
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.3	-0.55	1.1e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20887711	chr4:1340912	KIAA1530	0.48	8.59	0.37	1.35e-16	Obesity-related traits;
LGG	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg17545662	chr6:170176663	C6orf70	0.69	8.68	0.37	6.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7084402	0.967	rs1427199	chr10:60274941	C/T	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.71e-12	Refractive error;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg17445987	chr19:10305305	DNMT1	0.43	6.99	0.31	9.75e-12	Corneal astigmatism;
LGG	cis	rs4732038	0.739	rs7812163	chr7:134231640	A/G	cg06906464	chr7:134288099	NA	0.48	11.23	0.46	4.6e-26	Longevity;
LGG	cis	rs9303401	0.632	rs7222087	chr17:57221619	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.49	8.23	0.36	1.94e-15	Cognitive test performance;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg02725872	chr8:58115012	NA	-0.84	-16.2	-0.6	4.53e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs6460942	0.778	rs74993124	chr7:12462917	A/G	cg06484146	chr7:12443880	VWDE	-0.36	-6.94	-0.31	1.32e-11	Coronary artery disease;
LGG	cis	rs12368653	0.651	rs2307097	chr12:58195801	T/C	cg02175503	chr12:58329896	NA	-0.44	-7.04	-0.31	7.03e-12	Multiple sclerosis;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18000306	chr6:288505	NA	0.46	8.43	0.36	4.35e-16	Menopause (age at onset);
LGG	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg08250081	chr4:10125330	NA	0.66	12.61	0.51	1.56e-31	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1263173	0.696	rs1263172	chr11:116680918	C/T	cg20608306	chr11:116969690	SIK3	0.26	6.69	0.3	6.32e-11	HDL cholesterol;
LGG	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22496380	chr5:211416	CCDC127	-1.23	-17.03	-0.62	7.28e-51	Breast cancer;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg18279126	chr7:2041391	MAD1L1	0.33	7.07	0.31	5.84e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10861342	1.000	rs11112359	chr12:105471661	C/A	cg23923672	chr12:105501055	KIAA1033	0.82	7.23	0.32	2.02e-12	IgG glycosylation;
LGG	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.19	0.36	2.5e-15	Aortic root size;
LGG	trans	rs78049276	0.736	rs72957606	chr4:148400011	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-7.64	-0.33	1.28e-13	Pulse pressure;
LGG	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.8	0.34	4.05e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	cis	rs883565	0.569	rs1274971	chr3:39161464	G/A	cg01426195	chr3:39028469	NA	-0.65	-14.08	-0.55	1.02e-37	Handedness;
LGG	cis	rs1475718	0.526	rs10785875	chr9:137122570	C/T	cg21243944	chr9:137118148	NA	-0.3	-7.64	-0.33	1.22e-13	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.43	-8.05	-0.35	7.12e-15	Schizophrenia;
LGG	trans	rs6598955	0.671	rs11247880	chr1:26568926	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.72	-0.51	5.34e-32	Obesity-related traits;
LGG	cis	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.49	0.69	7.04e-67	Primary sclerosing cholangitis;
LGG	cis	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07988820	chr12:82153109	PPFIA2	-0.73	-10.65	-0.44	7.6e-24	Resting heart rate;
LGG	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg16339924	chr4:17578868	LAP3	0.6	10.42	0.44	5.75e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg14500267	chr11:67383377	NA	-0.39	-6.79	-0.3	3.35e-11	Mean corpuscular volume;
LGG	cis	rs1577917	0.958	rs12198061	chr6:86550985	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.69e-30	Response to antipsychotic treatment;
LGG	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg18876405	chr7:65276391	NA	-0.56	-10.01	-0.42	1.75e-21	Aortic root size;
LGG	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.72	0.51	5.16e-32	Mean corpuscular hemoglobin;
LGG	cis	rs7582720	0.945	rs116773016	chr2:203811902	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9527	0.545	rs10883847	chr10:104958284	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.16e-12	Arsenic metabolism;
LGG	trans	rs1459104	0.789	rs12802739	chr11:54899892	A/G	cg15704280	chr7:45808275	SEPT13	0.78	7.74	0.34	6.5e-14	Body mass index;
LGG	trans	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg12045294	chr17:78518616	RPTOR	-0.47	-7.28	-0.32	1.44e-12	Glycated hemoglobin levels;
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg06108461	chr20:60628389	TAF4	0.67	9.87	0.42	5.55e-21	Obesity-related traits;
LGG	cis	rs73198271	0.531	rs3827812	chr8:8654898	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.13	0.35	3.99e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.4	-0.33	6.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg24575275	chr7:1094737	C7orf50	-0.39	-7.29	-0.32	1.36e-12	Longevity;Endometriosis;
LGG	cis	rs2456568	0.548	rs10765647	chr11:93662459	T/C	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg01145232	chr6:150245071	RAET1G	0.4	7.54	0.33	2.58e-13	Testicular germ cell tumor;
LGG	cis	rs12701220	0.655	rs11489405	chr7:1139892	C/G	cg00990874	chr7:1149470	C7orf50	-0.8	-14.06	-0.55	1.21e-37	Bronchopulmonary dysplasia;
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.94	-0.31	1.37e-11	Iron status biomarkers;
LGG	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg04691961	chr3:161091175	C3orf57	-0.49	-10.59	-0.44	1.31e-23	Morning vs. evening chronotype;
LGG	cis	rs7084402	0.967	rs1649028	chr10:60280428	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs6663390	0.510	rs2300055	chr1:208065380	C/T	cg03990033	chr1:208084030	CD34	0.6	7.61	0.33	1.58e-13	Facial morphology (factor 18);
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs778371	1.000	rs778371	chr2:233743109	A/G	cg25237894	chr2:233734115	C2orf82	-0.43	-6.88	-0.3	1.91e-11	Schizophrenia;
LGG	cis	rs4936894	0.500	rs4935875	chr11:124130019	G/C	cg27160556	chr11:124181099	OR8D1	-0.44	-10.27	-0.43	1.98e-22	Aging (time to death);
LGG	cis	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg19338460	chr6:170058176	WDR27	-0.83	-9.75	-0.41	1.46e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1348850	0.874	rs4893822	chr2:178285727	G/T	cg27490568	chr2:178487706	NA	0.56	10.96	0.45	5.14e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9362426	0.524	rs9353480	chr6:88068616	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	-1.02	-16.55	-0.61	1.12e-48	Depressive episodes in bipolar disorder;
LGG	cis	rs4242434	0.597	rs4066629	chr8:22529073	A/C	cg19455335	chr8:22457658	C8orf58	0.4	8.14	0.35	3.63e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg24642844	chr7:1081250	C7orf50	-0.45	-8.54	-0.37	1.9e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs57590327	0.503	rs6802480	chr3:81906671	G/A	cg07356753	chr3:81810745	GBE1	-0.46	-7.35	-0.32	8.91e-13	Extraversion;
LGG	cis	rs113835537	0.597	rs57288351	chr11:66307489	C/T	cg24851651	chr11:66362959	CCS	0.46	7.8	0.34	4.22e-14	Airway imaging phenotypes;
LGG	cis	rs17428076	0.751	rs1008152	chr2:172912090	A/G	cg21435375	chr2:172878103	MAP1D	0.46	9.73	0.41	1.74e-20	Myopia;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.33	0.4	4.29e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.850	rs34033205	chr16:89922959	G/T	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.29	-0.63	5.07e-52	Skin colour saturation;
LGG	cis	rs9549367	0.774	rs2287246	chr13:113889127	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.72	-0.38	4.94e-17	Platelet distribution width;
LGG	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg04469686	chr1:162760199	HSD17B7	-0.39	-6.66	-0.3	7.91e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9948	0.786	rs6756482	chr2:97458561	A/G	cg26665480	chr2:98280029	ACTR1B	-0.64	-6.91	-0.31	1.6e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs981844	0.922	rs75543972	chr4:154664792	G/C	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	7.87e-27	Response to statins (LDL cholesterol change);
LGG	trans	rs1941687	0.672	rs1026257	chr18:31418131	C/T	cg27147174	chr7:100797783	AP1S1	0.51	8.64	0.37	8.94e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs2270927	1.000	rs31243	chr5:75594360	A/G	cg13563193	chr19:33072644	PDCD5	0.78	10.38	0.43	7.87e-23	Mean corpuscular volume;
LGG	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg21665744	chr7:39171113	POU6F2	0.4	8.02	0.35	8.65e-15	IgG glycosylation;
LGG	cis	rs9398803	0.687	rs6569469	chr6:127008431	C/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.53	-0.41	8.61e-20	Male-pattern baldness;
LGG	cis	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.52e-22	Diabetic kidney disease;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.48	0.37	2.99e-16	Obesity-related traits;
LGG	cis	rs2842992	0.830	rs2025189	chr6:160137518	C/T	cg11366901	chr6:160182831	ACAT2	1.04	16.83	0.62	6.43e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs941408	1.000	rs1076447	chr19:2792128	C/G	cg06609049	chr19:2785107	THOP1	0.62	9.65	0.41	3.37e-20	Total cholesterol levels;
LGG	cis	rs6456156	0.774	rs1556413	chr6:167524743	G/A	cg07741184	chr6:167504864	NA	-0.31	-6.83	-0.3	2.74e-11	Primary biliary cholangitis;
LGG	cis	rs12643440	0.538	rs16894428	chr4:17142974	A/G	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg14346243	chr4:90757452	SNCA	-0.34	-6.85	-0.3	2.43e-11	Dementia with Lewy bodies;
LGG	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg02574844	chr11:5959923	NA	-0.58	-10.61	-0.44	1.1e-23	DNA methylation (variation);
LGG	cis	rs1318772	0.577	rs9326899	chr5:112972120	C/A	cg12552261	chr5:112820674	MCC	0.58	6.92	0.31	1.47e-11	F-cell distribution;
LGG	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg14675211	chr2:100938903	LONRF2	0.63	11.13	0.46	1.19e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	9.55	0.41	7.81e-20	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.48	-0.44	3.3e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg27411982	chr8:10470053	RP1L1	0.39	6.73	0.3	4.97e-11	Retinal vascular caliber;
LGG	cis	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg27411982	chr8:10470053	RP1L1	-0.46	-7.95	-0.35	1.48e-14	Neuroticism;
LGG	cis	rs7444	0.941	rs11089629	chr22:21958872	T/G	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg06074448	chr4:187884817	NA	0.59	13.23	0.52	3.89e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	9.95	0.42	2.93e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs752010	0.574	rs10890161	chr1:42121623	T/C	cg06885757	chr1:42089581	HIVEP3	0.49	10.95	0.45	5.51e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9354308	0.764	rs4710550	chr6:66612442	T/G	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs7582720	1.000	rs72936326	chr2:204054141	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.42	0.4	2.21e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2282300	0.739	rs1222216	chr11:30346052	C/T	cg25418670	chr11:30344373	C11orf46	-0.57	-7.89	-0.34	2.18e-14	Morning vs. evening chronotype;
LGG	cis	rs528418	0.592	rs7756319	chr6:145670668	C/G	cg03642472	chr6:145670687	NA	0.55	7.12	0.31	4.09e-12	Methadone dose in opioid dependence;
LGG	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg25554036	chr4:6271136	WFS1	0.51	8.34	0.36	8.72e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10463554	0.963	rs34381	chr5:102396556	C/T	cg23492399	chr5:102201601	PAM	-0.53	-7.83	-0.34	3.42e-14	Parkinson's disease;
LGG	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.12	0.31	4.12e-12	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7582720	1.000	rs72934749	chr2:203746816	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs1814175	0.646	rs61904497	chr11:49883449	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs1014246	0.826	rs7921785	chr10:118470658	G/C	cg14919929	chr10:118506882	NA	-0.63	-12.67	-0.51	8.29e-32	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7582720	1.000	rs72932784	chr2:203698470	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.69	0.41	2.38e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs17767392	0.881	rs7152674	chr14:72016613	G/T	cg02058870	chr14:72053146	SIPA1L1	-0.43	-8.85	-0.38	1.88e-17	Mitral valve prolapse;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12188830	chr3:57741926	SLMAP	0.44	7.03	0.31	7.47e-12	Cognitive performance;
LGG	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg03806693	chr22:41940476	POLR3H	-0.54	-8.26	-0.36	1.55e-15	Neuroticism;
LGG	cis	rs10937275	0.826	rs34695488	chr3:186644463	A/G	cg16751732	chr3:186648392	ST6GAL1	0.7	6.99	0.31	9.37e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg13939156	chr17:80058883	NA	0.55	11.23	0.46	4.96e-26	Life satisfaction;
LGG	cis	rs9443189	0.813	rs2842556	chr6:76447204	T/C	cg01950844	chr6:76311363	SENP6	-0.53	-6.99	-0.31	9.39e-12	Prostate cancer;
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg10189774	chr4:17578691	LAP3	0.42	7.51	0.33	3.13e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.73	-0.3	5e-11	Mood instability;
LGG	cis	rs68170813	0.559	rs7793594	chr7:106891829	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.7	-0.45	5.18e-24	Coronary artery disease;
LGG	cis	rs7493	1.000	rs17166875	chr7:95041271	C/T	cg08461772	chr7:95026248	PON3	0.39	8.41	0.36	5.3e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg09699651	chr6:150184138	LRP11	0.52	9.4	0.4	2.62e-19	Lung cancer;
LGG	cis	rs7769051	0.522	rs60133731	chr6:133095818	T/C	cg07930552	chr6:133119739	C6orf192	1.16	10.58	0.44	1.46e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg11742103	chr11:62369870	EML3;MTA2	-0.55	-12.86	-0.51	1.37e-32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.19	-0.32	2.56e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11875185	0.588	rs79476889	chr18:55640451	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11969893	0.850	rs9791284	chr6:101353886	G/A	cg12253828	chr6:101329408	ASCC3	1.15	8.66	0.37	7.86e-17	Economic and political preferences (immigration/crime);
LGG	trans	rs9467711	0.651	rs35402046	chr6:26099472	G/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.05	-0.31	6.71e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9358372	0.574	rs6925153	chr6:20803687	G/A	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.4	-0.4	2.48e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2486288	0.656	rs7166580	chr15:45571209	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.94	-0.45	6.43e-25	Glomerular filtration rate;
LGG	cis	rs892961	0.899	rs3650	chr17:75415835	T/C	cg05865280	chr17:75406074	SEPT9	0.41	9.41	0.4	2.42e-19	Airflow obstruction;
LGG	cis	rs4919087	0.683	rs11189121	chr10:99072036	T/C	cg25902810	chr10:99078978	FRAT1	-0.41	-7.11	-0.31	4.37e-12	Monocyte count;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.23	0.58	9.18e-43	Platelet count;
LGG	cis	rs4363385	0.693	rs582345	chr1:153033406	G/A	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.53	0.44	2.12e-23	Diabetic retinopathy;
LGG	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.45	0.33	4.75e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs703842	0.616	rs871871	chr12:58219681	G/A	cg02175503	chr12:58329896	NA	0.5	8.16	0.35	3.11e-15	Multiple sclerosis;
LGG	cis	rs17376456	0.877	rs28539612	chr5:93499099	C/T	cg21475434	chr5:93447410	FAM172A	0.72	7.37	0.32	7.95e-13	Diabetic retinopathy;
LGG	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.02	-0.49	3.69e-29	Height;
LGG	cis	rs5758659	0.714	rs5751220	chr22:42516205	A/C	cg15128208	chr22:42549153	NA	0.51	10.33	0.43	1.15e-22	Cognitive function;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg00409905	chr10:38381863	ZNF37A	0.47	7.05	0.31	6.7e-12	Obesity (extreme);
LGG	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg15704280	chr7:45808275	SEPT13	-1.0	-21.96	-0.71	9.16e-74	Height;
LGG	cis	rs7084402	0.967	rs1623568	chr10:60320446	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.31e-12	Refractive error;
LGG	cis	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg09021430	chr5:549028	NA	-0.82	-12.79	-0.51	2.73e-32	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22945302	chr1:26606601	SH3BGRL3	0.47	7.21	0.32	2.26e-12	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.629	rs12991172	chr2:100941671	A/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11711311	1.000	rs10934243	chr3:113430239	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.56	-0.33	2.17e-13	IgG glycosylation;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.32	0.4	4.89e-19	Schizophrenia;
LGG	cis	rs7772486	0.686	rs9390357	chr6:146129347	A/G	cg23711669	chr6:146136114	FBXO30	0.4	6.73	0.3	5.05e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs758324	0.812	rs13170176	chr5:131138736	G/C	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.41e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs28735056	0.592	rs10853392	chr18:77708781	A/G	cg05926928	chr17:57297772	GDPD1	-0.53	-9.1	-0.39	2.76e-18	Schizophrenia;
LGG	cis	rs897080	0.515	rs4953088	chr2:44564518	C/T	cg00619915	chr2:44497795	NA	0.49	6.89	0.31	1.79e-11	Height;
LGG	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg13298116	chr11:62369859	EML3;MTA2	-0.58	-13.49	-0.53	3.18e-35	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13641692	chr5:176730160	RAB24;PRELID1	-0.41	-6.7	-0.3	5.93e-11	Pancreatic cancer;
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.3	-0.36	1.13e-15	Total body bone mineral density;
LGG	cis	rs1318772	1.000	rs458055	chr5:112799883	C/T	cg12552261	chr5:112820674	MCC	-0.71	-7.93	-0.35	1.69e-14	F-cell distribution;
LGG	cis	rs7215564	0.822	rs10871488	chr17:78739079	T/C	cg06153925	chr17:78755379	RPTOR	-0.41	-7.25	-0.32	1.79e-12	Myopia (pathological);
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg14092988	chr3:52407081	DNAH1	-0.29	-7.68	-0.34	9.75e-14	Electroencephalogram traits;
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs3540	0.557	rs11634314	chr15:91042066	A/C	cg22089800	chr15:90895588	ZNF774	-0.67	-12.17	-0.49	9.08e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6694672	1.000	rs857020	chr1:197017473	C/T	cg13682187	chr1:196946512	CFHR5	0.52	7.3	0.32	1.25e-12	Asthma;
LGG	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg19980929	chr12:42632907	YAF2	0.35	7.81	0.34	3.93e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs12517041	1.000	rs6452110	chr5:23299802	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs4330281	0.608	rs11128841	chr3:17721451	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.58	-0.33	1.95e-13	Schizophrenia;
LGG	cis	rs10791097	0.748	rs4937580	chr11:130734270	T/C	cg12179176	chr11:130786555	SNX19	0.83	17.54	0.63	3.59e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs1595825	0.891	rs58111212	chr2:198889896	T/C	cg00982548	chr2:198649783	BOLL	-0.5	-6.82	-0.3	2.77e-11	Ulcerative colitis;
LGG	cis	rs67311347	1.000	rs73078123	chr3:40458963	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.67	0.3	7.28e-11	Renal cell carcinoma;
LGG	cis	rs2073499	0.935	rs2526394	chr3:50189057	T/C	cg03645007	chr3:50255295	SLC38A3	-0.61	-7.02	-0.31	7.79e-12	Schizophrenia;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18053345	chr5:37370947	NUP155	0.48	7.54	0.33	2.42e-13	Gut microbiome composition (summer);
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg01423820	chr14:77228690	VASH1	0.41	6.9	0.31	1.76e-11	Prudent dietary pattern;
LGG	cis	rs8013055	0.846	rs10139300	chr14:105974501	A/G	cg25008857	chr14:105974488	NA	0.57	10.24	0.43	2.52e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.81	0.64	2.07e-54	Alzheimer's disease;
LGG	cis	rs3784262	0.512	rs4646571	chr15:58343137	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.07	-0.31	5.57e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21452766	chr1:70877088	CTH	-0.44	-7.45	-0.33	4.64e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9868809	0.772	rs12107418	chr3:48689787	A/G	cg00383909	chr3:49044727	WDR6	0.77	9.54	0.41	8.26e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9487094	0.645	rs1322818	chr6:109691101	A/G	cg01125227	chr6:109776195	MICAL1	0.45	7.01	0.31	8.28e-12	Height;
LGG	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.81	-0.34	3.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2953174	1.000	rs2975754	chr2:241522634	G/A	cg07929629	chr2:241523174	NA	0.58	7.09	0.31	5.15e-12	Bipolar disorder;
LGG	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg08344181	chr3:125677491	NA	-0.91	-9.4	-0.4	2.47e-19	Depression;
LGG	cis	rs2839186	0.708	rs6518285	chr21:47644667	T/C	cg11766577	chr21:47581405	C21orf56	-0.56	-10.34	-0.43	1.09e-22	Testicular germ cell tumor;
LGG	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.59	0.37	1.33e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12493885	0.628	rs61790905	chr3:153653032	A/G	cg17054900	chr3:154042577	DHX36	-0.58	-7.3	-0.32	1.31e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2839186	0.732	rs8131458	chr21:47694712	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-8.6	-0.37	1.29e-16	Testicular germ cell tumor;
LGG	cis	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.25e-11	Obesity-related traits;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.96	-0.42	2.61e-21	Lung cancer;
LGG	cis	rs4808199	0.895	rs2163805	chr19:19575945	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.66	0.34	1.13e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg20608306	chr11:116969690	SIK3	0.35	10.58	0.44	1.38e-23	Blood protein levels;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	trans	rs7647973	0.626	rs4855846	chr3:49683526	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs6088590	0.931	rs12625149	chr20:33425812	A/C	cg06115741	chr20:33292138	TP53INP2	-0.54	-8.31	-0.36	1.05e-15	Coronary artery disease;
LGG	cis	rs66887589	0.616	rs11732621	chr4:120212883	A/C	cg09307838	chr4:120376055	NA	0.48	7.96	0.35	1.35e-14	Diastolic blood pressure;
LGG	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9902453	0.899	rs8067580	chr17:28471248	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.59	0.53	1.2e-35	Coffee consumption (cups per day);
LGG	cis	rs4356932	0.967	rs12509593	chr4:76987746	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.78	-0.3	3.76e-11	Blood protein levels;
LGG	trans	rs6787172	0.702	rs827101	chr3:157998142	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs12291225	0.585	rs34171876	chr11:14353957	G/C	cg19336497	chr11:14380999	RRAS2	-0.63	-13.35	-0.53	1.3e-34	Sense of smell;
LGG	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg17376030	chr22:41985996	PMM1	0.62	10.04	0.42	1.33e-21	Vitiligo;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg13395646	chr4:1353034	KIAA1530	-0.6	-10.47	-0.44	3.76e-23	Obesity-related traits;
LGG	trans	rs10028773	0.515	rs9994488	chr4:120587781	C/T	cg25214090	chr10:38739885	LOC399744	0.48	8.04	0.35	7.58e-15	Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24306779	chr16:58060336	MMP15	0.49	7.39	0.32	7.05e-13	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.967	rs12602258	chr17:28317657	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.4	0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg00426182	chr6:28072559	NA	0.93	6.96	0.31	1.21e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6089584	0.850	rs6142938	chr20:60627723	A/C	cg06470251	chr20:60548479	NA	0.49	8.01	0.35	9.67e-15	Body mass index;
LGG	cis	rs11190604	0.767	rs10883477	chr10:102161396	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	10.18	0.43	4.35e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg00490583	chr16:1843685	IGFALS	-0.43	-7.15	-0.32	3.47e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs72827839	0.740	rs10514938	chr17:46322604	A/T	cg02219949	chr17:45927392	SP6	0.52	7.74	0.34	6.08e-14	Ease of getting up in the morning;
LGG	cis	rs4478858	0.647	rs4949380	chr1:31764160	A/G	cg19084893	chr1:31688959	NA	0.31	6.69	0.3	6.65e-11	Alcohol dependence;
LGG	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg03098644	chr7:100410630	EPHB4	0.47	6.99	0.31	9.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7635838	0.617	rs347587	chr3:11287155	A/G	cg00170343	chr3:11313890	ATG7	-0.55	-9.6	-0.41	4.95e-20	HDL cholesterol;
LGG	cis	rs2180341	0.618	rs12199451	chr6:127597780	C/G	cg24812749	chr6:127587940	RNF146	0.63	10.51	0.44	2.5e-23	Breast cancer;
LGG	cis	rs79387448	0.638	rs7600961	chr2:103035455	G/A	cg20060108	chr2:102954350	IL1RL1	-0.45	-6.82	-0.3	2.82e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg18446336	chr7:2847575	GNA12	-0.31	-8.2	-0.36	2.46e-15	Height;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.58	10.58	0.44	1.36e-23	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.93	-0.31	1.44e-11	Menopause (age at onset);
LGG	cis	rs58688157	0.705	rs12290989	chr11:615010	G/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.46	-0.4	1.58e-19	Systemic lupus erythematosus;
LGG	cis	rs6450176	0.638	rs3822497	chr5:53299693	C/G	ch.5.1024479R	chr5:53302184	ARL15	-1.07	-16.44	-0.61	3.45e-48	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs4731207	0.596	rs12533918	chr7:124647263	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06739520	chr20:5891968	CHGB	0.46	7.08	0.31	5.44e-12	Gut microbiome composition (summer);
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.22	-0.39	1.09e-18	Personality dimensions;
LGG	trans	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg06521331	chr12:34319734	NA	0.43	7.73	0.34	6.89e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9467160	1.000	rs9467158	chr6:24441215	G/A	cg20631270	chr6:24437470	GPLD1	0.53	7.67	0.34	1.01e-13	Liver enzyme levels;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg08888203	chr3:10149979	C3orf24	0.58	9.77	0.41	1.22e-20	Alzheimer's disease;
LGG	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	7.72	0.34	7.37e-14	Schizophrenia;
LGG	cis	rs283228	1.000	rs2852496	chr6:101827251	C/T	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs875971	0.545	rs10950027	chr7:65634151	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.35	0.43	1.03e-22	Aortic root size;
LGG	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg07677032	chr17:61819896	STRADA	0.66	12.09	0.49	1.96e-29	Prudent dietary pattern;
LGG	cis	rs17023223	0.581	rs61808932	chr1:119643820	T/C	cg05756136	chr1:119680316	WARS2	-0.42	-7.75	-0.34	5.96e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg12310025	chr6:25882481	NA	-0.41	-7.35	-0.32	9.18e-13	Height;
LGG	cis	rs9393692	0.599	rs9358920	chr6:26292029	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.38	-0.4	2.97e-19	Educational attainment;
LGG	cis	rs3799379	0.550	rs9467736	chr6:26380032	A/G	cg12826209	chr6:26865740	GUSBL1	0.46	7.25	0.32	1.71e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.539	rs7699776	chr4:122753885	A/G	cg20573242	chr4:122745356	CCNA2	0.55	10.17	0.43	4.5e-22	Type 2 diabetes;
LGG	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg24209194	chr3:40518798	ZNF619	0.44	6.86	0.3	2.18e-11	Renal cell carcinoma;
LGG	cis	rs7010267	0.596	rs7013203	chr8:120017159	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.33	-8.53	-0.37	2.13e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs4742903	0.584	rs57737671	chr9:107006652	G/C	cg14250997	chr9:106856677	SMC2	0.35	7.05	0.31	6.63e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs11608355	0.545	rs11613023	chr12:109898047	T/C	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs62238980	0.614	rs117185558	chr22:32403523	A/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs12519773	0.525	rs57542119	chr5:92538853	T/C	cg18783429	chr5:92414398	NA	0.32	7.76	0.34	5.42e-14	Migraine;
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg27400746	chr16:89904261	SPIRE2	-0.71	-10.89	-0.45	9.61e-25	Skin colour saturation;
LGG	cis	rs2204008	0.720	rs11181343	chr12:38323616	G/T	cg13010199	chr12:38710504	ALG10B	0.7	14.15	0.55	4.95e-38	Bladder cancer;
LGG	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg01194073	chr14:101175302	NA	0.46	7.36	0.32	8.38e-13	Plateletcrit;
LGG	cis	rs367943	1.000	rs348946	chr5:112822814	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24903225	chr12:108956097	SART3;ISCU	-0.53	-7.88	-0.34	2.36e-14	Systemic lupus erythematosus;
LGG	cis	rs7666738	0.830	rs2865977	chr4:99017916	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.75	13.81	0.54	1.44e-36	Lymphocyte counts;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg06112835	chr11:68658793	MRPL21	-0.61	-10.44	-0.44	4.54e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs701145	0.585	rs1727940	chr3:153827257	C/G	cg12800244	chr3:153838788	SGEF	0.78	8.47	0.37	3.33e-16	Coronary artery disease;
LGG	trans	rs11989744	0.957	rs61099147	chr8:23573953	A/G	cg03492747	chr16:86543808	FOXF1	0.52	7.63	0.33	1.4e-13	Waist-hip ratio;
LGG	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg05677249	chr15:77158041	SCAPER	-0.32	-6.96	-0.31	1.17e-11	Blood metabolite levels;
LGG	trans	rs7615952	1.000	rs9289275	chr3:125648659	A/T	cg07211511	chr3:129823064	LOC729375	-1.32	-20.78	-0.69	3.07e-68	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs12681366	0.663	rs2919665	chr8:95465375	G/A	cg13257157	chr8:95487014	RAD54B	0.38	6.92	0.31	1.5e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6977660	0.943	rs10240816	chr7:19819620	A/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.44	0.33	4.79e-13	Thyroid stimulating hormone;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.61e-14	Lung cancer;
LGG	cis	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg09764611	chr12:132620959	NA	-0.57	-8.52	-0.37	2.3e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs4650994	1.000	rs10798615	chr1:178513895	T/G	cg19399532	chr1:178512495	C1orf220	0.43	8.36	0.36	7.39e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs62400317	0.859	rs10456121	chr6:45092545	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.25	-0.43	2.32e-22	Total body bone mineral density;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg20607798	chr8:58055168	NA	0.63	7.32	0.32	1.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11785400	1.000	rs754957	chr8:143746416	A/G	cg24634471	chr8:143751801	JRK	0.53	8.43	0.36	4.4e-16	Schizophrenia;
LGG	cis	rs6964587	0.967	rs4626516	chr7:91807153	G/C	cg17063962	chr7:91808500	NA	0.55	9.85	0.42	6.79e-21	Breast cancer;
LGG	cis	rs31872	1.000	rs31872	chr5:140372222	A/G	cg19650706	chr5:140594406	PCDHB13	-0.47	-7.95	-0.35	1.48e-14	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs2075371	0.611	rs1862045	chr7:134023412	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	8.07	0.35	5.94e-15	Mean platelet volume;
LGG	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg13010199	chr12:38710504	ALG10B	0.55	9.75	0.41	1.51e-20	Resting heart rate;
LGG	cis	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg21775007	chr8:11205619	TDH	-0.47	-7.61	-0.33	1.51e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4696584	0.816	rs1490652	chr4:155407089	G/A	cg13738195	chr4:155413469	DCHS2	-0.38	-7.75	-0.34	5.98e-14	Folding of antihelix;
LGG	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.89	-0.34	2.24e-14	Aortic root size;
LGG	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg18446336	chr7:2847575	GNA12	-0.33	-8.56	-0.37	1.66e-16	Height;
LGG	cis	rs2153535	0.541	rs9505456	chr6:8479001	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs12421382	0.543	rs10890996	chr11:109328421	A/G	cg15948088	chr11:109293068	C11orf87	-0.81	-15.46	-0.58	8.69e-44	Schizophrenia;
LGG	cis	rs10089	0.903	rs6862701	chr5:127391249	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.44	0.47	7.49e-27	Ileal carcinoids;
LGG	cis	rs3820068	0.581	rs16849152	chr1:15921774	A/C	cg05660106	chr1:15850417	CASP9	0.86	17.7	0.64	6.49e-54	Systolic blood pressure;
LGG	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.27	-0.36	1.39e-15	Retinal vascular caliber;
LGG	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg07274523	chr3:49395745	GPX1	0.58	9.62	0.41	4.44e-20	Educational attainment;
LGG	cis	rs10267417	0.544	rs2072185	chr7:19748700	G/A	cg05791153	chr7:19748676	TWISTNB	1.29	25.21	0.76	6.93e-89	Night sleep phenotypes;
LGG	cis	rs7765175	0.598	rs2842818	chr6:113643678	G/T	cg26552650	chr6:113682475	NA	0.34	7.51	0.33	2.97e-13	Coronary artery calcification;
LGG	cis	rs17102423	0.594	rs4902360	chr14:65546722	A/C	cg16583315	chr14:65563665	MAX	-0.42	-8.8	-0.38	2.66e-17	Obesity-related traits;
LGG	cis	rs9814567	1.000	rs3932818	chr3:134206069	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.37	-0.53	1.06e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs9972944	0.729	rs1541609	chr17:63773564	G/A	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs8067545	0.750	rs11869616	chr17:19992713	G/A	cg13482628	chr17:19912719	NA	0.63	12.61	0.51	1.57e-31	Schizophrenia;
LGG	cis	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.54	0.37	1.95e-16	Mean corpuscular volume;
LGG	cis	rs72634258	0.842	rs4908727	chr1:8163122	C/T	cg00042356	chr1:8021962	PARK7	0.54	7.37	0.32	7.72e-13	Inflammatory bowel disease;
LGG	cis	rs3816183	1.000	rs3816184	chr2:43015757	A/G	cg27299406	chr2:43020013	HAAO	0.27	6.68	0.3	6.66e-11	Hypospadias;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.18e-20	Aortic root size;
LGG	cis	rs4820539	1.000	rs2157710	chr22:23457486	C/T	cg14186256	chr22:23484241	RTDR1	0.97	24.38	0.75	4.81e-85	Bone mineral density;
LGG	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg13010199	chr12:38710504	ALG10B	-0.56	-10.68	-0.44	6.18e-24	Morning vs. evening chronotype;
LGG	cis	rs988958	0.675	rs111621311	chr2:42219214	T/G	cg27428208	chr2:42229179	NA	0.53	9.39	0.4	2.82e-19	Hypospadias;
LGG	cis	rs10911232	0.507	rs5022057	chr1:182997761	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs2952156	0.920	rs907090	chr17:37833632	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.39	-0.61	6.21e-48	Asthma;
LGG	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg05484508	chr16:89589025	SPG7	0.53	8.37	0.36	6.66e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs4843747	0.671	rs13334603	chr16:88116016	T/C	cg09044154	chr16:88155775	NA	-0.5	-7.54	-0.33	2.5e-13	Menopause (age at onset);
LGG	cis	rs9394152	0.845	rs4713632	chr6:33472990	G/T	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.75e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg07362569	chr17:61921086	SMARCD2	-0.38	-6.99	-0.31	9.86e-12	Prudent dietary pattern;
LGG	cis	rs12220238	1.000	rs10824105	chr10:75952881	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.15	0.46	9.44e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4740619	0.507	rs10962251	chr9:16012225	C/A	cg14451791	chr9:16040625	NA	0.28	6.87	0.3	2.14e-11	Body mass index;
LGG	trans	rs2562456	0.834	rs2650848	chr19:21586637	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.48e-13	Pain;
LGG	cis	rs10875746	0.669	rs11168499	chr12:48662670	A/G	cg24011408	chr12:48396354	COL2A1	-0.58	-7.49	-0.33	3.47e-13	Longevity (90 years and older);
LGG	cis	rs2712184	0.967	rs2541385	chr2:217669595	C/T	cg05032264	chr2:217675019	NA	-0.53	-12.52	-0.5	3.56e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg16434002	chr17:42200994	HDAC5	0.47	8.32	0.36	9.73e-16	Total body bone mineral density;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg13939156	chr17:80058883	NA	-0.46	-9.0	-0.39	5.88e-18	Life satisfaction;
LGG	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg15269541	chr15:43626905	ADAL	-0.45	-7.83	-0.34	3.46e-14	Lung cancer in ever smokers;
LGG	cis	rs796364	0.951	rs281776	chr2:200834282	T/G	cg17644776	chr2:200775616	C2orf69	0.58	7.15	0.32	3.33e-12	Schizophrenia;
LGG	cis	rs7481584	1.000	rs12804412	chr11:3020782	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.32	-0.36	1.02e-15	Calcium levels;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg16141378	chr3:129829833	LOC729375	0.43	9.91	0.42	4.08e-21	Neuroticism;
LGG	cis	rs6547741	0.935	rs6761095	chr2:27778010	G/T	cg22903471	chr2:27725779	GCKR	0.36	8.19	0.36	2.59e-15	Oral cavity cancer;
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg07511668	chr11:68622177	NA	0.48	9.09	0.39	2.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6933660	0.745	rs9397405	chr6:151736084	G/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	15.21	0.58	1.14e-42	Menarche (age at onset);
LGG	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg26384229	chr12:38710491	ALG10B	0.71	14.23	0.55	2.21e-38	Morning vs. evening chronotype;
LGG	cis	rs63406760	1	rs63406760	chr12:123742692	TG/T	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	9.98e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs240764	0.817	rs239206	chr6:101137332	T/G	cg09795085	chr6:101329169	ASCC3	0.45	7.57	0.33	1.99e-13	Neuroticism;
LGG	cis	rs4788570	0.615	rs4788550	chr16:71720523	C/T	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.79	0.34	4.39e-14	Prudent dietary pattern;
LGG	cis	rs35123781	1.000	rs12108986	chr5:139068126	C/G	cg21230503	chr5:139085173	NA	0.33	7.76	0.34	5.33e-14	Schizophrenia;
LGG	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs6964587	0.708	rs38800	chr7:92046191	C/G	cg17063962	chr7:91808500	NA	-0.41	-7.02	-0.31	7.92e-12	Breast cancer;
LGG	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	12.33	0.5	2.06e-30	Mean platelet volume;
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	cis	rs1348850	0.757	rs4893969	chr2:178478476	T/A	cg27490568	chr2:178487706	NA	0.54	10.79	0.45	2.39e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9467711	0.659	rs72844462	chr6:26563864	A/C	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6076065	0.748	rs2424542	chr20:23386800	C/T	cg11657817	chr20:23433608	CST11	0.4	8.21	0.36	2.21e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs67478160	0.643	rs7156697	chr14:104211136	G/A	cg26031613	chr14:104095156	KLC1	-0.44	-7.25	-0.32	1.72e-12	Schizophrenia;
LGG	cis	rs2901331	0.533	rs35433415	chr2:125419087	T/C	cg07771321	chr2:125368595	CNTNAP5	-0.46	-8.07	-0.35	6.19e-15	Response to statin therapy;
LGG	cis	rs559928	0.576	rs750830	chr11:64163446	G/A	cg26318627	chr11:63887540	MACROD1	-0.39	-7.11	-0.31	4.52e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg08888203	chr3:10149979	C3orf24	0.54	9.23	0.39	9.49e-19	Alzheimer's disease;
LGG	cis	rs4474465	1.000	rs7128417	chr11:78205974	C/G	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs9810089	0.758	rs12492510	chr3:136151631	G/T	cg21827317	chr3:136751795	NA	0.47	8.43	0.36	4.46e-16	Gestational age at birth (child effect);
LGG	cis	rs514406	0.708	rs480299	chr1:53320274	G/T	cg08859206	chr1:53392774	SCP2	-0.42	-8.4	-0.36	5.5e-16	Monocyte count;
LGG	cis	rs2228479	0.850	rs17232910	chr16:89839766	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs883565	0.569	rs784509	chr3:39166355	G/A	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07132326	chr6:150258058	NA	0.39	8.29	0.36	1.21e-15	Testicular germ cell tumor;
LGG	cis	rs11098499	0.604	rs2389886	chr4:120570422	C/T	cg24375607	chr4:120327624	NA	0.64	10.44	0.44	4.62e-23	Corneal astigmatism;
LGG	cis	rs6960043	0.818	rs10228066	chr7:15063569	C/T	cg19272540	chr7:15055459	NA	-0.35	-7.77	-0.34	5.1e-14	Type 2 diabetes;
LGG	cis	rs875971	0.862	rs937494	chr7:65764678	T/A	cg18876405	chr7:65276391	NA	-0.54	-9.74	-0.41	1.61e-20	Aortic root size;
LGG	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg05802129	chr4:122689817	NA	-0.4	-6.73	-0.3	5.05e-11	Type 2 diabetes;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20887711	chr4:1340912	KIAA1530	-0.77	-16.09	-0.6	1.34e-46	Obesity-related traits;
LGG	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs72772090	0.539	rs13601	chr5:96110596	G/A	cg00188032	chr5:96141721	ERAP1	0.53	7.01	0.31	8.23e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04530015	chr2:215796436	ABCA12	-0.47	-7.95	-0.35	1.41e-14	Neuroblastoma;
LGG	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg11038491	chr20:34638489	LOC647979	-0.55	-7.29	-0.32	1.4e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2916247	0.954	rs6981723	chr8:93175044	G/A	cg10183463	chr8:93005414	RUNX1T1	0.35	6.99	0.31	9.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14373873	chr11:113211441	TTC12	0.42	8.35	0.36	8.19e-16	Alcoholic chronic pancreatitis;
LGG	cis	rs3820068	0.705	rs2145397	chr1:15896199	G/A	cg05660106	chr1:15850417	CASP9	1.16	25.48	0.76	3.71e-90	Systolic blood pressure;
LGG	cis	rs2652834	1.000	rs2729830	chr15:63395812	G/C	cg05507819	chr15:63340323	TPM1	0.58	7.83	0.34	3.29e-14	HDL cholesterol;
LGG	cis	rs6964587	0.967	rs28615927	chr7:91600648	C/A	cg17063962	chr7:91808500	NA	0.48	8.52	0.37	2.29e-16	Breast cancer;
LGG	trans	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg27411982	chr8:10470053	RP1L1	-0.4	-6.66	-0.3	7.72e-11	Mood instability;
LGG	cis	rs7828089	1.000	rs7823832	chr8:22264426	A/G	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.74	-0.3	4.86e-11	Verbal declarative memory;
LGG	cis	rs7216064	0.531	rs62084683	chr17:66031725	A/G	cg02705964	chr17:66097276	LOC651250	-0.45	-8.07	-0.35	6.28e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-11.96	-0.49	6.7200000000000006e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7103648	0.966	rs11500477	chr11:47409051	T/A	cg20307385	chr11:47447363	PSMC3	0.93	20.88	0.7	1e-68	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg05973401	chr12:123451056	ABCB9	-0.5	-7.12	-0.31	4.18e-12	Neutrophil percentage of white cells;
LGG	cis	rs6912958	0.703	rs9353483	chr6:88097180	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.04	0.46	2.55e-25	Monocyte percentage of white cells;
LGG	cis	rs10781543	0.839	rs6560632	chr9:139371786	A/C	cg14019695	chr9:139328340	INPP5E	0.42	7.51	0.33	3.17e-13	Monocyte percentage of white cells;
LGG	cis	rs4653767	1.000	rs10495249	chr1:226919119	A/G	cg00279406	chr1:226924739	ITPKB	0.26	6.66	0.3	7.88e-11	Parkinson's disease;
LGG	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg07615347	chr10:60278583	BICC1	-0.63	-17.57	-0.63	2.41e-53	Refractive error;
LGG	cis	rs7959452	0.535	rs10784771	chr12:69621264	A/G	cg14784868	chr12:69753453	YEATS4	0.71	13.16	0.52	8.24e-34	Blood protein levels;
LGG	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.62	0.59	1.74e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs5758511	0.514	rs5758629	chr22:42574555	C/T	cg15128208	chr22:42549153	NA	0.75	11.35	0.47	1.7e-26	Birth weight;
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.67	-0.54	5.87e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg15595755	chr5:1867978	NA	0.51	10.18	0.43	4.22e-22	Cardiovascular disease risk factors;
LGG	cis	rs4689642	0.507	rs11723611	chr4:7218349	C/G	cg21353189	chr4:7228343	SORCS2	0.32	6.95	0.31	1.27e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs1971762	0.527	rs784562	chr12:53919700	A/C	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.76	-0.3	4.19e-11	Height;
LGG	cis	rs1555322	0.872	rs2425048	chr20:33872723	C/T	cg03689076	chr20:33865952	NA	0.64	6.67	0.3	7.2e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.59	-0.41	5.31e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7085104	0.591	rs4919683	chr10:104585125	G/T	cg04362960	chr10:104952993	NT5C2	0.53	10.07	0.42	1.06e-21	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs36051895	0.530	rs60768043	chr9:5224676	T/G	cg02405213	chr9:5042618	JAK2	-0.66	-11.49	-0.47	4.5e-27	Pediatric autoimmune diseases;
LGG	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg24503407	chr1:205819492	PM20D1	-0.4	-7.14	-0.32	3.56e-12	Menarche (age at onset);
LGG	cis	rs829402	1.000	rs829396	chr1:22003793	A/G	cg14212983	chr1:21985742	RAP1GAP	0.73	11.55	0.47	2.66e-27	High light scatter reticulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09343402	chr19:24216269	NA	0.5	7.82	0.34	3.58e-14	Gut microbiome composition (summer);
LGG	cis	rs2730245	0.527	rs2730237	chr7:158706166	A/G	cg11984989	chr7:158649758	WDR60	1.04	14.94	0.57	1.83e-41	Height;
LGG	cis	rs7766436	0.770	rs11751669	chr6:22571037	A/G	cg13666174	chr6:22585274	NA	-0.49	-11.02	-0.46	3.2e-25	Coronary artery disease;
LGG	trans	rs1478897	0.898	rs2249040	chr8:11390779	A/T	cg02002194	chr4:3960332	NA	0.41	7.36	0.32	8.37e-13	Systemic lupus erythematosus;
LGG	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.12	0.55	6.4e-38	IgG glycosylation;
LGG	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	cg07928641	chr1:182991847	LAMC1	0.45	9.06	0.39	3.62e-18	Hypertriglyceridemia;
LGG	cis	rs56235845	0.694	rs6875461	chr5:176754665	C/T	cg17509989	chr5:176798049	RGS14	-0.65	-10.88	-0.45	1.06e-24	Hemoglobin concentration;Hematocrit;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg00166722	chr3:10149974	C3orf24	0.51	8.7	0.37	6.04e-17	Alzheimer's disease;
LGG	cis	rs7289126	0.966	rs2267378	chr22:38630956	G/A	cg25457927	chr22:38595422	NA	-0.32	-7.68	-0.34	9.64e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs2594989	0.836	rs347609	chr3:11269999	G/C	cg01796438	chr3:11312864	ATG7	-0.5	-6.85	-0.3	2.3e-11	Circulating chemerin levels;
LGG	trans	rs2018683	0.739	rs10233884	chr7:28972307	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.23	-0.39	9.91e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs783540	0.934	rs7182403	chr15:83297613	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.7	-0.3	5.93e-11	Schizophrenia;
LGG	cis	rs1577917	0.958	rs1838955	chr6:86565449	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.69e-30	Response to antipsychotic treatment;
LGG	cis	rs765787	0.530	rs11855435	chr15:45522117	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.06	-0.31	5.96e-12	Uric acid levels;
LGG	cis	rs35306767	0.855	rs12771179	chr10:872347	A/G	cg20503657	chr10:835505	NA	0.95	13.02	0.52	3.16e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	cis	rs4629710	0.617	rs28360555	chr6:131538952	C/A	cg12606694	chr6:131520996	AKAP7	0.51	8.36	0.36	7.33e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7666738	0.830	rs60007031	chr4:98824753	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.82	0.34	3.57e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg21724239	chr8:58056113	NA	0.58	8.97	0.38	7.22e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg12419862	chr22:24373484	LOC391322	0.93	19.02	0.66	4.86e-60	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4961252	0.545	rs1107258	chr8:142104071	G/A	cg07964753	chr8:142112622	NA	-0.49	-7.37	-0.32	7.93e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09723155	chr17:79633271	C17orf90;CCDC137	0.55	8.63	0.37	9.85e-17	Gut microbiome composition (summer);
LGG	cis	rs6032067	0.759	rs1007138	chr20:43816835	A/C	cg10761708	chr20:43804764	PI3	0.62	9.32	0.4	4.93e-19	Blood protein levels;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs778371	0.578	rs2675956	chr2:233753340	G/A	cg08000102	chr2:233561755	GIGYF2	-0.51	-8.34	-0.36	8.37e-16	Schizophrenia;
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.06	-0.35	6.77e-15	Personality dimensions;
LGG	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg05313129	chr8:58192883	C8orf71	-0.59	-7.47	-0.33	4.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9287719	0.967	rs12464908	chr2:10761496	T/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.45	-0.33	4.67e-13	Prostate cancer;
LGG	cis	rs881375	0.933	rs2239657	chr9:123671520	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.62	-11.79	-0.48	3.09e-28	Rheumatoid arthritis;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs765787	0.530	rs12439643	chr15:45529767	A/G	cg25801113	chr15:45476975	SHF	-0.87	-18.68	-0.66	1.85e-58	Uric acid levels;
LGG	cis	rs7241530	0.610	rs7231480	chr18:75893067	G/A	cg14642773	chr18:75888474	NA	0.48	9.1	0.39	2.74e-18	Educational attainment (years of education);
LGG	cis	rs787274	0.867	rs787279	chr9:115539514	T/C	cg13803584	chr9:115635662	SNX30	-0.55	-7.73	-0.34	6.75e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg12708336	chr17:41446283	NA	-0.31	-7.14	-0.32	3.6e-12	Menopause (age at onset);
LGG	cis	rs9534288	0.912	rs4942468	chr13:46618290	C/A	cg15192986	chr13:46630673	CPB2	-0.71	-15.73	-0.59	5.61e-45	Blood protein levels;
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg16507663	chr6:150244633	RAET1G	-0.45	-7.36	-0.32	8.37e-13	Lung cancer;
LGG	trans	rs7937682	0.632	rs14133	chr11:111782697	C/G	cg18187862	chr3:45730750	SACM1L	-0.59	-9.65	-0.41	3.4e-20	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.69	-9.26	-0.4	7.55e-19	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs12176034	chr6:150121693	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.05	0.55	1.31e-37	Lung cancer;
LGG	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9768139	0.696	rs4909177	chr7:158117047	A/T	cg25566285	chr7:158114605	PTPRN2	0.89	19.95	0.68	2.3e-64	Calcium levels;
LGG	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg15627072	chr1:2432621	PLCH2	-0.36	-7.83	-0.34	3.46e-14	Ulcerative colitis;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg15537850	chr8:144661051	NAPRT1	0.96	7.51	0.33	3.02e-13	Attention deficit hyperactivity disorder;
LGG	trans	rs853679	0.607	rs67340775	chr6:28304384	A/C	cg01620082	chr3:125678407	NA	-1.08	-10.54	-0.44	1.97e-23	Depression;
LGG	cis	rs870825	0.860	rs2705899	chr4:185596219	A/G	cg04058563	chr4:185651563	MLF1IP	0.99	19.47	0.67	4.08e-62	Blood protein levels;
LGG	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.54	9.2	0.39	1.26e-18	Birth weight;
LGG	cis	rs9547692	1.000	rs493248	chr13:37473386	C/T	cg01493522	chr13:37497338	NA	-0.5	-8.64	-0.37	8.99e-17	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.95	-0.31	1.28e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs11716531	0.574	rs13075192	chr3:27279235	C/T	cg02860705	chr3:27208620	NA	0.82	14.86	0.57	3.85e-41	Diastolic blood pressure;
LGG	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg10494973	chr17:80897199	TBCD	0.41	7.23	0.32	1.99e-12	Breast cancer;
LGG	cis	rs140365914	1	rs140365914	chr7:155106570	C/T	cg06963709	chr7:155150793	NA	0.37	7.22	0.32	2.2e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg20916646	chr4:852691	GAK	0.56	9.81	0.41	9.02e-21	Sjögren's syndrome;
LGG	cis	rs36051895	0.659	rs12339666	chr9:5063296	A/C	cg02405213	chr9:5042618	JAK2	0.83	16.58	0.61	8.49e-49	Pediatric autoimmune diseases;
LGG	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.23	0.36	1.89e-15	Colorectal cancer;
LGG	cis	rs9467773	0.620	rs2101581	chr6:26622769	G/T	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.26e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1497828	0.956	rs2646833	chr1:217545039	A/G	cg04411442	chr1:217543379	NA	0.47	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.83	0.34	3.32e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs7572644	0.679	rs17006365	chr2:28123374	T/G	cg27432699	chr2:27873401	GPN1	-0.45	-6.84	-0.3	2.48e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs2180341	0.814	rs6914131	chr6:127737489	T/C	cg27446573	chr6:127587934	RNF146	0.93	17.56	0.63	2.92e-53	Breast cancer;
LGG	cis	rs17321999	0.909	rs17009315	chr2:30491392	A/G	cg05247661	chr2:30472410	LBH	0.46	7.44	0.33	4.79e-13	Systemic lupus erythematosus;
LGG	cis	rs283228	1.000	rs283188	chr6:101742714	A/G	cg27451362	chr6:101846650	GRIK2	0.54	9.07	0.39	3.34e-18	Coenzyme Q10 levels;
LGG	cis	rs6976053	0.518	rs314358	chr7:100410657	A/G	cg03098644	chr7:100410630	EPHB4	-0.6	-11.31	-0.47	2.34e-26	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.05e-13	Bipolar disorder;
LGG	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.04	-0.31	7.01e-12	Chronic lymphocytic leukemia;
LGG	cis	rs5750830	0.649	rs4384886	chr22:39793766	C/T	cg04986931	chr22:39850128	NA	0.32	7.35	0.32	8.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2249694	0.919	rs7093170	chr10:135402904	C/T	cg20169779	chr10:135381914	SYCE1	-0.5	-7.8	-0.34	4.19e-14	Obesity-related traits;
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg08645402	chr16:4508243	NA	0.55	9.92	0.42	3.84e-21	Schizophrenia;
LGG	cis	rs6725041	0.819	rs4375810	chr2:213094412	T/C	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.59e-11	QT interval (ambient particulate matter interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01420426	chr1:41832032	NA	0.46	7.85	0.34	2.9e-14	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-14.19	-0.55	3.39e-38	Colorectal cancer;
LGG	cis	rs17376456	0.877	rs9314101	chr5:93461593	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.63e-19	Diabetic retinopathy;
LGG	cis	rs273218	1.000	rs156438	chr5:53374120	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.65	9.21	0.39	1.13e-18	Migraine;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.67	-0.41	2.97e-20	Neuroticism;
LGG	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.98	-0.54	2.6e-37	Gut microbiome composition (summer);
LGG	trans	rs60515486	0.702	rs11820650	chr11:47424963	A/G	cg15704280	chr7:45808275	SEPT13	0.63	7.1	0.31	4.78e-12	Lymphocyte counts;
LGG	cis	rs1801251	1.000	rs895430	chr2:233725483	C/A	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.28	-0.4	6.31e-19	Coronary artery disease;
LGG	cis	rs6752107	1.000	rs2241878	chr2:234183718	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.68	13.07	0.52	1.91e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg08498830	chr11:832797	CD151	-0.46	-7.49	-0.33	3.55e-13	Mean platelet volume;
LGG	cis	rs5769765	0.908	rs9616396	chr22:50317825	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-12.61	-0.51	1.57e-31	Schizophrenia;
LGG	cis	rs7829975	0.523	rs9644774	chr8:8559832	G/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.44	-0.33	4.91e-13	Mood instability;
LGG	cis	rs2303745	0.544	rs12710308	chr19:17395879	T/A	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.07	-0.39	3.5e-18	Systemic lupus erythematosus;
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg14668632	chr7:2872130	GNA12	-0.33	-6.94	-0.31	1.34e-11	Height;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.8e-16	Tonsillectomy;
LGG	cis	rs9397585	0.857	rs9397124	chr6:153368153	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs476633	0.708	rs111717706	chr15:41441162	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.72	-11.7	-0.48	7.15e-28	Glomerular filtration rate (creatinine);
LGG	cis	rs12431410	0.584	rs17096614	chr14:60243594	A/T	cg07950296	chr14:60194823	RTN1	0.41	7.9	0.34	2.09e-14	Schizophrenia;
LGG	trans	rs1997103	1.000	rs9649851	chr7:55398692	C/A	cg20935933	chr6:143382018	AIG1	0.59	9.12	0.39	2.29e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs523522	0.924	rs11065150	chr12:120958875	T/G	cg27279351	chr12:120934652	DYNLL1	0.81	12.94	0.52	6.49e-33	High light scatter reticulocyte count;
LGG	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs6601327	0.635	rs34782826	chr8:9663630	G/T	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.77	-0.3	3.96e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg05044414	chr3:183734942	ABCC5	0.59	11.7	0.48	6.79e-28	Anterior chamber depth;
LGG	cis	rs8072100	0.512	rs9303533	chr17:45386540	A/G	cg08085267	chr17:45401833	C17orf57	-0.61	-12.16	-0.49	1.01e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.42	6.84	0.3	2.58e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1620921	0.622	rs60507137	chr6:161273066	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.19	-0.32	2.58e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg05234568	chr11:5960015	NA	-0.66	-10.61	-0.44	1.1e-23	DNA methylation (variation);
LGG	cis	rs11628318	0.851	rs4243735	chr14:103023574	T/C	cg23461800	chr14:103021989	NA	-0.58	-9.95	-0.42	2.78e-21	Platelet count;
LGG	cis	rs7617773	0.746	rs7619865	chr3:48370580	G/A	cg11946769	chr3:48343235	NME6	0.6	10.17	0.43	4.47e-22	Coronary artery disease;
LGG	cis	rs4838594	0.549	rs3888909	chr10:49687284	C/T	cg17291251	chr10:49678358	ARHGAP22	0.41	8.04	0.35	7.71e-15	Daytime sleep phenotypes;
LGG	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.87	0.51	1.29e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg24375607	chr4:120327624	NA	-0.55	-9.24	-0.39	8.85e-19	Corneal astigmatism;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.59	11.49	0.47	4.71e-27	Lymphocyte counts;
LGG	cis	rs7647973	0.731	rs7617480	chr3:49210732	G/T	cg18654377	chr3:49208889	KLHDC8B	0.47	6.71	0.3	5.61e-11	Menarche (age at onset);
LGG	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg19913688	chr11:428466	ANO9	-0.64	-8.05	-0.35	7.05e-15	Body mass index;
LGG	cis	rs3008870	1.000	rs12039172	chr1:67447450	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.72e-15	Obesity-related traits;
LGG	cis	rs3857536	0.730	rs7761295	chr6:66932532	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	cis	rs977747	0.872	rs6658125	chr1:47677015	C/T	cg03885399	chr1:47691550	TAL1	-0.36	-7.66	-0.34	1.1e-13	Body mass index;
LGG	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg06212747	chr3:49208901	KLHDC8B	0.66	11.45	0.47	6.56e-27	Parkinson's disease;
LGG	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg07395648	chr5:131743802	NA	-0.43	-9.13	-0.39	2.06e-18	Blood metabolite levels;
LGG	cis	rs2307022	0.586	rs3785126	chr16:68388661	C/T	cg07273125	chr16:68295692	NA	0.43	9.49	0.4	1.23e-19	Body mass index;
LGG	cis	rs6692729	0.933	rs6759	chr1:227069737	C/T	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs17376456	0.877	rs28575883	chr5:93346035	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.4	8.06e-19	Diabetic retinopathy;
LGG	cis	rs6684428	0.536	rs7538008	chr1:56396084	A/G	cg11651538	chr1:56320950	NA	-0.44	-8.32	-0.36	9.76e-16	Airflow obstruction;
LGG	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.36	-0.32	8.34e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs61931739	0.817	rs304313	chr12:34216898	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.55	0.37	1.81e-16	Morning vs. evening chronotype;
LGG	trans	rs877282	0.786	rs10904558	chr10:797509	C/T	cg22713356	chr15:30763199	NA	0.57	8.82	0.38	2.38e-17	Uric acid levels;
LGG	trans	rs225245	0.755	rs226432	chr17:34043825	G/A	cg19694781	chr19:47549865	TMEM160	0.42	7.18	0.32	2.78e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs736801	0.504	rs2070721	chr5:131825842	T/G	cg21138405	chr5:131827807	IRF1	0.35	9.29	0.4	6.04e-19	Breast cancer;Mosquito bite size;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg04025307	chr7:1156635	C7orf50	0.79	16.73	0.61	1.72e-49	Longevity;Endometriosis;
LGG	cis	rs12579753	0.879	rs11615729	chr12:82128318	T/A	cg07988820	chr12:82153109	PPFIA2	-0.79	-12.16	-0.49	1.04e-29	Resting heart rate;
LGG	cis	rs7493	0.755	rs17166861	chr7:95020602	G/C	cg17330251	chr7:94953956	PON1	-0.45	-8.5	-0.37	2.61e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14119616	chr11:17099403	RPS13	0.41	6.94	0.31	1.32e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08704250	chr15:31115839	NA	0.48	8.64	0.37	8.87e-17	Huntington's disease progression;
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg01943577	chr7:158741284	NA	-0.44	-8.01	-0.35	9.2e-15	Height;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg14789911	chr21:47582049	C21orf56	-0.4	-6.77	-0.3	4e-11	Testicular germ cell tumor;
LGG	cis	rs4917300	0.802	rs11167111	chr8:143097622	G/C	cg06573787	chr8:143070187	NA	0.62	11.42	0.47	8.75e-27	Amyotrophic lateral sclerosis;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19003646	chr3:184053927	FAM131A	0.49	7.26	0.32	1.67e-12	Hip circumference;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg24642844	chr7:1081250	C7orf50	-0.43	-8.3	-0.36	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs412000	0.598	rs8263	chr17:56423114	C/T	cg25039879	chr17:56429692	SUPT4H1	0.43	6.96	0.31	1.16e-11	Primary tooth development (time to first tooth eruption);
LGG	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	9.83	0.42	7.46e-21	Mood instability;
LGG	cis	rs7851660	0.679	rs4297160	chr9:100585506	G/A	cg13688889	chr9:100608707	NA	-0.66	-13.64	-0.54	7.3e-36	Strep throat;
LGG	cis	rs7949566	0.647	rs4935967	chr11:126288956	C/T	cg05055844	chr11:126275997	ST3GAL4	-0.33	-6.69	-0.3	6.38e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg24642439	chr20:33292090	TP53INP2	0.46	7.36	0.32	8.32e-13	Height;
LGG	cis	rs3762637	0.943	rs6762156	chr3:122236025	A/C	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	cis	rs11169552	0.510	rs10876053	chr12:50934785	A/G	cg12884762	chr12:50931848	DIP2B	-0.42	-7.93	-0.35	1.63e-14	Colorectal cancer;
LGG	cis	rs4731207	0.596	rs10272889	chr7:124576641	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs7712401	0.562	rs383638	chr5:122324678	A/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.27e-23	Resting heart rate;
LGG	cis	rs2952156	0.920	rs2934956	chr17:37830447	T/A	cg00129232	chr17:37814104	STARD3	-0.75	-16.33	-0.6	1.18e-47	Asthma;
LGG	cis	rs10888329	0.707	rs6587437	chr1:248355867	T/G	cg00666640	chr1:248458726	OR2T12	0.45	6.65	0.3	8.03e-11	Autism spectrum disorder;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs6460942	0.778	rs17444259	chr7:12462428	C/T	cg06484146	chr7:12443880	VWDE	-0.35	-6.97	-0.31	1.08e-11	Coronary artery disease;
LGG	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg00149659	chr3:10157352	C3orf10	0.56	8.18	0.36	2.85e-15	Alzheimer's disease;
LGG	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg11995313	chr8:8860691	ERI1	0.45	7.67	0.34	1.05e-13	Joint mobility (Beighton score);
LGG	trans	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.64	-0.33	1.22e-13	Mood instability;
LGG	cis	rs2404602	0.647	rs36114653	chr15:77025393	G/A	cg23625390	chr15:77176239	SCAPER	-0.7	-13.54	-0.53	2e-35	Blood metabolite levels;
LGG	cis	rs2730245	0.636	rs710421	chr7:158668575	T/C	cg23730037	chr7:158596552	ESYT2	-0.41	-7.16	-0.32	3.15e-12	Height;
LGG	cis	rs1497828	1.000	rs2810767	chr1:217564937	T/C	cg04411442	chr1:217543379	NA	0.45	7.62	0.33	1.41e-13	Dialysis-related mortality;
LGG	cis	rs10850519	0.783	rs9971932	chr12:115948892	C/T	cg18639984	chr12:115943877	NA	-0.42	-9.13	-0.39	2.18e-18	Diastolic blood pressure;
LGG	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg02002194	chr4:3960332	NA	0.48	8.84	0.38	2.09e-17	Retinal vascular caliber;
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg14074117	chr16:1909714	C16orf73	0.54	7.76	0.34	5.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7711186	0.881	rs61216284	chr5:178013597	C/A	cg17371294	chr5:178012716	COL23A1	-0.92	-8.89	-0.38	1.38e-17	Urate levels in obese individuals;
LGG	cis	rs1707322	1.000	rs785484	chr1:46574015	T/C	cg03146154	chr1:46216737	IPP	-0.53	-9.59	-0.41	5.35e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs7208859	0.673	rs216410	chr17:28903831	C/G	cg01831904	chr17:28903510	LRRC37B2	0.9	11.82	0.48	2.25e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg21775007	chr8:11205619	TDH	-0.56	-9.26	-0.4	7.94e-19	Neuroticism;
LGG	trans	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.02	-0.35	8.74e-15	Monocyte count;
LGG	trans	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.23e-16	Personality dimensions;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg04863758	chr4:1303710	MAEA	0.43	7.39	0.32	6.72e-13	Obesity-related traits;
LGG	cis	rs2279817	0.735	rs11203432	chr1:17991196	A/G	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-9.53	-0.4	9.08e-20	Neuroticism;
LGG	cis	rs7615952	0.688	rs12485622	chr3:125710739	T/C	cg05084668	chr3:125655381	ALG1L	-0.57	-7.71	-0.34	7.64e-14	Blood pressure (smoking interaction);
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.13	-0.35	3.91e-15	Personality dimensions;
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg22077389	chr15:40226273	EIF2AK4	0.59	8.54	0.37	1.88e-16	Response to haloperidol in psychosis;
LGG	cis	rs11676348	0.967	rs4672873	chr2:219005210	A/G	cg04731861	chr2:219085781	ARPC2	0.28	6.68	0.3	6.96e-11	Ulcerative colitis;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs77633900	0.772	rs157761	chr15:76796078	C/A	cg21673338	chr15:77095150	SCAPER	-0.64	-8.46	-0.37	3.61e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg24690094	chr11:67383802	NA	0.5	8.94	0.38	9.39e-18	Mean corpuscular volume;
LGG	cis	rs9783347	1.000	rs10741742	chr11:18342160	G/T	cg15585147	chr11:18324498	HPS5	0.41	8.63	0.37	9.6e-17	Pancreatic cancer;
LGG	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg24450063	chr1:156163899	SLC25A44	1.22	30.96	0.82	7.43e-115	Testicular germ cell tumor;
LGG	cis	rs8005677	1.000	rs1956881	chr14:23394069	A/C	cg25600027	chr14:23388339	RBM23	-0.45	-7.35	-0.32	8.99e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg13010199	chr12:38710504	ALG10B	-0.57	-11.11	-0.46	1.41e-25	Morning vs. evening chronotype;
LGG	cis	rs2070488	0.804	rs1870914	chr3:38494220	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.64	0.56	3.76e-40	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.57	-0.33	2.02e-13	Lung cancer;
LGG	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs8180040	0.764	rs12630534	chr3:47001043	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-14.13	-0.55	5.81e-38	Colorectal cancer;
LGG	trans	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.61	-0.41	4.81e-20	Monocyte percentage of white cells;
LGG	cis	rs977987	0.806	rs12924920	chr16:75440133	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.43	-0.58	1.24e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg13939156	chr17:80058883	NA	0.54	10.99	0.45	3.97e-25	Life satisfaction;
LGG	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg24189917	chr7:1970923	MAD1L1	0.57	8.67	0.37	7.16e-17	Bipolar disorder;
LGG	cis	rs10229583	0.527	rs6943219	chr7:127308386	A/G	cg25855768	chr7:127472121	SND1	-0.38	-6.68	-0.3	6.7e-11	Type 2 diabetes;
LGG	cis	rs9355814	0.539	rs6926458	chr6:161019866	A/G	cg04181478	chr6:161122748	PLG	0.46	7.36	0.32	8.39e-13	Lipoprotein (a) levels;
LGG	cis	rs10876993	0.784	rs10083154	chr12:58020933	G/A	cg18357645	chr12:58087776	OS9	-0.66	-11.33	-0.47	1.98e-26	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg14500267	chr11:67383377	NA	0.45	8.46	0.37	3.61e-16	Mean corpuscular volume;
LGG	cis	rs4075765	0.773	rs11604717	chr11:26180662	G/T	cg19182008	chr11:26298241	NA	-0.74	-7.57	-0.33	1.97e-13	Cannabis dependence symptom count;
LGG	cis	rs6088590	0.813	rs1884668	chr20:33285514	A/G	cg08999081	chr20:33150536	PIGU	0.39	9.77	0.41	1.26e-20	Coronary artery disease;
LGG	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.48e-19	Life satisfaction;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg13047869	chr3:10149882	C3orf24	0.48	7.53	0.33	2.62e-13	Alzheimer's disease;
LGG	cis	rs3820928	0.874	rs10439363	chr2:227815065	C/T	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.92	-0.35	1.72e-14	Pulmonary function;
LGG	cis	rs2028299	0.879	rs986505	chr15:90418413	T/A	cg23731826	chr15:90371692	NA	0.36	8.72	0.38	5.15e-17	Type 2 diabetes;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.0	0.49	4.6e-29	Prudent dietary pattern;
LGG	cis	rs758324	0.947	rs1566427	chr5:131191672	G/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs7178375	0.654	rs2525008	chr15:31109784	T/A	cg04373760	chr16:53404718	NA	0.62	9.49	0.4	1.25e-19	Hypertriglyceridemia;
LGG	cis	rs12731740	1.000	rs6701558	chr1:207997813	A/G	cg22525895	chr1:207977042	MIR29B2	-0.66	-7.48	-0.33	3.74e-13	Biomedical quantitative traits;
LGG	cis	rs6087990	0.899	rs1003521	chr20:31366598	T/C	cg13636640	chr20:31349939	DNMT3B	0.98	21.64	0.71	2.99e-72	Ulcerative colitis;
LGG	cis	rs1062177	0.756	rs2915827	chr5:151119705	T/A	cg00977110	chr5:151150581	G3BP1	-0.47	-7.51	-0.33	3.13e-13	Preschool internalizing problems;
LGG	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.6e-16	Axial length;
LGG	cis	rs67133203	0.950	rs12371463	chr12:51428807	A/T	cg14688905	chr12:51403056	SLC11A2	0.79	11.96	0.49	6.43e-29	Urinary tract infection frequency;
LGG	cis	rs2131877	0.913	rs58434965	chr3:194846096	C/G	cg07250128	chr3:194833983	C3orf21	0.4	7.31	0.32	1.19e-12	Non-small cell lung cancer;
LGG	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg23649088	chr2:200775458	C2orf69	0.61	8.14	0.35	3.66e-15	Schizophrenia;
LGG	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7107174	1.000	rs2373115	chr11:78091150	G/T	cg02023728	chr11:77925099	USP35	0.44	7.84	0.34	3.12e-14	Testicular germ cell tumor;
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg07234876	chr8:600039	NA	0.93	10.04	0.42	1.38e-21	IgG glycosylation;
LGG	cis	rs9549367	0.789	rs9549361	chr13:113898329	C/T	cg18105134	chr13:113819100	PROZ	0.66	13.59	0.53	1.19e-35	Platelet distribution width;
LGG	cis	rs1461503	0.966	rs10892937	chr11:122841904	T/C	cg27398637	chr11:122830231	C11orf63	-0.71	-13.88	-0.54	7.46e-37	Menarche (age at onset);
LGG	cis	rs3126085	1.000	rs72696952	chr1:152172694	A/T	cg26876637	chr1:152193138	HRNR	-0.51	-7.27	-0.32	1.56e-12	Atopic dermatitis;
LGG	cis	rs17824933	1.000	rs17824933	chr11:60760612	C/G	cg16817237	chr11:60793675	NA	0.37	7.04	0.31	6.76e-12	Multiple sclerosis;
LGG	trans	rs2840044	1.000	rs225262	chr17:33959697	A/G	cg19694781	chr19:47549865	TMEM160	-0.55	-9.12	-0.39	2.34e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg17294928	chr15:75287854	SCAMP5	-0.91	-16.75	-0.61	1.46e-49	Blood trace element (Zn levels);
LGG	cis	rs4727027	0.933	rs1468369	chr7:148839840	G/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	3.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg00933542	chr6:150070202	PCMT1	0.38	7.0	0.31	9.18e-12	Lung cancer;
LGG	cis	rs7086627	0.507	rs7077907	chr10:82017082	A/G	cg01528321	chr10:82214614	TSPAN14	0.64	11.22	0.46	5.17e-26	Post bronchodilator FEV1;
LGG	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg00101154	chr16:420108	MRPL28	-0.66	-11.3	-0.47	2.49e-26	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs7192380	0.964	rs55780735	chr16:69740374	A/G	cg00738113	chr16:70207722	CLEC18C	0.29	8.33	0.36	9e-16	Sjögren's syndrome;
LGG	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg00990874	chr7:1149470	C7orf50	-0.69	-10.92	-0.45	7.1e-25	Bronchopulmonary dysplasia;
LGG	cis	rs701145	0.556	rs355764	chr3:154013480	A/T	cg16511985	chr3:153974050	SGEF	0.49	8.22	0.36	2.11e-15	Coronary artery disease;
LGG	cis	rs943466	1.000	rs6930201	chr6:33738749	A/C	cg07519485	chr6:33762594	MLN	0.55	11.5	0.47	4.47e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg08297393	chr2:100937505	LONRF2	-0.57	-9.82	-0.42	8.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg12070911	chr6:150209640	RAET1E	0.31	7.45	0.33	4.47e-13	Lung cancer;
LGG	cis	rs763121	0.853	rs4820345	chr22:39091151	T/C	cg06022373	chr22:39101656	GTPBP1	0.88	17.8	0.64	2.17e-54	Menopause (age at onset);
LGG	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.31	0.32	1.17e-12	Morning vs. evening chronotype;
LGG	cis	rs12282928	1.000	rs7952009	chr11:48286845	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.3	-0.32	1.3e-12	Migraine - clinic-based;
LGG	cis	rs67460515	0.563	rs9883566	chr3:160770323	C/T	cg03342759	chr3:160939853	NMD3	0.68	11.53	0.47	3.23e-27	Parkinson's disease;
LGG	cis	rs2171564	0.727	rs6788567	chr3:112437047	A/C	cg06685282	chr3:112453648	NA	-0.46	-8.41	-0.36	5.3e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg21782813	chr7:2030301	MAD1L1	-0.51	-12.71	-0.51	6.05e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg00149659	chr3:10157352	C3orf10	0.57	8.12	0.35	4.33e-15	Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg23533926	chr12:111358616	MYL2	-0.39	-6.86	-0.3	2.28e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs1850744	0.826	rs9291607	chr4:9708798	C/G	cg15442990	chr4:9534313	NA	-0.78	-6.85	-0.3	2.4e-11	Economic and political preferences;
LGG	cis	rs7937682	0.924	rs875258	chr11:111530607	C/A	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.13	-0.78	1.01e-97	Primary sclerosing cholangitis;
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg06197492	chr11:2016605	H19	-0.5	-10.23	-0.43	2.76e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7647973	0.580	rs11130184	chr3:49229930	C/T	cg06212747	chr3:49208901	KLHDC8B	0.74	13.23	0.52	4.17e-34	Menarche (age at onset);
LGG	cis	rs4319547	0.698	rs10744217	chr12:122942070	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-16.87	-0.62	4.23e-50	Body mass index;
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.04	-0.39	4.38e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1355223	0.902	rs1578622	chr11:34725915	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.83	-0.3	2.75e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12282928	0.743	rs10769322	chr11:48213446	C/T	cg26585981	chr11:48327164	OR4S1	-0.39	-6.83	-0.3	2.63e-11	Migraine - clinic-based;
LGG	cis	rs2290416	0.892	rs76225457	chr8:144666052	G/T	cg19357499	chr8:144660631	NAPRT1	0.89	7.06	0.31	6.18e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs34734847	0.842	rs7308648	chr12:121144144	C/G	cg21892295	chr12:121157589	UNC119B	-0.41	-7.82	-0.34	3.65e-14	Mean corpuscular volume;
LGG	cis	rs11764590	0.666	rs3996325	chr7:2053747	T/C	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.05	-0.31	6.62e-12	Neuroticism;
LGG	cis	rs2688608	0.725	rs2675666	chr10:75682651	G/T	cg10168709	chr10:75599394	CAMK2G	-0.36	-7.19	-0.32	2.56e-12	Inflammatory bowel disease;
LGG	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg10056627	chr6:42928773	GNMT	0.26	7.04	0.31	6.84e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-10.23	-0.43	2.84e-22	Height;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg14926445	chr8:58193284	C8orf71	-0.87	-10.88	-0.45	1.04e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	1.000	rs61991250	chr14:71869684	G/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	trans	rs783540	0.967	rs2870966	chr15:83295244	G/A	cg16105309	chr15:79090380	ADAMTS7	0.4	7.14	0.31	3.56e-12	Schizophrenia;
LGG	cis	rs3816183	0.958	rs2278579	chr2:43020835	C/T	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.24e-18	Hypospadias;
LGG	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-9.29	-0.4	6.11e-19	Blood protein levels;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg05025164	chr4:1340916	KIAA1530	0.46	7.62	0.33	1.41e-13	Obesity-related traits;
LGG	cis	rs4363385	0.818	rs426360	chr1:153014710	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.64	-0.37	9.07e-17	Inflammatory skin disease;
LGG	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg17294928	chr15:75287854	SCAMP5	0.61	11.31	0.47	2.38e-26	Breast cancer;
LGG	cis	rs9810089	0.527	rs661739	chr3:135953476	C/T	cg12473912	chr3:136751656	NA	0.48	8.44	0.37	4.06e-16	Gestational age at birth (child effect);
LGG	cis	rs1577917	1.000	rs1577919	chr6:86757296	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.65	-0.41	3.42e-20	Response to antipsychotic treatment;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg05896524	chr21:47604654	C21orf56	0.56	9.52	0.4	9.93e-20	Testicular germ cell tumor;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs3806843	0.735	rs2563333	chr5:140052271	A/G	cg19875535	chr5:140030758	IK	-0.53	-10.76	-0.45	2.94e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg02711726	chr17:80685570	FN3KRP	-0.4	-7.81	-0.34	3.74e-14	Breast cancer;
LGG	cis	rs8179	0.700	rs42044	chr7:92250140	T/G	cg15732164	chr7:92237376	CDK6	-0.48	-9.09	-0.39	2.98e-18	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs12580194	0.635	rs61957879	chr12:55716971	A/C	cg19537932	chr12:55886519	OR6C68	-0.54	-9.42	-0.4	2.15e-19	Cancer;
LGG	cis	rs11690935	0.959	rs10204501	chr2:172588865	C/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs1278769	0.786	rs9577175	chr13:113543355	C/T	cg00823993	chr13:113535758	ATP11A	0.64	9.67	0.41	2.9e-20	Interstitial lung disease;
LGG	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06850241	chr22:41845214	NA	-0.42	-6.84	-0.3	2.45e-11	Vitiligo;
LGG	cis	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg06521331	chr12:34319734	NA	-0.38	-6.72	-0.3	5.27e-11	Morning vs. evening chronotype;
LGG	cis	rs7289126	1.000	rs5995558	chr22:38647639	A/G	cg25457927	chr22:38595422	NA	-0.32	-7.71	-0.34	7.78e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs2562456	0.837	rs11085462	chr19:21750251	C/G	cg00806126	chr19:22604979	ZNF98	-0.64	-9.46	-0.4	1.61e-19	Pain;
LGG	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg27426351	chr10:43362370	NA	0.59	8.34	0.36	8.64e-16	Blood protein levels;
LGG	cis	rs12200560	0.505	rs211182	chr6:97074513	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.24	0.36	1.79e-15	Mean platelet volume;
LGG	cis	rs9368481	0.761	rs9357028	chr6:26967224	T/G	cg18867708	chr6:26865862	GUSBL1	-0.46	-7.65	-0.34	1.16e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4423214	0.559	rs7949129	chr11:71193135	G/C	cg10847948	chr11:71163743	NADSYN1	0.59	8.81	0.38	2.6e-17	Vitamin D levels;
LGG	cis	rs3820068	0.577	rs9728986	chr1:16040603	G/A	cg05660106	chr1:15850417	CASP9	0.76	14.24	0.55	1.98e-38	Systolic blood pressure;
LGG	cis	rs875971	0.965	rs10267430	chr7:65743023	G/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.16e-16	Aortic root size;
LGG	cis	rs9916302	0.800	rs11869259	chr17:37518141	C/A	cg00129232	chr17:37814104	STARD3	0.61	11.55	0.47	2.7e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs3733585	0.673	rs4697914	chr4:9952266	G/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg09021430	chr5:549028	NA	-0.71	-9.49	-0.4	1.18e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.69	-0.41	2.4e-20	Mean corpuscular volume;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg21782813	chr7:2030301	MAD1L1	0.43	9.95	0.42	2.92e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg08344181	chr3:125677491	NA	-0.9	-8.76	-0.38	3.73e-17	Intelligence (multi-trait analysis);
LGG	cis	rs74781061	0.932	rs11072498	chr15:74954187	G/T	cg02384859	chr15:74862662	ARID3B	-0.32	-6.76	-0.3	4.25e-11	Endometriosis;
LGG	cis	rs898097	0.812	rs56274787	chr17:80862682	C/T	cg22432760	chr17:80829718	TBCD	0.41	7.1	0.31	4.61e-12	Breast cancer;
LGG	cis	rs7572733	0.840	rs1065949	chr2:198627055	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs7582720	1.000	rs72936869	chr2:203788950	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg18357526	chr6:26021779	HIST1H4A	0.83	15.92	0.59	7.77e-46	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs2327056	chr6:8443305	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	cis	rs9815354	0.812	rs59138513	chr3:41908611	T/G	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.546	rs2092274	chr22:42123737	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-10.14	-0.43	5.98e-22	Vitiligo;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.73	-0.41	1.77e-20	Lung cancer;
LGG	cis	rs4731207	0.672	rs7792883	chr7:124448021	A/G	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs4262150	0.508	rs4342320	chr5:151909029	T/A	cg12297329	chr5:152029980	NA	-0.65	-11.75	-0.48	4.6e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs62458065	0.713	rs62463968	chr7:32501242	G/A	cg00845942	chr12:64062724	DPY19L2	-0.52	-6.8	-0.3	3.27e-11	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg18252515	chr7:66147081	NA	-1.35	-18.65	-0.65	2.68e-58	Diabetic kidney disease;
LGG	cis	rs13191362	1.000	rs1333963	chr6:163192571	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.96	10.03	0.42	1.5e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1577917	1.000	rs10944170	chr6:86685469	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs17711722	0.510	rs11767457	chr7:65290615	C/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.29	7.03	0.31	7.61e-12	Calcium levels;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg22433210	chr17:43662623	NA	0.92	15.26	0.58	6.93e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg26850624	chr5:429559	AHRR	-0.35	-7.38	-0.32	7.49e-13	Cystic fibrosis severity;
LGG	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg20302533	chr7:39170763	POU6F2	0.58	14.87	0.57	3.81e-41	IgG glycosylation;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg18357526	chr6:26021779	HIST1H4A	0.59	10.43	0.44	5.31e-23	Height;
LGG	trans	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	17.36	0.63	2.25e-52	Exhaled nitric oxide levels;
LGG	cis	rs7811528	0.527	rs7787450	chr7:2707709	A/G	cg11411865	chr7:2701802	TTYH3	0.44	6.67	0.3	7.41e-11	Schizophrenia;
LGG	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.85	-0.3	2.36e-11	Blood metabolite levels;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.805	rs3788062	chr21:44991159	C/T	cg04455712	chr21:45112962	RRP1B	0.51	10.0	0.42	1.89e-21	Mean corpuscular volume;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	7.59	0.33	1.77e-13	Schizophrenia;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.65	11.92	0.48	9.44e-29	Obesity-related traits;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg12379764	chr21:47803548	PCNT	0.5	8.17	0.35	2.97e-15	Testicular germ cell tumor;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg22968622	chr17:43663579	NA	1.04	19.65	0.67	5.59e-63	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10861661	0.963	rs3782707	chr12:107185187	G/A	cg15890332	chr12:107067104	RFX4	0.3	6.83	0.3	2.61e-11	Triglyceride levels;
LGG	cis	rs7020830	0.867	rs13301916	chr9:37361455	A/C	cg14294708	chr9:37120828	ZCCHC7	1.14	30.21	0.81	1.57e-111	Schizophrenia;
LGG	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.21	-0.43	3.17e-22	Hip circumference adjusted for BMI;
LGG	cis	rs9467773	0.620	rs2504540	chr6:26641626	A/G	cg09904177	chr6:26538194	HMGN4	0.67	14.01	0.55	1.99e-37	Intelligence (multi-trait analysis);
LGG	cis	rs561341	1.000	rs550923	chr17:30327013	G/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg11441379	chr12:63026424	NA	0.69	9.72	0.41	1.91e-20	IgG glycosylation;
LGG	cis	rs975739	0.872	rs1759981	chr13:78370573	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.7	0.3	6.25e-11	Hair color;
LGG	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.38	0.32	7.36e-13	Monocyte count;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11328140	chr12:108079443	PWP1	0.41	7.16	0.32	3.26e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4720575	1.000	rs6463383	chr7:47091686	A/G	cg00036614	chr7:47093842	NA	0.49	9.97	0.42	2.38e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs5015933	0.734	rs10126025	chr9:128146064	C/G	cg14078157	chr9:128172775	NA	-0.35	-6.73	-0.3	5.04e-11	Body mass index;
LGG	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	trans	rs561341	1.000	rs508192	chr17:30315147	C/T	cg20587970	chr11:113659929	NA	1.33	21.98	0.71	7.18e-74	Hip circumference adjusted for BMI;
LGG	cis	rs12478296	0.901	rs56318767	chr2:243046591	T/A	cg18898632	chr2:242989856	NA	-0.8	-9.91	-0.42	4.01e-21	Obesity-related traits;
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.13	0.43	6.63e-22	Height;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.31	0.36	1.05e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2880765	0.805	rs34598679	chr15:86042205	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22880714	chr6:43138798	SRF	0.39	6.84	0.3	2.47e-11	Obesity-related traits;
LGG	cis	rs11098499	0.913	rs10006304	chr4:120124305	A/G	cg24375607	chr4:120327624	NA	0.6	9.75	0.41	1.54e-20	Corneal astigmatism;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg00631329	chr6:26305371	NA	-0.53	-9.98	-0.42	2.21e-21	Educational attainment;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13546538	chr9:111754815	CTNNAL1	-0.55	-6.69	-0.3	6.59e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	1.000	rs2027003	chr20:25350498	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg22358067	chr17:16797159	NA	-0.51	-7.15	-0.32	3.32e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs300774	0.925	rs300713	chr2:138363	A/G	cg04617936	chr2:214353	NA	-0.49	-7.49	-0.33	3.54e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg11317459	chr13:21872234	NA	-1.17	-18.82	-0.66	4.33e-59	White matter hyperintensity burden;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs35306767	0.668	rs35657988	chr10:1103590	A/G	cg25019033	chr10:957182	NA	-0.46	-8.73	-0.38	4.65e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs4696584	0.877	rs56137436	chr4:155389000	A/C	cg04517429	chr4:155413618	DCHS2	-0.33	-7.13	-0.31	3.99e-12	Folding of antihelix;
LGG	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-24.14	-0.75	6.25e-84	Lymphocyte percentage of white cells;
LGG	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.89	17.14	0.62	2.44e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10875595	0.836	rs3749780	chr5:140682757	C/T	cg24830062	chr5:140700576	TAF7	-0.58	-7.34	-0.32	9.41e-13	Pulmonary function decline;
LGG	cis	rs6762477	0.748	rs9831967	chr3:50217234	C/T	cg24110177	chr3:50126178	RBM5	0.55	9.57	0.41	6.58e-20	Menarche (age at onset);
LGG	trans	rs1728785	1.000	rs1182968	chr16:68573945	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.54	0.44	1.92e-23	Ulcerative colitis;
LGG	cis	rs910873	0.505	rs6058089	chr20:33194257	C/T	cg12302830	chr20:33297742	TP53INP2	0.44	6.92	0.31	1.47e-11	Melanoma;
LGG	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.09e-16	Total body bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11699826	chr1:26438425	PDIK1L	-0.42	-7.06	-0.31	6.03e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs1010254	0.510	rs2348421	chr5:151759901	T/C	cg08593883	chr5:151785301	NMUR2	-0.45	-6.91	-0.31	1.62e-11	Optic nerve measurement (cup area);
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg15948088	chr11:109293068	C11orf87	0.51	8.94	0.38	9.08e-18	Schizophrenia;
LGG	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-10.63	-0.44	9.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7769051	0.708	rs9483514	chr6:133228716	G/A	cg07930552	chr6:133119739	C6orf192	0.69	8.76	0.38	3.65e-17	Type 2 diabetes nephropathy;
LGG	cis	rs16957091	0.866	rs7166775	chr15:43042690	A/G	cg07484255	chr15:43025164	CDAN1	0.46	6.8	0.3	3.31e-11	MGMT methylation in smokers;
LGG	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg06470251	chr20:60548479	NA	0.49	8.05	0.35	7.19e-15	Body mass index;
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg05335186	chr13:53173507	NA	0.43	8.5	0.37	2.65e-16	Lewy body disease;
LGG	cis	rs73416724	1.000	rs78014492	chr6:43289599	C/T	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10267417	0.603	rs10224406	chr7:19904088	T/C	cg05791153	chr7:19748676	TWISTNB	0.56	7.32	0.32	1.1e-12	Night sleep phenotypes;
LGG	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.84	-0.38	2.08e-17	Eosinophil percentage of white cells;
LGG	cis	rs12738007	0.717	rs12021667	chr1:29311074	A/G	cg01115565	chr1:29584222	PTPRU	-0.28	-7.56	-0.33	2.13e-13	Schizophrenia;
LGG	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.31e-14	Coronary artery disease;
LGG	cis	rs9549367	0.773	rs9549717	chr13:113908826	A/G	cg18105134	chr13:113819100	PROZ	-0.68	-14.04	-0.55	1.54e-37	Platelet distribution width;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.1	-20.39	-0.69	1.94e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.5	-0.53	3.05e-35	Personality dimensions;
LGG	trans	rs9929218	1.000	rs2113200	chr16:68814948	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.51	-0.5	3.72e-31	Colorectal cancer;
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg24503407	chr1:205819492	PM20D1	0.49	8.26	0.36	1.52e-15	Parkinson's disease;
LGG	cis	rs2731664	0.792	rs335432	chr5:176866258	G/A	cg23176889	chr5:176863531	GRK6	-0.64	-12.37	-0.5	1.46e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	1.000	rs2056604	chr3:134312648	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg11608241	chr8:8085544	FLJ10661	-0.29	-6.69	-0.3	6.61e-11	Systolic blood pressure;
LGG	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7208859	0.623	rs8079891	chr17:29058863	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg21972741	chr5:435613	AHRR	0.51	9.1	0.39	2.63e-18	Cystic fibrosis severity;
LGG	cis	rs698813	0.604	rs10865200	chr2:44482884	G/C	cg00619915	chr2:44497795	NA	-0.59	-8.76	-0.38	3.83e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.48	-0.33	3.74e-13	Life satisfaction;
LGG	cis	rs8141529	0.748	rs9620841	chr22:29290981	C/T	cg02153584	chr22:29168773	CCDC117	0.6	9.77	0.41	1.29e-20	Lymphocyte counts;
LGG	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg16576597	chr16:28551801	NUPR1	0.31	7.05	0.31	6.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg05059571	chr16:84539110	KIAA1609	-0.57	-11.12	-0.46	1.31e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1816752	0.870	rs7981480	chr13:25015104	A/G	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs7129556	0.690	rs668701	chr11:77583476	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.35	0.32	8.76e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg16797656	chr11:68205561	LRP5	0.41	7.27	0.32	1.53e-12	Total body bone mineral density;
LGG	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg13683864	chr3:40499215	RPL14	1.15	28.92	0.8	8.46e-106	Renal cell carcinoma;
LGG	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg22630939	chr7:1135958	C7orf50	0.33	6.78	0.3	3.64e-11	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.42	-0.33	5.83e-13	Neuroticism;
LGG	cis	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs1190596	0.526	rs8003556	chr14:102659667	T/C	cg23904247	chr14:102554826	HSP90AA1	0.24	6.74	0.3	4.73e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs131656	1	rs131656	chr22:21917450	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-6.91	-0.31	1.56e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.51	-9.81	-0.41	9.05e-21	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg23461800	chr14:103021989	NA	0.53	8.41	0.36	5.01e-16	Platelet count;
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.13	-0.43	6.4e-22	Tonsillectomy;
LGG	cis	rs4731207	0.536	rs7792731	chr7:124653436	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg13770153	chr20:60521292	NA	-0.42	-6.85	-0.3	2.33e-11	Body mass index;
LGG	cis	rs9527	0.590	rs2274339	chr10:104860053	T/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.13	-0.31	3.99e-12	Arsenic metabolism;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.39e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.11	0.31	4.55e-12	Height;
LGG	cis	rs9815354	0.680	rs114714860	chr3:41882905	G/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6815814	0.950	rs11727978	chr4:38811051	T/A	cg06935464	chr4:38784597	TLR10	0.6	8.2	0.36	2.32e-15	Breast cancer;
LGG	cis	rs4660306	0.677	rs781060	chr1:45934166	C/T	cg15896098	chr1:45966115	MMACHC;CCDC163P	0.43	6.87	0.3	2.04e-11	Homocysteine levels;
LGG	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.92	0.38	1.12e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg10505658	chr17:80084571	CCDC57	0.33	6.65	0.3	8.3e-11	Life satisfaction;
LGG	trans	rs3942852	0.806	rs1875696	chr11:48133526	G/A	cg15704280	chr7:45808275	SEPT13	-0.65	-9.07	-0.39	3.43e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10463554	1.000	rs10463554	chr5:102318974	T/C	cg23492399	chr5:102201601	PAM	-0.54	-8.34	-0.36	8.32e-16	Parkinson's disease;
LGG	cis	rs11700980	0.551	rs2832043	chr21:30116146	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs9815354	0.812	rs60796012	chr3:41908668	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13040088	1.000	rs6090159	chr20:61531351	C/G	cg23096297	chr20:61557774	DIDO1	0.88	12.51	0.5	3.88e-31	Menopause (age at onset);
LGG	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg26384229	chr12:38710491	ALG10B	-0.84	-19.72	-0.68	2.61e-63	Heart rate;
LGG	cis	rs7428	0.545	rs4832163	chr2:85541083	T/C	cg24342717	chr2:85555507	TGOLN2	-0.72	-13.61	-0.53	9.74e-36	Ear protrusion;
LGG	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22857025	chr5:266934	NA	-1.52	-26.72	-0.78	7.32e-96	Breast cancer;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg02018176	chr4:1364513	KIAA1530	-0.48	-11.15	-0.46	1.01e-25	Obesity-related traits;
LGG	trans	rs6076960	0.652	rs3852945	chr20:6254118	T/C	cg24759859	chr6:86352639	SYNCRIP	0.41	6.81	0.3	3.07e-11	Smooth-surface caries;
LGG	cis	rs4696584	0.941	rs6536012	chr4:155398445	C/G	cg13738195	chr4:155413469	DCHS2	0.37	7.55	0.33	2.27e-13	Folding of antihelix;
LGG	trans	rs116095464	1.000	rs56700778	chr5:313186	A/T	cg00938859	chr5:1591904	SDHAP3	0.8	7.66	0.34	1.11e-13	Breast cancer;
LGG	cis	rs16966142	0.681	rs62052247	chr16:90041170	C/G	cg08854185	chr16:90077956	DBNDD1	-0.61	-7.31	-0.32	1.22e-12	Caffeine consumption;
LGG	cis	rs68170813	0.559	rs3823959	chr7:107009379	T/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.63e-22	Coronary artery disease;
LGG	cis	rs4423214	0.570	rs7118246	chr11:71231124	G/C	cg05163923	chr11:71159392	DHCR7	0.59	10.19	0.43	3.86e-22	Vitamin D levels;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.11	-0.31	4.5e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21879454	chr1:76080924	NA	0.46	6.99	0.31	9.63e-12	Gut microbiome composition (summer);
LGG	cis	rs11105298	0.891	rs11105287	chr12:89829470	C/T	cg00757033	chr12:89920650	WDR51B	0.59	8.56	0.37	1.64e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs950027	0.620	rs1145089	chr15:45652054	G/C	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs5758511	0.633	rs5758690	chr22:42668295	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.27	0.32	1.58e-12	Birth weight;
LGG	cis	rs5769765	0.913	rs8135071	chr22:50299587	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.18	-0.43	4.29e-22	Schizophrenia;
LGG	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.86	-0.38	1.67e-17	Morning vs. evening chronotype;
LGG	cis	rs7113850	0.541	rs78652241	chr11:24234956	A/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.48	0.44	3.31e-23	Bone fracture in osteoporosis;
LGG	cis	rs10771431	0.817	rs10843149	chr12:9362067	G/A	cg00504896	chr12:9437009	LOC642846	-0.52	-10.18	-0.43	4.32e-22	Breast size;
LGG	cis	rs34929064	0.718	rs1476483	chr7:22731199	C/T	cg18045685	chr7:22629474	NA	-0.59	-8.41	-0.36	5.28e-16	Major depression and alcohol dependence;
LGG	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg21775007	chr8:11205619	TDH	0.43	7.03	0.31	7.55e-12	Joint mobility (Beighton score);
LGG	cis	rs2018055	0.618	rs13206063	chr6:117791607	G/A	cg14611402	chr6:117803162	DCBLD1	0.29	8.69	0.37	6.23e-17	Diastolic blood pressure;
LGG	trans	rs10838798	0.504	rs7479393	chr11:48295303	G/C	cg21153622	chr11:89784906	NA	-0.39	-6.66	-0.3	7.87e-11	Height;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.46	-0.37	3.55e-16	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16211055	chr1:228594250	TRIM11	0.44	6.97	0.31	1.13e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.93	-0.31	1.4e-11	Lung cancer;
LGG	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg06885757	chr1:42089581	HIVEP3	-0.57	-13.38	-0.53	9.64e-35	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs283228	1.000	rs283228	chr6:101754993	A/C	cg27451362	chr6:101846650	GRIK2	0.53	8.99	0.39	6.43e-18	Coenzyme Q10 levels;
LGG	cis	rs7927592	0.763	rs10896351	chr11:68386896	G/A	cg01657329	chr11:68192670	LRP5	-0.58	-10.91	-0.45	7.79e-25	Total body bone mineral density;
LGG	trans	rs826838	0.874	rs11183816	chr12:38834656	T/G	cg06521331	chr12:34319734	NA	-0.45	-7.66	-0.34	1.1e-13	Heart rate;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg17178900	chr1:205818956	PM20D1	0.35	6.79	0.3	3.37e-11	Prostate cancer;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg08621203	chr6:150244597	RAET1G	-0.41	-7.06	-0.31	6.13e-12	Lung cancer;
LGG	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.81	0.41	8.86e-21	Height;
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg03351412	chr1:154909251	PMVK	0.66	12.41	0.5	1.03e-30	Prostate cancer;
LGG	cis	rs367615	0.959	rs17161951	chr5:108930590	A/G	cg17395555	chr5:108820864	NA	-0.61	-8.54	-0.37	1.94e-16	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs6956675	0.915	rs7780762	chr7:62654263	T/C	cg01314568	chr7:57830625	NA	-0.48	-7.77	-0.34	5.1e-14	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15364784	chr14:24584561	DCAF11	0.48	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg21775007	chr8:11205619	TDH	-0.83	-14.78	-0.57	8.98e-41	Retinal vascular caliber;
LGG	cis	rs12367572	0.930	rs11615964	chr12:45261564	C/T	cg04608330	chr12:45269318	NELL2	-0.64	-11.31	-0.47	2.37e-26	Gut microbiome composition (summer);
LGG	cis	rs1270639	0.722	rs6950817	chr7:157439636	A/G	cg13357408	chr7:157437802	PTPRN2	0.64	10.19	0.43	3.78e-22	Colorectal cancer;
LGG	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg04117972	chr1:227635322	NA	0.57	9.42	0.4	2.09e-19	Major depressive disorder;
LGG	cis	rs9487051	0.676	rs6913093	chr6:109636205	T/C	cg21918786	chr6:109611834	NA	-0.5	-9.26	-0.4	7.39e-19	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17221829	0.733	rs10501708	chr11:89394435	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.1e-18	Anxiety in major depressive disorder;
LGG	cis	rs7953249	0.514	rs1169312	chr12:121441461	G/T	cg14101638	chr12:121416612	HNF1A	0.36	7.48	0.33	3.77e-13	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs3735485	0.738	rs62458150	chr7:45101046	T/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs933688	1.000	rs933688	chr5:90762748	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	18.55	0.65	7.97e-58	Smoking behavior;
LGG	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg08807101	chr21:30365312	RNF160	-0.89	-18.38	-0.65	4.9e-57	Dental caries;
LGG	cis	rs4330281	0.647	rs55701200	chr3:17690427	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.53	-0.33	2.64e-13	Schizophrenia;
LGG	cis	rs2635047	0.710	rs2684838	chr18:44748079	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.2	0.32	2.4e-12	Educational attainment;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg19147129	chr2:74230310	NA	-0.38	-7.3	-0.32	1.23e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1949733	0.582	rs61258495	chr4:8534017	G/A	cg13073564	chr4:8508604	NA	0.41	7.36	0.32	8.5e-13	Response to antineoplastic agents;
LGG	cis	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg13443165	chr9:33130375	B4GALT1	-0.72	-11.37	-0.47	1.37e-26	IgG glycosylation;
LGG	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg02002194	chr4:3960332	NA	0.49	9.3	0.4	5.37e-19	Neuroticism;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs11758351	0.660	rs11757754	chr6:26219744	A/C	cg23601095	chr6:26197514	HIST1H3D	0.71	9.0	0.39	6.01e-18	Gout;Renal underexcretion gout;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg05025164	chr4:1340916	KIAA1530	0.89	17.73	0.64	4.7e-54	Longevity;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg10950524	chr7:2139216	MAD1L1	0.33	7.02	0.31	7.76e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4776059	1.000	rs11853917	chr15:52922054	T/C	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.79	-0.34	4.33e-14	Schizophrenia;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg21775007	chr8:11205619	TDH	-0.51	-7.87	-0.34	2.59e-14	Neuroticism;
LGG	cis	rs72781680	1.000	rs72781643	chr2:24208746	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.41	0.4	2.4e-19	Lymphocyte counts;
LGG	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg19784903	chr17:45786737	TBKBP1	0.37	8.16	0.35	3.14e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4474465	0.850	rs10899545	chr11:78250371	C/T	cg27205649	chr11:78285834	NARS2	0.49	8.48	0.37	2.99e-16	Alzheimer's disease (survival time);
LGG	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg18240062	chr17:79603768	NPLOC4	0.62	10.41	0.44	6.07e-23	Eye color traits;
LGG	trans	rs6601327	0.767	rs10109026	chr8:9411986	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.96	-0.31	1.19e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg00721468	chr6:8102731	EEF1E1	-0.44	-6.92	-0.31	1.54e-11	Coronary artery disease;
LGG	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg03264133	chr6:25882463	NA	-0.4	-7.02	-0.31	7.75e-12	Height;
LGG	cis	rs1927790	0.697	rs61966875	chr13:96936525	C/A	cg02571835	chr13:96230311	CLDN10	-0.36	-7.19	-0.32	2.62e-12	Body mass index;
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg14668632	chr7:2872130	GNA12	-0.35	-7.23	-0.32	1.98e-12	Height;
LGG	cis	rs12731740	1.000	rs115671492	chr1:208029063	C/T	cg22525895	chr1:207977042	MIR29B2	-0.6	-6.72	-0.3	5.25e-11	Biomedical quantitative traits;
LGG	cis	rs4969178	0.965	rs12451715	chr17:76397334	A/C	cg20026190	chr17:76395443	PGS1	0.57	10.1	0.42	8.26e-22	HDL cholesterol levels;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Electroencephalogram traits;
LGG	cis	rs4474465	0.850	rs4285892	chr11:78243134	C/A	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.91e-11	Alzheimer's disease (survival time);
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.61	-10.68	-0.44	6.06e-24	Lymphocyte counts;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg06925179	chr17:43578568	NA	0.43	10.15	0.43	5.66e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs2204008	0.774	rs2387811	chr12:38369794	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.19e-18	Bladder cancer;
LGG	cis	rs5742933	0.817	rs1233297	chr2:190694175	C/T	cg04003228	chr2:190539410	ANKAR	0.49	7.22	0.32	2.16e-12	Ferritin levels;
LGG	cis	rs7572733	0.534	rs700674	chr2:198693703	C/T	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.37	0.4	3.12e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.830	rs10017557	chr4:98983969	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3087591	0.960	rs2952995	chr17:29541061	T/C	cg24425628	chr17:29625626	OMG;NF1	0.69	14.35	0.55	7.09e-39	Hip circumference;
LGG	cis	rs6430585	0.583	rs73957037	chr2:136588031	C/A	cg07169764	chr2:136633963	MCM6	1.25	24.73	0.75	1.05e-86	Corneal structure;
LGG	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg25358565	chr5:93447407	FAM172A	-0.71	-10.28	-0.43	1.88e-22	Diabetic retinopathy;
LGG	cis	rs2067615	0.521	rs1216002	chr12:107213601	A/T	cg15890332	chr12:107067104	RFX4	0.29	7.64	0.33	1.23e-13	Heart rate;
LGG	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	7.84	0.34	3.24e-14	Bipolar disorder;
LGG	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.29	-0.5	3.14e-30	Vitiligo;
LGG	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs7953508	0.750	rs7310389	chr12:93976636	A/G	cg18151635	chr12:93972918	NA	-0.46	-8.2	-0.36	2.31e-15	Pubertal anthropometrics;
LGG	cis	rs12950390	0.853	rs4793647	chr17:45854090	G/C	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.37e-16	IgG glycosylation;
LGG	cis	rs881375	0.967	rs10435843	chr9:123668033	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.97	-0.45	4.78e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	0.872	rs9386791	chr6:109608497	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	19.79	0.68	1.3e-63	Alzheimer's disease;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg17951613	chr5:131705445	SLC22A5	-0.62	-7.24	-0.32	1.82e-12	Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09964705	chr19:19030333	DDX49;COPE	0.42	7.04	0.31	6.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9462027	0.628	rs2764208	chr6:34714322	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.44	-0.47	7.35e-27	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg00689492	chr4:1303491	MAEA	0.48	8.4	0.36	5.38e-16	Obesity-related traits;
LGG	cis	rs4804815	0.780	rs2081100	chr19:7840273	T/C	cg00371453	chr19:7854482	CLEC4GP1	0.7	10.57	0.44	1.61e-23	Neutrophil count;
LGG	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg18681998	chr4:17616180	MED28	0.83	17.69	0.64	6.99e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs151997	1.000	rs27284	chr5:50198086	A/G	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs7551222	0.752	rs4252725	chr1:204513256	A/G	cg20240347	chr1:204465584	NA	-0.56	-11.32	-0.47	2.25e-26	Schizophrenia;
LGG	cis	rs2290159	0.706	rs11923427	chr3:12663835	C/G	cg23032965	chr3:12705835	RAF1	0.67	8.97	0.38	7.12e-18	Cholesterol, total;
LGG	trans	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg05926928	chr17:57297772	GDPD1	1.37	21.24	0.7	2.08e-70	Opioid sensitivity;
LGG	cis	rs9479482	1.000	rs9478362	chr6:150340526	T/C	cg03788504	chr6:150331562	NA	-0.59	-13.55	-0.53	1.85e-35	Alopecia areata;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg11878867	chr6:150167359	LRP11	-0.57	-12.32	-0.5	2.27e-30	Lung cancer;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg05827058	chr17:7620372	NA	0.44	7.23	0.32	2.04e-12	Hepatitis;
LGG	trans	rs3942852	0.955	rs1910364	chr11:48113232	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.3	-0.36	1.17e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg20821713	chr7:1055600	C7orf50	-0.5	-8.1	-0.35	5.01e-15	Bronchopulmonary dysplasia;
LGG	cis	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg12395012	chr8:11607386	GATA4	-0.38	-7.11	-0.31	4.53e-12	Monocyte count;
LGG	cis	rs7662987	0.517	rs2034696	chr4:100024322	C/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg05084668	chr3:125655381	ALG1L	-0.57	-7.66	-0.34	1.12e-13	Blood pressure (smoking interaction);
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18252515	chr7:66147081	NA	0.43	7.43	0.33	5.43e-13	Aortic root size;
LGG	cis	rs57221529	0.545	rs55955015	chr5:575182	A/G	cg14541582	chr5:601475	NA	-0.71	-10.94	-0.45	5.99e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.99	0.39	6.38e-18	Bipolar disorder;
LGG	cis	rs11190604	1.000	rs2495750	chr10:102327708	A/G	cg07080220	chr10:102295463	HIF1AN	0.73	11.92	0.48	9.19e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6065	0.618	rs16942630	chr17:4878437	C/G	cg01912298	chr17:4872499	CAMTA2;SPAG7	-0.6	-8.08	-0.35	5.72e-15	Platelet count;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg02002194	chr4:3960332	NA	0.38	6.71	0.3	5.86e-11	Neuroticism;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16318349	chr1:154917307	PBXIP1	0.26	7.13	0.31	3.94e-12	Prostate cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10589851	chr12:62653931	USP15	0.45	7.14	0.31	3.76e-12	Cognitive performance;
LGG	cis	rs11098499	0.739	rs10013032	chr4:120149419	C/T	cg24375607	chr4:120327624	NA	-0.56	-9.33	-0.4	4.4e-19	Corneal astigmatism;
LGG	cis	rs9640161	0.673	rs34489187	chr7:150044379	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-14.94	-0.57	1.76e-41	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg14893161	chr1:205819251	PM20D1	0.62	11.97	0.49	5.88e-29	Menarche (age at onset);
LGG	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs12210905	1.000	rs6938397	chr6:27231224	C/G	cg15325629	chr6:28072465	NA	0.7	6.86	0.3	2.24e-11	Hip circumference adjusted for BMI;
LGG	cis	rs523522	0.962	rs3893104	chr12:120903936	G/A	cg12219531	chr12:120966889	COQ5	0.66	10.72	0.45	4.28e-24	High light scatter reticulocyte count;
LGG	cis	rs1620921	0.711	rs2565725	chr6:161244359	A/G	cg01280913	chr6:161186852	NA	-0.32	-6.66	-0.3	7.64e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2933343	0.621	rs6764682	chr3:128568383	G/A	cg25356066	chr3:128598488	ACAD9	-0.45	-6.7	-0.3	6.01e-11	IgG glycosylation;
LGG	trans	rs7939886	0.920	rs1481926	chr11:55973281	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs2836950	0.565	rs8134214	chr21:40542367	A/C	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.88e-19	Menarche (age at onset);
LGG	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg03264133	chr6:25882463	NA	-0.38	-6.66	-0.3	8e-11	Height;
LGG	cis	rs9487094	0.666	rs7748669	chr6:109745342	A/G	cg01125227	chr6:109776195	MICAL1	0.43	7.58	0.33	1.95e-13	Height;
LGG	cis	rs9814567	0.964	rs9820425	chr3:134223018	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.91	-0.51	8.87e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4639966	0.723	rs11217022	chr11:118641606	A/G	cg20110707	chr11:118481992	PHLDB1	-0.44	-7.0	-0.31	8.83e-12	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05665937	chr4:1216051	CTBP1	0.54	9.96	0.42	2.56e-21	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24887139	chr7:145813494	CNTNAP2	0.43	7.1	0.31	4.66e-12	Gut microbiome composition (summer);
LGG	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg24675658	chr1:53192096	ZYG11B	0.49	9.91	0.42	4.02e-21	Monocyte count;
LGG	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	-0.74	-14.66	-0.56	2.95e-40	Menarche (age at onset);
LGG	cis	rs11631955	1	rs11631955	chr15:79085915	A/G	cg00540400	chr15:79124168	NA	-0.39	-7.63	-0.33	1.37e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2229238	0.911	rs4633282	chr1:154507899	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.13e-11	Coronary heart disease;
LGG	trans	rs12543645	0.525	rs4349986	chr8:10278851	T/C	cg02002194	chr4:3960332	NA	0.41	7.32	0.32	1.12e-12	Schizophrenia;
LGG	trans	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.65	0.37	8.8e-17	Mood instability;
LGG	cis	rs9902453	0.904	rs4461132	chr17:28423430	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.24	0.52	3.85e-34	Coffee consumption (cups per day);
LGG	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.14	-0.32	3.56e-12	Type 2 diabetes;
LGG	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.32	-7.09	-0.31	4.94e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs988958	0.636	rs7581391	chr2:42219967	G/C	cg19376973	chr2:42229025	NA	0.61	9.8	0.41	9.77e-21	Hypospadias;
LGG	cis	rs7853377	0.723	rs10114889	chr9:86553106	G/C	cg12437157	chr9:86433764	GKAP1	0.39	6.72	0.3	5.28e-11	Height;
LGG	cis	rs7599312	0.534	rs2371615	chr2:213405660	G/T	cg16329650	chr2:213403929	ERBB4	0.78	16.74	0.61	1.51e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg13282195	chr8:144660772	NAPRT1	0.98	7.59	0.33	1.83e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs3741404	0.791	rs7102177	chr11:63909228	T/C	cg04000281	chr11:63949212	NA	-0.43	-8.28	-0.36	1.3e-15	Platelet count;
LGG	cis	rs78545713	0.649	rs79988778	chr6:26210621	G/T	cg01420254	chr6:26195488	NA	0.8	7.57	0.33	1.97e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs2000999	0.514	rs36061252	chr16:72217613	T/G	cg04254540	chr16:71951199	KIAA0174	-0.57	-6.8	-0.3	3.21e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg27297192	chr10:134578999	INPP5A	0.31	6.92	0.31	1.47e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg11441553	chr12:57614120	NXPH4	-0.58	-7.24	-0.32	1.89e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs8064299	0.597	rs9944506	chr17:72782726	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.98	22.86	0.73	5.89e-78	Monocyte count;
LGG	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg14228332	chr4:119757509	SEC24D	0.92	9.41	0.4	2.34e-19	Cannabis dependence symptom count;
LGG	cis	rs11664298	0.832	rs11665567	chr18:77563334	G/A	cg13263691	chr18:77568018	NA	0.56	7.17	0.32	3.07e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7463659	1.000	rs7836944	chr8:135436202	A/G	cg09855544	chr8:135498122	ZFAT	0.43	7.8	0.34	4.28e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg21775007	chr8:11205619	TDH	0.44	7.04	0.31	7.19e-12	Joint mobility (Beighton score);
LGG	cis	rs7267979	0.816	rs376742	chr20:25487417	A/C	cg06421707	chr20:25228305	PYGB	0.43	8.96	0.38	7.8e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg06618935	chr21:46677482	NA	-0.47	-9.16	-0.39	1.62e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8114671	0.562	rs7263157	chr20:33459127	G/A	cg07148914	chr20:33460835	GGT7	0.57	9.28	0.4	6.35e-19	Height;
LGG	cis	rs2885056	0.739	rs4363951	chr19:10649473	G/A	cg06392426	chr19:10676186	KRI1	0.67	11.1	0.46	1.49e-25	Red cell distribution width;
LGG	trans	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.06	-0.35	6.64e-15	Heart rate;
LGG	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.94	18.28	0.65	1.31e-56	Platelet count;
LGG	cis	rs5758659	0.652	rs5751195	chr22:42380001	A/C	cg15557168	chr22:42548783	NA	-0.33	-7.51	-0.33	3.09e-13	Cognitive function;
LGG	cis	rs73001065	0.792	rs16996148	chr19:19658472	G/T	cg03709012	chr19:19516395	GATAD2A	0.86	7.9	0.34	2.02e-14	LDL cholesterol;
LGG	cis	rs7296418	0.961	rs4148862	chr12:123568619	A/C	cg00376283	chr12:123451042	ABCB9	0.65	12.26	0.5	3.91e-30	Platelet count;
LGG	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg27490568	chr2:178487706	NA	-0.69	-12.2	-0.49	7.19e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7177699	0.557	rs9806363	chr15:79110302	A/G	cg00540400	chr15:79124168	NA	-0.54	-11.46	-0.47	6.32e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.28	0.75	1.42e-84	Chronic sinus infection;
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.95	0.35	1.45e-14	Height;
LGG	cis	rs11920090	0.800	rs6444957	chr3:170754885	C/G	cg09710316	chr3:170744871	SLC2A2	0.63	8.35	0.36	8.01e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg24829409	chr8:58192753	C8orf71	-0.86	-12.97	-0.52	4.81e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs861020	0.630	rs628300	chr1:209998298	C/T	cg05527609	chr1:210001259	C1orf107	0.62	9.76	0.41	1.39e-20	Orofacial clefts;
LGG	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg12463550	chr7:65579703	CRCP	0.73	8.33	0.36	9.56e-16	Diabetic kidney disease;
LGG	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg21053147	chr12:120880522	NA	-0.54	-7.96	-0.35	1.38e-14	Type 1 diabetes nephropathy;
LGG	cis	rs12971120	0.947	rs8083001	chr18:72165058	A/G	cg25817165	chr18:72167213	CNDP2	-0.67	-15.4	-0.58	1.61e-43	Refractive error;
LGG	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg09324608	chr17:30823087	MYO1D	0.31	7.42	0.33	5.71e-13	Schizophrenia;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs992157	0.732	rs10932771	chr2:219170236	A/T	cg04731861	chr2:219085781	ARPC2	-0.43	-10.69	-0.44	5.38e-24	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.38e-12	Menopause (age at onset);
LGG	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.71	0.3	5.71e-11	Parkinson's disease;
LGG	cis	rs2916247	1.000	rs11775644	chr8:93042425	C/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.15	-0.35	3.45e-15	Intelligence (multi-trait analysis);
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01148728	chr11:117198424	CEP164	-0.41	-6.65	-0.3	8.35e-11	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02234479	chr17:16342158	NCRNA00188;SNORD49B;SNORD49A	0.45	7.65	0.33	1.21e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg05533552	chr11:34074141	CAPRIN1	0.44	7.39	0.32	6.84e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs526631	0.564	rs10896051	chr11:65578759	C/T	cg17712092	chr4:129076599	LARP1B	-0.66	-12.15	-0.49	1.13e-29	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs459571	0.959	rs465535	chr9:136910905	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	10.34	0.43	1.06e-22	Platelet distribution width;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg22903471	chr2:27725779	GCKR	-0.57	-12.9	-0.51	9.37e-33	Total body bone mineral density;
LGG	cis	rs4808199	0.947	rs751858	chr19:19602821	G/C	cg03709012	chr19:19516395	GATAD2A	1.06	17.49	0.63	5.74e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg03511173	chr18:77590860	NA	0.66	8.33	0.36	9.56e-16	Opioid sensitivity;
LGG	cis	rs6708331	0.941	rs11903933	chr2:70376944	A/C	cg01613454	chr2:70366299	NA	0.54	9.39	0.4	2.83e-19	Obesity-related traits;
LGG	cis	rs516946	1.000	rs6989203	chr8:41523745	A/G	cg01678292	chr8:41522873	ANK1	-0.35	-8.1	-0.35	4.96e-15	Type 2 diabetes;
LGG	cis	rs2013441	0.965	rs2703808	chr17:20109665	A/C	cg13482628	chr17:19912719	NA	-0.51	-9.42	-0.4	2.16e-19	Obesity-related traits;
LGG	cis	rs1497828	0.956	rs2815234	chr1:217540734	T/C	cg04411442	chr1:217543379	NA	-0.49	-8.23	-0.36	1.87e-15	Dialysis-related mortality;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	trans	rs225245	0.817	rs225297	chr17:33924587	G/A	cg19694781	chr19:47549865	TMEM160	-0.41	-7.08	-0.31	5.47e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg27661571	chr11:113659931	NA	-0.66	-9.12	-0.39	2.24e-18	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg05368731	chr17:41323189	NBR1	0.88	17.46	0.63	8.33e-53	Menopause (age at onset);
LGG	cis	rs2342371	0.539	rs35959625	chr3:196131941	C/T	cg15048948	chr3:196158458	UBXN7	0.51	9.09	0.39	2.81e-18	Fat distribution (HIV);
LGG	cis	rs4665809	0.887	rs28699126	chr2:26357294	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.77	-0.34	5.19e-14	Gut microbiome composition (summer);
LGG	trans	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg18187862	chr3:45730750	SACM1L	-0.54	-8.77	-0.38	3.35e-17	Primary sclerosing cholangitis;
LGG	cis	rs13191362	1.000	rs36113695	chr6:163004733	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs644799	0.896	rs12146644	chr11:95492878	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	7.43	0.33	5.44e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs7212991	chr17:29143749	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12367572	0.501	rs3858731	chr12:45465934	C/T	cg03114573	chr12:45410052	DBX2	-0.51	-8.71	-0.38	5.31e-17	Gut microbiome composition (summer);
LGG	cis	rs7215564	0.908	rs2316063	chr17:78663360	G/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.23	-0.36	1.96e-15	Myopia (pathological);
LGG	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg20821713	chr7:1055600	C7orf50	-0.54	-8.64	-0.37	9.04e-17	Bronchopulmonary dysplasia;
LGG	cis	rs11583043	0.708	rs915405	chr1:101574145	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.52	8.25	0.36	1.64e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.29	0.46	2.79e-26	Colorectal cancer;
LGG	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg17646820	chr3:66848679	NA	0.51	7.83	0.34	3.32e-14	Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs564113	chr18:44364389	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.52	0.44	2.46e-23	Personality dimensions;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.44	0.33	5.06e-13	Lung cancer;
LGG	cis	rs1568889	1.000	rs33937991	chr11:28045260	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs4561483	0.801	rs33619	chr16:12008941	T/G	cg08843971	chr16:11963173	GSPT1	-0.68	-18.56	-0.65	6.74e-58	Testicular germ cell tumor;
LGG	cis	rs12493885	0.769	rs61791507	chr3:153748886	C/A	cg12800244	chr3:153838788	SGEF	-0.76	-8.56	-0.37	1.71e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9329221	0.712	rs1962073	chr8:10260553	A/G	cg21775007	chr8:11205619	TDH	-0.48	-7.31	-0.32	1.19e-12	Neuroticism;
LGG	trans	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg26043149	chr18:55253948	FECH	-0.47	-7.81	-0.34	3.84e-14	Bone mineral density;
LGG	cis	rs9837602	0.507	rs1718244	chr3:99512608	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.31	-0.36	1.11e-15	Breast cancer;
LGG	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	6.77e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg11812906	chr14:75593930	NEK9	0.52	9.84	0.42	6.95e-21	Height;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg06656553	chr16:89960601	TCF25	-0.73	-7.09	-0.31	4.99e-12	Skin colour saturation;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.79e-12	Life satisfaction;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg16359550	chr11:109292809	C11orf87	0.42	8.21	0.36	2.16e-15	Schizophrenia;
LGG	cis	rs7808935	0.958	rs67152137	chr7:27975919	G/C	cg22168087	chr7:27702803	HIBADH	0.62	9.42	0.4	2.11e-19	Prostate cancer;
LGG	cis	rs7208859	0.623	rs8075341	chr17:29136565	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4423214	0.524	rs4944046	chr11:71123794	C/G	cg10847948	chr11:71163743	NADSYN1	-0.41	-7.29	-0.32	1.33e-12	Vitamin D levels;
LGG	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg19678392	chr7:94953810	PON1	-0.41	-10.21	-0.43	3.4e-22	Paraoxonase activity;
LGG	cis	rs340630	0.967	rs13126334	chr4:87909890	A/G	cg11209507	chr4:87813803	C4orf36	-0.47	-7.98	-0.35	1.14e-14	Systemic lupus erythematosus;
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.84	0.42	6.92e-21	Monocyte count;
LGG	cis	rs1949733	0.523	rs16842560	chr4:8544238	G/A	cg13073564	chr4:8508604	NA	0.42	7.09	0.31	4.94e-12	Response to antineoplastic agents;
LGG	cis	rs4865875	1.000	rs4865875	chr5:54117443	T/C	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs2637030	0.559	rs2607497	chr5:52995482	A/G	cg06476337	chr5:52856530	NDUFS4	0.44	6.84	0.3	2.56e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs16922576	0.623	rs2093446	chr9:5230371	G/C	cg02405213	chr9:5042618	JAK2	-0.67	-11.66	-0.48	1.03e-27	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9290065	0.585	rs716779	chr3:160645428	G/A	cg03342759	chr3:160939853	NMD3	0.48	8.13	0.35	3.83e-15	Kawasaki disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20173334	chr8:42698483	THAP1	0.48	7.68	0.34	9.42e-14	Cognitive performance;
LGG	cis	rs10875746	0.624	rs7297298	chr12:48672306	C/G	cg24011408	chr12:48396354	COL2A1	-0.55	-7.08	-0.31	5.37e-12	Longevity (90 years and older);
LGG	cis	rs270601	0.721	rs270621	chr5:131605821	C/A	cg07395648	chr5:131743802	NA	-0.36	-6.94	-0.31	1.35e-11	Acylcarnitine levels;
LGG	cis	rs36051895	0.632	rs7038813	chr9:5177685	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.88	-0.57	3.43e-41	Pediatric autoimmune diseases;
LGG	cis	rs57502260	0.764	rs7105218	chr11:68222461	C/A	cg01657329	chr11:68192670	LRP5	-0.55	-7.32	-0.32	1.14e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs1707322	1.000	rs4660332	chr1:46461418	T/A	cg03146154	chr1:46216737	IPP	0.53	9.7	0.41	2.25e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9926296	0.712	rs2434872	chr16:89716915	C/G	cg03605463	chr16:89740564	NA	0.61	11.08	0.46	1.79e-25	Vitiligo;
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04950361	chr8:22552624	NA	0.5	7.46	0.33	4.39e-13	Gut microbiome composition (summer);
LGG	cis	rs9880211	1.000	rs9828088	chr3:136247790	C/T	cg21827317	chr3:136751795	NA	-0.49	-7.35	-0.32	8.94e-13	Body mass index;Height;
LGG	cis	rs2032447	0.610	rs189911	chr6:25965942	A/G	cg18357526	chr6:26021779	HIST1H4A	0.86	15.59	0.59	2.44e-44	Intelligence (multi-trait analysis);
LGG	cis	rs7241530	0.662	rs12456683	chr18:75909031	C/T	cg14642773	chr18:75888474	NA	0.45	8.66	0.37	8.11e-17	Educational attainment (years of education);
LGG	cis	rs17209837	0.607	rs45560338	chr7:87111106	T/C	cg25823085	chr7:87105416	ABCB4	0.3	7.41	0.33	6.09e-13	Gallbladder cancer;
LGG	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.24	-0.32	1.85e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg03806693	chr22:41940476	POLR3H	1.08	19.75	0.68	2e-63	Vitiligo;
LGG	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.97e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs10220309	1.000	rs10149279	chr14:80579214	G/T	cg08183125	chr14:80678293	DIO2	0.48	7.12	0.31	4.03e-12	Lung function (FEV1);
LGG	trans	rs10506458	0.915	rs2013042	chr12:63394211	A/G	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs490234	0.932	rs577026	chr9:128341023	C/T	cg14078157	chr9:128172775	NA	-0.39	-7.25	-0.32	1.72e-12	Mean arterial pressure;
LGG	trans	rs853679	0.546	rs200490	chr6:27796935	G/T	cg01620082	chr3:125678407	NA	-0.83	-9.66	-0.41	3.09e-20	Depression;
LGG	cis	rs1318772	0.932	rs348919	chr5:112842837	G/C	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs4727027	0.933	rs34578816	chr7:148847606	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.18	-0.62	1.56e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21850852	chr17:73746186	ITGB4	0.47	7.37	0.32	8.17e-13	Gut microbiome composition (summer);
LGG	cis	rs868036	0.681	rs28688285	chr15:68110297	T/C	cg18567174	chr15:68126065	LBXCOR1	-0.37	-6.69	-0.3	6.49e-11	Restless legs syndrome;
LGG	cis	rs5758511	0.524	rs738257	chr22:42569298	C/A	cg15128208	chr22:42549153	NA	0.77	11.81	0.48	2.57e-28	Birth weight;
LGG	cis	rs7098414	0.511	rs7898787	chr10:82156042	G/A	cg00277334	chr10:82204260	NA	-0.35	-7.68	-0.34	9.63e-14	Post bronchodilator FEV1;
LGG	cis	rs7666738	0.830	rs62318470	chr4:98925846	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs763121	0.853	rs5757226	chr22:39070550	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs9912468	0.901	rs17706845	chr17:64310185	A/G	cg19474267	chr17:64306194	PRKCA	0.94	24.87	0.76	2.53e-87	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2594989	0.943	rs2594970	chr3:11400877	C/T	cg01796438	chr3:11312864	ATG7	-0.53	-7.03	-0.31	7.3e-12	Circulating chemerin levels;
LGG	cis	rs2371030	0.714	rs13006513	chr2:211571641	A/G	cg18417063	chr2:211583084	NA	0.52	8.18	0.36	2.7e-15	Non-small cell lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20288129	chr3:122745632	SEMA5B	0.44	7.18	0.32	2.71e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7937682	0.593	rs1944123	chr11:111356407	T/C	cg09085632	chr11:111637200	PPP2R1B	0.6	10.31	0.43	1.42e-22	Primary sclerosing cholangitis;
LGG	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg02198044	chr15:56286336	NEDD4	-0.7	-11.82	-0.48	2.41e-28	Keloid;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg06719900	chr11:109292894	C11orf87	-0.44	-8.17	-0.35	3.03e-15	Schizophrenia;
LGG	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg06221963	chr1:154839813	KCNN3	-0.53	-11.07	-0.46	1.92e-25	Prostate cancer;
LGG	cis	rs16854884	1.000	rs16854886	chr3:143781492	A/G	cg06585982	chr3:143692056	C3orf58	0.54	8.29	0.36	1.24e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs3820928	0.874	rs10210997	chr2:227859108	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.39	-0.32	6.91e-13	Pulmonary function;
LGG	cis	rs9911578	1.000	rs302848	chr17:56686454	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs11229555	0.645	rs4579945	chr11:58190873	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12497850	0.931	rs10780033	chr3:48891275	T/C	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-12.95	-0.52	5.8e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487094	0.696	rs11153188	chr6:109879450	C/T	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg07511668	chr11:68622177	NA	0.48	9.15	0.39	1.86e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9914988	0.832	rs34267753	chr17:27157586	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg22348356	chr13:114891224	RASA3	0.42	8.15	0.35	3.42e-15	Schizophrenia;
LGG	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg23601095	chr6:26197514	HIST1H3D	0.69	8.73	0.38	4.72e-17	Gout;Renal underexcretion gout;
LGG	trans	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs875971	1.000	rs10244498	chr7:66116056	A/G	cg11764359	chr7:65958608	NA	0.77	14.37	0.56	5.67e-39	Aortic root size;
LGG	cis	rs35146811	0.555	rs2527898	chr7:99534030	C/G	cg22906224	chr7:99728672	NA	0.44	6.92	0.31	1.51e-11	Coronary artery disease;
LGG	cis	rs9858542	0.537	rs9818758	chr3:49382925	G/A	cg00383909	chr3:49044727	WDR6	0.58	8.23	0.36	1.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs60871478	0.947	rs4074610	chr7:791755	G/A	cg04727924	chr7:799746	HEATR2	-0.5	-7.93	-0.35	1.69e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs16854884	0.837	rs13083224	chr3:143801696	C/T	cg06585982	chr3:143692056	C3orf58	0.55	9.11	0.39	2.57e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.44	0.37	4.12e-16	Prostate cancer;
LGG	cis	rs12431204	0.834	rs9548087	chr13:38442757	T/A	cg23307680	chr13:38443104	TRPC4	0.4	6.92	0.31	1.48e-11	Schizophrenia;
LGG	trans	rs12517041	0.671	rs13160333	chr5:23272168	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.44	-6.98	-0.31	1.01e-11	Calcium levels;
LGG	trans	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.04	-0.46	2.5e-25	Neuroticism;
LGG	cis	rs2228479	0.850	rs11642010	chr16:89845111	T/C	cg04287289	chr16:89883240	FANCA	0.84	7.93	0.35	1.68e-14	Skin colour saturation;
LGG	trans	rs7395662	0.963	rs12800770	chr11:48604927	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.6	-0.33	1.66e-13	HDL cholesterol;
LGG	cis	rs7572733	0.515	rs1518368	chr2:198839145	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.09	0.46	1.6e-25	Dermatomyositis;
LGG	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5e-17	Aortic root size;
LGG	cis	rs7607369	0.648	rs7559629	chr2:219657013	A/T	cg01130898	chr2:219473002	PLCD4	0.41	6.73	0.3	5.01e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg11878867	chr6:150167359	LRP11	-0.56	-11.67	-0.48	9.16e-28	Lung cancer;
LGG	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg03806693	chr22:41940476	POLR3H	-0.82	-14.41	-0.56	3.77e-39	Vitiligo;
LGG	cis	rs4780401	0.678	rs7189287	chr16:11764608	A/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.23	-0.32	2.03e-12	Rheumatoid arthritis;
LGG	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.66	-0.41	3.03e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.61	9.08	0.39	3.05e-18	Renal function-related traits (BUN);
LGG	cis	rs4481887	1.000	rs7527822	chr1:248467301	A/G	cg00666640	chr1:248458726	OR2T12	0.6	9.71	0.41	2.14e-20	Common traits (Other);
LGG	cis	rs116095464	1.000	rs7736	chr5:314935	T/C	cg22857025	chr5:266934	NA	-1.29	-13.25	-0.52	3.26e-34	Breast cancer;
LGG	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.82	-0.42	8.3e-21	Response to antipsychotic treatment;
LGG	cis	rs9878978	0.554	rs1354241	chr3:2462577	C/G	cg21928760	chr3:2462534	CNTN4	0.52	12.62	0.51	1.34e-31	Blood pressure (smoking interaction);
LGG	cis	rs8170	0.603	rs4808622	chr19:17415457	C/G	cg04749549	chr19:17459798	NA	-0.39	-7.08	-0.31	5.38e-12	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs12926788	0.542	rs6497759	chr16:24801737	G/A	cg06028605	chr16:24865363	SLC5A11	0.47	7.75	0.34	5.87e-14	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2842992	0.789	rs7765490	chr6:160204326	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	7.05	0.31	6.52e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg12292205	chr6:26970375	C6orf41	0.73	14.22	0.55	2.39e-38	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2073300	1.000	rs6114101	chr20:23446322	C/T	cg12062639	chr20:23401060	NAPB	0.82	6.75	0.3	4.44e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6942756	0.659	rs624118	chr7:129096653	C/T	cg02491457	chr7:128862824	NA	-0.67	-11.67	-0.48	9.56e-28	White matter hyperintensity burden;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg23188684	chr11:67383651	NA	0.51	8.69	0.37	6.43e-17	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg26513180	chr16:89883248	FANCA	1.0	9.57	0.41	6.29e-20	Skin colour saturation;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.34	7.37	0.32	8.12e-13	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg25427524	chr10:38739819	LOC399744	-0.69	-12.97	-0.52	5.15e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg09904177	chr6:26538194	HMGN4	-0.37	-6.66	-0.3	7.81e-11	Schizophrenia;
LGG	cis	rs9650657	0.805	rs6982210	chr8:10599994	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-6.82	-0.3	2.9e-11	Neuroticism;
LGG	cis	rs9816226	0.591	rs76880877	chr3:185802628	A/C	cg00760338	chr3:185826511	ETV5	-0.82	-10.15	-0.43	5.57e-22	Obesity;Body mass index;
LGG	cis	rs3741151	1.000	rs76610873	chr11:73084387	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	10.08	0.42	9.91e-22	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7927592	0.913	rs66752716	chr11:68273626	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg02733842	chr7:1102375	C7orf50	0.57	8.47	0.37	3.35e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6496044	0.568	rs12898783	chr15:86066100	G/C	cg13263323	chr15:86062960	AKAP13	-0.37	-8.2	-0.36	2.32e-15	Interstitial lung disease;
LGG	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg04691961	chr3:161091175	C3orf57	0.42	8.86	0.38	1.67e-17	Morning vs. evening chronotype;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg26668828	chr6:292823	DUSP22	-0.69	-12.06	-0.49	2.6e-29	Menopause (age at onset);
LGG	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg03576123	chr11:487126	PTDSS2	-1.31	-17.34	-0.63	2.84e-52	Body mass index;
LGG	cis	rs936229	0.813	rs8033381	chr15:75080685	G/A	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.23	-0.43	2.74e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.39	0.32	7.03e-13	Renal function-related traits (BUN);
LGG	cis	rs7267979	0.966	rs2261790	chr20:25262789	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg14346243	chr4:90757452	SNCA	-0.39	-7.75	-0.34	5.96e-14	Dementia with Lewy bodies;
LGG	cis	rs2279817	0.735	rs12067869	chr1:17989765	G/T	cg21791023	chr1:18019539	ARHGEF10L	-0.61	-9.53	-0.4	9.02e-20	Neuroticism;
LGG	cis	rs3858526	0.834	rs10839160	chr11:6002113	T/C	cg25319279	chr11:5960081	NA	-0.53	-8.35	-0.36	7.9e-16	DNA methylation (variation);
LGG	cis	rs79349575	0.783	rs4255820	chr17:46996583	T/A	cg16584676	chr17:46985605	UBE2Z	0.47	8.01	0.35	9.22e-15	Type 2 diabetes;
LGG	cis	rs6815814	0.851	rs11736207	chr4:38766285	G/A	cg06935464	chr4:38784597	TLR10	0.53	7.07	0.31	5.69e-12	Breast cancer;
LGG	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6539267	0.741	rs35816179	chr12:106693710	T/C	cg00173435	chr12:106696525	TCP11L2	0.67	10.21	0.43	3.2800000000000002e-22	Tourette syndrome;
LGG	cis	rs12765878	1.000	rs11191846	chr10:105649813	A/G	cg11005552	chr10:105648138	OBFC1	1.03	27.22	0.78	4.08e-98	Coronary artery disease;
LGG	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	trans	rs1814175	0.817	rs28679516	chr11:50055998	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.82	-0.76	4.07e-87	Height;
LGG	cis	rs10865541	0.806	rs4971503	chr2:3417221	G/A	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.33e-11	Obesity-related traits;
LGG	cis	rs6692729	0.966	rs6697001	chr1:227014835	C/T	cg08708961	chr1:227070630	PSEN2	-0.29	-7.32	-0.32	1.14e-12	Electrodermal activity;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.29	0.55	1.19e-38	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15032444	chr6:43027766	KLC4;MRPL2	0.51	7.7	0.34	8.45e-14	Gut microbiome composition (summer);
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.12	0.35	4.25e-15	Tonsillectomy;
LGG	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg26384229	chr12:38710491	ALG10B	0.97	21.75	0.71	8.55e-73	Bladder cancer;
LGG	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg20503657	chr10:835505	NA	0.76	10.5	0.44	2.78e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs7945718	0.870	rs10765988	chr11:12731218	C/T	cg25843174	chr11:12811716	TEAD1	0.42	8.45	0.37	3.84e-16	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15057251	chr18:32621312	MAPRE2	0.5	7.63	0.33	1.32e-13	Gut microbiome composition (summer);
LGG	cis	rs9914544	0.628	rs4924924	chr17:18677774	C/G	cg26378065	chr17:18585709	ZNF286B	0.42	8.07	0.35	6.3e-15	Educational attainment (years of education);
LGG	cis	rs17767392	0.756	rs11626445	chr14:71739134	C/T	cg02058870	chr14:72053146	SIPA1L1	0.41	7.98	0.35	1.15e-14	Mitral valve prolapse;
LGG	cis	rs2731664	0.792	rs2630764	chr5:176880085	C/T	cg23176889	chr5:176863531	GRK6	-0.66	-13.15	-0.52	8.55e-34	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.515	rs1405031	chr12:33958931	A/C	cg26384229	chr12:38710491	ALG10B	0.71	14.25	0.55	1.86e-38	Morning vs. evening chronotype;
LGG	cis	rs7615952	0.932	rs7630077	chr3:125649676	T/C	cg05084668	chr3:125655381	ALG1L	-0.88	-11.17	-0.46	8.28e-26	Blood pressure (smoking interaction);
LGG	cis	rs79349575	0.783	rs62078372	chr17:47028989	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs7646881	0.812	rs73015665	chr3:158453934	A/T	cg19483011	chr3:158453295	NA	-0.6	-8.15	-0.35	3.34e-15	Tetralogy of Fallot;
LGG	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs7937890	0.559	rs2167160	chr11:14507449	C/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs4242434	0.927	rs57594397	chr8:22475657	T/C	cg19455335	chr8:22457658	C8orf58	-0.44	-8.9	-0.38	1.31e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12477438	0.520	rs1133978	chr2:99741964	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs9880211	1.000	rs6771002	chr3:136241028	T/A	cg21827317	chr3:136751795	NA	-0.48	-7.17	-0.32	2.91e-12	Body mass index;Height;
LGG	cis	rs4671458	0.802	rs12463603	chr2:63798198	C/A	cg17519650	chr2:63277830	OTX1	-0.56	-7.38	-0.32	7.38e-13	Subjective well-being;
LGG	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27286337	chr10:134555280	INPP5A	-0.84	-12.47	-0.5	5.41e-31	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1799949	1.000	rs4793192	chr17:41204390	T/C	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg08822215	chr16:89438651	ANKRD11	-0.37	-7.19	-0.32	2.58e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg02462569	chr6:150064036	NUP43	-0.35	-7.45	-0.33	4.73e-13	Lung cancer;
LGG	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg08645402	chr16:4508243	NA	0.51	9.62	0.41	4.34e-20	Schizophrenia;
LGG	cis	rs447735	0.587	rs11640702	chr16:89729169	A/G	cg08949735	chr16:89699720	DPEP1	0.37	7.39	0.33	6.7e-13	Hemoglobin concentration;
LGG	trans	rs6787172	0.622	rs10446336	chr3:158119655	C/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg09263875	chr16:632152	PIGQ	0.66	13.05	0.52	2.23e-33	Height;
LGG	cis	rs7659604	0.521	rs4833232	chr4:122684367	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.3	0.32	1.3e-12	Type 2 diabetes;
LGG	cis	rs1580019	0.961	rs1580021	chr7:32497702	T/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs7633787	0.510	rs601598	chr3:23040110	A/G	cg00327796	chr3:23032191	NA	-0.42	-8.2	-0.36	2.42e-15	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs721917	0.506	rs2493722	chr10:81656745	G/A	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs1401999	0.966	rs2313216	chr3:183637251	C/T	cg20387954	chr3:183756860	HTR3D	0.62	12.45	0.5	6.57e-31	Anterior chamber depth;
LGG	cis	rs7635838	0.785	rs2606738	chr3:11396562	T/C	cg00170343	chr3:11313890	ATG7	0.5	8.21	0.36	2.18e-15	HDL cholesterol;
LGG	cis	rs9814567	1.000	rs11706117	chr3:134212526	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.92	-0.51	7.8e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1008375	0.931	rs6449309	chr4:17573208	C/T	cg18681998	chr4:17616180	MED28	0.79	16.06	0.6	1.83e-46	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7523273	0.517	rs2985106	chr1:207892033	T/G	cg22525895	chr1:207977042	MIR29B2	-0.44	-8.21	-0.36	2.18e-15	Schizophrenia;
LGG	cis	rs7312933	0.501	rs7296357	chr12:42729891	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.48	-7.67	-0.34	1e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10197940	0.662	rs13555	chr2:152333304	C/A	cg06191203	chr2:152266755	RIF1	-0.42	-7.41	-0.33	6.15e-13	Lung cancer;
LGG	cis	rs12286929	0.736	rs11215397	chr11:115044076	G/A	cg04055981	chr11:115044050	NA	0.39	7.19	0.32	2.65e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.52	-0.33	2.96e-13	Neuroticism;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg22907277	chr7:1156413	C7orf50	0.45	7.51	0.33	3.15e-13	Longevity;Endometriosis;
LGG	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg03806693	chr22:41940476	POLR3H	-0.98	-17.46	-0.63	7.93e-53	Vitiligo;
LGG	cis	rs4819052	1.000	rs13052356	chr21:46663588	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	13.06	0.52	2.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg13010199	chr12:38710504	ALG10B	-0.65	-13.67	-0.54	5.59e-36	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03811519	chr9:134001305	NUP214	0.43	6.76	0.3	4.19e-11	Gut microbiome composition (summer);
LGG	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg20892847	chr12:58011875	NA	0.35	7.21	0.32	2.31e-12	Multiple sclerosis;
LGG	cis	rs7020830	0.522	rs10814509	chr9:37111057	A/G	cg14294708	chr9:37120828	ZCCHC7	0.79	15.33	0.58	3.26e-43	Schizophrenia;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg24829409	chr8:58192753	C8orf71	-0.82	-13.18	-0.52	6.61e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs10991814	0.920	rs7856668	chr9:94040209	C/A	cg14446406	chr9:93919335	NA	-0.72	-8.12	-0.35	4.4e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs883565	0.569	rs784489	chr3:39173426	T/C	cg01426195	chr3:39028469	NA	0.65	14.1	0.55	8.48e-38	Handedness;
LGG	cis	rs4664308	0.618	rs6722275	chr2:160893260	C/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.57	-0.47	2.32e-27	Idiopathic membranous nephropathy;
LGG	cis	rs1867631	0.876	rs10889637	chr1:67097465	C/T	cg13052034	chr1:66999238	SGIP1	0.46	8.95	0.38	8.84e-18	Menopause (age at onset);
LGG	cis	rs9914988	1.000	rs901975	chr17:27189774	A/G	cg20469991	chr17:27169893	C17orf63	0.55	6.93	0.31	1.46e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22624255	chr19:19779476	ZNF101	0.46	7.61	0.33	1.56e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs34638686	1	rs34638686	chr3:48682658	C/T	cg00383909	chr3:49044727	WDR6	0.87	9.73	0.41	1.73e-20	Educational attainment (years of education);
LGG	cis	rs7086627	0.515	rs4933390	chr10:82213081	A/C	cg00277334	chr10:82204260	NA	-0.53	-12.57	-0.5	2.27e-31	Post bronchodilator FEV1;
LGG	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg03959625	chr15:84868606	LOC388152	0.57	9.03	0.39	4.55e-18	Schizophrenia;
LGG	cis	rs7264396	0.635	rs6060656	chr20:34466382	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.45e-12	Total cholesterol levels;
LGG	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg08564027	chr20:61660810	NA	1.02	25.21	0.76	6.33e-89	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg04450456	chr4:17643702	FAM184B	0.32	7.06	0.31	6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs17321999	1.000	rs111597890	chr2:30492116	G/A	cg05247661	chr2:30472410	LBH	0.56	8.64	0.37	9.06e-17	Systemic lupus erythematosus;
LGG	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg06637938	chr14:75390232	RPS6KL1	0.59	11.19	0.46	7.14e-26	Height;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	cis	rs2371030	1.000	rs10184528	chr2:211575134	A/T	cg18417063	chr2:211583084	NA	-0.63	-12.3	-0.5	2.68e-30	Non-small cell lung cancer;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.44	0.44	4.84e-23	Testicular germ cell tumor;
LGG	cis	rs701145	0.762	rs896014	chr3:153842691	A/G	cg17054900	chr3:154042577	DHX36	0.78	9.31	0.4	5.17e-19	Coronary artery disease;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg02772935	chr3:125709198	NA	-0.54	-6.96	-0.31	1.15e-11	Blood pressure (smoking interaction);
LGG	cis	rs6121246	0.567	rs6060399	chr20:30220823	C/T	cg13852791	chr20:30311386	BCL2L1	0.68	9.06	0.39	3.55e-18	Mean corpuscular hemoglobin;
LGG	cis	rs9300255	0.664	rs28636834	chr12:123871070	A/C	cg00376283	chr12:123451042	ABCB9	-0.53	-7.96	-0.35	1.34e-14	Neutrophil percentage of white cells;
LGG	cis	rs902774	0.530	rs11834907	chr12:53350985	C/T	cg05393297	chr12:53359155	NA	-0.58	-7.37	-0.32	8.06e-13	Prostate cancer;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.39	-0.32	7.09e-13	Bipolar disorder;
LGG	trans	rs4714291	1.000	rs4714290	chr6:40003502	A/G	cg02267698	chr19:7991119	CTXN1	0.53	8.18	0.36	2.73e-15	Strep throat;
LGG	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg03264133	chr6:25882463	NA	-0.46	-7.57	-0.33	2.06e-13	Iron status biomarkers;
LGG	trans	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.75	-0.34	5.72e-14	Neuroticism;
LGG	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.1	0.31	4.86e-12	Educational attainment;
LGG	cis	rs10214930	0.723	rs56139857	chr7:27678971	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.83	0.3	2.67e-11	Hypospadias;
LGG	cis	rs765787	0.530	rs2413782	chr15:45538490	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs9790314	0.967	rs336586	chr3:161081347	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-15.52	-0.59	4.64e-44	Morning vs. evening chronotype;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs638893	0.636	rs2186781	chr11:118605447	T/C	cg13782932	chr11:118662891	DDX6	0.37	6.78	0.3	3.58e-11	Vitiligo;
LGG	cis	rs4731207	0.597	rs12536017	chr7:124562301	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs7737355	0.947	rs10477736	chr5:130922125	T/C	cg06307176	chr5:131281290	NA	0.56	9.31	0.4	5.06e-19	Life satisfaction;
LGG	cis	rs16957091	0.909	rs4265781	chr15:43028749	T/A	cg07484255	chr15:43025164	CDAN1	-0.49	-7.03	-0.31	7.33e-12	MGMT methylation in smokers;
LGG	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg09696939	chr10:60272079	BICC1	0.39	7.5	0.33	3.23e-13	Refractive error;
LGG	cis	rs2888674	0.505	rs7795051	chr7:150504341	A/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.31	7.9	0.34	1.99e-14	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs34734847	1.000	rs3021338	chr12:121162989	A/G	cg21892295	chr12:121157589	UNC119B	-0.47	-8.96	-0.38	8.23e-18	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.13	-0.31	3.81e-12	Menopause (age at onset);
LGG	cis	rs6496044	0.568	rs6496039	chr15:86061963	A/T	cg13263323	chr15:86062960	AKAP13	-0.38	-8.29	-0.36	1.21e-15	Interstitial lung disease;
LGG	cis	rs988958	0.675	rs35531047	chr2:42220435	T/A	cg19376973	chr2:42229025	NA	0.61	9.83	0.42	7.7e-21	Hypospadias;
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.65	0.3	8.51e-11	Electroencephalogram traits;
LGG	cis	rs9902453	0.845	rs2259855	chr17:28097860	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.92	-0.54	5e-37	Coffee consumption (cups per day);
LGG	cis	rs9290877	0.743	rs9877192	chr3:188426256	A/G	cg17392043	chr3:188495102	LPP	-0.4	-6.85	-0.3	2.35e-11	IgE levels;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs17453880	0.929	rs4958324	chr5:152022385	T/C	cg10931792	chr5:152022470	NA	0.4	8.82	0.38	2.41e-17	Subjective well-being;
LGG	cis	rs4262150	0.883	rs72799143	chr5:152100749	A/G	cg12297329	chr5:152029980	NA	-0.75	-13.55	-0.53	1.81e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2710642	0.962	rs6545972	chr2:63084682	G/A	cg17519650	chr2:63277830	OTX1	0.49	8.13	0.35	3.99e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.05	0.55	1.3e-37	Obesity-related traits;
LGG	cis	rs9443189	0.526	rs6902898	chr6:76201856	G/A	cg01950844	chr6:76311363	SENP6	0.73	9.3	0.4	5.76e-19	Prostate cancer;
LGG	cis	rs4919694	0.572	rs12243903	chr10:104906992	T/C	cg04362960	chr10:104952993	NT5C2	0.88	13.41	0.53	7.14e-35	Arsenic metabolism;
LGG	cis	rs1190596	0.732	rs7156564	chr14:102558588	A/G	cg23904247	chr14:102554826	HSP90AA1	-0.27	-7.05	-0.31	6.57e-12	Behavioural disinhibition (generation interaction);
LGG	cis	rs1003719	0.788	rs1543748	chr21:38446581	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.58	0.63	2.37e-53	Eye color traits;
LGG	cis	rs283228	0.550	rs687497	chr6:101792897	G/A	cg02011392	chr6:101847541	GRIK2	0.54	7.32	0.32	1.1e-12	Coenzyme Q10 levels;
LGG	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg00717180	chr2:96193071	NA	-0.46	-8.31	-0.36	1.05e-15	HDL cholesterol;
LGG	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg05692746	chr2:100937584	LONRF2	-0.59	-10.33	-0.43	1.16e-22	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25993851	chr11:46722334	ARHGAP1;ZNF408	0.47	7.46	0.33	4.19e-13	Cognitive performance;
LGG	cis	rs653465	0.708	rs12487340	chr3:27208975	C/T	cg02860705	chr3:27208620	NA	0.42	8.02	0.35	8.76e-15	Breast cancer (early onset);
LGG	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg16797656	chr11:68205561	LRP5	0.39	6.85	0.3	2.4e-11	Total body bone mineral density;
LGG	cis	rs2274273	0.934	rs8021940	chr14:55719715	G/A	cg04306507	chr14:55594613	LGALS3	0.63	17.37	0.63	2.09e-52	Protein biomarker;
LGG	cis	rs78487399	0.710	rs7572923	chr2:43685109	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.85	-0.3	2.31e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs1816752	0.721	rs7399656	chr13:24989846	A/G	cg22771759	chr13:24902376	NA	0.41	6.88	0.3	1.9e-11	Obesity-related traits;
LGG	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg08085267	chr17:45401833	C17orf57	0.63	13.03	0.52	2.84e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7188861	0.813	rs34787601	chr16:11399538	T/A	cg01510278	chr16:11456238	NA	0.31	7.38	0.32	7.47e-13	HDL cholesterol;
LGG	cis	rs2916247	0.908	rs7002049	chr8:93114414	T/C	cg10183463	chr8:93005414	RUNX1T1	0.4	8.18	0.36	2.85e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4604732	0.631	rs74154672	chr1:247625625	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.667	rs9892469	chr17:80093657	T/C	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.28e-16	Life satisfaction;
LGG	cis	rs9902453	1.000	rs59274738	chr17:28437635	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.18	0.52	6.65e-34	Coffee consumption (cups per day);
LGG	cis	rs897080	0.552	rs1067384	chr2:44644554	G/A	cg00619915	chr2:44497795	NA	-0.49	-6.87	-0.3	2.07e-11	Height;
LGG	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg07636037	chr3:49044803	WDR6	0.54	7.32	0.32	1.07e-12	Menarche (age at onset);
LGG	cis	rs877282	0.947	rs7904978	chr10:768078	C/T	cg17470449	chr10:769945	NA	0.61	7.62	0.33	1.46e-13	Uric acid levels;
LGG	cis	rs6732160	0.691	rs6728147	chr2:73423490	A/G	cg01422370	chr2:73384389	NA	-0.48	-9.24	-0.39	9.18e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6121246	0.821	rs115585940	chr20:30317902	T/C	cg13852791	chr20:30311386	BCL2L1	0.8	12.61	0.51	1.48e-31	Mean corpuscular hemoglobin;
LGG	cis	rs2236918	0.710	rs2797602	chr1:242029206	G/T	cg17736920	chr1:242011382	EXO1	0.39	7.0	0.31	9.23e-12	Menopause (age at onset);
LGG	trans	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg08862035	chr2:2617432	NA	0.43	6.95	0.31	1.25e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9463078	0.625	rs1329710	chr6:44969125	T/C	cg25276700	chr6:44698697	NA	-0.34	-6.98	-0.31	9.97e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs8180040	0.966	rs6800271	chr3:47470787	A/T	cg16586182	chr3:47516702	SCAP	0.77	15.4	0.58	1.63e-43	Colorectal cancer;
LGG	cis	rs977987	0.778	rs11149825	chr16:75434878	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.1	0.42	8.55e-22	Dupuytren's disease;
LGG	cis	rs17286411	0.750	rs4788579	chr16:71951845	A/C	cg06353428	chr16:71660113	MARVELD3	0.41	7.25	0.32	1.79e-12	Blood protein levels;
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.85	0.3	2.35e-11	Lung cancer;
LGG	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg16325326	chr1:53192061	ZYG11B	0.83	22.44	0.72	4.99e-76	Monocyte count;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.45	0.33	4.66e-13	Schizophrenia;
LGG	cis	rs774359	0.789	rs17769038	chr9:27489693	G/A	cg22262168	chr9:27528999	MOBKL2B	0.46	6.85	0.3	2.44e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	cis	rs4481887	0.861	rs1339989	chr1:248511624	C/G	cg01631408	chr1:248437212	OR2T33	-0.5	-9.02	-0.39	4.91e-18	Common traits (Other);
LGG	cis	rs283228	1.000	rs2518177	chr6:101827414	T/A	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	trans	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.56	-0.44	1.73e-23	Total cholesterol levels;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs6430585	0.528	rs114760827	chr2:136661110	G/A	cg07169764	chr2:136633963	MCM6	1.22	22.34	0.72	1.46e-75	Corneal structure;
LGG	cis	rs2304069	0.545	rs13168011	chr5:149392377	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.24	0.36	1.84e-15	HIV-1 control;
LGG	cis	rs9815354	0.812	rs73069356	chr3:41752845	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.03	0.39	4.55e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs5750830	0.649	rs5757664	chr22:39821536	A/G	cg04986931	chr22:39850128	NA	0.34	7.8	0.34	4.05e-14	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.74	-0.38	4.31e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4642101	0.561	rs9831765	chr3:12805934	A/T	cg24848339	chr3:12840334	CAND2	0.37	8.31	0.36	1.06e-15	QRS complex (12-leadsum);
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg26384229	chr12:38710491	ALG10B	-0.83	-18.28	-0.65	1.35e-56	Morning vs. evening chronotype;
LGG	cis	rs9894429	0.646	rs7405870	chr17:79617284	G/A	cg10661904	chr17:79619235	PDE6G	-0.51	-10.33	-0.43	1.22e-22	Eye color traits;
LGG	cis	rs2228479	0.850	rs2238525	chr16:89809902	T/C	cg06558623	chr16:89946397	TCF25	1.06	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg13012494	chr21:47604986	C21orf56	0.58	10.14	0.43	5.94e-22	Testicular germ cell tumor;
LGG	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg12310025	chr6:25882481	NA	-0.58	-11.34	-0.47	1.81e-26	Blood metabolite levels;
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18876405	chr7:65276391	NA	0.53	9.46	0.4	1.59e-19	Aortic root size;
LGG	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.94	-0.38	9.51e-18	Neuroticism;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.01	0.52	3.35e-33	Prudent dietary pattern;
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.85	-0.38	1.87e-17	Aortic root size;
LGG	cis	rs2540226	0.539	rs2716682	chr2:39909067	A/T	cg18968196	chr2:39892502	TMEM178	0.31	8.5	0.37	2.56e-16	Personality dimensions;
LGG	trans	rs8073060	0.785	rs11659054	chr17:33867678	C/T	cg19694781	chr19:47549865	TMEM160	0.62	9.85	0.42	6.76e-21	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.73	-0.3	5.17e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs11239187	0.523	rs35033359	chr10:45100712	T/C	cg03916630	chr10:45065415	NA	0.4	7.15	0.32	3.37e-12	Body mass index;
LGG	cis	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs9972944	0.783	rs9972942	chr17:63771007	A/G	cg07283582	chr17:63770753	CCDC46	0.42	8.16	0.35	3.2e-15	Total body bone mineral density;
LGG	cis	rs2228479	0.718	rs11645376	chr16:89912281	G/C	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg02158880	chr13:53174818	NA	0.7	16.32	0.6	1.22e-47	Lewy body disease;
LGG	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg08645402	chr16:4508243	NA	0.45	7.38	0.32	7.57e-13	Schizophrenia;
LGG	trans	rs9354308	1.000	rs9354308	chr6:66565353	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.55	9.47	0.4	1.45e-19	Metabolite levels;
LGG	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg26597838	chr10:835615	NA	0.75	10.25	0.43	2.35e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg05084668	chr3:125655381	ALG1L	-0.67	-8.47	-0.37	3.29e-16	Blood pressure (smoking interaction);
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg04166393	chr7:2884313	GNA12	0.49	9.3	0.4	5.42e-19	Height;
LGG	cis	rs745080	0.698	rs8003291	chr14:52922654	G/T	cg23333723	chr14:53022898	GPR137C	-0.29	-6.65	-0.3	8.52e-11	Orofacial clefts;
LGG	cis	rs951366	0.677	rs1775140	chr1:205672107	C/CA	cg23034840	chr1:205782522	SLC41A1	-0.74	-8.48	-0.37	2.99e-16	Menarche (age at onset);
LGG	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg23422044	chr7:1970798	MAD1L1	0.61	10.25	0.43	2.37e-22	Bipolar disorder;
LGG	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11644478	chr21:40555479	PSMG1	0.89	15.6	0.59	2.11e-44	Cognitive function;
LGG	cis	rs7712401	0.623	rs26372	chr5:122206447	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.71	-0.3	5.7e-11	Mean platelet volume;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14237749	chr9:136344651	SLC2A6	-0.4	-6.68	-0.3	6.93e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.69	-0.37	6.15e-17	Skin colour saturation;
LGG	cis	rs9463078	0.691	rs9349313	chr6:45119782	T/C	cg25276700	chr6:44698697	NA	-0.32	-6.7	-0.3	6.14e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10421328	0.848	rs7253821	chr19:19784891	G/A	cg11584989	chr19:19387371	SF4	0.5	7.44	0.33	5.07e-13	Parental longevity (combined parental age at death);
LGG	cis	rs9880211	0.948	rs9872178	chr3:135986438	T/G	cg21827317	chr3:136751795	NA	-0.46	-6.77	-0.3	3.97e-11	Body mass index;Height;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg21782813	chr7:2030301	MAD1L1	0.54	13.44	0.53	5.4e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.58	-0.59	2.57e-44	Rheumatoid arthritis;
LGG	trans	rs7647973	0.593	rs55997059	chr3:49858661	A/T	cg21659725	chr3:3221576	CRBN	0.59	7.79	0.34	4.43e-14	Menarche (age at onset);
LGG	cis	rs4819052	0.808	rs2838825	chr21:46655651	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.3	0.5	2.74e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2718058	0.692	rs2718041	chr7:37783944	A/G	cg24998770	chr7:37888106	TXNDC3	0.52	8.76	0.38	3.77e-17	Alzheimer's disease (late onset);
LGG	cis	rs9815354	1.000	rs12639255	chr3:41861738	T/C	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs116095464	0.558	rs73031482	chr5:227594	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs58365910	1	rs58365910	chr15:78849034	T/C	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.56	-0.33	2.23e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.04	-0.35	7.35e-15	Neuroticism;
LGG	cis	rs3768617	0.510	rs2296293	chr1:183095477	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg03474202	chr17:45855739	NA	-0.27	-7.98	-0.35	1.14e-14	IgG glycosylation;
LGG	cis	rs240764	0.764	rs6910391	chr6:100925774	T/C	cg21058520	chr6:100914733	NA	0.5	8.83	0.38	2.16e-17	Neuroticism;
LGG	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.71	-0.34	7.83e-14	Iron status biomarkers;
LGG	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.96	10.44	0.44	4.73e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg02187348	chr16:89574699	SPG7	0.46	7.45	0.33	4.77e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7666738	0.962	rs1527515	chr4:99025733	C/A	cg05340658	chr4:99064831	C4orf37	0.43	6.81	0.3	3.02e-11	Colonoscopy-negative controls vs population controls;
LGG	trans	rs4650994	0.544	rs2811306	chr1:178599248	C/G	cg05059571	chr16:84539110	KIAA1609	0.54	10.12	0.43	6.93e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9341835	0.772	rs9294202	chr6:64138954	A/G	cg00787780	chr6:64151745	NA	0.4	7.35	0.32	9.28e-13	Schizophrenia;
LGG	cis	rs2472297	1.000	rs2472297	chr15:75027880	A/G	cg17294928	chr15:75287854	SCAMP5	-0.56	-7.48	-0.33	3.65e-13	Caffeine metabolism (plasma 1,3,7-trimethylxanthine (caffeine) level);Coffee consumption (cups per day);Coffee consumption;Caffeine metabolism (plasma 1,3-dimethylxanthine (theophylline) level);Caffeine metabolism (plasma 1,7-dimethylxanthine (paraxanthine) to 1,3,7-trimethylxanthine (caffeine) ratio);
LGG	cis	rs283228	0.959	rs1385763	chr6:101808219	T/C	cg27451362	chr6:101846650	GRIK2	0.52	8.79	0.38	2.9e-17	Coenzyme Q10 levels;
LGG	cis	rs7084402	0.967	rs1658439	chr10:60325986	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.21	0.65	2.89e-56	Refractive error;
LGG	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg18479299	chr3:125709523	NA	-0.58	-7.4	-0.33	6.44e-13	Blood pressure (smoking interaction);
LGG	cis	rs7432375	0.610	rs4420814	chr3:136513282	T/C	cg21827317	chr3:136751795	NA	0.44	7.93	0.35	1.7e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.6	-9.1	-0.39	2.77e-18	Birth weight;
LGG	cis	rs60843830	1.000	rs62114497	chr2:214837	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.43	0.56	3.16e-39	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4819052	0.851	rs8130285	chr21:46671701	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.71	0.51	5.81e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs424971	0.933	rs8051462	chr16:85947327	C/T	cg10334323	chr16:85945517	IRF8	0.32	6.92	0.31	1.53e-11	Monocyte count;
LGG	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.5	0.5	4.25e-31	Colorectal cancer;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg20120463	chr17:44301886	NA	-0.48	-7.46	-0.33	4.43e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg09699651	chr6:150184138	LRP11	0.54	9.33	0.4	4.31e-19	Lung cancer;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00684032	chr4:1343700	KIAA1530	0.42	8.07	0.35	5.92e-15	Obesity-related traits;
LGG	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.4	-6.97	-0.31	1.1e-11	Coronary artery disease;
LGG	cis	rs1577917	0.839	rs6454504	chr6:86580330	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.22	-0.43	3.04e-22	Response to antipsychotic treatment;
LGG	cis	rs765787	0.556	rs2413778	chr15:45539397	C/A	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06394585	chr2:148777915	ORC4L	0.44	6.92	0.31	1.54e-11	Gut microbiome composition (summer);
LGG	cis	rs42235	0.683	rs60814640	chr7:92286918	A/G	cg15732164	chr7:92237376	CDK6	-0.47	-9.69	-0.41	2.44e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1256531	0.590	rs4902382	chr14:65764557	T/C	cg15999311	chr14:65749247	NA	0.72	7.68	0.34	9.64e-14	Conduct disorder (symptom count);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18045831	chr1:19577885	MRTO4;KIAA0090	-0.46	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	trans	rs9354308	0.809	rs9363461	chr6:66557574	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.64	-0.37	9.09e-17	Metabolite levels;
LGG	cis	rs7481584	1.000	rs4758623	chr11:3014953	T/C	cg08508325	chr11:3079039	CARS	0.39	7.13	0.31	3.8e-12	Calcium levels;
LGG	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg08344181	chr3:125677491	NA	-0.67	-8.0	-0.35	9.78e-15	Breast cancer;
LGG	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	10.29	0.43	1.75e-22	Multiple sclerosis;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg03727229	chr11:118479170	PHLDB1	0.39	7.01	0.31	8.71e-12	Systemic lupus erythematosus;
LGG	trans	rs9354308	0.764	rs9453462	chr6:66583491	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.42	7.23	0.32	2.02e-12	Metabolite levels;
LGG	cis	rs9399135	0.967	rs34546690	chr6:135369709	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.61	0.41	4.63e-20	Red blood cell count;
LGG	cis	rs977987	0.843	rs2059256	chr16:75395835	G/T	cg03315344	chr16:75512273	CHST6	0.51	10.44	0.44	4.73e-23	Dupuytren's disease;
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.19	-0.32	2.63e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487094	0.813	rs67857472	chr6:109680328	C/T	cg01125227	chr6:109776195	MICAL1	0.49	8.34	0.36	8.82e-16	Height;
LGG	cis	rs2120019	0.938	rs59094290	chr15:75308561	G/T	cg09165964	chr15:75287851	SCAMP5	-1.07	-22.29	-0.72	2.7e-75	Blood trace element (Zn levels);
LGG	cis	rs12200782	1.000	rs6456741	chr6:26617058	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.16	-0.35	3.25e-15	Small cell lung carcinoma;
LGG	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg19812747	chr11:111475976	SIK2	-0.49	-10.3	-0.43	1.49e-22	Primary sclerosing cholangitis;
LGG	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg25358565	chr5:93447407	FAM172A	1.37	17.02	0.62	8.51e-51	Diabetic retinopathy;
LGG	cis	rs597583	0.775	rs12806865	chr11:117404769	C/T	cg27161313	chr11:117392002	DSCAML1	0.4	7.25	0.32	1.76e-12	Putamen volume;
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg00800038	chr16:89945340	TCF25	-0.7	-9.21	-0.39	1.13e-18	Skin colour saturation;
LGG	cis	rs2734839	0.927	rs2734837	chr11:113286829	C/T	cg14159747	chr11:113255604	NA	0.28	7.45	0.33	4.49e-13	Information processing speed;
LGG	cis	rs994014	0.640	rs58706636	chr4:82218003	A/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.29	-0.32	1.37e-12	Height;
LGG	cis	rs16957091	1.000	rs28549876	chr15:43025524	T/G	cg07484255	chr15:43025164	CDAN1	-0.49	-7.03	-0.31	7.33e-12	MGMT methylation in smokers;
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.24	-0.43	2.45e-22	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.99	0.31	9.9e-12	Prudent dietary pattern;
LGG	cis	rs9393692	0.905	rs4412192	chr6:26290377	A/G	cg00631329	chr6:26305371	NA	0.55	10.25	0.43	2.28e-22	Educational attainment;
LGG	cis	rs12477438	0.765	rs6735801	chr2:99657995	G/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs1793639	0.777	rs10894496	chr11:131967658	C/G	cg13908476	chr11:131942942	NTM	0.42	8.58	0.37	1.46e-16	Myopia;
LGG	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg18393722	chr15:85113863	UBE2QP1	-0.42	-7.06	-0.31	5.95e-12	Schizophrenia;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.7	-0.34	8.13e-14	Lung cancer;
LGG	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.17	0.46	7.85e-26	Bone mineral density;
LGG	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg22348356	chr13:114891224	RASA3	0.4	7.78	0.34	4.63e-14	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26523407	chr4:152021314	RPS3A	0.44	7.37	0.32	7.99e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6598955	0.585	rs11577098	chr1:26602525	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg15664640	chr17:80829946	TBCD	0.49	9.53	0.41	8.55e-20	Breast cancer;
LGG	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg20302533	chr7:39170763	POU6F2	0.32	7.75	0.34	6.08e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg17809284	chr5:56205270	C5orf35	-0.54	-8.84	-0.38	2.02e-17	Initial pursuit acceleration;
LGG	cis	rs8060686	0.641	rs12445396	chr16:68155121	G/A	cg04539111	chr16:67997858	SLC12A4	-0.4	-6.65	-0.3	8.24e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.71	0.3	5.75e-11	Nose size;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg19223190	chr17:80058835	NA	0.43	8.32	0.36	1.01e-15	Life satisfaction;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg22907277	chr7:1156413	C7orf50	0.69	8.71	0.38	5.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9457247	1.000	rs9457247	chr6:167392174	C/T	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	cis	rs2371030	1.000	rs12473077	chr2:211565470	G/C	cg18417063	chr2:211583084	NA	0.63	12.09	0.49	1.96e-29	Non-small cell lung cancer;
LGG	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.83	0.34	3.46e-14	Lung cancer;
LGG	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg15325629	chr6:28072465	NA	0.95	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9457247	0.765	rs6900701	chr6:167434112	A/G	cg07741184	chr6:167504864	NA	0.41	9.28	0.4	6.64e-19	Crohn's disease;
LGG	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg20913747	chr6:44695427	NA	-0.59	-10.04	-0.42	1.37e-21	Total body bone mineral density;
LGG	trans	rs9929218	0.581	rs12185157	chr16:68784587	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.99	22.11	0.72	1.83e-74	Colorectal cancer;
LGG	cis	rs710841	0.562	rs1551236	chr4:82299687	C/A	cg07938847	chr4:82126349	PRKG2	-0.28	-6.84	-0.3	2.53e-11	Height;Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs2243480	1.000	rs387676	chr7:65598220	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs4704187	0.687	rs11950665	chr5:74423339	A/G	cg03227963	chr5:74354835	NA	0.31	6.69	0.3	6.61e-11	Response to amphetamines;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs17534004	0.844	rs71436423	chr13:31480720	G/A	cg00367615	chr13:31480979	C13orf33	0.35	6.9	0.31	1.68e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg25703541	chr22:24373054	LOC391322	-0.86	-16.85	-0.62	5.22e-50	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2717559	0.522	rs10956987	chr8:143886613	T/C	cg06565975	chr8:143823917	SLURP1	-0.28	-6.89	-0.3	1.88e-11	Urinary tract infection frequency;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07734253	chr16:30194717	CORO1A	0.41	6.86	0.3	2.28e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1506636	1.000	rs767637	chr7:123321978	C/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs12618769	0.597	rs3769723	chr2:99105988	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	2.02e-16	Bipolar disorder;
LGG	cis	rs4731207	0.506	rs12531282	chr7:124625462	A/G	cg05630886	chr7:124431682	NA	-0.29	-6.72	-0.3	5.4e-11	Cutaneous malignant melanoma;
LGG	cis	rs910187	0.597	rs2073172	chr20:45809176	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.07	-0.39	3.35e-18	Migraine;
LGG	cis	rs9427116	0.840	rs9427113	chr1:154626477	A/G	cg11650704	chr1:154556575	ADAR	-0.41	-8.05	-0.35	7.01e-15	Blood protein levels;
LGG	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg18654377	chr3:49208889	KLHDC8B	-0.52	-8.38	-0.36	6.38e-16	Menarche (age at onset);
LGG	cis	rs653465	0.739	rs67565656	chr3:27124194	G/A	cg02860705	chr3:27208620	NA	-0.4	-7.71	-0.34	7.75e-14	Breast cancer (early onset);
LGG	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg17211192	chr8:82754475	SNX16	-0.72	-12.01	-0.49	4.19e-29	Diastolic blood pressure;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg07701084	chr6:150067640	NUP43	0.69	13.18	0.52	6.28e-34	Lung cancer;
LGG	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.13e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg19223190	chr17:80058835	NA	0.44	8.47	0.37	3.26e-16	Life satisfaction;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.84	-0.48	1.87e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1728785	0.901	rs2862781	chr16:68639234	A/T	cg02972257	chr16:68554789	NA	-0.53	-7.83	-0.34	3.47e-14	Ulcerative colitis;
LGG	cis	rs5742933	0.857	rs1437891	chr2:190562708	C/T	cg10453823	chr2:190539512	ANKAR	0.45	6.72	0.3	5.39e-11	Ferritin levels;
LGG	cis	rs7851660	0.548	rs1156850	chr9:100573164	G/A	cg13688889	chr9:100608707	NA	-0.85	-18.4	-0.65	3.78e-57	Strep throat;
LGG	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg13010199	chr12:38710504	ALG10B	-0.65	-13.88	-0.54	7.38e-37	Bladder cancer;
LGG	cis	rs7666738	0.830	rs10049985	chr4:99023517	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16680214	chr1:154839983	KCNN3	-0.45	-8.92	-0.38	1.08e-17	Prostate cancer;
LGG	cis	rs11122272	0.603	rs2998427	chr1:231528112	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.7	-0.3	6.09e-11	Bipolar disorder;
LGG	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg02002194	chr4:3960332	NA	-0.42	-8.08	-0.35	5.84e-15	Mood instability;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.33	0.5	2.03e-30	Lymphocyte counts;
LGG	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg03806693	chr22:41940476	POLR3H	1.04	17.66	0.63	9.46e-54	Cannabis dependence symptom count;
LGG	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-12.18	-0.49	8.54e-30	Hemoglobin concentration;
LGG	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg05368731	chr17:41323189	NBR1	0.95	18.94	0.66	1.16e-59	Menopause (age at onset);
LGG	cis	rs6583826	0.596	rs6583825	chr10:94345227	T/G	cg25093409	chr10:94429542	NA	0.34	6.69	0.3	6.33e-11	Type 2 diabetes;
LGG	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg12560992	chr17:57184187	TRIM37	-0.54	-8.67	-0.37	7.25e-17	Testicular germ cell tumor;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.94	-0.31	1.34e-11	Monocyte percentage of white cells;
LGG	cis	rs283228	0.617	rs2518173	chr6:101799129	A/G	cg27451362	chr6:101846650	GRIK2	0.83	12.96	0.52	5.42e-33	Coenzyme Q10 levels;
LGG	cis	rs1408799	0.772	rs1543587	chr9:12751741	T/C	cg05274944	chr9:12693694	TYRP1	0.35	8.13	0.35	3.85e-15	Eye color;Blue vs. green eyes;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16162927	chr6:136610857	BCLAF1	0.39	6.72	0.3	5.24e-11	Bilirubin levels;
LGG	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg06521331	chr12:34319734	NA	0.4	6.71	0.3	5.7e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg21100191	chr22:23484243	RTDR1	0.52	7.83	0.34	3.37e-14	Serum parathyroid hormone levels;
LGG	cis	rs9303401	0.659	rs72828726	chr17:56951217	C/G	cg25039879	chr17:56429692	SUPT4H1	0.63	8.81	0.38	2.58e-17	Cognitive test performance;
LGG	trans	rs9657904	0.865	rs1470283	chr3:105557701	C/G	cg14088669	chr1:158435396	OR10K1	0.42	7.96	0.35	1.31e-14	Multiple sclerosis;
LGG	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.46	-0.4	1.56e-19	Common traits (Other);
LGG	cis	rs963731	0.579	rs10205802	chr2:39284882	T/C	cg04010122	chr2:39346883	SOS1	-0.7	-7.64	-0.33	1.26e-13	Corticobasal degeneration;
LGG	cis	rs526231	0.511	rs58344084	chr5:102378212	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.09	-0.39	3.02e-18	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg05793240	chr7:2802953	GNA12	0.34	8.12	0.35	4.24e-15	Height;
LGG	trans	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg16006296	chr10:38738647	LOC399744	0.35	6.78	0.3	3.58e-11	Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04887335	chr3:196044632	TCTEX1D2	0.47	7.55	0.33	2.39e-13	Cognitive performance;
LGG	cis	rs9354308	0.899	rs2814099	chr6:66555130	A/G	cg07460842	chr6:66804631	NA	0.59	9.7	0.41	2.24e-20	Metabolite levels;
LGG	cis	rs950169	0.840	rs72748702	chr15:84915246	A/G	cg03959625	chr15:84868606	LOC388152	0.55	8.7	0.38	5.63e-17	Schizophrenia;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg12692727	chr7:1102344	C7orf50	0.48	6.75	0.3	4.37e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	0.960	rs4263003	chr17:29438508	G/T	cg24425628	chr17:29625626	OMG;NF1	0.7	14.49	0.56	1.61e-39	Hip circumference;
LGG	cis	rs4474465	1.000	rs11237499	chr11:78163164	A/T	cg27205649	chr11:78285834	NARS2	-0.48	-8.27	-0.36	1.47e-15	Alzheimer's disease (survival time);
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs757278	0.646	rs17140352	chr7:117344368	G/C	cg10524701	chr7:117356490	CTTNBP2	0.46	8.21	0.36	2.24e-15	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg23978390	chr7:1156363	C7orf50	0.44	6.69	0.3	6.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg23625390	chr15:77176239	SCAPER	0.49	9.68	0.41	2.59e-20	Blood metabolite levels;
LGG	cis	rs62380364	0.602	rs606393	chr5:88058163	T/C	cg22951263	chr5:87985283	NA	-0.54	-10.04	-0.42	1.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.841	rs115987912	chr4:119737085	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs7811142	0.830	rs705866	chr7:99965285	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	17.61	0.63	1.73e-53	Platelet count;
LGG	cis	rs9487051	0.735	rs351745	chr6:109529169	C/T	cg21918786	chr6:109611834	NA	0.43	7.95	0.35	1.44e-14	Reticulocyte fraction of red cells;
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg00080972	chr5:178986291	RUFY1	0.52	8.99	0.39	6.52e-18	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11541479	chr19:11039306	YIPF2;C19orf52	0.48	7.09	0.31	5.2e-12	Gut microbiome composition (summer);
LGG	cis	rs514406	0.607	rs6665324	chr1:53201610	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.45	-0.71	2.31e-71	Monocyte count;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg21782813	chr7:2030301	MAD1L1	0.47	11.36	0.47	1.5e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs2413785	chr15:45530381	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.36	-0.32	8.18e-13	Uric acid levels;
LGG	cis	rs950776	0.616	rs495090	chr15:78870003	A/G	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.51	-0.4	1.07e-19	Sudden cardiac arrest;
LGG	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg16850897	chr7:100343110	ZAN	-0.65	-9.73	-0.41	1.79e-20	Other erythrocyte phenotypes;
LGG	cis	rs7742824	0.692	rs7756198	chr6:44104395	T/C	cg04074908	chr6:44101190	TMEM63B	0.52	10.86	0.45	1.28e-24	Major depressive disorder;
LGG	cis	rs12681287	0.547	rs7461366	chr8:87511685	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs514024	0.700	rs557749	chr9:130492039	G/A	cg13643465	chr9:130375613	STXBP1	0.59	11.05	0.46	2.33e-25	Eating disorders (purging via substances);
LGG	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg00887848	chr4:3482507	DOK7	-0.43	-7.26	-0.32	1.69e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs7914558	1.000	rs943036	chr10:104836047	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.66	0.44	6.99e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg24101359	chr6:42928495	GNMT	0.59	17.65	0.63	1.04e-53	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9467160	0.734	rs10946702	chr6:24462672	A/G	cg20631270	chr6:24437470	GPLD1	-0.54	-8.33	-0.36	9.49e-16	Liver enzyme levels;
LGG	cis	rs7937682	0.593	rs4598705	chr11:111345840	G/A	cg09085632	chr11:111637200	PPP2R1B	0.61	10.32	0.43	1.25e-22	Primary sclerosing cholangitis;
LGG	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg03160526	chr17:80928410	B3GNTL1	0.49	7.85	0.34	2.98e-14	Glycated hemoglobin levels;
LGG	trans	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg26043149	chr18:55253948	FECH	0.4	6.75	0.3	4.31e-11	Bone mineral density;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1577917	0.958	rs13207354	chr6:86700263	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.61	-0.41	4.49e-20	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg16405210	chr4:1374714	KIAA1530	0.43	7.04	0.31	6.95e-12	Obesity-related traits;
LGG	cis	rs7651736	0.835	rs6439679	chr3:136757463	C/T	cg12473912	chr3:136751656	NA	-0.5	-8.64	-0.37	9.26e-17	Neuroticism;
LGG	cis	rs12318506	0.826	rs17804612	chr12:75671271	T/C	cg04728562	chr12:75699417	CAPS2	-1.13	-9.45	-0.4	1.74e-19	Coronary artery calcification;
LGG	trans	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.81	-0.38	2.53e-17	Bladder cancer;
LGG	cis	rs7572263	0.724	rs10497896	chr2:209049899	G/C	cg00164906	chr2:209055251	C2orf80	0.72	9.77	0.41	1.24e-20	Glioma;Non-glioblastoma glioma;
LGG	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.51	-0.47	3.92e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg08603382	chr10:743973	NA	-0.62	-11.84	-0.48	1.95e-28	Psychosis in Alzheimer's disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23000464	chr19:633785	POLRMT	-0.46	-6.66	-0.3	7.66e-11	Systemic lupus erythematosus;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg24398932	chr17:33570020	SLFN5	-0.4	-6.82	-0.3	2.92e-11	Leprosy;
LGG	cis	rs909341	0.537	rs6011098	chr20:62398935	C/T	cg14758556	chr20:62440591	NA	-0.55	-6.65	-0.3	8.35e-11	Atopic dermatitis;
LGG	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	7.21e-22	Morning vs. evening chronotype;
LGG	cis	rs28655083	0.529	rs285019	chr16:77099450	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.46	8.13	0.35	4.02e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.45	-0.33	4.47e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10751667	0.666	rs7934963	chr11:957220	C/T	cg22143635	chr11:980567	AP2A2	0.43	8.1	0.35	4.84e-15	Alzheimer's disease (late onset);
LGG	cis	rs28595532	0.841	rs114175487	chr4:119733580	C/G	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs367943	1.000	rs348928	chr5:112815295	C/T	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-10.97	-0.45	4.74e-25	HDL cholesterol;
LGG	trans	rs11165623	0.564	rs12752866	chr1:97000181	T/C	cg10631902	chr5:14652156	NA	-0.45	-9.38	-0.4	2.86e-19	Hip circumference;Waist circumference;
LGG	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg04450456	chr4:17643702	FAM184B	0.32	7.11	0.31	4.46e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	0.504	rs7522945	chr1:248357857	C/A	cg00666640	chr1:248458726	OR2T12	0.45	6.66	0.3	7.68e-11	Common traits (Other);
LGG	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg03605463	chr16:89740564	NA	0.61	11.07	0.46	1.91e-25	Vitiligo;
LGG	cis	rs9894429	0.700	rs113915083	chr17:79552696	G/C	cg18240062	chr17:79603768	NPLOC4	-0.82	-15.58	-0.59	2.71e-44	Eye color traits;
LGG	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06677660	chr19:49140777	SEC1;DBP	-0.51	-8.57	-0.37	1.55e-16	Myeloid white cell count;
LGG	cis	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	cis	rs7000551	0.680	rs28546543	chr8:22314872	A/C	cg12081754	chr8:22256438	SLC39A14	0.68	13.23	0.52	4.11e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs656319	0.605	rs13252276	chr8:9904713	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.08	-0.39	3.27e-18	Myopia (pathological);
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg02002194	chr4:3960332	NA	0.49	9.79	0.41	1.1e-20	Mood instability;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg27532560	chr4:187881888	NA	-0.6	-13.14	-0.52	9.48e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-15.09	-0.57	4e-42	Platelet count;
LGG	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg06951627	chr6:26196580	NA	0.51	7.82	0.34	3.53e-14	Gout;Renal underexcretion gout;
LGG	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.37	-0.4	3.32e-19	Calcium levels;
LGG	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.33	0.65	8.02e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-10.97	-0.45	4.84e-25	Longevity;Endometriosis;
LGG	cis	rs9911578	0.967	rs8075786	chr17:56819216	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.87	-0.42	5.78e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg01262667	chr19:19385393	TM6SF2	0.37	7.33	0.32	1.06e-12	Bipolar disorder;
LGG	cis	rs36051895	0.632	rs7850425	chr9:5170645	G/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.05	-0.57	5.9e-42	Pediatric autoimmune diseases;
LGG	cis	rs7917772	0.503	rs7096072	chr10:104299976	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.08	0.31	5.21e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs1991651	0.507	rs17778581	chr8:10743421	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.05	-0.31	6.48e-12	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs568617	1.000	rs693824	chr11:65654783	A/G	cg26695010	chr11:65641043	EFEMP2	-0.47	-6.74	-0.3	4.81e-11	Crohn's disease;
LGG	cis	rs9815354	0.951	rs1717018	chr3:41913617	G/A	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg02640540	chr1:67518911	SLC35D1	0.37	7.12	0.31	4.16e-12	Lymphocyte percentage of white cells;
LGG	cis	rs2408955	0.568	rs12099462	chr12:48503104	T/C	cg24011408	chr12:48396354	COL2A1	-0.57	-9.5	-0.4	1.15e-19	Glycated hemoglobin levels;
LGG	cis	rs6942756	0.915	rs6966595	chr7:129006202	A/C	cg02491457	chr7:128862824	NA	-0.66	-12.01	-0.49	4.26e-29	White matter hyperintensity burden;
LGG	cis	rs17125944	0.686	rs4450307	chr14:53334783	G/A	cg00686598	chr14:53173677	PSMC6	-0.71	-7.62	-0.33	1.46e-13	Alzheimer's disease (late onset);
LGG	trans	rs1941687	0.769	rs1493911	chr18:31356019	A/G	cg27147174	chr7:100797783	AP1S1	-0.53	-8.81	-0.38	2.46e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2797160	0.967	rs1954360	chr6:126001064	A/G	cg05901451	chr6:126070800	HEY2	-0.44	-7.46	-0.33	4.3e-13	Endometrial cancer;
LGG	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg14019146	chr3:50243930	SLC38A3	-0.52	-10.75	-0.45	3.33e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13732083	chr21:47605072	C21orf56	0.49	8.53	0.37	2.13e-16	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06736685	chr16:85589349	NA	0.45	6.66	0.3	7.62e-11	Gut microbiome composition (summer);
LGG	cis	rs240764	0.658	rs1336244	chr6:101197953	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs4629710	0.592	rs749375	chr6:131553692	C/G	cg12606694	chr6:131520996	AKAP7	0.51	8.33	0.36	9.55e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs9300255	0.679	rs58809476	chr12:123724880	C/T	cg05973401	chr12:123451056	ABCB9	-0.46	-6.64	-0.3	8.61e-11	Neutrophil percentage of white cells;
LGG	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	8.29	0.36	1.28e-15	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs977987	0.806	rs17696696	chr16:75393352	G/T	cg03315344	chr16:75512273	CHST6	-0.5	-10.09	-0.42	9.3e-22	Dupuytren's disease;
LGG	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg27129171	chr3:47204927	SETD2	-0.78	-15.27	-0.58	6.07e-43	Colorectal cancer;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.644	rs6662414	chr1:53198893	A/G	cg24675658	chr1:53192096	ZYG11B	0.63	13.77	0.54	2.21e-36	Monocyte count;
LGG	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg04568710	chr12:38710424	ALG10B	0.37	8.1	0.35	5.08e-15	Heart rate;
LGG	cis	rs1577917	0.958	rs12196175	chr6:86779370	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.47	-0.53	3.81e-35	Response to antipsychotic treatment;
LGG	cis	rs1776421	0.760	rs78493155	chr1:53898195	G/A	cg10892335	chr1:53966318	NA	0.84	11.99	0.49	5.15e-29	PR interval in Tripanosoma cruzi seropositivity;
LGG	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg20302533	chr7:39170763	POU6F2	0.57	14.7	0.56	1.96e-40	IgG glycosylation;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg02462569	chr6:150064036	NUP43	-0.31	-6.68	-0.3	6.82e-11	Testicular germ cell tumor;
LGG	cis	rs7572733	0.555	rs11903129	chr2:198918591	A/T	cg00792783	chr2:198669748	PLCL1	0.61	9.74	0.41	1.67e-20	Dermatomyositis;
LGG	cis	rs559928	0.502	rs11601686	chr11:64189110	C/T	cg05555928	chr11:63887634	MACROD1	-0.58	-9.69	-0.41	2.34e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs950169	0.887	rs12903946	chr15:84954430	T/C	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs6502050	0.835	rs7221544	chr17:80087337	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.44e-16	Life satisfaction;
LGG	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	11.29	0.46	2.69e-26	Emphysema distribution in smoking;
LGG	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26714650	chr12:56694279	CS	1.48	18.03	0.64	1.97e-55	Psoriasis vulgaris;
LGG	cis	rs17453880	0.852	rs6882013	chr5:152049652	T/C	cg10931792	chr5:152022470	NA	0.42	9.01	0.39	5.63e-18	Subjective well-being;
LGG	cis	rs372883	0.532	rs425989	chr21:30715275	T/C	cg08807101	chr21:30365312	RNF160	-0.5	-8.26	-0.36	1.53e-15	Pancreatic cancer;
LGG	trans	rs3960554	0.733	rs59170362	chr7:75629267	G/C	cg19862616	chr7:65841803	NCRNA00174	0.88	13.07	0.52	1.92e-33	Eotaxin levels;
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.86	-0.38	1.69e-17	Neuroticism;
LGG	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg03146154	chr1:46216737	IPP	0.49	6.76	0.3	4.26e-11	Platelet count;
LGG	cis	rs368123	1.000	rs446809	chr6:160737581	A/C	cg07349212	chr6:160770346	SLC22A3	0.34	7.13	0.31	3.85e-12	Waist circumference;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.64	0.37	9.33e-17	Bipolar disorder;
LGG	cis	rs6594713	0.679	rs34147627	chr5:112948161	G/A	cg12552261	chr5:112820674	MCC	0.6	7.54	0.33	2.5e-13	Brain cytoarchitecture;
LGG	cis	rs1577917	0.958	rs9647601	chr6:86449827	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.67e-30	Response to antipsychotic treatment;
LGG	cis	rs7523273	0.565	rs2796280	chr1:207889345	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.67	-0.37	7.41e-17	Schizophrenia;
LGG	cis	rs12479064	0.507	rs17022564	chr2:99939031	A/G	cg23527387	chr2:100056660	REV1	0.44	9.81	0.41	9.41e-21	Chronic sinus infection;
LGG	cis	rs763014	0.931	rs2071981	chr16:630025	C/G	cg07243736	chr16:783730	NARFL	0.42	7.18	0.32	2.74e-12	Height;
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22633769	chr20:60982531	CABLES2	0.53	8.23	0.36	1.91e-15	Colorectal cancer;
LGG	cis	rs10089	0.552	rs11955148	chr5:127557814	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.54	7.7	0.34	8.29e-14	Ileal carcinoids;
LGG	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg08470875	chr2:26401718	FAM59B	0.43	8.4	0.36	5.47e-16	Gut microbiome composition (summer);
LGG	cis	rs1801251	0.778	rs809639	chr2:233731244	C/G	cg08000102	chr2:233561755	GIGYF2	0.41	6.84	0.3	2.46e-11	Coronary artery disease;
LGG	cis	rs1707322	0.721	rs7520123	chr1:46235219	C/G	cg03146154	chr1:46216737	IPP	0.57	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7085104	0.632	rs7096475	chr10:104609676	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.13	0.39	2.2e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs7843479	0.965	rs9314269	chr8:21804989	A/G	cg17168535	chr8:21777572	XPO7	0.61	9.97	0.42	2.36e-21	Mean corpuscular volume;
LGG	cis	rs698813	0.604	rs1596009	chr2:44492102	G/T	cg00619915	chr2:44497795	NA	-0.6	-8.88	-0.38	1.45e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs892961	0.932	rs12452788	chr17:75406866	T/C	cg05865280	chr17:75406074	SEPT9	0.42	9.86	0.42	6.09e-21	Airflow obstruction;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs28595532	0.920	rs116146507	chr4:119749556	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs16937	0.597	rs3862949	chr1:205103070	A/T	cg00889227	chr1:205173544	DSTYK	-0.3	-7.47	-0.33	4.09e-13	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs826838	0.651	rs1843896	chr12:38612913	G/C	cg04568710	chr12:38710424	ALG10B	0.35	7.1	0.31	4.81e-12	Heart rate;
LGG	cis	rs300703	0.515	rs424292	chr2:191931	C/T	cg21211680	chr2:198530	NA	-1.21	-19.58	-0.67	1.2e-62	Blood protein levels;
LGG	cis	rs9649465	0.688	rs34967330	chr7:123318560	A/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.62e-17	Migraine;
LGG	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	trans	rs1814175	0.754	rs10839453	chr11:49955815	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.05	-0.78	2.35e-97	Height;
LGG	cis	rs651907	0.535	rs1460097	chr3:101497569	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.31	0.5	2.63e-30	Colorectal cancer;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.84	0.34	3.19e-14	Lung cancer;
LGG	cis	rs870825	0.550	rs59051283	chr4:185646476	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg02002194	chr4:3960332	NA	0.37	6.67	0.3	7.21e-11	Joint mobility (Beighton score);
LGG	cis	rs2576037	0.501	rs557661	chr18:44365657	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.91	0.35	1.9e-14	Personality dimensions;
LGG	trans	rs1997103	1.000	rs4947503	chr7:55409427	G/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs2013441	1.000	rs2165897	chr17:20209721	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs10489202	0.608	rs7553238	chr1:168076768	G/A	cg24449463	chr1:168025552	DCAF6	-0.56	-9.99	-0.42	2.03e-21	Schizophrenia;
LGG	cis	rs5758511	0.680	rs1107554	chr22:42667594	C/G	cg00645731	chr22:42541494	CYP2D7P1	0.44	7.45	0.33	4.67e-13	Birth weight;
LGG	cis	rs7582720	1.000	rs72934715	chr2:203713280	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.78	0.34	4.71e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10276381	1.000	rs10281214	chr7:28185544	G/C	cg23620719	chr7:28220237	JAZF1	0.81	10.42	0.44	5.57e-23	Crohn's disease;
LGG	cis	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg13010199	chr12:38710504	ALG10B	0.76	16.24	0.6	2.86e-47	Heart rate;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35146811	0.735	rs1636975	chr7:99812089	A/G	cg13334819	chr7:99746414	C7orf59	0.47	7.34	0.32	9.79e-13	Coronary artery disease;
LGG	cis	rs9487051	0.872	rs9400269	chr6:109606065	C/G	cg12927641	chr6:109611667	NA	-0.37	-7.16	-0.32	3.2e-12	Reticulocyte fraction of red cells;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg04234412	chr22:24373322	LOC391322	-0.77	-15.48	-0.58	7.46e-44	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs6828577	0.695	rs62324878	chr4:119455605	G/A	cg26518628	chr1:97050305	NA	-0.54	-8.64	-0.37	8.89e-17	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg05484376	chr2:27715224	FNDC4	-0.41	-8.84	-0.38	1.98e-17	Total body bone mineral density;
LGG	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.2	-0.49	7.1e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg14186256	chr22:23484241	RTDR1	1.0	24.71	0.75	1.39e-86	Bone mineral density;
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Electroencephalogram traits;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg07142201	chr11:109293216	C11orf87	0.54	9.65	0.41	3.24e-20	Schizophrenia;
LGG	cis	rs7829975	0.500	rs7841082	chr8:8168987	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.95	-0.35	1.49e-14	Mood instability;
LGG	cis	rs7918232	0.662	rs10764662	chr10:27300643	T/A	cg14442939	chr10:27389572	ANKRD26	0.54	8.47	0.37	3.23e-16	Breast cancer;
LGG	cis	rs7219021	0.705	rs28635466	chr17:46983820	G/A	cg16584676	chr17:46985605	UBE2Z	-0.43	-7.12	-0.31	4.21e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg06112835	chr11:68658793	MRPL21	0.6	9.93	0.42	3.51e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10089	1.000	rs11957052	chr5:127524055	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.55	0.47	2.63e-27	Ileal carcinoids;
LGG	cis	rs61931739	0.649	rs864174	chr12:33729352	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.86	-0.3	2.22e-11	Morning vs. evening chronotype;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg18138400	chr11:64073849	ESRRA	0.39	6.76	0.3	4.26e-11	Eye color traits;
LGG	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.65	-0.48	1.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg08048268	chr3:133502702	NA	0.62	11.55	0.47	2.71e-27	Iron status biomarkers;
LGG	cis	rs2658782	0.724	rs2605629	chr11:93264037	C/G	cg15737290	chr11:93063684	CCDC67	-0.46	-6.77	-0.3	3.93e-11	Pulmonary function decline;
LGG	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg08885076	chr2:99613938	TSGA10	-0.57	-11.6	-0.47	1.76e-27	Chronic sinus infection;
LGG	cis	rs11239187	0.566	rs1002589	chr10:45126887	C/T	cg03916630	chr10:45065415	NA	-0.29	-6.76	-0.3	4.1e-11	Body mass index;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs10799590	1.000	rs169888	chr1:224839082	G/A	cg01808320	chr1:224927238	CNIH3	-0.4	-7.23	-0.32	2.07e-12	Opioid dependence;
LGG	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg16400903	chr5:693638	TPPP	0.44	6.72	0.3	5.34e-11	Obesity-related traits;
LGG	cis	rs988958	0.526	rs60056083	chr2:42242928	A/T	cg27252766	chr2:42229092	NA	0.52	7.08	0.31	5.24e-12	Hypospadias;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.38	0.53	9.43e-35	Lung cancer;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs7851660	0.967	rs7043885	chr9:100596439	C/T	cg13688889	chr9:100608707	NA	-0.68	-14.54	-0.56	1.04e-39	Strep throat;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01521154	chr12:26111162	RASSF8	0.45	6.83	0.3	2.73e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg03528353	chr17:61819722	STRADA	-0.42	-6.88	-0.3	1.9e-11	Prudent dietary pattern;
LGG	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg03162506	chr22:38580953	NA	0.39	9.97	0.42	2.35e-21	Cutaneous nevi;
LGG	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17221829	0.528	rs2860553	chr11:89355296	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.19e-18	Anxiety in major depressive disorder;
LGG	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.52	0.33	2.84e-13	Cystic fibrosis severity;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.85e-15	Obesity-related traits;
LGG	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg16583315	chr14:65563665	MAX	0.38	7.38	0.32	7.18e-13	Obesity-related traits;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16611736	chr16:25123254	LCMT1	0.41	7.47	0.33	4.04e-13	Obesity-related traits;
LGG	cis	rs4665809	0.549	rs34075014	chr2:26520842	T/C	cg08470875	chr2:26401718	FAM59B	0.41	7.49	0.33	3.6e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg11494091	chr17:61959527	GH2	0.99	24.19	0.75	3.53e-84	Prudent dietary pattern;
LGG	cis	rs11204677	1	rs11204677	chr1:150574695	C/G	cg13175981	chr1:150552382	MCL1	0.59	10.18	0.43	4.26e-22	Monocyte percentage of white cells;Granulocyte percentage of myeloid white cells;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg18402987	chr7:1209562	NA	0.39	6.95	0.31	1.26e-11	Longevity;Endometriosis;
LGG	cis	rs752092	1.000	rs7182945	chr15:101784223	C/T	cg19997662	chr15:101784653	CHSY1	-0.87	-19.1	-0.66	2.02e-60	Corneal structure;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.93	-0.42	3.33e-21	Lung cancer;
LGG	cis	rs7638995	0.652	rs77902570	chr3:69194090	A/T	cg26574240	chr3:69171822	LMOD3	-0.71	-10.45	-0.44	4.4e-23	Alzheimer's disease (late onset);
LGG	cis	rs1775715	0.678	rs2778649	chr10:32146803	C/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.82	0.3	2.8e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs35272691	1	rs35272691	chr17:38157841	T/C	cg17467752	chr17:38218738	THRA	-0.59	-9.73	-0.41	1.71e-20	White blood cell count (neutrophil);
LGG	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs867371	0.519	rs1566559	chr15:82524461	T/C	cg00614314	chr15:82944287	LOC80154	0.47	7.81	0.34	3.96e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs1577917	0.771	rs2842612	chr6:86303091	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.27	-0.63	6.03e-52	Response to antipsychotic treatment;
LGG	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	10.8	0.45	2.05e-24	Crohn's disease;
LGG	cis	rs7590368	0.673	rs17365209	chr2:10939117	C/T	cg15705551	chr2:10952987	PDIA6	0.57	7.33	0.32	1.05e-12	Educational attainment (years of education);
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67460515	0.665	rs28384382	chr3:160939141	C/T	cg03342759	chr3:160939853	NMD3	-0.78	-13.55	-0.53	1.87e-35	Parkinson's disease;
LGG	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg17691542	chr6:26056736	HIST1H1C	0.63	10.37	0.43	8.24e-23	Iron status biomarkers;
LGG	cis	rs74781061	0.858	rs58473469	chr15:74885063	C/T	cg02384859	chr15:74862662	ARID3B	-0.33	-6.88	-0.3	1.95e-11	Endometriosis;
LGG	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21659725	chr3:3221576	CRBN	0.63	11.6	0.47	1.67e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9321453	1.000	rs4896048	chr6:134770472	A/T	cg08754004	chr6:134775465	NA	-0.45	-6.67	-0.3	7.23e-11	Urate levels;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.91	-0.34	1.96e-14	Menarche (age at onset);
LGG	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg24189917	chr7:1970923	MAD1L1	-0.4	-6.77	-0.3	3.81e-11	Neuroticism;
LGG	cis	rs4474465	1.000	rs7927722	chr11:78210893	T/C	cg27205649	chr11:78285834	NARS2	0.51	8.51	0.37	2.43e-16	Alzheimer's disease (survival time);
LGG	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg08048268	chr3:133502702	NA	-0.67	-13.2	-0.52	5.56e-34	Iron status biomarkers;
LGG	trans	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg16141378	chr3:129829833	LOC729375	-0.43	-9.97	-0.42	2.39e-21	Red cell distribution width;
LGG	cis	rs9878978	0.722	rs34953825	chr3:2437538	G/C	cg21928760	chr3:2462534	CNTN4	0.39	7.77	0.34	5.1e-14	Blood pressure (smoking interaction);
LGG	cis	rs11098499	0.779	rs7674500	chr4:120303593	C/T	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs3816183	0.680	rs10200363	chr2:43083518	C/G	cg14631114	chr2:43023945	NA	0.45	8.14	0.35	3.7e-15	Hypospadias;
LGG	cis	rs208520	0.690	rs1318604	chr6:66825278	A/C	cg07460842	chr6:66804631	NA	-0.98	-18.47	-0.65	1.75e-57	Exhaled nitric oxide output;
LGG	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.52	-0.33	2.79e-13	Refractive error;
LGG	cis	rs41271951	0.512	rs77306500	chr1:151080096	G/C	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.02	-0.31	7.83e-12	Blood protein levels;
LGG	cis	rs2188554	0.675	rs10278953	chr7:117023237	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.37	-7.38	-0.32	7.24e-13	Esophageal adenocarcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13423282	chr19:19174731	SLC25A42	0.44	7.37	0.32	7.82e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6575793	0.512	rs7147982	chr14:101046649	C/T	cg22806444	chr17:72968764	C17orf28	0.49	7.79	0.34	4.31e-14	Menarche (age at onset);
LGG	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.54e-21	Lung cancer;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs28374715	0.662	rs111522288	chr15:41480169	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-18.14	-0.64	6.12e-56	Ulcerative colitis;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs2708240	0.540	rs1723438	chr7:147546659	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.31	-0.32	1.17e-12	QT interval (drug interaction);
LGG	cis	rs6547741	0.967	rs4665995	chr2:27813827	T/G	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs6500395	0.735	rs2883641	chr16:48664446	T/C	cg04672837	chr16:48644449	N4BP1	0.47	7.9	0.34	2e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs793571	0.544	rs1427282	chr15:58914326	C/T	cg05156742	chr15:59063176	FAM63B	0.56	9.72	0.41	1.86e-20	Schizophrenia;
LGG	cis	rs4925386	1.000	rs6121990	chr20:60919263	G/A	cg06026331	chr20:60912101	LAMA5	-0.49	-9.19	-0.39	1.29e-18	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs656319	0.564	rs11776035	chr8:10071527	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.66	-0.34	1.1e-13	Myopia (pathological);
LGG	cis	rs4077515	0.839	rs3812563	chr9:139271106	A/G	cg21253087	chr9:139290292	SNAPC4	0.36	7.47	0.33	3.97e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1005277	0.603	rs1998062	chr10:38457652	G/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.08	-0.49	2.13e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs2732480	0.500	rs1387257	chr12:48636666	C/A	cg21466736	chr12:48725269	NA	-0.36	-7.37	-0.32	8.13e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs28655083	0.529	rs285026	chr16:77100089	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.41	7.01	0.31	8.44e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg05147244	chr20:61493195	TCFL5	0.75	7.24	0.32	1.85e-12	Obesity-related traits;
LGG	cis	rs17023223	0.508	rs12096448	chr1:119683390	G/A	cg05756136	chr1:119680316	WARS2	-0.45	-9.34	-0.4	4.06e-19	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.13	-0.31	3.87e-12	Schizophrenia;
LGG	cis	rs67460515	0.528	rs11915989	chr3:160902259	A/G	cg04691961	chr3:161091175	C3orf57	-0.46	-8.8	-0.38	2.69e-17	Parkinson's disease;
LGG	trans	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.68	-0.37	6.65e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg00319359	chr11:70116639	PPFIA1	0.58	6.73	0.3	5.04e-11	Coronary artery disease;
LGG	cis	rs10493773	1.000	rs3767163	chr1:86121895	T/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.92	-0.38	1.1e-17	Urate levels in overweight individuals;
LGG	cis	rs3747547	1.000	rs55979334	chr9:37934702	T/A	cg13774184	chr9:37916125	SHB	-0.71	-7.05	-0.31	6.47e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs6032067	0.759	rs3761193	chr20:43885827	C/T	cg10761708	chr20:43804764	PI3	0.6	9.18	0.39	1.39e-18	Blood protein levels;
LGG	cis	rs10752881	1.000	rs10797800	chr1:182969828	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.79	0.41	1.05e-20	Colorectal cancer;
LGG	cis	rs1003719	0.872	rs8128474	chr21:38446319	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.79	15.28	0.58	5.96e-43	Eye color traits;
LGG	cis	rs7129556	0.813	rs11237249	chr11:77341135	G/A	cg12586386	chr11:77299805	AQP11	0.54	8.29	0.36	1.2e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs611744	0.608	rs612744	chr8:109245991	G/A	cg18478394	chr8:109455254	TTC35	0.42	8.41	0.36	5.01e-16	Dupuytren's disease;
LGG	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg05535760	chr7:792225	HEATR2	-0.79	-11.29	-0.46	2.8e-26	Cerebrospinal P-tau181p levels;
LGG	cis	rs9547692	1.000	rs61950374	chr13:37475485	C/T	cg02985381	chr13:37494744	SMAD9	0.73	12.87	0.51	1.3e-32	Coronary artery disease;
LGG	cis	rs7851660	0.874	rs10818175	chr9:100633386	T/C	cg13688889	chr9:100608707	NA	-0.59	-11.65	-0.48	1.14e-27	Strep throat;
LGG	cis	rs11764590	0.950	rs11514731	chr7:2051503	C/G	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.88	-0.3	1.9e-11	Neuroticism;
LGG	cis	rs10197940	0.545	rs2444267	chr2:152308611	T/G	cg19508488	chr2:152266495	RIF1	0.48	8.65	0.37	8.75e-17	Lung cancer;
LGG	cis	rs1014246	0.813	rs1014245	chr10:118466129	G/A	cg14919929	chr10:118506882	NA	0.58	10.48	0.44	3.27e-23	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs78456975	1.000	rs10208449	chr2:1563257	G/A	cg01028140	chr2:1542097	TPO	-0.58	-8.52	-0.37	2.28e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs61990749	0.597	rs17106157	chr14:78146878	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.17	-0.32	3.05e-12	Fibroblast growth factor basic levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02139671	chr12:123237174	DENR	0.53	8.26	0.36	1.52e-15	Gut microbiome composition (summer);
LGG	cis	rs2249625	0.526	rs17781511	chr6:72845455	C/T	cg27608224	chr6:72922399	RIMS1	-0.33	-7.27	-0.32	1.57e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs793571	0.500	rs2555356	chr15:59016431	T/G	cg05156742	chr15:59063176	FAM63B	0.59	10.12	0.43	6.89e-22	Schizophrenia;
LGG	cis	rs782590	0.902	rs782595	chr2:55845596	C/G	cg18811423	chr2:55921094	PNPT1	0.88	20.18	0.68	2e-65	Metabolic syndrome;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.07	-0.31	5.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs483180	0.512	rs612430	chr1:120216025	A/G	cg19096424	chr1:120255104	PHGDH	0.63	11.13	0.46	1.16e-25	Macular telangiectasia type 2;
LGG	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.5	-12.33	-0.5	2.08e-30	Tonsillectomy;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg05165339	chr4:1420672	NA	-0.29	-7.75	-0.34	5.75e-14	Longevity;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.76	-0.41	1.35e-20	Lung cancer;
LGG	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg04166393	chr7:2884313	GNA12	0.46	8.29	0.36	1.25e-15	Height;
LGG	cis	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg12826209	chr6:26865740	GUSBL1	0.8	8.62	0.37	1.07e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg03806693	chr22:41940476	POLR3H	-1.01	-17.36	-0.63	2.31e-52	Vitiligo;
LGG	cis	rs4417704	0.551	rs4334491	chr2:241892478	G/A	cg14055004	chr2:241860995	NA	0.27	7.14	0.31	3.71e-12	Joint mobility (Beighton score);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg05861140	chr6:150128134	PCMT1	-0.32	-7.23	-0.32	1.99e-12	Testicular germ cell tumor;
LGG	cis	rs58688157	0.705	rs7928902	chr11:609068	G/A	cg16486109	chr11:613632	IRF7	0.42	7.01	0.31	8.35e-12	Systemic lupus erythematosus;
LGG	cis	rs8114671	0.528	rs6119542	chr20:33484545	G/T	cg24642439	chr20:33292090	TP53INP2	0.44	7.09	0.31	5.11e-12	Height;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs2153535	0.580	rs9393021	chr6:8466123	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg21775007	chr8:11205619	TDH	-0.49	-7.97	-0.35	1.23e-14	Retinal vascular caliber;
LGG	cis	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.5	-0.33	3.26e-13	Neuroticism;
LGG	cis	rs2067615	0.542	rs11113120	chr12:107203460	T/C	cg15890332	chr12:107067104	RFX4	0.4	11.66	0.48	9.96e-28	Heart rate;
LGG	cis	rs6964587	0.900	rs4279	chr7:91764128	C/A	cg17063962	chr7:91808500	NA	0.51	9.34	0.4	3.96e-19	Breast cancer;
LGG	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.03	0.57	7.39e-42	Alzheimer's disease;
LGG	trans	rs853679	0.607	rs13197176	chr6:28129232	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs12549902	1.000	rs12550613	chr8:41510260	G/C	cg25883020	chr8:41504993	NKX6-3	0.32	7.13	0.31	4e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs1957429	0.808	rs4902325	chr14:65330843	A/G	cg23373153	chr14:65346875	NA	-1.02	-12.89	-0.51	1.09e-32	Pediatric areal bone mineral density (radius);
LGG	cis	rs8005677	1.000	rs7145494	chr14:23399790	T/C	cg01529538	chr14:23388837	RBM23	0.36	6.68	0.3	6.9e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.32	-0.32	1.08e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2117029	0.521	rs12229524	chr12:49585353	C/T	cg24176009	chr12:49580217	TUBA1A	0.63	12.19	0.49	7.93e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.593	rs6694406	chr1:178532010	C/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.5	-0.33	3.3e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.89	-0.3	1.87e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.638	rs7460436	chr8:10254322	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	6.94	0.31	1.32e-11	Neuroticism;
LGG	cis	rs910316	1.000	rs1043674	chr14:75549370	T/C	cg06637938	chr14:75390232	RPS6KL1	0.58	10.68	0.44	5.92e-24	Height;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs6960043	0.818	rs6967891	chr7:15065074	T/C	cg19272540	chr7:15055459	NA	-0.36	-7.9	-0.34	2.07e-14	Type 2 diabetes;
LGG	cis	rs17253792	0.822	rs74940664	chr14:56135065	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.7	0.34	8.26e-14	Obesity-related traits;
LGG	cis	rs7077256	0.564	rs34230554	chr10:65200575	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.21	-0.32	2.23e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs72781680	0.651	rs13019016	chr2:23894773	C/G	cg08917208	chr2:24149416	ATAD2B	0.73	8.02	0.35	8.96e-15	Lymphocyte counts;
LGG	cis	rs113835537	0.529	rs2277302	chr11:66240882	T/C	cg24851651	chr11:66362959	CCS	0.44	7.88	0.34	2.38e-14	Airway imaging phenotypes;
LGG	cis	rs6088590	0.648	rs6059991	chr20:33280836	C/T	cg08999081	chr20:33150536	PIGU	0.39	9.91	0.42	3.9e-21	Coronary artery disease;
LGG	cis	rs79146658	0.736	rs6707222	chr2:179743923	C/T	cg17765952	chr2:179737173	CCDC141	-0.58	-8.85	-0.38	1.9e-17	Diastolic blood pressure;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg14926445	chr8:58193284	C8orf71	-0.76	-9.29	-0.4	5.82e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.555	rs7969922	chr12:38529491	C/T	cg06521331	chr12:34319734	NA	-0.47	-8.26	-0.36	1.54e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.67	-0.34	9.96e-14	Iron status biomarkers;
LGG	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg24623649	chr8:11872141	NA	-0.34	-8.16	-0.35	3.08e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3106136	0.901	rs17623135	chr4:95213091	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.19	-0.36	2.54e-15	Capecitabine sensitivity;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg11494091	chr17:61959527	GH2	1.04	26.42	0.78	1.8e-94	Prudent dietary pattern;
LGG	cis	rs9875589	0.957	rs6778731	chr3:13947504	T/C	cg19554555	chr3:13937349	NA	0.7	13.51	0.53	2.75e-35	Ovarian reserve;
LGG	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg05890377	chr2:74357713	NA	0.49	9.5	0.4	1.12e-19	Gestational age at birth (maternal effect);
LGG	cis	rs1552244	0.882	rs13077641	chr3:10022935	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-9.73	-0.41	1.74e-20	Lung cancer;
LGG	cis	rs992157	0.710	rs6752254	chr2:219058743	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.56	9.48	0.4	1.36e-19	Colorectal cancer;
LGG	cis	rs721917	0.525	rs2758541	chr10:81655557	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	2.01e-14	Chronic obstructive pulmonary disease;
LGG	trans	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg22232500	chr2:134024266	NCKAP5	0.55	7.89	0.34	2.21e-14	Bipolar disorder;
LGG	cis	rs4262150	0.883	rs12657097	chr5:152257408	G/A	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	1.000	rs460079	chr5:112800525	G/A	cg12552261	chr5:112820674	MCC	-0.75	-13.93	-0.54	4.3e-37	Type 2 diabetes;
LGG	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg05527609	chr1:210001259	C1orf107	0.73	11.0	0.46	3.59e-25	Orofacial clefts;
LGG	cis	rs12447804	0.734	rs9926693	chr16:58097357	C/T	cg03859792	chr16:58121049	NA	-0.5	-7.99	-0.35	1.09e-14	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.9	0.42	4.36e-21	Lymphocyte counts;
LGG	cis	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg25319279	chr11:5960081	NA	-0.52	-8.21	-0.36	2.22e-15	DNA methylation (variation);
LGG	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.25	0.39	8.28e-19	Diabetic retinopathy;
LGG	cis	rs4302748	0.908	rs4723482	chr7:36192249	G/A	cg24442661	chr7:36192818	EEPD1	0.57	7.48	0.33	3.78e-13	Platelet count;
LGG	cis	rs4595586	0.545	rs1400284	chr12:39400419	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs1971256	0.500	rs1971255	chr6:151816094	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	0.6	6.96	0.31	1.17e-11	Endometriosis;
LGG	cis	rs644799	1.000	rs7749	chr11:95565789	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1256531	0.661	rs61987781	chr14:66195583	G/A	cg15999311	chr14:65749247	NA	0.83	6.91	0.31	1.65e-11	Conduct disorder (symptom count);
LGG	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg06453172	chr10:134556979	INPP5A	-0.56	-8.42	-0.36	4.85e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs9467711	0.591	rs13216785	chr6:26079185	C/T	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17767392	0.794	rs61989259	chr14:71733506	T/C	cg02058870	chr14:72053146	SIPA1L1	0.43	8.59	0.37	1.29e-16	Mitral valve prolapse;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.18	0.43	4.09e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg03115019	chr17:80708279	FN3K	-0.36	-6.83	-0.3	2.73e-11	Glycated hemoglobin levels;
LGG	cis	rs1153858	1.000	rs1346266	chr15:45694516	G/T	cg21132104	chr15:45694354	SPATA5L1	0.7	10.47	0.44	3.71e-23	Homoarginine levels;
LGG	cis	rs2762353	0.524	rs9467596	chr6:25783022	A/G	cg03264133	chr6:25882463	NA	0.47	8.17	0.36	2.94e-15	Blood metabolite levels;
LGG	cis	rs1348850	0.632	rs1405718	chr2:178499809	C/T	cg05169160	chr2:178484487	TTC30A	0.34	6.65	0.3	8.3e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg08250081	chr4:10125330	NA	0.39	7.65	0.34	1.14e-13	Bone mineral density;
LGG	cis	rs472402	0.580	rs3733773	chr5:6652252	G/A	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.43	-6.82	-0.3	2.81e-11	Response to amphetamines;
LGG	cis	rs7119	0.717	rs11636529	chr15:77816220	T/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs2204008	0.818	rs7313608	chr12:38383428	C/A	cg04568710	chr12:38710424	ALG10B	-0.36	-7.84	-0.34	3.1e-14	Bladder cancer;
LGG	cis	rs7523050	0.643	rs35526993	chr1:109405107	A/T	cg08274380	chr1:109419600	GPSM2	0.99	12.11	0.49	1.58e-29	Fat distribution (HIV);
LGG	cis	rs2172802	0.924	rs10018746	chr4:62445246	T/C	cg04118610	chr4:62707027	LPHN3	-0.47	-7.33	-0.32	1.01e-12	Partial epilepsies;
LGG	trans	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.65	0.41	3.49e-20	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg07701084	chr6:150067640	NUP43	-0.46	-6.86	-0.3	2.26e-11	Lung cancer;
LGG	cis	rs10193935	0.901	rs2118889	chr2:42451683	G/T	cg27598129	chr2:42591480	NA	-0.51	-7.37	-0.32	7.79e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg20744362	chr22:50050164	C22orf34	0.39	7.57	0.33	2.07e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9815354	0.812	rs35263917	chr3:41952852	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9325144	0.534	rs6582538	chr12:38629997	A/C	cg13010199	chr12:38710504	ALG10B	-0.59	-11.76	-0.48	4.14e-28	Morning vs. evening chronotype;
LGG	cis	rs2997447	0.655	rs12059101	chr1:26384013	A/G	cg19633962	chr1:26362018	EXTL1	-0.64	-9.16	-0.39	1.62e-18	QRS complex (12-leadsum);
LGG	cis	rs2963155	0.518	rs10515522	chr5:142758394	A/G	cg17617527	chr5:142782415	NR3C1	0.93	12.17	0.49	9.13e-30	Breast cancer;
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg08621203	chr6:150244597	RAET1G	0.46	7.91	0.34	1.94e-14	Lung cancer;
LGG	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg20891558	chr2:74357851	NA	-0.41	-7.34	-0.32	9.76e-13	Gestational age at birth (maternal effect);
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.67	-0.44	6.68e-24	Lung cancer;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg04369109	chr6:150039330	LATS1	-0.41	-6.91	-0.31	1.61e-11	Lung cancer;
LGG	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	ch.1.3577855R	chr1:183094577	LAMC1	-0.44	-9.0	-0.39	5.9e-18	Colorectal cancer;
LGG	trans	rs7824557	0.628	rs6601580	chr8:11193736	T/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.25	0.32	1.77e-12	Retinal vascular caliber;
LGG	cis	rs12911832	1.000	rs12911832	chr15:58985904	A/T	cg05156742	chr15:59063176	FAM63B	0.57	9.09	0.39	2.83e-18	Schizophrenia;
LGG	cis	rs75920871	0.528	rs11216255	chr11:116929995	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-7.35	-0.32	9.29e-13	Subjective well-being;
LGG	cis	rs2635047	0.542	rs1512236	chr18:44768493	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-7.13	-0.31	3.76e-12	Educational attainment;
LGG	cis	rs7945718	0.934	rs10831905	chr11:12776467	C/T	cg25843174	chr11:12811716	TEAD1	-0.41	-8.4	-0.36	5.49e-16	Educational attainment (years of education);
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg15971980	chr6:150254442	NA	0.42	7.48	0.33	3.7e-13	Lung cancer;
LGG	cis	rs6692729	0.966	rs6688068	chr1:227010730	A/T	cg08708961	chr1:227070630	PSEN2	-0.28	-7.24	-0.32	1.89e-12	Electrodermal activity;
LGG	cis	rs9916302	0.851	rs12936996	chr17:37665554	A/G	cg07936489	chr17:37558343	FBXL20	0.84	15.71	0.59	6.66e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs28374715	0.510	rs8034073	chr15:41545613	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.79	-13.55	-0.53	1.76e-35	Ulcerative colitis;
LGG	cis	rs7927592	0.956	rs12365160	chr11:68250419	A/G	cg16797656	chr11:68205561	LRP5	0.4	7.08	0.31	5.38e-12	Total body bone mineral density;
LGG	cis	rs7945718	0.934	rs7114040	chr11:12781659	C/T	cg25843174	chr11:12811716	TEAD1	-0.39	-8.07	-0.35	5.89e-15	Educational attainment (years of education);
LGG	cis	rs1862618	0.853	rs1423621	chr5:56101035	G/T	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.3	-0.32	1.29e-12	Initial pursuit acceleration;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7918232	1.000	rs6482595	chr10:27380261	A/G	cg14442939	chr10:27389572	ANKRD26	-0.72	-11.23	-0.46	4.79e-26	Breast cancer;
LGG	cis	rs2070488	0.931	rs7630012	chr3:38552250	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.62	-0.63	1.53e-53	Electrocardiographic conduction measures;
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs3733585	0.699	rs17245723	chr4:9962218	A/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.91	-0.34	1.93e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg12292205	chr6:26970375	C6orf41	-0.65	-8.59	-0.37	1.37e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7010267	0.623	rs13254554	chr8:120010805	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.35	9.0	0.39	5.8e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg10621924	chr7:39171070	POU6F2	0.43	8.51	0.37	2.47e-16	IgG glycosylation;
LGG	trans	rs800082	0.934	rs6788831	chr3:144290498	G/T	cg24215973	chr2:240111563	HDAC4	-0.51	-9.05	-0.39	3.84e-18	Smoking behavior;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg24375607	chr4:120327624	NA	-0.52	-8.9	-0.38	1.24e-17	Corneal astigmatism;
LGG	trans	rs34421088	0.532	rs2736385	chr8:11148613	T/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.69	-0.3	6.51e-11	Neuroticism;
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.55	-0.44	1.82e-23	Intelligence (multi-trait analysis);
LGG	cis	rs11622475	1.000	rs2269186	chr14:104379912	C/T	cg20488157	chr14:104394430	TDRD9	0.55	9.15	0.39	1.88e-18	Bipolar disorder;
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14893161	chr1:205819251	PM20D1	0.57	11.06	0.46	2.08e-25	Menarche (age at onset);
LGG	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	10.23	0.43	2.9e-22	Aortic root size;
LGG	cis	rs7149242	0.849	rs10146962	chr14:101170540	A/G	cg18089426	chr14:101175970	NA	0.41	9.24	0.39	8.91e-19	Platelet count;
LGG	cis	rs7508	0.694	rs2073574	chr8:17921921	A/G	cg18067069	chr8:17937731	ASAH1	-0.37	-8.57	-0.37	1.57e-16	Atrial fibrillation;
LGG	cis	rs4423214	1.000	rs11233746	chr11:71171440	A/G	cg05163923	chr11:71159392	DHCR7	0.72	14.27	0.55	1.56e-38	Vitamin D levels;
LGG	cis	rs714515	0.934	rs2227198	chr1:172360164	A/G	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs6912958	0.559	rs242287	chr6:88071825	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	12.7	0.51	6.42e-32	Monocyte percentage of white cells;
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg23594656	chr7:65796392	TPST1	0.42	9.23	0.39	9.57e-19	Aortic root size;
LGG	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg23625390	chr15:77176239	SCAPER	0.71	14.14	0.55	5.67e-38	Blood metabolite levels;
LGG	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg26585981	chr11:48327164	OR4S1	-0.39	-6.83	-0.3	2.63e-11	Migraine - clinic-based;
LGG	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg12463550	chr7:65579703	CRCP	0.54	9.02	0.39	4.99e-18	Aortic root size;
LGG	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.35	-0.32	9.01e-13	Inflammatory bowel disease;
LGG	cis	rs7582180	0.652	rs11675901	chr2:100951189	G/A	cg14675211	chr2:100938903	LONRF2	0.67	12.13	0.49	1.35e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.91	-0.42	4.08e-21	Personality dimensions;
LGG	trans	rs6089829	0.889	rs6062773	chr20:61663262	G/C	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.06	-0.49	2.63e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg07538946	chr5:131705188	SLC22A5	0.65	7.66	0.34	1.09e-13	Rheumatoid arthritis;
LGG	cis	rs11645898	0.872	rs72787070	chr16:72151101	T/C	cg14768367	chr16:72042858	DHODH	-0.81	-11.13	-0.46	1.19e-25	Blood protein levels;
LGG	trans	rs11651000	0.817	rs7502875	chr17:45823227	A/C	cg06529181	chr19:52193933	NA	0.54	8.02	0.35	9.01e-15	IgG glycosylation;
LGG	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg03929089	chr4:120376271	NA	0.45	7.21	0.32	2.3e-12	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03516708	chr14:24024880	THTPA	0.49	7.59	0.33	1.83e-13	Gut microbiome composition (summer);
LGG	cis	rs17092148	0.887	rs932542	chr20:33171368	G/C	cg12302830	chr20:33297742	TP53INP2	-0.44	-7.08	-0.31	5.5e-12	Neuroticism;
LGG	trans	rs1814175	0.791	rs11040513	chr11:49778153	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.19	-0.49	7.9e-30	Height;
LGG	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg19257562	chr1:2043853	PRKCZ	0.29	7.51	0.33	3.09e-13	Height;
LGG	cis	rs2880765	0.835	rs7161880	chr15:86018746	C/T	cg10818794	chr15:86012489	AKAP13	-0.39	-8.24	-0.36	1.77e-15	Coronary artery disease;
LGG	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg12179176	chr11:130786555	SNX19	0.84	17.68	0.63	8.06e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg00012203	chr2:219082015	ARPC2	-0.69	-12.89	-0.51	1.07e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.76	0.3	4.04e-11	Glomerular filtration rate;
LGG	cis	rs733592	0.931	rs765260	chr12:48431936	C/T	cg24011408	chr12:48396354	COL2A1	-0.68	-11.65	-0.48	1.12e-27	Plateletcrit;
LGG	trans	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.9	-0.31	1.74e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.51	8.75	0.38	4.14e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.86	-0.42	6.22e-21	Aortic root size;
LGG	cis	rs2668423	1.000	rs2668419	chr19:1366994	A/G	cg02639931	chr19:1387894	NDUFS7	-0.84	-14.14	-0.55	5.26e-38	Nonalcoholic fatty liver disease;
LGG	cis	rs1707322	0.721	rs4660314	chr1:46229885	T/C	cg03146154	chr1:46216737	IPP	0.59	10.85	0.45	1.33e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.36	-0.47	1.56e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs113835537	0.597	rs11227523	chr11:66305938	C/T	cg24851651	chr11:66362959	CCS	0.46	7.99	0.35	1.06e-14	Airway imaging phenotypes;
LGG	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs6459804	0.787	rs78566714	chr7:157508951	G/A	cg24764310	chr7:157512201	PTPRN2	-0.47	-10.17	-0.43	4.62e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg03264133	chr6:25882463	NA	-0.43	-7.61	-0.33	1.52e-13	Height;
LGG	cis	rs13082711	0.863	rs35797268	chr3:27418862	T/C	cg02860705	chr3:27208620	NA	0.79	14.4	0.56	3.96e-39	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg12560992	chr17:57184187	TRIM37	-0.54	-8.12	-0.35	4.39e-15	Primary tooth development (time to first tooth eruption);
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg17809284	chr5:56205270	C5orf35	-0.56	-9.11	-0.39	2.54e-18	Initial pursuit acceleration;
LGG	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg12615879	chr12:58013172	SLC26A10	-0.37	-8.69	-0.37	6.5e-17	Multiple sclerosis;
LGG	cis	rs9916302	0.768	rs11078900	chr17:37614641	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.36	-0.47	1.44e-26	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26708280	chr2:190649305	PMS1;ORMDL1	0.59	9.39	0.4	2.82e-19	Gut microbiome composition (summer);
LGG	cis	rs17253792	0.822	rs76201070	chr14:56063604	A/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08045932	chr20:61659980	NA	0.6	13.26	0.52	3.07e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13102973	0.965	rs13126242	chr4:135860948	T/C	cg14419869	chr4:135874104	NA	0.57	10.9	0.45	9.16e-25	Subjective well-being;
LGG	cis	rs2013441	1.000	rs2703801	chr17:20100600	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	cg07928641	chr1:182991847	LAMC1	-0.46	-9.13	-0.39	2.13e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3796352	1.000	rs71301809	chr3:53090312	C/T	cg12962167	chr3:53033115	SFMBT1	0.8	7.94	0.35	1.56e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7666738	0.830	rs62321565	chr4:98976571	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.63	-0.37	9.91e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg02297831	chr4:17616191	MED28	0.44	7.91	0.34	1.95e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.63	-0.56	4.13e-40	Prudent dietary pattern;
LGG	trans	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.38	-0.36	6.19e-16	Neuroticism;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.17	0.32	2.98e-12	Menopause (age at onset);
LGG	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg10189774	chr4:17578691	LAP3	0.43	7.47	0.33	4.16e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7944735	0.786	rs7123436	chr11:48013484	G/A	cg03929089	chr4:120376271	NA	0.71	8.54	0.37	2e-16	Intraocular pressure;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs6541297	1.000	rs11122405	chr1:230282997	C/A	cg05784532	chr1:230284198	GALNT2	0.52	9.19	0.39	1.3e-18	Coronary artery disease;
LGG	trans	rs853679	1.000	rs1936365	chr6:28268452	C/G	cg06606381	chr12:133084897	FBRSL1	0.68	8.31	0.36	1.04e-15	Depression;
LGG	cis	rs3780378	1.000	rs7847294	chr9:5097281	A/C	cg02405213	chr9:5042618	JAK2	-0.51	-8.92	-0.38	1.13e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2274273	0.648	rs58553156	chr14:55582694	T/A	cg04306507	chr14:55594613	LGALS3	0.52	12.36	0.5	1.64e-30	Protein biomarker;
LGG	cis	rs11758351	0.518	rs79922979	chr6:26224975	A/G	cg06951627	chr6:26196580	NA	0.46	6.78	0.3	3.6e-11	Gout;Renal underexcretion gout;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06422693	chr4:48833587	OCIAD1	0.45	7.4	0.33	6.55e-13	Cognitive performance;
LGG	cis	rs7107174	1.000	rs2256464	chr11:77917305	C/A	cg02023728	chr11:77925099	USP35	0.42	7.35	0.32	9.03e-13	Testicular germ cell tumor;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06634786	chr22:41940651	POLR3H	0.79	13.0	0.52	3.6e-33	Vitiligo;
LGG	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9788682	1.000	rs12441354	chr15:78821016	G/A	cg24631222	chr15:78858424	CHRNA5	0.49	7.44	0.33	4.77e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2694528	0.844	rs1444238	chr5:60064844	A/G	cg11474532	chr5:59995715	DEPDC1B	0.72	7.65	0.34	1.17e-13	Parkinson's disease;
LGG	cis	rs10048158	0.546	rs7501961	chr17:64285792	C/A	cg19474267	chr17:64306194	PRKCA	0.72	14.87	0.57	3.77e-41	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs3768617	0.966	rs10797850	chr1:183094802	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.11e-11	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.23	-0.32	2.01e-12	Breast cancer;
LGG	cis	rs4243971	0.516	rs6141716	chr20:31012361	C/T	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.91e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.41	-6.67	-0.3	7.36e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3126085	0.935	rs10888468	chr1:152181539	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg03342759	chr3:160939853	NMD3	-0.61	-10.58	-0.44	1.43e-23	Morning vs. evening chronotype;
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg00800038	chr16:89945340	TCF25	-0.67	-7.91	-0.34	1.94e-14	Skin colour saturation;
LGG	cis	rs9354308	0.764	rs9354327	chr6:66587509	C/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs12579753	1.000	rs11115017	chr12:82176914	C/A	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.26	-0.46	3.81e-26	Resting heart rate;
LGG	cis	rs116095464	0.558	rs9312978	chr5:221930	C/G	cg22857025	chr5:266934	NA	-1.54	-25.08	-0.76	2.55e-88	Breast cancer;
LGG	cis	rs4330281	0.653	rs4908970	chr3:17788866	A/G	cg20981856	chr3:17787350	NA	-0.39	-7.17	-0.32	3.01e-12	Schizophrenia;
LGG	cis	rs300703	0.935	rs300704	chr2:240255	A/C	cg24565620	chr2:194026	NA	-0.72	-9.07	-0.39	3.51e-18	Blood protein levels;
LGG	cis	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg02158880	chr13:53174818	NA	0.41	8.03	0.35	7.95e-15	Lewy body disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16836995	chr17:43662488	NA	0.41	7.23	0.32	1.98e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17376030	chr22:41985996	PMM1	0.58	9.23	0.39	9.61e-19	Vitiligo;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg14369405	chr18:32556760	MAPRE2	0.39	6.73	0.3	5e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs61931739	0.963	rs12298565	chr12:34036188	C/T	cg26384229	chr12:38710491	ALG10B	-0.6	-10.96	-0.45	5.4e-25	Morning vs. evening chronotype;
LGG	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	cis	rs9486715	1.000	rs11153082	chr6:97059666	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.24	-0.39	8.73e-19	Headache;
LGG	trans	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg25214090	chr10:38739885	LOC399744	0.68	12.04	0.49	2.99e-29	Corneal astigmatism;
LGG	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg08125733	chr17:73851984	WBP2	0.43	7.16	0.32	3.16e-12	White matter hyperintensity burden;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05665937	chr4:1216051	CTBP1	0.56	10.28	0.43	1.79e-22	Obesity-related traits;
LGG	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.62	0.33	1.4e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs13424612	1.000	rs4149551	chr2:240921463	C/T	cg01812947	chr2:240904978	NDUFA10	0.41	6.95	0.31	1.29e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs7619833	0.685	rs3213930	chr3:27297816	G/C	cg02860705	chr3:27208620	NA	0.39	7.56	0.33	2.24e-13	Breast cancer;
LGG	cis	rs4073582	0.595	rs3016319	chr11:65981846	C/T	cg16950941	chr11:66035639	RAB1B	0.56	10.21	0.43	3.31e-22	Gout;
LGG	cis	rs7219014	1	rs7219014	chr17:37624790	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.49	-0.47	4.9e-27	Urinary metabolites;
LGG	cis	rs950776	0.714	rs3743073	chr15:78909539	G/T	cg16751781	chr15:78858589	CHRNA5	-0.39	-7.4	-0.33	6.51e-13	Sudden cardiac arrest;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg03528353	chr17:61819722	STRADA	-0.44	-7.37	-0.32	8.14e-13	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7980799	0.716	rs10161311	chr12:33623204	G/A	cg06521331	chr12:34319734	NA	0.41	6.87	0.3	2.08e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg05491587	chr18:77659695	KCNG2	-0.41	-7.4	-0.33	6.66e-13	Schizophrenia;
LGG	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg17376030	chr22:41985996	PMM1	0.55	9.12	0.39	2.28e-18	Vitiligo;
LGG	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs4901869	0.966	rs4901868	chr14:59333792	C/T	cg02291164	chr14:59296302	NA	-0.27	-6.78	-0.3	3.77e-11	Panic disorder;
LGG	cis	rs8064024	0.538	rs12596053	chr16:4946794	A/C	cg08329684	chr16:4932620	PPL	-0.56	-12.63	-0.51	1.2e-31	Cancer;
LGG	cis	rs258892	0.895	rs10039408	chr5:72069110	G/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs926938	0.527	rs360583	chr1:115462743	C/T	cg12756093	chr1:115239321	AMPD1	0.44	8.2	0.36	2.31e-15	Autism;
LGG	cis	rs8072100	0.967	rs8075411	chr17:45676760	C/T	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2066819	1.000	rs2306694	chr12:56680636	C/T	cg26714650	chr12:56694279	CS	1.58	16.18	0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs668210	0.793	rs1786172	chr11:65770658	A/G	cg02202077	chr11:65769826	EIF1AD;BANF1	0.73	9.82	0.42	8.22e-21	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17345786	0.817	rs11720560	chr3:101328484	C/T	cg12386194	chr3:101231763	SENP7	0.7	12.15	0.49	1.1e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7808935	0.628	rs72598552	chr7:27939961	G/A	cg22168087	chr7:27702803	HIBADH	0.71	9.93	0.42	3.46e-21	Prostate cancer;
LGG	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs2153535	0.580	rs6920779	chr6:8437624	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.13e-31	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07656362	chr1:32688117	C1orf91;EIF3I	0.47	7.1	0.31	4.84e-12	Gut microbiome composition (summer);
LGG	cis	rs727563	0.594	rs132807	chr22:42071584	T/C	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.71	-0.41	2.06e-20	Primary sclerosing cholangitis;
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg11211951	chr8:145729740	GPT	-0.52	-12.44	-0.5	7.4e-31	Age at first birth;
LGG	cis	rs3784262	0.669	rs3742960	chr15:58248088	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.23	-0.32	1.98e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7503807	0.515	rs12453880	chr17:78637655	A/G	cg06872548	chr17:78716983	RPTOR	0.38	6.98	0.31	1.06e-11	Obesity;
LGG	cis	rs4629180	0.586	rs1848699	chr2:102137903	C/G	cg16435561	chr2:102091048	RFX8	0.48	9.03	0.39	4.62e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs73086581	0.947	rs73084523	chr20:3875626	T/C	cg02187196	chr20:3869020	PANK2	0.9	12.86	0.51	1.37e-32	Response to antidepressants in depression;
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg20978937	chr14:105399321	PLD4	0.49	11.07	0.46	1.92e-25	Rheumatoid arthritis;
LGG	cis	rs6663390	0.510	rs6540445	chr1:208081467	A/G	cg03990033	chr1:208084030	CD34	-0.55	-7.46	-0.33	4.23e-13	Facial morphology (factor 18);
LGG	trans	rs208520	0.690	rs1580430	chr6:66715162	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	17.52	0.63	4.17e-53	Exhaled nitric oxide output;
LGG	cis	rs12478296	1.000	rs12469535	chr2:243044147	G/A	cg18898632	chr2:242989856	NA	-0.81	-9.99	-0.42	2.04e-21	Obesity-related traits;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.49	-7.76	-0.34	5.53e-14	Longevity;
LGG	cis	rs7843479	0.601	rs4872204	chr8:21841396	T/C	cg17168535	chr8:21777572	XPO7	0.81	15.84	0.59	1.87e-45	Mean corpuscular volume;
LGG	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg08508325	chr11:3079039	CARS	0.42	8.08	0.35	5.59e-15	Calcium levels;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg04025307	chr7:1156635	C7orf50	0.58	7.69	0.34	9.16e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4746818	1.000	rs10762259	chr10:70890929	C/T	cg11621586	chr10:70884670	VPS26A	1.19	23.03	0.73	8.55e-79	Left atrial antero-posterior diameter;
LGG	cis	rs6831352	1.000	rs6822348	chr4:100053894	A/T	cg13256891	chr4:100009986	ADH5	0.54	9.66	0.41	3.04e-20	Alcohol dependence;
LGG	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg18135555	chr8:22132992	PIWIL2	0.39	10.41	0.44	6.29e-23	Hypertriglyceridemia;
LGG	cis	rs7582720	1.000	rs72932753	chr2:203670122	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.63	0.41	3.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg10596483	chr8:143751796	JRK	0.58	9.49	0.4	1.27e-19	Schizophrenia;
LGG	trans	rs931812	0.757	rs13251801	chr8:101902629	A/T	cg20993868	chr7:22813445	NA	0.61	12.01	0.49	4.28e-29	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs77106637	0.530	rs1785212	chr11:72462375	T/C	cg04827223	chr11:72435913	ARAP1	-0.43	-7.15	-0.32	3.31e-12	Type 2 diabetes;
LGG	cis	rs854765	0.547	rs9894138	chr17:17964345	G/A	cg05444541	chr17:17804740	TOM1L2	0.69	16.29	0.6	1.71e-47	Total body bone mineral density;
LGG	trans	rs225245	0.817	rs1049379	chr17:33998802	G/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg14835575	chr10:16859367	RSU1	0.36	7.3	0.32	1.26e-12	Platelet distribution width;
LGG	cis	rs722599	0.628	rs12896360	chr14:75278181	A/C	cg06637938	chr14:75390232	RPS6KL1	0.55	9.09	0.39	2.95e-18	IgG glycosylation;
LGG	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs877282	1.000	rs877281	chr10:771557	T/G	cg22713356	chr15:30763199	NA	0.57	8.59	0.37	1.34e-16	Uric acid levels;
LGG	cis	rs10883723	0.668	rs12414479	chr10:104420902	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.67	10.93	0.45	6.83e-25	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg21963583	chr11:68658836	MRPL21	0.61	10.22	0.43	3.13e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs911555	0.692	rs7145753	chr14:103866100	G/A	cg24130564	chr14:104152367	KLC1	0.37	6.97	0.31	1.12e-11	Intelligence (multi-trait analysis);
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg12395012	chr8:11607386	GATA4	0.37	6.89	0.31	1.78e-11	Neuroticism;
LGG	cis	rs36051895	0.659	rs10815150	chr9:5067301	C/A	cg02405213	chr9:5042618	JAK2	-0.83	-16.12	-0.6	1.04e-46	Pediatric autoimmune diseases;
LGG	cis	rs73198271	0.601	rs11997731	chr8:8649848	C/T	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2540226	0.539	rs2716684	chr2:39907681	T/A	cg02886589	chr2:39892450	TMEM178	0.31	8.6	0.37	1.22e-16	Personality dimensions;
LGG	cis	rs7737355	1.000	rs76753180	chr5:130763701	A/T	cg06307176	chr5:131281290	NA	-0.55	-9.28	-0.4	6.41e-19	Life satisfaction;
LGG	cis	rs2361718	0.568	rs1042397	chr17:78092063	G/A	cg09238746	chr17:78121135	EIF4A3	-0.57	-9.87	-0.42	5.5e-21	Yeast infection;
LGG	cis	rs34638952	0.577	rs1994663	chr17:27437710	C/G	cg13672501	chr17:27410685	MYO18A	-0.4	-7.22	-0.32	2.22e-12	Sitting height ratio;
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg08847335	chr10:891726	LARP4B	-0.52	-9.31	-0.4	5.08e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg13385521	chr17:29058706	SUZ12P	0.9	10.23	0.43	2.69e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs975739	0.872	rs1279665	chr13:78368799	A/G	cg07847733	chr13:78271382	SLAIN1	0.38	6.87	0.3	2.09e-11	Hair color;
LGG	cis	rs10752881	1.000	rs10752885	chr1:182982878	C/G	cg07928641	chr1:182991847	LAMC1	0.49	9.99	0.42	2.13e-21	Colorectal cancer;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg00405596	chr8:11794950	NA	-0.46	-7.21	-0.32	2.23e-12	Myopia (pathological);
LGG	cis	rs1371867	0.846	rs1788191	chr8:101260844	C/T	cg06636551	chr8:101224915	SPAG1	0.49	8.97	0.38	7.53e-18	Atrioventricular conduction;
LGG	cis	rs11718455	1.000	rs11718455	chr3:44056898	C/T	cg21419209	chr3:44054225	NA	-0.45	-7.08	-0.31	5.38e-12	Coronary artery disease;
LGG	cis	rs9467773	1.000	rs9393731	chr6:26529374	C/T	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.71	-0.3	5.62e-11	Menarche (age at onset);
LGG	cis	rs4148087	1.000	rs4148087	chr21:43622267	C/T	cg08841829	chr21:43638893	ABCG1	-0.56	-7.69	-0.34	9.14e-14	Eating disorder in bipolar disorder;
LGG	cis	rs9326248	0.817	rs1242127	chr11:117076564	A/G	cg11861562	chr11:117069780	TAGLN	-0.26	-7.24	-0.32	1.83e-12	Blood protein levels;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.66	0.34	1.09e-13	Rheumatoid arthritis;
LGG	cis	rs2865126	0.644	rs10775415	chr18:10737373	C/T	cg21165219	chr18:10698044	FAM38B	0.48	7.8	0.34	4.27e-14	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg20578329	chr17:80767326	TBCD	0.38	6.91	0.31	1.59e-11	Glycated hemoglobin levels;
LGG	cis	rs11971779	0.680	rs4077889	chr7:139033914	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.37e-11	Diisocyanate-induced asthma;
LGG	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg01181863	chr3:195395398	SDHAP2	0.48	7.26	0.32	1.67e-12	Mean corpuscular volume;
LGG	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg08250081	chr4:10125330	NA	0.38	7.32	0.32	1.1e-12	Bone mineral density;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg00908189	chr16:619842	PIGQ	0.85	15.62	0.59	1.72e-44	Height;
LGG	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg20607798	chr8:58055168	NA	0.58	6.71	0.3	5.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	0.716	rs6699444	chr1:46135120	G/C	cg03146154	chr1:46216737	IPP	0.55	10.76	0.45	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2905347	0.624	rs2905323	chr7:22705723	T/C	cg23521230	chr7:22704884	NA	0.47	8.62	0.37	1.09e-16	Major depression and alcohol dependence;
LGG	cis	rs7647973	0.626	rs1491985	chr3:49739507	G/C	cg13072238	chr3:49761600	GMPPB	-0.55	-7.62	-0.33	1.48e-13	Menarche (age at onset);
LGG	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg14703610	chr5:56206110	C5orf35	0.43	7.51	0.33	2.98e-13	Coronary artery disease;
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg19318889	chr4:1322082	MAEA	0.47	8.05	0.35	6.9e-15	Longevity;
LGG	cis	rs2153535	0.580	rs9505458	chr6:8479215	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	cis	rs7208859	0.673	rs9914271	chr17:29232625	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg09307838	chr4:120376055	NA	0.81	13.57	0.53	1.56e-35	Corneal astigmatism;
LGG	cis	rs17023223	0.537	rs2645295	chr1:119582448	C/T	cg05756136	chr1:119680316	WARS2	-0.36	-7.59	-0.33	1.76e-13	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg21475434	chr5:93447410	FAM172A	0.66	6.72	0.3	5.42e-11	Diabetic retinopathy;
LGG	cis	rs6076065	1.000	rs2405231	chr20:23342239	A/C	cg11657817	chr20:23433608	CST11	0.34	6.74	0.3	4.73e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg27297192	chr10:134578999	INPP5A	0.33	7.14	0.31	3.63e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.89e-16	Life satisfaction;
LGG	cis	rs9398803	0.678	rs4621655	chr6:126896107	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.96e-19	Male-pattern baldness;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs3008870	0.629	rs12742428	chr1:67426487	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.71	0.59	6.78e-45	Lymphocyte percentage of white cells;
LGG	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg06873352	chr17:61820015	STRADA	0.46	7.34	0.32	9.94e-13	Height;
LGG	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg00599393	chr8:22457479	C8orf58	-0.39	-7.09	-0.31	5.2e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg05064044	chr6:292385	DUSP22	-0.65	-11.2	-0.46	6.2e-26	Menopause (age at onset);
LGG	cis	rs6963495	0.818	rs56177071	chr7:105165648	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs6963495	0.818	rs73190166	chr7:105159955	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4774830	0.744	rs62045232	chr15:56284419	A/G	cg24530489	chr15:56299380	NA	-0.85	-7.84	-0.34	3.22e-14	Delta-5 desaturase activity;
LGG	trans	rs6825911	0.597	rs2348207	chr4:111343941	A/G	cg10580549	chr19:53101634	ZNF137	0.55	7.13	0.31	3.88e-12	Blood pressure;
LGG	cis	rs10206020	0.885	rs13388254	chr2:1577209	A/G	cg26248373	chr2:1572462	NA	-0.88	-15.18	-0.58	1.58e-42	IgG glycosylation;
LGG	cis	rs10876993	0.893	rs1678504	chr12:58085498	G/C	cg18357645	chr12:58087776	OS9	0.73	13.42	0.53	6.65e-35	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs16912285	0.688	rs11827298	chr11:24324000	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	13.27	0.52	2.75e-34	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4822044	0.568	rs1883370	chr22:42143740	C/A	cg06481639	chr22:41940642	POLR3H	0.53	7.45	0.33	4.52e-13	Cannabis dependence symptom count;
LGG	cis	rs2072732	0.861	rs66693767	chr1:2955930	A/G	cg08733933	chr1:2954429	NA	-0.41	-8.6	-0.37	1.22e-16	Plateletcrit;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	-0.6	-11.1	-0.46	1.55e-25	Birth weight;
LGG	cis	rs258892	0.895	rs35317818	chr5:72073502	G/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.68	-0.3	6.87e-11	Small cell lung carcinoma;
LGG	cis	rs903263	1.000	rs10874432	chr1:84673951	T/C	cg10977910	chr1:84465055	TTLL7	0.4	6.76	0.3	4.12e-11	Breast cancer (male);
LGG	cis	rs36051895	0.659	rs7046077	chr9:5045328	C/G	cg02405213	chr9:5042618	JAK2	-0.85	-16.89	-0.62	3.34e-50	Pediatric autoimmune diseases;
LGG	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.44	0.37	4.21e-16	Alzheimer's disease (survival time);
LGG	cis	rs8056893	0.523	rs4783619	chr16:68359280	A/G	cg07273125	chr16:68295692	NA	0.39	8.49	0.37	2.75e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs16973500	0.711	rs72801789	chr16:71959748	C/T	cg00732059	chr16:71740210	PHLPP2	-0.6	-9.83	-0.42	7.58e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs4595586	0.545	rs11615718	chr12:39395335	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs9287719	0.901	rs6432109	chr2:10736821	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs679087	1.000	rs439639	chr12:29917641	A/C	cg14258853	chr12:29935411	TMTC1	-0.43	-8.61	-0.37	1.17e-16	Schizophrenia;
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6088580	0.634	rs6059860	chr20:33063830	A/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs8067287	0.597	rs4985783	chr17:16857787	C/T	cg26910001	chr17:16838321	NA	-0.39	-7.64	-0.33	1.23e-13	Diabetic kidney disease;
LGG	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg23649088	chr2:200775458	C2orf69	0.54	8.09	0.35	5.19e-15	Schizophrenia;
LGG	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg10523679	chr1:76189770	ACADM	-0.82	-14.55	-0.56	9.39e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7833790	0.676	rs7834555	chr8:82697625	A/G	cg27398817	chr8:82754497	SNX16	-0.64	-10.07	-0.42	1.04e-21	Diastolic blood pressure;
LGG	cis	rs2862064	1.000	rs1948759	chr5:156442657	C/T	cg12943317	chr5:156479607	HAVCR1	0.75	9.81	0.41	9.18e-21	Platelet count;
LGG	cis	rs151997	0.671	rs152926	chr5:50201787	G/A	cg06027927	chr5:50259733	NA	-0.62	-10.7	-0.45	4.89e-24	Callous-unemotional behaviour;
LGG	trans	rs9325144	0.555	rs4550281	chr12:38689937	A/G	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.7e-12	Morning vs. evening chronotype;
LGG	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs3849570	1.000	rs9842330	chr3:81814688	G/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.81	-0.34	3.75e-14	Waist circumference;Body mass index;
LGG	cis	rs7084402	0.967	rs1626606	chr10:60328088	C/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs9527	0.590	rs7920868	chr10:104795409	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.55	0.44	1.8e-23	Arsenic metabolism;
LGG	cis	rs11645898	0.504	rs75888697	chr16:71985222	A/C	cg14768367	chr16:72042858	DHODH	-0.59	-7.3	-0.32	1.25e-12	Blood protein levels;
LGG	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg11707556	chr5:10655725	ANKRD33B	0.66	11.35	0.47	1.6e-26	Coronary artery disease;
LGG	cis	rs60180747	1.000	rs11630608	chr15:66745137	T/C	cg07575407	chr15:66541975	MEGF11	0.34	6.8	0.3	3.25e-11	Testicular germ cell tumor;
LGG	cis	rs7129556	0.737	rs537811	chr11:77468088	C/A	cg12586386	chr11:77299805	AQP11	0.45	7.42	0.33	5.49e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs7072216	0.655	rs3830025	chr10:100176104	A/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.07	-0.31	5.85e-12	Metabolite levels;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg15971980	chr6:150254442	NA	0.46	8.58	0.37	1.43e-16	Lung cancer;
LGG	trans	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	cis	rs4595586	0.566	rs7135104	chr12:39411086	C/T	cg26384229	chr12:38710491	ALG10B	0.52	9.28	0.4	6.66e-19	Morning vs. evening chronotype;
LGG	trans	rs4843747	0.709	rs72818521	chr16:88058751	C/G	cg26811252	chr16:29126840	RRN3P2	0.7	10.74	0.45	3.4e-24	Menopause (age at onset);
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg08859206	chr1:53392774	SCP2	-0.37	-7.33	-0.32	1.04e-12	Monocyte count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11788450	chr12:56521719	ESYT1	-0.41	-6.76	-0.3	4.19e-11	Pancreatic cancer;
LGG	trans	rs61931739	0.500	rs11053185	chr12:34428857	A/G	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg13443165	chr9:33130375	B4GALT1	-0.72	-13.95	-0.54	3.75e-37	IgG glycosylation;
LGG	cis	rs9354308	0.764	rs9342515	chr6:66591303	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs6088580	0.634	rs945673	chr20:32964265	C/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10865541	0.902	rs33997548	chr2:3419366	A/G	cg11642891	chr2:3452563	TTC15	-0.47	-9.48	-0.4	1.37e-19	Obesity-related traits;
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg11764359	chr7:65958608	NA	0.73	13.2	0.52	5.46e-34	Aortic root size;
LGG	cis	rs597583	0.715	rs1940040	chr11:117393294	G/C	cg27161313	chr11:117392002	DSCAML1	-0.63	-10.07	-0.42	1.04e-21	Putamen volume;
LGG	cis	rs9616064	0.531	rs9616086	chr22:47050744	G/A	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.84	-0.3	2.48e-11	Urate levels in obese individuals;
LGG	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg27489772	chr12:121021490	NA	0.59	7.75	0.34	5.84e-14	Type 1 diabetes nephropathy;
LGG	cis	rs4148087	0.932	rs2032259	chr21:43621473	G/C	cg08841829	chr21:43638893	ABCG1	-0.6	-8.13	-0.35	4.1e-15	Eating disorder in bipolar disorder;
LGG	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg26655873	chr3:72818019	SHQ1	0.32	6.85	0.3	2.37e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17445240	0.892	rs2312921	chr2:3696140	G/A	cg16123090	chr2:3699210	NA	0.77	8.34	0.36	8.28e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.8	0.34	4.26e-14	Schizophrenia;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.12	-0.49	1.53e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7777484	0.571	rs2527686	chr7:2834413	G/A	cg19717773	chr7:2847554	GNA12	-0.42	-9.94	-0.42	3.04e-21	Height;
LGG	cis	rs7773004	0.905	rs6932584	chr6:26327081	A/C	cg00631329	chr6:26305371	NA	-0.38	-6.7	-0.3	5.97e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg13010199	chr12:38710504	ALG10B	0.48	9.13	0.39	2.07e-18	Morning vs. evening chronotype;
LGG	cis	rs892961	0.867	rs1079354	chr17:75415713	C/T	cg05865280	chr17:75406074	SEPT9	0.42	9.65	0.41	3.39e-20	Airflow obstruction;
LGG	cis	rs72615157	0.634	rs11762932	chr7:99792666	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.62	8.9	0.38	1.23e-17	Lung function (FEV1/FVC);
LGG	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.15	-0.32	3.35e-12	Iron status biomarkers;
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg03647317	chr4:187891568	NA	-0.41	-8.74	-0.38	4.19e-17	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13268671	chr2:166810585	TTC21B	0.39	7.09	0.31	4.95e-12	Bilirubin levels;
LGG	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg26597838	chr10:835615	NA	0.54	6.92	0.31	1.52e-11	Eosinophil percentage of granulocytes;
LGG	trans	rs4714291	0.674	rs3008837	chr6:40046725	C/T	cg02267698	chr19:7991119	CTXN1	-0.62	-9.97	-0.42	2.53e-21	Strep throat;
LGG	cis	rs9457247	1.000	rs10946199	chr6:167404492	G/A	cg07741184	chr6:167504864	NA	0.32	6.95	0.31	1.24e-11	Crohn's disease;
LGG	cis	rs2243480	1.000	rs34815098	chr7:65292254	A/C	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs2271404	0.506	rs4848426	chr2:112002130	T/G	cg23466623	chr2:111982296	NA	-0.35	-6.77	-0.3	3.91e-11	Atopic dermatitis;
LGG	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg13147721	chr7:65941812	NA	-0.79	-9.72	-0.41	1.92e-20	Diabetic kidney disease;
LGG	cis	rs10173297	0.686	rs1965733	chr2:3709129	T/C	cg20720597	chr2:3699334	NA	0.53	6.84	0.3	2.45e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs988958	0.526	rs10166598	chr2:42242872	A/G	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Hypospadias;
LGG	cis	rs7666738	0.830	rs10010698	chr4:98981594	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.86	0.34	2.79e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg02711726	chr17:80685570	FN3KRP	-0.58	-10.2	-0.43	3.63e-22	Glycated hemoglobin levels;
LGG	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg01244601	chr4:120671846	NA	0.37	6.8	0.3	3.22e-11	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-16.45	-0.61	3.21e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	1.000	rs8125868	chr20:25324410	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.3	-0.43	1.52e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs868036	0.918	rs4238411	chr15:68079424	A/T	cg05925327	chr15:68127851	NA	-0.35	-8.18	-0.36	2.7e-15	Restless legs syndrome;
LGG	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg01620082	chr3:125678407	NA	-1.04	-9.8	-0.41	9.71e-21	Depression;
LGG	cis	rs651907	0.513	rs34963630	chr3:101504817	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.03	0.35	8.08e-15	Colorectal cancer;
LGG	cis	rs17125944	0.572	rs79312783	chr14:53250296	A/T	cg00686598	chr14:53173677	PSMC6	1.33	14.23	0.55	2.27e-38	Alzheimer's disease (late onset);
LGG	cis	rs61931739	0.500	rs7312938	chr12:34378708	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.41	-0.4	2.34e-19	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg18357526	chr6:26021779	HIST1H4A	0.61	10.7	0.45	5.23e-24	Blood metabolite levels;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6450176	0.564	rs374050	chr5:53331646	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.23	-0.46	5e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs9929218	0.817	rs3114404	chr16:68722096	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.47	-0.61	2.5e-48	Colorectal cancer;
LGG	cis	rs3126085	0.935	rs74129461	chr1:152285099	C/T	cg26876637	chr1:152193138	HRNR	-0.52	-8.01	-0.35	9.58e-15	Atopic dermatitis;
LGG	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg19761014	chr17:28927070	LRRC37B2	0.59	7.41	0.33	6.13e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs826838	0.967	rs10875979	chr12:39095149	G/A	cg26384229	chr12:38710491	ALG10B	0.95	23.78	0.74	2.77e-82	Heart rate;
LGG	cis	rs7166081	1.000	rs12324222	chr15:67581282	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6912958	0.728	rs7773906	chr6:88251869	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.63	-0.37	9.57e-17	Monocyte percentage of white cells;
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg07747251	chr5:1868357	NA	0.46	9.41	0.4	2.31e-19	Cardiovascular disease risk factors;
LGG	cis	rs10464366	0.746	rs17171537	chr7:39145647	C/T	cg21665744	chr7:39171113	POU6F2	0.39	7.91	0.35	1.85e-14	IgG glycosylation;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs7617773	0.963	rs6800730	chr3:48174210	C/T	cg11946769	chr3:48343235	NME6	0.52	8.43	0.36	4.39e-16	Coronary artery disease;
LGG	cis	rs2997447	0.600	rs1335759	chr1:26471743	G/T	cg08133631	chr1:26527909	CATSPER4	-0.32	-6.77	-0.3	3.85e-11	QRS complex (12-leadsum);
LGG	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg19507638	chr5:93509721	C5orf36	-0.72	-9.81	-0.41	9.49e-21	Diabetic retinopathy;
LGG	cis	rs72945132	0.882	rs61177215	chr11:70129534	G/A	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs941408	0.515	rs878893	chr19:2781325	A/G	cg19676328	chr12:49525230	TUBA1B	-0.54	-7.91	-0.35	1.91e-14	Total cholesterol levels;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs10773046	0.740	rs11057383	chr12:124369421	T/C	cg18594669	chr12:124364423	DNAH10	0.34	6.92	0.31	1.5e-11	Osteoarthritis (hip);
LGG	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-7.98	-0.35	1.13e-14	Type 2 diabetes;
LGG	cis	rs208520	0.731	rs12206488	chr6:66999917	G/T	cg07460842	chr6:66804631	NA	0.89	13.74	0.54	2.79e-36	Exhaled nitric oxide output;
LGG	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg09699651	chr6:150184138	LRP11	0.48	8.58	0.37	1.49e-16	Lung cancer;
LGG	cis	rs7927771	1.000	rs11039255	chr11:47495746	G/T	cg20307385	chr11:47447363	PSMC3	-0.52	-9.29	-0.4	6.13e-19	Subjective well-being;
LGG	cis	rs4780401	0.609	rs8047190	chr16:11807097	T/C	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.91	-0.51	8.9e-33	Rheumatoid arthritis;
LGG	cis	rs77106637	0.858	rs7109575	chr11:72463435	G/A	cg03713592	chr11:72463424	ARAP1	0.43	7.38	0.32	7.46e-13	Type 2 diabetes;
LGG	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.27e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15128208	chr22:42549153	NA	-0.37	-7.36	-0.32	8.41e-13	Cognitive function;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.01	-0.39	5.26e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6598955	0.670	rs3795685	chr1:26601385	A/G	cg04990556	chr1:26633338	UBXN11	0.67	13.79	0.54	1.8e-36	Obesity-related traits;
LGG	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.65	-0.37	8.64e-17	Retinal vascular caliber;
LGG	cis	rs9359856	0.517	rs112527288	chr6:90509141	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-10.43	-0.44	5.2e-23	Bipolar disorder;
LGG	cis	rs202126107	1	rs202126107	chr17:38006767	GCATATTATA/G	cg19468946	chr17:37922297	IKZF3	-0.44	-7.97	-0.35	1.25e-14	Eosinophil percentage of white cells;
LGG	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.18	-0.36	2.76e-15	Neuroticism;
LGG	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg06421707	chr20:25228305	PYGB	0.52	11.66	0.48	1.01e-27	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1163251	0.902	rs514491	chr1:120216743	C/T	cg19096424	chr1:120255104	PHGDH	0.63	11.01	0.46	3.33e-25	Blood metabolite levels;
LGG	cis	rs1153858	0.895	rs12593402	chr15:45617392	G/A	cg10760299	chr15:45669010	GATM	0.4	7.73	0.34	6.81e-14	Homoarginine levels;
LGG	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21659725	chr3:3221576	CRBN	0.63	11.63	0.48	1.32e-27	Intelligence (multi-trait analysis);
LGG	trans	rs73198271	0.960	rs73198287	chr8:8612786	C/T	cg16141378	chr3:129829833	LOC729375	0.38	6.93	0.31	1.37e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs8005677	1.000	rs11157930	chr14:23403171	T/G	cg25600027	chr14:23388339	RBM23	-0.43	-7.1	-0.31	4.82e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs921968	0.541	rs636723	chr2:219373197	A/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs75804782	0.641	rs59499060	chr2:239341411	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.89	0.38	1.42e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10766496	1.000	rs4264132	chr11:18739075	T/A	cg02515468	chr11:18743222	IGSF22	-0.47	-7.92	-0.35	1.83e-14	Diabetic kidney disease;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg01673284	chr16:4527211	HMOX2	0.32	6.76	0.3	4.23e-11	Schizophrenia;
LGG	cis	rs3784262	0.765	rs11631127	chr15:58270009	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.16	-0.32	3.18e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs6866344	0.697	rs62392823	chr5:178126968	T/C	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	trans	rs9657904	0.724	rs1443102	chr3:105525291	T/G	cg14088669	chr1:158435396	OR10K1	0.41	7.81	0.34	3.97e-14	Multiple sclerosis;
LGG	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.22	-0.36	2e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9515201	0.787	rs9521734	chr13:111037289	A/T	cg06243866	chr13:111019493	COL4A2	-0.62	-11.64	-0.48	1.23e-27	White matter hyperintensity burden;
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.85	13.62	0.53	9.27e-36	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs3806843	0.576	rs246032	chr5:140332547	C/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.25	-0.36	1.63e-15	Breast cancer;
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs9547996	0.879	rs7333205	chr13:38187458	A/T	cg13634560	chr13:38173852	POSTN	-0.34	-6.75	-0.3	4.4e-11	Diastolic blood pressure;
LGG	cis	rs7587476	0.906	rs62201985	chr2:215658638	A/G	cg04530015	chr2:215796436	ABCA12	-0.44	-6.96	-0.31	1.17e-11	Neuroblastoma;
LGG	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs10276381	1.000	rs10263857	chr7:28187284	C/G	cg23620719	chr7:28220237	JAZF1	0.81	10.42	0.44	5.57e-23	Crohn's disease;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.25	-0.32	1.71e-12	Mean corpuscular volume;
LGG	cis	rs13394619	0.565	rs12478958	chr2:11748037	A/G	cg07314298	chr2:11723111	GREB1	-0.4	-8.24	-0.36	1.78e-15	Endometriosis;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.97e-26	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg14668632	chr7:2872130	GNA12	-0.34	-6.88	-0.3	1.99e-11	Height;
LGG	cis	rs35771425	0.600	rs34027321	chr1:211448871	T/C	cg10512769	chr1:211675356	NA	-0.65	-8.47	-0.37	3.32e-16	Educational attainment (years of education);
LGG	cis	rs2688608	0.560	rs10128354	chr10:75470045	T/C	cg23231163	chr10:75533350	FUT11	-0.43	-7.22	-0.32	2.13e-12	Inflammatory bowel disease;
LGG	cis	rs72945132	0.882	rs12282678	chr11:70152457	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg12560992	chr17:57184187	TRIM37	0.82	13.27	0.52	2.7200000000000002e-34	Intelligence (multi-trait analysis);
LGG	cis	rs7827545	1.000	rs1372660	chr8:135566788	C/G	cg17885191	chr8:135476712	NA	0.44	6.99	0.31	9.83e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs1355223	0.583	rs2941041	chr11:34874734	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.77	15.0	0.57	1.01e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4731207	0.596	rs10954050	chr7:124577901	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs909674	0.865	rs5757682	chr22:39848259	T/G	cg11247378	chr22:39784982	NA	-0.32	-8.6	-0.37	1.26e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg01134436	chr17:81009848	B3GNTL1	0.83	8.67	0.37	7.49e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7044106	0.762	rs10760115	chr9:123476952	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.32	0.32	1.12e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4650994	1.000	rs4354501	chr1:178524596	T/C	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs35771425	0.600	rs67764962	chr1:211465579	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.35	-0.36	8.05e-16	Educational attainment (years of education);
LGG	cis	rs295137	0.836	rs1217456	chr2:201092279	C/T	cg17644776	chr2:200775616	C2orf69	0.54	9.15	0.39	1.84e-18	Asthma (bronchodilator response);
LGG	cis	rs12928939	0.769	rs34680964	chr16:71658594	G/A	cg08717414	chr16:71523259	ZNF19	-0.48	-7.31	-0.32	1.15e-12	Post bronchodilator FEV1;
LGG	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg27129171	chr3:47204927	SETD2	0.48	7.72	0.34	7.4e-14	Birth weight;
LGG	cis	rs1408799	0.679	rs7025771	chr9:12760762	C/T	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	4.99e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs60311166	1.000	rs934839	chr3:52683898	G/T	cg13174197	chr3:52720522	GNL3;PBRM1	1.01	8.64	0.37	9.17e-17	CTACK levels;
LGG	cis	rs4423214	1.000	rs12785878	chr11:71167449	G/T	cg05163923	chr11:71159392	DHCR7	0.71	13.85	0.54	9.45e-37	Vitamin D levels;
LGG	cis	rs7851660	0.809	rs35324451	chr9:100660136	A/T	cg13688889	chr9:100608707	NA	-0.63	-12.44	-0.5	7.68e-31	Strep throat;
LGG	cis	rs6840360	0.615	rs6831810	chr4:152461995	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.57	-0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504073	0.647	rs12546839	chr8:50009020	C/T	cg00325661	chr8:49890786	NA	0.74	14.34	0.55	7.46e-39	Blood metabolite ratios;
LGG	cis	rs17604090	0.938	rs28664977	chr7:29685369	C/T	cg19413766	chr7:29689036	LOC646762	-0.63	-7.96	-0.35	1.32e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg21385522	chr1:16154831	NA	0.54	9.67	0.41	2.76e-20	Systolic blood pressure;
LGG	cis	rs10463316	0.894	rs6579875	chr5:150782574	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.25	-0.43	2.38e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg04546413	chr19:29218101	NA	0.75	12.65	0.51	1.04e-31	Methadone dose in opioid dependence;
LGG	cis	rs7107174	0.892	rs10899482	chr11:78060081	A/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.51	-0.33	2.98e-13	Testicular germ cell tumor;
LGG	cis	rs11645898	0.515	rs61747473	chr16:72258743	C/T	cg14768367	chr16:72042858	DHODH	-0.69	-8.99	-0.39	6.16e-18	Blood protein levels;
LGG	cis	rs13420028	0.628	rs2315385	chr2:133182494	A/G	cg02570563	chr2:133174168	GPR39	0.4	6.78	0.3	3.72e-11	Hypertension (SNP x SNP interaction);
LGG	trans	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.65	-0.33	1.2e-13	Joint mobility (Beighton score);
LGG	cis	rs2072732	0.808	rs67758087	chr1:2937031	A/G	cg08733933	chr1:2954429	NA	-0.42	-8.33	-0.36	9.26e-16	Plateletcrit;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26012541	chr22:22307070	PPM1F	-0.45	-7.07	-0.31	5.77e-12	Pancreatic cancer;
LGG	cis	rs8072100	0.764	rs2644349	chr17:45641743	G/A	cg19784903	chr17:45786737	TBKBP1	0.37	8.27	0.36	1.45e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17776563	0.593	rs11073793	chr15:89143785	G/A	cg05013243	chr15:89149849	MIR1179	-0.34	-7.05	-0.31	6.56e-12	Thyroid hormone levels;
LGG	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.1e-11	Retinal vascular caliber;
LGG	cis	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.38	-0.32	7.3e-13	Mood instability;
LGG	cis	rs9303280	0.754	rs3816470	chr17:37985801	A/G	cg00129232	chr17:37814104	STARD3	-0.42	-7.74	-0.34	6.51e-14	Self-reported allergy;
LGG	cis	rs2060793	0.506	rs10741658	chr11:14924736	T/C	cg18937875	chr11:14930189	NA	-0.48	-7.99	-0.35	1.08e-14	Vitamin D levels;
LGG	cis	rs11792861	0.926	rs2271878	chr9:111868885	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.73	-0.34	6.98e-14	Gut microbiome composition (summer);
LGG	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.54	-10.62	-0.44	1.03e-23	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg02002194	chr4:3960332	NA	-0.48	-8.53	-0.37	2.15e-16	Retinal vascular caliber;
LGG	cis	rs2361710	0.668	rs2304855	chr17:78118266	T/A	cg06718696	chr17:78121285	EIF4A3	0.45	7.04	0.31	6.95e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.46e-16	Life satisfaction;
LGG	cis	rs2439831	0.867	rs2264876	chr15:43757419	G/T	cg15269541	chr15:43626905	ADAL	-0.42	-7.35	-0.32	8.91e-13	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	7.02	0.31	7.88e-12	Schizophrenia;
LGG	cis	rs12325245	0.536	rs71375919	chr16:58547522	C/T	cg19824325	chr16:58548873	SETD6	1.23	11.21	0.46	5.86e-26	Schizophrenia;
LGG	cis	rs875971	0.522	rs1701760	chr7:65473688	A/G	cg18876405	chr7:65276391	NA	0.66	12.76	0.51	3.81e-32	Aortic root size;
LGG	trans	rs7395662	1.000	rs10769371	chr11:48531184	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-8.01	-0.35	9.69e-15	HDL cholesterol;
LGG	cis	rs477895	1.000	rs41294396	chr11:64078581	G/A	cg22916017	chr11:64110731	CCDC88B	-0.52	-6.97	-0.31	1.07e-11	Mean platelet volume;
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.86e-12	Menopause (age at onset);
LGG	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg00334542	chr7:100209784	MOSPD3	-0.59	-8.06	-0.35	6.35e-15	Mean corpuscular hemoglobin;
LGG	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg13271783	chr10:134563150	INPP5A	-0.59	-8.67	-0.37	7.34e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16680214	chr1:154839983	KCNN3	-0.47	-9.25	-0.39	8.2e-19	Prostate cancer;
LGG	cis	rs9747201	1.000	rs58119191	chr17:80155329	T/C	cg09264619	chr17:80180166	NA	-0.5	-10.05	-0.42	1.28e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9354308	0.764	rs9342510	chr6:66589332	A/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9399135	0.967	rs7750300	chr6:135350950	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.45	0.4	1.73e-19	Red blood cell count;
LGG	cis	rs4639966	0.836	rs7943039	chr11:118603030	G/A	cg20309703	chr11:118481025	PHLDB1	-0.51	-7.51	-0.33	3.1400000000000003e-13	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.541	rs9392222	chr6:8467649	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs977987	0.806	rs7188604	chr16:75451170	T/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg21775007	chr8:11205619	TDH	-0.5	-8.13	-0.35	4.03e-15	Triglycerides;
LGG	cis	rs8058578	1.000	rs56656810	chr16:30788759	C/A	cg05768032	chr16:30646687	NA	0.41	6.78	0.3	3.61e-11	Multiple myeloma;
LGG	trans	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg10840412	chr1:235813424	GNG4	0.63	8.61	0.37	1.17e-16	Bipolar disorder;
LGG	cis	rs4911259	0.552	rs13038881	chr20:31468113	T/C	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.78	-0.48	3.42e-28	Inflammatory bowel disease;
LGG	cis	rs7267979	1.000	rs6115146	chr20:25304507	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6504108	0.624	rs1316657	chr17:46251391	T/C	cg02219949	chr17:45927392	SP6	0.43	8.07	0.35	6.18e-15	Body mass index;
LGG	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.38	-0.43	7.52e-23	Aortic root size;
LGG	cis	rs798554	0.797	rs798493	chr7:2798731	A/G	cg04166393	chr7:2884313	GNA12	0.42	7.77	0.34	5.01e-14	Height;
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg15145296	chr3:125709740	NA	-0.62	-8.02	-0.35	8.78e-15	Blood pressure (smoking interaction);
LGG	cis	rs1577917	0.655	rs6454472	chr6:86224053	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.46	8.46	0.37	3.65e-16	Response to antipsychotic treatment;
LGG	cis	rs9788682	1.000	rs7181447	chr15:78814567	A/G	cg06917634	chr15:78832804	PSMA4	-0.64	-9.76	-0.41	1.39e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.71	13.12	0.52	1.21e-33	Obesity-related traits;
LGG	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3815700	1.000	rs10406750	chr19:33097144	C/T	cg02997394	chr19:33096574	ANKRD27	0.89	13.39	0.53	8.31e-35	Eosinophilic esophagitis;
LGG	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg25457927	chr22:38595422	NA	-0.39	-9.26	-0.4	7.37e-19	Cutaneous nevi;
LGG	cis	rs9443645	0.901	rs9361466	chr6:79618352	T/C	cg18132916	chr6:79620363	NA	-0.32	-8.79	-0.38	2.85e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.72	0.48	5.94e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3806843	0.966	rs10053945	chr5:140160127	C/T	cg19875535	chr5:140030758	IK	0.51	10.67	0.44	6.5e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg22920501	chr2:26401640	FAM59B	0.39	7.78	0.34	4.74e-14	Gut microbiome composition (summer);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14868726	chr18:2571660	METTL4;NDC80	0.39	7.24	0.32	1.86e-12	Bilirubin levels;
LGG	cis	rs2070488	0.965	rs13079145	chr3:38517992	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	17.96	0.64	4.04e-55	Electrocardiographic conduction measures;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg07142201	chr11:109293216	C11orf87	0.51	9.41	0.4	2.25e-19	Schizophrenia;
LGG	cis	rs9487094	0.961	rs12524639	chr6:109709459	A/G	cg01125227	chr6:109776195	MICAL1	0.52	8.98	0.39	6.75e-18	Height;
LGG	cis	rs708547	0.874	rs1718869	chr4:57880232	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg12310025	chr6:25882481	NA	-0.49	-9.11	-0.39	2.44e-18	Height;
LGG	cis	rs17854409	0.803	rs1063247	chr20:61472118	C/G	cg06598544	chr20:61472147	COL9A3	-0.9	-9.84	-0.42	6.9299999999999992e-21	Obesity-related traits;
LGG	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs9300255	0.679	rs4759409	chr12:123719585	G/C	cg05973401	chr12:123451056	ABCB9	0.51	7.73	0.34	6.88e-14	Neutrophil percentage of white cells;
LGG	cis	rs7215564	0.818	rs4889881	chr17:78664157	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.16	-0.35	3.17e-15	Myopia (pathological);
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg02753203	chr1:228287806	NA	-0.65	-11.91	-0.48	9.82e-29	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg08677398	chr8:58056175	NA	0.45	7.45	0.33	4.69e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	1.000	rs10484442	chr6:26555879	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.6	0.41	4.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs514406	0.571	rs11206004	chr1:53210958	G/A	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.38	-0.7	4.74e-71	Monocyte count;
LGG	cis	rs7945705	0.747	rs2742480	chr11:8993130	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.38	-0.36	6.48e-16	Hemoglobin concentration;
LGG	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.05	0.84	6.52e-124	Chronic sinus infection;
LGG	trans	rs8002861	0.935	rs1811464	chr13:44469290	T/G	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg03806693	chr22:41940476	POLR3H	-1.0	-17.3	-0.63	4.23e-52	Vitiligo;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.21	-0.46	5.52e-26	Neuroticism;
LGG	cis	rs3849570	1.000	rs3772883	chr3:81802802	C/T	cg07356753	chr3:81810745	GBE1	-0.43	-7.46	-0.33	4.23e-13	Waist circumference;Body mass index;
LGG	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.59	0.5	1.85e-31	Coronary artery disease;
LGG	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.62	0.33	1.49e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15642758	chr15:83876612	HDGFRP3	0.44	6.97	0.31	1.12e-11	Cognitive performance;
LGG	cis	rs7312774	0.618	rs4964501	chr12:107330079	C/T	cg16260113	chr12:107380972	MTERFD3	-0.91	-8.47	-0.37	3.24e-16	Severe influenza A (H1N1) infection;
LGG	cis	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg08564027	chr20:61660810	NA	1.02	25.15	0.76	1.2e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17767392	0.958	rs6574016	chr14:72040525	G/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.16	0.35	3.29e-15	Mitral valve prolapse;
LGG	cis	rs7241530	0.636	rs4798996	chr18:75889558	G/A	cg14642773	chr18:75888474	NA	0.47	9.67	0.41	2.98e-20	Educational attainment (years of education);
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg08742575	chr21:47604166	C21orf56	-0.45	-7.43	-0.33	5.23e-13	Testicular germ cell tumor;
LGG	cis	rs1371867	0.875	rs1788174	chr8:101330957	C/G	cg06636551	chr8:101224915	SPAG1	0.47	8.71	0.38	5.32e-17	Atrioventricular conduction;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.73	0.34	6.8e-14	Longevity;
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.65	11.92	0.48	9.74e-29	Total body bone mineral density;
LGG	cis	rs9790314	0.747	rs6789244	chr3:160866230	A/C	cg04691961	chr3:161091175	C3orf57	-0.46	-10.05	-0.42	1.3e-21	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs1593569	chr4:99017485	C/G	cg05340658	chr4:99064831	C4orf37	0.48	7.93	0.35	1.71e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs3096299	0.582	rs12935119	chr16:89542874	A/T	cg06640241	chr16:89574553	SPG7	0.88	16.38	0.61	6.61e-48	Multiple myeloma (IgH translocation);
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg16141378	chr3:129829833	LOC729375	-0.41	-9.6	-0.41	5.19e-20	Neuroticism;
LGG	cis	rs634534	0.562	rs1151505	chr11:65734539	C/T	cg26695010	chr11:65641043	EFEMP2	-0.58	-10.21	-0.43	3.39e-22	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs13082711	0.953	rs35124294	chr3:27539526	A/G	cg02860705	chr3:27208620	NA	0.84	14.83	0.57	5.73e-41	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4959677	1.000	rs4959677	chr6:2500820	C/G	cg23817096	chr6:1620687	NA	0.31	7.27	0.32	1.49e-12	Orthostatic hypotension;
LGG	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.95	-0.35	1.45e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.76	0.3	4.07e-11	Bladder cancer;
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.65	8.61	0.37	1.18e-16	Lung function (FEV1/FVC);
LGG	cis	rs12496230	1.000	rs36016775	chr3:66838437	A/G	cg17646820	chr3:66848679	NA	0.5	7.63	0.33	1.39e-13	Type 2 diabetes;
LGG	cis	rs6087990	0.806	rs875041	chr20:31383530	C/T	cg13636640	chr20:31349939	DNMT3B	0.94	20.12	0.68	3.61e-65	Ulcerative colitis;
LGG	cis	rs1387259	0.790	rs2732445	chr12:48645533	C/T	cg21466736	chr12:48725269	NA	-0.37	-7.39	-0.33	6.69e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg16583315	chr14:65563665	MAX	-0.38	-7.3	-0.32	1.25e-12	Obesity-related traits;
LGG	cis	rs7216064	1.000	rs55896768	chr17:65913358	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-9.12	-0.39	2.26e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.73	0.38	4.78e-17	Neuroticism;
LGG	cis	rs10089	0.953	rs2190797	chr5:127352875	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	11.17	0.46	8.42e-26	Ileal carcinoids;
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00495681	chr13:53174319	NA	0.56	10.41	0.44	6.3e-23	Lewy body disease;
LGG	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg22974920	chr21:40686053	BRWD1	-0.42	-6.65	-0.3	8.22e-11	Cognitive function;
LGG	cis	rs7927771	0.524	rs7101597	chr11:47797917	A/T	cg20307385	chr11:47447363	PSMC3	0.56	10.98	0.45	4.39e-25	Subjective well-being;
LGG	cis	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg06521331	chr12:34319734	NA	-0.39	-6.86	-0.3	2.24e-11	Morning vs. evening chronotype;
LGG	cis	rs12493885	0.585	rs61790900	chr3:153642726	A/G	cg12800244	chr3:153838788	SGEF	-0.59	-7.06	-0.31	6.12e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.81	-0.3	3.12e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9522267	0.535	rs11069897	chr13:112231319	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.42	-0.33	5.84e-13	Hepatitis;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	2.01e-16	Lung cancer;
LGG	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg04362960	chr10:104952993	NT5C2	0.57	10.77	0.45	2.74e-24	Arsenic metabolism;
LGG	cis	rs7208859	0.673	rs73271887	chr17:29154935	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.78	-9.32	-0.4	4.95e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg26384229	chr12:38710491	ALG10B	-0.79	-16.09	-0.6	1.35e-46	Morning vs. evening chronotype;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg10588770	chr3:125314608	OSBPL11	0.44	6.68	0.3	6.9e-11	Breast cancer;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg07747251	chr5:1868357	NA	0.44	8.53	0.37	2.06e-16	Cardiovascular disease risk factors;
LGG	cis	rs4631830	1.000	rs4631830	chr10:51543344	C/T	cg10326726	chr10:51549505	MSMB	-0.6	-12.37	-0.5	1.48e-30	Prostate-specific antigen levels;
LGG	cis	rs4819052	0.851	rs2236444	chr21:46678226	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.81	0.38	2.61e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs701145	0.585	rs1470664	chr3:153865193	C/T	cg12800244	chr3:153838788	SGEF	0.77	8.38	0.36	6.21e-16	Coronary artery disease;
LGG	cis	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg19847130	chr8:10466454	RP1L1	0.32	6.98	0.31	1.04e-11	Neuroticism;
LGG	cis	rs2116941	1.000	rs2033493	chr19:10340854	A/C	cg01850179	chr19:10340795	S1PR2	-0.65	-10.22	-0.43	2.99e-22	Pulse pressure;
LGG	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.28	-0.32	1.42e-12	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.72	-0.38	4.91e-17	Life satisfaction;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg01988459	chr11:68622903	NA	0.4	8.24	0.36	1.77e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs909674	0.775	rs8138462	chr22:39839670	G/C	cg11247378	chr22:39784982	NA	-0.32	-8.6	-0.37	1.22e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs1348850	0.519	rs10201883	chr2:178471407	T/C	cg27490568	chr2:178487706	NA	1.01	18.17	0.65	4.3e-56	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg11965913	chr1:205819406	PM20D1	0.94	22.27	0.72	3.33e-75	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg25358565	chr5:93447407	FAM172A	1.37	17.05	0.62	6.38e-51	Diabetic retinopathy;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13732083	chr21:47605072	C21orf56	-0.49	-8.46	-0.37	3.64e-16	Testicular germ cell tumor;
LGG	cis	rs3008870	0.920	rs3008865	chr1:67402838	T/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.09	0.73	4.54e-79	Lymphocyte percentage of white cells;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs42235	0.683	rs2282982	chr7:92277030	T/C	cg15732164	chr7:92237376	CDK6	-0.43	-9.02	-0.39	5.08e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6815814	0.861	rs10034903	chr4:38784678	C/G	cg06935464	chr4:38784597	TLR10	0.54	8.89	0.38	1.37e-17	Breast cancer;
LGG	cis	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg06521331	chr12:34319734	NA	0.55	9.79	0.41	1.08e-20	Morning vs. evening chronotype;
LGG	cis	rs9355610	0.609	rs9366076	chr6:167373708	C/T	cg18261144	chr6:167370276	RNASET2	-0.37	-6.71	-0.3	5.79e-11	Graves' disease;
LGG	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg18225595	chr11:63971243	STIP1	0.56	7.47	0.33	4.17e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.24	-0.39	8.88e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.96	0.38	7.8e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.85	0.42	6.35e-21	Coronary artery disease;
LGG	trans	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.89	-0.45	9.61e-25	Triglycerides;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.26	0.46	3.66e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg02297831	chr4:17616191	MED28	0.48	8.87	0.38	1.65e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs16976116	0.951	rs8043029	chr15:55486011	C/G	cg11288833	chr15:55489084	RSL24D1	0.55	7.51	0.33	3.04e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9790314	0.540	rs9844862	chr3:161076188	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-11.32	-0.47	2.1e-26	Morning vs. evening chronotype;
LGG	cis	rs6028335	0.674	rs66526549	chr20:37588360	A/G	cg16355469	chr20:37678765	NA	0.6	8.03	0.35	8.08e-15	Alcohol and nicotine co-dependence;
LGG	cis	rs11864453	0.826	rs8062041	chr16:72088964	C/T	cg23815491	chr16:72088622	HP	0.56	12.12	0.49	1.46e-29	Fibrinogen levels;
LGG	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg02228329	chr11:64053129	BAD;GPR137	0.77	14.52	0.56	1.18e-39	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg20916646	chr4:852691	GAK	0.51	9.02	0.39	4.95e-18	Sjögren's syndrome;
LGG	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.2e-14	Hip circumference adjusted for BMI;
LGG	cis	rs614226	0.935	rs588132	chr12:121024066	A/G	cg21053147	chr12:120880522	NA	-0.55	-8.2	-0.36	2.44e-15	Type 1 diabetes nephropathy;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg26513180	chr16:89883248	FANCA	0.97	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg21552867	chr2:84686507	SUCLG1	0.42	6.91	0.31	1.57e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2274273	1.000	rs15870	chr14:55619311	A/G	cg04306507	chr14:55594613	LGALS3	0.61	17.21	0.62	1.11e-51	Protein biomarker;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03082763	chr19:12662438	ZNF564	0.47	7.68	0.34	9.24e-14	Cognitive performance;
LGG	cis	rs4148087	1.000	rs4148092	chr21:43635162	T/C	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	cis	rs10991814	1.000	rs17579908	chr9:93948636	G/C	cg14446406	chr9:93919335	NA	-0.8	-8.7	-0.38	5.66e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs4363385	0.530	rs6663448	chr1:152894627	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.4	-0.4	2.6e-19	Inflammatory skin disease;
LGG	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg02931644	chr1:25747376	RHCE	0.42	9.15	0.39	1.86e-18	Erythrocyte sedimentation rate;
LGG	cis	rs9467773	0.609	rs12663780	chr6:26397573	T/C	cg09904177	chr6:26538194	HMGN4	-0.41	-7.3	-0.32	1.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs11657990	chr17:29124200	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.44	-0.44	4.75e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9715521	0.900	rs62299249	chr4:59824174	G/A	cg11281224	chr4:60001000	NA	-0.44	-7.31	-0.32	1.16e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.22	0.32	2.12e-12	Tonsillectomy;
LGG	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg10760299	chr15:45669010	GATM	0.4	8.02	0.35	8.96e-15	Homoarginine levels;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.13	-0.31	3.85e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2070677	0.935	rs11101887	chr10:135418062	G/A	cg20169779	chr10:135381914	SYCE1	-0.99	-12.87	-0.51	1.34e-32	Gout;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg09359103	chr1:154839909	KCNN3	-0.48	-9.49	-0.4	1.25e-19	Prostate cancer;
LGG	cis	rs858239	0.539	rs6971673	chr7:23159523	C/G	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.15e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg06112835	chr11:68658793	MRPL21	0.6	9.96	0.42	2.55e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7091957	1.000	rs7091957	chr10:134439478	C/T	cg27286337	chr10:134555280	INPP5A	0.52	9.44	0.4	1.78e-19	Gait speed in old age;
LGG	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg01200585	chr1:228362443	C1orf69	0.47	7.92	0.35	1.75e-14	Diastolic blood pressure;
LGG	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.07	0.52	1.88e-33	Morning vs. evening chronotype;
LGG	cis	rs60871478	0.786	rs62432898	chr7:826102	G/A	cg27478167	chr7:817139	HEATR2	-0.48	-6.94	-0.31	1.33e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26862731	chr10:120801850	EIF3A	-0.35	-6.97	-0.31	1.07e-11	Bipolar disorder;
LGG	cis	rs3096299	0.658	rs4785679	chr16:89566113	G/T	cg05484508	chr16:89589025	SPG7	0.47	7.74	0.34	6.28e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs988958	0.526	rs13024096	chr2:42252950	A/G	cg27428208	chr2:42229179	NA	0.48	7.58	0.33	1.91e-13	Hypospadias;
LGG	cis	rs10992471	0.756	rs10123342	chr9:95087824	T/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.13	-0.31	3.87e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs3862435	0.572	rs2589969	chr15:90908051	T/C	cg22089800	chr15:90895588	ZNF774	0.53	6.65	0.3	8.03e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs988958	0.675	rs111621311	chr2:42219214	T/G	cg27252766	chr2:42229092	NA	0.54	8.52	0.37	2.24e-16	Hypospadias;
LGG	cis	rs4740619	0.619	rs1410454	chr9:16042193	C/A	cg14451791	chr9:16040625	NA	-0.41	-10.96	-0.45	5.03e-25	Body mass index;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.45	0.37	3.79e-16	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02372393	chr17:45973417	SP2	0.46	6.84	0.3	2.57e-11	Gut microbiome composition (summer);
LGG	cis	rs12931792	0.748	rs11150585	chr16:30184286	A/G	cg17640201	chr16:30407289	ZNF48	0.53	9.11	0.39	2.42e-18	Tonsillectomy;
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.39	-0.32	7.04e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs992157	0.798	rs2382817	chr2:219151218	A/C	cg00012203	chr2:219082015	ARPC2	0.66	11.85	0.48	1.73e-28	Colorectal cancer;
LGG	cis	rs9878978	0.722	rs62233832	chr3:2512099	T/C	cg21928760	chr3:2462534	CNTN4	0.35	6.83	0.3	2.63e-11	Blood pressure (smoking interaction);
LGG	cis	rs2273669	0.667	rs7766248	chr6:109347262	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs861020	0.630	rs657861	chr1:210006884	C/G	cg23166289	chr1:210001082	C1orf107	0.32	6.75	0.3	4.42e-11	Orofacial clefts;
LGG	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg02466173	chr16:30829666	NA	-0.49	-8.22	-0.36	2.12e-15	Dementia with Lewy bodies;
LGG	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg00012203	chr2:219082015	ARPC2	-0.76	-14.58	-0.56	7.05e-40	Colorectal cancer;
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.19	0.39	1.34e-18	Aortic root size;
LGG	trans	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.3	-0.32	1.24e-12	Myopia (pathological);
LGG	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg20587970	chr11:113659929	NA	-1.21	-21.65	-0.71	2.57e-72	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.64	-0.56	3.62e-40	Prudent dietary pattern;
LGG	trans	rs78049276	0.651	rs59415853	chr4:148378225	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.87	-0.34	2.55e-14	Pulse pressure;
LGG	cis	rs7408868	1.000	rs2074617	chr19:15276055	C/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs6066825	0.644	rs4810864	chr20:47319142	G/C	cg18078177	chr20:47281410	PREX1	0.48	8.11	0.35	4.73e-15	Colorectal cancer;
LGG	cis	rs6688613	0.649	rs2280995	chr1:166846069	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.54	7.95	0.35	1.4e-14	Refractive astigmatism;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.7	-0.34	8.06e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487051	0.872	rs9487042	chr6:109610443	T/G	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs6882076	1.000	rs6878680	chr5:156387137	G/C	cg12943317	chr5:156479607	HAVCR1	-0.67	-12.02	-0.49	3.77e-29	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs2658782	0.547	rs3020064	chr11:93060851	A/G	cg15737290	chr11:93063684	CCDC67	0.67	11.16	0.46	8.91e-26	Pulmonary function decline;
LGG	cis	rs1401999	0.966	rs1533682	chr3:183634879	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.95	0.62	1.74e-50	Anterior chamber depth;
LGG	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.73	-0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs10911232	0.507	rs10911212	chr1:183024469	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.43e-21	Hypertriglyceridemia;
LGG	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.01	0.39	5.58e-18	Educational attainment;
LGG	trans	rs656319	0.629	rs11774276	chr8:10070309	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.48	-0.37	3.04e-16	Myopia (pathological);
LGG	cis	rs17253792	0.822	rs10143002	chr14:56074278	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg02002194	chr4:3960332	NA	-0.46	-8.68	-0.37	6.79e-17	Monocyte count;
LGG	cis	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05901451	chr6:126070800	HEY2	0.6	10.89	0.45	9.95e-25	Endometrial cancer;
LGG	cis	rs9790314	1.000	rs4370045	chr3:160943865	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.65	-0.48	1.13e-27	Morning vs. evening chronotype;
LGG	cis	rs774359	0.789	rs2783009	chr9:27514584	T/C	cg14173147	chr9:27528300	MOBKL2B	0.45	8.68	0.37	6.93e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs1538970	0.816	rs61788356	chr1:46006675	C/T	cg05343316	chr1:45956843	TESK2	0.79	13.3	0.53	2.01e-34	Platelet count;
LGG	cis	rs2439831	0.717	rs10518820	chr15:43888976	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.35	0.43	1.01e-22	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg20607798	chr8:58055168	NA	0.73	8.17	0.36	2.87e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11722228	1.000	rs6825187	chr4:9915325	T/C	cg08250081	chr4:10125330	NA	-0.47	-8.78	-0.38	3.19e-17	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs2073300	1.000	rs79169006	chr20:23443535	A/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg21862992	chr11:68658383	NA	0.49	8.28	0.36	1.29e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg11584989	chr19:19387371	SF4	0.7	11.57	0.47	2.24e-27	Bipolar disorder;
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg27476859	chr7:2772710	GNA12	0.39	6.83	0.3	2.76e-11	Height;
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03878208	chr11:72483293	STARD10	0.49	7.0	0.31	9.12e-12	Type 2 diabetes;
LGG	cis	rs6933660	0.646	rs6911456	chr6:151778934	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.83	-15.84	-0.59	1.88e-45	Menarche (age at onset);
LGG	cis	rs7582720	1.000	rs72932765	chr2:203679183	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.66	0.41	3.06e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504073	0.647	rs9643395	chr8:50014500	A/C	cg00325661	chr8:49890786	NA	0.7	13.75	0.54	2.65e-36	Blood metabolite ratios;
LGG	cis	rs113835537	0.597	rs7939759	chr11:66337964	C/T	cg24851651	chr11:66362959	CCS	0.48	8.27	0.36	1.45e-15	Airway imaging phenotypes;
LGG	cis	rs679087	1.000	rs302315	chr12:29919054	G/C	cg14258853	chr12:29935411	TMTC1	-0.43	-8.6	-0.37	1.2e-16	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17662034	chr8:74207518	RDH10	0.42	7.15	0.32	3.51e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg26155939	chr18:44337853	ST8SIA5	0.37	6.96	0.31	1.17e-11	Personality dimensions;
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg01145232	chr6:150245071	RAET1G	0.48	8.74	0.38	4.23e-17	Lung cancer;
LGG	cis	rs2769264	0.546	rs12047617	chr1:151392597	G/A	cg18801370	chr1:151430492	POGZ	0.85	14.25	0.55	1.85e-38	Blood trace element (Cu levels);
LGG	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7980687	0.678	rs7132277	chr12:123593382	C/T	cg00376283	chr12:123451042	ABCB9	-0.55	-7.97	-0.35	1.26e-14	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg27205649	chr11:78285834	NARS2	-0.5	-8.69	-0.37	6.46e-17	Alzheimer's disease (survival time);
LGG	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2282802	0.685	rs1529693	chr5:139678213	A/G	cg26211634	chr5:139558579	C5orf32	0.34	7.48	0.33	3.87e-13	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs10256544	chr7:65675128	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.62	-0.37	1.11e-16	Aortic root size;
LGG	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg15704280	chr7:45808275	SEPT13	0.76	7.92	0.35	1.83e-14	Axial length;
LGG	cis	rs796364	1.000	rs281760	chr2:200787804	A/G	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	cis	rs10871290	0.650	rs12600126	chr16:74489732	A/T	cg01733217	chr16:74700730	RFWD3	-0.57	-10.86	-0.45	1.27e-24	Breast cancer;
LGG	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg22771759	chr13:24902376	NA	0.41	7.01	0.31	8.54e-12	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs787274	0.850	rs2025544	chr9:115632969	C/T	cg13803584	chr9:115635662	SNX30	0.69	8.06	0.35	6.55e-15	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs3942852	0.955	rs1532754	chr11:48115279	A/T	cg15704280	chr7:45808275	SEPT13	-0.67	-8.35	-0.36	7.82e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg05182265	chr7:156933206	UBE3C	0.37	7.64	0.33	1.25e-13	Body mass index;
LGG	cis	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-17.48	-0.63	6.77e-53	Morning vs. evening chronotype;
LGG	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.05	-0.31	6.44e-12	Mood instability;
LGG	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.0	-0.71	5.87e-74	Schizophrenia;
LGG	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg11644478	chr21:40555479	PSMG1	-0.75	-13.73	-0.54	3.13e-36	Cognitive function;
LGG	cis	rs1451375	0.583	rs3807555	chr7:50610569	A/G	cg20336341	chr7:50628841	DDC	0.45	8.03	0.35	8.29e-15	Malaria;
LGG	cis	rs4887067	1	rs4887067	chr15:78886947	G/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.41	-0.33	5.86e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23954171	chr22:20862589	MED15	0.39	6.89	0.3	1.85e-11	Gut microbiome composition (summer);
LGG	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08109568	chr15:31115862	NA	-0.53	-8.87	-0.38	1.62e-17	Huntington's disease progression;
LGG	cis	rs2354432	0.607	rs72692962	chr1:146802674	C/A	cg25205988	chr1:146714368	CHD1L	-1.43	-14.5	-0.56	1.55e-39	Mitochondrial DNA levels;
LGG	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg04287289	chr16:89883240	FANCA	0.61	10.5	0.44	2.73e-23	Vitiligo;
LGG	cis	rs1185460	0.546	rs17075	chr11:118959331	A/G	cg24687335	chr11:118901407	SLC37A4	-0.55	-10.14	-0.43	5.89e-22	Coronary artery disease;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg05863683	chr7:1912471	MAD1L1	0.4	7.73	0.34	6.6e-14	Schizophrenia;
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg00294572	chr6:26285232	NA	-0.41	-7.38	-0.32	7.46e-13	Educational attainment;
LGG	cis	rs765787	0.530	rs1706764	chr15:45524256	T/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.39e-13	Uric acid levels;
LGG	cis	rs9952991	0.883	rs2542148	chr18:12777573	C/G	cg23544223	chr18:12777786	NA	0.62	9.38	0.4	2.95e-19	Inflammatory skin disease;
LGG	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-12.11	-0.49	1.63e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs78487399	0.808	rs7573500	chr2:43685625	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.85	-0.3	2.31e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg21782813	chr7:2030301	MAD1L1	0.44	10.49	0.44	2.93e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs4696584	0.816	rs4696587	chr4:155405655	C/T	cg13738195	chr4:155413469	DCHS2	0.4	8.34	0.36	8.68e-16	Folding of antihelix;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10457504	chr17:19281708	MAPK7	0.48	7.03	0.31	7.67e-12	Gut microbiome composition (summer);
LGG	cis	rs1348850	0.914	rs7565022	chr2:178320222	A/T	cg22681709	chr2:178499509	PDE11A	-0.47	-9.02	-0.39	5.16e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.58	9.55	0.41	7.38e-20	Height;
LGG	cis	rs1915146	0.507	rs9423024	chr10:126862256	C/A	cg23000734	chr10:126850823	CTBP2	0.25	7.23	0.32	2.05e-12	Menarche (age at onset);
LGG	cis	rs68170813	0.652	rs79295036	chr7:107193669	C/A	cg02696742	chr7:106810147	HBP1	-0.66	-8.49	-0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs116095464	0.850	rs10057272	chr5:340188	T/C	cg22496380	chr5:211416	CCDC127	-1.27	-10.24	-0.43	2.59e-22	Breast cancer;
LGG	cis	rs751728	1.000	rs6904991	chr6:33732262	T/G	cg25922239	chr6:33757077	LEMD2	0.67	11.57	0.47	2.18e-27	Crohn's disease;
LGG	cis	rs9296092	0.517	rs56206922	chr6:33522567	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6142618	0.562	rs6061198	chr20:30750464	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs11098499	0.754	rs7672778	chr4:120248585	A/G	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs2916247	1.000	rs1814032	chr8:93005447	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.43	-0.36	4.5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2197308	0.813	rs11504316	chr12:38219320	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-8.82	-0.38	2.33e-17	Morning vs. evening chronotype;
LGG	cis	rs228769	0.635	rs228754	chr17:42116056	C/A	cg19774624	chr17:42201019	HDAC5	0.57	8.19	0.36	2.64e-15	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs76419734	0.510	rs2553461	chr4:106731410	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	-0.55	-7.65	-0.33	1.17e-13	Post bronchodilator FEV1;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02326931	chr13:37572901	ALG5	0.48	7.47	0.33	3.94e-13	Gut microbiome composition (summer);
LGG	cis	rs6500637	0.619	rs77997837	chr16:4944256	C/T	cg08329684	chr16:4932620	PPL	0.46	7.98	0.35	1.15e-14	Cancer;
LGG	cis	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg12463550	chr7:65579703	CRCP	0.78	8.52	0.37	2.26e-16	Diabetic kidney disease;
LGG	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg02002194	chr4:3960332	NA	0.5	9.35	0.4	3.84e-19	Retinal vascular caliber;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	17.73	0.64	4.78e-54	Platelet count;
LGG	cis	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-12.16	-0.49	1e-29	Bladder cancer;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg11062466	chr8:58055876	NA	0.58	13.41	0.53	7.44e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg09264619	chr17:80180166	NA	0.52	9.97	0.42	2.39e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.63	0.33	1.34e-13	Longevity;
LGG	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg26597838	chr10:835615	NA	0.52	7.25	0.32	1.77e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs6120849	0.754	rs6120812	chr20:33629427	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.67	0.3	7.23e-11	Protein C levels;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg04490037	chr7:50633773	DDC	0.32	6.96	0.31	1.19e-11	Body mass index;
LGG	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.45	-7.0	-0.31	9.32e-12	Tuberculosis;
LGG	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg16141378	chr3:129829833	LOC729375	-0.31	-6.66	-0.3	7.7e-11	Retinal vascular caliber;
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg00495681	chr13:53174319	NA	0.86	18.72	0.66	1.3e-58	Lewy body disease;
LGG	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.68	-0.44	6.17e-24	Aortic root size;
LGG	cis	rs7584330	0.910	rs7606177	chr2:238394913	G/C	cg16989719	chr2:238392110	NA	-0.34	-7.51	-0.33	2.99e-13	Prostate cancer;
LGG	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg01028140	chr2:1542097	TPO	-0.47	-8.81	-0.38	2.57e-17	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15586420	chr15:90294517	MESP1	0.44	6.69	0.3	6.26e-11	Gut microbiome composition (summer);
LGG	cis	rs6088590	0.561	rs6059926	chr20:33164804	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.69	0.37	6.18e-17	Coronary artery disease;
LGG	cis	rs4073582	0.595	rs1115508	chr11:65923149	A/G	cg16950941	chr11:66035639	RAB1B	0.55	10.41	0.44	5.87e-23	Gout;
LGG	cis	rs7166081	1.000	rs10438355	chr15:67487549	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.03	-0.31	7.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4481887	0.927	rs4345830	chr1:248474845	G/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg23730037	chr7:158596552	ESYT2	-0.47	-8.47	-0.37	3.34e-16	Height;
LGG	cis	rs959260	0.502	rs11658023	chr17:73308722	C/T	cg14668889	chr17:73230827	NUP85	-0.54	-9.14	-0.39	1.91e-18	Systemic lupus erythematosus;
LGG	cis	rs2479724	0.905	rs2274578	chr6:41888827	C/G	cg17623882	chr6:41773611	USP49	-0.52	-9.37	-0.4	3.13e-19	Menarche (age at onset);
LGG	cis	rs986417	0.901	rs7150630	chr14:61019458	T/A	cg27398547	chr14:60952738	C14orf39	0.72	7.11	0.31	4.31e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17428076	0.836	rs57718990	chr2:172662614	T/G	cg21435375	chr2:172878103	MAP1D	0.41	8.91	0.38	1.14e-17	Myopia;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg06848047	chr4:90757629	SNCA	-0.38	-7.11	-0.31	4.37e-12	Dementia with Lewy bodies;
LGG	cis	rs11997175	0.574	rs4733456	chr8:33656359	C/T	ch.8.33884649F	chr8:33765107	NA	0.39	7.14	0.31	3.63e-12	Body mass index;
LGG	cis	rs258892	0.894	rs155435	chr5:72200093	G/A	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.7e-11	Small cell lung carcinoma;
LGG	cis	rs981844	0.712	rs1037654	chr4:154750300	C/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs4481887	0.927	rs4603165	chr1:248473799	T/A	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs12497850	1.000	rs4858798	chr3:48727112	C/T	cg06212747	chr3:49208901	KLHDC8B	0.61	10.31	0.43	1.47e-22	Parkinson's disease;
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.68	0.37	6.95e-17	Bipolar disorder;
LGG	cis	rs2836974	0.932	rs8129416	chr21:40617145	C/T	cg11890956	chr21:40555474	PSMG1	1.17	28.31	0.8	4.65e-103	Cognitive function;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs10173297	0.686	rs62108696	chr2:3707852	T/C	cg16123090	chr2:3699210	NA	0.58	7.69	0.34	8.89e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3849570	0.925	rs1464791	chr3:81893929	A/C	cg07356753	chr3:81810745	GBE1	0.43	7.01	0.31	8.73e-12	Waist circumference;Body mass index;
LGG	trans	rs8002861	0.869	rs7989857	chr13:44464090	C/T	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg21775007	chr8:11205619	TDH	-0.51	-8.26	-0.36	1.56e-15	Triglycerides;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs526231	0.511	rs17154965	chr5:102359566	C/A	cg23492399	chr5:102201601	PAM	-0.56	-8.3	-0.36	1.16e-15	Primary biliary cholangitis;
LGG	cis	rs7666738	0.618	rs10856932	chr4:98819992	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.81	0.34	3.83e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7712401	0.601	rs34348084	chr5:122335114	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	trans	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.27	-0.32	1.57e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs950776	0.518	rs62008194	chr15:78813805	G/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.19	0.39	1.36e-18	Sudden cardiac arrest;
LGG	cis	rs17401966	0.838	rs1538557	chr1:10297230	T/C	cg15208524	chr1:10270712	KIF1B	0.45	7.87	0.34	2.54e-14	Hepatocellular carcinoma;
LGG	cis	rs12477438	0.765	rs6737257	chr2:99683330	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	trans	rs9354308	0.764	rs9354323	chr6:66586561	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2859741	0.967	rs534131	chr1:37484237	T/C	cg09363841	chr1:37513479	NA	-0.65	-15.64	-0.59	1.48e-44	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06527865	chr1:234746497	IRF2BP2	0.42	7.14	0.31	3.74e-12	Bipolar disorder;
LGG	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg12386194	chr3:101231763	SENP7	0.7	12.03	0.49	3.51e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3741404	0.757	rs2282492	chr11:63918589	A/G	cg04000281	chr11:63949212	NA	-0.43	-8.13	-0.35	3.98e-15	Platelet count;
LGG	cis	rs59104589	0.617	rs3771561	chr2:242353704	A/G	cg10021735	chr2:242295487	FARP2	-0.45	-6.67	-0.3	7.3e-11	Fibrinogen levels;
LGG	cis	rs6558530	0.799	rs62477060	chr8:1706498	A/T	cg19131313	chr8:1704013	NA	-0.3	-6.72	-0.3	5.35e-11	Systolic blood pressure;
LGG	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg06618935	chr21:46677482	NA	-0.53	-9.43	-0.4	1.97e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg09324608	chr17:30823087	MYO1D	0.36	8.28	0.36	1.37e-15	Schizophrenia;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg09493857	chr2:55459644	RPS27A;C2orf63	-0.42	-6.65	-0.3	8.52e-11	Body fat mass;
LGG	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg02711726	chr17:80685570	FN3KRP	-0.39	-7.24	-0.32	1.94e-12	Breast cancer;
LGG	cis	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg00405596	chr8:11794950	NA	-0.61	-10.52	-0.44	2.37e-23	Monocyte count;
LGG	cis	rs2072732	0.687	rs10489588	chr1:2951834	C/T	cg08733933	chr1:2954429	NA	-0.33	-7.58	-0.33	1.95e-13	Plateletcrit;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg11245990	chr11:68621969	NA	-0.37	-7.94	-0.35	1.59e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08263361	chr15:77713262	HMG20A	0.43	7.16	0.32	3.27e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1978968	1.000	rs11704827	chr22:18450287	A/T	cg03078520	chr22:18463400	MICAL3	-0.63	-12.67	-0.51	8.35e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs2486288	0.656	rs8039540	chr15:45551842	C/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs2204008	0.640	rs11520199	chr12:38211026	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg26818010	chr10:134567672	INPP5A	-0.75	-11.59	-0.47	1.86e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg16482183	chr6:26056742	HIST1H1C	0.39	6.84	0.3	2.59e-11	Height;
LGG	cis	rs2860975	1.000	rs10882514	chr10:96782898	T/C	cg09036531	chr10:96991505	NA	-0.47	-8.54	-0.37	1.89e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs71403859	0.614	rs12935422	chr16:71664225	T/A	cg08717414	chr16:71523259	ZNF19	-1.03	-13.09	-0.52	1.55e-33	Post bronchodilator FEV1;
LGG	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg00431813	chr7:1051703	C7orf50	-0.37	-8.18	-0.36	2.76e-15	Longevity;Endometriosis;
LGG	cis	rs12802200	0.561	rs746707	chr11:571984	C/T	cg16486109	chr11:613632	IRF7	0.42	7.51	0.33	3.03e-13	Systemic lupus erythematosus;
LGG	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg13852791	chr20:30311386	BCL2L1	-0.79	-12.83	-0.51	1.83e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.26	-0.55	1.61e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg13047869	chr3:10149882	C3orf24	0.49	7.69	0.34	8.81e-14	Alzheimer's disease;
LGG	cis	rs9512730	0.592	rs9581865	chr13:28054578	A/C	cg04070771	chr13:27998621	GTF3A	0.5	7.5	0.33	3.18e-13	Schizophrenia;
LGG	cis	rs10751667	0.643	rs7396623	chr11:934104	G/A	cg22143635	chr11:980567	AP2A2	0.43	7.88	0.34	2.41e-14	Alzheimer's disease (late onset);
LGG	cis	rs701145	0.537	rs1713842	chr3:153786243	T/A	cg17054900	chr3:154042577	DHX36	-0.74	-9.02	-0.39	5e-18	Coronary artery disease;
LGG	cis	rs447735	0.587	rs11647958	chr16:89720909	A/T	cg03605463	chr16:89740564	NA	0.46	7.91	0.34	1.96e-14	Hemoglobin concentration;
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg25767906	chr1:53392781	SCP2	-0.41	-8.43	-0.36	4.45e-16	Monocyte count;
LGG	cis	rs73198271	0.515	rs76620708	chr8:8619083	C/T	cg01851573	chr8:8652454	MFHAS1	0.5	6.71	0.3	5.7e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.93	-0.42	3.34e-21	Lung cancer;
LGG	cis	rs7552404	0.727	rs12122939	chr1:76276353	T/C	cg03433033	chr1:76189801	ACADM	0.65	9.89	0.42	4.75e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg16339924	chr4:17578868	LAP3	0.65	10.96	0.45	5.22e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg08847335	chr10:891726	LARP4B	0.52	9.51	0.4	1.07e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs887829	0.569	rs6431628	chr2:234647478	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.38	-0.36	6.22e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg06521331	chr12:34319734	NA	0.46	8.73	0.38	4.74e-17	Heart rate;
LGG	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg24503407	chr1:205819492	PM20D1	0.84	20.35	0.69	3.19e-66	Menarche (age at onset);
LGG	cis	rs9354308	0.866	rs2802054	chr6:66544766	G/C	cg07460842	chr6:66804631	NA	0.57	9.55	0.41	7.54e-20	Metabolite levels;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	8.99	0.39	6.48e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23843019	chr19:53445988	ZNF321	0.39	6.87	0.3	2.08e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4467006	0.519	rs4243654	chr14:77685535	A/G	cg22824376	chr14:77648248	TMEM63C	0.54	6.66	0.3	7.56e-11	Bipolar disorder;
LGG	cis	rs7166081	1.000	rs4776350	chr15:67542179	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.23	-0.32	1.96e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs9611565	0.681	rs6002372	chr22:41801299	A/T	cg03806693	chr22:41940476	POLR3H	1.01	17.78	0.64	2.66e-54	Vitiligo;
LGG	trans	rs6787172	0.702	rs9784311	chr3:158030903	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.91e-17	Subjective well-being;
LGG	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg25237894	chr2:233734115	C2orf82	-0.46	-7.5	-0.33	3.22e-13	Schizophrenia;
LGG	cis	rs12497850	0.931	rs9840684	chr3:48893780	T/C	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg00204512	chr16:28754710	NA	0.26	7.24	0.32	1.9e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs757278	0.580	rs4730799	chr7:117372998	T/C	cg10524701	chr7:117356490	CTTNBP2	0.41	7.22	0.32	2.13e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs7084402	0.902	rs3001715	chr10:60285509	A/G	cg07615347	chr10:60278583	BICC1	0.63	17.37	0.63	2.2e-52	Refractive error;
LGG	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg26384229	chr12:38710491	ALG10B	0.88	19.79	0.68	1.36e-63	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4474465	1.000	rs10899523	chr11:78190808	C/T	cg02023728	chr11:77925099	USP35	0.4	7.07	0.31	5.7e-12	Alzheimer's disease (survival time);
LGG	cis	rs11608355	0.545	rs4766604	chr12:109892179	T/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs58688157	0.739	rs56333810	chr11:575408	C/G	cg02461776	chr11:598696	PHRF1	0.47	7.76	0.34	5.43e-14	Systemic lupus erythematosus;
LGG	cis	rs11700980	0.551	rs2832022	chr21:30112718	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7572733	0.534	rs4369854	chr2:198800630	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs875971	0.895	rs7788984	chr7:65915616	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg13126279	chr21:47581558	C21orf56	-0.46	-7.98	-0.35	1.17e-14	Testicular germ cell tumor;
LGG	cis	rs7226408	0.857	rs55895201	chr18:34478630	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.98	-0.31	1.03e-11	Obesity-related traits;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.79e-31	Lymphocyte counts;
LGG	cis	rs10489202	0.632	rs202268	chr1:167927339	T/C	cg24449463	chr1:168025552	DCAF6	-0.59	-10.46	-0.44	4e-23	Schizophrenia;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg13390975	chr5:34915890	BRIX1;RAD1	-0.4	-6.69	-0.3	6.34e-11	Leprosy;
LGG	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg19507638	chr5:93509721	C5orf36	-0.62	-8.98	-0.39	6.85e-18	Diabetic retinopathy;
LGG	trans	rs2235573	0.551	rs139892	chr22:38388203	C/T	cg19894588	chr14:64061835	NA	0.6	9.98	0.42	2.33e-21	Glioblastoma;Glioma;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12379764	chr21:47803548	PCNT	0.39	6.66	0.3	7.74e-11	Testicular germ cell tumor;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07308232	chr7:1071921	C7orf50	0.62	11.64	0.48	1.19e-27	Longevity;Endometriosis;
LGG	cis	rs12505749	0.542	rs6554358	chr4:57372576	A/T	cg07846311	chr4:57371927	ARL9	-0.34	-8.26	-0.36	1.55e-15	Airflow obstruction;
LGG	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg10295955	chr4:187884368	NA	-1.14	-31.98	-0.83	2.65e-119	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08879241	chr10:74927972	FAM149B1;ECD	-0.39	-6.9	-0.31	1.72e-11	Brain structure;
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs147858478	1	rs147858478	chr5:131682785	CCTGAGTT/C	cg07395648	chr5:131743802	NA	-0.55	-13.17	-0.52	7.26e-34	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2084898	0.882	rs7114201	chr11:120050113	T/A	cg13907859	chr11:120009124	TRIM29	0.88	11.92	0.48	9.72e-29	Stroke (pediatric);
LGG	cis	rs7503807	0.688	rs12600403	chr17:78602477	A/T	cg16980736	chr17:78789706	RPTOR	-0.37	-6.72	-0.3	5.39e-11	Obesity;
LGG	trans	rs853679	0.546	rs200948	chr6:27835272	T/C	cg01620082	chr3:125678407	NA	-0.82	-8.97	-0.38	7.37e-18	Depression;
LGG	cis	rs208515	0.525	rs1484577	chr6:66688397	A/G	cg07460842	chr6:66804631	NA	0.94	17.41	0.63	1.35e-52	Exhaled nitric oxide levels;
LGG	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.79	-0.59	2.94e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs4077515	0.934	rs10781507	chr9:139272058	A/G	cg21253087	chr9:139290292	SNAPC4	0.36	7.18	0.32	2.86e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9325144	0.647	rs12231313	chr12:39101929	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.45	-0.33	4.49e-13	Morning vs. evening chronotype;
LGG	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg11752832	chr7:134001865	SLC35B4	0.6	10.89	0.45	9.85e-25	Mean platelet volume;
LGG	cis	rs11118993	0.532	rs7544370	chr1:206727140	A/G	cg17220933	chr1:206729613	RASSF5	0.46	8.81	0.38	2.57e-17	Neurofibrillary tangles;
LGG	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg07061783	chr6:25882402	NA	-0.39	-6.91	-0.31	1.56e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9467711	0.651	rs13200797	chr6:26122957	G/A	cg21479132	chr6:26055353	NA	0.79	7.59	0.33	1.8e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.7	-0.37	5.67e-17	Menopause (age at onset);
LGG	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg23740940	chr11:68924746	NA	0.44	6.98	0.31	1e-11	Blond vs. brown hair color;
LGG	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	12.1	0.49	1.86e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.59	0.56	6.18e-40	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.86	-0.38	1.67e-17	Lung cancer;
LGG	cis	rs2463822	1.000	rs11231050	chr11:62131660	C/G	cg06239285	chr11:62104954	ASRGL1	-1.13	-15.15	-0.58	2.13e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7527798	0.592	rs11118359	chr1:207858546	T/C	cg09232269	chr1:207846808	CR1L	-0.38	-7.15	-0.32	3.5e-12	Erythrocyte sedimentation rate;
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg18252515	chr7:66147081	NA	0.42	7.07	0.31	5.73e-12	Aortic root size;
LGG	cis	rs897984	0.762	rs4889599	chr16:30968589	C/T	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.04	-0.31	7.03e-12	Aortic root size;
LGG	cis	rs13108043	0.605	rs34227282	chr4:87932645	C/T	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.22	-0.32	2.21e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1894633	0.574	rs17277918	chr1:172322620	A/G	cg01573306	chr1:172330400	DNM3	-0.4	-7.08	-0.31	5.28e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9487051	0.714	rs7757347	chr6:109633815	G/A	cg21918786	chr6:109611834	NA	-0.5	-9.35	-0.4	3.62e-19	Reticulocyte fraction of red cells;
LGG	cis	rs7662987	0.517	rs1377689	chr4:100021787	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs9463078	0.691	rs9381361	chr6:45011417	A/C	cg25276700	chr6:44698697	NA	-0.32	-6.74	-0.3	4.71e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4684776	1.000	rs7625881	chr3:11550723	A/G	cg24705426	chr3:11550659	ATG7	-0.47	-8.31	-0.36	1.07e-15	Small vessel stroke;
LGG	cis	rs8141529	0.748	rs1318025	chr22:29283757	C/T	cg15103426	chr22:29168792	CCDC117	0.59	8.95	0.38	8.58e-18	Lymphocyte counts;
LGG	cis	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.23	0.39	9.57e-19	Neuroticism;
LGG	cis	rs796364	0.806	rs11684942	chr2:201009136	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.49	-0.4	1.2e-19	Mean corpuscular volume;
LGG	cis	rs1719271	0.908	rs2630503	chr15:65179287	C/G	cg11671771	chr15:65133392	PLEKHO2	-0.53	-7.2	-0.32	2.49e-12	Platelet count;
LGG	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg14210321	chr2:106509881	NCK2	0.52	8.87	0.38	1.55e-17	Addiction;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg12708336	chr17:41446283	NA	-0.33	-8.03	-0.35	8.19e-15	Menopause (age at onset);
LGG	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg25566285	chr7:158114605	PTPRN2	0.7	11.74	0.48	4.91e-28	Response to amphetamines;
LGG	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.55	-10.37	-0.43	8.86e-23	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4660214	0.666	rs2490946	chr1:39837627	G/A	cg18385671	chr1:39797026	MACF1	0.47	10.0	0.42	1.89e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg03733263	chr8:22462867	KIAA1967	0.94	21.41	0.71	3.31e-71	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2274273	0.967	rs67756714	chr14:55589823	G/A	cg04306507	chr14:55594613	LGALS3	0.61	16.83	0.62	6.14e-50	Protein biomarker;
LGG	cis	rs360798	0.512	rs2215870	chr2:63132342	C/G	cg17519650	chr2:63277830	OTX1	0.49	7.99	0.35	1.05e-14	Coronary artery disease;
LGG	cis	rs796364	1.000	rs166845	chr2:200823360	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	trans	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.95	0.35	1.45e-14	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.71	13.43	0.53	5.89e-35	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.54e-18	Alzheimer's disease;
LGG	cis	rs4517514	0.509	rs10830396	chr11:89831383	G/A	cg21153622	chr11:89784906	NA	-0.61	-6.71	-0.3	5.86e-11	Trans fatty acid levels;
LGG	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	11.06	0.46	2.25e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10752881	0.935	rs3935221	chr1:182969010	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.88	0.38	1.53e-17	Colorectal cancer;
LGG	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg13683864	chr3:40499215	RPL14	1.16	30.43	0.82	1.56e-112	Renal cell carcinoma;
LGG	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.47	7.72	0.34	7.18e-14	Osteoporosis;
LGG	cis	rs3816183	0.531	rs11124902	chr2:43148132	T/C	cg14631114	chr2:43023945	NA	0.38	6.66	0.3	7.75e-11	Hypospadias;
LGG	cis	rs6141769	0.542	rs28523897	chr20:31301248	C/T	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.83	-0.3	2.71e-11	Subjective well-being;
LGG	cis	rs1552244	1.000	rs6768102	chr3:10149380	A/G	cg15117754	chr3:10150083	C3orf24	0.49	6.97	0.31	1.08e-11	Alzheimer's disease;
LGG	cis	rs12210905	1.000	rs12213361	chr6:27138387	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-7.71	-0.34	7.88e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.84	15.0	0.57	9.33e-42	Response to antipsychotic treatment;
LGG	cis	rs4253772	0.530	rs6008623	chr22:46710024	G/A	cg24881330	chr22:46731750	TRMU	0.73	7.35	0.32	9.03e-13	LDL cholesterol;Cholesterol, total;
LGG	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.36	-0.32	8.73e-13	Morning vs. evening chronotype;
LGG	cis	rs5769765	0.740	rs2103932	chr22:50272515	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.73e-13	Schizophrenia;
LGG	cis	rs9964724	0.865	rs1557341	chr18:35127427	A/C	cg27332583	chr18:35150602	NA	-0.39	-8.18	-0.36	2.79e-15	Educational attainment (years of education);
LGG	cis	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg07777115	chr5:623756	CEP72	-0.56	-7.16	-0.32	3.29e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs4642101	0.824	rs9820977	chr3:12842932	G/A	cg05775895	chr3:12838266	CAND2	0.69	12.78	0.51	2.99e-32	QRS complex (12-leadsum);
LGG	cis	rs7918232	0.607	rs1755401	chr10:27405763	A/C	cg14240646	chr10:27532245	ACBD5	-0.74	-8.87	-0.38	1.54e-17	Breast cancer;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11203032	0.831	rs10887926	chr10:90940358	G/A	cg16672925	chr10:90967113	CH25H	0.77	11.02	0.46	3.11e-25	Heart failure;
LGG	cis	rs12210905	1.000	rs9368492	chr6:27221518	A/G	cg15325629	chr6:28072465	NA	0.7	6.69	0.3	6.52e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.947	rs31587	chr5:131000711	A/T	cg06307176	chr5:131281290	NA	0.57	9.31	0.4	5.1e-19	Life satisfaction;
LGG	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.64	-11.04	-0.46	2.5e-25	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11383747	chr17:260000	C17orf97	0.58	9.01	0.39	5.32e-18	Gut microbiome composition (summer);
LGG	cis	rs6542838	0.704	rs12474283	chr2:99527310	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.97	-0.31	1.11e-11	Fear of minor pain;
LGG	trans	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.59	-0.37	1.33e-16	Triglycerides;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11150308	chr17:74068434	SRP68	0.38	6.77	0.3	3.92e-11	Obesity-related traits;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.57	-9.98	-0.42	2.22e-21	Longevity;Endometriosis;
LGG	cis	rs7666738	0.830	rs1426667	chr4:98949772	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg09845145	chr15:78292470	TBC1D2B	-0.64	-10.58	-0.44	1.47e-23	Coronary artery disease or large artery stroke;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12630974	chr1:28655517	MED18	-0.33	-6.76	-0.3	4.27e-11	Pancreatic cancer;
LGG	cis	rs6993244	1	rs6993244	chr8:8863059	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.46	0.33	4.21e-13	Mean corpuscular hemoglobin;
LGG	trans	rs7829975	1.000	rs7829975	chr8:8548117	T/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.08	-0.31	5.48e-12	Mood instability;
LGG	cis	rs2131877	0.701	rs61231387	chr3:194832120	G/T	cg07250128	chr3:194833983	C3orf21	0.39	6.82	0.3	2.93e-11	Non-small cell lung cancer;
LGG	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg20503657	chr10:835505	NA	0.63	9.47	0.4	1.39e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	0.61	11.0	0.46	3.82e-25	Alzheimer's disease;
LGG	cis	rs2404602	0.622	rs4886506	chr15:77207277	G/T	cg23625390	chr15:77176239	SCAPER	0.71	13.95	0.54	3.51e-37	Blood metabolite levels;
LGG	cis	rs9916302	0.645	rs1053651	chr17:37822311	A/C	cg00129232	chr17:37814104	STARD3	-0.78	-16.62	-0.61	5.52e-49	Glomerular filtration rate (creatinine);
LGG	cis	rs7301016	0.846	rs7297093	chr12:63033387	C/T	cg01804193	chr12:63026212	NA	0.55	7.13	0.31	3.82e-12	IgG glycosylation;
LGG	trans	rs34421088	0.532	rs2409754	chr8:11155613	A/G	cg02002194	chr4:3960332	NA	-0.4	-7.15	-0.32	3.39e-12	Neuroticism;
LGG	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg19507638	chr5:93509721	C5orf36	0.62	9.08	0.39	3.22e-18	Diabetic retinopathy;
LGG	cis	rs617791	0.530	rs7952056	chr11:65744597	C/T	cg26695010	chr11:65641043	EFEMP2	0.46	7.19	0.32	2.6e-12	Breast cancer;
LGG	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.08	-0.78	1.69e-97	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg23782820	chr8:58130467	NA	0.44	6.72	0.3	5.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9747201	1.000	rs62078307	chr17:80090053	G/T	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	3e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg14222797	chr10:16859974	RSU1	-0.63	-7.61	-0.33	1.58e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs877282	1.000	rs7100358	chr10:773681	G/A	cg17470449	chr10:769945	NA	0.65	8.36	0.36	7.43e-16	Uric acid levels;
LGG	cis	rs36715	0.953	rs2546146	chr5:127546539	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.38	0.32	7.52e-13	Breast cancer;
LGG	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg20673091	chr1:2541236	MMEL1	0.58	12.9	0.51	9.74e-33	Ulcerative colitis;
LGG	cis	rs7122539	0.576	rs3741194	chr11:66626234	T/C	cg01599099	chr11:66649832	PC	0.46	8.87	0.38	1.62e-17	HIV-1 susceptibility;
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg00405596	chr8:11794950	NA	-0.39	-6.77	-0.3	4e-11	Neuroticism;
LGG	cis	rs523522	0.962	rs10849757	chr12:120964014	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.81	0.51	2.24e-32	High light scatter reticulocyte count;
LGG	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg02269571	chr22:50332266	NA	-0.68	-10.66	-0.44	6.92e-24	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg24829409	chr8:58192753	C8orf71	0.79	11.26	0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs17826219	0.568	rs11658027	chr17:29094882	A/G	cg01831904	chr17:28903510	LRRC37B2	0.79	9.76	0.41	1.35e-20	Body mass index;
LGG	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg07882059	chr11:68924751	NA	0.41	7.33	0.32	1.02e-12	Blond vs. brown hair color;
LGG	cis	rs8180040	0.620	rs56217494	chr3:47048452	T/G	cg27129171	chr3:47204927	SETD2	-0.81	-14.7	-0.56	1.98e-40	Colorectal cancer;
LGG	cis	rs4538187	0.627	rs11694253	chr2:63948135	T/G	cg02541582	chr2:64069798	UGP2	-0.55	-10.16	-0.43	4.87e-22	Systolic blood pressure;
LGG	cis	rs9783347	0.961	rs4150526	chr11:18343209	G/A	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg04248312	chr19:17393744	ANKLE1	-0.65	-10.61	-0.44	1.09e-23	Systemic lupus erythematosus;
LGG	cis	rs7770628	0.682	rs7772437	chr6:161115245	A/T	cg04181478	chr6:161122748	PLG	-0.41	-8.38	-0.36	6.3e-16	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01044731	chr13:24554006	NA	0.51	8.26	0.36	1.59e-15	Cognitive performance;
LGG	cis	rs377457	0.718	rs11649172	chr16:85742950	A/C	cg08768472	chr16:85689701	KIAA0182	0.43	7.82	0.34	3.56e-14	Type 2 diabetes;
LGG	cis	rs2380220	0.576	rs4498363	chr6:96042338	A/C	cg04719120	chr6:96025338	MANEA	0.56	7.92	0.35	1.72e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.73e-18	Aortic root size;
LGG	cis	rs4604732	0.536	rs7528219	chr1:247628307	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.06	0.39	3.56e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg01448562	chr3:133502909	NA	-0.52	-8.67	-0.37	7.1e-17	Iron status biomarkers;
LGG	cis	rs6032067	0.640	rs13043809	chr20:43753220	A/G	cg10761708	chr20:43804764	PI3	0.7	10.21	0.43	3.32e-22	Blood protein levels;
LGG	cis	rs12780845	0.540	rs12360050	chr10:17201645	T/C	cg01003015	chr10:17271136	VIM	-0.43	-7.03	-0.31	7.64e-12	Homocysteine levels;
LGG	cis	rs4665809	0.549	rs72809635	chr2:26411674	G/A	cg08470875	chr2:26401718	FAM59B	0.41	7.79	0.34	4.29e-14	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.25e-14	Vitiligo;
LGG	cis	rs637571	0.726	rs689274	chr11:65665988	A/G	cg26695010	chr11:65641043	EFEMP2	0.63	11.4	0.47	1.01e-26	Eosinophil percentage of white cells;
LGG	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.6e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg03806693	chr22:41940476	POLR3H	-0.9	-14.92	-0.57	2.18e-41	Vitiligo;
LGG	cis	rs9911578	0.967	rs6503890	chr17:57064167	A/G	cg12560992	chr17:57184187	TRIM37	0.92	16.11	0.6	1.12e-46	Intelligence (multi-trait analysis);
LGG	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg04691961	chr3:161091175	C3orf57	-0.39	-7.89	-0.34	2.16e-14	Educational attainment (years of education);
LGG	cis	rs368123	1.000	rs436348	chr6:160729705	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs4938330	0.629	rs12269901	chr11:116973929	C/G	cg20608306	chr11:116969690	SIK3	-0.29	-7.72	-0.34	7.08e-14	Blood protein levels;
LGG	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-17.21	-0.62	1.08e-51	Dental caries;
LGG	trans	rs7395662	1.000	rs7482176	chr11:48604620	C/G	cg03929089	chr4:120376271	NA	-0.46	-7.45	-0.33	4.48e-13	HDL cholesterol;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg25072359	chr17:41440525	NA	0.53	10.21	0.43	3.31e-22	Menopause (age at onset);
LGG	cis	rs638893	0.578	rs485901	chr11:118622245	G/A	cg13782932	chr11:118662891	DDX6	0.37	6.72	0.3	5.44e-11	Vitiligo;
LGG	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.7	-0.3	6.09e-11	Bipolar disorder;
LGG	cis	rs2739330	0.703	rs5760112	chr22:24259772	C/G	cg15242686	chr22:24348715	GSTTP1	0.44	8.09	0.35	5.28e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9815354	0.812	rs73071358	chr3:41830487	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg06718696	chr17:78121285	EIF4A3	0.41	6.95	0.31	1.22e-11	Yeast infection;
LGG	cis	rs10927875	0.526	rs35340817	chr1:16178917	T/C	cg07117364	chr1:16154769	NA	-0.51	-7.51	-0.33	3.03e-13	Dilated cardiomyopathy;
LGG	cis	rs9400467	0.537	rs12202411	chr6:111488518	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	7.16	0.32	3.27e-12	Blood metabolite levels;Amino acid levels;
LGG	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg02002194	chr4:3960332	NA	0.47	8.4	0.36	5.69e-16	Retinal vascular caliber;
LGG	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg06640241	chr16:89574553	SPG7	0.93	17.56	0.63	2.8e-53	Multiple myeloma (IgH translocation);
LGG	cis	rs8028182	0.636	rs11638974	chr15:75799306	G/A	cg20655648	chr15:75932815	IMP3	0.45	7.5	0.33	3.32e-13	Sudden cardiac arrest;
LGG	trans	rs10248839	0.518	rs34011864	chr7:29698499	G/A	cg27349345	chr7:35225932	NA	-0.52	-7.49	-0.33	3.62e-13	Facial emotion recognition (angry faces);
LGG	cis	rs3806843	0.548	rs246038	chr5:140331699	A/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25636833	chr22:41864805	PHF5A;ACO2	0.43	7.33	0.32	1.05e-12	Bipolar disorder;
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg04709771	chr16:646395	RAB40C	0.37	6.76	0.3	4.16e-11	Height;
LGG	cis	rs721917	0.506	rs1923540	chr10:81690372	G/C	cg25562619	chr10:81652821	NA	-0.34	-7.65	-0.33	1.18e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs6743226	0.603	rs62186410	chr2:242235858	T/C	cg10021735	chr2:242295487	FARP2	0.4	6.96	0.31	1.2e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg24687543	chr11:63912206	MACROD1	0.6	8.21	0.36	2.17e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3126085	0.825	rs868303	chr1:152178563	C/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.38e-17	Atopic dermatitis;
LGG	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs6868223	0.617	rs12186654	chr5:33644456	C/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg06532163	chr17:45867833	NA	-0.49	-7.87	-0.34	2.53e-14	IgG glycosylation;
LGG	cis	rs738321	0.723	rs9622726	chr22:38506688	A/G	cg25457927	chr22:38595422	NA	-0.35	-7.98	-0.35	1.13e-14	Breast cancer;
LGG	cis	rs12519773	0.576	rs55971857	chr5:92441594	A/C	cg18783429	chr5:92414398	NA	0.34	8.63	0.37	9.6e-17	Migraine;
LGG	cis	rs5771225	0.563	rs6010220	chr22:50693554	A/G	cg16473166	chr22:50639996	SELO	0.64	9.71	0.41	2.01e-20	Late-onset Alzheimer's disease;
LGG	cis	rs11690935	0.694	rs312921	chr2:172567225	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.45	-0.79	3.62e-99	Schizophrenia;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg12379764	chr21:47803548	PCNT	-0.48	-8.41	-0.36	5.11e-16	Testicular germ cell tumor;
LGG	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.56	-0.33	2.17e-13	IgG glycosylation;
LGG	cis	rs765787	0.530	rs2554457	chr15:45520926	G/A	cg25801113	chr15:45476975	SHF	0.87	19.95	0.68	2.28e-64	Uric acid levels;
LGG	cis	rs12780845	0.522	rs10795457	chr10:17230150	A/G	cg01003015	chr10:17271136	VIM	-0.44	-7.46	-0.33	4.32e-13	Homocysteine levels;
LGG	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg01620082	chr3:125678407	NA	-1.08	-10.54	-0.44	1.91e-23	Depression;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg24642844	chr7:1081250	C7orf50	-0.73	-9.29	-0.4	5.93e-19	Longevity;Endometriosis;
LGG	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.7	-11.84	-0.48	1.99e-28	Height;
LGG	cis	rs936229	0.813	rs7085	chr15:75095483	T/C	cg14664628	chr15:75095509	CSK	-1.14	-27.39	-0.79	6.42e-99	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.87	0.34	2.58e-14	Tonsillectomy;
LGG	cis	rs11264213	0.892	rs6661867	chr1:36195809	C/A	cg27506609	chr1:36549197	TEKT2	0.7	7.88	0.34	2.3e-14	Schizophrenia;
LGG	cis	rs13314892	0.764	rs62251033	chr3:69865352	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs72781680	0.821	rs11894756	chr2:24170214	A/G	cg08917208	chr2:24149416	ATAD2B	-0.65	-8.69	-0.37	6.24e-17	Lymphocyte counts;
LGG	cis	rs832540	0.656	rs702689	chr5:56177443	G/A	cg12654349	chr5:56205094	C5orf35	-0.39	-6.89	-0.3	1.85e-11	Coronary artery disease;
LGG	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg17050807	chr22:42548356	NA	-0.38	-7.28	-0.32	1.42e-12	Schizophrenia;
LGG	cis	rs17401966	0.838	rs4846206	chr1:10310258	G/C	cg15208524	chr1:10270712	KIF1B	0.45	8.04	0.35	7.48e-15	Hepatocellular carcinoma;
LGG	cis	rs2288073	0.965	rs10469924	chr2:24416230	G/A	cg06627628	chr2:24431161	ITSN2	-0.66	-10.65	-0.44	7.94e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs11023332	0.832	rs10832289	chr11:14669496	A/T	cg19336497	chr11:14380999	RRAS2	0.37	7.28	0.32	1.48e-12	Adiponectin levels;Vitamin D levels;
LGG	cis	rs2597513	0.860	rs2655227	chr3:13558561	T/C	cg24006715	chr3:13568212	NA	0.64	10.58	0.44	1.42e-23	Hip circumference adjusted for BMI;Height;
LGG	trans	rs73198271	0.632	rs477018	chr8:8600817	T/A	cg16141378	chr3:129829833	LOC729375	0.36	7.0	0.31	9.19e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs5756391	0.568	rs10222232	chr22:37317970	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	9.66	0.41	3.17e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9894429	0.752	rs6565610	chr17:79592652	A/G	cg10661904	chr17:79619235	PDE6G	-0.4	-8.14	-0.35	3.63e-15	Eye color traits;
LGG	cis	rs1451375	1.000	rs2329340	chr7:50620229	C/T	cg00647317	chr7:50633725	DDC	-0.35	-7.66	-0.34	1.09e-13	Malaria;
LGG	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	cis	rs12580194	0.593	rs7976828	chr12:55726450	A/T	cg19537932	chr12:55886519	OR6C68	-0.56	-9.89	-0.42	4.75e-21	Cancer;
LGG	cis	rs6840360	0.870	rs1372978	chr4:152456180	A/G	cg25486957	chr4:152246857	NA	-0.4	-7.0	-0.31	9.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.817	rs7985394	chr13:25012852	C/G	cg02811702	chr13:24901961	NA	0.4	7.68	0.34	9.81e-14	Obesity-related traits;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-13.27	-0.52	2.82e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	0.872	rs9480922	chr6:109607211	G/A	cg12927641	chr6:109611667	NA	-0.37	-7.17	-0.32	3.03e-12	Reticulocyte fraction of red cells;
LGG	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg15979348	chr13:112237479	NA	0.41	6.96	0.31	1.2e-11	Menarche (age at onset);
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg24503407	chr1:205819492	PM20D1	0.82	19.92	0.68	3.09e-64	Menarche (age at onset);
LGG	cis	rs16866061	0.517	rs7594223	chr2:225472985	T/C	cg12698349	chr2:225449008	CUL3	0.53	8.99	0.39	6.16e-18	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg13010199	chr12:38710504	ALG10B	0.48	9.32	0.4	4.91e-19	Morning vs. evening chronotype;
LGG	cis	rs9902453	1.000	rs4350617	chr17:28423088	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.13	0.52	1.09e-33	Coffee consumption (cups per day);
LGG	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg20673091	chr1:2541236	MMEL1	0.77	18.0	0.64	2.58e-55	Multiple sclerosis;
LGG	cis	rs17767392	0.748	rs55896578	chr14:71712185	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.39	-0.32	6.95e-13	Mitral valve prolapse;
LGG	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg06573787	chr8:143070187	NA	0.49	8.57	0.37	1.53e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.18	0.32	2.75e-12	Menopause (age at onset);
LGG	cis	rs11098499	0.863	rs58452170	chr4:120459674	A/T	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.18e-25	Corneal astigmatism;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg08989290	chr16:615782	NHLRC4	0.32	6.66	0.3	7.71e-11	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20560182	chr5:140700478	TAF7	-0.41	-6.77	-0.3	3.94e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg10596483	chr8:143751796	JRK	0.48	7.52	0.33	2.79e-13	Schizophrenia;
LGG	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21659725	chr3:3221576	CRBN	0.66	12.4	0.5	1.06e-30	Intelligence (multi-trait analysis);
LGG	cis	rs981844	1.000	rs2606332	chr4:154655372	G/A	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.22e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs3733585	0.699	rs6449179	chr4:9969117	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.81	-0.34	3.81e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10463316	0.747	rs10077700	chr5:150768324	A/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.11	-0.43	7.32e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs66887589	0.870	rs59590064	chr4:120539753	T/C	cg09307838	chr4:120376055	NA	-0.48	-8.36	-0.36	7.53e-16	Diastolic blood pressure;
LGG	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.47	8.26	0.36	1.53e-15	Glycated hemoglobin levels;
LGG	cis	rs3785574	0.927	rs2854160	chr17:61977248	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.51	0.33	3.11e-13	Height;
LGG	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg03576123	chr11:487126	PTDSS2	-0.49	-6.71	-0.3	5.63e-11	Systemic lupus erythematosus;
LGG	cis	rs79976124	0.837	rs11751145	chr6:66642039	T/C	cg07460842	chr6:66804631	NA	0.72	12.48	0.5	5.11e-31	Type 2 diabetes;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08645402	chr16:4508243	NA	0.51	9.79	0.41	1.09e-20	Schizophrenia;
LGG	cis	rs6456042	0.893	rs1134482	chr6:166571157	G/A	cg11088901	chr6:166572345	T	-0.38	-8.0	-0.35	1.02e-14	Asthma;
LGG	cis	rs4595586	0.545	rs12809435	chr12:39404341	C/T	cg13010199	chr12:38710504	ALG10B	-0.42	-7.57	-0.33	2.07e-13	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.67	-0.44	6.5e-24	Lung cancer;
LGG	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs9849248	0.627	rs13074910	chr3:88193835	T/C	cg14530983	chr3:88190749	ZNF654	-0.58	-7.91	-0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg11494091	chr17:61959527	GH2	0.61	10.1	0.42	8.53e-22	Height;
LGG	cis	rs7635838	0.654	rs347585	chr3:11286220	C/T	cg00170343	chr3:11313890	ATG7	0.5	7.88	0.34	2.42e-14	HDL cholesterol;
LGG	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg04731861	chr2:219085781	ARPC2	0.46	11.31	0.47	2.33e-26	Colorectal cancer;
LGG	cis	rs861020	0.582	rs630065	chr1:209998662	C/T	cg05527609	chr1:210001259	C1orf107	0.6	9.7	0.41	2.26e-20	Orofacial clefts;
LGG	trans	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.9	0.34	2.01e-14	Retinal vascular caliber;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.82	-0.34	3.73e-14	Life satisfaction;
LGG	cis	rs12210905	0.858	rs858988	chr6:27179195	G/A	cg23155468	chr6:27110703	HIST1H2BK	0.53	6.7	0.3	6.07e-11	Hip circumference adjusted for BMI;
LGG	trans	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg11693508	chr17:37793320	STARD3	0.75	10.51	0.44	2.5e-23	Bipolar disorder;
LGG	trans	rs853679	0.585	rs201004	chr6:27804934	T/C	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.41	-0.33	6.21e-13	Depression;
LGG	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg22232500	chr2:134024266	NCKAP5	0.55	7.96	0.35	1.39e-14	Bipolar disorder;
LGG	cis	rs3749237	0.595	rs7643845	chr3:49530711	A/G	cg02487422	chr3:49467188	NICN1	0.58	10.75	0.45	3.16e-24	Resting heart rate;
LGG	cis	rs17807624	0.780	rs13277929	chr8:11453030	G/A	cg00405596	chr8:11794950	NA	0.43	6.83	0.3	2.72e-11	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg08297393	chr2:100937505	LONRF2	-0.44	-7.1	-0.31	4.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.512	rs139562	chr22:42196684	G/C	cg17376030	chr22:41985996	PMM1	0.67	10.84	0.45	1.43e-24	Vitiligo;
LGG	cis	rs854765	0.647	rs7406744	chr17:17981938	C/G	cg04398451	chr17:18023971	MYO15A	-0.79	-17.3	-0.63	4.18e-52	Total body bone mineral density;
LGG	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg16400903	chr5:693638	TPPP	0.44	6.78	0.3	3.72e-11	Obesity-related traits;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.53	8.97	0.38	7.64e-18	Obesity-related traits;
LGG	cis	rs12950390	0.853	rs10445375	chr17:45864314	C/T	cg06532163	chr17:45867833	NA	-0.55	-9.18	-0.39	1.46e-18	IgG glycosylation;
LGG	cis	rs10504229	0.516	rs4060631	chr8:57990757	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-7.44	-0.33	5.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg12623918	chr2:306882	NA	0.51	9.68	0.41	2.62e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs858239	0.600	rs7789237	chr7:23124713	T/G	cg23682824	chr7:23144976	KLHL7	0.43	7.54	0.33	2.52e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1670533	1.000	rs13135215	chr4:1054364	A/G	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg20913747	chr6:44695427	NA	-0.63	-10.54	-0.44	2e-23	Total body bone mineral density;
LGG	cis	rs10991814	1.000	rs60953089	chr9:93948053	A/G	cg14446406	chr9:93919335	NA	-0.78	-8.93	-0.38	9.89e-18	Neutrophil percentage of granulocytes;
LGG	cis	rs751728	0.664	rs9394167	chr6:33754396	A/G	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs62158211	1.000	rs1807282	chr2:114110036	A/T	cg17784749	chr2:114082611	LOC440839	0.62	8.73	0.38	4.69e-17	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs6747952	0.899	rs4663856	chr2:239089624	C/A	cg17459225	chr2:239074497	NA	0.44	7.96	0.35	1.3e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg13147721	chr7:65941812	NA	-0.44	-6.76	-0.3	4.05e-11	Corneal structure;
LGG	cis	rs283228	0.535	rs2852504	chr6:101842891	G/A	cg27451362	chr6:101846650	GRIK2	0.98	15.39	0.58	1.76e-43	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg26338869	chr17:61819248	STRADA	0.59	9.93	0.42	3.34e-21	Prudent dietary pattern;
LGG	cis	rs367615	0.959	rs4957830	chr5:108911758	G/T	cg17395555	chr5:108820864	NA	0.62	8.76	0.38	3.67e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs644799	0.664	rs603625	chr11:95554283	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.65	0.3	8.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg03959625	chr15:84868606	LOC388152	0.56	8.65	0.37	8.47e-17	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.56	-0.41	7.03e-20	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg01620082	chr3:125678407	NA	-0.67	-7.12	-0.31	4.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	9.34	0.4	4.17e-19	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg20336341	chr7:50628841	DDC	-0.43	-7.37	-0.32	7.98e-13	Malaria;
LGG	cis	rs11864453	0.928	rs3213420	chr16:72042433	C/T	cg01557791	chr16:72042693	DHODH	-0.6	-11.19	-0.46	6.85e-26	Fibrinogen levels;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.37	-0.36	6.65e-16	Personality dimensions;
LGG	cis	rs12367572	1.000	rs7304472	chr12:45262324	A/G	cg03114573	chr12:45410052	DBX2	-0.52	-9.03	-0.39	4.76e-18	Gut microbiome composition (summer);
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg24846343	chr22:24311635	DDTL	0.58	11.05	0.46	2.4e-25	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs981844	1.000	rs56331473	chr4:154668052	C/A	cg14289246	chr4:154710475	SFRP2	0.69	11.51	0.47	4.02e-27	Response to statins (LDL cholesterol change);
LGG	trans	rs6076960	0.598	rs3905168	chr20:6226752	C/T	cg17788362	chr6:86352627	SYNCRIP	0.51	8.69	0.37	6.28e-17	Smooth-surface caries;
LGG	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs4006360	0.601	rs7501863	chr17:39249898	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.5	-10.88	-0.45	1.06e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs1020064	0.895	rs2250659	chr2:105889684	A/G	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.4	0.44	6.4e-23	AIDS;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7695597	0.539	rs1217956	chr4:185165472	G/A	cg12654155	chr4:185238627	NA	0.42	7.66	0.34	1.08e-13	Night sleep phenotypes;
LGG	cis	rs2274273	0.773	rs28430823	chr14:55816560	C/G	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	4.92e-51	Protein biomarker;
LGG	trans	rs11098499	0.779	rs10857066	chr4:120286596	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.07	0.46	1.99e-25	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	cis	rs9393692	0.620	rs9393696	chr6:26291591	T/C	cg00631329	chr6:26305371	NA	-0.45	-7.61	-0.33	1.56e-13	Educational attainment;
LGG	cis	rs3096299	0.967	rs2965937	chr16:89488779	A/T	cg06640241	chr16:89574553	SPG7	0.71	12.19	0.49	8.08e-30	Multiple myeloma (IgH translocation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13157315	chr19:48774652	ZNF114	0.49	7.53	0.33	2.7e-13	Gut microbiome composition (summer);
LGG	cis	rs920590	0.758	rs1817836	chr8:19664852	T/C	cg01411142	chr8:19674711	INTS10	0.47	7.35	0.32	9.33e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7447593	0.666	rs10866705	chr5:176801131	G/T	cg05207973	chr5:176823642	SLC34A1	-0.39	-7.55	-0.33	2.31e-13	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs11700980	0.636	rs118001912	chr21:30210959	C/A	cg08807101	chr21:30365312	RNF160	-0.62	-6.76	-0.3	4.21e-11	QRS complex (12-leadsum);
LGG	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg08875078	chr22:50639485	SELO	0.46	6.88	0.3	1.99e-11	Late-onset Alzheimer's disease;
LGG	cis	rs911119	1.000	rs1064039	chr20:23618427	C/T	cg16589663	chr20:23618590	CST3	0.48	6.75	0.3	4.41e-11	Chronic kidney disease;
LGG	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-12.07	-0.49	2.46e-29	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-10.38	-0.43	8.09e-23	Personality dimensions;
LGG	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg04117972	chr1:227635322	NA	0.84	12.14	0.49	1.22e-29	Major depressive disorder;
LGG	cis	rs60180747	0.909	rs76549445	chr15:66826898	T/C	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.17	0.43	4.64e-22	Testicular germ cell tumor;
LGG	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg05585630	chr7:157510462	PTPRN2	-0.46	-8.51	-0.37	2.36e-16	Intelligence (multi-trait analysis);
LGG	cis	rs67460515	0.563	rs73023235	chr3:160864123	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-8.42	-0.36	4.89e-16	Parkinson's disease;
LGG	cis	rs7444	0.941	rs181363	chr22:21932264	A/G	cg05046821	chr22:21984468	YDJC	-0.37	-7.03	-0.31	7.31e-12	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05665937	chr4:1216051	CTBP1	0.55	10.27	0.43	1.95e-22	Obesity-related traits;
LGG	cis	rs11711311	1.000	rs3806641	chr3:113465761	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.66	-0.34	1.07e-13	IgG glycosylation;
LGG	cis	rs1801251	1.000	rs283469	chr2:233656997	G/T	cg25237894	chr2:233734115	C2orf82	0.65	12.05	0.49	2.95e-29	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg19077165	chr18:44547161	KATNAL2	0.69	13.26	0.52	3.15e-34	Personality dimensions;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg03517284	chr6:25882590	NA	-0.72	-13.8	-0.54	1.53e-36	Intelligence (multi-trait analysis);
LGG	trans	rs8002861	0.641	rs2028813	chr13:44422126	G/T	cg12856521	chr11:46389249	DGKZ	0.54	9.72	0.41	1.87e-20	Leprosy;
LGG	cis	rs919433	0.889	rs6711624	chr2:198207607	C/G	cg00792783	chr2:198669748	PLCL1	-0.45	-6.97	-0.31	1.09e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9611565	0.649	rs5758442	chr22:42133060	T/C	cg06634786	chr22:41940651	POLR3H	0.66	10.76	0.45	3.03e-24	Vitiligo;
LGG	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-9.02	-0.39	4.91e-18	Chronic sinus infection;
LGG	cis	rs801193	0.660	rs4610622	chr7:66224497	T/C	cg12463550	chr7:65579703	CRCP	0.49	8.29	0.36	1.27e-15	Aortic root size;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg07414643	chr4:187882934	NA	0.57	11.84	0.48	1.97e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2134046	0.555	rs11854483	chr15:82559558	T/C	cg00614314	chr15:82944287	LOC80154	0.41	6.7	0.3	5.88e-11	Cognitive ability;
LGG	cis	rs787274	0.557	rs4979183	chr9:115667355	G/A	cg13803584	chr9:115635662	SNX30	-0.68	-7.47	-0.33	4.14e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg14926445	chr8:58193284	C8orf71	-0.69	-9.17	-0.39	1.55e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10779751	0.686	rs2791656	chr1:11128329	A/G	cg08854313	chr1:11322531	MTOR	0.73	14.97	0.57	1.31e-41	Body mass index;
LGG	cis	rs6692729	0.933	rs1295641	chr1:227070695	C/T	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs28475163	0.958	rs7395116	chr11:324880	C/G	cg03071500	chr11:325964	NA	0.41	7.08	0.31	5.55e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9911578	0.935	rs6503878	chr17:56884581	T/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.85e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg02975922	chr3:195473998	MUC4	-0.45	-7.28	-0.32	1.44e-12	Pancreatic cancer;
LGG	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.42	0.44	5.73e-23	Cognitive test performance;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	15.97	0.6	4.7e-46	Obesity-related traits;
LGG	cis	rs882632	0.668	rs17744093	chr2:29294754	C/G	cg23429306	chr2:29287725	C2orf71	-0.37	-7.38	-0.32	7.37e-13	Major depressive disorder;
LGG	trans	rs3824488	0.920	rs16909902	chr9:98236202	C/T	cg23979923	chr15:90777592	C15orf58;CIB1	-0.44	-6.74	-0.3	4.7e-11	Neuroticism;
LGG	cis	rs7619833	0.620	rs9820391	chr3:27238725	G/A	cg02860705	chr3:27208620	NA	0.42	8.27	0.36	1.47e-15	Breast cancer;
LGG	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg17330251	chr7:94953956	PON1	-0.43	-8.38	-0.36	6.2e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7831492	0.564	rs6981979	chr8:41612255	C/T	cg17182837	chr8:41585554	ANK1	-0.6	-10.8	-0.45	2.12e-24	Colorectal cancer;
LGG	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg27053975	chr1:166958233	MAEL	-0.49	-7.02	-0.31	7.98e-12	Obesity-related traits;
LGG	trans	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg17712092	chr4:129076599	LARP1B	-0.67	-12.25	-0.49	4.3e-30	Eosinophil percentage of white cells;
LGG	cis	rs28595532	0.920	rs116791817	chr4:119763303	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.12	-0.39	2.27e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs9715521	0.815	rs7441547	chr4:59838120	A/G	cg11281224	chr4:60001000	NA	-0.47	-7.8	-0.34	4.25e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.11	0.35	4.62e-15	Lung cancer;
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg18225595	chr11:63971243	STIP1	0.57	7.48	0.33	3.66e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg01338084	chr22:32026380	PISD	1.49	12.14	0.49	1.22e-29	Age-related hearing impairment;
LGG	cis	rs8017423	0.866	rs10184	chr14:90744672	G/A	cg04374321	chr14:90722782	PSMC1	-0.87	-17.47	-0.63	7.2e-53	Mortality in heart failure;
LGG	cis	rs6500395	0.926	rs2883643	chr16:48693018	C/G	cg04672837	chr16:48644449	N4BP1	0.51	8.4	0.36	5.53e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.17	31.46	0.83	4.95e-117	Chronic sinus infection;
LGG	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg16141378	chr3:129829833	LOC729375	-0.39	-8.86	-0.38	1.69e-17	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08677398	chr8:58056175	NA	-0.56	-9.08	-0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg23583168	chr7:148888333	NA	-0.74	-11.94	-0.49	7.78e-29	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.02	0.39	4.89e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-9.86	-0.42	6e-21	IgG glycosylation;
LGG	cis	rs7843479	0.601	rs2306646	chr8:21846586	C/G	cg17168535	chr8:21777572	XPO7	0.81	15.68	0.59	9.47e-45	Mean corpuscular volume;
LGG	cis	rs8064029	1.000	rs1045643	chr16:4931513	C/T	cg04440724	chr16:4920505	UBN1	-0.65	-7.92	-0.35	1.81e-14	Cancer;
LGG	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg15596359	chr8:11213517	TDH	0.38	7.96	0.35	1.37e-14	Retinal vascular caliber;
LGG	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg09307838	chr4:120376055	NA	-0.74	-12.73	-0.51	5.08e-32	Corneal astigmatism;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg11814155	chr7:99998594	ZCWPW1	0.63	9.65	0.41	3.39e-20	Platelet count;
LGG	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg00908189	chr16:619842	PIGQ	0.88	16.88	0.62	3.59e-50	Height;
LGG	cis	rs7937890	0.631	rs7118886	chr11:14427517	T/C	cg02886208	chr11:14281011	SPON1	-0.42	-8.3	-0.36	1.11e-15	Mitochondrial DNA levels;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg27329371	chr17:19651940	ALDH3A1	-0.81	-19.49	-0.67	3.14e-62	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs59197085	0.636	rs62479621	chr7:128465246	C/A	cg00734629	chr7:128471146	FLNC	0.34	6.93	0.31	1.41e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00400334	chr2:85981962	ATOH8	0.5	7.53	0.33	2.71e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs9549367	0.713	rs2476328	chr13:113829350	C/T	cg18105134	chr13:113819100	PROZ	0.75	15.84	0.59	1.78e-45	Platelet distribution width;
LGG	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg03517284	chr6:25882590	NA	-0.54	-10.28	-0.43	1.84e-22	Blood metabolite levels;
LGG	cis	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs11039798	0.588	rs10838970	chr11:48606267	G/T	cg03929089	chr4:120376271	NA	0.71	9.79	0.41	1.05e-20	Axial length;
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01423820	chr14:77228690	VASH1	0.43	7.26	0.32	1.7e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs10463316	0.817	rs1508772	chr5:150816561	A/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.3	-0.43	1.51e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg14191688	chr11:70257035	CTTN	0.56	8.25	0.36	1.61e-15	Coronary artery disease;
LGG	trans	rs458649	0.947	rs457961	chr5:4277869	A/G	cg19972287	chr10:38689165	CDC10L	0.44	7.23	0.32	1.99e-12	Endometriosis;
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg14912033	chr15:79043428	NA	-0.35	-8.35	-0.36	7.92e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg05901451	chr6:126070800	HEY2	-0.82	-17.46	-0.63	8.32e-53	Brugada syndrome;
LGG	cis	rs1018836	0.608	rs7843149	chr8:91474961	C/T	cg16814680	chr8:91681699	NA	-0.59	-9.86	-0.42	5.85e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs8056064	0.690	rs67501551	chr16:82814710	G/A	cg08271366	chr16:82816457	CDH13	-0.46	-8.21	-0.36	2.16e-15	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs6500602	0.964	rs13335685	chr16:4469284	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.36	6.77	0.3	4.01e-11	Schizophrenia;
LGG	cis	rs8013055	0.846	rs35723046	chr14:105970548	C/T	cg25008857	chr14:105974488	NA	0.57	10.01	0.42	1.72e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.65e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4843747	0.671	rs4072871	chr16:88106614	C/T	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	cis	rs4917300	0.606	rs10875481	chr8:143100478	G/A	cg26003909	chr8:143102224	NA	0.34	6.75	0.3	4.54e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs28595532	0.920	rs116634064	chr4:119736514	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs709400	0.628	rs6575983	chr14:103869849	C/G	cg12935359	chr14:103987150	CKB	-0.4	-6.77	-0.3	3.97e-11	Body mass index;
LGG	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg09307838	chr4:120376055	NA	0.8	13.56	0.53	1.68e-35	Corneal astigmatism;
LGG	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg08400814	chr5:56204995	C5orf35	0.39	6.93	0.31	1.45e-11	Initial pursuit acceleration;
LGG	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.56	-10.22	-0.43	2.98e-22	Height;
LGG	trans	rs9467711	0.651	rs17586784	chr6:25935227	C/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.31	-0.32	1.17e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg17971929	chr21:40555470	PSMG1	0.88	17.65	0.63	1.08e-53	Cognitive function;
LGG	cis	rs651907	0.617	rs797776	chr3:101610243	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.52	8.6	0.37	1.25e-16	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg27661571	chr11:113659931	NA	-0.63	-6.99	-0.31	9.65e-12	Hip circumference adjusted for BMI;
LGG	cis	rs72925845	0.519	rs72907433	chr17:76425881	C/A	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg24130564	chr14:104152367	KLC1	-0.39	-6.98	-0.31	1.02e-11	Reticulocyte count;
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.34	-0.32	9.7e-13	Bipolar disorder;
LGG	cis	rs174601	0.721	rs174530	chr11:61546592	A/G	cg19610905	chr11:61596333	FADS2	-0.76	-13.85	-0.54	9.52e-37	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs9487094	0.813	rs34320275	chr6:109757963	A/G	cg01125227	chr6:109776195	MICAL1	0.54	8.95	0.38	8.61e-18	Height;
LGG	cis	rs4242434	0.819	rs6558167	chr8:22473850	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.17	-0.36	2.94e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs1493916	0.905	rs34910379	chr18:31400047	A/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.33	-0.53	1.47e-34	Life satisfaction;
LGG	cis	rs11690935	1.000	rs6721680	chr2:172543913	G/T	cg13550731	chr2:172543902	DYNC1I2	1.06	27.22	0.78	3.97e-98	Schizophrenia;
LGG	cis	rs12612619	0.505	rs1368889	chr2:27093844	A/C	cg12045002	chr2:27069975	DPYSL5	-0.33	-7.11	-0.31	4.37e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs6840360	0.642	rs2034061	chr4:152420756	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	8.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12586317	0.547	rs2038254	chr14:35462134	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.65	0.54	6.54e-36	Psoriasis;
LGG	cis	rs4740619	0.967	rs4339736	chr9:15689563	G/A	cg14451791	chr9:16040625	NA	-0.38	-9.86	-0.42	6.15e-21	Body mass index;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg14926445	chr8:58193284	C8orf71	-0.66	-8.25	-0.36	1.61e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.586	rs7639366	chr3:143752034	T/G	cg06585982	chr3:143692056	C3orf58	0.68	12.34	0.5	1.84e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs6694672	1.000	rs857017	chr1:197019055	T/C	cg13682187	chr1:196946512	CFHR5	0.51	7.06	0.31	6.02e-12	Asthma;
LGG	cis	rs910316	0.763	rs175014	chr14:75456927	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-9.74	-0.41	1.67e-20	Height;
LGG	cis	rs367615	0.918	rs10054960	chr5:108866448	C/A	cg17395555	chr5:108820864	NA	0.66	9.28	0.4	6.35e-19	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs78049276	0.736	rs6841473	chr4:148407652	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.57	-7.71	-0.34	7.76e-14	Pulse pressure;
LGG	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg20503657	chr10:835505	NA	0.95	13.02	0.52	3.16e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs8141529	0.673	rs132548	chr22:29317559	C/G	cg15103426	chr22:29168792	CCDC117	-0.61	-9.42	-0.4	2.21e-19	Lymphocyte counts;
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg20102877	chr2:27665638	KRTCAP3	-0.3	-6.85	-0.3	2.36e-11	Total body bone mineral density;
LGG	cis	rs6964587	1.000	rs10235941	chr7:91587050	T/G	cg17063962	chr7:91808500	NA	0.48	8.54	0.37	1.93e-16	Breast cancer;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	8.86	0.38	1.68e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs295140	1.000	rs7578220	chr2:201183701	A/G	cg25099087	chr2:201172481	SPATS2L	0.27	6.79	0.3	3.37e-11	QT interval;
LGG	cis	rs2880765	0.835	rs4842886	chr15:86035773	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.1	-0.35	4.8e-15	Coronary artery disease;
LGG	cis	rs2836950	0.545	rs2836959	chr21:40623668	T/G	cg17971929	chr21:40555470	PSMG1	-0.54	-9.23	-0.39	9.9e-19	Menarche (age at onset);
LGG	cis	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg26384229	chr12:38710491	ALG10B	0.93	21.26	0.7	1.72e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg23782820	chr8:58130467	NA	-0.54	-7.66	-0.34	1.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08645402	chr16:4508243	NA	-0.47	-8.44	-0.37	4.01e-16	Schizophrenia;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.78	0.45	2.52e-24	Longevity;
LGG	cis	rs225245	0.791	rs8067294	chr17:34027964	T/C	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21619639	chr4:155471134	PLRG1	0.47	7.31	0.32	1.22e-12	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg18099408	chr3:52552593	STAB1	-0.37	-7.19	-0.32	2.71e-12	Bipolar disorder;
LGG	cis	rs137603	0.602	rs9611146	chr22:39718120	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.71	-13.91	-0.54	5.22e-37	Primary biliary cholangitis;
LGG	cis	rs11098499	0.909	rs73842633	chr4:120375464	G/A	cg24375607	chr4:120327624	NA	0.67	10.29	0.43	1.72e-22	Corneal astigmatism;
LGG	cis	rs950776	0.616	rs12901300	chr15:78892952	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.78	0.3	3.74e-11	Sudden cardiac arrest;
LGG	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg24006582	chr15:45444508	DUOX1	0.66	12.23	0.49	5.47e-30	Uric acid levels;
LGG	cis	rs3785574	0.962	rs2665842	chr17:61878535	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	28.06	0.79	6.13e-102	Height;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.61	-0.33	1.5700000000000001e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2795502	0.873	rs1891324	chr10:43399581	A/G	cg20628663	chr10:43360327	NA	0.37	7.36	0.32	8.62e-13	Blood protein levels;
LGG	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg05535760	chr7:792225	HEATR2	-0.82	-10.81	-0.45	1.98e-24	Cerebrospinal P-tau181p levels;
LGG	cis	rs62064224	0.560	rs12162135	chr17:30805795	A/C	cg25809561	chr17:30822961	MYO1D	0.32	7.77	0.34	5.02e-14	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg17595323	chr11:93583763	C11orf90	-0.45	-8.05	-0.35	6.84e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03517284	chr6:25882590	NA	-0.72	-13.99	-0.55	2.35e-37	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs67283107	chr11:70221204	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	2.05e-14	Coronary artery disease;
LGG	trans	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg18187862	chr3:45730750	SACM1L	-0.67	-10.48	-0.44	3.23e-23	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.29	0.36	1.27e-15	Lung cancer;
LGG	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg02269571	chr22:50332266	NA	-0.63	-10.08	-0.42	1e-21	Schizophrenia;
LGG	trans	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg00938859	chr5:1591904	SDHAP3	0.78	6.97	0.31	1.08e-11	Asthma (childhood onset);
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.4	-6.78	-0.3	3.58e-11	Schizophrenia;
LGG	cis	rs67460515	0.892	rs73026976	chr3:160964271	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.39e-20	Parkinson's disease;
LGG	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.34	0.63	2.85e-52	Sudden cardiac arrest;
LGG	cis	rs4740619	0.689	rs1590750	chr9:15953422	G/C	cg14451791	chr9:16040625	NA	-0.4	-9.92	-0.42	3.73e-21	Body mass index;
LGG	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.76	-0.41	1.32e-20	Primary sclerosing cholangitis;
LGG	cis	rs8180040	1.000	rs11130127	chr3:47398793	C/G	cg27129171	chr3:47204927	SETD2	-0.81	-15.71	-0.59	7.05e-45	Colorectal cancer;
LGG	cis	rs7582180	0.903	rs6755791	chr2:100895872	G/A	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg26513180	chr16:89883248	FANCA	0.7	7.77	0.34	5.23e-14	Skin colour saturation;
LGG	cis	rs7246865	0.603	rs10423719	chr19:17211568	T/C	cg19418318	chr19:17219073	MYO9B	0.26	7.43	0.33	5.22e-13	Reticulocyte fraction of red cells;
LGG	cis	rs7551222	0.752	rs11240756	chr1:204482594	C/T	cg20240347	chr1:204465584	NA	-0.57	-11.37	-0.47	1.32e-26	Schizophrenia;
LGG	cis	rs17453880	0.963	rs11956179	chr5:151947064	T/G	cg10931792	chr5:152022470	NA	0.37	7.84	0.34	3.2e-14	Subjective well-being;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs1372520	0.577	rs2737028	chr4:90717016	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.2	-0.36	2.4e-15	Neuroticism;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.22e-26	Personality dimensions;
LGG	cis	rs61192259	1.000	rs9470888	chr6:38453037	A/G	cg07362130	chr6:38359646	BTBD9	0.29	6.88	0.3	1.92e-11	Restless legs syndrome;
LGG	cis	rs858239	0.601	rs12539331	chr7:23151330	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.33	0.32	1.06e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg09085632	chr11:111637200	PPP2R1B	-0.98	-19.09	-0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs35306767	0.903	rs35637113	chr10:874149	G/C	cg08847335	chr10:891726	LARP4B	-0.49	-8.89	-0.38	1.41e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03517284	chr6:25882590	NA	-0.38	-6.83	-0.3	2.68e-11	Height;
LGG	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg19676328	chr12:49525230	TUBA1B	-0.63	-10.14	-0.43	5.74e-22	Total cholesterol levels;
LGG	cis	rs4919044	0.808	rs9419765	chr10:94798171	C/T	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs977987	0.902	rs4888430	chr16:75494424	T/C	cg03315344	chr16:75512273	CHST6	0.58	11.55	0.47	2.75e-27	Dupuytren's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12649615	chr1:150602426	ENSA	0.42	6.82	0.3	2.81e-11	Cognitive performance;
LGG	cis	rs362296	0.698	rs3095080	chr4:3264418	C/T	cg06533319	chr4:3265114	C4orf44	0.51	10.02	0.42	1.67e-21	Parental longevity (mother's age at death);
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.72	0.54	3.33e-36	Lung cancer;
LGG	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.53	-0.33	2.66e-13	Joint mobility (Beighton score);
LGG	cis	rs2070488	0.560	rs1381798	chr3:38437471	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-10.3	-0.43	1.5e-22	Electrocardiographic conduction measures;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg27189623	chr16:705930	WDR90	0.41	7.92	0.35	1.8e-14	Height;
LGG	cis	rs13202913	0.837	rs9383901	chr6:151788059	T/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.63	7.33	0.32	1.04e-12	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg14428628	chr17:77806922	NA	0.35	7.18	0.32	2.88e-12	Electrocardiographic conduction measures;
LGG	cis	rs765787	0.530	rs2413776	chr15:45544170	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.35	-0.32	8.82e-13	Uric acid levels;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-7.99	-0.35	1.06e-14	Lung cancer;
LGG	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg05234568	chr11:5960015	NA	-0.75	-12.09	-0.49	1.88e-29	DNA methylation (variation);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg16507663	chr6:150244633	RAET1G	0.43	8.1	0.35	4.88e-15	Lung cancer;
LGG	cis	rs2841277	0.802	rs2841269	chr14:105386149	C/G	cg14403583	chr14:105418241	AHNAK2	-0.76	-14.93	-0.57	2.02e-41	Rheumatoid arthritis;
LGG	cis	rs6466055	0.637	rs1144	chr7:104756355	T/C	cg04380332	chr7:105027541	SRPK2	-0.39	-7.29	-0.32	1.32e-12	Schizophrenia;
LGG	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg04851639	chr8:1020857	NA	-0.44	-9.04	-0.39	4.39e-18	Schizophrenia;
LGG	trans	rs3780486	0.846	rs10813954	chr9:33137596	A/C	cg20290983	chr6:43655470	MRPS18A	1.12	24.95	0.76	1.02e-87	IgG glycosylation;
LGG	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg08847533	chr14:75593920	NEK9	0.63	12.02	0.49	3.62e-29	Height;
LGG	cis	rs4704187	0.663	rs12523187	chr5:74379625	A/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	5.95e-11	Response to amphetamines;
LGG	cis	rs868036	0.957	rs9920662	chr15:68104297	G/A	cg08079166	chr15:68083412	MAP2K5	0.35	7.87	0.34	2.47e-14	Restless legs syndrome;
LGG	cis	rs9549367	0.577	rs3024713	chr13:113813321	G/A	cg18105134	chr13:113819100	PROZ	-0.78	-13.96	-0.54	3.4e-37	Platelet distribution width;
LGG	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	7.56	0.33	2.16e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg00579200	chr11:133705235	NA	-0.55	-10.22	-0.43	3.12e-22	Childhood ear infection;
LGG	cis	rs1420338	0.837	rs17753041	chr7:34176925	G/A	cg01275685	chr7:34179230	BMPER	-0.52	-9.66	-0.41	3.15e-20	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg21775007	chr8:11205619	TDH	-0.46	-7.31	-0.32	1.21e-12	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg08499158	chr17:42289980	UBTF	0.6	11.43	0.47	8.28e-27	Total body bone mineral density;
LGG	cis	rs2562456	0.834	rs2173727	chr19:21673957	C/T	cg00806126	chr19:22604979	ZNF98	0.62	9.28	0.4	6.37e-19	Pain;
LGG	cis	rs7089973	0.604	rs11196929	chr10:116582080	G/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs61931739	0.583	rs1873011	chr12:33752808	T/C	cg26384229	chr12:38710491	ALG10B	0.47	8.47	0.37	3.39e-16	Morning vs. evening chronotype;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11653500	chr13:80915061	SPRY2	0.37	6.65	0.3	8.12e-11	Obesity-related traits;
LGG	cis	rs2251381	0.808	rs7364112	chr21:30548968	C/A	cg24692254	chr21:30365293	RNF160	0.82	16.73	0.61	1.79e-49	Selective IgA deficiency;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.52	0.4	9.47e-20	Life satisfaction;
LGG	trans	rs1814175	0.817	rs12287396	chr11:49819798	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.27	-0.5	3.81e-30	Height;
LGG	cis	rs8064029	1.000	rs17771215	chr16:4916876	T/G	cg04440724	chr16:4920505	UBN1	-0.65	-7.84	-0.34	3.07e-14	Cancer;
LGG	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg27446573	chr6:127587934	RNF146	-0.78	-14.5	-0.56	1.57e-39	Breast cancer;
LGG	cis	rs7577696	0.597	rs34197800	chr2:32389646	C/A	cg02381751	chr2:32503542	YIPF4	-0.46	-6.69	-0.3	6.64e-11	Inflammatory biomarkers;
LGG	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg16339924	chr4:17578868	LAP3	0.59	10.15	0.43	5.66e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6426558	0.502	rs1929858	chr1:227220175	C/A	cg10327440	chr1:227177885	CDC42BPA	0.64	10.67	0.44	6.6e-24	Neutrophil percentage of white cells;
LGG	cis	rs8072100	0.745	rs7214410	chr17:45422628	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.85	-0.38	1.85e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs2072153	0.715	rs12948327	chr17:47333478	C/T	cg11430096	chr6:110968061	CDK19	0.5	8.55	0.37	1.86e-16	Height;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg11608241	chr8:8085544	FLJ10661	0.31	7.18	0.32	2.77e-12	Morning vs. evening chronotype;
LGG	cis	rs2120243	0.572	rs6441129	chr3:157125828	A/G	cg24825693	chr3:157122686	VEPH1	0.59	13.59	0.53	1.25e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08483876	chr8:145910754	NA	0.4	6.76	0.3	4.13e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	6.99	0.31	9.56e-12	Multiple sclerosis;
LGG	cis	rs3820928	1.000	rs1346618	chr2:227771988	C/T	cg11843606	chr2:227700838	RHBDD1	0.43	7.3	0.32	1.23e-12	Pulmonary function;
LGG	cis	rs7103648	0.897	rs2278890	chr11:47399602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	20.5	0.69	6.54e-67	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs3749237	0.964	rs7431078	chr3:49808190	G/A	cg02487422	chr3:49467188	NICN1	0.43	7.0	0.31	9.06e-12	Resting heart rate;
LGG	cis	rs9611565	0.608	rs2003816	chr22:42095140	T/G	cg06634786	chr22:41940651	POLR3H	0.67	10.69	0.44	5.39e-24	Vitiligo;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.39	-7.46	-0.33	4.22e-13	Obesity;
LGG	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg12310025	chr6:25882481	NA	0.71	13.96	0.54	3.13e-37	Blood metabolite levels;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.91	-0.51	8.39e-33	Alzheimer's disease;
LGG	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27026585	chr18:14747080	ANKRD30B	0.42	6.74	0.3	4.85e-11	Pancreatic cancer;
LGG	cis	rs7766436	0.885	rs4712699	chr6:22592884	C/A	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs4466137	0.953	rs7735476	chr5:83015140	G/C	cg16102102	chr5:83017553	HAPLN1	-0.59	-10.84	-0.45	1.52e-24	Prostate cancer;
LGG	cis	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05901451	chr6:126070800	HEY2	0.59	10.76	0.45	3.06e-24	Endometrial cancer;
LGG	cis	rs11630290	1.000	rs11630290	chr15:63915786	C/T	cg12036633	chr15:63758958	NA	-0.62	-8.42	-0.36	4.93e-16	Iris characteristics;
LGG	cis	rs470119	1.000	rs470119	chr22:50966914	C/T	cg12969734	chr22:50962224	SCO2	-0.68	-12.86	-0.51	1.37e-32	Mean corpuscular hemoglobin;
LGG	cis	rs909674	0.541	rs5750812	chr22:39793079	G/A	cg04986931	chr22:39850128	NA	0.32	7.53	0.33	2.72e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs36071027	0.554	rs9918118	chr5:158394846	C/T	cg23468002	chr5:158532401	NA	0.41	6.91	0.31	1.62e-11	Carotid intima media thickness;
LGG	cis	rs10744422	0.528	rs6489245	chr12:123360151	G/A	cg25930673	chr12:123319894	HIP1R	-0.72	-9.14	-0.39	2.04e-18	Schizophrenia;
LGG	cis	rs7000551	0.715	rs1600877	chr8:22378118	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	12.58	0.5	1.93e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6601327	0.965	rs7016732	chr8:9397227	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.45	0.37	3.69e-16	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg15485101	chr11:133734466	NA	0.59	10.49	0.44	3.05e-23	Childhood ear infection;
LGG	cis	rs10231759	0.761	rs6955948	chr7:150508720	C/T	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.31	8.08	0.35	5.49e-15	Height;
LGG	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg13852791	chr20:30311386	BCL2L1	0.78	12.71	0.51	6.04e-32	Mean corpuscular hemoglobin;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg19803976	chr18:11850907	CHMP1B;GNAL	0.41	7.23	0.32	1.95e-12	Menarche (age at onset);
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg02353165	chr6:42928485	GNMT	0.47	14.22	0.55	2.4e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4917300	1.000	rs4917300	chr8:143121671	T/C	cg06573787	chr8:143070187	NA	0.52	9.5	0.4	1.11e-19	Amyotrophic lateral sclerosis;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18976355	chr4:3680970	NA	0.39	7.6	0.33	1.62e-13	Electrocardiographic conduction measures;
LGG	cis	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6988985	0.765	rs4736317	chr8:143982753	A/G	cg10324643	chr8:143916377	GML	0.4	7.89	0.34	2.24e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg24634471	chr8:143751801	JRK	0.5	7.61	0.33	1.51e-13	Schizophrenia;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.89	-0.3	1.84e-11	Total body bone mineral density;
LGG	cis	rs6840360	0.571	rs875667	chr4:152525477	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg15971980	chr6:150254442	NA	0.46	9.14	0.39	1.9e-18	Testicular germ cell tumor;
LGG	cis	rs6840360	0.554	rs13108359	chr4:152727852	T/C	cg22705602	chr4:152727874	NA	0.4	9.88	0.42	5.14e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	1.000	rs4902365	chr14:65602064	T/C	cg11161011	chr14:65562177	MAX	-0.63	-11.7	-0.48	7.3e-28	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09720833	chr4:124427045	NA	0.47	7.24	0.32	1.91e-12	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.721	rs4843093	chr15:86237433	G/A	cg04173714	chr15:86211321	AKAP13	0.47	8.03	0.35	8.38e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9291683	0.588	rs3756237	chr4:10013378	G/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.04e-11	Bone mineral density;
LGG	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg02461776	chr11:598696	PHRF1	0.53	8.24	0.36	1.83e-15	Systemic lupus erythematosus;
LGG	cis	rs62244186	0.541	rs62244226	chr3:44831831	G/A	cg02073558	chr3:44770973	ZNF501	0.86	18.74	0.66	1.04e-58	Depressive symptoms;
LGG	cis	rs950169	0.881	rs4081123	chr15:84956235	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs2115630	0.691	rs8040066	chr15:85176465	G/C	cg12501888	chr15:85177176	SCAND2	-0.55	-9.1	-0.39	2.66e-18	P wave terminal force;
LGG	trans	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.27	-0.4	7.02e-19	Systolic blood pressure;
LGG	cis	rs6582630	0.513	rs11181246	chr12:38302670	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.8	0.3	3.17e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.5	7.46	0.33	4.17e-13	Renal function-related traits (BUN);
LGG	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.76	0.3	4.29e-11	Sudden cardiac arrest;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg11062466	chr8:58055876	NA	0.52	9.03	0.39	4.74e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg14926445	chr8:58193284	C8orf71	-0.85	-10.52	-0.44	2.3e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2273669	0.667	rs12204576	chr6:109318843	A/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs4148087	0.860	rs9976024	chr21:43641657	A/G	cg10192877	chr21:43641690	ABCG1	0.39	7.08	0.31	5.56e-12	Eating disorder in bipolar disorder;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.88	-0.42	5.12e-21	Lung cancer;
LGG	cis	rs367943	1.000	rs348931	chr5:112812864	G/C	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	cis	rs897984	0.762	rs2054213	chr16:30971810	A/G	cg02466173	chr16:30829666	NA	0.45	8.12	0.35	4.34e-15	Dementia with Lewy bodies;
LGG	cis	rs9831754	1.000	rs112170848	chr3:78359996	G/A	cg06138941	chr3:78371609	NA	-0.97	-20.71	-0.69	6.26e-68	Calcium levels;
LGG	cis	rs7084402	0.967	rs1658436	chr10:60326910	G/A	cg09696939	chr10:60272079	BICC1	-0.36	-6.98	-0.31	1.02e-11	Refractive error;
LGG	cis	rs9357271	0.505	rs6920488	chr6:38444040	A/G	cg07362130	chr6:38359646	BTBD9	-0.35	-7.68	-0.34	9.64e-14	Restless legs syndrome;
LGG	trans	rs7937682	0.593	rs1944111	chr11:111364432	G/C	cg18187862	chr3:45730750	SACM1L	-0.45	-7.11	-0.31	4.47e-12	Primary sclerosing cholangitis;
LGG	cis	rs2404602	0.647	rs7178250	chr15:77099107	T/C	cg15268244	chr15:77196840	NA	0.47	10.12	0.43	7.23e-22	Blood metabolite levels;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.42	0.44	5.36e-23	Obesity-related traits;
LGG	cis	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg00405596	chr8:11794950	NA	0.64	11.3	0.46	2.58e-26	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12472274	1.000	rs12472274	chr2:239095422	G/A	cg17459225	chr2:239074497	NA	0.79	13.06	0.52	2.12e-33	Phospholipid levels (plasma);
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01570182	chr17:44337453	NA	0.73	12.24	0.49	4.78e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.89	-0.38	1.34e-17	Height;
LGG	cis	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.871	rs339114	chr3:161109220	C/T	cg04691961	chr3:161091175	C3orf57	0.56	12.97	0.52	4.88e-33	Morning vs. evening chronotype;
LGG	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg24838063	chr12:130822603	PIWIL1	0.7	13.17	0.52	7.52e-34	Menopause (age at onset);
LGG	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg27165867	chr14:105738592	BRF1	-0.47	-8.01	-0.35	9.09e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg26874164	chr19:58962979	ZNF324B	0.38	7.53	0.33	2.7e-13	Uric acid clearance;
LGG	cis	rs12135062	0.851	rs2651926	chr1:3101820	C/T	cg21609526	chr1:3105151	PRDM16	-0.66	-11.47	-0.47	5.57e-27	Migraine;
LGG	cis	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg04990556	chr1:26633338	UBXN11	-0.71	-14.59	-0.56	5.91e-40	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs36051895	0.622	rs10815143	chr9:5009541	G/A	cg02405213	chr9:5042618	JAK2	-0.78	-14.78	-0.57	9.19e-41	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg11062466	chr8:58055876	NA	0.6	10.03	0.42	1.52e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg21724239	chr8:58056113	NA	0.49	7.25	0.32	1.76e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13127421	chr17:48202128	SAMD14	-0.56	-11.7	-0.48	6.83e-28	Temporomandibular joint disorder;
LGG	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg17733084	chr1:78367295	NEXN	-0.32	-6.71	-0.3	5.57e-11	Testicular germ cell tumor;
LGG	cis	rs3096299	0.838	rs4785561	chr16:89429052	C/T	cg06640241	chr16:89574553	SPG7	0.61	10.64	0.44	8.62e-24	Multiple myeloma (IgH translocation);
LGG	trans	rs9467711	0.523	rs9379853	chr6:26357635	A/G	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg19761014	chr17:28927070	LRRC37B2	0.66	7.77	0.34	5.15e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12824058	0.831	rs12300308	chr12:130813825	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.74	0.34	6.34e-14	Menopause (age at onset);
LGG	cis	rs3741151	0.773	rs17310374	chr11:73274874	T/C	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs657075	0.697	rs34034297	chr5:131691176	C/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg23131131	chr22:24373011	LOC391322	-0.53	-9.1	-0.39	2.79e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.45	-0.61	3.24e-48	Skin colour saturation;
LGG	cis	rs9462027	0.651	rs7748203	chr6:34812054	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.32	-0.47	2.13e-26	Systemic lupus erythematosus;
LGG	cis	rs8016982	0.559	rs10133562	chr14:81732758	C/T	cg01989461	chr14:81687754	GTF2A1	-0.48	-7.4	-0.33	6.4e-13	Schizophrenia;
LGG	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg17971929	chr21:40555470	PSMG1	-0.66	-11.92	-0.48	9.65e-29	Cognitive function;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.24	0.84	1.06e-124	Prudent dietary pattern;
LGG	cis	rs721399	0.553	rs10109286	chr8:18243603	A/G	cg18736775	chr8:18248649	NAT2	-0.78	-12.63	-0.51	1.22e-31	Blood metabolite levels;
LGG	cis	rs7833790	0.632	rs6473308	chr8:82707708	G/A	cg17211192	chr8:82754475	SNX16	-0.72	-11.95	-0.49	6.85e-29	Diastolic blood pressure;
LGG	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg02002194	chr4:3960332	NA	0.42	7.69	0.34	8.73e-14	Triglycerides;
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs16976116	0.901	rs2899580	chr15:55491571	A/G	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.15	-0.32	3.32e-12	Lung cancer;
LGG	cis	rs2862064	0.872	rs6555776	chr5:156403505	C/A	cg12943317	chr5:156479607	HAVCR1	-0.84	-10.81	-0.45	1.92e-24	Platelet count;
LGG	trans	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.26	0.5	4.09e-30	Type 2 diabetes;
LGG	cis	rs7463659	0.845	rs35797542	chr8:135464721	T/C	cg09855544	chr8:135498122	ZFAT	-0.47	-8.69	-0.37	6.47e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs115575488	0.683	rs12727967	chr1:119595936	T/G	cg05756136	chr1:119680316	WARS2	0.41	6.75	0.3	4.32e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg21775007	chr8:11205619	TDH	-0.64	-10.31	-0.43	1.39e-22	Triglycerides;
LGG	cis	rs4144743	0.941	rs10438782	chr17:45323892	G/A	cg18085866	chr17:45331354	ITGB3	-0.77	-9.76	-0.41	1.36e-20	Body mass index;
LGG	cis	rs875971	0.862	rs1167408	chr7:65556108	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.3	0.36	1.13e-15	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14655249	chr9:86595816	HNRNPK;RMI1	0.45	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg12826209	chr6:26865740	GUSBL1	0.78	6.68	0.3	6.8e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg22852734	chr6:133119734	C6orf192	1.18	15.88	0.59	1.18e-45	Type 2 diabetes nephropathy;
LGG	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.26	0.36	1.58e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs9859260	0.744	rs492288	chr3:195784210	C/T	cg23484912	chr5:273055	PDCD6	-0.39	-7.67	-0.34	1e-13	Mean corpuscular volume;
LGG	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg21856205	chr7:94953877	PON1	-0.41	-9.81	-0.41	8.8e-21	Paraoxonase activity;
LGG	cis	rs2629751	0.512	rs2722169	chr12:104415450	C/T	cg14987745	chr12:104360022	TDG	-0.56	-7.76	-0.34	5.55e-14	Hepatitis C induced liver fibrosis;
LGG	cis	rs6964587	0.620	rs7808587	chr7:91620096	G/A	cg17063962	chr7:91808500	NA	0.49	9.2	0.39	1.26e-18	Breast cancer;
LGG	cis	rs9467773	1.000	rs6456734	chr6:26566965	G/T	cg09904177	chr6:26538194	HMGN4	0.77	17.17	0.62	1.66e-51	Intelligence (multi-trait analysis);
LGG	cis	rs7937890	0.599	rs2597204	chr11:14481017	C/T	cg02886208	chr11:14281011	SPON1	-0.43	-7.75	-0.34	5.92e-14	Mitochondrial DNA levels;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.52	-0.37	2.27e-16	Aortic root size;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg19168338	chr16:4465731	CORO7	-0.93	-18.18	-0.65	3.93e-56	Schizophrenia;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-7.17	-0.32	3.02e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg08916839	chr5:415575	AHRR	0.99	14.18	0.55	3.73e-38	Fat distribution (HIV);
LGG	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12949688	0.682	rs11871658	chr17:55839058	G/A	cg12582317	chr17:55822272	NA	0.51	11.75	0.48	4.55e-28	Schizophrenia;
LGG	trans	rs10506458	1.000	rs73128779	chr12:63441852	T/G	cg22491629	chr6:157744540	C6orf35	-0.91	-12.64	-0.51	1.13e-31	Hemostatic factors and hematological phenotypes;
LGG	cis	rs739401	0.611	rs402276	chr11:3051404	C/G	cg05729581	chr11:3078854	CARS	-0.54	-9.42	-0.4	2.2e-19	Longevity;
LGG	cis	rs28595532	0.841	rs115209862	chr4:119742225	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg18478394	chr8:109455254	TTC35	0.42	8.32	0.36	1e-15	Dupuytren's disease;
LGG	cis	rs61931739	1.000	rs12311881	chr12:34036100	A/G	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs10237118	0.915	rs6952414	chr7:140226191	C/A	cg09787580	chr7:140227335	DENND2A	0.72	8.49	0.37	2.73e-16	Optic nerve measurement (cup area);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13265914	chr8:21999630	REEP4	0.49	7.82	0.34	3.51e-14	Gut microbiome composition (summer);
LGG	cis	rs9325144	0.560	rs7971313	chr12:38653413	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-12.47	-0.5	5.52e-31	Morning vs. evening chronotype;
LGG	cis	rs4731207	0.596	rs1871771	chr7:124679051	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.74e-12	Cutaneous malignant melanoma;
LGG	cis	rs10979	1.000	rs34960207	chr6:143886398	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.49	-0.5	4.84e-31	Hypospadias;
LGG	cis	rs7483296	0.705	rs2513649	chr11:115425185	A/G	cg02820646	chr11:115398838	NA	0.39	6.81	0.3	3.03e-11	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg05987030	chr3:137834655	DZIP1L	0.38	6.78	0.3	3.78e-11	Menarche (age at onset);
LGG	cis	rs6964587	1.000	rs10281556	chr7:91660053	C/T	cg17063962	chr7:91808500	NA	-0.47	-8.52	-0.37	2.28e-16	Breast cancer;
LGG	cis	rs9557207	1.000	rs9585032	chr13:99935181	C/G	cg24509225	chr13:100037070	UBAC2	-0.65	-11.95	-0.49	7.21e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs10504073	0.669	rs55948643	chr8:50026403	C/G	cg00325661	chr8:49890786	NA	0.69	13.28	0.53	2.4e-34	Blood metabolite ratios;
LGG	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.12e-34	Heart rate;
LGG	cis	rs782590	0.620	rs7596377	chr2:55888612	T/A	cg18811423	chr2:55921094	PNPT1	-0.73	-13.47	-0.53	4.13e-35	Metabolic syndrome;
LGG	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg02993010	chr8:124780839	FAM91A1	-0.72	-10.59	-0.44	1.28e-23	Pancreatic cancer;
LGG	cis	rs7681440	0.904	rs28750169	chr4:90774303	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg05623727	chr3:50126028	RBM5	-0.37	-8.23	-0.36	1.98e-15	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08535374	chr1:110679730	NA	0.5	7.85	0.34	2.93e-14	Gut microbiome composition (summer);
LGG	cis	rs9811920	0.638	rs704581	chr3:99556160	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.75	-0.38	3.88e-17	Axial length;
LGG	cis	rs1044826	0.667	rs2083336	chr3:139201272	T/G	cg15131784	chr3:139108705	COPB2	0.41	6.84	0.3	2.48e-11	Obesity-related traits;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-8.06	-0.35	6.55e-15	Life satisfaction;
LGG	cis	rs7647973	0.600	rs13064780	chr3:49274826	T/G	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.77	-0.3	3.98e-11	Menarche (age at onset);
LGG	cis	rs7523273	0.565	rs12733108	chr1:207887210	C/T	cg22525895	chr1:207977042	MIR29B2	0.46	8.67	0.37	7.46e-17	Schizophrenia;
LGG	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg07435449	chr11:120005650	TRIM29	-0.73	-13.79	-0.54	1.7e-36	Stroke (pediatric);
LGG	cis	rs4975616	0.804	rs462608	chr5:1336626	T/A	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.09	-0.46	1.67e-25	Lung cancer;
LGG	trans	rs7824557	0.603	rs2246606	chr8:11219334	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-7.85	-0.34	2.89e-14	Retinal vascular caliber;
LGG	cis	rs7927592	0.673	rs498782	chr11:68275851	A/G	cg16797656	chr11:68205561	LRP5	0.52	10.08	0.42	1.01e-21	Total body bone mineral density;
LGG	cis	rs7208859	0.614	rs216474	chr17:28865091	C/T	cg01831904	chr17:28903510	LRRC37B2	0.68	8.46	0.37	3.52e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.1	-0.6	1.25e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg00684032	chr4:1343700	KIAA1530	0.41	8.04	0.35	7.62e-15	Longevity;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg15971980	chr6:150254442	NA	0.46	8.45	0.37	3.67e-16	Lung cancer;
LGG	cis	rs62064224	0.578	rs2109158	chr17:30695964	T/C	cg25809561	chr17:30822961	MYO1D	0.37	8.63	0.37	9.69e-17	Schizophrenia;
LGG	cis	rs6496667	0.533	rs7173201	chr15:90991195	A/T	cg22089800	chr15:90895588	ZNF774	0.51	8.36	0.36	7.39e-16	Rheumatoid arthritis;
LGG	cis	rs6688613	0.685	rs4657613	chr1:166870878	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.45	6.98	0.31	1.03e-11	Refractive astigmatism;
LGG	cis	rs1595825	1.000	rs6434950	chr2:198869979	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-7.07	-0.31	5.56e-12	Ulcerative colitis;
LGG	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg06606381	chr12:133084897	FBRSL1	-1.13	-9.84	-0.42	7.08e-21	Autism spectrum disorder or schizophrenia;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.17e-14	Total body bone mineral density;
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.31	-0.5	2.48e-30	Alzheimer's disease;
LGG	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21576698	chr1:46767971	LRRC41;UQCRH	-0.37	-6.99	-0.31	9.54e-12	Pancreatic cancer;
LGG	cis	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg13647721	chr17:30228624	UTP6	-0.71	-8.03	-0.35	8.34e-15	Hip circumference adjusted for BMI;
LGG	trans	rs1941687	0.510	rs1452649	chr18:31410858	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.49e-22	Tonsillectomy;
LGG	cis	rs7917772	0.636	rs2249850	chr10:104512006	A/G	cg04362960	chr10:104952993	NT5C2	-0.44	-6.77	-0.3	3.94e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9682041	0.935	rs11923053	chr3:170095281	T/C	cg11886554	chr3:170076028	SKIL	1.0	12.11	0.49	1.59e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7666738	0.680	rs11726233	chr4:99079773	G/A	cg05340658	chr4:99064831	C4orf37	0.45	7.34	0.32	9.87e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7980799	0.935	rs4931717	chr12:33521151	A/G	cg26384229	chr12:38710491	ALG10B	0.5	8.72	0.38	4.9e-17	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4509693	0.943	rs10732789	chr10:102496184	T/C	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.24e-11	Alzheimer's disease;
LGG	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg17971929	chr21:40555470	PSMG1	0.88	17.2	0.62	1.3e-51	Cognitive function;
LGG	cis	rs10791097	0.967	rs10791099	chr11:130718813	G/C	cg12179176	chr11:130786555	SNX19	0.75	14.29	0.55	1.24e-38	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.58	-0.44	1.44e-23	Total cholesterol levels;
LGG	cis	rs6547631	0.622	rs10206121	chr2:85930169	T/A	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.59e-22	Blood protein levels;
LGG	cis	rs7552404	1.000	rs11161521	chr1:76216330	T/C	cg10523679	chr1:76189770	ACADM	0.83	14.47	0.56	1.95e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18404041	chr3:52824283	ITIH1	-0.54	-10.37	-0.43	8.38e-23	Bipolar disorder;
LGG	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-12.1	-0.49	1.85e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs806215	0.526	rs58106688	chr7:127483211	T/C	cg25922125	chr7:127225783	GCC1	-0.48	-7.02	-0.31	7.79e-12	Type 2 diabetes;
LGG	cis	rs4730779	0.534	rs39320	chr7:116968834	G/C	cg10524701	chr7:117356490	CTTNBP2	0.38	7.35	0.32	9.06e-13	Waist circumference;
LGG	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg23173402	chr1:227635558	NA	0.5	8.51	0.37	2.38e-16	Major depressive disorder;
LGG	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs4919087	0.810	rs1468069	chr10:98988759	A/C	cg25902810	chr10:99078978	FRAT1	0.43	7.82	0.34	3.57e-14	Monocyte count;
LGG	cis	rs6430585	0.583	rs3769001	chr2:136626078	A/G	cg07169764	chr2:136633963	MCM6	1.28	26.29	0.77	6.87e-94	Corneal structure;
LGG	trans	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.68e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.5	0.4	1.13e-19	Lung cancer in ever smokers;
LGG	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs62238980	0.614	rs116829978	chr22:32547785	C/T	cg02631450	chr22:32366979	NA	0.95	9.52	0.4	9.38e-20	Childhood ear infection;
LGG	cis	rs523522	0.962	rs10849753	chr12:120910813	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	12.9	0.51	9.98e-33	High light scatter reticulocyte count;
LGG	cis	rs55728055	0.661	rs12165609	chr22:32036332	T/C	cg01338084	chr22:32026380	PISD	1.49	12.9	0.51	1.01e-32	Age-related hearing impairment;
LGG	trans	rs1814175	0.645	rs7952104	chr11:49964180	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.67	-0.37	7.22e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs238295	0.881	rs6116869	chr20:5594432	G/T	cg25486615	chr20:5591870	RP5-1022P6.2	0.4	6.67	0.3	7.4e-11	Occipital cortical area (total cortical area interaction);
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.38	0.36	6.21e-16	Life satisfaction;
LGG	cis	rs514406	0.929	rs564273	chr1:53332445	G/C	cg24675658	chr1:53192096	ZYG11B	-0.48	-9.31	-0.4	5.26e-19	Monocyte count;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg05556477	chr5:131705319	SLC22A5	0.85	10.09	0.42	8.8e-22	Rheumatoid arthritis;
LGG	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7937890	0.668	rs12361851	chr11:14267668	C/T	cg02886208	chr11:14281011	SPON1	0.41	8.31	0.36	1.08e-15	Mitochondrial DNA levels;
LGG	cis	rs1595825	1.000	rs73058832	chr2:198873214	G/T	cg00982548	chr2:198649783	BOLL	-0.49	-6.75	-0.3	4.48e-11	Ulcerative colitis;
LGG	cis	rs9611519	1.000	rs2273085	chr22:41615376	C/T	cg03806693	chr22:41940476	POLR3H	-0.49	-7.7	-0.34	8.29e-14	Neuroticism;
LGG	cis	rs7044106	0.512	rs7873848	chr9:123354222	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.76	14.21	0.55	2.77e-38	Hip circumference adjusted for BMI;
LGG	cis	rs8062405	0.755	rs4787457	chr16:28555400	A/G	cg00204512	chr16:28754710	NA	0.24	6.68	0.3	6.94e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg02002194	chr4:3960332	NA	-0.4	-7.06	-0.31	6.08e-12	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14592491	chr3:48594229	PFKFB4	0.46	6.87	0.3	2.05e-11	Gut microbiome composition (summer);
LGG	cis	rs4650994	0.935	rs2811289	chr1:178572693	G/A	cg19399532	chr1:178512495	C1orf220	-0.43	-8.34	-0.36	8.59e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7927592	0.913	rs948316	chr11:68309670	G/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07732421	chr5:74633253	HMGCR	0.55	8.92	0.38	1.11e-17	Gut microbiome composition (summer);
LGG	cis	rs2455799	0.574	rs2455798	chr3:15700505	G/C	cg16303742	chr3:15540471	COLQ	-0.42	-8.3	-0.36	1.17e-15	Mean platelet volume;
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg19774624	chr17:42201019	HDAC5	0.92	19.88	0.68	5.16e-64	Total body bone mineral density;
LGG	cis	rs4704846	1.000	rs4704737	chr5:156533219	A/G	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.27	-0.32	1.57e-12	Blood protein levels;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.41	0.33	6.09e-13	Tonsillectomy;
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-16.14	-0.6	8.21e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.818	rs62249866	chr3:72878632	T/C	cg01043669	chr3:72786069	NA	0.43	6.84	0.3	2.51e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.95	0.38	8.46e-18	Aortic root size;
LGG	cis	rs1046896	0.594	rs4075209	chr17:80800027	G/T	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.78	0.34	4.62e-14	Glycated hemoglobin levels;
LGG	cis	rs9863	0.794	rs12310367	chr12:124486678	A/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.23	-0.32	1.98e-12	White blood cell count;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg11859384	chr17:80120422	CCDC57	0.45	8.0	0.35	9.76e-15	Life satisfaction;
LGG	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	trans	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.27	0.43	1.94e-22	Neuroticism;
LGG	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.23	0.39	1e-18	Fuchs's corneal dystrophy;
LGG	cis	rs972578	0.875	rs5751412	chr22:43408257	A/G	cg01576275	chr22:43409880	NA	-0.24	-7.04	-0.31	6.87e-12	Mean platelet volume;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.81	-0.41	8.85e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.54	-0.37	1.9e-16	Monocyte count;
LGG	cis	rs7772486	0.658	rs4895683	chr6:146113654	T/A	cg23711669	chr6:146136114	FBXO30	-0.4	-6.72	-0.3	5.23e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6121246	0.909	rs6060923	chr20:30336655	A/C	cg21427119	chr20:30132790	HM13	-0.42	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg17340268	chr14:105411764	AHNAK2	0.39	7.18	0.32	2.75e-12	Rheumatoid arthritis;
LGG	trans	rs3960554	1.000	rs78663390	chr7:75845837	C/A	cg19862616	chr7:65841803	NCRNA00174	0.83	11.72	0.48	5.62e-28	Eotaxin levels;
LGG	cis	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg09021430	chr5:549028	NA	-0.7	-9.8	-0.41	9.59e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs13102973	0.682	rs13107817	chr4:135885535	C/T	cg14419869	chr4:135874104	NA	0.47	7.96	0.35	1.37e-14	Subjective well-being;
LGG	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.18e-23	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04278597	chr1:63154320	DOCK7	0.45	7.5	0.33	3.33e-13	Cognitive performance;
LGG	cis	rs721399	0.568	rs34987019	chr8:18274443	T/C	cg18736775	chr8:18248649	NAT2	-0.7	-10.56	-0.44	1.65e-23	Blood metabolite levels;
LGG	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.71	0.45	4.65e-24	Mood instability;
LGG	cis	rs977987	0.806	rs11644306	chr16:75490053	T/C	cg03315344	chr16:75512273	CHST6	0.55	10.93	0.45	6.87e-25	Dupuytren's disease;
LGG	trans	rs8073060	0.572	rs1634683	chr17:33941560	G/C	cg19694781	chr19:47549865	TMEM160	-1.15	-17.38	-0.63	1.8e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2832191	0.967	rs2832216	chr21:30521921	C/T	cg08807101	chr21:30365312	RNF160	0.77	14.81	0.57	6.85e-41	Dental caries;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg03036210	chr16:89904091	SPIRE2	-0.68	-8.07	-0.35	6.25e-15	Skin colour saturation;
LGG	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.26	-0.36	1.49e-15	Obesity-related traits;
LGG	cis	rs7615952	0.673	rs3811677	chr3:125648080	G/A	cg05084668	chr3:125655381	ALG1L	-0.87	-10.79	-0.45	2.33e-24	Blood pressure (smoking interaction);
LGG	cis	rs7223966	0.655	rs7209961	chr17:61633705	C/T	cg05941027	chr17:61774174	LIMD2	0.32	7.63	0.33	1.35e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06634786	chr22:41940651	POLR3H	-0.74	-12.49	-0.5	4.91e-31	Vitiligo;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs10489202	0.608	rs4657733	chr1:168086434	G/A	cg24449463	chr1:168025552	DCAF6	-0.56	-9.97	-0.42	2.49e-21	Schizophrenia;
LGG	cis	rs9287719	0.935	rs1309	chr2:10743546	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs28655083	0.912	rs2171097	chr16:77085037	C/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.72	-0.34	7.49e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13314892	0.764	rs60438183	chr3:69880729	C/T	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.71e-14	QRS complex (12-leadsum);
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.44	-6.83	-0.3	2.64e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs981844	0.775	rs55986083	chr4:154765640	A/C	cg14289246	chr4:154710475	SFRP2	0.67	10.91	0.45	8.1e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg07685180	chr8:600429	NA	1.06	10.82	0.45	1.82e-24	IgG glycosylation;
LGG	cis	rs6963495	0.818	rs6955796	chr7:105170321	T/G	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs36051895	0.623	rs10118267	chr9:5243736	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-12.32	-0.5	2.3e-30	Pediatric autoimmune diseases;
LGG	cis	rs6500602	0.627	rs11639998	chr16:4527109	T/C	cg06916706	chr16:4465613	CORO7	-0.93	-16.99	-0.62	1.17e-50	Schizophrenia;
LGG	cis	rs9715521	0.712	rs58171535	chr4:59847742	T/A	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg22398616	chr13:53314203	LECT1	-0.53	-11.52	-0.47	3.54e-27	Lewy body disease;
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.69	-13.06	-0.52	2.08e-33	Lymphocyte counts;
LGG	cis	rs7208859	0.623	rs11650271	chr17:29213943	C/T	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg07777115	chr5:623756	CEP72	-0.56	-7.21	-0.32	2.29e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg21058520	chr6:100914733	NA	-0.39	-6.79	-0.3	3.44e-11	Neuroticism;
LGG	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg26150922	chr2:100937072	LONRF2	-0.58	-11.08	-0.46	1.89e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	0.959	rs9560108	chr13:112180303	A/C	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs2540226	0.539	rs10186346	chr2:39914192	C/T	cg18968196	chr2:39892502	TMEM178	0.31	8.63	0.37	9.76e-17	Personality dimensions;
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg07870213	chr5:140052090	DND1	0.69	13.48	0.53	3.45e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.22	0.32	2.18e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9783347	1.000	rs4150579	chr11:18357180	C/T	cg03595886	chr11:18357587	GTF2H1	0.38	7.65	0.34	1.17e-13	Pancreatic cancer;
LGG	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg13334819	chr7:99746414	C7orf59	0.48	7.52	0.33	2.88e-13	Coronary artery disease;
LGG	cis	rs2153535	0.563	rs1796688	chr6:8536423	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	2.89e-18	Motion sickness;
LGG	cis	rs2243480	1.000	rs6958289	chr7:65657111	T/G	cg13147721	chr7:65941812	NA	0.84	10.08	0.42	1.02e-21	Diabetic kidney disease;
LGG	cis	rs9581857	0.556	rs9581863	chr13:28040171	A/G	cg01674679	chr13:27998804	GTF3A	-0.59	-8.11	-0.35	4.72e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs475616	0.917	rs866919	chr10:30513283	C/T	cg14639822	chr9:136131484	ABO	0.36	6.71	0.3	5.55e-11	Monocyte count;
LGG	cis	rs4262150	0.920	rs4478368	chr5:152291650	C/T	cg12297329	chr5:152029980	NA	0.62	11.84	0.48	2.01e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2273669	0.915	rs7753554	chr6:109292133	G/C	cg05315195	chr6:109294784	ARMC2	-0.51	-7.28	-0.32	1.42e-12	Prostate cancer;
LGG	cis	rs9815354	0.953	rs1716655	chr3:41918706	A/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.26	-0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.835	rs8078087	chr17:80113322	T/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs3857747	0.931	rs4332041	chr7:40367897	A/T	cg00420559	chr7:40367873	C7orf10	-0.42	-8.49	-0.37	2.83e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg25937216	chr8:58172855	NA	-0.57	-9.18	-0.39	1.45e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11718235	chr19:56915184	ZNF583	-0.5	-7.41	-0.33	6.17e-13	Systemic lupus erythematosus;
LGG	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06873352	chr17:61820015	STRADA	0.47	6.91	0.31	1.63e-11	Height;
LGG	cis	rs4665809	0.590	rs5001914	chr2:26415429	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	cis	rs9381040	0.610	rs2268195	chr6:41024340	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.71	-0.3	5.7e-11	Alzheimer's disease (late onset);
LGG	cis	rs6466055	0.777	rs917114	chr7:104907507	C/T	cg04380332	chr7:105027541	SRPK2	0.37	6.99	0.31	9.47e-12	Schizophrenia;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg03806693	chr22:41940476	POLR3H	-1.12	-20.23	-0.68	1.2e-65	Vitiligo;
LGG	cis	rs4363385	0.510	rs56241316	chr1:152901748	A/G	cg13444842	chr1:152974279	SPRR3	-0.47	-9.28	-0.4	6.4e-19	Inflammatory skin disease;
LGG	trans	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg06521331	chr12:34319734	NA	0.44	7.6	0.33	1.69e-13	Morning vs. evening chronotype;
LGG	cis	rs36715	1.000	rs251386	chr5:127547298	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.68	0.34	9.77e-14	Breast cancer;
LGG	trans	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.7	-12.34	-0.5	1.92e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg22920501	chr2:26401640	FAM59B	-0.41	-8.11	-0.35	4.65e-15	Gut microbiome composition (summer);
LGG	cis	rs10884984	0.710	rs7090060	chr10:112269400	A/G	cg18756771	chr10:112261994	DUSP5	-0.68	-12.87	-0.51	1.28e-32	Facial morphology (factor 22);
LGG	cis	rs2201728	0.739	rs7663184	chr4:100153496	G/T	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg05793240	chr7:2802953	GNA12	0.33	7.87	0.34	2.5e-14	Height;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.92	0.48	9.75e-29	Tonsillectomy;
LGG	cis	rs7712401	0.601	rs62377430	chr5:122334688	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs4692589	0.606	rs11943813	chr4:170938243	T/C	cg19918862	chr4:170955249	NA	0.39	6.79	0.3	3.41e-11	Anxiety disorder;
LGG	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15557168	chr22:42548783	NA	-0.31	-6.66	-0.3	7.96e-11	Cognitive function;
LGG	cis	rs2737618	0.698	rs2737678	chr1:200088041	C/T	cg21825944	chr1:200113062	NR5A2	-0.6	-11.56	-0.47	2.47e-27	Uric acid levels;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs10089	1.000	rs3805612	chr5:127505316	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.63	0.48	1.33e-27	Ileal carcinoids;
LGG	cis	rs9457247	0.905	rs453184	chr6:167387404	A/C	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg25019033	chr10:957182	NA	-0.53	-8.98	-0.39	7.03e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs72772090	0.539	rs72773991	chr5:96163775	T/G	cg00188032	chr5:96141721	ERAP1	0.55	7.24	0.32	1.9e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2694528	0.844	rs9291696	chr5:60064385	C/T	cg11474532	chr5:59995715	DEPDC1B	0.73	7.54	0.33	2.57e-13	Parkinson's disease;
LGG	cis	rs11608355	0.508	rs11066411	chr12:109804194	A/G	cg19025524	chr12:109796872	NA	-0.47	-8.36	-0.36	7.23e-16	Neuroticism;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg02725872	chr8:58115012	NA	-0.94	-12.36	-0.5	1.54e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4262150	0.842	rs17113771	chr5:152278020	C/T	cg12297329	chr5:152029980	NA	-0.61	-11.78	-0.48	3.29e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.64e-13	Prudent dietary pattern;
LGG	cis	rs7927771	1.000	rs4752856	chr11:47648042	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-8.47	-0.37	3.16e-16	Subjective well-being;
LGG	cis	rs1144	0.537	rs2470950	chr7:104592077	C/T	cg03782966	chr7:104585482	NA	0.34	7.8	0.34	4.06e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs1577917	0.771	rs2842609	chr6:86296788	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.24	-0.63	8.08e-52	Response to antipsychotic treatment;
LGG	cis	rs4363385	0.667	rs399550	chr1:153049917	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs701145	0.643	rs453699	chr3:153924784	A/G	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs1185460	0.967	rs1786141	chr11:118938315	C/T	cg23280166	chr11:118938394	VPS11	0.6	11.25	0.46	4.08e-26	Coronary artery disease;
LGG	cis	rs6580649	1.000	rs6580647	chr12:48403229	G/T	cg24011408	chr12:48396354	COL2A1	-0.6	-7.65	-0.33	1.19e-13	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01685689	chr11:126081170	FAM118B;RPUSD4	0.46	7.0	0.31	9.26e-12	Gut microbiome composition (summer);
LGG	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.95	0.38	8.85e-18	Colorectal cancer;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg24112000	chr20:60950667	NA	0.34	7.8	0.34	4.04e-14	Colorectal cancer;
LGG	cis	rs7267979	0.966	rs6050532	chr20:25308793	A/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg07332563	chr6:291687	DUSP22	-0.44	-7.57	-0.33	2.06e-13	Menopause (age at onset);
LGG	cis	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg08603382	chr10:743973	NA	0.44	8.07	0.35	6.2e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg17376030	chr22:41985996	PMM1	0.65	10.18	0.43	4.24e-22	Vitiligo;
LGG	cis	rs7312933	0.558	rs11181463	chr12:42763636	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.92	0.35	1.8e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2011503	0.882	rs8108777	chr19:19359058	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.0	0.31	8.99e-12	Bipolar disorder;
LGG	trans	rs2018683	0.835	rs7782264	chr7:28978986	A/G	cg19402173	chr7:128379420	CALU	0.58	10.38	0.43	7.92e-23	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg05484376	chr2:27715224	FNDC4	0.46	9.96	0.42	2.68e-21	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.55	-0.53	1.84e-35	Personality dimensions;
LGG	cis	rs271738	0.642	rs271765	chr1:234673913	A/T	cg05133706	chr1:234667230	NA	0.29	6.66	0.3	7.86e-11	Bipolar disorder;
LGG	cis	rs9303401	0.659	rs36109237	chr17:56653834	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.05	0.57	5.76e-42	Cognitive test performance;
LGG	cis	rs847649	0.961	rs7456502	chr7:102596022	C/A	cg18108683	chr7:102477205	FBXL13	0.64	14.18	0.55	3.58e-38	Morning vs. evening chronotype;
LGG	cis	rs6964587	1.000	rs6964587	chr7:91630620	G/T	cg17063962	chr7:91808500	NA	0.47	8.51	0.37	2.45e-16	Breast cancer;
LGG	cis	rs988958	0.637	rs7595175	chr2:42220015	T/C	cg27252766	chr2:42229092	NA	0.56	8.66	0.37	8.06e-17	Hypospadias;
LGG	trans	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg13009111	chr11:71350975	NA	0.31	6.79	0.3	3.38e-11	Triglycerides;
LGG	trans	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.45	0.4	1.7e-19	Mood instability;
LGG	cis	rs10504229	0.769	rs17215649	chr8:58152791	A/G	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9875589	0.957	rs60060718	chr3:13950333	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.33	-0.4	4.47e-19	Ovarian reserve;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	7.03e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg04025307	chr7:1156635	C7orf50	0.61	11.07	0.46	2.01e-25	Longevity;Endometriosis;
LGG	cis	rs6940638	0.688	rs9348750	chr6:27057945	T/G	cg12826209	chr6:26865740	GUSBL1	0.47	7.86	0.34	2.74e-14	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13237843	chr11:6640720	TPP1	0.45	6.79	0.3	3.44e-11	Gut microbiome composition (summer);
LGG	cis	rs926392	0.896	rs7268772	chr20:37684501	A/G	cg16355469	chr20:37678765	NA	0.46	7.68	0.34	9.62e-14	Dialysis-related mortality;
LGG	cis	rs4430311	0.688	rs13376709	chr1:243690491	T/C	cg25706552	chr1:244017396	NA	-0.67	-15.52	-0.58	4.85e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs3096299	0.606	rs2965960	chr16:89541795	G/A	cg05484508	chr16:89589025	SPG7	0.49	7.64	0.33	1.29e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs56235845	0.694	rs6860069	chr5:176755841	C/T	cg17509989	chr5:176798049	RGS14	0.67	10.89	0.45	9.31e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs7552404	0.920	rs2788654	chr1:76219569	C/T	cg03433033	chr1:76189801	ACADM	0.71	12.5	0.5	4.26e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.86	-0.42	5.91e-21	Lung cancer;
LGG	trans	rs1814175	0.817	rs1988416	chr11:49932324	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	cis	rs1185460	0.967	rs1177563	chr11:118949083	C/T	cg23280166	chr11:118938394	VPS11	0.58	10.35	0.43	9.94e-23	Coronary artery disease;
LGG	cis	rs4689388	0.581	rs4688985	chr4:6285715	A/G	cg25554036	chr4:6271136	WFS1	0.51	8.34	0.36	8.72e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.25	0.49	4.6e-30	Type 2 diabetes;
LGG	cis	rs9815354	0.597	rs80066790	chr3:42000843	A/G	cg03022575	chr3:42003672	ULK4	0.77	8.95	0.38	8.64e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7843479	0.544	rs11135735	chr8:21791557	C/T	cg17168535	chr8:21777572	XPO7	0.8	15.59	0.59	2.27e-44	Mean corpuscular volume;
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg18402987	chr7:1209562	NA	0.5	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1003719	0.715	rs2835647	chr21:38546773	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs7619708	1	rs7619708	chr3:195810187	T/C	cg00031303	chr3:195681400	NA	-0.51	-7.47	-0.33	4.05e-13	Red cell distribution width;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08645402	chr16:4508243	NA	-0.55	-9.86	-0.42	5.95e-21	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg23762105	chr12:34175262	ALG10	-0.33	-6.71	-0.3	5.76e-11	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.15	0.39	1.81e-18	Motion sickness;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg04287289	chr16:89883240	FANCA	0.88	8.41	0.36	5.18e-16	Skin colour saturation;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.09	-0.31	5.06e-12	Aortic root size;
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.48	7.65	0.34	1.14e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.28	0.32	1.47e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1506636	0.525	rs7812023	chr7:123260228	C/T	cg03229431	chr7:123269106	ASB15	-0.67	-13.13	-0.52	1.07e-33	Plateletcrit;Platelet count;
LGG	cis	rs7843479	0.601	rs1031882	chr8:21788934	T/G	cg17168535	chr8:21777572	XPO7	0.82	15.9	0.59	1.03e-45	Mean corpuscular volume;
LGG	cis	rs701145	0.585	rs1727954	chr3:153871272	T/A	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs5769765	0.671	rs138832	chr22:50178082	A/G	cg02269571	chr22:50332266	NA	-0.55	-8.62	-0.37	1.08e-16	Schizophrenia;
LGG	cis	rs1728785	1.000	rs1728792	chr16:68596534	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2408955	0.522	rs4760679	chr12:48461635	G/T	cg24011408	chr12:48396354	COL2A1	-0.58	-9.67	-0.41	2.81e-20	Glycated hemoglobin levels;
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.79e-31	Lymphocyte counts;
LGG	cis	rs938554	0.735	rs12498742	chr4:9944052	A/G	cg25986240	chr4:9926439	SLC2A9	0.37	6.79	0.3	3.48e-11	Blood metabolite levels;
LGG	cis	rs9457247	0.765	rs10946203	chr6:167446735	A/C	cg07741184	chr6:167504864	NA	0.43	9.52	0.4	9.3e-20	Crohn's disease;
LGG	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg27286337	chr10:134555280	INPP5A	0.87	13.68	0.54	4.92e-36	Migraine;
LGG	cis	rs875971	1.000	rs6460292	chr7:65810075	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.8	-0.41	9.96e-21	Aortic root size;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg11050988	chr7:1952600	MAD1L1	0.29	7.19	0.32	2.62e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3099143	1.000	rs3099138	chr15:77115524	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-10.36	-0.43	9.38e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg00405596	chr8:11794950	NA	-0.4	-6.68	-0.3	6.91e-11	Neuroticism;
LGG	trans	rs2572431	0.543	rs2256016	chr8:11162602	C/A	cg06636001	chr8:8085503	FLJ10661	0.39	6.82	0.3	2.88e-11	Neuroticism;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg26578617	chr4:90757533	SNCA	-0.47	-9.49	-0.4	1.2e-19	Dementia with Lewy bodies;
LGG	trans	rs7824557	0.767	rs11775635	chr8:11164865	G/A	cg08975724	chr8:8085496	FLJ10661	0.43	7.78	0.34	4.91e-14	Retinal vascular caliber;
LGG	cis	rs5753037	0.702	rs249398	chr22:30214704	G/C	cg01021169	chr22:30184971	ASCC2	-0.37	-7.37	-0.32	7.8e-13	Type 1 diabetes;
LGG	cis	rs1552244	0.938	rs7647987	chr3:10140696	A/G	cg00166722	chr3:10149974	C3orf24	0.5	8.43	0.36	4.52e-16	Alzheimer's disease;
LGG	cis	rs7737355	0.853	rs10051003	chr5:131072410	C/T	cg06307176	chr5:131281290	NA	0.52	8.55	0.37	1.8e-16	Life satisfaction;
LGG	cis	rs138249	0.934	rs138228	chr22:50557120	A/C	cg07310406	chr22:50524374	MLC1	-0.41	-7.97	-0.35	1.29e-14	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs283228	0.798	rs2787586	chr6:101811030	C/T	cg27451362	chr6:101846650	GRIK2	0.64	10.56	0.44	1.61e-23	Coenzyme Q10 levels;
LGG	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.03	0.39	4.76e-18	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10860527	chr2:109403091	CCDC138	0.43	6.72	0.3	5.27e-11	Gut microbiome composition (summer);
LGG	cis	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg06521331	chr12:34319734	NA	0.55	9.47	0.4	1.41e-19	Morning vs. evening chronotype;
LGG	cis	rs4743820	0.590	rs7045796	chr9:93919427	G/C	cg14446406	chr9:93919335	NA	-0.91	-15.44	-0.58	1.1e-43	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs68170813	0.559	rs11769861	chr7:106979559	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.3	-0.43	1.59e-22	Coronary artery disease;
LGG	cis	rs4740619	0.544	rs9407655	chr9:15830622	C/T	cg14451791	chr9:16040625	NA	0.32	7.91	0.35	1.91e-14	Body mass index;
LGG	cis	rs2249694	1.000	rs2480259	chr10:135352076	A/G	cg20169779	chr10:135381914	SYCE1	0.5	7.58	0.33	1.91e-13	Obesity-related traits;
LGG	cis	rs7927592	0.913	rs12272917	chr11:68263370	T/C	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	trans	rs1728785	1.000	rs4783657	chr16:68586322	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.35	0.43	1.02e-22	Ulcerative colitis;
LGG	cis	rs9815354	0.627	rs73073268	chr3:42021403	C/A	cg03022575	chr3:42003672	ULK4	0.75	8.19	0.36	2.58e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2153535	0.541	rs6905934	chr6:8440043	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	6.67e-18	Motion sickness;
LGG	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg25358565	chr5:93447407	FAM172A	1.26	15.38	0.58	2.02e-43	Diabetic retinopathy;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs9583531	0.891	rs61969072	chr13:111380701	T/G	cg24331049	chr13:111365604	ING1	-0.88	-12.54	-0.5	2.89e-31	Coronary artery disease;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg20916646	chr4:852691	GAK	0.51	8.86	0.38	1.79e-17	Sjögren's syndrome;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.72	0.41	1.97e-20	Schizophrenia;
LGG	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg07303275	chr16:75499416	TMEM170A	0.36	6.67	0.3	7.54e-11	Dupuytren's disease;
LGG	cis	rs1348850	0.914	rs12469386	chr2:178358281	A/G	cg22681709	chr2:178499509	PDE11A	0.46	8.48	0.37	3.14e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg11062466	chr8:58055876	NA	0.5	8.08	0.35	5.81e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4268898	0.662	rs58971404	chr2:24403753	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-12.47	-0.5	5.89e-31	Asthma;
LGG	cis	rs7851660	0.809	rs7044799	chr9:100665393	A/T	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	trans	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	16.99	0.62	1.16e-50	Exhaled nitric oxide levels;
LGG	cis	rs1595825	0.891	rs16825786	chr2:198794681	G/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.99	-0.31	9.93e-12	Ulcerative colitis;
LGG	cis	rs10214930	0.697	rs1880370	chr7:27583312	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.76	0.3	4.27e-11	Hypospadias;
LGG	cis	rs5757673	1	rs5757673	chr22:39837920	T/C	cg04986931	chr22:39850128	NA	0.42	8.96	0.38	7.86e-18	Post bronchodilator FEV1;
LGG	cis	rs1267303	0.642	rs1267301	chr1:46992853	C/G	cg25110126	chr1:46999211	NA	-0.65	-9.79	-0.41	1.04e-20	Monobrow;
LGG	cis	rs11098499	0.954	rs3733523	chr4:120423719	C/T	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.07	-0.31	5.83e-12	Monocyte count;
LGG	cis	rs9547996	0.765	rs9547977	chr13:38185811	G/C	cg13634560	chr13:38173852	POSTN	-0.34	-6.75	-0.3	4.4e-11	Diastolic blood pressure;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07867558	chr2:219524465	ZNF142;BCS1L	0.45	7.04	0.31	7.02e-12	Gut microbiome composition (summer);
LGG	cis	rs2273669	0.667	rs79285264	chr6:109318279	G/T	cg05315195	chr6:109294784	ARMC2	-0.69	-8.39	-0.36	5.83e-16	Prostate cancer;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg27205649	chr11:78285834	NARS2	0.5	8.47	0.37	3.19e-16	Alzheimer's disease (survival time);
LGG	cis	rs8031584	0.918	rs34095794	chr15:31269691	C/T	cg08704250	chr15:31115839	NA	-0.43	-7.92	-0.35	1.81e-14	Huntington's disease progression;
LGG	trans	rs6598955	0.671	rs41285347	chr1:26644399	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.71	-0.51	5.79e-32	Obesity-related traits;
LGG	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg16590910	chr6:42928470	GNMT	0.29	6.89	0.3	1.89e-11	Blood protein levels;
LGG	cis	rs4423214	1.000	rs11600569	chr11:71173747	C/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	cis	rs7599312	0.517	rs10192988	chr2:213407782	T/G	cg16329650	chr2:213403929	ERBB4	0.78	16.6	0.61	6.92e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	12.15	0.49	1.13e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg20887711	chr4:1340912	KIAA1530	0.51	9.55	0.41	7.72e-20	Obesity-related traits;
LGG	cis	rs2236918	0.710	rs1776174	chr1:242031839	G/T	cg17736920	chr1:242011382	EXO1	0.39	7.0	0.31	9.12e-12	Menopause (age at onset);
LGG	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08045932	chr20:61659980	NA	0.6	13.02	0.52	3.16e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs79349575	0.783	rs2088139	chr17:47000110	C/T	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs6547741	1.000	rs6547741	chr2:27855924	G/A	cg22903471	chr2:27725779	GCKR	0.38	8.48	0.37	2.97e-16	Oral cavity cancer;
LGG	cis	rs7737355	0.947	rs4706028	chr5:130946227	T/C	cg06307176	chr5:131281290	NA	0.58	9.44	0.4	1.87e-19	Life satisfaction;
LGG	cis	rs7928758	0.887	rs34702205	chr11:134270721	G/A	cg15243474	chr11:134282918	B3GAT1	1.15	15.22	0.58	1.02e-42	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7267979	0.527	rs6083891	chr20:25574272	C/G	cg06421707	chr20:25228305	PYGB	-0.37	-7.72	-0.34	7.41e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6546550	0.901	rs6716937	chr2:70127229	G/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.99	-0.35	1.08e-14	Prevalent atrial fibrillation;
LGG	cis	rs9814567	1.000	rs2056603	chr3:134312749	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03885022	chr7:92158293	C7orf64;PEX1	0.47	7.17	0.32	2.98e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17308151	chr11:8703888	RPL27A	0.5	7.78	0.34	4.86e-14	Gut microbiome composition (summer);
LGG	cis	rs7814319	0.838	rs4598220	chr8:97232832	C/G	cg20787634	chr8:97240163	UQCRB	-0.71	-15.52	-0.59	4.74e-44	Lung function (FVC);
LGG	cis	rs9297145	0.715	rs62473008	chr7:98751541	A/G	cg05967295	chr7:98741636	SMURF1	0.92	15.32	0.58	3.95e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs654950	0.774	rs941972	chr1:42040740	T/C	cg06885757	chr1:42089581	HIVEP3	-0.64	-15.02	-0.57	8.28e-42	Airway imaging phenotypes;
LGG	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg12310025	chr6:25882481	NA	-0.63	-11.74	-0.48	4.72e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1555895	0.566	rs1057304	chr10:853106	T/C	cg10556349	chr10:835070	NA	-0.33	-8.26	-0.36	1.53e-15	Survival in rectal cancer;
LGG	trans	rs970548	0.730	rs61854092	chr10:45934795	G/A	cg14222797	chr10:16859974	RSU1	-0.61	-7.04	-0.31	7.17e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs2066819	1.000	rs17118439	chr12:56667604	C/T	cg26714650	chr12:56694279	CS	1.61	16.24	0.6	2.86e-47	Psoriasis vulgaris;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg04025307	chr7:1156635	C7orf50	0.81	14.62	0.56	4.6e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7178909	0.902	rs10459674	chr15:90438295	G/C	cg19708238	chr15:90437601	AP3S2	0.4	6.68	0.3	6.99e-11	Common traits (Other);
LGG	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.91	-0.45	7.83e-25	Body mass index;
LGG	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg10518543	chr12:38710700	ALG10B	-0.41	-6.68	-0.3	6.67e-11	Morning vs. evening chronotype;
LGG	cis	rs7107174	0.901	rs2511159	chr11:77974193	G/T	cg02023728	chr11:77925099	USP35	-0.43	-7.54	-0.33	2.58e-13	Testicular germ cell tumor;
LGG	cis	rs9815354	1.000	rs17063649	chr3:41863406	C/T	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg05234568	chr11:5960015	NA	-0.71	-11.72	-0.48	6.02e-28	DNA methylation (variation);
LGG	cis	rs2439831	0.867	rs2255051	chr15:43846161	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.75	0.41	1.52e-20	Lung cancer in ever smokers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13987042	chr11:74660265	XRRA1;SPCS2	-0.44	-6.81	-0.3	2.99e-11	Gut microbiome composition (summer);
LGG	cis	rs9790314	0.632	rs62280333	chr3:160689060	G/A	cg03342759	chr3:160939853	NMD3	0.43	7.25	0.32	1.77e-12	Morning vs. evening chronotype;
LGG	trans	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.36	-0.32	8.41e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35883536	0.609	rs1855631	chr1:101040010	C/T	cg06223162	chr1:101003688	GPR88	-0.41	-9.94	-0.42	3.24e-21	Monocyte count;
LGG	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7666738	0.822	rs17484018	chr4:98988960	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9972944	0.902	rs9972883	chr17:63771316	C/A	cg07283582	chr17:63770753	CCDC46	0.44	8.77	0.38	3.35e-17	Total body bone mineral density;
LGG	cis	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg00405596	chr8:11794950	NA	-0.45	-7.63	-0.33	1.32e-13	Retinal vascular caliber;
LGG	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg12463550	chr7:65579703	CRCP	0.46	7.62	0.33	1.42e-13	Aortic root size;
LGG	cis	rs908922	0.676	rs1123567	chr1:152516023	G/A	cg09873164	chr1:152488093	CRCT1	0.64	15.98	0.6	4.5e-46	Hair morphology;
LGG	cis	rs3099143	1.000	rs1114717	chr15:77086078	A/G	cg21673338	chr15:77095150	SCAPER	0.65	10.55	0.44	1.88e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs7192380	0.639	rs7186296	chr16:69808998	A/G	cg00738113	chr16:70207722	CLEC18C	0.37	10.26	0.43	2.2e-22	Sjögren's syndrome;
LGG	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg03735888	chr19:58951602	ZNF132	0.42	8.36	0.36	7.27e-16	Uric acid clearance;
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22433210	chr17:43662623	NA	-0.87	-14.15	-0.55	5.13e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9359856	0.600	rs17584763	chr6:90502088	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.9	-0.42	4.31e-21	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.6	0.37	1.24e-16	Lung cancer;
LGG	cis	rs736408	0.609	rs2336545	chr3:52787603	C/T	cg18099408	chr3:52552593	STAB1	0.36	7.15	0.32	3.44e-12	Bipolar disorder;
LGG	cis	rs4434138	0.664	rs62255364	chr3:52701502	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.15	0.35	3.44e-15	Intelligence (multi-trait analysis);
LGG	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg14664628	chr15:75095509	CSK	1.15	27.65	0.79	4.46e-100	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03100196	chr7:143077761	ZYX	-0.42	-6.92	-0.31	1.49e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.11	-0.49	1.58e-29	Height;
LGG	cis	rs8114671	0.836	rs17404569	chr20:33674077	A/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.01	-0.42	1.8e-21	Bipolar disorder;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.44	-0.47	7.36e-27	Obesity-related traits;
LGG	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg07245641	chr1:182991651	LAMC1	0.41	9.53	0.4	8.85e-20	Hypertriglyceridemia;
LGG	trans	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg02023728	chr11:77925099	USP35	0.45	8.02	0.35	8.43e-15	Testicular germ cell tumor;
LGG	cis	rs2274273	0.682	rs10145268	chr14:55504514	T/C	cg04306507	chr14:55594613	LGALS3	0.43	10.73	0.45	4.01e-24	Protein biomarker;
LGG	cis	rs10743315	0.732	rs7299776	chr12:19442572	G/C	cg02471346	chr12:19282374	PLEKHA5	0.65	7.25	0.32	1.74e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.56	-0.47	2.57e-27	Tonsillectomy;
LGG	cis	rs4363385	0.720	rs1338178	chr1:152981550	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.03	-0.39	4.64e-18	Inflammatory skin disease;
LGG	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg18198730	chr1:247681584	NA	0.73	12.28	0.5	3.21e-30	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13191362	1.000	rs13213408	chr6:162998049	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg19847130	chr8:10466454	RP1L1	0.34	7.46	0.33	4.41e-13	Neuroticism;
LGG	cis	rs7917772	0.503	rs2031601	chr10:104308064	T/G	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.53e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9398803	0.678	rs9372841	chr6:126898541	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.69e-20	Male-pattern baldness;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg14926445	chr8:58193284	C8orf71	0.82	10.58	0.44	1.4e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2820315	0.867	rs2819348	chr1:201884952	T/C	cg10061532	chr1:201886748	LMOD1	0.32	6.66	0.3	7.75e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.48e-12	Retinal vascular caliber;
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.47	-0.33	3.96e-13	Bipolar disorder;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20879576	chr11:125034747	PKNOX2	0.45	7.19	0.32	2.59e-12	Cognitive performance;
LGG	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6500395	1.000	rs3826174	chr16:48591012	T/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg27532560	chr4:187881888	NA	-0.6	-13.05	-0.52	2.39e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4917300	0.606	rs1492367	chr8:143103498	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.9	-0.31	1.76e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs12410462	0.636	rs1495849	chr1:227736363	G/A	cg04117972	chr1:227635322	NA	0.48	8.9	0.38	1.23e-17	Major depressive disorder;
LGG	cis	rs151997	0.925	rs27260	chr5:50166696	C/T	cg06027927	chr5:50259733	NA	0.68	11.26	0.46	3.59e-26	Callous-unemotional behaviour;
LGG	cis	rs537930	0.961	rs674079	chr5:134349342	T/G	cg24576358	chr5:134350122	NA	0.49	10.32	0.43	1.33e-22	Height;
LGG	cis	rs11270836	1	rs11270836	chr4:38625915	T/TACATTATGTCATTTCACA	cg18361445	chr4:38666374	KLF3;FLJ13197	0.47	7.67	0.34	9.92e-14	Mumps;
LGG	cis	rs1665650	0.957	rs1638421	chr10:118488715	C/G	cg14919929	chr10:118506882	NA	0.49	8.61	0.37	1.15e-16	Colorectal cancer;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg11517789	chr2:97402180	LMAN2L	-0.45	-7.02	-0.31	8.09e-12	Apolipoprotein A-IV levels;
LGG	cis	rs7107174	1.000	rs10899460	chr11:78010080	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs7770628	0.589	rs1406888	chr6:161091593	C/T	cg04181478	chr6:161122748	PLG	-0.41	-8.02	-0.35	8.79e-15	Protein quantitative trait loci;Lipoprotein (a) levels;
LGG	cis	rs2201728	0.702	rs28364311	chr4:100205829	T/G	cg07219303	chr4:100140905	ADH6	-0.36	-6.66	-0.3	7.89e-11	Cardiac Troponin-T levels;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg12708336	chr17:41446283	NA	-0.31	-7.0	-0.31	9.15e-12	Menopause (age at onset);
LGG	cis	rs4356203	0.905	rs7930058	chr11:17066618	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.31	-0.32	1.19e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg23815491	chr16:72088622	HP	0.49	10.68	0.44	5.83e-24	Fibrinogen levels;
LGG	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg12165864	chr7:66369176	NA	-0.55	-8.7	-0.37	6.05e-17	Corneal structure;
LGG	cis	rs9300255	0.722	rs12304248	chr12:123810425	C/T	cg00376283	chr12:123451042	ABCB9	-0.56	-8.67	-0.37	7.06e-17	Neutrophil percentage of white cells;
LGG	cis	rs988958	0.526	rs13424176	chr2:42239532	A/G	cg19376973	chr2:42229025	NA	0.63	9.43	0.4	1.97e-19	Hypospadias;
LGG	cis	rs7089973	0.604	rs10885620	chr10:116630048	A/T	cg08188268	chr10:116634841	FAM160B1	0.31	6.85	0.3	2.29e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs975739	0.657	rs6563028	chr13:78605496	A/T	cg07847733	chr13:78271382	SLAIN1	0.46	7.89	0.34	2.14e-14	Hair color;
LGG	cis	rs919433	0.927	rs13032495	chr2:198189346	C/T	cg00792783	chr2:198669748	PLCL1	-0.47	-7.28	-0.32	1.41e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.78	0.3	3.78e-11	Longevity;
LGG	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.57e-13	Refractive error;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg07701084	chr6:150067640	NUP43	0.64	12.31	0.5	2.54e-30	Lung cancer;
LGG	cis	rs6028335	0.867	rs6028261	chr20:37699572	A/T	cg16355469	chr20:37678765	NA	0.57	7.37	0.32	7.88e-13	Alcohol and nicotine co-dependence;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg11062466	chr8:58055876	NA	0.51	8.12	0.35	4.28e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1023500	0.505	rs134891	chr22:42675882	T/C	cg05082376	chr22:42548792	NA	-0.39	-8.28	-0.36	1.29e-15	Schizophrenia;
LGG	cis	rs2228479	0.850	rs117880578	chr16:89910230	C/G	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs6121246	0.609	rs6060955	chr20:30385071	A/G	cg13852791	chr20:30311386	BCL2L1	0.93	17.84	0.64	1.47e-54	Mean corpuscular hemoglobin;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.27	0.32	1.58e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9815354	0.812	rs111277902	chr3:41950312	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2836974	0.965	rs8131126	chr21:40655754	A/G	cg11644478	chr21:40555479	PSMG1	0.89	16.84	0.62	5.63e-50	Cognitive function;
LGG	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-9.17	-0.39	1.52e-18	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg16606324	chr3:10149918	C3orf24	0.55	7.29	0.32	1.36e-12	Alzheimer's disease;
LGG	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg16127683	chr15:40268777	EIF2AK4	-0.85	-9.27	-0.4	6.88e-19	Corneal curvature;
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	-0.42	-6.66	-0.3	7.62e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7312933	0.669	rs7974476	chr12:42542484	C/A	cg19980929	chr12:42632907	YAF2	0.37	8.19	0.36	2.62e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.26	-0.32	1.63e-12	Iron status biomarkers;
LGG	cis	rs1707322	0.929	rs785513	chr1:46538320	T/C	cg03146154	chr1:46216737	IPP	-0.56	-10.15	-0.43	5.27e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg09998033	chr7:158218633	PTPRN2	-0.56	-10.41	-0.44	6.28e-23	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.54e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs12949688	0.600	rs10083861	chr17:55838072	C/T	cg12582317	chr17:55822272	NA	0.47	10.78	0.45	2.62e-24	Schizophrenia;
LGG	cis	rs17767392	0.788	rs7156194	chr14:71698616	C/A	cg02058870	chr14:72053146	SIPA1L1	0.35	6.93	0.31	1.42e-11	Mitral valve prolapse;
LGG	cis	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg13385794	chr1:248469461	NA	0.46	7.85	0.34	2.82e-14	Common traits (Other);
LGG	cis	rs72945132	0.619	rs34552378	chr11:70243208	C/T	cg13802316	chr11:70253460	CTTN	-0.68	-9.15	-0.39	1.89e-18	Coronary artery disease;
LGG	cis	rs10818894	0.611	rs10117455	chr9:126692599	G/T	cg16191174	chr9:126692580	DENND1A	0.62	8.95	0.38	8.31e-18	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LGG	cis	rs78366141	0.649	rs76273989	chr4:89730737	C/A	cg01026744	chr4:89619053	NAP1L5;HERC3	1.1	8.93	0.38	1.04e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.6	-8.94	-0.38	9.25e-18	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	9.09e-48	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg12046867	chr14:103022105	NA	-0.76	-13.08	-0.52	1.68e-33	Platelet count;
LGG	cis	rs6815814	0.950	rs11722889	chr4:38810975	C/T	cg06935464	chr4:38784597	TLR10	0.6	8.2	0.36	2.32e-15	Breast cancer;
LGG	cis	rs1816752	0.870	rs9581027	chr13:24997928	G/A	cg22771759	chr13:24902376	NA	0.42	7.22	0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg12458913	chr13:53173898	NA	0.63	12.29	0.5	3.09e-30	Lewy body disease;
LGG	trans	rs7937682	0.575	rs34558891	chr11:111737912	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs12908161	1.000	rs12905057	chr15:85210765	A/G	cg24253500	chr15:84953950	NA	0.42	6.97	0.31	1.09e-11	Schizophrenia;
LGG	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg18128536	chr17:47092178	IGF2BP1	-0.41	-8.08	-0.35	5.49e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs12681287	0.604	rs7017716	chr8:87429001	A/C	cg27223183	chr8:87520930	FAM82B	-0.51	-7.87	-0.34	2.53e-14	Caudate activity during reward;
LGG	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg23825213	chr18:77623475	KCNG2	-0.4	-7.01	-0.31	8.2e-12	Schizophrenia;
LGG	cis	rs4959677	0.662	rs4959186	chr6:2477763	T/G	cg20147862	chr6:2634573	C6orf195	-0.38	-8.37	-0.36	7.08e-16	Orthostatic hypotension;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg06494592	chr3:125709126	NA	-0.57	-7.26	-0.32	1.59e-12	Blood pressure (smoking interaction);
LGG	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs8048589	0.750	rs12926900	chr16:12184084	C/G	cg02910054	chr16:12241554	SNX29	0.41	7.05	0.31	6.5e-12	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.21	-0.43	3.42e-22	Bladder cancer;
LGG	cis	rs2439831	0.867	rs7170489	chr15:43636651	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.555	rs11182202	chr12:38476451	C/G	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4919087	0.651	rs12240590	chr10:99072066	C/G	cg25902810	chr10:99078978	FRAT1	-0.42	-7.26	-0.32	1.68e-12	Monocyte count;
LGG	cis	rs757081	0.579	rs11024221	chr11:17274550	T/A	cg15432903	chr11:17409602	KCNJ11	-0.43	-7.95	-0.35	1.44e-14	Systolic blood pressure;
LGG	cis	rs9443645	0.527	rs9343861	chr6:79744868	C/A	cg18132916	chr6:79620363	NA	-0.27	-7.07	-0.31	5.69e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	0.967	rs6456732	chr6:26514445	T/C	cg09904177	chr6:26538194	HMGN4	0.78	18.09	0.64	9.69e-56	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.616	rs7660064	chr4:185617529	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg17376030	chr22:41985996	PMM1	0.54	9.0	0.39	6.08e-18	Vitiligo;
LGG	cis	rs8114671	0.562	rs8117491	chr20:33510120	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.02	0.31	8.09e-12	Height;
LGG	cis	rs4740619	0.511	rs3008731	chr9:16003441	G/A	cg14451791	chr9:16040625	NA	-0.43	-11.65	-0.48	1.06e-27	Body mass index;
LGG	cis	rs2764208	0.526	rs2814997	chr6:34622991	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.49	-0.33	3.56e-13	Systemic lupus erythematosus;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18393173	chr6:34856135	ANKS1A;TAF11	-0.46	-7.61	-0.33	1.51e-13	Body fat percentage;
LGG	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-14.92	-0.57	2.24e-41	Colorectal cancer;
LGG	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg17201900	chr20:34330562	RBM39	0.51	6.92	0.31	1.47e-11	Total cholesterol levels;
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg13047869	chr3:10149882	C3orf24	0.54	8.98	0.39	6.63e-18	Alzheimer's disease;
LGG	cis	rs7589342	0.628	rs62152201	chr2:106411664	C/T	cg16077055	chr2:106428750	NCK2	0.3	7.23	0.32	1.99e-12	Addiction;
LGG	cis	rs1707322	1.000	rs785470	chr1:46519622	C/A	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	8.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2204008	0.774	rs11180977	chr12:38263094	G/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs4740619	0.836	rs1891211	chr9:15900709	C/G	cg14451791	chr9:16040625	NA	-0.39	-10.08	-0.42	1.01e-21	Body mass index;
LGG	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg26384229	chr12:38710491	ALG10B	-0.8	-18.15	-0.64	5.21e-56	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18805835	chr5:138775054	DNAJC18	0.46	7.03	0.31	7.23e-12	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.697	rs6088857	chr20:30226764	G/C	cg21427119	chr20:30132790	HM13	-0.5	-8.26	-0.36	1.59e-15	Mean corpuscular hemoglobin;
LGG	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg07936489	chr17:37558343	FBXL20	1.0	15.52	0.58	5.07e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.882	rs61429272	chr3:10037320	G/C	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs2070997	0.756	rs11793941	chr9:133682085	C/A	cg13397898	chr9:133768931	QRFP	0.33	6.72	0.3	5.43e-11	Response to amphetamines;
LGG	cis	rs6909430	0.731	rs13203162	chr6:98614497	C/T	cg12860156	chr6:98744658	NA	-0.39	-6.95	-0.31	1.23e-11	Quantitative traits;
LGG	cis	rs9506514	0.712	rs11838795	chr13:21258328	T/C	cg27499820	chr13:21296301	IL17D	-0.24	-6.89	-0.3	1.87e-11	Coronary artery calcification;
LGG	trans	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg24247370	chr13:99142703	STK24	-0.37	-6.89	-0.3	1.8e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg26924012	chr15:45694286	SPATA5L1	1.03	21.09	0.7	1.08e-69	Homoarginine levels;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.6	-0.53	1.17e-35	Alzheimer's disease;
LGG	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.46	7.42	0.33	5.79e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7660520	0.524	rs4862100	chr4:183732709	G/T	cg09197432	chr4:183729176	NA	0.59	7.8	0.34	4.09e-14	Pediatric autoimmune diseases;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01742905	chr11:88071023	CTSC	0.39	7.24	0.32	1.87e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs208520	0.690	rs851465	chr6:66840293	G/A	cg07460842	chr6:66804631	NA	-0.97	-18.2	-0.65	3.3e-56	Exhaled nitric oxide output;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26676845	chr2:153280733	FMNL2	-0.41	-7.4	-0.33	6.27e-13	Apolipoprotein A-IV levels;
LGG	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg19539972	chr4:7069911	GRPEL1	0.67	10.01	0.42	1.76e-21	Monocyte percentage of white cells;
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg03175030	chr11:2018143	H19;MIR675	-0.59	-11.43	-0.47	7.74e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7937890	1.000	rs6486190	chr11:14401216	A/C	cg22961513	chr11:14280813	SPON1	-0.33	-7.97	-0.35	1.24e-14	Mitochondrial DNA levels;
LGG	cis	rs17253792	0.558	rs10083353	chr14:56066370	G/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.3	-0.5	2.85e-30	Putamen volume;
LGG	cis	rs2204008	0.627	rs10878488	chr12:38148666	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.75	0.71	8.55e-73	Bladder cancer;
LGG	cis	rs13191362	1.000	rs13220048	chr6:163004325	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg14520079	chr3:106825871	NA	-0.39	-6.82	-0.3	2.83e-11	Iris color (L* coordinate);
LGG	trans	rs9354308	0.764	rs2000386	chr6:66597937	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs10927875	0.501	rs61782229	chr1:16220118	G/A	cg21385522	chr1:16154831	NA	-0.94	-15.17	-0.58	1.81e-42	Dilated cardiomyopathy;
LGG	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg01028140	chr2:1542097	TPO	-0.58	-8.9	-0.38	1.27e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9549367	0.713	rs9549681	chr13:113829873	T/C	cg00898013	chr13:113819073	PROZ	-0.51	-10.02	-0.42	1.55e-21	Platelet distribution width;
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg08461457	chr11:2027003	NA	0.4	7.72	0.34	7.37e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06470251	chr20:60548479	NA	0.51	8.55	0.37	1.79e-16	Body mass index;
LGG	cis	rs12210905	0.688	rs72845028	chr6:27528408	T/C	cg15325629	chr6:28072465	NA	0.95	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg12438819	chr7:158236134	PTPRN2	0.31	8.34	0.36	8.52e-16	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg01206211	chr2:36825736	FEZ2	0.39	7.31	0.32	1.2e-12	Height;
LGG	cis	rs1978968	0.912	rs1110666	chr22:18457720	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.64	13.25	0.52	3.33e-34	Presence of antiphospholipid antibodies;
LGG	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg03433033	chr1:76189801	ACADM	0.8	14.03	0.55	1.62e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs801193	1.000	rs17566701	chr7:66193183	T/C	cg11764359	chr7:65958608	NA	0.61	10.14	0.43	5.69e-22	Aortic root size;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24441022	chr1:154946677	SHC1;CKS1B	0.41	7.18	0.32	2.82e-12	Menarche (age at onset);
LGG	cis	rs67478160	0.634	rs941475	chr14:104240618	A/C	cg26031613	chr14:104095156	KLC1	-0.43	-7.07	-0.31	5.77e-12	Schizophrenia;
LGG	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06481639	chr22:41940642	POLR3H	0.54	7.64	0.33	1.24e-13	Cannabis dependence symptom count;
LGG	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg23173402	chr1:227635558	NA	0.63	10.42	0.44	5.76e-23	Major depressive disorder;
LGG	cis	rs868036	1.000	rs9972436	chr15:68098027	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs6840360	0.593	rs4696287	chr4:152606723	C/T	cg22705602	chr4:152727874	NA	-0.36	-8.9	-0.38	1.24e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs8078723	0.714	rs9915252	chr17:38145088	C/G	cg17467752	chr17:38218738	THRA	-0.62	-11.2	-0.46	6e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg16473166	chr22:50639996	SELO	-0.53	-8.41	-0.36	5.16e-16	Obesity-related traits;
LGG	cis	rs644799	0.648	rs1016031	chr11:95473365	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.63	-12.45	-0.5	6.94e-31	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg15875120	chr10:15902605	FAM188A	0.4	7.36	0.32	8.26e-13	Obesity-related traits;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg16600119	chr3:129033604	NA	0.45	7.12	0.31	4.09e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs4974559	0.895	rs12646130	chr4:1330530	G/C	cg02980000	chr4:1222292	CTBP1	0.65	7.87	0.34	2.51e-14	Systolic blood pressure;
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg21171335	chr12:122356390	WDR66	0.28	7.6	0.33	1.64e-13	Mean corpuscular volume;
LGG	cis	rs897984	0.721	rs2305884	chr16:30970741	G/A	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs10905065	0.827	rs10752111	chr10:5837286	T/C	cg11519256	chr10:5708881	ASB13	0.41	7.06	0.31	6.08e-12	Menopause (age at onset);
LGG	cis	rs4700695	0.614	rs2561241	chr5:65206565	C/T	cg21114390	chr5:65439923	SFRS12	0.62	6.93	0.31	1.45e-11	Facial morphology (factor 19);
LGG	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg24675658	chr1:53192096	ZYG11B	0.5	10.22	0.43	3.12e-22	Monocyte count;
LGG	trans	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg12045294	chr17:78518616	RPTOR	-0.46	-7.16	-0.32	3.24e-12	Glycated hemoglobin levels;
LGG	trans	rs6601327	0.641	rs4129360	chr8:9573284	T/A	cg02002194	chr4:3960332	NA	0.39	7.11	0.31	4.57e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs8062405	0.722	rs3785354	chr16:28550667	C/T	cg16576597	chr16:28551801	NUPR1	0.44	10.47	0.44	3.58e-23	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4959677	0.725	rs1680832	chr6:2504051	G/C	cg20147862	chr6:2634573	C6orf195	-0.38	-8.42	-0.36	4.72e-16	Orthostatic hypotension;
LGG	cis	rs977987	0.806	rs7204984	chr16:75475520	G/C	cg03315344	chr16:75512273	CHST6	0.51	10.22	0.43	3.13e-22	Dupuytren's disease;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg09771049	chr17:66031798	KPNA2	-0.39	-6.68	-0.3	6.73e-11	Hematological and biochemical traits;
LGG	cis	rs7937682	0.564	rs1944116	chr11:111366792	A/C	cg09085632	chr11:111637200	PPP2R1B	0.65	10.98	0.45	4.37e-25	Primary sclerosing cholangitis;
LGG	cis	rs67311347	1.000	rs9822909	chr3:40457084	G/T	cg13683864	chr3:40499215	RPL14	-1.15	-24.32	-0.75	9.2e-85	Renal cell carcinoma;
LGG	trans	rs1032833	0.732	rs16866665	chr2:180025336	C/A	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs11734570	0.581	rs76682731	chr4:38586045	T/C	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.2	0.36	2.31e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs654950	0.783	rs639298	chr1:42001530	A/G	cg06885757	chr1:42089581	HIVEP3	-0.48	-10.93	-0.45	6.78e-25	Airway imaging phenotypes;
LGG	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	8.96	0.38	8.24e-18	Retinal vascular caliber;
LGG	trans	rs1493916	0.837	rs1027332	chr18:31410097	A/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs10463554	0.927	rs257316	chr5:102422443	A/G	cg23492399	chr5:102201601	PAM	0.52	7.77	0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs7084402	0.967	rs7098606	chr10:60277089	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.28	-0.63	5.43e-52	Refractive error;
LGG	cis	rs3767633	0.925	rs6427633	chr1:161849569	C/T	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.62e-18	IgG glycosylation;
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.27	-0.32	1.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.539	rs1533827	chr7:2074290	A/G	cg02743256	chr7:2109353	MAD1L1	0.33	6.89	0.3	1.83e-11	Bipolar disorder;
LGG	cis	rs7659604	1.000	rs6816071	chr4:122665185	G/A	cg20573242	chr4:122745356	CCNA2	0.42	7.7	0.34	8.31e-14	Type 2 diabetes;
LGG	cis	rs755249	0.567	rs3818806	chr1:39748271	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.43	0.33	5.22e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1878931	0.858	rs3760083	chr16:3450052	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.93	-19.39	-0.67	9.38e-62	Body mass index (adult);
LGG	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg19748678	chr4:122722346	EXOSC9	0.68	13.77	0.54	2.18e-36	Type 2 diabetes;
LGG	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00204512	chr16:28754710	NA	0.25	7.22	0.32	2.12e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.38	-0.32	7.47e-13	Alzheimer's disease (late onset);
LGG	cis	rs12282928	1.000	rs10769338	chr11:48294256	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.12	-0.31	4.22e-12	Migraine - clinic-based;
LGG	trans	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg21659725	chr3:3221576	CRBN	-0.45	-7.42	-0.33	5.51e-13	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs3767633	0.858	rs4300199	chr1:161852057	A/G	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg15485101	chr11:133734466	NA	0.49	8.46	0.37	3.46e-16	Childhood ear infection;
LGG	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg01221209	chr5:554886	NA	-0.47	-6.8	-0.3	3.32e-11	Obesity-related traits;
LGG	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-7.82	-0.34	3.69e-14	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs763121	0.785	rs5757199	chr22:39040617	T/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg08648136	chr8:956695	NA	0.42	8.77	0.38	3.39e-17	Schizophrenia;
LGG	cis	rs1707322	0.682	rs3014241	chr1:46087879	A/G	cg03146154	chr1:46216737	IPP	-0.58	-10.98	-0.45	4.37e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs11874712	0.507	rs7239525	chr18:43654033	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.22	-0.39	1.08e-18	Migraine - clinic-based;
LGG	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.32	-0.36	1.03e-15	Neuroticism;
LGG	cis	rs2455826	1.000	rs2471806	chr3:15674587	A/G	cg16303742	chr3:15540471	COLQ	0.41	7.02	0.31	8.16e-12	Inflammatory skin disease;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg05863683	chr7:1912471	MAD1L1	-0.44	-8.61	-0.37	1.19e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4423214	0.918	rs11233789	chr11:71181085	A/G	cg05163923	chr11:71159392	DHCR7	0.73	14.18	0.55	3.58e-38	Vitamin D levels;
LGG	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.21	-0.36	2.17e-15	Restless legs syndrome;
LGG	trans	rs2270927	0.510	rs34596551	chr5:75577143	C/T	cg13563193	chr19:33072644	PDCD5	0.87	10.31	0.43	1.39e-22	Mean corpuscular volume;
LGG	cis	rs1670533	0.932	rs11731289	chr4:1057773	T/G	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.67	-0.3	7.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8058578	1.000	rs3747481	chr16:30666367	C/T	cg02466173	chr16:30829666	NA	-0.55	-9.91	-0.42	4.1e-21	Multiple myeloma;
LGG	cis	rs1920116	0.778	rs12492588	chr3:169558711	T/A	cg08193579	chr3:169529701	LRRC34	0.42	7.28	0.32	1.47e-12	Glioma (high-grade);
LGG	cis	rs701145	0.585	rs357468	chr3:153898560	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.55	0.37	1.77e-16	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg20607798	chr8:58055168	NA	0.57	6.86	0.3	2.26e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.704	rs798503	chr7:2789704	G/A	cg19717773	chr7:2847554	GNA12	-0.38	-8.78	-0.38	3.18e-17	Height;
LGG	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs11122272	0.735	rs2739507	chr1:231527329	T/C	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.27e-13	Hemoglobin concentration;
LGG	cis	rs9747201	1.000	rs4597372	chr17:80175444	G/A	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs853679	0.517	rs1904840	chr6:28108232	C/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.43e-11	Depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02784848	chr19:50316878	FUZ	0.43	7.2	0.32	2.44e-12	Gut microbiome composition (summer);
LGG	cis	rs559928	0.606	rs55942618	chr11:63936005	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.54	0.33	2.43e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7618915	0.547	rs11720432	chr3:52672742	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.68	0.41	2.71e-20	Bipolar disorder;
LGG	cis	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.33e-17	Mean corpuscular volume;
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg09303159	chr6:26284866	NA	0.36	8.18	0.36	2.83e-15	Educational attainment;
LGG	cis	rs12681287	0.640	rs12544463	chr8:87481114	A/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs2455601	1.000	rs7104661	chr11:8902501	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-9.92	-0.42	3.78e-21	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg08621203	chr6:150244597	RAET1G	0.47	8.26	0.36	1.51e-15	Lung cancer;
LGG	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.22	-0.32	2.12e-12	Mean corpuscular hemoglobin;
LGG	cis	rs919433	0.783	rs2565165	chr2:198233575	T/G	cg00792783	chr2:198669748	PLCL1	0.46	7.31	0.32	1.22e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs72781680	0.660	rs72780104	chr2:23983715	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs2229238	0.868	rs72999415	chr1:154513712	C/T	cg10237817	chr1:154519846	TDRD10	0.35	6.98	0.31	1.04e-11	Coronary heart disease;
LGG	cis	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg13010199	chr12:38710504	ALG10B	0.68	13.11	0.52	1.3e-33	Bladder cancer;
LGG	cis	rs7649275	0.882	rs877257	chr3:53784503	A/G	cg21503701	chr3:53781065	CACNA1D	-0.41	-6.77	-0.3	3.87e-11	Trans fatty acid levels;
LGG	cis	rs10193935	1.000	rs10190326	chr2:42388262	A/C	cg27598129	chr2:42591480	NA	0.6	8.92	0.38	1.07e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs977987	0.778	rs34222958	chr16:75398252	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26597500	chr13:73356092	PIBF1;DIS3	0.41	6.75	0.3	4.43e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4595586	1.000	rs3803020	chr12:39233771	A/G	cg26384229	chr12:38710491	ALG10B	-0.42	-7.38	-0.32	7.48e-13	Morning vs. evening chronotype;
LGG	cis	rs9527	0.545	rs7915816	chr10:104881750	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs2171564	0.537	rs9815847	chr3:112439054	G/A	cg06685282	chr3:112453648	NA	0.62	11.46	0.47	6.17e-27	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs950169	0.881	rs4842852	chr15:84941961	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.69	0.37	6.23e-17	Schizophrenia;
LGG	trans	rs2161208	0.565	rs2974084	chr5:85346713	T/C	cg01787110	chr1:109008453	NBPF6	0.44	6.66	0.3	7.58e-11	Daytime sleep phenotypes;
LGG	trans	rs9393777	0.513	rs6913660	chr6:27091425	C/A	cg06606381	chr12:133084897	FBRSL1	-0.6	-7.16	-0.32	3.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04530015	chr2:215796436	ABCA12	-0.45	-7.69	-0.34	9.02e-14	Neuroblastoma;
LGG	cis	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg06521331	chr12:34319734	NA	-0.41	-7.3	-0.32	1.25e-12	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.26	0.43	2.25e-22	Prudent dietary pattern;
LGG	cis	rs1719271	0.831	rs2630502	chr15:65188903	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.94	-0.31	1.3e-11	Platelet count;
LGG	cis	rs2455601	0.638	rs2742478	chr11:8996099	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-11.13	-0.46	1.21e-25	Schizophrenia;
LGG	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs910316	0.935	rs175076	chr14:75505486	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-11.01	-0.46	3.22e-25	Height;
LGG	cis	rs7638909	0.512	rs6804918	chr3:38598956	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-7.67	-0.34	1.03e-13	Electrocardiographic conduction measures;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.49	-0.37	2.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7582720	1.000	rs72926787	chr2:203818299	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg13939156	chr17:80058883	NA	0.44	7.77	0.34	5.23e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9309473	0.948	rs11884776	chr2:73746923	C/T	cg20560298	chr2:73613845	ALMS1	-0.48	-7.94	-0.35	1.55e-14	Metabolite levels;
LGG	cis	rs12765878	1.000	rs3850671	chr10:105659387	T/C	cg11005552	chr10:105648138	OBFC1	1.04	26.78	0.78	4.04e-96	Coronary artery disease;
LGG	cis	rs999943	0.846	rs10947420	chr6:33611061	C/G	cg14003231	chr6:33640908	ITPR3	0.59	13.75	0.54	2.45e-36	Obesity (extreme);
LGG	cis	rs7614311	0.681	rs73119022	chr3:63979834	T/C	cg22134162	chr3:63841271	THOC7	-0.4	-7.15	-0.32	3.41e-12	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs514406	0.505	rs856721	chr1:53162156	C/A	cg16325326	chr1:53192061	ZYG11B	0.85	22.91	0.73	3.31e-78	Monocyte count;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg05165339	chr4:1420672	NA	-0.35	-8.99	-0.39	6.2e-18	Longevity;
LGG	cis	rs916888	0.779	rs199528	chr17:44843136	C/T	cg26656751	chr17:43910226	CRHR1	0.48	8.65	0.37	8.68e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9783347	0.857	rs2124374	chr11:18313911	A/C	cg15585147	chr11:18324498	HPS5	0.44	9.2	0.39	1.24e-18	Pancreatic cancer;
LGG	cis	rs2911132	0.660	rs754615	chr5:96086334	C/G	cg17330273	chr5:96107758	CAST;ERAP1	0.31	6.71	0.3	5.77e-11	Urate levels (BMI interaction);
LGG	cis	rs7508	0.512	rs3886398	chr8:17880616	T/C	cg18067069	chr8:17937731	ASAH1	-0.29	-6.76	-0.3	4.14e-11	Atrial fibrillation;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	9.9e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.73	-0.41	1.75e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg08847533	chr14:75593920	NEK9	0.49	9.0	0.39	6.06e-18	Height;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.68e-123	Prudent dietary pattern;
LGG	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg26384229	chr12:38710491	ALG10B	0.84	16.28	0.6	1.93e-47	Morning vs. evening chronotype;
LGG	cis	rs804280	0.638	rs36038176	chr8:11609995	C/T	cg12395012	chr8:11607386	GATA4	0.7	11.42	0.47	9.01e-27	Myopia (pathological);
LGG	cis	rs7119	0.717	rs12910951	chr15:77806797	A/G	cg10437265	chr15:77819839	NA	0.25	6.84	0.3	2.52e-11	Type 2 diabetes;
LGG	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14386496	chr4:66536463	EPHA5	-0.42	-7.01	-0.31	8.39e-12	Menarche (age at onset);
LGG	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg22348356	chr13:114891224	RASA3	0.37	7.17	0.32	2.9e-12	Schizophrenia;
LGG	cis	rs2404602	0.716	rs284895	chr15:76751225	C/G	cg15268244	chr15:77196840	NA	0.33	7.36	0.32	8.25e-13	Blood metabolite levels;
LGG	cis	rs12999616	0.817	rs55933640	chr2:98328721	C/T	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.35	3.7e-15	Colorectal cancer;
LGG	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg02820901	chr13:113351484	ATP11A	0.59	7.12	0.31	4.26e-12	Glycated hemoglobin levels;
LGG	cis	rs3862030	0.720	rs7341995	chr10:104223831	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.29	-0.43	1.71e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs2963155	0.518	rs72801090	chr5:142774692	C/T	cg17617527	chr5:142782415	NR3C1	0.96	12.67	0.51	8.96e-32	Breast cancer;
LGG	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg23788917	chr6:8435910	SLC35B3	-0.52	-9.02	-0.39	4.96e-18	Motion sickness;
LGG	cis	rs7737355	0.947	rs6883034	chr5:130920415	T/C	cg06307176	chr5:131281290	NA	0.57	9.32	0.4	4.77e-19	Life satisfaction;
LGG	cis	rs7924176	0.601	rs10824107	chr10:75961799	T/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.86	-0.3	2.23e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs2594989	0.943	rs77630528	chr3:11314041	A/G	cg01796438	chr3:11312864	ATG7	-0.61	-8.22	-0.36	2.12e-15	Circulating chemerin levels;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg10950524	chr7:2139216	MAD1L1	0.32	6.99	0.31	9.53e-12	Schizophrenia;
LGG	cis	rs10991814	0.844	rs58307373	chr9:94070782	T/C	cg14446406	chr9:93919335	NA	-0.66	-8.1	-0.35	4.88e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.860	rs55974219	chr4:185600733	G/A	cg04058563	chr4:185651563	MLF1IP	1.08	20.51	0.69	5.61e-67	Blood protein levels;
LGG	trans	rs12412942	1.000	rs12412942	chr10:2357702	C/T	cg06476344	chr2:26396290	FAM59B	0.43	7.05	0.31	6.44e-12	Schizophrenia;
LGG	cis	rs2274273	1.000	rs4644	chr14:55604935	C/A	cg04306507	chr14:55594613	LGALS3	0.61	17.0	0.62	1.01e-50	Protein biomarker;
LGG	cis	rs9314323	0.592	rs6981737	chr8:26271100	T/G	cg11498726	chr8:26250323	BNIP3L	-0.46	-9.87	-0.42	5.59e-21	Red cell distribution width;
LGG	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg02503808	chr4:7069936	GRPEL1	-0.77	-12.09	-0.49	1.96e-29	Monocyte percentage of white cells;
LGG	cis	rs1568889	0.838	rs10835276	chr11:28167147	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.28e-61	Bipolar disorder;
LGG	cis	rs5750830	0.594	rs6001568	chr22:39775786	G/A	cg04986931	chr22:39850128	NA	0.35	7.68	0.34	9.4e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7173743	1.000	rs11632020	chr15:79143759	C/T	cg00540400	chr15:79124168	NA	-0.43	-8.64	-0.37	9.17e-17	Coronary artery disease;
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg10935138	chr17:73851978	WBP2	0.73	10.71	0.45	4.78e-24	Psoriasis;
LGG	cis	rs11866815	0.602	rs60907769	chr16:380547	C/A	cg07915516	chr16:377344	AXIN1	-0.5	-11.37	-0.47	1.43e-26	Body mass index;
LGG	cis	rs7851660	0.967	rs10046805	chr9:100613956	G/A	cg13688889	chr9:100608707	NA	-0.69	-14.71	-0.56	1.9e-40	Strep throat;
LGG	cis	rs11074306	0.561	rs9806334	chr15:28071567	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs72945132	0.882	rs67244582	chr11:70122009	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.62	0.33	1.49e-13	Coronary artery disease;
LGG	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg08999081	chr20:33150536	PIGU	0.44	11.5	0.47	4.28e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs2727020	0.634	rs11040331	chr11:49345726	T/C	cg03929089	chr4:120376271	NA	-0.77	-11.41	-0.47	9.55e-27	Coronary artery disease;
LGG	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg02269571	chr22:50332266	NA	-0.65	-9.74	-0.41	1.63e-20	Schizophrenia;
LGG	cis	rs9534288	0.762	rs9534292	chr13:46611340	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs240764	0.612	rs2157342	chr6:100920655	A/T	cg21058520	chr6:100914733	NA	-0.46	-8.05	-0.35	7.11e-15	Neuroticism;
LGG	cis	rs7107174	1.000	rs7111986	chr11:78102266	G/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.64	-0.33	1.28e-13	Testicular germ cell tumor;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.12	-0.35	4.19e-15	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs969422	chr6:8451780	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs10463316	0.894	rs7707745	chr5:150765198	G/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.27	-0.43	2e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6450176	0.909	rs255755	chr5:53307772	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.03	-0.46	2.87e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs28595532	0.841	rs114123875	chr4:119733408	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg05091796	chr16:4465799	CORO7	0.63	9.71	0.41	2.12e-20	Schizophrenia;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg19318889	chr4:1322082	MAEA	0.47	8.13	0.35	4e-15	Longevity;
LGG	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	13.96	0.54	3.1e-37	Menarche (age at onset);
LGG	cis	rs10861342	1.000	rs115224406	chr12:105578060	C/T	cg23923672	chr12:105501055	KIAA1033	0.83	7.33	0.32	1.07e-12	IgG glycosylation;
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.87	-0.3	2.11e-11	Menopause (age at onset);
LGG	trans	rs9650657	0.617	rs28680211	chr8:10519445	T/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.77	-0.34	5.22e-14	Neuroticism;
LGG	trans	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg25214090	chr10:38739885	LOC399744	0.46	8.27	0.36	1.4e-15	Diastolic blood pressure;
LGG	cis	rs9326248	0.813	rs474488	chr11:117068977	A/G	cg20608306	chr11:116969690	SIK3	0.31	6.83	0.3	2.68e-11	Blood protein levels;
LGG	cis	rs1865760	0.532	rs2794719	chr6:26088890	T/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.66	0.41	3.21e-20	Height;
LGG	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg17971929	chr21:40555470	PSMG1	-0.67	-12.25	-0.49	4.33e-30	Cognitive function;
LGG	cis	rs7267979	1.000	rs6515651	chr20:25414539	T/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.14	-0.43	6.11e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg02219949	chr17:45927392	SP6	0.45	7.6	0.33	1.68e-13	Ease of getting up in the morning;
LGG	cis	rs12048904	0.505	rs4517368	chr1:101255052	C/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.42	-7.53	-0.33	2.74e-13	Multiple sclerosis;
LGG	cis	rs9460578	0.561	rs6913323	chr6:20891190	A/T	cg13405222	chr6:20811065	CDKAL1	-0.56	-9.85	-0.42	6.75e-21	Breast cancer;
LGG	cis	rs868036	0.718	rs4776985	chr15:68123021	T/G	cg05925327	chr15:68127851	NA	-0.37	-7.73	-0.34	6.82e-14	Restless legs syndrome;
LGG	cis	rs62025270	0.632	rs62022943	chr15:86259470	G/T	cg25843651	chr15:86329602	KLHL25	0.58	9.0	0.39	6.05e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs9814567	0.752	rs9846111	chr3:134335034	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.96	-0.45	5.38e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7614311	0.681	rs3774708	chr3:63881549	A/C	cg22134162	chr3:63841271	THOC7	-0.45	-8.08	-0.35	5.65e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs11920090	0.800	rs12486657	chr3:170738349	T/A	cg09710316	chr3:170744871	SLC2A2	0.64	8.75	0.38	3.86e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg14500267	chr11:67383377	NA	-0.41	-7.43	-0.33	5.4e-13	Mean corpuscular volume;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	10.57	0.44	1.57e-23	Longevity;
LGG	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg03929089	chr4:120376271	NA	-0.62	-7.89	-0.34	2.2e-14	Axial length;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg03709012	chr19:19516395	GATAD2A	0.81	15.51	0.58	5.49e-44	Tonsillectomy;
LGG	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.32	-0.36	1.02e-15	Morning vs. evening chronotype;
LGG	cis	rs561341	0.941	rs8066558	chr17:30272879	G/T	cg13647721	chr17:30228624	UTP6	0.61	8.01	0.35	9.67e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2380220	0.606	rs4571572	chr6:96004823	T/C	cg15832292	chr6:96025679	MANEA	0.51	7.02	0.31	7.86e-12	Behavioural disinhibition (generation interaction);
LGG	cis	rs679087	0.606	rs302344	chr12:29940953	A/G	cg14258853	chr12:29935411	TMTC1	0.4	6.86	0.3	2.27e-11	Schizophrenia;
LGG	cis	rs35110281	0.501	rs162381	chr21:44920915	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-7.92	-0.35	1.75e-14	Mean corpuscular volume;
LGG	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg03929089	chr4:120376271	NA	-0.88	-15.59	-0.59	2.37e-44	Coronary artery disease;
LGG	cis	rs240764	0.507	rs9404022	chr6:101199726	T/C	cg09795085	chr6:101329169	ASCC3	0.44	7.07	0.31	5.81e-12	Neuroticism;
LGG	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.63	0.33	1.35e-13	Neuroticism;
LGG	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07570687	chr10:102243282	WNT8B	0.41	7.06	0.31	6.22e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35110281	0.720	rs162400	chr21:44950305	A/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.73	-0.38	4.79e-17	Mean corpuscular volume;
LGG	cis	rs1978968	0.556	rs5992962	chr22:18486282	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-10.47	-0.44	3.55e-23	Presence of antiphospholipid antibodies;
LGG	cis	rs9783347	0.621	rs4150678	chr11:18384170	C/G	cg15585147	chr11:18324498	HPS5	0.31	7.02	0.31	7.83e-12	Pancreatic cancer;
LGG	cis	rs1862618	0.573	rs832532	chr5:56221938	T/C	cg12402800	chr5:56204917	C5orf35	-0.44	-6.86	-0.3	2.2e-11	Initial pursuit acceleration;
LGG	cis	rs9611198	0.755	rs5757719	chr22:39945791	T/C	cg03390717	chr22:39966585	CACNA1I	0.33	6.91	0.31	1.57e-11	Schizophrenia;
LGG	cis	rs7424096	0.613	rs17332671	chr2:37244124	C/G	cg14987922	chr2:37194071	STRN	0.46	6.83	0.3	2.72e-11	High light scatter reticulocyte percentage of red cells;
LGG	trans	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-11.51	-0.47	3.93e-27	Platelet distribution width;
LGG	cis	rs6032067	0.929	rs56168207	chr20:43803971	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs13177180	0.777	rs6892071	chr5:114847795	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.37	-8.05	-0.35	7.25e-15	Conotruncal heart defects (inherited effects);
LGG	cis	rs7119	0.717	rs12916642	chr15:77818426	G/T	cg10437265	chr15:77819839	NA	0.25	7.01	0.31	8.53e-12	Type 2 diabetes;
LGG	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg08603382	chr10:743973	NA	-0.37	-6.65	-0.3	8.11e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs9443645	0.901	rs9448580	chr6:79551812	C/G	cg18132916	chr6:79620363	NA	-0.31	-8.56	-0.37	1.68e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7648466	1.000	rs7648466	chr3:46187522	C/T	cg12441928	chr3:46249985	CCR1	0.54	9.7	0.41	2.26e-20	Eotaxin levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10592090	chr5:34915808	RAD1;BRIX1	-0.43	-6.8	-0.3	3.31e-11	Pancreatic cancer;
LGG	cis	rs734999	0.505	rs10797437	chr1:2539006	T/C	cg15627072	chr1:2432621	PLCH2	0.32	7.03	0.31	7.42e-12	Ulcerative colitis;
LGG	cis	rs9378357	0.850	rs7770256	chr6:3294153	G/A	cg08754725	chr6:3293098	SLC22A23	-0.8	-8.0	-0.35	1.02e-14	Obesity-related traits;
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg19524238	chr7:2802976	GNA12	0.42	9.71	0.41	2.06e-20	Height;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg24690094	chr11:67383802	NA	-0.55	-9.45	-0.4	1.65e-19	Mean corpuscular volume;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13910583	chr8:56987998	RPS20	0.34	6.92	0.31	1.52e-11	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.845	rs3102559	chr17:28029723	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg11266682	chr4:10021025	SLC2A9	0.57	11.66	0.48	9.85e-28	Bone mineral density;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	trans	rs6956675	0.831	rs4718878	chr7:62656497	T/C	cg01314568	chr7:57830625	NA	-0.48	-7.79	-0.34	4.3e-14	Obesity-related traits;
LGG	cis	rs2692947	0.655	rs4605406	chr2:96583735	A/C	cg22654517	chr2:96458247	NA	0.39	7.71	0.34	7.57e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.45	-7.78	-0.34	4.61e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg23205692	chr1:25664452	TMEM50A	0.44	9.16	0.39	1.66e-18	Erythrocyte sedimentation rate;
LGG	cis	rs12410462	0.551	rs12070539	chr1:227865316	C/T	cg23173402	chr1:227635558	NA	0.35	6.65	0.3	8.38e-11	Major depressive disorder;
LGG	cis	rs4704187	0.687	rs12653162	chr5:74391666	C/T	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.49e-11	Response to amphetamines;
LGG	cis	rs17221829	0.614	rs10765236	chr11:89450030	G/A	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.66	-0.34	1.11e-13	Anxiety in major depressive disorder;
LGG	cis	rs2153535	0.601	rs2143352	chr6:8530248	G/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	trans	rs7395662	1.000	rs7483920	chr11:48599969	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.22	-0.32	2.09e-12	HDL cholesterol;
LGG	cis	rs244731	0.959	rs9313752	chr5:176645435	G/T	cg17509989	chr5:176798049	RGS14	-0.59	-8.37	-0.36	6.82e-16	Urate levels in lean individuals;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.24	0.49	4.84e-30	Colorectal cancer;
LGG	cis	rs3540	0.574	rs2256388	chr15:90969335	A/C	cg22089800	chr15:90895588	ZNF774	-0.69	-12.58	-0.5	2.03e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.0	0.42	1.91e-21	Height;
LGG	cis	rs240764	0.817	rs239239	chr6:101094554	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs7127900	0.614	rs11564708	chr11:2206326	C/G	cg04484994	chr11:2181039	INS-IGF2;INS	-0.45	-7.54	-0.33	2.48e-13	Prostate cancer;Prostate cancer (SNP x SNP interaction);Prostate cancer (early onset);
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.29	-8.36	-0.36	7.55e-16	IgG glycosylation;
LGG	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.44	0.63	9.61e-53	Chronic sinus infection;
LGG	cis	rs774359	0.744	rs700782	chr9:27526047	C/T	cg21249376	chr9:27528432	MOBKL2B	0.43	8.23	0.36	1.85e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg02389323	chr16:88786976	FAM38A	0.77	7.94	0.35	1.55e-14	Plateletcrit;
LGG	cis	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg00405596	chr8:11794950	NA	0.64	11.41	0.47	9.3e-27	Neuroticism;
LGG	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg18252515	chr7:66147081	NA	-0.69	-10.49	-0.44	3e-23	Corneal structure;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg11878867	chr6:150167359	LRP11	-0.49	-10.03	-0.42	1.48e-21	Lung cancer;
LGG	cis	rs4595586	0.545	rs7967295	chr12:39376866	G/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg16270222	chr17:41446396	NA	-0.31	-7.42	-0.33	5.48e-13	Menopause (age at onset);
LGG	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg08085267	chr17:45401833	C17orf57	0.59	11.76	0.48	4.13e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.73e-11	Migraine;Coronary artery disease;
LGG	cis	rs8133932	0.637	rs7283688	chr21:47301354	T/A	cg11214348	chr21:47283868	PCBP3	0.45	8.07	0.35	5.93e-15	Schizophrenia;
LGG	trans	rs11650494	0.908	rs79768864	chr17:47446968	C/A	cg11430096	chr6:110968061	CDK19	0.67	7.03	0.31	7.37e-12	Prostate cancer;
LGG	cis	rs1843834	0.505	rs3820763	chr2:225347270	A/G	cg22455342	chr2:225449267	CUL3	-0.87	-15.34	-0.58	3.07e-43	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01061025	chr1:212209225	INTS7;DTL	0.38	6.74	0.3	4.71e-11	Obesity-related traits;
LGG	cis	rs2235573	0.625	rs713991	chr22:38426043	A/G	cg19171272	chr22:38449367	NA	-0.55	-10.7	-0.45	5.22e-24	Glioblastoma;Glioma;
LGG	cis	rs9384488	0.524	rs9480379	chr6:157020791	A/G	cg08839808	chr6:156983304	NA	-0.45	-7.23	-0.32	2.06e-12	Alzheimer's disease biomarkers;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg20607798	chr8:58055168	NA	0.55	6.72	0.3	5.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg11941060	chr3:133502564	NA	-0.47	-8.05	-0.35	7.08e-15	Iron status biomarkers;
LGG	trans	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg02002194	chr4:3960332	NA	0.38	6.93	0.31	1.39e-11	Mood instability;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20808462	chr4:2243252	HAUS3	0.46	7.59	0.33	1.83e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg11901034	chr3:128598214	ACAD9	0.47	6.97	0.31	1.07e-11	IgG glycosylation;
LGG	cis	rs7523050	0.643	rs35050241	chr1:109404876	T/C	cg08274380	chr1:109419600	GPSM2	0.99	12.11	0.49	1.58e-29	Fat distribution (HIV);
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.84	16.35	0.61	9.01e-48	Lymphocyte counts;
LGG	cis	rs3784262	0.692	rs12907125	chr15:58282621	C/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.8	-0.3	3.17e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs700651	0.752	rs1850631	chr2:198829468	T/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Intracranial aneurysm;
LGG	cis	rs9457247	1.000	rs408080	chr6:167392522	T/C	cg07741184	chr6:167504864	NA	0.32	7.12	0.31	4.24e-12	Crohn's disease;
LGG	cis	rs2074585	0.708	rs2601190	chr15:90932966	A/C	cg22089800	chr15:90895588	ZNF774	0.69	12.8	0.51	2.51e-32	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.08	0.31	5.36e-12	Lung cancer;
LGG	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg08344181	chr3:125677491	NA	-0.65	-6.77	-0.3	3.89e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	trans	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.67	-0.37	7.21e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.56	0.37	1.64e-16	Aortic root size;
LGG	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg22232500	chr2:134024266	NCKAP5	-0.59	-8.55	-0.37	1.86e-16	Bipolar disorder;
LGG	cis	rs62238980	0.614	rs10483163	chr22:32459451	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs17021463	0.676	rs11097421	chr4:95302915	T/C	cg11021082	chr4:95130006	SMARCAD1	0.4	7.0	0.31	8.94e-12	Testicular germ cell tumor;
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.57	-7.21	-0.32	2.36e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs537930	0.925	rs627294	chr5:134353743	A/C	cg24576358	chr5:134350122	NA	0.43	8.88	0.38	1.43e-17	Height;
LGG	cis	rs6495367	0.898	rs2049176	chr15:79392548	A/C	cg17916960	chr15:79447300	NA	0.54	9.98	0.42	2.32e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg03160526	chr17:80928410	B3GNTL1	0.42	6.89	0.3	1.87e-11	Glycated hemoglobin levels;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.25	0.36	1.7e-15	Obesity-related traits;
LGG	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.42	-0.33	5.82e-13	Restless legs syndrome;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.66	-0.41	3.12e-20	Platelet count;
LGG	cis	rs6598955	0.670	rs3795688	chr1:26560481	C/A	cg04990556	chr1:26633338	UBXN11	-0.69	-13.98	-0.54	2.75e-37	Obesity-related traits;
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg11984989	chr7:158649758	WDR60	1.04	23.03	0.73	8.84e-79	Height;
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.75e-21	Schizophrenia;
LGG	cis	rs7937890	0.668	rs12361851	chr11:14267668	C/T	cg22961513	chr11:14280813	SPON1	0.29	6.92	0.31	1.48e-11	Mitochondrial DNA levels;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs7444	0.941	rs5754426	chr22:21980638	T/C	cg15846791	chr22:21984385	YDJC	-0.45	-6.77	-0.3	3.81e-11	Systemic lupus erythematosus;
LGG	cis	rs9867325	1.000	rs9840500	chr3:136621338	A/G	cg21827317	chr3:136751795	NA	-0.51	-7.41	-0.33	5.85e-13	Body mass index;
LGG	cis	rs2282802	0.685	rs6580473	chr5:139646962	C/T	cg26211634	chr5:139558579	C5orf32	-0.34	-7.16	-0.32	3.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.733	rs12277139	chr11:89389606	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs7444	0.941	rs5749502	chr22:21945096	T/A	cg22858872	chr22:21984481	YDJC	-0.37	-6.81	-0.3	3.08e-11	Systemic lupus erythematosus;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg13264159	chr8:625131	ERICH1	-0.99	-11.31	-0.47	2.34e-26	IgG glycosylation;
LGG	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg14346243	chr4:90757452	SNCA	-0.35	-7.1	-0.31	4.8e-12	Dementia with Lewy bodies;
LGG	cis	rs12618769	0.625	rs56240302	chr2:99148970	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.57	0.37	1.57e-16	Bipolar disorder;
LGG	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg10483660	chr13:112241077	NA	-0.35	-7.71	-0.34	7.81e-14	Hepatitis;
LGG	cis	rs477692	1.000	rs513736	chr10:131406489	C/T	cg05714579	chr10:131428358	MGMT	0.52	10.78	0.45	2.6e-24	Response to temozolomide;
LGG	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg02002194	chr4:3960332	NA	0.45	8.07	0.35	6.28e-15	Retinal vascular caliber;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg27467005	chr19:17622279	PGLS	0.45	7.83	0.34	3.41e-14	Lung adenocarcinoma;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg21775007	chr8:11205619	TDH	-0.41	-6.66	-0.3	7.67e-11	Joint mobility (Beighton score);
LGG	cis	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.66	0.41	3.01e-20	Joint mobility (Beighton score);
LGG	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.85	0.34	2.85e-14	Acne (severe);
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.67	12.3	0.5	2.66e-30	Obesity-related traits;
LGG	cis	rs11690935	0.632	rs12991740	chr2:172885996	C/T	cg13550731	chr2:172543902	DYNC1I2	0.72	14.66	0.56	2.9e-40	Schizophrenia;
LGG	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	cis	rs6933660	0.512	rs9383905	chr6:151804296	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	7.68	0.34	9.68e-14	Menarche (age at onset);
LGG	trans	rs11989744	1.000	rs34389484	chr8:23572963	T/G	cg03492747	chr16:86543808	FOXF1	0.52	7.78	0.34	4.83e-14	Waist-hip ratio;
LGG	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	2e-16	Body mass index;
LGG	cis	rs7113850	0.541	rs76005477	chr11:24233322	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	10.43	0.44	5.12e-23	Bone fracture in osteoporosis;
LGG	cis	rs4716602	0.596	rs10270517	chr7:156160010	A/G	cg16983916	chr7:156159713	NA	-0.49	-9.58	-0.41	5.92e-20	Anti-saccade response;
LGG	cis	rs3820068	0.705	rs72643683	chr1:15824905	C/A	cg05660106	chr1:15850417	CASP9	1.11	26.82	0.78	2.77e-96	Systolic blood pressure;
LGG	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.82	-0.34	3.57e-14	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2888674	1.000	rs2888674	chr7:150510915	G/A	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.25	6.69	0.3	6.5500000000000006e-11	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs6087990	0.735	rs1040555	chr20:31380201	A/T	cg13636640	chr20:31349939	DNMT3B	-0.8	-16.46	-0.61	2.94e-48	Ulcerative colitis;
LGG	cis	rs7264396	0.733	rs2425105	chr20:34312834	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.44	-7.9	-0.34	2.08e-14	Total cholesterol levels;
LGG	cis	rs60871478	0.898	rs35928069	chr7:823067	G/C	cg04727924	chr7:799746	HEATR2	-0.47	-7.16	-0.32	3.28e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg11871910	chr12:69753446	YEATS4	0.92	21.48	0.71	1.53e-71	Blood protein levels;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	cis	rs6763768	0.606	rs12490667	chr3:53293986	G/A	cg16894138	chr3:53270350	TKT	0.41	7.81	0.34	3.92e-14	Bacterial meningitis;
LGG	cis	rs7481584	0.624	rs375579	chr11:3065300	G/C	cg05729581	chr11:3078854	CARS	0.42	6.74	0.3	4.68e-11	Calcium levels;
LGG	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.06	0.39	3.71e-18	Blood metabolite levels;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04008888	chr11:68622739	NA	-0.55	-11.83	-0.48	2.19e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs12579753	0.830	rs12825476	chr12:82238350	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg13385794	chr1:248469461	NA	0.42	7.36	0.32	8.66e-13	Common traits (Other);
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs45544231	0.544	rs3112580	chr16:52571605	T/C	cg09051775	chr16:52580266	TOX3	-0.43	-7.15	-0.32	3.37e-12	Restless legs syndrome;
LGG	cis	rs4732038	0.967	rs2670234	chr7:134246371	G/A	cg06906464	chr7:134288099	NA	-0.51	-12.73	-0.51	4.65e-32	Longevity;
LGG	cis	rs209489	0.892	rs74663205	chr6:53114417	T/C	cg15607103	chr6:53167650	ELOVL5	0.59	7.23	0.32	1.96e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4819052	0.724	rs1304487	chr21:46657283	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.69	-12.1	-0.49	1.84e-29	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg11062466	chr8:58055876	NA	0.49	8.16	0.35	3.25e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs36071027	0.615	rs17643640	chr5:158407296	C/G	cg04248271	chr5:158524404	EBF1	0.41	7.32	0.32	1.13e-12	Carotid intima media thickness;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6750047	0.546	rs1367696	chr2:38286914	C/T	cg07380506	chr2:38303506	CYP1B1	0.47	7.89	0.34	2.13e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg00405596	chr8:11794950	NA	-0.42	-6.72	-0.3	5.27e-11	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20859525	chr6:80714300	TTK	0.5	8.08	0.35	5.51e-15	Gut microbiome composition (summer);
LGG	cis	rs6977660	0.943	rs6959678	chr7:19821759	C/A	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg19507638	chr5:93509721	C5orf36	-0.67	-9.37	-0.4	3.12e-19	Diabetic retinopathy;
LGG	cis	rs8177253	0.509	rs6762415	chr3:133478557	T/G	cg16414030	chr3:133502952	NA	-0.42	-7.12	-0.31	4.27e-12	Iron status biomarkers;
LGG	cis	rs2251666	0.514	rs17630889	chr16:4881209	C/G	cg04440724	chr16:4920505	UBN1	-0.62	-9.05	-0.39	4.04e-18	Cancer;
LGG	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs1062177	0.756	rs2915815	chr5:151115883	G/C	cg00977110	chr5:151150581	G3BP1	-0.47	-7.56	-0.33	2.21e-13	Preschool internalizing problems;
LGG	cis	rs611744	0.870	rs635941	chr8:109235457	G/A	cg21045802	chr8:109455806	TTC35	0.41	7.41	0.33	6.15e-13	Dupuytren's disease;
LGG	cis	rs4774899	0.966	rs6493901	chr15:57405451	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.38	-0.32	7.22e-13	Urinary tract infection frequency;
LGG	cis	rs6686643	0.629	rs9333464	chr1:165618717	A/G	cg19407955	chr1:165599744	MGST3	-0.55	-6.84	-0.3	2.54e-11	Total ventricular volume;
LGG	cis	rs6763768	0.814	rs998411	chr3:53519767	G/A	cg16894138	chr3:53270350	TKT	0.4	7.74	0.34	6.31e-14	Bacterial meningitis;
LGG	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs9467773	1.000	rs1884949	chr6:26568067	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.02	0.62	8.32e-51	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.554	rs34650360	chr15:91059017	T/C	cg22089800	chr15:90895588	ZNF774	-0.67	-12.25	-0.49	4.56e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2948294	0.524	rs13270062	chr8:8112650	C/A	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.1	-0.31	4.71e-12	Red cell distribution width;
LGG	cis	rs9527	0.830	rs3740392	chr10:104636855	T/C	cg04362960	chr10:104952993	NT5C2	0.63	11.05	0.46	2.28e-25	Arsenic metabolism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13619988	chr14:58894515	KIAA0586;TIMM9	0.4	7.06	0.31	6.14e-12	Cognitive performance;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.33e-17	Lung cancer;
LGG	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg16400903	chr5:693638	TPPP	0.45	6.75	0.3	4.33e-11	Obesity-related traits;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.59	0.33	1.74e-13	Obesity-related traits;
LGG	cis	rs10754283	0.901	rs10922683	chr1:90116068	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.16	-0.32	3.24e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs10504073	0.647	rs2292399	chr8:49987230	A/G	cg00325661	chr8:49890786	NA	0.75	14.62	0.56	4.51e-40	Blood metabolite ratios;
LGG	trans	rs17685	0.712	rs60232511	chr7:75800082	A/G	cg19862616	chr7:65841803	NCRNA00174	1.06	25.01	0.76	5.67e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.56	0.37	1.64e-16	Lung cancer;
LGG	cis	rs7619833	0.685	rs2370941	chr3:27292683	C/A	cg02860705	chr3:27208620	NA	0.4	7.57	0.33	1.99e-13	Breast cancer;
LGG	cis	rs61931739	0.592	rs815042	chr12:33724221	C/A	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg14338887	chr6:42928500	GNMT	0.27	8.87	0.38	1.62e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs68170813	0.523	rs11762152	chr7:106811374	G/A	cg02696742	chr7:106810147	HBP1	-0.78	-11.5	-0.47	4.38e-27	Coronary artery disease;
LGG	cis	rs9880211	0.752	rs9881831	chr3:136389718	T/C	cg21827317	chr3:136751795	NA	-0.48	-6.93	-0.31	1.46e-11	Body mass index;Height;
LGG	cis	rs1639906	1.000	rs1639906	chr7:2219966	T/C	cg20308403	chr7:2120281	MAD1L1	0.34	7.47	0.33	3.9e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12291225	0.679	rs11369	chr11:14288096	A/G	cg02886208	chr11:14281011	SPON1	-0.36	-6.95	-0.31	1.25e-11	Sense of smell;
LGG	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg09408571	chr1:101003634	GPR88	0.32	8.02	0.35	8.57e-15	Breast cancer;
LGG	cis	rs1015291	0.701	rs2417810	chr12:20008461	G/A	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs57590327	0.503	rs1524557	chr3:81892031	A/G	cg07356753	chr3:81810745	GBE1	-0.45	-7.18	-0.32	2.81e-12	Extraversion;
LGG	cis	rs4423214	1.000	rs12793530	chr11:71161656	G/A	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg04287289	chr16:89883240	FANCA	0.84	8.02	0.35	8.81e-15	Skin colour saturation;
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg13264159	chr8:625131	ERICH1	0.96	9.02	0.39	4.84e-18	IgG glycosylation;
LGG	cis	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg03476357	chr21:30257390	N6AMT1	0.58	8.8	0.38	2.66e-17	Cognitive test performance;
LGG	cis	rs9916302	0.706	rs7503081	chr17:37482673	A/G	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.97e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs62400317	0.826	rs62438867	chr6:45049787	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.55e-22	Total body bone mineral density;
LGG	cis	rs12802244	1	rs12802244	chr11:47932666	G/A	cg20307385	chr11:47447363	PSMC3	-0.52	-9.18	-0.39	1.49e-18	Neuroticism;
LGG	cis	rs7582180	0.700	rs1437971	chr2:100986964	A/C	cg05692746	chr2:100937584	LONRF2	-0.49	-6.66	-0.3	7.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2354432	0.607	rs2297752	chr1:146765454	C/G	cg25205988	chr1:146714368	CHD1L	-1.34	-15.69	-0.59	8.62e-45	Mitochondrial DNA levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19214477	chr19:34856139	GPI	0.41	7.18	0.32	2.74e-12	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg02002194	chr4:3960332	NA	-0.44	-8.23	-0.36	1.94e-15	Mood instability;
LGG	cis	rs42648	0.935	rs42664	chr7:89984409	A/G	cg25739043	chr7:89950458	NA	-0.38	-7.97	-0.35	1.24e-14	Homocysteine levels;
LGG	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-9.95	-0.42	2.85e-21	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23858410	chr22:46276678	NA	0.42	6.85	0.3	2.31e-11	Gut microbiome composition (summer);
LGG	cis	rs2540226	0.627	rs2192686	chr2:39928722	A/G	cg18968196	chr2:39892502	TMEM178	0.28	7.26	0.32	1.65e-12	Personality dimensions;
LGG	trans	rs11098499	0.874	rs9995277	chr4:120108603	G/A	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg15556689	chr8:8085844	FLJ10661	0.46	8.3	0.36	1.17e-15	Mood instability;
LGG	cis	rs9581857	0.512	rs9507886	chr13:27957286	G/A	cg01674679	chr13:27998804	GTF3A	-0.74	-8.16	-0.35	3.22e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs73086581	0.787	rs73084505	chr20:3856874	C/T	cg02187196	chr20:3869020	PANK2	0.93	12.77	0.51	3.22e-32	Response to antidepressants in depression;
LGG	cis	rs4639966	0.836	rs11217014	chr11:118626286	T/C	cg20110707	chr11:118481992	PHLDB1	-0.42	-6.88	-0.3	2.01e-11	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.729	rs12165508	chr22:41819960	T/C	cg17376030	chr22:41985996	PMM1	-0.44	-7.29	-0.32	1.38e-12	Vitiligo;
LGG	cis	rs9394438	0.628	rs4714078	chr6:37543852	G/A	cg00985040	chr6:37553208	NA	-0.37	-8.21	-0.36	2.27e-15	IgG glycosylation;
LGG	trans	rs7944735	0.545	rs4752805	chr11:48018355	A/G	cg03929089	chr4:120376271	NA	0.67	9.22	0.39	1.08e-18	Intraocular pressure;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg09699651	chr6:150184138	LRP11	0.53	9.39	0.4	2.74e-19	Lung cancer;
LGG	cis	rs2153535	0.580	rs2327067	chr6:8518482	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs10499694	0.967	rs11765748	chr7:50615616	T/A	cg00647317	chr7:50633725	DDC	0.38	9.22	0.39	1.08e-18	Body mass index;
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs4820539	1.000	rs4822358	chr22:23474795	A/G	cg21100191	chr22:23484243	RTDR1	1.0	23.07	0.73	5.96e-79	Bone mineral density;
LGG	cis	rs2072732	0.861	rs72629498	chr1:2954203	C/T	cg22517653	chr1:2918612	NA	-0.47	-6.92	-0.31	1.48e-11	Plateletcrit;
LGG	cis	rs1555895	0.599	rs997615	chr10:865214	A/G	cg09361094	chr10:834503	NA	-0.29	-7.65	-0.33	1.19e-13	Survival in rectal cancer;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-8.98	-0.39	6.75e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.694	rs202664	chr22:41813886	C/T	cg03806693	chr22:41940476	POLR3H	1.01	18.05	0.64	1.58e-55	Vitiligo;
LGG	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.24	0.32	1.84e-12	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.7	-0.34	8.12e-14	Systolic blood pressure;
LGG	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg14675211	chr2:100938903	LONRF2	0.49	7.51	0.33	3.1400000000000003e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9527	0.590	rs10509766	chr10:104926334	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.4	0.44	6.63e-23	Arsenic metabolism;
LGG	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21659725	chr3:3221576	CRBN	0.75	12.05	0.49	2.75e-29	Resting heart rate;
LGG	trans	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg21659725	chr3:3221576	CRBN	0.56	7.5	0.33	3.36e-13	Menarche (age at onset);
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg27384695	chr19:19271486	LOC729991-MEF2B;MEF2B	0.23	6.67	0.3	7.18e-11	IgG glycosylation;
LGG	cis	rs6460942	1.000	rs2033871	chr7:12405098	C/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.89	-0.31	1.79e-11	Coronary artery disease;
LGG	cis	rs9783347	1.000	rs3740711	chr11:18379839	T/C	cg15585147	chr11:18324498	HPS5	0.42	8.86	0.38	1.72e-17	Pancreatic cancer;
LGG	cis	rs17401966	0.838	rs17034643	chr1:10332102	A/G	cg15208524	chr1:10270712	KIF1B	-0.44	-7.78	-0.34	4.84e-14	Hepatocellular carcinoma;
LGG	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg03806693	chr22:41940476	POLR3H	-1.01	-17.51	-0.63	4.61e-53	Vitiligo;
LGG	cis	rs2303319	1.000	rs2194727	chr2:162245871	C/G	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg07402800	chr8:145582003	FBXL6;GPR172A	-0.41	-7.21	-0.32	2.23e-12	Sexual dysfunction (SSRI/SNRI-related);
LGG	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21659725	chr3:3221576	CRBN	0.92	20.44	0.69	1.16e-66	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.616	rs7680639	chr4:185652915	C/T	cg04058563	chr4:185651563	MLF1IP	-1.0	-22.1	-0.72	2.05e-74	Blood protein levels;
LGG	cis	rs4481887	0.800	rs4278391	chr1:248450495	C/T	cg13385794	chr1:248469461	NA	0.47	7.85	0.34	2.84e-14	Common traits (Other);
LGG	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg16329650	chr2:213403929	ERBB4	0.78	16.75	0.61	1.45e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs3812049	0.737	rs1112956	chr5:127433798	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.63	-10.21	-0.43	3.34e-22	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs2439831	0.681	rs498837	chr15:43608024	G/A	cg15269541	chr15:43626905	ADAL	-0.46	-8.34	-0.36	8.77e-16	Lung cancer in ever smokers;
LGG	trans	rs3749237	1.000	rs4768	chr3:49758764	A/G	cg21659725	chr3:3221576	CRBN	0.74	11.68	0.48	8.64e-28	Resting heart rate;
LGG	cis	rs875971	0.545	rs6961853	chr7:66002022	G/A	cg11764359	chr7:65958608	NA	0.63	9.81	0.41	8.89e-21	Aortic root size;
LGG	cis	rs10048158	0.565	rs13340928	chr17:64248928	C/T	cg19474267	chr17:64306194	PRKCA	-0.62	-12.32	-0.5	2.27e-30	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.2	0.49	6.81e-30	Hip circumference adjusted for BMI;
LGG	cis	rs6694672	0.867	rs10732295	chr1:197136645	T/C	cg13682187	chr1:196946512	CFHR5	0.48	6.81	0.3	3.05e-11	Asthma;
LGG	cis	rs10197940	0.624	rs6731486	chr2:152410732	C/T	cg19508488	chr2:152266495	RIF1	-0.59	-10.77	-0.45	2.75e-24	Lung cancer;
LGG	cis	rs7695597	0.629	rs1217945	chr4:185170812	G/A	cg12654155	chr4:185238627	NA	0.39	6.96	0.31	1.15e-11	Night sleep phenotypes;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs372883	0.600	rs1153277	chr21:30666867	A/T	cg08807101	chr21:30365312	RNF160	-0.61	-10.22	-0.43	2.94e-22	Pancreatic cancer;
LGG	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Myopia (pathological);
LGG	cis	rs68170813	0.559	rs7798223	chr7:106829223	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.81	-0.45	1.92e-24	Coronary artery disease;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.42	0.33	5.56e-13	Schizophrenia;
LGG	cis	rs4663969	0.733	rs6741669	chr2:234653192	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.82	-0.34	3.7e-14	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs6066825	0.644	rs2869669	chr20:47321449	T/C	cg18078177	chr20:47281410	PREX1	0.48	8.18	0.36	2.71e-15	Colorectal cancer;
LGG	cis	rs3812831	0.572	rs3118896	chr13:114931769	C/G	cg22348356	chr13:114891224	RASA3	0.42	8.34	0.36	8.56e-16	Schizophrenia;
LGG	cis	rs4474465	0.850	rs4945287	chr11:78226521	C/T	cg27205649	chr11:78285834	NARS2	0.51	8.58	0.37	1.39e-16	Alzheimer's disease (survival time);
LGG	cis	rs490234	0.702	rs1339499	chr9:128406453	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.11	-0.43	7.62e-22	Mean arterial pressure;
LGG	cis	rs10256972	0.758	rs11979275	chr7:1069335	A/T	cg23978390	chr7:1156363	C7orf50	0.44	7.21	0.32	2.3e-12	Longevity;Endometriosis;
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7193541	0.684	rs7191665	chr16:74688948	T/G	cg01733217	chr16:74700730	RFWD3	1.1	35.02	0.85	3.28e-132	Multiple myeloma;
LGG	cis	rs72925845	0.577	rs72907463	chr17:76428660	G/A	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	trans	rs6582630	0.537	rs12823925	chr12:38409323	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.95	-0.38	8.92e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6575793	0.532	rs6575794	chr14:101039724	C/T	cg09399377	chr6:136611038	BCLAF1	0.49	7.23	0.32	2.06e-12	Menarche (age at onset);
LGG	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.43	-6.67	-0.3	7.15e-11	Parkinson's disease;
LGG	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27286337	chr10:134555280	INPP5A	0.82	11.91	0.48	1.07e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg08677398	chr8:58056175	NA	0.53	7.99	0.35	1.1e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs10031751	chr4:98939134	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg27411982	chr8:10470053	RP1L1	0.42	7.18	0.32	2.8e-12	Mood instability;
LGG	cis	rs796364	0.951	rs7608668	chr2:201000017	T/C	cg23649088	chr2:200775458	C2orf69	-0.65	-9.26	-0.4	7.63e-19	Schizophrenia;
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.94	0.35	1.53e-14	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04048802	chr15:63334937	TPM1	0.44	6.68	0.3	6.71e-11	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg11644478	chr21:40555479	PSMG1	-0.6	-9.83	-0.42	7.55e-21	Menarche (age at onset);
LGG	cis	rs453301	0.686	rs3895823	chr8:8873646	T/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.35	-0.32	8.98e-13	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg08621203	chr6:150244597	RAET1G	0.47	8.07	0.35	6.09e-15	Lung cancer;
LGG	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg11584989	chr19:19387371	SF4	0.65	10.78	0.45	2.6e-24	Bipolar disorder;
LGG	cis	rs13191362	0.935	rs4273664	chr6:162955494	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.71e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14952266	chr13:112191215	NA	-0.41	-7.55	-0.33	2.31e-13	Menarche (age at onset);
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg22398616	chr13:53314203	LECT1	-0.42	-8.01	-0.35	9.6e-15	Lewy body disease;
LGG	cis	rs6674970	1.000	rs7546304	chr1:151114484	C/G	cg11822372	chr1:151115635	SEMA6C	0.49	8.63	0.37	1.01e-16	Childhood ear infection;
LGG	cis	rs10088262	0.629	rs6990565	chr8:124785645	C/A	cg02993010	chr8:124780839	FAM91A1	-0.66	-9.79	-0.41	1.09e-20	Pancreatic cancer;
LGG	cis	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.34	-0.32	9.62e-13	Triglycerides;
LGG	cis	rs806215	0.526	rs62481447	chr7:127563189	G/T	cg25922125	chr7:127225783	GCC1	-0.48	-7.04	-0.31	7.12e-12	Type 2 diabetes;
LGG	cis	rs7666738	0.861	rs5014702	chr4:99052102	C/A	cg05340658	chr4:99064831	C4orf37	0.51	8.5	0.37	2.62e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2629540	0.847	rs12763093	chr10:126395688	C/G	cg08799069	chr10:126477246	METTL10	-0.64	-13.07	-0.52	1.9e-33	Cocaine dependence;
LGG	cis	rs12450239	0.732	rs35133947	chr17:77444512	G/A	cg07832143	chr17:77435199	HRNBP3	0.46	8.72	0.38	5.13e-17	Body mass index;
LGG	cis	rs9354308	0.764	rs4538687	chr6:66585568	A/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs6693567	0.565	rs1260457	chr1:150347374	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.78	0.3	3.61e-11	Migraine;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	1.98e-17	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07362569	chr17:61921086	SMARCD2	-0.5	-9.61	-0.41	4.81e-20	Prudent dietary pattern;
LGG	cis	rs9326248	0.581	rs10892063	chr11:116896155	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.78	0.45	2.5e-24	Blood protein levels;
LGG	trans	rs9467711	0.606	rs9379857	chr6:26367654	G/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs1797081	1.000	rs812426	chr10:16857133	C/G	cg22980697	chr10:16874865	CUBN	0.38	7.13	0.31	3.88e-12	Platelet distribution width;
LGG	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg19784903	chr17:45786737	TBKBP1	0.36	8.0	0.35	1.01e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26825614	chr11:112097280	PTS	0.5	7.49	0.33	3.56e-13	Gut microbiome composition (summer);
LGG	cis	rs2243480	1.000	rs316325	chr7:65609518	G/A	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs17270561	0.609	rs4712965	chr6:25742022	G/T	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg08847335	chr10:891726	LARP4B	0.37	7.24	0.32	1.84e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg26897989	chr16:1907736	C16orf73	0.67	10.27	0.43	2.03e-22	Insulin-like growth factors;
LGG	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg02227867	chr8:22457446	C8orf58	-0.45	-8.72	-0.38	4.89e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg14004847	chr7:1930337	MAD1L1	-0.48	-8.58	-0.37	1.46e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs67311347	0.866	rs9826419	chr3:40352051	G/A	cg13683864	chr3:40499215	RPL14	-0.86	-16.8	-0.62	8.55e-50	Renal cell carcinoma;
LGG	cis	rs986417	0.818	rs10143831	chr14:61081961	G/T	cg27398547	chr14:60952738	C14orf39	0.69	7.11	0.31	4.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9636202	1.000	rs9636202	chr19:18449238	A/G	cg02383626	chr19:18455508	PGPEP1	-0.91	-18.64	-0.65	2.8e-58	Life satisfaction;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg02002194	chr4:3960332	NA	0.44	7.54	0.33	2.53e-13	Neuroticism;
LGG	cis	rs986417	0.901	rs4640083	chr14:61097779	G/A	cg27398547	chr14:60952738	C14orf39	0.75	7.03	0.31	7.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg16606324	chr3:10149918	C3orf24	0.52	6.95	0.31	1.22e-11	Alzheimer's disease;
LGG	cis	rs6840360	0.533	rs13121178	chr4:152729047	T/C	cg22705602	chr4:152727874	NA	0.31	7.65	0.33	1.21e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	0.902	rs34751755	chr11:34694243	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.21	-0.32	2.24e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg13880726	chr7:1868755	MAD1L1	0.4	7.09	0.31	5.03e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg06092702	chr1:163392909	NA	0.46	8.09	0.35	5.21e-15	Motion sickness;
LGG	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.29	0.43	1.65e-22	Diabetic retinopathy;
LGG	cis	rs9389248	0.737	rs12664956	chr6:135384188	T/C	cg24558204	chr6:135376177	HBS1L	0.61	10.39	0.43	7.18e-23	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg11366901	chr6:160182831	ACAT2	0.99	15.11	0.57	3.26e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7408868	0.908	rs1044006	chr19:15285052	T/C	cg14696996	chr19:15285081	NOTCH3	1.09	12.97	0.52	4.84e-33	Pulse pressure;
LGG	cis	rs2228479	0.850	rs11644526	chr16:89898660	C/T	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.38e-50	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs6601327	0.551	rs13272424	chr8:9575319	T/G	cg16141378	chr3:129829833	LOC729375	0.36	8.14	0.35	3.69e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7133214	0.771	rs34311349	chr12:27925037	T/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.98	-0.31	1.03e-11	Gut microbiota (functional units);
LGG	cis	rs2735413	0.599	rs77209133	chr16:78076724	A/T	cg04733911	chr16:78082701	NA	0.57	7.77	0.34	4.97e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg00689492	chr4:1303491	MAEA	0.51	8.66	0.37	8.11e-17	Obesity-related traits;
LGG	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg22467129	chr15:76604101	ETFA	-0.44	-7.3	-0.32	1.24e-12	Blood metabolite levels;
LGG	cis	rs4481887	1.000	rs4916124	chr1:248466495	T/C	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	trans	rs1459104	1.000	rs35726021	chr11:55191206	G/A	cg15704280	chr7:45808275	SEPT13	0.72	6.8	0.3	3.25e-11	Body mass index;
LGG	cis	rs9443645	0.870	rs9350799	chr6:79723651	C/A	cg18132916	chr6:79620363	NA	-0.26	-6.85	-0.3	2.32e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.74	14.75	0.57	1.25e-40	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03713592	chr11:72463424	ARAP1	0.41	7.71	0.34	7.91e-14	Type 2 diabetes;
LGG	cis	rs11229555	0.609	rs12273517	chr11:58201094	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4824093	0.610	rs13340054	chr22:50311726	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-6.92	-0.31	1.52e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3096299	0.933	rs2965823	chr16:89454924	G/A	cg02187348	chr16:89574699	SPG7	0.46	7.47	0.33	4.09e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs75804782	0.572	rs56330821	chr2:239273949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9300255	0.537	rs1618679	chr12:123650714	A/G	cg00376283	chr12:123451042	ABCB9	0.64	10.33	0.43	1.24e-22	Neutrophil percentage of white cells;
LGG	cis	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg24375607	chr4:120327624	NA	0.64	10.47	0.44	3.78e-23	Corneal astigmatism;
LGG	cis	rs7617773	1.000	rs6442106	chr3:48190815	G/A	cg11946769	chr3:48343235	NME6	-0.51	-8.06	-0.35	6.5e-15	Coronary artery disease;
LGG	cis	rs1059312	0.932	rs4760593	chr12:129287220	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.15	0.32	3.44e-12	Systemic lupus erythematosus;
LGG	cis	rs787274	0.850	rs7047914	chr9:115620773	A/C	cg13803584	chr9:115635662	SNX30	-0.65	-7.93	-0.35	1.66e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs877282	0.891	rs34652870	chr10:772218	T/C	cg22713356	chr15:30763199	NA	0.57	8.55	0.37	1.82e-16	Uric acid levels;
LGG	cis	rs7156960	0.639	rs2360983	chr14:76727099	C/T	cg13981132	chr14:76734493	NA	-0.32	-6.97	-0.31	1.07e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	trans	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg23484912	chr5:273055	PDCD6	0.52	10.12	0.43	6.92e-22	Pancreatic cancer;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.71	-0.45	4.42e-24	Neuroticism;
LGG	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs10193935	0.901	rs62142599	chr2:42548935	G/A	cg27598129	chr2:42591480	NA	-0.56	-8.49	-0.37	2.82e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	7.48	0.33	3.7e-13	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10870270	0.917	rs9971362	chr10:133790150	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.4	-0.5	1.1e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	4.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.83	-0.42	7.76e-21	Aortic root size;
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg05552183	chr6:42928497	GNMT	0.37	10.45	0.44	4.31e-23	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7843479	0.509	rs899428	chr8:21770763	T/C	cg17168535	chr8:21777572	XPO7	0.72	13.64	0.54	7.91e-36	Mean corpuscular volume;
LGG	cis	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	cis	rs8017423	1.000	rs769044	chr14:90671138	A/G	cg04374321	chr14:90722782	PSMC1	0.8	16.49	0.61	2.21e-48	Mortality in heart failure;
LGG	cis	rs3096299	0.658	rs3934737	chr16:89560209	G/A	cg06640241	chr16:89574553	SPG7	0.93	17.92	0.64	6.53e-55	Multiple myeloma (IgH translocation);
LGG	cis	rs4975709	0.609	rs2232373	chr5:1882280	C/G	cg07747251	chr5:1868357	NA	0.4	6.89	0.31	1.79e-11	Cardiovascular disease risk factors;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.507	rs6443274	chr3:9995288	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.74	0.51	4.42e-32	Alzheimer's disease;
LGG	cis	rs7394190	0.748	rs3088070	chr10:75530013	C/T	cg07699608	chr10:75541558	CHCHD1	0.55	7.35	0.32	9.27e-13	Incident atrial fibrillation;
LGG	cis	rs1904096	0.506	rs11097408	chr4:95165662	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.07	-0.46	1.92e-25	Type 2 diabetes;
LGG	cis	rs9814567	0.752	rs13075253	chr3:134329600	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.51	0.44	2.6e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs875971	0.660	rs10263935	chr7:66096028	A/G	cg18876405	chr7:65276391	NA	0.47	8.33	0.36	9.4e-16	Aortic root size;
LGG	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg14346243	chr4:90757452	SNCA	-0.33	-6.67	-0.3	7.16e-11	Dementia with Lewy bodies;
LGG	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg23335576	chr14:104009727	NA	0.39	6.67	0.3	7.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.926	rs1060491	chr20:61665817	C/A	cg18188782	chr20:61659543	NA	-0.4	-6.85	-0.3	2.33e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11875185	0.510	rs74925190	chr18:55622197	G/A	cg15513957	chr14:69354734	ACTN1	-0.86	-8.71	-0.38	5.52e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	cis	rs941764	0.965	rs8018155	chr14:91842978	G/C	cg10511902	chr14:91842949	CCDC88C	0.72	16.39	0.61	5.9e-48	Breast cancer;
LGG	cis	rs11122272	0.668	rs2808616	chr1:231554993	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	10.74	0.45	3.56e-24	Hemoglobin concentration;
LGG	cis	rs2070433	1.000	rs11701310	chr21:47962836	G/C	cg12379764	chr21:47803548	PCNT	0.58	8.27	0.36	1.39e-15	Lymphocyte counts;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg09699651	chr6:150184138	LRP11	0.51	9.03	0.39	4.79e-18	Lung cancer;
LGG	cis	rs11190604	0.697	rs10748795	chr10:102194818	A/T	cg07570687	chr10:102243282	WNT8B	-0.41	-7.46	-0.33	4.22e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4262150	0.672	rs60402008	chr5:152357620	T/C	cg12297329	chr5:152029980	NA	-0.54	-8.24	-0.36	1.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10197940	0.686	rs12616688	chr2:152242099	C/G	cg06191203	chr2:152266755	RIF1	-0.48	-8.4	-0.36	5.6e-16	Lung cancer;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg23758822	chr17:41437982	NA	0.82	13.63	0.54	7.95e-36	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18252515	chr7:66147081	NA	0.44	7.32	0.32	1.1e-12	Aortic root size;
LGG	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.91	-0.31	1.66e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.52	0.37	2.22e-16	Thyroid stimulating hormone;
LGG	cis	rs2836950	0.501	rs62223052	chr21:40708702	A/C	cg17971929	chr21:40555470	PSMG1	-0.52	-8.77	-0.38	3.56e-17	Menarche (age at onset);
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs117598310	0.541	rs16939030	chr8:75995493	T/C	cg14283968	chr8:75896801	CRISPLD1	0.49	6.78	0.3	3.72e-11	Optic cup area;
LGG	cis	rs9611565	0.503	rs5751156	chr22:42170025	A/G	cg06481639	chr22:41940642	POLR3H	0.56	7.9	0.34	2.03e-14	Vitiligo;
LGG	cis	rs9926296	0.568	rs7203907	chr16:89833774	C/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.83	0.3	2.63e-11	Vitiligo;
LGG	cis	rs8180040	0.966	rs57346147	chr3:47410564	C/G	cg16586182	chr3:47516702	SCAP	0.79	15.91	0.59	8.84e-46	Colorectal cancer;
LGG	cis	rs13343954	0.518	rs8106293	chr19:33536376	C/T	cg03563238	chr19:33554763	RHPN2	-0.38	-8.52	-0.37	2.28e-16	Colorectal cancer;
LGG	cis	rs1045714	0.895	rs4719594	chr7:2639790	G/A	cg14042143	chr7:2646782	IQCE	0.82	12.61	0.51	1.58e-31	Urate levels in lean individuals;
LGG	cis	rs4780401	0.609	rs35902600	chr16:11800848	C/T	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.92	-0.51	7.73e-33	Rheumatoid arthritis;
LGG	trans	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg16141378	chr3:129829833	LOC729375	-0.31	-6.85	-0.3	2.31e-11	Retinal vascular caliber;
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg16268157	chr7:99778414	STAG3	-0.42	-6.74	-0.3	4.77e-11	Lung function (FEV1/FVC);
LGG	cis	rs28595532	0.920	rs115085630	chr4:119741765	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs4731207	0.596	rs7810299	chr7:124645104	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.8	-0.3	3.17e-11	Cutaneous malignant melanoma;
LGG	cis	rs6963495	0.818	rs73190202	chr7:105166510	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg12310025	chr6:25882481	NA	-0.46	-8.03	-0.35	8.25e-15	Height;
LGG	trans	rs1941687	0.527	rs6507059	chr18:31303643	A/G	cg27147174	chr7:100797783	AP1S1	-0.6	-10.67	-0.44	6.64e-24	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7267979	0.816	rs6138593	chr20:25504492	A/G	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.68e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg21475434	chr5:93447410	FAM172A	0.66	6.72	0.3	5.42e-11	Diabetic retinopathy;
LGG	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg26384229	chr12:38710491	ALG10B	0.9	20.03	0.68	9.83e-65	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg03929089	chr4:120376271	NA	-0.43	-7.01	-0.31	8.35e-12	HDL cholesterol;
LGG	trans	rs2204008	0.837	rs12581130	chr12:38319387	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.27	-0.4	6.89e-19	Bladder cancer;
LGG	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	3.09e-11	Corneal structure;
LGG	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg06623630	chr22:50017776	C22orf34	-0.37	-7.76	-0.34	5.5e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs368123	1.000	rs414130	chr6:160719280	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.1	-0.31	4.87e-12	Waist circumference;
LGG	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg11644478	chr21:40555479	PSMG1	-0.75	-14.01	-0.55	1.92e-37	Cognitive function;
LGG	cis	rs3096299	0.583	rs2965949	chr16:89520452	A/G	cg06640241	chr16:89574553	SPG7	0.69	10.77	0.45	2.67e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs12701220	0.553	rs34062359	chr7:1139076	C/T	cg00990874	chr7:1149470	C7orf50	-0.78	-12.39	-0.5	1.21e-30	Bronchopulmonary dysplasia;
LGG	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg11494091	chr17:61959527	GH2	0.6	10.09	0.42	9.35e-22	Height;
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg06916706	chr16:4465613	CORO7	0.83	14.29	0.55	1.29e-38	Schizophrenia;
LGG	cis	rs10751667	0.643	rs10751666	chr11:941933	C/T	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs7552404	1.000	rs7518038	chr1:76154430	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.64	0.56	3.85e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg15556689	chr8:8085844	FLJ10661	-0.55	-10.36	-0.43	9.65e-23	Triglycerides;
LGG	trans	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg02030672	chr11:45687055	CHST1	-0.5	-9.04	-0.39	4.25e-18	Obesity-related traits;
LGG	cis	rs73416724	1.000	rs41281796	chr6:43323917	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.45	0.37	3.75e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.08	-0.35	5.67e-15	Neuroticism;
LGG	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg02023728	chr11:77925099	USP35	0.47	8.44	0.36	4.24e-16	Testicular germ cell tumor;
LGG	cis	rs240764	0.610	rs41288423	chr6:101166095	G/A	cg09795085	chr6:101329169	ASCC3	-0.44	-7.47	-0.33	3.97e-13	Neuroticism;
LGG	cis	rs2153535	0.546	rs1335640	chr6:8485325	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.33e-31	Motion sickness;
LGG	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg26031613	chr14:104095156	KLC1	-0.67	-10.89	-0.45	9.68e-25	Reticulocyte count;
LGG	cis	rs7945705	0.869	rs11042154	chr11:9029700	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.36	-7.01	-0.31	8.45e-12	Hemoglobin concentration;
LGG	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg17971929	chr21:40555470	PSMG1	0.85	16.4	0.61	5.37e-48	Cognitive function;
LGG	cis	rs7647973	0.925	rs9834003	chr3:49216472	T/C	cg07636037	chr3:49044803	WDR6	0.78	13.85	0.54	9.79e-37	Menarche (age at onset);
LGG	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg12310025	chr6:25882481	NA	0.5	9.2	0.39	1.25e-18	Blood metabolite levels;
LGG	cis	rs59197085	0.636	rs62479620	chr7:128463971	C/T	cg00734629	chr7:128471146	FLNC	0.34	6.98	0.31	1.01e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs847577	0.609	rs11765552	chr7:97822115	T/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.77	-0.3	3.96e-11	Breast cancer;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg10596483	chr8:143751796	JRK	0.52	8.21	0.36	2.21e-15	Schizophrenia;
LGG	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg10253484	chr15:75165896	SCAMP2	0.69	11.12	0.46	1.28e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs9814567	1.000	rs7645295	chr3:134307734	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.06	-0.52	2.05e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7712401	0.601	rs415534	chr5:122325301	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs9534288	0.797	rs7328081	chr13:46611695	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs7904368	0.806	rs7899853	chr10:16857603	A/T	cg14835575	chr10:16859367	RSU1	0.79	14.49	0.56	1.65e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs8141529	0.702	rs5762870	chr22:29261159	C/T	cg15103426	chr22:29168792	CCDC117	0.63	10.09	0.42	8.74e-22	Lymphocyte counts;
LGG	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.31e-14	Calcium levels;
LGG	cis	rs1270639	0.778	rs1796271	chr7:157438129	T/G	cg13357408	chr7:157437802	PTPRN2	0.65	10.42	0.44	5.78e-23	Colorectal cancer;
LGG	cis	rs6028335	0.610	rs67882716	chr20:37573239	T/C	cg16355469	chr20:37678765	NA	0.55	7.34	0.32	9.59e-13	Alcohol and nicotine co-dependence;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07498778	chr8:38325092	FGFR1	0.42	7.13	0.31	4e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2276314	1.000	rs58054756	chr18:33554053	G/C	cg05985134	chr18:33552581	C18orf21	0.65	10.25	0.43	2.32e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs4481887	0.893	rs4423045	chr1:248479495	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.15	-0.39	1.86e-18	Common traits (Other);
LGG	cis	rs778371	0.723	rs2592104	chr2:233645970	G/A	cg08000102	chr2:233561755	GIGYF2	0.69	11.21	0.46	5.6e-26	Schizophrenia;
LGG	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg04132472	chr17:19861366	AKAP10	0.25	7.03	0.31	7.45e-12	Schizophrenia;
LGG	cis	rs2718058	0.606	rs1349393	chr7:37869525	C/T	cg24998770	chr7:37888106	TXNDC3	0.45	7.29	0.32	1.32e-12	Alzheimer's disease (late onset);
LGG	trans	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg00938859	chr5:1591904	SDHAP3	0.88	12.08	0.49	2.18e-29	Breast cancer;
LGG	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.0	-0.35	1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs34172651	0.876	rs964782	chr16:24811740	T/C	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.32	-0.36	1.02e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4144743	0.877	rs7218773	chr17:45324211	C/T	cg18085866	chr17:45331354	ITGB3	-0.77	-9.64	-0.41	3.54e-20	Body mass index;
LGG	cis	rs11997175	0.550	rs7459565	chr8:33836717	C/T	ch.8.33884649F	chr8:33765107	NA	0.41	7.7	0.34	8.28e-14	Body mass index;
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg05084668	chr3:125655381	ALG1L	-0.54	-7.33	-0.32	1.05e-12	Blood pressure (smoking interaction);
LGG	cis	rs2439831	0.867	rs3213991	chr15:43670280	C/T	cg15269541	chr15:43626905	ADAL	-0.45	-7.76	-0.34	5.65e-14	Lung cancer in ever smokers;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg06636001	chr8:8085503	FLJ10661	0.39	7.1	0.31	4.74e-12	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg18876405	chr7:65276391	NA	0.68	13.0	0.52	3.82e-33	Calcium levels;
LGG	cis	rs2718058	0.589	rs10274478	chr7:37792902	T/C	cg15028436	chr7:37888078	TXNDC3	-0.46	-7.5	-0.33	3.18e-13	Alzheimer's disease (late onset);
LGG	cis	rs7572733	0.773	rs56858593	chr2:198494468	A/G	cg00792783	chr2:198669748	PLCL1	0.4	6.71	0.3	5.54e-11	Dermatomyositis;
LGG	cis	rs477895	1.000	rs477895	chr11:64048912	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.6	-7.41	-0.33	6.19e-13	Mean platelet volume;
LGG	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg16339924	chr4:17578868	LAP3	0.61	10.42	0.44	5.38e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs654950	0.776	rs2759252	chr1:42021854	G/A	cg06885757	chr1:42089581	HIVEP3	-0.65	-15.05	-0.57	5.67e-42	Airway imaging phenotypes;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.45e-15	Lymphocyte counts;
LGG	cis	rs854765	0.534	rs7207461	chr17:17949789	T/G	cg04398451	chr17:18023971	MYO15A	0.74	15.49	0.58	6.32e-44	Total body bone mineral density;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg15726326	chr17:19651983	ALDH3A1	-0.73	-16.07	-0.6	1.62e-46	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg01191920	chr7:158217561	PTPRN2	-0.8	-18.85	-0.66	2.96e-59	Obesity-related traits;
LGG	cis	rs9811920	0.609	rs793501	chr3:99591638	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	trans	rs1814175	0.817	rs12295885	chr11:50036762	T/G	cg03929089	chr4:120376271	NA	-1.03	-24.54	-0.75	8.43e-86	Height;
LGG	cis	rs7558370	0.520	rs76221161	chr2:3700123	A/G	cg13452994	chr2:3699195	NA	0.67	7.25	0.32	1.71e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.39	-0.43	6.92e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12738007	1.000	rs12738007	chr1:29521705	C/T	cg11747820	chr1:29584023	PTPRU	-0.35	-8.04	-0.35	7.61e-15	Schizophrenia;
LGG	trans	rs3942852	0.910	rs10742829	chr11:48115837	C/T	cg03929089	chr4:120376271	NA	0.66	8.23	0.36	1.93e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg07747251	chr5:1868357	NA	0.48	9.57	0.41	6.28e-20	Cardiovascular disease risk factors;
LGG	cis	rs977747	0.689	rs7545034	chr1:47659445	C/T	cg03885399	chr1:47691550	TAL1	0.32	6.84	0.3	2.45e-11	Body mass index;
LGG	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg03929089	chr4:120376271	NA	0.79	8.14	0.35	3.74e-15	Myopia (pathological);
LGG	cis	rs10089	0.552	rs17607942	chr5:127555435	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.57	8.29	0.36	1.22e-15	Ileal carcinoids;
LGG	cis	rs2832191	0.935	rs67287920	chr21:30523519	C/A	cg08807101	chr21:30365312	RNF160	-0.76	-14.63	-0.56	4e-40	Dental caries;
LGG	cis	rs10504229	0.516	rs11776524	chr8:57983246	A/G	cg02725872	chr8:58115012	NA	-0.48	-7.91	-0.34	1.94e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg01206211	chr2:36825736	FEZ2	0.42	8.08	0.35	5.77e-15	Height;
LGG	cis	rs6815814	0.851	rs11466645	chr4:38778203	A/T	cg06935464	chr4:38784597	TLR10	0.55	7.69	0.34	8.93e-14	Breast cancer;
LGG	cis	rs4604732	0.631	rs11490199	chr1:247625737	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs11098499	0.566	rs7664440	chr4:120578540	A/G	cg01244601	chr4:120671846	NA	-0.4	-7.71	-0.34	7.59e-14	Corneal astigmatism;
LGG	cis	rs1008375	0.966	rs6449329	chr4:17703677	T/C	cg02297831	chr4:17616191	MED28	0.42	7.78	0.34	4.69e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9473924	0.505	rs2817416	chr6:50809777	T/C	cg14470998	chr6:50812995	TFAP2B	0.69	8.18	0.36	2.7e-15	Body mass index;
LGG	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg16141378	chr3:129829833	LOC729375	-0.37	-8.25	-0.36	1.62e-15	Neuroticism;
LGG	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg20578329	chr17:80767326	TBCD	0.46	7.78	0.34	4.78e-14	Breast cancer;
LGG	cis	rs79976124	0.837	rs12201218	chr6:66653619	C/T	cg07460842	chr6:66804631	NA	-0.72	-12.65	-0.51	1e-31	Type 2 diabetes;
LGG	trans	rs2727020	0.729	rs1164666	chr11:49295867	C/T	cg03929089	chr4:120376271	NA	-0.89	-17.9	-0.64	7.54e-55	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg24375607	chr4:120327624	NA	0.67	10.9	0.45	8.81e-25	Corneal astigmatism;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg16920238	chr17:80076378	CCDC57	0.35	8.2	0.36	2.42e-15	Life satisfaction;
LGG	cis	rs9899728	0.539	rs12938889	chr17:73039929	A/C	cg27626185	chr17:73056755	KCTD2	1.01	12.55	0.5	2.72e-31	Alzheimer's disease or small vessel stroke;
LGG	cis	rs2836974	0.965	rs8130984	chr21:40639966	A/C	cg17971929	chr21:40555470	PSMG1	0.87	17.36	0.63	2.21e-52	Cognitive function;
LGG	cis	rs738322	0.868	rs8139952	chr22:38606989	C/A	cg25457927	chr22:38595422	NA	0.43	11.19	0.46	6.83e-26	Cutaneous nevi;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg00800038	chr16:89945340	TCF25	-0.71	-8.62	-0.37	1.05e-16	Skin colour saturation;
LGG	cis	rs7923609	0.936	rs10740125	chr10:65209609	T/C	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg04398451	chr17:18023971	MYO15A	-0.86	-19.64	-0.67	6.83e-63	Total body bone mineral density;
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs8133932	0.667	rs760436	chr21:47278055	C/T	cg13695288	chr21:47294981	PCBP3	-0.35	-7.01	-0.31	8.4e-12	Schizophrenia;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg02725872	chr8:58115012	NA	-0.86	-11.83	-0.48	2.05e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs5756813	0.754	rs13057133	chr22:38179473	C/T	cg19894588	chr14:64061835	NA	-0.6	-9.29	-0.4	6.11e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2016266	0.820	rs11170496	chr12:53666195	G/A	cg13445358	chr12:53661749	ESPL1	-0.39	-7.38	-0.32	7.56e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Electroencephalogram traits;
LGG	cis	rs7937612	0.802	rs36011588	chr11:120196433	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.49	-11.54	-0.47	3.06e-27	Intraocular pressure;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg08888203	chr3:10149979	C3orf24	0.54	8.66	0.37	7.85e-17	Alzheimer's disease;
LGG	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.47	-7.5	-0.33	3.19e-13	Eosinophil percentage of white cells;
LGG	cis	rs2070677	0.935	rs2070676	chr10:135351137	C/G	cg20169779	chr10:135381914	SYCE1	0.97	12.6	0.51	1.62e-31	Gout;
LGG	cis	rs9393692	0.620	rs12525187	chr6:26337537	A/G	cg00631329	chr6:26305371	NA	-0.46	-7.69	-0.34	9.14e-14	Educational attainment;
LGG	trans	rs1493916	1.000	rs4393645	chr18:31394407	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-13.25	-0.52	3.36e-34	Life satisfaction;
LGG	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg22432760	chr17:80829718	TBCD	0.4	6.99	0.31	9.79e-12	Breast cancer;
LGG	cis	rs10744422	0.748	rs1671688	chr12:123255733	A/T	cg25930673	chr12:123319894	HIP1R	-0.67	-8.09	-0.35	5.32e-15	Schizophrenia;
LGG	cis	rs3862030	0.668	rs12781718	chr10:104227433	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.14e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg17691542	chr6:26056736	HIST1H1C	0.55	9.84	0.42	7.18e-21	Height;
LGG	cis	rs17401966	0.809	rs12406943	chr1:10308545	T/C	cg15208524	chr1:10270712	KIF1B	0.45	8.11	0.35	4.51e-15	Hepatocellular carcinoma;
LGG	cis	rs42648	0.738	rs13247172	chr7:89889204	A/C	cg25739043	chr7:89950458	NA	-0.33	-6.69	-0.3	6.54e-11	Homocysteine levels;
LGG	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg10223061	chr2:219282414	VIL1	0.3	6.71	0.3	5.79e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2000999	0.515	rs2854956	chr16:72115238	A/T	cg01557791	chr16:72042693	DHODH	-0.58	-10.59	-0.44	1.35e-23	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs193541	0.632	rs154503	chr5:122204499	G/A	cg19412675	chr5:122181750	SNX24	0.53	8.47	0.37	3.29e-16	Glucose homeostasis traits;
LGG	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg07027305	chr7:2059796	MAD1L1	-0.35	-8.84	-0.38	2.09e-17	Neuroticism;
LGG	cis	rs7918232	0.882	rs6415983	chr10:27357211	A/G	cg14442939	chr10:27389572	ANKRD26	0.68	10.61	0.44	1.13e-23	Breast cancer;
LGG	trans	rs7819412	0.668	rs2409714	chr8:11010118	A/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.12	-0.31	4.27e-12	Triglycerides;
LGG	cis	rs9325144	0.505	rs826893	chr12:39100536	A/G	cg13010199	chr12:38710504	ALG10B	-0.61	-13.13	-0.52	1.06e-33	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg13852791	chr20:30311386	BCL2L1	0.76	10.84	0.45	1.45e-24	Mean corpuscular hemoglobin;
LGG	cis	rs10870270	1.000	rs7078692	chr10:133775370	T/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.67	-0.54	5.85e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7267979	0.780	rs6050679	chr20:25537827	A/T	cg06421707	chr20:25228305	PYGB	0.41	8.56	0.37	1.63e-16	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9354308	0.764	rs9351532	chr6:66591290	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg10587741	chr22:38071170	LGALS1	-0.33	-6.71	-0.3	5.62e-11	Glioblastoma;Glioma;
LGG	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.43	0.58	1.19e-43	Hair morphology;
LGG	trans	rs7939886	0.920	rs12226441	chr11:55867822	G/A	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.5e-11	Myopia (pathological);
LGG	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg06634786	chr22:41940651	POLR3H	-0.42	-6.67	-0.3	7.12e-11	Neuroticism;
LGG	cis	rs6725041	0.532	rs12623803	chr2:213201642	G/C	cg16329650	chr2:213403929	ERBB4	-0.38	-6.69	-0.3	6.61e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs3857067	0.773	rs2865344	chr4:95103040	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.78	-0.34	4.71e-14	QT interval;
LGG	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.36e-16	Aortic root size;
LGG	cis	rs9527	0.590	rs11191540	chr10:104822809	G/C	cg04362960	chr10:104952993	NT5C2	0.57	10.75	0.45	3.23e-24	Arsenic metabolism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01458961	chr4:102269425	PPP3CA	0.51	8.6	0.37	1.23e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg18350739	chr11:68623251	NA	-0.86	-22.16	-0.72	1.02e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4076764	0.958	rs6688181	chr1:163384193	C/T	cg06092702	chr1:163392909	NA	0.42	7.49	0.33	3.51e-13	Motion sickness;
LGG	cis	rs2842992	0.789	rs10945635	chr6:160214487	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	12.18	0.49	8.75e-30	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7633770	0.841	rs11709936	chr3:46680483	C/G	cg11219411	chr3:46661640	NA	0.58	13.77	0.54	2.07e-36	Coronary artery disease;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg23782820	chr8:58130467	NA	0.49	7.54	0.33	2.44e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.69	0.48	7.78e-28	IgG glycosylation;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg09699651	chr6:150184138	LRP11	0.46	6.94	0.31	1.32e-11	Lung cancer;
LGG	trans	rs4843747	0.671	rs72818576	chr16:88111019	C/G	cg00711542	chr16:29343894	RUNDC2C	0.39	6.67	0.3	7.54e-11	Menopause (age at onset);
LGG	cis	rs28830936	1.000	rs2412622	chr15:41960311	A/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.85	-0.3	2.43e-11	Diastolic blood pressure;
LGG	cis	rs561341	0.740	rs11080174	chr17:30208521	C/A	cg13647721	chr17:30228624	UTP6	-0.76	-11.0	-0.46	3.63e-25	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.77	0.38	3.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg06886374	chr16:1844152	IGFALS	0.47	9.24	0.39	9.01e-19	Insulin-like growth factors;
LGG	cis	rs7215564	0.908	rs35112467	chr17:78677562	C/T	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.14e-15	Myopia (pathological);
LGG	cis	rs9911578	1.000	rs12936058	chr17:57017420	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6938	0.534	rs12913293	chr15:75184458	G/C	cg14664628	chr15:75095509	CSK	-0.55	-10.69	-0.44	5.46e-24	Breast cancer;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.64	-0.37	8.91e-17	Menopause (age at onset);
LGG	cis	rs2244613	0.507	rs7205803	chr16:55794849	C/T	cg27396498	chr16:55794478	CES4	0.43	7.84	0.34	3.12e-14	Response to dabigatran etexilate treatment;
LGG	cis	rs1728785	1.000	rs1728780	chr16:68567642	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs9443645	0.901	rs9443632	chr6:79664440	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.64	-0.37	9.26e-17	Intelligence (multi-trait analysis);
LGG	cis	rs10206020	0.759	rs11903889	chr2:1576601	C/T	cg01028140	chr2:1542097	TPO	-0.43	-8.16	-0.35	3.24e-15	IgG glycosylation;
LGG	cis	rs1790761	0.692	rs611663	chr11:67312221	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.25	-0.32	1.77e-12	Mean corpuscular volume;
LGG	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg02002194	chr4:3960332	NA	0.44	7.94	0.35	1.51e-14	Retinal vascular caliber;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.72	-0.54	3.5e-36	Tonsillectomy;
LGG	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.56	7.7	0.34	8.49e-14	Schizophrenia;
LGG	cis	rs4853012	0.838	rs60705299	chr2:74345370	C/G	cg19729930	chr2:74357872	NA	0.53	11.44	0.47	7.09e-27	Gestational age at birth (maternal effect);
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12016809	chr21:47604291	C21orf56	-0.59	-9.91	-0.42	3.93e-21	Testicular germ cell tumor;
LGG	trans	rs6787172	1.000	rs6787172	chr3:158187811	T/G	cg23275840	chr4:47708675	CORIN	-0.34	-7.18	-0.32	2.86e-12	Subjective well-being;
LGG	cis	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg03213289	chr20:61660250	NA	0.66	14.48	0.56	1.84e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17641971	0.684	rs12545097	chr8:49951977	A/G	cg00325661	chr8:49890786	NA	0.53	10.0	0.42	1.9e-21	Blood metabolite levels;
LGG	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.26	0.32	1.63e-12	Retinal vascular caliber;
LGG	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.03	-0.52	2.69e-33	Response to antipsychotic treatment;
LGG	cis	rs6598163	0.712	rs10751695	chr12:132291061	A/C	cg00078996	chr12:132293329	NA	-0.37	-7.94	-0.35	1.59e-14	Migraine;
LGG	cis	rs77106637	1.000	rs11605166	chr11:72669777	T/C	cg03878208	chr11:72483293	STARD10	0.5	7.0	0.31	9.06e-12	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg09699651	chr6:150184138	LRP11	0.53	9.42	0.4	2.16e-19	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10870443	chr9:98270489	PTCH1	0.42	6.78	0.3	3.68e-11	Gut microbiome composition (summer);
LGG	trans	rs9657904	0.774	rs2399056	chr3:105517330	A/G	cg14088669	chr1:158435396	OR10K1	0.41	7.7	0.34	8.56e-14	Multiple sclerosis;
LGG	cis	rs2070488	0.804	rs7646429	chr3:38467713	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.71	0.56	1.78e-40	Electrocardiographic conduction measures;
LGG	cis	rs7937682	0.883	rs490492	chr11:111465150	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	9.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg08392591	chr16:89556376	ANKRD11	0.43	6.71	0.3	5.8200000000000003e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs9325144	0.560	rs11182952	chr12:38636278	C/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg04672837	chr16:48644449	N4BP1	0.53	8.61	0.37	1.13e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2153535	0.580	rs915352	chr6:8442766	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	trans	rs4942242	0.512	rs9533552	chr13:44187194	C/T	cg19169023	chr15:41853346	TYRO3	-0.45	-8.65	-0.37	8.55e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg21017887	chr14:105400489	NA	0.44	8.89	0.38	1.39e-17	Rheumatoid arthritis;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.65	10.94	0.45	6.4e-25	Obesity-related traits;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.57	0.37	1.61e-16	Personality dimensions;
LGG	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.85	-0.3	2.33e-11	Neuroticism;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg02725872	chr8:58115012	NA	-0.75	-10.46	-0.44	4.07e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs6921919	0.945	rs16901847	chr6:28375851	G/A	cg06606381	chr12:133084897	FBRSL1	-0.52	-7.25	-0.32	1.8e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg03342759	chr3:160939853	NMD3	-0.63	-11.25	-0.46	4.03e-26	Morning vs. evening chronotype;
LGG	cis	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg21775007	chr8:11205619	TDH	-0.52	-7.95	-0.35	1.45e-14	Triglycerides;
LGG	cis	rs8028313	0.731	rs4776964	chr15:68016955	T/G	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.34	-0.32	9.85e-13	Obesity;
LGG	cis	rs963731	0.649	rs2888585	chr2:39246683	C/T	cg04010122	chr2:39346883	SOS1	-0.83	-7.43	-0.33	5.31e-13	Corticobasal degeneration;
LGG	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg16576597	chr16:28551801	NUPR1	0.38	8.92	0.38	1.13e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg18446336	chr7:2847575	GNA12	-0.29	-6.79	-0.3	3.49e-11	Height;
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg27476859	chr7:2772710	GNA12	0.52	10.34	0.43	1.06e-22	Height;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg15971980	chr6:150254442	NA	0.46	8.68	0.37	6.58e-17	Lung cancer;
LGG	cis	rs9513627	1.000	rs7334274	chr13:100120801	G/A	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs9783347	1.000	rs9783347	chr11:18384938	A/G	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.47	-0.33	4.09e-13	Pancreatic cancer;
LGG	cis	rs896854	0.714	rs572547	chr8:95966286	A/G	cg16049864	chr8:95962084	TP53INP1	0.4	8.7	0.37	5.74e-17	Type 2 diabetes;
LGG	cis	rs977987	0.966	rs11643207	chr16:75498793	C/T	cg03315344	chr16:75512273	CHST6	0.59	11.7	0.48	7.21e-28	Dupuytren's disease;
LGG	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg09137382	chr11:130731461	NA	0.41	7.9	0.34	2e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs981844	1.000	rs1371161	chr4:154655171	T/C	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.22e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs3812049	0.506	rs36694	chr5:127548955	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.56	0.33	2.26e-13	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.36	0.43	9.08e-23	Diabetic retinopathy;
LGG	cis	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg27411982	chr8:10470053	RP1L1	0.46	7.99	0.35	1.06e-14	Retinal vascular caliber;
LGG	cis	rs8032158	0.963	rs1912402	chr15:56161919	C/T	cg02198044	chr15:56286336	NEDD4	-0.68	-11.74	-0.48	4.69e-28	Keloid;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg26668828	chr6:292823	DUSP22	0.69	12.14	0.49	1.21e-29	Menopause (age at onset);
LGG	cis	rs6977660	0.714	rs6954046	chr7:19820388	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.46	0.37	3.41e-16	Thyroid stimulating hormone;
LGG	cis	rs2074193	0.573	rs215363	chr12:47740388	A/G	cg02516419	chr12:47771422	NA	-0.64	-9.21	-0.39	1.09e-18	Migraine with aura;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.27	-0.36	1.46e-15	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13436085	chr3:183904316	ABCF3	0.44	7.04	0.31	6.98e-12	Cognitive performance;
LGG	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg03959625	chr15:84868606	LOC388152	0.55	8.71	0.38	5.43e-17	Schizophrenia;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-11.87	-0.48	1.45e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg00677455	chr12:58241039	CTDSP2	0.39	7.4	0.33	6.34e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10743315	0.778	rs10841184	chr12:19370768	T/G	cg02471346	chr12:19282374	PLEKHA5	-0.52	-7.23	-0.32	2.03e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs992157	0.798	rs4996257	chr2:219162836	C/T	cg04731861	chr2:219085781	ARPC2	-0.44	-10.9	-0.45	8.82e-25	Colorectal cancer;
LGG	cis	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg19847130	chr8:10466454	RP1L1	0.32	7.0	0.31	8.96e-12	Neuroticism;
LGG	cis	rs3741404	0.560	rs12362602	chr11:63908660	G/A	cg18225595	chr11:63971243	STIP1	-0.52	-10.45	-0.44	4.35e-23	Platelet count;
LGG	cis	rs28595532	0.920	rs55671478	chr4:119753811	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7011049	0.778	rs113723883	chr8:53867487	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg12159575	chr19:4910274	UHRF1	-0.4	-6.79	-0.3	3.47e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg18538332	chr22:24372958	LOC391322	-0.48	-7.03	-0.31	7.67e-12	Beard thickness;
LGG	cis	rs1062753	0.527	rs2187959	chr22:42347844	T/G	cg15128208	chr22:42549153	NA	0.39	7.19	0.32	2.57e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs9915657	0.660	rs975772	chr17:70067810	T/G	cg09344028	chr17:70110421	NA	0.55	11.69	0.48	7.42e-28	Thyroid hormone levels;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg02269571	chr22:50332266	NA	-0.63	-10.16	-0.43	5.21e-22	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17438055	chr6:75953690	COX7A2	0.42	6.98	0.31	1.02e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs988958	0.565	rs35733689	chr2:42236778	G/C	cg27252766	chr2:42229092	NA	0.54	7.37	0.32	8.16e-13	Hypospadias;
LGG	cis	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg17545662	chr6:170176663	C6orf70	0.69	8.85	0.38	1.85e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-9.7	-0.41	2.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg05313129	chr8:58192883	C8orf71	-0.74	-9.78	-0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11874712	0.527	rs1866321	chr18:43698309	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.21	-0.39	1.15e-18	Migraine - clinic-based;
LGG	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg08528231	chr16:12997261	SHISA9	-0.33	-6.78	-0.3	3.68e-11	Positive affect;Subjective well-being;
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	0.901	rs778732	chr7:65822360	C/T	cg12463550	chr7:65579703	CRCP	0.74	7.94	0.35	1.54e-14	Diabetic kidney disease;
LGG	cis	rs1847202	0.859	rs4274693	chr3:72949375	A/G	cg25664220	chr3:72788482	NA	-0.26	-7.59	-0.33	1.81e-13	Motion sickness;
LGG	cis	rs6547631	0.622	rs4240202	chr2:85925680	T/G	cg24620635	chr2:85921963	GNLY	0.5	9.99	0.42	2.02e-21	Blood protein levels;
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.51	0.33	3.03e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs6961069	0.749	rs4316098	chr7:80259988	C/T	cg04458919	chr7:80252533	CD36	0.29	6.93	0.31	1.39e-11	Platelet count;
LGG	trans	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs11169552	0.510	rs11169493	chr12:50959426	C/T	cg12884762	chr12:50931848	DIP2B	0.41	7.72	0.34	7.36e-14	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7572644	0.723	rs13019037	chr2:28024642	C/T	cg27432699	chr2:27873401	GPN1	0.48	6.85	0.3	2.4e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.35	0.43	1.05e-22	Prudent dietary pattern;
LGG	cis	rs4731207	0.671	rs7811607	chr7:124447843	T/G	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	trans	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9937943	0.667	rs9945	chr16:74490556	G/A	cg01733217	chr16:74700730	RFWD3	0.65	8.5	0.37	2.71e-16	Neutrophil percentage of white cells;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg19318889	chr4:1322082	MAEA	0.48	8.17	0.35	2.95e-15	Longevity;
LGG	trans	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.2	0.39	1.19e-18	Aortic root size;
LGG	cis	rs9381040	0.655	rs2268187	chr6:41042993	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.44	-0.33	4.78e-13	Alzheimer's disease (late onset);
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.62	-0.56	4.62e-40	Prudent dietary pattern;
LGG	cis	rs929354	0.772	rs1182442	chr7:157026633	G/A	cg17757837	chr7:157058334	UBE3C	-0.79	-15.98	-0.6	4.14e-46	Body mass index;
LGG	cis	rs2832191	0.632	rs1984011	chr21:30337831	T/A	cg08807101	chr21:30365312	RNF160	-0.9	-18.76	-0.66	8.21e-59	Dental caries;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	-0.56	-9.62	-0.41	4.25e-20	Bipolar disorder;
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.69	-0.44	5.42e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.66	0.34	1.08e-13	Glycated hemoglobin levels;
LGG	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.56	-0.33	2.2e-13	IgG glycosylation;
LGG	cis	rs4774899	0.752	rs2703576	chr15:57355156	A/G	cg08128148	chr15:57256372	TCF12	-0.29	-7.18	-0.32	2.75e-12	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg21775007	chr8:11205619	TDH	0.43	6.8	0.3	3.28e-11	Neuroticism;
LGG	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg25342872	chr17:79175132	AZI1	-0.48	-8.11	-0.35	4.47e-15	Frontotemporal dementia;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08677398	chr8:58056175	NA	0.5	7.98	0.35	1.18e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg21427119	chr20:30132790	HM13	0.41	7.12	0.31	4.27e-12	Mean corpuscular hemoglobin;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26791985	chr3:52008971	ABHD14A;ABHD14B	0.4	6.66	0.3	7.82e-11	Cognitive performance;
LGG	cis	rs3849570	0.883	rs28435942	chr3:81679692	C/T	cg07356753	chr3:81810745	GBE1	-0.44	-7.13	-0.31	4.01e-12	Waist circumference;Body mass index;
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9788682	0.747	rs11072766	chr15:78771546	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.1	-0.35	4.78e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9814567	0.762	rs13075332	chr3:134329836	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.07	0.46	1.94e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11608355	1.000	rs10774695	chr12:109868040	G/A	cg19025524	chr12:109796872	NA	-0.48	-9.11	-0.39	2.55e-18	Neuroticism;
LGG	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.12	0.31	4.16e-12	Educational attainment;
LGG	cis	rs10464366	0.544	rs4723824	chr7:39153698	T/C	cg18850127	chr7:39170497	POU6F2	0.63	16.11	0.6	1.14e-46	IgG glycosylation;
LGG	cis	rs8032158	0.702	rs11632977	chr15:56131609	T/C	cg05129572	chr15:56138634	NEDD4	-0.4	-6.79	-0.3	3.53e-11	Keloid;
LGG	cis	rs1881509	0.660	rs7102279	chr11:1434680	T/C	cg07067744	chr11:1421172	BRSK2	0.35	6.87	0.3	2.13e-11	Heroin dependence;
LGG	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.15	-0.35	3.41e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09844983	chr1:28240714	RPA2	0.44	6.89	0.3	1.78e-11	Gut microbiome composition (summer);
LGG	cis	rs7772486	0.686	rs9403746	chr6:146103768	C/A	cg23711669	chr6:146136114	FBXO30	-0.4	-6.72	-0.3	5.32e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs477692	0.647	rs524804	chr10:131430686	G/A	cg05714579	chr10:131428358	MGMT	-0.71	-16.03	-0.6	2.55e-46	Response to temozolomide;
LGG	cis	rs921968	0.541	rs664514	chr2:219329819	A/G	cg01130898	chr2:219473002	PLCD4	-0.42	-7.25	-0.32	1.72e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg06634786	chr22:41940651	POLR3H	-0.67	-11.21	-0.46	5.86e-26	Vitiligo;
LGG	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg00187635	chr16:83986795	OSGIN1	0.49	7.37	0.32	7.8e-13	Pursuit maintenance gain;
LGG	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg26677194	chr12:130822605	PIWIL1	0.57	10.24	0.43	2.59e-22	Menopause (age at onset);
LGG	cis	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg08975724	chr8:8085496	FLJ10661	0.44	8.35	0.36	8.26e-16	Mood instability;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	16.83	0.62	6.17e-50	Tonsillectomy;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg13628971	chr7:2884303	GNA12	0.54	11.73	0.48	5.37e-28	Height;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.63	0.54	8.42e-36	Obesity-related traits;
LGG	cis	rs2721195	0.874	rs2721173	chr8:145744429	C/T	cg26752003	chr8:145688521	CYHR1	-0.38	-8.05	-0.35	6.98e-15	Age at first birth;
LGG	cis	rs2839186	0.934	rs2839197	chr21:47708133	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	trans	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg10756647	chr7:56101905	PSPH	0.75	8.58	0.37	1.43e-16	Gout;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.62	-10.98	-0.45	4.53e-25	Lymphocyte counts;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg09840472	chr7:22764397	NA	-0.42	-6.81	-0.3	2.96e-11	Apolipoprotein A-IV levels;
LGG	cis	rs981844	1.000	rs62325085	chr4:154663283	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs908922	0.743	rs10888499	chr1:152532742	C/A	cg20991723	chr1:152506922	NA	-0.56	-9.45	-0.4	1.66e-19	Hair morphology;
LGG	cis	rs2361718	0.631	rs2289539	chr17:78152119	T/C	cg09238746	chr17:78121135	EIF4A3	-0.73	-13.54	-0.53	2.09e-35	Yeast infection;
LGG	trans	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg02002194	chr4:3960332	NA	0.43	7.93	0.35	1.64e-14	Neuroticism;
LGG	cis	rs8013055	0.846	rs10151805	chr14:105974781	T/C	cg25008857	chr14:105974488	NA	0.57	10.24	0.43	2.52e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs8078723	0.763	rs4433838	chr17:38143532	C/T	cg17467752	chr17:38218738	THRA	-0.62	-11.29	-0.46	2.91e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	cis	rs6942756	1.000	rs7806089	chr7:128972215	C/G	cg02491457	chr7:128862824	NA	-0.74	-13.48	-0.53	3.47e-35	White matter hyperintensity burden;
LGG	cis	rs694739	0.894	rs11601860	chr11:64110422	A/T	cg22916017	chr11:64110731	CCDC88B	0.51	10.49	0.44	3.08e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs17401966	0.838	rs4529713	chr1:10307295	A/G	cg15208524	chr1:10270712	KIF1B	0.45	7.8	0.34	4.03e-14	Hepatocellular carcinoma;
LGG	cis	rs806795	0.605	rs6935954	chr6:26255451	A/G	cg00631329	chr6:26305371	NA	-0.51	-8.71	-0.38	5.5e-17	Mosquito bite size;
LGG	cis	rs9964724	0.835	rs7243102	chr18:35161833	C/T	cg27332583	chr18:35150602	NA	-0.46	-10.09	-0.42	9.35e-22	Educational attainment (years of education);
LGG	cis	rs1639906	0.708	rs3779013	chr7:2210844	A/G	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.18	-0.32	2.76e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg06532163	chr17:45867833	NA	0.52	7.96	0.35	1.32e-14	IgG glycosylation;
LGG	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg09307838	chr4:120376055	NA	-0.77	-12.98	-0.52	4.67e-33	Corneal astigmatism;
LGG	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg11317459	chr13:21872234	NA	1.18	18.95	0.66	1.09e-59	White matter hyperintensity burden;
LGG	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg24449463	chr1:168025552	DCAF6	-0.6	-10.6	-0.44	1.2e-23	Schizophrenia;
LGG	trans	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg02002194	chr4:3960332	NA	-0.44	-8.27	-0.36	1.41e-15	Mood instability;
LGG	cis	rs7394190	0.748	rs4746139	chr10:75407649	A/C	cg07699608	chr10:75541558	CHCHD1	0.58	7.72	0.34	7.16e-14	Incident atrial fibrillation;
LGG	cis	rs9467711	0.591	rs10484435	chr6:26031811	A/C	cg21479132	chr6:26055353	NA	0.81	7.46	0.33	4.36e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12135894	0.562	rs6688969	chr1:3743391	C/T	cg10555106	chr1:3691387	LOC388588	0.29	6.89	0.3	1.89e-11	Mean corpuscular volume;
LGG	cis	rs4538187	0.760	rs116503511	chr2:64155736	T/C	cg19915305	chr2:64069682	UGP2	-0.64	-12.8	-0.51	2.43e-32	Systolic blood pressure;
LGG	cis	rs1669338	0.510	rs3804788	chr3:3169466	C/A	cg16797762	chr3:3221439	CRBN	-0.98	-12.91	-0.51	9.05e-33	White matter integrity;
LGG	cis	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg08250081	chr4:10125330	NA	0.47	8.69	0.37	6.33e-17	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs654950	0.934	rs641974	chr1:42002137	G/A	cg16096631	chr1:42092165	HIVEP3	-0.41	-8.42	-0.36	4.66e-16	Airway imaging phenotypes;
LGG	cis	rs7615952	0.515	rs4267608	chr3:125680500	C/T	cg05084668	chr3:125655381	ALG1L	-0.74	-10.56	-0.44	1.66e-23	Blood pressure (smoking interaction);
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.35	-0.43	1.03e-22	Lymphocyte counts;
LGG	cis	rs68170813	0.559	rs77185844	chr7:106812916	A/C	cg02696742	chr7:106810147	HBP1	-0.76	-10.93	-0.45	7e-25	Coronary artery disease;
LGG	cis	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg06521331	chr12:34319734	NA	-0.58	-9.98	-0.42	2.25e-21	Morning vs. evening chronotype;
LGG	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg00701064	chr4:6280414	WFS1	0.74	16.12	0.6	9.68e-47	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2073300	0.609	rs17757442	chr20:23421101	A/G	cg12062639	chr20:23401060	NAPB	-0.88	-8.42	-0.36	4.72e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs875971	0.861	rs801215	chr7:66011938	A/T	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs11252926	0.661	rs7077209	chr10:484159	A/G	cg08603382	chr10:743973	NA	-0.42	-7.64	-0.33	1.23e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg05313129	chr8:58192883	C8orf71	-0.61	-8.51	-0.37	2.48e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs367943	0.966	rs455435	chr5:112799412	T/C	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs240764	0.746	rs239197	chr6:101133600	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.6	0.33	1.61e-13	Neuroticism;
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg16141378	chr3:129829833	LOC729375	0.42	9.72	0.41	1.86e-20	Neuroticism;
LGG	cis	rs12476592	0.602	rs6724160	chr2:63786423	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	cis	rs514406	0.793	rs4500255	chr1:53213279	A/G	cg24675658	chr1:53192096	ZYG11B	0.51	10.4	0.44	6.36e-23	Monocyte count;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg02484708	chr17:57409001	YPEL2	-0.4	-6.93	-0.31	1.46e-11	Iris color (L* coordinate);
LGG	cis	rs8012	0.517	rs1060218	chr19:13008607	G/T	cg23899408	chr19:12877188	HOOK2	-0.47	-7.62	-0.33	1.4e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs8032158	1.000	rs67505007	chr15:56196253	C/T	cg02198044	chr15:56286336	NEDD4	-0.71	-12.44	-0.5	7.8e-31	Keloid;
LGG	cis	rs1401999	0.966	rs2292998	chr3:183663833	T/C	cg20387954	chr3:183756860	HTR3D	0.65	13.12	0.52	1.14e-33	Anterior chamber depth;
LGG	cis	rs2235649	0.833	rs55684627	chr16:1848817	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg25665528	chr16:2260870	C16orf79	-0.35	-7.78	-0.34	4.65e-14	Height;
LGG	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg08601574	chr20:25228251	PYGB	0.38	7.92	0.35	1.73e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg19774624	chr17:42201019	HDAC5	-0.84	-16.46	-0.61	3.02e-48	Total body bone mineral density;
LGG	cis	rs17767392	0.914	rs7147668	chr14:71857427	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.94	-0.38	9.54e-18	Mitral valve prolapse;
LGG	cis	rs11252926	0.624	rs7085214	chr10:468133	A/G	cg18196295	chr10:418757	DIP2C	0.58	11.43	0.47	8.02e-27	Psychosis in Alzheimer's disease;
LGG	cis	rs62400317	1.000	rs62400317	chr6:45284923	C/T	cg18551225	chr6:44695536	NA	-0.61	-10.01	-0.42	1.77e-21	Total body bone mineral density;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-11.7	-0.48	6.83e-28	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs2832191	0.720	rs2832200	chr21:30499165	G/A	cg08807101	chr21:30365312	RNF160	-0.82	-16.77	-0.61	1.16e-49	Dental caries;
LGG	cis	rs9911578	0.933	rs11868348	chr17:57179238	C/T	cg12560992	chr17:57184187	TRIM37	0.93	16.69	0.61	2.65e-49	Intelligence (multi-trait analysis);
LGG	cis	rs2832191	0.703	rs2853827	chr21:30443596	T/C	cg24692254	chr21:30365293	RNF160	1.05	29.94	0.81	2.28e-110	Dental caries;
LGG	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg09165964	chr15:75287851	SCAMP5	-0.53	-9.8	-0.41	1e-20	Breast cancer;
LGG	trans	rs7944735	0.507	rs10742827	chr11:48102350	C/T	cg11707556	chr5:10655725	ANKRD33B	0.47	7.34	0.32	9.6e-13	Intraocular pressure;
LGG	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg02487422	chr3:49467188	NICN1	0.57	10.47	0.44	3.72e-23	Resting heart rate;
LGG	cis	rs11676348	0.712	rs12694426	chr2:218942351	T/G	cg00012203	chr2:219082015	ARPC2	-0.48	-8.49	-0.37	2.84e-16	Ulcerative colitis;
LGG	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg24397884	chr7:158709396	WDR60	-1.05	-25.19	-0.76	7.83e-89	Height;
LGG	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg00343986	chr7:65444356	GUSB	0.49	8.6	0.37	1.23e-16	Aortic root size;
LGG	cis	rs2075371	0.966	rs2544224	chr7:133995832	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	15.0	0.57	9.65e-42	Mean platelet volume;
LGG	cis	rs834603	0.547	rs834599	chr7:47463842	T/G	cg09696706	chr7:47479511	TNS3	0.35	7.81	0.34	3.79e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs4427176	0.507	rs6601361	chr8:9579743	A/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs537930	0.560	rs28330	chr5:134352534	C/T	cg24576358	chr5:134350122	NA	0.41	9.14	0.39	2e-18	Height;
LGG	cis	rs10992471	0.756	rs10115222	chr9:95128149	C/T	cg13798575	chr9:95087839	CENPP;NOL8	0.45	7.19	0.32	2.67e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg13207630	chr7:32358064	NA	0.79	8.14	0.35	3.78e-15	Body mass index;
LGG	cis	rs16944613	0.588	rs8042497	chr15:91110331	T/A	cg26821196	chr15:91095069	CRTC3	0.58	8.78	0.38	3.1e-17	Colorectal cancer;
LGG	cis	rs7582180	0.627	rs2241811	chr2:101011724	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	6.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg06713675	chr4:122721982	EXOSC9	-0.63	-10.47	-0.44	3.67e-23	Type 2 diabetes;
LGG	trans	rs9354308	0.903	rs9360158	chr6:66558164	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-8.79	-0.38	2.96e-17	Metabolite levels;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg06138931	chr13:21896616	NA	0.46	9.97	0.42	2.44e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.66	0.41	3.18e-20	Prudent dietary pattern;
LGG	cis	rs11758351	0.660	rs55643278	chr6:26222888	C/A	cg06951627	chr6:26196580	NA	0.46	6.87	0.3	2.07e-11	Gout;Renal underexcretion gout;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg17145862	chr1:211918768	LPGAT1	0.79	17.3	0.63	4.34e-52	Leprosy;
LGG	trans	rs7944735	0.832	rs7130876	chr11:48050995	A/G	cg15704280	chr7:45808275	SEPT13	0.73	8.82	0.38	2.26e-17	Intraocular pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25341131	chr3:38066777	PLCD1	0.49	7.03	0.31	7.33e-12	Gut microbiome composition (summer);
LGG	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg08999081	chr20:33150536	PIGU	-0.31	-7.16	-0.32	3.15e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7177699	0.557	rs6495335	chr15:79117133	G/T	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg14168545	chr13:41235199	FOXO1	-0.44	-6.99	-0.31	9.95e-12	Apolipoprotein A-IV levels;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg24607181	chr17:41446203	NA	-0.3	-7.08	-0.31	5.37e-12	Menopause (age at onset);
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg18963800	chr10:38644991	HSD17B7P2	0.44	7.09	0.31	4.94e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs780096	0.546	rs35073769	chr2:27731376	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.32	-0.53	1.68e-34	Total body bone mineral density;
LGG	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg02811702	chr13:24901961	NA	0.41	7.84	0.34	3.12e-14	Obesity-related traits;
LGG	cis	rs7394190	0.748	rs2292307	chr10:75549916	C/A	cg07699608	chr10:75541558	CHCHD1	0.55	7.39	0.32	6.75e-13	Incident atrial fibrillation;
LGG	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg20503657	chr10:835505	NA	0.75	10.36	0.43	9.18e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs62238980	0.614	rs77132907	chr22:32501006	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs7582720	1.000	rs72934510	chr2:203925360	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.34	0.4	3.94e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.92	9.87	0.42	5.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs514406	0.893	rs522287	chr1:53365493	C/T	cg24675658	chr1:53192096	ZYG11B	-0.48	-9.55	-0.41	7.5e-20	Monocyte count;
LGG	cis	rs1318772	0.689	rs35565569	chr5:112965621	T/C	cg12552261	chr5:112820674	MCC	0.6	6.71	0.3	5.74e-11	F-cell distribution;
LGG	cis	rs6763768	0.577	rs35536048	chr3:53388950	C/G	cg16894138	chr3:53270350	TKT	0.42	8.08	0.35	5.75e-15	Bacterial meningitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04260516	chr14:24630327	IRF9	0.47	7.41	0.33	6.03e-13	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg19812747	chr11:111475976	SIK2	0.35	6.73	0.3	4.92e-11	Primary sclerosing cholangitis;
LGG	cis	rs9914988	0.778	rs9907192	chr17:27122426	C/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6977660	1.000	rs4719584	chr7:19823388	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.89	0.38	1.42e-17	Thyroid stimulating hormone;
LGG	cis	rs35110281	0.667	rs2250773	chr21:45087786	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.91	-0.38	1.22e-17	Mean corpuscular volume;
LGG	cis	rs2273669	0.915	rs3734650	chr6:109295017	A/G	cg05315195	chr6:109294784	ARMC2	-0.51	-7.34	-0.32	9.62e-13	Prostate cancer;
LGG	cis	rs4730779	0.534	rs10255092	chr7:117012241	A/G	cg10524701	chr7:117356490	CTTNBP2	0.39	7.65	0.33	1.18e-13	Waist circumference;
LGG	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-7.53	-0.33	2.66e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg20578329	chr17:80767326	TBCD	-0.78	-11.81	-0.48	2.52e-28	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg20744362	chr22:50050164	C22orf34	0.41	7.13	0.31	3.82e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs8032158	1.000	rs10851599	chr15:56154064	T/G	cg02198044	chr15:56286336	NEDD4	-0.69	-11.96	-0.49	6.23e-29	Keloid;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg02158880	chr13:53174818	NA	0.5	10.23	0.43	2.7e-22	Lewy body disease;
LGG	cis	rs4727027	0.834	rs7811446	chr7:148773226	G/T	cg23583168	chr7:148888333	NA	-0.85	-16.24	-0.6	2.82e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7129556	0.737	rs484363	chr11:77492594	A/G	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.23e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.55	-0.33	2.41e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12950390	0.853	rs8071192	chr17:45856141	A/G	cg00777063	chr17:45855553	NA	-0.32	-6.76	-0.3	4.05e-11	IgG glycosylation;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.21e-20	Life satisfaction;
LGG	cis	rs79985863	0.702	rs2838942	chr21:46904833	A/G	cg01885814	chr21:46910559	COL18A1	-0.68	-7.31	-0.32	1.21e-12	Alzheimer disease and age of onset;
LGG	cis	rs12971120	0.891	rs71359051	chr18:72169723	G/A	cg25817165	chr18:72167213	CNDP2	-0.66	-13.5	-0.53	2.98e-35	Refractive error;
LGG	cis	rs7917772	0.636	rs4418737	chr10:104525123	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.98	-0.35	1.16e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg12419862	chr22:24373484	LOC391322	1.12	28.07	0.79	5.81e-102	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2242116	1.000	rs2168443	chr3:46947087	A/T	cg16586182	chr3:47516702	SCAP	0.47	7.71	0.34	7.64e-14	Birth weight;
LGG	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.72	0.34	7e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1497406	0.744	rs10907282	chr1:16510139	A/G	cg20430773	chr1:16534157	ARHGEF19	0.29	8.05	0.35	6.85e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs735539	0.645	rs1052209	chr13:21216850	C/T	cg04906043	chr13:21280425	IL17D	-0.54	-8.66	-0.37	7.72e-17	Dental caries;
LGG	cis	rs262150	0.625	rs55882200	chr7:158769280	G/C	cg13444538	chr7:158905317	VIPR2	-0.47	-7.0	-0.31	8.88e-12	Facial morphology (factor 20);
LGG	cis	rs7917772	0.503	rs11191342	chr10:104344450	G/A	cg05096777	chr10:104283225	SUFU	0.31	6.82	0.3	2.9e-11	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.66	-8.82	-0.38	2.3e-17	Diabetic retinopathy;
LGG	cis	rs13323323	0.691	rs9814256	chr3:44668037	A/T	cg02073558	chr3:44770973	ZNF501	0.53	7.72	0.34	7.05e-14	IgG glycosylation;
LGG	cis	rs8180040	0.966	rs59586735	chr3:47518325	C/T	cg16586182	chr3:47516702	SCAP	0.77	15.38	0.58	2.06e-43	Colorectal cancer;
LGG	cis	rs7833790	0.724	rs72603871	chr8:82754460	C/G	cg06027949	chr8:82754900	SNX16	0.54	8.34	0.36	8.36e-16	Diastolic blood pressure;
LGG	cis	rs798554	0.757	rs1182185	chr7:2872233	A/G	cg04166393	chr7:2884313	GNA12	0.44	8.44	0.37	4.04e-16	Height;
LGG	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs1336900	0.641	rs6587756	chr1:150546865	A/T	cg13175981	chr1:150552382	MCL1	0.44	6.92	0.31	1.53e-11	Blood protein levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09238957	chr16:46723420	ORC6L;VPS35	-0.48	-6.9	-0.31	1.69e-11	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs3735485	0.738	rs4392784	chr7:45130513	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.12	-0.39	2.22e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg23306229	chr2:178417860	TTC30B	0.74	9.25	0.4	8.18e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17221829	0.733	rs11018679	chr11:89362869	G/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.3e-18	Anxiety in major depressive disorder;
LGG	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg20818283	chr2:191399100	TMEM194B	-0.28	-6.83	-0.3	2.72e-11	Pulse pressure;
LGG	cis	rs2285947	1.000	rs2285946	chr7:21583329	T/C	cg04471919	chr7:21584483	DNAH11	0.49	13.84	0.54	1.02e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg21775007	chr8:11205619	TDH	-0.45	-7.33	-0.32	1.02e-12	Neuroticism;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg23782820	chr8:58130467	NA	0.57	8.36	0.36	7.61e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	ch.9.2262725R	chr9:134308523	BAT2L1	0.45	7.37	0.32	7.94e-13	Cognitive performance;
LGG	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.77	-0.48	3.71e-28	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.47e-12	HDL cholesterol;
LGG	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.26e-14	Cystic fibrosis severity;
LGG	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.96	-0.91	1.19e-174	Myeloid white cell count;
LGG	cis	rs77633900	0.614	rs280013	chr15:76978139	C/T	cg21673338	chr15:77095150	SCAPER	0.66	10.44	0.44	4.64e-23	Non-glioblastoma glioma;Glioma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03337784	chr13:41768818	KBTBD7	0.48	7.36	0.32	8.69e-13	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.88	-0.38	1.47e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs911119	1.000	rs35488434	chr20:23620401	T/C	cg16589663	chr20:23618590	CST3	0.47	6.75	0.3	4.46e-11	Chronic kidney disease;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg02018176	chr4:1364513	KIAA1530	0.45	9.9	0.42	4.43e-21	Obesity-related traits;
LGG	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg11764359	chr7:65958608	NA	-0.64	-10.59	-0.44	1.25e-23	Aortic root size;
LGG	cis	rs1620921	0.625	rs10945701	chr6:161266812	C/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs317689	0.690	rs10878946	chr12:69642315	C/T	cg20891283	chr12:69753455	YEATS4	0.45	6.87	0.3	2.13e-11	Response to diuretic therapy;
LGG	cis	rs62238980	0.522	rs77418985	chr22:32380919	C/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg04529724	chr6:150244392	RAET1G	0.33	6.67	0.3	7.37e-11	Testicular germ cell tumor;
LGG	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg14673194	chr17:80132900	CCDC57	0.42	7.25	0.32	1.72e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg04149295	chr10:70884716	VPS26A	0.48	7.12	0.31	4.05e-12	Left atrial antero-posterior diameter;
LGG	cis	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg10402321	chr1:26617780	UBXN11	-0.36	-7.17	-0.32	2.91e-12	Obesity-related traits;
LGG	cis	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg05368731	chr17:41323189	NBR1	0.93	18.23	0.65	2.41e-56	Menopause (age at onset);
LGG	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg13550731	chr2:172543902	DYNC1I2	-0.99	-22.47	-0.72	3.86e-76	Schizophrenia;
LGG	cis	rs4242434	0.927	rs13264187	chr8:22506098	C/T	cg02227867	chr8:22457446	C8orf58	-0.46	-8.73	-0.38	4.69e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3091242	0.933	rs9438905	chr1:25764177	A/G	cg27572855	chr1:25598939	RHD	0.49	10.95	0.45	5.93e-25	Erythrocyte sedimentation rate;
LGG	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.23	-0.32	2.07e-12	Mood instability;
LGG	cis	rs72945132	0.598	rs61887432	chr11:70239065	A/C	cg00319359	chr11:70116639	PPFIA1	0.62	6.74	0.3	4.67e-11	Coronary artery disease;
LGG	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg26769984	chr7:1090371	C7orf50	0.43	7.69	0.34	8.88e-14	Bronchopulmonary dysplasia;
LGG	cis	rs4696584	0.877	rs59686383	chr4:155400718	T/C	cg04517429	chr4:155413618	DCHS2	-0.31	-7.06	-0.31	6.33e-12	Folding of antihelix;
LGG	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg11317459	chr13:21872234	NA	-1.2	-19.65	-0.67	6.07e-63	White matter hyperintensity burden;
LGG	cis	rs9660992	0.674	rs17345837	chr1:205263122	C/T	cg00857998	chr1:205179979	DSTYK	0.47	6.7	0.3	6.09e-11	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.23	0.63	9.13e-52	Exhaled nitric oxide levels;
LGG	cis	rs4750440	0.706	rs1031753	chr10:14020110	T/C	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.82	-0.51	2.02e-32	Adiponectin levels;
LGG	cis	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg00383909	chr3:49044727	WDR6	0.44	7.35	0.32	9.02e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9880211	0.898	rs6770476	chr3:136073920	C/T	cg12473912	chr3:136751656	NA	-0.47	-7.48	-0.33	3.69e-13	Body mass index;Height;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.2	-0.36	2.44e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7973719	0.769	rs61917956	chr12:7348659	T/C	cg07052231	chr12:7363540	PEX5	0.39	6.71	0.3	5.76e-11	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24546549	chr8:141467794	TRAPPC9	0.49	7.18	0.32	2.78e-12	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.680	rs73073250	chr3:42016559	G/T	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2645694	0.626	rs2703124	chr4:77820626	G/T	cg18351406	chr4:77819688	ANKRD56	0.47	8.04	0.35	7.31e-15	Emphysema distribution in smoking;
LGG	cis	rs35771425	0.564	rs34813082	chr1:211424681	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.23	-0.36	1.9e-15	Educational attainment (years of education);
LGG	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.53	0.53	2.19e-35	Bladder cancer;
LGG	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg06889755	chr6:150326021	RAET1K	-0.4	-8.26	-0.36	1.54e-15	Alopecia areata;
LGG	cis	rs1401999	1.000	rs4148579	chr3:183685249	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.63	0.61	4.88e-49	Anterior chamber depth;
LGG	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg18252515	chr7:66147081	NA	1.43	20.72	0.69	5.87e-68	Diabetic kidney disease;
LGG	cis	rs2421770	0.532	rs4756216	chr11:35366112	G/A	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.56	-0.33	2.11e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs4538187	1.000	rs7590399	chr2:64081466	C/A	cg14150252	chr2:64069583	UGP2	0.5	9.87	0.42	5.63e-21	Systolic blood pressure;
LGG	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg00717180	chr2:96193071	NA	-0.41	-7.28	-0.32	1.49e-12	HDL cholesterol;
LGG	trans	rs8073060	0.963	rs35614987	chr17:33869466	A/C	cg19694781	chr19:47549865	TMEM160	0.65	10.44	0.44	4.71e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	10.25	0.43	2.35e-22	Tonsillectomy;
LGG	cis	rs12701220	0.725	rs13242971	chr7:1055515	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-7.33	-0.32	1.05e-12	Bronchopulmonary dysplasia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08982381	chr9:80647290	GNAQ	0.51	7.83	0.34	3.44e-14	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs35330014	chr17:41212547	C/T	cg05368731	chr17:41323189	NBR1	0.93	18.36	0.65	5.48e-57	Menopause (age at onset);
LGG	cis	rs9291683	0.588	rs2240721	chr4:10020564	G/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.87	0.3	2.12e-11	Bone mineral density;
LGG	cis	rs12493885	0.818	rs1713817	chr3:153872345	A/G	cg17054900	chr3:154042577	DHX36	0.68	8.65	0.37	8.68e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs5758511	0.508	rs2854827	chr22:42461918	G/A	cg00645731	chr22:42541494	CYP2D7P1	0.42	6.79	0.3	3.41e-11	Birth weight;
LGG	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.36	0.53	1.13e-34	Tonsillectomy;
LGG	cis	rs735396	0.731	rs1182933	chr12:121454622	C/T	cg02403541	chr12:121454288	C12orf43	0.64	10.18	0.43	4.35e-22	N-glycan levels;
LGG	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg07507251	chr3:52567010	NT5DC2	0.34	6.97	0.31	1.11e-11	Electroencephalogram traits;
LGG	cis	rs10267417	0.603	rs2214320	chr7:19946700	T/C	cg05791153	chr7:19748676	TWISTNB	0.52	6.81	0.3	3.01e-11	Night sleep phenotypes;
LGG	cis	rs7726839	0.561	rs72703050	chr5:582917	A/C	cg09021430	chr5:549028	NA	-0.81	-12.81	-0.51	2.17e-32	Obesity-related traits;
LGG	trans	rs9329221	0.935	rs3750310	chr8:10283426	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.69	-0.41	2.38e-20	Neuroticism;
LGG	cis	rs4629710	0.592	rs11758994	chr6:131582022	A/C	cg12606694	chr6:131520996	AKAP7	0.52	8.53	0.37	2.11e-16	Multiple myeloma (IgH translocation);
LGG	trans	rs7395662	0.926	rs7122869	chr11:48727999	G/T	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	trans	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg00711542	chr16:29343894	RUNDC2C	0.4	6.86	0.3	2.22e-11	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg04703951	chr17:43578652	NA	-0.37	-7.55	-0.33	2.34e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs4481887	0.927	rs28524655	chr1:248474331	C/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs4727027	0.866	rs35599790	chr7:148806012	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.71	0.3	5.68e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21442773	chr1:236029828	LYST	0.43	7.12	0.31	4.24e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-8.01	-0.35	9.09e-15	Lung cancer;
LGG	cis	rs7681440	0.904	rs28507349	chr4:90767063	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.06	-0.39	3.82e-18	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	11.12	0.46	1.28e-25	Obesity-related traits;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg07157834	chr1:205819609	PM20D1	0.73	16.65	0.61	4.12e-49	Menarche (age at onset);
LGG	cis	rs12477438	0.798	rs6732579	chr2:99560239	A/T	cg08885076	chr2:99613938	TSGA10	-0.59	-12.16	-0.49	1.04e-29	Chronic sinus infection;
LGG	cis	rs889398	0.617	rs4985450	chr16:69901106	A/T	cg00738113	chr16:70207722	CLEC18C	0.27	7.77	0.34	5.03e-14	Body mass index;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg12419862	chr22:24373484	LOC391322	-0.94	-19.44	-0.67	5.74e-62	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg02297831	chr4:17616191	MED28	0.47	8.79	0.38	2.91e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.830	rs4443295	chr4:99044935	G/A	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7659604	1.000	rs72678650	chr4:122666000	A/G	cg06713675	chr4:122721982	EXOSC9	-0.44	-6.99	-0.31	9.74e-12	Type 2 diabetes;
LGG	cis	rs7659604	0.539	rs3217753	chr4:122746325	A/G	cg19748678	chr4:122722346	EXOSC9	0.68	13.85	0.54	9.75e-37	Type 2 diabetes;
LGG	cis	rs7191439	0.789	rs4598894	chr16:88776141	G/A	cg02389323	chr16:88786976	FAM38A	1.07	12.97	0.52	4.98e-33	Plateletcrit;
LGG	cis	rs7590368	0.651	rs56093996	chr2:10931302	T/C	cg15705551	chr2:10952987	PDIA6	0.58	7.51	0.33	3.12e-13	Educational attainment (years of education);
LGG	cis	rs12950390	0.853	rs11079791	chr17:45859099	C/T	cg03474202	chr17:45855739	NA	-0.27	-7.96	-0.35	1.31e-14	IgG glycosylation;
LGG	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg13902645	chr11:5959945	NA	-0.73	-11.35	-0.47	1.61e-26	DNA methylation (variation);
LGG	trans	rs7819412	0.521	rs10100660	chr8:11038885	T/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.66	-0.3	7.92e-11	Triglycerides;
LGG	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.47	-0.4	1.46e-19	Triglycerides;
LGG	trans	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg11441553	chr12:57614120	NXPH4	-0.57	-7.3	-0.32	1.3e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2762353	0.808	rs1747522	chr6:25821807	T/A	cg18357526	chr6:26021779	HIST1H4A	0.6	10.58	0.44	1.37e-23	Blood metabolite levels;
LGG	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg02527881	chr3:46936655	PTH1R	0.33	7.94	0.35	1.51e-14	Birth weight;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg05368731	chr17:41323189	NBR1	0.96	18.74	0.66	9.83e-59	Menopause (age at onset);
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg04025307	chr7:1156635	C7orf50	0.58	8.22	0.36	2.02e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9814567	0.712	rs4306900	chr3:134334327	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	11.17	0.46	8.52e-26	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7851660	0.933	rs12341377	chr9:100610382	C/G	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.58e-40	Strep throat;
LGG	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	1.04	20.28	0.69	6.67e-66	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17979863	chr2:231852034	NA	0.47	7.19	0.32	2.68e-12	Gut microbiome composition (summer);
LGG	cis	rs17253792	0.687	rs10137995	chr14:56173687	A/G	cg01858014	chr14:56050164	KTN1	-0.71	-10.46	-0.44	4.07e-23	Putamen volume;
LGG	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.92	-0.31	1.51e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3735485	0.661	rs11761702	chr7:45126183	G/A	cg03440944	chr7:45023329	C7orf40	-0.55	-9.08	-0.39	3.08e-18	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg06917634	chr15:78832804	PSMA4	-0.83	-17.42	-0.63	1.21e-52	Sudden cardiac arrest;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs7618915	0.547	rs13069481	chr3:52666866	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs2760061	0.545	rs1745423	chr1:228224153	G/T	cg18477163	chr1:228402036	OBSCN	-0.29	-7.29	-0.32	1.31e-12	Diastolic blood pressure;
LGG	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg05044414	chr3:183734942	ABCC5	0.56	11.2	0.46	6.17e-26	Anterior chamber depth;
LGG	cis	rs1865760	0.613	rs7749342	chr6:25920265	T/C	cg12310025	chr6:25882481	NA	-0.51	-9.84	-0.42	7.29e-21	Height;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.33	-7.01	-0.31	8.43e-12	Schizophrenia;
LGG	cis	rs2976388	0.647	rs2082801	chr8:143786461	A/G	cg06565975	chr8:143823917	SLURP1	0.37	9.6	0.41	5.2e-20	Urinary tract infection frequency;
LGG	cis	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg03511173	chr18:77590860	NA	0.62	7.71	0.34	7.78e-14	Opioid sensitivity;
LGG	cis	rs10464366	0.746	rs12674262	chr7:39141728	G/T	cg18850127	chr7:39170497	POU6F2	0.61	14.92	0.57	2.25e-41	IgG glycosylation;
LGG	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs774359	0.797	rs4609281	chr9:27514962	G/T	cg21249376	chr9:27528432	MOBKL2B	-0.39	-7.85	-0.34	2.83e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs35110281	0.774	rs162404	chr21:44963264	G/A	cg04455712	chr21:45112962	RRP1B	0.52	9.91	0.42	3.99e-21	Mean corpuscular volume;
LGG	cis	rs5742933	0.817	rs13035966	chr2:190591233	T/G	cg10453823	chr2:190539512	ANKAR	-0.46	-6.88	-0.3	1.9e-11	Ferritin levels;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs7822232	0.908	rs6558297	chr8:145143934	C/T	cg06495924	chr8:145149574	CYC1	-0.9	-7.16	-0.32	3.19e-12	Blood metabolite levels;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.44	-0.5	7.76e-31	Lymphocyte counts;
LGG	cis	rs4330281	0.669	rs9756494	chr3:17588575	A/G	cg20981856	chr3:17787350	NA	0.38	7.03	0.31	7.41e-12	Schizophrenia;
LGG	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg01570182	chr17:44337453	NA	-0.5	-9.08	-0.39	3.11e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2404602	0.684	rs10851888	chr15:76902506	C/T	cg23625390	chr15:77176239	SCAPER	-0.7	-13.51	-0.53	2.67e-35	Blood metabolite levels;
LGG	cis	rs1978968	0.763	rs35276871	chr22:18459040	C/T	cg03078520	chr22:18463400	MICAL3	-0.7	-14.97	-0.57	1.38e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs8180040	0.577	rs12493425	chr3:47176946	T/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.07	-0.52	1.96e-33	Colorectal cancer;
LGG	cis	rs10791097	0.694	rs2155749	chr11:130751094	G/T	cg12179176	chr11:130786555	SNX19	0.84	17.66	0.63	1.02e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14523723	chr18:9335432	TWSG1	0.45	6.65	0.3	8.34e-11	Gut microbiome composition (summer);
LGG	cis	rs1018836	0.851	rs6986359	chr8:91643162	A/G	cg16814680	chr8:91681699	NA	-0.82	-15.64	-0.59	1.36e-44	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs61931739	0.649	rs708136	chr12:33737411	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.14	-0.31	3.73e-12	Morning vs. evening chronotype;
LGG	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg26384229	chr12:38710491	ALG10B	0.7	13.02	0.52	3.2e-33	Resting heart rate;
LGG	cis	rs8032158	0.702	rs1042477	chr15:56121886	C/A	cg05129572	chr15:56138634	NEDD4	-0.4	-6.89	-0.3	1.87e-11	Keloid;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.27	0.32	1.54e-12	Obesity-related traits;
LGG	cis	rs12681287	0.640	rs7820234	chr8:87350950	A/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.05e-13	Caudate activity during reward;
LGG	cis	rs10484885	0.887	rs2273246	chr6:90453263	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-12.94	-0.52	6.68e-33	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7577696	0.719	rs3752916	chr2:32354558	C/T	cg02381751	chr2:32503542	YIPF4	-0.41	-6.67	-0.3	7.31e-11	Inflammatory biomarkers;
LGG	cis	rs6840360	0.530	rs62327350	chr4:152641202	G/A	cg25486957	chr4:152246857	NA	-0.5	-7.96	-0.35	1.34e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg03701759	chr13:99174930	STK24	-0.37	-7.26	-0.32	1.67e-12	Longevity;
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg09263875	chr16:632152	PIGQ	0.64	12.63	0.51	1.21e-31	Height;
LGG	cis	rs2074585	0.560	rs12903058	chr15:91061121	G/T	cg22089800	chr15:90895588	ZNF774	-0.5	-8.19	-0.36	2.53e-15	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg26924012	chr15:45694286	SPATA5L1	-1.04	-22.37	-0.72	1.07e-75	Homoarginine levels;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg14926445	chr8:58193284	C8orf71	-0.87	-12.16	-0.49	9.87e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg13010199	chr12:38710504	ALG10B	0.51	9.89	0.42	4.73e-21	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs72781680	0.848	rs72798057	chr2:23976731	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	8.95	0.38	8.91e-18	Lymphocyte counts;
LGG	cis	rs77741769	0.571	rs4766979	chr12:121281748	G/A	cg02419362	chr12:121203948	SPPL3	0.53	9.24	0.39	8.67e-19	Mean corpuscular volume;
LGG	trans	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	8.1	0.35	4.87e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg25174290	chr11:3078921	CARS	-0.43	-7.56	-0.33	2.2e-13	Calcium levels;
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg05793240	chr7:2802953	GNA12	0.38	8.81	0.38	2.55e-17	Height;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg08677398	chr8:58056175	NA	0.47	6.98	0.31	1.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg06353428	chr16:71660113	MARVELD3	0.51	8.19	0.36	2.64e-15	Blood protein levels;
LGG	cis	rs262150	0.546	rs7798337	chr7:158801089	G/A	cg19418458	chr7:158789849	NA	0.42	7.86	0.34	2.68e-14	Facial morphology (factor 20);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11129291	chr2:136742688	DARS	0.44	6.85	0.3	2.41e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg20887711	chr4:1340912	KIAA1530	0.53	9.97	0.42	2.44e-21	Obesity-related traits;
LGG	cis	rs2018055	0.644	rs13202333	chr6:117798235	G/T	cg14611402	chr6:117803162	DCBLD1	0.31	8.9	0.38	1.25e-17	Diastolic blood pressure;
LGG	cis	rs10927875	0.619	rs2013019	chr1:16129320	T/C	cg21385522	chr1:16154831	NA	-0.75	-15.46	-0.58	8.66e-44	Dilated cardiomyopathy;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.92	0.38	1.06e-17	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg08888203	chr3:10149979	C3orf24	0.54	9.23	0.39	9.49e-19	Alzheimer's disease;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2413583	0.591	rs116136126	chr22:39729557	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.79	0.34	4.57e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1459104	0.636	rs559362	chr11:55275456	T/G	cg15704280	chr7:45808275	SEPT13	0.64	7.55	0.33	2.32e-13	Body mass index;
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg03264133	chr6:25882463	NA	0.5	9.23	0.39	9.72e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.501	rs767418	chr3:52767427	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.13	0.39	2.11e-18	Bipolar disorder;
LGG	cis	rs4253772	0.591	rs11703435	chr22:46685563	C/T	cg09461388	chr22:46763229	CELSR1	-0.65	-7.02	-0.31	7.89e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.71	-0.3	5.63e-11	HDL cholesterol;
LGG	cis	rs4843747	0.671	rs74729706	chr16:88104159	C/T	cg09044154	chr16:88155775	NA	-0.51	-7.77	-0.34	5.19e-14	Menopause (age at onset);
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs10193935	1.000	rs10195776	chr2:42425098	G/A	cg27598129	chr2:42591480	NA	-0.63	-9.52	-0.4	9.94e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg03606772	chr1:152487856	CRCT1	0.29	6.83	0.3	2.6e-11	Hair morphology;
LGG	cis	rs7551222	0.752	rs12039454	chr1:204542580	C/T	cg20240347	chr1:204465584	NA	0.54	10.88	0.45	1.04e-24	Schizophrenia;
LGG	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.54	-12.42	-0.5	9.31e-31	Diastolic blood pressure;
LGG	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg06481639	chr22:41940642	POLR3H	-0.59	-8.27	-0.36	1.48e-15	Vitiligo;
LGG	cis	rs867371	1.000	rs8041924	chr15:82473661	A/T	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	3.2e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg17340268	chr14:105411764	AHNAK2	-0.4	-7.42	-0.33	5.48e-13	Rheumatoid arthritis;
LGG	cis	rs611744	0.967	rs652485	chr8:109202696	G/A	cg21045802	chr8:109455806	TTC35	0.37	6.67	0.3	7.46e-11	Dupuytren's disease;
LGG	cis	rs548181	0.545	rs76179820	chr11:125616379	A/G	cg03464685	chr11:125439445	EI24	-1.21	-17.03	-0.62	7.71e-51	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6964587	1.000	rs10234290	chr7:91716951	T/C	cg17063962	chr7:91808500	NA	0.47	8.42	0.36	4.67e-16	Breast cancer;
LGG	cis	rs2635047	0.713	rs9952628	chr18:44754651	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.36	0.36	7.48e-16	Educational attainment;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg27411982	chr8:10470053	RP1L1	0.41	7.14	0.31	3.71e-12	Mood instability;
LGG	cis	rs78456975	1.000	rs11891809	chr2:1566001	A/G	cg01028140	chr2:1542097	TPO	-0.52	-8.34	-0.36	8.86e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.8	-0.38	2.65e-17	Life satisfaction;
LGG	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg02227867	chr8:22457446	C8orf58	-0.41	-7.93	-0.35	1.68e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9467773	0.869	rs742090	chr6:26415637	A/C	cg11502198	chr6:26597334	ABT1	-0.56	-9.56	-0.41	7.18e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.06	0.42	1.11e-21	Iron status biomarkers;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.12	-0.31	4.27e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1018836	0.923	rs2105965	chr8:91537690	T/C	cg16814680	chr8:91681699	NA	-0.78	-14.25	-0.55	1.86e-38	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg20503657	chr10:835505	NA	0.56	7.35	0.32	8.92e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs910316	1.000	rs2268617	chr14:75608728	G/A	cg08847533	chr14:75593920	NEK9	0.62	11.85	0.48	1.71e-28	Height;
LGG	trans	rs1814175	0.817	rs11040651	chr11:49938395	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.3	-0.75	1.15e-84	Height;
LGG	cis	rs5756813	0.688	rs12484134	chr22:38126728	T/C	cg19171272	chr22:38449367	NA	0.41	6.96	0.31	1.17e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7191439	0.674	rs4782430	chr16:88792047	A/G	cg02389323	chr16:88786976	FAM38A	0.9	12.09	0.49	2.04e-29	Plateletcrit;
LGG	cis	rs13392177	0.672	rs1877715	chr2:219052546	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.49	7.99	0.35	1.07e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs7444	0.882	rs140492	chr22:21923144	A/C	cg15846791	chr22:21984385	YDJC	-0.45	-7.14	-0.31	3.66e-12	Systemic lupus erythematosus;
LGG	cis	rs4737010	0.644	rs506763	chr8:41612487	C/T	cg17182837	chr8:41585554	ANK1	0.46	7.3	0.32	1.28e-12	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg26513180	chr16:89883248	FANCA	0.8	8.89	0.38	1.41e-17	Skin colour saturation;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg11644478	chr21:40555479	PSMG1	0.9	17.28	0.63	5.24e-52	Cognitive function;
LGG	cis	rs6141769	0.542	rs6058821	chr20:31304713	C/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.8	-0.3	3.32e-11	Subjective well-being;
LGG	trans	rs3960554	0.867	rs11489553	chr7:75843062	G/A	cg19862616	chr7:65841803	NCRNA00174	0.84	11.56	0.47	2.57e-27	Eotaxin levels;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg02776251	chr12:62654319	USP15	-0.46	-7.14	-0.31	3.71e-12	Coronary artery disease;
LGG	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg05484376	chr2:27715224	FNDC4	0.41	8.92	0.38	1.13e-17	Total body bone mineral density;
LGG	cis	rs10207628	0.823	rs749006	chr2:127859766	G/A	cg06223080	chr2:127868745	NA	-0.77	-14.92	-0.57	2.19e-41	Psychosis and Alzheimer's disease;
LGG	cis	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg07274523	chr3:49395745	GPX1	0.55	8.99	0.39	6.16e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.42	0.33	5.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13191362	1.000	rs35820211	chr6:163046252	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.87	9.25	0.4	8.05e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg02297831	chr4:17616191	MED28	0.49	9.35	0.4	3.83e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7264396	0.635	rs3827030	chr20:34474947	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	-0.49	-7.08	-0.31	5.42e-12	Total cholesterol levels;
LGG	cis	rs12143943	0.866	rs4252745	chr1:204519187	C/G	cg20240347	chr1:204465584	NA	0.34	7.41	0.33	5.96e-13	Cognitive performance;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg02725872	chr8:58115012	NA	-0.8	-11.86	-0.48	1.67e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	0.954	rs4790974	chr17:65951107	A/T	cg12091567	chr17:66097778	LOC651250	0.62	9.02	0.39	4.88e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg18850127	chr7:39170497	POU6F2	0.62	15.15	0.58	2.23e-42	IgG glycosylation;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg24250549	chr1:154909240	PMVK	0.75	15.06	0.57	5.44e-42	Prostate cancer;
LGG	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg09021430	chr5:549028	NA	-0.73	-10.36	-0.43	9.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg09173681	chr1:183549694	NCF2	0.38	8.51	0.37	2.36e-16	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.604	rs2250025	chr11:133710914	G/A	cg06766960	chr11:133703094	NA	-0.57	-11.15	-0.46	1.02e-25	Childhood ear infection;
LGG	cis	rs2836974	0.897	rs2836925	chr21:40532353	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg15556689	chr8:8085844	FLJ10661	0.52	9.24	0.39	9.04e-19	Triglycerides;
LGG	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg05234568	chr11:5960015	NA	-0.73	-11.92	-0.48	9.5e-29	DNA methylation (variation);
LGG	cis	rs68170813	0.559	rs77422419	chr7:106957932	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.76	-0.45	3.11e-24	Coronary artery disease;
LGG	cis	rs4732038	0.510	rs57309811	chr7:134279208	G/A	cg06906464	chr7:134288099	NA	-0.67	-17.35	-0.63	2.46e-52	Longevity;
LGG	cis	rs17270561	0.636	rs9358880	chr6:25743161	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg11693508	chr17:37793320	STARD3	0.5	7.06	0.31	6.2e-12	Bipolar disorder;
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg02002194	chr4:3960332	NA	0.55	10.63	0.44	9.41e-24	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6964587	1.000	rs34043009	chr7:91578447	T/C	cg17063962	chr7:91808500	NA	-0.48	-8.59	-0.37	1.34e-16	Breast cancer;
LGG	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs7805747	0.961	rs10224002	chr7:151415041	C/T	cg17611936	chr7:151411526	PRKAG2	-0.52	-8.02	-0.35	8.62e-15	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs2153535	0.580	rs5001324	chr6:8451604	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs2860975	0.905	rs10882516	chr10:96791217	A/C	cg09036531	chr10:96991505	NA	-0.52	-9.59	-0.41	5.53e-20	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3806843	0.741	rs4912597	chr5:140106857	C/G	cg19875535	chr5:140030758	IK	-0.59	-11.94	-0.49	8.03e-29	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg25558440	chr8:11882962	NA	0.37	6.71	0.3	5.6e-11	Monocyte count;
LGG	cis	rs2838344	0.776	rs2298561	chr21:45085234	A/G	cg04455712	chr21:45112962	RRP1B	0.54	10.27	0.43	1.91e-22	Coronary artery disease;
LGG	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg02297831	chr4:17616191	MED28	0.46	8.39	0.36	5.76e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs35306767	0.761	rs34480046	chr10:1027440	A/G	cg25019033	chr10:957182	NA	-0.58	-10.63	-0.44	9.5e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs832540	0.966	rs252923	chr5:56205662	T/G	cg17809284	chr5:56205270	C5orf35	-0.38	-7.25	-0.32	1.82e-12	Coronary artery disease;
LGG	cis	rs986417	1.000	rs4243618	chr14:61067022	T/C	cg27398547	chr14:60952738	C14orf39	0.76	7.07	0.31	5.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs283228	0.652	rs528879	chr6:101738024	A/G	cg27451362	chr6:101846650	GRIK2	0.84	13.16	0.52	8.32e-34	Coenzyme Q10 levels;
LGG	cis	rs936229	0.651	rs12908814	chr15:75132490	C/G	cg17294928	chr15:75287854	SCAMP5	0.5	8.81	0.38	2.48e-17	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg03806693	chr22:41940476	POLR3H	-0.96	-16.43	-0.61	4.03e-48	Vitiligo;
LGG	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.2800000000000005e-13	Hemoglobin concentration;
LGG	cis	rs35306767	0.761	rs12359796	chr10:1021479	G/C	cg20503657	chr10:835505	NA	0.59	7.64	0.33	1.24e-13	Eosinophil percentage of granulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02212000	chr8:63951669	GGH	0.39	6.76	0.3	4.17e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg08470875	chr2:26401718	FAM59B	-0.37	-6.79	-0.3	3.36e-11	Gut microbiome composition (summer);
LGG	cis	rs8040855	0.644	rs2342120	chr15:85728820	G/T	cg04831495	chr15:85060580	GOLGA6L5	0.34	6.78	0.3	3.74e-11	Bulimia nervosa;
LGG	cis	rs5758659	0.652	rs133349	chr22:42428727	A/T	cg15557168	chr22:42548783	NA	-0.33	-7.38	-0.32	7.46e-13	Cognitive function;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg22963979	chr7:1858916	MAD1L1	0.56	11.06	0.46	2.23e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.764	rs115916994	chr4:119688758	A/G	cg21605333	chr4:119757512	SEC24D	1.41	13.12	0.52	1.21e-33	Cannabis dependence symptom count;
LGG	cis	rs4740619	0.905	rs10756677	chr9:15615321	C/T	cg14451791	chr9:16040625	NA	-0.39	-10.0	-0.42	1.94e-21	Body mass index;
LGG	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	trans	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg27661571	chr11:113659931	NA	0.54	6.76	0.3	4.06e-11	Hip circumference adjusted for BMI;
LGG	cis	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg19761014	chr17:28927070	LRRC37B2	0.65	8.22	0.36	2.02e-15	Body mass index;
LGG	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06481639	chr22:41940642	POLR3H	-0.62	-9.08	-0.39	3.08e-18	Vitiligo;
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.88e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.723	rs853981	chr6:127045460	C/T	cg19875578	chr6:126661172	C6orf173	-0.51	-9.31	-0.4	5.12e-19	Male-pattern baldness;
LGG	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg27165867	chr14:105738592	BRF1	-0.47	-7.56	-0.33	2.18e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs701145	0.585	rs365119	chr3:153916502	A/T	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg16680214	chr1:154839983	KCNN3	-0.44	-8.51	-0.37	2.51e-16	Prostate cancer;
LGG	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg22990158	chr14:24802150	ADCY4	-0.31	-6.75	-0.3	4.33e-11	Height;
LGG	cis	rs4731207	0.671	rs12530981	chr7:124521722	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.77	-0.34	5.26e-14	Cutaneous malignant melanoma;
LGG	trans	rs9650657	0.771	rs6601513	chr8:10594843	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.0	-0.35	9.86e-15	Neuroticism;
LGG	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	8.0	0.35	9.72e-15	Mean corpuscular volume;
LGG	cis	rs2221894	0.506	rs77628389	chr8:28845548	T/C	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.88	-0.34	2.31e-14	Obesity-related traits;
LGG	cis	rs11105298	0.891	rs10858906	chr12:89934474	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs611744	0.608	rs667742	chr8:109254003	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs10781543	0.775	rs10870194	chr9:139327034	A/G	cg14169450	chr9:139327907	INPP5E	0.41	7.47	0.33	4.16e-13	Monocyte percentage of white cells;
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg24687543	chr11:63912206	MACROD1	0.54	7.81	0.34	3.98e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.13	-0.31	3.97e-12	Diastolic blood pressure;
LGG	cis	rs1552244	0.882	rs34779351	chr3:10021801	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.52	9.04	0.39	4.29e-18	Longevity;
LGG	trans	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.9	-0.38	1.29e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2562456	1.000	rs2562456	chr19:21666210	A/G	cg00806126	chr19:22604979	ZNF98	-0.61	-9.26	-0.4	7.96e-19	Pain;
LGG	cis	rs7647973	0.769	rs6446204	chr3:49034879	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.22	0.36	2.14e-15	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.791	rs7219163	chr17:28210703	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.11	0.55	7.09e-38	Coffee consumption (cups per day);
LGG	cis	rs9397585	0.857	rs7761503	chr6:153371328	C/T	cg17707550	chr6:153380415	RGS17	0.61	14.59	0.56	6.32e-40	Body mass index;
LGG	cis	rs7552167	0.636	rs4090311	chr1:24513768	G/A	cg01960748	chr1:24522592	NA	-0.45	-7.15	-0.32	3.42e-12	Psoriasis vulgaris;
LGG	cis	rs7249142	0.549	rs12975253	chr19:19279745	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.53	-0.33	2.63e-13	IgG glycosylation;
LGG	cis	rs17453880	0.926	rs6885111	chr5:152027557	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg12856521	chr11:46389249	DGKZ	0.39	6.71	0.3	5.71e-11	Leprosy;
LGG	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg07636037	chr3:49044803	WDR6	0.84	14.55	0.56	9.05e-40	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg14092988	chr3:52407081	DNAH1	0.26	7.09	0.31	4.99e-12	Electroencephalogram traits;
LGG	cis	rs7582720	1.000	rs72936847	chr2:203774748	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs75804782	0.641	rs56000747	chr2:239318541	T/G	cg01134436	chr17:81009848	B3GNTL1	0.85	8.98	0.39	6.82e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9354308	0.738	rs9294673	chr6:66604824	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg12386194	chr3:101231763	SENP7	0.46	8.15	0.35	3.31e-15	Colorectal cancer;
LGG	cis	rs807669	0.525	rs9604934	chr22:19194868	C/T	cg02655711	chr22:19163373	SLC25A1	0.49	8.81	0.38	2.44e-17	Metabolite levels;
LGG	cis	rs7216064	1.000	rs12451721	chr17:65939075	G/A	cg12091567	chr17:66097778	LOC651250	-0.62	-9.07	-0.39	3.52e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs75920871	0.623	rs56227539	chr11:116964469	T/C	cg20608306	chr11:116969690	SIK3	-0.34	-8.02	-0.35	8.83e-15	Subjective well-being;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg02002194	chr4:3960332	NA	0.44	8.06	0.35	6.55e-15	Neuroticism;
LGG	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg06027949	chr8:82754900	SNX16	0.54	8.35	0.36	7.79e-16	Diastolic blood pressure;
LGG	cis	rs4262150	0.883	rs72802852	chr5:152216893	G/T	cg12297329	chr5:152029980	NA	-0.68	-12.61	-0.51	1.56e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs283228	0.524	rs2813644	chr6:101576255	T/A	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.86e-15	Coenzyme Q10 levels;
LGG	trans	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg07393940	chr7:158741817	NA	0.59	10.77	0.45	2.69e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11875185	0.510	rs4572489	chr18:55611505	T/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs921968	0.509	rs3856548	chr2:219398164	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.29	0.32	1.33e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs709400	0.663	rs62007683	chr14:103894071	G/T	cg26031613	chr14:104095156	KLC1	0.79	13.6	0.53	1.07e-35	Body mass index;
LGG	cis	rs2070433	0.528	rs68063691	chr21:47759237	T/C	cg12379764	chr21:47803548	PCNT	0.65	9.14	0.39	1.99e-18	Lymphocyte counts;
LGG	trans	rs4650994	0.544	rs2476561	chr1:178619900	C/T	cg05059571	chr16:84539110	KIAA1609	-0.51	-9.52	-0.4	9.32e-20	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10189230	0.904	rs13029372	chr2:222348434	A/G	cg14652038	chr2:222343519	EPHA4	0.61	12.63	0.51	1.28e-31	Urate levels in lean individuals;
LGG	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.94	0.52	6.37e-33	Cognitive test performance;
LGG	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg14598338	chr9:96623480	NA	-0.54	-9.64	-0.41	3.7799999999999997e-20	DNA methylation (variation);
LGG	cis	rs861020	0.606	rs627459	chr1:210004682	C/G	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg05090351	chr10:126851162	NA	0.34	8.31	0.36	1.1e-15	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg16507663	chr6:150244633	RAET1G	0.45	8.35	0.36	8.11e-16	Lung cancer;
LGG	cis	rs7614311	0.639	rs111234932	chr3:63842449	C/T	cg22134162	chr3:63841271	THOC7	-0.45	-8.06	-0.35	6.79e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	cg07928641	chr1:182991847	LAMC1	-0.47	-9.56	-0.41	7.06e-20	Colorectal cancer;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg20120463	chr17:44301886	NA	-0.47	-7.23	-0.32	1.95e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg15485101	chr11:133734466	NA	0.58	10.32	0.43	1.3e-22	Childhood ear infection;
LGG	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg26174226	chr8:58114915	NA	0.52	7.15	0.32	3.4e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6784615	0.744	rs9855470	chr3:52493275	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.58	7.02	0.31	7.88e-12	Waist-hip ratio;
LGG	cis	rs1800682	0.528	rs11202918	chr10:90742008	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.72	14.48	0.56	1.92e-39	Chronic lymphocytic leukemia;
LGG	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg04691961	chr3:161091175	C3orf57	0.44	9.29	0.4	6.26e-19	Morning vs. evening chronotype;
LGG	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.35	0.32	9.13e-13	Coronary artery disease;
LGG	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs6752107	0.935	rs11690131	chr2:234148383	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.15	0.32	3.45e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.68	-0.3	7.04e-11	Menopause (age at onset);
LGG	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.27	-0.32	1.5e-12	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg20607798	chr8:58055168	NA	0.6	7.23	0.32	2.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2764208	0.770	rs112283401	chr6:34797756	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.84	-0.45	1.49e-24	Systemic lupus erythematosus;
LGG	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.77	14.26	0.55	1.58e-38	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2204008	0.837	rs12146734	chr12:38237079	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs6032067	0.777	rs13038275	chr20:43780988	A/T	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	trans	rs9650657	0.593	rs1968401	chr8:10615383	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.88	-0.34	2.32e-14	Neuroticism;
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.46	-6.72	-0.3	5.44e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7727544	0.625	rs3864277	chr5:131420249	G/A	cg07395648	chr5:131743802	NA	-0.42	-9.05	-0.39	3.94e-18	Blood metabolite levels;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7929679	0.602	rs11032870	chr11:34805524	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.39	6.69	0.3	6.36e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	17.3	0.63	4.36e-52	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7582720	1.000	rs114520702	chr2:203697092	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.69	0.41	2.38e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg17376030	chr22:41985996	PMM1	-0.55	-9.03	-0.39	4.63e-18	Vitiligo;
LGG	cis	rs4676380	0.927	rs1583259	chr2:241644934	G/T	cg06356454	chr2:241631498	AQP12A	0.4	7.74	0.34	6.25e-14	Response to metformin (IC50);
LGG	cis	rs6867032	0.834	rs10043083	chr5:1995687	C/G	cg26168224	chr5:2018326	NA	-1.1	-20.15	-0.68	2.63e-65	Gut microbiome composition (winter);
LGG	cis	rs7166081	1.000	rs8031440	chr15:67483979	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.3	-6.72	-0.3	5.26e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs733592	0.524	rs10875744	chr12:48498440	G/C	cg24011408	chr12:48396354	COL2A1	0.68	11.86	0.48	1.63e-28	Plateletcrit;
LGG	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg17108064	chr15:78857060	CHRNA5	0.44	9.09	0.39	2.92e-18	Sudden cardiac arrest;
LGG	cis	rs7215564	0.730	rs1125587	chr17:78581696	A/G	cg16980736	chr17:78789706	RPTOR	-0.55	-6.94	-0.31	1.36e-11	Myopia (pathological);
LGG	cis	rs2131877	0.956	rs2279631	chr3:194869328	T/C	cg07250128	chr3:194833983	C3orf21	0.41	7.62	0.33	1.43e-13	Non-small cell lung cancer;
LGG	cis	rs3096299	0.781	rs3102381	chr16:89409720	G/C	cg06640241	chr16:89574553	SPG7	0.59	10.04	0.42	1.35e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs2361718	0.967	rs2361719	chr17:78103403	A/G	cg21238619	chr17:78079768	GAA	0.32	6.82	0.3	2.81e-11	Yeast infection;
LGG	trans	rs7395662	0.853	rs10769356	chr11:48444654	T/G	cg03929089	chr4:120376271	NA	-0.42	-6.81	-0.3	3.01e-11	HDL cholesterol;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.1	0.35	4.93e-15	Prostate cancer;
LGG	cis	rs7937682	0.575	rs12808601	chr11:111776066	G/A	cg09085632	chr11:111637200	PPP2R1B	1.02	21.01	0.7	2.47e-69	Primary sclerosing cholangitis;
LGG	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg21385522	chr1:16154831	NA	-1.03	-18.68	-0.66	1.9e-58	Dilated cardiomyopathy;
LGG	cis	rs11158026	0.757	rs56206440	chr14:55450886	T/C	cg04306507	chr14:55594613	LGALS3	0.31	7.1	0.31	4.63e-12	Parkinson's disease;
LGG	cis	rs2820315	1.000	rs2820315	chr1:201872264	A/G	cg10061532	chr1:201886748	LMOD1	-0.36	-7.29	-0.32	1.32e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs1497828	0.956	rs2815223	chr1:217527843	C/A	cg04411442	chr1:217543379	NA	-0.48	-8.11	-0.35	4.55e-15	Dialysis-related mortality;
LGG	cis	rs3857067	0.806	rs4560373	chr4:95113229	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs2562456	0.755	rs1879234	chr19:21704479	T/G	cg00806126	chr19:22604979	ZNF98	0.63	9.31	0.4	5.07e-19	Pain;
LGG	cis	rs1552244	0.882	rs7633769	chr3:10020622	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.23	0.63	9.32e-52	Alzheimer's disease;
LGG	cis	rs6582630	0.519	rs8189618	chr12:38276281	A/C	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	0.681	rs528517	chr15:43612925	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	12.36	0.5	1.56e-30	Lung cancer in ever smokers;
LGG	cis	rs7929679	0.602	rs1396885	chr11:34805210	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.84	0.3	2.53e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg12692727	chr7:1102344	C7orf50	0.49	6.89	0.31	1.81e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg08344181	chr3:125677491	NA	-0.64	-7.48	-0.33	3.64e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6594713	0.570	rs35933960	chr5:112841469	T/C	cg12552261	chr5:112820674	MCC	0.63	7.96	0.35	1.35e-14	Brain cytoarchitecture;
LGG	trans	rs3857536	0.785	rs1935895	chr6:66936606	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg05335186	chr13:53173507	NA	0.8	20.46	0.69	9.7e-67	Lewy body disease;
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	3.92e-21	Bipolar disorder;
LGG	cis	rs11166927	1.000	rs13256946	chr8:140805101	G/A	cg16909799	chr8:140841666	TRAPPC9	0.59	12.54	0.5	3.04e-31	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.1	-0.31	4.81e-12	Lung cancer;
LGG	cis	rs6669919	0.647	rs1578838	chr1:211671118	T/G	cg10512769	chr1:211675356	NA	-0.57	-11.74	-0.48	4.7e-28	Intelligence (multi-trait analysis);
LGG	cis	rs490234	0.841	rs2793135	chr9:128338620	A/G	cg14078157	chr9:128172775	NA	0.42	7.83	0.34	3.35e-14	Mean arterial pressure;
LGG	cis	rs11700980	0.515	rs12481795	chr21:30113730	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs6087990	0.842	rs4911105	chr20:31330413	G/A	cg13636640	chr20:31349939	DNMT3B	0.9	18.97	0.66	8.3e-60	Ulcerative colitis;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg08707078	chr7:23720292	C7orf46	-0.42	-9.71	-0.41	2.13e-20	Schizophrenia;
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg16141378	chr3:129829833	LOC729375	0.43	10.44	0.44	4.61e-23	Mood instability;
LGG	cis	rs9487051	0.768	rs9398188	chr6:109526615	G/A	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.47e-11	Reticulocyte fraction of red cells;
LGG	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs9473924	0.505	rs9296644	chr6:50828247	G/A	cg14470998	chr6:50812995	TFAP2B	0.64	7.59	0.33	1.79e-13	Body mass index;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.59	9.52	0.4	9.83e-20	Renal function-related traits (BUN);
LGG	cis	rs17376456	0.825	rs74825443	chr5:93254973	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.96	0.6	5.5e-46	Diabetic retinopathy;
LGG	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14298792	chr15:30685198	CHRFAM7A	-0.47	-7.14	-0.32	3.59e-12	Huntington's disease progression;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg21775007	chr8:11205619	TDH	-0.79	-14.17	-0.55	4.24e-38	Retinal vascular caliber;
LGG	cis	rs7226408	0.857	rs72887066	chr18:34496371	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.97	-0.31	1.09e-11	Obesity-related traits;
LGG	cis	rs3857747	0.827	rs8180744	chr7:40452861	T/A	cg00420559	chr7:40367873	C7orf10	-0.38	-7.89	-0.34	2.16e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs16912285	0.585	rs7950920	chr11:24356464	G/A	ch.11.24196551F	chr11:24239977	NA	0.92	12.7	0.51	6.21e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.6e-29	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20819397	chr9:123964132	RAB14	0.43	6.83	0.3	2.72e-11	Cognitive performance;
LGG	cis	rs11920090	0.932	rs1280	chr3:170713290	T/C	cg09710316	chr3:170744871	SLC2A2	0.6	8.44	0.37	4.12e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg07132326	chr6:150258058	NA	-0.37	-7.9	-0.34	2.12e-14	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14123153	chr12:6602654	NCAPD2;MRPL51	0.48	7.83	0.34	3.34e-14	Cognitive performance;
LGG	trans	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.43	-0.33	5.35e-13	Menarche (age at onset);
LGG	cis	rs10991814	0.920	rs76218486	chr9:94027677	T/A	cg14446406	chr9:93919335	NA	-0.72	-8.08	-0.35	5.55e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs4330281	0.647	rs13320693	chr3:17464812	A/T	cg20981856	chr3:17787350	NA	0.36	6.81	0.3	2.96e-11	Schizophrenia;
LGG	cis	rs41271473	0.607	rs10916361	chr1:228859971	A/T	cg16512390	chr1:228756714	NA	0.43	7.1	0.31	4.73e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7100689	0.646	rs1953971	chr10:82145647	G/C	cg01528321	chr10:82214614	TSPAN14	0.88	15.59	0.59	2.42e-44	Post bronchodilator FEV1;
LGG	cis	rs8112449	0.964	rs12977594	chr19:10520313	A/G	cg21868191	chr19:10515988	NA	-0.48	-8.29	-0.36	1.21e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs3106136	0.934	rs35995707	chr4:95167150	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.01	-0.35	9.11e-15	Capecitabine sensitivity;
LGG	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.37	-7.1	-0.31	4.86e-12	Educational attainment;
LGG	cis	rs847577	0.609	rs6465658	chr7:97816638	C/G	cg13397024	chr7:97797637	LMTK2	-0.37	-6.96	-0.31	1.15e-11	Breast cancer;
LGG	cis	rs875971	0.545	rs73142245	chr7:65691649	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.52	0.44	2.44e-23	Aortic root size;
LGG	cis	rs12762955	0.677	rs11250267	chr10:1156487	A/G	cg25019033	chr10:957182	NA	-0.42	-7.85	-0.34	2.95e-14	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-8.68	-0.37	6.81e-17	Colorectal cancer;
LGG	cis	rs9398803	0.835	rs59698523	chr6:126733094	T/C	cg19875578	chr6:126661172	C6orf173	0.56	10.14	0.43	5.75e-22	Male-pattern baldness;
LGG	cis	rs1806153	0.673	rs3026357	chr11:31829223	G/A	cg11990419	chr11:31841155	NA	0.36	7.51	0.33	3.11e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg05973401	chr12:123451056	ABCB9	0.5	8.01	0.35	9.52e-15	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7943191	0.810	rs7942991	chr11:62337203	A/G	cg13298116	chr11:62369859	EML3;MTA2	-0.6	-13.18	-0.52	6.44e-34	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	9.0	0.39	6.08e-18	Platelet count;
LGG	cis	rs763121	0.719	rs9610995	chr22:39057763	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.53	0.63	3.8e-53	Menopause (age at onset);
LGG	cis	rs4846580	0.660	rs4846582	chr1:219898214	G/C	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	cis	rs1912483	0.505	rs11079772	chr17:45393739	A/C	cg25173405	chr17:45401733	C17orf57	0.75	12.52	0.5	3.68e-31	Coronary artery disease;
LGG	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs2204008	0.805	rs11522896	chr12:38234427	T/C	cg26384229	chr12:38710491	ALG10B	0.96	21.74	0.71	9.56e-73	Bladder cancer;
LGG	cis	rs3784262	1.000	rs9325	chr15:58245986	A/T	cg12031962	chr15:58353849	ALDH1A2	0.38	8.32	0.36	1.02e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg11814155	chr7:99998594	ZCWPW1	0.61	8.81	0.38	2.54e-17	Platelet count;
LGG	cis	rs2624839	0.704	rs13067082	chr3:50221715	A/G	cg24110177	chr3:50126178	RBM5	0.55	8.82	0.38	2.27e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.59	-0.37	1.38e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18252515	chr7:66147081	NA	-0.4	-6.82	-0.3	2.94e-11	Aortic root size;
LGG	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg16662043	chr16:48846231	NA	0.36	7.06	0.31	6.09e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-6.84	-0.3	2.59e-11	Diastolic blood pressure;
LGG	cis	rs7659604	0.517	rs6856996	chr4:122671271	C/T	cg19748678	chr4:122722346	EXOSC9	0.6	9.89	0.42	4.74e-21	Type 2 diabetes;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.667	rs598811	chr11:67311676	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.27	-0.32	1.51e-12	Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs6975729	chr7:100028187	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg27523141	chr10:43048294	ZNF37B	-0.38	-7.81	-0.34	3.92e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2953174	0.720	rs2975794	chr2:241515813	C/T	cg07929629	chr2:241523174	NA	0.57	7.91	0.34	1.97e-14	Bipolar disorder;
LGG	cis	rs8060686	0.641	rs12447931	chr16:68179195	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs9914544	0.545	rs8078993	chr17:18797126	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs10931896	0.531	rs295118	chr2:201144004	C/T	cg17644776	chr2:200775616	C2orf69	0.48	8.1	0.35	4.83e-15	Systolic blood pressure;
LGG	cis	rs2652834	0.950	rs4774474	chr15:63405580	C/G	cg05507819	chr15:63340323	TPM1	0.57	7.85	0.34	2.94e-14	HDL cholesterol;
LGG	cis	rs6456042	1.000	rs3127413	chr6:166535728	G/T	cg11088901	chr6:166572345	T	-0.35	-7.29	-0.32	1.32e-12	Asthma;
LGG	cis	rs2836974	0.966	rs7283420	chr21:40666865	T/C	cg11644478	chr21:40555479	PSMG1	0.87	16.09	0.6	1.39e-46	Cognitive function;
LGG	trans	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.42	0.4	2.15e-19	Aortic root size;
LGG	cis	rs1010254	0.510	rs888877	chr5:151760425	C/T	cg08593883	chr5:151785301	NMUR2	-0.45	-6.89	-0.3	1.83e-11	Optic nerve measurement (cup area);
LGG	cis	rs9894429	0.527	rs7405469	chr17:79566596	G/C	cg10661904	chr17:79619235	PDE6G	0.45	8.52	0.37	2.26e-16	Eye color traits;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg27400746	chr16:89904261	SPIRE2	-0.84	-13.65	-0.54	6.65e-36	Skin colour saturation;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.73e-15	Obesity-related traits;
LGG	cis	rs1008375	0.966	rs10006317	chr4:17702525	A/G	cg16339924	chr4:17578868	LAP3	0.5	8.45	0.37	3.75e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	11.09	0.46	1.73e-25	Obesity-related traits;
LGG	cis	rs208520	1.000	rs12192261	chr6:66985268	A/G	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs26232	0.521	rs3776856	chr5:102358806	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.24e-16	Rheumatoid arthritis;
LGG	cis	rs17122278	0.613	rs573971	chr11:118393396	A/G	cg19182353	chr11:118479428	PHLDB1	0.45	6.83	0.3	2.63e-11	Total cholesterol levels;
LGG	cis	rs17221829	0.733	rs72952851	chr11:89393495	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.1e-18	Anxiety in major depressive disorder;
LGG	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg03433033	chr1:76189801	ACADM	0.63	10.17	0.43	4.46e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2439831	0.850	rs28718261	chr15:44043793	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.32	0.4	4.65e-19	Lung cancer in ever smokers;
LGG	trans	rs7395662	1.000	rs4882010	chr11:48559173	T/G	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	cis	rs72615157	0.634	rs2272343	chr7:99778285	A/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.58	7.75	0.34	6.03e-14	Lung function (FEV1/FVC);
LGG	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg00647317	chr7:50633725	DDC	0.34	7.64	0.33	1.27e-13	Malaria;
LGG	cis	rs7512552	0.839	rs696616	chr1:150336173	G/A	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg00495681	chr13:53174319	NA	0.6	11.28	0.46	3.12e-26	Lewy body disease;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.74	0.3	4.87e-11	Schizophrenia;
LGG	cis	rs7077256	0.521	rs1054693	chr10:65225450	C/T	cg02276361	chr10:65351566	REEP3	-0.34	-6.87	-0.3	2.08e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.98	-0.31	1.06e-11	Neuroticism;
LGG	cis	rs8062405	0.965	rs8049439	chr16:28837515	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.44	0.33	4.84e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.47	-8.05	-0.35	7.06e-15	Longevity;Endometriosis;
LGG	cis	rs4622507	0.618	rs2388878	chr16:55066103	C/A	cg09947736	chr16:55091198	NA	0.77	11.33	0.47	1.92e-26	Social communication problems;
LGG	cis	rs17767392	0.958	rs3825719	chr14:72053097	A/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.67	0.41	2.96e-20	Mitral valve prolapse;
LGG	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg08847533	chr14:75593920	NEK9	-0.61	-11.06	-0.46	2.11e-25	Height;
LGG	cis	rs7953249	0.807	rs7310409	chr12:121424861	A/G	cg14101638	chr12:121416612	HNF1A	-0.36	-8.21	-0.36	2.26e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs6993813	0.678	rs7824837	chr8:120008736	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.84	0.34	3.04e-14	Bone mineral density (hip);
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg09699651	chr6:150184138	LRP11	0.49	8.6	0.37	1.26e-16	Lung cancer;
LGG	cis	rs6142618	0.562	rs4911543	chr20:30695145	A/C	cg00028034	chr20:30779307	TSPYL3	0.36	7.98	0.35	1.12e-14	Inflammatory bowel disease;
LGG	cis	rs10751647	0.804	rs3809112	chr11:307036	C/T	cg06950634	chr11:304351	NA	0.39	6.97	0.31	1.07e-11	Monocyte count;
LGG	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7927592	0.763	rs624003	chr11:68231240	C/T	cg01657329	chr11:68192670	LRP5	-0.56	-10.47	-0.44	3.49e-23	Total body bone mineral density;
LGG	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.45	-0.33	4.65e-13	Joint mobility (Beighton score);
LGG	cis	rs8028313	0.630	rs12900208	chr15:67963058	C/G	cg05925327	chr15:68127851	NA	-0.34	-7.0	-0.31	8.96e-12	Obesity;
LGG	cis	rs7074356	0.569	rs7090863	chr10:82021393	C/A	cg27171509	chr10:82033454	MAT1A	-0.42	-8.51	-0.37	2.45e-16	Borderline personality disorder;
LGG	cis	rs16933812	0.510	rs7026469	chr9:36991227	A/G	cg13738729	chr9:36989127	PAX5	0.42	9.31	0.4	4.98e-19	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.25	-0.52	3.44e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4808199	0.901	rs11669516	chr19:19532682	G/A	cg03709012	chr19:19516395	GATAD2A	1.07	17.83	0.64	1.63e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs7107174	1.000	rs2256051	chr11:77920457	G/A	cg27205649	chr11:78285834	NARS2	-0.41	-6.72	-0.3	5.29e-11	Testicular germ cell tumor;
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.79	-0.34	4.42e-14	Systolic blood pressure;
LGG	trans	rs941408	1.000	rs1640271	chr19:2799979	C/T	cg19676328	chr12:49525230	TUBA1B	-0.63	-10.06	-0.42	1.16e-21	Total cholesterol levels;
LGG	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg26850624	chr5:429559	AHRR	-0.38	-8.39	-0.36	5.81e-16	Cystic fibrosis severity;
LGG	cis	rs7937890	0.559	rs2597206	chr11:14477538	A/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.89	-0.34	2.15e-14	Mitochondrial DNA levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17441280	chr6:41888715	MED20;BYSL	0.42	7.12	0.31	4.11e-12	Gut microbiome composition (summer);
LGG	cis	rs965513	1.000	rs4743131	chr9:100554907	C/G	cg13688889	chr9:100608707	NA	-0.54	-9.85	-0.42	6.79e-21	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg03929089	chr4:120376271	NA	-0.46	-7.63	-0.33	1.38e-13	HDL cholesterol;
LGG	cis	rs8072100	0.935	rs12943464	chr17:45690351	A/T	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6977660	1.000	rs5017194	chr7:19820035	A/T	cg05791153	chr7:19748676	TWISTNB	0.58	8.75	0.38	3.9e-17	Thyroid stimulating hormone;
LGG	cis	rs7566780	0.575	rs4383328	chr2:16693124	A/T	cg09580478	chr2:16689509	NA	0.47	7.38	0.32	7.38e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs11168351	0.864	rs10875743	chr12:48498413	C/T	cg24011408	chr12:48396354	COL2A1	-0.57	-9.58	-0.41	5.9e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01252659	chr19:7198410	INSR	0.39	6.7	0.3	6.19e-11	Bipolar disorder;
LGG	cis	rs4665809	0.652	rs6728090	chr2:26524726	C/T	cg22920501	chr2:26401640	FAM59B	-0.39	-7.94	-0.35	1.57e-14	Gut microbiome composition (summer);
LGG	cis	rs42648	0.596	rs194513	chr7:89850170	G/T	cg25739043	chr7:89950458	NA	-0.34	-6.98	-0.31	1.04e-11	Homocysteine levels;
LGG	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg06521331	chr12:34319734	NA	-0.46	-7.99	-0.35	1.08e-14	Bladder cancer;
LGG	cis	rs2842992	0.830	rs2273819	chr6:160183325	G/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.68	0.54	4.87e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.99	0.71	6.89e-74	Bladder cancer;
LGG	cis	rs4969178	0.600	rs2376583	chr17:76402105	A/T	cg20026190	chr17:76395443	PGS1	0.42	7.22	0.32	2.14e-12	HDL cholesterol levels;
LGG	cis	rs2188554	0.740	rs6957018	chr7:117210368	C/T	cg10524701	chr7:117356490	CTTNBP2	0.39	6.75	0.3	4.54e-11	Esophageal adenocarcinoma;
LGG	cis	rs12971120	1.000	rs3829640	chr18:72174980	A/G	cg25817165	chr18:72167213	CNDP2	-0.64	-13.66	-0.54	6.2e-36	Refractive error;
LGG	cis	rs2084898	0.550	rs470941	chr11:119999755	C/T	cg07435449	chr11:120005650	TRIM29	0.71	12.34	0.5	1.93e-30	Stroke (pediatric);
LGG	cis	rs870825	0.929	rs56106324	chr4:185589901	C/A	cg04058563	chr4:185651563	MLF1IP	1.04	19.07	0.66	2.88e-60	Blood protein levels;
LGG	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.5	0.5	4.3e-31	Cognitive test performance;
LGG	cis	rs4481887	0.676	rs6691314	chr1:248548020	G/A	cg15454534	chr1:248569605	OR2T1	0.38	6.85	0.3	2.39e-11	Common traits (Other);
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13126279	chr21:47581558	C21orf56	-0.52	-9.39	-0.4	2.69e-19	Testicular germ cell tumor;
LGG	cis	rs861020	0.606	rs2184919	chr1:210000015	C/T	cg23166289	chr1:210001082	C1orf107	-0.32	-6.7	-0.3	6.15e-11	Orofacial clefts;
LGG	cis	rs7572733	0.905	rs6434945	chr2:198797960	G/C	cg00792783	chr2:198669748	PLCL1	0.48	8.16	0.35	3.1e-15	Dermatomyositis;
LGG	cis	rs7598759	0.679	rs10202701	chr2:232328681	C/T	cg11015011	chr2:232329588	NCL	0.42	6.87	0.3	2.06e-11	Noise-induced hearing loss;
LGG	cis	rs9467711	0.606	rs66823108	chr6:26377939	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	7.79	0.34	4.47e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg07777115	chr5:623756	CEP72	-0.63	-8.26	-0.36	1.49e-15	Obesity-related traits;
LGG	cis	rs754466	0.510	rs55893027	chr10:79588209	C/T	cg17075019	chr10:79541650	NA	-0.85	-17.77	-0.64	3.01e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2247341	0.965	rs11736125	chr4:1744939	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.85	-0.45	1.42e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg07701084	chr6:150067640	NUP43	0.61	11.37	0.47	1.41e-26	Lung cancer;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-13.42	-0.53	6.36e-35	Longevity;Endometriosis;
LGG	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg14088196	chr11:70211408	PPFIA1	0.96	13.23	0.52	4.13e-34	Coronary artery disease;
LGG	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.51	9.26	0.4	7.88e-19	Rheumatoid arthritis;
LGG	cis	rs2290159	0.948	rs73130305	chr3:12621075	C/T	cg23032965	chr3:12705835	RAF1	0.55	8.23	0.36	1.94e-15	Cholesterol, total;
LGG	cis	rs4417704	0.551	rs4464265	chr2:241891799	A/G	cg05025159	chr2:241905733	NA	0.46	9.65	0.41	3.28e-20	Joint mobility (Beighton score);
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs11264213	0.892	rs72659664	chr1:36185467	G/A	cg27506609	chr1:36549197	TEKT2	0.7	7.88	0.34	2.3e-14	Schizophrenia;
LGG	cis	rs11711311	0.955	rs12636240	chr3:113391282	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.13	-0.31	3.84e-12	IgG glycosylation;
LGG	cis	rs8064029	1.000	rs2734741	chr16:4946029	G/C	cg04440724	chr16:4920505	UBN1	-0.64	-7.45	-0.33	4.69e-13	Cancer;
LGG	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg02825527	chr7:2087843	MAD1L1	-0.4	-7.68	-0.34	9.29e-14	Neuroticism;
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	trans	rs2736345	0.788	rs2736337	chr8:11341880	T/C	cg06636001	chr8:8085503	FLJ10661	0.42	6.66	0.3	7.99e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15754109	chr8:67974431	COPS5	0.47	6.98	0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs9443645	0.901	rs1538235	chr6:79689450	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.69e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2717559	0.522	rs2572918	chr8:143875721	C/A	cg06565975	chr8:143823917	SLURP1	0.29	7.02	0.31	8.07e-12	Urinary tract infection frequency;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg15971980	chr6:150254442	NA	0.45	8.28	0.36	1.29e-15	Lung cancer;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.67e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11785693	0.862	rs11780705	chr8:4988221	G/A	cg26367366	chr8:4980734	NA	0.99	15.82	0.59	2.26e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs13040088	0.580	rs11905041	chr20:61563408	C/T	cg23096297	chr20:61557774	DIDO1	0.65	9.43	0.4	2.04e-19	Menopause (age at onset);
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.35	0.5	1.8e-30	Obesity-related traits;
LGG	cis	rs1707322	1.000	rs10890382	chr1:46469674	A/G	cg03146154	chr1:46216737	IPP	0.56	10.15	0.43	5.41e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg14675211	chr2:100938903	LONRF2	0.64	11.51	0.47	3.91e-27	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg25482853	chr8:67687455	SGK3	1.02	13.2	0.52	5.57e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs2594989	0.943	rs2454512	chr3:11487506	A/G	cg01796438	chr3:11312864	ATG7	-0.54	-7.45	-0.33	4.71e-13	Circulating chemerin levels;
LGG	cis	rs73198271	0.562	rs11774860	chr8:8651879	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.51	0.37	2.38e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg03959625	chr15:84868606	LOC388152	0.49	7.28	0.32	1.44e-12	Schizophrenia;
LGG	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg16141378	chr3:129829833	LOC729375	0.36	8.03	0.35	8.13e-15	Retinal vascular caliber;
LGG	trans	rs853679	1.000	rs10456362	chr6:28221816	A/G	cg01620082	chr3:125678407	NA	0.62	7.89	0.34	2.22e-14	Depression;
LGG	trans	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg16141378	chr3:129829833	LOC729375	0.36	8.05	0.35	7.04e-15	Triglycerides;
LGG	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.23	0.55	2.22e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs28595532	0.841	rs114768988	chr4:119744451	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.62e-12	Cognitive ability;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26077228	chr17:80408536	C17orf62	-0.47	-7.21	-0.32	2.27e-12	Pancreatic cancer;
LGG	cis	rs2718058	0.519	rs2598054	chr7:37884640	C/T	cg02531859	chr7:37888154	TXNDC3	-0.46	-7.09	-0.31	5.13e-12	Alzheimer's disease (late onset);
LGG	cis	rs12410462	0.591	rs965942	chr1:227772974	A/G	cg23173402	chr1:227635558	NA	0.39	7.29	0.32	1.34e-12	Major depressive disorder;
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg23939001	chr4:940644	TMEM175	0.63	13.3	0.53	2.02e-34	Sjögren's syndrome;
LGG	cis	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19171272	chr22:38449367	NA	-0.55	-10.75	-0.45	3.21e-24	Glioblastoma;Glioma;
LGG	cis	rs4363385	0.747	rs6678107	chr1:152966818	T/G	cg13444842	chr1:152974279	SPRR3	-0.45	-9.26	-0.4	7.4e-19	Inflammatory skin disease;
LGG	cis	rs12477438	0.765	rs7591794	chr2:99567514	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.88	-0.51	1.18e-32	Chronic sinus infection;
LGG	cis	rs10197940	0.967	rs4664423	chr2:152266311	T/C	cg06191203	chr2:152266755	RIF1	-0.54	-10.01	-0.42	1.82e-21	Lung cancer;
LGG	cis	rs4851254	0.579	rs78633727	chr2:100669457	T/C	cg17356467	chr2:100759845	AFF3	0.44	7.3	0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3780486	1.000	rs12342831	chr9:33124872	A/G	cg04842962	chr6:43655489	MRPS18A	0.98	16.97	0.62	1.41e-50	IgG glycosylation;
LGG	cis	rs2976388	1.000	rs1045531	chr8:143763547	C/A	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs7236492	0.748	rs80321964	chr18:77210152	G/C	cg15532942	chr18:77220712	NFATC1	0.47	7.51	0.33	3.17e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4629180	0.586	rs10172555	chr2:102126837	C/T	cg16435561	chr2:102091048	RFX8	0.47	8.81	0.38	2.47e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs12347191	0.500	rs1465965	chr9:100620326	C/T	cg13688889	chr9:100608707	NA	-0.82	-16.07	-0.6	1.65e-46	Orofacial clefts;
LGG	cis	rs3806843	0.966	rs2563264	chr5:140137503	T/G	cg19875535	chr5:140030758	IK	-0.52	-10.79	-0.45	2.34e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7110818	0.510	rs3862807	chr11:76283081	C/T	cg17647271	chr11:76299819	NA	-0.39	-6.94	-0.31	1.29e-11	Gut microbiota (functional units);
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg25427524	chr10:38739819	LOC399744	0.63	11.59	0.47	1.94e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg23601095	chr6:26197514	HIST1H3D	0.73	9.48	0.4	1.38e-19	Gout;Renal underexcretion gout;
LGG	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg08851530	chr6:28072375	NA	0.84	6.68	0.3	6.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs9640161	0.789	rs28439010	chr7:150046276	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.02	-0.57	8.13e-42	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10791323	0.582	rs2851120	chr11:133708065	A/G	cg15485101	chr11:133734466	NA	0.57	10.15	0.43	5.48e-22	Childhood ear infection;
LGG	cis	rs620875	1.000	rs535244	chr11:126858753	G/A	cg06504925	chr11:126872760	NA	-0.53	-7.44	-0.33	5.09e-13	Response to antipsychotic treatment;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.09	0.31	5.19e-12	Longevity;
LGG	cis	rs9747201	1.000	rs4239020	chr17:80176641	C/T	cg09264619	chr17:80180166	NA	-0.53	-10.29	-0.43	1.73e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.91e-19	Life satisfaction;
LGG	cis	rs2463822	0.513	rs72919445	chr11:62029078	A/C	cg06239285	chr11:62104954	ASRGL1	-0.97	-12.1	-0.49	1.82e-29	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7312933	0.607	rs7965392	chr12:42540280	G/A	cg19980929	chr12:42632907	YAF2	0.36	7.98	0.35	1.16e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3790455	0.610	rs1171554	chr1:156474119	G/A	cg14087168	chr1:156450669	MEF2D	-0.67	-10.05	-0.42	1.23e-21	Migraine;
LGG	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.63e-11	Coronary artery disease;
LGG	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.61	-10.56	-0.44	1.68e-23	Glomerular filtration rate;
LGG	cis	rs1062177	1.000	rs12518722	chr5:151231460	A/G	cg00977110	chr5:151150581	G3BP1	0.51	7.98	0.35	1.19e-14	Preschool internalizing problems;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg11584989	chr19:19387371	SF4	-0.4	-7.17	-0.32	2.96e-12	Tonsillectomy;
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg08302650	chr8:145750040	LRRC24;LRRC14	-0.41	-8.73	-0.38	4.61e-17	Age at first birth;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.61	0.37	1.17e-16	Renal function-related traits (BUN);
LGG	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.17e-20	Parkinson's disease;
LGG	cis	rs4253772	0.832	rs6008259	chr22:46633782	G/A	cg24881330	chr22:46731750	TRMU	0.63	7.53	0.33	2.68e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg11062466	chr8:58055876	NA	0.59	9.26	0.4	7.68e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.854	rs8117075	chr20:60613766	T/C	cg06470251	chr20:60548479	NA	0.51	8.51	0.37	2.35e-16	Body mass index;
LGG	cis	rs4808199	0.947	rs754255	chr19:19578890	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg07520158	chr7:32535189	LSM5;AVL9	0.57	9.67	0.41	2.96e-20	Cognitive ability;
LGG	cis	rs17376456	0.877	rs10060160	chr5:93387879	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs7737355	0.812	rs2189645	chr5:130804979	A/G	cg06307176	chr5:131281290	NA	-0.51	-8.51	-0.37	2.42e-16	Life satisfaction;
LGG	cis	rs2688608	0.620	rs11000767	chr10:75516626	G/T	cg23231163	chr10:75533350	FUT11	-0.43	-7.23	-0.32	2.06e-12	Inflammatory bowel disease;
LGG	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg16141378	chr3:129829833	LOC729375	0.32	7.1	0.31	4.83e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1534166	0.540	rs55970437	chr3:133516872	A/G	cg27366882	chr3:133540807	NA	-0.47	-6.79	-0.3	3.55e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs1018836	0.608	rs6992512	chr8:91477936	C/A	cg16814680	chr8:91681699	NA	-0.59	-9.82	-0.42	8.72e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.61	-0.41	4.65e-20	Lung cancer;
LGG	trans	rs1493916	0.837	rs8088362	chr18:31413016	A/G	cg04226714	chr8:49833948	SNAI2	-0.44	-7.89	-0.34	2.14e-14	Life satisfaction;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-9.97	-0.42	2.52e-21	Platelet count;
LGG	cis	rs9300255	0.679	rs12829456	chr12:123725395	C/T	cg00376283	chr12:123451042	ABCB9	-0.61	-9.18	-0.39	1.4e-18	Neutrophil percentage of white cells;
LGG	cis	rs11190604	0.767	rs35508946	chr10:102191156	A/G	cg07570687	chr10:102243282	WNT8B	0.41	7.49	0.33	3.59e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.3	0.36	1.15e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs6732160	0.510	rs57825971	chr2:73384796	C/G	cg20246863	chr2:73402720	NA	-0.27	-6.87	-0.3	2.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6723226	0.806	rs2249109	chr2:32750879	G/A	cg02381751	chr2:32503542	YIPF4	0.74	12.55	0.5	2.73e-31	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.966	rs11741994	chr5:140145949	G/A	cg19875535	chr5:140030758	IK	0.53	11.2	0.46	6.25e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs34845616	0.581	rs167915	chr11:133797581	A/T	cg06067394	chr11:133789110	IGSF9B	0.39	8.05	0.35	7.23e-15	Hand grip strength;
LGG	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg25143771	chr10:104629124	AS3MT	0.42	6.78	0.3	3.62e-11	Arsenic metabolism;
LGG	trans	rs9650657	0.537	rs7016385	chr8:10779472	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.97	0.35	1.24e-14	Neuroticism;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	11.83	0.48	2.22e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.36	0.36	7.17e-16	Bipolar disorder;
LGG	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs1125355	0.690	rs1515929	chr2:159629637	C/G	cg02251393	chr2:159651559	DAPL1	0.43	8.52	0.37	2.21e-16	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg11846333	chr4:119757529	SEC24D	0.84	7.8	0.34	4.07e-14	Cannabis dependence symptom count;
LGG	cis	rs62238980	0.614	rs117959136	chr22:32373225	T/C	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.690	rs2425171	chr20:34443173	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.34	-0.32	9.39e-13	Total cholesterol levels;
LGG	cis	rs644799	1.000	rs557079	chr11:95530125	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg09754948	chr16:28834200	ATXN2L	0.45	6.88	0.3	1.98e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11875185	1.000	rs67464131	chr18:55636342	A/G	cg15513957	chr14:69354734	ACTN1	-0.72	-8.01	-0.35	9.62e-15	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg16301924	chr13:53314226	LECT1	0.44	8.96	0.38	8.09e-18	Lewy body disease;
LGG	cis	rs1015291	0.708	rs1466687	chr12:19996058	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.17	-0.32	2.94e-12	Diastolic blood pressure;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.4	0.36	5.64e-16	Tonsillectomy;
LGG	cis	rs367943	0.666	rs12332129	chr5:112977983	A/G	cg12552261	chr5:112820674	MCC	0.52	9.03	0.39	4.58e-18	Type 2 diabetes;
LGG	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg02297831	chr4:17616191	MED28	0.49	8.98	0.39	6.86e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg11494091	chr17:61959527	GH2	0.63	10.68	0.44	6.11e-24	Height;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg24829409	chr8:58192753	C8orf71	-0.65	-9.1	-0.39	2.62e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	trans	rs1814175	0.817	rs10839397	chr11:49857074	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.94	-0.78	7.39e-97	Height;
LGG	cis	rs2070488	0.775	rs13072731	chr3:38533335	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.54	0.56	9.81e-40	Electrocardiographic conduction measures;
LGG	cis	rs10752881	1.000	rs10797807	chr1:182978873	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	trans	rs1032833	0.732	rs4101465	chr2:179960550	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.68	0.37	6.76e-17	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs11078917	1	rs11078917	chr17:37746359	A/C	cg00129232	chr17:37814104	STARD3	-0.71	-14.22	-0.55	2.41e-38	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14585611	chr2:175260420	CIR1;SCRN3	0.47	7.71	0.34	7.77e-14	Cognitive performance;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg05313129	chr8:58192883	C8orf71	-0.63	-8.47	-0.37	3.37e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22335246	chr12:120763591	PLA2G1B	0.56	8.64	0.37	9.3e-17	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00399650	chr7:141402322	KIAA1147	0.5	7.61	0.33	1.55e-13	Gut microbiome composition (summer);
LGG	cis	rs6088580	0.634	rs6058073	chr20:33116483	T/C	cg08999081	chr20:33150536	PIGU	0.4	10.16	0.43	5.03e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.96	0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg11905131	chr22:24372483	LOC391322	-0.42	-7.24	-0.32	1.89e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9287719	0.674	rs1387566	chr2:10828650	C/T	cg02196655	chr2:10830764	NOL10	0.5	8.79	0.38	2.96e-17	Prostate cancer;
LGG	cis	rs2282300	0.739	rs7952339	chr11:30327344	C/T	cg06241208	chr11:30344200	C11orf46	0.5	6.69	0.3	6.53e-11	Morning vs. evening chronotype;
LGG	cis	rs9926296	0.712	rs258319	chr16:89732024	A/T	cg04287289	chr16:89883240	FANCA	-0.44	-7.79	-0.34	4.39e-14	Vitiligo;
LGG	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg05707623	chr12:122985044	ZCCHC8	0.59	9.04	0.39	4.3e-18	Body mass index;
LGG	cis	rs4819388	0.669	rs8128292	chr21:45642227	C/T	cg01992765	chr21:45622493	NA	0.47	9.12	0.39	2.37e-18	Celiac disease;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.9	-0.38	1.25e-17	Obesity-related traits;
LGG	cis	rs911263	0.540	rs7158493	chr14:68812330	C/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.36	0.36	7.28e-16	Primary biliary cholangitis;
LGG	cis	rs36071027	0.577	rs12109219	chr5:158393842	T/G	cg23468002	chr5:158532401	NA	0.41	6.91	0.31	1.62e-11	Carotid intima media thickness;
LGG	cis	rs4478858	0.709	rs3766296	chr1:31820223	G/A	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs17376456	0.741	rs7718842	chr5:93480568	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.99	10.65	0.44	7.74e-24	Diabetic retinopathy;
LGG	cis	rs1008375	1.000	rs17507481	chr4:17620066	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.36	0.43	8.96e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	6.94	0.31	1.33e-11	Renal function-related traits (BUN);
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg10295955	chr4:187884368	NA	0.83	15.37	0.58	2.32e-43	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7617773	0.674	rs13069029	chr3:48355024	A/G	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.5	0.4	1.17e-19	Bipolar disorder;
LGG	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg16325326	chr1:53192061	ZYG11B	-0.8	-20.5	-0.69	6.06e-67	Monocyte count;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.49	-0.33	3.63e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg23205692	chr1:25664452	TMEM50A	0.5	10.96	0.45	5.34e-25	Erythrocyte sedimentation rate;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.16	0.35	3.18e-15	Triglycerides;
LGG	trans	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.42	-0.4	2.21e-19	Bladder cancer;
LGG	trans	rs7395662	1.000	rs11039800	chr11:48542579	C/T	cg15704280	chr7:45808275	SEPT13	0.49	7.92	0.35	1.83e-14	HDL cholesterol;
LGG	cis	rs2832191	0.716	rs2297252	chr21:30377104	G/A	cg24692254	chr21:30365293	RNF160	1.04	29.87	0.81	4.89e-110	Dental caries;
LGG	cis	rs7267979	1.000	rs6050602	chr20:25401203	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.5	-0.44	2.81e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg21724239	chr8:58056113	NA	0.5	7.61	0.33	1.5e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs727505	1.000	rs2402751	chr7:124434760	C/T	cg23710748	chr7:124431027	NA	-0.5	-9.0	-0.39	5.7e-18	Lewy body disease;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg18252515	chr7:66147081	NA	-0.44	-7.42	-0.33	5.63e-13	Aortic root size;
LGG	cis	rs6062302	0.522	rs3787107	chr20:62230576	G/A	cg16989086	chr20:62203971	PRIC285	0.48	6.97	0.31	1.07e-11	Glioblastoma;
LGG	cis	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg22398616	chr13:53314203	LECT1	-0.54	-11.75	-0.48	4.49e-28	Lewy body disease;
LGG	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg24110177	chr3:50126178	RBM5	0.61	11.16	0.46	8.67e-26	Body mass index;
LGG	cis	rs1451375	0.959	rs17133878	chr7:50620927	T/C	cg20336341	chr7:50628841	DDC	0.35	6.83	0.3	2.72e-11	Malaria;
LGG	cis	rs36051895	0.632	rs11791350	chr9:5172907	G/T	cg02405213	chr9:5042618	JAK2	-0.74	-13.15	-0.52	9.17e-34	Pediatric autoimmune diseases;
LGG	cis	rs1153858	1.000	rs12441971	chr15:45671957	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs17270561	1.000	rs12211184	chr6:25823774	G/A	cg17691542	chr6:26056736	HIST1H1C	0.91	13.38	0.53	9.25e-35	Iron status biomarkers;
LGG	cis	rs477895	0.653	rs34113693	chr11:63900123	G/T	cg04317338	chr11:64019027	PLCB3	0.66	8.16	0.35	3.28e-15	Mean platelet volume;
LGG	trans	rs1814175	0.654	rs1164676	chr11:49324868	T/C	cg15704280	chr7:45808275	SEPT13	0.92	18.0	0.64	2.68e-55	Height;
LGG	cis	rs6542838	0.641	rs4851176	chr2:99534859	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.41	-0.33	6e-13	Fear of minor pain;
LGG	cis	rs9815354	0.767	rs60943892	chr3:41852307	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg08621203	chr6:150244597	RAET1G	0.48	8.15	0.35	3.48e-15	Lung cancer;
LGG	cis	rs17209837	0.915	rs12672720	chr7:87126438	A/G	cg00919237	chr7:87102261	ABCB4	-0.71	-11.06	-0.46	2.14e-25	Gallbladder cancer;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg12708336	chr17:41446283	NA	-0.33	-8.08	-0.35	5.72e-15	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg06925179	chr17:43578568	NA	-0.41	-9.67	-0.41	2.82e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9399137	0.507	rs4520025	chr6:135278619	G/T	cg22676075	chr6:135203613	NA	0.46	8.13	0.35	3.89e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs8002861	0.664	rs4942247	chr13:44405107	A/G	cg12856521	chr11:46389249	DGKZ	0.51	9.16	0.39	1.65e-18	Leprosy;
LGG	cis	rs4434138	0.594	rs7653028	chr3:52763000	A/T	cg15147215	chr3:52552868	STAB1	-0.35	-6.7	-0.3	6.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10464366	0.544	rs2280667	chr7:39172228	A/C	cg10621924	chr7:39171070	POU6F2	0.47	9.61	0.41	4.84e-20	IgG glycosylation;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs1358748	0.522	rs4655675	chr1:67576075	C/T	cg02640540	chr1:67518911	SLC35D1	0.52	6.66	0.3	7.81e-11	Tuberculosis;
LGG	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06850241	chr22:41845214	NA	0.45	7.1	0.31	4.71e-12	Vitiligo;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs7666738	0.791	rs10005118	chr4:99038196	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.1e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs939658	1.000	rs8031504	chr15:79458589	G/T	cg17916960	chr15:79447300	NA	0.63	12.27	0.5	3.61e-30	Refractive error;
LGG	cis	rs9790314	1.000	rs336569	chr3:161072346	T/G	cg03342759	chr3:160939853	NMD3	-0.62	-11.01	-0.46	3.47e-25	Morning vs. evening chronotype;
LGG	cis	rs6445975	0.628	rs7231	chr3:58413465	C/G	cg24175188	chr3:58374923	PXK	0.52	8.63	0.37	9.78e-17	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg26174226	chr8:58114915	NA	-0.5	-7.06	-0.31	6.13e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.755	rs3789849	chr8:8687054	G/C	cg00405596	chr8:11794950	NA	0.42	6.96	0.31	1.19e-11	Mood instability;
LGG	cis	rs10267417	0.603	rs6960607	chr7:19869407	A/G	cg05791153	chr7:19748676	TWISTNB	0.62	8.44	0.37	4.02e-16	Night sleep phenotypes;
LGG	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.89	-0.34	2.2e-14	Initial pursuit acceleration;
LGG	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs72781680	1.000	rs72796351	chr2:24158425	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs11920090	0.722	rs66863493	chr3:170671990	A/G	cg09710316	chr3:170744871	SLC2A2	0.62	7.31	0.32	1.17e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.92	-0.42	3.55e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg06558623	chr16:89946397	TCF25	1.24	13.52	0.53	2.52e-35	Skin colour saturation;
LGG	cis	rs4824093	0.610	rs73443906	chr22:50274293	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.93	-0.31	1.43e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs8049040	0.609	rs11866859	chr16:71478888	G/A	cg08717414	chr16:71523259	ZNF19	-0.56	-8.78	-0.38	3.15e-17	Blood protein levels;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.58	0.59	2.54e-44	Platelet count;
LGG	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.25	-0.36	1.7e-15	Joint mobility (Beighton score);
LGG	trans	rs78049276	0.736	rs6841581	chr4:148401190	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.86	-0.34	2.69e-14	Pulse pressure;
LGG	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg19507638	chr5:93509721	C5orf36	-0.39	-6.74	-0.3	4.76e-11	Diabetic retinopathy;
LGG	cis	rs2735413	0.521	rs8053331	chr16:78044700	T/A	cg04733911	chr16:78082701	NA	0.51	6.99	0.31	9.38e-12	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs8180040	0.701	rs11130111	chr3:47009805	C/T	cg27129171	chr3:47204927	SETD2	0.82	15.19	0.58	1.38e-42	Colorectal cancer;
LGG	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-6.77	-0.3	4.03e-11	Lung cancer in ever smokers;
LGG	cis	rs9381040	0.674	rs3747742	chr6:41162518	C/T	cg03644281	chr6:41068752	NFYA;LOC221442	0.42	6.97	0.31	1.12e-11	Alzheimer's disease (late onset);
LGG	cis	rs9467773	0.566	rs66972160	chr6:26359306	T/C	cg09904177	chr6:26538194	HMGN4	-0.47	-8.41	-0.36	5.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13427251	0.903	rs6746402	chr2:100150443	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.53	-9.69	-0.41	2.4e-20	Chronic sinus infection;
LGG	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.87	-0.48	1.53e-28	Depression;
LGG	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-6.88	-0.3	1.96e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.21	0.49	6.61e-30	Corneal astigmatism;
LGG	cis	rs2236918	1.000	rs1627006	chr1:242038004	C/T	cg17736920	chr1:242011382	EXO1	0.49	8.68	0.37	6.66e-17	Menopause (age at onset);
LGG	cis	rs2531992	0.563	rs2531988	chr16:4028417	T/G	cg05927578	chr16:4029543	ADCY9	0.72	10.07	0.42	1.04e-21	Waist circumference;
LGG	cis	rs4363385	0.510	rs11590835	chr1:153047166	T/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.24	-0.39	8.9e-19	Inflammatory skin disease;
LGG	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	cis	rs4268898	0.636	rs72803210	chr2:24615710	A/G	cg06627628	chr2:24431161	ITSN2	-0.77	-11.78	-0.48	3.28e-28	Asthma;
LGG	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg10792982	chr14:105748885	BRF1	0.54	10.75	0.45	3.34e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06028808	chr11:68637592	NA	0.71	12.34	0.5	1.99e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.19	-0.36	2.48e-15	Restless legs syndrome;
LGG	cis	rs765787	0.530	rs11070445	chr15:45513163	T/A	cg24006582	chr15:45444508	DUOX1	0.66	12.09	0.49	1.95e-29	Uric acid levels;
LGG	cis	rs867371	1.000	rs7180584	chr15:82455834	A/G	cg00614314	chr15:82944287	LOC80154	0.57	9.38	0.4	2.91e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs1577917	0.545	rs7755958	chr6:86488511	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.5	8.4	0.36	5.68e-16	Response to antipsychotic treatment;
LGG	trans	rs10028773	0.700	rs7671797	chr4:120248157	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.59e-25	Educational attainment;
LGG	cis	rs2280018	0.526	rs2941257	chr16:15166445	T/C	cg07549590	chr16:15018862	NA	-0.53	-9.24	-0.39	8.67e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs9354308	0.764	rs4644030	chr6:66582238	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.88	-0.3	1.99e-11	Metabolite levels;
LGG	cis	rs6502050	0.814	rs62079997	chr17:80076888	C/T	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	trans	rs11662586	0.573	rs7238269	chr18:77706294	A/G	cg05926928	chr17:57297772	GDPD1	0.63	10.74	0.45	3.69e-24	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs4891159	0.505	rs680253	chr18:74167427	A/C	cg24786174	chr18:74118243	ZNF516	-0.6	-14.36	-0.56	6.05e-39	Longevity;
LGG	cis	rs11025559	0.773	rs10833334	chr11:20498640	T/C	cg19653624	chr11:20408972	PRMT3	-0.51	-8.45	-0.37	3.92e-16	Pursuit maintenance gain;
LGG	cis	rs2153904	0.793	rs12132270	chr1:205660940	C/T	cg23034840	chr1:205782522	SLC41A1	-0.75	-8.46	-0.37	3.47e-16	Prostate-specific antigen levels;
LGG	trans	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg06529181	chr19:52193933	NA	0.52	7.84	0.34	3.24e-14	IgG glycosylation;
LGG	cis	rs4563143	0.514	rs112540771	chr19:29316100	C/T	cg04546413	chr19:29218101	NA	0.82	11.98	0.49	5.58e-29	Methadone dose in opioid dependence;
LGG	cis	rs1256061	0.603	rs1256041	chr14:64738029	A/G	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs11229555	0.645	rs7926682	chr11:58189495	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	cg07245641	chr1:182991651	LAMC1	0.4	8.94	0.38	8.97e-18	Colorectal cancer;
LGG	cis	rs77669868	0.929	rs3782002	chr11:114070563	A/T	cg01914181	chr11:114070210	ZBTB16	0.7	9.21	0.39	1.09e-18	Monocyte percentage of white cells;
LGG	cis	rs883565	0.606	rs7650682	chr3:39079418	C/A	cg01426195	chr3:39028469	NA	-0.67	-15.18	-0.58	1.64e-42	Handedness;
LGG	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs11225247	0.881	rs117275062	chr11:102309494	A/G	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg01988459	chr11:68622903	NA	-0.61	-12.53	-0.5	3.36e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6815814	0.950	rs9306967	chr4:38807911	G/C	cg06935464	chr4:38784597	TLR10	0.48	7.74	0.34	6.23e-14	Breast cancer;
LGG	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg08250081	chr4:10125330	NA	0.35	6.92	0.31	1.51e-11	Bone mineral density;
LGG	cis	rs4253772	0.591	rs9615348	chr22:46729338	C/G	cg09461388	chr22:46763229	CELSR1	-0.68	-7.07	-0.31	5.81e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.94	-0.38	9.63e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1620921	0.506	rs13201433	chr6:161269959	C/G	cg01280913	chr6:161186852	NA	-0.35	-7.1	-0.31	4.62e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7589342	0.831	rs34554853	chr2:106448931	G/A	cg16077055	chr2:106428750	NCK2	0.31	8.14	0.35	3.71e-15	Addiction;
LGG	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg09044154	chr16:88155775	NA	-0.51	-7.59	-0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs2718058	0.639	rs2597270	chr7:37762014	A/G	cg24998770	chr7:37888106	TXNDC3	-0.49	-7.97	-0.35	1.22e-14	Alzheimer's disease (late onset);
LGG	cis	rs35146811	0.735	rs1727139	chr7:99815367	C/T	cg22906224	chr7:99728672	NA	-0.58	-9.57	-0.41	6.41e-20	Coronary artery disease;
LGG	cis	rs7940866	0.874	rs1433979	chr11:130871617	G/A	cg12179176	chr11:130786555	SNX19	0.71	13.03	0.52	2.77e-33	Schizophrenia;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg19147129	chr2:74230310	NA	0.37	6.88	0.3	1.96e-11	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.03e-13	Prudent dietary pattern;
LGG	cis	rs73086581	0.947	rs73084531	chr20:3878429	G/A	cg02187196	chr20:3869020	PANK2	0.89	12.48	0.5	5.05e-31	Response to antidepressants in depression;
LGG	cis	rs12497850	0.931	rs9876848	chr3:48844059	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	cis	rs6901004	0.803	rs354545	chr6:111531412	G/A	cg15721981	chr6:111408429	SLC16A10	-0.41	-7.31	-0.32	1.16e-12	Blood metabolite levels;
LGG	cis	rs13421350	0.579	rs76738244	chr2:173382986	G/A	cg15021238	chr2:173305865	ITGA6	-0.8	-8.63	-0.37	1.03e-16	Diabetic kidney disease;
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg13628971	chr7:2884303	GNA12	0.37	7.71	0.34	7.54e-14	Height;
LGG	cis	rs977987	0.806	rs11149833	chr16:75464002	G/C	cg03315344	chr16:75512273	CHST6	0.5	9.96	0.42	2.55e-21	Dupuytren's disease;
LGG	cis	rs516946	0.666	rs6986080	chr8:41488038	G/C	cg21772509	chr8:41503840	NKX6-3	-0.53	-8.14	-0.35	3.68e-15	Type 2 diabetes;
LGG	trans	rs7762018	0.607	rs80106119	chr6:170048309	T/C	cg06875740	chr19:51307921	C19orf48	-0.72	-6.78	-0.3	3.62e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs950776	0.642	rs61630816	chr15:78965866	T/C	cg03762349	chr15:79060523	ADAMTS7	0.37	8.11	0.35	4.42e-15	Sudden cardiac arrest;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05489143	chr3:40498640	RPL14	-0.5	-7.4	-0.33	6.5e-13	Systemic lupus erythematosus;
LGG	cis	rs950776	0.531	rs12915652	chr15:78831928	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.31	0.4	5.1e-19	Sudden cardiac arrest;
LGG	cis	rs7827545	1.000	rs7827545	chr8:135566567	C/T	cg09855544	chr8:135498122	ZFAT	0.46	7.84	0.34	3.13e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs2980439	0.525	rs2980508	chr8:8171732	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.77	0.41	1.26e-20	Neuroticism;
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg19077165	chr18:44547161	KATNAL2	0.54	9.7	0.41	2.31e-20	Personality dimensions;
LGG	cis	rs10463554	0.963	rs34771	chr5:102450417	G/A	cg23492399	chr5:102201601	PAM	-0.5	-7.49	-0.33	3.41e-13	Parkinson's disease;
LGG	cis	rs986417	0.579	rs1254281	chr14:60854300	T/C	cg27398547	chr14:60952738	C14orf39	-0.71	-7.02	-0.31	7.89e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg12070911	chr6:150209640	RAET1E	0.32	7.84	0.34	3.11e-14	Lung cancer;
LGG	cis	rs72772090	0.710	rs11750400	chr5:96077968	A/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-8.16	-0.35	3.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17691542	chr6:26056736	HIST1H1C	1.09	17.65	0.63	1.12e-53	Iron status biomarkers;
LGG	trans	rs7395662	1.000	rs10838931	chr11:48540973	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.93	-0.31	1.41e-11	HDL cholesterol;
LGG	cis	rs992157	0.835	rs12987219	chr2:219144149	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.07e-22	Colorectal cancer;
LGG	cis	rs8067545	0.586	rs2526463	chr17:20078297	G/A	cg13482628	chr17:19912719	NA	-0.54	-10.28	-0.43	1.76e-22	Schizophrenia;
LGG	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg06026331	chr20:60912101	LAMA5	0.7	12.55	0.5	2.65e-31	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1371867	0.846	rs1616833	chr8:101271821	C/T	cg06636551	chr8:101224915	SPAG1	0.47	8.71	0.38	5.52e-17	Atrioventricular conduction;
LGG	trans	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7555523	0.887	rs4657471	chr1:165686873	T/C	cg24409356	chr1:165738333	TMCO1	0.79	9.34	0.4	3.99e-19	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.56	-0.44	1.66e-23	IgG glycosylation;
LGG	cis	rs9581857	0.685	rs11839899	chr13:28041780	G/A	cg01674679	chr13:27998804	GTF3A	-0.68	-7.94	-0.35	1.51e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg24846343	chr22:24311635	DDTL	-0.59	-11.79	-0.48	2.96e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12693043	0.727	rs2163236	chr2:175431707	C/G	cg26362616	chr2:175440004	WIPF1	0.36	6.65	0.3	8.41e-11	Urate levels (BMI interaction);
LGG	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.78e-25	Aortic root size;
LGG	cis	rs4919087	0.748	rs11189131	chr10:99085835	G/A	cg25902810	chr10:99078978	FRAT1	-0.46	-8.0	-0.35	1.01e-14	Monocyte count;
LGG	cis	rs7615952	0.576	rs6804482	chr3:125815762	C/T	cg02772935	chr3:125709198	NA	-0.53	-6.66	-0.3	7.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs72781680	0.898	rs2879640	chr2:24043573	T/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.71e-18	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11416597	chr1:33722623	ZNF362	0.36	7.0	0.31	8.81e-12	Gut microbiome composition (summer);
LGG	cis	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg11502198	chr6:26597334	ABT1	-0.88	-7.48	-0.33	3.65e-13	Small cell lung carcinoma;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs950169	0.922	rs12911223	chr15:84831671	G/A	cg24253500	chr15:84953950	NA	-0.56	-10.29	-0.43	1.65e-22	Schizophrenia;
LGG	cis	rs7918232	0.825	rs4749233	chr10:27467967	G/A	cg14240646	chr10:27532245	ACBD5	-0.73	-10.28	-0.43	1.82e-22	Breast cancer;
LGG	cis	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.62	-0.33	1.48e-13	Menarche (age at onset);
LGG	cis	rs6696846	0.765	rs11240360	chr1:205083865	T/C	cg00857998	chr1:205179979	DSTYK	0.57	9.3	0.4	5.77e-19	Red blood cell count;
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.37	-0.36	6.68e-16	Tonsillectomy;
LGG	cis	rs9487051	0.872	rs9400271	chr6:109607556	G/A	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs4716602	0.596	rs12386634	chr7:156158373	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.5	-0.4	1.12e-19	Anti-saccade response;
LGG	cis	rs12493885	0.697	rs55681402	chr3:153659873	G/A	cg12800244	chr3:153838788	SGEF	-0.8	-8.5	-0.37	2.56e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.52	8.75	0.38	4.07e-17	Eosinophil percentage of white cells;
LGG	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-11.21	-0.46	5.6e-26	Vitamin D levels;
LGG	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11644478	chr21:40555479	PSMG1	0.87	16.02	0.6	2.91e-46	Cognitive function;
LGG	cis	rs17209837	0.607	rs45553044	chr7:87085613	A/G	cg25823085	chr7:87105416	ABCB4	0.3	7.43	0.33	5.35e-13	Gallbladder cancer;
LGG	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.4	-6.91	-0.31	1.64e-11	Total body bone mineral density;
LGG	cis	rs12048904	0.505	rs10493936	chr1:101213335	A/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.43	-7.79	-0.34	4.56e-14	Multiple sclerosis;
LGG	cis	rs1707322	0.721	rs6697821	chr1:46216722	A/G	cg03146154	chr1:46216737	IPP	0.57	11.04	0.46	2.56e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs115986297	0.559	rs3800159	chr6:2130774	C/T	cg20365419	chr10:67074019	NA	0.32	6.79	0.3	3.41e-11	Hematocrit;Hemoglobin concentration;Red blood cell count;
LGG	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg00198680	chr16:28758506	NA	0.31	7.45	0.33	4.66e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10744422	1.000	rs4993320	chr12:123338092	T/C	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	5.17e-19	Schizophrenia;
LGG	cis	rs7208859	0.623	rs75136574	chr17:28934549	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.27	-0.46	3.33e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg11502198	chr6:26597334	ABT1	0.44	7.18	0.32	2.75e-12	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7216064	1.000	rs11870068	chr17:65944515	A/C	cg12091567	chr17:66097778	LOC651250	-0.62	-9.05	-0.39	3.89e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs763121	0.886	rs1013339	chr22:38974680	C/T	cg06022373	chr22:39101656	GTPBP1	0.84	17.07	0.62	4.99e-51	Menopause (age at onset);
LGG	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg24110177	chr3:50126178	RBM5	0.56	10.14	0.43	5.79e-22	Intelligence (multi-trait analysis);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg27405321	chr20:34359917	PHF20	-0.38	-7.45	-0.33	4.47e-13	Iris color (L* coordinate);
LGG	cis	rs72781680	0.898	rs56216411	chr2:23934533	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.3	0.4	5.55e-19	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs67133203	0.796	rs1005559	chr12:51414232	T/A	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.71e-30	Urinary tract infection frequency;
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-12.8	-0.51	2.49e-32	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08215925	chr3:71633214	FOXP1	0.42	6.87	0.3	2.09e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg16141378	chr3:129829833	LOC729375	0.38	8.4	0.36	5.59e-16	Neuroticism;
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg04287289	chr16:89883240	FANCA	0.81	17.15	0.62	2.12e-51	Vitiligo;
LGG	cis	rs17221829	0.733	rs112601489	chr11:89365849	A/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs1014246	0.848	rs758362	chr10:118457905	G/A	cg14919929	chr10:118506882	NA	0.61	11.76	0.48	3.92e-28	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs752010	0.749	rs12141084	chr1:42117737	C/T	cg16096631	chr1:42092165	HIVEP3	0.63	15.87	0.59	1.38e-45	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.51	-0.44	2.63e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg04362960	chr10:104952993	NT5C2	0.58	10.05	0.42	1.3e-21	Arsenic metabolism;
LGG	cis	rs1620921	0.967	rs1652482	chr6:161197885	G/A	cg01280913	chr6:161186852	NA	-0.35	-7.36	-0.32	8.23e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19524238	chr7:2802976	GNA12	0.4	9.07	0.39	3.44e-18	Height;
LGG	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg21644426	chr2:191273491	MFSD6	0.57	9.89	0.42	4.71e-21	Pulse pressure;
LGG	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	cis	rs3740909	1.000	rs7119527	chr11:125887311	C/T	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs55692411	0.537	rs35012435	chr3:50031840	C/T	cg24110177	chr3:50126178	RBM5	-0.54	-8.22	-0.36	2.08e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6138458	0.816	rs2151463	chr20:24911819	A/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	cg07928641	chr1:182991847	LAMC1	0.45	9.13	0.39	2.1e-18	Colorectal cancer;
LGG	cis	rs1008375	0.932	rs9283698	chr4:17662471	T/C	cg18681998	chr4:17616180	MED28	0.85	17.59	0.63	2.04e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1957429	0.901	rs2884308	chr14:65350406	A/T	cg23373153	chr14:65346875	NA	-1.08	-14.94	-0.57	1.85e-41	Pediatric areal bone mineral density (radius);
LGG	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.31	0.36	1.1e-15	Menarche (age at onset);
LGG	trans	rs7939886	0.920	rs2460212	chr11:55886155	C/T	cg03929089	chr4:120376271	NA	-0.71	-7.21	-0.32	2.35e-12	Myopia (pathological);
LGG	cis	rs988958	0.565	rs13030802	chr2:42237344	T/C	cg27252766	chr2:42229092	NA	0.52	7.09	0.31	5.05e-12	Hypospadias;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg21782813	chr7:2030301	MAD1L1	0.37	8.76	0.38	3.71e-17	Schizophrenia;
LGG	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg04149295	chr10:70884716	VPS26A	0.48	7.16	0.32	3.29e-12	Left atrial antero-posterior diameter;
LGG	cis	rs910187	1.000	rs6063085	chr20:45840459	A/C	cg27589058	chr20:45804311	EYA2	-0.31	-7.43	-0.33	5.19e-13	Migraine;
LGG	cis	rs4689642	0.507	rs12648511	chr4:7222350	T/G	cg21353189	chr4:7228343	SORCS2	0.33	7.04	0.31	6.81e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs4665809	0.590	rs34728554	chr2:26481959	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.19	-0.39	1.29e-18	Bone mineral density;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg05234568	chr11:5960015	NA	-0.68	-11.49	-0.47	4.74e-27	DNA methylation (variation);
LGG	cis	rs7829975	0.533	rs35900578	chr8:8719513	G/A	cg08975724	chr8:8085496	FLJ10661	0.37	6.8	0.3	3.29e-11	Mood instability;
LGG	cis	rs9948	1.000	rs62152790	chr2:97478579	G/A	cg01990225	chr2:97406019	LMAN2L	-0.65	-6.84	-0.3	2.44e-11	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	cis	rs1595825	0.945	rs7581202	chr2:198836777	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.73	-0.3	4.99e-11	Ulcerative colitis;
LGG	cis	rs16976116	0.901	rs28564077	chr15:55495151	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs986417	0.901	rs6573314	chr14:60972045	C/T	cg27398547	chr14:60952738	C14orf39	0.71	6.92	0.31	1.56e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg24623649	chr8:11872141	NA	0.31	7.24	0.32	1.93e-12	Triglycerides;
LGG	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg13385521	chr17:29058706	SUZ12P	0.7	8.24	0.36	1.81e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg18402987	chr7:1209562	NA	0.57	7.88	0.34	2.28e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg02825527	chr7:2087843	MAD1L1	-0.43	-7.81	-0.34	3.74e-14	Bipolar disorder;
LGG	cis	rs6909430	0.901	rs4144177	chr6:98715164	A/T	cg12860156	chr6:98744658	NA	0.43	7.82	0.34	3.68e-14	Quantitative traits;
LGG	cis	rs2952156	0.920	rs2517958	chr17:37838751	G/A	cg00129232	chr17:37814104	STARD3	-0.75	-16.22	-0.6	3.59e-47	Asthma;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11232610	chr5:140027381	NDUFA2;IK	0.5	8.12	0.35	4.14e-15	Cognitive performance;
LGG	cis	rs6554196	0.525	rs2237036	chr4:55526175	G/C	cg18836493	chr4:55524333	KIT	-0.44	-8.14	-0.35	3.62e-15	Monocyte count;
LGG	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	cg07928641	chr1:182991847	LAMC1	0.46	8.96	0.38	7.8e-18	Colorectal cancer;
LGG	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg12310025	chr6:25882481	NA	-0.54	-10.47	-0.44	3.57e-23	Blood metabolite levels;
LGG	cis	rs12775980	0.737	rs75269469	chr10:29847532	T/A	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	cis	rs9399135	0.935	rs2150680	chr6:135347131	G/C	cg24558204	chr6:135376177	HBS1L	0.53	9.82	0.42	8.69e-21	Red blood cell count;
LGG	cis	rs16986825	0.607	rs5762852	chr22:29242473	T/C	cg02153584	chr22:29168773	CCDC117	0.59	7.13	0.31	3.86e-12	Pancreatic cancer;
LGG	cis	rs427394	0.582	rs274661	chr5:6704848	C/T	cg15145174	chr5:6755386	POLS	-0.41	-7.65	-0.34	1.15e-13	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg08742575	chr21:47604166	C21orf56	0.49	8.55	0.37	1.79e-16	Testicular germ cell tumor;
LGG	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.86e-20	Retinal vascular caliber;
LGG	cis	rs6121246	0.909	rs6060679	chr20:30270772	C/G	cg21427119	chr20:30132790	HM13	0.41	7.13	0.31	3.93e-12	Mean corpuscular hemoglobin;
LGG	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg00490583	chr16:1843685	IGFALS	-0.46	-10.02	-0.42	1.65e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6450176	0.909	rs3776721	chr5:53292522	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.0	-0.46	3.53e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2075371	0.933	rs2244548	chr7:133986234	A/G	cg11752832	chr7:134001865	SLC35B4	0.62	11.43	0.47	7.73e-27	Mean platelet volume;
LGG	cis	rs968567	0.539	rs174560	chr11:61581764	T/C	cg19610905	chr11:61596333	FADS2	-0.74	-12.66	-0.51	9.85e-32	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs6693567	0.586	rs4970979	chr1:150483840	C/T	cg15654264	chr1:150340011	RPRD2	0.32	6.67	0.3	7.38e-11	Migraine;
LGG	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.33	-0.47	1.89e-26	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg19524238	chr7:2802976	GNA12	0.31	7.74	0.34	6.37e-14	Height;
LGG	cis	rs7129220	0.588	rs61878634	chr11:10140114	A/T	cg01453529	chr11:10209919	SBF2	-0.42	-6.78	-0.3	3.67e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1570884	0.516	rs2146144	chr13:50170245	C/T	cg08779649	chr13:50194554	NA	0.36	9.11	0.39	2.48e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs17767392	0.881	rs17767680	chr14:71997594	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.77	-0.38	3.45e-17	Mitral valve prolapse;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs834603	0.547	rs1704966	chr7:47469948	G/A	cg23694490	chr7:47445681	TNS3	-0.41	-11.79	-0.48	3e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2235649	0.798	rs78540053	chr16:1853275	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.39	-6.7	-0.3	5.9e-11	Blood metabolite levels;
LGG	cis	rs4319547	0.794	rs61954972	chr12:123074167	T/G	cg23029597	chr12:123009494	RSRC2	-0.97	-18.68	-0.66	1.85e-58	Body mass index;
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.82	-0.42	8.45e-21	Educational attainment;
LGG	cis	rs757278	0.517	rs35415299	chr7:117101282	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	8.49	0.37	2.74e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.77	-0.54	2.06e-36	Alzheimer's disease;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-12.39	-0.5	1.19e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs12410462	0.901	rs1120000	chr1:227659615	T/C	cg04117972	chr1:227635322	NA	0.64	10.58	0.44	1.4e-23	Major depressive disorder;
LGG	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.74	11.95	0.49	7.04e-29	Hip circumference adjusted for BMI;
LGG	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg11644478	chr21:40555479	PSMG1	-0.75	-13.54	-0.53	1.99e-35	Cognitive function;
LGG	cis	rs911555	0.755	rs8018400	chr14:103901085	A/G	cg24130564	chr14:104152367	KLC1	0.38	7.18	0.32	2.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs112790992	1	rs112790992	chr14:105758217	A/C	cg10792982	chr14:105748885	BRF1	0.54	10.89	0.45	9.23e-25	Platelet count;
LGG	cis	rs2067615	0.542	rs10861654	chr12:107122896	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.06	0.49	2.62e-29	Heart rate;
LGG	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg05973401	chr12:123451056	ABCB9	0.5	7.61	0.33	1.54e-13	Neutrophil percentage of white cells;
LGG	cis	rs2235642	0.691	rs2281235	chr16:1603535	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.44	0.4	1.89e-19	Coronary artery disease;
LGG	cis	rs2204008	0.539	rs1283295	chr12:38146014	A/C	cg26384229	chr12:38710491	ALG10B	-0.68	-13.28	-0.53	2.48e-34	Bladder cancer;
LGG	cis	rs75920871	0.925	rs76523703	chr11:116749509	T/G	cg20608306	chr11:116969690	SIK3	-0.32	-6.8	-0.3	3.29e-11	Subjective well-being;
LGG	cis	rs56399783	0.803	rs17132665	chr7:2802173	T/C	cg19731401	chr7:2775893	GNA12	0.36	7.27	0.32	1.49e-12	Childhood ear infection;
LGG	cis	rs2404602	0.647	rs11631394	chr15:76973209	G/T	cg15268244	chr15:77196840	NA	0.48	10.25	0.43	2.28e-22	Blood metabolite levels;
LGG	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-12.25	-0.49	4.27e-30	Vitiligo;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg04553112	chr3:125709451	NA	-0.54	-6.92	-0.31	1.5e-11	Blood pressure (smoking interaction);
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9287719	0.935	rs7600495	chr2:10739800	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs4780401	0.609	rs35649585	chr16:11813899	G/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.82	-0.51	2e-32	Rheumatoid arthritis;
LGG	trans	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.78	-0.41	1.13e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs7904368	0.806	rs4612698	chr10:16855070	C/A	cg22980697	chr10:16874865	CUBN	0.6	9.74	0.41	1.59e-20	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs17767392	0.813	rs12880291	chr14:71884567	G/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.21	0.36	2.14e-15	Mitral valve prolapse;
LGG	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg06481639	chr22:41940642	POLR3H	-0.61	-8.68	-0.37	6.65e-17	Vitiligo;
LGG	trans	rs2727020	0.521	rs937430	chr11:49542457	A/G	cg11707556	chr5:10655725	ANKRD33B	0.66	11.39	0.47	1.2e-26	Coronary artery disease;
LGG	cis	rs12464559	0.649	rs11894672	chr2:152657055	C/T	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg19635926	chr16:89946313	TCF25	0.71	6.98	0.31	1.02e-11	Skin colour saturation;
LGG	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.96	-0.31	1.19e-11	Retinal vascular caliber;
LGG	cis	rs9467711	0.606	rs9379863	chr6:26372427	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs67311347	1.000	rs1047855	chr3:40468896	A/G	cg13683864	chr3:40499215	RPL14	1.12	25.41	0.76	7.95e-90	Renal cell carcinoma;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg19901994	chr8:27288146	PTK2B	0.36	6.71	0.3	5.87e-11	Electrocardiographic conduction measures;
LGG	cis	rs709400	0.930	rs10134399	chr14:104083457	G/A	cg26031613	chr14:104095156	KLC1	1.2	31.04	0.82	3.26e-115	Body mass index;
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.57e-23	Bipolar disorder;
LGG	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg20608306	chr11:116969690	SIK3	0.3	6.81	0.3	3.01e-11	Blood protein levels;
LGG	trans	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.88	0.45	1.09e-24	Ulcerative colitis;
LGG	trans	rs75804782	0.630	rs11900807	chr2:239309989	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	6.81	0.3	3.07e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg12310025	chr6:25882481	NA	-0.39	-7.02	-0.31	7.93e-12	Height;
LGG	cis	rs7301826	1.000	rs4759523	chr12:131315412	T/C	cg11011512	chr12:131303247	STX2	0.34	7.48	0.33	3.78e-13	Plasma plasminogen activator levels;
LGG	cis	rs7089973	0.604	rs7903663	chr10:116609904	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs11165623	0.602	rs4619021	chr1:97025910	T/C	cg10631902	chr5:14652156	NA	-0.45	-9.41	-0.4	2.36e-19	Hip circumference;Waist circumference;
LGG	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg00405596	chr8:11794950	NA	0.66	11.72	0.48	5.9e-28	Neuroticism;
LGG	cis	rs4740619	0.661	rs10962227	chr9:15944352	G/T	cg14451791	chr9:16040625	NA	-0.4	-10.06	-0.42	1.13e-21	Body mass index;
LGG	cis	rs882300	0.967	rs11692725	chr2:136929883	A/G	cg07169764	chr2:136633963	MCM6	0.46	7.36	0.32	8.44e-13	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.94	0.31	1.3e-11	Resting heart rate;
LGG	cis	rs3099143	1.000	rs3099134	chr15:77133168	T/G	cg21673338	chr15:77095150	SCAPER	-0.65	-10.69	-0.44	5.58e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs2717559	0.522	rs35816096	chr8:143884938	C/T	cg06565975	chr8:143823917	SLURP1	-0.29	-6.99	-0.31	9.89e-12	Urinary tract infection frequency;
LGG	cis	rs7584262	0.737	rs12996528	chr2:42239901	T/C	cg19376973	chr2:42229025	NA	0.63	9.43	0.4	1.97e-19	Bone mineral density;
LGG	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg20336341	chr7:50628841	DDC	0.5	9.44	0.4	1.9e-19	Malaria;
LGG	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.55	7.97	0.35	1.22e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg10295955	chr4:187884368	NA	-1.07	-24.69	-0.75	1.74e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs16866061	0.515	rs13020268	chr2:225437923	C/T	cg22455342	chr2:225449267	CUL3	0.44	7.37	0.32	7.81e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg09264619	chr17:80180166	NA	-0.37	-7.51	-0.33	2.97e-13	Life satisfaction;
LGG	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg12373951	chr3:133503437	NA	-0.39	-6.82	-0.3	2.93e-11	Iron status biomarkers;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.33	-0.47	1.96e-26	Obesity-related traits;
LGG	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7208859	0.524	rs8065744	chr17:29099449	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.46	0.5	6.16e-31	Lymphocyte counts;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.06	-0.35	6.46e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs67133203	0.799	rs12828536	chr12:51426035	C/T	cg14688905	chr12:51403056	SLC11A2	0.8	12.25	0.49	4.45e-30	Urinary tract infection frequency;
LGG	cis	rs2540226	0.575	rs4670954	chr2:39908324	G/C	cg18968196	chr2:39892502	TMEM178	0.31	8.56	0.37	1.7e-16	Personality dimensions;
LGG	cis	rs4731207	0.724	rs6953168	chr7:124506341	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs1816752	0.905	rs4770680	chr13:25015248	T/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg22903657	chr4:1355424	KIAA1530	-0.3	-6.95	-0.31	1.21e-11	Longevity;
LGG	cis	rs9354308	0.764	rs9453478	chr6:66605558	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs13314892	0.728	rs55735918	chr3:69874297	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2204008	0.777	rs8189597	chr12:38307739	G/C	cg04568710	chr12:38710424	ALG10B	-0.33	-6.64	-0.3	8.62e-11	Bladder cancer;
LGG	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg06197492	chr11:2016605	H19	0.4	8.36	0.36	7.44e-16	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs5750830	0.649	rs2413590	chr22:39790191	G/C	cg11247378	chr22:39784982	NA	-0.31	-9.03	-0.39	4.48e-18	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg13010199	chr12:38710504	ALG10B	0.52	9.95	0.42	2.82e-21	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg25358565	chr5:93447407	FAM172A	-0.82	-11.35	-0.47	1.58e-26	Diabetic retinopathy;
LGG	cis	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.27	-0.36	1.39e-15	Triglycerides;
LGG	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg03605463	chr16:89740564	NA	-0.4	-6.92	-0.31	1.52e-11	Vitiligo;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg08280861	chr8:58055591	NA	0.61	7.63	0.33	1.36e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg26874164	chr19:58962979	ZNF324B	0.36	7.17	0.32	2.9e-12	Uric acid clearance;
LGG	cis	rs11966931	0.947	rs11968258	chr6:108133059	G/A	cg04749840	chr6:108095067	SCML4	0.45	7.6	0.33	1.65e-13	Neutrophil percentage of white cells;
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.4	9.23e-20	Bipolar disorder;
LGG	cis	rs17253792	0.545	rs71412688	chr14:56021539	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs2180341	0.960	rs6913424	chr6:127707010	A/C	cg24812749	chr6:127587940	RNF146	0.96	15.89	0.59	1.09e-45	Breast cancer;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg14789911	chr21:47582049	C21orf56	0.49	8.68	0.37	6.95e-17	Testicular germ cell tumor;
LGG	cis	rs12580194	0.593	rs7311751	chr12:55748847	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.68	-0.41	2.55e-20	Cancer;
LGG	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg25809561	chr17:30822961	MYO1D	0.4	9.42	0.4	2.19e-19	Schizophrenia;
LGG	cis	rs7577696	0.597	rs56322034	chr2:32353013	T/C	cg02381751	chr2:32503542	YIPF4	-0.46	-6.74	-0.3	4.78e-11	Inflammatory biomarkers;
LGG	cis	rs300703	0.515	rs300694	chr2:182277	G/T	cg24565620	chr2:194026	NA	0.65	10.36	0.43	9.28e-23	Blood protein levels;
LGG	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg13385794	chr1:248469461	NA	0.45	7.94	0.35	1.55e-14	Common traits (Other);
LGG	cis	rs2953174	0.507	rs34568097	chr2:241540989	A/G	cg07929629	chr2:241523174	NA	0.61	9.31	0.4	5.25e-19	Bipolar disorder;
LGG	cis	rs638893	0.947	rs1170396	chr11:118703817	T/A	cg22253036	chr11:118662786	DDX6	0.41	6.94	0.31	1.32e-11	Vitiligo;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg09264619	chr17:80180166	NA	0.37	7.34	0.32	9.93e-13	Life satisfaction;
LGG	cis	rs9393777	0.528	rs9467989	chr6:27064275	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-8.76	-0.38	3.67e-17	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg02733842	chr7:1102375	C7orf50	-0.48	-7.88	-0.34	2.38e-14	Bronchopulmonary dysplasia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15574263	chr11:911693	CHID1	-0.47	-7.01	-0.31	8.28e-12	Systemic lupus erythematosus;
LGG	cis	rs1555895	0.656	rs61831439	chr10:840244	A/G	cg10556349	chr10:835070	NA	-0.32	-8.14	-0.35	3.66e-15	Survival in rectal cancer;
LGG	cis	rs1555895	0.576	rs752375	chr10:863329	C/T	cg09361094	chr10:834503	NA	-0.29	-7.69	-0.34	8.63e-14	Survival in rectal cancer;
LGG	cis	rs8016982	0.633	rs55822231	chr14:81708677	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	20.19	0.68	1.78e-65	Schizophrenia;
LGG	cis	rs870825	0.790	rs12513128	chr4:185576729	G/C	cg04058563	chr4:185651563	MLF1IP	1.0	17.99	0.64	2.89e-55	Blood protein levels;
LGG	cis	rs7267979	1.000	rs4815411	chr20:25350223	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.21	-0.43	3.32e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21893314	chr15:40453133	BUB1B	0.46	7.7	0.34	8.11e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.546	rs6500442	chr16:89828862	T/C	cg26513180	chr16:89883248	FANCA	0.94	20.98	0.7	3.69e-69	Vitiligo;
LGG	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	17.34	0.63	2.99e-52	Smoking behavior;
LGG	cis	rs9291683	0.530	rs10939620	chr4:9946132	C/T	cg25986240	chr4:9926439	SLC2A9	0.49	10.64	0.44	8.51e-24	Bone mineral density;
LGG	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg04546413	chr19:29218101	NA	0.75	12.74	0.51	4.35e-32	Methadone dose in opioid dependence;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.69	-0.3	6.32e-11	Lung cancer;
LGG	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg07936489	chr17:37558343	FBXL20	0.83	15.49	0.58	6.42e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.78	-0.38	3.1e-17	Coronary artery disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08761447	chr12:3982140	PARP11	-0.47	-6.81	-0.3	3.09e-11	Systemic lupus erythematosus;
LGG	cis	rs4595586	0.505	rs11613808	chr12:39390823	T/A	cg13010199	chr12:38710504	ALG10B	0.45	7.91	0.35	1.85e-14	Morning vs. evening chronotype;
LGG	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg16262614	chr3:133464971	TF	0.47	8.72	0.38	4.85e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs4891159	0.790	rs35516239	chr18:74129942	C/T	cg24786174	chr18:74118243	ZNF516	-0.57	-13.45	-0.53	4.6e-35	Longevity;
LGG	cis	rs2346177	0.844	rs13010062	chr2:46644137	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.82	0.34	3.56e-14	HDL cholesterol;
LGG	cis	rs17508449	0.547	rs35173468	chr1:114398821	G/C	cg26035817	chr1:114414802	PTPN22	-0.46	-6.75	-0.3	4.33e-11	Leprosy;
LGG	cis	rs6964587	0.692	rs7807490	chr7:91773359	A/G	cg17063962	chr7:91808500	NA	0.55	10.53	0.44	2.1e-23	Breast cancer;
LGG	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg05084668	chr3:125655381	ALG1L	-0.54	-7.34	-0.32	9.49e-13	Blood pressure (smoking interaction);
LGG	cis	rs1059312	0.545	rs12303387	chr12:129276733	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	10.92	0.45	7.63e-25	Systemic lupus erythematosus;
LGG	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.42	-7.32	-0.32	1.07e-12	Bipolar disorder;
LGG	cis	rs1348850	0.514	rs4893974	chr2:178497026	A/G	cg22681709	chr2:178499509	PDE11A	-0.45	-6.7	-0.3	5.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg20321706	chr12:132845874	GALNT9	-0.31	-6.78	-0.3	3.57e-11	Migraine with aura;
LGG	cis	rs7524258	0.903	rs4908449	chr1:7292700	T/C	cg07173049	chr1:7289937	CAMTA1	0.78	19.42	0.67	6.95e-62	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.73	-0.34	6.7e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.78	0.54	2e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs12517041	0.935	rs35858834	chr5:23325233	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.77	-0.48	3.61e-28	Calcium levels;
LGG	cis	rs4925386	0.840	rs8124907	chr20:60913127	A/G	cg24112000	chr20:60950667	NA	-0.38	-7.67	-0.34	1.01e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg06221963	chr1:154839813	KCNN3	0.52	10.81	0.45	1.98e-24	Prostate cancer;
LGG	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg02527881	chr3:46936655	PTH1R	-0.34	-8.1	-0.35	5.06e-15	Birth weight;
LGG	cis	rs6456156	1.000	rs6456156	chr6:167522300	T/C	cg07741184	chr6:167504864	NA	0.33	7.53	0.33	2.63e-13	Primary biliary cholangitis;
LGG	trans	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg24247370	chr13:99142703	STK24	-0.38	-7.03	-0.31	7.56e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9487051	0.735	rs380774	chr6:109519623	C/T	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.7e-13	Reticulocyte fraction of red cells;
LGG	cis	rs7565124	1.000	rs12472043	chr2:20256838	G/A	cg24657347	chr2:20261756	NA	-0.76	-14.88	-0.57	3.21e-41	Major depressive disorder;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.76	-0.34	5.52e-14	Life satisfaction;
LGG	cis	rs4851254	0.550	rs13402299	chr2:100659409	C/T	cg17356467	chr2:100759845	AFF3	0.43	7.21	0.32	2.26e-12	Intelligence (multi-trait analysis);
LGG	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3733585	0.781	rs57250714	chr4:9984529	C/T	cg11266682	chr4:10021025	SLC2A9	0.43	8.19	0.36	2.54e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.83	0.45	1.68e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12780845	0.505	rs10795462	chr10:17245119	A/C	cg01003015	chr10:17271136	VIM	-0.43	-7.35	-0.32	8.85e-13	Homocysteine levels;
LGG	cis	rs17270561	0.609	rs9358886	chr6:25758253	T/A	cg16482183	chr6:26056742	HIST1H1C	0.54	8.45	0.37	3.79e-16	Iron status biomarkers;
LGG	cis	rs9398803	0.687	rs1826189	chr6:126922214	C/T	cg19875578	chr6:126661172	C6orf173	0.52	9.6	0.41	4.98e-20	Male-pattern baldness;
LGG	cis	rs9875589	0.957	rs62234598	chr3:13964610	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.34	-0.4	3.94e-19	Ovarian reserve;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg06873352	chr17:61820015	STRADA	0.49	7.64	0.33	1.23e-13	Height;
LGG	cis	rs13191362	0.872	rs73020362	chr6:163005737	A/C	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2797160	1.000	rs2747722	chr6:126009629	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg22535103	chr8:58192502	C8orf71	-0.79	-9.87	-0.42	5.43e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.793	rs13027299	chr2:178455501	T/G	cg27490568	chr2:178487706	NA	0.5	9.71	0.41	2.02e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.7	-0.34	8.29e-14	Retinal vascular caliber;
LGG	cis	rs12627970	0.565	rs5757613	chr22:39715262	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.97	22.33	0.72	1.73e-75	Inflammatory bowel disease;
LGG	cis	rs13217239	0.646	rs35691005	chr6:26972070	A/G	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Schizophrenia;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09981013	chr16:88008551	BANP	0.4	7.25	0.32	1.77e-12	Electrocardiographic conduction measures;
LGG	trans	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg13010199	chr12:38710504	ALG10B	0.58	11.12	0.46	1.27e-25	Morning vs. evening chronotype;
LGG	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.0	-0.35	1e-14	Coronary artery disease;
LGG	cis	rs2066819	0.901	rs773665	chr12:56717466	C/T	cg26734620	chr12:56694298	CS	-0.74	-6.73	-0.3	4.99e-11	Psoriasis vulgaris;
LGG	cis	rs10463554	0.963	rs6883113	chr5:102377889	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs523522	0.962	rs655530	chr12:121022275	T/C	cg12219531	chr12:120966889	COQ5	0.67	11.14	0.46	1.06e-25	High light scatter reticulocyte count;
LGG	cis	rs79149102	0.579	rs78664321	chr15:75339575	G/A	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.25	-0.36	1.7e-15	Lung cancer;
LGG	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg06611532	chr13:114900021	NA	0.28	7.18	0.32	2.82e-12	Schizophrenia;
LGG	cis	rs193541	0.632	rs173481	chr5:122254552	G/A	cg19412675	chr5:122181750	SNX24	0.55	8.72	0.38	5.04e-17	Glucose homeostasis traits;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.82	-0.45	1.71e-24	Longevity;Endometriosis;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.25	-0.32	1.77e-12	Skin colour saturation;
LGG	cis	rs7814319	0.840	rs10504961	chr8:97240129	C/T	cg20787634	chr8:97240163	UQCRB	-0.77	-18.32	-0.65	8.78e-57	Lung function (FVC);
LGG	cis	rs9633740	0.685	rs4934284	chr10:82277297	C/G	cg01528321	chr10:82214614	TSPAN14	-0.7	-6.93	-0.31	1.38e-11	Post bronchodilator FEV1;
LGG	cis	rs910316	1.000	rs11845639	chr14:75570293	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.56	0.44	1.74e-23	Height;
LGG	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg06606381	chr12:133084897	FBRSL1	-1.34	-12.2	-0.49	7.24e-30	Depression;
LGG	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.93	0.35	1.6e-14	Colorectal cancer;
LGG	trans	rs4714291	1.000	rs847769	chr6:40050171	T/C	cg02267698	chr19:7991119	CTXN1	0.55	8.48	0.37	3.02e-16	Strep throat;
LGG	cis	rs7617773	0.817	rs6796490	chr3:48237104	A/C	cg11946769	chr3:48343235	NME6	0.56	9.26	0.4	7.95e-19	Coronary artery disease;
LGG	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg09021430	chr5:549028	NA	-0.52	-10.15	-0.43	5.34e-22	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs2032447	0.714	rs199739	chr6:25960509	A/C	cg03264133	chr6:25882463	NA	-0.72	-13.52	-0.53	2.51e-35	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.56	0.56	8.55e-40	Obesity-related traits;
LGG	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.67	0.54	5.66e-36	Obesity-related traits;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg00495681	chr13:53174319	NA	0.6	11.28	0.46	3.01e-26	Lewy body disease;
LGG	cis	rs1335587	0.580	rs9518405	chr13:102086377	A/G	cg13538571	chr13:102108074	ITGBL1	0.39	7.44	0.33	4.96e-13	Obesity-related traits;
LGG	cis	rs975739	0.669	rs7986312	chr13:78584793	T/G	cg07847733	chr13:78271382	SLAIN1	0.49	8.32	0.36	9.99e-16	Hair color;
LGG	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg07541023	chr7:19748670	TWISTNB	0.58	7.84	0.34	3.15e-14	Thyroid stimulating hormone;
LGG	cis	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.14	0.55	5.53e-38	Bladder cancer;
LGG	cis	rs7107174	1.000	rs2512541	chr11:77981747	A/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg11814155	chr7:99998594	ZCWPW1	0.59	9.2	0.39	1.2e-18	Platelet count;
LGG	cis	rs61332075	0.518	rs10209564	chr2:239459603	C/T	cg18131467	chr2:239335373	ASB1	-0.63	-7.31	-0.32	1.17e-12	Lung function (FEV1/FVC);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08142263	chr19:17420206	DDA1	0.47	7.59	0.33	1.75e-13	Cognitive performance;
LGG	cis	rs4950322	0.802	rs72694705	chr1:146834025	G/A	cg22381352	chr1:146742008	CHD1L	-0.49	-7.99	-0.35	1.09e-14	Protein quantitative trait loci;
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs2640806	0.670	rs28629440	chr8:97325622	C/T	cg22138393	chr8:97340270	PTDSS1	0.31	7.76	0.34	5.42e-14	Obesity-related traits;
LGG	cis	rs1008375	0.646	rs13120449	chr4:17560728	G/T	cg10189774	chr4:17578691	LAP3	-0.44	-7.19	-0.32	2.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg08435079	chr1:36615170	TRAPPC3	-0.36	-7.23	-0.32	1.98e-12	Iris color (L* coordinate);
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg11494091	chr17:61959527	GH2	1.0	24.51	0.75	1.11e-85	Prudent dietary pattern;
LGG	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg19168338	chr16:4465731	CORO7	0.71	12.27	0.5	3.62e-30	Schizophrenia;
LGG	cis	rs2071403	0.527	rs2071402	chr2:1417199	A/G	cg06500727	chr2:1417164	TPO	0.62	13.03	0.52	2.91e-33	Thyroid peroxidase antibody positivity;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg23758822	chr17:41437982	NA	-0.87	-15.29	-0.58	5.25e-43	Menopause (age at onset);
LGG	cis	rs3820928	0.874	rs6717168	chr2:227901342	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.28	-0.32	1.47e-12	Pulmonary function;
LGG	cis	rs6940638	0.688	rs7744759	chr6:27119826	G/A	cg12826209	chr6:26865740	GUSBL1	0.47	7.72	0.34	7.38e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7781557	0.640	rs55681588	chr7:102577338	C/G	cg18108683	chr7:102477205	FBXL13	-0.54	-8.1	-0.35	5.06e-15	Colorectal adenoma (advanced);
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg17911788	chr17:44343683	NA	-0.59	-9.0	-0.39	5.95e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg08470875	chr2:26401718	FAM59B	-0.42	-8.22	-0.36	2.06e-15	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg08297393	chr2:100937505	LONRF2	-0.53	-10.07	-0.42	1.1e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.936	rs2241978	chr2:113954006	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.34	-0.5	1.88e-30	Lymphocyte counts;
LGG	cis	rs1801251	1.000	rs6761324	chr2:233582793	T/G	cg08000102	chr2:233561755	GIGYF2	0.58	9.42	0.4	2.16e-19	Coronary artery disease;
LGG	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.13e-12	Blood metabolite levels;
LGG	cis	rs8062405	0.755	rs4788078	chr16:28559981	G/A	cg16576597	chr16:28551801	NUPR1	0.43	10.21	0.43	3.38e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1577917	1.000	rs35760725	chr6:86648985	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	trans	rs1941687	0.831	rs12958029	chr18:31388680	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.57	-0.37	1.56e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg05484508	chr16:89589025	SPG7	0.46	7.5	0.33	3.23e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg08355456	chr11:67383691	NA	-0.49	-7.91	-0.35	1.87e-14	Mean corpuscular volume;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg01326531	chr9:138392790	C9orf116;MRPS2	-0.4	-7.05	-0.31	6.69e-12	Blood metabolite levels;
LGG	cis	rs16976116	0.901	rs7165491	chr15:55500455	A/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.22	0.32	2.19e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1493916	1.000	rs7238717	chr18:31395186	C/T	cg04226714	chr8:49833948	SNAI2	-0.48	-8.61	-0.37	1.17e-16	Life satisfaction;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg19223190	chr17:80058835	NA	-0.46	-8.73	-0.38	4.53e-17	Life satisfaction;
LGG	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg00757033	chr12:89920650	WDR51B	0.63	9.2	0.39	1.19e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1719271	0.710	rs1684041	chr15:65200804	C/T	cg11671771	chr15:65133392	PLEKHO2	-0.51	-7.03	-0.31	7.26e-12	Platelet count;
LGG	trans	rs7824557	0.815	rs2572430	chr8:11105304	G/T	cg06636001	chr8:8085503	FLJ10661	0.55	9.63	0.41	4.05e-20	Retinal vascular caliber;
LGG	cis	rs9397585	0.857	rs9371664	chr6:153377440	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs40363	0.645	rs250631	chr16:3523215	G/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.44	-6.66	-0.3	7.86e-11	Tuberculosis;
LGG	cis	rs4430311	0.723	rs10927081	chr1:243994216	T/C	cg25706552	chr1:244017396	NA	-0.65	-16.13	-0.6	8.98e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs35740288	0.822	rs4843092	chr15:86233180	G/A	cg07943548	chr15:86304357	KLHL25	-0.35	-6.88	-0.3	2.01e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs701145	0.878	rs433903	chr3:153980130	A/G	cg17054900	chr3:154042577	DHX36	0.99	12.3	0.5	2.68e-30	Coronary artery disease;
LGG	cis	rs7617773	0.817	rs11130163	chr3:48312658	T/C	cg11946769	chr3:48343235	NME6	0.59	9.85	0.42	6.67e-21	Coronary artery disease;
LGG	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg09904177	chr6:26538194	HMGN4	0.78	18.03	0.64	1.96e-55	Intelligence (multi-trait analysis);
LGG	trans	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.16	-0.39	1.66e-18	Neuroticism;
LGG	cis	rs11690935	0.921	rs4668414	chr2:172704291	A/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-25.79	-0.77	1.37e-91	Schizophrenia;
LGG	cis	rs12477438	0.834	rs10179043	chr2:99687490	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-12.1	-0.49	1.73e-29	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg07701084	chr6:150067640	NUP43	0.71	13.89	0.54	6.76e-37	Lung cancer;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg15971980	chr6:150254442	NA	0.46	8.72	0.38	5.18e-17	Lung cancer;
LGG	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg11871910	chr12:69753446	YEATS4	0.48	7.76	0.34	5.59e-14	Response to diuretic therapy;
LGG	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg06115741	chr20:33292138	TP53INP2	0.59	9.93	0.42	3.31e-21	Coronary artery disease;
LGG	cis	rs4740619	0.740	rs58517712	chr9:15773019	G/T	cg14451791	chr9:16040625	NA	0.35	8.83	0.38	2.16e-17	Body mass index;
LGG	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg10523679	chr1:76189770	ACADM	0.83	14.11	0.55	7.04e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs11971779	0.527	rs4379397	chr7:139043385	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs12545109	0.800	rs1996106	chr8:57412963	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg12070911	chr6:150209640	RAET1E	0.28	6.76	0.3	4.14e-11	Lung cancer;
LGG	cis	rs10927875	0.793	rs1763619	chr1:16326935	A/G	cg22431228	chr1:16359049	CLCNKA	-0.43	-7.45	-0.33	4.65e-13	Dilated cardiomyopathy;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.76	0.3	4.04e-11	Schizophrenia;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg02234479	chr17:16342158	NCRNA00188;SNORD49B;SNORD49A	-0.43	-6.67	-0.3	7.45e-11	Coronary artery disease;
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg03188948	chr7:1209495	NA	0.55	7.59	0.33	1.78e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	0.779	rs72918579	chr4:120333222	G/C	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.53e-28	Corneal astigmatism;
LGG	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg04727924	chr7:799746	HEATR2	-0.48	-7.66	-0.34	1.06e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs9790314	1.000	rs4350933	chr3:160955879	G/T	cg03342759	chr3:160939853	NMD3	-0.66	-12.0	-0.49	4.51e-29	Morning vs. evening chronotype;
LGG	cis	rs4851266	1.000	rs11689201	chr2:100820431	A/G	cg21926883	chr2:100939477	LONRF2	-0.44	-7.9	-0.34	2.06e-14	Educational attainment;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg13628971	chr7:2884303	GNA12	0.5	10.19	0.43	3.8e-22	Height;
LGG	cis	rs17301259	0.587	rs2519947	chr7:88398603	T/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.12	-0.31	4.11e-12	Heschl's gyrus morphology;
LGG	cis	rs28595532	0.841	rs116452272	chr4:119770802	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg25566285	chr7:158114605	PTPRN2	0.89	19.98	0.68	1.69e-64	Calcium levels;
LGG	cis	rs9682041	0.561	rs7643214	chr3:170144281	C/T	cg11886554	chr3:170076028	SKIL	0.68	8.12	0.35	4.36e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.55	0.33	2.4e-13	Lung cancer;
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.61	-0.47	1.56e-27	Retinal vascular caliber;
LGG	trans	rs4714291	0.748	rs3008829	chr6:39953963	C/T	cg02267698	chr19:7991119	CTXN1	-0.53	-8.26	-0.36	1.56e-15	Strep throat;
LGG	cis	rs2629540	0.889	rs4962699	chr10:126477209	A/G	cg08799069	chr10:126477246	METTL10	-0.69	-14.29	-0.55	1.27e-38	Cocaine dependence;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.45	0.47	6.94e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg19147804	chr7:1989927	MAD1L1	-0.53	-10.37	-0.43	8.67e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs7939886	0.920	rs11227854	chr11:56081744	T/C	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs1062746	0.777	rs34400756	chr16:87372078	A/G	cg02258303	chr16:87377426	FBXO31	-0.61	-11.94	-0.49	7.56e-29	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs4740619	0.868	rs10732335	chr9:15862077	A/C	cg14451791	chr9:16040625	NA	-0.4	-10.03	-0.42	1.52e-21	Body mass index;
LGG	cis	rs8056893	0.513	rs3785111	chr16:68309971	A/T	cg07273125	chr16:68295692	NA	0.49	11.12	0.46	1.27e-25	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.79	0.3	3.43e-11	Educational attainment;
LGG	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg00599393	chr8:22457479	C8orf58	-0.43	-7.97	-0.35	1.23e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2976388	0.609	rs2572899	chr8:143785549	A/G	cg06565975	chr8:143823917	SLURP1	0.35	9.09	0.39	2.97e-18	Urinary tract infection frequency;
LGG	trans	rs800082	0.671	rs800099	chr3:144398547	A/T	cg24215973	chr2:240111563	HDAC4	-0.74	-13.54	-0.53	2.04e-35	Smoking behavior;
LGG	cis	rs6817170	0.692	rs9760689	chr4:154372361	G/A	cg07229402	chr4:154369277	NA	0.34	6.84	0.3	2.48e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs4788570	0.584	rs7204608	chr16:71678679	C/G	cg06353428	chr16:71660113	MARVELD3	-1.19	-19.38	-0.67	1.05e-61	Intelligence (multi-trait analysis);
LGG	cis	rs7765175	0.598	rs9384862	chr6:113656446	C/T	cg26552650	chr6:113682475	NA	0.33	7.33	0.32	1.01e-12	Coronary artery calcification;
LGG	cis	rs1577917	1.000	rs4707239	chr6:86610717	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.2e-16	Response to antipsychotic treatment;
LGG	cis	rs9399135	0.967	rs45544135	chr6:135324051	T/C	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Red blood cell count;
LGG	cis	rs9443645	0.901	rs7742431	chr6:79679577	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.72	-0.38	4.91e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6908034	0.607	rs73376680	chr6:19808099	G/A	cg02682789	chr6:19804855	NA	0.92	8.74	0.38	4.25e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14240646	chr10:27532245	ACBD5	0.74	10.2	0.43	3.69e-22	Breast cancer;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg05863683	chr7:1912471	MAD1L1	-0.44	-8.48	-0.37	3.07e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg14789911	chr21:47582049	C21orf56	-0.41	-7.1	-0.31	4.88e-12	Testicular germ cell tumor;
LGG	cis	rs1008375	1.000	rs2058339	chr4:17678456	C/T	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.29e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13191362	0.938	rs28360532	chr6:162997477	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg26656751	chr17:43910226	CRHR1	-0.43	-7.76	-0.34	5.6e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9309473	0.539	rs6732440	chr2:73827099	T/G	cg20560298	chr2:73613845	ALMS1	0.36	6.7	0.3	5.98e-11	Metabolite levels;
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.36	4.24e-16	Bipolar disorder;
LGG	cis	rs6089829	0.692	rs6122349	chr20:61664096	T/C	cg08564027	chr20:61660810	NA	0.86	15.69	0.59	8.56e-45	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg24006582	chr15:45444508	DUOX1	0.67	12.24	0.49	4.88e-30	Uric acid levels;
LGG	cis	rs11753937	0.774	rs569833	chr6:133527935	T/C	cg14017655	chr6:133562193	EYA4	0.43	7.43	0.33	5.21e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9457247	0.565	rs12193698	chr6:167512073	C/A	cg07741184	chr6:167504864	NA	0.45	10.09	0.42	8.72e-22	Crohn's disease;
LGG	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg03877680	chr5:178157825	ZNF354A	0.81	14.3	0.55	1.13e-38	Neutrophil percentage of white cells;
LGG	cis	rs9354308	0.834	rs9354307	chr6:66552953	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.05	-0.35	7.15e-15	Metabolite levels;
LGG	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.42	7.29	0.32	1.32e-12	Menarche (age at onset);
LGG	cis	rs7582180	0.652	rs12997725	chr2:100935136	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.71	-0.61	2.08e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	1.000	rs6050630	chr20:25430745	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3741151	0.686	rs11828904	chr11:73139116	T/C	cg17517138	chr11:73019481	ARHGEF17	0.76	8.23	0.36	1.87e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg05729581	chr11:3078854	CARS	0.53	9.22	0.39	1.01e-18	Longevity;
LGG	cis	rs2404602	0.692	rs55864032	chr15:77122548	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.05	0.39	4.01e-18	Blood metabolite levels;
LGG	trans	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg20587970	chr11:113659929	NA	0.93	12.95	0.52	5.99e-33	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg04025307	chr7:1156635	C7orf50	0.77	11.15	0.46	9.63e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4595586	0.545	rs1588970	chr12:39403122	C/A	cg26384229	chr12:38710491	ALG10B	0.6	10.75	0.45	3.27e-24	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs7211776	chr17:29120196	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.64	-8.15	-0.35	3.49e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28830936	1.000	rs4924575	chr15:42096926	C/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.65	-0.3	8.17e-11	Diastolic blood pressure;
LGG	cis	rs6088580	0.634	rs4277599	chr20:33008905	A/G	cg24642439	chr20:33292090	TP53INP2	-0.54	-8.97	-0.38	7.14e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs13424612	1.000	rs10189996	chr2:240908800	G/A	cg01812947	chr2:240904978	NDUFA10	0.43	7.25	0.32	1.72e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs3784262	0.771	rs4775005	chr15:58208165	C/T	cg12031962	chr15:58353849	ALDH1A2	0.34	7.21	0.32	2.36e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs9912468	0.568	rs8079676	chr17:64236953	A/G	cg19474267	chr17:64306194	PRKCA	-0.7	-14.32	-0.55	9.21e-39	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	9.96	0.42	2.61e-21	Rheumatoid arthritis;
LGG	cis	rs2549003	1.000	rs2070722	chr5:131824486	A/C	cg21138405	chr5:131827807	IRF1	0.38	9.96	0.42	2.69e-21	Asthma (sex interaction);
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs36051895	0.559	rs7868706	chr9:5210936	T/G	cg02405213	chr9:5042618	JAK2	-0.65	-11.6	-0.47	1.68e-27	Pediatric autoimmune diseases;
LGG	cis	rs36051895	0.626	rs9695934	chr9:5153108	C/G	cg02405213	chr9:5042618	JAK2	-0.77	-15.1	-0.57	3.72e-42	Pediatric autoimmune diseases;
LGG	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.96	0.6	5.5e-46	Diabetic retinopathy;
LGG	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg27129171	chr3:47204927	SETD2	0.79	15.3	0.58	4.51e-43	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs61998259	chr8:58192290	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1949733	1.000	rs2631758	chr4:8495304	G/A	cg11789530	chr4:8429930	ACOX3	-0.88	-17.56	-0.63	2.74e-53	Response to antineoplastic agents;
LGG	cis	rs11122272	0.701	rs11582413	chr1:231530098	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1348850	0.526	rs10497504	chr2:178370040	T/C	cg23306229	chr2:178417860	TTC30B	0.72	8.6	0.37	1.27e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12681287	0.673	rs4464946	chr8:87326259	G/A	cg27223183	chr8:87520930	FAM82B	-0.47	-7.0	-0.31	9.24e-12	Caudate activity during reward;
LGG	cis	rs7666738	0.830	rs62321564	chr4:98976496	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.84	-0.45	1.54e-24	Bipolar disorder;
LGG	trans	rs9929218	0.954	rs7198799	chr16:68818390	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.56	-0.5	2.34e-31	Colorectal cancer;
LGG	cis	rs4262150	0.883	rs12659715	chr5:152310058	A/G	cg12297329	chr5:152029980	NA	-0.63	-11.5	-0.47	4.2e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11627756	0.957	rs11846451	chr14:103131723	T/C	cg12046867	chr14:103022105	NA	0.46	8.47	0.37	3.21e-16	Mean platelet volume;
LGG	cis	rs57590327	0.716	rs3772891	chr3:81776760	A/G	cg07356753	chr3:81810745	GBE1	0.5	7.46	0.33	4.39e-13	Extraversion;
LGG	cis	rs6835098	0.692	rs6822683	chr4:174063974	G/A	cg08422745	chr4:174089978	GALNT7	-0.68	-11.77	-0.48	3.65e-28	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs17401966	0.858	rs61778404	chr1:10432879	A/G	cg19773385	chr1:10388646	KIF1B	-0.49	-10.36	-0.43	9.45e-23	Hepatocellular carcinoma;
LGG	cis	rs131777	0.532	rs131747	chr22:51025074	C/T	cg05418105	chr22:50981406	NA	-0.43	-7.75	-0.34	5.9e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs1008375	1.000	rs28693609	chr4:17645233	C/T	cg15017067	chr4:17643749	FAM184B	0.31	7.3	0.32	1.3e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg26043149	chr18:55253948	FECH	0.41	6.82	0.3	2.88e-11	Bone mineral density;
LGG	trans	rs853679	0.607	rs35749575	chr6:28114818	G/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg10757852	chr3:141319363	RASA2	-0.38	-6.93	-0.31	1.38e-11	Iris color (L* coordinate);
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.43	0.36	4.32e-16	Life satisfaction;
LGG	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.95	-0.38	8.97e-18	Aortic root size;
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs13082711	0.522	rs594466	chr3:27362069	A/G	cg02860705	chr3:27208620	NA	-0.58	-11.27	-0.46	3.41e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs62238980	0.614	rs116872567	chr22:32460255	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.32	-0.4	4.67e-19	Common traits (Other);
LGG	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg21972741	chr5:435613	AHRR	0.47	7.99	0.35	1.1e-14	Cystic fibrosis severity;
LGG	cis	rs7932354	0.528	rs4752952	chr11:47082858	T/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.87	-0.42	5.65e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs875971	0.545	rs6460276	chr7:65647277	G/A	cg11764359	chr7:65958608	NA	0.64	9.8	0.41	9.68e-21	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21086156	chr19:54694904	MBOAT7;TSEN34	0.4	6.79	0.3	3.36e-11	Gut microbiome composition (summer);
LGG	cis	rs6964587	1.000	rs10225885	chr7:91671007	A/G	cg17063962	chr7:91808500	NA	0.47	8.43	0.36	4.35e-16	Breast cancer;
LGG	trans	rs9650657	0.665	rs7002117	chr8:10616169	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.64	0.33	1.23e-13	Neuroticism;
LGG	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg16583315	chr14:65563665	MAX	-0.37	-7.2	-0.32	2.42e-12	Obesity-related traits;
LGG	cis	rs6582630	0.555	rs10785454	chr12:38476260	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.33	0.32	1.01e-12	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.1	-0.46	1.47e-25	Coronary artery disease;
LGG	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg12310025	chr6:25882481	NA	0.75	14.79	0.57	8.2e-41	Blood metabolite levels;
LGG	cis	rs4946717	0.740	rs9480634	chr6:106468486	C/T	cg02270332	chr6:106475062	NA	0.38	7.97	0.35	1.23e-14	Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03226245	chr19:36486125	SDHAF1	0.57	8.97	0.38	7.16e-18	Gut microbiome composition (summer);
LGG	cis	rs9302635	0.513	rs13334151	chr16:72189727	A/C	cg01557791	chr16:72042693	DHODH	-0.58	-9.12	-0.39	2.32e-18	Blood protein levels;
LGG	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg17757837	chr7:157058334	UBE3C	-0.78	-15.94	-0.6	6.35e-46	Body mass index;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	3.91e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.605	rs1507994	chr4:122749541	C/T	cg06713675	chr4:122721982	EXOSC9	-0.59	-9.84	-0.42	7.27e-21	Type 2 diabetes;
LGG	cis	rs8028313	0.731	rs13380201	chr15:67973665	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.25	-0.32	1.72e-12	Obesity;
LGG	trans	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg16141378	chr3:129829833	LOC729375	0.36	8.08	0.35	5.6e-15	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.918	rs7290404	chr22:41749796	C/T	cg17376030	chr22:41985996	PMM1	0.51	8.21	0.36	2.28e-15	Vitiligo;
LGG	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.32	0.36	9.68e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg08975724	chr8:8085496	FLJ10661	-0.48	-8.94	-0.38	9.66e-18	Triglycerides;
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.32	-0.53	1.73e-34	Aortic root size;
LGG	cis	rs6539288	0.677	rs10735418	chr12:107343376	T/C	cg26297688	chr12:107349093	C12orf23	-0.38	-7.14	-0.31	3.74e-12	Total body bone mineral density;
LGG	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	trans	rs911186	0.786	rs72842197	chr6:27067083	C/T	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.07	-0.31	5.79e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg12826209	chr6:26865740	GUSBL1	0.8	9.01	0.39	5.54e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.56	-0.47	2.57e-27	Tonsillectomy;
LGG	cis	rs7567389	0.740	rs4536600	chr2:128002572	A/G	cg10021288	chr2:128175891	PROC	0.38	7.05	0.31	6.47e-12	Self-rated health;
LGG	cis	rs1552244	1.000	rs1552244	chr3:10135577	A/G	cg00166722	chr3:10149974	C3orf24	0.51	8.57	0.37	1.52e-16	Alzheimer's disease;
LGG	cis	rs67460515	0.892	rs34896809	chr3:161059804	C/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.7	-0.41	2.19e-20	Parkinson's disease;
LGG	cis	rs8078723	0.546	rs8067817	chr17:38163936	C/T	cg17467752	chr17:38218738	THRA	0.62	11.27	0.46	3.29e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs4493873	0.840	rs28429767	chr8:92083230	C/T	cg16814680	chr8:91681699	NA	0.44	6.86	0.3	2.25e-11	Migraine - clinic-based;
LGG	cis	rs7918232	0.567	rs4749215	chr10:27312005	T/C	cg14442939	chr10:27389572	ANKRD26	0.53	8.63	0.37	9.7e-17	Breast cancer;
LGG	cis	rs1978968	0.869	rs35035092	chr22:18463274	G/T	cg03078520	chr22:18463400	MICAL3	-0.73	-15.23	-0.58	9.13e-43	Presence of antiphospholipid antibodies;
LGG	cis	rs4665809	0.590	rs11552518	chr2:26455127	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	18.0	0.64	2.63e-55	Alzheimer's disease;
LGG	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg03959625	chr15:84868606	LOC388152	0.49	7.28	0.32	1.44e-12	Schizophrenia;
LGG	cis	rs11112613	0.713	rs12316204	chr12:105944244	G/A	cg03607813	chr12:105948248	NA	0.62	10.63	0.44	9.11e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.76	10.97	0.45	4.62e-25	Lung function (FEV1/FVC);
LGG	cis	rs13177180	0.769	rs6860557	chr5:114852581	T/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.37	-7.98	-0.35	1.17e-14	Conotruncal heart defects (inherited effects);
LGG	trans	rs7746199	0.736	rs13209332	chr6:27520752	T/A	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7937612	0.965	rs4938799	chr11:120208257	T/G	cg24566217	chr11:120254723	ARHGEF12	-0.51	-12.06	-0.49	2.53e-29	Intraocular pressure;
LGG	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg10326726	chr10:51549505	MSMB	0.62	12.55	0.5	2.64e-31	Prostate-specific antigen levels;
LGG	cis	rs887829	0.609	rs7597496	chr2:234630443	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.43	-7.4	-0.33	6.37e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9397585	0.857	rs4527723	chr6:153375468	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.47	0.56	2.05e-39	Body mass index;
LGG	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.72	-0.38	5.02e-17	Menarche (age at onset);
LGG	cis	rs7945718	0.621	rs10831896	chr11:12693361	G/A	cg25843174	chr11:12811716	TEAD1	0.35	7.28	0.32	1.48e-12	Educational attainment (years of education);
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.46	-0.44	4.05e-23	Longevity;Endometriosis;
LGG	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06133097	chr7:32552212	AVL9	-0.4	-7.62	-0.33	1.48e-13	Cognitive ability;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg16606324	chr3:10149918	C3orf24	0.56	7.41	0.33	5.94e-13	Alzheimer's disease;
LGG	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.54	-0.33	2.57e-13	Cerebrospinal P-tau181p levels;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg16141378	chr3:129829833	LOC729375	0.43	9.66	0.41	3.16e-20	Neuroticism;
LGG	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg20735989	chr4:730612	PCGF3	-0.61	-10.58	-0.44	1.45e-23	White blood cell count;
LGG	cis	rs4474465	0.831	rs10899510	chr11:78170841	G/A	cg02023728	chr11:77925099	USP35	0.4	6.97	0.31	1.1e-11	Alzheimer's disease (survival time);
LGG	cis	rs4927850	1.000	rs10881563	chr3:195750225	A/G	cg01181863	chr3:195395398	SDHAP2	-0.65	-10.23	-0.43	2.88e-22	Pancreatic cancer;
LGG	cis	rs7312774	0.618	rs4964510	chr12:107357251	A/G	cg16260113	chr12:107380972	MTERFD3	1.13	10.48	0.44	3.44e-23	Severe influenza A (H1N1) infection;
LGG	cis	rs950169	0.526	rs698620	chr15:85177208	G/A	cg24253500	chr15:84953950	NA	-0.4	-7.31	-0.32	1.22e-12	Schizophrenia;
LGG	cis	rs981844	1.000	rs62325093	chr4:154669733	G/A	cg14289246	chr4:154710475	SFRP2	0.71	11.75	0.48	4.61e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs6599388	1.000	rs6599388	chr4:939087	C/T	cg10113582	chr4:905918	GAK	-0.41	-7.36	-0.32	8.21e-13	Parkinson's disease;
LGG	cis	rs6735179	0.607	rs10202812	chr2:1746468	A/T	cg08534653	chr2:1747700	PXDN	0.49	7.25	0.32	1.79e-12	Response to antipsychotic treatment;
LGG	cis	rs1348850	0.874	rs12996447	chr2:178283592	C/T	cg27490568	chr2:178487706	NA	0.47	9.35	0.4	3.66e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9457247	0.637	rs9459846	chr6:167441023	T/G	cg07741184	chr6:167504864	NA	0.39	8.68	0.37	7.05e-17	Crohn's disease;
LGG	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg14675211	chr2:100938903	LONRF2	0.47	7.26	0.32	1.62e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.727	rs9344539	chr6:86353621	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.19	-0.46	6.72e-26	Response to antipsychotic treatment;
LGG	cis	rs12210905	0.920	rs72839453	chr6:27265761	A/G	cg15325629	chr6:28072465	NA	0.85	6.73	0.3	5.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7222240	1.000	rs11079425	chr17:43144288	A/G	cg24806326	chr17:43207588	PLCD3	0.44	7.44	0.33	4.9e-13	Craniofacial microsomia;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.41	-6.79	-0.3	3.54e-11	Lung cancer;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.87	0.3	2.09e-11	Schizophrenia;
LGG	cis	rs9467773	0.933	rs35355150	chr6:26526039	G/A	cg11502198	chr6:26597334	ABT1	0.52	8.82	0.38	2.33e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4959677	0.935	rs10458145	chr6:2493582	G/T	cg23817096	chr6:1620687	NA	-0.31	-7.38	-0.32	7.51e-13	Orthostatic hypotension;
LGG	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-6.68	-0.3	6.76e-11	Vitiligo;
LGG	cis	rs7766436	0.885	rs12524244	chr6:22585287	T/C	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs72781680	1.000	rs72781689	chr2:24256349	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.72	0.41	1.8899999999999998e-20	Lymphocyte counts;
LGG	cis	rs11122272	0.701	rs1009227	chr1:231480507	A/G	cg10503236	chr1:231470652	EXOC8	-0.35	-6.71	-0.3	5.7e-11	Hemoglobin concentration;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.07	-0.31	5.59e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3820068	0.603	rs72647128	chr1:15963908	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.72	0.61	1.94e-49	Systolic blood pressure;
LGG	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07725970	chr12:27091851	FGFR1OP2;C12orf11	0.4	6.65	0.3	8.27e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg02975922	chr3:195473998	MUC4	0.44	7.15	0.32	3.45e-12	Mean corpuscular volume;
LGG	cis	rs36051895	0.664	rs10815153	chr9:5092864	G/C	cg02405213	chr9:5042618	JAK2	-0.82	-15.9	-0.59	9.45e-46	Pediatric autoimmune diseases;
LGG	trans	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg02002194	chr4:3960332	NA	0.49	9.31	0.4	5.36e-19	Neuroticism;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg15971980	chr6:150254442	NA	0.45	8.59	0.37	1.36e-16	Lung cancer;
LGG	cis	rs1784581	0.588	rs1784583	chr6:162410132	C/T	cg17173639	chr6:162384350	PARK2	-0.65	-13.81	-0.54	1.36e-36	Itch intensity from mosquito bite;
LGG	cis	rs67460515	0.892	rs4856703	chr3:161047720	G/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.17e-20	Parkinson's disease;
LGG	cis	rs4689388	0.679	rs1046316	chr4:6304087	A/G	cg14416269	chr4:6271139	WFS1	0.45	7.79	0.34	4.47e-14	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06634786	chr22:41940651	POLR3H	-0.72	-11.57	-0.47	2.2e-27	Vitiligo;
LGG	trans	rs2921036	0.505	rs35190619	chr8:8361823	A/C	cg16141378	chr3:129829833	LOC729375	0.44	9.33	0.4	4.37e-19	Neuroticism;
LGG	cis	rs929354	0.713	rs6946947	chr7:156948787	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs11239187	0.586	rs4350324	chr10:45084553	G/A	cg03916630	chr10:45065415	NA	0.35	8.29	0.36	1.19e-15	Body mass index;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01570182	chr17:44337453	NA	0.66	11.27	0.46	3.35e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1167827	1.000	rs1167827	chr7:75163169	A/G	cg04978709	chr7:75101039	POM121C	0.45	9.94	0.42	3.23e-21	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937682	0.632	rs12785809	chr11:111776055	T/A	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg09696939	chr10:60272079	BICC1	0.38	7.36	0.32	8.26e-13	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14751398	chr6:20402153	E2F3	0.48	7.71	0.34	7.8500000000000006e-14	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg04861929	chr11:109293070	C11orf87	0.52	9.73	0.41	1.74e-20	Schizophrenia;
LGG	cis	rs7715811	1.000	rs67731984	chr5:13774014	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.96	-0.42	2.55e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg10326726	chr10:51549505	MSMB	-0.68	-14.34	-0.55	7.41e-39	Prostate-specific antigen levels;
LGG	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg10661904	chr17:79619235	PDE6G	-0.4	-8.15	-0.35	3.48e-15	Eye color traits;
LGG	cis	rs7558370	0.737	rs17017879	chr2:3713658	C/G	cg14882966	chr2:3699353	NA	0.77	6.97	0.31	1.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2304069	0.954	rs1433010	chr5:149383954	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.59	-7.87	-0.34	2.5e-14	HIV-1 control;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.13	0.52	1.11e-33	Lung cancer;
LGG	cis	rs7267979	1.000	rs2027004	chr20:25350618	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg19168338	chr16:4465731	CORO7	-1.18	-27.88	-0.79	3.87e-101	Schizophrenia;
LGG	cis	rs9341808	0.718	rs2322631	chr6:80843956	A/C	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.84e-14	Sitting height ratio;
LGG	cis	rs4974559	0.947	rs10006381	chr4:1359309	C/T	cg02980000	chr4:1222292	CTBP1	0.65	7.97	0.35	1.24e-14	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg11062466	chr8:58055876	NA	0.57	9.06	0.39	3.67e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.769	rs17389198	chr1:209922058	G/A	cg05527609	chr1:210001259	C1orf107	-0.52	-6.96	-0.31	1.15e-11	Red blood cell count;
LGG	cis	rs9811920	0.599	rs61148087	chr3:99539891	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.51	-8.64	-0.37	9.47e-17	Axial length;
LGG	cis	rs11214589	0.651	rs17600713	chr11:113259947	C/T	cg14373873	chr11:113211441	TTC12	0.42	8.71	0.38	5.58e-17	Neuroticism;
LGG	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.25	0.52	3.34e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg25937216	chr8:58172855	NA	-0.57	-9.14	-0.39	2e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.85e-44	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg08888203	chr3:10149979	C3orf24	0.51	8.54	0.37	2.01e-16	Alzheimer's disease;
LGG	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg11878867	chr6:150167359	LRP11	0.4	6.8	0.3	3.17e-11	Lung cancer;
LGG	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg25801113	chr15:45476975	SHF	0.89	20.48	0.69	7.7e-67	Uric acid levels;
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs6500395	1.000	rs11644518	chr16:48616789	A/G	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3733585	0.673	rs7434391	chr4:9967682	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	4.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg08400814	chr5:56204995	C5orf35	-0.41	-7.39	-0.32	6.83e-13	Initial pursuit acceleration;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.07e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs4891159	1.000	rs4891159	chr18:74101941	A/G	cg24786174	chr18:74118243	ZNF516	0.49	11.2	0.46	6.43e-26	Longevity;
LGG	cis	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg06609049	chr19:2785107	THOP1	0.96	16.63	0.61	4.79e-49	Total cholesterol levels;
LGG	cis	rs57221529	0.709	rs72703034	chr5:577101	C/T	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs6495367	0.803	rs2870111	chr15:79403585	C/T	cg17916960	chr15:79447300	NA	0.55	10.21	0.43	3.41e-22	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12142240	0.698	rs112089006	chr1:46812360	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.46e-15	Menopause (age at onset);
LGG	cis	rs3206736	0.548	rs1649224	chr7:34990996	G/C	cg13400248	chr7:35225412	NA	0.53	9.15	0.39	1.85e-18	Diastolic blood pressure;
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.41	0.33	5.94e-13	Menopause (age at onset);
LGG	cis	rs873946	0.557	rs34854637	chr10:134582962	A/G	cg13271783	chr10:134563150	INPP5A	-0.59	-8.91	-0.38	1.17e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9952991	1.000	rs9952991	chr18:12780464	G/A	cg23544223	chr18:12777786	NA	0.62	9.4	0.4	2.56e-19	Inflammatory skin disease;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.68	12.83	0.51	1.96e-32	Lymphocyte counts;
LGG	trans	rs3960554	0.932	rs4728597	chr7:75821062	C/T	cg19862616	chr7:65841803	NCRNA00174	0.84	11.35	0.47	1.69e-26	Eotaxin levels;
LGG	cis	rs7503807	0.515	rs12943155	chr17:78667125	A/G	cg08454507	chr17:78755406	RPTOR	-0.47	-9.32	-0.4	4.93e-19	Obesity;
LGG	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg19168338	chr16:4465731	CORO7	-1.0	-18.58	-0.65	5.26e-58	Schizophrenia;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg03806693	chr22:41940476	POLR3H	-1.16	-20.96	-0.7	4.23e-69	Vitiligo;
LGG	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg27165867	chr14:105738592	BRF1	-0.49	-8.22	-0.36	2.02e-15	Mean platelet volume;Platelet distribution width;
LGG	trans	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg24247370	chr13:99142703	STK24	-0.43	-7.81	-0.34	3.92e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs17504614	0.648	rs78864136	chr2:51080916	T/A	cg08066024	chr2:51057548	NRXN1	0.52	6.81	0.3	3.1e-11	Educational attainment (years of education);
LGG	trans	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.99	0.45	4.04e-25	Corneal astigmatism;
LGG	cis	rs774359	0.830	rs774357	chr9:27559835	G/A	cg14173147	chr9:27528300	MOBKL2B	0.44	8.02	0.35	8.49e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg13010199	chr12:38710504	ALG10B	0.74	15.67	0.59	1.07e-44	Heart rate;
LGG	trans	rs877282	0.898	rs36064821	chr10:760952	C/T	cg22713356	chr15:30763199	NA	0.49	7.43	0.33	5.27e-13	Uric acid levels;
LGG	cis	rs9325144	0.647	rs61931899	chr12:38892422	A/G	cg04568710	chr12:38710424	ALG10B	-0.39	-8.15	-0.35	3.32e-15	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	trans	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.86	-0.3	2.16e-11	Retinal vascular caliber;
LGG	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg22437258	chr11:111473054	SIK2	-0.53	-8.87	-0.38	1.66e-17	Primary sclerosing cholangitis;
LGG	cis	rs6840360	0.571	rs12650655	chr4:152556075	G/A	cg25486957	chr4:152246857	NA	-0.48	-7.98	-0.35	1.13e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.784	rs13407840	chr2:99569928	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.55	-0.44	1.79e-23	Chronic sinus infection;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg08677398	chr8:58056175	NA	0.53	8.33	0.36	9.54e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg04000281	chr11:63949212	NA	-0.44	-8.55	-0.37	1.86e-16	Platelet count;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.67	0.3	7.43e-11	Schizophrenia;
LGG	cis	rs2635047	0.904	rs2635046	chr18:44728429	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.97	0.31	1.07e-11	Educational attainment;
LGG	cis	rs2236293	0.754	rs10814285	chr9:35857624	C/G	cg12876594	chr9:35791798	NPR2	-0.4	-7.43	-0.33	5.1e-13	Blood protein levels;
LGG	cis	rs8133932	0.667	rs2839033	chr21:47296381	T/C	cg13695288	chr21:47294981	PCBP3	-0.37	-7.47	-0.33	4.15e-13	Schizophrenia;
LGG	cis	rs4319547	0.656	rs10161534	chr12:122873864	T/C	cg23029597	chr12:123009494	RSRC2	-0.89	-16.92	-0.62	2.35e-50	Body mass index;
LGG	cis	rs4732038	0.510	rs10245625	chr7:134279424	A/G	cg06906464	chr7:134288099	NA	-0.72	-20.97	-0.7	3.96e-69	Longevity;
LGG	cis	rs644799	0.710	rs10765771	chr11:95521044	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.27	0.58	6.14e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7917772	0.604	rs4917977	chr10:104363119	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.49e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4737010	0.570	rs2111804	chr8:41644266	A/T	cg08923054	chr8:41654455	ANK1	0.77	13.16	0.52	8.27e-34	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27151812	chr13:88323452	SLITRK5	0.49	8.02	0.35	8.91e-15	Gut microbiome composition (summer);
LGG	cis	rs12479064	0.724	rs3792143	chr2:100057020	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-10.8	-0.45	2.02e-24	Chronic sinus infection;
LGG	cis	rs736408	0.812	rs4687654	chr3:52827566	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.68	0.34	9.62e-14	Bipolar disorder;
LGG	cis	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg21775007	chr8:11205619	TDH	-0.5	-8.24	-0.36	1.8e-15	Triglycerides;
LGG	cis	rs4732038	0.510	rs12673257	chr7:134278732	C/A	cg06906464	chr7:134288099	NA	-0.67	-17.35	-0.63	2.46e-52	Longevity;
LGG	trans	rs1994135	0.669	rs2121831	chr12:33697674	G/A	cg13010199	chr12:38710504	ALG10B	0.54	9.67	0.41	2.88e-20	Resting heart rate;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.01	-0.42	1.75e-21	Lung cancer;
LGG	cis	rs17376456	0.877	rs10059230	chr5:93450347	A/G	cg25358565	chr5:93447407	FAM172A	1.37	17.01	0.62	9.21e-51	Diabetic retinopathy;
LGG	cis	rs4356203	0.870	rs603618	chr11:17246362	G/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	8.12e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-8.18	-0.36	2.8e-15	Lung cancer;
LGG	trans	rs12579753	1.000	rs12367791	chr12:82237278	C/T	cg07923666	chr12:49932857	KCNH3	-0.53	-7.87	-0.34	2.61e-14	Resting heart rate;
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg00761968	chr13:53314142	LECT1	0.32	6.68	0.3	6.73e-11	Lewy body disease;
LGG	cis	rs7227917	0.536	rs72916011	chr18:45510657	G/A	cg22195133	chr18:45534586	NA	0.77	7.0	0.31	9.3e-12	Lung cancer in ever smokers;
LGG	cis	rs7215564	0.908	rs34710385	chr17:78676494	G/A	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.14e-15	Myopia (pathological);
LGG	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.79	0.73	1.18e-77	Homoarginine levels;
LGG	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.7	-0.3	6.2e-11	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.5	0.71	1.25e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs35306767	0.714	rs12783621	chr10:1083304	C/T	cg25019033	chr10:957182	NA	-0.46	-8.83	-0.38	2.2e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs8077889	0.917	rs1859048	chr17:41892039	A/C	cg26893861	chr17:41843967	DUSP3	-0.93	-15.83	-0.59	1.93e-45	Triglycerides;
LGG	cis	rs1620921	0.625	rs9347455	chr6:161276752	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7789940	0.904	rs6953281	chr7:75946943	C/T	cg10167463	chr7:75959203	YWHAG	-0.46	-7.42	-0.33	5.61e-13	Multiple sclerosis;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg05896524	chr21:47604654	C21orf56	-0.56	-9.79	-0.41	1.07e-20	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23182539	chr10:121355708	TIAL1	0.51	8.35	0.36	7.84e-16	Gut microbiome composition (summer);
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg22968622	chr17:43663579	NA	0.99	19.09	0.66	2.36e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg25885449	chr18:77638415	KCNG2	0.35	6.68	0.3	6.96e-11	Schizophrenia;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg17306884	chr12:132379720	ULK1	0.4	6.95	0.31	1.27e-11	Coronary artery disease;
LGG	cis	rs1843834	0.755	rs10194591	chr2:225574276	T/A	cg22455342	chr2:225449267	CUL3	0.48	8.12	0.35	4.41e-15	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs975722	0.638	rs11975043	chr7:117096492	C/G	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.04	-0.39	4.14e-18	Coronary artery disease;
LGG	cis	rs769267	0.930	rs2304098	chr19:19646272	T/C	cg01262667	chr19:19385393	TM6SF2	0.43	10.66	0.44	7.18e-24	Tonsillectomy;
LGG	cis	rs9814567	1.000	rs4572812	chr3:134291177	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2153535	0.580	rs969421	chr6:8451949	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs6489785	0.637	rs2014374	chr12:121374885	A/C	cg02419362	chr12:121203948	SPPL3	0.44	6.73	0.3	5.16e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.69	-0.3	6.62e-11	Retinal vascular caliber;
LGG	cis	rs1010254	0.559	rs56261934	chr5:151750431	C/A	cg12297329	chr5:152029980	NA	-0.47	-6.77	-0.3	3.88e-11	Optic nerve measurement (cup area);
LGG	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg16339924	chr4:17578868	LAP3	0.61	10.49	0.44	3.01e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.91	-0.34	1.94e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.73	-13.44	-0.53	5.22e-35	Longevity;Endometriosis;
LGG	cis	rs9487051	0.676	rs6568566	chr6:109596792	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.38e-14	Reticulocyte fraction of red cells;
LGG	cis	rs67133203	0.851	rs4768964	chr12:51508073	C/T	cg14688905	chr12:51403056	SLC11A2	-0.64	-9.83	-0.42	8.03e-21	Urinary tract infection frequency;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg00149659	chr3:10157352	C3orf10	0.88	10.61	0.44	1.11e-23	Alzheimer's disease;
LGG	cis	rs4330281	0.608	rs11128842	chr3:17735345	G/C	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs2916247	1.000	rs2976510	chr8:93005015	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.32	-0.36	9.89e-16	Intelligence (multi-trait analysis);
LGG	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg22916017	chr11:64110731	CCDC88B	0.47	9.45	0.4	1.66e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-12.74	-0.51	4.62e-32	Bladder cancer;
LGG	cis	rs6032067	0.777	rs2868234	chr20:43794026	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs7851660	0.809	rs1561961	chr9:100667599	C/T	cg13688889	chr9:100608707	NA	-0.6	-11.97	-0.49	6.04e-29	Strep throat;
LGG	cis	rs6450176	0.564	rs406621	chr5:53326232	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.28	-0.46	3.05e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs61332075	0.503	rs113377546	chr2:239303870	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	6.74	0.3	4.74e-11	Lung function (FEV1/FVC);
LGG	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg04851639	chr8:1020857	NA	-0.41	-8.71	-0.38	5.6e-17	Schizophrenia;
LGG	cis	rs3762637	0.941	rs9863712	chr3:122099906	C/T	cg24169773	chr3:122142474	KPNA1	-0.57	-9.11	-0.39	2.52e-18	LDL cholesterol levels;
LGG	cis	rs7166081	1.000	rs4776908	chr15:67540087	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.84	-0.3	2.46e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9914988	1.000	rs9914988	chr17:27183104	G/A	cg20469991	chr17:27169893	C17orf63	0.53	6.69	0.3	6.47e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7666738	0.830	rs34890015	chr4:99023769	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10924309	0.880	rs12141908	chr1:245857829	C/A	cg00036263	chr1:245852353	KIF26B	-0.54	-7.63	-0.33	1.38e-13	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs9487051	0.676	rs9386788	chr6:109600523	C/T	cg21918786	chr6:109611834	NA	0.45	8.25	0.36	1.61e-15	Reticulocyte fraction of red cells;
LGG	cis	rs72772090	0.539	rs72773947	chr5:96125533	T/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9807841	0.670	rs2738042	chr19:10790143	C/G	cg17710535	chr19:10819994	QTRT1	0.45	6.89	0.3	1.82e-11	Inflammatory skin disease;
LGG	cis	rs9660992	0.573	rs12126439	chr1:205200720	C/T	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9381040	0.610	rs9381028	chr6:41025081	C/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.71	-0.3	5.7e-11	Alzheimer's disease (late onset);
LGG	cis	rs2050392	0.624	rs303449	chr10:30726845	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-12.23	-0.49	5.13e-30	Inflammatory bowel disease;
LGG	cis	rs4746818	0.793	rs2805914	chr10:70859291	A/G	cg11621586	chr10:70884670	VPS26A	0.92	13.89	0.54	6.41e-37	Left atrial antero-posterior diameter;
LGG	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.53	-0.4	9.12e-20	Retinal vascular caliber;
LGG	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg03342759	chr3:160939853	NMD3	-0.58	-10.11	-0.43	7.47e-22	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.56	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs3816183	0.958	rs7582883	chr2:43023004	C/T	cg27299406	chr2:43020013	HAAO	-0.27	-6.72	-0.3	5.39e-11	Hypospadias;
LGG	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg12623918	chr2:306882	NA	0.51	9.69	0.41	2.41e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11123610	0.679	rs34705357	chr2:3716032	C/T	cg20493526	chr2:3714936	ALLC	0.48	9.85	0.42	6.47e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg05299278	chr17:33885742	SLFN14	0.43	8.21	0.36	2.18e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	trans	rs9650657	0.645	rs4841408	chr8:10516336	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.95	-0.35	1.44e-14	Neuroticism;
LGG	cis	rs2386661	0.826	rs4427479	chr10:5682855	T/C	cg26603656	chr10:5671107	NA	-0.38	-7.61	-0.33	1.5700000000000001e-13	Breast cancer;
LGG	cis	rs7666738	0.570	rs1921415	chr4:99093804	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.8	0.3	3.14e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs526231	0.511	rs62362545	chr5:102347452	A/G	cg23492399	chr5:102201601	PAM	-0.56	-8.38	-0.36	6.52e-16	Primary biliary cholangitis;
LGG	cis	rs13191362	1.000	rs34138336	chr6:163144929	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.97	0.42	2.39e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg13010199	chr12:38710504	ALG10B	0.46	8.9	0.38	1.3e-17	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg22963979	chr7:1858916	MAD1L1	0.45	8.88	0.38	1.45e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.832	rs3732968	chr3:10013273	A/G	cg00149659	chr3:10157352	C3orf10	0.75	9.21	0.39	1.12e-18	Alzheimer's disease;
LGG	cis	rs9487094	0.961	rs12192847	chr6:109801631	G/A	cg16315928	chr6:109776240	MICAL1	0.55	9.04	0.39	4.17e-18	Height;
LGG	cis	rs2033908	0.619	rs10765994	chr11:12850819	A/G	cg25843174	chr11:12811716	TEAD1	0.35	7.36	0.32	8.5e-13	Sitting height ratio;
LGG	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	8.84	0.38	2.09e-17	Cognitive test performance;
LGG	cis	rs10743315	0.557	rs74478800	chr12:19367517	A/T	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs3768617	1.000	rs12026314	chr1:183104527	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.37	7.2	0.32	2.4e-12	Fuchs's corneal dystrophy;
LGG	cis	rs7216064	1.000	rs73352808	chr17:65875157	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-8.89	-0.38	1.37e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	trans	rs79976124	0.719	rs34488909	chr6:66637850	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	12.25	0.49	4.6e-30	Type 2 diabetes;
LGG	cis	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.27	-0.32	1.55e-12	Mean corpuscular volume;
LGG	cis	rs172166	0.769	rs149965	chr6:28018689	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.86	-0.3	2.16e-11	Cardiac Troponin-T levels;
LGG	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg17644776	chr2:200775616	C2orf69	-0.58	-7.15	-0.32	3.33e-12	Schizophrenia;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg11878867	chr6:150167359	LRP11	-0.56	-11.64	-0.48	1.18e-27	Lung cancer;
LGG	cis	rs3784262	0.669	rs4646555	chr15:58355345	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.87	-0.3	2.14e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs977987	0.843	rs4146810	chr16:75415831	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.33	0.43	1.22e-22	Dupuytren's disease;
LGG	trans	rs208515	0.525	rs1351866	chr6:66696969	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.13	0.62	2.59e-51	Exhaled nitric oxide levels;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg13397359	chr6:42928475	GNMT	-0.62	-18.37	-0.65	5.16e-57	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.88e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16041611	chr6:43139680	SRF	0.44	7.54	0.33	2.54e-13	Bipolar disorder;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg03264133	chr6:25882463	NA	-0.42	-7.27	-0.32	1.5e-12	Height;
LGG	trans	rs2832077	0.527	rs11088095	chr21:30223188	A/T	cg14791747	chr16:20752902	THUMPD1	0.56	10.31	0.43	1.43e-22	Cognitive test performance;
LGG	cis	rs4363385	0.818	rs377768	chr1:153016594	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.87	-0.38	1.58e-17	Inflammatory skin disease;
LGG	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg11890956	chr21:40555474	PSMG1	-0.73	-12.46	-0.5	6.21e-31	Menarche (age at onset);
LGG	cis	rs2692947	0.673	rs3111873	chr2:96781986	G/C	cg22654517	chr2:96458247	NA	-0.38	-7.76	-0.34	5.4e-14	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1348850	0.608	rs10176632	chr2:178225934	G/T	cg27490568	chr2:178487706	NA	0.4	8.16	0.35	3.19e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12497850	0.966	rs6792510	chr3:48723302	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.83	0.3	2.73e-11	Parkinson's disease;
LGG	cis	rs16854884	0.632	rs59287916	chr3:143638337	G/A	cg06585982	chr3:143692056	C3orf58	0.65	11.34	0.47	1.84e-26	Economic and political preferences (feminism/equality);
LGG	cis	rs9788721	0.868	rs17486278	chr15:78867482	A/C	cg18825076	chr15:78729989	IREB2	-0.44	-7.23	-0.32	2.04e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg12439423	chr8:41522721	ANK1	0.45	8.35	0.36	8.05e-16	Type 2 diabetes;
LGG	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg27147174	chr7:100797783	AP1S1	-0.7	-13.25	-0.52	3.43e-34	Life satisfaction;
LGG	cis	rs7666738	0.830	rs2865980	chr4:99027422	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.41	0.36	5.06e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs994014	0.572	rs10028610	chr4:82318524	C/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.92	-0.31	1.53e-11	Height;
LGG	cis	rs6496932	0.635	rs28559998	chr15:85903836	G/A	cg19183879	chr15:85880815	NA	-0.43	-7.12	-0.31	4.25e-12	Central corneal thickness;Corneal structure;
LGG	trans	rs11875185	0.510	rs79102797	chr18:55649256	G/C	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs1371614	0.569	rs486582	chr2:27104131	C/T	cg12045002	chr2:27069975	DPYSL5	0.31	6.72	0.3	5.35e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07791516	chr6:150247246	NA	0.31	6.92	0.31	1.51e-11	Testicular germ cell tumor;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.25	-0.32	1.8e-12	Bipolar disorder;
LGG	cis	rs8114671	0.967	rs2069952	chr20:33763951	C/T	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs7647973	0.925	rs9881860	chr3:49352522	A/T	cg06212747	chr3:49208901	KLHDC8B	0.52	8.06	0.35	6.38e-15	Menarche (age at onset);
LGG	cis	rs9487094	0.626	rs12215077	chr6:110052880	A/C	cg01125227	chr6:109776195	MICAL1	-0.43	-7.49	-0.33	3.58e-13	Height;
LGG	cis	rs7267979	0.934	rs6037085	chr20:25305202	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg00376283	chr12:123451042	ABCB9	-0.63	-10.2	-0.43	3.47e-22	Neutrophil percentage of white cells;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg00157179	chr1:2383687	NA	-0.79	-15.48	-0.58	7.3e-44	Non-obstructive azoospermia;
LGG	cis	rs6430585	0.527	rs1446586	chr2:136407445	C/T	cg07169764	chr2:136633963	MCM6	-0.99	-16.41	-0.61	4.77e-48	Corneal structure;
LGG	cis	rs1023500	0.596	rs133369	chr22:42463814	C/T	cg05082376	chr22:42548792	NA	-0.35	-7.29	-0.32	1.37e-12	Schizophrenia;
LGG	cis	rs4642101	0.686	rs9822382	chr3:12828828	T/G	cg24848339	chr3:12840334	CAND2	0.43	9.94	0.42	3.06e-21	QRS complex (12-leadsum);
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg26554054	chr8:600488	NA	0.88	9.67	0.41	2.78e-20	IgG glycosylation;
LGG	trans	rs783540	0.934	rs783530	chr15:83266549	G/C	cg16105309	chr15:79090380	ADAMTS7	0.42	7.36	0.32	8.19e-13	Schizophrenia;
LGG	cis	rs9462027	0.628	rs2815004	chr6:34636268	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.86	-0.45	1.25e-24	Systemic lupus erythematosus;
LGG	cis	rs7552404	0.690	rs2029681	chr1:76333846	G/A	cg03433033	chr1:76189801	ACADM	-0.63	-9.39	-0.4	2.82e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7552404	1.000	rs72686191	chr1:76218319	G/T	cg03433033	chr1:76189801	ACADM	0.77	12.27	0.5	3.63e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.86	-0.38	1.74e-17	Restless legs syndrome;
LGG	cis	rs2735413	0.918	rs12925605	chr16:78071715	G/A	cg04733911	chr16:78082701	NA	-0.77	-18.31	-0.65	9.95e-57	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10851411	0.559	rs56172155	chr15:42882182	C/T	cg21293051	chr15:42870591	STARD9	0.54	7.66	0.34	1.1e-13	Glucose homeostasis traits;
LGG	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg16386425	chr10:429943	DIP2C	0.39	7.07	0.31	5.89e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.63e-13	Lung cancer;
LGG	cis	rs6580649	0.941	rs72644847	chr12:48516093	C/A	cg24011408	chr12:48396354	COL2A1	-0.57	-7.03	-0.31	7.68e-12	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25485084	chr12:118809325	TAOK3	0.48	7.92	0.35	1.8e-14	Gut microbiome composition (summer);
LGG	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg01420254	chr6:26195488	NA	0.91	12.42	0.5	8.86e-31	Gout;Renal underexcretion gout;
LGG	cis	rs7605378	1.000	rs769957	chr2:200695524	A/C	cg17644776	chr2:200775616	C2orf69	0.54	8.6	0.37	1.2e-16	Osteoporosis;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg16507663	chr6:150244633	RAET1G	0.43	8.04	0.35	7.82e-15	Lung cancer;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.13	0.46	1.17e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.38	-0.47	1.22e-26	Height;
LGG	cis	rs514406	0.505	rs437954	chr1:53173321	C/G	cg16325326	chr1:53192061	ZYG11B	0.85	23.08	0.73	5.01e-79	Monocyte count;
LGG	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg17830980	chr10:43048298	ZNF37B	-0.43	-9.66	-0.41	3.22e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs2640806	0.645	rs11786602	chr8:97327229	T/C	cg22138393	chr8:97340270	PTDSS1	0.31	7.79	0.34	4.56e-14	Obesity-related traits;
LGG	cis	rs295140	1.000	rs11888462	chr2:201160499	G/T	cg25099087	chr2:201172481	SPATS2L	0.27	6.66	0.3	7.94e-11	QT interval;
LGG	cis	rs240764	0.658	rs10872634	chr6:101199579	C/T	cg09795085	chr6:101329169	ASCC3	-0.46	-7.69	-0.34	8.84e-14	Neuroticism;
LGG	cis	rs35306767	0.903	rs12761424	chr10:967295	C/T	cg08847335	chr10:891726	LARP4B	-0.36	-6.99	-0.31	9.42e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7666738	0.606	rs13108868	chr4:99083753	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.95	0.31	1.22e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9583531	0.843	rs7999702	chr13:111382264	A/C	cg24331049	chr13:111365604	ING1	-0.86	-12.28	-0.5	3.39e-30	Coronary artery disease;
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	16.69	0.61	2.71e-49	Alzheimer's disease;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07132326	chr6:150258058	NA	0.38	7.9	0.34	2.03e-14	Testicular germ cell tumor;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg18402987	chr7:1209562	NA	0.52	7.63	0.33	1.37e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7215564	0.908	rs8076854	chr17:78663962	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs4481887	0.893	rs4529743	chr1:248473683	G/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg03929089	chr4:120376271	NA	0.45	7.36	0.32	8.74e-13	HDL cholesterol;
LGG	cis	rs9581857	0.579	rs7332104	chr13:27957831	C/G	cg01674679	chr13:27998804	GTF3A	0.74	8.33	0.36	8.95e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg11766577	chr21:47581405	C21orf56	0.58	10.74	0.45	3.68e-24	Testicular germ cell tumor;
LGG	cis	rs7192750	0.586	rs6499552	chr16:71943169	G/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg20891283	chr12:69753455	YEATS4	0.5	7.95	0.35	1.45e-14	Response to diuretic therapy;
LGG	cis	rs1790761	0.505	rs6591245	chr11:67310936	G/C	cg14500267	chr11:67383377	NA	-0.39	-7.07	-0.31	5.78e-12	Mean corpuscular volume;
LGG	cis	rs713587	0.646	rs34697209	chr2:25127394	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	9.56e-33	Body mass index in non-asthmatics;
LGG	cis	rs611744	0.647	rs1448151	chr8:109276283	C/A	cg21045802	chr8:109455806	TTC35	0.53	9.95	0.42	2.83e-21	Dupuytren's disease;
LGG	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg04727924	chr7:799746	HEATR2	-0.5	-7.11	-0.31	4.36e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg04008888	chr11:68622739	NA	-0.55	-11.62	-0.48	1.43e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9291683	0.588	rs3756238	chr4:10013202	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.49	0.47	4.55e-27	Bone mineral density;
LGG	cis	rs8064024	0.649	rs9934930	chr16:4902038	A/G	cg08329684	chr16:4932620	PPL	0.52	11.66	0.48	1e-27	Cancer;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg09448879	chr15:79043637	NA	-0.5	-11.86	-0.48	1.61e-28	Coronary artery disease or large artery stroke;
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg14668632	chr7:2872130	GNA12	-0.36	-7.38	-0.32	7.5e-13	Height;
LGG	cis	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg20368463	chr18:77673604	PQLC1	0.53	6.98	0.31	1.02e-11	Opioid sensitivity;
LGG	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg05535760	chr7:792225	HEATR2	0.93	14.49	0.56	1.75e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg23422044	chr7:1970798	MAD1L1	0.75	13.54	0.53	1.95e-35	Bipolar disorder;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25926008	chr6:110012635	AKD1;FIG4	0.43	7.06	0.31	6.22e-12	Hip circumference;
LGG	cis	rs8060686	0.641	rs2107369	chr16:68116018	A/C	cg27539214	chr16:67997921	SLC12A4	-0.45	-7.15	-0.32	3.43e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-7.39	-0.32	7e-13	Autism spectrum disorder;
LGG	cis	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs7853377	0.723	rs10868071	chr9:86532613	A/T	cg12437157	chr9:86433764	GKAP1	0.38	6.66	0.3	7.56e-11	Height;
LGG	cis	rs12586317	0.545	rs58342373	chr14:35395269	T/C	cg05294307	chr14:35346193	BAZ1A	-0.5	-7.84	-0.34	3.19e-14	Psoriasis;
LGG	cis	rs7222240	1.000	rs1132898	chr17:43171154	C/T	cg24806326	chr17:43207588	PLCD3	0.46	7.89	0.34	2.18e-14	Craniofacial microsomia;
LGG	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg07936489	chr17:37558343	FBXL20	0.86	16.11	0.6	1.07e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.48	-0.33	3.88e-13	Tonsillectomy;
LGG	cis	rs7301826	0.627	rs61937256	chr12:131302645	G/A	cg11011512	chr12:131303247	STX2	-0.39	-8.39	-0.36	5.74e-16	Plasma plasminogen activator levels;
LGG	cis	rs1977876	0.852	rs12405155	chr1:211713414	A/G	cg01575408	chr1:211752895	SLC30A1	0.48	6.71	0.3	5.56e-11	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Electroencephalogram traits;
LGG	cis	rs778371	0.624	rs6733495	chr2:233616709	A/G	cg08000102	chr2:233561755	GIGYF2	0.71	12.01	0.49	4.02e-29	Schizophrenia;
LGG	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7493	0.755	rs17883791	chr7:94999438	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.48	-0.37	3.11e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs774359	0.797	rs774353	chr9:27516436	C/G	cg21249376	chr9:27528432	MOBKL2B	0.43	8.89	0.38	1.42e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.35	-0.32	9.03e-13	Bladder cancer;
LGG	cis	rs757278	0.571	rs4730797	chr7:117352536	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.44	-7.98	-0.35	1.17e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs3857536	0.813	rs6455090	chr6:66948909	G/A	cg07460842	chr6:66804631	NA	-0.45	-7.72	-0.34	7.35e-14	Blood trace element (Cu levels);
LGG	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.38	-6.81	-0.3	2.97e-11	Educational attainment;
LGG	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-8.98	-0.39	6.89e-18	Myopia (pathological);
LGG	cis	rs7555523	0.779	rs2790049	chr1:165743523	A/G	cg24409356	chr1:165738333	TMCO1	0.74	8.75	0.38	4.09e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs936229	0.861	rs7162232	chr15:75115895	G/A	cg14664628	chr15:75095509	CSK	-1.15	-27.73	-0.79	2e-100	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs28588043	0.938	rs28876968	chr1:170973388	C/A	cg03458344	chr1:170964477	C1orf129	-0.5	-7.3	-0.32	1.3e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-14.46	-0.56	2.34e-39	Platelet count;
LGG	cis	rs12369179	1.000	rs12369179	chr12:122963550	C/T	cg18578876	chr12:123200353	GPR109B	-1.12	-10.5	-0.44	2.91e-23	Age-related diseases, mortality and associated endophenotypes;Age-related disease endophenotypes;
LGG	trans	rs7395662	0.856	rs117753969	chr11:48760328	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.38	-0.32	7.46e-13	HDL cholesterol;
LGG	cis	rs11064837	0.523	rs7963248	chr12:120095686	T/G	cg25937854	chr12:120150414	CIT	-0.67	-10.84	-0.45	1.47e-24	Schizophrenia;
LGG	cis	rs72772090	0.710	rs56122780	chr5:96059895	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.47	-7.06	-0.31	5.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.21	-0.32	2.26e-12	Monocyte count;
LGG	cis	rs701145	0.537	rs1713815	chr3:153872445	T/C	cg17054900	chr3:154042577	DHX36	0.69	8.83	0.38	2.19e-17	Coronary artery disease;
LGG	cis	rs4865875	1.000	rs4591702	chr5:54107905	G/A	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs2133450	0.712	rs17697952	chr3:7368066	T/C	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.68e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg26384229	chr12:38710491	ALG10B	0.96	20.88	0.7	1.01e-68	Bladder cancer;
LGG	cis	rs892961	0.899	rs66749226	chr17:75412826	G/A	cg05865280	chr17:75406074	SEPT9	0.43	10.04	0.42	1.35e-21	Airflow obstruction;
LGG	trans	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.86	-0.34	2.68e-14	Joint mobility (Beighton score);
LGG	cis	rs10540	1.000	rs61877760	chr11:506596	C/T	cg03352830	chr11:487213	PTDSS2	0.85	10.77	0.45	2.72e-24	Body mass index;
LGG	cis	rs4820539	1.000	rs916585	chr22:23469438	G/A	cg14186256	chr22:23484241	RTDR1	1.0	25.82	0.77	1.05e-91	Bone mineral density;
LGG	cis	rs7098414	0.530	rs4146515	chr10:82116602	G/A	cg00277334	chr10:82204260	NA	-0.34	-7.2	-0.32	2.4e-12	Post bronchodilator FEV1;
LGG	cis	rs1552244	0.872	rs35988239	chr3:10074145	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	16.34	0.6	9.72e-48	Alzheimer's disease;
LGG	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1949733	0.598	rs55765509	chr4:8532732	T/A	cg13073564	chr4:8508604	NA	0.43	7.4	0.33	6.68e-13	Response to antineoplastic agents;
LGG	trans	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.83	-0.38	2.2e-17	Morning vs. evening chronotype;
LGG	cis	rs7586879	0.575	rs6706316	chr2:25128351	C/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg13944838	chr5:179740914	GFPT2	-0.69	-12.61	-0.51	1.57e-31	Height;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02472486	chr20:42143502	L3MBTL	-0.42	-6.96	-0.31	1.14e-11	Brain structure;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg08508337	chr8:144660607	NAPRT1	0.89	7.17	0.32	2.94e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs8112449	0.893	rs12983665	chr19:10538373	A/G	cg21868191	chr19:10515988	NA	-0.47	-7.9	-0.34	1.98e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs6594499	0.872	rs6865932	chr5:110436852	G/C	cg04022379	chr5:110408740	TSLP	0.41	7.59	0.33	1.79e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.4	-7.68	-0.34	9.82e-14	Platelet count;
LGG	cis	rs9818758	0.607	rs9837237	chr3:49215583	G/T	cg00383909	chr3:49044727	WDR6	0.97	12.52	0.5	3.45e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03264133	chr6:25882463	NA	0.54	10.18	0.43	4.35e-22	Blood metabolite levels;
LGG	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg16339924	chr4:17578868	LAP3	0.63	11.06	0.46	2.19e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg00149659	chr3:10157352	C3orf10	-0.55	-8.06	-0.35	6.54e-15	Alzheimer's disease;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.74	-15.27	-0.58	6.03e-43	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.644	rs2389880	chr4:120559870	T/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg24642844	chr7:1081250	C7orf50	-0.64	-10.72	-0.45	4.32e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16097330	chr5:171615472	STK10	0.51	7.69	0.34	9.01e-14	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.21	0.36	2.21e-15	Schizophrenia;
LGG	cis	rs7833790	0.963	rs6473312	chr8:82732515	C/A	cg17211192	chr8:82754475	SNX16	-0.8	-12.48	-0.5	5.39e-31	Diastolic blood pressure;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06873352	chr17:61820015	STRADA	0.72	13.41	0.53	7.43e-35	Prudent dietary pattern;
LGG	cis	rs7493	1.000	rs7493	chr7:95034775	C/G	cg08461772	chr7:95026248	PON3	-0.38	-8.4	-0.36	5.56e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs1847505	0.609	rs9539004	chr13:61587049	T/C	cg25164009	chr13:61490935	NA	-0.61	-11.76	-0.48	4.09e-28	Polychlorinated biphenyl levels;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.62e-13	Lung cancer;
LGG	trans	rs17685	0.672	rs1639618	chr7:75701987	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7726839	0.718	rs6887972	chr5:597274	C/G	cg09021430	chr5:549028	NA	-0.69	-11.92	-0.48	8.98e-29	Obesity-related traits;
LGG	cis	rs2249694	0.960	rs6537613	chr10:135412414	T/G	cg20169779	chr10:135381914	SYCE1	-0.52	-7.92	-0.35	1.76e-14	Obesity-related traits;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.27	-0.43	1.98e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17826219	0.562	rs719600	chr17:28731262	G/A	cg01831904	chr17:28903510	LRRC37B2	0.64	8.06	0.35	6.61e-15	Body mass index;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg04025307	chr7:1156635	C7orf50	0.74	14.75	0.57	1.21e-40	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20470467	chr16:30886130	NA	0.48	7.31	0.32	1.16e-12	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.5	-0.33	3.36e-13	HDL cholesterol;
LGG	cis	rs57590327	0.555	rs13062054	chr3:81833906	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-8.04	-0.35	7.74e-15	Extraversion;
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg14500267	chr11:67383377	NA	0.46	8.55	0.37	1.83e-16	Mean corpuscular volume;
LGG	trans	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg11887960	chr12:57824829	NA	0.57	6.93	0.31	1.45e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs250677	0.687	rs250666	chr5:148454622	A/G	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.39	-0.32	6.84e-13	Breast cancer;
LGG	cis	rs2404602	0.692	rs1838048	chr15:76931679	A/G	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg23324259	chr8:82754387	SNX16	-0.42	-6.79	-0.3	3.49e-11	Diastolic blood pressure;
LGG	cis	rs1401999	0.836	rs34571027	chr3:183726644	T/C	cg05044414	chr3:183734942	ABCC5	0.77	16.51	0.61	1.8e-48	Anterior chamber depth;
LGG	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-12.88	-0.51	1.12e-32	Chronic sinus infection;
LGG	cis	rs10744422	1.000	rs3852537	chr12:123361501	T/C	cg25930673	chr12:123319894	HIP1R	-0.7	-9.21	-0.39	1.15e-18	Schizophrenia;
LGG	cis	rs758324	0.898	rs510434	chr5:131292503	C/T	cg06307176	chr5:131281290	NA	-0.59	-9.5	-0.4	1.16e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs11096990	0.634	rs6531704	chr4:39283746	T/C	cg24403649	chr4:39172243	NA	-0.4	-7.16	-0.32	3.18e-12	Cognitive function;
LGG	cis	rs6952808	0.582	rs871925	chr7:2047875	G/A	cg22963979	chr7:1858916	MAD1L1	0.44	8.76	0.38	3.74e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs1728785	1.000	rs864741	chr16:68576577	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs2842992	0.830	rs752779	chr6:160133957	G/A	cg27624424	chr6:160112604	SOD2	0.65	9.72	0.41	1.83e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11764590	0.694	rs6461115	chr7:2103668	A/G	cg02951883	chr7:2050386	MAD1L1	0.44	7.36	0.32	8.38e-13	Neuroticism;
LGG	cis	rs936229	0.813	rs1350193	chr15:75084281	G/C	cg14664628	chr15:75095509	CSK	-1.14	-25.84	-0.77	8.62e-92	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg05696931	chr1:227175867	NA	-0.4	-7.85	-0.34	3e-14	Myeloid white cell count;
LGG	cis	rs9611565	0.592	rs5751129	chr22:42015765	C/T	cg06481639	chr22:41940642	POLR3H	0.49	7.11	0.31	4.36e-12	Vitiligo;
LGG	cis	rs7614311	0.636	rs3821902	chr3:63941697	T/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.98	-0.35	1.15e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs17270561	0.666	rs17320090	chr6:25720215	C/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.26	0.43	2.07e-22	Iron status biomarkers;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg11645453	chr3:52864694	ITIH4	0.39	6.69	0.3	6.57e-11	Electroencephalogram traits;
LGG	cis	rs701145	0.537	rs1713832	chr3:153835833	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.59	0.63	2.06e-53	Alzheimer's disease;
LGG	cis	rs4538187	0.661	rs17562423	chr2:64200119	T/C	cg19915305	chr2:64069682	UGP2	-0.65	-11.56	-0.47	2.49e-27	Systolic blood pressure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22704520	chr2:200820451	C2orf60;C2orf47	0.4	6.81	0.3	2.96e-11	Bipolar disorder;
LGG	cis	rs9297145	0.678	rs62473051	chr7:98781955	C/T	cg05967295	chr7:98741636	SMURF1	0.92	14.92	0.57	2.2e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs7089973	0.604	rs17095662	chr10:116596071	A/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.33	0.32	1.01e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs10892173	0.703	rs1014034	chr11:117661734	G/C	cg21640587	chr11:117668038	DSCAML1	0.48	8.13	0.35	3.9e-15	Myopia;
LGG	cis	rs17039065	0.920	rs11945254	chr4:109469292	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs614226	0.938	rs787824	chr12:120924638	A/G	cg27489772	chr12:121021490	NA	-0.55	-7.47	-0.33	4.08e-13	Type 1 diabetes nephropathy;
LGG	cis	rs9611519	0.929	rs12484971	chr22:41439304	A/T	cg06634786	chr22:41940651	POLR3H	-0.43	-6.81	-0.3	3.13e-11	Neuroticism;
LGG	cis	rs2836950	0.565	rs2150413	chr21:40614878	C/T	cg11890956	chr21:40555474	PSMG1	-0.76	-13.35	-0.53	1.27e-34	Menarche (age at onset);
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs6763768	0.634	rs2358740	chr3:53455569	G/T	cg16894138	chr3:53270350	TKT	0.44	8.28	0.36	1.38e-15	Bacterial meningitis;
LGG	cis	rs7769051	1.000	rs73554431	chr6:133129922	T/G	cg07930552	chr6:133119739	C6orf192	0.86	12.06	0.49	2.49e-29	Type 2 diabetes nephropathy;
LGG	cis	rs1729951	0.575	rs1682356	chr3:136692037	T/C	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.36e-14	Neuroticism;
LGG	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg21605333	chr4:119757512	SEC24D	1.46	13.66	0.54	5.92e-36	Cannabis dependence symptom count;
LGG	cis	rs854765	0.647	rs6826	chr17:18011140	C/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.87	-0.51	1.25e-32	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg12179176	chr11:130786555	SNX19	0.84	17.67	0.63	9.25e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs5758511	0.679	rs55867855	chr22:42623258	G/A	cg15128208	chr22:42549153	NA	0.74	11.39	0.47	1.13e-26	Birth weight;
LGG	trans	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg02002194	chr4:3960332	NA	0.52	10.48	0.44	3.2e-23	Neuroticism;
LGG	cis	rs1801251	1.000	rs10933412	chr2:233707226	G/C	cg25237894	chr2:233734115	C2orf82	-0.65	-12.33	-0.5	2.06e-30	Coronary artery disease;
LGG	trans	rs78049276	0.736	rs10305838	chr4:148400256	T/C	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-7.64	-0.33	1.28e-13	Pulse pressure;
LGG	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg12458913	chr13:53173898	NA	0.86	19.02	0.66	5.06e-60	Lewy body disease;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.7	12.9	0.51	9.73e-33	Obesity-related traits;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg22907277	chr7:1156413	C7orf50	0.84	15.05	0.57	5.96e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg03213289	chr20:61660250	NA	0.65	14.36	0.56	5.95e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2228479	0.850	rs62056068	chr16:89909737	C/T	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg27663799	chr12:49504641	LMBR1L	0.4	6.69	0.3	6.42e-11	Corneal astigmatism;
LGG	cis	rs2046867	0.818	rs62249860	chr3:72866073	T/G	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2032447	0.670	rs198852	chr6:26104448	A/G	cg13736514	chr6:26305472	NA	0.34	6.81	0.3	3.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg04293180	chr8:144700367	TSTA3	0.9	6.97	0.31	1.12e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.53	-0.33	2.6e-13	Life satisfaction;
LGG	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	trans	rs2727020	0.729	rs4980439	chr11:49342246	G/C	cg15704280	chr7:45808275	SEPT13	-0.94	-19.19	-0.67	7.73e-61	Coronary artery disease;
LGG	cis	rs2268241	0.877	rs17887186	chr21:34779202	G/A	cg14850771	chr21:34775459	IFNGR2	0.76	9.2	0.39	1.24e-18	Obesity-related traits;
LGG	cis	rs12362504	0.504	rs12360818	chr11:9914904	T/C	cg07197493	chr11:9884649	SBF2	-0.35	-6.71	-0.3	5.52e-11	Survival in pancreatic cancer;
LGG	cis	rs11134654	0.627	rs4868033	chr5:170234264	A/T	cg01579024	chr5:170288757	RANBP17	0.4	6.84	0.3	2.56e-11	Smooth-surface caries;
LGG	cis	rs13191362	1.000	rs66529337	chr6:163005662	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.69	0.34	9e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21659725	chr3:3221576	CRBN	0.63	11.82	0.48	2.39e-28	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	1.000	rs13184940	chr5:140172918	T/C	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2735413	0.564	rs1882595	chr16:78100684	G/A	cg04733911	chr16:78082701	NA	0.62	8.89	0.38	1.36e-17	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs34421088	0.532	rs11782742	chr8:11165009	C/T	cg02002194	chr4:3960332	NA	-0.43	-7.76	-0.34	5.48e-14	Neuroticism;
LGG	cis	rs10462794	1.000	rs6555293	chr5:4486674	T/A	cg18482690	chr5:4511582	NA	0.38	6.7	0.3	6.22e-11	DNA methylation (variation);
LGG	trans	rs208520	0.690	rs207112	chr6:66792092	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-12.54	-0.5	2.93e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00495681	chr13:53174319	NA	0.65	12.47	0.5	5.74e-31	Lewy body disease;
LGG	cis	rs1707322	0.964	rs785496	chr1:46588006	T/C	cg03146154	chr1:46216737	IPP	-0.54	-9.41	-0.4	2.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4731207	0.698	rs12538083	chr7:124554057	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04008888	chr11:68622739	NA	-0.56	-11.72	-0.48	5.68e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1949733	0.701	rs940136	chr4:8448992	G/A	cg13073564	chr4:8508604	NA	-0.53	-10.92	-0.45	7.56e-25	Response to antineoplastic agents;
LGG	cis	rs3008870	0.727	rs11208971	chr1:67383901	G/A	cg02640540	chr1:67518911	SLC35D1	0.38	7.04	0.31	7.18e-12	Lymphocyte percentage of white cells;
LGG	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11696845	1.000	rs6073534	chr20:43365504	C/T	cg25301532	chr20:43378953	KCNK15	0.37	8.14	0.35	3.57e-15	Obesity-related traits;
LGG	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg00919237	chr7:87102261	ABCB4	0.81	16.38	0.61	6.41e-48	Gallbladder cancer;
LGG	cis	rs6831352	0.918	rs13112176	chr4:100055825	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs8135665	0.625	rs8142185	chr22:38451080	A/C	cg13116946	chr22:38479732	SLC16A8	0.52	8.63	0.37	9.64e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs74781061	0.860	rs4887151	chr15:74737467	C/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs5998509	1	rs5998509	chr22:21917479	C/T	cg15846791	chr22:21984385	YDJC	-0.47	-7.01	-0.31	8.41e-12	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs897080	0.515	rs1067321	chr2:44631312	G/T	cg00619915	chr2:44497795	NA	-0.48	-6.75	-0.3	4.39e-11	Height;
LGG	cis	rs9303401	0.659	rs12150264	chr17:56939927	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.77	0.57	9.82e-41	Cognitive test performance;
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	1.000	rs7689714	chr4:122665943	T/A	cg19748678	chr4:122722346	EXOSC9	0.49	9.19	0.39	1.37e-18	Type 2 diabetes;
LGG	trans	rs73191547	0.706	rs17748267	chr8:10040977	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.89	-0.34	2.24e-14	Schizophrenia;
LGG	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg26585981	chr11:48327164	OR4S1	-0.39	-6.74	-0.3	4.85e-11	Migraine - clinic-based;
LGG	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Schizophrenia;
LGG	cis	rs13040088	0.935	rs3787513	chr20:61573736	G/A	cg23096297	chr20:61557774	DIDO1	0.87	12.02	0.49	3.71e-29	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg08677398	chr8:58056175	NA	0.47	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg14668632	chr7:2872130	GNA12	-0.38	-7.71	-0.34	7.52e-14	Height;
LGG	cis	rs9303401	0.614	rs34900851	chr17:56566399	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.03	0.39	4.71e-18	Cognitive test performance;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs977987	0.806	rs4638613	chr16:75425553	C/T	cg03315344	chr16:75512273	CHST6	0.52	10.57	0.44	1.5e-23	Dupuytren's disease;
LGG	cis	rs7503807	0.688	rs11150745	chr17:78757626	A/G	cg22878693	chr17:78755604	RPTOR	-0.42	-7.35	-0.32	9.23e-13	Obesity;
LGG	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg10760299	chr15:45669010	GATM	0.41	8.13	0.35	4.04e-15	Homoarginine levels;
LGG	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg22153745	chr1:153894579	GATAD2B	0.59	8.76	0.38	3.64e-17	Total cholesterol levels;
LGG	trans	rs79911532	0.515	rs8509	chr7:75616577	G/A	cg19862616	chr7:65841803	NCRNA00174	0.77	7.83	0.34	3.45e-14	Mononucleosis;
LGG	cis	rs739401	0.611	rs10833048	chr11:3020040	A/G	cg08508325	chr11:3079039	CARS	-0.61	-12.94	-0.52	6.55e-33	Longevity;
LGG	cis	rs10736390	0.640	rs10888858	chr1:55108978	A/G	cg01517571	chr1:55089959	ACOT11;FAM151A	-0.71	-16.43	-0.61	4.06e-48	Survival in pancreatic cancer;
LGG	cis	rs6500395	1.000	rs904819	chr16:48622583	C/A	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.6e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg20307385	chr11:47447363	PSMC3	-0.43	-7.0	-0.31	8.93e-12	Migraine - clinic-based;
LGG	cis	rs9902453	0.791	rs3098950	chr17:27998385	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.49	0.56	1.59e-39	Coffee consumption (cups per day);
LGG	cis	rs8028182	0.636	rs4451914	chr15:75739824	C/T	cg20655648	chr15:75932815	IMP3	0.47	7.83	0.34	3.34e-14	Sudden cardiac arrest;
LGG	cis	rs10220309	0.501	rs4899765	chr14:80643110	C/T	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.11e-11	Lung function (FEV1);
LGG	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.96	0.35	1.3e-14	Colorectal cancer;
LGG	cis	rs3096299	0.967	rs16965692	chr16:89471482	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.63	0.51	1.24e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs4919087	1.000	rs7067835	chr10:99074649	T/C	cg25902810	chr10:99078978	FRAT1	0.52	9.6	0.41	5.06e-20	Monocyte count;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.74	-0.45	3.46e-24	Lung cancer;
LGG	cis	rs35110281	0.667	rs4819286	chr21:45120121	G/A	cg04455712	chr21:45112962	RRP1B	0.55	10.57	0.44	1.58e-23	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.77	0.38	3.37e-17	Lung cancer;
LGG	cis	rs6430585	0.536	rs60397494	chr2:136470219	C/T	cg07169764	chr2:136633963	MCM6	1.08	17.98	0.64	3.19e-55	Corneal structure;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.6	0.37	1.27e-16	Prudent dietary pattern;
LGG	cis	rs4660214	0.666	rs636083	chr1:39821681	A/G	cg18385671	chr1:39797026	MACF1	0.46	9.41	0.4	2.27e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs614226	1.000	rs1167725	chr12:120968559	A/T	cg01236616	chr12:121019343	POP5	1.29	23.47	0.74	7.75e-81	Type 1 diabetes nephropathy;
LGG	cis	rs2298450	0.717	rs2835330	chr21:37631173	G/A	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.04	-0.35	7.67e-15	Schizophrenia;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg17178900	chr1:205818956	PM20D1	0.58	12.79	0.51	2.71e-32	Menarche (age at onset);
LGG	cis	rs2153535	0.580	rs7767756	chr6:8453428	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs300774	0.800	rs300716	chr2:136844	G/A	cg04617936	chr2:214353	NA	-0.49	-7.46	-0.33	4.25e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs55788414	0.932	rs2317122	chr16:81182819	A/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	6.07e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg11598736	chr3:195384522	SDHAP2	-0.76	-10.3	-0.43	1.55e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs9462027	0.628	rs7752060	chr6:34760325	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.5	-0.47	4.19e-27	Systemic lupus erythematosus;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03439990	chr19:47164505	DACT3	-0.42	-7.1	-0.31	4.58e-12	Pancreatic cancer;
LGG	cis	rs228437	1.000	rs450801	chr6:134905309	T/C	cg24504307	chr6:134963096	NA	0.41	7.93	0.35	1.62e-14	Melanoma;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg00149659	chr3:10157352	C3orf10	0.87	11.33	0.47	1.9e-26	Alzheimer's disease;
LGG	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs17875496	0.912	rs11630277	chr15:81592891	C/T	cg19620333	chr15:81596332	IL16	0.48	9.29	0.4	5.9e-19	Number of common colds;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg18379455	chr17:41446167	NA	-0.32	-7.44	-0.33	5.01e-13	Menopause (age at onset);
LGG	trans	rs6600671	1.000	rs7532615	chr1:121172840	G/T	cg17023122	chr1:144479586	NA	-0.33	-7.29	-0.32	1.35e-12	Hip geometry;
LGG	cis	rs7614311	0.731	rs73117087	chr3:63948696	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.82	-0.34	3.57e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs2880765	0.835	rs12324277	chr15:86041735	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.43e-11	Coronary artery disease;
LGG	trans	rs28735056	0.967	rs61090726	chr18:77631219	A/G	cg05926928	chr17:57297772	GDPD1	-0.49	-7.81	-0.34	3.75e-14	Schizophrenia;
LGG	trans	rs7762018	0.769	rs4716385	chr6:170127608	G/T	cg06875740	chr19:51307921	C19orf48	-0.7	-8.19	-0.36	2.5e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4740619	0.619	rs1887668	chr9:16033321	G/C	cg14451791	chr9:16040625	NA	-0.43	-11.3	-0.46	2.61e-26	Body mass index;
LGG	cis	rs7202877	0.610	rs8053632	chr16:75364940	C/T	cg03315344	chr16:75512273	CHST6	0.55	7.51	0.33	3.03e-13	Type 2 diabetes;Type 1 diabetes;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16675644	chr19:48897005	GRIN2D	0.48	7.41	0.33	6.21e-13	Hip circumference;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg16301924	chr13:53314226	LECT1	-0.54	-11.65	-0.48	1.11e-27	Lewy body disease;
LGG	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg04455712	chr21:45112962	RRP1B	-0.54	-9.87	-0.42	5.44e-21	Mean corpuscular volume;
LGG	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg02002194	chr4:3960332	NA	-0.42	-7.82	-0.34	3.7e-14	Neuroticism;
LGG	cis	rs853679	0.517	rs4711165	chr6:28115184	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs975739	0.815	rs1279661	chr13:78369539	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.79	0.3	3.54e-11	Hair color;
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.9e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.0	-0.39	5.65e-18	Triglycerides;
LGG	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.26	0.83	1.59e-120	Chronic sinus infection;
LGG	trans	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3816183	1.000	rs893730	chr2:43015366	T/A	cg14631114	chr2:43023945	NA	0.51	9.59	0.41	5.27e-20	Hypospadias;
LGG	cis	rs10752881	0.901	rs10911201	chr1:183001622	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Colorectal cancer;
LGG	cis	rs2204008	0.840	rs7136347	chr12:38453531	G/A	cg26384229	chr12:38710491	ALG10B	0.99	23.25	0.73	8.9e-80	Bladder cancer;
LGG	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.18	0.39	1.46e-18	Sudden cardiac arrest;
LGG	cis	rs10779751	0.708	rs2746640	chr1:11292952	T/A	cg08854313	chr1:11322531	MTOR	0.72	15.74	0.59	4.96e-45	Body mass index;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.13	0.49	1.38e-29	Prudent dietary pattern;
LGG	cis	rs2576037	0.583	rs9954336	chr18:44465945	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.52	0.37	2.18e-16	Personality dimensions;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg26666512	chr16:30934656	NCRNA00095;FBXL19	0.46	6.83	0.3	2.6e-11	Hip circumference;
LGG	cis	rs5769765	0.862	rs138897	chr22:50231067	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-10.56	-0.44	1.61e-23	Schizophrenia;
LGG	cis	rs7149242	1.000	rs7145337	chr14:101155536	C/T	cg18089426	chr14:101175970	NA	-0.37	-7.35	-0.32	9.11e-13	Platelet count;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.36	-0.32	8.28e-13	Personality dimensions;
LGG	cis	rs4302748	0.862	rs59125899	chr7:36182857	G/A	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs9463078	0.866	rs9395087	chr6:45238226	T/A	cg25276700	chr6:44698697	NA	-0.37	-7.53	-0.33	2.6e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg21775007	chr8:11205619	TDH	-0.42	-6.89	-0.3	1.78e-11	Joint mobility (Beighton score);
LGG	cis	rs7107174	0.901	rs10899496	chr11:78123831	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.39	-0.32	6.74e-13	Testicular germ cell tumor;
LGG	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.1	-0.42	8.09e-22	Mood instability;
LGG	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg11247378	chr22:39784982	NA	-0.31	-9.17	-0.39	1.51e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg04287289	chr16:89883240	FANCA	0.62	7.24	0.32	1.91e-12	Skin colour saturation;
LGG	cis	rs7264396	0.635	rs6060682	chr20:34506331	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.16	-0.32	3.23e-12	Total cholesterol levels;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg19168338	chr16:4465731	CORO7	-0.75	-13.96	-0.54	3.34e-37	Schizophrenia;
LGG	cis	rs1417569	0.517	rs2994625	chr10:31195319	G/A	cg00428179	chr10:31322131	ZNF438	-0.37	-8.81	-0.38	2.61e-17	Tuberculosis;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10936602	0.520	rs9290375	chr3:169566090	A/G	cg00832555	chr3:169529716	LRRC34	0.36	7.21	0.32	2.29e-12	Renal cell carcinoma;
LGG	cis	rs2404602	0.735	rs56246286	chr15:76690731	C/T	cg23625390	chr15:77176239	SCAPER	-0.67	-13.68	-0.54	5.26e-36	Blood metabolite levels;
LGG	cis	rs137603	0.966	rs137616	chr22:39703883	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.46	-7.72	-0.34	7.11e-14	Primary biliary cholangitis;
LGG	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.47	-0.37	3.38e-16	IgG glycosylation;
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.05	0.39	4.09e-18	Alzheimer's disease;
LGG	trans	rs4957048	0.891	rs11960196	chr5:568857	C/A	cg25482853	chr8:67687455	SGK3	0.86	11.22	0.46	5.18e-26	Ulcerative colitis;
LGG	cis	rs4818225	1.000	rs4818225	chr21:42629895	A/G	cg21268422	chr21:42620091	BACE2	0.5	8.71	0.38	5.41e-17	Educational attainment;
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg09263875	chr16:632152	PIGQ	0.67	13.48	0.53	3.69e-35	Height;
LGG	cis	rs7767084	0.611	rs12212724	chr6:160917135	G/A	cg04181478	chr6:161122748	PLG	0.49	6.96	0.31	1.16e-11	Coronary heart disease;
LGG	cis	rs6467136	0.580	rs17150996	chr7:127174679	G/A	cg25922125	chr7:127225783	GCC1	-0.45	-6.81	-0.3	3.03e-11	Type 2 diabetes;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.4	6.79	0.3	3.34e-11	Bipolar disorder;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg18402987	chr7:1209562	NA	0.43	6.82	0.3	2.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2658782	0.789	rs2259633	chr11:93141580	C/A	cg15737290	chr11:93063684	CCDC67	0.52	7.76	0.34	5.46e-14	Pulmonary function decline;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.47	6.83	0.3	2.76e-11	Renal function-related traits (BUN);
LGG	cis	rs2694528	1.000	rs4647151	chr5:60170558	T/C	cg11474532	chr5:59995715	DEPDC1B	0.72	7.63	0.33	1.33e-13	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21641552	chr12:88535903	TMTC3;CEP290	0.46	7.39	0.32	6.86e-13	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24539604	chr2:191184750	HIBCH	0.4	6.81	0.3	3.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.649	rs5758466	chr22:42176059	G/A	cg03806693	chr22:41940476	POLR3H	0.9	14.88	0.57	3.2e-41	Vitiligo;
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg16606324	chr3:10149918	C3orf24	0.55	7.25	0.32	1.79e-12	Alzheimer's disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg12174498	chr8:80942140	MRPS28	-0.41	-6.85	-0.3	2.41e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9948	0.655	rs17119562	chr2:97381844	G/C	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.47	-0.33	4.06e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	9.98	0.42	2.34e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs4820539	0.934	rs3788348	chr22:23467946	G/C	cg14186256	chr22:23484241	RTDR1	1.0	25.39	0.76	1.01e-89	Bone mineral density;
LGG	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg01181863	chr3:195395398	SDHAP2	-0.49	-7.58	-0.33	1.9e-13	Pancreatic cancer;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.01	-0.49	4.03e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg06521331	chr12:34319734	NA	-0.45	-7.73	-0.34	6.88e-14	Heart rate;
LGG	cis	rs2069757	0.561	rs77143352	chr5:131985990	A/T	cg04303330	chr5:131992430	IL13	0.29	6.84	0.3	2.49e-11	Hodgkin's lymphoma;
LGG	cis	rs748404	0.578	rs576557	chr15:43597737	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	8.1	0.35	4.82e-15	Lung cancer;
LGG	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg13939156	chr17:80058883	NA	0.4	7.26	0.32	1.66e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7633787	0.571	rs6807204	chr3:23146772	G/A	cg00327796	chr3:23032191	NA	-0.4	-7.45	-0.33	4.59e-13	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7512552	0.803	rs59898460	chr1:150493004	T/C	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.12e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg24247370	chr13:99142703	STK24	-0.42	-7.59	-0.33	1.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27511599	chr7:32358540	NA	0.57	6.76	0.3	4.23e-11	Body mass index;
LGG	trans	rs11039798	0.660	rs28435129	chr11:48629795	A/T	cg15704280	chr7:45808275	SEPT13	0.74	10.17	0.43	4.5e-22	Axial length;
LGG	cis	rs74781061	0.585	rs11072484	chr15:74730748	T/C	cg02384859	chr15:74862662	ARID3B	-0.41	-6.65	-0.3	8.13e-11	Endometriosis;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08677398	chr8:58056175	NA	0.52	8.14	0.35	3.67e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs970548	0.688	rs10900228	chr10:46082128	A/G	cg14222797	chr10:16859974	RSU1	-0.63	-7.24	-0.32	1.93e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg22535103	chr8:58192502	C8orf71	-0.96	-12.64	-0.51	1.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7843479	1.000	rs13248727	chr8:21842063	T/C	cg17168535	chr8:21777572	XPO7	0.59	9.68	0.41	2.62e-20	Mean corpuscular volume;
LGG	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg16141378	chr3:129829833	LOC729375	0.32	7.17	0.32	3e-12	Monocyte count;
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.47	-0.33	4.09e-13	Dementia with Lewy bodies;
LGG	cis	rs16854884	0.586	rs4613453	chr3:143735600	C/G	cg06585982	chr3:143692056	C3orf58	0.68	12.32	0.5	2.39e-30	Economic and political preferences (feminism/equality);
LGG	trans	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg18187862	chr3:45730750	SACM1L	0.59	9.72	0.41	1.8899999999999998e-20	Primary sclerosing cholangitis;
LGG	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg24690094	chr11:67383802	NA	-0.4	-7.01	-0.31	8.38e-12	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs2298450	0.717	rs2835324	chr21:37610551	C/G	cg02919814	chr21:37666008	DOPEY2	0.45	8.24	0.36	1.85e-15	Schizophrenia;
LGG	cis	rs1754541	1.000	rs1188752	chr1:101632277	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-7.1	-0.31	4.77e-12	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg17554472	chr22:41940697	POLR3H	0.47	6.73	0.3	5.14e-11	Vitiligo;
LGG	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Bone mineral density;
LGG	cis	rs4732038	1.000	rs889877	chr7:134232615	T/C	cg06906464	chr7:134288099	NA	-0.49	-12.2	-0.49	7.07e-30	Longevity;
LGG	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg27286337	chr10:134555280	INPP5A	0.87	13.79	0.54	1.8e-36	Migraine;
LGG	cis	rs11098499	0.908	rs2017057	chr4:120257711	A/G	cg24375607	chr4:120327624	NA	0.65	10.7	0.45	4.86e-24	Corneal astigmatism;
LGG	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg21775007	chr8:11205619	TDH	-0.51	-7.88	-0.34	2.38e-14	Triglycerides;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04139300	chr20:40247070	CHD6	0.4	6.88	0.3	1.99e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs240764	0.817	rs240154	chr6:101065792	G/T	cg09795085	chr6:101329169	ASCC3	0.47	7.79	0.34	4.45e-14	Neuroticism;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs892961	0.932	rs35657663	chr17:75412482	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs4671458	0.656	rs72806010	chr2:63753802	C/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.11	-0.31	4.41e-12	Subjective well-being;
LGG	cis	rs6429082	0.523	rs704718	chr1:235666159	A/T	cg26050004	chr1:235667680	B3GALNT2	0.84	17.34	0.63	2.79e-52	Adiposity;
LGG	cis	rs2278491	0.557	rs10283129	chr8:117778673	G/A	cg23513447	chr8:117778558	UTP23	-0.51	-6.83	-0.3	2.63e-11	Body mass index;
LGG	cis	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg25427524	chr10:38739819	LOC399744	-0.62	-12.55	-0.5	2.72e-31	Extrinsic epigenetic age acceleration;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg06925179	chr17:43578568	NA	-0.4	-9.61	-0.41	4.53e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg00908189	chr16:619842	PIGQ	0.88	16.58	0.61	8.21e-49	Height;
LGG	cis	rs977987	0.815	rs4887829	chr16:75488935	C/T	cg03315344	chr16:75512273	CHST6	0.54	10.77	0.45	2.69e-24	Dupuytren's disease;
LGG	cis	rs694739	0.657	rs11231770	chr11:64140625	G/A	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.99	0.52	3.89e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs10870270	0.913	rs4880326	chr10:133745547	C/A	cg17892150	chr10:133769511	PPP2R2D	-0.66	-13.24	-0.52	3.74e-34	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1707322	1.000	rs12097761	chr1:46291162	T/C	cg03146154	chr1:46216737	IPP	0.55	10.31	0.43	1.43e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg16325326	chr1:53192061	ZYG11B	-0.62	-12.74	-0.51	4.59e-32	Monocyte count;
LGG	cis	rs2587949	0.571	rs2322589	chr3:4229371	G/C	cg16519197	chr3:4211558	NA	-0.36	-7.25	-0.32	1.81e-12	Periodontitis (DPAL);
LGG	cis	rs7301016	0.802	rs11613011	chr12:63023078	T/C	cg01804193	chr12:63026212	NA	0.54	7.1	0.31	4.65e-12	IgG glycosylation;
LGG	cis	rs868036	0.681	rs28376010	chr15:68063739	G/T	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.0	-0.31	8.86e-12	Restless legs syndrome;
LGG	cis	rs62238980	0.614	rs77034034	chr22:32466661	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg07962218	chr7:65219954	SNORA22;CCT6P1	0.29	6.94	0.31	1.36e-11	Calcium levels;
LGG	cis	rs758324	0.947	rs6861732	chr5:131156462	A/C	cg06307176	chr5:131281290	NA	0.57	9.51	0.4	1.08e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs13108043	0.541	rs28633398	chr4:87821134	C/A	cg11209507	chr4:87813803	C4orf36	0.67	9.05	0.39	4e-18	Red blood cell count;
LGG	cis	rs7618915	0.798	rs353547	chr3:52268866	A/G	cg22484793	chr3:52261325	TLR9	-0.36	-8.77	-0.38	3.51e-17	Bipolar disorder;
LGG	cis	rs7408868	0.520	rs10417567	chr19:15308068	C/T	cg14696996	chr19:15285081	NOTCH3	-0.83	-10.71	-0.45	4.78e-24	Pulse pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08037420	chr3:172428855	NCEH1	0.53	8.36	0.36	7.62e-16	Gut microbiome composition (summer);
LGG	cis	rs2075371	0.734	rs13225086	chr7:134011411	C/T	cg11752832	chr7:134001865	SLC35B4	0.6	10.71	0.45	4.49e-24	Mean platelet volume;
LGG	cis	rs2455601	1.000	rs12418190	chr11:8899818	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-10.1	-0.42	8.23e-22	Schizophrenia;
LGG	cis	rs6977660	0.943	rs10263564	chr7:19842898	G/C	cg07541023	chr7:19748670	TWISTNB	0.46	7.19	0.32	2.59e-12	Thyroid stimulating hormone;
LGG	cis	rs9467773	1.000	rs1321481	chr6:26538210	A/T	cg11502198	chr6:26597334	ABT1	0.54	9.34	0.4	3.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.678	rs2000384	chr6:66597429	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.9e-11	Metabolite levels;
LGG	cis	rs870825	0.655	rs1527870	chr4:185616631	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg22834771	chr12:69754056	YEATS4	-0.45	-7.72	-0.34	7.18e-14	Blood protein levels;
LGG	trans	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg13565492	chr6:43139072	SRF	-0.69	-8.53	-0.37	2.15e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7246657	0.525	rs1667351	chr19:37478027	A/T	cg18154014	chr19:37997991	ZNF793	0.44	7.84	0.34	3.21e-14	Coronary artery calcification;
LGG	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg14210321	chr2:106509881	NCK2	-0.49	-8.39	-0.36	5.86e-16	Addiction;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.54	-0.37	1.91e-16	Obesity-related traits;
LGG	trans	rs1997103	0.906	rs2177806	chr7:55402609	A/T	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3743102	0.527	rs117959961	chr15:83339895	C/T	cg00614314	chr15:82944287	LOC80154	-0.71	-7.09	-0.31	5.07e-12	Colorectal adenoma (advanced);
LGG	cis	rs9938149	0.706	rs7498700	chr16:88320620	T/C	cg05435882	chr16:88311214	NA	-0.39	-6.86	-0.3	2.16e-11	Corneal structure;Central corneal thickness;
LGG	trans	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-7.02	-0.31	8.2e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7106204	0.748	rs6484028	chr11:24222438	A/G	ch.11.24196551F	chr11:24239977	NA	1.04	16.5	0.61	2.02e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1401999	1.000	rs939336	chr3:183685534	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.86	0.62	4.61e-50	Anterior chamber depth;
LGG	cis	rs12926788	0.542	rs11862971	chr16:24767574	C/A	cg02428538	chr16:24856791	SLC5A11	-0.72	-11.11	-0.46	1.42e-25	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.896	rs33933393	chr17:41317432	C/T	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg13073564	chr4:8508604	NA	0.43	7.45	0.33	4.65e-13	Response to antineoplastic agents;
LGG	cis	rs17253792	0.822	rs78522049	chr14:56071203	A/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs8180040	0.966	rs13079098	chr3:47442863	A/G	cg16586182	chr3:47516702	SCAP	-0.77	-15.52	-0.58	5.1e-44	Colorectal cancer;
LGG	cis	rs7833790	0.929	rs28464834	chr8:82797356	A/T	cg27398817	chr8:82754497	SNX16	0.77	10.99	0.45	3.96e-25	Diastolic blood pressure;
LGG	cis	rs208520	0.690	rs851464	chr6:66839802	C/T	cg07460842	chr6:66804631	NA	-0.97	-18.2	-0.65	3.3e-56	Exhaled nitric oxide output;
LGG	cis	rs3617	0.625	rs7617468	chr3:52849549	T/C	cg11645453	chr3:52864694	ITIH4	0.43	7.28	0.32	1.48e-12	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4380275	1.000	rs73143802	chr2:773826	T/C	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.5	8.75	0.38	4e-17	Longevity;
LGG	cis	rs10819861	0.645	rs4443780	chr9:98851767	T/C	cg14508093	chr9:98862825	NA	0.3	7.06	0.31	6.07e-12	Electrocardiographic traits;
LGG	cis	rs1801251	1.000	rs283479	chr2:233648754	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.63	0.48	1.33e-27	Coronary artery disease;
LGG	cis	rs13191362	0.935	rs35100164	chr6:162963003	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.34	0.32	9.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1801251	1.000	rs2592105	chr2:233645968	C/G	cg25237894	chr2:233734115	C2orf82	0.66	12.4	0.5	1.04e-30	Coronary artery disease;
LGG	cis	rs8005677	0.962	rs10130756	chr14:23396600	C/G	cg01529538	chr14:23388837	RBM23	0.36	6.68	0.3	6.9e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.81	0.38	2.6e-17	Platelet count;
LGG	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.68	-8.76	-0.38	3.7e-17	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg13206674	chr6:150067644	NUP43	0.67	15.36	0.58	2.44e-43	Lung cancer;
LGG	cis	rs7000551	0.751	rs2461482	chr8:22382898	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	12.5	0.5	4.12e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2836950	0.545	rs11700813	chr21:40517469	T/G	cg17971929	chr21:40555470	PSMG1	-0.55	-9.27	-0.4	7.25e-19	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.79	-0.38	2.85e-17	Lung cancer;
LGG	cis	rs72772090	0.710	rs112178674	chr5:96060355	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.47	-7.08	-0.31	5.39e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.82	-0.3	2.92e-11	Lung cancer;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.89	-0.38	1.38e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	1.000	rs60205400	chr3:49800272	C/T	cg21582582	chr3:182698605	DCUN1D1	0.52	9.65	0.41	3.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs5758659	0.652	rs133314	chr22:42401841	G/A	cg15557168	chr22:42548783	NA	-0.33	-7.52	-0.33	2.88e-13	Cognitive function;
LGG	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg25237894	chr2:233734115	C2orf82	0.65	12.34	0.5	1.85e-30	Coronary artery disease;
LGG	cis	rs2742417	0.967	rs9825559	chr3:45740278	T/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg22961513	chr11:14280813	SPON1	-0.29	-6.79	-0.3	3.37e-11	Mitochondrial DNA levels;
LGG	cis	rs787274	0.867	rs10739374	chr9:115602703	G/C	cg13803584	chr9:115635662	SNX30	-0.59	-7.38	-0.32	7.19e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9487094	0.689	rs699700	chr6:109688731	C/A	cg16315928	chr6:109776240	MICAL1	0.44	7.7	0.34	8.15e-14	Height;
LGG	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg23730037	chr7:158596552	ESYT2	0.41	6.98	0.31	1.05e-11	Height;
LGG	cis	rs3087591	0.919	rs2072131	chr17:29559588	G/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.39	-0.56	4.73e-39	Hip circumference;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg06656553	chr16:89960601	TCF25	-0.7	-6.93	-0.31	1.42e-11	Skin colour saturation;
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg00713939	chr8:144660590	NAPRT1	0.87	6.93	0.31	1.42e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg19147804	chr7:1989927	MAD1L1	-0.52	-10.19	-0.43	3.98e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9388451	0.874	rs9398787	chr6:126090608	A/G	cg05901451	chr6:126070800	HEY2	-0.81	-17.49	-0.63	5.94e-53	Brugada syndrome;
LGG	cis	rs9815354	0.951	rs6599168	chr3:41750323	T/C	cg03022575	chr3:42003672	ULK4	0.57	7.16	0.32	3.11e-12	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg16141378	chr3:129829833	LOC729375	0.42	9.46	0.4	1.62e-19	Neuroticism;
LGG	cis	rs2816316	0.731	rs4557955	chr1:192495174	C/T	cg02586212	chr1:192544902	RGS1	-0.32	-6.78	-0.3	3.74e-11	Celiac disease;
LGG	cis	rs2668423	1.000	rs2526136	chr19:1368398	A/G	cg02639931	chr19:1387894	NDUFS7	-0.84	-14.48	-0.56	1.81e-39	Nonalcoholic fatty liver disease;
LGG	cis	rs1670533	0.932	rs3796620	chr4:1095079	A/G	cg27284194	chr4:1044797	NA	-0.55	-9.92	-0.42	3.54e-21	Recombination rate (females);
LGG	cis	rs9948	0.541	rs62152902	chr2:97569119	C/T	cg26665480	chr2:98280029	ACTR1B	-0.68	-7.03	-0.31	7.66e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.66	0.34	1.07e-13	Joint mobility (Beighton score);
LGG	cis	rs11992162	0.508	rs7003792	chr8:11781464	T/C	cg12395012	chr8:11607386	GATA4	0.42	7.5	0.33	3.28e-13	Monocyte count;
LGG	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg07636037	chr3:49044803	WDR6	0.82	14.3	0.55	1.17e-38	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-9.25	-0.39	8.2e-19	Vitiligo;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15398939	chr12:50506234	C12orf62	0.41	6.95	0.31	1.26e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9790314	1.000	rs336583	chr3:161081981	A/T	cg04691961	chr3:161091175	C3orf57	0.65	15.68	0.59	9.29e-45	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.838	rs7565843	chr2:26292912	G/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.26e-14	Gut microbiome composition (summer);
LGG	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.49	0.44	2.94e-23	Resting heart rate;
LGG	cis	rs868036	1.000	rs1026735	chr15:68101700	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs7084402	0.967	rs1649057	chr10:60318114	C/T	cg07615347	chr10:60278583	BICC1	0.65	17.67	0.63	8.95e-54	Refractive error;
LGG	cis	rs9300255	0.568	rs1621194	chr12:123651018	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1.05e-13	Neutrophil percentage of white cells;
LGG	cis	rs798554	0.660	rs1182196	chr7:2866478	T/G	cg27476859	chr7:2772710	GNA12	0.54	10.33	0.43	1.16e-22	Height;
LGG	trans	rs783540	0.867	rs10906984	chr15:83366296	A/C	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.16	-0.32	3.18e-12	Schizophrenia;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.66	-0.56	3.02e-40	Prudent dietary pattern;
LGG	cis	rs367943	1.000	rs168365	chr5:112817984	G/A	cg12552261	chr5:112820674	MCC	-0.75	-14.3	-0.55	1.07e-38	Type 2 diabetes;
LGG	cis	rs36051895	0.695	rs7043489	chr9:5023604	A/C	cg02405213	chr9:5042618	JAK2	-0.83	-16.0	-0.6	3.64e-46	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg24829409	chr8:58192753	C8orf71	-0.69	-9.47	-0.4	1.48e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.816	rs404775	chr20:25481117	A/G	cg06421707	chr20:25228305	PYGB	0.42	8.86	0.38	1.69e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.85e-15	Obesity-related traits;
LGG	cis	rs782590	0.967	rs35504023	chr2:55806503	C/T	cg18811423	chr2:55921094	PNPT1	-0.88	-20.25	-0.69	8.76e-66	Metabolic syndrome;
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	9.97	0.42	2.37e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs887829	0.570	rs4261716	chr2:234593117	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.09	-0.35	5.3e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs734999	0.588	rs2260976	chr1:2527678	A/G	cg18854424	chr1:2615690	NA	-0.35	-7.16	-0.32	3.2e-12	Ulcerative colitis;
LGG	cis	rs6988985	0.625	rs6995865	chr8:143933652	G/A	cg10324643	chr8:143916377	GML	0.42	8.54	0.37	1.94e-16	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg26384229	chr12:38710491	ALG10B	0.8	16.12	0.6	9.96e-47	Morning vs. evening chronotype;
LGG	cis	rs9462027	0.628	rs7739771	chr6:34779801	C/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	cis	rs3771570	1.000	rs57196672	chr2:242235193	G/A	cg21155796	chr2:242212141	HDLBP	0.74	9.12	0.39	2.23e-18	Prostate cancer;
LGG	trans	rs3942852	0.726	rs10742836	chr11:48175831	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg20283391	chr11:68216788	NA	0.5	8.32	0.36	9.770000000000001e-16	Total body bone mineral density;
LGG	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg00717180	chr2:96193071	NA	-0.46	-8.34	-0.36	8.86e-16	HDL cholesterol;
LGG	cis	rs8072100	0.575	rs1221385	chr17:45527574	T/G	cg08085267	chr17:45401833	C17orf57	-0.48	-8.89	-0.38	1.35e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.04e-23	Lymphocyte counts;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.68	12.38	0.5	1.36e-30	Lymphocyte counts;
LGG	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg06618935	chr21:46677482	NA	-0.35	-6.88	-0.3	1.89e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg13206674	chr6:150067644	NUP43	0.66	15.13	0.58	2.54e-42	Lung cancer;
LGG	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg10523679	chr1:76189770	ACADM	0.8	13.64	0.54	7.49e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9467773	1.000	rs1535277	chr6:26567802	G/T	cg11502198	chr6:26597334	ABT1	0.58	10.09	0.42	9.13e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9486715	0.867	rs9384585	chr6:96875664	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs951366	1.000	rs4951261	chr1:205717823	A/C	cg07157834	chr1:205819609	PM20D1	-0.45	-8.79	-0.38	2.92e-17	Menarche (age at onset);
LGG	cis	rs75059851	0.756	rs11223646	chr11:133839560	C/T	cg20042908	chr11:133852938	NA	-0.77	-14.53	-0.56	1.12e-39	Schizophrenia;
LGG	cis	rs9944715	0.954	rs55747741	chr18:43748913	A/T	cg26436583	chr18:43649176	PSTPIP2	0.38	6.94	0.31	1.33e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg10818794	chr15:86012489	AKAP13	-0.37	-7.69	-0.34	9.01e-14	Coronary artery disease;
LGG	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg04025307	chr7:1156635	C7orf50	0.46	6.71	0.3	5.68e-11	Bronchopulmonary dysplasia;
LGG	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-7.03	-0.31	7.62e-12	Joint mobility (Beighton score);
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg15145296	chr3:125709740	NA	-0.63	-8.21	-0.36	2.18e-15	Blood pressure (smoking interaction);
LGG	cis	rs7666738	0.830	rs17027225	chr4:99028564	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs61990749	0.597	rs717683	chr14:78255453	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	6.99	0.31	9.84e-12	Fibroblast growth factor basic levels;
LGG	cis	rs4950322	0.543	rs4568882	chr1:146788598	T/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs3008870	0.755	rs1024229	chr1:67512903	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.7	13.75	0.54	2.62e-36	Lymphocyte percentage of white cells;
LGG	cis	rs3764563	1.000	rs601410	chr19:15693247	C/T	cg20725493	chr19:15740067	CYP4F8	0.57	6.79	0.3	3.52e-11	Inflammatory biomarkers;
LGG	cis	rs1799949	0.965	rs8176198	chr17:41230537	A/T	cg23758822	chr17:41437982	NA	0.72	11.74	0.48	4.8e-28	Menopause (age at onset);
LGG	cis	rs8177179	0.904	rs1130459	chr3:133465283	A/G	cg24879335	chr3:133465180	TF	0.45	7.34	0.32	9.79e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs883565	0.740	rs7624734	chr3:39108503	G/A	cg01426195	chr3:39028469	NA	-0.7	-15.93	-0.6	6.94e-46	Handedness;
LGG	trans	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.24	0.39	8.82e-19	Systolic blood pressure;
LGG	cis	rs7662987	0.517	rs2851263	chr4:100030354	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg00689492	chr4:1303491	MAEA	0.44	7.62	0.33	1.48e-13	Obesity-related traits;
LGG	trans	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs11105298	0.891	rs10858896	chr12:89920184	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg00830817	chr11:109293614	C11orf87	0.42	6.91	0.31	1.63e-11	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10335659	chr2:99757356	C2orf15;TSGA10	-0.42	-7.15	-0.32	3.34e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07343612	chr16:622815	PIGQ	-0.76	-15.85	-0.59	1.71e-45	Height;
LGG	cis	rs28595532	0.920	rs115320476	chr4:119759680	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg08677398	chr8:58056175	NA	0.42	6.91	0.31	1.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1419980	0.673	rs12366473	chr12:7728270	G/C	cg10578777	chr12:7781093	NA	0.63	8.55	0.37	1.76e-16	HDL cholesterol levels;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.19e-14	Lung cancer;
LGG	cis	rs62238980	0.614	rs79045014	chr22:32509595	C/T	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs72960926	1.000	rs72956938	chr6:75092873	G/A	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	trans	rs58106596	0.800	rs67402940	chr2:232566499	T/C	cg01370599	chr3:116745421	NA	0.65	9.99	0.42	2.04e-21	White blood cell count;Lymphocyte counts;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.0	0.31	9.31e-12	Lung cancer;
LGG	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg12432903	chr7:1882776	MAD1L1	0.46	7.73	0.34	6.84e-14	Bipolar disorder;
LGG	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs4430311	0.623	rs10927058	chr1:243838630	T/C	cg25706552	chr1:244017396	NA	-0.64	-15.11	-0.57	3.18e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19300632	chr2:55746645	CCDC104	0.37	6.85	0.3	2.29e-11	Bilirubin levels;
LGG	cis	rs28595532	0.920	rs115354352	chr4:119750358	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	trans	rs9354308	0.727	rs2351720	chr6:66602762	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg01114163	chr5:1856713	NA	-0.41	-7.2	-0.32	2.48e-12	Cardiovascular disease risk factors;
LGG	cis	rs963731	0.649	rs2278913	chr2:39199880	A/G	cg04010122	chr2:39346883	SOS1	-0.78	-6.9	-0.31	1.67e-11	Corticobasal degeneration;
LGG	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg06027949	chr8:82754900	SNX16	-0.46	-6.7	-0.3	6.06e-11	Diastolic blood pressure;
LGG	cis	rs8133932	0.861	rs74459266	chr21:47236206	C/T	cg11214348	chr21:47283868	PCBP3	-0.44	-7.14	-0.31	3.7e-12	Schizophrenia;
LGG	cis	rs4356975	0.563	rs7685151	chr4:69979773	C/T	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg15212455	chr7:39170539	POU6F2	0.37	8.28	0.36	1.33e-15	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg11062466	chr8:58055876	NA	0.48	8.22	0.36	2.06e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs939658	0.805	rs35230534	chr15:79441093	T/C	cg17916960	chr15:79447300	NA	-0.66	-12.8	-0.51	2.6e-32	Refractive error;
LGG	cis	rs4684776	1.000	rs35990666	chr3:11463505	T/C	cg24705426	chr3:11550659	ATG7	-0.42	-7.64	-0.33	1.27e-13	Small vessel stroke;
LGG	cis	rs854765	0.647	rs854791	chr17:18029857	C/T	cg04398451	chr17:18023971	MYO15A	-0.85	-17.78	-0.64	2.68e-54	Total body bone mineral density;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.27	-0.43	2.03e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4538187	0.851	rs11674020	chr2:64134894	G/A	cg14150252	chr2:64069583	UGP2	-0.51	-10.15	-0.43	5.28e-22	Systolic blood pressure;
LGG	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg04455712	chr21:45112962	RRP1B	-0.51	-9.29	-0.4	6.13e-19	Mean corpuscular volume;
LGG	cis	rs3126085	0.935	rs991231	chr1:152211898	T/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.35	-0.36	8.05e-16	Atopic dermatitis;
LGG	cis	rs6835098	0.962	rs3733477	chr4:174090004	G/A	cg08422745	chr4:174089978	GALNT7	-0.86	-15.36	-0.58	2.5e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs9314323	0.692	rs6557914	chr8:26208744	G/C	cg11498726	chr8:26250323	BNIP3L	-0.54	-11.31	-0.47	2.36e-26	Red cell distribution width;
LGG	cis	rs533581	0.816	rs1559446	chr16:88975332	A/G	cg08484992	chr16:88977278	CBFA2T3	0.4	9.22	0.39	1.07e-18	Social autistic-like traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08800530	chr5:175788722	KIAA1191	0.45	7.18	0.32	2.85e-12	Cognitive performance;
LGG	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg20821713	chr7:1055600	C7orf50	-0.5	-7.84	-0.34	3.14e-14	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05025164	chr4:1340916	KIAA1530	-0.49	-8.67	-0.37	7.19e-17	Obesity-related traits;
LGG	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg22903471	chr2:27725779	GCKR	0.53	12.16	0.49	1.01e-29	Total body bone mineral density;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg17691542	chr6:26056736	HIST1H1C	0.56	9.98	0.42	2.22e-21	Height;
LGG	cis	rs72781680	0.716	rs2712086	chr2:24004739	G/C	cg08917208	chr2:24149416	ATAD2B	0.64	8.3	0.36	1.12e-15	Lymphocyte counts;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs58616815	0.819	rs10881792	chr10:92156550	G/A	cg17905462	chr10:92153495	NA	-0.25	-6.75	-0.3	4.31e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg25172604	chr17:41446521	NA	-0.31	-7.0	-0.31	9.28e-12	Menopause (age at onset);
LGG	trans	rs561341	0.623	rs4795665	chr17:30233657	C/T	cg20587970	chr11:113659929	NA	-0.9	-13.81	-0.54	1.47e-36	Hip circumference adjusted for BMI;
LGG	cis	rs6993813	0.814	rs1905783	chr8:120014836	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.86	0.3	2.28e-11	Bone mineral density (hip);
LGG	cis	rs7552404	0.924	rs1611823	chr1:76221706	T/G	cg10523679	chr1:76189770	ACADM	0.75	13.92	0.54	4.85e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs5742933	0.817	rs4667297	chr2:190528996	C/T	cg04003228	chr2:190539410	ANKAR	-0.52	-7.49	-0.33	3.6e-13	Ferritin levels;
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06634786	chr22:41940651	POLR3H	-0.8	-12.81	-0.51	2.28e-32	Vitiligo;
LGG	cis	rs490234	0.683	rs9409281	chr9:128159171	C/G	cg14078157	chr9:128172775	NA	-0.51	-9.59	-0.41	5.67e-20	Mean arterial pressure;
LGG	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.89	0.42	4.7e-21	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg26384229	chr12:38710491	ALG10B	0.92	20.2	0.68	1.49e-65	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9479482	0.686	rs13199618	chr6:150384648	C/A	cg03788504	chr6:150331562	NA	-0.48	-10.1	-0.42	8.18e-22	Alopecia areata;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.03	-0.6	2.62e-46	Calcium levels;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.66	-0.34	1.13e-13	Lung cancer;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.0	-16.98	-0.62	1.26e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs910316	1.000	rs876403	chr14:75602834	A/T	cg11812906	chr14:75593930	NEK9	0.55	10.18	0.43	4.18e-22	Height;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg07395648	chr5:131743802	NA	-0.43	-9.47	-0.4	1.49e-19	Blood metabolite levels;
LGG	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg05901451	chr6:126070800	HEY2	-0.83	-17.77	-0.64	2.93e-54	Brugada syndrome;
LGG	cis	rs9397585	0.857	rs9371279	chr6:153378876	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.52e-39	Body mass index;
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00166722	chr3:10149974	C3orf24	0.54	8.86	0.38	1.68e-17	Alzheimer's disease;
LGG	cis	rs3764563	1.000	rs4808326	chr19:15726147	A/G	cg20725493	chr19:15740067	CYP4F8	-0.65	-7.8	-0.34	4.05e-14	Inflammatory biomarkers;
LGG	cis	rs9658691	0.607	rs9658791	chr10:90777338	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.71	-8.5	-0.37	2.54e-16	Mosquito bite size;
LGG	cis	rs17767392	0.918	rs17767410	chr14:71771967	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-8.86	-0.38	1.76e-17	Dementia with Lewy bodies;
LGG	trans	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19894588	chr14:64061835	NA	-0.56	-8.8	-0.38	2.81e-17	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs916888	0.773	rs199447	chr17:44812188	C/T	cg22433210	chr17:43662623	NA	0.91	14.8	0.57	7.3e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.04	-0.39	4.16e-18	Life satisfaction;
LGG	cis	rs11122272	0.735	rs11122279	chr1:231519804	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.34	-0.32	9.52e-13	Hemoglobin concentration;
LGG	cis	rs1218582	0.710	rs9793588	chr1:154878878	C/G	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.46	-0.33	4.4e-13	Prostate cancer;
LGG	cis	rs1466045	0.841	rs2166567	chr11:3157534	C/T	cg01418188	chr11:3145609	OSBPL5	0.28	7.02	0.31	7.89e-12	Cisplatin-induced ototoxicity;
LGG	cis	rs3087591	0.664	rs2525565	chr17:29666588	T/C	cg24425628	chr17:29625626	OMG;NF1	0.59	12.45	0.5	6.74e-31	Hip circumference;
LGG	cis	rs295140	1.000	rs13028959	chr2:201185919	C/A	cg25099087	chr2:201172481	SPATS2L	0.28	6.85	0.3	2.43e-11	QT interval;
LGG	cis	rs9462027	0.628	rs7774697	chr6:34791027	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.53	11.03	0.46	2.81e-25	Systemic lupus erythematosus;
LGG	cis	rs9972944	0.622	rs1895033	chr17:63777493	A/C	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg19168338	chr16:4465731	CORO7	-0.75	-14.03	-0.55	1.57e-37	Schizophrenia;
LGG	cis	rs12431410	0.892	rs1957988	chr14:60159779	T/C	cg07950296	chr14:60194823	RTN1	0.39	7.32	0.32	1.11e-12	Schizophrenia;
LGG	cis	rs2470578	0.792	rs283912	chr3:17331582	A/T	cg20981856	chr3:17787350	NA	0.35	6.74	0.3	4.83e-11	Schizophrenia;
LGG	cis	rs17253792	0.822	rs77544029	chr14:56087917	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.26	-0.5	3.85e-30	Putamen volume;
LGG	cis	rs72945132	0.714	rs72947077	chr11:70197431	A/G	cg00319359	chr11:70116639	PPFIA1	0.74	7.75	0.34	5.94e-14	Coronary artery disease;
LGG	cis	rs3793683	0.928	rs10781585	chr10:134553369	C/A	cg27286337	chr10:134555280	INPP5A	-1.05	-24.03	-0.74	1.97e-83	Migraine;
LGG	cis	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.71	0.34	7.88e-14	Eosinophil percentage of white cells;
LGG	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.33	0.53	1.6e-34	Anterior chamber depth;
LGG	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg05084668	chr3:125655381	ALG1L	-0.54	-7.34	-0.32	9.49e-13	Blood pressure (smoking interaction);
LGG	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08109568	chr15:31115862	NA	-0.53	-9.47	-0.4	1.42e-19	Huntington's disease progression;
LGG	cis	rs62344088	0.590	rs60845955	chr5:185094	C/T	cg22857025	chr5:266934	NA	-1.12	-9.12	-0.39	2.3e-18	Asthma (childhood onset);
LGG	cis	rs3091242	0.933	rs10903129	chr1:25768937	A/G	cg09222892	chr1:25734099	RHCE	0.46	9.77	0.41	1.28e-20	Erythrocyte sedimentation rate;
LGG	cis	rs10895140	0.756	rs6590894	chr11:101509793	A/G	cg23650423	chr11:101454676	TRPC6	-0.42	-6.85	-0.3	2.35e-11	Menarche (age at onset);
LGG	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg14101638	chr12:121416612	HNF1A	-0.35	-7.37	-0.32	7.96e-13	N-glycan levels;
LGG	cis	rs9858542	0.537	rs35869135	chr3:49359102	A/G	cg03060546	chr3:49711283	APEH	-0.53	-7.07	-0.31	5.77e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6089829	0.816	rs6062397	chr20:61668268	A/G	cg08045932	chr20:61659980	NA	0.6	13.11	0.52	1.27e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs929354	1.000	rs1182414	chr7:157058363	G/A	cg17757837	chr7:157058334	UBE3C	-0.94	-21.42	-0.71	3.01e-71	Body mass index;
LGG	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg25358565	chr5:93447407	FAM172A	1.4	17.18	0.62	1.52e-51	Diabetic retinopathy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26597500	chr13:73356092	PIBF1;DIS3	0.46	7.75	0.34	5.94e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.47	-0.33	3.91e-13	Menopause (age at onset);
LGG	cis	rs6956675	0.915	rs7786464	chr7:62615322	C/A	cg08930214	chr7:62859557	LOC100287834	0.48	7.85	0.34	2.84e-14	Obesity-related traits;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg27432699	chr2:27873401	GPN1	-0.52	-8.95	-0.38	8.7e-18	Total body bone mineral density;
LGG	cis	rs17092148	0.836	rs4564863	chr20:33179367	T/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs3796352	1.000	rs11707575	chr3:53113762	G/T	cg12962167	chr3:53033115	SFMBT1	0.64	6.94	0.31	1.34e-11	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.13e-12	HDL cholesterol;
LGG	cis	rs11608355	0.705	rs4766601	chr12:109890080	C/G	cg04065206	chr12:109973212	UBE3B	-0.45	-7.01	-0.31	8.26e-12	Neuroticism;
LGG	cis	rs41271473	0.526	rs12353961	chr1:228738252	G/C	cg10167378	chr1:228756711	NA	0.71	9.49	0.4	1.18e-19	Chronic lymphocytic leukemia;
LGG	cis	rs2710642	0.962	rs7557501	chr2:63086639	C/T	cg17519650	chr2:63277830	OTX1	0.47	7.81	0.34	3.75e-14	LDL cholesterol levels;LDL cholesterol;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	ch.2.1448966F	chr2:63344642	NA	-0.39	-6.88	-0.3	1.99e-11	Pancreatic cancer;
LGG	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg20848291	chr7:100343083	ZAN	-0.66	-9.81	-0.41	9.15e-21	Other erythrocyte phenotypes;
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs6430585	0.583	rs58116536	chr2:136585323	C/T	cg07169764	chr2:136633963	MCM6	1.31	26.4	0.78	2.26e-94	Corneal structure;
LGG	cis	rs7811142	0.830	rs11768967	chr7:99967644	G/A	cg11814155	chr7:99998594	ZCWPW1	0.53	8.06	0.35	6.66e-15	Platelet count;
LGG	trans	rs8002861	0.515	rs9525846	chr13:44390857	A/G	cg17145862	chr1:211918768	LPGAT1	-0.78	-16.67	-0.61	3.42e-49	Leprosy;
LGG	cis	rs4948102	0.767	rs4948096	chr7:56053118	C/T	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.16	-0.32	3.16e-12	Coronary artery disease;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg08645402	chr16:4508243	NA	0.54	9.9	0.42	4.4e-21	Schizophrenia;
LGG	cis	rs1018836	0.669	rs6471243	chr8:91656967	C/T	cg16814680	chr8:91681699	NA	1.06	24.28	0.75	1.29e-84	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs34172651	0.517	rs2303083	chr16:24835168	G/A	cg02428538	chr16:24856791	SLC5A11	-0.69	-10.13	-0.43	6.58e-22	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	1.000	rs12153912	chr6:27179829	A/G	cg23155468	chr6:27110703	HIST1H2BK	0.55	6.75	0.3	4.36e-11	Hip circumference adjusted for BMI;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.45	6.93	0.31	1.4e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10832963	1.000	rs11024739	chr11:18645843	A/C	cg20219074	chr11:18656078	SPTY2D1	-0.82	-15.48	-0.58	7.09e-44	Breast cancer;
LGG	trans	rs853679	0.607	rs13216117	chr6:27938484	A/G	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.73	0.38	4.78e-17	Myopia (pathological);
LGG	cis	rs10540	1.000	rs116876680	chr11:517473	G/T	cg03352830	chr11:487213	PTDSS2	0.83	10.01	0.42	1.78e-21	Body mass index;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.66	-0.56	3.04e-40	Platelet count;
LGG	cis	rs9902453	0.765	rs2628180	chr17:28101723	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.24	-0.55	1.97e-38	Coffee consumption (cups per day);
LGG	cis	rs4417704	0.551	rs4610050	chr2:241891914	A/G	cg26818257	chr2:241905806	NA	0.48	10.87	0.45	1.17e-24	Joint mobility (Beighton score);
LGG	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.94	0.31	1.32e-11	Cognitive ability;
LGG	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg13009111	chr11:71350975	NA	0.33	7.17	0.32	2.99e-12	Monocyte count;
LGG	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs8180040	0.726	rs1463393	chr3:46994987	G/A	cg16586182	chr3:47516702	SCAP	0.72	13.2	0.52	5.38e-34	Colorectal cancer;
LGG	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg27121462	chr16:89883253	FANCA	-0.58	-10.44	-0.44	4.61e-23	Vitiligo;
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.56	9.95	0.42	2.78e-21	Lymphocyte counts;
LGG	cis	rs854765	0.547	rs2955359	chr17:17946730	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg07701084	chr6:150067640	NUP43	0.64	12.26	0.5	4.01e-30	Lung cancer;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.75	-0.34	5.78e-14	IgG glycosylation;
LGG	cis	rs4650994	0.593	rs10798618	chr1:178519124	A/C	cg19399532	chr1:178512495	C1orf220	-0.4	-7.5	-0.33	3.23e-13	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs57046232	0.552	rs6054166	chr20:6348251	A/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.87	0.3	2.08e-11	Colorectal cancer;
LGG	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.08	27.32	0.79	1.44e-98	Cognitive ability;
LGG	cis	rs11711311	0.955	rs9823423	chr3:113419741	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.21	-0.32	2.25e-12	IgG glycosylation;
LGG	cis	rs72772090	0.539	rs11742261	chr5:96167608	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.44	-0.37	4.02e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg26174226	chr8:58114915	NA	-0.5	-7.44	-0.33	4.95e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13193676	chr8:80942319	MRPS28	0.44	7.46	0.33	4.28e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7932354	0.502	rs11600668	chr11:47193566	G/A	cg03339077	chr11:47165057	C11orf49	0.54	10.38	0.43	8.14e-23	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4750440	0.706	rs4503425	chr10:14019034	C/G	cg00551146	chr10:14014579	FRMD4A	0.29	6.98	0.31	1.06e-11	Adiponectin levels;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.42	-0.36	4.8e-16	Obesity-related traits;
LGG	cis	rs883565	0.771	rs1053530	chr3:39138082	A/G	cg01426195	chr3:39028469	NA	0.67	13.7	0.54	4.07e-36	Handedness;
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg27476859	chr7:2772710	GNA12	0.45	8.57	0.37	1.59e-16	Height;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.44	9.05	0.39	4.01e-18	Schizophrenia;
LGG	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg12924262	chr12:102091054	CHPT1	0.66	13.3	0.53	2e-34	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15691003	chr1:22351864	HSPC157	0.43	6.88	0.3	2e-11	Cognitive performance;
LGG	cis	rs80282103	0.717	rs41299206	chr10:1120236	T/C	cg08668510	chr10:1095578	IDI1	0.79	7.98	0.35	1.19e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs6867032	0.958	rs4505990	chr5:2015811	A/G	cg26168224	chr5:2018326	NA	1.29	31.3	0.82	2.45e-116	Gut microbiome composition (winter);
LGG	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg24006582	chr15:45444508	DUOX1	0.65	11.85	0.48	1.76e-28	Uric acid levels;
LGG	cis	rs870825	0.860	rs2696044	chr4:185595988	C/G	cg04058563	chr4:185651563	MLF1IP	0.98	19.18	0.67	9.07e-61	Blood protein levels;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.84	0.54	1.05e-36	Lung cancer;
LGG	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg18709589	chr6:96969512	KIAA0776	0.45	7.02	0.31	8e-12	Migraine;Coronary artery disease;
LGG	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg02428538	chr16:24856791	SLC5A11	-0.7	-10.61	-0.44	1.07e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7794364	0.681	rs10242758	chr7:117522956	G/T	cg21880328	chr7:117514017	CTTNBP2	-0.34	-7.04	-0.31	7.12e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs7647973	0.592	rs6774202	chr3:49687779	T/G	cg03060546	chr3:49711283	APEH	0.62	8.63	0.37	9.86e-17	Menarche (age at onset);
LGG	cis	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08564027	chr20:61660810	NA	1.03	25.42	0.76	6.91e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17767392	0.958	rs117821900	chr14:71985670	A/T	cg02058870	chr14:72053146	SIPA1L1	0.41	8.53	0.37	2.05e-16	Mitral valve prolapse;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg17178900	chr1:205818956	PM20D1	0.57	12.75	0.51	3.94e-32	Menarche (age at onset);
LGG	cis	rs2180341	0.782	rs6912552	chr6:127722946	C/G	cg24812749	chr6:127587940	RNF146	-0.7	-11.56	-0.47	2.41e-27	Breast cancer;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-8.06	-0.35	6.71e-15	Personality dimensions;
LGG	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs7760949	0.963	rs1330117	chr6:13920926	C/T	cg27413430	chr6:13925136	RNF182	0.43	6.74	0.3	4.69e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg14979609	chr8:8086686	FLJ10661	-0.33	-8.38	-0.36	6.2e-16	Neuroticism;
LGG	cis	rs920590	0.921	rs4922099	chr8:19648486	T/C	cg03894339	chr8:19674705	INTS10	0.51	8.58	0.37	1.46e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.0	-0.31	9.27e-12	Myopia (pathological);
LGG	cis	rs2540226	0.816	rs4670958	chr2:39980724	A/G	cg13254588	chr2:40006314	THUMPD2	0.39	6.72	0.3	5.49e-11	Personality dimensions;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.22	0.36	2.11e-15	Personality dimensions;
LGG	cis	rs2640806	0.525	rs11784595	chr8:97341390	A/C	cg22138393	chr8:97340270	PTDSS1	-0.26	-6.73	-0.3	5.03e-11	Obesity-related traits;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg24503407	chr1:205819492	PM20D1	0.83	20.08	0.68	5.62e-65	Menarche (age at onset);
LGG	cis	rs2455799	0.573	rs2455833	chr3:15752830	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.88	-0.34	2.31e-14	Mean platelet volume;
LGG	cis	rs6500602	0.893	rs6500601	chr16:4497199	G/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	6.92	0.31	1.51e-11	Schizophrenia;
LGG	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg06636001	chr8:8085503	FLJ10661	0.6	11.76	0.48	4.06e-28	Retinal vascular caliber;
LGG	trans	rs7830939	0.586	rs7007562	chr8:9328926	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.81	0.3	3.03e-11	Neuroticism;
LGG	trans	rs6598955	0.515	rs61776655	chr1:26541430	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.58	0.33	1.9e-13	Obesity-related traits;
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg23594656	chr7:65796392	TPST1	0.41	9.05	0.39	3.84e-18	Aortic root size;
LGG	cis	rs6743226	0.603	rs62186405	chr2:242232153	C/G	cg10021735	chr2:242295487	FARP2	0.4	7.01	0.31	8.56e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg24375607	chr4:120327624	NA	0.6	10.14	0.43	5.84e-22	Corneal astigmatism;
LGG	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.48	-0.44	3.36e-23	Bone mineral density;
LGG	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg27446573	chr6:127587934	RNF146	1.14	22.4	0.72	8.31e-76	Breast cancer;
LGG	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10754283	0.967	rs7552896	chr1:90103194	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.15	0.49	1.08e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg24247370	chr13:99142703	STK24	-0.38	-6.96	-0.31	1.21e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs73416724	0.925	rs2651201	chr6:43293366	G/A	cg26312998	chr6:43337775	ZNF318	-0.55	-7.82	-0.34	3.61e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1577917	0.655	rs9444354	chr6:86291935	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.37	0.47	1.37e-26	Response to antipsychotic treatment;
LGG	cis	rs7208859	0.623	rs55811708	chr17:29104731	G/T	cg13385521	chr17:29058706	SUZ12P	0.93	10.84	0.45	1.48e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg10295955	chr4:187884368	NA	-1.15	-30.73	-0.82	7.77e-114	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2916247	1.000	rs6982094	chr8:93047827	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11150308	chr17:74068434	SRP68	0.43	7.25	0.32	1.75e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11644478	chr21:40555479	PSMG1	0.68	9.38	0.4	3.02e-19	Cognitive function;
LGG	cis	rs6121246	0.559	rs6121038	chr20:30254773	T/G	cg21427119	chr20:30132790	HM13	-0.38	-6.9	-0.31	1.74e-11	Mean corpuscular hemoglobin;
LGG	trans	rs7939886	0.841	rs11227582	chr11:55995736	C/A	cg15704280	chr7:45808275	SEPT13	0.83	7.77	0.34	5.04e-14	Myopia (pathological);
LGG	cis	rs11190604	1.000	rs7073586	chr10:102307671	A/G	cg07570687	chr10:102243282	WNT8B	0.39	6.67	0.3	7.22e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11252926	0.931	rs12355162	chr10:563472	G/A	cg18196295	chr10:418757	DIP2C	-0.58	-10.45	-0.44	4.49e-23	Psychosis in Alzheimer's disease;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	9.38	0.4	2.97e-19	Obesity-related traits;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-14.8	-0.57	7.71e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9309473	0.607	rs6546824	chr2:73587331	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-8.57	-0.37	1.53e-16	Metabolite levels;
LGG	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg07636037	chr3:49044803	WDR6	0.6	10.56	0.44	1.68e-23	Resting heart rate;
LGG	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.61	0.67	8.63e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6032067	1.000	rs13038434	chr20:43888106	G/A	cg10761708	chr20:43804764	PI3	0.74	10.84	0.45	1.54e-24	Blood protein levels;
LGG	cis	rs9487051	0.834	rs436880	chr6:109553069	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.83	-0.3	2.69e-11	Reticulocyte fraction of red cells;
LGG	cis	rs5769765	0.955	rs5769767	chr22:50276909	G/A	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs734999	0.588	rs10910099	chr1:2533552	G/T	cg20673091	chr1:2541236	MMEL1	-0.77	-17.43	-0.63	1.09e-52	Ulcerative colitis;
LGG	cis	rs780096	0.506	rs2303369	chr2:27715416	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg18867708	chr6:26865862	GUSBL1	0.44	7.18	0.32	2.74e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs990171	1.000	rs1468791	chr2:103092021	A/G	cg05295703	chr2:102895712	NA	-0.52	-9.0	-0.39	6.02e-18	Lymphocyte counts;
LGG	cis	rs4330281	0.669	rs7650617	chr3:17743260	A/G	cg20981856	chr3:17787350	NA	-0.38	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs9393692	0.557	rs2893820	chr6:26295686	G/A	cg00631329	chr6:26305371	NA	-0.47	-7.93	-0.35	1.67e-14	Educational attainment;
LGG	cis	rs3008870	0.755	rs12562761	chr1:67396739	C/T	cg02640540	chr1:67518911	SLC35D1	0.39	7.35	0.32	9.02e-13	Lymphocyte percentage of white cells;
LGG	cis	rs4253772	0.591	rs10854854	chr22:46684706	C/G	cg09461388	chr22:46763229	CELSR1	-0.66	-7.03	-0.31	7.31e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20707008	chr6:160210612	MRPL18;TCP1	0.4	6.76	0.3	4.24e-11	Cognitive performance;
LGG	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg21475434	chr5:93447410	FAM172A	0.72	7.34	0.32	9.64e-13	Diabetic retinopathy;
LGG	cis	rs17767392	0.918	rs61991201	chr14:71762623	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.7	-0.41	2.16e-20	Diabetic retinopathy;
LGG	cis	rs757278	0.513	rs214164	chr7:117292696	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	7.7	0.34	8.14e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs34929064	1.000	rs6942567	chr7:22724643	C/A	cg18045685	chr7:22629474	NA	0.56	8.94	0.38	9.02e-18	Major depression and alcohol dependence;
LGG	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg11965913	chr1:205819406	PM20D1	0.83	18.16	0.64	5.03e-56	Menarche (age at onset);
LGG	cis	rs11252926	0.897	rs7092330	chr10:583771	G/C	cg18196295	chr10:418757	DIP2C	-0.6	-11.09	-0.46	1.59e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs9902453	0.765	rs34585141	chr17:28336432	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs28595532	0.920	rs115484560	chr4:119756781	T/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg11430096	chr6:110968061	CDK19	0.67	6.97	0.31	1.08e-11	Prostate cancer;
LGG	cis	rs9596863	0.898	rs34107297	chr13:54374962	A/T	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	10.01	0.42	1.82e-21	Lymphocyte counts;
LGG	cis	rs4450131	0.898	rs10794173	chr10:126330565	C/T	cg08799069	chr10:126477246	METTL10	0.32	6.88	0.3	1.9e-11	White blood cell count (basophil);
LGG	cis	rs1552244	1.000	rs6782602	chr3:10116541	G/T	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.08	0.31	5.22e-12	Menopause (age at onset);
LGG	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.26	-0.43	2.15e-22	Schizophrenia;
LGG	cis	rs2797160	0.967	rs2747718	chr6:126009109	C/A	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs6500395	0.569	rs12934452	chr16:48706139	C/T	cg04672837	chr16:48644449	N4BP1	-0.48	-8.38	-0.36	6.39e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg07211511	chr3:129823064	LOC729375	-0.66	-9.06	-0.39	3.75e-18	Blood pressure (smoking interaction);
LGG	trans	rs12517041	1.000	rs10064991	chr5:23318464	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.1e-25	Calcium levels;
LGG	cis	rs798554	0.759	rs2644309	chr7:2889034	T/C	cg13628971	chr7:2884303	GNA12	0.55	11.49	0.47	4.59e-27	Height;
LGG	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs9611565	0.506	rs1883825	chr22:41703408	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-12.31	-0.5	2.57e-30	Vitiligo;
LGG	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	trans	rs8002861	0.846	rs56408817	chr13:44471983	A/G	cg12856521	chr11:46389249	DGKZ	-0.46	-7.88	-0.34	2.39e-14	Leprosy;
LGG	cis	rs11074306	0.561	rs9806728	chr15:28073367	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs11214589	0.747	rs2155462	chr11:113206799	A/C	cg14373873	chr11:113211441	TTC12	0.54	11.69	0.48	7.94e-28	Neuroticism;
LGG	trans	rs72991	0.737	rs297526	chr11:121244010	C/G	cg27192990	chr6:129479024	LAMA2	-0.42	-7.15	-0.32	3.42e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg07701084	chr6:150067640	NUP43	0.68	11.9	0.48	1.15e-28	Lung cancer;
LGG	cis	rs74781061	1.000	rs4887166	chr15:74897598	C/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.06	-0.31	6.27e-12	Endometriosis;
LGG	trans	rs1997103	0.871	rs9649855	chr7:55410222	T/C	cg20935933	chr6:143382018	AIG1	0.55	8.7	0.37	5.91e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs240764	0.621	rs9404052	chr6:101249718	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	trans	rs6810798	0.520	rs61435515	chr4:148329369	C/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.48	-7.0	-0.31	8.83e-12	Coronary artery disease;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs7144547	0.803	rs8008602	chr14:81890171	T/A	cg23690444	chr14:81902736	NA	0.66	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs709400	0.663	rs8015918	chr14:103942991	A/G	cg26031613	chr14:104095156	KLC1	0.78	13.9	0.54	5.86e-37	Body mass index;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg21782813	chr7:2030301	MAD1L1	-0.41	-9.39	-0.4	2.72e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.23	-0.32	2.01e-12	Longevity;Endometriosis;
LGG	cis	rs1008375	0.966	rs6449313	chr4:17588320	A/G	cg07005078	chr4:17578674	LAP3	0.37	6.74	0.3	4.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg16482183	chr6:26056742	HIST1H1C	0.56	9.19	0.39	1.29e-18	Iron status biomarkers;
LGG	cis	rs7215564	0.908	rs2316061	chr17:78663660	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.22	-0.36	2.11e-15	Myopia (pathological);
LGG	cis	rs10489202	0.513	rs4657731	chr1:168081255	C/T	cg24449463	chr1:168025552	DCAF6	-0.56	-10.03	-0.42	1.47e-21	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21483475	chr3:154042025	DHX36	0.43	7.08	0.31	5.47e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6489882	0.867	rs7134391	chr12:113366691	A/G	cg25319449	chr12:113376135	OAS3	0.35	6.67	0.3	7.45e-11	Chronic lymphocytic leukemia;
LGG	cis	rs78456975	0.527	rs11885279	chr2:1560633	T/C	cg26248373	chr2:1572462	NA	-0.85	-14.21	-0.55	2.66e-38	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg04568710	chr12:38710424	ALG10B	0.38	8.12	0.35	4.22e-15	Morning vs. evening chronotype;
LGG	cis	rs10927875	0.578	rs10927859	chr1:16141862	C/T	cg07117364	chr1:16154769	NA	-0.48	-9.06	-0.39	3.66e-18	Dilated cardiomyopathy;
LGG	cis	rs12711979	0.509	rs13021385	chr2:3826387	T/C	cg17052675	chr2:3827356	NA	-0.49	-9.67	-0.41	2.98e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg23302884	chr18:44338147	ST8SIA5	0.34	6.68	0.3	6.97e-11	Personality dimensions;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs4732038	0.510	rs12669728	chr7:134272965	G/A	cg06906464	chr7:134288099	NA	-0.66	-17.15	-0.62	2.18e-51	Longevity;
LGG	cis	rs8031584	0.678	rs798127	chr15:31117403	T/C	cg08704250	chr15:31115839	NA	0.49	8.77	0.38	3.49e-17	Huntington's disease progression;
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg21775007	chr8:11205619	TDH	0.5	8.37	0.36	6.68e-16	Mood instability;
LGG	cis	rs7751419	0.527	rs4714216	chr6:39106207	G/A	cg08089693	chr6:39098871	NA	-0.5	-9.5	-0.4	1.15e-19	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.53e-20	Bipolar disorder;
LGG	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.79	-9.51	-0.4	1.01e-19	Schizophrenia;
LGG	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs12711979	0.509	rs10192699	chr2:3824297	A/G	cg17052675	chr2:3827356	NA	-0.49	-9.7	-0.41	2.29e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg12373951	chr3:133503437	NA	0.43	7.67	0.34	1.02e-13	Iron status biomarkers;
LGG	trans	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg27661571	chr11:113659931	NA	-0.65	-9.42	-0.4	2.12e-19	Hip circumference adjusted for BMI;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg14092988	chr3:52407081	DNAH1	0.31	8.07	0.35	5.89e-15	Bipolar disorder;
LGG	cis	rs11971779	0.680	rs9683	chr7:139107739	T/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9457247	1.000	rs408087	chr6:167398952	C/T	cg07741184	chr6:167504864	NA	0.32	7.13	0.31	4e-12	Crohn's disease;
LGG	cis	rs6743226	0.840	rs10933549	chr2:242240702	A/G	cg10021735	chr2:242295487	FARP2	0.53	9.6	0.41	4.95e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs5758511	0.680	rs56111723	chr22:42664883	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.43	7.21	0.32	2.27e-12	Birth weight;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-10.06	-0.42	1.11e-21	IgG glycosylation;
LGG	cis	rs2012796	0.704	rs57670850	chr14:81841577	C/T	cg02996355	chr14:81879375	NA	0.59	9.79	0.41	1.06e-20	Night sleep phenotypes;
LGG	cis	rs17356983	1.000	rs17356983	chr13:21915114	C/T	cg25811766	chr13:21894605	NA	-0.44	-6.71	-0.3	5.74e-11	Obesity-related traits;
LGG	trans	rs1814175	0.645	rs4411280	chr11:49962750	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg03433033	chr1:76189801	ACADM	0.62	8.67	0.37	7.2e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg24250549	chr1:154909240	PMVK	0.7	13.61	0.53	9.71e-36	Prostate cancer;
LGG	cis	rs939658	0.776	rs35904425	chr15:79444567	G/A	cg17916960	chr15:79447300	NA	-0.66	-12.91	-0.51	8.61e-33	Refractive error;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11719291	0.504	rs71324924	chr3:48865444	G/A	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	Cognitive function;
LGG	cis	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.7e-21	Corneal astigmatism;
LGG	cis	rs3820068	0.581	rs34453754	chr1:15993208	G/C	cg05660106	chr1:15850417	CASP9	0.82	15.88	0.59	1.15e-45	Systolic blood pressure;
LGG	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.39e-16	Restless legs syndrome;
LGG	cis	rs16866061	0.816	rs115900205	chr2:225467840	G/C	cg12698349	chr2:225449008	CUL3	0.87	16.55	0.61	1.15e-48	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	trans	rs2048656	0.598	rs7846399	chr8:9493129	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.78	0.34	4.74e-14	Schizophrenia;
LGG	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-9.25	-0.39	8.38e-19	Vitiligo;
LGG	cis	rs12477438	0.834	rs1563107	chr2:99701276	A/G	cg08885076	chr2:99613938	TSGA10	0.49	10.01	0.42	1.7e-21	Chronic sinus infection;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.34e-16	Life satisfaction;
LGG	cis	rs1978968	1.000	rs1110662	chr22:18444908	G/A	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs72960926	0.744	rs72964214	chr6:74864851	T/C	cg03266952	chr6:74778945	NA	-0.62	-6.71	-0.3	5.75e-11	Metabolite levels (MHPG);
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs4563143	0.675	rs56123392	chr19:29255631	A/C	cg03161606	chr19:29218774	NA	0.69	10.65	0.44	7.89e-24	Methadone dose in opioid dependence;
LGG	cis	rs35306767	0.903	rs11815185	chr10:923617	T/A	cg08847335	chr10:891726	LARP4B	-0.52	-9.39	-0.4	2.73e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7666738	0.800	rs13107586	chr4:99028788	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12681288	0.862	rs11996703	chr8:1009093	T/C	cg04851639	chr8:1020857	NA	-0.43	-9.0	-0.39	5.69e-18	Schizophrenia;
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg21017887	chr14:105400489	NA	0.42	8.27	0.36	1.39e-15	Rheumatoid arthritis;
LGG	cis	rs6964587	0.692	rs2374550	chr7:91820987	A/G	cg17063962	chr7:91808500	NA	0.53	10.37	0.43	8.71e-23	Breast cancer;
LGG	cis	rs2486288	0.656	rs12899058	chr15:45547324	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.9	-0.42	4.31e-21	Glomerular filtration rate;
LGG	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.53	-0.61	1.45e-48	Blood trace element (Zn levels);
LGG	cis	rs57927100	1.000	rs57927100	chr17:75317300	C/G	cg18271897	chr17:75316784	SEPT9	0.46	10.53	0.44	2.2e-23	Systolic blood pressure;
LGG	cis	rs801193	0.527	rs2707837	chr7:66181073	G/C	cg11764359	chr7:65958608	NA	0.71	12.92	0.51	7.77e-33	Aortic root size;
LGG	cis	rs7945718	0.775	rs10500759	chr11:12822588	A/G	cg25843174	chr11:12811716	TEAD1	-0.39	-7.83	-0.34	3.25e-14	Educational attainment (years of education);
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.1e-21	Rheumatoid arthritis;
LGG	cis	rs9397585	0.637	rs9478386	chr6:153402830	A/G	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg23758822	chr17:41437982	NA	0.88	15.39	0.58	1.8e-43	Menopause (age at onset);
LGG	cis	rs16966142	0.681	rs72813466	chr16:90049234	G/A	cg08854185	chr16:90077956	DBNDD1	-0.65	-7.77	-0.34	5.01e-14	Caffeine consumption;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18695931	chr4:887295	GAK	0.4	6.86	0.3	2.19e-11	Menarche (age at onset);
LGG	cis	rs1639906	0.560	rs1639915	chr7:2258084	C/G	cg08027265	chr7:2291960	NA	-0.55	-11.21	-0.46	5.73e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg27476859	chr7:2772710	GNA12	0.53	10.27	0.43	1.91e-22	Height;
LGG	cis	rs9611565	0.512	rs5758450	chr22:42141640	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.79	0.34	4.45e-14	Vitiligo;
LGG	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg04831495	chr15:85060580	GOLGA6L5	0.34	6.79	0.3	3.52e-11	Bulimia nervosa;
LGG	cis	rs9543976	0.623	rs7986566	chr13:76197931	C/T	cg01531495	chr13:76123901	UCHL3	0.52	6.65	0.3	8.12e-11	Diabetic retinopathy;
LGG	cis	rs66573146	0.831	rs56320732	chr4:6974319	G/A	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9443645	0.869	rs1507154	chr6:79503700	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.39	-0.36	5.8e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2346177	0.806	rs56048837	chr2:46656647	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.52	-9.54	-0.41	7.94e-20	HDL cholesterol;
LGG	trans	rs9859260	0.614	rs493661	chr3:195786489	T/A	cg23484912	chr5:273055	PDCD6	-0.41	-7.91	-0.35	1.89e-14	Mean corpuscular volume;
LGG	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.61	-0.44	1.09e-23	Initial pursuit acceleration;
LGG	cis	rs4684776	1.000	rs4684073	chr3:11557341	A/G	cg24705426	chr3:11550659	ATG7	-0.45	-8.15	-0.35	3.39e-15	Small vessel stroke;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs7681440	0.715	rs17016305	chr4:90791381	A/G	cg26578617	chr4:90757533	SNCA	-0.36	-6.96	-0.31	1.17e-11	Dementia with Lewy bodies;
LGG	cis	rs2688608	0.839	rs2633311	chr10:75598099	C/T	cg23231163	chr10:75533350	FUT11	0.4	6.77	0.3	3.88e-11	Inflammatory bowel disease;
LGG	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24125890	chr12:21654287	RECQL;GOLT1B	0.49	7.24	0.32	1.85e-12	Gut microbiome composition (summer);
LGG	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg23750338	chr8:142222470	SLC45A4	-0.57	-11.38	-0.47	1.24e-26	Immature fraction of reticulocytes;
LGG	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.17	0.36	2.9e-15	Colorectal cancer;
LGG	cis	rs35110281	0.633	rs2329593	chr21:45121987	T/C	cg04455712	chr21:45112962	RRP1B	0.53	9.78	0.41	1.14e-20	Mean corpuscular volume;
LGG	cis	rs7712401	0.601	rs246271	chr5:122212822	A/G	cg19412675	chr5:122181750	SNX24	0.42	6.89	0.3	1.88e-11	Mean platelet volume;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.39	-0.36	5.83e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.81	-0.34	3.73e-14	Height;
LGG	cis	rs9381040	0.655	rs6903444	chr6:41014220	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	0.4	7.01	0.31	8.33e-12	Alzheimer's disease (late onset);
LGG	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg05729581	chr11:3078854	CARS	-0.54	-9.37	-0.4	3.25e-19	Longevity;
LGG	cis	rs62209	0.948	rs201085	chr10:11011810	T/C	cg26901096	chr10:10994189	LOC254312	0.49	7.99	0.35	1.06e-14	Alzheimer's disease (late onset);
LGG	trans	rs7615952	0.575	rs35949599	chr3:125544202	G/A	cg07211511	chr3:129823064	LOC729375	-1.05	-15.08	-0.57	4.16e-42	Blood pressure (smoking interaction);
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.56	10.04	0.42	1.35e-21	Longevity;
LGG	cis	rs9467160	0.834	rs9467171	chr6:24455155	G/A	cg20631270	chr6:24437470	GPLD1	0.54	8.1	0.35	4.98e-15	Liver enzyme levels;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.67	-0.3	7.42e-11	Lung cancer;
LGG	trans	rs7762018	0.943	rs7772889	chr6:170142458	T/C	cg06875740	chr19:51307921	C19orf48	-0.62	-7.97	-0.35	1.29e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7660883	1.000	rs7660883	chr4:87982876	C/G	cg21988461	chr4:88008667	AFF1	0.31	8.47	0.37	3.38e-16	HDL cholesterol levels;
LGG	cis	rs6083	0.512	rs17269397	chr15:58857378	A/G	cg05156742	chr15:59063176	FAM63B	-0.48	-8.7	-0.37	5.76e-17	Schizophrenia;
LGG	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg12395012	chr8:11607386	GATA4	0.38	6.99	0.31	9.51e-12	Neuroticism;
LGG	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg13010199	chr12:38710504	ALG10B	-0.6	-11.72	-0.48	5.96e-28	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs7977186	chr12:34431486	C/G	cg13010199	chr12:38710504	ALG10B	0.69	13.63	0.54	8.6e-36	Morning vs. evening chronotype;
LGG	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg27478167	chr7:817139	HEATR2	-0.44	-7.03	-0.31	7.5e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs11239187	0.530	rs10900068	chr10:45062732	A/G	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.31e-18	Body mass index;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.5	-7.9	-0.34	2.01e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	cis	rs637571	0.584	rs659824	chr11:65636509	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.44	-7.16	-0.32	3.29e-12	Eosinophil percentage of white cells;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg05091796	chr16:4465799	CORO7	-0.61	-10.0	-0.42	1.91e-21	Schizophrenia;
LGG	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg06212747	chr3:49208901	KLHDC8B	0.43	6.89	0.31	1.78e-11	Resting heart rate;
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.25	0.32	1.78e-12	Schizophrenia;
LGG	cis	rs2228479	0.717	rs1061647	chr16:89806063	G/C	cg06558623	chr16:89946397	TCF25	1.1	12.09	0.49	1.98e-29	Skin colour saturation;
LGG	cis	rs7552404	0.731	rs12090849	chr1:76400261	A/G	cg03433033	chr1:76189801	ACADM	0.55	8.17	0.36	2.86e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3806843	0.900	rs116210441	chr5:140128649	T/A	cg19875535	chr5:140030758	IK	-0.54	-11.19	-0.46	7.1e-26	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19462523	chr3:181429908	SOX2;SOX2OT	0.47	7.83	0.34	3.36e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1355223	0.837	rs11600402	chr11:34691751	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.09	-0.31	5.07e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7937612	0.965	rs7131046	chr11:120238534	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.52	-0.5	3.48e-31	Intraocular pressure;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13129662	chr17:48227708	PPP1R9B	0.4	7.02	0.31	8.06e-12	Bilirubin levels;
LGG	trans	rs28595532	0.841	rs116582665	chr4:119487248	G/C	cg26518628	chr1:97050305	NA	-0.83	-6.82	-0.3	2.85e-11	Cannabis dependence symptom count;
LGG	cis	rs988958	0.526	rs10084239	chr2:42253746	G/T	cg27252766	chr2:42229092	NA	-0.55	-7.55	-0.33	2.41e-13	Hypospadias;
LGG	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg22906224	chr7:99728672	NA	-0.57	-9.34	-0.4	4.06e-19	Coronary artery disease;
LGG	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.47e-24	Aortic root size;
LGG	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12654349	chr5:56205094	C5orf35	0.81	12.32	0.5	2.26e-30	Initial pursuit acceleration;
LGG	cis	rs950169	0.580	rs11635597	chr15:85165699	C/T	cg24253500	chr15:84953950	NA	0.46	7.77	0.34	5.11e-14	Schizophrenia;
LGG	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg27490568	chr2:178487706	NA	1.07	19.78	0.68	1.41e-63	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05025164	chr4:1340916	KIAA1530	0.44	7.53	0.33	2.75e-13	Obesity-related traits;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.54	-10.55	-0.44	1.79e-23	Prudent dietary pattern;
LGG	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg22601191	chr20:60968625	CABLES2	0.41	7.89	0.34	2.19e-14	Colorectal cancer;
LGG	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg04450456	chr4:17643702	FAM184B	0.34	7.59	0.33	1.8e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg10883421	chr6:151773342	RMND1;C6orf211	0.69	14.53	0.56	1.12e-39	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg18478394	chr8:109455254	TTC35	0.4	7.97	0.35	1.25e-14	Dupuytren's disease;
LGG	cis	rs2797160	0.967	rs80303782	chr6:126004193	C/T	cg05901451	chr6:126070800	HEY2	-0.49	-8.0	-0.35	1.04e-14	Endometrial cancer;
LGG	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.88	-0.38	1.46e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Iron status biomarkers;
LGG	cis	rs8180040	0.932	rs62246474	chr3:47398130	C/T	cg16586182	chr3:47516702	SCAP	0.76	14.91	0.57	2.44e-41	Colorectal cancer;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg08355456	chr11:67383691	NA	0.44	7.69	0.34	9.11e-14	Mean corpuscular volume;
LGG	cis	rs7241530	0.585	rs12956802	chr18:75891002	G/A	cg14642773	chr18:75888474	NA	0.46	9.09	0.39	2.88e-18	Educational attainment (years of education);
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-9.78	-0.41	1.15e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg09222892	chr1:25734099	RHCE	0.46	9.47	0.4	1.43e-19	Erythrocyte sedimentation rate;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg11235426	chr6:292522	DUSP22	-0.59	-9.9	-0.42	4.53e-21	Menopause (age at onset);
LGG	trans	rs9929218	1.000	rs7186084	chr16:68816260	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	11.66	0.48	1.01e-27	Colorectal cancer;
LGG	cis	rs6772849	1.000	rs9848975	chr3:128311983	T/C	cg08795948	chr3:128337044	NA	0.53	8.66	0.37	8.1e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs11153147	0.649	rs10456863	chr6:109299092	A/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.37	-0.36	6.98e-16	Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4730250	0.707	rs78472146	chr7:106967491	C/A	cg02696742	chr7:106810147	HBP1	-0.73	-10.33	-0.43	1.19e-22	Osteoarthritis;
LGG	cis	rs4356203	0.870	rs214918	chr11:17239849	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.5e-14	Bipolar disorder;
LGG	cis	rs9291683	0.530	rs4235346	chr4:9945296	C/T	cg08250081	chr4:10125330	NA	-0.35	-6.68	-0.3	6.67e-11	Bone mineral density;
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.64	0.69	1.4e-67	Alzheimer's disease;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.5e-14	Bipolar disorder;
LGG	cis	rs10504130	0.660	rs79691523	chr8:52684733	C/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs6089584	0.888	rs2386555	chr20:60612373	C/T	cg06470251	chr20:60548479	NA	0.51	8.5	0.37	2.64e-16	Body mass index;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.0	0.42	1.83e-21	Longevity;
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22618164	chr12:122356400	WDR66	0.38	10.88	0.45	1.04e-24	Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.9	0.31	1.77e-11	Lung cancer;
LGG	cis	rs12580194	0.593	rs57050414	chr12:55776926	G/A	cg19537932	chr12:55886519	OR6C68	-0.55	-10.05	-0.42	1.25e-21	Cancer;
LGG	cis	rs7208859	0.623	rs1054397	chr17:29110196	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.8	0.45	2.17e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7617480	0.648	rs4858830	chr3:48734002	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.99	0.35	1.11e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg11693508	chr17:37793320	STARD3	0.52	7.43	0.33	5.3e-13	Bipolar disorder;
LGG	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.31	-0.36	1.06e-15	Depression;
LGG	cis	rs4330281	0.647	rs4243835	chr3:17706179	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg26597838	chr10:835615	NA	0.64	9.65	0.41	3.5e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs5769765	0.908	rs138891	chr22:50227741	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.73	-10.49	-0.44	3.18e-23	Schizophrenia;
LGG	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg15556689	chr8:8085844	FLJ10661	0.51	9.48	0.4	1.38e-19	Mood instability;
LGG	cis	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.17	-0.36	2.88e-15	Bipolar disorder;
LGG	trans	rs116095464	0.510	rs73016876	chr5:244475	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	trans	rs1814175	0.935	rs7950947	chr11:49668369	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.59	-0.47	1.93e-27	Height;
LGG	cis	rs4478858	0.735	rs6687819	chr1:31801112	G/A	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs60871478	1.000	rs4721124	chr7:823761	T/C	cg27478167	chr7:817139	HEATR2	-0.48	-7.49	-0.33	3.45e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs9467773	1.000	rs2224380	chr6:26553943	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.85e-52	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.59	-0.56	6.29e-40	Platelet count;
LGG	cis	rs35883536	0.588	rs17403878	chr1:101105310	C/T	cg06223162	chr1:101003688	GPR88	0.34	7.25	0.32	1.8e-12	Monocyte count;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg25072359	chr17:41440525	NA	0.52	9.87	0.42	5.38e-21	Menopause (age at onset);
LGG	cis	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg00405596	chr8:11794950	NA	-0.6	-10.67	-0.44	6.56e-24	Monocyte count;
LGG	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.34e-17	Self-reported allergy;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg18350739	chr11:68623251	NA	-0.87	-22.45	-0.72	4.75e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14490761	chr5:137878937	ETF1	-0.48	-7.25	-0.32	1.78e-12	Pancreatic cancer;
LGG	cis	rs2229238	0.911	rs7551873	chr1:154505857	A/G	cg10237817	chr1:154519846	TDRD10	-0.34	-6.96	-0.31	1.15e-11	Coronary heart disease;
LGG	cis	rs2860975	1.000	rs10159983	chr10:96774437	C/T	cg09036531	chr10:96991505	NA	-0.49	-8.83	-0.38	2.14e-17	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs4771450	0.962	rs4296133	chr13:103970481	G/C	cg02987523	chr13:103978230	NA	-0.32	-6.84	-0.3	2.54e-11	Uric acid levels;
LGG	cis	rs10791323	0.569	rs2298738	chr11:133715153	G/C	cg15485101	chr11:133734466	NA	0.61	10.57	0.44	1.52e-23	Childhood ear infection;
LGG	cis	rs12618769	0.681	rs72823792	chr2:99215142	G/A	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg14914809	chr2:171705073	GAD1	0.37	7.63	0.33	1.38e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	12.48	0.5	5.06e-31	Lung cancer in ever smokers;
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg00405596	chr8:11794950	NA	-0.43	-6.96	-0.31	1.18e-11	Neuroticism;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg05025164	chr4:1340916	KIAA1530	0.58	10.21	0.43	3.24e-22	Obesity-related traits;
LGG	cis	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg05623727	chr3:50126028	RBM5	0.32	6.9	0.31	1.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9863	0.861	rs10846579	chr12:124407403	C/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.03	-0.31	7.39e-12	White blood cell count;
LGG	cis	rs910187	0.605	rs6122559	chr20:45810617	T/G	cg27589058	chr20:45804311	EYA2	-0.37	-9.58	-0.41	5.76e-20	Migraine;
LGG	cis	rs9368481	0.743	rs9368480	chr6:26955750	A/C	cg12292205	chr6:26970375	C6orf41	0.78	15.76	0.59	4.1e-45	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12136530	0.651	rs10917438	chr1:19711749	A/G	cg17081867	chr1:19768096	CAPZB	0.31	6.78	0.3	3.76e-11	Lead levels in blood;
LGG	cis	rs3858526	0.584	rs10734559	chr11:5861788	A/C	cg05234568	chr11:5960015	NA	-0.63	-10.95	-0.45	5.85e-25	DNA methylation (variation);
LGG	cis	rs6977660	0.714	rs6976854	chr7:19818311	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	trans	rs61931739	0.500	rs6488211	chr12:34375620	A/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.22	-0.49	5.98e-30	Morning vs. evening chronotype;
LGG	cis	rs12155623	0.619	rs11775403	chr8:49877323	A/T	cg00325661	chr8:49890786	NA	0.51	8.9	0.38	1.25e-17	Sudden cardiac arrest;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.61	12.14	0.49	1.22e-29	Prudent dietary pattern;
LGG	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg09324608	chr17:30823087	MYO1D	0.33	7.96	0.35	1.38e-14	Schizophrenia;
LGG	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs1256531	0.661	rs11845391	chr14:66182378	A/G	cg15999311	chr14:65749247	NA	0.83	6.91	0.31	1.65e-11	Conduct disorder (symptom count);
LGG	cis	rs4742903	0.935	rs1889284	chr9:106926980	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.16	0.35	3.09e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9814567	0.752	rs1534029	chr3:134330213	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.69	-0.45	5.35e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9354308	0.764	rs9354326	chr6:66587473	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2976388	0.507	rs13279795	chr8:143838669	G/A	cg06565975	chr8:143823917	SLURP1	0.35	8.55	0.37	1.82e-16	Urinary tract infection frequency;
LGG	cis	rs7615952	0.576	rs2276729	chr3:125826214	G/A	cg05084668	chr3:125655381	ALG1L	-0.54	-7.33	-0.32	1.04e-12	Blood pressure (smoking interaction);
LGG	cis	rs8032158	0.702	rs12910830	chr15:56122664	T/C	cg02198044	chr15:56286336	NEDD4	-0.53	-9.0	-0.39	6.03e-18	Keloid;
LGG	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg03264133	chr6:25882463	NA	-0.57	-10.9	-0.45	9.05e-25	Blood metabolite levels;
LGG	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg12432903	chr7:1882776	MAD1L1	-0.51	-7.9	-0.34	2.06e-14	Bipolar disorder;
LGG	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg08885076	chr2:99613938	TSGA10	0.41	8.6	0.37	1.2e-16	Chronic sinus infection;
LGG	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	7.33	0.32	1.04e-12	Cognitive test performance;
LGG	cis	rs4363385	0.510	rs11488175	chr1:153039778	A/G	cg13444842	chr1:152974279	SPRR3	0.44	8.69	0.37	6.27e-17	Inflammatory skin disease;
LGG	cis	rs12368653	0.616	rs1027315	chr12:58034192	T/C	cg00700412	chr12:58011837	NA	0.4	7.96	0.35	1.34e-14	Multiple sclerosis;
LGG	cis	rs11676348	0.774	rs13397673	chr2:219047782	A/G	cg04731861	chr2:219085781	ARPC2	0.32	7.6	0.33	1.71e-13	Ulcerative colitis;
LGG	cis	rs6693567	0.565	rs1313569	chr1:150344171	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.78	0.3	3.61e-11	Migraine;
LGG	cis	rs8056064	0.739	rs35518553	chr16:82820768	C/G	cg08271366	chr16:82816457	CDH13	-0.46	-8.18	-0.36	2.68e-15	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.3	-0.4	5.62e-19	Type 2 diabetes;
LGG	cis	rs2270450	0.959	rs1805017	chr6:46684222	A/G	cg10156739	chr6:46714674	LOC100287718	0.36	8.25	0.36	1.7e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs1003719	0.688	rs2835660	chr21:38568882	G/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.87	-0.57	3.73e-41	Eye color traits;
LGG	cis	rs17102884	0.506	rs11845397	chr14:75404587	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.63	-11.44	-0.47	7.12e-27	Neuroticism;
LGG	trans	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12220238	0.722	rs4745749	chr10:76393742	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.5	6.72	0.3	5.22e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.78	14.07	0.55	1.15e-37	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg04672837	chr16:48644449	N4BP1	0.56	9.31	0.4	5.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg20503657	chr10:835505	NA	0.75	10.21	0.43	3.31e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.35e-13	HDL cholesterol;
LGG	cis	rs113835537	0.529	rs7943327	chr11:66256581	G/C	cg24851651	chr11:66362959	CCS	0.44	7.76	0.34	5.56e-14	Airway imaging phenotypes;
LGG	cis	rs975722	1.000	rs1208528	chr7:117339002	C/T	cg10524701	chr7:117356490	CTTNBP2	0.51	11.58	0.47	2.16e-27	Coronary artery disease;
LGG	cis	rs457717	1.000	rs2455219	chr5:75922581	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.35	7.27	0.32	1.52e-12	Hearing impairment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00328900	chr5:82769097	VCAN	0.42	6.72	0.3	5.36e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.568	rs5751159	chr22:42175365	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.1	-0.39	2.67e-18	Vitiligo;
LGG	cis	rs56235845	0.694	rs11738681	chr5:176761535	A/G	cg17509989	chr5:176798049	RGS14	0.67	11.03	0.46	2.85e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs1580019	0.510	rs4723162	chr7:32543804	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.58e-22	Cognitive ability;
LGG	cis	rs10274279	1.000	rs2021742	chr7:157381671	T/A	cg09270525	chr7:157391030	PTPRN2	0.74	9.61	0.41	4.56e-20	Myopia (pathological);
LGG	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg02269571	chr22:50332266	NA	0.65	10.31	0.43	1.4e-22	Schizophrenia;
LGG	cis	rs11229555	1.000	rs7102510	chr11:58371283	T/G	cg15696309	chr11:58395628	NA	-0.98	-17.39	-0.63	1.62e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg12458913	chr13:53173898	NA	-0.59	-10.32	-0.43	1.26e-22	Lewy body disease;
LGG	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.78	-0.57	8.88e-41	Calcium levels;
LGG	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg14675211	chr2:100938903	LONRF2	-0.63	-10.86	-0.45	1.25e-24	Intelligence (multi-trait analysis);
LGG	cis	rs10462794	0.853	rs1450827	chr5:4511087	A/C	cg18482690	chr5:4511582	NA	0.41	7.12	0.31	4.04e-12	DNA methylation (variation);
LGG	cis	rs3126085	0.935	rs4511111	chr1:152211624	C/G	cg26876637	chr1:152193138	HRNR	-0.49	-6.99	-0.31	9.83e-12	Atopic dermatitis;
LGG	cis	rs6546537	0.911	rs62133968	chr2:69891910	C/T	cg10773587	chr2:69614142	GFPT1	-0.44	-7.19	-0.32	2.55e-12	Serum thyroid-stimulating hormone levels;
LGG	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg23649088	chr2:200775458	C2orf69	0.61	8.12	0.35	4.26e-15	Schizophrenia;
LGG	trans	rs6089829	0.962	rs11086151	chr20:61664644	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs7000551	0.689	rs2449339	chr8:22387981	G/A	cg12081754	chr8:22256438	SLC39A14	0.67	12.77	0.51	3.46e-32	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs9399135	0.967	rs9402676	chr6:135355507	C/T	cg24558204	chr6:135376177	HBS1L	0.54	9.85	0.42	6.56e-21	Red blood cell count;
LGG	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.16	0.49	1.03e-29	Lung cancer in ever smokers;
LGG	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg04226714	chr8:49833948	SNAI2	0.49	8.69	0.37	6.38e-17	Life satisfaction;
LGG	trans	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg06521331	chr12:34319734	NA	0.44	7.99	0.35	1.07e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9914988	0.887	rs12947735	chr17:27156866	A/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.33	-0.32	1.01e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7572733	0.935	rs4850816	chr2:198789765	C/A	cg00792783	chr2:198669748	PLCL1	-0.49	-8.28	-0.36	1.37e-15	Dermatomyositis;
LGG	cis	rs28595532	0.920	rs114724233	chr4:119754918	T/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.44e-31	Motion sickness;
LGG	cis	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.78	-0.38	3.3e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.66	-0.48	1.02e-27	Schizophrenia;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.6	-11.85	-0.48	1.74e-28	Prudent dietary pattern;
LGG	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg26441486	chr22:50317300	CRELD2	0.42	7.89	0.34	2.14e-14	Schizophrenia;
LGG	trans	rs7395662	0.963	rs11499897	chr11:48717866	G/A	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg04025307	chr7:1156635	C7orf50	0.64	8.27	0.36	1.42e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg02297831	chr4:17616191	MED28	0.51	9.33	0.4	4.28e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4740619	0.568	rs2891008	chr9:15897536	T/A	cg14451791	chr9:16040625	NA	-0.28	-6.76	-0.3	4.09e-11	Body mass index;
LGG	cis	rs7659604	0.521	rs13130789	chr4:122690166	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	8.1	0.35	4.86e-15	Type 2 diabetes;
LGG	cis	rs34330	0.562	rs10845615	chr12:12863470	C/T	cg09462578	chr12:12878428	APOLD1	-0.57	-7.86	-0.34	2.81e-14	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1348850	0.958	rs10497501	chr2:178462299	C/G	cg27490568	chr2:178487706	NA	0.47	9.24	0.39	9.26e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9814567	0.752	rs4605591	chr3:134328361	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.69	-0.45	5.35e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10929925	0.966	rs2693834	chr2:6150778	G/A	cg00493617	chr2:6141445	NA	0.32	7.26	0.32	1.64e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs239198	0.534	rs1813223	chr6:101331909	C/T	cg09795085	chr6:101329169	ASCC3	0.42	6.94	0.31	1.3e-11	Menarche (age at onset);
LGG	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.47	-0.37	3.25e-16	Total body bone mineral density;
LGG	trans	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg25214090	chr10:38739885	LOC399744	-0.64	-11.52	-0.47	3.46e-27	Corneal astigmatism;
LGG	cis	rs8044995	0.706	rs111948678	chr16:68255959	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	Schizophrenia;
LGG	cis	rs908922	0.676	rs7529441	chr1:152531629	A/G	cg20991723	chr1:152506922	NA	0.71	14.43	0.56	3.02e-39	Hair morphology;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.05	-0.31	6.38e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1107366	0.750	rs9825571	chr3:125900161	A/G	cg11252792	chr3:125932053	NA	0.52	9.67	0.41	2.92e-20	Metabolite levels;
LGG	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	14.99	0.57	1.11e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs68170813	0.652	rs75136686	chr7:107180949	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-8.34	-0.36	8.83e-16	Coronary artery disease;
LGG	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg03795903	chr2:30669940	LCLAT1	0.61	7.95	0.35	1.49e-14	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs208515	0.560	rs207084	chr6:66776966	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.11	-28.66	-0.8	1.17e-104	Exhaled nitric oxide levels;
LGG	cis	rs4077515	0.967	rs11145874	chr9:139290011	G/A	cg21253087	chr9:139290292	SNAPC4	0.36	7.25	0.32	1.78e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3825932	0.961	rs10400881	chr15:79234384	G/C	cg25744700	chr15:79237217	CTSH	0.34	6.67	0.3	7.37e-11	Type 1 diabetes;
LGG	cis	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg13010199	chr12:38710504	ALG10B	0.7	14.02	0.55	1.84e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs751728	0.897	rs3806110	chr6:33770629	G/A	cg25922239	chr6:33757077	LEMD2	0.72	12.38	0.5	1.31e-30	Crohn's disease;
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg14092988	chr3:52407081	DNAH1	0.3	7.86	0.34	2.74e-14	Bipolar disorder;
LGG	cis	rs854037	0.698	rs67214905	chr5:57072318	G/A	cg08523694	chr5:57076192	NA	0.51	7.12	0.31	4.03e-12	Birth weight;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.534	rs12372721	chr12:34175301	C/T	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg15557168	chr22:42548783	NA	0.41	8.8	0.38	2.67e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg06606381	chr12:133084897	FBRSL1	-1.09	-10.38	-0.43	8.04e-23	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs7143963	0.832	rs4906272	chr14:103376031	C/T	cg23020514	chr14:103360112	TRAF3	0.48	8.89	0.38	1.35e-17	Body mass index;
LGG	cis	rs9916302	0.706	rs590051	chr17:37446571	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.33	0.63	3.17e-52	Response to antipsychotic treatment;
LGG	cis	rs910187	0.631	rs2228	chr20:45809941	G/A	cg27589058	chr20:45804311	EYA2	-0.36	-9.22	-0.39	1.09e-18	Migraine;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs8067545	0.611	rs7219615	chr17:20132558	T/A	cg13482628	chr17:19912719	NA	-0.52	-9.96	-0.42	2.61e-21	Schizophrenia;
LGG	trans	rs826838	0.967	rs11183622	chr12:38792849	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.64	-0.33	1.24e-13	Heart rate;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.26	0.32	1.69e-12	Obesity-related traits;
LGG	cis	rs889398	0.835	rs12925429	chr16:69801539	G/A	cg00738113	chr16:70207722	CLEC18C	0.24	6.83	0.3	2.6e-11	Body mass index;
LGG	cis	rs1620921	0.625	rs2465856	chr6:161271369	C/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2304069	0.614	rs216140	chr5:149443298	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.49	7.73	0.34	6.55e-14	HIV-1 control;
LGG	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.84e-13	Menopause (age at onset);
LGG	cis	rs9326248	0.603	rs7396061	chr11:116750874	A/C	cg20608306	chr11:116969690	SIK3	0.42	13.49	0.53	3.18e-35	Blood protein levels;
LGG	cis	rs9560113	1.000	rs914026	chr13:112182029	G/A	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.66e-12	Menarche (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg19932177	chr13:34392073	RFC3	-0.52	-7.99	-0.35	1.1e-14	Pancreatic cancer;
LGG	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.69	13.12	0.52	1.15e-33	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg20607798	chr8:58055168	NA	0.77	8.51	0.37	2.43e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6831352	0.918	rs29001232	chr4:100046654	G/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.79	-0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs10791097	0.694	rs2236711	chr11:130739284	G/A	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7737355	0.812	rs28610	chr5:130832382	T/C	cg06307176	chr5:131281290	NA	0.51	8.55	0.37	1.86e-16	Life satisfaction;
LGG	cis	rs9486715	0.758	rs9386528	chr6:96928514	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-14.34	-0.55	7.53e-39	Headache;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.48e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3820068	0.705	rs16851727	chr1:15857918	C/T	cg05660106	chr1:15850417	CASP9	1.12	27.01	0.78	3.75e-97	Systolic blood pressure;
LGG	cis	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg00405596	chr8:11794950	NA	0.63	10.78	0.45	2.5300000000000002e-24	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs16976116	0.901	rs28589384	chr15:55494366	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6688613	0.729	rs7545806	chr1:166938555	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.48	7.06	0.31	6.01e-12	Refractive astigmatism;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg02002194	chr4:3960332	NA	0.44	8.04	0.35	7.63e-15	Triglycerides;
LGG	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.89	-0.34	2.27e-14	Initial pursuit acceleration;
LGG	cis	rs17039065	0.920	rs9790677	chr4:109443588	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.8	0.34	4.24e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12724450	0.655	rs11801190	chr1:150484004	G/A	cg03818307	chr1:150480534	ECM1	0.48	6.87	0.3	2.1e-11	Blood protein levels;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg25072359	chr17:41440525	NA	0.51	10.06	0.42	1.15e-21	Menopause (age at onset);
LGG	cis	rs7827545	0.644	rs3739427	chr8:135524938	T/C	cg17885191	chr8:135476712	NA	-0.5	-8.28	-0.36	1.34e-15	Hypertension (SNP x SNP interaction);
LGG	cis	rs11785400	0.753	rs9694286	chr8:143737157	G/T	cg10596483	chr8:143751796	JRK	0.51	8.0	0.35	1.04e-14	Schizophrenia;
LGG	trans	rs2727020	0.786	rs10839263	chr11:49354462	A/G	cg15704280	chr7:45808275	SEPT13	-0.81	-13.54	-0.53	2.05e-35	Coronary artery disease;
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg15665833	chr6:26285013	NA	0.42	8.13	0.35	4.07e-15	Educational attainment;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg05665937	chr4:1216051	CTBP1	0.49	8.68	0.37	6.71e-17	Obesity-related traits;
LGG	cis	rs2652834	0.851	rs2652795	chr15:63409265	T/C	cg05507819	chr15:63340323	TPM1	0.5	7.03	0.31	7.23e-12	HDL cholesterol;
LGG	cis	rs1577917	0.545	rs9294338	chr6:86474368	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.49	8.42	0.36	4.82e-16	Response to antipsychotic treatment;
LGG	cis	rs854765	0.647	rs9303144	chr17:17977355	T/C	cg04398451	chr17:18023971	MYO15A	-0.79	-17.0	-0.62	9.89e-51	Total body bone mineral density;
LGG	cis	rs35306767	0.904	rs10904584	chr10:983747	A/T	cg25019033	chr10:957182	NA	-0.59	-12.06	-0.49	2.62e-29	Eosinophil percentage of granulocytes;
LGG	cis	rs504918	0.584	rs9847323	chr3:123985684	C/T	cg05766129	chr3:123988013	KALRN	0.62	11.82	0.48	2.24e-28	Schizophrenia;
LGG	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg03060546	chr3:49711283	APEH	-0.63	-10.38	-0.43	7.65e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs965513	1.000	rs7847663	chr9:100544868	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.46	-0.4	1.55e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs2732480	0.538	rs1387260	chr12:48703091	A/C	cg24011408	chr12:48396354	COL2A1	0.51	8.07	0.35	6.18e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs7181230	0.922	rs4924410	chr15:40339494	A/C	cg22705835	chr10:65332833	REEP3	0.57	9.44	0.4	1.85e-19	Dehydroepiandrosterone sulphate levels;
LGG	trans	rs11992162	0.573	rs13275808	chr8:11782815	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.06	-0.35	6.5e-15	Monocyte count;
LGG	cis	rs3857536	0.813	rs9360190	chr6:66942302	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.77	-0.48	3.72e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2806731	0.581	rs9596839	chr13:54264395	G/A	ch.13.53330881F	chr13:54432880	NA	0.43	6.97	0.31	1.11e-11	Obesity-related traits;
LGG	cis	rs853679	0.517	rs6932109	chr6:28078303	A/G	cg18032046	chr6:28092343	ZSCAN16	0.55	7.47	0.33	4.15e-13	Depression;
LGG	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg26818010	chr10:134567672	INPP5A	-0.72	-11.18	-0.46	7.38e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6694672	1.000	rs4350226	chr1:197132378	G/A	cg13682187	chr1:196946512	CFHR5	0.48	6.76	0.3	4.06e-11	Asthma;
LGG	cis	rs4650994	0.571	rs6676507	chr1:178508743	C/G	cg12486710	chr1:178512616	C1orf220	-0.34	-6.71	-0.3	5.8e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17030434	0.906	rs11099901	chr4:154671468	T/A	cg14289246	chr4:154710475	SFRP2	-0.72	-11.14	-0.46	1.1e-25	Electrocardiographic conduction measures;
LGG	cis	rs1153858	0.725	rs74572151	chr15:45647526	T/G	cg10760299	chr15:45669010	GATM	0.41	8.09	0.35	5.19e-15	Homoarginine levels;
LGG	cis	rs7737355	1.000	rs257390	chr5:130740617	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.69	-0.37	6.23e-17	Life satisfaction;
LGG	cis	rs3087591	0.960	rs2905797	chr17:29537458	G/C	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs55871839	0.708	rs10112089	chr8:59813429	C/T	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	trans	rs637571	0.607	rs589253	chr11:65693080	G/A	cg17712092	chr4:129076599	LARP1B	0.87	17.63	0.63	1.29e-53	Eosinophil percentage of white cells;
LGG	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg13009111	chr11:71350975	NA	0.35	7.6	0.33	1.63e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12135191	0.967	rs12724870	chr1:236467533	G/A	cg21399712	chr1:236511386	NA	-0.39	-7.5	-0.33	3.18e-13	Urate levels (BMI interaction);
LGG	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg24375607	chr4:120327624	NA	0.6	10.09	0.42	8.88e-22	Corneal astigmatism;
LGG	cis	rs17102423	0.593	rs11624558	chr14:65615653	T/C	cg11161011	chr14:65562177	MAX	-0.74	-13.02	-0.52	3.12e-33	Obesity-related traits;
LGG	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg15596359	chr8:11213517	TDH	0.42	8.73	0.38	4.49e-17	Retinal vascular caliber;
LGG	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg05555928	chr11:63887634	MACROD1	0.42	7.73	0.34	6.76e-14	Platelet count;
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs13257813	0.727	rs691619	chr8:19028849	A/G	cg15587955	chr8:19026658	NA	0.46	6.97	0.31	1.07e-11	Mean platelet volume;
LGG	cis	rs4665809	1.000	rs4665816	chr2:26305094	G/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.65	-0.33	1.2e-13	Gut microbiome composition (summer);
LGG	cis	rs7954584	0.611	rs3887885	chr12:122336486	C/T	cg22618164	chr12:122356400	WDR66	0.39	11.98	0.49	5.3e-29	Mean corpuscular volume;
LGG	cis	rs2576037	0.526	rs10853547	chr18:44530548	A/C	cg19077165	chr18:44547161	KATNAL2	-0.59	-11.18	-0.46	7.25e-26	Personality dimensions;
LGG	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg00409905	chr10:38381863	ZNF37A	-0.66	-13.42	-0.53	6.18e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487094	0.961	rs11153180	chr6:109744441	C/T	cg01125227	chr6:109776195	MICAL1	0.53	8.97	0.38	7.31e-18	Height;
LGG	cis	rs546131	0.928	rs553789	chr11:34827579	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	11.01	0.46	3.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs4363385	0.720	rs6680624	chr1:152983872	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.99e-18	Inflammatory skin disease;
LGG	cis	rs897984	0.520	rs12928081	chr16:30885159	T/G	cg02466173	chr16:30829666	NA	0.51	8.38	0.36	6.56e-16	Dementia with Lewy bodies;
LGG	cis	rs2204008	0.627	rs10878486	chr12:38148601	T/G	cg13010199	chr12:38710504	ALG10B	0.69	13.75	0.54	2.51e-36	Bladder cancer;
LGG	cis	rs9326248	0.861	rs494356	chr11:117071970	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.59	6.68	0.3	6.69e-11	Blood protein levels;
LGG	cis	rs9859260	0.744	rs539816	chr3:195784076	T/A	cg01181863	chr3:195395398	SDHAP2	0.48	7.38	0.32	7.3e-13	Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs13357713	chr5:93145423	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.66	0.41	3.09e-20	Diabetic retinopathy;
LGG	cis	rs11771526	0.901	rs11771230	chr7:32315546	C/T	cg27532318	chr7:32358331	NA	-0.71	-7.23	-0.32	1.98e-12	Body mass index;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.75	-0.64	3.78e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs11785400	1.000	rs4484678	chr8:143730796	A/G	cg24634471	chr8:143751801	JRK	0.53	8.41	0.36	5.25e-16	Schizophrenia;
LGG	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.95	10.48	0.44	3.21e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3126085	0.935	rs12063165	chr1:152176357	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.83	0.38	2.21e-17	Atopic dermatitis;
LGG	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.37	-0.32	8.08e-13	Total cholesterol levels;
LGG	cis	rs9290877	0.667	rs9820669	chr3:188462854	T/C	cg17392043	chr3:188495102	LPP	-0.45	-7.87	-0.34	2.47e-14	IgE levels;
LGG	cis	rs4517514	0.509	rs12417652	chr11:89905239	T/G	cg14505434	chr11:89522851	NA	0.61	7.84	0.34	3.2e-14	Trans fatty acid levels;
LGG	cis	rs9636252	0.887	rs1397496	chr2:9263253	G/A	cg20341998	chr2:9276514	NA	0.38	6.94	0.31	1.33e-11	IgG glycosylation;
LGG	cis	rs9487094	1.000	rs9480933	chr6:109671391	C/G	cg01125227	chr6:109776195	MICAL1	0.44	7.44	0.33	4.86e-13	Height;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg18427987	chr14:74551089	LIN52;ALDH6A1	-0.38	-6.88	-0.3	1.96e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs7937840	0.597	rs3867138	chr11:61911422	C/T	cg01969543	chr11:61895209	INCENP	-0.41	-7.05	-0.31	6.39e-12	Breast cancer;
LGG	cis	rs1719271	0.831	rs1002311	chr15:65188424	C/G	cg11671771	chr15:65133392	PLEKHO2	0.5	7.12	0.31	4.25e-12	Platelet count;
LGG	trans	rs3780486	0.846	rs4584234	chr9:33147479	G/A	cg04842962	chr6:43655489	MRPS18A	1.09	23.27	0.73	6.84e-80	IgG glycosylation;
LGG	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.35	-6.72	-0.3	5.23e-11	Educational attainment;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.88	-0.45	1.03e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg15921436	chr17:44337874	NA	-0.54	-11.56	-0.47	2.6e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs240764	0.621	rs11752659	chr6:101212241	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.92	-0.35	1.8e-14	Neuroticism;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg15948088	chr11:109293068	C11orf87	0.51	8.94	0.38	9.5e-18	Schizophrenia;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg08742575	chr21:47604166	C21orf56	0.57	10.26	0.43	2.16e-22	Testicular germ cell tumor;
LGG	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg24675658	chr1:53192096	ZYG11B	0.52	9.26	0.4	7.96e-19	Monocyte count;
LGG	cis	rs2880765	0.835	rs7180213	chr15:86021187	G/A	cg10818794	chr15:86012489	AKAP13	-0.39	-8.28	-0.36	1.3e-15	Coronary artery disease;
LGG	trans	rs9650657	0.623	rs7004253	chr8:10600857	A/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.37	-0.32	7.75e-13	Neuroticism;
LGG	cis	rs4077515	1.000	rs10781499	chr9:139266405	G/A	cg21253087	chr9:139290292	SNAPC4	0.35	7.06	0.31	6.18e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4740619	0.525	rs7866641	chr9:15812396	C/T	cg14451791	chr9:16040625	NA	0.3	7.36	0.32	8.61e-13	Body mass index;
LGG	cis	rs2735413	0.563	rs72800909	chr16:78047502	T/C	cg04733911	chr16:78082701	NA	0.56	7.45	0.33	4.77e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs870825	0.929	rs72689258	chr4:185590550	G/C	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	cis	rs2905347	0.591	rs12155285	chr7:22678637	G/A	cg23521230	chr7:22704884	NA	0.38	6.96	0.31	1.21e-11	Major depression and alcohol dependence;
LGG	trans	rs2018683	1.000	rs4719963	chr7:29011064	A/G	cg19402173	chr7:128379420	CALU	0.69	13.35	0.53	1.29e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.74	0.38	4.26e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg03477792	chr4:77819574	ANKRD56	0.5	8.8	0.38	2.64e-17	Emphysema distribution in smoking;
LGG	cis	rs950776	0.518	rs12910978	chr15:78810017	A/G	cg16751781	chr15:78858589	CHRNA5	0.47	9.2	0.39	1.24e-18	Sudden cardiac arrest;
LGG	cis	rs12497850	0.863	rs4974084	chr3:48939080	G/A	cg06212747	chr3:49208901	KLHDC8B	0.68	11.44	0.47	7.08e-27	Parkinson's disease;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs13119913	chr4:98977983	G/T	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg25237894	chr2:233734115	C2orf82	-0.57	-10.69	-0.44	5.66e-24	Coronary artery disease;
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs9733	0.818	rs7520022	chr1:150659173	C/G	cg13175981	chr1:150552382	MCL1	0.54	9.08	0.39	3.09e-18	Tonsillectomy;
LGG	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-11.46	-0.47	5.89e-27	Height;
LGG	cis	rs7216064	0.651	rs12947658	chr17:65903006	A/G	cg12091567	chr17:66097778	LOC651250	0.49	7.89	0.34	2.23e-14	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4148087	0.858	rs28435557	chr21:43634623	A/G	cg10192877	chr21:43641690	ABCG1	-0.4	-7.02	-0.31	7.97e-12	Eating disorder in bipolar disorder;
LGG	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.45e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs739401	0.611	rs391188	chr11:3047634	G/A	cg08508325	chr11:3079039	CARS	-0.61	-13.5	-0.53	2.93e-35	Longevity;
LGG	cis	rs4650994	0.544	rs2476560	chr1:178594919	A/G	cg12486710	chr1:178512616	C1orf220	-0.51	-10.56	-0.44	1.73e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4888262	0.508	rs4544266	chr16:74660993	C/A	cg01733217	chr16:74700730	RFWD3	0.82	15.27	0.58	6.01e-43	Testicular germ cell tumor;
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg15556689	chr8:8085844	FLJ10661	0.41	7.2	0.32	2.42e-12	Monocyte count;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg11859384	chr17:80120422	CCDC57	0.45	7.95	0.35	1.46e-14	Life satisfaction;
LGG	cis	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-13.1	-0.52	1.45e-33	Cognitive test performance;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.45	0.4	1.66e-19	Height;
LGG	cis	rs13314892	0.764	rs62251019	chr3:69859651	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.69e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500395	1.000	rs2355297	chr16:48685338	T/C	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg25019033	chr10:957182	NA	-0.55	-9.99	-0.42	2.14e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs11758351	0.518	rs78871852	chr6:26221566	A/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.09	0.39	2.81e-18	Gout;Renal underexcretion gout;
LGG	cis	rs10791323	0.569	rs1944734	chr11:133720077	G/A	cg00579200	chr11:133705235	NA	-0.59	-11.22	-0.46	5.04e-26	Childhood ear infection;
LGG	cis	rs12586317	0.547	rs45531432	chr14:35484423	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.63	0.54	8.18e-36	Psoriasis;
LGG	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs62400317	0.859	rs10948204	chr6:45124300	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs9486719	0.741	rs976356	chr6:96849437	T/A	cg06623918	chr6:96969491	KIAA0776	0.73	9.82	0.42	8.34e-21	Migraine;Coronary artery disease;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs2415984	0.622	rs10147795	chr14:46936528	C/T	cg14871534	chr14:47121158	RPL10L	-0.57	-10.17	-0.43	4.43e-22	Number of children ever born;
LGG	cis	rs10462794	0.756	rs896133	chr5:4511589	C/T	cg18482690	chr5:4511582	NA	0.43	7.59	0.33	1.72e-13	DNA methylation (variation);
LGG	cis	rs360798	0.512	rs2058566	chr2:63179076	C/T	cg17519650	chr2:63277830	OTX1	0.47	7.67	0.34	1.04e-13	Coronary artery disease;
LGG	cis	rs11785400	0.753	rs9773415	chr8:143731170	G/A	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.34e-14	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08491964	chr18:53255771	TCF4	0.38	6.71	0.3	5.54e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7613875	0.620	rs2526747	chr3:50082914	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	7.21	0.32	2.28e-12	Body mass index;
LGG	cis	rs7953249	0.807	rs2393791	chr12:121423956	A/G	cg14101638	chr12:121416612	HNF1A	0.36	8.18	0.36	2.68e-15	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs523522	0.923	rs1048830	chr12:120882217	G/T	cg12219531	chr12:120966889	COQ5	0.61	9.73	0.41	1.69e-20	High light scatter reticulocyte count;
LGG	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg25019033	chr10:957182	NA	-0.54	-9.18	-0.39	1.42e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9902453	1.000	rs56280226	chr17:28429575	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.12	0.52	1.14e-33	Coffee consumption (cups per day);
LGG	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg18937875	chr11:14930189	NA	-0.49	-8.02	-0.35	8.86e-15	Vitamin D levels;
LGG	cis	rs4629710	0.645	rs34601891	chr6:131551238	C/T	cg12606694	chr6:131520996	AKAP7	0.51	8.37	0.36	6.92e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs3862030	0.839	rs12570859	chr10:104257226	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-10.2	-0.43	3.52e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg02023728	chr11:77925099	USP35	0.44	7.91	0.35	1.88e-14	Testicular germ cell tumor;
LGG	cis	rs611744	0.625	rs11779824	chr8:109278689	G/A	cg21045802	chr8:109455806	TTC35	0.53	9.94	0.42	3.22e-21	Dupuytren's disease;
LGG	cis	rs41271473	1.000	rs41270187	chr1:228878871	T/C	cg00850481	chr1:228891306	NA	-0.48	-8.28	-0.36	1.3e-15	Chronic lymphocytic leukemia;
LGG	trans	rs2727020	0.729	rs2866328	chr11:49282421	A/G	cg11707556	chr5:10655725	ANKRD33B	0.51	9.78	0.41	1.13e-20	Coronary artery disease;
LGG	cis	rs6951245	0.505	rs56117635	chr7:1030034	G/C	cg18402987	chr7:1209562	NA	0.61	6.77	0.3	3.89e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.01	-0.55	2e-37	Alzheimer's disease;
LGG	cis	rs7765175	0.598	rs2637534	chr6:113654133	A/G	cg26552650	chr6:113682475	NA	-0.33	-7.4	-0.33	6.55e-13	Coronary artery calcification;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21862992	chr11:68658383	NA	0.52	8.49	0.37	2.91e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs35110281	0.686	rs162399	chr21:44950020	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.6	0.47	1.77e-27	Mean corpuscular volume;
LGG	cis	rs7659604	1.000	rs35249024	chr4:122664538	C/A	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.93	-0.31	1.4e-11	Type 2 diabetes;
LGG	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg26039829	chr8:22132926	PIWIL2	0.54	12.3	0.5	2.69e-30	Hypertriglyceridemia;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.91	-0.35	1.93e-14	Joint mobility (Beighton score);
LGG	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.22	-0.32	2.1e-12	Mood instability;
LGG	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.83e-29	Chronic sinus infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02399570	chr3:156877196	CCNL1	0.44	7.38	0.32	7.4e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg03264133	chr6:25882463	NA	-0.49	-8.85	-0.38	1.88e-17	Height;
LGG	cis	rs6089584	0.606	rs7270469	chr20:60577258	G/A	cg13770153	chr20:60521292	NA	-0.44	-7.3	-0.32	1.27e-12	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21925296	chr8:22102597	POLR3D;MIR320A	-0.39	-7.3	-0.32	1.25e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg03098644	chr7:100410630	EPHB4	0.47	7.16	0.32	3.22e-12	Other erythrocyte phenotypes;
LGG	cis	rs2494938	0.766	rs707973	chr6:40530686	T/G	cg14084896	chr6:40530702	LRFN2	-0.31	-6.81	-0.3	3.04e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg21724239	chr8:58056113	NA	0.52	7.49	0.33	3.46e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12681288	0.523	rs11137122	chr8:954702	A/G	cg15309053	chr8:964076	NA	0.38	8.03	0.35	8.13e-15	Schizophrenia;
LGG	cis	rs2046867	0.818	rs6786469	chr3:72873809	A/G	cg26655873	chr3:72818019	SHQ1	0.37	7.24	0.32	1.92e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2549003	1.000	rs13170412	chr5:131823519	A/G	cg21138405	chr5:131827807	IRF1	0.38	10.07	0.42	1.03e-21	Asthma (sex interaction);
LGG	cis	rs611744	0.967	rs859788	chr8:109227570	A/G	cg21045802	chr8:109455806	TTC35	0.37	6.68	0.3	7.04e-11	Dupuytren's disease;
LGG	cis	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.26e-25	Resting heart rate;
LGG	cis	rs9486715	0.867	rs4839842	chr6:96955387	A/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.9	0.59	1e-45	Headache;
LGG	cis	rs6835098	0.961	rs17322893	chr4:174122556	A/G	cg08422745	chr4:174089978	GALNT7	0.85	14.56	0.56	8.07e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs7932354	0.528	rs10838654	chr11:47095511	G/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.8	-0.41	9.96e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs4595586	0.545	rs925827	chr12:39364307	C/T	cg13010199	chr12:38710504	ALG10B	0.42	7.73	0.34	6.63e-14	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg02725872	chr8:58115012	NA	-0.76	-10.71	-0.45	4.79e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg23782820	chr8:58130467	NA	0.5	6.93	0.31	1.42e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7010267	0.935	rs11573829	chr8:119959623	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.43	0.44	5.18e-23	Total body bone mineral density (age 45-60);
LGG	trans	rs2727020	0.658	rs10839269	chr11:49385596	A/G	cg03929089	chr4:120376271	NA	-0.95	-20.3	-0.69	5.39e-66	Coronary artery disease;
LGG	cis	rs2274273	0.624	rs10141396	chr14:55816925	A/C	cg04306507	chr14:55594613	LGALS3	0.53	12.29	0.5	3.02e-30	Protein biomarker;
LGG	cis	rs2236918	1.000	rs1629051	chr1:242026344	A/G	cg17736920	chr1:242011382	EXO1	-0.53	-9.42	-0.4	2.09e-19	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.66	0.37	7.79e-17	Personality dimensions;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg14789911	chr21:47582049	C21orf56	-0.52	-9.34	-0.4	4.18e-19	Testicular germ cell tumor;
LGG	cis	rs1915146	0.904	rs28414241	chr10:126851739	A/T	cg03862225	chr10:126850454	CTBP2	0.26	7.18	0.32	2.79e-12	Menarche (age at onset);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg15586420	chr15:90294517	MESP1	0.37	6.79	0.3	3.37e-11	Bilirubin levels;
LGG	cis	rs10489202	1.000	rs7538251	chr1:168001752	C/G	cg24449463	chr1:168025552	DCAF6	-0.62	-9.88	-0.42	5.26e-21	Schizophrenia;
LGG	cis	rs7851660	0.839	rs2417575	chr9:100628642	G/A	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs2072499	0.966	rs2842869	chr1:156160696	A/G	cg25208724	chr1:156163844	SLC25A44	1.27	32.35	0.83	6.52e-121	Testicular germ cell tumor;
LGG	cis	rs16854884	0.632	rs10513234	chr3:143670957	A/G	cg06585982	chr3:143692056	C3orf58	-0.58	-9.81	-0.41	9.43e-21	Economic and political preferences (feminism/equality);
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg23262073	chr20:60523788	NA	-0.63	-9.82	-0.42	8.49e-21	Obesity-related traits;
LGG	cis	rs42648	0.935	rs42621	chr7:89956484	A/G	cg25739043	chr7:89950458	NA	-0.42	-8.97	-0.38	7.34e-18	Homocysteine levels;
LGG	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs13102973	1.000	rs13127573	chr4:135900768	C/A	cg14419869	chr4:135874104	NA	0.56	10.36	0.43	9.64e-23	Subjective well-being;
LGG	cis	rs7408868	1.000	rs8107180	chr19:15275430	T/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24131141	chr5:1270787	TERT	0.35	6.81	0.3	2.95e-11	Menarche (age at onset);
LGG	cis	rs2730245	0.527	rs2527187	chr7:158716912	T/C	cg11984989	chr7:158649758	WDR60	-1.0	-14.41	-0.56	3.78e-39	Height;
LGG	cis	rs283228	1.000	rs705629	chr6:101734815	A/T	cg27451362	chr6:101846650	GRIK2	-0.53	-8.84	-0.38	1.95e-17	Coenzyme Q10 levels;
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.0	-0.31	8.81e-12	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20011833	chr6:90348585	LYRM2	-0.46	-7.05	-0.31	6.56e-12	Pancreatic cancer;
LGG	cis	rs13191362	0.872	rs13213421	chr6:163203805	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.32	0.32	1.11e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg11062466	chr8:58055876	NA	0.48	8.22	0.36	2.09e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs317689	0.819	rs317660	chr12:69686203	G/A	cg14784868	chr12:69753453	YEATS4	0.44	6.66	0.3	7.68e-11	Response to diuretic therapy;
LGG	cis	rs55665837	0.540	rs12290926	chr11:14695046	A/G	cg18937875	chr11:14930189	NA	-0.49	-8.03	-0.35	7.91e-15	Vitamin D levels;
LGG	cis	rs58688157	0.960	rs1061502	chr11:614318	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.5	-0.4	1.14e-19	Systemic lupus erythematosus;
LGG	cis	rs2694528	0.858	rs6862622	chr5:60395289	T/A	cg11474532	chr5:59995715	DEPDC1B	0.67	7.22	0.32	2.15e-12	Parkinson's disease;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg13701509	chr5:170833685	NPM1	0.37	6.77	0.3	3.83e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs1620921	0.711	rs1937479	chr6:161255544	C/T	cg01280913	chr6:161186852	NA	-0.33	-6.73	-0.3	4.93e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg04450456	chr4:17643702	FAM184B	0.3	6.7	0.3	6e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11644478	chr21:40555479	PSMG1	0.92	17.59	0.63	2.07e-53	Cognitive function;
LGG	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.55	-10.57	-0.44	1.6e-23	Coronary artery disease;
LGG	cis	rs919433	0.679	rs55656916	chr2:198519628	T/C	cg00792783	chr2:198669748	PLCL1	0.57	9.25	0.39	8.52e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.09	0.42	9.12e-22	Prudent dietary pattern;
LGG	cis	rs8016982	0.674	rs1951615	chr14:81671762	G/A	cg01989461	chr14:81687754	GTF2A1	0.79	19.89	0.68	4.2e-64	Schizophrenia;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg23302884	chr18:44338147	ST8SIA5	0.46	9.22	0.39	1.05e-18	Personality dimensions;
LGG	cis	rs7666738	0.830	rs58367603	chr4:99015350	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.18e-29	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg19717773	chr7:2847554	GNA12	-0.33	-6.89	-0.3	1.82e-11	Height;
LGG	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg08498830	chr11:832797	CD151	-0.45	-7.34	-0.32	9.82e-13	Mean platelet volume;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg07120314	chr15:79043507	NA	-0.72	-16.9	-0.62	2.92e-50	Coronary artery disease or large artery stroke;
LGG	cis	rs1620921	0.564	rs67591610	chr6:161268474	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg12386194	chr3:101231763	SENP7	-0.47	-8.48	-0.37	3.03e-16	Colorectal cancer;
LGG	cis	rs6964587	0.692	rs12536220	chr7:91805595	T/G	cg17063962	chr7:91808500	NA	0.55	10.55	0.44	1.78e-23	Breast cancer;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25072359	chr17:41440525	NA	0.51	9.7	0.41	2.29e-20	Menopause (age at onset);
LGG	cis	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.45	0.33	4.77e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg11477892	chr4:106580295	NA	-0.42	-6.84	-0.3	2.51e-11	Post bronchodilator FEV1;
LGG	trans	rs6601327	0.606	rs4841204	chr8:9583407	G/A	cg16141378	chr3:129829833	LOC729375	0.36	8.06	0.35	6.53e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.26	-0.36	1.54e-15	Restless legs syndrome;
LGG	cis	rs4742903	0.904	rs10991187	chr9:106996271	C/T	cg14250997	chr9:106856677	SMC2	0.36	7.6	0.33	1.68e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1475911	0.708	rs8129075	chr21:43523430	G/T	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.59	-9.83	-0.42	7.52e-21	IgG glycosylation;
LGG	cis	rs757278	0.704	rs4730802	chr7:117380622	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.38	-6.89	-0.3	1.83e-11	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.19e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.698	rs4731216	chr7:124466512	T/G	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg24450063	chr1:156163899	SLC25A44	1.25	31.98	0.83	2.58e-119	Testicular germ cell tumor;
LGG	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21659725	chr3:3221576	CRBN	0.74	13.98	0.54	2.77e-37	Intelligence (multi-trait analysis);
LGG	cis	rs950169	0.922	rs2033284	chr15:84946273	C/T	cg24253500	chr15:84953950	NA	0.57	10.18	0.43	4.26e-22	Schizophrenia;
LGG	cis	rs4242434	0.892	rs71513892	chr8:22456517	C/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.25	-0.36	1.67e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3796352	0.527	rs11714793	chr3:52924930	A/G	cg04865290	chr3:52927548	TMEM110	-0.5	-7.91	-0.34	1.94e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs490234	0.966	rs829312	chr9:128377873	C/T	cg14078157	chr9:128172775	NA	-0.39	-7.41	-0.33	6.23e-13	Mean arterial pressure;
LGG	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg23306229	chr2:178417860	TTC30B	0.72	8.77	0.38	3.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.34	-0.58	3.2e-43	Chronic sinus infection;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg14338887	chr6:42928500	GNMT	0.27	8.9	0.38	1.23e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7107174	1.000	rs10899469	chr11:78018313	T/C	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs6723226	0.698	rs13409142	chr2:32666137	C/T	cg02381751	chr2:32503542	YIPF4	0.68	11.44	0.47	7.29e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.33	-0.36	9.09e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs477692	0.699	rs576175	chr10:131386408	A/T	cg05714579	chr10:131428358	MGMT	0.47	9.1	0.39	2.69e-18	Response to temozolomide;
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg24634471	chr8:143751801	JRK	-0.51	-8.02	-0.35	8.92e-15	Schizophrenia;
LGG	cis	rs2688608	0.587	rs2894040	chr10:75478159	A/C	cg19442545	chr10:75533431	FUT11	-0.43	-7.04	-0.31	6.77e-12	Inflammatory bowel disease;
LGG	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.36	-0.43	9.43e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7635838	0.686	rs347589	chr3:11288419	A/G	cg00170343	chr3:11313890	ATG7	0.57	9.57	0.41	6.67e-20	HDL cholesterol;
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.48	-0.33	3.87e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg14952266	chr13:112191215	NA	0.5	10.49	0.44	2.94e-23	Hepatitis;
LGG	cis	rs9807989	0.507	rs7584093	chr2:102997721	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.19e-20	Asthma;
LGG	cis	rs785830	0.811	rs661356	chr9:244457	G/A	cg14500300	chr9:211689	NA	0.28	6.69	0.3	6.57e-11	Platelet distribution width;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05277466	chr16:88082055	BANP	-0.57	-6.88	-0.3	1.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4555082	0.957	rs2816622	chr14:105733114	T/C	cg06808227	chr14:105710500	BRF1	-0.63	-11.21	-0.46	5.82e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg01346077	chr3:125931526	NA	0.43	11.19	0.46	6.98e-26	Metabolite levels;
LGG	cis	rs7267979	0.844	rs8184820	chr20:25250577	C/T	cg06421707	chr20:25228305	PYGB	-0.54	-12.14	-0.49	1.25e-29	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18277986	chr14:78174010	C14orf156;ALKBH1	0.47	7.02	0.31	7.82e-12	Gut microbiome composition (summer);
LGG	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg19507638	chr5:93509721	C5orf36	0.69	9.65	0.41	3.33e-20	Diabetic retinopathy;
LGG	trans	rs1459104	0.925	rs7106287	chr11:54978166	G/A	cg15704280	chr7:45808275	SEPT13	0.73	7.13	0.31	3.79e-12	Body mass index;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03352830	chr11:487213	PTDSS2	0.85	10.42	0.44	5.78e-23	Body mass index;
LGG	cis	rs1728785	1.000	rs1645927	chr16:68589300	T/G	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs11628318	0.614	rs1190338	chr14:103105792	T/G	cg23461800	chr14:103021989	NA	-0.53	-8.31	-0.36	1.05e-15	Platelet count;
LGG	cis	rs367943	0.665	rs6877548	chr5:112970054	C/T	cg12552261	chr5:112820674	MCC	0.51	8.79	0.38	2.96e-17	Type 2 diabetes;
LGG	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.48	0.37	3.04e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs62238980	0.614	rs76349379	chr22:32415063	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs2858942	0.575	rs2858011	chr16:247938	C/T	cg08400316	chr16:204221	HBZ	0.55	8.43	0.36	4.31e-16	Mean corpuscular hemoglobin;
LGG	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg11266682	chr4:10021025	SLC2A9	0.55	10.97	0.45	4.72e-25	Bone mineral density;
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg00294572	chr6:26285232	NA	0.41	7.43	0.33	5.2e-13	Educational attainment;
LGG	cis	rs17767392	0.813	rs12887261	chr14:71941979	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.9	-0.38	1.3e-17	Mitral valve prolapse;
LGG	trans	rs526821	0.595	rs532278	chr11:55344983	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg07636037	chr3:49044803	WDR6	0.99	22.0	0.71	5.65e-74	Menarche (age at onset);
LGG	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg21399703	chr1:247681439	NA	-0.65	-11.89	-0.48	1.23e-28	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3096299	0.935	rs3114890	chr16:89449546	C/G	cg06640241	chr16:89574553	SPG7	0.7	11.98	0.49	5.55e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs6500395	1.000	rs3848319	chr16:48610933	T/C	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.46e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg14673194	chr17:80132900	CCDC57	-0.44	-7.72	-0.34	7.15e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1978968	0.784	rs71328248	chr22:18452501	C/A	cg03078520	chr22:18463400	MICAL3	-0.7	-13.91	-0.54	5.29e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs7010267	1.000	rs7010267	chr8:119946656	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.38	9.99	0.42	2.07e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs7103648	1.000	rs10838705	chr11:47424931	G/A	cg20307385	chr11:47447363	PSMC3	0.97	23.92	0.74	6.66e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs67478160	0.529	rs12880413	chr14:104267407	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	cis	rs6752107	0.936	rs1045100	chr2:234203597	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	7.65	0.34	1.15e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs4481887	0.893	rs10788763	chr1:248429070	A/T	cg13385794	chr1:248469461	NA	-0.45	-7.65	-0.33	1.19e-13	Common traits (Other);
LGG	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg08773314	chr2:239334832	ASB1	0.42	7.98	0.35	1.18e-14	Multiple system atrophy;
LGG	cis	rs10851411	0.697	rs41315252	chr15:42837497	A/G	cg21293051	chr15:42870591	STARD9	0.49	7.02	0.31	7.82e-12	Glucose homeostasis traits;
LGG	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg26578617	chr4:90757533	SNCA	-0.36	-7.12	-0.31	4.04e-12	Dementia with Lewy bodies;
LGG	cis	rs9354308	0.764	rs1499703	chr6:66610713	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs2404602	0.716	rs17364076	chr15:76760891	C/T	cg23625390	chr15:77176239	SCAPER	0.5	9.85	0.42	6.55e-21	Blood metabolite levels;
LGG	cis	rs875971	0.545	rs316306	chr7:65618674	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.36	-0.43	9.61e-23	Aortic root size;
LGG	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg13385794	chr1:248469461	NA	0.48	8.24	0.36	1.76e-15	Common traits (Other);
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg19635926	chr16:89946313	TCF25	-0.7	-8.51	-0.37	2.37e-16	Skin colour saturation;
LGG	cis	rs7106204	0.609	rs12276488	chr11:24250211	G/A	ch.11.24196551F	chr11:24239977	NA	0.87	10.67	0.44	6.76e-24	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-7.93	-0.35	1.61e-14	Life satisfaction;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.08	-0.57	4.37e-42	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19719120	chr19:12780479	MORG1;C19orf56	0.41	6.93	0.31	1.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12701220	0.602	rs9638882	chr7:1023617	C/A	cg00990874	chr7:1149470	C7orf50	-0.63	-9.5	-0.4	1.15e-19	Bronchopulmonary dysplasia;
LGG	cis	rs8067545	0.750	rs11870111	chr17:19992738	G/A	cg13482628	chr17:19912719	NA	0.63	12.54	0.5	2.92e-31	Schizophrenia;
LGG	cis	rs10861342	1.000	rs12316054	chr12:105569143	T/C	cg23923672	chr12:105501055	KIAA1033	0.82	7.26	0.32	1.66e-12	IgG glycosylation;
LGG	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.49	0.4	1.24e-19	Red blood cell count;
LGG	cis	rs9487094	0.961	rs9480948	chr6:109728351	A/G	cg01125227	chr6:109776195	MICAL1	0.53	9.07	0.39	3.28e-18	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05884522	chr6:13615538	NOL7	-0.45	-6.75	-0.3	4.4e-11	Pancreatic cancer;
LGG	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg08648136	chr8:956695	NA	0.46	10.07	0.42	1.08e-21	Schizophrenia;
LGG	cis	rs77633900	0.614	rs2468122	chr15:76918686	A/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.9	-0.42	4.41e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Bone mineral density;
LGG	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs6496932	0.635	rs8023859	chr15:85904771	A/T	cg19183879	chr15:85880815	NA	-0.43	-7.12	-0.31	4.25e-12	Central corneal thickness;Corneal structure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04122974	chr22:39916495	ATF4	0.42	6.76	0.3	4.25e-11	Cognitive performance;
LGG	cis	rs988958	0.565	rs34818443	chr2:42233809	C/T	cg19376973	chr2:42229025	NA	0.62	9.12	0.39	2.31e-18	Hypospadias;
LGG	cis	rs2114646	0.806	rs6754950	chr2:170630370	G/A	cg17598339	chr2:170624727	NA	0.41	7.19	0.32	2.63e-12	Obesity-related traits;
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.53	-8.91	-0.38	1.16e-17	Bipolar disorder;
LGG	cis	rs9896933	0.778	rs80112422	chr17:80827719	G/T	cg19500275	chr17:80737654	TBCD	0.52	6.84	0.3	2.5e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs13065560	0.562	rs6786732	chr3:38920203	C/T	cg01426195	chr3:39028469	NA	-0.46	-9.36	-0.4	3.55e-19	Interleukin-18 levels;
LGG	cis	rs11167764	1.000	rs11167764	chr5:141479065	A/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.86	-0.3	2.28e-11	Crohn's disease;
LGG	cis	rs911555	0.504	rs4444269	chr14:104072724	G/C	cg24130564	chr14:104152367	KLC1	-0.77	-17.21	-0.62	1.19e-51	Intelligence (multi-trait analysis);
LGG	cis	rs6694672	1.000	rs6680497	chr1:197083329	G/A	cg13682187	chr1:196946512	CFHR5	0.5	6.93	0.31	1.45e-11	Asthma;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg16507663	chr6:150244633	RAET1G	0.49	9.82	0.42	8.45e-21	Lung cancer;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg07117364	chr1:16154769	NA	0.38	6.82	0.3	2.86e-11	Dilated cardiomyopathy;
LGG	cis	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg01181863	chr3:195395398	SDHAP2	0.49	7.46	0.33	4.23e-13	Mean corpuscular volume;
LGG	trans	rs11039798	0.620	rs10838833	chr11:48238880	C/T	cg15704280	chr7:45808275	SEPT13	0.73	7.96	0.35	1.32e-14	Axial length;
LGG	cis	rs875971	0.660	rs7807944	chr7:66087195	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.49	-0.4	1.21e-19	Aortic root size;
LGG	cis	rs7107174	1.000	rs1017908	chr11:77948095	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-7.85	-0.34	2.96e-14	Testicular germ cell tumor;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.83	0.34	3.26e-14	Tonsillectomy;
LGG	cis	rs2274273	1.000	rs3825613	chr14:55593172	A/C	cg04306507	chr14:55594613	LGALS3	0.61	16.99	0.62	1.11e-50	Protein biomarker;
LGG	cis	rs12643440	0.655	rs7685926	chr4:17196890	G/A	cg22650099	chr4:17144496	NA	-0.49	-7.21	-0.32	2.35e-12	Metabolite levels (Pyroglutamine);
LGG	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg01324343	chr3:183735012	ABCC5	0.87	18.6	0.65	4.45e-58	Anterior chamber depth;
LGG	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg12386194	chr3:101231763	SENP7	0.44	7.71	0.34	7.6e-14	Colorectal cancer;
LGG	cis	rs17092148	0.945	rs6060009	chr20:33303974	T/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.21	-0.36	2.3e-15	Retinal vascular caliber;
LGG	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg26666090	chr16:58549219	SETD6	1.17	10.31	0.43	1.42e-22	Schizophrenia;
LGG	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06481639	chr22:41940642	POLR3H	0.48	6.91	0.31	1.65e-11	Vitiligo;
LGG	trans	rs7980799	0.653	rs10844613	chr12:33605362	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-11.64	-0.48	1.26e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg04672837	chr16:48644449	N4BP1	0.52	8.54	0.37	1.97e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs68170813	0.521	rs75035695	chr7:106818731	T/C	cg02696742	chr7:106810147	HBP1	-0.77	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg00761968	chr13:53314142	LECT1	-0.36	-7.32	-0.32	1.08e-12	Lewy body disease;
LGG	cis	rs9393692	0.645	rs28446029	chr6:26305801	C/G	cg00631329	chr6:26305371	NA	-0.53	-9.35	-0.4	3.85e-19	Educational attainment;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25072359	chr17:41440525	NA	0.52	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs4740619	0.836	rs10756713	chr9:15880555	A/G	cg14451791	chr9:16040625	NA	-0.39	-9.83	-0.42	7.51e-21	Body mass index;
LGG	cis	rs7250872	0.647	rs2304612	chr19:1817866	A/G	cg18850929	chr19:1828978	REXO1	-0.48	-8.07	-0.35	6.06e-15	Bipolar disorder;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs11096990	0.613	rs4974995	chr4:39218123	C/T	cg24403649	chr4:39172243	NA	-0.41	-7.42	-0.33	5.79e-13	Cognitive function;
LGG	cis	rs4820539	0.966	rs5759600	chr22:23483769	C/A	cg14186256	chr22:23484241	RTDR1	1.0	26.04	0.77	9.72e-93	Bone mineral density;
LGG	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs9611519	0.929	rs926914	chr22:41418154	C/T	cg03806693	chr22:41940476	POLR3H	-0.55	-8.3	-0.36	1.15e-15	Neuroticism;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg11473876	chr11:109292803	C11orf87	0.45	9.13	0.39	2.13e-18	Schizophrenia;
LGG	cis	rs8056893	0.679	rs4783552	chr16:68310312	A/G	cg07273125	chr16:68295692	NA	0.4	8.33	0.36	9.01e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs8141529	0.871	rs5762877	chr22:29277555	G/A	cg02153584	chr22:29168773	CCDC117	0.6	9.55	0.41	7.4e-20	Lymphocyte counts;
LGG	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg00631329	chr6:26305371	NA	-0.46	-7.74	-0.34	6.29e-14	Educational attainment;
LGG	cis	rs6502050	0.604	rs9897355	chr17:80078095	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.84e-16	Lung cancer;
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.44	-0.33	4.83e-13	Neuroticism;
LGG	cis	rs75920871	0.528	rs12274465	chr11:116957189	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.54	-7.82	-0.34	3.48e-14	Subjective well-being;
LGG	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg22771759	chr13:24902376	NA	0.42	7.22	0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs10904908	0.733	rs359299	chr10:17334378	G/A	cg01003015	chr10:17271136	VIM	0.51	8.38	0.36	6.46e-16	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg22907277	chr7:1156413	C7orf50	0.5	8.64	0.37	9.28e-17	Longevity;Endometriosis;
LGG	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg18171855	chr10:2543474	NA	-0.4	-7.97	-0.35	1.22e-14	Age-related hearing impairment;
LGG	cis	rs56283067	0.504	rs62436021	chr6:44705375	C/A	cg18551225	chr6:44695536	NA	-0.69	-11.28	-0.46	3.05e-26	Total body bone mineral density;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg02733842	chr7:1102375	C7orf50	0.64	10.35	0.43	1e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1198872	0.526	rs57282335	chr2:10928207	G/A	cg15705551	chr2:10952987	PDIA6	0.49	7.21	0.32	2.28e-12	Cardiac Troponin-T levels;
LGG	cis	rs6665290	0.669	rs3738725	chr1:227174210	T/C	cg05696931	chr1:227175867	NA	-0.42	-8.51	-0.37	2.44e-16	Myeloid white cell count;
LGG	cis	rs533581	0.866	rs4995274	chr16:88970040	T/C	cg16701003	chr16:89028210	CBFA2T3	0.46	7.5	0.33	3.35e-13	Social autistic-like traits;
LGG	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs11696739	0.513	rs2209313	chr20:1599142	A/G	cg27365103	chr20:1578550	SIRPB1	0.39	6.76	0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs6076065	0.723	rs2424545	chr20:23390876	A/G	cg12633918	chr20:23549525	CST9L	0.35	6.76	0.3	4.22e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6840360	0.681	rs4519779	chr4:152301185	G/A	cg25486957	chr4:152246857	NA	-0.43	-7.77	-0.34	5.05e-14	Intelligence (multi-trait analysis);
LGG	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg00405596	chr8:11794950	NA	0.63	11.3	0.46	2.64e-26	Myopia (pathological);
LGG	cis	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg05863683	chr7:1912471	MAD1L1	0.45	8.86	0.38	1.78e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7100689	0.622	rs7897994	chr10:82133304	T/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6674970	0.932	rs12569193	chr1:151115186	C/T	cg03258749	chr1:151040405	MLLT11	-0.47	-8.34	-0.36	8.33e-16	Childhood ear infection;
LGG	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg15764593	chr10:829463	NA	-0.68	-10.14	-0.43	6e-22	Uric acid levels;
LGG	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	trans	rs526821	0.553	rs510095	chr11:55289154	T/C	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg07659893	chr17:61819838	STRADA	-0.46	-7.67	-0.34	1.03e-13	Prudent dietary pattern;
LGG	cis	rs68170813	0.559	rs12537011	chr7:107027833	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	cis	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg21775007	chr8:11205619	TDH	-0.55	-9.08	-0.39	3.15e-18	Triglycerides;
LGG	cis	rs73086581	0.687	rs73082600	chr20:3844365	G/A	cg02187196	chr20:3869020	PANK2	0.89	12.14	0.49	1.23e-29	Response to antidepressants in depression;
LGG	cis	rs4731207	0.698	rs6959712	chr7:124499003	T/A	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs7586879	0.616	rs10203386	chr2:25136866	T/A	cg04586622	chr2:25135609	ADCY3	0.47	13.06	0.52	2.17e-33	Body mass index;
LGG	cis	rs10875746	0.623	rs10875793	chr12:48697430	T/A	cg24011408	chr12:48396354	COL2A1	-0.57	-7.23	-0.32	1.95e-12	Longevity (90 years and older);
LGG	cis	rs1977876	0.929	rs60707186	chr1:211707950	T/C	cg01575408	chr1:211752895	SLC30A1	0.49	6.99	0.31	9.46e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	11.4	0.47	1.06e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9790314	1.000	rs9872514	chr3:161042833	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-14.46	-0.56	2.31e-39	Morning vs. evening chronotype;
LGG	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg23752985	chr2:85803571	VAMP8	0.4	7.61	0.33	1.59e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	15.84	0.59	1.88e-45	Total body bone mineral density;
LGG	trans	rs9818758	0.607	rs9990153	chr3:49291883	C/T	cg21659725	chr3:3221576	CRBN	-0.64	-7.01	-0.31	8.67e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg21051568	chr5:9365294	SEMA5A	-0.42	-6.72	-0.3	5.52e-11	Apolipoprotein A-IV levels;
LGG	cis	rs9611565	0.512	rs4512	chr22:42206084	G/C	cg03806693	chr22:41940476	POLR3H	-1.04	-17.66	-0.63	1.02e-53	Vitiligo;
LGG	cis	rs7084402	0.967	rs7087528	chr10:60301294	A/T	cg09696939	chr10:60272079	BICC1	0.36	6.96	0.31	1.15e-11	Refractive error;
LGG	cis	rs11690935	0.595	rs788170	chr2:172919958	T/C	cg13550731	chr2:172543902	DYNC1I2	0.71	14.57	0.56	7.47e-40	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01132139	chr11:76091836	PRKRIR	0.38	7.09	0.31	5.19e-12	Gut microbiome composition (summer);
LGG	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg25019033	chr10:957182	NA	0.58	10.84	0.45	1.49e-24	Eosinophil percentage of granulocytes;
LGG	cis	rs11098499	0.588	rs6534149	chr4:120559292	T/G	cg09307838	chr4:120376055	NA	-0.67	-11.7	-0.48	6.94e-28	Corneal astigmatism;
LGG	cis	rs1707322	0.752	rs28507722	chr1:46206540	A/G	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8067545	0.717	rs7207625	chr17:20001612	G/A	cg09818912	chr17:20140352	CYTSB	-0.3	-6.93	-0.31	1.43e-11	Schizophrenia;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.22	-0.39	1.07e-18	Menopause (age at onset);
LGG	cis	rs6460942	1.000	rs118083671	chr7:12466036	C/T	cg06484146	chr7:12443880	VWDE	-0.4	-7.12	-0.31	4.21e-12	Coronary artery disease;
LGG	cis	rs7086627	0.515	rs7078254	chr10:82212193	C/T	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.81	-0.38	2.53e-17	Post bronchodilator FEV1;
LGG	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9522267	0.535	rs9522305	chr13:112237550	A/G	cg14952266	chr13:112191215	NA	0.52	10.89	0.45	9.48e-25	Hepatitis;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	14.55	0.56	8.75e-40	Platelet count;
LGG	trans	rs11039798	0.614	rs11039954	chr11:48741818	A/G	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs3106136	0.527	rs2632410	chr4:95149507	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.01	-0.46	3.26e-25	Capecitabine sensitivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08058610	chr19:52674483	ZNF836	0.46	6.92	0.31	1.49e-11	Gut microbiome composition (summer);
LGG	cis	rs4631830	0.720	rs11599333	chr10:51499655	A/C	cg10326726	chr10:51549505	MSMB	0.64	12.91	0.51	9.1e-33	Prostate-specific antigen levels;
LGG	cis	rs7712401	0.601	rs154501	chr5:122211594	T/C	cg19412675	chr5:122181750	SNX24	0.42	6.89	0.3	1.88e-11	Mean platelet volume;
LGG	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs516946	1.000	rs516946	chr8:41519248	C/T	cg01678292	chr8:41522873	ANK1	0.35	8.08	0.35	5.68e-15	Type 2 diabetes;
LGG	cis	rs7219021	0.892	rs66866087	chr17:46849323	C/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.74	-0.3	4.75e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs701145	0.585	rs1713846	chr3:153787632	C/T	cg17054900	chr3:154042577	DHX36	0.78	9.36	0.4	3.34e-19	Coronary artery disease;
LGG	cis	rs68170813	0.559	rs75007274	chr7:106814543	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-11.06	-0.46	2.18e-25	Coronary artery disease;
LGG	cis	rs2832191	0.740	rs2832177	chr21:30478353	G/A	cg08807101	chr21:30365312	RNF160	-0.92	-19.25	-0.67	4.28e-61	Dental caries;
LGG	cis	rs2898857	0.524	rs2960172	chr17:47379581	G/A	cg08112188	chr17:47440006	ZNF652	0.46	7.56	0.33	2.26e-13	Cancer;
LGG	cis	rs58649573	0.509	rs13284685	chr9:126792515	C/G	cg14112217	chr9:126806003	NA	0.4	7.79	0.34	4.46e-14	Post-traumatic stress disorder;
LGG	trans	rs2204008	0.837	rs4432085	chr12:38181146	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.96	-0.38	8.22e-18	Bladder cancer;
LGG	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.8	-0.34	4.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4950322	0.543	rs4453096	chr1:146788287	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	cg07928641	chr1:182991847	LAMC1	0.45	9.05	0.39	4.12e-18	Colorectal cancer;
LGG	trans	rs17060993	0.557	rs116802698	chr8:26869892	A/G	cg19071002	chr6:63940486	NA	-0.61	-8.1	-0.35	4.84e-15	Musician's dystonia;
LGG	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg27411982	chr8:10470053	RP1L1	0.41	7.08	0.31	5.37e-12	Mood instability;
LGG	cis	rs2832077	0.506	rs2832093	chr21:30164855	C/T	cg24692254	chr21:30365293	RNF160	-0.64	-11.29	-0.46	2.92e-26	Cognitive test performance;
LGG	cis	rs7818345	0.512	rs4922028	chr8:19303771	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.34	7.69	0.34	9.21e-14	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs4363385	0.588	rs6661059	chr1:153027257	A/T	cg13444842	chr1:152974279	SPRR3	-0.48	-9.69	-0.41	2.37e-20	Inflammatory skin disease;
LGG	trans	rs826838	1.000	rs860400	chr12:39081279	A/G	cg06521331	chr12:34319734	NA	0.46	8.45	0.37	3.9e-16	Heart rate;
LGG	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg03162506	chr22:38580953	NA	0.28	6.94	0.31	1.35e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs7084402	0.523	rs10740730	chr10:60334939	T/C	cg07615347	chr10:60278583	BICC1	0.5	12.31	0.5	2.52e-30	Refractive error;
LGG	cis	rs5769765	0.773	rs9616391	chr22:50314573	C/T	cg02269571	chr22:50332266	NA	-0.75	-11.02	-0.46	3.07e-25	Schizophrenia;
LGG	cis	rs9463078	0.817	rs2145826	chr6:44763781	G/A	cg25276700	chr6:44698697	NA	0.42	8.61	0.37	1.12e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg12310025	chr6:25882481	NA	0.71	14.17	0.55	3.93e-38	Blood metabolite levels;
LGG	cis	rs137603	0.644	rs137636	chr22:39722477	C/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.71	-13.86	-0.54	8.67e-37	Primary biliary cholangitis;
LGG	cis	rs2242116	0.932	rs7646906	chr3:46949379	G/A	cg02527881	chr3:46936655	PTH1R	-0.37	-9.38	-0.4	2.87e-19	Birth weight;
LGG	cis	rs10209697	1	rs10209697	chr2:222549197	G/A	cg27403388	chr2:222639321	NA	-0.68	-7.99	-0.35	1.11e-14	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg01673284	chr16:4527211	HMOX2	0.32	6.7	0.3	6.24e-11	Schizophrenia;
LGG	cis	rs7615952	0.599	rs6438953	chr3:125724951	T/C	cg05084668	chr3:125655381	ALG1L	-0.6	-8.25	-0.36	1.64e-15	Blood pressure (smoking interaction);
LGG	cis	rs8064299	0.597	rs7210318	chr17:72783385	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.7	0.73	3.12e-77	Monocyte count;
LGG	cis	rs7727544	0.508	rs10900804	chr5:131401845	C/T	cg07395648	chr5:131743802	NA	-0.41	-8.62	-0.37	1.09e-16	Blood metabolite levels;
LGG	cis	rs7089973	0.604	rs11196943	chr10:116598865	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.45	0.33	4.56e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg15269541	chr15:43626905	ADAL	-0.45	-7.72	-0.34	7.07e-14	Lung cancer in ever smokers;
LGG	cis	rs9472414	0.771	rs720988	chr6:44765660	C/T	cg20913747	chr6:44695427	NA	0.46	6.91	0.31	1.66e-11	Height;
LGG	cis	rs7666738	0.649	rs28865589	chr4:98954279	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.21	0.36	2.15e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11122272	0.735	rs2474634	chr1:231487017	T/C	cg10503236	chr1:231470652	EXOC8	-0.38	-7.41	-0.33	5.88e-13	Hemoglobin concentration;
LGG	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg26396452	chr14:65542826	MAX	0.47	9.42	0.4	2.19e-19	Obesity-related traits;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.96	0.31	1.16e-11	Obesity-related traits;
LGG	cis	rs2236918	0.932	rs1776178	chr1:242011534	C/T	cg17736920	chr1:242011382	EXO1	-0.49	-8.94	-0.38	9.2e-18	Menopause (age at onset);
LGG	cis	rs2346160	0.899	rs172283	chr6:167691225	T/C	cg20683250	chr6:167653907	NA	-0.42	-6.81	-0.3	3e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs10189230	0.967	rs1864460	chr2:222347655	A/C	cg14652038	chr2:222343519	EPHA4	0.61	12.63	0.51	1.28e-31	Urate levels in lean individuals;
LGG	cis	rs7143963	0.943	rs7147331	chr14:103380208	T/A	cg23020514	chr14:103360112	TRAF3	0.46	8.94	0.38	9.24e-18	Body mass index;
LGG	cis	rs968567	0.689	rs61897795	chr11:61618169	A/G	cg19610905	chr11:61596333	FADS2	-0.62	-6.73	-0.3	5.14e-11	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs950169	0.544	rs62021193	chr15:85170583	C/G	cg03959625	chr15:84868606	LOC388152	0.48	7.11	0.31	4.5e-12	Schizophrenia;
LGG	cis	rs2624839	0.629	rs2526397	chr3:50187790	A/C	cg14019146	chr3:50243930	SLC38A3	0.46	9.33	0.4	4.39e-19	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.58	11.55	0.47	2.63e-27	Prudent dietary pattern;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.67	-0.3	7.53e-11	Obesity-related traits;
LGG	cis	rs6754311	0.517	rs1865452	chr2:136539330	C/T	cg07169764	chr2:136633963	MCM6	1.0	19.13	0.66	1.53e-60	Mosquito bite size;
LGG	cis	rs7927771	1.000	rs1317149	chr11:47486885	C/T	cg20307385	chr11:47447363	PSMC3	-0.51	-9.08	-0.39	3.07e-18	Subjective well-being;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg18402987	chr7:1209562	NA	0.39	7.04	0.31	7.02e-12	Longevity;Endometriosis;
LGG	cis	rs7100689	0.599	rs6585968	chr10:82139807	T/C	cg01528321	chr10:82214614	TSPAN14	0.87	15.27	0.58	6.15e-43	Post bronchodilator FEV1;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05533552	chr11:34074141	CAPRIN1	0.39	6.66	0.3	7.83e-11	Bipolar disorder;
LGG	cis	rs2227564	0.672	rs10824042	chr10:75645628	C/T	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.93	-0.38	9.8e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18252515	chr7:66147081	NA	0.44	7.31	0.32	1.15e-12	Aortic root size;
LGG	cis	rs12580194	0.593	rs59466585	chr12:55722736	T/G	cg19537932	chr12:55886519	OR6C68	-0.53	-9.46	-0.4	1.61e-19	Cancer;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg18350739	chr11:68623251	NA	-0.87	-22.45	-0.72	4.75e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9291683	0.546	rs6820188	chr4:10051655	C/T	cg11266682	chr4:10021025	SLC2A9	0.5	9.85	0.42	6.45e-21	Bone mineral density;
LGG	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.76	11.16	0.46	9.32e-26	Schizophrenia;
LGG	trans	rs1814175	0.534	rs1983448	chr11:49933856	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-20.82	-0.7	2.06e-68	Height;
LGG	cis	rs2131877	0.956	rs10933699	chr3:194869391	G/A	cg07250128	chr3:194833983	C3orf21	0.41	7.62	0.33	1.43e-13	Non-small cell lung cancer;
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg21775007	chr8:11205619	TDH	0.51	8.48	0.37	3.12e-16	Neuroticism;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg11062466	chr8:58055876	NA	0.5	8.08	0.35	5.81e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg15948088	chr11:109293068	C11orf87	0.8	15.07	0.57	4.65e-42	Schizophrenia;
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.47	2.48e-26	Bipolar disorder;
LGG	cis	rs7084402	0.967	rs7097576	chr10:60277055	G/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.28	-0.63	5.43e-52	Refractive error;
LGG	cis	rs11098499	0.820	rs13122709	chr4:120555356	T/A	cg01244601	chr4:120671846	NA	-0.37	-7.07	-0.31	5.59e-12	Corneal astigmatism;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.61	9.61	0.41	4.77e-20	Renal function-related traits (BUN);
LGG	cis	rs9878978	0.722	rs11719351	chr3:2459872	T/C	cg21928760	chr3:2462534	CNTN4	0.47	9.18	0.39	1.44e-18	Blood pressure (smoking interaction);
LGG	cis	rs62400317	0.518	rs1321080	chr6:45358323	G/T	cg20913747	chr6:44695427	NA	-0.54	-8.11	-0.35	4.52e-15	Total body bone mineral density;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg16359550	chr11:109292809	C11orf87	0.43	8.34	0.36	8.29e-16	Schizophrenia;
LGG	cis	rs56283067	0.847	rs10456535	chr6:44692758	G/A	cg18551225	chr6:44695536	NA	-0.7	-12.4	-0.5	1.11e-30	Total body bone mineral density;
LGG	cis	rs9914988	0.673	rs9890212	chr17:27169890	G/C	cg20469991	chr17:27169893	C17orf63	-0.58	-7.22	-0.32	2.08e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2797160	1.000	rs2797158	chr6:126009398	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs56283067	0.671	rs1028608	chr6:44681721	C/T	cg20913747	chr6:44695427	NA	-0.58	-10.92	-0.45	7.19e-25	Total body bone mineral density;
LGG	cis	rs2133450	0.712	rs10510358	chr3:7368190	C/T	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.68e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs769267	0.895	rs1000237	chr19:19518316	T/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.31	0.47	2.29e-26	Tonsillectomy;
LGG	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.57	-8.84	-0.38	2.07e-17	Chronic sinus infection;
LGG	cis	rs4262150	0.883	rs12659802	chr5:152274478	A/G	cg12297329	chr5:152029980	NA	-0.65	-12.33	-0.5	2.09e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs80130819	0.515	rs1793912	chr12:48387052	A/C	cg24011408	chr12:48396354	COL2A1	0.63	7.66	0.34	1.11e-13	Prostate cancer;
LGG	cis	rs7568458	0.684	rs6731700	chr2:85760991	C/G	cg17127132	chr2:85788382	GGCX	0.51	8.07	0.35	6.07e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg12419862	chr22:24373484	LOC391322	0.8	12.8	0.51	2.47e-32	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs7799006	0.929	rs745565	chr7:2256689	G/C	cg02951883	chr7:2050386	MAD1L1	-0.41	-6.86	-0.3	2.16e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg07790826	chr11:70049435	FADD	0.58	6.67	0.3	7.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.689	rs7158239	chr14:65520616	G/A	cg16583315	chr14:65563665	MAX	-0.39	-7.95	-0.35	1.39e-14	Obesity-related traits;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.65	0.37	8.6e-17	Bipolar disorder;
LGG	cis	rs4077515	0.527	rs10870146	chr9:139308054	G/A	cg14169450	chr9:139327907	INPP5E	0.35	6.68	0.3	7.07e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-10.57	-0.44	1.51e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg05084668	chr3:125655381	ALG1L	-1.2	-13.88	-0.54	6.9e-37	Blood pressure (smoking interaction);
LGG	cis	rs17162190	0.698	rs7539320	chr1:26850665	C/T	cg23229016	chr1:26872525	RPS6KA1	0.26	6.97	0.31	1.11e-11	Mean corpuscular volume;
LGG	trans	rs2921073	0.605	rs2976933	chr8:8254875	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-9.04	-0.39	4.21e-18	Parkinson's disease;
LGG	cis	rs10276381	0.786	rs10255700	chr7:28220228	C/T	cg23620719	chr7:28220237	JAZF1	0.83	10.57	0.44	1.53e-23	Crohn's disease;
LGG	cis	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg08930214	chr7:62859557	LOC100287834	0.48	7.9	0.34	2.03e-14	Obesity-related traits;
LGG	cis	rs952623	0.649	rs6944670	chr7:39057109	A/G	cg18850127	chr7:39170497	POU6F2	0.35	8.22	0.36	2.09e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.816	rs6115094	chr20:25210827	A/G	cg08601574	chr20:25228251	PYGB	0.4	8.06	0.35	6.45e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg26384229	chr12:38710491	ALG10B	0.92	21.34	0.7	7.28e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg04990556	chr1:26633338	UBXN11	-0.5	-7.74	-0.34	6.44e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6942756	0.774	rs2566885	chr7:128917587	C/T	cg02491457	chr7:128862824	NA	0.64	12.05	0.49	2.9e-29	White matter hyperintensity burden;
LGG	cis	rs3812831	0.654	rs9314900	chr13:114937618	A/C	cg25338242	chr13:114786047	RASA3	0.4	7.37	0.32	8.05e-13	Schizophrenia;
LGG	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg08807101	chr21:30365312	RNF160	-0.68	-11.69	-0.48	7.66e-28	Cognitive test performance;
LGG	cis	rs13126513	0.510	rs10516445	chr4:100524679	C/G	cg10778915	chr4:100576610	NA	0.37	7.48	0.33	3.68e-13	Metabolite levels (MHPG);
LGG	cis	rs7143963	1.000	rs12590238	chr14:103350197	C/G	cg23020514	chr14:103360112	TRAF3	0.51	9.89	0.42	4.55e-21	Body mass index;
LGG	cis	rs12477438	0.765	rs2167930	chr2:99592551	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs12190007	0.573	rs3006218	chr6:169868769	G/A	cg15038512	chr6:170123185	PHF10	-0.45	-8.62	-0.37	1.03e-16	Obesity-related traits;
LGG	cis	rs7717393	1.000	rs72798928	chr5:155790471	G/A	cg19569526	chr5:155754265	SGCD	0.78	7.78	0.34	4.68e-14	Egg allergy;
LGG	cis	rs9467773	1.000	rs6922824	chr6:26553815	C/G	cg11502198	chr6:26597334	ABT1	-0.55	-9.65	-0.41	3.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs7623023	chr3:48914238	G/A	cg07636037	chr3:49044803	WDR6	1.06	25.74	0.77	2.38e-91	Parkinson's disease;
LGG	cis	rs1008375	1.000	rs555	chr4:17625658	A/G	cg15017067	chr4:17643749	FAM184B	0.3	6.99	0.31	9.62e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10779751	0.770	rs2258621	chr1:11141187	C/G	cg08854313	chr1:11322531	MTOR	0.73	14.93	0.57	2.07e-41	Body mass index;
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg16301924	chr13:53314226	LECT1	-0.41	-7.78	-0.34	4.7e-14	Lewy body disease;
LGG	cis	rs8017423	0.967	rs11626011	chr14:90693572	A/G	cg04374321	chr14:90722782	PSMC1	0.88	17.84	0.64	1.51e-54	Mortality in heart failure;
LGG	cis	rs8072100	0.790	rs6505048	chr17:45674998	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.06	0.31	6.29e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3764563	1.000	rs2031061	chr19:15721961	T/C	cg20725493	chr19:15740067	CYP4F8	-0.65	-7.6	-0.33	1.61e-13	Inflammatory biomarkers;
LGG	cis	rs11718455	0.960	rs4682712	chr3:43997971	T/C	cg21419209	chr3:44054225	NA	-0.41	-6.75	-0.3	4.54e-11	Coronary artery disease;
LGG	cis	rs7474896	0.537	rs598857	chr10:38302926	A/G	cg25427524	chr10:38739819	LOC399744	0.52	7.68	0.34	9.5e-14	Obesity (extreme);
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	7.97e-18	Testicular germ cell tumor;
LGG	trans	rs2018683	0.707	rs1874974	chr7:28967647	G/C	cg19402173	chr7:128379420	CALU	-0.53	-9.22	-0.39	1.05e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.55	10.76	0.45	3.09e-24	Obesity-related traits;
LGG	cis	rs7582720	0.943	rs72926798	chr2:203827675	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.03	-18.5	-0.65	1.27e-57	Chronic sinus infection;
LGG	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs4262150	0.846	rs113568682	chr5:152299754	A/T	cg12297329	chr5:152029980	NA	-0.62	-11.32	-0.47	2.18e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg11342453	chr6:26196699	NA	0.49	6.68	0.3	6.85e-11	Gout;Renal underexcretion gout;
LGG	cis	rs244899	0.935	rs244900	chr5:167912022	G/A	cg06604206	chr5:167912465	RARS	-0.54	-11.77	-0.48	3.54e-28	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg06112835	chr11:68658793	MRPL21	0.63	10.31	0.43	1.38e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.28	0.46	3.12e-26	Vitamin D levels;
LGG	cis	rs17655565	1.000	rs17655565	chr12:52691958	T/C	cg02645295	chr12:52705424	NA	-0.58	-7.9	-0.34	2.11e-14	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs896854	0.631	rs10097617	chr8:95961626	T/C	cg13393036	chr8:95962371	TP53INP1	-0.27	-7.09	-0.31	5.05e-12	Type 2 diabetes;
LGG	cis	rs2133450	0.526	rs41346444	chr3:7341994	A/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.36	-0.4	3.56e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs1506636	0.962	rs1019220	chr7:123365122	G/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.49	-0.65	1.39e-57	Plateletcrit;Platelet count;
LGG	cis	rs9890032	0.509	rs11656986	chr17:29021342	A/T	cg19761014	chr17:28927070	LRRC37B2	0.44	6.91	0.31	1.62e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg20637307	chr2:213403960	ERBB4	0.46	8.69	0.37	6.26e-17	Symmetrical dimethylarginine levels;
LGG	cis	rs11410354	1	rs11410354	chr11:442472	C/CT	cg03576123	chr11:487126	PTDSS2	0.98	13.96	0.54	3.33e-37	Breast cancer;
LGG	trans	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1153858	1.000	rs59889118	chr15:45618730	G/A	cg10760299	chr15:45669010	GATM	0.4	7.65	0.33	1.18e-13	Homoarginine levels;
LGG	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03264133	chr6:25882463	NA	-0.64	-11.66	-0.48	9.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs919433	0.963	rs4850430	chr2:198182796	A/T	cg00792783	chr2:198669748	PLCL1	-0.45	-7.03	-0.31	7.33e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg26513180	chr16:89883248	FANCA	0.66	12.79	0.51	2.75e-32	Vitiligo;
LGG	cis	rs4771450	0.962	rs7983135	chr13:103975834	A/G	cg02987523	chr13:103978230	NA	-0.34	-7.05	-0.31	6.57e-12	Uric acid levels;
LGG	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg09307838	chr4:120376055	NA	0.72	12.16	0.49	1.06e-29	Corneal astigmatism;
LGG	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.73	-10.33	-0.43	1.22e-22	Chronic sinus infection;
LGG	cis	rs4731207	0.596	rs2017928	chr7:124672323	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.12	-0.31	4.19e-12	Cutaneous malignant melanoma;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg04267008	chr7:1944627	MAD1L1	-0.75	-13.41	-0.53	6.95e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg22072935	chr14:105399595	NA	0.52	10.12	0.43	7.21e-22	Rheumatoid arthritis;
LGG	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.73	0.64	4.74e-54	Smoking behavior;
LGG	cis	rs3820928	0.934	rs60141402	chr2:227761445	A/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.36	-0.32	8.54e-13	Pulmonary function;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs9951602	0.512	rs9946120	chr18:76654548	A/T	cg24134504	chr18:76639479	NA	-0.46	-8.14	-0.35	3.67e-15	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg21399703	chr1:247681439	NA	0.66	11.33	0.47	1.96e-26	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs9557207	0.756	rs9557193	chr13:99952021	C/T	cg24509225	chr13:100037070	UBAC2	-0.63	-11.88	-0.48	1.34e-28	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25517755	chr10:38738941	LOC399744	-0.38	-6.99	-0.31	9.39e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg07234876	chr8:600039	NA	1.23	12.09	0.49	1.98e-29	IgG glycosylation;
LGG	cis	rs9549367	0.713	rs3024744	chr13:113821477	A/C	cg18105134	chr13:113819100	PROZ	-0.76	-15.96	-0.6	5.39e-46	Platelet distribution width;
LGG	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	cis	rs3796352	0.881	rs13100714	chr3:53074824	T/G	cg12962167	chr3:53033115	SFMBT1	0.7	7.19	0.32	2.65e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs6062788	0.840	rs6090220	chr20:61702847	T/G	cg04883260	chr20:61718941	NA	0.31	7.02	0.31	8.05e-12	Body mass index;
LGG	cis	rs9463078	0.665	rs9472339	chr6:44711791	A/G	cg25276700	chr6:44698697	NA	0.44	9.11	0.39	2.58e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1784581	0.722	rs1789993	chr6:162398976	T/C	cg17173639	chr6:162384350	PARK2	-0.75	-16.56	-0.61	1.09e-48	Itch intensity from mosquito bite;
LGG	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg19784903	chr17:45786737	TBKBP1	0.32	6.86	0.3	2.2e-11	Multiple sclerosis or amyotrophic lateral sclerosis;
LGG	trans	rs9467711	0.606	rs34878490	chr6:26370572	C/T	cg08344181	chr3:125677491	NA	-0.61	-7.03	-0.31	7.33e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg19904058	chr10:135279010	LOC619207	-0.28	-6.82	-0.3	2.77e-11	Systemic lupus erythematosus;
LGG	cis	rs950776	0.507	rs12912673	chr15:78810216	T/C	cg17108064	chr15:78857060	CHRNA5	0.45	9.55	0.41	7.73e-20	Sudden cardiac arrest;
LGG	cis	rs11750568	1.000	rs1136377	chr5:178513141	C/T	cg10208897	chr5:178548229	ADAMTS2	0.42	6.87	0.3	2.07e-11	Height;
LGG	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg00071950	chr4:10020882	SLC2A9	-0.33	-6.92	-0.31	1.5e-11	Bone mineral density;
LGG	cis	rs12210905	1.000	rs72843609	chr6:27125877	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-7.86	-0.34	2.8e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg00701064	chr4:6280414	WFS1	0.74	16.51	0.61	1.68e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1669338	0.588	rs3749360	chr3:3213775	G/A	cg16797762	chr3:3221439	CRBN	-0.97	-12.63	-0.51	1.24e-31	White matter integrity;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.12	-0.49	1.44e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs80282103	0.867	rs17155821	chr10:1071701	A/G	cg08668510	chr10:1095578	IDI1	0.72	7.65	0.34	1.15e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs11074306	0.561	rs17747086	chr15:28070740	G/A	cg26402630	chr15:28053930	OCA2	0.36	7.26	0.32	1.66e-12	Uveal melanoma;
LGG	cis	rs7336332	0.598	rs9581852	chr13:28013748	A/G	cg01674679	chr13:27998804	GTF3A	-0.66	-8.47	-0.37	3.32e-16	Weight;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg08621203	chr6:150244597	RAET1G	0.43	7.4	0.33	6.29e-13	Lung cancer;
LGG	cis	rs35110281	0.720	rs162392	chr21:44941406	A/G	cg04455712	chr21:45112962	RRP1B	0.53	9.62	0.41	4.22e-20	Mean corpuscular volume;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg12381575	chr19:36485972	SDHAF1	-0.36	-6.71	-0.3	5.78e-11	Iris color (L* coordinate);
LGG	cis	rs1185460	0.934	rs1006195	chr11:118958869	A/C	cg23280166	chr11:118938394	VPS11	-0.53	-9.42	-0.4	2.18e-19	Coronary artery disease;
LGG	cis	rs1143633	0.530	rs4538207	chr2:113701863	G/T	cg06156847	chr2:113672199	IL1F7	-0.37	-7.39	-0.32	6.99e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3824867	0.920	rs7105907	chr11:47450318	A/T	cg20307385	chr11:47447363	PSMC3	-0.46	-7.3	-0.32	1.22e-12	Mean corpuscular hemoglobin;
LGG	cis	rs11700980	0.748	rs17734876	chr21:30260144	C/T	cg24692254	chr21:30365293	RNF160	-0.63	-7.07	-0.31	5.74e-12	QRS complex (12-leadsum);
LGG	cis	rs7766436	0.848	rs6931450	chr6:22582076	T/C	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22664368	chr17:4634740	MED11	0.39	6.87	0.3	2.14e-11	Obesity-related traits;
LGG	cis	rs11700980	0.551	rs2832020	chr21:30112231	G/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	trans	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg07393940	chr7:158741817	NA	0.56	10.42	0.44	5.67e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg06521331	chr12:34319734	NA	-0.48	-8.47	-0.37	3.27e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7264396	0.790	rs6058290	chr20:34247702	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.53	-0.33	2.68e-13	Total cholesterol levels;
LGG	cis	rs11209002	0.545	rs2093332	chr1:67531974	G/A	cg02640540	chr1:67518911	SLC35D1	0.4	6.73	0.3	5.16e-11	Crohn's disease;
LGG	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.29	0.53	2.26e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12701220	0.762	rs7777565	chr7:1003011	C/A	cg00990874	chr7:1149470	C7orf50	-0.5	-7.41	-0.33	5.95e-13	Bronchopulmonary dysplasia;
LGG	cis	rs9309473	0.898	rs6546861	chr2:73849861	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-7.25	-0.32	1.81e-12	Metabolite levels;
LGG	cis	rs9486715	0.867	rs4438964	chr6:96917563	T/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.72	0.59	6.32e-45	Headache;
LGG	cis	rs7582720	1.000	rs74421437	chr2:203831252	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4684776	0.867	rs7625184	chr3:11333734	C/T	cg24705426	chr3:11550659	ATG7	0.45	8.49	0.37	2.78e-16	Small vessel stroke;
LGG	cis	rs780096	0.546	rs1104	chr2:27599875	T/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.96	-0.35	1.3e-14	Total body bone mineral density;
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg02002194	chr4:3960332	NA	-0.45	-8.5	-0.37	2.69e-16	Monocyte count;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-15.19	-0.58	1.48e-42	Platelet count;
LGG	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.85	-0.3	2.31e-11	Neuroticism;
LGG	cis	rs2072499	0.750	rs10159384	chr1:156160822	C/T	cg25208724	chr1:156163844	SLC25A44	1.15	20.54	0.69	3.99e-67	Testicular germ cell tumor;
LGG	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.29	-6.94	-0.31	1.36e-11	Restless legs syndrome;
LGG	cis	rs986417	1.000	rs4901994	chr14:61090202	C/T	cg27398547	chr14:60952738	C14orf39	0.76	7.08	0.31	5.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4319547	1.000	rs9705654	chr12:123083508	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.6	-9.2	-0.39	1.21e-18	Body mass index;
LGG	cis	rs2013441	1.000	rs11870147	chr17:20216095	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.38e-11	Obesity-related traits;
LGG	cis	rs9547996	0.876	rs9547941	chr13:38130243	C/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.96	-0.31	1.2e-11	Diastolic blood pressure;
LGG	cis	rs7666738	0.830	rs17548431	chr4:98923768	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg14074117	chr16:1909714	C16orf73	0.54	8.09	0.35	5.28e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs713587	0.713	rs4665276	chr2:25213333	C/T	cg04586622	chr2:25135609	ADCY3	-0.37	-9.73	-0.41	1.71e-20	Body mass index in non-asthmatics;
LGG	cis	rs700651	0.821	rs770661	chr2:198725444	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.53e-25	Intracranial aneurysm;
LGG	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.61	0.63	1.65e-53	Smoking behavior;
LGG	cis	rs9916302	0.861	rs593480	chr17:37453780	A/C	cg00129232	chr17:37814104	STARD3	0.6	11.28	0.46	3.07e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2075371	0.611	rs12531769	chr7:134016899	C/G	cg11752832	chr7:134001865	SLC35B4	0.51	8.58	0.37	1.48e-16	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18247638	chr13:103451366	KDELC1;BIVM	0.48	7.25	0.32	1.81e-12	Gut microbiome composition (summer);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09922871	chr2:71559595	ZNF638	-0.4	-6.68	-0.3	7.07e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg26174226	chr8:58114915	NA	-0.51	-7.1	-0.31	4.81e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-7.99	-0.35	1.07e-14	Dementia with Lewy bodies;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg21548813	chr6:291882	DUSP22	-0.54	-9.44	-0.4	1.78e-19	Menopause (age at onset);
LGG	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg11861562	chr11:117069780	TAGLN	0.27	7.35	0.32	8.95e-13	Blood protein levels;
LGG	cis	rs4650994	0.593	rs2761459	chr1:178551576	G/A	cg12486710	chr1:178512616	C1orf220	-0.35	-6.88	-0.3	1.92e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	-0.51	-8.54	-0.37	2e-16	Cognitive test performance;
LGG	cis	rs3749237	1.000	rs11130216	chr3:49736172	C/A	cg02487422	chr3:49467188	NICN1	0.42	6.82	0.3	2.82e-11	Resting heart rate;
LGG	cis	rs12474201	0.588	rs3768719	chr2:46987935	T/G	cg06386533	chr2:46925753	SOCS5	0.6	10.72	0.45	4.35e-24	Height;
LGG	cis	rs62283056	0.512	rs10028875	chr4:6283460	C/T	cg25554036	chr4:6271136	WFS1	0.53	9.05	0.39	3.83e-18	Cisplatin-induced ototoxicity;
LGG	trans	rs66887589	0.616	rs7659403	chr4:120207254	T/A	cg25214090	chr10:38739885	LOC399744	0.46	8.4	0.36	5.49e-16	Diastolic blood pressure;
LGG	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg02297831	chr4:17616191	MED28	0.45	8.15	0.35	3.37e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg14159672	chr1:205819179	PM20D1	0.45	7.26	0.32	1.6e-12	Prostate-specific antigen levels;
LGG	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg00666640	chr1:248458726	OR2T12	0.6	9.73	0.41	1.71e-20	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17300391	chr3:116164035	LSAMP	0.4	6.76	0.3	4.29e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg05887092	chr17:76393375	PGS1	0.71	15.8	0.59	2.8e-45	HDL cholesterol levels;
LGG	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06108461	chr20:60628389	TAF4	-0.77	-13.89	-0.54	6.56e-37	Body mass index;
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg09448879	chr15:79043637	NA	0.52	10.99	0.45	3.99e-25	Coronary artery disease or large artery stroke;
LGG	trans	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg06521331	chr12:34319734	NA	0.44	8.04	0.35	7.49e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg21427119	chr20:30132790	HM13	-0.42	-7.2	-0.32	2.53e-12	Mean corpuscular hemoglobin;
LGG	cis	rs701145	0.556	rs355751	chr3:153971602	T/C	cg17054900	chr3:154042577	DHX36	0.48	7.29	0.32	1.34e-12	Coronary artery disease;
LGG	cis	rs5742933	0.744	rs13009889	chr2:190628568	G/A	cg10453823	chr2:190539512	ANKAR	-0.47	-6.84	-0.3	2.48e-11	Ferritin levels;
LGG	cis	rs1256061	0.603	rs1269056	chr14:64743890	T/C	cg23250157	chr14:64679961	SYNE2	0.39	7.1	0.31	4.8e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4555082	0.874	rs1008628	chr14:105722726	T/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.13	-0.31	3.86e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6502050	0.835	rs7212441	chr17:80080047	T/G	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs6879260	0.714	rs888926	chr5:179738101	A/G	cg13944838	chr5:179740914	GFPT2	-0.63	-10.7	-0.45	4.86e-24	Height;
LGG	cis	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg13443165	chr9:33130375	B4GALT1	-0.59	-11.5	-0.47	4.36e-27	IgG glycosylation;
LGG	cis	rs2270450	0.765	rs10807344	chr6:46625635	C/T	cg10156739	chr6:46714674	LOC100287718	-0.41	-8.69	-0.37	6.46e-17	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.87	-0.45	1.1e-24	Height;
LGG	cis	rs17767392	0.813	rs35831373	chr14:71918421	C/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.14	0.35	3.76e-15	Mitral valve prolapse;
LGG	cis	rs17321999	0.516	rs72787748	chr2:30506642	G/A	cg05247661	chr2:30472410	LBH	0.65	8.06	0.35	6.76e-15	Systemic lupus erythematosus;
LGG	cis	rs13191362	0.507	rs2023015	chr6:163060528	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-8.33	-0.36	9.39e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4689388	0.890	rs4342257	chr4:6290037	G/C	cg25554036	chr4:6271136	WFS1	0.61	11.62	0.48	1.51e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs10506458	0.915	rs1463821	chr12:63402875	C/G	cg22491629	chr6:157744540	C6orf35	0.9	12.54	0.5	2.95e-31	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9790314	0.663	rs778648	chr3:160708943	A/G	cg03342759	chr3:160939853	NMD3	-0.45	-7.55	-0.33	2.38e-13	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.614	rs2240719	chr17:56582477	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.54	0.56	9.64e-40	Cognitive test performance;
LGG	cis	rs10791323	0.536	rs4937842	chr11:133734542	C/G	cg00579200	chr11:133705235	NA	0.56	10.44	0.44	4.8e-23	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg26338869	chr17:61819248	STRADA	0.54	9.03	0.39	4.75e-18	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.05	-0.31	6.35e-12	Lung cancer;
LGG	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg14191688	chr11:70257035	CTTN	0.56	8.2	0.36	2.39e-15	Coronary artery disease;
LGG	cis	rs7824557	0.591	rs2043510	chr8:11225168	G/A	cg15596359	chr8:11213517	TDH	0.39	7.94	0.35	1.49e-14	Retinal vascular caliber;
LGG	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.49	0.33	3.49e-13	Cystic fibrosis severity;
LGG	cis	rs1467026	0.523	rs9865548	chr3:12801785	C/T	cg05775895	chr3:12838266	CAND2	0.71	12.57	0.5	2.14e-31	P wave duration;
LGG	cis	rs9325144	0.647	rs1875609	chr12:39018259	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.54	-0.33	2.52e-13	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.77	-0.54	2.06e-36	Alzheimer's disease;
LGG	cis	rs1909881	1.000	rs16917786	chr8:96515724	T/C	cg04203453	chr8:96504381	NA	-1.08	-18.43	-0.65	2.6e-57	Obesity-related traits;
LGG	cis	rs1843834	0.716	rs6716600	chr2:225481991	A/T	cg22455342	chr2:225449267	CUL3	0.63	10.79	0.45	2.25e-24	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg14829155	chr15:31115871	NA	-0.58	-10.18	-0.43	4.21e-22	Huntington's disease progression;
LGG	cis	rs171408	0.895	rs165176	chr3:8619105	A/G	cg03557445	chr3:8615444	LOH3CR2A	-0.48	-8.53	-0.37	2.08e-16	Mitral valve prolapse;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs1682825	0.585	rs13091714	chr3:10768096	A/G	cg23512531	chr3:10780469	NA	0.6	9.57	0.41	6.62e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs853679	0.517	rs9393901	chr6:28136797	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs12765878	0.541	rs7091346	chr10:105608824	C/T	cg11005552	chr10:105648138	OBFC1	-0.71	-12.43	-0.5	8.14e-31	Coronary artery disease;
LGG	cis	rs7937890	0.559	rs2575823	chr11:14521354	C/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs6032067	0.543	rs7272524	chr20:43908694	A/T	cg10761708	chr20:43804764	PI3	0.47	7.5	0.33	3.21e-13	Blood protein levels;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg13628971	chr7:2884303	GNA12	0.49	9.57	0.41	6.63e-20	Height;
LGG	cis	rs7166081	1.000	rs12595334	chr15:67485156	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.88	-0.3	1.89e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.36	0.32	8.47e-13	Total cholesterol levels;
LGG	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	cis	rs2242116	0.932	rs4683301	chr3:46931478	A/T	cg02527881	chr3:46936655	PTH1R	0.38	9.64	0.41	3.61e-20	Birth weight;
LGG	cis	rs4845570	0.850	rs4618976	chr1:151766588	A/G	cg07092448	chr1:151763213	TDRKH	1.14	17.86	0.64	1.15e-54	Coronary artery disease;
LGG	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.83e-16	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03031773	chr17:46970570	ATP5G1	0.41	6.92	0.31	1.52e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs10506458	1.000	rs12425655	chr12:63434463	C/T	cg22491629	chr6:157744540	C6orf35	-0.84	-12.37	-0.5	1.45e-30	Hemostatic factors and hematological phenotypes;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg02951883	chr7:2050386	MAD1L1	0.66	13.27	0.52	2.85e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs422249	0.512	rs174574	chr11:61600342	A/C	cg19610905	chr11:61596333	FADS2	0.76	14.09	0.55	9.41e-38	Trans fatty acid levels;
LGG	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg26384229	chr12:38710491	ALG10B	0.63	12.22	0.49	5.98e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.25e-12	Bipolar disorder;
LGG	trans	rs7395662	1.000	rs12365220	chr11:48555957	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.03	-0.31	7.34e-12	HDL cholesterol;
LGG	cis	rs2463822	0.920	rs7924998	chr11:62073980	C/G	cg06239285	chr11:62104954	ASRGL1	-1.18	-15.45	-0.58	9.51e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.46	-0.44	3.8e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg08498830	chr11:832797	CD151	-0.44	-7.04	-0.31	6.83e-12	Mean platelet volume;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg07701084	chr6:150067640	NUP43	0.42	7.63	0.33	1.31e-13	Lung cancer;
LGG	cis	rs11711311	1.000	rs12637066	chr3:113527574	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.1	0.55	8.18e-38	IgG glycosylation;
LGG	cis	rs17227506	0.583	rs13257017	chr8:13435361	G/C	cg03566418	chr8:13424080	C8orf48	0.58	8.74	0.38	4.17e-17	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7635838	0.859	rs6768611	chr3:11434465	G/A	cg00170343	chr3:11313890	ATG7	0.42	6.84	0.3	2.54e-11	HDL cholesterol;
LGG	cis	rs4595586	0.525	rs7968566	chr12:39377200	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.45	0.53	4.85e-35	Height;
LGG	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg07636037	chr3:49044803	WDR6	1.01	22.65	0.73	5.17e-77	Parkinson's disease;
LGG	cis	rs12049351	0.665	rs11809370	chr1:229587133	A/G	cg13547644	chr1:229569608	ACTA1	0.32	7.17	0.32	2.92e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg16850897	chr7:100343110	ZAN	-0.68	-10.02	-0.42	1.61e-21	Other erythrocyte phenotypes;
LGG	cis	rs3731896	0.752	rs11889536	chr2:220163543	A/G	cg14987769	chr2:220197576	RESP18	0.48	6.94	0.31	1.33e-11	Educational attainment;
LGG	cis	rs2290159	0.752	rs3773349	chr3:12649732	T/C	cg23032965	chr3:12705835	RAF1	0.68	9.84	0.42	7.33e-21	Cholesterol, total;
LGG	cis	rs9815354	0.680	rs57525756	chr3:41843591	A/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg05163923	chr11:71159392	DHCR7	0.71	14.16	0.55	4.46e-38	Vitamin D levels;
LGG	cis	rs921968	0.541	rs620596	chr2:219462419	G/A	cg01130898	chr2:219473002	PLCD4	-0.43	-7.51	-0.33	3.01e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9378357	0.702	rs7748835	chr6:3293939	A/G	cg08754725	chr6:3293098	SLC22A23	-0.77	-7.18	-0.32	2.83e-12	Obesity-related traits;
LGG	cis	rs12048904	0.964	rs12027668	chr1:101330984	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	9.68	0.41	2.7e-20	Multiple sclerosis;
LGG	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.92	0.38	1.12e-17	Motion sickness;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.61	11.88	0.48	1.39e-28	Obesity-related traits;
LGG	cis	rs1659258	0.568	rs1258437	chr2:88608769	T/G	cg00685853	chr2:88648947	NA	-0.45	-6.73	-0.3	4.91e-11	Visceral fat;
LGG	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg08085267	chr17:45401833	C17orf57	-0.54	-9.79	-0.41	1.06e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg17691542	chr6:26056736	HIST1H1C	-0.59	-9.79	-0.41	1.12e-20	Iron status biomarkers;
LGG	cis	rs9325144	0.600	rs61931871	chr12:38829889	G/A	cg04568710	chr12:38710424	ALG10B	-0.39	-8.05	-0.35	6.85e-15	Morning vs. evening chronotype;
LGG	cis	rs4690686	0.500	rs11728314	chr4:177268373	G/A	cg17059388	chr4:177262070	NA	1.02	24.01	0.74	2.44e-83	Essential tremor;
LGG	cis	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.87	0.3	2.14e-11	Neuroticism;
LGG	cis	rs3733346	0.520	rs62297086	chr4:909040	G/A	cg20814179	chr4:940893	TMEM175	0.53	10.85	0.45	1.35e-24	Sjögren's syndrome;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg05091796	chr16:4465799	CORO7	-0.82	-13.84	-0.54	1.04e-36	Schizophrenia;
LGG	cis	rs1775715	0.707	rs2808088	chr10:32146150	A/G	cg14930904	chr10:32216787	ARHGAP12	0.36	6.98	0.31	1.04e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs4740619	0.647	rs1355173	chr9:15759602	C/A	cg14451791	chr9:16040625	NA	0.36	9.38	0.4	2.84e-19	Body mass index;
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.0	-0.35	1e-14	IgG glycosylation;
LGG	cis	rs4774830	0.744	rs62046391	chr15:56310688	C/T	cg24530489	chr15:56299380	NA	-0.84	-7.73	-0.34	6.59e-14	Delta-5 desaturase activity;
LGG	cis	rs12291225	0.585	rs12270374	chr11:14375079	T/C	cg19336497	chr11:14380999	RRAS2	-0.63	-13.39	-0.53	8.83e-35	Sense of smell;
LGG	cis	rs13421350	0.579	rs77167534	chr2:173319930	C/T	cg15021238	chr2:173305865	ITGA6	-0.83	-9.57	-0.41	6.52e-20	Diabetic kidney disease;
LGG	trans	rs9329221	0.683	rs525726	chr8:9887797	G/C	cg00405596	chr8:11794950	NA	-0.41	-6.73	-0.3	4.98e-11	Neuroticism;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.71	0.3	5.71e-11	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09417774	chr12:112037791	ATXN2	0.5	7.76	0.34	5.32e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg16507663	chr6:150244633	RAET1G	-0.43	-8.05	-0.35	6.99e-15	Lung cancer;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs12144309	0.554	rs2476599	chr1:114363459	G/A	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.34	6.68	0.3	7.06e-11	Coronary artery disease;
LGG	cis	rs9783347	0.643	rs4150581	chr11:18357270	C/T	cg15585147	chr11:18324498	HPS5	-0.32	-7.26	-0.32	1.65e-12	Pancreatic cancer;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg27471124	chr11:109292789	C11orf87	0.49	9.32	0.4	4.91e-19	Schizophrenia;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg13628971	chr7:2884303	GNA12	0.36	7.4	0.33	6.27e-13	Height;
LGG	cis	rs11122272	0.735	rs2739509	chr1:231526765	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.78	-0.34	4.93e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7727544	0.716	rs72793283	chr5:131566941	G/A	cg07395648	chr5:131743802	NA	-0.42	-8.91	-0.38	1.16e-17	Blood metabolite levels;
LGG	cis	rs754466	0.606	rs11002309	chr10:79594931	C/T	cg17075019	chr10:79541650	NA	-0.96	-20.4	-0.69	1.89e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs597583	0.502	rs3016797	chr11:117409884	G/C	cg27161313	chr11:117392002	DSCAML1	-0.54	-6.66	-0.3	7.62e-11	Putamen volume;
LGG	cis	rs9325144	0.560	rs2013804	chr12:38631079	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-12.35	-0.5	1.72e-30	Morning vs. evening chronotype;
LGG	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg05234568	chr11:5960015	NA	-0.67	-11.14	-0.46	1.06e-25	DNA methylation (variation);
LGG	trans	rs3942852	0.868	rs10769315	chr11:48110367	A/G	cg03929089	chr4:120376271	NA	-0.65	-8.13	-0.35	4.04e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs896854	0.654	rs13281625	chr8:95972738	T/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.77e-17	Type 2 diabetes;
LGG	cis	rs4774899	1.000	rs2116065	chr15:57254593	T/A	cg08128148	chr15:57256372	TCF12	-0.34	-7.98	-0.35	1.12e-14	Urinary tract infection frequency;
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg13047869	chr3:10149882	C3orf24	0.53	8.75	0.38	3.93e-17	Alzheimer's disease;
LGG	cis	rs35740288	0.929	rs1978391	chr15:86311695	A/G	cg07943548	chr15:86304357	KLHL25	0.36	7.21	0.32	2.31e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-7.24	-0.32	1.82e-12	Diastolic blood pressure;
LGG	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg24112000	chr20:60950667	NA	0.39	7.89	0.34	2.2e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.6	0.53	1.13e-35	Lung cancer in ever smokers;
LGG	cis	rs7633770	0.786	rs4234464	chr3:46679675	C/T	cg11219411	chr3:46661640	NA	-0.58	-13.52	-0.53	2.38e-35	Coronary artery disease;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg20110707	chr11:118481992	PHLDB1	-0.49	-9.71	-0.41	2.08e-20	Cholesterol, total;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.89	0.38	1.41e-17	Lung cancer;
LGG	cis	rs9399135	0.967	rs9389251	chr6:135325717	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Red blood cell count;
LGG	cis	rs2415984	0.622	rs61993305	chr14:46950955	C/T	cg14871534	chr14:47121158	RPL10L	-0.57	-9.95	-0.42	2.88e-21	Number of children ever born;
LGG	cis	rs1978968	1.000	rs1076540	chr22:18439958	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.2	-0.49	6.82e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	12.09	0.49	1.95e-29	Nonalcoholic fatty liver disease;
LGG	cis	rs7937682	0.575	rs7124696	chr11:111747297	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs2274273	0.624	rs67386901	chr14:55757364	C/T	cg04306507	chr14:55594613	LGALS3	0.54	12.57	0.5	2.2e-31	Protein biomarker;
LGG	cis	rs7829975	0.511	rs2980426	chr8:8145609	T/C	cg06636001	chr8:8085503	FLJ10661	0.6	11.62	0.48	1.44e-27	Mood instability;
LGG	trans	rs7181230	0.885	rs9919974	chr15:40337462	T/G	cg22705835	chr10:65332833	REEP3	-0.6	-9.98	-0.42	2.27e-21	Dehydroepiandrosterone sulphate levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06620762	chr15:76136437	UBE2Q2	0.46	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg21775007	chr8:11205619	TDH	0.43	6.82	0.3	2.84e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.03	0.52	2.73e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg05313129	chr8:58192883	C8orf71	-0.84	-12.29	-0.5	3.18e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7717393	1.000	rs7725121	chr5:155753983	A/T	cg04435420	chr5:155754009	SGCD	1.17	13.25	0.52	3.42e-34	Egg allergy;
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	17.28	0.63	5.42e-52	Personality dimensions;
LGG	cis	rs11920090	0.789	rs57966513	chr3:170746170	G/A	cg09710316	chr3:170744871	SLC2A2	0.62	8.08	0.35	5.75e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg00031303	chr3:195681400	NA	0.56	9.05	0.39	4.03e-18	Pancreatic cancer;
LGG	trans	rs35110281	0.667	rs4819291	chr21:45123139	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.73	0.41	1.77e-20	Mean corpuscular volume;
LGG	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg19748678	chr4:122722346	EXOSC9	0.53	10.37	0.43	8.73e-23	Type 2 diabetes;
LGG	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg09085632	chr11:111637200	PPP2R1B	-0.91	-18.01	-0.64	2.43e-55	Primary sclerosing cholangitis;
LGG	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg03605463	chr16:89740564	NA	0.6	11.03	0.46	2.71e-25	Vitiligo;
LGG	cis	rs7568458	0.870	rs1010	chr2:85808982	C/T	cg23752985	chr2:85803571	VAMP8	-0.43	-8.44	-0.37	4.01e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg18538332	chr22:24372958	LOC391322	-0.47	-7.86	-0.34	2.71e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7011049	0.908	rs72640866	chr8:53843014	C/T	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21211866	chr9:35111727	KIAA1539	0.5	7.56	0.33	2.21e-13	Gut microbiome composition (summer);
LGG	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg05585630	chr7:157510462	PTPRN2	0.47	8.66	0.37	7.93e-17	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.6	-0.44	1.21e-23	Triglycerides;
LGG	trans	rs1941687	0.702	rs4392137	chr18:31316708	T/C	cg27147174	chr7:100797783	AP1S1	-0.53	-8.75	-0.38	3.94e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.55	-0.33	2.36e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg14500267	chr11:67383377	NA	-0.41	-7.36	-0.32	8.19e-13	Mean corpuscular volume;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg11584989	chr19:19387371	SF4	0.41	7.33	0.32	1.01e-12	Tonsillectomy;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg05287481	chr11:17249967	NA	0.42	7.26	0.32	1.69e-12	Menarche (age at onset);
LGG	cis	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg24232236	chr22:38142998	TRIOBP	-0.36	-7.01	-0.31	8.66e-12	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs9329221	0.537	rs6986911	chr8:9978523	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.69	-0.37	6.15e-17	Neuroticism;
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg24397884	chr7:158709396	WDR60	0.92	20.17	0.68	2.23e-65	Height;
LGG	cis	rs7917772	0.503	rs7896841	chr10:104294665	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs894734	0.567	rs7138907	chr12:54324576	C/T	cg12374095	chr12:54320830	NA	-0.4	-7.21	-0.32	2.27e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg23324259	chr8:82754387	SNX16	-0.43	-6.88	-0.3	1.98e-11	Diastolic blood pressure;
LGG	cis	rs7172677	0.501	rs56266638	chr15:75393205	T/A	cg14664628	chr15:75095509	CSK	0.51	9.07	0.39	3.37e-18	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg01620082	chr3:125678407	NA	-0.84	-7.77	-0.34	5.02e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.66	-0.34	1.08e-13	Life satisfaction;
LGG	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg01631408	chr1:248437212	OR2T33	0.37	6.79	0.3	3.4e-11	Common traits (Other);
LGG	cis	rs988958	0.675	rs1866668	chr2:42222004	C/T	cg27252766	chr2:42229092	NA	0.56	8.7	0.37	6.07e-17	Hypospadias;
LGG	cis	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.64	-0.33	1.25e-13	Morning vs. evening chronotype;
LGG	cis	rs6696846	0.905	rs12117194	chr1:205040943	C/G	cg00857998	chr1:205179979	DSTYK	-0.45	-7.47	-0.33	4.09e-13	Red blood cell count;
LGG	cis	rs926938	0.527	rs360665	chr1:115478503	A/T	cg12756093	chr1:115239321	AMPD1	0.43	8.02	0.35	8.46e-15	Autism;
LGG	cis	rs4746818	1.000	rs7899844	chr10:70949694	A/G	cg11621586	chr10:70884670	VPS26A	1.13	20.36	0.69	2.85e-66	Left atrial antero-posterior diameter;
LGG	cis	rs7928758	0.943	rs78975867	chr11:134264729	G/A	cg22777979	chr11:134283252	B3GAT1	1.02	12.86	0.51	1.4e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2066819	1.000	rs79718165	chr12:56644251	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs2270450	0.513	rs1421373	chr6:46715067	C/T	cg10156739	chr6:46714674	LOC100287718	-0.29	-6.94	-0.31	1.36e-11	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.56	-9.15	-0.39	1.8e-18	Longevity;
LGG	cis	rs7582180	0.638	rs6734316	chr2:100976210	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	2.98e-27	Intelligence (multi-trait analysis);
LGG	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg07120314	chr15:79043507	NA	0.66	14.62	0.56	4.47e-40	Coronary artery disease or large artery stroke;
LGG	cis	rs1983891	0.955	rs7753653	chr6:41548430	C/T	cg20194872	chr6:41519635	FOXP4	-0.59	-10.42	-0.44	5.64e-23	Prostate cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11328140	chr12:108079443	PWP1	0.42	6.94	0.31	1.33e-11	Cognitive performance;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg18446336	chr7:2847575	GNA12	-0.3	-7.13	-0.31	3.82e-12	Height;
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.81	-0.3	3.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs735396	0.770	rs1169315	chr12:121443753	T/G	cg02403541	chr12:121454288	C12orf43	0.64	10.3	0.43	1.49e-22	N-glycan levels;
LGG	cis	rs1790761	1.000	rs1790761	chr11:67221854	T/C	cg00290607	chr11:67383545	NA	-0.5	-9.02	-0.39	4.94e-18	Mean corpuscular volume;
LGG	cis	rs3785574	0.536	rs2854190	chr17:61960219	G/A	cg09997372	chr17:61989759	CSHL1	-0.34	-6.67	-0.3	7.18e-11	Height;
LGG	cis	rs4555082	0.874	rs28822720	chr14:105746282	T/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.24	-0.46	4.21e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7226408	0.842	rs9958203	chr18:34348958	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.66	-0.3	7.64e-11	Obesity-related traits;
LGG	trans	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-10.14	-0.43	5.81e-22	Triglycerides;
LGG	cis	rs11696845	0.649	rs6031782	chr20:43383832	A/G	cg25301532	chr20:43378953	KCNK15	-0.48	-11.78	-0.48	3.43e-28	Obesity-related traits;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26059977	chr11:110916892	NA	-0.36	-6.74	-0.3	4.79e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg03433033	chr1:76189801	ACADM	0.75	12.52	0.5	3.68e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg22963979	chr7:1858916	MAD1L1	-0.5	-9.84	-0.42	6.97e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7216064	0.953	rs1966410	chr17:65837215	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.52	10.13	0.43	6.45e-22	Longevity;
LGG	cis	rs11785400	0.701	rs9297968	chr8:143723009	A/G	cg10596483	chr8:143751796	JRK	0.51	7.95	0.35	1.48e-14	Schizophrenia;
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg13009111	chr11:71350975	NA	0.36	8.4	0.36	5.61e-16	Monocyte count;
LGG	cis	rs258892	0.895	rs34206264	chr5:72059806	C/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs36093844	0.752	rs56396016	chr11:85596390	C/A	cg16165120	chr11:85566439	CCDC83	-0.43	-6.71	-0.3	5.62e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs12802200	0.535	rs35541591	chr11:570538	C/A	cg02461776	chr11:598696	PHRF1	0.42	6.91	0.31	1.65e-11	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.601	rs9379224	chr6:8538413	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.52	0.5	3.4e-31	Motion sickness;
LGG	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.11	0.31	4.47e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7216064	1.000	rs1976054	chr17:65833224	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.91	-0.38	1.22e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg02725872	chr8:58115012	NA	-0.84	-16.12	-0.6	1.05e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg21100191	chr22:23484243	RTDR1	1.0	22.93	0.73	2.65e-78	Bone mineral density;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.39	-0.43	7.01e-23	Prostate cancer;
LGG	cis	rs8072100	0.967	rs7219303	chr17:45737701	A/G	cg25173405	chr17:45401733	C17orf57	0.47	8.06	0.35	6.79e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.33	0.32	1.03e-12	Longevity;
LGG	cis	rs7186908	0.793	rs7191623	chr16:72212044	G/A	cg01557791	chr16:72042693	DHODH	-0.52	-7.97	-0.35	1.28e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7959452	0.570	rs10878964	chr12:69720691	T/G	cg14784868	chr12:69753453	YEATS4	0.72	13.89	0.54	6.77e-37	Blood protein levels;
LGG	cis	rs854765	0.619	rs1101727	chr17:18016148	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	13.84	0.54	1.02e-36	Total body bone mineral density;
LGG	cis	rs7044106	0.762	rs966397	chr9:123453312	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	6.09e-49	Hip circumference adjusted for BMI;
LGG	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg15873301	chr3:12045459	SYN2	0.56	9.79	0.41	1.07e-20	Plateletcrit;Lymphocyte counts;White blood cell count;
LGG	cis	rs763121	0.853	rs6001191	chr22:39074452	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.53	10.24	0.43	2.45e-22	Longevity;
LGG	cis	rs2072499	0.966	rs2984615	chr1:156165317	G/C	cg25208724	chr1:156163844	SLC25A44	1.26	31.72	0.83	3.75e-118	Testicular germ cell tumor;
LGG	cis	rs745080	0.519	rs67565529	chr14:52914315	A/G	cg23333723	chr14:53022898	GPR137C	-0.42	-8.49	-0.37	2.74e-16	Orofacial clefts;
LGG	cis	rs12579753	1.000	rs12830268	chr12:82233627	A/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	13.91	0.54	5.32e-37	Obesity-related traits;
LGG	cis	rs858239	0.601	rs2068459	chr7:23154313	A/C	cg23682824	chr7:23144976	KLHL7	0.43	7.33	0.32	1e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs736801	0.808	rs2522057	chr5:131801947	C/G	cg07395648	chr5:131743802	NA	-0.5	-10.61	-0.44	1.13e-23	Breast cancer;Mosquito bite size;
LGG	cis	rs17376456	0.569	rs11948511	chr5:93286601	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.76	-0.34	5.39e-14	Diabetic retinopathy;
LGG	trans	rs7248779	0.532	rs10153475	chr19:2413961	G/C	cg25835954	chr13:50160062	RCBTB1	0.53	7.97	0.35	1.26e-14	Cortisol levels (saliva);
LGG	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	trans	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.54	-0.33	2.54e-13	Morning vs. evening chronotype;
LGG	cis	rs2905347	0.737	rs756879	chr7:22634005	A/G	cg23521230	chr7:22704884	NA	0.41	7.46	0.33	4.29e-13	Major depression and alcohol dependence;
LGG	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.7	0.37	5.95e-17	Systolic blood pressure;
LGG	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg17644776	chr2:200775616	C2orf69	-0.6	-7.01	-0.31	8.46e-12	Schizophrenia;
LGG	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.74	0.3	4.58e-11	Vitiligo;
LGG	cis	rs60180747	1.000	rs17851970	chr15:66612965	C/T	cg07575407	chr15:66541975	MEGF11	-0.36	-7.48	-0.33	3.77e-13	Testicular germ cell tumor;
LGG	cis	rs11098499	0.743	rs11098501	chr4:120252017	T/G	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg08344181	chr3:125677491	NA	0.56	7.28	0.32	1.45e-12	Depression;
LGG	cis	rs4509693	0.943	rs4917907	chr10:102498140	A/G	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg24803719	chr17:45855879	NA	0.23	7.14	0.32	3.58e-12	IgG glycosylation;
LGG	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs7998202	0.667	rs914017	chr13:113355037	G/A	cg02820901	chr13:113351484	ATP11A	0.62	7.35	0.32	9.1e-13	Glycated hemoglobin levels;
LGG	cis	rs72945132	0.882	rs17160753	chr11:70131462	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs1371867	0.846	rs1788181	chr8:101334068	C/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.2	-0.46	6.44e-26	Urinary metabolites;
LGG	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg17509989	chr5:176798049	RGS14	0.87	15.21	0.58	1.17e-42	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs9790314	0.659	rs13066683	chr3:160847410	A/G	cg04691961	chr3:161091175	C3orf57	-0.52	-11.45	-0.47	6.57e-27	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg12458913	chr13:53173898	NA	0.58	10.95	0.45	5.51e-25	Lewy body disease;
LGG	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg15268244	chr15:77196840	NA	-0.34	-7.37	-0.32	7.87e-13	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.63	0.33	1.31e-13	Menopause (age at onset);
LGG	cis	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.43	0.36	4.56e-16	Mood instability;
LGG	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.39	-0.32	6.77e-13	Coronary artery disease;
LGG	trans	rs11148252	0.904	rs9526927	chr13:53051627	C/T	cg18335740	chr13:41363409	SLC25A15	0.66	13.58	0.53	1.39e-35	Lewy body disease;
LGG	cis	rs9388451	0.874	rs1159974	chr6:126090277	C/T	cg05901451	chr6:126070800	HEY2	0.79	16.87	0.62	3.89e-50	Brugada syndrome;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg02951883	chr7:2050386	MAD1L1	0.66	13.55	0.53	1.74e-35	Schizophrenia;
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg21911579	chr5:131705225	SLC22A5	0.61	6.76	0.3	4.11e-11	Rheumatoid arthritis;
LGG	cis	rs4660214	0.724	rs2484751	chr1:39748539	C/A	cg18385671	chr1:39797026	MACF1	-0.48	-9.61	-0.41	4.84e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs656319	0.625	rs34427895	chr8:9875221	G/C	cg12395012	chr8:11607386	GATA4	0.41	7.16	0.32	3.19e-12	Myopia (pathological);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17581312	chr6:76644770	IMPG1	0.43	7.3	0.32	1.26e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.16	-0.49	1.07e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6087771	0.890	rs6089056	chr20:30325773	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs10992471	0.702	rs10820967	chr9:95101729	C/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.44	-6.96	-0.31	1.17e-11	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs9329221	0.537	rs13254175	chr8:9978772	C/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.78	-0.38	3.29e-17	Neuroticism;
LGG	cis	rs11864453	0.713	rs6680	chr16:72146570	T/C	cg01557791	chr16:72042693	DHODH	-0.52	-9.68	-0.41	2.6e-20	Fibrinogen levels;
LGG	trans	rs62458065	0.513	rs702831	chr7:32579715	C/T	cg00845942	chr12:64062724	DPY19L2	-0.59	-7.74	-0.34	6.49e-14	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs9733	0.744	rs12125650	chr1:150760174	A/G	cg13175981	chr1:150552382	MCL1	0.54	8.73	0.38	4.55e-17	Tonsillectomy;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.33	-0.32	1.01e-12	Lung cancer;
LGG	cis	rs2865126	0.818	rs7242408	chr18:10757868	A/G	cg21165219	chr18:10698044	FAM38B	-0.45	-7.27	-0.32	1.51e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.6	-0.33	1.61e-13	Gut microbiome composition (summer);
LGG	cis	rs727505	1.000	rs113394869	chr7:124518172	G/C	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg20821713	chr7:1055600	C7orf50	-0.51	-7.97	-0.35	1.22e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2386661	0.547	rs11259540	chr10:5646706	A/T	cg17085576	chr10:5658249	NA	-0.42	-7.76	-0.34	5.34e-14	Breast cancer;
LGG	trans	rs453301	0.506	rs476845	chr8:8622877	A/G	cg02002194	chr4:3960332	NA	0.37	6.96	0.31	1.18e-11	Joint mobility (Beighton score);
LGG	trans	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg27661571	chr11:113659931	NA	-0.67	-9.58	-0.41	5.98e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg13206674	chr6:150067644	NUP43	0.66	14.8	0.57	7.65e-41	Lung cancer;
LGG	cis	rs6500395	0.588	rs2354580	chr16:48637178	C/T	cg04672837	chr16:48644449	N4BP1	0.51	8.83	0.38	2.15e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg11707556	chr5:10655725	ANKRD33B	0.38	6.78	0.3	3.77e-11	Coronary artery disease;
LGG	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.69	-0.41	2.36e-20	Diabetic retinopathy;
LGG	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg15664640	chr17:80829946	TBCD	-0.65	-8.97	-0.38	7.64e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.23	-0.32	2e-12	Prostate cancer;
LGG	cis	rs9372078	1.000	rs9372079	chr6:150914050	C/T	cg01013955	chr6:150918915	NA	-0.33	-7.07	-0.31	5.73e-12	Panic disorder;
LGG	cis	rs796364	0.951	rs36086821	chr2:201067436	G/A	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.45e-17	Schizophrenia;
LGG	cis	rs11098499	0.954	rs1546505	chr4:120241224	A/G	cg09307838	chr4:120376055	NA	0.8	12.99	0.52	4.01e-33	Corneal astigmatism;
LGG	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.57	7.9	0.34	2.02e-14	Diabetic retinopathy;
LGG	cis	rs2717559	0.522	rs2572922	chr8:143871652	G/A	cg06565975	chr8:143823917	SLURP1	0.29	6.97	0.31	1.08e-11	Urinary tract infection frequency;
LGG	cis	rs9863	0.931	rs4575361	chr12:124410529	A/T	cg13487667	chr12:124434373	CCDC92	-0.37	-7.14	-0.31	3.69e-12	White blood cell count;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg02725872	chr8:58115012	NA	-0.78	-10.55	-0.44	1.9e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.53	-0.33	2.59e-13	HDL cholesterol;
LGG	trans	rs1814175	0.645	rs28549248	chr11:50042740	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg13395646	chr4:1353034	KIAA1530	0.52	9.32	0.4	4.58e-19	Obesity-related traits;
LGG	cis	rs7552404	0.731	rs10873788	chr1:76367857	A/C	cg10523679	chr1:76189770	ACADM	0.61	9.03	0.39	4.6e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07234876	chr8:600039	NA	1.19	11.76	0.48	3.92e-28	IgG glycosylation;
LGG	cis	rs939658	0.683	rs8041222	chr15:79465549	A/G	cg17916960	chr15:79447300	NA	-0.54	-10.06	-0.42	1.19e-21	Refractive error;
LGG	cis	rs763121	0.853	rs5757196	chr22:39039855	G/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg00745463	chr17:30367425	LRRC37B	-0.69	-10.2	-0.43	3.57e-22	Hip circumference adjusted for BMI;
LGG	cis	rs2072499	0.868	rs2758600	chr1:156195205	C/T	cg24450063	chr1:156163899	SLC25A44	1.14	24.05	0.75	1.6e-83	Testicular germ cell tumor;
LGG	cis	rs2802728	1.000	rs78450135	chr1:243517825	A/G	cg05593162	chr1:243577377	SDCCAG8	0.54	7.09	0.31	5.04e-12	Toenail selenium levels;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.48	0.58	7.68e-44	Lung cancer;
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg00495681	chr13:53174319	NA	-0.68	-13.61	-0.53	1.01e-35	Lewy body disease;
LGG	cis	rs11866815	0.817	rs9935993	chr16:401209	C/T	cg12437481	chr16:420112	MRPL28	0.56	9.05	0.39	3.88e-18	Body mass index;
LGG	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg03213289	chr20:61660250	NA	0.63	12.8	0.51	2.58e-32	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.37	7.05	0.31	6.51e-12	Schizophrenia;
LGG	trans	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg11441553	chr12:57614120	NXPH4	-0.58	-7.2	-0.32	2.44e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs701145	0.585	rs1713822	chr3:153863505	A/G	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.82e-19	Coronary artery disease;
LGG	cis	rs11190604	1.000	rs2489037	chr10:102319918	A/G	cg11040518	chr10:102331378	NA	0.39	7.0	0.31	8.78e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6445975	0.726	rs4330265	chr3:58468028	C/G	cg24175188	chr3:58374923	PXK	0.44	8.1	0.35	4.84e-15	Systemic lupus erythematosus;
LGG	trans	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg11693508	chr17:37793320	STARD3	0.61	8.52	0.37	2.31e-16	Bipolar disorder;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26822480	chr16:84341323	WFDC1	0.37	6.76	0.3	4.11e-11	Pancreatic cancer;
LGG	cis	rs2762353	0.808	rs1165150	chr6:25842032	C/T	cg03264133	chr6:25882463	NA	-0.57	-10.71	-0.45	4.72e-24	Blood metabolite levels;
LGG	trans	rs7746199	0.736	rs13195636	chr6:27509493	A/C	cg08344181	chr3:125677491	NA	-0.9	-8.71	-0.38	5.3e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9522267	0.535	rs9522290	chr13:112233130	A/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs13421350	0.579	rs57587465	chr2:173399767	T/C	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.67	0.41	2.89e-20	Menarche (age at onset);
LGG	cis	rs7107174	1.000	rs11602622	chr11:78010830	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.63	-0.33	1.39e-13	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06784845	chr3:133614993	RAB6B	0.48	7.96	0.35	1.31e-14	Cognitive performance;
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg14338887	chr6:42928500	GNMT	0.27	8.94	0.38	9.31e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10791323	0.521	rs10894756	chr11:133745852	G/A	cg06766960	chr11:133703094	NA	-0.51	-10.08	-0.42	9.82e-22	Childhood ear infection;
LGG	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08209042	chr3:196295218	WDR53;FBXO45	0.45	7.27	0.32	1.56e-12	Cognitive performance;
LGG	cis	rs637571	0.544	rs500161	chr11:65695438	C/T	cg26695010	chr11:65641043	EFEMP2	-0.5	-8.23	-0.36	1.97e-15	Eosinophil percentage of white cells;
LGG	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs975722	0.659	rs13245795	chr7:117089889	T/A	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.3	-0.4	5.73e-19	Coronary artery disease;
LGG	cis	rs7937890	1.000	rs7937890	chr11:14396485	C/T	cg19336497	chr11:14380999	RRAS2	-0.38	-7.6	-0.33	1.68e-13	Mitochondrial DNA levels;
LGG	cis	rs2587949	0.615	rs2120512	chr3:4211943	T/G	cg16519197	chr3:4211558	NA	-0.32	-6.74	-0.3	4.75e-11	Periodontitis (DPAL);
LGG	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.07	0.39	3.29e-18	Retinal vascular caliber;
LGG	cis	rs9916302	0.904	rs4795355	chr17:37427382	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs72827839	0.740	rs72823509	chr17:46044589	G/A	cg02219949	chr17:45927392	SP6	0.49	7.44	0.33	5.04e-13	Ease of getting up in the morning;
LGG	cis	rs12478296	1.000	rs12478296	chr2:243048760	A/G	cg18898632	chr2:242989856	NA	0.73	9.15	0.39	1.88e-18	Obesity-related traits;
LGG	cis	rs847851	0.630	rs9469905	chr6:34797747	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.39	-0.47	1.16e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.24	0.65	1.99e-56	Personality dimensions;
LGG	cis	rs4959677	0.698	rs9501850	chr6:2480110	C/T	cg23817096	chr6:1620687	NA	0.35	8.56	0.37	1.72e-16	Orthostatic hypotension;
LGG	cis	rs8067545	0.611	rs9907516	chr17:20070490	G/A	cg09818912	chr17:20140352	CYTSB	-0.32	-7.53	-0.33	2.71e-13	Schizophrenia;
LGG	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg13736514	chr6:26305472	NA	-0.45	-8.98	-0.39	6.9e-18	Educational attainment;
LGG	cis	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg24623649	chr8:11872141	NA	0.3	7.31	0.32	1.18e-12	Monocyte count;
LGG	cis	rs13257813	0.727	rs2672266	chr8:19027926	G/A	cg15587955	chr8:19026658	NA	-0.47	-6.96	-0.31	1.18e-11	Mean platelet volume;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.87	-0.3	2.04e-11	Personality dimensions;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.29	-0.36	1.22e-15	Tonsillectomy;
LGG	cis	rs17767392	0.871	rs2108706	chr14:71799175	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.37	-8.39	-0.36	5.78e-16	Mitral valve prolapse;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg12458913	chr13:53173898	NA	0.63	12.36	0.5	1.66e-30	Lewy body disease;
LGG	cis	rs514406	0.505	rs374662	chr1:53164549	C/A	cg16325326	chr1:53192061	ZYG11B	0.84	23.23	0.73	1.05e-79	Monocyte count;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg10189774	chr4:17578691	LAP3	0.42	7.55	0.33	2.27e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg13565492	chr6:43139072	SRF	-0.79	-10.11	-0.43	7.42e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4714291	1.000	rs847752	chr6:40034557	T/C	cg02267698	chr19:7991119	CTXN1	0.54	8.17	0.35	2.89e-15	Strep throat;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg02725872	chr8:58115012	NA	-0.78	-11.09	-0.46	1.73e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs36071027	0.577	rs12109219	chr5:158393842	T/G	cg00594129	chr5:158524270	EBF1	0.45	8.09	0.35	5.32e-15	Carotid intima media thickness;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.11	-0.49	1.66e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg21605333	chr4:119757512	SEC24D	1.48	14.89	0.57	2.87e-41	Cannabis dependence symptom count;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg07685180	chr8:600429	NA	1.13	11.18	0.46	7.22e-26	IgG glycosylation;
LGG	cis	rs77669868	0.568	rs3825045	chr11:114073200	C/T	cg01914181	chr11:114070210	ZBTB16	0.67	7.87	0.34	2.48e-14	Monocyte percentage of white cells;
LGG	cis	rs7084402	0.967	rs1593674	chr10:60291908	A/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.71e-13	Refractive error;
LGG	cis	rs10504229	1.000	rs67594249	chr8:58180521	T/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.35e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs6787172	0.702	rs2693527	chr3:157991013	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.7	0.37	6.03e-17	Subjective well-being;
LGG	cis	rs4481887	0.800	rs4639798	chr1:248515703	A/G	cg00666640	chr1:248458726	OR2T12	0.5	8.43	0.36	4.48e-16	Common traits (Other);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg04747728	chr16:31725053	ZNF720	-0.41	-6.93	-0.31	1.41e-11	Brain structure;
LGG	cis	rs13260300	0.657	rs4302822	chr8:75485033	G/A	cg22993706	chr8:75542856	NA	0.38	7.09	0.31	5e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00149659	chr3:10157352	C3orf10	0.74	9.06	0.39	3.56e-18	Alzheimer's disease;
LGG	cis	rs7044106	0.762	rs966396	chr9:123453281	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.94	0.49	7.72e-29	Hip circumference adjusted for BMI;
LGG	cis	rs2084898	1.000	rs569044	chr11:119999191	A/G	cg07435449	chr11:120005650	TRIM29	0.65	7.26	0.32	1.7e-12	Stroke (pediatric);
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.05	-0.6	2.09e-46	Longevity;
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg02002194	chr4:3960332	NA	0.42	7.64	0.33	1.26e-13	Neuroticism;
LGG	cis	rs713587	0.713	rs11682135	chr2:25205377	G/A	cg04586622	chr2:25135609	ADCY3	-0.38	-9.72	-0.41	1.97e-20	Body mass index in non-asthmatics;
LGG	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg25947184	chr8:1697459	NA	0.47	8.24	0.36	1.75e-15	Systolic blood pressure;
LGG	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg16141378	chr3:129829833	LOC729375	0.36	8.04	0.35	7.62e-15	Multiple myeloma (hyperdiploidy);
LGG	trans	rs55986470	0.817	rs11883735	chr2:239407644	G/A	cg01134436	chr17:81009848	B3GNTL1	0.62	7.12	0.31	4.18e-12	Chronotype;
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.21	0.36	2.2e-15	Aortic root size;
LGG	cis	rs5750830	0.649	rs5757659	chr22:39812409	A/C	cg04986931	chr22:39850128	NA	0.33	7.34	0.32	9.93e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs870825	0.655	rs28726376	chr4:185638954	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.56	0.72	1.44e-76	Blood protein levels;
LGG	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	2.93e-31	Motion sickness;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg18621852	chr3:10150065	C3orf24	0.4	6.8	0.3	3.15e-11	Alzheimer's disease;
LGG	trans	rs72991	0.639	rs10790444	chr11:121235129	A/T	cg27192990	chr6:129479024	LAMA2	0.6	9.57	0.41	6.54e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.28	-0.43	1.87e-22	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13436085	chr3:183904316	ABCF3	0.4	6.73	0.3	4.96e-11	Bipolar disorder;
LGG	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.41	6.84	0.3	2.46e-11	Electroencephalogram traits;
LGG	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg04117972	chr1:227635322	NA	-0.77	-12.24	-0.49	4.96e-30	Major depressive disorder;
LGG	trans	rs7939886	0.920	rs80232778	chr11:55970655	G/A	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs9815354	1.000	rs6599175	chr3:41786009	C/T	cg03022575	chr3:42003672	ULK4	-0.59	-7.56	-0.33	2.18e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.51	0.61	1.77e-48	Obesity-related traits;
LGG	trans	rs7824557	0.547	rs2572391	chr8:11235614	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.56	-0.37	1.65e-16	Retinal vascular caliber;
LGG	trans	rs9650657	0.836	rs3905581	chr8:10603705	G/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.85	-0.3	2.35e-11	Neuroticism;
LGG	cis	rs2549003	0.674	rs960757	chr5:131826310	G/A	cg00578828	chr5:131826934	IRF1	0.39	7.0	0.31	8.89e-12	Asthma (sex interaction);
LGG	cis	rs3796352	1.000	rs71617204	chr3:53042951	G/A	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7659604	0.791	rs57316471	chr4:122663939	A/G	cg06713675	chr4:122721982	EXOSC9	-0.55	-8.94	-0.38	9.09e-18	Type 2 diabetes;
LGG	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg21926883	chr2:100939477	LONRF2	-0.48	-9.41	-0.4	2.29e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.65	-0.74	1.17e-81	Primary sclerosing cholangitis;
LGG	cis	rs7552404	0.731	rs61770556	chr1:76421902	T/C	cg03433033	chr1:76189801	ACADM	0.64	8.86	0.38	1.72e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg05059571	chr16:84539110	KIAA1609	0.53	9.97	0.42	2.41e-21	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01436700	chr2:105953902	C2orf49	0.41	6.78	0.3	3.74e-11	Cognitive performance;
LGG	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg20991723	chr1:152506922	NA	-0.73	-14.99	-0.57	1.09e-41	Hair morphology;
LGG	trans	rs61931739	0.534	rs11053021	chr12:34111157	C/T	cg26384229	chr12:38710491	ALG10B	0.82	16.51	0.61	1.77e-48	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00933542	chr6:150070202	PCMT1	0.39	7.04	0.31	6.99e-12	Lung cancer;
LGG	cis	rs12579753	0.667	rs7959589	chr12:82304439	A/G	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.3	-0.32	1.29e-12	Resting heart rate;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg03351412	chr1:154909251	PMVK	0.66	12.46	0.5	6.02e-31	Prostate cancer;
LGG	cis	rs4474465	0.831	rs12287010	chr11:78161452	A/T	cg27205649	chr11:78285834	NARS2	0.5	8.45	0.37	3.89e-16	Alzheimer's disease (survival time);
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	trans	rs6601327	0.641	rs6601350	chr8:9573956	C/G	cg02002194	chr4:3960332	NA	0.39	7.07	0.31	5.9e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs79149102	0.579	rs74023908	chr15:75310710	T/C	cg17294928	chr15:75287854	SCAMP5	-0.82	-9.01	-0.39	5.51e-18	Lung cancer;
LGG	cis	rs3768617	0.903	rs10911251	chr1:183081194	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.37	7.14	0.32	3.54e-12	Fuchs's corneal dystrophy;
LGG	cis	rs7666738	0.753	rs2903143	chr4:99040480	C/T	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02685901	chr6:43597772	MAD2L1BP;GTPBP2	0.47	7.14	0.31	3.66e-12	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.901	rs56360477	chr18:34456833	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs644799	1.000	rs617999	chr11:95589935	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.83	0.34	3.24e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg12458913	chr13:53173898	NA	0.55	9.93	0.42	3.33e-21	Lewy body disease;
LGG	cis	rs1669338	0.588	rs3846135	chr3:3195574	C/T	cg16797762	chr3:3221439	CRBN	-0.94	-12.56	-0.5	2.34e-31	White matter integrity;
LGG	cis	rs56399783	0.901	rs73047387	chr7:2774125	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.0	0.31	9.2e-12	Childhood ear infection;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.935	rs7769048	chr6:163010040	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs933688	1.000	rs11948075	chr5:90680579	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs11105298	0.891	rs11105319	chr12:89927177	G/A	cg00757033	chr12:89920650	WDR51B	0.63	9.15	0.39	1.83e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs657075	0.697	rs71583477	chr5:131686040	A/G	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6692729	0.901	rs4653470	chr1:227082726	T/A	cg08708961	chr1:227070630	PSEN2	0.31	7.81	0.34	3.77e-14	Electrodermal activity;
LGG	trans	rs9467711	0.606	rs9348712	chr6:26366511	T/A	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.99	-0.42	2.05e-21	Schizophrenia;
LGG	cis	rs7928758	0.830	rs11223780	chr11:134261150	C/T	cg15243474	chr11:134282918	B3GAT1	-1.02	-14.92	-0.57	2.31e-41	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg18350739	chr11:68623251	NA	-0.87	-22.15	-0.72	1.16e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7000551	0.715	rs12544074	chr8:22338378	A/G	cg12081754	chr8:22256438	SLC39A14	0.67	12.62	0.51	1.36e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg06353428	chr16:71660113	MARVELD3	-0.5	-7.96	-0.35	1.37e-14	Blood protein levels;
LGG	cis	rs614226	0.872	rs787827	chr12:120937794	A/G	cg01236616	chr12:121019343	POP5	1.27	23.11	0.73	3.65e-79	Type 1 diabetes nephropathy;
LGG	cis	rs12188164	0.930	rs11743825	chr5:475463	C/T	cg26076054	chr5:421317	AHRR	-0.43	-6.96	-0.31	1.14e-11	Cystic fibrosis severity;
LGG	cis	rs919433	0.927	rs1429412	chr2:198190894	A/G	cg00792783	chr2:198669748	PLCL1	-0.46	-7.25	-0.32	1.79e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg18681998	chr4:17616180	MED28	0.84	18.03	0.64	1.88e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3750082	0.603	rs2278818	chr7:32961180	C/T	cg08946731	chr7:32981826	RP9P	0.47	6.99	0.31	9.91e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs620875	1.000	rs600947	chr11:126847694	A/T	cg06504925	chr11:126872760	NA	-0.54	-7.54	-0.33	2.47e-13	Response to antipsychotic treatment;
LGG	trans	rs9929218	1.000	rs12930371	chr16:68802936	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.76	12.96	0.52	5.66e-33	Colorectal cancer;
LGG	cis	rs9368481	0.761	rs9379952	chr6:26987900	A/T	cg18278486	chr6:26987575	LOC100270746;C6orf41	-0.41	-6.84	-0.3	2.53e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs77972916	0.561	rs17406174	chr2:43557484	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-7.06	-0.31	6.04e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7590368	0.715	rs12463454	chr2:10958235	G/A	cg15705551	chr2:10952987	PDIA6	0.55	6.65	0.3	8.45e-11	Educational attainment (years of education);
LGG	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs7572733	0.935	rs13394871	chr2:198846337	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.3	0.36	1.15e-15	Dermatomyositis;
LGG	cis	rs3768617	0.510	rs4651145	chr1:183098900	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs2832077	0.527	rs59730679	chr21:30226244	T/C	cg14791747	chr16:20752902	THUMPD1	0.56	10.31	0.43	1.43e-22	Cognitive test performance;
LGG	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg20821713	chr7:1055600	C7orf50	-0.51	-8.2	-0.36	2.32e-15	Bronchopulmonary dysplasia;
LGG	cis	rs73086581	0.947	rs67356712	chr20:3892886	A/G	cg02187196	chr20:3869020	PANK2	0.89	12.57	0.5	2.18e-31	Response to antidepressants in depression;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.63	0.44	8.93e-24	Personality dimensions;
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg21171335	chr12:122356390	WDR66	0.29	8.29	0.36	1.2e-15	Mean corpuscular volume;
LGG	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg03929089	chr4:120376271	NA	0.9	18.41	0.65	3.31e-57	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.68	0.34	9.3e-14	Prostate cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19233923	chr11:63753598	OTUB1	0.54	8.84	0.38	2.05e-17	Cognitive performance;
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg16339924	chr4:17578868	LAP3	0.63	10.69	0.44	5.54e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3796352	1.000	rs11713859	chr3:53042080	C/A	cg12962167	chr3:53033115	SFMBT1	0.79	8.16	0.35	3.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.0	-0.46	3.64e-25	Lung cancer;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.04	-0.31	6.94e-12	Bipolar disorder;
LGG	cis	rs9341808	0.935	rs4706113	chr6:80839315	C/T	cg08355045	chr6:80787529	NA	0.38	7.7	0.34	8.59e-14	Sitting height ratio;
LGG	cis	rs644799	1.000	rs543530	chr11:95545170	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.73	7.92	0.35	1.75e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.0	-0.31	8.79e-12	Neuroticism;
LGG	cis	rs7208859	0.524	rs28760584	chr17:29141017	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2290402	0.536	rs3775129	chr4:875155	G/A	cg09237302	chr4:906077	GAK	-0.43	-7.31	-0.32	1.2e-12	Type 2 diabetes;
LGG	cis	rs17030434	0.682	rs1339	chr4:154631563	T/C	cg14289246	chr4:154710475	SFRP2	-0.62	-9.48	-0.4	1.3e-19	Electrocardiographic conduction measures;
LGG	cis	rs4262150	0.767	rs4360032	chr5:151963064	C/T	cg12297329	chr5:152029980	NA	0.79	15.56	0.59	3.24e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs2070488	0.965	rs7373828	chr3:38524311	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.93	0.64	5.61e-55	Electrocardiographic conduction measures;
LGG	cis	rs35146811	0.844	rs34031156	chr7:99677917	T/A	cg13334819	chr7:99746414	C7orf59	-0.45	-6.98	-0.31	1.03e-11	Coronary artery disease;
LGG	cis	rs8013055	0.796	rs11628497	chr14:105970789	C/T	cg19700328	chr14:106028568	NA	-0.6	-10.13	-0.43	6.42e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	trans	rs45509595	0.841	rs17751184	chr6:27775028	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.65	-0.37	8.26e-17	Breast cancer;
LGG	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg15309053	chr8:964076	NA	0.36	7.34	0.32	9.45e-13	Schizophrenia;
LGG	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.99	0.49	4.76e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1018836	0.892	rs7819519	chr8:91565504	C/T	cg16814680	chr8:91681699	NA	-0.72	-12.67	-0.51	8.57e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs559928	0.597	rs2096706	chr11:63924446	T/G	cg26318627	chr11:63887540	MACROD1	-0.47	-6.78	-0.3	3.57e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09178368	chr17:16472757	ZNF287	0.5	7.64	0.33	1.29e-13	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.76	-0.34	5.46e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.16	-0.35	3.14e-15	Small cell lung carcinoma;
LGG	trans	rs9354308	0.764	rs9354327	chr6:66587509	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs11622475	0.911	rs55908053	chr14:104386173	T/C	cg20488157	chr14:104394430	TDRD9	0.56	9.3	0.4	5.52e-19	Bipolar disorder;
LGG	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg14926445	chr8:58193284	C8orf71	-0.53	-7.47	-0.33	4.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	trans	rs61931739	0.649	rs12424046	chr12:33714374	C/T	cg26384229	chr12:38710491	ALG10B	-0.48	-8.61	-0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg26513180	chr16:89883248	FANCA	1.02	9.73	0.41	1.71e-20	Skin colour saturation;
LGG	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg10596483	chr8:143751796	JRK	0.51	8.0	0.35	1.04e-14	Schizophrenia;
LGG	cis	rs947474	0.590	rs744253	chr10:6393009	A/G	cg19837174	chr10:6389707	NA	0.49	7.7	0.34	8.6e-14	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.07	17.02	0.62	8.55e-51	Smoking behavior;
LGG	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.53	0.37	2.16e-16	Neuroticism;
LGG	trans	rs7395662	1.000	rs7482528	chr11:48640052	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.17	-0.32	2.93e-12	HDL cholesterol;
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg20110707	chr11:118481992	PHLDB1	0.51	10.27	0.43	1.97e-22	Cholesterol, total;
LGG	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11890956	chr21:40555474	PSMG1	1.04	20.09	0.68	4.94e-65	Cognitive function;
LGG	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg02753203	chr1:228287806	NA	0.76	14.49	0.56	1.72e-39	Diastolic blood pressure;
LGG	cis	rs9467773	0.620	rs2494694	chr6:26619328	A/T	cg09904177	chr6:26538194	HMGN4	0.67	13.93	0.54	4.36e-37	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg05484508	chr16:89589025	SPG7	0.49	7.62	0.33	1.46e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2836974	0.796	rs77153312	chr21:40695499	G/A	cg11890956	chr21:40555474	PSMG1	1.14	26.31	0.77	5.89e-94	Cognitive function;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.03	0.31	7.62e-12	Longevity;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg14789911	chr21:47582049	C21orf56	-0.4	-6.77	-0.3	3.91e-11	Testicular germ cell tumor;
LGG	cis	rs6121246	0.609	rs6060948	chr20:30376393	C/G	cg13852791	chr20:30311386	BCL2L1	0.93	17.93	0.64	5.8e-55	Mean corpuscular hemoglobin;
LGG	cis	rs769267	0.896	rs11882123	chr19:19386339	A/G	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	cis	rs11514810	1.000	rs9648619	chr7:1427949	G/T	cg24899294	chr7:1481343	MICALL2	-0.74	-8.87	-0.38	1.64e-17	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	trans	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.0	-0.31	9.25e-12	Joint mobility (Beighton score);
LGG	trans	rs79976124	0.877	rs79507557	chr6:66640908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.23	0.49	5.31e-30	Type 2 diabetes;
LGG	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	9.92	0.42	3.78e-21	Sudden cardiac arrest;
LGG	cis	rs1552244	1.000	rs6804473	chr3:10060425	C/T	cg08888203	chr3:10149979	C3orf24	0.56	9.46	0.4	1.61e-19	Alzheimer's disease;
LGG	cis	rs3087591	1.000	rs9902893	chr17:29625638	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.59	-0.56	5.94e-40	Hip circumference;
LGG	trans	rs67340775	0.834	rs13218875	chr6:27884012	C/T	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Lung cancer in ever smokers;
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg16359550	chr11:109292809	C11orf87	0.42	8.14	0.35	3.58e-15	Schizophrenia;
LGG	cis	rs7937682	1.000	rs7121011	chr11:111568681	C/T	cg19812747	chr11:111475976	SIK2	0.48	9.5	0.4	1.13e-19	Primary sclerosing cholangitis;
LGG	cis	rs2075371	0.501	rs1643051	chr7:134025372	A/G	cg11752832	chr7:134001865	SLC35B4	-0.48	-8.44	-0.36	4.24e-16	Mean platelet volume;
LGG	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg03433033	chr1:76189801	ACADM	0.65	8.9	0.38	1.24e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg16401465	chr10:63809170	ARID5B	0.38	7.37	0.32	7.74e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.14e-21	Lung cancer;
LGG	cis	rs11122272	0.701	rs971533	chr1:231522097	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7945705	0.846	rs4929911	chr11:8816495	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.43	8.8	0.38	2.79e-17	Hemoglobin concentration;
LGG	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg18963800	chr10:38644991	HSD17B7P2	0.41	6.83	0.3	2.61e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg13565492	chr6:43139072	SRF	-0.76	-9.1	-0.39	2.62e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg09021430	chr5:549028	NA	-0.69	-9.72	-0.41	1.91e-20	Obesity-related traits;
LGG	cis	rs9291683	0.546	rs4529049	chr4:10045389	C/T	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.22	-0.32	2.13e-12	Bone mineral density;
LGG	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg14137381	chr5:502291	SLC9A3	-0.32	-6.67	-0.3	7.18e-11	Cystic fibrosis severity;
LGG	cis	rs28588043	1.000	rs28496733	chr1:170967824	A/C	cg03458344	chr1:170964477	C1orf129	-0.52	-7.61	-0.33	1.5700000000000001e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs1793639	0.616	rs12222235	chr11:131984330	C/T	cg13908476	chr11:131942942	NTM	0.52	10.22	0.43	3.01e-22	Myopia;
LGG	cis	rs6502050	0.731	rs12150589	chr17:80158233	A/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9341808	0.718	rs11962614	chr6:80823306	A/T	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg21926883	chr2:100939477	LONRF2	-0.64	-13.88	-0.54	7.29e-37	Intelligence (multi-trait analysis);
LGG	cis	rs9947295	0.649	rs8099153	chr18:11775522	G/A	cg14735704	chr18:11749182	GNAL	0.48	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg05863683	chr7:1912471	MAD1L1	0.38	6.82	0.3	2.87e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7638995	0.628	rs4855550	chr3:69185740	C/A	cg26574240	chr3:69171822	LMOD3	-0.67	-8.58	-0.37	1.43e-16	Alzheimer's disease (late onset);
LGG	cis	rs7928758	0.887	rs117735303	chr11:134271893	C/T	cg25213107	chr11:134282864	B3GAT1	1.22	15.03	0.57	7.48e-42	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2046867	0.908	rs11928067	chr3:72796340	T/C	cg25664220	chr3:72788482	NA	-0.32	-8.77	-0.38	3.34e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2334880	0.678	rs12922597	chr16:71452393	T/C	cg06353428	chr16:71660113	MARVELD3	-0.66	-9.29	-0.4	6.22e-19	Malaria;
LGG	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	cis	rs6912958	0.781	rs6916732	chr6:88259225	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.64	-0.37	9.55e-17	Monocyte percentage of white cells;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs546131	0.928	rs572690	chr11:34833614	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.61	10.94	0.45	6.12e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.49	-0.33	3.63e-13	Colorectal cancer;
LGG	cis	rs7474896	0.537	rs2749589	chr10:38266870	C/T	cg25427524	chr10:38739819	LOC399744	0.53	8.03	0.35	7.9e-15	Obesity (extreme);
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg02462569	chr6:150064036	NUP43	-0.44	-8.89	-0.38	1.36e-17	Lung cancer;
LGG	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06481639	chr22:41940642	POLR3H	0.58	8.44	0.37	4.15e-16	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4788570	0.566	rs72791974	chr16:71478574	A/T	cg06353428	chr16:71660113	MARVELD3	-0.99	-13.4	-0.53	7.6e-35	Intelligence (multi-trait analysis);
LGG	cis	rs721399	0.553	rs13282367	chr8:18244986	T/G	cg18736775	chr8:18248649	NAT2	-0.79	-12.48	-0.5	5.23e-31	Blood metabolite levels;
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.55e-15	Bipolar disorder;
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg02951883	chr7:2050386	MAD1L1	0.46	6.75	0.3	4.54e-11	Bipolar disorder;
LGG	cis	rs7523273	0.564	rs1570565	chr1:207881256	G/A	cg22525895	chr1:207977042	MIR29B2	0.46	8.7	0.37	5.98e-17	Schizophrenia;
LGG	cis	rs62025270	0.632	rs62022924	chr15:86235507	A/G	cg25843651	chr15:86329602	KLHL25	0.59	9.02	0.39	4.92e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs11098499	0.863	rs1552095	chr4:120460306	A/G	cg09307838	chr4:120376055	NA	0.78	12.97	0.52	5.12e-33	Corneal astigmatism;
LGG	cis	rs9581857	0.547	rs74518675	chr13:27972180	A/G	cg01674679	chr13:27998804	GTF3A	-0.77	-8.7	-0.37	5.83e-17	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs908922	0.651	rs4845442	chr1:152485545	G/A	cg09873164	chr1:152488093	CRCT1	0.64	15.69	0.59	8.18e-45	Hair morphology;
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg08222618	chr4:941054	TMEM175	0.77	16.24	0.6	2.85e-47	Sjögren's syndrome;
LGG	cis	rs4918072	0.834	rs7923008	chr10:105711383	A/G	cg11005552	chr10:105648138	OBFC1	0.43	7.43	0.33	5.29e-13	Coronary artery disease;
LGG	trans	rs853679	0.607	rs35001169	chr6:28187632	T/G	cg01620082	chr3:125678407	NA	-1.08	-10.57	-0.44	1.5e-23	Depression;
LGG	cis	rs4493873	1.000	rs7014578	chr8:92077568	C/G	cg16814680	chr8:91681699	NA	0.46	7.01	0.31	8.35e-12	Migraine - clinic-based;
LGG	cis	rs7715811	1.000	rs1502050	chr5:13779743	A/G	cg07548982	chr5:13769939	DNAH5	-0.48	-10.03	-0.42	1.53e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.62	-0.48	1.49e-27	Personality dimensions;
LGG	cis	rs8062405	0.690	rs762634	chr16:28603335	T/C	cg16576597	chr16:28551801	NUPR1	0.44	10.29	0.43	1.65e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7674212	0.541	rs2615539	chr4:104081106	C/G	cg16532752	chr4:104119610	CENPE	-0.42	-7.34	-0.32	9.77e-13	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg04450456	chr4:17643702	FAM184B	0.34	7.57	0.33	1.98e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4622507	0.618	rs12917636	chr16:55070189	G/A	cg09947736	chr16:55091198	NA	0.78	11.69	0.48	7.51e-28	Social communication problems;
LGG	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	cis	rs2404602	0.716	rs17460201	chr15:76673627	C/T	cg23625390	chr15:77176239	SCAPER	-0.47	-9.26	-0.4	7.64e-19	Blood metabolite levels;
LGG	cis	rs1153858	1.000	rs1049508	chr15:45653592	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.32	-8.31	-0.36	1.05e-15	IgG glycosylation;
LGG	cis	rs4740619	0.740	rs1396706	chr9:15732420	C/A	cg14451791	chr9:16040625	NA	0.34	8.66	0.37	7.75e-17	Body mass index;
LGG	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg19729930	chr2:74357872	NA	0.54	11.51	0.47	4.04e-27	Gestational age at birth (maternal effect);
LGG	cis	rs78366141	0.649	rs17747153	chr4:89724638	T/G	cg01026744	chr4:89619053	NAP1L5;HERC3	1.06	8.65	0.37	8.51e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1065852	0.526	rs9611711	chr22:42410695	G/A	cg15128208	chr22:42549153	NA	0.42	7.14	0.31	3.69e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs644799	0.562	rs669973	chr11:95571839	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.17	0.52	7.59e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs490234	0.812	rs2900229	chr9:128466312	A/G	cg14078157	chr9:128172775	NA	-0.43	-7.74	-0.34	6.5e-14	Mean arterial pressure;
LGG	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.04	-0.31	6.89e-12	HDL cholesterol;
LGG	cis	rs3087591	0.659	rs8065496	chr17:29720140	T/C	cg24425628	chr17:29625626	OMG;NF1	0.59	11.97	0.49	5.78e-29	Hip circumference;
LGG	cis	rs7666738	0.830	rs6855393	chr4:99056534	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.37	0.36	6.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg06640241	chr16:89574553	SPG7	0.7	11.84	0.48	1.96e-28	Multiple myeloma (IgH translocation);
LGG	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg05169160	chr2:178484487	TTC30A	0.34	6.66	0.3	7.91e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs9911578	0.835	rs1476596	chr17:56485358	C/T	cg05425664	chr17:57184151	TRIM37	-0.58	-9.24	-0.39	9.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.642	rs11735957	chr4:152427506	G/A	cg17217059	chr4:152329364	FAM160A1	0.21	7.41	0.33	6.07e-13	Intelligence (multi-trait analysis);
LGG	trans	rs877282	0.898	rs12358513	chr10:757571	A/G	cg22713356	chr15:30763199	NA	0.48	7.24	0.32	1.93e-12	Uric acid levels;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg22753661	chr15:79092743	ADAMTS7	-0.41	-7.07	-0.31	5.58e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs7949566	0.535	rs1316361	chr11:126279365	A/T	cg05055844	chr11:126275997	ST3GAL4	0.39	7.64	0.33	1.27e-13	Platelet distribution width;Mean platelet volume;
LGG	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.88	-0.3	1.95e-11	Blood metabolite levels;
LGG	cis	rs9814567	0.964	rs9820150	chr3:134223011	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.91	-0.51	8.87e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg06636001	chr8:8085503	FLJ10661	0.4	7.2	0.32	2.5e-12	Myopia (pathological);
LGG	cis	rs7584330	0.955	rs13432426	chr2:238388631	T/G	cg16989719	chr2:238392110	NA	-0.34	-7.27	-0.32	1.5e-12	Prostate cancer;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg21862992	chr11:68658383	NA	-0.45	-7.76	-0.34	5.32e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4819388	0.709	rs2329712	chr21:45639245	C/T	cg01992765	chr21:45622493	NA	0.48	9.05	0.39	3.94e-18	Celiac disease;
LGG	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg17218041	chr13:113365319	ATP11A	-0.47	-7.74	-0.34	6.49e-14	Glycated hemoglobin levels;
LGG	cis	rs11170631	0.504	rs12817180	chr12:54035448	A/G	cg06632207	chr12:54070931	ATP5G2	0.23	7.26	0.32	1.66e-12	Height;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs735396	1.000	rs1169313	chr12:121442670	C/T	cg02403541	chr12:121454288	C12orf43	-0.53	-8.69	-0.37	6.48e-17	N-glycan levels;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg10852096	chr15:79043040	NA	0.28	8.04	0.35	7.6e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4820539	0.966	rs5759594	chr22:23470660	G/A	cg14186256	chr22:23484241	RTDR1	1.0	25.52	0.76	2.42e-90	Bone mineral density;
LGG	trans	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.2	-0.36	2.32e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg04990556	chr1:26633338	UBXN11	-0.71	-13.68	-0.54	4.92e-36	Obesity-related traits;
LGG	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg00106254	chr7:1943704	MAD1L1	-0.45	-7.81	-0.34	3.82e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs7980799	0.565	rs2200159	chr12:33648544	G/C	cg26384229	chr12:38710491	ALG10B	-0.66	-12.1	-0.49	1.85e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4731207	0.562	rs6466991	chr7:124691966	T/G	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.83e-12	Cutaneous malignant melanoma;
LGG	cis	rs11967485	0.609	rs62435815	chr6:157151225	C/T	cg23222435	chr6:157204239	ARID1B	-0.76	-7.06	-0.31	6.05e-12	Calcium levels;
LGG	cis	rs12549902	0.966	rs10504042	chr8:41515993	G/A	cg25883020	chr8:41504993	NKX6-3	0.33	7.24	0.32	1.86e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs7918232	0.567	rs11015463	chr10:27319258	A/G	cg14442939	chr10:27389572	ANKRD26	0.53	8.48	0.37	3.02e-16	Breast cancer;
LGG	cis	rs10911251	0.508	rs10797854	chr1:183106739	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.87	0.38	1.55e-17	Colorectal cancer;
LGG	cis	rs9487094	0.961	rs12190920	chr6:109800599	G/T	cg01125227	chr6:109776195	MICAL1	0.53	8.84	0.38	2.04e-17	Height;
LGG	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg25801113	chr15:45476975	SHF	0.86	19.11	0.66	1.88e-60	Uric acid levels;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg07701084	chr6:150067640	NUP43	0.64	12.06	0.49	2.53e-29	Lung cancer;
LGG	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.06	-0.31	6.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2013441	0.508	rs34756775	chr17:19982838	A/G	cg13482628	chr17:19912719	NA	0.42	7.2	0.32	2.39e-12	Obesity-related traits;
LGG	cis	rs9325144	0.600	rs6582634	chr12:38748041	G/A	cg04568710	chr12:38710424	ALG10B	0.39	8.15	0.35	3.53e-15	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	0.553	rs9536236	chr13:53255012	T/A	cg12458913	chr13:53173898	NA	0.95	22.58	0.72	1.1e-76	Lewy body disease;
LGG	cis	rs3857067	0.772	rs10018905	chr4:95076767	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.83	-0.34	3.42e-14	QT interval;
LGG	cis	rs875971	0.660	rs12698534	chr7:65986845	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	9.68	0.41	2.7e-20	Aortic root size;
LGG	cis	rs9359856	0.564	rs55722352	chr6:90365853	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.64	-0.41	3.75e-20	Bipolar disorder;
LGG	cis	rs2011503	0.941	rs11555053	chr19:19390185	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.86	0.3	2.24e-11	Bipolar disorder;
LGG	cis	rs4474465	0.850	rs10899549	chr11:78255389	T/C	cg02023728	chr11:77925099	USP35	-0.4	-7.01	-0.31	8.31e-12	Alzheimer's disease (survival time);
LGG	cis	rs10504229	1.000	rs61212428	chr8:58173963	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.955	rs61136468	chr22:50312679	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.09	-0.42	8.64e-22	Schizophrenia;
LGG	cis	rs7107174	1.000	rs2511175	chr11:77975081	A/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs2531992	0.702	rs1045475	chr16:4015316	A/G	cg05927578	chr16:4029543	ADCY9	0.68	10.47	0.44	3.61e-23	Waist circumference;
LGG	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg03433033	chr1:76189801	ACADM	0.67	9.68	0.41	2.59e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4481887	0.636	rs4397683	chr1:248411089	C/T	cg00666640	chr1:248458726	OR2T12	0.48	7.33	0.32	1.05e-12	Common traits (Other);
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg06925179	chr17:43578568	NA	-0.32	-8.33	-0.36	9.37e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2836974	0.602	rs8130854	chr21:40707041	G/A	cg06238570	chr21:40685208	BRWD1	-0.51	-8.24	-0.36	1.84e-15	Cognitive function;
LGG	cis	rs11098499	0.865	rs10213221	chr4:120255926	G/A	cg24375607	chr4:120327624	NA	0.59	10.06	0.42	1.13e-21	Corneal astigmatism;
LGG	cis	rs8005677	0.828	rs2295680	chr14:23374435	A/G	cg25600027	chr14:23388339	RBM23	0.48	7.95	0.35	1.48e-14	Cognitive ability (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-6.91	-0.31	1.62e-11	Longevity;
LGG	cis	rs6541297	1.000	rs2144298	chr1:230280198	T/C	cg05784532	chr1:230284198	GALNT2	0.52	9.22	0.39	1.01e-18	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17852997	chr13:21100460	CRYL1	0.43	7.17	0.32	2.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs701145	0.938	rs189588	chr3:153995855	T/G	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg16414030	chr3:133502952	NA	-0.6	-10.48	-0.44	3.22e-23	Iron status biomarkers;
LGG	cis	rs78456975	0.941	rs13412229	chr2:1520381	C/T	cg26248373	chr2:1572462	NA	-0.66	-7.8	-0.34	4.11e-14	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.15	-0.32	3.4e-12	Life satisfaction;
LGG	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg16482183	chr6:26056742	HIST1H1C	0.57	9.32	0.4	4.6e-19	Iron status biomarkers;
LGG	cis	rs62238980	0.614	rs4821027	chr22:32442074	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2274273	0.934	rs10144418	chr14:55817708	T/C	cg04306507	chr14:55594613	LGALS3	0.61	16.66	0.61	3.49e-49	Protein biomarker;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg19143629	chr17:61920732	SMARCD2	-0.42	-7.21	-0.32	2.27e-12	Prudent dietary pattern;
LGG	cis	rs12310956	0.532	rs10844715	chr12:33968444	A/G	cg06521331	chr12:34319734	NA	-0.59	-10.95	-0.45	5.8e-25	Morning vs. evening chronotype;
LGG	cis	rs10901296	0.660	rs11991	chr9:133762558	T/C	cg13397898	chr9:133768931	QRFP	0.42	7.98	0.35	1.13e-14	Bilirubin levels;
LGG	cis	rs7188861	0.681	rs66718203	chr16:11428643	C/G	cg01510278	chr16:11456238	NA	0.29	6.82	0.3	2.78e-11	HDL cholesterol;
LGG	cis	rs9486715	0.867	rs2475025	chr6:96988696	A/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-8.95	-0.38	8.54e-18	Headache;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.85	-0.34	2.94e-14	Obesity-related traits;
LGG	cis	rs17453880	0.712	rs7733573	chr5:152048219	C/T	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.66	0.3	7.64e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12188164	0.965	rs56346498	chr5:423595	C/T	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.61e-14	Cystic fibrosis severity;
LGG	cis	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	8.16	0.35	3.27e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10492096	0.945	rs1045546	chr12:6567907	C/T	cg13857086	chr12:6580257	VAMP1	0.64	9.08	0.39	3.03e-18	Hip geometry;
LGG	cis	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg05084668	chr3:125655381	ALG1L	-0.6	-8.14	-0.35	3.72e-15	Blood pressure (smoking interaction);
LGG	cis	rs908922	0.847	rs499697	chr1:152493154	A/G	cg20991723	chr1:152506922	NA	0.57	9.68	0.41	2.65e-20	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17168838	chr19:54663528	LENG1	0.46	7.26	0.32	1.69e-12	Cognitive performance;
LGG	cis	rs975722	0.632	rs980574	chr7:117151828	A/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.87	0.42	5.65e-21	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg19507638	chr5:93509721	C5orf36	-0.7	-9.79	-0.41	1.06e-20	Diabetic retinopathy;
LGG	cis	rs137603	0.562	rs137644	chr22:39728139	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.71	-13.77	-0.54	2.04e-36	Primary biliary cholangitis;
LGG	cis	rs9807989	0.507	rs3732124	chr2:103018052	A/G	cg03938978	chr2:103052716	IL18RAP	-0.41	-9.59	-0.41	5.33e-20	Asthma;
LGG	trans	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.23	-0.32	2.01e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.16	-0.35	3.28e-15	HDL cholesterol;
LGG	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg12288994	chr5:1860383	NA	0.71	11.65	0.48	1.08e-27	Cardiovascular disease risk factors;
LGG	cis	rs9560113	1.000	rs4771757	chr13:112176379	G/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs7172689	1.000	rs67093094	chr15:81530848	C/T	cg11808699	chr15:81528661	IL16	-0.48	-9.59	-0.41	5.46e-20	Inattentive symptoms;
LGG	cis	rs4363385	0.747	rs4845332	chr1:152982632	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.76	0.38	3.79e-17	Motion sickness;
LGG	cis	rs7811142	0.830	rs78256546	chr7:99952970	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.81e-21	Platelet count;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.04	-0.39	4.38e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs3219090	1.000	rs2048426	chr1:226594301	C/T	cg17127702	chr1:226594323	PARP1	0.38	12.25	0.49	4.45e-30	Melanoma;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg21830797	chr15:40226279	EIF2AK4	-0.59	-6.88	-0.3	1.94e-11	Response to haloperidol in psychosis;
LGG	trans	rs61931739	0.649	rs815037	chr12:33725193	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs2084898	0.941	rs73004793	chr11:120061255	T/C	cg07435449	chr11:120005650	TRIM29	-0.64	-7.32	-0.32	1.11e-12	Stroke (pediatric);
LGG	cis	rs12493885	0.725	rs61791468	chr3:153739520	G/C	cg17054900	chr3:154042577	DHX36	-0.72	-8.85	-0.38	1.82e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg26879891	chr1:152191343	HRNR	-0.33	-6.83	-0.3	2.66e-11	Inflammatory skin disease;
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.63	-0.44	8.88e-24	IgG glycosylation;
LGG	cis	rs9796	0.689	rs28497404	chr15:41449510	A/C	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.85	-0.42	6.51e-21	Menopause (age at onset);
LGG	cis	rs988958	0.675	rs67312072	chr2:42230670	T/C	cg19376973	chr2:42229025	NA	0.61	9.67	0.41	2.94e-20	Hypospadias;
LGG	cis	rs11122272	0.677	rs2808615	chr1:231550171	G/A	cg10503236	chr1:231470652	EXOC8	0.37	7.26	0.32	1.65e-12	Hemoglobin concentration;
LGG	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.53	0.37	2.03e-16	Personality dimensions;
LGG	cis	rs1003719	0.591	rs2835633	chr21:38525019	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.71	-13.11	-0.52	1.35e-33	Eye color traits;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.97	-0.42	2.35e-21	Lung cancer;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9388451	0.872	rs2008027	chr6:126052359	A/G	cg05901451	chr6:126070800	HEY2	-0.78	-16.08	-0.6	1.55e-46	Brugada syndrome;
LGG	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	trans	rs7404843	0.925	rs72774861	chr16:15509634	C/A	cg02716450	chr16:28638775	NA	0.67	7.15	0.32	3.4e-12	Testicular germ cell tumor;
LGG	cis	rs258892	0.895	rs34656	chr5:72148117	C/T	cg21869765	chr5:72125136	TNPO1	0.42	6.67	0.3	7.11e-11	Small cell lung carcinoma;
LGG	trans	rs17685	0.697	rs2302437	chr7:75677016	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.77	-0.77	1.82e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.3	-0.32	1.25e-12	Height;
LGG	cis	rs4665809	1.000	rs6709595	chr2:26259885	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.34e-14	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs6878061	chr5:223072	A/G	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs9790314	1.000	rs336548	chr3:161058412	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.12	-0.46	1.25e-25	Morning vs. evening chronotype;
LGG	cis	rs2964802	0.505	rs4314375	chr5:10803435	C/T	cg14521931	chr5:10832172	NA	0.74	16.58	0.61	8.23e-49	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs9359856	0.600	rs1179899	chr6:90320258	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.59	-7.8	-0.34	4.09e-14	Bipolar disorder;
LGG	cis	rs7119	0.679	rs12902698	chr15:77809010	A/C	cg10437265	chr15:77819839	NA	0.25	6.86	0.3	2.2e-11	Type 2 diabetes;
LGG	cis	rs13421350	0.579	rs2293645	chr2:173366960	C/T	cg15021238	chr2:173305865	ITGA6	-0.78	-8.49	-0.37	2.87e-16	Diabetic kidney disease;
LGG	cis	rs4804815	0.780	rs2081100	chr19:7840273	T/C	cg09310891	chr19:7854403	CLEC4GP1	0.52	8.13	0.35	3.94e-15	Neutrophil count;
LGG	cis	rs3784262	0.935	rs4646563	chr15:58353335	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.05	-0.35	7.17e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg26441486	chr22:50317300	CRELD2	0.41	7.51	0.33	2.99e-13	Schizophrenia;
LGG	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.82e-44	Colorectal cancer;
LGG	cis	rs1348850	0.554	rs11679519	chr2:178432110	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-7.61	-0.33	1.54e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.36	-0.43	8.94e-23	Bipolar disorder;
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg19524238	chr7:2802976	GNA12	0.32	7.79	0.34	4.29e-14	Height;
LGG	cis	rs17445240	1.000	rs78506209	chr2:3699715	G/A	cg16123090	chr2:3699210	NA	0.81	8.75	0.38	3.94e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg18551225	chr6:44695536	NA	-0.62	-10.14	-0.43	6.07e-22	Total body bone mineral density;
LGG	trans	rs3960554	0.529	rs7793844	chr7:75883147	C/T	cg19862616	chr7:65841803	NCRNA00174	0.6	9.51	0.4	1.02e-19	Eotaxin levels;
LGG	cis	rs208520	0.837	rs208467	chr6:66914837	T/C	cg07460842	chr6:66804631	NA	-0.92	-16.06	-0.6	1.84e-46	Exhaled nitric oxide output;
LGG	cis	rs10754283	0.967	rs7546518	chr1:90109956	C/T	cg06121193	chr1:90282411	NA	-0.36	-7.01	-0.31	8.39e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs4650994	0.525	rs2493865	chr1:178545016	G/A	cg05059571	chr16:84539110	KIAA1609	0.57	10.85	0.45	1.39e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7106204	0.748	rs2403891	chr11:24213130	C/T	ch.11.24196551F	chr11:24239977	NA	1.05	16.54	0.61	1.24e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6499188	0.522	rs10153230	chr16:68671741	C/G	cg02972257	chr16:68554789	NA	-0.46	-6.77	-0.3	3.98e-11	Ulcerative colitis;
LGG	cis	rs3813359	0.545	rs56301352	chr6:130556674	C/T	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.09e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2224391	0.554	rs928170	chr6:5255154	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.44	-0.33	4.94e-13	Height;
LGG	cis	rs11971779	0.680	rs10271297	chr7:139052310	A/T	cg07862535	chr7:139043722	LUC7L2	0.43	7.16	0.32	3.27e-12	Diisocyanate-induced asthma;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1.05e-12	Neuroticism;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.75	0.48	4.49e-28	Prudent dietary pattern;
LGG	cis	rs9487094	0.670	rs1406899	chr6:109816305	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs1005277	0.579	rs1780138	chr10:38501654	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10620501	chr8:37620046	PROSC	0.42	7.29	0.32	1.39e-12	Bipolar disorder;
LGG	cis	rs11628318	0.614	rs8013886	chr14:103117389	A/G	cg01864069	chr14:103024347	NA	0.47	8.31	0.36	1.07e-15	Platelet count;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg22111723	chr13:21872664	NA	0.38	6.65	0.3	8.41e-11	Bilirubin levels;
LGG	cis	rs644799	0.965	rs11021317	chr11:95517576	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.51	0.53	2.57e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11758351	1.000	rs3734530	chr6:26195408	G/C	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg13271783	chr10:134563150	INPP5A	-0.62	-9.38	-0.4	2.87e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg21017887	chr14:105400489	NA	0.44	8.88	0.38	1.53e-17	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs1865760	0.593	rs3903852	chr6:25915147	G/T	cg03517284	chr6:25882590	NA	-0.52	-9.96	-0.42	2.57e-21	Height;
LGG	cis	rs9916302	0.706	rs8067511	chr17:37611352	C/T	cg00129232	chr17:37814104	STARD3	-0.57	-8.29	-0.36	1.26e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9487051	0.704	rs1741930	chr6:109519797	T/A	cg21918786	chr6:109611834	NA	-0.41	-7.6	-0.33	1.65e-13	Reticulocyte fraction of red cells;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg14817848	chr12:12715558	DUSP16	0.38	6.73	0.3	4.94e-11	Migraine with aura;
LGG	cis	rs10847980	0.590	rs1696326	chr12:123311981	A/G	cg25930673	chr12:123319894	HIP1R	-1.05	-8.72	-0.38	5.06e-17	Adiponectin levels;
LGG	cis	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg15704280	chr7:45808275	SEPT13	0.81	14.35	0.55	6.49e-39	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.5	0.4	1.14e-19	Bipolar disorder;
LGG	cis	rs2880765	0.835	rs2170735	chr15:86043485	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.75	-0.3	4.56e-11	Coronary artery disease;
LGG	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12756686	chr19:29218302	NA	0.82	13.79	0.54	1.71e-36	Methadone dose in opioid dependence;
LGG	cis	rs7727544	0.660	rs272886	chr5:131665840	T/C	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.18e-34	Blood metabolite levels;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg11360546	chr7:1094263	C7orf50	-0.4	-7.16	-0.32	3.28e-12	Longevity;Endometriosis;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg11245990	chr11:68621969	NA	0.42	9.04	0.39	4.45e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25161386	chr17:27621177	NUFIP2	-0.41	-6.86	-0.3	2.19e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg11494091	chr17:61959527	GH2	0.51	8.25	0.36	1.63e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10752881	1.000	rs8179283	chr1:182974602	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs9611519	0.964	rs5995992	chr22:41487218	T/C	cg03806693	chr22:41940476	POLR3H	-0.55	-8.48	-0.37	2.97e-16	Neuroticism;
LGG	cis	rs55986470	0.703	rs11887099	chr2:239447550	T/C	cg18131467	chr2:239335373	ASB1	-0.55	-6.8	-0.3	3.18e-11	Chronotype;
LGG	cis	rs7916697	0.891	rs4746748	chr10:70009388	G/A	cg18338521	chr10:69995036	NA	0.33	7.22	0.32	2.21e-12	Optic disc area;
LGG	trans	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg18187862	chr3:45730750	SACM1L	0.57	9.25	0.39	8.5e-19	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg12751644	chr20:60527061	NA	-0.47	-10.26	-0.43	2.12e-22	Obesity-related traits;
LGG	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg03929089	chr4:120376271	NA	0.75	8.5	0.37	2.53e-16	Axial length;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09507928	chr5:140027484	IK;NDUFA2	0.44	8.0	0.35	1.02e-14	Obesity-related traits;
LGG	cis	rs4919044	0.808	rs1750741	chr10:94804530	G/T	cg05127821	chr10:94822908	CYP26C1	-0.45	-7.96	-0.35	1.32e-14	Coronary artery disease;
LGG	cis	rs8031584	0.678	rs798125	chr15:31116800	C/T	cg08704250	chr15:31115839	NA	0.49	8.75	0.38	3.95e-17	Huntington's disease progression;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg07959490	chr17:80112427	CCDC57	-0.46	-9.22	-0.39	1.02e-18	Life satisfaction;
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg07234876	chr8:600039	NA	1.17	11.5	0.47	4.26e-27	IgG glycosylation;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16405210	chr4:1374714	KIAA1530	-0.51	-8.94	-0.38	9.45e-18	Longevity;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg02725872	chr8:58115012	NA	-1.02	-13.46	-0.53	4.45e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9644630	0.932	rs6991941	chr8:19352377	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.42	-0.47	8.63e-27	Oropharynx cancer;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.79	14.76	0.57	1.13e-40	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1620921	0.563	rs9355320	chr6:161269256	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.3	-0.32	1.29e-12	Neuroticism;
LGG	trans	rs10435719	0.809	rs77601743	chr8:11790569	G/A	cg06636001	chr8:8085503	FLJ10661	0.48	8.66	0.37	7.73e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg01620082	chr3:125678407	NA	0.7	7.09	0.31	4.88e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs459482	1.000	rs459498	chr21:42795027	G/A	cg14166395	chr21:42792516	MX1	0.44	7.27	0.32	1.56e-12	IgG glycosylation;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.44	-0.37	3.95e-16	Tonsillectomy;
LGG	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg13514129	chr1:39547527	MACF1	0.68	12.69	0.51	7.17e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs2729354	0.729	rs2729353	chr11:57248003	C/T	cg24343310	chr11:57249947	NA	0.43	8.26	0.36	1.52e-15	Blood protein levels;
LGG	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg06481639	chr22:41940642	POLR3H	0.58	8.44	0.37	4e-16	Vitiligo;
LGG	cis	rs35306767	0.855	rs11253459	chr10:886402	C/T	cg26597838	chr10:835615	NA	0.75	10.46	0.44	3.94e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs78545713	0.649	rs11757549	chr6:26231608	G/A	cg01420254	chr6:26195488	NA	0.76	7.36	0.32	8.65e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.3	-0.36	1.15e-15	Schizophrenia;
LGG	cis	rs6977660	0.660	rs12531278	chr7:19816439	A/T	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	trans	rs2975734	0.680	rs1052453	chr8:10108325	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.02	-0.35	8.47e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg12438819	chr7:158236134	PTPRN2	0.34	8.97	0.38	7.12e-18	Obesity-related traits;
LGG	trans	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg24247370	chr13:99142703	STK24	-0.39	-7.06	-0.31	6.2e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7312774	0.618	rs35435903	chr12:107346572	G/C	cg16260113	chr12:107380972	MTERFD3	0.94	8.75	0.38	3.87e-17	Severe influenza A (H1N1) infection;
LGG	trans	rs1459104	0.850	rs12802447	chr11:55039889	C/T	cg15704280	chr7:45808275	SEPT13	0.75	6.86	0.3	2.15e-11	Body mass index;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg09263875	chr16:632152	PIGQ	0.66	13.37	0.53	1.04e-34	Height;
LGG	cis	rs6669919	0.516	rs11577717	chr1:211668920	C/T	cg10512769	chr1:211675356	NA	-0.93	-23.57	-0.74	2.75e-81	Intelligence (multi-trait analysis);
LGG	cis	rs1059312	1.000	rs1059312	chr12:129278864	A/G	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.3	-7.31	-0.32	1.17e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg23782820	chr8:58130467	NA	0.5	7.61	0.33	1.51e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.527	rs842707	chr7:158656012	C/T	cg18245976	chr7:158708271	WDR60	-0.55	-7.12	-0.31	4.1e-12	Height;
LGG	cis	rs9487094	0.600	rs10457193	chr6:109828567	C/T	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.04e-14	Height;
LGG	cis	rs4631830	0.720	rs2611471	chr10:51503559	G/C	cg16070123	chr10:51489643	NA	-0.41	-7.5	-0.33	3.3e-13	Prostate-specific antigen levels;
LGG	cis	rs262150	0.502	rs73167295	chr7:158782949	T/A	cg19418458	chr7:158789849	NA	0.43	6.69	0.3	6.26e-11	Facial morphology (factor 20);
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.74	0.59	5.02e-45	Lung cancer;
LGG	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg05535760	chr7:792225	HEATR2	0.45	7.79	0.34	4.52e-14	Perceived unattractiveness to mosquitoes;
LGG	trans	rs9329221	0.538	rs9650651	chr8:10267540	C/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.27	0.32	1.52e-12	Neuroticism;
LGG	trans	rs28595532	0.557	rs12498329	chr4:119311524	C/T	cg26518628	chr1:97050305	NA	-0.88	-12.62	-0.51	1.44e-31	Cannabis dependence symptom count;
LGG	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg02187348	chr16:89574699	SPG7	0.43	6.84	0.3	2.52e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs17321999	0.516	rs7563661	chr2:30497757	G/A	cg05247661	chr2:30472410	LBH	0.63	7.87	0.34	2.53e-14	Systemic lupus erythematosus;
LGG	cis	rs7192380	0.964	rs6499231	chr16:69588016	A/G	cg00738113	chr16:70207722	CLEC18C	-0.26	-7.55	-0.33	2.26e-13	Sjögren's syndrome;
LGG	trans	rs9354308	0.764	rs9342510	chr6:66589332	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs929354	0.605	rs7806314	chr7:156946903	A/T	cg17757837	chr7:157058334	UBE3C	0.77	15.41	0.58	1.46e-43	Body mass index;
LGG	cis	rs911186	0.679	rs67330695	chr6:27103654	G/A	cg12292205	chr6:26970375	C6orf41	-0.62	-8.23	-0.36	1.85e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11343086	chr1:202113710	ARL8A	0.52	7.74	0.34	6.11e-14	Gut microbiome composition (summer);
LGG	cis	rs4631830	0.720	rs2125771	chr10:51506957	C/T	cg10326726	chr10:51549505	MSMB	-0.61	-12.2	-0.49	7.18e-30	Prostate-specific antigen levels;
LGG	cis	rs8180040	0.627	rs9821119	chr3:47198437	C/G	cg27129171	chr3:47204927	SETD2	0.82	14.92	0.57	2.3e-41	Colorectal cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20940459	chr1:173793922	CENPL;DARS2	-0.51	-7.58	-0.33	1.86e-13	Systemic lupus erythematosus;
LGG	cis	rs7246760	0.867	rs1820114	chr19:9805692	G/A	cg16876255	chr19:9731953	ZNF561	0.83	7.72	0.34	7.47e-14	Pursuit maintenance gain;
LGG	cis	rs10267417	0.603	rs4721831	chr7:19876769	T/C	cg05791153	chr7:19748676	TWISTNB	0.64	8.28	0.36	1.35e-15	Night sleep phenotypes;
LGG	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.7	-0.41	2.24e-20	Height;
LGG	cis	rs7843479	0.965	rs17581910	chr8:21799626	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.01	0.42	1.75e-21	Mean corpuscular volume;
LGG	cis	rs11264213	0.901	rs2791961	chr1:36371419	C/G	cg27506609	chr1:36549197	TEKT2	-0.65	-8.11	-0.35	4.46e-15	Schizophrenia;
LGG	cis	rs7599312	0.532	rs7564590	chr2:213387900	C/T	cg20637307	chr2:213403960	ERBB4	0.46	8.12	0.35	4.35e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs801193	0.569	rs11761542	chr7:66218196	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.66	-0.34	1.09e-13	Aortic root size;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg11878867	chr6:150167359	LRP11	-0.49	-9.95	-0.42	2.77e-21	Lung cancer;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.07	-0.31	5.82e-12	Bipolar disorder;
LGG	cis	rs7412746	0.658	rs1546376	chr1:150937661	A/G	cg15448220	chr1:150897856	SETDB1	0.4	7.38	0.32	7.22e-13	Melanoma;
LGG	cis	rs858239	0.600	rs10488077	chr7:23144182	A/T	cg23682824	chr7:23144976	KLHL7	0.43	7.42	0.33	5.55e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9397585	0.857	rs28628884	chr6:153374001	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.47	0.56	2.05e-39	Body mass index;
LGG	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg16414030	chr3:133502952	NA	0.6	10.28	0.43	1.78e-22	Iron status biomarkers;
LGG	cis	rs3750450	0.718	rs6415807	chr9:111958345	G/A	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.09	-0.35	5.24e-15	Low vWF levels;
LGG	cis	rs8013055	0.898	rs8004007	chr14:105971435	G/C	cg19700328	chr14:106028568	NA	-0.6	-10.12	-0.43	6.96e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	10.01	0.42	1.75e-21	Schizophrenia;
LGG	cis	rs209489	0.892	rs9474463	chr6:53109956	A/C	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs7119	0.717	rs7176307	chr15:77816684	G/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs2370759	1.000	rs11008865	chr10:32574842	C/T	cg01819863	chr10:32635814	EPC1	1.11	15.33	0.58	3.27e-43	Sexual dysfunction (female);
LGG	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.98	0.35	1.17e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.67	-0.44	6.36e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-14.4	-0.56	4.04e-39	Gut microbiome composition (summer);
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.32	0.36	9.64e-16	Tonsillectomy;
LGG	cis	rs4535700	0.501	rs9642405	chr7:55978166	C/T	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	3.97e-11	Macular telangiectasia type 2;
LGG	cis	rs4948275	0.773	rs2787738	chr10:63253359	A/G	cg03237606	chr10:63212265	TMEM26	0.37	6.84	0.3	2.57e-11	Night sleep phenotypes;
LGG	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg17294928	chr15:75287854	SCAMP5	0.62	11.52	0.47	3.68e-27	Breast cancer;
LGG	cis	rs3857747	0.827	rs7782097	chr7:40473004	C/G	cg00420559	chr7:40367873	C7orf10	0.38	7.86	0.34	2.71e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.46	-7.42	-0.33	5.76e-13	Response to amphetamines;
LGG	cis	rs7552404	0.924	rs2173378	chr1:76201992	G/T	cg22875332	chr1:76189707	ACADM	0.59	10.51	0.44	2.48e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg08835221	chr22:38071607	LGALS1	0.27	7.36	0.32	8.37e-13	Fat distribution (HIV);
LGG	trans	rs11039798	0.582	rs60764175	chr11:48775856	T/G	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	6.72e-22	Axial length;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg02353165	chr6:42928485	GNMT	0.48	14.18	0.55	3.74e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.96e-13	Life satisfaction;
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg09699651	chr6:150184138	LRP11	-0.46	-6.97	-0.31	1.11e-11	Lung cancer;
LGG	cis	rs11711311	0.747	rs7638378	chr3:113343630	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.13	-0.31	3.89e-12	IgG glycosylation;
LGG	cis	rs1978968	1.000	rs5992922	chr22:18445287	A/G	cg03078520	chr22:18463400	MICAL3	-0.62	-12.48	-0.5	4.93e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg23188684	chr11:67383651	NA	0.43	7.05	0.31	6.52e-12	Mean corpuscular volume;
LGG	cis	rs7444	0.941	rs4820091	chr22:21940189	T/G	cg05046821	chr22:21984468	YDJC	-0.37	-6.79	-0.3	3.36e-11	Systemic lupus erythematosus;
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.19	-0.32	2.68e-12	Longevity;Endometriosis;
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12379764	chr21:47803548	PCNT	0.5	8.17	0.35	2.97e-15	Testicular germ cell tumor;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.15	19.05	0.66	3.62e-60	Platelet count;
LGG	cis	rs9487094	0.744	rs13199519	chr6:109709175	G/A	cg16315928	chr6:109776240	MICAL1	0.54	9.05	0.39	4.13e-18	Height;
LGG	cis	rs9880211	0.898	rs35304385	chr3:136386253	T/C	cg21827317	chr3:136751795	NA	-0.49	-7.29	-0.32	1.31e-12	Body mass index;Height;
LGG	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg02487422	chr3:49467188	NICN1	0.58	10.68	0.44	5.81e-24	Resting heart rate;
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg00864171	chr11:67383662	NA	-0.45	-7.48	-0.33	3.73e-13	Mean corpuscular volume;
LGG	cis	rs7100689	0.577	rs10788545	chr10:82034675	A/G	cg01528321	chr10:82214614	TSPAN14	0.82	13.91	0.54	5.17e-37	Post bronchodilator FEV1;
LGG	cis	rs12479064	0.507	rs59178618	chr2:99993701	G/A	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	cis	rs2455799	0.613	rs13071303	chr3:15958203	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-7.29	-0.32	1.33e-12	Mean platelet volume;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg14338887	chr6:42928500	GNMT	0.27	8.45	0.37	3.86e-16	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs17125944	0.505	rs80211268	chr14:53265483	C/G	cg13660082	chr14:53194042	PSMC6	-0.54	-7.51	-0.33	3.04e-13	Alzheimer's disease (late onset);
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.97	-0.31	1.12e-11	Triglycerides;
LGG	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg15627072	chr1:2432621	PLCH2	0.39	8.37	0.36	6.88e-16	Ulcerative colitis;
LGG	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg10847948	chr11:71163743	NADSYN1	-0.53	-9.97	-0.42	2.52e-21	Vitamin D levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11797228	chr1:151319782	RFX5	0.45	6.69	0.3	6.35e-11	Gut microbiome composition (summer);
LGG	trans	rs4713118	0.628	rs9295740	chr6:27689502	G/A	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.7	-0.3	6.23e-11	Parkinson's disease;
LGG	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.04e-23	Lymphocyte counts;
LGG	cis	rs7769051	1.000	rs6910639	chr6:133120553	A/G	cg07930552	chr6:133119739	C6orf192	0.88	12.14	0.49	1.21e-29	Type 2 diabetes nephropathy;
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg13939156	chr17:80058883	NA	-0.46	-8.94	-0.38	9.24e-18	Life satisfaction;
LGG	cis	rs9915657	0.870	rs720244	chr17:70131643	G/T	cg09344028	chr17:70110421	NA	0.46	9.92	0.42	3.78e-21	Thyroid hormone levels;
LGG	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg17971929	chr21:40555470	PSMG1	0.77	13.58	0.53	1.29e-35	Cognitive function;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.78e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.735	rs283789	chr15:76777577	G/A	cg23625390	chr15:77176239	SCAPER	0.62	12.22	0.49	5.66e-30	Blood metabolite levels;
LGG	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs4363385	0.818	rs1334848	chr1:153004721	A/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg06112835	chr11:68658793	MRPL21	0.54	9.07	0.39	3.32e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6988985	0.530	rs57268571	chr8:143942602	A/G	cg10324643	chr8:143916377	GML	0.44	9.11	0.39	2.58e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.5	-8.14	-0.35	3.6e-15	Longevity;
LGG	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.55	-0.33	2.27e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs972578	0.740	rs1983648	chr22:43255397	T/A	cg01576275	chr22:43409880	NA	-0.23	-6.98	-0.31	1.01e-11	Mean platelet volume;
LGG	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg11984989	chr7:158649758	WDR60	1.02	14.54	0.56	9.78e-40	Height;
LGG	cis	rs3733585	0.624	rs58130873	chr4:9972081	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.91	-0.31	1.57e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-9.08	-0.39	3.2e-18	Menopause (age at onset);
LGG	trans	rs7937682	0.889	rs1940529	chr11:111498523	G/C	cg18187862	chr3:45730750	SACM1L	0.64	10.57	0.44	1.57e-23	Primary sclerosing cholangitis;
LGG	cis	rs6901004	0.688	rs34151782	chr6:111574537	T/A	cg15721981	chr6:111408429	SLC16A10	0.45	7.87	0.34	2.5e-14	Blood metabolite levels;
LGG	cis	rs3857536	0.813	rs1029401	chr6:66952268	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.9	-0.34	2.04e-14	Blood trace element (Cu levels);
LGG	cis	rs2880765	0.835	rs2170736	chr15:86043398	A/G	cg10818794	chr15:86012489	AKAP13	-0.38	-8.0	-0.35	9.94e-15	Coronary artery disease;
LGG	cis	rs1707322	0.686	rs3014242	chr1:46087577	G/A	cg03146154	chr1:46216737	IPP	-0.58	-11.31	-0.47	2.45e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12643440	0.538	rs62296685	chr4:17137580	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.58	-0.37	1.45e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.47	-7.09	-0.31	4.96e-12	Childhood ear infection;
LGG	cis	rs4748857	0.898	rs4747462	chr10:23601892	T/G	cg18853376	chr10:23633759	C10orf67	0.37	6.99	0.31	9.6e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3206736	0.556	rs328924	chr7:35035704	T/A	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs35146811	0.735	rs2528900	chr7:99805319	A/G	cg13334819	chr7:99746414	C7orf59	0.44	6.93	0.31	1.43e-11	Coronary artery disease;
LGG	cis	rs12422267	0.536	rs11831679	chr12:132609960	C/T	cg08270023	chr12:132619174	NA	-0.42	-7.05	-0.31	6.58e-12	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg00689492	chr4:1303491	MAEA	0.4	6.74	0.3	4.62e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13415434	chr3:49044522	P4HTM;WDR6	0.47	8.31	0.36	1.11e-15	Gut microbiome composition (summer);
LGG	trans	rs6601327	0.602	rs7829463	chr8:9649691	C/G	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.76	-0.3	4.3e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg05665937	chr4:1216051	CTBP1	0.39	7.05	0.31	6.49e-12	Longevity;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs9916302	0.904	rs11078898	chr17:37536480	A/G	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs1555322	1.000	rs2425027	chr20:33849390	C/G	cg17927777	chr20:33865990	NA	0.68	7.71	0.34	7.77e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs6752107	1.000	rs35300242	chr2:234168790	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.03e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10850519	0.502	rs2384616	chr12:115951160	T/G	cg18639984	chr12:115943877	NA	0.34	6.65	0.3	8.47e-11	Diastolic blood pressure;
LGG	cis	rs9463078	0.866	rs9395084	chr6:45220175	T/C	cg25276700	chr6:44698697	NA	-0.38	-7.79	-0.34	4.51e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg05484376	chr2:27715224	FNDC4	0.45	9.71	0.41	2.02e-20	Menopause (age at onset);
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg16680214	chr1:154839983	KCNN3	-0.47	-9.27	-0.4	7.2e-19	Prostate cancer;
LGG	cis	rs637571	0.565	rs633800	chr11:65638719	G/A	cg26695010	chr11:65641043	EFEMP2	0.64	11.46	0.47	6.15e-27	Eosinophil percentage of white cells;
LGG	cis	rs5769707	0.521	rs6009805	chr22:50058715	T/C	cg06623630	chr22:50017776	C22orf34	-0.45	-8.91	-0.38	1.21e-17	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs758324	0.812	rs667437	chr5:131275509	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.41	-0.36	4.94e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs2153535	0.580	rs7767926	chr6:8453557	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs9487094	0.922	rs68042406	chr6:109803595	G/A	cg01125227	chr6:109776195	MICAL1	0.52	8.67	0.37	7.31e-17	Height;
LGG	cis	rs9308433	0.643	rs4655330	chr1:214466068	A/G	cg06198575	chr1:214491504	SMYD2	-0.45	-6.65	-0.3	8.29e-11	IgG glycosylation;
LGG	cis	rs7647973	1.000	rs3870339	chr3:49536863	T/A	cg06212747	chr3:49208901	KLHDC8B	0.51	8.05	0.35	6.87e-15	Menarche (age at onset);
LGG	cis	rs372883	0.532	rs388707	chr21:30714776	T/C	cg08807101	chr21:30365312	RNF160	-0.51	-8.5	-0.37	2.68e-16	Pancreatic cancer;
LGG	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.17	-0.43	4.64e-22	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-13.02	-0.52	2.95e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.93	-0.78	8.57e-97	Height;
LGG	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg08048268	chr3:133502702	NA	0.58	10.2	0.43	3.51e-22	Iron status biomarkers;
LGG	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg15369054	chr17:80825471	TBCD	-0.38	-7.23	-0.32	2.07e-12	Breast cancer;
LGG	cis	rs600231	0.665	rs1616810	chr11:65220105	A/G	cg17120908	chr11:65337727	SSSCA1	-0.49	-8.8	-0.38	2.74e-17	Bone mineral density;
LGG	trans	rs9354308	0.933	rs1938068	chr6:66607807	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	9.92	0.42	3.56e-21	Metabolite levels;
LGG	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg27398817	chr8:82754497	SNX16	-0.8	-11.61	-0.47	1.58e-27	Diastolic blood pressure;
LGG	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.62	-0.33	1.42e-13	Mood instability;
LGG	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg15103426	chr22:29168792	CCDC117	0.68	10.2	0.43	3.6e-22	Lymphocyte counts;
LGG	cis	rs35306767	0.903	rs7914758	chr10:891702	T/C	cg20503657	chr10:835505	NA	0.95	13.04	0.52	2.6e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs6582630	0.555	rs56228141	chr12:38518652	T/G	cg13010199	chr12:38710504	ALG10B	0.7	14.72	0.56	1.74e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2180341	1.000	rs7756336	chr6:127650299	T/C	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs258892	0.895	rs9293443	chr5:72055622	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	cis	rs10267417	0.603	rs10267511	chr7:19896924	A/G	cg05791153	chr7:19748676	TWISTNB	0.6	7.85	0.34	2.98e-14	Night sleep phenotypes;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.68	-12.4	-0.5	1.09e-30	Obesity-related traits;
LGG	cis	rs12748961	0.557	rs823127	chr1:205713139	G/A	cg23034840	chr1:205782522	SLC41A1	0.66	8.96	0.38	7.81e-18	White blood cell types;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg20887711	chr4:1340912	KIAA1530	0.58	11.17	0.46	8.3e-26	Obesity-related traits;
LGG	cis	rs8114671	0.804	rs3803936	chr20:33632775	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs57590327	0.716	rs56106807	chr3:81765270	A/G	cg07356753	chr3:81810745	GBE1	-0.5	-7.45	-0.33	4.69e-13	Extraversion;
LGG	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg22676075	chr6:135203613	NA	0.43	7.57	0.33	2e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs4820539	1.000	rs3788347	chr22:23467804	G/A	cg21100191	chr22:23484243	RTDR1	0.98	21.7	0.71	1.48e-72	Bone mineral density;
LGG	cis	rs6866344	0.697	rs17184302	chr5:178127676	C/T	cg03877680	chr5:178157825	ZNF354A	0.79	12.69	0.51	7.42e-32	Neutrophil percentage of white cells;
LGG	cis	rs2688608	0.617	rs6480709	chr10:75479125	T/C	cg19442545	chr10:75533431	FUT11	-0.46	-7.49	-0.33	3.48e-13	Inflammatory bowel disease;
LGG	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg08999081	chr20:33150536	PIGU	0.44	11.52	0.47	3.73e-27	Coronary artery disease;
LGG	cis	rs7208859	0.673	rs55658077	chr17:29156519	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.13	-0.39	2.11e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.74	0.41	1.62e-20	Diabetic retinopathy;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg17660078	chr3:149688926	PFN2	0.45	6.74	0.3	4.62e-11	Lung cancer in ever smokers;
LGG	cis	rs4950322	0.570	rs76236344	chr1:146769674	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs6430585	0.527	rs6753232	chr2:136436317	C/T	cg07169764	chr2:136633963	MCM6	-0.92	-14.66	-0.56	2.94e-40	Corneal structure;
LGG	cis	rs7113850	0.541	rs4451727	chr11:24216855	G/C	ch.11.24196551F	chr11:24239977	NA	0.92	10.94	0.45	6.41e-25	Bone fracture in osteoporosis;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg02725872	chr8:58115012	NA	-0.94	-12.31	-0.5	2.54e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg13647721	chr17:30228624	UTP6	0.65	8.36	0.36	7.41e-16	Hip circumference adjusted for BMI;
LGG	cis	rs2963155	1.000	rs2963155	chr5:142756004	C/T	cg17617527	chr5:142782415	NR3C1	-0.63	-9.5	-0.4	1.15e-19	Breast cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08351019	chr7:90893462	FZD1	-0.46	-6.85	-0.3	2.44e-11	Systemic lupus erythematosus;
LGG	cis	rs757081	0.533	rs56030184	chr11:17067849	C/T	cg15432903	chr11:17409602	KCNJ11	-0.51	-7.68	-0.34	9.86e-14	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg04166393	chr7:2884313	GNA12	0.44	8.16	0.35	3.19e-15	Height;
LGG	cis	rs9916302	0.560	rs3764352	chr17:37790939	C/T	cg07936489	chr17:37558343	FBXL20	-0.75	-11.6	-0.47	1.69e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6963495	0.745	rs73192151	chr7:105211876	A/G	cg19920283	chr7:105172520	RINT1	0.64	8.24	0.36	1.78e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs4595586	0.525	rs34204378	chr12:39425759	C/T	cg26384229	chr12:38710491	ALG10B	0.69	12.75	0.51	4.02e-32	Morning vs. evening chronotype;
LGG	cis	rs367943	1.000	rs191553	chr5:112823659	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs2016266	0.855	rs930900	chr12:53727545	T/C	cg04065151	chr12:53682969	ESPL1	-0.51	-8.15	-0.35	3.35e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6665290	0.904	rs1343744	chr1:227183022	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.8	-0.34	4.11e-14	Myeloid white cell count;
LGG	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg26597838	chr10:835615	NA	0.52	6.82	0.3	2.81e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg00647317	chr7:50633725	DDC	0.36	8.52	0.37	2.33e-16	Body mass index;
LGG	cis	rs12950390	0.853	rs11658511	chr17:45856918	T/C	cg06532163	chr17:45867833	NA	0.55	9.3	0.4	5.63e-19	IgG glycosylation;
LGG	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-8.05	-0.35	7.22e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11229555	0.645	rs11601296	chr11:58423297	A/G	cg15696309	chr11:58395628	NA	-0.91	-12.18	-0.49	8.87e-30	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg08677398	chr8:58056175	NA	0.42	6.69	0.3	6.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	0.867	rs4131519	chr6:96964939	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	14.96	0.57	1.45e-41	Headache;
LGG	cis	rs13314892	0.764	rs55738162	chr3:69859270	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs9649465	0.967	rs11765790	chr7:123293152	A/C	cg03229431	chr7:123269106	ASB15	-0.42	-9.08	-0.39	3.1e-18	Migraine;
LGG	cis	rs17767392	0.881	rs12881957	chr14:71909854	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.81	-0.38	2.45e-17	Mitral valve prolapse;
LGG	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg22232500	chr2:134024266	NCKAP5	0.56	7.96	0.35	1.31e-14	Bipolar disorder;
LGG	trans	rs10838798	0.563	rs4752902	chr11:48148779	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.78	-0.3	3.7e-11	Height;
LGG	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg27087555	chr16:88793112	FAM38A	-1.25	-11.78	-0.48	3.26e-28	Plateletcrit;
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg19524238	chr7:2802976	GNA12	0.31	7.63	0.33	1.35e-13	Height;
LGG	cis	rs7580658	0.750	rs6761391	chr2:128154284	C/G	cg10021288	chr2:128175891	PROC	-0.56	-11.19	-0.46	6.61e-26	Protein C levels;
LGG	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs2991971	0.967	rs10789465	chr1:45971759	T/C	cg24296786	chr1:45957014	TESK2	0.42	7.55	0.33	2.32e-13	High light scatter reticulocyte count;
LGG	cis	rs7586879	0.681	rs6545800	chr2:25118885	A/G	cg04586622	chr2:25135609	ADCY3	-0.47	-12.8	-0.51	2.42e-32	Body mass index;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.55	-9.32	-0.4	4.74e-19	Longevity;Endometriosis;
LGG	cis	rs2354432	0.556	rs2353984	chr1:146813358	C/T	cg25205988	chr1:146714368	CHD1L	1.24	12.76	0.51	3.73e-32	Mitochondrial DNA levels;
LGG	cis	rs6665290	0.904	rs10916075	chr1:227184074	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.96	-0.91	1.19e-174	Myeloid white cell count;
LGG	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg19554555	chr3:13937349	NA	-0.55	-9.81	-0.41	8.85e-21	Ovarian reserve;
LGG	cis	rs9916302	0.904	rs10852933	chr17:37698194	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.52	-0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs11039798	0.920	rs11039848	chr11:48598243	C/T	cg15704280	chr7:45808275	SEPT13	0.74	7.9	0.34	2.12e-14	Axial length;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs7166081	1.000	rs78553942	chr15:67521810	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.04	-0.31	7.07e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9814567	1.000	rs9832785	chr3:134213070	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.92	-0.51	7.9e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7737355	0.773	rs31239	chr5:130813377	G/T	cg06307176	chr5:131281290	NA	-0.5	-8.4	-0.36	5.41e-16	Life satisfaction;
LGG	cis	rs9611565	0.649	rs139553	chr22:42187199	A/G	cg03806693	chr22:41940476	POLR3H	0.89	14.75	0.57	1.18e-40	Vitiligo;
LGG	trans	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg19894588	chr14:64061835	NA	-0.64	-10.21	-0.43	3.18e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7267979	1.000	rs2424710	chr20:25283886	C/G	cg06421707	chr20:25228305	PYGB	0.47	10.17	0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs477692	0.648	rs10829599	chr10:131321881	C/T	cg05714579	chr10:131428358	MGMT	0.45	8.55	0.37	1.82e-16	Response to temozolomide;
LGG	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg14675211	chr2:100938903	LONRF2	0.67	12.04	0.49	3.04e-29	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.7	-12.86	-0.51	1.41e-32	Obesity-related traits;
LGG	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg06027949	chr8:82754900	SNX16	-0.55	-8.6	-0.37	1.23e-16	Diastolic blood pressure;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.37	-0.36	6.98e-16	Dementia with Lewy bodies;
LGG	trans	rs9393777	0.777	rs56114371	chr6:27274834	C/T	cg08344181	chr3:125677491	NA	-0.85	-8.49	-0.37	2.89e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17826219	0.706	rs61643715	chr17:29057762	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.51e-13	Body mass index;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg12708336	chr17:41446283	NA	-0.31	-7.37	-0.32	7.92e-13	Menopause (age at onset);
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg17691542	chr6:26056736	HIST1H1C	0.56	10.01	0.42	1.75e-21	Height;
LGG	cis	rs2708977	0.901	rs3731938	chr2:97166204	A/G	cg22654517	chr2:96458247	NA	0.33	6.65	0.3	8.08e-11	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6448317	0.906	rs4053966	chr4:24901466	A/G	cg21108841	chr4:24914750	CCDC149	-0.53	-7.42	-0.33	5.57e-13	Heschl's gyrus morphology;
LGG	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg05775895	chr3:12838266	CAND2	0.79	15.92	0.59	7.93e-46	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.882	rs4261311	chr11:70132902	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs11676348	0.808	rs4674261	chr2:219005009	G/C	cg00012203	chr2:219082015	ARPC2	-0.48	-8.47	-0.37	3.32e-16	Ulcerative colitis;
LGG	cis	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg19338460	chr6:170058176	WDR27	-0.85	-9.98	-0.42	2.24e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg23845249	chr11:68861649	NA	0.45	7.99	0.35	1.09e-14	Blond vs. brown hair color;
LGG	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg03894339	chr8:19674705	INTS10	0.64	10.45	0.44	4.13e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs4538187	0.737	rs36033991	chr2:64150441	A/G	cg02541582	chr2:64069798	UGP2	-0.62	-14.28	-0.55	1.31e-38	Systolic blood pressure;
LGG	cis	rs10905065	0.965	rs2890365	chr10:5773876	C/A	cg11519256	chr10:5708881	ASB13	-0.41	-7.18	-0.32	2.74e-12	Menopause (age at onset);
LGG	cis	rs9902453	0.704	rs2628179	chr17:28071796	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.9	-0.54	6.12e-37	Coffee consumption (cups per day);
LGG	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg03474202	chr17:45855739	NA	-0.27	-8.01	-0.35	9.51e-15	IgG glycosylation;
LGG	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.54	9.29	0.4	6.05e-19	Menarche (age at onset);
LGG	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg06611532	chr13:114900021	NA	0.3	7.55	0.33	2.35e-13	Schizophrenia;
LGG	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.27e-18	Motion sickness;
LGG	cis	rs561341	1.000	rs554078	chr17:30330109	A/C	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.41e-11	Hip circumference adjusted for BMI;
LGG	cis	rs8180040	1.000	rs11714294	chr3:47339723	G/A	cg27129171	chr3:47204927	SETD2	-0.8	-15.59	-0.59	2.43e-44	Colorectal cancer;
LGG	cis	rs17767392	0.914	rs35613269	chr14:71887814	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs4774899	0.752	rs2439919	chr15:57368459	T/C	cg08128148	chr15:57256372	TCF12	-0.28	-6.76	-0.3	4.08e-11	Urinary tract infection frequency;
LGG	cis	rs9487094	0.670	rs12201356	chr6:110015875	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.2e-15	Height;
LGG	cis	rs1799949	0.965	rs1842147	chr17:41435192	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.3	0.65	1.09e-56	Menopause (age at onset);
LGG	cis	rs1847505	0.609	rs79087755	chr13:61482054	C/T	cg25164009	chr13:61490935	NA	0.59	9.14	0.39	1.96e-18	Polychlorinated biphenyl levels;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg26174226	chr8:58114915	NA	-0.53	-7.46	-0.33	4.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs34421088	0.623	rs4841515	chr8:11097166	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.11	-0.31	4.41e-12	Neuroticism;
LGG	cis	rs2991971	0.967	rs6661321	chr1:45954599	C/G	cg24296786	chr1:45957014	TESK2	0.42	7.67	0.34	1.05e-13	High light scatter reticulocyte count;
LGG	cis	rs919433	0.680	rs4685	chr2:198257795	C/T	cg00792783	chr2:198669748	PLCL1	-0.5	-7.98	-0.35	1.18e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7786877	0.723	rs73407376	chr7:100215200	C/T	cg16850897	chr7:100343110	ZAN	-0.57	-8.19	-0.36	2.64e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8017423	1.000	rs11622075	chr14:90669894	G/T	cg04374321	chr14:90722782	PSMC1	0.85	18.06	0.64	1.47e-55	Mortality in heart failure;
LGG	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.85	0.79	5.27e-101	Height;
LGG	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg27411982	chr8:10470053	RP1L1	-0.47	-8.0	-0.35	9.99e-15	Neuroticism;
LGG	trans	rs9650657	0.557	rs11783418	chr8:10841858	G/A	cg02002194	chr4:3960332	NA	0.48	8.39	0.36	5.74e-16	Neuroticism;
LGG	cis	rs11722228	0.522	rs62286604	chr4:10131161	A/G	cg08250081	chr4:10125330	NA	0.66	12.23	0.49	5.11e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg02343648	chr10:102133165	C10orf75	0.34	6.68	0.3	7.08e-11	Parkinson's disease (motor and cognition);
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg23213688	chr1:231473791	C1orf124;EXOC8	0.42	7.17	0.32	3.02e-12	Lung adenocarcinoma;
LGG	cis	rs1865760	0.593	rs9295678	chr6:25937033	G/A	cg03264133	chr6:25882463	NA	-0.5	-9.02	-0.39	5.17e-18	Height;
LGG	cis	rs2046867	0.628	rs62249880	chr3:72918940	C/T	cg25664220	chr3:72788482	NA	-0.27	-8.08	-0.35	5.78e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2839186	0.508	rs12626873	chr21:47714848	G/T	cg09417038	chr21:47716443	C21orf57	-0.43	-8.62	-0.37	1.07e-16	Testicular germ cell tumor;
LGG	cis	rs2011503	1.000	rs11670761	chr19:19649327	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	8.33	0.36	8.95e-16	Neuroticism;
LGG	cis	rs4888378	0.535	rs9319483	chr16:75345791	T/C	cg07303275	chr16:75499416	TMEM170A	-0.42	-6.75	-0.3	4.33e-11	Coronary artery disease;
LGG	cis	rs4356203	0.905	rs618331	chr11:17247336	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07659893	chr17:61819838	STRADA	0.47	7.97	0.35	1.21e-14	Prudent dietary pattern;
LGG	cis	rs67366981	0.925	rs56245630	chr14:77714185	T/C	cg22824376	chr14:77648248	TMEM63C	0.66	7.03	0.31	7.54e-12	Obsessive-compulsive symptoms;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.2	-0.36	2.33e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs240764	0.619	rs239198	chr6:101134077	C/T	cg09795085	chr6:101329169	ASCC3	0.49	8.12	0.35	4.26e-15	Neuroticism;
LGG	cis	rs10893109	0.538	rs1377605	chr11:123775782	G/A	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.48	-0.37	2.94e-16	Diabetic kidney disease;
LGG	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15557168	chr22:42548783	NA	-0.4	-8.99	-0.39	6.39e-18	Cognitive function;
LGG	cis	rs4650994	0.789	rs2761471	chr1:178599348	A/C	cg19399532	chr1:178512495	C1orf220	-0.37	-7.01	-0.31	8.57e-12	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs8073060	0.544	rs225274	chr17:33971221	C/T	cg19694781	chr19:47549865	TMEM160	1.08	16.68	0.61	3.02e-49	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.39e-12	Diabetic retinopathy;
LGG	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg22681709	chr2:178499509	PDE11A	-0.45	-8.16	-0.35	3.1e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.32	-0.47	2.22e-26	Personality dimensions;
LGG	cis	rs4671458	0.649	rs17348176	chr2:63449561	A/G	cg17519650	chr2:63277830	OTX1	-0.71	-7.19	-0.32	2.58e-12	Subjective well-being;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg05091796	chr16:4465799	CORO7	-0.6	-9.88	-0.42	5.21e-21	Schizophrenia;
LGG	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.91	0.35	1.91e-14	Platelet count;
LGG	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg06634786	chr22:41940651	POLR3H	0.43	7.48	0.33	3.81e-13	Alzheimer's disease biomarkers;
LGG	cis	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg22496380	chr5:211416	CCDC127	-0.96	-9.07	-0.39	3.38e-18	Breast cancer;
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg11584989	chr19:19387371	SF4	-0.39	-7.16	-0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.5	-0.44	2.77e-23	Bipolar disorder;
LGG	cis	rs9354308	0.764	rs9354323	chr6:66586561	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs7633770	1.000	rs7633770	chr3:46688562	G/A	cg11219411	chr3:46661640	NA	0.54	12.23	0.49	5.55e-30	Coronary artery disease;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg04703951	chr17:43578652	NA	0.39	7.69	0.34	8.98e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.48e-12	Retinal vascular caliber;
LGG	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg22974920	chr21:40686053	BRWD1	-0.43	-6.92	-0.31	1.52e-11	Cognitive function;
LGG	cis	rs526231	0.508	rs34805	chr5:102428312	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Primary biliary cholangitis;
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs16941017	chr15:45543281	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.35	-0.32	8.92e-13	Uric acid levels;
LGG	cis	rs1580019	0.563	rs34319173	chr7:32585904	G/A	cg06133097	chr7:32552212	AVL9	-0.38	-7.19	-0.32	2.55e-12	Cognitive ability;
LGG	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg10223061	chr2:219282414	VIL1	0.3	6.78	0.3	3.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10463316	0.817	rs2112419	chr5:150797804	T/C	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.37	-0.43	8.52e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs6573604	1.000	rs8013568	chr14:65774875	T/A	cg15999311	chr14:65749247	NA	0.46	6.69	0.3	6.26e-11	N-glycan levels;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg13047869	chr3:10149882	C3orf24	0.4	7.15	0.32	3.45e-12	Alzheimer's disease;
LGG	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.3	0.43	1.56e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg22232500	chr2:134024266	NCKAP5	0.54	7.45	0.33	4.76e-13	Bipolar disorder;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg14092988	chr3:52407081	DNAH1	0.29	7.68	0.34	9.79e-14	Bipolar disorder;
LGG	cis	rs17270561	0.943	rs4478398	chr6:25694684	T/C	cg17691542	chr6:26056736	HIST1H1C	0.81	11.29	0.46	2.85e-26	Iron status biomarkers;
LGG	cis	rs801193	1.000	rs2707856	chr7:66211010	A/T	cg11764359	chr7:65958608	NA	0.63	10.93	0.45	6.8e-25	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18652923	chr2:109745344	SH3RF3;LOC100287216	0.42	6.84	0.3	2.58e-11	Cognitive performance;
LGG	cis	rs7918232	0.596	rs7902540	chr10:27304693	C/T	cg14442939	chr10:27389572	ANKRD26	0.46	7.95	0.35	1.42e-14	Breast cancer;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg25172604	chr17:41446521	NA	-0.31	-6.99	-0.31	9.45e-12	Menopause (age at onset);
LGG	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.21	-0.32	2.28e-12	Inflammatory bowel disease;
LGG	cis	rs1707322	1.000	rs785498	chr1:46592414	C/T	cg03146154	chr1:46216737	IPP	-0.56	-9.92	-0.42	3.66e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7493	1.000	rs3779492	chr7:95044183	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.33	-0.36	9.21e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6977660	1.000	rs10279601	chr7:19822171	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	8.91	0.38	1.18e-17	Thyroid stimulating hormone;
LGG	cis	rs4356932	0.967	rs6856958	chr4:76952356	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs7580658	0.963	rs6732279	chr2:128089540	G/T	cg10021288	chr2:128175891	PROC	-0.65	-13.4	-0.53	8.08e-35	Protein C levels;
LGG	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs769267	0.930	rs6511038	chr19:19607564	A/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg19168338	chr16:4465731	CORO7	-0.94	-18.77	-0.66	7.61e-59	Schizophrenia;
LGG	cis	rs4356932	0.905	rs4859597	chr4:76956630	A/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs546131	0.928	rs550313	chr11:34830919	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.58	10.37	0.43	8.59e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs2050392	1.000	rs2265185	chr10:30691777	A/C	cg25182066	chr10:30743637	MAP3K8	-0.51	-10.63	-0.44	9.32e-24	Inflammatory bowel disease;
LGG	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg24110177	chr3:50126178	RBM5	-0.57	-10.44	-0.44	4.54e-23	Intelligence (multi-trait analysis);
LGG	cis	rs4853012	0.887	rs7570950	chr2:74338942	T/C	cg05890377	chr2:74357713	NA	0.48	9.09	0.39	2.96e-18	Gestational age at birth (maternal effect);
LGG	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg01657329	chr11:68192670	LRP5	-0.57	-9.08	-0.39	3.2e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs73086581	1.000	rs3746666	chr20:3910861	A/G	cg02187196	chr20:3869020	PANK2	0.84	11.72	0.48	5.6e-28	Response to antidepressants in depression;
LGG	cis	rs7973719	0.865	rs12830671	chr12:7347278	T/G	cg07052231	chr12:7363540	PEX5	0.38	6.65	0.3	8.53e-11	IgG glycosylation;
LGG	trans	rs877282	0.853	rs11593836	chr10:756715	G/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17376030	chr22:41985996	PMM1	-0.43	-7.05	-0.31	6.61e-12	Vitiligo;
LGG	cis	rs754466	0.914	rs12218917	chr10:79701479	C/T	cg17075019	chr10:79541650	NA	-0.8	-13.42	-0.53	6.41e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17539620	0.624	rs62432735	chr6:154834055	T/C	cg17771515	chr6:154831774	CNKSR3	0.62	7.66	0.34	1.08e-13	Lipoprotein (a) levels;
LGG	cis	rs4006360	0.524	rs7219230	chr17:39286180	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.39	-8.19	-0.36	2.5e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs35110281	0.774	rs9978811	chr21:44998683	C/T	cg04455712	chr21:45112962	RRP1B	0.52	10.05	0.42	1.22e-21	Mean corpuscular volume;
LGG	cis	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg09021430	chr5:549028	NA	-0.77	-10.06	-0.42	1.19e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg01516881	chr6:292596	DUSP22	-0.68	-11.3	-0.46	2.58e-26	Menopause (age at onset);
LGG	cis	rs10504073	0.584	rs1511365	chr8:49975321	A/T	cg00325661	chr8:49890786	NA	0.79	15.19	0.58	1.39e-42	Blood metabolite ratios;
LGG	cis	rs10991814	0.920	rs7043552	chr9:94025991	G/A	cg14446406	chr9:93919335	NA	-0.74	-8.29	-0.36	1.21e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.32	-0.43	1.26e-22	Platelet count;
LGG	cis	rs6496932	0.563	rs2344083	chr15:85897432	T/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.06	-0.35	6.54e-15	Central corneal thickness;Corneal structure;
LGG	cis	rs11124272	0.543	rs11676456	chr2:32331511	A/G	cg02381751	chr2:32503542	YIPF4	-0.48	-6.65	-0.3	8.29e-11	Interleukin-18 levels;
LGG	cis	rs2735413	0.918	rs4309408	chr16:78071507	G/A	cg04733911	chr16:78082701	NA	-0.77	-18.44	-0.65	2.55e-57	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs34734847	0.898	rs696339	chr12:121169436	A/T	cg21892295	chr12:121157589	UNC119B	-0.38	-7.28	-0.32	1.46e-12	Mean corpuscular volume;
LGG	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg17644776	chr2:200775616	C2orf69	-0.6	-7.58	-0.33	1.87e-13	Schizophrenia;
LGG	trans	rs2204008	0.837	rs2127955	chr12:37969194	A/G	cg06521331	chr12:34319734	NA	-0.5	-9.21	-0.39	1.17e-18	Bladder cancer;
LGG	cis	rs3008870	0.785	rs10889651	chr1:67463513	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-16.37	-0.61	7.44e-48	Lymphocyte percentage of white cells;
LGG	cis	rs8141529	1.000	rs132534	chr22:29299806	T/C	cg15103426	chr22:29168792	CCDC117	-0.6	-8.48	-0.37	3.08e-16	Lymphocyte counts;
LGG	cis	rs9487094	0.813	rs35969918	chr6:109763040	G/C	cg01125227	chr6:109776195	MICAL1	0.54	9.09	0.39	2.9e-18	Height;
LGG	cis	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg02972257	chr16:68554789	NA	-0.52	-7.82	-0.34	3.57e-14	Ulcerative colitis;
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02951883	chr7:2050386	MAD1L1	0.46	6.67	0.3	7.43e-11	Bipolar disorder;
LGG	cis	rs2224391	1.000	rs2753247	chr6:5261987	A/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.18	-0.36	2.69e-15	Height;
LGG	trans	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs10189230	0.674	rs2710506	chr2:222379489	A/C	cg14652038	chr2:222343519	EPHA4	0.41	8.02	0.35	8.65e-15	Urate levels in lean individuals;
LGG	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg08048268	chr3:133502702	NA	-0.7	-13.71	-0.54	3.62e-36	Iron status biomarkers;
LGG	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg11812906	chr14:75593930	NEK9	-0.48	-8.93	-0.38	1e-17	Height;
LGG	cis	rs981844	0.683	rs1037647	chr4:154737991	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.56e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs2115536	0.720	rs12916091	chr15:80222572	T/G	cg00225070	chr15:80189496	MTHFS	0.38	6.88	0.3	1.99e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9381107	0.932	rs13198509	chr6:9479610	C/T	cg14735645	chr6:9486422	NA	-0.5	-8.17	-0.36	2.9e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7084402	1.000	rs7095501	chr10:60271940	T/C	cg09696939	chr10:60272079	BICC1	0.38	7.37	0.32	7.86e-13	Refractive error;
LGG	cis	rs2797160	1.000	rs2747723	chr6:126010790	C/T	cg05901451	chr6:126070800	HEY2	0.44	7.49	0.33	3.55e-13	Endometrial cancer;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.76	0.54	2.35e-36	Obesity-related traits;
LGG	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg05308233	chr10:104796373	CNNM2	-0.3	-6.75	-0.3	4.37e-11	Arsenic metabolism;
LGG	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg13010199	chr12:38710504	ALG10B	0.74	15.79	0.59	3.05e-45	Heart rate;
LGG	cis	rs4561483	0.801	rs40311	chr16:11963190	C/G	cg08843971	chr16:11963173	GSPT1	0.67	18.12	0.64	7.66e-56	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.46e-16	Life satisfaction;
LGG	cis	rs4919087	0.715	rs2484880	chr10:98998355	T/C	cg25902810	chr10:99078978	FRAT1	-0.44	-7.45	-0.33	4.62e-13	Monocyte count;
LGG	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	11.01	0.46	3.5e-25	Breast cancer;
LGG	cis	rs1577917	1.000	rs1337844	chr6:86677273	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.36	-0.4	3.55e-19	Response to antipsychotic treatment;
LGG	cis	rs6429082	0.818	rs210037	chr1:235649501	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.1	0.42	8.3e-22	Adiposity;
LGG	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg05753993	chr18:77199432	NFATC1	0.41	6.77	0.3	3.8e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7129556	0.539	rs1945747	chr11:77277387	A/T	cg12586386	chr11:77299805	AQP11	0.39	6.87	0.3	2.1e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	6.99	0.31	9.55e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7215564	0.908	rs59252837	chr17:78717155	A/G	cg06153925	chr17:78755379	RPTOR	0.41	7.12	0.31	4.15e-12	Myopia (pathological);
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.07	0.39	3.38e-18	Lung cancer;
LGG	cis	rs2235642	0.750	rs2974845	chr16:1648162	T/C	cg09025071	chr16:1593152	IFT140;TMEM204	0.38	9.24	0.39	8.71e-19	Coronary artery disease;
LGG	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	trans	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg18335740	chr13:41363409	SLC25A15	0.57	10.57	0.44	1.58e-23	Lewy body disease;
LGG	cis	rs67478160	0.619	rs12885018	chr14:104273812	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.47	-0.33	4.12e-13	Schizophrenia;
LGG	cis	rs4684776	0.935	rs11713733	chr3:11400552	G/A	cg24705426	chr3:11550659	ATG7	-0.44	-8.08	-0.35	5.57e-15	Small vessel stroke;
LGG	cis	rs9463078	0.605	rs17422760	chr6:44885288	C/T	cg25276700	chr6:44698697	NA	0.33	6.92	0.31	1.48e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg21775007	chr8:11205619	TDH	-0.78	-13.64	-0.54	7.32e-36	Retinal vascular caliber;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg11235426	chr6:292522	DUSP22	-0.45	-7.64	-0.33	1.22e-13	Menopause (age at onset);
LGG	cis	rs1256061	0.646	rs1256059	chr14:64710417	A/G	cg23250157	chr14:64679961	SYNE2	0.39	7.01	0.31	8.67e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs11190604	1.000	rs7084810	chr10:102297546	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.39	0.32	6.72e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2267681	0.603	rs12534299	chr7:139538522	A/G	cg14116596	chr7:139528673	TBXAS1	-0.33	-7.31	-0.32	1.17e-12	Cervical cancer;
LGG	cis	rs6539267	0.741	rs10861572	chr12:106688576	A/G	cg00173435	chr12:106696525	TCP11L2	-0.64	-9.67	-0.41	2.76e-20	Tourette syndrome;
LGG	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.18	0.52	6.48e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7760949	0.963	rs1467729	chr6:13911167	C/T	cg27413430	chr6:13925136	RNF182	-0.41	-6.7	-0.3	6.06e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs765787	0.505	rs11630884	chr15:45532246	C/T	cg24006582	chr15:45444508	DUOX1	-0.71	-13.65	-0.54	6.87e-36	Uric acid levels;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg08562543	chr2:27593465	SNX17;EIF2B4	-0.42	-7.14	-0.31	3.61e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs2764208	0.576	rs4711399	chr6:34676237	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.46	8.28	0.36	1.3e-15	Systemic lupus erythematosus;
LGG	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.18	-0.49	8.56e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs8017423	0.967	rs55667096	chr14:90714798	C/T	cg04374321	chr14:90722782	PSMC1	0.88	18.55	0.65	7.3e-58	Mortality in heart failure;
LGG	cis	rs4731207	0.596	rs7795218	chr7:124578380	C/A	cg05630886	chr7:124431682	NA	-0.3	-6.84	-0.3	2.53e-11	Cutaneous malignant melanoma;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.29	-0.36	1.23e-15	Longevity;Endometriosis;
LGG	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.6	-0.33	1.66e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4731207	0.698	rs6961292	chr7:124503189	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg06634786	chr22:41940651	POLR3H	-0.8	-12.83	-0.51	1.95e-32	Vitiligo;
LGG	cis	rs9399135	1.000	rs1014021	chr6:135334600	C/T	cg24558204	chr6:135376177	HBS1L	-0.51	-9.46	-0.4	1.55e-19	Red blood cell count;
LGG	cis	rs561341	0.769	rs12941700	chr17:30185022	A/G	cg00745463	chr17:30367425	LRRC37B	0.55	7.08	0.31	5.52e-12	Hip circumference adjusted for BMI;
LGG	cis	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg11995313	chr8:8860691	ERI1	0.44	7.39	0.32	6.96e-13	Joint mobility (Beighton score);
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.1e-17	Aortic root size;
LGG	cis	rs9911578	1.000	rs2567911	chr17:56734977	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs644148	0.770	rs2571113	chr19:44999814	A/G	cg15540054	chr19:45004280	ZNF180	-0.56	-10.72	-0.45	4.21e-24	Personality dimensions;
LGG	cis	rs701145	0.529	rs355746	chr3:153961627	C/G	cg12800244	chr3:153838788	SGEF	0.57	8.23	0.36	1.87e-15	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.54	0.44	2.02e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.12	-0.35	4.39e-15	Retinal vascular caliber;
LGG	cis	rs11239187	0.586	rs7069381	chr10:45104415	G/T	cg03916630	chr10:45065415	NA	0.34	8.26	0.36	1.51e-15	Body mass index;
LGG	cis	rs3204270	0.684	rs62080212	chr17:79642500	G/A	cg18367735	chr17:79674897	NA	0.59	7.82	0.34	3.7e-14	Dental caries;
LGG	cis	rs368123	1.000	rs500199	chr6:160701403	G/A	cg07349212	chr6:160770346	SLC22A3	-0.33	-7.06	-0.31	6.07e-12	Waist circumference;
LGG	cis	rs972578	0.967	rs5759082	chr22:43401079	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.68	-0.3	6.73e-11	Mean platelet volume;
LGG	cis	rs17023223	0.537	rs12081327	chr1:119686358	A/G	cg05756136	chr1:119680316	WARS2	-0.44	-9.22	-0.39	1.07e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg13147721	chr7:65941812	NA	-0.82	-10.29	-0.43	1.67e-22	Diabetic kidney disease;
LGG	trans	rs45509595	0.841	rs401754	chr6:27782538	T/A	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg14228332	chr4:119757509	SEC24D	0.92	9.41	0.4	2.34e-19	Cannabis dependence symptom count;
LGG	cis	rs2380220	0.938	rs6923253	chr6:95970141	C/G	cg04719120	chr6:96025338	MANEA	0.52	6.79	0.3	3.38e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs3733585	0.683	rs6449140	chr4:9936437	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.31	-0.32	1.16e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7119	0.717	rs11631274	chr15:77816431	A/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs2836974	0.932	rs35571600	chr21:40590624	A/C	cg17971929	chr21:40555470	PSMG1	0.87	17.22	0.62	1.01e-51	Cognitive function;
LGG	cis	rs17666538	0.792	rs1703912	chr8:600643	A/G	cg07234876	chr8:600039	NA	1.37	12.86	0.51	1.39e-32	IgG glycosylation;
LGG	cis	rs6582630	0.537	rs35336822	chr12:38346251	T/C	cg26384229	chr12:38710491	ALG10B	0.91	20.04	0.68	8.35e-65	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-7.1	-0.31	4.79e-12	Height;
LGG	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg16850897	chr7:100343110	ZAN	-0.65	-9.7	-0.41	2.23e-20	Other erythrocyte phenotypes;
LGG	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg24623649	chr8:11872141	NA	0.32	7.66	0.34	1.12e-13	Monocyte count;
LGG	cis	rs9325144	0.510	rs7952795	chr12:38720686	C/T	cg04568710	chr12:38710424	ALG10B	0.39	8.38	0.36	6.21e-16	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.8	0.3	3.2e-11	Schizophrenia;
LGG	cis	rs801193	0.839	rs6968619	chr7:66068867	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.62	-0.44	9.89e-24	Aortic root size;
LGG	cis	rs4690686	0.538	rs4690687	chr4:177259635	A/G	cg17059388	chr4:177262070	NA	-0.95	-21.03	-0.7	2.16e-69	Essential tremor;
LGG	cis	rs7169223	0.653	rs1976007	chr15:79085023	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.36	-7.1	-0.31	4.59e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs3096299	0.748	rs3102339	chr16:89442711	C/T	cg02187348	chr16:89574699	SPG7	0.44	7.05	0.31	6.72e-12	Multiple myeloma (IgH translocation);
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg02002194	chr4:3960332	NA	-0.47	-8.8	-0.38	2.65e-17	Monocyte count;
LGG	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-7.04	-0.31	6.98e-12	Total body bone mineral density;
LGG	cis	rs2247341	0.577	rs2236996	chr4:1703646	A/G	cg08446824	chr4:1720184	TMEM129	-0.51	-9.16	-0.39	1.62e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.31	3.71e-12	Life satisfaction;
LGG	cis	rs12908161	0.959	rs12906348	chr15:85329421	A/C	cg03959625	chr15:84868606	LOC388152	0.48	7.16	0.32	3.22e-12	Schizophrenia;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07701084	chr6:150067640	NUP43	0.45	8.2	0.36	2.32e-15	Testicular germ cell tumor;
LGG	cis	rs1107366	1.000	rs1107364	chr3:125904263	G/A	cg17230874	chr3:125932073	NA	0.53	11.04	0.46	2.67e-25	Metabolite levels;
LGG	cis	rs7086627	0.515	rs10887903	chr10:82210641	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	12.25	0.49	4.23e-30	Post bronchodilator FEV1;
LGG	cis	rs68170813	0.652	rs74374590	chr7:107172470	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-8.34	-0.36	8.83e-16	Coronary artery disease;
LGG	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg21699342	chr2:239360505	ASB1	0.39	7.53	0.33	2.6e-13	Multiple system atrophy;
LGG	cis	rs2221894	0.506	rs17454230	chr8:28926081	G/T	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.81	-0.34	3.95e-14	Obesity-related traits;
LGG	cis	rs2549003	0.933	rs7719499	chr5:131814091	C/G	cg00578828	chr5:131826934	IRF1	0.42	7.64	0.33	1.23e-13	Asthma (sex interaction);
LGG	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg15369054	chr17:80825471	TBCD	-0.48	-7.33	-0.32	1.03e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs8177253	0.898	rs8177258	chr3:133480387	C/A	cg11941060	chr3:133502564	NA	-0.48	-8.15	-0.35	3.55e-15	Iron status biomarkers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04949219	chr11:64863633	C11orf2	0.4	6.71	0.3	5.74e-11	Cognitive performance;
LGG	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	9.54	0.41	8.03e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg11245990	chr11:68621969	NA	0.4	8.75	0.38	4e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7666738	0.830	rs1426665	chr4:99027764	C/T	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.58e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2479724	0.840	rs10498752	chr6:41768510	T/C	cg17623882	chr6:41773611	USP49	0.52	9.03	0.39	4.62e-18	Menarche (age at onset);
LGG	cis	rs1497828	0.956	rs2815230	chr1:217536114	T/C	cg04411442	chr1:217543379	NA	-0.48	-8.1	-0.35	5.07e-15	Dialysis-related mortality;
LGG	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg07423050	chr13:99094983	FARP1	-0.57	-11.0	-0.46	3.79e-25	Longevity;
LGG	cis	rs4253772	0.786	rs4253765	chr22:46622888	C/T	cg24881330	chr22:46731750	TRMU	0.56	6.86	0.3	2.28e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11690935	0.918	rs11757	chr2:172641045	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.77	-0.78	4.6e-96	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.82	0.3	2.79e-11	Lung cancer;
LGG	cis	rs12367572	0.965	rs7979717	chr12:45242272	A/T	cg03114573	chr12:45410052	DBX2	-0.53	-9.16	-0.39	1.62e-18	Gut microbiome composition (summer);
LGG	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	cis	rs6087990	0.806	rs6141814	chr20:31368960	C/A	cg13636640	chr20:31349939	DNMT3B	0.96	20.28	0.69	6.96e-66	Ulcerative colitis;
LGG	cis	rs10791097	0.694	rs10791100	chr11:130738946	T/A	cg09137382	chr11:130731461	NA	0.35	6.81	0.3	3.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs78545713	0.536	rs56119218	chr6:26225881	C/A	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs8114671	0.562	rs6087641	chr20:33467717	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.15	0.32	3.3e-12	Height;
LGG	cis	rs10426930	0.607	rs2613768	chr19:5074637	G/A	cg18473234	chr19:5097819	KDM4B	-0.44	-7.64	-0.33	1.28e-13	Monocyte percentage of white cells;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg23102388	chr7:1867652	MAD1L1	0.35	6.95	0.31	1.22e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1801251	1.000	rs283474	chr2:233654627	A/G	cg25237894	chr2:233734115	C2orf82	0.62	11.6	0.47	1.76e-27	Coronary artery disease;
LGG	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2404602	0.669	rs12595313	chr15:76978370	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.35e-18	Blood metabolite levels;
LGG	trans	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg26043149	chr18:55253948	FECH	-0.5	-8.04	-0.35	7.55e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7646881	0.812	rs6788069	chr3:158459459	C/T	cg19483011	chr3:158453295	NA	0.61	8.2	0.36	2.44e-15	Tetralogy of Fallot;
LGG	cis	rs10824796	0.638	rs10824789	chr10:54518282	C/G	cg27418851	chr10:54531653	MBL2	0.4	7.45	0.33	4.64e-13	Blood protein levels;
LGG	cis	rs3740540	0.507	rs10794161	chr10:126291327	C/A	cg04949429	chr10:126290192	LHPP	0.6	11.5	0.47	4.35e-27	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg19168338	chr16:4465731	CORO7	-0.84	-16.36	-0.61	8.46e-48	Schizophrenia;
LGG	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg07936489	chr17:37558343	FBXL20	1.0	15.5	0.58	5.97e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs7818345	0.845	rs11782540	chr8:19268251	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.71	0.3	5.86e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs4862750	0.872	rs7672831	chr4:187898882	C/T	cg27532560	chr4:187881888	NA	-0.58	-12.95	-0.52	5.7e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7072216	0.655	rs3830024	chr10:100176106	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.07	-0.31	5.85e-12	Metabolite levels;
LGG	cis	rs988958	0.526	rs58351981	chr2:42245125	T/G	cg19376973	chr2:42229025	NA	0.64	9.52	0.4	9.38e-20	Hypospadias;
LGG	cis	rs7568458	0.905	rs6547620	chr2:85755928	C/T	cg23752985	chr2:85803571	VAMP8	0.42	8.35	0.36	7.72e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs16866061	1.000	rs16866061	chr2:225439844	A/G	cg12698349	chr2:225449008	CUL3	0.91	18.82	0.66	4.15e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs10504130	0.569	rs35032384	chr8:52823084	T/A	cg22653915	chr8:52722023	PXDNL	-0.44	-6.98	-0.31	1e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6772849	0.805	rs13325747	chr3:128336023	G/A	cg08795948	chr3:128337044	NA	0.6	10.48	0.44	3.29e-23	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg24829409	chr8:58192753	C8orf71	0.86	12.99	0.52	4.03e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg08677398	chr8:58056175	NA	0.43	6.84	0.3	2.56e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.840	rs2896002	chr15:84945121	A/G	cg03959625	chr15:84868606	LOC388152	0.57	8.79	0.38	3.03e-17	Schizophrenia;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.81	0.3	3.01e-11	Longevity;
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg06719900	chr11:109292894	C11orf87	0.45	8.37	0.36	7.11e-16	Schizophrenia;
LGG	cis	rs6138458	0.626	rs6050261	chr20:25014206	C/T	cg26195577	chr20:24973756	C20orf3	0.89	16.24	0.6	2.9e-47	Blood protein levels;
LGG	cis	rs12956009	0.583	rs11662486	chr18:44868325	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.04	0.31	7.08e-12	Educational attainment (years of education);
LGG	cis	rs4808199	0.947	rs4808960	chr19:19574277	G/C	cg03709012	chr19:19516395	GATAD2A	1.08	17.55	0.63	3.13e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs483180	0.855	rs562038	chr1:120254545	G/C	cg19096424	chr1:120255104	PHGDH	0.87	14.83	0.57	5.62e-41	Macular telangiectasia type 2;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg06719900	chr11:109292894	C11orf87	0.5	8.91	0.38	1.14e-17	Schizophrenia;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg18099408	chr3:52552593	STAB1	0.35	6.97	0.31	1.1e-11	Bipolar disorder;
LGG	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.49	-7.46	-0.33	4.34e-13	Parkinson's disease;
LGG	cis	rs6942756	1.000	rs67997229	chr7:128957366	G/C	cg02491457	chr7:128862824	NA	-0.75	-13.56	-0.53	1.67e-35	White matter hyperintensity burden;
LGG	cis	rs3785574	0.962	rs2597632	chr17:61894739	A/T	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg16301924	chr13:53314226	LECT1	-0.36	-7.15	-0.32	3.49e-12	Lewy body disease;
LGG	cis	rs9463078	0.715	rs9357459	chr6:44782562	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.52	-0.37	2.32e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs3960554	0.808	rs868555	chr7:75697418	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.47	0.5	5.6e-31	Eotaxin levels;
LGG	trans	rs4819388	1.000	rs4819388	chr21:45647421	T/C	cg17383793	chr5:52405638	MOCS2	0.45	7.03	0.31	7.3e-12	Celiac disease;
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-8.03	-0.35	8.12e-15	Skin colour saturation;
LGG	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.24e-20	Mean corpuscular volume;
LGG	cis	rs2933343	0.761	rs789225	chr3:128600229	G/A	cg11901034	chr3:128598214	ACAD9	-0.45	-6.9	-0.31	1.7e-11	IgG glycosylation;
LGG	cis	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg08807101	chr21:30365312	RNF160	0.68	11.47	0.47	5.51e-27	Cognitive test performance;
LGG	cis	rs4595586	0.845	rs11169768	chr12:39233038	A/G	cg26384229	chr12:38710491	ALG10B	-0.41	-6.95	-0.31	1.24e-11	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10943359	chr4:165304531	MARCH1	0.37	6.96	0.31	1.16e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.18	-0.43	4.15e-22	Total body bone mineral density;
LGG	cis	rs12893668	0.645	rs35229468	chr14:104052057	C/T	cg23335576	chr14:104009727	NA	0.49	8.54	0.37	1.9e-16	Reticulocyte count;
LGG	cis	rs6032067	0.759	rs118190342	chr20:43843130	A/C	cg10761708	chr20:43804764	PI3	0.58	8.93	0.38	9.74e-18	Blood protein levels;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-10.26	-0.43	2.1e-22	Personality dimensions;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg14979609	chr8:8086686	FLJ10661	0.28	6.73	0.3	4.89e-11	Triglycerides;
LGG	trans	rs853679	0.546	rs35353359	chr6:28324378	C/T	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs60843830	0.928	rs55742348	chr2:217563	T/A	cg04617936	chr2:214353	NA	-0.39	-7.18	-0.32	2.84e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg15979348	chr13:112237479	NA	-0.46	-7.9	-0.34	2.11e-14	Menarche (age at onset);
LGG	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg27478167	chr7:817139	HEATR2	-0.43	-6.97	-0.31	1.11e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1387259	0.839	rs7486941	chr12:48578631	C/G	cg24011408	chr12:48396354	COL2A1	-0.51	-8.41	-0.36	4.94e-16	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg24623649	chr8:11872141	NA	0.3	7.0	0.31	8.82e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4901847	0.716	rs7157427	chr14:58561961	C/T	cg15908186	chr14:58618357	C14orf37	0.41	7.26	0.32	1.6e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6840360	0.573	rs11099807	chr4:152269228	C/T	cg25486957	chr4:152246857	NA	-0.41	-7.31	-0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3219090	0.962	rs3754376	chr1:226561064	C/A	cg17127702	chr1:226594323	PARP1	-0.38	-12.18	-0.49	8.58e-30	Melanoma;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.85	-0.54	9.69e-37	Tonsillectomy;
LGG	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg12633918	chr20:23549525	CST9L	-0.33	-6.74	-0.3	4.82e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs79976124	0.760	rs74295030	chr6:66654441	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.39	0.5	1.15e-30	Type 2 diabetes;
LGG	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg20290983	chr6:43655470	MRPS18A	1.12	24.9	0.76	1.77e-87	IgG glycosylation;
LGG	cis	rs9660992	0.762	rs1668871	chr1:205237137	T/C	cg21545522	chr1:205238299	TMCC2	0.45	8.41	0.36	5.25e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs35306767	0.903	rs10508208	chr10:910983	C/T	cg25019033	chr10:957182	NA	-0.52	-9.5	-0.4	1.16e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg07211511	chr3:129823064	LOC729375	-1.05	-12.9	-0.51	9.95e-33	Blood pressure (smoking interaction);
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg02002194	chr4:3960332	NA	0.54	10.5	0.44	2.71e-23	Retinal vascular caliber;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.99	0.31	9.63e-12	Obesity-related traits;
LGG	cis	rs11225247	0.881	rs11603677	chr11:102259992	A/T	cg06323957	chr11:102217781	BIRC2	0.78	6.72	0.3	5.33e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs42648	0.935	rs42668	chr7:89986525	A/C	cg25739043	chr7:89950458	NA	-0.38	-8.08	-0.35	5.75e-15	Homocysteine levels;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg02753203	chr1:228287806	NA	-0.64	-11.94	-0.49	7.54e-29	Diastolic blood pressure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01174096	chr2:196521556	SLC39A10	0.38	6.65	0.3	8.16e-11	Bipolar disorder;
LGG	cis	rs6988985	0.678	rs7831617	chr8:144002283	G/T	cg10324643	chr8:143916377	GML	0.45	9.44	0.4	1.8e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9972944	0.756	rs6504349	chr17:63764140	G/A	cg07283582	chr17:63770753	CCDC46	-0.43	-8.38	-0.36	6.42e-16	Total body bone mineral density;
LGG	cis	rs6580649	0.941	rs4760614	chr12:48427884	A/G	cg24011408	chr12:48396354	COL2A1	-0.55	-6.79	-0.3	3.45e-11	Lung cancer;
LGG	cis	rs7737355	0.947	rs251014	chr5:131029463	A/G	cg06307176	chr5:131281290	NA	0.56	9.27	0.4	6.99e-19	Life satisfaction;
LGG	cis	rs5753037	0.702	rs131301	chr22:30185889	A/T	cg01021169	chr22:30184971	ASCC2	-0.37	-7.36	-0.32	8.31e-13	Type 1 diabetes;
LGG	cis	rs12496230	0.953	rs1036972	chr3:66846010	C/T	cg04995300	chr3:66848608	NA	0.56	8.01	0.35	9.14e-15	Type 2 diabetes;
LGG	cis	rs68170813	0.559	rs76307631	chr7:107058018	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.46	-0.44	4.04e-23	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.98	0.35	1.16e-14	Lung cancer;
LGG	cis	rs1904096	0.506	rs7439869	chr4:95173779	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.61	-11.25	-0.46	3.91e-26	Type 2 diabetes;
LGG	cis	rs4731207	0.596	rs2170354	chr7:124665919	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.46	-0.33	4.26e-13	Cutaneous malignant melanoma;
LGG	cis	rs1568889	1.000	rs61889027	chr11:28281908	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.77	13.46	0.53	4.25e-35	Bipolar disorder;
LGG	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	5.86e-21	Neuroticism;
LGG	cis	rs6815814	0.898	rs2174284	chr4:38859339	C/T	cg06935464	chr4:38784597	TLR10	0.55	7.43	0.33	5.31e-13	Breast cancer;
LGG	cis	rs7666738	0.830	rs28615340	chr4:98896922	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.76	0.34	5.32e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg09307838	chr4:120376055	NA	0.63	10.67	0.44	6.27e-24	Corneal astigmatism;
LGG	cis	rs17826219	0.568	rs9907834	chr17:29154013	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.32	-0.32	1.11e-12	Body mass index;
LGG	cis	rs910316	0.967	rs175505	chr14:75529619	C/T	cg08847533	chr14:75593920	NEK9	-0.61	-11.52	-0.47	3.44e-27	Height;
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg03709012	chr19:19516395	GATAD2A	0.85	17.4	0.63	1.5e-52	Tonsillectomy;
LGG	cis	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg05335186	chr13:53173507	NA	0.48	10.16	0.43	4.91e-22	Lewy body disease;
LGG	trans	rs2727020	0.658	rs10839278	chr11:49450847	G/C	cg03929089	chr4:120376271	NA	-0.96	-20.24	-0.69	1.01e-65	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg25358565	chr5:93447407	FAM172A	1.37	17.01	0.62	9.21e-51	Diabetic retinopathy;
LGG	cis	rs7011049	1.000	rs72643583	chr8:53847269	C/G	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs826838	0.684	rs12367400	chr12:38618673	G/T	cg04568710	chr12:38710424	ALG10B	0.34	6.81	0.3	2.96e-11	Heart rate;
LGG	trans	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg27523141	chr10:43048294	ZNF37B	0.37	7.53	0.33	2.69e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1580019	0.922	rs1376289	chr7:32486980	C/G	cg06627557	chr7:32535165	LSM5;AVL9	-0.83	-15.66	-0.59	1.17e-44	Cognitive ability;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.96	-0.54	3.12e-37	Tonsillectomy;
LGG	cis	rs7301016	1.000	rs7301016	chr12:62886123	A/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	trans	rs7178375	1.000	rs9806159	chr15:31209654	G/T	cg04373760	chr16:53404718	NA	0.5	7.76	0.34	5.67e-14	Hypertriglyceridemia;
LGG	cis	rs6489785	0.737	rs2701181	chr12:121362481	A/G	cg02419362	chr12:121203948	SPPL3	0.44	6.93	0.31	1.46e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs975722	0.543	rs2157946	chr7:117030698	G/T	cg10524701	chr7:117356490	CTTNBP2	0.35	7.55	0.33	2.29e-13	Coronary artery disease;
LGG	cis	rs713587	0.521	rs6545766	chr2:25077856	C/T	cg04586622	chr2:25135609	ADCY3	0.39	10.26	0.43	2.19e-22	Body mass index in non-asthmatics;
LGG	cis	rs2242663	0.705	rs551708	chr11:66486143	T/C	cg01599099	chr11:66649832	PC	-0.44	-8.81	-0.38	2.56e-17	Bipolar disorder;
LGG	cis	rs2249625	0.584	rs2496506	chr6:72891324	A/C	cg27608224	chr6:72922399	RIMS1	0.32	7.29	0.32	1.35e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6121246	0.909	rs6060793	chr20:30288830	T/G	cg04935436	chr20:30431758	NA	0.41	7.21	0.32	2.3e-12	Mean corpuscular hemoglobin;
LGG	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.76	-11.04	-0.46	2.66e-25	Chronic sinus infection;
LGG	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.24	0.52	3.71e-34	Morning vs. evening chronotype;
LGG	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	6.78e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16599901	chr7:100210097	MOSPD3	0.44	7.01	0.31	8.21e-12	Gut microbiome composition (summer);
LGG	cis	rs751728	0.664	rs12196293	chr6:33749151	A/G	cg07519485	chr6:33762594	MLN	-0.3	-6.73	-0.3	4.98e-11	Crohn's disease;
LGG	cis	rs7615952	0.546	rs112919177	chr3:125346070	G/A	cg21696256	chr3:125484277	NA	-0.46	-6.87	-0.3	2.02e-11	Blood pressure (smoking interaction);
LGG	cis	rs924607	1.000	rs1697978	chr5:642829	A/G	cg07001201	chr5:642380	CEP72	-0.41	-6.89	-0.31	1.79e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs4075765	0.764	rs17308943	chr11:26263950	A/C	cg19182008	chr11:26298241	NA	0.99	8.79	0.38	3e-17	Cannabis dependence symptom count;
LGG	cis	rs2070488	0.965	rs2284819	chr3:38557161	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.84	17.2	0.62	1.21e-51	Electrocardiographic conduction measures;
LGG	cis	rs2274273	0.967	rs1009978	chr14:55603061	C/G	cg04306507	chr14:55594613	LGALS3	0.64	18.29	0.65	1.25e-56	Protein biomarker;
LGG	cis	rs17021463	0.807	rs6532480	chr4:95277038	T/C	cg11021082	chr4:95130006	SMARCAD1	0.42	7.6	0.33	1.68e-13	Testicular germ cell tumor;
LGG	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg05791153	chr7:19748676	TWISTNB	0.59	8.85	0.38	1.87e-17	Thyroid stimulating hormone;
LGG	cis	rs2731664	0.792	rs2545795	chr5:176887106	A/C	cg23176889	chr5:176863531	GRK6	-0.64	-12.89	-0.51	1.08e-32	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.657	rs920159	chr3:143753194	A/T	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs2404602	0.692	rs4360890	chr15:77173295	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs62064224	0.638	rs9748130	chr17:30739113	A/G	cg18200150	chr17:30822561	MYO1D	0.48	9.19	0.39	1.31e-18	Schizophrenia;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs7927771	0.507	rs7111606	chr11:47787538	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg10847948	chr11:71163743	NADSYN1	0.66	11.72	0.48	5.62e-28	Vitamin D levels;
LGG	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg05775895	chr3:12838266	CAND2	0.69	12.77	0.51	3.3e-32	QRS complex (12-leadsum);
LGG	cis	rs4665809	0.549	rs3828255	chr2:26413252	G/A	cg08470875	chr2:26401718	FAM59B	0.41	7.71	0.34	7.96e-14	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.776	rs8186824	chr12:38316537	A/C	cg26384229	chr12:38710491	ALG10B	0.87	19.85	0.68	7.0400000000000007e-64	Bladder cancer;
LGG	cis	rs362272	0.545	rs2749783	chr4:3326098	A/C	cg06533319	chr4:3265114	C4orf44	-0.33	-6.8	-0.3	3.31e-11	Serum sulfate level;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.683	rs8180642	chr6:151756612	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.59	-0.37	1.34e-16	Menarche (age at onset);
LGG	cis	rs12971120	0.891	rs4891558	chr18:72170359	A/G	cg25817165	chr18:72167213	CNDP2	-0.65	-13.03	-0.52	2.81e-33	Refractive error;
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg07959490	chr17:80112427	CCDC57	0.37	7.2	0.32	2.45e-12	Life satisfaction;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg24101359	chr6:42928495	GNMT	0.61	18.15	0.64	5.43e-56	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs800082	0.646	rs2717394	chr3:144280612	A/T	cg24215973	chr2:240111563	HDAC4	0.58	11.11	0.46	1.43e-25	Smoking behavior;
LGG	cis	rs4006360	0.503	rs1848808	chr17:39249321	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.31	-0.47	2.46e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4919044	0.808	rs1238178	chr10:94804043	G/A	cg05127821	chr10:94822908	CYP26C1	-0.45	-7.97	-0.35	1.27e-14	Coronary artery disease;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg03647317	chr4:187891568	NA	-0.41	-8.88	-0.38	1.53e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3206736	0.520	rs1637674	chr7:34998087	G/A	cg13400248	chr7:35225412	NA	0.53	9.27	0.4	7.28e-19	Diastolic blood pressure;
LGG	cis	rs8133932	0.701	rs7279887	chr21:47301148	T/C	cg11214348	chr21:47283868	PCBP3	0.45	8.13	0.35	4.05e-15	Schizophrenia;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg11301795	chr4:187892539	NA	-0.94	-25.17	-0.76	9.59e-89	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6582630	0.516	rs8186746	chr12:38347638	G/T	cg06521331	chr12:34319734	NA	0.45	7.8	0.34	4e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg04568710	chr12:38710424	ALG10B	0.36	7.71	0.34	7.7e-14	Bladder cancer;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.61	0.37	1.19e-16	Personality dimensions;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7572263	0.528	rs12623549	chr2:209075793	C/T	cg00164906	chr2:209055251	C2orf80	0.47	7.37	0.32	7.98e-13	Glioma;Non-glioblastoma glioma;
LGG	cis	rs9611565	0.592	rs5996037	chr22:41965292	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.45e-12	Vitiligo;
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg02503808	chr4:7069936	GRPEL1	0.91	14.11	0.55	7.09e-38	Monocyte percentage of white cells;
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg08975724	chr8:8085496	FLJ10661	0.39	6.78	0.3	3.63e-11	Neuroticism;
LGG	cis	rs6088580	0.505	rs6058106	chr20:33278255	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-6.91	-0.31	1.6e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.57	0.67	1.37e-62	Personality dimensions;
LGG	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg08822215	chr16:89438651	ANKRD11	0.38	7.42	0.33	5.77e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2046867	0.819	rs34132129	chr3:72829100	A/G	cg25664220	chr3:72788482	NA	-0.33	-9.21	-0.39	1.17e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10915437	0.516	rs4233260	chr1:4197987	A/G	cg27165836	chr1:4193882	NA	0.38	7.39	0.33	6.69e-13	Migraine - clinic-based;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.09e-19	Obesity-related traits;
LGG	cis	rs2235642	0.592	rs743963	chr16:1657350	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.32	7.33	0.32	1.04e-12	Coronary artery disease;
LGG	trans	rs1728785	1.000	rs7195979	chr16:68586801	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	10.93	0.45	6.95e-25	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.28	-0.53	2.56e-34	Schizophrenia;
LGG	cis	rs4481887	0.604	rs6694598	chr1:248409490	A/G	cg01631408	chr1:248437212	OR2T33	-0.43	-7.21	-0.32	2.32e-12	Common traits (Other);
LGG	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.74	-0.41	1.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17209837	1.000	rs7802555	chr7:87130350	A/C	cg00919237	chr7:87102261	ABCB4	-0.69	-10.93	-0.45	7.07e-25	Gallbladder cancer;
LGG	cis	rs1707322	0.721	rs10749856	chr1:46164846	A/T	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2486288	0.656	rs12904150	chr15:45547605	T/C	cg15395560	chr15:45543142	SLC28A2	0.42	6.92	0.31	1.51e-11	Glomerular filtration rate;
LGG	cis	rs2066819	1.000	rs41363748	chr12:56696056	C/T	cg26714650	chr12:56694279	CS	1.65	16.53	0.61	1.46e-48	Psoriasis vulgaris;
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.83	-0.34	3.45e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg01449415	chr16:3184811	ZNF213	0.48	6.7	0.3	6.08e-11	Breast cancer;
LGG	cis	rs9487051	0.872	rs9487038	chr6:109610152	T/C	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1107366	0.722	rs9862438	chr3:125910381	C/T	cg17230874	chr3:125932073	NA	0.6	11.99	0.49	4.94e-29	Metabolite levels;
LGG	cis	rs7267979	1.000	rs10966	chr20:25282944	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.42	0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg08677398	chr8:58056175	NA	0.46	7.63	0.33	1.32e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8078723	0.701	rs2305482	chr17:38140927	A/C	cg17467752	chr17:38218738	THRA	-0.61	-11.14	-0.46	1.11e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs896854	1.000	rs896854	chr8:95960511	T/C	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.16	-0.39	1.66e-18	Type 2 diabetes;
LGG	cis	rs651907	0.588	rs1707608	chr3:101644769	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.41	7.61	0.33	1.56e-13	Colorectal cancer;
LGG	cis	rs6772849	0.830	rs7633674	chr3:128355026	G/A	cg08795948	chr3:128337044	NA	0.66	11.3	0.47	2.47e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6496044	0.568	rs6496040	chr15:86064129	C/G	cg13263323	chr15:86062960	AKAP13	-0.37	-8.2	-0.36	2.32e-15	Interstitial lung disease;
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg13628971	chr7:2884303	GNA12	0.5	9.91	0.42	3.93e-21	Height;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13732083	chr21:47605072	C21orf56	0.46	7.51	0.33	2.98e-13	Testicular germ cell tumor;
LGG	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg08916839	chr5:415575	AHRR	0.9	13.58	0.53	1.35e-35	Fat distribution (HIV);
LGG	cis	rs9581943	0.967	rs8000004	chr13:28477590	A/G	cg16302790	chr13:28498334	PDX1	0.5	8.51	0.37	2.45e-16	Pancreatic cancer;
LGG	cis	rs758324	0.773	rs608834	chr5:131271528	G/C	cg06307176	chr5:131281290	NA	-0.53	-8.62	-0.37	1.07e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2084898	0.527	rs561498	chr11:120002927	C/T	cg07435449	chr11:120005650	TRIM29	0.73	13.19	0.52	5.84e-34	Stroke (pediatric);
LGG	cis	rs9527	0.830	rs12249194	chr10:104643698	T/C	cg25143771	chr10:104629124	AS3MT	0.4	6.73	0.3	5.05e-11	Arsenic metabolism;
LGG	cis	rs9636252	0.605	rs4668605	chr2:9272857	G/A	cg20341998	chr2:9276514	NA	0.41	8.2	0.36	2.41e-15	IgG glycosylation;
LGG	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg03606772	chr1:152487856	CRCT1	0.3	7.3	0.32	1.29e-12	Hair morphology;
LGG	cis	rs7824557	0.836	rs1435278	chr8:11123029	G/T	cg21775007	chr8:11205619	TDH	-0.59	-9.63	-0.41	3.9e-20	Retinal vascular caliber;
LGG	cis	rs919433	0.680	rs787983	chr2:198345797	C/T	cg00792783	chr2:198669748	PLCL1	0.5	7.84	0.34	3.2e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs8056893	0.513	rs1965308	chr16:68355181	A/T	cg07273125	chr16:68295692	NA	0.39	8.61	0.37	1.18e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	7.84	0.34	3.15e-14	Renal function-related traits (BUN);
LGG	cis	rs11628318	0.802	rs2277471	chr14:103024387	A/C	cg01864069	chr14:103024347	NA	0.65	10.57	0.44	1.5e-23	Platelet count;
LGG	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg08994789	chr17:28903642	LRRC37B2	0.7	8.33	0.36	9.13e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg00666640	chr1:248458726	OR2T12	0.55	8.89	0.38	1.37e-17	Common traits (Other);
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg14912033	chr15:79043428	NA	-0.4	-10.0	-0.42	1.86e-21	Coronary artery disease or large artery stroke;
LGG	cis	rs2285947	1.000	rs6970985	chr7:21583597	G/T	cg03697024	chr7:21583438	DNAH11	0.35	8.72	0.38	5.19e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg16301924	chr13:53314226	LECT1	-0.46	-8.68	-0.37	7.01e-17	Lewy body disease;
LGG	cis	rs4631830	0.863	rs2926494	chr10:51517356	T/C	cg10326726	chr10:51549505	MSMB	-0.69	-14.44	-0.56	2.82e-39	Prostate-specific antigen levels;
LGG	cis	rs73787773	0.594	rs25788	chr5:111466355	T/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.51	-6.8	-0.3	3.16e-11	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs6121246	0.528	rs6060252	chr20:30191084	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs6500602	0.627	rs2270363	chr16:4526292	A/G	cg01673284	chr16:4527211	HMOX2	0.34	6.74	0.3	4.65e-11	Schizophrenia;
LGG	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg13385521	chr17:29058706	SUZ12P	0.83	9.42	0.4	2.22e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs61542988	0.570	rs10950919	chr7:22833821	A/G	cg11367502	chr7:22862612	TOMM7	0.5	6.75	0.3	4.45e-11	Fibrinogen levels;
LGG	cis	rs13314892	0.881	rs62250977	chr3:69836592	G/A	cg17445875	chr3:69859618	MITF	-0.36	-7.39	-0.32	7.13e-13	QRS complex (12-leadsum);
LGG	cis	rs589448	0.902	rs315131	chr12:69761839	T/G	cg20891283	chr12:69753455	YEATS4	1.09	29.07	0.8	1.81e-106	Cerebrospinal fluid biomarker levels;
LGG	trans	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg23762105	chr12:34175262	ALG10	0.33	6.67	0.3	7.19e-11	Morning vs. evening chronotype;
LGG	cis	rs1243572	0.590	rs1243561	chr14:95369886	C/T	cg13737829	chr14:95358161	NA	-0.39	-6.82	-0.3	2.89e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg08949735	chr16:89699720	DPEP1	-0.48	-9.69	-0.41	2.41e-20	Vitiligo;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg05368731	chr17:41323189	NBR1	0.87	17.08	0.62	4.49e-51	Menopause (age at onset);
LGG	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg25809561	chr17:30822961	MYO1D	0.37	8.75	0.38	3.94e-17	Schizophrenia;
LGG	cis	rs6694672	1.000	rs4915148	chr1:197035538	C/T	cg13682187	chr1:196946512	CFHR5	-0.5	-6.93	-0.31	1.43e-11	Asthma;
LGG	cis	rs11105298	0.891	rs12369195	chr12:89934972	G/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.19	-0.39	1.36e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2985684	0.894	rs7152110	chr14:50018218	T/C	cg02151108	chr14:50098012	C14orf104	-0.42	-8.87	-0.38	1.63e-17	Carotid intima media thickness;
LGG	cis	rs721399	0.524	rs7005648	chr8:18278208	T/A	cg18736775	chr8:18248649	NAT2	0.74	11.15	0.46	9.42e-26	Blood metabolite levels;
LGG	cis	rs1372520	0.684	rs2572318	chr4:90718719	C/T	cg15133208	chr4:90757351	SNCA	-0.4	-8.2	-0.36	2.31e-15	Neuroticism;
LGG	trans	rs17639063	0.571	rs17696120	chr3:62551030	C/T	cg09501314	chr15:25919674	NA	-0.48	-6.78	-0.3	3.58e-11	QT interval (sulfonylurea treatment interaction);
LGG	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.6	0.33	1.71e-13	Parkinson's disease;
LGG	cis	rs9814567	1.000	rs13081688	chr3:134259954	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.03	0.52	2.84e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg07414643	chr4:187882934	NA	0.53	10.85	0.45	1.4e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17818399	1.000	rs17818399	chr2:46826026	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.45	-0.4	1.68e-19	Height;
LGG	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg00579200	chr11:133705235	NA	-0.59	-11.28	-0.46	3.07e-26	Childhood ear infection;
LGG	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg21475434	chr5:93447410	FAM172A	0.71	7.24	0.32	1.9e-12	Diabetic retinopathy;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg07511668	chr11:68622177	NA	0.5	9.22	0.39	1.06e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10499694	0.933	rs11575334	chr7:50597301	G/A	cg00647317	chr7:50633725	DDC	0.36	8.61	0.37	1.17e-16	Body mass index;
LGG	cis	rs2228479	0.850	rs62056066	chr16:89906563	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.77	-0.34	5.16e-14	Skin colour saturation;
LGG	cis	rs4356975	0.527	rs4694645	chr4:69992918	G/A	cg27372994	chr4:70080453	UGT2B11	0.38	6.93	0.31	1.41e-11	Obesity-related traits;
LGG	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.31	-0.5	2.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	1.000	rs283486	chr2:233644223	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.77	0.51	3.27e-32	Coronary artery disease;
LGG	cis	rs11098499	0.820	rs6534140	chr4:120455311	C/T	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.12e-24	Corneal astigmatism;
LGG	cis	rs722599	0.562	rs2287400	chr14:75182937	G/A	cg06637938	chr14:75390232	RPS6KL1	0.49	7.9	0.34	2.05e-14	IgG glycosylation;
LGG	cis	rs61931739	0.534	rs1608912	chr12:34008574	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.42	-0.47	8.73e-27	Morning vs. evening chronotype;
LGG	cis	rs4631830	0.600	rs11004324	chr10:51496623	G/T	cg10326726	chr10:51549505	MSMB	-0.66	-12.34	-0.5	1.86e-30	Prostate-specific antigen levels;
LGG	cis	rs2204008	0.902	rs11520218	chr12:38223227	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.64	0.71	2.9e-72	Bladder cancer;
LGG	cis	rs2404602	0.647	rs4312276	chr15:77164361	T/C	cg15268244	chr15:77196840	NA	0.49	10.4	0.44	6.56e-23	Blood metabolite levels;
LGG	cis	rs2204008	0.811	rs8189445	chr12:38276295	T/C	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22834172	chr17:37774349	NA	0.65	10.38	0.43	7.69e-23	Gut microbiome composition (summer);
LGG	cis	rs13091206	1	rs13091206	chr3:49238718	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	7.69	0.34	9.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9462027	0.628	rs2038839	chr6:34777791	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.3	-0.46	2.64e-26	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.65	0.44	7.75e-24	Joint mobility (Beighton score);
LGG	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.55	-0.37	1.78e-16	Aortic root size;
LGG	cis	rs972578	0.691	rs738380	chr22:43400937	T/C	cg01576275	chr22:43409880	NA	-0.25	-7.49	-0.33	3.63e-13	Mean platelet volume;
LGG	cis	rs6459788	0.720	rs11974772	chr7:157250645	G/A	cg04198125	chr7:157211777	NA	0.41	7.62	0.33	1.47e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	3.02e-16	Personality dimensions;
LGG	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg18876405	chr7:65276391	NA	0.56	10.04	0.42	1.42e-21	Aortic root size;
LGG	cis	rs4750440	0.637	rs2457859	chr10:14032099	T/G	cg27542038	chr10:14027202	FRMD4A	-0.53	-9.97	-0.42	2.5e-21	Adiponectin levels;
LGG	cis	rs7666738	0.830	rs921522	chr4:98841608	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.09e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4950322	0.570	rs77118461	chr1:146792436	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg13902645	chr11:5959945	NA	-0.54	-8.6	-0.37	1.23e-16	DNA methylation (variation);
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6445975	0.726	rs7616659	chr3:58467587	G/A	cg24175188	chr3:58374923	PXK	0.44	8.09	0.35	5.38e-15	Systemic lupus erythematosus;
LGG	cis	rs367615	0.537	rs431669	chr5:108663115	G/A	cg17395555	chr5:108820864	NA	0.75	12.16	0.49	9.94e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.1	17.49	0.63	5.75e-53	Platelet count;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.33	0.32	1.03e-12	Prudent dietary pattern;
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.68e-16	Bipolar disorder;
LGG	cis	rs35110281	0.713	rs6518310	chr21:45098670	T/A	cg04455712	chr21:45112962	RRP1B	0.53	10.41	0.44	6.13e-23	Mean corpuscular volume;
LGG	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg24397884	chr7:158709396	WDR60	-1.06	-25.37	-0.76	1.26e-89	Height;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	6.8	0.3	3.34e-11	Schizophrenia;
LGG	cis	rs17776563	0.887	rs72763807	chr15:89131572	T/C	cg05013243	chr15:89149849	MIR1179	-0.5	-10.43	-0.44	5.32e-23	Thyroid hormone levels;
LGG	cis	rs9462027	0.651	rs1543559	chr6:34784104	G/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg02002194	chr4:3960332	NA	-0.5	-9.42	-0.4	2.12e-19	Neuroticism;
LGG	cis	rs457717	0.730	rs460294	chr5:75944395	G/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.91	0.31	1.61e-11	Hearing impairment;
LGG	cis	rs1005277	1.000	rs1005277	chr10:38218259	A/C	cg18963800	chr10:38644991	HSD17B7P2	0.47	6.83	0.3	2.68e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs115464801	chr4:119730673	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs1865760	0.865	rs9467652	chr6:25959127	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs55883249	1.000	rs62119392	chr2:9714033	G/C	cg23886495	chr2:9695866	ADAM17	0.66	9.47	0.4	1.38e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs9354308	0.868	rs9363464	chr6:66557759	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.73	-0.34	6.77e-14	Metabolite levels;
LGG	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg22283653	chr8:49824208	NA	0.52	9.7	0.41	2.24e-20	Sudden cardiac arrest;
LGG	cis	rs4642101	0.512	rs9813960	chr3:12818205	A/G	cg24848339	chr3:12840334	CAND2	0.46	11.25	0.46	4.09e-26	QRS complex (12-leadsum);
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg18258770	chr4:90757814	SNCA	-0.4	-7.35	-0.32	9.23e-13	Dementia with Lewy bodies;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg03351412	chr1:154909251	PMVK	0.63	11.92	0.48	8.99e-29	Prostate cancer;
LGG	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg03929089	chr4:120376271	NA	-0.53	-8.76	-0.38	3.64e-17	HDL cholesterol;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg14346243	chr4:90757452	SNCA	0.38	7.73	0.34	6.7e-14	Dementia with Lewy bodies;
LGG	trans	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg23762105	chr12:34175262	ALG10	-0.33	-6.88	-0.3	1.98e-11	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.79e-11	Personality dimensions;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16281248	chr11:64014554	PPP1R14B	0.42	7.07	0.31	5.56e-12	Bipolar disorder;
LGG	cis	rs9879311	0.966	rs7619385	chr3:10414909	G/A	cg11030744	chr3:10328490	GHRL;GHRLOS	0.36	7.16	0.32	3.2e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	7.98	0.35	1.15e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4474465	0.850	rs10793324	chr11:78251485	C/T	cg02023728	chr11:77925099	USP35	0.38	6.66	0.3	7.99e-11	Alzheimer's disease (survival time);
LGG	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg15733309	chr7:157513707	PTPRN2	0.62	14.85	0.57	4.54e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs977987	0.806	rs12444589	chr16:75454404	A/T	cg07303275	chr16:75499416	TMEM170A	-0.36	-6.66	-0.3	8.01e-11	Dupuytren's disease;
LGG	cis	rs2204008	0.774	rs8186954	chr12:38318566	C/A	cg26384229	chr12:38710491	ALG10B	0.91	20.27	0.69	7.53e-66	Bladder cancer;
LGG	cis	rs7089973	0.604	rs7904188	chr10:116610271	G/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2932538	0.922	rs2932535	chr1:113201412	G/C	cg22162597	chr1:113214053	CAPZA1	-0.62	-11.74	-0.48	4.98e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs12681287	0.547	rs10087788	chr8:87544174	G/A	cg27223183	chr8:87520930	FAM82B	0.49	7.4	0.33	6.39e-13	Caudate activity during reward;
LGG	cis	rs773506	0.565	rs773512	chr9:93952033	G/A	cg14446406	chr9:93919335	NA	0.45	7.24	0.32	1.9e-12	Type 2 diabetes nephropathy;
LGG	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg03806693	chr22:41940476	POLR3H	1.05	17.73	0.64	4.76e-54	Vitiligo;
LGG	cis	rs2795502	1.000	rs2795503	chr10:43347224	T/A	cg20628663	chr10:43360327	NA	-0.42	-8.61	-0.37	1.17e-16	Blood protein levels;
LGG	cis	rs17453880	0.750	rs2964240	chr5:151924531	T/C	cg12297329	chr5:152029980	NA	-0.62	-13.1	-0.52	1.38e-33	Subjective well-being;
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07685180	chr8:600429	NA	-1.04	-10.69	-0.44	5.39e-24	IgG glycosylation;
LGG	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-10.95	-0.45	5.61e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9398803	0.830	rs4053271	chr6:126830512	T/C	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.74	0.54	2.92e-36	Lung cancer;
LGG	cis	rs4740619	0.967	rs10756688	chr9:15660497	T/C	cg14451791	chr9:16040625	NA	-0.38	-9.92	-0.42	3.75e-21	Body mass index;
LGG	cis	rs4774899	0.966	rs12914418	chr15:57506355	C/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.34	-0.32	9.79e-13	Urinary tract infection frequency;
LGG	cis	rs7660883	0.897	rs342452	chr4:88018408	A/G	cg21988461	chr4:88008667	AFF1	0.35	9.76	0.41	1.35e-20	HDL cholesterol levels;
LGG	cis	rs7044106	0.615	rs10818470	chr9:123359204	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.87	0.48	1.5e-28	Hip circumference adjusted for BMI;
LGG	cis	rs9467773	0.549	rs9467805	chr6:26583366	C/T	cg11502198	chr6:26597334	ABT1	0.69	12.43	0.5	8.32e-31	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg11366901	chr6:160182831	ACAT2	0.99	15.11	0.57	3.26e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs5015933	0.703	rs7037034	chr9:128144637	T/C	cg14078157	chr9:128172775	NA	-0.35	-6.66	-0.3	8.02e-11	Body mass index;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.04	0.46	2.61e-25	Lymphocyte counts;
LGG	cis	rs6032067	0.714	rs6032073	chr20:43881630	A/G	cg10761708	chr20:43804764	PI3	0.57	8.69	0.37	6.2e-17	Blood protein levels;
LGG	cis	rs9863	0.828	rs11057413	chr12:124489162	A/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.25	-0.32	1.7e-12	White blood cell count;
LGG	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.2	-0.52	5.5e-34	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs9815354	1.000	rs2128834	chr3:41862645	A/G	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9486719	1.000	rs3906199	chr6:97049899	C/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.02	-0.46	3.15e-25	Migraine;Coronary artery disease;
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg17178900	chr1:205818956	PM20D1	0.36	7.25	0.32	1.73e-12	Menarche (age at onset);
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg02297831	chr4:17616191	MED28	0.51	9.44	0.4	1.88e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6735179	0.550	rs13396286	chr2:1759021	A/G	cg08534653	chr2:1747700	PXDN	0.46	7.11	0.31	4.35e-12	Response to antipsychotic treatment;
LGG	cis	rs752010	0.684	rs10789402	chr1:42084649	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	14.1	0.55	8.1e-38	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2439831	0.541	rs12440854	chr15:43610672	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	11.13	0.46	1.18e-25	Lung cancer in ever smokers;
LGG	cis	rs7786877	0.521	rs4729607	chr7:100326744	T/A	cg00334542	chr7:100209784	MOSPD3	-0.54	-7.41	-0.33	5.99e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.7	-0.3	5.91e-11	Mean platelet volume;
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.34	-0.5	1.88e-30	Lymphocyte counts;
LGG	trans	rs4811340	0.600	rs2207195	chr20:51182264	G/T	cg18917495	chr2:74006961	DUSP11	0.44	6.93	0.31	1.46e-11	Thyroid peroxidase antibody positivity;
LGG	cis	rs7914558	1.000	rs8139	chr10:104848123	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.82	0.45	1.78e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs7937682	0.883	rs510388	chr11:111451869	G/T	cg18187862	chr3:45730750	SACM1L	-0.53	-8.8	-0.38	2.77e-17	Primary sclerosing cholangitis;
LGG	cis	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg15596359	chr8:11213517	TDH	0.43	9.0	0.39	5.9e-18	Retinal vascular caliber;
LGG	cis	rs10791323	0.628	rs2851118	chr11:133705995	A/C	cg15485101	chr11:133734466	NA	0.6	10.71	0.45	4.67e-24	Childhood ear infection;
LGG	cis	rs7432375	0.901	rs6802702	chr3:136489563	G/A	cg21827317	chr3:136751795	NA	-0.47	-8.42	-0.36	4.78e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2016266	0.819	rs6580942	chr12:53662624	C/A	cg04065151	chr12:53682969	ESPL1	-0.62	-10.1	-0.42	8.62e-22	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs42648	0.642	rs11771963	chr7:89887587	G/T	cg25739043	chr7:89950458	NA	-0.34	-7.05	-0.31	6.43e-12	Homocysteine levels;
LGG	cis	rs3020736	0.500	rs6002603	chr22:42492362	C/G	cg04733989	chr22:42467013	NAGA	-0.58	-10.27	-0.43	2.01e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9487051	0.676	rs9398193	chr6:109593134	G/T	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.02e-14	Reticulocyte fraction of red cells;
LGG	cis	rs644799	0.526	rs568120	chr11:95578734	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.21	0.52	5.06e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-9.16	-0.39	1.67e-18	Schizophrenia;
LGG	cis	rs6831352	0.918	rs29001231	chr4:100046680	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.79	-0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2854160	0.581	rs2727319	chr17:61960215	C/T	cg09997372	chr17:61989759	CSHL1	-0.34	-6.67	-0.3	7.18e-11	Height;
LGG	cis	rs875971	0.545	rs7783889	chr7:65748353	T/A	cg11764359	chr7:65958608	NA	0.63	9.73	0.41	1.82e-20	Aortic root size;
LGG	cis	rs7598759	0.548	rs1584462	chr2:232369798	A/G	cg19187155	chr2:232395269	NMUR1	0.53	9.9	0.42	4.27e-21	Noise-induced hearing loss;
LGG	cis	rs11190604	1.000	rs4919469	chr10:102298855	C/A	cg07570687	chr10:102243282	WNT8B	0.44	7.52	0.33	2.85e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8180040	0.903	rs13094438	chr3:47277885	G/A	cg27129171	chr3:47204927	SETD2	0.81	15.48	0.58	7.37e-44	Colorectal cancer;
LGG	cis	rs6088590	0.931	rs6088624	chr20:33436852	T/A	cg06115741	chr20:33292138	TP53INP2	0.57	8.91	0.38	1.2e-17	Coronary artery disease;
LGG	cis	rs7546	0.501	rs12102426	chr16:4922450	T/G	cg08329684	chr16:4932620	PPL	0.56	12.48	0.5	5.26e-31	Cancer;
LGG	cis	rs9462027	0.628	rs2814967	chr6:34712838	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.2	-0.46	6.53e-26	Systemic lupus erythematosus;
LGG	cis	rs3816183	0.916	rs920393	chr2:43022408	T/G	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.2e-18	Hypospadias;
LGG	cis	rs7301016	0.846	rs11174575	chr12:63026392	G/A	cg11441379	chr12:63026424	NA	0.7	9.71	0.41	2.14e-20	IgG glycosylation;
LGG	cis	rs929596	0.564	rs2741029	chr2:234530160	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.56	-8.91	-0.38	1.16e-17	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03264133	chr6:25882463	NA	-0.54	-10.07	-0.42	1.1e-21	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.617	rs685002	chr6:101743677	A/G	cg27451362	chr6:101846650	GRIK2	0.86	13.5	0.53	3.05e-35	Coenzyme Q10 levels;
LGG	cis	rs9640161	0.750	rs73170185	chr7:150030191	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.8	-17.13	-0.62	2.64e-51	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9393692	0.557	rs1883213	chr6:26303178	A/C	cg13736514	chr6:26305472	NA	-0.49	-9.78	-0.41	1.17e-20	Educational attainment;
LGG	cis	rs798554	0.634	rs1182180	chr7:2873279	G/T	cg19524238	chr7:2802976	GNA12	0.3	7.27	0.32	1.55e-12	Height;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg16162927	chr6:136610857	BCLAF1	0.39	6.72	0.3	5.28e-11	Body mass index;
LGG	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg07382826	chr16:28625726	SULT1A1	0.41	8.9	0.38	1.26e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.65e-12	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg18032289	chr17:61959525	GH2	-0.38	-6.65	-0.3	8.05e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg19338460	chr6:170058176	WDR27	-0.62	-8.39	-0.36	5.99e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1577917	0.958	rs4707236	chr6:86583967	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-11.46	-0.47	6.13e-27	Response to antipsychotic treatment;
LGG	cis	rs7587476	0.601	rs13021937	chr2:215673937	C/T	cg04004882	chr2:215674386	BARD1	-0.56	-8.79	-0.38	3.06e-17	Neuroblastoma;
LGG	cis	rs7584262	0.737	rs58360854	chr2:42243076	A/G	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Bone mineral density;
LGG	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg03342759	chr3:160939853	NMD3	-0.73	-12.29	-0.5	2.94e-30	Parkinson's disease;
LGG	cis	rs28374715	0.617	rs28626792	chr15:41562218	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.83	-14.56	-0.56	7.95e-40	Ulcerative colitis;
LGG	cis	rs317689	0.690	rs595348	chr12:69638610	T/C	cg20891283	chr12:69753455	YEATS4	0.43	6.65	0.3	8.03e-11	Response to diuretic therapy;
LGG	cis	rs7819412	0.740	rs28633434	chr8:11053922	G/A	cg21775007	chr8:11205619	TDH	-0.52	-8.39	-0.36	5.92e-16	Triglycerides;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04533881	chr14:50583218	C14orf138	0.49	8.08	0.35	5.88e-15	Cognitive performance;
LGG	cis	rs3806843	1.000	rs1548700	chr5:140164889	A/T	cg19875535	chr5:140030758	IK	0.51	10.67	0.44	6.5e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7122257	0.507	rs7103691	chr11:11150830	A/C	cg16931664	chr11:11169707	NA	-0.26	-7.45	-0.33	4.74e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs28595532	1.000	rs116030177	chr4:119650768	T/C	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.91	-0.51	8.89e-33	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.57	-10.17	-0.43	4.7e-22	Longevity;
LGG	cis	rs8044868	0.586	rs12917999	chr16:72089451	T/C	cg23815491	chr16:72088622	HP	0.37	7.88	0.34	2.4e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs4740619	0.619	rs10756741	chr9:16041911	A/G	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs7666738	0.830	rs35491210	chr4:99003364	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.89	0.34	2.26e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.4e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12618769	0.597	rs72821908	chr2:99085359	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1693575	0.584	rs2978101	chr8:101679224	T/G	cg06874326	chr8:101662790	SNX31	-0.36	-7.21	-0.32	2.31e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs1030877	0.515	rs17030766	chr2:105911905	G/A	cg02079111	chr2:105885981	TGFBRAP1	-0.58	-8.86	-0.38	1.77e-17	Obesity-related traits;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg07243736	chr16:783730	NARFL	0.42	7.21	0.32	2.22e-12	Height;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg07701084	chr6:150067640	NUP43	0.7	13.37	0.53	1.01e-34	Lung cancer;
LGG	cis	rs1348850	0.567	rs880897	chr2:178532503	C/T	cg05169160	chr2:178484487	TTC30A	0.35	6.89	0.3	1.86e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg05973401	chr12:123451056	ABCB9	0.5	7.94	0.35	1.55e-14	Neutrophil percentage of white cells;
LGG	cis	rs765787	0.530	rs1631533	chr15:45518628	C/T	cg25801113	chr15:45476975	SHF	0.87	19.92	0.68	3.13e-64	Uric acid levels;
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg22535103	chr8:58192502	C8orf71	-0.98	-15.74	-0.59	5.17e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.84	-0.54	1.06e-36	Tonsillectomy;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs751728	0.571	rs4713691	chr6:33790415	A/G	cg25922239	chr6:33757077	LEMD2	-0.52	-7.59	-0.33	1.8e-13	Crohn's disease;
LGG	cis	rs4727027	0.704	rs1123992	chr7:148907201	C/G	cg23583168	chr7:148888333	NA	-0.81	-15.21	-0.58	1.19e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4629710	0.563	rs9483238	chr6:131567196	A/T	cg12606694	chr6:131520996	AKAP7	0.51	8.26	0.36	1.58e-15	Multiple myeloma (IgH translocation);
LGG	trans	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg13010199	chr12:38710504	ALG10B	0.47	8.98	0.39	6.59e-18	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15962187	chr10:103052327	NA	0.49	7.33	0.32	1.06e-12	Gut microbiome composition (summer);
LGG	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	Neuroticism;
LGG	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.03	0.55	1.59e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs561341	0.629	rs7216107	chr17:30224419	G/A	cg13647721	chr17:30228624	UTP6	0.71	11.33	0.47	2.01e-26	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.87	0.34	2.47e-14	Lung cancer;
LGG	cis	rs4604732	1.000	rs4604732	chr1:247623872	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	-0.48	-7.9	-0.34	2.06e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2455799	0.574	rs2102212	chr3:15704223	C/T	cg16303742	chr3:15540471	COLQ	-0.44	-8.89	-0.38	1.32e-17	Mean platelet volume;
LGG	cis	rs17253792	0.822	rs8009239	chr14:56062490	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg16077055	chr2:106428750	NCK2	0.32	8.37	0.36	6.86e-16	Addiction;
LGG	trans	rs35883536	1.000	rs6663612	chr1:101085835	A/G	cg05208423	chr11:13689596	FAR1	-0.4	-6.66	-0.3	7.87e-11	Monocyte count;
LGG	cis	rs17767392	0.918	rs72728427	chr14:71769989	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.08	-0.39	3.21e-18	Mitral valve prolapse;
LGG	cis	rs367943	0.665	rs6889298	chr5:112965011	C/T	cg12552261	chr5:112820674	MCC	0.52	9.02	0.39	4.86e-18	Type 2 diabetes;
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.42	-0.44	5.8e-23	Bipolar disorder;
LGG	cis	rs2916247	1.000	rs2920466	chr8:92998096	A/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.65	-0.37	8.82e-17	Intelligence (multi-trait analysis);
LGG	trans	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg24247370	chr13:99142703	STK24	-0.38	-6.93	-0.31	1.43e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs11088226	0.541	rs75873023	chr21:33910658	G/A	cg09050820	chr6:167586206	TCP10L2	0.55	8.72	0.38	5.05e-17	Gastritis;
LGG	cis	rs5769707	0.609	rs739247	chr22:49996657	T/C	cg06623630	chr22:50017776	C22orf34	-0.45	-9.04	-0.39	4.29e-18	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7296418	0.517	rs73231928	chr12:123724325	T/C	cg05973401	chr12:123451056	ABCB9	0.43	7.31	0.32	1.16e-12	Platelet count;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19492446	chr18:35145650	BRUNOL4	0.41	6.78	0.3	3.57e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7737355	0.812	rs245796	chr5:130680184	G/A	cg06307176	chr5:131281290	NA	-0.49	-8.14	-0.35	3.58e-15	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16784092	chr12:53400507	EIF4B	0.41	6.72	0.3	5.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.04	-20.27	-0.69	7.36e-66	Gut microbiome composition (summer);
LGG	cis	rs17453880	0.764	rs60835300	chr5:151928760	A/G	cg12297329	chr5:152029980	NA	-0.62	-12.83	-0.51	1.95e-32	Subjective well-being;
LGG	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg05444541	chr17:17804740	TOM1L2	0.69	16.46	0.61	2.89e-48	Total body bone mineral density;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg14926445	chr8:58193284	C8orf71	-0.46	-7.2	-0.32	2.51e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.650	rs6582631	chr12:38744135	T/C	cg04568710	chr12:38710424	ALG10B	0.39	8.14	0.35	3.58e-15	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs7811142	1.000	rs11761725	chr7:100039815	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.22	0.68	1.2e-65	Platelet count;
LGG	cis	rs4319547	0.695	rs10734915	chr12:122873408	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.55	-8.22	-0.36	2.03e-15	Body mass index;
LGG	cis	rs921968	0.509	rs626432	chr2:219355658	C/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs992157	0.775	rs7559428	chr2:219150238	A/G	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	2e-29	Colorectal cancer;
LGG	cis	rs7100689	0.560	rs10887891	chr10:82207717	A/C	cg01528321	chr10:82214614	TSPAN14	0.82	14.82	0.57	5.91e-41	Post bronchodilator FEV1;
LGG	cis	rs2635047	0.713	rs28666933	chr18:44762408	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.36	0.36	7.46e-16	Educational attainment;
LGG	cis	rs7301016	0.520	rs73126004	chr12:63004975	T/C	cg11441379	chr12:63026424	NA	0.44	7.17	0.32	2.9e-12	IgG glycosylation;
LGG	cis	rs10929925	0.966	rs2693828	chr2:6159640	T/C	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs34929064	0.718	rs34788132	chr7:22738917	A/G	cg18045685	chr7:22629474	NA	0.57	8.0	0.35	9.83e-15	Major depression and alcohol dependence;
LGG	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg11757124	chr7:157526947	PTPRN2	0.78	15.56	0.59	3.2e-44	Intelligence (multi-trait analysis);
LGG	cis	rs9640161	0.830	rs6722	chr7:150068933	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.17	-0.43	4.74e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7107174	1.000	rs948662	chr11:77979829	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs2576037	0.526	rs605487	chr18:44444778	G/C	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.79e-11	Personality dimensions;
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs11122272	0.735	rs2808600	chr1:231534723	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.38	-0.32	7.56e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1620921	0.967	rs1247552	chr6:161187744	G/T	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.44e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9896933	0.832	rs79103992	chr17:80855483	G/A	cg15369054	chr17:80825471	TBCD	0.5	6.79	0.3	3.52e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7932354	0.528	rs7103581	chr11:47072805	G/T	cg03339077	chr11:47165057	C11orf49	-0.53	-9.98	-0.42	2.23e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.42	-7.08	-0.31	5.28e-12	Uric acid levels;
LGG	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg03342759	chr3:160939853	NMD3	-0.44	-7.29	-0.32	1.32e-12	Morning vs. evening chronotype;
LGG	cis	rs17301259	0.524	rs3890882	chr7:88405722	C/T	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-7.15	-0.32	3.47e-12	Heschl's gyrus morphology;
LGG	cis	rs620875	0.660	rs541783	chr11:126864588	A/C	cg06504925	chr11:126872760	NA	0.46	6.84	0.3	2.58e-11	Response to antipsychotic treatment;
LGG	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs12310956	0.532	rs11052951	chr12:33986181	T/A	cg06521331	chr12:34319734	NA	-0.6	-11.19	-0.46	6.75e-26	Morning vs. evening chronotype;
LGG	cis	rs7223966	0.621	rs72845875	chr17:61639269	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.52	7.85	0.34	2.82e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg08280861	chr8:58055591	NA	0.53	6.79	0.3	3.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg07701084	chr6:150067640	NUP43	0.47	7.18	0.32	2.86e-12	Lung cancer;
LGG	cis	rs12188164	0.543	rs2672722	chr5:453567	G/A	cg16584290	chr5:462447	EXOC3	0.45	9.39	0.4	2.76e-19	Cystic fibrosis severity;
LGG	cis	rs4740619	0.598	rs4741552	chr9:15959700	G/A	cg14451791	chr9:16040625	NA	-0.4	-9.82	-0.42	8.1e-21	Body mass index;
LGG	cis	rs2276314	0.857	rs62101393	chr18:33592168	T/C	cg19628046	chr18:33552617	C18orf21	0.51	7.5	0.33	3.28e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs3768617	0.510	rs3768624	chr1:183079252	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.94e-18	Fuchs's corneal dystrophy;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg26668828	chr6:292823	DUSP22	-0.68	-11.75	-0.48	4.47e-28	Menopause (age at onset);
LGG	cis	rs875971	0.964	rs6978721	chr7:65883204	A/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs9557207	1.000	rs9585038	chr13:100000852	A/G	cg24509225	chr13:100037070	UBAC2	0.7	12.72	0.51	5.53e-32	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2270875	0.778	rs79685424	chr8:132935380	T/A	cg24184792	chr8:132919238	EFR3A	-0.43	-6.73	-0.3	5.08e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg27532560	chr4:187881888	NA	-0.59	-12.79	-0.51	2.66e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9341808	0.690	rs9448909	chr6:80909031	G/A	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg13047869	chr3:10149882	C3orf24	0.46	7.45	0.33	4.55e-13	Alzheimer's disease;
LGG	cis	rs9399135	0.967	rs952674	chr6:135349157	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.92e-20	Red blood cell count;
LGG	cis	rs755249	0.567	rs2036464	chr1:39688242	A/G	cg18385671	chr1:39797026	MACF1	0.43	7.13	0.31	3.84e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.79e-31	Lymphocyte counts;
LGG	cis	rs7572733	0.534	rs700680	chr2:198707950	A/T	cg00792783	chr2:198669748	PLCL1	-0.69	-11.2	-0.46	6.05e-26	Dermatomyositis;
LGG	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.41e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs9486719	1.000	rs2273622	chr6:97058567	A/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.36	-0.43	9.16e-23	Migraine;Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg25427524	chr10:38739819	LOC399744	-0.63	-11.59	-0.47	1.84e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04008888	chr11:68622739	NA	-0.55	-11.8	-0.48	2.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7617773	0.817	rs6787500	chr3:48299439	T/C	cg11946769	chr3:48343235	NME6	0.58	9.76	0.41	1.36e-20	Coronary artery disease;
LGG	cis	rs7945705	0.747	rs1980429	chr11:9010474	C/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.44	-0.37	4.03e-16	Hemoglobin concentration;
LGG	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg14101638	chr12:121416612	HNF1A	0.42	8.89	0.38	1.39e-17	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
LGG	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.81	0.38	2.63e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7824557	0.806	rs6601574	chr8:11094885	G/A	cg02002194	chr4:3960332	NA	0.47	8.38	0.36	6.29e-16	Retinal vascular caliber;
LGG	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg14664628	chr15:75095509	CSK	-0.66	-12.33	-0.5	2.05e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs8114671	0.562	rs6120746	chr20:33448496	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	6.93	0.31	1.4e-11	Height;
LGG	cis	rs12762955	0.561	rs7076107	chr10:1043647	T/C	cg25019033	chr10:957182	NA	0.34	7.08	0.31	5.44e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs8072100	0.967	rs12452315	chr17:45479446	G/T	cg08085267	chr17:45401833	C17orf57	0.63	12.99	0.52	4.24e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg26043149	chr18:55253948	FECH	-0.41	-6.73	-0.3	5.01e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2073300	1.000	rs6106656	chr20:23444301	A/G	cg12062639	chr20:23401060	NAPB	0.82	6.73	0.3	5.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4417704	0.551	rs10204458	chr2:241899236	C/G	cg05025159	chr2:241905733	NA	0.52	10.72	0.45	4.35e-24	Joint mobility (Beighton score);
LGG	cis	rs9807989	0.507	rs6726985	chr2:103048580	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.52	0.4	9.77e-20	Asthma;
LGG	cis	rs2011503	1.000	rs2965184	chr19:19545428	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.73	-0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs72949976	0.584	rs12471471	chr2:214023052	C/T	cg08319019	chr2:214017104	IKZF2	-0.66	-12.68	-0.51	7.81e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs2249694	0.919	rs11101867	chr10:135400250	C/T	cg20169779	chr10:135381914	SYCE1	-0.48	-7.54	-0.33	2.53e-13	Obesity-related traits;
LGG	trans	rs73191547	0.809	rs11786120	chr8:10038518	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.58	0.33	1.96e-13	Schizophrenia;
LGG	cis	rs2717559	0.542	rs2717586	chr8:143897882	C/T	cg07661805	chr8:143867942	LY6D	0.3	8.14	0.35	3.71e-15	Urinary tract infection frequency;
LGG	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg11812906	chr14:75593930	NEK9	0.54	9.97	0.42	2.49e-21	Height;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs7917772	0.582	rs4919665	chr10:104366042	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-11.48	-0.47	5.32e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.45e-28	Tonsillectomy;
LGG	cis	rs7662987	0.517	rs2602882	chr4:100040765	C/T	cg12011299	chr4:100065546	ADH4	0.4	7.86	0.34	2.69e-14	Smoking initiation;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.12	-0.31	4.01e-12	Aortic root size;
LGG	cis	rs4363385	0.658	rs426147	chr1:153045011	G/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs755249	0.567	rs61779309	chr1:39940499	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.45	0.33	4.72e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4363385	0.934	rs6667418	chr1:152969685	A/G	cg13444842	chr1:152974279	SPRR3	-0.39	-7.67	-0.34	9.93e-14	Inflammatory skin disease;
LGG	cis	rs17169635	0.601	rs2347900	chr7:134546405	G/T	cg02516134	chr7:134575187	CALD1	-0.33	-7.39	-0.32	6.79e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg21699342	chr2:239360505	ASB1	0.39	7.44	0.33	4.82e-13	Multiple system atrophy;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg20887711	chr4:1340912	KIAA1530	0.5	9.19	0.39	1.29e-18	Obesity-related traits;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.15	-0.32	3.36e-12	Lung cancer;
LGG	cis	rs4262150	0.580	rs2964248	chr5:151916767	G/A	cg12297329	chr5:152029980	NA	-0.61	-11.09	-0.46	1.68e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs457717	1.000	rs416451	chr5:75922072	C/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.33	6.75	0.3	4.37e-11	Hearing impairment;
LGG	cis	rs4472734	0.965	rs4655345	chr1:214608704	A/G	cg00063699	chr1:214624242	PTPN14	-0.34	-6.8	-0.3	3.26e-11	Height;
LGG	cis	rs1873147	0.569	rs11071710	chr15:63309193	A/G	cg12160578	chr15:63334699	TPM1	0.57	7.9	0.34	1.99e-14	Orofacial clefts;
LGG	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg06640241	chr16:89574553	SPG7	0.66	11.08	0.46	1.89e-25	Multiple myeloma (IgH translocation);
LGG	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg22484793	chr3:52261325	TLR9	0.32	7.42	0.33	5.78e-13	Bipolar disorder;
LGG	cis	rs10754283	0.967	rs10801757	chr1:90103080	A/G	cg21401794	chr1:90099060	LRRC8C	0.55	11.87	0.48	1.5e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.69	-0.34	8.98e-14	Lung cancer;
LGG	cis	rs11690935	0.959	rs10206062	chr2:172577276	A/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.02	-0.78	3.19e-97	Schizophrenia;
LGG	cis	rs4774899	0.966	rs12917093	chr15:57522301	G/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.17e-12	Urinary tract infection frequency;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs1659258	0.568	rs1659262	chr2:88600380	T/A	cg00685853	chr2:88648947	NA	-0.45	-6.7	-0.3	6.2e-11	Visceral fat;
LGG	cis	rs3768617	0.510	rs7549768	chr1:183097382	T/G	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.12e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg10253484	chr15:75165896	SCAMP2	-0.56	-9.42	-0.4	2.12e-19	Airflow obstruction;
LGG	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg08499158	chr17:42289980	UBTF	0.39	7.09	0.31	4.94e-12	Total body bone mineral density;
LGG	cis	rs2688608	0.592	rs11814282	chr10:75490217	T/C	cg19442545	chr10:75533431	FUT11	-0.43	-6.96	-0.31	1.16e-11	Inflammatory bowel disease;
LGG	cis	rs12220238	1.000	rs10824103	chr10:75949415	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.11	0.46	1.44e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs28595532	0.841	rs56388366	chr4:119769242	A/G	cg21605333	chr4:119757512	SEC24D	1.44	14.86	0.57	4.02e-41	Cannabis dependence symptom count;
LGG	cis	rs4243830	0.850	rs12029123	chr1:6607142	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	12.79	0.51	2.78e-32	Body mass index;
LGG	cis	rs8056893	0.523	rs11647636	chr16:68369740	C/T	cg07273125	chr16:68295692	NA	0.39	8.5	0.37	2.72e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg11644478	chr21:40555479	PSMG1	-0.61	-10.01	-0.42	1.78e-21	Menarche (age at onset);
LGG	cis	rs7301016	0.948	rs11174498	chr12:62865345	T/C	cg11441379	chr12:63026424	NA	0.65	8.62	0.37	1.05e-16	IgG glycosylation;
LGG	cis	rs8177253	0.761	rs12490148	chr3:133523973	C/T	cg08048268	chr3:133502702	NA	-0.7	-13.71	-0.54	3.62e-36	Iron status biomarkers;
LGG	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg02705964	chr17:66097276	LOC651250	-0.47	-8.32	-0.36	1.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10463554	0.892	rs2195272	chr5:102295504	G/T	cg23492399	chr5:102201601	PAM	-0.56	-8.56	-0.37	1.68e-16	Parkinson's disease;
LGG	cis	rs2228479	0.557	rs62056097	chr16:89933420	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.6	-0.37	1.28e-16	Skin colour saturation;
LGG	cis	rs1318772	0.932	rs4705829	chr5:112870894	G/A	cg12552261	chr5:112820674	MCC	-0.69	-7.45	-0.33	4.47e-13	F-cell distribution;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	trans	rs7246760	1.000	rs7250487	chr19:9886358	T/C	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs8180040	0.739	rs66539935	chr3:47025327	C/T	cg27129171	chr3:47204927	SETD2	-0.79	-14.65	-0.56	3.25e-40	Colorectal cancer;
LGG	cis	rs920590	0.643	rs3855754	chr8:19659499	C/G	cg03894339	chr8:19674705	INTS10	0.49	8.45	0.37	3.77e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg08048268	chr3:133502702	NA	-0.6	-11.12	-0.46	1.22e-25	Iron status biomarkers;
LGG	cis	rs590121	0.876	rs585821	chr11:75282882	C/T	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.66	-0.37	7.94e-17	Coronary artery disease;
LGG	cis	rs1062177	1.000	rs17741826	chr5:151149262	C/T	cg00977110	chr5:151150581	G3BP1	-0.48	-7.7	-0.34	8.08e-14	Preschool internalizing problems;
LGG	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.9e-22	Diabetic retinopathy;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04156016	chr5:1868137	NA	0.32	6.97	0.31	1.07e-11	Cardiovascular disease risk factors;
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.78	-0.34	4.7e-14	Neuroticism;
LGG	cis	rs4919044	1.000	rs4919044	chr10:94771895	T/C	cg05127821	chr10:94822908	CYP26C1	-0.49	-7.54	-0.33	2.48e-13	Coronary artery disease;
LGG	cis	rs1185460	0.547	rs666741	chr11:118911350	A/C	cg23280166	chr11:118938394	VPS11	-0.44	-7.58	-0.33	1.96e-13	Coronary artery disease;
LGG	cis	rs9877502	0.746	rs9862175	chr3:190596086	C/T	cg25724246	chr3:190595776	SNAR-I	-0.35	-7.12	-0.31	4.28e-12	Alzheimer's disease biomarkers;
LGG	cis	rs11690935	0.851	rs6433319	chr2:172830953	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.89	-19.78	-0.68	1.37e-63	Schizophrenia;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg08645402	chr16:4508243	NA	0.45	7.82	0.34	3.66e-14	Schizophrenia;
LGG	cis	rs2200578	0.841	rs111592987	chr2:99601250	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	0.55	6.65	0.3	8.31e-11	IgG glycosylation;
LGG	cis	rs1165472	0.755	rs12239009	chr1:56166508	G/T	cg11523071	chr1:56160889	NA	0.57	12.35	0.5	1.72e-30	Paclitaxel-induced neuropathy;
LGG	cis	rs3741151	0.892	rs11821094	chr11:73061905	C/G	cg17517138	chr11:73019481	ARHGEF17	0.88	9.61	0.41	4.65e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.21	0.43	3.43e-22	Mean corpuscular volume;
LGG	cis	rs7847628	0.765	rs7026635	chr9:123550027	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.81	-13.16	-0.52	7.75e-34	Birth weight;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.34	0.53	1.42e-34	Lung cancer;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg18379455	chr17:41446167	NA	-0.32	-7.55	-0.33	2.32e-13	Menopause (age at onset);
LGG	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg11266682	chr4:10021025	SLC2A9	0.41	6.95	0.31	1.27e-11	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2963155	0.518	rs9324918	chr5:142767160	T/C	cg17617527	chr5:142782415	NR3C1	0.95	12.57	0.5	2.2e-31	Breast cancer;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.77	-0.38	3.33e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg02002194	chr4:3960332	NA	0.46	8.11	0.35	4.67e-15	Retinal vascular caliber;
LGG	cis	rs4566357	1.000	rs2177597	chr2:227922546	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs1941023	0.584	rs7935082	chr11:60155000	T/C	cg08716584	chr11:60157161	MS4A7	-0.44	-8.94	-0.38	9.33e-18	Congenital heart disease (maternal effect);
LGG	cis	rs2153535	0.580	rs2327062	chr6:8453858	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs8064024	0.680	rs8056320	chr16:4918017	T/C	cg08329684	chr16:4932620	PPL	0.52	11.87	0.48	1.54e-28	Cancer;
LGG	cis	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg21775007	chr8:11205619	TDH	-0.52	-8.63	-0.37	1.02e-16	Systolic blood pressure;
LGG	cis	rs17209837	0.607	rs1014283	chr7:87076587	C/A	cg25823085	chr7:87105416	ABCB4	0.32	7.73	0.34	6.8e-14	Gallbladder cancer;
LGG	cis	rs72772090	0.539	rs10515250	chr5:96150193	T/C	cg00188032	chr5:96141721	ERAP1	0.54	7.16	0.32	3.26e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg21775007	chr8:11205619	TDH	-0.51	-8.14	-0.35	3.66e-15	Triglycerides;
LGG	cis	rs2735413	0.837	rs7194946	chr16:78095274	G/A	cg04733911	chr16:78082701	NA	0.75	17.47	0.63	7.5e-53	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs35306767	0.714	rs7075188	chr10:1088746	G/T	cg25019033	chr10:957182	NA	0.42	8.43	0.36	4.52e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg20607798	chr8:58055168	NA	0.71	7.97	0.35	1.22e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg21775007	chr8:11205619	TDH	-0.51	-8.34	-0.36	8.72e-16	Neuroticism;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-11.13	-0.46	1.17e-25	Autism spectrum disorder or schizophrenia;
LGG	cis	rs61931739	0.578	rs61927759	chr12:33713297	C/T	cg06521331	chr12:34319734	NA	0.39	6.8	0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg15596359	chr8:11213517	TDH	-0.41	-8.41	-0.36	4.95e-16	Retinal vascular caliber;
LGG	cis	rs2075371	0.829	rs11770521	chr7:133936251	A/C	cg20476274	chr7:133979776	SLC35B4	0.7	13.16	0.52	7.72e-34	Mean platelet volume;
LGG	cis	rs9894429	1.000	rs9748176	chr17:79584043	C/G	cg18240062	chr17:79603768	NPLOC4	0.74	13.57	0.53	1.47e-35	Eye color traits;
LGG	cis	rs11690935	0.959	rs66835971	chr2:172677459	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.64	-0.78	1.83e-95	Schizophrenia;
LGG	cis	rs17767392	1.000	rs35122644	chr14:71780768	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.34e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg24829409	chr8:58192753	C8orf71	-0.6	-8.17	-0.35	3.07e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.72	-0.45	4.41e-24	Triglycerides;
LGG	trans	rs2197308	0.692	rs7488528	chr12:37912971	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.28	-0.4	6.64e-19	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.863	rs28718422	chr4:120466304	C/A	cg09307838	chr4:120376055	NA	0.8	13.41	0.53	7.15e-35	Corneal astigmatism;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.669	rs11040455	chr11:49669829	G/C	cg03929089	chr4:120376271	NA	-0.78	-14.94	-0.57	1.8e-41	Height;
LGG	cis	rs1018836	0.631	rs2205158	chr8:91472515	C/T	cg16814680	chr8:91681699	NA	-0.61	-10.18	-0.43	4.26e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12497850	0.865	rs13072911	chr3:48962128	T/G	cg07636037	chr3:49044803	WDR6	1.1	27.97	0.79	1.57e-101	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23805780	chr6:130342187	L3MBTL3	0.43	6.95	0.31	1.25e-11	Cognitive performance;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.31	0.32	1.15e-12	Prudent dietary pattern;
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg26150922	chr2:100937072	LONRF2	-0.57	-10.87	-0.45	1.19e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.818	rs407103	chr1:153007106	C/T	cg13444842	chr1:152974279	SPRR3	0.42	8.63	0.37	1e-16	Inflammatory skin disease;
LGG	cis	rs4718428	1.000	rs4718428	chr7:66421446	T/G	cg18252515	chr7:66147081	NA	-0.6	-9.98	-0.42	2.34e-21	Corneal structure;
LGG	cis	rs9911578	0.967	rs4076229	chr17:56937256	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1185460	0.546	rs592190	chr11:118955314	G/A	cg24687335	chr11:118901407	SLC37A4	-0.58	-10.4	-0.44	6.8e-23	Coronary artery disease;
LGG	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg11247378	chr22:39784982	NA	0.31	8.92	0.38	1.07e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs6831256	1.000	rs6831256	chr4:3473139	A/G	cg00887848	chr4:3482507	DOK7	-0.46	-9.2	-0.39	1.18e-18	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs4509693	1.000	rs4917908	chr10:102502674	G/C	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.28e-11	Alzheimer's disease;
LGG	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg22643751	chr7:855365	UNC84A	0.36	6.94	0.31	1.32e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs3091242	0.902	rs36003018	chr1:25784318	A/G	cg23205692	chr1:25664452	TMEM50A	-0.44	-9.2	-0.39	1.2e-18	Erythrocyte sedimentation rate;
LGG	cis	rs763121	0.752	rs5757222	chr22:39060473	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.48	0.63	6.84e-53	Menopause (age at onset);
LGG	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-9.07	-0.39	3.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.78	0.51	2.98e-32	Alzheimer's disease;
LGG	cis	rs73001065	0.591	rs57009615	chr19:19613622	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	11.87	0.48	1.53e-28	LDL cholesterol;
LGG	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg13939156	chr17:80058883	NA	-0.39	-7.08	-0.31	5.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3747547	0.892	rs72726022	chr9:38019703	C/T	cg13774184	chr9:37916125	SHB	-0.71	-7.24	-0.32	1.87e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.31	0.32	1.16e-12	Schizophrenia;
LGG	cis	rs2644899	0.750	rs2249835	chr19:41269766	G/A	cg24958765	chr19:41283667	RAB4B	-0.51	-7.83	-0.34	3.39e-14	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7222240	1.000	rs12568	chr17:43100831	G/T	cg24806326	chr17:43207588	PLCD3	-0.47	-7.89	-0.34	2.14e-14	Craniofacial microsomia;
LGG	cis	rs9291683	0.561	rs3733584	chr4:10036506	T/C	cg08250081	chr4:10125330	NA	0.41	8.16	0.35	3.1e-15	Bone mineral density;
LGG	trans	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs9517320	0.515	rs4772099	chr13:99196121	A/C	cg03701759	chr13:99174930	STK24	-0.36	-6.98	-0.31	1.05e-11	Longevity;
LGG	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg25986240	chr4:9926439	SLC2A9	0.35	7.21	0.32	2.25e-12	Bone mineral density;
LGG	cis	rs4481887	0.830	rs6686474	chr1:248477116	A/C	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs11098499	0.599	rs3864142	chr4:120266191	A/T	cg24375607	chr4:120327624	NA	0.54	9.22	0.39	1.08e-18	Corneal astigmatism;
LGG	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg02733842	chr7:1102375	C7orf50	-0.56	-8.29	-0.36	1.25e-15	Bronchopulmonary dysplasia;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg00106254	chr7:1943704	MAD1L1	-0.4	-7.08	-0.31	5.51e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12920938	chr3:46037457	FYCO1	0.46	6.96	0.31	1.17e-11	Gut microbiome composition (summer);
LGG	trans	rs4714291	0.963	rs1923466	chr6:39965946	A/C	cg02267698	chr19:7991119	CTXN1	0.53	7.88	0.34	2.36e-14	Strep throat;
LGG	cis	rs12586317	0.547	rs74243586	chr14:35477325	C/T	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs2404602	0.735	rs11632222	chr15:76712927	C/G	cg15268244	chr15:77196840	NA	0.45	9.76	0.41	1.42e-20	Blood metabolite levels;
LGG	cis	rs75059851	0.756	rs73036086	chr11:133841782	C/T	cg20042908	chr11:133852938	NA	-0.76	-14.2	-0.55	3.1e-38	Schizophrenia;
LGG	cis	rs7733403	1	rs7733403	chr5:140154215	A/G	cg19875535	chr5:140030758	IK	0.53	11.02	0.46	3e-25	Schizophrenia;
LGG	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.49	-0.33	3.62e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs35123781	0.533	rs7728485	chr5:139077144	A/G	cg21230503	chr5:139085173	NA	0.37	8.57	0.37	1.58e-16	Schizophrenia;
LGG	cis	rs7129220	0.512	rs1867136	chr11:10228843	C/T	cg01453529	chr11:10209919	SBF2	-0.47	-7.7	-0.34	8.04e-14	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9942416	0.660	rs10462356	chr5:74987108	C/T	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs17001868	0.527	rs73167009	chr22:40734249	T/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs295140	0.546	rs295134	chr2:201110223	A/G	cg17644776	chr2:200775616	C2orf69	-0.5	-8.33	-0.36	9.4e-16	QT interval;
LGG	cis	rs4788570	0.566	rs10468265	chr16:71476943	T/C	cg06353428	chr16:71660113	MARVELD3	-1.0	-13.56	-0.53	1.62e-35	Intelligence (multi-trait analysis);
LGG	cis	rs12887734	0.546	rs12885509	chr14:104273325	T/C	cg26031613	chr14:104095156	KLC1	-0.55	-8.67	-0.37	7.55e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6784615	0.744	rs728408	chr3:52517206	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.28	-0.32	1.42e-12	Waist-hip ratio;
LGG	trans	rs7980799	0.682	rs10844612	chr12:33603676	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-7.98	-0.35	1.18e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Electroencephalogram traits;
LGG	cis	rs3106136	0.527	rs4235050	chr4:95157156	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.01	-0.46	3.26e-25	Capecitabine sensitivity;
LGG	cis	rs9515201	0.748	rs9583489	chr13:111032833	C/T	cg06243866	chr13:111019493	COL4A2	-0.56	-9.44	-0.4	1.9e-19	White matter hyperintensity burden;
LGG	trans	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg22232500	chr2:134024266	NCKAP5	0.51	7.05	0.31	6.37e-12	Bipolar disorder;
LGG	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg02711726	chr17:80685570	FN3KRP	0.4	7.71	0.34	7.87e-14	Breast cancer;
LGG	cis	rs4262150	0.544	rs17549488	chr5:151917354	C/A	cg12297329	chr5:152029980	NA	-0.64	-11.56	-0.47	2.55e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs4666002	0.789	rs13023094	chr2:27910706	G/T	cg27432699	chr2:27873401	GPN1	-0.53	-7.41	-0.33	6.17e-13	Phospholipid levels (plasma);
LGG	cis	rs950169	0.845	rs4106951	chr15:84833394	C/G	cg03959625	chr15:84868606	LOC388152	0.55	8.71	0.38	5.36e-17	Schizophrenia;
LGG	cis	rs425535	0.757	rs2117721	chr4:74786885	T/C	cg01447579	chr4:74847100	PF4	0.54	7.08	0.31	5.51e-12	Blood protein levels;
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg13607699	chr17:42295918	UBTF	0.64	10.97	0.45	4.86e-25	Total body bone mineral density;
LGG	cis	rs11971779	0.816	rs11979272	chr7:139074069	C/T	cg07862535	chr7:139043722	LUC7L2	0.67	10.09	0.42	9.02e-22	Diisocyanate-induced asthma;
LGG	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg12633918	chr20:23549525	CST9L	-0.36	-7.22	-0.32	2.13e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs10463554	0.667	rs34782	chr5:102454470	G/T	cg23492399	chr5:102201601	PAM	-0.52	-7.71	-0.34	7.75e-14	Parkinson's disease;
LGG	cis	rs360798	0.512	rs17027429	chr2:63079983	C/T	cg17519650	chr2:63277830	OTX1	0.47	7.83	0.34	3.45e-14	Coronary artery disease;
LGG	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg06212747	chr3:49208901	KLHDC8B	0.42	6.87	0.3	2.03e-11	Resting heart rate;
LGG	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.09	0.55	9.43e-38	Bladder cancer;
LGG	cis	rs16976116	0.806	rs117064453	chr15:55492319	T/A	cg11288833	chr15:55489084	RSL24D1	0.55	7.17	0.32	2.95e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7226408	0.857	rs55809464	chr18:34608316	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs4478037	1.000	rs4076086	chr3:33161898	C/T	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs7010267	0.596	rs4336637	chr8:120016636	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.89	0.38	1.4e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs12479254	0.701	rs6718026	chr2:242495392	C/T	cg24828208	chr2:242500484	BOK	-0.29	-6.96	-0.31	1.14e-11	Brain structure;
LGG	trans	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg18335740	chr13:41363409	SLC25A15	0.66	13.39	0.53	8.8e-35	Lewy body disease;
LGG	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	14.71	0.56	1.79e-40	Mean platelet volume;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg08677398	chr8:58056175	NA	0.48	7.12	0.31	4.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12421382	0.507	rs2186673	chr11:109285519	G/A	cg06719900	chr11:109292894	C11orf87	0.75	15.22	0.58	1.08e-42	Schizophrenia;
LGG	cis	rs6831352	1.000	rs6532798	chr4:100054827	C/T	cg12011299	chr4:100065546	ADH4	0.45	9.34	0.4	3.99e-19	Alcohol dependence;
LGG	cis	rs10493773	1.000	rs55654440	chr1:86176158	G/C	cg17807903	chr1:86174739	ZNHIT6	-0.6	-10.15	-0.43	5.53e-22	Urate levels in overweight individuals;
LGG	cis	rs8067545	0.750	rs3862152	chr17:19959693	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.88	-0.3	1.9e-11	Schizophrenia;
LGG	trans	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg13565492	chr6:43139072	SRF	-0.9	-15.7	-0.59	7.3e-45	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2371030	0.632	rs2371028	chr2:211568414	C/A	cg18417063	chr2:211583084	NA	0.53	8.38	0.36	6.54e-16	Non-small cell lung cancer;
LGG	cis	rs4132509	1.000	rs73128287	chr1:243952150	T/G	cg21452805	chr1:244014465	NA	0.67	8.22	0.36	2.07e-15	RR interval (heart rate);
LGG	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg06885757	chr1:42089581	HIVEP3	0.52	12.02	0.49	3.57e-29	Airway imaging phenotypes;
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-9.69	-0.41	2.52e-20	IgG glycosylation;
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg02002194	chr4:3960332	NA	-0.46	-8.73	-0.38	4.63e-17	Systolic blood pressure;
LGG	cis	rs5744897	0.867	rs5744773	chr12:133250550	C/T	cg16945633	chr12:133170342	NA	0.66	6.95	0.31	1.24e-11	Urate levels in overweight individuals;
LGG	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg22681709	chr2:178499509	PDE11A	-0.42	-7.76	-0.34	5.34e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg00364696	chr7:1142433	C7orf50	-0.39	-7.49	-0.33	3.63e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7851660	0.809	rs7866436	chr9:100650096	G/A	cg13688889	chr9:100608707	NA	-0.6	-11.68	-0.48	8.65e-28	Strep throat;
LGG	cis	rs12887734	0.546	rs4900597	chr14:104266664	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.21	0.32	2.24e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg05425664	chr17:57184151	TRIM37	-0.46	-7.23	-0.32	1.99e-12	Testicular germ cell tumor;
LGG	cis	rs734999	0.545	rs28568531	chr1:2555640	T/A	cg20673091	chr1:2541236	MMEL1	0.76	18.7	0.66	1.61e-58	Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12580194	0.593	rs7485053	chr12:55770126	T/C	cg19537932	chr12:55886519	OR6C68	-0.55	-10.02	-0.42	1.67e-21	Cancer;
LGG	cis	rs7326068	0.610	rs2477165	chr13:21445435	A/G	cg04906043	chr13:21280425	IL17D	-0.45	-7.25	-0.32	1.76e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg19676328	chr12:49525230	TUBA1B	-0.65	-10.02	-0.42	1.66e-21	Total cholesterol levels;
LGG	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg14541582	chr5:601475	NA	-0.71	-11.05	-0.46	2.29e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs4689388	0.890	rs1801206	chr4:6302707	C/T	cg25554036	chr4:6271136	WFS1	0.59	11.28	0.46	3.11e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4555082	0.834	rs2735826	chr14:105710866	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.6	0.53	1.14e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.74	-0.3	4.6e-11	Mean corpuscular volume;
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg14689365	chr7:158441557	NCAPG2	0.6	9.94	0.42	3.14e-21	Height;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.646	rs13103430	chr4:17567355	A/C	cg16339924	chr4:17578868	LAP3	-0.56	-9.15	-0.39	1.83e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg06640241	chr16:89574553	SPG7	0.87	16.18	0.6	5.4e-47	Multiple myeloma (IgH translocation);
LGG	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg05973401	chr12:123451056	ABCB9	0.53	8.49	0.37	2.9e-16	Neutrophil percentage of white cells;
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg00713939	chr8:144660590	NAPRT1	0.9	7.09	0.31	5.19e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg04731861	chr2:219085781	ARPC2	-0.49	-12.6	-0.51	1.65e-31	Colorectal cancer;
LGG	cis	rs4650994	1.000	rs35810840	chr1:178522642	G/A	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7681440	0.904	rs58864428	chr4:90766986	T/C	cg15133208	chr4:90757351	SNCA	-0.38	-8.66	-0.37	7.95e-17	Dementia with Lewy bodies;
LGG	trans	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg02002194	chr4:3960332	NA	-0.45	-8.44	-0.37	4.12e-16	Systolic blood pressure;
LGG	trans	rs34421088	0.576	rs2572432	chr8:11101723	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.0	-0.35	1.03e-14	Neuroticism;
LGG	cis	rs2735413	0.846	rs12923626	chr16:78080139	A/C	cg04733911	chr16:78082701	NA	-0.78	-18.87	-0.66	2.54e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs12476592	0.571	rs2592386	chr2:63894064	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs17776563	0.614	rs10852103	chr15:89136690	A/G	cg05013243	chr15:89149849	MIR1179	-0.34	-7.0	-0.31	9.21e-12	Thyroid hormone levels;
LGG	cis	rs13421350	0.579	rs60096331	chr2:173375391	C/G	cg15021238	chr2:173305865	ITGA6	-0.8	-8.63	-0.37	1.03e-16	Diabetic kidney disease;
LGG	cis	rs858239	0.600	rs7788821	chr7:23133645	A/T	cg23682824	chr7:23144976	KLHL7	0.42	7.26	0.32	1.7e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9527	0.615	rs7089065	chr10:104723022	C/T	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	trans	rs877282	1.000	rs11253370	chr10:773712	G/A	cg22713356	chr15:30763199	NA	0.55	8.58	0.37	1.42e-16	Uric acid levels;
LGG	cis	rs920590	0.642	rs6993525	chr8:19671104	A/G	cg01411142	chr8:19674711	INTS10	-0.48	-7.49	-0.33	3.6e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs78366141	0.649	rs7666372	chr4:89687531	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.94	8.73	0.38	4.52e-17	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs11711311	1.000	rs13070720	chr3:113473754	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.44	-7.88	-0.34	2.32e-14	IgG glycosylation;
LGG	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg18252515	chr7:66147081	NA	0.41	6.91	0.31	1.63e-11	Aortic root size;
LGG	cis	rs459571	0.920	rs417142	chr9:136891370	G/T	cg13789015	chr9:136890014	NCRNA00094	0.59	11.01	0.46	3.43e-25	Platelet distribution width;
LGG	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs7100689	0.646	rs11202721	chr10:82135762	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.46e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2075371	0.863	rs9641966	chr7:133961205	G/A	cg20476274	chr7:133979776	SLC35B4	0.71	13.53	0.53	2.13e-35	Mean platelet volume;
LGG	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg15309053	chr8:964076	NA	0.41	8.77	0.38	3.34e-17	Schizophrenia;
LGG	cis	rs62400317	0.723	rs12196188	chr6:44976426	G/C	cg18551225	chr6:44695536	NA	-0.68	-11.29	-0.46	2.92e-26	Total body bone mineral density;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg11062466	chr8:58055876	NA	0.52	8.91	0.38	1.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg13385794	chr1:248469461	NA	0.5	8.48	0.37	3.04e-16	Common traits (Other);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg18137450	chr1:224620806	WDR26	-0.36	-6.81	-0.3	3.04e-11	Body fat percentage;
LGG	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg26769984	chr7:1090371	C7orf50	0.54	9.58	0.41	6.07e-20	Bronchopulmonary dysplasia;
LGG	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg25237894	chr2:233734115	C2orf82	-0.61	-11.61	-0.47	1.66e-27	Coronary artery disease;
LGG	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg09818912	chr17:20140352	CYTSB	-0.34	-8.04	-0.35	7.8e-15	Schizophrenia;
LGG	cis	rs8067545	0.611	rs7216599	chr17:20015600	G/C	cg13482628	chr17:19912719	NA	0.53	10.12	0.43	7.1e-22	Schizophrenia;
LGG	cis	rs4727027	0.901	rs4727018	chr7:148822247	G/C	cg23583168	chr7:148888333	NA	-0.86	-16.59	-0.61	7.85e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7551222	0.714	rs930947	chr1:204541197	G/A	cg20240347	chr1:204465584	NA	-0.46	-8.12	-0.35	4.36e-15	Schizophrenia;
LGG	cis	rs787274	1.000	rs787296	chr9:115541703	A/G	cg13803584	chr9:115635662	SNX30	-0.58	-7.45	-0.33	4.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.76	-0.34	5.33e-14	Testicular germ cell tumor;
LGG	cis	rs1595825	0.891	rs75163179	chr2:198895402	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs7712401	0.562	rs377316	chr5:122259875	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg09699651	chr6:150184138	LRP11	0.53	9.45	0.4	1.73e-19	Lung cancer;
LGG	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.17e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4478137	0.931	rs7665672	chr4:164236875	G/A	cg06758707	chr4:164254230	NPY1R	0.71	12.59	0.5	1.89e-31	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs57244997	0.932	rs73026582	chr6:162406460	C/T	cg17173639	chr6:162384350	PARK2	-0.62	-7.48	-0.33	3.72e-13	Mosquito bite size;
LGG	cis	rs4788570	0.625	rs2434885	chr16:71583859	C/T	cg06353428	chr16:71660113	MARVELD3	-0.74	-9.95	-0.42	2.78e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.734	rs2791648	chr1:11132638	G/T	cg08854313	chr1:11322531	MTOR	0.75	16.76	0.61	1.31e-49	Body mass index;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg05861140	chr6:150128134	PCMT1	-0.32	-7.32	-0.32	1.09e-12	Lung cancer;
LGG	trans	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg21775007	chr8:11205619	TDH	-0.46	-7.33	-0.32	1.03e-12	Joint mobility (Beighton score);
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.29	-0.63	5.07e-52	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg12070911	chr6:150209640	RAET1E	0.31	7.49	0.33	3.43e-13	Lung cancer;
LGG	cis	rs920590	0.560	rs10090638	chr8:19673750	T/G	cg03894339	chr8:19674705	INTS10	-0.54	-9.06	-0.39	3.76e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4900538	0.819	rs72698591	chr14:102838896	G/A	cg18135206	chr14:102964638	TECPR2	-0.7	-12.46	-0.5	6e-31	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs3820068	0.603	rs7537618	chr1:15977682	G/A	cg05660106	chr1:15850417	CASP9	0.82	16.81	0.62	7.6e-50	Systolic blood pressure;
LGG	trans	rs225245	0.782	rs178649	chr17:33908197	C/G	cg19694781	chr19:47549865	TMEM160	-0.42	-7.08	-0.31	5.24e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7172689	0.866	rs8025180	chr15:81574743	C/T	cg11808699	chr15:81528661	IL16	-0.41	-8.54	-0.37	1.88e-16	Inattentive symptoms;
LGG	cis	rs5758511	0.680	rs5758699	chr22:42688034	C/G	cg15128208	chr22:42549153	NA	0.72	11.17	0.46	8.12e-26	Birth weight;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg02725872	chr8:58115012	NA	-0.98	-14.73	-0.56	1.48e-40	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	7.99	0.35	1.05e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12464559	0.579	rs2293221	chr2:152653380	C/T	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	trans	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg18187862	chr3:45730750	SACM1L	0.55	9.09	0.39	2.99e-18	Primary sclerosing cholangitis;
LGG	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg01191920	chr7:158217561	PTPRN2	-0.93	-24.36	-0.75	5.46e-85	Obesity-related traits;
LGG	trans	rs637571	0.780	rs653914	chr11:65676516	A/G	cg17712092	chr4:129076599	LARP1B	0.92	19.95	0.68	2.26e-64	Eosinophil percentage of white cells;
LGG	cis	rs10857712	0.687	rs11101742	chr10:135224372	C/G	cg00491522	chr10:135256596	NA	0.52	9.4	0.4	2.52e-19	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.602	rs2836987	chr21:40706594	C/T	cg11890956	chr21:40555474	PSMG1	-0.95	-18.8	-0.66	5.45e-59	Cognitive function;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.74	15.27	0.58	6.31e-43	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09567311	chr17:53316197	NA	0.42	6.67	0.3	7.4e-11	Gut microbiome composition (summer);
LGG	trans	rs7762018	0.607	rs77972667	chr6:170130456	G/C	cg06875740	chr19:51307921	C19orf48	-0.72	-6.69	-0.3	6.58e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4588572	1.000	rs72778243	chr5:77634236	G/A	cg11446398	chr5:77624930	NA	-0.41	-6.87	-0.3	2.11e-11	Triglycerides;
LGG	cis	rs61931739	0.500	rs3924704	chr12:34557833	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.41	-0.4	2.27e-19	Morning vs. evening chronotype;
LGG	cis	rs11190604	0.790	rs11190535	chr10:102197441	A/T	cg07570687	chr10:102243282	WNT8B	0.42	7.53	0.33	2.63e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12153243	0.714	rs6895860	chr5:142913679	C/T	cg13907255	chr5:142895549	NA	-0.5	-8.74	-0.38	4.43e-17	Migraine;
LGG	cis	rs7717393	1.000	rs72813881	chr5:155760241	C/T	cg12904904	chr5:155754151	SGCD	0.91	8.55	0.37	1.77e-16	Egg allergy;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03764092	chr7:139690853	TBXAS1	0.35	6.87	0.3	2.06e-11	Pancreatic cancer;
LGG	cis	rs7177699	0.557	rs11072807	chr15:79111517	A/G	cg00540400	chr15:79124168	NA	0.54	11.46	0.47	6.32e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg23985595	chr17:80112537	CCDC57	0.39	7.8	0.34	4.2e-14	Life satisfaction;
LGG	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg05791153	chr7:19748676	TWISTNB	0.58	8.74	0.38	4.29e-17	Thyroid stimulating hormone;
LGG	cis	rs2115536	1.000	rs11072871	chr15:80197931	T/C	cg11839771	chr15:80205821	ST20	-0.37	-7.99	-0.35	1.07e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg20110707	chr11:118481992	PHLDB1	0.5	10.48	0.44	3.33e-23	Cholesterol, total;
LGG	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg14259594	chr22:18958660	DGCR5	0.88	14.59	0.56	6.09e-40	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.73	-0.38	4.57e-17	Retinal vascular caliber;
LGG	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg17376030	chr22:41985996	PMM1	0.55	9.12	0.39	2.28e-18	Vitiligo;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg05313129	chr8:58192883	C8orf71	-0.79	-11.9	-0.48	1.15e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs1519814	0.956	rs7827008	chr8:121130281	A/T	cg22335954	chr8:121166405	COL14A1	-0.53	-10.8	-0.45	2.14e-24	Breast cancer;
LGG	cis	rs3735485	0.579	rs10269518	chr7:45116269	C/T	cg03440944	chr7:45023329	C7orf40	-0.57	-9.52	-0.4	9.66e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs3008870	1.000	rs2985795	chr1:67426223	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.49	0.74	6.36e-81	Lymphocyte percentage of white cells;
LGG	cis	rs2562456	0.833	rs8106025	chr19:21634724	A/C	cg00806126	chr19:22604979	ZNF98	0.56	7.96	0.35	1.34e-14	Pain;
LGG	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg17809284	chr5:56205270	C5orf35	-0.59	-9.39	-0.4	2.7e-19	Initial pursuit acceleration;
LGG	cis	rs2486288	0.656	rs9921025	chr15:45546602	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.11	-0.43	7.58e-22	Glomerular filtration rate;
LGG	cis	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg09044154	chr16:88155775	NA	-0.48	-7.46	-0.33	4.45e-13	Menopause (age at onset);
LGG	cis	rs17122278	1.000	rs57438673	chr11:118459039	G/A	cg27286069	chr11:118481882	PHLDB1	-0.56	-6.72	-0.3	5.24e-11	Total cholesterol levels;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.72e-15	Obesity-related traits;
LGG	cis	rs209489	0.892	rs2294870	chr6:53156464	A/C	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11209002	0.567	rs983110	chr1:67539215	A/T	cg02640540	chr1:67518911	SLC35D1	0.39	6.65	0.3	8.13e-11	Crohn's disease;
LGG	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs12210905	1.000	rs9379967	chr6:27233427	T/C	cg15325629	chr6:28072465	NA	0.7	6.86	0.3	2.24e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.31	-0.32	1.15e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg05868516	chr6:26286170	HIST1H4H	0.47	8.25	0.36	1.69e-15	Educational attainment;
LGG	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.66e-18	Aortic root size;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs6430585	0.528	rs12464050	chr2:136663110	G/T	cg07169764	chr2:136633963	MCM6	1.22	22.34	0.72	1.46e-75	Corneal structure;
LGG	cis	rs910316	0.699	rs175039	chr14:75468950	G/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.46	-0.4	1.51e-19	Height;
LGG	trans	rs330048	0.561	rs330088	chr8:9149746	T/C	cg15556689	chr8:8085844	FLJ10661	0.41	7.36	0.32	8.18e-13	Systemic lupus erythematosus;
LGG	cis	rs123509	0.687	rs73077214	chr3:42838020	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.78	-0.3	3.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg16339924	chr4:17578868	LAP3	0.64	11.16	0.46	9.25e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg00149659	chr3:10157352	C3orf10	0.6	8.64	0.37	9.35e-17	Alzheimer's disease;
LGG	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg27572855	chr1:25598939	RHD	0.49	10.94	0.45	6.31e-25	Erythrocyte sedimentation rate;
LGG	cis	rs4332037	0.624	rs11764124	chr7:1891723	C/G	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.78	-0.34	4.78e-14	Bipolar disorder;
LGG	cis	rs735539	0.521	rs574139	chr13:21425816	T/G	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs16854884	0.770	rs7621079	chr3:143814500	G/C	cg06585982	chr3:143692056	C3orf58	0.53	8.28	0.36	1.35e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg01631408	chr1:248437212	OR2T33	0.54	9.86	0.42	5.81e-21	Common traits (Other);
LGG	cis	rs7916697	0.947	rs7916410	chr10:69995667	T/C	cg18338521	chr10:69995036	NA	0.33	7.13	0.31	3.84e-12	Optic disc area;
LGG	cis	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.86e-11	Bone mineral density;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09807452	chr4:140099025	NA	0.5	7.3	0.32	1.23e-12	Gut microbiome composition (summer);
LGG	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.4	0.47	1.05e-26	Schizophrenia;
LGG	trans	rs453301	0.686	rs6748	chr8:8890802	C/T	cg02002194	chr4:3960332	NA	0.38	7.03	0.31	7.67e-12	Joint mobility (Beighton score);
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg18110333	chr6:292329	DUSP22	-0.55	-9.55	-0.41	7.35e-20	Menopause (age at onset);
LGG	trans	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.43	-0.4	1.91e-19	Extrinsic epigenetic age acceleration;
LGG	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg00383909	chr3:49044727	WDR6	0.43	7.02	0.31	8.12e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9796	0.674	rs6492978	chr15:41317702	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.38	-0.36	6.55e-16	Menopause (age at onset);
LGG	cis	rs740474	0.768	rs6880745	chr5:140981247	C/A	cg00076195	chr5:140892677	NA	0.48	8.77	0.38	3.45e-17	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.81	0.54	1.48e-36	Obesity-related traits;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg14004847	chr7:1930337	MAD1L1	-0.59	-10.62	-0.44	1.04e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs561341	1.000	rs550923	chr17:30327013	G/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg00990874	chr7:1149470	C7orf50	-0.65	-9.76	-0.41	1.42e-20	Bronchopulmonary dysplasia;
LGG	cis	rs6909430	0.665	rs2502943	chr6:98615667	C/G	cg12860156	chr6:98744658	NA	-0.38	-6.87	-0.3	2.03e-11	Quantitative traits;
LGG	cis	rs357618	1.000	rs193299	chr5:150847655	G/C	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.03	0.39	4.49e-18	Obesity-related traits;
LGG	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg05973401	chr12:123451056	ABCB9	0.51	7.73	0.34	6.88e-14	Neutrophil percentage of white cells;
LGG	cis	rs28602670	1	rs28602670	chr15:78768167	C/G	cg06917634	chr15:78832804	PSMA4	-0.53	-8.04	-0.35	7.35e-15	Post bronchodilator FEV1;
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg14403583	chr14:105418241	AHNAK2	0.75	14.91	0.57	2.5e-41	Rheumatoid arthritis;
LGG	cis	rs10186029	0.616	rs12616255	chr2:213978895	T/A	cg08319019	chr2:214017104	IKZF2	0.44	7.75	0.34	5.68e-14	Systemic sclerosis;
LGG	trans	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg06521331	chr12:34319734	NA	0.44	7.36	0.32	8.46e-13	Morning vs. evening chronotype;
LGG	cis	rs17672112	1.000	rs17672112	chr6:101274689	T/C	cg27451362	chr6:101846650	GRIK2	0.72	9.12	0.39	2.27e-18	Putamen volume;
LGG	cis	rs6723226	0.750	rs1033751	chr2:32695759	T/C	cg02381751	chr2:32503542	YIPF4	0.61	10.42	0.44	5.57e-23	Intelligence (multi-trait analysis);
LGG	trans	rs1493916	1.000	rs9964702	chr18:31390427	A/C	cg04226714	chr8:49833948	SNAI2	-0.48	-8.63	-0.37	9.95e-17	Life satisfaction;
LGG	trans	rs208520	0.690	rs2126120	chr6:66742754	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.75	0.64	3.64e-54	Exhaled nitric oxide output;
LGG	cis	rs9467711	0.606	rs71557334	chr6:26365913	G/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7503807	0.688	rs731452	chr17:78599052	G/T	cg06872548	chr17:78716983	RPTOR	0.4	8.68	0.37	6.78e-17	Obesity;
LGG	cis	rs6912958	0.559	rs242281	chr6:88048916	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.03	0.52	2.84e-33	Monocyte percentage of white cells;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg06112835	chr11:68658793	MRPL21	0.56	9.45	0.4	1.72e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12618769	0.597	rs3769743	chr2:99063653	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9611519	0.929	rs9611509	chr22:41565827	A/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.41	-0.36	4.99e-16	Neuroticism;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg17788362	chr6:86352627	SYNCRIP	-0.56	-9.84	-0.42	7.11e-21	Smooth-surface caries;
LGG	cis	rs3733585	0.806	rs11723382	chr4:9954660	T/C	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.15	-0.39	1.8e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9487051	0.714	rs9386797	chr6:109632520	C/A	cg21918786	chr6:109611834	NA	-0.49	-9.11	-0.39	2.48e-18	Reticulocyte fraction of red cells;
LGG	trans	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.43	-0.33	5.12e-13	Joint mobility (Beighton score);
LGG	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	2.02e-13	Colorectal cancer;
LGG	cis	rs4363385	0.747	rs11205149	chr1:152958840	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.05	-0.39	4.1e-18	Inflammatory skin disease;
LGG	cis	rs116095464	0.558	rs62346526	chr5:220614	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs17321999	1.000	rs9309678	chr2:30487198	A/G	cg05247661	chr2:30472410	LBH	0.54	8.4	0.36	5.5e-16	Systemic lupus erythematosus;
LGG	cis	rs7928758	0.767	rs1866769	chr11:134274676	C/T	cg25213107	chr11:134282864	B3GAT1	-0.71	-10.17	-0.43	4.48e-22	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.71e-17	Lung cancer;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.54	0.37	1.88e-16	Lung cancer;
LGG	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg14893161	chr1:205819251	PM20D1	0.48	7.76	0.34	5.53e-14	Parkinson's disease;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-14.66	-0.56	3.07e-40	Platelet count;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg04008888	chr11:68622739	NA	-0.55	-12.06	-0.49	2.63e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg26116260	chr4:7069785	GRPEL1	0.62	11.53	0.47	3.34e-27	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24052530	chr1:44820828	ERI3	-0.42	-6.75	-0.3	4.34e-11	Pancreatic cancer;
LGG	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg22875332	chr1:76189707	ACADM	-0.6	-10.15	-0.43	5.61e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17767392	0.881	rs7157241	chr14:72001296	A/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.96	0.38	8.13e-18	Mitral valve prolapse;
LGG	cis	rs4006360	0.632	rs4986668	chr17:39250408	T/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg11644478	chr21:40555479	PSMG1	-0.6	-10.14	-0.43	6.07e-22	Menarche (age at onset);
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg07343612	chr16:622815	PIGQ	-0.77	-15.78	-0.59	3.46e-45	Height;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg00449899	chr8:53626436	RB1CC1	0.39	6.71	0.3	5.64e-11	Body mass index;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg01341218	chr17:43662625	NA	0.67	12.14	0.49	1.21e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg02503808	chr4:7069936	GRPEL1	-0.97	-13.28	-0.53	2.46e-34	Monocyte percentage of white cells;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	10.0	0.42	1.83e-21	Longevity;
LGG	cis	rs4690686	0.500	rs11723131	chr4:177268602	G/A	cg17059388	chr4:177262070	NA	1.03	24.15	0.75	5.54e-84	Essential tremor;
LGG	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.26	-0.4	7.51e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.12	0.39	2.22e-18	Blood metabolite levels;
LGG	cis	rs9790314	0.560	rs1450521	chr3:161091237	C/A	cg03342759	chr3:160939853	NMD3	-0.62	-10.54	-0.44	2.02e-23	Morning vs. evening chronotype;
LGG	cis	rs35306767	0.714	rs12762955	chr10:1078782	A/C	cg20503657	chr10:835505	NA	0.49	6.74	0.3	4.82e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs17453880	0.890	rs4958319	chr5:151961998	T/A	cg10931792	chr5:152022470	NA	0.38	8.29	0.36	1.25e-15	Subjective well-being;
LGG	trans	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg11608241	chr8:8085544	FLJ10661	-0.29	-6.71	-0.3	5.69e-11	Neuroticism;
LGG	cis	rs62244186	0.632	rs1402751	chr3:44594030	C/A	cg02073558	chr3:44770973	ZNF501	0.66	12.07	0.49	2.31e-29	Depressive symptoms;
LGG	cis	rs12188164	1.000	rs72717411	chr5:429124	C/G	cg21972741	chr5:435613	AHRR	0.5	8.95	0.38	8.72e-18	Cystic fibrosis severity;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg18538332	chr22:24372958	LOC391322	-0.49	-8.38	-0.36	6.3e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.89	-0.34	2.25e-14	Mood instability;
LGG	cis	rs9650657	0.571	rs4240673	chr8:10787612	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.33	-0.32	1.07e-12	Neuroticism;
LGG	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.84	-0.34	3.16e-14	Neuroticism;
LGG	cis	rs1728785	1.000	rs1645938	chr16:68595197	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs4819052	0.851	rs13052312	chr21:46662359	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.1	0.39	2.73e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6754311	0.593	rs656326	chr2:136428460	A/C	cg07169764	chr2:136633963	MCM6	0.76	13.2	0.52	5.32e-34	Mosquito bite size;
LGG	cis	rs708547	0.647	rs1403233	chr4:57885053	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.5	-8.06	-0.35	6.45e-15	Response to bleomycin (chromatid breaks);
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs60871478	0.898	rs62432897	chr7:825429	A/G	cg27478167	chr7:817139	HEATR2	-0.48	-6.93	-0.31	1.39e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7552404	1.000	rs7513559	chr1:76173744	A/G	cg22875332	chr1:76189707	ACADM	0.59	9.51	0.4	1.06e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9715521	0.557	rs13146381	chr4:59853842	T/C	cg11281224	chr4:60001000	NA	-0.51	-8.85	-0.38	1.87e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2481665	0.772	rs6668421	chr1:62536619	C/G	cg18591186	chr1:62594603	INADL	-0.49	-9.92	-0.42	3.56e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs4936891	0.557	rs470242	chr11:123909342	G/A	cg22125253	chr11:123886957	OR10G4	-0.54	-9.04	-0.39	4.42e-18	Male fertility;
LGG	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg18404041	chr3:52824283	ITIH1	-0.43	-7.63	-0.33	1.39e-13	Bipolar disorder;
LGG	cis	rs2404602	0.684	rs1603860	chr15:76849591	A/T	cg23625390	chr15:77176239	SCAPER	-0.7	-13.74	-0.54	2.84e-36	Blood metabolite levels;
LGG	cis	rs41271473	0.500	rs4440831	chr1:228887522	C/T	cg16512390	chr1:228756714	NA	-0.45	-7.55	-0.33	2.31e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg17201900	chr20:34330562	RBM39	-0.51	-6.93	-0.31	1.43e-11	Total cholesterol levels;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.9	-0.59	1e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs11758351	0.500	rs76607472	chr6:26191557	C/T	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.82e-12	Gout;Renal underexcretion gout;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg17895289	chr1:241682884	FH	-0.4	-6.95	-0.31	1.26e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg23815491	chr16:72088622	HP	0.37	7.51	0.33	2.99e-13	Coronary artery disease;
LGG	cis	rs9818758	0.607	rs11716445	chr3:49406095	C/T	cg00383909	chr3:49044727	WDR6	1.09	12.12	0.49	1.51e-29	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs66887589	0.967	rs7678973	chr4:120511817	T/C	cg09307838	chr4:120376055	NA	-0.47	-8.18	-0.36	2.81e-15	Diastolic blood pressure;
LGG	cis	rs2797369	0.600	rs2813656	chr6:101586603	A/G	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	trans	rs11039798	1.000	rs12225599	chr11:48755868	T/C	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg15627072	chr1:2432621	PLCH2	0.38	8.15	0.35	3.52e-15	Ulcerative colitis;
LGG	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg18446336	chr7:2847575	GNA12	-0.31	-8.16	-0.35	3.15e-15	Height;
LGG	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg07541023	chr7:19748670	TWISTNB	0.62	8.54	0.37	1.97e-16	Thyroid stimulating hormone;
LGG	cis	rs561341	0.883	rs72821942	chr17:30234460	C/T	cg13647721	chr17:30228624	UTP6	0.78	10.24	0.43	2.64e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7584262	0.513	rs34163130	chr2:42263449	A/C	cg27252766	chr2:42229092	NA	0.47	8.49	0.37	2.73e-16	Bone mineral density;
LGG	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg05169099	chr5:481640	SLC9A3	0.46	6.84	0.3	2.59e-11	Fat distribution (HIV);
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.6	-0.33	1.61e-13	Prudent dietary pattern;
LGG	trans	rs61931739	0.500	rs28624237	chr12:34457171	G/T	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs216418	chr17:28936537	G/A	cg19761014	chr17:28927070	LRRC37B2	0.69	8.74	0.38	4.39e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1003719	0.788	rs1543750	chr21:38446918	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	1.07e-29	Prudent dietary pattern;
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg12463550	chr7:65579703	CRCP	0.49	8.21	0.36	2.22e-15	Aortic root size;
LGG	trans	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs740474	0.831	rs1479585	chr5:140976528	G/C	cg00076195	chr5:140892677	NA	0.48	8.77	0.38	3.45e-17	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	trans	rs208520	0.770	rs1342960	chr6:66883514	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.93	-16.72	-0.61	1.99e-49	Exhaled nitric oxide output;
LGG	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.35	-0.36	7.94e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2120019	1.000	rs2415255	chr15:75332412	A/G	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.32	-0.65	8.65e-57	Blood trace element (Zn levels);
LGG	cis	rs4237845	0.537	rs10747786	chr12:58260601	G/T	cg02175503	chr12:58329896	NA	0.52	8.94	0.38	9.56e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6956675	0.512	rs4718841	chr7:62618562	A/G	cg08930214	chr7:62859557	LOC100287834	0.4	7.1	0.31	4.57e-12	Obesity-related traits;
LGG	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg19784903	chr17:45786737	TBKBP1	-0.31	-6.83	-0.3	2.65e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.33	-0.58	3.3400000000000002e-43	Chronic sinus infection;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg00684032	chr4:1343700	KIAA1530	0.62	12.33	0.5	2.2e-30	Obesity-related traits;
LGG	trans	rs11782517	0.920	rs4563888	chr8:10105661	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-6.67	-0.3	7.22e-11	Nose size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11409205	chr12:48357772	TMEM106C	0.41	6.8	0.3	3.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62064224	0.589	rs9910731	chr17:30784034	A/G	cg25809561	chr17:30822961	MYO1D	0.4	9.44	0.4	1.87e-19	Schizophrenia;
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg26597838	chr10:835615	NA	0.64	9.55	0.41	7.41e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs9807989	0.507	rs7581119	chr2:103049865	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.52	0.4	9.77e-20	Asthma;
LGG	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg22906224	chr7:99728672	NA	-0.58	-9.55	-0.41	7.39e-20	Coronary artery disease;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.06	15.79	0.59	3.1e-45	Platelet count;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.76	0.54	2.29e-36	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg02931644	chr1:25747376	RHCE	0.42	9.15	0.39	1.86e-18	Erythrocyte sedimentation rate;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.29e-12	Lung cancer;
LGG	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg26597838	chr10:835615	NA	0.75	10.14	0.43	5.94e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.64	0.41	3.62e-20	Menopause (age at onset);
LGG	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	12.74	0.51	4.45e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.58	-0.37	1.39e-16	Bone mineral density;
LGG	cis	rs4237845	0.537	rs12312955	chr12:58265223	A/G	cg00677455	chr12:58241039	CTDSP2	0.39	7.18	0.32	2.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17575087	chr5:154237720	CNOT8	-0.41	-6.75	-0.3	4.44e-11	Pancreatic cancer;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.31	0.43	1.39e-22	Longevity;
LGG	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg26513180	chr16:89883248	FANCA	-0.6	-11.12	-0.46	1.33e-25	Vitiligo;
LGG	cis	rs12497850	0.931	rs4974087	chr3:48919232	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.64e-25	Parkinson's disease;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg16301924	chr13:53314226	LECT1	-0.47	-9.61	-0.41	4.65e-20	Lewy body disease;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg23034840	chr1:205782522	SLC41A1	0.56	9.12	0.39	2.32e-18	Menarche (age at onset);
LGG	cis	rs9487051	0.714	rs9487053	chr6:109619697	T/C	cg21918786	chr6:109611834	NA	-0.49	-9.19	-0.39	1.35e-18	Reticulocyte fraction of red cells;
LGG	cis	rs7527798	0.592	rs2296159	chr1:207851760	G/A	cg09232269	chr1:207846808	CR1L	-0.38	-7.2	-0.32	2.38e-12	Erythrocyte sedimentation rate;
LGG	cis	rs951366	0.576	rs1832775	chr1:205734032	C/T	cg26354017	chr1:205819088	PM20D1	-0.42	-7.31	-0.32	1.19e-12	Menarche (age at onset);
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg13397359	chr6:42928475	GNMT	0.64	18.54	0.65	8.02e-58	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9487094	0.666	rs4946970	chr6:109706010	C/A	cg01125227	chr6:109776195	MICAL1	0.38	6.69	0.3	6.58e-11	Height;
LGG	cis	rs7818345	0.845	rs4256608	chr8:19267560	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.66	0.3	7.71e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20295040	chr1:192778396	RGS2	0.41	7.26	0.32	1.61e-12	Obesity-related traits;
LGG	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-14.79	-0.57	8.31e-41	Chronic sinus infection;
LGG	cis	rs757278	0.591	rs214159	chr7:117314406	C/A	cg10524701	chr7:117356490	CTTNBP2	0.43	7.81	0.34	3.88e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs7395662	1.000	rs10769390	chr11:48618222	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg05556477	chr5:131705319	SLC22A5	0.84	10.01	0.42	1.69e-21	Rheumatoid arthritis;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02018176	chr4:1364513	KIAA1530	0.65	16.06	0.6	1.94e-46	Longevity;
LGG	trans	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg12395012	chr8:11607386	GATA4	-0.37	-6.76	-0.3	4.18e-11	Neuroticism;
LGG	cis	rs6121246	0.909	rs6087778	chr20:30354142	G/A	cg04935436	chr20:30431758	NA	0.4	7.09	0.31	5.1e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6964587	1.000	rs2097739	chr7:91711466	C/T	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.84e-16	Breast cancer;
LGG	cis	rs12580194	0.554	rs12579852	chr12:55716569	T/A	cg19537932	chr12:55886519	OR6C68	-0.57	-9.98	-0.42	2.32e-21	Cancer;
LGG	cis	rs2016266	0.787	rs4520636	chr12:53752133	G/T	cg04065151	chr12:53682969	ESPL1	-0.49	-7.64	-0.33	1.23e-13	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg06112835	chr11:68658793	MRPL21	0.63	10.57	0.44	1.57e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg24247370	chr13:99142703	STK24	-0.37	-7.11	-0.31	4.49e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs35160687	0.644	rs11687392	chr2:86502663	A/G	cg10973622	chr2:86423274	IMMT	-0.41	-7.24	-0.32	1.83e-12	Night sleep phenotypes;
LGG	cis	rs2342371	0.848	rs13092653	chr3:196200188	C/T	cg15048948	chr3:196158458	UBXN7	-0.4	-6.83	-0.3	2.61e-11	Fat distribution (HIV);
LGG	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg25358565	chr5:93447407	FAM172A	1.35	16.53	0.61	1.46e-48	Diabetic retinopathy;
LGG	cis	rs12701220	0.655	rs10215292	chr7:1135263	A/G	cg00990874	chr7:1149470	C7orf50	-0.81	-14.45	-0.56	2.42e-39	Bronchopulmonary dysplasia;
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg02158880	chr13:53174818	NA	0.68	15.81	0.59	2.47e-45	Lewy body disease;
LGG	cis	rs6750795	0.542	rs1797388	chr2:232415981	T/G	cg19187155	chr2:232395269	NMUR1	0.5	9.27	0.4	7.07e-19	Height;
LGG	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg19676328	chr12:49525230	TUBA1B	-0.65	-10.26	-0.43	2.23e-22	Total cholesterol levels;
LGG	cis	rs6764363	0.504	rs4684335	chr3:283415	T/C	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.69e-13	Sudden cardiac arrest;
LGG	trans	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg27053975	chr1:166958233	MAEL	-0.47	-6.66	-0.3	7.62e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.14	-0.32	3.53e-12	Bipolar disorder;
LGG	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg10556349	chr10:835070	NA	-0.34	-8.62	-0.37	1.04e-16	Survival in rectal cancer;
LGG	cis	rs16912285	0.688	rs1899541	chr11:24339624	T/C	ch.11.24196551F	chr11:24239977	NA	0.93	14.08	0.55	1.01e-37	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg10326726	chr10:51549505	MSMB	0.72	14.61	0.56	5.24e-40	Prostate-specific antigen levels;
LGG	cis	rs9513627	0.920	rs7334943	chr13:100121287	C/G	cg15490075	chr13:100150979	NA	0.68	7.16	0.32	3.14e-12	Obesity-related traits;
LGG	cis	rs9487094	0.813	rs12528712	chr6:109660884	G/T	cg01125227	chr6:109776195	MICAL1	0.51	8.62	0.37	1.07e-16	Height;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg10056627	chr6:42928773	GNMT	0.26	7.15	0.32	3.5e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9611565	0.918	rs9611561	chr22:41757234	C/G	cg03806693	chr22:41940476	POLR3H	-0.96	-16.46	-0.61	2.94e-48	Vitiligo;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.34	7.35	0.32	8.81e-13	Schizophrenia;
LGG	cis	rs7949030	0.626	rs11231144	chr11:62328038	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.41	0.61	4.77e-48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7766436	0.885	rs7742025	chr6:22575798	A/T	cg13666174	chr6:22585274	NA	-0.51	-11.35	-0.47	1.6e-26	Coronary artery disease;
LGG	cis	rs9291683	0.620	rs4383618	chr4:10125151	T/C	cg00071950	chr4:10020882	SLC2A9	-0.33	-6.89	-0.3	1.83e-11	Bone mineral density;
LGG	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg06212747	chr3:49208901	KLHDC8B	0.53	8.63	0.37	9.71e-17	Red cell distribution width;
LGG	cis	rs7296418	0.885	rs1716184	chr12:123637509	G/C	cg00376283	chr12:123451042	ABCB9	0.67	12.43	0.5	8.19e-31	Platelet count;
LGG	cis	rs6586163	1.000	rs6586164	chr10:90752031	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.92	-0.31	1.5e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg17971929	chr21:40555470	PSMG1	-0.71	-13.42	-0.53	6.33e-35	Cognitive function;
LGG	trans	rs3960554	0.808	rs60481386	chr7:75700962	A/G	cg19862616	chr7:65841803	NCRNA00174	0.84	12.73	0.51	4.75e-32	Eotaxin levels;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg00080972	chr5:178986291	RUFY1	-0.48	-8.18	-0.36	2.66e-15	Lung cancer;
LGG	trans	rs7824557	0.564	rs2572386	chr8:11236975	A/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs7646881	1.000	rs73015655	chr3:158451882	A/C	cg19483011	chr3:158453295	NA	-0.64	-9.57	-0.41	6.43e-20	Tetralogy of Fallot;
LGG	cis	rs1065656	0.571	rs12149777	chr16:1834724	A/G	cg00490583	chr16:1843685	IGFALS	-0.42	-9.95	-0.42	2.96e-21	Insulin-like growth factors;
LGG	cis	rs1707322	0.656	rs2991981	chr1:46057144	A/G	cg03146154	chr1:46216737	IPP	-0.54	-10.14	-0.43	6.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3824344	0.507	rs10814501	chr9:37019304	C/T	cg14294708	chr9:37120828	ZCCHC7	0.48	8.06	0.35	6.54e-15	Intelligence;
LGG	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.95	-0.38	8.85e-18	Chronic sinus infection;
LGG	cis	rs2154319	0.887	rs7518880	chr1:41503820	C/A	cg02290550	chr1:41487317	SLFNL1	-0.48	-8.91	-0.38	1.14e-17	Height;
LGG	cis	rs9896933	0.830	rs607544	chr17:80768760	C/G	cg15664640	chr17:80829946	TBCD	-0.66	-9.38	-0.4	2.85e-19	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.6	10.88	0.45	1.02e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg13443165	chr9:33130375	B4GALT1	0.68	11.56	0.47	2.59e-27	IgG glycosylation;
LGG	cis	rs644799	0.544	rs499637	chr11:95569183	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.17	0.52	7.59e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs9467711	0.659	rs66941101	chr6:26530376	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.12	-0.31	4.16e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1555322	0.530	rs7004	chr20:33866753	G/C	cg17927777	chr20:33865990	NA	0.75	10.03	0.42	1.42e-21	Attention deficit hyperactivity disorder;
LGG	cis	rs2404602	0.692	rs2304920	chr15:76993867	T/C	cg05677249	chr15:77158041	SCAPER	-0.31	-6.67	-0.3	7.47e-11	Blood metabolite levels;
LGG	cis	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg19338460	chr6:170058176	WDR27	-0.87	-9.11	-0.39	2.53e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1459104	1.000	rs17580126	chr11:55289993	C/G	cg15704280	chr7:45808275	SEPT13	-0.69	-6.7	-0.3	6.16e-11	Body mass index;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg07414643	chr4:187882934	NA	-0.53	-10.96	-0.45	5.39e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg03517284	chr6:25882590	NA	-0.4	-7.21	-0.32	2.36e-12	Height;
LGG	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg11757124	chr7:157526947	PTPRN2	-0.52	-9.4	-0.4	2.52e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs518919	chr11:95623313	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.67	0.67	4.85e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9913711	0.899	rs9913936	chr17:70074148	A/G	cg09344028	chr17:70110421	NA	0.39	7.66	0.34	1.06e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg14191688	chr11:70257035	CTTN	0.56	8.12	0.35	4.24e-15	Coronary artery disease;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.39	-7.44	-0.33	4.78e-13	Schizophrenia;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.56	0.53	1.69e-35	Lung cancer;
LGG	cis	rs35110281	0.667	rs4819285	chr21:45118970	C/T	cg04455712	chr21:45112962	RRP1B	-0.55	-10.42	-0.44	5.34e-23	Mean corpuscular volume;
LGG	cis	rs12681287	0.640	rs13282351	chr8:87484669	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.71	-0.34	7.58e-14	Caudate activity during reward;
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg09060608	chr5:178986726	RUFY1	0.5	8.93	0.38	1.01e-17	Lung cancer;
LGG	cis	rs1728785	1.000	rs11647432	chr16:68565426	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs911555	0.673	rs7144271	chr14:103890674	A/G	cg24130564	chr14:104152367	KLC1	-0.38	-7.14	-0.32	3.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs622082	chr11:68703959	A/G	cg01988459	chr11:68622903	NA	-0.62	-12.64	-0.51	1.11e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12134245	0.776	rs6688261	chr1:91987034	C/T	cg21854759	chr1:92012499	NA	-0.34	-7.17	-0.32	3.03e-12	Breast cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16160182	chr1:2574031	NA	-0.43	-7.3	-0.32	1.29e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7586879	0.575	rs6712981	chr2:25126230	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg25706552	chr1:244017396	NA	0.51	8.17	0.36	2.91e-15	RR interval (heart rate);
LGG	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg06558623	chr16:89946397	TCF25	0.8	10.28	0.43	1.9e-22	Skin colour saturation;
LGG	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg03929089	chr4:120376271	NA	-0.63	-11.36	-0.47	1.49e-26	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs7169587	chr15:45640379	A/G	cg10760299	chr15:45669010	GATM	0.4	8.0	0.35	9.82e-15	Homoarginine levels;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg16885296	chr6:26284938	NA	0.38	8.27	0.36	1.43e-15	Educational attainment;
LGG	cis	rs17102423	0.661	rs45604339	chr14:65543102	C/T	cg26396452	chr14:65542826	MAX	0.42	8.15	0.35	3.32e-15	Obesity-related traits;
LGG	cis	rs12368653	1.000	rs12371356	chr12:58135420	T/C	cg02175503	chr12:58329896	NA	-0.56	-9.85	-0.42	6.51e-21	Multiple sclerosis;
LGG	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg24692254	chr21:30365293	RNF160	0.64	11.74	0.48	4.92e-28	Pancreatic cancer;
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7829975	0.711	rs4841051	chr8:8685646	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.72	-0.41	1.86e-20	Mood instability;
LGG	cis	rs883565	0.740	rs2037655	chr3:39072754	T/C	cg01426195	chr3:39028469	NA	-0.71	-16.05	-0.6	1.98e-46	Handedness;
LGG	cis	rs9325144	0.560	rs1601745	chr12:38647828	G/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.41	-0.33	6e-13	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	6.98	0.31	1.01e-11	Longevity;
LGG	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	8.12	0.35	4.32e-15	Bone mineral density;
LGG	cis	rs4450131	0.897	rs10901796	chr10:126335586	T/C	cg08799069	chr10:126477246	METTL10	0.31	6.69	0.3	6.31e-11	White blood cell count (basophil);
LGG	cis	rs8180040	0.715	rs6772670	chr3:47191349	G/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg27189623	chr16:705930	WDR90	0.4	7.63	0.33	1.39e-13	Height;
LGG	cis	rs67133203	0.904	rs11169637	chr12:51361608	A/G	cg14688905	chr12:51403056	SLC11A2	0.76	11.3	0.46	2.57e-26	Urinary tract infection frequency;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08793459	chr17:57784647	PTRH2;TMEM49	-0.53	-8.01	-0.35	9.66e-15	Systemic lupus erythematosus;
LGG	cis	rs6665290	0.545	rs6426584	chr1:227374949	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.95	-17.37	-0.63	2.04e-52	Myeloid white cell count;
LGG	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.95	0.42	2.85e-21	Height;
LGG	cis	rs3735485	0.678	rs10258996	chr7:45155888	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.23	-0.39	9.94e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.74	-0.51	4.51e-32	Colorectal cancer;
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.0	-0.46	3.7e-25	Prostate cancer;
LGG	cis	rs4474465	1.000	rs10793315	chr11:78190716	C/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.32	-0.36	9.9e-16	Alzheimer's disease (survival time);
LGG	cis	rs2346177	0.638	rs34186951	chr2:46657659	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.4	7.05	0.31	6.7e-12	HDL cholesterol;
LGG	cis	rs6500395	0.588	rs12918232	chr16:48690695	C/A	cg04672837	chr16:48644449	N4BP1	-0.49	-8.45	-0.37	3.89e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg23762105	chr12:34175262	ALG10	-0.33	-6.88	-0.3	1.98e-11	Morning vs. evening chronotype;
LGG	cis	rs6430585	0.527	rs76380759	chr2:136438517	G/A	cg07169764	chr2:136633963	MCM6	0.99	16.58	0.61	8.75e-49	Corneal structure;
LGG	cis	rs2985684	0.894	rs8005990	chr14:50022248	G/A	cg02151108	chr14:50098012	C14orf104	-0.42	-9.0	-0.39	5.98e-18	Carotid intima media thickness;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.8	0.3	3.29e-11	Schizophrenia;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.45	-0.33	4.62e-13	Lung cancer;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.83	-0.3	2.67e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg21775007	chr8:11205619	TDH	-0.56	-8.75	-0.38	4.05e-17	Retinal vascular caliber;
LGG	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg03735888	chr19:58951602	ZNF132	0.41	8.13	0.35	4.05e-15	Uric acid clearance;
LGG	cis	rs9815354	0.812	rs73069292	chr3:41973963	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2011503	0.882	rs72999030	chr19:19364240	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.83	0.3	2.65e-11	Bipolar disorder;
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg11608241	chr8:8085544	FLJ10661	-0.33	-7.62	-0.33	1.4e-13	Triglycerides;
LGG	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.36	-0.61	8.04e-48	Intelligence (multi-trait analysis);
LGG	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg02071572	chr4:1403502	NA	-0.41	-7.07	-0.31	5.83e-12	Longevity;
LGG	cis	rs61990749	0.597	rs2267768	chr14:78216014	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg05526886	chr2:227700861	RHBDD1	0.4	6.98	0.31	1.01e-11	Pulmonary function;
LGG	cis	rs9341835	0.518	rs6942342	chr6:64176447	T/C	cg00787780	chr6:64151745	NA	0.4	7.0	0.31	8.88e-12	Schizophrenia;
LGG	trans	rs2562456	0.833	rs56187954	chr19:21528060	T/A	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.6e-13	Pain;
LGG	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs3816183	0.756	rs4284880	chr2:43077192	T/C	cg14631114	chr2:43023945	NA	0.45	8.07	0.35	6.2e-15	Hypospadias;
LGG	cis	rs4148883	0.689	rs1800760	chr4:100065626	A/T	cg12011299	chr4:100065546	ADH4	0.42	8.95	0.38	8.59e-18	Alcohol dependence;
LGG	trans	rs1422110	0.718	rs10079231	chr5:85439369	A/G	cg01787110	chr1:109008453	NBPF6	0.68	11.96	0.49	6.23e-29	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs9513627	0.915	rs73556174	chr13:100121797	T/C	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs6708331	1.000	rs10195155	chr2:70354475	G/T	cg01613454	chr2:70366299	NA	0.48	8.8	0.38	2.78e-17	Obesity-related traits;
LGG	cis	rs9560113	0.573	rs1888304	chr13:112242454	A/G	cg14154082	chr13:112174009	NA	0.36	7.84	0.34	3.14e-14	Menarche (age at onset);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14971810	chr2:20251361	LAPTM4A	-0.42	-7.64	-0.33	1.26e-13	Brain structure;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.68	0.34	9.4e-14	Lung cancer;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.698	rs4731217	chr7:124471889	T/C	cg05630886	chr7:124431682	NA	0.33	7.82	0.34	3.6e-14	Cutaneous malignant melanoma;
LGG	cis	rs9309473	0.607	rs11686504	chr2:73579812	T/C	cg20560298	chr2:73613845	ALMS1	-0.49	-8.85	-0.38	1.87e-17	Metabolite levels;
LGG	cis	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.75	-0.57	1.27e-40	IgG glycosylation;
LGG	cis	rs4654748	0.507	rs10799702	chr1:21821880	A/G	cg02390115	chr1:21767211	NBPF3	-0.54	-9.73	-0.41	1.7e-20	Folate pathway vitamin levels;
LGG	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs17039065	1.000	rs11945200	chr4:109402213	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs4950322	0.563	rs6686480	chr1:146583568	G/A	cg22381352	chr1:146742008	CHD1L	-0.43	-7.31	-0.32	1.15e-12	Protein quantitative trait loci;
LGG	cis	rs1348850	0.526	rs6723063	chr2:178491398	C/T	cg22681709	chr2:178499509	PDE11A	-0.51	-6.88	-0.3	1.9e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6598955	0.724	rs12754536	chr1:26639605	T/C	cg10402321	chr1:26617780	UBXN11	-0.36	-6.67	-0.3	7.38e-11	Obesity-related traits;
LGG	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs10851411	0.688	rs17709596	chr15:42767981	C/T	cg21293051	chr15:42870591	STARD9	0.49	7.16	0.32	3.25e-12	Glucose homeostasis traits;
LGG	cis	rs55633855	0.516	rs72970466	chr11:88151320	T/C	cg08522340	chr11:88068493	CTSC	-0.4	-7.11	-0.31	4.47e-12	Body mass index;
LGG	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg06453172	chr10:134556979	INPP5A	-0.56	-8.44	-0.37	3.97e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg15596359	chr8:11213517	TDH	0.42	8.46	0.37	3.67e-16	Retinal vascular caliber;
LGG	cis	rs6582630	0.519	rs8189609	chr12:38281408	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg15971980	chr6:150254442	NA	0.45	8.53	0.37	2.13e-16	Lung cancer;
LGG	cis	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg22437258	chr11:111473054	SIK2	0.41	6.86	0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg17691542	chr6:26056736	HIST1H1C	0.55	9.91	0.42	4.05e-21	Height;
LGG	cis	rs2470578	0.792	rs2733518	chr3:17249603	C/T	cg20981856	chr3:17787350	NA	-0.36	-6.89	-0.31	1.81e-11	Schizophrenia;
LGG	cis	rs4563143	0.675	rs73029049	chr19:29275534	C/A	cg04546413	chr19:29218101	NA	0.75	12.74	0.51	4.35e-32	Methadone dose in opioid dependence;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18515171	chr17:58156344	HEATR6	0.43	7.18	0.32	2.73e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6960043	1.000	rs6972516	chr7:15051789	G/T	cg19272540	chr7:15055459	NA	-0.35	-7.69	-0.34	8.97e-14	Type 2 diabetes;
LGG	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.08	0.42	1.01e-21	Iron status biomarkers;
LGG	cis	rs6988985	0.618	rs62525983	chr8:143988986	C/G	cg10324643	chr8:143916377	GML	0.46	9.48	0.4	1.28e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7937612	1.000	rs10750173	chr11:120288368	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-13.1	-0.52	1.45e-33	Intraocular pressure;
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg20453264	chr5:131705742	SLC22A5	0.57	7.23	0.32	1.99e-12	Rheumatoid arthritis;
LGG	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs9486719	1.000	rs9486719	chr6:97060124	G/A	cg06623918	chr6:96969491	KIAA0776	-0.71	-10.25	-0.43	2.43e-22	Migraine;Coronary artery disease;
LGG	cis	rs9814567	1.000	rs7426847	chr3:134267519	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs854037	0.759	rs13354591	chr5:57056022	C/T	cg08523694	chr5:57076192	NA	0.49	6.86	0.3	2.2e-11	Birth weight;
LGG	cis	rs4730779	0.571	rs10242827	chr7:117067040	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	7.88	0.34	2.4e-14	Waist circumference;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.59	-0.41	5.42e-20	Life satisfaction;
LGG	cis	rs7129556	0.702	rs650171	chr11:77498486	T/C	cg12586386	chr11:77299805	AQP11	0.44	7.23	0.32	2.03e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs2224391	0.554	rs2224392	chr6:5261136	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.09	-0.31	5.06e-12	Height;
LGG	cis	rs3784262	0.740	rs12917536	chr15:58288247	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.1	-0.31	4.61e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs9329221	0.527	rs4841351	chr8:10327367	G/A	cg19847130	chr8:10466454	RP1L1	0.36	7.49	0.33	3.51e-13	Neuroticism;
LGG	cis	rs258892	0.843	rs16901116	chr5:72053382	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg20308403	chr7:2120281	MAD1L1	0.35	7.22	0.32	2.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs981844	0.712	rs4632640	chr4:154742389	G/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.79	-0.41	1.07e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs765787	0.530	rs1648289	chr15:45516494	A/G	cg24006582	chr15:45444508	DUOX1	-0.7	-13.54	-0.53	2.08e-35	Uric acid levels;
LGG	cis	rs9487094	1.000	rs17070580	chr6:109738714	C/T	cg01125227	chr6:109776195	MICAL1	-0.46	-7.83	-0.34	3.43e-14	Height;
LGG	cis	rs7264396	0.623	rs2590984	chr20:34597031	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.48	-0.33	3.68e-13	Total cholesterol levels;
LGG	trans	rs11088226	0.581	rs2236430	chr21:33973408	A/G	cg09050820	chr6:167586206	TCP10L2	-0.8	-13.59	-0.53	1.27e-35	Gastritis;
LGG	cis	rs11122272	0.735	rs2491403	chr1:231511185	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs1620921	0.591	rs2489969	chr6:161264604	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg16507663	chr6:150244633	RAET1G	0.44	7.18	0.32	2.73e-12	Lung cancer;
LGG	trans	rs783540	0.967	rs1269134	chr15:83282628	T/C	cg16105309	chr15:79090380	ADAMTS7	0.4	7.04	0.31	6.86e-12	Schizophrenia;
LGG	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.84e-16	Aortic root size;
LGG	cis	rs10504073	0.525	rs10081464	chr8:50058707	A/G	cg00325661	chr8:49890786	NA	0.53	9.55	0.41	7.41e-20	Blood metabolite ratios;
LGG	cis	rs1010254	0.510	rs723427	chr5:151695769	G/A	cg12297329	chr5:152029980	NA	-0.5	-7.21	-0.32	2.26e-12	Optic nerve measurement (cup area);
LGG	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg04234412	chr22:24373322	LOC391322	0.67	12.18	0.49	8.83e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg13147721	chr7:65941812	NA	0.62	7.26	0.32	1.66e-12	Diabetic kidney disease;
LGG	cis	rs757278	0.507	rs117863639	chr7:117288078	G/A	cg10524701	chr7:117356490	CTTNBP2	0.46	7.84	0.34	3.1e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs75920871	1.000	rs17120233	chr11:116871223	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg09783858	chr11:65769428	EIF1AD;BANF1	0.5	8.9	0.38	1.26e-17	Breast cancer;
LGG	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg20913747	chr6:44695427	NA	-0.6	-10.19	-0.43	3.85e-22	Total body bone mineral density;
LGG	cis	rs3750450	0.718	rs4978776	chr9:111937552	C/T	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	3.07e-48	Diabetic retinopathy;
LGG	cis	rs1401999	0.690	rs6768149	chr3:183636195	T/C	cg01324343	chr3:183735012	ABCC5	0.66	12.73	0.51	4.92e-32	Anterior chamber depth;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14737592	chr12:57914238	DDIT3	0.49	7.46	0.33	4.23e-13	Gut microbiome composition (summer);
LGG	trans	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg21659725	chr3:3221576	CRBN	0.5	7.67	0.34	1.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs3809566	0.526	rs35829897	chr15:63334688	G/C	cg05507819	chr15:63340323	TPM1	-0.69	-9.44	-0.4	1.84e-19	Platelet count;
LGG	cis	rs6714710	0.627	rs6748124	chr2:98519014	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.07e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs6582630	0.599	rs1851114	chr12:38424671	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.52	-0.44	2.34e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs644799	0.672	rs11021347	chr11:95653494	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.79	15.52	0.59	4.72e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg22232500	chr2:134024266	NCKAP5	0.56	7.85	0.34	3.02e-14	Bipolar disorder;
LGG	cis	rs3126085	0.935	rs12742573	chr1:152260103	A/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.09	-0.35	5.16e-15	Atopic dermatitis;
LGG	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg10845886	chr2:3471009	TTC15	-0.48	-9.76	-0.41	1.39e-20	Neurofibrillary tangles;
LGG	cis	rs870825	0.616	rs2310108	chr4:185639475	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	cis	rs67460515	0.892	rs1478566	chr3:161030335	A/T	cg04691961	chr3:161091175	C3orf57	-0.47	-9.47	-0.4	1.46e-19	Parkinson's disease;
LGG	cis	rs6692729	0.769	rs12758915	chr1:227058344	A/G	cg08708961	chr1:227070630	PSEN2	-0.3	-7.62	-0.33	1.41e-13	Electrodermal activity;
LGG	cis	rs10744625	0.836	rs12424738	chr12:3866895	A/G	cg22221074	chr12:3862810	EFCAB4B	0.35	7.51	0.33	3.1400000000000003e-13	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04533881	chr14:50583218	C14orf138	0.37	6.71	0.3	5.86e-11	Obesity-related traits;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg22348356	chr13:114891224	RASA3	0.37	7.0	0.31	9.2e-12	Schizophrenia;
LGG	cis	rs727563	0.635	rs5758444	chr22:42133921	T/A	cg06481639	chr22:41940642	POLR3H	0.53	7.65	0.33	1.21e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg00666640	chr1:248458726	OR2T12	0.57	9.15	0.39	1.78e-18	Common traits (Other);
LGG	cis	rs71636213	0.527	rs12652103	chr5:79660190	A/G	cg12576332	chr5:79646847	LOC441089	-0.49	-7.73	-0.34	6.97e-14	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs8067545	0.578	rs9901336	chr17:20064190	G/A	cg09818912	chr17:20140352	CYTSB	-0.32	-7.46	-0.33	4.28e-13	Schizophrenia;
LGG	cis	rs10876993	0.855	rs1689604	chr12:58048304	T/C	cg18357645	chr12:58087776	OS9	0.69	12.36	0.5	1.59e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg03264133	chr6:25882463	NA	-0.63	-11.59	-0.47	1.93e-27	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.708	rs2854307	chr17:29652147	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.07	-0.35	5.9e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2721811	0.738	rs1544366	chr7:24758248	A/G	cg06301139	chr7:24798175	DFNA5	-0.39	-7.28	-0.32	1.42e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg24631222	chr15:78858424	CHRNA5	0.47	7.26	0.32	1.64e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7264396	0.635	rs6060719	chr20:34546013	A/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.13	-0.31	3.88e-12	Total cholesterol levels;
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.99	-0.45	3.89e-25	Personality dimensions;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs7546668	1.000	rs4233535	chr1:15845197	G/C	cg21858823	chr1:15850916	CASP9	0.37	6.87	0.3	2.03e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9810089	0.843	rs696081	chr3:136047189	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.3	-0.36	1.18e-15	Gestational age at birth (child effect);
LGG	cis	rs10046574	0.561	rs7781454	chr7:135205422	A/G	cg27474649	chr7:135195673	CNOT4	0.7	9.13	0.39	2.21e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.88	0.42	5.21e-21	Tonsillectomy;
LGG	cis	rs504918	0.616	rs4289301	chr3:123982611	C/T	cg05766129	chr3:123988013	KALRN	0.62	11.58	0.47	2.03e-27	Schizophrenia;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg19673125	chr6:150240577	RAET1G	0.35	8.51	0.37	2.38e-16	Lung cancer;
LGG	cis	rs7666738	0.830	rs28451101	chr4:99001190	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1018836	0.923	rs4735268	chr8:91629715	C/T	cg16814680	chr8:91681699	NA	-0.82	-14.98	-0.57	1.22e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs9914544	1.000	rs9916245	chr17:18766825	C/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.38	-0.32	7.55e-13	Educational attainment (years of education);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17004212	chr13:50656130	DLEU1;DLEU2	0.31	6.67	0.3	7.11e-11	Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23237976	chr1:236318493	GPR137B	0.38	7.35	0.32	9.17e-13	Menarche (age at onset);
LGG	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg23625390	chr15:77176239	SCAPER	-0.69	-13.42	-0.53	6.22e-35	Blood metabolite levels;
LGG	trans	rs8002861	0.902	rs1445557	chr13:44464827	C/T	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.58	-0.33	1.9e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs919433	0.648	rs3097384	chr2:198278834	T/A	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10751667	0.666	rs7396509	chr11:956761	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.7e-15	Alzheimer's disease (late onset);
LGG	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12923728	chr3:195709715	SDHAP1	-0.76	-14.45	-0.56	2.42e-39	Pancreatic cancer;
LGG	cis	rs476633	0.691	rs6492997	chr15:41541171	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.38	-0.43	8.06e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs1784581	0.651	rs3016568	chr6:162388158	G/A	cg17173639	chr6:162384350	PARK2	-0.76	-17.12	-0.62	2.83e-51	Itch intensity from mosquito bite;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg06925179	chr17:43578568	NA	0.41	9.75	0.41	1.51e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs2074585	0.517	rs11638010	chr15:91079920	A/G	cg22089800	chr15:90895588	ZNF774	-0.52	-8.68	-0.37	6.72e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.12	-0.43	6.97e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs600231	0.542	rs34527830	chr11:65240863	G/A	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.65	-0.37	8.55e-17	Bone mineral density;
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg26513180	chr16:89883248	FANCA	0.61	10.73	0.45	3.99e-24	Vitiligo;
LGG	cis	rs3733585	0.746	rs4318650	chr4:10016868	T/C	cg08250081	chr4:10125330	NA	0.43	8.37	0.36	6.88e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg04287289	chr16:89883240	FANCA	0.8	16.56	0.61	1.08e-48	Vitiligo;
LGG	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg16141378	chr3:129829833	LOC729375	0.38	8.37	0.36	6.64e-16	Triglycerides;
LGG	cis	rs116095464	0.558	rs1812843	chr5:267658	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg20368463	chr18:77673604	PQLC1	0.57	11.04	0.46	2.67e-25	Schizophrenia;
LGG	cis	rs950776	0.518	rs4886571	chr15:78833758	G/A	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.44	-0.4	1.81e-19	Sudden cardiac arrest;
LGG	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.04	0.35	7.37e-15	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.29	0.4	6.12e-19	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05901451	chr6:126070800	HEY2	0.7	13.47	0.53	3.87e-35	Brugada syndrome;
LGG	cis	rs4478037	0.558	rs4456812	chr3:33080882	G/A	cg19404215	chr3:33155277	CRTAP	-0.68	-6.79	-0.3	3.52e-11	Major depressive disorder;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.41	-0.36	5.28e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1008375	0.898	rs7670500	chr4:17586957	A/G	cg10189774	chr4:17578691	LAP3	0.41	7.44	0.33	5.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618501	0.633	rs2252833	chr3:50004209	C/T	cg05623727	chr3:50126028	RBM5	0.33	7.27	0.32	1.58e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.79	-0.41	1.07e-20	Lung cancer;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.09	-0.46	1.72e-25	Personality dimensions;
LGG	cis	rs10937275	0.826	rs71322421	chr3:186640688	T/A	cg13419791	chr3:186648285	ST6GAL1	0.77	7.76	0.34	5.38e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs17685	0.712	rs1859792	chr7:75789264	T/C	cg19862616	chr7:65841803	NCRNA00174	1.05	23.71	0.74	6.24e-82	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs74781061	0.929	rs8025976	chr15:74870038	T/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.09	-0.31	5.13e-12	Endometriosis;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.6	-0.41	5.09e-20	Lung cancer;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.14	-0.32	3.54e-12	Menopause (age at onset);
LGG	cis	rs3008870	0.755	rs2815360	chr1:67494458	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.71	15.17	0.58	1.77e-42	Lymphocyte percentage of white cells;
LGG	cis	rs896854	0.715	rs12548874	chr8:95935164	A/C	cg16049864	chr8:95962084	TP53INP1	0.39	8.53	0.37	2.09e-16	Type 2 diabetes;
LGG	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg16586182	chr3:47516702	SCAP	0.78	15.58	0.59	2.55e-44	Colorectal cancer;
LGG	trans	rs9929218	0.559	rs11642362	chr16:68811307	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	18.47	0.65	1.74e-57	Colorectal cancer;
LGG	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.85	0.34	2.96e-14	Retinal vascular caliber;
LGG	trans	rs1814175	0.791	rs7395713	chr11:49877887	A/G	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg00717180	chr2:96193071	NA	-0.43	-7.59	-0.33	1.73e-13	HDL cholesterol;
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg11584989	chr19:19387371	SF4	-0.43	-7.69	-0.34	8.68e-14	Tonsillectomy;
LGG	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.22	-0.32	2.09e-12	Aortic root size;
LGG	cis	rs2836974	0.568	rs2836969	chr21:40648265	G/A	cg11890956	chr21:40555474	PSMG1	-0.99	-21.9	-0.71	1.78e-73	Cognitive function;
LGG	cis	rs875971	0.660	rs10229345	chr7:65982168	G/C	cg11764359	chr7:65958608	NA	0.63	10.7	0.45	5.02e-24	Aortic root size;
LGG	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg03644281	chr6:41068752	NFYA;LOC221442	-0.42	-6.95	-0.31	1.28e-11	Alzheimer's disease (late onset);
LGG	cis	rs12476592	0.602	rs11898615	chr2:63748284	C/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.34e-11	Childhood ear infection;
LGG	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.9	-0.31	1.75e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg13047869	chr3:10149882	C3orf24	0.49	7.69	0.34	9.19e-14	Alzheimer's disease;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs11098499	0.775	rs10021601	chr4:120282563	G/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.23e-12	Lung cancer;
LGG	trans	rs453301	0.506	rs476845	chr8:8622877	A/G	cg21775007	chr8:11205619	TDH	-0.42	-6.81	-0.3	3.06e-11	Joint mobility (Beighton score);
LGG	cis	rs11700980	0.551	rs8127818	chr21:30117123	G/T	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg13334819	chr7:99746414	C7orf59	-0.48	-7.37	-0.32	8.11e-13	Coronary artery disease;
LGG	cis	rs9902453	1.000	rs4465649	chr17:28394747	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.41	-0.53	6.99e-35	Coffee consumption (cups per day);
LGG	cis	rs57590327	0.503	rs12638997	chr3:81844912	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.83	-0.34	3.33e-14	Extraversion;
LGG	cis	rs2204008	0.837	rs11180549	chr12:38236950	A/G	cg13010199	chr12:38710504	ALG10B	0.69	13.78	0.54	1.94e-36	Bladder cancer;
LGG	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.59	0.41	5.6e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17270561	0.579	rs10456326	chr6:25919662	G/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.68	-0.3	6.69e-11	Iron status biomarkers;
LGG	cis	rs35146811	0.807	rs6465761	chr7:99620277	G/C	cg22906224	chr7:99728672	NA	0.55	8.95	0.38	8.97e-18	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs34974928	chr7:65364006	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs644148	0.730	rs2117383	chr19:44978298	A/C	cg15540054	chr19:45004280	ZNF180	0.45	8.06	0.35	6.35e-15	Personality dimensions;
LGG	cis	rs10883723	0.810	rs7074343	chr10:104283165	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17270561	0.636	rs6923367	chr6:25745852	A/T	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.24e-12	Iron status biomarkers;
LGG	cis	rs72945132	0.882	rs7942613	chr11:70210675	C/T	cg14088196	chr11:70211408	PPFIA1	0.92	12.98	0.52	4.42e-33	Coronary artery disease;
LGG	trans	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg18187862	chr3:45730750	SACM1L	-0.68	-11.01	-0.46	3.4e-25	Primary sclerosing cholangitis;
LGG	cis	rs638893	0.636	rs61901411	chr11:118665324	C/T	cg22253036	chr11:118662786	DDX6	-0.49	-7.28	-0.32	1.41e-12	Vitiligo;
LGG	cis	rs9646954	0.542	rs4149512	chr2:101022886	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.21	0.49	6.64e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	1.000	rs7954584	chr12:122461566	G/A	cg22168489	chr12:122356033	WDR66	0.32	7.66	0.34	1.07e-13	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	trans	rs1728785	0.688	rs7203363	chr16:68587692	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.77	-0.48	3.79e-28	Tonsillectomy;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.46e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg19847130	chr8:10466454	RP1L1	0.31	6.65	0.3	8.27e-11	Neuroticism;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg04025307	chr7:1156635	C7orf50	0.65	12.55	0.5	2.78e-31	Longevity;Endometriosis;
LGG	cis	rs6688613	0.685	rs6427047	chr1:166914258	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.45	6.96	0.31	1.15e-11	Refractive astigmatism;
LGG	trans	rs4714291	0.802	rs3008833	chr6:39986303	G/A	cg02267698	chr19:7991119	CTXN1	-0.59	-9.5	-0.4	1.12e-19	Strep throat;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg08621203	chr6:150244597	RAET1G	0.45	7.76	0.34	5.52e-14	Lung cancer;
LGG	cis	rs7267979	0.932	rs6107052	chr20:25530838	G/A	cg06421707	chr20:25228305	PYGB	0.46	9.74	0.41	1.65e-20	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08483876	chr8:145910754	NA	0.44	7.98	0.35	1.15e-14	Obesity-related traits;
LGG	cis	rs9815354	0.812	rs73073326	chr3:41834195	G/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg21963583	chr11:68658836	MRPL21	0.59	10.19	0.43	3.97e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35123781	1.000	rs589153	chr5:139057548	A/G	cg21230503	chr5:139085173	NA	0.31	7.46	0.33	4.28e-13	Schizophrenia;
LGG	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg10326726	chr10:51549505	MSMB	-0.67	-14.03	-0.55	1.57e-37	Prostate-specific antigen levels;
LGG	cis	rs896854	0.625	rs13281709	chr8:95972819	T/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.77e-17	Type 2 diabetes;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.05	0.39	3.85e-18	Lung cancer;
LGG	cis	rs9487094	0.848	rs1322816	chr6:109703727	C/A	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.15e-18	Height;
LGG	trans	rs12310956	0.510	rs10772109	chr12:33839548	A/C	cg13010199	chr12:38710504	ALG10B	-0.43	-8.37	-0.36	6.85e-16	Morning vs. evening chronotype;
LGG	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.5	-0.37	2.64e-16	Blood protein levels;
LGG	cis	rs9309473	1.000	rs6724782	chr2:73679990	T/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.5	-0.33	3.22e-13	Metabolite levels;
LGG	cis	rs3796352	1.000	rs10510761	chr3:52965255	A/G	cg12962167	chr3:53033115	SFMBT1	-0.72	-7.99	-0.35	1.07e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs11627756	0.915	rs11850368	chr14:103131770	G/C	cg01864069	chr14:103024347	NA	0.42	6.77	0.3	3.82e-11	Mean platelet volume;
LGG	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg25373794	chr1:162760220	HSD17B7	-0.41	-6.69	-0.3	6.41e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs36093844	0.706	rs11828105	chr11:85550384	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.36	-0.32	8.23e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg20587970	chr11:113659929	NA	-1.42	-24.91	-0.76	1.57e-87	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.771	rs10275045	chr7:1920826	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-7.83	-0.34	3.46e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs735539	0.521	rs2585896	chr13:21398861	A/G	cg04906043	chr13:21280425	IL17D	-0.46	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs4819052	0.959	rs8130866	chr21:46672112	G/A	cg06618935	chr21:46677482	NA	-0.53	-9.43	-0.4	1.97e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Vitiligo;
LGG	trans	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs4731207	0.596	rs1481343	chr7:124652271	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs9894429	1.000	rs9674872	chr17:79581931	T/A	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs4363385	0.818	rs407448	chr1:153007504	C/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.88	-0.38	1.5e-17	Inflammatory skin disease;
LGG	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg13010199	chr12:38710504	ALG10B	0.64	13.5	0.53	2.83e-35	Bladder cancer;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg11301795	chr4:187892539	NA	-0.95	-24.86	-0.76	2.69e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4740619	0.619	rs1328280	chr9:16030903	C/T	cg14451791	chr9:16040625	NA	0.44	11.32	0.47	2.24e-26	Body mass index;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00101895	chr6:108279135	SEC63	0.43	7.4	0.33	6.32e-13	Bipolar disorder;
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg07308232	chr7:1071921	C7orf50	-0.73	-14.47	-0.56	2.14e-39	Longevity;Endometriosis;
LGG	cis	rs988958	0.567	rs34117938	chr2:42258394	A/C	cg27252766	chr2:42229092	NA	0.53	8.07	0.35	6.1e-15	Hypospadias;
LGG	cis	rs9322193	0.923	rs1112729	chr6:150087627	C/A	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.17	0.58	1.75e-42	Alzheimer's disease;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg07142201	chr11:109293216	C11orf87	0.52	9.03	0.39	4.8e-18	Schizophrenia;
LGG	cis	rs2415984	0.600	rs2415958	chr14:46806262	C/G	cg14871534	chr14:47121158	RPL10L	-0.55	-9.45	-0.4	1.63e-19	Number of children ever born;
LGG	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg04455712	chr21:45112962	RRP1B	0.52	10.02	0.42	1.67e-21	Mean corpuscular volume;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg26513180	chr16:89883248	FANCA	1.03	9.61	0.41	4.82e-20	Skin colour saturation;
LGG	cis	rs9467773	0.584	rs1021372	chr6:26632444	T/C	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	trans	rs11088226	1.000	rs2833888	chr21:33927560	A/G	cg09050820	chr6:167586206	TCP10L2	0.66	9.71	0.41	2.1e-20	Gastritis;
LGG	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.53	0.37	2.17e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6694672	1.000	rs6702340	chr1:196945050	G/T	cg13682187	chr1:196946512	CFHR5	-0.49	-6.68	-0.3	6.73e-11	Asthma;
LGG	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg15454534	chr1:248569605	OR2T1	0.38	6.9	0.31	1.74e-11	Common traits (Other);
LGG	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.87	-0.3	2.1e-11	Blood metabolite levels;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs898097	0.607	rs2199111	chr17:80823203	A/G	cg02711726	chr17:80685570	FN3KRP	0.4	7.87	0.34	2.61e-14	Breast cancer;
LGG	trans	rs9467711	0.659	rs13216828	chr6:26373507	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs988958	0.675	rs11894053	chr2:42229545	C/T	cg19376973	chr2:42229025	NA	-0.61	-9.86	-0.42	6.28e-21	Hypospadias;
LGG	cis	rs3770081	1.000	rs3770066	chr2:86392350	A/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-7.14	-0.32	3.55e-12	Facial emotion recognition (sad faces);
LGG	cis	rs4936894	0.500	rs6590056	chr11:124170064	A/G	cg27160556	chr11:124181099	OR8D1	0.47	10.82	0.45	1.83e-24	Aging (time to death);
LGG	cis	rs10191773	0.535	rs56187472	chr2:113111668	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.77	9.51	0.4	1.02e-19	Yeast infection;
LGG	cis	rs6964587	1.000	rs3753108	chr7:91629984	T/G	cg17063962	chr7:91808500	NA	0.49	8.71	0.38	5.43e-17	Breast cancer;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.34	-0.32	9.46e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs41005	0.967	rs17433703	chr2:8115300	A/G	cg03155496	chr2:8117019	LOC339788	0.93	22.71	0.73	2.72e-77	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7712401	0.601	rs40818	chr5:122295073	T/C	cg19412675	chr5:122181750	SNX24	0.41	6.9	0.31	1.76e-11	Mean platelet volume;
LGG	cis	rs10463554	0.963	rs3776859	chr5:102352034	A/C	cg23492399	chr5:102201601	PAM	-0.49	-7.4	-0.33	6.45e-13	Parkinson's disease;
LGG	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg06494592	chr3:125709126	NA	-0.52	-6.65	-0.3	8.41e-11	Blood pressure (smoking interaction);
LGG	cis	rs4684776	0.935	rs6781986	chr3:11374899	T/A	cg24705426	chr3:11550659	ATG7	-0.47	-8.77	-0.38	3.44e-17	Small vessel stroke;
LGG	cis	rs1451375	0.669	rs4469404	chr7:50647062	C/T	cg00647317	chr7:50633725	DDC	0.33	7.49	0.33	3.47e-13	Malaria;
LGG	trans	rs75804782	0.641	rs72983853	chr2:239324210	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.92	0.38	1.11e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg01221209	chr5:554886	NA	-0.49	-7.77	-0.34	5.22e-14	Obesity-related traits;
LGG	cis	rs6500395	0.962	rs9922356	chr16:48640025	C/T	cg16662043	chr16:48846231	NA	0.38	7.51	0.33	3.1400000000000003e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.02	-0.55	1.73e-37	Alzheimer's disease;
LGG	cis	rs2120243	0.538	rs4680360	chr3:157094479	C/T	cg24825693	chr3:157122686	VEPH1	0.57	12.66	0.51	9.73e-32	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg05861140	chr6:150128134	PCMT1	-0.35	-6.68	-0.3	6.79e-11	Lung cancer;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs875971	0.545	rs801199	chr7:66025273	A/G	cg11764359	chr7:65958608	NA	-0.63	-9.81	-0.41	8.89e-21	Aortic root size;
LGG	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.81	0.3	3.09e-11	Total cholesterol levels;
LGG	cis	rs6878727	0.850	rs11241738	chr5:123721425	A/T	cg01806427	chr5:123737813	NA	0.32	6.85	0.3	2.36e-11	Breast cancer;
LGG	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	7.44	0.33	5.08e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.42e-31	Motion sickness;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg05863683	chr7:1912471	MAD1L1	0.37	7.37	0.32	8.16e-13	Schizophrenia;
LGG	cis	rs3767633	0.800	rs2880055	chr1:161922365	C/T	cg09175582	chr1:161736000	ATF6	0.6	7.45	0.33	4.58e-13	IgG glycosylation;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.62	0.59	1.74e-44	Obesity-related traits;
LGG	trans	rs6787172	0.622	rs4680426	chr3:158053448	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.39	-0.32	6.99e-13	Subjective well-being;
LGG	cis	rs6809651	0.524	rs4686730	chr3:185805993	C/T	cg00760338	chr3:185826511	ETV5	-0.9	-14.77	-0.57	1.03e-40	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.89	0.34	2.15e-14	Retinal vascular caliber;
LGG	cis	rs700651	0.789	rs882954	chr2:198907444	A/G	cg00792783	chr2:198669748	PLCL1	0.62	9.77	0.41	1.27e-20	Intracranial aneurysm;
LGG	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.38	-0.32	7.36e-13	Systolic blood pressure;
LGG	cis	rs7945705	0.902	rs10769980	chr11:9014180	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.35	0.47	1.62e-26	Hemoglobin concentration;
LGG	cis	rs6088580	0.542	rs6059882	chr20:33090167	T/C	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	8.92e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.95	0.31	1.23e-11	Lung cancer;
LGG	cis	rs4936894	0.519	rs11219530	chr11:124118080	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-10.27	-0.43	1.91e-22	Aging (time to death);
LGG	cis	rs7551222	0.752	rs10793767	chr1:204549564	A/C	cg20240347	chr1:204465584	NA	-0.54	-10.93	-0.45	6.86e-25	Schizophrenia;
LGG	trans	rs2797160	0.651	rs1268067	chr6:126036621	T/C	cg05039488	chr6:79577232	IRAK1BP1	0.47	8.14	0.35	3.57e-15	Endometrial cancer;
LGG	cis	rs17253792	0.822	rs74051609	chr14:56171132	G/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.81	-0.51	2.18e-32	Putamen volume;
LGG	cis	rs1691799	0.867	rs1168348	chr12:66757168	G/A	cg16791601	chr12:66731901	HELB	-0.65	-15.45	-0.58	1.02e-43	White blood cell count (basophil);
LGG	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg11764359	chr7:65958608	NA	0.81	15.1	0.57	3.7e-42	Aortic root size;
LGG	cis	rs1816752	0.819	rs4770665	chr13:24988948	G/A	cg22771759	chr13:24902376	NA	0.4	6.77	0.3	3.84e-11	Obesity-related traits;
LGG	cis	rs17688076	0.511	rs2418738	chr16:68122604	G/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.91e-12	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg05091796	chr16:4465799	CORO7	-0.85	-13.54	-0.53	2.02e-35	Schizophrenia;
LGG	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs7647973	1.000	rs7648995	chr3:49438803	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.69	-0.34	8.96e-14	Menarche (age at onset);
LGG	cis	rs11997175	0.550	rs7463110	chr8:33837033	A/C	ch.8.33884649F	chr8:33765107	NA	0.41	7.57	0.33	2.02e-13	Body mass index;
LGG	cis	rs6725041	0.766	rs7560301	chr2:213091598	C/T	cg20637307	chr2:213403960	ERBB4	-0.36	-6.84	-0.3	2.53e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs1419980	1.000	rs1419980	chr12:7774892	A/G	cg25828445	chr12:7781288	NA	-0.74	-7.89	-0.34	2.18e-14	HDL cholesterol levels;
LGG	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs8014204	0.804	rs35641442	chr14:75207263	G/A	cg06637938	chr14:75390232	RPS6KL1	0.77	15.34	0.58	3.17e-43	Caffeine consumption;
LGG	cis	rs9463078	0.774	rs9357484	chr6:45265882	C/A	cg25276700	chr6:44698697	NA	-0.4	-8.53	-0.37	2.08e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-11.75	-0.48	4.48e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.51	8.49	0.37	2.81e-16	Colorectal cancer;
LGG	cis	rs4936894	0.500	rs12283067	chr11:124070087	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.07	-0.42	1.1e-21	Aging (time to death);
LGG	cis	rs2952156	0.920	rs2517957	chr17:37838716	G/A	cg00129232	chr17:37814104	STARD3	-0.75	-16.22	-0.6	3.59e-47	Asthma;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs12477438	0.520	rs13010904	chr2:99754289	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	trans	rs9354308	0.714	rs9342512	chr6:66589763	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.89	-0.3	1.85e-11	Metabolite levels;
LGG	cis	rs8062405	0.755	rs7193402	chr16:28586127	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.14	0.43	5.88e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs868036	0.718	rs4776984	chr15:68118194	A/C	cg22044901	chr15:68126292	NA	-0.39	-6.74	-0.3	4.74e-11	Restless legs syndrome;
LGG	cis	rs424971	1.000	rs768410	chr16:85945728	A/C	cg10334323	chr16:85945517	IRF8	-0.33	-6.97	-0.31	1.08e-11	Monocyte count;
LGG	cis	rs6743376	0.556	rs1374285	chr2:113818738	G/A	cg05949173	chr2:113825882	IL1F10	0.48	9.07	0.39	3.42e-18	Inflammatory biomarkers;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg00405596	chr8:11794950	NA	-0.58	-9.97	-0.42	2.52e-21	Monocyte count;
LGG	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg08344181	chr3:125677491	NA	-0.91	-9.05	-0.39	3.86e-18	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2204008	0.594	rs2711545	chr12:38061039	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.46	-0.37	3.5e-16	Bladder cancer;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg18538332	chr22:24372958	LOC391322	-0.49	-8.08	-0.35	5.84e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg22974920	chr21:40686053	BRWD1	-0.44	-7.03	-0.31	7.55e-12	Cognitive function;
LGG	cis	rs897080	0.552	rs1067323	chr2:44630018	T/G	cg00619915	chr2:44497795	NA	-0.49	-6.78	-0.3	3.67e-11	Height;
LGG	trans	rs9914544	0.545	rs8068683	chr17:18761827	T/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.57	-0.33	2.01e-13	Educational attainment (years of education);
LGG	cis	rs1682825	0.547	rs17028925	chr3:10777632	A/G	cg23512531	chr3:10780469	NA	0.56	9.06	0.39	3.58e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs4481887	0.800	rs10888342	chr1:248441999	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.59	-0.41	5.58e-20	Common traits (Other);
LGG	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg19336497	chr11:14380999	RRAS2	-0.57	-11.65	-0.48	1.08e-27	Sense of smell;
LGG	cis	rs62025270	0.547	rs338536	chr15:86197240	G/A	cg25843651	chr15:86329602	KLHL25	0.55	9.27	0.4	6.94e-19	Idiopathic pulmonary fibrosis;
LGG	cis	rs9464760	0.527	rs9476759	chr6:15158709	T/C	cg15799072	chr6:15248335	JARID2	0.62	8.02	0.35	8.97e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7168592	1.000	rs6598435	chr15:101742947	A/G	cg24254196	chr15:101719523	CHSY1	-0.64	-7.16	-0.32	3.11e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs11627756	0.958	rs10131189	chr14:103091440	C/G	cg01864069	chr14:103024347	NA	-0.41	-6.76	-0.3	4.15e-11	Mean platelet volume;
LGG	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg16680214	chr1:154839983	KCNN3	-0.36	-6.83	-0.3	2.63e-11	Prostate cancer;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg15971980	chr6:150254442	NA	0.44	8.32	0.36	1.02e-15	Lung cancer;
LGG	cis	rs4900538	0.855	rs1209151	chr14:102893756	C/T	cg18135206	chr14:102964638	TECPR2	-0.7	-12.37	-0.5	1.47e-30	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg19182353	chr11:118479428	PHLDB1	-0.55	-10.98	-0.45	4.36e-25	Cholesterol, total;
LGG	cis	rs258892	0.895	rs7737643	chr5:72058445	G/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs3761847	0.622	rs10818498	chr9:123787566	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	9.99	0.42	2.1e-21	Rheumatoid arthritis;
LGG	trans	rs8073060	0.586	rs225300	chr17:33922428	C/T	cg19694781	chr19:47549865	TMEM160	-1.13	-17.25	-0.63	7.77e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs763121	0.853	rs6519119	chr22:38989007	C/G	cg06022373	chr22:39101656	GTPBP1	0.86	17.24	0.63	8.38e-52	Menopause (age at onset);
LGG	cis	rs617791	0.530	rs10791835	chr11:65750924	C/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	8.63	0.37	9.79e-17	Breast cancer;
LGG	cis	rs12431410	0.584	rs34006462	chr14:60236571	G/A	cg07950296	chr14:60194823	RTN1	-0.41	-7.7	-0.34	8.08e-14	Schizophrenia;
LGG	cis	rs7089973	0.604	rs17663670	chr10:116596269	A/C	cg03647239	chr10:116582469	FAM160B1	-0.42	-7.44	-0.33	4.99e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9790314	0.715	rs7622047	chr3:160770505	G/A	cg03342759	chr3:160939853	NMD3	-0.5	-8.34	-0.36	8.42e-16	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11765430	chr4:331396	ZNF141	0.45	7.21	0.32	2.32e-12	Cognitive performance;
LGG	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg21479132	chr6:26055353	NA	0.81	8.18	0.36	2.71e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs75920871	0.588	rs1815788	chr11:116834971	T/C	cg20608306	chr11:116969690	SIK3	-0.41	-10.8	-0.45	2.18e-24	Subjective well-being;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg18402987	chr7:1209562	NA	0.72	10.67	0.44	6.25e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg20673091	chr1:2541236	MMEL1	0.78	19.08	0.66	2.66e-60	Ulcerative colitis;
LGG	cis	rs4891159	0.548	rs617823	chr18:74120233	A/G	cg24786174	chr18:74118243	ZNF516	0.69	17.11	0.62	3.36e-51	Longevity;
LGG	trans	rs9393777	0.778	rs66841633	chr6:27382386	G/T	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs736801	0.740	rs12515180	chr5:131785684	C/T	cg21138405	chr5:131827807	IRF1	-0.29	-6.97	-0.31	1.1e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs13082711	0.522	rs653886	chr3:27343549	C/T	cg02860705	chr3:27208620	NA	0.58	11.11	0.46	1.39e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg17971929	chr21:40555470	PSMG1	0.69	9.79	0.41	1.11e-20	Cognitive function;
LGG	trans	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg16141378	chr3:129829833	LOC729375	-0.5	-12.12	-0.49	1.52e-29	Mood instability;
LGG	cis	rs10934753	0.609	rs2077523	chr3:125905389	A/C	cg11252792	chr3:125932053	NA	0.52	10.65	0.44	7.83e-24	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2587949	0.615	rs2262390	chr3:4202180	C/T	cg16519197	chr3:4211558	NA	-0.32	-6.76	-0.3	4.21e-11	Periodontitis (DPAL);
LGG	cis	rs4740619	0.870	rs9650677	chr9:15544388	A/G	cg14451791	chr9:16040625	NA	-0.39	-9.87	-0.42	5.53e-21	Body mass index;
LGG	cis	rs7973719	1.000	rs12828421	chr12:7335217	C/T	cg01074767	chr12:7262137	C1RL;LOC283314	0.3	7.72	0.34	7.12e-14	IgG glycosylation;
LGG	cis	rs2730245	1.000	rs2730241	chr7:158723014	T/C	cg11984989	chr7:158649758	WDR60	-0.96	-19.69	-0.68	3.8e-63	Height;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg11062466	chr8:58055876	NA	0.53	9.07	0.39	3.36e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.623	rs11127021	chr2:86474919	C/T	cg10973622	chr2:86423274	IMMT	-0.42	-7.41	-0.33	6.08e-13	Night sleep phenotypes;
LGG	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg11812906	chr14:75593930	NEK9	0.53	9.87	0.42	5.79e-21	Height;
LGG	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.63	0.59	1.5e-44	Body mass index;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.31	0.32	1.21e-12	Obesity-related traits;
LGG	cis	rs11700980	0.551	rs2832019	chr21:30112207	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.7	-0.3	5.95e-11	QRS complex (12-leadsum);
LGG	trans	rs2736345	0.788	rs2409780	chr8:11337587	T/C	cg02002194	chr4:3960332	NA	-0.42	-6.8	-0.3	3.21e-11	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs11098499	1.000	rs11098499	chr4:120187611	C/T	cg24375607	chr4:120327624	NA	0.64	10.62	0.44	9.95e-24	Corneal astigmatism;
LGG	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg26513180	chr16:89883248	FANCA	0.43	7.11	0.31	4.29e-12	Vitiligo;
LGG	cis	rs11626933	1.000	rs61989986	chr14:90739180	G/A	cg14092571	chr14:90743983	NA	-0.81	-16.35	-0.61	9.06e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.826	rs12205642	chr6:45331765	T/C	cg20913747	chr6:44695427	NA	-0.6	-9.89	-0.42	4.85e-21	Total body bone mineral density;
LGG	trans	rs61931739	0.629	rs1842886	chr12:33704257	A/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.6	-0.37	1.25e-16	Morning vs. evening chronotype;
LGG	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15664640	chr17:80829946	TBCD	0.81	16.03	0.6	2.55e-46	Breast cancer;
LGG	cis	rs7615952	0.641	rs7632497	chr3:125783086	A/C	cg18479299	chr3:125709523	NA	-0.58	-7.47	-0.33	4.01e-13	Blood pressure (smoking interaction);
LGG	cis	rs75229567	0.618	rs11177849	chr12:70182473	C/T	cg10114359	chr12:70132523	RAB3IP	-1.24	-10.61	-0.44	1.05e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-9.22	-0.39	1.08e-18	Yeast infection;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01148728	chr11:117198424	CEP164	0.39	6.8	0.3	3.33e-11	Body mass index;
LGG	trans	rs2243480	1.000	rs2420171	chr7:65637760	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	6.91e-19	Diabetic kidney disease;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg06197492	chr11:2016605	H19	0.49	9.99	0.42	2.02e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11207507	chr13:80915118	SPRY2	0.46	7.39	0.32	7.09e-13	Gut microbiome composition (summer);
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.16	-0.32	3.2e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg05650719	chr12:132293520	NA	-0.34	-7.21	-0.32	2.25e-12	Migraine;
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs67478160	0.619	rs8018062	chr14:104281954	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.64	-0.33	1.23e-13	Schizophrenia;
LGG	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg10483660	chr13:112241077	NA	-0.35	-7.71	-0.34	7.81e-14	Hepatitis;
LGG	cis	rs8062405	0.755	rs4788073	chr16:28594549	A/G	cg00204512	chr16:28754710	NA	0.25	6.92	0.31	1.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2011503	1.000	rs113527843	chr19:19643343	A/T	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs17376456	0.542	rs6556833	chr5:93104707	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.57	7.9	0.34	2.04e-14	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7717393	0.786	rs13355607	chr5:155801758	G/A	cg04435420	chr5:155754009	SGCD	0.76	8.94	0.38	8.98e-18	Egg allergy;
LGG	cis	rs78366141	0.649	rs78114325	chr4:89682189	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.87	8.23	0.36	1.87e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9318086	0.712	rs9318099	chr13:24442462	C/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.49	-9.61	-0.41	4.66e-20	Myopia (pathological);
LGG	cis	rs7618915	0.570	rs4687633	chr3:52630548	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs6665290	0.594	rs17592479	chr1:227173892	T/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-30.41	-0.82	2.01e-112	Myeloid white cell count;
LGG	cis	rs4690686	1.000	rs4690686	chr4:177242959	C/T	cg17059388	chr4:177262070	NA	0.73	15.28	0.58	5.46e-43	Essential tremor;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.36	2.92e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.41	0.63	1.42e-52	Obesity-related traits;
LGG	cis	rs11514810	1.000	rs57444112	chr7:1430892	T/C	cg24899294	chr7:1481343	MICALL2	-0.73	-8.43	-0.36	4.53e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs3858526	0.508	rs10838734	chr11:5876325	T/G	cg02574844	chr11:5959923	NA	-0.56	-9.16	-0.39	1.66e-18	DNA methylation (variation);
LGG	cis	rs11190604	1.000	rs2489046	chr10:102346282	A/C	cg07080220	chr10:102295463	HIF1AN	0.67	11.44	0.47	7.32e-27	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9951602	0.541	rs56882694	chr18:76647010	C/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.59	0.53	1.25e-35	Obesity-related traits;
LGG	cis	rs7923609	0.519	rs34576511	chr10:65327084	C/T	cg02276361	chr10:65351566	REEP3	-0.32	-6.99	-0.31	9.88e-12	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17221980	chr6:117996486	NUS1	0.41	6.68	0.3	6.7e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6547741	1.000	rs1919125	chr2:27801403	C/G	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.69	10.96	0.45	5.03e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7144547	0.950	rs8004137	chr14:81884857	A/G	cg02996355	chr14:81879375	NA	-0.72	-12.2	-0.49	6.91e-30	Prudent dietary pattern;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs11883676	chr2:99800814	G/T	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs72945132	0.882	rs7941933	chr11:70123351	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	7.57	0.33	2.09e-13	Coronary artery disease;
LGG	cis	rs9783347	0.714	rs10832918	chr11:18335684	A/G	cg03595886	chr11:18357587	GTF2H1	0.48	11.6	0.47	1.66e-27	Pancreatic cancer;
LGG	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg08999081	chr20:33150536	PIGU	0.39	9.7	0.41	2.2e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg22496380	chr5:211416	CCDC127	-1.18	-16.73	-0.61	1.81e-49	Breast cancer;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg08621203	chr6:150244597	RAET1G	0.44	7.5	0.33	3.39e-13	Lung cancer;
LGG	cis	rs7192380	1.000	rs7191292	chr16:69669427	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.72	-0.34	7.06e-14	Sjögren's syndrome;
LGG	cis	rs3206736	0.549	rs57221424	chr7:35215670	C/G	cg13400248	chr7:35225412	NA	0.53	9.42	0.4	2.17e-19	Diastolic blood pressure;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.64	0.37	9.51e-17	Prudent dietary pattern;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg21963583	chr11:68658836	MRPL21	-0.57	-9.85	-0.42	6.43e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7084402	0.967	rs10763552	chr10:60273977	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.57	-0.63	2.47e-53	Refractive error;
LGG	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.6	0.53	1.07e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs72848980	0.512	rs56984020	chr10:105386275	C/A	cg00126946	chr10:105363258	SH3PXD2A	0.8	13.36	0.53	1.13e-34	White matter hyperintensity burden;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.78e-18	Skin colour saturation;
LGG	cis	rs4535700	0.501	rs60517461	chr7:56017645	G/T	cg17215666	chr7:56131930	SUMF2	-0.44	-6.78	-0.3	3.64e-11	Macular telangiectasia type 2;
LGG	cis	rs7107174	1.000	rs12277648	chr11:78054336	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.44	-0.33	4.9e-13	Testicular germ cell tumor;
LGG	cis	rs34734847	0.965	rs2005455	chr12:121128699	A/G	cg21892295	chr12:121157589	UNC119B	-0.45	-8.65	-0.37	8.49e-17	Mean corpuscular volume;
LGG	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.39	-0.43	6.91e-23	Initial pursuit acceleration;
LGG	trans	rs9650657	0.801	rs2409663	chr8:10643233	G/T	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	9.14e-14	Neuroticism;
LGG	cis	rs926938	0.563	rs360576	chr1:115459174	A/C	cg12756093	chr1:115239321	AMPD1	-0.47	-8.4	-0.36	5.39e-16	Autism;
LGG	cis	rs3806843	0.608	rs246042	chr5:140330967	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10191773	0.589	rs72831636	chr2:112948248	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.72	8.68	0.37	6.55e-17	Yeast infection;
LGG	cis	rs4851266	1.000	rs4851267	chr2:100824104	G/A	cg21926883	chr2:100939477	LONRF2	-0.44	-7.95	-0.35	1.43e-14	Educational attainment;
LGG	cis	rs3820928	0.967	rs12622456	chr2:227768868	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.36	-0.32	8.26e-13	Pulmonary function;
LGG	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.3	-0.4	5.46e-19	Intelligence (multi-trait analysis);
LGG	cis	rs40363	0.645	rs250629	chr16:3525431	C/A	cg21433313	chr16:3507492	NAT15	0.41	6.65	0.3	8.44e-11	Tuberculosis;
LGG	cis	rs9914988	0.943	rs3181215	chr17:27077331	C/T	cg20469991	chr17:27169893	C17orf63	0.54	6.78	0.3	3.59e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2836950	0.501	rs2836984	chr21:40700949	A/C	cg17971929	chr21:40555470	PSMG1	-0.53	-8.92	-0.38	1.1e-17	Menarche (age at onset);
LGG	cis	rs2117029	0.653	rs1476137	chr12:49523713	A/G	cg24176009	chr12:49580217	TUBA1A	0.65	12.86	0.51	1.44e-32	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg10845886	chr2:3471009	TTC15	-0.49	-9.86	-0.42	5.99e-21	Neurofibrillary tangles;
LGG	cis	rs28595532	0.925	rs115651057	chr4:119486708	A/G	cg21605333	chr4:119757512	SEC24D	1.28	12.4	0.5	1.12e-30	Cannabis dependence symptom count;
LGG	cis	rs1005277	0.505	rs200935	chr10:38132810	T/A	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-7.04	-0.31	7.16e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4631830	0.863	rs2843549	chr10:51521247	C/A	cg16070123	chr10:51489643	NA	-0.39	-7.25	-0.32	1.76e-12	Prostate-specific antigen levels;
LGG	cis	rs7617773	0.539	rs17593974	chr3:48387334	G/T	cg11946769	chr3:48343235	NME6	0.52	8.84	0.38	1.99e-17	Coronary artery disease;
LGG	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-7.66	-0.34	1.12e-13	Vitiligo;
LGG	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs8072100	0.701	rs2013383	chr17:45791123	T/G	cg25173405	chr17:45401733	C17orf57	-0.55	-9.0	-0.39	5.99e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1218582	0.710	rs4845687	chr1:154878911	A/G	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.47	-0.33	3.94e-13	Prostate cancer;
LGG	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg03733263	chr8:22462867	KIAA1967	1.04	27.18	0.78	5.71e-98	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2046867	0.908	rs62251636	chr3:72792650	A/G	cg25664220	chr3:72788482	NA	-0.32	-8.86	-0.38	1.66e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10267417	0.604	rs7785317	chr7:19853482	G/T	cg05791153	chr7:19748676	TWISTNB	-0.57	-8.36	-0.36	7.34e-16	Night sleep phenotypes;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg27400746	chr16:89904261	SPIRE2	-1.1	-16.67	-0.61	3.31e-49	Skin colour saturation;
LGG	trans	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.2	-0.32	2.47e-12	Retinal vascular caliber;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg08355456	chr11:67383691	NA	0.55	9.29	0.4	5.98e-19	Mean corpuscular volume;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs2011503	1.000	rs2916072	chr19:19525712	G/A	cg11584989	chr19:19387371	SF4	0.74	12.08	0.49	2.11e-29	Bipolar disorder;
LGG	cis	rs4132509	1.000	rs9782883	chr1:243892532	A/G	cg21452805	chr1:244014465	NA	0.66	7.98	0.35	1.13e-14	RR interval (heart rate);
LGG	cis	rs7786808	0.707	rs10247026	chr7:158230595	C/T	cg09998033	chr7:158218633	PTPRN2	-0.53	-9.52	-0.4	9.83e-20	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.39	-0.32	7.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11239187	0.927	rs10900079	chr10:45107555	A/G	cg03916630	chr10:45065415	NA	0.34	7.56	0.33	2.24e-13	Body mass index;
LGG	cis	rs2760061	0.626	rs596208	chr1:228117982	G/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.23	-0.32	2.05e-12	Diastolic blood pressure;
LGG	trans	rs877282	1.000	rs877282	chr10:771532	G/A	cg22713356	chr15:30763199	NA	0.56	8.5	0.37	2.71e-16	Uric acid levels;
LGG	cis	rs7084402	0.967	rs2577392	chr10:60329183	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.29	-0.32	1.38e-12	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06583696	chr2:26101536	ASXL2	0.55	9.19	0.39	1.35e-18	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.95	-0.62	1.8e-50	Skin colour saturation;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07791516	chr6:150247246	NA	0.31	6.72	0.3	5.45e-11	Testicular germ cell tumor;
LGG	cis	rs780096	0.546	rs1528533	chr2:27595756	G/C	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.04e-11	Total body bone mineral density;
LGG	cis	rs11758351	0.500	rs113738935	chr6:26196567	T/A	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.53e-12	Gout;Renal underexcretion gout;
LGG	cis	rs5758659	0.652	rs133322	chr22:42405659	A/G	cg15557168	chr22:42548783	NA	-0.34	-7.59	-0.33	1.76e-13	Cognitive function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12580275	chr1:205744413	RAB7L1	0.59	9.15	0.39	1.77e-18	Gut microbiome composition (summer);
LGG	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg00186954	chr11:8933980	ST5;C11orf17	0.4	8.13	0.35	3.98e-15	Hemoglobin concentration;
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.39e-12	Aortic root size;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg22379573	chr1:197704774	DENND1B	0.49	6.75	0.3	4.56e-11	Airflow obstruction;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg03528353	chr17:61819722	STRADA	0.45	7.64	0.33	1.23e-13	Prudent dietary pattern;
LGG	cis	rs12295403	0.691	rs12808591	chr11:18677311	G/A	cg09201001	chr11:18656081	SPTY2D1	0.39	6.64	0.3	8.59e-11	Ovarian reserve;
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.09	-0.31	4.89e-12	Bipolar disorder;
LGG	cis	rs2282032	0.527	rs8020828	chr14:90768183	C/T	cg04374321	chr14:90722782	PSMC1	0.48	7.89	0.34	2.2e-14	Longevity;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.51e-37	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07775675	chr17:74379922	SPHK1	0.58	9.43	0.4	1.98e-19	Gut microbiome composition (summer);
LGG	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg14664628	chr15:75095509	CSK	-0.64	-12.97	-0.52	5.1e-33	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs9303280	0.806	rs9907088	chr17:38035116	G/A	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.43e-12	Self-reported allergy;
LGG	cis	rs2932538	0.961	rs10745332	chr1:113189053	G/A	cg22162597	chr1:113214053	CAPZA1	-0.62	-11.68	-0.48	8.53e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	trans	rs2548003	0.764	rs1423297	chr5:28767987	G/A	cg12623145	chr2:97778927	ANKRD36	0.46	7.02	0.31	7.74e-12	Hip geometry;
LGG	cis	rs2133450	0.780	rs2030154	chr3:7361512	T/A	cg19930620	chr3:7340148	GRM7	-0.36	-7.73	-0.34	6.81e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs4363385	0.588	rs6698361	chr1:153023184	T/G	cg13444842	chr1:152974279	SPRR3	-0.48	-9.77	-0.41	1.24e-20	Inflammatory skin disease;
LGG	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.1e-14	Colorectal cancer;
LGG	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg15325629	chr6:28072465	NA	1.07	8.11	0.35	4.62e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2067615	0.524	rs9804754	chr12:107083031	G/A	cg15890332	chr12:107067104	RFX4	0.44	12.83	0.51	1.86e-32	Heart rate;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.26	0.4	7.65e-19	Electroencephalogram traits;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg27476859	chr7:2772710	GNA12	0.44	7.44	0.33	4.92e-13	Height;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg03188948	chr7:1209495	NA	0.64	8.28	0.36	1.3e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs559928	0.606	rs7941773	chr11:63952759	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.11	0.39	2.56e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg24247370	chr13:99142703	STK24	-0.37	-6.82	-0.3	2.85e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6445975	0.726	rs7639532	chr3:58467656	A/G	cg24175188	chr3:58374923	PXK	-0.42	-7.83	-0.34	3.34e-14	Systemic lupus erythematosus;
LGG	cis	rs62380364	0.542	rs601499	chr5:88052687	A/C	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.49e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.73	-0.34	6.73e-14	Lung cancer;
LGG	cis	rs28595532	0.925	rs116785973	chr4:119611350	G/A	cg14228332	chr4:119757509	SEC24D	0.98	9.77	0.41	1.27e-20	Cannabis dependence symptom count;
LGG	cis	rs6723226	0.732	rs390480	chr2:32510072	A/C	cg02381751	chr2:32503542	YIPF4	-0.73	-12.34	-0.5	1.91e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg19171272	chr22:38449367	NA	-0.62	-12.28	-0.5	3.3e-30	Glioblastoma;Glioma;
LGG	cis	rs7572733	0.840	rs770667	chr2:198613308	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs894344	0.572	rs16905168	chr8:135550179	C/T	cg09855544	chr8:135498122	ZFAT	0.43	7.67	0.34	1.04e-13	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg14926445	chr8:58193284	C8orf71	-0.73	-9.22	-0.39	1.05e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23415489	chr3:47324472	KIF9;KLHL18	-0.44	-6.68	-0.3	7.02e-11	Pancreatic cancer;
LGG	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg06219351	chr7:158114137	PTPRN2	-0.8	-15.99	-0.6	4.03e-46	Calcium levels;
LGG	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-9.71	-0.41	2.1e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2243480	1.000	rs160637	chr7:65584318	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.32e-17	Diabetic kidney disease;
LGG	cis	rs3806843	0.576	rs246029	chr5:140333226	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs35849525	0.814	rs7635601	chr3:50044006	A/T	cg24110177	chr3:50126178	RBM5	-0.51	-7.82	-0.34	3.53e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	0.717	rs2253862	chr1:46081960	C/T	cg03146154	chr1:46216737	IPP	-0.55	-10.64	-0.44	8.57e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs807029	0.544	rs55646950	chr10:102760996	C/T	cg04662943	chr10:102668895	NA	0.47	6.75	0.3	4.37e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04280677	chr19:10654493	ATG4D	0.43	6.87	0.3	2.04e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg14703610	chr5:56206110	C5orf35	0.41	7.05	0.31	6.54e-12	Breast cancer;Breast cancer (early onset);
LGG	cis	rs2916247	0.954	rs7013145	chr8:93170892	T/A	cg10183463	chr8:93005414	RUNX1T1	0.34	6.9	0.31	1.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1797081	0.967	rs780632	chr10:16861400	A/G	cg22980697	chr10:16874865	CUBN	-0.37	-7.07	-0.31	5.89e-12	Platelet distribution width;
LGG	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg24375607	chr4:120327624	NA	0.67	11.01	0.46	3.46e-25	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg24829409	chr8:58192753	C8orf71	-0.89	-13.53	-0.53	2.11e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs1859407	chr17:20078137	T/C	cg13482628	chr17:19912719	NA	-0.54	-10.1	-0.42	8.5e-22	Schizophrenia;
LGG	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.91	-0.31	1.65e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg08344181	chr3:125677491	NA	-0.53	-7.04	-0.31	6.85e-12	Lung cancer in ever smokers;
LGG	cis	rs7523273	0.606	rs859705	chr1:207959665	A/G	cg22525895	chr1:207977042	MIR29B2	0.62	12.05	0.49	2.73e-29	Schizophrenia;
LGG	cis	rs57221529	0.546	rs72707044	chr5:677239	T/C	cg16400903	chr5:693638	TPPP	0.47	6.66	0.3	7.82e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs644799	0.760	rs7114555	chr11:95648242	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.42	0.56	3.38e-39	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6541297	1.000	rs4846836	chr1:230281316	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.65	0.33	1.2e-13	Coronary artery disease;
LGG	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.29e-45	Mean platelet volume;
LGG	cis	rs3849046	0.817	rs6874487	chr5:137907006	A/G	cg10920316	chr5:137946599	NA	0.43	6.99	0.31	9.88e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9393692	0.557	rs10946810	chr6:26288055	G/A	cg00631329	chr6:26305371	NA	-0.45	-7.23	-0.32	1.99e-12	Educational attainment;
LGG	cis	rs7255436	0.830	rs4350678	chr19:8447366	A/G	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.69	-0.3	6.54e-11	HDL cholesterol;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg07701084	chr6:150067640	NUP43	0.7	12.95	0.52	5.72e-33	Lung cancer;
LGG	cis	rs1707322	1.000	rs11211235	chr1:46440375	G/A	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.88	0.38	1.47e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6088580	0.634	rs6142157	chr20:32984172	C/G	cg08999081	chr20:33150536	PIGU	-0.39	-9.84	-0.42	7.36e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg00933542	chr6:150070202	PCMT1	0.39	7.04	0.31	6.95e-12	Lung cancer;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.59	0.56	6.06e-40	Cognitive test performance;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.49	-8.82	-0.38	2.4e-17	Total body bone mineral density;
LGG	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.71	0.3	5.52e-11	Bladder cancer;
LGG	cis	rs611744	0.647	rs9969614	chr8:109260581	A/G	cg18478394	chr8:109455254	TTC35	0.42	8.48	0.37	3.06e-16	Dupuytren's disease;
LGG	cis	rs13102973	0.899	rs13126625	chr4:135900322	C/T	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.01e-15	Subjective well-being;
LGG	cis	rs6964587	0.626	rs10266424	chr7:91503228	C/T	cg17063962	chr7:91808500	NA	-0.43	-7.81	-0.34	3.84e-14	Breast cancer;
LGG	trans	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg18335740	chr13:41363409	SLC25A15	0.6	11.89	0.48	1.27e-28	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15563057	chr5:139493612	PURA	0.52	8.1	0.35	4.93e-15	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.773	rs715439	chr10:104257809	A/C	cg05096777	chr10:104283225	SUFU	0.33	7.16	0.32	3.27e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs62103177	0.525	rs62101233	chr18:77724288	C/T	cg05926928	chr17:57297772	GDPD1	0.9	12.2	0.49	7.27e-30	Opioid sensitivity;
LGG	cis	rs2408955	0.521	rs1476607	chr12:48524804	A/G	cg24011408	chr12:48396354	COL2A1	-0.58	-9.57	-0.41	6.33e-20	Glycated hemoglobin levels;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs514406	0.584	rs7548832	chr1:53193576	A/T	cg16325326	chr1:53192061	ZYG11B	0.89	25.78	0.77	1.6e-91	Monocyte count;
LGG	cis	rs2228479	0.850	rs12600051	chr16:89992072	G/T	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.2	-0.32	2.44e-12	Skin colour saturation;
LGG	cis	rs1421811	0.606	rs62369523	chr5:32713365	T/G	cg16267343	chr5:32710456	NPR3	0.64	8.99	0.39	6.35e-18	Blood pressure;
LGG	cis	rs34311866	0.808	rs3755958	chr4:963042	C/A	cg07828340	chr4:882639	GAK	0.84	9.1	0.39	2.73e-18	Parkinson's disease;
LGG	cis	rs1401999	0.650	rs3792585	chr3:183646222	A/G	cg05044414	chr3:183734942	ABCC5	0.56	11.28	0.46	3.01e-26	Anterior chamber depth;
LGG	cis	rs4595586	0.545	rs1303886	chr12:39366876	G/A	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	trans	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg17830980	chr10:43048298	ZNF37B	0.4	8.89	0.38	1.35e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg12253571	chr8:8283032	NA	-0.33	-7.2	-0.32	2.46e-12	Parkinson's disease;
LGG	cis	rs7681440	0.801	rs1372513	chr4:90790237	G/A	cg18258770	chr4:90757814	SNCA	-0.38	-6.94	-0.31	1.34e-11	Dementia with Lewy bodies;
LGG	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	cis	rs7192380	0.737	rs9783756	chr16:69580432	G/T	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.45	-0.37	3.94e-16	Sjögren's syndrome;
LGG	cis	rs3733585	0.648	rs35954357	chr4:9978758	G/C	cg08250081	chr4:10125330	NA	0.36	6.92	0.31	1.5e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.57	-0.33	2.03e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg08470875	chr2:26401718	FAM59B	-0.37	-6.78	-0.3	3.61e-11	Gut microbiome composition (summer);
LGG	cis	rs7552404	0.696	rs10782602	chr1:76464261	T/C	cg03433033	chr1:76189801	ACADM	0.66	8.75	0.38	3.94e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs79149102	0.579	rs8039433	chr15:75367367	T/C	cg09165964	chr15:75287851	SCAMP5	-0.62	-6.95	-0.31	1.28e-11	Lung cancer;
LGG	cis	rs2235642	0.507	rs2235645	chr16:1597924	C/T	cg04525384	chr16:1557733	TELO2	0.45	7.21	0.32	2.3e-12	Coronary artery disease;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg00830817	chr11:109293614	C11orf87	-0.43	-7.01	-0.31	8.66e-12	Schizophrenia;
LGG	cis	rs644799	0.930	rs3802764	chr11:95514599	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.24e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7635838	0.619	rs346087	chr3:11274354	A/G	cg00170343	chr3:11313890	ATG7	0.54	9.0	0.39	5.98e-18	HDL cholesterol;
LGG	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.18	-0.32	2.73e-12	Obesity;
LGG	cis	rs7493	1.000	rs17876123	chr7:95045307	C/A	cg08461772	chr7:95026248	PON3	0.37	8.08	0.35	5.87e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.85e-37	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg04691961	chr3:161091175	C3orf57	-0.55	-12.63	-0.51	1.24e-31	Morning vs. evening chronotype;
LGG	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg19980929	chr12:42632907	YAF2	0.35	7.84	0.34	3.07e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.62e-16	Aortic root size;
LGG	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs55788414	0.860	rs28697180	chr16:81185079	C/T	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	trans	rs1459104	1.000	rs12574577	chr11:55306742	G/A	cg15704280	chr7:45808275	SEPT13	0.68	6.69	0.3	6.43e-11	Body mass index;
LGG	cis	rs12195424	0.730	rs10484787	chr6:56304291	G/A	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs2046867	0.862	rs11920131	chr3:72858630	C/G	cg01043669	chr3:72786069	NA	0.42	7.04	0.31	6.8e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7618501	0.966	rs9882639	chr3:49799475	A/C	cg21582582	chr3:182698605	DCUN1D1	0.52	9.65	0.41	3.36e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.25e-12	Refractive error;
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03517284	chr6:25882590	NA	0.52	9.79	0.41	1.05e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg22168489	chr12:122356033	WDR66	0.32	7.42	0.33	5.67e-13	Mean corpuscular volume;
LGG	trans	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg26043149	chr18:55253948	FECH	-0.43	-7.18	-0.32	2.8e-12	Bone mineral density;
LGG	cis	rs763014	0.932	rs7204439	chr16:661335	T/C	cg00908189	chr16:619842	PIGQ	0.87	16.32	0.6	1.28e-47	Height;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26349504	chr20:43126168	SERINC3	-0.44	-6.91	-0.31	1.58e-11	Apolipoprotein A-IV levels;
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg00800038	chr16:89945340	TCF25	-0.62	-8.71	-0.38	5.56e-17	Skin colour saturation;
LGG	cis	rs6424115	0.767	rs11591202	chr1:24102080	A/C	cg15997130	chr1:24165203	NA	-0.42	-10.18	-0.43	4.32e-22	Immature fraction of reticulocytes;
LGG	trans	rs9393777	0.720	rs56401801	chr6:27301512	T/A	cg08344181	chr3:125677491	NA	-0.85	-8.17	-0.35	3.03e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs4533971	chr6:66606314	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs9915657	0.933	rs17246133	chr17:70140485	A/G	cg09344028	chr17:70110421	NA	0.48	10.94	0.45	6.26e-25	Thyroid hormone levels;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg13395646	chr4:1353034	KIAA1530	-0.41	-6.92	-0.31	1.47e-11	Longevity;
LGG	cis	rs7619833	0.755	rs583298	chr3:27361880	T/C	cg02860705	chr3:27208620	NA	0.39	7.34	0.32	9.83e-13	Breast cancer;
LGG	cis	rs912057	0.671	rs1024246	chr6:6743505	A/T	cg06612196	chr6:6737390	NA	0.5	10.89	0.45	9.81e-25	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs758324	0.617	rs77937	chr5:131322294	G/T	cg06307176	chr5:131281290	NA	0.46	6.9	0.31	1.71e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg19183879	chr15:85880815	NA	0.41	7.54	0.33	2.55e-13	Bulimia nervosa;
LGG	cis	rs12681288	0.676	rs35389636	chr8:1010613	G/T	cg15309053	chr8:964076	NA	0.43	8.35	0.36	7.91e-16	Schizophrenia;
LGG	cis	rs12618769	0.625	rs72819982	chr2:99043337	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs703842	1.000	rs10747783	chr12:58176614	T/C	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.97	0.35	1.23e-14	Multiple sclerosis;
LGG	cis	rs4684776	0.867	rs1562615	chr3:11373357	A/C	cg24705426	chr3:11550659	ATG7	-0.46	-8.57	-0.37	1.61e-16	Small vessel stroke;
LGG	cis	rs7000551	0.606	rs7844699	chr8:22248920	G/T	cg12081754	chr8:22256438	SLC39A14	-1.1	-25.15	-0.76	1.31e-88	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12950390	0.853	rs17700008	chr17:45863591	A/C	cg06532163	chr17:45867833	NA	-0.55	-8.93	-0.38	9.86e-18	IgG glycosylation;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg09759432	chr2:219928399	NA	-0.39	-7.95	-0.35	1.47e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9911578	1.000	rs2567905	chr17:56782297	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs9768139	0.733	rs10156158	chr7:158122287	G/T	cg06219351	chr7:158114137	PTPRN2	-0.76	-14.81	-0.57	6.66e-41	Calcium levels;
LGG	cis	rs2288073	1.000	rs6708328	chr2:24412413	A/G	cg06627628	chr2:24431161	ITSN2	-0.64	-10.39	-0.43	7.16e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9467773	1.000	rs9467783	chr6:26542894	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.55	0.63	3.25e-53	Intelligence (multi-trait analysis);
LGG	cis	rs6541297	1.000	rs1998065	chr1:230286647	T/G	cg05784532	chr1:230284198	GALNT2	0.52	9.25	0.39	8.48e-19	Coronary artery disease;
LGG	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg21775007	chr8:11205619	TDH	-0.77	-13.35	-0.53	1.32e-34	Retinal vascular caliber;
LGG	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg11752832	chr7:134001865	SLC35B4	0.48	7.93	0.35	1.62e-14	Mean platelet volume;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07276083	chr5:54848335	NA	-0.41	-7.81	-0.34	3.75e-14	Brain structure;
LGG	cis	rs13177180	0.736	rs256938	chr5:114868337	A/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.34	-0.32	9.65e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg20887711	chr4:1340912	KIAA1530	-0.75	-15.88	-0.59	1.15e-45	Obesity-related traits;
LGG	cis	rs7633787	0.594	rs9859062	chr3:23126495	C/T	cg00327796	chr3:23032191	NA	-0.38	-7.1	-0.31	4.58e-12	Facial morphology (factor 7, width of cartilaginous portion of nose);
LGG	cis	rs7917772	0.503	rs7899576	chr10:104307504	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.51	0.56	1.43e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.56	0.44	1.68e-23	Resting heart rate;
LGG	cis	rs2304069	0.729	rs2066934	chr5:149433596	T/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.5	6.66	0.3	7.6e-11	HIV-1 control;
LGG	cis	rs11690935	0.885	rs6750058	chr2:172786909	G/T	cg21435375	chr2:172878103	MAP1D	-0.33	-7.48	-0.33	3.79e-13	Schizophrenia;
LGG	cis	rs16976116	0.901	rs1061822	chr15:55496058	A/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9914988	0.887	rs11656272	chr17:27091153	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs9296092	0.538	rs9461887	chr6:33526827	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.17	-0.7	4.79e-70	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs4363385	0.703	rs4845517	chr1:153003893	T/A	cg13444842	chr1:152974279	SPRR3	-0.4	-8.23	-0.36	1.91e-15	Inflammatory skin disease;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs3008870	1.000	rs3008871	chr1:67419089	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.03	-21.78	-0.71	6.06e-73	Lymphocyte percentage of white cells;
LGG	cis	rs7681423	0.951	rs11099961	chr4:155503212	C/T	cg20735720	chr4:155535218	FGG	-0.54	-9.25	-0.39	8.52e-19	Fibrinogen;
LGG	cis	rs6866344	0.697	rs11748497	chr5:178130012	C/G	cg03877680	chr5:178157825	ZNF354A	0.8	12.81	0.51	2.35e-32	Neutrophil percentage of white cells;
LGG	cis	rs9863	0.861	rs4930726	chr12:124428331	T/C	cg13487667	chr12:124434373	CCDC92	-0.35	-7.04	-0.31	7.01e-12	White blood cell count;
LGG	cis	rs9487094	0.961	rs3807005	chr6:109791110	T/C	cg16315928	chr6:109776240	MICAL1	0.55	9.06	0.39	3.76e-18	Height;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg06873352	chr17:61820015	STRADA	0.75	14.07	0.55	1.05e-37	Prudent dietary pattern;
LGG	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.27	-0.43	1.97e-22	Initial pursuit acceleration;
LGG	cis	rs67460515	0.563	rs16831886	chr3:160799830	A/C	cg03342759	chr3:160939853	NMD3	-0.72	-11.93	-0.48	8.39e-29	Parkinson's disease;
LGG	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg01631408	chr1:248437212	OR2T33	-0.5	-9.18	-0.39	1.48e-18	Common traits (Other);
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg03452623	chr4:187889614	NA	-1.05	-32.56	-0.83	8.78e-122	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4566357	0.615	rs12618793	chr2:227909552	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.15	-0.39	1.85e-18	Coronary artery disease;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg02951883	chr7:2050386	MAD1L1	-0.79	-16.22	-0.6	3.67e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs910316	0.967	rs12147532	chr14:75651858	T/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.88	-0.45	1.02e-24	Height;
LGG	trans	rs8002861	0.870	rs9525855	chr13:44431660	A/G	cg17145862	chr1:211918768	LPGAT1	0.96	24.56	0.75	7.04e-86	Leprosy;
LGG	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg12310025	chr6:25882481	NA	-0.54	-10.2	-0.43	3.68e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4930561	0.765	rs10896304	chr11:67981714	T/G	cg16338278	chr11:67432957	ALDH3B2	0.41	7.55	0.33	2.36e-13	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg14912033	chr15:79043428	NA	-0.39	-9.82	-0.42	8.44e-21	Coronary artery disease or large artery stroke;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17376030	chr22:41985996	PMM1	0.53	8.5	0.37	2.63e-16	Vitiligo;
LGG	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg01262667	chr19:19385393	TM6SF2	0.33	6.8	0.3	3.26e-11	Bipolar disorder;
LGG	cis	rs9467773	1.000	rs10946834	chr6:26533664	G/C	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	cis	rs9326248	1.000	rs7946257	chr11:117053165	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.51	0.4	1.06e-19	Blood protein levels;
LGG	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg07636037	chr3:49044803	WDR6	0.6	10.45	0.44	4.39e-23	Resting heart rate;
LGG	cis	rs11098499	0.954	rs2306455	chr4:120421969	G/A	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.56	-0.33	2.18e-13	Personality dimensions;
LGG	cis	rs1707322	0.752	rs11488313	chr1:46224780	G/C	cg03146154	chr1:46216737	IPP	0.59	10.56	0.44	1.74e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-9.32	-0.4	4.83e-19	Skin colour saturation;
LGG	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg03342759	chr3:160939853	NMD3	-0.75	-13.4	-0.53	7.74e-35	Parkinson's disease;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg23131131	chr22:24373011	LOC391322	-0.52	-9.05	-0.39	3.87e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs113835537	0.559	rs74933537	chr11:66274958	A/C	cg24851651	chr11:66362959	CCS	0.43	7.44	0.33	4.79e-13	Airway imaging phenotypes;
LGG	cis	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.17	-0.36	2.94e-15	Joint mobility (Beighton score);
LGG	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs4731207	0.535	rs11769711	chr7:124574924	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1065852	0.503	rs9620006	chr22:42399547	T/A	cg15128208	chr22:42549153	NA	0.41	7.09	0.31	5.01e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs9657904	0.738	rs4894954	chr3:105532497	C/T	cg14088669	chr1:158435396	OR10K1	0.42	7.87	0.34	2.58e-14	Multiple sclerosis;
LGG	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg08994789	chr17:28903642	LRRC37B2	0.68	8.67	0.37	7.4e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6831352	0.693	rs2602875	chr4:100039495	C/G	cg13256891	chr4:100009986	ADH5	0.54	9.56	0.41	6.96e-20	Alcohol dependence;
LGG	cis	rs2030746	0.521	rs2311598	chr2:121331102	A/G	cg22272644	chr2:121334640	NA	-0.37	-9.71	-0.41	2.11e-20	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs73086581	0.891	rs11907503	chr20:3887590	C/T	cg02187196	chr20:3869020	PANK2	0.87	12.42	0.5	8.88e-31	Response to antidepressants in depression;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.02	-0.39	4.87e-18	Menopause (age at onset);
LGG	cis	rs7582180	0.563	rs4851304	chr2:100963871	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.2e-48	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.556	rs11774220	chr8:10070148	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.07	-0.31	5.57e-12	Neuroticism;
LGG	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.84	0.34	3.05e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg01448562	chr3:133502909	NA	-0.52	-8.67	-0.37	7.1e-17	Iron status biomarkers;
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs2120243	0.592	rs1869857	chr3:157123357	G/T	cg24825693	chr3:157122686	VEPH1	0.5	11.7	0.48	6.87e-28	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs1865760	0.929	rs12195653	chr6:25958621	A/G	cg03517284	chr6:25882590	NA	-0.39	-7.01	-0.31	8.5e-12	Height;
LGG	cis	rs35740288	0.770	rs11632750	chr15:86215614	A/C	cg04173714	chr15:86211321	AKAP13	0.49	8.94	0.38	9.21e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1978968	1.000	rs13053667	chr22:18443404	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs17612678	1.000	rs17612699	chr15:93816360	A/G	cg19550034	chr15:93814737	NA	-0.34	-6.66	-0.3	7.84e-11	Obesity-related traits;
LGG	cis	rs58649573	0.552	rs7049157	chr9:126787006	A/G	cg14112217	chr9:126806003	NA	0.39	7.77	0.34	5.2e-14	Post-traumatic stress disorder;
LGG	cis	rs7312774	0.748	rs7966019	chr12:107297502	G/T	cg16260113	chr12:107380972	MTERFD3	0.65	6.82	0.3	2.83e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs9325144	0.555	rs1973292	chr12:38679626	T/C	cg04568710	chr12:38710424	ALG10B	0.41	8.76	0.38	3.76e-17	Morning vs. evening chronotype;
LGG	cis	rs10463554	0.927	rs257314	chr5:102421095	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs870825	0.929	rs72689273	chr4:185592750	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	19.01	0.66	5.58e-60	Blood protein levels;
LGG	cis	rs12477438	0.501	rs2516833	chr2:99777405	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs7444	0.825	rs2298428	chr22:21982892	C/T	cg11654148	chr22:21984483	YDJC	-0.4	-7.31	-0.32	1.15e-12	Systemic lupus erythematosus;
LGG	cis	rs9397585	0.857	rs7750297	chr6:153376268	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	cis	rs4959677	0.698	rs1891199	chr6:2481290	A/G	cg23817096	chr6:1620687	NA	-0.34	-8.42	-0.36	4.63e-16	Orthostatic hypotension;
LGG	cis	rs2361718	0.527	rs7211994	chr17:78152514	A/G	cg06718696	chr17:78121285	EIF4A3	-0.4	-6.68	-0.3	6.73e-11	Yeast infection;
LGG	cis	rs9910055	0.502	rs1684662	chr17:42180822	T/A	cg19774624	chr17:42201019	HDAC5	0.64	11.25	0.46	4.08e-26	Total body bone mineral density;
LGG	cis	rs9644630	0.862	rs7830404	chr8:19357346	A/T	cg06699216	chr8:19333253	CSGALNACT1	-0.48	-11.03	-0.46	2.91e-25	Oropharynx cancer;
LGG	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg22437258	chr11:111473054	SIK2	0.54	9.54	0.41	8.01e-20	Primary sclerosing cholangitis;
LGG	trans	rs61931739	0.620	rs61927734	chr12:33691977	A/T	cg26384229	chr12:38710491	ALG10B	-0.49	-8.74	-0.38	4.26e-17	Morning vs. evening chronotype;
LGG	cis	rs597583	0.755	rs562422	chr11:117428278	G/A	cg27161313	chr11:117392002	DSCAML1	-0.46	-7.55	-0.33	2.39e-13	Putamen volume;
LGG	cis	rs644799	1.000	rs500054	chr11:95593806	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	7.64	0.33	1.28e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6835098	0.828	rs28612521	chr4:174085294	G/A	cg08422745	chr4:174089978	GALNT7	-0.86	-15.25	-0.58	7.98e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg04851639	chr8:1020857	NA	-0.46	-9.9	-0.42	4.39e-21	Schizophrenia;
LGG	cis	rs727505	0.521	rs66787780	chr7:124791849	G/A	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs2404602	0.709	rs11072597	chr15:76763514	C/A	cg23625390	chr15:77176239	SCAPER	-0.65	-12.89	-0.51	1.08e-32	Blood metabolite levels;
LGG	cis	rs4919694	1.000	rs17787717	chr10:104695699	T/G	cg04362960	chr10:104952993	NT5C2	1.05	13.59	0.53	1.2e-35	Arsenic metabolism;
LGG	cis	rs4629180	0.675	rs908132	chr2:102093096	A/G	cg16435561	chr2:102091048	RFX8	0.49	9.14	0.39	1.92e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs4356203	0.870	rs10832747	chr11:17250019	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg08035479	chr8:58172643	NA	-0.52	-7.97	-0.35	1.24e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs1976403	0.633	rs1780324	chr1:21821757	A/G	cg20417195	chr1:21767127	NBPF3	0.44	7.96	0.35	1.37e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7633857	0.536	rs1447609	chr3:160696311	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.81	-0.38	2.56e-17	Educational attainment (years of education);
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.85	0.42	6.52e-21	Tonsillectomy;
LGG	cis	rs72781680	0.752	rs72796119	chr2:23917179	C/T	cg08917208	chr2:24149416	ATAD2B	0.83	8.86	0.38	1.71e-17	Lymphocyte counts;
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg13047869	chr3:10149882	C3orf24	0.48	7.87	0.34	2.6e-14	Alzheimer's disease;
LGG	cis	rs10791323	0.601	rs7946883	chr11:133733864	T/C	cg00579200	chr11:133705235	NA	-0.54	-10.19	-0.43	4.03e-22	Childhood ear infection;
LGG	cis	rs17169635	0.718	rs3778854	chr7:134550234	G/A	cg02516134	chr7:134575187	CALD1	-0.39	-7.65	-0.33	1.18e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs4555082	0.834	rs2816624	chr14:105733909	A/G	cg10792982	chr14:105748885	BRF1	0.67	13.34	0.53	1.33e-34	Mean platelet volume;Platelet distribution width;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23116984	chr15:34517290	TMEM85	-0.45	-7.07	-0.31	5.87e-12	Pancreatic cancer;
LGG	cis	rs752010	0.574	rs6671999	chr1:42120416	G/A	cg06885757	chr1:42089581	HIVEP3	0.49	10.95	0.45	5.51e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2131877	0.830	rs62290330	chr3:194843755	A/G	cg07250128	chr3:194833983	C3orf21	0.41	6.7	0.3	6.14e-11	Non-small cell lung cancer;
LGG	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg18188782	chr20:61659543	NA	0.4	6.78	0.3	3.67e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-11.12	-0.46	1.26e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7615952	0.599	rs12496921	chr3:125701948	C/G	cg05084668	chr3:125655381	ALG1L	-0.58	-7.76	-0.34	5.48e-14	Blood pressure (smoking interaction);
LGG	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg26384229	chr12:38710491	ALG10B	0.62	11.46	0.47	6.23e-27	Morning vs. evening chronotype;
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg27411982	chr8:10470053	RP1L1	-0.41	-7.28	-0.32	1.42e-12	Neuroticism;
LGG	cis	rs1018697	1.000	rs7911528	chr10:104551567	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.02	0.39	5.16e-18	Colorectal adenoma (advanced);
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs34452667	chr5:131713555	G/T	cg06968155	chr5:131705112	SLC22A5	0.75	8.59	0.37	1.38e-16	Rheumatoid arthritis;
LGG	cis	rs9912468	0.933	rs12601850	chr17:64302652	C/T	cg19474267	chr17:64306194	PRKCA	0.95	25.57	0.77	1.43e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs11758351	1.000	rs3757135	chr6:26200707	G/A	cg01420254	chr6:26195488	NA	0.88	11.73	0.48	5.33e-28	Gout;Renal underexcretion gout;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg23034840	chr1:205782522	SLC41A1	0.61	10.14	0.43	6.03e-22	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11328140	chr12:108079443	PWP1	0.43	7.37	0.32	8.04e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs12519773	0.597	rs4342312	chr5:92477890	C/A	cg18783429	chr5:92414398	NA	0.33	8.19	0.36	2.65e-15	Migraine;
LGG	cis	rs1003719	0.762	rs11088381	chr21:38478429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.33	0.63	3.07e-52	Eye color traits;
LGG	cis	rs3741151	0.686	rs12288753	chr11:73136261	A/T	cg17517138	chr11:73019481	ARHGEF17	0.76	8.23	0.36	1.87e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.72	11.84	0.48	1.98e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3820928	0.874	rs10199655	chr2:227892428	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.4	-0.33	6.68e-13	Pulmonary function;
LGG	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs929354	0.772	rs3802117	chr7:156987000	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs7267979	1.000	rs2500404	chr20:25359758	A/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg20848291	chr7:100343083	ZAN	-0.6	-8.47	-0.37	3.34e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg11062466	chr8:58055876	NA	0.45	7.22	0.32	2.1e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11864453	0.612	rs12708925	chr16:72122706	A/T	cg01557791	chr16:72042693	DHODH	-0.46	-8.41	-0.36	4.94e-16	Fibrinogen levels;
LGG	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg18876405	chr7:65276391	NA	0.59	10.87	0.45	1.19e-24	Aortic root size;
LGG	cis	rs7394190	0.748	rs34163229	chr10:75406912	G/T	cg07699608	chr10:75541558	CHCHD1	0.57	7.71	0.34	7.56e-14	Incident atrial fibrillation;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg14675211	chr2:100938903	LONRF2	0.61	10.69	0.45	5.29e-24	Intelligence (multi-trait analysis);
LGG	trans	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg22232500	chr2:134024266	NCKAP5	0.67	9.21	0.39	1.13e-18	Bipolar disorder;
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg19524238	chr7:2802976	GNA12	0.39	8.79	0.38	2.97e-17	Height;
LGG	cis	rs17345786	0.906	rs11708616	chr3:101231731	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.84	0.38	2.05e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9815354	0.812	rs78342280	chr3:41948810	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4538187	0.851	rs35960986	chr2:64221195	G/A	cg14150252	chr2:64069583	UGP2	-0.49	-9.66	-0.41	3.11e-20	Systolic blood pressure;
LGG	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs2832191	0.716	rs1984012	chr21:30392472	T/C	cg08807101	chr21:30365312	RNF160	0.92	19.42	0.67	6.8e-62	Dental caries;
LGG	cis	rs9290877	0.667	rs9833602	chr3:188462284	A/G	cg17392043	chr3:188495102	LPP	-0.46	-8.01	-0.35	9.41e-15	IgE levels;
LGG	cis	rs657075	0.595	rs35724182	chr5:131580301	C/T	cg14196790	chr5:131705035	SLC22A5	0.49	6.86	0.3	2.22e-11	Rheumatoid arthritis;
LGG	trans	rs61931739	0.500	rs7979240	chr12:34509026	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.37	0.53	1.07e-34	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02842629	chr19:12267796	ZNF625	0.5	7.44	0.33	4.83e-13	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.701	rs62248439	chr3:46996448	A/G	cg27129171	chr3:47204927	SETD2	-0.84	-15.72	-0.59	6.18e-45	Colorectal cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17127309	chr10:43599563	RET	0.37	7.26	0.32	1.66e-12	Pancreatic cancer;
LGG	cis	rs283228	0.798	rs606901	chr6:101751104	T/A	cg27451362	chr6:101846650	GRIK2	0.65	10.65	0.44	7.94e-24	Coenzyme Q10 levels;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg06138931	chr13:21896616	NA	0.39	7.89	0.34	2.2e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg00761968	chr13:53314142	LECT1	-0.37	-7.98	-0.35	1.18e-14	Lewy body disease;
LGG	cis	rs68170813	0.521	rs61673847	chr7:106892431	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.53	-0.44	2.12e-23	Coronary artery disease;
LGG	trans	rs11252926	0.565	rs60553947	chr10:474284	T/C	cg00953403	chr17:74099816	EXOC7	-0.45	-7.39	-0.32	6.77e-13	Psychosis in Alzheimer's disease;
LGG	trans	rs931812	1.000	rs4734495	chr8:101917817	C/A	cg20993868	chr7:22813445	NA	0.67	12.72	0.51	5.43e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs36093844	0.706	rs1445501	chr11:85542876	G/A	cg16165120	chr11:85566439	CCDC83	-0.45	-7.07	-0.31	5.59e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9611565	0.512	rs5751148	chr22:42139078	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.77	-0.45	2.64e-24	Vitiligo;
LGG	cis	rs17021463	0.643	rs6841656	chr4:95300532	A/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.0	0.31	8.94e-12	Testicular germ cell tumor;
LGG	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.1	0.72	1.94e-74	Bladder cancer;
LGG	cis	rs8180040	0.726	rs2385867	chr3:47059323	C/T	cg27129171	chr3:47204927	SETD2	0.85	16.33	0.6	1.15e-47	Colorectal cancer;
LGG	cis	rs11190604	1.000	rs11190578	chr10:102238953	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.73	0.34	6.54e-14	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs12517041	0.872	rs78861527	chr5:23283534	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.9	-0.45	8.86e-25	Calcium levels;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.8	-0.41	9.6e-21	Personality dimensions;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg23743428	chr13:21893420	NA	-0.47	-10.83	-0.45	1.65e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03517284	chr6:25882590	NA	-0.49	-9.37	-0.4	3.26e-19	Blood metabolite levels;
LGG	trans	rs9657904	1.000	rs1039544	chr3:105592655	C/G	cg14088669	chr1:158435396	OR10K1	0.38	6.67	0.3	7.44e-11	Multiple sclerosis;
LGG	cis	rs4959677	0.725	rs1680830	chr6:2503734	C/G	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.6e-15	Orthostatic hypotension;
LGG	cis	rs908922	0.676	rs4240883	chr1:152526260	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.83e-41	Hair morphology;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.85	-14.42	-0.56	3.46e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg12395012	chr8:11607386	GATA4	0.4	6.99	0.31	9.6e-12	Neuroticism;
LGG	cis	rs7851660	0.844	rs10119760	chr9:100624602	G/C	cg13688889	chr9:100608707	NA	-0.63	-12.51	-0.5	4.06e-31	Strep throat;
LGG	cis	rs7107174	1.000	rs10899481	chr11:78058721	A/T	cg27205649	chr11:78285834	NARS2	0.45	7.53	0.33	2.63e-13	Testicular germ cell tumor;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.46	7.65	0.33	1.2e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs61931739	0.517	rs4931771	chr12:34044557	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.63	0.44	9.1e-24	Morning vs. evening chronotype;
LGG	cis	rs774359	0.789	rs3849939	chr9:27525221	G/C	cg14173147	chr9:27528300	MOBKL2B	-0.42	-8.31	-0.36	1.1e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs8062405	0.755	rs1074631	chr16:28554108	A/G	cg16576597	chr16:28551801	NUPR1	-0.44	-10.34	-0.43	1.06e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg06521331	chr12:34319734	NA	0.43	7.77	0.34	4.98e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8180040	0.620	rs9845728	chr3:47103376	C/T	cg16586182	chr3:47516702	SCAP	-0.73	-13.25	-0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs7444	0.941	rs140491	chr22:21922364	T/C	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.55e-14	Systemic lupus erythematosus;
LGG	cis	rs7166081	1.000	rs12442323	chr15:67654919	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.27	-0.32	1.58e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg26513180	chr16:89883248	FANCA	0.82	8.66	0.37	7.85e-17	Skin colour saturation;
LGG	cis	rs3206736	0.803	rs329580	chr7:35091875	C/T	cg13400248	chr7:35225412	NA	-0.43	-7.9	-0.34	2.05e-14	Diastolic blood pressure;
LGG	cis	rs56163509	1	rs56163509	chr16:28864471	A/G	cg16576597	chr16:28551801	NUPR1	0.31	7.02	0.31	7.72e-12	Tonsillectomy;Mean corpuscular volume;
LGG	cis	rs7681440	0.626	rs6812593	chr4:90817991	C/T	cg26578617	chr4:90757533	SNCA	-0.35	-6.89	-0.31	1.78e-11	Dementia with Lewy bodies;
LGG	cis	rs16866061	1.000	rs10498163	chr2:225434445	A/G	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs9581943	0.901	rs9551414	chr13:28474237	C/T	cg16302790	chr13:28498334	PDX1	0.52	8.8	0.38	2.78e-17	Pancreatic cancer;
LGG	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg20240347	chr1:204465584	NA	-0.53	-10.59	-0.44	1.27e-23	Schizophrenia;
LGG	cis	rs4356932	0.967	rs4407534	chr4:76979326	G/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs4629180	0.586	rs10206804	chr2:102132431	C/T	cg16435561	chr2:102091048	RFX8	-0.46	-8.42	-0.36	4.65e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs9944715	0.906	rs4453596	chr18:43749826	T/C	cg26436583	chr18:43649176	PSTPIP2	0.4	7.47	0.33	3.94e-13	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.54e-23	Bipolar disorder;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg21724239	chr8:58056113	NA	0.81	19.64	0.67	6.5e-63	Developmental language disorder (linguistic errors);
LGG	cis	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg04455712	chr21:45112962	RRP1B	-0.46	-8.3	-0.36	1.18e-15	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg04503457	chr17:41445688	NA	-0.39	-9.42	-0.4	2.11e-19	Menopause (age at onset);
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg05091796	chr16:4465799	CORO7	-0.75	-12.74	-0.51	4.34e-32	Schizophrenia;
LGG	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg03806693	chr22:41940476	POLR3H	-1.05	-19.2	-0.67	7.26e-61	Vitiligo;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg03528353	chr17:61819722	STRADA	-0.44	-7.48	-0.33	3.75e-13	Prudent dietary pattern;
LGG	cis	rs7828089	0.582	rs13282084	chr8:22266280	T/C	cg12081754	chr8:22256438	SLC39A14	0.97	20.93	0.7	6.2e-69	Verbal declarative memory;
LGG	cis	rs10267417	0.522	rs34867920	chr7:19936646	G/A	cg05791153	chr7:19748676	TWISTNB	0.53	6.76	0.3	4.08e-11	Night sleep phenotypes;
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.65	0.3	8.19e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2270927	0.510	rs67560206	chr5:75591986	G/C	cg13563193	chr19:33072644	PDCD5	0.81	9.65	0.41	3.42e-20	Mean corpuscular volume;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02071572	chr4:1403502	NA	0.41	7.07	0.31	5.57e-12	Longevity;
LGG	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg00717180	chr2:96193071	NA	0.39	7.04	0.31	7.15e-12	Coronary artery disease;
LGG	cis	rs4472734	1.000	rs4655346	chr1:214609127	T/G	cg00063699	chr1:214624242	PTPN14	-0.35	-7.04	-0.31	6.79e-12	Height;
LGG	cis	rs6500395	1.000	rs9933329	chr16:48646572	T/C	cg04672837	chr16:48644449	N4BP1	0.55	9.02	0.39	5.09e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7246865	0.768	rs11669463	chr19:17199314	T/C	cg19418318	chr19:17219073	MYO9B	0.31	8.03	0.35	8.01e-15	Reticulocyte fraction of red cells;
LGG	cis	rs36051895	0.623	rs4358852	chr9:5251238	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-13.19	-0.52	5.71e-34	Pediatric autoimmune diseases;
LGG	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg07636037	chr3:49044803	WDR6	1.07	25.01	0.76	5.7e-88	Parkinson's disease;
LGG	cis	rs16854884	0.586	rs2011080	chr3:143756149	T/G	cg06585982	chr3:143692056	C3orf58	0.68	12.27	0.5	3.66e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs9322193	0.923	rs9322214	chr6:150025122	C/T	cg15971980	chr6:150254442	NA	0.45	8.45	0.37	3.68e-16	Lung cancer;
LGG	cis	rs738322	0.836	rs4821741	chr22:38514745	A/G	cg25457927	chr22:38595422	NA	-0.35	-8.31	-0.36	1.04e-15	Cutaneous nevi;
LGG	cis	rs7216064	1.000	rs62084238	chr17:65856573	T/A	cg12091567	chr17:66097778	LOC651250	-0.59	-8.65	-0.37	8.68e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6831352	0.879	rs36034266	chr4:100061388	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.67	-0.41	2.82e-20	Alcohol dependence;
LGG	cis	rs12410462	0.551	rs1923821	chr1:227862055	G/T	cg04117972	chr1:227635322	NA	0.43	8.04	0.35	7.4e-15	Major depressive disorder;
LGG	trans	rs12439619	0.530	rs7162177	chr15:82474069	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-7.74	-0.34	6.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.758	rs4723649	chr7:1071905	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.7	-0.38	5.65e-17	Longevity;Endometriosis;
LGG	cis	rs4148883	0.737	rs13148577	chr4:100060836	G/A	cg13256891	chr4:100009986	ADH5	0.38	6.69	0.3	6.44e-11	Alcohol dependence;
LGG	cis	rs62244186	0.545	rs725866	chr3:44765533	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.83	0.34	3.25e-14	Depressive symptoms;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	9.95	0.42	2.92e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs4356203	0.905	rs512852	chr11:17214929	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs8060686	0.641	rs2285910	chr16:68104422	T/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.63	-0.33	1.32e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7927771	0.560	rs4752858	chr11:47685829	C/T	cg20307385	chr11:47447363	PSMC3	-0.55	-10.72	-0.45	4.3e-24	Subjective well-being;
LGG	cis	rs9487094	0.689	rs7754650	chr6:109726739	A/G	cg16315928	chr6:109776240	MICAL1	0.44	7.9	0.34	2.01e-14	Height;
LGG	cis	rs6901004	0.803	rs2757571	chr6:111511124	T/G	cg15721981	chr6:111408429	SLC16A10	-0.42	-7.58	-0.33	1.87e-13	Blood metabolite levels;
LGG	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg17046650	chr2:3699563	NA	0.97	11.17	0.46	8.51e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7208859	0.623	rs9893422	chr17:29111715	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg07117364	chr1:16154769	NA	-0.5	-9.46	-0.4	1.58e-19	Dilated cardiomyopathy;
LGG	cis	rs4730779	0.545	rs3808184	chr7:117214125	T/C	cg10524701	chr7:117356490	CTTNBP2	0.34	6.82	0.3	2.92e-11	Waist circumference;
LGG	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg00850481	chr1:228891306	NA	0.48	7.98	0.35	1.14e-14	Chronic lymphocytic leukemia;
LGG	cis	rs17001868	0.568	rs9611315	chr22:40736900	A/T	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs1152591	0.729	rs1255988	chr14:64657684	C/A	cg23250157	chr14:64679961	SYNE2	0.47	8.96	0.38	7.96e-18	Atrial fibrillation;
LGG	cis	rs9462027	0.545	rs3800458	chr6:34663487	A/T	cg07306190	chr6:34760872	UHRF1BP1	0.48	9.49	0.4	1.24e-19	Systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs1618874	chr15:45622786	A/G	cg21132104	chr15:45694354	SPATA5L1	0.69	10.15	0.43	5.42e-22	Homoarginine levels;
LGG	cis	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Bladder cancer;
LGG	cis	rs4356203	0.905	rs7478986	chr11:17131249	T/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.95	-0.35	1.45e-14	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs7020830	0.867	rs1339553	chr9:37266123	C/G	cg14294708	chr9:37120828	ZCCHC7	1.15	32.15	0.83	4.83e-120	Schizophrenia;
LGG	cis	rs7737355	0.947	rs31253	chr5:130833011	A/C	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	7.04e-18	Life satisfaction;
LGG	cis	rs9816226	0.591	rs78785910	chr3:185812634	G/A	cg00760338	chr3:185826511	ETV5	-0.81	-10.11	-0.43	7.53e-22	Obesity;Body mass index;
LGG	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.21	0.43	3.4e-22	Neuroticism;
LGG	cis	rs2303319	1.000	rs62194492	chr2:162215563	C/A	cg13806767	chr2:162164127	PSMD14	-0.66	-7.74	-0.34	6.5e-14	Cognitive function;
LGG	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg15596359	chr8:11213517	TDH	0.41	8.26	0.36	1.51e-15	Retinal vascular caliber;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg15147215	chr3:52552868	STAB1	-0.4	-8.09	-0.35	5.46e-15	Bipolar disorder;
LGG	cis	rs2243480	0.803	rs13224048	chr7:65993766	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.23	0.36	1.99e-15	Diabetic kidney disease;
LGG	cis	rs62400317	0.731	rs12208523	chr6:45058828	C/T	cg18551225	chr6:44695536	NA	-0.55	-8.02	-0.35	9.01e-15	Total body bone mineral density;
LGG	cis	rs1167827	0.680	rs1167800	chr7:75176196	G/A	cg09988129	chr7:74988866	PMS2L2;STAG3L1	0.46	8.09	0.35	5.43e-15	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg24450063	chr1:156163899	SLC25A44	1.08	23.6	0.74	1.98e-81	Testicular germ cell tumor;
LGG	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs10540	1.000	rs12788729	chr11:502371	G/A	cg19913688	chr11:428466	ANO9	-0.65	-8.3	-0.36	1.19e-15	Body mass index;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.76	-0.3	4.25e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg27490568	chr2:178487706	NA	0.8	13.59	0.53	1.26e-35	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9467711	0.659	rs35433030	chr6:26529890	G/A	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.25	-0.43	2.37e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20383558	chr5:138629182	MATR3	0.43	7.05	0.31	6.48e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9527	0.590	rs2182348	chr10:104872684	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.32	0.43	1.3e-22	Arsenic metabolism;
LGG	cis	rs68170813	0.523	rs12535093	chr7:107020182	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-9.41	-0.4	2.37e-19	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs17528590	chr2:26505858	A/G	cg08470875	chr2:26401718	FAM59B	0.43	8.24	0.36	1.73e-15	Gut microbiome composition (summer);
LGG	cis	rs62103177	0.733	rs62096747	chr18:77619568	A/G	cg03511173	chr18:77590860	NA	0.62	7.82	0.34	3.58e-14	Opioid sensitivity;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg09412850	chr12:132835834	GALNT9	0.34	7.3	0.32	1.22e-12	Electrocardiographic conduction measures;
LGG	cis	rs3857067	0.806	rs7669168	chr4:95104881	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.98	-0.35	1.17e-14	QT interval;
LGG	cis	rs2439831	0.867	rs933941	chr15:43632226	G/A	cg15269541	chr15:43626905	ADAL	-0.41	-6.8	-0.3	3.33e-11	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg13010199	chr12:38710504	ALG10B	-0.52	-10.12	-0.43	6.85e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8177253	0.665	rs9831392	chr3:133451473	A/T	cg16414030	chr3:133502952	NA	-0.49	-7.98	-0.35	1.18e-14	Iron status biomarkers;
LGG	cis	rs2239815	0.515	rs5762848	chr22:29236308	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.65	0.34	1.17e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs7552404	0.961	rs448710	chr1:76116554	T/C	cg03433033	chr1:76189801	ACADM	-0.77	-13.28	-0.53	2.43e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4417704	0.551	rs6735127	chr2:241885932	G/T	cg05025159	chr2:241905733	NA	0.49	10.0	0.42	1.89e-21	Joint mobility (Beighton score);
LGG	trans	rs1493916	0.748	rs34501189	chr18:31314196	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.62	-0.48	1.5e-27	Life satisfaction;
LGG	cis	rs1552244	0.816	rs13059144	chr3:10010197	A/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs11122272	0.735	rs2009873	chr1:231499236	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.63e-26	Hemoglobin concentration;
LGG	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg03929089	chr4:120376271	NA	-0.96	-20.24	-0.69	1.01e-65	Coronary artery disease;
LGG	cis	rs1018836	0.632	rs6995399	chr8:91481629	T/C	cg16814680	chr8:91681699	NA	-0.66	-11.28	-0.46	3.14e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7546668	1.000	rs6686966	chr1:15835472	C/T	cg21858823	chr1:15850916	CASP9	0.38	6.99	0.31	9.69e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs9912468	1.000	rs4577128	chr17:64308473	A/G	cg19474267	chr17:64306194	PRKCA	-0.96	-27.76	-0.79	1.43e-100	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	8.98e-30	Prudent dietary pattern;
LGG	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg03433033	chr1:76189801	ACADM	-0.66	-9.58	-0.41	6.02e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17102423	0.826	rs17825846	chr14:65598752	C/G	cg11161011	chr14:65562177	MAX	-0.71	-13.84	-0.54	1.06e-36	Obesity-related traits;
LGG	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.3e-45	Intelligence (multi-trait analysis);
LGG	cis	rs8018808	1.000	rs12101153	chr14:77863091	A/C	cg20045696	chr14:77926864	AHSA1	-0.42	-7.04	-0.31	7.12e-12	Myeloid white cell count;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg20607798	chr8:58055168	NA	0.65	7.17	0.32	3.04e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs504918	0.934	rs9878723	chr3:124079272	A/C	cg05766129	chr3:123988013	KALRN	0.37	6.72	0.3	5.38e-11	Schizophrenia;
LGG	cis	rs9926296	0.533	rs9938865	chr16:89867797	A/G	cg04287289	chr16:89883240	FANCA	0.8	17.02	0.62	8.08e-51	Vitiligo;
LGG	cis	rs11150038	0.826	rs4490015	chr16:78067711	C/G	cg04733911	chr16:78082701	NA	-0.69	-9.23	-0.39	1e-18	Colorectal or endometrial cancer;
LGG	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs870825	0.860	rs2705895	chr4:185598404	C/T	cg04058563	chr4:185651563	MLF1IP	-1.0	-20.08	-0.68	5.93e-65	Blood protein levels;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.9	-13.57	-0.53	1.5e-35	Platelet count;
LGG	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg15017067	chr4:17643749	FAM184B	0.32	7.43	0.33	5.39e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2180341	0.618	rs11961994	chr6:127649350	A/G	cg27446573	chr6:127587934	RNF146	-0.73	-13.41	-0.53	7.06e-35	Breast cancer;
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg18876405	chr7:65276391	NA	-0.54	-9.65	-0.41	3.42e-20	Aortic root size;
LGG	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg12395012	chr8:11607386	GATA4	0.37	6.92	0.31	1.53e-11	Systolic blood pressure;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.58	0.37	1.4e-16	Alzheimer's disease;
LGG	cis	rs10463316	0.817	rs3846713	chr5:150799739	C/T	cg03212797	chr5:150827313	SLC36A1	-0.55	-9.73	-0.41	1.71e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.32	6.77	0.3	4e-11	Schizophrenia;
LGG	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg12458913	chr13:53173898	NA	0.44	7.34	0.32	9.67e-13	Lewy body disease;
LGG	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.53	8.57	0.37	1.59e-16	Cognitive ability;
LGG	cis	rs11098499	0.863	rs2127823	chr4:120485670	G/T	cg09307838	chr4:120376055	NA	0.8	13.51	0.53	2.73e-35	Corneal astigmatism;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg17441724	chr20:271417	C20orf96	0.41	6.92	0.31	1.53e-11	Apolipoprotein A-IV levels;
LGG	cis	rs12618769	0.597	rs17032870	chr2:99132786	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.43	0.56	3.1e-39	Cognitive test performance;
LGG	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg11038491	chr20:34638489	LOC647979	-0.7	-10.14	-0.43	5.92e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2415984	0.579	rs2415999	chr14:46966224	T/C	cg14871534	chr14:47121158	RPL10L	-0.58	-10.17	-0.43	4.45e-22	Number of children ever born;
LGG	cis	rs2033732	0.706	rs1370419	chr8:85068424	G/A	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	4.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.505	rs200937	chr10:38135772	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.09	-0.31	5.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	7.44	0.33	5.01e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg00717180	chr2:96193071	NA	-0.42	-7.46	-0.33	4.37e-13	HDL cholesterol;
LGG	cis	rs1577917	1.000	rs16876529	chr6:86591202	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-11.52	-0.47	3.52e-27	Response to antipsychotic treatment;
LGG	cis	rs2688608	0.592	rs2306328	chr10:75579510	C/T	cg19442545	chr10:75533431	FUT11	-0.44	-7.37	-0.32	7.69e-13	Inflammatory bowel disease;
LGG	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg26597838	chr10:835615	NA	0.53	7.03	0.31	7.32e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs12310956	0.532	rs2087270	chr12:33850109	C/T	cg13010199	chr12:38710504	ALG10B	0.46	8.64	0.37	9.22e-17	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.45e-20	Life satisfaction;
LGG	trans	rs7829975	0.514	rs2976929	chr8:8258712	T/C	cg02002194	chr4:3960332	NA	-0.49	-9.68	-0.41	2.73e-20	Mood instability;
LGG	cis	rs4851266	1.000	rs4303732	chr2:100830040	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.29	0.63	4.96e-52	Response to antipsychotic treatment;
LGG	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.17e-18	Motion sickness;
LGG	trans	rs12310956	0.510	rs11052882	chr12:33890017	T/C	cg26384229	chr12:38710491	ALG10B	0.64	12.44	0.5	7.61e-31	Morning vs. evening chronotype;
LGG	cis	rs41271473	0.948	rs17437060	chr1:228822374	C/T	cg00850481	chr1:228891306	NA	-0.49	-7.99	-0.35	1.05e-14	Chronic lymphocytic leukemia;
LGG	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	cis	rs9463078	0.585	rs10456552	chr6:45313952	G/A	cg25276700	chr6:44698697	NA	0.32	6.78	0.3	3.65e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg12856521	chr11:46389249	DGKZ	-0.49	-8.95	-0.38	8.43e-18	Leprosy;
LGG	cis	rs9300255	0.602	rs1727296	chr12:123647725	G/C	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.07	0.7	1.33e-69	Alzheimer's disease;
LGG	cis	rs59918340	0.728	rs2304279	chr8:142229891	A/G	cg03653399	chr8:142233436	SLC45A4	0.43	8.5	0.37	2.67e-16	Immature fraction of reticulocytes;
LGG	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.63	0.37	9.81e-17	Lung cancer;
LGG	cis	rs9354308	0.764	rs4529284	chr6:66603919	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.8	-0.3	3.23e-11	Metabolite levels;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg22567473	chr15:63902661	HERC1	0.45	6.75	0.3	4.41e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg24687543	chr11:63912206	MACROD1	0.61	8.55	0.37	1.87e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2836974	0.799	rs13047550	chr21:40515495	T/C	cg11890956	chr21:40555474	PSMG1	1.18	25.68	0.77	4.68e-91	Cognitive function;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg05863683	chr7:1912471	MAD1L1	0.44	8.5	0.37	2.57e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2188554	0.785	rs2518881	chr7:117172731	A/G	cg10524701	chr7:117356490	CTTNBP2	0.38	6.72	0.3	5.28e-11	Esophageal adenocarcinoma;
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.3	0.65	1.1e-56	Menopause (age at onset);
LGG	cis	rs919433	0.963	rs12693815	chr2:198168403	T/C	cg00792783	chr2:198669748	PLCL1	-0.44	-6.84	-0.3	2.5e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs12478296	1.000	rs113129906	chr2:243004253	C/T	cg18898632	chr2:242989856	NA	-0.91	-10.09	-0.42	9.27e-22	Obesity-related traits;
LGG	cis	rs7226408	0.553	rs8083306	chr18:34549840	G/A	cg15022739	chr18:34823045	BRUNOL4	0.42	9.12	0.39	2.39e-18	Obesity-related traits;
LGG	cis	rs4870684	0.509	rs11763804	chr7:57702125	G/C	cg01314568	chr7:57830625	NA	-0.62	-10.06	-0.42	1.15e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs2048656	0.508	rs7387886	chr8:9676575	T/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.55	-0.33	2.31e-13	Schizophrenia;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg00933542	chr6:150070202	PCMT1	0.39	7.11	0.31	4.53e-12	Lung cancer;
LGG	cis	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg12486710	chr1:178512616	C1orf220	0.51	10.68	0.44	6.03e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7615952	0.512	rs11921452	chr3:125359750	A/G	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	cis	rs8072100	0.840	rs9893901	chr17:45506682	T/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.33	-0.43	1.22e-22	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg15147215	chr3:52552868	STAB1	-0.46	-9.2	-0.39	1.26e-18	Electroencephalogram traits;
LGG	trans	rs1493916	0.837	rs4992177	chr18:31407020	C/T	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.57e-12	Bladder cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00760200	chr1:115053833	TRIM33	0.58	6.68	0.3	6.7e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10046574	0.561	rs7789858	chr7:135212285	A/G	cg27474649	chr7:135195673	CNOT4	0.73	9.12	0.39	2.28e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg11941060	chr3:133502564	NA	-0.48	-8.07	-0.35	6.17e-15	Iron status biomarkers;
LGG	cis	rs7572733	1.000	rs1025549	chr2:198881183	G/A	cg00792783	chr2:198669748	PLCL1	0.45	7.45	0.33	4.53e-13	Dermatomyositis;
LGG	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	trans	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg10756647	chr7:56101905	PSPH	0.8	9.52	0.4	9.67e-20	Diabetic kidney disease;
LGG	cis	rs12762955	0.507	rs10737004	chr10:1039019	T/C	cg25019033	chr10:957182	NA	0.34	7.0	0.31	8.98e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs11648796	0.757	rs3809665	chr16:764520	G/C	cg07343612	chr16:622815	PIGQ	-0.52	-8.61	-0.37	1.16e-16	Height;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg23758822	chr17:41437982	NA	0.83	14.83	0.57	5.36e-41	Menopause (age at onset);
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg21724239	chr8:58056113	NA	0.59	8.58	0.37	1.47e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	1.000	rs550264	chr17:30317540	G/T	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs929354	0.739	rs1182439	chr7:157027367	G/A	cg17757837	chr7:157058334	UBE3C	-0.78	-15.89	-0.59	1.12e-45	Body mass index;
LGG	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.2	-0.39	1.25e-18	Educational attainment;
LGG	trans	rs2980439	0.807	rs2980438	chr8:8094825	T/C	cg16141378	chr3:129829833	LOC729375	-0.58	-15.29	-0.58	5.2e-43	Neuroticism;
LGG	cis	rs1806153	0.673	rs3026354	chr11:31830657	A/G	cg11990419	chr11:31841155	NA	0.34	7.13	0.31	3.82e-12	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.8	-0.51	2.49e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11634705	chr7:873449	UNC84A	0.42	7.33	0.32	1e-12	Subjective well-being;
LGG	cis	rs9420907	0.688	rs911547	chr10:105639421	A/G	cg11005552	chr10:105648138	OBFC1	-0.65	-8.54	-0.37	2.02e-16	Telomere length;
LGG	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs3213961	0.786	rs1947179	chr2:33821517	T/G	cg04131969	chr2:33951647	MYADML	0.49	7.22	0.32	2.22e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs6961069	0.777	rs1953299	chr7:80265625	T/G	cg04458919	chr7:80252533	CD36	0.28	6.79	0.3	3.56e-11	Platelet count;
LGG	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg16950941	chr11:66035639	RAB1B	0.55	10.23	0.43	2.8e-22	Gout;
LGG	cis	rs7945718	0.810	rs10831910	chr11:12830974	A/G	cg25843174	chr11:12811716	TEAD1	-0.34	-7.01	-0.31	8.7e-12	Educational attainment (years of education);
LGG	cis	rs9487051	0.872	rs9487033	chr6:109605388	C/G	cg21918786	chr6:109611834	NA	0.47	8.76	0.38	3.76e-17	Reticulocyte fraction of red cells;
LGG	cis	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.4	0.33	6.64e-13	Joint mobility (Beighton score);
LGG	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.16	12.6	0.51	1.68e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2531992	0.858	rs2230742	chr16:4016676	C/T	cg05927578	chr16:4029543	ADCY9	-0.69	-9.57	-0.41	6.2e-20	Waist circumference;
LGG	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.08	0.7	1.2e-69	Bladder cancer;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.7	0.37	6.02e-17	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04232541	chr6:144384895	PLAGL1	0.37	7.12	0.31	4.14e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9467160	0.651	rs9393557	chr6:24453195	C/G	cg20631270	chr6:24437470	GPLD1	0.46	7.75	0.34	5.88e-14	Liver enzyme levels;
LGG	cis	rs9399135	1.000	rs9399135	chr6:135368314	G/A	cg24558204	chr6:135376177	HBS1L	0.53	9.44	0.4	1.78e-19	Red blood cell count;
LGG	cis	rs4740619	0.619	rs1328298	chr9:16046417	T/C	cg14451791	chr9:16040625	NA	-0.43	-11.38	-0.47	1.21e-26	Body mass index;
LGG	trans	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg04529724	chr6:150244392	RAET1G	0.34	6.88	0.3	1.96e-11	Testicular germ cell tumor;
LGG	cis	rs1555322	0.872	rs2425046	chr20:33871661	A/G	cg17927777	chr20:33865990	NA	0.78	8.47	0.37	3.18e-16	Attention deficit hyperactivity disorder;
LGG	trans	rs61931739	0.517	rs11052977	chr12:34035030	A/C	cg13010199	chr12:38710504	ALG10B	0.55	10.23	0.43	2.9e-22	Morning vs. evening chronotype;
LGG	cis	rs9290065	0.538	rs9840600	chr3:160769101	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.24	-0.39	8.63e-19	Kawasaki disease;
LGG	cis	rs9942416	0.617	rs72633979	chr5:74990178	A/T	cg19683494	chr5:74908142	NA	0.45	6.83	0.3	2.71e-11	Age-related disease endophenotypes;
LGG	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg23594656	chr7:65796392	TPST1	0.42	8.92	0.38	1.1e-17	Aortic root size;
LGG	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.82	-0.3	2.81e-11	Mood instability;
LGG	trans	rs66573146	0.572	rs67252699	chr4:6946411	A/G	cg07817883	chr1:32538562	TMEM39B	1.17	12.32	0.5	2.26e-30	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1110701	0.525	rs11764792	chr7:50496841	C/T	cg00647317	chr7:50633725	DDC	0.34	8.18	0.36	2.66e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg00405596	chr8:11794950	NA	0.41	6.81	0.3	3.09e-11	Neuroticism;
LGG	cis	rs4481887	0.508	rs7349159	chr1:248386242	C/T	cg01631408	chr1:248437212	OR2T33	-0.42	-7.15	-0.32	3.43e-12	Common traits (Other);
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.6	-0.44	1.15e-23	Lung cancer;
LGG	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg06640241	chr16:89574553	SPG7	0.71	11.27	0.46	3.25e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg15557168	chr22:42548783	NA	-0.38	-7.14	-0.32	3.54e-12	Schizophrenia;
LGG	cis	rs62238980	0.614	rs78017579	chr22:32381234	T/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.12	0.31	4.02e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9596863	0.898	rs9563177	chr13:54368853	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.06	0.31	6.33e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg09263875	chr16:632152	PIGQ	0.65	12.72	0.51	5.27e-32	Height;
LGG	cis	rs9733	0.650	rs3738485	chr1:150552392	C/G	cg13175981	chr1:150552382	MCL1	0.61	10.51	0.44	2.65e-23	Tonsillectomy;
LGG	cis	rs721048	1.000	rs62179283	chr2:62991718	G/A	cg17519650	chr2:63277830	OTX1	0.55	6.66	0.3	7.65e-11	Prostate cancer;
LGG	cis	rs2153535	0.580	rs6912193	chr6:8456306	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.67	-11.65	-0.48	1.09e-27	Longevity;Endometriosis;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg03060546	chr3:49711283	APEH	-0.63	-10.46	-0.44	3.82e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4555082	1.000	rs4555082	chr14:105758964	C/T	cg10792982	chr14:105748885	BRF1	0.54	10.71	0.45	4.66e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11148252	0.740	rs7983971	chr13:52790700	C/T	cg05335186	chr13:53173507	NA	0.4	7.96	0.35	1.39e-14	Lewy body disease;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg04166393	chr7:2884313	GNA12	0.48	8.79	0.38	3.03e-17	Height;
LGG	cis	rs8060686	0.545	rs117751972	chr16:68171968	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg27471124	chr11:109292789	C11orf87	0.47	9.36	0.4	3.5e-19	Schizophrenia;
LGG	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg10792982	chr14:105748885	BRF1	0.67	14.01	0.55	2.02e-37	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6121246	0.609	rs6087783	chr20:30421224	T/G	cg13852791	chr20:30311386	BCL2L1	0.92	17.66	0.63	1.01e-53	Mean corpuscular hemoglobin;
LGG	cis	rs60180747	1.000	rs79809053	chr15:66753168	G/C	cg07575407	chr15:66541975	MEGF11	0.33	6.67	0.3	7.48e-11	Testicular germ cell tumor;
LGG	trans	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg04842962	chr6:43655489	MRPS18A	1.11	23.71	0.74	5.99e-82	IgG glycosylation;
LGG	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.9	-0.57	2.6e-41	Hair morphology;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.89	0.38	1.35e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2172802	0.693	rs10004368	chr4:62496325	A/G	cg04118610	chr4:62707027	LPHN3	-0.47	-7.53	-0.33	2.65e-13	Partial epilepsies;
LGG	cis	rs1983891	0.553	rs3800283	chr6:41558358	A/G	cg20194872	chr6:41519635	FOXP4	0.51	8.8	0.38	2.67e-17	Prostate cancer;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg05335186	chr13:53173507	NA	0.43	8.34	0.36	8.73e-16	Lewy body disease;
LGG	cis	rs7633770	0.643	rs58413466	chr3:46689154	G/T	cg11219411	chr3:46661640	NA	-0.49	-10.68	-0.44	6.08e-24	Coronary artery disease;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg24642844	chr7:1081250	C7orf50	-0.45	-8.51	-0.37	2.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3771570	1.000	rs62190370	chr2:242384194	C/G	cg21155796	chr2:242212141	HDLBP	0.77	10.1	0.42	8.59e-22	Prostate cancer;
LGG	cis	rs9911578	0.835	rs9788975	chr17:56460800	G/A	cg12560992	chr17:57184187	TRIM37	-0.78	-13.16	-0.52	7.9e-34	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.965	rs1056465	chr5:442438	T/A	cg26076054	chr5:421317	AHRR	-0.45	-7.58	-0.33	1.93e-13	Cystic fibrosis severity;
LGG	cis	rs13082711	0.911	rs2131205	chr3:27428501	A/G	cg02860705	chr3:27208620	NA	0.69	12.36	0.5	1.57e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs12791968	0.917	rs11038238	chr11:45002010	A/G	cg11846598	chr11:44996168	LOC221122	-0.67	-12.57	-0.5	2.26e-31	Inhibitory control;
LGG	cis	rs713587	0.520	rs487617	chr2:25309756	C/G	cg04586622	chr2:25135609	ADCY3	-0.31	-7.9	-0.34	2.03e-14	Body mass index in non-asthmatics;
LGG	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs2455601	0.882	rs11042116	chr11:8928472	G/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.68	-11.49	-0.47	4.7e-27	Schizophrenia;
LGG	cis	rs4700695	0.841	rs251306	chr5:65252453	C/T	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	trans	rs6787172	0.686	rs12631196	chr3:158171455	A/G	cg23275840	chr4:47708675	CORIN	-0.39	-8.3	-0.36	1.16e-15	Subjective well-being;
LGG	cis	rs3820928	0.874	rs10176882	chr2:227896432	A/T	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.15	-0.32	3.4e-12	Pulmonary function;
LGG	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg08305652	chr11:111469057	NA	0.43	8.44	0.37	3.96e-16	Primary sclerosing cholangitis;
LGG	cis	rs992157	0.835	rs2045434	chr2:219144498	A/G	cg00012203	chr2:219082015	ARPC2	-0.69	-12.32	-0.5	2.26e-30	Colorectal cancer;
LGG	cis	rs62025270	0.632	rs62022919	chr15:86218310	C/A	cg25843651	chr15:86329602	KLHL25	0.57	8.57	0.37	1.56e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.48	-8.11	-0.35	4.61e-15	Longevity;Endometriosis;
LGG	trans	rs35110281	0.575	rs2876854	chr21:44979232	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.39	0.47	1.14e-26	Mean corpuscular volume;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg07701084	chr6:150067640	NUP43	-0.63	-11.64	-0.48	1.23e-27	Lung cancer;
LGG	cis	rs7572733	0.935	rs1401094	chr2:198779849	C/T	cg00792783	chr2:198669748	PLCL1	-0.49	-8.27	-0.36	1.39e-15	Dermatomyositis;
LGG	cis	rs2282802	0.685	rs2337081	chr5:139642414	A/C	cg26211634	chr5:139558579	C5orf32	0.34	7.58	0.33	1.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9341808	0.754	rs9352808	chr6:80997342	G/T	cg08355045	chr6:80787529	NA	0.38	7.3	0.32	1.25e-12	Sitting height ratio;
LGG	trans	rs1814175	0.817	rs3974439	chr11:50022607	G/A	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16524936	chr4:1340807	KIAA1530	-0.46	-7.57	-0.33	2.03e-13	Longevity;
LGG	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.59	-0.33	1.84e-13	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg19399532	chr1:178512495	C1orf220	0.43	8.33	0.36	9.2e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.31e-86	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02209504	chr10:64576388	EGR2	0.43	6.68	0.3	6.95e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.81	-0.41	9.29e-21	Lung cancer;
LGG	cis	rs2046867	0.862	rs62251656	chr3:72827393	T/C	cg25664220	chr3:72788482	NA	-0.33	-8.95	-0.38	8.95e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7589342	0.792	rs13426321	chr2:106500280	G/A	cg16077055	chr2:106428750	NCK2	0.28	7.11	0.31	4.46e-12	Addiction;
LGG	trans	rs79911532	0.515	rs10235228	chr7:75833282	G/A	cg19862616	chr7:65841803	NCRNA00174	0.66	7.48	0.33	3.82e-13	Mononucleosis;
LGG	cis	rs1417569	0.517	rs2934637	chr10:31193339	T/C	cg00428179	chr10:31322131	ZNF438	-0.37	-8.81	-0.38	2.61e-17	Tuberculosis;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg00424166	chr6:150045504	NUP43	-0.33	-6.94	-0.31	1.33e-11	Lung cancer;
LGG	trans	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.31	-0.32	1.22e-12	Triglycerides;
LGG	cis	rs1862618	0.671	rs2591956	chr5:56244604	G/A	cg08400814	chr5:56204995	C5orf35	0.4	7.12	0.31	4.02e-12	Initial pursuit acceleration;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg21782813	chr7:2030301	MAD1L1	-0.54	-14.12	-0.55	6.64e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.42	-0.33	5.82e-13	Menopause (age at onset);
LGG	cis	rs6815814	0.950	rs66979032	chr4:38814700	A/G	cg06935464	chr4:38784597	TLR10	0.6	7.99	0.35	1.07e-14	Breast cancer;
LGG	cis	rs58649573	0.574	rs10818907	chr9:126770250	C/G	cg14112217	chr9:126806003	NA	-0.39	-7.79	-0.34	4.54e-14	Post-traumatic stress disorder;
LGG	cis	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg09307838	chr4:120376055	NA	0.8	13.41	0.53	7.15e-35	Corneal astigmatism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13022174	chr18:23671059	SS18	0.44	7.38	0.32	7.44e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6076960	0.811	rs6053960	chr20:6176778	T/C	cg17788362	chr6:86352627	SYNCRIP	0.5	8.39	0.36	5.74e-16	Smooth-surface caries;
LGG	cis	rs9790314	0.586	rs34727114	chr3:161138929	A/C	cg04691961	chr3:161091175	C3orf57	-0.42	-8.36	-0.36	7.34e-16	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg16885296	chr6:26284938	NA	0.39	8.45	0.37	3.82e-16	Educational attainment;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.31	-0.43	1.46e-22	Tonsillectomy;
LGG	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs12731740	1.000	rs12568741	chr1:208020677	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.43	-0.33	5.41e-13	Biomedical quantitative traits;
LGG	cis	rs11792861	0.926	rs7470160	chr9:111844246	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.55	0.41	7.32e-20	Menarche (age at onset);
LGG	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.29	0.6	1.71e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs72991	0.793	rs10892743	chr11:121236693	C/A	cg27192990	chr6:129479024	LAMA2	-0.44	-7.44	-0.33	5.1e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs981844	1.000	rs2251997	chr4:154654067	A/G	cg14289246	chr4:154710475	SFRP2	-0.67	-11.18	-0.46	7.37e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs17376456	1.000	rs10514382	chr5:93566534	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.91	8.99	0.39	6.38e-18	Diabetic retinopathy;
LGG	cis	rs7617773	0.817	rs6791930	chr3:48329900	A/G	cg11946769	chr3:48343235	NME6	0.63	10.61	0.44	1.07e-23	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg13206674	chr6:150067644	NUP43	0.4	8.57	0.37	1.61e-16	Testicular germ cell tumor;
LGG	cis	rs4969178	0.932	rs3744219	chr17:76400236	G/A	cg02836325	chr17:76403955	PGS1	-0.7	-14.27	-0.55	1.47e-38	HDL cholesterol levels;
LGG	cis	rs368123	0.920	rs7450667	chr6:160716220	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.15	-0.32	3.34e-12	Waist circumference;
LGG	cis	rs13082711	0.954	rs34772035	chr3:27468872	C/G	cg02860705	chr3:27208620	NA	0.83	15.15	0.58	2.04e-42	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25072359	chr17:41440525	NA	0.52	10.05	0.42	1.27e-21	Menopause (age at onset);
LGG	cis	rs9487094	1.000	rs10080429	chr6:109738106	C/T	cg01125227	chr6:109776195	MICAL1	0.46	7.88	0.34	2.32e-14	Height;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg02071572	chr4:1403502	NA	0.41	7.01	0.31	8.37e-12	Longevity;
LGG	trans	rs9657904	1.000	rs6437620	chr3:105552878	A/G	cg14088669	chr1:158435396	OR10K1	-0.39	-6.72	-0.3	5.38e-11	Multiple sclerosis;
LGG	cis	rs734999	0.545	rs10752748	chr1:2544640	G/A	cg20673091	chr1:2541236	MMEL1	0.77	17.87	0.64	1.03e-54	Ulcerative colitis;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg15383120	chr6:291909	DUSP22	-0.52	-8.36	-0.36	7.32e-16	Menopause (age at onset);
LGG	cis	rs9457247	0.935	rs9348211	chr6:167375173	G/C	cg07741184	chr6:167504864	NA	-0.32	-7.08	-0.31	5.45e-12	Crohn's disease;
LGG	cis	rs6502050	0.805	rs4789740	chr17:80119202	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-8.05	-0.35	6.94e-15	Life satisfaction;
LGG	cis	rs138665726	1	rs138665726	chr22:21917859	A/C	cg15846791	chr22:21984385	YDJC	-0.47	-7.01	-0.31	8.48e-12	Mean corpuscular volume;Red cell distribution width;
LGG	cis	rs523522	0.962	rs7471	chr12:120941215	T/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.81	0.51	2.3e-32	High light scatter reticulocyte count;
LGG	cis	rs12200782	0.649	rs9467743	chr6:26386506	T/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.51	-0.4	1.03e-19	Triglycerides;
LGG	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.88	-0.42	5.07e-21	Primary sclerosing cholangitis;
LGG	cis	rs897984	0.542	rs7199949	chr16:31096164	G/C	cg00531865	chr16:30841666	NA	-0.48	-10.14	-0.43	5.93e-22	Dementia with Lewy bodies;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.62	-0.48	1.49e-27	Neuroticism;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.47	-0.37	3.33e-16	Schizophrenia;
LGG	cis	rs9811920	0.695	rs793497	chr3:99505610	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.32	-0.36	1.01e-15	Axial length;
LGG	cis	rs1348850	0.914	rs10497503	chr2:178371739	G/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.6	-0.37	1.29e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7226408	0.543	rs323321	chr18:34672766	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.13	-0.39	2.17e-18	Obesity-related traits;
LGG	cis	rs1015291	0.680	rs1388676	chr12:19993958	G/A	cg25401612	chr12:20009446	NA	-0.34	-7.27	-0.32	1.57e-12	Diastolic blood pressure;
LGG	cis	rs9534288	0.797	rs1319712	chr13:46591707	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.3	-0.53	2.12e-34	Blood protein levels;
LGG	cis	rs4774830	0.744	rs62046389	chr15:56307688	T/G	cg05129572	chr15:56138634	NEDD4	0.68	6.67	0.3	7.31e-11	Delta-5 desaturase activity;
LGG	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.22	-0.62	1.03e-51	Chronic sinus infection;
LGG	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg20040747	chr15:74715105	SEMA7A	0.4	8.66	0.37	8.13e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.61	0.44	1.08e-23	Lung function (FEV1/FVC);
LGG	cis	rs7255045	0.788	rs7250751	chr19:12962648	A/G	cg07955356	chr19:12992479	DNASE2	0.43	7.29	0.32	1.31e-12	Mean corpuscular volume;
LGG	trans	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.37	-0.36	7.01e-16	Breast cancer;
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg08499158	chr17:42289980	UBTF	-0.65	-11.93	-0.48	8.72e-29	Total body bone mineral density;
LGG	cis	rs17221829	0.733	rs12365125	chr11:89359929	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs8072100	0.902	rs12051716	chr17:45582395	G/A	cg25173405	chr17:45401733	C17orf57	0.47	8.01	0.35	9.27e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7208859	0.623	rs8067035	chr17:29102188	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg13334819	chr7:99746414	C7orf59	-0.49	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs1552244	0.554	rs9878047	chr3:9985457	T/C	cg00149659	chr3:10157352	C3orf10	0.56	8.06	0.35	6.36e-15	Alzheimer's disease;
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg19847130	chr8:10466454	RP1L1	0.3	6.73	0.3	4.92e-11	Joint mobility (Beighton score);
LGG	cis	rs72945132	0.882	rs7122057	chr11:70201430	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.19	0.36	2.59e-15	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.29	-0.32	1.36e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.95	0.42	2.83e-21	Prudent dietary pattern;
LGG	cis	rs10186029	0.680	rs1530238	chr2:213957928	G/C	cg08319019	chr2:214017104	IKZF2	0.45	7.94	0.35	1.53e-14	Systemic sclerosis;
LGG	cis	rs4538187	0.660	rs67615384	chr2:64133432	T/C	cg14150252	chr2:64069583	UGP2	-0.49	-9.08	-0.39	3.12e-18	Systolic blood pressure;
LGG	cis	rs4865875	0.792	rs6891667	chr5:54139679	C/T	cg22421804	chr5:54100067	NA	0.47	6.76	0.3	4.28e-11	Sense of smell;
LGG	cis	rs79976124	0.837	rs74327235	chr6:66648353	T/A	cg07460842	chr6:66804631	NA	0.73	12.56	0.5	2.52e-31	Type 2 diabetes;
LGG	trans	rs9467711	0.591	rs16891315	chr6:26111756	T/C	cg06606381	chr12:133084897	FBRSL1	-0.67	-6.74	-0.3	4.62e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg21963583	chr11:68658836	MRPL21	-0.38	-6.76	-0.3	4.09e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9560113	1.000	rs4773379	chr13:112176088	G/C	cg14952266	chr13:112191215	NA	-0.41	-7.47	-0.33	3.98e-13	Menarche (age at onset);
LGG	cis	rs7937682	0.632	rs7128862	chr11:111755435	C/T	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs9788682	0.895	rs3813570	chr15:78832832	T/C	cg24631222	chr15:78858424	CHRNA5	0.47	7.1	0.31	4.85e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.74	-0.38	4.26e-17	Aortic root size;
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg01988459	chr11:68622903	NA	-0.64	-12.33	-0.5	2.15e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35306767	0.855	rs55697724	chr10:885622	T/C	cg08847335	chr10:891726	LARP4B	-0.53	-9.0	-0.39	5.96e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs2985684	0.748	rs2985686	chr14:50100683	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.42	6.95	0.31	1.22e-11	Carotid intima media thickness;
LGG	cis	rs12681288	0.676	rs6983981	chr8:1016011	A/C	cg04851639	chr8:1020857	NA	-0.44	-8.79	-0.38	2.93e-17	Schizophrenia;
LGG	trans	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg26043149	chr18:55253948	FECH	-0.67	-10.85	-0.45	1.35e-24	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7301826	0.651	rs6486601	chr12:131301237	A/T	cg11011512	chr12:131303247	STX2	-0.39	-8.4	-0.36	5.45e-16	Plasma plasminogen activator levels;
LGG	cis	rs7294478	1.000	rs7294478	chr12:7266805	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.45	-12.29	-0.5	2.97e-30	Neuritic plaque;
LGG	cis	rs975722	0.509	rs34665848	chr7:117356666	T/C	cg10524701	chr7:117356490	CTTNBP2	0.46	8.25	0.36	1.61e-15	Coronary artery disease;
LGG	cis	rs952623	0.649	rs12538487	chr7:39075380	A/G	cg18850127	chr7:39170497	POU6F2	0.35	8.17	0.35	2.98e-15	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	1.000	rs72796337	chr2:24142957	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs9875589	0.509	rs9867041	chr3:14014615	T/C	cg19554555	chr3:13937349	NA	-0.54	-9.8	-0.41	9.73e-21	Ovarian reserve;
LGG	cis	rs2629751	0.537	rs2722200	chr12:104365122	G/A	cg14987745	chr12:104360022	TDG	-0.51	-8.05	-0.35	7.08e-15	Hepatitis C induced liver fibrosis;
LGG	cis	rs807669	0.903	rs2854643	chr22:19189706	T/C	cg02655711	chr22:19163373	SLC25A1	0.77	15.64	0.59	1.38e-44	Metabolite levels;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.94	-0.42	3.01e-21	Lung cancer;
LGG	cis	rs262147	1.000	rs262147	chr7:158745142	A/G	cg20533982	chr7:158533927	ESYT2	0.53	6.9	0.31	1.75e-11	Hippocampal volume;
LGG	cis	rs2287838	0.704	rs12977419	chr19:10000199	T/C	cg00846166	chr19:10022875	OLFM2	0.32	7.28	0.32	1.4e-12	Sleep duration;
LGG	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-10.16	-0.43	5.12e-22	Common traits (Other);
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4006360	0.628	rs34859541	chr17:39226322	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.33	-0.43	1.15e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9303401	0.659	rs7210700	chr17:56668186	G/A	cg25039879	chr17:56429692	SUPT4H1	0.65	9.24	0.39	9.2e-19	Cognitive test performance;
LGG	cis	rs4631830	0.863	rs7081532	chr10:51526093	A/G	cg16070123	chr10:51489643	NA	-0.4	-7.38	-0.32	7.19e-13	Prostate-specific antigen levels;
LGG	cis	rs208520	0.909	rs9453672	chr6:66991431	A/G	cg07460842	chr6:66804631	NA	0.89	14.69	0.56	2.35e-40	Exhaled nitric oxide output;
LGG	cis	rs4774830	0.744	rs2036739	chr15:56289745	G/T	cg24530489	chr15:56299380	NA	-0.85	-7.71	-0.34	7.92e-14	Delta-5 desaturase activity;
LGG	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Colorectal cancer;
LGG	cis	rs8180040	1.000	rs1638676	chr3:47327651	A/G	cg16586182	chr3:47516702	SCAP	-0.76	-15.06	-0.57	5.06e-42	Colorectal cancer;
LGG	cis	rs137887	0.935	rs137885	chr22:50463231	T/C	cg17558497	chr22:50464837	TTLL8	0.45	8.46	0.37	3.63e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.21e-20	Life satisfaction;
LGG	cis	rs4930103	0.935	rs2525881	chr11:2019333	T/C	cg06197492	chr11:2016605	H19	0.49	10.08	0.42	1.02e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.57	0.5	2.25e-31	Alzheimer's disease;
LGG	cis	rs6840360	0.593	rs4696107	chr4:152606823	G/A	cg22705602	chr4:152727874	NA	-0.37	-8.88	-0.38	1.5e-17	Intelligence (multi-trait analysis);
LGG	cis	rs12282928	0.743	rs1109906	chr11:48284033	C/T	cg26585981	chr11:48327164	OR4S1	-0.41	-7.03	-0.31	7.48e-12	Migraine - clinic-based;
LGG	cis	rs76419734	0.510	rs17036102	chr4:106603098	C/T	cg11477892	chr4:106580295	NA	0.42	6.87	0.3	2.1e-11	Post bronchodilator FEV1;
LGG	cis	rs17776563	0.959	rs17197194	chr15:89111610	G/A	cg05013243	chr15:89149849	MIR1179	-0.51	-10.32	-0.43	1.35e-22	Thyroid hormone levels;
LGG	cis	rs7927771	0.896	rs12794570	chr11:47658314	C/T	cg20307385	chr11:47447363	PSMC3	-0.48	-8.56	-0.37	1.64e-16	Subjective well-being;
LGG	cis	rs9611565	0.921	rs5751080	chr22:41736267	A/G	cg06634786	chr22:41940651	POLR3H	-0.62	-10.53	-0.44	2.15e-23	Vitiligo;
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg05484376	chr2:27715224	FNDC4	0.45	9.56	0.41	6.92e-20	Menopause (age at onset);
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.04	0.62	6.63e-51	Alzheimer's disease;
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg18252515	chr7:66147081	NA	0.42	7.1	0.31	4.59e-12	Aortic root size;
LGG	cis	rs4679904	0.921	rs1920663	chr3:160304350	A/G	cg20378687	chr3:160281681	KPNA4	-0.35	-6.68	-0.3	6.75e-11	Primary biliary cholangitis;
LGG	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg23594656	chr7:65796392	TPST1	0.37	7.78	0.34	4.7e-14	Aortic root size;
LGG	cis	rs7572733	0.935	rs9288281	chr2:198744366	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.43	0.36	4.58e-16	Dermatomyositis;
LGG	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg08885076	chr2:99613938	TSGA10	-0.59	-12.09	-0.49	2.05e-29	Chronic sinus infection;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.23	0.58	9.89e-43	Platelet count;
LGG	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg13009111	chr11:71350975	NA	0.35	7.62	0.33	1.45e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8049634	0.732	rs11149631	chr16:84228770	G/C	cg26466773	chr16:84211947	TAF1C	0.42	6.98	0.31	1.04e-11	Small cell lung carcinoma;
LGG	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg01221209	chr5:554886	NA	-0.49	-7.77	-0.34	5.22e-14	Obesity-related traits;
LGG	cis	rs6866344	0.601	rs4419608	chr5:178097049	C/T	cg10224037	chr5:178157518	ZNF354A	0.52	7.56	0.33	2.15e-13	Neutrophil percentage of white cells;
LGG	cis	rs12586317	0.620	rs8021414	chr14:35581480	T/A	cg16230307	chr14:35515116	FAM177A1	0.88	13.03	0.52	2.91e-33	Psoriasis;
LGG	trans	rs116095464	0.558	rs1971229	chr5:268187	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.61	0.53	1.02e-35	Breast cancer;
LGG	cis	rs4237845	0.591	rs10747788	chr12:58315338	C/T	cg02175503	chr12:58329896	NA	0.8	14.71	0.56	1.84e-40	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9462027	0.628	rs7769961	chr6:34760162	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs2273669	0.667	rs116189763	chr6:109302894	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs11971779	0.616	rs2883772	chr7:139072756	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9611565	1.000	rs1109151	chr22:41752944	A/G	cg06481639	chr22:41940642	POLR3H	-0.46	-7.02	-0.31	7.9e-12	Vitiligo;
LGG	cis	rs3768617	0.510	rs6424889	chr1:183091796	G/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6088580	0.608	rs1205342	chr20:32921842	C/T	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.42	-0.36	4.73e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg10556349	chr10:835070	NA	-0.33	-8.36	-0.36	7.65e-16	Survival in rectal cancer;
LGG	cis	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg05084668	chr3:125655381	ALG1L	-0.56	-7.53	-0.33	2.76e-13	Blood pressure (smoking interaction);
LGG	cis	rs9443645	0.901	rs1542977	chr6:79550307	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.81	-0.38	2.58e-17	Intelligence (multi-trait analysis);
LGG	cis	rs112591243	0.614	rs78654337	chr21:47824372	A/G	cg10657630	chr21:48055338	PRMT2	0.93	7.8	0.34	4.11e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs5769765	0.955	rs7511159	chr22:50307896	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.22	-0.43	3.12e-22	Schizophrenia;
LGG	cis	rs6504108	0.647	rs3805371	chr17:46259101	G/A	cg02219949	chr17:45927392	SP6	0.43	8.06	0.35	6.72e-15	Body mass index;
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg10505658	chr17:80084571	CCDC57	-0.4	-8.17	-0.35	2.99e-15	Life satisfaction;
LGG	cis	rs11690935	0.885	rs7602037	chr2:172817794	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-22.35	-0.72	1.35e-75	Schizophrenia;
LGG	cis	rs3096299	0.606	rs4785674	chr16:89536613	A/G	cg06640241	chr16:89574553	SPG7	0.68	10.69	0.44	5.63e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs5758659	0.714	rs5758574	chr22:42481400	G/C	cg04733989	chr22:42467013	NAGA	-0.37	-6.66	-0.3	7.91e-11	Cognitive function;
LGG	cis	rs11645898	1.000	rs11645898	chr16:72229532	A/G	cg14768367	chr16:72042858	DHODH	-0.75	-10.4	-0.44	6.33e-23	Blood protein levels;
LGG	cis	rs2153535	0.601	rs330105	chr6:8543981	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.12	0.39	2.36e-18	Motion sickness;
LGG	cis	rs3020736	0.500	rs5996111	chr22:42493902	C/T	cg04733989	chr22:42467013	NAGA	-0.58	-10.32	-0.43	1.31e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg26695010	chr11:65641043	EFEMP2	-0.57	-9.84	-0.42	7.16e-21	Eosinophil percentage of white cells;
LGG	cis	rs72945132	0.709	rs28634008	chr11:70225719	A/C	cg14191688	chr11:70257035	CTTN	0.59	7.97	0.35	1.22e-14	Coronary artery disease;
LGG	cis	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg22437258	chr11:111473054	SIK2	0.56	9.74	0.41	1.68e-20	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg24607181	chr17:41446203	NA	0.29	6.65	0.3	8.03e-11	Menopause (age at onset);
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg16482183	chr6:26056742	HIST1H1C	0.41	7.01	0.31	8.52e-12	Height;
LGG	cis	rs6952808	0.573	rs12668848	chr7:2020995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.87	-0.42	5.68e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg02023728	chr11:77925099	USP35	0.46	8.14	0.35	3.63e-15	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.11	-0.31	4.29e-12	Lung cancer;
LGG	cis	rs4363385	0.510	rs12083211	chr1:153032131	A/T	cg13444842	chr1:152974279	SPRR3	0.46	9.23	0.39	9.92e-19	Inflammatory skin disease;
LGG	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs2839186	1.000	rs2839181	chr21:47685939	A/G	cg05896524	chr21:47604654	C21orf56	0.64	11.33	0.47	2.03e-26	Testicular germ cell tumor;
LGG	cis	rs7226408	0.600	rs323330	chr18:34701175	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.12	-0.39	2.37e-18	Obesity-related traits;
LGG	trans	rs9354308	0.868	rs1938063	chr6:66559098	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.52	-8.75	-0.38	3.97e-17	Metabolite levels;
LGG	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.01	0.39	5.49e-18	Systolic blood pressure;
LGG	cis	rs1784581	0.674	rs1789990	chr6:162406957	G/T	cg17173639	chr6:162384350	PARK2	-0.66	-14.25	-0.55	1.82e-38	Itch intensity from mosquito bite;
LGG	cis	rs1728785	1.000	rs698712	chr16:68561879	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.22	-0.36	2.04e-15	Ulcerative colitis;
LGG	cis	rs6952808	0.771	rs4719336	chr7:1916397	T/C	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.35	-0.43	1.01e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.78	0.38	3.13e-17	Platelet count;
LGG	cis	rs703842	0.616	rs10877024	chr12:58226709	C/T	cg02175503	chr12:58329896	NA	0.49	7.75	0.34	5.71e-14	Multiple sclerosis;
LGG	cis	rs4906332	1.000	rs10459573	chr14:103925457	A/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.85	-0.34	2.97e-14	Coronary artery disease;
LGG	cis	rs2371030	0.659	rs12997044	chr2:211644461	T/C	cg18417063	chr2:211583084	NA	0.55	8.9	0.38	1.26e-17	Non-small cell lung cancer;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg05556477	chr5:131705319	SLC22A5	0.85	10.23	0.43	2.86e-22	Rheumatoid arthritis;
LGG	cis	rs854037	0.698	rs67100825	chr5:57071365	A/T	cg08523694	chr5:57076192	NA	0.5	7.09	0.31	4.95e-12	Birth weight;
LGG	cis	rs7523273	0.505	rs34277355	chr1:207881491	C/A	cg22525895	chr1:207977042	MIR29B2	0.46	8.7	0.37	5.98e-17	Schizophrenia;
LGG	cis	rs3617	0.539	rs11922975	chr3:52936763	C/T	cg11645453	chr3:52864694	ITIH4	-0.44	-7.37	-0.32	8e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04076212	chr1:179335396	C1orf125	0.49	7.53	0.33	2.71e-13	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg19143629	chr17:61920732	SMARCD2	0.41	7.11	0.31	4.54e-12	Prudent dietary pattern;
LGG	cis	rs12421382	0.659	rs60143378	chr11:109385513	T/C	cg15948088	chr11:109293068	C11orf87	0.51	8.95	0.38	8.5e-18	Schizophrenia;
LGG	cis	rs2282300	0.739	rs34951229	chr11:30265166	C/G	cg25418670	chr11:30344373	C11orf46	-0.56	-7.91	-0.35	1.88e-14	Morning vs. evening chronotype;
LGG	cis	rs62103177	0.535	rs34299914	chr18:77949236	C/A	cg20368463	chr18:77673604	PQLC1	0.53	6.88	0.3	1.92e-11	Opioid sensitivity;
LGG	cis	rs763121	0.853	rs5750677	chr22:39147715	C/T	cg06022373	chr22:39101656	GTPBP1	0.86	16.89	0.62	3.14e-50	Menopause (age at onset);
LGG	cis	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.77	-0.34	5.04e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-9.47	-0.4	1.42e-19	Type 2 diabetes;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg12070911	chr6:150209640	RAET1E	0.28	6.92	0.31	1.53e-11	Lung cancer;
LGG	cis	rs6088580	0.634	rs6120669	chr20:33105028	T/C	cg08999081	chr20:33150536	PIGU	0.4	10.13	0.43	6.34e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7589342	0.801	rs13411829	chr2:106466101	G/C	cg14210321	chr2:106509881	NCK2	-0.55	-9.61	-0.41	4.5e-20	Addiction;
LGG	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs17321999	0.516	rs7569754	chr2:30502177	A/C	cg05247661	chr2:30472410	LBH	0.57	7.26	0.32	1.65e-12	Systemic lupus erythematosus;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	4.08e-20	Schizophrenia;
LGG	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg21153622	chr11:89784906	NA	-0.41	-7.0	-0.31	9.21e-12	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.56	0.33	2.23e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2133450	0.712	rs17698091	chr3:7371151	T/C	cg19930620	chr3:7340148	GRM7	-0.37	-7.82	-0.34	3.69e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg06481639	chr22:41940642	POLR3H	0.54	7.86	0.34	2.7e-14	Vitiligo;
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg16141378	chr3:129829833	LOC729375	0.43	10.04	0.42	1.32e-21	Triglycerides;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg02297831	chr4:17616191	MED28	0.45	7.88	0.34	2.41e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs1983372	chr7:65611351	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.79e-21	Aortic root size;
LGG	cis	rs9815354	0.812	rs73069240	chr3:41950973	A/T	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28595532	0.841	rs114385163	chr4:119737058	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs16854884	0.710	rs9829796	chr3:143801416	C/T	cg06585982	chr3:143692056	C3orf58	0.51	8.38	0.36	6.52e-16	Economic and political preferences (feminism/equality);
LGG	cis	rs7089973	0.584	rs758585	chr10:116582560	C/A	cg08188268	chr10:116634841	FAM160B1	0.3	6.68	0.3	6.73e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg12179176	chr11:130786555	SNX19	0.76	14.57	0.56	7.72e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg26384229	chr12:38710491	ALG10B	-0.67	-13.37	-0.53	1.05e-34	Heart rate;
LGG	cis	rs7586879	0.929	rs6545807	chr2:25124358	C/T	cg04586622	chr2:25135609	ADCY3	0.39	9.87	0.42	5.71e-21	Body mass index;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.84e-16	Lung cancer;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg26617929	chr16:1858877	NA	-0.61	-8.6	-0.37	1.24e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.81	-0.3	2.98e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17711722	0.640	rs13237956	chr7:65318029	G/A	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Calcium levels;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg23758822	chr17:41437982	NA	0.9	15.7	0.59	7.84e-45	Menopause (age at onset);
LGG	cis	rs55823223	0.503	rs55699990	chr17:73859186	A/G	cg14829360	chr17:73884958	NA	-0.84	-15.41	-0.58	1.51e-43	Psoriasis;
LGG	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg27476859	chr7:2772710	GNA12	0.53	10.54	0.44	2e-23	Height;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06112835	chr11:68658793	MRPL21	0.63	10.17	0.43	4.58e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs34546498	1	rs34546498	chr6:26961280	C/T	cg08344181	chr3:125677491	NA	-0.95	-8.99	-0.39	6.44e-18	Breast cancer;
LGG	cis	rs4953318	0.796	rs10168349	chr2:46360907	G/C	cg12428440	chr2:46370979	PRKCE	0.42	8.01	0.35	9.63e-15	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.11e-12	Electroencephalogram traits;
LGG	cis	rs1843834	1.000	rs1843834	chr2:225558042	A/G	cg22455342	chr2:225449267	CUL3	0.57	9.62	0.41	4.47e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg05696931	chr1:227175867	NA	0.41	8.41	0.36	5.25e-16	Myeloid white cell count;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg18402987	chr7:1209562	NA	0.67	9.13	0.39	2.09e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs78487399	0.808	rs17030818	chr2:43680318	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs7503807	0.515	rs12944407	chr17:78691979	C/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs7799006	0.929	rs35791351	chr7:2269248	C/T	cg02951883	chr7:2050386	MAD1L1	-0.42	-7.35	-0.32	9.15e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs208520	0.770	rs2224422	chr6:66883993	G/A	cg07460842	chr6:66804631	NA	-0.95	-17.42	-0.63	1.25e-52	Exhaled nitric oxide output;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.95	0.35	1.41e-14	Lung cancer;
LGG	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg08000102	chr2:233561755	GIGYF2	-0.64	-10.2	-0.43	3.64e-22	Schizophrenia;
LGG	trans	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	trans	rs6601327	0.602	rs12678014	chr8:9649165	T/C	cg06636001	chr8:8085503	FLJ10661	0.39	7.06	0.31	6.1e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg13607699	chr17:42295918	UBTF	0.55	9.12	0.39	2.35e-18	Total body bone mineral density;
LGG	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg03733263	chr8:22462867	KIAA1967	1.01	23.5	0.74	5.91e-81	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs921968	0.612	rs496908	chr2:219357742	A/T	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.49e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4363385	0.626	rs11205179	chr1:153021399	A/G	cg13444842	chr1:152974279	SPRR3	-0.48	-9.89	-0.42	4.67e-21	Inflammatory skin disease;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg03605463	chr16:89740564	NA	0.42	7.08	0.31	5.33e-12	Vitiligo;
LGG	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg19455335	chr8:22457658	C8orf58	-0.44	-8.85	-0.38	1.86e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg15556689	chr8:8085844	FLJ10661	0.54	10.22	0.43	3.03e-22	Mood instability;
LGG	cis	rs7917772	0.582	rs7906115	chr10:104327164	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.52	0.47	3.57e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10791323	0.569	rs10791328	chr11:133713730	A/G	cg00579200	chr11:133705235	NA	-0.58	-10.95	-0.45	5.56e-25	Childhood ear infection;
LGG	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg22437258	chr11:111473054	SIK2	-0.57	-9.87	-0.42	5.76e-21	Primary sclerosing cholangitis;
LGG	cis	rs533581	0.844	rs548591	chr16:88974516	A/G	cg16701003	chr16:89028210	CBFA2T3	0.6	10.26	0.43	2.15e-22	Social autistic-like traits;
LGG	cis	rs6582630	0.538	rs12305104	chr12:38336353	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.1	-0.42	8.13e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7086627	0.515	rs6585994	chr10:82191643	A/G	cg01528321	chr10:82214614	TSPAN14	0.73	13.37	0.53	1.09e-34	Post bronchodilator FEV1;
LGG	cis	rs9878978	1.000	rs1542901	chr3:2474012	A/G	cg21928760	chr3:2462534	CNTN4	0.41	8.92	0.38	1.12e-17	Blood pressure (smoking interaction);
LGG	cis	rs2777491	0.540	rs7164684	chr15:41705008	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.23	-0.85	4.27e-133	Ulcerative colitis;
LGG	cis	rs7666738	0.830	rs35644814	chr4:98886111	G/C	cg05340658	chr4:99064831	C4orf37	0.47	7.79	0.34	4.39e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	1.000	rs10257427	chr7:65743208	T/C	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.69e-16	Aortic root size;
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg21775007	chr8:11205619	TDH	-0.43	-6.84	-0.3	2.49e-11	Neuroticism;
LGG	cis	rs773506	0.628	rs10991816	chr9:93950513	C/T	cg14232218	chr9:93922330	NA	0.35	6.78	0.3	3.73e-11	Type 2 diabetes nephropathy;
LGG	cis	rs12477438	0.520	rs717454	chr2:100022772	T/C	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg25173405	chr17:45401733	C17orf57	0.56	9.19	0.39	1.33e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg00405596	chr8:11794950	NA	0.63	11.29	0.46	2.76e-26	Neuroticism;
LGG	cis	rs35740288	1.000	rs35740288	chr15:86297085	T/A	cg04173714	chr15:86211321	AKAP13	0.4	7.05	0.31	6.64e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg03188948	chr7:1209495	NA	0.45	8.3	0.36	1.16e-15	Longevity;Endometriosis;
LGG	trans	rs10853191	0.558	rs7244914	chr18:10849472	G/C	cg11727592	chr13:46916922	C13orf18	0.3	6.91	0.31	1.58e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs17102423	0.661	rs4468529	chr14:65611968	C/T	cg11161011	chr14:65562177	MAX	-0.73	-13.19	-0.52	5.9e-34	Obesity-related traits;
LGG	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg04568710	chr12:38710424	ALG10B	0.35	7.46	0.33	4.19e-13	Morning vs. evening chronotype;
LGG	cis	rs2816316	1.000	rs2816317	chr1:192536385	G/A	cg10861751	chr1:192544716	RGS1	0.33	6.74	0.3	4.82e-11	Celiac disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06747863	chr12:118810789	TAOK3	0.54	8.55	0.37	1.87e-16	Gut microbiome composition (summer);
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.27	0.6	2.19e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs629535	0.862	rs662725	chr8:70029616	C/T	cg21567404	chr3:27674614	NA	0.4	6.69	0.3	6.5500000000000006e-11	Dupuytren's disease;
LGG	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg11984989	chr7:158649758	WDR60	1.01	14.39	0.56	4.67e-39	Height;
LGG	trans	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg25214090	chr10:38739885	LOC399744	0.43	7.82	0.34	3.62e-14	Diastolic blood pressure;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg18187862	chr3:45730750	SACM1L	0.64	10.57	0.44	1.59e-23	Primary sclerosing cholangitis;
LGG	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg03606772	chr1:152487856	CRCT1	0.31	7.36	0.32	8.57e-13	Hair morphology;
LGG	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg17201900	chr20:34330562	RBM39	0.51	6.92	0.31	1.46e-11	Total cholesterol levels;
LGG	cis	rs4481887	0.741	rs6587467	chr1:248550976	T/G	cg01631408	chr1:248437212	OR2T33	-0.4	-7.15	-0.32	3.33e-12	Common traits (Other);
LGG	cis	rs2180341	0.842	rs9372860	chr6:127546605	G/A	cg27446573	chr6:127587934	RNF146	1.05	18.45	0.65	2.24e-57	Breast cancer;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg04503457	chr17:41445688	NA	-0.4	-9.45	-0.4	1.66e-19	Menopause (age at onset);
LGG	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg15556689	chr8:8085844	FLJ10661	0.49	8.96	0.38	8.3e-18	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs2197308	0.740	rs10880619	chr12:37922720	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.35	0.36	7.83e-16	Personality dimensions;
LGG	cis	rs12479064	0.671	rs4851207	chr2:100105775	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.64	-9.9	-0.42	4.39e-21	Chronic sinus infection;
LGG	cis	rs11209002	0.614	rs6670381	chr1:67562106	G/T	cg02640540	chr1:67518911	SLC35D1	0.42	7.27	0.32	1.59e-12	Crohn's disease;
LGG	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.68	-0.37	6.61e-17	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg16507663	chr6:150244633	RAET1G	0.43	8.08	0.35	5.7e-15	Lung cancer;
LGG	cis	rs7172677	0.768	rs12148425	chr15:75354972	T/C	cg10253484	chr15:75165896	SCAMP2	0.52	7.56	0.33	2.25e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7503807	0.688	rs7503203	chr17:78590528	G/A	cg18469159	chr17:78755841	RPTOR	-0.38	-7.02	-0.31	7.73e-12	Obesity;
LGG	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.49	0.5	4.73e-31	Motion sickness;
LGG	cis	rs6088580	0.634	rs6087577	chr20:32955423	C/T	cg24642439	chr20:33292090	TP53INP2	0.56	9.48	0.4	1.38e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs7769051	0.711	rs7738071	chr6:133085116	G/A	cg07930552	chr6:133119739	C6orf192	0.86	11.42	0.47	8.69e-27	Type 2 diabetes nephropathy;
LGG	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg09517075	chr8:22133004	PIWIL2	0.44	9.59	0.41	5.47e-20	Hypertriglyceridemia;
LGG	cis	rs58616815	0.857	rs34884069	chr10:92157247	T/C	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs11711311	1.000	rs2566968	chr3:113474154	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	13.08	0.52	1.67e-33	IgG glycosylation;
LGG	trans	rs57046232	0.552	rs6085506	chr20:6326507	T/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.89	0.3	1.82e-11	Colorectal cancer;
LGG	cis	rs9875589	0.509	rs4685051	chr3:13981760	A/G	cg19554555	chr3:13937349	NA	-0.55	-9.72	-0.41	1.8899999999999998e-20	Ovarian reserve;
LGG	cis	rs2032447	0.802	rs199755	chr6:25990367	G/A	cg03517284	chr6:25882590	NA	-0.65	-12.08	-0.49	2.17e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.505	rs4708888	chr6:161206490	A/C	cg01280913	chr6:161186852	NA	-0.5	-10.36	-0.43	9.41e-23	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.06	-0.6	1.84e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs972578	0.791	rs5751380	chr22:43227867	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.81	-0.3	3.02e-11	Mean platelet volume;
LGG	cis	rs853679	0.569	rs9348798	chr6:28143011	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	8.61e-14	Depression;
LGG	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.73	0.41	1.79e-20	Lung cancer in ever smokers;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.43	-9.22	-0.39	1.08e-18	Schizophrenia;
LGG	cis	rs2635047	0.615	rs938134	chr18:44751374	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	6.93	0.31	1.38e-11	Educational attainment;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs7524258	0.868	rs4243825	chr1:7308264	T/C	cg07173049	chr1:7289937	CAMTA1	0.78	18.38	0.65	4.52e-57	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.818	rs2070964	chr1:153004213	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.82	-0.38	2.35e-17	Inflammatory skin disease;
LGG	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg05484508	chr16:89589025	SPG7	0.44	7.22	0.32	2.15e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg18402987	chr7:1209562	NA	0.67	9.29	0.4	5.95e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4262150	0.883	rs72801026	chr5:152203902	C/T	cg12297329	chr5:152029980	NA	-0.66	-12.35	-0.5	1.77e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs847649	0.842	rs7789252	chr7:102624227	C/A	cg18108683	chr7:102477205	FBXL13	-0.6	-12.87	-0.51	1.33e-32	Morning vs. evening chronotype;
LGG	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg09165964	chr15:75287851	SCAMP5	0.69	13.03	0.52	2.81e-33	Breast cancer;
LGG	cis	rs9943753	0.508	rs5013021	chr12:109790752	C/A	cg19025524	chr12:109796872	NA	-0.56	-11.81	-0.48	2.66e-28	HDL cholesterol;
LGG	cis	rs7188861	0.768	rs412861	chr16:11382756	T/G	cg01510278	chr16:11456238	NA	0.29	7.07	0.31	5.66e-12	HDL cholesterol;
LGG	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.21	-0.32	2.31e-12	Menarche (age at onset);
LGG	cis	rs7681440	0.838	rs1348224	chr4:90761946	G/A	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg26150922	chr2:100937072	LONRF2	-0.5	-9.18	-0.39	1.4e-18	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs4974582	chr4:1279687	C/T	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs1408799	0.704	rs10960783	chr9:12763809	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.34	0.36	8.86e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs1697139	0.935	rs1627990	chr5:66513326	C/T	cg16691251	chr5:66510806	NA	-0.33	-6.65	-0.3	8.47e-11	Breast cancer;
LGG	cis	rs561341	0.800	rs7209766	chr17:30234848	T/A	cg13647721	chr17:30228624	UTP6	0.79	11.29	0.46	2.72e-26	Hip circumference adjusted for BMI;
LGG	cis	rs503734	0.666	rs10936664	chr3:101215356	T/C	cg27318481	chr3:100970896	IMPG2	0.35	7.12	0.31	4.25e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg03160526	chr17:80928410	B3GNTL1	0.5	7.65	0.34	1.14e-13	Glycated hemoglobin levels;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	8.34	0.36	8.59e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22618164	chr12:122356400	WDR66	0.37	10.57	0.44	1.58e-23	Mean corpuscular volume;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg02462569	chr6:150064036	NUP43	-0.42	-8.99	-0.39	6.59e-18	Lung cancer;
LGG	cis	rs17331151	0.541	rs11709430	chr3:52862055	G/A	cg04865290	chr3:52927548	TMEM110	-0.41	-6.97	-0.31	1.12e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg00409905	chr10:38381863	ZNF37A	-0.52	-9.49	-0.4	1.25e-19	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.54	7.87	0.34	2.47e-14	Renal function-related traits (BUN);
LGG	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg06532163	chr17:45867833	NA	0.54	9.1	0.39	2.67e-18	IgG glycosylation;
LGG	cis	rs9916302	0.904	rs8077104	chr17:37530510	A/G	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg26384229	chr12:38710491	ALG10B	0.93	20.82	0.7	1.9e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg08888203	chr3:10149979	C3orf24	0.56	9.47	0.4	1.43e-19	Alzheimer's disease;
LGG	cis	rs1466045	0.698	rs10833326	chr11:3158634	C/T	cg01418188	chr11:3145609	OSBPL5	0.28	7.06	0.31	6.05e-12	Cisplatin-induced ototoxicity;
LGG	cis	rs798554	1.000	rs798550	chr7:2760609	A/G	cg13628971	chr7:2884303	GNA12	0.5	9.82	0.42	8.39e-21	Height;
LGG	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.28e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg16662043	chr16:48846231	NA	0.37	7.22	0.32	2.16e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.65e-12	Blood metabolite levels;
LGG	cis	rs908922	0.628	rs488393	chr1:152489548	C/T	cg09873164	chr1:152488093	CRCT1	0.65	16.1	0.6	1.26e-46	Hair morphology;
LGG	cis	rs2013441	1.000	rs8079701	chr17:20216565	G/A	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs9287719	0.967	rs1541574	chr2:10773508	A/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.33	-0.32	1.06e-12	Prostate cancer;
LGG	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg14186256	chr22:23484241	RTDR1	0.97	23.59	0.74	2.12e-81	Bone mineral density;
LGG	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.64	-8.17	-0.36	2.86e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6087990	0.814	rs2424895	chr20:31335978	C/T	cg13636640	chr20:31349939	DNMT3B	-0.84	-16.9	-0.62	2.83e-50	Ulcerative colitis;
LGG	cis	rs4417704	0.551	rs6437221	chr2:241896418	C/T	cg14055004	chr2:241860995	NA	-0.28	-7.35	-0.32	9.04e-13	Joint mobility (Beighton score);
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg08742575	chr21:47604166	C21orf56	-0.42	-6.97	-0.31	1.11e-11	Testicular germ cell tumor;
LGG	cis	rs6942756	0.774	rs66479871	chr7:129009687	T/C	cg02491457	chr7:128862824	NA	-0.61	-11.22	-0.46	5.14e-26	White matter hyperintensity burden;
LGG	cis	rs3857536	0.740	rs6455080	chr6:66887413	T/A	cg07460842	chr6:66804631	NA	-0.48	-8.41	-0.36	5.29e-16	Blood trace element (Cu levels);
LGG	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.21	0.36	2.23e-15	Retinal vascular caliber;
LGG	cis	rs9290065	0.519	rs9857743	chr3:160677732	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.86	-0.38	1.71e-17	Kawasaki disease;
LGG	cis	rs4665809	1.000	rs6546727	chr2:26275282	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	2.96e-33	Gut microbiome composition (summer);
LGG	cis	rs732765	1.000	rs732765	chr14:75365729	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.47	-6.69	-0.3	6.65e-11	Non-small cell lung cancer;
LGG	cis	rs10937275	1.000	rs35923019	chr3:186651388	C/T	cg24050613	chr3:186648279	ST6GAL1	0.86	8.86	0.38	1.74e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6703335	0.547	rs12748751	chr1:243640881	A/G	cg25706552	chr1:244017396	NA	-0.37	-7.97	-0.35	1.28e-14	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs7100689	0.784	rs10736342	chr10:82130005	A/G	cg01528321	chr10:82214614	TSPAN14	0.94	16.77	0.61	1.15e-49	Post bronchodilator FEV1;
LGG	cis	rs2204008	0.558	rs66545149	chr12:38204694	A/G	cg26384229	chr12:38710491	ALG10B	0.95	20.58	0.69	2.67e-67	Bladder cancer;
LGG	cis	rs10791097	0.702	rs10894267	chr11:130714861	C/T	cg12179176	chr11:130786555	SNX19	-0.64	-11.54	-0.47	2.9e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2976388	0.590	rs4736322	chr8:143822208	T/C	cg06565975	chr8:143823917	SLURP1	-0.53	-13.5	-0.53	2.95e-35	Urinary tract infection frequency;
LGG	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg09165964	chr15:75287851	SCAMP5	0.64	12.23	0.49	5.36e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs151997	0.671	rs493507	chr5:50219675	G/T	cg06027927	chr5:50259733	NA	-0.6	-10.15	-0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs8014204	0.587	rs6574201	chr14:75387256	T/C	cg03030879	chr14:75389066	RPS6KL1	0.46	8.11	0.35	4.61e-15	Caffeine consumption;
LGG	cis	rs4727027	0.704	rs12535115	chr7:148895087	C/T	cg23583168	chr7:148888333	NA	-0.93	-19.23	-0.67	5.08e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9815354	0.680	rs57945879	chr3:42038842	C/G	cg03022575	chr3:42003672	ULK4	0.75	8.19	0.36	2.52e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg11062466	chr8:58055876	NA	0.43	7.21	0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6500395	0.962	rs2101372	chr16:48627306	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.64	0.37	9.51e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6665290	0.904	rs6677602	chr1:227187838	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.16	-29.34	-0.81	1.15e-107	Myeloid white cell count;
LGG	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.71	0.45	4.42e-24	Height;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.83	-14.45	-0.56	2.48e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11690935	0.610	rs59844139	chr2:172731983	C/A	cg13550731	chr2:172543902	DYNC1I2	0.67	12.96	0.52	5.4e-33	Schizophrenia;
LGG	cis	rs12580194	0.593	rs12580661	chr12:55803129	G/A	cg19537932	chr12:55886519	OR6C68	-0.58	-10.63	-0.44	9e-24	Cancer;
LGG	cis	rs3820928	0.874	rs13423046	chr2:227901805	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.33	-0.32	1.05e-12	Pulmonary function;
LGG	cis	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs875971	0.964	rs6945032	chr7:65922486	C/T	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs196889	0.611	rs2976427	chr8:24819904	C/T	cg25352397	chr8:24800883	NA	-0.46	-7.03	-0.31	7.61e-12	Seasonality;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06134546	chr15:64753130	NA	0.48	7.04	0.31	7.05e-12	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.37	-0.5	1.48e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs17767392	0.881	rs34061264	chr14:71785276	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.74	-0.38	4.36e-17	Mitral valve prolapse;
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg27400746	chr16:89904261	SPIRE2	-1.05	-15.38	-0.58	1.97e-43	Skin colour saturation;
LGG	cis	rs67478160	0.619	rs11628481	chr14:104241499	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.55	-0.33	2.41e-13	Schizophrenia;
LGG	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg04117972	chr1:227635322	NA	0.87	12.33	0.5	2.1000000000000002e-30	Major depressive disorder;
LGG	cis	rs66573146	0.831	rs66645969	chr4:6985614	G/A	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg11987759	chr7:65425863	GUSB	-0.4	-7.84	-0.34	3.2e-14	Aortic root size;
LGG	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg02227867	chr8:22457446	C8orf58	-0.41	-7.88	-0.34	2.32e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.3e-13	Menopause (age at onset);
LGG	cis	rs11608355	0.545	rs4766473	chr12:109900596	C/T	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25172604	chr17:41446521	NA	-0.29	-6.66	-0.3	7.72e-11	Menopause (age at onset);
LGG	cis	rs9611565	0.579	rs73178621	chr22:41921665	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-20.61	-0.69	1.82e-67	Vitiligo;
LGG	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.27	0.4	6.92e-19	Diabetic retinopathy;
LGG	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.87	16.92	0.62	2.28e-50	Response to antipsychotic treatment;
LGG	cis	rs11718455	0.960	rs6781618	chr3:44001933	C/T	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.56e-11	Coronary artery disease;
LGG	cis	rs8014204	0.566	rs11629369	chr14:75162021	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	12.07	0.49	2.33e-29	Caffeine consumption;
LGG	trans	rs17783634	0.509	rs11775489	chr8:11036843	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.86	-0.3	2.23e-11	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20065903	chr7:766203	HEATR2;PRKAR1B	0.45	6.73	0.3	4.89e-11	Gut microbiome composition (summer);
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.76	0.38	3.69e-17	Bipolar disorder;
LGG	cis	rs9296092	0.538	rs7761268	chr6:33519300	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.71	-0.71	1.3e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs742320	0.756	rs3765263	chr16:840378	A/G	cg03433313	chr16:819064	MIR662	-0.57	-10.19	-0.43	3.99e-22	Mean corpuscular volume;
LGG	cis	rs6142618	0.562	rs6061173	chr20:30717115	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs992157	0.737	rs3731860	chr2:219156979	G/A	cg04731861	chr2:219085781	ARPC2	0.45	10.74	0.45	3.67e-24	Colorectal cancer;
LGG	cis	rs6665290	0.904	rs3795451	chr1:227181923	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.88	-0.34	2.42e-14	Myeloid white cell count;
LGG	cis	rs6489785	0.775	rs1105416	chr12:121340799	T/C	cg02419362	chr12:121203948	SPPL3	-0.43	-6.76	-0.3	4.28e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg22961513	chr11:14280813	SPON1	0.35	8.53	0.37	2.1e-16	Mitochondrial DNA levels;
LGG	cis	rs7524258	0.900	rs1476047	chr1:7312172	C/T	cg07173049	chr1:7289937	CAMTA1	0.69	16.6	0.61	6.59e-49	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs3806843	0.547	rs246033	chr5:140332115	A/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs739401	0.967	rs451041	chr11:3060725	C/T	cg25174290	chr11:3078921	CARS	0.59	12.12	0.49	1.54e-29	Longevity;
LGG	trans	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.67	0.69	1.01e-67	Platelet count;
LGG	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.45e-13	Body mass index;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg22535103	chr8:58192502	C8orf71	-0.96	-13.26	-0.52	2.91e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs73198271	0.562	rs55657655	chr8:8675491	G/A	cg01851573	chr8:8652454	MFHAS1	0.5	7.91	0.35	1.85e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.57e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.49	-0.4	1.23e-19	Common traits (Other);
LGG	cis	rs9611565	0.571	rs2050032	chr22:42152429	C/T	cg06634786	chr22:41940651	POLR3H	0.68	11.01	0.46	3.39e-25	Vitiligo;
LGG	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg03733263	chr8:22462867	KIAA1967	0.96	22.41	0.72	6.82e-76	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg21582582	chr3:182698605	DCUN1D1	0.51	9.31	0.4	5.12e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.92	0.59	8.13e-46	Lung cancer;
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.41	0.33	5.97e-13	Life satisfaction;
LGG	cis	rs7760949	0.852	rs9475801	chr6:13933115	G/A	cg27413430	chr6:13925136	RNF182	0.48	7.23	0.32	1.95e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6754311	0.550	rs1438307	chr2:136499166	A/C	cg07169764	chr2:136633963	MCM6	0.77	13.59	0.53	1.25e-35	Mosquito bite size;
LGG	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg05234568	chr11:5960015	NA	-0.68	-11.45	-0.47	6.9e-27	DNA methylation (variation);
LGG	cis	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.09	-0.35	5.11e-15	Retinal vascular caliber;
LGG	cis	rs6061231	0.755	rs11699160	chr20:60958651	T/C	cg22601191	chr20:60968625	CABLES2	0.41	7.92	0.35	1.73e-14	Colorectal cancer;
LGG	cis	rs227833	0.955	rs227836	chr6:44682740	C/G	cg20913747	chr6:44695427	NA	0.46	7.71	0.34	7.54e-14	Monobrow;
LGG	cis	rs3768617	0.528	rs10737242	chr1:183098249	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	trans	rs2270927	0.510	rs2972840	chr5:75572956	G/A	cg13563193	chr19:33072644	PDCD5	0.76	9.36	0.4	3.54e-19	Mean corpuscular volume;
LGG	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs11864453	0.713	rs8051882	chr16:72142072	A/G	cg23815491	chr16:72088622	HP	-0.51	-11.49	-0.47	4.52e-27	Fibrinogen levels;
LGG	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg04833646	chr19:10679720	CDKN2D	1.13	19.07	0.66	2.86e-60	Red cell distribution width;
LGG	cis	rs2247341	0.965	rs798761	chr4:1731126	G/A	cg08629884	chr4:1719983	TMEM129	-0.58	-11.27	-0.46	3.22e-26	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg17764715	chr19:33622953	WDR88	0.51	9.01	0.39	5.52e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11098499	0.863	rs11933966	chr4:120476715	G/A	cg24375607	chr4:120327624	NA	0.68	11.11	0.46	1.44e-25	Corneal astigmatism;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg12288994	chr5:1860383	NA	0.78	15.63	0.59	1.54e-44	Cardiovascular disease risk factors;
LGG	cis	rs1729951	0.546	rs12054218	chr3:136677496	C/G	cg12473912	chr3:136751656	NA	0.43	7.63	0.33	1.34e-13	Neuroticism;
LGG	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg12292205	chr6:26970375	C6orf41	0.56	10.93	0.45	6.79e-25	Schizophrenia;
LGG	cis	rs7508	0.512	rs2283114	chr8:17880260	C/G	cg18067069	chr8:17937731	ASAH1	-0.29	-6.76	-0.3	4.14e-11	Atrial fibrillation;
LGG	cis	rs651907	0.557	rs11720745	chr3:101441690	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.42e-12	Colorectal cancer;
LGG	cis	rs950027	0.620	rs1617634	chr15:45615578	A/G	cg26924012	chr15:45694286	SPATA5L1	0.65	11.45	0.47	6.7399999999999993e-27	Response to fenofibrate (adiponectin levels);
LGG	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg11987759	chr7:65425863	GUSB	0.4	7.62	0.33	1.46e-13	Aortic root size;
LGG	cis	rs10915437	0.605	rs4654492	chr1:4201815	A/G	cg27165836	chr1:4193882	NA	-0.44	-8.76	-0.38	3.71e-17	Migraine - clinic-based;
LGG	cis	rs7226408	0.857	rs11659681	chr18:34458035	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs12174639	chr6:26373121	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.43	-0.78	1.53e-94	Renal cell carcinoma;
LGG	cis	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg21775007	chr8:11205619	TDH	-0.49	-7.56	-0.33	2.25e-13	Triglycerides;
LGG	cis	rs9916302	0.706	rs801427	chr17:37436711	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-15.2	-0.58	1.27e-42	Glomerular filtration rate (creatinine);
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg02002194	chr4:3960332	NA	0.44	7.98	0.35	1.13e-14	Neuroticism;
LGG	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg27624424	chr6:160112604	SOD2	-0.59	-9.27	-0.4	6.83e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg22244940	chr12:132335942	MMP17	0.39	6.7	0.3	5.89e-11	Migraine;
LGG	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	10.54	0.44	2e-23	Educational attainment;
LGG	cis	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg09307838	chr4:120376055	NA	0.79	12.98	0.52	4.66e-33	Corneal astigmatism;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg15971980	chr6:150254442	NA	0.43	8.23	0.36	1.87e-15	Lung cancer;
LGG	cis	rs875971	0.862	rs10263690	chr7:65766453	G/C	cg18876405	chr7:65276391	NA	-0.54	-9.64	-0.41	3.67e-20	Aortic root size;
LGG	cis	rs9807841	0.517	rs10404348	chr19:10840201	A/G	cg17710535	chr19:10819994	QTRT1	0.53	9.22	0.39	1.09e-18	Inflammatory skin disease;
LGG	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.17	0.75	4.23e-84	Chronic sinus infection;
LGG	cis	rs1048238	0.506	rs12039892	chr1:16167974	A/G	cg22431228	chr1:16359049	CLCNKA	-0.4	-7.23	-0.32	2.03e-12	Systolic blood pressure;
LGG	cis	rs2404602	0.692	rs66866130	chr15:77128574	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.28	0.4	6.7e-19	Blood metabolite levels;
LGG	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg07537917	chr2:241836409	C2orf54	-0.42	-8.08	-0.35	5.88e-15	Urinary metabolites;
LGG	trans	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.34	-0.36	8.81e-16	Retinal vascular caliber;
LGG	cis	rs1538970	0.816	rs10789464	chr1:45959102	C/T	cg05343316	chr1:45956843	TESK2	0.75	13.25	0.52	3.44e-34	Platelet count;
LGG	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg14835575	chr10:16859367	RSU1	0.79	14.53	0.56	1.13e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs258892	0.947	rs266436	chr5:72174553	G/A	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.11e-11	Small cell lung carcinoma;
LGG	cis	rs5769765	0.955	rs1321	chr22:50297435	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.62	0.33	1.45e-13	Schizophrenia;
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg00405596	chr8:11794950	NA	0.42	7.01	0.31	8.64e-12	Mood instability;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg10505658	chr17:80084571	CCDC57	-0.42	-8.54	-0.37	1.96e-16	Life satisfaction;
LGG	cis	rs1345301	1.000	rs12474199	chr2:102868980	G/A	cg05295703	chr2:102895712	NA	0.38	7.51	0.33	3.1e-13	Waist circumference;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.31	-0.32	1.22e-12	Lung cancer;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg07791516	chr6:150247246	NA	0.37	6.73	0.3	4.98e-11	Lung cancer;
LGG	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg16077055	chr2:106428750	NCK2	0.33	8.68	0.37	6.61e-17	Addiction;
LGG	trans	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs77633900	0.614	rs280028	chr15:77031466	A/G	cg21673338	chr15:77095150	SCAPER	-0.67	-10.64	-0.44	8.59e-24	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.58	-0.37	1.47e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.958	rs3900313	chr6:86537154	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.35	-0.4	3.66e-19	Retinal vascular caliber;
LGG	cis	rs138880	0.542	rs9616215	chr22:50318834	C/T	cg02269571	chr22:50332266	NA	-0.79	-9.38	-0.4	3.06e-19	Schizophrenia;
LGG	cis	rs362272	0.502	rs2857839	chr4:3036630	T/C	cg13731523	chr4:3047190	NA	-0.43	-9.78	-0.41	1.15e-20	Serum sulfate level;
LGG	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg09324608	chr17:30823087	MYO1D	0.3	7.07	0.31	5.65e-12	Schizophrenia;
LGG	cis	rs11623869	0.711	rs2403173	chr14:103909289	T/C	cg26031613	chr14:104095156	KLC1	0.77	13.82	0.54	1.3e-36	Bone mineral density;
LGG	cis	rs73110464	0.609	rs6580923	chr12:53358352	A/G	cg05393297	chr12:53359155	NA	-0.64	-15.18	-0.58	1.54e-42	Cancer (pleiotropy);
LGG	cis	rs7727544	0.507	rs9791170	chr5:131569627	A/G	cg07395648	chr5:131743802	NA	-0.36	-7.2	-0.32	2.41e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12866938	chr5:145583408	RBM27	0.51	7.48	0.33	3.78e-13	Gut microbiome composition (summer);
LGG	cis	rs11877825	0.826	rs8082984	chr18:10571904	C/T	cg07277756	chr18:10589357	NA	0.57	10.1	0.42	8.14e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs2084898	1.000	rs2084898	chr11:120026748	C/T	cg13907859	chr11:120009124	TRIM29	0.85	11.34	0.47	1.74e-26	Stroke (pediatric);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17076397	chr5:10353763	MARCH6	0.6	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg23894439	chr1:183413866	NA	-0.47	-8.76	-0.38	3.68e-17	Systemic lupus erythematosus;
LGG	cis	rs736408	0.522	rs6445535	chr3:52771468	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.86e-12	Bipolar disorder;
LGG	cis	rs4804815	0.697	rs73008237	chr19:7841188	T/C	cg00371453	chr19:7854482	CLEC4GP1	0.71	10.6	0.44	1.17e-23	Neutrophil count;
LGG	cis	rs2124969	0.562	rs4665164	chr2:161070078	T/G	cg03641300	chr2:160917029	PLA2R1	-0.6	-11.32	-0.47	2.13e-26	Waist circumference adjusted for body mass index;
LGG	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.27e-12	Cystic fibrosis severity;
LGG	cis	rs11229555	0.645	rs7946522	chr11:58197905	G/C	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7166081	0.672	rs3865018	chr15:67892766	A/G	cg02273617	chr15:68117586	LBXCOR1	0.36	8.93	0.38	1.01e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg13010199	chr12:38710504	ALG10B	0.72	14.77	0.57	9.61e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.43e-20	Aortic root size;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg02690350	chr17:27620209	NUFIP2	0.4	6.73	0.3	4.94e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9303401	0.614	rs68100606	chr17:56500898	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.5	0.56	1.58e-39	Cognitive test performance;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg16359550	chr11:109292809	C11orf87	0.4	8.03	0.35	8.12e-15	Schizophrenia;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg00684032	chr4:1343700	KIAA1530	0.53	10.65	0.44	7.77e-24	Obesity-related traits;
LGG	trans	rs5756813	0.754	rs762982	chr22:38144235	A/G	cg19894588	chr14:64061835	NA	0.55	8.67	0.37	7.21e-17	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9660992	0.573	rs4400674	chr1:205218425	A/C	cg21545522	chr1:205238299	TMCC2	-0.42	-8.0	-0.35	1.02e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs8048589	0.615	rs12599107	chr16:12238602	G/A	cg02910054	chr16:12241554	SNX29	0.64	9.47	0.4	1.45e-19	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24656492	chr10:70940659	SUPV3L1	0.43	6.81	0.3	2.96e-11	Gut microbiome composition (summer);
LGG	cis	rs7546668	1.000	rs7516435	chr1:15868692	A/G	cg21858823	chr1:15850916	CASP9	0.38	6.76	0.3	4.28e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs526231	0.511	rs62362558	chr5:102368493	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.28	-0.36	1.3e-15	Educational attainment;
LGG	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg09448879	chr15:79043637	NA	0.44	8.05	0.35	7.02e-15	Post bronchodilator FEV1;
LGG	cis	rs806321	0.510	rs1149866	chr13:50900431	T/C	cg10393508	chr13:50950265	NA	-0.33	-8.5	-0.37	2.56e-16	Multiple sclerosis;
LGG	cis	rs12476592	0.543	rs12105140	chr2:63797218	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.25e-11	Childhood ear infection;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.6	-0.33	1.63e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs1997103	0.911	rs6949931	chr7:55391081	T/C	cg20935933	chr6:143382018	AIG1	0.6	9.24	0.39	9.19e-19	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg13565492	chr6:43139072	SRF	-0.75	-9.06	-0.39	3.55e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.02e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-15.31	-0.58	4.17e-43	Headache;
LGG	cis	rs798554	0.679	rs1639036	chr7:2885089	G/A	cg14668632	chr7:2872130	GNA12	-0.33	-7.01	-0.31	8.57e-12	Height;
LGG	cis	rs6089584	0.508	rs6061988	chr20:60626300	C/T	cg06470251	chr20:60548479	NA	0.4	6.76	0.3	4.15e-11	Body mass index;
LGG	cis	rs6840360	0.550	rs6853955	chr4:152510806	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.25	-0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	1.000	rs12710454	chr21:40656919	A/G	cg17971929	chr21:40555470	PSMG1	0.85	16.35	0.61	8.93e-48	Cognitive function;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26695837	chr4:37688098	RELL1	-0.48	-7.64	-0.33	1.29e-13	Pancreatic cancer;
LGG	cis	rs3206736	0.548	rs2526545	chr7:35020183	C/T	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.19e-19	Diastolic blood pressure;
LGG	cis	rs1003719	0.667	rs2835606	chr21:38490851	G/C	cg10648535	chr21:38446584	PIGP;TTC3	0.72	13.15	0.52	8.77e-34	Eye color traits;
LGG	cis	rs35123781	0.696	rs13154510	chr5:139071301	A/C	cg10513866	chr5:139070639	NA	0.4	7.76	0.34	5.67e-14	Schizophrenia;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg00166722	chr3:10149974	C3orf24	0.54	8.86	0.38	1.71e-17	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19741408	chr1:90460434	ZNF326;LOC492303	0.51	8.09	0.35	5.29e-15	Gut microbiome composition (summer);
LGG	cis	rs1707322	1.000	rs6677777	chr1:46475836	A/G	cg03146154	chr1:46216737	IPP	0.53	9.44	0.4	1.9e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.67	0.59	1.01e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	8.1	0.35	4.87e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.49e-48	Intelligence (multi-trait analysis);
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14893161	chr1:205819251	PM20D1	-0.42	-8.21	-0.36	2.21e-15	Prostate-specific antigen levels;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.18	0.39	1.48e-18	Obesity-related traits;
LGG	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg07636037	chr3:49044803	WDR6	0.59	10.4	0.44	6.54e-23	Intelligence (multi-trait analysis);
LGG	trans	rs8073060	0.544	rs225287	chr17:33929487	G/T	cg19694781	chr19:47549865	TMEM160	-1.14	-17.42	-0.63	1.29e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs35110281	0.774	rs2838323	chr21:44999086	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.28	0.43	1.83e-22	Mean corpuscular volume;
LGG	cis	rs4268898	0.931	rs7603997	chr2:24524958	C/T	cg06627628	chr2:24431161	ITSN2	-0.53	-8.97	-0.38	7.13e-18	Asthma;
LGG	cis	rs2594989	0.943	rs2454504	chr3:11498423	G/A	cg01796438	chr3:11312864	ATG7	-0.52	-7.17	-0.32	2.9e-12	Circulating chemerin levels;
LGG	cis	rs2718058	0.630	rs2709120	chr7:37809412	T/C	cg15028436	chr7:37888078	TXNDC3	0.52	8.15	0.35	3.33e-15	Alzheimer's disease (late onset);
LGG	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg07061783	chr6:25882402	NA	0.48	8.21	0.36	2.21e-15	Blood metabolite levels;
LGG	cis	rs12738007	0.935	rs4654391	chr1:29493866	T/C	cg11747820	chr1:29584023	PTPRU	-0.33	-7.46	-0.33	4.46e-13	Schizophrenia;
LGG	cis	rs7712401	0.601	rs30039	chr5:122277179	A/C	cg19412675	chr5:122181750	SNX24	-0.45	-7.47	-0.33	4.11e-13	Mean platelet volume;
LGG	cis	rs11583043	1.000	rs12750667	chr1:101498682	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	8.45	0.37	3.73e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.61	11.27	0.46	3.3e-26	Longevity;
LGG	trans	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg24247370	chr13:99142703	STK24	-0.38	-7.14	-0.31	3.76e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs981844	0.601	rs1337	chr4:154631587	C/G	cg14289246	chr4:154710475	SFRP2	0.62	9.45	0.4	1.74e-19	Response to statins (LDL cholesterol change);
LGG	cis	rs988958	0.565	rs7576782	chr2:42218378	C/A	cg19376973	chr2:42229025	NA	0.64	9.27	0.4	7.06e-19	Hypospadias;
LGG	cis	rs4481887	0.790	rs7546964	chr1:248414960	A/G	cg13385794	chr1:248469461	NA	0.42	7.11	0.31	4.3e-12	Common traits (Other);
LGG	cis	rs3768617	0.510	rs6424885	chr1:183066254	T/G	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs3087591	0.887	rs2905875	chr17:29541339	A/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.28	0.55	1.39e-38	Hip circumference;
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg01262667	chr19:19385393	TM6SF2	0.33	6.77	0.3	4.02e-11	Bipolar disorder;
LGG	cis	rs9788682	0.747	rs8042494	chr15:78908010	C/T	cg06917634	chr15:78832804	PSMA4	-0.5	-7.64	-0.33	1.25e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.54	0.37	2.02e-16	Personality dimensions;
LGG	cis	rs7072216	0.763	rs6584198	chr10:100169906	G/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.83e-12	Metabolite levels;
LGG	cis	rs62238980	0.614	rs55739336	chr22:32505773	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.2e-19	Bipolar disorder;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.11	0.35	4.59e-15	Longevity;
LGG	cis	rs754466	0.580	rs17516020	chr10:79538734	C/T	cg17075019	chr10:79541650	NA	-0.92	-15.94	-0.6	6.41e-46	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg09307838	chr4:120376055	NA	-0.72	-11.67	-0.48	9.55e-28	Corneal astigmatism;
LGG	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg12310025	chr6:25882481	NA	-0.59	-11.21	-0.46	5.88e-26	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23961059	chr19:57874869	ZNF547;TRAPPC2P1	0.52	8.17	0.35	2.88e-15	Gut microbiome composition (summer);
LGG	trans	rs9657904	0.774	rs4894950	chr3:105507929	T/C	cg14088669	chr1:158435396	OR10K1	0.4	7.42	0.33	5.79e-13	Multiple sclerosis;
LGG	cis	rs2120243	0.539	rs1563420	chr3:157119326	A/G	cg24825693	chr3:157122686	VEPH1	-0.59	-13.57	-0.53	1.46e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg00204512	chr16:28754710	NA	0.25	7.22	0.32	2.12e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12824058	0.831	rs4759657	chr12:130815818	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.04	0.52	2.62e-33	Menopause (age at onset);
LGG	cis	rs975722	0.543	rs12333572	chr7:117051949	T/A	cg10524701	chr7:117356490	CTTNBP2	0.4	8.54	0.37	1.92e-16	Coronary artery disease;
LGG	cis	rs6089584	0.830	rs4925331	chr20:60580174	T/C	cg06108461	chr20:60628389	TAF4	-0.88	-16.89	-0.62	3.15e-50	Body mass index;
LGG	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg08975724	chr8:8085496	FLJ10661	0.47	8.56	0.37	1.68e-16	Retinal vascular caliber;
LGG	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg13444842	chr1:152974279	SPRR3	-0.39	-7.23	-0.32	2.04e-12	Inflammatory skin disease;
LGG	cis	rs7617773	0.780	rs11706277	chr3:48360433	A/G	cg11946769	chr3:48343235	NME6	0.7	11.31	0.47	2.39e-26	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09690659	chr20:33680871	TRPC4AP	0.43	7.26	0.32	1.6e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg09033563	chr22:24373618	LOC391322	-0.49	-8.12	-0.35	4.2e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4731207	0.596	rs7788458	chr7:124630141	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.9	-0.31	1.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04531710	chr3:184032412	EIF4G1	0.48	7.54	0.33	2.49e-13	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.603	rs17142178	chr7:19951840	G/A	cg05791153	chr7:19748676	TWISTNB	0.52	6.82	0.3	2.89e-11	Night sleep phenotypes;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg02462569	chr6:150064036	NUP43	0.39	8.38	0.36	6.24e-16	Lung cancer;
LGG	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg10792982	chr14:105748885	BRF1	0.65	12.92	0.51	8.33e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4727027	0.522	rs6956736	chr7:148893472	G/C	cg23583168	chr7:148888333	NA	-0.7	-11.06	-0.46	2.24e-25	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg19784903	chr17:45786737	TBKBP1	-0.31	-6.9	-0.31	1.67e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2712184	0.967	rs1014680	chr2:217672824	A/G	cg05032264	chr2:217675019	NA	0.53	12.62	0.51	1.44e-31	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs12477438	0.765	rs10181422	chr2:99558970	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.06	-0.42	1.18e-21	Chronic sinus infection;
LGG	cis	rs59918340	0.523	rs4961255	chr8:142208248	T/C	cg23750338	chr8:142222470	SLC45A4	0.54	10.35	0.43	9.68e-23	Immature fraction of reticulocytes;
LGG	cis	rs1008375	1.000	rs10939749	chr4:17692319	A/C	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs612683	0.894	rs10875290	chr1:100853755	G/T	cg06223162	chr1:101003688	GPR88	0.41	9.69	0.41	2.43e-20	Breast cancer;
LGG	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.6	0.41	5.14e-20	Colorectal cancer;
LGG	cis	rs7589342	0.899	rs10185551	chr2:106492201	A/C	cg14210321	chr2:106509881	NCK2	-0.57	-10.02	-0.42	1.56e-21	Addiction;
LGG	cis	rs300703	0.719	rs378738	chr2:194039	A/G	cg24565620	chr2:194026	NA	-0.76	-11.05	-0.46	2.29e-25	Blood protein levels;
LGG	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg23461800	chr14:103021989	NA	-0.58	-10.34	-0.43	1.11e-22	Platelet count;
LGG	cis	rs9341808	0.718	rs12203867	chr6:80820833	G/T	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs9381040	0.610	rs6940356	chr6:41020360	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.73	-0.3	4.96e-11	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.22	-0.46	5.34e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03981592	chr3:86061698	CADM2	0.39	6.82	0.3	2.88e-11	Menarche (age at onset);
LGG	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg26076054	chr5:421317	AHRR	0.43	7.88	0.34	2.37e-14	Cystic fibrosis severity;
LGG	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg25174290	chr11:3078921	CARS	0.76	16.34	0.6	9.91e-48	Longevity;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg08219700	chr8:58056026	NA	0.47	7.11	0.31	4.55e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.933	rs1540275	chr6:26036476	T/C	cg03517284	chr6:25882590	NA	-0.64	-12.1	-0.49	1.73e-29	Intelligence (multi-trait analysis);
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg25703541	chr22:24373054	LOC391322	0.89	13.79	0.54	1.77e-36	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs11039798	0.920	rs11040015	chr11:48783130	G/T	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	5.81e-18	Axial length;
LGG	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg02574844	chr11:5959923	NA	-0.55	-8.54	-0.37	1.95e-16	DNA methylation (variation);
LGG	cis	rs1008375	0.932	rs9884565	chr4:17655096	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.74	0.45	3.66e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs916888	0.821	rs199514	chr17:44856881	G/A	cg20120463	chr17:44301886	NA	0.45	6.93	0.31	1.38e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg19168338	chr16:4465731	CORO7	-0.91	-17.41	-0.63	1.36e-52	Schizophrenia;
LGG	cis	rs801193	0.569	rs2659908	chr7:66160822	G/A	cg11764359	chr7:65958608	NA	0.71	12.92	0.51	7.77e-33	Aortic root size;
LGG	cis	rs2247341	0.965	rs11248073	chr4:1737502	C/T	cg08446824	chr4:1720184	TMEM129	-0.67	-12.69	-0.51	7.13e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7765175	0.926	rs9400612	chr6:113675766	C/T	cg26552650	chr6:113682475	NA	-0.33	-7.02	-0.31	7.98e-12	Coronary artery calcification;
LGG	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs7551222	0.716	rs4951078	chr1:204491802	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.36	-0.47	1.51e-26	Schizophrenia;
LGG	trans	rs7395662	1.000	rs11039817	chr11:48561480	A/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00656411	chr7:140773422	NA	0.43	7.04	0.31	6.89e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg26769984	chr7:1090371	C7orf50	0.42	7.29	0.32	1.36e-12	Bronchopulmonary dysplasia;
LGG	cis	rs6960043	0.764	rs7798124	chr7:15055616	A/G	cg19272540	chr7:15055459	NA	-0.36	-8.21	-0.36	2.15e-15	Type 2 diabetes;
LGG	trans	rs7819412	0.558	rs11777486	chr8:10908287	C/A	cg02002194	chr4:3960332	NA	-0.39	-6.67	-0.3	7.41e-11	Triglycerides;
LGG	cis	rs11671005	0.735	rs56290606	chr19:58919320	A/G	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05051152	chr8:124408913	ATAD2	0.43	6.84	0.3	2.44e-11	Cognitive performance;
LGG	cis	rs9560113	0.509	rs4773390	chr13:112208904	G/A	cg14952266	chr13:112191215	NA	-0.36	-6.69	-0.3	6.48e-11	Menarche (age at onset);
LGG	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg11189052	chr15:85197271	WDR73	-0.56	-9.1	-0.39	2.71e-18	P wave terminal force;
LGG	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg12395012	chr8:11607386	GATA4	0.37	6.69	0.3	6.62e-11	Neuroticism;
LGG	cis	rs2540226	0.539	rs2716684	chr2:39907681	T/A	cg18968196	chr2:39892502	TMEM178	0.31	8.53	0.37	2.13e-16	Personality dimensions;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg07511668	chr11:68622177	NA	0.51	9.88	0.42	5.1e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10754283	0.967	rs10922680	chr1:90101326	C/T	cg06121193	chr1:90282411	NA	0.37	7.12	0.31	4.14e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg24375607	chr4:120327624	NA	0.66	10.75	0.45	3.36e-24	Corneal astigmatism;
LGG	cis	rs11105298	0.891	rs10858898	chr12:89922111	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.46	-0.4	1.5e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.16	0.35	3.27e-15	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs896854	0.654	rs10104909	chr8:95977973	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.52	-0.37	2.24e-16	Type 2 diabetes;
LGG	cis	rs1620921	0.653	rs55968870	chr6:161264803	A/T	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg00294572	chr6:26285232	NA	0.4	7.14	0.31	3.72e-12	Educational attainment;
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12681288	0.723	rs35425201	chr8:971062	C/T	cg08648136	chr8:956695	NA	0.41	8.98	0.39	6.69e-18	Schizophrenia;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg23978390	chr7:1156363	C7orf50	0.49	8.54	0.37	2e-16	Longevity;Endometriosis;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg18252515	chr7:66147081	NA	0.44	7.31	0.32	1.21e-12	Aortic root size;
LGG	trans	rs11875185	0.510	rs80203942	chr18:55593549	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs28595532	0.920	rs115681185	chr4:119757700	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs11585357	0.947	rs6666990	chr1:17611520	G/A	cg08277548	chr1:17600880	PADI3	0.7	8.37	0.36	6.82e-16	Hair shape;
LGG	cis	rs2239547	0.563	rs9839035	chr3:52909877	C/T	cg11645453	chr3:52864694	ITIH4	0.7	10.92	0.45	7.19e-25	Schizophrenia;
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg02524346	chr8:600233	NA	1.17	11.34	0.47	1.83e-26	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg05313129	chr8:58192883	C8orf71	-0.6	-8.42	-0.36	4.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	1.07e-29	Prudent dietary pattern;
LGG	cis	rs2075371	0.830	rs2077671	chr7:133951204	C/T	cg20476274	chr7:133979776	SLC35B4	0.74	14.6	0.56	5.38e-40	Mean platelet volume;
LGG	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.22	-0.36	2.13e-15	Aortic root size;
LGG	cis	rs7953508	0.506	rs768775	chr12:93968197	T/C	cg18151635	chr12:93972918	NA	-0.56	-10.48	-0.44	3.35e-23	Pubertal anthropometrics;
LGG	cis	rs11122272	0.735	rs2808595	chr1:231526238	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.23	-0.46	4.67e-26	Hemoglobin concentration;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.82	16.26	0.6	2.39e-47	Obesity-related traits;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	8.05e-13	Morning vs. evening chronotype;
LGG	cis	rs72634258	0.945	rs12735338	chr1:8078569	T/C	cg00042356	chr1:8021962	PARK7	0.84	11.31	0.47	2.27e-26	Inflammatory bowel disease;
LGG	cis	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg13385521	chr17:29058706	SUZ12P	0.81	9.6	0.41	5.05e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1697139	0.583	rs11739587	chr5:66540481	A/C	cg11553311	chr5:66541588	NA	-0.45	-10.19	-0.43	3.74e-22	Breast cancer;
LGG	cis	rs2832191	0.791	rs2251517	chr21:30531951	T/G	cg08807101	chr21:30365312	RNF160	0.86	17.64	0.63	1.22e-53	Dental caries;
LGG	cis	rs2832077	0.943	rs2832084	chr21:30154798	A/G	cg03476357	chr21:30257390	N6AMT1	-0.55	-8.32	-0.36	9.73e-16	Cognitive test performance;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg15595755	chr5:1867978	NA	0.52	10.33	0.43	1.2e-22	Cardiovascular disease risk factors;
LGG	cis	rs10089	0.552	rs55902659	chr5:127545505	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.55	8.08	0.35	5.54e-15	Ileal carcinoids;
LGG	cis	rs62064224	0.597	rs7207268	chr17:30725155	T/G	cg18200150	chr17:30822561	MYO1D	0.48	9.17	0.39	1.54e-18	Schizophrenia;
LGG	trans	rs4718428	0.705	rs4717328	chr7:66352665	T/C	cg10756647	chr7:56101905	PSPH	0.46	6.88	0.3	1.93e-11	Corneal structure;
LGG	cis	rs228437	0.770	rs376192	chr6:134904524	A/G	cg24504307	chr6:134963096	NA	-0.34	-6.79	-0.3	3.55e-11	Melanoma;
LGG	cis	rs9715521	0.677	rs62301200	chr4:59855179	G/A	cg11281224	chr4:60001000	NA	-0.57	-10.05	-0.42	1.23e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8077059	0.513	rs9892194	chr17:55825825	C/T	cg12582317	chr17:55822272	NA	-0.5	-11.87	-0.48	1.42e-28	Sex hormone-binding globulin levels;
LGG	cis	rs6565180	0.926	rs8046445	chr16:30386262	A/G	cg17640201	chr16:30407289	ZNF48	-0.88	-18.13	-0.64	6.51e-56	Tonsillectomy;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.13	0.46	1.17e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg15556689	chr8:8085844	FLJ10661	0.6	11.91	0.48	1.04e-28	Mood instability;
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	7.95e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3805663	1.000	rs888685	chr5:134365790	A/T	cg24576358	chr5:134350122	NA	0.35	7.36	0.32	8.61e-13	Testicular germ cell tumor;
LGG	cis	rs3816788	0.792	rs13257744	chr8:21872853	T/C	cg17168535	chr8:21777572	XPO7	0.78	14.87	0.57	3.71e-41	Lung cancer in ever smokers;
LGG	cis	rs12476592	0.602	rs6736411	chr2:63674060	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.94	-0.31	1.37e-11	Childhood ear infection;
LGG	cis	rs7208859	0.623	rs55938328	chr17:29117010	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22024508	chr19:16771032	TMEM38A;C19orf42	0.44	6.72	0.3	5.25e-11	Gut microbiome composition (summer);
LGG	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg13647721	chr17:30228624	UTP6	0.63	7.86	0.34	2.74e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12476592	0.571	rs68183503	chr2:63802888	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs11018874	0.532	rs11018867	chr11:89862345	C/T	cg21153622	chr11:89784906	NA	-0.69	-8.74	-0.38	4.25e-17	White blood cell types;
LGG	cis	rs6860806	0.507	rs272891	chr5:131664394	G/T	cg07395648	chr5:131743802	NA	-0.49	-9.99	-0.42	2.01e-21	Breast cancer;
LGG	cis	rs9486715	0.867	rs9372106	chr6:96875058	T/C	cg18709589	chr6:96969512	KIAA0776	0.4	7.79	0.34	4.3e-14	Headache;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22018784	chr9:98079448	FANCC	0.39	6.65	0.3	8.53e-11	Bipolar disorder;
LGG	cis	rs2964802	0.505	rs1438714	chr5:10811422	G/A	cg14521931	chr5:10832172	NA	-0.75	-16.38	-0.61	6.42e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg16507663	chr6:150244633	RAET1G	0.47	8.71	0.38	5.44e-17	Lung cancer;
LGG	cis	rs537930	0.890	rs299364	chr5:134331921	T/G	cg24576358	chr5:134350122	NA	0.44	8.97	0.38	7.34e-18	Height;
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.58	-0.33	1.88e-13	Menopause (age at onset);
LGG	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg16797656	chr11:68205561	LRP5	0.56	10.49	0.44	2.97e-23	Total body bone mineral density;
LGG	cis	rs3815700	1.000	rs7247420	chr19:33096786	G/A	cg02997394	chr19:33096574	ANKRD27	0.9	13.63	0.54	8.27e-36	Eosinophilic esophagitis;
LGG	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg05707623	chr12:122985044	ZCCHC8	0.66	9.76	0.41	1.38e-20	Body mass index;
LGG	cis	rs172166	0.694	rs203877	chr6:28048624	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.11	-0.31	4.43e-12	Cardiac Troponin-T levels;
LGG	cis	rs657075	0.697	rs3828673	chr5:131651565	C/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	trans	rs4714291	0.802	rs1474870	chr6:39980359	C/T	cg02267698	chr19:7991119	CTXN1	0.59	9.32	0.4	4.85e-19	Strep throat;
LGG	cis	rs6993813	0.620	rs4546691	chr8:120025004	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.74	0.34	6.39e-14	Bone mineral density (hip);
LGG	cis	rs11203032	0.634	rs3802658	chr10:90965691	C/T	cg16672925	chr10:90967113	CH25H	-0.86	-13.18	-0.52	6.84e-34	Heart failure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04132851	chr1:85155548	SSX2IP	0.39	6.66	0.3	7.99e-11	Cognitive performance;
LGG	cis	rs1559088	0.744	rs12462426	chr19:33536683	A/C	cg03563238	chr19:33554763	RHPN2	-0.39	-8.26	-0.36	1.58e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	cis	rs4304924	0.500	rs9601109	chr13:79220114	A/G	cg01819759	chr13:79234251	RNF219	0.54	8.34	0.36	8.86e-16	Large artery stroke;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg16854524	chr4:83931902	LIN54	0.4	6.91	0.31	1.61e-11	Body mass index;
LGG	cis	rs1355223	0.525	rs10836316	chr11:34874295	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.34	-0.36	8.35e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg00383909	chr3:49044727	WDR6	0.43	7.12	0.31	4.21e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7017697	0.642	rs3927029	chr8:19681933	G/A	cg03894339	chr8:19674705	INTS10	-0.71	-11.77	-0.48	3.86e-28	Breast cancer;
LGG	cis	rs9547996	1.000	rs9547999	chr13:38223366	T/C	cg17979426	chr13:38220150	TRPC4	-0.45	-8.64	-0.37	9.12e-17	Diastolic blood pressure;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg04529724	chr6:150244392	RAET1G	0.34	6.88	0.3	1.96e-11	Testicular germ cell tumor;
LGG	cis	rs77372450	0.636	rs11465225	chr5:157003849	G/T	cg25387487	chr5:157003181	ADAM19	-0.58	-7.29	-0.32	1.37e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs12681287	0.640	rs7846090	chr8:87467724	A/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg16301924	chr13:53314226	LECT1	0.41	8.17	0.35	3.04e-15	Lewy body disease;
LGG	trans	rs1814175	0.715	rs10839409	chr11:49884647	G/T	cg03929089	chr4:120376271	NA	-1.03	-24.54	-0.75	7.99e-86	Height;
LGG	cis	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg20368463	chr18:77673604	PQLC1	0.5	7.56	0.33	2.17e-13	Opioid sensitivity;
LGG	cis	rs3857536	0.813	rs7757118	chr6:66946661	T/C	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs3741151	0.656	rs56884659	chr11:73252947	C/G	cg17517138	chr11:73019481	ARHGEF17	0.82	7.86	0.34	2.64e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs968451	0.865	rs5757610	chr22:39707979	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	11.92	0.48	9.42e-29	Primary biliary cholangitis;
LGG	trans	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg00938859	chr5:1591904	SDHAP3	0.9	12.33	0.5	2.01e-30	Breast cancer;
LGG	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.77	0.57	9.99e-41	Cognitive test performance;
LGG	cis	rs4253772	0.550	rs6007823	chr22:46706249	C/T	cg00784671	chr22:46762841	CELSR1	-0.57	-7.29	-0.32	1.35e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg13010199	chr12:38710504	ALG10B	0.56	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs9660992	0.710	rs7367930	chr1:205235512	A/G	cg00857998	chr1:205179979	DSTYK	0.47	6.91	0.31	1.65e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs787274	1.000	rs1711739	chr9:115464474	G/A	cg13803584	chr9:115635662	SNX30	0.5	7.25	0.32	1.81e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9915657	0.870	rs759499	chr17:70133177	C/T	cg09344028	chr17:70110421	NA	0.45	10.09	0.42	9.32e-22	Thyroid hormone levels;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg04267008	chr7:1944627	MAD1L1	-0.62	-10.19	-0.43	3.9e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg11657817	chr20:23433608	CST11	0.4	8.17	0.35	2.99e-15	Facial morphology (factor 15, philtrum width);
LGG	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.86	-0.34	2.8e-14	Joint mobility (Beighton score);
LGG	cis	rs7647973	0.848	rs4292260	chr3:49148890	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.52	0.33	2.86e-13	Menarche (age at onset);
LGG	cis	rs35264875	0.796	rs72930637	chr11:68869967	C/T	cg23740940	chr11:68924746	NA	0.44	6.78	0.3	3.58e-11	Blond vs. brown hair color;
LGG	cis	rs3818285	0.610	rs642938	chr10:111633025	A/C	cg00817464	chr10:111662876	XPNPEP1	0.49	10.2	0.43	3.51e-22	Superior crus of antihelix expression;
LGG	cis	rs875971	1.000	rs7781698	chr7:65896312	A/T	cg18876405	chr7:65276391	NA	0.53	9.3	0.4	5.51e-19	Aortic root size;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.07	0.42	1.09e-21	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.24	-0.32	1.87e-12	Lung cancer;
LGG	cis	rs62400317	0.686	rs860741	chr6:44808435	G/A	cg18551225	chr6:44695536	NA	0.65	11.7	0.48	7.21e-28	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05316309	chr22:43011028	POLDIP3;RNU12	0.41	6.8	0.3	3.23e-11	Gut microbiome composition (summer);
LGG	cis	rs4538187	0.671	rs56904032	chr2:64236488	C/T	cg19915305	chr2:64069682	UGP2	-0.67	-13.4	-0.53	7.96e-35	Systolic blood pressure;
LGG	trans	rs61931739	0.534	rs11052984	chr12:34045904	T/C	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs67460515	0.527	rs34221255	chr3:160854123	T/C	cg03342759	chr3:160939853	NMD3	-0.63	-10.7	-0.45	4.83e-24	Parkinson's disease;
LGG	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg06606381	chr12:133084897	FBRSL1	-0.7	-8.35	-0.36	7.98e-16	Depression;
LGG	cis	rs9811920	0.809	rs4928151	chr3:99767553	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.5	-0.37	2.64e-16	Axial length;
LGG	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg03929089	chr4:120376271	NA	-0.42	-6.74	-0.3	4.68e-11	HDL cholesterol;
LGG	cis	rs6138458	0.828	rs6138466	chr20:24997137	A/G	cg26195577	chr20:24973756	C20orf3	1.02	19.81	0.68	1.02e-63	Blood protein levels;
LGG	cis	rs73198271	0.562	rs17698256	chr8:8659613	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.32	0.36	1.02e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs920590	0.758	rs7010174	chr8:19661930	G/C	cg03894339	chr8:19674705	INTS10	0.63	10.23	0.43	2.8e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs9329221	0.638	rs12543645	chr8:10246325	C/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.12	-0.31	4.09e-12	Neuroticism;
LGG	cis	rs10823500	0.777	rs7919014	chr10:71944577	T/C	cg02100629	chr10:71892760	AIFM2	-0.3	-7.16	-0.32	3.13e-12	Blood protein levels;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg17691542	chr6:26056736	HIST1H1C	0.58	10.49	0.44	3e-23	Height;
LGG	cis	rs1707322	1.000	rs1768801	chr1:46549137	C/G	cg03146154	chr1:46216737	IPP	-0.53	-9.66	-0.41	3.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14159672	chr1:205819179	PM20D1	-0.5	-7.9	-0.34	2.1e-14	Parkinson's disease;
LGG	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.37	0.83	5.51e-121	Chronic sinus infection;
LGG	trans	rs941408	0.515	rs1640262	chr19:2779134	C/T	cg19676328	chr12:49525230	TUBA1B	0.59	8.85	0.38	1.8e-17	Total cholesterol levels;
LGG	cis	rs4700695	0.764	rs10066817	chr5:65319853	A/G	cg21114390	chr5:65439923	SFRS12	0.58	7.16	0.32	3.12e-12	Facial morphology (factor 19);
LGG	cis	rs10504073	0.647	rs4873096	chr8:49995201	A/G	cg00325661	chr8:49890786	NA	0.75	14.4	0.56	4.31e-39	Blood metabolite ratios;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg13939156	chr17:80058883	NA	-0.44	-8.52	-0.37	2.24e-16	Life satisfaction;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs11690935	0.959	rs10167419	chr2:172649826	A/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.65	-0.78	1.57e-95	Schizophrenia;
LGG	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg01493522	chr13:37497338	NA	-0.5	-8.38	-0.36	6.29e-16	Coronary artery disease;
LGG	cis	rs992157	0.710	rs10167446	chr2:219056866	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.56	9.47	0.4	1.44e-19	Colorectal cancer;
LGG	cis	rs6547631	0.622	rs4240201	chr2:85925667	G/A	cg24620635	chr2:85921963	GNLY	0.51	10.14	0.43	6.14e-22	Blood protein levels;
LGG	cis	rs2282802	0.685	rs12717951	chr5:139589309	A/G	cg26211634	chr5:139558579	C5orf32	0.34	7.44	0.33	4.96e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg10847948	chr11:71163743	NADSYN1	0.64	11.28	0.46	3.12e-26	Vitamin D levels;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.14	-0.52	9.51e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.13	-0.49	1.36e-29	Height;
LGG	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg08807101	chr21:30365312	RNF160	0.91	19.0	0.66	6.09e-60	Dental caries;
LGG	cis	rs774359	0.789	rs9969707	chr9:27491104	A/G	cg22262168	chr9:27528999	MOBKL2B	0.47	6.9	0.31	1.71e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2463822	1.000	rs1406384	chr11:62083530	A/G	cg06239285	chr11:62104954	ASRGL1	-1.15	-16.39	-0.61	6.33e-48	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs11690935	0.959	rs2292815	chr2:172586651	C/G	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.33	-0.77	4.73e-94	Schizophrenia;
LGG	cis	rs7226408	0.857	rs8094856	chr18:34548299	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02759489	chr4:55098483	PDGFRA	0.38	6.85	0.3	2.36e-11	Obesity-related traits;
LGG	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	trans	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.11	0.39	2.53e-18	Aortic root size;
LGG	cis	rs3008870	1.000	rs3008874	chr1:67431365	A/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	23.62	0.74	1.61e-81	Lymphocyte percentage of white cells;
LGG	cis	rs16976116	0.901	rs8028525	chr15:55492317	T/C	cg11288833	chr15:55489084	RSL24D1	0.55	7.17	0.32	2.95e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg06521331	chr12:34319734	NA	-0.59	-11.03	-0.46	2.9e-25	Morning vs. evening chronotype;
LGG	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg24623649	chr8:11872141	NA	-0.3	-7.1	-0.31	4.63e-12	Systolic blood pressure;
LGG	cis	rs4936894	0.500	rs11606880	chr11:124125213	T/C	cg27160556	chr11:124181099	OR8D1	-0.47	-10.93	-0.45	7e-25	Aging (time to death);
LGG	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg02297831	chr4:17616191	MED28	0.5	9.53	0.4	9.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs754466	0.512	rs67607593	chr10:79649050	A/G	cg17075019	chr10:79541650	NA	-0.94	-18.85	-0.66	2.94e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2242194	0.816	rs2242193	chr1:154995503	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.72	-16.77	-0.61	1.1e-49	Schizophrenia;
LGG	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	18.73	0.66	1.13e-58	Platelet count;
LGG	cis	rs13191362	1.000	rs35383933	chr6:163002869	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg16606324	chr3:10149918	C3orf24	0.51	6.7	0.3	5.98e-11	Alzheimer's disease;
LGG	cis	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg27411982	chr8:10470053	RP1L1	-0.48	-8.27	-0.36	1.4e-15	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12501923	chr17:73937416	FBF1	0.43	7.22	0.32	2.17e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2463822	0.583	rs72917377	chr11:62025930	A/G	cg06239285	chr11:62104954	ASRGL1	-1.0	-12.09	-0.49	1.92e-29	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs72925845	0.519	rs691674	chr17:76424502	C/G	cg03830375	chr17:76426088	DNAH17	0.49	6.89	0.31	1.79e-11	Triglycerides;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs7727544	0.735	rs272884	chr5:131668654	G/C	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.25e-34	Blood metabolite levels;
LGG	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.13	0.39	2.21e-18	Neuroticism;
LGG	cis	rs10771431	0.935	rs1988852	chr12:9372862	G/A	cg00504896	chr12:9437009	LOC642846	-0.6	-12.78	-0.51	3.01e-32	Breast size;
LGG	cis	rs7208859	0.614	rs28758251	chr17:29223312	A/T	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3087591	0.708	rs2107359	chr17:29697223	A/T	cg24425628	chr17:29625626	OMG;NF1	0.6	12.56	0.5	2.47e-31	Hip circumference;
LGG	cis	rs3813359	0.545	rs2326949	chr6:130550326	C/T	cg23281432	chr6:130554730	NA	0.52	7.54	0.33	2.56e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.82	0.45	1.84e-24	Arsenic metabolism;
LGG	cis	rs36051895	0.623	rs2146040	chr9:5260039	C/G	cg02405213	chr9:5042618	JAK2	0.72	13.14	0.52	9.67e-34	Pediatric autoimmune diseases;
LGG	trans	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg02002194	chr4:3960332	NA	0.39	7.21	0.32	2.29e-12	Joint mobility (Beighton score);
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.0	-0.35	1e-14	IgG glycosylation;
LGG	cis	rs6582630	0.555	rs10880607	chr12:38508184	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.05	0.31	6.71e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg15352829	chr14:105391018	PLD4	0.48	11.44	0.47	7.1e-27	Rheumatoid arthritis;
LGG	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg10792982	chr14:105748885	BRF1	0.65	12.89	0.51	1.11e-32	Mean platelet volume;Platelet distribution width;
LGG	trans	rs8002861	0.781	rs7322781	chr13:44442238	T/C	cg17145862	chr1:211918768	LPGAT1	0.98	25.29	0.76	2.75e-89	Leprosy;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.09e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg13647721	chr17:30228624	UTP6	0.65	8.73	0.38	4.55e-17	Hip circumference adjusted for BMI;
LGG	cis	rs4474465	0.850	rs7936232	chr11:78266602	A/G	cg27205649	chr11:78285834	NARS2	0.52	8.87	0.38	1.62e-17	Alzheimer's disease (survival time);
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg19422253	chr3:149212391	TM4SF4	0.43	6.73	0.3	5.01e-11	Beard thickness;
LGG	cis	rs651907	0.588	rs1672380	chr3:101633171	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.85	0.34	2.96e-14	Colorectal cancer;
LGG	cis	rs988958	0.833	rs1440097	chr2:42289765	A/C	cg19376973	chr2:42229025	NA	-0.47	-7.13	-0.31	3.89e-12	Hypospadias;
LGG	cis	rs4262150	0.764	rs72795376	chr5:151930769	T/C	cg12297329	chr5:152029980	NA	-0.73	-13.92	-0.54	4.7e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs8017423	0.935	rs8012303	chr14:90715829	G/A	cg04374321	chr14:90722782	PSMC1	0.86	18.16	0.65	4.62e-56	Mortality in heart failure;
LGG	cis	rs11645898	0.688	rs437638	chr16:72095452	C/T	cg14768367	chr16:72042858	DHODH	-0.99	-12.6	-0.51	1.68e-31	Blood protein levels;
LGG	cis	rs7177699	0.581	rs7181432	chr15:79123779	C/T	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6477694	0.571	rs4978774	chr9:111925315	C/T	cg14171727	chr9:111936775	EPB41L4B	0.34	6.71	0.3	5.84e-11	Body mass index;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.05	-0.49	2.87e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	0.46	7.68	0.34	9.76e-14	Cognitive performance;
LGG	cis	rs11874712	0.527	rs9965812	chr18:43702733	A/G	cg26436583	chr18:43649176	PSTPIP2	0.44	8.98	0.39	6.6e-18	Migraine - clinic-based;
LGG	cis	rs72949976	0.646	rs1441170	chr2:214033563	A/G	cg08319019	chr2:214017104	IKZF2	-0.64	-11.74	-0.48	4.84e-28	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs447735	0.565	rs10852626	chr16:89914633	T/G	cg26513180	chr16:89883248	FANCA	0.61	10.84	0.45	1.45e-24	Hemoglobin concentration;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg14668632	chr7:2872130	GNA12	-0.33	-6.98	-0.31	1.01e-11	Height;
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.75	-0.41	1.47e-20	Bipolar disorder;
LGG	trans	rs9657904	0.826	rs9841500	chr3:105584066	C/T	cg14088669	chr1:158435396	OR10K1	0.42	8.0	0.35	1.03e-14	Multiple sclerosis;
LGG	cis	rs17376456	0.825	rs13164315	chr5:93147421	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.66	0.41	3.09e-20	Diabetic retinopathy;
LGG	cis	rs4950322	1.000	rs1986987	chr1:146869283	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-7.0	-0.31	9.06e-12	Protein quantitative trait loci;
LGG	cis	rs7580658	0.724	rs4662711	chr2:127990840	G/A	cg10021288	chr2:128175891	PROC	-0.61	-12.45	-0.5	6.98e-31	Protein C levels;
LGG	cis	rs4330281	0.647	rs6768637	chr3:17692849	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.49	-0.33	3.58e-13	Schizophrenia;
LGG	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6725041	0.547	rs61696052	chr2:213201295	G/C	cg16329650	chr2:213403929	ERBB4	-0.38	-6.69	-0.3	6.61e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs4740619	0.870	rs12552653	chr9:15797980	T/C	cg14451791	chr9:16040625	NA	-0.39	-10.03	-0.42	1.43e-21	Body mass index;
LGG	cis	rs12410462	0.591	rs11802190	chr1:227635162	A/C	cg04117972	chr1:227635322	NA	0.42	7.54	0.33	2.51e-13	Major depressive disorder;
LGG	cis	rs9534288	0.830	rs7987953	chr13:46634395	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.7	-0.3	6.11e-11	Mood instability;
LGG	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg03342759	chr3:160939853	NMD3	-0.7	-11.67	-0.48	9.34e-28	Parkinson's disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08741578	chr4:4250464	TMEM128	0.39	6.71	0.3	5.66e-11	Bilirubin levels;
LGG	cis	rs6964587	0.692	rs418	chr7:91583334	C/T	cg17063962	chr7:91808500	NA	-0.5	-9.34	-0.4	4.22e-19	Breast cancer;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg17178900	chr1:205818956	PM20D1	0.58	13.04	0.52	2.41e-33	Menarche (age at onset);
LGG	cis	rs45544231	0.569	rs3803660	chr16:52586568	G/A	cg09051775	chr16:52580266	TOX3	0.45	7.6	0.33	1.67e-13	Restless legs syndrome;
LGG	trans	rs6076960	0.684	rs6054049	chr20:6254909	A/G	cg24759859	chr6:86352639	SYNCRIP	-0.42	-6.94	-0.31	1.29e-11	Smooth-surface caries;
LGG	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	8.17	0.36	2.88e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11676348	0.901	rs7562334	chr2:219003360	G/A	cg00012203	chr2:219082015	ARPC2	-0.5	-8.87	-0.38	1.58e-17	Ulcerative colitis;
LGG	cis	rs7975161	0.572	rs11111919	chr12:104569918	C/A	cg25273343	chr12:104657179	TXNRD1	-0.79	-7.33	-0.32	1.05e-12	Toenail selenium levels;
LGG	cis	rs9911578	0.730	rs55759249	chr17:57027135	A/G	cg12560992	chr17:57184187	TRIM37	-0.82	-12.61	-0.51	1.56e-31	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg00204512	chr16:28754710	NA	0.26	7.05	0.31	6.68e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg07117364	chr1:16154769	NA	-0.4	-7.0	-0.31	8.8e-12	Dilated cardiomyopathy;
LGG	cis	rs7953508	0.506	rs3869308	chr12:93959918	A/G	cg18151635	chr12:93972918	NA	-0.57	-10.78	-0.45	2.5300000000000002e-24	Pubertal anthropometrics;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.78	0.34	4.83e-14	Prudent dietary pattern;
LGG	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.46	0.37	3.41e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06634786	chr22:41940651	POLR3H	-0.74	-12.49	-0.5	4.81e-31	Vitiligo;
LGG	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg05313129	chr8:58192883	C8orf71	-0.6	-7.81	-0.34	3.94e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs752092	0.894	rs8042989	chr15:101770761	T/A	cg25114630	chr15:101792522	CHSY1	0.56	9.54	0.41	8.37e-20	Corneal structure;
LGG	cis	rs2645694	0.626	rs2703115	chr4:77824442	C/T	cg03477792	chr4:77819574	ANKRD56	0.53	9.42	0.4	2.23e-19	Emphysema distribution in smoking;
LGG	cis	rs6748734	0.548	rs12618707	chr2:241874559	T/C	cg05025159	chr2:241905733	NA	-0.47	-9.73	-0.41	1.7e-20	Urinary metabolites;
LGG	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg17376030	chr22:41985996	PMM1	0.47	7.76	0.34	5.56e-14	Vitiligo;
LGG	cis	rs3749237	0.595	rs7621003	chr3:49411404	T/C	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.04e-23	Resting heart rate;
LGG	cis	rs6502050	0.799	rs34448080	chr17:80121275	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg25358565	chr5:93447407	FAM172A	1.31	16.08	0.6	1.46e-46	Diabetic retinopathy;
LGG	cis	rs9341808	1.000	rs1359239	chr6:80956146	G/A	cg08355045	chr6:80787529	NA	0.37	7.19	0.32	2.68e-12	Sitting height ratio;
LGG	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg16400903	chr5:693638	TPPP	0.45	6.87	0.3	2.05e-11	Obesity-related traits;
LGG	cis	rs703842	1.000	rs6581155	chr12:58178162	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	7.85	0.34	2.93e-14	Multiple sclerosis;
LGG	trans	rs6787172	0.677	rs1095626	chr3:157977962	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs59918340	0.616	rs3739222	chr8:142205904	C/G	cg23750338	chr8:142222470	SLC45A4	0.53	10.49	0.44	3.06e-23	Immature fraction of reticulocytes;
LGG	cis	rs6546537	1.000	rs4852892	chr2:69866769	T/A	cg10773587	chr2:69614142	GFPT1	-0.49	-8.33	-0.36	9.42e-16	Serum thyroid-stimulating hormone levels;
LGG	cis	rs1152591	0.562	rs872227	chr14:64656165	T/C	cg21174375	chr14:64681225	SYNE2	0.44	8.4	0.36	5.54e-16	Atrial fibrillation;
LGG	cis	rs4481887	0.610	rs28763387	chr1:248559244	T/C	cg13385794	chr1:248469461	NA	0.43	7.4	0.33	6.2800000000000005e-13	Common traits (Other);
LGG	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg17201900	chr20:34330562	RBM39	0.5	6.75	0.3	4.45e-11	Total cholesterol levels;
LGG	cis	rs6831352	0.877	rs29001183	chr4:100056539	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.05e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00080312	chr3:45730181	SACM1L	0.42	7.37	0.32	8.03e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9916302	0.904	rs4794814	chr17:37696852	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.69	-0.59	8.14e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs4076764	1.000	rs4076764	chr1:163441286	A/G	cg06092702	chr1:163392909	NA	-0.47	-8.35	-0.36	7.96e-16	Motion sickness;
LGG	cis	rs2282300	0.739	rs1765139	chr11:30353725	T/C	cg25418670	chr11:30344373	C11orf46	-0.55	-7.79	-0.34	4.54e-14	Morning vs. evening chronotype;
LGG	cis	rs4076764	0.846	rs10753616	chr1:163415855	G/T	cg06092702	chr1:163392909	NA	0.4	7.28	0.32	1.45e-12	Motion sickness;
LGG	cis	rs7572644	0.699	rs2016616	chr2:28134037	A/G	cg27432699	chr2:27873401	GPN1	-0.44	-6.7	-0.3	6.1e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.98	-0.49	5.64e-29	Morning vs. evening chronotype;
LGG	cis	rs1408799	0.745	rs10960774	chr9:12739313	A/G	cg05274944	chr9:12693694	TYRP1	0.33	7.95	0.35	1.45e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs317689	0.513	rs529268	chr12:69687051	G/A	cg14784868	chr12:69753453	YEATS4	0.67	11.93	0.48	8.85e-29	Response to diuretic therapy;
LGG	cis	rs7937840	0.559	rs2000957	chr11:61877744	A/G	cg01969543	chr11:61895209	INCENP	-0.48	-9.81	-0.41	8.96e-21	Breast cancer;
LGG	cis	rs7937612	0.965	rs10892564	chr11:120224650	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.51	-12.37	-0.5	1.5e-30	Intraocular pressure;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg04772025	chr11:68637568	NA	0.71	12.68	0.51	7.65e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28595532	0.920	rs112097820	chr4:119746532	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs4925386	0.625	rs3810550	chr20:60912117	C/T	cg22307297	chr20:60903441	LAMA5	0.43	8.06	0.35	6.54e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2236918	0.901	rs1635502	chr1:242039382	A/G	cg17736920	chr1:242011382	EXO1	0.46	8.15	0.35	3.31e-15	Menopause (age at onset);
LGG	cis	rs12579753	0.917	rs7138895	chr12:82203280	T/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs7818345	0.637	rs13280711	chr8:19353600	T/A	cg06699216	chr8:19333253	CSGALNACT1	-0.4	-8.67	-0.37	7.32e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.77	-0.34	5.08e-14	Colorectal cancer;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.6	-11.53	-0.47	3.22e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs250677	0.687	rs250664	chr5:148453823	C/T	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.39	-0.32	6.84e-13	Breast cancer;
LGG	cis	rs2652822	1.000	rs1126309	chr15:63429062	A/G	cg02713581	chr15:63449717	RPS27L	0.49	8.38	0.36	6.52e-16	Metabolic traits;
LGG	cis	rs6558174	0.630	rs6558176	chr8:22522502	C/T	cg03733263	chr8:22462867	KIAA1967	-0.62	-10.59	-0.44	1.28e-23	Breast cancer;
LGG	cis	rs4919087	0.748	rs793516	chr10:98987985	G/T	cg25902810	chr10:99078978	FRAT1	-0.41	-7.04	-0.31	7.11e-12	Monocyte count;
LGG	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.38	-6.9	-0.31	1.69e-11	Restless legs syndrome;
LGG	cis	rs700651	0.754	rs1518367	chr2:198807015	T/A	cg00792783	chr2:198669748	PLCL1	0.68	11.08	0.46	1.85e-25	Intracranial aneurysm;
LGG	cis	rs11655198	1	rs11655198	chr17:38026169	C/T	cg00129232	chr17:37814104	STARD3	-0.5	-9.55	-0.41	7.29e-20	Asthma;
LGG	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg09448879	chr15:79043637	NA	0.29	6.65	0.3	8.28e-11	Sudden cardiac arrest;
LGG	cis	rs3771570	0.901	rs55811034	chr2:242406245	C/T	cg21155796	chr2:242212141	HDLBP	0.73	9.56	0.41	7.07e-20	Prostate cancer;
LGG	trans	rs17685	0.712	rs28456330	chr7:75810542	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	23.84	0.74	1.55e-82	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6459804	1.000	rs58278053	chr7:157512934	A/T	cg05585630	chr7:157510462	PTPRN2	-0.66	-13.82	-0.54	1.33e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs12195424	0.730	rs77121579	chr6:56303963	A/G	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs644799	0.930	rs631099	chr11:95563482	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12042938	0.600	rs823161	chr1:231775017	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.59	10.38	0.43	7.76e-23	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4409675	0.527	rs12067053	chr1:28227122	T/G	cg23691781	chr1:28212827	C1orf38	0.41	11.07	0.46	2.06e-25	Corneal astigmatism;
LGG	cis	rs2540226	0.539	rs6711206	chr2:39919736	A/G	cg18968196	chr2:39892502	TMEM178	0.3	8.14	0.35	3.57e-15	Personality dimensions;
LGG	cis	rs2013441	1.000	rs2703785	chr17:20152418	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs7107174	0.681	rs881337	chr11:78128335	G/C	cg02023728	chr11:77925099	USP35	0.44	7.58	0.33	1.95e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.82e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg14926445	chr8:58193284	C8orf71	-0.8	-10.33	-0.43	1.16e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6735179	0.607	rs10188708	chr2:1746032	G/C	cg20311673	chr2:1746207	PXDN	-0.39	-6.7	-0.3	5.92e-11	Response to antipsychotic treatment;
LGG	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg09021430	chr5:549028	NA	-0.81	-12.83	-0.51	1.8e-32	Obesity-related traits;
LGG	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg06634786	chr22:41940651	POLR3H	-0.55	-9.03	-0.39	4.51e-18	Neuroticism;
LGG	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg14664628	chr15:75095509	CSK	-0.57	-11.17	-0.46	8.24e-26	Breast cancer;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00407393	chr6:158464296	SYNJ2	0.35	6.94	0.31	1.36e-11	Electrocardiographic conduction measures;
LGG	cis	rs9611565	0.729	rs137831	chr22:41903813	A/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.71	-0.48	6.31e-28	Vitiligo;
LGG	cis	rs7523273	0.546	rs2796261	chr1:207888760	C/T	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.67	-0.37	7.41e-17	Schizophrenia;
LGG	cis	rs73198271	0.653	rs10099808	chr8:8659873	A/G	cg01851573	chr8:8652454	MFHAS1	-0.36	-6.71	-0.3	5.69e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg15103426	chr22:29168792	CCDC117	0.72	11.52	0.47	3.64e-27	Lymphocyte counts;
LGG	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.32	0.32	1.07e-12	Retinal vascular caliber;
LGG	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg04691961	chr3:161091175	C3orf57	-0.67	-16.18	-0.6	5.55e-47	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.782	rs66468703	chr11:48738773	T/C	cg00717180	chr2:96193071	NA	-0.45	-8.32	-0.36	9.75e-16	HDL cholesterol;
LGG	trans	rs7829975	0.582	rs6982832	chr8:8792217	A/C	cg16141378	chr3:129829833	LOC729375	0.34	7.53	0.33	2.64e-13	Mood instability;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.689	rs10810507	chr9:15955369	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.21	-0.43	3.3e-22	Body mass index;
LGG	cis	rs67366981	0.925	rs41438045	chr14:77692781	A/T	cg22824376	chr14:77648248	TMEM63C	0.7	7.75	0.34	6.03e-14	Obsessive-compulsive symptoms;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg16606324	chr3:10149918	C3orf24	0.51	6.82	0.3	2.89e-11	Alzheimer's disease;
LGG	cis	rs6694672	0.764	rs7554890	chr1:197148618	T/G	cg13682187	chr1:196946512	CFHR5	0.48	6.75	0.3	4.38e-11	Asthma;
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01171360	chr6:293285	DUSP22	-0.58	-9.71	-0.41	2.11e-20	Menopause (age at onset);
LGG	cis	rs56399783	0.901	rs11971014	chr7:2778444	C/T	cg19731401	chr7:2775893	GNA12	0.36	7.47	0.33	3.97e-13	Childhood ear infection;
LGG	trans	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08862035	chr2:2617432	NA	0.41	6.66	0.3	7.9e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9487094	0.666	rs13219952	chr6:109712287	C/T	cg16315928	chr6:109776240	MICAL1	0.43	7.56	0.33	2.17e-13	Height;
LGG	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.88	0.3	1.98e-11	Triglycerides;
LGG	cis	rs10463554	0.857	rs3776871	chr5:102292211	C/T	cg23492399	chr5:102201601	PAM	-0.56	-8.56	-0.37	1.68e-16	Parkinson's disease;
LGG	trans	rs6787172	0.629	rs865454	chr3:158013923	G/A	cg23275840	chr4:47708675	CORIN	0.4	8.59	0.37	1.33e-16	Subjective well-being;
LGG	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg22105103	chr4:187893119	NA	0.54	10.39	0.43	7.19e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg18404041	chr3:52824283	ITIH1	-0.41	-7.91	-0.34	1.95e-14	Bipolar disorder;
LGG	cis	rs9790314	0.589	rs1447618	chr3:160610438	C/T	cg03342759	chr3:160939853	NMD3	0.45	7.61	0.33	1.52e-13	Morning vs. evening chronotype;
LGG	cis	rs6456042	0.893	rs1134481	chr6:166571164	T/G	cg11088901	chr6:166572345	T	-0.39	-8.14	-0.35	3.73e-15	Asthma;
LGG	cis	rs2455799	0.613	rs4685264	chr3:15858347	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.81	-0.34	3.79e-14	Mean platelet volume;
LGG	trans	rs1728785	1.000	rs11648314	chr16:68596775	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.8	0.45	2.1e-24	Ulcerative colitis;
LGG	trans	rs7939886	0.841	rs79254833	chr11:55986896	T/C	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	trans	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg07817883	chr1:32538562	TMEM39B	1.19	11.85	0.48	1.86e-28	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7786877	0.723	rs11764045	chr7:100212754	C/T	cg21055462	chr7:100276975	NA	0.35	6.76	0.3	4.17e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs796364	1.000	rs281785	chr2:200749566	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.79	0.45	2.38e-24	Schizophrenia;
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.6	-0.37	1.25e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6840360	1.000	rs28710456	chr4:152667171	T/C	cg22705602	chr4:152727874	NA	-0.27	-6.81	-0.3	2.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6426558	0.537	rs694740	chr1:227293451	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	10.24	0.43	2.52e-22	Neutrophil percentage of white cells;
LGG	cis	rs7666738	0.830	rs10029849	chr4:99059362	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.14	-0.35	3.59e-15	HDL cholesterol;
LGG	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-10.96	-0.45	5.25e-25	Diastolic blood pressure;
LGG	cis	rs1729951	0.514	rs75977	chr3:136700549	C/A	cg21827317	chr3:136751795	NA	0.53	9.81	0.41	9.3e-21	Neuroticism;
LGG	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.88	0.3	1.9e-11	Educational attainment;
LGG	trans	rs6582630	0.519	rs12582285	chr12:38298753	C/T	cg06521331	chr12:34319734	NA	-0.49	-8.63	-0.37	9.57e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11645898	0.622	rs4788463	chr16:72223716	G/T	cg14768367	chr16:72042858	DHODH	-0.73	-9.83	-0.42	7.73e-21	Blood protein levels;
LGG	cis	rs4740619	0.619	rs4741560	chr9:16043170	C/T	cg14451791	chr9:16040625	NA	0.42	11.38	0.47	1.29e-26	Body mass index;
LGG	cis	rs1994135	0.647	rs11052745	chr12:33695999	G/T	cg06521331	chr12:34319734	NA	-0.51	-8.62	-0.37	1.03e-16	Resting heart rate;
LGG	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.26	0.4	7.96e-19	Rheumatoid arthritis;
LGG	cis	rs9583531	0.600	rs7986286	chr13:111357207	A/G	cg15841412	chr13:111365552	ING1	0.43	6.86	0.3	2.27e-11	Coronary artery disease;
LGG	cis	rs2067615	0.579	rs3782709	chr12:107205753	A/G	cg15890332	chr12:107067104	RFX4	0.39	11.07	0.46	1.92e-25	Heart rate;
LGG	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg08847335	chr10:891726	LARP4B	-0.48	-8.14	-0.35	3.63e-15	Eosinophil percentage of granulocytes;
LGG	trans	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.08	-0.35	5.81e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg16507663	chr6:150244633	RAET1G	0.5	10.26	0.43	2.09e-22	Lung cancer;
LGG	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03264133	chr6:25882463	NA	-0.71	-13.6	-0.53	1.08e-35	Blood metabolite levels;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs9462027	0.585	rs2814976	chr6:34576237	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.06	-0.42	1.12e-21	Systemic lupus erythematosus;
LGG	cis	rs7998202	0.667	rs695163	chr13:113363300	G/A	cg17218041	chr13:113365319	ATP11A	-0.44	-7.25	-0.32	1.72e-12	Glycated hemoglobin levels;
LGG	cis	rs2133450	0.712	rs1499213	chr3:7370210	T/A	cg19930620	chr3:7340148	GRM7	-0.37	-7.89	-0.34	2.27e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.72	-0.34	7.03e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs1497828	0.956	rs2646808	chr1:217523045	G/C	cg04411442	chr1:217543379	NA	-0.49	-8.21	-0.36	2.17e-15	Dialysis-related mortality;
LGG	cis	rs60871478	0.636	rs6976929	chr7:901382	C/T	cg22643751	chr7:855365	UNC84A	-0.44	-7.63	-0.33	1.34e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.28	-0.32	1.43e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs62238980	0.614	rs4821022	chr22:32414335	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs35110281	0.720	rs230647	chr21:44919654	C/T	cg04455712	chr21:45112962	RRP1B	-0.51	-8.88	-0.38	1.45e-17	Mean corpuscular volume;
LGG	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg13385794	chr1:248469461	NA	-0.44	-7.69	-0.34	8.64e-14	Common traits (Other);
LGG	cis	rs7647973	0.710	rs11130207	chr3:49611666	T/G	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	trans	rs1493916	0.905	rs4239383	chr18:31401066	T/C	cg27147174	chr7:100797783	AP1S1	-0.7	-13.33	-0.53	1.47e-34	Life satisfaction;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-6.95	-0.31	1.26e-11	Longevity;
LGG	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs3858526	0.755	rs10769368	chr11:5962084	C/T	cg13902645	chr11:5959945	NA	0.56	8.91	0.38	1.15e-17	DNA methylation (variation);
LGG	cis	rs4478037	0.822	rs9865342	chr3:33118631	G/A	cg19404215	chr3:33155277	CRTAP	0.81	9.51	0.4	1.08e-19	Major depressive disorder;
LGG	cis	rs7851660	0.967	rs3758249	chr9:100614140	T/C	cg13688889	chr9:100608707	NA	-0.69	-14.71	-0.56	1.9e-40	Strep throat;
LGG	trans	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg07817883	chr1:32538562	TMEM39B	1.24	11.59	0.47	1.91e-27	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1577917	0.917	rs4098044	chr6:86462066	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.46	-0.5	6.43e-31	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg07959490	chr17:80112427	CCDC57	0.39	7.51	0.33	3.02e-13	Life satisfaction;
LGG	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg17545662	chr6:170176663	C6orf70	0.7	8.89	0.38	1.32e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2455799	0.613	rs11712323	chr3:15891360	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.98	-0.35	1.15e-14	Mean platelet volume;
LGG	cis	rs9815354	0.812	rs73081321	chr3:41890231	G/A	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3862030	0.839	rs7078679	chr10:104284017	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-10.33	-0.43	1.25e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg22980697	chr10:16874865	CUBN	0.55	8.97	0.38	7.44e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg11366901	chr6:160182831	ACAT2	1.05	16.8	0.62	8.09e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.54	-9.6	-0.41	5.01e-20	Height;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg10802521	chr3:52805072	NEK4	-0.41	-7.02	-0.31	8.13e-12	Bipolar disorder;
LGG	cis	rs1691799	0.806	rs1168319	chr12:66744857	T/A	cg16791601	chr12:66731901	HELB	-0.66	-15.52	-0.58	4.9e-44	White blood cell count (basophil);
LGG	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg26384229	chr12:38710491	ALG10B	0.62	11.46	0.47	6.23e-27	Morning vs. evening chronotype;
LGG	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg24375607	chr4:120327624	NA	0.64	10.29	0.43	1.62e-22	Corneal astigmatism;
LGG	cis	rs16937	0.711	rs11240384	chr1:205172175	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs11969893	0.850	rs3734351	chr6:101307131	C/T	cg12253828	chr6:101329408	ASCC3	1.23	10.39	0.43	7.23e-23	Economic and political preferences (immigration/crime);
LGG	trans	rs2048656	0.578	rs7817784	chr8:9682553	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.26	0.32	1.61e-12	Schizophrenia;
LGG	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg05425664	chr17:57184151	TRIM37	-0.6	-9.69	-0.41	2.43e-20	Intelligence (multi-trait analysis);
LGG	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs806215	0.813	rs806175	chr7:127289435	A/G	cg25922125	chr7:127225783	GCC1	0.64	8.96	0.38	7.88e-18	Type 2 diabetes;
LGG	cis	rs7226408	0.857	rs72890516	chr18:34591601	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs3820928	0.874	rs10202239	chr2:227901819	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.33	-0.32	1.05e-12	Pulmonary function;
LGG	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg00666640	chr1:248458726	OR2T12	0.6	9.65	0.41	3.28e-20	Common traits (Other);
LGG	cis	rs8067287	0.554	rs56092540	chr17:16841417	C/T	cg26910001	chr17:16838321	NA	-0.5	-9.47	-0.4	1.49e-19	Diabetic kidney disease;
LGG	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	2.89e-18	Motion sickness;
LGG	cis	rs1451375	0.550	rs10239830	chr7:50603829	A/G	cg14593290	chr7:50529359	DDC	0.64	11.71	0.48	6.39e-28	Malaria;
LGG	cis	rs3540	0.533	rs7495080	chr15:91056681	G/A	cg22089800	chr15:90895588	ZNF774	-0.66	-12.12	-0.49	1.48e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg21659725	chr3:3221576	CRBN	0.65	10.14	0.43	6e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12200782	1.000	rs12208390	chr6:26437106	C/T	cg11502198	chr6:26597334	ABT1	-0.83	-6.81	-0.3	3.07e-11	Small cell lung carcinoma;
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg17951613	chr5:131705445	SLC22A5	0.61	6.86	0.3	2.18e-11	Rheumatoid arthritis;
LGG	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg00745463	chr17:30367425	LRRC37B	-0.55	-7.52	-0.33	2.84e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7737355	0.947	rs32115	chr5:131051328	A/G	cg06307176	chr5:131281290	NA	0.58	9.33	0.4	4.45e-19	Life satisfaction;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg27284194	chr4:1044797	NA	0.56	11.68	0.48	8.27e-28	Recombination rate (males);
LGG	cis	rs765787	0.530	rs28396110	chr15:45536909	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	trans	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg02002194	chr4:3960332	NA	-0.4	-7.34	-0.32	9.54e-13	Myopia (pathological);
LGG	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg27411982	chr8:10470053	RP1L1	0.45	8.03	0.35	8.17e-15	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.46	-0.5	5.98e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg11494091	chr17:61959527	GH2	0.92	20.49	0.69	6.69e-67	Prudent dietary pattern;
LGG	cis	rs7100689	0.784	rs7082705	chr10:82170856	C/T	cg01528321	chr10:82214614	TSPAN14	-1.0	-19.03	-0.66	4.51e-60	Post bronchodilator FEV1;
LGG	trans	rs11039798	0.588	rs1814768	chr11:48987455	T/C	cg15704280	chr7:45808275	SEPT13	0.75	10.31	0.43	1.48e-22	Axial length;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.71e-14	Testicular germ cell tumor;
LGG	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs12410462	0.591	rs2644146	chr1:227733917	C/G	cg23173402	chr1:227635558	NA	0.38	7.25	0.32	1.75e-12	Major depressive disorder;
LGG	cis	rs8062405	1.000	rs62037371	chr16:28890131	C/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.66	0.34	1.07e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.69	0.41	2.49e-20	Mean corpuscular volume;
LGG	cis	rs7208859	0.673	rs216424	chr17:28943064	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.71	-8.98	-0.39	6.78e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.685	rs169363	chr22:41853117	G/T	cg17376030	chr22:41985996	PMM1	-0.55	-8.7	-0.37	5.79e-17	Vitiligo;
LGG	cis	rs1372356	0.816	rs4144361	chr14:88533234	C/T	cg18078958	chr14:88630771	NA	-0.31	-7.26	-0.32	1.64e-12	Food antigen IgG levels;
LGG	cis	rs2131877	0.830	rs62285221	chr3:194875140	A/G	cg07250128	chr3:194833983	C3orf21	0.4	6.8	0.3	3.18e-11	Non-small cell lung cancer;
LGG	cis	rs13191362	0.935	rs34603926	chr6:163266793	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.83	9.35	0.4	3.81e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs68170813	0.562	rs17429825	chr7:107050731	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.18	-0.43	4.3e-22	Coronary artery disease;
LGG	trans	rs6940638	0.956	rs13207365	chr6:27030980	T/C	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs988958	0.526	rs2119171	chr2:42254637	T/G	cg27428208	chr2:42229179	NA	0.48	7.59	0.33	1.82e-13	Hypospadias;
LGG	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	4.91e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06475006	chr16:89985975	MC1R	-0.6	-7.1	-0.31	4.72e-12	Skin colour saturation;
LGG	cis	rs908922	0.676	rs545418	chr1:152497338	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	cis	rs3733585	0.673	rs4235347	chr4:9951956	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg22496380	chr5:211416	CCDC127	-1.15	-17.23	-0.63	9.11e-52	Breast cancer;
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg05692746	chr2:100937584	LONRF2	-0.64	-11.68	-0.48	8.43e-28	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs3816183	0.597	rs4952909	chr2:42912381	T/C	cg14631114	chr2:43023945	NA	0.35	6.94	0.31	1.32e-11	Hypospadias;
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs2303319	1.000	rs16845807	chr2:162247399	A/G	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg20120463	chr17:44301886	NA	-0.48	-7.37	-0.32	7.67e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg00647317	chr7:50633725	DDC	-0.34	-7.63	-0.33	1.38e-13	Malaria;
LGG	trans	rs10435719	0.718	rs7813935	chr8:11795636	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.97	-0.35	1.26e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.04	0.39	4.35e-18	Obesity-related traits;
LGG	trans	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg05926928	chr17:57297772	GDPD1	-0.5	-8.02	-0.35	8.65e-15	Schizophrenia;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg00405596	chr8:11794950	NA	-0.41	-6.72	-0.3	5.23e-11	Neuroticism;
LGG	cis	rs4604732	0.588	rs12045675	chr1:247623915	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	9.13	0.39	2.11e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg07870213	chr5:140052090	DND1	0.8	15.13	0.58	2.7e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg09264619	chr17:80180166	NA	0.36	7.32	0.32	1.08e-12	Life satisfaction;
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg02002194	chr4:3960332	NA	-0.39	-6.93	-0.31	1.45e-11	Morning vs. evening chronotype;
LGG	cis	rs2075064	0.814	rs76496856	chr9:126780167	C/T	cg14112217	chr9:126806003	NA	0.36	6.82	0.3	2.8e-11	Waist circumference;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg21724239	chr8:58056113	NA	0.53	7.62	0.33	1.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.853	rs12660725	chr6:100978570	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.86	-0.3	2.28e-11	Neuroticism;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg09699651	chr6:150184138	LRP11	0.57	11.13	0.46	1.12e-25	Testicular germ cell tumor;
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	6.96	0.31	1.16e-11	Schizophrenia;
LGG	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.89e-41	Vitiligo;
LGG	cis	rs7444	0.941	rs4821116	chr22:21973319	A/G	cg05046821	chr22:21984468	YDJC	0.39	7.12	0.31	4.05e-12	Systemic lupus erythematosus;
LGG	cis	rs9379945	1	rs9379945	chr6:26907831	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	9.22	0.39	1.07e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg17467752	chr17:38218738	THRA	0.42	6.83	0.3	2.67e-11	Self-reported allergy;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs11209002	1.000	rs2863202	chr1:67584335	T/C	cg02640540	chr1:67518911	SLC35D1	0.47	6.96	0.31	1.19e-11	Crohn's disease;
LGG	cis	rs9397585	0.667	rs1933264	chr6:153391618	C/T	cg17707550	chr6:153380415	RGS17	-0.55	-11.59	-0.47	1.96e-27	Body mass index;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg21171335	chr12:122356390	WDR66	0.28	8.0	0.35	1.02e-14	Mean corpuscular volume;
LGG	cis	rs62238980	0.614	rs117161237	chr22:32501630	C/T	cg00543991	chr22:32367038	NA	0.79	8.56	0.37	1.69e-16	Childhood ear infection;
LGG	cis	rs10504229	0.861	rs67966192	chr8:58188172	A/C	cg24829409	chr8:58192753	C8orf71	-0.81	-13.09	-0.52	1.64e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.571	rs4696273	chr4:152528477	G/A	cg22705602	chr4:152727874	NA	-0.32	-7.75	-0.34	6.03e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.564	rs6960622	chr7:124654080	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs2361718	0.631	rs4889989	chr17:78151860	C/G	cg09238746	chr17:78121135	EIF4A3	0.69	12.79	0.51	2.74e-32	Yeast infection;
LGG	cis	rs921968	0.643	rs832801	chr2:219488698	G/A	cg01130898	chr2:219473002	PLCD4	-0.39	-6.81	-0.3	3.01e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7769051	0.522	rs73554461	chr6:133139087	T/G	cg22852734	chr6:133119734	C6orf192	1.21	9.56	0.41	6.76e-20	Type 2 diabetes nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20859708	chr9:88556622	NAA35	0.5	7.43	0.33	5.19e-13	Gut microbiome composition (summer);
LGG	cis	rs4262150	0.810	rs4958565	chr5:152006087	T/C	cg12297329	chr5:152029980	NA	-0.8	-15.46	-0.58	9.21e-44	Bipolar disorder and schizophrenia;
LGG	trans	rs8073060	0.586	rs4796098	chr17:33913436	T/C	cg19694781	chr19:47549865	TMEM160	1.14	17.13	0.62	2.7e-51	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6920372	0.748	rs12190372	chr6:110084534	G/A	cg16315928	chr6:109776240	MICAL1	0.43	7.47	0.33	4.06e-13	Height;
LGG	cis	rs2019137	0.967	rs902695	chr2:113955074	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.45e-15	Lymphocyte counts;
LGG	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.84	-0.3	2.45e-11	Neuroticism;
LGG	cis	rs853679	0.517	rs3734573	chr6:28059437	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg07928641	chr1:182991847	LAMC1	0.46	9.12	0.39	2.36e-18	Colorectal cancer;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg05861140	chr6:150128134	PCMT1	-0.46	-10.38	-0.43	7.9e-23	Lung cancer;
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	cis	rs9354308	0.764	rs9354311	chr6:66568384	A/T	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs564799	0.842	rs480134	chr3:159729532	C/T	cg04855961	chr3:159719849	NA	-0.27	-7.4	-0.33	6.41e-13	Systemic lupus erythematosus;
LGG	cis	rs2249625	0.545	rs60835713	chr6:72880349	T/C	cg27608224	chr6:72922399	RIMS1	-0.33	-7.39	-0.32	6.75e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs9715521	0.868	rs62301181	chr4:59834246	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.34	-0.32	9.72e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2303745	0.589	rs891018	chr19:17396761	C/T	cg04248312	chr19:17393744	ANKLE1	0.68	11.35	0.47	1.63e-26	Systemic lupus erythematosus;
LGG	cis	rs672413	0.620	rs663646	chr5:78285778	G/A	cg04677158	chr5:78279841	ARSB	0.34	6.67	0.3	7.49e-11	Blood and toenail selenium levels;Blood protein levels;
LGG	cis	rs911263	0.603	rs11626138	chr14:68786993	A/G	cg18825221	chr14:68749962	RAD51L1	0.37	8.08	0.35	5.8e-15	Primary biliary cholangitis;
LGG	cis	rs4969178	0.930	rs4580257	chr17:76403028	T/G	cg05887092	chr17:76393375	PGS1	0.72	15.8	0.59	2.72e-45	HDL cholesterol levels;
LGG	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg26874164	chr19:58962979	ZNF324B	0.39	7.56	0.33	2.19e-13	Uric acid clearance;
LGG	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg20913747	chr6:44695427	NA	-0.61	-10.36	-0.43	8.93e-23	Total body bone mineral density;
LGG	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg14784868	chr12:69753453	YEATS4	0.74	12.62	0.51	1.34e-31	Response to diuretic therapy;
LGG	cis	rs7215564	0.908	rs36100789	chr17:78701117	C/T	cg06153925	chr17:78755379	RPTOR	0.39	6.7	0.3	6.25e-11	Myopia (pathological);
LGG	cis	rs524281	0.861	rs11227403	chr11:65858428	T/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs11190604	0.943	rs11190568	chr10:102224277	C/T	cg07080220	chr10:102295463	HIF1AN	0.65	10.75	0.45	3.34e-24	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9467711	0.606	rs2235251	chr6:26431982	C/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.74	-0.38	4.31e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-10.41	-0.44	6.25e-23	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg00933542	chr6:150070202	PCMT1	0.4	7.12	0.31	4.07e-12	Lung cancer;
LGG	cis	rs2439831	0.717	rs2470132	chr15:43835481	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.79	0.41	1.06e-20	Lung cancer in ever smokers;
LGG	cis	rs9400467	0.506	rs12207199	chr6:111525906	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	7.12	0.31	4.04e-12	Blood metabolite levels;Amino acid levels;
LGG	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.74	-0.41	1.65e-20	Retinal vascular caliber;
LGG	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs57590327	0.555	rs13099615	chr3:81729101	T/A	cg07356753	chr3:81810745	GBE1	-0.52	-8.34	-0.36	8.68e-16	Extraversion;
LGG	cis	rs7215564	0.730	rs34588273	chr17:78571465	C/T	cg16980736	chr17:78789706	RPTOR	-0.68	-8.46	-0.37	3.44e-16	Myopia (pathological);
LGG	cis	rs9487051	1.000	rs13191948	chr6:109634599	C/T	cg21918786	chr6:109611834	NA	-0.45	-8.29	-0.36	1.2e-15	Reticulocyte fraction of red cells;
LGG	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs7660883	0.897	rs236995	chr4:88000423	C/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.68	-0.41	2.55e-20	HDL cholesterol levels;
LGG	trans	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.4e-18	Neuroticism;
LGG	cis	rs503734	0.841	rs348874	chr3:100930681	A/T	cg27318481	chr3:100970896	IMPG2	-0.38	-8.24	-0.36	1.8e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7945705	0.806	rs12224436	chr11:8815825	C/A	cg21881798	chr11:8931708	C11orf17;ST5	0.43	8.76	0.38	3.71e-17	Hemoglobin concentration;
LGG	trans	rs11098499	0.754	rs10006259	chr4:120242145	C/T	cg25214090	chr10:38739885	LOC399744	0.61	11.09	0.46	1.64e-25	Corneal astigmatism;
LGG	trans	rs3779273	1.000	rs3779272	chr7:77828991	A/T	cg05596911	chr5:118502651	DMXL1	-0.44	-9.3	-0.4	5.63e-19	Body mass index;
LGG	cis	rs1555895	0.576	rs12413763	chr10:849454	A/G	cg09361094	chr10:834503	NA	-0.3	-7.82	-0.34	3.53e-14	Survival in rectal cancer;
LGG	cis	rs7914558	0.902	rs7092200	chr10:104844872	T/C	cg04362960	chr10:104952993	NT5C2	0.52	10.06	0.42	1.17e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg24642439	chr20:33292090	TP53INP2	0.83	15.27	0.58	6.15e-43	Coronary artery disease;
LGG	cis	rs13190036	0.748	rs28395268	chr5:176710547	C/G	cg06733329	chr5:176740039	MXD3	-0.45	-7.44	-0.33	5.06e-13	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs7267979	0.586	rs6050445	chr20:25195394	C/T	cg06421707	chr20:25228305	PYGB	0.4	8.22	0.36	2.13e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs751728	0.664	rs943478	chr6:33750940	T/A	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs2120019	0.517	rs872263	chr15:75136444	C/T	cg09165964	chr15:75287851	SCAMP5	-0.87	-11.94	-0.49	7.46e-29	Blood trace element (Zn levels);
LGG	cis	rs67460515	0.500	rs964533	chr3:160749019	C/A	cg04691961	chr3:161091175	C3orf57	-0.41	-7.94	-0.35	1.5e-14	Parkinson's disease;
LGG	cis	rs7619833	0.719	rs646157	chr3:27352143	T/A	cg02860705	chr3:27208620	NA	0.39	7.39	0.32	6.94e-13	Breast cancer;
LGG	trans	rs6787172	0.702	rs1730028	chr3:157900789	T/G	cg23275840	chr4:47708675	CORIN	0.41	8.71	0.38	5.45e-17	Subjective well-being;
LGG	cis	rs11229555	0.645	rs12273638	chr11:58186335	T/C	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1843834	0.823	rs2129610	chr2:225505345	G/A	cg22455342	chr2:225449267	CUL3	0.64	10.87	0.45	1.1e-24	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs10262624	0.935	rs6966641	chr7:23906598	C/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.89	-0.3	1.86e-11	Schizophrenia;
LGG	trans	rs12545912	0.820	rs11779335	chr8:9587854	C/T	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2455826	1.000	rs2455822	chr3:15674669	A/G	cg16303742	chr3:15540471	COLQ	0.41	7.02	0.31	8.16e-12	Inflammatory skin disease;
LGG	cis	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.98	-0.31	1.06e-11	Neuroticism;
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg11965913	chr1:205819406	PM20D1	0.45	7.11	0.31	4.36e-12	Parkinson's disease;
LGG	cis	rs6032067	0.714	rs3761194	chr20:43885935	C/T	cg10761708	chr20:43804764	PI3	0.57	8.66	0.37	7.9e-17	Blood protein levels;
LGG	cis	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg06374794	chr16:88002281	BANP	0.43	7.78	0.34	4.92e-14	Menopause (age at onset);
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg03395511	chr6:291903	DUSP22	-0.69	-11.78	-0.48	3.34e-28	Menopause (age at onset);
LGG	cis	rs832540	0.830	rs252907	chr5:56120646	G/A	cg12654349	chr5:56205094	C5orf35	-0.38	-6.78	-0.3	3.71e-11	Coronary artery disease;
LGG	trans	rs12545912	0.908	rs7016839	chr8:9587949	C/T	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs17539620	0.565	rs61225515	chr6:154841625	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	7.53	0.33	2.69e-13	Lipoprotein (a) levels;
LGG	cis	rs9303280	0.901	rs2305479	chr17:38062217	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-9.28	-0.4	6.43e-19	Self-reported allergy;
LGG	cis	rs2635047	0.615	rs2571005	chr18:44714365	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.39	-7.04	-0.31	6.96e-12	Educational attainment;
LGG	trans	rs6575793	0.513	rs1190867	chr14:101069135	G/T	cg22806444	chr17:72968764	C17orf28	-0.43	-7.47	-0.33	3.94e-13	Menarche (age at onset);
LGG	cis	rs7216064	1.000	rs12600941	chr17:65918807	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.03	-0.39	4.57e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg03342759	chr3:160939853	NMD3	-0.58	-9.89	-0.42	4.55e-21	Educational attainment (years of education);
LGG	cis	rs2658782	0.951	rs72972357	chr11:93118840	T/C	cg15737290	chr11:93063684	CCDC67	-0.55	-8.13	-0.35	4.07e-15	Pulmonary function decline;
LGG	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.32	2.01e-12	Blood metabolite levels;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg04025307	chr7:1156635	C7orf50	0.91	20.57	0.69	2.98e-67	Longevity;Endometriosis;
LGG	cis	rs9311474	0.569	rs7614981	chr3:52566914	G/T	cg15147215	chr3:52552868	STAB1	-0.39	-7.54	-0.33	2.56e-13	Electroencephalogram traits;
LGG	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg18876405	chr7:65276391	NA	0.55	9.8	0.41	1.01e-20	Aortic root size;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.23	-0.46	4.73e-26	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.54	-0.37	2e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.881	rs17767686	chr14:72006744	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.84	0.38	1.97e-17	Mitral valve prolapse;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg12458913	chr13:53173898	NA	0.51	8.64	0.37	9.21e-17	Lewy body disease;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08280861	chr8:58055591	NA	0.67	8.17	0.36	2.94e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.592	rs815042	chr12:33724221	C/A	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg14500267	chr11:67383377	NA	0.46	8.55	0.37	1.84e-16	Mean corpuscular volume;
LGG	cis	rs988958	0.565	rs6737944	chr2:42226621	G/A	cg19376973	chr2:42229025	NA	0.67	9.34	0.4	4.01e-19	Hypospadias;
LGG	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg23740940	chr11:68924746	NA	0.42	6.78	0.3	3.65e-11	Blond vs. brown hair color;
LGG	trans	rs629535	0.814	rs604254	chr8:70059164	A/G	cg21567404	chr3:27674614	NA	0.4	6.68	0.3	6.84e-11	Dupuytren's disease;
LGG	cis	rs2652834	0.950	rs2729787	chr15:63401493	G/T	cg05507819	chr15:63340323	TPM1	0.59	7.98	0.35	1.2e-14	HDL cholesterol;
LGG	cis	rs11225247	1.000	rs75493121	chr11:102269132	T/C	cg06323957	chr11:102217781	BIRC2	0.79	6.81	0.3	3.09e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs13394619	1.000	rs13394619	chr2:11727507	A/G	cg07314298	chr2:11723111	GREB1	0.49	10.18	0.43	4.07e-22	Endometriosis;
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg00857998	chr1:205179979	DSTYK	0.47	7.55	0.33	2.36e-13	Red blood cell count;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg24189917	chr7:1970923	MAD1L1	-0.51	-7.86	-0.34	2.67e-14	Bipolar disorder;
LGG	cis	rs11096990	0.964	rs16988409	chr4:39269350	A/G	cg24403649	chr4:39172243	NA	0.4	6.65	0.3	8.2e-11	Cognitive function;
LGG	cis	rs74417235	0.684	rs11167699	chr5:154050914	C/T	cg08754654	chr5:154026448	NA	0.61	11.62	0.48	1.47e-27	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	trans	rs7937682	0.855	rs10891285	chr11:111527775	T/C	cg18187862	chr3:45730750	SACM1L	0.66	10.9	0.45	8.68e-25	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01104198	chr2:203735673	ICA1L	0.47	7.15	0.32	3.51e-12	Gut microbiome composition (summer);
LGG	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg19077165	chr18:44547161	KATNAL2	-0.45	-7.52	-0.33	2.86e-13	Educational attainment;
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg13126279	chr21:47581558	C21orf56	0.46	7.6	0.33	1.64e-13	Testicular germ cell tumor;
LGG	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg17133734	chr15:86042851	AKAP13	0.28	6.79	0.3	3.39e-11	Coronary artery disease;
LGG	cis	rs6993813	0.589	rs4397431	chr8:120018413	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.9	0.34	2.11e-14	Bone mineral density (hip);
LGG	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg17757837	chr7:157058334	UBE3C	0.78	15.75	0.59	4.4e-45	Body mass index;
LGG	cis	rs12780845	0.540	rs11254431	chr10:17222673	T/C	cg01003015	chr10:17271136	VIM	-0.45	-7.61	-0.33	1.55e-13	Homocysteine levels;
LGG	trans	rs7939886	0.920	rs12226794	chr11:56110959	C/T	cg15704280	chr7:45808275	SEPT13	0.79	7.18	0.32	2.8e-12	Myopia (pathological);
LGG	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.79	-0.3	3.47e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2019137	0.560	rs11123172	chr2:113984303	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.83	-16.4	-0.61	5.6e-48	Lymphocyte counts;
LGG	trans	rs17060993	0.717	rs4055053	chr8:26869148	A/T	cg19071002	chr6:63940486	NA	-0.53	-7.02	-0.31	7.92e-12	Musician's dystonia;
LGG	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg00490583	chr16:1843685	IGFALS	-0.44	-9.54	-0.41	7.92e-20	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs12210905	1.000	rs12189835	chr6:27198271	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-7.34	-0.32	9.73e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6121246	0.821	rs6058448	chr20:30332396	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg03433033	chr1:76189801	ACADM	0.77	14.0	0.55	2.18e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17465130	chr10:135192054	PAOX	0.49	7.4	0.33	6.52e-13	Gut microbiome composition (summer);
LGG	cis	rs36051895	0.659	rs7046511	chr9:5045695	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-16.44	-0.61	3.55e-48	Pediatric autoimmune diseases;
LGG	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.04	-0.35	7.4e-15	Calcium levels;
LGG	cis	rs526231	0.697	rs422115	chr5:102634340	A/T	cg23492399	chr5:102201601	PAM	-0.56	-7.48	-0.33	3.77e-13	Primary biliary cholangitis;
LGG	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg14088196	chr11:70211408	PPFIA1	0.74	9.93	0.42	3.44e-21	Coronary artery disease;
LGG	cis	rs7107174	1.000	rs2510049	chr11:77985459	G/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6430585	0.528	rs309113	chr2:136737460	C/A	cg07169764	chr2:136633963	MCM6	1.14	20.23	0.68	1.18e-65	Corneal structure;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg16606324	chr3:10149918	C3orf24	0.63	7.23	0.32	2.07e-12	Alzheimer's disease;
LGG	cis	rs10791097	0.694	rs61910787	chr11:130744473	G/A	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9325144	0.600	rs10785621	chr12:38744912	C/T	cg13010199	chr12:38710504	ALG10B	0.58	11.3	0.47	2.52e-26	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	9.04e-26	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.99	-0.39	6.23e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	1.000	rs6663817	chr1:248495613	A/G	cg01631408	chr1:248437212	OR2T33	-0.57	-10.18	-0.43	4.06e-22	Common traits (Other);
LGG	trans	rs800082	0.668	rs9856190	chr3:144288547	G/C	cg24215973	chr2:240111563	HDAC4	-0.64	-12.49	-0.5	4.63e-31	Smoking behavior;
LGG	cis	rs4144027	0.904	rs10438242	chr14:104345075	C/T	cg26031613	chr14:104095156	KLC1	0.43	7.03	0.31	7.23e-12	Blood metabolite levels;
LGG	cis	rs7072216	0.763	rs7910247	chr10:100172252	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.17	-0.32	3.07e-12	Metabolite levels;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25072359	chr17:41440525	NA	0.53	10.17	0.43	4.45e-22	Menopause (age at onset);
LGG	cis	rs853679	0.517	rs2273564	chr6:28057594	A/T	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs2016266	0.859	rs11170507	chr12:53740682	C/A	cg04065151	chr12:53682969	ESPL1	0.58	9.05	0.39	4.03e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs8072100	0.967	rs4289035	chr17:45707211	C/T	cg19784903	chr17:45786737	TBKBP1	-0.36	-8.03	-0.35	8.35e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs131777	0.575	rs131760	chr22:51011936	T/C	cg05418105	chr22:50981406	NA	-0.63	-10.72	-0.45	4.3e-24	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs9393777	0.513	rs9368451	chr6:26654333	A/G	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21465180	chr2:54682970	SPTBN1	0.4	7.22	0.32	2.11e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8141529	0.719	rs5762825	chr22:29223642	A/G	cg15103426	chr22:29168792	CCDC117	0.73	11.86	0.48	1.7e-28	Lymphocyte counts;
LGG	trans	rs7647973	0.710	rs2029591	chr3:49646981	C/T	cg21659725	chr3:3221576	CRBN	0.57	7.36	0.32	8.37e-13	Menarche (age at onset);
LGG	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg19773385	chr1:10388646	KIF1B	-0.45	-9.83	-0.42	8.04e-21	Hepatocellular carcinoma;
LGG	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-8.17	-0.36	2.9e-15	Colorectal cancer;
LGG	cis	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.58	-11.71	-0.48	6.53e-28	IgG glycosylation;
LGG	cis	rs4268898	0.662	rs2303296	chr2:24432839	A/G	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs73198271	0.562	rs2048420	chr8:8667603	G/A	cg01851573	chr8:8652454	MFHAS1	0.51	8.06	0.35	6.38e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Electroencephalogram traits;
LGG	cis	rs4731207	0.596	rs4406330	chr7:124641491	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs4948102	0.731	rs10229446	chr7:56064262	A/G	cg17215666	chr7:56131930	SUMF2	-0.44	-6.92	-0.31	1.5e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg02725872	chr8:58115012	NA	-0.86	-11.65	-0.48	1.1e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.920	rs4938336	chr11:116948442	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-6.94	-0.31	1.33e-11	Subjective well-being;
LGG	cis	rs17376456	0.825	rs10057130	chr5:93282557	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	6.03e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg08773314	chr2:239334832	ASB1	-0.43	-8.28	-0.36	1.3e-15	Multiple system atrophy;
LGG	cis	rs2952156	0.920	rs2517959	chr17:37846512	A/T	cg00129232	chr17:37814104	STARD3	-0.69	-13.95	-0.54	3.63e-37	Asthma;
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.51	0.4	1.01e-19	Bipolar disorder;
LGG	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg18876405	chr7:65276391	NA	0.68	13.0	0.52	3.72e-33	Aortic root size;
LGG	cis	rs9815354	1.000	rs1717024	chr3:41984888	G/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.38	-0.36	6.43e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg27286337	chr10:134555280	INPP5A	0.86	12.91	0.51	8.41e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs806215	0.526	rs3808086	chr7:127539245	G/C	cg25922125	chr7:127225783	GCC1	-0.46	-6.74	-0.3	4.61e-11	Type 2 diabetes;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6558174	0.965	rs4872524	chr8:22489537	A/G	cg03733263	chr8:22462867	KIAA1967	0.65	10.99	0.45	3.87e-25	Breast cancer;
LGG	trans	rs116095464	0.614	rs4371799	chr5:268192	C/A	cg00938859	chr5:1591904	SDHAP3	0.92	13.61	0.53	1.02e-35	Breast cancer;
LGG	cis	rs240764	0.764	rs6903206	chr6:100929516	A/G	cg21058520	chr6:100914733	NA	-0.52	-8.98	-0.39	6.84e-18	Neuroticism;
LGG	cis	rs5758659	0.714	rs5751216	chr22:42508937	G/T	cg15557168	chr22:42548783	NA	0.35	7.93	0.35	1.62e-14	Cognitive function;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg19147804	chr7:1989927	MAD1L1	-0.5	-10.02	-0.42	1.56e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg07308232	chr7:1071921	C7orf50	-0.58	-11.14	-0.46	1.06e-25	Longevity;Endometriosis;
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs11166927	0.524	rs2035088	chr8:140831403	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.62	-12.6	-0.51	1.7e-31	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs17767294	0.612	rs12332927	chr6:27955115	T/C	cg15325629	chr6:28072465	NA	0.64	6.72	0.3	5.19e-11	Parkinson's disease;
LGG	cis	rs7582180	0.614	rs1030901	chr2:101007314	G/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.2e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.538	rs35454383	chr17:56475599	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.79	12.34	0.5	1.84e-30	Cognitive test performance;
LGG	cis	rs3785574	0.927	rs2008018	chr17:61954471	C/T	cg06873352	chr17:61820015	STRADA	0.43	6.9	0.31	1.76e-11	Height;
LGG	cis	rs13102973	0.965	rs13108037	chr4:135885643	A/G	cg14419869	chr4:135874104	NA	-0.56	-10.52	-0.44	2.28e-23	Subjective well-being;
LGG	cis	rs6540556	0.723	rs9430014	chr1:209905372	A/C	cg23920097	chr1:209922102	NA	-0.42	-7.04	-0.31	6.79e-12	Red blood cell count;
LGG	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg15268244	chr15:77196840	NA	-0.33	-7.23	-0.32	1.96e-12	Blood metabolite levels;
LGG	cis	rs2051211	1.000	rs2051211	chr3:38559749	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.62	-9.76	-0.41	1.38e-20	QRS duration;
LGG	cis	rs300774	0.925	rs424939	chr2:128894	C/T	cg04617936	chr2:214353	NA	-0.49	-7.43	-0.33	5.41e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg07460842	chr6:66804631	NA	-0.93	-17.0	-0.62	1.01e-50	Exhaled nitric oxide levels;
LGG	cis	rs738321	0.756	rs4821740	chr22:38514423	C/G	cg03162506	chr22:38580953	NA	0.36	8.77	0.38	3.37e-17	Breast cancer;
LGG	cis	rs4302748	0.818	rs61387197	chr7:36184016	T/A	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg18279126	chr7:2041391	MAD1L1	0.34	7.05	0.31	6.42e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9837602	0.529	rs793459	chr3:99520591	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.43	-0.36	4.55e-16	Breast cancer;
LGG	cis	rs13082711	0.522	rs514668	chr3:27330972	A/G	cg02860705	chr3:27208620	NA	0.6	11.39	0.47	1.11e-26	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6121246	0.567	rs6087700	chr20:30217560	A/G	cg13852791	chr20:30311386	BCL2L1	0.67	8.89	0.38	1.42e-17	Mean corpuscular hemoglobin;
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.66	-0.37	7.67e-17	Systolic blood pressure;
LGG	cis	rs9815354	0.812	rs73071203	chr3:41977464	A/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9487094	0.689	rs6939548	chr6:109785214	C/T	cg01125227	chr6:109776195	MICAL1	0.39	6.84	0.3	2.54e-11	Height;
LGG	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	trans	rs7819412	0.669	rs7823349	chr8:10998630	G/T	cg02002194	chr4:3960332	NA	0.41	7.09	0.31	4.96e-12	Triglycerides;
LGG	cis	rs10267417	0.584	rs10247789	chr7:19863570	G/C	cg05791153	chr7:19748676	TWISTNB	0.58	7.44	0.33	5.06e-13	Night sleep phenotypes;
LGG	cis	rs10893109	0.520	rs2000895	chr11:123789414	A/G	cg12387464	chr11:123775935	OR8D4	0.39	8.36	0.36	7.3e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	trans	rs2235573	0.653	rs6519095	chr22:38431917	G/A	cg19894588	chr14:64061835	NA	0.51	8.56	0.37	1.63e-16	Glioblastoma;Glioma;
LGG	cis	rs16976116	0.803	rs7168737	chr15:55501344	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1.03e-12	Body mass index;
LGG	cis	rs453301	0.522	rs2929455	chr8:9083433	A/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.49	-0.4	1.24e-19	Joint mobility (Beighton score);
LGG	cis	rs11920090	0.932	rs55989805	chr3:170714470	A/T	cg09710316	chr3:170744871	SLC2A2	0.59	8.38	0.36	6.26e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg15948088	chr11:109293068	C11orf87	0.44	7.41	0.33	6.03e-13	Schizophrenia;
LGG	cis	rs9486719	1.000	rs10872018	chr6:97026429	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.32	0.4	4.82e-19	Height;
LGG	cis	rs7975161	0.572	rs7957725	chr12:104574749	A/T	cg25273343	chr12:104657179	TXNRD1	-0.7	-8.27	-0.36	1.48e-15	Toenail selenium levels;
LGG	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.61	0.33	1.51e-13	Systolic blood pressure;
LGG	cis	rs62025270	0.688	rs7164373	chr15:86265663	T/A	cg25843651	chr15:86329602	KLHL25	0.58	8.96	0.38	8.08e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs350251	1.000	rs350251	chr16:12202572	A/G	cg02910054	chr16:12241554	SNX29	0.45	8.31	0.36	1.03e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.92	-0.35	1.78e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg22105103	chr4:187893119	NA	0.58	11.07	0.46	2.04e-25	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs970548	0.779	rs2310783	chr10:45972810	G/C	cg20477318	chr10:51623047	TIMM23	0.57	6.81	0.3	3e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.47	8.14	0.35	3.65e-15	Educational attainment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26755928	chr19:10363173	MRPL4	0.49	7.14	0.31	3.54e-12	Gut microbiome composition (summer);
LGG	cis	rs4838594	0.537	rs2166224	chr10:49696926	G/A	cg17291251	chr10:49678358	ARHGAP22	0.41	8.0	0.35	1.03e-14	Daytime sleep phenotypes;
LGG	cis	rs3806843	0.735	rs2530240	chr5:140060547	T/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	trans	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg08344181	chr3:125677491	NA	-0.47	-6.78	-0.3	3.71e-11	Depression;
LGG	cis	rs270601	0.837	rs367805	chr5:131701279	T/C	cg07395648	chr5:131743802	NA	-0.48	-9.96	-0.42	2.67e-21	Acylcarnitine levels;
LGG	cis	rs10256972	0.706	rs12701970	chr7:1121958	T/C	cg22907277	chr7:1156413	C7orf50	0.66	11.91	0.48	1.03e-28	Longevity;Endometriosis;
LGG	cis	rs2760061	0.626	rs672907	chr1:228120345	G/A	cg18477163	chr1:228402036	OBSCN	-0.26	-7.2	-0.32	2.49e-12	Diastolic blood pressure;
LGG	cis	rs10463554	0.926	rs34778	chr5:102452556	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.59	-0.33	1.81e-13	Parkinson's disease;
LGG	cis	rs1552244	0.816	rs56271597	chr3:10042790	C/T	cg08888203	chr3:10149979	C3orf24	0.55	9.29	0.4	6.26e-19	Alzheimer's disease;
LGG	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg14505434	chr11:89522851	NA	0.65	8.33	0.36	9.48e-16	Trans fatty acid levels;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.86	0.3	2.19e-11	Lung cancer;
LGG	cis	rs2820315	0.867	rs2820321	chr1:201880296	G/C	cg10061532	chr1:201886748	LMOD1	0.33	7.04	0.31	6.94e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs2011503	1.000	rs6511031	chr19:19471506	T/C	cg11584989	chr19:19387371	SF4	-0.74	-12.3	-0.5	2.88e-30	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.23e-19	Life satisfaction;
LGG	cis	rs4731207	0.565	rs1552118	chr7:124628858	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2153535	0.562	rs6901765	chr6:8455436	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs780096	0.526	rs72819536	chr2:27682850	G/T	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs12908161	0.959	rs3748376	chr15:85328352	C/T	cg03959625	chr15:84868606	LOC388152	0.49	7.17	0.32	2.92e-12	Schizophrenia;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs3858145	0.588	rs4142048	chr10:70044031	T/C	cg04882175	chr6:131122610	NA	-0.56	-8.06	-0.35	6.51e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg01200585	chr1:228362443	C1orf69	-0.45	-7.89	-0.34	2.2e-14	Diastolic blood pressure;
LGG	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.82	0.3	2.85e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg00409905	chr10:38381863	ZNF37A	-0.67	-12.59	-0.5	1.9e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs490234	0.676	rs4838264	chr9:128225561	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.11	-0.43	7.85e-22	Mean arterial pressure;
LGG	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg17376030	chr22:41985996	PMM1	0.52	8.57	0.37	1.51e-16	Vitiligo;
LGG	cis	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.81	0.41	9.16e-21	Colorectal cancer;
LGG	cis	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg01221209	chr5:554886	NA	-0.48	-7.23	-0.32	1.97e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg15596359	chr8:11213517	TDH	0.33	6.73	0.3	5.04e-11	Retinal vascular caliber;
LGG	cis	rs9815354	1.000	rs9852303	chr3:41759525	C/T	cg03022575	chr3:42003672	ULK4	0.59	7.59	0.33	1.76e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg08270023	chr12:132619174	NA	0.43	7.14	0.31	3.74e-12	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs7106204	0.534	rs76474760	chr11:24292598	T/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.73	0.38	4.5e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.49	8.61	0.37	1.15e-16	HDL cholesterol;
LGG	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg00531865	chr16:30841666	NA	0.54	11.28	0.46	3.06e-26	Dementia with Lewy bodies;
LGG	cis	rs4481887	0.830	rs4916126	chr1:248466604	G/A	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.93	0.38	1.03e-17	Fuchs's corneal dystrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12311644	chr22:31687046	PIK3IP1	0.57	9.02	0.39	4.93e-18	Gut microbiome composition (summer);
LGG	cis	rs758324	0.773	rs804058	chr5:131266362	T/C	cg06307176	chr5:131281290	NA	-0.53	-8.62	-0.37	1.07e-16	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs2832077	1.000	rs9983229	chr21:30137674	A/G	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.44	-0.33	4.98e-13	Cognitive test performance;
LGG	cis	rs2836950	0.545	rs8132143	chr21:40584258	A/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.24	-0.39	8.96e-19	Menarche (age at onset);
LGG	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06481639	chr22:41940642	POLR3H	-0.5	-7.46	-0.33	4.36e-13	Vitiligo;
LGG	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.71	0.34	7.95e-14	Retinal vascular caliber;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09155575	chr17:38084037	ORMDL3	-0.53	-8.03	-0.35	8.38e-15	Systemic lupus erythematosus;
LGG	cis	rs7805747	0.961	rs10253736	chr7:151415256	C/T	cg17611936	chr7:151411526	PRKAG2	0.48	7.0	0.31	9.09e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	trans	rs57046232	0.508	rs2148814	chr20:6352589	G/A	cg21095983	chr6:86352623	SYNCRIP	0.41	6.93	0.31	1.43e-11	Colorectal cancer;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg21724239	chr8:58056113	NA	0.44	6.93	0.31	1.42e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2742540	0.503	rs7106539	chr11:8897533	T/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.53	-11.51	-0.47	3.87e-27	Hematocrit;
LGG	cis	rs35740288	0.929	rs3858927	chr15:86301616	C/G	cg07943548	chr15:86304357	KLHL25	-0.38	-7.48	-0.33	3.69e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg25019033	chr10:957182	NA	-0.6	-12.53	-0.5	3.16e-31	Eosinophil percentage of granulocytes;
LGG	trans	rs8002861	0.905	rs12428350	chr13:44446161	G/A	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.48	-0.71	1.57e-71	Leprosy;
LGG	cis	rs12200782	0.530	rs6929908	chr6:26555289	C/A	cg11502198	chr6:26597334	ABT1	0.84	11.65	0.48	1.05e-27	Small cell lung carcinoma;
LGG	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg00717180	chr2:96193071	NA	0.41	7.31	0.32	1.17e-12	HDL cholesterol;
LGG	trans	rs1032833	0.643	rs77956380	chr2:180111404	T/G	cg23654767	chr2:101192981	PDCL3	0.72	8.29	0.36	1.23e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs4711350	0.678	rs680608	chr6:33713169	C/T	cg06471254	chr6:33690276	IP6K3	0.49	7.13	0.31	3.9e-12	Schizophrenia;
LGG	cis	rs936229	0.861	rs7176022	chr15:75107880	G/T	cg10253484	chr15:75165896	SCAMP2	0.68	10.52	0.44	2.34e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02731540	chr11:31391568	DCDC1;DNAJC24	0.42	7.14	0.31	3.75e-12	Cognitive performance;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Electroencephalogram traits;
LGG	trans	rs877282	0.945	rs11599043	chr10:777972	C/T	cg22713356	chr15:30763199	NA	0.56	8.61	0.37	1.11e-16	Uric acid levels;
LGG	cis	rs1957429	0.520	rs12435626	chr14:65295215	A/G	cg23373153	chr14:65346875	NA	0.67	7.02	0.31	7.98e-12	Pediatric areal bone mineral density (radius);
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.29	-0.32	1.35e-12	Lung cancer;
LGG	cis	rs8031584	0.706	rs798084	chr15:31126935	C/T	cg08704250	chr15:31115839	NA	-0.5	-8.88	-0.38	1.47e-17	Huntington's disease progression;
LGG	cis	rs4356932	1.000	rs12510335	chr4:76980539	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs56283067	0.578	rs12211510	chr6:45361189	A/G	cg20913747	chr6:44695427	NA	-0.54	-8.17	-0.35	3.06e-15	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08908148	chr7:39606013	C7orf36	0.44	7.35	0.32	8.77e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg20290983	chr6:43655470	MRPS18A	0.82	15.69	0.59	8.14e-45	IgG glycosylation;
LGG	cis	rs1881396	0.783	rs10181342	chr2:27757343	A/G	cg27432699	chr2:27873401	GPN1	0.56	8.49	0.37	2.73e-16	Nonalcoholic fatty liver disease;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.9	-0.38	1.3e-17	Menopause (age at onset);
LGG	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg01028140	chr2:1542097	TPO	-0.45	-8.33	-0.36	9.44e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7615952	0.641	rs12487875	chr3:125787224	C/A	cg15145296	chr3:125709740	NA	-0.6	-7.72	-0.34	7.05e-14	Blood pressure (smoking interaction);
LGG	trans	rs6601327	0.641	rs4840437	chr8:9606264	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.1	-0.31	4.73e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7301016	0.846	rs7297093	chr12:63033387	C/T	cg11441379	chr12:63026424	NA	0.69	9.61	0.41	4.83e-20	IgG glycosylation;
LGG	cis	rs6977660	0.943	rs10254261	chr7:19846001	A/G	cg07541023	chr7:19748670	TWISTNB	-0.47	-7.43	-0.33	5.16e-13	Thyroid stimulating hormone;
LGG	cis	rs7267979	0.966	rs2261698	chr20:25259910	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	2.96e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3796352	1.000	rs7645611	chr3:53125297	G/C	cg12962167	chr3:53033115	SFMBT1	0.63	6.74	0.3	4.72e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs873946	0.586	rs3829130	chr10:134563122	C/T	cg26818010	chr10:134567672	INPP5A	-0.75	-11.59	-0.47	1.86e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.63	-0.33	1.33e-13	Morning vs. evening chronotype;
LGG	cis	rs9581857	0.685	rs9319367	chr13:28042197	T/C	cg01674679	chr13:27998804	GTF3A	-0.69	-7.97	-0.35	1.2e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01240161	chr13:41706543	KBTBD6	0.38	6.88	0.3	1.98e-11	Obesity-related traits;
LGG	cis	rs72781680	0.846	rs55707417	chr2:24029928	G/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.48	0.4	1.29e-19	Lymphocyte counts;
LGG	cis	rs7267979	0.546	rs8115804	chr20:25438783	C/T	cg06421707	chr20:25228305	PYGB	-0.36	-7.13	-0.31	3.98e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4268898	0.931	rs2551121	chr2:24539967	T/C	cg06627628	chr2:24431161	ITSN2	-0.54	-8.98	-0.39	6.89e-18	Asthma;
LGG	cis	rs17767392	0.834	rs72728406	chr14:71734992	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.68	-0.37	6.7e-17	Mitral valve prolapse;
LGG	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg11477892	chr4:106580295	NA	-0.42	-6.84	-0.3	2.51e-11	Post bronchodilator FEV1;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.35	-0.32	9.22e-13	Obesity-related traits;
LGG	cis	rs3862030	0.720	rs11593971	chr10:104234090	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.08	-0.42	9.45e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.46e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.839	rs6929514	chr6:86525768	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-10.1	-0.42	8.48e-22	Response to antipsychotic treatment;
LGG	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg03929089	chr4:120376271	NA	0.76	11.98	0.49	5.52e-29	Coronary artery disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26642667	chr7:127292389	SND1	-0.46	-7.38	-0.32	7.44e-13	Pancreatic cancer;
LGG	cis	rs559928	0.556	rs11607903	chr11:63932140	G/A	cg24687543	chr11:63912206	MACROD1	0.61	8.55	0.37	1.87e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10782582	0.593	rs1412717	chr1:76125471	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-7.0	-0.31	9.13e-12	Daytime sleep phenotypes;
LGG	cis	rs8053891	0.615	rs3794695	chr16:72097827	C/T	cg23815491	chr16:72088622	HP	0.47	7.8	0.34	4.08e-14	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06872176	chr1:68697386	GPR177	0.52	8.63	0.37	9.73e-17	Cognitive performance;
LGG	cis	rs1719271	0.908	rs1719263	chr15:65176192	G/T	cg11671771	chr15:65133392	PLEKHO2	-0.54	-7.18	-0.32	2.84e-12	Platelet count;
LGG	cis	rs4655537	0.568	rs4655783	chr1:66143044	T/C	cg04111102	chr1:66153794	NA	0.27	6.85	0.3	2.42e-11	Blood protein levels;
LGG	trans	rs853679	0.607	rs34243448	chr6:28193102	C/A	cg01620082	chr3:125678407	NA	-1.08	-10.61	-0.44	1.07e-23	Depression;
LGG	trans	rs4942242	0.663	rs9525816	chr13:44223898	A/G	cg19169023	chr15:41853346	TYRO3	-0.45	-8.8	-0.38	2.67e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs75804782	0.690	rs56198112	chr2:239348887	A/G	cg01134436	chr17:81009848	B3GNTL1	0.82	8.63	0.37	1.01e-16	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg03929089	chr4:120376271	NA	0.79	8.2	0.36	2.45e-15	Myopia (pathological);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg01707076	chr7:158220990	PTPRN2	0.35	6.66	0.3	7.89e-11	Body fat percentage;
LGG	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg21775007	chr8:11205619	TDH	0.61	10.02	0.42	1.64e-21	Retinal vascular caliber;
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg08499158	chr17:42289980	UBTF	-0.66	-12.22	-0.49	5.92e-30	Total body bone mineral density;
LGG	cis	rs10752881	1.000	rs8179282	chr1:182974598	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24965497	chr17:7227181	NEURL4	0.38	6.78	0.3	3.72e-11	Pancreatic cancer;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg23782820	chr8:58130467	NA	0.5	6.93	0.31	1.42e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.76	-0.38	3.57e-17	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.08	-0.52	1.78e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg21138405	chr5:131827807	IRF1	-0.29	-6.95	-0.31	1.21e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.72	0.51	5.19e-32	Prudent dietary pattern;
LGG	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.32	-0.4	4.66e-19	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.75	14.07	0.55	1.06e-37	Obesity-related traits;
LGG	cis	rs657075	0.697	rs34604423	chr5:131653511	T/C	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.1e-21	Rheumatoid arthritis;
LGG	cis	rs4730250	0.802	rs77936580	chr7:106946343	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.61	-0.44	1.1e-23	Osteoarthritis;
LGG	cis	rs9303280	0.806	rs4795395	chr17:37962987	T/A	cg19468946	chr17:37922297	IKZF3	-0.45	-8.2	-0.36	2.33e-15	Self-reported allergy;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.45	-0.33	4.75e-13	Bipolar disorder;
LGG	cis	rs7940866	0.845	rs1433976	chr11:130875123	C/T	cg12179176	chr11:130786555	SNX19	-0.71	-13.2	-0.52	5.65e-34	Schizophrenia;
LGG	cis	rs7312933	0.531	rs2406674	chr12:42720150	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.1	-0.35	4.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs883565	0.569	rs7637036	chr3:38997778	C/T	cg01426195	chr3:39028469	NA	-0.6	-12.77	-0.51	3.33e-32	Handedness;
LGG	cis	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg24375607	chr4:120327624	NA	0.67	10.96	0.45	5.05e-25	Corneal astigmatism;
LGG	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg03929089	chr4:120376271	NA	0.73	7.78	0.34	4.81e-14	Axial length;
LGG	cis	rs5769765	0.908	rs4074304	chr22:50309446	G/A	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	trans	rs7246760	0.867	rs61011126	chr19:9814421	A/C	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	cis	rs2370759	1.000	rs16933225	chr10:32599464	C/T	cg01819863	chr10:32635814	EPC1	1.05	14.8	0.57	7.71e-41	Sexual dysfunction (female);
LGG	cis	rs17376456	0.825	rs36042718	chr5:93180997	C/T	cg19507638	chr5:93509721	C5orf36	-0.66	-9.25	-0.4	7.98e-19	Diabetic retinopathy;
LGG	cis	rs8180040	0.934	rs62260710	chr3:47564462	C/G	cg16586182	chr3:47516702	SCAP	0.76	14.75	0.57	1.23e-40	Colorectal cancer;
LGG	cis	rs2013441	1.000	rs2034109	chr17:20196633	C/T	cg13482628	chr17:19912719	NA	-0.51	-9.35	-0.4	3.91e-19	Obesity-related traits;
LGG	cis	rs77633900	0.772	rs157760	chr15:76800260	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2273669	0.667	rs12196010	chr6:109302173	C/A	cg05315195	chr6:109294784	ARMC2	-0.67	-8.64	-0.37	9.38e-17	Prostate cancer;
LGG	trans	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg26384229	chr12:38710491	ALG10B	-0.61	-11.08	-0.46	1.75e-25	Morning vs. evening chronotype;
LGG	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.76	-0.34	5.39e-14	Testicular germ cell tumor;
LGG	cis	rs2404602	0.716	rs8039545	chr15:76707247	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.13	-0.31	3.98e-12	Blood metabolite levels;
LGG	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg05044414	chr3:183734942	ABCC5	0.77	16.74	0.61	1.5e-49	Anterior chamber depth;
LGG	cis	rs9611519	0.780	rs5751072	chr22:41656509	C/T	cg03806693	chr22:41940476	POLR3H	-0.66	-11.06	-0.46	2.17e-25	Neuroticism;
LGG	cis	rs7246760	0.867	rs55914342	chr19:9824447	A/T	cg16876255	chr19:9731953	ZNF561	0.82	7.68	0.34	9.71e-14	Pursuit maintenance gain;
LGG	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg20608306	chr11:116969690	SIK3	0.42	13.33	0.53	1.58e-34	Blood protein levels;
LGG	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.76	-0.48	3.94e-28	Mean platelet volume;
LGG	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.61	-10.61	-0.44	1.06e-23	Chronic sinus infection;
LGG	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	6.85e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg13129888	chr1:28415099	EYA3	0.45	7.69	0.34	8.75e-14	Bipolar disorder;
LGG	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06481639	chr22:41940642	POLR3H	-0.64	-9.02	-0.39	5.19e-18	Vitiligo;
LGG	cis	rs2836974	0.568	rs2183573	chr21:40574305	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.68	-0.37	6.76e-17	Cognitive function;
LGG	cis	rs3741404	0.583	rs640999	chr11:63869425	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.32	0.58	3.77e-43	Platelet count;
LGG	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg09795085	chr6:101329169	ASCC3	-0.41	-6.93	-0.31	1.39e-11	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24475210	chr4:6642433	MRFAP1	0.46	7.44	0.33	4.84e-13	Cognitive performance;
LGG	trans	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.22	-0.52	4.29e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs7587476	0.906	rs2070096	chr2:215645545	C/G	cg04004882	chr2:215674386	BARD1	0.51	7.03	0.31	7.24e-12	Neuroblastoma;
LGG	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg25457927	chr22:38595422	NA	0.38	8.94	0.38	9.49e-18	Breast cancer;
LGG	cis	rs1801251	1.000	rs6714245	chr2:233580505	T/C	cg25237894	chr2:233734115	C2orf82	0.66	12.54	0.5	2.88e-31	Coronary artery disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08951907	chr17:18218556	TOP3A;SMCR8	0.39	6.8	0.3	3.28e-11	Bilirubin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16256106	chr19:3970885	DAPK3	0.56	8.47	0.37	3.17e-16	Gut microbiome composition (summer);
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.72e-13	Height;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs1811113	chr22:42073134	C/T	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Vitiligo;
LGG	cis	rs35176054	0.730	rs12779039	chr10:105502836	T/C	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.97	-0.31	1.09e-11	Atrial fibrillation;
LGG	trans	rs61931739	0.500	rs6488209	chr12:34319309	A/G	cg26384229	chr12:38710491	ALG10B	0.73	15.0	0.57	9.53e-42	Morning vs. evening chronotype;
LGG	cis	rs6735179	0.565	rs73182754	chr2:1747733	A/C	cg08534653	chr2:1747700	PXDN	0.49	7.36	0.32	8.27e-13	Response to antipsychotic treatment;
LGG	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg06046430	chr4:77819534	ANKRD56	0.54	10.97	0.45	4.63e-25	Emphysema distribution in smoking;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg21963583	chr11:68658836	MRPL21	-0.53	-9.27	-0.4	7.21e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4330281	0.647	rs6442680	chr3:17418533	T/C	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.5e-11	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9379783	chr6:25725207	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.44	0.44	4.88e-23	Iron status biomarkers;
LGG	cis	rs4262150	0.810	rs72799168	chr5:152140996	T/A	cg12297329	chr5:152029980	NA	-0.7	-12.97	-0.52	4.97e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs7814319	0.838	rs2643342	chr8:97234255	A/G	cg20787634	chr8:97240163	UQCRB	-0.71	-15.52	-0.59	4.74e-44	Lung function (FVC);
LGG	cis	rs9783347	1.000	rs4150622	chr11:18365710	A/G	cg15585147	chr11:18324498	HPS5	0.43	9.4	0.4	2.55e-19	Pancreatic cancer;
LGG	cis	rs9868809	0.881	rs13063312	chr3:48661985	G/A	cg00383909	chr3:49044727	WDR6	0.83	9.59	0.41	5.61e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg12395012	chr8:11607386	GATA4	0.38	6.83	0.3	2.71e-11	Neuroticism;
LGG	cis	rs9291683	0.507	rs6845554	chr4:10013173	T/G	cg00071950	chr4:10020882	SLC2A9	0.38	7.84	0.34	3.15e-14	Bone mineral density;
LGG	cis	rs28588043	0.877	rs61816864	chr1:170992716	T/A	cg03458344	chr1:170964477	C1orf129	-0.53	-7.21	-0.32	2.28e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2841277	0.708	rs4465542	chr14:105407798	A/G	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.71	-0.34	7.73e-14	Rheumatoid arthritis;
LGG	cis	rs6740322	0.748	rs6720087	chr2:43468745	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.63	9.81	0.41	9.4e-21	Coronary artery disease;
LGG	cis	rs1256531	0.661	rs56182635	chr14:66189618	G/A	cg15999311	chr14:65749247	NA	0.77	6.98	0.31	1.03e-11	Conduct disorder (symptom count);
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs2066819	0.901	rs1274490	chr12:56649601	A/G	cg26734620	chr12:56694298	CS	-0.75	-6.84	-0.3	2.46e-11	Psoriasis vulgaris;
LGG	cis	rs644799	1.000	rs560854	chr11:95584905	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	14.02	0.55	1.89e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg24375607	chr4:120327624	NA	0.65	10.53	0.44	2.26e-23	Corneal astigmatism;
LGG	cis	rs4671458	0.724	rs56219461	chr2:63669666	G/A	cg17519650	chr2:63277830	OTX1	-0.55	-7.3	-0.32	1.25e-12	Subjective well-being;
LGG	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg17764715	chr19:33622953	WDR88	-0.63	-11.55	-0.47	2.76e-27	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg27119904	chr13:114814333	RASA3	0.37	8.58	0.37	1.4e-16	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs6960043	0.818	rs10258074	chr7:15064216	A/T	cg19272540	chr7:15055459	NA	-0.35	-7.76	-0.34	5.45e-14	Type 2 diabetes;
LGG	cis	rs9547692	0.938	rs55639205	chr13:37469994	A/C	cg02985381	chr13:37494744	SMAD9	0.73	12.87	0.51	1.3e-32	Coronary artery disease;
LGG	trans	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg05926928	chr17:57297772	GDPD1	0.71	12.82	0.51	1.98e-32	Schizophrenia;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.0	-0.31	9.31e-12	Bipolar disorder;
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.8	-0.41	9.56e-21	Aortic root size;
LGG	cis	rs79349575	0.716	rs595767	chr17:46957987	A/G	cg16584676	chr17:46985605	UBE2Z	0.45	7.67	0.34	1.02e-13	Type 2 diabetes;
LGG	cis	rs4423214	0.879	rs1790345	chr11:71145941	G/A	cg10847948	chr11:71163743	NADSYN1	0.63	11.35	0.47	1.59e-26	Vitamin D levels;
LGG	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg13736514	chr6:26305472	NA	-0.43	-8.84	-0.38	2.08e-17	Educational attainment;
LGG	cis	rs11758351	0.500	rs4593350	chr6:26184800	T/C	cg01420254	chr6:26195488	NA	0.97	7.39	0.32	6.97e-13	Gout;Renal underexcretion gout;
LGG	cis	rs7267979	0.586	rs6083776	chr20:25186116	G/A	cg06421707	chr20:25228305	PYGB	0.39	7.98	0.35	1.14e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs854765	0.505	rs2955358	chr17:17946623	A/G	cg04398451	chr17:18023971	MYO15A	0.74	15.76	0.59	4.12e-45	Total body bone mineral density;
LGG	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	19.38	0.67	1.08e-61	Smoking behavior;
LGG	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg12082025	chr19:1064218	ABCA7	-0.47	-7.4	-0.33	6.66e-13	Alzheimer's disease (late onset);
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.34	-0.47	1.77e-26	Triglycerides;
LGG	trans	rs11250098	0.600	rs4240671	chr8:10767748	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.08	0.35	5.79e-15	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	7.64	0.33	1.23e-13	Schizophrenia;
LGG	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	trans	rs7618501	1.000	rs6775384	chr3:49853073	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	12.98	0.52	4.29e-33	Intelligence (multi-trait analysis);
LGG	cis	rs2749592	0.550	rs10764135	chr10:37866845	C/T	cg25427524	chr10:38739819	LOC399744	0.47	8.82	0.38	2.27e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs61931739	0.890	rs1849160	chr12:34140191	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.54	-0.33	2.43e-13	Morning vs. evening chronotype;
LGG	cis	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs8016982	0.662	rs8014406	chr14:81657760	A/C	cg01989461	chr14:81687754	GTF2A1	0.57	9.06	0.39	3.69e-18	Schizophrenia;
LGG	cis	rs4631830	0.720	rs11004415	chr10:51498181	G/A	cg10326726	chr10:51549505	MSMB	0.64	12.8	0.51	2.4e-32	Prostate-specific antigen levels;
LGG	cis	rs875971	0.617	rs810400	chr7:66022889	G/C	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.14e-29	Aortic root size;
LGG	cis	rs752092	0.802	rs2412005	chr15:101767591	T/A	cg19997662	chr15:101784653	CHSY1	-0.79	-16.57	-0.61	9.79e-49	Corneal structure;
LGG	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg12386194	chr3:101231763	SENP7	0.44	7.69	0.34	8.81e-14	Colorectal cancer;
LGG	cis	rs2404602	0.532	rs284892	chr15:76721037	A/G	cg15268244	chr15:77196840	NA	-0.37	-8.13	-0.35	4.07e-15	Blood metabolite levels;
LGG	trans	rs75804782	0.625	rs59039294	chr2:239470654	G/A	cg01134436	chr17:81009848	B3GNTL1	0.73	7.72	0.34	7.07e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7717393	1.000	rs10079754	chr5:155747951	G/C	cg04435420	chr5:155754009	SGCD	1.13	12.38	0.5	1.26e-30	Egg allergy;
LGG	cis	rs4824093	0.610	rs3761496	chr22:50246466	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-6.99	-0.31	9.85e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08280861	chr8:58055591	NA	0.64	7.84	0.34	3.1e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1788820	0.917	rs1624695	chr18:21142992	A/T	cg14672496	chr18:21087552	C18orf8	0.38	7.04	0.31	7.09e-12	Body mass index;
LGG	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs7766436	0.885	rs13209127	chr6:22597625	A/G	cg13666174	chr6:22585274	NA	0.47	10.36	0.43	9.35e-23	Coronary artery disease;
LGG	trans	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.96e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4702718	0.616	rs267985	chr5:10713395	A/G	cg14521931	chr5:10832172	NA	0.44	8.38	0.36	6.42e-16	Obesity-related traits;
LGG	cis	rs220324	0.954	rs511045	chr21:43581865	T/C	cg08841829	chr21:43638893	ABCG1	0.42	6.87	0.3	2.07e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs7100689	0.646	rs7899791	chr10:82091950	A/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.59	0.56	6.02e-40	Post bronchodilator FEV1;
LGG	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg13114125	chr14:105738426	BRF1	-0.85	-15.96	-0.6	5.17e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.6	-10.08	-0.42	9.74e-22	Iron status biomarkers;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg14926445	chr8:58193284	C8orf71	-0.72	-9.07	-0.39	3.39e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.545	rs11766183	chr7:65839160	G/C	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs6964587	0.869	rs10250014	chr7:91490208	T/C	cg17063962	chr7:91808500	NA	-0.4	-6.94	-0.31	1.35e-11	Breast cancer;
LGG	cis	rs7786877	0.723	rs62482239	chr7:100217810	C/T	cg03098644	chr7:100410630	EPHB4	0.5	7.45	0.33	4.6e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg11757124	chr7:157526947	PTPRN2	-0.52	-9.41	-0.4	2.31e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs12681287	0.673	rs2976178	chr8:87332552	C/G	cg27223183	chr8:87520930	FAM82B	-0.48	-7.04	-0.31	6.93e-12	Caudate activity during reward;
LGG	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg26384229	chr12:38710491	ALG10B	-0.62	-11.88	-0.48	1.29e-28	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10848704	0.956	rs10848703	chr12:2882250	C/T	cg19995117	chr12:2880862	NA	0.38	6.71	0.3	5.64e-11	Quantitative traits;
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs4538187	0.950	rs12996866	chr2:64130965	G/A	cg14150252	chr2:64069583	UGP2	-0.48	-9.48	-0.4	1.28e-19	Systolic blood pressure;
LGG	cis	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg09307838	chr4:120376055	NA	0.73	12.4	0.5	1.09e-30	Corneal astigmatism;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	1.000	rs28494082	chr21:43634547	A/G	cg15319517	chr21:43638949	ABCG1	-0.5	-6.8	-0.3	3.22e-11	Eating disorder in bipolar disorder;
LGG	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg08603382	chr10:743973	NA	-0.52	-8.9	-0.38	1.29e-17	Psychosis in Alzheimer's disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07235253	chr7:99156031	ZNF655	-0.4	-6.82	-0.3	2.82e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27620946	chr8:42011116	AP3M2	0.41	6.68	0.3	6.81e-11	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27110132	chr16:3661765	BTBD12	0.47	7.68	0.34	9.72e-14	Cognitive performance;
LGG	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg20608306	chr11:116969690	SIK3	0.32	8.36	0.36	7.49e-16	Blood protein levels;
LGG	cis	rs2304069	0.779	rs245081	chr5:149356075	G/T	cg12661370	chr5:149340060	SLC26A2	0.55	8.23	0.36	1.97e-15	HIV-1 control;
LGG	cis	rs11690935	0.959	rs6709156	chr2:172591944	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs7172689	1.000	rs72746144	chr15:81550686	A/G	cg11808699	chr15:81528661	IL16	-0.5	-10.43	-0.44	5.12e-23	Inattentive symptoms;
LGG	cis	rs1570884	0.890	rs6561541	chr13:50127280	C/T	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.66	-0.3	8.02e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1799949	1.000	rs8077486	chr17:41212805	C/T	cg05368731	chr17:41323189	NBR1	0.86	16.77	0.61	1.19e-49	Menopause (age at onset);
LGG	cis	rs9863	0.931	rs11057407	chr12:124449829	G/A	cg13487667	chr12:124434373	CCDC92	-0.37	-7.06	-0.31	6.19e-12	White blood cell count;
LGG	cis	rs17826219	0.706	rs9893922	chr17:29068425	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Body mass index;
LGG	trans	rs7824557	0.652	rs12677504	chr8:11133175	G/A	cg02002194	chr4:3960332	NA	0.5	9.16	0.39	1.67e-18	Retinal vascular caliber;
LGG	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs3770081	1.000	rs111295372	chr2:86283357	T/C	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.19	0.32	2.64e-12	Facial emotion recognition (sad faces);
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg02018176	chr4:1364513	KIAA1530	0.43	9.97	0.42	2.46e-21	Obesity-related traits;
LGG	trans	rs11088226	0.581	rs2833862	chr21:33884390	A/G	cg09050820	chr6:167586206	TCP10L2	0.46	7.42	0.33	5.67e-13	Gastritis;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.4	0.4	2.62e-19	Lung cancer;
LGG	cis	rs780096	0.526	rs809058	chr2:27616790	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.17e-14	Total body bone mineral density;
LGG	trans	rs970548	0.779	rs11239532	chr10:45964505	C/T	cg20477318	chr10:51623047	TIMM23	0.6	7.19	0.32	2.58e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs62064224	0.675	rs12150479	chr17:30636200	T/A	cg18200150	chr17:30822561	MYO1D	0.5	9.62	0.41	4.43e-20	Schizophrenia;
LGG	cis	rs11864453	0.793	rs7197869	chr16:72079352	G/C	cg01557791	chr16:72042693	DHODH	-0.62	-11.2	-0.46	6.51e-26	Fibrinogen levels;
LGG	cis	rs12893668	0.703	rs55751606	chr14:104028806	G/A	cg23335576	chr14:104009727	NA	0.51	8.89	0.38	1.37e-17	Reticulocyte count;
LGG	cis	rs2901656	0.677	rs10752957	chr1:172408271	A/G	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.81	0.3	3.01e-11	Red cell distribution width;Platelet distribution width;
LGG	cis	rs7020830	0.825	rs7036132	chr9:37317241	A/G	cg14294708	chr9:37120828	ZCCHC7	1.19	33.61	0.84	2.64e-126	Schizophrenia;
LGG	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.97	-0.45	4.65e-25	Height;
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	11.22	0.46	5.13e-26	Total body bone mineral density;
LGG	cis	rs72827839	0.894	rs41336845	chr17:46215110	A/G	cg02219949	chr17:45927392	SP6	-0.54	-8.25	-0.36	1.64e-15	Ease of getting up in the morning;
LGG	cis	rs701145	0.730	rs2666192	chr3:154004009	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.37	0.5	1.49e-30	Coronary artery disease;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg15948088	chr11:109293068	C11orf87	0.62	10.65	0.44	7.47e-24	Schizophrenia;
LGG	cis	rs28374715	0.528	rs7178360	chr15:41631175	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.33	-33.66	-0.84	1.68e-126	Ulcerative colitis;
LGG	cis	rs9467711	0.651	rs16891264	chr6:26072445	C/T	cg21479132	chr6:26055353	NA	-0.74	-6.76	-0.3	4.04e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12210905	0.925	rs7740207	chr6:27001623	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.53	-0.33	2.74e-13	Hip circumference adjusted for BMI;
LGG	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.77	-0.41	1.27e-20	Lung cancer;
LGG	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg24692254	chr21:30365293	RNF160	0.7	12.71	0.51	5.63e-32	Cognitive test performance;
LGG	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg12438819	chr7:158236134	PTPRN2	0.33	8.57	0.37	1.61e-16	Obesity-related traits;
LGG	cis	rs757278	0.564	rs35454880	chr7:117366592	A/G	cg10524701	chr7:117356490	CTTNBP2	0.45	7.66	0.34	1.12e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.85	-0.34	2.94e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4430311	0.723	rs2220276	chr1:243717592	A/T	cg25706552	chr1:244017396	NA	-0.63	-15.17	-0.58	1.69e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10463554	0.892	rs59292735	chr5:102382751	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.51	-0.33	3.12e-13	Parkinson's disease;
LGG	cis	rs57221529	0.709	rs111352378	chr5:577079	G/A	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs4478858	0.684	rs3766289	chr1:31760128	G/A	cg19084893	chr1:31688959	NA	0.32	6.88	0.3	2e-11	Alcohol dependence;
LGG	cis	rs12477438	0.520	rs13018891	chr2:99755099	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs9560113	0.959	rs4773385	chr13:112178452	C/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	cis	rs7737355	0.947	rs32110	chr5:131045835	T/C	cg06307176	chr5:131281290	NA	0.57	9.18	0.39	1.43e-18	Life satisfaction;
LGG	cis	rs17030434	0.784	rs6835960	chr4:154650460	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.57	-0.41	6.64e-20	Electrocardiographic conduction measures;
LGG	cis	rs7529073	0.740	rs340883	chr1:214145706	A/G	cg24083324	chr1:214162604	PROX1	-0.5	-8.88	-0.38	1.53e-17	Schizophrenia;
LGG	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	trans	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg22358067	chr17:16797159	NA	-0.5	-6.89	-0.3	1.83e-11	Body mass index;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg18760916	chr13:48611517	NUDT15	0.74	7.21	0.32	2.27e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs4731207	0.564	rs6466972	chr7:124596249	T/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2836974	0.897	rs2836924	chr21:40525639	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	2e-53	Cognitive function;
LGG	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg11764359	chr7:65958608	NA	0.71	12.92	0.51	7.77e-33	Aortic root size;
LGG	cis	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg24375607	chr4:120327624	NA	0.64	10.6	0.44	1.17e-23	Corneal astigmatism;
LGG	cis	rs62025270	0.806	rs62025262	chr15:86293233	G/A	cg25843651	chr15:86329602	KLHL25	0.61	9.91	0.42	4.14e-21	Idiopathic pulmonary fibrosis;
LGG	cis	rs4742903	0.791	rs6479226	chr9:106972872	T/G	cg14250997	chr9:106856677	SMC2	0.39	8.19	0.36	2.52e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.52	0.4	9.33e-20	Blood metabolite levels;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs7589342	0.839	rs6747023	chr2:106431856	A/G	cg16077055	chr2:106428750	NCK2	0.32	8.35	0.36	7.91e-16	Addiction;
LGG	cis	rs17453880	0.890	rs60862272	chr5:152009347	A/G	cg10931792	chr5:152022470	NA	0.37	8.02	0.35	8.78e-15	Subjective well-being;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg04234412	chr22:24373322	LOC391322	-0.77	-15.68	-0.59	9.42e-45	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2236267	0.726	rs2208547	chr14:88604515	C/T	cg18078958	chr14:88630771	NA	-0.3	-7.09	-0.31	5.13e-12	Food antigen IgG levels;
LGG	cis	rs12478296	0.685	rs35577962	chr2:242993575	A/G	cg18898632	chr2:242989856	NA	-0.76	-8.9	-0.38	1.28e-17	Obesity-related traits;
LGG	cis	rs372883	0.600	rs2832295	chr21:30739843	C/T	cg08807101	chr21:30365312	RNF160	0.61	10.21	0.43	3.18e-22	Pancreatic cancer;
LGG	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg03606772	chr1:152487856	CRCT1	0.29	6.7	0.3	6.13e-11	Hair morphology;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg22105103	chr4:187893119	NA	0.57	10.9	0.45	8.75e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2070677	0.736	rs4529856	chr10:135414020	C/G	cg20169779	chr10:135381914	SYCE1	-1.0	-10.68	-0.44	5.91e-24	Gout;
LGG	cis	rs7904985	1.000	rs11201991	chr10:88117122	T/C	cg07322936	chr10:88137208	NA	-0.48	-7.19	-0.32	2.7e-12	Barrett's esophagus;
LGG	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.45	-7.0	-0.31	9.32e-12	Tuberculosis;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.77	-0.3	3.92e-11	Lung cancer;
LGG	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg11494091	chr17:61959527	GH2	0.49	7.35	0.32	9.14e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1945213	0.694	rs7122627	chr11:55862565	A/G	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg12828819	chr4:126236816	FAT4	0.6	6.93	0.31	1.37e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6693567	0.545	rs1260385	chr1:150316385	G/A	cg15654264	chr1:150340011	RPRD2	0.33	6.74	0.3	4.75e-11	Migraine;
LGG	cis	rs2479724	0.811	rs6905726	chr6:41750812	T/C	cg17623882	chr6:41773611	USP49	0.49	8.43	0.36	4.47e-16	Menarche (age at onset);
LGG	cis	rs9549367	0.756	rs2302756	chr13:113900197	G/A	cg00898013	chr13:113819073	PROZ	0.43	8.56	0.37	1.64e-16	Platelet distribution width;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg20110707	chr11:118481992	PHLDB1	0.49	10.33	0.43	1.18e-22	Cholesterol, total;
LGG	cis	rs1983891	0.673	rs9369296	chr6:41570251	A/G	cg20194872	chr6:41519635	FOXP4	0.48	8.32	0.36	9.89e-16	Prostate cancer;
LGG	cis	rs10791323	0.604	rs2851116	chr11:133705759	G/A	cg15485101	chr11:133734466	NA	0.59	10.43	0.44	5.19e-23	Childhood ear infection;
LGG	trans	rs9467711	0.606	rs34104395	chr6:26478252	C/T	cg06606381	chr12:133084897	FBRSL1	-1.05	-10.19	-0.43	3.79e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg01765077	chr12:122356316	WDR66	0.27	7.49	0.33	3.58e-13	Mean corpuscular volume;
LGG	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg14019146	chr3:50243930	SLC38A3	0.32	6.76	0.3	4.15e-11	Body mass index;
LGG	cis	rs9557207	0.853	rs11620194	chr13:99918466	C/T	cg24509225	chr13:100037070	UBAC2	0.68	12.14	0.49	1.26e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04160501	chr7:4723667	FOXK1	0.39	6.75	0.3	4.54e-11	Gut microbiome composition (summer);
LGG	cis	rs4363385	0.818	rs10788852	chr1:153000491	C/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.54	-0.37	1.99e-16	Inflammatory skin disease;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg11584989	chr19:19387371	SF4	0.39	7.12	0.31	4.06e-12	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02775028	chr4:184580387	C4orf41;RWDD4A	0.49	7.95	0.35	1.47e-14	Cognitive performance;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg18032289	chr17:61959525	GH2	-0.41	-7.06	-0.31	5.97e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg06873352	chr17:61820015	STRADA	0.73	13.38	0.53	9.84e-35	Prudent dietary pattern;
LGG	cis	rs10799590	1.000	rs10799590	chr1:224822482	C/T	cg01808320	chr1:224927238	CNIH3	-0.37	-6.79	-0.3	3.45e-11	Opioid dependence;
LGG	cis	rs977987	0.806	rs4888390	chr16:75400320	G/A	cg03315344	chr16:75512273	CHST6	0.52	10.45	0.44	4.26e-23	Dupuytren's disease;
LGG	cis	rs7937612	0.897	rs11217821	chr11:120202099	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.51	-11.94	-0.49	7.95e-29	Intraocular pressure;
LGG	trans	rs13090388	1	rs13090388	chr3:49391082	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.11	-0.35	4.45e-15	Intelligence (multi-trait analysis);Educational attainment (years of education);
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.46	-0.53	4.49e-35	Personality dimensions;
LGG	cis	rs11785400	0.793	rs1137521	chr8:143739162	C/T	cg24634471	chr8:143751801	JRK	0.5	7.72	0.34	7.48e-14	Schizophrenia;
LGG	trans	rs2727020	0.523	rs4115783	chr11:49556026	G/A	cg15704280	chr7:45808275	SEPT13	0.86	13.78	0.54	1.96e-36	Coronary artery disease;
LGG	cis	rs977987	0.581	rs8056141	chr16:75497162	A/T	cg03315344	chr16:75512273	CHST6	0.57	11.22	0.46	5.14e-26	Dupuytren's disease;
LGG	trans	rs61931739	0.817	rs11053071	chr12:34201400	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.5	0.37	2.6e-16	Morning vs. evening chronotype;
LGG	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg01152986	chr16:58549298	SETD6	0.84	7.37	0.32	7.71e-13	Schizophrenia;
LGG	cis	rs9467773	0.869	rs1796520	chr6:26410800	C/T	cg09904177	chr6:26538194	HMGN4	-0.63	-12.55	-0.5	2.63e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	2.01e-18	Colorectal cancer;
LGG	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.12e-41	Aortic root size;
LGG	cis	rs4006360	0.628	rs439075	chr17:39239467	A/C	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.51	-0.47	3.96e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg24558204	chr6:135376177	HBS1L	-0.62	-10.96	-0.45	5.1e-25	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg15971980	chr6:150254442	NA	0.43	7.44	0.33	5.02e-13	Lung cancer;
LGG	cis	rs7811142	0.830	rs11761426	chr7:99956893	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	2.03e-57	Platelet count;
LGG	cis	rs2439831	1.000	rs2467736	chr15:43784917	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs4604732	0.631	rs10802509	chr1:247627158	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg21211680	chr2:198530	NA	1.18	20.53	0.69	4.64e-67	Blood protein levels;
LGG	cis	rs35110281	0.633	rs4818860	chr21:45119617	C/T	cg04455712	chr21:45112962	RRP1B	0.55	10.59	0.44	1.31e-23	Mean corpuscular volume;
LGG	cis	rs950169	0.922	rs4842939	chr15:84827966	C/T	cg24253500	chr15:84953950	NA	-0.47	-9.12	-0.39	2.31e-18	Schizophrenia;
LGG	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg21926883	chr2:100939477	LONRF2	-0.68	-15.47	-0.58	8.21e-44	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.77	-14.49	-0.56	1.75e-39	Longevity;Endometriosis;
LGG	cis	rs4555082	1.000	rs7146643	chr14:105757392	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-17.01	-0.62	9.58e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4716602	0.596	rs10265909	chr7:156158095	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.5	-0.4	1.12e-19	Anti-saccade response;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg02071572	chr4:1403502	NA	0.41	7.02	0.31	7.82e-12	Longevity;
LGG	cis	rs780094	0.585	rs7586601	chr2:27584666	A/G	cg27432699	chr2:27873401	GPN1	-0.42	-7.04	-0.31	6.96e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs17401966	0.931	rs17410217	chr1:10371854	A/G	cg15208524	chr1:10270712	KIF1B	0.44	7.37	0.32	7.78e-13	Hepatocellular carcinoma;
LGG	cis	rs4330281	0.608	rs7645756	chr3:17397336	T/C	cg20981856	chr3:17787350	NA	0.36	6.82	0.3	2.87e-11	Schizophrenia;
LGG	cis	rs1023500	0.573	rs133381	chr22:42470608	C/G	cg15557168	chr22:42548783	NA	-0.41	-8.75	-0.38	4.11e-17	Schizophrenia;
LGG	cis	rs151997	0.962	rs28090	chr5:50177509	T/C	cg06027927	chr5:50259733	NA	0.67	11.11	0.46	1.37e-25	Callous-unemotional behaviour;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.89	0.38	1.35e-17	Lung cancer;
LGG	trans	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg08975724	chr8:8085496	FLJ10661	0.46	8.5	0.37	2.6e-16	Neuroticism;
LGG	cis	rs7666738	0.753	rs34164013	chr4:98976333	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.964	rs778735	chr7:65814809	C/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.51	-0.37	2.41e-16	Aortic root size;
LGG	cis	rs2905347	0.965	rs2961272	chr7:22624736	C/G	cg18045685	chr7:22629474	NA	-0.8	-17.64	-0.63	1.2e-53	Major depression and alcohol dependence;
LGG	cis	rs8018808	0.935	rs11159261	chr14:77921120	A/G	cg20045696	chr14:77926864	AHSA1	0.41	6.72	0.3	5.49e-11	Myeloid white cell count;
LGG	cis	rs412000	0.507	rs2680688	chr17:56450524	T/C	cg25039879	chr17:56429692	SUPT4H1	-0.44	-6.8	-0.3	3.2e-11	Primary tooth development (time to first tooth eruption);
LGG	cis	rs9463078	0.764	rs1576382	chr6:44957553	G/A	cg25276700	chr6:44698697	NA	-0.4	-8.45	-0.37	3.71e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25883402	chr1:173837173	SNORD76;SNORD74;SNORD75;GAS5;ZBTB37	0.47	6.92	0.31	1.51e-11	Gut microbiome composition (summer);
LGG	cis	rs2172802	0.924	rs12715703	chr4:62432010	C/T	cg04118610	chr4:62707027	LPHN3	-0.44	-6.84	-0.3	2.58e-11	Partial epilepsies;
LGG	cis	rs10267417	0.603	rs10241914	chr7:19932429	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs10895140	0.756	rs7107512	chr11:101507383	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg05863683	chr7:1912471	MAD1L1	0.44	8.63	0.37	9.82e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9513627	0.915	rs73556173	chr13:100121766	C/T	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg11266682	chr4:10021025	SLC2A9	0.47	9.07	0.39	3.4e-18	Bone mineral density;
LGG	trans	rs7824557	0.614	rs4394351	chr8:11212875	G/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.67	0.34	1.01e-13	Retinal vascular caliber;
LGG	cis	rs4144743	0.528	rs12940207	chr17:45352194	G/T	cg18085866	chr17:45331354	ITGB3	-0.78	-7.99	-0.35	1.08e-14	Body mass index;
LGG	cis	rs4700695	0.719	rs27082	chr5:65436152	A/C	cg21114390	chr5:65439923	SFRS12	-0.69	-9.86	-0.42	5.95e-21	Facial morphology (factor 19);
LGG	cis	rs300703	0.748	rs4484059	chr2:286812	G/A	cg21211680	chr2:198530	NA	1.28	15.9	0.59	1e-45	Blood protein levels;
LGG	cis	rs6120849	0.615	rs11167248	chr20:33538721	G/T	cg24642439	chr20:33292090	TP53INP2	0.55	6.88	0.3	1.95e-11	Protein C levels;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg04503457	chr17:41445688	NA	-0.4	-9.75	-0.41	1.48e-20	Menopause (age at onset);
LGG	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs7572733	0.576	rs4850441	chr2:198913413	A/G	cg00792783	chr2:198669748	PLCL1	-0.61	-9.43	-0.4	2e-19	Dermatomyositis;
LGG	cis	rs1348850	0.645	rs7571386	chr2:178442687	A/C	cg22681709	chr2:178499509	PDE11A	-0.45	-7.09	-0.31	5.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.81	-0.34	3.84e-14	Life satisfaction;
LGG	cis	rs950027	0.620	rs1145093	chr15:45649813	C/A	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.33e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3820068	0.581	rs59991988	chr1:15950552	T/A	cg05660106	chr1:15850417	CASP9	0.84	17.07	0.62	4.82e-51	Systolic blood pressure;
LGG	cis	rs35883536	0.967	rs1582091	chr1:101177133	G/T	cg06223162	chr1:101003688	GPR88	0.28	6.72	0.3	5.48e-11	Monocyte count;
LGG	cis	rs6784615	1.000	rs13060192	chr3:52378540	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.63	-7.59	-0.33	1.76e-13	Waist-hip ratio;
LGG	cis	rs2404602	0.692	rs72738889	chr15:76992063	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.92e-12	Blood metabolite levels;
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg22398616	chr13:53314203	LECT1	-0.46	-9.72	-0.41	1.96e-20	Lewy body disease;
LGG	cis	rs1461503	0.534	rs7123283	chr11:122809055	C/T	cg27398637	chr11:122830231	C11orf63	-0.64	-12.42	-0.5	8.66e-31	Menarche (age at onset);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14163061	chr2:44223239	LRPPRC	-0.36	-6.75	-0.3	4.46e-11	Brain structure;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.63	0.37	9.59e-17	Lung cancer;
LGG	cis	rs4330281	0.608	rs6577617	chr3:17715644	G/T	cg20981856	chr3:17787350	NA	-0.4	-7.47	-0.33	4e-13	Schizophrenia;
LGG	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg27661571	chr11:113659931	NA	-0.56	-8.24	-0.36	1.85e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6547741	0.874	rs28381983	chr2:27804432	T/C	cg27432699	chr2:27873401	GPN1	0.68	13.8	0.54	1.64e-36	Oral cavity cancer;
LGG	cis	rs10504229	0.906	rs113745779	chr8:58191301	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs4821025	chr22:32416892	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.54e-19	Childhood ear infection;
LGG	cis	rs9486719	1.000	rs12210146	chr6:96903962	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.61	0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs7577696	0.512	rs12478134	chr2:32240783	C/G	cg02381751	chr2:32503542	YIPF4	-0.49	-6.86	-0.3	2.21e-11	Inflammatory biomarkers;
LGG	cis	rs17818399	0.926	rs35350086	chr2:46834036	C/G	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.95	0.31	1.25e-11	Height;
LGG	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg08344181	chr3:125677491	NA	-0.79	-7.06	-0.31	6.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9309473	1.000	rs6546836	chr2:73677833	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.51	-0.33	3.04e-13	Metabolite levels;
LGG	cis	rs11758351	0.500	rs4593350	chr6:26184800	T/C	cg03181300	chr6:26195995	NA	0.88	6.68	0.3	6.88e-11	Gout;Renal underexcretion gout;
LGG	cis	rs5742933	0.750	rs10197331	chr2:190632838	A/C	cg04003228	chr2:190539410	ANKAR	-0.51	-7.46	-0.33	4.26e-13	Ferritin levels;
LGG	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs8049040	0.586	rs16972663	chr16:71460564	C/T	cg08717414	chr16:71523259	ZNF19	-0.49	-7.39	-0.32	6.86e-13	Blood protein levels;
LGG	cis	rs12980942	0.872	rs12327659	chr19:41796472	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.51	7.12	0.31	4.26e-12	Coronary artery disease;
LGG	cis	rs2735413	0.507	rs11647817	chr16:78036967	A/G	cg04733911	chr16:78082701	NA	0.5	6.65	0.3	8.22e-11	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs11800820	0.536	rs10802409	chr1:246632031	C/T	cg16700716	chr1:246684329	NA	0.43	7.72	0.34	7.32e-14	Obesity-related traits;
LGG	cis	rs12681288	0.823	rs12681230	chr8:994422	G/A	cg04851639	chr8:1020857	NA	-0.45	-9.64	-0.41	3.68e-20	Schizophrenia;
LGG	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg03060546	chr3:49711283	APEH	-0.62	-10.31	-0.43	1.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg05025164	chr4:1340916	KIAA1530	0.46	7.54	0.33	2.52e-13	Obesity-related traits;
LGG	cis	rs1348850	0.519	rs13034781	chr2:178523550	C/A	cg22681709	chr2:178499509	PDE11A	-0.45	-8.11	-0.35	4.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg03036210	chr16:89904091	SPIRE2	-0.68	-8.09	-0.35	5.48e-15	Skin colour saturation;
LGG	cis	rs4748857	0.836	rs4748854	chr10:23598880	C/T	cg18853376	chr10:23633759	C10orf67	0.37	7.06	0.31	5.95e-12	Systemic lupus erythematosus;
LGG	cis	rs9487051	0.700	rs7773815	chr6:109602343	A/C	cg21918786	chr6:109611834	NA	-0.49	-9.06	-0.39	3.73e-18	Reticulocyte fraction of red cells;
LGG	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.39	6.97	0.31	1.07e-11	Homoarginine levels;
LGG	cis	rs57221529	0.713	rs12522724	chr5:590742	T/C	cg07777115	chr5:623756	CEP72	-0.57	-7.29	-0.32	1.31e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11626933	1.000	rs11626016	chr14:90747979	C/T	cg14092571	chr14:90743983	NA	-0.81	-16.57	-0.61	9.38e-49	Gut microbiota (bacterial taxa);
LGG	cis	rs1790761	0.554	rs3758938	chr11:67402362	T/G	cg23188684	chr11:67383651	NA	-0.52	-7.89	-0.34	2.2e-14	Mean corpuscular volume;
LGG	trans	rs2048656	0.569	rs35300296	chr8:9653697	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-6.67	-0.3	7.48e-11	Schizophrenia;
LGG	cis	rs4925386	0.759	rs2427293	chr20:60925859	A/G	cg22307297	chr20:60903441	LAMA5	-0.43	-8.36	-0.36	7.22e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs2018683	0.523	rs1499224	chr7:29029468	T/G	cg19402173	chr7:128379420	CALU	-0.53	-8.55	-0.37	1.77e-16	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg04207632	chr4:6986609	TBC1D14	-0.42	-7.93	-0.35	1.69e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.26	0.4	7.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs6787172	0.806	rs1435641	chr3:158275921	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.23	-0.32	2.06e-12	Subjective well-being;
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-8.75	-0.38	4.07e-17	Vitiligo;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs4734806	1.000	rs4734805	chr8:105700583	A/G	cg01675814	chr8:105601641	LRP12	0.55	7.45	0.33	4.69e-13	Periodontitis (DPAL);
LGG	cis	rs1697139	0.710	rs6866416	chr5:66517476	A/G	cg11553311	chr5:66541588	NA	0.53	11.29	0.46	2.87e-26	Breast cancer;
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.1	0.42	8.34e-22	Height;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg22535103	chr8:58192502	C8orf71	-0.76	-10.4	-0.44	6.75e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12493885	0.654	rs11925207	chr3:153699886	C/T	cg17054900	chr3:154042577	DHX36	-0.73	-8.46	-0.37	3.42e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	17.61	0.63	1.63e-53	Smoking behavior;
LGG	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.12	-0.31	4.14e-12	Joint mobility (Beighton score);
LGG	cis	rs7582180	0.627	rs4149517	chr2:101014247	C/A	cg21926883	chr2:100939477	LONRF2	-0.68	-16.4	-0.61	5.56e-48	Intelligence (multi-trait analysis);
LGG	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg17788362	chr6:86352627	SYNCRIP	0.55	9.72	0.41	1.94e-20	Smooth-surface caries;
LGG	cis	rs80282103	0.764	rs10047382	chr10:1102868	T/C	cg08668510	chr10:1095578	IDI1	0.75	7.67	0.34	9.93e-14	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07631383	chr7:131012765	MKLN1	0.6	9.61	0.41	4.52e-20	Gut microbiome composition (summer);
LGG	cis	rs16986825	0.546	rs9625612	chr22:29258140	T/A	cg02153584	chr22:29168773	CCDC117	0.57	6.66	0.3	7.6e-11	Pancreatic cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22100476	chr1:43638037	WDR65;EBNA1BP2	0.43	7.27	0.32	1.53e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28595532	0.920	rs115154776	chr4:119774803	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs2013441	0.613	rs11204422	chr17:19996429	A/T	cg13482628	chr17:19912719	NA	-0.51	-9.44	-0.4	1.77e-19	Obesity-related traits;
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg10935494	chr17:80760059	TBCD	-0.39	-6.66	-0.3	7.9e-11	Glycated hemoglobin levels;
LGG	cis	rs7666738	0.830	rs10010223	chr4:99021758	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7737355	0.812	rs11242070	chr5:130626621	A/G	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs9287719	0.839	rs11683335	chr2:10756665	C/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.27	0.32	1.55e-12	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	cis	rs9788682	0.694	rs3825845	chr15:78910258	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-7.87	-0.34	2.6e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs3857067	1.000	rs1397026	chr4:95013729	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.729	rs203320	chr22:41913477	T/C	cg03806693	chr22:41940476	POLR3H	-0.94	-16.41	-0.61	4.83e-48	Vitiligo;
LGG	cis	rs7927771	0.770	rs11039203	chr11:47384597	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-10.21	-0.43	3.29e-22	Subjective well-being;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg17834180	chr10:124768240	IKZF5;ACADSB	0.42	6.98	0.31	1.04e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7084402	0.967	rs1658438	chr10:60326583	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.22	0.32	2.13e-12	Refractive error;
LGG	trans	rs853679	0.607	rs17763089	chr6:27835218	G/A	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	cis	rs2916247	0.954	rs7845971	chr8:93022095	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.62	-0.37	1.05e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.693	rs12372025	chr12:38202028	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.91	0.54	5.18e-37	Bladder cancer;
LGG	cis	rs1816752	0.837	rs4769355	chr13:25015197	G/A	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs6582630	0.502	rs11495393	chr12:38341194	T/C	cg26384229	chr12:38710491	ALG10B	0.91	19.93	0.68	2.85e-64	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg01620082	chr3:125678407	NA	-0.87	-8.64	-0.37	9.04e-17	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs9470366	0.772	rs9918353	chr6:36622677	A/C	cg08179530	chr6:36648295	CDKN1A	0.61	8.81	0.38	2.53e-17	QRS duration;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.65	-0.34	1.14e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs972578	0.728	rs2284092	chr22:43325269	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.73	-0.3	4.89e-11	Mean platelet volume;
LGG	trans	rs7939886	0.920	rs1842675	chr11:56080824	G/C	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg06232512	chr2:240612347	NA	0.42	7.89	0.34	2.26e-14	Electrocardiographic conduction measures;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg22907277	chr7:1156413	C7orf50	0.69	12.97	0.52	4.71e-33	Longevity;Endometriosis;
LGG	cis	rs17208368	0.628	rs61446595	chr16:55093788	A/C	cg11181171	chr16:55090946	NA	0.46	7.66	0.34	1.09e-13	Hypospadias;
LGG	cis	rs701145	0.585	rs357466	chr3:153902868	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.55	0.37	1.77e-16	Coronary artery disease;
LGG	cis	rs367615	0.552	rs2115511	chr5:108725403	A/T	cg17395555	chr5:108820864	NA	-0.71	-11.58	-0.47	2.01e-27	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs636291	0.517	rs12565133	chr1:10544988	A/C	cg25013184	chr1:10487953	NA	0.43	9.63	0.41	4.05e-20	Prostate cancer;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg09699651	chr6:150184138	LRP11	0.54	9.36	0.4	3.35e-19	Lung cancer;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.79	0.3	3.48e-11	Schizophrenia;
LGG	cis	rs67311347	1.000	rs6599102	chr3:40468406	G/A	cg13683864	chr3:40499215	RPL14	-0.98	-20.43	-0.69	1.39e-66	Renal cell carcinoma;
LGG	cis	rs2072732	0.861	rs72629493	chr1:2951347	G/A	cg22517653	chr1:2918612	NA	-0.44	-6.99	-0.31	9.87e-12	Plateletcrit;
LGG	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg14088196	chr11:70211408	PPFIA1	0.81	10.87	0.45	1.14e-24	Coronary artery disease;
LGG	cis	rs3204270	0.639	rs7216239	chr17:79660187	C/T	cg18367735	chr17:79674897	NA	0.58	7.53	0.33	2.63e-13	Dental caries;
LGG	cis	rs504918	0.561	rs11712039	chr3:123973586	C/T	cg05766129	chr3:123988013	KALRN	-0.6	-10.65	-0.44	7.71e-24	Schizophrenia;
LGG	cis	rs36051895	0.623	rs1830610	chr9:5260079	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-12.99	-0.52	4.07e-33	Pediatric autoimmune diseases;
LGG	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg21972741	chr5:435613	AHRR	0.5	9.06	0.39	3.56e-18	Cystic fibrosis severity;
LGG	cis	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg25427524	chr10:38739819	LOC399744	-0.66	-12.22	-0.49	5.69e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs12476592	0.602	rs262487	chr2:63880517	G/T	cg17519650	chr2:63277830	OTX1	0.44	6.88	0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs4262150	0.660	rs72806703	chr5:152333304	A/T	cg12297329	chr5:152029980	NA	-0.69	-11.53	-0.47	3.14e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs7613875	0.620	rs34312088	chr3:50032133	C/T	cg21659725	chr3:3221576	CRBN	0.55	9.51	0.4	1.06e-19	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03712816	chr18:76741157	SALL3	0.41	6.96	0.31	1.14e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.6	-0.37	1.25e-16	Life satisfaction;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg06656553	chr16:89960601	TCF25	-0.71	-6.97	-0.31	1.07e-11	Skin colour saturation;
LGG	cis	rs738322	0.967	rs4383	chr22:38570927	C/G	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs11722228	0.549	rs73212828	chr4:10078756	C/T	cg25986240	chr4:9926439	SLC2A9	-0.56	-10.58	-0.44	1.4e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg06494592	chr3:125709126	NA	-0.55	-7.03	-0.31	7.53e-12	Blood pressure (smoking interaction);
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg13047869	chr3:10149882	C3orf24	0.46	7.48	0.33	3.74e-13	Alzheimer's disease;
LGG	cis	rs651907	0.535	rs2290859	chr3:101525625	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.13	0.35	3.9e-15	Colorectal cancer;
LGG	cis	rs72925845	0.519	rs72907438	chr17:76425973	G/A	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg14728415	chr7:32535168	LSM5;AVL9	-0.42	-6.69	-0.3	6.5e-11	Cognitive ability;
LGG	cis	rs9596837	0.514	rs9568884	chr13:54265629	T/C	ch.13.53330881F	chr13:54432880	NA	0.42	6.69	0.3	6.49e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9515201	1.000	rs9515201	chr13:111040798	A/C	cg06243866	chr13:111019493	COL4A2	0.42	7.1	0.31	4.64e-12	White matter hyperintensity burden;
LGG	cis	rs7179456	0.545	rs605928	chr15:59046163	C/G	cg05156742	chr15:59063176	FAM63B	0.6	9.89	0.42	4.78e-21	Asperger disorder;
LGG	cis	rs10864302	0.525	rs11579620	chr1:7432615	A/G	cg08923594	chr1:7462176	CAMTA1	-0.59	-8.05	-0.35	6.9e-15	Photic sneeze reflex;
LGG	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg27286337	chr10:134555280	INPP5A	-0.79	-12.19	-0.49	7.83e-30	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7241530	0.636	rs72985797	chr18:75904096	C/T	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg25187227	chr4:40058080	N4BP2;LOC344967	0.42	6.92	0.31	1.54e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1707322	0.964	rs6697830	chr1:46290477	C/A	cg03146154	chr1:46216737	IPP	0.55	10.54	0.44	1.94e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs8060686	0.565	rs75735284	chr16:68126635	C/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.18e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs35740288	0.770	rs11638278	chr15:86211404	C/T	cg04173714	chr15:86211321	AKAP13	0.48	8.65	0.37	8.81e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs66716358	0.710	rs12793949	chr11:44317265	C/T	cg16977035	chr11:44330474	ALX4	0.36	9.15	0.39	1.86e-18	Monobrow;
LGG	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg14979609	chr8:8086686	FLJ10661	-0.36	-9.53	-0.4	8.94e-20	Mood instability;
LGG	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs1552244	0.554	rs3774207	chr3:9985656	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	13.04	0.52	2.48e-33	Alzheimer's disease;
LGG	cis	rs62238980	0.614	rs5998272	chr22:32560045	A/C	cg00543991	chr22:32367038	NA	0.7	7.89	0.34	2.28e-14	Childhood ear infection;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs1949733	0.628	rs2688231	chr4:8490981	G/A	cg13073564	chr4:8508604	NA	-0.54	-11.2	-0.46	6.34e-26	Response to antineoplastic agents;
LGG	cis	rs4330281	0.647	rs4513482	chr3:17708780	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg19223190	chr17:80058835	NA	-0.46	-8.96	-0.38	7.72e-18	Life satisfaction;
LGG	cis	rs4950322	0.570	rs945742	chr1:146785157	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg16583315	chr14:65563665	MAX	-0.41	-8.36	-0.36	7.28e-16	Obesity-related traits;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.63	-0.37	9.57e-17	Obesity-related traits;
LGG	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg02175503	chr12:58329896	NA	0.5	8.11	0.35	4.65e-15	Multiple sclerosis;
LGG	cis	rs1908814	0.503	rs34657250	chr8:11795373	A/G	cg00405596	chr8:11794950	NA	-0.63	-11.35	-0.47	1.68e-26	Neuroticism;
LGG	cis	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.36	0.36	7.66e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6121246	0.559	rs6087771	chr20:30306724	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs7831492	0.564	rs11787479	chr8:41613496	A/G	cg17182837	chr8:41585554	ANK1	-0.56	-10.1	-0.42	8.11e-22	Colorectal cancer;
LGG	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg17885191	chr8:135476712	NA	0.44	6.99	0.31	9.83e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs9863	0.861	rs11057399	chr12:124425078	A/G	cg13487667	chr12:124434373	CCDC92	-0.37	-7.41	-0.33	5.96e-13	White blood cell count;
LGG	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg23166289	chr1:210001082	C1orf107	0.32	6.76	0.3	4.07e-11	Orofacial clefts;
LGG	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.84	-0.38	1.99e-17	Bone mineral density;
LGG	cis	rs8064029	1.000	rs72633273	chr16:4907616	G/T	cg04440724	chr16:4920505	UBN1	-0.61	-7.42	-0.33	5.81e-13	Cancer;
LGG	cis	rs28530618	0.580	rs11167174	chr20:31248879	G/A	cg13636640	chr20:31349939	DNMT3B	-0.45	-7.09	-0.31	5.2e-12	Birth weight;
LGG	cis	rs701145	0.585	rs6769099	chr3:153852442	T/C	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs12586317	0.553	rs3809448	chr14:35515096	C/T	cg05294307	chr14:35346193	BAZ1A	-0.57	-7.73	-0.34	6.69e-14	Psoriasis;
LGG	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.69	0.48	7.46e-28	IgG glycosylation;
LGG	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg01448562	chr3:133502909	NA	-0.73	-13.58	-0.53	1.33e-35	Iron status biomarkers;
LGG	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.11	0.39	2.44e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg17470184	chr11:118478236	PHLDB1	-0.42	-7.26	-0.32	1.68e-12	Cholesterol, total;
LGG	cis	rs2295359	0.892	rs17375018	chr1:67655147	A/G	cg12940439	chr1:67600707	NA	-0.47	-9.25	-0.39	8.33e-19	Psoriasis;
LGG	cis	rs734999	0.545	rs4074789	chr1:2537464	A/G	cg20673091	chr1:2541236	MMEL1	0.79	19.4	0.67	8.87e-62	Ulcerative colitis;
LGG	cis	rs933688	0.938	rs7720235	chr5:90659329	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	19.33	0.67	1.72e-61	Smoking behavior;
LGG	cis	rs11096990	0.855	rs4974986	chr4:39166928	A/G	cg24403649	chr4:39172243	NA	-0.5	-8.09	-0.35	5.38e-15	Cognitive function;
LGG	cis	rs10193935	0.901	rs13022188	chr2:42704423	A/C	cg27598129	chr2:42591480	NA	0.67	9.79	0.41	1.12e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg04568710	chr12:38710424	ALG10B	-0.41	-9.1	-0.39	2.66e-18	Bladder cancer;
LGG	cis	rs13191362	1.000	rs67042566	chr6:163006541	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.1	0.35	4.79e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9303401	0.580	rs2013166	chr17:56637630	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.94	0.57	1.79e-41	Cognitive test performance;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.47	-0.53	4.15e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg08975724	chr8:8085496	FLJ10661	0.36	6.71	0.3	5.8e-11	Systolic blood pressure;
LGG	trans	rs7944735	0.567	rs76477746	chr11:48103368	G/C	cg15704280	chr7:45808275	SEPT13	0.73	7.12	0.31	4.18e-12	Intraocular pressure;
LGG	cis	rs9534288	0.664	rs1926447	chr13:46629944	C/T	cg15192986	chr13:46630673	CPB2	0.65	13.56	0.53	1.68e-35	Blood protein levels;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.06	-0.42	1.12e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg21171335	chr12:122356390	WDR66	0.29	8.0	0.35	9.98e-15	Mean corpuscular volume;
LGG	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg08648136	chr8:956695	NA	0.46	10.02	0.42	1.56e-21	Schizophrenia;
LGG	cis	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg05623727	chr3:50126028	RBM5	-0.39	-8.61	-0.37	1.15e-16	Body mass index;
LGG	cis	rs11122272	0.735	rs910822	chr1:231498721	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-11.37	-0.47	1.39e-26	Hemoglobin concentration;
LGG	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg13902645	chr11:5959945	NA	-0.68	-10.87	-0.45	1.16e-24	DNA methylation (variation);
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg21963583	chr11:68658836	MRPL21	0.61	10.22	0.43	3.13e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9354308	0.868	rs9453438	chr6:66540534	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.85	-0.34	2.86e-14	Metabolite levels;
LGG	cis	rs9900972	1.000	rs9900972	chr17:76868614	A/G	cg00961940	chr17:76876995	TIMP2	0.46	8.49	0.37	2.75e-16	Obesity-related traits;
LGG	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg15268244	chr15:77196840	NA	0.47	9.92	0.42	3.68e-21	Blood metabolite levels;
LGG	cis	rs6700896	0.522	rs4655778	chr1:66142336	G/A	cg04111102	chr1:66153794	NA	0.33	6.86	0.3	2.15e-11	C-reactive protein;Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg00290607	chr11:67383545	NA	0.66	12.79	0.51	2.78e-32	Mean corpuscular volume;
LGG	cis	rs7412746	0.658	rs59988025	chr1:150940358	C/T	cg15448220	chr1:150897856	SETDB1	0.4	7.38	0.32	7.22e-13	Melanoma;
LGG	cis	rs9467160	0.520	rs9379660	chr6:24441635	C/G	cg20631270	chr6:24437470	GPLD1	0.39	6.66	0.3	7.74e-11	Liver enzyme levels;
LGG	cis	rs7011049	0.908	rs72640860	chr8:53840500	G/A	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs9649465	0.967	rs3757505	chr7:123391641	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.72	-0.38	5.04e-17	Migraine;
LGG	cis	rs2133450	0.712	rs28571091	chr3:7367231	A/G	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.64e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg27471124	chr11:109292789	C11orf87	-0.48	-9.36	-0.4	3.35e-19	Schizophrenia;
LGG	cis	rs300774	0.925	rs408074	chr2:150853	T/C	cg04617936	chr2:214353	NA	-0.5	-7.49	-0.33	3.48e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs62064224	0.554	rs9889352	chr17:30775761	T/C	cg18200150	chr17:30822561	MYO1D	0.51	9.76	0.41	1.38e-20	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10706266	chr8:66546233	ARMC1	0.5	7.6	0.33	1.64e-13	Gut microbiome composition (summer);
LGG	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg19680485	chr15:31195859	MTMR15	-0.45	-7.28	-0.32	1.43e-12	Huntington's disease progression;
LGG	trans	rs61931739	0.513	rs7956626	chr12:33901640	C/T	cg26384229	chr12:38710491	ALG10B	0.64	12.4	0.5	1.14e-30	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.547	rs1913576	chr4:119297789	C/T	cg21605333	chr4:119757512	SEC24D	0.89	8.38	0.36	6.27e-16	Cannabis dependence symptom count;
LGG	cis	rs1580019	0.563	rs34201720	chr7:32568935	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.58	9.88	0.42	4.96e-21	Cognitive ability;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.63e-12	Height;
LGG	cis	rs17376456	0.809	rs10476602	chr5:93445255	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.3	0.43	1.58e-22	Diabetic retinopathy;
LGG	cis	rs34929064	0.536	rs2905307	chr7:22638963	A/G	cg18045685	chr7:22629474	NA	0.83	19.07	0.66	2.87e-60	Major depression and alcohol dependence;
LGG	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg27661571	chr11:113659931	NA	-0.62	-8.89	-0.38	1.34e-17	Hip circumference adjusted for BMI;
LGG	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg05234568	chr11:5960015	NA	0.79	14.49	0.56	1.62e-39	DNA methylation (variation);
LGG	cis	rs6964587	1.000	rs6465347	chr7:91693837	A/G	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	cis	rs9527	0.571	rs10786715	chr10:104620735	G/C	cg04362960	chr10:104952993	NT5C2	0.53	9.65	0.41	3.4e-20	Arsenic metabolism;
LGG	cis	rs7084402	0.967	rs1649082	chr10:60292434	A/C	cg07615347	chr10:60278583	BICC1	0.63	18.32	0.65	8.79e-57	Refractive error;
LGG	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg26597838	chr10:835615	NA	0.64	9.31	0.4	4.99e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs2228479	0.850	rs11641147	chr16:89813589	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	cis	rs10540	1.000	rs61876334	chr11:487201	T/C	cg03352830	chr11:487213	PTDSS2	0.86	10.87	0.45	1.14e-24	Body mass index;
LGG	trans	rs11039798	0.764	rs2089208	chr11:48899860	C/T	cg03929089	chr4:120376271	NA	0.74	8.58	0.37	1.39e-16	Axial length;
LGG	cis	rs5758659	0.652	rs5758553	chr22:42431429	G/A	cg15557168	chr22:42548783	NA	-0.33	-7.44	-0.33	4.87e-13	Cognitive function;
LGG	cis	rs9462027	0.628	rs6937314	chr6:34799308	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs858239	0.539	rs10247268	chr7:23187179	G/A	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.49e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg17294928	chr15:75287854	SCAMP5	-0.8	-8.47	-0.37	3.35e-16	Lung cancer;
LGG	cis	rs72615157	0.539	rs4729575	chr7:99686873	G/T	cg12813108	chr7:99719912	CNPY4	-0.84	-16.21	-0.6	3.96e-47	Lung function (FEV1/FVC);
LGG	cis	rs457717	0.730	rs428121	chr5:75927222	A/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.32	6.68	0.3	6.77e-11	Hearing impairment;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg08280861	chr8:58055591	NA	0.65	7.93	0.35	1.68e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs2098934	chr4:98992403	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11971779	0.553	rs36002669	chr7:139113161	T/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs11039798	0.623	rs588700	chr11:48449889	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.84	-0.42	7.41e-21	Axial length;
LGG	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg12923728	chr3:195709715	SDHAP1	-0.52	-8.7	-0.37	5.81e-17	Mean corpuscular volume;
LGG	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.3	-0.32	1.24e-12	Sudden cardiac arrest;
LGG	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg24209194	chr3:40518798	ZNF619	-0.42	-6.73	-0.3	4.9e-11	Renal cell carcinoma;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs2439831	1.000	rs690436	chr15:43761205	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.99	12.66	0.51	9.84e-32	Lung cancer in ever smokers;
LGG	cis	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg03060546	chr3:49711283	APEH	-0.65	-10.26	-0.43	2.2e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs10888343	chr1:248446642	A/G	cg00666640	chr1:248458726	OR2T12	0.6	9.61	0.41	4.79e-20	Common traits (Other);
LGG	cis	rs4356975	0.563	rs4314345	chr4:69973640	A/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.84e-11	Obesity-related traits;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg15242686	chr22:24348715	GSTTP1	0.38	6.83	0.3	2.74e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs258892	0.793	rs56762233	chr5:72056882	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.69	-0.3	6.5500000000000006e-11	Small cell lung carcinoma;
LGG	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg01017244	chr2:74357527	NA	0.45	7.95	0.35	1.4e-14	Gestational age at birth (maternal effect);
LGG	cis	rs7737355	0.947	rs6875058	chr5:130882702	C/G	cg06307176	chr5:131281290	NA	0.56	9.31	0.4	5.3e-19	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26431298	chr1:156737036	PRCC	0.44	7.39	0.32	7.1e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3768617	0.510	rs6424888	chr1:183085696	C/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.49	-0.4	1.26e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg03804240	chr11:118481350	PHLDB1	-0.39	-7.5	-0.33	3.39e-13	Cholesterol, total;
LGG	cis	rs2916247	0.954	rs1484564	chr8:93122508	G/A	cg10183463	chr8:93005414	RUNX1T1	0.4	8.15	0.35	3.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.595	rs4902916	chr14:71656430	A/T	cg13720639	chr14:72061746	SIPA1L1	0.34	6.99	0.31	9.36e-12	Mitral valve prolapse;
LGG	cis	rs8114671	0.933	rs6142327	chr20:33793147	T/A	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.43	-0.33	5.4e-13	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20879576	chr11:125034747	PKNOX2	-0.48	-6.88	-0.3	1.96e-11	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	9.63	0.41	3.94e-20	Obesity-related traits;
LGG	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg05527609	chr1:210001259	C1orf107	0.59	8.57	0.37	1.54e-16	Orofacial clefts;
LGG	cis	rs568617	0.953	rs658524	chr11:65647260	A/G	cg26695010	chr11:65641043	EFEMP2	0.47	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs7924176	0.601	rs10824073	chr10:75875216	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-7.07	-0.31	5.72e-12	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs4417704	0.526	rs6733049	chr2:241902718	C/G	cg05025159	chr2:241905733	NA	0.53	10.73	0.45	3.72e-24	Joint mobility (Beighton score);
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-12.24	-0.49	5.03e-30	Personality dimensions;
LGG	cis	rs9815354	0.767	rs73073342	chr3:41839455	A/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg19908139	chr1:38061735	GNL2	0.33	6.76	0.3	4.22e-11	Hepatitis;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg18379455	chr17:41446167	NA	-0.33	-7.29	-0.32	1.31e-12	Menopause (age at onset);
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg01879757	chr17:41196368	BRCA1	-0.41	-8.54	-0.37	1.9e-16	Menopause (age at onset);
LGG	cis	rs4639966	0.836	rs3825057	chr11:118622985	T/C	cg19182353	chr11:118479428	PHLDB1	-0.51	-8.41	-0.36	5.2e-16	Systemic lupus erythematosus;
LGG	trans	rs9929218	0.954	rs12919719	chr16:68822341	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.69	-11.58	-0.47	2.07e-27	Colorectal cancer;
LGG	cis	rs7010267	0.869	rs1982763	chr8:119947828	C/T	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-10.04	-0.42	1.32e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs3761218	0.738	rs6084472	chr20:3771858	G/T	cg25011176	chr20:3776985	CDC25B	-0.42	-6.68	-0.3	7.01e-11	Bipolar disorder;
LGG	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg03060546	chr3:49711283	APEH	0.59	8.33	0.36	9.07e-16	Menarche (age at onset);
LGG	cis	rs208520	0.690	rs207096	chr6:66797287	T/C	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	cis	rs7829975	0.514	rs2979139	chr8:8268313	A/G	cg12253571	chr8:8283032	NA	-0.31	-6.86	-0.3	2.25e-11	Mood instability;
LGG	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg27532318	chr7:32358331	NA	0.85	8.34	0.36	8.51e-16	Body mass index;
LGG	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.25	0.55	1.9e-38	Bladder cancer;
LGG	cis	rs17767392	0.881	rs34993988	chr14:71923692	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.85	0.38	1.92e-17	Mitral valve prolapse;
LGG	cis	rs17376456	0.809	rs12152763	chr5:93405509	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.15	0.43	5.36e-22	Diabetic retinopathy;
LGG	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg05535760	chr7:792225	HEATR2	0.94	13.74	0.54	2.77e-36	Cerebrospinal P-tau181p levels;
LGG	cis	rs11098499	0.863	rs1552092	chr4:120488496	C/T	cg24375607	chr4:120327624	NA	0.67	11.08	0.46	1.77e-25	Corneal astigmatism;
LGG	trans	rs62458065	0.513	rs10245103	chr7:32534829	T/G	cg00845942	chr12:64062724	DPY19L2	-0.56	-7.34	-0.32	9.45e-13	Metabolite levels (HVA/MHPG ratio);
LGG	trans	rs4714291	0.926	rs847771	chr6:40048586	T/C	cg02267698	chr19:7991119	CTXN1	0.55	8.42	0.36	4.91e-16	Strep throat;
LGG	cis	rs12638540	0.543	rs12487678	chr3:32603358	A/C	cg11605617	chr3:32612461	DYNC1LI1	0.93	10.83	0.45	1.59e-24	Mortality in heart failure;
LGG	cis	rs747650	0.926	rs11039119	chr11:47201924	G/A	cg03339077	chr11:47165057	C11orf49	0.54	10.42	0.44	5.5e-23	Acne (severe);
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.69	12.46	0.5	6.42e-31	Lymphocyte counts;
LGG	cis	rs12780845	0.505	rs973307	chr10:17246333	C/T	cg01003015	chr10:17271136	VIM	-0.44	-7.42	-0.33	5.72e-13	Homocysteine levels;
LGG	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg17809284	chr5:56205270	C5orf35	-0.54	-9.98	-0.42	2.24e-21	Initial pursuit acceleration;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs2836974	0.931	rs2776309	chr21:40715791	A/G	cg11644478	chr21:40555479	PSMG1	0.82	14.14	0.55	5.65e-38	Cognitive function;
LGG	trans	rs7937682	0.632	rs11214029	chr11:111761230	C/T	cg18187862	chr3:45730750	SACM1L	-0.61	-10.05	-0.42	1.3e-21	Primary sclerosing cholangitis;
LGG	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.85	-0.42	6.69e-21	Response to antipsychotic treatment;
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg26850624	chr5:429559	AHRR	-0.37	-7.94	-0.35	1.53e-14	Cystic fibrosis severity;
LGG	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg00031303	chr3:195681400	NA	-0.45	-6.94	-0.31	1.33e-11	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.21	0.32	2.23e-12	Menopause (age at onset);
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg25072359	chr17:41440525	NA	0.53	10.06	0.42	1.2e-21	Menopause (age at onset);
LGG	cis	rs9296092	0.560	rs9469502	chr6:33526648	G/A	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Neuroticism;
LGG	cis	rs6831352	0.918	rs13140423	chr4:100050400	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-8.12	-0.35	4.19e-15	Personality dimensions;
LGG	cis	rs17102423	0.964	rs11627859	chr14:65602384	G/A	cg16583315	chr14:65563665	MAX	-0.35	-6.65	-0.3	8.04e-11	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.41	-0.5	1e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	0.714	rs7245	chr22:42481849	G/A	cg15128208	chr22:42549153	NA	0.48	9.59	0.41	5.61e-20	Cognitive function;
LGG	cis	rs6800768	0.658	rs6764378	chr3:24114668	G/T	cg10674438	chr3:24145617	LOC152024	-0.32	-6.67	-0.3	7.53e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2455601	0.638	rs2568092	chr11:8987438	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.56	10.07	0.42	1.05e-21	Schizophrenia;
LGG	cis	rs208520	0.690	rs12197578	chr6:66725905	C/T	cg07460842	chr6:66804631	NA	0.96	17.9	0.64	7.68e-55	Exhaled nitric oxide output;
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg23958373	chr8:599963	NA	1.18	11.85	0.48	1.85e-28	IgG glycosylation;
LGG	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg02002194	chr4:3960332	NA	-0.46	-8.71	-0.38	5.4e-17	Mood instability;
LGG	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg13010199	chr12:38710504	ALG10B	0.47	8.95	0.38	8.61e-18	Morning vs. evening chronotype;
LGG	cis	rs8008758	0.517	rs1620117	chr14:101696931	C/A	cg26224664	chr14:101693935	NA	-0.86	-20.39	-0.69	2.13e-66	Body mass index (alcohol intake interaction);
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg07677032	chr17:61819896	STRADA	0.68	12.59	0.51	1.75e-31	Prudent dietary pattern;
LGG	cis	rs4731207	0.596	rs1481329	chr7:124631334	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7927592	0.913	rs10047412	chr11:68232912	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.26	-0.36	1.56e-15	Total body bone mineral density;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.91	-0.38	1.15e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6429082	0.714	rs704719	chr1:235667170	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	10.2	0.43	3.48e-22	Adiposity;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg00166722	chr3:10149974	C3orf24	0.53	8.88	0.38	1.52e-17	Alzheimer's disease;
LGG	cis	rs7945705	0.692	rs11042149	chr11:9010737	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.61	-0.37	1.13e-16	Hemoglobin concentration;
LGG	cis	rs2072732	0.821	rs12037307	chr1:2947756	C/A	cg08733933	chr1:2954429	NA	-0.46	-9.03	-0.39	4.63e-18	Plateletcrit;
LGG	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15128208	chr22:42549153	NA	-0.37	-7.31	-0.32	1.16e-12	Cognitive function;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16405210	chr4:1374714	KIAA1530	0.85	15.8	0.59	2.71e-45	Longevity;
LGG	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg11644478	chr21:40555479	PSMG1	0.71	12.01	0.49	4.16e-29	Cognitive function;
LGG	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg05696931	chr1:227175867	NA	0.4	7.94	0.35	1.51e-14	Myeloid white cell count;
LGG	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg21775007	chr8:11205619	TDH	0.43	6.87	0.3	2.07e-11	Joint mobility (Beighton score);
LGG	cis	rs887829	0.569	rs7574296	chr2:234638249	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.74	-0.34	6.41e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs7395662	0.525	rs4882060	chr11:48441874	G/C	cg15704280	chr7:45808275	SEPT13	-0.57	-9.51	-0.4	1.05e-19	HDL cholesterol;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.909	rs6119729	chr20:30413163	A/G	cg04935436	chr20:30431758	NA	-0.41	-7.17	-0.32	2.99e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7226408	0.857	rs72890574	chr18:34623479	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.06e-17	Menopause (age at onset);
LGG	cis	rs10462794	0.853	rs4702793	chr5:4507375	T/C	cg18482690	chr5:4511582	NA	-0.42	-7.42	-0.33	5.51e-13	DNA methylation (variation);
LGG	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg18351406	chr4:77819688	ANKRD56	0.45	7.77	0.34	5.23e-14	Emphysema distribution in smoking;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01185801	chr11:65265397	MALAT1	0.45	7.25	0.32	1.71e-12	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.75	0.38	4.03e-17	Platelet count;
LGG	cis	rs4820539	0.708	rs5751591	chr22:23489042	G/A	cg21100191	chr22:23484243	RTDR1	0.87	17.22	0.62	1.01e-51	Bone mineral density;
LGG	cis	rs78456975	1.000	rs6720874	chr2:1580504	A/G	cg01028140	chr2:1542097	TPO	-0.47	-7.61	-0.33	1.56e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10927875	0.632	rs10927863	chr1:16165247	C/A	cg21385522	chr1:16154831	NA	-1.04	-26.56	-0.78	4.22e-95	Dilated cardiomyopathy;
LGG	cis	rs7973719	0.868	rs7315553	chr12:7353838	A/C	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.62e-12	IgG glycosylation;
LGG	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg07005078	chr4:17578674	LAP3	0.36	6.72	0.3	5.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg07777115	chr5:623756	CEP72	-0.43	-6.82	-0.3	2.83e-11	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg04672837	chr16:48644449	N4BP1	0.56	9.3	0.4	5.54e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9309711	0.666	rs11127430	chr2:3485242	G/C	cg15506890	chr2:3487001	NA	-0.55	-10.58	-0.44	1.36e-23	Neurofibrillary tangles;
LGG	cis	rs1532815	0.959	rs4657412	chr1:165177033	G/A	cg03428399	chr1:165174748	LMX1A	-0.55	-11.45	-0.47	6.8e-27	Response to acetaminophen (hepatotoxicity);
LGG	cis	rs67311347	0.955	rs6782746	chr3:40510592	A/G	cg13683864	chr3:40499215	RPL14	1.15	28.92	0.8	8.46e-106	Renal cell carcinoma;
LGG	cis	rs881375	0.967	rs1548783	chr9:123658639	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.44	7.56	0.33	2.13e-13	Rheumatoid arthritis;
LGG	cis	rs988958	0.526	rs10177811	chr2:42263580	G/A	cg27252766	chr2:42229092	NA	0.51	6.84	0.3	2.45e-11	Hypospadias;
LGG	cis	rs7107174	1.000	rs11237480	chr11:78110385	C/A	cg02023728	chr11:77925099	USP35	0.43	7.66	0.34	1.13e-13	Testicular germ cell tumor;
LGG	cis	rs2836974	0.627	rs9981301	chr21:40686078	G/C	cg06238570	chr21:40685208	BRWD1	-0.54	-8.94	-0.38	8.98e-18	Cognitive function;
LGG	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg24375607	chr4:120327624	NA	0.62	10.15	0.43	5.42e-22	Corneal astigmatism;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.85	0.3	2.33e-11	Prudent dietary pattern;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg18350739	chr11:68623251	NA	-0.82	-20.62	-0.69	1.63e-67	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.42	-6.97	-0.31	1.07e-11	Ulcerative colitis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg12683173	chr7:69063404	AUTS2	0.6	6.82	0.3	2.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9560113	0.580	rs9560116	chr13:112193731	G/A	cg14154082	chr13:112174009	NA	0.39	8.29	0.36	1.2e-15	Menarche (age at onset);
LGG	cis	rs4481887	0.927	rs4472779	chr1:248474603	G/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs11969893	0.850	rs9498414	chr6:101322976	C/T	cg12253828	chr6:101329408	ASCC3	0.99	8.96	0.38	8.26e-18	Economic and political preferences (immigration/crime);
LGG	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Bladder cancer;
LGG	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg27572855	chr1:25598939	RHD	0.52	11.73	0.48	5.4e-28	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.58	10.08	0.42	9.73e-22	Obesity-related traits;
LGG	trans	rs1459104	0.925	rs67465952	chr11:55194045	T/A	cg15704280	chr7:45808275	SEPT13	0.7	6.86	0.3	2.19e-11	Body mass index;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.02e-23	Prudent dietary pattern;
LGG	cis	rs2221894	0.506	rs17524494	chr8:28779203	A/C	cg07962641	chr8:28805897	HMBOX1	-0.55	-8.29	-0.36	1.23e-15	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs16950804	chr15:67554479	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs561341	1.000	rs693116	chr17:30246124	C/T	cg13647721	chr17:30228624	UTP6	0.64	7.88	0.34	2.35e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg23131131	chr22:24373011	LOC391322	0.5	8.04	0.35	7.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs449303	1	rs449303	chr14:60605788	A/G	cg00846580	chr14:60632234	DHRS7	0.64	7.31	0.32	1.18e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6694672	1.000	rs12677	chr1:197053373	G/A	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs2797160	0.905	rs1418641	chr6:125999854	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	cis	rs12780845	0.505	rs11598987	chr10:17250230	C/G	cg01003015	chr10:17271136	VIM	-0.44	-7.36	-0.32	8.53e-13	Homocysteine levels;
LGG	cis	rs7647973	0.925	rs4955439	chr3:49245645	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.05	-0.35	7.09e-15	Menarche (age at onset);
LGG	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.94	0.31	1.31e-11	Cognitive ability;
LGG	cis	rs990171	0.802	rs1558650	chr2:103060024	T/A	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4689642	0.540	rs13119783	chr4:7218580	G/C	cg21353189	chr4:7228343	SORCS2	0.31	6.65	0.3	8.12e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11648796	0.757	rs66649828	chr16:766078	A/G	cg07343612	chr16:622815	PIGQ	-0.5	-8.35	-0.36	8.15e-16	Height;
LGG	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg24375607	chr4:120327624	NA	0.54	9.18	0.39	1.49e-18	Corneal astigmatism;
LGG	cis	rs7568458	0.905	rs59877521	chr2:85759494	C/T	cg17127132	chr2:85788382	GGCX	0.44	7.72	0.34	7.02e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg08521684	chr3:195488725	MUC4	0.6	7.81	0.34	3.8e-14	Lung disease severity in cystic fibrosis;
LGG	cis	rs4319547	1.000	rs7295397	chr12:123116209	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.62	-0.41	4.37e-20	Body mass index;
LGG	cis	rs7937682	0.737	rs542275	chr11:111431614	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.93	-18.14	-0.64	6.21e-56	Primary sclerosing cholangitis;
LGG	cis	rs7937682	0.924	rs11213968	chr11:111527629	G/C	cg22437258	chr11:111473054	SIK2	0.57	9.86	0.42	6.22e-21	Primary sclerosing cholangitis;
LGG	cis	rs2204008	0.811	rs12368410	chr12:38305705	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.06	0.55	1.19e-37	Bladder cancer;
LGG	cis	rs317689	0.690	rs607797	chr12:69646010	T/C	cg20891283	chr12:69753455	YEATS4	0.45	6.9	0.31	1.71e-11	Response to diuretic therapy;
LGG	cis	rs4969178	0.641	rs4969141	chr17:76391653	C/T	cg02836325	chr17:76403955	PGS1	-0.81	-17.87	-0.64	1.11e-54	HDL cholesterol levels;
LGG	cis	rs9583531	0.574	rs61971615	chr13:111353111	C/T	cg15841412	chr13:111365552	ING1	-0.44	-6.99	-0.31	9.49e-12	Coronary artery disease;
LGG	cis	rs2072732	0.808	rs55784203	chr1:2936754	G/T	cg22517653	chr1:2918612	NA	-0.51	-7.24	-0.32	1.94e-12	Plateletcrit;
LGG	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.75	14.04	0.55	1.53e-37	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs56397034	1	rs56397034	chr19:13000550	G/C	cg06417478	chr19:12876846	HOOK2	-0.4	-6.75	-0.3	4.37e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg24846343	chr22:24311635	DDTL	0.53	9.56	0.41	7.23e-20	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2386661	0.826	rs2386651	chr10:5678031	C/A	cg26603656	chr10:5671107	NA	0.4	7.79	0.34	4.57e-14	Breast cancer;
LGG	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg19131313	chr8:1704013	NA	-0.3	-6.72	-0.3	5.39e-11	Systolic blood pressure;
LGG	trans	rs1459104	0.925	rs12577653	chr11:55077102	G/A	cg15704280	chr7:45808275	SEPT13	0.75	6.89	0.3	1.85e-11	Body mass index;
LGG	cis	rs4731207	0.724	rs57458159	chr7:124500810	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	trans	rs783540	1.000	rs783531	chr15:83249119	C/T	cg16105309	chr15:79090380	ADAMTS7	0.41	7.24	0.32	1.84e-12	Schizophrenia;
LGG	cis	rs283228	0.570	rs2852511	chr6:101845912	G/A	cg02011392	chr6:101847541	GRIK2	0.52	7.3	0.32	1.23e-12	Coenzyme Q10 levels;
LGG	cis	rs2898279	0.815	rs9792397	chr8:11302721	T/C	cg26274995	chr8:11302983	FAM167A	0.54	11.01	0.46	3.25e-25	Small cell lung carcinoma;
LGG	trans	rs7618501	1.000	rs7618501	chr3:49772647	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.74	-0.41	1.58e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4132509	0.948	rs7517921	chr1:243856420	T/C	cg21452805	chr1:244014465	NA	0.63	7.67	0.34	1.03e-13	RR interval (heart rate);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15852731	chr22:44208246	EFCAB6	0.5	7.7	0.34	8.29e-14	Gut microbiome composition (summer);
LGG	cis	rs988958	0.805	rs10185599	chr2:42283886	A/G	cg27428208	chr2:42229179	NA	0.4	7.17	0.32	2.99e-12	Hypospadias;
LGG	cis	rs4330281	0.647	rs13085167	chr3:17717405	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	10.59	0.44	1.35e-23	Total body bone mineral density;
LGG	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.77	-0.34	5.06e-14	Systemic lupus erythematosus;
LGG	cis	rs1784581	0.588	rs6415086	chr6:162418147	C/T	cg17173639	chr6:162384350	PARK2	0.64	13.4	0.53	8.06e-35	Itch intensity from mosquito bite;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg26876001	chr16:88951664	CBFA2T3	0.36	6.67	0.3	7.54e-11	Electrocardiographic conduction measures;
LGG	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg26150922	chr2:100937072	LONRF2	-0.59	-11.7	-0.48	7.18e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4925386	0.802	rs6142735	chr20:60918087	G/C	cg24112000	chr20:60950667	NA	-0.38	-7.41	-0.33	6.04e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs283228	0.761	rs1905920	chr6:101773004	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs2839186	1.000	rs2839186	chr21:47690068	C/T	cg14789911	chr21:47582049	C21orf56	-0.43	-7.33	-0.32	1.05e-12	Testicular germ cell tumor;
LGG	cis	rs10875746	0.768	rs4760676	chr12:48421663	G/A	cg24011408	chr12:48396354	COL2A1	-0.5	-6.8	-0.3	3.27e-11	Longevity (90 years and older);
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg06654118	chr4:1303317	MAEA	0.49	8.56	0.37	1.7e-16	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8028182	0.636	rs4322627	chr15:75810659	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.41	0.33	6.11e-13	Sudden cardiac arrest;
LGG	cis	rs888194	0.738	rs6606732	chr12:109984561	G/A	cg19025524	chr12:109796872	NA	-0.35	-7.1	-0.31	4.58e-12	Neuroticism;
LGG	trans	rs826838	0.900	rs1403523	chr12:39130570	T/A	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg08297393	chr2:100937505	LONRF2	-0.58	-9.99	-0.42	2.02e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.74	-0.34	6.32e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.36	0.36	7.61e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs116095464	0.558	rs9688045	chr5:254035	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24023618	chr6:114292459	HDAC2	0.47	7.36	0.32	8.58e-13	Gut microbiome composition (summer);
LGG	cis	rs4629180	0.675	rs13388183	chr2:102111912	A/G	cg16435561	chr2:102091048	RFX8	0.47	8.57	0.37	1.53e-16	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg13009111	chr11:71350975	NA	-0.32	-7.11	-0.31	4.55e-12	Neuroticism;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.51	-8.69	-0.37	6.51e-17	Lymphocyte counts;
LGG	cis	rs1008375	0.898	rs7678654	chr4:17575376	T/G	cg16339924	chr4:17578868	LAP3	0.63	10.78	0.45	2.54e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs806215	0.950	rs989099	chr7:127220827	A/G	cg25922125	chr7:127225783	GCC1	-0.73	-10.31	-0.43	1.4e-22	Type 2 diabetes;
LGG	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg01346077	chr3:125931526	NA	0.41	10.47	0.44	3.51e-23	Metabolite levels;
LGG	trans	rs61931739	0.534	rs10844801	chr12:34230940	A/T	cg26384229	chr12:38710491	ALG10B	0.79	15.59	0.59	2.42e-44	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.735	rs2024878	chr1:231528415	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.61	11.02	0.46	3.19e-25	Hemoglobin concentration;
LGG	cis	rs644799	1.000	rs488246	chr11:95560473	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2806561	0.929	rs6694445	chr1:23540428	A/G	cg19743168	chr1:23544995	NA	0.37	8.14	0.35	3.67e-15	Height;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.82e-12	Life satisfaction;
LGG	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.44	0.33	5.05e-13	Total cholesterol levels;
LGG	cis	rs2836950	0.527	rs2836958	chr21:40623526	T/C	cg17971929	chr21:40555470	PSMG1	-0.54	-9.27	-0.4	7.24e-19	Menarche (age at onset);
LGG	cis	rs11229555	0.645	rs12801475	chr11:58189034	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24930797	chr15:66083595	DENND4A	0.43	7.3	0.32	1.28e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.5	-0.33	3.19e-13	Refractive error;
LGG	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg04025307	chr7:1156635	C7orf50	0.47	6.97	0.31	1.1e-11	Bronchopulmonary dysplasia;
LGG	cis	rs7107174	1.000	rs2450129	chr11:77940385	T/C	cg02023728	chr11:77925099	USP35	0.44	7.7	0.34	8.49e-14	Testicular germ cell tumor;
LGG	trans	rs10754283	0.967	rs10754285	chr1:90116587	A/G	cg22493809	chr1:120838387	FAM72B	-0.43	-6.84	-0.3	2.53e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1018836	0.544	rs10112371	chr8:91457626	C/T	cg16814680	chr8:91681699	NA	0.46	7.67	0.34	1.03e-13	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6489785	0.689	rs791713	chr12:121308381	C/T	cg02419362	chr12:121203948	SPPL3	-0.44	-6.83	-0.3	2.69e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg12292205	chr6:26970375	C6orf41	-0.75	-15.05	-0.57	5.67e-42	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg03060546	chr3:49711283	APEH	0.56	8.64	0.37	9.26e-17	Resting heart rate;
LGG	cis	rs868036	0.756	rs2241421	chr15:68082825	G/A	cg05925327	chr15:68127851	NA	-0.35	-8.21	-0.36	2.25e-15	Restless legs syndrome;
LGG	cis	rs8060686	0.545	rs55897859	chr16:68286748	G/C	cg27539214	chr16:67997921	SLC12A4	-0.52	-7.5	-0.33	3.32e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11890956	chr21:40555474	PSMG1	1.18	30.85	0.82	2.21e-114	Cognitive function;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.6	-0.44	1.19e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.835	rs7559416	chr2:219150211	A/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.44	-0.44	4.78e-23	Colorectal cancer;
LGG	cis	rs300774	0.841	rs410690	chr2:203346	G/A	cg04617936	chr2:214353	NA	0.59	8.51	0.37	2.53e-16	Suicide attempts in bipolar disorder;
LGG	cis	rs17384381	0.953	rs11161597	chr1:85784936	G/A	cg16011679	chr1:85725395	C1orf52	0.62	10.26	0.43	2.1e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.49	8.16	0.35	3.15e-15	Bipolar disorder;
LGG	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg10935138	chr17:73851978	WBP2	0.54	8.06	0.35	6.36e-15	Psoriasis;
LGG	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.57	-0.37	1.6e-16	Menarche (age at onset);
LGG	cis	rs903263	0.601	rs6669045	chr1:84560735	A/T	cg10977910	chr1:84465055	TTLL7	0.42	7.42	0.33	5.75e-13	Breast cancer (male);
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.99	-0.35	1.11e-14	Neuroticism;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg18106800	chr5:94890715	ARSK;TTC37	0.42	7.07	0.31	5.62e-12	Prudent dietary pattern;
LGG	cis	rs473651	0.777	rs550890	chr2:239332555	G/A	cg18131467	chr2:239335373	ASB1	0.85	15.42	0.58	1.34e-43	Multiple system atrophy;
LGG	cis	rs13102973	0.640	rs34037497	chr4:135833698	C/G	cg14419869	chr4:135874104	NA	0.51	9.46	0.4	1.54e-19	Subjective well-being;
LGG	cis	rs7666738	0.791	rs13120773	chr4:98972589	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2777491	0.574	rs316616	chr15:41746276	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.95	-0.84	9.49e-128	Ulcerative colitis;
LGG	cis	rs8112449	0.964	rs10854116	chr19:10523086	T/C	cg21868191	chr19:10515988	NA	-0.47	-8.21	-0.36	2.22e-15	Multiple sclerosis;Gastritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26594331	chr5:178053244	CLK4	-0.46	-6.71	-0.3	5.63e-11	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.71	-13.29	-0.53	2.37e-34	Personality dimensions;
LGG	cis	rs1218582	0.774	rs4845683	chr1:154877407	T/C	cg24250549	chr1:154909240	PMVK	0.7	13.81	0.54	1.37e-36	Prostate cancer;
LGG	cis	rs9398803	0.661	rs864937	chr6:127015083	G/A	cg19875578	chr6:126661172	C6orf173	-0.52	-9.53	-0.41	8.63e-20	Male-pattern baldness;
LGG	trans	rs1814175	0.529	rs1988417	chr11:49932430	A/G	cg03929089	chr4:120376271	NA	-0.87	-15.29	-0.58	5.02e-43	Height;
LGG	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.16	0.35	3.15e-15	Mean platelet volume;
LGG	cis	rs9916302	0.904	rs12452509	chr17:37574722	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs7027203	0.688	rs4075733	chr9:96624645	C/T	cg14598338	chr9:96623480	NA	-0.58	-11.03	-0.46	2.79e-25	DNA methylation (variation);
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.53	0.37	2.16e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg16339924	chr4:17578868	LAP3	0.65	10.96	0.45	5.22e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs17401966	0.894	rs11587309	chr1:10446596	G/T	cg15208524	chr1:10270712	KIF1B	0.46	7.92	0.35	1.83e-14	Hepatocellular carcinoma;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.54	-0.44	2.04e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs17102884	0.506	rs4899540	chr14:75403408	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.63	-11.44	-0.47	7.12e-27	Neuroticism;
LGG	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg20891558	chr2:74357851	NA	0.51	9.95	0.42	2.77e-21	Gestational age at birth (maternal effect);
LGG	cis	rs4731207	0.596	rs13224820	chr7:124655399	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7937840	0.581	rs4963461	chr11:61884044	G/A	cg01969543	chr11:61895209	INCENP	-0.49	-9.94	-0.42	3.05e-21	Breast cancer;
LGG	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg16584290	chr5:462447	EXOC3	0.46	9.45	0.4	1.67e-19	Cystic fibrosis severity;
LGG	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg05527609	chr1:210001259	C1orf107	-0.49	-6.72	-0.3	5.26e-11	Red blood cell count;
LGG	cis	rs1580019	0.885	rs4460269	chr7:32496445	T/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs4356932	0.967	rs4318674	chr4:76934422	C/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.41	-6.82	-0.3	2.78e-11	Blood protein levels;
LGG	cis	rs760805	0.965	rs4648883	chr1:25261203	T/C	cg22509179	chr1:25234806	RUNX3	-0.65	-13.86	-0.54	8.52e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.64	0.71	2.9e-72	Bladder cancer;
LGG	cis	rs9768139	0.611	rs12698211	chr7:158119623	G/A	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.78	-0.57	8.88e-41	Calcium levels;
LGG	cis	rs2067615	0.524	rs10778505	chr12:107143126	G/C	cg15890332	chr12:107067104	RFX4	0.41	12.16	0.49	1.04e-29	Heart rate;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09805943	chr6:69345293	BAI3	-0.46	-6.89	-0.3	1.78e-11	Pancreatic cancer;
LGG	cis	rs42648	0.564	rs7777651	chr7:89822344	G/A	cg04070188	chr7:89809444	NA	-0.28	-6.69	-0.3	6.32e-11	Homocysteine levels;
LGG	cis	rs4924935	0.851	rs966811	chr17:18830287	G/A	cg26378065	chr17:18585709	ZNF286B	-0.45	-6.88	-0.3	1.98e-11	Pancreatic cancer;
LGG	cis	rs6120849	0.754	rs6087666	chr20:33640242	G/A	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.85	-0.66	3.05e-59	Monocyte count;
LGG	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.73	-0.38	4.69e-17	Eosinophil percentage of white cells;
LGG	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg09448879	chr15:79043637	NA	-0.33	-7.38	-0.32	7.33e-13	Sudden cardiac arrest;
LGG	cis	rs1909881	0.504	rs59057318	chr8:96499947	T/C	cg04203453	chr8:96504381	NA	-0.76	-11.79	-0.48	3.05e-28	Obesity-related traits;
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.06	-0.31	6.31e-12	Intelligence (multi-trait analysis);
LGG	trans	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg02002194	chr4:3960332	NA	0.4	7.48	0.33	3.78e-13	Joint mobility (Beighton score);
LGG	trans	rs6601327	0.641	rs10096462	chr8:9614993	C/A	cg12395012	chr8:11607386	GATA4	-0.39	-7.14	-0.31	3.7e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4776059	1.000	rs4776058	chr15:52880263	A/G	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.09	-0.35	5.14e-15	Schizophrenia;
LGG	cis	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg21775007	chr8:11205619	TDH	-0.59	-9.56	-0.41	7.24e-20	Retinal vascular caliber;
LGG	cis	rs3770081	1.000	rs56104203	chr2:86336256	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.86	-7.48	-0.33	3.75e-13	Facial emotion recognition (sad faces);
LGG	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs240764	0.853	rs12206182	chr6:101033379	A/C	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.41e-12	Neuroticism;
LGG	cis	rs1920116	0.778	rs7647824	chr3:169552381	A/G	cg08193579	chr3:169529701	LRRC34	0.42	7.35	0.32	9.01e-13	Glioma (high-grade);
LGG	cis	rs427394	0.664	rs274722	chr5:6718668	C/T	cg15145174	chr5:6755386	POLS	-0.38	-7.2	-0.32	2.38e-12	Menopause (age at onset);
LGG	trans	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg12045294	chr17:78518616	RPTOR	-0.44	-6.98	-0.31	1.01e-11	Glycated hemoglobin levels;
LGG	cis	rs28595532	0.920	rs115841156	chr4:119740073	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs738322	0.574	rs28653361	chr22:38570700	C/A	cg25457927	chr22:38595422	NA	-0.41	-9.61	-0.41	4.58e-20	Cutaneous nevi;
LGG	cis	rs11758351	0.500	rs75551401	chr6:26185387	T/C	cg23601095	chr6:26197514	HIST1H3D	0.89	6.77	0.3	3.94e-11	Gout;Renal underexcretion gout;
LGG	cis	rs1348850	0.567	rs1527401	chr2:178522104	C/T	cg27490568	chr2:178487706	NA	0.49	9.6	0.41	5e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg11764359	chr7:65958608	NA	0.78	14.62	0.56	4.51e-40	Aortic root size;
LGG	cis	rs4930561	0.765	rs4930229	chr11:67944080	G/A	cg16338278	chr11:67432957	ALDH3B2	0.41	7.7	0.34	8.22e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	trans	rs853679	1.000	rs735765	chr6:28170297	G/A	cg08344181	chr3:125677491	NA	-0.6	-7.65	-0.33	1.2e-13	Depression;
LGG	cis	rs854765	0.547	rs4643387	chr17:17972973	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.76	15.13	0.58	2.72e-42	Total body bone mineral density;
LGG	cis	rs4423214	0.840	rs1123007	chr11:71185357	G/A	cg05163923	chr11:71159392	DHCR7	-0.64	-11.02	-0.46	2.99e-25	Vitamin D levels;
LGG	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.717	rs11040450	chr11:49650638	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.97	-0.74	3.67e-83	Height;
LGG	trans	rs2562456	0.876	rs2562413	chr19:21602886	G/C	cg00806126	chr19:22604979	ZNF98	-0.54	-7.28	-0.32	1.48e-12	Pain;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06745235	chr1:180471494	ACBD6	0.54	8.51	0.37	2.45e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs9929218	0.954	rs17715799	chr16:68830511	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-11.75	-0.48	4.28e-28	Colorectal cancer;
LGG	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.24	-0.36	1.75e-15	Retinal vascular caliber;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12548227	chr7:6144298	USP42	0.42	6.83	0.3	2.66e-11	Cognitive performance;
LGG	cis	rs28595532	0.920	rs114019902	chr4:119755564	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg10852096	chr15:79043040	NA	-0.26	-7.5	-0.33	3.38e-13	Coronary artery disease or large artery stroke;
LGG	cis	rs7572733	0.840	rs1065953	chr2:198614612	C/T	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg03517284	chr6:25882590	NA	0.4	7.09	0.31	4.9e-12	Height;
LGG	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01570182	chr17:44337453	NA	-0.48	-8.66	-0.37	7.79e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs74781061	0.929	rs7178219	chr15:74794893	C/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.07	-0.31	5.62e-12	Endometriosis;
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.54	-8.46	-0.37	3.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11105298	0.891	rs10858900	chr12:89925081	C/A	cg00757033	chr12:89920650	WDR51B	0.63	9.17	0.39	1.51e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs236352	0.538	rs449840	chr6:36865177	C/T	cg03410223	chr6:36853544	C6orf89	0.4	7.65	0.33	1.21e-13	Heart rate;
LGG	cis	rs7129220	0.588	rs16907462	chr11:10137404	T/C	cg01453529	chr11:10209919	SBF2	-0.42	-6.78	-0.3	3.67e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.39	-0.32	7.04e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg13206674	chr6:150067644	NUP43	-0.64	-14.42	-0.56	3.34e-39	Lung cancer;
LGG	cis	rs1552244	0.748	rs9862221	chr3:10059658	G/T	cg08888203	chr3:10149979	C3orf24	0.5	8.09	0.35	5.33e-15	Alzheimer's disease;
LGG	trans	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg15704280	chr7:45808275	SEPT13	0.47	7.73	0.34	6.7e-14	HDL cholesterol;
LGG	cis	rs6815814	0.847	rs5743596	chr4:38802528	G/A	cg06935464	chr4:38784597	TLR10	0.65	7.62	0.33	1.48e-13	Breast cancer;
LGG	cis	rs11098499	0.618	rs6858383	chr4:120296772	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs9308731	0.644	rs7593638	chr2:111876941	A/C	cg19992207	chr2:111874495	ACOXL	-0.36	-6.64	-0.3	8.58e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	cis	rs2120243	0.539	rs1456105	chr3:157123461	A/C	cg24825693	chr3:157122686	VEPH1	-0.59	-13.63	-0.54	8.58e-36	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs72991	0.793	rs72992	chr11:121243662	T/C	cg27192990	chr6:129479024	LAMA2	-0.43	-7.36	-0.32	8.48e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3126085	0.935	rs56013982	chr1:152176503	C/T	cg26876637	chr1:152193138	HRNR	-0.49	-7.05	-0.31	6.38e-12	Atopic dermatitis;
LGG	cis	rs8060686	0.545	rs76495028	chr16:68177036	G/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.24	-0.32	1.86e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1816854	0.938	rs10506231	chr12:44206027	C/T	cg00106942	chr12:44200524	TWF1	0.41	6.69	0.3	6.64e-11	Inflammatory bowel disease;
LGG	cis	rs12142240	0.698	rs17413701	chr1:46818452	A/G	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg05335186	chr13:53173507	NA	0.48	10.24	0.43	2.57e-22	Lewy body disease;
LGG	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg23250157	chr14:64679961	SYNE2	-0.48	-8.88	-0.38	1.43e-17	Atrial fibrillation;
LGG	cis	rs2016266	0.502	rs9971671	chr12:53634238	G/C	cg04065151	chr12:53682969	ESPL1	-0.82	-15.92	-0.59	7.91e-46	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7044106	0.791	rs4836829	chr9:123482747	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.44	0.33	4.8e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1949733	1.000	rs1949733	chr4:8503359	C/T	cg13073564	chr4:8508604	NA	0.61	12.19	0.49	7.86e-30	Response to antineoplastic agents;
LGG	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg11040518	chr10:102331378	NA	-0.36	-6.76	-0.3	4.09e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1949733	1.000	rs1880023	chr4:8480831	C/T	cg13073564	chr4:8508604	NA	0.59	11.78	0.48	3.38e-28	Response to antineoplastic agents;
LGG	cis	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg08807101	chr21:30365312	RNF160	0.69	11.78	0.48	3.26e-28	Cognitive test performance;
LGG	cis	rs910316	0.763	rs6574205	chr14:75453039	G/C	cg06637938	chr14:75390232	RPS6KL1	0.53	9.41	0.4	2.38e-19	Height;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.77	-0.34	5.18e-14	Skin colour saturation;
LGG	cis	rs35740288	0.787	rs727379	chr15:86229890	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.14	0.35	3.56e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs5750830	0.645	rs756640	chr22:39779300	G/A	cg04986931	chr22:39850128	NA	0.34	7.66	0.34	1.08e-13	Intelligence (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09238957	chr16:46723420	ORC6L;VPS35	0.42	6.81	0.3	3.02e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11098499	0.954	rs7437420	chr4:120312903	A/G	cg09307838	chr4:120376055	NA	0.81	13.53	0.53	2.25e-35	Corneal astigmatism;
LGG	trans	rs4714291	1.000	rs1100103	chr6:40040424	T/C	cg02267698	chr19:7991119	CTXN1	0.55	8.4	0.36	5.34e-16	Strep throat;
LGG	cis	rs433406	0.733	rs426690	chr11:131372044	T/G	cg27203895	chr11:131369037	NTM	0.79	18.44	0.65	2.34e-57	Male fertility;
LGG	cis	rs9948	1.000	rs62152834	chr2:97504863	C/G	cg01990225	chr2:97406019	LMAN2L	-0.62	-6.9	-0.31	1.69e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs11122272	0.735	rs2749704	chr1:231526243	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg08975724	chr8:8085496	FLJ10661	0.42	7.66	0.34	1.1e-13	Retinal vascular caliber;
LGG	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg00700412	chr12:58011837	NA	0.38	7.41	0.33	5.92e-13	Multiple sclerosis;
LGG	cis	rs2235649	0.663	rs6600168	chr16:1848927	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.91	-0.31	1.65e-11	Blood metabolite levels;
LGG	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs66887589	0.748	rs28439855	chr4:120262256	G/A	cg09307838	chr4:120376055	NA	0.47	8.08	0.35	5.62e-15	Diastolic blood pressure;
LGG	cis	rs9677476	0.863	rs57199832	chr2:232069083	T/G	cg14237567	chr2:232057245	NA	-0.34	-6.91	-0.31	1.62e-11	Food antigen IgG levels;
LGG	cis	rs13217239	0.646	rs62401067	chr6:27018101	T/A	cg09904177	chr6:26538194	HMGN4	0.39	6.9	0.31	1.75e-11	Schizophrenia;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg05313129	chr8:58192883	C8orf71	-0.78	-11.85	-0.48	1.84e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs6466055	0.777	rs11765045	chr7:104922115	T/A	cg04380332	chr7:105027541	SRPK2	0.38	7.04	0.31	7.2e-12	Schizophrenia;
LGG	trans	rs7560272	0.723	rs6722867	chr2:73816285	A/G	cg23020402	chr6:24666573	ACOT13;TTRAP	0.43	6.78	0.3	3.71e-11	Schizophrenia;
LGG	cis	rs722599	0.715	rs2300598	chr14:75359229	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.19	-0.43	4.03e-22	IgG glycosylation;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.72	-13.25	-0.52	3.39e-34	Longevity;Endometriosis;
LGG	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.77	-0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg24247370	chr13:99142703	STK24	-0.4	-7.3	-0.32	1.29e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs62054601	chr16:89811751	C/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	cis	rs17767392	0.746	rs61989246	chr14:71720243	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.33	-7.34	-0.32	9.48e-13	Mitral valve prolapse;
LGG	cis	rs3735485	0.562	rs62458146	chr7:45091004	A/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.56	-0.37	1.69e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1808579	0.904	rs1788781	chr18:21165080	A/C	cg14672496	chr18:21087552	C18orf8	-0.35	-7.0	-0.31	8.8e-12	Hip circumference;Body mass index;BMI (adjusted for smoking behaviour);
LGG	cis	rs5758659	0.652	rs133330	chr22:42409456	G/A	cg15557168	chr22:42548783	NA	-0.34	-7.63	-0.33	1.3e-13	Cognitive function;
LGG	cis	rs10851411	0.657	rs62022313	chr15:42749476	C/T	cg21293051	chr15:42870591	STARD9	0.5	7.01	0.31	8.38e-12	Glucose homeostasis traits;
LGG	cis	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg15596359	chr8:11213517	TDH	-0.34	-6.93	-0.31	1.4e-11	Retinal vascular caliber;
LGG	trans	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg22358067	chr17:16797159	NA	-0.47	-6.7	-0.3	6.13e-11	Body mass index;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg20120463	chr17:44301886	NA	-0.48	-7.42	-0.33	5.76e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	8.11	0.35	4.49e-15	Response to antipsychotic treatment;
LGG	cis	rs28595532	0.920	rs114751999	chr4:119759651	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.2	0.43	3.66e-22	Cannabis dependence symptom count;
LGG	cis	rs6594713	1.000	rs6594713	chr5:112715374	A/C	cg12552261	chr5:112820674	MCC	0.5	7.22	0.32	2.2e-12	Brain cytoarchitecture;
LGG	cis	rs17767294	0.541	rs72845042	chr6:27568734	A/T	cg15325629	chr6:28072465	NA	0.94	7.24	0.32	1.93e-12	Parkinson's disease;
LGG	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	12.05	0.49	2.88e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1908814	0.516	rs13252854	chr8:11792978	T/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	Neuroticism;
LGG	cis	rs4702718	0.574	rs5745281	chr5:10684841	C/T	cg18867653	chr5:10760375	DAP	0.29	7.06	0.31	6.09e-12	Obesity-related traits;
LGG	trans	rs11875185	0.510	rs74736660	chr18:55630560	A/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg05444541	chr17:17804740	TOM1L2	0.61	14.35	0.55	6.88e-39	Total body bone mineral density;
LGG	trans	rs1493916	0.837	rs10401087	chr18:31320716	A/G	cg04226714	chr8:49833948	SNAI2	-0.45	-7.86	-0.34	2.78e-14	Life satisfaction;
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg02725872	chr8:58115012	NA	-1.07	-14.84	-0.57	5.01e-41	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07187585	chr17:10600923	C17orf48;SCO1	0.41	6.77	0.3	3.94e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2115630	1.000	rs10220733	chr15:85280864	G/A	cg12501888	chr15:85177176	SCAND2	-0.42	-7.05	-0.31	6.59e-12	P wave terminal force;
LGG	cis	rs2737618	0.651	rs2248967	chr1:200084893	A/G	cg21825944	chr1:200113062	NR5A2	0.59	11.57	0.47	2.23e-27	Uric acid levels;
LGG	trans	rs1032833	0.732	rs77225055	chr2:179947564	C/T	cg23654767	chr2:101192981	PDCL3	0.68	8.13	0.35	3.98e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9811920	0.683	rs16841874	chr3:99720564	A/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-7.38	-0.32	7.43e-13	Axial length;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg26338869	chr17:61819248	STRADA	-0.47	-7.69	-0.34	9.09e-14	Prudent dietary pattern;
LGG	cis	rs7582180	0.764	rs7425797	chr2:100928337	T/C	cg26150922	chr2:100937072	LONRF2	-0.57	-10.87	-0.45	1.16e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.58	0.47	2.1e-27	Bipolar disorder;
LGG	cis	rs7737355	0.947	rs31240	chr5:130811146	T/A	cg06307176	chr5:131281290	NA	0.53	9.01	0.39	5.52e-18	Life satisfaction;
LGG	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg14036092	chr11:66035641	RAB1B	0.46	7.97	0.35	1.23e-14	Gout;
LGG	cis	rs972578	0.668	rs9611930	chr22:43235978	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.68	-0.3	6.9e-11	Mean platelet volume;
LGG	cis	rs4799461	0.788	rs12607755	chr18:35134259	C/T	cg27332583	chr18:35150602	NA	-0.56	-11.18	-0.46	7.72e-26	Neuroticism;
LGG	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-6.78	-0.3	3.79e-11	Electroencephalogram traits;
LGG	cis	rs9902453	0.791	rs55655651	chr17:28244286	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.59	0.53	1.24e-35	Coffee consumption (cups per day);
LGG	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Body mass index;
LGG	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg10021288	chr2:128175891	PROC	-0.38	-7.01	-0.31	8.74e-12	Self-rated health;
LGG	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg19507638	chr5:93509721	C5orf36	0.42	6.97	0.31	1.09e-11	Diabetic retinopathy;
LGG	cis	rs875971	0.545	rs1796226	chr7:66087710	C/T	cg11764359	chr7:65958608	NA	0.64	9.81	0.41	8.96e-21	Aortic root size;
LGG	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg17201900	chr20:34330562	RBM39	0.54	7.27	0.32	1.54e-12	Total cholesterol levels;
LGG	cis	rs12042938	0.507	rs2570408	chr1:231732934	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.77	-15.04	-0.57	6.28e-42	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4474465	0.688	rs7940720	chr11:78276674	C/T	cg27205649	chr11:78285834	NARS2	0.59	10.9	0.45	9.05e-25	Alzheimer's disease (survival time);
LGG	cis	rs3733585	0.598	rs28677023	chr4:9958326	C/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs283228	1.000	rs2518182	chr6:101782211	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.89	0.38	1.32e-17	Coenzyme Q10 levels;
LGG	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg16339924	chr4:17578868	LAP3	0.59	10.3	0.43	1.48e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.37	-0.36	6.83e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs13108043	0.605	rs10489044	chr4:87976387	A/G	cg11209507	chr4:87813803	C4orf36	0.55	7.36	0.32	8.58e-13	Red blood cell count;
LGG	cis	rs7582180	0.652	rs11687865	chr2:100947000	T/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7236492	0.683	rs78250476	chr18:77198934	G/A	cg15644404	chr18:77186268	NFATC1	-0.81	-10.11	-0.43	7.74e-22	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6938	0.534	rs1127796	chr15:75193004	C/T	cg14664628	chr15:75095509	CSK	0.53	10.16	0.43	4.88e-22	Breast cancer;
LGG	cis	rs9911578	1.000	rs2079703	chr17:56603978	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20257096	chr14:21851954	SUPT16H	0.42	6.75	0.3	4.53e-11	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00251705	chr11:57434686	ZDHHC5	0.49	7.47	0.33	4.16e-13	Gut microbiome composition (summer);
LGG	cis	rs17401966	0.867	rs6696056	chr1:10305992	C/A	cg15208524	chr1:10270712	KIF1B	0.45	7.87	0.34	2.55e-14	Hepatocellular carcinoma;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.08e-14	Height;
LGG	cis	rs9399135	0.967	rs9389253	chr6:135329755	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.06e-19	Red blood cell count;
LGG	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg08949735	chr16:89699720	DPEP1	0.47	9.92	0.42	3.81e-21	Vitiligo;
LGG	cis	rs2732480	0.577	rs1489108	chr12:48738781	G/A	cg21466736	chr12:48725269	NA	-0.39	-7.74	-0.34	6.5e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs10779751	0.770	rs11585553	chr1:11233814	G/A	cg08854313	chr1:11322531	MTOR	-0.73	-14.27	-0.55	1.52e-38	Body mass index;
LGG	cis	rs2282300	0.739	rs34234618	chr11:30241701	T/C	cg25418670	chr11:30344373	C11orf46	-0.57	-7.75	-0.34	6e-14	Morning vs. evening chronotype;
LGG	cis	rs992157	0.835	rs2292550	chr2:219140288	G/C	cg04731861	chr2:219085781	ARPC2	0.46	11.32	0.47	2.12e-26	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22045228	chr2:85581875	ELMOD3;RETSAT	0.43	6.89	0.3	1.8e-11	Cognitive performance;
LGG	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg08305652	chr11:111469057	NA	-0.45	-9.25	-0.39	8.19e-19	Primary sclerosing cholangitis;
LGG	cis	rs9308731	0.644	rs1439287	chr2:111871897	G/A	cg19992207	chr2:111874495	ACOXL	-0.37	-6.71	-0.3	5.85e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9649465	1.000	rs6951138	chr7:123362070	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg06917634	chr15:78832804	PSMA4	0.66	12.16	0.49	9.9e-30	Sudden cardiac arrest;
LGG	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg06392426	chr19:10676186	KRI1	0.65	10.91	0.45	7.93e-25	Red cell distribution width;
LGG	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg19761014	chr17:28927070	LRRC37B2	0.61	7.29	0.32	1.37e-12	Body mass index;
LGG	cis	rs4919694	0.667	rs75890466	chr10:105076383	C/T	cg04362960	chr10:104952993	NT5C2	0.93	11.8	0.48	2.74e-28	Arsenic metabolism;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg14004847	chr7:1930337	MAD1L1	0.51	9.0	0.39	5.78e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.49	-0.33	3.4e-13	Life satisfaction;
LGG	cis	rs698833	0.828	rs2850298	chr2:44731590	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.49	7.32	0.32	1.13e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs1814175	0.935	rs7479914	chr11:49661351	T/C	cg03929089	chr4:120376271	NA	-1.02	-22.56	-0.72	1.44e-76	Height;
LGG	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg21226059	chr5:178986404	RUFY1	-0.46	-8.18	-0.36	2.75e-15	Lung cancer;
LGG	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs908922	0.676	rs1856119	chr1:152512483	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.68	-12.88	-0.51	1.13e-32	Lymphocyte counts;
LGG	cis	rs3741151	0.686	rs12285885	chr11:73294478	A/G	cg17517138	chr11:73019481	ARHGEF17	0.71	7.48	0.33	3.64e-13	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg11441553	chr12:57614120	NXPH4	-0.6	-7.48	-0.33	3.72e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4974559	0.947	rs58750335	chr4:1364764	G/A	cg02980000	chr4:1222292	CTBP1	0.66	7.85	0.34	3.02e-14	Systolic blood pressure;
LGG	cis	rs1538970	0.504	rs3790585	chr1:46023356	A/T	cg05343316	chr1:45956843	TESK2	0.65	8.35	0.36	8.12e-16	Platelet count;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg04025307	chr7:1156635	C7orf50	0.69	8.67	0.37	7.56e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg14004847	chr7:1930337	MAD1L1	-0.6	-10.69	-0.44	5.51e-24	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.66e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs12453935	0.627	rs6504074	chr17:59899790	G/T	cg14757157	chr17:59911755	BRIP1	0.31	6.77	0.3	3.83e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs2028299	1.000	rs4932143	chr15:90372067	G/C	cg23731826	chr15:90371692	NA	0.38	8.9	0.38	1.24e-17	Type 2 diabetes;
LGG	cis	rs7223966	1.000	rs9899788	chr17:61756384	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	2e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9650657	0.707	rs2005309	chr8:10652170	T/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.25	-0.32	1.8e-12	Neuroticism;
LGG	cis	rs1062746	0.528	rs12149622	chr16:87340235	A/G	cg02258303	chr16:87377426	FBXO31	-0.43	-7.86	-0.34	2.79e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs4664308	0.870	rs2305818	chr2:161029218	G/A	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.96	-0.6	5.09e-46	Idiopathic membranous nephropathy;
LGG	cis	rs1865760	0.593	rs9393676	chr6:25936944	G/A	cg17691542	chr6:26056736	HIST1H1C	0.49	8.48	0.37	2.94e-16	Height;
LGG	cis	rs2290159	0.800	rs5746195	chr3:12653800	A/G	cg23032965	chr3:12705835	RAF1	0.67	9.72	0.41	1.97e-20	Cholesterol, total;
LGG	cis	rs9926296	0.632	rs9935559	chr16:89800529	C/T	cg23057051	chr16:89984268	MC1R	0.36	6.86	0.3	2.15e-11	Vitiligo;
LGG	cis	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg24110177	chr3:50126178	RBM5	0.39	6.78	0.3	3.59e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg13866156	chr1:1669148	SLC35E2	0.66	12.98	0.52	4.53e-33	Body mass index;
LGG	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg26384229	chr12:38710491	ALG10B	-0.84	-19.53	-0.67	2.15e-62	Heart rate;
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg06873352	chr17:61820015	STRADA	0.74	13.95	0.54	3.47e-37	Prudent dietary pattern;
LGG	cis	rs769267	0.566	rs9304962	chr19:19679992	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.44	-6.79	-0.3	3.38e-11	Tonsillectomy;
LGG	cis	rs8070463	0.515	rs11655943	chr17:45385640	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.6	-0.37	1.23e-16	Multiple sclerosis;Ankylosing spondylitis;
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.92	0.68	3.36e-64	Platelet count;
LGG	cis	rs12780845	0.540	rs11254435	chr10:17224426	A/T	cg01003015	chr10:17271136	VIM	0.41	7.03	0.31	7.27e-12	Homocysteine levels;
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg14092988	chr3:52407081	DNAH1	0.28	7.23	0.32	2.05e-12	Bipolar disorder;
LGG	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg11812906	chr14:75593930	NEK9	-0.52	-9.2	-0.39	1.2e-18	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19125715	chr8:67525489	MYBL1	0.46	7.67	0.34	1.04e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs112591243	0.685	rs2839294	chr21:47917664	T/C	cg10657630	chr21:48055338	PRMT2	0.87	7.67	0.34	1.01e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs2576037	0.583	rs9947131	chr18:44534769	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.22	-0.39	1.02e-18	Personality dimensions;
LGG	cis	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.28	-0.43	1.76e-22	Diabetic kidney disease;
LGG	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg03605463	chr16:89740564	NA	0.62	11.17	0.46	8.18e-26	Vitiligo;
LGG	cis	rs9467160	0.651	rs9393558	chr6:24454196	G/T	cg20631270	chr6:24437470	GPLD1	0.46	7.76	0.34	5.63e-14	Liver enzyme levels;
LGG	cis	rs13272623	0.536	rs11985127	chr8:71743943	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	0.79	8.36	0.36	7.63e-16	IgG glycosylation;
LGG	trans	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.97	0.45	4.87e-25	Resting heart rate;
LGG	cis	rs883565	0.655	rs4676670	chr3:39049594	A/C	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	cis	rs368123	0.960	rs373715	chr6:160716460	T/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.13e-12	Waist circumference;
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg13009111	chr11:71350975	NA	0.38	8.54	0.37	1.94e-16	Monocyte count;
LGG	cis	rs7949566	0.801	rs11220475	chr11:126272158	A/C	cg05055844	chr11:126275997	ST3GAL4	0.44	9.63	0.41	4.1e-20	Platelet distribution width;Mean platelet volume;
LGG	cis	rs7811142	1.000	rs113738841	chr7:100081306	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs9487094	0.645	rs34533653	chr6:109800691	T/A	cg16315928	chr6:109776240	MICAL1	0.5	7.65	0.34	1.17e-13	Height;
LGG	cis	rs654950	0.934	rs665223	chr1:42000654	A/T	cg06885757	chr1:42089581	HIVEP3	-0.61	-13.85	-0.54	9.85e-37	Airway imaging phenotypes;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.44e-19	Bladder cancer;
LGG	cis	rs10870270	0.830	rs11146269	chr10:133761820	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.72	-0.51	5.38e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg03264133	chr6:25882463	NA	-0.41	-7.12	-0.31	4.13e-12	Height;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg05368731	chr17:41323189	NBR1	0.85	16.38	0.61	6.84e-48	Menopause (age at onset);
LGG	cis	rs9393692	0.620	rs9379842	chr6:26289310	C/T	cg13736514	chr6:26305472	NA	0.46	9.1	0.39	2.69e-18	Educational attainment;
LGG	cis	rs807669	0.770	rs807458	chr22:19220648	G/A	cg26795923	chr22:19165960	SLC25A1	0.94	8.81	0.38	2.51e-17	Metabolite levels;
LGG	cis	rs4319547	0.656	rs9788145	chr12:122899522	C/T	cg23029597	chr12:123009494	RSRC2	-0.93	-17.32	-0.63	3.54e-52	Body mass index;
LGG	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg11812906	chr14:75593930	NEK9	0.55	10.14	0.43	6.11e-22	Height;
LGG	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg12573674	chr2:1569213	NA	-0.61	-9.05	-0.39	4.11e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg18350739	chr11:68623251	NA	0.54	12.2	0.49	7.03e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs453301	0.579	rs10096850	chr8:8798222	A/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.99	-0.31	9.56e-12	Joint mobility (Beighton score);
LGG	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg15979348	chr13:112237479	NA	-0.46	-7.93	-0.35	1.7e-14	Menarche (age at onset);
LGG	cis	rs853679	0.517	rs2275508	chr6:28094731	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.73	0.3	4.88e-11	Depression;
LGG	cis	rs634534	0.563	rs470192	chr11:65724291	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	7.36	0.32	8.62e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00114084	chr1:33502651	AK2	0.39	7.1	0.31	4.77e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.17	-0.32	2.9e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6558174	0.965	rs2003908	chr8:22491518	T/C	cg03733263	chr8:22462867	KIAA1967	0.65	10.68	0.44	5.97e-24	Breast cancer;
LGG	cis	rs9399137	0.507	rs6918512	chr6:135284839	T/G	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.25	0.46	4.05e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs911186	0.786	rs13211901	chr6:27187612	G/A	cg12292205	chr6:26970375	C6orf41	-0.66	-9.62	-0.41	4.14e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.4	6.86	0.3	2.24e-11	Longevity;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg09303159	chr6:26284866	NA	0.37	8.18	0.36	2.8e-15	Educational attainment;
LGG	cis	rs1691799	0.867	rs1168316	chr12:66746239	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg08994789	chr17:28903642	LRRC37B2	0.59	7.1	0.31	4.84e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.79	0.3	3.43e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg11584989	chr19:19387371	SF4	-0.38	-6.75	-0.3	4.42e-11	Tonsillectomy;
LGG	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs240764	0.619	rs17190683	chr6:101158143	A/C	cg09795085	chr6:101329169	ASCC3	0.41	6.85	0.3	2.4e-11	Neuroticism;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.07	-0.31	5.79e-12	Bipolar disorder;
LGG	cis	rs4824093	0.610	rs7410773	chr22:50313727	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.81	-6.76	-0.3	4.09e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	10.14	0.43	6.01e-22	Obesity-related traits;
LGG	cis	rs62244186	0.748	rs12635624	chr3:44678498	G/A	cg15225532	chr3:44803084	KIF15;KIAA1143	0.4	6.84	0.3	2.5e-11	Depressive symptoms;
LGG	cis	rs3796727	0.690	rs6447885	chr4:8620023	G/A	cg05284713	chr4:8621361	CPZ	-0.34	-6.89	-0.3	1.89e-11	Sporadic neuroblastoma;
LGG	cis	rs4566357	1.000	rs2396444	chr2:227921314	T/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.29	0.46	2.73e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.92	0.42	3.66e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06925236	chr11:68039653	C11orf24	0.39	6.67	0.3	7.26e-11	Menarche (age at onset);
LGG	cis	rs4740619	0.766	rs11521158	chr9:15801649	T/C	cg14451791	chr9:16040625	NA	0.32	8.09	0.35	5.21e-15	Body mass index;
LGG	cis	rs7192750	0.586	rs9934812	chr16:71981652	T/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.71	0.45	4.59e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs9467711	0.722	rs35825164	chr6:26117404	T/C	cg06606381	chr12:133084897	FBRSL1	-0.71	-7.0	-0.31	9.29e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12291225	0.585	rs4757250	chr11:14375683	C/A	cg19336497	chr11:14380999	RRAS2	-0.63	-13.2	-0.52	5.51e-34	Sense of smell;
LGG	cis	rs11098499	0.739	rs2203039	chr4:120132347	T/C	cg09307838	chr4:120376055	NA	-0.58	-9.35	-0.4	3.81e-19	Corneal astigmatism;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg15242686	chr22:24348715	GSTTP1	0.39	7.23	0.32	2.07e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs56104184	0.725	rs4347731	chr19:49385154	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.64	-9.05	-0.39	4.01e-18	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6594713	0.605	rs66540465	chr5:112840706	G/A	cg12552261	chr5:112820674	MCC	0.64	8.06	0.35	6.58e-15	Brain cytoarchitecture;
LGG	cis	rs1966248	0.543	rs1414668	chr6:134108060	C/T	cg25632230	chr6:134101081	NA	0.34	7.44	0.33	4.89e-13	Coronary artery disease;
LGG	cis	rs3764563	1.000	rs681417	chr19:15694802	G/T	cg20725493	chr19:15740067	CYP4F8	0.57	6.79	0.3	3.52e-11	Inflammatory biomarkers;
LGG	cis	rs738321	0.756	rs11089863	chr22:38512402	G/A	cg25457927	chr22:38595422	NA	-0.36	-8.33	-0.36	9.43e-16	Breast cancer;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg06719900	chr11:109292894	C11orf87	0.45	8.43	0.36	4.57e-16	Schizophrenia;
LGG	cis	rs5769765	0.874	rs11703411	chr22:50258751	G/A	cg02269571	chr22:50332266	NA	0.62	9.98	0.42	2.28e-21	Schizophrenia;
LGG	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.32	-0.32	1.09e-12	Obesity (extreme);
LGG	cis	rs208520	0.690	rs4710564	chr6:66823478	A/G	cg07460842	chr6:66804631	NA	0.93	15.82	0.59	2.29e-45	Exhaled nitric oxide output;
LGG	cis	rs7223966	1.000	rs73337598	chr17:61732576	T/C	cg05941027	chr17:61774174	LIMD2	0.34	8.66	0.37	7.66e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3857067	0.933	rs10023582	chr4:95035811	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.71	-0.34	7.53e-14	QT interval;
LGG	cis	rs7786808	0.552	rs896762	chr7:158182029	A/G	cg01191920	chr7:158217561	PTPRN2	0.73	15.73	0.59	5.53e-45	Obesity-related traits;
LGG	cis	rs12477438	0.798	rs6542848	chr2:99573732	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs9287719	0.967	rs12464817	chr2:10707212	A/G	cg02196655	chr2:10830764	NOL10	-0.42	-7.19	-0.32	2.7e-12	Prostate cancer;
LGG	cis	rs7659604	0.540	rs11724322	chr4:122697850	A/T	cg20573242	chr4:122745356	CCNA2	-0.47	-8.14	-0.35	3.58e-15	Type 2 diabetes;
LGG	cis	rs1816752	1.000	rs9511265	chr13:25012359	T/C	cg02811702	chr13:24901961	NA	0.43	7.95	0.35	1.42e-14	Obesity-related traits;
LGG	trans	rs9409565	0.855	rs7042481	chr9:97064273	C/A	cg05679027	chr9:99775184	HIATL2	0.51	8.4	0.36	5.57e-16	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs1847202	0.826	rs7640629	chr3:72925997	C/T	cg25664220	chr3:72788482	NA	-0.27	-7.71	-0.34	7.76e-14	Motion sickness;
LGG	trans	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg12575136	chr18:32820987	ZNF397	0.47	8.66	0.37	7.7e-17	White blood cell count;
LGG	cis	rs1153858	0.832	rs1145078	chr15:45682277	C/T	cg21132104	chr15:45694354	SPATA5L1	0.71	10.48	0.44	3.42e-23	Homoarginine levels;
LGG	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.04e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12210905	0.925	rs72838245	chr6:26987316	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.63	-0.48	1.38e-27	Mean platelet volume;Platelet distribution width;
LGG	trans	rs9393777	0.841	rs34332556	chr6:27357414	C/G	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.64	-0.44	8.52e-24	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.61	-0.41	4.5e-20	Triglycerides;
LGG	cis	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg04568710	chr12:38710424	ALG10B	0.34	6.81	0.3	3.08e-11	Morning vs. evening chronotype;
LGG	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.1	0.31	4.58e-12	Height;
LGG	cis	rs9916302	0.861	rs632202	chr17:37453294	C/A	cg00129232	chr17:37814104	STARD3	0.6	11.34	0.47	1.82e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs701145	0.585	rs357482	chr3:153889855	A/G	cg17054900	chr3:154042577	DHX36	0.82	9.7	0.41	2.17e-20	Coronary artery disease;
LGG	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg17467752	chr17:38218738	THRA	-0.47	-7.46	-0.33	4.31e-13	Self-reported allergy;
LGG	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg18196295	chr10:418757	DIP2C	-0.57	-11.14	-0.46	1.02e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.83	-0.59	1.91e-45	Skin colour saturation;
LGG	cis	rs7928758	0.943	rs79449985	chr11:134265121	C/T	cg22777979	chr11:134283252	B3GAT1	0.92	11.79	0.48	2.97e-28	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1568889	0.838	rs10835299	chr11:28277693	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.86	-18.85	-0.66	3.22e-59	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.62e-18	Menopause (age at onset);
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg06654118	chr4:1303317	MAEA	0.4	6.92	0.31	1.52e-11	Obesity-related traits;
LGG	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg03060546	chr3:49711283	APEH	0.58	8.86	0.38	1.71e-17	Resting heart rate;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg21782813	chr7:2030301	MAD1L1	0.51	12.26	0.5	4e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs79146658	0.920	rs12693173	chr2:179757013	C/T	cg17765952	chr2:179737173	CCDC141	-0.54	-7.71	-0.34	8e-14	Diastolic blood pressure;
LGG	cis	rs7208859	0.673	rs9915963	chr17:29019643	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	10.43	0.44	5.08e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg15971980	chr6:150254442	NA	0.46	8.71	0.38	5.32e-17	Lung cancer;
LGG	cis	rs2933343	1.000	rs789227	chr3:128600585	C/G	cg25356066	chr3:128598488	ACAD9	0.45	6.68	0.3	6.79e-11	IgG glycosylation;
LGG	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.56	0.37	1.67e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4423214	0.879	rs736894	chr11:71152258	A/G	cg05163923	chr11:71159392	DHCR7	0.63	11.29	0.46	2.81e-26	Vitamin D levels;
LGG	cis	rs2694528	0.844	rs7701624	chr5:60027752	C/T	cg11474532	chr5:59995715	DEPDC1B	0.77	7.88	0.34	2.39e-14	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.44	7.19	0.32	2.6e-12	Cognitive performance;
LGG	cis	rs12282928	1.000	rs12292297	chr11:48329794	C/A	cg26585981	chr11:48327164	OR4S1	0.45	7.24	0.32	1.9e-12	Migraine - clinic-based;
LGG	cis	rs11748327	0.580	rs7732134	chr5:4008585	C/T	cg01025095	chr5:4101132	NA	-0.44	-7.09	-0.31	4.94e-12	Myocardial infarction;
LGG	cis	rs4865875	1.000	rs10940428	chr5:54104649	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg24503407	chr1:205819492	PM20D1	0.49	8.15	0.35	3.45e-15	Parkinson's disease;
LGG	cis	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg12432903	chr7:1882776	MAD1L1	0.49	8.67	0.37	7.3e-17	Bipolar disorder;
LGG	cis	rs35146811	0.807	rs6953441	chr7:99617067	G/A	cg22906224	chr7:99728672	NA	0.55	8.94	0.38	9.65e-18	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs4960412	chr6:8438261	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.22	0.43	3.01e-22	Motion sickness;
LGG	cis	rs774359	0.789	rs2764331	chr9:27492934	C/T	cg22262168	chr9:27528999	MOBKL2B	0.45	6.91	0.31	1.64e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs35306767	0.903	rs765867	chr10:869901	G/T	cg26597838	chr10:835615	NA	0.76	10.5	0.44	2.71e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs12451471	0.559	rs1042396	chr17:78084769	G/A	cg24585782	chr17:78113791	EIF4A3	-0.47	-7.85	-0.34	3.02e-14	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg04503457	chr17:41445688	NA	-0.39	-8.83	-0.38	2.12e-17	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg26174226	chr8:58114915	NA	-0.51	-7.41	-0.33	5.97e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs2238527	chr16:89840708	C/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs7737355	0.812	rs244735	chr5:130818061	C/T	cg06307176	chr5:131281290	NA	0.51	8.46	0.37	3.49e-16	Life satisfaction;
LGG	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.86e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs524281	1.000	rs524281	chr11:65886662	C/A	cg14541915	chr11:65894463	PACS1	-0.3	-6.8	-0.3	3.23e-11	Electroencephalogram traits;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg04863758	chr4:1303710	MAEA	0.45	7.61	0.33	1.55e-13	Obesity-related traits;
LGG	cis	rs12410462	0.591	rs2814059	chr1:227721233	A/G	cg23173402	chr1:227635558	NA	0.37	6.99	0.31	9.62e-12	Major depressive disorder;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg05091796	chr16:4465799	CORO7	-0.59	-9.53	-0.4	9.09e-20	Schizophrenia;
LGG	cis	rs2735413	0.709	rs8051521	chr16:78088156	G/C	cg04733911	chr16:78082701	NA	0.75	16.12	0.6	1.05e-46	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9341835	0.772	rs4445042	chr6:64139997	C/T	cg00787780	chr6:64151745	NA	0.41	7.4	0.33	6.43e-13	Schizophrenia;
LGG	cis	rs250677	0.652	rs250670	chr5:148446646	G/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.16	-0.32	3.14e-12	Breast cancer;
LGG	cis	rs11920090	0.932	rs12496734	chr3:170693767	C/G	cg09710316	chr3:170744871	SLC2A2	0.59	8.41	0.36	5.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2243480	1.000	rs160634	chr7:65528664	C/T	cg12463550	chr7:65579703	CRCP	-0.74	-8.06	-0.35	6.57e-15	Diabetic kidney disease;
LGG	cis	rs4330281	0.630	rs4482690	chr3:17767046	T/A	cg20981856	chr3:17787350	NA	-0.42	-7.73	-0.34	6.63e-14	Schizophrenia;
LGG	cis	rs12681287	0.640	rs13261901	chr8:87478717	G/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs17253792	0.822	rs79398217	chr14:56067350	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs9902453	0.817	rs62068625	chr17:28176581	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.0	0.55	2.18e-37	Coffee consumption (cups per day);
LGG	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg10204951	chr7:910479	UNC84A	-0.53	-7.17	-0.32	2.98e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6860806	0.507	rs200837	chr5:131699958	G/A	cg07395648	chr5:131743802	NA	-0.49	-10.02	-0.42	1.67e-21	Breast cancer;
LGG	cis	rs3816183	0.626	rs11690432	chr2:42910983	A/T	cg14631114	chr2:43023945	NA	0.36	7.14	0.31	3.68e-12	Hypospadias;
LGG	cis	rs7747724	0.715	rs4712545	chr6:20774410	A/G	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.49	-0.4	1.24e-19	Bladder cancer;
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg20790798	chr5:1857306	NA	-0.44	-7.18	-0.32	2.86e-12	Cardiovascular disease risk factors;
LGG	cis	rs9790314	0.535	rs4679922	chr3:160642984	T/C	cg03342759	chr3:160939853	NMD3	0.43	7.11	0.31	4.34e-12	Morning vs. evening chronotype;
LGG	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs888194	0.898	rs10850379	chr12:110002777	A/G	cg08884029	chr12:110012500	MVK;MMAB	0.35	7.24	0.32	1.83e-12	Neuroticism;
LGG	cis	rs2354432	1.000	rs10900325	chr1:146692174	C/T	cg25205988	chr1:146714368	CHD1L	-1.26	-16.35	-0.6	9.69e-48	Mitochondrial DNA levels;
LGG	cis	rs8032158	0.702	rs2414444	chr15:56128117	C/T	cg02198044	chr15:56286336	NEDD4	0.5	8.44	0.37	4.05e-16	Keloid;
LGG	cis	rs9354308	0.738	rs1353874	chr6:66609996	T/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs3771570	1.000	rs4675811	chr2:242402062	A/T	cg21155796	chr2:242212141	HDLBP	0.61	8.19	0.36	2.53e-15	Prostate cancer;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg08621203	chr6:150244597	RAET1G	0.53	9.65	0.41	3.51e-20	Testicular germ cell tumor;
LGG	cis	rs9952991	0.882	rs2847274	chr18:12777603	T/C	cg23544223	chr18:12777786	NA	0.62	9.38	0.4	2.95e-19	Inflammatory skin disease;
LGG	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.35	-0.47	1.62e-26	Blood metabolite levels;
LGG	cis	rs1109114	1.000	rs59032271	chr5:148618749	C/T	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.27	-0.58	6.01e-43	Body mass index;
LGG	cis	rs1790761	0.554	rs12787511	chr11:67401635	G/C	cg23188684	chr11:67383651	NA	-0.52	-7.89	-0.34	2.2e-14	Mean corpuscular volume;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.69	-12.36	-0.5	1.59e-30	Obesity-related traits;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg06108461	chr20:60628389	TAF4	0.69	9.98	0.42	2.27e-21	Obesity-related traits;
LGG	cis	rs4820294	0.646	rs9622675	chr22:38053665	G/T	cg10587741	chr22:38071170	LGALS1	0.59	13.58	0.53	1.32e-35	Fat distribution (HIV);
LGG	cis	rs963731	0.579	rs1947433	chr2:39227481	A/G	cg04010122	chr2:39346883	SOS1	-0.68	-6.93	-0.31	1.42e-11	Corticobasal degeneration;
LGG	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg25706281	chr1:46860511	FAAH	-0.28	-6.84	-0.3	2.58e-11	Menopause (age at onset);
LGG	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.8	14.28	0.55	1.41e-38	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.85	0.42	6.4e-21	Schizophrenia;
LGG	cis	rs9291683	0.588	rs6844329	chr4:10018544	T/C	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.37e-14	Bone mineral density;
LGG	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.54	0.33	2.5e-13	Retinal vascular caliber;
LGG	cis	rs2820292	0.678	rs4494199	chr1:201884668	C/T	cg10061532	chr1:201886748	LMOD1	0.29	6.68	0.3	6.8e-11	Waist circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs1552244	0.882	rs9812006	chr3:10022658	T/C	cg08888203	chr3:10149979	C3orf24	0.51	8.49	0.37	2.88e-16	Alzheimer's disease;
LGG	trans	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg06606381	chr12:133084897	FBRSL1	-0.79	-7.37	-0.32	8.03e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.88	-0.34	2.42e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.590	rs7582341	chr2:26416301	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.573	rs73277960	chr17:29177441	T/C	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3540	0.574	rs8035980	chr15:90974390	C/G	cg22089800	chr15:90895588	ZNF774	0.68	12.44	0.5	7.26e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs1385374	0.858	rs10773578	chr12:129290026	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs17491951	0.706	rs13034398	chr2:2887003	C/T	cg02105481	chr2:2853515	NA	-0.43	-8.83	-0.38	2.24e-17	White matter integrity (bipolar disorder risk interaction);
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs2694528	0.858	rs6893210	chr5:60434760	A/T	cg11474532	chr5:59995715	DEPDC1B	0.68	7.29	0.32	1.35e-12	Parkinson's disease;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.07	-0.31	5.77e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg18681998	chr4:17616180	MED28	0.82	17.79	0.64	2.44e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1144	0.537	rs2470943	chr7:104583843	C/T	cg03782966	chr7:104585482	NA	0.35	8.02	0.35	8.74e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs9457247	1.000	rs386548	chr6:167385533	A/T	cg07741184	chr6:167504864	NA	-0.32	-7.11	-0.31	4.45e-12	Crohn's disease;
LGG	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg17545662	chr6:170176663	C6orf70	0.67	8.03	0.35	7.92e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-10.12	-0.43	7.05e-22	Glycated hemoglobin levels;
LGG	cis	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs9911578	0.904	rs7209253	chr17:56908987	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.6	10.64	0.44	8.31e-24	Birth weight;
LGG	trans	rs637571	0.522	rs542332	chr11:65744421	C/T	cg17712092	chr4:129076599	LARP1B	0.74	14.34	0.55	7.19e-39	Eosinophil percentage of white cells;
LGG	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	7.73	0.34	6.61e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg07701084	chr6:150067640	NUP43	0.49	7.52	0.33	2.96e-13	Lung cancer;
LGG	cis	rs427394	0.659	rs419128	chr5:6739791	G/A	cg15145174	chr5:6755386	POLS	-0.44	-8.13	-0.35	3.96e-15	Menopause (age at onset);
LGG	cis	rs7172689	1.000	rs4128768	chr15:81543267	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.31	-0.43	1.45e-22	Inattentive symptoms;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.76	-0.38	3.84e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.735	rs2454450	chr15:76831236	G/A	cg23625390	chr15:77176239	SCAPER	-0.68	-13.71	-0.54	3.86e-36	Blood metabolite levels;
LGG	trans	rs826838	0.967	rs11183577	chr12:38781887	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.7	-0.34	8.55e-14	Heart rate;
LGG	trans	rs2562456	0.833	rs7246339	chr19:21475297	T/C	cg00806126	chr19:22604979	ZNF98	-0.56	-7.33	-0.32	1.04e-12	Pain;
LGG	cis	rs432925	0.529	rs9925945	chr16:393564	A/C	cg00101154	chr16:420108	MRPL28	-0.46	-6.71	-0.3	5.55e-11	Morning vs. evening chronotype;
LGG	cis	rs10078	0.571	rs2721014	chr5:463539	G/A	cg07599136	chr5:415885	AHRR	0.85	11.58	0.47	2.06e-27	Fat distribution (HIV);
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg02772935	chr3:125709198	NA	-0.54	-6.97	-0.31	1.1e-11	Blood pressure (smoking interaction);
LGG	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg14416269	chr4:6271139	WFS1	0.51	9.6	0.41	4.86e-20	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs113084984	0.718	rs4669746	chr2:11682018	G/A	cg07314298	chr2:11723111	GREB1	0.36	6.67	0.3	7.11e-11	Breast cancer;
LGG	cis	rs600231	0.542	rs10896009	chr11:65246054	A/G	cg17120908	chr11:65337727	SSSCA1	0.58	8.36	0.36	7.43e-16	Bone mineral density;
LGG	cis	rs1256061	0.603	rs1256039	chr14:64738979	G/C	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs67133203	0.851	rs12366756	chr12:51403206	A/G	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.71e-30	Urinary tract infection frequency;
LGG	cis	rs3733585	0.673	rs116046986	chr4:9957794	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.92	-0.31	1.55e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6831352	0.918	rs29001195	chr4:100054244	G/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.42	-0.33	5.83e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19972287	chr10:38689165	CDC10L	-0.58	-7.32	-0.32	1.1e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9868809	0.881	rs13096357	chr3:48675856	C/A	cg00383909	chr3:49044727	WDR6	0.81	9.34	0.4	4.12e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg06133097	chr7:32552212	AVL9	0.38	7.04	0.31	7.14e-12	Cognitive ability;
LGG	cis	rs11758351	0.925	rs2183948	chr6:26180332	A/G	cg06951627	chr6:26196580	NA	0.53	7.85	0.34	2.87e-14	Gout;Renal underexcretion gout;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25072359	chr17:41440525	NA	0.5	9.67	0.41	2.94e-20	Menopause (age at onset);
LGG	cis	rs17221829	0.733	rs10765228	chr11:89385132	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.12	-0.39	2.26e-18	Anxiety in major depressive disorder;
LGG	cis	rs2688608	0.653	rs12775558	chr10:75570868	G/A	cg04320760	chr10:75533139	FUT11	-0.41	-6.82	-0.3	2.92e-11	Inflammatory bowel disease;
LGG	cis	rs1018836	0.770	rs13266461	chr8:91652817	T/C	cg16814680	chr8:91681699	NA	-0.97	-20.08	-0.68	5.79e-65	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg15557168	chr22:42548783	NA	-0.38	-8.39	-0.36	6.15e-16	Schizophrenia;
LGG	cis	rs10851411	0.559	rs17767270	chr15:42898612	A/G	cg21293051	chr15:42870591	STARD9	-0.47	-7.01	-0.31	8.63e-12	Glucose homeostasis traits;
LGG	cis	rs9308731	0.931	rs616130	chr2:111912681	C/A	cg19992207	chr2:111874495	ACOXL	-0.39	-7.02	-0.31	8.18e-12	Chronic lymphocytic leukemia;
LGG	cis	rs4979906	1.000	rs68092325	chr10:79446719	T/A	cg07817648	chr10:79422355	NA	-0.5	-7.97	-0.35	1.29e-14	Mortality in heart failure;
LGG	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Bladder cancer;
LGG	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.93	-0.35	1.63e-14	Bladder cancer;
LGG	cis	rs28595532	0.920	rs114382134	chr4:119733215	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.07e-15	Aortic root size;
LGG	cis	rs1555895	0.544	rs1555897	chr10:853674	A/C	cg09361094	chr10:834503	NA	-0.29	-7.75	-0.34	5.81e-14	Survival in rectal cancer;
LGG	cis	rs1577917	0.629	rs9450285	chr6:86208096	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	8.06	0.35	6.34e-15	Response to antipsychotic treatment;
LGG	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Colorectal cancer;
LGG	cis	rs17767392	0.881	rs8006300	chr14:72050162	C/T	cg13720639	chr14:72061746	SIPA1L1	0.37	8.2	0.36	2.43e-15	Mitral valve prolapse;
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg00080972	chr5:178986291	RUFY1	-0.54	-8.82	-0.38	2.42e-17	Lung cancer;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.56	0.37	1.68e-16	Bipolar disorder;
LGG	cis	rs7100689	0.646	rs10466235	chr10:82149655	C/T	cg01528321	chr10:82214614	TSPAN14	-0.83	-14.83	-0.57	5.29e-41	Post bronchodilator FEV1;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg13012494	chr21:47604986	C21orf56	0.51	8.45	0.37	3.86e-16	Testicular germ cell tumor;
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg14689365	chr7:158441557	NCAPG2	0.59	9.99	0.42	2.15e-21	Height;
LGG	cis	rs6868223	0.617	rs6870538	chr5:33648906	G/C	cg10594543	chr5:33649717	ADAMTS12	0.66	15.5	0.58	6.2e-44	Mortality in heart failure;
LGG	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.71	-0.34	7.97e-14	Educational attainment;
LGG	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg11965913	chr1:205819406	PM20D1	-0.41	-6.89	-0.3	1.84e-11	Menarche (age at onset);
LGG	cis	rs7681423	1.000	rs7681423	chr4:155542248	C/T	cg20735720	chr4:155535218	FGG	-0.59	-10.86	-0.45	1.29e-24	Fibrinogen;
LGG	cis	rs4555082	0.957	rs2975216	chr14:105713134	T/C	cg06808227	chr14:105710500	BRF1	-0.65	-12.02	-0.49	3.63e-29	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg00717180	chr2:96193071	NA	-0.42	-7.48	-0.33	3.76e-13	HDL cholesterol;
LGG	cis	rs6547741	0.816	rs10201652	chr2:27874332	A/C	cg22903471	chr2:27725779	GCKR	-0.36	-7.98	-0.35	1.19e-14	Oral cavity cancer;
LGG	cis	rs4919087	0.715	rs8181326	chr10:98998195	G/A	cg25902810	chr10:99078978	FRAT1	0.46	8.22	0.36	2.13e-15	Monocyte count;
LGG	cis	rs2734839	0.537	rs11214603	chr11:113279922	G/A	cg14373873	chr11:113211441	TTC12	0.41	8.26	0.36	1.49e-15	Information processing speed;
LGG	cis	rs67366981	1.000	rs55923743	chr14:77711454	G/A	cg22824376	chr14:77648248	TMEM63C	0.68	7.29	0.32	1.36e-12	Obsessive-compulsive symptoms;
LGG	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/G	cg20655648	chr15:75932815	IMP3	0.47	7.79	0.34	4.31e-14	Sudden cardiac arrest;
LGG	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21941374	chr3:120461451	GTF2E1;RABL3	0.46	7.42	0.33	5.58e-13	Cognitive performance;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.99	0.35	1.11e-14	Personality dimensions;
LGG	cis	rs4595586	0.545	rs11609541	chr12:39378331	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg14893161	chr1:205819251	PM20D1	0.48	7.69	0.34	9.15e-14	Parkinson's disease;
LGG	trans	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg16141378	chr3:129829833	LOC729375	0.49	11.04	0.46	2.65e-25	Neuroticism;
LGG	cis	rs2860975	0.875	rs2211272	chr10:96765905	G/A	cg09036531	chr10:96991505	NA	-0.49	-9.07	-0.39	3.36e-18	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7223966	1.000	rs11542436	chr17:61778689	A/C	cg05941027	chr17:61774174	LIMD2	0.37	9.5	0.4	1.17e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.85e-20	Bone mineral density;
LGG	cis	rs888468	1.000	rs12368351	chr12:4535781	G/A	cg25948690	chr12:4554596	FGF6	0.39	6.66	0.3	7.98e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg03315344	chr16:75512273	CHST6	0.5	10.14	0.43	5.69e-22	Dupuytren's disease;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.17e-35	Personality dimensions;
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.05	0.35	7.24e-15	Lung cancer;
LGG	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg06970220	chr1:156163860	SLC25A44	0.44	6.65	0.3	8.29e-11	Testicular germ cell tumor;
LGG	cis	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg21775007	chr8:11205619	TDH	0.64	11.08	0.46	1.85e-25	Retinal vascular caliber;
LGG	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.82	0.42	8.25e-21	Primary sclerosing cholangitis;
LGG	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs10463554	0.927	rs158250	chr5:102406779	G/C	cg23492399	chr5:102201601	PAM	-0.51	-7.58	-0.33	1.92e-13	Parkinson's disease;
LGG	cis	rs7587476	0.601	rs6715570	chr2:215673440	T/C	cg04530015	chr2:215796436	ABCA12	0.47	8.67	0.37	7.59e-17	Neuroblastoma;
LGG	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg05623727	chr3:50126028	RBM5	0.36	6.74	0.3	4.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11920090	0.800	rs11917504	chr3:170736708	A/T	cg09710316	chr3:170744871	SLC2A2	0.64	8.79	0.38	2.91e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.26	-0.32	1.7e-12	Height;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-1.09	-32.95	-0.84	1.85e-123	Birth weight;
LGG	trans	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.67	-0.37	7.15e-17	Triglycerides;
LGG	cis	rs9309473	0.687	rs6710659	chr2:73607510	A/G	cg20560298	chr2:73613845	ALMS1	-0.5	-8.98	-0.39	6.7e-18	Metabolite levels;
LGG	cis	rs12049351	0.612	rs10916487	chr1:229612742	A/T	cg13547644	chr1:229569608	ACTA1	0.32	7.06	0.31	6.1e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs12545109	0.800	rs1561224	chr8:57419922	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	trans	rs12439619	1.000	rs35152457	chr15:82546548	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-9.08	-0.39	3.09e-18	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg02002194	chr4:3960332	NA	0.5	9.26	0.4	7.8e-19	Retinal vascular caliber;
LGG	cis	rs7843479	0.965	rs1564305	chr8:21803816	A/C	cg17168535	chr8:21777572	XPO7	0.61	9.99	0.42	2.06e-21	Mean corpuscular volume;
LGG	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.86	0.34	2.76e-14	Response to antipsychotic treatment;
LGG	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.11	0.35	4.55e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2797369	0.713	rs4840177	chr6:101505874	A/G	cg27451362	chr6:101846650	GRIK2	-0.85	-11.38	-0.47	1.3e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs7084402	0.764	rs2033149	chr10:60264741	A/T	cg07615347	chr10:60278583	BICC1	0.53	13.76	0.54	2.38e-36	Refractive error;
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg02725872	chr8:58115012	NA	-1.06	-14.83	-0.57	5.51e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs2067615	0.579	rs1922435	chr12:107082455	A/G	cg15890332	chr12:107067104	RFX4	0.41	11.92	0.48	9.05e-29	Heart rate;
LGG	cis	rs2486288	0.656	rs10519018	chr15:45549265	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.78	0.3	3.78e-11	Glomerular filtration rate;
LGG	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg04691961	chr3:161091175	C3orf57	-0.64	-15.08	-0.57	4.52e-42	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs12995780	chr2:42218610	C/T	cg27252766	chr2:42229092	NA	0.58	8.17	0.36	2.89e-15	Hypospadias;
LGG	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg15556689	chr8:8085844	FLJ10661	0.51	8.82	0.38	2.37e-17	Neuroticism;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01069170	chr19:44031473	ETHE1	0.58	6.69	0.3	6.63e-11	Intelligence (multi-trait analysis);
LGG	cis	rs933688	0.877	rs10474352	chr5:90732225	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.95	18.54	0.65	8.42e-58	Smoking behavior;
LGG	cis	rs12431410	0.550	rs10151510	chr14:60181856	G/A	cg07950296	chr14:60194823	RTN1	-0.39	-7.53	-0.33	2.61e-13	Schizophrenia;
LGG	trans	rs6089829	0.889	rs6122348	chr20:61663921	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9902453	0.791	rs3115086	chr17:28025949	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	14.9	0.57	2.75e-41	Coffee consumption (cups per day);
LGG	trans	rs7762018	0.770	rs3823466	chr6:170189926	C/T	cg11441553	chr12:57614120	NXPH4	-0.61	-8.17	-0.35	2.89e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12318506	0.826	rs11180433	chr12:75661470	T/C	cg04728562	chr12:75699417	CAPS2	-1.1	-9.51	-0.4	1.04e-19	Coronary artery calcification;
LGG	cis	rs17023223	0.553	rs72691108	chr1:119762175	G/A	cg05756136	chr1:119680316	WARS2	-0.42	-7.75	-0.34	5.72e-14	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs4714291	0.802	rs1923465	chr6:39971376	A/T	cg02267698	chr19:7991119	CTXN1	-0.58	-9.24	-0.39	8.77e-19	Strep throat;
LGG	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg20913747	chr6:44695427	NA	-0.62	-10.51	-0.44	2.64e-23	Total body bone mineral density;
LGG	cis	rs1008375	0.863	rs4590022	chr4:17614434	T/C	cg04450456	chr4:17643702	FAM184B	0.32	6.81	0.3	3.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg16103275	chr6:290800	DUSP22	0.49	7.96	0.35	1.33e-14	Menopause (age at onset);
LGG	cis	rs1867631	1.000	rs7546090	chr1:67083981	G/A	cg13052034	chr1:66999238	SGIP1	0.46	8.92	0.38	1.12e-17	Menopause (age at onset);
LGG	cis	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.13	-0.39	2.15e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.68	0.37	6.65e-17	Lung cancer;
LGG	cis	rs11209002	0.567	rs2224501	chr1:67532526	G/T	cg02640540	chr1:67518911	SLC35D1	0.4	6.73	0.3	5.16e-11	Crohn's disease;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg20887711	chr4:1340912	KIAA1530	0.48	8.64	0.37	9.19e-17	Obesity-related traits;
LGG	cis	rs897984	0.762	rs11150601	chr16:30977799	G/A	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs3784262	1.000	rs12908953	chr15:58277812	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.22	-0.36	2.13e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6933660	0.721	rs2128945	chr6:151767907	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	8.03	0.35	8.05e-15	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.9	-0.45	8.65e-25	Lung cancer;
LGG	cis	rs4474465	0.920	rs7947824	chr11:78223731	C/G	cg27205649	chr11:78285834	NARS2	0.49	8.24	0.36	1.73e-15	Alzheimer's disease (survival time);
LGG	cis	rs921968	0.591	rs13421421	chr2:219519286	A/G	cg01130898	chr2:219473002	PLCD4	-0.43	-7.35	-0.32	8.98e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg06634786	chr22:41940651	POLR3H	-0.49	-8.13	-0.35	3.89e-15	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09273779	chr9:35605990	TESK1	0.44	7.11	0.31	4.35e-12	Gut microbiome composition (summer);
LGG	cis	rs9487094	0.666	rs9480956	chr6:109745508	A/C	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.18e-11	Height;
LGG	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg21665744	chr7:39171113	POU6F2	-0.42	-8.75	-0.38	3.98e-17	IgG glycosylation;
LGG	cis	rs4689388	0.889	rs4629534	chr4:6294124	G/T	cg14416269	chr4:6271139	WFS1	0.51	9.35	0.4	3.86e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg10840412	chr1:235813424	GNG4	0.54	7.44	0.33	4.89e-13	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26576481	chr12:76478884	NAP1L1	-0.4	-6.84	-0.3	2.47e-11	Pancreatic cancer;
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-7.99	-0.35	1.06e-14	IgG glycosylation;
LGG	cis	rs60871478	0.945	rs4719279	chr7:813618	T/C	cg04727924	chr7:799746	HEATR2	-0.5	-7.9	-0.34	2.1e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg24642439	chr20:33292090	TP53INP2	-0.54	-9.15	-0.39	1.8e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs2197308	0.703	rs10880251	chr12:37903297	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg00149659	chr3:10157352	C3orf10	0.85	10.97	0.45	4.63e-25	Alzheimer's disease;
LGG	cis	rs975739	0.798	rs2094840	chr13:78613586	T/A	cg07847733	chr13:78271382	SLAIN1	0.38	6.71	0.3	5.77e-11	Hair color;
LGG	cis	rs4664308	0.837	rs56172865	chr2:160967333	C/T	cg03641300	chr2:160917029	PLA2R1	-0.81	-16.19	-0.6	5.03e-47	Idiopathic membranous nephropathy;
LGG	cis	rs2073499	0.935	rs2526395	chr3:50188886	T/C	cg03645007	chr3:50255295	SLC38A3	-0.63	-7.0	-0.31	9.02e-12	Schizophrenia;
LGG	cis	rs17604090	0.938	rs68072609	chr7:29682467	C/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.21	-0.32	2.25e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs10155981	0.510	rs4719705	chr7:22592707	C/T	cg06110297	chr7:22589830	NA	-0.71	-7.21	-0.32	2.33e-12	Bilirubin levels;
LGG	trans	rs783540	0.900	rs4778686	chr15:83310835	C/T	cg16105309	chr15:79090380	ADAMTS7	0.4	6.97	0.31	1.08e-11	Schizophrenia;
LGG	cis	rs6963495	0.818	rs117845382	chr7:105152040	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.85	0.34	2.86e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg10150615	chr22:24372951	LOC391322	-0.39	-6.66	-0.3	7.99e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg08847533	chr14:75593920	NEK9	-0.6	-11.65	-0.48	1.07e-27	Height;
LGG	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg07274523	chr3:49395745	GPX1	0.57	9.57	0.41	6.61e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg15596359	chr8:11213517	TDH	-0.4	-8.48	-0.37	3.15e-16	Retinal vascular caliber;
LGG	cis	rs704010	0.669	rs1250006	chr10:80846517	T/A	cg17823346	chr10:80848143	ZMIZ1	0.29	6.76	0.3	4.19e-11	Breast cancer;
LGG	cis	rs3806843	1.000	rs13157397	chr5:140184442	G/A	cg19875535	chr5:140030758	IK	0.49	10.08	0.42	9.84e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2544523	0.511	rs10929387	chr2:15912926	A/G	cg26669897	chr2:15909070	NA	0.45	11.92	0.48	9.35e-29	Asthma or chronic obstructive pulmonary disease;
LGG	cis	rs1046896	0.553	rs9893885	chr17:80837107	C/T	cg08200770	chr17:80723486	TBCD	-0.46	-8.21	-0.36	2.27e-15	Glycated hemoglobin levels;
LGG	cis	rs17854409	1.000	rs66956644	chr20:61484499	T/C	cg05147244	chr20:61493195	TCFL5	0.75	7.23	0.32	2.07e-12	Obesity-related traits;
LGG	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12229367	chr17:55822335	NA	-0.43	-8.05	-0.35	6.91e-15	Schizophrenia;
LGG	cis	rs9616064	0.506	rs3747255	chr22:47074281	G/A	cg05621596	chr22:47072043	GRAMD4	-0.37	-7.56	-0.33	2.14e-13	Urate levels in obese individuals;
LGG	cis	rs4148883	0.675	rs10000357	chr4:100099942	G/C	cg12011299	chr4:100065546	ADH4	0.4	8.51	0.37	2.4e-16	Alcohol dependence;
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg14338887	chr6:42928500	GNMT	0.29	9.42	0.4	2.12e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.43	0.47	8.34e-27	Vitiligo;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.57	-0.44	1.55e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg12292205	chr6:26970375	C6orf41	0.52	9.94	0.42	3.2e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-11.41	-0.47	1e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	11.21	0.46	5.5e-26	Lung cancer in ever smokers;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg16920238	chr17:80076378	CCDC57	0.33	7.42	0.33	5.52e-13	Life satisfaction;
LGG	cis	rs9815354	0.812	rs17219090	chr3:42051952	G/C	cg03022575	chr3:42003672	ULK4	0.66	7.87	0.34	2.58e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.71	0.34	7.94e-14	Lung cancer;
LGG	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg15704280	chr7:45808275	SEPT13	-0.87	-15.1	-0.57	3.37e-42	Coronary artery disease;
LGG	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg16262614	chr3:133464971	TF	0.48	8.78	0.38	3.22e-17	Iron status biomarkers;
LGG	cis	rs1348850	0.668	rs12618542	chr2:178494520	A/G	cg23306229	chr2:178417860	TTC30B	0.62	7.96	0.35	1.36e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6087990	0.871	rs2424905	chr20:31352927	T/C	cg13636640	chr20:31349939	DNMT3B	0.92	19.33	0.67	1.83e-61	Ulcerative colitis;
LGG	cis	rs2013441	0.932	rs2526479	chr17:20130221	T/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.24e-19	Obesity-related traits;
LGG	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg22437258	chr11:111473054	SIK2	-0.5	-7.98	-0.35	1.2e-14	Primary sclerosing cholangitis;
LGG	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg22044901	chr15:68126292	NA	-0.41	-6.91	-0.31	1.6e-11	Restless legs syndrome;
LGG	cis	rs4474465	0.850	rs10899536	chr11:78216992	C/A	cg27205649	chr11:78285834	NARS2	0.48	8.18	0.36	2.7e-15	Alzheimer's disease (survival time);
LGG	cis	rs10493773	0.748	rs6576784	chr1:86149476	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.63	-12.84	-0.51	1.78e-32	Urate levels in overweight individuals;
LGG	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg24634471	chr8:143751801	JRK	0.51	7.8	0.34	4.17e-14	Schizophrenia;
LGG	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg25019033	chr10:957182	NA	-0.56	-9.37	-0.4	3.25e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	trans	rs56804039	1.000	rs11780966	chr8:8383396	T/G	cg02002194	chr4:3960332	NA	0.44	6.99	0.31	9.54e-12	Cervical cancer;
LGG	cis	rs526231	0.697	rs253754	chr5:102631962	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.35	-0.32	8.77e-13	Primary biliary cholangitis;
LGG	cis	rs3735485	0.738	rs6956310	chr7:45095332	A/G	cg03440944	chr7:45023329	C7orf40	-0.55	-9.54	-0.41	8.15e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg24616589	chr7:151038719	NUB1	-0.38	-6.72	-0.3	5.45e-11	Brain structure;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg05313129	chr8:58192883	C8orf71	-0.78	-12.28	-0.5	3.23e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg06968155	chr5:131705112	SLC22A5	0.76	8.74	0.38	4.19e-17	Rheumatoid arthritis;
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs734999	0.933	rs4648648	chr1:2512452	G/A	cg18854424	chr1:2615690	NA	0.33	7.3	0.32	1.24e-12	Ulcerative colitis;
LGG	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg08975724	chr8:8085496	FLJ10661	0.38	6.92	0.31	1.55e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9419702	0.568	rs11156445	chr10:133542301	T/C	cg04492858	chr10:133558786	NA	0.41	8.45	0.37	3.85e-16	Survival in rectal cancer;
LGG	cis	rs6942756	0.956	rs7792317	chr7:128963971	G/A	cg02491457	chr7:128862824	NA	-0.74	-13.48	-0.53	3.47e-35	White matter hyperintensity burden;
LGG	cis	rs7507204	1.000	rs7507204	chr19:3428834	G/C	cg08380311	chr19:3435252	NFIC	0.8	12.32	0.5	2.34e-30	Height;
LGG	cis	rs1143633	0.615	rs4364030	chr2:113664409	C/G	cg06156847	chr2:113672199	IL1F7	0.37	7.4	0.33	6.5e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8072100	0.790	rs11079783	chr17:45686016	C/T	cg08085267	chr17:45401833	C17orf57	0.52	9.66	0.41	3.12e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504130	0.569	rs34364864	chr8:52729646	T/C	cg22653915	chr8:52722023	PXDNL	-0.43	-6.85	-0.3	2.33e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs826838	1.000	rs860400	chr12:39081279	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-13.52	-0.53	2.41e-35	Heart rate;
LGG	cis	rs4731207	0.596	rs11767737	chr7:124637905	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7481584	0.962	rs11024759	chr11:2982092	T/C	cg08508325	chr11:3079039	CARS	0.39	7.22	0.32	2.18e-12	Calcium levels;
LGG	cis	rs6976053	0.846	rs2894713	chr7:100500105	C/T	cg03098644	chr7:100410630	EPHB4	-0.41	-7.43	-0.33	5.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs7395662	0.963	rs11040172	chr11:48968497	A/T	cg03929089	chr4:120376271	NA	-0.43	-6.99	-0.31	9.92e-12	HDL cholesterol;
LGG	cis	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg12893428	chr3:195717962	SDHAP1	0.41	7.74	0.34	6.47e-14	Pancreatic cancer;
LGG	cis	rs1519814	0.654	rs1543201	chr8:121018888	A/T	cg22335954	chr8:121166405	COL14A1	0.45	8.25	0.36	1.68e-15	Breast cancer;
LGG	trans	rs9747201	0.889	rs4789784	chr17:80179213	G/A	cg07393940	chr7:158741817	NA	0.59	10.66	0.44	7.12e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1707322	1.000	rs4606257	chr1:46307268	G/A	cg03146154	chr1:46216737	IPP	0.55	10.23	0.43	2.82e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7666738	0.830	rs7662596	chr4:99019962	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.73	-0.34	6.94e-14	Mood instability;
LGG	cis	rs7129220	0.588	rs61878628	chr11:10128872	T/G	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4481887	1.000	rs6681423	chr1:248482834	C/A	cg00666640	chr1:248458726	OR2T12	0.61	9.76	0.41	1.37e-20	Common traits (Other);
LGG	cis	rs7582720	1.000	rs72934706	chr2:203707752	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.74	0.41	1.64e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.03	-0.39	4.65e-18	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.02	-0.42	1.67e-21	Lung cancer;
LGG	cis	rs1682825	0.615	rs239961	chr3:10777950	A/G	cg25137700	chr3:10780651	NA	0.48	6.82	0.3	2.9100000000000002e-11	Economic and political preferences (feminism/equality);
LGG	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.03	-0.42	1.44e-21	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs2153535	0.580	rs9406163	chr6:8466642	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs4595586	0.525	rs7136425	chr12:39376005	C/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs12497850	0.931	rs9835307	chr3:48857805	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.52	-0.37	2.22e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.72	0.48	5.77e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg02725872	chr8:58115012	NA	-0.78	-10.5	-0.44	2.9e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.45e-35	Morning vs. evening chronotype;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg24101359	chr6:42928495	GNMT	0.46	12.61	0.51	1.55e-31	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg24829409	chr8:58192753	C8orf71	-0.65	-9.15	-0.39	1.84e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	1.000	rs11130190	chr3:49402137	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	7.7	0.34	8.31e-14	Menarche (age at onset);
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg08645402	chr16:4508243	NA	0.5	9.45	0.4	1.67e-19	Schizophrenia;
LGG	cis	rs250677	0.687	rs10040624	chr5:148437579	A/G	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.63e-12	Breast cancer;
LGG	cis	rs77372450	0.636	rs11750662	chr5:157027718	T/C	cg25387487	chr5:157003181	ADAM19	-0.56	-7.03	-0.31	7.62e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs17776563	1.000	rs17776563	chr15:89119104	G/A	cg05013243	chr15:89149849	MIR1179	-0.53	-10.5	-0.44	2.9e-23	Thyroid hormone levels;
LGG	cis	rs9487094	0.670	rs7767525	chr6:109967390	C/G	cg16315928	chr6:109776240	MICAL1	0.46	8.15	0.35	3.52e-15	Height;
LGG	cis	rs10421328	0.797	rs919778	chr19:19772722	A/G	cg11584989	chr19:19387371	SF4	-0.46	-6.95	-0.31	1.27e-11	Parental longevity (combined parental age at death);
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg08621203	chr6:150244597	RAET1G	-0.44	-7.49	-0.33	3.44e-13	Lung cancer;
LGG	cis	rs2486288	0.656	rs8037583	chr15:45546378	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.36	-0.43	9.18e-23	Glomerular filtration rate;
LGG	cis	rs6868223	1.000	rs6868223	chr5:33636594	A/G	cg10594543	chr5:33649717	ADAMTS12	-0.56	-12.36	-0.5	1.62e-30	Mortality in heart failure;
LGG	cis	rs7432375	0.610	rs6793936	chr3:136509793	A/C	cg21827317	chr3:136751795	NA	0.44	7.95	0.35	1.4e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs8064024	0.557	rs2251666	chr16:4923091	C/T	cg08329684	chr16:4932620	PPL	0.48	9.94	0.42	3.01e-21	Cancer;
LGG	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg03806693	chr22:41940476	POLR3H	0.89	14.9	0.57	2.81e-41	Vitiligo;
LGG	cis	rs1387259	0.899	rs7307566	chr12:48604682	A/G	cg24011408	chr12:48396354	COL2A1	0.5	8.04	0.35	7.57e-15	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	trans	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg01221209	chr5:554886	NA	-0.47	-6.98	-0.31	1.02e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs258892	0.895	rs153320	chr5:72138452	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.69	-0.3	6.54e-11	Small cell lung carcinoma;
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7216064	1.000	rs2052187	chr17:65834737	T/C	cg12091567	chr17:66097778	LOC651250	-0.61	-8.96	-0.38	7.76e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs12579753	0.956	rs7959951	chr12:82231132	T/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs732765	1.000	rs709888	chr14:75369346	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.0	-0.31	9.03e-12	Non-small cell lung cancer;
LGG	cis	rs4742903	0.935	rs10820602	chr9:106861282	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.5e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4474465	0.790	rs7932315	chr11:78214878	G/A	cg02023728	chr11:77925099	USP35	-0.38	-6.73	-0.3	5.03e-11	Alzheimer's disease (survival time);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg26649251	chr19:44598564	ZNF224	0.4	6.66	0.3	8.01e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7580658	0.637	rs4560059	chr2:127972228	T/C	cg10021288	chr2:128175891	PROC	-0.59	-12.16	-0.49	1.06e-29	Protein C levels;
LGG	cis	rs875971	0.964	rs55748098	chr7:65763618	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.83	-0.42	7.76e-21	Aortic root size;
LGG	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs17253792	0.822	rs74412558	chr14:56054311	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg16414030	chr3:133502952	NA	-0.65	-11.72	-0.48	5.88e-28	Iron status biomarkers;
LGG	cis	rs11168618	1.000	rs11168621	chr12:48938971	G/A	cg24011408	chr12:48396354	COL2A1	0.5	8.07	0.35	6.05e-15	Adiponectin levels;
LGG	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg22437258	chr11:111473054	SIK2	0.57	9.82	0.42	8.47e-21	Primary sclerosing cholangitis;
LGG	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.67	-11.44	-0.47	7.14e-27	Parkinson's disease;
LGG	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg27432699	chr2:27873401	GPN1	-0.42	-7.03	-0.31	7.53e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6500602	0.685	rs62037617	chr16:4435163	G/C	cg06916706	chr16:4465613	CORO7	-0.66	-10.52	-0.44	2.44e-23	Schizophrenia;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg26513180	chr16:89883248	FANCA	1.02	9.57	0.41	6.44e-20	Skin colour saturation;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.59	-9.87	-0.42	5.51e-21	Longevity;Endometriosis;
LGG	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.67	0.44	6.78e-24	Height;
LGG	cis	rs2028299	0.959	rs893617	chr15:90381278	C/T	cg23731826	chr15:90371692	NA	0.37	8.68	0.37	6.64e-17	Type 2 diabetes;
LGG	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg03433033	chr1:76189801	ACADM	-0.65	-9.54	-0.41	7.95e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04218592	chr16:11890465	NA	0.6	6.66	0.3	7.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10864302	0.525	rs3752543	chr1:7430394	A/G	cg08923594	chr1:7462176	CAMTA1	0.67	8.7	0.37	5.84e-17	Photic sneeze reflex;
LGG	cis	rs9309473	1.000	rs13398956	chr2:73720258	C/A	cg20560298	chr2:73613845	ALMS1	-0.47	-7.78	-0.34	4.69e-14	Metabolite levels;
LGG	trans	rs61931739	0.500	rs11519123	chr12:34436478	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs4650994	0.525	rs2224811	chr1:178544323	C/T	cg12486710	chr1:178512616	C1orf220	-0.52	-10.69	-0.44	5.49e-24	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.13	-0.52	1.04e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs924607	1.000	rs4045344	chr5:595870	G/T	cg09021430	chr5:549028	NA	0.54	10.46	0.44	3.89e-23	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs12291225	0.753	rs1431374	chr11:14303975	T/C	cg02886208	chr11:14281011	SPON1	-0.36	-6.88	-0.3	1.93e-11	Sense of smell;
LGG	cis	rs7674212	0.541	rs2720448	chr4:104030589	C/T	cg16532752	chr4:104119610	CENPE	-0.4	-6.92	-0.31	1.48e-11	Type 2 diabetes;
LGG	cis	rs1816752	0.819	rs7316961	chr13:24985177	C/T	cg22771759	chr13:24902376	NA	0.43	7.14	0.32	3.57e-12	Obesity-related traits;
LGG	trans	rs2963482	0.507	rs4704942	chr5:157893360	C/G	cg04842472	chr7:39872851	NA	0.37	6.69	0.3	6.49e-11	Nonsyndromic cleft lip with or without cleft palate;
LGG	cis	rs9463078	0.753	rs636845	chr6:44935341	C/T	cg25276700	chr6:44698697	NA	-0.39	-8.12	-0.35	4.14e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2247341	0.965	rs3752747	chr4:1737108	C/T	cg08446824	chr4:1720184	TMEM129	-0.68	-12.89	-0.51	1.1e-32	Hip circumference adjusted for BMI;Height;
LGG	cis	rs919433	0.680	rs2564383	chr2:198310862	A/G	cg00792783	chr2:198669748	PLCL1	0.5	7.86	0.34	2.75e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.38	-0.36	6.57e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2033732	0.673	rs2401050	chr8:85054711	C/T	cg05716166	chr8:85095498	RALYL	0.43	6.86	0.3	2.24e-11	Body mass index;
LGG	cis	rs4417704	0.526	rs4130554	chr2:241881642	G/A	cg14055004	chr2:241860995	NA	0.31	7.84	0.34	3.09e-14	Joint mobility (Beighton score);
LGG	cis	rs875971	1.000	rs811880	chr7:65818646	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg15971980	chr6:150254442	NA	0.45	8.35	0.36	8.03e-16	Lung cancer;
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg12016809	chr21:47604291	C21orf56	-0.59	-9.91	-0.42	3.93e-21	Testicular germ cell tumor;
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg02002194	chr4:3960332	NA	-0.49	-9.34	-0.4	3.95e-19	Triglycerides;
LGG	cis	rs8062405	0.964	rs7187333	chr16:28865916	G/A	cg00204512	chr16:28754710	NA	0.26	7.06	0.31	6.33e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs10877945	1.000	rs10877942	chr12:63416152	A/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.35	6.77	0.3	3.99e-11	Obesity-related traits;
LGG	cis	rs2120243	0.539	rs12486427	chr3:157113276	A/C	cg24825693	chr3:157122686	VEPH1	-0.58	-13.53	-0.53	2.17e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs13082711	0.522	rs7651661	chr3:27362773	G/C	cg02860705	chr3:27208620	NA	0.59	11.12	0.46	1.28e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07546770	chr5:68665590	RAD17;TAF9	0.42	6.74	0.3	4.64e-11	Cognitive performance;
LGG	cis	rs10463554	0.927	rs12055075	chr5:102380257	T/C	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	cis	rs773506	0.966	rs773515	chr9:93982932	C/T	cg14446406	chr9:93919335	NA	0.47	8.4	0.36	5.57e-16	Type 2 diabetes nephropathy;
LGG	cis	rs7191439	0.858	rs8044367	chr16:88783374	A/G	cg27087555	chr16:88793112	FAM38A	-1.5	-19.22	-0.67	5.86e-61	Plateletcrit;
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.58	-0.37	1.46e-16	Aortic root size;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg19318889	chr4:1322082	MAEA	-0.41	-7.16	-0.32	3.28e-12	Obesity-related traits;
LGG	cis	rs673604	1.000	rs925718	chr1:35675764	C/G	cg12633102	chr1:35676489	NA	-0.51	-9.74	-0.41	1.59e-20	Endometrial cancer;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg02018176	chr4:1364513	KIAA1530	0.41	9.41	0.4	2.33e-19	Obesity-related traits;
LGG	trans	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg01620082	chr3:125678407	NA	-1.1	-9.09	-0.39	2.9e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg00531865	chr16:30841666	NA	-0.53	-10.42	-0.44	5.39e-23	Dementia with Lewy bodies;
LGG	cis	rs62400317	0.859	rs72870950	chr6:45154779	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.39	-0.43	6.9e-23	Total body bone mineral density;
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.73	-12.3	-0.5	2.87e-30	Alzheimer's disease;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00689492	chr4:1303491	MAEA	0.49	8.47	0.37	3.32e-16	Obesity-related traits;
LGG	trans	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg20325293	chr4:54244256	FIP1L1	0.86	7.97	0.35	1.29e-14	IgG glycosylation;
LGG	cis	rs6866614	0.639	rs1858074	chr5:131371999	A/G	cg07395648	chr5:131743802	NA	-0.38	-6.93	-0.31	1.42e-11	Perceived unattractiveness to mosquitoes;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg06925179	chr17:43578568	NA	0.32	8.27	0.36	1.41e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg25173464	chr15:68126554	NA	-0.34	-7.1	-0.31	4.86e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2243480	0.901	rs35256305	chr7:65306405	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs72827839	0.696	rs117974417	chr17:46156510	C/G	cg02219949	chr17:45927392	SP6	0.54	6.83	0.3	2.64e-11	Ease of getting up in the morning;
LGG	cis	rs209489	1.000	rs209525	chr6:53215440	G/A	cg15607103	chr6:53167650	ELOVL5	-0.55	-7.71	-0.34	7.99e-14	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs73198271	0.765	rs534103	chr8:8634069	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.99	0.31	9.59e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4363385	0.510	rs11590369	chr1:152903603	G/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.39	-0.4	2.79e-19	Inflammatory skin disease;
LGG	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg22643751	chr7:855365	UNC84A	0.4	6.84	0.3	2.56e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16361266	chr1:1313144	NA	-0.32	-7.37	-0.32	8.12e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg21862992	chr11:68658383	NA	0.51	8.64	0.37	9.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.85	-0.3	2.31e-11	Arsenic metabolism;
LGG	cis	rs4356203	0.875	rs527810	chr11:17201066	A/G	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.16	-0.32	3.1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10504229	0.683	rs34804288	chr8:58117570	C/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7582720	1.000	rs72934563	chr2:203995405	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.29	0.4	6.08e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg11245990	chr11:68621969	NA	0.39	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg23131131	chr22:24373011	LOC391322	-0.48	-7.81	-0.34	3.75e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9790314	0.812	rs7631479	chr3:161139566	C/T	cg03342759	chr3:160939853	NMD3	-0.5	-8.53	-0.37	2.17e-16	Morning vs. evening chronotype;
LGG	cis	rs12282928	0.921	rs7479951	chr11:48295508	C/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.0	-0.31	9.07e-12	Migraine - clinic-based;
LGG	cis	rs9790314	0.765	rs4856768	chr3:161004392	G/A	cg03342759	chr3:160939853	NMD3	-0.71	-13.64	-0.54	7.25e-36	Morning vs. evening chronotype;
LGG	cis	rs12579753	0.719	rs11115060	chr12:82269624	C/T	cg07988820	chr12:82153109	PPFIA2	-0.56	-8.07	-0.35	6.17e-15	Resting heart rate;
LGG	cis	rs6088580	0.634	rs6088488	chr20:32992631	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.26	-0.43	2.24e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg06618935	chr21:46677482	NA	-0.5	-9.71	-0.41	2.05e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9398803	0.865	rs9385400	chr6:126764190	G/T	cg19875578	chr6:126661172	C6orf173	-0.57	-10.48	-0.44	3.27e-23	Male-pattern baldness;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.08	-26.94	-0.78	7.12e-97	Prudent dietary pattern;
LGG	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg23625390	chr15:77176239	SCAPER	-0.72	-14.41	-0.56	3.76e-39	Blood metabolite levels;
LGG	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg13010199	chr12:38710504	ALG10B	0.43	7.64	0.33	1.25e-13	Morning vs. evening chronotype;
LGG	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs12479064	0.505	rs62153764	chr2:99818612	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.68	-10.41	-0.44	6.09e-23	Chronic sinus infection;
LGG	cis	rs1865760	0.927	rs6915834	chr6:25935427	A/C	cg18357526	chr6:26021779	HIST1H4A	0.43	7.02	0.31	7.8e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18458026	chr19:3557538	C19orf28	0.45	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs17331151	0.573	rs79664140	chr3:52866936	A/G	cg04865290	chr3:52927548	TMEM110	-0.42	-7.11	-0.31	4.46e-12	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg00340584	chr1:149512963	NA	0.27	7.7	0.34	8.4e-14	Hip geometry;
LGG	cis	rs7954584	0.813	rs1523261	chr12:122462877	C/A	cg22168489	chr12:122356033	WDR66	0.33	7.8	0.34	4.28e-14	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs56389935	chr4:119683571	G/A	cg14228332	chr4:119757509	SEC24D	0.92	9.24	0.39	8.94e-19	Cannabis dependence symptom count;
LGG	cis	rs7666738	0.830	rs3846444	chr4:99032888	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.966	rs11733730	chr4:17625209	G/C	cg16339924	chr4:17578868	LAP3	0.6	10.35	0.43	1.02e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11018904	0.906	rs35129016	chr11:89948689	T/C	cg16176437	chr11:89678848	NA	0.4	6.82	0.3	2.82e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.515	rs12945216	chr17:78670642	C/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.31	-0.4	5.26e-19	Obesity;
LGG	cis	rs9397585	0.588	rs6932473	chr6:153438573	A/T	cg17707550	chr6:153380415	RGS17	0.46	10.0	0.42	1.83e-21	Body mass index;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg09264619	chr17:80180166	NA	0.37	7.44	0.33	4.82e-13	Life satisfaction;
LGG	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg08949735	chr16:89699720	DPEP1	-0.48	-10.0	-0.42	1.9e-21	Vitiligo;
LGG	cis	rs6142618	0.562	rs2281358	chr20:30723348	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs59104589	0.521	rs62190414	chr2:242424687	A/G	cg13788902	chr2:242434635	STK25	0.4	6.89	0.31	1.78e-11	Fibrinogen levels;
LGG	cis	rs7811142	1.000	rs1000215	chr7:100004543	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	19.36	0.67	1.25e-61	Platelet count;
LGG	cis	rs67133203	0.731	rs10747604	chr12:51505903	C/T	cg14688905	chr12:51403056	SLC11A2	-0.58	-8.88	-0.38	1.44e-17	Urinary tract infection frequency;
LGG	cis	rs17208368	0.723	rs4784468	chr16:55090245	C/A	cg09947736	chr16:55091198	NA	0.79	13.83	0.54	1.15e-36	Hypospadias;
LGG	cis	rs68170813	0.559	rs4515482	chr7:107072681	A/C	cg02696742	chr7:106810147	HBP1	-0.7	-9.89	-0.42	4.9e-21	Coronary artery disease;
LGG	cis	rs2862064	0.932	rs1393208	chr5:156477725	G/A	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.59	-0.44	1.33e-23	Platelet count;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-6.84	-0.3	2.56e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.79	0.41	1.06e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8060686	0.641	rs9923710	chr16:68224018	C/T	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.23	-0.32	1.97e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs13102973	0.720	rs13137075	chr4:135889366	G/A	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs7089973	0.604	rs1359079	chr10:116582502	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.5	-8.58	-0.37	1.47e-16	Height;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs78456975	1.000	rs13429866	chr2:1555211	C/A	cg01028140	chr2:1542097	TPO	-0.55	-8.44	-0.37	3.97e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4731207	0.698	rs10223980	chr7:124536558	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs12209877	1.000	rs4710962	chr6:21031435	A/G	cg13405222	chr6:20811065	CDKAL1	-0.36	-6.71	-0.3	5.77e-11	Cognitive function;
LGG	cis	rs4819052	0.851	rs914218	chr21:46698445	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.29	0.4	6.05e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01326531	chr9:138392790	C9orf116;MRPS2	0.58	8.91	0.38	1.15e-17	Gut microbiome composition (summer);
LGG	cis	rs9814567	0.929	rs13316205	chr3:134223563	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.27	-0.52	2.84e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.48	-7.78	-0.34	4.68e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg02002194	chr4:3960332	NA	-0.38	-6.7	-0.3	6.04e-11	Retinal vascular caliber;
LGG	cis	rs62064224	0.791	rs11656289	chr17:30761160	T/C	cg12561776	chr17:30844705	MYO1D	-0.27	-6.91	-0.31	1.57e-11	Schizophrenia;
LGG	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg11584989	chr19:19387371	SF4	0.65	10.67	0.44	6.51e-24	Bipolar disorder;
LGG	cis	rs12579753	0.879	rs1987116	chr12:82156478	G/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.46	-0.5	6.29e-31	Resting heart rate;
LGG	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.85	-0.45	1.37e-24	Vitiligo;
LGG	cis	rs8031584	0.958	rs61997076	chr15:31216225	C/T	cg19680485	chr15:31195859	MTMR15	-0.45	-6.78	-0.3	3.78e-11	Huntington's disease progression;
LGG	trans	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.65	0.48	1.12e-27	Corneal astigmatism;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg04234412	chr22:24373322	LOC391322	0.91	20.68	0.69	8.7e-68	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs597583	0.755	rs685440	chr11:117429718	G/T	cg27161313	chr11:117392002	DSCAML1	-0.52	-8.37	-0.36	6.94e-16	Putamen volume;
LGG	cis	rs2070488	0.775	rs6599208	chr3:38558104	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.34	-0.55	7.72e-39	Electrocardiographic conduction measures;
LGG	cis	rs7666738	0.830	rs13130923	chr4:99046281	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg09517075	chr8:22133004	PIWIL2	0.42	9.34	0.4	4.09e-19	Hypertriglyceridemia;
LGG	trans	rs61931739	0.517	rs7958856	chr12:34294737	T/C	cg13010199	chr12:38710504	ALG10B	0.58	10.97	0.45	4.72e-25	Morning vs. evening chronotype;
LGG	cis	rs17373728	0.526	rs13275074	chr8:76159360	C/A	cg07016329	chr8:76221503	NA	0.47	8.51	0.37	2.42e-16	Diabetic kidney disease;
LGG	cis	rs2084898	0.891	rs2511023	chr11:120009145	A/G	cg13907859	chr11:120009124	TRIM29	-0.86	-13.34	-0.53	1.41e-34	Stroke (pediatric);
LGG	cis	rs9527	0.590	rs7906754	chr10:104782557	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.97	-0.31	1.13e-11	Arsenic metabolism;
LGG	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg27284194	chr4:1044797	NA	0.57	11.79	0.48	3.21e-28	Recombination rate (males);
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.37e-17	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs9911490	chr17:29073013	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2762353	0.935	rs11754288	chr6:25776949	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.29	-0.4	6.23e-19	Blood metabolite levels;
LGG	cis	rs17270561	1.000	rs12200962	chr6:25828986	T/C	cg16482183	chr6:26056742	HIST1H1C	0.79	11.08	0.46	1.82e-25	Iron status biomarkers;
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg04703951	chr17:43578652	NA	0.34	7.13	0.31	3.81e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4919044	0.599	rs10882124	chr10:94665826	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.18	-0.32	2.82e-12	Coronary artery disease;
LGG	cis	rs4363385	0.747	rs4323653	chr1:152983359	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.99e-18	Inflammatory skin disease;
LGG	cis	rs2816062	1.000	rs2816062	chr1:18903902	G/A	cg18795169	chr1:18902165	NA	-1.02	-28.58	-0.8	2.7e-104	Urate levels in lean individuals;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.44	8.89	0.38	1.33e-17	Prostate cancer;
LGG	cis	rs2963155	0.518	rs72801080	chr5:142751990	T/C	cg17617527	chr5:142782415	NR3C1	1.0	12.24	0.49	4.87e-30	Breast cancer;
LGG	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.34	-0.58	3e-43	Chronic sinus infection;
LGG	cis	rs734999	0.566	rs10797435	chr1:2534801	G/C	cg18854424	chr1:2615690	NA	0.35	7.16	0.32	3.16e-12	Ulcerative colitis;
LGG	cis	rs7617773	0.817	rs9819094	chr3:48319558	C/T	cg11946769	chr3:48343235	NME6	0.61	10.13	0.43	6.5600000000000005e-22	Coronary artery disease;
LGG	cis	rs9926296	0.687	rs258317	chr16:89732238	C/T	cg03605463	chr16:89740564	NA	0.61	10.97	0.45	4.74e-25	Vitiligo;
LGG	cis	rs2599510	0.783	rs2710630	chr2:32765997	A/C	cg02381751	chr2:32503542	YIPF4	-0.49	-7.85	-0.34	3e-14	Interleukin-18 levels;
LGG	cis	rs4650994	0.524	rs1998544	chr1:178605276	T/C	cg12486710	chr1:178512616	C1orf220	-0.5	-10.38	-0.43	7.73e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4853012	0.941	rs7571083	chr2:74342260	C/G	cg01017244	chr2:74357527	NA	0.42	7.29	0.32	1.39e-12	Gestational age at birth (maternal effect);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg18926786	chr6:150244388	RAET1G	0.31	6.76	0.3	4.26e-11	Testicular germ cell tumor;
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg07157834	chr1:205819609	PM20D1	0.65	14.5	0.56	1.57e-39	Menarche (age at onset);
LGG	cis	rs2880765	0.835	rs56406982	chr15:86036379	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.74	-0.3	4.87e-11	Coronary artery disease;
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.69	-0.54	4.55e-36	Personality dimensions;
LGG	cis	rs7949030	0.590	rs12225213	chr11:62350248	T/A	cg13298116	chr11:62369859	EML3;MTA2	0.71	17.37	0.63	2e-52	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.69	-0.34	8.68e-14	Neuroticism;
LGG	cis	rs3806843	1.000	rs3756340	chr5:140180451	T/G	cg19875535	chr5:140030758	IK	0.51	10.4	0.44	6.34e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg21724239	chr8:58056113	NA	0.56	8.25	0.36	1.69e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs10797802	chr1:182973158	A/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.67	-0.41	2.96e-20	Colorectal cancer;
LGG	cis	rs13424612	1.000	rs10206993	chr2:240900919	C/A	cg01812947	chr2:240904978	NDUFA10	0.42	7.18	0.32	2.78e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs17039065	1.000	rs17039065	chr4:109385403	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.88	0.3	1.9e-11	Gut microbiome composition (summer);
LGG	cis	rs208520	1.000	rs208521	chr6:66953625	C/T	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.74	-0.3	4.77e-11	Blood metabolite levels;
LGG	cis	rs41271473	0.750	rs17352829	chr1:228889664	A/G	cg00850481	chr1:228891306	NA	-0.58	-10.35	-0.43	9.75e-23	Chronic lymphocytic leukemia;
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.08	-0.31	5.55e-12	Bipolar disorder;
LGG	cis	rs7129220	0.623	rs35815123	chr11:10119764	G/A	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.23e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9527	0.590	rs10786744	chr10:104945028	A/C	cg04362960	chr10:104952993	NT5C2	-0.56	-10.63	-0.44	9.12e-24	Arsenic metabolism;
LGG	cis	rs637571	0.607	rs589253	chr11:65693080	G/A	cg26695010	chr11:65641043	EFEMP2	-0.5	-8.23	-0.36	1.97e-15	Eosinophil percentage of white cells;
LGG	cis	rs3796619	1.000	rs4045481	chr4:1090625	C/T	cg27284194	chr4:1044797	NA	0.56	11.51	0.47	4.01e-27	Recombination rate (males);
LGG	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg04617936	chr2:214353	NA	-0.38	-7.1	-0.31	4.82e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4595586	0.545	rs3858553	chr12:39381291	A/C	cg26384229	chr12:38710491	ALG10B	0.65	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs1062177	0.547	rs2915818	chr5:151115290	T/A	cg00977110	chr5:151150581	G3BP1	-0.44	-7.27	-0.32	1.53e-12	Preschool internalizing problems;
LGG	cis	rs17270561	0.697	rs9366633	chr6:25838054	A/G	cg03264133	chr6:25882463	NA	-0.44	-6.81	-0.3	3.04e-11	Iron status biomarkers;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg20887711	chr4:1340912	KIAA1530	0.94	21.33	0.7	8.07e-71	Longevity;
LGG	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.44	0.44	4.7e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8064299	0.636	rs9915279	chr17:72772848	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.98	22.31	0.72	2.06e-75	Monocyte count;
LGG	trans	rs7210837	0.591	rs35313632	chr17:16779081	A/G	cg11294312	chr17:28900046	NA	-0.75	-9.28	-0.4	6.62e-19	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs4906332	1.000	rs35862113	chr14:103857229	G/T	cg26031613	chr14:104095156	KLC1	-0.53	-7.99	-0.35	1.12e-14	Coronary artery disease;
LGG	cis	rs910316	0.763	rs175044	chr14:75472109	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-9.82	-0.42	8.2e-21	Height;
LGG	cis	rs3780486	0.846	rs10738905	chr9:33123627	A/G	cg13443165	chr9:33130375	B4GALT1	-0.77	-15.15	-0.58	2.07e-42	IgG glycosylation;
LGG	cis	rs6088590	0.965	rs6119534	chr20:33441257	C/T	cg08999081	chr20:33150536	PIGU	0.31	6.89	0.31	1.78e-11	Coronary artery disease;
LGG	cis	rs7399018	0.739	rs7953955	chr12:51608467	A/G	cg25754956	chr12:51612065	POU6F1	0.61	10.1	0.42	8.56e-22	Cisplatin-induced ototoxicity;
LGG	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg04234412	chr22:24373322	LOC391322	0.7	10.86	0.45	1.27e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs637571	0.522	rs12792888	chr11:65761446	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.74	0.34	6.15e-14	Eosinophil percentage of white cells;
LGG	cis	rs9487094	0.689	rs12214147	chr6:109746257	A/G	cg01125227	chr6:109776195	MICAL1	0.39	6.8	0.3	3.18e-11	Height;
LGG	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg00031303	chr3:195681400	NA	0.51	8.08	0.35	5.75e-15	Pancreatic cancer;
LGG	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-7.47	-0.33	4.02e-13	Morning vs. evening chronotype;
LGG	cis	rs1957429	0.901	rs1467570	chr14:65347858	A/G	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg11764359	chr7:65958608	NA	-0.8	-14.75	-0.57	1.22e-40	Aortic root size;
LGG	cis	rs3768617	0.510	rs4651143	chr1:183097398	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg11608241	chr8:8085544	FLJ10661	0.33	7.68	0.34	9.56e-14	Neuroticism;
LGG	trans	rs3808502	0.527	rs56177149	chr8:11247298	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	6.9	0.31	1.74e-11	Neuroticism;
LGG	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg02297831	chr4:17616191	MED28	0.44	8.1	0.35	4.84e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6456156	0.774	rs1012657	chr6:167525142	A/C	cg07741184	chr6:167504864	NA	-0.31	-6.92	-0.31	1.48e-11	Primary biliary cholangitis;
LGG	cis	rs7937682	0.883	rs2212520	chr11:111462096	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg02733842	chr7:1102375	C7orf50	0.74	10.99	0.45	4.17e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22496380	chr5:211416	CCDC127	-1.29	-11.62	-0.48	1.39e-27	Breast cancer;
LGG	trans	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	7.03e-19	Diabetic kidney disease;
LGG	cis	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17092148	0.836	rs4322911	chr20:33182577	G/A	cg12302830	chr20:33297742	TP53INP2	-0.43	-7.05	-0.31	6.34e-12	Neuroticism;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22491279	chr19:8008671	TIMM44	-0.39	-6.79	-0.3	3.42e-11	Brain structure;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.79	-0.34	4.33e-14	Skin colour saturation;
LGG	cis	rs7539409	0.915	rs4001467	chr1:84275858	A/T	cg10977910	chr1:84465055	TTLL7	-0.67	-7.87	-0.34	2.48e-14	Alzheimer's disease;
LGG	cis	rs7927771	0.832	rs10838698	chr11:47385923	G/A	cg20307385	chr11:47447363	PSMC3	0.57	10.43	0.44	5.25e-23	Subjective well-being;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.29e-12	Menopause (age at onset);
LGG	trans	rs3812049	0.667	rs6888037	chr5:127406259	G/T	cg16011800	chr17:1958478	HIC1	-0.62	-9.58	-0.41	6.16e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs8005677	1.000	rs4982710	chr14:23398902	C/T	cg25600027	chr14:23388339	RBM23	-0.44	-7.3	-0.32	1.29e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs10256972	0.758	rs9801444	chr7:1080444	A/C	cg23978390	chr7:1156363	C7orf50	-0.43	-7.23	-0.32	2.01e-12	Longevity;Endometriosis;
LGG	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.6	-0.33	1.66e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs6500395	0.926	rs7192297	chr16:48670421	G/A	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs58688157	0.705	rs2396545	chr11:601785	T/C	cg03909863	chr11:638404	DRD4	-0.41	-6.91	-0.31	1.63e-11	Systemic lupus erythematosus;
LGG	trans	rs61931739	0.500	rs34107854	chr12:34482333	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.28	0.53	2.42e-34	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.69	-0.3	6.64e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg08250081	chr4:10125330	NA	0.41	8.16	0.35	3.1e-15	Bone mineral density;
LGG	cis	rs7582180	0.677	rs2067783	chr2:100877370	T/C	cg14675211	chr2:100938903	LONRF2	0.5	7.99	0.35	1.09e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs72781680	0.948	rs72796319	chr2:24133027	T/C	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.17	12.34	0.5	2e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6430585	0.527	rs62168836	chr2:136463117	G/A	cg07169764	chr2:136633963	MCM6	1.0	16.89	0.62	3.35e-50	Corneal structure;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg16359550	chr11:109292809	C11orf87	0.42	8.28	0.36	1.31e-15	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs5756391	0.810	rs5756393	chr22:37300290	A/C	cg21209356	chr22:37319042	CSF2RB	0.37	7.98	0.35	1.15e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs826838	0.872	rs826878	chr12:39088837	A/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.6	-0.33	1.68e-13	Heart rate;
LGG	cis	rs9381040	0.701	rs722442	chr6:41089681	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-6.96	-0.31	1.2e-11	Alzheimer's disease (late onset);
LGG	cis	rs6450176	0.909	rs3776720	chr5:53296158	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.13	-0.46	1.21e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6762	0.748	rs5030780	chr11:838110	C/T	cg10580341	chr11:889148	CHID1	-0.36	-6.67	-0.3	7.16e-11	Mean platelet volume;
LGG	cis	rs9815354	1.000	rs57479675	chr3:41798038	C/T	cg03022575	chr3:42003672	ULK4	0.59	7.62	0.33	1.44e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg05861140	chr6:150128134	PCMT1	-0.32	-7.27	-0.32	1.56e-12	Testicular germ cell tumor;
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg09263875	chr16:632152	PIGQ	0.66	13.39	0.53	8.24e-35	Height;
LGG	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Vitiligo;
LGG	cis	rs3806843	0.735	rs801168	chr5:140080298	A/G	cg19875535	chr5:140030758	IK	-0.56	-11.71	-0.48	6.59e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs34172651	0.876	rs11074653	chr16:24795959	C/T	cg00339695	chr16:24857497	SLC5A11	0.34	6.74	0.3	4.87e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.83	-0.3	2.64e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12410462	1.000	rs75198003	chr1:227623853	C/A	cg23173402	chr1:227635558	NA	0.62	10.36	0.43	9e-23	Major depressive disorder;
LGG	cis	rs3796352	0.571	rs11713926	chr3:53155072	C/T	cg12962167	chr3:53033115	SFMBT1	0.72	7.34	0.32	9.95e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7998202	0.667	rs914016	chr13:113355057	A/C	cg02820901	chr13:113351484	ATP11A	0.62	7.35	0.32	9.1e-13	Glycated hemoglobin levels;
LGG	cis	rs16957091	0.909	rs731984	chr15:43014477	G/A	cg07484255	chr15:43025164	CDAN1	-0.48	-6.81	-0.3	3.02e-11	MGMT methylation in smokers;
LGG	cis	rs877426	0.591	rs56188498	chr13:114827804	A/G	cg25338242	chr13:114786047	RASA3	0.44	6.78	0.3	3.7e-11	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs3750082	0.817	rs3750078	chr7:32969489	G/A	cg08946731	chr7:32981826	RP9P	-0.41	-6.93	-0.31	1.45e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2274273	0.638	rs17672364	chr14:55705904	G/T	cg04306507	chr14:55594613	LGALS3	0.51	11.78	0.48	3.51e-28	Protein biomarker;
LGG	cis	rs151234	0.676	rs151320	chr16:28568678	A/G	cg01378222	chr16:28622494	SULT1A1	0.71	9.68	0.41	2.63e-20	Platelet distribution width;
LGG	cis	rs7119	1.000	rs7119	chr15:77777632	C/T	cg05673287	chr15:77411982	SGK269	-0.32	-7.11	-0.31	4.57e-12	Type 2 diabetes;
LGG	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg00405596	chr8:11794950	NA	0.66	11.66	0.48	1.02e-27	Neuroticism;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg22105103	chr4:187893119	NA	0.58	11.18	0.46	7.48e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.72	-0.41	1.96e-20	Lewy body disease;
LGG	cis	rs9926296	0.656	rs2376882	chr16:89827002	T/C	cg04287289	chr16:89883240	FANCA	0.52	9.4	0.4	2.62e-19	Vitiligo;
LGG	cis	rs17767392	0.813	rs11848785	chr14:72057355	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.43	-8.96	-0.38	8.18e-18	Mitral valve prolapse;
LGG	cis	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.45	-0.33	4.48e-13	Monocyte count;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs787274	1.000	rs2796037	chr9:115511826	C/T	cg13803584	chr9:115635662	SNX30	0.54	7.6	0.33	1.62e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg04657146	chr19:12876947	HOOK2	0.44	7.13	0.31	3.98e-12	Red blood cell traits;
LGG	cis	rs887829	0.569	rs2008595	chr2:234637192	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.21	-0.36	2.22e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg01988459	chr11:68622903	NA	-0.63	-12.62	-0.51	1.38e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.850	rs17226966	chr16:89825338	A/G	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs266717	0.816	rs266752	chr3:186509079	G/A	cg00373256	chr3:186519153	RFC4	-0.41	-8.45	-0.37	3.81e-16	Adiponectin levels;
LGG	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.78	0.51	2.98e-32	Alzheimer's disease;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.41	0.47	9.33e-27	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9859260	0.710	rs366268	chr3:195782177	A/G	cg23484912	chr5:273055	PDCD6	-0.4	-7.93	-0.35	1.66e-14	Mean corpuscular volume;
LGG	trans	rs1941687	0.800	rs17753910	chr18:31387643	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.02	-0.39	5.02e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3789045	0.826	rs55979051	chr1:204567041	A/G	cg17419461	chr1:204415978	PIK3C2B	-0.47	-9.39	-0.4	2.71e-19	Educational attainment (college completion);
LGG	trans	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17712092	chr4:129076599	LARP1B	0.74	13.79	0.54	1.72e-36	Eosinophil percentage of white cells;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs35306767	0.903	rs11253485	chr10:919362	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.16	-0.39	1.62e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9457247	0.663	rs6456143	chr6:167415440	C/A	cg07741184	chr6:167504864	NA	0.4	8.84	0.38	1.99e-17	Crohn's disease;
LGG	cis	rs919433	0.963	rs7582736	chr2:198170342	A/G	cg00792783	chr2:198669748	PLCL1	-0.45	-7.04	-0.31	7.18e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1566085	0.766	rs7005575	chr8:142656269	C/T	cg26331504	chr8:142652174	NA	-0.31	-7.2	-0.32	2.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.87	-0.3	2.14e-11	Menopause (age at onset);
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.61	-11.51	-0.47	3.96e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.55	0.37	1.87e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg02711726	chr17:80685570	FN3KRP	-0.57	-10.13	-0.43	6.69e-22	Glycated hemoglobin levels;
LGG	cis	rs1048238	0.506	rs698890	chr1:16267371	C/G	cg21385522	chr1:16154831	NA	-0.57	-10.59	-0.44	1.3e-23	Systolic blood pressure;
LGG	cis	rs4148087	0.656	rs57137919	chr21:43639018	G/A	cg15319517	chr21:43638949	ABCG1	-0.5	-6.81	-0.3	3.11e-11	Eating disorder in bipolar disorder;
LGG	cis	rs943466	0.614	rs4713677	chr6:33731225	C/G	cg25922239	chr6:33757077	LEMD2	-0.44	-7.45	-0.33	4.52e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs12579753	0.672	rs4509857	chr12:82268017	C/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-8.11	-0.35	4.46e-15	Resting heart rate;
LGG	cis	rs6692729	0.933	rs2793461	chr1:227062129	C/A	cg08708961	chr1:227070630	PSEN2	-0.31	-7.92	-0.35	1.76e-14	Electrodermal activity;
LGG	cis	rs1018836	0.663	rs3950221	chr8:91478108	G/A	cg16814680	chr8:91681699	NA	-0.69	-11.82	-0.48	2.37e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs370915	0.890	rs1425952	chr4:187833545	A/G	cg19519643	chr4:187840862	NA	-0.49	-9.01	-0.39	5.6e-18	Gout;
LGG	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg03517284	chr6:25882590	NA	0.49	9.32	0.4	4.79e-19	Blood metabolite levels;
LGG	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg27165867	chr14:105738592	BRF1	0.44	7.42	0.33	5.62e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg09783236	chr20:3185276	DDRGK1	0.39	6.75	0.3	4.33e-11	Body mass index;
LGG	trans	rs8073060	0.586	rs72829927	chr17:34049992	A/G	cg19694781	chr19:47549865	TMEM160	1.16	17.64	0.63	1.17e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg03929089	chr4:120376271	NA	-0.45	-7.51	-0.33	3.01e-13	HDL cholesterol;
LGG	cis	rs514406	0.644	rs928451	chr1:53195800	A/G	cg16325326	chr1:53192061	ZYG11B	-0.91	-25.63	-0.77	7.69e-91	Monocyte count;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg12419862	chr22:24373484	LOC391322	-0.97	-20.69	-0.69	8.22e-68	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg14926445	chr8:58193284	C8orf71	-0.86	-12.11	-0.49	1.59e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg06740897	chr17:46124821	NFE2L1	-0.39	-6.92	-0.31	1.48e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.47	0.44	3.69e-23	Thyroid stimulating hormone;
LGG	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg06808227	chr14:105710500	BRF1	-0.64	-10.89	-0.45	9.9e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2404602	0.735	rs4886493	chr15:76679026	A/G	cg23625390	chr15:77176239	SCAPER	-0.67	-13.62	-0.53	9.56e-36	Blood metabolite levels;
LGG	trans	rs7395662	1.000	rs7481308	chr11:48600067	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.16	-0.35	3.28e-15	HDL cholesterol;
LGG	cis	rs644799	0.648	rs1255181	chr11:95472148	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.45	7.62	0.33	1.4e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs7695620	chr4:120452776	G/A	cg24375607	chr4:120327624	NA	0.66	10.71	0.45	4.62e-24	Corneal astigmatism;
LGG	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg06421707	chr20:25228305	PYGB	0.5	10.9	0.45	9.05e-25	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs17021463	0.617	rs34872198	chr4:95326957	T/C	cg11021082	chr4:95130006	SMARCAD1	0.49	7.64	0.33	1.28e-13	Testicular germ cell tumor;
LGG	cis	rs60871478	0.947	rs7790823	chr7:788923	T/G	cg05535760	chr7:792225	HEATR2	0.76	11.84	0.48	1.86e-28	Cerebrospinal P-tau181p levels;
LGG	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11644478	chr21:40555479	PSMG1	0.73	13.12	0.52	1.12e-33	Cognitive function;
LGG	cis	rs806215	0.526	rs16871926	chr7:127517785	C/T	cg25922125	chr7:127225783	GCC1	-0.48	-6.98	-0.31	1.04e-11	Type 2 diabetes;
LGG	cis	rs240764	0.612	rs4840132	chr6:100914602	C/T	cg21058520	chr6:100914733	NA	0.46	7.99	0.35	1.11e-14	Neuroticism;
LGG	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.52	8.51	0.37	2.39e-16	Menarche (age at onset);
LGG	cis	rs11122272	0.732	rs999010	chr1:231495316	A/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.39e-13	Hemoglobin concentration;
LGG	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.08	-0.31	5.3e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg15556689	chr8:8085844	FLJ10661	0.48	8.98	0.39	6.89e-18	Mood instability;
LGG	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg10523679	chr1:76189770	ACADM	0.81	14.81	0.57	6.49e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs7527798	0.592	rs12025522	chr1:207854355	A/C	cg09232269	chr1:207846808	CR1L	0.36	6.78	0.3	3.7e-11	Erythrocyte sedimentation rate;
LGG	cis	rs9790314	0.521	rs60625846	chr3:161084525	G/T	cg04691961	chr3:161091175	C3orf57	-0.53	-11.32	-0.47	2.18e-26	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.32	0.4	4.74e-19	Height;
LGG	cis	rs2270450	0.650	rs10948300	chr6:46696342	A/T	cg10156739	chr6:46714674	LOC100287718	-0.44	-9.54	-0.41	8.34e-20	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.83	-0.34	3.31e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7937612	1.000	rs7939137	chr11:120343271	C/T	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.71	-0.51	5.88e-32	Intraocular pressure;
LGG	cis	rs4246949	0.681	rs10902810	chr10:125521877	G/C	cg12769705	chr10:125521557	CPXM2	-0.36	-7.28	-0.32	1.42e-12	Ulcerative colitis;
LGG	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.82	-0.34	3.5e-14	Bladder cancer;
LGG	cis	rs8014204	0.836	rs12588415	chr14:75278211	G/A	cg06637938	chr14:75390232	RPS6KL1	0.77	15.42	0.58	1.35e-43	Caffeine consumption;
LGG	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs910316	0.967	rs4903285	chr14:75609268	A/T	cg08847533	chr14:75593920	NEK9	0.62	12.02	0.49	3.58e-29	Height;
LGG	cis	rs4788570	0.584	rs11862723	chr16:71704222	T/C	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Intelligence (multi-trait analysis);
LGG	cis	rs7444	0.941	rs1034329	chr22:21943938	T/C	cg15846791	chr22:21984385	YDJC	-0.45	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	cis	rs6594713	0.819	rs10061462	chr5:112726205	A/T	cg12552261	chr5:112820674	MCC	0.54	8.15	0.35	3.51e-15	Brain cytoarchitecture;
LGG	cis	rs9912468	0.933	rs35687884	chr17:64321828	C/T	cg19474267	chr17:64306194	PRKCA	0.94	25.49	0.76	3.45e-90	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg17328964	chr8:145687451	CYHR1	-0.61	-11.14	-0.46	1.09e-25	Age at first birth;
LGG	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-10.65	-0.44	7.52e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	cis	rs17767392	0.670	rs61989257	chr14:71730470	C/A	cg02058870	chr14:72053146	SIPA1L1	0.36	7.69	0.34	8.92e-14	Mitral valve prolapse;
LGG	cis	rs17376456	0.935	rs13156002	chr5:93508931	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.33	0.43	1.21e-22	Diabetic retinopathy;
LGG	trans	rs208520	0.661	rs851466	chr6:66840476	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.67	-0.63	8.49e-54	Exhaled nitric oxide output;
LGG	cis	rs7786808	0.712	rs12671981	chr7:158202971	G/A	cg09998033	chr7:158218633	PTPRN2	-0.49	-8.65	-0.37	8.45e-17	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg16434002	chr17:42200994	HDAC5	0.53	9.85	0.42	6.47e-21	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05828906	chr6:126278519	HINT3	0.49	7.65	0.33	1.18e-13	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.742	rs1533058	chr8:8685190	A/G	cg06636001	chr8:8085503	FLJ10661	0.48	9.01	0.39	5.4e-18	Mood instability;
LGG	cis	rs7247513	0.964	rs8100964	chr19:12720631	C/T	cg01871581	chr19:12707946	ZNF490	-0.43	-8.76	-0.38	3.76e-17	Bipolar disorder;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg06636001	chr8:8085503	FLJ10661	0.48	8.64	0.37	9.04e-17	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.812	rs56290987	chr3:42004882	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg22907277	chr7:1156413	C7orf50	0.64	8.4	0.36	5.44e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg27432699	chr2:27873401	GPN1	-0.47	-8.0	-0.35	9.78e-15	Total body bone mineral density;
LGG	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.89	-0.38	1.37e-17	Triglycerides;
LGG	cis	rs244293	0.672	rs9901526	chr17:53012379	G/T	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-6.9	-0.31	1.72e-11	Menarche (age at onset);
LGG	cis	rs4132509	1.000	rs2125230	chr1:243885848	A/G	cg25706552	chr1:244017396	NA	-0.49	-8.14	-0.35	3.58e-15	RR interval (heart rate);
LGG	cis	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.87	-0.3	2.02e-11	Joint mobility (Beighton score);
LGG	cis	rs7666738	0.830	rs17550630	chr4:99008332	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3087591	0.960	rs2018634	chr17:29560678	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.5	-0.56	1.56e-39	Hip circumference;
LGG	cis	rs6977660	0.714	rs10231980	chr7:19789383	C/G	cg05791153	chr7:19748676	TWISTNB	0.78	10.6	0.44	1.22e-23	Thyroid stimulating hormone;
LGG	cis	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg22496380	chr5:211416	CCDC127	-1.34	-18.64	-0.65	3e-58	Breast cancer;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg26338869	chr17:61819248	STRADA	-0.55	-9.13	-0.39	2.06e-18	Prudent dietary pattern;
LGG	cis	rs11169552	0.510	rs4768892	chr12:50960308	C/T	cg12884762	chr12:50931848	DIP2B	-0.42	-7.88	-0.34	2.43e-14	Colorectal cancer;
LGG	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg20302533	chr7:39170763	POU6F2	0.48	11.13	0.46	1.14e-25	IgG glycosylation;
LGG	cis	rs11105298	0.891	rs10858879	chr12:89886578	A/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.67	9.36	0.4	3.53e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2404602	0.647	rs11072610	chr15:76930805	C/A	cg23625390	chr15:77176239	SCAPER	-0.67	-12.94	-0.52	6.31e-33	Blood metabolite levels;
LGG	cis	rs9649465	0.846	rs13044	chr7:123322716	T/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg04287289	chr16:89883240	FANCA	0.49	8.7	0.37	5.96e-17	Vitiligo;
LGG	cis	rs514406	0.584	rs12095247	chr1:53193796	A/C	cg24675658	chr1:53192096	ZYG11B	0.64	14.04	0.55	1.47e-37	Monocyte count;
LGG	cis	rs9914544	1.000	rs1037036	chr17:18764077	C/T	cg26378065	chr17:18585709	ZNF286B	0.5	9.16	0.39	1.64e-18	Educational attainment (years of education);
LGG	cis	rs4731207	0.596	rs922713	chr7:124607059	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs1493916	0.967	rs9953768	chr18:31399468	A/G	cg04226714	chr8:49833948	SNAI2	-0.48	-8.45	-0.37	3.84e-16	Life satisfaction;
LGG	cis	rs952623	0.717	rs12669446	chr7:39046908	A/G	cg20302533	chr7:39170763	POU6F2	-0.3	-7.26	-0.32	1.68e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg21782813	chr7:2030301	MAD1L1	0.49	11.65	0.48	1.08e-27	Schizophrenia;
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg00864171	chr11:67383662	NA	0.55	9.56	0.41	7.18e-20	Mean corpuscular volume;
LGG	cis	rs2075371	0.611	rs13235296	chr7:134019192	A/G	cg20476274	chr7:133979776	SLC35B4	-0.66	-11.91	-0.48	1.01e-28	Mean platelet volume;
LGG	cis	rs9287719	0.967	rs1541573	chr2:10773385	T/G	cg02196655	chr2:10830764	NOL10	-0.43	-7.33	-0.32	1.06e-12	Prostate cancer;
LGG	cis	rs12476592	0.602	rs6546018	chr2:63817422	G/T	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.27e-11	Childhood ear infection;
LGG	cis	rs7226408	0.857	rs11662905	chr18:34433270	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs12447804	0.798	rs12926803	chr16:58097600	G/C	cg03859792	chr16:58121049	NA	0.48	7.42	0.33	5.72e-13	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs9393692	0.905	rs9393693	chr6:26277408	C/A	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.33e-13	Educational attainment;
LGG	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.05	-0.46	2.34e-25	Coronary artery disease;
LGG	cis	rs2290402	0.572	rs3775119	chr4:893712	C/T	cg09237302	chr4:906077	GAK	-0.49	-7.88	-0.34	2.35e-14	Type 2 diabetes;
LGG	trans	rs7395662	0.655	rs2202458	chr11:48856547	T/G	cg03929089	chr4:120376271	NA	0.44	7.14	0.31	3.75e-12	HDL cholesterol;
LGG	cis	rs10464366	0.843	rs13242209	chr7:39110241	C/T	cg20302533	chr7:39170763	POU6F2	0.47	10.86	0.45	1.2e-24	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs13063098	chr3:10009919	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.57	0.63	2.57e-53	Alzheimer's disease;
LGG	cis	rs2413583	0.591	rs12484030	chr22:39712936	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.76	0.34	5.49e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg00684032	chr4:1343700	KIAA1530	0.41	7.83	0.34	3.27e-14	Obesity-related traits;
LGG	cis	rs96067	0.805	rs11263860	chr1:36601368	C/G	cg24686825	chr1:36642396	MAP7D1	-0.4	-7.09	-0.31	4.93e-12	Corneal structure;
LGG	cis	rs6598955	0.724	rs10902731	chr1:26600793	A/G	cg10402321	chr1:26617780	UBXN11	-0.36	-7.17	-0.32	2.91e-12	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.63e-23	Lung cancer;
LGG	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg05234568	chr11:5960015	NA	-0.64	-11.47	-0.47	5.5e-27	DNA methylation (variation);
LGG	cis	rs3796352	1.000	rs13092352	chr3:52969697	C/T	cg12962167	chr3:53033115	SFMBT1	0.7	7.76	0.34	5.61e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg11062466	chr8:58055876	NA	0.61	9.69	0.41	2.43e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.706	rs7208487	chr17:37543449	T/G	cg07936489	chr17:37558343	FBXL20	1.0	15.52	0.59	4.73e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs2952156	0.959	rs2517956	chr17:37843859	G/A	cg00129232	chr17:37814104	STARD3	-0.69	-13.95	-0.54	3.63e-37	Asthma;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg11878867	chr6:150167359	LRP11	-0.54	-11.05	-0.46	2.42e-25	Lung cancer;
LGG	cis	rs7527798	0.592	rs4097398	chr1:207857760	C/T	cg09232269	chr1:207846808	CR1L	-0.38	-7.27	-0.32	1.58e-12	Erythrocyte sedimentation rate;
LGG	cis	rs5762813	0.566	rs4055	chr22:29352495	A/C	cg15103426	chr22:29168792	CCDC117	0.59	6.95	0.31	1.23e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.98	0.35	1.15e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs544119	chr11:95538624	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg12982090	chr3:42733453	KBTBD5	0.96	15.92	0.59	7.99e-46	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg12070911	chr6:150209640	RAET1E	0.32	7.63	0.33	1.39e-13	Lung cancer;
LGG	cis	rs2204008	0.617	rs11831608	chr12:38210687	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.67	-0.44	6.34e-24	Bladder cancer;
LGG	cis	rs7546668	1.000	rs3795759	chr1:15853628	C/T	cg21858823	chr1:15850916	CASP9	0.38	7.0	0.31	9.03e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg01191920	chr7:158217561	PTPRN2	-0.94	-24.52	-0.75	1.02e-85	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05665937	chr4:1216051	CTBP1	0.49	9.03	0.39	4.71e-18	Obesity-related traits;
LGG	cis	rs9388451	0.839	rs980014	chr6:126068001	T/G	cg10911889	chr6:126070802	HEY2	0.44	7.52	0.33	2.95e-13	Brugada syndrome;
LGG	cis	rs2213920	0.679	rs4979533	chr9:118210764	C/T	cg13918206	chr9:118159781	DEC1	0.61	8.72	0.38	4.89e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs864537	0.676	rs1773560	chr1:167421763	A/G	cg09179987	chr1:167433047	CD247	0.43	9.41	0.4	2.36e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs7937682	1.000	rs11608122	chr11:111535105	C/T	cg22437258	chr11:111473054	SIK2	-0.57	-9.57	-0.41	6.3e-20	Primary sclerosing cholangitis;
LGG	cis	rs3816183	0.616	rs3937908	chr2:42761804	C/G	cg14631114	chr2:43023945	NA	0.44	8.11	0.35	4.68e-15	Hypospadias;
LGG	cis	rs2188561	0.697	rs4730258	chr7:107396232	A/G	cg16793755	chr7:107334138	SLC26A4	0.39	7.11	0.31	4.44e-12	Alcohol consumption;
LGG	cis	rs225245	0.755	rs8078905	chr17:34009029	T/C	cg05299278	chr17:33885742	SLFN14	0.42	8.11	0.35	4.52e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4740619	0.792	rs10810397	chr9:15553591	G/C	cg14451791	chr9:16040625	NA	-0.31	-7.92	-0.35	1.73e-14	Body mass index;
LGG	cis	rs1577917	0.883	rs9450375	chr6:86756629	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.54	9.58	0.41	6.06e-20	Response to antipsychotic treatment;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.62	-10.82	-0.45	1.76e-24	Longevity;Endometriosis;
LGG	cis	rs11696845	1.000	rs13038016	chr20:43370497	A/G	cg25301532	chr20:43378953	KCNK15	0.37	8.11	0.35	4.67e-15	Obesity-related traits;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg07538946	chr5:131705188	SLC22A5	0.68	7.87	0.34	2.61e-14	Rheumatoid arthritis;
LGG	cis	rs10752881	1.000	rs10752886	chr1:182987248	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs7647973	1.000	rs73088137	chr3:49448423	G/A	cg07636037	chr3:49044803	WDR6	-0.78	-13.63	-0.54	8.16e-36	Menarche (age at onset);
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg24690094	chr11:67383802	NA	0.47	8.42	0.36	4.78e-16	Mean corpuscular volume;
LGG	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs4253772	0.530	rs6008774	chr22:46755298	C/G	cg24881330	chr22:46731750	TRMU	0.85	9.83	0.42	7.6e-21	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6089829	0.925	rs11086152	chr20:61664656	T/C	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9300255	0.537	rs1716182	chr12:123686127	A/C	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Neutrophil percentage of white cells;
LGG	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg07382826	chr16:28625726	SULT1A1	0.35	7.26	0.32	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg20503657	chr10:835505	NA	0.56	7.35	0.32	8.92e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.08	-0.42	1.01e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17125944	1.000	rs17125924	chr14:53391680	A/G	cg00686598	chr14:53173677	PSMC6	0.76	7.33	0.32	1.04e-12	Alzheimer's disease (late onset);
LGG	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg18225595	chr11:63971243	STIP1	0.64	11.94	0.49	8.09e-29	Platelet count;
LGG	cis	rs11190604	1.000	rs10883503	chr10:102275504	C/A	cg07570687	chr10:102243282	WNT8B	0.45	7.52	0.33	2.96e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35110281	0.748	rs2838322	chr21:44998615	G/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.74	-0.38	4.24e-17	Mean corpuscular volume;
LGG	cis	rs41271473	0.526	rs12143098	chr1:228720965	A/C	cg16512390	chr1:228756714	NA	0.61	8.06	0.35	6.48e-15	Chronic lymphocytic leukemia;
LGG	cis	rs12431410	0.550	rs11623439	chr14:60226293	G/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.28	-0.32	1.44e-12	Schizophrenia;
LGG	trans	rs116095464	0.558	rs9687621	chr5:229194	C/T	cg09048205	chr5:1608656	LOC728613	-0.51	-8.42	-0.36	4.74e-16	Breast cancer;
LGG	cis	rs62400317	0.762	rs10948176	chr6:44833913	A/G	cg18551225	chr6:44695536	NA	-0.68	-11.37	-0.47	1.4e-26	Total body bone mineral density;
LGG	cis	rs8017423	0.647	rs12895269	chr14:90822430	T/C	cg04374321	chr14:90722782	PSMC1	-0.64	-12.83	-0.51	1.91e-32	Mortality in heart failure;
LGG	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg16414030	chr3:133502952	NA	-0.6	-10.47	-0.44	3.62e-23	Iron status biomarkers;
LGG	cis	rs9467773	1.000	rs767471	chr6:26557854	C/T	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg19418458	chr7:158789849	NA	-0.55	-11.49	-0.47	4.73e-27	Facial morphology (factor 20);
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg14092988	chr3:52407081	DNAH1	0.31	8.14	0.35	3.75e-15	Bipolar disorder;
LGG	trans	rs8002861	1.000	rs8002861	chr13:44474517	G/A	cg17145862	chr1:211918768	LPGAT1	0.97	24.91	0.76	1.69e-87	Leprosy;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg25711079	chr2:64880901	SERTAD2	-0.42	-6.96	-0.31	1.2e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs62238980	0.614	rs4820062	chr22:32392437	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12681288	0.645	rs35040046	chr8:989973	C/T	cg04851639	chr8:1020857	NA	-0.42	-8.54	-0.37	1.91e-16	Schizophrenia;
LGG	cis	rs2730245	0.959	rs2527201	chr7:158738611	G/T	cg24397884	chr7:158709396	WDR60	-1.05	-25.19	-0.76	7.83e-89	Height;
LGG	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg13009111	chr11:71350975	NA	0.36	7.87	0.34	2.48e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg09085632	chr11:111637200	PPP2R1B	0.99	19.1	0.66	2.17e-60	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs8028182	0.636	rs4886703	chr15:75730366	C/T	cg20655648	chr15:75932815	IMP3	0.46	7.81	0.34	3.91e-14	Sudden cardiac arrest;
LGG	cis	rs8036030	0.604	rs11856835	chr15:74716174	G/A	cg05926586	chr15:74592786	CCDC33	0.29	6.67	0.3	7.54e-11	Airflow obstruction;
LGG	cis	rs6696846	0.749	rs6692170	chr1:205074019	G/A	cg00857998	chr1:205179979	DSTYK	0.46	7.45	0.33	4.52e-13	Red blood cell count;
LGG	cis	rs9771228	1.000	rs215600	chr7:32333642	G/A	cg27532318	chr7:32358331	NA	-0.45	-6.99	-0.31	9.95e-12	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs12681287	0.640	rs72606633	chr8:87476236	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs208520	0.586	rs208442	chr6:66900618	T/A	cg07460842	chr6:66804631	NA	-0.72	-12.63	-0.51	1.27e-31	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.59	-0.56	5.91e-40	Prudent dietary pattern;
LGG	cis	rs11718455	0.960	rs17076254	chr3:44000361	C/T	cg21419209	chr3:44054225	NA	-0.41	-6.84	-0.3	2.47e-11	Coronary artery disease;
LGG	cis	rs868036	1.000	rs868036	chr15:68055013	T/A	cg24231037	chr15:68117551	LBXCOR1	0.32	7.71	0.34	7.93e-14	Restless legs syndrome;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg02951883	chr7:2050386	MAD1L1	-0.78	-17.31	-0.63	4.01e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs4919694	1.000	rs11191490	chr10:104745174	T/A	cg04362960	chr10:104952993	NT5C2	1.06	14.85	0.57	4.51e-41	Arsenic metabolism;
LGG	cis	rs9486715	0.867	rs7451950	chr6:96879974	T/C	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	trans	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg25214090	chr10:38739885	LOC399744	0.66	11.65	0.48	1.12e-27	Corneal astigmatism;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg12070911	chr6:150209640	RAET1E	0.29	7.01	0.31	8.72e-12	Lung cancer;
LGG	cis	rs1008375	0.900	rs12650220	chr4:17595365	A/T	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.32e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1816752	0.774	rs2862895	chr13:24984466	T/A	cg02811702	chr13:24901961	NA	0.4	7.32	0.32	1.09e-12	Obesity-related traits;
LGG	cis	rs17776563	0.664	rs12593758	chr15:89111719	G/A	cg05013243	chr15:89149849	MIR1179	-0.33	-6.92	-0.31	1.51e-11	Thyroid hormone levels;
LGG	cis	rs6582630	0.533	rs11181379	chr12:38332381	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.2	0.32	2.41e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3771570	1.000	rs62193256	chr2:242362168	C/T	cg21155796	chr2:242212141	HDLBP	0.75	9.95	0.42	2.8e-21	Prostate cancer;
LGG	trans	rs643955	0.583	rs13250399	chr8:9872810	C/T	cg12395012	chr8:11607386	GATA4	0.42	7.38	0.32	7.31e-13	Systemic lupus erythematosus;
LGG	trans	rs7395662	0.571	rs10838947	chr11:48568693	G/T	cg03929089	chr4:120376271	NA	-0.53	-9.0	-0.39	5.78e-18	HDL cholesterol;
LGG	cis	rs3008870	0.755	rs2815381	chr1:67514591	G/A	cg02640540	chr1:67518911	SLC35D1	0.59	11.6	0.47	1.81e-27	Lymphocyte percentage of white cells;
LGG	cis	rs6714710	0.603	rs17489984	chr2:98421364	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	9.96	0.42	2.72e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg06212747	chr3:49208901	KLHDC8B	0.73	12.73	0.51	4.72e-32	Parkinson's disease;
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg26752003	chr8:145688521	CYHR1	0.54	11.73	0.48	5.3e-28	Age at first birth;
LGG	cis	rs7927592	0.871	rs17603185	chr11:68376241	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs2836950	0.561	rs34705151	chr21:40553344	G/A	cg17971929	chr21:40555470	PSMG1	-0.54	-9.09	-0.39	2.86e-18	Menarche (age at onset);
LGG	cis	rs7312933	0.558	rs2178753	chr12:42732804	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-7.76	-0.34	5.49e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10752881	1.000	rs4402094	chr1:182986441	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	trans	rs2204008	0.805	rs12146846	chr12:37985847	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs6594713	0.717	rs10056194	chr5:112857862	T/G	cg12552261	chr5:112820674	MCC	0.61	8.39	0.36	5.84e-16	Brain cytoarchitecture;
LGG	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg15733309	chr7:157513707	PTPRN2	0.78	18.18	0.65	3.81e-56	Bipolar disorder and schizophrenia;
LGG	trans	rs66887589	0.616	rs11098498	chr4:120187119	T/C	cg25214090	chr10:38739885	LOC399744	0.46	8.4	0.36	5.49e-16	Diastolic blood pressure;
LGG	cis	rs2933343	0.700	rs789233	chr3:128603150	G/T	cg25356066	chr3:128598488	ACAD9	0.46	7.09	0.31	5.03e-12	IgG glycosylation;
LGG	trans	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg20587970	chr11:113659929	NA	0.74	11.95	0.49	7.08e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	7.59	0.33	1.8e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg06916706	chr16:4465613	CORO7	-0.89	-15.42	-0.58	1.31e-43	Schizophrenia;
LGG	cis	rs12580194	0.598	rs12582005	chr12:55772837	A/T	cg19537932	chr12:55886519	OR6C68	-0.57	-10.29	-0.43	1.69e-22	Cancer;
LGG	cis	rs4713118	0.515	rs9368549	chr6:28050047	T/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Parkinson's disease;
LGG	cis	rs10751667	0.666	rs10902243	chr11:949900	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.91	0.35	1.89e-14	Alzheimer's disease (late onset);
LGG	cis	rs9560113	1.000	rs4773383	chr13:112177764	C/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs35110281	0.508	rs2838351	chr21:45110784	A/G	cg04455712	chr21:45112962	RRP1B	0.48	8.66	0.37	7.79e-17	Mean corpuscular volume;
LGG	cis	rs9325144	0.723	rs3887436	chr12:39189526	A/C	cg04568710	chr12:38710424	ALG10B	-0.33	-6.78	-0.3	3.62e-11	Morning vs. evening chronotype;
LGG	cis	rs472402	0.623	rs7727273	chr5:6635933	A/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-6.97	-0.31	1.06e-11	Response to amphetamines;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27574168	chr18:54318782	WDR7	0.45	7.82	0.34	3.69e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs12472274	0.646	rs11688732	chr2:239096622	G/T	cg17459225	chr2:239074497	NA	0.75	10.83	0.45	1.62e-24	Phospholipid levels (plasma);
LGG	cis	rs2481665	0.765	rs2481678	chr1:62634020	T/C	cg18591186	chr1:62594603	INADL	-0.46	-9.88	-0.42	5.28e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2289328	0.943	rs3803359	chr15:40662748	A/G	cg13931752	chr15:40660718	DISP2	-0.31	-6.83	-0.3	2.72e-11	Intelligence (multi-trait analysis);Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	trans	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.66	0.41	3.08e-20	Mean corpuscular volume;
LGG	trans	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg11693508	chr17:37793320	STARD3	0.47	7.17	0.32	2.9e-12	Neuroticism;
LGG	trans	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg18335740	chr13:41363409	SLC25A15	-0.85	-18.64	-0.65	2.8e-58	Lewy body disease;
LGG	cis	rs6768930	0.509	rs2061573	chr3:57763642	G/A	cg01571842	chr3:57934672	NA	0.3	6.66	0.3	7.73e-11	Obesity-related traits;
LGG	cis	rs9611565	0.559	rs4822048	chr22:41988225	C/T	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Vitiligo;
LGG	cis	rs2282300	0.739	rs7926465	chr11:30333016	C/T	cg25418670	chr11:30344373	C11orf46	0.56	7.79	0.34	4.37e-14	Morning vs. evening chronotype;
LGG	cis	rs240764	0.612	rs9322076	chr6:100952020	C/T	cg21058520	chr6:100914733	NA	0.48	8.19	0.36	2.56e-15	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22541254	chr6:101846779	GRIK2	0.39	7.25	0.32	1.75e-12	Gut microbiome composition (summer);
LGG	cis	rs34929064	0.512	rs2157958	chr7:22706707	C/T	cg18045685	chr7:22629474	NA	-0.7	-15.4	-0.58	1.59e-43	Major depression and alcohol dependence;
LGG	cis	rs4740619	1.000	rs1533040	chr9:15638364	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.59	-0.44	1.31e-23	Body mass index;
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08677398	chr8:58056175	NA	0.57	9.17	0.39	1.54e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7017914	0.902	rs35893260	chr8:71620073	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs9341808	0.718	rs9359408	chr6:80820132	T/G	cg08355045	chr6:80787529	NA	0.42	8.11	0.35	4.49e-15	Sitting height ratio;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs2204008	0.592	rs2320501	chr12:38145285	T/G	cg13010199	chr12:38710504	ALG10B	0.66	13.2	0.52	5.28e-34	Bladder cancer;
LGG	cis	rs1620921	0.657	rs7382435	chr6:161276434	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9942416	0.660	rs67054144	chr5:74991443	G/A	cg19683494	chr5:74908142	NA	0.45	6.92	0.31	1.46e-11	Age-related disease endophenotypes;
LGG	cis	rs6459804	0.844	rs76501205	chr7:157508941	A/T	cg11757124	chr7:157526947	PTPRN2	-0.51	-9.35	-0.4	3.63e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.830	rs4718358	chr7:65973668	T/C	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.34e-21	Aortic root size;
LGG	cis	rs3796619	1.000	rs3796619	chr4:1095281	A/G	cg21130718	chr4:1044621	NA	0.39	7.62	0.33	1.46e-13	Recombination rate (males);
LGG	cis	rs1707322	0.752	rs10430105	chr1:46138876	G/A	cg03146154	chr1:46216737	IPP	0.55	10.71	0.45	4.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6840360	0.642	rs10454251	chr4:152383962	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.92e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg16576597	chr16:28551801	NUPR1	0.3	6.75	0.3	4.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs4481887	0.893	rs4244186	chr1:248493319	A/G	cg00666640	chr1:248458726	OR2T12	0.57	9.15	0.39	1.78e-18	Common traits (Other);
LGG	cis	rs9611565	0.512	rs9607841	chr22:42186838	G/A	cg06481639	chr22:41940642	POLR3H	-0.55	-7.72	-0.34	7.35e-14	Vitiligo;
LGG	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.7	-9.31	-0.4	5.12e-19	Schizophrenia;
LGG	cis	rs4538187	0.906	rs6546035	chr2:64092331	C/T	cg14150252	chr2:64069583	UGP2	0.47	9.61	0.41	4.59e-20	Systolic blood pressure;
LGG	cis	rs909674	0.818	rs8136980	chr22:39844574	G/A	cg04986931	chr22:39850128	NA	0.38	8.49	0.37	2.93e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs12464483	0.524	rs4952173	chr2:30888346	G/T	cg07150166	chr2:30669952	LCLAT1	0.64	8.87	0.38	1.55e-17	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs4731207	0.698	rs4731218	chr7:124472015	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.93	-0.35	1.64e-14	Cutaneous malignant melanoma;
LGG	cis	rs41271473	0.718	rs4500282	chr1:228878375	T/A	cg00850481	chr1:228891306	NA	-0.56	-11.16	-0.46	9.15e-26	Chronic lymphocytic leukemia;
LGG	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.84	0.34	3.17e-14	Birth weight;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg05793240	chr7:2802953	GNA12	0.34	8.38	0.36	6.35e-16	Height;
LGG	cis	rs2013441	1.000	rs2243732	chr17:20088589	C/G	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14373873	chr11:113211441	TTC12	0.42	8.67	0.37	7.35e-17	Neuroticism;
LGG	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.74	0.34	6.2e-14	Mood instability;
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.65	8.37	0.36	7.03e-16	Lung function (FEV1/FVC);
LGG	cis	rs2204008	0.754	rs11181643	chr12:38380553	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.96	0.54	3.11e-37	Bladder cancer;
LGG	cis	rs4423214	0.840	rs1792226	chr11:71176574	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs4819052	0.851	rs2838866	chr21:46713014	G/C	cg06618935	chr21:46677482	NA	-0.47	-8.77	-0.38	3.42e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs559928	0.502	rs7127926	chr11:64190767	G/T	cg26318627	chr11:63887540	MACROD1	-0.38	-6.86	-0.3	2.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg18350739	chr11:68623251	NA	-0.89	-22.06	-0.72	2.94e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4474465	1.000	rs11237522	chr11:78209879	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.38	-0.36	6.25e-16	Alzheimer's disease (survival time);
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg00908189	chr16:619842	PIGQ	0.87	16.74	0.61	1.61e-49	Height;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.85	-0.34	3e-14	Lung cancer;
LGG	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg18681998	chr4:17616180	MED28	0.89	19.34	0.67	1.67e-61	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6840360	0.582	rs2709823	chr4:152340446	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	6.78	0.3	3.66e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2011503	0.941	rs72999063	chr19:19380596	G/T	cg01262667	chr19:19385393	TM6SF2	0.36	7.25	0.32	1.71e-12	Bipolar disorder;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg21862992	chr11:68658383	NA	0.51	8.44	0.37	4.05e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08109568	chr15:31115862	NA	-0.54	-9.56	-0.41	6.73e-20	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25654697	chr7:7680075	RPA3	0.49	7.76	0.34	5.31e-14	Gut microbiome composition (summer);
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg20790798	chr5:1857306	NA	-0.43	-7.11	-0.31	4.56e-12	Cardiovascular disease risk factors;
LGG	cis	rs4555082	1.000	rs4334224	chr14:105759198	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-11.15	-0.46	9.42e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.32	-0.32	1.09e-12	Coronary artery disease;
LGG	cis	rs1927790	0.759	rs12871890	chr13:96987910	C/T	cg02571835	chr13:96230311	CLDN10	-0.33	-6.73	-0.3	4.94e-11	Body mass index;
LGG	cis	rs11690935	0.959	rs6724337	chr2:172735329	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.02	-0.77	1.23e-92	Schizophrenia;
LGG	cis	rs13082711	0.522	rs11927257	chr3:27334294	C/T	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.61	0.41	4.5e-20	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116405053	chr4:119739352	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg14789911	chr21:47582049	C21orf56	0.42	7.34	0.32	9.58e-13	Testicular germ cell tumor;
LGG	cis	rs4803468	1.000	rs1473248	chr19:41923314	C/T	cg14132834	chr19:41945861	ATP5SL	0.49	9.67	0.41	2.92e-20	Height;
LGG	cis	rs13202913	0.837	rs6906678	chr6:151772395	A/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.6	6.91	0.31	1.56e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs3813359	0.545	rs10485398	chr6:130556410	C/T	cg23281432	chr6:130554730	NA	-0.5	-6.65	-0.3	8.03e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23526055	chr8:74884794	TCEB1	0.45	7.66	0.34	1.11e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg10189774	chr4:17578691	LAP3	-0.42	-7.03	-0.31	7.57e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.680	rs34267968	chr4:99002574	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7937612	1.000	rs6589810	chr11:120233908	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.51	-12.01	-0.49	4.02e-29	Intraocular pressure;
LGG	cis	rs9942416	0.660	rs60423072	chr5:75006113	T/A	cg19683494	chr5:74908142	NA	0.43	6.67	0.3	7.22e-11	Age-related disease endophenotypes;
LGG	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	7.63	0.33	1.39e-13	Schizophrenia;
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg01341218	chr17:43662625	NA	-0.63	-11.44	-0.47	7.3e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9487094	0.558	rs10457194	chr6:109828569	T/A	cg16315928	chr6:109776240	MICAL1	0.46	8.09	0.35	5.25e-15	Height;
LGG	cis	rs9611565	1.000	rs5751086	chr22:41768862	C/T	cg06634786	chr22:41940651	POLR3H	-0.61	-10.87	-0.45	1.16e-24	Vitiligo;
LGG	cis	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg03060546	chr3:49711283	APEH	-0.62	-10.25	-0.43	2.37e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.22	0.36	2.13e-15	Rheumatoid arthritis;
LGG	cis	rs12540874	0.698	rs3807566	chr7:50564204	G/T	cg04490037	chr7:50633773	DDC	0.33	7.3	0.32	1.29e-12	Systemic sclerosis;
LGG	cis	rs10479542	0.929	rs10078796	chr5:178978883	T/A	cg26516362	chr5:178986906	RUFY1	0.43	7.93	0.35	1.62e-14	Lung cancer;
LGG	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg06026331	chr20:60912101	LAMA5	0.61	10.39	0.43	7.23e-23	Colorectal cancer;
LGG	cis	rs977987	0.806	rs34996006	chr16:75479434	A/G	cg03315344	chr16:75512273	CHST6	0.52	10.29	0.43	1.6400000000000001e-22	Dupuytren's disease;
LGG	trans	rs61931739	0.500	rs7977194	chr12:34408459	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.34	0.7	6.93e-71	Morning vs. evening chronotype;
LGG	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg00784671	chr22:46762841	CELSR1	-0.56	-7.31	-0.32	1.18e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2243480	1.000	rs73150014	chr7:65450919	A/C	cg12463550	chr7:65579703	CRCP	0.73	8.03	0.35	8.4e-15	Diabetic kidney disease;
LGG	cis	rs7172689	0.908	rs11634869	chr15:81566613	A/T	cg11808699	chr15:81528661	IL16	-0.47	-9.48	-0.4	1.32e-19	Inattentive symptoms;
LGG	trans	rs2204008	0.837	rs7315255	chr12:37949279	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.13	-0.39	2.17e-18	Bladder cancer;
LGG	cis	rs3768617	0.510	rs10911242	chr1:183072147	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.32	0.4	4.65e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2075371	0.796	rs1646644	chr7:134011817	A/T	cg20476274	chr7:133979776	SLC35B4	0.69	13.01	0.52	3.49e-33	Mean platelet volume;
LGG	cis	rs7226408	0.857	rs72890583	chr18:34627906	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.7	14.64	0.56	3.58e-40	Obesity-related traits;
LGG	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs9880211	0.800	rs9813376	chr3:136475426	C/T	cg21827317	chr3:136751795	NA	-0.48	-6.89	-0.31	1.78e-11	Body mass index;Height;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg05489143	chr3:40498640	RPL14	0.53	6.68	0.3	6.92e-11	Colorectal cancer;
LGG	cis	rs977987	0.806	rs12599361	chr16:75434973	A/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.73	0.3	5.13e-11	Dupuytren's disease;
LGG	cis	rs4268898	0.722	rs7564420	chr2:24414002	C/T	cg06627628	chr2:24431161	ITSN2	-0.47	-7.85	-0.34	2.99e-14	Asthma;
LGG	cis	rs9486719	1.000	rs12190397	chr6:97036465	G/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.08	-0.46	1.75e-25	Migraine;Coronary artery disease;
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg04503457	chr17:41445688	NA	-0.4	-9.33	-0.4	4.47e-19	Menopause (age at onset);
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg21782813	chr7:2030301	MAD1L1	0.49	11.91	0.48	1.01e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs4718428	0.705	rs3800817	chr7:66263550	T/A	cg13147721	chr7:65941812	NA	-0.44	-6.77	-0.3	4.02e-11	Corneal structure;
LGG	cis	rs4478037	0.555	rs60749629	chr3:33105319	G/A	cg19404215	chr3:33155277	CRTAP	1.01	9.83	0.42	7.47e-21	Major depressive disorder;
LGG	trans	rs853679	0.882	rs9468287	chr6:28079741	G/T	cg08344181	chr3:125677491	NA	-0.65	-7.73	-0.34	6.73e-14	Depression;
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg00713939	chr8:144660590	NAPRT1	0.88	7.22	0.32	2.11e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12174276	chr6:166401921	LOC441177;C6orf176	0.48	8.25	0.36	1.6e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4262150	0.672	rs7725791	chr5:152343015	A/G	cg12297329	chr5:152029980	NA	-0.55	-8.76	-0.38	3.82e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.571	rs28897216	chr17:42240824	A/G	cg19774624	chr17:42201019	HDAC5	-0.95	-20.65	-0.69	1.17e-67	Total body bone mineral density;
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.47	0.37	3.34e-16	Alzheimer's disease;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs10781543	0.839	rs7863766	chr9:139381314	T/G	cg14169450	chr9:139327907	INPP5E	0.37	6.76	0.3	4.11e-11	Monocyte percentage of white cells;
LGG	cis	rs887829	0.569	rs6711351	chr2:234634916	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.32	-0.36	9.69e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.79	-13.7	-0.54	4.29e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2124969	0.548	rs983916	chr2:161015066	T/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.18	-0.39	1.39e-18	Waist circumference adjusted for body mass index;
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.4	6.78	0.3	3.68e-11	Carotid intima media thickness;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg11494091	chr17:61959527	GH2	0.99	23.75	0.74	4.14e-82	Prudent dietary pattern;
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs975722	0.646	rs2082056	chr7:117211853	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.8	0.41	9.99e-21	Coronary artery disease;
LGG	cis	rs9381107	0.932	rs16892227	chr6:9425046	A/G	cg14735645	chr6:9486422	NA	-0.41	-6.8	-0.3	3.24e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg12082025	chr19:1064218	ABCA7	-0.46	-7.05	-0.31	6.64e-12	Alzheimer's disease (late onset);
LGG	cis	rs9486719	0.843	rs2205754	chr6:96843134	T/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs3796352	1.000	rs3097417	chr3:53088601	C/G	cg12962167	chr3:53033115	SFMBT1	-0.75	-7.48	-0.33	3.88e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7659604	0.539	rs11731917	chr4:122783233	G/A	cg20573242	chr4:122745356	CCNA2	0.53	9.88	0.42	5.06e-21	Type 2 diabetes;
LGG	cis	rs6964587	0.967	rs6974827	chr7:91772945	C/T	cg17063962	chr7:91808500	NA	0.53	9.81	0.42	8.76e-21	Breast cancer;
LGG	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.92	-0.31	1.5e-11	Colorectal cancer;
LGG	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg15103426	chr22:29168792	CCDC117	0.73	11.78	0.48	3.23e-28	Lymphocyte counts;
LGG	cis	rs7523273	0.564	rs1977268	chr1:207881036	A/C	cg22525895	chr1:207977042	MIR29B2	0.46	8.76	0.38	3.78e-17	Schizophrenia;
LGG	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg18850127	chr7:39170497	POU6F2	-0.63	-15.9	-0.59	9.71e-46	IgG glycosylation;
LGG	cis	rs17776563	0.639	rs10852102	chr15:89110885	C/A	cg05013243	chr15:89149849	MIR1179	-0.33	-6.7	-0.3	6.16e-11	Thyroid hormone levels;
LGG	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg05335186	chr13:53173507	NA	0.69	16.93	0.62	2.19e-50	Lewy body disease;
LGG	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg19336497	chr11:14380999	RRAS2	0.39	7.74	0.34	6.22e-14	Mitochondrial DNA levels;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg03188948	chr7:1209495	NA	0.4	7.02	0.31	7.82e-12	Longevity;Endometriosis;
LGG	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs9300255	0.739	rs1879380	chr12:123739111	G/A	cg00376283	chr12:123451042	ABCB9	-0.62	-9.47	-0.4	1.4e-19	Neutrophil percentage of white cells;
LGG	cis	rs12188164	0.930	rs72717440	chr5:449701	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.7	0.56	1.95e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1008375	1.000	rs10939747	chr4:17691166	C/A	cg02297831	chr4:17616191	MED28	0.46	8.43	0.36	4.56e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.77	0.3	3.94e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg00409905	chr10:38381863	ZNF37A	-0.66	-12.54	-0.5	2.94e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs977987	0.843	rs7499872	chr16:75426529	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.36	0.43	8.99e-23	Dupuytren's disease;
LGG	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	11.92	0.48	9.52e-29	Mean platelet volume;
LGG	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg12386194	chr3:101231763	SENP7	0.75	13.05	0.52	2.33e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg23758822	chr17:41437982	NA	0.89	15.68	0.59	9.31e-45	Menopause (age at onset);
LGG	cis	rs734999	0.588	rs3001837	chr1:2532506	G/A	cg20673091	chr1:2541236	MMEL1	-0.77	-18.14	-0.64	6.09e-56	Ulcerative colitis;
LGG	cis	rs6714710	0.603	rs11678591	chr2:98541001	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.48	0.4	1.31e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs798554	0.757	rs1182172	chr7:2878103	G/A	cg05793240	chr7:2802953	GNA12	0.33	7.32	0.32	1.1e-12	Height;
LGG	cis	rs7975161	0.938	rs10400561	chr12:104640920	A/G	cg25273343	chr12:104657179	TXNRD1	-0.77	-10.23	-0.43	2.68e-22	Toenail selenium levels;
LGG	cis	rs240764	0.764	rs12208241	chr6:100933472	T/C	cg21058520	chr6:100914733	NA	0.53	9.26	0.4	7.53e-19	Neuroticism;
LGG	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg05677249	chr15:77158041	SCAPER	0.32	6.76	0.3	4.11e-11	Blood metabolite levels;
LGG	cis	rs300774	1.000	rs2015419	chr2:118385	A/G	cg04617936	chr2:214353	NA	-0.48	-7.07	-0.31	5.59e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs1580019	0.547	rs56981934	chr7:32535202	C/G	cg06627557	chr7:32535165	LSM5;AVL9	1.12	28.19	0.79	1.64e-102	Cognitive ability;
LGG	cis	rs17162190	0.698	rs4659442	chr1:26823580	T/G	cg23229016	chr1:26872525	RPS6KA1	0.25	6.82	0.3	2.82e-11	Mean corpuscular volume;
LGG	cis	rs7666738	0.753	rs28390295	chr4:99028497	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.45e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg24503407	chr1:205819492	PM20D1	-0.4	-7.18	-0.32	2.75e-12	Menarche (age at onset);
LGG	cis	rs2640806	0.645	rs11782979	chr8:97327116	G/A	cg22138393	chr8:97340270	PTDSS1	0.31	7.85	0.34	2.94e-14	Obesity-related traits;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.660	rs79009421	chr7:66068509	G/C	cg11764359	chr7:65958608	NA	-0.62	-10.8	-0.45	2.09e-24	Aortic root size;
LGG	cis	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg12193833	chr17:30244370	NA	-0.28	-6.91	-0.31	1.6e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9354308	0.764	rs1938071	chr6:66583180	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs208520	1.000	rs72884017	chr6:66992513	T/G	cg07460842	chr6:66804631	NA	0.9	14.84	0.57	5.13e-41	Exhaled nitric oxide output;
LGG	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg03929089	chr4:120376271	NA	-0.46	-7.33	-0.32	1.06e-12	HDL cholesterol;
LGG	cis	rs1577917	0.771	rs2783171	chr6:86382765	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.89	17.54	0.63	3.3e-53	Response to antipsychotic treatment;
LGG	cis	rs9894429	0.550	rs6565617	chr17:79612333	G/A	cg18240062	chr17:79603768	NPLOC4	0.62	10.39	0.43	6.97e-23	Eye color traits;
LGG	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg08344181	chr3:125677491	NA	-0.9	-8.76	-0.38	3.73e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg20283391	chr11:68216788	NA	-0.41	-6.97	-0.31	1.13e-11	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05489143	chr3:40498640	RPL14	0.43	6.91	0.31	1.59e-11	Cognitive performance;
LGG	trans	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.15e-19	Gout;
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.4	7.62	0.33	1.44e-13	Personality dimensions;
LGG	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	12.85	0.51	1.53e-32	Hip circumference adjusted for BMI;
LGG	cis	rs4731207	0.689	rs1481341	chr7:124567123	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.37	-0.32	7.81e-13	Cutaneous malignant melanoma;
LGG	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg06453172	chr10:134556979	INPP5A	-0.49	-7.46	-0.33	4.27e-13	Migraine;
LGG	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg20637307	chr2:213403960	ERBB4	-0.45	-8.57	-0.37	1.6e-16	Symmetrical dimethylarginine levels;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg19524238	chr7:2802976	GNA12	-0.38	-8.67	-0.37	7.18e-17	Height;
LGG	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg21211680	chr2:198530	NA	-1.25	-19.07	-0.66	2.83e-60	Blood protein levels;
LGG	cis	rs1707322	1.000	rs4660331	chr1:46458783	A/C	cg03146154	chr1:46216737	IPP	0.54	9.98	0.42	2.26e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9811920	0.809	rs793475	chr3:99543764	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.42	-0.36	4.79e-16	Axial length;
LGG	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6831352	0.918	rs17218141	chr4:100055908	T/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg08499158	chr17:42289980	UBTF	-0.67	-12.23	-0.49	5.34e-30	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12405341	chr2:233415195	TIGD1;EIF4E2	0.46	6.98	0.31	1.01e-11	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg07606381	chr6:8435919	SLC35B3	-0.67	-12.48	-0.5	5.16e-31	Motion sickness;
LGG	cis	rs36051895	0.658	rs62541531	chr9:5011795	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-15.67	-0.59	1.04e-44	Pediatric autoimmune diseases;
LGG	cis	rs8177179	0.967	rs6439436	chr3:133453779	C/T	cg16262614	chr3:133464971	TF	-0.47	-8.65	-0.37	8.39e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs3785574	0.962	rs8079161	chr17:61808561	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.79e-19	Height;
LGG	cis	rs11190604	0.767	rs11190513	chr10:102165238	A/G	cg07080220	chr10:102295463	HIF1AN	0.58	10.07	0.42	1.04e-21	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-6.72	-0.3	5.48e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg02574844	chr11:5959923	NA	-0.55	-9.74	-0.41	1.6e-20	DNA methylation (variation);
LGG	cis	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg09307838	chr4:120376055	NA	0.78	13.12	0.52	1.14e-33	Corneal astigmatism;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.73	0.3	5.04e-11	Schizophrenia;
LGG	cis	rs220324	1.000	rs220324	chr21:43586699	C/T	cg08841829	chr21:43638893	ABCG1	0.41	6.86	0.3	2.21e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.57	-0.41	6.32e-20	Life satisfaction;
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg15145296	chr3:125709740	NA	-0.63	-8.21	-0.36	2.25e-15	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg05313129	chr8:58192883	C8orf71	-0.71	-9.89	-0.42	4.83e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg08621203	chr6:150244597	RAET1G	0.53	9.96	0.42	2.62e-21	Testicular germ cell tumor;
LGG	trans	rs9650657	0.812	rs10089615	chr8:10634132	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.95	-0.31	1.23e-11	Neuroticism;
LGG	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg03517284	chr6:25882590	NA	0.43	7.35	0.32	9.3e-13	Iron status biomarkers;
LGG	cis	rs753955	0.553	rs1886973	chr13:24423070	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.42	-7.53	-0.33	2.64e-13	Lung cancer;
LGG	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg19645103	chr12:69753606	YEATS4	-0.51	-7.58	-0.33	1.91e-13	Response to diuretic therapy;
LGG	cis	rs11148252	0.574	rs61958118	chr13:53170226	C/T	cg12458913	chr13:53173898	NA	0.91	21.52	0.71	1.09e-71	Lewy body disease;
LGG	cis	rs28595532	0.720	rs72670233	chr4:119316237	C/G	cg21605333	chr4:119757512	SEC24D	0.94	8.67	0.37	7.19e-17	Cannabis dependence symptom count;
LGG	trans	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg25482853	chr8:67687455	SGK3	0.93	11.64	0.48	1.15e-27	Obesity-related traits;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg22398616	chr13:53314203	LECT1	-0.49	-9.88	-0.42	4.93e-21	Lewy body disease;
LGG	cis	rs1218582	0.772	rs4845682	chr1:154877105	T/C	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg21724239	chr8:58056113	NA	0.54	8.03	0.35	8.22e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg00405596	chr8:11794950	NA	0.42	7.01	0.31	8.45e-12	Monocyte count;
LGG	cis	rs6062302	0.522	rs3761126	chr20:62252044	C/T	cg16989086	chr20:62203971	PRIC285	0.48	7.11	0.31	4.4e-12	Glioblastoma;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.14	-0.39	1.96e-18	Prostate cancer;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.4	-0.36	5.6e-16	Renal function-related traits (BUN);
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg16359550	chr11:109292809	C11orf87	0.41	7.8	0.34	4.26e-14	Schizophrenia;
LGG	cis	rs72945132	0.882	rs7123602	chr11:70181489	C/T	cg14088196	chr11:70211408	PPFIA1	0.92	13.09	0.52	1.54e-33	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07557355	chr1:155904306	KIAA0907	0.49	7.87	0.34	2.59e-14	Cognitive performance;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.22	-0.58	1.08e-42	Prudent dietary pattern;
LGG	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg16077055	chr2:106428750	NCK2	0.31	8.22	0.36	2.08e-15	Addiction;
LGG	cis	rs11885103	0.716	rs2685268	chr2:557590	C/T	cg21195176	chr2:593345	NA	0.38	7.28	0.32	1.43e-12	Heschl's gyrus morphology;
LGG	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	cis	rs8177253	0.965	rs4854760	chr3:133498741	C/T	cg11941060	chr3:133502564	NA	0.5	8.52	0.37	2.19e-16	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg13206674	chr6:150067644	NUP43	0.67	15.43	0.58	1.23e-43	Lung cancer;
LGG	cis	rs834603	0.546	rs869170	chr7:47484299	C/T	cg23694490	chr7:47445681	TNS3	-0.36	-9.83	-0.42	8.06e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.07	0.39	3.36e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4804815	0.780	rs4804814	chr19:7840310	A/G	cg09310891	chr19:7854403	CLEC4GP1	-0.5	-7.88	-0.34	2.31e-14	Neutrophil count;
LGG	cis	rs920590	0.549	rs10749625	chr8:19635117	T/C	cg03894339	chr8:19674705	INTS10	0.43	7.26	0.32	1.67e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10186029	0.667	rs6734174	chr2:213981428	A/C	cg08319019	chr2:214017104	IKZF2	-0.41	-7.1	-0.31	4.66e-12	Systemic sclerosis;
LGG	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg08847533	chr14:75593920	NEK9	-0.51	-9.33	-0.4	4.45e-19	Height;
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.37	-0.43	8.54e-23	Tonsillectomy;
LGG	cis	rs2046867	0.628	rs7617996	chr3:72915315	C/T	cg01043669	chr3:72786069	NA	0.4	7.18	0.32	2.77e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7412746	0.658	rs2230061	chr1:150727539	G/A	cg15448220	chr1:150897856	SETDB1	0.39	7.3	0.32	1.29e-12	Melanoma;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg00149659	chr3:10157352	C3orf10	0.84	10.73	0.45	3.88e-24	Alzheimer's disease;
LGG	cis	rs1568889	1.000	rs12800354	chr11:28047723	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	13.93	0.54	4.38e-37	Bipolar disorder;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg04772025	chr11:68637568	NA	0.76	13.31	0.53	1.89e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.55	-0.33	2.3e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7220401	0.789	rs4794859	chr17:27962393	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.6	-10.95	-0.45	5.7e-25	Coronary artery disease;
LGG	cis	rs7173389	1.000	rs7173389	chr15:73663903	A/T	cg01796676	chr15:73680284	NA	0.49	8.39	0.36	5.75e-16	Resting heart rate;
LGG	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.62	0.41	4.23e-20	Coronary artery disease;
LGG	cis	rs12188164	0.965	rs41282625	chr5:475626	C/G	cg26850624	chr5:429559	AHRR	-0.35	-7.57	-0.33	1.97e-13	Cystic fibrosis severity;
LGG	cis	rs975722	0.569	rs39315	chr7:116963562	T/C	cg10524701	chr7:117356490	CTTNBP2	0.37	7.84	0.34	3.12e-14	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs910316	1.000	rs876402	chr14:75601862	C/T	cg11812906	chr14:75593930	NEK9	-0.54	-10.11	-0.43	7.78e-22	Height;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg03452623	chr4:187889614	NA	-1.04	-30.48	-0.82	9.59e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg18402987	chr7:1209562	NA	0.67	9.29	0.4	5.95e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2952156	0.920	rs2517954	chr17:37843550	T/C	cg07936489	chr17:37558343	FBXL20	-0.42	-6.76	-0.3	4.06e-11	Asthma;
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg26138144	chr22:38071188	LGALS1	0.91	24.49	0.75	1.35e-85	Fat distribution (HIV);
LGG	cis	rs9868809	0.656	rs73078362	chr3:48703917	G/C	cg00383909	chr3:49044727	WDR6	1.01	10.54	0.44	2.02e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3784262	0.739	rs1550574	chr15:58213368	G/T	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.25	-0.32	1.72e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs3857067	1.000	rs7682116	chr4:95002704	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.46	-0.33	4.34e-13	QT interval;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg02018176	chr4:1364513	KIAA1530	0.37	8.41	0.36	5.16e-16	Obesity-related traits;
LGG	cis	rs67311347	1.000	rs9968170	chr3:40494274	A/G	cg13683864	chr3:40499215	RPL14	1.05	22.3	0.72	2.35e-75	Renal cell carcinoma;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg10296513	chr8:37963428	ASH2L	0.45	7.2	0.32	2.4e-12	Hepatitis;
LGG	cis	rs2075184	1	rs2075184	chr2:103080592	T/C	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Pediatric autoimmune diseases;
LGG	cis	rs9877502	0.746	rs13323015	chr3:190595760	C/T	cg25724246	chr3:190595776	SNAR-I	-0.35	-7.13	-0.31	3.8e-12	Alzheimer's disease biomarkers;
LGG	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	-0.49	-8.6	-0.37	1.28e-16	Menarche (age at onset);
LGG	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.11	0.31	4.52e-12	Height;
LGG	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-7.98	-0.35	1.16e-14	IgG glycosylation;
LGG	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.8	0.48	2.77e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.66	0.51	9.05e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg04935436	chr20:30431758	NA	0.41	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4561483	0.583	rs12149833	chr16:12003723	C/T	cg08843971	chr16:11963173	GSPT1	0.59	14.76	0.57	1.16e-40	Testicular germ cell tumor;
LGG	trans	rs8002861	0.781	rs3816311	chr13:44453783	G/A	cg12856521	chr11:46389249	DGKZ	0.43	7.35	0.32	9.17e-13	Leprosy;
LGG	cis	rs12681288	0.676	rs2701901	chr8:1017816	G/C	cg04851639	chr8:1020857	NA	-0.44	-8.79	-0.38	2.93e-17	Schizophrenia;
LGG	cis	rs4740619	0.544	rs7857601	chr9:15813937	T/G	cg14451791	chr9:16040625	NA	0.3	7.58	0.33	1.9e-13	Body mass index;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.47	-0.37	3.18e-16	Lung cancer;
LGG	cis	rs9916302	0.706	rs28482878	chr17:37497100	A/G	cg07936489	chr17:37558343	FBXL20	1.0	15.63	0.59	1.55e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs2573652	0.722	rs8041337	chr15:100541808	T/C	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.3	-0.32	1.29e-12	Height;
LGG	cis	rs524281	0.861	rs11227411	chr11:65879478	C/T	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs870825	0.929	rs1405939	chr4:185591444	C/T	cg04058563	chr4:185651563	MLF1IP	1.01	16.69	0.61	2.56e-49	Blood protein levels;
LGG	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg27432699	chr2:27873401	GPN1	0.68	13.99	0.55	2.47e-37	Oral cavity cancer;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1670533	1.000	rs1010342	chr4:1068819	C/T	cg27284194	chr4:1044797	NA	0.53	9.65	0.41	3.36e-20	Recombination rate (females);
LGG	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14442939	chr10:27389572	ANKRD26	0.74	11.21	0.46	5.51e-26	Breast cancer;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25427524	chr10:38739819	LOC399744	0.62	11.66	0.48	9.85e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	6.65	0.3	8.25e-11	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.46	-0.53	4.22e-35	Personality dimensions;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg07959490	chr17:80112427	CCDC57	0.38	7.38	0.32	7.34e-13	Life satisfaction;
LGG	cis	rs12477438	0.798	rs9808541	chr2:99642179	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs2153535	0.580	rs1577470	chr6:8462426	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.5e-18	Motion sickness;
LGG	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08045932	chr20:61659980	NA	0.58	12.21	0.49	6.44e-30	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg06654118	chr4:1303317	MAEA	0.45	7.86	0.34	2.66e-14	Obesity-related traits;
LGG	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg09137382	chr11:130731461	NA	0.35	6.66	0.3	7.63e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs694739	0.536	rs671976	chr11:64046029	G/A	cg05555928	chr11:63887634	MACROD1	-0.44	-8.26	-0.36	1.51e-15	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.42	0.33	5.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17030434	0.863	rs17030382	chr4:154650887	A/G	cg14289246	chr4:154710475	SFRP2	-0.69	-10.77	-0.45	2.85e-24	Electrocardiographic conduction measures;
LGG	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg02073558	chr3:44770973	ZNF501	0.86	19.14	0.66	1.43e-60	Depressive symptoms;
LGG	cis	rs778371	0.723	rs34707169	chr2:233699459	C/T	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.11	-0.46	1.34e-25	Schizophrenia;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg00684032	chr4:1343700	KIAA1530	0.51	9.88	0.42	5.3e-21	Obesity-related traits;
LGG	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg24692254	chr21:30365293	RNF160	-0.99	-26.24	-0.77	1.23e-93	Dental caries;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.84	-0.3	2.44e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.3e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.21	0.36	2.14e-15	Retinal vascular caliber;
LGG	cis	rs4417704	0.551	rs4606922	chr2:241891207	G/A	cg14055004	chr2:241860995	NA	0.28	7.52	0.33	2.93e-13	Joint mobility (Beighton score);
LGG	trans	rs2197308	0.667	rs61920838	chr12:37856814	T/C	cg06521331	chr12:34319734	NA	0.52	9.42	0.4	2.19e-19	Morning vs. evening chronotype;
LGG	cis	rs13394619	1.000	rs2884374	chr2:11731846	C/T	cg07314298	chr2:11723111	GREB1	0.48	10.06	0.42	1.15e-21	Endometriosis;
LGG	cis	rs35176054	0.730	rs35053579	chr10:105510755	C/T	cg00730670	chr10:105510713	SH3PXD2A	-0.52	-6.94	-0.31	1.37e-11	Atrial fibrillation;
LGG	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.06	0.39	3.65e-18	Schizophrenia;
LGG	trans	rs61931739	0.500	rs11836198	chr12:34552782	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.97	-0.31	1.08e-11	Height;
LGG	cis	rs763121	0.853	rs138712	chr22:39141600	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	17.45	0.63	9.44e-53	Menopause (age at onset);
LGG	cis	rs12824058	0.831	rs4759452	chr12:130812799	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg07061783	chr6:25882402	NA	0.39	6.88	0.3	1.9e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	1.000	rs34089239	chr17:20057959	G/T	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg12458913	chr13:53173898	NA	0.68	13.14	0.52	9.57e-34	Lewy body disease;
LGG	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	7.04	0.31	6.89e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10426930	0.607	rs56251289	chr19:5042732	C/A	cg18473234	chr19:5097819	KDM4B	0.44	7.61	0.33	1.5e-13	Monocyte percentage of white cells;
LGG	cis	rs10911232	0.560	rs6697320	chr1:183037377	T/G	cg15522984	chr1:182991683	LAMC1	0.45	9.14	0.39	2.01e-18	Hypertriglyceridemia;
LGG	trans	rs11039798	0.541	rs12283728	chr11:48796407	G/A	cg15704280	chr7:45808275	SEPT13	0.77	8.96	0.38	8.01e-18	Axial length;
LGG	cis	rs2033732	0.673	rs10808858	chr8:85070841	C/T	cg05716166	chr8:85095498	RALYL	0.44	7.18	0.32	2.84e-12	Body mass index;
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.15	0.39	1.76e-18	Life satisfaction;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg08280861	chr8:58055591	NA	0.52	6.98	0.31	1.01e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs227808	0.812	rs9472322	chr6:44645974	C/T	cg18551225	chr6:44695536	NA	-0.48	-7.05	-0.31	6.59e-12	Male-pattern baldness;
LGG	cis	rs3796619	1.000	rs1453605	chr4:1075771	C/T	cg21130718	chr4:1044621	NA	0.39	7.68	0.34	9.53e-14	Recombination rate (males);
LGG	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.82	-0.3	2.93e-11	Bone mineral density;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg18479299	chr3:125709523	NA	-0.6	-7.8	-0.34	4.1e-14	Blood pressure (smoking interaction);
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg19635926	chr16:89946313	TCF25	0.75	7.36	0.32	8.74e-13	Skin colour saturation;
LGG	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.9	0.31	1.68e-11	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg19077165	chr18:44547161	KATNAL2	0.69	13.28	0.53	2.41e-34	Personality dimensions;
LGG	cis	rs9660992	0.573	rs7368327	chr1:205214792	C/T	cg00857998	chr1:205179979	DSTYK	0.5	7.9	0.34	2.06e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6502050	0.835	rs8080625	chr17:80115447	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg13147721	chr7:65941812	NA	-0.44	-6.76	-0.3	4.05e-11	Corneal structure;
LGG	trans	rs12439619	0.883	rs62012045	chr15:82521707	G/A	cg04831495	chr15:85060580	GOLGA6L5	-0.46	-8.79	-0.38	3e-17	Intelligence (multi-trait analysis);
LGG	cis	rs16976116	0.855	rs28649719	chr15:55500211	C/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8141529	0.778	rs5762795	chr22:29182500	C/A	cg02153584	chr22:29168773	CCDC117	0.7	11.84	0.48	1.9e-28	Lymphocyte counts;
LGG	cis	rs4788815	0.513	rs12929547	chr16:71794734	A/G	cg06353428	chr16:71660113	MARVELD3	1.25	18.8	0.66	5.04e-59	Metabolite levels;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs3818285	0.556	rs941864	chr10:111656948	T/C	cg00817464	chr10:111662876	XPNPEP1	-0.55	-10.04	-0.42	1.42e-21	Superior crus of antihelix expression;
LGG	cis	rs26232	0.521	rs11958562	chr5:102363061	C/T	cg23492399	chr5:102201601	PAM	-0.55	-8.17	-0.36	2.91e-15	Rheumatoid arthritis;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22968622	chr17:43663579	NA	1.07	20.05	0.68	7.69e-65	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs67460515	0.892	rs13073147	chr3:161045237	T/C	cg03342759	chr3:160939853	NMD3	-0.76	-13.57	-0.53	1.53e-35	Parkinson's disease;
LGG	cis	rs864537	0.676	rs1773561	chr1:167421951	C/T	cg09179987	chr1:167433047	CD247	0.42	9.21	0.39	1.14e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs4936894	0.500	rs4393330	chr11:124108956	A/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.43	-0.44	5.17e-23	Aging (time to death);
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg06850241	chr22:41845214	NA	-0.44	-6.83	-0.3	2.67e-11	Vitiligo;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg00800038	chr16:89945340	TCF25	-0.71	-8.62	-0.37	1.05e-16	Skin colour saturation;
LGG	cis	rs9290065	0.519	rs6774203	chr3:160705217	G/T	cg03342759	chr3:160939853	NMD3	-0.49	-8.38	-0.36	6.54e-16	Kawasaki disease;
LGG	cis	rs6088590	0.561	rs11167239	chr20:33140472	G/A	cg08999081	chr20:33150536	PIGU	0.44	11.09	0.46	1.6e-25	Coronary artery disease;
LGG	trans	rs7395662	0.927	rs8188938	chr11:48690866	C/T	cg00717180	chr2:96193071	NA	0.41	7.28	0.32	1.49e-12	HDL cholesterol;
LGG	cis	rs3806843	0.868	rs2262573	chr5:140123627	T/A	cg19875535	chr5:140030758	IK	-0.54	-11.23	-0.46	4.99e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6489882	0.510	rs61478890	chr12:113364375	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.38e-13	Chronic lymphocytic leukemia;
LGG	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.05	-0.42	1.23e-21	Joint mobility (Beighton score);
LGG	cis	rs7432375	1.000	rs6439649	chr3:136371691	G/T	cg12473912	chr3:136751656	NA	-0.4	-6.85	-0.3	2.36e-11	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	cis	rs11001765	0.530	rs11001752	chr10:78125882	C/T	cg16072382	chr10:78096093	C10orf11	0.53	6.89	0.31	1.78e-11	Chin dimples;
LGG	cis	rs4481887	0.893	rs10888349	chr1:248448625	T/C	cg01631408	chr1:248437212	OR2T33	-0.55	-10.02	-0.42	1.59e-21	Common traits (Other);
LGG	cis	rs4417704	0.551	rs11688859	chr2:241904001	G/C	cg14055004	chr2:241860995	NA	0.28	7.15	0.32	3.36e-12	Joint mobility (Beighton score);
LGG	trans	rs9914544	0.583	rs11078422	chr17:18804413	C/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.61	-0.33	1.59e-13	Educational attainment (years of education);
LGG	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.09	-0.35	5.33e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4969178	0.965	rs2292643	chr17:76395421	G/A	cg02836325	chr17:76403955	PGS1	-0.72	-14.47	-0.56	2e-39	HDL cholesterol levels;
LGG	cis	rs35306767	0.669	rs2101051	chr10:1158791	G/T	cg25019033	chr10:957182	NA	-0.47	-8.3	-0.36	1.18e-15	Eosinophil percentage of granulocytes;
LGG	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg20503657	chr10:835505	NA	0.75	10.27	0.43	2.02e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs10189230	0.967	rs13026380	chr2:222352715	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.7	0.51	6.37e-32	Urate levels in lean individuals;
LGG	cis	rs10504130	0.502	rs10087958	chr8:52866669	A/G	cg13492337	chr8:52722140	PXDNL	-0.49	-7.52	-0.33	2.95e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs765787	0.530	rs12903149	chr15:45539076	G/A	cg25801113	chr15:45476975	SHF	-0.87	-18.68	-0.66	1.96e-58	Uric acid levels;
LGG	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs4926298	1.000	rs4926298	chr19:13153035	C/T	cg04657146	chr19:12876947	HOOK2	-0.41	-6.83	-0.3	2.65e-11	Bipolar disorder;
LGG	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg22437258	chr11:111473054	SIK2	0.56	9.58	0.41	5.96e-20	Primary sclerosing cholangitis;
LGG	cis	rs2120243	0.539	rs988587	chr3:157054271	A/C	cg24825693	chr3:157122686	VEPH1	-0.51	-11.27	-0.46	3.25e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6752107	0.936	rs10178603	chr2:234206610	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.23	0.32	2e-12	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.37	-0.36	6.97e-16	Retinal vascular caliber;
LGG	cis	rs10744422	0.843	rs3896870	chr12:123333611	T/C	cg25930673	chr12:123319894	HIP1R	-0.73	-9.11	-0.39	2.45e-18	Schizophrenia;
LGG	trans	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg24247370	chr13:99142703	STK24	-0.39	-7.16	-0.32	3.29e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg15971980	chr6:150254442	NA	0.44	8.36	0.36	7.59e-16	Lung cancer;
LGG	cis	rs66887589	0.616	rs10032299	chr4:120206419	C/T	cg09307838	chr4:120376055	NA	0.48	7.84	0.34	3.05e-14	Diastolic blood pressure;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.23	-0.58	9.04e-43	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.534	rs7911971	chr10:60305160	G/A	cg07615347	chr10:60278583	BICC1	-0.52	-12.67	-0.51	8.5e-32	Refractive error;
LGG	cis	rs17401966	1.000	rs12132635	chr1:10430479	G/A	cg19773385	chr1:10388646	KIF1B	-0.48	-9.61	-0.41	4.52e-20	Hepatocellular carcinoma;
LGG	cis	rs9467160	0.581	rs2760140	chr6:24481039	A/G	cg20631270	chr6:24437470	GPLD1	0.42	6.67	0.3	7.45e-11	Liver enzyme levels;
LGG	cis	rs1055129	0.682	rs7217432	chr17:73834604	A/G	cg14829360	chr17:73884958	NA	-0.45	-8.16	-0.35	3.29e-15	White matter hyperintensity burden;
LGG	cis	rs7208859	0.623	rs73269913	chr17:29092183	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.88	0.45	1.06e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg16583315	chr14:65563665	MAX	-0.4	-8.23	-0.36	1.87e-15	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18039855	chr11:57434952	ZDHHC5	0.44	7.44	0.33	5.09e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.01	-0.42	1.74e-21	Triglycerides;
LGG	cis	rs1348850	0.874	rs1348848	chr2:178358233	A/C	cg27490568	chr2:178487706	NA	-0.5	-10.13	-0.43	6.31e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs736408	0.505	rs2083180	chr3:52668119	G/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.29	-0.32	1.38e-12	Bipolar disorder;
LGG	cis	rs736408	0.522	rs998909	chr3:52805093	A/G	cg14092988	chr3:52407081	DNAH1	0.3	7.97	0.35	1.28e-14	Bipolar disorder;
LGG	cis	rs4689592	0.546	rs2359012	chr4:7066053	A/C	cg06697600	chr4:7070879	GRPEL1	-0.55	-9.74	-0.41	1.65e-20	Monocyte percentage of white cells;
LGG	cis	rs477692	1.000	rs567700	chr10:131423126	C/T	cg05714579	chr10:131428358	MGMT	0.56	11.5	0.47	4.42e-27	Response to temozolomide;
LGG	cis	rs2439831	0.850	rs28578398	chr15:44075046	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.54e-24	Lung cancer in ever smokers;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.3	-0.4	5.47e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.31	-0.43	1.41e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9467773	0.550	rs9379874	chr6:26440429	A/T	cg09904177	chr6:26538194	HMGN4	-0.43	-7.72	-0.34	7.24e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3820928	1.000	rs3731593	chr2:227773924	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.26	-0.32	1.68e-12	Pulmonary function;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg06221963	chr1:154839813	KCNN3	-0.53	-10.86	-0.45	1.26e-24	Prostate cancer;
LGG	cis	rs4730250	0.707	rs61014091	chr7:106810107	A/C	cg02696742	chr7:106810147	HBP1	-0.85	-12.31	-0.5	2.47e-30	Osteoarthritis;
LGG	cis	rs10870270	0.957	rs3753008	chr10:133785129	A/C	cg08754478	chr10:133766260	PPP2R2D	-0.67	-12.43	-0.5	8.17e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg08621203	chr6:150244597	RAET1G	0.46	7.95	0.35	1.41e-14	Lung cancer;
LGG	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs7072216	0.763	rs3750601	chr10:100174561	C/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.2	-0.32	2.42e-12	Metabolite levels;
LGG	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg15268244	chr15:77196840	NA	0.43	8.1	0.35	4.82e-15	Blood metabolite levels;
LGG	cis	rs909674	0.541	rs5750816	chr22:39810379	A/G	cg04986931	chr22:39850128	NA	-0.33	-7.66	-0.34	1.06e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg21659725	chr3:3221576	CRBN	0.55	7.4	0.33	6.25e-13	Menarche (age at onset);
LGG	cis	rs453301	0.686	rs13252797	chr8:8861430	A/G	cg11995313	chr8:8860691	ERI1	-0.45	-7.85	-0.34	2.99e-14	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.610	rs199442	chr17:44820122	G/A	cg01341218	chr17:43662625	NA	0.67	12.14	0.49	1.21e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11628318	0.851	rs4243734	chr14:103023569	T/C	cg12046867	chr14:103022105	NA	-0.8	-14.8	-0.57	7.62e-41	Platelet count;
LGG	cis	rs12220238	1.000	rs11000912	chr10:75948477	A/C	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.13	0.46	1.17e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9487094	1.000	rs9480955	chr6:109744533	T/A	cg01125227	chr6:109776195	MICAL1	0.46	7.78	0.34	4.77e-14	Height;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	7.27	0.32	1.57e-12	Obesity-related traits;
LGG	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg25019033	chr10:957182	NA	-0.57	-10.57	-0.44	1.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs2439831	0.867	rs2614811	chr15:43913487	C/T	cg15269541	chr15:43626905	ADAL	-0.42	-6.65	-0.3	8.44e-11	Lung cancer in ever smokers;
LGG	cis	rs709400	0.658	rs72708874	chr14:103899251	T/G	cg26031613	chr14:104095156	KLC1	0.78	13.53	0.53	2.21e-35	Body mass index;
LGG	cis	rs9467773	1.000	rs6925703	chr6:26521589	G/A	cg09904177	chr6:26538194	HMGN4	0.78	18.11	0.64	8.44e-56	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg15485101	chr11:133734466	NA	0.6	10.71	0.45	4.6e-24	Childhood ear infection;
LGG	cis	rs79839061	0.610	rs3775130	chr4:875144	G/A	cg07828340	chr4:882639	GAK	0.88	9.35	0.4	3.7e-19	Intelligence (multi-trait analysis);
LGG	trans	rs6089829	0.851	rs4809460	chr20:61661355	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.04e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11967485	0.534	rs62435817	chr6:157154688	A/G	cg23222435	chr6:157204239	ARID1B	-0.8	-7.35	-0.32	9.26e-13	Calcium levels;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.65	-0.33	1.17e-13	Lung cancer;
LGG	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15857475	chr8:145742913	RECQL4;LRRC14	0.61	10.81	0.45	1.95e-24	Age at first birth;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.52	-8.7	-0.37	6.06e-17	Bipolar disorder;
LGG	cis	rs11677416	1.000	rs2856837	chr2:113541925	G/A	cg27083787	chr2:113543245	IL1A	0.53	8.95	0.38	8.71e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs8014204	0.544	rs2286913	chr14:75386576	G/A	cg06637938	chr14:75390232	RPS6KL1	1.09	26.18	0.77	2.27e-93	Caffeine consumption;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.54	9.72	0.41	1.98e-20	Longevity;
LGG	cis	rs10089	1.000	rs10478803	chr5:127488855	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.8	0.48	2.79e-28	Ileal carcinoids;
LGG	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	trans	rs17685	0.753	rs8200	chr7:75696606	C/G	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.48	-0.76	3.9e-90	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.51	0.37	2.43e-16	Thyroid stimulating hormone;
LGG	cis	rs9527	0.662	rs743575	chr10:104594906	T/G	cg04362960	chr10:104952993	NT5C2	0.51	8.98	0.39	6.73e-18	Arsenic metabolism;
LGG	cis	rs4423214	1.000	rs2282621	chr11:71183474	C/T	cg05163923	chr11:71159392	DHCR7	0.73	14.14	0.55	5.25e-38	Vitamin D levels;
LGG	cis	rs7727544	0.606	rs10060615	chr5:131708877	T/C	cg07395648	chr5:131743802	NA	-0.44	-9.68	-0.41	2.61e-20	Blood metabolite levels;
LGG	cis	rs208520	0.690	rs851467	chr6:66802721	A/G	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	cis	rs1218582	0.772	rs6699043	chr1:154913021	T/C	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.68	0.34	9.3e-14	Prostate cancer;
LGG	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	trans	rs9325144	0.532	rs1352121	chr12:39130696	A/G	cg06521331	chr12:34319734	NA	0.43	7.32	0.32	1.09e-12	Morning vs. evening chronotype;
LGG	cis	rs7572644	0.640	rs12617113	chr2:28059937	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.81	0.3	2.95e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.79	-0.34	4.57e-14	Dementia with Lewy bodies;
LGG	cis	rs61192259	0.566	rs10947739	chr6:38469323	C/T	cg07362130	chr6:38359646	BTBD9	-0.35	-7.58	-0.33	1.94e-13	Restless legs syndrome;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7100689	0.599	rs7077847	chr10:82134952	A/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.05	0.57	5.6e-42	Post bronchodilator FEV1;
LGG	cis	rs2470578	0.766	rs62245860	chr3:17292933	T/C	cg20981856	chr3:17787350	NA	0.35	6.66	0.3	7.58e-11	Schizophrenia;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.53	-0.33	2.64e-13	Skin colour saturation;
LGG	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg05973401	chr12:123451056	ABCB9	0.43	7.17	0.32	2.95e-12	Platelet count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg09270044	chr1:186344798	TPR;C1orf27;MIR548F1	0.61	6.96	0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.615	rs35423199	chr11:49514914	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.71	-0.48	6.37e-28	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.7e-13	Menopause (age at onset);
LGG	cis	rs4481887	1.000	rs6659039	chr1:248465689	C/T	cg01631408	chr1:248437212	OR2T33	-0.53	-9.61	-0.41	4.58e-20	Common traits (Other);
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.1	-0.35	4.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7766436	0.848	rs13207207	chr6:22579066	G/A	cg13666174	chr6:22585274	NA	-0.51	-11.87	-0.48	1.5e-28	Coronary artery disease;
LGG	cis	rs2072499	0.966	rs2244144	chr1:156184598	G/A	cg24450063	chr1:156163899	SLC25A44	1.14	24.36	0.75	5.89e-85	Testicular germ cell tumor;
LGG	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg13009111	chr11:71350975	NA	0.35	7.55	0.33	2.32e-13	Myopia (pathological);
LGG	trans	rs116095464	0.558	rs10059907	chr5:205360	G/C	cg09048205	chr5:1608656	LOC728613	-0.52	-8.45	-0.37	3.82e-16	Breast cancer;
LGG	cis	rs4517514	0.509	rs11018869	chr11:89865168	A/G	cg14505434	chr11:89522851	NA	0.65	8.36	0.36	7.34e-16	Trans fatty acid levels;
LGG	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg22862634	chr11:62369728	EML3;MTA2	-0.54	-10.97	-0.45	4.82e-25	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs8073060	0.586	rs225292	chr17:33926383	G/A	cg19694781	chr19:47549865	TMEM160	-0.96	-14.35	-0.55	6.84e-39	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-11.37	-0.47	1.36e-26	Morning vs. evening chronotype;
LGG	cis	rs2916247	1.000	rs55701498	chr8:93039932	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.39	-0.36	6e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.57	-0.33	1.97e-13	Menopause (age at onset);
LGG	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-18.43	-0.65	2.64e-57	Cognitive function;
LGG	cis	rs11971779	0.648	rs9656512	chr7:139054046	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs4731207	0.596	rs6980448	chr7:124569418	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.39	-0.32	7.08e-13	Cutaneous malignant melanoma;
LGG	cis	rs11771526	0.901	rs7357136	chr7:32302338	G/T	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg06627557	chr7:32535165	LSM5;AVL9	1.12	28.51	0.8	5.81e-104	Cognitive ability;
LGG	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.42	-7.38	-0.32	7.47e-13	Alzheimer's disease (late onset);
LGG	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.11	0.31	4.39e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.15	-0.39	1.84e-18	Life satisfaction;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg03395511	chr6:291903	DUSP22	-0.69	-11.8	-0.48	2.84e-28	Menopause (age at onset);
LGG	cis	rs62400317	0.793	rs12190367	chr6:45208938	A/G	cg18551225	chr6:44695536	NA	-0.63	-10.04	-0.42	1.41e-21	Total body bone mineral density;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg01943577	chr7:158741284	NA	-0.46	-8.61	-0.37	1.19e-16	Height;
LGG	cis	rs7226408	0.600	rs7244957	chr18:34519270	C/G	cg15022739	chr18:34823045	BRUNOL4	0.41	8.82	0.38	2.32e-17	Obesity-related traits;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg12929805	chr1:2399054	NA	-0.52	-10.18	-0.43	4.39e-22	Non-obstructive azoospermia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09771049	chr17:66031798	KPNA2	0.4	6.69	0.3	6.27e-11	Bipolar disorder;
LGG	cis	rs5750830	0.649	rs4337572	chr22:39800704	C/G	cg04986931	chr22:39850128	NA	0.35	7.52	0.33	2.93e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg02254774	chr11:50257496	LOC441601	0.52	6.7	0.3	5.99e-11	Axial length;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07727872	chr19:33463030	C19orf40;CCDC123	-0.48	-7.03	-0.31	7.46e-12	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.6	0.37	1.23e-16	Personality dimensions;
LGG	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.27	-0.32	1.5e-12	Mood instability;
LGG	cis	rs4538187	0.760	rs11558741	chr2:64124722	C/A	cg02541582	chr2:64069798	UGP2	-0.61	-13.17	-0.52	7.37e-34	Systolic blood pressure;
LGG	cis	rs9581857	0.579	rs76614377	chr13:27974251	A/T	cg01674679	chr13:27998804	GTF3A	-0.76	-8.63	-0.37	1.02e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.69	0.3	6.58e-11	Homoarginine levels;
LGG	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg09222892	chr1:25734099	RHCE	0.46	9.72	0.41	1.97e-20	Erythrocyte sedimentation rate;
LGG	trans	rs7830939	0.586	rs10108359	chr8:9327086	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.99	0.31	9.75e-12	Neuroticism;
LGG	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg02297831	chr4:17616191	MED28	0.51	9.51	0.4	1.03e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6456042	0.893	rs3099283	chr6:166554170	A/C	cg11088901	chr6:166572345	T	-0.39	-8.14	-0.35	3.76e-15	Asthma;
LGG	cis	rs1670533	1.000	rs10026482	chr4:1051128	C/G	cg27284194	chr4:1044797	NA	0.54	9.82	0.42	8.6e-21	Recombination rate (females);
LGG	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg24812749	chr6:127587940	RNF146	0.65	10.93	0.45	6.63e-25	Breast cancer;
LGG	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg16586182	chr3:47516702	SCAP	-0.76	-14.19	-0.55	3.26e-38	Colorectal cancer;
LGG	cis	rs9463078	0.526	rs1159131	chr6:44972209	T/C	cg25276700	chr6:44698697	NA	0.34	6.96	0.31	1.14e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.46	0.4	1.54e-19	Bipolar disorder;
LGG	cis	rs1558375	0.679	rs31676	chr7:87069880	T/C	cg00919237	chr7:87102261	ABCB4	0.55	9.74	0.41	1.64e-20	Gallbladder cancer;
LGG	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	cg07245641	chr1:182991651	LAMC1	0.4	9.11	0.39	2.51e-18	Colorectal cancer;
LGG	cis	rs7666738	0.791	rs2865958	chr4:99040732	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6956675	1.000	rs10231112	chr7:62601257	A/G	cg08930214	chr7:62859557	LOC100287834	0.47	7.63	0.33	1.38e-13	Obesity-related traits;
LGG	cis	rs898097	0.812	rs55794221	chr17:80849003	G/A	cg15369054	chr17:80825471	TBCD	0.57	10.43	0.44	5.13e-23	Breast cancer;
LGG	cis	rs72960926	1.000	rs72950596	chr6:74921364	C/T	cg03266952	chr6:74778945	NA	-0.74	-7.11	-0.31	4.48e-12	Metabolite levels (MHPG);
LGG	cis	rs11677416	1.000	rs72825514	chr2:113527706	G/T	cg27083787	chr2:113543245	IL1A	0.53	8.89	0.38	1.42e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs9467773	0.596	rs2451751	chr6:26646714	T/C	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs1461503	0.809	rs7121955	chr11:122845478	A/T	cg27398637	chr11:122830231	C11orf63	-0.69	-13.43	-0.53	5.59e-35	Menarche (age at onset);
LGG	cis	rs7113850	0.541	rs7116120	chr11:24235050	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	10.48	0.44	3.26e-23	Bone fracture in osteoporosis;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00472445	chr6:101329307	ASCC3	0.59	6.86	0.3	2.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	15.3	0.58	4.59e-43	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10504130	0.569	rs9650180	chr8:52824866	C/T	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	14.46	0.56	2.32e-39	Alzheimer's disease;
LGG	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg08564027	chr20:61660810	NA	1.02	23.77	0.74	3.03e-82	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg08621203	chr6:150244597	RAET1G	0.39	6.72	0.3	5.37e-11	Lung cancer;
LGG	cis	rs62238980	0.614	rs4820061	chr22:32378359	G/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs35160687	0.901	rs6713456	chr2:86507653	T/A	cg10973622	chr2:86423274	IMMT	0.39	6.79	0.3	3.36e-11	Night sleep phenotypes;
LGG	cis	rs11583043	0.918	rs17525451	chr1:101422409	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.15	0.39	1.82e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg12379764	chr21:47803548	PCNT	-0.47	-7.93	-0.35	1.62e-14	Testicular germ cell tumor;
LGG	cis	rs4665809	0.590	rs1049987	chr2:26413817	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.14	0.35	3.63e-15	Gut microbiome composition (summer);
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg08499158	chr17:42289980	UBTF	-0.58	-11.0	-0.46	3.66e-25	Total body bone mineral density;
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg16301924	chr13:53314226	LECT1	-0.37	-7.34	-0.32	9.75e-13	Lewy body disease;
LGG	cis	rs2282300	0.739	rs10835647	chr11:30313268	A/G	cg06241208	chr11:30344200	C11orf46	-0.51	-6.71	-0.3	5.6e-11	Morning vs. evening chronotype;
LGG	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg24623649	chr8:11872141	NA	-0.28	-6.74	-0.3	4.69e-11	Neuroticism;
LGG	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg19913688	chr11:428466	ANO9	-0.66	-8.48	-0.37	3.14e-16	Body mass index;
LGG	cis	rs9831754	0.756	rs2872626	chr3:78435049	A/T	cg06138941	chr3:78371609	NA	-0.78	-15.26	-0.58	7.14e-43	Calcium levels;
LGG	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.51	0.5	3.78e-31	Motion sickness;
LGG	cis	rs657075	0.697	rs2073839	chr5:131650245	C/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01565703	chr14:103245090	TRAF3	-0.38	-6.93	-0.31	1.46e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs10861342	1.000	rs1444608	chr12:105559157	A/G	cg23923672	chr12:105501055	KIAA1033	0.82	7.24	0.32	1.9e-12	IgG glycosylation;
LGG	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg24830062	chr5:140700576	TAF7	-0.56	-7.0	-0.31	9.11e-12	Pulmonary function decline;
LGG	cis	rs4689388	0.890	rs4501291	chr4:6298582	C/T	cg25554036	chr4:6271136	WFS1	0.61	11.47	0.47	5.59e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22601191	chr20:60968625	CABLES2	0.58	10.08	0.42	9.62e-22	Colorectal cancer;
LGG	cis	rs3780486	0.846	rs10113903	chr9:33122645	C/G	cg13443165	chr9:33130375	B4GALT1	0.73	14.06	0.55	1.2e-37	IgG glycosylation;
LGG	cis	rs2070488	0.965	rs13097628	chr3:38521156	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.22	0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.75	-0.34	5.68e-14	Testicular germ cell tumor;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.13	-0.35	4.01e-15	IgG glycosylation;
LGG	cis	rs11098499	0.913	rs12186259	chr4:120152039	C/T	cg24375607	chr4:120327624	NA	0.63	10.22	0.43	3.04e-22	Corneal astigmatism;
LGG	trans	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6840360	0.593	rs11723227	chr4:152689717	G/A	cg22705602	chr4:152727874	NA	-0.4	-10.26	-0.43	2.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.25	0.32	1.72e-12	Refractive error;
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg17951613	chr5:131705445	SLC22A5	0.61	6.86	0.3	2.18e-11	Rheumatoid arthritis;
LGG	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs9783347	1.000	rs4150562	chr11:18354995	A/G	cg15585147	chr11:18324498	HPS5	0.41	8.63	0.37	9.6e-17	Pancreatic cancer;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg07538946	chr5:131705188	SLC22A5	0.65	7.59	0.33	1.75e-13	Rheumatoid arthritis;
LGG	cis	rs597583	0.806	rs11605509	chr11:117396433	T/C	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.27	-0.36	1.4e-15	Putamen volume;
LGG	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg02487422	chr3:49467188	NICN1	0.41	6.95	0.31	1.28e-11	Parkinson's disease;
LGG	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4356203	0.875	rs667984	chr11:17200766	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.25	-0.32	1.76e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10791323	0.576	rs4937840	chr11:133734322	C/G	cg15485101	chr11:133734466	NA	0.64	11.18	0.46	7.58e-26	Childhood ear infection;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg15948088	chr11:109293068	C11orf87	0.45	8.08	0.35	5.81e-15	Schizophrenia;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg09699651	chr6:150184138	LRP11	0.55	10.28	0.43	1.77e-22	Testicular germ cell tumor;
LGG	cis	rs701145	1.000	rs701145	chr3:154054799	T/C	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	trans	rs35110281	0.748	rs162403	chr21:44963365	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.67	12.09	0.49	2.02e-29	Mean corpuscular volume;
LGG	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg13207630	chr7:32358064	NA	0.8	7.93	0.35	1.71e-14	Body mass index;
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg11965913	chr1:205819406	PM20D1	-0.38	-7.18	-0.32	2.78e-12	Prostate-specific antigen levels;
LGG	cis	rs2075371	0.933	rs1421481	chr7:133964380	A/C	cg20476274	chr7:133979776	SLC35B4	0.75	14.69	0.56	2.13e-40	Mean platelet volume;
LGG	cis	rs1707322	1.000	rs9803784	chr1:46401907	T/C	cg03146154	chr1:46216737	IPP	0.54	10.15	0.43	5.47e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7395662	0.500	rs1605360	chr11:48685714	G/A	cg15704280	chr7:45808275	SEPT13	-0.61	-11.01	-0.46	3.33e-25	HDL cholesterol;
LGG	cis	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg18252515	chr7:66147081	NA	1.41	20.63	0.69	1.54e-67	Gout;
LGG	cis	rs12210905	1.000	rs5030958	chr6:27214257	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.62	-7.1	-0.31	4.57e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6740322	0.895	rs10166994	chr2:43557977	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.62	-0.41	4.2e-20	Coronary artery disease;
LGG	cis	rs796364	1.000	rs769950	chr2:200730028	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs72781680	0.851	rs12612830	chr2:24134599	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs6430585	0.697	rs115944351	chr2:136515458	G/A	cg07169764	chr2:136633963	MCM6	1.27	24.14	0.75	5.96e-84	Corneal structure;
LGG	trans	rs6787172	0.622	rs9882274	chr3:158120433	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg20892847	chr12:58011875	NA	0.37	7.71	0.34	7.6e-14	Multiple sclerosis;
LGG	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.31	-0.4	5.04e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.42	-0.33	5.83e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9381040	0.655	rs7738684	chr6:41038552	G/A	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.17	-0.32	2.95e-12	Alzheimer's disease (late onset);
LGG	cis	rs4731207	0.698	rs10245872	chr7:124535253	A/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	trans	rs6601327	0.665	rs10113155	chr8:9655358	T/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.95	-0.31	1.22e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1577917	0.958	rs12213331	chr6:86504797	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.99	-0.42	2.11e-21	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.29	0.36	1.21e-15	Lung cancer;
LGG	trans	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg02002194	chr4:3960332	NA	0.38	7.03	0.31	7.67e-12	Joint mobility (Beighton score);
LGG	cis	rs10193935	0.901	rs7601905	chr2:42494144	A/G	cg27598129	chr2:42591480	NA	-0.57	-8.53	-0.37	2.14e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg19847130	chr8:10466454	RP1L1	0.32	6.68	0.3	6.98e-11	Myopia (pathological);
LGG	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg10253484	chr15:75165896	SCAMP2	-0.41	-6.81	-0.3	3.11e-11	Breast cancer;
LGG	cis	rs74781061	0.932	rs2415245	chr15:74970432	A/G	cg02384859	chr15:74862662	ARID3B	-0.32	-6.76	-0.3	4.25e-11	Endometriosis;
LGG	cis	rs854765	0.655	rs4470201	chr17:17844870	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	13.01	0.52	3.23e-33	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.59e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.32	-0.36	9.88e-16	Triglycerides;
LGG	cis	rs12949688	1.000	rs7212186	chr17:55818454	C/A	cg12582317	chr17:55822272	NA	0.65	17.54	0.63	3.42e-53	Schizophrenia;
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs11229555	0.645	rs12803648	chr11:58177561	G/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11230563	1.000	rs2074227	chr11:60776781	T/C	cg19307003	chr11:60775715	CD6	0.52	8.52	0.37	2.26e-16	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7659604	0.592	rs56077950	chr4:122721412	C/T	cg20573242	chr4:122745356	CCNA2	0.53	9.66	0.41	3.12e-20	Type 2 diabetes;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	8.05e-29	Prudent dietary pattern;
LGG	cis	rs17102423	0.755	rs11158574	chr14:65579467	T/G	cg16583315	chr14:65563665	MAX	-0.36	-6.84	-0.3	2.53e-11	Obesity-related traits;
LGG	cis	rs3780486	0.505	rs10117038	chr9:33122626	T/C	cg13443165	chr9:33130375	B4GALT1	-0.61	-12.03	-0.49	3.51e-29	IgG glycosylation;
LGG	trans	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.37e-30	Corneal astigmatism;
LGG	cis	rs2731664	0.792	rs2630767	chr5:176870700	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-12.44	-0.5	7.53e-31	Intelligence (multi-trait analysis);
LGG	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg01403660	chr11:68851641	TPCN2	0.53	7.44	0.33	4.78e-13	Blond vs. brown hair color;
LGG	cis	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.46	0.33	4.36e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09978545	chr11:66035829	RAB1B	0.38	6.87	0.3	2.12e-11	Obesity-related traits;
LGG	cis	rs7264396	0.635	rs6060709	chr20:34536022	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.12	-0.31	4.14e-12	Total cholesterol levels;
LGG	cis	rs41563	0.607	rs6955349	chr7:104601236	G/A	cg03782966	chr7:104585482	NA	0.32	7.09	0.31	5.06e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs7173389	0.530	rs6495064	chr15:73682867	C/T	cg01796676	chr15:73680284	NA	-0.49	-9.2	-0.39	1.24e-18	Resting heart rate;
LGG	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg05096777	chr10:104283225	SUFU	0.32	7.06	0.31	6.2e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7086627	0.515	rs11202963	chr10:82210392	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg12751644	chr20:60527061	NA	0.47	10.37	0.43	8.45e-23	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.42	-0.44	5.63e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg26384229	chr12:38710491	ALG10B	-0.73	-14.11	-0.55	7.51e-38	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs12712820	chr2:42236370	C/T	cg19376973	chr2:42229025	NA	0.63	9.32	0.4	4.95e-19	Hypospadias;
LGG	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg19628046	chr18:33552617	C18orf21	0.52	7.56	0.33	2.25e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg00071950	chr4:10020882	SLC2A9	0.44	9.35	0.4	3.74e-19	Bone mineral density;
LGG	cis	rs936229	0.813	rs2301249	chr15:75092384	T/C	cg10253484	chr15:75165896	SCAMP2	-0.67	-9.99	-0.42	2.04e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg26841017	chr5:34929960	DNAJC21	-0.41	-7.27	-0.32	1.52e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	6.94	0.31	1.35e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg14664628	chr15:75095509	CSK	-0.56	-10.57	-0.44	1.6e-23	Breast cancer;
LGG	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg09441152	chr18:77712293	PQLC1	0.49	8.74	0.38	4.23e-17	Schizophrenia;
LGG	cis	rs3820928	0.874	rs3769646	chr2:227896330	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.46e-13	Pulmonary function;
LGG	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg24642439	chr20:33292090	TP53INP2	0.54	9.13	0.39	2.2e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs7216064	1.000	rs7210027	chr17:65977053	C/T	cg12091567	chr17:66097778	LOC651250	0.61	8.98	0.39	6.94e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.29e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1021993	0.545	rs60534728	chr1:209548171	G/A	cg24446417	chr1:209558027	NA	-0.75	-11.23	-0.46	4.73e-26	Gut microbiome composition (winter);
LGG	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.42	0.33	5.58e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6831352	0.879	rs67311928	chr4:100048999	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs9324022	0.858	rs1004572	chr14:101178330	G/A	cg18089426	chr14:101175970	NA	0.68	11.33	0.47	1.9e-26	Plateletcrit;
LGG	cis	rs7618501	0.602	rs2301166	chr3:50148305	C/G	cg24110177	chr3:50126178	RBM5	0.59	10.83	0.45	1.59e-24	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg18404041	chr3:52824283	ITIH1	0.48	9.13	0.39	2.21e-18	Electroencephalogram traits;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26085197	chr3:178789612	ZMAT3	-0.5	-6.71	-0.3	5.72e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7143963	1.000	rs7143963	chr14:103304425	C/T	cg23020514	chr14:103360112	TRAF3	0.52	10.02	0.42	1.55e-21	Body mass index;
LGG	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg06890432	chr16:12997467	SHISA9	-0.32	-7.0	-0.31	9.3e-12	Positive affect;Subjective well-being;
LGG	cis	rs9329221	0.682	rs11786677	chr8:10264260	A/G	cg27411982	chr8:10470053	RP1L1	0.4	6.68	0.3	7.09e-11	Neuroticism;
LGG	cis	rs6694672	0.850	rs10801587	chr1:197058380	C/T	cg13682187	chr1:196946512	CFHR5	0.51	7.2	0.32	2.43e-12	Asthma;
LGG	cis	rs2978263	0.657	rs10088923	chr8:30315455	A/G	cg05780722	chr8:30327988	RBPMS	-0.33	-6.65	-0.3	8.08e-11	Cognitive performance;
LGG	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg07701084	chr6:150067640	NUP43	0.65	12.15	0.49	1.09e-29	Lung cancer;
LGG	cis	rs1015291	0.836	rs2049614	chr12:19989625	G/C	cg25401612	chr12:20009446	NA	-0.31	-6.67	-0.3	7.43e-11	Diastolic blood pressure;
LGG	cis	rs7660520	1.000	rs7660520	chr4:183745321	C/T	cg09197432	chr4:183729176	NA	0.37	6.66	0.3	7.89e-11	Pediatric autoimmune diseases;
LGG	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.6e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2839186	0.708	rs17183123	chr21:47671961	G/C	cg11766577	chr21:47581405	C21orf56	-0.6	-10.97	-0.45	4.71e-25	Testicular germ cell tumor;
LGG	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.37	0.36	6.88e-16	Colorectal cancer;
LGG	trans	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4727443	1.000	rs4727443	chr7:99593346	C/A	cg12813108	chr7:99719912	CNPY4	-0.48	-9.07	-0.39	3.49e-18	Interstitial lung disease;
LGG	cis	rs4332037	0.539	rs56305291	chr7:2048706	A/G	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.75	-0.3	4.46e-11	Bipolar disorder;
LGG	cis	rs11785400	0.793	rs10956992	chr8:143736235	A/C	cg24634471	chr8:143751801	JRK	0.5	7.79	0.34	4.31e-14	Schizophrenia;
LGG	cis	rs3767633	0.925	rs2134696	chr1:161781200	A/T	cg09175582	chr1:161736000	ATF6	-0.59	-7.63	-0.33	1.35e-13	IgG glycosylation;
LGG	cis	rs2154319	0.836	rs6674290	chr1:41561232	C/G	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.0	-0.39	5.91e-18	Height;
LGG	trans	rs78049276	0.736	rs77028772	chr4:148364920	G/A	cg13149281	chr14:23389818	RBM23;PRMT5	-0.56	-7.34	-0.32	9.37e-13	Pulse pressure;
LGG	cis	rs892961	0.932	rs7223768	chr17:75410521	G/A	cg05865280	chr17:75406074	SEPT9	0.42	9.93	0.42	3.26e-21	Airflow obstruction;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07017284	chr1:173684020	KLHL20	0.38	6.81	0.3	3e-11	Bipolar disorder;
LGG	cis	rs17270561	0.636	rs1575535	chr6:25809909	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.17	-0.32	3.06e-12	Iron status biomarkers;
LGG	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg25358565	chr5:93447407	FAM172A	-0.68	-9.79	-0.41	1.04e-20	Diabetic retinopathy;
LGG	cis	rs883565	1.000	rs883565	chr3:39055317	C/T	cg01426195	chr3:39028469	NA	-0.62	-12.0	-0.49	4.43e-29	Handedness;
LGG	cis	rs2235573	0.805	rs132934	chr22:38489558	G/T	cg19171272	chr22:38449367	NA	0.45	8.53	0.37	2.04e-16	Glioblastoma;Glioma;
LGG	cis	rs12915845	0.545	rs17197019	chr15:89079672	C/T	cg05013243	chr15:89149849	MIR1179	-0.35	-7.09	-0.31	4.9e-12	Menarche (age at onset);
LGG	cis	rs816535	1	rs816535	chr20:26255996	C/T	cg20395967	chr20:26190347	MIR663	0.34	6.73	0.3	4.88e-11	Parkinson disease and lewy body pathology;
LGG	trans	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg02002194	chr4:3960332	NA	-0.4	-7.28	-0.32	1.4e-12	Joint mobility (Beighton score);
LGG	cis	rs977987	0.751	rs56004344	chr16:75474189	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.17	0.43	4.78e-22	Dupuytren's disease;
LGG	cis	rs826838	1.000	rs10875991	chr12:39108886	G/C	cg13010199	chr12:38710504	ALG10B	0.72	15.02	0.57	7.64e-42	Heart rate;
LGG	cis	rs11214589	0.747	rs11214582	chr11:113218050	C/T	cg14373873	chr11:113211441	TTC12	0.56	12.54	0.5	3.06e-31	Neuroticism;
LGG	cis	rs300774	1.000	rs146562	chr2:119663	T/G	cg04617936	chr2:214353	NA	-0.5	-7.37	-0.32	7.96e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17376030	chr22:41985996	PMM1	0.59	9.39	0.4	2.76e-19	Vitiligo;
LGG	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg26031613	chr14:104095156	KLC1	1.18	29.68	0.81	3.29e-109	Body mass index;
LGG	cis	rs721399	0.568	rs35942058	chr8:18274398	G/A	cg18736775	chr8:18248649	NAT2	-0.71	-10.92	-0.45	7.14e-25	Blood metabolite levels;
LGG	trans	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.28	-0.36	1.29e-15	Intelligence (multi-trait analysis);
LGG	cis	rs910187	0.532	rs6066209	chr20:45762795	G/T	cg27589058	chr20:45804311	EYA2	-0.29	-6.91	-0.31	1.57e-11	Migraine;
LGG	cis	rs6908034	0.607	rs73376657	chr6:19805960	C/T	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.35	0.63	2.57e-52	Obesity-related traits;
LGG	trans	rs2797160	0.651	rs1268092	chr6:126029043	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.46	-7.87	-0.34	2.57e-14	Endometrial cancer;
LGG	trans	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-13.04	-0.52	2.54e-33	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	trans	rs67340775	0.541	rs200966	chr6:27862152	T/C	cg08344181	chr3:125677491	NA	-0.53	-7.08	-0.31	5.35e-12	Lung cancer in ever smokers;
LGG	cis	rs490234	0.545	rs10117700	chr9:128250651	C/T	cg14078157	chr9:128172775	NA	-0.4	-7.46	-0.33	4.25e-13	Mean arterial pressure;
LGG	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg15017067	chr4:17643749	FAM184B	0.31	7.12	0.31	4.08e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg23782820	chr8:58130467	NA	0.44	6.77	0.3	3.98e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2985684	1.000	rs7142457	chr14:50097862	C/T	cg04989706	chr14:50066350	PPIL5	-0.53	-8.35	-0.36	7.82e-16	Carotid intima media thickness;
LGG	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.79e-21	Diabetic retinopathy;
LGG	cis	rs7000551	0.532	rs55726237	chr8:22252985	C/T	cg12081754	chr8:22256438	SLC39A14	1.16	27.04	0.78	2.53e-97	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg27476859	chr7:2772710	GNA12	0.5	9.83	0.42	7.63e-21	Height;
LGG	cis	rs920590	0.758	rs1907799	chr8:19664668	A/G	cg01411142	chr8:19674711	INTS10	-0.46	-7.23	-0.32	2.04e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg04861929	chr11:109293070	C11orf87	0.58	9.63	0.41	4.1e-20	Schizophrenia;
LGG	cis	rs9398803	0.865	rs4418209	chr6:126819699	T/G	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs7224668	0.545	rs9901514	chr17:79237900	A/G	cg03823431	chr17:79229385	SLC38A10	0.35	7.52	0.33	2.86e-13	IgG glycosylation;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg02018176	chr4:1364513	KIAA1530	0.49	11.86	0.48	1.6e-28	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03905094	chr5:59996421	DEPDC1B	0.45	6.84	0.3	2.58e-11	Gut microbiome composition (summer);
LGG	cis	rs4132509	1.000	rs3766673	chr1:243720473	T/C	cg25706552	chr1:244017396	NA	0.5	8.17	0.36	2.91e-15	RR interval (heart rate);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22111038	chr5:57879168	RAB3C	0.47	7.8	0.34	4.08e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg26513180	chr16:89883248	FANCA	-0.53	-9.34	-0.4	3.97e-19	Vitiligo;
LGG	cis	rs7312933	0.703	rs11181380	chr12:42616040	A/T	cg19980929	chr12:42632907	YAF2	0.38	8.57	0.37	1.55e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg08677398	chr8:58056175	NA	0.56	12.31	0.5	2.6e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1030877	0.515	rs2576735	chr2:105888839	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.66	10.51	0.44	2.54e-23	Obesity-related traits;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.1	-0.42	8.57e-22	Longevity;Endometriosis;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.42	-0.36	4.72e-16	Neuroticism;
LGG	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg11502198	chr6:26597334	ABT1	0.54	9.43	0.4	2.02e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg02018176	chr4:1364513	KIAA1530	-0.59	-13.85	-0.54	9.7e-37	Longevity;
LGG	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg06238570	chr21:40685208	BRWD1	0.43	6.65	0.3	8.53e-11	Cognitive function;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00415582	chr6:43027202	KLC4;MRPL2	0.4	7.11	0.31	4.52e-12	Obesity-related traits;
LGG	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.68e-19	Diabetic retinopathy;
LGG	cis	rs4629710	0.645	rs35561719	chr6:131551244	G/A	cg12606694	chr6:131520996	AKAP7	0.51	8.37	0.36	6.92e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7945705	0.935	rs11042103	chr11:8888700	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.38	7.65	0.34	1.16e-13	Hemoglobin concentration;
LGG	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg11764359	chr7:65958608	NA	-0.55	-9.41	-0.4	2.25e-19	Aortic root size;
LGG	cis	rs4919694	1.000	rs12257935	chr10:104803062	C/A	cg04362960	chr10:104952993	NT5C2	1.07	15.29	0.58	5.26e-43	Arsenic metabolism;
LGG	trans	rs6601327	0.670	rs9987266	chr8:9659346	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.78	0.34	4.76e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs209489	1.000	rs209527	chr6:53216426	G/A	cg15607103	chr6:53167650	ELOVL5	-0.55	-7.71	-0.34	7.99e-14	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs9636252	0.887	rs13415242	chr2:9267500	T/A	cg20341998	chr2:9276514	NA	0.37	7.15	0.32	3.5e-12	IgG glycosylation;
LGG	cis	rs9902453	0.730	rs2020939	chr17:28550732	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.63	-12.37	-0.5	1.45e-30	Coffee consumption (cups per day);
LGG	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.36	-0.36	7.45e-16	Joint mobility (Beighton score);
LGG	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg08344181	chr3:125677491	NA	-0.69	-7.3	-0.32	1.28e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2576037	0.899	rs7233515	chr18:44585955	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.48	-8.13	-0.35	3.89e-15	Personality dimensions;
LGG	cis	rs9611519	0.780	rs2235849	chr22:41653540	T/G	cg03806693	chr22:41940476	POLR3H	-0.61	-9.87	-0.42	5.76e-21	Neuroticism;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg03499777	chr13:98085463	RAP2A	-0.42	-6.67	-0.3	7.37e-11	Coronary artery disease;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg07414643	chr4:187882934	NA	0.54	10.95	0.45	5.83e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg14668632	chr7:2872130	GNA12	-0.36	-7.17	-0.32	3.05e-12	Height;
LGG	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg07274523	chr3:49395745	GPX1	0.57	9.56	0.41	7.08e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6964587	0.967	rs1978061	chr7:91779242	G/A	cg17063962	chr7:91808500	NA	0.53	9.81	0.42	8.76e-21	Breast cancer;
LGG	cis	rs526231	0.511	rs12109860	chr5:102393112	A/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs1318772	0.932	rs35364742	chr5:112922254	T/G	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.69e-13	F-cell distribution;
LGG	cis	rs1153858	1.000	rs66528868	chr15:45668547	A/C	cg10760299	chr15:45669010	GATM	0.4	7.89	0.34	2.26e-14	Homoarginine levels;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg05064044	chr6:292385	DUSP22	-0.63	-10.52	-0.44	2.3e-23	Menopause (age at onset);
LGG	cis	rs796364	0.789	rs1653297	chr2:201075483	C/T	cg17644776	chr2:200775616	C2orf69	0.58	8.69	0.37	6.41e-17	Schizophrenia;
LGG	cis	rs2635047	0.811	rs17723754	chr18:44771481	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.81	-0.3	3.08e-11	Educational attainment;
LGG	cis	rs8067545	0.750	rs4925079	chr17:19986861	T/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.84	-0.3	2.49e-11	Schizophrenia;
LGG	cis	rs12220238	1.000	rs10824099	chr10:75943625	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.07	0.46	1.96e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs656319	0.586	rs35013996	chr8:9947145	A/G	cg12395012	chr8:11607386	GATA4	0.39	6.86	0.3	2.17e-11	Myopia (pathological);
LGG	cis	rs7172689	0.866	rs4616256	chr15:81575754	G/A	cg11808699	chr15:81528661	IL16	-0.47	-9.47	-0.4	1.49e-19	Inattentive symptoms;
LGG	trans	rs6787172	0.702	rs827093	chr3:157984743	C/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs12348691	0.503	rs7024345	chr9:100595238	A/G	cg13688889	chr9:100608707	NA	-0.81	-15.84	-0.59	1.72e-45	Alopecia areata;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs3008870	1.000	rs12740884	chr1:67459855	C/A	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs919433	0.679	rs13394214	chr2:198527371	C/T	cg00792783	chr2:198669748	PLCL1	0.57	9.25	0.39	8.52e-19	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg05887092	chr17:76393375	PGS1	0.72	15.74	0.59	5.32e-45	HDL cholesterol levels;
LGG	cis	rs981844	0.885	rs72731673	chr4:154667446	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.56	0.47	2.4e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs3206736	0.548	rs6959047	chr7:35210211	G/A	cg13400248	chr7:35225412	NA	0.37	6.79	0.3	3.37e-11	Diastolic blood pressure;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs6912958	1.000	rs13214153	chr6:88153983	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.77	-0.45	2.67e-24	Monocyte percentage of white cells;
LGG	cis	rs7106204	0.748	rs4598670	chr11:24236524	G/A	ch.11.24196551F	chr11:24239977	NA	0.99	16.17	0.6	6.24e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg18357526	chr6:26021779	HIST1H4A	0.48	8.06	0.35	6.4e-15	Height;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg05665937	chr4:1216051	CTBP1	0.48	8.6	0.37	1.23e-16	Obesity-related traits;
LGG	cis	rs6735179	0.688	rs2382563	chr2:1763599	T/C	cg08534653	chr2:1747700	PXDN	0.47	7.27	0.32	1.59e-12	Response to antipsychotic treatment;
LGG	cis	rs2421770	0.532	rs7127824	chr11:35373851	A/G	cg10331829	chr11:35343789	SLC1A2	-0.33	-7.35	-0.32	8.85e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs736408	0.716	rs2239550	chr3:52822509	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.21	0.36	2.27e-15	Bipolar disorder;
LGG	cis	rs1107366	0.722	rs9862438	chr3:125910381	C/T	cg11252792	chr3:125932053	NA	0.61	12.29	0.5	2.97e-30	Metabolite levels;
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.06	0.42	1.12e-21	Height;
LGG	cis	rs26232	0.517	rs154356	chr5:102499144	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.82	-0.34	3.49e-14	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg11878867	chr6:150167359	LRP11	-0.57	-11.77	-0.48	3.83e-28	Lung cancer;
LGG	cis	rs9303401	0.659	rs12946852	chr17:57013337	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.86	0.57	4.05e-41	Cognitive test performance;
LGG	cis	rs939658	0.683	rs1474256	chr15:79463847	C/T	cg17916960	chr15:79447300	NA	0.54	10.1	0.42	8.22e-22	Refractive error;
LGG	cis	rs4727027	0.704	rs12704083	chr7:148909759	G/A	cg23583168	chr7:148888333	NA	-0.91	-18.35	-0.65	6.36e-57	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11098499	0.775	rs10029303	chr4:120286755	T/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12915591	chr11:43965360	LOC387763	0.38	6.67	0.3	7.26e-11	Obesity-related traits;
LGG	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg10189774	chr4:17578691	LAP3	0.4	6.79	0.3	3.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2439831	0.764	rs12324584	chr15:43683446	G/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.15	0.52	8.93e-34	Lung cancer in ever smokers;
LGG	cis	rs7223966	1.000	rs2854219	chr17:61942682	C/T	cg05941027	chr17:61774174	LIMD2	0.35	8.83	0.38	2.21e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2204008	0.811	rs2139752	chr12:38370398	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.88	0.7	1.03e-68	Bladder cancer;
LGG	cis	rs4423214	1.000	rs11546509	chr11:71162785	A/G	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs17539620	0.624	rs56737784	chr6:154848694	C/T	cg17771515	chr6:154831774	CNKSR3	0.63	7.39	0.32	6.82e-13	Lipoprotein (a) levels;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.08	0.55	9.71e-38	Platelet count;
LGG	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg18876405	chr7:65276391	NA	0.68	13.0	0.52	3.7e-33	Aortic root size;
LGG	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs6466055	0.669	rs10808141	chr7:104715490	T/G	cg03782966	chr7:104585482	NA	0.31	6.73	0.3	4.92e-11	Schizophrenia;
LGG	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg10840412	chr1:235813424	GNG4	0.54	7.44	0.33	4.89e-13	Bipolar disorder;
LGG	cis	rs992157	0.835	rs2292555	chr2:219146882	G/C	cg00012203	chr2:219082015	ARPC2	-0.68	-12.14	-0.49	1.25e-29	Colorectal cancer;
LGG	cis	rs1499614	1.000	rs2707840	chr7:66158015	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.49	0.37	2.73e-16	Gout;
LGG	cis	rs4684776	0.867	rs921226	chr3:11324794	A/G	cg24705426	chr3:11550659	ATG7	0.46	8.77	0.38	3.45e-17	Small vessel stroke;
LGG	cis	rs2011503	1.000	rs78883953	chr19:19630002	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.83	0.3	2.64e-11	Bipolar disorder;
LGG	cis	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg12591125	chr7:1885375	MAD1L1	-0.49	-7.47	-0.33	4e-13	Bipolar disorder;
LGG	cis	rs2797160	1.000	rs9491471	chr6:125991715	C/T	cg05901451	chr6:126070800	HEY2	-0.43	-7.1	-0.31	4.59e-12	Endometrial cancer;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.72	-0.38	5.01e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2408955	0.522	rs2051851	chr12:48485940	G/C	cg24011408	chr12:48396354	COL2A1	-0.58	-9.67	-0.41	2.77e-20	Glycated hemoglobin levels;
LGG	cis	rs11758351	0.500	rs4593350	chr6:26184800	T/C	cg02612650	chr6:26195910	NA	0.88	6.84	0.3	2.54e-11	Gout;Renal underexcretion gout;
LGG	cis	rs780096	0.526	rs3845687	chr2:27689899	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.87	-0.34	2.46e-14	Total body bone mineral density;
LGG	cis	rs10193935	0.901	rs72800020	chr2:42655615	A/G	cg27598129	chr2:42591480	NA	-0.68	-10.02	-0.42	1.59e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs908922	0.651	rs7529157	chr1:152531365	C/A	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs2916247	1.000	rs746142	chr8:93060566	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.34	-0.36	8.5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.643	rs730089	chr6:109715084	G/A	cg01125227	chr6:109776195	MICAL1	0.38	6.67	0.3	7.24e-11	Height;
LGG	cis	rs4604732	0.588	rs74154678	chr1:247626202	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.89	0.38	1.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-8.38	-0.36	6.26e-16	Bronchopulmonary dysplasia;
LGG	cis	rs561341	0.689	rs578635	chr17:30289897	A/C	cg13647721	chr17:30228624	UTP6	0.51	7.5	0.33	3.21e-13	Hip circumference adjusted for BMI;
LGG	cis	rs34638952	0.577	rs11080078	chr17:27456255	C/G	cg13672501	chr17:27410685	MYO18A	0.42	7.62	0.33	1.47e-13	Sitting height ratio;
LGG	cis	rs7928758	0.767	rs7932600	chr11:134276142	A/G	cg22777979	chr11:134283252	B3GAT1	0.56	8.31	0.36	1.07e-15	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg23533926	chr12:111358616	MYL2	-0.44	-7.4	-0.33	6.57e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg02002194	chr4:3960332	NA	0.52	10.41	0.44	6.17e-23	Neuroticism;
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.66e-13	Rheumatoid arthritis;
LGG	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs6754311	0.731	rs10207652	chr2:136588478	T/A	cg07169764	chr2:136633963	MCM6	-0.78	-13.32	-0.53	1.64e-34	Mosquito bite size;
LGG	cis	rs7084402	1.000	rs1863664	chr10:60266839	A/G	cg07615347	chr10:60278583	BICC1	-0.63	-17.57	-0.63	2.41e-53	Refractive error;
LGG	cis	rs4356203	0.870	rs214914	chr11:17241892	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9527	0.590	rs12775302	chr10:104911356	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.45	0.44	4.28e-23	Arsenic metabolism;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.15	0.32	3.48e-12	Lung cancer;
LGG	cis	rs11696845	1.000	rs11696845	chr20:43371320	C/T	cg25301532	chr20:43378953	KCNK15	0.37	8.1	0.35	5.03e-15	Obesity-related traits;
LGG	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.51	-8.33	-0.36	9.45e-16	Height;
LGG	cis	rs9896933	0.830	rs8074277	chr17:80789628	T/C	cg15369054	chr17:80825471	TBCD	0.49	7.09	0.31	4.97e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.5	0.47	4.26e-27	Electroencephalogram traits;
LGG	cis	rs8049040	0.547	rs891131	chr16:71432417	G/A	cg08717414	chr16:71523259	ZNF19	-0.48	-7.35	-0.32	8.81e-13	Blood protein levels;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg21724239	chr8:58056113	NA	0.43	6.75	0.3	4.53e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02886208	chr11:14281011	SPON1	0.54	11.96	0.49	6.3e-29	Mitochondrial DNA levels;
LGG	cis	rs9354308	0.764	rs2351721	chr6:66602789	G/C	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs68170813	0.559	rs17350182	chr7:106909637	T/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.45	-0.44	4.33e-23	Coronary artery disease;
LGG	cis	rs9951602	0.512	rs1903722	chr18:76646539	G/A	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.66e-15	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	19.41	0.67	7.3e-62	Alzheimer's disease;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01776903	chr15:38543564	SPRED1	0.47	7.9	0.34	2.12e-14	Gut microbiome composition (summer);
LGG	cis	rs1577917	1.000	rs6933377	chr6:86705255	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.66	0.37	7.88e-17	Response to antipsychotic treatment;
LGG	cis	rs3749237	0.595	rs1568661	chr3:49520958	A/G	cg03060546	chr3:49711283	APEH	0.73	12.91	0.51	8.68e-33	Resting heart rate;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg05064044	chr6:292385	DUSP22	-0.67	-11.39	-0.47	1.2e-26	Menopause (age at onset);
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg08219700	chr8:58056026	NA	0.45	7.03	0.31	7.69e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg08888203	chr3:10149979	C3orf24	0.56	8.06	0.35	6.56e-15	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs17023223	0.537	rs2794311	chr1:119595949	A/G	cg05756136	chr1:119680316	WARS2	0.4	8.39	0.36	6.13e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs1005277	0.540	rs1814077	chr10:37992018	G/C	cg27523141	chr10:43048294	ZNF37B	0.35	7.29	0.32	1.37e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.569	rs188057	chr22:41822305	T/G	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs79976124	0.879	rs12214239	chr6:66636059	A/G	cg07460842	chr6:66804631	NA	0.73	12.62	0.51	1.32e-31	Type 2 diabetes;
LGG	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg04132472	chr17:19861366	AKAP10	0.26	7.18	0.32	2.77e-12	Schizophrenia;
LGG	cis	rs13314892	0.764	rs55946371	chr3:69871412	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.71	-0.34	7.76e-14	QRS complex (12-leadsum);
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg06494592	chr3:125709126	NA	-0.55	-7.0	-0.31	9.02e-12	Blood pressure (smoking interaction);
LGG	cis	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg12458913	chr13:53173898	NA	0.67	12.92	0.51	8.07e-33	Lewy body disease;
LGG	cis	rs9435341	0.965	rs1730859	chr1:107617707	A/G	cg09367891	chr1:107599246	PRMT6	0.61	11.06	0.46	2.07e-25	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg00531865	chr16:30841666	NA	-0.69	-16.67	-0.61	3.22e-49	Dementia with Lewy bodies;
LGG	cis	rs7615952	0.558	rs7641353	chr3:125339879	T/C	cg21696256	chr3:125484277	NA	-0.45	-7.52	-0.33	2.91e-13	Blood pressure (smoking interaction);
LGG	trans	rs12517041	1.000	rs7734279	chr5:23300161	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.07	-0.46	1.91e-25	Calcium levels;
LGG	trans	rs853679	1.000	rs11965538	chr6:28239915	G/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.31	-0.36	1.06e-15	Depression;
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06109379	chr12:247315	IQSEC3	0.35	6.85	0.3	2.29e-11	Menarche (age at onset);
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.39	0.69	2.06e-66	Alzheimer's disease;
LGG	cis	rs6868223	0.964	rs55943381	chr5:33637396	T/C	cg10594543	chr5:33649717	ADAMTS12	0.57	12.66	0.51	9.74e-32	Mortality in heart failure;
LGG	cis	rs11690935	0.843	rs9784070	chr2:172785007	C/T	cg21435375	chr2:172878103	MAP1D	-0.34	-7.63	-0.33	1.31e-13	Schizophrenia;
LGG	cis	rs4953318	0.619	rs10183887	chr2:46361808	T/A	cg12428440	chr2:46370979	PRKCE	0.5	9.24	0.39	8.91e-19	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg02951883	chr7:2050386	MAD1L1	-0.57	-10.14	-0.43	5.8e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg19336497	chr11:14380999	RRAS2	-0.57	-11.67	-0.48	9.48e-28	Sense of smell;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.82	0.45	1.7e-24	Personality dimensions;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20887711	chr4:1340912	KIAA1530	0.61	11.93	0.48	8.29e-29	Obesity-related traits;
LGG	trans	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg18335740	chr13:41363409	SLC25A15	0.85	20.18	0.68	1.98e-65	Lewy body disease;
LGG	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg00717180	chr2:96193071	NA	-0.51	-9.55	-0.41	7.49e-20	Coronary artery disease;
LGG	cis	rs8053891	0.673	rs11645540	chr16:72028930	T/G	cg00732059	chr16:71740210	PHLPP2	-0.35	-6.73	-0.3	5.03e-11	Coronary artery disease;
LGG	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.83	-0.34	3.33e-14	Neuroticism;
LGG	cis	rs10751667	0.666	rs7395182	chr11:927553	A/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg21775007	chr8:11205619	TDH	-0.62	-10.18	-0.43	4.09e-22	Retinal vascular caliber;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.62	-0.41	4.27e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.38	-0.36	6.37e-16	Blood metabolite levels;
LGG	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg14456004	chr13:21872349	NA	1.39	24.41	0.75	3.48e-85	White matter hyperintensity burden;
LGG	cis	rs13191362	0.935	rs66962088	chr6:162963891	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.34	0.32	9.39e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.09	0.7	1.08e-69	Gut microbiome composition (summer);
LGG	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg24848339	chr3:12840334	CAND2	0.38	8.67	0.37	7.33e-17	QRS complex (12-leadsum);
LGG	cis	rs7267979	1.000	rs2424704	chr20:25273929	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.45	0.44	4.38e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7927592	0.913	rs12363722	chr11:68236291	A/C	cg01657329	chr11:68192670	LRP5	-0.47	-7.88	-0.34	2.34e-14	Total body bone mineral density;
LGG	cis	rs735539	1.000	rs3000676	chr13:21286442	A/T	cg04906043	chr13:21280425	IL17D	-0.6	-10.29	-0.43	1.71e-22	Dental caries;
LGG	cis	rs7215564	0.818	rs36034584	chr17:78671478	A/G	cg06153925	chr17:78755379	RPTOR	0.4	6.8	0.3	3.25e-11	Myopia (pathological);
LGG	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-10.09	-0.42	9.21e-22	Height;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	0.4	6.98	0.31	9.97e-12	Bipolar disorder;
LGG	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg00976097	chr5:421733	AHRR	-0.43	-7.17	-0.32	3.01e-12	Cystic fibrosis severity;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08677398	chr8:58056175	NA	0.6	9.39	0.4	2.71e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.37	6.96	0.31	1.15e-11	Schizophrenia;
LGG	cis	rs4650994	0.525	rs2493864	chr1:178545003	A/C	cg19399532	chr1:178512495	C1orf220	0.54	10.96	0.45	5.19e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg06238570	chr21:40685208	BRWD1	0.44	6.77	0.3	4.03e-11	Cognitive function;
LGG	cis	rs9796	0.727	rs12101934	chr15:41353079	C/T	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.31	-0.4	5.35e-19	Menopause (age at onset);
LGG	cis	rs9308433	0.529	rs867445	chr1:214502230	C/G	cg06198575	chr1:214491504	SMYD2	0.49	7.46	0.33	4.36e-13	IgG glycosylation;
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg15147215	chr3:52552868	STAB1	0.4	7.77	0.34	5.22e-14	Electroencephalogram traits;
LGG	cis	rs612683	0.735	rs10493923	chr1:100930254	A/G	cg06223162	chr1:101003688	GPR88	-0.42	-10.38	-0.43	7.62e-23	Breast cancer;
LGG	cis	rs6089584	0.850	rs6089634	chr20:60632566	T/C	cg12751644	chr20:60527061	NA	-0.31	-6.98	-0.31	1.02e-11	Body mass index;
LGG	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	cis	rs4262150	0.846	rs55830548	chr5:152188126	C/T	cg12297329	chr5:152029980	NA	-0.69	-12.88	-0.51	1.13e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg16434002	chr17:42200994	HDAC5	0.45	7.96	0.35	1.34e-14	Total body bone mineral density;
LGG	cis	rs9549367	0.756	rs2316463	chr13:113901406	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.09	-0.55	9.27e-38	Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01506871	chr11:14541756	PSMA1	0.46	6.68	0.3	6.73e-11	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.44	-0.37	4.13e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg06026331	chr20:60912101	LAMA5	0.7	12.47	0.5	5.79e-31	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg21724239	chr8:58056113	NA	0.61	9.06	0.39	3.65e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg02018176	chr4:1364513	KIAA1530	0.38	8.32	0.36	1.01e-15	Obesity-related traits;
LGG	cis	rs1577917	0.710	rs9342041	chr6:86280875	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	12.76	0.51	3.73e-32	Response to antipsychotic treatment;
LGG	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg17809284	chr5:56205270	C5orf35	-0.48	-7.88	-0.34	2.35e-14	Initial pursuit acceleration;
LGG	cis	rs240764	0.817	rs239207	chr6:101137765	A/C	cg09795085	chr6:101329169	ASCC3	0.45	7.61	0.33	1.6e-13	Neuroticism;
LGG	cis	rs7552404	1.000	rs4949876	chr1:76173377	C/T	cg22875332	chr1:76189707	ACADM	0.62	10.38	0.43	7.65e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.9	-14.55	-0.56	9.32e-40	Cognitive test performance;
LGG	cis	rs13082711	0.520	rs2643825	chr3:27562613	A/G	cg02860705	chr3:27208620	NA	0.52	8.9	0.38	1.26e-17	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2832191	0.646	rs2832210	chr21:30508723	T/G	cg08807101	chr21:30365312	RNF160	-0.62	-10.52	-0.44	2.28e-23	Dental caries;
LGG	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg26811252	chr16:29126840	RRN3P2	0.67	10.58	0.44	1.37e-23	Menopause (age at onset);
LGG	cis	rs948562	0.647	rs71486418	chr11:58240133	C/T	cg15696309	chr11:58395628	NA	-0.62	-11.45	-0.47	6.6e-27	Lymphoma;
LGG	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.64	0.82	1.91e-113	Cognitive function;
LGG	cis	rs7084402	0.967	rs1658468	chr10:60292664	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.29	0.65	1.2e-56	Refractive error;
LGG	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.66	0.34	1.1e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs929354	0.772	rs2366214	chr7:156992461	A/G	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs4803468	1.000	rs4803463	chr19:41911040	C/G	cg09537434	chr19:41945824	ATP5SL	-0.89	-23.02	-0.73	1.05e-78	Height;
LGG	cis	rs4363385	0.507	rs6587710	chr1:152870716	A/G	cg07796016	chr1:152779584	LCE1C	-0.62	-10.14	-0.43	5.99e-22	Inflammatory skin disease;
LGG	cis	rs1707322	1.000	rs6695421	chr1:46380207	T/C	cg03146154	chr1:46216737	IPP	0.54	10.1	0.42	8.47e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6089584	0.587	rs3787423	chr20:60555485	G/A	cg06470251	chr20:60548479	NA	0.47	8.29	0.36	1.21e-15	Body mass index;
LGG	cis	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.56	-0.41	6.82e-20	Mood instability;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs4731207	0.698	rs2079368	chr7:124485311	C/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	trans	rs2197308	0.692	rs67352173	chr12:37906912	A/T	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.15e-20	Morning vs. evening chronotype;
LGG	cis	rs7267979	0.833	rs6138556	chr20:25243310	C/T	cg08601574	chr20:25228251	PYGB	0.33	6.65	0.3	8.31e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9611565	0.694	rs79011	chr22:41866938	A/G	cg03806693	chr22:41940476	POLR3H	1.04	19.29	0.67	2.66e-61	Vitiligo;
LGG	cis	rs929354	0.772	rs1182438	chr7:157027438	G/A	cg05182265	chr7:156933206	UBE3C	0.37	7.64	0.33	1.25e-13	Body mass index;
LGG	cis	rs709400	1.000	rs709400	chr14:104149475	A/G	cg24130564	chr14:104152367	KLC1	-0.44	-8.42	-0.36	4.79e-16	Body mass index;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.41	-0.4	2.4e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs4319547	0.737	rs7964138	chr12:122950375	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-17.02	-0.62	8.53e-51	Body mass index;
LGG	cis	rs12476592	0.571	rs112194	chr2:63876872	T/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.88	-0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs698833	0.961	rs1223162	chr2:44737704	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	6.85	0.3	2.36e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	trans	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.6	-0.33	1.61e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2404618	0.624	rs28439223	chr8:1476901	C/G	cg13402656	chr8:1511478	DLGAP2	-0.74	-13.84	-0.54	1.05e-36	Lung cancer;
LGG	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg21775007	chr8:11205619	TDH	0.44	7.29	0.32	1.39e-12	Mood instability;
LGG	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.75	0.3	4.35e-11	Neuroticism;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4731207	0.698	rs1468377	chr7:124458599	A/G	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.655	rs10444809	chr15:77124536	G/C	cg23625390	chr15:77176239	SCAPER	-0.54	-10.81	-0.45	1.94e-24	Blood metabolite levels;
LGG	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg05333889	chr7:157238977	NA	-0.52	-9.8	-0.41	9.63e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6704644	0.872	rs6746234	chr2:234433081	G/A	cg27060346	chr2:234359958	DGKD	-0.58	-7.13	-0.31	3.8e-12	Bilirubin levels;
LGG	cis	rs7980687	0.657	rs2851447	chr12:123665113	G/C	cg00376283	chr12:123451042	ABCB9	0.66	11.43	0.47	8.1e-27	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7582180	0.630	rs13021801	chr2:100935129	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.79	-0.48	3.08e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg02389323	chr16:88786976	FAM38A	0.87	8.47	0.37	3.39e-16	Hair color;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.54e-12	Retinal vascular caliber;
LGG	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg17960426	chr8:142067321	NA	0.37	7.4	0.33	6.62e-13	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs2075371	0.829	rs35897155	chr7:134002711	G/A	cg11752832	chr7:134001865	SLC35B4	0.63	11.31	0.47	2.4e-26	Mean platelet volume;
LGG	cis	rs9341808	0.718	rs2179842	chr6:80979053	T/C	cg08355045	chr6:80787529	NA	0.39	7.41	0.33	6.07e-13	Sitting height ratio;
LGG	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6519955	0.897	rs4073601	chr22:46434686	A/G	cg00209037	chr22:46443395	NA	-0.24	-7.03	-0.31	7.67e-12	Dupuytren's disease;
LGG	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.94	-18.03	-0.64	2.01e-55	Platelet count;
LGG	cis	rs6963495	0.818	rs56268110	chr7:105166712	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.83	0.34	3.3e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7918232	0.830	rs10764672	chr10:27392541	A/C	cg14442939	chr10:27389572	ANKRD26	-0.74	-11.58	-0.47	2.13e-27	Breast cancer;
LGG	cis	rs8114671	0.967	rs3746427	chr20:33730464	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.25	0.32	1.71e-12	Height;
LGG	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-10.88	-0.45	1.05e-24	Hemoglobin concentration;
LGG	trans	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.82e-17	Bladder cancer;
LGG	cis	rs75920871	1.000	rs61905681	chr11:116836209	A/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.04e-12	Subjective well-being;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg16507663	chr6:150244633	RAET1G	0.45	7.31	0.32	1.15e-12	Lung cancer;
LGG	cis	rs990171	1.000	rs6746271	chr2:103052995	G/C	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg03474202	chr17:45855739	NA	0.22	7.2	0.32	2.46e-12	IgG glycosylation;
LGG	cis	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.98	0.39	6.81e-18	Mood instability;
LGG	cis	rs10751667	0.666	rs6597966	chr11:950750	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.2e-14	Alzheimer's disease (late onset);
LGG	cis	rs1552244	0.882	rs3732967	chr3:10015437	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs60843830	1.000	rs3828165	chr2:220889	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.48	0.37	2.95e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4242434	0.646	rs6988593	chr8:22527440	A/G	cg19455335	chr8:22457658	C8orf58	0.36	7.12	0.31	4.09e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7843479	0.601	rs2002941	chr8:21834366	A/C	cg17168535	chr8:21777572	XPO7	0.82	16.04	0.6	2.22e-46	Mean corpuscular volume;
LGG	cis	rs3858526	0.834	rs6578712	chr11:5987071	C/T	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.41e-17	DNA methylation (variation);
LGG	cis	rs9534288	0.797	rs7338189	chr13:46571035	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.23	-0.52	3.87e-34	Blood protein levels;
LGG	cis	rs4930103	0.935	rs11042167	chr11:2020901	G/A	cg15394860	chr11:2017084	H19	0.63	13.87	0.54	7.66e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7917772	0.582	rs7907760	chr10:104345197	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.59e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6688613	0.765	rs56229522	chr1:166816108	T/A	ch.1.3259774R	chr1:166827647	TADA1	0.52	8.31	0.36	1.11e-15	Refractive astigmatism;
LGG	cis	rs11122272	0.766	rs2808614	chr1:231550168	A/G	cg10503236	chr1:231470652	EXOC8	0.37	7.26	0.32	1.65e-12	Hemoglobin concentration;
LGG	cis	rs17666538	0.792	rs7820788	chr8:601846	C/T	cg07234876	chr8:600039	NA	1.38	12.95	0.52	5.79e-33	IgG glycosylation;
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs11608355	0.532	rs7968387	chr12:109788019	A/C	cg19025524	chr12:109796872	NA	-0.51	-10.97	-0.45	4.78e-25	Neuroticism;
LGG	trans	rs9354308	0.764	rs9363486	chr6:66615551	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.4	6.8	0.3	3.27e-11	Metabolite levels;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-7.86	-0.34	2.69e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs921943	0.554	rs163132	chr5:78285921	A/G	cg18828365	chr5:78281819	ARSB	0.5	8.01	0.35	9.66e-15	Blood and toenail selenium levels;Blood trace element (Se levels);
LGG	cis	rs6831352	0.918	rs2851248	chr4:100045974	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.55	0.41	7.32e-20	Alcohol dependence;
LGG	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.82	-0.34	3.51e-14	HDL cholesterol;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07592090	chr1:153700121	INTS3	-0.43	-6.83	-0.3	2.72e-11	Pancreatic cancer;
LGG	trans	rs2727020	0.636	rs10839275	chr11:49438962	T/A	cg15704280	chr7:45808275	SEPT13	-0.98	-21.28	-0.7	1.35e-70	Coronary artery disease;
LGG	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg15921436	chr17:44337874	NA	-0.44	-10.39	-0.43	7.2e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2735413	0.528	rs11640182	chr16:78040451	G/T	cg04733911	chr16:78082701	NA	0.49	6.79	0.3	3.54e-11	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6500602	0.673	rs4786512	chr16:4573040	A/G	cg01673284	chr16:4527211	HMOX2	0.35	6.91	0.31	1.64e-11	Schizophrenia;
LGG	cis	rs11169552	0.510	rs10876061	chr12:50968685	G/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.62	-0.33	1.47e-13	Colorectal cancer;
LGG	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs317689	0.819	rs317677	chr12:69691806	G/A	cg11871910	chr12:69753446	YEATS4	0.47	7.51	0.33	2.97e-13	Response to diuretic therapy;
LGG	cis	rs12477438	0.798	rs1580068	chr2:99649969	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg11890956	chr21:40555474	PSMG1	-0.75	-13.08	-0.52	1.78e-33	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs6786638	chr3:10118075	G/C	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs78456975	0.943	rs6721243	chr2:1580250	A/G	cg26248373	chr2:1572462	NA	-0.76	-10.95	-0.45	5.89e-25	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs61332075	0.501	rs56387323	chr2:239387399	T/C	cg01134436	chr17:81009848	B3GNTL1	0.83	8.76	0.38	3.7e-17	Lung function (FEV1/FVC);
LGG	cis	rs1670533	1.000	rs641987	chr4:1077542	C/T	cg27284194	chr4:1044797	NA	0.54	9.92	0.42	3.6e-21	Recombination rate (females);
LGG	cis	rs4774830	0.744	rs10438326	chr15:56158075	A/G	cg05129572	chr15:56138634	NEDD4	-0.86	-8.0	-0.35	1.04e-14	Delta-5 desaturase activity;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg11062466	chr8:58055876	NA	0.44	6.95	0.31	1.28e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg16583315	chr14:65563665	MAX	-0.42	-8.39	-0.36	6.11e-16	Obesity-related traits;
LGG	cis	rs2742417	0.603	rs1468542	chr3:45779136	A/T	cg04837898	chr3:45731254	SACM1L	0.48	9.61	0.41	4.61e-20	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9487051	0.676	rs1829694	chr6:109593860	G/T	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs11785400	0.793	rs4467920	chr8:143736846	C/T	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs10504229	0.953	rs67886764	chr8:58187117	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10979	0.597	rs9399449	chr6:143908376	C/T	cg25407410	chr6:143891975	LOC285740	-0.54	-8.06	-0.35	6.52e-15	Hypospadias;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.01	-0.46	3.25e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1461503	0.966	rs1461504	chr11:122845129	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.76	0.51	3.79e-32	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	trans	rs2736345	0.502	rs12680762	chr8:11332026	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.41	-0.33	6.23e-13	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg24006582	chr15:45444508	DUOX1	0.67	12.1	0.49	1.76e-29	Uric acid levels;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.05	0.35	7.01e-15	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs252902	chr5:56116085	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	cis	rs2077654	0.822	rs7944045	chr11:17439590	C/T	cg25308976	chr11:17434268	ABCC8	0.84	9.84	0.42	6.89e-21	Gout;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10781543	0.763	rs10781539	chr9:139320965	G/A	cg14019695	chr9:139328340	INPP5E	0.46	8.34	0.36	8.53e-16	Monocyte percentage of white cells;
LGG	cis	rs11864453	0.713	rs9926156	chr16:72142895	G/C	cg01557791	chr16:72042693	DHODH	-0.51	-9.29	-0.4	5.88e-19	Fibrinogen levels;
LGG	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg27624424	chr6:160112604	SOD2	0.65	9.26	0.4	7.67e-19	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23025395	chr11:18127696	SAAL1	0.55	8.58	0.37	1.44e-16	Gut microbiome composition (summer);
LGG	cis	rs7945705	0.902	rs11042152	chr11:9020987	C/T	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.26	0.46	3.76e-26	Hemoglobin concentration;
LGG	cis	rs11098499	0.738	rs72918577	chr4:120326701	G/A	cg09307838	chr4:120376055	NA	0.82	13.85	0.54	9.76e-37	Corneal astigmatism;
LGG	trans	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.54	-0.41	8.27e-20	Bladder cancer;
LGG	cis	rs11644362	0.966	rs11645507	chr16:12992570	C/A	cg06890432	chr16:12997467	SHISA9	-0.33	-6.94	-0.31	1.33e-11	Positive affect;Subjective well-being;
LGG	cis	rs62400317	0.821	rs12202232	chr6:45208345	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.04	-0.42	1.41e-21	Total body bone mineral density;
LGG	cis	rs6500395	0.963	rs961951	chr16:48716720	A/G	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.64	0.54	7.83e-36	Lung cancer;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs10170846	0.530	rs56353541	chr2:223421187	G/C	cg25565276	chr2:223520875	FARSB	0.73	12.26	0.5	4.05e-30	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-7.6	-0.33	1.68e-13	Testicular germ cell tumor;
LGG	cis	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg15596359	chr8:11213517	TDH	-0.41	-8.57	-0.37	1.58e-16	Retinal vascular caliber;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12282928	0.959	rs11500496	chr11:48304436	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs12195424	0.730	rs9475698	chr6:56298924	A/G	cg10030658	chr6:56298004	NA	0.54	6.74	0.3	4.62e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg16359550	chr11:109292809	C11orf87	0.41	7.9	0.34	2.04e-14	Schizophrenia;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.98	-0.42	2.16e-21	Educational attainment;
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	cis	rs149163995	1	rs149163995	chr2:203777226	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Migraine;
LGG	cis	rs7147624	0.938	rs7151148	chr14:65936665	G/C	cg03016385	chr14:66212404	NA	-0.78	-10.04	-0.42	1.35e-21	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg14456004	chr13:21872349	NA	1.33	24.74	0.75	1.01e-86	White matter hyperintensity burden;
LGG	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.66	0.63	9.65e-54	Cognitive function;
LGG	cis	rs116095464	0.558	rs61492827	chr5:225774	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs7927771	0.832	rs11605672	chr11:47413733	A/G	cg20307385	chr11:47447363	PSMC3	-0.6	-11.09	-0.46	1.62e-25	Subjective well-being;
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg00142150	chr22:38071001	LGALS1	0.91	19.37	0.67	1.21e-61	Fat distribution (HIV);
LGG	cis	rs888468	1.000	rs12367170	chr12:4535774	T/C	cg25948690	chr12:4554596	FGF6	0.39	6.78	0.3	3.65e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs6964587	0.967	rs13233496	chr7:91813035	T/C	cg17063962	chr7:91808500	NA	0.52	9.57	0.41	6.63e-20	Breast cancer;
LGG	cis	rs35110281	0.777	rs7276215	chr21:44990697	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.65	0.41	3.41e-20	Mean corpuscular volume;
LGG	cis	rs7587476	0.689	rs10498025	chr2:215749256	A/G	cg04004882	chr2:215674386	BARD1	0.52	7.31	0.32	1.15e-12	Neuroblastoma;
LGG	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg11812906	chr14:75593930	NEK9	-0.4	-7.21	-0.32	2.37e-12	Coronary artery disease;
LGG	cis	rs6141769	0.542	rs28456361	chr20:31299597	T/C	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.76	-0.3	4.07e-11	Subjective well-being;
LGG	cis	rs6121246	0.567	rs6058189	chr20:30192389	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.16e-25	Aortic root size;
LGG	cis	rs4664308	0.577	rs62175519	chr2:160915624	C/G	cg03641300	chr2:160917029	PLA2R1	-0.69	-10.27	-0.43	2.06e-22	Idiopathic membranous nephropathy;
LGG	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg10483660	chr13:112241077	NA	0.36	6.97	0.31	1.07e-11	Menarche (age at onset);
LGG	cis	rs7246760	1.000	rs7246772	chr19:9886283	C/T	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	cis	rs10540	1.000	rs12786555	chr11:506229	C/T	cg19913688	chr11:428466	ANO9	-0.64	-8.05	-0.35	7.05e-15	Body mass index;
LGG	cis	rs60871478	0.947	rs62432255	chr7:804219	G/A	cg22643751	chr7:855365	UNC84A	0.36	6.94	0.31	1.32e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs9400467	0.537	rs12191266	chr6:111528041	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.12	0.31	4.04e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs2084898	1.000	rs56391092	chr11:120010550	C/T	cg13907859	chr11:120009124	TRIM29	0.9	11.96	0.49	6.57e-29	Stroke (pediatric);
LGG	cis	rs1971762	0.527	rs4019971	chr12:53978715	A/G	cg06632207	chr12:54070931	ATP5G2	0.22	6.85	0.3	2.31e-11	Height;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs11874712	0.623	rs3753069	chr18:43678035	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.21	-0.39	1.13e-18	Migraine - clinic-based;
LGG	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg08344181	chr3:125677491	NA	-0.91	-9.21	-0.39	1.11e-18	Depression;
LGG	cis	rs4959677	0.935	rs10458145	chr6:2493582	G/T	cg20147862	chr6:2634573	C6orf195	-0.41	-8.77	-0.38	3.4e-17	Orthostatic hypotension;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.78	-0.34	4.93e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4478858	0.611	rs7527645	chr1:31763787	T/C	cg19084893	chr1:31688959	NA	0.32	6.88	0.3	2e-11	Alcohol dependence;
LGG	cis	rs754466	0.874	rs10430531	chr10:79660125	T/C	cg17075019	chr10:79541650	NA	-0.83	-13.87	-0.54	7.67e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs253959	0.545	rs10072350	chr5:115433526	G/T	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.78	0.3	3.63e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6714710	0.603	rs11690687	chr2:98461821	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	9.13	0.39	2.15e-18	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	6.21e-34	Resting heart rate;
LGG	cis	rs4740619	0.716	rs10810510	chr9:15958991	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.03	-0.42	1.47e-21	Body mass index;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.57	-0.41	6.32e-20	Life satisfaction;
LGG	cis	rs875971	1.000	rs6979382	chr7:65886375	C/T	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	trans	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg07211511	chr3:129823064	LOC729375	-0.66	-9.09	-0.39	2.82e-18	Blood pressure (smoking interaction);
LGG	trans	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.91	0.51	9.14e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.3	-0.32	1.3e-12	Electroencephalogram traits;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg13206674	chr6:150067644	NUP43	0.44	7.56	0.33	2.2e-13	Lung cancer;
LGG	cis	rs9733	0.650	rs61820165	chr1:150555987	C/T	cg13175981	chr1:150552382	MCL1	0.6	10.49	0.44	3.04e-23	Tonsillectomy;
LGG	cis	rs7129220	0.588	rs16907481	chr11:10144108	A/T	cg01453529	chr11:10209919	SBF2	-0.43	-6.79	-0.3	3.48e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs193541	0.530	rs2045626	chr5:122081253	A/C	cg19412675	chr5:122181750	SNX24	0.5	8.14	0.35	3.78e-15	Glucose homeostasis traits;
LGG	cis	rs10489202	0.955	rs17557162	chr1:167985950	A/T	cg24449463	chr1:168025552	DCAF6	0.59	9.62	0.41	4.17e-20	Schizophrenia;
LGG	cis	rs1816752	0.819	rs9511240	chr13:24985906	G/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.39	-0.32	6.95e-13	Neuroticism;
LGG	cis	rs35883536	0.545	rs115017855	chr1:101101830	T/A	cg06223162	chr1:101003688	GPR88	0.35	7.93	0.35	1.67e-14	Monocyte count;
LGG	cis	rs78456975	0.943	rs13391932	chr2:1577679	T/C	cg01028140	chr2:1542097	TPO	-0.46	-7.38	-0.32	7.63e-13	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7717393	0.786	rs13355607	chr5:155801758	G/A	cg12904904	chr5:155754151	SGCD	0.68	7.13	0.31	3.84e-12	Egg allergy;
LGG	cis	rs9611519	0.565	rs8135524	chr22:41436442	T/C	cg03806693	chr22:41940476	POLR3H	-0.48	-7.79	-0.34	4.32e-14	Neuroticism;
LGG	cis	rs6763768	0.668	rs312475	chr3:53513354	A/G	cg16894138	chr3:53270350	TKT	0.42	7.66	0.34	1.06e-13	Bacterial meningitis;
LGG	cis	rs7077256	0.564	rs72829202	chr10:65020018	T/C	cg02276361	chr10:65351566	REEP3	-0.33	-6.75	-0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11018874	0.597	rs4393275	chr11:89886397	C/T	cg14505434	chr11:89522851	NA	0.62	9.17	0.39	1.5e-18	White blood cell types;
LGG	cis	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg20368463	chr18:77673604	PQLC1	-0.55	-7.9	-0.34	1.98e-14	Opioid sensitivity;
LGG	cis	rs72777070	0.857	rs66484704	chr2:9795776	C/T	cg14973360	chr2:9800511	NA	-0.5	-6.93	-0.31	1.46e-11	Platelet-derived growth factor BB levels;
LGG	cis	rs36051895	0.626	rs7870694	chr9:5100628	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-15.98	-0.6	4.26e-46	Pediatric autoimmune diseases;
LGG	cis	rs35146811	0.735	rs1727138	chr7:99815247	A/G	cg13334819	chr7:99746414	C7orf59	0.43	6.81	0.3	3.08e-11	Coronary artery disease;
LGG	cis	rs4330281	0.669	rs9310526	chr3:17643034	T/G	cg20981856	chr3:17787350	NA	0.4	7.37	0.32	8.08e-13	Schizophrenia;
LGG	cis	rs17767392	0.958	rs12889866	chr14:71937439	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg14952266	chr13:112191215	NA	-0.52	-10.97	-0.45	4.9e-25	Hepatitis;
LGG	cis	rs977987	0.806	rs8054769	chr16:75401113	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.45	0.44	4.26e-23	Dupuytren's disease;
LGG	trans	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg24247370	chr13:99142703	STK24	-0.43	-7.95	-0.35	1.47e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1018836	0.632	rs1028255	chr8:91485578	A/T	cg16814680	chr8:91681699	NA	-0.65	-11.16	-0.46	9.15e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg24623649	chr8:11872141	NA	-0.34	-7.95	-0.35	1.42e-14	Triglycerides;
LGG	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg04058563	chr4:185651563	MLF1IP	0.37	7.64	0.33	1.22e-13	Kawasaki disease;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg26513180	chr16:89883248	FANCA	0.88	8.81	0.38	2.58e-17	Skin colour saturation;
LGG	cis	rs477692	0.637	rs2388331	chr10:131314173	G/A	cg05714579	chr10:131428358	MGMT	0.45	8.47	0.37	3.19e-16	Response to temozolomide;
LGG	cis	rs4819052	0.918	rs34886433	chr21:46680538	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.83	13.16	0.52	8.04e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs151234	0.741	rs11647881	chr16:28606173	C/A	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.48	-0.4	1.37e-19	Platelet distribution width;
LGG	cis	rs2842992	0.789	rs4235925	chr6:160202860	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.75	12.47	0.5	5.92e-31	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12893668	0.572	rs4906350	chr14:104111794	C/T	cg26031613	chr14:104095156	KLC1	-0.67	-10.79	-0.45	2.3e-24	Reticulocyte count;
LGG	cis	rs73086581	1.000	rs17286768	chr20:3924569	A/G	cg02187196	chr20:3869020	PANK2	0.82	11.46	0.47	6.39e-27	Response to antidepressants in depression;
LGG	trans	rs11098499	0.954	rs11098526	chr4:120390359	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.27	0.5	3.6e-30	Corneal astigmatism;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg26174226	chr8:58114915	NA	-0.59	-7.92	-0.35	1.74e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.17	0.39	1.56e-18	Electroencephalogram traits;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.69	-0.37	6.17e-17	Skin colour saturation;
LGG	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2229238	0.911	rs3811448	chr1:154516578	G/A	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs2180341	1.000	rs9285460	chr6:127640190	A/G	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs8058578	0.943	rs3747486	chr16:30786927	C/T	cg05768032	chr16:30646687	NA	0.43	7.26	0.32	1.65e-12	Multiple myeloma;
LGG	cis	rs919433	0.679	rs6708239	chr2:198525084	A/G	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.45	-0.37	3.9e-16	Systolic blood pressure;
LGG	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg02524346	chr8:600233	NA	1.24	11.93	0.48	8.75e-29	IgG glycosylation;
LGG	cis	rs638893	0.636	rs61901410	chr11:118661197	C/G	cg13782932	chr11:118662891	DDX6	-0.38	-6.86	-0.3	2.15e-11	Vitiligo;
LGG	cis	rs2075371	0.829	rs1993058	chr7:133930361	G/A	cg11752832	chr7:134001865	SLC35B4	0.56	10.03	0.42	1.43e-21	Mean platelet volume;
LGG	cis	rs7444	0.941	rs73166619	chr22:21930093	C/T	cg05046821	chr22:21984468	YDJC	-0.4	-7.12	-0.31	4.19e-12	Systemic lupus erythematosus;
LGG	cis	rs9868809	0.881	rs9878063	chr3:48678971	T/G	cg00383909	chr3:49044727	WDR6	0.78	9.39	0.4	2.75e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs933688	1.000	rs6452951	chr5:90653868	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	19.25	0.67	4.26e-61	Smoking behavior;
LGG	cis	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.23	-0.36	1.94e-15	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs892961	1.000	rs2117924	chr17:75401310	C/T	cg05865280	chr17:75406074	SEPT9	0.42	10.01	0.42	1.73e-21	Airflow obstruction;
LGG	cis	rs2016266	0.502	rs34745537	chr12:53635435	G/A	cg04065151	chr12:53682969	ESPL1	-0.82	-16.45	-0.61	3.28e-48	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg10756647	chr7:56101905	PSPH	0.83	9.75	0.41	1.44e-20	Diabetic kidney disease;
LGG	cis	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.09	-0.31	5.03e-12	Neuroticism;
LGG	cis	rs11792861	0.530	rs1772047	chr9:111679012	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.5	-8.2	-0.36	2.3e-15	Menarche (age at onset);
LGG	trans	rs7395662	0.571	rs12421145	chr11:48624725	C/A	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	2.01e-11	HDL cholesterol;
LGG	cis	rs28830936	0.967	rs9672671	chr15:41917075	C/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.7	-0.3	6.13e-11	Diastolic blood pressure;
LGG	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg08888203	chr3:10149979	C3orf24	0.36	6.74	0.3	4.86e-11	Alzheimer's disease;
LGG	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.32	-0.32	1.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs72945132	0.882	rs7932431	chr11:70166059	A/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg04617936	chr2:214353	NA	-0.4	-7.43	-0.33	5.24e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg27165867	chr14:105738592	BRF1	-0.46	-7.39	-0.32	7.05e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6541297	0.645	rs4846919	chr1:230301451	A/G	cg05784532	chr1:230284198	GALNT2	0.47	7.2	0.32	2.51e-12	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18685883	chr3:51705045	TEX264	0.44	7.45	0.33	4.69e-13	Cognitive performance;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.43	0.58	1.24e-43	Lung cancer;
LGG	trans	rs1814175	0.817	rs12277258	chr11:49940216	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.53	-0.5	3.21e-31	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25478109	chr3:179322476	NDUFB5;MRPL47	0.4	6.67	0.3	7.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9868809	1.000	rs2310997	chr3:48678011	G/C	cg00383909	chr3:49044727	WDR6	0.84	9.67	0.41	2.82e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs17023223	0.537	rs12085308	chr1:119677553	T/C	cg05756136	chr1:119680316	WARS2	-0.45	-8.93	-0.38	1.05e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.54	0.59	3.81e-44	Lung cancer;
LGG	cis	rs17784882	0.524	rs7433300	chr3:47120640	G/A	cg27129171	chr3:47204927	SETD2	0.78	13.98	0.54	2.76e-37	QT interval;
LGG	cis	rs3849046	0.817	rs4835687	chr5:137872056	C/T	cg10920316	chr5:137946599	NA	-0.43	-6.83	-0.3	2.61e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6121246	0.909	rs1994250	chr20:30287494	A/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.63	0.51	1.29e-31	Mean corpuscular hemoglobin;
LGG	trans	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg16141378	chr3:129829833	LOC729375	0.3	6.76	0.3	4.07e-11	Triglycerides;
LGG	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.32	-0.36	1.02e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs701145	0.938	rs813141	chr3:154066521	T/C	cg17054900	chr3:154042577	DHX36	0.99	12.36	0.5	1.63e-30	Coronary artery disease;
LGG	trans	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs818427	0.750	rs153562	chr5:112253119	G/A	cg07820702	chr5:112228657	REEP5	-0.36	-6.71	-0.3	5.54e-11	Total body bone mineral density;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg06916706	chr16:4465613	CORO7	-0.84	-15.45	-0.58	9.69e-44	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg13802316	chr11:70253460	CTTN	-0.57	-7.39	-0.32	6.77e-13	Coronary artery disease;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg05091796	chr16:4465799	CORO7	-0.79	-13.83	-0.54	1.19e-36	Schizophrenia;
LGG	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg11766577	chr21:47581405	C21orf56	-0.59	-10.71	-0.45	4.5e-24	Testicular germ cell tumor;
LGG	cis	rs9487094	0.848	rs7372	chr6:109688114	A/G	cg01125227	chr6:109776195	MICAL1	0.51	8.82	0.38	2.41e-17	Height;
LGG	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg14703610	chr5:56206110	C5orf35	0.45	7.73	0.34	6.87e-14	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06009432	chr2:178483847	TTC30A	0.54	8.09	0.35	5.3e-15	Gut microbiome composition (summer);
LGG	cis	rs7089973	0.565	rs7082836	chr10:116646237	G/A	cg03647239	chr10:116582469	FAM160B1	0.42	7.23	0.32	2.02e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7106204	0.748	rs6484031	chr11:24237115	A/C	ch.11.24196551F	chr11:24239977	NA	1.01	16.38	0.61	6.64e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs709400	0.827	rs2274269	chr14:104029246	G/A	cg26031613	chr14:104095156	KLC1	1.13	25.87	0.77	5.96e-92	Body mass index;
LGG	cis	rs13038095	1	rs13038095	chr20:46425576	A/C	cg21798815	chr20:46414765	SULF2	-0.76	-9.49	-0.4	1.24e-19	Atrial fibrillation;
LGG	cis	rs2236918	0.710	rs2488470	chr1:242019580	A/G	cg17736920	chr1:242011382	EXO1	0.39	7.07	0.31	5.75e-12	Menopause (age at onset);
LGG	trans	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg25214090	chr10:38739885	LOC399744	0.63	11.06	0.46	2.11e-25	Corneal astigmatism;
LGG	trans	rs1814175	0.727	rs2140597	chr11:49873946	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.11	-0.49	1.65e-29	Height;
LGG	cis	rs34172651	0.517	rs2287783	chr16:24831727	C/T	cg02428538	chr16:24856791	SLC5A11	-0.67	-10.31	-0.43	1.39e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg19168338	chr16:4465731	CORO7	-0.91	-18.41	-0.65	3.25e-57	Schizophrenia;
LGG	cis	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg11995313	chr8:8860691	ERI1	-0.4	-6.7	-0.3	6.01e-11	Joint mobility (Beighton score);
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs7561149	0.500	rs35770984	chr2:179626080	T/A	cg03991736	chr2:179345203	MIR548N;PLEKHA3	0.39	7.06	0.31	6.16e-12	QT interval;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.16	-0.35	3.15e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs763121	0.925	rs4821797	chr22:39016182	T/C	cg06022373	chr22:39101656	GTPBP1	0.84	17.12	0.62	2.88e-51	Menopause (age at onset);
LGG	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.1	0.35	5.06e-15	Colorectal cancer;
LGG	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs7192380	0.737	rs11641722	chr16:69580402	C/T	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.36	-0.36	7.31e-16	Sjögren's syndrome;
LGG	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs11608355	0.672	rs9943689	chr12:109890339	G/A	cg05360138	chr12:110035743	NA	0.6	8.34	0.36	8.65e-16	Neuroticism;
LGG	cis	rs3768617	0.966	rs10911253	chr1:183086190	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.11e-11	Fuchs's corneal dystrophy;
LGG	cis	rs12210905	0.920	rs858995	chr6:27181701	T/C	cg23155468	chr6:27110703	HIST1H2BK	0.58	7.06	0.31	6.2e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7572733	0.935	rs4850817	chr2:198795204	A/G	cg00792783	chr2:198669748	PLCL1	-0.47	-7.76	-0.34	5.35e-14	Dermatomyositis;
LGG	trans	rs7824557	0.628	rs7005469	chr8:11194457	G/A	cg15556689	chr8:8085844	FLJ10661	0.43	7.32	0.32	1.1e-12	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs2727295	chr17:61887693	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.56	11.0	0.46	3.56e-25	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg04287289	chr16:89883240	FANCA	0.77	7.61	0.33	1.55e-13	Skin colour saturation;
LGG	cis	rs10979	1.000	rs9496681	chr6:143896964	G/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.64	-0.51	1.11e-31	Hypospadias;
LGG	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg23280166	chr11:118938394	VPS11	-0.5	-8.75	-0.38	4.14e-17	Coronary artery disease;
LGG	cis	rs368123	1.000	rs316170	chr6:160756037	A/G	cg07349212	chr6:160770346	SLC22A3	0.34	7.37	0.32	7.7e-13	Waist circumference;
LGG	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07659893	chr17:61819838	STRADA	0.47	7.96	0.35	1.3e-14	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg04455712	chr21:45112962	RRP1B	0.51	9.78	0.41	1.2e-20	Mean corpuscular volume;
LGG	cis	rs77633900	0.614	rs280012	chr15:76974854	G/T	cg21673338	chr15:77095150	SCAPER	-0.65	-10.22	-0.43	2.95e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9715521	0.775	rs62301198	chr4:59848776	C/T	cg11281224	chr4:60001000	NA	-0.5	-8.46	-0.37	3.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1420338	0.933	rs62451689	chr7:34178719	C/T	cg01275685	chr7:34179230	BMPER	-0.52	-9.49	-0.4	1.23e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs864537	0.584	rs7523907	chr1:167427247	A/G	cg09179987	chr1:167433047	CD247	0.37	8.36	0.36	7.32e-16	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs694739	0.628	rs508168	chr11:64135435	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.77e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.41e-17	Life satisfaction;
LGG	cis	rs10892173	0.846	rs7943887	chr11:117670282	C/G	cg21640587	chr11:117668038	DSCAML1	0.45	7.59	0.33	1.83e-13	Myopia;
LGG	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg22601191	chr20:60968625	CABLES2	0.37	7.2	0.32	2.48e-12	Colorectal cancer;
LGG	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.46	-0.44	3.8e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62238980	0.614	rs117744580	chr22:32566631	G/T	cg00543991	chr22:32367038	NA	0.74	9.19	0.39	1.29e-18	Childhood ear infection;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg26516362	chr5:178986906	RUFY1	0.43	7.94	0.35	1.53e-14	Lung cancer;
LGG	cis	rs7951870	0.617	rs12274785	chr11:46714279	T/C	cg03339077	chr11:47165057	C11orf49	0.43	7.41	0.33	6.05e-13	Schizophrenia;
LGG	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.26	0.4	7.38e-19	Blood metabolite levels;
LGG	trans	rs453301	0.624	rs7014430	chr8:8827737	T/G	cg02002194	chr4:3960332	NA	-0.36	-6.77	-0.3	4.03e-11	Joint mobility (Beighton score);
LGG	trans	rs2197308	0.765	rs11182992	chr12:37935572	G/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs5769707	0.521	rs7285764	chr22:50058561	T/C	cg20744362	chr22:50050164	C22orf34	0.41	7.13	0.31	3.82e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2735413	0.563	rs72800910	chr16:78047902	C/T	cg04733911	chr16:78082701	NA	0.56	7.45	0.33	4.77e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg12193833	chr17:30244370	NA	-0.28	-7.08	-0.31	5.38e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.54e-16	Common traits (Other);
LGG	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg12395012	chr8:11607386	GATA4	0.41	7.33	0.32	1e-12	Morning vs. evening chronotype;
LGG	cis	rs7572263	0.959	rs6725512	chr2:209050418	A/G	cg00164906	chr2:209055251	C2orf80	0.52	8.74	0.38	4.17e-17	Glioma;Non-glioblastoma glioma;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg04008888	chr11:68622739	NA	-0.55	-11.73	-0.48	5.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs921968	0.540	rs10190250	chr2:219457731	C/T	cg10223061	chr2:219282414	VIL1	0.31	6.85	0.3	2.42e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg00204512	chr16:28754710	NA	0.24	6.68	0.3	7.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1408799	0.750	rs7036899	chr9:12620266	A/G	cg05274944	chr9:12693694	TYRP1	0.32	7.4	0.33	6.43e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs12545109	0.800	rs1960725	chr8:57411807	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg11995313	chr8:8860691	ERI1	0.42	6.96	0.31	1.17e-11	Joint mobility (Beighton score);
LGG	trans	rs61931739	0.620	rs1905241	chr12:33709729	G/A	cg26384229	chr12:38710491	ALG10B	-0.48	-8.58	-0.37	1.49e-16	Morning vs. evening chronotype;
LGG	cis	rs209489	0.892	rs1429144	chr6:53176537	C/T	cg15607103	chr6:53167650	ELOVL5	0.71	9.03	0.39	4.71e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs2576037	0.542	rs4630643	chr18:44508142	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.67	0.44	6.72e-24	Personality dimensions;
LGG	trans	rs17685	0.753	rs11764129	chr7:75761890	T/C	cg19862616	chr7:65841803	NCRNA00174	1.08	25.85	0.77	7.32e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg19774624	chr17:42201019	HDAC5	-0.84	-16.46	-0.61	3.02e-48	Total body bone mineral density;
LGG	cis	rs7927592	0.956	rs11228251	chr11:68244558	G/T	cg16797656	chr11:68205561	LRP5	0.41	7.34	0.32	9.42e-13	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg21475434	chr5:93447410	FAM172A	0.7	7.14	0.31	3.72e-12	Diabetic retinopathy;
LGG	cis	rs7666738	0.830	rs991169	chr4:98928567	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.966	rs758483	chr4:17703614	G/T	cg02297831	chr4:17616191	MED28	-0.44	-7.92	-0.35	1.77e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg03060546	chr3:49711283	APEH	-0.65	-10.87	-0.45	1.1e-24	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11168618	0.904	rs4359253	chr12:48927708	G/A	cg24011408	chr12:48396354	COL2A1	0.44	7.24	0.32	1.88e-12	Adiponectin levels;
LGG	cis	rs1007190	0.570	rs2906781	chr17:42793967	T/G	cg15406952	chr17:42872593	NA	0.97	10.62	0.44	1.01e-23	DNA methylation (variation);
LGG	cis	rs12731740	1.000	rs72729053	chr1:208012294	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.28	-0.32	1.4e-12	Biomedical quantitative traits;
LGG	cis	rs9768139	0.935	rs10434944	chr7:158116911	C/T	cg15736062	chr7:158136485	PTPRN2	0.35	6.92	0.31	1.52e-11	Calcium levels;
LGG	cis	rs7727544	0.735	rs273913	chr5:131661156	A/G	cg07395648	chr5:131743802	NA	-0.54	-12.38	-0.5	1.34e-30	Blood metabolite levels;
LGG	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg09624528	chr10:1369823	ADARB2	0.39	6.65	0.3	8.35e-11	Radiation response;
LGG	trans	rs11989744	0.500	rs7826966	chr8:23569106	G/T	cg03492747	chr16:86543808	FOXF1	-0.6	-10.92	-0.45	7.32e-25	Waist-hip ratio;
LGG	cis	rs6582630	0.519	rs7294300	chr12:38277359	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08645402	chr16:4508243	NA	0.53	10.28	0.43	1.8e-22	Schizophrenia;
LGG	cis	rs13260300	0.657	rs10957730	chr8:75522401	T/G	cg22993706	chr8:75542856	NA	0.41	8.14	0.35	3.62e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs1670533	0.932	rs2248083	chr4:1052166	A/C	cg27284194	chr4:1044797	NA	0.56	10.09	0.42	9.15e-22	Recombination rate (females);
LGG	cis	rs2439831	1.000	rs2444032	chr15:43755346	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.44	0.5	7.4e-31	Lung cancer in ever smokers;
LGG	cis	rs12477438	0.501	rs6708878	chr2:99801564	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs1983891	0.742	rs755304	chr6:41552101	T/C	cg20194872	chr6:41519635	FOXP4	0.54	9.34	0.4	4.18e-19	Prostate cancer;
LGG	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg20818283	chr2:191399100	TMEM194B	-0.31	-7.19	-0.32	2.67e-12	Pulse pressure;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg06494592	chr3:125709126	NA	-0.56	-7.09	-0.31	5.02e-12	Blood pressure (smoking interaction);
LGG	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.5	-0.4	1.16e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg20503657	chr10:835505	NA	0.75	10.29	0.43	1.66e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs9660992	0.710	rs1172111	chr1:205232980	C/T	cg00857998	chr1:205179979	DSTYK	0.46	6.86	0.3	2.25e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs911263	0.603	rs7147852	chr14:68796799	C/T	cg18825221	chr14:68749962	RAD51L1	0.37	8.05	0.35	6.94e-15	Primary biliary cholangitis;
LGG	cis	rs1816752	0.819	rs4770664	chr13:24988833	C/T	cg02811702	chr13:24901961	NA	0.39	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs2370759	1.000	rs11594963	chr10:32625736	G/A	cg01819863	chr10:32635814	EPC1	1.11	15.6	0.59	2.07e-44	Sexual dysfunction (female);
LGG	cis	rs5756813	0.754	rs34848977	chr22:38165587	G/A	cg24232236	chr22:38142998	TRIOBP	0.37	7.13	0.31	3.95e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg18825076	chr15:78729989	IREB2	-0.46	-7.42	-0.33	5.7e-13	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.61	-0.51	1.5e-31	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.895	rs1974769	chr7:65950614	G/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs7267979	0.873	rs6132822	chr20:25228695	C/T	cg06421707	chr20:25228305	PYGB	0.54	12.2	0.49	7.06e-30	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.12	-0.39	2.33e-18	Neuroticism;
LGG	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg24692254	chr21:30365293	RNF160	1.04	29.93	0.81	2.68e-110	Dental caries;
LGG	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg25664220	chr3:72788482	NA	-0.32	-8.99	-0.39	6.37e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.94	0.38	9.57e-18	Platelet count;
LGG	cis	rs922692	0.744	rs4886592	chr15:79082547	T/C	cg00540400	chr15:79124168	NA	-0.39	-7.63	-0.33	1.33e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg02743256	chr7:2109353	MAD1L1	-0.34	-6.97	-0.31	1.11e-11	Bipolar disorder;
LGG	cis	rs11920090	0.932	rs6785803	chr3:170729873	G/C	cg09710316	chr3:170744871	SLC2A2	0.6	8.55	0.37	1.74e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.74	0.64	4.35e-54	Exhaled nitric oxide output;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.89	-0.3	1.82e-11	Longevity;
LGG	cis	rs10193935	0.792	rs7559001	chr2:42474301	C/T	cg27598129	chr2:42591480	NA	-0.6	-9.18	-0.39	1.43e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7143963	0.636	rs2896460	chr14:103306106	A/T	cg23020514	chr14:103360112	TRAF3	0.41	8.56	0.37	1.72e-16	Body mass index;
LGG	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg13147721	chr7:65941812	NA	-0.83	-9.94	-0.42	3.14e-21	Diabetic kidney disease;
LGG	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs7523050	0.643	rs12741194	chr1:109400390	T/C	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	trans	rs116095464	0.614	rs62344339	chr5:252995	T/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs8180040	0.966	rs6787422	chr3:47418509	G/T	cg16586182	chr3:47516702	SCAP	-0.78	-15.94	-0.6	6.2e-46	Colorectal cancer;
LGG	cis	rs1862618	0.853	rs252898	chr5:56188931	T/C	cg17809284	chr5:56205270	C5orf35	-0.56	-9.11	-0.39	2.54e-18	Initial pursuit acceleration;
LGG	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg06917634	chr15:78832804	PSMA4	-0.66	-10.23	-0.43	2.85e-22	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.99	-0.31	9.5e-12	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	trans	rs141342723	1	rs141342723	chr6:27622084	T/C	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg12633918	chr20:23549525	CST9L	-0.34	-6.8	-0.3	3.27e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg25427524	chr10:38739819	LOC399744	-0.64	-11.92	-0.48	9.05e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.97	-0.31	1.09e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg12741488	chr16:2933841	FLYWCH2	0.4	6.94	0.31	1.37e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs763121	0.853	rs5750673	chr22:39110124	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.14	0.64	6e-56	Menopause (age at onset);
LGG	cis	rs8017423	0.967	rs4904658	chr14:90721640	C/T	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs11971779	0.680	rs11764236	chr7:139118514	C/T	cg07862535	chr7:139043722	LUC7L2	0.46	7.46	0.33	4.23e-13	Diisocyanate-induced asthma;
LGG	cis	rs7582180	0.629	rs11682557	chr2:100948008	C/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.22e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.517	rs246031	chr5:140333107	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7444	0.941	rs5998672	chr22:21966442	G/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg24130564	chr14:104152367	KLC1	-0.4	-7.51	-0.33	2.98e-13	Body mass index;
LGG	cis	rs3008870	0.920	rs3008860	chr1:67391003	G/C	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.68	0.73	3.76e-77	Lymphocyte percentage of white cells;
LGG	cis	rs832540	0.898	rs2662024	chr5:56257515	T/C	cg12654349	chr5:56205094	C5orf35	0.4	7.02	0.31	8.19e-12	Coronary artery disease;
LGG	cis	rs17253792	0.822	rs17746033	chr14:56061837	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs6456042	0.964	rs3127418	chr6:166538176	G/T	cg11088901	chr6:166572345	T	-0.36	-7.45	-0.33	4.6e-13	Asthma;
LGG	cis	rs1784581	0.722	rs1621456	chr6:162399985	C/T	cg17173639	chr6:162384350	PARK2	-0.75	-16.55	-0.61	1.13e-48	Itch intensity from mosquito bite;
LGG	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	1.0	9.97	0.42	2.38e-21	Diabetic retinopathy;
LGG	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg07120314	chr15:79043507	NA	0.68	13.58	0.53	1.33e-35	Coronary artery disease or large artery stroke;
LGG	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22496380	chr5:211416	CCDC127	-1.27	-16.65	-0.61	3.87e-49	Breast cancer;
LGG	trans	rs35110281	0.641	rs4819283	chr21:45083011	T/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.32	0.4	4.69e-19	Mean corpuscular volume;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.55	-9.34	-0.4	4.2e-19	Longevity;Endometriosis;
LGG	cis	rs5758659	0.652	rs133323	chr22:42405922	T/C	cg15128208	chr22:42549153	NA	-0.37	-7.31	-0.32	1.16e-12	Cognitive function;
LGG	cis	rs774359	0.789	rs868857	chr9:27488906	G/A	cg14173147	chr9:27528300	MOBKL2B	0.46	8.67	0.37	7.6e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs270601	0.739	rs3900945	chr5:131592870	T/C	cg07395648	chr5:131743802	NA	-0.37	-7.44	-0.33	5.05e-13	Acylcarnitine levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg21660531	chr2:207024562	EEF1B2;NDUFS1	-0.47	-6.82	-0.3	2.9100000000000002e-11	Systemic lupus erythematosus;
LGG	trans	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08862035	chr2:2617432	NA	0.42	6.94	0.31	1.32e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs35110281	0.811	rs4819264	chr21:45017349	G/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.13	0.49	1.37e-29	Mean corpuscular volume;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs7582180	0.764	rs11686293	chr2:100922830	C/T	cg14675211	chr2:100938903	LONRF2	0.66	11.43	0.47	8.38e-27	Intelligence (multi-trait analysis);
LGG	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg09021430	chr5:549028	NA	-0.74	-10.57	-0.44	1.58e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs3126085	0.935	rs11204967	chr1:152249720	A/G	cg26876637	chr1:152193138	HRNR	-0.56	-9.05	-0.39	3.86e-18	Atopic dermatitis;
LGG	cis	rs9902453	0.904	rs4994353	chr17:28386280	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.39	-0.53	8.29e-35	Coffee consumption (cups per day);
LGG	cis	rs765787	0.530	rs1706835	chr15:45517884	G/A	cg25801113	chr15:45476975	SHF	0.87	19.92	0.68	3.13e-64	Uric acid levels;
LGG	cis	rs4891159	0.790	rs72975929	chr18:74144630	G/C	cg24786174	chr18:74118243	ZNF516	-0.57	-13.32	-0.53	1.67e-34	Longevity;
LGG	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg19168338	chr16:4465731	CORO7	-0.94	-16.92	-0.62	2.47e-50	Schizophrenia;
LGG	cis	rs12210905	1.000	rs4636015	chr6:27097316	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3806843	1.000	rs3756339	chr5:140180537	A/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs459571	0.959	rs465724	chr9:136910097	C/T	cg13789015	chr9:136890014	NCRNA00094	0.56	10.34	0.43	1.09e-22	Platelet distribution width;
LGG	cis	rs72772090	0.539	rs56120748	chr5:96110622	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.98	0.31	1.03e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg07005078	chr4:17578674	LAP3	0.37	6.89	0.31	1.79e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.41	0.44	6.18e-23	Diabetic retinopathy;
LGG	cis	rs71403859	0.667	rs35538253	chr16:71677975	C/T	cg08717414	chr16:71523259	ZNF19	-1.01	-12.56	-0.5	2.47e-31	Post bronchodilator FEV1;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03550506	chr22:32149733	DEPDC5	0.47	6.94	0.31	1.35e-11	Gut microbiome composition (summer);
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg14159672	chr1:205819179	PM20D1	0.77	16.43	0.61	4.01e-48	Menarche (age at onset);
LGG	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24308560	chr3:49941425	MST1R	-0.22	-6.8	-0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.741	rs6587471	chr1:248560741	C/T	cg15454534	chr1:248569605	OR2T1	0.38	6.93	0.31	1.44e-11	Common traits (Other);
LGG	cis	rs524281	1.000	rs472518	chr11:65851902	A/G	cg14541915	chr11:65894463	PACS1	-0.3	-7.0	-0.31	9.18e-12	Electroencephalogram traits;
LGG	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg00578828	chr5:131826934	IRF1	-0.41	-7.32	-0.32	1.08e-12	Asthma (sex interaction);
LGG	trans	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg18335740	chr13:41363409	SLC25A15	0.88	21.81	0.71	4.8e-73	Lewy body disease;
LGG	cis	rs3793683	0.545	rs12784446	chr10:134589094	T/G	cg27297192	chr10:134578999	INPP5A	0.33	7.62	0.33	1.43e-13	Migraine;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	trans	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.56	-0.41	6.87e-20	Monocyte percentage of white cells;
LGG	cis	rs10504073	0.584	rs62507178	chr8:49938572	A/C	cg00325661	chr8:49890786	NA	0.8	15.73	0.59	5.45e-45	Blood metabolite ratios;
LGG	cis	rs9457247	0.935	rs2149093	chr6:167373045	T/C	cg07741184	chr6:167504864	NA	-0.32	-7.08	-0.31	5.48e-12	Crohn's disease;
LGG	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg07080220	chr10:102295463	HIF1AN	0.7	11.72	0.48	5.94e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9992101	0.645	rs72657825	chr4:77290561	G/A	cg17010112	chr4:77227123	STBD1	-0.47	-9.69	-0.41	2.36e-20	Creatinine levels;
LGG	cis	rs13126513	0.708	rs2172138	chr4:100489785	G/C	cg05468953	chr4:100565104	NA	0.39	7.85	0.34	3.01e-14	Metabolite levels (MHPG);
LGG	trans	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.14	-0.39	1.94e-18	Bladder cancer;
LGG	cis	rs7000551	0.556	rs35359294	chr8:22249755	G/A	cg12081754	chr8:22256438	SLC39A14	1.18	28.14	0.79	2.73e-102	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15613982	chr20:18488017	SEC23B	0.5	7.64	0.33	1.28e-13	Gut microbiome composition (summer);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15046935	chr19:45595006	NA	0.44	7.44	0.33	4.84e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs875971	0.862	rs2909688	chr7:65841612	C/A	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Body mass index;
LGG	cis	rs2204008	0.744	rs67889662	chr12:38327042	T/A	cg13010199	chr12:38710504	ALG10B	0.72	14.4	0.56	4.12e-39	Bladder cancer;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs1023500	0.506	rs6002625	chr22:42517689	A/G	cg05082376	chr22:42548792	NA	0.4	8.21	0.36	2.16e-15	Schizophrenia;
LGG	trans	rs941408	0.515	rs2110118	chr19:2775144	T/C	cg19676328	chr12:49525230	TUBA1B	-0.58	-8.67	-0.37	7.37e-17	Total cholesterol levels;
LGG	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg18478394	chr8:109455254	TTC35	0.42	8.46	0.37	3.57e-16	Dupuytren's disease;
LGG	cis	rs17767392	0.958	rs35231795	chr14:71987374	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.04	-0.39	4.22e-18	Mitral valve prolapse;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20555477	chr9:86594889	HNRNPK;RMI1	0.47	7.91	0.35	1.91e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7172689	1.000	rs58541174	chr15:81543794	G/A	cg11808699	chr15:81528661	IL16	-0.51	-10.71	-0.45	4.53e-24	Inattentive symptoms;
LGG	cis	rs6502050	0.799	rs4789674	chr17:80123200	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.37	-0.32	7.93e-13	Life satisfaction;
LGG	trans	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg02030672	chr11:45687055	CHST1	0.59	10.62	0.44	1.02e-23	Obesity-related traits;
LGG	cis	rs4740619	0.655	rs10810487	chr9:15943629	A/G	cg14451791	chr9:16040625	NA	-0.4	-9.84	-0.42	6.98e-21	Body mass index;
LGG	cis	rs9660992	0.710	rs1172136	chr1:205247097	T/G	cg00857998	chr1:205179979	DSTYK	0.47	6.76	0.3	4.25e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1552244	1.000	rs9881859	chr3:10072814	A/T	cg16606324	chr3:10149918	C3orf24	0.52	6.89	0.3	1.87e-11	Alzheimer's disease;
LGG	cis	rs3816183	0.958	rs7583085	chr2:43022968	A/G	cg14631114	chr2:43023945	NA	-0.49	-9.18	-0.39	1.39e-18	Hypospadias;
LGG	cis	rs6500395	1.000	rs9938633	chr16:48682093	G/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs41271473	0.526	rs942853	chr1:228730949	G/T	cg16512390	chr1:228756714	NA	0.61	8.07	0.35	6.21e-15	Chronic lymphocytic leukemia;
LGG	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg12310025	chr6:25882481	NA	0.74	14.62	0.56	4.56e-40	Blood metabolite levels;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg27476859	chr7:2772710	GNA12	0.53	10.46	0.44	3.92e-23	Height;
LGG	cis	rs12200782	1.000	rs6456742	chr6:26617075	T/C	cg11502198	chr6:26597334	ABT1	-0.92	-7.86	-0.34	2.77e-14	Small cell lung carcinoma;
LGG	cis	rs2153535	0.580	rs1889715	chr6:8443475	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.1	0.42	8.14e-22	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23752198	chr20:30311963	BCL2L1	0.45	7.24	0.32	1.84e-12	Cognitive performance;
LGG	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg23173402	chr1:227635558	NA	-0.64	-10.4	-0.44	6.64e-23	Major depressive disorder;
LGG	trans	rs7939886	0.920	rs58405266	chr11:55863225	G/A	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.69e-11	Myopia (pathological);
LGG	trans	rs1962073	0.528	rs9329223	chr8:10331754	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.71	-0.34	7.84e-14	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.99	0.31	9.55e-12	Monocyte count;
LGG	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg20892847	chr12:58011875	NA	0.35	7.15	0.32	3.32e-12	Multiple sclerosis;
LGG	trans	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg17712092	chr4:129076599	LARP1B	-0.64	-10.91	-0.45	8.38e-25	DNA methylation (variation);
LGG	cis	rs11966931	1.000	rs6925509	chr6:108140504	A/T	cg04749840	chr6:108095067	SCML4	-0.42	-7.15	-0.32	3.38e-12	Neutrophil percentage of white cells;
LGG	cis	rs4731207	0.844	rs2402749	chr7:124389723	A/T	cg05630886	chr7:124431682	NA	0.31	6.81	0.3	2.98e-11	Cutaneous malignant melanoma;
LGG	cis	rs7493	0.950	rs7785846	chr7:95033841	C/T	cg08461772	chr7:95026248	PON3	0.38	8.29	0.36	1.28e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs514406	0.621	rs2003250	chr1:53196666	T/C	cg24675658	chr1:53192096	ZYG11B	0.62	13.16	0.52	7.85e-34	Monocyte count;
LGG	cis	rs875971	0.545	rs1267814	chr7:66044409	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-10.35	-0.43	1.04e-22	Aortic root size;
LGG	cis	rs867371	1.000	rs2867579	chr15:82475384	G/C	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	3.2e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.37	-7.16	-0.32	3.09e-12	Personality dimensions;
LGG	cis	rs2075371	0.897	rs1643033	chr7:134004662	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	13.12	0.52	1.13e-33	Mean platelet volume;
LGG	cis	rs2013441	1.000	rs2526462	chr17:20079460	A/T	cg13482628	chr17:19912719	NA	-0.5	-9.18	-0.39	1.41e-18	Obesity-related traits;
LGG	cis	rs8180040	0.620	rs17784127	chr3:47061700	T/C	cg27129171	chr3:47204927	SETD2	-0.81	-14.9	-0.57	2.72e-41	Colorectal cancer;
LGG	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.41	6.66	0.3	7.96e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.958	rs34994386	chr6:86524135	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.58	-0.37	1.43e-16	Response to antipsychotic treatment;
LGG	trans	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.85	-0.38	1.84e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1355223	0.902	rs11603774	chr11:34732891	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.03	-0.31	7.48e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs74781061	0.858	rs12592906	chr15:74774152	G/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.5e-12	Endometriosis;
LGG	cis	rs854765	0.647	rs4426402	chr17:17977926	C/T	cg05444541	chr17:17804740	TOM1L2	0.6	13.13	0.52	1.09e-33	Total body bone mineral density;
LGG	trans	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.07	-0.42	1.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs2718058	0.606	rs2722273	chr7:37808298	T/C	cg24998770	chr7:37888106	TXNDC3	0.45	7.22	0.32	2.18e-12	Alzheimer's disease (late onset);
LGG	cis	rs6938	0.534	rs8025447	chr15:75192222	T/G	cg09165964	chr15:75287851	SCAMP5	0.54	10.02	0.42	1.63e-21	Breast cancer;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.13	0.55	6.07e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26722544	chr5:179393917	RNF130	0.35	6.7	0.3	5.89e-11	Menarche (age at onset);
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.07	0.31	5.7e-12	Longevity;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg05025164	chr4:1340916	KIAA1530	0.87	17.24	0.63	8.19e-52	Longevity;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg05665937	chr4:1216051	CTBP1	0.54	9.93	0.42	3.44e-21	Obesity-related traits;
LGG	trans	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg00938859	chr5:1591904	SDHAP3	0.82	8.77	0.38	3.54e-17	Breast cancer;
LGG	cis	rs9902453	0.765	rs2259857	chr17:28097780	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.23	-0.55	2.19e-38	Coffee consumption (cups per day);
LGG	cis	rs6582630	0.548	rs8189608	chr12:38327775	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-12.31	-0.5	2.6e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4595586	0.525	rs7968458	chr12:39377139	C/A	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	7.49	0.33	3.44e-13	Mood instability;
LGG	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.99	0.39	6.1e-18	Fuchs's corneal dystrophy;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22777513	chr4:713393	PCGF3	0.35	6.73	0.3	5.08e-11	Electrocardiographic conduction measures;
LGG	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg10792982	chr14:105748885	BRF1	0.68	13.75	0.54	2.67e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs11608355	0.545	rs7969313	chr12:109907303	A/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.27	-0.5	3.78e-30	Alzheimer's disease;
LGG	cis	rs7044106	0.762	rs10739570	chr9:123381222	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.85	0.48	1.77e-28	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.48	-0.44	3.35e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs9457247	1.000	rs2757042	chr6:167371234	A/T	cg07741184	chr6:167504864	NA	-0.33	-7.14	-0.31	3.67e-12	Crohn's disease;
LGG	cis	rs2153535	0.601	rs9505451	chr6:8469950	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs2798269	0.528	rs9509810	chr13:22169006	C/T	cg18095732	chr13:22033692	ZDHHC20	0.45	7.79	0.34	4.38e-14	PR segment;
LGG	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	27.23	0.78	3.43e-98	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs13108043	0.605	rs431836	chr4:87973705	C/T	cg11209507	chr4:87813803	C4orf36	0.53	7.03	0.31	7.4e-12	Red blood cell count;
LGG	cis	rs9368481	0.554	rs2754603	chr6:26965139	T/C	cg18867708	chr6:26865862	GUSBL1	-0.46	-7.65	-0.34	1.16e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg17712092	chr4:129076599	LARP1B	-0.66	-12.23	-0.49	5.33e-30	Eosinophil percentage of white cells;
LGG	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.79	0.34	4.52e-14	Retinal vascular caliber;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg22535103	chr8:58192502	C8orf71	-0.87	-11.12	-0.46	1.3e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs56163556	chr17:29101868	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17739794	0.517	rs6559193	chr8:775451	C/T	cg11667643	chr8:748456	NA	-0.37	-6.69	-0.3	6.38e-11	Clozapine-induced cytotoxicity;
LGG	cis	rs7074356	0.688	rs34894697	chr10:82169888	T/C	cg27171509	chr10:82033454	MAT1A	-0.37	-7.39	-0.32	6.75e-13	Borderline personality disorder;
LGG	cis	rs1799949	0.896	rs8176086	chr17:41274778	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg24642439	chr20:33292090	TP53INP2	-0.55	-9.19	-0.39	1.32e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs4740619	0.619	rs10962260	chr9:16039883	T/G	cg14451791	chr9:16040625	NA	-0.42	-11.24	-0.46	4.57e-26	Body mass index;
LGG	cis	rs402219	0.533	rs443088	chr6:160739263	G/A	cg04181478	chr6:161122748	PLG	-0.39	-6.67	-0.3	7.41e-11	Monocyte early outgrowth colony forming units;
LGG	cis	rs10779751	1.000	rs11121706	chr1:11302065	C/T	cg08854313	chr1:11322531	MTOR	0.75	16.2	0.6	4.21e-47	Body mass index;
LGG	cis	rs8060686	0.641	rs16957696	chr16:68039850	C/T	cg27539214	chr16:67997921	SLC12A4	-0.47	-7.4	-0.33	6.55e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg17127132	chr2:85788382	GGCX	0.44	7.61	0.33	1.55e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2276314	0.857	rs6507158	chr18:33636066	A/C	cg05985134	chr18:33552581	C18orf21	0.63	9.92	0.42	3.84e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.33	-0.36	9.28e-16	Type 2 diabetes;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.99	-0.35	1.09e-14	Skin colour saturation;
LGG	cis	rs6840360	0.615	rs12647586	chr4:152607568	G/C	cg22705602	chr4:152727874	NA	-0.38	-9.22	-0.39	1.02e-18	Intelligence (multi-trait analysis);
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.49e-24	Aortic root size;
LGG	cis	rs9357271	0.505	rs4714163	chr6:38438771	T/C	cg07362130	chr6:38359646	BTBD9	-0.34	-7.25	-0.32	1.78e-12	Restless legs syndrome;
LGG	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.53	0.33	2.63e-13	Electroencephalogram traits;
LGG	cis	rs28655083	0.636	rs61117898	chr16:77050736	A/C	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-6.67	-0.3	7.21e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs765787	0.530	rs4775831	chr15:45534722	A/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg01657329	chr11:68192670	LRP5	-0.6	-10.77	-0.45	2.83e-24	Total body bone mineral density;
LGG	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	12.04	0.49	3.07e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	0.502	rs7647118	chr3:161016165	T/C	cg03342759	chr3:160939853	NMD3	-0.77	-13.65	-0.54	7.09e-36	Morning vs. evening chronotype;
LGG	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.26	-0.43	2.22e-22	Morning vs. evening chronotype;
LGG	cis	rs17384381	1.000	rs12758237	chr1:85870783	G/A	cg16011679	chr1:85725395	C1orf52	0.57	10.19	0.43	3.99e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs975722	0.540	rs10249651	chr7:117064625	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	8.14	0.35	3.71e-15	Coronary artery disease;
LGG	cis	rs8067545	0.750	rs4925077	chr17:19982276	C/T	cg09818912	chr17:20140352	CYTSB	-0.3	-7.05	-0.31	6.44e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs1908814	0.504	rs7830734	chr8:11795639	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs1153858	1.000	rs1288775	chr15:45661678	T/A	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs300774	0.925	rs300722	chr2:134249	A/C	cg04617936	chr2:214353	NA	-0.48	-7.47	-0.33	3.91e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg17644776	chr2:200775616	C2orf69	0.61	8.48	0.37	3.02e-16	Schizophrenia;
LGG	cis	rs6582630	0.533	rs2120464	chr12:38280289	A/C	cg04568710	chr12:38710424	ALG10B	0.42	9.23	0.39	9.96e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.43	-8.89	-0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg25039879	chr17:56429692	SUPT4H1	0.55	9.01	0.39	5.33e-18	Primary tooth development (time to first tooth eruption);
LGG	cis	rs9527	0.590	rs11191547	chr10:104843148	C/T	cg05308233	chr10:104796373	CNNM2	-0.33	-7.32	-0.32	1.1e-12	Arsenic metabolism;
LGG	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg24375607	chr4:120327624	NA	-0.64	-10.21	-0.43	3.33e-22	Corneal astigmatism;
LGG	cis	rs9393813	0.626	rs12664996	chr6:27363644	A/C	cg18711553	chr6:27366782	ZNF391	-0.5	-9.81	-0.41	9.2e-21	Bipolar disorder;
LGG	cis	rs950027	0.620	rs1153855	chr15:45660758	C/G	cg26924012	chr15:45694286	SPATA5L1	0.68	12.31	0.5	2.57e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg13452994	chr2:3699195	NA	0.68	7.31	0.32	1.2e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs2836950	0.520	rs8130240	chr21:40538108	G/A	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.88e-19	Menarche (age at onset);
LGG	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg06951627	chr6:26196580	NA	0.53	8.04	0.35	7.36e-15	Gout;Renal underexcretion gout;
LGG	cis	rs61612642	0.537	rs73434275	chr6:42156239	G/A	cg10382835	chr6:42185730	MRPS10	0.67	7.35	0.32	8.92e-13	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	trans	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.92e-30	Corneal astigmatism;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg14668632	chr7:2872130	GNA12	-0.35	-7.41	-0.33	5.85e-13	Height;
LGG	cis	rs1348850	0.914	rs12104588	chr2:178253675	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-8.18	-0.36	2.85e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.86e-13	Mood instability;
LGG	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg02403541	chr12:121454288	C12orf43	0.53	8.56	0.37	1.69e-16	N-glycan levels;
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg07157834	chr1:205819609	PM20D1	0.5	9.72	0.41	1.85e-20	Menarche (age at onset);
LGG	cis	rs11771526	1.000	rs11764617	chr7:32339102	T/C	cg13207630	chr7:32358064	NA	0.78	7.68	0.34	9.79e-14	Body mass index;
LGG	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg12183467	chr14:104352244	NA	-0.45	-8.24	-0.36	1.84e-15	Bipolar disorder;
LGG	cis	rs614226	1.000	rs1167727	chr12:120965508	C/A	cg27489772	chr12:121021490	NA	0.59	7.79	0.34	4.39e-14	Type 1 diabetes nephropathy;
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg06074448	chr4:187884817	NA	-0.58	-12.77	-0.51	3.47e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg11887960	chr12:57824829	NA	0.6	7.36	0.32	8.23e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs7246760	0.867	rs56307296	chr19:9744099	G/T	cg16876255	chr19:9731953	ZNF561	0.85	7.8	0.34	4.27e-14	Pursuit maintenance gain;
LGG	cis	rs6748734	1.000	rs11898716	chr2:241828311	A/G	cg26818257	chr2:241905806	NA	0.39	7.37	0.32	7.74e-13	Urinary metabolites;
LGG	cis	rs17767392	0.957	rs36057816	chr14:71760546	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.2	-0.39	1.21e-18	Mitral valve prolapse;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs3849046	0.817	rs2268439	chr5:137880792	C/T	cg10920316	chr5:137946599	NA	0.43	6.76	0.3	4.06e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.6	0.37	1.22e-16	Menarche (age at onset);
LGG	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg15627072	chr1:2432621	PLCH2	-0.38	-8.26	-0.36	1.53e-15	Ulcerative colitis;
LGG	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg12667521	chr19:29218732	NA	0.63	9.86	0.42	6.16e-21	Methadone dose in opioid dependence;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08280861	chr8:58055591	NA	0.64	7.91	0.35	1.89e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4803455	0.565	rs1025497	chr19:41871254	A/G	cg08477640	chr19:41863820	B9D2	0.35	6.96	0.31	1.19e-11	Migraine;Coronary artery disease;
LGG	cis	rs7927771	1.000	rs7927771	chr11:47781306	A/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.64	-0.37	9.18e-17	Subjective well-being;
LGG	cis	rs28595532	0.920	rs17324968	chr4:119772316	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.19	0.43	3.9e-22	Cannabis dependence symptom count;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.43	0.36	4.54e-16	Schizophrenia;
LGG	cis	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg12165864	chr7:66369176	NA	-0.58	-9.33	-0.4	4.54e-19	Corneal structure;
LGG	cis	rs929596	0.556	rs10202865	chr2:234587707	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.71	-0.45	4.46e-24	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs758324	0.717	rs246999	chr5:131348171	A/G	cg06307176	chr5:131281290	NA	0.48	7.05	0.31	6.48e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.28	-0.32	1.41e-12	Iron status biomarkers;
LGG	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg20578329	chr17:80767326	TBCD	-0.48	-8.18	-0.36	2.84e-15	Breast cancer;
LGG	cis	rs4950322	1.000	rs72694750	chr1:146868586	G/A	cg22381352	chr1:146742008	CHD1L	-0.44	-7.0	-0.31	9.06e-12	Protein quantitative trait loci;
LGG	cis	rs9547996	1.000	rs9547996	chr13:38220161	T/G	cg17979426	chr13:38220150	TRPC4	-0.44	-8.33	-0.36	9.16e-16	Diastolic blood pressure;
LGG	cis	rs10857712	0.754	rs2297031	chr10:135232654	C/T	cg00491522	chr10:135256596	NA	0.5	7.9	0.34	2.12e-14	Systemic lupus erythematosus;
LGG	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg20587970	chr11:113659929	NA	-1.26	-21.75	-0.71	8.42e-73	Hip circumference adjusted for BMI;
LGG	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg20387954	chr3:183756860	HTR3D	0.66	13.55	0.53	1.82e-35	Anterior chamber depth;
LGG	cis	rs2072499	0.722	rs61462713	chr1:156161682	C/T	cg24450063	chr1:156163899	SLC25A44	1.07	18.74	0.66	9.54e-59	Testicular germ cell tumor;
LGG	cis	rs698813	0.637	rs4952706	chr2:44500536	T/C	cg00619915	chr2:44497795	NA	-0.61	-8.62	-0.37	1.06e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs73086581	1.000	rs6107386	chr20:3972756	A/C	cg02187196	chr20:3869020	PANK2	0.79	11.05	0.46	2.34e-25	Response to antidepressants in depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05446994	chr1:20960538	PINK1	0.45	7.18	0.32	2.83e-12	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs6909430	0.908	rs667320	chr6:98673816	A/G	cg12860156	chr6:98744658	NA	0.43	7.25	0.32	1.78e-12	Quantitative traits;
LGG	cis	rs7666738	0.830	rs7696686	chr4:98938445	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-8.05	-0.35	7.27e-15	Lung cancer;
LGG	trans	rs2562456	0.761	rs35008138	chr19:21731624	A/T	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	cis	rs9354308	0.933	rs2802064	chr6:66564352	C/T	cg07460842	chr6:66804631	NA	0.57	9.46	0.4	1.59e-19	Metabolite levels;
LGG	cis	rs6893807	0.620	rs34483452	chr5:87986314	C/A	cg22951263	chr5:87985283	NA	0.53	6.66	0.3	7.91e-11	Body mass index;
LGG	trans	rs61931739	0.517	rs10844802	chr12:34231001	C/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.38e-45	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg26174226	chr8:58114915	NA	-0.51	-7.23	-0.32	2.01e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg12310025	chr6:25882481	NA	-0.55	-10.34	-0.43	1.07e-22	Intelligence (multi-trait analysis);
LGG	cis	rs8112449	0.861	rs34266232	chr19:10502968	T/C	cg21868191	chr19:10515988	NA	-0.47	-7.88	-0.34	2.32e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs7945718	1.000	rs12269900	chr11:12748518	G/A	cg25843174	chr11:12811716	TEAD1	0.41	8.41	0.36	5.08e-16	Educational attainment (years of education);
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs7928758	0.943	rs877456	chr11:134265315	T/C	cg25213107	chr11:134282864	B3GAT1	1.19	14.23	0.55	2.21e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7939886	0.920	rs11227321	chr11:55904828	A/G	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs11785400	1.000	rs13265663	chr8:143732255	A/C	cg24634471	chr8:143751801	JRK	0.53	8.41	0.36	5.25e-16	Schizophrenia;
LGG	cis	rs7072216	0.763	rs7910014	chr10:100172110	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.17	-0.32	3.07e-12	Metabolite levels;
LGG	cis	rs6665290	0.901	rs2104860	chr1:227208637	G/C	cg05696931	chr1:227175867	NA	-0.4	-7.82	-0.34	3.61e-14	Myeloid white cell count;
LGG	cis	rs735396	0.770	rs2264782	chr12:121432603	C/T	cg14101638	chr12:121416612	HNF1A	0.36	7.53	0.33	2.71e-13	N-glycan levels;
LGG	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg22875332	chr1:76189707	ACADM	-0.6	-9.16	-0.39	1.7e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6088590	1.000	rs6088607	chr20:33378733	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.4	0.58	1.69e-43	Coronary artery disease;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg16885296	chr6:26284938	NA	0.44	9.52	0.4	9.31e-20	Educational attainment;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg23782820	chr8:58130467	NA	0.44	7.0	0.31	9.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	1.000	rs2176824	chr3:183654029	C/G	cg05044414	chr3:183734942	ABCC5	0.77	17.16	0.62	1.9e-51	Anterior chamber depth;
LGG	cis	rs875971	0.545	rs35459055	chr7:65944386	G/A	cg11764359	chr7:65958608	NA	0.64	9.89	0.42	4.77e-21	Aortic root size;
LGG	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg23752985	chr2:85803571	VAMP8	-0.39	-7.51	-0.33	3.07e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg13047869	chr3:10149882	C3orf24	-0.53	-9.1	-0.39	2.73e-18	Alzheimer's disease;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	0.34	8.99	0.39	6.13e-18	IgG glycosylation;
LGG	cis	rs9303401	0.646	rs8067682	chr17:57219391	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.48	8.11	0.35	4.49e-15	Cognitive test performance;
LGG	cis	rs4660214	0.666	rs3116387	chr1:39742869	T/G	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11711311	1.000	rs3732793	chr3:113442198	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.19	0.55	3.32e-38	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg05368731	chr17:41323189	NBR1	0.94	18.66	0.66	2.28e-58	Menopause (age at onset);
LGG	cis	rs9443645	0.869	rs9343848	chr6:79621101	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.57	-0.37	1.5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06771106	chr2:113671356	IL1F7	0.37	7.14	0.31	3.61e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs13191362	1.000	rs34398656	chr6:162999612	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.91	0.35	1.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11628318	0.803	rs2277468	chr14:103024080	A/G	cg12046867	chr14:103022105	NA	-0.79	-14.93	-0.57	2.03e-41	Platelet count;
LGG	cis	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg12826209	chr6:26865740	GUSBL1	0.8	8.58	0.37	1.47e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.43e-18	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.55	-0.37	1.82e-16	Lung cancer;
LGG	cis	rs6977660	0.714	rs12700075	chr7:19791476	G/T	cg05791153	chr7:19748676	TWISTNB	0.77	10.54	0.44	1.92e-23	Thyroid stimulating hormone;
LGG	cis	rs4474465	0.920	rs7947852	chr11:78198030	T/C	cg02023728	chr11:77925099	USP35	0.4	7.07	0.31	5.56e-12	Alzheimer's disease (survival time);
LGG	trans	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.97	0.31	1.09e-11	Monocyte count;
LGG	trans	rs9657904	0.774	rs769315	chr3:105521025	A/G	cg14088669	chr1:158435396	OR10K1	0.41	7.69	0.34	9.21e-14	Multiple sclerosis;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.82	-0.3	2.8e-11	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	0.898	rs12623333	chr2:24111823	T/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.06	0.39	3.8e-18	Lymphocyte counts;
LGG	cis	rs12824058	0.831	rs12310049	chr12:130811260	C/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	cis	rs227833	0.586	rs660953	chr6:44645943	C/T	cg20913747	chr6:44695427	NA	-0.4	-6.78	-0.3	3.71e-11	Monobrow;
LGG	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg14675211	chr2:100938903	LONRF2	0.65	11.28	0.46	3e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg11062466	chr8:58055876	NA	0.48	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.14	-0.31	3.66e-12	Lung cancer;
LGG	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg01420254	chr6:26195488	NA	0.91	12.31	0.5	2.58e-30	Gout;Renal underexcretion gout;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg19673125	chr6:150240577	RAET1G	0.37	9.06	0.39	3.61e-18	Testicular germ cell tumor;
LGG	cis	rs36071027	0.615	rs17643640	chr5:158407296	C/G	cg00594129	chr5:158524270	EBF1	0.45	8.23	0.36	1.91e-15	Carotid intima media thickness;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08951907	chr17:18218556	TOP3A;SMCR8	0.42	7.02	0.31	7.73e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs10927875	0.632	rs2862162	chr1:16142960	A/C	cg07117364	chr1:16154769	NA	0.47	8.4	0.36	5.69e-16	Dilated cardiomyopathy;
LGG	cis	rs597583	1.000	rs597583	chr11:117421799	C/G	cg27161313	chr11:117392002	DSCAML1	-0.4	-6.7	-0.3	6.03e-11	Putamen volume;
LGG	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg26655873	chr3:72818019	SHQ1	0.37	7.12	0.31	4.24e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg00424166	chr6:150045504	NUP43	0.37	7.78	0.34	4.78e-14	Lung cancer;
LGG	cis	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg27427491	chr17:78079615	GAA	-0.31	-6.75	-0.3	4.31e-11	Yeast infection;
LGG	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.48e-12	Iron status biomarkers;
LGG	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg25866889	chr13:114914595	NA	-0.35	-6.97	-0.31	1.07e-11	Schizophrenia;
LGG	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.6	-0.47	1.67e-27	Schizophrenia;
LGG	trans	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.2	-0.32	2.41e-12	Neuroticism;
LGG	cis	rs8067545	0.750	rs9944451	chr17:20001316	T/C	cg13482628	chr17:19912719	NA	0.63	12.4	0.5	1.13e-30	Schizophrenia;
LGG	cis	rs7412746	0.622	rs11552229	chr1:150783985	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.13	0.31	3.94e-12	Melanoma;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg14668821	chr17:77704760	ENPP7	0.43	8.47	0.37	3.23e-16	Menopause (age at onset);
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs12482904	1.000	rs9979841	chr21:43843079	A/G	cg23042151	chr21:43824109	UBASH3A	0.41	6.78	0.3	3.57e-11	Vitiligo;
LGG	cis	rs193541	0.530	rs6595405	chr5:122084745	C/T	cg19412675	chr5:122181750	SNX24	0.51	8.18	0.36	2.8e-15	Glucose homeostasis traits;
LGG	cis	rs2594989	0.837	rs2454497	chr3:11501597	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.71e-13	Circulating chemerin levels;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.63	0.37	9.6e-17	Bipolar disorder;
LGG	cis	rs4650994	0.816	rs2811304	chr1:178596794	A/T	cg12486710	chr1:178512616	C1orf220	-0.4	-8.06	-0.35	6.34e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg20337934	chr2:70121059	SNRNP27	0.45	6.67	0.3	7.41e-11	Apolipoprotein A-IV levels;
LGG	cis	rs990171	0.955	rs2058658	chr2:103054803	T/C	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg23825213	chr18:77623475	KCNG2	-0.4	-7.17	-0.32	3.04e-12	Schizophrenia;
LGG	trans	rs8002861	0.935	rs1373903	chr13:44475514	G/T	cg17145862	chr1:211918768	LPGAT1	0.95	24.15	0.75	5.67e-84	Leprosy;
LGG	cis	rs1978968	0.525	rs4819649	chr22:18396329	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	0.38	7.49	0.33	3.49e-13	Presence of antiphospholipid antibodies;
LGG	cis	rs9972944	0.756	rs7222190	chr17:63764953	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.37	-0.36	7e-16	Total body bone mineral density;
LGG	cis	rs758324	0.853	rs6882899	chr5:131172467	G/C	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.44	7.95	0.35	1.47e-14	Schizophrenia;
LGG	cis	rs796364	0.806	rs203769	chr2:200900866	C/T	cg17644776	chr2:200775616	C2orf69	-0.59	-6.86	-0.3	2.18e-11	Schizophrenia;
LGG	cis	rs752092	0.925	rs8032007	chr15:101790817	C/T	cg25114630	chr15:101792522	CHSY1	-0.59	-10.15	-0.43	5.26e-22	Corneal structure;
LGG	cis	rs4076764	0.535	rs4409627	chr1:163382050	A/G	cg24596788	chr1:163392923	NA	0.54	10.06	0.42	1.14e-21	Motion sickness;
LGG	cis	rs2070488	0.804	rs13092539	chr3:38458725	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.67	0.56	2.68e-40	Electrocardiographic conduction measures;
LGG	cis	rs2016266	0.819	rs7398228	chr12:53660285	T/C	cg04065151	chr12:53682969	ESPL1	-0.59	-9.56	-0.41	7e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7666738	0.830	rs10014284	chr4:98681951	G/C	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.25e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg16141378	chr3:129829833	LOC729375	0.41	9.47	0.4	1.42e-19	Neuroticism;
LGG	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg15704280	chr7:45808275	SEPT13	-0.9	-14.27	-0.55	1.55e-38	Height;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg00800038	chr16:89945340	TCF25	-0.59	-7.88	-0.34	2.39e-14	Skin colour saturation;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg05863683	chr7:1912471	MAD1L1	-0.45	-8.92	-0.38	1.08e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs698813	0.763	rs786615	chr2:44590608	T/C	cg00619915	chr2:44497795	NA	-0.49	-6.79	-0.3	3.51e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2415984	0.562	rs1389605	chr14:46964784	T/C	cg14871534	chr14:47121158	RPL10L	0.46	7.48	0.33	3.83e-13	Number of children ever born;
LGG	cis	rs7546668	0.947	rs4233538	chr1:15849855	G/T	cg21858823	chr1:15850916	CASP9	0.37	6.87	0.3	2.01e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs8177253	0.965	rs1525889	chr3:133490033	A/C	cg11941060	chr3:133502564	NA	-0.48	-8.09	-0.35	5.35e-15	Iron status biomarkers;
LGG	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.32e-17	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	1.000	rs890159	chr15:31291634	G/A	cg08704250	chr15:31115839	NA	-0.41	-7.12	-0.31	4.02e-12	Huntington's disease progression;
LGG	cis	rs875971	0.628	rs6974355	chr7:65841981	A/G	cg11764359	chr7:65958608	NA	0.63	10.4	0.44	6.41e-23	Aortic root size;
LGG	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg11839771	chr15:80205821	ST20	-0.39	-8.57	-0.37	1.57e-16	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9875589	0.509	rs1844108	chr3:14024328	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.49	10.13	0.43	6.33e-22	Ovarian reserve;
LGG	cis	rs953492	0.517	rs2247527	chr1:243309983	A/C	cg02356786	chr1:243265016	LOC731275	0.38	6.9	0.31	1.71e-11	Diastolic blood pressure;
LGG	cis	rs7512552	0.839	rs1694362	chr1:150366963	T/A	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.92e-12	Life satisfaction;
LGG	cis	rs116095464	0.558	rs61689490	chr5:224904	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs4689642	0.507	rs57861290	chr4:7219345	G/C	cg21353189	chr4:7228343	SORCS2	0.33	7.17	0.32	2.96e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs10463316	0.862	rs1983171	chr5:150778691	A/G	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.64	-0.44	8.2e-24	Metabolite levels (Pyroglutamine);
LGG	trans	rs7944735	0.507	rs17198607	chr11:48028343	A/C	cg15704280	chr7:45808275	SEPT13	-0.71	-7.58	-0.33	1.9e-13	Intraocular pressure;
LGG	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg22903471	chr2:27725779	GCKR	0.38	8.6	0.37	1.28e-16	Oral cavity cancer;
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg22968622	chr17:43663579	NA	-1.02	-18.96	-0.66	9.9e-60	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6539288	0.677	rs11113144	chr12:107323422	T/C	cg26297688	chr12:107349093	C12orf23	-0.37	-6.87	-0.3	2.08e-11	Total body bone mineral density;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.52	-0.37	2.21e-16	Personality dimensions;
LGG	cis	rs9880211	0.898	rs13434116	chr3:136353074	G/C	cg21827317	chr3:136751795	NA	-0.5	-7.33	-0.32	1.01e-12	Body mass index;Height;
LGG	cis	rs17776563	0.614	rs55652124	chr15:89132024	C/T	cg05013243	chr15:89149849	MIR1179	-0.34	-6.98	-0.31	1.05e-11	Thyroid hormone levels;
LGG	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg12386194	chr3:101231763	SENP7	0.69	11.98	0.49	5.17e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13082711	0.522	rs4973760	chr3:27349047	G/A	cg02860705	chr3:27208620	NA	0.59	11.13	0.46	1.15e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg09426994	chr11:118478258	PHLDB1	-0.43	-7.49	-0.33	3.61e-13	Cholesterol, total;
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg19524238	chr7:2802976	GNA12	0.33	7.94	0.35	1.59e-14	Height;
LGG	trans	rs9354308	0.764	rs9354319	chr6:66583656	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-7.1	-0.31	4.57e-12	Metabolite levels;
LGG	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Neuroticism;
LGG	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg03929089	chr4:120376271	NA	0.79	13.84	0.54	1.09e-36	Coronary artery disease;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg11494091	chr17:61959527	GH2	1.02	25.42	0.76	7.21e-90	Prudent dietary pattern;
LGG	cis	rs6724607	0.905	rs10173771	chr2:191439248	T/C	cg21644426	chr2:191273491	MFSD6	0.6	10.38	0.43	7.76e-23	Pulse pressure;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.32	0.63	3.56e-52	Obesity-related traits;
LGG	cis	rs4975616	0.869	rs401681	chr5:1322087	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.59	-10.66	-0.44	7.36e-24	Lung cancer;
LGG	cis	rs939658	0.776	rs68147688	chr15:79443848	G/A	cg17916960	chr15:79447300	NA	-0.66	-12.91	-0.51	8.61e-33	Refractive error;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	1.000	rs778694	chr7:65871558	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.67	0.37	7.11e-17	Aortic root size;
LGG	cis	rs9905704	0.647	rs12940492	chr17:56954655	C/G	cg12560992	chr17:57184187	TRIM37	0.53	8.53	0.37	2.06e-16	Testicular germ cell tumor;
LGG	cis	rs10193935	0.901	rs6713242	chr2:42470794	C/T	cg27598129	chr2:42591480	NA	-0.65	-8.9	-0.38	1.3e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg16507663	chr6:150244633	RAET1G	0.44	7.94	0.35	1.56e-14	Lung cancer;
LGG	cis	rs1395	0.744	rs11126932	chr2:27476282	G/A	cg23587288	chr2:27483067	SLC30A3	-0.35	-8.12	-0.35	4.16e-15	Blood metabolite levels;
LGG	cis	rs67311347	0.577	rs2887951	chr3:40282104	C/G	cg13683864	chr3:40499215	RPL14	-0.78	-14.89	-0.57	2.88e-41	Renal cell carcinoma;
LGG	cis	rs55665837	0.540	rs10128681	chr11:14701576	T/C	cg19336497	chr11:14380999	RRAS2	-0.39	-7.48	-0.33	3.67e-13	Vitamin D levels;
LGG	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg22437258	chr11:111473054	SIK2	-0.42	-6.99	-0.31	9.94e-12	Primary sclerosing cholangitis;
LGG	cis	rs68170813	0.559	rs77605964	chr7:106962948	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.72e-22	Coronary artery disease;
LGG	cis	rs35110281	0.743	rs2329443	chr21:45059431	C/T	cg04455712	chr21:45112962	RRP1B	0.5	9.29	0.4	6.02e-19	Mean corpuscular volume;
LGG	trans	rs8002861	0.691	rs9525851	chr13:44402132	T/A	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.48	-0.56	1.91e-39	Leprosy;
LGG	cis	rs826838	1.000	rs851934	chr12:39104453	G/T	cg04568710	chr12:38710424	ALG10B	-0.31	-6.65	-0.3	8.44e-11	Heart rate;
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg18000306	chr6:288505	NA	0.44	8.18	0.36	2.83e-15	Menopause (age at onset);
LGG	cis	rs11064837	0.560	rs7952841	chr12:120058154	A/G	cg25937854	chr12:120150414	CIT	-0.6	-9.65	-0.41	3.31e-20	Schizophrenia;
LGG	cis	rs1799949	0.628	rs4474733	chr17:41433660	G/T	cg04503457	chr17:41445688	NA	-0.4	-8.3	-0.36	1.11e-15	Menopause (age at onset);
LGG	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg12623918	chr2:306882	NA	0.53	9.93	0.42	3.27e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs755249	0.567	rs2296175	chr1:39924398	G/A	cg18385671	chr1:39797026	MACF1	0.45	7.55	0.33	2.29e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg27523141	chr10:43048294	ZNF37B	0.34	7.2	0.32	2.5e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg09307838	chr4:120376055	NA	0.64	10.27	0.43	2.04e-22	Corneal astigmatism;
LGG	cis	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg01244601	chr4:120671846	NA	-0.39	-7.58	-0.33	1.89e-13	Corneal astigmatism;
LGG	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs4788570	0.667	rs8052910	chr16:71790221	A/G	cg06353428	chr16:71660113	MARVELD3	1.26	20.24	0.69	1.04e-65	Intelligence (multi-trait analysis);
LGG	cis	rs12410462	1.000	rs75652886	chr1:227654485	G/T	cg21459583	chr1:227974177	NA	0.46	7.1	0.31	4.75e-12	Major depressive disorder;
LGG	cis	rs8056893	0.569	rs36010241	chr16:68306037	C/T	cg07273125	chr16:68295692	NA	0.47	10.39	0.43	7.28e-23	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs7577262	0.573	rs10490012	chr2:234843494	C/T	cg00793935	chr2:234847769	TRPM8	-0.45	-6.81	-0.3	3.09e-11	Blood pressure measurement (cold pressor test);
LGG	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg04149295	chr10:70884716	VPS26A	0.49	7.44	0.33	4.84e-13	Left atrial antero-posterior diameter;
LGG	cis	rs6489785	0.775	rs7300722	chr12:121362324	T/C	cg02419362	chr12:121203948	SPPL3	0.44	6.98	0.31	1.02e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9311474	0.632	rs6445528	chr3:52572447	C/T	cg18099408	chr3:52552593	STAB1	0.36	7.22	0.32	2.12e-12	Electroencephalogram traits;
LGG	cis	rs17376456	0.877	rs17316137	chr5:93456577	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.05	0.42	1.29e-21	Diabetic retinopathy;
LGG	cis	rs780096	0.526	rs7602534	chr2:27592423	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.28	-6.99	-0.31	9.39e-12	Total body bone mineral density;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg13395646	chr4:1353034	KIAA1530	-0.4	-6.8	-0.3	3.18e-11	Obesity-related traits;
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg11965913	chr1:205819406	PM20D1	0.45	7.06	0.31	6.05e-12	Parkinson's disease;
LGG	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg26666090	chr16:58549219	SETD6	1.13	10.04	0.42	1.32e-21	Schizophrenia;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.1	0.57	3.57e-42	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs67311347	1.000	rs73078169	chr3:40483798	G/A	cg13683864	chr3:40499215	RPL14	-1.13	-26.51	-0.78	7.16e-95	Renal cell carcinoma;
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.13	-0.35	3.84e-15	Schizophrenia;
LGG	cis	rs2797160	0.967	rs8180614	chr6:126000599	G/C	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	cis	rs2760061	0.583	rs708110	chr1:228190805	T/A	cg02753203	chr1:228287806	NA	0.92	18.72	0.66	1.3e-58	Diastolic blood pressure;
LGG	cis	rs12188164	0.686	rs72711369	chr5:420517	C/T	cg00976097	chr5:421733	AHRR	-0.47	-7.77	-0.34	5.24e-14	Cystic fibrosis severity;
LGG	cis	rs10949662	1.000	rs28716556	chr7:157535368	T/C	cg15733309	chr7:157513707	PTPRN2	0.64	14.5	0.56	1.46e-39	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	cis	rs7635838	0.654	rs164101	chr3:11281082	G/A	cg00170343	chr3:11313890	ATG7	0.58	9.73	0.41	1.81e-20	HDL cholesterol;
LGG	cis	rs1461503	0.966	rs11218907	chr11:122841562	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs7998202	0.667	rs388382	chr13:113353999	G/T	cg02820901	chr13:113351484	ATP11A	0.56	6.78	0.3	3.56e-11	Glycated hemoglobin levels;
LGG	cis	rs2228479	0.850	rs62056091	chr16:89930414	G/A	cg06558623	chr16:89946397	TCF25	1.24	13.57	0.53	1.44e-35	Skin colour saturation;
LGG	cis	rs9300255	0.739	rs1402275	chr12:123750895	A/G	cg05973401	chr12:123451056	ABCB9	0.5	7.54	0.33	2.57e-13	Neutrophil percentage of white cells;
LGG	cis	rs7216064	0.911	rs12449442	chr17:65947640	G/A	cg12091567	chr17:66097778	LOC651250	-0.62	-8.95	-0.38	8.69e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg07936489	chr17:37558343	FBXL20	-0.52	-8.84	-0.38	1.97e-17	Asthma;
LGG	cis	rs3793683	0.597	rs12783367	chr10:134587334	T/C	cg26818010	chr10:134567672	INPP5A	-0.63	-9.85	-0.42	6.39e-21	Migraine;
LGG	cis	rs7927771	0.832	rs11601603	chr11:47401171	A/C	cg20307385	chr11:47447363	PSMC3	-0.58	-10.66	-0.44	7.16e-24	Subjective well-being;
LGG	cis	rs9815354	0.857	rs9816772	chr3:41872877	C/T	cg03022575	chr3:42003672	ULK4	0.68	8.66	0.37	7.79e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2635047	0.783	rs8084241	chr18:44798139	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.38e-12	Educational attainment;
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.06	-0.39	3.68e-18	Neuroticism;
LGG	cis	rs7241530	0.569	rs12965943	chr18:75900225	T/G	cg14642773	chr18:75888474	NA	0.47	9.12	0.39	2.29e-18	Educational attainment (years of education);
LGG	cis	rs2032447	0.677	rs199737	chr6:25933538	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.42	-6.82	-0.3	2.81e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg00864171	chr11:67383662	NA	0.55	9.6	0.41	4.89e-20	Mean corpuscular volume;
LGG	cis	rs28830936	0.510	rs7175346	chr15:42100674	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.79	-26.98	-0.78	4.81e-97	Diastolic blood pressure;
LGG	cis	rs9302635	0.745	rs35909200	chr16:72156666	T/G	cg01557791	chr16:72042693	DHODH	-0.54	-7.24	-0.32	1.84e-12	Blood protein levels;
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg08888203	chr3:10149979	C3orf24	0.57	7.99	0.35	1.07e-14	Alzheimer's disease;
LGG	cis	rs1461503	0.966	rs10892939	chr11:122841959	T/C	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02753865	chr7:56119046	CCT6A;PSPH	0.42	7.07	0.31	5.59e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs2270927	0.510	rs35930860	chr5:75579946	T/C	cg13563193	chr19:33072644	PDCD5	0.85	10.15	0.43	5.58e-22	Mean corpuscular volume;
LGG	trans	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg24247370	chr13:99142703	STK24	-0.39	-7.0	-0.31	9.13e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg06453172	chr10:134556979	INPP5A	-0.56	-8.21	-0.36	2.21e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11168187	0.891	rs10875683	chr12:48128283	C/G	cg12761788	chr12:48120090	P11	0.46	7.6	0.33	1.63e-13	Vertical cup-disc ratio;
LGG	cis	rs17401966	0.540	rs1467653	chr1:10413123	A/G	cg17425144	chr1:10567563	PEX14	0.39	8.48	0.37	3.01e-16	Hepatocellular carcinoma;
LGG	cis	rs7590720	1.000	rs6755934	chr2:216907198	C/A	cg12620499	chr2:216877984	MREG	0.76	13.89	0.54	6.25e-37	Alcohol dependence;
LGG	cis	rs6762	0.748	rs7929032	chr11:839078	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.95	-0.35	1.48e-14	Mean platelet volume;
LGG	cis	rs944722	0.511	rs2297520	chr17:26108040	T/C	cg07704981	chr17:26127537	NOS2	-0.75	-14.61	-0.56	5.21e-40	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg27478167	chr7:817139	HEATR2	0.47	6.78	0.3	3.76e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg23250157	chr14:64679961	SYNE2	0.39	7.09	0.31	4.89e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg17376030	chr22:41985996	PMM1	0.48	7.76	0.34	5.35e-14	Vitiligo;
LGG	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18876405	chr7:65276391	NA	0.59	10.88	0.45	1.02e-24	Aortic root size;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg15971980	chr6:150254442	NA	0.45	8.57	0.37	1.55e-16	Lung cancer;
LGG	cis	rs12579753	0.833	rs1922566	chr12:82135030	T/C	cg07988820	chr12:82153109	PPFIA2	-0.8	-12.34	-0.5	1.92e-30	Resting heart rate;
LGG	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg12310025	chr6:25882481	NA	-0.4	-7.17	-0.32	3.08e-12	Height;
LGG	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg00938859	chr5:1591904	SDHAP3	0.93	13.78	0.54	1.85e-36	Breast cancer;
LGG	cis	rs2274273	0.837	rs6573017	chr14:55802243	G/A	cg04306507	chr14:55594613	LGALS3	0.63	17.9	0.64	8.02e-55	Protein biomarker;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg00689492	chr4:1303491	MAEA	0.5	8.49	0.37	2.86e-16	Obesity-related traits;
LGG	trans	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.32	-0.36	9.96e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7937682	0.640	rs587010	chr11:111425658	C/A	cg22437258	chr11:111473054	SIK2	0.41	7.08	0.31	5.55e-12	Primary sclerosing cholangitis;
LGG	cis	rs11690935	0.921	rs10200608	chr2:172597929	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.35	-0.77	3.84e-94	Schizophrenia;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.29	0.4	6.24e-19	Lung cancer;
LGG	cis	rs1790761	0.777	rs917570	chr11:67196544	C/G	cg14500267	chr11:67383377	NA	-0.38	-6.72	-0.3	5.35e-11	Mean corpuscular volume;
LGG	cis	rs9682041	0.569	rs4955724	chr3:170146532	A/G	cg11886554	chr3:170076028	SKIL	0.67	8.04	0.35	7.46e-15	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg12419862	chr22:24373484	LOC391322	-0.79	-13.77	-0.54	2.17e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg18357526	chr6:26021779	HIST1H4A	0.59	10.44	0.44	4.82e-23	Height;
LGG	cis	rs7928758	0.945	rs28625034	chr11:134280504	C/T	cg22777979	chr11:134283252	B3GAT1	0.85	10.84	0.45	1.44e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6909430	0.901	rs13196036	chr6:98595064	G/A	cg12860156	chr6:98744658	NA	-0.45	-7.56	-0.33	2.15e-13	Quantitative traits;
LGG	cis	rs7617480	0.616	rs7429596	chr3:48808531	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	8.11	0.35	4.56e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs898097	0.841	rs4986136	chr17:80865119	A/G	cg15369054	chr17:80825471	TBCD	-0.57	-10.3	-0.43	1.48e-22	Breast cancer;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs17221829	0.692	rs2773236	chr11:89454836	C/T	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.66	-0.34	1.11e-13	Anxiety in major depressive disorder;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.716	rs6817529	chr4:99023213	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs727505	1.000	rs10230610	chr7:124425398	A/C	cg23710748	chr7:124431027	NA	-0.54	-10.23	-0.43	2.81e-22	Lewy body disease;
LGG	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg02574844	chr11:5959923	NA	0.65	11.11	0.46	1.45e-25	DNA methylation (variation);
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg24250549	chr1:154909240	PMVK	0.75	15.06	0.57	5.44e-42	Prostate cancer;
LGG	cis	rs55794721	0.509	rs909834	chr1:25757996	A/G	cg02931644	chr1:25747376	RHCE	0.42	9.38	0.4	2.95e-19	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs11025559	1.000	rs11025559	chr11:20443875	A/G	cg19653624	chr11:20408972	PRMT3	0.48	7.44	0.33	5e-13	Pursuit maintenance gain;
LGG	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.65	0.33	1.14e-13	Retinal vascular caliber;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.6	-10.37	-0.43	8.59e-23	Obesity-related traits;
LGG	cis	rs7674212	0.541	rs2045746	chr4:104083578	A/C	cg16532752	chr4:104119610	CENPE	0.4	6.91	0.31	1.58e-11	Type 2 diabetes;
LGG	cis	rs240764	0.594	rs7356804	chr6:101078438	A/G	cg09795085	chr6:101329169	ASCC3	0.41	6.92	0.31	1.55e-11	Neuroticism;
LGG	cis	rs9398803	0.865	rs4422634	chr6:126806676	A/G	cg19875578	chr6:126661172	C6orf173	0.56	10.06	0.42	1.18e-21	Male-pattern baldness;
LGG	cis	rs12643440	0.574	rs12651694	chr4:17139359	G/A	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs16854884	0.770	rs13091882	chr3:143818661	C/T	cg06585982	chr3:143692056	C3orf58	0.54	8.77	0.38	3.37e-17	Economic and political preferences (feminism/equality);
LGG	cis	rs7659604	0.539	rs2221628	chr4:122795361	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	13.42	0.53	6.67e-35	Type 2 diabetes;
LGG	cis	rs35146811	0.695	rs858508	chr7:99821381	C/G	cg13334819	chr7:99746414	C7orf59	0.48	7.52	0.33	2.88e-13	Coronary artery disease;
LGG	cis	rs2576037	0.507	rs2571019	chr18:44585287	A/T	cg23129478	chr18:44337922	ST8SIA5	0.36	6.91	0.31	1.62e-11	Personality dimensions;
LGG	cis	rs3857067	0.967	rs1904096	chr4:95012684	C/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.5	-0.33	3.38e-13	QT interval;
LGG	cis	rs4843747	0.605	rs28399183	chr16:88107277	G/A	cg06374794	chr16:88002281	BANP	0.46	8.68	0.37	6.64e-17	Menopause (age at onset);
LGG	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg03563238	chr19:33554763	RHPN2	-0.45	-10.13	-0.43	6.47e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22509189	chr2:225307070	NA	-0.62	-10.03	-0.42	1.43e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg17376030	chr22:41985996	PMM1	0.58	9.09	0.39	2.96e-18	Vitiligo;
LGG	cis	rs4538187	0.865	rs35474183	chr2:63982523	C/T	cg14150252	chr2:64069583	UGP2	-0.47	-9.38	-0.4	3.07e-19	Systolic blood pressure;
LGG	cis	rs6964587	0.626	rs7807765	chr7:91531974	C/A	cg17063962	chr7:91808500	NA	-0.44	-8.03	-0.35	8.38e-15	Breast cancer;
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.66	-0.34	1.1e-13	Personality dimensions;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.585	rs4363678	chr12:38624514	G/A	cg26384229	chr12:38710491	ALG10B	0.7	14.16	0.55	4.46e-38	Heart rate;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.84e-12	Prudent dietary pattern;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15202738	chr19:53636108	ZNF415	0.45	6.98	0.31	1.03e-11	Hip circumference;
LGG	trans	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg25482853	chr8:67687455	SGK3	0.84	11.06	0.46	2.19e-25	Obesity-related traits;
LGG	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.29	-0.32	1.32e-12	Uric acid levels;
LGG	cis	rs3008870	0.583	rs3008892	chr1:67373558	A/T	cg11518657	chr1:67396239	MIER1	0.47	7.16	0.32	3.17e-12	Lymphocyte percentage of white cells;
LGG	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18252515	chr7:66147081	NA	0.42	6.9	0.31	1.69e-11	Aortic root size;
LGG	cis	rs3820068	0.705	rs4646072	chr1:15827711	G/A	cg05660106	chr1:15850417	CASP9	1.11	26.82	0.78	2.75e-96	Systolic blood pressure;
LGG	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg23173402	chr1:227635558	NA	-0.52	-9.14	-0.39	2e-18	Major depressive disorder;
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg09263875	chr16:632152	PIGQ	0.66	12.92	0.51	7.87e-33	Height;
LGG	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg02227867	chr8:22457446	C8orf58	-0.46	-8.91	-0.38	1.14e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9549367	0.789	rs9604040	chr13:113910611	A/G	cg00898013	chr13:113819073	PROZ	0.43	8.8	0.38	2.75e-17	Platelet distribution width;
LGG	cis	rs12477438	0.520	rs11123763	chr2:99750673	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg06889755	chr6:150326021	RAET1K	-0.38	-7.83	-0.34	3.31e-14	Alopecia areata;
LGG	cis	rs1125355	0.622	rs1515920	chr2:159615764	T/C	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	13.84	0.54	1.11e-36	Cognitive test performance;
LGG	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg00717180	chr2:96193071	NA	-0.42	-7.5	-0.33	3.36e-13	HDL cholesterol;
LGG	cis	rs72781680	0.898	rs113027486	chr2:24098371	G/A	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.79e-18	Lymphocyte counts;
LGG	cis	rs6960043	1.000	rs6980437	chr7:15054916	T/G	cg19272540	chr7:15055459	NA	-0.39	-8.65	-0.37	8.73e-17	Type 2 diabetes;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14019158	chr19:45754992	MARK4	-0.42	-7.69	-0.34	9.01e-14	Pancreatic cancer;
LGG	cis	rs12472274	0.646	rs11677736	chr2:239087198	A/T	cg17459225	chr2:239074497	NA	0.74	11.15	0.46	9.77e-26	Phospholipid levels (plasma);
LGG	trans	rs2562456	0.558	rs62108173	chr19:21427188	C/T	cg00806126	chr19:22604979	ZNF98	-0.5	-6.67	-0.3	7.46e-11	Pain;
LGG	trans	rs12545912	0.866	rs4626603	chr8:9588107	C/G	cg16141378	chr3:129829833	LOC729375	0.34	6.68	0.3	6.86e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9611519	0.828	rs9611460	chr22:41418297	T/C	cg03806693	chr22:41940476	POLR3H	-0.5	-7.26	-0.32	1.64e-12	Neuroticism;
LGG	cis	rs6028335	0.610	rs10392	chr20:37550935	C/T	cg16355469	chr20:37678765	NA	0.51	6.82	0.3	2.87e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs2242116	0.727	rs10865943	chr3:46969970	T/C	cg27129171	chr3:47204927	SETD2	0.62	10.49	0.44	3.01e-23	Birth weight;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg22753661	chr15:79092743	ADAMTS7	0.41	7.01	0.31	8.51e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs10781543	0.845	rs10781540	chr9:139321836	G/A	cg14019695	chr9:139328340	INPP5E	0.43	7.77	0.34	5e-14	Monocyte percentage of white cells;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg02297831	chr4:17616191	MED28	0.51	9.55	0.41	7.45e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13126279	chr21:47581558	C21orf56	-0.45	-7.45	-0.33	4.75e-13	Testicular germ cell tumor;
LGG	cis	rs3762637	0.943	rs28403550	chr3:122251838	C/A	cg24169773	chr3:122142474	KPNA1	-0.64	-11.11	-0.46	1.43e-25	LDL cholesterol levels;
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg18258770	chr4:90757814	SNCA	-0.42	-7.64	-0.33	1.28e-13	Dementia with Lewy bodies;
LGG	cis	rs1865760	0.566	rs4529296	chr6:26083135	C/G	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs4073582	0.595	rs801741	chr11:65917084	A/G	cg14036092	chr11:66035641	RAB1B	0.44	7.71	0.34	7.51e-14	Gout;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11287903	chr10:115613834	DCLRE1A;NHLRC2	0.52	8.17	0.35	2.92e-15	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg11247378	chr22:39784982	NA	-0.31	-8.52	-0.37	2.22e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg00830817	chr11:109293614	C11orf87	0.4	6.88	0.3	2.01e-11	Schizophrenia;
LGG	cis	rs4851254	0.660	rs58683655	chr2:100686519	G/C	cg17356467	chr2:100759845	AFF3	0.45	7.28	0.32	1.45e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.665	rs13207864	chr6:110029730	C/T	cg16315928	chr6:109776240	MICAL1	0.52	8.39	0.36	6.03e-16	Height;
LGG	cis	rs9682041	0.740	rs6444929	chr3:170150076	C/T	cg11886554	chr3:170076028	SKIL	0.96	10.61	0.44	1.12e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2916247	0.954	rs1484559	chr8:93111532	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.34	-7.04	-0.31	6.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.27e-18	Motion sickness;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.91e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1941687	0.797	rs2976	chr18:31403254	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.02	-0.39	5.14e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9296092	0.538	rs9461879	chr6:33516907	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.82	-0.7	2.08e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg03476357	chr21:30257390	N6AMT1	-0.58	-8.8	-0.38	2.66e-17	Cognitive test performance;
LGG	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg15440763	chr7:158190612	PTPRN2	-0.44	-9.15	-0.39	1.85e-18	Obesity-related traits;
LGG	cis	rs4356203	0.818	rs214927	chr11:17231245	T/A	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.21	-0.32	2.36e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7246760	0.867	rs66943818	chr19:9746367	G/A	cg16876255	chr19:9731953	ZNF561	0.85	7.78	0.34	4.76e-14	Pursuit maintenance gain;
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg25660036	chr4:7070649	GRPEL1	-0.46	-7.07	-0.31	5.74e-12	Monocyte percentage of white cells;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg13732083	chr21:47605072	C21orf56	0.52	8.4	0.36	5.61e-16	Testicular germ cell tumor;
LGG	cis	rs3008870	1.000	rs2985794	chr1:67425311	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.49	0.74	6.36e-81	Lymphocyte percentage of white cells;
LGG	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg02002194	chr4:3960332	NA	0.4	7.1	0.31	4.68e-12	Neuroticism;
LGG	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg16141378	chr3:129829833	LOC729375	0.4	9.09	0.39	2.92e-18	Retinal vascular caliber;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg05793240	chr7:2802953	GNA12	0.32	7.15	0.32	3.51e-12	Height;
LGG	cis	rs8051149	0.625	rs28483765	chr16:87882509	C/T	cg02614661	chr16:87878292	SLC7A5	-0.37	-7.03	-0.31	7.3e-12	Blood metabolite levels;
LGG	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg06238570	chr21:40685208	BRWD1	-0.55	-9.08	-0.39	3.16e-18	Cognitive function;
LGG	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg09021430	chr5:549028	NA	-0.72	-9.87	-0.42	5.44e-21	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7615952	0.688	rs12638224	chr3:125541320	C/T	cg05084668	chr3:125655381	ALG1L	-0.65	-8.27	-0.36	1.48e-15	Blood pressure (smoking interaction);
LGG	cis	rs763014	0.898	rs1981484	chr16:630710	A/G	cg09263875	chr16:632152	PIGQ	0.64	12.67	0.51	8.29e-32	Height;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg26554054	chr8:600488	NA	-1.13	-10.18	-0.43	4.34e-22	IgG glycosylation;
LGG	cis	rs67311347	0.502	rs3924444	chr3:40576061	T/C	cg13683864	chr3:40499215	RPL14	-0.61	-10.76	-0.45	3.09e-24	Renal cell carcinoma;
LGG	cis	rs7027203	0.797	rs7870672	chr9:96606693	A/C	cg14598338	chr9:96623480	NA	-0.54	-9.64	-0.41	3.7799999999999997e-20	DNA methylation (variation);
LGG	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg20891558	chr2:74357851	NA	0.52	10.32	0.43	1.26e-22	Gestational age at birth (maternal effect);
LGG	trans	rs970548	0.779	rs2310783	chr10:45972810	G/C	cg14222797	chr10:16859974	RSU1	-0.62	-7.3	-0.32	1.27e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs11088226	0.681	rs2833912	chr21:33949822	G/A	cg09050820	chr6:167586206	TCP10L2	0.94	13.81	0.54	1.38e-36	Gastritis;
LGG	cis	rs5758659	0.652	rs133301	chr22:42390093	C/T	cg15128208	chr22:42549153	NA	-0.37	-7.45	-0.33	4.77e-13	Cognitive function;
LGG	cis	rs4665809	0.549	rs7577896	chr2:26524493	C/T	cg08470875	chr2:26401718	FAM59B	0.39	7.14	0.31	3.61e-12	Gut microbiome composition (summer);
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.15	0.39	1.76e-18	Aortic root size;
LGG	trans	rs75804782	0.641	rs41264155	chr2:239342096	G/A	cg01134436	chr17:81009848	B3GNTL1	0.85	8.77	0.38	3.53e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.32	-0.4	4.67e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs77305932	chr7:1100861	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4716602	0.596	rs10258194	chr7:156156610	T/C	cg16983916	chr7:156159713	NA	-0.49	-9.38	-0.4	3.04e-19	Anti-saccade response;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.54	0.33	2.51e-13	Lung cancer;
LGG	cis	rs12997796	0.556	rs13004867	chr2:86982504	C/G	cg25203885	chr2:87302643	LOC285074	-0.66	-7.77	-0.34	5.17e-14	Schizophrenia;
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg23594656	chr7:65796392	TPST1	0.4	8.83	0.38	2.18e-17	Aortic root size;
LGG	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg10523679	chr1:76189770	ACADM	-0.41	-6.73	-0.3	4.97e-11	Daytime sleep phenotypes;
LGG	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.01	0.31	8.39e-12	Hip circumference adjusted for BMI;
LGG	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg12573674	chr2:1569213	NA	-0.54	-7.32	-0.32	1.13e-12	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10214930	0.697	rs13242248	chr7:27682871	C/T	cg22168087	chr7:27702803	HIBADH	0.45	6.74	0.3	4.79e-11	Hypospadias;
LGG	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.85	-0.38	1.87e-17	Bipolar disorder;
LGG	cis	rs6066825	0.605	rs761274	chr20:47315362	T/C	cg18078177	chr20:47281410	PREX1	0.48	8.07	0.35	5.97e-15	Colorectal cancer;
LGG	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	7.74	0.34	6.46e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1153858	0.945	rs1974981	chr15:45729123	C/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.43	-7.58	-0.33	1.97e-13	Homoarginine levels;
LGG	cis	rs9300255	0.739	rs6633	chr12:123745809	G/T	cg00376283	chr12:123451042	ABCB9	-0.63	-9.48	-0.4	1.34e-19	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg09904177	chr6:26538194	HMGN4	0.62	11.87	0.48	1.51e-28	Intelligence (multi-trait analysis);
LGG	cis	rs416603	0.967	rs11644184	chr16:11365104	G/A	cg00044050	chr16:11439710	C16orf75	-0.56	-9.35	-0.4	3.9e-19	Type 1 diabetes;
LGG	cis	rs11150038	0.623	rs61321449	chr16:78015879	C/T	cg04733911	chr16:78082701	NA	0.56	7.2	0.32	2.46e-12	Colorectal or endometrial cancer;
LGG	cis	rs4642101	0.640	rs2305398	chr3:12856856	A/G	cg05775895	chr3:12838266	CAND2	0.51	8.53	0.37	2.17e-16	QRS complex (12-leadsum);
LGG	cis	rs10463554	0.892	rs1561404	chr5:102299351	G/C	cg23492399	chr5:102201601	PAM	-0.56	-8.5	-0.37	2.57e-16	Parkinson's disease;
LGG	cis	rs11608355	1.000	rs3742020	chr12:109883254	T/C	cg19025524	chr12:109796872	NA	-0.48	-9.1	-0.39	2.64e-18	Neuroticism;
LGG	cis	rs7666738	0.830	rs7657490	chr4:99043973	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg02297831	chr4:17616191	MED28	0.48	8.74	0.38	4.41e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs2599510	0.744	rs4952212	chr2:32618493	G/C	cg02381751	chr2:32503542	YIPF4	-0.53	-8.61	-0.37	1.11e-16	Interleukin-18 levels;
LGG	trans	rs459571	0.920	rs433402	chr9:136898627	A/G	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.7	-11.93	-0.48	8.92e-29	Platelet distribution width;
LGG	cis	rs10911232	0.507	rs10737239	chr1:183030170	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg13073564	chr4:8508604	NA	0.52	10.6	0.44	1.22e-23	Response to antineoplastic agents;
LGG	cis	rs73787773	0.668	rs73787779	chr5:111480610	G/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.57	-7.53	-0.33	2.64e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2456568	0.548	rs10501809	chr11:93666263	C/G	cg17595323	chr11:93583763	C11orf90	-0.45	-8.06	-0.35	6.71e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs977987	0.806	rs11862095	chr16:75385418	T/A	cg03315344	chr16:75512273	CHST6	0.52	10.64	0.44	8.74e-24	Dupuytren's disease;
LGG	cis	rs2247341	0.965	rs2854921	chr4:1715250	C/T	cg08629884	chr4:1719983	TMEM129	-0.57	-11.13	-0.46	1.19e-25	Hip circumference adjusted for BMI;Height;
LGG	cis	rs6088590	0.687	rs73106933	chr20:33287425	T/C	cg08999081	chr20:33150536	PIGU	0.37	9.29	0.4	5.99e-19	Coronary artery disease;
LGG	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	9.16	0.39	1.69e-18	Mood instability;
LGG	cis	rs1018836	0.851	rs2023624	chr8:91618874	T/C	cg16814680	chr8:91681699	NA	-0.84	-16.11	-0.6	1.06e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg25358565	chr5:93447407	FAM172A	-0.68	-9.84	-0.42	7.11e-21	Diabetic retinopathy;
LGG	cis	rs5769707	0.935	rs739239	chr22:50050468	G/A	cg20744362	chr22:50050164	C22orf34	0.4	7.76	0.34	5.47e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.06	-0.52	1.99e-33	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs941764	0.862	rs8021298	chr14:91840153	G/A	cg10511902	chr14:91842949	CCDC88C	0.64	14.37	0.56	5.75e-39	Breast cancer;
LGG	cis	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg09307838	chr4:120376055	NA	0.82	13.72	0.54	3.33e-36	Corneal astigmatism;
LGG	trans	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg27467005	chr19:17622279	PGLS	0.41	7.1	0.31	4.77e-12	Dupuytren's disease;
LGG	cis	rs2120243	0.565	rs13087207	chr3:157099638	G/A	cg24825693	chr3:157122686	VEPH1	-0.59	-13.67	-0.54	5.89e-36	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15369054	chr17:80825471	TBCD	0.4	7.8	0.34	4.07e-14	Breast cancer;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.03	0.49	3.39e-29	Prudent dietary pattern;
LGG	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg12042659	chr19:58951599	ZNF132	0.35	6.98	0.31	1.03e-11	Uric acid clearance;
LGG	cis	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.12	-0.49	1.44e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.531	rs77146033	chr3:52701501	G/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	8.82	0.38	2.43e-17	Bipolar disorder;
LGG	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg11752832	chr7:134001865	SLC35B4	0.48	8.47	0.37	3.37e-16	Mean platelet volume;
LGG	cis	rs4862750	0.872	rs6553030	chr4:187899234	T/C	cg27532560	chr4:187881888	NA	-0.59	-12.98	-0.52	4.44e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.86	0.38	1.7e-17	Lung cancer;
LGG	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg00686598	chr14:53173677	PSMC6	1.34	14.88	0.57	3.38e-41	Alzheimer's disease (late onset);
LGG	cis	rs55665837	0.524	rs2882128	chr11:14414634	A/C	cg19336497	chr11:14380999	RRAS2	-0.51	-10.23	-0.43	2.75e-22	Vitamin D levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02147989	chr7:138794603	ZC3HAV1	0.42	7.12	0.31	4.23e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6942756	1.000	rs12112374	chr7:128950071	A/G	cg02491457	chr7:128862824	NA	-0.75	-13.63	-0.54	8.66e-36	White matter hyperintensity burden;
LGG	cis	rs35740288	0.770	rs11638379	chr15:86111290	G/T	cg04173714	chr15:86211321	AKAP13	0.49	8.87	0.38	1.66e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs75920871	0.623	rs57582454	chr11:116961892	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-8.01	-0.35	9.14e-15	Subjective well-being;
LGG	trans	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.85	0.42	6.64e-21	Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7481584	0.624	rs449164	chr11:3053454	C/T	cg08508325	chr11:3079039	CARS	0.43	8.37	0.36	6.66e-16	Calcium levels;
LGG	cis	rs240764	0.658	rs9322183	chr6:101225121	G/A	cg21058520	chr6:100914733	NA	0.39	6.83	0.3	2.68e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11136969	chr8:23299153	ENTPD4	-0.36	-6.9	-0.31	1.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs873946	0.586	rs12251911	chr10:134570595	A/G	cg26818010	chr10:134567672	INPP5A	-0.73	-11.34	-0.47	1.84e-26	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6558530	0.666	rs10113471	chr8:1695827	C/A	cg08198773	chr8:1697536	NA	0.44	7.73	0.34	6.8e-14	Systolic blood pressure;
LGG	cis	rs2797160	0.874	rs58305111	chr6:126008386	G/T	cg05901451	chr6:126070800	HEY2	0.46	7.77	0.34	5.1e-14	Endometrial cancer;
LGG	trans	rs561341	0.709	rs8068049	chr17:30183857	T/C	cg27661571	chr11:113659931	NA	0.56	6.73	0.3	5.19e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7107174	1.000	rs2510048	chr11:77987464	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	4.89e-12	Leprosy;
LGG	cis	rs1270639	0.778	rs1796272	chr7:157437832	C/T	cg13357408	chr7:157437802	PTPRN2	-0.63	-10.15	-0.43	5.54e-22	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16092991	chr4:15004611	CPEB2	0.45	6.8	0.3	3.2e-11	Gut microbiome composition (summer);
LGG	cis	rs17014483	0.749	rs2860408	chr4:89639032	A/G	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.76	0.3	4.06e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.29	-7.48	-0.33	3.85e-13	Total body bone mineral density;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg01585723	chr16:33734837	NA	-0.47	-8.23	-0.36	1.94e-15	Menopause (age at onset);
LGG	cis	rs6998277	1.000	rs6998277	chr8:103639941	T/C	cg10187029	chr8:103597600	NA	0.79	11.62	0.48	1.46e-27	Migraine;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06350097	chr1:161474970	FCGR2A	0.4	7.64	0.33	1.26e-13	Menarche (age at onset);
LGG	cis	rs7660520	0.556	rs4862103	chr4:183735309	G/A	cg25287198	chr4:183728479	NA	0.48	7.55	0.33	2.37e-13	Pediatric autoimmune diseases;
LGG	cis	rs3741151	1.000	rs111882289	chr11:73053714	T/C	cg17517138	chr11:73019481	ARHGEF17	1.02	10.4	0.44	6.47e-23	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06825833	chr13:111566802	ANKRD10	0.47	6.79	0.3	3.38e-11	Gut microbiome composition (summer);
LGG	cis	rs41563	0.674	rs2192932	chr7:104653265	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.05	0.31	6.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg04986931	chr22:39850128	NA	0.33	7.53	0.33	2.65e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs7937682	0.921	rs10891280	chr11:111433609	A/T	cg18187862	chr3:45730750	SACM1L	-0.53	-8.39	-0.36	6.15e-16	Primary sclerosing cholangitis;
LGG	cis	rs61931739	0.500	rs11053193	chr12:34438838	G/T	cg06521331	chr12:34319734	NA	-0.58	-10.1	-0.42	8.28e-22	Morning vs. evening chronotype;
LGG	cis	rs8064024	0.680	rs2063101	chr16:4916348	A/G	cg04440724	chr16:4920505	UBN1	-0.56	-12.61	-0.51	1.55e-31	Cancer;
LGG	trans	rs12517041	0.935	rs10077662	chr5:23294524	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.03e-25	Calcium levels;
LGG	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.31	-0.32	1.18e-12	Iron status biomarkers;
LGG	cis	rs2880765	0.835	rs4842884	chr15:86035174	T/C	cg10818794	chr15:86012489	AKAP13	-0.37	-7.97	-0.35	1.26e-14	Coronary artery disease;
LGG	cis	rs11690935	0.851	rs7581072	chr2:172859849	C/T	cg21435375	chr2:172878103	MAP1D	-0.35	-7.93	-0.35	1.62e-14	Schizophrenia;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.35	-0.36	8.16e-16	Longevity;Endometriosis;
LGG	cis	rs3747547	0.892	rs17439509	chr9:38016419	A/C	cg13774184	chr9:37916125	SHB	-0.7	-7.08	-0.31	5.36e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs12681288	0.832	rs2123060	chr8:1009313	T/C	cg08648136	chr8:956695	NA	0.38	7.89	0.34	2.22e-14	Schizophrenia;
LGG	cis	rs868036	0.718	rs8025790	chr15:68076399	G/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.4	-0.36	5.4e-16	Restless legs syndrome;
LGG	cis	rs7945718	0.905	rs7124484	chr11:12745271	G/A	cg25843174	chr11:12811716	TEAD1	0.41	8.33	0.36	9.48e-16	Educational attainment (years of education);
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg04568710	chr12:38710424	ALG10B	-0.36	-7.33	-0.32	1.06e-12	Morning vs. evening chronotype;
LGG	trans	rs7980799	0.646	rs9971799	chr12:33592003	G/T	cg26384229	chr12:38710491	ALG10B	-0.46	-7.87	-0.34	2.58e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4481887	0.741	rs4360554	chr1:248553206	C/T	cg13385794	chr1:248469461	NA	0.43	7.45	0.33	4.72e-13	Common traits (Other);
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs35883536	0.566	rs12566440	chr1:101095202	A/G	cg06223162	chr1:101003688	GPR88	0.33	7.61	0.33	1.54e-13	Monocyte count;
LGG	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg12658694	chr1:38397304	INPP5B	0.46	9.37	0.4	3.24e-19	Coronary artery disease;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs981844	0.736	rs1036614	chr4:154639105	G/A	cg14289246	chr4:154710475	SFRP2	0.67	10.69	0.44	5.5e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs9397585	0.667	rs6557259	chr6:153412938	A/G	cg17707550	chr6:153380415	RGS17	0.47	10.05	0.42	1.21e-21	Body mass index;
LGG	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.37e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1670533	1.000	rs2290411	chr4:1051077	T/C	cg27284194	chr4:1044797	NA	0.54	9.82	0.42	8.6e-21	Recombination rate (females);
LGG	cis	rs8180040	0.764	rs11708451	chr3:47198826	G/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs7124681	0.584	rs10769285	chr11:47709212	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.18	0.46	7.26e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs5998509	1	rs5998509	chr22:21917479	C/T	cg11654148	chr22:21984483	YDJC	-0.41	-7.79	-0.34	4.53e-14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07851189	chr5:178053231	CLK4	0.55	8.47	0.37	3.33e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg23782820	chr8:58130467	NA	0.51	7.83	0.34	3.43e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	cis	rs75920871	0.688	rs61905679	chr11:116834787	C/T	cg20608306	chr11:116969690	SIK3	-0.32	-6.84	-0.3	2.49e-11	Subjective well-being;
LGG	cis	rs785830	0.721	rs682251	chr9:271455	C/T	cg14500300	chr9:211689	NA	-0.3	-7.6	-0.33	1.65e-13	Platelet distribution width;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	trans	rs853679	0.607	rs34661125	chr6:28281894	G/A	cg01620082	chr3:125678407	NA	-1.05	-10.43	-0.44	4.92e-23	Depression;
LGG	cis	rs300703	0.935	rs300749	chr2:208143	G/T	cg24565620	chr2:194026	NA	-0.71	-9.76	-0.41	1.39e-20	Blood protein levels;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	7.14	0.32	3.52e-12	Schizophrenia;
LGG	cis	rs62400317	0.821	rs34455867	chr6:45172071	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.1	-0.43	7.97e-22	Total body bone mineral density;
LGG	cis	rs910187	0.605	rs8124995	chr20:45811788	G/T	cg27589058	chr20:45804311	EYA2	-0.36	-9.22	-0.39	1.09e-18	Migraine;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.22	0.55	2.43e-38	Obesity-related traits;
LGG	cis	rs7095944	0.584	rs11245347	chr10:126427037	G/T	cg08799069	chr10:126477246	METTL10	-0.47	-10.39	-0.43	7e-23	Asthma;
LGG	cis	rs7607369	0.759	rs10179708	chr2:219390967	T/A	cg10223061	chr2:219282414	VIL1	0.31	6.96	0.31	1.17e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs11724804	0.532	rs73207782	chr4:848764	G/C	cg04824913	chr4:887549	GAK	0.47	6.83	0.3	2.65e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs897080	0.552	rs1068714	chr2:44634063	T/C	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs854037	0.698	rs66639127	chr5:57077482	G/A	cg08523694	chr5:57076192	NA	0.61	7.49	0.33	3.45e-13	Birth weight;
LGG	cis	rs4642101	0.765	rs1985428	chr3:12829315	A/G	cg24848339	chr3:12840334	CAND2	-0.42	-9.61	-0.41	4.78e-20	QRS complex (12-leadsum);
LGG	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-7.99	-0.35	1.06e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg13770153	chr20:60521292	NA	1.09	19.69	0.68	3.83e-63	Obesity-related traits;
LGG	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg01631408	chr1:248437212	OR2T33	-0.38	-7.1	-0.31	4.75e-12	Common traits (Other);
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.05	0.57	5.65e-42	Platelet count;
LGG	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg12463550	chr7:65579703	CRCP	0.52	8.72	0.38	5e-17	Aortic root size;
LGG	trans	rs9329221	0.505	rs7840347	chr8:10072350	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.99	-0.31	9.34e-12	Neuroticism;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.17	-0.32	2.9e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg06558623	chr16:89946397	TCF25	1.16	14.89	0.57	2.95e-41	Skin colour saturation;
LGG	cis	rs4148883	0.504	rs2000864	chr4:100123776	A/C	cg12011299	chr4:100065546	ADH4	0.35	7.55	0.33	2.33e-13	Alcohol dependence;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg03806693	chr22:41940476	POLR3H	1.09	19.86	0.68	5.84e-64	Vitiligo;
LGG	trans	rs116095464	0.558	rs28636067	chr5:199415	G/A	cg09048205	chr5:1608656	LOC728613	-0.51	-8.02	-0.35	8.94e-15	Breast cancer;
LGG	cis	rs6831352	0.959	rs6532795	chr4:100042221	C/T	cg12011299	chr4:100065546	ADH4	-0.42	-8.54	-0.37	1.97e-16	Alcohol dependence;
LGG	cis	rs611744	0.625	rs11991891	chr8:109294858	G/A	cg18478394	chr8:109455254	TTC35	0.45	9.09	0.39	2.95e-18	Dupuytren's disease;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg06848047	chr4:90757629	SNCA	-0.38	-7.3	-0.32	1.27e-12	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg13206674	chr6:150067644	NUP43	0.64	14.43	0.56	3.11e-39	Lung cancer;
LGG	cis	rs8114671	0.662	rs3761143	chr20:33545745	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.84	0.38	2.04e-17	Height;
LGG	cis	rs11239187	0.814	rs34902441	chr10:45110623	A/G	cg03916630	chr10:45065415	NA	0.34	7.4	0.33	6.37e-13	Body mass index;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg16318349	chr1:154917307	PBXIP1	-0.25	-6.65	-0.3	8.38e-11	Prostate cancer;
LGG	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg06872548	chr17:78716983	RPTOR	0.46	11.33	0.47	1.99e-26	Obesity;
LGG	cis	rs2742417	0.603	rs2742374	chr3:45784082	T/C	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9527	0.590	rs7092029	chr10:104823909	A/T	cg04362960	chr10:104952993	NT5C2	0.57	10.75	0.45	3.23e-24	Arsenic metabolism;
LGG	cis	rs1799949	0.965	rs35954893	chr17:41333786	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg13385794	chr1:248469461	NA	0.49	8.14	0.35	3.63e-15	Common traits (Other);
LGG	cis	rs12477438	0.798	rs1453562	chr2:99615850	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs4409675	0.576	rs10751724	chr1:28215631	C/T	cg23691781	chr1:28212827	C1orf38	0.42	11.6	0.47	1.74e-27	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.91e-12	Prudent dietary pattern;
LGG	cis	rs10504229	0.906	rs7842855	chr8:58167718	G/C	cg21724239	chr8:58056113	NA	0.42	6.71	0.3	5.83e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62025270	0.576	rs62022947	chr15:86271322	G/C	cg25843651	chr15:86329602	KLHL25	0.57	8.96	0.38	7.74e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs7179456	0.547	rs6494035	chr15:59015888	C/G	cg05156742	chr15:59063176	FAM63B	0.6	9.58	0.41	5.8e-20	Asperger disorder;
LGG	cis	rs975739	0.872	rs1279660	chr13:78369851	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.79	0.3	3.54e-11	Hair color;
LGG	cis	rs11608355	1.000	rs11611370	chr12:109870291	A/G	cg19025524	chr12:109796872	NA	0.49	9.37	0.4	3.29e-19	Neuroticism;
LGG	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.85	-0.42	6.47e-21	Sudden cardiac arrest;
LGG	cis	rs73001065	0.901	rs73004926	chr19:19671266	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	7.09	0.31	5.07e-12	LDL cholesterol;
LGG	cis	rs2455799	0.613	rs4685260	chr3:15832417	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.88	-0.34	2.4e-14	Mean platelet volume;
LGG	cis	rs9303280	0.806	rs11078928	chr17:38064469	T/C	cg17467752	chr17:38218738	THRA	-0.45	-7.23	-0.32	2.06e-12	Self-reported allergy;
LGG	cis	rs1218582	0.772	rs11264282	chr1:154867370	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.25	-0.32	1.74e-12	Prostate cancer;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg14196790	chr5:131705035	SLC22A5	0.61	7.65	0.33	1.17e-13	Rheumatoid arthritis;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg21862992	chr11:68658383	NA	0.51	8.61	0.37	1.12e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs62238980	0.614	rs79738052	chr22:32455812	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg20003494	chr4:90757398	SNCA	-0.35	-6.82	-0.3	2.77e-11	Dementia with Lewy bodies;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.1	-0.31	4.63e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.32	-8.21	-0.36	2.26e-15	IgG glycosylation;
LGG	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.02	0.57	7.99e-42	Cognitive test performance;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg22398616	chr13:53314203	LECT1	0.55	12.21	0.49	6.2e-30	Lewy body disease;
LGG	cis	rs17376456	0.757	rs10476591	chr5:93333723	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.48	0.44	3.24e-23	Diabetic retinopathy;
LGG	trans	rs11098499	0.863	rs6853998	chr4:120475860	C/A	cg25214090	chr10:38739885	LOC399744	0.66	11.64	0.48	1.16e-27	Corneal astigmatism;
LGG	cis	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.48e-12	Retinal vascular caliber;
LGG	cis	rs9457247	0.534	rs4710154	chr6:167394634	A/T	cg18261144	chr6:167370276	RNASET2	-0.38	-7.8	-0.34	4.1e-14	Crohn's disease;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg18032289	chr17:61959525	GH2	-0.38	-6.68	-0.3	6.74e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs758324	0.588	rs421377	chr5:131327157	A/T	cg06307176	chr5:131281290	NA	0.46	7.04	0.31	6.95e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7134594	0.677	rs7137190	chr12:109866108	G/C	cg19025524	chr12:109796872	NA	-0.47	-9.57	-0.41	6.45e-20	HDL cholesterol;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.51e-20	Prudent dietary pattern;
LGG	cis	rs4731207	0.698	rs7793258	chr7:124448012	G/A	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs4740619	0.846	rs10810419	chr9:15642909	C/T	cg14451791	chr9:16040625	NA	0.35	9.04	0.39	4.22e-18	Body mass index;
LGG	cis	rs12477438	0.501	rs3792144	chr2:100056736	T/C	cg23527387	chr2:100056660	REV1	0.42	9.46	0.4	1.52e-19	Chronic sinus infection;
LGG	trans	rs73198271	0.565	rs575920	chr8:8594254	C/T	cg16141378	chr3:129829833	LOC729375	0.34	6.86	0.3	2.28e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9534288	0.797	rs4942467	chr13:46599817	A/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	cis	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs2304069	0.545	rs4705404	chr5:149381952	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.47	8.13	0.35	3.93e-15	HIV-1 control;
LGG	cis	rs11229555	0.645	rs12802819	chr11:58174747	T/G	cg15696309	chr11:58395628	NA	-0.94	-15.2	-0.58	1.22e-42	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2795502	1.000	rs3121279	chr10:43378449	T/A	cg27426351	chr10:43362370	NA	0.47	7.0	0.31	9.09e-12	Blood protein levels;
LGG	cis	rs7998202	0.614	rs420431	chr13:113346317	C/G	cg17218041	chr13:113365319	ATP11A	0.47	7.6	0.33	1.66e-13	Glycated hemoglobin levels;
LGG	cis	rs9611565	0.694	rs9607816	chr22:41950897	G/A	cg17376030	chr22:41985996	PMM1	0.58	9.08	0.39	3.23e-18	Vitiligo;
LGG	cis	rs10267417	0.589	rs13239768	chr7:19951233	C/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.87	0.3	2.09e-11	Night sleep phenotypes;
LGG	cis	rs6121246	0.779	rs6060763	chr20:30282223	A/G	cg04935436	chr20:30431758	NA	0.39	6.81	0.3	3.13e-11	Mean corpuscular hemoglobin;
LGG	cis	rs6032067	0.929	rs7344269	chr20:43828668	C/T	cg10761708	chr20:43804764	PI3	-0.75	-11.1	-0.46	1.52e-25	Blood protein levels;
LGG	cis	rs2694528	0.858	rs79365162	chr5:60383389	T/C	cg11474532	chr5:59995715	DEPDC1B	0.69	7.4	0.33	6.31e-13	Parkinson's disease;
LGG	cis	rs1783925	1.000	rs640364	chr11:125300766	G/A	cg03464685	chr11:125439445	EI24	-0.6	-9.67	-0.41	2.89e-20	Formal thought disorder in schizophrenia;
LGG	cis	rs74781061	0.860	rs4887152	chr15:74756354	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg09307838	chr4:120376055	NA	0.68	11.75	0.48	4.47e-28	Corneal astigmatism;
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg06112835	chr11:68658793	MRPL21	-0.4	-6.98	-0.31	1.02e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs774359	0.789	rs10967972	chr9:27523082	C/G	cg14173147	chr9:27528300	MOBKL2B	0.47	8.86	0.38	1.78e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs6499188	1.000	rs6499188	chr16:68674788	G/A	cg02972257	chr16:68554789	NA	-0.46	-6.65	-0.3	8.48e-11	Ulcerative colitis;
LGG	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg25801113	chr15:45476975	SHF	0.89	20.31	0.69	4.81e-66	Uric acid levels;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.93	-0.35	1.64e-14	Personality dimensions;
LGG	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg00290607	chr11:67383545	NA	-0.48	-8.75	-0.38	4.02e-17	Mean corpuscular volume;
LGG	cis	rs7614311	0.731	rs1053338	chr3:63967900	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.95	-0.35	1.45e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.66	-0.3	7.89e-11	Menarche (age at onset);
LGG	cis	rs9549367	0.577	rs3024711	chr13:113813268	A/G	cg00898013	chr13:113819073	PROZ	-0.46	-7.8	-0.34	4.08e-14	Platelet distribution width;
LGG	trans	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg06521331	chr12:34319734	NA	0.45	8.06	0.35	6.37e-15	Bladder cancer;
LGG	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.33	-0.32	1.07e-12	Height;
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg13939156	chr17:80058883	NA	0.5	9.92	0.42	3.61e-21	Life satisfaction;
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.87e-21	Aortic root size;
LGG	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg00990874	chr7:1149470	C7orf50	-0.65	-10.02	-0.42	1.64e-21	Bronchopulmonary dysplasia;
LGG	cis	rs3540	0.513	rs2601154	chr15:90894284	T/C	cg22089800	chr15:90895588	ZNF774	0.74	13.46	0.53	4.39e-35	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4423214	0.592	rs7114252	chr11:71237606	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-8.12	-0.35	4.3e-15	Vitamin D levels;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg23978390	chr7:1156363	C7orf50	0.56	9.68	0.41	2.71e-20	Longevity;Endometriosis;
LGG	cis	rs7945718	0.591	rs7102432	chr11:12700132	T/C	cg25843174	chr11:12811716	TEAD1	0.33	7.13	0.31	3.91e-12	Educational attainment (years of education);
LGG	cis	rs637571	0.522	rs542332	chr11:65744421	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.98	0.39	6.99e-18	Eosinophil percentage of white cells;
LGG	cis	rs11792861	0.781	rs874864	chr9:111728718	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.45	0.44	4.42e-23	Menarche (age at onset);
LGG	cis	rs7089973	0.872	rs7094072	chr10:116627160	T/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.7	0.34	8.5e-14	Lung cancer;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.75	0.38	3.99e-17	Prudent dietary pattern;
LGG	cis	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg21775007	chr8:11205619	TDH	0.81	14.76	0.57	1.13e-40	Retinal vascular caliber;
LGG	cis	rs8067545	0.641	rs203481	chr17:19828728	C/T	cg13482628	chr17:19912719	NA	0.52	9.54	0.41	7.97e-20	Schizophrenia;
LGG	cis	rs4919087	1.000	rs10882898	chr10:99087330	G/A	cg25902810	chr10:99078978	FRAT1	-0.5	-9.07	-0.39	3.41e-18	Monocyte count;
LGG	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.37	-0.56	5.53e-39	Heart rate;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg17202724	chr17:61916730	SMARCD2	-0.63	-15.42	-0.58	1.42e-43	Prudent dietary pattern;
LGG	cis	rs9400467	0.537	rs12111379	chr6:111434809	T/C	cg15721981	chr6:111408429	SLC16A10	0.55	6.69	0.3	6.36e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.99	-0.35	1.06e-14	Height;
LGG	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg22903471	chr2:27725779	GCKR	-0.56	-12.68	-0.51	7.5e-32	Total body bone mineral density;
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.43	7.33	0.32	1e-12	Cognitive function;
LGG	trans	rs11039798	1.000	rs34044596	chr11:48527936	T/C	cg03929089	chr4:120376271	NA	0.73	8.44	0.37	4.1e-16	Axial length;
LGG	cis	rs6450176	0.680	rs255756	chr5:53309364	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-16.72	-0.61	1.9e-49	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs350251	0.899	rs350245	chr16:12200115	C/T	cg02910054	chr16:12241554	SNX29	0.45	8.35	0.36	8.18e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg18402987	chr7:1209562	NA	0.39	7.09	0.31	5.05e-12	Longevity;Endometriosis;
LGG	cis	rs9948	0.655	rs62156232	chr2:97431161	C/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.55e-13	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04270274	chr16:58662988	CNOT1	0.43	6.65	0.3	8.21e-11	Gut microbiome composition (summer);
LGG	cis	rs12200782	0.929	rs72843734	chr6:26448344	C/G	cg11502198	chr6:26597334	ABT1	-0.83	-6.81	-0.3	3.07e-11	Small cell lung carcinoma;
LGG	cis	rs16933812	0.500	rs883967	chr9:36993788	T/C	cg13738729	chr9:36989127	PAX5	0.42	9.11	0.39	2.43e-18	Obesity-related traits;
LGG	cis	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.21	-0.36	2.22e-15	Retinal vascular caliber;
LGG	cis	rs6547631	0.594	rs12620113	chr2:85936833	G/T	cg19805943	chr2:85933069	NA	0.32	6.78	0.3	3.74e-11	Blood protein levels;
LGG	cis	rs727505	0.826	rs11532793	chr7:124747952	A/G	cg23710748	chr7:124431027	NA	-0.48	-9.05	-0.39	4.01e-18	Lewy body disease;
LGG	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.48	-0.33	3.71e-13	Cognitive ability;
LGG	cis	rs5769765	0.954	rs5770739	chr22:50268014	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.17	-0.43	4.64e-22	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.44	-0.33	4.94e-13	Life satisfaction;
LGG	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg02002194	chr4:3960332	NA	-0.48	-8.53	-0.37	2.18e-16	Systolic blood pressure;
LGG	cis	rs12780845	0.522	rs725355	chr10:17202865	T/C	cg01003015	chr10:17271136	VIM	-0.45	-7.62	-0.33	1.4e-13	Homocysteine levels;
LGG	cis	rs2439831	1.000	rs2439831	chr15:43784475	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.49	0.44	3.07e-23	Lung cancer in ever smokers;
LGG	cis	rs6942756	1.000	rs11763056	chr7:128960871	C/A	cg02491457	chr7:128862824	NA	-0.74	-13.52	-0.53	2.48e-35	White matter hyperintensity burden;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs514406	0.679	rs12563825	chr1:53238324	G/T	cg25767906	chr1:53392781	SCP2	0.43	8.44	0.37	3.98e-16	Monocyte count;
LGG	cis	rs11148252	0.574	rs2038826	chr13:53280013	G/A	cg02158880	chr13:53174818	NA	0.67	15.36	0.58	2.47e-43	Lewy body disease;
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07648498	chr16:89883185	FANCA	-0.4	-6.93	-0.31	1.44e-11	Vitiligo;
LGG	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg10160682	chr2:1713001	PXDN	-0.58	-9.87	-0.42	5.48e-21	Response to antipsychotic treatment;
LGG	trans	rs1728785	1.000	rs1749793	chr16:68569312	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.71	11.04	0.46	2.53e-25	Ulcerative colitis;
LGG	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg24675658	chr1:53192096	ZYG11B	0.5	10.18	0.43	4.18e-22	Monocyte count;
LGG	cis	rs7918232	0.782	rs7910168	chr10:27465296	G/A	cg14240646	chr10:27532245	ACBD5	-0.73	-10.28	-0.43	1.82e-22	Breast cancer;
LGG	cis	rs3768617	0.510	rs20558	chr1:183094547	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-8.91	-0.38	1.14e-17	Obesity-related traits;
LGG	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14373873	chr11:113211441	TTC12	0.53	11.44	0.47	7.25e-27	Neuroticism;
LGG	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg05491587	chr18:77659695	KCNG2	-0.42	-7.49	-0.33	3.42e-13	Schizophrenia;
LGG	cis	rs10751667	0.643	rs10902234	chr11:935578	A/G	cg22143635	chr11:980567	AP2A2	0.43	7.88	0.34	2.41e-14	Alzheimer's disease (late onset);
LGG	cis	rs2032447	0.966	rs9358901	chr6:26024436	G/T	cg12310025	chr6:25882481	NA	-0.55	-10.3	-0.43	1.51e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06108461	chr20:60628389	TAF4	-1.01	-19.74	-0.68	2.24e-63	Body mass index;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.38e-17	Prudent dietary pattern;
LGG	trans	rs2562456	0.833	rs62107534	chr19:21512191	C/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	trans	rs9354308	0.677	rs9363462	chr6:66557612	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-8.47	-0.37	3.39e-16	Metabolite levels;
LGG	cis	rs6547741	0.935	rs12615690	chr2:27851120	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.47	0.37	3.34e-16	Oral cavity cancer;
LGG	cis	rs7829975	0.628	rs1109618	chr8:8571364	A/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.13	-0.31	3.86e-12	Mood instability;
LGG	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg03060546	chr3:49711283	APEH	-0.75	-13.28	-0.53	2.54e-34	Resting heart rate;
LGG	cis	rs9640161	0.702	rs11765692	chr7:150026567	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.76	-15.81	-0.59	2.46e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg04025307	chr7:1156635	C7orf50	0.62	11.66	0.48	1.02e-27	Longevity;Endometriosis;
LGG	cis	rs2456568	0.548	rs10466334	chr11:93663512	A/G	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs13082711	0.863	rs36055621	chr3:27436797	T/C	cg02860705	chr3:27208620	NA	0.72	13.38	0.53	9.7e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs10540	0.818	rs12806089	chr11:501468	G/A	cg03352830	chr11:487213	PTDSS2	0.86	11.19	0.46	6.74e-26	Body mass index;
LGG	cis	rs896854	0.625	rs4735336	chr8:95973410	A/C	cg16049864	chr8:95962084	TP53INP1	0.38	8.43	0.36	4.39e-16	Type 2 diabetes;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs8070624	0.574	rs11078408	chr17:17876011	A/G	cg04398451	chr17:18023971	MYO15A	-0.69	-13.77	-0.54	2.1e-36	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.93	-0.45	6.77e-25	Lung cancer;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.08	-0.35	5.61e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7647973	0.961	rs11130186	chr3:49275828	A/G	cg07636037	chr3:49044803	WDR6	0.76	13.56	0.53	1.62e-35	Menarche (age at onset);
LGG	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg04608330	chr12:45269318	NELL2	-0.65	-11.62	-0.48	1.47e-27	Gut microbiome composition (summer);
LGG	cis	rs3812831	0.695	rs6560935	chr13:114945867	G/A	cg25338242	chr13:114786047	RASA3	0.43	7.82	0.34	3.53e-14	Schizophrenia;
LGG	cis	rs9790314	0.747	rs9990242	chr3:160838461	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-11.78	-0.48	3.24e-28	Morning vs. evening chronotype;
LGG	cis	rs3087591	0.960	rs11870097	chr17:29448097	C/T	cg24425628	chr17:29625626	OMG;NF1	0.7	14.48	0.56	1.78e-39	Hip circumference;
LGG	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg16576597	chr16:28551801	NUPR1	0.37	8.67	0.37	7.34e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1707322	0.686	rs3014235	chr1:46091512	A/G	cg03146154	chr1:46216737	IPP	-0.56	-10.79	-0.45	2.38e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10462794	0.853	rs10061389	chr5:4509952	C/G	cg18482690	chr5:4511582	NA	-0.42	-7.3	-0.32	1.25e-12	DNA methylation (variation);
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg16141378	chr3:129829833	LOC729375	0.49	12.5	0.5	4.17e-31	Mood instability;
LGG	cis	rs3858526	1.000	rs3858526	chr11:5959757	A/C	cg25319279	chr11:5960081	NA	-0.56	-8.75	-0.38	4.11e-17	DNA methylation (variation);
LGG	cis	rs7717393	1.000	rs72813881	chr5:155760241	C/T	cg04435420	chr5:155754009	SGCD	1.19	13.24	0.52	3.65e-34	Egg allergy;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg00814883	chr7:100076585	TSC22D4	-0.67	-9.76	-0.41	1.39e-20	Platelet count;
LGG	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	cis	rs12282928	0.959	rs1354293	chr11:48264370	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.13	-0.31	3.82e-12	Migraine - clinic-based;
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg04850017	chr11:63683019	RCOR2	0.5	13.94	0.54	3.99e-37	Pulse pressure;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	7.64	0.33	1.29e-13	Schizophrenia;
LGG	cis	rs2816316	1.000	rs1323292	chr1:192541021	G/A	cg10861751	chr1:192544716	RGS1	0.34	6.9	0.31	1.76e-11	Celiac disease;
LGG	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg20608306	chr11:116969690	SIK3	-0.41	-10.53	-0.44	2.23e-23	Blood protein levels;
LGG	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg26384229	chr12:38710491	ALG10B	0.98	23.13	0.73	3.17e-79	Bladder cancer;
LGG	cis	rs755249	0.567	rs60323161	chr1:39710459	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.2	0.32	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4919087	0.561	rs61861844	chr10:99064171	G/A	cg25902810	chr10:99078978	FRAT1	-0.42	-6.71	-0.3	5.63e-11	Monocyte count;
LGG	cis	rs8102732	1.000	rs8102732	chr19:1023867	C/G	cg00515755	chr19:1005248	GRIN3B	-0.37	-6.73	-0.3	5.04e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs847577	0.588	rs12666406	chr7:97790991	G/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.69	-0.3	6.37e-11	Breast cancer;
LGG	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg22432760	chr17:80829718	TBCD	0.39	6.8	0.3	3.14e-11	Breast cancer;
LGG	cis	rs11792861	0.505	rs12377869	chr9:111907803	C/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.45	7.16	0.32	3.11e-12	Menarche (age at onset);
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.28	-0.32	1.44e-12	Schizophrenia;
LGG	cis	rs7945718	0.875	rs9888258	chr11:12782716	A/G	cg25843174	chr11:12811716	TEAD1	0.39	8.1	0.35	5.03e-15	Educational attainment (years of education);
LGG	cis	rs9894429	1.000	rs9894429	chr17:79596811	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.56	-0.37	1.62e-16	Eye color traits;
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg06697600	chr4:7070879	GRPEL1	-0.55	-9.69	-0.41	2.37e-20	Monocyte percentage of white cells;
LGG	cis	rs2286885	1.000	rs10987296	chr9:129245316	C/T	cg14319473	chr9:129242481	FAM125B	0.44	8.12	0.35	4.34e-15	Intraocular pressure;
LGG	cis	rs12612619	0.557	rs1368888	chr2:27068577	G/C	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.88	-0.3	1.97e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11739541	chr12:49582842	TUBA1A	0.49	8.41	0.36	5.09e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg02023728	chr11:77925099	USP35	0.45	7.95	0.35	1.39e-14	Testicular germ cell tumor;
LGG	cis	rs2764208	0.576	rs2814954	chr6:34698146	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.47	-8.38	-0.36	6.37e-16	Systemic lupus erythematosus;
LGG	cis	rs6500395	1.000	rs871903	chr16:48593643	A/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg07930552	chr6:133119739	C6orf192	0.93	9.06	0.39	3.66e-18	Type 2 diabetes nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19909895	chr3:128368930	RPN1	0.52	8.28	0.36	1.34e-15	Gut microbiome composition (summer);
LGG	cis	rs4732038	0.739	rs6467536	chr7:134236067	G/A	cg06906464	chr7:134288099	NA	-0.47	-11.06	-0.46	2.19e-25	Longevity;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.4	-0.36	5.38e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1691799	0.899	rs1168315	chr12:66746694	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	cis	rs7010267	0.570	rs6469798	chr8:120018291	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.6	0.37	1.27e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.67	-9.1	-0.39	2.62e-18	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	trans	rs72766638	0.895	rs55924785	chr9:136929586	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.76	-0.34	5.44e-14	Mosquito bite size;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg07701084	chr6:150067640	NUP43	0.69	13.12	0.52	1.21e-33	Lung cancer;
LGG	cis	rs6582630	0.502	rs7311700	chr12:38463232	T/A	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.57e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg17691542	chr6:26056736	HIST1H1C	0.6	9.83	0.42	8e-21	Iron status biomarkers;
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07167872	chr1:205819463	PM20D1	0.69	14.77	0.57	1.04e-40	Menarche (age at onset);
LGG	cis	rs4481887	0.927	rs4341391	chr1:248475720	A/G	cg00666640	chr1:248458726	OR2T12	0.59	9.31	0.4	5.04e-19	Common traits (Other);
LGG	cis	rs2072732	0.904	rs9660819	chr1:2952823	C/T	cg08733933	chr1:2954429	NA	-0.39	-8.58	-0.37	1.47e-16	Plateletcrit;
LGG	cis	rs1008375	1.000	rs1006722	chr4:17618713	A/G	cg02297831	chr4:17616191	MED28	-0.47	-8.88	-0.38	1.51e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17345786	1.000	rs997739	chr3:101313940	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	9.04	0.39	4.45e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2204008	0.869	rs34438288	chr12:38211582	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs11650494	0.908	rs118099826	chr17:47447836	G/T	cg08112188	chr17:47440006	ZNF652	1.19	13.83	0.54	1.14e-36	Prostate cancer;
LGG	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.31	-0.32	1.17e-12	Pancreatic cancer;
LGG	cis	rs7945718	0.967	rs10831904	chr11:12760937	A/G	cg25843174	chr11:12811716	TEAD1	0.42	8.57	0.37	1.52e-16	Educational attainment (years of education);
LGG	cis	rs3768617	0.528	rs6686682	chr1:183080539	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7503807	0.515	rs12946206	chr17:78687270	G/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03000156	chr6:79577260	IRAK1BP1	0.54	8.37	0.36	6.74e-16	Gut microbiome composition (summer);
LGG	cis	rs597583	0.760	rs688968	chr11:117406739	C/G	cg27161313	chr11:117392002	DSCAML1	-0.58	-9.3	-0.4	5.66e-19	Putamen volume;
LGG	cis	rs17169635	0.601	rs3778853	chr7:134545098	A/G	cg02516134	chr7:134575187	CALD1	-0.39	-8.48	-0.37	3.16e-16	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.9	-18.38	-0.65	4.76e-57	Lung cancer;
LGG	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.96	-0.35	1.39e-14	Joint mobility (Beighton score);
LGG	cis	rs1021993	0.545	rs1507331	chr1:209516897	C/G	cg24446417	chr1:209558027	NA	-0.69	-10.0	-0.42	1.85e-21	Gut microbiome composition (winter);
LGG	cis	rs897984	0.806	rs1458202	chr16:30953202	A/G	cg00531865	chr16:30841666	NA	-0.57	-12.1	-0.49	1.86e-29	Dementia with Lewy bodies;
LGG	cis	rs2880765	0.835	rs7164106	chr15:86032590	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	cis	rs151234	0.800	rs231972	chr16:28538336	A/C	cg01378222	chr16:28622494	SULT1A1	-0.68	-8.65	-0.37	8.59e-17	Platelet distribution width;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg02951883	chr7:2050386	MAD1L1	-0.6	-11.95	-0.49	7.31e-29	Schizophrenia;
LGG	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg06212747	chr3:49208901	KLHDC8B	0.47	6.82	0.3	2.82e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.79	-0.3	3.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs115744897	chr4:119749064	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.54	-0.33	2.53e-13	Mood instability;
LGG	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg24692254	chr21:30365293	RNF160	1.04	29.42	0.81	4.58e-108	Dental caries;
LGG	cis	rs8060686	0.565	rs8057577	chr16:68033143	C/T	cg27539214	chr16:67997921	SLC12A4	-0.45	-6.92	-0.31	1.51e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs9902453	1.000	rs11080114	chr17:28407287	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.3	-0.53	2.08e-34	Coffee consumption (cups per day);
LGG	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg08847335	chr10:891726	LARP4B	-0.53	-8.99	-0.39	6.21e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs12431410	0.584	rs7140886	chr14:60245013	C/T	cg07950296	chr14:60194823	RTN1	0.37	7.0	0.31	8.82e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.48	0.53	3.43e-35	Lung cancer;
LGG	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg08250081	chr4:10125330	NA	0.39	7.6	0.33	1.65e-13	Bone mineral density;
LGG	cis	rs9472414	0.680	rs9463040	chr6:44752286	C/T	cg20913747	chr6:44695427	NA	0.46	7.11	0.31	4.49e-12	Height;
LGG	cis	rs9291683	0.530	rs73227883	chr4:9979279	T/C	cg00071950	chr4:10020882	SLC2A9	0.37	7.68	0.34	9.88e-14	Bone mineral density;
LGG	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9616064	0.506	rs6008944	chr22:47060976	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	8.87	0.38	1.59e-17	Urate levels in obese individuals;
LGG	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.5	-0.33	3.3e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg05091796	chr16:4465799	CORO7	0.65	10.87	0.45	1.15e-24	Schizophrenia;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7617480	0.648	rs9859473	chr3:48837182	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.42	0.36	4.82e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06636077	chr6:44224934	SLC35B2	0.48	7.03	0.31	7.51e-12	Gut microbiome composition (summer);
LGG	cis	rs8180040	0.726	rs9843075	chr3:47195630	A/G	cg16586182	chr3:47516702	SCAP	-0.74	-13.02	-0.52	3.04e-33	Colorectal cancer;
LGG	cis	rs3857536	0.679	rs1964856	chr6:66952886	G/A	cg07460842	chr6:66804631	NA	-0.44	-7.34	-0.32	1e-12	Blood trace element (Cu levels);
LGG	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg11965913	chr1:205819406	PM20D1	0.45	7.03	0.31	7.43e-12	Parkinson's disease;
LGG	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg06766960	chr11:133703094	NA	-0.59	-12.03	-0.49	3.35e-29	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27482856	chr7:99214447	ZNF498	0.44	7.36	0.32	8.33e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14893161	chr1:205819251	PM20D1	0.86	20.08	0.68	5.89e-65	Menarche (age at onset);
LGG	cis	rs4237845	0.967	rs4553410	chr12:58301211	G/A	cg02175503	chr12:58329896	NA	0.72	13.77	0.54	2.21e-36	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg11584989	chr19:19387371	SF4	-0.38	-6.75	-0.3	4.42e-11	Tonsillectomy;
LGG	cis	rs11645898	0.810	rs72787046	chr16:72079342	A/G	cg14768367	chr16:72042858	DHODH	-0.88	-11.59	-0.47	1.98e-27	Blood protein levels;
LGG	cis	rs4740619	0.905	rs955369	chr9:15787502	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.35	-0.43	1.05e-22	Body mass index;
LGG	cis	rs1506636	1.000	rs659416	chr7:123401764	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.3	-0.65	1.1e-56	Plateletcrit;Platelet count;
LGG	cis	rs9470366	0.527	rs733590	chr6:36645203	A/G	cg08179530	chr6:36648295	CDKN1A	0.75	13.59	0.53	1.23e-35	QRS duration;
LGG	cis	rs7811142	1.000	rs73405353	chr7:100091215	G/A	cg11814155	chr7:99998594	ZCWPW1	0.62	9.62	0.41	4.15e-20	Platelet count;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg08180459	chr4:100870737	LOC256880;H2AFZ	0.48	7.64	0.33	1.25e-13	Response to platinum-based chemotherapy (carboplatin);
LGG	trans	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.34e-17	Bladder cancer;
LGG	cis	rs11098499	0.691	rs9996644	chr4:120238877	G/T	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.7e-21	Corneal astigmatism;
LGG	cis	rs1577917	1.000	rs12216328	chr6:86703418	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.3	-0.53	2.07e-34	Response to antipsychotic treatment;
LGG	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs17102423	0.594	rs1953232	chr14:65570386	A/C	cg11161011	chr14:65562177	MAX	0.65	12.06	0.49	2.55e-29	Obesity-related traits;
LGG	trans	rs6011368	0.678	rs6089801	chr20:62911391	T/G	cg13869341	chr1:15865	WASH5P	0.57	10.37	0.43	8.6e-23	Clozapine-induced cytotoxicity;
LGG	cis	rs35740288	0.770	rs62023931	chr15:86132752	T/C	cg07943548	chr15:86304357	KLHL25	-0.32	-6.66	-0.3	7.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg17178900	chr1:205818956	PM20D1	0.56	12.61	0.51	1.54e-31	Menarche (age at onset);
LGG	cis	rs478607	0.831	rs11602411	chr11:64449223	A/G	cg19395706	chr11:64412079	NRXN2	-0.42	-7.25	-0.32	1.71e-12	Urate levels;
LGG	cis	rs11688816	0.569	rs7591708	chr2:63022050	T/C	cg17519650	chr2:63277830	OTX1	-0.59	-10.02	-0.42	1.59e-21	Body mass index;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg18979581	chr8:9413415	TNKS	-0.43	-7.59	-0.33	1.8e-13	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs9633740	0.947	rs7096909	chr10:82284512	A/T	cg01528321	chr10:82214614	TSPAN14	-1.03	-16.13	-0.6	8.65e-47	Post bronchodilator FEV1;
LGG	cis	rs593982	0.843	rs680948	chr11:65472394	C/G	cg08755490	chr11:65554678	OVOL1	0.68	8.44	0.37	4.19e-16	Atopic dermatitis;
LGG	cis	rs9611565	0.592	rs4822038	chr22:41958495	G/A	cg06481639	chr22:41940642	POLR3H	-0.61	-8.63	-0.37	1.03e-16	Vitiligo;
LGG	cis	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.67e-12	Neuroticism;
LGG	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg06889755	chr6:150326021	RAET1K	-0.39	-8.22	-0.36	2.05e-15	Alopecia areata;
LGG	cis	rs7998202	0.667	rs99126	chr13:113359336	C/G	cg02820901	chr13:113351484	ATP11A	-0.57	-6.7	-0.3	6.04e-11	Glycated hemoglobin levels;
LGG	cis	rs28374715	0.733	rs7167706	chr15:41569644	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.3	-26.88	-0.78	1.34e-96	Ulcerative colitis;
LGG	trans	rs4714291	0.928	rs761799	chr6:39990050	T/A	cg02267698	chr19:7991119	CTXN1	0.59	9.14	0.39	1.96e-18	Strep throat;
LGG	cis	rs11203032	0.831	rs11203023	chr10:90954240	T/C	cg16672925	chr10:90967113	CH25H	0.51	7.89	0.34	2.25e-14	Heart failure;
LGG	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg14673194	chr17:80132900	CCDC57	0.47	8.52	0.37	2.25e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.43	7.03	0.31	7.68e-12	Carotid intima media thickness;
LGG	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.68	-0.3	7.04e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2072732	0.861	rs67025412	chr1:2951806	T/C	cg08733933	chr1:2954429	NA	-0.39	-8.75	-0.38	4.14e-17	Plateletcrit;
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg26513180	chr16:89883248	FANCA	0.95	21.84	0.71	3.16e-73	Vitiligo;
LGG	cis	rs1318772	0.932	rs35274088	chr5:112872958	G/T	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg18379455	chr17:41446167	NA	-0.31	-7.27	-0.32	1.54e-12	Menopause (age at onset);
LGG	trans	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg18335740	chr13:41363409	SLC25A15	0.87	20.81	0.7	2.15e-68	Lewy body disease;
LGG	cis	rs11252926	0.966	rs61831030	chr10:578869	C/T	cg08603382	chr10:743973	NA	-0.67	-12.78	-0.51	3.09e-32	Psychosis in Alzheimer's disease;
LGG	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15532942	chr18:77220712	NFATC1	0.47	7.67	0.34	1.03e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg23029597	chr12:123009494	RSRC2	0.94	17.3	0.63	4.53e-52	Body mass index;
LGG	cis	rs3741151	0.881	rs10898917	chr11:73065979	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	10.03	0.42	1.46e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9517320	0.534	rs9556962	chr13:99156648	C/T	cg03701759	chr13:99174930	STK24	-0.36	-6.91	-0.31	1.63e-11	Longevity;
LGG	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg25358565	chr5:93447407	FAM172A	-0.74	-10.5	-0.44	2.74e-23	Diabetic retinopathy;
LGG	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg21238619	chr17:78079768	GAA	0.52	10.13	0.43	6.25e-22	Yeast infection;
LGG	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg17467752	chr17:38218738	THRA	-0.45	-7.23	-0.32	2.06e-12	Self-reported allergy;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.53	9.57	0.41	6.47e-20	Longevity;
LGG	cis	rs4803468	1.000	rs11880539	chr19:41918949	A/C	cg14132834	chr19:41945861	ATP5SL	0.52	9.38	0.4	2.86e-19	Height;
LGG	cis	rs6754311	0.593	rs1446584	chr2:136419961	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-13.08	-0.52	1.76e-33	Mosquito bite size;
LGG	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg15212455	chr7:39170539	POU6F2	0.51	11.95	0.49	7.29e-29	IgG glycosylation;
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.84	0.3	2.54e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg08975724	chr8:8085496	FLJ10661	0.48	9.12	0.39	2.39e-18	Joint mobility (Beighton score);
LGG	cis	rs7614311	0.681	rs10510903	chr3:63970192	C/G	cg22134162	chr3:63841271	THOC7	-0.44	-8.02	-0.35	8.7e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg19455335	chr8:22457658	C8orf58	-0.4	-8.11	-0.35	4.53e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7811142	0.943	rs73403312	chr7:100024153	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs9326248	1.000	rs7107152	chr11:117056080	C/T	cg20608306	chr11:116969690	SIK3	-0.27	-7.55	-0.33	2.26e-13	Blood protein levels;
LGG	trans	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg02002194	chr4:3960332	NA	0.45	8.7	0.37	5.79e-17	Mood instability;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.15e-21	Aortic root size;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21160610	chr15:43662639	TUBGCP4;ZSCAN29	-0.41	-6.68	-0.3	7.05e-11	Brain structure;
LGG	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg12310025	chr6:25882481	NA	0.45	8.01	0.35	9.72e-15	Blood metabolite levels;
LGG	cis	rs61906588	0.595	rs556436	chr11:116352523	A/G	cg12564567	chr11:116371188	NA	-0.38	-6.96	-0.31	1.2e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs853679	0.517	rs16893666	chr6:28054707	C/T	cg18032046	chr6:28092343	ZSCAN16	0.56	7.52	0.33	2.85e-13	Depression;
LGG	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg00376283	chr12:123451042	ABCB9	0.67	11.77	0.48	3.63e-28	Neutrophil percentage of white cells;
LGG	cis	rs3796352	1.000	rs11707780	chr3:53084326	A/G	cg12962167	chr3:53033115	SFMBT1	-0.65	-7.23	-0.32	2.04e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.12	17.88	0.64	9.78e-55	Platelet count;
LGG	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.77	0.3	4.02e-11	Carotid intima media thickness;
LGG	cis	rs6831352	0.819	rs1230155	chr4:99989259	C/T	cg13256891	chr4:100009986	ADH5	0.5	8.53	0.37	2.08e-16	Alcohol dependence;
LGG	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg11502198	chr6:26597334	ABT1	0.55	9.4	0.4	2.52e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7617773	1.000	rs6442109	chr3:48192981	G/A	cg11946769	chr3:48343235	NME6	-0.54	-8.58	-0.37	1.47e-16	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	trans	rs2898857	0.545	rs12942379	chr17:47358733	C/T	cg11430096	chr6:110968061	CDK19	0.48	8.38	0.36	6.55e-16	Cancer;
LGG	cis	rs921968	0.541	rs514356	chr2:219375018	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07826235	chr1:167906354	BRP44;DCAF6	-0.37	-6.66	-0.3	7.8e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.7	-0.34	8.38e-14	Life satisfaction;
LGG	cis	rs7216064	0.953	rs12601759	chr17:65955284	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.05	-0.39	3.89e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg07120314	chr15:79043507	NA	0.67	12.42	0.5	8.81e-31	Coronary artery disease or large artery stroke;
LGG	cis	rs12458462	0.892	rs58675823	chr18:77463672	G/A	cg11879182	chr18:77439856	CTDP1	0.79	14.84	0.57	4.71e-41	Monocyte count;
LGG	cis	rs78487399	0.808	rs74821293	chr2:43742923	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-6.87	-0.3	2.11e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.13	0.35	3.83e-15	Longevity;
LGG	cis	rs2952156	0.883	rs8077172	chr17:37834977	G/T	cg00129232	chr17:37814104	STARD3	-0.75	-16.44	-0.61	3.47e-48	Asthma;
LGG	cis	rs9596863	0.898	rs8000371	chr13:54344502	A/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.16	0.32	3.15e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs988958	0.565	rs1440095	chr2:42289666	T/C	cg19376973	chr2:42229025	NA	0.38	6.87	0.3	2.01e-11	Hypospadias;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.54	-0.44	2.04e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	trans	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3825932	0.961	rs11856301	chr15:79232330	T/C	cg25744700	chr15:79237217	CTSH	0.35	6.89	0.3	1.85e-11	Type 1 diabetes;
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg10056627	chr6:42928773	GNMT	0.27	7.15	0.32	3.39e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.04	-0.31	7.15e-12	Red cell distribution width;
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg13009111	chr11:71350975	NA	-0.32	-7.05	-0.31	6.64e-12	Retinal vascular caliber;
LGG	cis	rs735539	1.000	rs6490604	chr13:21284828	A/G	cg04906043	chr13:21280425	IL17D	-0.58	-9.48	-0.4	1.36e-19	Dental caries;
LGG	trans	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs12210905	1.000	rs9379965	chr6:27227061	C/T	cg15325629	chr6:28072465	NA	0.71	6.71	0.3	5.68e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1014246	0.796	rs2420331	chr10:118471197	A/G	cg14919929	chr10:118506882	NA	-0.62	-12.42	-0.5	8.74e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs2235573	0.653	rs3026670	chr22:38426774	T/C	cg19894588	chr14:64061835	NA	0.5	8.44	0.37	4.23e-16	Glioblastoma;Glioma;
LGG	cis	rs8054556	0.647	rs4077410	chr16:29998200	A/G	cg06326092	chr16:30034487	C16orf92	0.35	7.11	0.31	4.51e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10929925	0.931	rs2609188	chr2:6159942	T/C	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs12618769	0.625	rs2278207	chr2:99163261	T/A	cg18455616	chr2:99124870	INPP4A	0.27	7.65	0.33	1.19e-13	Bipolar disorder;
LGG	cis	rs12474201	0.619	rs17821827	chr2:46918682	C/T	cg06386533	chr2:46925753	SOCS5	0.57	8.63	0.37	9.74e-17	Height;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg06138931	chr13:21896616	NA	0.45	9.79	0.41	1.12e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10739663	0.520	rs13294786	chr9:128156961	A/G	cg14078157	chr9:128172775	NA	-0.57	-10.82	-0.45	1.75e-24	Resting heart rate;
LGG	cis	rs11098499	0.955	rs11944880	chr4:120159334	A/G	cg24375607	chr4:120327624	NA	-0.63	-10.46	-0.44	3.83e-23	Corneal astigmatism;
LGG	cis	rs7666738	0.830	rs7678557	chr4:99057329	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.46	0.37	3.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7712401	0.601	rs30045	chr5:122271619	C/T	cg19412675	chr5:122181750	SNX24	0.41	6.92	0.31	1.55e-11	Mean platelet volume;
LGG	cis	rs4481887	0.741	rs6681758	chr1:248540413	T/A	cg00666640	chr1:248458726	OR2T12	0.54	9.09	0.39	2.86e-18	Common traits (Other);
LGG	cis	rs12946454	0.696	rs4792819	chr17:43247957	A/C	cg10701640	chr17:43249399	NA	0.39	7.16	0.32	3.23e-12	Systolic blood pressure;
LGG	cis	rs1062177	1.000	rs2915878	chr5:151149662	A/G	cg00977110	chr5:151150581	G3BP1	0.49	7.93	0.35	1.69e-14	Preschool internalizing problems;
LGG	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23598886	chr18:12777645	NA	0.75	10.45	0.44	4.23e-23	Inflammatory skin disease;
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.7	-0.48	6.74e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2718058	0.501	rs2717938	chr7:37702545	C/T	cg24998770	chr7:37888106	TXNDC3	-0.4	-7.2	-0.32	2.42e-12	Alzheimer's disease (late onset);
LGG	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	cis	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg21775007	chr8:11205619	TDH	-0.51	-7.77	-0.34	4.99e-14	Triglycerides;
LGG	trans	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-9.02	-0.39	4.89e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg04672837	chr16:48644449	N4BP1	0.52	8.44	0.37	4.01e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.51	-0.33	3.02e-13	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg15971980	chr6:150254442	NA	0.44	8.26	0.36	1.56e-15	Lung cancer;
LGG	cis	rs6982240	0.514	rs9324543	chr8:142275662	T/C	cg20799268	chr8:142275649	NA	-0.25	-6.96	-0.31	1.17e-11	Tonsillectomy;
LGG	cis	rs258892	0.895	rs34660	chr5:72151858	T/A	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg05091796	chr16:4465799	CORO7	-0.74	-12.51	-0.5	3.82e-31	Schizophrenia;
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg03036210	chr16:89904091	SPIRE2	-0.64	-7.52	-0.33	2.87e-13	Skin colour saturation;
LGG	cis	rs7208859	0.623	rs1054400	chr17:29109954	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.51	0.33	3.03e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs988958	0.958	rs13419707	chr2:42280927	C/T	cg27428208	chr2:42229179	NA	0.39	7.04	0.31	6.87e-12	Hypospadias;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.29	-0.36	1.2e-15	Menopause (age at onset);
LGG	cis	rs73198271	0.740	rs11781430	chr8:8651733	G/C	cg01851573	chr8:8652454	MFHAS1	0.38	6.92	0.31	1.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18252515	chr7:66147081	NA	0.42	6.95	0.31	1.27e-11	Aortic root size;
LGG	cis	rs3858526	0.920	rs11039548	chr11:5930283	G/A	cg05234568	chr11:5960015	NA	-0.72	-11.8	-0.48	2.9e-28	DNA methylation (variation);
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg00129232	chr17:37814104	STARD3	0.61	11.43	0.47	8.14e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7587476	0.736	rs62202002	chr2:215690600	T/C	cg04004882	chr2:215674386	BARD1	0.55	8.05	0.35	6.95e-15	Neuroblastoma;
LGG	cis	rs2070488	0.730	rs2268759	chr3:38514327	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.35	0.55	6.72e-39	Electrocardiographic conduction measures;
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.72	-0.56	1.64e-40	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9611565	0.802	rs73176694	chr22:41786788	C/T	cg03806693	chr22:41940476	POLR3H	-0.98	-17.41	-0.63	1.34e-52	Vitiligo;
LGG	cis	rs12477438	0.765	rs72957180	chr2:99694452	G/A	cg08885076	chr2:99613938	TSGA10	-0.59	-12.09	-0.49	2.05e-29	Chronic sinus infection;
LGG	cis	rs5758659	0.652	rs133335	chr22:42416056	C/T	cg15128208	chr22:42549153	NA	0.37	7.28	0.32	1.47e-12	Cognitive function;
LGG	cis	rs4555082	0.834	rs2816651	chr14:105708470	A/G	cg10792982	chr14:105748885	BRF1	0.67	14.01	0.55	2.06e-37	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9296092	0.538	rs75652975	chr6:33516251	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.82	-0.7	2.08e-68	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs870825	0.872	rs12506750	chr4:185571123	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	16.83	0.62	6.2e-50	Blood protein levels;
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg21775007	chr8:11205619	TDH	-0.46	-7.32	-0.32	1.07e-12	Neuroticism;
LGG	trans	rs2727020	0.590	rs7949936	chr11:49378902	G/A	cg03929089	chr4:120376271	NA	-0.78	-11.63	-0.48	1.31e-27	Coronary artery disease;
LGG	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-9.56	-0.41	7.18e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7264396	0.790	rs761825	chr20:34194054	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.45	6.98	0.31	1.02e-11	Total cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11073833	chr1:153936127	SLC39A1	0.44	6.77	0.3	3.82e-11	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.77	0.34	4.98e-14	Retinal vascular caliber;
LGG	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg21926883	chr2:100939477	LONRF2	-0.47	-8.48	-0.37	2.94e-16	Intelligence (multi-trait analysis);
LGG	cis	rs12580194	0.554	rs59097302	chr12:55719030	C/T	cg19537932	chr12:55886519	OR6C68	-0.54	-9.42	-0.4	2.15e-19	Cancer;
LGG	cis	rs7129556	0.701	rs72947668	chr11:77428933	C/T	cg12586386	chr11:77299805	AQP11	0.46	7.37	0.32	8.16e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg12365681	chr11:67980256	SUV420H1	0.39	6.89	0.3	1.89e-11	Body mass index;
LGG	trans	rs7939886	0.920	rs11227857	chr11:56082112	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.39e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6598955	0.627	rs12143920	chr1:26575834	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	cis	rs2798269	0.902	rs12861578	chr13:22092762	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.27	-0.32	1.59e-12	PR segment;
LGG	cis	rs1943345	0.686	rs10898088	chr11:82874970	G/A	cg07047830	chr11:82868014	PCF11	0.56	10.39	0.43	7.35e-23	Obesity-related traits;
LGG	cis	rs1983891	0.955	rs6917029	chr6:41548540	C/G	cg20194872	chr6:41519635	FOXP4	0.6	10.4	0.44	6.69e-23	Prostate cancer;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg11584989	chr19:19387371	SF4	0.39	7.1	0.31	4.81e-12	Tonsillectomy;
LGG	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg00700412	chr12:58011837	NA	0.35	7.03	0.31	7.55e-12	Multiple sclerosis;
LGG	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.24e-17	Height;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.965	rs499076	chr11:95546341	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs4775906	chr15:45638294	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.75	0.34	5.92e-14	Homoarginine levels;
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.7	-0.51	6.42e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs1865760	0.865	rs9467645	chr6:25955176	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg05941027	chr17:61774174	LIMD2	0.35	8.84	0.38	2.06e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12701220	0.503	rs13222294	chr7:1172969	G/A	cg00990874	chr7:1149470	C7orf50	-0.72	-11.77	-0.48	3.71e-28	Bronchopulmonary dysplasia;
LGG	cis	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg24308560	chr3:49941425	MST1R	0.23	7.2	0.32	2.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.904	rs11655531	chr17:37697959	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.56	-0.47	2.56e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4740619	0.619	rs1328277	chr9:16029126	G/C	cg14451791	chr9:16040625	NA	-0.42	-11.15	-0.46	9.68e-26	Body mass index;
LGG	trans	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs67311347	1.000	rs73080126	chr3:40509153	A/G	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs9462027	0.583	rs11755420	chr6:34760956	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs7927771	0.800	rs11039200	chr11:47379646	A/C	cg20307385	chr11:47447363	PSMC3	-0.55	-9.73	-0.41	1.8e-20	Subjective well-being;
LGG	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.63	0.44	9.47e-24	Lung cancer in ever smokers;
LGG	cis	rs1927790	0.727	rs9554338	chr13:96966314	G/A	cg02571835	chr13:96230311	CLDN10	-0.35	-7.09	-0.31	4.98e-12	Body mass index;
LGG	cis	rs1793639	0.967	rs1015053	chr11:131933511	A/T	cg13908476	chr11:131942942	NTM	0.44	9.32	0.4	4.81e-19	Myopia;
LGG	cis	rs4538187	0.865	rs11686956	chr2:63938708	T/G	cg02541582	chr2:64069798	UGP2	-0.55	-12.59	-0.51	1.76e-31	Systolic blood pressure;
LGG	cis	rs397969	0.596	rs17668529	chr17:19899788	G/T	cg13482628	chr17:19912719	NA	0.52	8.51	0.37	2.4e-16	Platelet count;
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs2290257	chr2:100016713	G/C	cg23527387	chr2:100056660	REV1	0.45	9.93	0.42	3.53e-21	Chronic sinus infection;
LGG	cis	rs10227331	1.000	rs10255520	chr7:157292087	C/T	cg04156418	chr7:157293606	NA	0.64	14.95	0.57	1.65e-41	Inattentive symptoms;
LGG	cis	rs2410601	0.520	rs1426916	chr8:18882501	C/G	cg19414122	chr8:18896631	NA	0.4	7.22	0.32	2.11e-12	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs7215564	0.908	rs34969384	chr17:78678716	A/G	cg16980736	chr17:78789706	RPTOR	-0.61	-8.09	-0.35	5.23e-15	Myopia (pathological);
LGG	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.23e-14	HDL cholesterol;
LGG	cis	rs2404602	0.684	rs3910756	chr15:76945369	C/T	cg23625390	chr15:77176239	SCAPER	-0.69	-12.43	-0.5	8.25e-31	Blood metabolite levels;
LGG	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs9300255	0.569	rs1727320	chr12:123700476	T/A	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs6435862	0.517	rs6757091	chr2:215672793	G/C	cg04004882	chr2:215674386	BARD1	-0.61	-10.58	-0.44	1.36e-23	Neuroblastoma (high-risk);
LGG	cis	rs7617773	0.780	rs13082158	chr3:48372470	T/C	cg11946769	chr3:48343235	NME6	0.7	11.6	0.47	1.66e-27	Coronary artery disease;
LGG	cis	rs61990749	0.597	rs176946	chr14:78178439	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.22	0.32	2.1e-12	Fibroblast growth factor basic levels;
LGG	cis	rs270601	0.913	rs273916	chr5:131659830	C/A	cg07395648	chr5:131743802	NA	-0.48	-9.9	-0.42	4.18e-21	Acylcarnitine levels;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg07342512	chr1:65886002	LEPROT;LEPR	0.37	6.76	0.3	4.2e-11	Hepatitis;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg19182353	chr11:118479428	PHLDB1	-0.56	-11.35	-0.47	1.58e-26	Cholesterol, total;
LGG	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.86	-0.42	6.06e-21	Coronary artery disease;
LGG	cis	rs537626	0.767	rs680618	chr11:69316881	T/C	cg08353955	chr11:69289746	NA	-0.62	-9.19	-0.39	1.28e-18	Breast cancer (early onset);
LGG	cis	rs17209837	1.000	rs2302385	chr7:87091826	T/C	cg00919237	chr7:87102261	ABCB4	-0.69	-11.18	-0.46	7.65e-26	Gallbladder cancer;
LGG	cis	rs908922	0.651	rs1885531	chr1:152480233	T/G	cg20991723	chr1:152506922	NA	-0.69	-13.29	-0.53	2.17e-34	Hair morphology;
LGG	cis	rs1552244	0.882	rs17081288	chr3:10042113	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.91	-0.51	8.39e-33	Alzheimer's disease;
LGG	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg18393722	chr15:85113863	UBE2QP1	0.4	6.71	0.3	5.62e-11	Schizophrenia;
LGG	cis	rs6547631	0.808	rs13011848	chr2:85907694	G/A	cg24620635	chr2:85921963	GNLY	0.39	7.47	0.33	3.93e-13	Blood protein levels;
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg08925882	chr11:67350491	GSTP1	-0.35	-6.87	-0.3	2.03e-11	Mean corpuscular volume;
LGG	cis	rs78456975	0.527	rs72778003	chr2:1571487	G/A	cg12573674	chr2:1569213	NA	-0.63	-9.53	-0.41	8.63e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg05484508	chr16:89589025	SPG7	0.47	7.6	0.33	1.61e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6429082	0.818	rs704706	chr1:235614378	G/A	cg26050004	chr1:235667680	B3GALNT2	0.6	9.85	0.42	6.73e-21	Adiposity;
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	cis	rs13132184	0.507	rs35308860	chr4:38035526	T/G	cg24826020	chr4:38070998	TBC1D1	0.5	8.49	0.37	2.83e-16	Verbal declarative memory;
LGG	cis	rs5769707	0.681	rs4824068	chr22:50024801	G/A	cg06623630	chr22:50017776	C22orf34	-0.49	-10.08	-0.42	9.77e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs11771526	0.901	rs10282699	chr7:32297967	C/T	cg27532318	chr7:32358331	NA	0.72	7.5	0.33	3.3e-13	Body mass index;
LGG	trans	rs853679	0.513	rs13437444	chr6:28070998	C/T	cg01620082	chr3:125678407	NA	-0.54	-6.73	-0.3	4.91e-11	Depression;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg18681998	chr4:17616180	MED28	0.86	18.37	0.65	5.37e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.12	0.62	3.06e-51	Cognitive function;
LGG	trans	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg07393940	chr7:158741817	NA	-0.6	-10.75	-0.45	3.13e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1018836	0.668	rs9297857	chr8:91480964	A/C	cg16814680	chr8:91681699	NA	-0.66	-11.26	-0.46	3.67e-26	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4363385	0.747	rs1015996	chr1:152976108	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	cis	rs41271473	0.898	rs72750015	chr1:228811318	A/G	cg10167378	chr1:228756711	NA	0.57	7.82	0.34	3.52e-14	Chronic lymphocytic leukemia;
LGG	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg13385794	chr1:248469461	NA	0.48	8.21	0.36	2.29e-15	Common traits (Other);
LGG	cis	rs7572733	0.515	rs6724526	chr2:198858401	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.09	0.46	1.65e-25	Dermatomyositis;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg18402987	chr7:1209562	NA	0.67	9.35	0.4	3.74e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs68170813	0.559	rs77013162	chr7:107071674	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.11	-0.43	7.54e-22	Coronary artery disease;
LGG	cis	rs6546550	0.867	rs4401231	chr2:70063563	G/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.99	-0.35	1.06e-14	Prevalent atrial fibrillation;
LGG	cis	rs3733585	0.638	rs17185835	chr4:9958180	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	5.22e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg00405596	chr8:11794950	NA	-0.6	-10.52	-0.44	2.32e-23	Monocyte count;
LGG	cis	rs4671458	0.762	rs17618045	chr2:63793255	T/C	cg17519650	chr2:63277830	OTX1	-0.56	-7.31	-0.32	1.18e-12	Subjective well-being;
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-10.91	-0.45	8.06e-25	Prostate cancer;
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg24101359	chr6:42928495	GNMT	0.51	14.36	0.56	5.92e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9890032	0.581	rs62070592	chr17:29022549	T/C	cg13385521	chr17:29058706	SUZ12P	0.45	6.75	0.3	4.46e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2712184	0.756	rs2712181	chr2:217654869	C/T	cg05032264	chr2:217675019	NA	0.42	8.91	0.38	1.15e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg04851639	chr8:1020857	NA	-0.34	-7.15	-0.32	3.41e-12	Schizophrenia;
LGG	cis	rs1401999	0.714	rs13066518	chr3:183635498	T/A	cg01324343	chr3:183735012	ABCC5	0.66	12.7	0.51	6.48e-32	Anterior chamber depth;
LGG	cis	rs11150038	0.623	rs7186388	chr16:78019753	G/A	cg04733911	chr16:78082701	NA	0.57	7.36	0.32	8.67e-13	Colorectal or endometrial cancer;
LGG	trans	rs208520	0.802	rs208516	chr6:66946119	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.46	-0.58	8.81e-44	Exhaled nitric oxide output;
LGG	cis	rs34330	0.562	rs12229100	chr12:12865836	A/G	cg09462578	chr12:12878428	APOLD1	0.58	7.89	0.34	2.24e-14	Systemic lupus erythematosus;
LGG	cis	rs36051895	0.664	rs3780374	chr9:5099677	G/A	cg02405213	chr9:5042618	JAK2	-0.8	-14.92	-0.57	2.27e-41	Pediatric autoimmune diseases;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17910375	chr12:57023577	BAZ2A	0.46	6.69	0.3	6.52e-11	Gut microbiome composition (summer);
LGG	cis	rs1003719	0.788	rs7275582	chr21:38451130	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.25	0.63	7.24e-52	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27167642	chr13:29105544	NA	0.59	9.65	0.41	3.32e-20	Gut microbiome composition (summer);
LGG	trans	rs11992162	0.967	rs7836456	chr8:11829175	T/G	cg13009111	chr11:71350975	NA	0.36	8.36	0.36	7.67e-16	Monocyte count;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs9303280	0.806	rs35569035	chr17:38035624	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.17	-0.32	3.04e-12	Self-reported allergy;
LGG	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg14664628	chr15:75095509	CSK	-0.89	-18.11	-0.64	8.44e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7615952	0.599	rs12485717	chr3:125707075	C/T	cg06494592	chr3:125709126	NA	0.54	6.89	0.31	1.8e-11	Blood pressure (smoking interaction);
LGG	cis	rs262150	0.545	rs73167302	chr7:158789762	G/A	cg19418458	chr7:158789849	NA	0.48	7.24	0.32	1.86e-12	Facial morphology (factor 20);
LGG	cis	rs12431410	0.514	rs7144616	chr14:60221449	A/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.28	-0.32	1.44e-12	Schizophrenia;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.34	-8.93	-0.38	1.03e-17	IgG glycosylation;
LGG	cis	rs12200782	0.790	rs72840194	chr6:26361369	A/G	cg11502198	chr6:26597334	ABT1	-0.87	-7.34	-0.32	9.93e-13	Small cell lung carcinoma;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg02018176	chr4:1364513	KIAA1530	0.41	9.31	0.4	5.3e-19	Obesity-related traits;
LGG	cis	rs6840360	0.582	rs7691601	chr4:152321631	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	6.96	0.31	1.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs9303401	0.646	rs9892425	chr17:57241938	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.46	7.57	0.33	2.1e-13	Cognitive test performance;
LGG	cis	rs10864302	0.525	rs1894656	chr1:7417331	C/T	cg08923594	chr1:7462176	CAMTA1	0.67	8.29	0.36	1.27e-15	Photic sneeze reflex;
LGG	cis	rs713587	0.563	rs2384057	chr2:25100167	C/G	cg04586622	chr2:25135609	ADCY3	0.42	11.29	0.46	2.93e-26	Body mass index in non-asthmatics;
LGG	cis	rs2806561	1.000	rs2746553	chr1:23493246	T/C	cg19743168	chr1:23544995	NA	0.34	7.16	0.32	3.29e-12	Height;
LGG	cis	rs7084402	0.967	rs1649055	chr10:60320045	T/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.31e-12	Refractive error;
LGG	cis	rs4466137	0.953	rs6869030	chr5:83007311	C/T	cg16102102	chr5:83017553	HAPLN1	-0.6	-11.27	-0.46	3.46e-26	Prostate cancer;
LGG	cis	rs2594989	0.831	rs13324245	chr3:11570769	T/G	cg01796438	chr3:11312864	ATG7	0.53	7.24	0.32	1.9e-12	Circulating chemerin levels;
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg16270222	chr17:41446396	NA	0.28	6.7	0.3	5.91e-11	Menopause (age at onset);
LGG	cis	rs920590	0.721	rs67989257	chr8:19660278	G/A	cg03894339	chr8:19674705	INTS10	0.63	10.23	0.43	2.8e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6456156	0.586	rs12527827	chr6:167469271	C/T	cg07741184	chr6:167504864	NA	0.4	9.16	0.39	1.68e-18	Primary biliary cholangitis;
LGG	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.24	-0.32	1.85e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs6598955	0.671	rs10493030	chr1:26561856	T/C	cg04990556	chr1:26633338	UBXN11	0.61	8.24	0.36	1.72e-15	Obesity-related traits;
LGG	cis	rs6867032	0.527	rs9312971	chr5:2012888	C/A	cg26168224	chr5:2018326	NA	0.94	18.23	0.65	2.36e-56	Gut microbiome composition (winter);
LGG	cis	rs10274279	0.688	rs4716762	chr7:157403939	C/T	cg09270525	chr7:157391030	PTPRN2	0.84	11.18	0.46	7.26e-26	Myopia (pathological);
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	8.09e-13	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03768106	chr11:111957237	TIMM8B;SDHD	0.42	6.94	0.31	1.34e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6967414	0.786	rs9639026	chr7:6746736	A/G	cg00387323	chr7:6746715	ZNF12	0.66	7.32	0.32	1.14e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg21856205	chr7:94953877	PON1	0.41	9.67	0.41	2.83e-20	Paraoxonase activity;
LGG	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg19812747	chr11:111475976	SIK2	-0.5	-10.62	-0.44	9.77e-24	Primary sclerosing cholangitis;
LGG	cis	rs62400317	0.893	rs62436782	chr6:45143118	T/A	cg18551225	chr6:44695536	NA	-0.61	-10.15	-0.43	5.24e-22	Total body bone mineral density;
LGG	cis	rs73198271	0.562	rs73519953	chr8:8660278	G/T	cg01851573	chr8:8652454	MFHAS1	0.53	8.6	0.37	1.21e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6724607	1.000	rs4853513	chr2:191479455	C/T	cg10560079	chr2:191398806	TMEM194B	-0.35	-7.54	-0.33	2.52e-13	Pulse pressure;
LGG	cis	rs1046896	0.621	rs7216058	chr17:80696622	A/C	cg02711726	chr17:80685570	FN3KRP	-0.62	-11.57	-0.47	2.22e-27	Glycated hemoglobin levels;
LGG	cis	rs11190604	1.000	rs4919471	chr10:102299239	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.38	0.32	7.28e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs2235573	0.551	rs139897	chr22:38399098	A/G	cg19894588	chr14:64061835	NA	0.59	9.79	0.41	1.1e-20	Glioblastoma;Glioma;
LGG	cis	rs3736594	0.513	rs59876138	chr2:27792323	A/C	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs644799	0.526	rs530914	chr11:95632156	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.65	12.39	0.5	1.18e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg16976520	chr7:158588852	ESYT2	0.63	7.11	0.31	4.51e-12	Hippocampal volume;
LGG	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg08975724	chr8:8085496	FLJ10661	0.46	8.96	0.38	8.27e-18	Mood instability;
LGG	cis	rs7552404	0.855	rs385897	chr1:76106962	T/C	cg03433033	chr1:76189801	ACADM	-0.78	-13.04	-0.52	2.42e-33	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3740540	0.530	rs2362506	chr10:126290751	C/G	cg04949429	chr10:126290192	LHPP	0.6	11.5	0.47	4.45e-27	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9467711	0.606	rs9393713	chr6:26373678	C/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.18	0.36	2.73e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9419702	0.614	rs9419567	chr10:133535149	C/G	cg20568497	chr10:133558893	NA	0.35	7.5	0.33	3.39e-13	Survival in rectal cancer;
LGG	cis	rs1018836	0.599	rs9643295	chr8:91492283	T/G	cg16814680	chr8:91681699	NA	-0.6	-9.9	-0.42	4.4e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs889312	0.521	rs12651942	chr5:56088484	C/T	cg12654349	chr5:56205094	C5orf35	-0.38	-6.81	-0.3	3.08e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs9486719	1.000	rs2145535	chr6:97034715	G/A	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.72	-0.3	5.51e-11	Migraine;Coronary artery disease;
LGG	cis	rs796364	0.951	rs13029537	chr2:200998950	T/C	cg23649088	chr2:200775458	C2orf69	-0.6	-7.93	-0.35	1.66e-14	Schizophrenia;
LGG	cis	rs7662987	0.517	rs2851277	chr4:100022910	G/T	cg12011299	chr4:100065546	ADH4	0.4	7.88	0.34	2.32e-14	Smoking initiation;
LGG	cis	rs7937890	0.559	rs1548074	chr11:14534825	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.4e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.94	-0.49	7.96e-29	Depression;
LGG	cis	rs11650494	0.908	rs75092916	chr17:47412578	T/C	cg08112188	chr17:47440006	ZNF652	1.33	15.68	0.59	9.63e-45	Prostate cancer;
LGG	cis	rs12449964	0.515	rs7225141	chr17:17570827	A/G	cg05444541	chr17:17804740	TOM1L2	0.34	6.93	0.31	1.41e-11	Coronary artery disease or ischemic stroke;
LGG	cis	rs16937	0.662	rs12137294	chr1:205182872	A/C	cg00889227	chr1:205173544	DSTYK	-0.28	-7.05	-0.31	6.52e-12	Schizophrenia;
LGG	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.59e-59	Diabetic kidney disease;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg03395511	chr6:291903	DUSP22	-0.66	-11.24	-0.46	4.5e-26	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg06558623	chr16:89946397	TCF25	1.24	13.55	0.53	1.82e-35	Skin colour saturation;
LGG	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg19628046	chr18:33552617	C18orf21	0.52	7.6	0.33	1.66e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26671554	chr17:57784674	TMEM49;PTRH2	-0.48	-6.98	-0.31	1.06e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg22535103	chr8:58192502	C8orf71	-0.81	-10.69	-0.44	5.67e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7394190	0.748	rs11000728	chr10:75404300	C/G	cg07699608	chr10:75541558	CHCHD1	0.56	7.65	0.34	1.15e-13	Incident atrial fibrillation;
LGG	cis	rs4906332	1.000	rs11541718	chr14:103852164	C/G	cg26031613	chr14:104095156	KLC1	-0.53	-8.05	-0.35	7.12e-15	Coronary artery disease;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg11584989	chr19:19387371	SF4	-0.42	-7.51	-0.33	3.1e-13	Tonsillectomy;
LGG	cis	rs9325144	0.560	rs6582539	chr12:38630097	C/T	cg13010199	chr12:38710504	ALG10B	-0.62	-12.3	-0.5	2.78e-30	Morning vs. evening chronotype;
LGG	cis	rs295140	0.605	rs295149	chr2:201175244	A/G	cg23649088	chr2:200775458	C2orf69	-0.4	-6.91	-0.31	1.66e-11	QT interval;
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6732160	0.588	rs13407363	chr2:73372558	T/C	cg01422370	chr2:73384389	NA	0.57	9.93	0.42	3.47e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9287719	0.967	rs4669598	chr2:10757838	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15393197	chr17:37213172	NA	0.44	6.88	0.3	1.96e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs4666002	0.956	rs2384656	chr2:27832055	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.72	0.3	5.3e-11	Phospholipid levels (plasma);
LGG	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg11161011	chr14:65562177	MAX	-0.65	-12.54	-0.5	2.83e-31	Obesity-related traits;
LGG	cis	rs12048904	1.000	rs12048904	chr1:101331536	C/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.46	-9.52	-0.4	9.51e-20	Multiple sclerosis;
LGG	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-6.91	-0.31	1.6e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7166081	1.000	rs10518716	chr15:67494823	C/G	cg24231037	chr15:68117551	LBXCOR1	0.32	7.16	0.32	3.28e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg26617929	chr16:1858877	NA	0.61	8.74	0.38	4.33e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg07460842	chr6:66804631	NA	-0.93	-16.37	-0.61	7.73e-48	Exhaled nitric oxide output;
LGG	cis	rs9682041	0.696	rs11917147	chr3:170088448	C/T	cg11886554	chr3:170076028	SKIL	0.67	8.65	0.37	8.42e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10949834	0.878	rs2237501	chr7:73504359	A/G	cg07137043	chr7:73588983	EIF4H	-0.63	-7.25	-0.32	1.71e-12	Verbal memory performance (residualized delayed recall change);
LGG	trans	rs8073060	0.660	rs34184070	chr17:34003810	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.93	0.31	1.41e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10751667	0.643	rs10902238	chr11:944810	G/A	cg22143635	chr11:980567	AP2A2	0.42	7.74	0.34	6.41e-14	Alzheimer's disease (late onset);
LGG	cis	rs2201728	0.739	rs7694752	chr4:100156888	A/T	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs17321999	0.904	rs2089657	chr2:30470178	C/T	cg05247661	chr2:30472410	LBH	0.62	9.72	0.41	1.96e-20	Systemic lupus erythematosus;
LGG	cis	rs9783347	0.961	rs4150526	chr11:18343209	G/A	cg03595886	chr11:18357587	GTF2H1	-0.37	-7.44	-0.33	4.89e-13	Pancreatic cancer;
LGG	cis	rs17030434	0.953	rs74845915	chr4:154696778	G/T	cg14289246	chr4:154710475	SFRP2	-0.76	-11.69	-0.48	7.44e-28	Electrocardiographic conduction measures;
LGG	cis	rs2267681	0.544	rs4726838	chr7:139516964	T/C	cg14116596	chr7:139528673	TBXAS1	0.32	7.05	0.31	6.43e-12	Cervical cancer;
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg12708336	chr17:41446283	NA	-0.31	-7.34	-0.32	9.73e-13	Menopause (age at onset);
LGG	cis	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg22857025	chr5:266934	NA	-1.52	-26.17	-0.77	2.47e-93	Breast cancer;
LGG	cis	rs7503807	0.515	rs869190	chr17:78668593	G/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.41	-0.47	9.74e-27	Obesity;
LGG	cis	rs708547	0.647	rs1718878	chr4:57876955	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.31	0.36	1.05e-15	Response to bleomycin (chromatid breaks);
LGG	cis	rs9916302	0.904	rs7503069	chr17:37697128	C/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.73	-0.59	5.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg00800038	chr16:89945340	TCF25	-0.61	-8.64	-0.37	9.12e-17	Skin colour saturation;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.34	-0.36	8.58e-16	Personality dimensions;
LGG	cis	rs6882046	0.533	rs599402	chr5:88043656	G/C	cg22951263	chr5:87985283	NA	-0.56	-10.43	-0.44	5.24e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	cis	rs4774899	1.000	rs62025331	chr15:57231034	T/C	cg08128148	chr15:57256372	TCF12	-0.34	-7.92	-0.35	1.77e-14	Urinary tract infection frequency;
LGG	cis	rs524281	0.861	rs10896077	chr11:65851733	C/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs7444	0.941	rs2070512	chr22:21949411	A/C	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg04166393	chr7:2884313	GNA12	0.46	8.69	0.37	6.35e-17	Height;
LGG	cis	rs6840360	0.539	rs1443087	chr4:152450095	C/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.1	0.31	4.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg00990874	chr7:1149470	C7orf50	-0.48	-8.44	-0.37	3.98e-16	Bronchopulmonary dysplasia;
LGG	cis	rs721399	0.553	rs59416053	chr8:18240800	G/C	cg18736775	chr8:18248649	NAT2	-0.77	-11.95	-0.49	6.81e-29	Blood metabolite levels;
LGG	trans	rs2562456	0.833	rs552800	chr19:21484642	G/A	cg00806126	chr19:22604979	ZNF98	0.55	7.75	0.34	6.03e-14	Pain;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	trans	rs6921919	1.000	rs6921919	chr6:28325201	C/G	cg06606381	chr12:133084897	FBRSL1	-0.47	-6.66	-0.3	8.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7208859	0.623	rs9890855	chr17:29111707	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs16837677	1.000	rs16837638	chr1:156724953	A/G	cg14991358	chr1:156767203	PRCC	-0.69	-7.42	-0.33	5.73e-13	Sjögren's syndrome;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11328140	chr12:108079443	PWP1	0.38	6.65	0.3	8.26e-11	Bipolar disorder;
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg15212455	chr7:39170539	POU6F2	-0.29	-6.74	-0.3	4.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.08	0.39	3.16e-18	Red blood cell count;
LGG	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg09904177	chr6:26538194	HMGN4	-0.37	-6.66	-0.3	7.81e-11	Schizophrenia;
LGG	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg00129232	chr17:37814104	STARD3	-0.75	-15.94	-0.6	6.77e-46	Asthma;
LGG	cis	rs2153535	0.580	rs2327058	chr6:8447018	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg01411142	chr8:19674711	INTS10	0.47	7.35	0.32	9.33e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2764208	0.602	rs2744952	chr6:34627437	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.58	-0.33	1.91e-13	Systemic lupus erythematosus;
LGG	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg21775007	chr8:11205619	TDH	-0.51	-7.97	-0.35	1.24e-14	Triglycerides;
LGG	cis	rs7208859	0.623	rs9916727	chr17:29107472	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.5	-0.53	3.02e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.98	-0.39	6.72e-18	Response to antipsychotic treatment;
LGG	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.35	-0.32	8.83e-13	Joint mobility (Beighton score);
LGG	cis	rs12950390	0.893	rs11079789	chr17:45849715	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.6	-0.37	1.22e-16	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg11814155	chr7:99998594	ZCWPW1	0.58	8.93	0.38	9.82e-18	Platelet count;
LGG	trans	rs11875185	0.510	rs17692803	chr18:55599009	A/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs2242116	0.760	rs4682845	chr3:46955404	G/C	cg02527881	chr3:46936655	PTH1R	-0.33	-7.98	-0.35	1.15e-14	Birth weight;
LGG	cis	rs10504130	0.666	rs7813414	chr8:52860205	C/T	cg24946253	chr8:52722146	PXDNL	-0.49	-7.52	-0.33	2.9e-13	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg06112835	chr11:68658793	MRPL21	0.64	10.5	0.44	2.74e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.15	0.55	5.18e-38	Lung cancer;
LGG	cis	rs7772486	0.846	rs6908063	chr6:146403618	T/C	cg23711669	chr6:146136114	FBXO30	0.39	6.77	0.3	3.87e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs968567	0.528	rs174582	chr11:61607168	A/G	cg19610905	chr11:61596333	FADS2	-0.69	-10.25	-0.43	2.33e-22	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs7107174	0.892	rs4291702	chr11:78001248	C/T	cg27205649	chr11:78285834	NARS2	-0.43	-6.89	-0.31	1.79e-11	Testicular germ cell tumor;
LGG	trans	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg19862616	chr7:65841803	NCRNA00174	0.76	7.8	0.34	4.04e-14	Mononucleosis;
LGG	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg04568710	chr12:38710424	ALG10B	0.35	7.26	0.32	1.69e-12	Bladder cancer;
LGG	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	6.94	0.31	1.36e-11	Height;
LGG	cis	rs9297145	0.585	rs17147666	chr7:98781457	A/C	cg05967295	chr7:98741636	SMURF1	-0.65	-11.54	-0.47	3.04e-27	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	trans	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg13010199	chr12:38710504	ALG10B	0.47	9.16	0.39	1.7e-18	Morning vs. evening chronotype;
LGG	cis	rs7766436	0.885	rs12111204	chr6:22578227	C/T	cg13666174	chr6:22585274	NA	-0.51	-12.09	-0.49	1.96e-29	Coronary artery disease;
LGG	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg13114125	chr14:105738426	BRF1	-0.85	-15.78	-0.59	3.45e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg20573242	chr4:122745356	CCNA2	0.55	10.14	0.43	5.69e-22	Type 2 diabetes;
LGG	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg17644776	chr2:200775616	C2orf69	-0.67	-8.48	-0.37	3.05e-16	Schizophrenia;
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg11859384	chr17:80120422	CCDC57	0.4	6.97	0.31	1.1e-11	Life satisfaction;
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg15665833	chr6:26285013	NA	-0.39	-7.73	-0.34	6.77e-14	Educational attainment;
LGG	cis	rs9323205	0.953	rs7141012	chr14:51600948	C/G	cg23942311	chr14:51606299	NA	-0.38	-6.9	-0.31	1.71e-11	Cancer;
LGG	cis	rs1784581	0.651	rs1784588	chr6:162390027	T/A	cg17173639	chr6:162384350	PARK2	-0.76	-17.2	-0.62	1.21e-51	Itch intensity from mosquito bite;
LGG	cis	rs11758351	1.000	rs74363821	chr6:26189524	G/C	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.4	-8.07	-0.35	6.27e-15	Personality dimensions;
LGG	cis	rs4740619	0.933	rs6474954	chr9:15714811	C/G	cg14451791	chr9:16040625	NA	0.37	9.59	0.41	5.46e-20	Body mass index;
LGG	cis	rs6121246	0.559	rs6060716	chr20:30274847	C/G	cg13852791	chr20:30311386	BCL2L1	0.94	18.63	0.65	3.35e-58	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.745	rs2854162	chr17:61975610	T/C	cg11494091	chr17:61959527	GH2	-0.63	-10.71	-0.45	4.71e-24	Height;
LGG	cis	rs11997175	0.574	rs4520125	chr8:33648628	C/T	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.09e-12	Body mass index;
LGG	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24110177	chr3:50126178	RBM5	0.59	10.78	0.45	2.58e-24	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	0.48	7.4	0.33	6.61e-13	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg02002194	chr4:3960332	NA	0.43	7.7	0.34	8.21e-14	Neuroticism;
LGG	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg25566285	chr7:158114605	PTPRN2	-0.67	-11.56	-0.47	2.44e-27	Response to amphetamines;
LGG	cis	rs4917300	0.606	rs4506255	chr8:143111037	A/C	cg26003909	chr8:143102224	NA	-0.34	-6.77	-0.3	3.81e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg05025164	chr4:1340916	KIAA1530	0.58	10.43	0.44	4.97e-23	Obesity-related traits;
LGG	cis	rs7215564	0.908	rs9908112	chr17:78753455	A/G	cg06153925	chr17:78755379	RPTOR	-0.45	-7.54	-0.33	2.47e-13	Myopia (pathological);
LGG	cis	rs6933660	0.745	rs3800272	chr6:151744283	A/G	cg17179660	chr6:151773299	C6orf211;RMND1	0.47	8.1	0.35	4.82e-15	Menarche (age at onset);
LGG	cis	rs4262150	0.544	rs17549307	chr5:151914462	T/C	cg12297329	chr5:152029980	NA	-0.65	-11.67	-0.48	9.53e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg02900749	chr2:68251473	NA	-0.97	-10.56	-0.44	1.74e-23	Pursuit maintenance gain;
LGG	cis	rs7567389	0.740	rs1604817	chr2:127999921	C/T	cg10021288	chr2:128175891	PROC	-0.38	-6.92	-0.31	1.54e-11	Self-rated health;
LGG	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs7084402	0.935	rs893370	chr10:60360834	A/T	cg07615347	chr10:60278583	BICC1	0.61	16.56	0.61	1.07e-48	Refractive error;
LGG	cis	rs1927790	0.727	rs9556551	chr13:96947223	T/A	cg02571835	chr13:96230311	CLDN10	-0.34	-7.01	-0.31	8.62e-12	Body mass index;
LGG	cis	rs66887589	0.967	rs6844263	chr4:120433807	A/G	cg09307838	chr4:120376055	NA	0.48	8.26	0.36	1.59e-15	Diastolic blood pressure;
LGG	cis	rs889312	0.500	rs252920	chr5:56148741	C/A	cg14703610	chr5:56206110	C5orf35	0.4	6.9	0.31	1.67e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.92	-0.35	1.76e-14	Testicular germ cell tumor;
LGG	cis	rs2346177	0.519	rs13003074	chr2:46671420	A/T	cg26688816	chr2:46740690	ATP6V1E2	0.62	11.94	0.49	8.05e-29	HDL cholesterol;
LGG	trans	rs2243480	1.000	rs36033484	chr7:65390558	T/G	cg10756647	chr7:56101905	PSPH	0.84	9.88	0.42	5.27e-21	Diabetic kidney disease;
LGG	trans	rs1814175	0.817	rs7109440	chr11:49966296	C/T	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs6429082	0.764	rs291377	chr1:235695186	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.62	-10.16	-0.43	5.13e-22	Adiposity;
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg09845145	chr15:78292470	TBC1D2B	0.64	12.37	0.5	1.51e-30	Coronary artery disease or large artery stroke;
LGG	cis	rs10870270	0.956	rs7904594	chr10:133734671	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.84	-0.51	1.72e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.67	11.65	0.48	1.12e-27	Obesity-related traits;
LGG	trans	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs1801251	0.727	rs7557607	chr2:233557073	G/T	cg08000102	chr2:233561755	GIGYF2	0.54	9.13	0.39	2.17e-18	Coronary artery disease;
LGG	cis	rs5758659	0.714	rs5758578	chr22:42490292	A/C	cg15128208	chr22:42549153	NA	0.48	9.84	0.42	6.89e-21	Cognitive function;
LGG	trans	rs9914544	0.545	rs12451200	chr17:18778493	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg16528022	chr14:65438707	RAB15	-0.4	-7.24	-0.32	1.91e-12	Iris color (L* coordinate);
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.18	-0.52	6.74e-34	Alzheimer's disease;
LGG	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2050392	0.517	rs687036	chr10:30761249	G/A	cg25182066	chr10:30743637	MAP3K8	-0.64	-13.47	-0.53	4.05e-35	Inflammatory bowel disease;
LGG	cis	rs4430311	0.723	rs4639743	chr1:243946072	G/A	cg25706552	chr1:244017396	NA	-0.65	-15.93	-0.6	6.95e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.84	-0.42	7.17e-21	Life satisfaction;
LGG	cis	rs9527	0.615	rs7917295	chr10:104701187	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.08	0.42	9.95e-22	Arsenic metabolism;
LGG	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-22.52	-0.72	2.16e-76	Renal cell carcinoma;
LGG	cis	rs4666002	0.636	rs2272406	chr2:27892023	A/T	cg27432699	chr2:27873401	GPN1	0.55	7.68	0.34	9.32e-14	Phospholipid levels (plasma);
LGG	cis	rs13418717	0.793	rs6733255	chr2:127662386	C/T	cg25501666	chr2:127640322	NA	-1.13	-8.73	-0.38	4.73e-17	Heart failure;
LGG	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg06238570	chr21:40685208	BRWD1	-0.54	-8.96	-0.38	8.23e-18	Cognitive function;
LGG	cis	rs67311347	1.000	rs9857824	chr3:40459412	A/G	cg13683864	chr3:40499215	RPL14	-1.13	-26.6	-0.78	2.64e-95	Renal cell carcinoma;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg18402987	chr7:1209562	NA	0.49	8.3	0.36	1.12e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	1.000	rs6050542	chr20:25318879	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2070488	0.804	rs4678605	chr3:38444489	T/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	14.98	0.57	1.19e-41	Electrocardiographic conduction measures;
LGG	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg06637938	chr14:75390232	RPS6KL1	0.64	11.69	0.48	7.7e-28	Caffeine consumption;
LGG	cis	rs9325144	0.555	rs2387843	chr12:38711203	T/C	cg04568710	chr12:38710424	ALG10B	0.41	8.79	0.38	3.04e-17	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg20003494	chr4:90757398	SNCA	-0.43	-8.61	-0.37	1.16e-16	Dementia with Lewy bodies;
LGG	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg01448562	chr3:133502909	NA	-0.73	-13.6	-0.53	1.07e-35	Iron status biomarkers;
LGG	cis	rs2712184	0.729	rs2541397	chr2:217646693	G/A	cg05032264	chr2:217675019	NA	-0.43	-9.33	-0.4	4.48e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg06618935	chr21:46677482	NA	-0.49	-9.69	-0.41	2.46e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs888194	0.677	rs7956194	chr12:109877825	C/T	cg19025524	chr12:109796872	NA	-0.48	-9.61	-0.41	4.72e-20	Neuroticism;
LGG	cis	rs4650994	0.625	rs6681348	chr1:178526271	A/C	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4330281	0.692	rs7627732	chr3:17784818	T/C	cg20981856	chr3:17787350	NA	-0.41	-7.37	-0.32	7.96e-13	Schizophrenia;
LGG	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg25811766	chr13:21894605	NA	-0.58	-7.58	-0.33	1.95e-13	White matter hyperintensity burden;
LGG	trans	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg18258770	chr4:90757814	SNCA	-0.39	-7.21	-0.32	2.26e-12	Dementia with Lewy bodies;
LGG	cis	rs16922576	0.623	rs2104166	chr9:5230447	T/C	cg02405213	chr9:5042618	JAK2	-0.69	-12.29	-0.5	3.18e-30	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg16141378	chr3:129829833	LOC729375	-0.43	-10.35	-0.43	9.71e-23	Mood instability;
LGG	trans	rs2243480	0.901	rs12530490	chr7:65691647	G/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs6456042	1.000	rs3127417	chr6:166537734	A/G	cg11088901	chr6:166572345	T	-0.35	-7.28	-0.32	1.46e-12	Asthma;
LGG	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.86	-0.45	1.28e-24	Aortic root size;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.2e-14	Prudent dietary pattern;
LGG	cis	rs9443645	0.505	rs11752126	chr6:79707923	C/T	cg18132916	chr6:79620363	NA	-0.27	-6.98	-0.31	1.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg08621203	chr6:150244597	RAET1G	0.46	7.92	0.35	1.75e-14	Lung cancer;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg08621203	chr6:150244597	RAET1G	0.4	6.8	0.3	3.31e-11	Lung cancer;
LGG	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg20673091	chr1:2541236	MMEL1	0.59	13.25	0.52	3.28e-34	Ulcerative colitis;
LGG	cis	rs10934753	0.632	rs1447661	chr3:125924981	A/G	cg11252792	chr3:125932053	NA	0.81	17.38	0.63	1.86e-52	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs873946	0.648	rs12769533	chr10:134548685	C/T	cg27297192	chr10:134578999	INPP5A	-0.32	-7.43	-0.33	5.21e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.74	0.38	4.43e-17	Platelet count;
LGG	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg08048268	chr3:133502702	NA	-0.46	-7.94	-0.35	1.54e-14	Iron status biomarkers;
LGG	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs2154319	0.887	rs1740615	chr1:41538516	C/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.02	-0.39	5.11e-18	Height;
LGG	cis	rs8012	0.517	rs9384	chr19:13010643	G/T	cg23899408	chr19:12877188	HOOK2	-0.49	-7.95	-0.35	1.47e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs8114671	0.935	rs6058198	chr20:33748253	T/A	cg07148914	chr20:33460835	GGT7	0.45	7.11	0.31	4.3e-12	Height;
LGG	cis	rs858239	0.600	rs1115941	chr7:23137188	C/T	cg23682824	chr7:23144976	KLHL7	0.44	7.7	0.34	8.19e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs919433	0.679	rs6741314	chr2:198526088	G/A	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg23625390	chr15:77176239	SCAPER	-0.64	-12.79	-0.51	2.63e-32	Blood metabolite levels;
LGG	cis	rs11874712	1.000	rs11872985	chr18:43686578	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.53	-11.46	-0.47	5.97e-27	Migraine - clinic-based;
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg26116260	chr4:7069785	GRPEL1	1.15	22.29	0.72	2.56e-75	Monocyte percentage of white cells;
LGG	cis	rs7567389	0.704	rs4662714	chr2:127995213	A/G	cg10021288	chr2:128175891	PROC	-0.37	-6.76	-0.3	4.23e-11	Self-rated health;
LGG	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg15038512	chr6:170123185	PHF10	0.51	6.73	0.3	5.09e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1322639	0.614	rs9294967	chr6:169565406	C/T	cg04662567	chr6:169592167	NA	0.79	11.3	0.46	2.62e-26	Pulse pressure;
LGG	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.8	9.07	0.39	3.36e-18	Smoking behavior;
LGG	cis	rs61192259	0.827	rs60936387	chr6:38453774	C/G	cg07362130	chr6:38359646	BTBD9	0.28	6.75	0.3	4.34e-11	Restless legs syndrome;
LGG	trans	rs877282	0.842	rs35117541	chr10:764683	C/T	cg22713356	chr15:30763199	NA	0.52	7.68	0.34	9.24e-14	Uric acid levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15305172	chr6:116892775	RWDD1	-0.39	-6.67	-0.3	7.21e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.17	0.32	3.02e-12	Tonsillectomy;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg14668632	chr7:2872130	GNA12	-0.37	-7.79	-0.34	4.4e-14	Height;
LGG	cis	rs3096299	0.632	rs4399533	chr16:89539382	G/C	cg05484508	chr16:89589025	SPG7	0.46	7.45	0.33	4.73e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs12701220	1.000	rs12701220	chr7:1022728	T/C	cg26769984	chr7:1090371	C7orf50	0.58	9.98	0.42	2.27e-21	Bronchopulmonary dysplasia;
LGG	cis	rs7493	0.755	rs62467350	chr7:94970114	T/C	cg17330251	chr7:94953956	PON1	-0.43	-8.52	-0.37	2.24e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs17767392	0.958	rs9323561	chr14:72031563	A/C	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.83	-0.42	7.45e-21	Mitral valve prolapse;
LGG	cis	rs2243480	1.000	rs73142121	chr7:65311206	C/T	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs7089973	0.584	rs6585300	chr10:116639889	A/C	cg03647239	chr10:116582469	FAM160B1	0.41	7.33	0.32	1.02e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7580658	0.963	rs9789510	chr2:128137012	G/A	cg10021288	chr2:128175891	PROC	-0.65	-13.47	-0.53	3.96e-35	Protein C levels;
LGG	cis	rs2916247	0.954	rs7003305	chr8:93101992	T/C	cg10183463	chr8:93005414	RUNX1T1	0.38	7.78	0.34	4.72e-14	Intelligence (multi-trait analysis);
LGG	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg22903471	chr2:27725779	GCKR	-0.52	-11.42	-0.47	8.76e-27	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs561341	0.882	rs72825748	chr17:30367396	G/A	cg00745463	chr17:30367425	LRRC37B	-0.77	-10.48	-0.44	3.2e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs2276314	0.802	rs58906216	chr18:33630297	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.88	0.42	5.3e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs1109114	0.844	rs9325137	chr5:148633778	T/C	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.33	-0.47	1.94e-26	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08204369	chr17:73150733	HN1	0.5	8.37	0.36	7.11e-16	Gut microbiome composition (summer);
LGG	cis	rs8031584	0.697	rs8036176	chr15:31175269	A/G	cg14829155	chr15:31115871	NA	-0.61	-10.52	-0.44	2.28e-23	Huntington's disease progression;
LGG	cis	rs9611565	0.506	rs2024567	chr22:41699206	G/C	cg06634786	chr22:41940651	POLR3H	-0.56	-9.26	-0.4	7.71e-19	Vitiligo;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg02725872	chr8:58115012	NA	-0.78	-10.68	-0.44	6.23e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.98	0.66	7.58e-60	Bladder cancer;
LGG	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg08885076	chr2:99613938	TSGA10	0.37	8.11	0.35	4.72e-15	Chronic sinus infection;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg13397359	chr6:42928475	GNMT	0.58	16.3	0.6	1.48e-47	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg18709589	chr6:96969512	KIAA0776	-0.49	-9.77	-0.41	1.23e-20	Headache;
LGG	cis	rs2267681	0.603	rs2107900	chr7:139540601	G/A	cg14116596	chr7:139528673	TBXAS1	0.31	6.67	0.3	7.24e-11	Cervical cancer;
LGG	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.7	-9.29	-0.4	5.85e-19	Diabetic retinopathy;
LGG	cis	rs1801251	0.963	rs13021246	chr2:233623111	T/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	6.2800000000000005e-19	Coronary artery disease;
LGG	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg13009111	chr11:71350975	NA	-0.34	-7.32	-0.32	1.09e-12	Monocyte count;
LGG	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg08885076	chr2:99613938	TSGA10	-0.33	-7.02	-0.31	8.14e-12	Bipolar disorder;
LGG	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg26384229	chr12:38710491	ALG10B	0.6	10.9	0.45	8.89e-25	Morning vs. evening chronotype;
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.28	-7.32	-0.32	1.07e-12	IgG glycosylation;
LGG	trans	rs3960554	0.932	rs11975745	chr7:75843524	T/C	cg19862616	chr7:65841803	NCRNA00174	0.84	11.56	0.47	2.57e-27	Eotaxin levels;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14395634	chr11:65626208	CFL1	0.39	6.82	0.3	2.78e-11	Bilirubin levels;
LGG	cis	rs17286411	0.715	rs9932707	chr16:71862133	A/C	cg03805757	chr16:71968109	PKD1L3	0.34	7.0	0.31	9.23e-12	Blood protein levels;
LGG	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	cis	rs769267	0.965	rs4808200	chr19:19554803	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	17.05	0.62	6.11e-51	Tonsillectomy;
LGG	cis	rs2816316	0.945	rs2984919	chr1:192541172	A/T	cg02586212	chr1:192544902	RGS1	0.46	9.33	0.4	4.44e-19	Celiac disease;
LGG	trans	rs9818758	0.556	rs9880309	chr3:49304329	G/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.03	-0.31	7.25e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18917495	chr2:74006961	DUSP11	0.5	8.05	0.35	7.2e-15	Cognitive performance;
LGG	cis	rs986417	1.000	rs6573316	chr14:61058029	C/A	cg27398547	chr14:60952738	C14orf39	0.76	7.0	0.31	9.13e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7824557	0.767	rs3808513	chr8:11157460	G/T	cg15596359	chr8:11213517	TDH	0.34	7.01	0.31	8.25e-12	Retinal vascular caliber;
LGG	cis	rs41342147	0.660	rs11683764	chr2:242285545	A/G	cg10173475	chr2:242152697	ANO7	-0.58	-9.0	-0.39	5.98e-18	Vitiligo;
LGG	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg08085267	chr17:45401833	C17orf57	0.62	12.94	0.52	6.4e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2576037	0.526	rs9962523	chr18:44486414	A/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.18	0.46	7.72e-26	Personality dimensions;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg26354017	chr1:205819088	PM20D1	0.99	27.95	0.79	1.97e-101	Menarche (age at onset);
LGG	cis	rs721917	0.506	rs2819097	chr10:81699981	C/G	cg25562619	chr10:81652821	NA	-0.34	-7.55	-0.33	2.34e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg04016957	chr4:1044486	NA	0.39	7.73	0.34	6.76e-14	Recombination rate (males);
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.13	-0.35	3.84e-15	IgG glycosylation;
LGG	cis	rs981844	0.857	rs62325141	chr4:154716407	A/G	cg14289246	chr4:154710475	SFRP2	0.72	12.1	0.49	1.73e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg05868516	chr6:26286170	HIST1H4H	-0.45	-7.62	-0.33	1.44e-13	Educational attainment;
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg03709012	chr19:19516395	GATAD2A	-0.85	-16.56	-0.61	1.08e-48	Tonsillectomy;
LGG	trans	rs11577318	0.812	rs3795683	chr1:26632831	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.51	10.26	0.43	2.16e-22	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7085104	0.514	rs284855	chr10:104574422	A/G	cg04362960	chr10:104952993	NT5C2	-0.47	-8.51	-0.37	2.52e-16	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg20887711	chr4:1340912	KIAA1530	0.57	10.69	0.44	5.61e-24	Obesity-related traits;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.3	-0.36	1.17e-15	IgG glycosylation;
LGG	cis	rs7659604	0.540	rs116452657	chr4:122674147	A/G	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	1.01e-14	Type 2 diabetes;
LGG	cis	rs367943	0.608	rs6898912	chr5:112989978	C/T	cg12552261	chr5:112820674	MCC	0.5	8.9	0.38	1.26e-17	Type 2 diabetes;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.36	-0.43	9.01e-23	Lymphocyte counts;
LGG	cis	rs4843747	0.749	rs8053309	chr16:88044980	G/A	cg09044154	chr16:88155775	NA	-0.48	-7.0	-0.31	8.92e-12	Menopause (age at onset);
LGG	cis	rs4474465	1.000	rs11237514	chr11:78180179	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.56	-0.37	1.71e-16	Alzheimer's disease (survival time);
LGG	cis	rs920590	0.876	rs3907477	chr8:19657744	C/T	cg03894339	chr8:19674705	INTS10	0.55	9.01	0.39	5.46e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1662342	0.736	rs4404166	chr18:3285657	C/G	cg00760847	chr18:3262519	MYL12B	-0.61	-6.68	-0.3	6.97e-11	QRS duration;
LGG	cis	rs300774	0.920	rs378161	chr2:192983	A/T	cg04617936	chr2:214353	NA	0.58	8.41	0.36	5.25e-16	Suicide attempts in bipolar disorder;
LGG	cis	rs9291683	0.620	rs717615	chr4:10104670	C/T	cg08250081	chr4:10125330	NA	0.34	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg24375607	chr4:120327624	NA	0.64	9.9	0.42	4.49e-21	Corneal astigmatism;
LGG	trans	rs4942242	1.000	rs4942242	chr13:44217064	A/G	cg19169023	chr15:41853346	TYRO3	0.33	7.08	0.31	5.23e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5e-17	Aortic root size;
LGG	cis	rs8017423	0.904	rs7147212	chr14:90697809	A/C	cg04374321	chr14:90722782	PSMC1	0.88	18.48	0.65	1.59e-57	Mortality in heart failure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25891639	chr5:143584957	KCTD16	0.47	7.7	0.34	8.45e-14	Gut microbiome composition (summer);
LGG	cis	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg07460842	chr6:66804631	NA	0.57	9.51	0.4	1.05e-19	Metabolite levels;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.94	0.66	1.16e-59	Menopause (age at onset);
LGG	cis	rs4901847	0.562	rs11628610	chr14:58611212	G/A	cg15908186	chr14:58618357	C14orf37	0.69	12.84	0.51	1.67e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs629922	0.507	rs623418	chr11:114068474	G/A	cg01914181	chr11:114070210	ZBTB16	-0.53	-6.68	-0.3	6.99e-11	Paneth cell defects in Crohn's disease;
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg24503407	chr1:205819492	PM20D1	0.48	8.12	0.35	4.26e-15	Parkinson's disease;
LGG	cis	rs7312933	0.558	rs7305397	chr12:42850058	T/C	cg19980929	chr12:42632907	YAF2	0.35	7.75	0.34	6.08e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs561341	0.709	rs11542477	chr17:30185892	A/G	cg13647721	chr17:30228624	UTP6	-0.7	-8.04	-0.35	7.7e-15	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg14668632	chr7:2872130	GNA12	-0.37	-7.65	-0.34	1.14e-13	Height;
LGG	cis	rs12472274	0.529	rs11683094	chr2:239118057	G/A	cg17459225	chr2:239074497	NA	0.65	9.58	0.41	5.93e-20	Phospholipid levels (plasma);
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg24829409	chr8:58192753	C8orf71	-0.84	-13.26	-0.52	3.01e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1414350	chr6:8472331	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs9287719	0.967	rs13034061	chr2:10739651	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs9399135	0.660	rs9389248	chr6:135282656	T/C	cg22676075	chr6:135203613	NA	0.43	7.55	0.33	2.32e-13	Red blood cell count;
LGG	cis	rs6087990	0.899	rs1883729	chr20:31363193	G/A	cg13636640	chr20:31349939	DNMT3B	0.98	21.64	0.71	2.99e-72	Ulcerative colitis;
LGG	cis	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg21775007	chr8:11205619	TDH	0.52	8.11	0.35	4.46e-15	Triglycerides;
LGG	cis	rs4740619	0.819	rs2821545	chr9:15564904	G/A	cg14451791	chr9:16040625	NA	-0.32	-8.14	-0.35	3.79e-15	Body mass index;
LGG	cis	rs11700980	0.636	rs61735765	chr21:30255347	C/A	cg08807101	chr21:30365312	RNF160	-0.65	-7.35	-0.32	8.84e-13	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.775	rs55734109	chr8:58162322	G/A	cg11062466	chr8:58055876	NA	0.61	10.07	0.42	1.04e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.25	0.39	8.42e-19	Gout;Renal underexcretion gout;
LGG	cis	rs6032067	0.641	rs13038485	chr20:43767759	T/A	cg10761708	chr20:43804764	PI3	0.72	10.61	0.44	1.07e-23	Blood protein levels;
LGG	cis	rs3206736	0.548	rs329240	chr7:35058440	A/G	cg13400248	chr7:35225412	NA	-0.54	-9.31	-0.4	5.18e-19	Diastolic blood pressure;
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.8	-0.38	2.67e-17	Neuroticism;
LGG	cis	rs854765	0.533	rs2955354	chr17:17948716	G/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs7100689	0.646	rs10749579	chr10:82140959	C/T	cg01528321	chr10:82214614	TSPAN14	0.87	15.24	0.58	8.17e-43	Post bronchodilator FEV1;
LGG	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.86	0.62	4.42e-50	Anterior chamber depth;
LGG	cis	rs11690935	0.959	rs1113389	chr2:172635365	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-27.19	-0.78	5.4e-98	Schizophrenia;
LGG	cis	rs1950500	0.545	rs724165	chr14:24806229	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.5	8.82	0.38	2.42e-17	Height;
LGG	cis	rs6840360	0.571	rs4696098	chr4:152489053	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs13421350	0.579	rs59476799	chr2:173376319	T/C	cg15021238	chr2:173305865	ITGA6	-0.72	-8.11	-0.35	4.72e-15	Diabetic kidney disease;
LGG	trans	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.7	-0.3	6.05e-11	Mood instability;
LGG	cis	rs4474465	0.790	rs6592790	chr11:78262618	T/C	cg27205649	chr11:78285834	NARS2	0.51	8.79	0.38	2.91e-17	Alzheimer's disease (survival time);
LGG	cis	rs7223966	1.000	rs9912904	chr17:61763534	A/C	cg18032289	chr17:61959525	GH2	-0.4	-6.86	-0.3	2.26e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7589342	0.929	rs1465640	chr2:106439103	C/T	cg14210321	chr2:106509881	NCK2	-0.51	-8.82	-0.38	2.35e-17	Addiction;
LGG	cis	rs11190604	1.000	rs9420797	chr10:102331147	C/T	cg07570687	chr10:102243282	WNT8B	0.39	6.8	0.3	3.3e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg05313129	chr8:58192883	C8orf71	-0.77	-10.55	-0.44	1.86e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg16482183	chr6:26056742	HIST1H1C	0.65	10.17	0.43	4.47e-22	Height;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.23	-0.32	2.07e-12	Bipolar disorder;
LGG	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg00933542	chr6:150070202	PCMT1	0.37	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs11758351	0.500	rs17533076	chr6:26183816	G/A	cg02612650	chr6:26195910	NA	0.88	6.84	0.3	2.54e-11	Gout;Renal underexcretion gout;
LGG	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg22563815	chr15:78856949	CHRNA5	0.26	6.67	0.3	7.36e-11	Sudden cardiac arrest;
LGG	cis	rs9636252	0.962	rs4459703	chr2:9265057	T/C	cg20341998	chr2:9276514	NA	0.37	7.28	0.32	1.42e-12	IgG glycosylation;
LGG	cis	rs13108043	0.605	rs13136338	chr4:87958943	C/T	cg11209507	chr4:87813803	C4orf36	0.55	7.27	0.32	1.5e-12	Red blood cell count;
LGG	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.33	-0.32	1.03e-12	Schizophrenia;
LGG	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.42	-0.44	5.51e-23	Intelligence (multi-trait analysis);
LGG	cis	rs317689	0.690	rs547827	chr12:69669703	G/A	cg20891283	chr12:69753455	YEATS4	0.46	7.0	0.31	9.02e-12	Response to diuretic therapy;
LGG	cis	rs1451375	1.000	rs2329341	chr7:50620275	A/C	cg00647317	chr7:50633725	DDC	-0.35	-7.66	-0.34	1.09e-13	Malaria;
LGG	cis	rs11971779	0.648	rs28754644	chr7:139065057	C/T	cg07862535	chr7:139043722	LUC7L2	0.43	7.08	0.31	5.35e-12	Diisocyanate-induced asthma;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.38	-0.32	7.58e-13	Prostate cancer;
LGG	cis	rs17767392	0.958	rs35051046	chr14:71849308	T/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.05	0.39	3.92e-18	Mitral valve prolapse;
LGG	cis	rs7010267	0.596	rs6999476	chr8:120032259	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.85	0.38	1.81e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.16	0.32	3.16e-12	Retinal vascular caliber;
LGG	cis	rs734999	0.545	rs7364820	chr1:2556709	G/A	cg18854424	chr1:2615690	NA	0.36	7.64	0.33	1.28e-13	Ulcerative colitis;
LGG	cis	rs7568458	0.837	rs35215812	chr2:85792384	G/A	cg17127132	chr2:85788382	GGCX	0.46	8.0	0.35	9.92e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.23	0.36	1.92e-15	Retinal vascular caliber;
LGG	cis	rs7241530	0.636	rs35311649	chr18:75898456	G/T	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	cis	rs17767392	0.746	rs61989246	chr14:71720243	C/A	cg02058870	chr14:72053146	SIPA1L1	0.37	7.59	0.33	1.81e-13	Mitral valve prolapse;
LGG	cis	rs9463078	0.817	rs3799978	chr6:44837532	A/G	cg25276700	chr6:44698697	NA	-0.38	-7.84	-0.34	3.19e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4684776	0.935	rs11128547	chr3:11393268	A/G	cg24705426	chr3:11550659	ATG7	0.43	7.98	0.35	1.15e-14	Small vessel stroke;
LGG	cis	rs7122539	0.647	rs7120256	chr11:66650248	C/A	cg01599099	chr11:66649832	PC	0.46	9.23	0.39	9.51e-19	HIV-1 susceptibility;
LGG	cis	rs7107174	1.000	rs1942352	chr11:77970563	T/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.24	-0.32	1.89e-12	Testicular germ cell tumor;
LGG	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg03517284	chr6:25882590	NA	-0.51	-9.62	-0.41	4.23e-20	Blood metabolite levels;
LGG	cis	rs35146811	0.735	rs2272345	chr7:99797031	C/G	cg13334819	chr7:99746414	C7orf59	-0.46	-7.14	-0.32	3.53e-12	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg11494091	chr17:61959527	GH2	1.0	24.51	0.75	1.11e-85	Prudent dietary pattern;
LGG	cis	rs870825	0.616	rs4437299	chr4:185643223	T/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs858239	0.699	rs858260	chr7:23212934	G/T	cg23682824	chr7:23144976	KLHL7	0.42	6.95	0.31	1.23e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs929596	0.755	rs3771341	chr2:234673239	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.77	-14.14	-0.55	5.34e-38	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs11225247	0.649	rs12283885	chr11:102257902	G/T	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg12463550	chr7:65579703	CRCP	0.77	8.27	0.36	1.47e-15	Diabetic kidney disease;
LGG	cis	rs8072100	0.713	rs11651643	chr17:45483229	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-8.99	-0.39	6.37e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7615952	0.512	rs2922175	chr3:125361360	T/C	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg14668632	chr7:2872130	GNA12	-0.37	-7.61	-0.33	1.52e-13	Height;
LGG	cis	rs4650994	0.544	rs6664493	chr1:178494428	C/T	cg19399532	chr1:178512495	C1orf220	0.55	11.21	0.46	5.61e-26	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.61e-11	Total body bone mineral density;
LGG	cis	rs4319547	0.915	rs1473553	chr12:122985057	G/T	cg23029597	chr12:123009494	RSRC2	-0.96	-18.37	-0.65	5.1e-57	Body mass index;
LGG	cis	rs6456042	1.000	rs3127415	chr6:166537088	C/T	cg11088901	chr6:166572345	T	-0.35	-7.28	-0.32	1.46e-12	Asthma;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg19673125	chr6:150240577	RAET1G	0.36	8.56	0.37	1.65e-16	Testicular germ cell tumor;
LGG	cis	rs42648	0.902	rs17874789	chr7:90001160	A/T	cg25739043	chr7:89950458	NA	0.37	7.88	0.34	2.34e-14	Homocysteine levels;
LGG	cis	rs2213920	0.619	rs4979529	chr9:118197686	T/A	cg13918206	chr9:118159781	DEC1	0.63	8.93	0.38	1e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9682041	0.696	rs6786542	chr3:170105378	C/T	cg11886554	chr3:170076028	SKIL	0.65	8.43	0.36	4.56e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs9964724	0.896	rs11665070	chr18:35152563	C/T	cg27332583	chr18:35150602	NA	-0.41	-8.53	-0.37	2.11e-16	Educational attainment (years of education);
LGG	cis	rs7011049	1.000	rs72640849	chr8:53836430	A/T	cg26025543	chr8:53854495	NA	0.74	9.79	0.41	1.07e-20	Systolic blood pressure;
LGG	cis	rs4918072	0.753	rs36069350	chr10:105702833	A/G	cg11005552	chr10:105648138	OBFC1	0.45	7.37	0.32	8.12e-13	Coronary artery disease;
LGG	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.7	-0.3	5.94e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4910157	1	rs4910157	chr11:8941215	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.62	0.48	1.48e-27	Tonsillectomy;
LGG	cis	rs6489882	0.807	rs10774677	chr12:113362421	G/A	cg25319449	chr12:113376135	OAS3	-0.4	-7.36	-0.32	8.61e-13	Chronic lymphocytic leukemia;
LGG	trans	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg18335740	chr13:41363409	SLC25A15	0.54	9.18	0.39	1.44e-18	Lewy body disease;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg05036130	chr6:150231994	NA	0.34	6.73	0.3	5.16e-11	Testicular germ cell tumor;
LGG	trans	rs7395662	0.889	rs11039754	chr11:48475213	C/G	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.28e-13	HDL cholesterol;
LGG	cis	rs12580194	0.593	rs61957946	chr12:55755778	T/C	cg19537932	chr12:55886519	OR6C68	-0.57	-10.46	-0.44	3.93e-23	Cancer;
LGG	cis	rs7647973	0.710	rs7629322	chr3:49621994	C/T	cg03060546	chr3:49711283	APEH	0.6	7.94	0.35	1.5e-14	Menarche (age at onset);
LGG	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.05	14.07	0.55	1.14e-37	Lung cancer in ever smokers;
LGG	cis	rs9393813	0.516	rs4713098	chr6:27403605	C/T	cg18711553	chr6:27366782	ZNF391	-0.47	-9.05	-0.39	3.93e-18	Bipolar disorder;
LGG	cis	rs539514	0.664	rs479824	chr13:76308360	C/T	cg04757411	chr13:76259545	LMO7	-0.27	-6.88	-0.3	1.98e-11	Type 1 diabetes;
LGG	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.12	0.39	2.36e-18	HDL cholesterol;
LGG	trans	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg08344181	chr3:125677491	NA	-0.52	-7.01	-0.31	8.3e-12	Lung cancer in ever smokers;
LGG	cis	rs13260300	0.573	rs10957732	chr8:75523123	C/T	cg22993706	chr8:75542856	NA	0.41	8.14	0.35	3.62e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg17830980	chr10:43048298	ZNF37B	-0.35	-7.27	-0.32	1.59e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.9	-0.34	2.12e-14	Systolic blood pressure;
LGG	cis	rs17776563	0.959	rs2165247	chr15:89118141	C/T	cg05013243	chr15:89149849	MIR1179	-0.48	-9.78	-0.41	1.18e-20	Thyroid hormone levels;
LGG	trans	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg13565492	chr6:43139072	SRF	-0.89	-15.11	-0.57	3.1e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	12.37	0.5	1.38e-30	Prudent dietary pattern;
LGG	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg24110177	chr3:50126178	RBM5	0.46	7.8	0.34	4.2e-14	Menarche (age at onset);
LGG	cis	rs1909881	0.608	rs3133732	chr8:96507982	G/A	cg04203453	chr8:96504381	NA	-0.49	-8.94	-0.38	9.64e-18	Obesity-related traits;
LGG	trans	rs330071	0.686	rs10087406	chr8:9246598	C/T	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.85	-0.3	2.44e-11	Acne (severe);
LGG	cis	rs523522	0.962	rs3213565	chr12:120992401	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.18	0.46	7.65e-26	High light scatter reticulocyte count;
LGG	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.73	0.69	5.21e-68	Calcium levels;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2732480	0.500	rs7315820	chr12:48598938	C/T	cg24011408	chr12:48396354	COL2A1	0.51	8.07	0.35	6.02e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2439831	0.867	rs2447196	chr15:43893818	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.85	-9.87	-0.42	5.56e-21	Lung cancer in ever smokers;
LGG	cis	rs4740619	0.619	rs10810527	chr9:16043350	C/G	cg14451791	chr9:16040625	NA	0.44	11.59	0.47	1.98e-27	Body mass index;
LGG	cis	rs26232	0.520	rs26432	chr5:102365710	T/A	cg23492399	chr5:102201601	PAM	0.47	6.93	0.31	1.4e-11	Rheumatoid arthritis;
LGG	cis	rs858239	0.601	rs6962526	chr7:23158233	G/A	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.15e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.59	-9.73	-0.41	1.7e-20	Height;
LGG	cis	rs77372450	0.636	rs10476093	chr5:157007001	C/A	cg25387487	chr5:157003181	ADAM19	-0.58	-7.29	-0.32	1.37e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4700695	0.925	rs796728	chr5:65382500	C/T	cg21114390	chr5:65439923	SFRS12	-0.56	-7.1	-0.31	4.87e-12	Facial morphology (factor 19);
LGG	cis	rs4356203	0.905	rs621246	chr11:17203765	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6998277	1.000	rs4281092	chr8:103647956	A/G	cg10187029	chr8:103597600	NA	-0.77	-11.37	-0.47	1.44e-26	Migraine;
LGG	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg06598544	chr20:61472147	COL9A3	-0.89	-9.85	-0.42	6.62e-21	Obesity-related traits;
LGG	cis	rs7584262	0.737	rs58360854	chr2:42243076	A/G	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Bone mineral density;
LGG	cis	rs139371	0.684	rs139328	chr22:39502695	T/C	cg17972162	chr22:39496387	APOBEC3H	-0.27	-7.01	-0.31	8.66e-12	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs2797369	0.713	rs12200999	chr6:101592174	A/G	cg27451362	chr6:101846650	GRIK2	0.84	11.36	0.47	1.45e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs4888262	0.508	rs12598701	chr16:74539904	G/A	cg01733217	chr16:74700730	RFWD3	0.83	16.41	0.61	5.16e-48	Testicular germ cell tumor;
LGG	cis	rs9886651	0.869	rs4074704	chr8:128787032	C/T	cg24514600	chr8:128805414	PVT1	-0.54	-12.18	-0.49	8.45e-30	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg18404041	chr3:52824283	ITIH1	-0.5	-9.24	-0.39	8.64e-19	Electroencephalogram traits;
LGG	cis	rs7582180	0.764	rs1946799	chr2:100921136	C/A	cg14675211	chr2:100938903	LONRF2	0.64	11.2	0.46	6.28e-26	Intelligence (multi-trait analysis);
LGG	cis	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg21775007	chr8:11205619	TDH	-0.57	-9.41	-0.4	2.34e-19	Neuroticism;
LGG	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg23531748	chr20:60969906	CABLES2	0.45	8.2	0.36	2.43e-15	Colorectal cancer;
LGG	cis	rs3858526	0.883	rs7481882	chr11:5944221	A/G	cg13902645	chr11:5959945	NA	-0.67	-10.7	-0.45	5.07e-24	DNA methylation (variation);
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg21862992	chr11:68658383	NA	0.5	8.55	0.37	1.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs752010	0.619	rs10789406	chr1:42105182	G/T	cg16096631	chr1:42092165	HIVEP3	-0.57	-13.81	-0.54	1.38e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs1980288	chr15:45620612	T/C	cg10760299	chr15:45669010	GATM	0.4	7.68	0.34	9.31e-14	Homoarginine levels;
LGG	cis	rs11644362	0.932	rs34290494	chr16:12987705	A/C	cg06890432	chr16:12997467	SHISA9	-0.32	-7.07	-0.31	5.7e-12	Positive affect;Subjective well-being;
LGG	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg08305652	chr11:111469057	NA	-0.46	-9.27	-0.4	7.14e-19	Primary sclerosing cholangitis;
LGG	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.8	0.45	2.07e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7089973	0.604	rs11196941	chr10:116596258	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.45	0.33	4.56e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs910187	0.605	rs6018317	chr20:45803236	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.35	-0.4	3.67e-19	Migraine;
LGG	cis	rs798554	0.655	rs798492	chr7:2799184	C/T	cg19524238	chr7:2802976	GNA12	-0.3	-7.41	-0.33	6.04e-13	Height;
LGG	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	trans	rs637571	0.522	rs538954	chr11:65756808	A/G	cg17712092	chr4:129076599	LARP1B	0.75	14.46	0.56	2.19e-39	Eosinophil percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06845991	chr7:90032834	CLDN12	0.46	7.46	0.33	4.2e-13	Cognitive performance;
LGG	cis	rs62238980	0.614	rs17683448	chr22:32487744	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs3845702	0.736	rs16867131	chr2:180848651	A/G	cg01881094	chr2:180872142	CWC22	-1.29	-16.8	-0.62	8.69e-50	Schizophrenia;
LGG	cis	rs977987	0.778	rs12929908	chr16:75462071	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.86	0.42	6.22e-21	Dupuytren's disease;
LGG	trans	rs7726839	0.540	rs7434	chr5:660804	A/G	cg25482853	chr8:67687455	SGK3	-0.94	-11.74	-0.48	4.66e-28	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6578185	0.810	rs7816220	chr8:142453585	T/C	cg07762003	chr8:142452454	FLJ43860	-0.63	-13.09	-0.52	1.57e-33	Endometriosis;
LGG	cis	rs2154319	0.836	rs2749419	chr1:41551441	G/A	cg02290550	chr1:41487317	SLFNL1	-0.5	-9.15	-0.39	1.8e-18	Height;
LGG	cis	rs1008375	1.000	rs3846357	chr4:17635887	A/T	cg04450456	chr4:17643702	FAM184B	0.33	7.34	0.32	9.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3916	0.794	rs3021337	chr12:121163261	C/T	cg21892295	chr12:121157589	UNC119B	-0.4	-7.23	-0.32	1.95e-12	Urinary metabolites (H-NMR features);
LGG	cis	rs3093024	0.967	rs1571878	chr6:167540842	C/T	cg07741184	chr6:167504864	NA	-0.36	-8.0	-0.35	9.98e-15	Rheumatoid arthritis;
LGG	cis	rs10048158	0.530	rs7222710	chr17:64200241	C/T	cg19474267	chr17:64306194	PRKCA	0.63	12.71	0.51	6.16e-32	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs6694270	0.529	rs35941610	chr1:19104930	C/T	cg13786083	chr1:19110734	NA	-0.4	-6.91	-0.31	1.58e-11	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs3126085	0.932	rs72696991	chr1:152250235	T/C	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs4820294	0.669	rs35662099	chr22:38053909	C/T	cg00292662	chr22:38071168	LGALS1	0.65	14.91	0.57	2.31e-41	Fat distribution (HIV);
LGG	cis	rs28595532	0.920	rs115994609	chr4:119777273	G/A	cg21605333	chr4:119757512	SEC24D	1.47	13.64	0.54	7.78e-36	Cannabis dependence symptom count;
LGG	cis	rs42648	0.837	rs12375075	chr7:89940331	G/A	cg25739043	chr7:89950458	NA	-0.44	-9.46	-0.4	1.59e-19	Homocysteine levels;
LGG	cis	rs7599312	0.534	rs6435711	chr2:213410065	G/A	cg20637307	chr2:213403960	ERBB4	0.74	16.69	0.61	2.77e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2762353	0.562	rs1165206	chr6:25867566	G/A	cg03517284	chr6:25882590	NA	-0.55	-10.2	-0.43	3.49e-22	Blood metabolite levels;
LGG	cis	rs798554	0.679	rs2533870	chr7:2885274	C/G	cg19524238	chr7:2802976	GNA12	-0.37	-8.94	-0.38	9.32e-18	Height;
LGG	cis	rs11764590	0.694	rs11762413	chr7:2090387	C/G	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.27	-0.36	1.44e-15	Neuroticism;
LGG	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg25486957	chr4:152246857	NA	-0.53	-8.56	-0.37	1.68e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg19812747	chr11:111475976	SIK2	-0.51	-10.71	-0.45	4.78e-24	Primary sclerosing cholangitis;
LGG	cis	rs4363385	0.510	rs6686526	chr1:153044996	T/C	cg13444842	chr1:152974279	SPRR3	-0.46	-9.22	-0.39	1.07e-18	Inflammatory skin disease;
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.67	0.41	2.81e-20	Height;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg05552183	chr6:42928497	GNMT	0.44	13.05	0.52	2.24e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg17951613	chr5:131705445	SLC22A5	0.62	7.08	0.31	5.27e-12	Rheumatoid arthritis;
LGG	cis	rs10871290	0.881	rs11649338	chr16:74471420	C/T	cg01733217	chr16:74700730	RFWD3	-0.71	-13.71	-0.54	3.65e-36	Breast cancer;
LGG	cis	rs41271473	0.539	rs763519	chr1:228892855	A/G	cg00850481	chr1:228891306	NA	0.69	14.22	0.55	2.43e-38	Chronic lymphocytic leukemia;
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17376030	chr22:41985996	PMM1	-0.54	-8.63	-0.37	1.01e-16	Vitiligo;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.66e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.54	-0.63	3.44e-53	Morning vs. evening chronotype;
LGG	cis	rs8030485	0.536	rs1915724	chr15:79441027	A/G	cg17916960	chr15:79447300	NA	0.55	10.3	0.43	1.55e-22	Left ventricle wall thickness;
LGG	trans	rs459571	0.804	rs448918	chr9:136885979	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.42	-6.67	-0.3	7.42e-11	Platelet distribution width;
LGG	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg08807101	chr21:30365312	RNF160	0.59	8.29	0.36	1.27e-15	Cognitive test performance;
LGG	cis	rs13064447	0.845	rs67698281	chr3:12774921	G/T	cg23032965	chr3:12705835	RAF1	-0.45	-6.88	-0.3	2e-11	Major depression and alcohol dependence;
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.25	0.39	8.3e-19	Height;
LGG	cis	rs1461503	0.868	rs11602682	chr11:122842315	A/T	cg27398637	chr11:122830231	C11orf63	-0.7	-13.68	-0.54	5.08e-36	Menarche (age at onset);
LGG	cis	rs2040771	0.804	rs1340958	chr22:19253332	A/G	cg02655711	chr22:19163373	SLC25A1	-0.47	-8.26	-0.36	1.58e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs981844	1.000	rs72731669	chr4:154662464	G/A	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs701145	0.585	rs1727948	chr3:153876929	G/T	cg17054900	chr3:154042577	DHX36	0.79	9.45	0.4	1.72e-19	Coronary artery disease;
LGG	trans	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg11887960	chr12:57824829	NA	0.6	7.38	0.32	7.58e-13	Lung disease severity in cystic fibrosis;
LGG	trans	rs9354308	0.901	rs2814121	chr6:66566915	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.01	0.42	1.71e-21	Metabolite levels;
LGG	cis	rs10463554	0.927	rs158399	chr5:102413268	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg03264133	chr6:25882463	NA	-0.43	-7.66	-0.34	1.11e-13	Height;
LGG	cis	rs965513	1.000	rs10759927	chr9:100542176	A/G	cg13688889	chr9:100608707	NA	-0.52	-9.5	-0.4	1.14e-19	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.04	0.35	7.72e-15	Obesity-related traits;
LGG	cis	rs798554	0.679	rs13230995	chr7:2887284	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.97	0.38	7.68e-18	Height;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.29	-0.4	6.09e-19	Lung cancer;
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-11.77	-0.48	3.87e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs1878931	0.582	rs27232	chr16:3436782	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.73	-11.34	-0.47	1.82e-26	Body mass index (adult);
LGG	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg11984989	chr7:158649758	WDR60	0.89	12.17	0.49	9.23e-30	Height;
LGG	cis	rs8049040	0.586	rs13333985	chr16:71550853	T/C	cg08717414	chr16:71523259	ZNF19	-0.55	-8.45	-0.37	3.78e-16	Blood protein levels;
LGG	trans	rs7395662	0.581	rs10769445	chr11:48765594	A/C	cg15704280	chr7:45808275	SEPT13	0.5	8.13	0.35	3.83e-15	HDL cholesterol;
LGG	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg06271696	chr7:157225062	NA	-0.56	-11.85	-0.48	1.82e-28	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs2708377	0.929	rs73053768	chr12:11155747	A/G	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.63	-6.9	-0.31	1.77e-11	Bitter taste perception;
LGG	cis	rs2228479	0.717	rs11649210	chr16:89807233	C/G	cg00800038	chr16:89945340	TCF25	-0.68	-8.92	-0.38	1.11e-17	Skin colour saturation;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg19901468	chr14:105411992	AHNAK2	-0.89	-18.7	-0.66	1.55e-58	Rheumatoid arthritis;
LGG	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg21475434	chr5:93447410	FAM172A	0.72	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.57	-0.33	2.03e-13	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.15	0.43	5.36e-22	Diabetic retinopathy;
LGG	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg21775007	chr8:11205619	TDH	0.46	7.53	0.33	2.72e-13	Neuroticism;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.27	0.32	1.51e-12	Menopause (age at onset);
LGG	cis	rs1878931	0.580	rs8062722	chr16:3409161	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.94	20.45	0.69	1.08e-66	Body mass index (adult);
LGG	cis	rs2274273	0.905	rs8007944	chr14:55576816	A/C	cg04306507	chr14:55594613	LGALS3	0.65	18.55	0.65	7.97e-58	Protein biomarker;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg16507663	chr6:150244633	RAET1G	0.5	10.01	0.42	1.79e-21	Testicular germ cell tumor;
LGG	trans	rs6582630	0.519	rs7294292	chr12:38349540	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs877282	0.898	rs11253353	chr10:766862	C/A	cg22713356	chr15:30763199	NA	0.52	7.7	0.34	8.18e-14	Uric acid levels;
LGG	cis	rs7918232	0.882	rs788211	chr10:27479070	C/T	cg14442939	chr10:27389572	ANKRD26	-0.75	-11.77	-0.48	3.7e-28	Breast cancer;
LGG	cis	rs12908161	1.000	rs35726233	chr15:85337800	C/T	cg03959625	chr15:84868606	LOC388152	0.48	7.03	0.31	7.68e-12	Schizophrenia;
LGG	cis	rs1805008	0.535	rs4785621	chr16:90130735	C/T	cg02754936	chr16:89883356	FANCA	-0.64	-6.82	-0.3	2.86e-11	Skin colour saturation;
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.34	0.4	4.18e-19	Monocyte count;
LGG	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.31	0.32	1.17e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg21775007	chr8:11205619	TDH	-0.75	-12.86	-0.51	1.46e-32	Retinal vascular caliber;
LGG	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg14154082	chr13:112174009	NA	0.42	9.18	0.39	1.42e-18	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.11	0.52	1.34e-33	Lung cancer;
LGG	cis	rs6456156	0.583	rs7748224	chr6:167456860	C/T	cg07741184	chr6:167504864	NA	0.4	8.97	0.38	7.29e-18	Primary biliary cholangitis;
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg22398616	chr13:53314203	LECT1	-0.35	-6.95	-0.31	1.21e-11	Lewy body disease;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.29	0.4	6.12e-19	Electroencephalogram traits;
LGG	cis	rs2227564	0.597	rs12256103	chr10:75545251	A/G	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.87	-0.42	5.43e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6001982	0.510	rs55844816	chr22:40803112	C/T	cg07138101	chr22:40742427	ADSL	0.61	6.7	0.3	6.14e-11	Breast cancer;
LGG	cis	rs10504229	0.554	rs17802082	chr8:58095867	C/T	cg05313129	chr8:58192883	C8orf71	-0.63	-8.47	-0.37	3.35e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6594713	0.921	rs7729269	chr5:112720394	A/G	cg12552261	chr5:112820674	MCC	0.5	7.03	0.31	7.32e-12	Brain cytoarchitecture;
LGG	cis	rs35306767	0.903	rs1341741	chr10:888073	A/G	cg26597838	chr10:835615	NA	0.74	10.39	0.43	7.3e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg18050959	chr15:68126178	NA	-0.37	-6.68	-0.3	6.96e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs4650994	0.571	rs35758545	chr1:178511924	C/T	cg19399532	chr1:178512495	C1orf220	-0.4	-7.4	-0.33	6.39e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1577917	0.633	rs7770835	chr6:86608907	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.7	-0.34	8.2e-14	Response to antipsychotic treatment;
LGG	cis	rs62238980	0.614	rs74611447	chr22:32417612	T/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs11771526	0.901	rs10252755	chr7:32304676	G/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg23484912	chr5:273055	PDCD6	-0.48	-9.9	-0.42	4.4e-21	Pancreatic cancer;
LGG	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg03342759	chr3:160939853	NMD3	-0.73	-11.99	-0.49	4.71e-29	Parkinson's disease;
LGG	cis	rs2734839	0.964	rs1800498	chr11:113291588	G/A	cg14159747	chr11:113255604	NA	0.27	7.25	0.32	1.77e-12	Information processing speed;
LGG	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg02753203	chr1:228287806	NA	0.94	19.36	0.67	1.3e-61	Diastolic blood pressure;
LGG	cis	rs7296418	0.699	rs11057219	chr12:123750073	T/C	cg00376283	chr12:123451042	ABCB9	0.63	11.67	0.48	8.98e-28	Platelet count;
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg26668828	chr6:292823	DUSP22	-0.49	-8.81	-0.38	2.58e-17	Menopause (age at onset);
LGG	cis	rs1165205	0.500	rs629835	chr6:25879330	T/C	cg12310025	chr6:25882481	NA	-0.94	-20.4	-0.69	1.84e-66	Urate levels;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs370915	1.000	rs370915	chr4:187818256	C/G	cg19519643	chr4:187840862	NA	-0.45	-8.32	-0.36	9.96e-16	Gout;
LGG	cis	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.15	-0.32	3.37e-12	Joint mobility (Beighton score);
LGG	cis	rs9513627	0.915	rs73556182	chr13:100122107	A/G	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg11584989	chr19:19387371	SF4	-0.39	-7.1	-0.31	4.81e-12	Tonsillectomy;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs3762637	1.000	rs9867429	chr3:122232668	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.58	-0.44	1.41e-23	LDL cholesterol levels;
LGG	cis	rs4696584	0.877	rs6819298	chr4:155397921	G/T	cg13738195	chr4:155413469	DCHS2	0.36	7.36	0.32	8.71e-13	Folding of antihelix;
LGG	cis	rs7647973	1.000	rs1009051	chr3:49521549	G/A	cg06212747	chr3:49208901	KLHDC8B	0.51	8.05	0.35	6.87e-15	Menarche (age at onset);
LGG	cis	rs7769051	1.000	rs9493438	chr6:133098349	T/C	cg22852734	chr6:133119734	C6orf192	1.17	14.96	0.57	1.53e-41	Type 2 diabetes nephropathy;
LGG	cis	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg12826209	chr6:26865740	GUSBL1	0.73	6.68	0.3	6.71e-11	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02132458	chr4:57333267	SRP72	-0.44	-6.79	-0.3	3.41e-11	Systemic lupus erythematosus;
LGG	cis	rs1153858	1.000	rs12439274	chr15:45636667	A/G	cg10760299	chr15:45669010	GATM	0.4	7.97	0.35	1.29e-14	Homoarginine levels;
LGG	cis	rs13088645	0.729	rs7620040	chr3:134163082	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.47	-8.14	-0.35	3.57e-15	Coronary artery disease;
LGG	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg22920501	chr2:26401640	FAM59B	-0.45	-9.35	-0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg18128536	chr17:47092178	IGF2BP1	-0.5	-9.62	-0.41	4.17e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs7586879	0.796	rs11684619	chr2:25078859	G/A	cg04586622	chr2:25135609	ADCY3	0.36	8.69	0.37	6.24e-17	Body mass index;
LGG	trans	rs7395662	1.000	rs4882129	chr11:48588774	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg01620082	chr3:125678407	NA	-0.76	-7.62	-0.33	1.43e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg05535760	chr7:792225	HEATR2	-0.79	-11.08	-0.46	1.77e-25	Cerebrospinal P-tau181p levels;
LGG	cis	rs6489882	0.867	rs7315441	chr12:113365687	G/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.48	-0.33	3.73e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7662987	0.517	rs2851260	chr4:100033574	C/T	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs17345786	0.906	rs72946021	chr3:101250008	T/G	cg12386194	chr3:101231763	SENP7	0.73	12.6	0.51	1.72e-31	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2540226	0.575	rs2716683	chr2:39908418	T/C	cg02886589	chr2:39892450	TMEM178	0.31	8.6	0.37	1.26e-16	Personality dimensions;
LGG	cis	rs13102973	0.965	rs11730310	chr4:135861925	A/G	cg14419869	chr4:135874104	NA	0.58	10.9	0.45	8.78e-25	Subjective well-being;
LGG	cis	rs1707322	0.686	rs11211179	chr1:46228082	A/C	cg03146154	chr1:46216737	IPP	0.59	11.02	0.46	3.07e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3733346	0.529	rs73209867	chr4:899168	C/T	cg04824913	chr4:887549	GAK	0.45	7.1	0.31	4.71e-12	Sjögren's syndrome;
LGG	cis	rs7914558	0.966	rs3902934	chr10:104746649	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.53	0.44	2.19e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.615	rs1561917	chr4:152479233	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.92	-0.31	1.49e-11	Joint mobility (Beighton score);
LGG	cis	rs12477438	0.520	rs13009147	chr2:99803998	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs1348850	0.914	rs7587604	chr2:178309848	T/A	cg22681709	chr2:178499509	PDE11A	-0.47	-8.87	-0.38	1.65e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7582180	0.629	rs4850926	chr2:100954117	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.12e-23	Intelligence (multi-trait analysis);
LGG	cis	rs883565	0.916	rs12636980	chr3:39124132	C/T	cg01426195	chr3:39028469	NA	0.61	12.05	0.49	2.78e-29	Handedness;
LGG	cis	rs758324	0.812	rs1875176	chr5:131202457	A/G	cg06307176	chr5:131281290	NA	-0.54	-8.88	-0.38	1.53e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs9842133	1.000	rs9842133	chr3:179664102	A/G	cg00645897	chr1:46713442	RAD54L	-0.38	-7.01	-0.31	8.49e-12	Blood metabolite levels;
LGG	cis	rs11700980	0.636	rs77555990	chr21:30229776	C/A	cg08807101	chr21:30365312	RNF160	-0.62	-6.72	-0.3	5.52e-11	QRS complex (12-leadsum);
LGG	cis	rs950776	0.518	rs56007453	chr15:78826239	T/C	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs4648845	0.579	rs4592207	chr1:2369498	A/G	cg12929805	chr1:2399054	NA	-0.45	-10.82	-0.45	1.74e-24	Schizophrenia;
LGG	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg24375607	chr4:120327624	NA	0.6	10.0	0.42	1.94e-21	Corneal astigmatism;
LGG	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-7.14	-0.32	3.53e-12	Height;
LGG	cis	rs3126085	0.696	rs41266112	chr1:152185762	C/G	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.38e-17	Atopic dermatitis;
LGG	cis	rs62400317	0.859	rs10456543	chr6:45178907	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.2	-0.43	3.58e-22	Total body bone mineral density;
LGG	cis	rs7100689	0.754	rs10736339	chr10:82059970	G/C	cg01528321	chr10:82214614	TSPAN14	0.88	15.9	0.59	9.5e-46	Post bronchodilator FEV1;
LGG	cis	rs9880211	0.948	rs9857966	chr3:136279390	A/G	cg21827317	chr3:136751795	NA	-0.48	-7.13	-0.31	3.82e-12	Body mass index;Height;
LGG	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg26384229	chr12:38710491	ALG10B	0.74	14.87	0.57	3.56e-41	Morning vs. evening chronotype;
LGG	cis	rs17039065	0.920	rs1017432	chr4:109474255	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.27	0.32	1.51e-12	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.615	rs2120098	chr4:152457180	T/A	cg22705602	chr4:152727874	NA	-0.29	-6.97	-0.31	1.13e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg09855544	chr8:135498122	ZFAT	0.46	7.88	0.34	2.28e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4319547	0.774	rs7307233	chr12:123124301	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.59	-8.98	-0.39	6.82e-18	Body mass index;
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs6684428	0.536	rs12744110	chr1:56396309	T/C	cg11651538	chr1:56320950	NA	0.39	7.63	0.33	1.39e-13	Airflow obstruction;
LGG	cis	rs12476592	0.571	rs10865341	chr2:63824050	A/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.73	-0.3	5.16e-11	Childhood ear infection;
LGG	cis	rs765787	0.530	rs2458224	chr15:45522130	T/C	cg24006582	chr15:45444508	DUOX1	-0.63	-11.43	-0.47	8.01e-27	Uric acid levels;
LGG	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-7.99	-0.35	1.07e-14	Self-reported allergy;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg14338887	chr6:42928500	GNMT	-0.27	-8.65	-0.37	8.47e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg24060327	chr5:131705240	SLC22A5	0.63	6.79	0.3	3.47e-11	Rheumatoid arthritis;
LGG	cis	rs17776563	0.887	rs72763808	chr15:89132114	G/A	cg05013243	chr15:89149849	MIR1179	-0.51	-10.45	-0.44	4.4e-23	Thyroid hormone levels;
LGG	trans	rs3780486	0.718	rs10971418	chr9:33122024	A/C	cg04842962	chr6:43655489	MRPS18A	-0.86	-12.24	-0.49	4.7e-30	IgG glycosylation;
LGG	trans	rs1814175	0.647	rs2903409	chr11:49953612	C/G	cg03929089	chr4:120376271	NA	-0.8	-15.38	-0.58	2.01e-43	Height;
LGG	cis	rs75920871	0.528	rs10466590	chr11:116894413	C/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.42	-0.44	5.75e-23	Subjective well-being;
LGG	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg00383909	chr3:49044727	WDR6	0.43	7.1	0.31	4.63e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7760949	0.963	rs7761500	chr6:13917140	G/A	cg27413430	chr6:13925136	RNF182	0.43	6.79	0.3	3.4e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12478296	0.786	rs55876934	chr2:243033816	C/T	cg06360820	chr2:242988706	NA	-0.89	-11.57	-0.47	2.35e-27	Obesity-related traits;
LGG	cis	rs9815354	0.903	rs11705749	chr3:41947294	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2439831	0.850	rs7163245	chr15:43671294	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	13.15	0.52	9.13e-34	Lung cancer in ever smokers;
LGG	cis	rs7762018	0.607	rs79728466	chr6:170046405	T/C	cg19338460	chr6:170058176	WDR27	-0.87	-9.11	-0.39	2.49e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1401999	1.000	rs1402002	chr3:183642794	A/G	cg01324343	chr3:183735012	ABCC5	0.84	18.08	0.64	1.14e-55	Anterior chamber depth;
LGG	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9916302	0.904	rs2061342	chr17:37405657	T/G	cg00129232	chr17:37814104	STARD3	-0.62	-11.62	-0.48	1.48e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg18402987	chr7:1209562	NA	0.67	9.25	0.39	8.19e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg16346588	chr10:242978	ZMYND11	0.4	6.83	0.3	2.71e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs10504130	0.569	rs34372756	chr8:52821356	T/C	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.37e-17	Self-reported allergy;
LGG	cis	rs4732038	0.510	rs68103559	chr7:134279556	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.29	-0.63	4.85e-52	Longevity;
LGG	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg17809284	chr5:56205270	C5orf35	-0.35	-6.74	-0.3	4.81e-11	Coronary artery disease;
LGG	cis	rs7928758	0.943	rs7948031	chr11:134269091	T/C	cg25213107	chr11:134282864	B3GAT1	1.12	13.82	0.54	1.28e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2797369	0.883	rs2852547	chr6:101707835	C/T	cg27451362	chr6:101846650	GRIK2	0.84	11.15	0.46	1.01e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg01879757	chr17:41196368	BRCA1	-0.41	-8.58	-0.37	1.47e-16	Menopause (age at onset);
LGG	cis	rs727505	1.000	rs17246404	chr7:124462661	C/T	cg23710748	chr7:124431027	NA	-0.53	-10.05	-0.42	1.24e-21	Lewy body disease;
LGG	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg03929089	chr4:120376271	NA	-0.65	-11.71	-0.48	6.23e-28	Coronary artery disease;
LGG	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.85	-0.42	6.36e-21	Neuroticism;
LGG	trans	rs526821	0.595	rs608964	chr11:55339266	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg09754948	chr16:28834200	ATXN2L	0.43	6.82	0.3	2.94e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2842992	0.513	rs7759086	chr6:160193853	A/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.48	8.53	0.37	2.16e-16	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg23533926	chr12:111358616	MYL2	-0.43	-7.18	-0.32	2.71e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.879	rs4820437	chr22:41761290	T/C	cg17376030	chr22:41985996	PMM1	0.42	6.85	0.3	2.31e-11	Vitiligo;
LGG	cis	rs17767392	1.000	rs34011442	chr14:71779083	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.34e-18	Mitral valve prolapse;
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg14668632	chr7:2872130	GNA12	-0.33	-6.93	-0.31	1.38e-11	Height;
LGG	cis	rs2228479	0.702	rs11646374	chr16:89857935	G/A	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs2204008	0.623	rs1663281	chr12:38120936	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.98	-0.35	1.13e-14	Bladder cancer;
LGG	cis	rs977987	0.806	rs4888388	chr16:75394148	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	trans	rs9914544	0.689	rs11078421	chr17:18804385	A/G	cg21372672	chr17:16614065	CCDC144A	-0.41	-9.01	-0.39	5.4e-18	Educational attainment (years of education);
LGG	cis	rs9547996	0.808	rs9547976	chr13:38185728	A/G	cg13634560	chr13:38173852	POSTN	-0.34	-6.75	-0.3	4.4e-11	Diastolic blood pressure;
LGG	cis	rs12431410	0.550	rs10145018	chr14:60234274	A/G	cg07950296	chr14:60194823	RTN1	-0.4	-7.58	-0.33	1.87e-13	Schizophrenia;
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.9e-12	Electroencephalogram traits;
LGG	cis	rs4774830	0.744	rs62046386	chr15:56305252	G/A	cg24530489	chr15:56299380	NA	-0.84	-7.73	-0.34	6.56e-14	Delta-5 desaturase activity;
LGG	cis	rs11190604	1.000	rs4244338	chr10:102272802	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.33	0.32	1.04e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg24503407	chr1:205819492	PM20D1	0.52	8.71	0.38	5.26e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg05863683	chr7:1912471	MAD1L1	0.48	9.37	0.4	3.27e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.55	0.37	1.81e-16	Vitiligo;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25172604	chr17:41446521	NA	-0.3	-7.16	-0.32	3.15e-12	Menopause (age at onset);
LGG	cis	rs9309473	0.948	rs7603647	chr2:73817238	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.23	-0.32	2e-12	Metabolite levels;
LGG	cis	rs1153858	1.000	rs12437840	chr15:45669055	C/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg18876405	chr7:65276391	NA	-0.54	-9.7	-0.41	2.29e-20	Aortic root size;
LGG	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg13010199	chr12:38710504	ALG10B	0.45	8.05	0.35	6.92e-15	Morning vs. evening chronotype;
LGG	cis	rs721917	0.506	rs2475756	chr10:81656766	C/T	cg25562619	chr10:81652821	NA	-0.35	-8.17	-0.36	2.94e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg26513180	chr16:89883248	FANCA	0.94	21.2	0.7	3.43e-70	Vitiligo;
LGG	cis	rs7717393	0.786	rs10062636	chr5:155804588	G/C	cg12904904	chr5:155754151	SGCD	0.69	7.29	0.32	1.31e-12	Egg allergy;
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs35306767	0.855	rs35825568	chr10:950760	C/T	cg26597838	chr10:835615	NA	0.7	8.95	0.38	8.47e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7143963	0.502	rs11629241	chr14:103379225	T/C	cg23020514	chr14:103360112	TRAF3	0.35	7.1	0.31	4.64e-12	Body mass index;
LGG	cis	rs17253792	0.822	rs112739186	chr14:56065167	A/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs7615952	0.604	rs9837847	chr3:125623919	G/A	cg05084668	chr3:125655381	ALG1L	-1.13	-12.97	-0.52	4.81e-33	Blood pressure (smoking interaction);
LGG	cis	rs963731	0.579	rs297124	chr2:39313646	G/A	cg04010122	chr2:39346883	SOS1	-0.78	-8.06	-0.35	6.71e-15	Corticobasal degeneration;
LGG	cis	rs951366	0.622	rs11580015	chr1:205676088	G/C	cg13453750	chr1:205783389	SLC41A1	-0.4	-7.75	-0.34	5.99e-14	Menarche (age at onset);
LGG	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.13	0.52	1.04e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs4666002	0.789	rs12998770	chr2:27913188	T/C	cg27432699	chr2:27873401	GPN1	0.55	7.77	0.34	4.98e-14	Phospholipid levels (plasma);
LGG	trans	rs61931739	0.620	rs1482981	chr12:33691763	C/G	cg26384229	chr12:38710491	ALG10B	-0.49	-8.68	-0.37	6.55e-17	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg14500267	chr11:67383377	NA	0.46	8.57	0.37	1.54e-16	Mean corpuscular volume;
LGG	cis	rs7552404	1.000	rs1498312	chr1:76177849	C/T	cg22875332	chr1:76189707	ACADM	0.62	10.4	0.44	6.62e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg27490568	chr2:178487706	NA	0.7	13.14	0.52	9.23e-34	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg11301795	chr4:187892539	NA	-0.93	-25.33	-0.76	1.92e-89	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2404602	0.583	rs12908334	chr15:76581592	C/T	cg23625390	chr15:77176239	SCAPER	0.41	7.69	0.34	8.78e-14	Blood metabolite levels;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11245990	chr11:68621969	NA	0.44	9.12	0.39	2.24e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs853679	0.607	rs34396849	chr6:28250955	A/C	cg08344181	chr3:125677491	NA	-0.89	-9.12	-0.39	2.39e-18	Depression;
LGG	cis	rs7658486	0.661	rs17024223	chr4:148888491	G/A	cg05573550	chr4:148890890	ARHGAP10	-0.46	-7.04	-0.31	6.76e-12	Immune reponse to smallpox (secreted IL-12p40);
LGG	cis	rs9910055	0.552	rs4793084	chr17:42317371	G/T	cg19774624	chr17:42201019	HDAC5	0.5	8.25	0.36	1.69e-15	Total body bone mineral density;
LGG	cis	rs9611565	0.572	rs139569	chr22:42211141	A/G	cg06634786	chr22:41940651	POLR3H	-0.64	-10.45	-0.44	4.14e-23	Vitiligo;
LGG	cis	rs3820068	0.603	rs59475085	chr1:15911131	G/A	cg05660106	chr1:15850417	CASP9	1.02	22.0	0.71	5.78e-74	Systolic blood pressure;
LGG	cis	rs60843830	1.000	rs2126129	chr2:212548	C/T	cg04617936	chr2:214353	NA	-0.39	-7.22	-0.32	2.1e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs727505	1.000	rs66513837	chr7:124492763	A/G	cg23710748	chr7:124431027	NA	-0.53	-10.0	-0.42	1.83e-21	Lewy body disease;
LGG	cis	rs11722228	0.522	rs881641	chr4:10133747	G/A	cg08250081	chr4:10125330	NA	0.63	11.6	0.47	1.74e-27	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9543976	0.588	rs7324195	chr13:76192522	G/A	cg01531495	chr13:76123901	UCHL3	0.51	6.65	0.3	8.13e-11	Diabetic retinopathy;
LGG	cis	rs7523273	0.565	rs2488248	chr1:207899682	C/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.75	-0.38	4.07e-17	Schizophrenia;
LGG	trans	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.96	0.49	6.3e-29	Obesity-related traits;
LGG	cis	rs9596863	0.898	rs9568904	chr13:54330100	A/G	ch.13.53330881F	chr13:54432880	NA	0.54	7.3	0.32	1.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21008684	chr2:157198370	NA	0.45	7.66	0.34	1.08e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg10144569	chr3:42726640	KBTBD5	0.51	7.5	0.33	3.28e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs3780486	0.505	rs959749	chr9:33147858	T/C	cg20290983	chr6:43655470	MRPS18A	0.81	15.62	0.59	1.79e-44	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19740248	chr6:27114132	HIST1H2BK;HIST1H2AH	0.38	6.67	0.3	7.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs372883	0.648	rs11088117	chr21:30737816	G/C	cg24692254	chr21:30365293	RNF160	0.62	11.33	0.47	1.98e-26	Pancreatic cancer;
LGG	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg03060546	chr3:49711283	APEH	0.6	7.58	0.33	1.96e-13	Menarche (age at onset);
LGG	cis	rs8031584	0.918	rs61997140	chr15:31277312	A/G	cg08704250	chr15:31115839	NA	-0.42	-7.89	-0.34	2.15e-14	Huntington's disease progression;
LGG	trans	rs1814175	0.781	rs1851872	chr11:50009770	A/G	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg06532163	chr17:45867833	NA	-0.55	-9.26	-0.4	7.88e-19	IgG glycosylation;
LGG	cis	rs9926296	0.656	rs4522419	chr16:89853307	T/C	cg23057051	chr16:89984268	MC1R	-0.38	-7.28	-0.32	1.46e-12	Vitiligo;
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9487094	0.670	rs10457195	chr6:109855472	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs6502050	0.835	rs8070014	chr17:80115247	T/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9393777	0.513	rs6924727	chr6:26491234	A/G	cg12826209	chr6:26865740	GUSBL1	0.85	12.72	0.51	5.3e-32	Intelligence (multi-trait analysis);
LGG	cis	rs8114671	0.562	rs6120757	chr20:33488771	C/T	cg07148914	chr20:33460835	GGT7	0.56	9.4	0.4	2.53e-19	Height;
LGG	cis	rs7647973	0.600	rs35174559	chr3:49287759	T/C	cg02487422	chr3:49467188	NICN1	0.38	6.65	0.3	8.35e-11	Menarche (age at onset);
LGG	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg27129171	chr3:47204927	SETD2	0.82	15.11	0.57	3.32e-42	Colorectal cancer;
LGG	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg00976097	chr5:421733	AHRR	-0.4	-6.69	-0.3	6.41e-11	Cystic fibrosis severity;
LGG	cis	rs1580019	0.587	rs6972365	chr7:32548931	T/A	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.25e-22	Cognitive ability;
LGG	cis	rs2274273	1.000	rs11621351	chr14:55616740	C/A	cg04306507	chr14:55594613	LGALS3	0.61	17.06	0.62	5.74e-51	Protein biomarker;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg02609749	chr16:89786786	C16orf7;ZNF276	0.39	6.82	0.3	2.78e-11	Vitiligo;
LGG	cis	rs9487094	1.000	rs9320287	chr6:109744690	T/C	cg16315928	chr6:109776240	MICAL1	0.47	7.9	0.34	1.99e-14	Height;
LGG	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg18225595	chr11:63971243	STIP1	0.52	10.47	0.44	3.74e-23	Platelet count;
LGG	trans	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg01596870	chr19:55963115	NA	-0.46	-6.71	-0.3	5.87e-11	Obesity-related traits;
LGG	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg18225595	chr11:63971243	STIP1	0.48	9.35	0.4	3.85e-19	Platelet count;
LGG	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg15017067	chr4:17643749	FAM184B	0.32	7.43	0.33	5.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs35830138	chr6:149989771	T/C	cg09699651	chr6:150184138	LRP11	0.53	9.45	0.4	1.71e-19	Lung cancer;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg19673125	chr6:150240577	RAET1G	0.29	6.66	0.3	7.64e-11	Lung cancer;
LGG	cis	rs2430386	1.000	rs2430386	chr2:63178111	C/T	cg17519650	chr2:63277830	OTX1	0.61	11.44	0.47	7.15e-27	Prostate cancer;
LGG	cis	rs921968	0.541	rs2241527	chr2:219537224	A/G	cg01130898	chr2:219473002	PLCD4	-0.49	-8.38	-0.36	6.3e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg09699651	chr6:150184138	LRP11	0.57	11.0	0.46	3.8e-25	Lung cancer;
LGG	cis	rs7914558	0.966	rs10748837	chr10:104880236	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.41	0.44	6.06e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.45	-0.37	3.77e-16	Lewy body disease;
LGG	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg26354017	chr1:205819088	PM20D1	-0.42	-7.41	-0.33	5.84e-13	Menarche (age at onset);
LGG	cis	rs1535500	0.905	rs2146262	chr6:39283793	C/T	cg06347083	chr6:39282316	KCNK17	0.42	12.29	0.5	3.03e-30	Type 2 diabetes;
LGG	cis	rs79349575	0.756	rs937301	chr17:47046276	A/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-7.86	-0.34	2.67e-14	Type 2 diabetes;
LGG	cis	rs7208859	0.524	rs57670615	chr17:29069498	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg08344181	chr3:125677491	NA	0.63	6.68	0.3	6.9e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg22903657	chr4:1355424	KIAA1530	-0.31	-6.69	-0.3	6.41e-11	Obesity-related traits;
LGG	cis	rs4820539	0.966	rs2267005	chr22:23461723	A/G	cg14186256	chr22:23484241	RTDR1	0.98	24.8	0.76	5.11e-87	Bone mineral density;
LGG	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg07936489	chr17:37558343	FBXL20	1.0	15.87	0.59	1.4e-45	Glomerular filtration rate (creatinine);
LGG	trans	rs45509595	0.841	rs370155	chr6:27782031	T/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.65	-0.44	7.66e-24	Breast cancer;
LGG	cis	rs17453880	0.781	rs17113485	chr5:151978353	A/G	cg10931792	chr5:152022470	NA	0.38	8.3	0.36	1.11e-15	Subjective well-being;
LGG	cis	rs40363	0.645	rs6501177	chr16:3523681	C/T	cg21433313	chr16:3507492	NAT15	0.41	6.65	0.3	8.44e-11	Tuberculosis;
LGG	cis	rs7843479	0.870	rs1809498	chr8:21836384	C/G	cg17168535	chr8:21777572	XPO7	-0.6	-9.64	-0.41	3.64e-20	Mean corpuscular volume;
LGG	cis	rs11169225	0.906	rs399023	chr12:50338952	A/C	cg04450003	chr12:50355995	AQP5	0.37	7.31	0.32	1.22e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6840360	0.550	rs4696288	chr4:152621150	A/C	cg25486957	chr4:152246857	NA	-0.51	-8.11	-0.35	4.55e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7216064	1.000	rs11079706	chr17:65835470	G/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.81	-0.38	2.63e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7208859	0.623	rs3752020	chr17:29111125	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17221829	0.702	rs72969198	chr11:89357607	T/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.24	-0.39	9.04e-19	Anxiety in major depressive disorder;
LGG	cis	rs6500602	0.767	rs8060219	chr16:4480158	T/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.37	7.56	0.33	2.25e-13	Schizophrenia;
LGG	cis	rs1348850	0.668	rs6705405	chr2:178493713	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.49	-0.33	3.46e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs864537	0.622	rs1214598	chr1:167426424	C/T	cg09179987	chr1:167433047	CD247	0.43	9.26	0.4	7.45e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg15208524	chr1:10270712	KIF1B	0.44	7.99	0.35	1.11e-14	Hepatocellular carcinoma;
LGG	trans	rs11088226	0.692	rs8127603	chr21:33886658	T/C	cg09050820	chr6:167586206	TCP10L2	0.48	7.47	0.33	3.9e-13	Gastritis;
LGG	cis	rs9596863	0.898	rs35732706	chr13:54343886	T/G	ch.13.53330881F	chr13:54432880	NA	0.53	7.16	0.32	3.15e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs209489	0.892	rs77340995	chr6:53111758	A/G	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs11864453	0.826	rs6499560	chr16:72147666	G/T	cg23815491	chr16:72088622	HP	-0.52	-11.48	-0.47	4.92e-27	Fibrinogen levels;
LGG	cis	rs6977660	0.943	rs10277755	chr7:19826843	C/A	cg05791153	chr7:19748676	TWISTNB	0.54	8.12	0.35	4.12e-15	Thyroid stimulating hormone;
LGG	cis	rs7493	1.000	rs17876124	chr7:95045258	C/G	cg08461772	chr7:95026248	PON3	0.38	8.35	0.36	7.85e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs8018808	0.935	rs8018513	chr14:77928288	T/C	cg20045696	chr14:77926864	AHSA1	0.39	6.7	0.3	6.25e-11	Myeloid white cell count;
LGG	trans	rs8002861	0.840	rs1819596	chr13:44429554	A/G	cg17145862	chr1:211918768	LPGAT1	0.94	23.15	0.73	2.52e-79	Leprosy;
LGG	cis	rs72792276	1.000	rs72794370	chr5:127444907	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.75	0.3	4.57e-11	Red cell distribution width;
LGG	cis	rs68170813	0.641	rs61511581	chr7:106948091	T/A	cg02696742	chr7:106810147	HBP1	-0.71	-10.21	-0.43	3.22e-22	Coronary artery disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13717023	chr5:53606639	ARL15	-0.49	-7.24	-0.32	1.94e-12	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.23	-0.32	2.01e-12	Life satisfaction;
LGG	cis	rs6908034	0.505	rs76391302	chr6:19819116	G/A	cg02682789	chr6:19804855	NA	0.9	8.42	0.36	4.83e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2386661	0.826	rs1317516	chr10:5672720	A/G	cg26603656	chr10:5671107	NA	-0.37	-7.46	-0.33	4.4e-13	Breast cancer;
LGG	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs3785574	0.962	rs2665840	chr17:61873307	C/T	cg06873352	chr17:61820015	STRADA	-0.48	-7.45	-0.33	4.55e-13	Height;
LGG	cis	rs2018055	0.783	rs1885064	chr6:117790566	C/T	cg14611402	chr6:117803162	DCBLD1	0.31	8.48	0.37	3.11e-16	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	trans	rs6787172	0.702	rs827126	chr3:158011934	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.81	0.38	2.6e-17	Subjective well-being;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4819052	0.851	rs28501512	chr21:46676702	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.77	0.51	3.23e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs796364	0.906	rs1658810	chr2:200816382	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.02e-24	Schizophrenia;
LGG	cis	rs6582630	0.519	rs11519914	chr12:38287014	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.58	0.33	1.85e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.91	-0.42	4.08e-21	Personality dimensions;
LGG	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg27279351	chr12:120934652	DYNLL1	0.81	13.25	0.52	3.35e-34	High light scatter reticulocyte count;
LGG	trans	rs11088226	0.846	rs2154500	chr21:33926391	T/C	cg09050820	chr6:167586206	TCP10L2	0.69	10.79	0.45	2.27e-24	Gastritis;
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg13939156	chr17:80058883	NA	0.54	10.99	0.45	3.95e-25	Life satisfaction;
LGG	cis	rs26868	0.766	rs27556	chr16:2249325	T/C	cg02248941	chr16:2239361	CASKIN1	0.47	9.51	0.4	1.09e-19	Height;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg05368731	chr17:41323189	NBR1	0.95	19.0	0.66	6.52e-60	Menopause (age at onset);
LGG	cis	rs123509	0.687	rs73077220	chr3:42842340	T/C	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.19	-0.55	3.29e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg07169764	chr2:136633963	MCM6	-0.45	-7.27	-0.32	1.5e-12	Colorectal cancer;
LGG	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08862035	chr2:2617432	NA	0.42	6.8	0.3	3.31e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6088580	0.634	rs1890002	chr20:32919219	A/G	cg08999081	chr20:33150536	PIGU	-0.4	-10.08	-0.42	1e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs986417	1.000	rs761555	chr14:61109543	T/C	cg27398547	chr14:60952738	C14orf39	0.73	6.72	0.3	5.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs853679	0.513	rs9468296	chr6:28113730	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg00579200	chr11:133705235	NA	-0.6	-11.42	-0.47	8.55e-27	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22645636	chr2:55496232	MTIF2	0.48	6.96	0.31	1.16e-11	Gut microbiome composition (summer);
LGG	cis	rs9303401	0.538	rs2240258	chr17:56458183	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.51	0.5	3.85e-31	Cognitive test performance;
LGG	cis	rs367943	1.000	rs348955	chr5:112821643	C/T	cg27587195	chr5:112824172	MCC	-0.45	-7.25	-0.32	1.8e-12	Type 2 diabetes;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg24846343	chr22:24311635	DDTL	0.62	12.52	0.5	3.61e-31	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.13e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.48	-0.33	3.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs72781680	0.898	rs72790310	chr2:24116716	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	9.0	0.39	6.02e-18	Lymphocyte counts;
LGG	cis	rs6951245	1.000	rs79765398	chr7:1073764	A/G	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.71	12.83	0.51	1.96e-32	Obesity-related traits;
LGG	cis	rs483180	0.512	rs598685	chr1:120215269	G/A	cg19096424	chr1:120255104	PHGDH	0.63	11.13	0.46	1.13e-25	Macular telangiectasia type 2;
LGG	cis	rs2669010	1.000	rs4432068	chr12:76982825	A/C	cg14998926	chr12:77026162	NA	-0.39	-6.93	-0.31	1.41e-11	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg10295955	chr4:187884368	NA	-1.14	-29.54	-0.81	1.34e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7106204	0.609	rs11821417	chr11:24279139	G/T	ch.11.24196551F	chr11:24239977	NA	0.86	9.5	0.4	1.15e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1728785	0.901	rs3087783	chr16:68599668	C/T	cg02972257	chr16:68554789	NA	-0.56	-8.19	-0.36	2.62e-15	Ulcerative colitis;
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs4665809	0.878	rs6748745	chr2:26364190	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.91	-15.33	-0.58	3.33e-43	Gut microbiome composition (summer);
LGG	cis	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg06521331	chr12:34319734	NA	-0.61	-11.39	-0.47	1.18e-26	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs873946	0.648	rs1543593	chr10:134553185	A/T	cg13271783	chr10:134563150	INPP5A	-0.54	-7.89	-0.34	2.15e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	cis	rs240764	0.817	rs239229	chr6:101105975	T/C	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.76	0.38	3.76e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4665809	0.590	rs13022190	chr2:26515055	C/T	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Gut microbiome composition (summer);
LGG	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg17644776	chr2:200775616	C2orf69	0.57	7.18	0.32	2.84e-12	Schizophrenia;
LGG	cis	rs4740619	0.522	rs9407649	chr9:15826603	C/G	cg14451791	chr9:16040625	NA	0.31	7.8	0.34	4.06e-14	Body mass index;
LGG	cis	rs6121246	0.821	rs6121209	chr20:30311258	G/C	cg13852791	chr20:30311386	BCL2L1	0.78	12.7	0.51	6.29e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6121246	0.567	rs6060295	chr20:30198473	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.44	6.92	0.31	1.49e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.16	0.35	3.25e-15	Colorectal cancer;
LGG	cis	rs875971	0.862	rs35378740	chr7:65987712	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.1	0.35	4.95e-15	Iron status biomarkers;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21963583	chr11:68658836	MRPL21	0.61	10.38	0.43	7.53e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs734999	0.545	rs6666430	chr1:2698950	G/A	cg20673091	chr1:2541236	MMEL1	0.77	17.19	0.62	1.37e-51	Ulcerative colitis;
LGG	cis	rs9611565	0.512	rs5758436	chr22:42124265	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.78	-0.45	2.49e-24	Vitiligo;
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.03	0.52	2.89e-33	Tonsillectomy;
LGG	cis	rs1005277	0.540	rs11011351	chr10:38030525	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.99	-0.31	9.5e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg19671926	chr4:122722719	EXOSC9	0.53	8.15	0.35	3.34e-15	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs3806843	0.832	rs2531360	chr5:140116664	G/A	cg19875535	chr5:140030758	IK	-0.54	-11.14	-0.46	1.09e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10089	1.000	rs10463838	chr5:127518305	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.6	0.47	1.73e-27	Ileal carcinoids;
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	cis	rs7168592	1.000	rs60161668	chr15:101732683	A/C	cg24254196	chr15:101719523	CHSY1	-0.62	-6.97	-0.31	1.13e-11	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	trans	rs61931739	0.679	rs10844831	chr12:34311245	G/T	cg26384229	chr12:38710491	ALG10B	0.65	12.43	0.5	8.63e-31	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg27471124	chr11:109292789	C11orf87	0.5	9.5	0.4	1.17e-19	Schizophrenia;
LGG	cis	rs7216064	0.648	rs61676547	chr17:65892507	G/C	cg12091567	chr17:66097778	LOC651250	-0.63	-9.16	-0.39	1.74e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg18402987	chr7:1209562	NA	0.67	9.04	0.39	4.43e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg21775007	chr8:11205619	TDH	0.78	13.68	0.54	5.08e-36	Retinal vascular caliber;
LGG	cis	rs2236293	0.755	rs10758325	chr9:35804149	A/G	cg12876594	chr9:35791798	NPR2	-0.43	-8.24	-0.36	1.82e-15	Blood protein levels;
LGG	trans	rs3942852	0.910	rs10742831	chr11:48119691	G/A	cg03929089	chr4:120376271	NA	-0.64	-7.95	-0.35	1.44e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10875746	0.669	rs1021313	chr12:48638041	T/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.45	-0.33	4.59e-13	Longevity (90 years and older);
LGG	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	7.74	0.34	6.29e-14	Initial pursuit acceleration;
LGG	cis	rs12579753	0.956	rs34146892	chr12:82188581	T/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.37	-0.47	1.4e-26	Resting heart rate;
LGG	cis	rs4812048	1.000	rs6070692	chr20:57586374	A/G	cg23907860	chr20:57583709	CTSZ	0.5	7.23	0.32	2.03e-12	Mean platelet volume;
LGG	cis	rs2404602	0.669	rs12916324	chr15:77179603	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs17767392	0.834	rs61989252	chr14:71727914	G/A	cg02058870	chr14:72053146	SIPA1L1	0.39	7.57	0.33	2.03e-13	Mitral valve prolapse;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs12200560	0.505	rs211165	chr6:97068520	A/T	cg06623918	chr6:96969491	KIAA0776	0.45	7.62	0.33	1.48e-13	Coronary heart disease;
LGG	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-13.36	-0.53	1.19e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2227631	0.505	rs4729662	chr7:100765559	C/T	cg18465962	chr7:100767262	NA	0.53	9.05	0.39	3.91e-18	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	trans	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg05084668	chr3:125655381	ALG1L	-0.55	-7.44	-0.33	4.89e-13	Blood pressure (smoking interaction);
LGG	trans	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.16	-0.32	3.1e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs55823223	0.618	rs11867339	chr17:73862093	A/G	cg14829360	chr17:73884958	NA	-0.8	-12.31	-0.5	2.63e-30	Psoriasis;
LGG	cis	rs7250872	0.606	rs1078229	chr19:1826383	A/C	cg18850929	chr19:1828978	REXO1	0.49	8.11	0.35	4.6e-15	Bipolar disorder;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.59	7.89	0.34	2.25e-14	Lung function (FEV1/FVC);
LGG	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg00745463	chr17:30367425	LRRC37B	-0.71	-10.38	-0.43	7.63e-23	Hip circumference adjusted for BMI;
LGG	trans	rs7395662	1.000	rs6485911	chr11:48654784	A/C	cg03929089	chr4:120376271	NA	-0.45	-7.36	-0.32	8.73e-13	HDL cholesterol;
LGG	cis	rs6732160	0.613	rs10179063	chr2:73385111	T/A	cg01422370	chr2:73384389	NA	0.57	9.9	0.42	4.37e-21	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg11764359	chr7:65958608	NA	-0.8	-14.95	-0.57	1.66e-41	Aortic root size;
LGG	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.97	0.49	5.68e-29	Vitiligo;
LGG	cis	rs2070433	0.904	rs11701571	chr21:47963149	A/G	cg12379764	chr21:47803548	PCNT	0.51	7.21	0.32	2.3e-12	Lymphocyte counts;
LGG	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg21399703	chr1:247681439	NA	0.65	11.54	0.47	3.11e-27	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4919087	0.962	rs10882889	chr10:99045890	A/G	cg25902810	chr10:99078978	FRAT1	0.51	9.52	0.4	9.93e-20	Monocyte count;
LGG	cis	rs11888559	0.655	rs4675309	chr2:203879503	A/G	cg24605529	chr2:203879461	NBEAL1	0.7	6.95	0.31	1.26e-11	Height;
LGG	cis	rs941764	0.965	rs941765	chr14:91841358	G/C	cg10511902	chr14:91842949	CCDC88C	0.71	16.18	0.6	5.55e-47	Breast cancer;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg08305652	chr11:111469057	NA	-0.45	-9.12	-0.39	2.32e-18	Primary sclerosing cholangitis;
LGG	trans	rs8002861	0.846	rs12867732	chr13:44483084	C/A	cg12856521	chr11:46389249	DGKZ	-0.45	-7.88	-0.34	2.4e-14	Leprosy;
LGG	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg08847533	chr14:75593920	NEK9	-0.61	-11.26	-0.46	3.76e-26	Height;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.06e-13	Bipolar disorder;
LGG	cis	rs703842	0.642	rs10876994	chr12:58064737	A/C	cg18357645	chr12:58087776	OS9	-0.56	-8.19	-0.36	2.55e-15	Multiple sclerosis;
LGG	cis	rs1620921	0.774	rs812482	chr6:161227652	G/C	cg01280913	chr6:161186852	NA	-0.32	-6.71	-0.3	5.67e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg03060546	chr3:49711283	APEH	0.74	13.44	0.53	5.41e-35	Resting heart rate;
LGG	cis	rs7927771	0.832	rs11601173	chr11:47401058	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-10.66	-0.44	7.16e-24	Subjective well-being;
LGG	cis	rs10744422	1.000	rs7294991	chr12:123286780	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-8.29	-0.36	1.25e-15	Schizophrenia;
LGG	cis	rs12497850	0.931	rs13064911	chr3:48952385	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.66	0.79	4.06e-100	Parkinson's disease;
LGG	cis	rs6460942	0.915	rs1595800	chr7:12439816	G/A	cg06484146	chr7:12443880	VWDE	-0.42	-7.31	-0.32	1.16e-12	Coronary artery disease;
LGG	cis	rs60180747	1.000	rs8033122	chr15:66820455	T/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.99	0.45	4.1e-25	Testicular germ cell tumor;
LGG	cis	rs4423214	0.592	rs11233933	chr11:71210070	C/T	cg05163923	chr11:71159392	DHCR7	-0.53	-7.49	-0.33	3.46e-13	Vitamin D levels;
LGG	cis	rs793571	0.590	rs474875	chr15:59086703	A/C	cg05156742	chr15:59063176	FAM63B	0.6	10.18	0.43	4.24e-22	Schizophrenia;
LGG	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg03213289	chr20:61660250	NA	-0.64	-13.45	-0.53	4.83e-35	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7766436	0.922	rs2066338	chr6:22611393	C/T	cg13666174	chr6:22585274	NA	-0.48	-10.55	-0.44	1.82e-23	Coronary artery disease;
LGG	cis	rs4423214	0.515	rs4944042	chr11:71118788	C/A	cg10847948	chr11:71163743	NADSYN1	-0.52	-9.66	-0.41	2.99e-20	Vitamin D levels;
LGG	cis	rs7666738	0.830	rs6532701	chr4:98745134	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.54	0.33	2.55e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9325144	0.577	rs10876008	chr12:39126750	T/C	cg26384229	chr12:38710491	ALG10B	-0.7	-13.21	-0.52	4.79e-34	Morning vs. evening chronotype;
LGG	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-9.11	-0.39	2.4e-18	Hemoglobin concentration;
LGG	cis	rs1008375	0.898	rs2079892	chr4:17577163	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.97	0.45	4.84e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4330281	0.647	rs9812906	chr3:17525505	G/A	cg20981856	chr3:17787350	NA	0.37	6.94	0.31	1.34e-11	Schizophrenia;
LGG	cis	rs9303401	0.659	rs66514313	chr17:56714057	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg23129478	chr18:44337922	ST8SIA5	0.37	7.11	0.31	4.56e-12	Personality dimensions;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg22907277	chr7:1156413	C7orf50	0.49	8.58	0.37	1.47e-16	Longevity;Endometriosis;
LGG	cis	rs7851660	0.844	rs6478445	chr9:100624299	A/G	cg13688889	chr9:100608707	NA	-0.63	-12.56	-0.5	2.39e-31	Strep throat;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg00350652	chr1:109584526	WDR47	0.57	6.83	0.3	2.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg23782820	chr8:58130467	NA	0.43	6.68	0.3	6.82e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7633770	0.664	rs11130101	chr3:46685895	T/A	cg11219411	chr3:46661640	NA	-0.48	-10.53	-0.44	2.17e-23	Coronary artery disease;
LGG	cis	rs17453880	0.929	rs4537047	chr5:151953565	A/G	cg10931792	chr5:152022470	NA	0.38	8.22	0.36	2.07e-15	Subjective well-being;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg16386425	chr10:429943	DIP2C	-0.47	-9.69	-0.41	2.51e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs7044106	0.537	rs4434680	chr9:123489688	A/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.47	7.12	0.31	4.06e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6466055	0.777	rs3801282	chr7:104881530	A/G	cg04380332	chr7:105027541	SRPK2	0.37	6.95	0.31	1.21e-11	Schizophrenia;
LGG	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06873352	chr17:61820015	STRADA	0.47	7.29	0.32	1.35e-12	Height;
LGG	cis	rs950169	0.887	rs3860265	chr15:84945185	C/T	cg24253500	chr15:84953950	NA	0.58	10.43	0.44	4.94e-23	Schizophrenia;
LGG	cis	rs11098499	0.826	rs4472123	chr4:120236630	T/A	cg09307838	chr4:120376055	NA	0.71	11.99	0.49	4.81e-29	Corneal astigmatism;
LGG	cis	rs10206020	0.879	rs72778007	chr2:1573178	C/T	cg26248373	chr2:1572462	NA	-0.9	-15.7	-0.59	7.32e-45	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	trans	rs2243480	1.000	rs67728539	chr7:65378124	G/A	cg10756647	chr7:56101905	PSPH	0.84	10.17	0.43	4.44e-22	Diabetic kidney disease;
LGG	cis	rs2836950	0.805	rs2836961	chr21:40627020	A/C	cg11644478	chr21:40555479	PSMG1	-0.54	-8.77	-0.38	3.41e-17	Menarche (age at onset);
LGG	cis	rs367943	0.966	rs451425	chr5:112808637	A/G	cg12552261	chr5:112820674	MCC	-0.75	-14.31	-0.55	1.02e-38	Type 2 diabetes;
LGG	cis	rs12188164	0.714	rs11741954	chr5:421455	G/T	cg26850624	chr5:429559	AHRR	-0.38	-7.96	-0.35	1.35e-14	Cystic fibrosis severity;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	6.97	0.31	1.13e-11	Tonsillectomy;
LGG	cis	rs17376456	0.877	rs10476599	chr5:93383423	A/G	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs4888262	0.508	rs4888258	chr16:74634198	G/T	cg01733217	chr16:74700730	RFWD3	0.89	18.2	0.65	3.05e-56	Testicular germ cell tumor;
LGG	cis	rs796364	0.806	rs11674293	chr2:201026743	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.22	-0.36	2.1e-15	Schizophrenia;
LGG	cis	rs7737355	0.947	rs7725220	chr5:130877001	C/G	cg06307176	chr5:131281290	NA	0.56	9.31	0.4	5.3e-19	Life satisfaction;
LGG	cis	rs11920090	1.000	rs11920090	chr3:170717521	T/A	cg09710316	chr3:170744871	SLC2A2	0.6	8.45	0.37	3.92e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs9378357	0.702	rs4385351	chr6:3280591	A/C	cg08754725	chr6:3293098	SLC22A23	0.56	6.84	0.3	2.46e-11	Obesity-related traits;
LGG	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs3812831	0.599	rs428637	chr13:114927139	T/G	cg25338242	chr13:114786047	RASA3	0.41	7.3	0.32	1.24e-12	Schizophrenia;
LGG	trans	rs8002861	0.664	rs9567292	chr13:44444816	A/G	cg12856521	chr11:46389249	DGKZ	0.51	9.07	0.39	3.52e-18	Leprosy;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	trans	rs7618501	1.000	rs7649348	chr3:49772375	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.93	-0.52	7.28e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9649465	0.967	rs1506642	chr7:123390058	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.8	-0.38	2.76e-17	Migraine;
LGG	cis	rs9411298	0.630	rs9411299	chr9:139938793	C/G	cg14024893	chr9:139943146	ENTPD2	-0.76	-14.55	-0.56	9.58e-40	Monocyte percentage of white cells;
LGG	cis	rs6558530	0.965	rs730377	chr8:1707951	G/A	cg08198773	chr8:1697536	NA	0.36	7.02	0.31	7.88e-12	Systolic blood pressure;
LGG	trans	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	7.26	0.32	1.64e-12	Neuroticism;
LGG	cis	rs7953249	0.618	rs7954039	chr12:121398654	A/C	cg02403541	chr12:121454288	C12orf43	-0.54	-8.93	-0.38	1.04e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs12367572	0.965	rs1506678	chr12:45249492	A/G	cg04608330	chr12:45269318	NELL2	-0.62	-11.21	-0.46	5.55e-26	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22435132	chr17:59312558	BCAS3	0.4	7.82	0.34	3.66e-14	Gut microbiome composition (summer);
LGG	trans	rs11875185	0.588	rs74793472	chr18:55640224	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg08297393	chr2:100937505	LONRF2	0.57	9.82	0.42	8.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2303745	0.622	rs1864113	chr19:17393504	G/C	cg10664184	chr19:17420304	DDA1	0.56	8.7	0.37	5.76e-17	Systemic lupus erythematosus;
LGG	cis	rs6840360	0.638	rs6816002	chr4:152589439	C/T	cg25486957	chr4:152246857	NA	-0.43	-7.05	-0.31	6.74e-12	Intelligence (multi-trait analysis);
LGG	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg03511173	chr18:77590860	NA	0.44	7.36	0.32	8.33e-13	Schizophrenia;
LGG	cis	rs875971	1.000	rs12532998	chr7:65967459	A/C	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.2e-17	Aortic root size;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg10505658	chr17:80084571	CCDC57	-0.4	-8.03	-0.35	8.41e-15	Life satisfaction;
LGG	cis	rs9611565	0.532	rs202627	chr22:41847367	A/T	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Vitiligo;
LGG	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15369054	chr17:80825471	TBCD	-0.48	-6.65	-0.3	8.09e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs61931739	0.534	rs1852222	chr12:34008665	C/A	cg26384229	chr12:38710491	ALG10B	0.73	14.72	0.56	1.61e-40	Morning vs. evening chronotype;
LGG	trans	rs1997103	0.911	rs10238738	chr7:55412359	T/C	cg20935933	chr6:143382018	AIG1	0.54	8.48	0.37	3.13e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg19847130	chr8:10466454	RP1L1	0.31	6.89	0.3	1.88e-11	Neuroticism;
LGG	cis	rs3857536	0.706	rs1418854	chr6:66893284	C/T	cg07460842	chr6:66804631	NA	-0.48	-8.29	-0.36	1.28e-15	Blood trace element (Cu levels);
LGG	cis	rs2274273	1.000	rs7140872	chr14:55612744	C/T	cg04306507	chr14:55594613	LGALS3	0.61	17.22	0.62	9.69e-52	Protein biomarker;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01718711	chr8:8860266	ERI1	-0.41	-6.8	-0.3	3.31e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg11905131	chr22:24372483	LOC391322	-0.41	-7.21	-0.32	2.23e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7241530	0.662	rs12454883	chr18:75902642	G/A	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	trans	rs2018683	0.707	rs917218	chr7:28975122	A/C	cg19402173	chr7:128379420	CALU	-0.51	-8.87	-0.38	1.6e-17	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg02002194	chr4:3960332	NA	0.45	8.09	0.35	5.34e-15	Retinal vascular caliber;
LGG	cis	rs992157	1.000	rs13429408	chr2:219142860	C/A	cg04731861	chr2:219085781	ARPC2	-0.41	-9.99	-0.42	2.08e-21	Colorectal cancer;
LGG	cis	rs4819052	0.819	rs13046807	chr21:46672286	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.22	0.52	4.34e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500395	0.588	rs6500393	chr16:48568108	A/G	cg04672837	chr16:48644449	N4BP1	0.5	8.68	0.37	6.82e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1005277	0.563	rs2800550	chr10:38482929	T/C	cg25427524	chr10:38739819	LOC399744	-0.67	-12.43	-0.5	7.96e-31	Extrinsic epigenetic age acceleration;
LGG	trans	rs7615952	0.543	rs4645102	chr3:125424441	A/G	cg07211511	chr3:129823064	LOC729375	-0.5	-7.45	-0.33	4.76e-13	Blood pressure (smoking interaction);
LGG	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg21775007	chr8:11205619	TDH	-0.57	-9.5	-0.4	1.1e-19	Neuroticism;
LGG	cis	rs9902453	0.740	rs2254414	chr17:28061130	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-14.39	-0.56	4.41e-39	Coffee consumption (cups per day);
LGG	cis	rs1018836	0.923	rs6989123	chr8:91551234	A/T	cg16814680	chr8:91681699	NA	-0.8	-15.17	-0.58	1.69e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs611744	0.647	rs689275	chr8:109241822	T/C	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs11098499	0.954	rs12502423	chr4:120424172	A/C	cg09307838	chr4:120376055	NA	0.81	13.57	0.53	1.44e-35	Corneal astigmatism;
LGG	trans	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg18187862	chr3:45730750	SACM1L	0.57	9.43	0.4	1.95e-19	Primary sclerosing cholangitis;
LGG	cis	rs8053891	0.507	rs12919469	chr16:72028612	A/G	cg23815491	chr16:72088622	HP	0.37	7.45	0.33	4.77e-13	Coronary artery disease;
LGG	trans	rs7395662	0.833	rs1963073	chr11:48975094	T/A	cg00717180	chr2:96193071	NA	-0.47	-8.59	-0.37	1.3e-16	HDL cholesterol;
LGG	cis	rs10771431	0.597	rs3759274	chr12:9353875	T/C	cg08997352	chr12:9597637	DDX12	-0.75	-13.72	-0.54	3.57e-36	Breast size;
LGG	cis	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg03213289	chr20:61660250	NA	0.66	14.33	0.55	8.4e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg26384229	chr12:38710491	ALG10B	1.08	28.83	0.8	2.16e-105	Heart rate;
LGG	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg24623649	chr8:11872141	NA	-0.29	-6.97	-0.31	1.1e-11	Triglycerides;
LGG	cis	rs963731	0.522	rs958412	chr2:39187519	A/G	cg04010122	chr2:39346883	SOS1	-0.79	-6.96	-0.31	1.19e-11	Corticobasal degeneration;
LGG	cis	rs4629180	0.959	rs11896771	chr2:102098328	T/C	cg16435561	chr2:102091048	RFX8	0.4	6.7	0.3	5.97e-11	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg08508325	chr11:3079039	CARS	-0.57	-12.16	-0.49	1.06e-29	Longevity;
LGG	cis	rs11719291	0.584	rs13080725	chr3:49076092	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	Cognitive function;
LGG	cis	rs7503807	0.515	rs1485330	chr17:78640822	G/A	cg08454507	chr17:78755406	RPTOR	-0.47	-9.28	-0.4	6.55e-19	Obesity;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg23129478	chr18:44337922	ST8SIA5	0.35	6.8	0.3	3.21e-11	Personality dimensions;
LGG	cis	rs7172677	1.000	rs4886659	chr15:75414760	A/G	cg14664628	chr15:75095509	CSK	-0.47	-7.21	-0.32	2.3e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs34311866	0.808	rs4583705	chr4:973036	C/T	cg07828340	chr4:882639	GAK	0.83	8.96	0.38	8.02e-18	Parkinson's disease;
LGG	cis	rs11608355	0.515	rs11609921	chr12:109918405	A/G	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03773681	chr2:63815918	MDH1;C2orf86	0.41	6.85	0.3	2.29e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9513627	0.915	rs9585070	chr13:100118843	G/C	cg25919922	chr13:100150906	NA	-0.71	-7.19	-0.32	2.69e-12	Obesity-related traits;
LGG	trans	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.65	-0.3	8.27e-11	Triglycerides;
LGG	cis	rs7666738	0.830	rs6846229	chr4:99016546	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg04293180	chr8:144700367	TSTA3	0.89	6.83	0.3	2.72e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs6489882	0.867	rs1859335	chr12:113367325	C/T	cg25319449	chr12:113376135	OAS3	-0.43	-7.71	-0.34	7.84e-14	Chronic lymphocytic leukemia;
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.46	0.56	2.15e-39	Tonsillectomy;
LGG	cis	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg21775007	chr8:11205619	TDH	-0.52	-8.56	-0.37	1.63e-16	Triglycerides;
LGG	cis	rs6762	0.719	rs1130698	chr11:838542	C/T	cg08498830	chr11:832797	CD151	-0.45	-7.24	-0.32	1.94e-12	Mean platelet volume;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.79e-31	Lymphocyte counts;
LGG	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg05639522	chr1:247681581	NA	0.61	10.32	0.43	1.35e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg01620082	chr3:125678407	NA	-0.63	-6.96	-0.31	1.14e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10871290	0.881	rs3863436	chr16:74468038	T/C	cg01733217	chr16:74700730	RFWD3	-0.74	-14.23	-0.55	2.26e-38	Breast cancer;
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2050392	0.557	rs306588	chr10:30723593	G/A	cg25182066	chr10:30743637	MAP3K8	-0.6	-12.18	-0.49	8.64e-30	Inflammatory bowel disease;
LGG	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.22	0.43	3.1e-22	Retinal vascular caliber;
LGG	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.13	-0.31	3.85e-12	Total cholesterol levels;
LGG	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.65	0.51	9.99e-32	Motion sickness;
LGG	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg06453172	chr10:134556979	INPP5A	-0.55	-8.14	-0.35	3.62e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg19338460	chr6:170058176	WDR27	-0.62	-8.39	-0.36	5.99e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg00149659	chr3:10157352	C3orf10	0.76	9.55	0.41	7.6e-20	Alzheimer's disease;
LGG	cis	rs5756391	0.503	rs9607395	chr22:37315742	C/T	cg21209356	chr22:37319042	CSF2RB	0.41	9.35	0.4	3.73e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1355223	0.934	rs11602669	chr11:34695114	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.33	-0.32	1.06e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.13	0.43	6.44e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2019137	0.936	rs4849169	chr2:113953657	A/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.4e-21	Lymphocyte counts;
LGG	cis	rs2204008	0.577	rs2623049	chr12:38018831	G/A	cg04568710	chr12:38710424	ALG10B	-0.34	-7.23	-0.32	2.07e-12	Bladder cancer;
LGG	cis	rs4417704	0.551	rs60677070	chr2:241900494	A/G	cg14055004	chr2:241860995	NA	0.29	7.4	0.33	6.27e-13	Joint mobility (Beighton score);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07132326	chr6:150258058	NA	0.38	8.14	0.35	3.61e-15	Testicular germ cell tumor;
LGG	cis	rs2762353	0.776	rs1165190	chr6:25848019	A/G	cg12310025	chr6:25882481	NA	-0.59	-11.38	-0.47	1.27e-26	Blood metabolite levels;
LGG	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs36051895	0.632	rs10815164	chr9:5131312	T/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.59	-0.56	6.14e-40	Pediatric autoimmune diseases;
LGG	cis	rs4639966	0.836	rs3825057	chr11:118622985	T/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.9	-0.31	1.7e-11	Systemic lupus erythematosus;
LGG	cis	rs12681287	0.608	rs13273338	chr8:87453361	T/G	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs9914544	0.545	rs7222893	chr17:18811702	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.67	-0.34	1.06e-13	Educational attainment (years of education);
LGG	cis	rs2760061	0.819	rs964941	chr1:228193857	G/A	cg01200585	chr1:228362443	C1orf69	0.47	8.23	0.36	1.85e-15	Diastolic blood pressure;
LGG	cis	rs9287719	1.000	rs9287719	chr2:10710730	C/T	cg02196655	chr2:10830764	NOL10	-0.42	-7.2	-0.32	2.5e-12	Prostate cancer;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs3862030	0.720	rs12569526	chr10:104237007	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.21	-0.43	3.42e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs887829	0.570	rs10168333	chr2:234596988	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs922692	0.744	rs11639044	chr15:79083814	C/T	cg00540400	chr15:79124168	NA	-0.39	-7.46	-0.33	4.27e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs72827839	0.761	rs79541578	chr17:46102728	G/A	cg02219949	chr17:45927392	SP6	0.49	7.5	0.33	3.3e-13	Ease of getting up in the morning;
LGG	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg18825076	chr15:78729989	IREB2	-0.44	-7.04	-0.31	6.96e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4132509	1.000	rs28869008	chr1:243986344	C/A	cg21452805	chr1:244014465	NA	0.65	7.71	0.34	7.51e-14	RR interval (heart rate);
LGG	cis	rs72945132	0.825	rs947811	chr11:70209142	A/T	cg14191688	chr11:70257035	CTTN	0.58	8.32	0.36	1e-15	Coronary artery disease;
LGG	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg27121462	chr16:89883253	FANCA	0.62	11.49	0.47	4.6e-27	Vitiligo;
LGG	cis	rs68170813	0.641	rs12534124	chr7:107119047	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-9.84	-0.42	6.94e-21	Coronary artery disease;
LGG	trans	rs1814175	0.615	rs12417290	chr11:49876951	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs5758511	0.731	rs5751186	chr22:42349710	G/A	cg15128208	chr22:42549153	NA	-0.57	-8.92	-0.38	1.07e-17	Birth weight;
LGG	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg07061783	chr6:25882402	NA	-0.39	-7.05	-0.31	6.38e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19850565	chr19:35168394	ZNF302	0.46	7.15	0.32	3.38e-12	Gut microbiome composition (summer);
LGG	cis	rs868036	0.645	rs4776972	chr15:68083436	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.4	-8.47	-0.37	3.28e-16	Restless legs syndrome;
LGG	cis	rs6489882	0.932	rs4767045	chr12:113409413	C/T	cg25319449	chr12:113376135	OAS3	-0.38	-6.74	-0.3	4.61e-11	Chronic lymphocytic leukemia;
LGG	cis	rs17021463	0.555	rs7693950	chr4:95324901	A/T	cg11021082	chr4:95130006	SMARCAD1	0.42	6.78	0.3	3.71e-11	Testicular germ cell tumor;
LGG	cis	rs939658	1.000	rs8033963	chr15:79455350	C/T	cg17916960	chr15:79447300	NA	0.63	12.32	0.5	2.24e-30	Refractive error;
LGG	cis	rs155076	0.938	rs9509630	chr13:21844314	G/A	cg11317459	chr13:21872234	NA	-1.18	-19.43	-0.67	6.16e-62	White matter hyperintensity burden;
LGG	cis	rs2290159	0.800	rs55762590	chr3:12689451	C/T	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.06e-20	Cholesterol, total;
LGG	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg09998033	chr7:158218633	PTPRN2	-0.46	-8.21	-0.36	2.17e-15	Obesity-related traits;
LGG	cis	rs929354	0.772	rs2023977	chr7:156996022	C/G	cg17757837	chr7:157058334	UBE3C	0.77	15.54	0.59	4.15e-44	Body mass index;
LGG	cis	rs62025270	0.688	rs55738258	chr15:86316231	A/G	cg25843651	chr15:86329602	KLHL25	0.63	10.15	0.43	5.53e-22	Idiopathic pulmonary fibrosis;
LGG	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg02493740	chr2:85810744	VAMP5	0.38	6.78	0.3	3.62e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.99	0.55	2.37e-37	Obesity-related traits;
LGG	cis	rs35110281	1.000	rs35110281	chr21:45068947	T/A	cg04455712	chr21:45112962	RRP1B	0.5	9.36	0.4	3.59e-19	Mean corpuscular volume;
LGG	trans	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg24247370	chr13:99142703	STK24	-0.38	-6.95	-0.31	1.24e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.68	-0.3	7.06e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.05	-0.31	6.4e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6918586	0.658	rs198819	chr6:26124430	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.71	-0.41	2.06e-20	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg00933542	chr6:150070202	PCMT1	0.39	7.2	0.32	2.38e-12	Lung cancer;
LGG	cis	rs6032067	0.777	rs73907811	chr20:43801395	T/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	trans	rs35110281	0.693	rs2838345	chr21:45092715	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.96	0.42	2.76e-21	Mean corpuscular volume;
LGG	trans	rs7246760	1.000	rs12460571	chr19:9881746	C/A	cg02900749	chr2:68251473	NA	-1.04	-11.35	-0.47	1.63e-26	Pursuit maintenance gain;
LGG	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs4731207	0.565	rs7780392	chr7:124575655	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.27	0.4	7.32e-19	Lung cancer;
LGG	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.92	-0.31	1.55e-11	Bone mineral density;
LGG	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.31	-0.36	1.11e-15	Neuroticism;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs2304069	0.955	rs4288106	chr5:149394872	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	13.35	0.53	1.33e-34	HIV-1 control;
LGG	cis	rs137887	1.000	rs137887	chr22:50464439	C/G	cg17558497	chr22:50464837	TTLL8	0.44	8.41	0.36	5.12e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs3857067	0.740	rs6532470	chr4:95108211	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.35	1.87e-14	QT interval;
LGG	cis	rs7751419	0.651	rs4324776	chr6:39095146	G/T	cg08089693	chr6:39098871	NA	-0.48	-8.6	-0.37	1.24e-16	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs9948	0.786	rs72809850	chr2:97449762	A/C	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg15595755	chr5:1867978	NA	0.51	10.28	0.43	1.81e-22	Cardiovascular disease risk factors;
LGG	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	20.93	0.7	5.82e-69	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg09029085	chr17:47094198	IGF2BP1	0.32	8.55	0.37	1.86e-16	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.68	-0.34	9.56e-14	Obesity;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg02297831	chr4:17616191	MED28	0.48	8.74	0.38	4.41e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg05335186	chr13:53173507	NA	0.47	9.75	0.41	1.45e-20	Lewy body disease;
LGG	trans	rs12579753	0.917	rs7132465	chr12:82205840	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.48	9.31	0.4	5.1e-19	Obesity-related traits;
LGG	cis	rs17321999	1.000	rs72787721	chr2:30489411	C/T	cg05247661	chr2:30472410	LBH	0.56	8.74	0.38	4.23e-17	Systemic lupus erythematosus;
LGG	cis	rs6712932	0.925	rs10210149	chr2:105839324	C/T	cg27422857	chr2:105853526	NA	-0.41	-7.54	-0.33	2.55e-13	Type 2 diabetes;
LGG	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg09904177	chr6:26538194	HMGN4	-0.39	-7.17	-0.32	2.97e-12	Schizophrenia;
LGG	cis	rs990171	1.000	rs3755274	chr2:103002395	A/G	cg05295703	chr2:102895712	NA	-0.56	-9.95	-0.42	2.84e-21	Lymphocyte counts;
LGG	cis	rs6088590	1.000	rs6119535	chr20:33442138	A/C	cg08999081	chr20:33150536	PIGU	0.3	6.86	0.3	2.22e-11	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10698964	chr15:50647173	FLJ10038;GABPB1;LOC100129387	0.41	6.77	0.3	3.9e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611519	0.808	rs5751074	chr22:41665722	G/A	cg06634786	chr22:41940651	POLR3H	-0.51	-8.58	-0.37	1.41e-16	Neuroticism;
LGG	cis	rs61931739	0.890	rs1687020	chr12:34137924	G/C	cg06521331	chr12:34319734	NA	-0.41	-7.27	-0.32	1.52e-12	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10676527	chr19:35759696	USF2	0.44	7.28	0.32	1.44e-12	Gut microbiome composition (summer);
LGG	cis	rs3789045	0.685	rs12036042	chr1:204469314	T/C	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.67	-0.37	7.09e-17	Educational attainment (college completion);
LGG	trans	rs2562456	0.833	rs4429400	chr19:21520965	T/C	cg00806126	chr19:22604979	ZNF98	-0.57	-7.65	-0.33	1.2e-13	Pain;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg11789530	chr4:8429930	ACOX3	0.73	14.51	0.56	1.33e-39	Response to antineoplastic agents;
LGG	cis	rs4330281	0.647	rs12632570	chr3:17763501	A/C	cg20981856	chr3:17787350	NA	-0.38	-7.05	-0.31	6.44e-12	Schizophrenia;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg05335186	chr13:53173507	NA	0.48	10.22	0.43	3.02e-22	Lewy body disease;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg15971980	chr6:150254442	NA	0.45	8.44	0.37	4.05e-16	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01250699	chr8:22225185	SLC39A14	0.49	7.75	0.34	5.86e-14	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.837	rs10944157	chr6:86577199	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.39	-0.36	5.73e-16	Response to antipsychotic treatment;
LGG	cis	rs7717393	1.000	rs9313897	chr5:155791181	A/C	cg01474424	chr5:155754231	SGCD	0.74	7.41	0.33	6.03e-13	Egg allergy;
LGG	cis	rs921968	0.648	rs538483	chr2:219458656	T/C	cg02985541	chr2:219472218	PLCD4	0.28	6.69	0.3	6.5500000000000006e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.37	-0.43	8.32e-23	Bipolar disorder;
LGG	trans	rs7824557	0.583	rs2263512	chr8:11233419	T/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.38	-0.36	6.17e-16	Retinal vascular caliber;
LGG	cis	rs35176054	0.730	rs34943195	chr10:105517491	A/G	cg00730670	chr10:105510713	SH3PXD2A	-0.52	-6.95	-0.31	1.21e-11	Atrial fibrillation;
LGG	cis	rs7267979	0.744	rs6050463	chr20:25208990	G/A	cg08601574	chr20:25228251	PYGB	0.4	8.07	0.35	6.18e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10540	1.000	rs10540	chr11:494662	G/A	cg03352830	chr11:487213	PTDSS2	0.87	11.36	0.47	1.56e-26	Body mass index;
LGG	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg17376030	chr22:41985996	PMM1	0.54	8.6	0.37	1.24e-16	Vitiligo;
LGG	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg14391382	chr7:866102	UNC84A	0.53	9.24	0.39	9.11e-19	Subjective well-being;
LGG	cis	rs7580658	0.676	rs4662717	chr2:128013504	C/T	cg10021288	chr2:128175891	PROC	-0.58	-11.84	-0.48	1.89e-28	Protein C levels;
LGG	cis	rs2239547	0.603	rs59989280	chr3:53098875	T/C	cg11645453	chr3:52864694	ITIH4	0.66	10.53	0.44	2.11e-23	Schizophrenia;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.69	-0.3	6.32e-11	Obesity-related traits;
LGG	cis	rs6028335	0.674	rs61213966	chr20:37621906	A/G	cg16355469	chr20:37678765	NA	0.59	7.8	0.34	4.26e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.86	0.34	2.74e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg11266682	chr4:10021025	SLC2A9	-0.37	-6.67	-0.3	7.3e-11	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.94	-0.54	4.09e-37	Alzheimer's disease;
LGG	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2404602	0.660	rs11852777	chr15:76929792	A/G	cg15268244	chr15:77196840	NA	0.48	10.22	0.43	3.14e-22	Blood metabolite levels;
LGG	cis	rs875971	1.000	rs937495	chr7:65779798	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.56	0.37	1.64e-16	Aortic root size;
LGG	cis	rs61931739	0.746	rs1687003	chr12:34170099	T/A	cg06521331	chr12:34319734	NA	-0.39	-6.86	-0.3	2.24e-11	Morning vs. evening chronotype;
LGG	cis	rs11785400	0.793	rs7007891	chr8:143749228	C/T	cg10596483	chr8:143751796	JRK	-0.51	-7.99	-0.35	1.07e-14	Schizophrenia;
LGG	cis	rs2066819	1.000	rs2695782	chr12:56722830	C/T	cg26714650	chr12:56694279	CS	1.52	17.67	0.63	9.03e-54	Psoriasis vulgaris;
LGG	cis	rs526231	0.543	rs34808	chr5:102429188	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs7623687	0.579	rs73079014	chr3:49863483	C/T	cg19401529	chr3:49056140	DALRD3	0.74	7.08	0.31	5.44e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	trans	rs3960554	0.808	rs61303167	chr7:75671175	G/T	cg19862616	chr7:65841803	NCRNA00174	0.85	12.5	0.5	4.09e-31	Eotaxin levels;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg14159672	chr1:205819179	PM20D1	-0.44	-7.72	-0.34	7.14e-14	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs9463078	0.547	rs9472360	chr6:44747410	T/C	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.81e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg04058563	chr4:185651563	MLF1IP	-0.45	-9.66	-0.41	3e-20	Kawasaki disease;
LGG	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.59	-0.37	1.31e-16	Aortic root size;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg01272081	chr9:32551527	TOPORS	-0.41	-6.83	-0.3	2.71e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01688141	chr8:23539808	NKX3-1	0.46	7.47	0.33	4.13e-13	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.741	rs56243511	chr8:9805695	T/C	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.32	-0.36	1.03e-15	Neuroticism;
LGG	cis	rs4363385	0.510	rs2339386	chr1:152892307	C/T	cg13444842	chr1:152974279	SPRR3	-0.47	-9.28	-0.4	6.48e-19	Inflammatory skin disease;
LGG	cis	rs1372356	0.780	rs11159838	chr14:88545833	G/T	cg18078958	chr14:88630771	NA	0.33	7.65	0.34	1.15e-13	Food antigen IgG levels;
LGG	cis	rs7927592	0.513	rs608343	chr11:68196830	T/C	cg01657329	chr11:68192670	LRP5	-0.6	-10.84	-0.45	1.45e-24	Total body bone mineral density;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg26578617	chr4:90757533	SNCA	-0.44	-8.85	-0.38	1.93e-17	Dementia with Lewy bodies;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.97	14.26	0.55	1.74e-38	Platelet count;
LGG	cis	rs3741151	0.892	rs2027763	chr11:73035799	A/G	cg17517138	chr11:73019481	ARHGEF17	0.84	9.32	0.4	4.61e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs13082711	0.595	rs6778612	chr3:27370789	T/C	cg02860705	chr3:27208620	NA	-0.77	-14.17	-0.55	3.99e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.86	0.64	1.22e-54	Exhaled nitric oxide output;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs9291683	0.517	rs11736479	chr4:10017387	G/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Bone mineral density;
LGG	cis	rs3741151	1.000	rs7930880	chr11:73068769	A/C	cg17517138	chr11:73019481	ARHGEF17	0.89	9.72	0.41	1.9e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9400467	0.568	rs12204075	chr6:111489059	G/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.16	0.32	3.27e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg15948088	chr11:109293068	C11orf87	0.51	8.95	0.38	8.5e-18	Schizophrenia;
LGG	cis	rs941873	0.868	rs4980063	chr10:81105844	A/T	cg09469691	chr10:81107165	PPIF	0.62	11.04	0.46	2.57e-25	Height;
LGG	trans	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.01	-0.31	8.29e-12	Joint mobility (Beighton score);
LGG	cis	rs4718428	0.672	rs36038499	chr7:66289615	A/G	cg13147721	chr7:65941812	NA	-0.44	-6.81	-0.3	3.11e-11	Corneal structure;
LGG	cis	rs7107174	1.000	rs10899492	chr11:78109810	G/A	cg02023728	chr11:77925099	USP35	0.43	7.54	0.33	2.56e-13	Testicular germ cell tumor;
LGG	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	cg15522984	chr1:182991683	LAMC1	0.45	8.83	0.38	2.13e-17	Colorectal cancer;
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg18245976	chr7:158708271	WDR60	-0.56	-9.88	-0.42	5.08e-21	Height;
LGG	cis	rs972578	0.691	rs5758965	chr22:43226599	G/T	cg01576275	chr22:43409880	NA	-0.23	-6.85	-0.3	2.32e-11	Mean platelet volume;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08645402	chr16:4508243	NA	0.44	8.09	0.35	5.2e-15	Schizophrenia;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg16262614	chr3:133464971	TF	0.46	8.41	0.36	5.12e-16	Iron status biomarkers (transferrin levels);
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg17734273	chr15:78292508	TBC1D2B	-0.39	-9.59	-0.41	5.37e-20	Coronary artery disease or large artery stroke;
LGG	trans	rs9929218	1.000	rs12448448	chr16:68802516	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.85	-0.51	1.49e-32	Colorectal cancer;
LGG	cis	rs6878727	0.850	rs6881377	chr5:123731759	G/A	cg01806427	chr5:123737813	NA	0.33	6.96	0.31	1.16e-11	Breast cancer;
LGG	cis	rs7928758	0.887	rs78760579	chr11:134281332	T/G	cg15243474	chr11:134282918	B3GAT1	1.28	16.14	0.6	8.24e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11190604	0.767	rs7090150	chr10:102173446	G/T	cg07080220	chr10:102295463	HIF1AN	0.57	10.0	0.42	1.98e-21	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.62	-0.41	4.35e-20	Triglycerides;
LGG	cis	rs208520	0.837	rs208471	chr6:66916749	A/C	cg07460842	chr6:66804631	NA	-0.93	-16.16	-0.6	6.79e-47	Exhaled nitric oxide output;
LGG	cis	rs9486715	0.830	rs2255552	chr6:96999643	A/G	cg06623918	chr6:96969491	KIAA0776	-0.78	-15.71	-0.59	7.02e-45	Headache;
LGG	cis	rs889398	0.617	rs3790082	chr16:69896754	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.59	-0.33	1.81e-13	Body mass index;
LGG	cis	rs6960043	0.936	rs62448618	chr7:15052211	T/A	cg19272540	chr7:15055459	NA	-0.33	-7.38	-0.32	7.15e-13	Type 2 diabetes;
LGG	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.95	-0.45	5.67e-25	Chronic sinus infection;
LGG	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.52	-0.4	9.78e-20	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg21926883	chr2:100939477	LONRF2	-0.67	-15.69	-0.59	8.87e-45	Intelligence (multi-trait analysis);
LGG	cis	rs3008870	1.000	rs4655663	chr1:67430103	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.04	22.39	0.72	8.42e-76	Lymphocyte percentage of white cells;
LGG	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.65e-12	Blood metabolite levels;
LGG	cis	rs13191362	1.000	rs7769686	chr6:163199467	A/G	cg21926612	chr6:163149169	PACRG;PARK2	1.11	12.49	0.5	4.53e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4423214	0.959	rs11606033	chr11:71154204	A/G	cg10847948	chr11:71163743	NADSYN1	-0.66	-13.14	-0.52	9.21e-34	Vitamin D levels;
LGG	trans	rs877282	0.891	rs34383514	chr10:800181	T/C	cg22713356	chr15:30763199	NA	0.57	8.49	0.37	2.73e-16	Uric acid levels;
LGG	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg00976097	chr5:421733	AHRR	-0.43	-7.07	-0.31	5.79e-12	Cystic fibrosis severity;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.54	-0.44	1.94e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs3733585	0.699	rs6815001	chr4:9958662	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2153535	0.542	rs915353	chr6:8440370	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.94	0.38	9e-18	Motion sickness;
LGG	cis	rs7572733	0.555	rs7600269	chr2:198923468	C/G	cg00792783	chr2:198669748	PLCL1	0.61	9.66	0.41	3.1e-20	Dermatomyositis;
LGG	trans	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.39	0.5	1.17e-30	Type 2 diabetes;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.39	0.36	6.05e-16	Obesity-related traits;
LGG	trans	rs12517041	0.679	rs2356718	chr5:23313406	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.75	-10.77	-0.45	2.74e-24	Calcium levels;
LGG	cis	rs9470366	0.848	rs9470361	chr6:36623379	G/A	cg08179530	chr6:36648295	CDKN1A	0.6	8.86	0.38	1.69e-17	QRS duration;
LGG	cis	rs11098499	0.691	rs12510133	chr4:120271344	A/C	cg09307838	chr4:120376055	NA	0.66	11.32	0.47	2.19e-26	Corneal astigmatism;
LGG	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg00599393	chr8:22457479	C8orf58	-0.45	-8.12	-0.35	4.35e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs826838	0.967	rs12823908	chr12:38845686	T/C	cg26384229	chr12:38710491	ALG10B	1.06	28.12	0.79	3.3e-102	Heart rate;
LGG	cis	rs9326248	0.954	rs8521	chr11:117067699	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.35	0.4	3.77e-19	Blood protein levels;
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg17376030	chr22:41985996	PMM1	0.6	9.36	0.4	3.52e-19	Vitiligo;
LGG	cis	rs367943	0.501	rs960691	chr5:112971654	G/C	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	trans	rs5744897	0.708	rs5744929	chr12:133221239	G/T	cg04991071	chr3:71615924	FOXP1	0.61	7.07	0.31	5.68e-12	Urate levels in overweight individuals;
LGG	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg14784868	chr12:69753453	YEATS4	0.89	19.43	0.67	6.4e-62	Blood protein levels;
LGG	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7953249	0.656	rs2251468	chr12:121405126	A/C	cg02403541	chr12:121454288	C12orf43	0.51	8.45	0.37	3.89e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	trans	rs7939886	0.920	rs7950386	chr11:55931513	C/T	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs3816183	0.606	rs11883440	chr2:43123189	A/G	cg14631114	chr2:43023945	NA	0.41	7.22	0.32	2.11e-12	Hypospadias;
LGG	trans	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg18187862	chr3:45730750	SACM1L	0.58	9.57	0.41	6.29e-20	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20376447	chr17:60143446	MED13	0.49	7.37	0.32	7.7e-13	Gut microbiome composition (summer);
LGG	cis	rs5758659	0.737	rs10854749	chr22:42447341	G/T	cg15557168	chr22:42548783	NA	-0.36	-7.57	-0.33	2.02e-13	Cognitive function;
LGG	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg07507251	chr3:52567010	NT5DC2	0.35	7.08	0.31	5.27e-12	Hemoglobin concentration;
LGG	cis	rs62238980	0.614	rs117629537	chr22:32400579	C/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs9790314	0.846	rs6791213	chr3:161033721	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.16	-0.49	9.94e-30	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05145423	chr17:62492888	POLG2	0.47	7.06	0.31	5.94e-12	Gut microbiome composition (summer);
LGG	cis	rs564799	0.966	rs600519	chr3:159730417	G/A	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	3.97e-13	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	11.14	0.46	1.03e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs739401	0.595	rs6578304	chr11:2998279	A/G	cg08508325	chr11:3079039	CARS	0.55	11.63	0.48	1.31e-27	Longevity;
LGG	cis	rs4319547	1.000	rs4319547	chr12:123079035	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.52	-0.4	9.41e-20	Body mass index;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg19077165	chr18:44547161	KATNAL2	0.68	13.05	0.52	2.33e-33	Personality dimensions;
LGG	cis	rs2274273	0.686	rs28631821	chr14:55845987	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.98	0.64	3.12e-55	Protein biomarker;
LGG	cis	rs12188164	0.965	rs72717438	chr5:448663	C/T	cg26076054	chr5:421317	AHRR	-0.46	-7.58	-0.33	1.85e-13	Cystic fibrosis severity;
LGG	cis	rs12310956	0.532	rs10506119	chr12:33963684	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.63	10.91	0.45	8.23e-25	Obesity-related traits;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs62400317	0.826	rs12192890	chr6:45182434	A/G	cg18551225	chr6:44695536	NA	-0.63	-9.97	-0.42	2.39e-21	Total body bone mineral density;
LGG	cis	rs11190604	1.000	rs2489036	chr10:102319581	A/G	cg11040518	chr10:102331378	NA	-0.39	-6.96	-0.31	1.14e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg26554054	chr8:600488	NA	0.94	9.92	0.42	3.6e-21	IgG glycosylation;
LGG	cis	rs2836974	0.863	rs1065242	chr21:40567716	C/G	cg11890956	chr21:40555474	PSMG1	1.19	30.79	0.82	4.04e-114	Cognitive function;
LGG	cis	rs28595532	0.920	rs17259284	chr4:119779298	T/C	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs13082711	0.911	rs6797389	chr3:27502070	G/T	cg02860705	chr3:27208620	NA	0.74	13.2	0.52	5.57e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.7	12.8	0.51	2.39e-32	Obesity-related traits;
LGG	cis	rs1728785	1.000	rs1728801	chr16:68571457	A/C	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.31	-0.79	1.52e-98	Primary sclerosing cholangitis;
LGG	cis	rs3768617	0.510	rs2093984	chr1:183094314	T/C	cg15522984	chr1:182991683	LAMC1	0.45	8.83	0.38	2.25e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9547996	0.879	rs9547964	chr13:38151202	A/C	cg13634560	chr13:38173852	POSTN	-0.35	-7.04	-0.31	7e-12	Diastolic blood pressure;
LGG	cis	rs3087591	0.708	rs67065748	chr17:29605631	T/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.56	0.56	8.63e-40	Hip circumference;
LGG	cis	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg24375607	chr4:120327624	NA	0.61	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg07962051	chr8:9412923	TNKS	-0.38	-6.77	-0.3	3.96e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4974559	0.697	rs4974550	chr4:1315658	G/T	cg07110949	chr4:1309878	MAEA	-0.87	-7.42	-0.33	5.6e-13	Systolic blood pressure;
LGG	cis	rs11676348	0.846	rs3890158	chr2:218990292	G/A	cg00012203	chr2:219082015	ARPC2	-0.55	-9.77	-0.41	1.22e-20	Ulcerative colitis;
LGG	cis	rs909674	0.818	rs5750830	chr22:39840828	C/A	cg11247378	chr22:39784982	NA	-0.32	-8.48	-0.37	3.05e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs12135191	0.544	rs6664395	chr1:236510822	G/T	cg21399712	chr1:236511386	NA	-0.4	-7.93	-0.35	1.63e-14	Urate levels (BMI interaction);
LGG	cis	rs9462027	0.628	rs9296131	chr6:34776361	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.24	-0.46	4.43e-26	Systemic lupus erythematosus;
LGG	cis	rs11148252	0.538	rs9535879	chr13:52704624	T/A	cg00761968	chr13:53314142	LECT1	-0.39	-8.09	-0.35	5.47e-15	Lewy body disease;
LGG	cis	rs13314892	0.734	rs75308677	chr3:69854691	C/G	cg17445875	chr3:69859618	MITF	-0.39	-7.24	-0.32	1.91e-12	QRS complex (12-leadsum);
LGG	cis	rs988958	0.958	rs11891490	chr2:42285915	A/G	cg27252766	chr2:42229092	NA	-0.45	-7.25	-0.32	1.81e-12	Hypospadias;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6694672	1.000	rs6695300	chr1:197098143	G/C	cg13682187	chr1:196946512	CFHR5	0.49	6.73	0.3	4.96e-11	Asthma;
LGG	cis	rs969413	0.624	rs7213540	chr17:79255912	C/T	cg03823431	chr17:79229385	SLC38A10	0.32	6.66	0.3	7.83e-11	Frontotemporal dementia;
LGG	trans	rs561341	1.000	rs56903735	chr17:30254393	T/A	cg20587970	chr11:113659929	NA	-1.28	-23.4	-0.74	1.76e-80	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.17	-0.35	2.96e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4731207	0.596	rs1006334	chr7:124628307	G/T	cg05630886	chr7:124431682	NA	-0.3	-6.85	-0.3	2.41e-11	Cutaneous malignant melanoma;
LGG	cis	rs7737355	0.812	rs152789	chr5:131026590	C/A	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.31e-17	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02753865	chr7:56119046	CCT6A;PSPH	0.47	7.63	0.33	1.3e-13	Cognitive performance;
LGG	cis	rs1152591	0.524	rs1255992	chr14:64662895	A/G	cg23250157	chr14:64679961	SYNE2	0.4	7.16	0.32	3.12e-12	Atrial fibrillation;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.23	-0.36	1.94e-15	Prudent dietary pattern;
LGG	cis	rs6964587	0.904	rs2023785	chr7:91547369	C/A	cg17063962	chr7:91808500	NA	-0.45	-7.84	-0.34	3.11e-14	Breast cancer;
LGG	cis	rs113084984	0.718	rs10929754	chr2:11683074	T/G	cg07314298	chr2:11723111	GREB1	0.37	6.87	0.3	2.12e-11	Breast cancer;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg08888203	chr3:10149979	C3orf24	0.56	9.36	0.4	3.44e-19	Alzheimer's disease;
LGG	trans	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.83	-0.3	2.68e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs6076960	0.629	rs6054024	chr20:6229282	A/C	cg24759859	chr6:86352639	SYNCRIP	0.43	7.06	0.31	6.02e-12	Smooth-surface caries;
LGG	cis	rs2030746	0.521	rs13415147	chr2:121329768	A/G	cg22272644	chr2:121334640	NA	-0.37	-9.34	-0.4	3.99e-19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs9911578	0.867	rs4793941	chr17:56472366	G/A	cg05425664	chr17:57184151	TRIM37	0.59	9.35	0.4	3.83e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2880765	0.743	rs12906308	chr15:86008059	C/T	cg10818794	chr15:86012489	AKAP13	0.36	7.54	0.33	2.44e-13	Coronary artery disease;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg04287289	chr16:89883240	FANCA	0.73	8.07	0.35	5.93e-15	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05609751	chr17:4269695	UBE2G1	0.46	6.91	0.31	1.6e-11	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.866	rs12374352	chr4:120281977	C/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs2282300	0.739	rs6484478	chr11:30306440	A/G	cg25418670	chr11:30344373	C11orf46	0.56	7.9	0.34	2e-14	Morning vs. evening chronotype;
LGG	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg10818794	chr15:86012489	AKAP13	0.33	6.68	0.3	6.8e-11	Bulimia nervosa;
LGG	cis	rs2084898	1.000	rs7119954	chr11:120046224	T/C	cg07435449	chr11:120005650	TRIM29	-0.66	-7.78	-0.34	4.86e-14	Stroke (pediatric);
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.21	0.6	3.82e-47	Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27332243	chr1:154842767	KCNN3	0.44	7.26	0.32	1.64e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12421382	0.636	rs60266280	chr11:109387766	A/C	cg00830817	chr11:109293614	C11orf87	0.44	7.24	0.32	1.87e-12	Schizophrenia;
LGG	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg17809284	chr5:56205270	C5orf35	0.67	10.35	0.43	9.67e-23	Initial pursuit acceleration;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg22535103	chr8:58192502	C8orf71	-0.87	-11.15	-0.46	9.71e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs4077515	0.901	rs11791262	chr9:139271919	C/T	cg21253087	chr9:139290292	SNAPC4	0.35	7.1	0.31	4.62e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07318088	chr6:90539243	CASP8AP2	0.49	7.98	0.35	1.14e-14	Cognitive performance;
LGG	cis	rs798554	0.660	rs2644295	chr7:2860217	A/C	cg05793240	chr7:2802953	GNA12	0.31	7.68	0.34	9.6e-14	Height;
LGG	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg02002194	chr4:3960332	NA	0.43	7.69	0.34	8.97e-14	Retinal vascular caliber;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17200204	chr3:43732323	ABHD5	0.64	7.11	0.31	4.37e-12	Intelligence (multi-trait analysis);
LGG	cis	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg05835009	chr4:710272	PCGF3	0.49	8.24	0.36	1.78e-15	White blood cell count;
LGG	cis	rs7091068	0.659	rs10732241	chr10:95468573	T/C	cg20715218	chr10:95462985	C10orf4	0.69	10.98	0.45	4.52e-25	Urinary tract infection frequency;
LGG	cis	rs79349575	0.756	rs2643361	chr17:46977462	T/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs11148252	0.846	rs1056335	chr13:52989863	C/T	cg22398616	chr13:53314203	LECT1	-0.46	-9.69	-0.41	2.4e-20	Lewy body disease;
LGG	cis	rs10896135	0.526	rs624561	chr11:66414915	C/T	cg24851651	chr11:66362959	CCS	-0.41	-7.55	-0.33	2.29e-13	Bipolar disorder;
LGG	cis	rs2439831	1.000	rs2439850	chr15:43784854	C/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs12618769	0.652	rs17034171	chr2:99221095	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs988958	0.530	rs12996334	chr2:42218684	G/A	cg27252766	chr2:42229092	NA	0.58	8.17	0.36	2.89e-15	Hypospadias;
LGG	cis	rs7241530	0.662	rs72987826	chr18:75910795	T/C	cg14642773	chr18:75888474	NA	0.44	8.4	0.36	5.65e-16	Educational attainment (years of education);
LGG	cis	rs12148488	0.738	rs4886417	chr15:75330159	T/G	cg10253484	chr15:75165896	SCAMP2	-0.42	-6.82	-0.3	2.9e-11	Caffeine consumption;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25091820	chr14:20786069	CCNB1IP1	0.33	6.66	0.3	7.55e-11	Menarche (age at onset);
LGG	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg27490568	chr2:178487706	NA	0.51	10.12	0.43	7.18e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9902453	0.845	rs2617865	chr17:28049804	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.97	-0.54	3e-37	Coffee consumption (cups per day);
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17039065	0.920	rs1017430	chr4:109474062	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.13	0.31	3.99e-12	Gut microbiome composition (summer);
LGG	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg15921436	chr17:44337874	NA	0.44	10.45	0.44	4.16e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs67311347	1.000	rs7634375	chr3:40431946	C/T	cg13683864	chr3:40499215	RPL14	-1.15	-25.98	-0.77	1.83e-92	Renal cell carcinoma;
LGG	cis	rs858239	0.600	rs7456915	chr7:23143049	T/C	cg23682824	chr7:23144976	KLHL7	0.45	7.75	0.34	5.78e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4974559	0.594	rs59544360	chr4:1313575	G/T	cg02980000	chr4:1222292	CTBP1	0.66	8.89	0.38	1.35e-17	Systolic blood pressure;
LGG	cis	rs1348850	0.632	rs12616288	chr2:178503813	G/T	cg22681709	chr2:178499509	PDE11A	-0.53	-9.67	-0.41	2.95e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg21132104	chr15:45694354	SPATA5L1	0.7	10.44	0.44	4.69e-23	Homoarginine levels;
LGG	cis	rs614226	0.938	rs12857	chr12:120933946	T/G	cg21053147	chr12:120880522	NA	-0.54	-8.09	-0.35	5.25e-15	Type 1 diabetes nephropathy;
LGG	cis	rs35160687	0.644	rs1863061	chr2:86512907	C/T	cg10973622	chr2:86423274	IMMT	-0.4	-7.01	-0.31	8.36e-12	Night sleep phenotypes;
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-8.99	-0.39	6.14e-18	Life satisfaction;
LGG	cis	rs7236492	0.748	rs7228738	chr18:77231307	C/T	cg15532942	chr18:77220712	NFATC1	0.43	6.83	0.3	2.6e-11	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs57221529	0.713	rs72703072	chr5:590626	A/G	cg27053975	chr1:166958233	MAEL	-0.47	-6.66	-0.3	7.62e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs10979	0.597	rs9496684	chr6:143908687	C/A	cg25407410	chr6:143891975	LOC285740	-0.56	-8.23	-0.36	1.97e-15	Hypospadias;
LGG	trans	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg06529181	chr19:52193933	NA	0.53	7.91	0.35	1.93e-14	IgG glycosylation;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg27417846	chr2:88927289	EIF2AK3	0.38	6.89	0.3	1.81e-11	Obesity-related traits;
LGG	cis	rs11148252	0.967	rs4286007	chr13:53022518	A/G	cg00761968	chr13:53314142	LECT1	-0.42	-9.24	-0.39	8.77e-19	Lewy body disease;
LGG	trans	rs11088226	0.598	rs79634586	chr21:33959363	A/G	cg09050820	chr6:167586206	TCP10L2	0.95	13.47	0.53	3.93e-35	Gastritis;
LGG	trans	rs79911532	0.515	rs76760929	chr7:75625968	T/G	cg19862616	chr7:65841803	NCRNA00174	0.77	7.95	0.35	1.39e-14	Mononucleosis;
LGG	cis	rs10791323	0.604	rs2723605	chr11:133711241	C/G	cg00579200	chr11:133705235	NA	-0.61	-11.73	-0.48	5.37e-28	Childhood ear infection;
LGG	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.53	0.37	2.12e-16	Systemic lupus erythematosus;
LGG	cis	rs7084783	0.504	rs3781345	chr10:105412730	G/T	cg00126946	chr10:105363258	SH3PXD2A	0.41	7.71	0.34	7.52e-14	Fear of pain;
LGG	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs7712401	0.601	rs246303	chr5:122251717	C/G	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg08975724	chr8:8085496	FLJ10661	0.46	8.83	0.38	2.22e-17	Mood instability;
LGG	cis	rs526231	0.543	rs27361	chr5:102548967	G/A	cg23492399	chr5:102201601	PAM	-0.56	-8.24	-0.36	1.82e-15	Primary biliary cholangitis;
LGG	cis	rs765787	0.530	rs4775832	chr15:45534828	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs1015291	0.708	rs941232	chr12:19993733	G/C	cg25401612	chr12:20009446	NA	0.35	7.59	0.33	1.78e-13	Diastolic blood pressure;
LGG	cis	rs11122272	0.766	rs2790867	chr1:231548059	A/C	cg10503236	chr1:231470652	EXOC8	0.37	7.26	0.32	1.65e-12	Hemoglobin concentration;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.4	-0.44	6.33e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs12208493	chr6:86662267	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.55	-0.53	1.85e-35	Response to antipsychotic treatment;
LGG	trans	rs459571	1.000	rs456207	chr9:136911140	G/A	cg15028160	chr19:49622717	PPFIA3;C19orf73	-0.42	-6.8	-0.3	3.29e-11	Platelet distribution width;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg12458913	chr13:53173898	NA	0.66	12.74	0.51	4.61e-32	Lewy body disease;
LGG	cis	rs916888	0.610	rs199442	chr17:44820122	G/A	cg15921436	chr17:44337874	NA	0.45	10.58	0.44	1.37e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg08997352	chr12:9597637	DDX12	0.75	14.66	0.56	2.93e-40	Breast size;
LGG	cis	rs6429082	0.764	rs2481095	chr1:235695756	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.61	-10.15	-0.43	5.41e-22	Adiposity;
LGG	trans	rs3780486	0.957	rs10971434	chr9:33168891	C/A	cg20290983	chr6:43655470	MRPS18A	1.05	16.9	0.62	2.81e-50	IgG glycosylation;
LGG	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg27454842	chr22:32027588	PISD	-0.61	-6.81	-0.3	3e-11	Age-related hearing impairment;
LGG	cis	rs796364	0.625	rs4673837	chr2:201131159	A/G	cg17644776	chr2:200775616	C2orf69	0.52	7.03	0.31	7.23e-12	Schizophrenia;
LGG	cis	rs6960043	0.683	rs10278686	chr7:15031450	C/T	cg19272540	chr7:15055459	NA	0.34	7.25	0.32	1.78e-12	Type 2 diabetes;
LGG	cis	rs7659604	0.560	rs769238	chr4:122744942	G/A	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.26e-27	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg08677398	chr8:58056175	NA	-0.57	-8.78	-0.38	3.08e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.695	rs7851556	chr9:5022807	C/T	cg02405213	chr9:5042618	JAK2	-0.84	-16.12	-0.6	1.02e-46	Pediatric autoimmune diseases;
LGG	cis	rs17641971	0.708	rs1567555	chr8:49900154	G/A	cg00325661	chr8:49890786	NA	0.52	9.42	0.4	2.11e-19	Blood metabolite levels;
LGG	cis	rs7786808	0.579	rs4045391	chr7:158181826	T/C	cg15440763	chr7:158190612	PTPRN2	0.54	11.59	0.47	1.98e-27	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs5758405	chr22:42076381	C/A	cg03806693	chr22:41940476	POLR3H	0.99	16.75	0.61	1.45e-49	Vitiligo;
LGG	cis	rs412000	0.560	rs4793583	chr17:56451407	A/C	cg05425664	chr17:57184151	TRIM37	0.56	9.08	0.39	3.17e-18	Primary tooth development (time to first tooth eruption);
LGG	cis	rs11690462	0.794	rs2384364	chr2:26541427	C/G	cg26119090	chr2:26468346	HADHA;HADHB	0.41	7.28	0.32	1.4e-12	Coronary artery disease;
LGG	cis	rs798766	0.723	rs3134865	chr4:1723279	T/C	cg00006948	chr4:1768889	NA	-0.5	-6.86	-0.3	2.24e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg02487422	chr3:49467188	NICN1	0.58	10.64	0.44	8.24e-24	Resting heart rate;
LGG	cis	rs6142618	0.562	rs6141646	chr20:30831855	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	7.99	0.35	1.05e-14	Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs8074267	chr17:80158325	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	trans	rs7726839	0.540	rs7558	chr5:660491	C/T	cg25482853	chr8:67687455	SGK3	0.95	11.81	0.48	2.61e-28	Obesity-related traits;
LGG	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg23173402	chr1:227635558	NA	0.69	10.56	0.44	1.69e-23	Major depressive disorder;
LGG	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg08949735	chr16:89699720	DPEP1	-0.39	-7.81	-0.34	3.95e-14	Hemoglobin concentration;
LGG	cis	rs2346177	0.844	rs12991646	chr2:46643831	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.82	0.34	3.56e-14	HDL cholesterol;
LGG	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg17644776	chr2:200775616	C2orf69	-0.45	-7.52	-0.33	2.77e-13	QT interval;
LGG	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.58	8.83	0.38	2.13e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg19748678	chr4:122722346	EXOSC9	0.67	13.5	0.53	2.88e-35	Type 2 diabetes;
LGG	cis	rs7107174	1.000	rs10899468	chr11:78016650	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07157834	chr1:205819609	PM20D1	0.79	18.64	0.65	3.04e-58	Menarche (age at onset);
LGG	cis	rs7166081	1.000	rs4432221	chr15:67634862	C/T	cg02273617	chr15:68117586	LBXCOR1	0.29	6.75	0.3	4.31e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.27	-7.15	-0.32	3.45e-12	IgG glycosylation;
LGG	cis	rs8060686	0.641	rs112099181	chr16:68154230	T/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.05	-0.31	6.37e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.11	-0.31	4.47e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6728642	0.908	rs10203833	chr2:98017363	G/A	cg26665480	chr2:98280029	ACTR1B	-0.76	-9.22	-0.39	1.02e-18	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs11112613	0.653	rs59504344	chr12:105950837	C/T	cg03607813	chr12:105948248	NA	0.58	10.73	0.45	3.92e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs709400	0.633	rs1951391	chr14:103898313	T/C	cg26031613	chr14:104095156	KLC1	0.79	13.96	0.54	3.13e-37	Body mass index;
LGG	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg08603382	chr10:743973	NA	0.37	6.87	0.3	2.14e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs7208859	0.562	rs216408	chr17:28907757	C/G	cg01831904	chr17:28903510	LRRC37B2	0.93	12.39	0.5	1.24e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs36051895	0.589	rs6476945	chr9:5191793	C/T	cg02405213	chr9:5042618	JAK2	-0.8	-15.03	-0.57	7.23e-42	Pediatric autoimmune diseases;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg26247295	chr4:3528253	LRPAP1	-0.66	-6.82	-0.3	2.87e-11	Plasma thyroid-stimulating hormone levels;
LGG	trans	rs9657904	0.906	rs4894960	chr3:105594320	G/A	cg14088669	chr1:158435396	OR10K1	0.42	7.88	0.34	2.36e-14	Multiple sclerosis;
LGG	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg11890956	chr21:40555474	PSMG1	-0.96	-19.54	-0.67	1.89e-62	Cognitive function;
LGG	cis	rs11734570	0.581	rs4401459	chr4:38585268	G/T	cg18361445	chr4:38666374	KLF3;FLJ13197	-0.57	-8.05	-0.35	7.23e-15	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg16141378	chr3:129829833	LOC729375	-0.48	-12.15	-0.49	1.1e-29	Mood instability;
LGG	cis	rs11098499	0.532	rs4833624	chr4:120585497	C/T	cg09307838	chr4:120376055	NA	0.73	12.31	0.5	2.48e-30	Corneal astigmatism;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg02018176	chr4:1364513	KIAA1530	0.49	11.98	0.49	5.32e-29	Longevity;
LGG	cis	rs6594499	0.872	rs10043631	chr5:110443228	C/T	cg04022379	chr5:110408740	TSLP	0.4	7.46	0.33	4.38e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17301259	0.538	rs2538887	chr7:88317909	C/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.18	-0.32	2.86e-12	Heschl's gyrus morphology;
LGG	cis	rs9831754	1.000	rs9855903	chr3:78347988	C/A	cg06138941	chr3:78371609	NA	-0.97	-20.48	-0.69	7.95e-67	Calcium levels;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs10193935	0.792	rs2053349	chr2:42516205	G/A	cg27598129	chr2:42591480	NA	-0.57	-8.52	-0.37	2.32e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg19671926	chr4:122722719	EXOSC9	0.53	8.22	0.36	2e-15	Type 2 diabetes;
LGG	cis	rs6495367	1.000	rs6495367	chr15:79375347	C/T	cg17916960	chr15:79447300	NA	0.5	8.81	0.38	2.56e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4969178	1.000	rs4969178	chr17:76388202	C/T	cg02836325	chr17:76403955	PGS1	0.67	13.34	0.53	1.4e-34	HDL cholesterol levels;
LGG	cis	rs4780401	0.755	rs7194034	chr16:11770777	A/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.28	-0.32	1.44e-12	Rheumatoid arthritis;
LGG	cis	rs916888	0.821	rs199505	chr17:44859410	A/G	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs798766	1.000	rs1374469	chr4:1724799	C/T	cg05874882	chr4:1763078	NA	-0.48	-6.82	-0.3	2.81e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs11105298	0.891	rs3825330	chr12:89933710	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.66	-9.17	-0.39	1.61e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03352830	chr11:487213	PTDSS2	0.86	10.86	0.45	1.22e-24	Body mass index;
LGG	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg17376030	chr22:41985996	PMM1	0.67	10.59	0.44	1.29e-23	Vitiligo;
LGG	cis	rs9291683	0.609	rs3796836	chr4:10011345	A/G	cg16147221	chr4:10020634	SLC2A9	0.36	6.7	0.3	6.26e-11	Bone mineral density;
LGG	cis	rs11098499	0.955	rs56386062	chr4:120155135	T/C	cg24375607	chr4:120327624	NA	0.62	10.4	0.44	6.52e-23	Corneal astigmatism;
LGG	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg23845249	chr11:68861649	NA	0.45	7.99	0.35	1.09e-14	Blond vs. brown hair color;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.82	-0.38	2.3e-17	Lung cancer;
LGG	cis	rs17021463	0.583	rs10033901	chr4:95334983	C/G	cg11021082	chr4:95130006	SMARCAD1	0.44	6.96	0.31	1.14e-11	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25129765	chr6:99872940	SFRS18	0.52	7.89	0.34	2.16e-14	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	cis	rs2380220	0.576	rs4368819	chr6:96031109	T/G	cg04719120	chr6:96025338	MANEA	0.57	7.95	0.35	1.47e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg03433033	chr1:76189801	ACADM	-0.61	-9.17	-0.39	1.55e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2836974	0.897	rs8132295	chr21:40527774	A/G	cg11890956	chr21:40555474	PSMG1	-1.22	-30.44	-0.82	1.42e-112	Cognitive function;
LGG	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs62238980	0.614	rs79592563	chr22:32425982	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs2204008	0.728	rs12369538	chr12:38443942	C/T	cg26384229	chr12:38710491	ALG10B	0.91	20.46	0.69	9.46e-67	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00987630	chr7:2393812	EIF3B	0.48	7.16	0.32	3.09e-12	Gut microbiome composition (summer);
LGG	cis	rs908922	0.651	rs1988805	chr1:152531495	T/G	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs5758511	0.680	rs5758651	chr22:42609148	T/C	cg15128208	chr22:42549153	NA	0.74	11.23	0.46	4.77e-26	Birth weight;
LGG	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.62	-0.33	1.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2077654	0.822	rs7939973	chr11:17433291	G/T	cg25308976	chr11:17434268	ABCC8	0.84	10.0	0.42	1.9e-21	Gout;
LGG	cis	rs2050392	0.829	rs306589	chr10:30723831	A/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.87	-0.45	1.13e-24	Inflammatory bowel disease;
LGG	cis	rs17270561	0.609	rs1185976	chr6:25822363	A/G	cg03264133	chr6:25882463	NA	0.43	7.02	0.31	7.69e-12	Iron status biomarkers;
LGG	cis	rs2243480	0.808	rs12698508	chr7:65411958	A/T	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs941408	0.515	rs759067	chr19:2775668	C/T	cg06609049	chr19:2785107	THOP1	0.96	16.58	0.61	8.14e-49	Total cholesterol levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09047884	chr22:43484984	TTLL1	0.41	6.89	0.3	1.84e-11	Cognitive performance;
LGG	cis	rs1451375	0.617	rs9942686	chr7:50596381	G/A	cg20336341	chr7:50628841	DDC	0.43	7.53	0.33	2.72e-13	Malaria;
LGG	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.36	0.32	8.34e-13	Menopause (age at onset);
LGG	cis	rs6831352	0.918	rs4699714	chr4:100060538	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg03433033	chr1:76189801	ACADM	0.68	10.12	0.43	7.09e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4243830	0.850	rs10746502	chr1:6607199	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.81	-12.67	-0.51	8.98e-32	Body mass index;
LGG	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg09448879	chr15:79043637	NA	0.38	8.62	0.37	1.03e-16	Diastolic blood pressure;
LGG	cis	rs12681287	0.517	rs68008113	chr8:87520894	C/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.1e-13	Caudate activity during reward;
LGG	cis	rs988958	0.958	rs13001171	chr2:42279071	C/T	cg27428208	chr2:42229179	NA	0.41	7.36	0.32	8.67e-13	Hypospadias;
LGG	cis	rs6694672	1.000	rs857026	chr1:197012194	T/C	cg13682187	chr1:196946512	CFHR5	0.49	6.94	0.31	1.32e-11	Asthma;
LGG	cis	rs9359856	0.673	rs1179897	chr6:90318624	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.95	-0.35	1.44e-14	Bipolar disorder;
LGG	cis	rs1816752	0.870	rs2033954	chr13:25010567	C/T	cg22771759	chr13:24902376	NA	0.42	7.13	0.31	3.86e-12	Obesity-related traits;
LGG	cis	rs9393692	0.620	rs9393691	chr6:26272829	T/C	cg00631329	chr6:26305371	NA	-0.44	-7.39	-0.32	7.09e-13	Educational attainment;
LGG	cis	rs1552244	0.554	rs34883592	chr3:10046165	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.3	-0.43	1.6e-22	Alzheimer's disease;
LGG	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg19761014	chr17:28927070	LRRC37B2	0.68	8.48	0.37	2.96e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9527	0.590	rs10786741	chr10:104939182	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.2	-0.32	2.44e-12	Arsenic metabolism;
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.47e-20	Educational attainment;
LGG	cis	rs4555082	0.834	rs2816623	chr14:105733295	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.19	0.52	6.12e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2012796	1.000	rs8008024	chr14:81818492	A/G	cg02996355	chr14:81879375	NA	0.5	7.87	0.34	2.49e-14	Night sleep phenotypes;
LGG	cis	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg11050988	chr7:1952600	MAD1L1	-0.37	-8.88	-0.38	1.49e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2075371	0.933	rs2544201	chr7:133963561	C/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.73	0.45	4.03e-24	Mean platelet volume;
LGG	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.02	-0.35	8.64e-15	HDL cholesterol;
LGG	cis	rs7412746	0.658	rs17660092	chr1:150797748	T/C	cg15448220	chr1:150897856	SETDB1	0.38	7.12	0.31	4.14e-12	Melanoma;
LGG	cis	rs6964587	1.000	rs10488512	chr7:91753579	C/T	cg17063962	chr7:91808500	NA	0.5	9.04	0.39	4.28e-18	Breast cancer;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.78e-12	Lung cancer;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg01262667	chr19:19385393	TM6SF2	0.43	10.54	0.44	2.02e-23	Tonsillectomy;
LGG	cis	rs62344088	0.590	rs7700533	chr5:180646	C/T	cg22496380	chr5:211416	CCDC127	-0.88	-6.82	-0.3	2.9e-11	Asthma (childhood onset);
LGG	cis	rs12493885	0.654	rs61792350	chr3:153712959	A/G	cg12800244	chr3:153838788	SGEF	-0.81	-8.79	-0.38	2.86e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs739401	0.869	rs395188	chr11:3072631	A/G	cg05729581	chr11:3078854	CARS	0.49	8.58	0.37	1.4e-16	Longevity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14162034	chr15:78112026	NA	0.6	6.79	0.3	3.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg24503407	chr1:205819492	PM20D1	0.46	7.89	0.34	2.26e-14	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg20026190	chr17:76395443	PGS1	0.57	10.1	0.42	8.26e-22	HDL cholesterol levels;
LGG	trans	rs853679	0.607	rs13194781	chr6:27815639	A/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.87	-0.48	1.53e-28	Depression;
LGG	cis	rs10791097	0.694	rs10894273	chr11:130742155	G/T	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg05335186	chr13:53173507	NA	0.85	22.74	0.73	1.97e-77	Lewy body disease;
LGG	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.55	9.78	0.41	1.21e-20	Response to antipsychotic treatment;
LGG	cis	rs2072499	0.966	rs2842857	chr1:156168736	T/C	cg24450063	chr1:156163899	SLC25A44	1.25	32.16	0.83	4.38e-120	Testicular germ cell tumor;
LGG	cis	rs9341808	0.754	rs1015158	chr6:80945745	C/T	cg08355045	chr6:80787529	NA	0.4	7.6	0.33	1.69e-13	Sitting height ratio;
LGG	trans	rs7395662	0.864	rs7483617	chr11:48551659	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.39	-0.32	6.72e-13	HDL cholesterol;
LGG	cis	rs72925845	0.519	rs1623869	chr17:76426074	T/G	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs763121	0.853	rs2179142	chr22:39037954	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	17.98	0.64	3.23e-55	Menopause (age at onset);
LGG	cis	rs2067615	0.542	rs4433659	chr12:107082496	G/T	cg15890332	chr12:107067104	RFX4	0.43	12.6	0.51	1.66e-31	Heart rate;
LGG	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.58e-22	Iron status biomarkers;
LGG	cis	rs7633857	0.536	rs2889391	chr3:160696186	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.71	-0.38	5.34e-17	Educational attainment (years of education);
LGG	cis	rs2075371	0.579	rs11766422	chr7:134018160	T/C	cg11752832	chr7:134001865	SLC35B4	0.49	8.27	0.36	1.41e-15	Mean platelet volume;
LGG	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg03929089	chr4:120376271	NA	0.75	8.5	0.37	2.53e-16	Axial length;
LGG	cis	rs9425766	0.640	rs2067079	chr1:173835211	C/T	cg06124660	chr1:173389066	NA	-0.42	-7.22	-0.32	2.1e-12	Life satisfaction;
LGG	cis	rs61931739	0.500	rs34997501	chr12:34549828	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs988958	0.567	rs11899374	chr2:42220752	G/T	cg27252766	chr2:42229092	NA	0.59	8.67	0.37	7.57e-17	Hypospadias;
LGG	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs8177253	0.665	rs12493887	chr3:133440737	T/C	cg16414030	chr3:133502952	NA	-0.48	-7.95	-0.35	1.45e-14	Iron status biomarkers;
LGG	cis	rs8078723	0.966	rs57065891	chr17:38168227	C/T	cg17467752	chr17:38218738	THRA	0.74	13.92	0.54	5.02e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs17767392	0.918	rs61991201	chr14:71762623	T/C	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs7847628	0.550	rs12343516	chr9:123603469	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	19.19	0.67	7.88e-61	Birth weight;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg13047869	chr3:10149882	C3orf24	0.57	9.4	0.4	2.45e-19	Alzheimer's disease;
LGG	cis	rs67311347	1.000	rs2276870	chr3:40499182	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.02	-0.31	8.08e-12	Renal cell carcinoma;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.54	8.54	0.37	1.9e-16	Longevity;
LGG	cis	rs9611565	0.659	rs1810460	chr22:41927700	C/T	cg06481639	chr22:41940642	POLR3H	-0.61	-8.94	-0.38	9.3e-18	Vitiligo;
LGG	trans	rs8002861	0.727	rs9525852	chr13:44405197	G/C	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.55	-0.56	8.73e-40	Leprosy;
LGG	cis	rs939658	0.776	rs35382567	chr15:79440897	C/T	cg17916960	chr15:79447300	NA	-0.66	-12.8	-0.51	2.6e-32	Refractive error;
LGG	cis	rs2976388	0.647	rs2585174	chr8:143782044	A/G	cg06565975	chr8:143823917	SLURP1	0.35	8.94	0.38	9.68e-18	Urinary tract infection frequency;
LGG	cis	rs798554	0.660	rs2283783	chr7:2855326	G/A	cg05793240	chr7:2802953	GNA12	0.32	7.86	0.34	2.75e-14	Height;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.36	-7.01	-0.31	8.34e-12	Longevity;Endometriosis;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.49	0.37	2.81e-16	Schizophrenia;
LGG	cis	rs9527	0.641	rs4919684	chr10:104587024	A/G	cg04362960	chr10:104952993	NT5C2	0.52	9.36	0.4	3.58e-19	Arsenic metabolism;
LGG	cis	rs853679	0.517	rs2281588	chr6:28072602	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs1867631	1.000	rs11208928	chr1:67089562	G/T	cg13052034	chr1:66999238	SGIP1	0.48	9.29	0.4	5.88e-19	Menopause (age at onset);
LGG	cis	rs9361491	0.510	rs1507151	chr6:79483246	T/C	cg18132916	chr6:79620363	NA	-0.28	-7.14	-0.31	3.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs981844	0.807	rs56053818	chr4:154638126	T/A	cg14289246	chr4:154710475	SFRP2	0.62	10.12	0.43	7.25e-22	Response to statins (LDL cholesterol change);
LGG	trans	rs826838	0.967	rs1352123	chr12:39130992	T/C	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg06609049	chr19:2785107	THOP1	0.62	9.65	0.41	3.28e-20	Total cholesterol levels;
LGG	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg00198680	chr16:28758506	NA	0.28	6.96	0.31	1.21e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg13147721	chr7:65941812	NA	-0.84	-10.16	-0.43	4.94e-22	Diabetic kidney disease;
LGG	trans	rs7830939	0.586	rs28586878	chr8:9322144	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.76	0.3	4.25e-11	Neuroticism;
LGG	cis	rs17767392	0.958	rs8014349	chr14:72046496	C/A	cg02058870	chr14:72053146	SIPA1L1	-0.48	-9.86	-0.42	6.1e-21	Mitral valve prolapse;
LGG	cis	rs17270561	0.583	rs6908713	chr6:25703611	G/A	cg17691542	chr6:26056736	HIST1H1C	-0.63	-10.51	-0.44	2.58e-23	Iron status biomarkers;
LGG	trans	rs7395662	0.895	rs2221553	chr11:48688784	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs12477438	0.765	rs13406288	chr2:99589585	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.9	-0.51	9.97e-33	Chronic sinus infection;
LGG	cis	rs7975161	0.630	rs6539128	chr12:104618454	A/G	cg25273343	chr12:104657179	TXNRD1	-0.73	-8.14	-0.35	3.57e-15	Toenail selenium levels;
LGG	cis	rs360798	0.532	rs2136737	chr2:62969310	G/C	cg17519650	chr2:63277830	OTX1	-0.45	-7.2	-0.32	2.51e-12	Coronary artery disease;
LGG	cis	rs10504229	0.679	rs12675340	chr8:58035501	T/A	cg05313129	chr8:58192883	C8orf71	-0.6	-8.45	-0.37	3.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg03213289	chr20:61660250	NA	0.64	13.53	0.53	2.26e-35	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs876084	0.505	rs10955953	chr8:121106381	C/T	cg06265175	chr8:121136014	COL14A1	-0.47	-9.47	-0.4	1.46e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs8114671	0.562	rs1801310	chr20:33517014	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.02	0.31	8e-12	Height;
LGG	trans	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg06521331	chr12:34319734	NA	-0.48	-8.19	-0.36	2.54e-15	Heart rate;
LGG	cis	rs9788682	0.948	rs59133824	chr15:78833450	C/A	cg24631222	chr15:78858424	CHRNA5	0.46	6.95	0.31	1.27e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs10504229	1.000	rs58947041	chr8:58188934	G/A	cg11062466	chr8:58055876	NA	0.48	8.33	0.36	9.27e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs8042237	chr15:67556625	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.94	-0.31	1.34e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17125944	0.506	rs7160285	chr14:53311400	A/C	cg00686598	chr14:53173677	PSMC6	-0.68	-7.0	-0.31	9.05e-12	Alzheimer's disease (late onset);
LGG	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg02187348	chr16:89574699	SPG7	0.65	10.88	0.45	1.04e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.602	rs2510885	chr12:123614813	G/C	cg05973401	chr12:123451056	ABCB9	0.47	7.2	0.32	2.4e-12	Neutrophil percentage of white cells;
LGG	cis	rs2836974	0.932	rs2836955	chr21:40619887	G/A	cg11890956	chr21:40555474	PSMG1	1.16	27.19	0.78	5.23e-98	Cognitive function;
LGG	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.14	-0.43	5.86e-22	Colorectal cancer;
LGG	cis	rs57590327	0.528	rs2229519	chr3:81698130	T/C	cg07356753	chr3:81810745	GBE1	-0.48	-7.6	-0.33	1.7e-13	Extraversion;
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg18402987	chr7:1209562	NA	0.68	7.39	0.32	6.99e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10911363	0.592	rs2275675	chr1:183439483	C/T	cg09173681	chr1:183549694	NCF2	-0.36	-8.27	-0.36	1.39e-15	Systemic lupus erythematosus;
LGG	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg04398451	chr17:18023971	MYO15A	-0.82	-17.98	-0.64	3.12e-55	Total body bone mineral density;
LGG	cis	rs12410462	0.591	rs2819498	chr1:227724401	G/T	cg04117972	chr1:227635322	NA	0.46	8.45	0.37	3.69e-16	Major depressive disorder;
LGG	trans	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg16141378	chr3:129829833	LOC729375	-0.45	-10.84	-0.45	1.43e-24	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24341944	chr3:157827791	RSRC1	0.42	6.66	0.3	7.79e-11	Cognitive performance;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg03517284	chr6:25882590	NA	-0.41	-7.42	-0.33	5.69e-13	Height;
LGG	cis	rs35306767	0.715	rs17293580	chr10:1034895	T/C	cg20503657	chr10:835505	NA	0.56	7.18	0.32	2.87e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs6740322	0.843	rs6727237	chr2:43562000	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.56	-8.77	-0.38	3.39e-17	Coronary artery disease;
LGG	cis	rs3106136	0.872	rs10033662	chr4:95239462	G/A	cg11021082	chr4:95130006	SMARCAD1	0.44	7.42	0.33	5.69e-13	Capecitabine sensitivity;
LGG	cis	rs1978968	0.717	rs5992934	chr22:18457119	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-13.54	-0.53	2e-35	Presence of antiphospholipid antibodies;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg04863758	chr4:1303710	MAEA	0.43	7.4	0.33	6.52e-13	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs7216798	chr17:61740963	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.71	0.34	7.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg14074117	chr16:1909714	C16orf73	-0.53	-7.83	-0.34	3.36e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7786808	0.644	rs4909081	chr7:158200785	G/A	cg12438819	chr7:158236134	PTPRN2	0.32	8.29	0.36	1.26e-15	Obesity-related traits;
LGG	cis	rs870825	0.858	rs2014964	chr4:185588836	G/A	cg04058563	chr4:185651563	MLF1IP	1.13	19.33	0.67	1.87e-61	Blood protein levels;
LGG	cis	rs10908458	0.584	rs10908454	chr1:155066416	C/T	cg13808842	chr1:155066096	NA	-0.31	-7.79	-0.34	4.39e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg09263875	chr16:632152	PIGQ	0.66	13.39	0.53	8.24e-35	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13819250	chr17:41560934	DHX8	0.44	7.15	0.32	3.51e-12	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs4698649	chr4:17692782	A/G	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg24848339	chr3:12840334	CAND2	0.47	11.33	0.47	2e-26	QRS complex (12-leadsum);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02034563	chr2:179060011	OSBPL6	0.44	6.81	0.3	3.05e-11	Gut microbiome composition (summer);
LGG	cis	rs6997458	0.785	rs2432083	chr8:86340608	C/T	cg02393479	chr8:86352350	CA3	-0.32	-7.07	-0.31	5.64e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs4144743	1.000	rs10438781	chr17:45323819	A/G	cg18085866	chr17:45331354	ITGB3	-0.78	-9.87	-0.42	5.56e-21	Body mass index;
LGG	cis	rs9513627	0.512	rs9517759	chr13:100180108	T/G	cg15490075	chr13:100150979	NA	0.56	7.59	0.33	1.75e-13	Obesity-related traits;
LGG	cis	rs9660992	1.000	rs9660992	chr1:205249450	A/G	cg21545522	chr1:205238299	TMCC2	0.38	7.12	0.31	4.08e-12	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs11039798	1.000	rs7924372	chr11:48556319	T/A	cg15704280	chr7:45808275	SEPT13	0.74	7.88	0.34	2.39e-14	Axial length;
LGG	cis	rs16966142	1.000	rs3890534	chr16:89835289	A/G	cg27121462	chr16:89883253	FANCA	-0.7	-7.21	-0.32	2.32e-12	Caffeine consumption;
LGG	trans	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg24247370	chr13:99142703	STK24	-0.4	-7.29	-0.32	1.32e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2832191	0.740	rs13048618	chr21:30458684	A/G	cg24692254	chr21:30365293	RNF160	1.04	29.91	0.81	3.14e-110	Dental caries;
LGG	cis	rs12586317	0.547	rs10146699	chr14:35483577	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.81	-0.34	3.93e-14	Psoriasis;
LGG	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg05234568	chr11:5960015	NA	0.72	13.05	0.52	2.28e-33	DNA methylation (variation);
LGG	cis	rs17767392	0.560	rs1008517	chr14:72041434	A/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.27	0.36	1.44e-15	Mitral valve prolapse;
LGG	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg15557168	chr22:42548783	NA	-0.46	-10.18	-0.43	4.17e-22	Schizophrenia;
LGG	cis	rs240764	0.619	rs2134044	chr6:101075354	C/A	cg09795085	chr6:101329169	ASCC3	0.41	6.94	0.31	1.35e-11	Neuroticism;
LGG	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg11752832	chr7:134001865	SLC35B4	0.49	8.69	0.37	6.2e-17	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16682046	chr11:82612617	PRCP;C11orf82	0.48	7.62	0.33	1.46e-13	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg07005078	chr4:17578674	LAP3	0.37	6.94	0.31	1.36e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17401966	0.838	rs12141246	chr1:10327407	A/T	cg19773385	chr1:10388646	KIF1B	-0.45	-9.91	-0.42	3.89e-21	Hepatocellular carcinoma;
LGG	cis	rs7084402	0.967	rs1593677	chr10:60291642	A/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.85e-13	Refractive error;
LGG	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg10402321	chr1:26617780	UBXN11	-0.45	-7.49	-0.33	3.58e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.07	-0.39	3.44e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg06481639	chr22:41940642	POLR3H	-0.54	-7.85	-0.34	2.82e-14	Vitiligo;
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.23	-0.32	2.02e-12	Bipolar disorder;
LGG	cis	rs9522267	0.535	rs11069898	chr13:112231512	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.34	-0.32	9.99e-13	Hepatitis;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs3749237	0.595	rs6797765	chr3:49423976	A/G	cg03060546	chr3:49711283	APEH	0.73	13.14	0.52	9.68e-34	Resting heart rate;
LGG	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg11995313	chr8:8860691	ERI1	0.45	7.61	0.33	1.5e-13	Joint mobility (Beighton score);
LGG	cis	rs8179	0.645	rs11765954	chr7:92280695	A/G	cg15732164	chr7:92237376	CDK6	-0.5	-9.47	-0.4	1.47e-19	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs3087591	0.639	rs734403	chr17:29723346	T/C	cg24425628	chr17:29625626	OMG;NF1	0.57	11.84	0.48	1.93e-28	Hip circumference;
LGG	cis	rs1801251	1.000	rs36007169	chr2:233621834	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.69	0.51	7.32e-32	Coronary artery disease;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.55	8.59	0.37	1.38e-16	Tonsillectomy;
LGG	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs17401966	0.838	rs61775887	chr1:10284733	T/C	cg15208524	chr1:10270712	KIF1B	0.46	7.96	0.35	1.36e-14	Hepatocellular carcinoma;
LGG	cis	rs3796352	0.881	rs35385050	chr3:52997945	C/A	cg12962167	chr3:53033115	SFMBT1	0.77	8.07	0.35	6.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg09699651	chr6:150184138	LRP11	-0.45	-6.77	-0.3	3.98e-11	Lung cancer;
LGG	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg24642439	chr20:33292090	TP53INP2	-0.58	-9.84	-0.42	6.9e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs362272	0.525	rs2857849	chr4:3043638	A/T	cg02566259	chr4:3043199	NA	0.35	8.84	0.38	2.07e-17	Serum sulfate level;
LGG	cis	rs79976124	0.879	rs78012385	chr6:66618091	G/A	cg07460842	chr6:66804631	NA	0.73	12.28	0.5	3.48e-30	Type 2 diabetes;
LGG	cis	rs7312933	0.558	rs1796381	chr12:42842475	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.74	0.34	6.39e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg05484376	chr2:27715224	FNDC4	-0.47	-10.03	-0.42	1.46e-21	Total body bone mineral density;
LGG	trans	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.23	-0.32	2.06e-12	Neuroticism;
LGG	cis	rs10214930	0.697	rs3847001	chr7:27564305	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.92	0.31	1.53e-11	Hypospadias;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.63	0.61	5.11e-49	Platelet count;
LGG	cis	rs7216064	1.000	rs7214758	chr17:65880538	T/C	cg12091567	chr17:66097778	LOC651250	-0.62	-9.05	-0.39	4.08e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs41271473	0.687	rs4391637	chr1:228878379	A/C	cg00850481	chr1:228891306	NA	-0.56	-11.16	-0.46	9.15e-26	Chronic lymphocytic leukemia;
LGG	cis	rs8017423	0.967	rs7146640	chr14:90720114	C/T	cg04374321	chr14:90722782	PSMC1	-0.87	-17.75	-0.64	3.63e-54	Mortality in heart failure;
LGG	cis	rs6554196	0.644	rs7694444	chr4:55498515	G/T	cg18836493	chr4:55524333	KIT	-0.41	-7.67	-0.34	1.05e-13	Monocyte count;
LGG	cis	rs7851660	0.805	rs10759981	chr9:100635780	A/G	cg13688889	chr9:100608707	NA	-0.59	-11.64	-0.48	1.16e-27	Strep throat;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg16507663	chr6:150244633	RAET1G	0.44	8.34	0.36	8.38e-16	Lung cancer;
LGG	cis	rs9322193	0.962	rs9688809	chr6:150109056	C/T	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg08219700	chr8:58056026	NA	0.46	7.04	0.31	6.89e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.534	rs12418219	chr11:48988091	G/T	cg00717180	chr2:96193071	NA	-0.49	-9.21	-0.39	1.16e-18	HDL cholesterol;
LGG	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg20302533	chr7:39170763	POU6F2	0.59	14.99	0.57	1.09e-41	IgG glycosylation;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.9	-0.42	4.35e-21	Triglycerides;
LGG	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg10167378	chr1:228756711	NA	0.54	7.63	0.33	1.36e-13	Chronic lymphocytic leukemia;
LGG	cis	rs6076065	0.548	rs6048742	chr20:23327584	T/C	cg11657817	chr20:23433608	CST11	0.37	7.2	0.32	2.5e-12	Facial morphology (factor 15, philtrum width);
LGG	cis	rs12425451	0.544	rs7961302	chr12:3146436	G/C	cg05389053	chr12:3131226	TEAD4	-0.63	-10.74	-0.45	3.65e-24	Narcolepsy with cataplexy;
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg26150922	chr2:100937072	LONRF2	-0.61	-12.01	-0.49	3.99e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg07440826	chr16:89882328	FANCA	0.26	6.94	0.31	1.31e-11	Vitiligo;
LGG	cis	rs600231	0.542	rs11227205	chr11:65256164	G/A	cg17120908	chr11:65337727	SSSCA1	-0.64	-9.02	-0.39	4.93e-18	Bone mineral density;
LGG	cis	rs4936891	0.520	rs4936874	chr11:123870227	C/T	cg22125253	chr11:123886957	OR10G4	0.48	8.0	0.35	9.84e-15	Male fertility;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg06558623	chr16:89946397	TCF25	1.06	13.04	0.52	2.65e-33	Skin colour saturation;
LGG	trans	rs7178375	0.544	rs2525009	chr15:31109785	T/G	cg04373760	chr16:53404718	NA	0.62	9.49	0.4	1.25e-19	Hypertriglyceridemia;
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg22903471	chr2:27725779	GCKR	-0.59	-13.53	-0.53	2.26e-35	Total body bone mineral density;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	19.91	0.68	3.7e-64	Platelet count;
LGG	cis	rs1843834	1.000	rs4624372	chr2:225553128	A/G	cg22455342	chr2:225449267	CUL3	0.57	9.65	0.41	3.44e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs362296	0.698	rs3095081	chr4:3263776	C/T	cg06533319	chr4:3265114	C4orf44	0.51	10.43	0.44	5.2e-23	Parental longevity (mother's age at death);
LGG	trans	rs2727020	0.576	rs11040223	chr11:49034633	G/T	cg15704280	chr7:45808275	SEPT13	-0.61	-11.02	-0.46	3.02e-25	Coronary artery disease;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.75	13.74	0.54	2.88e-36	Obesity-related traits;
LGG	cis	rs2404602	0.530	rs12915184	chr15:76965922	G/A	cg15268244	chr15:77196840	NA	0.44	8.39	0.36	5.97e-16	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.63	-0.37	9.79e-17	Menopause (age at onset);
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg19774624	chr17:42201019	HDAC5	-0.84	-16.61	-0.61	5.92e-49	Total body bone mineral density;
LGG	cis	rs7618915	0.547	rs62253703	chr3:52632357	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs16976116	0.855	rs7172289	chr15:55501705	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10089	1.000	rs72794392	chr5:127490061	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	10.95	0.45	5.91e-25	Ileal carcinoids;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14850412	chr1:200860682	C1orf106	0.52	7.75	0.34	5.7e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2285947	0.901	rs2285943	chr7:21582963	G/T	cg23045935	chr7:21583304	DNAH11	0.43	9.24	0.39	8.67e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.79	-0.38	2.9e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.03	0.7	2.09e-69	Platelet count;
LGG	cis	rs889312	0.500	rs866223	chr5:56125353	A/G	cg14703610	chr5:56206110	C5orf35	0.39	6.9	0.31	1.72e-11	Breast cancer;Breast cancer (early onset);
LGG	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.25	-0.36	1.64e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs2760061	0.583	rs1774757	chr1:228211135	C/G	cg02753203	chr1:228287806	NA	0.93	19.26	0.67	3.95e-61	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.28	0.32	1.42e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6724607	1.000	rs7598979	chr2:191453375	A/G	cg10560079	chr2:191398806	TMEM194B	0.37	8.3	0.36	1.14e-15	Pulse pressure;
LGG	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg02487422	chr3:49467188	NICN1	0.58	10.67	0.44	6.75e-24	Resting heart rate;
LGG	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.14	-0.43	5.93e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4566357	0.615	rs2272200	chr2:227912331	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.06	-0.39	3.55e-18	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01532694	chr8:8243576	NA	0.43	7.01	0.31	8.57e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.07	-20.07	-0.68	6.7e-65	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.32	-0.4	4.6e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4262150	0.764	rs2961766	chr5:151931892	G/A	cg12297329	chr5:152029980	NA	-0.71	-13.53	-0.53	2.23e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg07243736	chr16:783730	NARFL	0.41	7.07	0.31	5.87e-12	Height;
LGG	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg14036092	chr11:66035641	RAB1B	0.45	7.79	0.34	4.46e-14	Gout;
LGG	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.02	-0.35	8.65e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.541	rs2009610	chr6:25967068	C/T	cg16482183	chr6:26056742	HIST1H1C	0.93	13.23	0.52	4.19e-34	Iron status biomarkers;
LGG	cis	rs9397585	0.857	rs1933260	chr6:153379377	C/T	cg17707550	chr6:153380415	RGS17	0.6	12.33	0.5	2.01e-30	Body mass index;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg04234412	chr22:24373322	LOC391322	-0.75	-15.37	-0.58	2.24e-43	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg21862992	chr11:68658383	NA	0.5	8.55	0.37	1.76e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg12751644	chr20:60527061	NA	-0.31	-7.05	-0.31	6.57e-12	Body mass index;
LGG	cis	rs698813	0.674	rs6544753	chr2:44501895	A/T	cg00619915	chr2:44497795	NA	-0.62	-8.77	-0.38	3.52e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs9462027	0.628	rs28675115	chr6:34732514	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.639	rs2318145	chr8:58114867	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23065468	chr2:136288564	R3HDM1;ZRANB3	-0.49	-7.17	-0.32	3.03e-12	Systemic lupus erythematosus;
LGG	cis	rs11158559	0.865	rs911001	chr14:65240485	C/T	cg22797773	chr14:65239943	SPTB	-0.4	-6.98	-0.31	9.96e-12	Obesity-related traits;
LGG	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg06219351	chr7:158114137	PTPRN2	-0.78	-15.16	-0.58	2e-42	Calcium levels;
LGG	cis	rs9308433	0.529	rs4655333	chr1:214493549	A/G	cg06198575	chr1:214491504	SMYD2	0.51	7.76	0.34	5.38e-14	IgG glycosylation;
LGG	cis	rs7100689	0.646	rs1340384	chr10:82088702	T/A	cg01528321	chr10:82214614	TSPAN14	0.82	14.65	0.56	3.21e-40	Post bronchodilator FEV1;
LGG	cis	rs61906588	0.595	rs549298	chr11:116354466	A/G	cg12564567	chr11:116371188	NA	-0.37	-6.86	-0.3	2.23e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.21	-0.58	1.14e-42	Colorectal cancer;
LGG	cis	rs4853012	0.838	rs6707729	chr2:74344685	G/A	cg01017244	chr2:74357527	NA	0.47	8.69	0.37	6.21e-17	Gestational age at birth (maternal effect);
LGG	cis	rs7216064	1.000	rs8067892	chr17:65837983	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg15971980	chr6:150254442	NA	0.46	9.29	0.4	6.14e-19	Testicular germ cell tumor;
LGG	cis	rs7567389	1.000	rs7567389	chr2:127982645	A/T	cg11380483	chr2:127933992	NA	-0.37	-7.14	-0.31	3.62e-12	Self-rated health;
LGG	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.9	0.31	1.67e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.7	-0.34	8.29e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6546537	0.869	rs13035491	chr2:69827456	G/A	cg10773587	chr2:69614142	GFPT1	-0.46	-7.72	-0.34	7.18e-14	Serum thyroid-stimulating hormone levels;
LGG	trans	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg27053975	chr1:166958233	MAEL	-0.47	-6.65	-0.3	8.18e-11	Obesity-related traits;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg11235426	chr6:292522	DUSP22	-0.59	-9.74	-0.41	1.59e-20	Menopause (age at onset);
LGG	cis	rs10504229	0.906	rs73607868	chr8:58172482	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1710354	1.000	rs1710354	chr19:51802140	C/T	cg04944904	chr19:51845941	VSIG10L	-0.31	-7.39	-0.32	7.13e-13	Blood protein levels;
LGG	cis	rs2816316	0.943	rs2760524	chr1:192530548	C/T	cg02586212	chr1:192544902	RGS1	-0.42	-8.55	-0.37	1.81e-16	Celiac disease;
LGG	cis	rs6951245	1.000	rs76388414	chr7:1100694	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3008870	1.000	rs2985821	chr1:67403787	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.99	0.73	1.39e-78	Lymphocyte percentage of white cells;
LGG	cis	rs7927592	0.956	rs948315	chr11:68309140	T/C	cg20283391	chr11:68216788	NA	-0.49	-8.09	-0.35	5.17e-15	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.11	-0.39	2.58e-18	Menopause (age at onset);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22859847	chr21:30396798	USP16	0.41	6.69	0.3	6.45e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs7937890	0.732	rs7946902	chr11:14273308	C/T	cg19336497	chr11:14380999	RRAS2	0.38	7.18	0.32	2.83e-12	Mitochondrial DNA levels;
LGG	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.18e-16	Aortic root size;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.772	rs2301916	chr7:156974127	G/T	cg00092383	chr7:157075207	NA	-0.39	-6.78	-0.3	3.57e-11	Body mass index;
LGG	cis	rs17453880	0.929	rs11948856	chr5:151983819	G/T	cg10931792	chr5:152022470	NA	-0.34	-7.17	-0.32	2.95e-12	Subjective well-being;
LGG	cis	rs151227923	1	rs151227923	chr7:155106564	C/T	cg14927855	chr7:155151427	NA	0.6	10.8	0.45	2.07e-24	Stem cell growth factor beta levels;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg18446336	chr7:2847575	GNA12	-0.3	-7.04	-0.31	6.79e-12	Height;
LGG	trans	rs11039798	0.512	rs11040205	chr11:49007360	G/C	cg03929089	chr4:120376271	NA	0.71	9.88	0.42	5.02e-21	Axial length;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg19635926	chr16:89946313	TCF25	0.8	8.29	0.36	1.2e-15	Skin colour saturation;
LGG	cis	rs10744422	1.000	rs4759387	chr12:123377569	C/T	cg25930673	chr12:123319894	HIP1R	-0.7	-9.24	-0.39	9.09e-19	Schizophrenia;
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg24397884	chr7:158709396	WDR60	0.88	18.02	0.64	2.12e-55	Height;
LGG	cis	rs13082711	0.911	rs35262121	chr3:27508277	G/A	cg02860705	chr3:27208620	NA	0.69	12.3	0.5	2.89e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2013441	0.965	rs7207611	chr17:20204516	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.33e-11	Obesity-related traits;
LGG	cis	rs1059312	0.808	rs900982	chr12:129304369	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.69	0.37	6.48e-17	Systemic lupus erythematosus;
LGG	cis	rs314370	0.855	rs17883557	chr7:100494949	G/T	cg10426581	chr7:100472382	SRRT	0.53	7.28	0.32	1.45e-12	Resting heart rate;
LGG	cis	rs4478037	1.000	rs59229836	chr3:33162622	T/C	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg02725872	chr8:58115012	NA	-1.06	-14.8	-0.57	7.59e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs708547	0.647	rs4864609	chr4:57878141	T/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs1348850	0.914	rs10170667	chr2:178336878	A/G	cg27490568	chr2:178487706	NA	0.51	10.07	0.42	1.07e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7107174	1.000	rs57738705	chr11:77994489	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.46	-0.33	4.36e-13	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02249930	chr10:70166207	RUFY2	0.47	8.14	0.35	3.57e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs503734	0.643	rs6441602	chr3:101123041	G/C	cg27318481	chr3:100970896	IMPG2	0.35	7.02	0.31	7.76e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs11098499	0.874	rs6851169	chr4:120117510	T/C	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs62064224	0.606	rs61390192	chr17:30837447	C/T	cg25809561	chr17:30822961	MYO1D	0.45	10.44	0.44	4.63e-23	Schizophrenia;
LGG	cis	rs17534004	0.720	rs78587212	chr13:31485323	A/C	cg00367615	chr13:31480979	C13orf33	0.32	6.88	0.3	1.94e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg25338242	chr13:114786047	RASA3	0.4	7.36	0.32	8.72e-13	Schizophrenia;
LGG	cis	rs7143963	0.666	rs66666997	chr14:103345026	G/C	cg23020514	chr14:103360112	TRAF3	0.4	8.35	0.36	8.14e-16	Body mass index;
LGG	cis	rs17102423	0.623	rs12100752	chr14:65611546	G/C	cg11161011	chr14:65562177	MAX	-0.66	-12.13	-0.49	1.3e-29	Obesity-related traits;
LGG	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg21775007	chr8:11205619	TDH	0.5	8.08	0.35	5.77e-15	Joint mobility (Beighton score);
LGG	cis	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg05025164	chr4:1340916	KIAA1530	0.6	11.03	0.46	2.88e-25	Longevity;
LGG	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg00198680	chr16:28758506	NA	-0.29	-6.76	-0.3	4.06e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg22437258	chr11:111473054	SIK2	0.56	9.88	0.42	4.98e-21	Primary sclerosing cholangitis;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg13395646	chr4:1353034	KIAA1530	-0.41	-7.08	-0.31	5.32e-12	Longevity;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg22907277	chr7:1156413	C7orf50	0.66	8.52	0.37	2.18e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg11814155	chr7:99998594	ZCWPW1	0.52	7.96	0.35	1.37e-14	Platelet count;
LGG	cis	rs7582180	0.764	rs11682748	chr2:100925934	C/A	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	trans	rs75804782	0.521	rs72993044	chr2:239397949	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.6	0.37	1.2e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg11494091	chr17:61959527	GH2	0.99	24.35	0.75	6.71e-85	Prudent dietary pattern;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg14893161	chr1:205819251	PM20D1	0.89	20.68	0.69	9.32e-68	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs17805656	chr8:58180318	T/C	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.67e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg19554555	chr3:13937349	NA	0.71	13.72	0.54	3.41e-36	Ovarian reserve;
LGG	cis	rs7639513	0.590	rs3729931	chr3:12626516	A/G	cg23032965	chr3:12705835	RAF1	-0.7	-13.01	-0.52	3.33e-33	Itch intensity from mosquito bite;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08121514	chr7:113726103	NA	0.43	7.38	0.32	7.15e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.74	-0.41	1.65e-20	Neuroticism;
LGG	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg06640241	chr16:89574553	SPG7	0.79	13.85	0.54	9.73e-37	Multiple myeloma (IgH translocation);
LGG	cis	rs8017423	0.967	rs61231898	chr14:90691696	G/A	cg04374321	chr14:90722782	PSMC1	0.87	18.54	0.65	8.42e-58	Mortality in heart failure;
LGG	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg22916017	chr11:64110731	CCDC88B	-0.49	-6.7	-0.3	6.08e-11	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04232466	chr8:21988724	HR	0.51	8.0	0.35	9.88e-15	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg05368731	chr17:41323189	NBR1	0.94	18.68	0.66	1.98e-58	Menopause (age at onset);
LGG	cis	rs9811920	0.809	rs7649349	chr3:99725629	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.79	-0.38	3e-17	Axial length;
LGG	cis	rs7828089	0.934	rs12544427	chr8:22263115	C/T	cg12081754	chr8:22256438	SLC39A14	-0.71	-13.7	-0.54	4.35e-36	Verbal declarative memory;
LGG	cis	rs1371867	0.846	rs1788167	chr8:101319996	C/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.59	-0.37	1.36e-16	Atrioventricular conduction;
LGG	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg11693508	chr17:37793320	STARD3	0.55	8.04	0.35	7.48e-15	Bipolar disorder;
LGG	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg10523679	chr1:76189770	ACADM	-0.43	-6.92	-0.31	1.55e-11	Daytime sleep phenotypes;
LGG	cis	rs4742903	0.584	rs58225668	chr9:107006661	A/C	cg14250997	chr9:106856677	SMC2	0.35	7.05	0.31	6.63e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg19399532	chr1:178512495	C1orf220	-0.53	-10.49	-0.44	3.13e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9399135	0.967	rs9321481	chr6:135352648	C/G	cg24558204	chr6:135376177	HBS1L	-0.51	-9.28	-0.4	6.73e-19	Red blood cell count;
LGG	cis	rs7786877	0.761	rs11772705	chr7:100298904	T/C	cg16850897	chr7:100343110	ZAN	-0.59	-9.74	-0.41	1.56e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8016982	0.559	rs8009888	chr14:81718381	C/T	cg01989461	chr14:81687754	GTF2A1	0.57	8.52	0.37	2.33e-16	Schizophrenia;
LGG	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg15549821	chr19:49342101	PLEKHA4	-0.79	-13.4	-0.53	7.72e-35	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs10220309	0.501	rs35191251	chr14:80661203	A/C	cg08183125	chr14:80678293	DIO2	-0.47	-7.33	-0.32	1.07e-12	Lung function (FEV1);
LGG	cis	rs698833	0.886	rs6721675	chr2:44566027	G/A	cg00619915	chr2:44497795	NA	-0.44	-6.68	-0.3	6.75e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs6831352	0.918	rs29001216	chr4:100051556	A/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs4423214	0.610	rs12789253	chr11:71125765	G/A	cg05163923	chr11:71159392	DHCR7	0.51	9.38	0.4	2.98e-19	Vitamin D levels;
LGG	cis	rs10979	0.964	rs35826562	chr6:143898672	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.09	-0.49	1.89e-29	Hypospadias;
LGG	cis	rs1862618	1.000	rs1862618	chr5:56096315	C/G	cg03609598	chr5:56110824	MAP3K1	-0.47	-6.95	-0.31	1.24e-11	Initial pursuit acceleration;
LGG	cis	rs67133203	0.904	rs12819296	chr12:51333329	G/T	cg14688905	chr12:51403056	SLC11A2	0.73	10.81	0.45	1.95e-24	Urinary tract infection frequency;
LGG	cis	rs10504130	0.569	rs11775611	chr8:52820274	A/G	cg22653915	chr8:52722023	PXDNL	-0.43	-6.87	-0.3	2.14e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02249930	chr10:70166207	RUFY2	-0.49	-7.37	-0.32	8.04e-13	Systemic lupus erythematosus;
LGG	cis	rs2842992	0.958	rs2758318	chr6:160069637	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.81	13.59	0.53	1.27e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1008375	1.000	rs28545485	chr4:17645376	C/T	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs5769765	0.773	rs138861	chr22:50202276	A/G	cg02269571	chr22:50332266	NA	-0.58	-9.06	-0.39	3.69e-18	Schizophrenia;
LGG	cis	rs787274	0.850	rs7862183	chr9:115529696	C/T	cg13803584	chr9:115635662	SNX30	-0.55	-7.73	-0.34	6.75e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.13	-0.43	6.35e-22	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg23594656	chr7:65796392	TPST1	0.4	8.85	0.38	1.86e-17	Aortic root size;
LGG	cis	rs12711979	0.509	rs10191674	chr2:3827891	C/T	cg17052675	chr2:3827356	NA	-0.49	-9.69	-0.41	2.53e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11792861	0.619	rs2289480	chr9:111705501	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	11.82	0.48	2.27e-28	Menarche (age at onset);
LGG	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg03733263	chr8:22462867	KIAA1967	1.04	22.19	0.72	7.59e-75	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs965513	1.000	rs7021576	chr9:100540541	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.55	-0.41	7.6e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-16.1	-0.6	1.23e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs947211	0.846	rs823155	chr1:205762946	T/C	cg24503407	chr1:205819492	PM20D1	0.54	9.13	0.39	2.19e-18	Parkinson's disease;
LGG	trans	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg25482853	chr8:67687455	SGK3	0.94	11.97	0.49	6.06e-29	Obesity-related traits;
LGG	cis	rs769267	0.598	rs8108705	chr19:19675367	G/T	cg03709012	chr19:19516395	GATAD2A	-0.6	-10.05	-0.42	1.22e-21	Tonsillectomy;
LGG	cis	rs9649465	1.000	rs9649465	chr7:123376560	G/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.94	-0.42	3.11e-21	Response to antipsychotic treatment;
LGG	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.95	-0.35	1.45e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9964724	0.796	rs28414828	chr18:35196274	A/G	cg27332583	chr18:35150602	NA	0.38	8.19	0.36	2.6e-15	Educational attainment (years of education);
LGG	cis	rs11700980	0.636	rs11701464	chr21:30285392	C/T	cg24692254	chr21:30365293	RNF160	0.62	7.8	0.34	4.14e-14	QRS complex (12-leadsum);
LGG	cis	rs7551222	0.752	rs4951393	chr1:204489557	A/C	cg20240347	chr1:204465584	NA	0.54	11.21	0.46	5.74e-26	Schizophrenia;
LGG	cis	rs765787	0.530	rs3759892	chr15:45542709	A/G	cg25801113	chr15:45476975	SHF	-0.88	-18.85	-0.66	3.19e-59	Uric acid levels;
LGG	cis	rs2594989	0.616	rs6442255	chr3:11474492	A/G	cg01796438	chr3:11312864	ATG7	-0.52	-7.2	-0.32	2.4e-12	Circulating chemerin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13922970	chr2:172016876	TLK1	0.46	7.34	0.32	9.57e-13	Cognitive performance;
LGG	cis	rs11230563	0.501	rs4939488	chr11:60786474	T/C	cg10158843	chr11:60776172	CD6	0.4	6.92	0.31	1.56e-11	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11096990	0.634	rs3733281	chr4:39271913	T/C	cg24403649	chr4:39172243	NA	-0.38	-6.68	-0.3	7.01e-11	Cognitive function;
LGG	cis	rs1620921	0.621	rs2489968	chr6:161264408	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg20368463	chr18:77673604	PQLC1	0.42	7.48	0.33	3.83e-13	Schizophrenia;
LGG	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg08250081	chr4:10125330	NA	0.38	7.3	0.32	1.3e-12	Bone mineral density;
LGG	cis	rs2712184	0.756	rs2541393	chr2:217651230	G/C	cg05032264	chr2:217675019	NA	-0.43	-9.29	-0.4	6.07e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.01	-0.31	8.6e-12	Electroencephalogram traits;
LGG	cis	rs11931598	0.509	rs10937771	chr4:6940034	C/T	cg12864912	chr4:6988209	TBC1D14	-0.48	-9.0	-0.39	5.85e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs61990749	0.597	rs8016416	chr14:78213100	T/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	6.96	0.31	1.2e-11	Fibroblast growth factor basic levels;
LGG	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.17	0.52	7.39e-34	Mean platelet volume;Platelet distribution width;
LGG	trans	rs281508	1.000	rs281508	chr2:46411207	A/C	cg11413715	chr19:37263704	NA	-0.4	-6.71	-0.3	5.75e-11	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs1348850	0.651	rs4893936	chr2:178240676	C/G	cg27490568	chr2:178487706	NA	0.37	7.42	0.33	5.79e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs35306767	0.715	rs17221456	chr10:1037234	T/C	cg20503657	chr10:835505	NA	0.57	7.21	0.32	2.25e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs738322	0.640	rs738321	chr22:38568833	C/G	cg03162506	chr22:38580953	NA	0.4	10.38	0.43	7.93e-23	Cutaneous nevi;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.67	0.34	1.02e-13	Lung cancer;
LGG	cis	rs3751667	0.506	rs4984718	chr16:974411	T/A	cg01816814	chr16:959883	LMF1	-0.43	-7.31	-0.32	1.22e-12	Non-glioblastoma glioma;Glioblastoma;Glioma;
LGG	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg12310025	chr6:25882481	NA	-0.49	-9.47	-0.4	1.43e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.08	16.63	0.61	5.11e-49	Platelet count;
LGG	cis	rs6952808	0.693	rs10950413	chr7:1912988	A/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.91	-0.48	1.03e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg16590910	chr6:42928470	GNMT	0.42	11.95	0.49	7.36e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.42	-0.33	5.56e-13	Joint mobility (Beighton score);
LGG	cis	rs875971	0.522	rs709604	chr7:65497434	A/G	cg18876405	chr7:65276391	NA	-0.65	-12.31	-0.5	2.56e-30	Aortic root size;
LGG	cis	rs6539288	0.677	rs10778518	chr12:107343950	C/T	cg15890332	chr12:107067104	RFX4	-0.31	-8.35	-0.36	7.91e-16	Total body bone mineral density;
LGG	cis	rs769267	0.965	rs2074550	chr19:19387743	A/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.03	0.31	7.6e-12	Tonsillectomy;
LGG	cis	rs3903072	0.528	rs11227306	chr11:65578672	C/A	cg26695010	chr11:65641043	EFEMP2	-0.42	-6.65	-0.3	8.18e-11	Breast cancer;
LGG	cis	rs7662987	0.517	rs2602873	chr4:100039032	G/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg11693508	chr17:37793320	STARD3	0.63	9.54	0.41	8.31e-20	Bipolar disorder;
LGG	cis	rs3764563	0.660	rs8107923	chr19:15737899	A/T	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.36	-0.36	7.5e-16	Inflammatory biomarkers;
LGG	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.72	-0.45	4.4e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg02158880	chr13:53174818	NA	0.35	6.67	0.3	7.51e-11	Lewy body disease;
LGG	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg07120314	chr15:79043507	NA	0.69	14.14	0.55	5.37e-38	Coronary artery disease or large artery stroke;
LGG	cis	rs11098499	0.954	rs1480931	chr4:120395809	G/T	cg09307838	chr4:120376055	NA	0.81	13.58	0.53	1.3e-35	Corneal astigmatism;
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.72	-0.54	3.5e-36	Tonsillectomy;
LGG	trans	rs1814175	0.618	rs1851843	chr11:50021846	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs11209002	0.614	rs7544189	chr1:67568351	C/T	cg02640540	chr1:67518911	SLC35D1	0.43	7.27	0.32	1.54e-12	Crohn's disease;
LGG	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs7742824	0.719	rs9349273	chr6:44104573	C/G	cg04074908	chr6:44101190	TMEM63B	0.52	10.92	0.45	7.26e-25	Major depressive disorder;
LGG	cis	rs4330281	0.669	rs6810235	chr3:17753801	C/A	cg20981856	chr3:17787350	NA	-0.39	-7.35	-0.32	9.31e-13	Schizophrenia;
LGG	cis	rs6088580	0.634	rs6059851	chr20:33047945	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.63e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2658782	0.901	rs10466368	chr11:93229756	T/C	cg15737290	chr11:93063684	CCDC67	0.51	7.37	0.32	8.1e-13	Pulmonary function decline;
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.88	0.3	1.92e-11	Prudent dietary pattern;
LGG	cis	rs939658	0.776	rs869672	chr15:79430860	G/A	cg17916960	chr15:79447300	NA	-0.67	-13.17	-0.52	7.11e-34	Refractive error;
LGG	cis	rs2033711	0.870	rs1051500	chr19:58944402	A/G	cg12042659	chr19:58951599	ZNF132	0.35	7.05	0.31	6.38e-12	Uric acid clearance;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17051395	chr17:78644292	RPTOR	0.41	7.04	0.31	6.89e-12	Electrocardiographic conduction measures;
LGG	cis	rs5758659	0.652	rs6519301	chr22:42385967	A/G	cg15128208	chr22:42549153	NA	-0.39	-7.81	-0.34	3.84e-14	Cognitive function;
LGG	cis	rs1669338	0.507	rs4685607	chr3:3179400	C/T	cg16797762	chr3:3221439	CRBN	0.98	13.03	0.52	2.78e-33	White matter integrity;
LGG	cis	rs78456975	1.000	rs13400784	chr2:1564473	T/A	cg26248373	chr2:1572462	NA	-0.71	-9.11	-0.39	2.48e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg14789911	chr21:47582049	C21orf56	-0.41	-7.29	-0.32	1.39e-12	Testicular germ cell tumor;
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg08355456	chr11:67383691	NA	-0.44	-7.57	-0.33	2.08e-13	Mean corpuscular volume;
LGG	cis	rs9902453	0.967	rs3813034	chr17:28524804	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	12.83	0.51	1.82e-32	Coffee consumption (cups per day);
LGG	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg12373951	chr3:133503437	NA	0.4	7.13	0.31	3.94e-12	Iron status biomarkers;
LGG	cis	rs74781061	0.929	rs12439113	chr15:74856147	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs6909430	0.901	rs1386549	chr6:98552463	G/A	cg12860156	chr6:98744658	NA	-0.43	-7.15	-0.32	3.46e-12	Quantitative traits;
LGG	cis	rs1707322	1.000	rs7532204	chr1:46485075	C/G	cg03146154	chr1:46216737	IPP	-0.52	-9.96	-0.42	2.66e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-13.42	-0.53	6.36e-35	Chronic sinus infection;
LGG	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg16797656	chr11:68205561	LRP5	-0.38	-6.82	-0.3	2.82e-11	Total body bone mineral density;
LGG	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs17292804	0.506	rs71417868	chr14:104046592	A/T	cg26031613	chr14:104095156	KLC1	-0.6	-9.65	-0.41	3.32e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4363385	0.818	rs3806223	chr1:153002646	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	cis	rs6598955	0.671	rs75517917	chr1:26612926	G/T	cg04990556	chr1:26633338	UBXN11	0.6	8.12	0.35	4.12e-15	Obesity-related traits;
LGG	cis	rs4144743	1.000	rs67615769	chr17:45325478	A/G	cg18085866	chr17:45331354	ITGB3	-0.76	-9.23	-0.39	9.91e-19	Body mass index;
LGG	cis	rs2836950	0.520	rs1980407	chr21:40543961	T/C	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.88e-19	Menarche (age at onset);
LGG	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg11878867	chr6:150167359	LRP11	-0.39	-8.18	-0.36	2.66e-15	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs66672857	chr8:58179817	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19524238	chr7:2802976	GNA12	0.4	8.84	0.38	1.96e-17	Height;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12940557	chr2:198299971	SF3B1	0.37	6.68	0.3	7.03e-11	Obesity-related traits;
LGG	cis	rs4363385	0.747	rs61811427	chr1:152968419	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.0	-0.39	5.96e-18	Inflammatory skin disease;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg00424166	chr6:150045504	NUP43	-0.36	-7.63	-0.33	1.32e-13	Lung cancer;
LGG	cis	rs7474896	0.526	rs1208633	chr10:38156873	A/C	cg00409905	chr10:38381863	ZNF37A	0.51	7.6	0.33	1.7e-13	Obesity (extreme);
LGG	cis	rs1008375	1.000	rs7436403	chr4:17692685	T/G	cg18681998	chr4:17616180	MED28	-0.73	-14.66	-0.56	2.93e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11628318	0.614	rs1190335	chr14:103111358	T/C	cg01864069	chr14:103024347	NA	-0.47	-8.31	-0.36	1.07e-15	Platelet count;
LGG	cis	rs9341808	0.905	rs9343977	chr6:80967001	C/T	cg08355045	chr6:80787529	NA	0.39	7.76	0.34	5.57e-14	Sitting height ratio;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg11584989	chr19:19387371	SF4	-0.42	-7.51	-0.33	3.1e-13	Tonsillectomy;
LGG	cis	rs1335587	0.582	rs3916910	chr13:102108308	A/G	cg13538571	chr13:102108074	ITGBL1	-0.49	-8.92	-0.38	1.12e-17	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs4815426	chr20:25405186	A/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.53	-0.44	2.26e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7552404	0.924	rs12136754	chr1:76230232	C/A	cg03433033	chr1:76189801	ACADM	0.77	13.62	0.53	9.39e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2067615	0.560	rs10861671	chr12:107220927	T/C	cg15890332	chr12:107067104	RFX4	0.41	12.03	0.49	3.45e-29	Heart rate;
LGG	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.21	-0.32	2.33e-12	Height;
LGG	cis	rs2307022	0.586	rs4783621	chr16:68383519	C/A	cg07273125	chr16:68295692	NA	0.44	9.97	0.42	2.53e-21	Body mass index;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg16141378	chr3:129829833	LOC729375	0.37	7.8	0.34	4.26e-14	Myopia (pathological);
LGG	cis	rs9393777	0.513	rs9379907	chr6:26654318	C/T	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6445797	0.632	rs2004199	chr3:56645866	A/G	cg13792233	chr3:56591045	CCDC66	-0.45	-6.91	-0.31	1.6e-11	Gastritis;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03031660	chr17:73257791	MRPS7;GGA3	0.4	6.76	0.3	4.29e-11	Body mass index;
LGG	cis	rs11676348	0.846	rs6723449	chr2:218997580	C/T	cg00012203	chr2:219082015	ARPC2	0.57	10.22	0.43	2.95e-22	Ulcerative colitis;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg18926786	chr6:150244388	RAET1G	0.32	6.92	0.31	1.51e-11	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs1553174	chr7:65731194	T/C	cg12463550	chr7:65579703	CRCP	-0.79	-8.66	-0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	-0.45	-7.36	-0.32	8.35e-13	Menopause (age at onset);
LGG	cis	rs6977660	1.000	rs1468288	chr7:19810580	C/G	cg07541023	chr7:19748670	TWISTNB	0.61	8.41	0.36	4.96e-16	Thyroid stimulating hormone;
LGG	cis	rs4481887	1.000	rs4554750	chr1:248496530	C/G	cg00666640	chr1:248458726	OR2T12	0.62	9.82	0.42	8.62e-21	Common traits (Other);
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.53	-0.33	2.59e-13	Menopause (age at onset);
LGG	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg13385521	chr17:29058706	SUZ12P	0.91	10.52	0.44	2.42e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg24375607	chr4:120327624	NA	0.67	11.16	0.46	9.18e-26	Corneal astigmatism;
LGG	cis	rs3857067	0.806	rs1876918	chr4:95099424	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.97	-0.35	1.27e-14	QT interval;
LGG	cis	rs7824557	1.000	rs2736371	chr8:11105529	A/G	cg21775007	chr8:11205619	TDH	-0.61	-9.82	-0.42	8.48e-21	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.61	10.25	0.43	2.32e-22	Prudent dietary pattern;
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs694739	0.628	rs645078	chr11:64135298	A/C	cg22916017	chr11:64110731	CCDC88B	0.48	9.55	0.41	7.31e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs11098499	0.909	rs10002083	chr4:120311152	C/T	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs62400317	0.859	rs12191751	chr6:45282111	G/T	cg18551225	chr6:44695536	NA	-0.63	-10.46	-0.44	3.93e-23	Total body bone mineral density;
LGG	cis	rs9547996	0.879	rs17258466	chr13:38194065	A/G	cg17979426	chr13:38220150	TRPC4	-0.38	-7.27	-0.32	1.52e-12	Diastolic blood pressure;
LGG	cis	rs7618915	0.501	rs7624716	chr3:52751534	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	cis	rs4478037	1.000	rs4074415	chr3:33161745	A/G	cg19404215	chr3:33155277	CRTAP	0.87	11.09	0.46	1.6e-25	Major depressive disorder;
LGG	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07570687	chr10:102243282	WNT8B	-0.4	-7.27	-0.32	1.57e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs62400317	0.762	rs3997499	chr6:44864552	G/T	cg18551225	chr6:44695536	NA	-0.68	-11.36	-0.47	1.45e-26	Total body bone mineral density;
LGG	cis	rs9596863	0.898	rs13378790	chr13:54372312	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.09	0.31	5.18e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg04863758	chr4:1303710	MAEA	0.44	7.75	0.34	5.75e-14	Obesity-related traits;
LGG	cis	rs9309473	1.000	rs2140195	chr2:73702344	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.37	-0.32	7.67e-13	Metabolite levels;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.87	-0.42	5.54e-21	Lung cancer;
LGG	cis	rs6752107	0.967	rs36001488	chr2:234185267	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.77	0.34	5.03e-14	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17662584	chr22:40440687	TNRC6B	0.48	7.59	0.33	1.72e-13	Gut microbiome composition (summer);
LGG	cis	rs963731	0.579	rs10165968	chr2:39350851	G/A	cg04010122	chr2:39346883	SOS1	0.77	8.0	0.35	9.96e-15	Corticobasal degeneration;
LGG	cis	rs701145	0.585	rs1713843	chr3:153786394	C/G	cg12800244	chr3:153838788	SGEF	-0.84	-10.01	-0.42	1.76e-21	Coronary artery disease;
LGG	cis	rs7647973	0.626	rs1996663	chr3:49878264	C/G	cg13072238	chr3:49761600	GMPPB	0.53	7.16	0.32	3.23e-12	Menarche (age at onset);
LGG	cis	rs9487094	0.670	rs12199154	chr6:109822996	C/T	cg01125227	chr6:109776195	MICAL1	-0.44	-7.73	-0.34	6.81e-14	Height;
LGG	cis	rs7659604	0.540	rs4833775	chr4:122716826	T/C	cg19671926	chr4:122722719	EXOSC9	0.54	8.43	0.36	4.5e-16	Type 2 diabetes;
LGG	cis	rs11792861	0.591	rs7044275	chr9:111717138	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	11.89	0.48	1.27e-28	Menarche (age at onset);
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.64e-26	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg04450456	chr4:17643702	FAM184B	0.33	6.99	0.31	9.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg00530320	chr1:46809349	NSUN4	0.45	8.25	0.36	1.63e-15	Menopause (age at onset);
LGG	trans	rs453301	0.631	rs4840376	chr8:8802101	T/G	cg02002194	chr4:3960332	NA	0.4	7.24	0.32	1.83e-12	Joint mobility (Beighton score);
LGG	cis	rs644799	0.601	rs568878	chr11:95578694	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.58	0.56	7.01e-40	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg18099408	chr3:52552593	STAB1	-0.33	-6.65	-0.3	8.47e-11	Electroencephalogram traits;
LGG	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg01043669	chr3:72786069	NA	-0.43	-6.96	-0.31	1.16e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.35	-0.32	8.97e-13	Neuroticism;
LGG	cis	rs1799949	0.965	rs11080034	chr17:41443014	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.64	-0.37	9.46e-17	Menopause (age at onset);
LGG	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg12924262	chr12:102091054	CHPT1	0.66	13.15	0.52	8.9e-34	Blood protein levels;
LGG	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg17971929	chr21:40555470	PSMG1	-0.72	-13.87	-0.54	7.73e-37	Cognitive function;
LGG	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg04198125	chr7:157211777	NA	0.42	7.78	0.34	4.61e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs936229	0.813	rs3784790	chr15:75081745	G/C	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.23	-0.43	2.74e-22	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6693295	0.877	rs4607842	chr1:246313723	A/G	cg11798871	chr1:246315928	SMYD3	-0.47	-6.88	-0.3	1.97e-11	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs8133932	0.701	rs2839054	chr21:47328449	A/G	cg11214348	chr21:47283868	PCBP3	0.45	7.99	0.35	1.05e-14	Schizophrenia;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg18379455	chr17:41446167	NA	-0.33	-7.5	-0.33	3.33e-13	Menopause (age at onset);
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.83e-16	Lung cancer;
LGG	trans	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg22358067	chr17:16797159	NA	-0.5	-6.89	-0.3	1.83e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9487094	0.744	rs13211604	chr6:110033728	G/C	cg01125227	chr6:109776195	MICAL1	0.5	8.12	0.35	4.12e-15	Height;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.85e-11	Obesity-related traits;
LGG	trans	rs9650657	0.711	rs10100209	chr8:10584212	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.04	-0.31	6.95e-12	Neuroticism;
LGG	cis	rs7215564	0.818	rs35059200	chr17:78661619	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.9e-16	Myopia (pathological);
LGG	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg22643751	chr7:855365	UNC84A	0.37	6.82	0.3	2.9100000000000002e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg11965913	chr1:205819406	PM20D1	0.87	19.48	0.67	3.49e-62	Menarche (age at onset);
LGG	cis	rs8051149	0.688	rs12444533	chr16:87869711	C/T	cg01412419	chr16:87856264	NA	0.63	10.54	0.44	2.07e-23	Blood metabolite levels;
LGG	cis	rs4538187	0.660	rs67615384	chr2:64133432	T/C	cg02541582	chr2:64069798	UGP2	-0.6	-12.95	-0.52	6.01e-33	Systolic blood pressure;
LGG	cis	rs9527	0.590	rs1807298	chr10:104870218	G/A	cg05308233	chr10:104796373	CNNM2	-0.3	-6.7	-0.3	6.02e-11	Arsenic metabolism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22627950	chr7:44622302	TMED4	0.51	8.08	0.35	5.78e-15	Gut microbiome composition (summer);
LGG	cis	rs2278034	0.502	rs3747672	chr3:195612034	T/C	cg12923728	chr3:195709715	SDHAP1	-0.61	-11.31	-0.47	2.27e-26	Bronchopulmonary dysplasia;
LGG	cis	rs4731207	0.596	rs10258873	chr7:124650489	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs10206020	0.885	rs11886082	chr2:1576683	T/C	cg26248373	chr2:1572462	NA	-0.82	-13.16	-0.52	8.34e-34	IgG glycosylation;
LGG	cis	rs17286411	0.750	rs4788575	chr16:71931126	T/G	cg06353428	chr16:71660113	MARVELD3	0.41	7.37	0.32	8.14e-13	Blood protein levels;
LGG	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg22903471	chr2:27725779	GCKR	0.39	8.75	0.38	4.14e-17	Oral cavity cancer;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg09033563	chr22:24373618	LOC391322	-0.49	-7.98	-0.35	1.17e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs600550	0.520	rs11560911	chr11:60090369	G/A	cg05040360	chr11:60102449	MS4A6E	-0.35	-7.57	-0.33	1.98e-13	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs62238980	0.614	rs75321866	chr22:32460707	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2576037	0.526	rs4258717	chr18:44456954	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.68	0.61	3.07e-49	Personality dimensions;
LGG	cis	rs564799	0.966	rs669003	chr3:159731885	C/T	cg04855961	chr3:159719849	NA	0.28	7.49	0.33	3.61e-13	Systemic lupus erythematosus;
LGG	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg12373951	chr3:133503437	NA	-0.41	-7.08	-0.31	5.22e-12	Iron status biomarkers;
LGG	cis	rs4774899	0.966	rs2414492	chr15:57519543	C/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.14	-0.32	3.52e-12	Urinary tract infection frequency;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg04025307	chr7:1156635	C7orf50	0.92	20.76	0.69	3.95e-68	Longevity;Endometriosis;
LGG	cis	rs9747201	1.000	rs57405744	chr17:80177465	A/G	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2120243	0.539	rs1456097	chr3:157098630	T/C	cg24825693	chr3:157122686	VEPH1	-0.57	-13.24	-0.52	3.68e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2952156	0.876	rs903504	chr17:37829570	C/G	cg07936489	chr17:37558343	FBXL20	-0.5	-8.36	-0.36	7.58e-16	Asthma;
LGG	cis	rs8005677	1.000	rs8014936	chr14:23375145	A/G	cg01529538	chr14:23388837	RBM23	0.37	6.82	0.3	2.8e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs700651	0.789	rs10184395	chr2:198894285	G/A	cg00792783	chr2:198669748	PLCL1	0.64	10.36	0.43	8.88e-23	Intracranial aneurysm;
LGG	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.94	0.31	1.37e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4481887	0.927	rs4581306	chr1:248476158	C/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs7659604	0.540	rs10007956	chr4:122700669	A/T	cg20573242	chr4:122745356	CCNA2	-0.41	-7.08	-0.31	5.3e-12	Type 2 diabetes;
LGG	cis	rs3091242	0.933	rs35403885	chr1:25784551	G/A	cg27572855	chr1:25598939	RHD	-0.49	-11.05	-0.46	2.44e-25	Erythrocyte sedimentation rate;
LGG	cis	rs7929679	0.551	rs10836302	chr11:34791897	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs4144027	0.967	rs12879686	chr14:104360741	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.08	-0.31	5.37e-12	Blood metabolite levels;
LGG	trans	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.09	-0.31	5.18e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg19554555	chr3:13937349	NA	-0.55	-10.08	-0.42	9.53e-22	Ovarian reserve;
LGG	cis	rs11096990	0.892	rs11932351	chr4:39231457	A/G	cg24403649	chr4:39172243	NA	-0.44	-7.19	-0.32	2.63e-12	Cognitive function;
LGG	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg06392426	chr19:10676186	KRI1	-0.71	-12.16	-0.49	9.94e-30	Red cell distribution width;
LGG	cis	rs1401999	0.510	rs2293001	chr3:183700211	C/T	cg01324343	chr3:183735012	ABCC5	0.56	10.25	0.43	2.43e-22	Anterior chamber depth;
LGG	cis	rs12282928	0.959	rs12290629	chr11:48298901	G/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg08677398	chr8:58056175	NA	0.46	7.39	0.32	7.04e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs7917772	0.502	rs4919670	chr10:104515799	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.47	-7.88	-0.34	2.35e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg12615879	chr12:58013172	SLC26A10	-0.38	-8.65	-0.37	8.5e-17	Multiple sclerosis;
LGG	cis	rs77216612	0.835	rs56692845	chr12:12887811	C/T	cg09462578	chr12:12878428	APOLD1	-1.02	-20.49	-0.69	6.99e-67	Lymphocyte counts;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg04025307	chr7:1156635	C7orf50	0.74	10.2	0.43	3.45e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6815814	0.731	rs10776482	chr4:38774785	A/G	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.84	0.3	2.53e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs4819052	0.788	rs13049700	chr21:46701909	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.64	10.37	0.43	8.75e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7827545	0.960	rs1372661	chr8:135566859	A/G	cg09855544	chr8:135498122	ZFAT	0.46	7.85	0.34	3.01e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs4925386	1.000	rs4925382	chr20:60918542	G/C	cg06026331	chr20:60912101	LAMA5	-0.49	-9.27	-0.4	6.95e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9527	0.590	rs10883843	chr10:104947493	C/G	cg05308233	chr10:104796373	CNNM2	-0.32	-7.04	-0.31	6.82e-12	Arsenic metabolism;
LGG	cis	rs657075	0.550	rs1468199	chr5:131757012	C/A	cg05556477	chr5:131705319	SLC22A5	0.58	7.48	0.33	3.64e-13	Rheumatoid arthritis;
LGG	cis	rs4924935	1.000	rs11658555	chr17:18817486	C/T	cg26378065	chr17:18585709	ZNF286B	-0.45	-7.57	-0.33	1.99e-13	Pancreatic cancer;
LGG	cis	rs2235649	0.833	rs9929264	chr16:1851934	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.96	-0.31	1.2e-11	Blood metabolite levels;
LGG	cis	rs2692947	0.740	rs4907280	chr2:96402126	A/G	cg22654517	chr2:96458247	NA	0.36	7.18	0.32	2.71e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg12310025	chr6:25882481	NA	-0.5	-9.5	-0.4	1.14e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg24110177	chr3:50126178	RBM5	0.58	10.66	0.44	7.31e-24	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	trans	rs6787172	0.582	rs1656377	chr3:158285280	C/T	cg23275840	chr4:47708675	CORIN	0.33	6.68	0.3	6.78e-11	Subjective well-being;
LGG	cis	rs17854409	0.764	rs8116995	chr20:61475824	A/G	cg06598544	chr20:61472147	COL9A3	-0.91	-10.21	-0.43	3.36e-22	Obesity-related traits;
LGG	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg16950941	chr11:66035639	RAB1B	-0.58	-10.63	-0.44	9.56e-24	Gout;
LGG	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-7.48	-0.33	3.88e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs992157	0.798	rs10193383	chr2:219157692	C/T	cg04731861	chr2:219085781	ARPC2	-0.44	-10.85	-0.45	1.36e-24	Colorectal cancer;
LGG	cis	rs7727544	0.684	rs272893	chr5:131663062	T/C	cg07395648	chr5:131743802	NA	-0.55	-12.96	-0.52	5.19e-33	Blood metabolite levels;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg00405596	chr8:11794950	NA	-0.41	-6.69	-0.3	6.54e-11	Neuroticism;
LGG	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg00579200	chr11:133705235	NA	-0.61	-11.64	-0.48	1.24e-27	Childhood ear infection;
LGG	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-9.99	-0.42	2.14e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs3001717	chr10:60329125	A/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.33	-0.32	1.02e-12	Refractive error;
LGG	cis	rs11166927	1.000	rs11166929	chr8:140801430	G/A	cg16909799	chr8:140841666	TRAPPC9	0.57	11.98	0.49	5.26e-29	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs769267	1.000	rs3764567	chr19:19440066	C/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.83	-0.59	2.06e-45	Tonsillectomy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10974632	chr14:51562381	TRIM9	-0.41	-6.72	-0.3	5.33e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg26248373	chr2:1572462	NA	-0.86	-15.28	-0.58	5.88e-43	IgG glycosylation;
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg26554054	chr8:600488	NA	0.94	9.92	0.42	3.6e-21	IgG glycosylation;
LGG	cis	rs12580194	0.593	rs61956292	chr12:55803346	T/C	cg19537932	chr12:55886519	OR6C68	-0.58	-10.63	-0.44	9e-24	Cancer;
LGG	cis	rs2072438	0.503	rs4837810	chr9:123881199	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.42	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs657075	0.640	rs2073838	chr5:131649222	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs11577318	0.853	rs4526602	chr1:26648034	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-7.64	-0.33	1.26e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg15522984	chr1:182991683	LAMC1	0.47	9.49	0.4	1.2e-19	Colorectal cancer;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg11493924	chr5:55008521	SLC38A9	0.72	7.0	0.31	9.09e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs7927771	1.000	rs10838747	chr11:47716324	G/C	cg20307385	chr11:47447363	PSMC3	-0.48	-8.43	-0.36	4.41e-16	Subjective well-being;
LGG	cis	rs8141529	0.748	rs132529	chr22:29296652	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-9.46	-0.4	1.61e-19	Lymphocyte counts;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16405210	chr4:1374714	KIAA1530	-0.62	-11.31	-0.47	2.44e-26	Longevity;
LGG	trans	rs62458065	0.513	rs7788809	chr7:32552622	T/A	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.65	-0.33	1.14e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs41271473	0.948	rs72750016	chr1:228816786	G/C	cg16512390	chr1:228756714	NA	0.5	6.81	0.3	3.08e-11	Chronic lymphocytic leukemia;
LGG	cis	rs78456975	1.000	rs55761535	chr2:1561450	A/G	cg01028140	chr2:1542097	TPO	-0.54	-8.62	-0.37	1.05e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs690037	0.551	rs690522	chr3:16377067	C/T	cg23474789	chr3:16306055	DPH3;OXNAD1	-0.51	-8.44	-0.37	4e-16	Optic nerve measurement (cup-to-disc ratio);Optic nerve measurement (cup area);
LGG	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs4918072	0.874	rs3850670	chr10:105659369	C/T	cg11005552	chr10:105648138	OBFC1	0.73	12.33	0.5	2.03e-30	Coronary artery disease;
LGG	cis	rs4631830	0.900	rs7920517	chr10:51532621	G/A	cg10326726	chr10:51549505	MSMB	-0.69	-14.31	-0.55	1.02e-38	Prostate-specific antigen levels;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg02725872	chr8:58115012	NA	-0.85	-16.18	-0.6	5.36e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg06713675	chr4:122721982	EXOSC9	-0.46	-7.22	-0.32	2.17e-12	Type 2 diabetes;
LGG	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg26076054	chr5:421317	AHRR	-0.5	-7.37	-0.32	7.93e-13	Cystic fibrosis severity;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.48	0.33	3.75e-13	Alzheimer's disease;
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg18479299	chr3:125709523	NA	-0.6	-7.8	-0.34	4.1e-14	Blood pressure (smoking interaction);
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07648498	chr16:89883185	FANCA	0.39	6.89	0.3	1.87e-11	Vitiligo;
LGG	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.88e-11	Type 2 diabetes;
LGG	trans	rs1814175	0.817	rs7947286	chr11:49874657	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.53	-0.75	9.75e-86	Height;
LGG	cis	rs9814567	0.752	rs7633868	chr3:134331048	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7107174	1.000	rs4945267	chr11:78037933	G/A	cg02023728	chr11:77925099	USP35	0.46	7.88	0.34	2.31e-14	Testicular germ cell tumor;
LGG	cis	rs11168618	0.967	rs1895996	chr12:48955571	A/C	cg24011408	chr12:48396354	COL2A1	0.48	7.79	0.34	4.39e-14	Adiponectin levels;
LGG	cis	rs116095464	1.000	rs10054850	chr5:335827	C/G	cg22496380	chr5:211416	CCDC127	-1.27	-10.24	-0.43	2.59e-22	Breast cancer;
LGG	trans	rs931812	0.757	rs4734015	chr8:101909258	C/G	cg20993868	chr7:22813445	NA	0.61	11.97	0.49	5.71e-29	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1577917	0.771	rs9353318	chr6:86231721	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.33	0.63	3.17e-52	Response to antipsychotic treatment;
LGG	cis	rs72772090	0.539	rs72773942	chr5:96123366	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4819052	0.851	rs28442024	chr21:46674475	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.12	0.35	4.25e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1355223	0.867	rs1869360	chr11:34698590	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.37	-0.32	7.85e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9859260	0.744	rs3933	chr3:195784997	C/T	cg00031303	chr3:195681400	NA	-0.44	-6.83	-0.3	2.72e-11	Mean corpuscular volume;
LGG	cis	rs11229555	1.000	rs2276153	chr11:58407740	C/G	cg15696309	chr11:58395628	NA	-0.99	-17.7	-0.64	6.12e-54	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs2289583	0.544	rs12050759	chr15:75265191	G/A	cg10253484	chr15:75165896	SCAMP2	0.51	7.54	0.33	2.47e-13	Systemic lupus erythematosus;
LGG	cis	rs2032447	0.901	rs1540276	chr6:26028819	T/G	cg03264133	chr6:25882463	NA	-0.63	-11.4	-0.47	1.06e-26	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.16	0.52	8.02e-34	Prudent dietary pattern;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs7044106	0.718	rs1981021	chr9:123388393	T/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.46e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.1	0.46	1.49e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7264396	0.561	rs66483315	chr20:34573575	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-7.21	-0.32	2.31e-12	Total cholesterol levels;
LGG	trans	rs9929218	1.000	rs9937664	chr16:68784603	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.98	-0.54	2.73e-37	Colorectal cancer;
LGG	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg14074117	chr16:1909714	C16orf73	0.47	6.84	0.3	2.46e-11	Insulin-like growth factors;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs4930561	0.765	rs34493482	chr11:67969508	T/C	cg16338278	chr11:67432957	ALDH3B2	0.42	7.84	0.34	3.13e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	trans	rs4427176	0.507	rs4841202	chr8:9582703	T/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs11771526	0.901	rs10264511	chr7:32304170	T/C	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.65	0.34	1.14e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg16662043	chr16:48846231	NA	0.37	7.29	0.32	1.39e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg14088196	chr11:70211408	PPFIA1	0.74	9.94	0.42	3.05e-21	Coronary artery disease;
LGG	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9527	0.590	rs7074395	chr10:104844928	A/C	cg05308233	chr10:104796373	CNNM2	0.32	7.12	0.31	4.16e-12	Arsenic metabolism;
LGG	cis	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs17253792	0.822	rs74824071	chr14:56095142	T/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.85	-0.45	1.37e-24	Vitiligo;
LGG	trans	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg12045294	chr17:78518616	RPTOR	-0.45	-6.71	-0.3	5.71e-11	Glycated hemoglobin levels;
LGG	cis	rs12893597	0.541	rs12589755	chr14:76841939	A/C	cg20290672	chr14:76816747	NA	-0.46	-6.99	-0.31	9.52e-12	Maximal oxygen uptake response;
LGG	cis	rs17345786	0.906	rs58835747	chr3:101243634	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.63	-10.63	-0.44	9.42e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7408868	1.000	rs2074622	chr19:15277620	G/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.03	0.39	4.81e-18	Lung cancer;
LGG	cis	rs9486719	1.000	rs2064947	chr6:97052754	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.9	-0.31	1.76e-11	Migraine;Coronary artery disease;
LGG	cis	rs2708240	1.000	rs2538988	chr7:147580325	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.76	-0.3	4.12e-11	QT interval (drug interaction);
LGG	cis	rs10735851	1	rs10735851	chr12:53743064	G/A	cg04065151	chr12:53682969	ESPL1	-0.53	-8.43	-0.36	4.49e-16	Total body bone mineral density;
LGG	cis	rs472402	0.540	rs3776431	chr5:6618756	T/C	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.13	-0.31	3.95e-12	Response to amphetamines;
LGG	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg16586182	chr3:47516702	SCAP	0.72	13.2	0.52	5.38e-34	Colorectal cancer;
LGG	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg06640241	chr16:89574553	SPG7	0.72	12.49	0.5	4.66e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs1577917	0.958	rs12665542	chr6:86544443	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.24	-0.43	2.62e-22	Response to antipsychotic treatment;
LGG	cis	rs7582720	1.000	rs72934556	chr2:203990789	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.14	0.39	2e-18	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs1997103	1.000	rs10228182	chr7:55406695	A/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs17376456	0.825	rs13161885	chr5:93071242	A/C	cg25358565	chr5:93447407	FAM172A	1.26	15.32	0.58	3.7e-43	Diabetic retinopathy;
LGG	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg15208524	chr1:10270712	KIF1B	0.47	8.02	0.35	8.44e-15	Hepatocellular carcinoma;
LGG	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg12310025	chr6:25882481	NA	0.53	9.91	0.42	4e-21	Blood metabolite levels;
LGG	cis	rs11785400	0.793	rs7459963	chr8:143737129	C/T	cg24634471	chr8:143751801	JRK	0.49	7.55	0.33	2.4e-13	Schizophrenia;
LGG	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg18131467	chr2:239335373	ASB1	1.03	23.95	0.74	4.8e-83	Multiple system atrophy;
LGG	cis	rs1371867	0.810	rs2860518	chr8:101238120	G/T	cg06636551	chr8:101224915	SPAG1	0.49	9.36	0.4	3.44e-19	Atrioventricular conduction;
LGG	cis	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg03060546	chr3:49711283	APEH	-0.64	-10.52	-0.44	2.45e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg02002194	chr4:3960332	NA	0.47	9.12	0.39	2.31e-18	Joint mobility (Beighton score);
LGG	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs7674212	0.540	rs2711897	chr4:104023567	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-7.17	-0.32	3.06e-12	Type 2 diabetes;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06739403	chr13:35516903	NBEA	0.59	6.75	0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1401999	0.966	rs2313212	chr3:183700928	A/G	cg01324343	chr3:183735012	ABCC5	0.86	18.39	0.65	4.13e-57	Anterior chamber depth;
LGG	cis	rs2247341	0.965	rs1530588	chr4:1742779	G/A	cg07465881	chr4:1713556	SLBP	-0.44	-6.93	-0.31	1.41e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs3733585	0.648	rs13103497	chr4:9979262	A/G	cg11266682	chr4:10021025	SLC2A9	0.42	7.94	0.35	1.56e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9878978	1.000	rs11716221	chr3:2464738	G/A	cg21928760	chr3:2462534	CNTN4	0.41	9.0	0.39	5.76e-18	Blood pressure (smoking interaction);
LGG	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.71	0.3	5.64e-11	Cognitive ability;
LGG	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg13256891	chr4:100009986	ADH5	0.57	9.74	0.41	1.66e-20	Smoking initiation;
LGG	cis	rs6867032	0.570	rs13166888	chr5:1982966	G/T	cg26168224	chr5:2018326	NA	-0.98	-14.8	-0.57	7.16e-41	Gut microbiome composition (winter);
LGG	cis	rs7737355	0.812	rs10059807	chr5:130877684	T/C	cg06307176	chr5:131281290	NA	0.52	8.65	0.37	8.71e-17	Life satisfaction;
LGG	cis	rs4700695	0.841	rs251294	chr5:65261848	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.26	0.32	1.69e-12	Facial morphology (factor 19);
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg05665937	chr4:1216051	CTBP1	0.49	8.58	0.37	1.41e-16	Obesity-related traits;
LGG	cis	rs67460515	0.563	rs16831981	chr3:160897780	T/C	cg04691961	chr3:161091175	C3orf57	-0.44	-8.3	-0.36	1.19e-15	Parkinson's disease;
LGG	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg01017244	chr2:74357527	NA	0.41	7.2	0.32	2.49e-12	Gestational age at birth (maternal effect);
LGG	cis	rs7769051	0.614	rs6912936	chr6:133102664	A/G	cg22852734	chr6:133119734	C6orf192	1.15	14.64	0.56	3.58e-40	Type 2 diabetes nephropathy;
LGG	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.68	12.72	0.51	5.16e-32	Response to antipsychotic treatment;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-6.66	-0.3	7.63e-11	Longevity;Endometriosis;
LGG	cis	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg09307838	chr4:120376055	NA	0.76	12.52	0.5	3.47e-31	Corneal astigmatism;
LGG	cis	rs6790105	1	rs6790105	chr3:49393409	C/T	cg07636037	chr3:49044803	WDR6	0.79	13.94	0.54	4.07e-37	Childhood ear infection;
LGG	cis	rs1465370	0.533	rs10239342	chr7:130009312	T/G	cg04743876	chr7:130013617	NA	0.31	6.8	0.3	3.23e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6426558	0.502	rs6697665	chr1:227474665	T/C	cg10327440	chr1:227177885	CDC42BPA	0.62	10.2	0.43	3.46e-22	Neutrophil percentage of white cells;
LGG	cis	rs2273669	0.667	rs17070136	chr6:109350550	T/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.6	0.33	1.66e-13	Tonsillectomy;
LGG	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.16	0.32	3.29e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg13010199	chr12:38710504	ALG10B	0.72	14.58	0.56	6.76e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg12751644	chr20:60527061	NA	-0.49	-10.84	-0.45	1.45e-24	Obesity-related traits;
LGG	cis	rs875971	0.660	rs801211	chr7:66015689	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.65	-0.41	3.5e-20	Aortic root size;
LGG	cis	rs6546324	0.625	rs11126138	chr2:67794476	C/T	cg18237512	chr2:67827392	NA	-0.41	-7.39	-0.32	6.72e-13	Endometriosis;
LGG	cis	rs17826219	0.500	rs61685770	chr17:29085713	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg23758822	chr17:41437982	NA	0.9	15.88	0.59	1.2e-45	Menopause (age at onset);
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg01238044	chr22:24384105	GSTT1	-0.44	-7.39	-0.32	6.8e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9457247	0.534	rs9366078	chr6:167399512	A/G	cg18261144	chr6:167370276	RNASET2	-0.38	-7.85	-0.34	2.88e-14	Crohn's disease;
LGG	cis	rs10864302	0.747	rs6577440	chr1:7450006	C/G	cg08923594	chr1:7462176	CAMTA1	-0.5	-7.47	-0.33	4.02e-13	Photic sneeze reflex;
LGG	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.6	-0.44	1.18e-23	Bladder cancer;
LGG	cis	rs2412208	0.795	rs4074964	chr1:7105079	A/G	cg20434152	chr1:7120926	CAMTA1	-0.45	-8.65	-0.37	8.48e-17	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs611744	0.625	rs4735055	chr8:109286642	G/A	cg21045802	chr8:109455806	TTC35	0.54	10.21	0.43	3.16e-22	Dupuytren's disease;
LGG	cis	rs1862618	0.853	rs2432195	chr5:56120413	C/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.58	-0.33	1.86e-13	Initial pursuit acceleration;
LGG	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg20821713	chr7:1055600	C7orf50	-0.55	-8.44	-0.37	4.07e-16	Bronchopulmonary dysplasia;
LGG	cis	rs3735485	0.722	rs10271709	chr7:45094080	A/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs116095464	0.558	rs10057626	chr5:239720	T/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.59	0.53	1.2e-35	Breast cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21809210	chr1:28995279	GMEB1	0.39	6.66	0.3	7.68e-11	Hip circumference;
LGG	cis	rs7119	0.717	rs12917175	chr15:77818193	A/G	cg10437265	chr15:77819839	NA	0.25	6.98	0.31	1.04e-11	Type 2 diabetes;
LGG	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg16400903	chr5:693638	TPPP	-0.45	-6.78	-0.3	3.74e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg25358565	chr5:93447407	FAM172A	1.31	15.98	0.6	4.4e-46	Diabetic retinopathy;
LGG	cis	rs7666738	0.830	rs28867388	chr4:98962794	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs17826219	0.561	rs562840	chr17:28949390	G/T	cg22358067	chr17:16797159	NA	-0.51	-7.23	-0.32	1.97e-12	Body mass index;
LGG	cis	rs59574136	1	rs59574136	chr7:2036460	T/C	cg21782813	chr7:2030301	MAD1L1	0.55	14.5	0.56	1.49e-39	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611519	0.929	rs4821991	chr22:41440683	T/C	cg06634786	chr22:41940651	POLR3H	-0.43	-6.75	-0.3	4.36e-11	Neuroticism;
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg05665937	chr4:1216051	CTBP1	0.67	12.96	0.52	5.4e-33	Obesity-related traits;
LGG	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10540	0.584	rs10751658	chr11:437401	C/G	cg19913688	chr11:428466	ANO9	0.68	10.61	0.44	1.08e-23	Body mass index;
LGG	cis	rs9547996	0.879	rs9547940	chr13:38129403	A/G	cg13634560	chr13:38173852	POSTN	-0.35	-7.06	-0.31	6.33e-12	Diastolic blood pressure;
LGG	cis	rs3820068	0.581	rs12385690	chr1:15932932	A/T	cg05660106	chr1:15850417	CASP9	0.8	16.23	0.6	3.06e-47	Systolic blood pressure;
LGG	trans	rs561341	0.843	rs4795666	chr17:30241409	A/G	cg20587970	chr11:113659929	NA	-1.06	-18.0	-0.64	2.79e-55	Hip circumference adjusted for BMI;
LGG	trans	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	1.000	rs17686798	chr17:20029170	A/C	cg13482628	chr17:19912719	NA	-0.49	-9.05	-0.39	3.91e-18	Obesity-related traits;
LGG	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.07	-0.42	1.08e-21	Bipolar disorder;
LGG	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.06	-0.52	2.09e-33	Schizophrenia;
LGG	cis	rs9462027	0.628	rs9368832	chr6:34679587	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.54	10.79	0.45	2.25e-24	Systemic lupus erythematosus;
LGG	cis	rs7215564	0.908	rs9972968	chr17:78652569	T/C	cg16980736	chr17:78789706	RPTOR	-0.63	-8.42	-0.36	4.75e-16	Myopia (pathological);
LGG	cis	rs10883723	0.810	rs7090034	chr10:104281155	C/G	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2916247	1.000	rs2920465	chr8:92996143	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.65	-0.37	8.82e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2072732	0.808	rs67908307	chr1:2954297	T/C	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.4	0.44	6.36e-23	Diabetic retinopathy;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg20110707	chr11:118481992	PHLDB1	-0.49	-9.72	-0.41	1.85e-20	Cholesterol, total;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg12233833	chr10:830825	NA	0.4	6.68	0.3	7.06e-11	Corneal astigmatism;
LGG	cis	rs12286929	0.617	rs12800807	chr11:115101353	T/C	cg04055981	chr11:115044050	NA	0.37	6.76	0.3	4.29e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs79149102	0.579	rs59303424	chr15:75370014	G/A	cg17294928	chr15:75287854	SCAMP5	-0.68	-7.74	-0.34	6.31e-14	Lung cancer;
LGG	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.95	-0.57	1.66e-41	Aortic root size;
LGG	cis	rs2066819	1.000	rs74673257	chr12:56638077	T/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg26516362	chr5:178986906	RUFY1	0.42	7.8	0.34	4.09e-14	Lung cancer;
LGG	cis	rs42648	0.869	rs12704518	chr7:89914388	G/T	cg25739043	chr7:89950458	NA	-0.43	-9.2	-0.39	1.28e-18	Homocysteine levels;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg26554054	chr8:600488	NA	0.96	10.07	0.42	1.1e-21	IgG glycosylation;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06481639	chr22:41940642	POLR3H	-0.64	-9.2	-0.39	1.21e-18	Vitiligo;
LGG	cis	rs2120243	0.647	rs60676003	chr3:157147939	G/A	cg24825693	chr3:157122686	VEPH1	-0.37	-7.51	-0.33	2.99e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7927771	0.524	rs10838739	chr11:47672743	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-11.09	-0.46	1.7e-25	Subjective well-being;
LGG	cis	rs12476592	0.516	rs1922421	chr2:63592792	G/A	cg17519650	chr2:63277830	OTX1	-0.5	-7.68	-0.34	9.46e-14	Childhood ear infection;
LGG	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.09	0.39	2.98e-18	Common traits (Other);
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.26	-0.49	4.15e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs1153858	1.000	rs4395020	chr15:45652889	A/C	cg10760299	chr15:45669010	GATM	0.41	8.22	0.36	2.14e-15	Homoarginine levels;
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10820262	chr4:111866929	NA	-0.58	-7.08	-0.31	5.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.511	rs2921028	chr8:8340477	T/C	cg08975724	chr8:8085496	FLJ10661	0.36	6.78	0.3	3.74e-11	Mood instability;
LGG	cis	rs1691799	0.899	rs903589	chr12:66745835	C/T	cg16791601	chr12:66731901	HELB	-0.64	-14.85	-0.57	4.58e-41	White blood cell count (basophil);
LGG	cis	rs9815354	0.812	rs73828283	chr3:41835099	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11098499	0.908	rs7695996	chr4:120322033	C/T	cg09307838	chr4:120376055	NA	0.81	13.25	0.52	3.25e-34	Corneal astigmatism;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg26578617	chr4:90757533	SNCA	-0.42	-8.59	-0.37	1.33e-16	Dementia with Lewy bodies;
LGG	cis	rs6912958	0.559	rs242280	chr6:88048714	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.03	0.52	2.76e-33	Monocyte percentage of white cells;
LGG	cis	rs2195525	0.572	rs3814760	chr11:119217556	G/A	cg01451205	chr11:119252210	USP2	0.41	6.88	0.3	1.98e-11	Urate levels;
LGG	cis	rs2013441	0.508	rs4925075	chr17:19969735	A/G	cg13482628	chr17:19912719	NA	-0.42	-7.29	-0.32	1.36e-12	Obesity-related traits;
LGG	cis	rs9487051	0.768	rs398944	chr6:109523444	T/G	cg21918786	chr6:109611834	NA	-0.38	-6.85	-0.3	2.35e-11	Reticulocyte fraction of red cells;
LGG	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-8.35	-0.36	8.13e-16	Cognitive test performance;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.85e-16	Life satisfaction;
LGG	cis	rs4774830	0.744	rs62046390	chr15:56308506	G/A	cg24530489	chr15:56299380	NA	-0.84	-7.52	-0.33	2.87e-13	Delta-5 desaturase activity;
LGG	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg04731861	chr2:219085781	ARPC2	0.47	11.39	0.47	1.11e-26	Colorectal cancer;
LGG	cis	rs4073221	0.520	rs66569729	chr3:18189623	A/C	cg07694806	chr3:18168406	NA	-0.67	-8.33	-0.36	9.56e-16	Parkinson's disease;
LGG	cis	rs7617773	0.643	rs78159520	chr3:48349023	T/C	cg11946769	chr3:48343235	NME6	0.72	12.05	0.49	2.82e-29	Coronary artery disease;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-12.15	-0.49	1.16e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs1023500	0.573	rs133380	chr22:42468910	C/T	cg04733989	chr22:42467013	NAGA	0.57	10.42	0.44	5.37e-23	Schizophrenia;
LGG	cis	rs1005277	0.579	rs176838	chr10:38371899	A/T	cg00409905	chr10:38381863	ZNF37A	0.63	11.82	0.48	2.26e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27556566	chr18:29671984	RNF138	0.53	8.34	0.36	8.43e-16	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg20637307	chr2:213403960	ERBB4	0.74	16.81	0.62	7.91e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs60843830	1.000	rs36216559	chr2:262335	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.31	0.36	1.04e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.67	-0.34	9.91e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.19	-0.46	6.79e-26	Lung cancer;
LGG	cis	rs12410462	0.591	rs2819507	chr1:227707534	A/G	cg04117972	chr1:227635322	NA	0.47	8.54	0.37	1.98e-16	Major depressive disorder;
LGG	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.91e-101	Cognitive ability;
LGG	cis	rs12497850	0.931	rs6446205	chr3:49035211	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.98	0.45	4.52e-25	Parkinson's disease;
LGG	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg20476274	chr7:133979776	SLC35B4	0.75	14.69	0.56	2.13e-40	Mean platelet volume;
LGG	trans	rs4714291	0.963	rs847759	chr6:40024483	G/A	cg02267698	chr19:7991119	CTXN1	0.58	8.7	0.37	5.67e-17	Strep throat;
LGG	cis	rs9457247	0.534	rs9347170	chr6:167405187	C/T	cg18261144	chr6:167370276	RNASET2	-0.38	-7.81	-0.34	3.97e-14	Crohn's disease;
LGG	cis	rs3784262	1.000	rs4646638	chr15:58248783	C/T	cg12031962	chr15:58353849	ALDH1A2	0.37	8.24	0.36	1.82e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg26384229	chr12:38710491	ALG10B	0.93	21.0	0.7	2.83e-69	Bladder cancer;
LGG	cis	rs9359856	0.564	rs56084221	chr6:90365349	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.64	-0.41	3.75e-20	Bipolar disorder;
LGG	trans	rs9951602	0.512	rs4799248	chr18:76653459	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs11711311	1.000	rs9811353	chr3:113483979	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.51e-13	IgG glycosylation;
LGG	cis	rs6500602	0.727	rs1477123	chr16:4560627	T/A	cg06916706	chr16:4465613	CORO7	-0.86	-15.02	-0.57	7.98e-42	Schizophrenia;
LGG	cis	rs9811920	0.695	rs1287284	chr3:99516962	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.47	-8.17	-0.35	3e-15	Axial length;
LGG	cis	rs28595532	0.920	rs56331118	chr4:119767054	G/T	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg19847130	chr8:10466454	RP1L1	-0.3	-6.67	-0.3	7.49e-11	Joint mobility (Beighton score);
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	trans	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.39e-17	Bladder cancer;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg18446336	chr7:2847575	GNA12	-0.27	-7.07	-0.31	5.76e-12	Height;
LGG	cis	rs10861342	1.000	rs11112373	chr12:105503708	G/A	cg23923672	chr12:105501055	KIAA1033	0.74	6.74	0.3	4.65e-11	IgG glycosylation;
LGG	cis	rs11190604	1.000	rs2003284	chr10:102202338	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.83	0.34	3.28e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7949030	0.626	rs7124057	chr11:62334096	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.39	0.65	4.1e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2073300	0.609	rs3746733	chr20:23349749	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2204008	0.806	rs11520229	chr12:38246448	C/A	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg12486710	chr1:178512616	C1orf220	0.51	10.59	0.44	1.25e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8078723	0.933	rs55846942	chr17:38164470	G/A	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg04267008	chr7:1944627	MAD1L1	-0.59	-10.06	-0.42	1.13e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	30.26	0.81	9.36e-112	Prudent dietary pattern;
LGG	cis	rs11603023	0.805	rs687190	chr11:118542383	C/T	cg20110707	chr11:118481992	PHLDB1	0.49	10.13	0.43	6.61e-22	Cholesterol, total;
LGG	cis	rs9303401	0.614	rs12950028	chr17:56510140	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	9.27	0.4	7.22e-19	Cognitive test performance;
LGG	cis	rs2916247	0.788	rs7004846	chr8:93127056	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.67	-0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.565	rs3768626	chr1:183078462	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.87e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1355223	0.902	rs704744	chr11:34736561	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.11	-0.31	4.51e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs3816183	0.626	rs6708408	chr2:42898915	A/G	cg14631114	chr2:43023945	NA	0.36	7.05	0.31	6.72e-12	Hypospadias;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg23985595	chr17:80112537	CCDC57	0.47	9.41	0.4	2.38e-19	Life satisfaction;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01423820	chr14:77228690	VASH1	0.41	7.39	0.32	7.05e-13	Obesity-related traits;
LGG	trans	rs9929218	0.501	rs12448999	chr16:68815549	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.87	18.16	0.64	4.92e-56	Colorectal cancer;
LGG	cis	rs4731207	0.596	rs6956910	chr7:124642364	A/C	cg05630886	chr7:124431682	NA	-0.3	-7.0	-0.31	9.25e-12	Cutaneous malignant melanoma;
LGG	cis	rs13108904	0.870	rs4493483	chr4:1279916	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	9.87	0.42	5.55e-21	Obesity-related traits;
LGG	trans	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg13565492	chr6:43139072	SRF	-0.75	-9.06	-0.39	3.55e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7937682	0.824	rs539524	chr11:111477325	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.68	-0.74	8.28e-82	Primary sclerosing cholangitis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02971882	chr4:71554083	UTP3	0.46	7.7	0.34	8.24e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg07460842	chr6:66804631	NA	1.15	32.5	0.83	1.59e-121	Exhaled nitric oxide output;
LGG	cis	rs593982	0.920	rs76925283	chr11:65548108	C/T	cg08755490	chr11:65554678	OVOL1	-0.75	-10.45	-0.44	4.48e-23	Atopic dermatitis;
LGG	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.96e-18	Cognitive test performance;
LGG	cis	rs10884984	0.770	rs11818445	chr10:112275267	A/G	cg18756771	chr10:112261994	DUSP5	-0.67	-12.21	-0.49	6.33e-30	Facial morphology (factor 22);
LGG	trans	rs6601327	0.670	rs12545250	chr8:9420566	T/C	cg16141378	chr3:129829833	LOC729375	-0.33	-7.15	-0.32	3.5e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11700980	0.636	rs116306600	chr21:30232542	T/C	cg24692254	chr21:30365293	RNF160	-0.62	-7.28	-0.32	1.41e-12	QRS complex (12-leadsum);
LGG	cis	rs6466055	0.739	rs7806591	chr7:104927776	C/T	cg04380332	chr7:105027541	SRPK2	0.38	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.23	-0.32	2e-12	Life satisfaction;
LGG	cis	rs3849570	1.000	rs6548773	chr3:81840222	C/T	cg07356753	chr3:81810745	GBE1	0.48	7.85	0.34	2.95e-14	Waist circumference;Body mass index;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs9768139	0.733	rs921617	chr7:158118198	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	20.21	0.68	1.36e-65	Calcium levels;
LGG	cis	rs758324	0.797	rs253949	chr5:131322976	T/C	cg06307176	chr5:131281290	NA	0.48	6.95	0.31	1.28e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1568889	0.712	rs10835306	chr11:28302410	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.16	0.67	1.07e-60	Bipolar disorder;
LGG	cis	rs25645	0.771	rs11078936	chr17:38197914	T/C	cg17467752	chr17:38218738	THRA	-0.71	-12.52	-0.5	3.43e-31	Myeloid white cell count;
LGG	cis	rs910316	0.737	rs175072	chr14:75502827	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.59	-0.41	5.64e-20	Height;
LGG	cis	rs873946	0.586	rs36084869	chr10:134566069	G/A	cg27286337	chr10:134555280	INPP5A	0.84	12.09	0.49	1.93e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9747201	0.962	rs62078313	chr17:80116708	A/C	cg14673194	chr17:80132900	CCDC57	0.47	8.52	0.37	2.34e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg04226714	chr8:49833948	SNAI2	-0.47	-8.43	-0.36	4.35e-16	Life satisfaction;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg02380278	chr5:71756236	ZNF366	-0.46	-6.92	-0.31	1.55e-11	Hepatitis;
LGG	cis	rs3733585	0.699	rs7437120	chr4:9967683	T/A	cg08250081	chr4:10125330	NA	-0.36	-6.81	-0.3	3.06e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1577917	0.958	rs13207173	chr6:86457522	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.54	-0.5	2.9e-31	Response to antipsychotic treatment;
LGG	cis	rs2797369	0.665	rs817234	chr6:101457707	C/T	cg27451362	chr6:101846650	GRIK2	0.76	10.36	0.43	9.04e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg07120314	chr15:79043507	NA	0.57	9.05	0.39	3.98e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7737355	0.947	rs1422081	chr5:130776053	A/C	cg06307176	chr5:131281290	NA	0.56	9.29	0.4	6.27e-19	Life satisfaction;
LGG	cis	rs17253792	0.822	rs45501402	chr14:56140115	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.25	-0.49	4.49e-30	Putamen volume;
LGG	cis	rs12042938	0.935	rs823159	chr1:231777168	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	10.81	0.45	1.87e-24	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs11785400	0.793	rs2978973	chr8:143747271	C/G	cg10596483	chr8:143751796	JRK	0.53	8.28	0.36	1.29e-15	Schizophrenia;
LGG	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg23649088	chr2:200775458	C2orf69	0.62	8.13	0.35	3.83e-15	Schizophrenia;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs7712401	0.601	rs257813	chr5:122217168	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.89	0.3	1.88e-11	Mean platelet volume;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg20308403	chr7:2120281	MAD1L1	-0.32	-6.74	-0.3	4.71e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17401966	0.931	rs1002076	chr1:10438892	G/A	cg19773385	chr1:10388646	KIF1B	-0.49	-10.13	-0.43	6.57e-22	Hepatocellular carcinoma;
LGG	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg19441908	chr8:41529140	ANK1	0.43	7.37	0.32	7.86e-13	Type 2 diabetes;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg08219700	chr8:58056026	NA	0.48	7.06	0.31	5.95e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg12163867	chr12:51592794	POU6F1	0.37	7.32	0.32	1.09e-12	Cisplatin-induced ototoxicity;
LGG	cis	rs17767392	0.829	rs56363446	chr14:71761577	A/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg23978390	chr7:1156363	C7orf50	0.44	6.64	0.3	8.59e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs73227498	0.590	rs73787781	chr5:111491959	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.48	-6.69	-0.3	6.43e-11	Thyroid cancer;
LGG	cis	rs11098499	0.863	rs3822195	chr4:120471660	C/T	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.63e-34	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg08621203	chr6:150244597	RAET1G	0.46	8.08	0.35	5.7e-15	Lung cancer;
LGG	cis	rs975739	0.966	rs116881483	chr13:78379140	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	4e-11	Hair color;
LGG	cis	rs4853012	0.838	rs72915068	chr2:74356185	G/A	cg05890377	chr2:74357713	NA	0.49	9.91	0.42	4.13e-21	Gestational age at birth (maternal effect);
LGG	cis	rs4356932	1.000	rs9884374	chr4:76946718	A/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs11676348	0.935	rs6716276	chr2:218962205	A/G	cg00012203	chr2:219082015	ARPC2	-0.5	-8.85	-0.38	1.84e-17	Ulcerative colitis;
LGG	cis	rs10752881	0.935	rs10911197	chr1:182995399	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.64e-20	Colorectal cancer;
LGG	trans	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.06	-0.35	6.33e-15	Neuroticism;
LGG	cis	rs1045902	0.967	rs1469530	chr2:73464948	C/T	cg01422370	chr2:73384389	NA	0.47	9.01	0.39	5.64e-18	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.643	rs522377	chr2:219437476	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.04	-0.31	6.78e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9910055	0.540	rs609292	chr17:42180436	G/A	cg19774624	chr17:42201019	HDAC5	0.65	11.36	0.47	1.56e-26	Total body bone mineral density;
LGG	cis	rs7512552	0.839	rs834229	chr1:150384665	G/C	cg15654264	chr1:150340011	RPRD2	0.46	9.43	0.4	1.95e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs4865875	0.901	rs7446423	chr5:54118770	A/G	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs4595586	0.545	rs1562728	chr12:39405740	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.49	0.33	3.42e-13	Morning vs. evening chronotype;
LGG	trans	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg02030672	chr11:45687055	CHST1	0.49	8.63	0.37	9.71e-17	Obesity-related traits;
LGG	cis	rs8177253	0.761	rs13079426	chr3:133522334	A/G	cg12373951	chr3:133503437	NA	0.44	7.89	0.34	2.17e-14	Iron status biomarkers;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg26174226	chr8:58114915	NA	-0.57	-7.67	-0.34	9.95e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06108461	chr20:60628389	TAF4	-0.85	-14.18	-0.55	3.7e-38	Body mass index;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg14707898	chr6:41888549	MED20;BYSL	0.49	6.93	0.31	1.41e-11	Apolipoprotein A-IV levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02598978	chr16:20817844	LOC81691;ERI2	0.42	7.13	0.31	3.94e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7010267	0.596	rs7010043	chr8:120011331	G/T	cg17171407	chr8:119960777	TNFRSF11B	0.36	9.11	0.39	2.48e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs6988985	0.693	rs4736357	chr8:143987218	T/A	cg10324643	chr8:143916377	GML	0.4	7.85	0.34	2.9e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2274273	0.773	rs10147765	chr14:55827826	G/A	cg04306507	chr14:55594613	LGALS3	0.6	16.7	0.61	2.4e-49	Protein biomarker;
LGG	cis	rs7267979	1.000	rs6037105	chr20:25374199	C/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs910316	1.000	rs4903275	chr14:75512509	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	10.76	0.45	2.97e-24	Height;
LGG	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg15325629	chr6:28072465	NA	0.95	7.25	0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg13207630	chr7:32358064	NA	0.67	7.18	0.32	2.88e-12	Body mass index;
LGG	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.01	0.7	2.42e-69	Morning vs. evening chronotype;
LGG	cis	rs9393692	0.875	rs9358917	chr6:26284417	T/C	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.23e-11	Educational attainment;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg12708336	chr17:41446283	NA	-0.3	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02207491	chr14:74551642	LIN52;ALDH6A1	-0.45	-6.74	-0.3	4.83e-11	Systemic lupus erythematosus;
LGG	cis	rs7177699	0.550	rs7182103	chr15:79123946	G/T	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg13047869	chr3:10149882	C3orf24	0.45	7.29	0.32	1.33e-12	Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs10911230	chr1:183051118	A/C	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs17030434	1.000	rs12646758	chr4:154731625	A/G	cg14289246	chr4:154710475	SFRP2	-0.73	-11.43	-0.47	8.36e-27	Electrocardiographic conduction measures;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00149659	chr3:10157352	C3orf10	0.71	8.84	0.38	2.03e-17	Alzheimer's disease;
LGG	cis	rs72717009	0.825	rs9427397	chr1:161476204	C/T	cg12643083	chr1:161476548	FCGR2A	-0.66	-9.79	-0.41	1.09e-20	Rheumatoid arthritis;
LGG	cis	rs4731207	0.724	rs10229152	chr7:124538285	G/A	cg05630886	chr7:124431682	NA	-0.33	-7.72	-0.34	7.09e-14	Cutaneous malignant melanoma;
LGG	cis	rs11018904	0.861	rs4589254	chr11:89963355	A/C	cg16176437	chr11:89678848	NA	-0.4	-6.76	-0.3	4.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg20120463	chr17:44301886	NA	0.43	6.79	0.3	3.43e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7927592	0.913	rs4084149	chr11:68288567	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs6840360	0.571	rs4696102	chr4:152529658	C/T	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg15596359	chr8:11213517	TDH	-0.34	-6.96	-0.31	1.14e-11	Retinal vascular caliber;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg18681998	chr4:17616180	MED28	-0.85	-19.17	-0.67	1.04e-60	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.88	11.53	0.47	3.18e-27	Mean platelet volume;
LGG	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg08949735	chr16:89699720	DPEP1	-0.48	-9.96	-0.42	2.64e-21	Vitiligo;
LGG	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg27411982	chr8:10470053	RP1L1	-0.45	-7.47	-0.33	4.13e-13	Triglycerides;
LGG	cis	rs7666738	0.830	rs28785514	chr4:98959135	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.1	-0.42	8.2e-22	Neuroticism;
LGG	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg20891558	chr2:74357851	NA	0.49	9.6	0.41	5.17e-20	Gestational age at birth (maternal effect);
LGG	cis	rs1577917	0.958	rs4707229	chr6:86546237	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.39	-0.5	1.16e-30	Response to antipsychotic treatment;
LGG	cis	rs17125944	0.686	rs2296495	chr14:53379878	G/A	cg00686598	chr14:53173677	PSMC6	0.81	8.17	0.35	2.98e-15	Alzheimer's disease (late onset);
LGG	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg14154082	chr13:112174009	NA	0.42	9.26	0.4	7.62e-19	Menarche (age at onset);
LGG	trans	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.39	0.4	2.64e-19	Diabetic kidney disease;
LGG	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg14784868	chr12:69753453	YEATS4	0.7	13.1	0.52	1.47e-33	Blood protein levels;
LGG	cis	rs1153858	1.000	rs56806728	chr15:45637814	A/G	cg10760299	chr15:45669010	GATM	0.4	8.01	0.35	9.16e-15	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.52	0.58	4.98e-44	Lung cancer;
LGG	cis	rs4282054	0.631	rs13081155	chr3:52732429	A/G	cg18404041	chr3:52824283	ITIH1	-0.41	-7.85	-0.34	2.97e-14	Cognitive function;
LGG	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg27205649	chr11:78285834	NARS2	0.5	8.52	0.37	2.33e-16	Alzheimer's disease (survival time);
LGG	cis	rs2070677	1.000	rs1410897	chr10:135349537	G/A	cg20169779	chr10:135381914	SYCE1	0.96	12.76	0.51	3.65e-32	Gout;
LGG	cis	rs7106204	0.764	rs7933686	chr11:24246790	G/C	ch.11.24196551F	chr11:24239977	NA	0.96	10.61	0.44	1.06e-23	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.25	-0.32	1.7e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1707322	0.721	rs4564187	chr1:46166861	G/C	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	3.97e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg15369054	chr17:80825471	TBCD	0.51	7.13	0.31	3.99e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg00343986	chr7:65444356	GUSB	-0.41	-6.95	-0.31	1.22e-11	Aortic root size;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs703842	0.964	rs2014886	chr12:58177437	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.34	0.36	8.53e-16	Multiple sclerosis;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17219203	chr10:38645113	HSD17B7P2	0.46	7.34	0.32	9.76e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs2562456	0.833	rs62109229	chr19:21537182	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.6e-13	Pain;
LGG	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.53	-0.33	2.61e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	cis	rs73198271	0.531	rs17154756	chr8:8652394	C/T	cg01851573	chr8:8652454	MFHAS1	0.51	8.46	0.37	3.61e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg21724239	chr8:58056113	NA	0.56	8.17	0.36	2.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg04117972	chr1:227635322	NA	0.73	11.71	0.48	6.57e-28	Major depressive disorder;
LGG	cis	rs9487094	0.744	rs12661287	chr6:110053250	A/T	cg01125227	chr6:109776195	MICAL1	0.47	7.62	0.33	1.46e-13	Height;
LGG	cis	rs61931739	0.649	rs12426686	chr12:33714473	A/G	cg06521331	chr12:34319734	NA	0.39	6.8	0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg14789911	chr21:47582049	C21orf56	-0.48	-8.55	-0.37	1.84e-16	Testicular germ cell tumor;
LGG	cis	rs11157436	0.581	rs17255433	chr14:22634947	C/G	cg00994629	chr14:22694547	NA	0.33	7.2	0.32	2.52e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg08923669	chr16:420230	MRPL28	-0.55	-9.04	-0.39	4.2e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg26031613	chr14:104095156	KLC1	-0.8	-14.36	-0.55	6.39e-39	Body mass index;
LGG	cis	rs10088262	0.629	rs12549683	chr8:124798276	G/C	cg15047889	chr8:124780837	FAM91A1	-0.49	-7.14	-0.32	3.53e-12	Pancreatic cancer;
LGG	cis	rs1801251	0.929	rs12694917	chr2:233707611	C/T	cg25237894	chr2:233734115	C2orf82	-0.66	-12.55	-0.5	2.73e-31	Coronary artery disease;
LGG	cis	rs2404602	0.692	rs56193230	chr15:76934472	C/T	cg23625390	chr15:77176239	SCAPER	0.47	9.22	0.39	1.04e-18	Blood metabolite levels;
LGG	cis	rs7589342	0.839	rs1465639	chr2:106439181	T/C	cg16077055	chr2:106428750	NCK2	0.31	8.26	0.36	1.56e-15	Addiction;
LGG	cis	rs12369635	1.000	rs9645723	chr12:129554501	C/T	cg01909103	chr12:129572610	TMEM132D	-0.7	-6.86	-0.3	2.19e-11	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs2797160	1.000	rs2747720	chr6:126009458	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.48e-13	Endometrial cancer;
LGG	cis	rs921968	0.541	rs549026	chr2:219339283	T/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.25	-0.32	1.72e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-8.35	-0.36	8.13e-16	Cognitive test performance;
LGG	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs7084402	0.967	rs1649026	chr10:60281400	A/G	cg09696939	chr10:60272079	BICC1	0.37	7.28	0.32	1.45e-12	Refractive error;
LGG	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg26150922	chr2:100937072	LONRF2	0.42	7.63	0.33	1.35e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1754541	0.956	rs11584140	chr1:101628617	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.37	-6.72	-0.3	5.51e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs11758351	0.866	rs2022448	chr6:26207928	C/T	cg01420254	chr6:26195488	NA	0.84	11.45	0.47	6.99e-27	Gout;Renal underexcretion gout;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2885056	0.783	rs12459941	chr19:10666112	A/G	cg04833646	chr19:10679720	CDKN2D	-1.12	-19.39	-0.67	9.6e-62	Red cell distribution width;
LGG	cis	rs9611565	0.765	rs132906	chr22:41799767	G/C	cg06481639	chr22:41940642	POLR3H	0.46	6.93	0.31	1.46e-11	Vitiligo;
LGG	cis	rs11190604	0.767	rs11190531	chr10:102187310	T/A	cg07570687	chr10:102243282	WNT8B	0.4	7.27	0.32	1.57e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7633770	0.735	rs4683271	chr3:46684823	A/G	cg11219411	chr3:46661640	NA	-0.54	-12.22	-0.49	6.05e-30	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.49	0.37	2.88e-16	Prudent dietary pattern;
LGG	cis	rs7084402	0.967	rs7094882	chr10:60276829	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.02	14.86	0.57	3.89e-41	Platelet count;
LGG	cis	rs1790761	0.505	rs17593068	chr11:67350932	G/T	cg09038676	chr11:67351608	GSTP1	0.36	7.1	0.31	4.77e-12	Mean corpuscular volume;
LGG	cis	rs2013441	1.000	rs2703816	chr17:20118887	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg14416269	chr4:6271139	WFS1	0.44	7.5	0.33	3.26e-13	Cisplatin-induced ototoxicity;
LGG	cis	rs1555322	0.932	rs1205411	chr20:33857242	C/T	cg17927777	chr20:33865990	NA	0.69	7.49	0.33	3.5e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs765787	0.530	rs12917187	chr15:45538297	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs968567	0.705	rs174572	chr11:61598288	C/T	cg19610905	chr11:61596333	FADS2	-0.73	-11.72	-0.48	5.59e-28	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs9309473	1.000	rs3738848	chr2:73761881	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.97	-0.35	1.26e-14	Metabolite levels;
LGG	cis	rs12893668	0.572	rs34000399	chr14:104101417	T/C	cg23335576	chr14:104009727	NA	0.43	7.31	0.32	1.18e-12	Reticulocyte count;
LGG	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg13385794	chr1:248469461	NA	0.48	8.1	0.35	4.8e-15	Common traits (Other);
LGG	cis	rs508618	0.666	rs480902	chr1:231531627	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.51	8.07	0.35	6.31e-15	Red blood cell count;
LGG	cis	rs883565	0.582	rs811969	chr3:39180162	A/C	cg01426195	chr3:39028469	NA	0.62	12.8	0.51	2.43e-32	Handedness;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg09033563	chr22:24373618	LOC391322	-0.56	-9.39	-0.4	2.63e-19	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12519773	0.555	rs1845840	chr5:92388210	G/A	cg18783429	chr5:92414398	NA	-0.31	-7.53	-0.33	2.77e-13	Migraine;
LGG	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg09137382	chr11:130731461	NA	0.35	6.7	0.3	5.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg17951613	chr5:131705445	SLC22A5	0.63	7.14	0.31	3.73e-12	Rheumatoid arthritis;
LGG	cis	rs2404602	0.669	rs9788684	chr15:77194838	A/T	cg22467129	chr15:76604101	ETFA	-0.41	-6.81	-0.3	3.02e-11	Blood metabolite levels;
LGG	cis	rs79149102	0.649	rs75985113	chr15:75379312	C/T	cg17294928	chr15:75287854	SCAMP5	-0.74	-7.71	-0.34	7.61e-14	Lung cancer;
LGG	cis	rs7551222	0.721	rs4951402	chr1:204539122	C/T	cg20240347	chr1:204465584	NA	-0.53	-10.62	-0.44	9.76e-24	Schizophrenia;
LGG	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.49	0.33	3.51e-13	Total cholesterol levels;
LGG	cis	rs6445975	0.667	rs2292676	chr3:58235928	G/T	cg24175188	chr3:58374923	PXK	0.39	7.22	0.32	2.15e-12	Systemic lupus erythematosus;
LGG	cis	rs727505	1.000	rs12111865	chr7:124498035	G/A	cg23710748	chr7:124431027	NA	-0.48	-8.99	-0.39	6.55e-18	Lewy body disease;
LGG	cis	rs754466	0.651	rs10762767	chr10:79645070	C/A	cg17075019	chr10:79541650	NA	-0.95	-20.24	-0.69	9.89e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs5769765	0.565	rs8137232	chr22:50256885	G/C	cg02269571	chr22:50332266	NA	0.66	8.76	0.38	3.6e-17	Schizophrenia;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg07538946	chr5:131705188	SLC22A5	-0.61	-7.06	-0.31	6.26e-12	Rheumatoid arthritis;
LGG	cis	rs17345786	0.906	rs72940399	chr3:101122575	A/T	cg12386194	chr3:101231763	SENP7	0.75	13.1	0.52	1.38e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs60695258	0.550	rs340636	chr4:87930760	T/G	cg11209507	chr4:87813803	C4orf36	-0.47	-8.01	-0.35	9.54e-15	Hematocrit;
LGG	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.39	0.32	6.9e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.01	-0.35	9.49e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs4474465	0.790	rs6592785	chr11:78235095	C/T	cg27205649	chr11:78285834	NARS2	0.51	8.59	0.37	1.39e-16	Alzheimer's disease (survival time);
LGG	cis	rs61931739	0.500	rs11053066	chr12:34185318	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs4713118	0.621	rs9368548	chr6:28034737	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.53	-6.89	-0.31	1.79e-11	Parkinson's disease;
LGG	cis	rs9487094	0.885	rs3818934	chr6:109668480	C/T	cg16315928	chr6:109776240	MICAL1	0.56	9.64	0.41	3.73e-20	Height;
LGG	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg03160526	chr17:80928410	B3GNTL1	0.5	7.95	0.35	1.42e-14	Glycated hemoglobin levels;
LGG	cis	rs11190604	1.000	rs3750633	chr10:102308214	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	11.79	0.48	3.1e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg07701084	chr6:150067640	NUP43	0.63	11.96	0.49	6.54e-29	Lung cancer;
LGG	cis	rs10936602	0.527	rs1920119	chr3:169540397	T/C	cg17737146	chr3:169530037	LRRC34	0.36	6.7	0.3	5.91e-11	Renal cell carcinoma;
LGG	trans	rs12579753	0.917	rs76240969	chr12:82195236	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs28595532	0.764	rs116302502	chr4:119748848	T/A	cg21605333	chr4:119757512	SEC24D	1.48	14.88	0.57	3.32e-41	Cannabis dependence symptom count;
LGG	cis	rs1971762	0.545	rs10783586	chr12:53980821	C/T	cg06632207	chr12:54070931	ATP5G2	0.22	6.91	0.31	1.57e-11	Height;
LGG	trans	rs9354308	0.764	rs9354324	chr6:66587013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs8051149	0.576	rs731710	chr16:87884547	A/G	cg01412419	chr16:87856264	NA	0.47	9.6	0.41	5.14e-20	Blood metabolite levels;
LGG	cis	rs2213920	0.619	rs6478174	chr9:118252779	C/T	cg13918206	chr9:118159781	DEC1	0.56	7.39	0.32	6.96e-13	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs6088590	0.561	rs764597	chr20:33161225	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.55	0.37	1.87e-16	Coronary artery disease;
LGG	cis	rs873946	0.564	rs2803991	chr10:134557068	A/G	cg26818010	chr10:134567672	INPP5A	-0.54	-8.72	-0.38	5.12e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17376456	0.877	rs114256265	chr5:93473130	T/A	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.8e-12	Diabetic retinopathy;
LGG	cis	rs6752107	0.512	rs1372097	chr2:234227047	T/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.39	6.71	0.3	5.79e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.65	0.44	7.44e-24	Personality dimensions;
LGG	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg08392591	chr16:89556376	ANKRD11	0.59	9.21	0.39	1.14e-18	Multiple myeloma (IgH translocation);
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.23	0.36	1.91e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs56114371	0.777	rs200483	chr6:27774824	C/T	cg08344181	chr3:125677491	NA	-0.65	-7.67	-0.34	1.04e-13	Breast cancer;
LGG	cis	rs4363385	0.509	rs11576882	chr1:152918785	T/G	cg13444842	chr1:152974279	SPRR3	-0.47	-9.37	-0.4	3.3e-19	Inflammatory skin disease;
LGG	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg02825527	chr7:2087843	MAD1L1	-0.35	-6.95	-0.31	1.26e-11	Neuroticism;
LGG	cis	rs9534288	0.619	rs1326397	chr13:46682122	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.21	-0.55	2.8e-38	Blood protein levels;
LGG	cis	rs13424612	1.000	rs10193610	chr2:240940618	A/G	cg01812947	chr2:240904978	NDUFA10	0.43	7.15	0.32	3.4e-12	Odorant perception (isobutyraldehyde);
LGG	trans	rs2562456	0.793	rs7258473	chr19:21514597	A/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs7715806	0.500	rs2291630	chr5:75013356	G/A	cg19683494	chr5:74908142	NA	0.52	6.87	0.3	2.09e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7503807	0.688	rs901060	chr17:78594990	G/A	cg18469159	chr17:78755841	RPTOR	-0.36	-6.83	-0.3	2.63e-11	Obesity;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg02002194	chr4:3960332	NA	0.44	8.06	0.35	6.61e-15	Triglycerides;
LGG	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg06618935	chr21:46677482	NA	-0.49	-9.64	-0.41	3.58e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3820928	0.648	rs1997484	chr2:227898962	T/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.28	-0.32	1.42e-12	Pulmonary function;
LGG	cis	rs9557207	1.000	rs12864099	chr13:99829311	G/A	cg24509225	chr13:100037070	UBAC2	0.7	12.54	0.5	2.85e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs3925075	1.000	rs9674009	chr16:31347541	C/A	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs3857747	0.827	rs4257934	chr7:40401647	T/C	cg00420559	chr7:40367873	C7orf10	-0.4	-8.07	-0.35	6.3e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs561341	0.769	rs7217004	chr17:30178092	A/G	cg20587970	chr11:113659929	NA	1.1	14.11	0.55	7.35e-38	Hip circumference adjusted for BMI;
LGG	cis	rs7617773	0.780	rs2541	chr3:48339618	A/G	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg05335186	chr13:53173507	NA	0.43	8.49	0.37	2.76e-16	Lewy body disease;
LGG	cis	rs7587476	1.000	rs2121285	chr2:215656168	C/G	cg04004882	chr2:215674386	BARD1	-0.53	-7.48	-0.33	3.8e-13	Neuroblastoma;
LGG	cis	rs216026	0.689	rs216051	chr12:2766899	C/A	cg19945202	chr12:2788847	CACNA1C	0.64	9.44	0.4	1.86e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg16359550	chr11:109292809	C11orf87	0.41	7.94	0.35	1.54e-14	Schizophrenia;
LGG	cis	rs7582720	1.000	rs6435169	chr2:203753016	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7106204	0.534	rs78257359	chr11:24338261	C/G	ch.11.24196551F	chr11:24239977	NA	0.84	8.6	0.37	1.28e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg00012203	chr2:219082015	ARPC2	0.85	17.52	0.63	4.27e-53	Colorectal cancer;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.89	0.3	1.85e-11	Longevity;
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg09303159	chr6:26284866	NA	0.35	7.96	0.35	1.38e-14	Educational attainment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04025590	chr1:26560450	CCDC21	0.41	6.72	0.3	5.21e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	9.99	0.42	2.08e-21	Neuroticism;
LGG	cis	rs57920188	0.640	rs4378174	chr1:4080885	C/T	cg20703997	chr1:4087676	NA	0.49	6.67	0.3	7.37e-11	Interleukin-17 levels;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.75	-0.59	4.45e-45	Skin colour saturation;
LGG	cis	rs8058578	1.000	rs67128646	chr16:30672097	A/C	cg02466173	chr16:30829666	NA	-0.54	-9.41	-0.4	2.39e-19	Multiple myeloma;
LGG	cis	rs7829975	0.535	rs4841005	chr8:8501230	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.66	-0.34	1.08e-13	Mood instability;
LGG	cis	rs2236918	0.710	rs2526700	chr1:242019999	C/A	cg17736920	chr1:242011382	EXO1	0.39	7.09	0.31	4.94e-12	Menopause (age at onset);
LGG	cis	rs8028182	0.636	rs12708519	chr15:75803200	T/C	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs17376456	0.569	rs896729	chr5:93222178	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.68	-0.37	6.82e-17	Diabetic retinopathy;
LGG	cis	rs12600053	0.687	rs8058664	chr16:84849100	A/G	cg09249803	chr16:84846936	NA	0.35	7.56	0.33	2.21e-13	Asthma (childhood onset);
LGG	cis	rs17030434	0.953	rs6535953	chr4:154728186	G/A	cg14289246	chr4:154710475	SFRP2	-0.73	-11.39	-0.47	1.2e-26	Electrocardiographic conduction measures;
LGG	trans	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg13565492	chr6:43139072	SRF	-0.91	-15.63	-0.59	1.52e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg26597838	chr10:835615	NA	0.73	10.0	0.42	1.85e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs947211	0.898	rs1772153	chr1:205745782	C/T	cg24503407	chr1:205819492	PM20D1	-0.45	-7.69	-0.34	9.15e-14	Parkinson's disease;
LGG	trans	rs9929218	0.954	rs12928043	chr16:68828885	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-11.65	-0.48	1.08e-27	Colorectal cancer;
LGG	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.56	-0.33	2.18e-13	Body mass index;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.43	0.47	8.11e-27	Electroencephalogram traits;
LGG	cis	rs10463316	0.894	rs6579866	chr5:150762524	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs787274	1.000	rs72768411	chr9:115502670	C/A	cg13803584	chr9:115635662	SNX30	0.56	7.59	0.33	1.8e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4665809	0.590	rs2303892	chr2:26461733	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs10743315	0.643	rs75009806	chr12:19466457	A/G	cg02471346	chr12:19282374	PLEKHA5	0.82	7.61	0.33	1.58e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.48	10.2	0.43	3.49e-22	Schizophrenia;
LGG	cis	rs56775891	1.000	rs56775891	chr18:77575613	C/T	cg13263691	chr18:77568018	NA	0.83	14.62	0.56	4.61e-40	Schizophrenia;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7726839	0.540	rs72703079	chr5:595173	T/C	cg25482853	chr8:67687455	SGK3	0.94	12.14	0.49	1.24e-29	Obesity-related traits;
LGG	cis	rs11122272	0.706	rs2749710	chr1:231535112	A/C	cg10503236	chr1:231470652	EXOC8	0.39	7.48	0.33	3.83e-13	Hemoglobin concentration;
LGG	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.9e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs8031584	0.918	rs34693097	chr15:31253984	A/G	cg14829155	chr15:31115871	NA	-0.56	-9.81	-0.41	9.13e-21	Huntington's disease progression;
LGG	cis	rs7582180	0.629	rs2164847	chr2:100958715	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.85e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg24110177	chr3:50126178	RBM5	-0.59	-10.79	-0.45	2.37e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7077256	0.564	rs67019024	chr10:65214571	A/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.57	0.41	6.28e-20	Longevity;
LGG	cis	rs929354	0.772	rs4716460	chr7:156970054	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.48	-0.53	3.62e-35	Total body bone mineral density;
LGG	cis	rs4262150	0.846	rs72799138	chr5:152096515	G/T	cg12297329	chr5:152029980	NA	-0.78	-14.43	-0.56	3.02e-39	Bipolar disorder and schizophrenia;
LGG	trans	rs13201294	1	rs13201294	chr6:27556141	A/T	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.4	-0.4	2.45e-19	Squamous cell lung carcinoma;
LGG	cis	rs17767392	0.958	rs61989374	chr14:71940581	A/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	trans	rs11098499	0.820	rs2389885	chr4:120533931	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.18	0.46	7.22e-26	Corneal astigmatism;
LGG	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg00334542	chr7:100209784	MOSPD3	-0.63	-8.44	-0.37	4.2e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg19006130	chr11:118478252	PHLDB1	-0.4	-6.78	-0.3	3.64e-11	Cholesterol, total;
LGG	cis	rs17154702	0.506	rs2427	chr8:8641125	A/G	cg01851573	chr8:8652454	MFHAS1	-0.51	-7.02	-0.31	7.98e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs977987	1.000	rs977987	chr16:75506593	G/A	cg07303275	chr16:75499416	TMEM170A	0.42	7.49	0.33	3.52e-13	Dupuytren's disease;
LGG	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg00645731	chr22:42541494	CYP2D7P1	0.45	7.5	0.33	3.29e-13	Birth weight;
LGG	cis	rs589448	0.902	rs642786	chr12:69758462	T/C	cg20891283	chr12:69753455	YEATS4	1.09	29.07	0.8	1.81e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg14541582	chr5:601475	NA	-0.69	-10.89	-0.45	9.94e-25	Obesity-related traits;
LGG	cis	rs4936894	0.500	rs4936916	chr11:124157440	G/A	cg27160556	chr11:124181099	OR8D1	-0.48	-11.12	-0.46	1.26e-25	Aging (time to death);
LGG	trans	rs1814175	0.817	rs1319547	chr11:49916705	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.12	-0.49	1.5e-29	Height;
LGG	trans	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.87	-0.34	2.56e-14	Resting heart rate;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09112613	chr19:8563861	PRAM1	0.43	7.69	0.34	9.04e-14	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs10716631	1	rs10716631	chr2:219138170	T/G	cg04731861	chr2:219085781	ARPC2	-0.42	-10.15	-0.43	5.66e-22	High light scatter reticulocyte percentage of red cells;Plateletcrit;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2952156	0.920	rs11078919	chr17:37835755	T/C	cg07936489	chr17:37558343	FBXL20	-0.5	-8.55	-0.37	1.83e-16	Asthma;
LGG	cis	rs7529073	0.545	rs1431985	chr1:214148246	C/T	cg00795024	chr1:214157026	NA	0.29	8.35	0.36	8.04e-16	Schizophrenia;
LGG	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.24	-0.36	1.75e-15	Schizophrenia;
LGG	cis	rs28374715	0.662	rs28493087	chr15:41486504	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.02	-18.07	-0.64	1.21e-55	Ulcerative colitis;
LGG	cis	rs9464760	0.527	rs9476757	chr6:15157289	A/G	cg15799072	chr6:15248335	JARID2	0.65	8.42	0.36	4.82e-16	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs6489882	0.902	rs3815178	chr12:113376320	C/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg06718696	chr17:78121285	EIF4A3	0.4	6.67	0.3	7.36e-11	Yeast infection;
LGG	cis	rs7129556	0.520	rs6592730	chr11:77274203	T/C	cg12586386	chr11:77299805	AQP11	0.39	6.87	0.3	2.1e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs7523273	0.526	rs2724394	chr1:208017072	T/A	cg22525895	chr1:207977042	MIR29B2	-0.61	-11.8	-0.48	2.72e-28	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.17	-0.32	2.94e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.34	0.58	2.99e-43	Chronic sinus infection;
LGG	cis	rs1982963	1.000	rs2029975	chr14:52506070	C/T	cg05884192	chr14:52515736	NID2	-0.34	-7.57	-0.33	2.01e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9487051	0.768	rs371960	chr6:109525082	A/G	cg21918786	chr6:109611834	NA	-0.37	-6.76	-0.3	4.14e-11	Reticulocyte fraction of red cells;
LGG	cis	rs477895	0.653	rs11231701	chr11:63893702	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.44	0.47	7.26e-27	Mean platelet volume;
LGG	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-9.12	-0.39	2.35e-18	Yeast infection;
LGG	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg14784868	chr12:69753453	YEATS4	-0.73	-14.04	-0.55	1.52e-37	Blood protein levels;
LGG	trans	rs7395662	0.963	rs4882137	chr11:48615671	A/T	cg15704280	chr7:45808275	SEPT13	-0.51	-8.23	-0.36	1.95e-15	HDL cholesterol;
LGG	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs970548	0.779	rs3891524	chr10:45971689	C/A	cg14222797	chr10:16859974	RSU1	-0.63	-7.42	-0.33	5.81e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg11644478	chr21:40555479	PSMG1	0.92	18.02	0.64	2.23e-55	Cognitive function;
LGG	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg07395648	chr5:131743802	NA	-0.55	-12.96	-0.52	5.19e-33	Blood metabolite levels;
LGG	cis	rs13177180	0.602	rs256959	chr5:114881530	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.33	-7.14	-0.31	3.72e-12	Conotruncal heart defects (inherited effects);
LGG	cis	rs4268898	0.735	rs12469585	chr2:24489054	A/T	cg06627628	chr2:24431161	ITSN2	0.43	7.29	0.32	1.38e-12	Asthma;
LGG	cis	rs28595532	0.920	rs116514715	chr4:119756280	G/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10927875	0.864	rs6674071	chr1:16144855	G/C	cg07117364	chr1:16154769	NA	-0.54	-8.56	-0.37	1.63e-16	Dilated cardiomyopathy;
LGG	cis	rs6815814	0.950	rs67719080	chr4:38787252	A/G	cg06935464	chr4:38784597	TLR10	0.56	8.49	0.37	2.87e-16	Breast cancer;
LGG	cis	rs2836950	0.501	rs4818018	chr21:40694072	C/T	cg11890956	chr21:40555474	PSMG1	-0.72	-12.4	-0.5	1.11e-30	Menarche (age at onset);
LGG	cis	rs9326248	0.581	rs6589582	chr11:116829200	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.63	0.44	8.99e-24	Blood protein levels;
LGG	trans	rs9409565	0.793	rs2486632	chr9:97196979	A/G	cg05679027	chr9:99775184	HIATL2	-0.49	-8.1	-0.35	4.95e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs2028299	0.839	rs2279848	chr15:90444681	G/T	cg23731826	chr15:90371692	NA	0.36	8.1	0.35	4.81e-15	Type 2 diabetes;
LGG	cis	rs41271473	1.000	rs1062060	chr1:228880021	A/G	cg00850481	chr1:228891306	NA	0.5	8.62	0.37	1.07e-16	Chronic lymphocytic leukemia;
LGG	cis	rs9875589	0.509	rs2731330	chr3:14111588	C/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.36	0.47	1.55e-26	Ovarian reserve;
LGG	cis	rs4466137	1.000	rs4466137	chr5:82985739	A/C	cg16102102	chr5:83017553	HAPLN1	-0.6	-11.12	-0.46	1.26e-25	Prostate cancer;
LGG	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg01620082	chr3:125678407	NA	-1.05	-10.28	-0.43	1.78e-22	Depression;
LGG	cis	rs7617773	0.780	rs34749846	chr3:48347168	T/G	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs41271473	1.000	rs11578216	chr1:228880098	A/T	cg10167378	chr1:228756711	NA	-0.55	-7.82	-0.34	3.71e-14	Chronic lymphocytic leukemia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16449840	chr12:54718606	COPZ1	0.46	7.75	0.34	6.06e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs72781680	0.848	rs72780199	chr2:24016269	A/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23151374	chr4:164415611	C4orf43	0.45	6.95	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg04703951	chr17:43578652	NA	0.39	7.83	0.34	3.36e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9393777	0.513	rs13195210	chr6:26646521	C/T	cg12826209	chr6:26865740	GUSBL1	0.83	12.27	0.5	3.8e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07274776	chr2:203241322	BMPR2	0.43	7.28	0.32	1.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.57e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs13421350	0.579	rs75979419	chr2:173299266	C/T	cg15021238	chr2:173305865	ITGA6	-0.81	-9.08	-0.39	3.07e-18	Diabetic kidney disease;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	16.65	0.61	4.01e-49	Obesity-related traits;
LGG	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.05	0.49	2.73e-29	Rheumatoid arthritis;
LGG	cis	rs3857067	0.806	rs6857967	chr4:95112303	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.18	-0.36	2.76e-15	QT interval;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14582248	chr6:5066984	NA	-0.59	-6.92	-0.31	1.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2455799	0.573	rs2470546	chr3:15733897	T/C	cg16303742	chr3:15540471	COLQ	-0.38	-7.35	-0.32	8.8e-13	Mean platelet volume;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg22907277	chr7:1156413	C7orf50	0.68	12.51	0.5	3.99e-31	Longevity;Endometriosis;
LGG	cis	rs1577917	0.958	rs7453105	chr6:86500761	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs9547996	0.879	rs1006416	chr13:38164445	G/A	cg13634560	chr13:38173852	POSTN	0.35	7.01	0.31	8.66e-12	Diastolic blood pressure;
LGG	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg04166393	chr7:2884313	GNA12	0.46	8.59	0.37	1.29e-16	Height;
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.74	9.88	0.42	5.28e-21	Lung function (FEV1/FVC);
LGG	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.67	-0.44	6.51e-24	Calcium levels;
LGG	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg21153622	chr11:89784906	NA	-0.39	-6.69	-0.3	6.54e-11	HDL cholesterol;
LGG	cis	rs9951602	1.000	rs1903723	chr18:76646571	A/G	cg24134504	chr18:76639479	NA	-0.61	-7.97	-0.35	1.23e-14	Obesity-related traits;
LGG	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg26384229	chr12:38710491	ALG10B	1.07	28.9	0.8	1.03e-105	Heart rate;
LGG	cis	rs2235642	0.717	rs9937922	chr16:1658154	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	9.01	0.39	5.58e-18	Coronary artery disease;
LGG	trans	rs2055729	0.848	rs506276	chr8:9790912	T/C	cg12395012	chr8:11607386	GATA4	-0.41	-7.03	-0.31	7.43e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11644478	chr21:40555479	PSMG1	0.91	17.51	0.63	4.81e-53	Cognitive function;
LGG	cis	rs17376456	1.000	rs13174700	chr5:93554644	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.06	0.42	1.14e-21	Diabetic retinopathy;
LGG	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg12183467	chr14:104352244	NA	-0.41	-7.02	-0.31	7.72e-12	Bipolar disorder;
LGG	cis	rs13065560	0.659	rs6776510	chr3:38887253	C/T	cg01426195	chr3:39028469	NA	-0.44	-9.03	-0.39	4.56e-18	Interleukin-18 levels;
LGG	cis	rs524281	0.861	rs7946917	chr11:65956577	A/G	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs68170813	0.559	rs7981	chr7:106843133	G/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.71	-0.45	4.71e-24	Coronary artery disease;
LGG	cis	rs6502050	0.736	rs12150322	chr17:80061582	T/G	cg23985595	chr17:80112537	CCDC57	0.39	7.75	0.34	5.98e-14	Life satisfaction;
LGG	cis	rs887829	0.569	rs4663333	chr2:234655303	G/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.7	-0.34	8.42e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs7072216	0.763	rs6584201	chr10:100170209	T/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.83e-12	Metabolite levels;
LGG	cis	rs708547	0.676	rs11133470	chr4:57864926	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	10.38	0.43	7.71e-23	Response to bleomycin (chromatid breaks);
LGG	cis	rs1801251	1.000	rs778166	chr2:233664097	A/T	cg08000102	chr2:233561755	GIGYF2	0.59	9.58	0.41	6.02e-20	Coronary artery disease;
LGG	cis	rs796364	0.951	rs7586284	chr2:201068002	G/A	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.45e-17	Schizophrenia;
LGG	cis	rs4820539	1.000	rs2267002	chr22:23456702	T/C	cg14186256	chr22:23484241	RTDR1	0.98	24.69	0.75	1.66e-86	Bone mineral density;
LGG	cis	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.77	-0.3	3.96e-11	Neuroticism;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9322193	0.736	rs3828701	chr6:150112199	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.85	-0.42	6.62e-21	Lung cancer;
LGG	cis	rs12447804	0.911	rs12445500	chr16:58095013	G/A	cg03859792	chr16:58121049	NA	0.48	7.3	0.32	1.25e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs4730250	0.707	rs3729877	chr7:106787065	T/G	cg02696742	chr7:106810147	HBP1	0.78	11.1	0.46	1.58e-25	Osteoarthritis;
LGG	cis	rs4727027	0.901	rs66800495	chr7:148763702	T/C	cg23583168	chr7:148888333	NA	-0.81	-15.12	-0.58	2.79e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.34e-12	Neuroticism;
LGG	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg09307838	chr4:120376055	NA	0.72	12.48	0.5	5.17e-31	Corneal astigmatism;
LGG	cis	rs4851254	0.618	rs13001130	chr2:100668699	G/A	cg17356467	chr2:100759845	AFF3	0.44	7.3	0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.47	-0.47	5.74e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg11062466	chr8:58055876	NA	0.56	8.9	0.38	1.31e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs2504140	chr10:38387579	T/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1707322	0.721	rs12045096	chr1:46114428	A/G	cg03146154	chr1:46216737	IPP	0.56	10.99	0.45	4.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs34734847	1.000	rs34734847	chr12:121154221	T/C	cg21892295	chr12:121157589	UNC119B	-0.47	-8.95	-0.38	8.31e-18	Mean corpuscular volume;
LGG	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.71	-0.56	1.78e-40	Calcium levels;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg07362569	chr17:61921086	SMARCD2	0.51	10.02	0.42	1.62e-21	Prudent dietary pattern;
LGG	cis	rs4771450	0.962	rs4772545	chr13:103973228	A/G	cg02987523	chr13:103978230	NA	-0.32	-6.85	-0.3	2.36e-11	Uric acid levels;
LGG	cis	rs5756813	0.754	rs4821711	chr22:38181115	C/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.07	0.31	5.9e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9325144	0.560	rs7980358	chr12:38640396	C/G	cg04568710	chr12:38710424	ALG10B	0.42	9.07	0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs7095944	0.584	rs4962691	chr10:126424137	C/T	cg08799069	chr10:126477246	METTL10	-0.42	-9.11	-0.39	2.5e-18	Asthma;
LGG	cis	rs13191362	0.507	rs2849520	chr6:163132038	T/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.65	-9.0	-0.39	5.98e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11711311	1.000	rs2603792	chr3:113509187	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.88	0.51	1.13e-32	IgG glycosylation;
LGG	cis	rs537930	0.925	rs2249596	chr5:134347956	T/C	cg24576358	chr5:134350122	NA	0.49	10.21	0.43	3.2800000000000002e-22	Height;
LGG	cis	rs9828933	0.766	rs704372	chr3:63867453	T/C	cg17941049	chr3:63904683	ATXN7	-0.7	-8.56	-0.37	1.7e-16	Type 2 diabetes;
LGG	cis	rs6860806	0.507	rs2631364	chr5:131706914	C/G	cg07395648	chr5:131743802	NA	0.49	9.99	0.42	2.13e-21	Breast cancer;
LGG	cis	rs2832191	0.671	rs73346699	chr21:30515529	C/T	cg24692254	chr21:30365293	RNF160	-0.73	-14.24	-0.55	1.95e-38	Dental caries;
LGG	cis	rs7726839	0.794	rs10474792	chr5:600058	G/A	cg14541582	chr5:601475	NA	-0.48	-8.46	-0.37	3.49e-16	Obesity-related traits;
LGG	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg06917634	chr15:78832804	PSMA4	0.72	14.12	0.55	6.58e-38	Sudden cardiac arrest;
LGG	cis	rs834603	0.575	rs834595	chr7:47472276	C/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.79	-0.48	3.09e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7666738	0.830	rs4699584	chr4:98952019	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7617773	0.694	rs13099560	chr3:48204768	C/T	cg11946769	chr3:48343235	NME6	-0.56	-9.38	-0.4	2.95e-19	Coronary artery disease;
LGG	cis	rs138249	0.763	rs138254	chr22:50571160	G/C	cg07310406	chr22:50524374	MLC1	0.42	8.42	0.36	4.69e-16	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs11748327	0.580	rs11739178	chr5:4006099	C/T	cg01025095	chr5:4101132	NA	-0.44	-7.04	-0.31	6.95e-12	Myocardial infarction;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs478607	0.749	rs61884370	chr11:64361955	T/G	cg19395706	chr11:64412079	NRXN2	0.42	6.94	0.31	1.33e-11	Urate levels;
LGG	cis	rs12477438	0.501	rs12995473	chr2:99764884	G/T	cg08885076	chr2:99613938	TSGA10	0.43	9.23	0.39	9.84e-19	Chronic sinus infection;
LGG	trans	rs116095464	0.558	rs10055405	chr5:265666	C/T	cg00938859	chr5:1591904	SDHAP3	0.92	13.69	0.54	4.8e-36	Breast cancer;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg05313129	chr8:58192883	C8orf71	-0.59	-7.43	-0.33	5.38e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg00990874	chr7:1149470	C7orf50	-0.69	-11.31	-0.47	2.27e-26	Bronchopulmonary dysplasia;
LGG	cis	rs57590327	0.503	rs7631052	chr3:81866235	C/A	cg07356753	chr3:81810745	GBE1	-0.49	-7.84	-0.34	3.15e-14	Extraversion;
LGG	cis	rs921968	0.541	rs7583449	chr2:219403022	A/C	cg01130898	chr2:219473002	PLCD4	0.46	7.91	0.34	1.93e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg15971980	chr6:150254442	NA	0.46	8.58	0.37	1.41e-16	Lung cancer;
LGG	cis	rs12928939	0.636	rs11639902	chr16:71755852	C/T	cg08717414	chr16:71523259	ZNF19	0.44	7.2	0.32	2.48e-12	Post bronchodilator FEV1;
LGG	cis	rs6942756	0.774	rs6946288	chr7:129004277	A/G	cg02491457	chr7:128862824	NA	-0.62	-11.39	-0.47	1.18e-26	White matter hyperintensity burden;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg16885296	chr6:26284938	NA	0.39	8.39	0.36	6.08e-16	Educational attainment;
LGG	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg06197492	chr11:2016605	H19	0.47	9.76	0.41	1.37e-20	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6502050	0.835	rs7222057	chr17:80087647	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.4	-0.36	5.44e-16	Life satisfaction;
LGG	cis	rs17376456	0.569	rs13186432	chr5:93336940	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.54	-7.53	-0.33	2.66e-13	Diabetic retinopathy;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05025164	chr4:1340916	KIAA1530	-0.69	-12.96	-0.52	5.56e-33	Obesity-related traits;
LGG	cis	rs2124969	0.548	rs62175388	chr2:161019664	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.18	-0.39	1.39e-18	Waist circumference adjusted for body mass index;
LGG	cis	rs4481887	0.893	rs28451623	chr1:248509783	G/A	cg01631408	chr1:248437212	OR2T33	-0.5	-9.09	-0.39	2.88e-18	Common traits (Other);
LGG	cis	rs2594989	1.000	rs346082	chr3:11329216	C/G	cg01796438	chr3:11312864	ATG7	-0.61	-8.41	-0.36	5.06e-16	Circulating chemerin levels;
LGG	cis	rs1506636	0.962	rs17623873	chr7:123417100	C/A	cg03229431	chr7:123269106	ASB15	0.7	16.31	0.6	1.42e-47	Plateletcrit;Platelet count;
LGG	cis	rs2373794	0.583	rs374153	chr2:40382712	C/T	cg17740179	chr2:40377776	SLC8A1	0.77	9.74	0.41	1.65e-20	Asthma;
LGG	cis	rs514406	0.570	rs1332776	chr1:53189816	C/T	cg16325326	chr1:53192061	ZYG11B	0.83	22.05	0.72	3.4e-74	Monocyte count;
LGG	cis	rs283228	0.517	rs661064	chr6:101801581	C/T	cg27451362	chr6:101846650	GRIK2	0.99	14.89	0.57	2.92e-41	Coenzyme Q10 levels;
LGG	cis	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg24375607	chr4:120327624	NA	0.69	11.01	0.46	3.36e-25	Corneal astigmatism;
LGG	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-8.68	-0.37	6.57e-17	Total body bone mineral density;
LGG	cis	rs7833790	0.963	rs1451997	chr8:82774053	A/T	cg27398817	chr8:82754497	SNX16	0.77	11.06	0.46	2.24e-25	Diastolic blood pressure;
LGG	trans	rs877282	0.898	rs12354872	chr10:763362	G/A	cg22713356	chr15:30763199	NA	0.52	7.7	0.34	8.12e-14	Uric acid levels;
LGG	cis	rs977987	0.806	rs35552529	chr16:75405879	G/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.17	-0.46	7.88e-26	Colonoscopy-negative controls vs population controls;
LGG	trans	rs75804782	0.625	rs10929277	chr2:239468639	T/G	cg01134436	chr17:81009848	B3GNTL1	0.69	7.43	0.33	5.45e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs854037	0.512	rs10461639	chr5:57123317	C/G	cg08523694	chr5:57076192	NA	-0.53	-7.12	-0.31	4.1e-12	Birth weight;
LGG	cis	rs78456975	0.943	rs10470006	chr2:1580971	A/C	cg26248373	chr2:1572462	NA	-0.69	-9.31	-0.4	5.12e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg08085267	chr17:45401833	C17orf57	0.63	13.1	0.52	1.41e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.56	8.88	0.38	1.45e-17	Height;
LGG	cis	rs7166081	0.951	rs16950805	chr15:67560677	T/G	cg05925327	chr15:68127851	NA	-0.33	-7.09	-0.31	5.03e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs2562456	0.833	rs77576302	chr19:21518187	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs62244186	0.606	rs6798590	chr3:44556861	T/A	cg02073558	chr3:44770973	ZNF501	0.68	12.53	0.5	3.13e-31	Depressive symptoms;
LGG	trans	rs12517041	0.938	rs71611218	chr5:23270886	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.62	-9.11	-0.39	2.56e-18	Calcium levels;
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06850241	chr22:41845214	NA	-0.45	-6.97	-0.31	1.12e-11	Vitiligo;
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.99	-0.31	9.86e-12	Bipolar disorder;
LGG	cis	rs3733585	0.699	rs28837683	chr4:9959808	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.17	-0.32	3.07e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7617773	0.780	rs11720026	chr3:48377921	T/C	cg11946769	chr3:48343235	NME6	0.69	11.26	0.46	3.54e-26	Coronary artery disease;
LGG	cis	rs34172651	0.517	rs11642954	chr16:24824248	G/A	cg06028605	chr16:24865363	SLC5A11	0.5	8.29	0.36	1.22e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.45	-0.4	1.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6542838	0.641	rs10192266	chr2:99521837	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.39	-6.76	-0.3	4.23e-11	Fear of minor pain;
LGG	cis	rs11864453	0.611	rs9926927	chr16:72130556	G/T	cg01557791	chr16:72042693	DHODH	-0.45	-8.19	-0.36	2.51e-15	Fibrinogen levels;
LGG	cis	rs9467773	1.000	rs9461271	chr6:26554968	G/A	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4253772	0.530	rs9627387	chr22:46684678	A/G	cg24881330	chr22:46731750	TRMU	0.78	9.46	0.4	1.62e-19	LDL cholesterol;Cholesterol, total;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07402800	chr8:145582003	FBXL6;GPR172A	0.54	9.35	0.4	3.82e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs17767392	0.813	rs7152842	chr14:71849740	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.62	-0.37	1.09e-16	Mitral valve prolapse;
LGG	cis	rs10991814	0.920	rs10512210	chr9:94048529	A/G	cg14446406	chr9:93919335	NA	0.69	7.79	0.34	4.29e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs7949030	0.626	rs11231145	chr11:62328854	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.35e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg05941027	chr17:61774174	LIMD2	0.34	8.63	0.37	1.03e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4975709	0.589	rs931508	chr5:1861224	C/G	cg20790798	chr5:1857306	NA	-0.43	-7.05	-0.31	6.37e-12	Cardiovascular disease risk factors;
LGG	cis	rs6831352	0.918	rs6813415	chr4:100048509	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	cis	rs589448	0.933	rs2249093	chr12:69753512	G/C	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	trans	rs11875185	0.510	rs79188176	chr18:55611805	A/C	cg15513957	chr14:69354734	ACTN1	-0.95	-9.2	-0.39	1.2e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg03175030	chr11:2018143	H19;MIR675	-0.6	-11.64	-0.48	1.2100000000000001e-27	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg11301795	chr4:187892539	NA	-0.95	-25.05	-0.76	3.61e-88	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6032067	0.561	rs2233093	chr20:43933196	C/T	cg10761708	chr20:43804764	PI3	0.43	7.2	0.32	2.43e-12	Blood protein levels;
LGG	cis	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg22907277	chr7:1156413	C7orf50	0.68	8.76	0.38	3.78e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg08534653	chr2:1747700	PXDN	-0.45	-7.03	-0.31	7.69e-12	Response to antipsychotic treatment;
LGG	cis	rs2576037	0.583	rs644731	chr18:44426877	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.58	0.65	5.62e-58	Personality dimensions;
LGG	trans	rs12579753	0.810	rs10862355	chr12:82162698	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-8.07	-0.35	6.11e-15	Resting heart rate;
LGG	cis	rs6964587	0.967	rs10231496	chr7:91741132	T/C	cg17063962	chr7:91808500	NA	0.51	9.31	0.4	5.25e-19	Breast cancer;
LGG	cis	rs61931739	0.817	rs866515	chr12:34215479	A/G	cg06521331	chr12:34319734	NA	-0.41	-7.33	-0.32	1.04e-12	Morning vs. evening chronotype;
LGG	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg27411982	chr8:10470053	RP1L1	-0.42	-7.04	-0.31	6.93e-12	Morning vs. evening chronotype;
LGG	cis	rs757081	0.658	rs214075	chr11:17300417	G/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.49	-0.33	3.5e-13	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07629094	chr19:52552213	ZNF432	0.44	6.86	0.3	2.24e-11	Gut microbiome composition (summer);
LGG	cis	rs10799590	1.000	rs2936575	chr1:224841619	A/T	cg01808320	chr1:224927238	CNIH3	-0.38	-6.76	-0.3	4.26e-11	Opioid dependence;
LGG	trans	rs7613875	0.578	rs2526749	chr3:50076734	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-9.74	-0.41	1.61e-20	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09238957	chr16:46723420	ORC6L;VPS35	0.44	6.89	0.3	1.87e-11	Cognitive performance;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Electroencephalogram traits;
LGG	cis	rs308971	0.611	rs307598	chr3:12102273	T/C	cg02700894	chr3:12045449	SYN2	0.48	6.87	0.3	2.1e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs7756236	0.521	rs9394368	chr6:36630525	C/G	cg08179530	chr6:36648295	CDKN1A	-0.66	-11.66	-0.48	9.88e-28	QRS duration;
LGG	cis	rs7106204	0.609	rs12791360	chr11:24286239	T/G	ch.11.24196551F	chr11:24239977	NA	0.87	10.07	0.42	1.03e-21	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg03894339	chr8:19674705	INTS10	0.53	8.46	0.37	3.47e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs12339094	0.932	rs7035272	chr9:90400734	C/T	cg24436365	chr6:63940138	NA	0.42	6.81	0.3	3.1e-11	Smoking quantity;
LGG	cis	rs9916302	0.851	rs11868029	chr17:37650304	A/G	cg07936489	chr17:37558343	FBXL20	-0.83	-15.35	-0.58	2.73e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7503807	0.701	rs1485329	chr17:78643561	A/G	cg06872548	chr17:78716983	RPTOR	0.37	8.21	0.36	2.26e-15	Obesity;
LGG	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.67	0.3	7.35e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg16606324	chr3:10149918	C3orf24	0.58	7.65	0.34	1.17e-13	Alzheimer's disease;
LGG	cis	rs36051895	0.658	rs10974914	chr9:5014332	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-15.92	-0.59	7.68e-46	Pediatric autoimmune diseases;
LGG	cis	rs9486719	0.857	rs4265039	chr6:96878929	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	11.41	0.47	9.35e-27	Migraine;Coronary artery disease;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg10950524	chr7:2139216	MAD1L1	0.32	6.86	0.3	2.25e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7267979	0.789	rs2260197	chr20:25284343	T/C	cg06421707	chr20:25228305	PYGB	0.38	7.9	0.34	2.05e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg24623649	chr8:11872141	NA	0.29	7.02	0.31	7.69e-12	Neuroticism;
LGG	cis	rs11168618	0.904	rs11495273	chr12:48929190	A/T	cg24011408	chr12:48396354	COL2A1	0.44	7.22	0.32	2.14e-12	Adiponectin levels;
LGG	cis	rs757278	0.513	rs213988	chr7:117262304	G/A	cg10524701	chr7:117356490	CTTNBP2	0.45	7.82	0.34	3.48e-14	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7954584	0.567	rs11043251	chr12:122373279	C/T	cg21171335	chr12:122356390	WDR66	0.29	8.1	0.35	5.07e-15	Mean corpuscular volume;
LGG	cis	rs7605378	1.000	rs10194076	chr2:200677663	T/C	cg17644776	chr2:200775616	C2orf69	0.54	8.63	0.37	9.59e-17	Osteoporosis;
LGG	cis	rs9914988	0.943	rs4795459	chr17:27113726	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs9303280	0.806	rs62067034	chr17:38063738	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-9.36	-0.4	3.5e-19	Self-reported allergy;
LGG	cis	rs8031584	0.872	rs11634761	chr15:31243173	A/C	cg08109568	chr15:31115862	NA	-0.53	-9.07	-0.39	3.49e-18	Huntington's disease progression;
LGG	cis	rs240764	0.658	rs7747014	chr6:101201898	T/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.94	-0.35	1.57e-14	Neuroticism;
LGG	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg15704280	chr7:45808275	SEPT13	-1.06	-23.98	-0.74	3.29e-83	Height;
LGG	cis	rs116095464	1.000	rs6873902	chr5:313337	C/G	cg22857025	chr5:266934	NA	-1.29	-13.28	-0.53	2.51e-34	Breast cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24942186	chr3:55521373	WNT5A	0.39	6.74	0.3	4.63e-11	Obesity-related traits;
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.37	-0.61	7.26e-48	Skin colour saturation;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02653800	chr10:60095305	UBE2D1	0.41	6.96	0.31	1.17e-11	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg12692727	chr7:1102344	C7orf50	0.48	6.71	0.3	5.8200000000000003e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9715521	0.867	rs6840137	chr4:59830872	A/G	cg11281224	chr4:60001000	NA	-0.43	-7.11	-0.31	4.5e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg01240734	chr10:71892593	AIFM2	-0.31	-6.84	-0.3	2.54e-11	Blood protein levels;
LGG	trans	rs6561151	0.681	rs7995955	chr13:44434836	C/G	cg17145862	chr1:211918768	LPGAT1	0.69	10.8	0.45	2.05e-24	Crohn's disease;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg20110707	chr11:118481992	PHLDB1	0.5	10.4	0.44	6.76e-23	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	cis	rs7296418	0.636	rs11057261	chr12:123797567	T/C	cg05973401	chr12:123451056	ABCB9	0.44	7.4	0.33	6.4e-13	Platelet count;
LGG	cis	rs2013441	1.000	rs34644796	chr17:20064128	C/G	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.98	-0.42	2.21e-21	Educational attainment;
LGG	cis	rs2239547	0.603	rs71301807	chr3:53085475	C/G	cg11645453	chr3:52864694	ITIH4	0.65	9.95	0.42	2.76e-21	Schizophrenia;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4076764	0.914	rs4638099	chr1:163365521	A/G	cg24596788	chr1:163392923	NA	0.71	13.34	0.53	1.47e-34	Motion sickness;
LGG	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg26384229	chr12:38710491	ALG10B	1.0	24.79	0.76	5.51e-87	Heart rate;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg00184235	chr8:126442434	TRIB1	-0.41	-6.89	-0.3	1.86e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs526231	0.511	rs7731395	chr5:102361761	G/T	cg23492399	chr5:102201601	PAM	-0.56	-8.3	-0.36	1.16e-15	Primary biliary cholangitis;
LGG	cis	rs7192750	0.539	rs12599192	chr16:71979097	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.71	0.45	4.59e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs4363385	0.747	rs2339493	chr1:152975277	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15912797	chr10:76586382	MYST4	0.5	7.69	0.34	8.75e-14	Gut microbiome composition (summer);
LGG	trans	rs9818758	0.556	rs11716614	chr3:49017208	C/G	cg21659725	chr3:3221576	CRBN	-0.71	-6.7	-0.3	6.03e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg03188948	chr7:1209495	NA	0.39	6.67	0.3	7.2e-11	Longevity;Endometriosis;
LGG	cis	rs56146971	0.763	rs77450079	chr14:91863924	A/C	cg14409461	chr14:91925021	SMEK1	-0.43	-7.0	-0.31	9.03e-12	Alzheimer disease and age of onset;
LGG	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.66	11.28	0.46	3.18e-26	Menarche (age at onset);
LGG	cis	rs7241530	0.662	rs7244362	chr18:75906793	T/C	cg14642773	chr18:75888474	NA	0.47	9.28	0.4	6.56e-19	Educational attainment (years of education);
LGG	cis	rs9467773	0.620	rs1027204	chr6:26639613	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.55	-0.5	2.61e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg25172604	chr17:41446521	NA	0.3	7.21	0.32	2.26e-12	Menopause (age at onset);
LGG	cis	rs12451471	0.637	rs12950757	chr17:78096800	T/G	cg06718696	chr17:78121285	EIF4A3	0.92	14.96	0.57	1.49e-41	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1878931	0.696	rs35175748	chr16:3445427	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	23.29	0.73	5.44e-80	Body mass index (adult);
LGG	cis	rs2901331	0.629	rs6737833	chr2:125361628	T/C	cg07771321	chr2:125368595	CNTNAP5	-0.48	-8.2	-0.36	2.36e-15	Response to statin therapy;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg16339924	chr4:17578868	LAP3	0.64	11.11	0.46	1.35e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg22907277	chr7:1156413	C7orf50	0.53	7.28	0.32	1.49e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs77303550	1.000	rs77303550	chr16:72079657	C/T	cg01557791	chr16:72042693	DHODH	0.58	8.25	0.36	1.71e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs12477438	0.520	rs6542863	chr2:99725138	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs4631830	0.720	rs898343	chr10:51505403	A/G	cg10326726	chr10:51549505	MSMB	0.62	12.54	0.5	2.87e-31	Prostate-specific antigen levels;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17554472	chr22:41940697	POLR3H	0.47	6.73	0.3	5.14e-11	Vitiligo;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg04287289	chr16:89883240	FANCA	0.89	8.6	0.37	1.23e-16	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01628954	chr18:60190696	ZCCHC2	0.5	7.55	0.33	2.3e-13	Gut microbiome composition (summer);
LGG	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg00012203	chr2:219082015	ARPC2	0.69	12.76	0.51	3.65e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs7395662	0.963	rs7119550	chr11:48927654	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.61	-0.33	1.56e-13	HDL cholesterol;
LGG	cis	rs1577917	0.761	rs117452258	chr6:86554211	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.23e-17	Response to antipsychotic treatment;
LGG	trans	rs7939886	0.841	rs11227702	chr11:56034774	A/C	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs2712184	0.756	rs2712182	chr2:217647525	T/C	cg05032264	chr2:217675019	NA	-0.43	-9.33	-0.4	4.5e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg27411982	chr8:10470053	RP1L1	-0.42	-6.98	-0.31	1.06e-11	Morning vs. evening chronotype;
LGG	cis	rs514406	0.929	rs557847	chr1:53333116	A/G	cg24675658	chr1:53192096	ZYG11B	-0.48	-9.4	-0.4	2.44e-19	Monocyte count;
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg09038676	chr11:67351608	GSTP1	-0.36	-7.14	-0.32	3.59e-12	Mean corpuscular volume;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.03	-0.35	7.92e-15	Personality dimensions;
LGG	cis	rs7911264	0.628	rs7921040	chr10:94418425	G/A	cg25093409	chr10:94429542	NA	0.43	8.78	0.38	3.18e-17	Inflammatory bowel disease;
LGG	cis	rs8031584	0.578	rs1088473	chr15:31139298	A/G	cg08109568	chr15:31115862	NA	0.59	10.03	0.42	1.49e-21	Huntington's disease progression;
LGG	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.3	-0.36	1.19e-15	Intelligence (multi-trait analysis);
LGG	cis	rs17504614	0.597	rs17569942	chr2:51077479	T/C	cg23851515	chr2:51057218	NRXN1	0.74	10.92	0.45	7.15e-25	Educational attainment (years of education);
LGG	cis	rs1218582	0.772	rs7528532	chr1:154874440	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs929354	0.772	rs1002389	chr7:156968323	C/G	cg17757837	chr7:157058334	UBE3C	0.76	15.42	0.58	1.3e-43	Body mass index;
LGG	cis	rs11651000	0.761	rs11079788	chr17:45820723	C/T	cg06532163	chr17:45867833	NA	0.51	7.82	0.34	3.72e-14	IgG glycosylation;
LGG	cis	rs26868	0.690	rs26835	chr16:2237549	C/T	cg02248941	chr16:2239361	CASKIN1	0.48	9.69	0.41	2.38e-20	Height;
LGG	cis	rs17767392	0.748	rs58952176	chr14:71704043	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.25	-0.32	1.74e-12	Mitral valve prolapse;
LGG	cis	rs7582720	1.000	rs114702158	chr2:203821793	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.86	-0.42	6.04e-21	Triglycerides;
LGG	cis	rs7264396	0.635	rs6088971	chr20:34535373	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.29	0.32	1.34e-12	Total cholesterol levels;
LGG	trans	rs10802346	0.545	rs12134404	chr1:246372144	A/G	cg22732515	chr19:44031385	ETHE1	0.54	9.41	0.4	2.27e-19	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs7980799	0.840	rs7315695	chr12:33551841	G/C	cg13010199	chr12:38710504	ALG10B	-0.38	-6.77	-0.3	4e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg02297831	chr4:17616191	MED28	0.44	8.01	0.35	9.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1801251	1.000	rs2012221	chr2:233566848	T/C	cg25237894	chr2:233734115	C2orf82	0.64	12.19	0.49	7.95e-30	Coronary artery disease;
LGG	cis	rs10463316	0.862	rs59390562	chr5:150776092	A/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.14	-0.43	5.91e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs9354308	0.868	rs2882754	chr6:66537341	A/G	cg07460842	chr6:66804631	NA	0.49	8.31	0.36	1.04e-15	Metabolite levels;
LGG	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg15704280	chr7:45808275	SEPT13	-0.98	-21.55	-0.71	7.94e-72	Height;
LGG	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg27129171	chr3:47204927	SETD2	-0.75	-14.26	-0.55	1.65e-38	Colorectal cancer;
LGG	cis	rs2730245	0.661	rs842696	chr7:158662698	T/C	cg24397884	chr7:158709396	WDR60	0.9	18.11	0.64	8.11e-56	Height;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs4646302	chr5:131712482	G/C	cg21911579	chr5:131705225	SLC22A5	0.67	7.49	0.33	3.41e-13	Rheumatoid arthritis;
LGG	cis	rs2762353	0.904	rs13197514	chr6:25785991	C/T	cg12310025	chr6:25882481	NA	0.53	9.84	0.42	7.17e-21	Blood metabolite levels;
LGG	cis	rs1806153	0.551	rs1540319	chr11:31837617	C/G	cg11990419	chr11:31841155	NA	0.34	7.86	0.34	2.8e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs1124376	1.000	rs11712709	chr3:20139777	G/C	cg05072819	chr3:20081367	KAT2B	0.64	8.53	0.37	2.15e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs887829	0.570	rs10168155	chr2:234596836	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9354308	0.764	rs9354326	chr6:66587473	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs34599045	0.901	rs12239648	chr1:152879091	A/T	cg07796016	chr1:152779584	LCE1C	-0.82	-8.48	-0.37	3.02e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6787172	0.783	rs6441201	chr3:158178324	G/A	cg23275840	chr4:47708675	CORIN	-0.33	-6.72	-0.3	5.35e-11	Subjective well-being;
LGG	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs7537765	0.696	rs2075538	chr1:11896602	C/T	cg02448276	chr1:11845238	NA	0.55	6.95	0.31	1.25e-11	QRS complex (12-leadsum);
LGG	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg11846333	chr4:119757529	SEC24D	0.84	7.8	0.34	4.07e-14	Cannabis dependence symptom count;
LGG	trans	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.52	0.4	9.67e-20	Diabetic kidney disease;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg05665937	chr4:1216051	CTBP1	-0.49	-8.81	-0.38	2.63e-17	Obesity-related traits;
LGG	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg14092988	chr3:52407081	DNAH1	0.43	11.66	0.48	9.77e-28	Bipolar disorder;
LGG	cis	rs2304069	0.545	rs7445660	chr5:149413610	A/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.0	0.35	1e-14	HIV-1 control;
LGG	cis	rs1577917	0.839	rs1447159	chr6:86609249	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.88	-0.42	5.12e-21	Response to antipsychotic treatment;
LGG	cis	rs13177180	0.602	rs813761	chr5:114871727	A/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.32	-6.93	-0.31	1.43e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.16e-41	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00657871	chr1:85156634	SSX2IP	0.45	7.41	0.33	6.17e-13	Cognitive performance;
LGG	cis	rs476633	0.691	rs28409265	chr15:41539404	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.4	-0.44	6.45e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs2236267	0.600	rs993688	chr14:88616722	A/T	cg02175263	chr14:88627849	NA	0.32	7.27	0.32	1.52e-12	Food antigen IgG levels;
LGG	cis	rs4077515	0.874	rs10781505	chr9:139271355	C/T	cg21253087	chr9:139290292	SNAPC4	-0.37	-7.53	-0.33	2.67e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1728785	1.000	rs1364109	chr16:68595505	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24395307	chr7:39990042	CDK13	0.41	7.21	0.32	2.24e-12	Bilirubin levels;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.32	-0.32	1.11e-12	Prostate cancer;
LGG	cis	rs1474256	0.630	rs79015977	chr15:79450147	G/A	cg17916960	chr15:79447300	NA	0.44	7.25	0.32	1.7e-12	Bronchopulmonary dysplasia;
LGG	cis	rs721917	0.506	rs2819098	chr10:81698097	G/A	cg25562619	chr10:81652821	NA	-0.34	-7.67	-0.34	1.01e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs6489882	0.807	rs61266553	chr12:113371977	A/G	cg25319449	chr12:113376135	OAS3	-0.39	-7.26	-0.32	1.67e-12	Chronic lymphocytic leukemia;
LGG	cis	rs911263	0.603	rs12885750	chr14:68770031	T/G	cg18825221	chr14:68749962	RAD51L1	0.36	7.92	0.35	1.84e-14	Primary biliary cholangitis;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	0.758	rs2971610	chr6:97027380	C/T	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.6	-0.37	1.24e-16	Headache;
LGG	cis	rs3816183	1.000	rs6544597	chr2:43013593	T/G	cg14631114	chr2:43023945	NA	0.51	9.6	0.41	5.08e-20	Hypospadias;
LGG	trans	rs9650657	0.504	rs6601566	chr8:11042974	G/T	cg16141378	chr3:129829833	LOC729375	0.33	7.62	0.33	1.49e-13	Neuroticism;
LGG	cis	rs9815354	0.597	rs17283481	chr3:41924015	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.29	0.36	1.2e-15	Lung cancer;
LGG	cis	rs929354	0.553	rs34498858	chr7:156931337	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs1949733	1.000	rs3103099	chr4:8511567	G/A	cg13073564	chr4:8508604	NA	0.55	10.17	0.43	4.61e-22	Response to antineoplastic agents;
LGG	cis	rs7208859	0.614	rs4794874	chr17:28841318	C/T	cg01831904	chr17:28903510	LRRC37B2	0.67	8.37	0.36	7.11e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg16400903	chr5:693638	TPPP	0.42	6.68	0.3	6.87e-11	Obesity-related traits;
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg23188684	chr11:67383651	NA	-0.42	-6.73	-0.3	5.12e-11	Mean corpuscular volume;
LGG	cis	rs4689388	0.926	rs10937720	chr4:6295451	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg11301795	chr4:187892539	NA	0.94	24.82	0.76	4.27e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg23461800	chr14:103021989	NA	-0.59	-10.93	-0.45	6.94e-25	Platelet count;
LGG	cis	rs2270450	0.513	rs1421369	chr6:46700706	C/T	cg10156739	chr6:46714674	LOC100287718	-0.3	-7.07	-0.31	5.58e-12	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs882632	0.645	rs17692899	chr2:29285254	C/T	cg23429306	chr2:29287725	C2orf71	0.37	7.34	0.32	9.98e-13	Major depressive disorder;
LGG	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg02975922	chr3:195473998	MUC4	-0.54	-9.03	-0.39	4.73e-18	Pancreatic cancer;
LGG	cis	rs62238980	0.614	rs79924624	chr22:32497245	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs514024	0.700	rs472144	chr9:130489558	A/G	cg13643465	chr9:130375613	STXBP1	0.59	11.3	0.46	2.65e-26	Eating disorders (purging via substances);
LGG	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg00405596	chr8:11794950	NA	0.48	8.26	0.36	1.53e-15	Neuroticism;
LGG	cis	rs7662987	0.517	rs2851256	chr4:100039549	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg07511668	chr11:68622177	NA	0.48	9.09	0.39	2.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg16141378	chr3:129829833	LOC729375	0.4	8.96	0.38	7.69e-18	Retinal vascular caliber;
LGG	cis	rs2204008	0.744	rs1115514	chr12:38280140	C/T	cg13010199	chr12:38710504	ALG10B	0.65	13.42	0.53	6.27e-35	Bladder cancer;
LGG	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.47	7.5	0.33	3.28e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11677416	0.677	rs2856840	chr2:113538604	T/A	cg27083787	chr2:113543245	IL1A	0.53	8.85	0.38	1.93e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs7923837	0.687	rs10882101	chr10:94462427	T/C	cg25093409	chr10:94429542	NA	0.52	10.46	0.44	3.92e-23	Body mass index;Multiple sclerosis;
LGG	cis	rs3858526	0.834	rs10838986	chr11:5977065	A/G	cg25319279	chr11:5960081	NA	-0.55	-8.62	-0.37	1.1e-16	DNA methylation (variation);
LGG	cis	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs2028299	0.959	rs4932144	chr15:90372102	T/C	cg23731826	chr15:90371692	NA	0.38	8.66	0.37	7.64e-17	Type 2 diabetes;
LGG	cis	rs8114671	0.967	rs6142320	chr20:33788193	A/G	cg07148914	chr20:33460835	GGT7	-0.42	-6.75	-0.3	4.47e-11	Height;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg26174226	chr8:58114915	NA	-0.6	-8.63	-0.37	9.85e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.739	rs9344532	chr6:86234070	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.78	0.48	3.5e-28	Response to antipsychotic treatment;
LGG	cis	rs922107	0.967	rs6428556	chr1:90019581	C/T	cg01128109	chr1:89989507	LRRC8B	-0.33	-7.48	-0.33	3.87e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	trans	rs587242	0.955	rs7541994	chr1:96984344	C/T	cg10631902	chr5:14652156	NA	0.42	7.56	0.33	2.25e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically inactive individuals;Body mass index;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.9	-11.31	-0.47	2.32e-26	Longevity;Endometriosis;
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg02772935	chr3:125709198	NA	-0.55	-7.09	-0.31	5.11e-12	Blood pressure (smoking interaction);
LGG	trans	rs9951602	0.512	rs9958376	chr18:76655167	G/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.66	0.54	6.3e-36	Obesity-related traits;
LGG	cis	rs3815700	0.920	rs10424732	chr19:33096487	C/T	cg02997394	chr19:33096574	ANKRD27	0.96	13.41	0.53	7.18e-35	Eosinophilic esophagitis;
LGG	cis	rs9715521	0.775	rs11931812	chr4:59844473	T/C	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg11984989	chr7:158649758	WDR60	-1.01	-14.33	-0.55	8.11e-39	Height;
LGG	cis	rs12464483	0.591	rs72800120	chr2:30897122	G/A	cg17749961	chr2:30669863	LCLAT1	0.8	10.8	0.45	2.2e-24	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.64	0.33	1.29e-13	Longevity;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg02725872	chr8:58115012	NA	-0.93	-11.99	-0.49	5.14e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs952623	0.501	rs12671046	chr7:39081866	C/T	cg18850127	chr7:39170497	POU6F2	-0.36	-8.36	-0.36	7.4e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.3e-11	Aortic root size;
LGG	cis	rs9403521	0.947	rs7741424	chr6:143981662	G/A	cg18240653	chr6:144019428	PHACTR2	-0.65	-9.73	-0.41	1.83e-20	Obesity-related traits;
LGG	cis	rs2404602	0.647	rs1443115	chr15:77041829	T/C	cg15268244	chr15:77196840	NA	0.49	10.46	0.44	3.94e-23	Blood metabolite levels;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg16590910	chr6:42928470	GNMT	0.44	12.98	0.52	4.67e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg26354017	chr1:205819088	PM20D1	0.87	20.7	0.69	7.15e-68	Menarche (age at onset);
LGG	cis	rs919433	0.647	rs13404366	chr2:198522632	A/G	cg00792783	chr2:198669748	PLCL1	0.49	7.89	0.34	2.13e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg05973401	chr12:123451056	ABCB9	0.45	6.67	0.3	7.33e-11	Neutrophil percentage of white cells;
LGG	cis	rs921968	0.541	rs488767	chr2:219466860	G/T	cg01130898	chr2:219473002	PLCD4	-0.44	-7.58	-0.33	1.86e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs8180040	0.966	rs3736177	chr3:47451411	C/T	cg16586182	chr3:47516702	SCAP	0.78	15.58	0.59	2.67e-44	Colorectal cancer;
LGG	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg15325629	chr6:28072465	NA	0.99	7.6	0.33	1.65e-13	Parkinson's disease;
LGG	cis	rs644799	0.763	rs2950521	chr11:95536870	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs727505	0.607	rs59635547	chr7:124796371	A/C	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg11062466	chr8:58055876	NA	0.51	7.83	0.34	3.3e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4006360	0.686	rs1848814	chr17:39240281	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.14	-0.46	1.04e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7927771	0.524	rs10838746	chr11:47706291	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.18	0.46	7.26e-26	Subjective well-being;
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg26174226	chr8:58114915	NA	0.51	7.65	0.34	1.15e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg05861140	chr6:150128134	PCMT1	-0.35	-6.73	-0.3	5.05e-11	Lung cancer;
LGG	cis	rs2011503	0.943	rs10406278	chr19:19494725	A/C	cg11584989	chr19:19387371	SF4	-0.74	-12.12	-0.49	1.54e-29	Bipolar disorder;
LGG	cis	rs7829975	0.714	rs11784052	chr8:8671962	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.48	0.37	3.12e-16	Mood instability;
LGG	cis	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg06636001	chr8:8085503	FLJ10661	0.64	12.71	0.51	5.64e-32	Systolic blood pressure;
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg10840412	chr1:235813424	GNG4	-0.54	-7.35	-0.32	9.21e-13	Bipolar disorder;
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.92	-0.31	1.49e-11	Monocyte percentage of white cells;
LGG	cis	rs1799949	0.602	rs4600503	chr17:41414324	C/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.7	-0.37	5.67e-17	Menopause (age at onset);
LGG	cis	rs17221829	0.965	rs10830368	chr11:89459706	C/T	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.68	-0.34	9.75e-14	Anxiety in major depressive disorder;
LGG	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.78	-0.41	1.22e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16519705	chr1:6240038	CHD5	0.58	6.79	0.3	3.37e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7086627	0.515	rs10887905	chr10:82210855	A/T	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs3796619	1.000	rs1466215	chr4:1072220	C/T	cg21130718	chr4:1044621	NA	0.39	7.63	0.33	1.31e-13	Recombination rate (males);
LGG	cis	rs10754283	0.967	rs7513928	chr1:90104834	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.26	-0.32	1.67e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg03701759	chr13:99174930	STK24	-0.35	-6.72	-0.3	5.48e-11	Longevity;
LGG	cis	rs1008375	0.932	rs7677212	chr4:17675932	A/G	cg18681998	chr4:17616180	MED28	-0.82	-17.42	-0.63	1.2e-52	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1729951	0.575	rs361241	chr3:136699561	C/A	cg21827317	chr3:136751795	NA	0.53	10.05	0.42	1.25e-21	Neuroticism;
LGG	cis	rs3768617	0.510	rs6691755	chr1:183099821	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs151450	1	rs151450	chr4:88016514	G/A	cg11209507	chr4:87813803	C4orf36	0.45	7.03	0.31	7.5e-12	Basophil percentage of white cells;
LGG	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg00938859	chr5:1591904	SDHAP3	0.89	13.05	0.52	2.23e-33	Breast cancer;
LGG	trans	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17712092	chr4:129076599	LARP1B	0.74	14.4	0.56	4.13e-39	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs55871839	0.684	rs10095333	chr8:59815629	G/A	cg07426533	chr8:59803705	TOX	-0.58	-13.2	-0.52	5.65e-34	Pneumonia;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg14926445	chr8:58193284	C8orf71	-0.84	-10.55	-0.44	1.76e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12410462	0.681	rs74582965	chr1:227610126	C/T	cg04117972	chr1:227635322	NA	0.82	13.05	0.52	2.26e-33	Major depressive disorder;
LGG	cis	rs10193935	0.901	rs7570083	chr2:42517859	G/A	cg27598129	chr2:42591480	NA	-0.56	-8.47	-0.37	3.22e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.71	0.34	7.75e-14	Retinal vascular caliber;
LGG	cis	rs35306767	0.807	rs61831436	chr10:837882	G/A	cg20503657	chr10:835505	NA	0.95	12.83	0.51	1.87e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7166081	0.950	rs12915601	chr15:67631271	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.87	-0.3	2.13e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9583531	0.600	rs6492306	chr13:111361693	G/A	cg24331049	chr13:111365604	ING1	0.84	15.46	0.58	8.69e-44	Coronary artery disease;
LGG	cis	rs9916302	0.706	rs594794	chr17:37453485	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs17125944	0.615	rs4901301	chr14:53306485	C/T	cg00686598	chr14:53173677	PSMC6	-0.73	-7.4	-0.33	6.51e-13	Alzheimer's disease (late onset);
LGG	cis	rs55871839	0.708	rs7000535	chr8:59804351	T/C	cg07426533	chr8:59803705	TOX	-0.56	-12.71	-0.51	5.65e-32	Pneumonia;
LGG	cis	rs988958	0.675	rs7597889	chr2:42220091	T/C	cg27252766	chr2:42229092	NA	0.52	8.26	0.36	1.58e-15	Hypospadias;
LGG	cis	rs4006360	0.646	rs11868364	chr17:39236968	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.56	-0.47	2.49e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs2243480	0.901	rs1701759	chr7:65470932	G/T	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	1.01e-20	Diabetic kidney disease;
LGG	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.39	-0.36	6.15e-16	Response to antipsychotic treatment;
LGG	cis	rs300774	0.925	rs300709	chr2:139743	C/T	cg04617936	chr2:214353	NA	0.44	6.67	0.3	7.51e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs10751667	0.666	rs7395823	chr11:942701	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs701145	0.617	rs9820619	chr3:154028294	G/T	cg12800244	chr3:153838788	SGEF	0.55	7.6	0.33	1.63e-13	Coronary artery disease;
LGG	cis	rs2455601	0.574	rs2568094	chr11:8992218	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.65	-11.21	-0.46	5.83e-26	Schizophrenia;
LGG	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg04568710	chr12:38710424	ALG10B	0.34	6.79	0.3	3.55e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1997103	1.000	rs2331064	chr7:55408610	C/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs41271951	0.512	rs12070256	chr1:151070090	C/T	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	cis	rs9952991	0.941	rs1893217	chr18:12809340	A/G	cg23598886	chr18:12777645	NA	-0.66	-8.85	-0.38	1.91e-17	Inflammatory skin disease;
LGG	cis	rs11722228	1.000	rs4697695	chr4:9915850	C/T	cg25986240	chr4:9926439	SLC2A9	-0.71	-16.22	-0.6	3.63e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs35740288	0.752	rs11636138	chr15:86287547	T/A	cg04173714	chr15:86211321	AKAP13	0.42	7.19	0.32	2.59e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.62	-0.37	1.09e-16	Body mass index;
LGG	cis	rs2562456	0.720	rs6511250	chr19:21656046	C/T	cg00806126	chr19:22604979	ZNF98	0.63	9.19	0.39	1.37e-18	Pain;
LGG	cis	rs7659604	0.540	rs7676867	chr4:122671315	T/C	cg19748678	chr4:122722346	EXOSC9	-0.45	-7.75	-0.34	5.79e-14	Type 2 diabetes;
LGG	cis	rs13082711	0.516	rs1492339	chr3:27371526	A/C	cg02860705	chr3:27208620	NA	-0.63	-11.96	-0.49	6.73e-29	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4332037	0.664	rs73046334	chr7:1887037	T/C	cg12591125	chr7:1885375	MAD1L1	0.46	7.2	0.32	2.49e-12	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg06558623	chr16:89946397	TCF25	1.19	13.77	0.54	2.19e-36	Skin colour saturation;
LGG	cis	rs911555	0.755	rs2756135	chr14:103962579	G/A	cg24130564	chr14:104152367	KLC1	0.39	7.23	0.32	2.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2718058	0.517	rs11972986	chr7:37799809	A/G	cg15028436	chr7:37888078	TXNDC3	-0.49	-7.81	-0.34	3.79e-14	Alzheimer's disease (late onset);
LGG	cis	rs953387	0.910	rs72976292	chr2:136929107	T/A	cg07169764	chr2:136633963	MCM6	0.53	8.62	0.37	1.04e-16	Arthritis (juvenile idiopathic);
LGG	cis	rs8177179	0.505	rs1405023	chr3:133481128	T/C	cg08048268	chr3:133502702	NA	0.42	7.53	0.33	2.72e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg19680485	chr15:31195859	MTMR15	-0.47	-7.61	-0.33	1.53e-13	Huntington's disease progression;
LGG	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.15	-0.32	3.38e-12	Blood metabolite levels;
LGG	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg12463550	chr7:65579703	CRCP	0.49	8.26	0.36	1.57e-15	Aortic root size;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.59	-10.23	-0.43	2.74e-22	Lymphocyte counts;
LGG	cis	rs13040088	1.000	rs2273412	chr20:61553802	G/A	cg23096297	chr20:61557774	DIDO1	0.88	12.12	0.49	1.43e-29	Menopause (age at onset);
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.14	-0.49	1.19e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2841277	0.646	rs3742935	chr14:105405599	G/C	cg22072935	chr14:105399595	NA	0.52	10.12	0.43	7.21e-22	Rheumatoid arthritis;
LGG	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.05	-0.35	7.24e-15	IgG glycosylation;
LGG	cis	rs174601	0.615	rs174534	chr11:61549458	C/T	cg19610905	chr11:61596333	FADS2	0.69	12.12	0.49	1.52e-29	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs9880211	1.000	rs9880211	chr3:136107549	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.9	-0.31	1.75e-11	Body mass index;Height;
LGG	cis	rs4704846	1.000	rs6555849	chr5:156529647	A/G	cg12943317	chr5:156479607	HAVCR1	-0.58	-7.47	-0.33	3.89e-13	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22798821	chr11:11864085	USP47	0.52	8.34	0.36	8.4e-16	Gut microbiome composition (summer);
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg06925179	chr17:43578568	NA	-0.31	-8.17	-0.35	2.97e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7681440	0.647	rs4522832	chr4:90819391	A/C	cg20003494	chr4:90757398	SNCA	-0.34	-6.7	-0.3	6.21e-11	Dementia with Lewy bodies;
LGG	cis	rs911119	0.909	rs111360484	chr20:23618984	G/C	cg16589663	chr20:23618590	CST3	0.48	6.75	0.3	4.41e-11	Chronic kidney disease;
LGG	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.65	-0.41	3.5e-20	Diabetic retinopathy;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg14004847	chr7:1930337	MAD1L1	-0.52	-9.12	-0.39	2.25e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs6988985	0.560	rs4736346	chr8:143951849	G/T	cg10324643	chr8:143916377	GML	0.43	8.87	0.38	1.65e-17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7312774	0.618	rs2888892	chr12:107328071	C/T	cg16260113	chr12:107380972	MTERFD3	1.03	9.63	0.41	3.88e-20	Severe influenza A (H1N1) infection;
LGG	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg18709589	chr6:96969512	KIAA0776	0.45	7.46	0.33	4.41e-13	Migraine;Coronary artery disease;
LGG	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.51e-13	IgG glycosylation;
LGG	cis	rs7241530	0.585	rs35890268	chr18:75891169	T/C	cg14642773	chr18:75888474	NA	0.46	9.05	0.39	3.9e-18	Educational attainment (years of education);
LGG	cis	rs9322193	0.923	rs10872644	chr6:150062955	T/C	cg16507663	chr6:150244633	RAET1G	0.43	8.14	0.35	3.66e-15	Lung cancer;
LGG	cis	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg03213289	chr20:61660250	NA	0.66	14.35	0.55	6.59e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9325144	0.581	rs6582564	chr12:38671282	G/A	cg26384229	chr12:38710491	ALG10B	-0.81	-17.23	-0.63	9.22e-52	Morning vs. evening chronotype;
LGG	cis	rs12908161	1.000	rs12908161	chr15:85207825	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.22	0.32	2.15e-12	Schizophrenia;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.51	0.33	3.11e-13	Menopause (age at onset);
LGG	cis	rs6977660	0.943	rs10227692	chr7:19850199	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	8.57	0.37	1.56e-16	Thyroid stimulating hormone;
LGG	cis	rs16854884	0.657	rs35193361	chr3:143716420	A/G	cg06585982	chr3:143692056	C3orf58	0.58	9.78	0.41	1.2e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs11971779	0.616	rs6949963	chr7:139054325	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg22961513	chr11:14280813	SPON1	-0.3	-7.35	-0.32	8.95e-13	Mitochondrial DNA levels;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg02951883	chr7:2050386	MAD1L1	-0.72	-14.49	-0.56	1.64e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg12473912	chr3:136751656	NA	-0.44	-7.77	-0.34	4.94e-14	Neuroticism;
LGG	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.86	0.54	8.56e-37	Cognitive test performance;
LGG	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-8.09	-0.35	5.37e-15	Blood metabolite levels;
LGG	trans	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1e-12	Myopia (pathological);
LGG	cis	rs13132184	0.586	rs57426850	chr4:38013956	C/T	cg24826020	chr4:38070998	TBC1D1	0.46	6.95	0.31	1.27e-11	Verbal declarative memory;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.11	-0.31	4.46e-12	Obesity-related traits;
LGG	cis	rs3820928	0.904	rs4129884	chr2:227820943	G/A	cg11843606	chr2:227700838	RHBDD1	-0.47	-8.08	-0.35	5.85e-15	Pulmonary function;
LGG	cis	rs3540	0.574	rs2657946	chr15:90967513	G/C	cg22089800	chr15:90895588	ZNF774	0.68	12.42	0.5	9.23e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs875971	0.862	rs4718330	chr7:65715243	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.6	-0.37	1.28e-16	Aortic root size;
LGG	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-7.95	-0.35	1.47e-14	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg15485101	chr11:133734466	NA	0.59	10.43	0.44	5.33e-23	Childhood ear infection;
LGG	trans	rs6582630	0.555	rs10748382	chr12:38504529	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.76	-0.38	3.75e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.692	rs57178708	chr15:76904069	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.06	0.39	3.76e-18	Blood metabolite levels;
LGG	cis	rs3780378	0.935	rs2149560	chr9:5082106	G/T	cg02405213	chr9:5042618	JAK2	-0.51	-8.84	-0.38	1.96e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg16751781	chr15:78858589	CHRNA5	-0.39	-7.15	-0.32	3.36e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.42	-0.47	8.94e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.754	rs2036856	chr4:120249288	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs7223966	0.921	rs7225092	chr17:61864005	G/T	cg05941027	chr17:61774174	LIMD2	0.37	9.45	0.4	1.73e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9878978	0.722	rs13074595	chr3:2502545	T/G	cg21928760	chr3:2462534	CNTN4	0.38	7.55	0.33	2.41e-13	Blood pressure (smoking interaction);
LGG	cis	rs6456042	0.965	rs6927190	chr6:166539539	G/A	cg11088901	chr6:166572345	T	-0.35	-7.38	-0.32	7.56e-13	Asthma;
LGG	cis	rs350251	0.934	rs350256	chr16:12207491	G/A	cg02910054	chr16:12241554	SNX29	0.43	7.93	0.35	1.63e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg04287289	chr16:89883240	FANCA	0.74	7.88	0.34	2.31e-14	Skin colour saturation;
LGG	cis	rs7916697	0.842	rs4746749	chr10:70009389	C/T	cg18338521	chr10:69995036	NA	0.33	7.22	0.32	2.21e-12	Optic disc area;
LGG	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.36	0.43	9.08e-23	Diabetic retinopathy;
LGG	cis	rs7666738	0.791	rs10856933	chr4:98958542	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9944715	1.000	rs7239351	chr18:43851338	A/T	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.74	-0.3	4.69e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2562456	0.917	rs2650804	chr19:21680184	A/G	cg00806126	chr19:22604979	ZNF98	-0.59	-8.88	-0.38	1.5e-17	Pain;
LGG	trans	rs10435719	0.834	rs6985792	chr8:11795335	T/C	cg06636001	chr8:8085503	FLJ10661	0.49	8.76	0.38	3.74e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4684776	1.000	rs4618208	chr3:11473679	A/G	cg24705426	chr3:11550659	ATG7	-0.44	-7.92	-0.35	1.8e-14	Small vessel stroke;
LGG	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg06637938	chr14:75390232	RPS6KL1	0.59	10.93	0.45	6.83e-25	Height;
LGG	cis	rs7017914	0.967	rs7014012	chr8:71672743	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs13191362	0.935	rs7763118	chr6:162954720	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	6.94	0.31	1.3e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2028299	0.840	rs17242083	chr15:90449476	C/T	cg23731826	chr15:90371692	NA	0.35	7.72	0.34	7.34e-14	Type 2 diabetes;
LGG	cis	rs9880211	0.898	rs6770476	chr3:136073920	C/T	cg21827317	chr3:136751795	NA	-0.51	-8.48	-0.37	3.01e-16	Body mass index;Height;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg19168338	chr16:4465731	CORO7	-0.96	-19.03	-0.66	4.54e-60	Schizophrenia;
LGG	cis	rs1847505	0.562	rs1554022	chr13:61429211	G/A	cg25164009	chr13:61490935	NA	0.57	9.61	0.41	4.56e-20	Polychlorinated biphenyl levels;
LGG	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.36	-0.43	9.58e-23	Neuroticism;
LGG	trans	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg04842962	chr6:43655489	MRPS18A	0.97	16.0	0.6	3.31e-46	IgG glycosylation;
LGG	cis	rs9309473	0.607	rs2421488	chr2:73590625	C/T	cg20560298	chr2:73613845	ALMS1	-0.5	-9.08	-0.39	3.21e-18	Metabolite levels;
LGG	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg20587970	chr11:113659929	NA	-1.3	-24.25	-0.75	1.8e-84	Hip circumference adjusted for BMI;
LGG	cis	rs2404602	0.655	rs34748201	chr15:77221530	G/T	cg23625390	chr15:77176239	SCAPER	0.48	9.1	0.39	2.79e-18	Blood metabolite levels;
LGG	cis	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs6787391	0.933	rs9871443	chr3:4747105	T/G	cg11584376	chr3:4789075	ITPR1	-0.34	-6.92	-0.31	1.5e-11	Breast cancer;
LGG	cis	rs2153535	0.580	rs1932283	chr6:8477661	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.56e-22	Motion sickness;
LGG	cis	rs36051895	0.632	rs12115301	chr9:5180548	A/G	cg02405213	chr9:5042618	JAK2	0.77	14.64	0.56	3.77e-40	Pediatric autoimmune diseases;
LGG	cis	rs1862618	0.613	rs252889	chr5:56227069	C/A	cg17809284	chr5:56205270	C5orf35	-0.54	-10.13	-0.43	6.2e-22	Initial pursuit acceleration;
LGG	cis	rs41271473	1.000	rs11580020	chr1:228880466	A/G	cg16512390	chr1:228756714	NA	-0.48	-6.69	-0.3	6.45e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1620921	0.625	rs12173859	chr6:161266513	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.06e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg16434002	chr17:42200994	HDAC5	-0.53	-9.71	-0.41	2.14e-20	Total body bone mineral density;
LGG	cis	rs2404602	0.692	rs12913810	chr15:77166675	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.44	0.4	1.84e-19	Blood metabolite levels;
LGG	cis	rs7726839	0.574	rs72705014	chr5:619815	C/G	cg14541582	chr5:601475	NA	-0.68	-10.59	-0.44	1.29e-23	Obesity-related traits;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg06873352	chr17:61820015	STRADA	-0.67	-11.77	-0.48	3.83e-28	Prudent dietary pattern;
LGG	cis	rs62238980	0.614	rs976916	chr22:32428558	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.3	0.4	5.52e-19	Rheumatoid arthritis;
LGG	cis	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg00405596	chr8:11794950	NA	0.42	7.13	0.31	3.95e-12	Monocyte count;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg22433210	chr17:43662623	NA	0.91	15.16	0.58	1.91e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg01420254	chr6:26195488	NA	0.88	11.69	0.48	7.89e-28	Gout;Renal underexcretion gout;
LGG	cis	rs6800768	0.633	rs57903454	chr3:24092407	A/T	cg10674438	chr3:24145617	LOC152024	-0.48	-8.71	-0.38	5.36e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg17467752	chr17:38218738	THRA	-0.43	-6.98	-0.31	1.02e-11	Self-reported allergy;
LGG	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs9302635	0.513	rs8044555	chr16:72152755	T/C	cg01557791	chr16:72042693	DHODH	-0.58	-9.09	-0.39	2.82e-18	Blood protein levels;
LGG	cis	rs113835537	0.529	rs2279865	chr11:66203025	A/C	cg24851651	chr11:66362959	CCS	0.44	7.71	0.34	7.89e-14	Airway imaging phenotypes;
LGG	cis	rs832540	0.864	rs832576	chr5:56163255	C/A	cg14703610	chr5:56206110	C5orf35	0.4	6.9	0.31	1.75e-11	Coronary artery disease;
LGG	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg23188684	chr11:67383651	NA	-0.42	-6.89	-0.3	1.84e-11	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg07701084	chr6:150067640	NUP43	0.69	13.29	0.53	2.25e-34	Lung cancer;
LGG	cis	rs7412746	0.658	rs897815	chr1:150879101	C/T	cg15448220	chr1:150897856	SETDB1	-0.4	-7.24	-0.32	1.82e-12	Melanoma;
LGG	cis	rs9487051	0.676	rs4406271	chr6:109598213	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.29e-14	Reticulocyte fraction of red cells;
LGG	cis	rs910316	0.737	rs424120	chr14:75482828	G/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.28	-0.4	6.67e-19	Height;
LGG	trans	rs526821	0.595	rs2926309	chr11:55314219	G/A	cg15704280	chr7:45808275	SEPT13	-0.42	-6.74	-0.3	4.8e-11	Pediatric bone mineral density (spine);
LGG	cis	rs6430585	0.528	rs6430594	chr2:136719173	C/T	cg07169764	chr2:136633963	MCM6	-1.26	-25.28	-0.76	3.17e-89	Corneal structure;
LGG	cis	rs9287719	0.639	rs7595845	chr2:10832860	T/C	cg02196655	chr2:10830764	NOL10	0.48	8.47	0.37	3.36e-16	Prostate cancer;
LGG	cis	rs9916302	0.861	rs33933929	chr17:37426441	A/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.42	0.47	9.01e-27	Systolic blood pressure;
LGG	cis	rs1620921	0.652	rs7382318	chr6:161276128	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs919433	0.680	rs1961558	chr2:198487278	C/T	cg00792783	chr2:198669748	PLCL1	0.52	8.08	0.35	5.83e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs11150038	0.826	rs8050709	chr16:78086427	T/G	cg04733911	chr16:78082701	NA	0.66	9.25	0.39	8.48e-19	Colorectal or endometrial cancer;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg11494091	chr17:61959527	GH2	1.04	26.28	0.77	8.03e-94	Prudent dietary pattern;
LGG	cis	rs11771526	0.892	rs62457541	chr7:32372566	G/A	cg13207630	chr7:32358064	NA	0.79	8.14	0.35	3.78e-15	Body mass index;
LGG	trans	rs11098499	0.955	rs7684942	chr4:120162201	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.22	0.46	5.07e-26	Corneal astigmatism;
LGG	cis	rs919433	0.617	rs700645	chr2:198605514	A/G	cg00792783	chr2:198669748	PLCL1	0.65	10.62	0.44	9.89e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg11252792	chr3:125932053	NA	0.59	11.94	0.49	7.84e-29	Metabolite levels;
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg12310025	chr6:25882481	NA	-0.42	-7.5	-0.33	3.36e-13	Height;
LGG	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.66	-0.37	8.2e-17	Retinal vascular caliber;
LGG	cis	rs7172689	1.000	rs4128766	chr15:81543469	C/T	cg11808699	chr15:81528661	IL16	-0.49	-10.28	-0.43	1.77e-22	Inattentive symptoms;
LGG	cis	rs4493873	1.000	rs4493873	chr8:92075643	A/C	cg16814680	chr8:91681699	NA	0.47	7.2	0.32	2.38e-12	Migraine - clinic-based;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg06558623	chr16:89946397	TCF25	1.07	11.2	0.46	6.1e-26	Skin colour saturation;
LGG	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg12193833	chr17:30244370	NA	-0.27	-7.31	-0.32	1.19e-12	Hip circumference adjusted for BMI;
LGG	cis	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg06521331	chr12:34319734	NA	-0.56	-10.17	-0.43	4.65e-22	Morning vs. evening chronotype;
LGG	trans	rs9929218	0.871	rs1862748	chr16:68832943	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-12.24	-0.49	4.94e-30	Colorectal cancer;
LGG	cis	rs6028335	0.867	rs60931333	chr20:37705547	A/G	cg16355469	chr20:37678765	NA	0.54	6.76	0.3	4.05e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.5	-7.95	-0.35	1.41e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17218495	chr19:11071743	SMARCA4	-0.48	-6.91	-0.31	1.59e-11	Systemic lupus erythematosus;
LGG	cis	rs2645694	0.626	rs2645705	chr4:77830434	G/A	cg03477792	chr4:77819574	ANKRD56	0.51	8.95	0.38	8.44e-18	Emphysema distribution in smoking;
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.41	-0.44	6.23e-23	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07923305	chr1:46598507	PIK3R3	0.49	7.55	0.33	2.35e-13	Gut microbiome composition (summer);
LGG	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.5	-9.78	-0.41	1.22e-20	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.43	0.44	5.08e-23	Prudent dietary pattern;
LGG	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg20493526	chr2:3714936	ALLC	0.48	10.59	0.44	1.24e-23	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6988985	0.728	rs1134096	chr8:143954223	C/A	cg10324643	chr8:143916377	GML	0.38	7.74	0.34	6.45e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs11875185	0.510	rs111342239	chr18:55632654	A/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg10167378	chr1:228756711	NA	0.53	7.23	0.32	2e-12	Chronic lymphocytic leukemia;
LGG	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg07005078	chr4:17578674	LAP3	0.37	6.72	0.3	5.28e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs16912285	0.892	rs75066256	chr11:24349052	A/G	ch.11.24196551F	chr11:24239977	NA	0.85	8.95	0.38	8.51e-18	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs12949688	0.967	rs9910446	chr17:55821485	G/C	cg12582317	chr17:55822272	NA	0.69	20.11	0.68	4.21e-65	Schizophrenia;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg26174226	chr8:58114915	NA	-0.61	-8.7	-0.37	5.82e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	0.742	rs4821767	chr22:38614129	G/T	cg25457927	chr22:38595422	NA	0.44	11.95	0.49	7.09e-29	Cutaneous nevi;
LGG	cis	rs751728	0.664	rs943475	chr6:33749978	C/T	cg07519485	chr6:33762594	MLN	0.29	6.67	0.3	7.18e-11	Crohn's disease;
LGG	cis	rs11190604	1.000	rs2273695	chr10:102259568	A/G	cg07080220	chr10:102295463	HIF1AN	0.66	11.54	0.47	3e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.39	0.36	5.81e-16	Alzheimer's disease;
LGG	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg15268244	chr15:77196840	NA	-0.34	-7.65	-0.33	1.18e-13	Blood metabolite levels;
LGG	cis	rs892961	0.932	rs9916143	chr17:75409282	C/G	cg05865280	chr17:75406074	SEPT9	-0.41	-9.7	-0.41	2.32e-20	Airflow obstruction;
LGG	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg21535247	chr6:8435926	SLC35B3	0.57	9.83	0.42	7.78e-21	Motion sickness;
LGG	cis	rs6964587	1.000	rs2299232	chr7:91626699	A/C	cg17063962	chr7:91808500	NA	0.48	8.47	0.37	3.23e-16	Breast cancer;
LGG	cis	rs11792861	0.781	rs838835	chr9:111758590	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.64	-10.36	-0.43	9.47e-23	Menarche (age at onset);
LGG	cis	rs2228479	0.867	rs12919804	chr16:89945369	G/A	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs9814567	1.000	rs12490835	chr3:134223730	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.91	-0.51	8.87e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs910316	0.737	rs2098251	chr14:75492696	G/A	cg06637938	chr14:75390232	RPS6KL1	0.52	9.45	0.4	1.64e-19	Height;
LGG	cis	rs7737355	0.738	rs7379696	chr5:130627460	G/A	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Life satisfaction;
LGG	cis	rs5756391	0.782	rs6000476	chr22:37300410	A/G	cg21209356	chr22:37319042	CSF2RB	0.36	8.28	0.36	1.36e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs3820068	0.581	rs72645893	chr1:15930943	C/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs4417704	0.551	rs10169006	chr2:241898824	A/G	cg05025159	chr2:241905733	NA	0.52	10.76	0.45	2.9e-24	Joint mobility (Beighton score);
LGG	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.39	-0.32	6.84e-13	HDL cholesterol;
LGG	trans	rs1478897	0.898	rs2248696	chr8:11393803	C/T	cg02002194	chr4:3960332	NA	0.43	7.73	0.34	6.67e-14	Systemic lupus erythematosus;
LGG	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg00343986	chr7:65444356	GUSB	0.48	8.24	0.36	1.84e-15	Aortic root size;
LGG	cis	rs2302729	0.625	rs13328976	chr12:2831151	C/T	cg19945202	chr12:2788847	CACNA1C	0.71	9.23	0.39	9.37e-19	Sleep quality;
LGG	cis	rs4595586	0.525	rs2892450	chr12:39363678	G/A	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs4481887	0.893	rs10736379	chr1:248455876	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-9.63	-0.41	4.09e-20	Common traits (Other);
LGG	cis	rs4330281	0.669	rs11717644	chr3:17461255	C/T	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.79e-11	Schizophrenia;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg03395511	chr6:291903	DUSP22	-0.5	-8.54	-0.37	1.91e-16	Menopause (age at onset);
LGG	cis	rs362272	0.502	rs2857839	chr4:3036630	T/C	cg02566259	chr4:3043199	NA	0.35	8.71	0.38	5.59e-17	Serum sulfate level;
LGG	cis	rs9914544	1.000	rs28436199	chr17:18751730	C/T	cg26306683	chr17:18585705	ZNF286B	0.5	9.45	0.4	1.7e-19	Educational attainment (years of education);
LGG	trans	rs916888	0.773	rs199534	chr17:44824213	T/G	cg01341218	chr17:43662625	NA	0.95	16.69	0.61	2.78e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.4	0.53	8.03e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7980687	0.628	rs2102949	chr12:123676763	G/A	cg05973401	chr12:123451056	ABCB9	0.5	8.03	0.35	8.03e-15	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs12476592	0.516	rs6706123	chr2:63801522	G/A	cg17519650	chr2:63277830	OTX1	-0.43	-6.82	-0.3	2.84e-11	Childhood ear infection;
LGG	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	7.3	0.32	1.29e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.91	-0.62	2.56e-50	Dental caries;
LGG	cis	rs4417704	0.577	rs7591322	chr2:241900403	T/C	cg14055004	chr2:241860995	NA	0.27	7.1	0.31	4.7e-12	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg25358565	chr5:93447407	FAM172A	1.38	17.11	0.62	3.41e-51	Diabetic retinopathy;
LGG	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.8	0.34	4.04e-14	Retinal vascular caliber;
LGG	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg05368731	chr17:41323189	NBR1	0.97	18.86	0.66	2.72e-59	Menopause (age at onset);
LGG	cis	rs17021463	0.966	rs1565062	chr4:95183000	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.35	-0.47	1.58e-26	Testicular germ cell tumor;
LGG	cis	rs3092073	0.624	rs13040315	chr20:44585793	A/G	cg27529037	chr20:44575021	PCIF1	0.38	7.2	0.32	2.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	trans	rs9650657	0.596	rs6989370	chr8:10616580	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	7.19	0.32	2.64e-12	Neuroticism;
LGG	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg13010199	chr12:38710504	ALG10B	0.65	13.07	0.52	1.97e-33	Bladder cancer;
LGG	cis	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.62e-15	Retinal vascular caliber;
LGG	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	cis	rs4737010	0.715	rs7461534	chr8:41628650	C/T	cg17182837	chr8:41585554	ANK1	-0.47	-7.55	-0.33	2.29e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16100392	chr6:132931717	TAAR3	0.34	6.69	0.3	6.61e-11	Gut microbiome composition (summer);
LGG	cis	rs4901847	0.529	rs12895032	chr14:58618345	T/G	cg15908186	chr14:58618357	C14orf37	0.69	12.85	0.51	1.51e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.32	-0.32	1.1e-12	Mood instability;
LGG	cis	rs6540556	0.859	rs11119341	chr1:209940675	A/G	cg05527609	chr1:210001259	C1orf107	0.58	7.55	0.33	2.36e-13	Red blood cell count;
LGG	cis	rs5769707	0.935	rs9616332	chr22:50047678	C/G	cg06623630	chr22:50017776	C22orf34	-0.36	-7.69	-0.34	8.98e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952809	0.532	rs6956223	chr7:2431331	T/C	cg23289794	chr7:2394357	EIF3B	-0.83	-10.37	-0.43	8.39e-23	Multiple sclerosis;
LGG	cis	rs6546550	0.935	rs4853027	chr2:70039224	A/G	cg02498382	chr2:70120550	SNRNP27	0.39	7.36	0.32	8.44e-13	Prevalent atrial fibrillation;
LGG	cis	rs9443645	0.901	rs1354832	chr6:79613763	A/G	cg18132916	chr6:79620363	NA	0.3	8.23	0.36	1.96e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg14926445	chr8:58193284	C8orf71	-0.71	-8.49	-0.37	2.8e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.726	rs10105545	chr8:22534232	A/G	cg03733263	chr8:22462867	KIAA1967	-0.97	-21.96	-0.71	8.92e-74	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9814567	0.574	rs4974488	chr3:134168137	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.52	-9.12	-0.39	2.29e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.62	-0.37	1.08e-16	Educational attainment (years of education);
LGG	cis	rs2576037	0.796	rs2576039	chr18:44582148	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.51	-0.4	1.07e-19	Personality dimensions;
LGG	trans	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg07817883	chr1:32538562	TMEM39B	-0.66	-9.07	-0.39	3.43e-18	Monocyte percentage of white cells;
LGG	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg13010199	chr12:38710504	ALG10B	0.66	13.1	0.52	1.46e-33	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.05	0.39	3.93e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.66	-10.9	-0.45	9.18e-25	Blood trace element (Cu levels);
LGG	cis	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs10267417	0.556	rs879661	chr7:19970658	A/G	cg05791153	chr7:19748676	TWISTNB	-0.51	-6.79	-0.3	3.46e-11	Night sleep phenotypes;
LGG	cis	rs8180040	0.726	rs4682842	chr3:46982773	C/G	cg16586182	chr3:47516702	SCAP	0.73	13.18	0.52	6.84e-34	Colorectal cancer;
LGG	cis	rs597583	0.715	rs7936795	chr11:117391736	A/G	cg27161313	chr11:117392002	DSCAML1	-0.63	-9.95	-0.42	2.97e-21	Putamen volume;
LGG	cis	rs655601	1.000	rs655601	chr5:180226673	G/T	cg13724780	chr5:180237085	MGAT1	-0.62	-6.81	-0.3	3.07e-11	Quantitative traits;
LGG	cis	rs6088580	0.524	rs6088569	chr20:33268199	G/A	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs28719689	1.000	rs28719689	chr8:1270670	C/T	cg22761795	chr8:1265118	NA	0.81	9.02	0.39	4.85e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4262150	0.883	rs72799196	chr5:152190622	C/T	cg12297329	chr5:152029980	NA	-0.68	-12.84	-0.51	1.71e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg19524238	chr7:2802976	GNA12	0.38	8.73	0.38	4.59e-17	Height;
LGG	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-46.12	-0.91	3.2e-175	Myeloid white cell count;
LGG	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg18876405	chr7:65276391	NA	-0.47	-8.15	-0.35	3.51e-15	Calcium levels;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.13	-0.35	4.02e-15	IgG glycosylation;
LGG	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg00666640	chr1:248458726	OR2T12	-0.59	-9.48	-0.4	1.28e-19	Common traits (Other);
LGG	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11758351	0.660	rs77130538	chr6:26210723	T/C	cg23601095	chr6:26197514	HIST1H3D	0.72	9.11	0.39	2.42e-18	Gout;Renal underexcretion gout;
LGG	cis	rs67460515	0.500	rs6806015	chr3:160724766	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.03	-0.35	8.17e-15	Parkinson's disease;
LGG	cis	rs644799	1.000	rs546809	chr11:95579938	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.14	0.7	6.56e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg16507663	chr6:150244633	RAET1G	-0.46	-7.45	-0.33	4.5e-13	Lung cancer;
LGG	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg12856521	chr11:46389249	DGKZ	0.89	14.77	0.57	1.05e-40	Crohn's disease;
LGG	cis	rs4959677	0.901	rs12210993	chr6:2480890	G/A	cg23817096	chr6:1620687	NA	-0.32	-7.57	-0.33	2.03e-13	Orthostatic hypotension;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.59	-0.41	5.32e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11792861	0.926	rs17628095	chr9:111889172	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.52	-8.07	-0.35	6.1e-15	Menarche (age at onset);
LGG	cis	rs1505368	0.781	rs10197836	chr2:213274278	T/C	cg16329650	chr2:213403929	ERBB4	0.46	8.12	0.35	4.24e-15	Symmetrical dimethylarginine levels;
LGG	trans	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg24247370	chr13:99142703	STK24	-0.37	-6.96	-0.31	1.14e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.583	rs9393661	chr6:25739080	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs9303401	0.614	rs8081058	chr17:57160513	G/C	cg25039879	chr17:56429692	SUPT4H1	0.56	8.04	0.35	7.82e-15	Cognitive test performance;
LGG	cis	rs6993813	0.967	rs4360322	chr8:120022478	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.3	7.79	0.34	4.33e-14	Bone mineral density (hip);
LGG	cis	rs11239187	0.586	rs1021055	chr10:45073211	G/A	cg03916630	chr10:45065415	NA	0.35	8.63	0.37	1e-16	Body mass index;
LGG	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg16662043	chr16:48846231	NA	-0.37	-7.26	-0.32	1.61e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7914558	0.901	rs35525740	chr10:104941112	A/T	cg04362960	chr10:104952993	NT5C2	0.56	10.83	0.45	1.68e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2180341	1.000	rs2144742	chr6:127595786	C/A	cg27446573	chr6:127587934	RNF146	1.12	21.83	0.71	3.72e-73	Breast cancer;
LGG	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg04851639	chr8:1020857	NA	-0.42	-9.11	-0.39	2.53e-18	Schizophrenia;
LGG	cis	rs79349575	0.783	rs62075820	chr17:46983171	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg11890956	chr21:40555474	PSMG1	1.0	21.47	0.71	1.74e-71	Cognitive function;
LGG	cis	rs738321	0.671	rs3761446	chr22:38595483	G/A	cg03162506	chr22:38580953	NA	0.39	9.27	0.4	6.95e-19	Breast cancer;
LGG	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg03264133	chr6:25882463	NA	-0.51	-9.21	-0.39	1.13e-18	Intelligence (multi-trait analysis);
LGG	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg02002194	chr4:3960332	NA	-0.55	-10.89	-0.45	9.37e-25	Neuroticism;
LGG	cis	rs896854	0.714	rs6471503	chr8:95990283	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.76	-0.38	3.57e-17	Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs718503	chr6:8527463	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs3087591	0.960	rs9898664	chr17:29567152	T/C	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.73	-0.56	1.55e-40	Hip circumference;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg07362569	chr17:61921086	SMARCD2	0.48	9.26	0.4	7.53e-19	Prudent dietary pattern;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg01988459	chr11:68622903	NA	-0.58	-11.93	-0.48	8.94e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs72772090	0.539	rs11750934	chr5:96118487	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2455826	1.000	rs2455826	chr3:15663060	G/T	cg16303742	chr3:15540471	COLQ	0.41	6.95	0.31	1.26e-11	Inflammatory skin disease;
LGG	trans	rs61931739	0.500	rs11053217	chr12:34470036	A/C	cg13010199	chr12:38710504	ALG10B	0.63	12.68	0.51	7.78e-32	Morning vs. evening chronotype;
LGG	cis	rs1519814	0.702	rs7846263	chr8:121039036	C/T	cg22335954	chr8:121166405	COL14A1	-0.48	-8.67	-0.37	7.23e-17	Breast cancer;
LGG	trans	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg12575136	chr18:32820987	ZNF397	0.48	8.8	0.38	2.67e-17	White blood cell count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06752270	chr8:42397250	C8orf40;SLC20A2	0.4	6.7	0.3	6.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12210905	0.688	rs12191373	chr6:27484330	C/T	cg08851530	chr6:28072375	NA	0.86	6.85	0.3	2.37e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg00684032	chr4:1343700	KIAA1530	0.43	8.65	0.37	8.56e-17	Longevity;
LGG	cis	rs986417	0.901	rs1007152	chr14:60999493	C/T	cg27398547	chr14:60952738	C14orf39	0.7	6.71	0.3	5.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4704846	1.000	rs4704851	chr5:156533174	C/T	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.27	-0.32	1.57e-12	Blood protein levels;
LGG	cis	rs6686643	0.762	rs9333433	chr1:165611455	G/C	cg19407955	chr1:165599744	MGST3	-0.62	-8.87	-0.38	1.55e-17	Total ventricular volume;
LGG	cis	rs677665	0.722	rs10746487	chr1:9338689	T/C	cg25755851	chr1:9335794	NA	-0.24	-7.01	-0.31	8.62e-12	Eosinophil percentage of white cells;
LGG	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg01579765	chr21:45077557	HSF2BP	0.34	7.75	0.34	5.84e-14	Mean corpuscular volume;
LGG	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg27129171	chr3:47204927	SETD2	0.63	10.62	0.44	1.04e-23	Birth weight;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.12	0.52	1.21e-33	Prudent dietary pattern;
LGG	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg21775007	chr8:11205619	TDH	0.44	6.83	0.3	2.61e-11	Myopia (pathological);
LGG	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.16e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.39	7.52	0.33	2.83e-13	Schizophrenia;
LGG	cis	rs7726839	0.540	rs7558	chr5:660491	C/T	cg16400903	chr5:693638	TPPP	0.46	6.85	0.3	2.41e-11	Obesity-related traits;
LGG	trans	rs931812	0.757	rs4734492	chr8:101901901	C/T	cg20993868	chr7:22813445	NA	-0.58	-11.73	-0.48	5.28e-28	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.13	-0.39	2.2e-18	Bladder cancer;
LGG	cis	rs2117029	0.587	rs57853986	chr12:49518395	T/G	cg24176009	chr12:49580217	TUBA1A	0.65	12.73	0.51	4.89e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg24083324	chr1:214162604	PROX1	-0.49	-8.87	-0.38	1.58e-17	Schizophrenia;
LGG	cis	rs950169	0.922	rs17531523	chr15:85132449	C/G	cg03959625	chr15:84868606	LOC388152	0.59	9.19	0.39	1.28e-18	Schizophrenia;
LGG	cis	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg04990556	chr1:26633338	UBXN11	-0.69	-14.16	-0.55	4.62e-38	Obesity-related traits;
LGG	cis	rs806215	1.000	rs806196	chr7:127248414	A/G	cg25922125	chr7:127225783	GCC1	0.75	10.3	0.43	1.48e-22	Type 2 diabetes;
LGG	cis	rs758324	0.947	rs2404778	chr5:131172886	T/C	cg06307176	chr5:131281290	NA	0.56	9.38	0.4	3.06e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Myopia (pathological);
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg07092213	chr7:1199455	ZFAND2A	0.49	7.93	0.35	1.64e-14	Longevity;Endometriosis;
LGG	trans	rs12517041	0.935	rs6894054	chr5:23305356	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	cis	rs477895	0.941	rs35692796	chr11:64110805	A/G	cg22916017	chr11:64110731	CCDC88B	-0.54	-7.22	-0.32	2.16e-12	Mean platelet volume;
LGG	trans	rs7824557	1.000	rs7824557	chr8:11104111	C/T	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.25	-0.36	1.63e-15	Retinal vascular caliber;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg11360546	chr7:1094263	C7orf50	-0.39	-6.99	-0.31	9.62e-12	Longevity;Endometriosis;
LGG	cis	rs34467563	0.740	rs2319815	chr8:97384315	A/T	cg22138393	chr8:97340270	PTDSS1	0.3	7.23	0.32	1.97e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.593	rs17794451	chr8:58019217	C/T	cg21724239	chr8:58056113	NA	0.53	7.53	0.33	2.67e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7613875	0.580	rs12634780	chr3:50043341	A/T	cg24110177	chr3:50126178	RBM5	0.6	11.09	0.46	1.61e-25	Body mass index;
LGG	cis	rs7072216	0.763	rs10748729	chr10:100171371	G/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.13	-0.31	3.82e-12	Metabolite levels;
LGG	trans	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-7.85	-0.34	2.87e-14	Triglycerides;
LGG	cis	rs9926296	0.609	rs4785709	chr16:89796665	G/A	cg26513180	chr16:89883248	FANCA	-0.59	-10.58	-0.44	1.37e-23	Vitiligo;
LGG	cis	rs370915	0.564	rs10027461	chr4:187837608	T/C	cg19519643	chr4:187840862	NA	-0.64	-13.35	-0.53	1.31e-34	Gout;
LGG	cis	rs6089584	0.888	rs2181590	chr20:60622843	T/C	cg06470251	chr20:60548479	NA	0.51	8.46	0.37	3.43e-16	Body mass index;
LGG	cis	rs11105298	0.891	rs10858894	chr12:89914261	T/C	cg00757033	chr12:89920650	WDR51B	0.65	9.49	0.4	1.2e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1568889	1.000	rs7951681	chr11:28273894	G/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.81	0.54	1.39e-36	Bipolar disorder;
LGG	cis	rs17641971	0.684	rs7835336	chr8:49957895	A/G	cg00325661	chr8:49890786	NA	0.54	9.7	0.41	2.17e-20	Blood metabolite levels;
LGG	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.83e-11	Aortic root size;
LGG	cis	rs8017423	0.935	rs2104704	chr14:90696609	A/G	cg04374321	chr14:90722782	PSMC1	-0.91	-18.58	-0.65	5.81e-58	Mortality in heart failure;
LGG	cis	rs9816784	0.901	rs56253832	chr3:195817175	G/A	cg02975922	chr3:195473998	MUC4	-0.41	-6.92	-0.31	1.53e-11	Mean corpuscular hemoglobin;
LGG	cis	rs1580019	0.587	rs2392069	chr7:32547154	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.29e-11	Cognitive ability;
LGG	cis	rs4474465	1.000	rs11237511	chr11:78173606	C/T	cg02023728	chr11:77925099	USP35	0.4	7.11	0.31	4.49e-12	Alzheimer's disease (survival time);
LGG	cis	rs8180040	0.966	rs12636851	chr3:47463567	C/T	cg27129171	chr3:47204927	SETD2	0.78	14.95	0.57	1.64e-41	Colorectal cancer;
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.65	-11.9	-0.48	1.17e-28	Personality dimensions;
LGG	cis	rs981844	0.712	rs4538465	chr4:154746763	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.34e-16	Life satisfaction;
LGG	cis	rs17666538	0.585	rs4735812	chr8:607766	C/G	cg07685180	chr8:600429	NA	1.06	10.82	0.45	1.82e-24	IgG glycosylation;
LGG	cis	rs763121	0.853	rs5750668	chr22:39079964	T/C	cg21395723	chr22:39101663	GTPBP1	0.38	6.72	0.3	5.43e-11	Menopause (age at onset);
LGG	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg26513180	chr16:89883248	FANCA	0.94	21.56	0.71	6.54e-72	Vitiligo;
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.63	0.54	8.39e-36	Prudent dietary pattern;
LGG	cis	rs738322	0.967	rs132971	chr22:38561911	T/G	cg03162506	chr22:38580953	NA	0.36	9.24	0.39	8.89e-19	Cutaneous nevi;
LGG	cis	rs7208859	0.623	rs9900144	chr17:29208389	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9815354	1.000	rs1716661	chr3:41962818	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.43	-0.36	4.46e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9914544	0.628	rs67053020	chr17:18680061	G/C	cg26306683	chr17:18585705	ZNF286B	0.38	7.28	0.32	1.4e-12	Educational attainment (years of education);
LGG	cis	rs6502050	0.740	rs4789748	chr17:80093061	A/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.84e-19	Life satisfaction;
LGG	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.43	-0.4	1.92e-19	Mood instability;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.82	0.38	2.26e-17	Neuroticism;
LGG	cis	rs7084402	0.935	rs1632584	chr10:60282078	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.16	-0.64	4.81e-56	Refractive error;
LGG	cis	rs7582180	0.629	rs11688285	chr2:100948054	A/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.72	-0.48	5.83e-28	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.649	rs79431889	chr2:39358410	G/A	cg04010122	chr2:39346883	SOS1	0.96	7.9	0.34	2.03e-14	Corticobasal degeneration;
LGG	cis	rs854037	0.630	rs1968422	chr5:57138990	A/C	cg08523694	chr5:57076192	NA	0.56	8.28	0.36	1.34e-15	Birth weight;
LGG	cis	rs7166081	1.000	rs35524716	chr15:67578987	G/A	cg05925327	chr15:68127851	NA	-0.34	-7.12	-0.31	4.21e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg05025164	chr4:1340916	KIAA1530	0.46	7.51	0.33	3.11e-13	Obesity-related traits;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.46	-0.5	6.48e-31	Lymphocyte counts;
LGG	trans	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg25482853	chr8:67687455	SGK3	1.0	13.11	0.52	1.31e-33	Lung disease severity in cystic fibrosis;
LGG	cis	rs56283067	0.887	rs62437968	chr6:44729495	G/A	cg18551225	chr6:44695536	NA	-0.71	-12.33	-0.5	2.07e-30	Total body bone mineral density;
LGG	cis	rs7666738	0.791	rs34088022	chr4:99001508	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3820068	0.626	rs61103742	chr1:15909153	A/C	cg05660106	chr1:15850417	CASP9	1.01	21.98	0.71	7.46e-74	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg15971980	chr6:150254442	NA	0.45	8.42	0.36	4.61e-16	Lung cancer;
LGG	trans	rs67340775	0.541	rs200975	chr6:27855625	G/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.42	-0.36	4.82e-16	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs57941207	chr8:58169821	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.68	-0.3	7.06e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg08508325	chr11:3079039	CARS	0.42	8.1	0.35	4.94e-15	Calcium levels;
LGG	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.36	0.36	7.17e-16	Neuroticism;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg18350739	chr11:68623251	NA	-0.85	-21.64	-0.71	2.95e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7975161	0.640	rs4477504	chr12:104710465	T/C	cg25273343	chr12:104657179	TXNRD1	-0.74	-9.66	-0.41	3.03e-20	Toenail selenium levels;
LGG	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg02631450	chr22:32366979	NA	0.96	9.22	0.39	1.02e-18	Childhood ear infection;
LGG	cis	rs11874712	0.527	rs12955201	chr18:43643435	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.66	-16.07	-0.6	1.66e-46	Migraine - clinic-based;
LGG	cis	rs3020736	0.500	rs764481	chr22:42518426	G/A	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg18321976	chr12:53893000	MAP3K12	0.55	6.78	0.3	3.67e-11	Skin pigmentation;
LGG	trans	rs4650994	0.507	rs12405456	chr1:178512331	T/G	cg05059571	chr16:84539110	KIAA1609	-0.61	-11.47	-0.47	5.46e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.49e-12	Prudent dietary pattern;
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg01765077	chr12:122356316	WDR66	0.3	8.16	0.35	3.18e-15	Mean corpuscular volume;
LGG	cis	rs10262624	0.967	rs12333669	chr7:23916886	C/T	cg09690326	chr7:23720549	C7orf46	-0.32	-6.66	-0.3	7.75e-11	Schizophrenia;
LGG	cis	rs6489785	0.737	rs662739	chr12:121229893	T/C	cg02419362	chr12:121203948	SPPL3	0.43	6.74	0.3	4.82e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg02158880	chr13:53174818	NA	-0.47	-9.79	-0.41	1.1e-20	Lewy body disease;
LGG	trans	rs9329221	0.662	rs11249996	chr8:10245463	G/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.38	-0.32	7.54e-13	Neuroticism;
LGG	cis	rs4862750	0.872	rs11947595	chr4:187899827	C/T	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9788682	0.948	rs28498264	chr15:78837673	C/T	cg24631222	chr15:78858424	CHRNA5	0.45	6.86	0.3	2.2e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg14085017	chr11:63775226	MACROD1	0.35	7.72	0.34	7.12e-14	Schizophrenia;
LGG	cis	rs2070488	0.574	rs57754356	chr3:38488706	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.64	0.56	3.89e-40	Electrocardiographic conduction measures;
LGG	cis	rs9916302	0.653	rs11657058	chr17:37699378	T/G	cg07936489	chr17:37558343	FBXL20	-0.99	-15.28	-0.58	5.95e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs8016982	0.632	rs4899786	chr14:81643800	G/T	cg01989461	chr14:81687754	GTF2A1	-0.56	-8.26	-0.36	1.49e-15	Schizophrenia;
LGG	cis	rs10892173	0.935	rs7108548	chr11:117674072	A/T	cg21640587	chr11:117668038	DSCAML1	0.53	8.82	0.38	2.41e-17	Myopia;
LGG	cis	rs2046867	0.583	rs13316962	chr3:72911994	T/C	cg01043669	chr3:72786069	NA	0.39	6.94	0.31	1.3e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11098499	0.909	rs11723757	chr4:120299669	C/T	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	2.99e-36	Corneal astigmatism;
LGG	cis	rs3741404	0.868	rs595880	chr11:64006466	T/G	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.41	-7.71	-0.34	7.78e-14	Platelet count;
LGG	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg03342759	chr3:160939853	NMD3	-0.72	-12.68	-0.51	7.47e-32	Parkinson's disease;
LGG	cis	rs929354	0.742	rs7785227	chr7:156999297	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs7106204	1.000	rs7925633	chr11:24214815	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	12.28	0.5	3.29e-30	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg16141378	chr3:129829833	LOC729375	-0.45	-10.87	-0.45	1.2e-24	Mood instability;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10089	0.953	rs1012851	chr5:127360241	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	10.67	0.44	6.59e-24	Ileal carcinoids;
LGG	cis	rs6540556	0.769	rs2272867	chr1:209929579	C/A	cg05527609	chr1:210001259	C1orf107	-0.53	-7.02	-0.31	7.74e-12	Red blood cell count;
LGG	cis	rs4889911	0.571	rs9907480	chr17:77852292	C/T	cg07923794	chr17:77834237	NA	0.61	7.91	0.35	1.87e-14	Electroencephalogram traits;
LGG	cis	rs1620921	0.712	rs2802358	chr6:161243584	C/A	cg01280913	chr6:161186852	NA	-0.34	-6.92	-0.31	1.52e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs236352	0.557	rs9368966	chr6:36825430	A/G	cg03410223	chr6:36853544	C6orf89	0.44	8.4	0.36	5.7e-16	Heart rate;
LGG	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg23625390	chr15:77176239	SCAPER	-0.63	-11.4	-0.47	1.03e-26	Blood metabolite levels;
LGG	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.71	0.64	5.51e-54	Refractive error;
LGG	cis	rs2587949	0.615	rs1485269	chr3:4222976	C/T	cg16519197	chr3:4211558	NA	0.32	6.67	0.3	7.12e-11	Periodontitis (DPAL);
LGG	cis	rs5758511	0.573	rs2284082	chr22:42240797	C/T	cg15128208	chr22:42549153	NA	-0.44	-7.45	-0.33	4.57e-13	Birth weight;
LGG	cis	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg26378065	chr17:18585709	ZNF286B	0.5	9.09	0.39	2.81e-18	Educational attainment (years of education);
LGG	cis	rs3857747	0.827	rs12234882	chr7:40451643	A/G	cg00420559	chr7:40367873	C7orf10	-0.38	-7.89	-0.34	2.14e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs6831352	0.734	rs1311620	chr4:100013091	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.09	0.35	5.26e-15	Alcohol dependence;
LGG	cis	rs11229555	0.645	rs4347409	chr11:58176252	C/T	cg15696309	chr11:58395628	NA	0.93	15.08	0.57	4.44e-42	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	7.28	0.32	1.46e-12	Obesity-related traits;
LGG	cis	rs6088580	0.524	rs6088560	chr20:33228549	T/C	cg24642439	chr20:33292090	TP53INP2	-0.42	-6.65	-0.3	8.15e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs1065656	0.553	rs344360	chr16:1839221	T/C	cg14074117	chr16:1909714	C16orf73	0.49	7.03	0.31	7.33e-12	Insulin-like growth factors;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16854524	chr4:83931902	LIN54	0.54	9.1	0.39	2.7e-18	Cognitive performance;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg10852096	chr15:79043040	NA	0.28	7.35	0.32	9.34e-13	Coronary artery disease or large artery stroke;
LGG	cis	rs990171	0.913	rs2241117	chr2:103003043	T/C	cg05295703	chr2:102895712	NA	-0.56	-9.95	-0.42	2.84e-21	Lymphocyte counts;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-9.82	-0.42	8.33e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg14784868	chr12:69753453	YEATS4	0.91	19.6	0.67	1.02e-62	Blood protein levels;
LGG	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg19468946	chr17:37922297	IKZF3	-0.45	-7.99	-0.35	1.07e-14	Self-reported allergy;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-9.41	-0.4	2.41e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs11700980	0.551	rs2832011	chr21:30110690	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.71	-0.3	5.77e-11	QRS complex (12-leadsum);
LGG	cis	rs4767841	0.935	rs3213626	chr12:120158541	G/A	cg25937854	chr12:120150414	CIT	0.39	6.68	0.3	6.8e-11	Urgency urinary incontinence;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.34	-0.32	9.72e-13	Lung cancer;
LGG	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg05082376	chr22:42548792	NA	-0.37	-7.77	-0.34	5.18e-14	Schizophrenia;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.64	0.37	9.48e-17	Schizophrenia;
LGG	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg15596359	chr8:11213517	TDH	-0.34	-6.9	-0.31	1.69e-11	Retinal vascular caliber;
LGG	cis	rs6500602	0.563	rs3810818	chr16:4432029	A/C	cg06916706	chr16:4465613	CORO7	-0.9	-14.96	-0.57	1.52e-41	Schizophrenia;
LGG	cis	rs7932354	0.528	rs7121418	chr11:47165106	G/A	cg03339077	chr11:47165057	C11orf49	-0.56	-10.64	-0.44	8.56e-24	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs644799	0.511	rs10831420	chr11:95478209	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.03	0.55	1.59e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.592	rs5996039	chr22:41981957	A/G	cg06481639	chr22:41940642	POLR3H	-0.49	-7.0	-0.31	8.77e-12	Vitiligo;
LGG	cis	rs477692	0.603	rs10829602	chr10:131326790	G/A	cg05714579	chr10:131428358	MGMT	0.47	8.88	0.38	1.43e-17	Response to temozolomide;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7928758	0.943	rs2360225	chr11:134265254	A/G	cg15243474	chr11:134282918	B3GAT1	1.19	15.33	0.58	3.48e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs10802346	0.545	rs2362253	chr1:246371676	G/A	cg13514129	chr1:39547527	MACF1	0.68	12.64	0.51	1.15e-31	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs1018836	0.786	rs10956736	chr8:91602067	C/T	cg16814680	chr8:91681699	NA	-0.76	-14.01	-0.55	1.93e-37	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10484885	0.824	rs72921954	chr6:90586656	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-10.76	-0.45	3.07e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12477438	0.520	rs4588238	chr2:99749350	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg06873352	chr17:61820015	STRADA	0.75	14.06	0.55	1.18e-37	Prudent dietary pattern;
LGG	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg04731861	chr2:219085781	ARPC2	-0.44	-10.55	-0.44	1.9e-23	Colorectal cancer;
LGG	cis	rs7107174	1.000	rs10899457	chr11:78001163	T/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs4891159	0.570	rs690132	chr18:74117261	T/C	cg24786174	chr18:74118243	ZNF516	0.68	17.2	0.62	1.24e-51	Longevity;
LGG	cis	rs4561483	0.583	rs1029285	chr16:11987118	G/A	cg08843971	chr16:11963173	GSPT1	0.59	14.52	0.56	1.24e-39	Testicular germ cell tumor;
LGG	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.78e-21	Aortic root size;
LGG	cis	rs897984	0.806	rs11150600	chr16:30940331	C/T	cg00531865	chr16:30841666	NA	0.56	12.01	0.49	3.98e-29	Dementia with Lewy bodies;
LGG	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.24	-0.49	4.94e-30	Chronic sinus infection;
LGG	trans	rs17685	0.712	rs11764119	chr7:75812358	T/G	cg19862616	chr7:65841803	NCRNA00174	1.05	23.97	0.74	3.79e-83	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg11871910	chr12:69753446	YEATS4	0.64	12.62	0.51	1.32e-31	Blood protein levels;
LGG	cis	rs1691799	0.863	rs1168291	chr12:66732488	T/C	cg16791601	chr12:66731901	HELB	-0.65	-15.53	-0.59	4.42e-44	White blood cell count (basophil);
LGG	cis	rs801193	0.967	rs2707841	chr7:66157020	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.01	0.39	5.47e-18	Aortic root size;
LGG	cis	rs7765175	0.524	rs2226244	chr6:113634490	C/A	cg26552650	chr6:113682475	NA	0.34	7.3	0.32	1.22e-12	Coronary artery calcification;
LGG	cis	rs1978968	1.000	rs7286219	chr22:18445709	G/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.05	0.39	3.89e-18	Cognitive test performance;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.43	-0.47	7.91e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2011503	0.882	rs751857	chr19:19602873	G/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg04267008	chr7:1944627	MAD1L1	-0.55	-9.4	-0.4	2.45e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg02018176	chr4:1364513	KIAA1530	-0.62	-14.8	-0.57	7.5e-41	Longevity;
LGG	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg03352830	chr11:487213	PTDSS2	-0.6	-8.64	-0.37	9.51e-17	Body mass index;
LGG	cis	rs2073300	0.609	rs6137931	chr20:23376875	G/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7044106	0.762	rs10760112	chr9:123467570	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.52	0.61	1.56e-48	Hip circumference adjusted for BMI;
LGG	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg08344181	chr3:125677491	NA	-0.59	-6.89	-0.3	1.78e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs734999	0.870	rs2147905	chr1:2482921	C/T	cg15627072	chr1:2432621	PLCH2	-0.4	-9.34	-0.4	4.1e-19	Ulcerative colitis;
LGG	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg06562184	chr8:19319451	CSGALNACT1	0.44	8.62	0.37	1.1e-16	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg24846343	chr22:24311635	DDTL	0.6	12.05	0.49	2.76e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27542512	chr1:153963550	RPS27	0.45	7.63	0.33	1.38e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6693295	0.536	rs6662962	chr1:246226180	T/A	cg11798871	chr1:246315928	SMYD3	-0.62	-8.34	-0.36	8.28e-16	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg06108461	chr20:60628389	TAF4	-0.76	-13.75	-0.54	2.61e-36	Body mass index;
LGG	cis	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg24189917	chr7:1970923	MAD1L1	0.55	8.48	0.37	3.1e-16	Bipolar disorder;
LGG	cis	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs7107174	0.901	rs7110387	chr11:78117875	A/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.36	-0.32	8.71e-13	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27118230	chr14:50998578	MAP4K5;ATL1	0.45	6.76	0.3	4.28e-11	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.565	rs2836945	chr21:40596757	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.28	-0.43	1.85e-22	Menarche (age at onset);
LGG	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg13628971	chr7:2884303	GNA12	0.54	11.02	0.46	3.14e-25	Height;
LGG	cis	rs7584262	0.535	rs114695310	chr2:42238625	C/T	cg27252766	chr2:42229092	NA	0.52	6.68	0.3	7.03e-11	Bone mineral density;
LGG	cis	rs11971779	1.000	rs75919582	chr7:139054919	G/A	cg07862535	chr7:139043722	LUC7L2	0.68	9.89	0.42	4.88e-21	Diisocyanate-induced asthma;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg15971980	chr6:150254442	NA	0.46	8.44	0.37	3.97e-16	Lung cancer;
LGG	cis	rs9487094	0.922	rs12208933	chr6:109903786	C/T	cg16315928	chr6:109776240	MICAL1	0.54	9.09	0.39	2.96e-18	Height;
LGG	cis	rs9788721	0.900	rs4243084	chr15:78911672	G/C	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.45	-0.33	4.63e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs4262150	0.695	rs56117655	chr5:152328969	A/G	cg12297329	chr5:152029980	NA	-0.66	-11.28	-0.46	3.21e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs8002861	0.967	rs7984393	chr13:44484361	T/C	cg17145862	chr1:211918768	LPGAT1	0.95	24.14	0.75	5.77e-84	Leprosy;
LGG	trans	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.27e-12	Morning vs. evening chronotype;
LGG	cis	rs9814567	1.000	rs10804632	chr3:134294501	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.4	-0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs75804782	0.581	rs13415491	chr2:239319901	C/T	cg01134436	chr17:81009848	B3GNTL1	0.85	8.97	0.38	7.27e-18	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7674212	0.541	rs4699050	chr4:104114297	A/G	cg16532752	chr4:104119610	CENPE	-0.39	-6.7	-0.3	6.02e-11	Type 2 diabetes;
LGG	trans	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.15	-0.35	3.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1793639	0.902	rs1015054	chr11:131933482	C/G	cg13908476	chr11:131942942	NTM	0.44	9.19	0.39	1.36e-18	Myopia;
LGG	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg21775007	chr8:11205619	TDH	-0.43	-7.03	-0.31	7.49e-12	Triglycerides;
LGG	trans	rs561341	1.000	rs530715	chr17:30320544	T/G	cg27661571	chr11:113659931	NA	-0.65	-9.31	-0.4	5.27e-19	Hip circumference adjusted for BMI;
LGG	cis	rs7927771	0.832	rs10769258	chr11:47391039	C/T	cg20307385	chr11:47447363	PSMC3	0.57	10.55	0.44	1.76e-23	Subjective well-being;
LGG	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg02187348	chr16:89574699	SPG7	0.64	10.77	0.45	2.85e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs10888329	0.720	rs4428922	chr1:248406894	C/T	cg00666640	chr1:248458726	OR2T12	0.44	6.75	0.3	4.43e-11	Autism spectrum disorder;
LGG	cis	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.56	0.37	1.66e-16	Mood instability;
LGG	cis	rs7833790	1.000	rs7833384	chr8:82730915	T/C	cg27398817	chr8:82754497	SNX16	-0.79	-11.65	-0.48	1.06e-27	Diastolic blood pressure;
LGG	cis	rs7208859	0.623	rs7214570	chr17:29147164	A/G	cg13385521	chr17:29058706	SUZ12P	0.91	10.74	0.45	3.66e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs708547	0.957	rs1623306	chr4:57773595	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	8.66	0.37	7.84e-17	Response to bleomycin (chromatid breaks);
LGG	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	cis	rs6831352	0.879	rs29001196	chr4:100054116	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg00290607	chr11:67383545	NA	0.73	14.81	0.57	6.77e-41	Mean corpuscular volume;
LGG	cis	rs3735485	0.738	rs10247593	chr7:45095718	G/A	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs12496230	1.000	rs13079612	chr3:66840534	T/C	cg04995300	chr3:66848608	NA	0.53	7.71	0.34	7.86e-14	Type 2 diabetes;
LGG	cis	rs8017423	0.765	rs8017170	chr14:90721849	T/A	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs11122272	0.525	rs2749713	chr1:231537921	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.54e-12	Hemoglobin concentration;
LGG	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.13	-0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs10227331	1.000	rs10227331	chr7:157294938	A/T	cg06076350	chr7:157294107	NA	0.35	6.77	0.3	3.95e-11	Inattentive symptoms;
LGG	cis	rs7572733	0.935	rs700665	chr2:198673379	A/C	cg00792783	chr2:198669748	PLCL1	0.48	8.21	0.36	2.27e-15	Dermatomyositis;
LGG	cis	rs2236267	0.693	rs8008120	chr14:88622367	A/C	cg02175263	chr14:88627849	NA	0.33	7.51	0.33	3.16e-13	Food antigen IgG levels;
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.77	-0.3	3.81e-11	Bipolar disorder;
LGG	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs7524258	0.868	rs6577428	chr1:7314655	C/T	cg07173049	chr1:7289937	CAMTA1	-0.69	-15.71	-0.59	7.08e-45	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg20891558	chr2:74357851	NA	0.49	9.52	0.4	9.87e-20	Gestational age at birth (maternal effect);
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.51	-0.33	3.07e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs7959452	0.868	rs10878967	chr12:69740869	T/C	cg14784868	chr12:69753453	YEATS4	0.76	15.11	0.57	3.12e-42	Blood protein levels;
LGG	cis	rs3820928	0.874	rs10188770	chr2:227877037	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.8	-0.34	4.01e-14	Pulmonary function;
LGG	cis	rs7618915	1.000	rs59565798	chr3:52307169	G/A	cg14092988	chr3:52407081	DNAH1	0.44	11.77	0.48	3.71e-28	Bipolar disorder;
LGG	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs9790314	0.631	rs9867582	chr3:160797405	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-11.11	-0.46	1.45e-25	Morning vs. evening chronotype;
LGG	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04492929	chr16:2155436	PKD1	-0.54	-9.87	-0.42	5.43e-21	Triglycerides;
LGG	trans	rs1493916	1.000	rs1493916	chr18:31392577	T/G	cg04226714	chr8:49833948	SNAI2	-0.48	-8.63	-0.37	9.95e-17	Life satisfaction;
LGG	cis	rs196889	0.611	rs2979704	chr8:24809067	C/T	cg25352397	chr8:24800883	NA	0.48	7.0	0.31	8.79e-12	Seasonality;
LGG	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.39e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02737830	chr12:64616354	C12orf66	0.51	8.06	0.35	6.5e-15	Gut microbiome composition (summer);
LGG	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg14210321	chr2:106509881	NCK2	0.53	9.3	0.4	5.41e-19	Addiction;
LGG	cis	rs17030434	0.906	rs5020754	chr4:154670444	T/C	cg14289246	chr4:154710475	SFRP2	-0.71	-11.07	-0.46	1.95e-25	Electrocardiographic conduction measures;
LGG	cis	rs2066819	1.000	rs77768890	chr12:56725121	A/G	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs1670533	1.000	rs13119276	chr4:1051574	T/C	cg27284194	chr4:1044797	NA	0.54	9.82	0.42	8.6e-21	Recombination rate (females);
LGG	cis	rs8017423	0.935	rs12884698	chr14:90750566	G/A	cg04374321	chr14:90722782	PSMC1	-0.86	-17.57	-0.63	2.48e-53	Mortality in heart failure;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg09359103	chr1:154839909	KCNN3	-0.53	-10.89	-0.45	9.73e-25	Prostate cancer;
LGG	cis	rs6088580	0.634	rs6058051	chr20:33044862	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9486719	1.000	rs11152959	chr6:96900272	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg04374321	chr14:90722782	PSMC1	0.51	8.95	0.38	8.38e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02071572	chr4:1403502	NA	0.41	7.03	0.31	7.43e-12	Longevity;
LGG	cis	rs9368481	0.729	rs9379950	chr6:26961548	T/C	cg18867708	chr6:26865862	GUSBL1	-0.46	-7.65	-0.33	1.18e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2463822	0.669	rs72919496	chr11:62052730	T/C	cg06239285	chr11:62104954	ASRGL1	-1.12	-13.67	-0.54	5.47e-36	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs17030434	0.871	rs78151744	chr4:154730266	C/T	cg14289246	chr4:154710475	SFRP2	-0.62	-10.08	-0.42	1.01e-21	Electrocardiographic conduction measures;
LGG	cis	rs2011503	0.941	rs80146298	chr19:19426317	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	6.85	0.3	2.3e-11	Bipolar disorder;
LGG	cis	rs6977660	0.714	rs10270468	chr7:19810559	T/C	cg07541023	chr7:19748670	TWISTNB	0.61	8.25	0.36	1.7e-15	Thyroid stimulating hormone;
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg21017887	chr14:105400489	NA	-0.39	-7.73	-0.34	6.63e-14	Rheumatoid arthritis;
LGG	trans	rs4942242	0.640	rs17460861	chr13:44230078	C/G	cg19169023	chr15:41853346	TYRO3	0.45	8.91	0.38	1.15e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1568889	1.000	rs7112860	chr11:28151609	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.61	0.56	5.2e-40	Bipolar disorder;
LGG	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg03806693	chr22:41940476	POLR3H	1.05	19.68	0.67	4.36e-63	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9831754	0.756	rs13084140	chr3:78426004	G/A	cg06138941	chr3:78371609	NA	-0.79	-15.58	-0.59	2.6e-44	Calcium levels;
LGG	cis	rs283228	0.920	rs1338160	chr6:101834491	C/G	cg27451362	chr6:101846650	GRIK2	0.55	9.41	0.4	2.31e-19	Coenzyme Q10 levels;
LGG	cis	rs9486715	0.867	rs2223238	chr6:96871855	G/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.06	0.35	6.68e-15	Headache;
LGG	cis	rs7923837	0.663	rs7903302	chr10:94429511	T/C	cg25093409	chr10:94429542	NA	0.47	9.38	0.4	2.89e-19	Body mass index;Multiple sclerosis;
LGG	cis	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg19399532	chr1:178512495	C1orf220	0.56	11.62	0.48	1.43e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.0	-0.31	8.93e-12	Bipolar disorder;
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg12379764	chr21:47803548	PCNT	-0.47	-8.17	-0.36	2.89e-15	Testicular germ cell tumor;
LGG	cis	rs7726839	0.561	rs4957050	chr5:579066	A/C	cg01221209	chr5:554886	NA	-0.48	-7.7	-0.34	8.35e-14	Obesity-related traits;
LGG	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg23248424	chr5:179741104	GFPT2	-0.62	-11.06	-0.46	2.25e-25	Height;
LGG	cis	rs17253792	0.731	rs28587929	chr14:56097492	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	trans	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg02002194	chr4:3960332	NA	0.42	7.73	0.34	6.68e-14	Neuroticism;
LGG	cis	rs2976388	1.000	rs2976392	chr8:143762932	G/A	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg13206674	chr6:150067644	NUP43	0.62	13.83	0.54	1.21e-36	Lung cancer;
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg02002194	chr4:3960332	NA	-0.44	-8.19	-0.36	2.5e-15	Mood instability;
LGG	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg11871910	chr12:69753446	YEATS4	0.92	22.2	0.72	6.71e-75	Blood protein levels;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg05165339	chr4:1420672	NA	0.35	8.99	0.39	6.28e-18	Longevity;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs11628318	0.614	rs7154538	chr14:103068112	A/G	cg23461800	chr14:103021989	NA	-0.49	-7.98	-0.35	1.14e-14	Platelet count;
LGG	cis	rs317689	0.702	rs544696	chr12:69749939	T/C	cg11871910	chr12:69753446	YEATS4	0.85	16.0	0.6	3.48e-46	Response to diuretic therapy;
LGG	trans	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.29	-0.43	1.62e-22	Neuroticism;
LGG	cis	rs12579753	1.000	rs7975863	chr12:82227288	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.07e-25	Resting heart rate;
LGG	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg11965913	chr1:205819406	PM20D1	-0.41	-6.89	-0.31	1.78e-11	Menarche (age at onset);
LGG	cis	rs1577917	1.000	rs11759855	chr6:86610841	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.43	-0.53	5.67e-35	Response to antipsychotic treatment;
LGG	cis	rs7927771	0.524	rs11039329	chr11:47684908	A/G	cg20307385	chr11:47447363	PSMC3	0.56	10.87	0.45	1.12e-24	Subjective well-being;
LGG	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs876084	0.722	rs1401813	chr8:121042513	A/G	cg22335954	chr8:121166405	COL14A1	0.32	6.72	0.3	5.3e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9790314	0.502	rs34972965	chr3:160984296	G/A	cg03342759	chr3:160939853	NMD3	-0.77	-13.84	-0.54	1.04e-36	Morning vs. evening chronotype;
LGG	cis	rs2486288	0.656	rs11629858	chr15:45547114	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.72	-0.41	1.91e-20	Glomerular filtration rate;
LGG	cis	rs10089	1.000	rs10061367	chr5:127449021	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg09307838	chr4:120376055	NA	0.81	13.5	0.53	2.96e-35	Corneal astigmatism;
LGG	cis	rs35740288	0.539	rs11629991	chr15:86336664	A/G	cg04173714	chr15:86211321	AKAP13	0.41	6.95	0.31	1.26e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12765878	0.603	rs10786773	chr10:105644275	A/T	cg11005552	chr10:105648138	OBFC1	-0.73	-12.87	-0.51	1.34e-32	Coronary artery disease;
LGG	cis	rs35771425	0.572	rs34552796	chr1:211422229	C/T	cg10512769	chr1:211675356	NA	-0.44	-7.7	-0.34	8.15e-14	Educational attainment (years of education);
LGG	cis	rs9400467	0.537	rs584937	chr6:111481577	T/G	cg15721981	chr6:111408429	SLC16A10	0.55	6.7	0.3	6.15e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	16.87	0.62	3.9e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4595586	0.525	rs11609150	chr12:39408622	A/C	cg26384229	chr12:38710491	ALG10B	0.66	11.9	0.48	1.13e-28	Morning vs. evening chronotype;
LGG	cis	rs6598955	0.671	rs17162105	chr1:26591255	A/G	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.45e-15	Obesity-related traits;
LGG	trans	rs7824557	0.547	rs6601570	chr8:11079367	G/A	cg02002194	chr4:3960332	NA	0.47	8.64	0.37	9.46e-17	Retinal vascular caliber;
LGG	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg14088196	chr11:70211408	PPFIA1	0.83	11.66	0.48	1.04e-27	Coronary artery disease;
LGG	cis	rs1185460	0.565	rs1043314	chr11:118915944	A/G	cg24687335	chr11:118901407	SLC37A4	-0.59	-10.57	-0.44	1.52e-23	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.5	0.44	2.84e-23	Diabetic retinopathy;
LGG	cis	rs7666738	0.830	rs10011009	chr4:98981749	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.86	0.34	2.79e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07157834	chr1:205819609	PM20D1	0.75	17.41	0.63	1.44e-52	Menarche (age at onset);
LGG	cis	rs16976116	0.901	rs1061873	chr15:55496756	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg05210886	chr1:245133216	EFCAB2	-0.43	-6.86	-0.3	2.24e-11	Coronary artery disease;
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg16141378	chr3:129829833	LOC729375	0.39	9.3	0.4	5.38e-19	Systolic blood pressure;
LGG	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs11997175	0.574	rs4370495	chr8:33654819	G/A	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	cis	rs1790761	0.904	rs630172	chr11:67253673	C/A	cg08355456	chr11:67383691	NA	0.41	6.7	0.3	6.22e-11	Mean corpuscular volume;
LGG	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg04450456	chr4:17643702	FAM184B	0.33	7.22	0.32	2.1e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs929354	0.713	rs10085650	chr7:156993413	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.64	0.59	1.46e-44	Body mass index;
LGG	cis	rs67478160	0.643	rs12891175	chr14:104274166	T/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.47	-0.33	4.12e-13	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg25358565	chr5:93447407	FAM172A	1.34	16.64	0.61	4.43e-49	Diabetic retinopathy;
LGG	cis	rs4474465	1.000	rs10793314	chr11:78174196	G/C	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs6963495	0.745	rs818620	chr7:105172685	G/C	cg19920283	chr7:105172520	RINT1	0.59	8.08	0.35	5.58e-15	Bipolar disorder (body mass index interaction);
LGG	cis	rs12477438	0.520	rs7605843	chr2:99811894	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	31.89	0.83	6.37e-119	Chronic sinus infection;
LGG	cis	rs7017914	0.967	rs35295900	chr8:71642061	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs526231	0.543	rs72785717	chr5:102333105	C/T	cg23492399	chr5:102201601	PAM	-0.68	-10.35	-0.43	1e-22	Primary biliary cholangitis;
LGG	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg01130898	chr2:219473002	PLCD4	-0.44	-7.71	-0.34	7.72e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6942756	1.000	rs17168512	chr7:128955033	A/G	cg02491457	chr7:128862824	NA	-0.74	-13.52	-0.53	2.48e-35	White matter hyperintensity burden;
LGG	cis	rs2304069	0.601	rs216143	chr5:149444147	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.67	10.06	0.42	1.11e-21	HIV-1 control;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg12070911	chr6:150209640	RAET1E	0.29	6.9	0.31	1.69e-11	Lung cancer;
LGG	cis	rs6912958	0.781	rs7750207	chr6:88303967	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.73	-0.38	4.6e-17	Monocyte percentage of white cells;
LGG	cis	rs10754283	0.967	rs10737706	chr1:90112579	G/T	cg06121193	chr1:90282411	NA	-0.37	-7.24	-0.32	1.94e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.14e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs75059851	0.756	rs2000853	chr11:133838417	A/G	cg17703048	chr11:133852993	NA	-0.87	-15.97	-0.6	4.75e-46	Schizophrenia;
LGG	cis	rs4851266	1.000	rs12991254	chr2:100817933	T/C	cg21926883	chr2:100939477	LONRF2	-0.43	-7.83	-0.34	3.35e-14	Educational attainment;
LGG	cis	rs10883723	0.810	rs12162	chr10:104240498	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.78	13.15	0.52	8.49e-34	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.58	-0.47	2.08e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504130	0.597	rs4598243	chr8:52709718	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.75	-0.3	4.54e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.04	0.31	6.93e-12	Lung cancer;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.07e-20	Lung cancer;
LGG	cis	rs3096299	0.933	rs747485	chr16:89474094	T/C	cg06640241	chr16:89574553	SPG7	0.72	12.62	0.51	1.35e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs9910055	0.659	rs7207464	chr17:42245033	C/T	cg13607699	chr17:42295918	UBTF	0.56	9.3	0.4	5.66e-19	Total body bone mineral density;
LGG	cis	rs4740619	0.755	rs7860992	chr9:15795865	C/G	cg14451791	chr9:16040625	NA	0.31	7.69	0.34	8.95e-14	Body mass index;
LGG	cis	rs35164067	1.000	rs34953890	chr19:10526854	C/A	cg21868191	chr19:10515988	NA	-0.52	-7.64	-0.33	1.23e-13	Inflammatory bowel disease;
LGG	cis	rs13040088	0.872	rs2295481	chr20:61574727	C/T	cg23096297	chr20:61557774	DIDO1	0.87	12.02	0.49	3.71e-29	Menopause (age at onset);
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg07308232	chr7:1071921	C7orf50	-0.69	-13.7	-0.54	4e-36	Longevity;Endometriosis;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg02725872	chr8:58115012	NA	-0.84	-12.11	-0.49	1.61e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs5743618	0.537	rs11466661	chr4:38774482	G/T	cg06935464	chr4:38784597	TLR10	0.37	6.72	0.3	5.19e-11	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7819412	0.522	rs4291231	chr8:10990164	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.74	0.3	4.78e-11	Triglycerides;
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg18538332	chr22:24372958	LOC391322	-0.46	-7.54	-0.33	2.56e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs270601	0.721	rs162894	chr5:131611872	T/G	cg07395648	chr5:131743802	NA	-0.36	-7.06	-0.31	6.3e-12	Acylcarnitine levels;
LGG	cis	rs258892	0.895	rs463250	chr5:72144463	G/C	cg21869765	chr5:72125136	TNPO1	0.42	6.68	0.3	7.01e-11	Small cell lung carcinoma;
LGG	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg18225595	chr11:63971243	STIP1	0.56	7.47	0.33	4.17e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs365132	0.875	rs353476	chr5:176424035	A/G	cg16309518	chr5:176445507	NA	-0.51	-11.16	-0.46	8.78e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.1	-0.35	5.09e-15	Coronary artery disease;
LGG	cis	rs896854	0.738	rs481887	chr8:95967838	A/G	cg16049864	chr8:95962084	TP53INP1	0.4	8.68	0.37	6.93e-17	Type 2 diabetes;
LGG	trans	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg22232500	chr2:134024266	NCKAP5	0.61	8.3	0.36	1.13e-15	Bipolar disorder;
LGG	cis	rs1401999	0.864	rs4148563	chr3:183725999	T/C	cg01324343	chr3:183735012	ABCC5	0.87	18.07	0.64	1.2e-55	Anterior chamber depth;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg19223190	chr17:80058835	NA	-0.46	-9.01	-0.39	5.25e-18	Life satisfaction;
LGG	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.65e-19	Neuroticism;
LGG	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	7.78	0.34	4.76e-14	Neuroticism;
LGG	cis	rs7103648	0.695	rs6485758	chr11:47530024	G/A	cg20307385	chr11:47447363	PSMC3	0.87	18.66	0.66	2.23e-58	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14373873	chr11:113211441	TTC12	-0.45	-9.46	-0.4	1.59e-19	Neuroticism;
LGG	cis	rs6582630	0.573	rs12319414	chr12:38267440	T/C	cg26384229	chr12:38710491	ALG10B	-0.63	-12.11	-0.49	1.63e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.35	-0.4	3.69e-19	Sudden cardiac arrest;
LGG	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.29	0.36	1.2e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs826838	0.967	rs6580726	chr12:39108623	T/C	cg13010199	chr12:38710504	ALG10B	-0.64	-13.6	-0.53	1.15e-35	Heart rate;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2084898	0.891	rs504236	chr11:120000263	T/C	cg13907859	chr11:120009124	TRIM29	-0.87	-12.45	-0.5	6.75e-31	Stroke (pediatric);
LGG	cis	rs12618769	0.597	rs3769713	chr2:99151434	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.71	0.34	7.52e-14	Bipolar disorder;
LGG	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg25319279	chr11:5960081	NA	0.56	8.61	0.37	1.12e-16	DNA methylation (variation);
LGG	trans	rs7937682	0.889	rs1789355	chr11:111499718	T/C	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs12579753	0.917	rs7954438	chr12:82184419	T/C	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.86	-0.45	1.29e-24	Resting heart rate;
LGG	trans	rs11989744	1.000	rs17782111	chr8:23565784	A/G	cg03492747	chr16:86543808	FOXF1	0.51	7.62	0.33	1.4e-13	Waist-hip ratio;
LGG	cis	rs4363385	0.818	rs529077	chr1:153012149	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg08916839	chr5:415575	AHRR	0.95	13.98	0.54	2.55e-37	Fat distribution (HIV);
LGG	cis	rs1505368	0.505	rs1394781	chr2:213248822	C/T	cg16329650	chr2:213403929	ERBB4	-0.42	-7.57	-0.33	2.08e-13	Symmetrical dimethylarginine levels;
LGG	cis	rs151349	0.564	rs2162593	chr20:57618794	T/C	cg23907860	chr20:57583709	CTSZ	-0.37	-6.86	-0.3	2.26e-11	Platelet distribution width;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg11878867	chr6:150167359	LRP11	-0.54	-11.16	-0.46	9.07e-26	Lung cancer;
LGG	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.6	-0.37	1.25e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.09	-0.42	9.04e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.61e-14	Cystic fibrosis severity;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.49e-22	Tonsillectomy;
LGG	cis	rs4538187	0.585	rs329478	chr2:64257746	A/G	cg14150252	chr2:64069583	UGP2	0.45	8.09	0.35	5.36e-15	Systolic blood pressure;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20366603	chr17:7218821	GPS2	0.4	6.82	0.3	2.84e-11	Body mass index;
LGG	cis	rs5766691	0.644	rs6007607	chr22:47529288	C/G	cg15757745	chr22:47558489	TBC1D22A	-0.68	-12.37	-0.5	1.48e-30	Longevity;
LGG	cis	rs12681287	0.640	rs7841690	chr8:87365359	T/C	cg27223183	chr8:87520930	FAM82B	0.5	7.66	0.34	1.11e-13	Caudate activity during reward;
LGG	cis	rs62244186	0.659	rs56231820	chr3:44530329	C/T	cg02073558	chr3:44770973	ZNF501	0.64	11.46	0.47	6.34e-27	Depressive symptoms;
LGG	cis	rs240764	0.782	rs239231	chr6:101105022	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	trans	rs6956675	0.915	rs4717501	chr7:62652936	C/T	cg01314568	chr7:57830625	NA	-0.47	-7.64	-0.33	1.26e-13	Obesity-related traits;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.46	-0.56	2.31e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs9393692	0.557	rs6918325	chr6:26327965	T/G	cg13736514	chr6:26305472	NA	-0.49	-9.42	-0.4	2.21e-19	Educational attainment;
LGG	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	13.06	0.52	2.15e-33	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs79839061	0.610	rs78590562	chr4:869715	C/T	cg07828340	chr4:882639	GAK	0.86	9.13	0.39	2.1e-18	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg19143629	chr17:61920732	SMARCD2	0.43	7.38	0.32	7.43e-13	Prudent dietary pattern;
LGG	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg07440826	chr16:89882328	FANCA	0.25	6.66	0.3	7.57e-11	Vitiligo;
LGG	cis	rs55665837	0.540	rs10832299	chr11:14769392	G/A	cg18937875	chr11:14930189	NA	-0.48	-7.83	-0.34	3.31e-14	Vitamin D levels;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg19847130	chr8:10466454	RP1L1	0.3	6.65	0.3	8.48e-11	Joint mobility (Beighton score);
LGG	cis	rs9944715	1.000	rs11082518	chr18:43842032	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.66	-0.3	7.83e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.45	-0.4	1.65e-19	Blood metabolite levels;
LGG	cis	rs12615966	0.651	rs60920571	chr2:105408284	C/G	cg16465502	chr2:105461796	NA	0.99	11.27	0.46	3.25e-26	Pancreatic cancer;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.12	-0.43	6.9e-22	Lung cancer;
LGG	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg19628046	chr18:33552617	C18orf21	0.52	7.58	0.33	1.96e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9309473	0.950	rs6546853	chr2:73833739	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.3e-14	Metabolite levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03773681	chr2:63815918	MDH1;C2orf86	0.39	6.74	0.3	4.61e-11	Bipolar disorder;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg04025307	chr7:1156635	C7orf50	0.92	20.78	0.69	3.2e-68	Longevity;Endometriosis;
LGG	cis	rs7546094	0.967	rs910697	chr1:113063125	A/G	cg22162597	chr1:113214053	CAPZA1	0.38	7.52	0.33	2.93e-13	Platelet distribution width;
LGG	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg03060546	chr3:49711283	APEH	0.74	13.34	0.53	1.35e-34	Resting heart rate;
LGG	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg08085267	chr17:45401833	C17orf57	-0.55	-10.01	-0.42	1.76e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs78487399	0.808	rs7586101	chr2:43669851	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.61	6.71	0.3	5.8e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.506	rs1984839	chr22:41685937	G/C	cg03806693	chr22:41940476	POLR3H	-0.73	-12.11	-0.49	1.62e-29	Vitiligo;
LGG	cis	rs6066825	0.555	rs6019378	chr20:47309716	C/T	cg18078177	chr20:47281410	PREX1	0.45	7.61	0.33	1.59e-13	Colorectal cancer;
LGG	cis	rs7819412	0.669	rs35499486	chr8:11074036	G/A	cg21775007	chr8:11205619	TDH	-0.54	-8.56	-0.37	1.7e-16	Triglycerides;
LGG	cis	rs11676855	0.893	rs6431329	chr2:235934338	C/T	cg06431347	chr2:235935754	SH3BP4	-0.5	-11.88	-0.48	1.35e-28	Dialysis-related mortality;
LGG	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg00319359	chr11:70116639	PPFIA1	0.74	7.83	0.34	3.41e-14	Coronary artery disease;
LGG	cis	rs4595586	0.545	rs1303887	chr12:39366523	C/T	cg13010199	chr12:38710504	ALG10B	0.4	7.2	0.32	2.53e-12	Morning vs. evening chronotype;
LGG	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.49	-0.33	3.42e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs11190604	1.000	rs3750626	chr10:102266316	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.75e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg09699651	chr6:150184138	LRP11	0.47	8.36	0.36	7.26e-16	Lung cancer;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9951602	0.541	rs12454297	chr18:76654445	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs2760061	0.545	rs1636196	chr1:228204030	A/G	cg02753203	chr1:228287806	NA	0.92	19.19	0.67	8.16e-61	Diastolic blood pressure;
LGG	cis	rs12928939	0.769	rs12445161	chr16:71741928	C/T	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.36	-0.4	3.61e-19	Post bronchodilator FEV1;
LGG	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.49	0.53	3.41e-35	Bladder cancer;
LGG	cis	rs35306767	0.903	rs35370435	chr10:898205	T/C	cg20503657	chr10:835505	NA	0.95	12.89	0.51	1.02e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs7091068	0.566	rs7909925	chr10:95507170	A/G	cg20715218	chr10:95462985	C10orf4	0.65	9.43	0.4	1.96e-19	Urinary tract infection frequency;
LGG	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg03517284	chr6:25882590	NA	-0.55	-10.56	-0.44	1.66e-23	Blood metabolite levels;
LGG	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.05	16.1	0.6	1.21e-46	Smoking behavior;
LGG	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg17376030	chr22:41985996	PMM1	0.55	8.97	0.38	7.18e-18	Vitiligo;
LGG	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.81	-0.51	2.25e-32	Response to antipsychotic treatment;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06634786	chr22:41940651	POLR3H	0.79	12.59	0.51	1.82e-31	Vitiligo;
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg04013166	chr16:89971882	TCF25	0.55	7.37	0.32	8.1e-13	Skin colour saturation;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs778371	0.748	rs2675953	chr2:233749565	G/C	cg25237894	chr2:233734115	C2orf82	-0.47	-7.92	-0.35	1.82e-14	Schizophrenia;
LGG	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg24687335	chr11:118901407	SLC37A4	-0.6	-10.86	-0.45	1.28e-24	Coronary artery disease;
LGG	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.81	-0.34	3.78e-14	Total cholesterol levels;
LGG	trans	rs9929218	0.954	rs35794312	chr16:68827785	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.2	-0.49	7.28e-30	Colorectal cancer;
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg27432699	chr2:27873401	GPN1	-0.48	-8.15	-0.35	3.35e-15	Total body bone mineral density;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	trans	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.77	-13.54	-0.53	1.93e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17767392	1.000	rs61991204	chr14:71768073	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs5756391	0.748	rs5756394	chr22:37300530	T/C	cg21209356	chr22:37319042	CSF2RB	0.37	8.28	0.36	1.33e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg12395012	chr8:11607386	GATA4	0.4	6.8	0.3	3.15e-11	Retinal vascular caliber;
LGG	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg16583315	chr14:65563665	MAX	-0.43	-8.68	-0.37	6.87e-17	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs4332037	0.539	rs56180486	chr7:2050747	C/T	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.2	-0.32	2.47e-12	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06942064	chr1:208417143	PLXNA2	-0.46	-6.85	-0.3	2.34e-11	Systemic lupus erythematosus;
LGG	cis	rs787274	0.718	rs4979170	chr9:115626918	C/G	cg13803584	chr9:115635662	SNX30	0.66	9.55	0.41	7.51e-20	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6977660	0.714	rs10252965	chr7:19822385	A/C	cg07541023	chr7:19748670	TWISTNB	0.58	7.86	0.34	2.64e-14	Thyroid stimulating hormone;
LGG	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs947211	0.950	rs1775145	chr1:205756143	C/A	cg24503407	chr1:205819492	PM20D1	0.49	8.21	0.36	2.26e-15	Parkinson's disease;
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.92	-0.31	1.54e-11	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19738812	chr7:99102438	ZKSCAN5	0.38	6.82	0.3	2.77e-11	Obesity-related traits;
LGG	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs7727544	0.582	rs10075459	chr5:131541363	C/G	cg07395648	chr5:131743802	NA	-0.39	-8.5	-0.37	2.69e-16	Blood metabolite levels;
LGG	cis	rs283228	1.000	rs2787584	chr6:101812581	A/G	cg27451362	chr6:101846650	GRIK2	0.54	9.06	0.39	3.81e-18	Coenzyme Q10 levels;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs28588043	1.000	rs28650053	chr1:170976969	C/T	cg03458344	chr1:170964477	C1orf129	-0.51	-7.47	-0.33	3.97e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7086627	0.515	rs7907969	chr10:82153005	T/A	cg00277334	chr10:82204260	NA	-0.34	-7.51	-0.33	3.1400000000000003e-13	Post bronchodilator FEV1;
LGG	cis	rs9640161	0.830	rs3757424	chr7:150067679	C/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.52	-10.22	-0.43	3.05e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-11.38	-0.47	1.23e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg21798802	chr22:38057573	PDXP	0.61	14.05	0.55	1.38e-37	Fat distribution (HIV);
LGG	cis	rs2371030	0.965	rs10932351	chr2:211566911	A/G	cg18417063	chr2:211583084	NA	-0.63	-12.23	-0.49	5.43e-30	Non-small cell lung cancer;
LGG	cis	rs4788570	0.615	rs2334880	chr16:71653637	A/G	cg06353428	chr16:71660113	MARVELD3	1.21	20.57	0.69	3.05e-67	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.805	rs6502061	chr17:80086158	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.86	0.3	2.16e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2760061	0.583	rs1636195	chr1:228211589	T/C	cg01200585	chr1:228362443	C1orf69	0.48	8.14	0.35	3.56e-15	Diastolic blood pressure;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg13939156	chr17:80058883	NA	0.5	9.92	0.42	3.61e-21	Life satisfaction;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09921682	chr7:50133131	ZPBP	0.34	8.6	0.37	1.26e-16	Menarche (age at onset);
LGG	trans	rs7208859	0.673	rs423151	chr17:28952286	A/G	cg22358067	chr17:16797159	NA	-0.51	-7.2	-0.32	2.49e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg24690094	chr11:67383802	NA	-0.4	-6.99	-0.31	9.41e-12	Mean corpuscular volume;
LGG	trans	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	trans	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg17830980	chr10:43048298	ZNF37B	0.62	14.22	0.55	2.46e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs6504108	0.624	rs7225865	chr17:46209964	A/G	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs9305556	1.000	rs9305556	chr21:36014908	A/G	cg24523685	chr21:36062813	CLIC6	-0.39	-7.42	-0.33	5.76e-13	Psoriasis;
LGG	cis	rs1577917	0.958	rs11758508	chr6:86506878	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	9.29	0.4	6.12e-19	Response to antipsychotic treatment;
LGG	cis	rs1497828	0.956	rs2815232	chr1:217538336	A/G	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg16141378	chr3:129829833	LOC729375	-0.36	-8.07	-0.35	5.9e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	1.07e-29	Prudent dietary pattern;
LGG	cis	rs9788721	1.000	rs55781567	chr15:78857986	C/G	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.37	-0.32	7.81e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1577917	1.000	rs7771342	chr6:86631936	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02994863	chr1:64059297	PGM1	0.5	8.14	0.35	3.7e-15	Cognitive performance;
LGG	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15664640	chr17:80829946	TBCD	0.68	13.18	0.52	6.86e-34	Breast cancer;
LGG	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00761968	chr13:53314142	LECT1	0.36	7.33	0.32	1.01e-12	Lewy body disease;
LGG	cis	rs4974559	0.739	rs59810282	chr4:1320968	A/G	cg02980000	chr4:1222292	CTBP1	0.81	9.38	0.4	2.84e-19	Systolic blood pressure;
LGG	cis	rs3768617	0.510	rs12061219	chr1:183101471	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs9362426	0.708	rs4707365	chr6:88100912	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.43	8.28	0.36	1.3e-15	Depressive episodes in bipolar disorder;
LGG	cis	rs7552404	1.000	rs7533888	chr1:76160449	A/C	cg10523679	chr1:76189770	ACADM	0.8	14.64	0.56	3.56e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4969178	0.965	rs3817295	chr17:76394526	T/A	cg05887092	chr17:76393375	PGS1	0.72	15.74	0.59	5.32e-45	HDL cholesterol levels;
LGG	cis	rs929354	0.772	rs7778193	chr7:156980087	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	cis	rs888194	0.966	rs1558804	chr12:109898732	A/G	cg19025524	chr12:109796872	NA	-0.39	-7.88	-0.34	2.28e-14	Neuroticism;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg07701084	chr6:150067640	NUP43	0.69	12.8	0.51	2.42e-32	Lung cancer;
LGG	cis	rs2522056	1.000	rs62385693	chr5:131773674	T/C	cg07395648	chr5:131743802	NA	0.42	7.27	0.32	1.57e-12	Lymphocyte counts;Fibrinogen;
LGG	trans	rs9467711	0.790	rs13198716	chr6:26582035	A/G	cg08344181	chr3:125677491	NA	0.79	7.99	0.35	1.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12681366	0.614	rs2930969	chr8:95464085	C/T	cg13257157	chr8:95487014	RAD54B	0.38	7.02	0.31	8.02e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7264396	0.790	rs6121015	chr20:34243017	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.43	0.33	5.22e-13	Total cholesterol levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09947615	chr4:42659549	ATP8A1	0.43	7.09	0.31	5.02e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12579753	0.871	rs10862363	chr12:82201254	T/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs4919087	0.590	rs1253401	chr10:99050270	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.07	-0.31	5.63e-12	Monocyte count;
LGG	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg27476859	chr7:2772710	GNA12	0.65	13.2	0.52	5.36e-34	Height;
LGG	cis	rs9324022	0.929	rs17099617	chr14:101170488	A/G	cg18089426	chr14:101175970	NA	0.68	11.21	0.46	5.9e-26	Plateletcrit;
LGG	trans	rs3857536	0.813	rs1029400	chr6:66952385	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.82	-0.34	3.57e-14	Blood trace element (Cu levels);
LGG	cis	rs780096	0.526	rs1647266	chr2:27693485	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.36	0.4	3.44e-19	Diabetic retinopathy;
LGG	cis	rs7819412	0.502	rs4841499	chr8:10988138	A/C	cg21775007	chr8:11205619	TDH	-0.51	-7.63	-0.33	1.38e-13	Triglycerides;
LGG	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg13147721	chr7:65941812	NA	-0.79	-9.55	-0.41	7.33e-20	Diabetic kidney disease;
LGG	cis	rs10206020	0.885	rs6720797	chr2:1574340	T/C	cg26248373	chr2:1572462	NA	-0.87	-15.31	-0.58	4.36e-43	IgG glycosylation;
LGG	cis	rs2573652	0.698	rs12916269	chr15:100530216	A/T	cg14911520	chr15:100542628	ADAMTS17	0.29	7.14	0.31	3.66e-12	Height;
LGG	cis	rs2236267	0.726	rs6574994	chr14:88614541	A/G	cg02175263	chr14:88627849	NA	0.32	7.27	0.32	1.52e-12	Food antigen IgG levels;
LGG	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.49	8.63	0.37	9.79e-17	Breast cancer;
LGG	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg05082376	chr22:42548792	NA	-0.42	-8.76	-0.38	3.79e-17	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.03	-0.31	7.42e-12	Lung cancer;
LGG	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.06	0.35	6.56e-15	HDL cholesterol;
LGG	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg01420254	chr6:26195488	NA	0.91	12.28	0.5	3.29e-30	Gout;Renal underexcretion gout;
LGG	trans	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg23762105	chr12:34175262	ALG10	0.34	6.76	0.3	4.18e-11	Morning vs. evening chronotype;
LGG	cis	rs738321	0.762	rs4820321	chr22:38579569	T/A	cg03162506	chr22:38580953	NA	0.38	9.15	0.39	1.86e-18	Breast cancer;
LGG	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg18252515	chr7:66147081	NA	-1.31	-19.1	-0.66	2.09e-60	Diabetic kidney disease;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.545	rs11191602	chr10:104954219	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.16	-0.32	3.16e-12	Arsenic metabolism;
LGG	cis	rs8038465	0.592	rs899981	chr15:73935329	G/A	cg15420318	chr15:73925796	NPTN	0.49	8.35	0.36	7.82e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.92	-0.38	1.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6879260	1.000	rs6874653	chr5:179730843	A/G	cg23248424	chr5:179741104	GFPT2	-0.6	-10.86	-0.45	1.3e-24	Height;
LGG	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg03433033	chr1:76189801	ACADM	-0.76	-13.3	-0.53	2.13e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg09307838	chr4:120376055	NA	0.79	12.92	0.51	8.27e-33	Corneal astigmatism;
LGG	cis	rs12908161	1.000	rs12899981	chr15:85302373	G/A	cg24253500	chr15:84953950	NA	0.42	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs4731207	0.651	rs28710776	chr7:124614472	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	trans	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.91	-0.38	1.15e-17	Bladder cancer;
LGG	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02711726	chr17:80685570	FN3KRP	-0.57	-9.6	-0.41	4.91e-20	Glycated hemoglobin levels;
LGG	cis	rs1010254	0.510	rs72791425	chr5:151770646	A/G	cg08593883	chr5:151785301	NMUR2	-0.45	-7.08	-0.31	5.5e-12	Optic nerve measurement (cup area);
LGG	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.81	9.18	0.39	1.48e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.38	0.56	4.8e-39	Morning vs. evening chronotype;
LGG	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.68	0.44	6.01e-24	Lung cancer in ever smokers;
LGG	cis	rs6088580	0.609	rs6059845	chr20:33036500	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.63e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg27286069	chr11:118481882	PHLDB1	0.56	10.18	0.43	4.08e-22	Cholesterol, total;
LGG	cis	rs929354	0.772	rs1182441	chr7:157026650	A/G	cg17757837	chr7:157058334	UBE3C	-0.78	-15.89	-0.59	1.12e-45	Body mass index;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.54	14.13	0.55	5.84e-38	Tonsillectomy;
LGG	cis	rs72781680	0.898	rs79023848	chr2:24038174	C/A	cg08917208	chr2:24149416	ATAD2B	0.9	9.54	0.41	7.94e-20	Lymphocyte counts;
LGG	cis	rs7586879	0.639	rs13407913	chr2:25097644	A/G	cg04586622	chr2:25135609	ADCY3	0.44	11.76	0.48	4.12e-28	Body mass index;
LGG	cis	rs7493	0.901	rs17883318	chr7:94958312	G/A	cg08461772	chr7:95026248	PON3	0.4	8.92	0.38	1.05e-17	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9951602	0.607	rs3017651	chr18:76668622	T/C	cg00806245	chr18:76673096	NA	-0.73	-11.62	-0.48	1.49e-27	Obesity-related traits;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg02158880	chr13:53174818	NA	0.72	16.4	0.61	5.21e-48	Lewy body disease;
LGG	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg13393036	chr8:95962371	TP53INP1	-0.26	-6.89	-0.3	1.88e-11	Type 2 diabetes;
LGG	cis	rs7107174	0.892	rs10793310	chr11:78099014	T/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg08000102	chr2:233561755	GIGYF2	-0.55	-8.75	-0.38	4.15e-17	Coronary artery disease;
LGG	cis	rs2463822	0.583	rs72917379	chr11:62026112	T/C	cg06239285	chr11:62104954	ASRGL1	-1.01	-12.13	-0.49	1.33e-29	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg12046867	chr14:103022105	NA	0.72	12.23	0.49	5.23e-30	Platelet count;
LGG	trans	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.47e-27	Corneal astigmatism;
LGG	cis	rs804280	0.662	rs7826055	chr8:11611723	G/C	cg12395012	chr8:11607386	GATA4	0.65	10.98	0.45	4.56e-25	Myopia (pathological);
LGG	cis	rs17209837	0.607	rs12539936	chr7:87110017	A/G	cg25823085	chr7:87105416	ABCB4	-0.3	-7.42	-0.33	5.48e-13	Gallbladder cancer;
LGG	cis	rs713587	0.806	rs6737082	chr2:25138040	A/C	cg04586622	chr2:25135609	ADCY3	0.41	11.22	0.46	5.48e-26	Body mass index in non-asthmatics;
LGG	cis	rs2124969	0.548	rs62175384	chr2:161011128	C/T	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.27	-0.4	7.23e-19	Waist circumference adjusted for body mass index;
LGG	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.1	-0.35	4.94e-15	Height;
LGG	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9303401	0.661	rs9902820	chr17:56637545	A/C	cg12560992	chr17:57184187	TRIM37	0.53	8.51	0.37	2.37e-16	Cognitive test performance;
LGG	cis	rs17221829	0.733	rs10830327	chr11:89389122	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs4566357	1.000	rs2141829	chr2:227922454	G/A	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.08	-0.31	5.55e-12	Coronary artery disease;
LGG	cis	rs6735179	0.798	rs7589077	chr2:1773183	C/T	cg10160682	chr2:1713001	PXDN	-0.52	-7.97	-0.35	1.22e-14	Response to antipsychotic treatment;
LGG	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.15	-0.72	1.23e-74	Primary sclerosing cholangitis;
LGG	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs867371	1.000	rs7181655	chr15:82455616	T/C	cg00614314	chr15:82944287	LOC80154	0.57	9.38	0.4	2.91e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg23958373	chr8:599963	NA	0.95	10.02	0.42	1.59e-21	IgG glycosylation;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02653800	chr10:60095305	UBE2D1	-0.46	-6.78	-0.3	3.72e-11	Systemic lupus erythematosus;
LGG	cis	rs13102973	0.965	rs4629509	chr4:135872410	C/T	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs1023500	0.551	rs2859438	chr22:42466980	A/T	cg05082376	chr22:42548792	NA	-0.37	-7.73	-0.34	6.9e-14	Schizophrenia;
LGG	cis	rs7572733	0.534	rs6434943	chr2:198762192	T/G	cg00792783	chr2:198669748	PLCL1	0.69	11.19	0.46	7.05e-26	Dermatomyositis;
LGG	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg14456004	chr13:21872349	NA	-1.15	-17.93	-0.64	5.35e-55	White matter hyperintensity burden;
LGG	cis	rs5756391	0.534	rs723590	chr22:37298682	A/G	cg21209356	chr22:37319042	CSF2RB	0.42	8.9	0.38	1.24e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs10504229	0.728	rs17804750	chr8:58155751	T/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12519773	0.517	rs17360811	chr5:92492349	G/A	cg18783429	chr5:92414398	NA	0.32	7.93	0.35	1.64e-14	Migraine;
LGG	cis	rs12286929	0.644	rs12099024	chr11:115082142	A/G	cg04055981	chr11:115044050	NA	0.38	6.99	0.31	9.37e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs62238980	0.521	rs80342684	chr22:32380494	G/A	cg00543991	chr22:32367038	NA	0.8	8.88	0.38	1.46e-17	Childhood ear infection;
LGG	cis	rs67133203	0.904	rs11169654	chr12:51380835	C/T	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg03235661	chr20:60525775	NA	0.32	7.47	0.33	4.01e-13	Obesity-related traits;
LGG	cis	rs12348691	0.503	rs7848950	chr9:100612774	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.18	-0.6	5.35e-47	Alopecia areata;
LGG	cis	rs9381040	1.000	rs9381040	chr6:41154650	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-6.92	-0.31	1.53e-11	Alzheimer's disease (late onset);
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg02158880	chr13:53174818	NA	0.37	7.0	0.31	9.18e-12	Lewy body disease;
LGG	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-0.97	-12.39	-0.5	1.15e-30	Lung cancer in ever smokers;
LGG	cis	rs4838594	0.563	rs9794032	chr10:49681286	A/G	cg17291251	chr10:49678358	ARHGAP22	0.5	10.84	0.45	1.44e-24	Daytime sleep phenotypes;
LGG	cis	rs1862618	0.671	rs906631	chr5:56245803	C/G	cg12654349	chr5:56205094	C5orf35	0.58	9.92	0.42	3.81e-21	Initial pursuit acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08696261	chr16:88923519	TRAPPC2L;GALNS	0.46	6.88	0.3	2.01e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs11098499	0.955	rs1511019	chr4:120166007	T/G	cg09307838	chr4:120376055	NA	0.71	11.79	0.48	3.09e-28	Corneal astigmatism;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg00814883	chr7:100076585	TSC22D4	-0.73	-10.71	-0.45	4.59e-24	Platelet count;
LGG	trans	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.51	0.4	1.07e-19	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg00166722	chr3:10149974	C3orf24	0.54	9.12	0.39	2.24e-18	Alzheimer's disease;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg13395646	chr4:1353034	KIAA1530	-0.5	-8.57	-0.37	1.56e-16	Obesity-related traits;
LGG	cis	rs2404602	0.532	rs744336	chr15:76674624	T/C	cg23625390	chr15:77176239	SCAPER	0.54	10.9	0.45	9.18e-25	Blood metabolite levels;
LGG	cis	rs7937682	0.883	rs1784775	chr11:111472460	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.65	-0.74	1.17e-81	Primary sclerosing cholangitis;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.13	0.6	8.94e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg15971980	chr6:150254442	NA	0.45	8.54	0.37	1.95e-16	Lung cancer;
LGG	cis	rs7177699	0.557	rs7165075	chr15:79115965	G/A	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg07148914	chr20:33460835	GGT7	0.59	9.75	0.41	1.55e-20	Height;
LGG	cis	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.66	0.37	7.86e-17	Mood instability;
LGG	cis	rs929596	0.564	rs2741030	chr2:234536152	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-9.43	-0.4	2.04e-19	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs2727020	0.658	rs4980431	chr11:49350071	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.77	-0.41	1.27e-20	Coronary artery disease;
LGG	cis	rs10089	1.000	rs7713877	chr5:127428825	G/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	11.98	0.49	5.29e-29	Ileal carcinoids;
LGG	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg00405596	chr8:11794950	NA	0.42	7.13	0.31	3.9e-12	Monocyte count;
LGG	cis	rs9467773	0.595	rs12525810	chr6:26623511	T/A	cg09904177	chr6:26538194	HMGN4	0.63	12.24	0.49	4.91e-30	Intelligence (multi-trait analysis);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23311950	chr12:74931760	LOC552889	-0.39	-7.76	-0.34	5.35e-14	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg18446336	chr7:2847575	GNA12	-0.39	-10.55	-0.44	1.76e-23	Height;
LGG	cis	rs9322193	0.962	rs6914319	chr6:150127440	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs72627123	0.500	rs67852564	chr14:74559920	A/G	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.49	6.91	0.31	1.58e-11	Morning vs. evening chronotype;
LGG	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg10883421	chr6:151773342	RMND1;C6orf211	0.84	18.17	0.65	4.46e-56	Menarche (age at onset);
LGG	cis	rs9549367	0.713	rs4907598	chr13:113861385	C/T	cg00898013	chr13:113819073	PROZ	0.47	9.68	0.41	2.67e-20	Platelet distribution width;
LGG	cis	rs6504108	0.624	rs2123341	chr17:46264626	A/C	cg02219949	chr17:45927392	SP6	0.41	7.38	0.32	7.51e-13	Body mass index;
LGG	cis	rs9916302	0.861	rs11658219	chr17:37709782	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.46	-0.58	8.97e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs9910055	0.530	rs7222349	chr17:42304644	C/T	cg13607699	chr17:42295918	UBTF	0.9	18.57	0.65	5.89e-58	Total body bone mineral density;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg13047869	chr3:10149882	C3orf24	0.6	8.69	0.37	6.21e-17	Alzheimer's disease;
LGG	cis	rs968451	0.547	rs11704319	chr22:39722886	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.89	-17.14	-0.62	2.47e-51	Primary biliary cholangitis;
LGG	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.87	14.19	0.55	3.43e-38	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg06558623	chr16:89946397	TCF25	0.89	11.53	0.47	3.24e-27	Interleukin-17 levels;
LGG	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-14.06	-0.55	1.19e-37	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.13	-0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs34172651	0.917	rs7204281	chr16:24784475	C/T	cg02428538	chr16:24856791	SLC5A11	-0.48	-8.16	-0.35	3.26e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7523273	0.565	rs3927459	chr1:207883907	A/C	cg22525895	chr1:207977042	MIR29B2	0.44	8.44	0.37	3.97e-16	Schizophrenia;
LGG	cis	rs2204008	0.774	rs3910796	chr12:38230660	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.94	0.54	3.87e-37	Bladder cancer;
LGG	cis	rs4642101	0.737	rs4299468	chr3:12825559	G/A	cg05775895	chr3:12838266	CAND2	0.65	11.75	0.48	4.53e-28	QRS complex (12-leadsum);
LGG	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg01448562	chr3:133502909	NA	0.74	13.75	0.54	2.52e-36	Iron status biomarkers;
LGG	trans	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9325144	0.624	rs12231544	chr12:38901956	C/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.82	-0.45	1.79e-24	Morning vs. evening chronotype;
LGG	cis	rs875971	0.767	rs12668005	chr7:65909021	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.19	0.36	2.63e-15	Aortic root size;
LGG	cis	rs7617773	0.539	rs12486935	chr3:48390164	C/T	cg11946769	chr3:48343235	NME6	0.5	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs919433	0.617	rs2037590	chr2:198584775	T/A	cg00792783	chr2:198669748	PLCL1	-0.61	-10.04	-0.42	1.32e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg11693508	chr17:37793320	STARD3	0.52	7.42	0.33	5.67e-13	Bipolar disorder;
LGG	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-13.61	-0.53	1.01e-35	Neuroticism;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.07e-20	Lung cancer;
LGG	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs1878931	0.615	rs4786412	chr16:3440390	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	23.26	0.73	7.81e-80	Body mass index (adult);
LGG	cis	rs7444	0.941	rs738128	chr22:21971010	G/A	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs4740619	0.740	rs13296276	chr9:15768683	G/A	cg14451791	chr9:16040625	NA	0.33	8.53	0.37	2.05e-16	Body mass index;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg16359550	chr11:109292809	C11orf87	0.46	8.37	0.36	6.66e-16	Schizophrenia;
LGG	cis	rs17209837	0.920	rs17149652	chr7:87087187	G/T	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg20628663	chr10:43360327	NA	0.36	7.11	0.31	4.42e-12	Blood protein levels;
LGG	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg14993813	chr1:46806288	NSUN4	-0.5	-8.14	-0.35	3.82e-15	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.44	-0.33	4.8e-13	Personality dimensions;
LGG	cis	rs4731207	0.596	rs7810120	chr7:124644945	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.27	-0.32	1.58e-12	Tonsillectomy;
LGG	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg26003909	chr8:143102224	NA	-0.39	-8.59	-0.37	1.34e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs988958	0.526	rs720043	chr2:42239044	T/C	cg19376973	chr2:42229025	NA	0.63	9.43	0.4	1.97e-19	Hypospadias;
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg00631329	chr6:26305371	NA	-0.5	-9.41	-0.4	2.31e-19	Educational attainment;
LGG	cis	rs8072100	0.817	rs9892497	chr17:45545919	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.39	-0.4	2.68e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg18252515	chr7:66147081	NA	0.44	7.46	0.33	4.29e-13	Aortic root size;
LGG	cis	rs12476592	0.602	rs1374308	chr2:63895436	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.38	-0.43	7.53e-23	Triglycerides;
LGG	trans	rs10435719	0.867	rs34583868	chr8:11791383	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg00495681	chr13:53174319	NA	0.74	15.27	0.58	6.51e-43	Lewy body disease;
LGG	cis	rs10089	0.953	rs758179	chr5:127354424	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.69	10.36	0.43	9e-23	Ileal carcinoids;
LGG	trans	rs916888	0.773	rs538628	chr17:44787313	G/C	cg10053473	chr17:62856997	LRRC37A3	-0.94	-14.92	-0.57	2.29e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2299587	1.000	rs2299587	chr8:17800769	T/G	cg18067069	chr8:17937731	ASAH1	-0.29	-6.7	-0.3	6.16e-11	Economic and political preferences;
LGG	cis	rs10864302	0.525	rs6677597	chr1:7422919	G/T	cg08923594	chr1:7462176	CAMTA1	0.59	7.57	0.33	2.02e-13	Photic sneeze reflex;
LGG	cis	rs9303401	0.659	rs61291849	chr17:56909867	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.17	0.58	1.72e-42	Cognitive test performance;
LGG	cis	rs6502050	0.835	rs56232956	chr17:80078929	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	trans	rs4714291	0.832	rs1923462	chr6:39976100	T/C	cg02267698	chr19:7991119	CTXN1	-0.6	-9.41	-0.4	2.41e-19	Strep throat;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg19143629	chr17:61920732	SMARCD2	0.39	6.75	0.3	4.32e-11	Prudent dietary pattern;
LGG	cis	rs7582180	0.715	rs11123823	chr2:100916315	A/G	cg05692746	chr2:100937584	LONRF2	-0.61	-10.7	-0.45	4.97e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.725	rs6505215	chr17:29189903	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.2	-0.39	1.24e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937612	1.000	rs11217841	chr11:120238721	C/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.33e-32	Intraocular pressure;
LGG	cis	rs9644630	1.000	rs9644630	chr8:19370598	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.47	-11.32	-0.47	2.18e-26	Oropharynx cancer;
LGG	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg18129748	chr3:49941408	MST1R	0.22	7.12	0.31	4.25e-12	Intelligence (multi-trait analysis);
LGG	trans	rs3942852	0.726	rs1503171	chr11:48175152	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-10.31	-0.43	1.47e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg25767906	chr1:53392781	SCP2	0.41	8.05	0.35	7.17e-15	Monocyte count;
LGG	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg08847335	chr10:891726	LARP4B	-0.35	-6.87	-0.3	2.02e-11	Eosinophil percentage of granulocytes;
LGG	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21659725	chr3:3221576	CRBN	-0.62	-10.07	-0.42	1.03e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg06609049	chr19:2785107	THOP1	0.95	15.88	0.59	1.15e-45	Total cholesterol levels;
LGG	cis	rs2797160	0.967	rs28629380	chr6:126004197	A/G	cg05901451	chr6:126070800	HEY2	-0.46	-7.66	-0.34	1.11e-13	Endometrial cancer;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg19441908	chr8:41529140	ANK1	0.43	7.47	0.33	4.02e-13	Type 2 diabetes;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.12	0.64	7.52e-56	Platelet count;
LGG	cis	rs6087990	0.735	rs2064350	chr20:31390533	T/C	cg13636640	chr20:31349939	DNMT3B	0.83	17.21	0.62	1.11e-51	Ulcerative colitis;
LGG	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10779751	0.770	rs2791643	chr1:11207269	C/T	cg08854313	chr1:11322531	MTOR	0.72	14.69	0.56	2.31e-40	Body mass index;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg20887711	chr4:1340912	KIAA1530	0.49	8.85	0.38	1.81e-17	Obesity-related traits;
LGG	trans	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg25482853	chr8:67687455	SGK3	0.93	11.74	0.48	4.78e-28	Obesity-related traits;
LGG	cis	rs6835098	0.962	rs4419455	chr4:174083622	C/T	cg08422745	chr4:174089978	GALNT7	0.86	15.04	0.57	6.66e-42	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs12724450	0.793	rs71515775	chr1:150304395	T/A	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	cis	rs10274279	0.623	rs221305	chr7:157371513	C/T	cg09270525	chr7:157391030	PTPRN2	-0.82	-13.14	-0.52	9.74e-34	Myopia (pathological);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25107268	chr6:89673349	RNGTT	0.44	7.12	0.31	4.14e-12	Cognitive performance;
LGG	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg26150922	chr2:100937072	LONRF2	0.51	9.19	0.39	1.32e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2916247	1.000	rs4415366	chr8:93052634	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.819	rs8137829	chr22:39061030	G/A	cg06022373	chr22:39101656	GTPBP1	0.87	17.48	0.63	6.84e-53	Menopause (age at onset);
LGG	cis	rs12134040	0.646	rs10925102	chr1:236507727	G/T	cg21399712	chr1:236511386	NA	-0.42	-8.49	-0.37	2.91e-16	Urate levels (BMI interaction);
LGG	cis	rs1018836	0.892	rs1476428	chr8:91555603	G/T	cg16814680	chr8:91681699	NA	-0.72	-12.45	-0.5	6.52e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg14773178	chr5:1868261	NA	0.35	7.62	0.33	1.41e-13	Cardiovascular disease risk factors;
LGG	trans	rs75804782	0.521	rs55973123	chr2:239416264	G/A	cg01134436	chr17:81009848	B3GNTL1	0.75	8.37	0.36	6.68e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs5769765	0.955	rs8138687	chr22:50291869	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.73e-27	Schizophrenia;
LGG	trans	rs12310956	0.532	rs6488186	chr12:33974122	G/A	cg26384229	chr12:38710491	ALG10B	0.73	14.7	0.56	2.12e-40	Morning vs. evening chronotype;
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg14074117	chr16:1909714	C16orf73	-0.51	-7.59	-0.33	1.73e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg09699651	chr6:150184138	LRP11	0.54	9.57	0.41	6.56e-20	Lung cancer;
LGG	cis	rs1465370	0.568	rs10253113	chr7:130009311	A/G	cg25718383	chr7:130020096	CPA1	0.3	7.49	0.33	3.58e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.791	rs10984994	chr9:123478769	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.67	-12.09	-0.49	1.97e-29	Hip circumference adjusted for BMI;
LGG	cis	rs6088580	0.601	rs6120668	chr20:33099793	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs634534	0.622	rs593525	chr11:65727799	T/C	cg17712092	chr4:129076599	LARP1B	0.73	14.02	0.55	1.84e-37	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs17270561	0.609	rs7746502	chr6:25718762	T/A	cg12310025	chr6:25882481	NA	0.44	7.56	0.33	2.16e-13	Iron status biomarkers;
LGG	cis	rs7918232	0.941	rs10829195	chr10:27431564	G/A	cg14240646	chr10:27532245	ACBD5	-0.73	-10.36	-0.43	9.22e-23	Breast cancer;
LGG	cis	rs3733585	0.673	rs6843873	chr4:9958788	A/C	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.76e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs198813	0.611	rs198823	chr6:26122933	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.46	-6.94	-0.31	1.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs721917	0.506	rs2758543	chr10:81662466	T/C	cg25562619	chr10:81652821	NA	-0.34	-7.87	-0.34	2.54e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg11995313	chr8:8860691	ERI1	0.46	7.86	0.34	2.79e-14	Joint mobility (Beighton score);
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14893161	chr1:205819251	PM20D1	0.91	21.88	0.71	2.25e-73	Menarche (age at onset);
LGG	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.48	-0.71	1.53e-71	Height;
LGG	trans	rs57046232	0.552	rs6054184	chr20:6354592	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.98	0.31	1.03e-11	Colorectal cancer;
LGG	cis	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.14	-0.46	1.08e-25	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07454558	chr2:159826472	TANC1	-0.49	-7.2	-0.32	2.41e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg26174226	chr8:58114915	NA	-0.57	-7.64	-0.33	1.29e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4423214	0.802	rs4616066	chr11:71183846	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	cis	rs72772090	0.539	rs111886458	chr5:96125047	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.75	0.41	1.51e-20	Prudent dietary pattern;
LGG	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg12698349	chr2:225449008	CUL3	1.04	27.73	0.79	1.96e-100	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg23752985	chr2:85803571	VAMP8	-0.4	-7.82	-0.34	3.71e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.98	0.31	1.02e-11	Sudden cardiac arrest;
LGG	cis	rs7917772	0.503	rs7100753	chr10:104300979	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg16507663	chr6:150244633	RAET1G	0.45	8.59	0.37	1.34e-16	Lung cancer;
LGG	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.55	0.37	1.76e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs17767392	1.000	rs34524083	chr14:71858372	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.13	0.39	2.14e-18	Mitral valve prolapse;
LGG	trans	rs783540	0.933	rs2567636	chr15:83263428	C/T	cg16105309	chr15:79090380	ADAMTS7	0.42	7.38	0.32	7.6e-13	Schizophrenia;
LGG	cis	rs798554	0.679	rs2527677	chr7:2882621	A/G	cg13628971	chr7:2884303	GNA12	0.55	11.46	0.47	6.3e-27	Height;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.11e-20	Lung cancer;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg13939156	chr17:80058883	NA	0.5	9.92	0.42	3.54e-21	Life satisfaction;
LGG	cis	rs11098499	0.866	rs7677068	chr4:120291704	C/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs72772090	0.539	rs11750671	chr5:96188482	A/C	cg00188032	chr5:96141721	ERAP1	0.56	7.29	0.32	1.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.644	rs17517414	chr4:120262101	G/C	cg09307838	chr4:120376055	NA	0.67	11.7	0.48	6.92e-28	Corneal astigmatism;
LGG	cis	rs721399	0.568	rs7816847	chr8:18275189	A/C	cg18736775	chr8:18248649	NAT2	-0.7	-10.6	-0.44	1.2e-23	Blood metabolite levels;
LGG	cis	rs2270450	0.650	rs9369631	chr6:46707519	A/G	cg10156739	chr6:46714674	LOC100287718	-0.49	-10.81	-0.45	2e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs881375	0.678	rs10760128	chr9:123696325	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	10.08	0.42	9.78e-22	Rheumatoid arthritis;
LGG	cis	rs2032447	0.839	rs9356995	chr6:25996673	G/A	cg07061783	chr6:25882402	NA	-0.4	-6.74	-0.3	4.6e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.5	-0.33	3.31e-13	Menarche (age at onset);
LGG	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg06808227	chr14:105710500	BRF1	-0.64	-11.02	-0.46	3.07e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13177180	0.590	rs10075869	chr5:114956959	A/G	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.4	-8.74	-0.38	4.27e-17	Conotruncal heart defects (inherited effects);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg19318889	chr4:1322082	MAEA	0.45	7.88	0.34	2.4e-14	Longevity;
LGG	cis	rs11967485	0.609	rs62434277	chr6:157225863	A/G	cg23222435	chr6:157204239	ARID1B	-0.8	-6.87	-0.3	2.08e-11	Calcium levels;
LGG	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg26384229	chr12:38710491	ALG10B	-0.68	-13.66	-0.54	6.17e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.13	0.55	6.15e-38	Bladder cancer;
LGG	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg04287289	chr16:89883240	FANCA	-0.45	-8.08	-0.35	5.53e-15	Vitiligo;
LGG	trans	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.76	0.57	1.1e-40	Cognitive test performance;
LGG	cis	rs2718058	0.589	rs1986618	chr7:37800116	C/G	cg15028436	chr7:37888078	TXNDC3	0.51	7.86	0.34	2.74e-14	Alzheimer's disease (late onset);
LGG	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg06699216	chr8:19333253	CSGALNACT1	-0.48	-11.13	-0.46	1.21e-25	Oropharynx cancer;
LGG	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg27165867	chr14:105738592	BRF1	-0.45	-7.49	-0.33	3.49e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg05335186	chr13:53173507	NA	0.59	13.17	0.52	7.5e-34	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00271154	chr2:113033418	ZC3H6	0.59	9.27	0.4	6.81e-19	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg13010199	chr12:38710504	ALG10B	0.52	9.98	0.42	2.17e-21	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.81	-0.38	2.6e-17	Menopause (age at onset);
LGG	cis	rs9611565	0.506	rs7364221	chr22:41650190	C/A	cg03806693	chr22:41940476	POLR3H	-0.71	-11.89	-0.48	1.26e-28	Vitiligo;
LGG	cis	rs6840360	0.870	rs6814554	chr4:152454334	G/A	cg25486957	chr4:152246857	NA	-0.4	-7.12	-0.31	4.28e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.635	rs6952727	chr7:1947958	A/G	cg11050988	chr7:1952600	MAD1L1	-0.46	-11.88	-0.48	1.29e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs28595532	0.841	rs55823625	chr4:119780600	T/A	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs7552404	0.924	rs7546641	chr1:76158035	T/C	cg03433033	chr1:76189801	ACADM	0.81	15.06	0.57	5.32e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg00543991	chr22:32367038	NA	0.78	8.5	0.37	2.68e-16	Childhood ear infection;
LGG	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg12561776	chr17:30844705	MYO1D	-0.27	-6.92	-0.31	1.49e-11	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62054257	chr16:89900195	G/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.77	-0.34	5.24e-14	Skin colour saturation;
LGG	cis	rs433852	0.718	rs386551	chr19:49138286	C/G	cg06677660	chr19:49140777	SEC1;DBP	-0.51	-8.79	-0.38	2.9e-17	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs11626933	0.851	rs2282031	chr14:90730943	A/G	cg14092571	chr14:90743983	NA	-0.66	-13.59	-0.53	1.26e-35	Gut microbiota (bacterial taxa);
LGG	cis	rs4555082	0.915	rs2816632	chr14:105741355	C/T	cg10792982	chr14:105748885	BRF1	-0.54	-11.02	-0.46	3.01e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg25039879	chr17:56429692	SUPT4H1	0.56	8.02	0.35	8.64e-15	Cognitive test performance;
LGG	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.44	-6.85	-0.3	2.43e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg16339924	chr4:17578868	LAP3	-0.62	-10.7	-0.45	5.16e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg00689492	chr4:1303491	MAEA	0.45	7.6	0.33	1.66e-13	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.57	0.41	6.33e-20	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21939482	chr7:6388130	C7orf70	0.51	8.22	0.36	2.09e-15	Gut microbiome composition (summer);
LGG	trans	rs2574985	0.739	rs2983359	chr10:52301659	G/A	cg18558237	chr10:81444220	LOC650623	0.44	6.7	0.3	6.18e-11	Subjective well-being;
LGG	cis	rs4925386	0.681	rs2427295	chr20:60927431	G/A	cg22307297	chr20:60903441	LAMA5	0.42	8.37	0.36	6.84e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs208520	0.874	rs208456	chr6:66907942	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-14.32	-0.55	8.83e-39	Exhaled nitric oxide output;
LGG	cis	rs4262150	0.693	rs4501386	chr5:152310278	G/T	cg12297329	chr5:152029980	NA	0.58	11.3	0.46	2.59e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg19847130	chr8:10466454	RP1L1	0.37	7.7	0.34	8.28e-14	Neuroticism;
LGG	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	7.84	0.34	3.1e-14	Retinal vascular caliber;
LGG	cis	rs977987	0.806	rs11860284	chr16:75412907	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.74	0.3	4.75e-11	Dupuytren's disease;
LGG	cis	rs7147624	0.608	rs4902413	chr14:66187091	T/C	cg03016385	chr14:66212404	NA	-0.77	-9.49	-0.4	1.27e-19	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2120019	1.000	rs2415253	chr15:75375699	A/G	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.71	-0.68	3.18e-63	Blood trace element (Zn levels);
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.41e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12586317	0.547	rs78609489	chr14:35497285	T/C	cg05294307	chr14:35346193	BAZ1A	-0.53	-7.33	-0.32	1.01e-12	Psoriasis;
LGG	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs698813	0.763	rs698764	chr2:44573658	T/C	cg00619915	chr2:44497795	NA	-0.5	-6.94	-0.31	1.34e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs2836974	0.549	rs34160989	chr21:40554118	C/G	cg11644478	chr21:40555479	PSMG1	0.69	9.37	0.4	3.31e-19	Cognitive function;
LGG	cis	rs6708331	0.878	rs12994100	chr2:70360917	A/G	cg01613454	chr2:70366299	NA	0.54	9.47	0.4	1.43e-19	Obesity-related traits;
LGG	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg20368463	chr18:77673604	PQLC1	-0.6	-11.59	-0.47	1.97e-27	Schizophrenia;
LGG	cis	rs1018836	0.923	rs13277387	chr8:91633713	C/G	cg16814680	chr8:91681699	NA	-0.81	-14.73	-0.56	1.44e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg08677398	chr8:58056175	NA	0.46	7.32	0.32	1.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs9902453	0.838	rs7217638	chr17:28336772	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg19761014	chr17:28927070	LRRC37B2	0.59	7.42	0.33	5.74e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.6	0.44	1.15e-23	Prudent dietary pattern;
LGG	cis	rs7923609	0.561	rs10995554	chr10:65295110	A/G	cg02276361	chr10:65351566	REEP3	-0.31	-6.74	-0.3	4.68e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs921968	0.643	rs484085	chr2:219396684	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs11098499	0.954	rs28572238	chr4:120316686	T/G	cg25214090	chr10:38739885	LOC399744	0.7	12.5	0.5	4.37e-31	Corneal astigmatism;
LGG	cis	rs3206736	0.548	rs329234	chr7:35055880	A/T	cg13400248	chr7:35225412	NA	0.55	9.5	0.4	1.13e-19	Diastolic blood pressure;
LGG	cis	rs7614311	0.636	rs73117041	chr3:63896266	A/T	cg22134162	chr3:63841271	THOC7	-0.45	-8.06	-0.35	6.47e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs4750440	0.642	rs1574583	chr10:14026870	C/G	cg27542038	chr10:14027202	FRMD4A	-0.78	-15.03	-0.57	7.09e-42	Adiponectin levels;
LGG	cis	rs5769765	0.908	rs9616370	chr22:50306316	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.12	-0.31	4.08e-12	Schizophrenia;
LGG	cis	rs9911578	1.000	rs9911578	chr17:56953147	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs11229555	0.645	rs10896778	chr11:58193925	T/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9910055	0.530	rs11652651	chr17:42302907	A/G	cg08499158	chr17:42289980	UBTF	0.39	7.17	0.32	2.9e-12	Total body bone mineral density;
LGG	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg03929089	chr4:120376271	NA	-0.46	-7.46	-0.33	4.39e-13	Height;
LGG	cis	rs1562975	0.567	rs7654972	chr4:109407499	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.4	6.95	0.31	1.22e-11	Height;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg16301924	chr13:53314226	LECT1	-0.48	-9.51	-0.4	1.02e-19	Lewy body disease;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg02725872	chr8:58115012	NA	-1.03	-13.55	-0.53	1.75e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg06191203	chr2:152266755	RIF1	-0.41	-6.66	-0.3	7.95e-11	Squamous cell lung carcinoma;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7927771	1.000	rs12418852	chr11:47868853	C/G	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg23306229	chr2:178417860	TTC30B	0.67	8.75	0.38	3.91e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg16590910	chr6:42928470	GNMT	0.41	11.6	0.47	1.68e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg01620082	chr3:125678407	NA	-0.68	-6.68	-0.3	6.96e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23166955	chr16:30077191	ALDOA	-0.42	-7.0	-0.31	8.83e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6061231	0.631	rs2427318	chr20:60975727	G/T	cg23531748	chr20:60969906	CABLES2	0.45	8.26	0.36	1.52e-15	Colorectal cancer;
LGG	cis	rs17826219	0.706	rs55764512	chr17:29085758	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Body mass index;
LGG	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg10523679	chr1:76189770	ACADM	0.82	15.69	0.59	8.13e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10131894	0.611	rs174994	chr14:75434102	A/G	cg08847533	chr14:75593920	NEK9	-0.45	-8.17	-0.35	2.95e-15	Coronary artery disease;
LGG	cis	rs7635838	0.718	rs2594979	chr3:11381910	T/G	cg00170343	chr3:11313890	ATG7	0.5	8.64	0.37	9.23e-17	HDL cholesterol;
LGG	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg02175503	chr12:58329896	NA	0.54	9.06	0.39	3.69e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.962	rs10788770	chr1:248457474	T/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.59	-0.41	5.34e-20	Common traits (Other);
LGG	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg05425664	chr17:57184151	TRIM37	0.72	11.75	0.48	4.58e-28	Intelligence (multi-trait analysis);
LGG	cis	rs634534	0.561	rs613924	chr11:65769295	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.75	0.34	5.98e-14	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs826838	0.754	rs2387920	chr12:38626351	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.54	-0.37	1.98e-16	Heart rate;
LGG	cis	rs1978968	0.912	rs13057016	chr22:18466779	G/A	cg03078520	chr22:18463400	MICAL3	-0.72	-14.75	-0.57	1.19e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs847649	0.765	rs10953383	chr7:102774076	C/T	cg18108683	chr7:102477205	FBXL13	0.55	11.28	0.46	3.06e-26	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs11608355	0.545	rs11613021	chr12:109897998	T/G	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs2130392	0.926	rs1107907	chr4:185620108	G/T	cg21366198	chr4:185655624	MLF1IP	-0.43	-7.54	-0.33	2.43e-13	Kawasaki disease;
LGG	cis	rs9457247	1.000	rs364451	chr6:167384756	G/A	cg07741184	chr6:167504864	NA	0.32	7.12	0.31	4.24e-12	Crohn's disease;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg25072359	chr17:41440525	NA	0.53	9.99	0.42	2.02e-21	Menopause (age at onset);
LGG	cis	rs6938	0.662	rs12487	chr15:75136694	A/G	cg17294928	chr15:75287854	SCAMP5	0.65	12.39	0.5	1.24e-30	Breast cancer;
LGG	cis	rs5769765	0.658	rs2157536	chr22:50190180	G/A	cg02269571	chr22:50332266	NA	-0.53	-8.41	-0.36	5.19e-16	Schizophrenia;
LGG	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.16	0.39	1.74e-18	Lung cancer in ever smokers;
LGG	cis	rs7927592	0.913	rs11228262	chr11:68274907	G/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.14	-0.35	3.63e-15	Total body bone mineral density;
LGG	cis	rs12477438	0.798	rs6712338	chr2:99585457	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs3813359	0.545	rs17058533	chr6:130549325	A/G	cg23281432	chr6:130554730	NA	-0.52	-7.42	-0.33	5.77e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs62103177	0.525	rs8086024	chr18:77746623	A/G	cg05926928	chr17:57297772	GDPD1	-0.83	-11.58	-0.47	2.09e-27	Opioid sensitivity;
LGG	cis	rs2242116	0.932	rs1531137	chr3:46943028	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-9.59	-0.41	5.56e-20	Birth weight;
LGG	cis	rs7172689	0.908	rs67847307	chr15:81565652	T/G	cg11808699	chr15:81528661	IL16	-0.46	-9.32	-0.4	4.7e-19	Inattentive symptoms;
LGG	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs4788570	0.727	rs7204118	chr16:71833658	G/C	cg06353428	chr16:71660113	MARVELD3	1.26	20.13	0.68	3.21e-65	Intelligence (multi-trait analysis);
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09256448	chr16:638327	NA	0.37	6.65	0.3	8.42e-11	Height;
LGG	cis	rs6582630	0.519	rs11181526	chr12:38360230	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.45e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10089	1.000	rs17764954	chr5:127514436	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.72	10.82	0.45	1.7e-24	Ileal carcinoids;
LGG	cis	rs9463078	0.774	rs9381383	chr6:45271893	G/A	cg25276700	chr6:44698697	NA	-0.4	-8.4	-0.36	5.53e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs477895	0.653	rs11602181	chr11:63896591	C/G	cg22916017	chr11:64110731	CCDC88B	-0.45	-6.69	-0.3	6.39e-11	Mean platelet volume;
LGG	cis	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg04568710	chr12:38710424	ALG10B	0.34	7.11	0.31	4.31e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg15320075	chr8:145703422	NA	0.73	14.76	0.57	1.07e-40	Age at first birth;
LGG	cis	rs2115630	1.000	rs11073730	chr15:85354596	C/T	cg12501888	chr15:85177176	SCAND2	-0.42	-6.86	-0.3	2.17e-11	P wave terminal force;
LGG	cis	rs3741404	0.584	rs645461	chr11:63893694	C/T	cg05555928	chr11:63887634	MACROD1	0.38	6.86	0.3	2.21e-11	Platelet count;
LGG	cis	rs7267979	0.966	rs8123949	chr20:25388133	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.41	-0.44	6.07e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg27144592	chr16:783916	NARFL	0.4	6.68	0.3	6.92e-11	Height;
LGG	cis	rs208520	0.690	rs12201156	chr6:66720874	G/T	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	4.82e-55	Exhaled nitric oxide output;
LGG	cis	rs7590368	1.000	rs13429247	chr2:10960529	A/G	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg02018176	chr4:1364513	KIAA1530	0.5	12.05	0.49	2.95e-29	Longevity;
LGG	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.72	0.3	5.36e-11	Cognitive function;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07791516	chr6:150247246	NA	0.32	7.1	0.31	4.8e-12	Testicular germ cell tumor;
LGG	cis	rs6604026	0.883	rs77741804	chr1:93324038	C/T	cg22128645	chr1:93425802	FAM69A	-0.41	-7.52	-0.33	2.89e-13	Multiple sclerosis;
LGG	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.22	0.39	1.07e-18	Aortic root size;
LGG	cis	rs240764	0.853	rs2062634	chr6:101002618	G/C	cg21058520	chr6:100914733	NA	0.41	7.07	0.31	5.82e-12	Neuroticism;
LGG	cis	rs9463078	0.753	rs10948186	chr6:44903248	C/T	cg25276700	chr6:44698697	NA	-0.39	-8.18	-0.36	2.81e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs503734	0.521	rs546105	chr3:100967920	A/G	cg27318481	chr3:100970896	IMPG2	-0.58	-12.91	-0.51	8.78e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6750047	0.628	rs2855655	chr2:38304488	T/C	cg07380506	chr2:38303506	CYP1B1	0.43	7.36	0.32	8.73e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs9393692	0.557	rs12660432	chr6:26317384	C/T	cg00631329	chr6:26305371	NA	-0.46	-7.68	-0.34	9.57e-14	Educational attainment;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg03853987	chr2:101034279	CHST10	-0.43	-7.22	-0.32	2.17e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs2727020	0.575	rs10769587	chr11:49549849	C/G	cg03929089	chr4:120376271	NA	-0.97	-20.49	-0.69	6.62e-67	Coronary artery disease;
LGG	cis	rs1983891	1.000	rs4714485	chr6:41536587	T/G	cg20194872	chr6:41519635	FOXP4	0.59	10.18	0.43	4.09e-22	Prostate cancer;
LGG	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.38	-0.32	7.51e-13	Neuroticism;
LGG	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.13	-0.39	2.08e-18	Triglycerides;
LGG	cis	rs75229567	0.618	rs1599745	chr12:70186029	A/G	cg10114359	chr12:70132523	RAB3IP	1.01	9.33	0.4	4.43e-19	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.42e-15	Prudent dietary pattern;
LGG	cis	rs7928758	1.000	rs7928758	chr11:134265967	T/G	cg22777979	chr11:134283252	B3GAT1	0.84	10.92	0.45	7.63e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg05926928	chr17:57297772	GDPD1	0.97	15.53	0.59	4.26e-44	Opioid sensitivity;
LGG	cis	rs1865760	1.000	rs3830057	chr6:25918510	G/T	cg16482183	chr6:26056742	HIST1H1C	0.52	9.32	0.4	4.91e-19	Height;
LGG	cis	rs2587949	0.571	rs795308	chr3:4164098	G/C	cg16519197	chr3:4211558	NA	-0.33	-6.67	-0.3	7.2e-11	Periodontitis (DPAL);
LGG	cis	rs6061231	0.631	rs927133	chr20:60972109	C/T	cg23531748	chr20:60969906	CABLES2	0.46	8.33	0.36	9.36e-16	Colorectal cancer;
LGG	cis	rs12824058	0.767	rs4759654	chr12:130815559	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	7.59	0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg26174226	chr8:58114915	NA	-0.55	-7.53	-0.33	2.76e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg21775007	chr8:11205619	TDH	0.43	6.88	0.3	1.96e-11	Joint mobility (Beighton score);
LGG	cis	rs8062405	0.824	rs62034326	chr16:28539293	A/G	cg07382826	chr16:28625726	SULT1A1	0.41	8.9	0.38	1.28e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9596863	0.898	rs34617186	chr13:54370594	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.05	0.31	6.62e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7674212	0.541	rs2720471	chr4:104023840	A/G	cg16532752	chr4:104119610	CENPE	-0.42	-7.38	-0.32	7.41e-13	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg24829409	chr8:58192753	C8orf71	-0.73	-10.46	-0.44	3.89e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9534288	0.797	rs2404727	chr13:46581697	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs7726839	0.540	rs28364691	chr5:664084	G/A	cg09021430	chr5:549028	NA	-0.71	-9.76	-0.41	1.36e-20	Obesity-related traits;
LGG	cis	rs9926296	0.568	rs886950	chr16:89836872	T/C	cg27121462	chr16:89883253	FANCA	0.62	11.57	0.47	2.22e-27	Vitiligo;
LGG	cis	rs191220855	1	rs191220855	chr2:200778130	A/G	cg23649088	chr2:200775458	C2orf69	-0.73	-9.99	-0.42	2.01e-21	Chickenpox;
LGG	cis	rs7122539	0.646	rs608248	chr11:66562248	C/T	cg01599099	chr11:66649832	PC	-0.37	-7.42	-0.33	5.54e-13	HIV-1 susceptibility;
LGG	cis	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.24	-0.43	2.54e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg00149659	chr3:10157352	C3orf10	0.76	9.64	0.41	3.55e-20	Alzheimer's disease;
LGG	cis	rs9660180	0.620	rs34298494	chr1:1663402	A/C	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.47	-8.08	-0.35	5.68e-15	Body mass index;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23888201	chr6:139456576	HECA	0.61	7.09	0.31	5.1e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg02030672	chr11:45687055	CHST1	0.57	10.44	0.44	4.65e-23	Obesity-related traits;
LGG	cis	rs9462027	0.540	rs4282407	chr6:34830162	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.25e-26	Systemic lupus erythematosus;
LGG	cis	rs2562456	0.920	rs2650784	chr19:21666597	T/C	cg00806126	chr19:22604979	ZNF98	0.6	9.16	0.39	1.63e-18	Pain;
LGG	cis	rs4950322	0.515	rs11239958	chr1:146719108	G/A	cg22381352	chr1:146742008	CHD1L	-0.47	-7.84	-0.34	3.18e-14	Protein quantitative trait loci;
LGG	cis	rs722599	0.715	rs8008785	chr14:75307600	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.08	-0.39	3.21e-18	IgG glycosylation;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg02951883	chr7:2050386	MAD1L1	0.79	17.92	0.64	6.07e-55	Bipolar disorder and schizophrenia;
LGG	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg21775007	chr8:11205619	TDH	-0.55	-9.15	-0.39	1.88e-18	Triglycerides;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.58	-0.33	1.91e-13	Personality dimensions;
LGG	cis	rs9682041	0.808	rs9875109	chr3:170064776	A/G	cg11886554	chr3:170076028	SKIL	-0.67	-8.57	-0.37	1.56e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2070488	0.931	rs6599212	chr3:38558906	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.54	-0.63	3.36e-53	Electrocardiographic conduction measures;
LGG	cis	rs1729951	0.575	rs361244	chr3:136697506	C/T	cg12473912	chr3:136751656	NA	0.44	7.74	0.34	6.34e-14	Neuroticism;
LGG	cis	rs11168618	0.904	rs10875829	chr12:48927197	A/C	cg24011408	chr12:48396354	COL2A1	0.45	7.25	0.32	1.72e-12	Adiponectin levels;
LGG	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg14581129	chr12:53358946	NA	-0.33	-7.37	-0.32	7.69e-13	Cancer (pleiotropy);
LGG	cis	rs11864453	0.713	rs12708926	chr16:72126063	T/C	cg01557791	chr16:72042693	DHODH	-0.51	-9.38	-0.4	2.93e-19	Fibrinogen levels;
LGG	cis	rs1862618	0.853	rs2113078	chr5:56087190	C/T	cg17809284	chr5:56205270	C5orf35	-0.52	-8.29	-0.36	1.2e-15	Initial pursuit acceleration;
LGG	cis	rs9815354	0.951	rs1717028	chr3:41902964	C/T	cg03022575	chr3:42003672	ULK4	0.65	8.4	0.36	5.68e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg15596359	chr8:11213517	TDH	-0.44	-8.93	-0.38	9.7e-18	Retinal vascular caliber;
LGG	cis	rs2860975	0.620	rs7087256	chr10:96795524	T/C	cg09036531	chr10:96991505	NA	-0.47	-8.18	-0.36	2.77e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.7	0.3	6.18e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9815354	1.000	rs73071329	chr3:41810539	G/A	cg03022575	chr3:42003672	ULK4	0.62	7.96	0.35	1.31e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-12.27	-0.5	3.65e-30	Bipolar disorder and schizophrenia;
LGG	trans	rs28735056	1.000	rs4798923	chr18:77629373	G/A	cg05926928	chr17:57297772	GDPD1	-0.49	-7.75	-0.34	5.7e-14	Schizophrenia;
LGG	cis	rs2629540	0.882	rs10901813	chr10:126429875	G/A	cg08799069	chr10:126477246	METTL10	-0.66	-13.0	-0.52	3.59e-33	Cocaine dependence;
LGG	cis	rs9354308	0.840	rs1827157	chr6:66615761	A/G	cg07460842	chr6:66804631	NA	0.6	9.86	0.42	5.88e-21	Metabolite levels;
LGG	cis	rs10870270	1.000	rs10870270	chr10:133754334	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.52	-0.53	2.5e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	cis	rs7103648	0.669	rs7114011	chr11:47811309	A/C	cg20307385	chr11:47447363	PSMC3	0.82	16.77	0.61	1.11e-49	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg26384229	chr12:38710491	ALG10B	0.94	21.33	0.7	7.98e-71	Bladder cancer;
LGG	cis	rs77372450	0.636	rs7707786	chr5:156996758	C/G	cg25387487	chr5:157003181	ADAM19	0.58	7.27	0.32	1.5e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs1218582	0.774	rs12036859	chr1:154859940	A/C	cg12436631	chr1:155007014	DCST1;DCST2	-0.42	-8.61	-0.37	1.14e-16	Prostate cancer;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg17470184	chr11:118478236	PHLDB1	0.43	7.76	0.34	5.45e-14	Cholesterol, total;
LGG	cis	rs9910055	0.664	rs433610	chr17:42197281	A/G	cg13607699	chr17:42295918	UBTF	-0.63	-10.69	-0.44	5.59e-24	Total body bone mineral density;
LGG	cis	rs9916302	0.706	rs597069	chr17:37458512	G/T	cg00129232	chr17:37814104	STARD3	0.58	8.48	0.37	2.95e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9604529	0.557	rs74841821	chr13:114742213	G/A	cg04826882	chr13:114838756	RASA3	-0.64	-9.54	-0.41	8.45e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg01028140	chr2:1542097	TPO	0.54	8.48	0.37	3.03e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-10.0	-0.42	1.98e-21	Bipolar disorder;
LGG	cis	rs11583043	0.874	rs72734253	chr1:101380718	A/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.41	7.3	0.32	1.26e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs57590327	0.503	rs17019299	chr3:81851643	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.86	-0.34	2.65e-14	Extraversion;
LGG	cis	rs73198271	0.531	rs11985640	chr8:8652504	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18839017	chr6:53660548	LRRC1	0.51	7.87	0.34	2.51e-14	Gut microbiome composition (summer);
LGG	cis	rs2013441	1.000	rs9325894	chr17:20197101	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6e-11	Obesity-related traits;
LGG	cis	rs7747724	0.702	rs9356752	chr6:20766431	A/G	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.98e-19	Bladder cancer;
LGG	cis	rs7945718	0.621	rs7931351	chr11:12692162	A/T	cg25843174	chr11:12811716	TEAD1	0.33	7.04	0.31	7.04e-12	Educational attainment (years of education);
LGG	cis	rs7572733	0.515	rs11887138	chr2:198805838	T/A	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9916302	0.851	rs4794810	chr17:37603774	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.28	-0.46	3.14e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs7010267	0.570	rs2326192	chr8:120028855	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.51	0.37	2.48e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg22903471	chr2:27725779	GCKR	-0.56	-12.7	-0.51	6.71e-32	Total body bone mineral density;
LGG	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg03709012	chr19:19516395	GATAD2A	0.81	15.75	0.59	4.66e-45	Tonsillectomy;
LGG	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg02487422	chr3:49467188	NICN1	0.58	10.74	0.45	3.46e-24	Resting heart rate;
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg19223190	chr17:80058835	NA	-0.45	-8.75	-0.38	3.89e-17	Life satisfaction;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg06654118	chr4:1303317	MAEA	0.47	8.03	0.35	8.13e-15	Obesity-related traits;
LGG	cis	rs12493885	0.725	rs73158427	chr3:153721493	T/A	cg12800244	chr3:153838788	SGEF	-0.73	-8.99	-0.39	6.53e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8062405	0.755	rs55792032	chr16:28599411	A/G	cg00198680	chr16:28758506	NA	0.28	6.77	0.3	4.02e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7937682	0.921	rs12806479	chr11:111443192	G/C	cg08305652	chr11:111469057	NA	0.43	8.31	0.36	1.04e-15	Primary sclerosing cholangitis;
LGG	cis	rs7192750	0.539	rs12926300	chr16:71978997	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.51	0.44	2.58e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg07142201	chr11:109293216	C11orf87	0.62	10.55	0.44	1.8e-23	Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10703331	chr7:138144619	TRIM24	-0.44	-6.68	-0.3	6.87e-11	Pancreatic cancer;
LGG	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg09873164	chr1:152488093	CRCT1	0.63	15.45	0.58	1.04e-43	Hair morphology;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg18402987	chr7:1209562	NA	0.4	7.09	0.31	5.07e-12	Longevity;Endometriosis;
LGG	cis	rs13177180	0.787	rs10053572	chr5:114877544	G/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.38	-8.2	-0.36	2.42e-15	Conotruncal heart defects (inherited effects);
LGG	cis	rs875971	0.522	rs2008188	chr7:65429013	G/C	cg11764359	chr7:65958608	NA	0.57	9.57	0.41	6.38e-20	Aortic root size;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.25	0.55	1.91e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2888674	0.527	rs10231759	chr7:150512172	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.29	7.57	0.33	2.03e-13	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs2718058	0.606	rs2718065	chr7:37859525	A/G	cg24998770	chr7:37888106	TXNDC3	0.45	7.25	0.32	1.72e-12	Alzheimer's disease (late onset);
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs62400317	0.701	rs12195339	chr6:44796179	T/C	cg20913747	chr6:44695427	NA	-0.63	-9.85	-0.42	6.36e-21	Total body bone mineral density;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg26656751	chr17:43910226	CRHR1	-0.43	-7.94	-0.35	1.53e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7760949	0.889	rs9475795	chr6:13931270	A/C	cg27413430	chr6:13925136	RNF182	0.45	6.86	0.3	2.2e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs643506	0.967	rs2850248	chr11:111644824	C/A	cg09085632	chr11:111637200	PPP2R1B	0.57	9.25	0.4	8.01e-19	Breast cancer;
LGG	cis	rs7945071	0.847	rs12798224	chr11:110323774	G/A	cg04157658	chr11:110243994	NA	0.29	6.68	0.3	6.94e-11	Cognitive function;
LGG	cis	rs2153535	0.580	rs9505457	chr6:8479142	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs17776563	0.614	rs67228335	chr15:89130034	G/A	cg05013243	chr15:89149849	MIR1179	-0.34	-6.98	-0.31	1.05e-11	Thyroid hormone levels;
LGG	cis	rs7819412	0.595	rs2409712	chr8:10986837	A/C	cg21775007	chr8:11205619	TDH	-0.51	-8.56	-0.37	1.67e-16	Triglycerides;
LGG	cis	rs17428076	0.872	rs56218609	chr2:172862314	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.97	0.42	2.49e-21	Myopia;
LGG	cis	rs1878931	0.582	rs27227	chr16:3429778	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.72	-11.43	-0.47	7.74e-27	Body mass index (adult);
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.43	0.5	8.26e-31	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.72e-31	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg05425664	chr17:57184151	TRIM37	-0.71	-11.67	-0.48	8.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.606	rs2736264	chr8:11186639	G/C	cg21775007	chr8:11205619	TDH	0.81	15.09	0.57	4.07e-42	Retinal vascular caliber;
LGG	trans	rs2727020	0.595	rs11040328	chr11:49339055	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.43	-0.33	5.2e-13	Coronary artery disease;
LGG	cis	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg05623727	chr3:50126028	RBM5	-0.4	-8.75	-0.38	4.05e-17	Body mass index;
LGG	cis	rs6500395	1.000	rs4493038	chr16:48683920	A/G	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4363385	0.626	rs10888531	chr1:153063406	T/C	cg13444842	chr1:152974279	SPRR3	-0.35	-6.71	-0.3	5.8200000000000003e-11	Inflammatory skin disease;
LGG	cis	rs3923380	0.585	rs6817593	chr4:77461011	T/C	cg07933720	chr4:77468187	SHROOM3	0.34	7.26	0.32	1.6e-12	Craniofacial microsomia;
LGG	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg24812749	chr6:127587940	RNF146	0.96	15.85	0.59	1.57e-45	Breast cancer;
LGG	cis	rs6976053	0.868	rs12705094	chr7:100477829	G/A	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.84e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.73	0.34	6.88e-14	Homoarginine levels;
LGG	cis	rs4509693	1.000	rs6584394	chr10:102497258	G/A	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	cis	rs7267979	1.000	rs2257496	chr20:25279315	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1983891	1.000	rs913074	chr6:41538545	T/C	cg20194872	chr6:41519635	FOXP4	0.58	9.9	0.42	4.48e-21	Prostate cancer;
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.78	-0.34	4.93e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00607566	chr17:45726993	KPNB1	0.49	7.06	0.31	6.01e-12	Gut microbiome composition (summer);
LGG	cis	rs7241530	0.662	rs4799261	chr18:75889293	G/A	cg14642773	chr18:75888474	NA	0.46	9.38	0.4	2.9e-19	Educational attainment (years of education);
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg19524238	chr7:2802976	GNA12	0.38	8.91	0.38	1.2e-17	Height;
LGG	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg26150922	chr2:100937072	LONRF2	-0.5	-9.2	-0.39	1.2e-18	Intelligence (multi-trait analysis);
LGG	cis	rs620875	1.000	rs474504	chr11:126867324	G/C	cg06504925	chr11:126872760	NA	-0.54	-7.6	-0.33	1.61e-13	Response to antipsychotic treatment;
LGG	cis	rs8067545	0.611	rs2042046	chr17:20018841	A/G	cg13482628	chr17:19912719	NA	0.54	10.01	0.42	1.78e-21	Schizophrenia;
LGG	cis	rs727505	0.721	rs56069273	chr7:124768604	G/A	cg23710748	chr7:124431027	NA	-0.41	-8.21	-0.36	2.15e-15	Lewy body disease;
LGG	cis	rs2658782	0.704	rs2658766	chr11:93232229	G/A	cg15737290	chr11:93063684	CCDC67	0.47	7.06	0.31	6.31e-12	Pulmonary function decline;
LGG	cis	rs3845702	1.000	rs3845697	chr2:180798553	C/T	cg01881094	chr2:180872142	CWC22	0.89	14.1	0.55	8.11e-38	Schizophrenia;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg13732083	chr21:47605072	C21orf56	-0.42	-6.72	-0.3	5.42e-11	Testicular germ cell tumor;
LGG	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27286337	chr10:134555280	INPP5A	0.89	13.01	0.52	3.28e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg26338869	chr17:61819248	STRADA	-0.59	-9.87	-0.42	5.67e-21	Prudent dietary pattern;
LGG	cis	rs561341	0.609	rs11658984	chr17:30186612	C/T	cg00745463	chr17:30367425	LRRC37B	0.53	7.09	0.31	5.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.614	rs1137042	chr16:89975638	A/G	cg00800038	chr16:89945340	TCF25	-0.48	-6.72	-0.3	5.39e-11	Skin colour saturation;
LGG	cis	rs4237845	0.773	rs6650217	chr12:58289072	T/G	cg02175503	chr12:58329896	NA	0.67	12.63	0.51	1.3e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4561483	0.603	rs11075033	chr16:12006338	C/T	cg08843971	chr16:11963173	GSPT1	0.59	14.76	0.57	1.16e-40	Testicular germ cell tumor;
LGG	cis	rs1570884	0.516	rs9526580	chr13:50164023	C/G	cg03651054	chr13:50194643	NA	-0.31	-7.0	-0.31	9.18e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs7395662	0.963	rs7951432	chr11:48591280	T/A	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs10789491	1.000	rs4660956	chr1:47158486	A/G	cg15501359	chr1:47185051	KIAA0494	0.72	13.63	0.54	7.95e-36	Response to hepatitis C treatment;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.26	-0.32	1.67e-12	Lung cancer;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg11766577	chr21:47581405	C21orf56	-0.48	-8.16	-0.35	3.24e-15	Testicular germ cell tumor;
LGG	cis	rs7829975	0.688	rs13270194	chr8:8378102	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	8.56	0.37	1.7e-16	Mood instability;
LGG	cis	rs3858526	0.959	rs11039699	chr11:5951091	G/A	cg25319279	chr11:5960081	NA	-0.57	-8.81	-0.38	2.57e-17	DNA methylation (variation);
LGG	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-15.4	-0.58	1.64e-43	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.71	-0.83	3.82e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28588043	0.818	rs7879279	chr1:170988151	G/A	cg03458344	chr1:170964477	C1orf129	-0.47	-7.04	-0.31	7.19e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2652834	0.904	rs7175602	chr15:63367032	T/C	cg05507819	chr15:63340323	TPM1	-0.63	-8.51	-0.37	2.37e-16	HDL cholesterol;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21214630	chr9:127631857	ARPC5L	0.6	6.79	0.3	3.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11532322	1	rs11532322	chr12:123731423	A/G	cg00376283	chr12:123451042	ABCB9	0.67	11.62	0.48	1.43e-27	Schizophrenia;
LGG	cis	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.64	0.3	8.57e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs35146811	0.735	rs2272344	chr7:99786819	C/T	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs4959677	0.725	rs9503212	chr6:2501535	A/G	cg23817096	chr6:1620687	NA	-0.33	-8.08	-0.35	5.48e-15	Orthostatic hypotension;
LGG	cis	rs11771526	0.901	rs62457471	chr7:32306737	A/C	cg27532318	chr7:32358331	NA	0.71	7.33	0.32	1e-12	Body mass index;
LGG	trans	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg06521331	chr12:34319734	NA	-0.4	-7.0	-0.31	8.82e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-17.38	-0.63	1.79e-52	Skin colour saturation;
LGG	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg03517284	chr6:25882590	NA	-0.59	-11.34	-0.47	1.81e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	1.000	rs336590	chr3:161079583	G/A	cg04691961	chr3:161091175	C3orf57	-0.65	-15.52	-0.59	4.64e-44	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg18252515	chr7:66147081	NA	-1.4	-19.16	-0.67	1.11e-60	Diabetic kidney disease;
LGG	cis	rs62244186	0.659	rs7649834	chr3:44503732	C/T	cg18165381	chr3:44552316	NA	-0.41	-6.71	-0.3	5.68e-11	Depressive symptoms;
LGG	cis	rs10779751	0.770	rs1417131	chr1:11191922	T/C	cg08854313	chr1:11322531	MTOR	-0.7	-14.3	-0.55	1.08e-38	Body mass index;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg14503796	chr3:15248442	DVWA;CAPN7	0.43	6.65	0.3	8.34e-11	Emphysema imaging phenotypes;
LGG	cis	rs7827545	1.000	rs7823948	chr8:135566580	G/A	cg09855544	chr8:135498122	ZFAT	0.46	7.85	0.34	3.01e-14	Hypertension (SNP x SNP interaction);
LGG	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs2832077	0.943	rs11701445	chr21:30160807	C/T	cg08807101	chr21:30365312	RNF160	-0.58	-8.14	-0.35	3.82e-15	Cognitive test performance;
LGG	cis	rs977987	0.735	rs11149831	chr16:75451461	G/A	cg07303275	chr16:75499416	TMEM170A	0.43	7.74	0.34	6.43e-14	Dupuytren's disease;
LGG	cis	rs10744422	1.000	rs2135014	chr12:123333065	C/T	cg25930673	chr12:123319894	HIP1R	-0.77	-9.86	-0.42	5.83e-21	Schizophrenia;
LGG	cis	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg00806126	chr19:22604979	ZNF98	-0.65	-9.6	-0.41	5.22e-20	Pain;
LGG	cis	rs1062177	0.906	rs2964573	chr5:151160122	A/T	cg00977110	chr5:151150581	G3BP1	0.5	8.03	0.35	7.96e-15	Preschool internalizing problems;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12188830	chr3:57741926	SLMAP	0.4	6.7	0.3	5.92e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4742903	0.875	rs7041529	chr9:106991539	G/A	cg14250997	chr9:106856677	SMC2	0.38	7.84	0.34	3.22e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs503734	0.666	rs6772703	chr3:101232736	T/C	cg27318481	chr3:100970896	IMPG2	0.36	7.2	0.32	2.44e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs9929218	0.679	rs9924886	chr16:68743939	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-15.35	-0.58	2.74e-43	Colorectal cancer;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs887829	0.569	rs4399719	chr2:234666461	T/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.55	-0.33	2.36e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4819852	0.958	rs2238792	chr22:19983213	C/T	cg07821417	chr22:19972146	ARVCF	0.63	13.54	0.53	2.1e-35	Pulse pressure;
LGG	cis	rs10865397	0.506	rs6546810	chr2:73389716	A/G	cg01422370	chr2:73384389	NA	0.54	10.16	0.43	4.93e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4642101	0.662	rs3901664	chr3:12824660	T/C	cg24848339	chr3:12840334	CAND2	0.46	11.13	0.46	1.21e-25	QRS complex (12-leadsum);
LGG	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg12310025	chr6:25882481	NA	-0.52	-9.98	-0.42	2.25e-21	Blood metabolite levels;
LGG	cis	rs7551222	0.752	rs10900593	chr1:204470096	G/T	cg20240347	chr1:204465584	NA	-0.56	-11.49	-0.47	4.71e-27	Schizophrenia;
LGG	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg20110707	chr11:118481992	PHLDB1	-0.49	-9.72	-0.41	1.85e-20	Cholesterol, total;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg21724239	chr8:58056113	NA	0.53	7.39	0.32	6.8e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs115673173	chr4:119755321	C/T	cg11846333	chr4:119757529	SEC24D	0.84	7.69	0.34	9.03e-14	Cannabis dependence symptom count;
LGG	cis	rs4975709	0.569	rs2353583	chr5:1858834	G/C	cg01114163	chr5:1856713	NA	-0.42	-7.28	-0.32	1.41e-12	Cardiovascular disease risk factors;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	16.82	0.62	6.88e-50	Platelet count;
LGG	cis	rs8056893	1.000	rs8056893	chr16:68304392	C/A	cg07273125	chr16:68295692	NA	0.37	6.73	0.3	4.99e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs2066819	1.000	rs871130	chr12:56648777	A/G	cg26714650	chr12:56694279	CS	1.49	15.0	0.57	9.51e-42	Psoriasis vulgaris;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg05335186	chr13:53173507	NA	-0.47	-9.76	-0.41	1.35e-20	Lewy body disease;
LGG	cis	rs477692	0.699	rs471357	chr10:131389373	C/G	cg05714579	chr10:131428358	MGMT	0.47	9.24	0.39	9.07e-19	Response to temozolomide;
LGG	cis	rs7552404	1.000	rs12123977	chr1:76209754	A/G	cg03433033	chr1:76189801	ACADM	-0.79	-12.11	-0.49	1.61e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1707322	0.896	rs785518	chr1:46568422	A/T	cg03146154	chr1:46216737	IPP	-0.54	-9.67	-0.41	2.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.3	-0.36	1.13e-15	Retinal vascular caliber;
LGG	cis	rs12893668	0.645	rs12889403	chr14:104034746	C/T	cg26031613	chr14:104095156	KLC1	-0.61	-9.57	-0.41	6.37e-20	Reticulocyte count;
LGG	cis	rs9325144	0.560	rs2387924	chr12:38662883	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-17.07	-0.62	4.7e-51	Morning vs. evening chronotype;
LGG	cis	rs368123	0.961	rs620121	chr6:160733663	T/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs1719271	0.831	rs1403328	chr15:65173097	T/C	cg11671771	chr15:65133392	PLEKHO2	-0.53	-7.46	-0.33	4.28e-13	Platelet count;
LGG	cis	rs6554196	0.525	rs6554194	chr4:55499810	T/G	cg18836493	chr4:55524333	KIT	-0.43	-8.06	-0.35	6.68e-15	Monocyte count;
LGG	trans	rs826838	0.967	rs4768329	chr12:39129394	T/C	cg06521331	chr12:34319734	NA	0.43	7.63	0.33	1.36e-13	Heart rate;
LGG	cis	rs7084402	0.967	rs2577393	chr10:60286159	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.81e-56	Refractive error;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs11645898	0.765	rs112439757	chr16:72168337	C/T	cg14768367	chr16:72042858	DHODH	-0.64	-9.11	-0.39	2.49e-18	Blood protein levels;
LGG	cis	rs28595532	0.920	rs114683212	chr4:119760209	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9858542	0.953	rs12330269	chr3:49513910	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.82e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8072100	0.811	rs9889709	chr17:45445229	C/T	cg25173405	chr17:45401733	C17orf57	-0.52	-8.86	-0.38	1.68e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2635047	0.593	rs7239323	chr18:44636506	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.54	0.33	2.52e-13	Educational attainment;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.39	-0.32	6.7e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12597458	0.763	rs7195958	chr16:72036577	A/G	cg01557791	chr16:72042693	DHODH	0.7	14.04	0.55	1.48e-37	Prostate cancer;
LGG	cis	rs1552244	0.935	rs2272124	chr3:10138189	T/C	cg08888203	chr3:10149979	C3orf24	0.53	8.96	0.38	8.27e-18	Alzheimer's disease;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.43e-30	Lung cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07318049	chr1:28562181	ATPIF1	0.42	7.45	0.33	4.51e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	cg15522984	chr1:182991683	LAMC1	0.42	8.49	0.37	2.79e-16	Colorectal cancer;
LGG	cis	rs9300255	0.739	rs4759417	chr12:123746510	C/T	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.19e-22	Neutrophil percentage of white cells;
LGG	cis	rs3733418	0.860	rs13129396	chr4:165936346	G/A	cg10852876	chr4:165953100	TRIM60	-0.49	-6.89	-0.31	1.79e-11	Obesity-related traits;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.35	-8.46	-0.37	3.52e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.38	-0.32	7.54e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1801251	1.000	rs6746294	chr2:233583050	C/G	cg25237894	chr2:233734115	C2orf82	-0.65	-12.12	-0.49	1.44e-29	Coronary artery disease;
LGG	cis	rs8028182	0.609	rs10220738	chr15:75666546	A/T	cg20655648	chr15:75932815	IMP3	-0.44	-7.4	-0.33	6.32e-13	Sudden cardiac arrest;
LGG	cis	rs4481887	1.000	rs4474293	chr1:248470438	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.82	-0.42	8.62e-21	Common traits (Other);
LGG	cis	rs6500602	0.701	rs4785968	chr16:4535307	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.46	9.7	0.41	2.17e-20	Schizophrenia;
LGG	trans	rs3942852	0.545	rs7395231	chr11:48091689	T/C	cg03929089	chr4:120376271	NA	-0.69	-10.83	-0.45	1.6e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4936894	0.500	rs11219511	chr11:124102839	C/T	cg27160556	chr11:124181099	OR8D1	-0.48	-11.09	-0.46	1.61e-25	Aging (time to death);
LGG	cis	rs7737355	0.947	rs3776004	chr5:130879431	G/C	cg06307176	chr5:131281290	NA	0.56	9.31	0.4	5.3e-19	Life satisfaction;
LGG	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg16400903	chr5:693638	TPPP	0.46	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10463554	0.892	rs257307	chr5:102417509	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs4363385	0.818	rs419721	chr1:153006902	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs9768139	0.733	rs13221388	chr7:158119270	G/A	cg15736062	chr7:158136485	PTPRN2	-0.41	-8.1	-0.35	5.06e-15	Calcium levels;
LGG	cis	rs36051895	0.632	rs7036536	chr9:5181610	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-14.54	-0.56	1.06e-39	Pediatric autoimmune diseases;
LGG	cis	rs981844	0.961	rs6827685	chr4:154662227	C/T	cg14289246	chr4:154710475	SFRP2	0.65	10.66	0.44	6.94e-24	Response to statins (LDL cholesterol change);
LGG	cis	rs7928758	0.945	rs7108756	chr11:134280860	C/A	cg22777979	chr11:134283252	B3GAT1	0.81	10.93	0.45	6.89e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg20607798	chr8:58055168	NA	0.65	7.17	0.32	3.04e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	1.000	rs7420157	chr2:243005204	G/A	cg18898632	chr2:242989856	NA	-0.73	-8.66	-0.37	8e-17	Obesity-related traits;
LGG	trans	rs9325144	0.624	rs10783330	chr12:39114084	A/G	cg06521331	chr12:34319734	NA	0.4	6.89	0.3	1.84e-11	Morning vs. evening chronotype;
LGG	cis	rs4474465	0.850	rs4945294	chr11:78256864	G/A	cg02023728	chr11:77925099	USP35	-0.39	-6.9	-0.31	1.76e-11	Alzheimer's disease (survival time);
LGG	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	13.67	0.54	5.77e-36	Colorectal cancer;
LGG	cis	rs16854884	0.657	rs2099543	chr3:143742164	C/T	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs2040771	0.745	rs361956	chr22:19265799	C/T	cg02655711	chr22:19163373	SLC25A1	0.46	8.02	0.35	8.82e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs9644630	1.000	rs9644629	chr8:19369290	T/C	cg01280390	chr8:19363452	CSGALNACT1	0.61	16.97	0.62	1.34e-50	Oropharynx cancer;
LGG	cis	rs6912958	0.558	rs9444530	chr6:88343318	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.45	7.85	0.34	2.87e-14	Monocyte percentage of white cells;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	cis	rs59104589	0.570	rs73006397	chr2:242415523	C/T	cg13788902	chr2:242434635	STK25	0.41	6.96	0.31	1.19e-11	Fibrinogen levels;
LGG	cis	rs9790314	0.663	rs4557202	chr3:160820524	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.55	-0.47	2.7e-27	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.871	rs55953412	chr11:68328283	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs6547631	0.622	rs10192752	chr2:85926142	T/G	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	cis	rs9790314	0.663	rs778657	chr3:160719577	C/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.62	-0.37	1.06e-16	Morning vs. evening chronotype;
LGG	cis	rs6435862	0.593	rs34732883	chr2:215674371	C/T	cg04004882	chr2:215674386	BARD1	-0.66	-11.47	-0.47	5.81e-27	Neuroblastoma (high-risk);
LGG	cis	rs17767392	0.670	rs11849508	chr14:71723064	T/C	cg02058870	chr14:72053146	SIPA1L1	0.35	7.52	0.33	2.87e-13	Mitral valve prolapse;
LGG	cis	rs28588043	0.938	rs28731151	chr1:170977601	C/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.47	-0.33	3.97e-13	Number of children (6+ vs. 0 or 1);
LGG	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg23533926	chr12:111358616	MYL2	-0.42	-6.91	-0.31	1.57e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg08885076	chr2:99613938	TSGA10	0.41	8.5	0.37	2.66e-16	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs875971	0.545	rs73378304	chr7:65640747	G/A	cg11764359	chr7:65958608	NA	0.63	9.89	0.42	4.69e-21	Aortic root size;
LGG	trans	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg03929089	chr4:120376271	NA	0.42	6.88	0.3	1.97e-11	HDL cholesterol;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg23173402	chr1:227635558	NA	0.69	10.69	0.44	5.61e-24	Major depressive disorder;
LGG	cis	rs6964587	1.000	rs10234434	chr7:91673308	A/T	cg17063962	chr7:91808500	NA	0.48	8.5	0.37	2.64e-16	Breast cancer;
LGG	cis	rs1620921	0.594	rs9355846	chr6:161269204	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.94	-12.56	-0.5	2.47e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4750440	0.706	rs4748065	chr10:14019876	G/T	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.76	-0.51	3.53e-32	Adiponectin levels;
LGG	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.11	0.31	4.47e-12	Retinal vascular caliber;
LGG	cis	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg00405596	chr8:11794950	NA	0.42	7.14	0.31	3.6e-12	Triglycerides;
LGG	cis	rs9297145	0.761	rs112155177	chr7:98747963	C/T	cg05967295	chr7:98741636	SMURF1	0.92	15.27	0.58	6.37e-43	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.15	-0.39	1.85e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7584262	0.737	rs12996528	chr2:42239901	T/C	cg27428208	chr2:42229179	NA	0.47	7.45	0.33	4.73e-13	Bone mineral density;
LGG	cis	rs6445975	0.617	rs4470539	chr3:58404486	C/G	cg24175188	chr3:58374923	PXK	-0.56	-9.13	-0.39	2.11e-18	Systemic lupus erythematosus;
LGG	cis	rs1008375	1.000	rs1121090	chr4:17676437	C/G	cg16339924	chr4:17578868	LAP3	0.58	10.21	0.43	3.36e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.65	-0.3	8.39e-11	Triglycerides;
LGG	cis	rs2708977	0.692	rs17685766	chr2:97319534	G/C	cg01950434	chr2:97203154	ARID5A	0.49	7.49	0.33	3.48e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs877282	0.891	rs12357999	chr10:796468	A/C	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs4740619	0.810	rs6474951	chr9:15707223	C/T	cg14451791	chr9:16040625	NA	0.33	8.33	0.36	8.98e-16	Body mass index;
LGG	cis	rs537626	0.848	rs624797	chr11:69308575	G/T	cg08353955	chr11:69289746	NA	0.68	10.22	0.43	3e-22	Breast cancer (early onset);
LGG	cis	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg24375607	chr4:120327624	NA	0.59	9.96	0.42	2.7e-21	Corneal astigmatism;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg26174226	chr8:58114915	NA	-0.59	-7.92	-0.35	1.8e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg20672465	chr1:153508596	S100A6	-0.4	-6.8	-0.3	3.19e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg10938836	chr2:166810420	TTC21B	-0.38	-7.06	-0.31	6.01e-12	Brain structure;
LGG	cis	rs10851411	0.559	rs79044457	chr15:42895208	G/T	cg21293051	chr15:42870591	STARD9	0.58	8.0	0.35	1.02e-14	Glucose homeostasis traits;
LGG	cis	rs11122272	0.735	rs2437149	chr1:231490105	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.04	-0.31	6.91e-12	Hemoglobin concentration;
LGG	cis	rs3820068	0.705	rs11589076	chr1:15827027	C/T	cg05660106	chr1:15850417	CASP9	1.11	26.82	0.78	2.75e-96	Systolic blood pressure;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg19318889	chr4:1322082	MAEA	0.46	8.05	0.35	7.15e-15	Longevity;
LGG	trans	rs73191547	0.867	rs56883717	chr8:10049485	G/C	cg16141378	chr3:129829833	LOC729375	-0.3	-6.73	-0.3	4.92e-11	Schizophrenia;
LGG	cis	rs72700829	0.576	rs6695311	chr1:151002758	G/A	cg11822372	chr1:151115635	SEMA6C	-0.69	-7.29	-0.32	1.38e-12	Schizophrenia;
LGG	cis	rs4731207	0.564	rs6466964	chr7:124572400	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.57	0.37	1.58e-16	Fuchs's corneal dystrophy;
LGG	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18876405	chr7:65276391	NA	0.49	8.85	0.38	1.84e-17	Aortic root size;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg15595755	chr5:1867978	NA	0.52	10.42	0.44	5.51e-23	Cardiovascular disease risk factors;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.62	11.55	0.47	2.66e-27	Obesity-related traits;
LGG	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-12.88	-0.51	1.16e-32	Morning vs. evening chronotype;
LGG	cis	rs7254114	0.578	rs73506605	chr19:11307564	G/A	cg02815516	chr19:11306319	KANK2	-0.28	-6.75	-0.3	4.38e-11	Immature fraction of reticulocytes;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg06028808	chr11:68637592	NA	0.67	11.54	0.47	3.04e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.501	rs11683107	chr2:99759235	T/A	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.31	-0.43	1.42e-22	Chronic sinus infection;
LGG	cis	rs7769051	0.808	rs1467404	chr6:133090141	A/G	cg22852734	chr6:133119734	C6orf192	-1.15	-14.8	-0.57	7.27e-41	Type 2 diabetes nephropathy;
LGG	cis	rs35110281	0.782	rs2329442	chr21:45041790	T/C	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.24e-20	Mean corpuscular volume;
LGG	cis	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg12826209	chr6:26865740	GUSBL1	0.78	8.25	0.36	1.69e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg13010199	chr12:38710504	ALG10B	0.72	14.29	0.55	1.25e-38	Bladder cancer;
LGG	cis	rs9902453	0.904	rs6505148	chr17:28289818	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.06	0.55	1.21e-37	Coffee consumption (cups per day);
LGG	cis	rs4332037	0.707	rs62435130	chr7:1890002	C/T	cg23422044	chr7:1970798	MAD1L1	-0.63	-10.88	-0.45	1.05e-24	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs67105789	chr8:58192002	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2916247	0.954	rs16914736	chr8:93082043	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.48	-0.33	3.71e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.53	-0.53	2.13e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.921	rs2143695	chr22:41728620	A/G	cg06634786	chr22:41940651	POLR3H	-0.61	-10.17	-0.43	4.5e-22	Vitiligo;
LGG	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.78	-0.64	2.64e-54	Breast cancer;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.7e-20	Testicular germ cell tumor;
LGG	trans	rs941408	1.000	rs1640273	chr19:2803227	C/T	cg22153745	chr1:153894579	GATAD2B	-0.66	-10.69	-0.44	5.28e-24	Total cholesterol levels;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg15948088	chr11:109293068	C11orf87	0.46	8.32	0.36	9.59e-16	Schizophrenia;
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6908034	0.607	rs76413455	chr6:19808964	T/G	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs780096	0.526	rs1647276	chr2:27688601	C/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	6.21e-34	Resting heart rate;
LGG	cis	rs9815354	0.812	rs56983571	chr3:41994473	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg21970626	chr13:21893289	NA	-0.46	-10.09	-0.42	8.78e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17001868	0.568	rs2294350	chr22:40784278	C/T	cg07138101	chr22:40742427	ADSL	0.68	8.79	0.38	3.01e-17	Mammographic density (dense area);
LGG	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.88	0.38	1.43e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg00106254	chr7:1943704	MAD1L1	0.43	7.59	0.33	1.75e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg12070911	chr6:150209640	RAET1E	0.3	7.41	0.33	5.97e-13	Lung cancer;
LGG	cis	rs7106204	0.609	rs12785699	chr11:24280489	C/T	ch.11.24196551F	chr11:24239977	NA	0.86	9.47	0.4	1.5e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7975161	0.640	rs10735394	chr12:104687142	C/A	cg25273343	chr12:104657179	TXNRD1	-0.76	-9.88	-0.42	5.17e-21	Toenail selenium levels;
LGG	cis	rs765787	0.530	rs55771002	chr15:45541566	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs826838	0.967	rs11183022	chr12:38652519	G/A	cg26384229	chr12:38710491	ALG10B	1.05	27.9	0.79	3.32e-101	Heart rate;
LGG	cis	rs6708331	1.000	rs12999430	chr2:70306785	C/G	cg01613454	chr2:70366299	NA	0.51	8.84	0.38	2.07e-17	Obesity-related traits;
LGG	cis	rs910316	1.000	rs12589376	chr14:75561152	C/T	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.62e-22	Height;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg03036210	chr16:89904091	SPIRE2	-0.58	-7.73	-0.34	6.78e-14	Skin colour saturation;
LGG	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.7e-56	Menopause (age at onset);
LGG	cis	rs262150	0.659	rs2527237	chr7:158798494	A/G	cg19418458	chr7:158789849	NA	0.54	11.41	0.47	9.31e-27	Facial morphology (factor 20);
LGG	cis	rs262150	0.530	rs2730232	chr7:158784469	C/T	cg13444538	chr7:158905317	VIPR2	-0.39	-7.09	-0.31	5.04e-12	Facial morphology (factor 20);
LGG	cis	rs7605378	0.528	rs281780	chr2:200756331	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	7.75	0.34	5.82e-14	Osteoporosis;
LGG	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg12751644	chr20:60527061	NA	-0.32	-6.89	-0.3	1.83e-11	Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05285606	chr16:70472963	ST3GAL2	-0.44	-7.07	-0.31	5.88e-12	Pancreatic cancer;
LGG	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27532318	chr7:32358331	NA	0.88	8.29	0.36	1.25e-15	Body mass index;
LGG	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.49	0.53	3.35e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7635838	0.684	rs2594965	chr3:11323799	G/C	cg00170343	chr3:11313890	ATG7	0.48	8.32	0.36	1.01e-15	HDL cholesterol;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-12.57	-0.5	2.19e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.22e-45	HDL cholesterol levels;
LGG	cis	rs13082711	0.911	rs57992391	chr3:27511567	A/C	cg02860705	chr3:27208620	NA	0.7	12.37	0.5	1.4e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4474465	1.000	rs10899511	chr11:78170923	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.59	-0.37	1.35e-16	Alzheimer's disease (survival time);
LGG	cis	rs798554	0.836	rs798490	chr7:2801542	C/T	cg05793240	chr7:2802953	GNA12	0.35	7.97	0.35	1.29e-14	Height;
LGG	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.17e-13	Refractive error;
LGG	cis	rs7620457	1.000	rs7620457	chr3:183747266	A/G	cg01324343	chr3:183735012	ABCC5	-0.62	-8.39	-0.36	5.96e-16	Body mass index;
LGG	cis	rs9394152	0.845	rs7743060	chr6:33470519	C/T	cg13560919	chr6:33536144	NA	0.68	12.35	0.5	1.68e-30	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs7226408	0.600	rs323302	chr18:34706871	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.59	-0.37	1.35e-16	Obesity-related traits;
LGG	cis	rs643506	0.774	rs11214033	chr11:111769702	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.43	-6.85	-0.3	2.31e-11	Breast cancer;
LGG	cis	rs8031584	0.958	rs11629793	chr15:31238423	G/A	cg14829155	chr15:31115871	NA	-0.58	-10.08	-0.42	9.66e-22	Huntington's disease progression;
LGG	cis	rs3617	0.625	rs11719137	chr3:52876389	G/T	cg11645453	chr3:52864694	ITIH4	-0.44	-7.4	-0.33	6.2800000000000005e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3540	0.960	rs4031435	chr15:91015566	G/C	cg22089800	chr15:90895588	ZNF774	0.51	8.04	0.35	7.49e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs3087591	0.683	rs12602834	chr17:29637308	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.28	0.5	3.42e-30	Hip circumference;
LGG	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.97	-0.35	1.25e-14	Initial pursuit acceleration;
LGG	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs9611565	0.765	rs132908	chr22:41801795	G/A	cg17376030	chr22:41985996	PMM1	-0.51	-8.25	-0.36	1.67e-15	Vitiligo;
LGG	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03352830	chr11:487213	PTDSS2	0.82	9.95	0.42	2.94e-21	Body mass index;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg25172604	chr17:41446521	NA	-0.3	-6.91	-0.31	1.59e-11	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs12437887	chr15:45669094	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs752010	0.905	rs10890150	chr1:42095603	A/C	cg06885757	chr1:42089581	HIVEP3	0.63	14.48	0.56	1.84e-39	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg27535305	chr1:53392650	SCP2	-0.3	-6.92	-0.31	1.49e-11	Monocyte count;
LGG	cis	rs2303745	0.589	rs1864116	chr19:17393015	C/T	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.48	-0.4	1.35e-19	Systemic lupus erythematosus;
LGG	cis	rs4696584	0.816	rs1388081	chr4:155405579	A/G	cg13738195	chr4:155413469	DCHS2	-0.38	-7.94	-0.35	1.51e-14	Folding of antihelix;
LGG	cis	rs6681460	0.604	rs7546825	chr1:67101802	A/G	cg20812318	chr1:67072952	SGIP1	-0.31	-7.23	-0.32	2.05e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg16141378	chr3:129829833	LOC729375	-0.44	-10.22	-0.43	3.07e-22	Mood instability;
LGG	cis	rs9633740	0.578	rs11185982	chr10:82305627	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	9.85	0.42	6.33e-21	Post bronchodilator FEV1;
LGG	cis	rs3087591	1.000	rs4541129	chr17:29442878	T/C	cg24425628	chr17:29625626	OMG;NF1	0.72	14.12	0.55	6.44e-38	Hip circumference;
LGG	trans	rs11875185	0.510	rs75000316	chr18:55650733	C/G	cg15513957	chr14:69354734	ACTN1	-1.09	-11.69	-0.48	7.48e-28	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg10840412	chr1:235813424	GNG4	-0.52	-7.15	-0.32	3.45e-12	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg08621203	chr6:150244597	RAET1G	0.39	6.75	0.3	4.38e-11	Lung cancer;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.84	0.3	2.52e-11	Lung cancer;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg23034840	chr1:205782522	SLC41A1	0.61	10.14	0.43	6.17e-22	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08208917	chr15:42565872	GANC;TMEM87A	0.47	8.07	0.35	5.95e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.48e-15	Menopause (age at onset);
LGG	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg07303275	chr16:75499416	TMEM170A	0.42	7.49	0.33	3.51e-13	Dupuytren's disease;
LGG	cis	rs7107174	0.901	rs10899498	chr11:78124575	C/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.16	-0.32	3.12e-12	Testicular germ cell tumor;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	cis	rs651907	0.557	rs3864012	chr3:101397623	T/C	cg12386194	chr3:101231763	SENP7	0.46	8.3	0.36	1.18e-15	Colorectal cancer;
LGG	cis	rs10484885	0.877	rs17735389	chr6:90323139	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.68	-8.76	-0.38	3.72e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1957429	0.614	rs117316280	chr14:65388641	T/C	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg17802220	chr15:77601643	NA	-0.54	-11.98	-0.49	5.46e-29	Type 2 diabetes;
LGG	cis	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg16606324	chr3:10149918	C3orf24	0.53	6.87	0.3	2.04e-11	Alzheimer's disease;
LGG	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg23594656	chr7:65796392	TPST1	0.39	8.5	0.37	2.55e-16	Aortic root size;
LGG	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg16395133	chr6:150326394	RAET1K	0.26	6.65	0.3	8.29e-11	Alopecia areata;
LGG	cis	rs7537765	0.649	rs2151654	chr1:11845524	G/A	cg21864959	chr1:11847863	MTHFR	0.38	6.75	0.3	4.37e-11	QRS complex (12-leadsum);
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg11494091	chr17:61959527	GH2	0.51	8.01	0.35	9.42e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.728	rs17215621	chr8:58152706	C/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg05791153	chr7:19748676	TWISTNB	1.26	22.48	0.72	3.41e-76	Night sleep phenotypes;
LGG	cis	rs3858526	1.000	rs10838909	chr11:5960490	G/A	cg13902645	chr11:5959945	NA	-0.74	-11.83	-0.48	2.11e-28	DNA methylation (variation);
LGG	cis	rs9487051	0.837	rs932223	chr6:109586656	A/G	cg21918786	chr6:109611834	NA	-0.41	-7.44	-0.33	4.86e-13	Reticulocyte fraction of red cells;
LGG	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg27478167	chr7:817139	HEATR2	-0.44	-6.99	-0.31	9.38e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs6963495	0.818	rs55691539	chr7:105165774	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-18.35	-0.65	6.39e-57	Vitiligo;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23123838	chr14:105886072	MTA1	0.66	7.55	0.33	2.39e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2028299	0.920	rs2043880	chr15:90432526	G/A	cg23731826	chr15:90371692	NA	0.34	7.53	0.33	2.71e-13	Type 2 diabetes;
LGG	cis	rs6426558	0.537	rs2718193	chr1:227404672	C/G	cg10327440	chr1:227177885	CDC42BPA	0.6	9.89	0.42	4.59e-21	Neutrophil percentage of white cells;
LGG	cis	rs9354308	0.868	rs9345696	chr6:66557641	C/T	cg07460842	chr6:66804631	NA	-0.45	-7.58	-0.33	1.97e-13	Metabolite levels;
LGG	cis	rs7264396	0.635	rs6058351	chr20:34486093	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.33	0.32	1.06e-12	Total cholesterol levels;
LGG	cis	rs62400317	0.826	rs11970412	chr6:45037516	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.28	-0.43	1.89e-22	Total body bone mineral density;
LGG	cis	rs3741404	0.560	rs17699798	chr11:63898806	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.74	-13.77	-0.54	2.05e-36	Platelet count;
LGG	cis	rs61931739	0.500	rs11053272	chr12:34547020	C/G	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.29	0.46	2.73e-26	Schizophrenia;
LGG	trans	rs34421088	0.576	rs2572437	chr8:11098441	C/T	cg02002194	chr4:3960332	NA	0.42	7.3	0.32	1.23e-12	Neuroticism;
LGG	cis	rs7737355	0.898	rs31590	chr5:131005181	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	2.92e-19	Life satisfaction;
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg07332563	chr6:291687	DUSP22	-0.46	-7.93	-0.35	1.65e-14	Menopause (age at onset);
LGG	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.88	0.38	1.5e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7100689	0.577	rs1143694	chr10:82040052	C/T	cg01528321	chr10:82214614	TSPAN14	-0.78	-13.8	-0.54	1.61e-36	Post bronchodilator FEV1;
LGG	cis	rs7539542	0.556	rs6686801	chr1:202874730	C/T	cg19681188	chr1:202830198	LOC148709	0.53	8.96	0.38	8.29e-18	Mean platelet volume;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15123824	chr2:85581917	ELMOD3;RETSAT	0.41	6.83	0.3	2.64e-11	Bipolar disorder;
LGG	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg16586182	chr3:47516702	SCAP	0.77	14.77	0.57	1.01e-40	Colorectal cancer;
LGG	cis	rs4268898	0.931	rs60716082	chr2:24526265	T/A	cg06627628	chr2:24431161	ITSN2	-0.53	-8.97	-0.38	7.13e-18	Asthma;
LGG	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs41271473	0.898	rs72750015	chr1:228811318	A/G	cg00850481	chr1:228891306	NA	-0.48	-7.99	-0.35	1.1e-14	Chronic lymphocytic leukemia;
LGG	trans	rs853679	1.000	rs1679709	chr6:28228342	A/G	cg01620082	chr3:125678407	NA	0.61	7.51	0.33	2.98e-13	Depression;
LGG	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg02002194	chr4:3960332	NA	-0.47	-8.87	-0.38	1.64e-17	Joint mobility (Beighton score);
LGG	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg15665833	chr6:26285013	NA	-0.37	-6.69	-0.3	6.37e-11	Mosquito bite size;
LGG	cis	rs472402	0.623	rs8192135	chr5:6636757	T/A	cg08700190	chr5:6636046	SRD5A1	-0.36	-7.63	-0.33	1.31e-13	Response to amphetamines;
LGG	cis	rs13082711	0.911	rs34878935	chr3:27466123	A/C	cg02860705	chr3:27208620	NA	0.73	13.17	0.52	7.03e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs12682352	0.602	rs6988939	chr8:8666916	C/T	cg02002194	chr4:3960332	NA	-0.38	-7.03	-0.31	7.31e-12	Neuroticism;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.93	0.68	2.75e-64	Platelet count;
LGG	cis	rs2470578	0.792	rs283944	chr3:17346655	G/T	cg20981856	chr3:17787350	NA	-0.35	-6.65	-0.3	8.05e-11	Schizophrenia;
LGG	cis	rs858239	0.600	rs6961131	chr7:23134790	A/G	cg23682824	chr7:23144976	KLHL7	0.44	7.66	0.34	1.08e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9303280	0.776	rs11078926	chr17:38062976	G/A	cg17467752	chr17:38218738	THRA	-0.45	-7.23	-0.32	2.06e-12	Self-reported allergy;
LGG	cis	rs7011049	0.915	rs11997706	chr8:53833202	T/G	cg26025543	chr8:53854495	NA	0.73	9.64	0.41	3.71e-20	Systolic blood pressure;
LGG	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.04	-0.35	7.56e-15	Joint mobility (Beighton score);
LGG	trans	rs11039798	0.858	rs11039730	chr11:48440495	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.0	0.35	9.74e-15	Axial length;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs4474465	0.850	rs7117513	chr11:78206418	T/G	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs826838	0.809	rs11169666	chr12:39211300	T/C	cg13010199	chr12:38710504	ALG10B	0.72	14.97	0.57	1.35e-41	Heart rate;
LGG	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg04568710	chr12:38710424	ALG10B	-0.41	-9.08	-0.39	3.18e-18	Bladder cancer;
LGG	cis	rs7226408	0.857	rs17567674	chr18:34480016	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-7.07	-0.31	5.92e-12	Obesity-related traits;
LGG	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	1.87e-29	Colorectal cancer;
LGG	trans	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.2	0.36	2.35e-15	Retinal vascular caliber;
LGG	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg00543991	chr22:32367038	NA	0.81	8.95	0.38	8.83e-18	Childhood ear infection;
LGG	trans	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg17830980	chr10:43048298	ZNF37B	0.39	8.84	0.38	1.98e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg23173402	chr1:227635558	NA	0.7	10.57	0.44	1.53e-23	Major depressive disorder;
LGG	cis	rs9611565	0.512	rs6519289	chr22:42170432	A/C	cg17376030	chr22:41985996	PMM1	-0.67	-10.74	-0.45	3.47e-24	Vitiligo;
LGG	cis	rs4950322	0.518	rs72692965	chr1:146803815	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	trans	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg18335740	chr13:41363409	SLC25A15	0.97	23.41	0.74	1.55e-80	Lewy body disease;
LGG	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg13385794	chr1:248469461	NA	0.44	7.43	0.33	5.12e-13	Common traits (Other);
LGG	cis	rs10174077	0.874	rs11892439	chr2:152469858	T/A	cg06191203	chr2:152266755	RIF1	-0.42	-7.41	-0.33	6.25e-13	Squamous cell lung carcinoma;
LGG	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg26384229	chr12:38710491	ALG10B	0.9	18.98	0.66	7.81e-60	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.817	rs592857	chr12:34197673	T/G	cg13010199	chr12:38710504	ALG10B	0.46	8.82	0.38	2.26e-17	Morning vs. evening chronotype;
LGG	cis	rs4774899	0.752	rs2951895	chr15:57357266	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.81	-0.3	2.99e-11	Urinary tract infection frequency;
LGG	cis	rs1863824	0.502	rs11202058	chr10:88282611	G/A	cg07322936	chr10:88137208	NA	-0.49	-7.73	-0.34	6.8e-14	Schizophrenia;
LGG	cis	rs4319547	0.956	rs9988963	chr12:122991478	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.61	-8.94	-0.38	9.66e-18	Body mass index;
LGG	cis	rs7607369	0.714	rs4674334	chr2:219622811	T/C	cg01130898	chr2:219473002	PLCD4	0.42	7.03	0.31	7.35e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs35740288	0.571	rs11631009	chr15:86318653	G/A	cg04173714	chr15:86211321	AKAP13	0.44	7.12	0.31	4.24e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs36051895	0.659	rs1322224	chr9:5267889	C/A	cg02405213	chr9:5042618	JAK2	-0.74	-12.65	-0.51	1.03e-31	Pediatric autoimmune diseases;
LGG	cis	rs875971	1.000	rs6961990	chr7:65888570	C/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg09873164	chr1:152488093	CRCT1	0.61	14.84	0.57	5.18e-41	Hair morphology;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs1018836	0.886	rs10956750	chr8:91621704	G/C	cg16814680	chr8:91681699	NA	-0.85	-15.78	-0.59	3.44e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.65	0.56	3.39e-40	Platelet count;
LGG	cis	rs763121	0.853	rs6001182	chr22:39047443	A/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg15736062	chr7:158136485	PTPRN2	0.41	8.02	0.35	8.83e-15	Calcium levels;
LGG	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg03060546	chr3:49711283	APEH	0.59	8.35	0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Body mass index;
LGG	cis	rs4474465	0.920	rs12271198	chr11:78158943	G/A	cg02023728	chr11:77925099	USP35	0.38	6.72	0.3	5.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.21e-15	Bipolar disorder;
LGG	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg26897989	chr16:1907736	C16orf73	0.52	9.76	0.41	1.35e-20	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg11965913	chr1:205819406	PM20D1	0.84	18.36	0.65	6.03e-57	Menarche (age at onset);
LGG	cis	rs11644362	0.966	rs976011	chr16:12992910	C/T	cg06890432	chr16:12997467	SHISA9	-0.32	-6.95	-0.31	1.25e-11	Positive affect;Subjective well-being;
LGG	cis	rs11190604	0.767	rs10883479	chr10:102162860	A/G	cg07080220	chr10:102295463	HIF1AN	0.57	10.03	0.42	1.53e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs62244186	0.659	rs9850129	chr3:44532047	C/T	cg02073558	chr3:44770973	ZNF501	0.64	11.62	0.48	1.43e-27	Depressive symptoms;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg13047869	chr3:10149882	C3orf24	0.45	7.17	0.32	2.95e-12	Alzheimer's disease;
LGG	cis	rs4380275	0.782	rs4335978	chr2:750078	A/G	cg14072418	chr2:740025	NA	-0.35	-6.99	-0.31	9.44e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs7737355	0.898	rs13164236	chr5:131079808	C/T	cg06307176	chr5:131281290	NA	0.57	9.33	0.4	4.31e-19	Life satisfaction;
LGG	cis	rs876084	0.505	rs12541796	chr8:121112830	G/A	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg25173405	chr17:45401733	C17orf57	-0.55	-9.12	-0.39	2.34e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2380220	0.541	rs72928283	chr6:96082490	A/C	cg04719120	chr6:96025338	MANEA	-0.53	-7.38	-0.32	7.53e-13	Behavioural disinhibition (generation interaction);
LGG	cis	rs7937840	0.597	rs3890102	chr11:61915823	C/T	cg01969543	chr11:61895209	INCENP	0.42	7.61	0.33	1.55e-13	Breast cancer;
LGG	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	cis	rs9399137	0.507	rs10484496	chr6:135299682	T/C	cg24558204	chr6:135376177	HBS1L	0.62	10.61	0.44	1.06e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1670533	0.872	rs6854793	chr4:1055768	T/C	cg27284194	chr4:1044797	NA	0.55	9.81	0.41	8.99e-21	Recombination rate (females);
LGG	cis	rs171408	0.744	rs355144	chr3:8628975	A/T	cg03557445	chr3:8615444	LOH3CR2A	-0.47	-7.94	-0.35	1.51e-14	Mitral valve prolapse;
LGG	cis	rs74781061	0.929	rs8026923	chr15:74858062	C/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.53e-12	Endometriosis;
LGG	cis	rs6546537	1.000	rs2048256	chr2:69847357	G/C	cg10773587	chr2:69614142	GFPT1	-0.48	-8.05	-0.35	6.89e-15	Serum thyroid-stimulating hormone levels;
LGG	cis	rs950776	0.518	rs62008174	chr15:78808947	C/T	cg06917634	chr15:78832804	PSMA4	0.82	17.09	0.62	3.96e-51	Sudden cardiac arrest;
LGG	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg25174290	chr11:3078921	CARS	0.68	13.47	0.53	4.08e-35	Type 2 diabetes;
LGG	cis	rs2479724	0.846	rs2254805	chr6:41846110	T/G	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg22437258	chr11:111473054	SIK2	0.58	9.85	0.42	6.56e-21	Primary sclerosing cholangitis;
LGG	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg24375607	chr4:120327624	NA	0.41	7.13	0.31	3.94e-12	Diastolic blood pressure;
LGG	cis	rs189798	1.000	rs189798	chr8:8990577	A/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.4	-0.33	6.47e-13	Myopia (pathological);
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.02	0.39	4.94e-18	Alzheimer's disease;
LGG	cis	rs60871478	1.000	rs67721251	chr7:825114	T/C	cg05535760	chr7:792225	HEATR2	0.8	12.59	0.51	1.78e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Myopia (pathological);
LGG	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg11995313	chr8:8860691	ERI1	0.45	7.73	0.34	6.59e-14	Joint mobility (Beighton score);
LGG	trans	rs7395662	0.597	rs2135684	chr11:48748469	G/A	cg00717180	chr2:96193071	NA	-0.4	-7.13	-0.31	3.97e-12	HDL cholesterol;
LGG	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg02151108	chr14:50098012	C14orf104	-0.43	-9.14	-0.39	1.98e-18	Carotid intima media thickness;
LGG	cis	rs6831352	0.703	rs3133152	chr4:100031721	C/G	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs10832963	0.686	rs11024743	chr11:18653712	A/G	cg09201001	chr11:18656081	SPTY2D1	0.99	20.64	0.69	1.4e-67	Breast cancer;
LGG	cis	rs67311347	1.000	rs73080137	chr3:40516412	A/G	cg13683864	chr3:40499215	RPL14	-1.16	-29.84	-0.81	6.67e-110	Renal cell carcinoma;
LGG	cis	rs4622507	0.773	rs12925215	chr16:55049850	T/A	cg09947736	chr16:55091198	NA	0.63	10.84	0.45	1.49e-24	Social communication problems;
LGG	trans	rs116095464	0.558	rs73024831	chr5:257192	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.95	0.7	4.78e-69	Alzheimer's disease;
LGG	cis	rs11690935	0.921	rs6710698	chr2:172596078	G/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.94	-0.31	1.36e-11	Schizophrenia;
LGG	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.51	9.0	0.39	5.87e-18	Menarche (age at onset);
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs34330	0.562	rs10492235	chr12:12851339	T/G	cg04607235	chr12:12878440	APOLD1	-0.62	-8.79	-0.38	2.92e-17	Systemic lupus erythematosus;
LGG	cis	rs10895140	0.645	rs10791509	chr11:101501021	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.85	-0.3	2.37e-11	Menarche (age at onset);
LGG	cis	rs7851660	0.874	rs7847010	chr9:100630439	T/C	cg13688889	chr9:100608707	NA	-0.63	-12.62	-0.51	1.33e-31	Strep throat;
LGG	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.2	0.49	6.93e-30	Hip circumference adjusted for BMI;
LGG	cis	rs2645694	0.626	rs12502590	chr4:77823642	G/A	cg18351406	chr4:77819688	ANKRD56	0.46	8.05	0.35	6.83e-15	Emphysema distribution in smoking;
LGG	cis	rs9788682	0.792	rs35031105	chr15:78772806	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.1	-0.35	4.78e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg15595755	chr5:1867978	NA	0.52	10.38	0.43	8e-23	Cardiovascular disease risk factors;
LGG	cis	rs9596837	0.514	rs12184586	chr13:54253801	T/C	ch.13.53330881F	chr13:54432880	NA	0.42	6.75	0.3	4.51e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9902453	0.967	rs7222685	chr17:28496430	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.52	0.53	2.49e-35	Coffee consumption (cups per day);
LGG	cis	rs372883	0.648	rs382732	chr21:30719010	A/G	cg08807101	chr21:30365312	RNF160	0.59	9.86	0.42	5.96e-21	Pancreatic cancer;
LGG	trans	rs826838	0.967	rs826876	chr12:39123843	T/C	cg06521331	chr12:34319734	NA	0.44	7.92	0.35	1.78e-14	Heart rate;
LGG	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg00343986	chr7:65444356	GUSB	0.49	8.62	0.37	1.05e-16	Calcium levels;
LGG	cis	rs12477438	0.798	rs972768	chr2:99682397	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.5	8.34	0.36	8.77e-16	Cognitive performance;
LGG	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg02002194	chr4:3960332	NA	0.45	7.84	0.34	3.1e-14	Systemic lupus erythematosus;
LGG	cis	rs4730250	0.634	rs257371	chr7:106795043	C/A	cg02696742	chr7:106810147	HBP1	-0.79	-11.28	-0.46	3.15e-26	Osteoarthritis;
LGG	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg08807101	chr21:30365312	RNF160	0.54	8.94	0.38	9.64e-18	Selective IgA deficiency;
LGG	cis	rs273218	0.724	rs392714	chr5:53382703	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.44	6.82	0.3	2.8e-11	Migraine;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15238008	chr12:9600875	DDX12	-0.4	-6.65	-0.3	8.26e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9814567	0.806	rs4074523	chr3:134325657	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.06	-0.46	2.22e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4363385	0.693	rs581447	chr1:153033269	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.57e-15	Inflammatory skin disease;
LGG	cis	rs9397585	0.857	rs2295232	chr6:153365384	T/G	cg17707550	chr6:153380415	RGS17	0.62	14.63	0.56	3.9e-40	Body mass index;
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs7666738	0.830	rs11932942	chr4:98998939	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs155076	0.666	rs4770128	chr13:21881922	A/G	cg06138931	chr13:21896616	NA	0.5	8.44	0.37	4.02e-16	White matter hyperintensity burden;
LGG	cis	rs10754283	0.967	rs7546410	chr1:90109815	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.26	0.49	4.2000000000000004e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7107174	1.000	rs7119933	chr11:78049750	A/C	cg02023728	chr11:77925099	USP35	0.46	8.12	0.35	4.17e-15	Testicular germ cell tumor;
LGG	cis	rs1270639	0.778	rs2707942	chr7:157445750	G/C	cg13357408	chr7:157437802	PTPRN2	0.65	10.51	0.44	2.66e-23	Colorectal cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11292385	chr22:29138453	CHEK2;HSCB	0.39	6.66	0.3	7.95e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7084402	0.967	rs1658478	chr10:60289551	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs208520	1.000	rs208535	chr6:66962286	G/A	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs2905347	0.895	rs2905308	chr7:22648194	G/A	cg18045685	chr7:22629474	NA	-0.73	-15.9	-0.59	9.69e-46	Major depression and alcohol dependence;
LGG	cis	rs9303280	0.840	rs12939457	chr17:38032188	T/C	cg17467752	chr17:38218738	THRA	-0.44	-7.07	-0.31	5.69e-12	Self-reported allergy;
LGG	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.32	-0.36	9.84e-16	Joint mobility (Beighton score);
LGG	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.88e-22	Diabetic kidney disease;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs801194	chr7:66028495	T/C	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs12136530	0.774	rs12137160	chr1:19763379	C/T	cg17081867	chr1:19768096	CAPZB	-0.39	-8.65	-0.37	8.34e-17	Lead levels in blood;
LGG	cis	rs6784615	0.744	rs2109559	chr3:52512318	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.62	-7.24	-0.32	1.9e-12	Waist-hip ratio;
LGG	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.21	-0.43	3.22e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8005677	1.000	rs8016061	chr14:23375809	A/G	cg01529538	chr14:23388837	RBM23	0.37	6.82	0.3	2.8e-11	Cognitive ability (multi-trait analysis);
LGG	trans	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg02227867	chr8:22457446	C8orf58	-0.44	-8.36	-0.36	7.2e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12545912	0.908	rs35159871	chr8:9580934	T/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7568458	0.811	rs3755015	chr2:85764041	G/A	cg17127132	chr2:85788382	GGCX	0.48	8.26	0.36	1.54e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1620921	0.535	rs66533808	chr6:161273302	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7208859	0.623	rs1061342	chr17:29114463	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg20720597	chr2:3699334	NA	0.89	9.45	0.4	1.66e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs546131	0.890	rs485845	chr11:34830389	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-6.73	-0.3	5.17e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs2692947	0.630	rs1168966	chr2:96798510	G/A	cg22654517	chr2:96458247	NA	0.38	8.33	0.36	9.54e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2382817	0.580	rs6756265	chr2:219095554	G/A	cg04731861	chr2:219085781	ARPC2	0.52	13.46	0.53	4.17e-35	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2404602	0.622	rs1567671	chr15:77209200	C/G	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.3e-22	Blood metabolite levels;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg02048412	chr16:4421654	VASN;CORO7	-0.27	-6.75	-0.3	4.49e-11	Schizophrenia;
LGG	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	8.96	0.38	8.23e-18	Bipolar disorder;
LGG	cis	rs2354432	0.607	rs12402309	chr1:146721983	T/A	cg25205988	chr1:146714368	CHD1L	-1.45	-15.29	-0.58	4.99e-43	Mitochondrial DNA levels;
LGG	cis	rs798554	0.610	rs2251491	chr7:2852835	T/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.94	-0.38	9.42e-18	Height;
LGG	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.13	-0.31	3.81e-12	Testicular germ cell tumor;
LGG	cis	rs1983891	0.955	rs4714480	chr6:41520891	T/C	cg20194872	chr6:41519635	FOXP4	0.58	9.87	0.42	5.74e-21	Prostate cancer;
LGG	cis	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Neuroticism;
LGG	cis	rs36051895	0.589	rs7850294	chr9:5191128	C/T	cg02405213	chr9:5042618	JAK2	0.79	14.98	0.57	1.23e-41	Pediatric autoimmune diseases;
LGG	cis	rs9300255	0.722	rs28458312	chr12:123863265	G/T	cg00376283	chr12:123451042	ABCB9	-0.53	-7.96	-0.35	1.34e-14	Neutrophil percentage of white cells;
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg13264159	chr8:625131	ERICH1	-0.75	-8.61	-0.37	1.12e-16	IgG glycosylation;
LGG	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg09117114	chr16:67998030	SLC12A4	-0.4	-6.97	-0.31	1.12e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21620608	chr2:139259466	SPOPL	-0.4	-6.86	-0.3	2.26e-11	Brain structure;
LGG	cis	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg06636001	chr8:8085503	FLJ10661	0.53	10.04	0.42	1.32e-21	Mood instability;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg24829409	chr8:58192753	C8orf71	-0.88	-13.53	-0.53	2.31e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs8038465	0.622	rs60696711	chr15:73873005	C/A	cg15420318	chr15:73925796	NPTN	0.5	8.43	0.36	4.56e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg13628971	chr7:2884303	GNA12	0.36	7.45	0.33	4.48e-13	Height;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg08187779	chr8:102217898	ZNF706	0.57	6.66	0.3	7.59e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.22	-0.43	2.93e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8060686	0.641	rs76984161	chr16:68139423	C/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.75	-0.3	4.48e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6750047	0.566	rs1157184	chr2:38285774	C/G	cg07380506	chr2:38303506	CYP1B1	0.48	8.1	0.35	4.8e-15	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs765787	0.530	rs3759895	chr15:45543870	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.31	-0.32	1.17e-12	Uric acid levels;
LGG	cis	rs780096	0.565	rs13022659	chr2:27743630	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.25	-0.36	1.7e-15	Total body bone mineral density;
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg12458913	chr13:53173898	NA	0.58	10.34	0.43	1.14e-22	Lewy body disease;
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.25	-0.36	1.61e-15	Obesity;
LGG	cis	rs2243480	1.000	rs1618893	chr7:66096119	C/T	cg18252515	chr7:66147081	NA	-0.96	-12.59	-0.51	1.83e-31	Diabetic kidney disease;
LGG	cis	rs34330	0.562	rs11055025	chr12:12866619	A/T	cg04607235	chr12:12878440	APOLD1	-0.57	-8.33	-0.36	9.21e-16	Systemic lupus erythematosus;
LGG	cis	rs7215564	0.908	rs35253080	chr17:78700167	G/A	cg16980736	chr17:78789706	RPTOR	-0.63	-8.25	-0.36	1.63e-15	Myopia (pathological);
LGG	cis	rs1008375	0.932	rs11935124	chr4:17668200	G/A	cg16339924	chr4:17578868	LAP3	-0.65	-11.22	-0.46	5.03e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16604136	chr1:163291493	NUF2	0.41	6.69	0.3	6.36e-11	Cognitive performance;
LGG	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg24375607	chr4:120327624	NA	0.52	8.87	0.38	1.55e-17	Corneal astigmatism;
LGG	cis	rs798554	0.607	rs1182151	chr7:2909225	C/G	cg13628971	chr7:2884303	GNA12	0.52	9.87	0.42	5.79e-21	Height;
LGG	cis	rs651907	0.640	rs771574	chr3:101620682	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.48	7.83	0.34	3.34e-14	Colorectal cancer;
LGG	trans	rs11976180	1.000	rs2951372	chr7:143749503	C/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.91	-0.31	1.63e-11	Obesity-related traits;
LGG	trans	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.48	7.41	0.33	6.11e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4683142	0.518	rs4682811	chr3:46164795	A/G	cg13144783	chr3:46249795	CCR1	-0.47	-8.09	-0.35	5.36e-15	Methadone dose in opioid dependence;
LGG	cis	rs2346160	0.899	rs206972	chr6:167689552	C/T	cg20683250	chr6:167653907	NA	-0.44	-7.42	-0.33	5.69e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs2071403	0.933	rs12328062	chr2:1400567	C/T	cg06500727	chr2:1417164	TPO	0.5	9.55	0.41	7.75e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs7619833	0.540	rs9832789	chr3:27228834	A/C	cg02860705	chr3:27208620	NA	0.41	8.02	0.35	8.91e-15	Breast cancer;
LGG	cis	rs4948102	0.686	rs11771788	chr7:56158040	T/C	cg17215666	chr7:56131930	SUMF2	0.45	7.24	0.32	1.91e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2976388	0.533	rs12543368	chr8:143819450	T/C	cg06565975	chr8:143823917	SLURP1	-0.56	-13.57	-0.53	1.56e-35	Urinary tract infection frequency;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	trans	rs1032833	0.732	rs76298720	chr2:179990353	C/G	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg23009067	chr7:2775923	GNA12	-0.25	-6.83	-0.3	2.74e-11	Height;
LGG	cis	rs12586317	0.547	rs28569331	chr14:35473584	T/C	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.82	-0.34	3.52e-14	Psoriasis;
LGG	cis	rs9393692	0.557	rs9379846	chr6:26314238	G/C	cg13736514	chr6:26305472	NA	-0.48	-9.39	-0.4	2.67e-19	Educational attainment;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.38e-11	Aortic root size;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg17330251	chr7:94953956	PON1	0.43	8.54	0.37	1.98e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs1003719	0.715	rs7280251	chr21:38567911	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.35	-0.58	2.74e-43	Eye color traits;
LGG	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg21926883	chr2:100939477	LONRF2	-0.48	-9.25	-0.39	8.44e-19	Intelligence (multi-trait analysis);
LGG	trans	rs941408	0.515	rs759066	chr19:2775337	G/T	cg22153745	chr1:153894579	GATAD2B	-0.67	-9.05	-0.39	3.99e-18	Total cholesterol levels;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs2486288	0.656	rs8040185	chr15:45552081	G/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs7208859	0.673	rs56085216	chr17:29217234	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7552404	0.960	rs4949877	chr1:76201668	C/G	cg03433033	chr1:76189801	ACADM	0.8	13.77	0.54	2.21e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg02297831	chr4:17616191	MED28	0.5	9.44	0.4	1.77e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35306767	0.953	rs11253509	chr10:964306	C/T	cg08847335	chr10:891726	LARP4B	-0.36	-6.99	-0.31	9.42e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7568458	0.846	rs6705839	chr2:85761279	A/T	cg02493740	chr2:85810744	VAMP5	-0.41	-7.39	-0.32	6.84e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17122278	0.613	rs477106	chr11:118363424	A/C	cg27286069	chr11:118481882	PHLDB1	0.51	7.03	0.31	7.42e-12	Total cholesterol levels;
LGG	cis	rs6993813	0.593	rs10086835	chr8:120040181	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.8	0.34	4.05e-14	Bone mineral density (hip);
LGG	cis	rs6032067	0.929	rs2868238	chr20:43826993	C/G	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06008158	chr8:17781352	PCM1	0.41	6.73	0.3	4.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs3806843	1.000	rs6891995	chr5:140172008	A/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg13009111	chr11:71350975	NA	0.32	7.17	0.32	3.02e-12	Neuroticism;
LGG	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg00343986	chr7:65444356	GUSB	-0.41	-7.09	-0.31	5.05e-12	Aortic root size;
LGG	cis	rs28595532	0.920	rs114966881	chr4:119761078	C/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg19524238	chr7:2802976	GNA12	0.3	7.29	0.32	1.31e-12	Height;
LGG	cis	rs7674212	0.570	rs2126470	chr4:104061762	T/C	cg16532752	chr4:104119610	CENPE	-0.42	-7.34	-0.32	9.75e-13	Type 2 diabetes;
LGG	cis	rs2084898	0.891	rs2511023	chr11:120009145	A/G	cg07435449	chr11:120005650	TRIM29	0.66	8.78	0.38	3.08e-17	Stroke (pediatric);
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg14159672	chr1:205819179	PM20D1	0.77	16.44	0.61	3.53e-48	Menarche (age at onset);
LGG	cis	rs2285947	0.967	rs2285944	chr7:21582964	A/T	cg23045935	chr7:21583304	DNAH11	0.43	9.24	0.39	8.67e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	cis	rs9359856	0.564	rs72913975	chr6:90387116	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.63	-0.41	4.08e-20	Bipolar disorder;
LGG	cis	rs13191362	0.507	rs2849527	chr6:163117932	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.5	6.82	0.3	2.81e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg05863683	chr7:1912471	MAD1L1	0.45	8.82	0.38	2.32e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7617773	0.780	rs13085251	chr3:48340045	C/T	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg20891558	chr2:74357851	NA	0.49	9.63	0.41	4.05e-20	Gestational age at birth (maternal effect);
LGG	cis	rs988958	0.805	rs10185599	chr2:42283886	A/G	cg19376973	chr2:42229025	NA	0.47	7.82	0.34	3.66e-14	Hypospadias;
LGG	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg26769984	chr7:1090371	C7orf50	0.53	8.92	0.38	1.09e-17	Bronchopulmonary dysplasia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19772723	chr7:77326842	RSBN1L	0.48	6.94	0.31	1.32e-11	Gut microbiome composition (summer);
LGG	cis	rs4787491	0.704	rs12447915	chr16:30089908	C/T	cg06326092	chr16:30034487	C16orf92	0.43	8.52	0.37	2.21e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs236352	0.521	rs2293393	chr6:36884042	A/G	cg03410223	chr6:36853544	C6orf89	0.4	7.51	0.33	3.07e-13	Heart rate;
LGG	trans	rs6956675	1.000	rs1609527	chr7:62599257	C/T	cg01314568	chr7:57830625	NA	-0.52	-8.18	-0.36	2.67e-15	Obesity-related traits;
LGG	cis	rs2836950	0.545	rs1888489	chr21:40533164	T/C	cg17971929	chr21:40555470	PSMG1	-0.56	-9.43	-0.4	2.06e-19	Menarche (age at onset);
LGG	cis	rs12497850	0.931	rs9755490	chr3:48871664	A/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.84e-25	Parkinson's disease;
LGG	cis	rs137603	0.644	rs470082	chr22:39715140	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.73	-14.31	-0.55	1.04e-38	Primary biliary cholangitis;
LGG	cis	rs12681287	0.640	rs13253296	chr8:87448245	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg09461388	chr22:46763229	CELSR1	-0.59	-6.66	-0.3	7.81e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11122272	0.735	rs2808603	chr1:231537738	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.54e-12	Hemoglobin concentration;
LGG	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg04842962	chr6:43655489	MRPS18A	1.12	24.45	0.75	2.26e-85	IgG glycosylation;
LGG	cis	rs36715	1.000	rs251212	chr5:127545910	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.64	0.33	1.26e-13	Breast cancer;
LGG	cis	rs2455601	0.786	rs3763914	chr11:8940703	G/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.74	-12.9	-0.51	9.69e-33	Schizophrenia;
LGG	cis	rs7766436	0.885	rs1418312	chr6:22589704	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg21775007	chr8:11205619	TDH	0.45	7.36	0.32	8.38e-13	Mood instability;
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg13939156	chr17:80058883	NA	0.53	10.89	0.45	9.74e-25	Life satisfaction;
LGG	cis	rs11971779	0.616	rs6944244	chr7:139051186	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	cis	rs7110818	0.528	rs10899232	chr11:76279179	C/T	cg17647271	chr11:76299819	NA	-0.38	-6.74	-0.3	4.85e-11	Gut microbiota (functional units);
LGG	trans	rs6787172	0.566	rs11719188	chr3:158106764	A/C	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	trans	rs783540	1.000	rs803688	chr15:83216793	A/G	cg16105309	chr15:79090380	ADAMTS7	0.43	7.46	0.33	4.25e-13	Schizophrenia;
LGG	cis	rs881375	0.678	rs7021049	chr9:123683982	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	12.6	0.51	1.71e-31	Rheumatoid arthritis;
LGG	cis	rs1062746	0.520	rs17698303	chr16:87329543	C/G	cg02258303	chr16:87377426	FBXO31	-0.42	-7.62	-0.33	1.46e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs1670533	0.932	rs2045067	chr4:1052355	C/T	cg27284194	chr4:1044797	NA	0.54	9.77	0.41	1.24e-20	Recombination rate (females);
LGG	cis	rs1568889	0.887	rs2062269	chr11:28116537	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.36	0.67	1.24e-61	Bipolar disorder;
LGG	cis	rs899997	1.000	rs11634628	chr15:79005579	G/A	cg10852096	chr15:79043040	NA	-0.28	-7.84	-0.34	3.11e-14	Coronary artery disease or large artery stroke;
LGG	trans	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg24247370	chr13:99142703	STK24	-0.42	-7.56	-0.33	2.11e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.75	-0.34	5.82e-14	Rheumatoid arthritis;
LGG	cis	rs3862030	0.720	rs7342070	chr10:104223628	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.24	-0.43	2.61e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs3735485	0.738	rs11765226	chr7:45131853	A/G	cg03440944	chr7:45023329	C7orf40	-0.51	-8.44	-0.37	4.08e-16	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs911263	0.603	rs3784109	chr14:68789911	T/G	cg18825221	chr14:68749962	RAD51L1	0.36	7.97	0.35	1.23e-14	Primary biliary cholangitis;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg17202724	chr17:61916730	SMARCD2	-0.47	-8.88	-0.38	1.44e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs796364	0.806	rs11691873	chr2:200966337	A/G	cg17644776	chr2:200775616	C2orf69	-0.6	-6.82	-0.3	2.93e-11	Schizophrenia;
LGG	cis	rs4919087	0.923	rs12357266	chr10:98978045	G/A	cg25902810	chr10:99078978	FRAT1	0.53	9.88	0.42	5.13e-21	Monocyte count;
LGG	cis	rs4595586	0.505	rs11615603	chr12:39409450	C/G	cg13010199	chr12:38710504	ALG10B	0.41	7.49	0.33	3.42e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg26174226	chr8:58114915	NA	-0.6	-8.58	-0.37	1.48e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs911263	0.603	rs12878627	chr14:68795149	G/A	cg18825221	chr14:68749962	RAD51L1	0.37	8.07	0.35	6.28e-15	Primary biliary cholangitis;
LGG	cis	rs3762637	0.943	rs9872708	chr3:122242807	C/G	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	cis	rs60936670	1	rs60936670	chr3:27332409	CTCAAAACA/C	cg02860705	chr3:27208620	NA	0.39	7.56	0.33	2.15e-13	Breast cancer;
LGG	cis	rs6988985	0.693	rs6996242	chr8:143941064	G/A	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9463078	0.616	rs2211393	chr6:44716366	A/C	cg25276700	chr6:44698697	NA	0.44	9.11	0.39	2.58e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.36	-0.4	3.48e-19	Body mass index;
LGG	cis	rs6912958	1.000	rs6912958	chr6:88133315	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.6	-11.01	-0.46	3.44e-25	Monocyte percentage of white cells;
LGG	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg11494091	chr17:61959527	GH2	0.59	9.95	0.42	2.77e-21	Height;
LGG	trans	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg06521331	chr12:34319734	NA	0.43	7.77	0.34	4.96e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.54	0.37	1.95e-16	Personality dimensions;
LGG	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg08884029	chr12:110012500	MVK;MMAB	-0.37	-7.6	-0.33	1.66e-13	Neuroticism;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg08742575	chr21:47604166	C21orf56	-0.53	-8.94	-0.38	9.62e-18	Testicular germ cell tumor;
LGG	cis	rs7666738	0.800	rs7683737	chr4:99070880	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.897	rs6820164	chr4:17630115	G/A	cg16339924	chr4:17578868	LAP3	0.64	10.62	0.44	1.03e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs644799	0.672	rs11021307	chr11:95501407	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.34	0.58	2.92e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	12.91	0.51	8.6e-33	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg18379455	chr17:41446167	NA	-0.31	-7.08	-0.31	5.34e-12	Menopause (age at onset);
LGG	cis	rs6500395	0.925	rs12920170	chr16:48701530	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg11764359	chr7:65958608	NA	0.63	9.74	0.41	1.64e-20	Aortic root size;
LGG	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg01152986	chr16:58549298	SETD6	0.84	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs798554	0.759	rs1636255	chr7:2892804	A/C	cg05793240	chr7:2802953	GNA12	-0.36	-8.6	-0.37	1.2e-16	Height;
LGG	cis	rs2227564	0.794	rs2688620	chr10:75684532	A/G	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.89	-0.38	1.41e-17	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7613875	0.654	rs3774751	chr3:50209053	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.88	-0.34	2.43e-14	Body mass index;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg17340268	chr14:105411764	AHNAK2	-0.4	-7.25	-0.32	1.75e-12	Rheumatoid arthritis;
LGG	cis	rs1461503	1.000	rs1461499	chr11:122843987	C/A	cg27398637	chr11:122830231	C11orf63	-0.67	-13.34	-0.53	1.3600000000000001e-34	Menarche (age at onset);
LGG	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.49	0.33	3.57e-13	Thyroid stimulating hormone;
LGG	cis	rs7944584	0.655	rs11039183	chr11:47346940	G/A	cg20307385	chr11:47447363	PSMC3	0.65	12.78	0.51	3.15e-32	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7493	0.853	rs2299266	chr7:95049073	A/G	cg17330251	chr7:94953956	PON1	-0.42	-8.28	-0.36	1.29e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg27467005	chr19:17622279	PGLS	0.42	7.12	0.31	4.23e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg18188782	chr20:61659543	NA	0.42	6.99	0.31	9.55e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7512552	0.839	rs2867894	chr1:150452912	T/A	cg15654264	chr1:150340011	RPRD2	0.45	9.18	0.39	1.41e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs713587	0.776	rs3731623	chr2:25163783	T/C	cg04586622	chr2:25135609	ADCY3	0.39	10.02	0.42	1.61e-21	Body mass index in non-asthmatics;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg03188948	chr7:1209495	NA	0.71	9.59	0.41	5.68e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3790455	0.965	rs10908505	chr1:156468243	T/A	cg14087168	chr1:156450669	MEF2D	0.48	7.84	0.34	3.15e-14	Migraine;
LGG	cis	rs10479542	0.784	rs6601050	chr5:178986261	C/G	cg19626725	chr5:178986131	RUFY1	-0.5	-7.92	-0.35	1.82e-14	Lung cancer;
LGG	trans	rs61931739	0.929	rs1825358	chr12:34011895	C/T	cg13010199	chr12:38710504	ALG10B	-0.44	-8.11	-0.35	4.58e-15	Morning vs. evening chronotype;
LGG	cis	rs644799	0.710	rs522536	chr11:95528714	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.62	0.59	1.74e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg18129748	chr3:49941408	MST1R	-0.22	-6.89	-0.31	1.81e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg10756647	chr7:56101905	PSPH	0.82	9.93	0.42	3.29e-21	Diabetic kidney disease;
LGG	cis	rs5750830	0.649	rs5757657	chr22:39798429	G/T	cg11247378	chr22:39784982	NA	-0.31	-9.23	-0.39	9.89e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7939886	0.920	rs11534518	chr11:55808146	C/T	cg15704280	chr7:45808275	SEPT13	0.87	9.18	0.39	1.4e-18	Myopia (pathological);
LGG	cis	rs11190604	0.767	rs11190534	chr10:102190930	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.92	0.42	3.82e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg06697600	chr4:7070879	GRPEL1	0.5	7.89	0.34	2.14e-14	Monocyte percentage of white cells;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2439831	0.764	rs2447193	chr15:43929733	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.74	0.45	3.65e-24	Lung cancer in ever smokers;
LGG	cis	rs6580649	0.941	rs7310579	chr12:48427523	G/A	cg24011408	chr12:48396354	COL2A1	-0.57	-6.98	-0.31	1.03e-11	Lung cancer;
LGG	cis	rs7582720	1.000	rs72932770	chr2:203680954	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.7	0.41	2.29e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11239187	0.586	rs10900074	chr10:45071312	G/A	cg03916630	chr10:45065415	NA	0.35	8.36	0.36	7.22e-16	Body mass index;
LGG	cis	rs4639966	0.836	rs7124498	chr11:118616253	G/A	cg19182353	chr11:118479428	PHLDB1	-0.53	-8.55	-0.37	1.79e-16	Systemic lupus erythematosus;
LGG	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg16576597	chr16:28551801	NUPR1	-0.43	-10.18	-0.43	4.09e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9815354	1.000	rs9869207	chr3:41878661	C/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7463659	0.512	rs7840196	chr8:135449371	A/C	cg09855544	chr8:135498122	ZFAT	0.38	6.72	0.3	5.34e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg13072238	chr3:49761600	GMPPB	0.52	6.82	0.3	2.81e-11	Menarche (age at onset);
LGG	cis	rs701145	0.585	rs1960241	chr3:153858398	T/C	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.04	-0.31	6.94e-12	Bipolar disorder;
LGG	trans	rs783540	0.967	rs1145172	chr15:83223616	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.97	-0.31	1.12e-11	Schizophrenia;
LGG	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg14088196	chr11:70211408	PPFIA1	0.95	13.37	0.53	1.07e-34	Coronary artery disease;
LGG	cis	rs561341	0.714	rs474455	chr17:30312465	A/T	cg13647721	chr17:30228624	UTP6	0.61	7.96	0.35	1.39e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg14598338	chr9:96623480	NA	-0.53	-9.62	-0.41	4.42e-20	DNA methylation (variation);
LGG	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18404041	chr3:52824283	ITIH1	-0.49	-9.06	-0.39	3.8e-18	Electroencephalogram traits;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.15	-0.32	3.35e-12	Personality dimensions;
LGG	cis	rs713587	0.875	rs6746013	chr2:25143649	C/G	cg04586622	chr2:25135609	ADCY3	0.45	12.22	0.49	5.89e-30	Body mass index in non-asthmatics;
LGG	cis	rs7917772	0.503	rs11191325	chr10:104302933	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12200782	1.000	rs4515370	chr6:26625319	T/C	cg11502198	chr6:26597334	ABT1	-0.92	-7.86	-0.34	2.77e-14	Small cell lung carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04165030	chr5:175843293	CLTB	0.41	6.67	0.3	7.39e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg16268157	chr7:99778414	STAG3	-0.44	-6.86	-0.3	2.19e-11	Lung function (FEV1/FVC);
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	cis	rs1982963	1.000	rs904061	chr14:52504624	T/C	cg05884192	chr14:52515736	NID2	-0.34	-7.55	-0.33	2.38e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2404618	0.534	rs2214861	chr8:1490604	A/G	cg02903104	chr8:1507517	DLGAP2	0.39	8.15	0.35	3.54e-15	Lung cancer;
LGG	trans	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg13010199	chr12:38710504	ALG10B	0.59	11.26	0.46	3.68e-26	Morning vs. evening chronotype;
LGG	cis	rs12210905	0.688	rs12199806	chr6:27435943	A/C	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs243505	0.660	rs243487	chr7:148448211	G/A	cg18940274	chr7:148469757	CUL1	0.36	6.68	0.3	7.08e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs736801	0.740	rs17622378	chr5:131778452	A/G	cg07395648	chr5:131743802	NA	-0.52	-11.03	-0.46	2.8e-25	Breast cancer;Mosquito bite size;
LGG	cis	rs10819861	0.611	rs10124975	chr9:98847030	T/C	cg14508093	chr9:98862825	NA	0.28	6.7	0.3	5.94e-11	Electrocardiographic traits;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg02725872	chr8:58115012	NA	-1.03	-14.3	-0.55	1.16e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.694	rs202631	chr22:41863423	A/G	cg06481639	chr22:41940642	POLR3H	0.57	8.64	0.37	8.95e-17	Vitiligo;
LGG	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg18105134	chr13:113819100	PROZ	-0.67	-12.52	-0.5	3.6e-31	Platelet distribution width;
LGG	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs9768139	0.566	rs729099	chr7:158114152	C/T	cg06219351	chr7:158114137	PTPRN2	-0.9	-20.9	-0.7	7.93e-69	Calcium levels;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg22535103	chr8:58192502	C8orf71	0.93	13.01	0.52	3.21e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg00290607	chr11:67383545	NA	0.67	13.24	0.52	3.58e-34	Mean corpuscular volume;
LGG	cis	rs17373728	0.526	rs1351226	chr8:76126385	T/C	cg07016329	chr8:76221503	NA	0.46	8.56	0.37	1.7e-16	Diabetic kidney disease;
LGG	cis	rs9398803	0.965	rs9491624	chr6:126679106	A/T	cg19875578	chr6:126661172	C6orf173	0.57	10.4	0.44	6.74e-23	Male-pattern baldness;
LGG	cis	rs11992162	0.967	rs10108320	chr8:11832263	A/T	cg24623649	chr8:11872141	NA	-0.31	-7.38	-0.32	7.39e-13	Monocyte count;
LGG	cis	rs1003719	0.646	rs7276711	chr21:38578189	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	trans	rs393155	0.517	rs330050	chr8:9087679	G/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.5	-0.4	1.17e-19	Neuroticism;
LGG	cis	rs36051895	0.623	rs10283467	chr9:5244356	C/G	cg02405213	chr9:5042618	JAK2	0.76	12.67	0.51	8.38e-32	Pediatric autoimmune diseases;
LGG	cis	rs6840360	0.593	rs28602726	chr4:152499788	T/C	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.76e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2290402	0.536	rs56223707	chr4:881896	C/T	cg09237302	chr4:906077	GAK	-0.46	-7.84	-0.34	3.05e-14	Type 2 diabetes;
LGG	cis	rs6735179	0.643	rs10200618	chr2:1746140	A/C	cg08534653	chr2:1747700	PXDN	0.49	7.27	0.32	1.56e-12	Response to antipsychotic treatment;
LGG	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg13271783	chr10:134563150	INPP5A	-0.45	-7.03	-0.31	7.23e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4819052	0.918	rs2330013	chr21:46658662	G/T	cg06618935	chr21:46677482	NA	-0.53	-9.36	-0.4	3.54e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg11050988	chr7:1952600	MAD1L1	-0.38	-8.95	-0.38	8.58e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7192750	0.586	rs28697038	chr16:71952354	G/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.77	0.45	2.77e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg23625390	chr15:77176239	SCAPER	-0.6	-10.92	-0.45	7.12e-25	Blood metabolite levels;
LGG	cis	rs4330281	0.669	rs7651998	chr3:17711127	G/A	cg20981856	chr3:17787350	NA	-0.38	-7.09	-0.31	5.21e-12	Schizophrenia;
LGG	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg25173405	chr17:45401733	C17orf57	-0.57	-9.46	-0.4	1.54e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8056893	0.885	rs6499166	chr16:68326917	G/A	cg07273125	chr16:68295692	NA	0.36	6.79	0.3	3.39e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg18379455	chr17:41446167	NA	-0.32	-7.6	-0.33	1.7e-13	Menopause (age at onset);
LGG	cis	rs8064299	0.597	rs4789098	chr17:72781292	C/G	cg25054828	chr17:72772726	NAT9;TMEM104	0.97	22.1	0.72	2.05e-74	Monocyte count;
LGG	cis	rs68170813	0.523	rs12154285	chr7:106993573	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-10.36	-0.43	9.02e-23	Coronary artery disease;
LGG	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	17.03	0.62	7.82e-51	Hip circumference adjusted for BMI;
LGG	cis	rs12210905	0.688	rs114843651	chr6:27449611	A/G	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.04e-47	Breast cancer;
LGG	trans	rs12310956	0.510	rs10844693	chr12:33865197	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.17	-0.49	9.03e-30	Morning vs. evening chronotype;
LGG	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg21427119	chr20:30132790	HM13	-0.43	-7.34	-0.32	9.61e-13	Mean corpuscular hemoglobin;
LGG	cis	rs7742824	0.917	rs4334980	chr6:44070931	C/T	cg04074908	chr6:44101190	TMEM63B	0.64	13.47	0.53	4.09e-35	Major depressive disorder;
LGG	cis	rs11608355	0.705	rs6663	chr12:109886603	G/A	cg05360138	chr12:110035743	NA	0.61	8.55	0.37	1.85e-16	Neuroticism;
LGG	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg25427524	chr10:38739819	LOC399744	-0.69	-13.94	-0.54	4.13e-37	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.517	rs13128825	chr4:1334007	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.24	0.32	1.83e-12	Obesity-related traits;
LGG	trans	rs7395662	0.591	rs4882085	chr11:48504569	C/G	cg00717180	chr2:96193071	NA	-0.44	-7.97	-0.35	1.22e-14	HDL cholesterol;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg01988459	chr11:68622903	NA	-0.62	-12.12	-0.49	1.45e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg06917634	chr15:78832804	PSMA4	-0.61	-9.39	-0.4	2.68e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs888194	0.738	rs1543897	chr12:109975211	A/T	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-6.68	-0.3	7.02e-11	Neuroticism;
LGG	cis	rs2797369	0.883	rs775943	chr6:101707957	A/C	cg27451362	chr6:101846650	GRIK2	0.77	10.79	0.45	2.24e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs2880765	0.743	rs6497191	chr15:86011501	T/C	cg17133734	chr15:86042851	AKAP13	-0.28	-6.66	-0.3	7.81e-11	Coronary artery disease;
LGG	cis	rs62400317	0.859	rs72860105	chr6:45265201	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.26	-0.43	2.12e-22	Total body bone mineral density;
LGG	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs8062405	0.698	rs7188071	chr16:28917644	T/C	cg07382826	chr16:28625726	SULT1A1	-0.34	-6.82	-0.3	2.83e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2294693	0.853	rs9296350	chr6:40977623	G/A	cg14769373	chr6:40998127	UNC5CL	-0.41	-7.16	-0.32	3.24e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs2251260	0.685	rs2246850	chr14:62009606	C/T	cg23386212	chr14:62041363	NA	0.58	8.28	0.36	1.34e-15	Yeast infection;
LGG	cis	rs7615952	0.673	rs35955861	chr3:125626201	T/C	cg05084668	chr3:125655381	ALG1L	-1.12	-12.91	-0.51	8.56e-33	Blood pressure (smoking interaction);
LGG	cis	rs36051895	0.658	rs10974912	chr9:5010885	A/C	cg02405213	chr9:5042618	JAK2	-0.81	-14.47	-0.56	2.08e-39	Pediatric autoimmune diseases;
LGG	cis	rs7923609	0.936	rs10822160	chr10:65112796	T/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.67	-0.3	7.09e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11976180	1.000	rs11975942	chr7:143740580	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.78	-0.3	3.71e-11	Obesity-related traits;
LGG	cis	rs368123	0.924	rs441892	chr6:160724971	G/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.15	-0.32	3.44e-12	Waist circumference;
LGG	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg24803719	chr17:45855879	NA	-0.3	-8.65	-0.37	8.66e-17	IgG glycosylation;
LGG	cis	rs3812831	0.695	rs7998546	chr13:114939914	C/G	cg22348356	chr13:114891224	RASA3	0.43	8.31	0.36	1.08e-15	Schizophrenia;
LGG	cis	rs7503807	0.515	rs12452916	chr17:78664655	C/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.2	-0.39	1.25e-18	Obesity;
LGG	cis	rs2486288	0.656	rs12910009	chr15:45572408	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.64	-11.06	-0.46	2.23e-25	Glomerular filtration rate;
LGG	cis	rs6988636	0.901	rs2602001	chr8:124195974	T/C	cg23067535	chr8:124195133	FAM83A	0.56	6.9	0.31	1.7e-11	Urinary uromodulin levels;
LGG	trans	rs17685	0.753	rs2302435	chr7:75676987	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.05	-24.63	-0.75	3.17e-86	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7267979	0.816	rs1044573	chr20:25206654	A/G	cg08601574	chr20:25228251	PYGB	0.39	7.86	0.34	2.65e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg04553112	chr3:125709451	NA	-0.54	-6.87	-0.3	2.03e-11	Blood pressure (smoking interaction);
LGG	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg03609598	chr5:56110824	MAP3K1	-0.51	-7.57	-0.33	2.05e-13	Initial pursuit acceleration;
LGG	cis	rs910316	0.967	rs4384542	chr14:75658013	A/C	cg11812906	chr14:75593930	NEK9	-0.54	-9.93	-0.42	3.28e-21	Height;
LGG	cis	rs36093844	0.800	rs78356210	chr11:85581267	G/A	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7777754	0.512	rs3757472	chr7:50537983	A/C	cg14593290	chr7:50529359	DDC	-0.45	-8.47	-0.37	3.3e-16	Response to zileuton treatment in asthma (FEV1 change interaction);
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03647317	chr4:187891568	NA	-0.41	-8.9	-0.38	1.31e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7267979	0.834	rs6115100	chr20:25225938	C/A	cg08601574	chr20:25228251	PYGB	0.33	6.71	0.3	5.85e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs910316	1.000	rs175443	chr14:75601963	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.83	-0.45	1.56e-24	Height;
LGG	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg03806693	chr22:41940476	POLR3H	-1.08	-17.88	-0.64	9.24e-55	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg20587970	chr11:113659929	NA	-1.36	-23.23	-0.73	1.07e-79	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.519	rs1527407	chr2:178525630	T/G	cg22681709	chr2:178499509	PDE11A	-0.45	-8.11	-0.35	4.41e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9911578	1.000	rs12449365	chr17:56600660	C/G	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7216064	0.601	rs35453056	chr17:66039668	A/G	cg02705964	chr17:66097276	LOC651250	-0.47	-8.32	-0.36	1.02e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs8002861	0.935	rs7318147	chr13:44445153	C/G	cg17145862	chr1:211918768	LPGAT1	-0.8	-15.14	-0.58	2.33e-42	Leprosy;
LGG	cis	rs6500602	0.674	rs7191664	chr16:4541924	T/C	cg05091796	chr16:4465799	CORO7	-0.81	-13.38	-0.53	9.54e-35	Schizophrenia;
LGG	cis	rs7010267	0.570	rs28893333	chr8:120046473	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.33	0.36	9.15e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs898097	0.625	rs6502017	chr17:80891135	C/T	cg10494973	chr17:80897199	TBCD	-0.42	-7.42	-0.33	5.64e-13	Breast cancer;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg18379455	chr17:41446167	NA	0.32	7.6	0.33	1.7e-13	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs1414349	chr6:8472290	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs5750830	0.594	rs9611166	chr22:39775268	T/C	cg04986931	chr22:39850128	NA	0.35	7.68	0.34	9.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.962	rs1872652	chr16:48642928	C/A	cg16662043	chr16:48846231	NA	0.38	7.48	0.33	3.78e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6735179	0.688	rs2382562	chr2:1763509	G/A	cg08534653	chr2:1747700	PXDN	0.43	6.73	0.3	5.14e-11	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.09e-11	Blood metabolite levels;
LGG	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg03060546	chr3:49711283	APEH	0.55	8.55	0.37	1.78e-16	Resting heart rate;
LGG	cis	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg16876255	chr19:9731953	ZNF561	0.81	7.57	0.33	2.08e-13	Pursuit maintenance gain;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs539514	0.539	rs1408060	chr13:76289980	G/C	cg04757411	chr13:76259545	LMO7	-0.3	-7.55	-0.33	2.26e-13	Type 1 diabetes;
LGG	cis	rs2243480	0.711	rs1626926	chr7:65435792	C/T	cg13147721	chr7:65941812	NA	-0.73	-9.09	-0.39	2.85e-18	Diabetic kidney disease;
LGG	cis	rs6558174	1.000	rs6558174	chr8:22492129	A/G	cg03733263	chr8:22462867	KIAA1967	0.66	10.83	0.45	1.65e-24	Breast cancer;
LGG	cis	rs12200782	0.872	rs41266837	chr6:26409729	G/A	cg27193005	chr6:26382695	BTN2A2	-0.59	-6.69	-0.3	6.31e-11	Small cell lung carcinoma;
LGG	cis	rs13108904	0.870	rs4974541	chr4:1244037	A/G	cg20887711	chr4:1340912	KIAA1530	0.5	9.41	0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs644799	0.932	rs572015	chr11:95637416	T/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.92	19.62	0.67	8.28e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9616064	0.531	rs17821649	chr22:47050387	G/A	cg25730555	chr22:47059586	GRAMD4	0.39	6.65	0.3	8.38e-11	Urate levels in obese individuals;
LGG	cis	rs4671458	0.626	rs72821630	chr2:63696212	C/T	cg17519650	chr2:63277830	OTX1	-0.52	-6.96	-0.31	1.17e-11	Subjective well-being;
LGG	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg03433033	chr1:76189801	ACADM	0.61	8.59	0.37	1.38e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4750440	0.702	rs4748068	chr10:14030692	T/A	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.64	-0.54	7.45e-36	Adiponectin levels;
LGG	cis	rs57221529	0.654	rs12515813	chr5:671826	A/T	cg16400903	chr5:693638	TPPP	0.47	6.9	0.31	1.71e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg14789911	chr21:47582049	C21orf56	-0.45	-7.4	-0.33	6.68e-13	Testicular germ cell tumor;
LGG	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs6502050	0.835	rs8073351	chr17:80127625	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	trans	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs6840360	0.615	rs7695412	chr4:152488075	A/G	cg25486957	chr4:152246857	NA	-0.51	-8.42	-0.36	4.86e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.927	rs11778693	chr8:22462852	T/C	cg19455335	chr8:22457658	C8orf58	-0.45	-9.3	-0.4	5.41e-19	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10484885	0.878	rs72921955	chr6:90588789	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.87	-10.98	-0.45	4.34e-25	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg18876405	chr7:65276391	NA	0.55	9.96	0.42	2.63e-21	Aortic root size;
LGG	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg08305652	chr11:111469057	NA	-0.36	-7.45	-0.33	4.61e-13	Primary sclerosing cholangitis;
LGG	trans	rs208520	0.754	rs851593	chr6:66875783	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.12	0.62	2.9e-51	Exhaled nitric oxide output;
LGG	cis	rs4665809	1.000	rs4665298	chr2:26256378	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.19	-0.52	5.75e-34	Gut microbiome composition (summer);
LGG	cis	rs4665809	0.590	rs1469523	chr2:26474631	T/A	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs7010267	0.596	rs13262276	chr8:120033918	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.88	0.38	1.46e-17	Total body bone mineral density (age 45-60);
LGG	trans	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.26	-0.32	1.61e-12	Monocyte count;
LGG	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg00490583	chr16:1843685	IGFALS	0.44	9.72	0.41	1.8899999999999998e-20	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9902453	0.845	rs62068583	chr17:28001482	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.97	0.54	2.82e-37	Coffee consumption (cups per day);
LGG	cis	rs7103648	0.966	rs874896	chr11:47418953	C/G	cg20307385	chr11:47447363	PSMC3	0.96	23.53	0.74	4.36e-81	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs360798	0.512	rs2430388	chr2:63106784	T/C	cg17519650	chr2:63277830	OTX1	0.5	8.19	0.36	2.52e-15	Coronary artery disease;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.97	-0.49	6.11e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06112835	chr11:68658793	MRPL21	0.63	10.38	0.43	7.82e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	1.000	rs7107184	chr11:48577069	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.35e-13	HDL cholesterol;
LGG	cis	rs17401966	0.838	rs12132134	chr1:10378428	A/G	cg19773385	chr1:10388646	KIF1B	-0.45	-9.54	-0.41	7.96e-20	Hepatocellular carcinoma;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg04772025	chr11:68637568	NA	0.75	12.91	0.51	8.36e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs1095575	chr12:39110284	C/G	cg13010199	chr12:38710504	ALG10B	-0.64	-13.48	-0.53	3.53e-35	Heart rate;
LGG	cis	rs7937612	1.000	rs2305008	chr11:120319064	A/C	cg24566217	chr11:120254723	ARHGEF12	-0.53	-13.02	-0.52	2.94e-33	Intraocular pressure;
LGG	cis	rs5769765	0.874	rs4624	chr22:50281917	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.38	0.47	1.26e-26	Schizophrenia;
LGG	cis	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg24692254	chr21:30365293	RNF160	-0.69	-12.99	-0.52	4.2e-33	Cognitive test performance;
LGG	cis	rs12580194	0.593	rs7960760	chr12:55722311	A/G	cg19537932	chr12:55886519	OR6C68	-0.53	-9.46	-0.4	1.61e-19	Cancer;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.47e-27	Personality dimensions;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07962043	chr11:60691582	TMEM132A	0.43	7.36	0.32	8.48e-13	Menarche (age at onset);
LGG	cis	rs933688	1.000	rs2367526	chr5:90740525	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs74781061	0.858	rs4887162	chr15:74872500	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.53e-12	Endometriosis;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9534288	0.797	rs9534282	chr13:46588944	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.43e-34	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04170460	chr16:29985301	TAOK2	0.57	9.2	0.39	1.25e-18	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg00599393	chr8:22457479	C8orf58	-0.44	-8.14	-0.35	3.59e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs13082711	0.522	rs6551192	chr3:27343376	C/T	cg02860705	chr3:27208620	NA	0.61	11.79	0.48	3.07e-28	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs826838	0.904	rs1554550	chr12:39208889	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.77	-0.34	5.23e-14	Heart rate;
LGG	cis	rs4888262	0.604	rs12935075	chr16:74676033	A/T	cg01733217	chr16:74700730	RFWD3	0.92	19.41	0.67	7.79e-62	Testicular germ cell tumor;
LGG	cis	rs3540	0.576	rs12907587	chr15:91045851	G/C	cg22089800	chr15:90895588	ZNF774	-0.67	-12.3	-0.5	2.88e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16702747	chr16:85955082	IRF8	-0.35	-7.31	-0.32	1.19e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11877577	chr6:133135687	RPS12;SNORD101	0.47	8.05	0.35	6.97e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs7819412	0.608	rs28417109	chr8:10975081	T/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.13	-0.35	4.02e-15	Triglycerides;
LGG	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg18252515	chr7:66147081	NA	-0.41	-6.9	-0.31	1.68e-11	Aortic root size;
LGG	cis	rs7737355	1.000	rs12654593	chr5:130756867	C/T	cg06307176	chr5:131281290	NA	-0.55	-9.27	-0.4	6.82e-19	Life satisfaction;
LGG	cis	rs3816183	0.585	rs11901849	chr2:42859537	G/A	cg14631114	chr2:43023945	NA	0.35	6.93	0.31	1.46e-11	Hypospadias;
LGG	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg25883020	chr8:41504993	NKX6-3	0.33	7.27	0.32	1.58e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs10191773	0.535	rs11123133	chr2:112965023	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.78	9.94	0.42	3.08e-21	Yeast infection;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.44	-0.37	3.98e-16	Morning vs. evening chronotype;
LGG	cis	rs17767392	1.000	rs723966	chr14:71765910	A/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs2640806	0.645	rs28588175	chr8:97327295	G/T	cg22138393	chr8:97340270	PTDSS1	0.31	7.85	0.34	2.94e-14	Obesity-related traits;
LGG	cis	rs977987	0.836	rs11646044	chr16:75312548	G/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.78	0.3	3.65e-11	Dupuytren's disease;
LGG	cis	rs881375	0.967	rs1014529	chr9:123684943	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.08	0.39	3.23e-18	Rheumatoid arthritis;
LGG	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg20913747	chr6:44695427	NA	0.61	10.06	0.42	1.13e-21	Total body bone mineral density;
LGG	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.6e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14240646	chr10:27532245	ACBD5	-0.73	-10.36	-0.43	9.22e-23	Breast cancer;
LGG	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.51	8.17	0.36	2.88e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs78545713	0.536	rs78653353	chr6:26208917	A/G	cg01420254	chr6:26195488	NA	0.8	7.59	0.33	1.77e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg15522984	chr1:182991683	LAMC1	0.45	8.83	0.38	2.25e-17	Fuchs's corneal dystrophy;
LGG	cis	rs509477	0.718	rs273344	chr18:32603927	C/T	cg23791764	chr18:32556832	MAPRE2	0.44	7.45	0.33	4.64e-13	Cerebrospinal fluid AB1-42 levels;
LGG	trans	rs7395662	0.929	rs12363679	chr11:48556023	G/C	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	5.92e-13	HDL cholesterol;
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg03647317	chr4:187891568	NA	-0.37	-8.04	-0.35	7.41e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.68	-0.37	6.9e-17	Aortic root size;
LGG	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg00666640	chr1:248458726	OR2T12	0.55	8.98	0.39	6.98e-18	Common traits (Other);
LGG	cis	rs4642101	0.694	rs12631514	chr3:12838293	G/C	cg24848339	chr3:12840334	CAND2	0.43	10.25	0.43	2.44e-22	QRS complex (12-leadsum);
LGG	cis	rs6450176	0.909	rs6866586	chr5:53295568	A/C	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.13	-0.46	1.21e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9875589	0.509	rs2733556	chr3:14100172	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.28	0.46	2.99e-26	Ovarian reserve;
LGG	cis	rs7236492	0.572	rs7244366	chr18:77179746	C/T	cg15644404	chr18:77186268	NFATC1	-0.82	-8.82	-0.38	2.34e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7811142	1.000	rs7783159	chr7:100017454	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.9	0.38	1.23e-17	Platelet count;
LGG	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg12437481	chr16:420112	MRPL28	0.48	8.28	0.36	1.31e-15	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs5758659	0.714	rs133373	chr22:42465788	G/A	cg15128208	chr22:42549153	NA	-0.48	-9.83	-0.42	7.84e-21	Cognitive function;
LGG	cis	rs7180079	0.502	rs6494466	chr15:64508763	A/G	cg02848875	chr15:64387786	SNX1	0.44	6.66	0.3	7.85e-11	Monocyte count;
LGG	cis	rs17376456	0.825	rs28534784	chr5:93063332	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.82	9.38	0.4	2.9e-19	Diabetic retinopathy;
LGG	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.07	-0.42	1.06e-21	Type 2 diabetes;
LGG	cis	rs3204270	0.516	rs62077189	chr17:79673088	G/A	cg18367735	chr17:79674897	NA	0.54	7.49	0.33	3.43e-13	Dental caries;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.36	0.36	7.48e-16	Platelet count;
LGG	cis	rs2267681	0.583	rs764745	chr7:139529928	G/C	cg14116596	chr7:139528673	TBXAS1	0.32	7.08	0.31	5.55e-12	Cervical cancer;
LGG	cis	rs2479724	0.901	rs1051130	chr6:41903782	A/C	cg17623882	chr6:41773611	USP49	-0.4	-6.71	-0.3	5.53e-11	Menarche (age at onset);
LGG	cis	rs1372520	0.564	rs2737011	chr4:90746219	T/C	cg15133208	chr4:90757351	SNCA	-0.4	-7.79	-0.34	4.58e-14	Neuroticism;
LGG	trans	rs9354308	0.764	rs9453468	chr6:66592880	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.83e-12	Metabolite levels;
LGG	cis	rs7833790	0.927	rs61020899	chr8:82757090	C/T	cg27398817	chr8:82754497	SNX16	0.78	11.26	0.46	3.74e-26	Diastolic blood pressure;
LGG	cis	rs4774830	1.000	rs11071227	chr15:56130286	A/T	cg05129572	chr15:56138634	NEDD4	-0.88	-7.61	-0.33	1.58e-13	Delta-5 desaturase activity;
LGG	cis	rs6940638	0.688	rs9393795	chr6:27217719	G/C	cg09904177	chr6:26538194	HMGN4	-0.44	-7.04	-0.31	6.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2117029	0.521	rs11168885	chr12:49539987	C/T	cg24176009	chr12:49580217	TUBA1A	0.63	12.24	0.49	4.74e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs73271842	chr17:29137155	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.84	-0.42	7.11e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs11165623	0.602	rs12120893	chr1:97007132	C/T	cg10631902	chr5:14652156	NA	-0.44	-9.11	-0.39	2.53e-18	Hip circumference;Waist circumference;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg01988459	chr11:68622903	NA	-0.63	-12.83	-0.51	1.85e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg02733842	chr7:1102375	C7orf50	0.73	10.84	0.45	1.54e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6598955	0.694	rs4659416	chr1:26580937	T/G	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.93	0.35	1.69e-14	Obesity-related traits;
LGG	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.13	-0.39	2.05e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.657	rs8186888	chr12:38334260	T/G	cg04568710	chr12:38710424	ALG10B	0.37	7.71	0.34	7.88e-14	Bladder cancer;
LGG	cis	rs258892	0.793	rs34655	chr5:72147269	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	cis	rs11608355	0.846	rs60945232	chr12:109854401	A/G	cg19025524	chr12:109796872	NA	-0.4	-6.78	-0.3	3.73e-11	Neuroticism;
LGG	trans	rs72991	0.793	rs10750189	chr11:121230248	A/G	cg27192990	chr6:129479024	LAMA2	-0.43	-7.2	-0.32	2.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs898097	0.510	rs10445242	chr17:80891666	G/T	cg15369054	chr17:80825471	TBCD	-0.4	-7.86	-0.34	2.73e-14	Breast cancer;
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs1345301	1.000	rs10200410	chr2:102870871	G/A	cg05295703	chr2:102895712	NA	0.38	7.53	0.33	2.59e-13	Waist circumference;
LGG	cis	rs6963495	0.818	rs55740553	chr7:105159551	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-8.02	-0.35	8.71e-15	Lung cancer;
LGG	trans	rs11039798	0.698	rs76315297	chr11:48240475	T/C	cg15704280	chr7:45808275	SEPT13	0.73	7.95	0.35	1.4e-14	Axial length;
LGG	cis	rs7923609	1.000	rs1935	chr10:64927823	C/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.87	-0.3	2.07e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1538970	0.739	rs4660863	chr1:45955868	T/C	cg05343316	chr1:45956843	TESK2	0.75	13.25	0.52	3.44e-34	Platelet count;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs7444	0.941	rs2266959	chr22:21922904	G/T	cg15846791	chr22:21984385	YDJC	-0.47	-7.04	-0.31	6.77e-12	Systemic lupus erythematosus;
LGG	cis	rs2011503	0.891	rs2965190	chr19:19451591	A/G	cg11584989	chr19:19387371	SF4	-0.74	-12.43	-0.5	7.87e-31	Bipolar disorder;
LGG	cis	rs2860975	0.620	rs1891072	chr10:96804978	G/A	cg09036531	chr10:96991505	NA	-0.49	-8.55	-0.37	1.85e-16	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg24397884	chr7:158709396	WDR60	0.9	18.11	0.64	8.11e-56	Height;
LGG	cis	rs7582180	0.627	rs6542947	chr2:100999647	C/G	cg08297393	chr2:100937505	LONRF2	0.53	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2777491	1.000	rs7168177	chr15:41715585	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.04	-0.68	8.76e-65	Ulcerative colitis;
LGG	trans	rs17685	0.672	rs1894760	chr7:75852140	A/G	cg19862616	chr7:65841803	NCRNA00174	1.03	22.63	0.72	6.62e-77	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	10.19	0.43	3.94e-22	Mood instability;
LGG	cis	rs11190604	1.000	rs2489040	chr10:102331298	G/A	cg07080220	chr10:102295463	HIF1AN	0.68	11.7	0.48	7.17e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.93e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	cis	rs17818399	0.890	rs34544165	chr2:46836906	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.94	0.35	1.54e-14	Height;
LGG	cis	rs1682825	1.000	rs6767067	chr3:10769034	G/T	cg23512531	chr3:10780469	NA	0.59	8.12	0.35	4.31e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs5753618	0.561	rs5753609	chr22:31819212	A/G	cg02404636	chr22:31891804	SFI1	0.38	6.96	0.31	1.15e-11	Colorectal cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08501054	chr8:9413133	TNKS	0.39	6.81	0.3	3.02e-11	Bipolar disorder;
LGG	cis	rs2204008	0.659	rs4002655	chr12:38169881	T/G	cg26384229	chr12:38710491	ALG10B	0.94	21.35	0.7	6.59e-71	Bladder cancer;
LGG	cis	rs10504229	1.000	rs55787104	chr8:58178519	C/T	cg22535103	chr8:58192502	C8orf71	-1.0	-15.81	-0.59	2.37e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs721917	0.506	rs2758555	chr10:81691034	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.64	-0.33	1.28e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	trans	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg07817883	chr1:32538562	TMEM39B	0.7	8.75	0.38	4.02e-17	Monocyte percentage of white cells;
LGG	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.36	-0.61	8.3e-48	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10193935	1.000	rs13399869	chr2:42386041	C/G	cg27598129	chr2:42591480	NA	-0.62	-9.31	-0.4	5.13e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg11644478	chr21:40555479	PSMG1	0.9	16.64	0.61	4.52e-49	Cognitive function;
LGG	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.35e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4774899	1.000	rs12899588	chr15:57476858	A/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.44	-0.33	5.05e-13	Urinary tract infection frequency;
LGG	cis	rs4006360	0.546	rs2874201	chr17:39238382	A/G	cg16985667	chr17:39306289	KRTAP4-5	0.51	11.35	0.47	1.7e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.927	rs4336885	chr1:248473168	A/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.84	0.3	2.58e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6089829	0.962	rs9680064	chr20:61666168	G/A	cg08862035	chr2:2617432	NA	0.42	6.92	0.31	1.49e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.56	-8.88	-0.38	1.5e-17	Menarche (age at onset);
LGG	cis	rs8179	0.552	rs2888877	chr7:92228400	C/T	cg15732164	chr7:92237376	CDK6	-0.49	-7.99	-0.35	1.05e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.610	rs2527696	chr7:2858315	T/C	cg05793240	chr7:2802953	GNA12	0.3	7.46	0.33	4.2e-13	Height;
LGG	cis	rs67311347	1.000	rs1119179	chr3:40424929	A/C	cg13683864	chr3:40499215	RPL14	1.08	23.81	0.74	2.14e-82	Renal cell carcinoma;
LGG	cis	rs2041895	0.565	rs10861679	chr12:107322915	T/C	cg15890332	chr12:107067104	RFX4	0.28	6.67	0.3	7.09e-11	Glaucoma (low intraocular pressure);
LGG	cis	rs7580658	0.545	rs13001184	chr2:127952206	A/G	cg10021288	chr2:128175891	PROC	-0.44	-8.53	-0.37	2.1e-16	Protein C levels;
LGG	cis	rs1670533	0.585	rs6827206	chr4:1065071	A/T	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.53e-21	Recombination rate (females);
LGG	cis	rs6495367	1.000	rs755362	chr15:79376601	C/T	cg17916960	chr15:79447300	NA	-0.49	-8.65	-0.37	8.67e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9303401	0.659	rs12940212	chr17:56674474	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.9	14.65	0.56	3.22e-40	Cognitive test performance;
LGG	cis	rs11585357	0.947	rs2977304	chr1:17611615	T/C	cg08277548	chr1:17600880	PADI3	0.7	8.37	0.36	6.82e-16	Hair shape;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg14926445	chr8:58193284	C8orf71	-0.7	-9.24	-0.39	8.78e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs7616815	chr3:48779715	C/T	cg07636037	chr3:49044803	WDR6	1.06	25.34	0.76	1.72e-89	Parkinson's disease;
LGG	cis	rs6693567	0.565	rs834237	chr1:150363930	A/G	cg15654264	chr1:150340011	RPRD2	0.32	6.69	0.3	6.47e-11	Migraine;
LGG	cis	rs2964802	0.617	rs13174269	chr5:10804759	C/T	cg14521931	chr5:10832172	NA	-0.62	-12.73	-0.51	4.72e-32	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs3859192	0.561	rs34453912	chr17:38180352	T/A	cg17467752	chr17:38218738	THRA	-0.58	-9.73	-0.41	1.7e-20	White blood cell count;
LGG	cis	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08564027	chr20:61660810	NA	1.02	25.08	0.76	2.78e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9880211	1.000	rs28811905	chr3:136252052	T/C	cg21827317	chr3:136751795	NA	-0.48	-7.24	-0.32	1.92e-12	Body mass index;Height;
LGG	cis	rs714515	0.900	rs9286854	chr1:172366806	A/G	cg01573306	chr1:172330400	DNM3	0.33	7.27	0.32	1.5e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg06112835	chr11:68658793	MRPL21	0.6	9.94	0.42	3.06e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7216064	0.954	rs12602556	chr17:65826861	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.56	-0.37	1.7e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs926938	0.520	rs6671984	chr1:115257521	C/T	cg12756093	chr1:115239321	AMPD1	-0.53	-9.44	-0.4	1.79e-19	Autism;
LGG	trans	rs1459104	1.000	rs35882309	chr11:55237464	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.67	0.3	7.28e-11	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05202084	chr12:95467612	NR2C1	0.39	6.94	0.31	1.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.6	-0.59	2.23e-44	Rheumatoid arthritis;
LGG	cis	rs35306767	0.953	rs10904583	chr10:983498	T/C	cg08847335	chr10:891726	LARP4B	-0.37	-6.85	-0.3	2.29e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs9912468	0.547	rs7210846	chr17:64324352	A/G	cg19474267	chr17:64306194	PRKCA	0.76	16.7	0.61	2.51e-49	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs2066819	1.000	rs79750959	chr12:56702012	C/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs3768617	0.510	rs723014	chr1:183076287	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs559928	0.593	rs112275221	chr11:63936994	C/T	cg24687543	chr11:63912206	MACROD1	0.6	8.34	0.36	8.39e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9308731	0.644	rs3789061	chr2:111918230	T/C	cg26001287	chr2:111877753	BCL2L11	-0.36	-7.23	-0.32	2.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs1568889	1.000	rs12803655	chr11:28060785	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg15133208	chr4:90757351	SNCA	0.34	7.55	0.33	2.36e-13	Dementia with Lewy bodies;
LGG	cis	rs977987	0.778	rs7206541	chr16:75436713	A/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.47e-11	Dupuytren's disease;
LGG	cis	rs7927592	0.513	rs3853616	chr11:68198252	A/G	cg16797656	chr11:68205561	LRP5	0.57	10.86	0.45	1.2e-24	Total body bone mineral density;
LGG	cis	rs4253772	0.550	rs6008615	chr22:46707928	G/A	cg09461388	chr22:46763229	CELSR1	-0.6	-6.77	-0.3	3.94e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs5758659	0.594	rs739292	chr22:42368857	G/A	cg15128208	chr22:42549153	NA	-0.41	-8.1	-0.35	4.77e-15	Cognitive function;
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs1008375	0.966	rs2098152	chr4:17684392	G/T	cg02297831	chr4:17616191	MED28	0.5	9.46	0.4	1.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg21926883	chr2:100939477	LONRF2	0.69	16.64	0.61	4.34e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1256531	0.661	rs55714222	chr14:65832491	A/T	cg15999311	chr14:65749247	NA	0.85	6.95	0.31	1.29e-11	Conduct disorder (symptom count);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25757737	chr3:47423140	PTPN23	0.45	6.67	0.3	7.16e-11	Gut microbiome composition (summer);
LGG	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg04935436	chr20:30431758	NA	0.39	6.76	0.3	4.11e-11	Monocyte count;
LGG	cis	rs28595532	0.920	rs115838006	chr4:119754356	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs4474465	0.790	rs4944206	chr11:78263127	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.51	0.37	2.48e-16	Alzheimer's disease (survival time);
LGG	cis	rs10823500	0.636	rs7082396	chr10:71945511	C/A	cg01240734	chr10:71892593	AIFM2	-0.3	-6.93	-0.31	1.42e-11	Blood protein levels;
LGG	cis	rs6121246	0.567	rs6060247	chr20:30190720	C/G	cg18721089	chr20:30220636	NA	-0.51	-7.67	-0.34	1.03e-13	Mean corpuscular hemoglobin;
LGG	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.84	-0.34	3.09e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6714710	0.603	rs13020776	chr2:98402753	T/A	cg26665480	chr2:98280029	ACTR1B	0.58	9.41	0.4	2.34e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs28595532	0.844	rs116721336	chr4:119536538	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.62	0.41	4.27e-20	Cannabis dependence symptom count;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.37	0.36	6.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg18551225	chr6:44695536	NA	-0.62	-10.25	-0.43	2.33e-22	Total body bone mineral density;
LGG	trans	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg06521331	chr12:34319734	NA	0.5	9.31	0.4	5.28e-19	Bladder cancer;
LGG	cis	rs7444	0.825	rs73166630	chr22:21945978	G/A	cg15846791	chr22:21984385	YDJC	-0.47	-7.08	-0.31	5.31e-12	Systemic lupus erythematosus;
LGG	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Schizophrenia;
LGG	cis	rs6964587	0.967	rs6973896	chr7:91778465	A/G	cg17063962	chr7:91808500	NA	0.53	9.81	0.42	8.76e-21	Breast cancer;
LGG	cis	rs35146811	0.844	rs13232115	chr7:99670932	T/C	cg22906224	chr7:99728672	NA	0.55	8.79	0.38	2.98e-17	Coronary artery disease;
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg27432699	chr2:27873401	GPN1	-0.48	-8.25	-0.36	1.68e-15	Total body bone mineral density;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg24690094	chr11:67383802	NA	0.6	11.34	0.47	1.76e-26	Mean corpuscular volume;
LGG	cis	rs965469	0.545	rs6051846	chr20:3403824	A/G	cg25506879	chr20:3388711	C20orf194	0.49	7.84	0.34	3.09e-14	IFN-related cytopenia;
LGG	cis	rs738322	0.967	rs133017	chr22:38572637	A/C	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs10911363	0.571	rs6424897	chr1:183419203	T/C	cg09173681	chr1:183549694	NCF2	-0.37	-8.35	-0.36	7.71e-16	Systemic lupus erythematosus;
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg22618164	chr12:122356400	WDR66	0.36	10.71	0.45	4.55e-24	Mean corpuscular volume;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11645453	chr3:52864694	ITIH4	0.39	6.74	0.3	4.58e-11	Bipolar disorder;
LGG	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg03264133	chr6:25882463	NA	-0.49	-7.97	-0.35	1.2e-14	Iron status biomarkers;
LGG	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-12.9	-0.51	9.82e-33	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg03647317	chr4:187891568	NA	-0.4	-8.75	-0.38	3.85e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs727505	0.721	rs17327715	chr7:124760611	G/C	cg23710748	chr7:124431027	NA	-0.43	-8.32	-0.36	9.87e-16	Lewy body disease;
LGG	cis	rs8114671	0.869	rs1544047	chr20:33670753	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.27	-0.36	1.43e-15	Height;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg02018176	chr4:1364513	KIAA1530	0.37	8.4	0.36	5.54e-16	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg21724239	chr8:58056113	NA	0.47	7.07	0.31	5.88e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg11707556	chr5:10655725	ANKRD33B	0.45	8.32	0.36	9.78e-16	Coronary artery disease;
LGG	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg01620082	chr3:125678407	NA	-0.76	-7.47	-0.33	4.09e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg25072359	chr17:41440525	NA	0.53	9.97	0.42	2.52e-21	Menopause (age at onset);
LGG	cis	rs7914558	1.000	rs7067970	chr10:104913870	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.48	0.44	3.21e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4917300	0.632	rs4917293	chr8:143116851	G/T	cg26003909	chr8:143102224	NA	-0.34	-6.65	-0.3	8.16e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg23815491	chr16:72088622	HP	0.5	11.26	0.46	3.58e-26	Fibrinogen levels;
LGG	cis	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg18252515	chr7:66147081	NA	-1.43	-20.57	-0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg06968155	chr5:131705112	SLC22A5	0.75	8.62	0.37	1.04e-16	Rheumatoid arthritis;
LGG	cis	rs7786877	0.521	rs2293767	chr7:100361675	A/G	cg20848291	chr7:100343083	ZAN	0.48	7.82	0.34	3.54e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116105567	chr4:119746204	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs4460629	0.742	rs7366355	chr1:155076734	C/T	cg13808842	chr1:155066096	NA	-0.29	-6.99	-0.31	9.43e-12	Serum magnesium levels;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.1	-0.31	4.72e-12	Bipolar disorder;
LGG	cis	rs9677476	0.821	rs6708809	chr2:232112730	A/C	cg23338755	chr2:231921595	PSMD1	0.46	6.97	0.31	1.1e-11	Food antigen IgG levels;
LGG	cis	rs10752881	1.000	rs12035773	chr1:182985716	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg25358565	chr5:93447407	FAM172A	1.34	16.64	0.61	4.43e-49	Diabetic retinopathy;
LGG	trans	rs116095464	0.558	rs6869925	chr5:264036	A/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs9547692	0.793	rs556429	chr13:37487021	C/A	cg01493522	chr13:37497338	NA	-0.49	-8.31	-0.36	1.1e-15	Coronary artery disease;
LGG	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.69	-0.3	6.61e-11	Neuroticism;
LGG	cis	rs2243480	0.803	rs423187	chr7:65509499	G/C	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	trans	rs7939886	0.920	rs59168428	chr11:55956018	G/A	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg23758822	chr17:41437982	NA	0.87	15.55	0.59	3.72e-44	Menopause (age at onset);
LGG	cis	rs910316	1.000	rs4899544	chr14:75546556	C/T	cg06637938	chr14:75390232	RPS6KL1	0.59	10.83	0.45	1.7e-24	Height;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg11494091	chr17:61959527	GH2	0.99	23.38	0.74	2.05e-80	Prudent dietary pattern;
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg03806693	chr22:41940476	POLR3H	1.09	19.77	0.68	1.52e-63	Vitiligo;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg04025307	chr7:1156635	C7orf50	0.47	8.19	0.36	2.53e-15	Longevity;Endometriosis;
LGG	cis	rs9649465	0.967	rs12534834	chr7:123307079	T/C	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs9902453	0.967	rs4294864	chr17:28440138	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.23	0.52	4.18e-34	Coffee consumption (cups per day);
LGG	cis	rs787274	0.764	rs787287	chr9:115534245	T/C	cg13803584	chr9:115635662	SNX30	-0.58	-7.45	-0.33	4.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg10935138	chr17:73851978	WBP2	0.72	10.5	0.44	2.82e-23	Psoriasis;
LGG	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.05	0.35	7.17e-15	Iron status biomarkers;
LGG	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg24812749	chr6:127587940	RNF146	0.96	15.85	0.59	1.57e-45	Breast cancer;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.38	0.56	5.26e-39	Lung cancer;
LGG	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg19784903	chr17:45786737	TBKBP1	-0.37	-8.09	-0.35	5.39e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11098499	0.754	rs10212714	chr4:120254302	T/C	cg09307838	chr4:120376055	NA	0.72	12.22	0.49	5.75e-30	Corneal astigmatism;
LGG	cis	rs3754214	0.836	rs12023277	chr1:150466737	A/G	cg15654264	chr1:150340011	RPRD2	0.33	6.76	0.3	4.17e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs617791	0.569	rs11227370	chr11:65747693	C/T	cg17712092	chr4:129076599	LARP1B	-0.58	-9.67	-0.41	2.95e-20	Breast cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02921472	chr20:5094039	C20orf30	0.44	6.68	0.3	6.86e-11	Hip circumference;
LGG	trans	rs7395662	0.963	rs4882072	chr11:48479891	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.03	-0.35	8.35e-15	HDL cholesterol;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg02475777	chr4:1388615	CRIPAK	0.43	7.86	0.34	2.67e-14	Longevity;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg06074448	chr4:187884817	NA	0.59	13.47	0.53	3.84e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs910316	1.000	rs175449	chr14:75590846	A/T	cg11812906	chr14:75593930	NEK9	-0.52	-9.65	-0.41	3.48e-20	Height;
LGG	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg00666640	chr1:248458726	OR2T12	0.62	9.7	0.41	2.17e-20	Common traits (Other);
LGG	cis	rs754466	0.606	rs11002315	chr10:79617385	T/G	cg17075019	chr10:79541650	NA	-0.94	-19.99	-0.68	1.47e-64	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg02002194	chr4:3960332	NA	-0.39	-6.84	-0.3	2.48e-11	Retinal vascular caliber;
LGG	cis	rs926938	0.560	rs360610	chr1:115393915	T/C	cg12756093	chr1:115239321	AMPD1	0.48	9.21	0.39	1.1e-18	Autism;
LGG	cis	rs6089584	0.586	rs1079755	chr20:60615262	G/A	cg13770153	chr20:60521292	NA	-0.45	-7.56	-0.33	2.14e-13	Body mass index;
LGG	cis	rs10870270	0.956	rs11146425	chr10:133734261	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.52	-0.5	3.58e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs2727020	0.619	rs1164665	chr11:49295630	T/C	cg15704280	chr7:45808275	SEPT13	0.8	12.84	0.51	1.66e-32	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25340675	chr3:121468720	GOLGB1	0.43	7.19	0.32	2.64e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.94	-0.42	3.06e-21	IgG glycosylation;
LGG	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.47	7.34	0.32	9.86e-13	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.69	12.73	0.51	4.83e-32	Obesity-related traits;
LGG	cis	rs79057730	0.599	rs79272827	chr7:807015	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.69	7.65	0.34	1.14e-13	Initial pursuit acceleration;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg06221963	chr1:154839813	KCNN3	0.52	10.99	0.45	3.96e-25	Prostate cancer;
LGG	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.76	-0.34	5.63e-14	Sudden cardiac arrest;
LGG	cis	rs992157	0.798	rs7557709	chr2:219167529	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.58	9.68	0.41	2.62e-20	Colorectal cancer;
LGG	cis	rs10540	1.000	rs35898083	chr11:484469	C/T	cg03576123	chr11:487126	PTDSS2	-1.31	-17.44	-0.63	9.68e-53	Body mass index;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05153347	chr5:171434267	FBXW11	0.38	6.82	0.3	2.79e-11	Obesity-related traits;
LGG	cis	rs12681288	0.576	rs7002793	chr8:963467	T/C	cg04851639	chr8:1020857	NA	-0.34	-6.99	-0.31	9.74e-12	Schizophrenia;
LGG	cis	rs11229555	0.874	rs7102852	chr11:58358348	G/A	cg15696309	chr11:58395628	NA	-0.99	-17.5	-0.63	5.41e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs853679	0.599	rs149943	chr6:28002388	G/A	cg06606381	chr12:133084897	FBRSL1	-0.85	-9.04	-0.39	4.16e-18	Depression;
LGG	cis	rs2916247	0.954	rs7845969	chr8:93022087	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.62	-0.37	1.05e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.600	rs10134317	chr14:55793448	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.32	0.5	2.34e-30	Protein biomarker;
LGG	cis	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.39	-0.32	6.74e-13	Neuroticism;
LGG	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	cis	rs6840360	0.615	rs12641441	chr4:152607623	A/G	cg22705602	chr4:152727874	NA	-0.38	-9.37	-0.4	3.21e-19	Intelligence (multi-trait analysis);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19233923	chr11:63753598	OTUB1	0.41	6.75	0.3	4.36e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg27400746	chr16:89904261	SPIRE2	-1.09	-16.55	-0.61	1.13e-48	Skin colour saturation;
LGG	cis	rs1519814	1.000	rs10104973	chr8:121104385	C/T	cg22335954	chr8:121166405	COL14A1	-0.51	-10.47	-0.44	3.67e-23	Breast cancer;
LGG	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	7.55	0.33	2.34e-13	Initial pursuit acceleration;
LGG	cis	rs3806843	1.000	rs10050455	chr5:140204650	A/G	cg19875535	chr5:140030758	IK	0.49	9.98	0.42	2.33e-21	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11122272	0.735	rs2739510	chr1:231526718	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.28	-0.32	1.45e-12	Hemoglobin concentration;
LGG	cis	rs2243480	1.000	rs55895244	chr7:65387678	C/G	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs240764	0.687	rs239248	chr6:101088315	T/A	cg09795085	chr6:101329169	ASCC3	0.46	7.82	0.34	3.69e-14	Neuroticism;
LGG	cis	rs11758351	0.734	rs56220351	chr6:26206884	A/G	cg06951627	chr6:26196580	NA	0.53	8.06	0.35	6.5e-15	Gout;Renal underexcretion gout;
LGG	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	9.96	0.42	2.54e-21	Diabetic retinopathy;
LGG	cis	rs17401966	0.838	rs12127604	chr1:10352800	T/G	cg19773385	chr1:10388646	KIF1B	-0.45	-9.8	-0.41	9.72e-21	Hepatocellular carcinoma;
LGG	cis	rs701145	0.585	rs1358405	chr3:153810992	A/G	cg17054900	chr3:154042577	DHX36	0.8	9.42	0.4	2.19e-19	Coronary artery disease;
LGG	cis	rs7937612	1.000	rs7951250	chr11:120309036	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.66	-0.51	9.13e-32	Intraocular pressure;
LGG	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs17030434	1.000	rs12645134	chr4:154713430	T/C	cg14289246	chr4:154710475	SFRP2	-0.74	-11.4	-0.47	1.07e-26	Electrocardiographic conduction measures;
LGG	trans	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg27053975	chr1:166958233	MAEL	-0.48	-6.76	-0.3	4.29e-11	Obesity-related traits;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg20453264	chr5:131705742	SLC22A5	0.58	7.39	0.32	6.74e-13	Rheumatoid arthritis;
LGG	trans	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg14791747	chr16:20752902	THUMPD1	0.5	7.5	0.33	3.23e-13	Cognitive test performance;
LGG	cis	rs13102973	0.645	rs6535055	chr4:135886101	A/C	cg14419869	chr4:135874104	NA	0.46	7.9	0.34	2.06e-14	Subjective well-being;
LGG	cis	rs1707322	0.752	rs3811436	chr1:46125880	T/C	cg03146154	chr1:46216737	IPP	0.55	10.71	0.45	4.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg11062466	chr8:58055876	NA	0.59	9.26	0.4	7.68e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4919044	0.600	rs78586043	chr10:94612458	T/G	cg05127821	chr10:94822908	CYP26C1	-0.39	-6.73	-0.3	5.18e-11	Coronary artery disease;
LGG	cis	rs590121	0.830	rs615896	chr11:75275301	T/C	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.59	-0.37	1.36e-16	Coronary artery disease;
LGG	cis	rs11105298	0.891	rs11105316	chr12:89925200	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.4	-0.4	2.46e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16166802	chr5:68485422	CENPH	0.44	6.66	0.3	7.98e-11	Gut microbiome composition (summer);
LGG	cis	rs62400317	0.859	rs12201005	chr6:45136922	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.15	-0.43	5.24e-22	Total body bone mineral density;
LGG	trans	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg02002194	chr4:3960332	NA	-0.52	-9.73	-0.41	1.8e-20	Retinal vascular caliber;
LGG	cis	rs3091242	0.900	rs4649086	chr1:25778967	T/A	cg27572855	chr1:25598939	RHD	0.5	11.14	0.46	1.07e-25	Erythrocyte sedimentation rate;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs9914988	1.000	rs9916866	chr17:27183155	C/G	cg20469991	chr17:27169893	C17orf63	0.53	6.69	0.3	6.47e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2228479	0.618	rs3212371	chr16:89987201	A/G	cg00800038	chr16:89945340	TCF25	-0.54	-7.49	-0.33	3.58e-13	Skin colour saturation;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.628	rs3828485	chr4:122722368	G/A	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.77	-0.48	3.81e-28	Type 2 diabetes;
LGG	cis	rs2404602	0.735	rs11637490	chr15:76759565	A/G	cg15268244	chr15:77196840	NA	0.43	9.46	0.4	1.55e-19	Blood metabolite levels;
LGG	cis	rs11608355	0.545	rs7139106	chr12:109908640	G/A	cg05360138	chr12:110035743	NA	0.84	12.02	0.49	3.87e-29	Neuroticism;
LGG	cis	rs483180	0.512	rs597308	chr1:120214953	G/A	cg19096424	chr1:120255104	PHGDH	0.62	11.05	0.46	2.41e-25	Macular telangiectasia type 2;
LGG	cis	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg06521331	chr12:34319734	NA	-0.63	-11.97	-0.49	6.09e-29	Morning vs. evening chronotype;
LGG	cis	rs10751667	0.643	rs7394436	chr11:970373	G/C	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs7552404	0.727	rs1159214	chr1:76317910	G/T	cg10523679	chr1:76189770	ACADM	-0.71	-11.16	-0.46	8.58e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg16576597	chr16:28551801	NUPR1	0.36	8.47	0.37	3.29e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs17039065	0.920	rs57121318	chr4:109456755	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.69	0.34	9e-14	Gut microbiome composition (summer);
LGG	cis	rs7928758	0.887	rs60337613	chr11:134264255	T/C	cg15243474	chr11:134282918	B3GAT1	1.22	16.0	0.6	3.6e-46	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2370759	1.000	rs2370759	chr10:32634972	G/A	cg01819863	chr10:32635814	EPC1	1.09	15.51	0.58	5.66e-44	Sexual dysfunction (female);
LGG	cis	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.16	-0.32	3.17e-12	Small cell lung carcinoma;
LGG	trans	rs11098499	0.821	rs3775852	chr4:120454556	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.48e-28	Corneal astigmatism;
LGG	cis	rs9325144	0.647	rs11169222	chr12:39105210	C/T	cg26384229	chr12:38710491	ALG10B	-0.71	-13.4	-0.53	7.62e-35	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4356932	0.905	rs7679394	chr4:76985890	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	trans	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg06606381	chr12:133084897	FBRSL1	-0.57	-7.27	-0.32	1.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.55	10.06	0.42	1.18e-21	Chronic sinus infection;
LGG	cis	rs4474465	1.000	rs10793316	chr11:78211928	C/A	cg27205649	chr11:78285834	NARS2	0.48	8.14	0.35	3.68e-15	Alzheimer's disease (survival time);
LGG	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs1153858	1.000	rs4774577	chr15:45644685	A/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	trans	rs7746199	0.736	rs34064842	chr6:27688625	G/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg25072359	chr17:41440525	NA	0.46	7.56	0.33	2.25e-13	Menopause (age at onset);
LGG	cis	rs4144743	1.000	rs4144746	chr17:45323355	C/G	cg18085866	chr17:45331354	ITGB3	-0.78	-9.87	-0.42	5.56e-21	Body mass index;
LGG	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs3087591	0.666	rs2953016	chr17:29494693	C/G	cg24425628	chr17:29625626	OMG;NF1	0.69	12.06	0.49	2.62e-29	Hip circumference;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07659893	chr17:61819838	STRADA	-0.44	-7.32	-0.32	1.09e-12	Prudent dietary pattern;
LGG	cis	rs7503807	0.515	rs12945216	chr17:78670642	C/T	cg06872548	chr17:78716983	RPTOR	0.37	6.98	0.31	1.03e-11	Obesity;
LGG	cis	rs8028182	0.636	rs4075522	chr15:75864335	G/A	cg20655648	chr15:75932815	IMP3	0.44	7.28	0.32	1.45e-12	Sudden cardiac arrest;
LGG	cis	rs17376456	0.825	rs6874766	chr5:93213807	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.96	-10.79	-0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs2762353	0.935	rs1165196	chr6:25813150	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.85	-0.42	6.42e-21	Blood metabolite levels;
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg26116260	chr4:7069785	GRPEL1	1.11	19.77	0.68	1.68e-63	Monocyte percentage of white cells;
LGG	cis	rs4788570	0.513	rs2113223	chr16:71607915	A/G	cg06353428	chr16:71660113	MARVELD3	-1.25	-18.63	-0.65	3.29e-58	Intelligence (multi-trait analysis);
LGG	cis	rs11945232	1.000	rs10027786	chr4:88347512	A/G	cg23841344	chr4:88312519	HSD17B11	-0.5	-8.75	-0.38	4.01e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7633857	0.512	rs1374787	chr3:160700144	C/T	cg04691961	chr3:161091175	C3orf57	-0.39	-8.01	-0.35	9.4e-15	Educational attainment (years of education);
LGG	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg02002194	chr4:3960332	NA	-0.44	-7.84	-0.34	3.04e-14	Retinal vascular caliber;
LGG	cis	rs12681288	0.823	rs2701907	chr8:1003292	A/G	cg08648136	chr8:956695	NA	0.36	7.57	0.33	1.98e-13	Schizophrenia;
LGG	cis	rs13191362	0.935	rs67084568	chr6:162988548	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.77	8.21	0.36	2.18e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.790	rs35162296	chr6:26318262	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-9.55	-0.41	7.62e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1801251	1.000	rs283484	chr2:233646505	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.24	0.39	8.78e-19	Coronary artery disease;
LGG	cis	rs2820315	0.505	rs10800792	chr1:201811144	G/A	cg06775570	chr1:201857621	SHISA4	0.34	7.39	0.32	7.03e-13	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.42e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6547741	1.000	rs6750943	chr2:27777904	T/G	cg27432699	chr2:27873401	GPN1	0.7	14.12	0.55	6.41e-38	Oral cavity cancer;
LGG	cis	rs7927771	0.524	rs11039392	chr11:47798753	A/G	cg20307385	chr11:47447363	PSMC3	0.56	10.98	0.45	4.39e-25	Subjective well-being;
LGG	cis	rs79911532	0.515	rs75257637	chr7:75712848	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-8.0	-0.35	9.72e-15	Mononucleosis;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg10852096	chr15:79043040	NA	-0.29	-8.29	-0.36	1.27e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs9906944	0.603	rs10853104	chr17:47092076	C/T	cg09029085	chr17:47094198	IGF2BP1	0.26	6.84	0.3	2.54e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg02487422	chr3:49467188	NICN1	0.58	10.71	0.45	4.79e-24	Resting heart rate;
LGG	cis	rs8031584	0.706	rs2177670	chr15:31157751	G/T	cg08109568	chr15:31115862	NA	-0.59	-10.02	-0.42	1.55e-21	Huntington's disease progression;
LGG	cis	rs4888262	0.545	rs36097721	chr16:74648267	C/G	cg01733217	chr16:74700730	RFWD3	0.9	18.32	0.65	8.41e-57	Testicular germ cell tumor;
LGG	trans	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg26043149	chr18:55253948	FECH	-0.49	-8.51	-0.37	2.5e-16	Bone mineral density;
LGG	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.38	0.47	1.24e-26	Colorectal cancer;
LGG	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	12.7	0.51	6.56e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2073300	1.000	rs79255223	chr20:23443559	G/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2760061	0.583	rs708118	chr1:228201801	A/G	cg02753203	chr1:228287806	NA	-0.89	-18.92	-0.66	1.46e-59	Diastolic blood pressure;
LGG	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.37	0.32	7.67e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7267979	1.000	rs2258617	chr20:25274318	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3008870	1.000	rs2065001	chr1:67486509	C/G	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.02	0.72	5e-74	Lymphocyte percentage of white cells;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.63	0.41	4.05e-20	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg04025307	chr7:1156635	C7orf50	0.57	10.67	0.44	6.54e-24	Longevity;Endometriosis;
LGG	cis	rs2247341	0.965	rs2854913	chr4:1723137	A/T	cg05026014	chr4:1749153	NA	-0.35	-9.74	-0.41	1.65e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	17.02	0.62	7.97e-51	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg12708336	chr17:41446283	NA	-0.32	-7.25	-0.32	1.77e-12	Menopause (age at onset);
LGG	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.59e-13	Intelligence (multi-trait analysis);
LGG	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.31	0.36	1.09e-15	Neuroticism;
LGG	cis	rs2028299	1.000	rs2351706	chr15:90384115	A/G	cg23731826	chr15:90371692	NA	0.38	8.92	0.38	1.06e-17	Type 2 diabetes;
LGG	cis	rs9362426	0.943	rs1884320	chr6:88089160	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	-0.52	-9.73	-0.41	1.71e-20	Depressive episodes in bipolar disorder;
LGG	cis	rs7267979	1.000	rs3761117	chr20:25388070	G/A	cg06421707	chr20:25228305	PYGB	-0.49	-10.55	-0.44	1.88e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs3126085	0.544	rs3126074	chr1:152279841	G/C	cg26876637	chr1:152193138	HRNR	-0.53	-8.64	-0.37	8.98e-17	Atopic dermatitis;
LGG	cis	rs6450176	0.625	rs67656636	chr5:53288455	C/A	ch.5.1024479R	chr5:53302184	ARL15	-0.84	-13.56	-0.53	1.67e-35	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7112925	0.738	rs12803688	chr11:66833265	G/A	cg24851651	chr11:66362959	CCS	-0.32	-6.74	-0.3	4.83e-11	Height;
LGG	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs12497850	0.931	rs11920534	chr3:48937761	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.94	0.31	1.34e-11	Parkinson's disease;
LGG	trans	rs62458065	0.513	rs787216	chr7:32578891	G/A	cg00845942	chr12:64062724	DPY19L2	-0.58	-7.71	-0.34	7.6e-14	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.0	-0.35	9.82e-15	Huntington's disease progression;
LGG	cis	rs2213920	0.516	rs35976675	chr9:118173444	T/C	cg13918206	chr9:118159781	DEC1	-0.76	-10.37	-0.43	8.85e-23	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs7020830	0.898	rs308492	chr9:37298020	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	31.59	0.83	1.36e-117	Schizophrenia;
LGG	cis	rs9912468	1.000	rs9892651	chr17:64303793	C/T	cg19474267	chr17:64306194	PRKCA	-0.96	-28.09	-0.79	4.66e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs28489187	0.706	rs2300634	chr1:85791257	T/C	cg16011679	chr1:85725395	C1orf52	0.35	6.7	0.3	6.01e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs3812831	0.695	rs7995986	chr13:114938802	A/G	cg25866889	chr13:114914595	NA	-0.35	-7.05	-0.31	6.58e-12	Schizophrenia;
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.57	-0.33	2.1e-13	Total body bone mineral density;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.3	-0.32	1.24e-12	Electroencephalogram traits;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg06873352	chr17:61820015	STRADA	-0.59	-10.31	-0.43	1.43e-22	Prudent dietary pattern;
LGG	cis	rs12143943	0.802	rs12117054	chr1:204454741	G/A	cg20240347	chr1:204465584	NA	-0.34	-7.22	-0.32	2.16e-12	Cognitive performance;
LGG	cis	rs4363385	0.782	rs1933381	chr1:153003255	C/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.72	-0.38	5.15e-17	Inflammatory skin disease;
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg18252515	chr7:66147081	NA	0.44	7.49	0.33	3.51e-13	Aortic root size;
LGG	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg15823100	chr22:32027580	PISD	-0.81	-9.03	-0.39	4.62e-18	Age-related hearing impairment;
LGG	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.37e-16	IgG glycosylation;
LGG	cis	rs3762637	0.943	rs9841897	chr3:122282569	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-10.19	-0.43	3.95e-22	LDL cholesterol levels;
LGG	cis	rs368123	0.960	rs316166	chr6:160750350	G/A	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.62	-0.33	1.46e-13	Waist circumference;
LGG	cis	rs1008375	0.966	rs10939736	chr4:17581617	T/A	cg16339924	chr4:17578868	LAP3	0.63	10.97	0.45	4.84e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.53	0.37	2.05e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.12e-18	Bladder cancer;
LGG	trans	rs9467711	0.606	rs16891727	chr6:26488860	C/A	cg01620082	chr3:125678407	NA	-0.66	-7.19	-0.32	2.55e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.4	9.04e-20	Bipolar disorder;
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg11645453	chr3:52864694	ITIH4	0.42	7.08	0.31	5.41e-12	Bipolar disorder;
LGG	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg08250081	chr4:10125330	NA	0.68	12.37	0.5	1.43e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs8067545	0.641	rs119672	chr17:19818601	A/G	cg13482628	chr17:19912719	NA	0.52	9.47	0.4	1.49e-19	Schizophrenia;
LGG	cis	rs738322	0.967	rs6001038	chr22:38570585	A/G	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs9733	0.540	rs4971041	chr1:150537357	C/T	cg13175981	chr1:150552382	MCL1	0.53	8.99	0.39	6.52e-18	Tonsillectomy;
LGG	cis	rs4774830	0.661	rs62045239	chr15:56294642	G/A	cg24530489	chr15:56299380	NA	-0.86	-7.93	-0.35	1.61e-14	Delta-5 desaturase activity;
LGG	cis	rs1348850	0.914	rs4893938	chr2:178250095	T/C	cg22681709	chr2:178499509	PDE11A	-0.44	-8.37	-0.36	6.95e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs61931739	0.929	rs3912551	chr12:34076696	C/T	cg06521331	chr12:34319734	NA	0.41	7.49	0.33	3.63e-13	Morning vs. evening chronotype;
LGG	cis	rs60180747	1.000	rs112914414	chr15:66833344	G/A	cg07575407	chr15:66541975	MEGF11	0.34	6.75	0.3	4.33e-11	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13610241	chr3:184032169	EIF4G1	0.49	8.29	0.36	1.27e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg26384229	chr12:38710491	ALG10B	0.63	12.33	0.5	2.04e-30	Morning vs. evening chronotype;
LGG	trans	rs72991	0.765	rs4935769	chr11:121236834	A/G	cg27192990	chr6:129479024	LAMA2	-0.42	-7.05	-0.31	6.69e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.35	-0.4	3.68e-19	Neuroticism;
LGG	cis	rs72772090	0.539	rs11741100	chr5:96113245	G/A	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.53	0.53	2.13e-35	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20284440	chr14:52118688	FRMD6	0.5	7.73	0.34	6.73e-14	Gut microbiome composition (summer);
LGG	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg00031303	chr3:195681400	NA	0.52	8.27	0.36	1.46e-15	Pancreatic cancer;
LGG	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9633740	0.945	rs6586030	chr10:82254047	C/T	cg01528321	chr10:82214614	TSPAN14	-0.97	-12.62	-0.51	1.38e-31	Post bronchodilator FEV1;
LGG	cis	rs2839186	0.504	rs11702278	chr21:47936295	T/G	cg12379764	chr21:47803548	PCNT	0.76	14.39	0.56	4.7e-39	Testicular germ cell tumor;
LGG	cis	rs262150	0.536	rs4909109	chr7:158787168	C/G	cg19418458	chr7:158789849	NA	0.45	7.56	0.33	2.26e-13	Facial morphology (factor 20);
LGG	cis	rs2242073	0.597	rs3820906	chr2:208993830	A/G	cg10392614	chr2:208977121	NA	0.34	7.05	0.31	6.66e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs35740288	0.770	rs62022867	chr15:86173281	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.46	0.37	3.44e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs796364	0.806	rs11694236	chr2:200916230	T/C	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs6121246	0.821	rs3181073	chr20:30307199	A/C	cg13852791	chr20:30311386	BCL2L1	-0.78	-12.74	-0.51	4.52e-32	Mean corpuscular hemoglobin;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-10.28	-0.43	1.77e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.94	0.6	6.7e-46	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.738	rs28408407	chr4:120376030	C/G	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.66e-25	Corneal astigmatism;
LGG	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg04727924	chr7:799746	HEATR2	-0.46	-7.41	-0.33	5.98e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs13260300	0.657	rs2553716	chr8:75534318	C/A	cg22993706	chr8:75542856	NA	0.41	7.78	0.34	4.73e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg26150922	chr2:100937072	LONRF2	0.58	11.38	0.47	1.26e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.82	-13.04	-0.52	2.42e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1267813	1	rs1267813	chr11:133981075	G/C	cg23319012	chr11:134007935	JAM3	-0.57	-10.51	-0.44	2.59e-23	Schizophrenia;
LGG	cis	rs16866061	0.855	rs11687736	chr2:225405122	A/T	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs35740288	0.822	rs34734963	chr15:86217644	C/T	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.28e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs76419734	0.510	rs6820671	chr4:106613821	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.72	10.66	0.44	7.33e-24	Post bronchodilator FEV1;
LGG	cis	rs4474465	0.607	rs7930161	chr11:78268878	C/A	cg27205649	chr11:78285834	NARS2	0.51	8.76	0.38	3.74e-17	Alzheimer's disease (survival time);
LGG	cis	rs11214589	0.747	rs11493880	chr11:113225144	C/T	cg14159747	chr11:113255604	NA	0.28	7.64	0.33	1.3e-13	Neuroticism;
LGG	cis	rs9326248	0.520	rs1446105	chr11:116798544	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	10.33	0.43	1.18e-22	Blood protein levels;
LGG	trans	rs3206736	0.514	rs1637679	chr7:35001022	C/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.91e-12	Diastolic blood pressure;
LGG	cis	rs7017914	0.935	rs7826483	chr8:71702893	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs67478160	0.634	rs1955660	chr14:104229985	C/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.26	-0.32	1.7e-12	Schizophrenia;
LGG	cis	rs1552244	0.882	rs13089863	chr3:10032259	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.03	-16.27	-0.6	2.02e-47	Alzheimer's disease;
LGG	cis	rs7000551	0.725	rs2461489	chr8:22370253	G/A	cg12081754	chr8:22256438	SLC39A14	0.66	12.4	0.5	1.12e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg02725872	chr8:58115012	NA	-1.04	-15.13	-0.58	2.61e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs11711311	0.869	rs1026364	chr3:113370010	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.23	-0.32	1.95e-12	IgG glycosylation;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.67	-0.44	6.68e-24	Longevity;Endometriosis;
LGG	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.67	-0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg14085017	chr11:63775226	MACROD1	0.51	12.35	0.5	1.75e-30	Pulse pressure;
LGG	trans	rs45509595	0.841	rs200501	chr6:27788942	C/T	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs503734	0.653	rs13320918	chr3:101167346	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs666930	0.519	rs532303	chr1:120265444	A/G	cg19096424	chr1:120255104	PHGDH	0.81	14.95	0.57	1.55e-41	Breast cancer;
LGG	cis	rs36051895	0.593	rs62541903	chr9:5146952	G/C	cg02405213	chr9:5042618	JAK2	-0.77	-14.31	-0.55	9.64e-39	Pediatric autoimmune diseases;
LGG	cis	rs8014204	0.870	rs3742790	chr14:75308758	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.77	-15.57	-0.59	3.02e-44	Caffeine consumption;
LGG	cis	rs2072732	0.861	rs55873718	chr1:2940012	A/G	cg22517653	chr1:2918612	NA	-0.49	-6.82	-0.3	2.84e-11	Plateletcrit;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.622	rs10974952	chr9:5079828	A/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.01	-0.57	9.19e-42	Pediatric autoimmune diseases;
LGG	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.04	0.35	7.77e-15	Colorectal cancer;
LGG	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs2703788	chr17:20159686	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.09	-0.42	9.28e-22	Schizophrenia;
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg18479299	chr3:125709523	NA	-0.6	-7.72	-0.34	7.34e-14	Blood pressure (smoking interaction);
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg24690094	chr11:67383802	NA	0.47	8.4	0.36	5.58e-16	Mean corpuscular volume;
LGG	cis	rs2273669	0.667	rs11757168	chr6:109301091	A/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.52	-0.37	2.21e-16	Prostate cancer;
LGG	cis	rs3733585	0.683	rs13112015	chr4:9933796	C/T	cg25986240	chr4:9926439	SLC2A9	0.51	11.37	0.47	1.43e-26	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs597539	0.652	rs660614	chr11:68659488	G/A	cg07511668	chr11:68622177	NA	0.51	9.74	0.41	1.58e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6787172	0.702	rs1193510	chr3:158030216	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.83	0.38	2.18e-17	Subjective well-being;
LGG	cis	rs75920871	0.528	rs12274388	chr11:116946238	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.39	-0.43	7.4e-23	Subjective well-being;
LGG	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg27297192	chr10:134578999	INPP5A	-0.32	-7.33	-0.32	1.04e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg18402987	chr7:1209562	NA	0.65	9.06	0.39	3.72e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1816752	0.712	rs6490932	chr13:25017451	A/G	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	trans	rs629535	0.814	rs506931	chr8:70068129	T/G	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.86e-11	Dupuytren's disease;
LGG	cis	rs4696584	0.877	rs1907156	chr4:155384995	C/T	cg13738195	chr4:155413469	DCHS2	-0.4	-7.42	-0.33	5.66e-13	Folding of antihelix;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15915129	chr11:124933008	SLC37A2	0.48	7.78	0.34	4.62e-14	Gut microbiome composition (summer);
LGG	trans	rs1728785	1.000	rs1645976	chr16:68563509	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	trans	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	cis	rs17253792	0.545	rs12883972	chr14:56018020	A/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg00405596	chr8:11794950	NA	0.44	7.36	0.32	8.22e-13	Neuroticism;
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg27532560	chr4:187881888	NA	0.58	12.68	0.51	7.71e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2012796	1.000	rs8009171	chr14:81820060	G/A	cg02996355	chr14:81879375	NA	0.51	8.16	0.35	3.18e-15	Night sleep phenotypes;
LGG	cis	rs2455799	0.613	rs12637353	chr3:15831525	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.84	-0.34	3.11e-14	Mean platelet volume;
LGG	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg12667521	chr19:29218732	NA	0.63	9.91	0.42	4.16e-21	Methadone dose in opioid dependence;
LGG	cis	rs7246760	0.867	rs1115825	chr19:9786121	C/G	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg00405596	chr8:11794950	NA	0.45	7.62	0.33	1.41e-13	Monocyte count;
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg00166722	chr3:10149974	C3orf24	0.5	8.25	0.36	1.7e-15	Alzheimer's disease;
LGG	cis	rs9341808	0.718	rs9294171	chr6:80839815	C/T	cg08355045	chr6:80787529	NA	0.4	7.85	0.34	3.01e-14	Sitting height ratio;
LGG	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs4132509	0.744	rs10803146	chr1:243709454	T/G	cg21452805	chr1:244014465	NA	0.86	7.99	0.35	1.04e-14	RR interval (heart rate);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg25216613	chr1:3541447	TPRG1L	0.56	6.8	0.3	3.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg16680214	chr1:154839983	KCNN3	-0.48	-9.6	-0.41	5.16e-20	Prostate cancer;
LGG	cis	rs139371	0.684	rs139340	chr22:39505609	T/G	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.71	-0.3	5.55e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs28595532	0.841	rs115907265	chr4:119730593	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs12410462	0.591	rs12080590	chr1:227759771	C/G	cg04117972	chr1:227635322	NA	-0.48	-8.77	-0.38	3.54e-17	Major depressive disorder;
LGG	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg04989706	chr14:50066350	PPIL5	-0.58	-9.14	-0.39	2e-18	Carotid intima media thickness;
LGG	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg09873164	chr1:152488093	CRCT1	-0.63	-15.55	-0.59	3.46e-44	Hair morphology;
LGG	cis	rs2777491	0.574	rs28700583	chr15:41714072	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.34	-34.3	-0.85	3.24e-129	Ulcerative colitis;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	7.01	0.31	8.71e-12	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08369258	chr7:73062418	NA	0.49	7.4	0.33	6.61e-13	Gut microbiome composition (summer);
LGG	cis	rs9403521	1.000	rs12208927	chr6:143993634	A/G	cg18240653	chr6:144019428	PHACTR2	-0.65	-10.04	-0.42	1.39e-21	Obesity-related traits;
LGG	cis	rs713587	0.607	rs6725517	chr2:25129473	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	9.56e-33	Body mass index in non-asthmatics;
LGG	cis	rs7584330	0.737	rs937392	chr2:238367130	C/T	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.74	15.27	0.58	6.31e-43	Obesity-related traits;
LGG	cis	rs1059312	0.808	rs2306683	chr12:129299675	C/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.8	-0.7	2.44e-68	Systemic lupus erythematosus;
LGG	cis	rs8179	1.000	rs8179	chr7:92236164	T/C	cg15732164	chr7:92237376	CDK6	0.7	12.59	0.51	1.81e-31	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06638463	chr19:10530633	PDE4A	0.45	7.16	0.32	3.1e-12	Cognitive performance;
LGG	cis	rs868036	0.522	rs3784711	chr15:68072527	C/T	cg08079166	chr15:68083412	MAP2K5	-0.33	-7.65	-0.33	1.21e-13	Restless legs syndrome;
LGG	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.81	7.06	0.31	6.21e-12	Facial emotion recognition (sad faces);
LGG	cis	rs4356932	1.000	rs4859595	chr4:76950062	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.62e-11	Blood protein levels;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg03395511	chr6:291903	DUSP22	-0.65	-10.79	-0.45	2.32e-24	Menopause (age at onset);
LGG	cis	rs12908161	1.000	rs12908549	chr15:85322351	C/G	cg24253500	chr15:84953950	NA	0.41	6.76	0.3	4.28e-11	Schizophrenia;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.830	rs11191442	chr10:104643596	T/A	cg04362960	chr10:104952993	NT5C2	0.58	10.05	0.42	1.3e-21	Arsenic metabolism;
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg05313129	chr8:58192883	C8orf71	-0.74	-9.81	-0.41	8.95e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.605	rs7843024	chr8:8799976	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.47	-0.33	4.02e-13	Joint mobility (Beighton score);
LGG	cis	rs514406	0.825	rs28817407	chr1:53226116	G/A	cg24675658	chr1:53192096	ZYG11B	0.5	10.01	0.42	1.7e-21	Monocyte count;
LGG	cis	rs1018836	0.608	rs11997663	chr8:91474484	A/C	cg16814680	chr8:91681699	NA	-0.6	-9.86	-0.42	5.81e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.7	-0.54	4.13e-36	Schizophrenia;
LGG	cis	rs7819412	0.775	rs11773990	chr8:10935082	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.34	-0.32	9.62e-13	Triglycerides;
LGG	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg00666640	chr1:248458726	OR2T12	0.6	9.73	0.41	1.78e-20	Common traits (Other);
LGG	cis	rs9658691	0.607	rs12411452	chr10:90780607	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-9.13	-0.39	2.12e-18	Mosquito bite size;
LGG	cis	rs1408224	0.688	rs4942566	chr13:47216011	C/G	cg24453118	chr13:47229927	LRCH1	0.3	7.01	0.31	8.72e-12	QRS complex (12-leadsum);
LGG	cis	rs8060686	0.545	rs12597573	chr16:68167521	A/C	cg09117114	chr16:67998030	SLC12A4	0.38	6.71	0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg10470783	chr12:48500294	SENP1;PFKM	-0.47	-6.66	-0.3	7.83e-11	Lung cancer in ever smokers;
LGG	cis	rs7267979	0.966	rs2482948	chr20:25296499	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.13	-0.43	6.64e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg26384229	chr12:38710491	ALG10B	0.97	21.88	0.71	2.17e-73	Bladder cancer;
LGG	cis	rs11608355	0.597	rs12579285	chr12:109832712	T/C	cg19025524	chr12:109796872	NA	-0.58	-12.94	-0.52	6.75e-33	Neuroticism;
LGG	cis	rs9400467	0.537	rs12195305	chr6:111449228	G/A	cg15721981	chr6:111408429	SLC16A10	0.58	7.17	0.32	3.06e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs68170813	0.599	rs77878465	chr7:106890996	G/A	cg02696742	chr7:106810147	HBP1	-0.72	-10.54	-0.44	2.08e-23	Coronary artery disease;
LGG	cis	rs300703	0.542	rs300691	chr2:180171	C/A	cg21211680	chr2:198530	NA	-1.17	-19.22	-0.67	5.82e-61	Blood protein levels;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg07077080	chr8:30585289	GSR	-0.42	-7.53	-0.33	2.73e-13	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	trans	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.92	-16.4	-0.61	5.27e-48	Colorectal cancer;
LGG	cis	rs2180341	1.000	rs6569483	chr6:127658855	G/A	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs8017423	0.647	rs12883357	chr14:90815032	A/G	cg04374321	chr14:90722782	PSMC1	-0.66	-12.65	-0.51	1.01e-31	Mortality in heart failure;
LGG	cis	rs910316	1.000	rs7156328	chr14:75532941	T/C	cg11812906	chr14:75593930	NEK9	0.53	9.92	0.42	3.68e-21	Height;
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs77857677	chr8:58170131	G/A	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08645402	chr16:4508243	NA	-0.5	-9.55	-0.41	7.44e-20	Schizophrenia;
LGG	cis	rs4731207	0.698	rs6466948	chr7:124444763	G/A	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs1559088	0.948	rs12608825	chr19:33581219	C/T	cg03563238	chr19:33554763	RHPN2	0.43	9.46	0.4	1.62e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Bone mineral density;
LGG	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg10840412	chr1:235813424	GNG4	0.53	7.46	0.33	4.21e-13	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-11.24	-0.46	4.47e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.4	-0.4	2.51e-19	Educational attainment;
LGG	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg25809561	chr17:30822961	MYO1D	0.44	10.76	0.45	3.05e-24	Schizophrenia;
LGG	cis	rs12618769	0.597	rs17031905	chr2:99070902	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.44e-16	Bipolar disorder;
LGG	cis	rs9942416	0.630	rs253388	chr5:74975912	A/G	cg19683494	chr5:74908142	NA	-0.47	-7.28	-0.32	1.43e-12	Age-related disease endophenotypes;
LGG	cis	rs9560113	1.000	rs9555811	chr13:112181532	A/C	cg14952266	chr13:112191215	NA	-0.42	-7.58	-0.33	1.92e-13	Menarche (age at onset);
LGG	cis	rs11864453	0.826	rs12448315	chr16:72147242	G/T	cg01557791	chr16:72042693	DHODH	-0.55	-9.92	-0.42	3.72e-21	Fibrinogen levels;
LGG	cis	rs2587949	0.615	rs2600115	chr3:4225026	G/T	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs920590	0.600	rs4921678	chr8:19663449	A/G	cg03894339	chr8:19674705	INTS10	0.5	8.52	0.37	2.18e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg22963979	chr7:1858916	MAD1L1	-0.46	-8.7	-0.37	5.67e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs10463316	0.817	rs730526	chr5:150789232	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.2	-0.43	3.46e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6688613	0.729	rs2072742	chr1:166929673	A/G	ch.1.3259774R	chr1:166827647	TADA1	0.49	7.09	0.31	5.07e-12	Refractive astigmatism;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00933542	chr6:150070202	PCMT1	0.4	7.34	0.32	9.6e-13	Lung cancer;
LGG	cis	rs3741151	0.773	rs73544710	chr11:73162273	A/G	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs12579753	0.595	rs7398614	chr12:82286339	C/G	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.23	-0.32	1.98e-12	Resting heart rate;
LGG	cis	rs7635838	0.620	rs1666988	chr3:11284950	A/G	cg00170343	chr3:11313890	ATG7	0.58	9.57	0.41	6.31e-20	HDL cholesterol;
LGG	cis	rs7508	0.680	rs7387916	chr8:17920359	C/A	cg18067069	chr8:17937731	ASAH1	0.38	8.52	0.37	2.3e-16	Atrial fibrillation;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg08645402	chr16:4508243	NA	0.5	9.05	0.39	4.04e-18	Schizophrenia;
LGG	cis	rs881375	1.000	rs10117059	chr9:123653477	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.97	0.49	5.73e-29	Rheumatoid arthritis;
LGG	cis	rs11877825	0.685	rs2099871	chr18:10578676	G/A	cg07277756	chr18:10589357	NA	0.57	10.21	0.43	3.16e-22	Gut microbiota (bacterial taxa);
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg26161643	chr5:24645024	CDH10	-0.49	-6.81	-0.3	3.09e-11	Leprosy;
LGG	cis	rs6582630	0.537	rs10785436	chr12:38461040	G/C	cg26384229	chr12:38710491	ALG10B	0.92	21.42	0.71	2.98e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg17211192	chr8:82754475	SNX16	-0.7	-11.83	-0.48	2.22e-28	Diastolic blood pressure;
LGG	cis	rs4764487	0.710	rs7964366	chr12:6346478	T/C	cg08284733	chr12:6341482	CD9	0.38	10.1	0.42	8.55e-22	Mean platelet volume;
LGG	cis	rs9443645	0.901	rs971994	chr6:79559602	G/C	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg11878867	chr6:150167359	LRP11	-0.46	-9.5	-0.4	1.1e-19	Lung cancer;
LGG	cis	rs9300255	0.602	rs1106240	chr12:123626982	C/T	cg05973401	chr12:123451056	ABCB9	0.46	6.65	0.3	8.36e-11	Neutrophil percentage of white cells;
LGG	cis	rs7582180	0.627	rs4851312	chr2:101011241	G/A	cg21926883	chr2:100939477	LONRF2	-0.68	-16.18	-0.6	5.53e-47	Intelligence (multi-trait analysis);
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg01494348	chr8:144660395	NAPRT1	0.91	7.3	0.32	1.24e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs2729354	0.768	rs2848635	chr11:57253931	T/C	cg24343310	chr11:57249947	NA	0.42	8.02	0.35	8.96e-15	Blood protein levels;
LGG	cis	rs344364	0.511	rs2982449	chr16:1947878	C/G	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.65	0.34	1.16e-13	Total cholesterol levels;
LGG	cis	rs2455799	0.613	rs6795100	chr3:15793798	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs796364	0.906	rs281766	chr2:200820505	T/G	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16448126	chr12:123921461	RILPL2	0.49	8.07	0.35	6.24e-15	Cognitive performance;
LGG	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg22431228	chr1:16359049	CLCNKA	0.39	7.22	0.32	2.21e-12	Systolic blood pressure;
LGG	cis	rs1816752	0.819	rs7400583	chr13:24990054	C/T	cg02811702	chr13:24901961	NA	0.41	7.66	0.34	1.09e-13	Obesity-related traits;
LGG	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg08847533	chr14:75593920	NEK9	-0.59	-11.44	-0.47	7.11e-27	Height;
LGG	cis	rs5769765	0.542	rs1535189	chr22:50249131	T/C	cg02269571	chr22:50332266	NA	0.65	8.63	0.37	1.02e-16	Schizophrenia;
LGG	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg04117972	chr1:227635322	NA	0.73	11.86	0.48	1.59e-28	Major depressive disorder;
LGG	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg21427119	chr20:30132790	HM13	-0.57	-8.99	-0.39	6.13e-18	Mean corpuscular hemoglobin;
LGG	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.6	-10.52	-0.44	2.42e-23	Educational attainment;
LGG	trans	rs941408	1.000	rs1624295	chr19:2792034	G/A	cg19676328	chr12:49525230	TUBA1B	-0.62	-9.89	-0.42	4.62e-21	Total cholesterol levels;
LGG	cis	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg04990556	chr1:26633338	UBXN11	0.62	8.23	0.36	1.89e-15	Obesity-related traits;
LGG	cis	rs2916247	0.954	rs4623479	chr8:93038708	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.39	-8.23	-0.36	1.93e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2629540	1.000	rs2629540	chr10:126426148	G/C	cg08799069	chr10:126477246	METTL10	0.68	12.82	0.51	2.03e-32	Cocaine dependence;
LGG	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg16482183	chr6:26056742	HIST1H1C	0.59	9.42	0.4	2.07e-19	Iron status biomarkers;
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.05	-0.39	3.85e-18	Lewy body disease;
LGG	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg11764359	chr7:65958608	NA	0.62	10.65	0.44	7.57e-24	Aortic root size;
LGG	cis	rs9467773	0.935	rs1056668	chr6:26510605	C/T	cg09904177	chr6:26538194	HMGN4	0.7	14.44	0.56	2.83e-39	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs7215564	0.908	rs34950888	chr17:78661779	T/G	cg06153925	chr17:78755379	RPTOR	0.38	6.67	0.3	7.39e-11	Myopia (pathological);
LGG	cis	rs9807989	0.507	rs2310300	chr2:103049074	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.52	0.4	9.77e-20	Asthma;
LGG	cis	rs2415984	0.622	rs2123126	chr14:46926609	C/T	cg14871534	chr14:47121158	RPL10L	-0.59	-10.28	-0.43	1.88e-22	Number of children ever born;
LGG	cis	rs4808199	0.947	rs10404728	chr19:19595014	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs75920871	0.528	rs4388921	chr11:116976778	T/C	cg20608306	chr11:116969690	SIK3	-0.4	-10.35	-0.43	9.92e-23	Subjective well-being;
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg18511798	chr11:2018149	H19;MIR675	-0.71	-14.36	-0.56	6.31e-39	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7737355	0.773	rs192166	chr5:130852525	T/C	cg06307176	chr5:131281290	NA	0.51	8.54	0.37	1.96e-16	Life satisfaction;
LGG	cis	rs6942756	0.531	rs9649531	chr7:128927659	T/C	cg02491457	chr7:128862824	NA	0.49	9.12	0.39	2.37e-18	White matter hyperintensity burden;
LGG	trans	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.49	-0.33	3.44e-13	Mood instability;
LGG	cis	rs11690935	0.632	rs12998411	chr2:172530707	G/C	cg13550731	chr2:172543902	DYNC1I2	0.7	14.29	0.55	1.21e-38	Schizophrenia;
LGG	cis	rs8180040	1.000	rs2302278	chr3:47361082	G/T	cg16586182	chr3:47516702	SCAP	0.77	15.16	0.58	1.93e-42	Colorectal cancer;
LGG	cis	rs2201728	0.739	rs34369278	chr4:100161258	T/C	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs1355223	0.506	rs7130774	chr11:34869267	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.45	-0.37	3.76e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs8067545	0.693	rs8066150	chr17:19886948	G/A	cg13482628	chr17:19912719	NA	0.55	10.01	0.42	1.79e-21	Schizophrenia;
LGG	cis	rs9915657	0.660	rs982534	chr17:70081366	T/G	cg09344028	chr17:70110421	NA	0.55	11.55	0.47	2.76e-27	Thyroid hormone levels;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg14912033	chr15:79043428	NA	0.38	8.78	0.38	3.11e-17	Coronary artery disease or large artery stroke;
LGG	cis	rs988958	0.567	rs11884781	chr2:42221093	C/T	cg27428208	chr2:42229179	NA	-0.54	-9.38	-0.4	2.85e-19	Hypospadias;
LGG	cis	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg24110177	chr3:50126178	RBM5	-0.4	-6.88	-0.3	1.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8077889	0.956	rs17742347	chr17:41846468	A/G	cg26893861	chr17:41843967	DUSP3	-1.0	-17.35	-0.63	2.48e-52	Triglycerides;
LGG	cis	rs28595532	0.920	rs114670456	chr4:119771202	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs2985684	0.947	rs1952013	chr14:50087357	C/G	cg02151108	chr14:50098012	C14orf104	-0.49	-10.58	-0.44	1.45e-23	Carotid intima media thickness;
LGG	cis	rs2016266	0.855	rs4759086	chr12:53666713	A/G	cg04065151	chr12:53682969	ESPL1	-0.59	-9.47	-0.4	1.45e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs3741151	0.686	rs7114376	chr11:73227361	T/C	cg17517138	chr11:73019481	ARHGEF17	0.69	7.25	0.32	1.74e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1322639	0.575	rs9294966	chr6:169565318	G/T	cg03254818	chr6:169586852	NA	0.53	8.23	0.36	1.93e-15	Pulse pressure;
LGG	cis	rs2486288	0.656	rs8039354	chr15:45551756	A/G	cg15395560	chr15:45543142	SLC28A2	-0.41	-6.72	-0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs769267	0.965	rs735273	chr19:19385411	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.41	-0.63	1.38e-52	Skin colour saturation;
LGG	cis	rs10791323	0.572	rs4412766	chr11:133742811	A/C	cg00579200	chr11:133705235	NA	-0.58	-11.19	-0.46	7.01e-26	Childhood ear infection;
LGG	cis	rs755249	0.501	rs2455648	chr1:39643712	C/T	cg18385671	chr1:39797026	MACF1	0.48	9.63	0.41	4.1e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12618769	0.597	rs7585939	chr2:99219206	T/A	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs10489202	0.632	rs149912	chr1:167957803	A/T	cg24449463	chr1:168025552	DCAF6	-0.6	-10.59	-0.44	1.25e-23	Schizophrenia;
LGG	cis	rs36093924	0.646	rs4822069	chr22:42351481	T/C	cg15128208	chr22:42549153	NA	0.36	6.84	0.3	2.54e-11	Intelligence;
LGG	cis	rs7799006	1.000	rs7799006	chr7:2278226	C/T	cg02951883	chr7:2050386	MAD1L1	-0.44	-7.67	-0.34	1.04e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs3740909	1.000	rs3740909	chr11:125889526	A/G	cg24940576	chr11:125904314	CDON	0.49	7.67	0.34	1.06e-13	Blood protein levels;
LGG	cis	rs9611565	0.512	rs7291736	chr22:42124874	C/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.78	-0.45	2.49e-24	Vitiligo;
LGG	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.47e-18	Motion sickness;
LGG	cis	rs6582630	0.584	rs12832156	chr12:38419435	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.76	-0.51	3.53e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6977660	0.943	rs10274447	chr7:19850640	C/T	cg07541023	chr7:19748670	TWISTNB	0.47	7.22	0.32	2.1e-12	Thyroid stimulating hormone;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg24677268	chr2:61764011	XPO1	-0.52	-7.46	-0.33	4.29e-13	Lung cancer in ever smokers;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg14159672	chr1:205819179	PM20D1	0.69	14.27	0.55	1.55e-38	Menarche (age at onset);
LGG	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg17644776	chr2:200775616	C2orf69	0.54	8.49	0.37	2.74e-16	Osteoporosis;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2373794	0.925	rs7572256	chr2:40371095	A/G	cg17740179	chr2:40377776	SLC8A1	-0.89	-18.74	-0.66	9.76e-59	Asthma;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg03452623	chr4:187889614	NA	-1.04	-29.29	-0.81	1.82e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1163251	0.623	rs493427	chr1:120207482	A/T	cg19096424	chr1:120255104	PHGDH	-0.48	-8.58	-0.37	1.47e-16	Blood metabolite levels;
LGG	cis	rs12618769	0.652	rs3754871	chr2:99224309	A/T	cg18455616	chr2:99124870	INPP4A	0.27	7.79	0.34	4.57e-14	Bipolar disorder;
LGG	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg04691961	chr3:161091175	C3orf57	-0.44	-8.39	-0.36	5.75e-16	Parkinson's disease;
LGG	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg02002194	chr4:3960332	NA	0.45	8.1	0.35	4.99e-15	Retinal vascular caliber;
LGG	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.75	0.3	4.33e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2494938	1.000	rs2494938	chr6:40536128	A/G	cg14084896	chr6:40530702	LRFN2	0.31	7.17	0.32	2.99e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2599510	0.811	rs2754523	chr2:32837110	A/G	cg02381751	chr2:32503542	YIPF4	0.47	7.57	0.33	2.06e-13	Interleukin-18 levels;
LGG	trans	rs7826238	0.594	rs2948285	chr8:8130538	A/T	cg19847130	chr8:10466454	RP1L1	-0.32	-6.96	-0.31	1.13e-11	Systolic blood pressure;
LGG	cis	rs6977660	1.000	rs12673970	chr7:19813018	T/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.82	0.38	2.39e-17	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10089	1.000	rs4836361	chr5:127459991	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.31	0.43	1.47e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg11752832	chr7:134001865	SLC35B4	0.63	11.54	0.47	3.11e-27	Mean platelet volume;
LGG	cis	rs9460578	0.537	rs9465899	chr6:20809854	A/G	cg13405222	chr6:20811065	CDKAL1	0.78	17.68	0.63	8.23e-54	Breast cancer;
LGG	cis	rs10267417	0.603	rs10253272	chr7:19916190	G/T	cg05791153	chr7:19748676	TWISTNB	0.53	6.81	0.3	2.95e-11	Night sleep phenotypes;
LGG	cis	rs7617773	0.780	rs71323395	chr3:48374077	G/A	cg11946769	chr3:48343235	NME6	0.7	11.6	0.47	1.66e-27	Coronary artery disease;
LGG	cis	rs6088580	0.634	rs4911422	chr20:32999345	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.67	-0.41	2.94e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg08344181	chr3:125677491	NA	-0.67	-7.56	-0.33	2.13e-13	Depression;
LGG	cis	rs875971	0.522	rs1968127	chr7:66056803	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.67	-0.41	2.77e-20	Aortic root size;
LGG	cis	rs72772090	0.539	rs11743410	chr5:96124453	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11168618	0.875	rs11168606	chr12:48892689	G/T	cg24011408	chr12:48396354	COL2A1	0.49	7.85	0.34	2.89e-14	Adiponectin levels;
LGG	trans	rs9650657	0.801	rs4841437	chr8:10596795	T/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.82	-0.3	2.9e-11	Neuroticism;
LGG	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg05335186	chr13:53173507	NA	0.75	18.55	0.65	7.28e-58	Lewy body disease;
LGG	cis	rs74781061	0.929	rs6495109	chr15:74797061	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.15	-0.32	3.35e-12	Endometriosis;
LGG	trans	rs9858542	0.903	rs11921590	chr3:49644193	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-10.01	-0.42	1.73e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg06875740	chr19:51307921	C19orf48	-0.66	-8.2	-0.36	2.4e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17776563	0.959	rs28526008	chr15:89118151	T/C	cg05013243	chr15:89149849	MIR1179	-0.49	-9.99	-0.42	2.06e-21	Thyroid hormone levels;
LGG	cis	rs9880211	1.000	rs28718456	chr3:136204006	A/G	cg21827317	chr3:136751795	NA	-0.48	-7.16	-0.32	3.09e-12	Body mass index;Height;
LGG	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg02297831	chr4:17616191	MED28	0.52	9.46	0.4	1.59e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg26384229	chr12:38710491	ALG10B	-0.69	-13.39	-0.53	8.65e-35	Bladder cancer;
LGG	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg11764359	chr7:65958608	NA	0.63	9.81	0.41	8.89e-21	Aortic root size;
LGG	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg22426938	chr7:1423890	NA	-0.63	-8.74	-0.38	4.33e-17	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs714515	0.934	rs9425587	chr1:172351809	A/C	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.1e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.3	0.36	1.13e-15	Tonsillectomy;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg03804240	chr11:118481350	PHLDB1	0.42	8.3	0.36	1.14e-15	Cholesterol, total;
LGG	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.92e-13	Restless legs syndrome;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.08	0.35	5.73e-15	Obesity-related traits;
LGG	cis	rs1728785	1.000	rs1624718	chr16:68580385	A/G	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs754466	0.874	rs61855849	chr10:79659934	G/A	cg17075019	chr10:79541650	NA	-0.83	-13.87	-0.54	7.67e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2415984	0.579	rs12147933	chr14:46972443	G/A	cg14871534	chr14:47121158	RPL10L	-0.56	-9.96	-0.42	2.63e-21	Number of children ever born;
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg17376030	chr22:41985996	PMM1	-0.56	-8.88	-0.38	1.46e-17	Vitiligo;
LGG	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs61931739	0.500	rs34167298	chr12:34534338	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4481887	0.962	rs10749653	chr1:248481384	C/G	cg00666640	chr1:248458726	OR2T12	0.6	9.69	0.41	2.37e-20	Common traits (Other);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg26516362	chr5:178986906	RUFY1	-0.42	-7.86	-0.34	2.64e-14	Lung cancer;
LGG	trans	rs8002861	0.664	rs4941474	chr13:44450289	C/T	cg12856521	chr11:46389249	DGKZ	0.51	9.17	0.39	1.52e-18	Leprosy;
LGG	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg23815491	chr16:72088622	HP	0.43	9.36	0.4	3.46e-19	Prostate cancer;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg17554472	chr22:41940697	POLR3H	-0.47	-6.68	-0.3	7e-11	Vitiligo;
LGG	cis	rs7769051	1.000	rs9493445	chr6:133125409	C/T	cg07930552	chr6:133119739	C6orf192	0.85	11.81	0.48	2.5e-28	Type 2 diabetes nephropathy;
LGG	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs62400317	0.859	rs62436779	chr6:45124911	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.13	-0.43	6.52e-22	Total body bone mineral density;
LGG	trans	rs1814175	0.645	rs7928714	chr11:49887622	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.47	-0.71	1.71e-71	Height;
LGG	cis	rs4794202	0.629	rs16948662	chr17:45913847	C/A	cg02219949	chr17:45927392	SP6	0.55	6.77	0.3	4.02e-11	Alzheimer's disease (cognitive decline);
LGG	cis	rs3780486	0.505	rs10758188	chr9:33123386	C/T	cg13443165	chr9:33130375	B4GALT1	0.6	12.09	0.49	2.02e-29	IgG glycosylation;
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	14.45	0.56	2.57e-39	Longevity;
LGG	cis	rs9362426	0.524	rs6454605	chr6:88100720	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	-0.88	-13.93	-0.54	4.53e-37	Depressive episodes in bipolar disorder;
LGG	cis	rs58235267	0.553	rs1025132	chr2:63360639	G/A	cg17519650	chr2:63277830	OTX1	0.57	10.48	0.44	3.46e-23	Prostate-specific antigen levels (conditioned on lead SNPs);
LGG	cis	rs1010254	0.510	rs72791425	chr5:151770646	A/G	cg12297329	chr5:152029980	NA	-0.49	-7.06	-0.31	6.14e-12	Optic nerve measurement (cup area);
LGG	cis	rs4919087	0.590	rs701821	chr10:99038562	G/A	cg25902810	chr10:99078978	FRAT1	-0.42	-6.83	-0.3	2.73e-11	Monocyte count;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg05165339	chr4:1420672	NA	-0.27	-6.93	-0.31	1.4e-11	Longevity;
LGG	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg08305652	chr11:111469057	NA	-0.45	-9.13	-0.39	2.15e-18	Primary sclerosing cholangitis;
LGG	cis	rs9790314	0.846	rs6768818	chr3:160951648	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.65e-30	Morning vs. evening chronotype;
LGG	cis	rs1506636	1.000	rs619575	chr7:123393460	C/T	cg03229431	chr7:123269106	ASB15	-0.51	-11.66	-0.48	9.8e-28	Plateletcrit;Platelet count;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01114951	chr1:117664707	TRIM45	0.38	6.82	0.3	2.82e-11	Obesity-related traits;
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.54	6.89	0.31	1.78e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs988958	0.565	rs12712819	chr2:42236349	A/G	cg27428208	chr2:42229179	NA	0.49	7.73	0.34	6.78e-14	Hypospadias;
LGG	cis	rs11771526	0.901	rs17161137	chr7:32323799	G/T	cg13207630	chr7:32358064	NA	0.68	7.21	0.32	2.33e-12	Body mass index;
LGG	cis	rs3106136	0.967	rs2129595	chr4:95224454	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.18	-0.36	2.74e-15	Capecitabine sensitivity;
LGG	cis	rs17169635	0.601	rs993034	chr7:134546809	T/A	cg02516134	chr7:134575187	CALD1	-0.34	-7.55	-0.33	2.41e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg11473876	chr11:109292803	C11orf87	-0.55	-10.86	-0.45	1.23e-24	Schizophrenia;
LGG	cis	rs7647973	1.000	rs6446268	chr3:49445695	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.49	-0.33	3.44e-13	Menarche (age at onset);
LGG	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.87	-0.3	2.07e-11	Mood instability;
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.11	-0.31	4.4e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2242116	0.796	rs4683297	chr3:46973673	T/C	cg16586182	chr3:47516702	SCAP	0.58	9.76	0.41	1.41e-20	Birth weight;
LGG	cis	rs3761847	0.622	rs10818500	chr9:123810883	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.54	-10.0	-0.42	1.84e-21	Rheumatoid arthritis;
LGG	cis	rs10504229	1.000	rs56740825	chr8:58175617	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2933343	0.621	rs4927921	chr3:128568868	A/G	cg25356066	chr3:128598488	ACAD9	-0.46	-6.9	-0.31	1.69e-11	IgG glycosylation;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07685180	chr8:600429	NA	1.06	10.89	0.45	9.59e-25	IgG glycosylation;
LGG	cis	rs7619833	0.649	rs6551176	chr3:27230587	A/G	cg02860705	chr3:27208620	NA	0.41	8.03	0.35	8.13e-15	Breast cancer;
LGG	cis	rs950027	0.967	rs3120975	chr15:45745125	T/C	cg26924012	chr15:45694286	SPATA5L1	0.42	7.24	0.32	1.93e-12	Response to fenofibrate (adiponectin levels);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg23963118	chr8:86375919	CA2	0.44	7.02	0.31	8.1e-12	Hip circumference;
LGG	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs4563143	0.675	rs73029042	chr19:29267979	A/T	cg04546413	chr19:29218101	NA	0.76	12.67	0.51	8.33e-32	Methadone dose in opioid dependence;
LGG	cis	rs4650994	0.550	rs10913573	chr1:178530455	G/A	cg19399532	chr1:178512495	C1orf220	-0.39	-7.31	-0.32	1.17e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9297145	0.724	rs6958790	chr7:98774738	C/T	cg05967295	chr7:98741636	SMURF1	-0.91	-14.92	-0.57	2.3e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg03264133	chr6:25882463	NA	-0.53	-9.73	-0.41	1.79e-20	Height;
LGG	trans	rs7246760	0.748	rs111564896	chr19:9722672	C/T	cg02900749	chr2:68251473	NA	-0.92	-9.07	-0.39	3.5e-18	Pursuit maintenance gain;
LGG	cis	rs7635838	0.819	rs12714866	chr3:11539058	C/T	cg00170343	chr3:11313890	ATG7	0.41	6.78	0.3	3.72e-11	HDL cholesterol;
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg04166393	chr7:2884313	GNA12	-0.45	-8.79	-0.38	2.98e-17	Height;
LGG	trans	rs7923837	0.687	rs1977833	chr10:94463945	G/A	cg27639046	chr2:171608303	NA	-0.36	-7.11	-0.31	4.42e-12	Body mass index;Multiple sclerosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03875450	chr9:98269581	PTCH1	0.46	7.41	0.33	6.18e-13	Cognitive performance;
LGG	cis	rs1505368	0.789	rs13419353	chr2:213271459	A/T	cg16329650	chr2:213403929	ERBB4	-0.45	-8.07	-0.35	5.91e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs2730245	0.527	rs2657362	chr7:158685095	A/G	cg18245976	chr7:158708271	WDR60	-0.58	-7.66	-0.34	1.09e-13	Height;
LGG	cis	rs7385804	0.766	rs1734909	chr7:100309582	C/G	cg16850897	chr7:100343110	ZAN	0.44	7.08	0.31	5.41e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs2270450	0.731	rs6907892	chr6:46625886	A/G	cg10156739	chr6:46714674	LOC100287718	0.34	8.13	0.35	3.97e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs62400317	0.859	rs12199256	chr6:45303493	T/G	cg18551225	chr6:44695536	NA	-0.6	-9.89	-0.42	4.8e-21	Total body bone mineral density;
LGG	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.27	0.43	1.95e-22	Aortic root size;
LGG	cis	rs698833	0.692	rs786410	chr2:44731156	C/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.77	0.3	3.91e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs3091242	0.935	rs4233043	chr1:25765483	A/G	cg02931644	chr1:25747376	RHCE	0.41	8.96	0.38	7.93e-18	Erythrocyte sedimentation rate;
LGG	cis	rs2011503	1.000	rs754256	chr19:19578591	A/G	cg11584989	chr19:19387371	SF4	-0.74	-12.1	-0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg02002194	chr4:3960332	NA	0.43	8.1	0.35	4.96e-15	Morning vs. evening chronotype;
LGG	cis	rs8077889	0.917	rs72836553	chr17:41909851	A/G	cg26893861	chr17:41843967	DUSP3	0.94	15.79	0.59	3.06e-45	Triglycerides;
LGG	cis	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg04568710	chr12:38710424	ALG10B	-0.38	-7.7	-0.34	8.21e-14	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.592	rs4822040	chr22:41963553	C/G	cg06634786	chr22:41940651	POLR3H	-0.72	-11.58	-0.47	2.11e-27	Vitiligo;
LGG	trans	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg04469686	chr1:162760199	HSD17B7	-0.48	-7.73	-0.34	6.89e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6964587	1.000	rs4265	chr7:91719608	A/G	cg17063962	chr7:91808500	NA	-0.46	-8.23	-0.36	1.87e-15	Breast cancer;
LGG	trans	rs11992162	0.560	rs13256329	chr8:11782214	G/A	cg02002194	chr4:3960332	NA	0.44	8.2	0.36	2.42e-15	Monocyte count;
LGG	cis	rs2204008	0.618	rs8186932	chr12:38338386	G/A	cg04568710	chr12:38710424	ALG10B	-0.4	-8.69	-0.37	6.26e-17	Bladder cancer;
LGG	cis	rs9400467	0.537	rs12199840	chr6:111428865	A/G	cg15721981	chr6:111408429	SLC16A10	0.54	6.67	0.3	7.11e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg04034577	chr2:241836375	C2orf54	0.53	11.12	0.46	1.24e-25	Urinary metabolites;
LGG	cis	rs7666738	0.830	rs34628820	chr4:99004764	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9400467	0.506	rs12207774	chr6:111657576	T/C	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs9457247	0.565	rs2239823	chr6:167512131	T/C	cg07741184	chr6:167504864	NA	0.45	10.09	0.42	8.72e-22	Crohn's disease;
LGG	cis	rs11112613	0.713	rs12321309	chr12:105943263	T/G	cg03607813	chr12:105948248	NA	0.58	9.66	0.41	3.08e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16511870	chr7:6145057	USP42	0.46	6.78	0.3	3.6e-11	Hip circumference;
LGG	cis	rs11931598	0.514	rs10937779	chr4:7039326	G/A	cg02503808	chr4:7069936	GRPEL1	0.47	8.04	0.35	7.56e-15	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg18402987	chr7:1209562	NA	0.75	10.87	0.45	1.16e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg20425293	chr12:93861147	MRPL42	-0.38	-7.07	-0.31	5.72e-12	Brain structure;
LGG	cis	rs1790761	0.967	rs7110021	chr11:67253564	T/C	cg14500267	chr11:67383377	NA	-0.41	-7.43	-0.33	5.15e-13	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07187585	chr17:10600923	C17orf48;SCO1	0.43	6.94	0.31	1.32e-11	Cognitive performance;
LGG	cis	rs561341	1.000	rs497479	chr17:30328605	C/T	cg00745463	chr17:30367425	LRRC37B	-0.73	-10.45	-0.44	4.35e-23	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg21782813	chr7:2030301	MAD1L1	0.54	14.05	0.55	1.33e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs4919694	0.711	rs113361908	chr10:104978126	T/C	cg04362960	chr10:104952993	NT5C2	1.04	13.47	0.53	3.84e-35	Arsenic metabolism;
LGG	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg18258770	chr4:90757814	SNCA	-0.37	-6.82	-0.3	2.88e-11	Dementia with Lewy bodies;
LGG	cis	rs7202877	0.610	rs468079	chr16:75428474	G/A	cg03315344	chr16:75512273	CHST6	-0.52	-7.26	-0.32	1.64e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs9911578	1.000	rs9904879	chr17:56864422	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.72	0.59	6.55e-45	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.616	rs9631782	chr4:185626379	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs1949733	0.598	rs4696838	chr4:8540349	A/G	cg13073564	chr4:8508604	NA	0.43	7.43	0.33	5.34e-13	Response to antineoplastic agents;
LGG	cis	rs12477438	0.798	rs6542849	chr2:99578493	G/C	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg09175582	chr1:161736000	ATF6	0.62	7.71	0.34	8e-14	IgG glycosylation;
LGG	cis	rs2180341	1.000	rs9385419	chr6:127597591	A/G	cg24812749	chr6:127587940	RNF146	0.97	16.06	0.6	1.86e-46	Breast cancer;
LGG	cis	rs908922	0.676	rs4112785	chr1:152533115	G/C	cg03606772	chr1:152487856	CRCT1	0.31	7.36	0.32	8.57e-13	Hair morphology;
LGG	cis	rs9309473	0.797	rs6723247	chr2:73846749	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.58	-0.33	1.94e-13	Metabolite levels;
LGG	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.79	-0.3	3.51e-11	Electroencephalogram traits;
LGG	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg06241208	chr11:30344200	C11orf46	-0.51	-6.69	-0.3	6.5500000000000006e-11	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.810	rs10962123	chr9:15704772	C/T	cg14451791	chr9:16040625	NA	0.32	8.26	0.36	1.57e-15	Body mass index;
LGG	cis	rs1577917	0.771	rs4419647	chr6:86225739	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.93	0.48	8.44e-29	Response to antipsychotic treatment;
LGG	cis	rs7208859	0.623	rs9891166	chr17:29111902	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7918232	0.882	rs2149413	chr10:27430311	C/T	cg14240646	chr10:27532245	ACBD5	0.73	10.21	0.43	3.25e-22	Breast cancer;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs7582180	0.764	rs13006224	chr2:100917109	C/T	cg05692746	chr2:100937584	LONRF2	-0.64	-11.59	-0.47	1.93e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg23978390	chr7:1156363	C7orf50	0.54	9.27	0.4	6.89e-19	Longevity;Endometriosis;
LGG	cis	rs651907	0.557	rs34947019	chr3:101532235	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.87	-0.34	2.62e-14	Colorectal cancer;
LGG	cis	rs6466055	0.777	rs66599006	chr7:104934271	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.03	0.31	7.21e-12	Schizophrenia;
LGG	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg02753203	chr1:228287806	NA	0.78	15.08	0.57	4.2e-42	Diastolic blood pressure;
LGG	trans	rs2727020	0.595	rs10839286	chr11:49497063	C/A	cg03929089	chr4:120376271	NA	-0.98	-21.38	-0.7	4.96e-71	Coronary artery disease;
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg23594656	chr7:65796392	TPST1	0.4	8.85	0.38	1.86e-17	Aortic root size;
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg23985595	chr17:80112537	CCDC57	0.39	7.61	0.33	1.5e-13	Life satisfaction;
LGG	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	7.99	0.35	1.1e-14	Colorectal cancer;
LGG	cis	rs11214589	0.747	rs1893695	chr11:113206085	A/C	cg14159747	chr11:113255604	NA	0.29	7.88	0.34	2.42e-14	Neuroticism;
LGG	cis	rs9644630	0.930	rs6586840	chr8:19365832	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.48	11.25	0.46	4.16e-26	Oropharynx cancer;
LGG	cis	rs7998202	0.667	rs282575	chr13:113359524	G/C	cg02820901	chr13:113351484	ATP11A	0.55	6.71	0.3	5.78e-11	Glycated hemoglobin levels;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07132326	chr6:150258058	NA	0.37	7.99	0.35	1.05e-14	Testicular germ cell tumor;
LGG	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg00666640	chr1:248458726	OR2T12	0.5	8.43	0.36	4.48e-16	Common traits (Other);
LGG	cis	rs7527798	0.592	rs6671969	chr1:207839667	C/T	cg09232269	chr1:207846808	CR1L	-0.35	-6.76	-0.3	4.23e-11	Erythrocyte sedimentation rate;
LGG	cis	rs11098499	0.954	rs9998585	chr4:120396802	T/A	cg09307838	chr4:120376055	NA	0.82	13.68	0.54	4.88e-36	Corneal astigmatism;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-6.85	-0.3	2.3e-11	Lung cancer;
LGG	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg05925327	chr15:68127851	NA	-0.36	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs883565	0.525	rs9833327	chr3:39029631	A/G	cg01426195	chr3:39028469	NA	-0.78	-18.53	-0.65	9.39e-58	Handedness;
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg08621203	chr6:150244597	RAET1G	0.42	7.2	0.32	2.53e-12	Lung cancer;
LGG	cis	rs4302748	0.862	rs4720196	chr7:36183300	C/T	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs7555523	0.943	rs4537525	chr1:165711089	T/G	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.41	-7.13	-0.31	3.85e-12	Total body bone mineral density;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg08621203	chr6:150244597	RAET1G	0.46	7.77	0.34	5.21e-14	Lung cancer;
LGG	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg17127132	chr2:85788382	GGCX	0.48	8.28	0.36	1.29e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-6.94	-0.31	1.33e-11	Schizophrenia;
LGG	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	cis	rs9443189	0.762	rs1321162	chr6:76456347	C/T	cg01950844	chr6:76311363	SENP6	0.56	7.57	0.33	2.11e-13	Prostate cancer;
LGG	cis	rs4731207	0.591	rs1471571	chr7:124650874	C/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg16606324	chr3:10149918	C3orf24	0.58	7.7	0.34	8.38e-14	Alzheimer's disease;
LGG	cis	rs3768617	0.811	rs6424883	chr1:183037695	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.83	0.3	2.76e-11	Fuchs's corneal dystrophy;
LGG	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23598886	chr18:12777645	NA	-0.72	-9.54	-0.41	8.34e-20	Inflammatory skin disease;
LGG	cis	rs5760092	0.755	rs915589	chr22:24261004	C/T	cg04234412	chr22:24373322	LOC391322	0.68	10.63	0.44	9.2e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs10504073	0.647	rs56057508	chr8:49982793	G/T	cg00325661	chr8:49890786	NA	0.73	14.09	0.55	8.83e-38	Blood metabolite ratios;
LGG	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs11190604	1.000	rs12355721	chr10:102244911	C/T	cg07080220	chr10:102295463	HIF1AN	0.64	11.11	0.46	1.45e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.8	-0.38	2.65e-17	Life satisfaction;
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg00864171	chr11:67383662	NA	-0.44	-7.21	-0.32	2.32e-12	Mean corpuscular volume;
LGG	cis	rs7503807	0.967	rs9915162	chr17:78614326	T/C	cg06872548	chr17:78716983	RPTOR	0.45	11.05	0.46	2.46e-25	Obesity;
LGG	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg18721089	chr20:30220636	NA	-0.5	-7.38	-0.32	7.28e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs11098499	0.604	rs2389887	chr4:120570644	T/C	cg25214090	chr10:38739885	LOC399744	0.59	10.2	0.43	3.59e-22	Corneal astigmatism;
LGG	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg08392591	chr16:89556376	ANKRD11	-0.59	-9.43	-0.4	1.94e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs368123	1.000	rs446887	chr6:160716588	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.13e-12	Waist circumference;
LGG	cis	rs4965869	0.824	rs4965868	chr15:101976044	G/T	cg12371147	chr15:101978424	PCSK6	-0.42	-7.69	-0.34	9.03e-14	Platelet-derived growth factor BB levels;
LGG	cis	rs7826238	0.601	rs2976907	chr8:8345168	C/T	cg08975724	chr8:8085496	FLJ10661	0.36	6.79	0.3	3.49e-11	Systolic blood pressure;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg05165339	chr4:1420672	NA	-0.35	-9.0	-0.39	5.83e-18	Longevity;
LGG	cis	rs933688	1.000	rs6869717	chr5:90694797	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs6912958	0.535	rs1753154	chr6:88032843	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.72	13.47	0.53	3.82e-35	Monocyte percentage of white cells;
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.7	13.32	0.53	1.75e-34	Personality dimensions;
LGG	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg02609749	chr16:89786786	C16orf7;ZNF276	0.41	6.98	0.31	1.02e-11	Vitiligo;
LGG	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg05925327	chr15:68127851	NA	-0.38	-7.84	-0.34	3.18e-14	Restless legs syndrome;
LGG	cis	rs3755397	1	rs3755397	chr2:242294913	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.9	-9.09	-0.39	2.94e-18	Chronic lymphocytic leukemia;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LGG	cis	rs7765175	0.598	rs2637526	chr6:113657311	T/G	cg26552650	chr6:113682475	NA	0.33	7.33	0.32	1.01e-12	Coronary artery calcification;
LGG	cis	rs2764208	0.576	rs2252551	chr6:34622676	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.58	-0.33	1.91e-13	Systemic lupus erythematosus;
LGG	cis	rs7917772	0.636	rs2249845	chr10:104512095	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.57	-0.33	2.08e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs629535	0.862	rs598548	chr8:70032438	C/T	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21582582	chr3:182698605	DCUN1D1	0.38	6.71	0.3	5.85e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.673	rs7375587	chr4:9954758	A/T	cg25986240	chr4:9926439	SLC2A9	-0.4	-8.12	-0.35	4.27e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg02951883	chr7:2050386	MAD1L1	-0.76	-15.62	-0.59	1.72e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs9906944	0.703	rs940088	chr17:47145848	T/C	cg09029085	chr17:47094198	IGF2BP1	0.31	8.42	0.36	4.85e-16	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg04455712	chr21:45112962	RRP1B	0.57	10.07	0.42	1.09e-21	Mean corpuscular volume;
LGG	cis	rs9911578	0.967	rs302842	chr17:56728102	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs10489202	0.632	rs12410730	chr1:168069477	T/C	cg24449463	chr1:168025552	DCAF6	-0.57	-10.11	-0.43	7.62e-22	Schizophrenia;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.71	-0.54	3.7e-36	Personality dimensions;
LGG	cis	rs10751667	0.643	rs7396951	chr11:927355	G/A	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs4242434	0.927	rs7843616	chr8:22466541	T/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.98	-0.39	6.82e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1003719	0.788	rs2835576	chr21:38457393	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg07747251	chr5:1868357	NA	0.41	7.19	0.32	2.64e-12	Cardiovascular disease risk factors;
LGG	cis	rs7524258	0.900	rs6577426	chr1:7306451	A/G	cg07173049	chr1:7289937	CAMTA1	0.72	16.82	0.62	6.96e-50	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.38	0.32	7.24e-13	Renal function-related traits (BUN);
LGG	cis	rs3859192	0.599	rs2227321	chr17:38171294	G/C	cg17467752	chr17:38218738	THRA	-0.58	-9.69	-0.41	2.51e-20	White blood cell count;
LGG	cis	rs35084382	1.000	rs2431663	chr5:172196711	A/C	cg19801141	chr5:172198162	DUSP1	1.03	8.52	0.37	2.29e-16	Optic cup area;
LGG	cis	rs7555523	0.778	rs2790052	chr1:165738463	G/C	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg25706281	chr1:46860511	FAAH	0.28	6.92	0.31	1.49e-11	Menopause (age at onset);
LGG	cis	rs427394	0.582	rs274665	chr5:6707981	C/T	cg15145174	chr5:6755386	POLS	-0.41	-7.67	-0.34	1.05e-13	Menopause (age at onset);
LGG	cis	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg14541582	chr5:601475	NA	-0.57	-9.16	-0.39	1.71e-18	Obesity-related traits;
LGG	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs875971	0.520	rs2420597	chr7:65915986	A/G	cg11764359	chr7:65958608	NA	0.75	13.54	0.53	2.08e-35	Aortic root size;
LGG	cis	rs796364	0.901	rs35572201	chr2:201035093	T/C	cg23649088	chr2:200775458	C2orf69	-0.62	-8.71	-0.38	5.3e-17	Schizophrenia;
LGG	cis	rs8077889	0.917	rs9901676	chr17:41911818	T/C	cg26893861	chr17:41843967	DUSP3	0.9	15.76	0.59	4.08e-45	Triglycerides;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-9.09	-0.39	2.89e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.71	0.3	5.75e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1580019	0.961	rs1610143	chr7:32498331	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs10870270	0.913	rs4550	chr10:133781798	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.73	-0.54	3.07e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs2404602	1.000	rs12898430	chr15:76874923	G/A	cg23625390	chr15:77176239	SCAPER	0.49	9.61	0.41	4.73e-20	Blood metabolite levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25302936	chr8:67579596	VCPIP1	-0.43	-7.11	-0.31	4.4e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11726039	chr2:208490019	FAM119A	0.6	6.81	0.3	3.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs72717009	0.825	rs9427398	chr1:161476205	A/G	cg23840854	chr1:161414152	NA	-0.74	-8.87	-0.38	1.61e-17	Rheumatoid arthritis;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05153347	chr5:171434267	FBXW11	0.4	6.76	0.3	4.23e-11	Bipolar disorder;
LGG	cis	rs7647973	0.626	rs2131108	chr3:49665390	C/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.51	-0.33	2.98e-13	Menarche (age at onset);
LGG	cis	rs6582630	0.638	rs7963994	chr12:38555535	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.53	-0.4	9.13e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9831754	0.906	rs6782626	chr3:78406178	T/C	cg06138941	chr3:78371609	NA	-0.89	-18.14	-0.64	5.8e-56	Calcium levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20620272	chr3:167968129	C3orf50	0.39	6.75	0.3	4.4e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg19680485	chr15:31195859	MTMR15	-0.43	-6.72	-0.3	5.23e-11	Huntington's disease progression;
LGG	cis	rs7226408	0.857	rs4344828	chr18:34613339	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs9916302	0.904	rs612194	chr17:37442707	T/A	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.01e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg24623649	chr8:11872141	NA	-0.32	-7.28	-0.32	1.48e-12	Triglycerides;
LGG	cis	rs1008375	1.000	rs7694020	chr4:17682597	C/T	cg02297831	chr4:17616191	MED28	0.5	9.54	0.41	8.14e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg09048205	chr5:1608656	LOC728613	-0.51	-8.56	-0.37	1.66e-16	Breast cancer;
LGG	cis	rs7932354	0.502	rs10769233	chr11:47072655	T/C	cg03339077	chr11:47165057	C11orf49	-0.53	-9.98	-0.42	2.23e-21	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22821026	chr1:155108104	RAG1AP1	0.45	7.06	0.31	5.97e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.5	-0.4	1.11e-19	Obesity-related traits;
LGG	cis	rs8180040	0.676	rs7636252	chr3:47013542	T/G	cg16586182	chr3:47516702	SCAP	-0.76	-14.14	-0.55	5.43e-38	Colorectal cancer;
LGG	cis	rs12549902	0.966	rs716199	chr8:41515531	A/G	cg21772509	chr8:41503840	NKX6-3	0.86	19.04	0.66	4e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs7100689	0.646	rs1815650	chr10:82157464	C/T	cg01528321	chr10:82214614	TSPAN14	0.88	16.52	0.61	1.54e-48	Post bronchodilator FEV1;
LGG	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.24	-0.36	1.77e-15	Body mass index;
LGG	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg25427524	chr10:38739819	LOC399744	0.51	7.59	0.33	1.82e-13	Obesity (extreme);
LGG	cis	rs7208859	0.614	rs9914534	chr17:29202664	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg03699307	chr16:75600014	GABARAPL2	0.41	6.86	0.3	2.23e-11	Body mass index;
LGG	cis	rs2070488	0.965	rs6796845	chr3:38567771	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.62	-0.63	1.53e-53	Electrocardiographic conduction measures;
LGG	cis	rs561341	0.710	rs9900031	chr17:30199537	T/C	cg13647721	chr17:30228624	UTP6	-0.7	-8.13	-0.35	4.09e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6456156	0.774	rs6931530	chr6:167527200	A/C	cg07741184	chr6:167504864	NA	-0.31	-7.03	-0.31	7.44e-12	Primary biliary cholangitis;
LGG	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2839186	0.504	rs4347941	chr21:47938239	T/C	cg12379764	chr21:47803548	PCNT	0.76	14.39	0.56	4.7e-39	Testicular germ cell tumor;
LGG	cis	rs4689388	0.926	rs10012946	chr4:6293350	C/T	cg14416269	chr4:6271139	WFS1	-0.49	-8.61	-0.37	1.17e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1408799	0.579	rs10756400	chr9:12738157	G/A	cg05274944	chr9:12693694	TYRP1	-0.31	-6.85	-0.3	2.4e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs4073582	0.595	rs801734	chr11:65931216	T/C	cg14036092	chr11:66035641	RAB1B	0.45	7.74	0.34	6.43e-14	Gout;
LGG	cis	rs2153535	0.563	rs1737584	chr6:8536742	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.31e-22	Motion sickness;
LGG	trans	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07923666	chr12:49932857	KCNH3	0.49	7.77	0.34	5.21e-14	Resting heart rate;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg13206674	chr6:150067644	NUP43	0.42	7.42	0.33	5.72e-13	Lung cancer;
LGG	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg11663600	chr3:49941416	MST1R	0.24	6.74	0.3	4.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg05368731	chr17:41323189	NBR1	0.94	18.68	0.66	1.98e-58	Menopause (age at onset);
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg11878867	chr6:150167359	LRP11	-0.57	-12.3	-0.5	2.65e-30	Lung cancer;
LGG	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.26e-11	Self-reported allergy;
LGG	cis	rs9487094	0.626	rs2273752	chr6:110059510	C/A	cg16315928	chr6:109776240	MICAL1	0.43	7.51	0.33	3.04e-13	Height;
LGG	cis	rs34783982	0.510	rs12915859	chr15:89529290	T/C	cg09489435	chr15:89561491	NA	-0.38	-7.21	-0.32	2.37e-12	Squamous cell lung carcinoma;
LGG	trans	rs10435719	0.899	rs9693925	chr8:11789963	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.07	-0.35	5.9e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg00405596	chr8:11794950	NA	-0.42	-6.76	-0.3	4.28e-11	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.51	-0.33	3.1e-13	Lung cancer;
LGG	cis	rs1894633	0.574	rs17369011	chr1:172321641	A/T	cg01573306	chr1:172330400	DNM3	-0.4	-7.05	-0.31	6.52e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6502050	0.871	rs6416857	chr17:80063004	A/G	cg16920238	chr17:80076378	CCDC57	0.36	8.22	0.36	1.99e-15	Life satisfaction;
LGG	cis	rs11771526	0.901	rs10252303	chr7:32304438	C/T	cg27532318	chr7:32358331	NA	0.71	7.32	0.32	1.14e-12	Body mass index;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.22	0.52	4.51e-34	Obesity-related traits;
LGG	trans	rs1499614	1.000	rs2659911	chr7:66158420	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs2046867	0.908	rs2679208	chr3:72787440	G/A	cg26655873	chr3:72818019	SHQ1	-0.36	-7.32	-0.32	1.13e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2470578	0.792	rs2733487	chr3:17315969	A/C	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs4819852	0.752	rs7284393	chr22:19974583	A/G	cg07821417	chr22:19972146	ARVCF	0.51	10.96	0.45	5.13e-25	Pulse pressure;
LGG	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06634786	chr22:41940651	POLR3H	0.62	10.59	0.44	1.27e-23	Vitiligo;
LGG	cis	rs4478037	1.000	rs4074417	chr3:33161153	A/C	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg27286069	chr11:118481882	PHLDB1	-0.55	-10.09	-0.42	9.3e-22	Cholesterol, total;
LGG	cis	rs9815354	0.857	rs7634985	chr3:42019565	C/T	cg03022575	chr3:42003672	ULK4	-0.6	-7.43	-0.33	5.31e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg06521331	chr12:34319734	NA	-0.55	-9.26	-0.4	7.45e-19	Morning vs. evening chronotype;
LGG	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg03891598	chr16:83986782	OSGIN1	-0.52	-8.46	-0.37	3.42e-16	Pursuit maintenance gain;
LGG	trans	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg14791747	chr16:20752902	THUMPD1	-0.49	-7.51	-0.33	2.99e-13	Cognitive test performance;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg15242686	chr22:24348715	GSTTP1	0.39	7.17	0.32	3.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6988985	0.728	rs4537287	chr8:143950786	C/T	cg10324643	chr8:143916377	GML	0.38	7.65	0.34	1.17e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs61931739	0.534	rs10844774	chr12:34166764	C/T	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	cis	rs473651	0.935	rs558924	chr2:239339511	A/G	cg18131467	chr2:239335373	ASB1	0.88	15.7	0.59	7.43e-45	Multiple system atrophy;
LGG	cis	rs9467773	0.565	rs4343916	chr6:26522675	A/T	cg11502198	chr6:26597334	ABT1	0.73	13.34	0.53	1.46e-34	Intelligence (multi-trait analysis);
LGG	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg18854424	chr1:2615690	NA	-0.33	-6.78	-0.3	3.61e-11	Ulcerative colitis;
LGG	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.74	-0.68	2.16e-63	Height;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg17554472	chr22:41940697	POLR3H	0.47	6.73	0.3	5.14e-11	Vitiligo;
LGG	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.576	rs1814175	chr11:49559172	T/C	cg03929089	chr4:120376271	NA	-0.97	-20.65	-0.69	1.29e-67	Coronary artery disease;
LGG	cis	rs6121246	0.697	rs6120970	chr20:30232452	C/T	cg21427119	chr20:30132790	HM13	-0.49	-8.24	-0.36	1.73e-15	Mean corpuscular hemoglobin;
LGG	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg04995300	chr3:66848608	NA	0.56	8.05	0.35	7.15e-15	Type 2 diabetes;
LGG	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg15556689	chr8:8085844	FLJ10661	0.4	7.27	0.32	1.51e-12	Joint mobility (Beighton score);
LGG	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg11995313	chr8:8860691	ERI1	0.43	7.18	0.32	2.8e-12	Joint mobility (Beighton score);
LGG	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg24101359	chr6:42928495	GNMT	0.39	8.72	0.38	4.85e-17	Blood protein levels;
LGG	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg20302533	chr7:39170763	POU6F2	0.47	11.1	0.46	1.48e-25	IgG glycosylation;
LGG	cis	rs71403859	0.502	rs17280181	chr16:71523514	C/T	cg08717414	chr16:71523259	ZNF19	-1.37	-18.52	-0.65	1.01e-57	Post bronchodilator FEV1;
LGG	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.43	0.36	4.5e-16	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.75	-0.45	3.4e-24	Alzheimer's disease;
LGG	cis	rs7432375	0.901	rs4408829	chr3:136404683	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.55	-0.37	1.87e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs644799	0.931	rs496305	chr11:95567035	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.37	0.7	5.15e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg11161011	chr14:65562177	MAX	-0.55	-10.2	-0.43	3.68e-22	Obesity-related traits;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10827011	chr4:980604	IDUA;SLC26A1	0.56	6.65	0.3	8.28e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg24623649	chr8:11872141	NA	0.32	7.76	0.34	5.37e-14	Neuroticism;
LGG	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg11518657	chr1:67396239	MIER1	-0.49	-7.42	-0.33	5.51e-13	Lymphocyte percentage of white cells;
LGG	cis	rs55871839	0.708	rs1448541	chr8:59812938	G/A	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs2635047	0.615	rs2684833	chr18:44719428	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.44	-7.19	-0.32	2.7e-12	Educational attainment;
LGG	cis	rs80130819	0.515	rs1793915	chr12:48386577	G/T	cg24011408	chr12:48396354	COL2A1	0.6	7.18	0.32	2.86e-12	Prostate cancer;
LGG	cis	rs7580658	0.929	rs11886231	chr2:128028130	G/A	cg10021288	chr2:128175891	PROC	-0.63	-13.06	-0.52	2e-33	Protein C levels;
LGG	cis	rs7100689	0.784	rs7082102	chr10:82104890	A/C	cg01528321	chr10:82214614	TSPAN14	0.88	15.77	0.59	3.81e-45	Post bronchodilator FEV1;
LGG	cis	rs992157	1.000	rs13003334	chr2:219124921	T/A	cg00012203	chr2:219082015	ARPC2	0.78	14.82	0.57	5.86e-41	Colorectal cancer;
LGG	cis	rs611744	0.647	rs628206	chr8:109247873	A/G	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs7226408	0.600	rs323295	chr18:34664093	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.13	-0.39	2.06e-18	Obesity-related traits;
LGG	cis	rs17445240	1.000	rs17445240	chr2:3703041	C/T	cg13452994	chr2:3699195	NA	-0.67	-7.39	-0.32	7.09e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.3	7.39	0.32	7.12e-13	Systemic lupus erythematosus;
LGG	cis	rs9926296	0.605	rs12448860	chr16:89849629	T/A	cg26513180	chr16:89883248	FANCA	0.94	21.06	0.7	1.45e-69	Vitiligo;
LGG	cis	rs7618501	0.633	rs6772095	chr3:49978069	C/T	cg24308560	chr3:49941425	MST1R	0.22	6.83	0.3	2.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4974559	0.501	rs900013	chr4:1240450	G/A	cg02980000	chr4:1222292	CTBP1	-0.97	-11.74	-0.48	4.73e-28	Systolic blood pressure;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg26174226	chr8:58114915	NA	-0.57	-7.77	-0.34	5.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	9.99	0.42	2e-21	Obesity-related traits;
LGG	cis	rs16866061	1.000	rs4674916	chr2:225365635	C/A	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs7572644	0.662	rs6706209	chr2:28101938	C/T	cg27432699	chr2:27873401	GPN1	-0.45	-6.9	-0.31	1.75e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs7523273	0.606	rs2724382	chr1:207928635	G/C	cg22525895	chr1:207977042	MIR29B2	0.6	11.9	0.48	1.08e-28	Schizophrenia;
LGG	cis	rs71403859	0.730	rs12927768	chr16:71645263	G/A	cg08717414	chr16:71523259	ZNF19	-1.11	-14.04	-0.55	1.49e-37	Post bronchodilator FEV1;
LGG	cis	rs344364	0.602	rs2983907	chr16:1913336	C/T	cg26897989	chr16:1907736	C16orf73	0.52	9.89	0.42	4.71e-21	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs600231	0.706	rs3782091	chr11:65336483	G/T	cg17120908	chr11:65337727	SSSCA1	0.62	11.26	0.46	3.69e-26	Bone mineral density;
LGG	trans	rs11098499	0.863	rs2291185	chr4:120434833	C/A	cg25214090	chr10:38739885	LOC399744	0.65	11.42	0.47	8.92e-27	Corneal astigmatism;
LGG	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg11038491	chr20:34638489	LOC647979	-0.61	-7.9	-0.34	2.08e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9341808	0.718	rs9448886	chr6:80825901	C/T	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg23782820	chr8:58130467	NA	0.56	8.34	0.36	8.6e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs911263	0.581	rs3825730	chr14:68790579	G/A	cg18825221	chr14:68749962	RAD51L1	0.35	7.68	0.34	9.35e-14	Primary biliary cholangitis;
LGG	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg05084668	chr3:125655381	ALG1L	-0.56	-7.58	-0.33	1.94e-13	Blood pressure (smoking interaction);
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.71	-0.34	7.76e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs11690935	0.959	rs12692973	chr2:172642057	A/G	cg13550731	chr2:172543902	DYNC1I2	1.05	26.61	0.78	2.37e-95	Schizophrenia;
LGG	cis	rs8062405	1.000	rs1987472	chr16:28825777	C/T	cg00198680	chr16:28758506	NA	0.29	7.26	0.32	1.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg11984989	chr7:158649758	WDR60	1.01	13.89	0.54	6.53e-37	Height;
LGG	cis	rs2762353	0.574	rs9467574	chr6:25705718	C/G	cg03264133	chr6:25882463	NA	0.69	13.18	0.52	6.69e-34	Blood metabolite levels;
LGG	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg12310025	chr6:25882481	NA	-0.44	-7.22	-0.32	2.09e-12	Iron status biomarkers;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs953387	1.000	rs4954392	chr2:136901607	A/G	cg07169764	chr2:136633963	MCM6	0.53	8.93	0.38	1.01e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs9560113	0.508	rs2774425	chr13:112235077	A/G	cg10483660	chr13:112241077	NA	-0.44	-9.16	-0.39	1.69e-18	Menarche (age at onset);
LGG	cis	rs1018836	0.923	rs6998150	chr8:91645969	A/C	cg16814680	chr8:91681699	NA	-0.84	-15.78	-0.59	3.48e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg04546413	chr19:29218101	NA	0.75	12.59	0.51	1.78e-31	Methadone dose in opioid dependence;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs503734	0.666	rs13087404	chr3:101140958	T/G	cg27318481	chr3:100970896	IMPG2	-0.35	-7.18	-0.32	2.81e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8060686	0.641	rs113896227	chr16:68101480	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.74	-0.3	4.78e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3764563	0.935	rs643442	chr19:15684087	T/C	cg20725493	chr19:15740067	CYP4F8	0.57	6.68	0.3	6.8e-11	Inflammatory biomarkers;
LGG	trans	rs853679	0.546	rs200952	chr6:27836976	C/T	cg01620082	chr3:125678407	NA	-0.82	-8.97	-0.38	7.37e-18	Depression;
LGG	cis	rs2073300	0.609	rs77673953	chr20:23398794	G/C	cg12062639	chr20:23401060	NAPB	0.93	9.05	0.39	3.99e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-7.13	-0.31	4e-12	Diastolic blood pressure;
LGG	cis	rs35740288	0.787	rs2291048	chr15:86225658	A/T	cg07943548	chr15:86304357	KLHL25	0.34	6.71	0.3	5.64e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg12011299	chr4:100065546	ADH4	0.45	9.29	0.4	5.86e-19	Alcohol dependence;
LGG	cis	rs17030434	0.834	rs6843172	chr4:154760600	T/C	cg14289246	chr4:154710475	SFRP2	-0.61	-9.99	-0.42	2.11e-21	Electrocardiographic conduction measures;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14283194	chr7:91763737	CYP51A1	0.42	6.72	0.3	5.25e-11	Cognitive performance;
LGG	trans	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg25214090	chr10:38739885	LOC399744	0.58	10.76	0.45	3.07e-24	Corneal astigmatism;
LGG	trans	rs1814175	0.533	rs4528310	chr11:49983106	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs2274273	0.934	rs10140869	chr14:55795283	G/A	cg04306507	chr14:55594613	LGALS3	0.61	16.84	0.62	5.67e-50	Protein biomarker;
LGG	trans	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg27053975	chr1:166958233	MAEL	-0.48	-6.66	-0.3	7.62e-11	Obesity-related traits;
LGG	cis	rs7584262	0.822	rs1550428	chr2:42240763	C/G	cg27252766	chr2:42229092	NA	0.48	6.86	0.3	2.22e-11	Bone mineral density;
LGG	cis	rs11771526	0.901	rs62457470	chr7:32303516	A/G	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	trans	rs11039798	0.511	rs2047812	chr11:48162042	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.34	-0.36	8.76e-16	Axial length;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg00166722	chr3:10149974	C3orf24	0.56	8.1	0.35	4.75e-15	Alzheimer's disease;
LGG	trans	rs7726839	0.540	rs72703080	chr5:595238	A/G	cg27053975	chr1:166958233	MAEL	-0.51	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	trans	rs1728785	1.000	rs1170431	chr16:68605639	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg02018176	chr4:1364513	KIAA1530	0.45	9.83	0.42	7.51e-21	Obesity-related traits;
LGG	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.43	0.33	5.3e-13	Asthma (sex interaction);
LGG	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg11764359	chr7:65958608	NA	0.81	15.26	0.58	7.15e-43	Aortic root size;
LGG	cis	rs651907	0.535	rs11712309	chr3:101519097	T/C	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs12479064	0.724	rs3792150	chr2:100041849	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.92	-0.45	7.61e-25	Chronic sinus infection;
LGG	cis	rs9952991	0.566	rs484020	chr18:12855440	G/A	cg23598886	chr18:12777645	NA	0.5	7.06	0.31	6.2e-12	Inflammatory skin disease;
LGG	cis	rs7122539	0.684	rs11227610	chr11:66629029	C/G	cg01599099	chr11:66649832	PC	0.46	9.25	0.4	8.12e-19	HIV-1 susceptibility;
LGG	cis	rs2836974	0.681	rs8128827	chr21:40710547	C/T	cg11890956	chr21:40555474	PSMG1	1.07	21.96	0.71	8.92e-74	Cognitive function;
LGG	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.76e-44	Lymphocyte percentage of white cells;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg16448126	chr12:123921461	RILPL2	0.4	6.86	0.3	2.18e-11	Bipolar disorder;
LGG	cis	rs1670533	1.000	rs2045065	chr4:1052488	A/G	cg27284194	chr4:1044797	NA	0.55	9.73	0.41	1.76e-20	Recombination rate (females);
LGG	trans	rs6601450	0.540	rs7824225	chr8:10273246	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.29	0.32	1.38e-12	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg15704280	chr7:45808275	SEPT13	0.73	7.96	0.35	1.32e-14	Intraocular pressure;
LGG	cis	rs4356932	0.935	rs4345214	chr4:76954169	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs1620921	0.591	rs12191314	chr6:161263721	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg24525913	chr1:72749880	NA	-0.32	-6.65	-0.3	8.44e-11	Pancreatic cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg24478630	chr2:74692696	MOGS	0.44	7.24	0.32	1.83e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4819052	0.765	rs2838827	chr21:46656146	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.55	0.37	1.82e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6964587	0.692	rs4729021	chr7:91758422	C/A	cg17063962	chr7:91808500	NA	0.51	9.61	0.41	4.73e-20	Breast cancer;
LGG	cis	rs701145	0.585	rs62276842	chr3:153784048	A/T	cg17054900	chr3:154042577	DHX36	-0.68	-8.56	-0.37	1.62e-16	Coronary artery disease;
LGG	trans	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.54	0.44	1.92e-23	Ulcerative colitis;
LGG	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.8	0.62	8.77e-50	Hip circumference adjusted for BMI;
LGG	trans	rs970548	0.779	rs752059	chr10:45942423	A/T	cg14222797	chr10:16859974	RSU1	-0.65	-7.64	-0.33	1.25e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs62238980	0.614	rs4821024	chr22:32414501	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs11122272	0.735	rs2066140	chr1:231504311	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs614226	0.935	rs7137953	chr12:120894685	C/T	cg21053147	chr12:120880522	NA	0.52	7.9	0.34	2.09e-14	Type 1 diabetes nephropathy;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.77	0.48	3.55e-28	Obesity-related traits;
LGG	cis	rs7107174	0.901	rs10899494	chr11:78122208	G/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.41	-0.33	5.97e-13	Testicular germ cell tumor;
LGG	trans	rs7824557	0.564	rs7839307	chr8:11198792	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.8	-0.38	2.7e-17	Retinal vascular caliber;
LGG	cis	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg19847130	chr8:10466454	RP1L1	0.32	6.82	0.3	2.85e-11	Neuroticism;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg05313129	chr8:58192883	C8orf71	-0.68	-8.74	-0.38	4.32e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg26528311	chr1:38462546	FHL3	-0.33	-7.33	-0.32	1.03e-12	Coronary artery disease;
LGG	cis	rs12135191	0.867	rs10925065	chr1:236475483	C/G	cg21399712	chr1:236511386	NA	-0.41	-7.88	-0.34	2.3e-14	Urate levels (BMI interaction);
LGG	cis	rs875971	0.862	rs10278014	chr7:66051264	C/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.67	-12.46	-0.5	6.47e-31	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs17376456	0.569	rs7721668	chr5:93290995	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.92	-0.35	1.83e-14	Diabetic retinopathy;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.53	9.66	0.41	3.07e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg07061783	chr6:25882402	NA	-0.43	-7.3	-0.32	1.28e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11627756	0.957	rs4906236	chr14:103077242	G/A	cg01864069	chr14:103024347	NA	-0.41	-6.72	-0.3	5.46e-11	Mean platelet volume;
LGG	cis	rs2359239	0.519	rs8007145	chr14:75185748	T/A	cg06637938	chr14:75390232	RPS6KL1	0.53	8.69	0.37	6.19e-17	Neuroticism (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs4275482	chr1:248473506	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.11	-0.39	2.51e-18	Prostate cancer;
LGG	cis	rs6426558	0.621	rs7521639	chr1:227223736	T/C	cg10327440	chr1:227177885	CDC42BPA	0.88	18.49	0.65	1.52e-57	Neutrophil percentage of white cells;
LGG	cis	rs2839186	0.616	rs4819213	chr21:47619300	G/A	cg13732083	chr21:47605072	C21orf56	-0.52	-8.43	-0.36	4.52e-16	Testicular germ cell tumor;
LGG	cis	rs3820068	0.626	rs11580170	chr1:15909744	C/T	cg05660106	chr1:15850417	CASP9	1.01	21.98	0.71	7.46e-74	Systolic blood pressure;
LGG	cis	rs7582180	0.739	rs11123822	chr2:100911582	G/T	cg14675211	chr2:100938903	LONRF2	0.56	9.43	0.4	1.99e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg03213289	chr20:61660250	NA	-0.59	-10.68	-0.44	5.98e-24	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg10911889	chr6:126070802	HEY2	0.43	7.35	0.32	9.15e-13	Brugada syndrome;
LGG	cis	rs270601	0.909	rs2569265	chr5:131704519	T/C	cg07395648	chr5:131743802	NA	0.49	10.03	0.42	1.51e-21	Acylcarnitine levels;
LGG	trans	rs7777677	0.889	rs6975391	chr7:142369835	C/T	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs73198271	0.562	rs112717383	chr8:8663216	T/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.22	0.36	2.03e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2334880	0.713	rs4788828	chr16:71724090	C/A	cg06353428	chr16:71660113	MARVELD3	1.28	21.77	0.71	6.8e-73	Malaria;
LGG	trans	rs253959	0.545	rs4921057	chr5:115426420	C/G	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.75	0.3	4.45e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2916247	1.000	rs6987763	chr8:93028518	G/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.49	-0.37	2.93e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.658	rs11493304	chr11:48895591	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.85	-0.34	2.83e-14	HDL cholesterol;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07167872	chr1:205819463	PM20D1	0.57	11.47	0.47	5.66e-27	Menarche (age at onset);
LGG	cis	rs12188164	0.965	rs55948934	chr5:423671	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.44	0.33	5.01e-13	Cystic fibrosis severity;
LGG	cis	rs919433	0.679	rs67492914	chr2:198523402	T/G	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs5758511	0.573	rs5996074	chr22:42236337	C/T	cg15128208	chr22:42549153	NA	-0.43	-7.12	-0.31	4.13e-12	Birth weight;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg26354017	chr1:205819088	PM20D1	-0.85	-20.38	-0.69	2.27e-66	Menarche (age at onset);
LGG	trans	rs853679	0.607	rs13205211	chr6:28203056	T/G	cg01620082	chr3:125678407	NA	-1.08	-10.61	-0.44	1.07e-23	Depression;
LGG	cis	rs990171	1.000	rs7603250	chr2:103068834	T/A	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.12e-18	Lymphocyte counts;
LGG	cis	rs9596863	1.000	rs9536557	chr13:54433190	A/G	ch.13.53330881F	chr13:54432880	NA	-0.5	-7.19	-0.32	2.54e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg06238570	chr21:40685208	BRWD1	-0.53	-8.61	-0.37	1.12e-16	Cognitive function;
LGG	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg19717773	chr7:2847554	GNA12	0.31	7.45	0.33	4.49e-13	Plateletcrit;
LGG	cis	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs11764590	0.671	rs62444906	chr7:2083161	G/T	cg02825527	chr7:2087843	MAD1L1	-0.53	-8.64	-0.37	9.36e-17	Neuroticism;
LGG	cis	rs933688	1.000	rs332531	chr5:90790451	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	16.38	0.61	7.07e-48	Smoking behavior;
LGG	cis	rs4363385	0.693	rs6690549	chr1:152930426	C/T	cg07796016	chr1:152779584	LCE1C	-0.46	-7.32	-0.32	1.12e-12	Inflammatory skin disease;
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg24829409	chr8:58192753	C8orf71	-0.67	-8.35	-0.36	8.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.634	rs11717836	chr3:52807736	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.52	0.37	2.3e-16	Bipolar disorder;
LGG	cis	rs755249	0.567	rs61779308	chr1:39938257	C/T	cg18385671	chr1:39797026	MACF1	0.46	7.6	0.33	1.61e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1256061	0.603	rs960069	chr14:64745002	C/T	cg23250157	chr14:64679961	SYNE2	0.37	6.79	0.3	3.54e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7932354	0.528	rs11039105	chr11:47157677	A/T	cg03339077	chr11:47165057	C11orf49	0.53	10.08	0.42	9.47e-22	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs875971	0.660	rs6460308	chr7:66084740	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.49	-0.4	1.21e-19	Aortic root size;
LGG	cis	rs11971779	0.680	rs12154842	chr7:139078484	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs6089584	0.821	rs2273990	chr20:60579149	G/T	cg06108461	chr20:60628389	TAF4	-0.88	-16.7	-0.61	2.27e-49	Body mass index;
LGG	trans	rs11098499	0.955	rs13113112	chr4:120156040	C/T	cg25214090	chr10:38739885	LOC399744	0.62	11.07	0.46	1.99e-25	Corneal astigmatism;
LGG	cis	rs7666738	0.724	rs28451676	chr4:98966990	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg02725872	chr8:58115012	NA	-0.77	-11.07	-0.46	1.99e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7503807	0.688	rs12952285	chr17:78596158	C/G	cg18469159	chr17:78755841	RPTOR	0.37	6.91	0.31	1.61e-11	Obesity;
LGG	cis	rs6459804	0.566	rs113592117	chr7:157511889	C/A	cg01625945	chr7:157512322	PTPRN2	-0.48	-9.84	-0.42	7.08e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	0.812	rs73077373	chr3:41852887	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg06713675	chr4:122721982	EXOSC9	0.44	7.2	0.32	2.4e-12	Type 2 diabetes;
LGG	cis	rs7408868	1.000	rs10420466	chr19:15261371	G/T	cg14696996	chr19:15285081	NOTCH3	1.06	12.57	0.5	2.24e-31	Pulse pressure;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg12070911	chr6:150209640	RAET1E	0.33	8.15	0.35	3.52e-15	Lung cancer;
LGG	cis	rs7949030	0.504	rs2516633	chr11:62371773	A/C	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-11.85	-0.48	1.8e-28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3008870	1.000	rs2755256	chr1:67471692	A/T	cg02640540	chr1:67518911	SLC35D1	0.37	6.64	0.3	8.61e-11	Lymphocyte percentage of white cells;
LGG	trans	rs9858542	0.953	rs34588335	chr3:49407660	G/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.12	-0.35	4.13e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08280861	chr8:58055591	NA	0.55	6.98	0.31	1e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg02002194	chr4:3960332	NA	-0.43	-7.95	-0.35	1.46e-14	Myopia (pathological);
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16405210	chr4:1374714	KIAA1530	0.66	11.75	0.48	4.3e-28	Obesity-related traits;
LGG	trans	rs149866169	1	rs149866169	chr6:27441723	T/A	cg08344181	chr3:125677491	NA	-0.79	-8.25	-0.36	1.68e-15	Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Subjective well-being (multi-trait analysis);Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs2832191	0.716	rs1888440	chr21:30454484	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.77	0.81	1.39e-109	Dental caries;
LGG	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg01043669	chr3:72786069	NA	0.43	6.94	0.31	1.35e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs16973500	0.808	rs112121746	chr16:71874983	G/A	cg09427745	chr16:71932006	KIAA0174	-0.5	-7.27	-0.32	1.59e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs6840360	0.615	rs6836249	chr4:152465829	T/G	cg25486957	chr4:152246857	NA	-0.51	-8.49	-0.37	2.88e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.602	rs1727315	chr12:123638930	A/G	cg00376283	chr12:123451042	ABCB9	-0.64	-10.33	-0.43	1.24e-22	Neutrophil percentage of white cells;
LGG	cis	rs2180341	0.960	rs6900074	chr6:127685893	A/G	cg24812749	chr6:127587940	RNF146	0.97	15.92	0.59	7.91e-46	Breast cancer;
LGG	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg25718383	chr7:130020096	CPA1	0.33	8.51	0.37	2.36e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs13217239	0.646	rs7768407	chr6:27016795	G/A	cg12292205	chr6:26970375	C6orf41	0.57	11.27	0.46	3.43e-26	Schizophrenia;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11245990	chr11:68621969	NA	0.41	8.7	0.37	5.75e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2916247	0.955	rs2976501	chr8:92976563	T/G	cg10183463	chr8:93005414	RUNX1T1	0.39	8.0	0.35	1.02e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.17	0.39	1.6e-18	Motion sickness;
LGG	cis	rs4732038	0.510	rs58505554	chr7:134275374	C/A	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg13206674	chr6:150067644	NUP43	0.66	14.97	0.57	1.28e-41	Lung cancer;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg16301924	chr13:53314226	LECT1	-0.47	-9.56	-0.41	7.16e-20	Lewy body disease;
LGG	cis	rs79349575	0.783	rs318096	chr17:46975370	G/A	cg16584676	chr17:46985605	UBE2Z	0.48	8.18	0.36	2.76e-15	Type 2 diabetes;
LGG	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg07075840	chr7:29603327	PRR15	-0.28	-6.65	-0.3	8.54e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7527798	0.501	rs12125256	chr1:207851361	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-7.1	-0.31	4.59e-12	Erythrocyte sedimentation rate;
LGG	cis	rs3857536	0.813	rs7766786	chr6:66932889	C/A	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.41e-14	Blood trace element (Cu levels);
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05435065	chr7:75544030	POR	0.41	6.78	0.3	3.77e-11	Cognitive performance;
LGG	cis	rs4731207	0.596	rs6942997	chr7:124648479	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs8040855	0.599	rs6496791	chr15:85725659	C/T	cg04831495	chr15:85060580	GOLGA6L5	0.33	6.79	0.3	3.44e-11	Bulimia nervosa;
LGG	cis	rs4819852	0.752	rs2238782	chr22:19970583	A/G	cg07821417	chr22:19972146	ARVCF	0.49	10.58	0.44	1.47e-23	Pulse pressure;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg07167872	chr1:205819463	PM20D1	0.64	13.35	0.53	1.25e-34	Menarche (age at onset);
LGG	cis	rs4950928	0.823	rs2494277	chr1:203168092	A/G	cg17014757	chr1:203156097	CHI3L1	-0.39	-7.92	-0.35	1.75e-14	YKL-40 levels;
LGG	trans	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs10186029	0.680	rs13007271	chr2:213937767	G/C	cg08319019	chr2:214017104	IKZF2	0.45	8.07	0.35	6.07e-15	Systemic sclerosis;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg16141378	chr3:129829833	LOC729375	0.4	9.72	0.41	1.8899999999999998e-20	Joint mobility (Beighton score);
LGG	cis	rs2439831	0.867	rs6493082	chr15:43634808	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	trans	rs61931739	1.000	rs11052967	chr12:34020030	T/G	cg26384229	chr12:38710491	ALG10B	-0.59	-10.79	-0.45	2.28e-24	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.501	rs1133977	chr2:99741984	G/T	cg08885076	chr2:99613938	TSGA10	-0.37	-8.13	-0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs17253792	0.731	rs8008528	chr14:56062052	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg25986240	chr4:9926439	SLC2A9	-0.51	-9.71	-0.41	2.06e-20	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9768139	0.658	rs28425474	chr7:158116360	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.22	-0.32	2.13e-12	Calcium levels;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg27136344	chr17:80606911	WDR45L	0.47	7.69	0.34	9.06e-14	Breast cancer;
LGG	cis	rs17445240	1.000	rs77719803	chr2:3701076	G/C	cg16123090	chr2:3699210	NA	0.82	8.86	0.38	1.79e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9646954	0.542	rs4149510	chr2:101023635	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.75	-0.48	4.51e-28	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20959564	chr11:47448208	PSMC3	0.48	7.27	0.32	1.57e-12	Gut microbiome composition (summer);
LGG	cis	rs10991814	0.920	rs6479335	chr9:94108790	T/C	cg14446406	chr9:93919335	NA	-0.69	-7.79	-0.34	4.29e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs60871478	0.541	rs56964970	chr7:910791	G/C	cg22643751	chr7:855365	UNC84A	-0.45	-7.78	-0.34	4.65e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs1355223	0.506	rs11032899	chr11:34870234	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.41	-0.36	4.99e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.7	-0.3	6.05e-11	Lung cancer;
LGG	cis	rs477692	0.583	rs2008387	chr10:131448764	C/T	cg05714579	chr10:131428358	MGMT	-0.87	-22.28	-0.72	2.91e-75	Response to temozolomide;
LGG	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg03060546	chr3:49711283	APEH	0.74	13.34	0.53	1.3600000000000001e-34	Intelligence (multi-trait analysis);
LGG	cis	rs12478296	0.748	rs10185596	chr2:243001029	C/A	cg06360820	chr2:242988706	NA	-0.59	-7.96	-0.35	1.33e-14	Obesity-related traits;
LGG	cis	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-8.48	-0.37	3.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11043280	0.703	rs11043275	chr12:122402723	T/C	cg22618164	chr12:122356400	WDR66	0.38	11.41	0.47	9.84e-27	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.16e-31	Prudent dietary pattern;
LGG	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.34	0.32	9.35e-13	Total cholesterol levels;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg02018176	chr4:1364513	KIAA1530	0.34	7.39	0.32	7.12e-13	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg02297831	chr4:17616191	MED28	0.5	9.53	0.4	9.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg14593290	chr7:50529359	DDC	-0.65	-11.78	-0.48	3.27e-28	Malaria;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg19635926	chr16:89946313	TCF25	0.74	8.14	0.35	3.69e-15	Skin colour saturation;
LGG	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg02503808	chr4:7069936	GRPEL1	0.87	13.83	0.54	1.21e-36	Monocyte percentage of white cells;
LGG	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg22437258	chr11:111473054	SIK2	0.57	9.83	0.42	7.57e-21	Primary sclerosing cholangitis;
LGG	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs3806843	0.648	rs2530233	chr5:140082876	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.75	-0.3	4.57e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9486715	1.000	rs6905737	chr6:97066659	A/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-14.43	-0.56	2.93e-39	Headache;
LGG	cis	rs13190036	0.901	rs28563911	chr5:176714943	T/C	cg06733329	chr5:176740039	MXD3	-0.48	-6.77	-0.3	3.94e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs2456568	0.548	rs4402256	chr11:93660803	T/C	cg26875233	chr11:93583750	C11orf90	-0.42	-8.11	-0.35	4.57e-15	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs330048	0.545	rs11774353	chr8:9153127	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.73	0.3	5e-11	Systemic lupus erythematosus;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.71	-0.3	5.75e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.92	-0.42	3.67e-21	Lung cancer;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.45	-7.27	-0.32	1.53e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg07659893	chr17:61819838	STRADA	-0.49	-8.21	-0.36	2.24e-15	Prudent dietary pattern;
LGG	trans	rs2562456	0.833	rs11667361	chr19:21539382	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.42	-0.33	5.6e-13	Pain;
LGG	cis	rs12220238	1.000	rs11000902	chr10:75920483	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.79	10.38	0.43	7.97e-23	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9816226	1.000	rs73052033	chr3:185828465	T/C	cg00760338	chr3:185826511	ETV5	-0.89	-12.53	-0.5	3.28e-31	Obesity;Body mass index;
LGG	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg03929089	chr4:120376271	NA	-1.03	-23.66	-0.74	1e-81	Height;
LGG	cis	rs832540	0.801	rs7731700	chr5:56111927	C/T	cg12654349	chr5:56205094	C5orf35	-0.38	-6.65	-0.3	8.33e-11	Coronary artery disease;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg05313129	chr8:58192883	C8orf71	-0.76	-10.56	-0.44	1.74e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.592	rs12936771	chr17:56725052	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg26248373	chr2:1572462	NA	-0.69	-9.07	-0.39	3.43e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4423214	1.000	rs2276360	chr11:71169547	C/G	cg05163923	chr11:71159392	DHCR7	0.74	14.43	0.56	3.09e-39	Vitamin D levels;
LGG	cis	rs9611519	0.894	rs4821998	chr22:41468273	C/G	cg06634786	chr22:41940651	POLR3H	-0.42	-6.67	-0.3	7.12e-11	Neuroticism;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1497828	0.956	rs2815239	chr1:217546728	G/A	cg04411442	chr1:217543379	NA	0.48	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	cis	rs10504130	0.530	rs4292674	chr8:52679772	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2153535	0.580	rs1577466	chr6:8444192	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.15	0.43	5.28e-22	Motion sickness;
LGG	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.43	-7.38	-0.32	7.43e-13	Total body bone mineral density;
LGG	cis	rs9557207	0.687	rs9557167	chr13:99807236	G/A	cg24509225	chr13:100037070	UBAC2	0.61	11.28	0.46	2.94e-26	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs883565	0.569	rs704959	chr3:39180263	G/A	cg01426195	chr3:39028469	NA	0.65	13.79	0.54	1.82e-36	Handedness;
LGG	cis	rs2842992	0.662	rs2273826	chr6:160211421	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs240764	0.853	rs11155498	chr6:101019551	G/C	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.46e-12	Neuroticism;
LGG	cis	rs113835537	0.597	rs2075792	chr11:66334556	G/A	cg24851651	chr11:66362959	CCS	0.48	8.35	0.36	8.23e-16	Airway imaging phenotypes;
LGG	cis	rs7618915	0.571	rs2289249	chr3:52597664	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.31	7.03e-12	Bipolar disorder;
LGG	cis	rs60871478	1.000	rs12531530	chr7:827366	T/C	cg13798912	chr7:905769	UNC84A	0.57	7.04	0.31	6.88e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg21798802	chr22:38057573	PDXP	0.46	8.59	0.37	1.37e-16	Fat distribution (HIV);
LGG	cis	rs787274	1.000	rs4549852	chr9:115584223	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7928758	0.887	rs11820880	chr11:134268453	T/C	cg25213107	chr11:134282864	B3GAT1	1.16	13.78	0.54	1.85e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11214589	0.774	rs7107223	chr11:113255574	A/T	cg14159747	chr11:113255604	NA	0.32	8.84	0.38	2.01e-17	Neuroticism;
LGG	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg09307838	chr4:120376055	NA	0.78	12.79	0.51	2.66e-32	Corneal astigmatism;
LGG	cis	rs3782089	1.000	rs11602375	chr11:65296540	C/T	cg21890820	chr11:65308645	LTBP3	0.7	7.44	0.33	4.8e-13	Height;
LGG	cis	rs7107174	1.000	rs58565853	chr11:78036707	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.61	-0.33	1.5e-13	Testicular germ cell tumor;
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.5700000000000001e-13	Personality dimensions;
LGG	cis	rs2153535	0.580	rs9406158	chr6:8464152	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.71e-15	Life satisfaction;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg12070911	chr6:150209640	RAET1E	0.28	6.76	0.3	4.29e-11	Lung cancer;
LGG	cis	rs8067545	0.611	rs2703814	chr17:20117151	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.14	-0.43	6.1e-22	Schizophrenia;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg07677032	chr17:61819896	STRADA	0.67	12.53	0.5	3.17e-31	Prudent dietary pattern;
LGG	cis	rs10884984	0.802	rs11594185	chr10:112262843	C/T	cg18756771	chr10:112261994	DUSP5	0.66	12.25	0.49	4.57e-30	Facial morphology (factor 22);
LGG	cis	rs208515	0.556	rs12206707	chr6:66697182	A/G	cg07460842	chr6:66804631	NA	0.95	17.16	0.62	1.85e-51	Exhaled nitric oxide levels;
LGG	cis	rs3857067	1.000	rs1509940	chr4:95018758	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.49	-0.33	3.53e-13	QT interval;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg14159672	chr1:205819179	PM20D1	0.49	8.75	0.38	3.98e-17	Prostate cancer;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.27e-17	Prudent dietary pattern;
LGG	cis	rs78487399	0.808	rs17039131	chr2:43652398	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.02e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs13102973	0.965	rs4864240	chr4:135856737	T/C	cg14419869	chr4:135874104	NA	-0.57	-10.9	-0.45	8.49e-25	Subjective well-being;
LGG	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg18850127	chr7:39170497	POU6F2	0.51	11.63	0.48	1.3e-27	IgG glycosylation;
LGG	cis	rs12474201	0.832	rs4953419	chr2:46989869	T/G	cg06386533	chr2:46925753	SOCS5	0.79	14.66	0.56	3e-40	Height;
LGG	cis	rs10875746	0.625	rs2898065	chr12:48644619	C/A	cg24011408	chr12:48396354	COL2A1	-0.56	-7.45	-0.33	4.59e-13	Longevity (90 years and older);
LGG	cis	rs17604090	0.761	rs115923387	chr7:29720702	A/G	cg19413766	chr7:29689036	LOC646762	-0.57	-6.92	-0.31	1.52e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg15971980	chr6:150254442	NA	0.44	8.84	0.38	1.99e-17	Testicular germ cell tumor;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.51	0.44	2.67e-23	Obesity-related traits;
LGG	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.57	-0.33	2.08e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6450176	0.638	rs56220547	chr5:53287952	A/G	ch.5.1024479R	chr5:53302184	ARL15	-1.06	-16.29	-0.6	1.7e-47	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg11584989	chr19:19387371	SF4	0.39	7.08	0.31	5.29e-12	Tonsillectomy;
LGG	cis	rs60843830	1.000	rs57542652	chr2:228088	G/A	cg04617936	chr2:214353	NA	-0.38	-7.05	-0.31	6.69e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14940636	chr12:56498092	PA2G4	0.45	7.26	0.32	1.7e-12	Cognitive performance;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.24	-0.39	9.07e-19	Life satisfaction;
LGG	cis	rs3784262	0.692	rs1441819	chr15:58243204	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.83	-0.3	2.66e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7647973	0.600	rs11920267	chr3:49275964	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.52	-8.34	-0.36	8.38e-16	Menarche (age at onset);
LGG	cis	rs3816183	1.000	rs3816181	chr2:43015612	G/T	cg27299406	chr2:43020013	HAAO	-0.27	-6.79	-0.3	3.44e-11	Hypospadias;
LGG	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg27147174	chr7:100797783	AP1S1	0.63	11.46	0.47	6.12e-27	Life satisfaction;
LGG	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg02073558	chr3:44770973	ZNF501	0.85	19.13	0.66	1.55e-60	Depressive symptoms;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22488975	chr1:184724009	EDEM3	-0.44	-6.96	-0.31	1.2e-11	Pancreatic cancer;
LGG	cis	rs6089584	0.526	rs6061965	chr20:60607858	A/C	cg06108461	chr20:60628389	TAF4	-0.72	-12.89	-0.51	1.05e-32	Body mass index;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.41	-0.33	6.05e-13	Lung cancer;
LGG	cis	rs7582180	0.607	rs6723909	chr2:100880058	A/T	cg21926883	chr2:100939477	LONRF2	-0.58	-12.4	-0.5	1.14e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6988985	0.818	rs6471583	chr8:143991092	G/A	cg10324643	chr8:143916377	GML	0.39	7.91	0.35	1.88e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs13323323	0.691	rs9815769	chr3:44663014	A/T	cg02073558	chr3:44770973	ZNF501	0.54	7.91	0.34	1.93e-14	IgG glycosylation;
LGG	cis	rs7715811	1.000	rs10050673	chr5:13761643	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.89	-0.42	4.92e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.42	0.33	5.54e-13	Homoarginine levels;
LGG	trans	rs656319	0.605	rs60278284	chr8:10003210	G/C	cg12395012	chr8:11607386	GATA4	0.41	7.3	0.32	1.22e-12	Myopia (pathological);
LGG	cis	rs9341835	0.740	rs9294215	chr6:64151771	C/G	cg00787780	chr6:64151745	NA	0.41	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs2273669	0.667	rs12215614	chr6:109313629	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.41	-0.36	5.07e-16	Prostate cancer;
LGG	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.03e-21	HDL cholesterol levels;
LGG	cis	rs9322193	0.884	rs7744105	chr6:150170444	A/G	cg08621203	chr6:150244597	RAET1G	0.46	8.05	0.35	7.14e-15	Lung cancer;
LGG	cis	rs10462794	0.853	rs4702795	chr5:4508002	A/G	cg18482690	chr5:4511582	NA	-0.42	-7.4	-0.33	6.48e-13	DNA methylation (variation);
LGG	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.65	0.48	1.15e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7208859	0.623	rs9898084	chr17:29082334	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.41	-0.36	5.28e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg26513180	chr16:89883248	FANCA	0.88	8.55	0.37	1.82e-16	Skin colour saturation;
LGG	cis	rs4604732	0.642	rs7515859	chr1:247640057	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.52	8.55	0.37	1.77e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.15	-0.32	3.41e-12	Morning vs. evening chronotype;
LGG	cis	rs7444	0.825	rs73166630	chr22:21945978	G/A	cg22858872	chr22:21984481	YDJC	-0.37	-6.79	-0.3	3.46e-11	Systemic lupus erythematosus;
LGG	cis	rs17504614	0.596	rs9636437	chr2:51063911	C/T	cg23851515	chr2:51057218	NRXN1	0.47	7.6	0.33	1.7e-13	Educational attainment (years of education);
LGG	cis	rs2228479	0.850	rs1800355	chr16:89813194	C/T	cg00800038	chr16:89945340	TCF25	-0.72	-8.39	-0.36	5.96e-16	Skin colour saturation;
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg00631329	chr6:26305371	NA	-0.53	-9.84	-0.42	6.94e-21	Educational attainment;
LGG	cis	rs754466	0.651	rs7895188	chr10:79623378	C/G	cg17075019	chr10:79541650	NA	0.95	20.38	0.69	2.35e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-14.28	-0.55	1.4e-38	Colorectal cancer;
LGG	trans	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg06521331	chr12:34319734	NA	-0.46	-8.01	-0.35	9.55e-15	Heart rate;
LGG	cis	rs6121246	0.567	rs7266471	chr20:30220599	T/A	cg21427119	chr20:30132790	HM13	-0.58	-8.9	-0.38	1.32e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2760061	0.598	rs632832	chr1:228121838	G/T	cg18477163	chr1:228402036	OBSCN	-0.25	-6.71	-0.3	5.73e-11	Diastolic blood pressure;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20332930	chr11:82997207	CCDC90B	0.4	6.69	0.3	6.27e-11	Body mass index;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.14	0.31	3.69e-12	Height;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg06074448	chr4:187884817	NA	-0.59	-13.58	-0.53	1.41e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg04034577	chr2:241836375	C2orf54	-0.53	-11.07	-0.46	1.95e-25	Urinary metabolites;
LGG	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg19766460	chr21:43528205	UMODL1;C21orf128	0.47	9.11	0.39	2.45e-18	IgG glycosylation;
LGG	cis	rs16912285	0.591	rs7929025	chr11:24363324	A/C	ch.11.24196551F	chr11:24239977	NA	0.85	12.05	0.49	2.88e-29	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.91	14.69	0.56	2.35e-40	Cognitive test performance;
LGG	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg08470875	chr2:26401718	FAM59B	-0.41	-8.05	-0.35	6.93e-15	Gut microbiome composition (summer);
LGG	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg19338460	chr6:170058176	WDR27	-0.64	-8.73	-0.38	4.61e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6868223	0.617	rs4866410	chr5:33643960	G/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	cis	rs701145	0.556	rs191651	chr3:153973887	T/G	cg12800244	chr3:153838788	SGEF	0.59	8.32	0.36	9.92e-16	Coronary artery disease;
LGG	cis	rs4319547	1.000	rs6489157	chr12:123101673	C/G	cg05707623	chr12:122985044	ZCCHC8	0.59	9.03	0.39	4.73e-18	Body mass index;
LGG	cis	rs2549003	1.000	rs2548997	chr5:131835395	C/T	cg21138405	chr5:131827807	IRF1	-0.38	-10.01	-0.42	1.78e-21	Asthma (sex interaction);
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.58	-0.37	1.45e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21961583	chr2:170684455	UBR3	0.44	6.86	0.3	2.2e-11	Gut microbiome composition (summer);
LGG	cis	rs2749592	0.531	rs994804	chr10:37900140	A/C	cg00409905	chr10:38381863	ZNF37A	0.53	10.63	0.44	8.88e-24	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg23262073	chr20:60523788	NA	0.59	9.21	0.39	1.12e-18	Obesity-related traits;
LGG	cis	rs8014204	0.935	rs10141438	chr14:75354600	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.83	-17.59	-0.63	2e-53	Caffeine consumption;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18959473	chr18:159310	USP14	0.38	6.75	0.3	4.47e-11	Body mass index;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg18765753	chr7:1198926	ZFAND2A	-0.45	-7.64	-0.33	1.26e-13	Longevity;Endometriosis;
LGG	trans	rs561341	0.769	rs559228	chr17:30294527	T/C	cg20587970	chr11:113659929	NA	-1.34	-24.01	-0.74	2.48e-83	Hip circumference adjusted for BMI;
LGG	cis	rs892961	0.932	rs55661113	chr17:75408386	A/C	cg05865280	chr17:75406074	SEPT9	0.42	9.85	0.42	6.48e-21	Airflow obstruction;
LGG	cis	rs7572733	0.534	rs1518361	chr2:198812874	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	trans	rs7178375	1.000	rs1474382	chr15:31214649	A/G	cg04373760	chr16:53404718	NA	0.53	8.05	0.35	6.81e-15	Hypertriglyceridemia;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg14646974	chr10:38645378	HSD17B7P2	0.44	7.07	0.31	5.64e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.08e-17	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24308560	chr3:49941425	MST1R	-0.22	-6.8	-0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7918232	0.941	rs1085782	chr10:27440517	G/A	cg14442939	chr10:27389572	ANKRD26	-0.75	-11.2	-0.46	6.34e-26	Breast cancer;
LGG	cis	rs10189230	0.834	rs10932914	chr2:222362999	C/A	cg14652038	chr2:222343519	EPHA4	0.59	12.1	0.49	1.7e-29	Urate levels in lean individuals;
LGG	cis	rs12410462	0.591	rs12082414	chr1:227786257	T/C	cg23173402	chr1:227635558	NA	0.38	7.19	0.32	2.69e-12	Major depressive disorder;
LGG	cis	rs9393777	0.513	rs61240102	chr6:27124904	G/C	cg12292205	chr6:26970375	C6orf41	-0.63	-8.34	-0.36	8.33e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10895140	0.665	rs1939453	chr11:101520496	G/A	cg23650423	chr11:101454676	TRPC6	-0.4	-6.77	-0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs875971	0.545	rs316328	chr7:65608838	A/G	cg11764359	chr7:65958608	NA	-0.62	-10.03	-0.42	1.47e-21	Aortic root size;
LGG	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg22643751	chr7:855365	UNC84A	0.36	6.93	0.31	1.42e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs10791323	0.569	rs10791335	chr11:133739571	A/T	cg00579200	chr11:133705235	NA	-0.55	-10.93	-0.45	6.51e-25	Childhood ear infection;
LGG	cis	rs11920090	0.720	rs6444956	chr3:170754477	G/C	cg09710316	chr3:170744871	SLC2A2	0.69	8.7	0.37	6.04e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4478858	0.735	rs1566961	chr1:31772450	G/A	cg19084893	chr1:31688959	NA	0.3	6.66	0.3	7.8e-11	Alcohol dependence;
LGG	cis	rs7715806	0.500	rs2307115	chr5:74990348	T/C	cg19683494	chr5:74908142	NA	0.52	6.97	0.31	1.13e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs35740288	0.770	rs4843082	chr15:86153390	A/G	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg09858108	chr8:58055024	NA	0.42	6.72	0.3	5.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7762018	0.556	rs75659875	chr6:170054800	A/C	cg06875740	chr19:51307921	C19orf48	-0.66	-6.86	-0.3	2.17e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12999616	0.817	rs62157581	chr2:98327502	G/T	cg26665480	chr2:98280029	ACTR1B	0.56	8.14	0.35	3.7e-15	Colorectal cancer;
LGG	cis	rs9302635	0.513	rs35460163	chr16:72177060	C/T	cg01557791	chr16:72042693	DHODH	-0.59	-9.07	-0.39	3.36e-18	Blood protein levels;
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	0.800	rs12209651	chr6:26660925	A/C	cg11502198	chr6:26597334	ABT1	-0.92	-7.87	-0.34	2.46e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9527	0.590	rs10883836	chr10:104891198	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs6445975	0.666	rs4681844	chr3:58332446	G/A	cg24175188	chr3:58374923	PXK	0.54	8.83	0.38	2.13e-17	Systemic lupus erythematosus;
LGG	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.17	-0.35	2.91e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7582180	0.934	rs2309822	chr2:100900406	G/A	cg21926883	chr2:100939477	LONRF2	-0.5	-9.55	-0.41	7.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.813	rs36052007	chr14:71984705	G/C	cg02058870	chr14:72053146	SIPA1L1	0.4	8.36	0.36	7.39e-16	Mitral valve prolapse;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.7	0.37	5.87e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8141529	0.719	rs6005916	chr22:29233342	T/C	cg15103426	chr22:29168792	CCDC117	0.72	11.73	0.48	5.57e-28	Lymphocyte counts;
LGG	cis	rs7089973	0.585	rs7907837	chr10:116610690	G/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.6	0.33	1.7e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs9951602	0.651	rs2959408	chr18:76681702	T/C	cg02800362	chr5:177631904	HNRNPAB	-0.71	-9.04	-0.39	4.42e-18	Obesity-related traits;
LGG	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.65	0.51	1.02e-31	Cognitive test performance;
LGG	cis	rs2236918	1.000	rs735943	chr1:242030151	C/T	cg17736920	chr1:242011382	EXO1	-0.5	-9.02	-0.39	4.88e-18	Menopause (age at onset);
LGG	cis	rs9768139	0.708	rs896780	chr7:158113972	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	cis	rs4481887	0.741	rs11488135	chr1:248568961	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.88	0.38	1.48e-17	Common traits (Other);
LGG	cis	rs2016266	0.784	rs7308162	chr12:53654956	G/A	cg04065151	chr12:53682969	ESPL1	-0.6	-9.96	-0.42	2.75e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.43e-44	Obesity-related traits;
LGG	cis	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg06521331	chr12:34319734	NA	0.64	11.17	0.46	8.48e-26	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg07701084	chr6:150067640	NUP43	0.43	7.81	0.34	3.94e-14	Testicular germ cell tumor;
LGG	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.21	-0.36	2.15e-15	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16021182	chr21:34961145	DONSON	0.47	6.9	0.31	1.71e-11	Gut microbiome composition (summer);
LGG	cis	rs2602381	0.599	rs2602380	chr2:234584306	C/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.4	7.06	0.31	6.16e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs9814567	0.574	rs7650509	chr3:134170971	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.51	9.0	0.39	6.02e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17401966	0.838	rs12120042	chr1:10345325	A/T	cg15208524	chr1:10270712	KIF1B	0.41	7.15	0.32	3.38e-12	Hepatocellular carcinoma;
LGG	cis	rs2075371	0.611	rs12707154	chr7:134015832	C/T	cg20476274	chr7:133979776	SLC35B4	0.67	11.94	0.49	7.65e-29	Mean platelet volume;
LGG	cis	rs6502050	0.634	rs11077973	chr17:80095191	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.57	-0.41	6.32e-20	Life satisfaction;
LGG	trans	rs17685	0.753	rs10262501	chr7:75668172	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.06	-25.55	-0.76	1.83e-90	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs4237845	0.636	rs11172371	chr12:58286188	C/T	cg02175503	chr12:58329896	NA	0.56	9.48	0.4	1.38e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9341808	0.754	rs3793000	chr6:80995137	G/A	cg08355045	chr6:80787529	NA	0.38	7.36	0.32	8.3e-13	Sitting height ratio;
LGG	trans	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg02002194	chr4:3960332	NA	0.39	7.33	0.32	1.02e-12	Joint mobility (Beighton score);
LGG	cis	rs9302065	0.565	rs2992908	chr13:95960600	G/A	cg26751094	chr13:95954534	ABCC4	-0.33	-7.86	-0.34	2.76e-14	Blood metabolite levels;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.55	-11.14	-0.46	1.08e-25	Personality dimensions;
LGG	cis	rs7075426	0.905	rs11202038	chr10:88204877	C/T	cg07322936	chr10:88137208	NA	0.42	7.33	0.32	1.03e-12	Migraine without aura;
LGG	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg04287289	chr16:89883240	FANCA	0.54	9.86	0.42	6.18e-21	Vitiligo;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg08621203	chr6:150244597	RAET1G	0.4	6.71	0.3	5.53e-11	Lung cancer;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg19318889	chr4:1322082	MAEA	0.47	8.05	0.35	6.9e-15	Longevity;
LGG	trans	rs11989744	0.500	rs1438456	chr8:23566909	T/C	cg03492747	chr16:86543808	FOXF1	-0.62	-11.09	-0.46	1.66e-25	Waist-hip ratio;
LGG	trans	rs656319	0.580	rs13279701	chr8:9969450	C/G	cg12395012	chr8:11607386	GATA4	0.4	7.06	0.31	6.32e-12	Myopia (pathological);
LGG	cis	rs6840360	0.571	rs62327277	chr4:152555905	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.798	rs1485840	chr6:101831210	A/G	cg27451362	chr6:101846650	GRIK2	0.7	11.24	0.46	4.4e-26	Coenzyme Q10 levels;
LGG	cis	rs1691799	0.528	rs1472314	chr12:66788838	C/G	cg16791601	chr12:66731901	HELB	-0.55	-12.15	-0.49	1.1e-29	White blood cell count (basophil);
LGG	cis	rs72945132	0.882	rs57810426	chr11:70230030	G/A	cg13802316	chr11:70253460	CTTN	-0.56	-7.35	-0.32	9.01e-13	Coronary artery disease;
LGG	cis	rs6754311	0.551	rs9287442	chr2:136522710	A/G	cg07169764	chr2:136633963	MCM6	-0.84	-15.02	-0.57	7.6e-42	Mosquito bite size;
LGG	cis	rs17826219	0.636	rs79565452	chr17:29142841	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Body mass index;
LGG	cis	rs7927592	0.731	rs2840367	chr11:68302101	G/A	cg01657329	chr11:68192670	LRP5	0.57	10.74	0.45	3.57e-24	Total body bone mineral density;
LGG	cis	rs10991814	1.000	rs76067199	chr9:93959395	C/T	cg14446406	chr9:93919335	NA	-0.76	-8.37	-0.36	6.82e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	trans	rs9348739	1	rs9348739	chr6:26923099	G/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-7.57	-0.33	2.05e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	cg15522984	chr1:182991683	LAMC1	0.44	8.86	0.38	1.79e-17	Colorectal cancer;
LGG	trans	rs9929218	0.953	rs2902323	chr16:68736292	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-15.8	-0.59	2.8e-45	Colorectal cancer;
LGG	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg04731861	chr2:219085781	ARPC2	-0.43	-10.45	-0.44	4.16e-23	Colorectal cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg06059345	chr1:161654727	RPL31P11	0.34	6.88	0.3	1.99e-11	Menarche (age at onset);
LGG	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.67	0.34	1.05e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs3820068	0.603	rs6695903	chr1:15985940	C/T	cg05660106	chr1:15850417	CASP9	0.8	15.41	0.58	1.46e-43	Systolic blood pressure;
LGG	cis	rs561341	0.941	rs72825746	chr17:30364610	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-10.92	-0.45	7.57e-25	Hip circumference adjusted for BMI;
LGG	cis	rs896854	0.654	rs896847	chr8:95972551	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.86	-0.38	1.77e-17	Type 2 diabetes;
LGG	cis	rs8180040	0.620	rs7373821	chr3:47080127	A/C	cg16586182	chr3:47516702	SCAP	-0.73	-13.25	-0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg13939156	chr17:80058883	NA	0.47	9.14	0.39	2.01e-18	Life satisfaction;
LGG	trans	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg27411982	chr8:10470053	RP1L1	0.43	7.45	0.33	4.67e-13	Mood instability;
LGG	cis	rs2742417	0.935	rs2742393	chr3:45757417	T/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg09699651	chr6:150184138	LRP11	0.51	8.9	0.38	1.25e-17	Lung cancer;
LGG	cis	rs4423214	0.840	rs1629220	chr11:71174553	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.7e-25	Vitamin D levels;
LGG	cis	rs78456975	1.000	rs6712176	chr2:1556393	C/T	cg26248373	chr2:1572462	NA	-0.71	-9.07	-0.39	3.47e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1878931	0.555	rs27228	chr16:3431933	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.74	-11.22	-0.46	5.42e-26	Body mass index (adult);
LGG	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg14664628	chr15:75095509	CSK	-0.79	-15.78	-0.59	3.35e-45	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs6580649	0.941	rs4589362	chr12:48478664	T/C	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.37	6.99	0.31	9.55e-12	Platelet count;
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.5e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11190604	1.000	rs11190556	chr10:102209223	G/A	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7617480	0.519	rs6790914	chr3:49206318	G/C	cg16497277	chr3:49208875	KLHDC8B	-0.45	-7.16	-0.32	3.21e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9457247	1.000	rs2149091	chr6:167372786	C/T	cg07741184	chr6:167504864	NA	-0.32	-7.01	-0.31	8.29e-12	Crohn's disease;
LGG	cis	rs6681460	0.604	rs7546825	chr1:67101802	A/G	cg13052034	chr1:66999238	SGIP1	0.35	6.9	0.31	1.68e-11	Presence of antiphospholipid antibodies;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg12070911	chr6:150209640	RAET1E	-0.32	-6.73	-0.3	5.11e-11	Lung cancer;
LGG	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.29	-0.4	6.11e-19	Retinal vascular caliber;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg13206674	chr6:150067644	NUP43	0.42	9.04	0.39	4.25e-18	Lung cancer;
LGG	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg23583168	chr7:148888333	NA	-0.84	-16.0	-0.6	3.46e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg22676075	chr6:135203613	NA	0.41	7.32	0.32	1.09e-12	Red blood cell count;
LGG	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg26384229	chr12:38710491	ALG10B	0.58	10.92	0.45	7.38e-25	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs35661897	0.920	rs13033214	chr2:227317638	T/C	cg03426602	chr2:227312417	NA	-0.43	-6.82	-0.3	2.88e-11	Urinary tract infection frequency;
LGG	cis	rs4073582	0.595	rs528842	chr11:66032390	G/A	cg14036092	chr11:66035641	RAB1B	0.46	7.97	0.35	1.23e-14	Gout;
LGG	cis	rs921968	0.608	rs832817	chr2:219358603	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.86	0.3	2.15e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2133450	0.508	rs17047072	chr3:7349526	A/G	cg19930620	chr3:7340148	GRM7	-0.43	-9.55	-0.41	7.48e-20	Early response to risperidone in schizophrenia;
LGG	cis	rs2243480	1.000	rs35542501	chr7:65431215	T/C	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs10751667	0.666	rs7936830	chr11:959686	A/G	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.61e-15	Alzheimer's disease (late onset);
LGG	cis	rs62238980	0.614	rs4821021	chr22:32414170	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14213517	chr2:102972205	NA	0.61	7.02	0.31	7.96e-12	Intelligence (multi-trait analysis);
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg14912033	chr15:79043428	NA	0.36	9.02	0.39	5.17e-18	Coronary artery disease or large artery stroke;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18755078	chr14:31028811	G2E3	0.49	7.22	0.32	2.18e-12	Gut microbiome composition (summer);
LGG	cis	rs2019137	0.936	rs902696	chr2:113954879	G/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.58	10.37	0.43	8.56e-23	Lymphocyte counts;
LGG	cis	rs8014204	0.566	rs7145575	chr14:75145528	T/A	cg17347104	chr14:75034677	LTBP2	-0.38	-6.9	-0.31	1.75e-11	Caffeine consumption;
LGG	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg19761014	chr17:28927070	LRRC37B2	0.7	8.75	0.38	3.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4417704	0.551	rs56237031	chr2:241875360	C/A	cg26818257	chr2:241905806	NA	-0.48	-10.73	-0.45	3.84e-24	Joint mobility (Beighton score);
LGG	cis	rs11105298	0.891	rs4842654	chr12:89834428	T/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6076960	0.564	rs3852935	chr20:6143180	C/G	cg21095983	chr6:86352623	SYNCRIP	0.52	9.11	0.39	2.54e-18	Smooth-surface caries;
LGG	cis	rs7208859	0.623	rs55724095	chr17:29153058	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.65	0.3	8.48e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7208859	0.623	rs7503542	chr17:29073830	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs7659604	0.540	rs28394772	chr4:122678543	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-7.88	-0.34	2.38e-14	Type 2 diabetes;
LGG	cis	rs6032067	0.777	rs62208386	chr20:43790872	G/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg08250081	chr4:10125330	NA	-0.39	-7.33	-0.32	1e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg21479132	chr6:26055353	NA	0.82	7.98	0.35	1.17e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.93e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs55986470	0.670	rs56313033	chr2:239346202	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.79	0.38	2.95e-17	Chronotype;
LGG	cis	rs12681288	0.578	rs56702775	chr8:968860	G/A	cg04851639	chr8:1020857	NA	-0.35	-7.33	-0.32	1.03e-12	Schizophrenia;
LGG	cis	rs739401	0.572	rs389285	chr11:3062673	G/A	cg08508325	chr11:3079039	CARS	-0.6	-13.13	-0.52	1.04e-33	Longevity;
LGG	cis	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	7.12	0.31	4.24e-12	Eosinophil percentage of white cells;
LGG	cis	rs651907	0.557	rs7651406	chr3:101393296	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.17	0.36	2.9e-15	Colorectal cancer;
LGG	cis	rs11971779	0.553	rs10228643	chr7:139115420	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.07	0.31	5.84e-12	Diisocyanate-induced asthma;
LGG	cis	rs1267303	0.798	rs1267304	chr1:46990426	C/T	cg25110126	chr1:46999211	NA	-0.57	-8.9	-0.38	1.22e-17	Monobrow;
LGG	cis	rs4713118	0.513	rs149951	chr6:28033087	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.9	-0.31	1.69e-11	Parkinson's disease;
LGG	cis	rs2273669	0.915	rs12191613	chr6:109289203	G/A	cg05315195	chr6:109294784	ARMC2	-0.52	-7.36	-0.32	8.2e-13	Prostate cancer;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs2721195	0.967	rs11777703	chr8:145703508	G/A	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.87	-17.24	-0.63	8.39e-52	Age at first birth;
LGG	trans	rs9354308	0.764	rs9294662	chr6:66596018	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs1806153	0.673	rs694617	chr11:31825518	T/G	cg11990419	chr11:31841155	NA	-0.36	-7.51	-0.33	3.11e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs7599312	0.534	rs7596285	chr2:213406961	G/A	cg20637307	chr2:213403960	ERBB4	0.74	16.77	0.61	1.09e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7615952	0.673	rs9821905	chr3:125620850	A/G	cg07211511	chr3:129823064	LOC729375	1.32	16.65	0.61	3.98e-49	Blood pressure (smoking interaction);
LGG	cis	rs2797160	1.000	rs1935773	chr6:125996475	A/G	cg05901451	chr6:126070800	HEY2	-0.47	-7.79	-0.34	4.57e-14	Endometrial cancer;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.77	-14.4	-0.56	4.21e-39	Intelligence (multi-trait analysis);
LGG	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14442939	chr10:27389572	ANKRD26	0.76	11.89	0.48	1.22e-28	Breast cancer;
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.61	-0.33	1.54e-13	Triglycerides;
LGG	cis	rs9309473	0.898	rs10170786	chr2:73812988	C/T	cg20560298	chr2:73613845	ALMS1	-0.44	-7.28	-0.32	1.45e-12	Metabolite levels;
LGG	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-8.9	-0.38	1.25e-17	Schizophrenia;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.43	-0.47	8.21e-27	Personality dimensions;
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg18621852	chr3:10150065	C3orf24	0.4	6.7	0.3	6.2e-11	Alzheimer's disease;
LGG	trans	rs7395662	0.500	rs7951327	chr11:48925359	C/T	cg21153622	chr11:89784906	NA	-0.38	-6.65	-0.3	8.03e-11	HDL cholesterol;
LGG	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg08885076	chr2:99613938	TSGA10	-0.48	-9.77	-0.41	1.22e-20	Chronic sinus infection;
LGG	cis	rs7927771	0.832	rs6485753	chr11:47410200	C/T	cg20307385	chr11:47447363	PSMC3	0.57	10.36	0.43	9.33e-23	Subjective well-being;
LGG	trans	rs1814175	0.817	rs4881645	chr11:49791168	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.19	-0.49	7.9e-30	Height;
LGG	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg06640241	chr16:89574553	SPG7	0.93	18.03	0.64	1.9e-55	Multiple myeloma (IgH translocation);
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.89	-0.31	1.77e-11	Menopause (age at onset);
LGG	cis	rs2798269	1.000	rs12430902	chr13:22146005	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.88	-0.3	1.94e-11	PR segment;
LGG	cis	rs3761847	0.622	rs10435888	chr9:123819603	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.18	0.36	2.81e-15	Rheumatoid arthritis;
LGG	cis	rs1005277	0.505	rs1208689	chr10:38097775	C/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-7.02	-0.31	8.15e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2120019	0.938	rs8030089	chr15:75290377	C/T	cg17294928	chr15:75287854	SCAMP5	-0.99	-18.74	-0.66	1.01e-58	Blood trace element (Zn levels);
LGG	cis	rs875971	0.545	rs73152714	chr7:65999628	G/A	cg11764359	chr7:65958608	NA	0.63	9.81	0.41	8.89e-21	Aortic root size;
LGG	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg07928641	chr1:182991847	LAMC1	-0.48	-9.92	-0.42	3.75e-21	Colorectal cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg07003055	chr20:3776921	CDC25B	0.42	6.89	0.3	1.78e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg05941027	chr17:61774174	LIMD2	0.35	8.75	0.38	3.91e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg04503457	chr17:41445688	NA	-0.38	-8.86	-0.38	1.75e-17	Menopause (age at onset);
LGG	cis	rs876084	0.505	rs7827219	chr8:121130164	G/A	cg06265175	chr8:121136014	COL14A1	0.46	9.25	0.39	8.19e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.52	-0.56	1.18e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs9583531	0.689	rs9521905	chr13:111352600	G/A	cg24331049	chr13:111365604	ING1	-0.87	-14.89	-0.57	3.05e-41	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs1992562	chr17:20218793	A/C	cg13482628	chr17:19912719	NA	-0.5	-9.17	-0.39	1.55e-18	Obesity-related traits;
LGG	cis	rs2072732	0.861	rs12034794	chr1:2937551	T/G	cg22517653	chr1:2918612	NA	-0.51	-7.24	-0.32	1.89e-12	Plateletcrit;
LGG	cis	rs9398803	0.687	rs9375450	chr6:126985351	G/A	cg19875578	chr6:126661172	C6orf173	0.52	9.66	0.41	3.16e-20	Male-pattern baldness;
LGG	cis	rs12282928	1.000	rs10769346	chr11:48336287	T/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs4936894	0.500	rs11219534	chr11:124119351	A/G	cg27160556	chr11:124181099	OR8D1	0.45	10.45	0.44	4.25e-23	Aging (time to death);
LGG	cis	rs9880211	0.800	rs75901823	chr3:136494151	T/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs10744422	0.925	rs897391	chr12:123326374	G/A	cg25930673	chr12:123319894	HIP1R	-0.71	-9.28	-0.4	6.3e-19	Schizophrenia;
LGG	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	4.17e-16	Retinal vascular caliber;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.3	-0.32	1.25e-12	Neuroticism;
LGG	cis	rs12477438	1.000	rs6732980	chr2:99921613	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-10.81	-0.45	1.92e-24	Chronic sinus infection;
LGG	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg10621924	chr7:39171070	POU6F2	0.42	8.39	0.36	5.9e-16	IgG glycosylation;
LGG	cis	rs7917772	0.507	rs2778036	chr10:104485725	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	9.03	0.39	4.79e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg10295955	chr4:187884368	NA	-1.16	-31.32	-0.82	2.04e-116	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.37	7.28	0.32	1.43e-12	Schizophrenia;
LGG	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg13919506	chr9:131535850	NA	0.32	6.7	0.3	6.14e-11	Lung cancer;
LGG	trans	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg13565492	chr6:43139072	SRF	-0.78	-10.27	-0.43	2.01e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs701145	0.556	rs355758	chr3:154007682	C/G	cg12800244	chr3:153838788	SGEF	-0.58	-8.35	-0.36	8.21e-16	Coronary artery disease;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.92	-0.38	1.06e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg08677398	chr8:58056175	NA	0.54	8.16	0.35	3.1e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.3	-0.32	1.29e-12	Lung cancer;
LGG	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs757278	0.591	rs1042180	chr7:117308413	C/T	cg10524701	chr7:117356490	CTTNBP2	0.43	7.63	0.33	1.36e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs1865760	0.865	rs4478388	chr6:25953633	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.59	-0.33	1.8e-13	Height;
LGG	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg17145862	chr1:211918768	LPGAT1	0.95	24.16	0.75	5.08e-84	Leprosy;
LGG	cis	rs2882926	0.697	rs16929279	chr8:63521558	A/G	cg20602954	chr8:63776762	NKAIN3	0.5	6.67	0.3	7.16e-11	Periodontitis (PAL4Q3);
LGG	cis	rs17209837	0.646	rs4148818	chr7:87083738	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.68	-0.59	9.41e-45	Gallbladder cancer;
LGG	cis	rs3816183	0.656	rs4953576	chr2:42935656	A/G	cg14631114	chr2:43023945	NA	0.36	7.18	0.32	2.86e-12	Hypospadias;
LGG	cis	rs611744	0.647	rs647907	chr8:109251374	T/C	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	trans	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.63	-0.41	3.91e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs116095464	1.000	rs56095714	chr5:311256	C/T	cg22857025	chr5:266934	NA	-1.38	-12.92	-0.51	8.07e-33	Breast cancer;
LGG	cis	rs36051895	0.664	rs10115172	chr9:5098549	C/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.49	-0.58	6.8e-44	Pediatric autoimmune diseases;
LGG	cis	rs2640806	0.670	rs7822351	chr8:97326087	T/G	cg22138393	chr8:97340270	PTDSS1	0.3	7.73	0.34	6.52e-14	Obesity-related traits;
LGG	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg03806693	chr22:41940476	POLR3H	0.98	16.27	0.6	2.17e-47	Vitiligo;
LGG	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg08851530	chr6:28072375	NA	-0.8	-6.66	-0.3	7.54e-11	Parkinson's disease;
LGG	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg25358565	chr5:93447407	FAM172A	1.39	17.13	0.62	2.67e-51	Diabetic retinopathy;
LGG	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg12982090	chr3:42733453	KBTBD5	0.97	16.04	0.6	2.31e-46	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7552404	0.924	rs1313071	chr1:76195542	C/G	cg10523679	chr1:76189770	ACADM	0.77	14.76	0.57	1.13e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9381040	0.610	rs2235678	chr6:41020510	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.73	-0.3	4.96e-11	Alzheimer's disease (late onset);
LGG	cis	rs796364	1.000	rs1704186	chr2:200769539	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs6594499	0.500	rs12514810	chr5:110455357	T/A	cg04022379	chr5:110408740	TSLP	0.47	7.94	0.35	1.55e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.26	31.97	0.83	2.98e-119	Chronic sinus infection;
LGG	cis	rs2204008	0.619	rs8189576	chr12:38307275	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.15	-0.49	1.13e-29	Bladder cancer;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg26338869	chr17:61819248	STRADA	-0.56	-9.19	-0.39	1.34e-18	Prudent dietary pattern;
LGG	cis	rs4950322	0.570	rs3737855	chr1:146742918	G/A	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	trans	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg06521331	chr12:34319734	NA	-0.52	-8.74	-0.38	4.23e-17	Bladder cancer;
LGG	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg15704280	chr7:45808275	SEPT13	-0.58	-9.97	-0.42	2.42e-21	HDL cholesterol;
LGG	cis	rs1572438	0.811	rs6916781	chr6:880493	G/A	cg21062780	chr6:887772	NA	0.36	6.76	0.3	4.26e-11	Aging;
LGG	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg05091796	chr16:4465799	CORO7	-1.04	-18.87	-0.66	2.53e-59	Schizophrenia;
LGG	cis	rs283228	0.958	rs2518337	chr6:101765942	C/T	cg27451362	chr6:101846650	GRIK2	0.53	8.89	0.38	1.32e-17	Coenzyme Q10 levels;
LGG	cis	rs12291225	0.679	rs11023172	chr11:14295367	C/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.71	-0.48	6.4e-28	Sense of smell;
LGG	cis	rs735396	1.000	rs1169309	chr12:121439192	G/T	cg14101638	chr12:121416612	HNF1A	0.36	7.48	0.33	3.76e-13	N-glycan levels;
LGG	cis	rs216026	0.638	rs12312322	chr12:2771806	A/G	cg19945202	chr12:2788847	CACNA1C	-0.66	-9.62	-0.41	4.33e-20	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15369054	chr17:80825471	TBCD	-0.55	-10.0	-0.42	1.86e-21	Breast cancer;
LGG	cis	rs1577917	0.559	rs1173418	chr6:86402916	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.46	0.47	6.07e-27	Response to antipsychotic treatment;
LGG	trans	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg20587970	chr11:113659929	NA	-1.28	-23.37	-0.74	2.35e-80	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2486288	0.656	rs12911861	chr15:45566718	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.64	-11.06	-0.46	2.11e-25	Glomerular filtration rate;
LGG	cis	rs5758511	0.514	rs5751240	chr22:42595258	G/C	cg15128208	chr22:42549153	NA	0.78	12.06	0.49	2.56e-29	Birth weight;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg02725872	chr8:58115012	NA	-0.94	-13.15	-0.52	8.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.516	rs9379818	chr6:26023206	G/T	cg18357526	chr6:26021779	HIST1H4A	0.48	7.92	0.35	1.8e-14	Height;
LGG	cis	rs67133203	0.606	rs11169743	chr12:51575533	G/C	cg14688905	chr12:51403056	SLC11A2	0.58	8.96	0.38	7.71e-18	Urinary tract infection frequency;
LGG	cis	rs3768617	0.510	rs1413390	chr1:183096634	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6964587	0.692	rs10227225	chr7:91571074	A/G	cg17063962	chr7:91808500	NA	-0.5	-9.39	-0.4	2.79e-19	Breast cancer;
LGG	cis	rs526231	0.543	rs27698	chr5:102526175	C/T	cg23492399	chr5:102201601	PAM	0.56	8.29	0.36	1.22e-15	Primary biliary cholangitis;
LGG	cis	rs738321	0.757	rs3788534	chr22:38533971	A/T	cg03162506	chr22:38580953	NA	0.4	10.01	0.42	1.73e-21	Breast cancer;
LGG	cis	rs1023500	0.573	rs6002592	chr22:42476754	A/C	cg15557168	chr22:42548783	NA	0.39	8.5	0.37	2.69e-16	Schizophrenia;
LGG	cis	rs11711311	1.000	rs9848993	chr3:113497914	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.51	-0.33	3.01e-13	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs55993747	chr6:149943152	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.64	-0.41	3.71e-20	Lung cancer;
LGG	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs7208859	0.673	rs999798	chr17:29158840	A/G	cg19761014	chr17:28927070	LRRC37B2	0.53	6.78	0.3	3.77e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7945718	0.621	rs7481252	chr11:12681682	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.2	0.32	2.46e-12	Educational attainment (years of education);
LGG	cis	rs6714710	0.603	rs78006955	chr2:98455510	G/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg25706281	chr1:46860511	FAAH	0.3	7.36	0.32	8.67e-13	Menopause (age at onset);
LGG	cis	rs7103648	0.864	rs12801188	chr11:47388214	G/A	cg20307385	chr11:47447363	PSMC3	0.92	20.56	0.69	3.3e-67	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs597539	0.652	rs544370	chr11:68653232	C/T	cg18350739	chr11:68623251	NA	-0.85	-21.88	-0.71	2.12e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.522	rs9530	chr7:65425894	A/G	cg18876405	chr7:65276391	NA	0.71	13.65	0.54	7.03e-36	Aortic root size;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25346576	chr17:28443852	CCDC55;MIR423	0.45	7.57	0.33	2.11e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-12.8	-0.51	2.49e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg10503236	chr1:231470652	EXOC8	-0.35	-6.68	-0.3	6.68e-11	Hemoglobin concentration;
LGG	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg05527609	chr1:210001259	C1orf107	0.49	6.9	0.31	1.67e-11	Red blood cell count;
LGG	cis	rs2290159	0.800	rs28462331	chr3:12660466	G/C	cg23032965	chr3:12705835	RAF1	0.67	9.71	0.41	2.03e-20	Cholesterol, total;
LGG	cis	rs1005277	0.579	rs116912400	chr10:38479207	G/T	cg25427524	chr10:38739819	LOC399744	-0.66	-12.39	-0.5	1.19e-30	Extrinsic epigenetic age acceleration;
LGG	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg23188684	chr11:67383651	NA	-0.41	-6.7	-0.3	6.18e-11	Mean corpuscular volume;
LGG	cis	rs4671458	0.626	rs72806058	chr2:63842399	C/T	cg17519650	chr2:63277830	OTX1	-0.54	-7.27	-0.32	1.56e-12	Subjective well-being;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.2	0.32	2.38e-12	Obesity-related traits;
LGG	cis	rs1943345	0.731	rs498292	chr11:82903283	C/T	cg07047830	chr11:82868014	PCF11	0.64	12.22	0.49	5.95e-30	Obesity-related traits;
LGG	cis	rs13418410	0.539	rs35866672	chr2:33842174	G/A	cg04131969	chr2:33951647	MYADML	-0.69	-12.47	-0.5	5.71e-31	Non-response to antidepressants and depression;
LGG	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg25319279	chr11:5960081	NA	-0.54	-8.65	-0.37	8.61e-17	DNA methylation (variation);
LGG	cis	rs1577917	0.958	rs10944136	chr6:86448499	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.32	-0.5	2.41e-30	Response to antipsychotic treatment;
LGG	cis	rs896854	0.902	rs896852	chr8:95960886	G/T	cg13393036	chr8:95962371	TP53INP1	-0.26	-6.89	-0.3	1.82e-11	Type 2 diabetes;
LGG	cis	rs4684776	0.935	rs12636305	chr3:11418924	T/G	cg24705426	chr3:11550659	ATG7	-0.41	-7.37	-0.32	7.79e-13	Small vessel stroke;
LGG	cis	rs72772090	0.539	rs72773969	chr5:96145196	C/T	cg00188032	chr5:96141721	ERAP1	0.55	7.26	0.32	1.63e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12431204	0.803	rs1538148	chr13:38438843	T/C	cg23307680	chr13:38443104	TRPC4	0.4	6.94	0.31	1.35e-11	Schizophrenia;
LGG	cis	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg22676075	chr6:135203613	NA	0.37	6.69	0.3	6.52e-11	Red blood cell count;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.28	-0.32	1.46e-12	Lung cancer;
LGG	trans	rs561341	1.000	rs8064843	chr17:30245744	A/G	cg27661571	chr11:113659931	NA	-0.59	-8.58	-0.37	1.5e-16	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg26597838	chr10:835615	NA	0.76	10.49	0.44	3.08e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs10754283	0.934	rs6684676	chr1:90102173	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.25	0.49	4.47e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg10845886	chr2:3471009	TTC15	-0.48	-9.47	-0.4	1.41e-19	Neurofibrillary tangles;
LGG	cis	rs6663390	0.510	rs2267897	chr1:208075378	C/T	cg03990033	chr1:208084030	CD34	0.58	7.76	0.34	5.43e-14	Facial morphology (factor 18);
LGG	cis	rs701145	0.585	rs1727887	chr3:153839465	G/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs7712401	0.601	rs390234	chr5:122331523	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs9611565	0.559	rs4822049	chr22:41993496	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Vitiligo;
LGG	trans	rs7824557	0.564	rs2736295	chr8:11234780	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.29	0.4	6.18e-19	Retinal vascular caliber;
LGG	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg22044901	chr15:68126292	NA	-0.4	-6.87	-0.3	2.12e-11	Restless legs syndrome;
LGG	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg19723775	chr5:179050963	HNRNPH1	0.63	10.12	0.43	6.74e-22	Lung cancer;
LGG	cis	rs829402	0.836	rs829373	chr1:21988563	C/T	cg20487231	chr1:21986101	RAP1GAP	0.55	11.54	0.47	3.11e-27	High light scatter reticulocyte count;
LGG	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg12615879	chr12:58013172	SLC26A10	0.38	8.75	0.38	3.93e-17	Multiple sclerosis;
LGG	cis	rs10911232	0.524	rs10911209	chr1:183013988	T/G	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs17021463	0.902	rs34465979	chr4:95257554	C/A	cg11021082	chr4:95130006	SMARCAD1	0.51	9.34	0.4	4.19e-19	Testicular germ cell tumor;
LGG	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.47	0.33	4.04e-13	Asthma (sex interaction);
LGG	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.65	-0.41	3.45e-20	Retinal vascular caliber;
LGG	cis	rs36051895	0.632	rs11793886	chr9:5125469	A/G	cg02405213	chr9:5042618	JAK2	-0.8	-14.97	-0.57	1.36e-41	Pediatric autoimmune diseases;
LGG	cis	rs10739663	0.520	rs3122937	chr9:128154808	A/G	cg14078157	chr9:128172775	NA	-0.57	-10.82	-0.45	1.7e-24	Resting heart rate;
LGG	cis	rs2011503	0.941	rs56278919	chr19:19367190	A/G	cg01262667	chr19:19385393	TM6SF2	0.35	6.78	0.3	3.61e-11	Bipolar disorder;
LGG	cis	rs8038465	0.638	rs8036954	chr15:73974282	T/C	cg15420318	chr15:73925796	NPTN	0.41	7.01	0.31	8.29e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9326248	0.953	rs488962	chr11:117072525	C/T	cg11861562	chr11:117069780	TAGLN	-0.26	-6.96	-0.31	1.16e-11	Blood protein levels;
LGG	cis	rs992157	0.965	rs62182826	chr2:219148723	C/A	cg04731861	chr2:219085781	ARPC2	-0.41	-9.83	-0.42	7.66e-21	Colorectal cancer;
LGG	cis	rs7241530	0.662	rs924887	chr18:75900912	C/G	cg14642773	chr18:75888474	NA	0.46	9.07	0.39	3.44e-18	Educational attainment (years of education);
LGG	cis	rs1048238	0.506	rs848210	chr1:16259813	A/G	cg21385522	chr1:16154831	NA	-0.52	-9.35	-0.4	3.62e-19	Systolic blood pressure;
LGG	trans	rs3206736	0.549	rs10282424	chr7:35211135	A/G	cg14337134	chr7:102920323	DPY19L2P2	-0.41	-7.14	-0.31	3.74e-12	Diastolic blood pressure;
LGG	cis	rs6750047	0.515	rs13417487	chr2:38289162	G/T	cg07380506	chr2:38303506	CYP1B1	0.44	7.35	0.32	9.17e-13	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs11098499	0.722	rs17595727	chr4:120262074	C/T	cg24375607	chr4:120327624	NA	-0.54	-9.22	-0.39	1.03e-18	Corneal astigmatism;
LGG	cis	rs4253772	0.550	rs6008729	chr22:46727428	C/G	cg24881330	chr22:46731750	TRMU	-0.63	-6.72	-0.3	5.31e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4363385	0.818	rs574649	chr1:153008471	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs10949834	1.000	rs8326	chr7:73483689	G/C	cg07137043	chr7:73588983	EIF4H	-0.61	-6.9	-0.31	1.73e-11	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs7166081	1.000	rs12443279	chr15:67561355	C/G	cg05925327	chr15:68127851	NA	-0.33	-7.09	-0.31	5.03e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3806843	1.000	rs3733710	chr5:140167463	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2735413	0.918	rs56397244	chr16:78081366	A/T	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.42	7.42	0.33	5.72e-13	Bipolar disorder;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25172604	chr17:41446521	NA	-0.3	-7.02	-0.31	8.03e-12	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs8131143	chr21:46671646	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-13.11	-0.52	1.25e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11229555	0.645	rs34794607	chr11:58188401	A/T	cg15696309	chr11:58395628	NA	-0.97	-15.58	-0.59	2.53e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2976388	0.647	rs2572898	chr8:143782274	G/C	cg06565975	chr8:143823917	SLURP1	0.37	9.32	0.4	4.83e-19	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14082241	chr19:10982830	CARM1	0.61	9.41	0.4	2.35e-19	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.717	rs62052210	chr16:89980158	A/G	cg04287289	chr16:89883240	FANCA	0.71	7.88	0.34	2.31e-14	Skin colour saturation;
LGG	cis	rs193541	0.632	rs119449	chr5:122283741	T/G	cg19412675	chr5:122181750	SNX24	0.57	9.12	0.39	2.31e-18	Glucose homeostasis traits;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.93	-0.31	1.44e-11	Prostate cancer;
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.74	0.38	4.26e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg13009111	chr11:71350975	NA	0.34	7.52	0.33	2.87e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4974559	0.790	rs5019560	chr4:1324793	G/A	cg02980000	chr4:1222292	CTBP1	0.75	10.8	0.45	2.08e-24	Systolic blood pressure;
LGG	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.32	0.32	1.09e-12	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg08621203	chr6:150244597	RAET1G	0.47	8.15	0.35	3.42e-15	Lung cancer;
LGG	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg07606381	chr6:8435919	SLC35B3	-0.65	-11.89	-0.48	1.22e-28	Motion sickness;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.63e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.67	12.24	0.49	4.96e-30	Obesity-related traits;
LGG	cis	rs875971	0.862	rs6460306	chr7:66060793	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.2e-20	Aortic root size;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.5	7.49	0.33	3.46e-13	Renal function-related traits (BUN);
LGG	trans	rs11650494	0.831	rs11650886	chr17:47449193	G/A	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.36e-12	Prostate cancer;
LGG	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg26119090	chr2:26468346	HADHA;HADHB	0.93	15.42	0.58	1.37e-43	Gut microbiome composition (summer);
LGG	cis	rs11626933	0.589	rs10140761	chr14:90740588	G/C	cg14092571	chr14:90743983	NA	0.55	10.36	0.43	9.65e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg26354017	chr1:205819088	PM20D1	0.46	7.65	0.33	1.18e-13	Parkinson's disease;
LGG	cis	rs7647973	0.710	rs12637313	chr3:49645458	A/G	cg07636037	chr3:49044803	WDR6	0.54	7.22	0.32	2.09e-12	Menarche (age at onset);
LGG	cis	rs1869026	1.000	rs9308615	chr2:121338985	T/C	cg13274077	chr2:121334614	NA	-0.32	-7.55	-0.33	2.4e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2274273	0.662	rs66476033	chr14:55660863	C/A	cg04306507	chr14:55594613	LGALS3	0.51	11.86	0.48	1.69e-28	Protein biomarker;
LGG	cis	rs4474465	1.000	rs57042969	chr11:78160120	C/T	cg27205649	chr11:78285834	NARS2	-0.49	-8.36	-0.36	7.42e-16	Alzheimer's disease (survival time);
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg14036092	chr11:66035641	RAB1B	0.45	7.9	0.34	2.09e-14	Gout;
LGG	cis	rs2734839	0.964	rs12808482	chr11:113294998	T/A	cg14159747	chr11:113255604	NA	0.27	7.06	0.31	6.24e-12	Information processing speed;
LGG	cis	rs1005277	0.579	rs2474586	chr10:38418882	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.46e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs2562456	0.833	rs62107479	chr19:21506764	G/A	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs9522267	1.000	rs1411628	chr13:112199321	G/A	cg10483660	chr13:112241077	NA	-0.37	-7.36	-0.32	8.57e-13	Hepatitis;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg17392909	chr10:135187035	ECHS1	0.38	6.68	0.3	6.8e-11	Corneal astigmatism;
LGG	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg00990874	chr7:1149470	C7orf50	0.71	11.45	0.47	6.98e-27	Bronchopulmonary dysplasia;
LGG	cis	rs4073582	0.595	rs10896104	chr11:66001869	C/T	cg16950941	chr11:66035639	RAB1B	0.56	10.25	0.43	2.4e-22	Gout;
LGG	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.32	0.4	4.74e-19	Fuchs's corneal dystrophy;
LGG	cis	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg04455712	chr21:45112962	RRP1B	0.55	10.08	0.42	9.95e-22	Mean corpuscular volume;
LGG	cis	rs57221529	0.766	rs12521988	chr5:556421	C/T	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs2072732	0.861	rs77840846	chr1:2968983	G/C	cg08733933	chr1:2954429	NA	-0.46	-8.74	-0.38	4.46e-17	Plateletcrit;
LGG	cis	rs7737355	0.812	rs12655240	chr5:130752006	G/A	cg06307176	chr5:131281290	NA	-0.52	-8.68	-0.37	6.84e-17	Life satisfaction;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg18402987	chr7:1209562	NA	0.63	8.6	0.37	1.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7312933	0.558	rs11181403	chr12:42682902	G/A	cg19980929	chr12:42632907	YAF2	0.4	9.07	0.39	3.48e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg03959625	chr15:84868606	LOC388152	0.47	7.06	0.31	6.08e-12	Schizophrenia;
LGG	cis	rs9815354	0.680	rs73075231	chr3:42051694	T/C	cg03022575	chr3:42003672	ULK4	0.74	8.27	0.36	1.39e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9457247	0.602	rs10484530	chr6:167461562	C/T	cg07741184	chr6:167504864	NA	0.44	10.07	0.42	1.03e-21	Crohn's disease;
LGG	cis	rs13421350	0.579	rs74483274	chr2:173303251	A/G	cg15021238	chr2:173305865	ITGA6	-0.8	-9.0	-0.39	6.04e-18	Diabetic kidney disease;
LGG	cis	rs9910055	0.708	rs2631298	chr17:42219832	T/C	cg13607699	chr17:42295918	UBTF	0.55	9.26	0.4	7.86e-19	Total body bone mineral density;
LGG	cis	rs2762353	0.808	rs1183201	chr6:25823444	A/T	cg12310025	chr6:25882481	NA	-0.58	-11.32	-0.47	2.24e-26	Blood metabolite levels;
LGG	cis	rs801193	0.591	rs2707839	chr7:66193084	A/G	cg11764359	chr7:65958608	NA	0.78	14.65	0.56	3.27e-40	Aortic root size;
LGG	cis	rs7000551	0.751	rs2449341	chr8:22390937	C/A	cg12081754	chr8:22256438	SLC39A14	0.63	11.8	0.48	2.94e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9309473	1.000	rs11901272	chr2:73720444	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-7.56	-0.33	2.2e-13	Metabolite levels;
LGG	trans	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.71e-27	Corneal astigmatism;
LGG	trans	rs9650657	0.812	rs11250072	chr8:10632121	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.05	-0.31	6.59e-12	Neuroticism;
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg01570182	chr17:44337453	NA	-0.65	-10.85	-0.45	1.36e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-6.96	-0.31	1.17e-11	Personality dimensions;
LGG	cis	rs55823223	0.648	rs11869977	chr17:73857382	C/G	cg10935138	chr17:73851978	WBP2	0.62	8.79	0.38	3.05e-17	Psoriasis;
LGG	cis	rs10799590	1.000	rs7537973	chr1:224831281	T/C	cg01808320	chr1:224927238	CNIH3	-0.38	-6.79	-0.3	3.36e-11	Opioid dependence;
LGG	cis	rs778371	0.723	rs10210953	chr2:233698830	G/A	cg08000102	chr2:233561755	GIGYF2	-0.74	-12.5	-0.5	4.25e-31	Schizophrenia;
LGG	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg00198680	chr16:28758506	NA	0.3	7.39	0.32	6.84e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8180040	0.903	rs2276853	chr3:47282303	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.37	-0.58	2.35e-43	Colorectal cancer;
LGG	cis	rs72781680	1.000	rs72781632	chr2:24198342	A/C	cg08917208	chr2:24149416	ATAD2B	0.93	10.18	0.43	4.41e-22	Lymphocyte counts;
LGG	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.15	-0.35	3.41e-15	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500395	1.000	rs7195684	chr16:48710750	G/A	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2727020	0.729	rs4315497	chr11:49214499	G/A	cg15704280	chr7:45808275	SEPT13	0.9	18.55	0.65	7.47e-58	Coronary artery disease;
LGG	cis	rs1862618	0.853	rs832553	chr5:56114786	A/G	cg12654349	chr5:56205094	C5orf35	-0.68	-10.7	-0.45	5.08e-24	Initial pursuit acceleration;
LGG	cis	rs17739794	0.677	rs17739674	chr8:801584	G/T	cg20652464	chr8:752313	NA	-0.36	-7.31	-0.32	1.15e-12	Clozapine-induced cytotoxicity;
LGG	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg02733842	chr7:1102375	C7orf50	0.74	10.88	0.45	1.03e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg13010199	chr12:38710504	ALG10B	-0.65	-13.39	-0.53	8.59e-35	Bladder cancer;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.534	rs11053010	chr12:34093228	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.1	-0.46	1.57e-25	Morning vs. evening chronotype;
LGG	cis	rs2373794	0.885	rs11688023	chr2:40379040	A/G	cg17740179	chr2:40377776	SLC8A1	0.89	17.08	0.62	4.27e-51	Asthma;
LGG	cis	rs1595825	0.891	rs60484833	chr2:198812181	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.86	-0.3	2.15e-11	Ulcerative colitis;
LGG	cis	rs11229555	0.645	rs12226725	chr11:58246332	G/A	cg15696309	chr11:58395628	NA	-0.97	-15.79	-0.59	3e-45	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4696584	0.816	rs72729002	chr4:155405405	A/G	cg04517429	chr4:155413618	DCHS2	-0.32	-7.45	-0.33	4.6e-13	Folding of antihelix;
LGG	cis	rs9517320	0.534	rs61969451	chr13:99167654	A/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.79	-0.45	2.34e-24	Longevity;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg06637938	chr14:75390232	RPS6KL1	0.56	10.33	0.43	1.17e-22	Coronary artery disease;
LGG	cis	rs4363385	0.747	rs6671414	chr1:152974119	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.37e-18	Inflammatory skin disease;
LGG	cis	rs16854884	0.690	rs35885310	chr3:143771333	A/G	cg06585982	chr3:143692056	C3orf58	0.63	10.83	0.45	1.68e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.71	-9.62	-0.41	4.22e-20	Diabetic retinopathy;
LGG	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg27490568	chr2:178487706	NA	0.66	11.87	0.48	1.53e-28	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2797369	0.570	rs1928070	chr6:101583773	G/T	cg27451362	chr6:101846650	GRIK2	0.56	8.32	0.36	1e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs9880211	1.000	rs13092193	chr3:136240366	T/C	cg21827317	chr3:136751795	NA	-0.48	-7.17	-0.32	2.91e-12	Body mass index;Height;
LGG	cis	rs2370759	1.000	rs78959390	chr10:32616346	C/T	cg01819863	chr10:32635814	EPC1	1.11	15.46	0.58	9.12e-44	Sexual dysfunction (female);
LGG	cis	rs7737355	1.000	rs9327608	chr5:130650134	G/A	cg06307176	chr5:131281290	NA	0.5	8.42	0.36	4.75e-16	Life satisfaction;
LGG	cis	rs1355223	1.000	rs11602909	chr11:34768003	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.25	-0.32	1.81e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2274273	0.624	rs66464079	chr14:55766164	G/T	cg04306507	chr14:55594613	LGALS3	0.54	12.57	0.5	2.2e-31	Protein biomarker;
LGG	cis	rs17818399	0.815	rs35837037	chr2:46861300	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.18	-0.39	1.39e-18	Height;
LGG	cis	rs35883536	0.611	rs61070860	chr1:101097628	G/A	cg06223162	chr1:101003688	GPR88	0.35	7.93	0.35	1.67e-14	Monocyte count;
LGG	trans	rs1908814	0.516	rs10113145	chr8:11793295	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.71	0.34	7.94e-14	Lung cancer;
LGG	cis	rs240764	0.853	rs11155496	chr6:100988939	T/C	cg21058520	chr6:100914733	NA	0.41	7.14	0.31	3.74e-12	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21930443	chr17:28443747	CCDC55;MIR423	0.38	6.75	0.3	4.31e-11	Obesity-related traits;
LGG	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7615952	0.641	rs6438951	chr3:125696999	A/G	cg04553112	chr3:125709451	NA	-0.55	-6.98	-0.31	1.01e-11	Blood pressure (smoking interaction);
LGG	cis	rs72615157	0.716	rs75779608	chr7:99768957	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.69	-9.4	-0.4	2.46e-19	Lung function (FEV1/FVC);
LGG	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg04731861	chr2:219085781	ARPC2	-0.42	-10.15	-0.43	5.38e-22	Colorectal cancer;
LGG	cis	rs988958	0.530	rs12996334	chr2:42218684	G/A	cg19376973	chr2:42229025	NA	0.65	9.31	0.4	5.08e-19	Hypospadias;
LGG	cis	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg18131467	chr2:239335373	ASB1	-0.66	-6.69	-0.3	6.43e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg14541582	chr5:601475	NA	-0.71	-11.11	-0.46	1.34e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs12369635	0.929	rs3851667	chr12:129550552	G/T	cg01909103	chr12:129572610	TMEM132D	0.7	7.2	0.32	2.43e-12	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs3816183	0.626	rs4952908	chr2:42912265	G/C	cg14631114	chr2:43023945	NA	0.34	6.86	0.3	2.27e-11	Hypospadias;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg15971980	chr6:150254442	NA	0.43	8.15	0.35	3.45e-15	Lung cancer;
LGG	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg06108461	chr20:60628389	TAF4	-0.73	-13.08	-0.52	1.8e-33	Body mass index;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg23752198	chr20:30311963	BCL2L1	-0.42	-6.65	-0.3	8.35e-11	Body fat mass;
LGG	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.26e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09866690	chr7:100081329	C7orf51	0.46	7.07	0.31	5.83e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg24846343	chr22:24311635	DDTL	0.6	12.05	0.49	2.76e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg11062466	chr8:58055876	NA	0.5	7.98	0.35	1.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1109114	0.816	rs2918278	chr5:148596841	G/A	cg06539116	chr5:148597365	ABLIM3	-0.62	-16.52	-0.61	1.6e-48	Body mass index;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg00424166	chr6:150045504	NUP43	0.35	7.29	0.32	1.33e-12	Lung cancer;
LGG	cis	rs1570884	0.539	rs7982445	chr13:50111622	C/T	cg11801959	chr13:50123613	RCBTB1	-0.38	-6.71	-0.3	5.65e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs4423214	0.840	rs1790339	chr11:71182761	C/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	8.45e-26	Vitamin D levels;
LGG	cis	rs1790761	0.505	rs34802338	chr11:67312466	G/A	cg00864171	chr11:67383662	NA	-0.45	-7.38	-0.32	7.55e-13	Mean corpuscular volume;
LGG	cis	rs4750440	0.733	rs2446585	chr10:14028086	C/T	cg27542038	chr10:14027202	FRMD4A	-0.6	-11.65	-0.48	1.15e-27	Adiponectin levels;
LGG	cis	rs62238980	0.614	rs77407792	chr22:32461465	C/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg26260386	chr4:140477698	SETD7	0.43	7.3	0.32	1.23e-12	Body mass index;
LGG	cis	rs2273669	0.915	rs6568554	chr6:109290319	C/A	cg05315195	chr6:109294784	ARMC2	-0.52	-7.29	-0.32	1.33e-12	Prostate cancer;
LGG	cis	rs526231	0.575	rs62362523	chr5:102313683	C/T	cg23492399	chr5:102201601	PAM	-0.62	-9.34	-0.4	4.14e-19	Primary biliary cholangitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05213609	chr16:51185407	SALL1	0.51	8.22	0.36	1.99e-15	Cognitive performance;
LGG	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg18876405	chr7:65276391	NA	0.45	7.78	0.34	4.75e-14	Calcium levels;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg21724239	chr8:58056113	NA	-0.47	-7.18	-0.32	2.81e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.544	rs7871232	chr9:15813871	C/T	cg14451791	chr9:16040625	NA	0.32	7.86	0.34	2.81e-14	Body mass index;
LGG	cis	rs2806561	0.796	rs1738467	chr1:23506521	C/T	cg19743168	chr1:23544995	NA	0.34	6.84	0.3	2.53e-11	Height;
LGG	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.5	8.08	0.35	5.82e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs858239	0.539	rs4294098	chr7:23185995	G/A	cg23682824	chr7:23144976	KLHL7	0.41	6.76	0.3	4.13e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs35740288	0.731	rs12913556	chr15:86102196	C/T	cg04173714	chr15:86211321	AKAP13	0.48	8.65	0.37	8.73e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg16507663	chr6:150244633	RAET1G	0.44	7.94	0.35	1.59e-14	Lung cancer;
LGG	trans	rs8073060	0.586	rs226090	chr17:34034059	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.44	-0.63	9.62e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6445975	0.666	rs4390943	chr3:58376639	A/C	cg24175188	chr3:58374923	PXK	0.55	8.99	0.39	6.46e-18	Systemic lupus erythematosus;
LGG	cis	rs36051895	0.632	rs11788963	chr9:5120157	C/A	cg02405213	chr9:5042618	JAK2	-0.8	-14.88	-0.57	3.18e-41	Pediatric autoimmune diseases;
LGG	cis	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg24623649	chr8:11872141	NA	0.29	6.71	0.3	5.66e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7737355	0.645	rs7731071	chr5:130973483	A/G	cg06307176	chr5:131281290	NA	0.57	9.33	0.4	4.51e-19	Life satisfaction;
LGG	cis	rs6460942	1.000	rs6460936	chr7:12404913	T/C	cg06484146	chr7:12443880	VWDE	-0.4	-6.86	-0.3	2.19e-11	Coronary artery disease;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.54	-0.33	2.45e-13	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14439950	chr11:64901879	SYVN1	0.46	6.96	0.31	1.15e-11	Gut microbiome composition (summer);
LGG	cis	rs6594713	0.679	rs9326890	chr5:112859994	C/T	cg12552261	chr5:112820674	MCC	0.6	7.77	0.34	5.01e-14	Brain cytoarchitecture;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	14.11	0.55	7.41e-38	Platelet count;
LGG	trans	rs11250097	0.506	rs13281992	chr8:11309294	C/T	cg16141378	chr3:129829833	LOC729375	0.37	7.93	0.35	1.61e-14	Neuroticism;
LGG	cis	rs2274273	0.773	rs8012380	chr14:55735010	T/G	cg04306507	chr14:55594613	LGALS3	0.64	17.83	0.64	1.56e-54	Protein biomarker;
LGG	cis	rs977987	0.527	rs62059844	chr16:75429737	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	cis	rs2032447	0.802	rs198853	chr6:26104096	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.87	-16.99	-0.62	1.1e-50	Intelligence (multi-trait analysis);
LGG	cis	rs4938330	0.681	rs12271169	chr11:116980021	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.62	-8.78	-0.38	3.1e-17	Blood protein levels;
LGG	cis	rs2841277	0.771	rs2819469	chr14:105394859	G/A	cg22072935	chr14:105399595	NA	-0.5	-9.54	-0.41	8.36e-20	Rheumatoid arthritis;
LGG	trans	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg25214090	chr10:38739885	LOC399744	0.61	10.49	0.44	2.94e-23	Corneal astigmatism;
LGG	cis	rs137887	0.817	rs137888	chr22:50464496	G/A	cg17558497	chr22:50464837	TTLL8	0.39	7.21	0.32	2.32e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg27523141	chr10:43048294	ZNF37B	0.39	7.73	0.34	6.84e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs875971	0.505	rs1167385	chr7:65513308	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.3	-0.43	1.5e-22	Aortic root size;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.78	-0.61	1.06e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.7	-0.34	8.11e-14	Neuroticism;
LGG	cis	rs2562456	0.917	rs2681377	chr19:21716520	T/C	cg00806126	chr19:22604979	ZNF98	0.64	9.53	0.4	9.2e-20	Pain;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg12950624	chr19:46000154	RTN2	-0.38	-7.14	-0.31	3.64e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs2727020	0.637	rs1164673	chr11:49328356	C/G	cg15704280	chr7:45808275	SEPT13	0.69	11.65	0.48	1.13e-27	Coronary artery disease;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.57	-0.33	2.07e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs9311474	0.659	rs1133415	chr3:52575831	G/A	cg14092988	chr3:52407081	DNAH1	0.27	7.13	0.31	3.76e-12	Electroencephalogram traits;
LGG	cis	rs2153535	0.580	rs2184582	chr6:8447793	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs2228479	0.850	rs1800339	chr16:89839637	C/A	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs1784581	0.775	rs7755404	chr6:162427731	T/C	cg17173639	chr6:162384350	PARK2	0.76	17.84	0.64	1.49e-54	Itch intensity from mosquito bite;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.48	-0.33	3.65e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg22980697	chr10:16874865	CUBN	0.57	9.46	0.4	1.62e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs62400317	0.731	rs12198982	chr6:45077914	C/A	cg20913747	chr6:44695427	NA	-0.57	-8.56	-0.37	1.64e-16	Total body bone mineral density;
LGG	cis	rs155076	0.702	rs482731	chr13:21846075	G/A	cg06138931	chr13:21896616	NA	-0.44	-7.22	-0.32	2.17e-12	White matter hyperintensity burden;
LGG	cis	rs3008870	1.000	rs4620509	chr1:67449941	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs28386778	0.897	rs894413	chr17:61916347	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.07	0.35	6.1e-15	Prudent dietary pattern;
LGG	cis	rs2635047	0.638	rs16954999	chr18:44610718	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.36	0.36	7.57e-16	Educational attainment;
LGG	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg08250081	chr4:10125330	NA	-0.48	-9.52	-0.4	9.83e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7166081	1.000	rs10152913	chr15:67647328	A/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.2	-0.32	2.38e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg08677398	chr8:58056175	NA	0.42	6.74	0.3	4.82e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.502	rs7124996	chr11:116928006	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04949219	chr11:64863633	C11orf2	0.48	7.25	0.32	1.79e-12	Gut microbiome composition (summer);
LGG	cis	rs11866815	0.901	rs758033	chr16:397044	G/T	cg26913058	chr16:419975	MRPL28	-0.49	-7.56	-0.33	2.18e-13	Body mass index;
LGG	cis	rs7394190	0.748	rs4114992	chr10:75566829	A/G	cg07699608	chr10:75541558	CHCHD1	0.53	7.35	0.32	9e-13	Incident atrial fibrillation;
LGG	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.57	0.44	1.57e-23	Cognitive test performance;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18876457	chr1:160071037	NA	0.39	6.65	0.3	8.37e-11	Menarche (age at onset);
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg05941027	chr17:61774174	LIMD2	0.34	8.43	0.36	4.57e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.61	-0.71	3.77e-72	Height;
LGG	cis	rs62238980	0.522	rs117086479	chr22:32389342	A/G	cg00543991	chr22:32367038	NA	0.8	8.9	0.38	1.27e-17	Childhood ear infection;
LGG	cis	rs763121	0.819	rs4560233	chr22:38982442	A/T	cg06022373	chr22:39101656	GTPBP1	0.86	17.27	0.63	6.04e-52	Menopause (age at onset);
LGG	cis	rs12681287	0.608	rs13270090	chr8:87553297	T/A	cg27223183	chr8:87520930	FAM82B	0.47	7.16	0.32	3.24e-12	Caudate activity during reward;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	0.625	rs13035260	chr2:201132377	A/G	cg23649088	chr2:200775458	C2orf69	-0.53	-7.58	-0.33	1.84e-13	Schizophrenia;
LGG	trans	rs6089829	0.962	rs6122352	chr20:61668284	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.3e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg16141378	chr3:129829833	LOC729375	-0.37	-8.32	-0.36	9.96e-16	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1298637	0.683	rs7543581	chr1:53922155	C/T	cg10892335	chr1:53966318	NA	0.51	9.47	0.4	1.5e-19	Nicotine use;
LGG	cis	rs9902453	0.817	rs55974138	chr17:28215546	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.44	0.53	5.25e-35	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27530629	chr1:151693960	C1orf230	0.45	6.79	0.3	3.38e-11	Gut microbiome composition (summer);
LGG	cis	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg16400903	chr5:693638	TPPP	0.45	6.86	0.3	2.2e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.13	0.31	3.87e-12	Lung cancer;
LGG	cis	rs11718455	0.921	rs11130020	chr3:44009459	C/T	cg21419209	chr3:44054225	NA	-0.43	-7.11	-0.31	4.38e-12	Coronary artery disease;
LGG	cis	rs62400317	0.762	rs529125	chr6:44797088	C/T	cg20913747	chr6:44695427	NA	0.66	11.12	0.46	1.26e-25	Total body bone mineral density;
LGG	cis	rs6500395	0.963	rs2111242	chr16:48708300	T/C	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.679	rs12375445	chr8:58040082	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.31	-0.43	1.47e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7572644	0.603	rs4666013	chr2:28019106	C/T	cg27432699	chr2:27873401	GPN1	0.47	6.65	0.3	8.23e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs4319547	0.695	rs10846699	chr12:122853073	A/G	cg05707623	chr12:122985044	ZCCHC8	0.68	10.12	0.43	7.16e-22	Body mass index;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg12288994	chr5:1860383	NA	0.72	13.16	0.52	8.24e-34	Cardiovascular disease risk factors;
LGG	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.79	13.15	0.52	8.67e-34	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg24046927	chr1:87794131	LMO4	0.51	6.65	0.3	8.51e-11	Skin pigmentation;
LGG	cis	rs9880211	0.706	rs9289513	chr3:136451746	G/T	cg21827317	chr3:136751795	NA	-0.46	-6.75	-0.3	4.33e-11	Body mass index;Height;
LGG	trans	rs4650994	1.000	rs10798616	chr1:178515642	G/C	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.1	-0.35	4.83e-15	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs9929218	0.954	rs7186333	chr16:68815838	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.73	-12.59	-0.51	1.85e-31	Colorectal cancer;
LGG	cis	rs1465370	0.682	rs741486	chr7:130024010	C/T	cg06917763	chr7:130033247	NA	-0.34	-7.34	-0.32	9.92e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs4474465	0.850	rs10899538	chr11:78237749	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.81	-0.3	2.96e-11	Alzheimer's disease (survival time);
LGG	cis	rs2075371	1.000	rs378358	chr7:133970628	A/G	cg11752832	chr7:134001865	SLC35B4	0.6	10.83	0.45	1.57e-24	Mean platelet volume;
LGG	cis	rs6964587	1.000	rs1063243	chr7:91726927	A/C	cg17063962	chr7:91808500	NA	0.47	8.33	0.36	9.11e-16	Breast cancer;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg26043149	chr18:55253948	FECH	0.79	13.31	0.53	1.9e-34	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7246865	0.859	rs7252102	chr19:17197012	A/G	cg19418318	chr19:17219073	MYO9B	0.33	8.64	0.37	9.13e-17	Reticulocyte fraction of red cells;
LGG	cis	rs62238980	0.614	rs76463308	chr22:32387270	C/T	cg00543991	chr22:32367038	NA	0.81	8.92	0.38	1.1e-17	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03315687	chr19:40932206	SERTAD1	0.37	6.71	0.3	5.6e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8056893	0.543	rs6499170	chr16:68370673	G/A	cg07273125	chr16:68295692	NA	0.39	8.5	0.37	2.72e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs7619833	0.593	rs2120890	chr3:27271224	C/T	cg02860705	chr3:27208620	NA	0.4	7.7	0.34	8.19e-14	Breast cancer;
LGG	cis	rs7666738	0.830	rs11947578	chr4:98930462	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1997103	1.000	rs4947499	chr7:55407196	T/C	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.17	-0.39	1.56e-18	Obesity-related traits;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.5	-0.33	3.22e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02357321	chr5:140345461	PCDHA7;PCDHAC2;PCDHA12;PCDHA6;PCDHA10;PCDHA4;PCDHA11;PCDHA8;PCDHA1;PCDHA2;PCDHA9;PCDHA13;PCDHA5;PCDHAC1;PCDHA3	0.45	7.11	0.31	4.33e-12	Gut microbiome composition (summer);
LGG	cis	rs12476592	0.602	rs2604614	chr2:63894133	T/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	cis	rs17253792	0.915	rs77161327	chr14:56178565	A/G	cg01858014	chr14:56050164	KTN1	-0.78	-10.01	-0.42	1.77e-21	Putamen volume;
LGG	cis	rs7727544	0.735	rs272894	chr5:131662460	C/T	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.18e-34	Blood metabolite levels;
LGG	cis	rs6120849	0.754	rs11167253	chr20:33614449	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg03929089	chr4:120376271	NA	0.73	8.47	0.37	3.18e-16	Axial length;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg27532560	chr4:187881888	NA	-0.58	-12.78	-0.51	2.93e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.06	0.35	6.73e-15	Longevity;
LGG	trans	rs7824557	0.679	rs7004362	chr8:11135974	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.88	0.38	1.45e-17	Retinal vascular caliber;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg11301795	chr4:187892539	NA	-0.94	-26.23	-0.77	1.4e-93	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504130	0.502	rs16916968	chr8:52844411	A/G	cg24946253	chr8:52722146	PXDNL	-0.5	-8.23	-0.36	1.89e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg10053473	chr17:62856997	LRRC37A3	0.89	13.97	0.54	2.93e-37	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1008375	0.866	rs12233712	chr4:17570063	T/A	cg16339924	chr4:17578868	LAP3	0.65	11.12	0.46	1.26e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.6	-0.47	1.78e-27	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11997175	0.574	rs4446694	chr8:33654978	A/G	ch.8.33884649F	chr8:33765107	NA	0.38	7.1	0.31	4.63e-12	Body mass index;
LGG	cis	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg02972257	chr16:68554789	NA	-0.56	-8.48	-0.37	2.97e-16	Ulcerative colitis;
LGG	cis	rs6964587	0.773	rs38793	chr7:92027187	A/G	cg17063962	chr7:91808500	NA	-0.49	-8.35	-0.36	7.86e-16	Breast cancer;
LGG	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg09165964	chr15:75287851	SCAMP5	0.77	8.69	0.37	6.2e-17	Lung cancer;
LGG	cis	rs526231	0.543	rs26819	chr5:102529401	G/A	cg23492399	chr5:102201601	PAM	-0.57	-8.31	-0.36	1.1e-15	Primary biliary cholangitis;
LGG	cis	rs7084402	0.967	rs1649074	chr10:60295342	T/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.12	-0.31	4.04e-12	Refractive error;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.54	-0.33	2.51e-13	Life satisfaction;
LGG	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.23	0.39	9.36e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs225245	0.687	rs321614	chr17:33881734	A/G	cg19694781	chr19:47549865	TMEM160	-0.5	-8.82	-0.38	2.4e-17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4474465	0.541	rs11237527	chr11:78219664	C/A	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs68170813	0.641	rs75254991	chr7:106938903	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.38	-0.43	7.82e-23	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10044066	chr5:93437580	T/C	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.79e-21	Diabetic retinopathy;
LGG	cis	rs6840360	0.571	rs62327269	chr4:152527973	G/C	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs59227481	1	rs59227481	chr12:110007993	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.54	-11.59	-0.47	1.9e-27	Age-related nuclear cataracts;
LGG	cis	rs11920090	0.932	rs6776099	chr3:170684314	T/C	cg09710316	chr3:170744871	SLC2A2	0.58	8.37	0.36	7.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs11074306	0.561	rs2311469	chr15:28069068	T/G	cg26402630	chr15:28053930	OCA2	0.36	7.29	0.32	1.31e-12	Uveal melanoma;
LGG	cis	rs7666738	0.830	rs4699595	chr4:99012827	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	29.6	0.81	7.89e-109	Prudent dietary pattern;
LGG	cis	rs62244186	0.683	rs6766334	chr3:44567065	T/C	cg02073558	chr3:44770973	ZNF501	0.66	11.81	0.48	2.61e-28	Depressive symptoms;
LGG	cis	rs9487094	0.689	rs9480949	chr6:109728441	T/C	cg01125227	chr6:109776195	MICAL1	0.45	7.93	0.35	1.67e-14	Height;
LGG	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.1	-0.39	2.78e-18	Neuroticism;
LGG	cis	rs62238980	0.614	rs117195584	chr22:32390013	C/A	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs367943	1.000	rs348925	chr5:112817533	T/A	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.62e-14	Testicular germ cell tumor;
LGG	cis	rs4731207	0.698	rs6968187	chr7:124563340	T/G	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg12395012	chr8:11607386	GATA4	0.42	7.5	0.33	3.22e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs875971	1.000	rs6956179	chr7:65806659	C/T	cg11764359	chr7:65958608	NA	-0.8	-15.2	-0.58	1.27e-42	Aortic root size;
LGG	cis	rs6882046	0.513	rs679232	chr5:88054763	A/C	cg22951263	chr5:87985283	NA	0.56	10.36	0.43	9.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.98	-0.31	9.99e-12	Mood instability;
LGG	cis	rs899997	0.773	rs12595461	chr15:78969172	T/G	cg07120314	chr15:79043507	NA	0.68	12.44	0.5	7.21e-31	Coronary artery disease or large artery stroke;
LGG	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg04691961	chr3:161091175	C3orf57	0.43	9.24	0.39	8.77e-19	Morning vs. evening chronotype;
LGG	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs896854	0.625	rs7823886	chr8:95986459	A/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.28e-18	Type 2 diabetes;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg12436631	chr1:155007014	DCST1;DCST2	-0.4	-8.1	-0.35	5e-15	Prostate cancer;
LGG	cis	rs7937612	1.000	rs1373270	chr11:120324080	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.81	-0.51	2.23e-32	Intraocular pressure;
LGG	cis	rs1552244	0.554	rs6768339	chr3:10006079	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.72	-12.55	-0.5	2.7e-31	Alzheimer's disease;
LGG	trans	rs1945213	0.625	rs7128190	chr11:55858550	A/T	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11885103	0.781	rs2724908	chr2:591575	G/A	cg21195176	chr2:593345	NA	0.42	7.88	0.34	2.38e-14	Heschl's gyrus morphology;
LGG	cis	rs4950928	0.823	rs2153101	chr1:203168474	A/T	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.9	-0.34	2.12e-14	YKL-40 levels;
LGG	cis	rs11190604	1.000	rs1106565	chr10:102211613	T/C	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6450176	0.556	rs111423662	chr5:53288661	T/C	ch.5.1024479R	chr5:53302184	ARL15	-1.08	-15.19	-0.58	1.49e-42	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7493	0.950	rs7802171	chr7:95030321	A/G	cg08461772	chr7:95026248	PON3	0.39	8.25	0.36	1.7e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg02476566	chr12:106696527	TCP11L2	0.52	7.44	0.33	5.08e-13	Tourette syndrome;
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.52	0.56	1.19e-39	Colorectal cancer;
LGG	cis	rs12155623	0.619	rs17641604	chr8:49842784	C/T	cg00325661	chr8:49890786	NA	0.49	8.69	0.37	6.1e-17	Sudden cardiac arrest;
LGG	cis	rs74781061	0.932	rs11072497	chr15:74951357	C/A	cg02384859	chr15:74862662	ARID3B	-0.32	-6.76	-0.3	4.25e-11	Endometriosis;
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03647317	chr4:187891568	NA	0.4	8.66	0.37	7.89e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.1	-0.42	8.53e-22	Lung cancer;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	cis	rs4601821	0.635	rs7114433	chr11:113208098	C/T	cg14373873	chr11:113211441	TTC12	0.42	8.26	0.36	1.56e-15	Alcoholic chronic pancreatitis;
LGG	cis	rs11690935	0.959	rs6754817	chr2:172663394	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.01	-23.36	-0.74	2.55e-80	Schizophrenia;
LGG	cis	rs2072732	0.861	rs10489589	chr1:2951244	T/C	cg22517653	chr1:2918612	NA	-0.44	-6.99	-0.31	9.87e-12	Plateletcrit;
LGG	cis	rs9487094	0.778	rs6914498	chr6:109934408	G/A	cg01125227	chr6:109776195	MICAL1	0.52	8.76	0.38	3.64e-17	Height;
LGG	cis	rs41278232	1.000	rs7260907	chr20:62663136	A/C	cg03065311	chr20:62601662	ZNF512B	0.65	9.16	0.39	1.68e-18	Tonsillectomy;
LGG	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs7618915	0.508	rs12498066	chr3:52627660	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.84	0.38	2.04e-17	Bipolar disorder;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg22963979	chr7:1858916	MAD1L1	0.49	10.2	0.43	3.44e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7737355	1.000	rs798415	chr5:130693723	T/G	cg06307176	chr5:131281290	NA	-0.52	-8.59	-0.37	1.39e-16	Life satisfaction;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg24846343	chr22:24311635	DDTL	0.6	11.91	0.48	1.04e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4595586	0.545	rs12821810	chr12:39375858	T/C	cg13010199	chr12:38710504	ALG10B	0.4	7.23	0.32	2.01e-12	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.544	rs4246030	chr5:151906048	C/T	cg12297329	chr5:152029980	NA	-0.65	-11.85	-0.48	1.78e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.647	rs4786519	chr16:4584406	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.82	0.38	2.41e-17	Schizophrenia;
LGG	cis	rs9549367	0.713	rs510160	chr13:113822481	A/G	cg00898013	chr13:113819073	PROZ	0.46	9.38	0.4	3.04e-19	Platelet distribution width;
LGG	cis	rs3736594	0.559	rs62141292	chr2:27784300	A/C	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7953249	0.656	rs2243616	chr12:121406370	G/T	cg14101638	chr12:121416612	HNF1A	-0.45	-9.86	-0.42	5.98e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg03188948	chr7:1209495	NA	0.65	8.4	0.36	5.69e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-9.45	-0.4	1.63e-19	Aortic root size;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg02018176	chr4:1364513	KIAA1530	0.33	7.05	0.31	6.54e-12	Obesity-related traits;
LGG	trans	rs747782	0.646	rs58119589	chr11:47571956	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.68	0.3	7.02e-11	Intraocular pressure;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg09448879	chr15:79043637	NA	0.48	10.86	0.45	1.21e-24	Coronary artery disease or large artery stroke;
LGG	cis	rs3784262	1.000	rs4646627	chr15:58255305	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.4	-0.36	5.72e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9354308	0.764	rs2351722	chr6:66602809	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg27446573	chr6:127587934	RNF146	0.67	12.04	0.49	3.1e-29	Breast cancer;
LGG	trans	rs6951245	0.872	rs75280240	chr7:1058511	C/T	cg13565492	chr6:43139072	SRF	-0.69	-8.58	-0.37	1.49e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7044106	0.718	rs1960421	chr9:123394894	C/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.25	0.32	1.8e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg26174226	chr8:58114915	NA	-0.52	-7.01	-0.31	8.7e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2201728	0.653	rs55972871	chr4:100159569	G/A	cg07219303	chr4:100140905	ADH6	-0.38	-7.02	-0.31	7.71e-12	Cardiac Troponin-T levels;
LGG	cis	rs360798	0.532	rs2421816	chr2:63075033	C/A	cg17519650	chr2:63277830	OTX1	0.45	7.35	0.32	8.92e-13	Coronary artery disease;
LGG	cis	rs2974760	0.606	rs6600143	chr16:201389	A/C	cg08400316	chr16:204221	HBZ	-0.92	-15.5	-0.58	5.71e-44	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg00689492	chr4:1303491	MAEA	0.44	7.68	0.34	9.81e-14	Obesity-related traits;
LGG	cis	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg18479299	chr3:125709523	NA	-0.58	-7.51	-0.33	3.07e-13	Blood pressure (smoking interaction);
LGG	cis	rs55871839	0.598	rs4737525	chr8:59799781	G/A	cg07426533	chr8:59803705	TOX	-0.57	-12.91	-0.51	8.7e-33	Pneumonia;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg05896524	chr21:47604654	C21orf56	0.66	11.92	0.48	9.01e-29	Testicular germ cell tumor;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg12070911	chr6:150209640	RAET1E	0.27	6.85	0.3	2.35e-11	Lung cancer;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.12e-15	Bipolar disorder;
LGG	cis	rs1550582	1.000	rs7822348	chr8:135542483	C/G	cg17885191	chr8:135476712	NA	0.67	10.52	0.44	2.41e-23	Educational attainment;
LGG	cis	rs2455601	0.638	rs11042148	chr11:9008674	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.64	-10.81	-0.45	1.9e-24	Schizophrenia;
LGG	cis	rs2067615	0.579	rs10861655	chr12:107129419	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-11.55	-0.47	2.82e-27	Heart rate;
LGG	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg00101154	chr16:420108	MRPL28	-0.5	-8.39	-0.36	6.01e-16	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg07393940	chr7:158741817	NA	0.57	10.28	0.43	1.89e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7208859	0.623	rs56325146	chr17:29151024	T/C	cg19761014	chr17:28927070	LRRC37B2	0.59	7.2	0.32	2.44e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12188164	0.965	rs72717415	chr5:430059	G/A	cg26850624	chr5:429559	AHRR	-0.38	-8.41	-0.36	5.04e-16	Cystic fibrosis severity;
LGG	cis	rs2243480	1.000	rs34702770	chr7:65344823	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	trans	rs561341	1.000	rs483301	chr17:30293398	G/T	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs6598955	0.671	rs12088858	chr1:26643708	C/A	cg04990556	chr1:26633338	UBXN11	0.61	8.14	0.35	3.71e-15	Obesity-related traits;
LGG	cis	rs6692729	0.966	rs1150900	chr1:227045029	A/G	cg08708961	chr1:227070630	PSEN2	-0.3	-7.49	-0.33	3.51e-13	Electrodermal activity;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg23782820	chr8:58130467	NA	0.58	8.6	0.37	1.25e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.55	-9.51	-0.4	1.07e-19	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg11878867	chr6:150167359	LRP11	-0.38	-7.94	-0.35	1.57e-14	Testicular germ cell tumor;
LGG	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg14664628	chr15:75095509	CSK	-0.56	-10.53	-0.44	2.09e-23	Breast cancer;
LGG	cis	rs9398803	0.687	rs4626447	chr6:126964675	G/A	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg02733842	chr7:1102375	C7orf50	0.69	10.39	0.43	7.16e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg09873164	chr1:152488093	CRCT1	0.65	16.11	0.6	1.12e-46	Hair morphology;
LGG	cis	rs1878931	0.668	rs11643983	chr16:3438865	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.01	23.22	0.73	1.17e-79	Body mass index (adult);
LGG	cis	rs988958	0.526	rs10195970	chr2:42249643	C/T	cg27428208	chr2:42229179	NA	0.47	7.43	0.33	5.27e-13	Hypospadias;
LGG	cis	rs988958	0.675	rs35637955	chr2:42217686	A/C	cg27252766	chr2:42229092	NA	0.53	8.33	0.36	9.47e-16	Hypospadias;
LGG	cis	rs2302729	0.860	rs7138079	chr12:2781304	G/A	cg19945202	chr12:2788847	CACNA1C	-0.82	-12.22	-0.49	5.72e-30	Sleep quality;
LGG	cis	rs142802669	1	rs142802669	chr3:41869427	A/C	cg03022575	chr3:42003672	ULK4	0.64	8.06	0.35	6.42e-15	Immunoglobulin light chain (AL) amyloidosis;
LGG	cis	rs4919087	0.590	rs1253397	chr10:99045556	C/T	cg25902810	chr10:99078978	FRAT1	-0.43	-6.95	-0.31	1.27e-11	Monocyte count;
LGG	cis	rs6062496	0.631	rs6062484	chr20:62301980	T/C	cg27236539	chr20:62289627	RTEL1	0.57	9.71	0.41	2e-20	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg26248373	chr2:1572462	NA	-0.86	-15.28	-0.58	5.88e-43	IgG glycosylation;
LGG	cis	rs1062746	0.528	rs891092	chr16:87338226	G/A	cg02258303	chr16:87377426	FBXO31	-0.42	-7.95	-0.35	1.41e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs8005677	0.770	rs56180741	chr14:23377246	T/C	cg25600027	chr14:23388339	RBM23	-0.44	-7.35	-0.32	8.87e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs4727027	0.933	rs1044358	chr7:148879951	C/A	cg23583168	chr7:148888333	NA	-0.88	-17.13	-0.62	2.58e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4789452	0.774	rs55727612	chr17:75381723	C/T	cg06761530	chr17:75373219	SEPT9	-0.36	-6.94	-0.31	1.32e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	trans	rs7395662	1.000	rs11039859	chr11:48611988	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.02e-12	HDL cholesterol;
LGG	cis	rs8060686	0.641	rs12447640	chr16:68150527	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.72	-0.3	5.45e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2732480	0.557	rs2732484	chr12:48737245	A/C	cg21466736	chr12:48725269	NA	-0.39	-7.79	-0.34	4.52e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg16507663	chr6:150244633	RAET1G	0.44	8.28	0.36	1.37e-15	Lung cancer;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.57	-8.05	-0.35	7.3e-15	Lung function (FEV1/FVC);
LGG	cis	rs10048158	0.565	rs8073755	chr17:64247928	T/A	cg19474267	chr17:64306194	PRKCA	-0.64	-13.24	-0.52	3.56e-34	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg09467607	chr2:36825704	FEZ2	0.51	9.18	0.39	1.44e-18	Height;
LGG	cis	rs116095464	0.558	rs56342538	chr5:225796	T/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs1882538	0.596	rs10281827	chr7:133081810	A/G	cg10665199	chr7:133106180	EXOC4	0.56	9.4	0.4	2.6e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg08198773	chr8:1697536	NA	0.46	8.09	0.35	5.37e-15	Systolic blood pressure;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.12	0.46	1.23e-25	Personality dimensions;
LGG	cis	rs10911232	0.507	rs10911222	chr1:183047363	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	trans	rs9354308	0.714	rs9354315	chr6:66573653	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-7.03	-0.31	7.63e-12	Metabolite levels;
LGG	cis	rs8180040	0.726	rs61729713	chr3:47027192	A/G	cg16586182	chr3:47516702	SCAP	0.73	13.67	0.54	5.62e-36	Colorectal cancer;
LGG	cis	rs854765	0.618	rs8068820	chr17:17834119	A/G	cg05444541	chr17:17804740	TOM1L2	-0.79	-22.21	-0.72	6.16e-75	Total body bone mineral density;
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg23461800	chr14:103021989	NA	-0.58	-10.31	-0.43	1.41e-22	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12995162	chr2:129079641	NA	0.49	7.16	0.32	3.28e-12	Gut microbiome composition (summer);
LGG	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg10792982	chr14:105748885	BRF1	0.54	10.75	0.45	3.38e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg25811766	chr13:21894605	NA	0.63	8.65	0.37	8.84e-17	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18023036	chr7:102036699	PRKRIP1	0.53	8.23	0.36	1.96e-15	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.94	0.57	1.73e-41	Platelet count;
LGG	trans	rs61931739	0.534	rs12372557	chr12:34363843	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.05	0.7	1.59e-69	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg07541023	chr7:19748670	TWISTNB	0.59	7.95	0.35	1.43e-14	Thyroid stimulating hormone;
LGG	cis	rs1953600	0.645	rs7071579	chr10:81910278	A/G	cg04850286	chr10:81895943	PLAC9	0.34	7.53	0.33	2.63e-13	Sarcoidosis;
LGG	cis	rs4764124	0.646	rs10846062	chr12:14965781	T/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.57	10.79	0.45	2.28e-24	Pubertal anthropometrics;
LGG	cis	rs2842992	0.789	rs2342446	chr6:160220687	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.83	0.54	1.18e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg00976097	chr5:421733	AHRR	-0.43	-7.23	-0.32	1.96e-12	Cystic fibrosis severity;
LGG	cis	rs4237845	0.537	rs7312623	chr12:58262523	G/T	cg02175503	chr12:58329896	NA	0.54	8.92	0.38	1.1e-17	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg01620082	chr3:125678407	NA	-0.65	-6.99	-0.31	9.74e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg00129232	chr17:37814104	STARD3	-0.63	-8.79	-0.38	2.86e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2011503	0.509	rs76347963	chr19:19780145	C/T	cg11584989	chr19:19387371	SF4	0.56	8.13	0.35	3.92e-15	Bipolar disorder;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg26505319	chr6:14408336	NA	-0.43	-7.13	-0.31	3.85e-12	Apolipoprotein A-IV levels;
LGG	cis	rs6032067	0.852	rs17333180	chr20:43803708	C/A	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg01493318	chr18:8705700	NA	-0.4	-6.94	-0.31	1.3e-11	Select biomarker traits;
LGG	cis	rs4319547	0.774	rs7954006	chr12:123131824	A/C	cg23029597	chr12:123009494	RSRC2	0.83	15.65	0.59	1.25e-44	Body mass index;
LGG	cis	rs9807841	0.592	rs11085743	chr19:10759442	G/A	cg17710535	chr19:10819994	QTRT1	0.47	7.61	0.33	1.5e-13	Inflammatory skin disease;
LGG	trans	rs7944735	0.507	rs17198607	chr11:48028343	A/C	cg03929089	chr4:120376271	NA	-0.66	-7.01	-0.31	8.52e-12	Intraocular pressure;
LGG	cis	rs8064024	0.564	rs7214	chr16:4932560	T/G	cg08329684	chr16:4932620	PPL	0.59	13.15	0.52	8.85e-34	Cancer;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.44	8.61	0.37	1.18e-16	Schizophrenia;
LGG	cis	rs9906944	0.707	rs4794019	chr17:47107290	G/T	cg09029085	chr17:47094198	IGF2BP1	0.3	8.13	0.35	3.87e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1497828	0.912	rs2646825	chr1:217539194	A/G	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	cis	rs78456975	1.000	rs6744743	chr2:1558161	C/T	cg26248373	chr2:1572462	NA	0.71	9.02	0.39	5.07e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7927592	0.913	rs3740629	chr11:68343593	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs6962151	chr7:100028484	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs2188554	0.606	rs39314	chr7:116960104	C/A	cg10524701	chr7:117356490	CTTNBP2	0.39	7.53	0.33	2.66e-13	Esophageal adenocarcinoma;
LGG	cis	rs62238980	0.614	rs117509300	chr22:32502206	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg02158880	chr13:53174818	NA	0.38	7.19	0.32	2.62e-12	Lewy body disease;
LGG	cis	rs3857536	0.813	rs1891600	chr6:66941645	G/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs873946	0.586	rs12776770	chr10:134564831	T/C	cg27286337	chr10:134555280	INPP5A	0.83	12.15	0.49	1.12e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs656319	0.559	rs60384372	chr8:9974584	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.72	-0.3	5.25e-11	Myopia (pathological);
LGG	cis	rs6912958	0.781	rs9444504	chr6:88181046	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.84	-0.38	2.08e-17	Monocyte percentage of white cells;
LGG	trans	rs2727020	0.658	rs1851992	chr11:49438110	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-21.29	-0.7	1.23e-70	Coronary artery disease;
LGG	cis	rs2549003	0.966	rs10072571	chr5:131816711	A/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.37e-22	Asthma (sex interaction);
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.3	0.69	5.56e-66	Alzheimer's disease;
LGG	cis	rs939658	0.805	rs59104559	chr15:79438784	A/G	cg17916960	chr15:79447300	NA	-0.66	-12.9	-0.51	9.39e-33	Refractive error;
LGG	cis	rs10875595	0.836	rs6889723	chr5:140676524	C/T	cg19650706	chr5:140594406	PCDHB13	-0.53	-6.68	-0.3	6.7e-11	Pulmonary function decline;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs988958	0.562	rs13397376	chr2:42221417	A/G	cg27252766	chr2:42229092	NA	0.56	7.97	0.35	1.26e-14	Hypospadias;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	-1.16	-19.5	-0.67	2.77e-62	Platelet count;
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg19223190	chr17:80058835	NA	-0.49	-9.77	-0.41	1.23e-20	Life satisfaction;
LGG	cis	rs600231	0.708	rs3132767	chr11:65234860	C/T	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.09	-0.39	3.03e-18	Bone mineral density;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23247000	chr7:138794512	ZC3HAV1	0.41	6.74	0.3	4.68e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg11245990	chr11:68621969	NA	0.44	9.15	0.39	1.78e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs11792861	0.926	rs72607172	chr9:111876523	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.34	0.4	4.03e-19	Menarche (age at onset);
LGG	cis	rs877282	0.628	rs11253435	chr10:824169	T/C	cg15764593	chr10:829463	NA	-0.69	-10.37	-0.43	8.27e-23	Uric acid levels;
LGG	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.83	-0.48	2.17e-28	Mean platelet volume;
LGG	cis	rs13118159	0.550	rs1137789	chr4:1381798	A/G	cg05165339	chr4:1420672	NA	-0.34	-8.85	-0.38	1.8e-17	Longevity;
LGG	trans	rs1814175	0.527	rs3974435	chr11:49619533	G/A	cg03929089	chr4:120376271	NA	-0.88	-13.98	-0.54	2.71e-37	Height;
LGG	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg14541582	chr5:601475	NA	0.69	10.64	0.44	8.45e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs870825	0.616	rs6833858	chr4:185639961	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	22.98	0.73	1.6e-78	Blood protein levels;
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.66	-0.41	3.06e-20	Lung cancer;
LGG	cis	rs1707322	1.000	rs785519	chr1:46568562	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.67	-0.41	2.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12477438	0.520	rs11678456	chr2:99708237	G/A	cg08885076	chr2:99613938	TSGA10	0.43	9.05	0.39	4.13e-18	Chronic sinus infection;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs9467711	0.591	rs116201501	chr6:25999149	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.54	0.33	2.54e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.22e-12	Menopause (age at onset);
LGG	trans	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	trans	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-10.65	-0.44	7.88e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7659604	0.676	rs6855269	chr4:122697418	T/G	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.72	-0.48	5.81e-28	Type 2 diabetes;
LGG	trans	rs57221529	0.766	rs28563961	chr5:554498	C/G	cg11887960	chr12:57824829	NA	0.6	7.14	0.31	3.75e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1568889	0.838	rs1525717	chr11:28081205	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.63e-61	Bipolar disorder;
LGG	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.88	-0.51	1.19e-32	Intelligence (multi-trait analysis);
LGG	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg03474202	chr17:45855739	NA	-0.27	-7.86	-0.34	2.81e-14	IgG glycosylation;
LGG	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg04733989	chr22:42467013	NAGA	-0.48	-9.18	-0.39	1.4e-18	Cognitive function;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06102690	chr4:24981807	CCDC149	-0.49	-7.2	-0.32	2.39e-12	Systemic lupus erythematosus;
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.53	0.47	3.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.924	rs6589244	chr11:111534333	T/C	cg22437258	chr11:111473054	SIK2	0.54	9.3	0.4	5.75e-19	Primary sclerosing cholangitis;
LGG	cis	rs6088580	0.634	rs4911419	chr20:32995873	G/A	cg08999081	chr20:33150536	PIGU	-0.41	-10.3	-0.43	1.56e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6909430	0.901	rs2087182	chr6:98590665	G/A	cg12860156	chr6:98744658	NA	-0.43	-7.42	-0.33	5.62e-13	Quantitative traits;
LGG	cis	rs7615952	0.534	rs1503072	chr3:125754691	C/T	cg06494592	chr3:125709126	NA	-0.54	-6.81	-0.3	3.08e-11	Blood pressure (smoking interaction);
LGG	cis	rs16870629	0.564	rs326050	chr5:1002620	C/T	cg07267674	chr5:1049712	NA	0.55	9.8	0.41	1.02e-20	QT interval;
LGG	cis	rs9399135	0.967	rs4895439	chr6:135318854	A/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs13421350	0.579	rs12052385	chr2:173316217	A/G	cg15021238	chr2:173305865	ITGA6	-0.84	-9.62	-0.41	4.42e-20	Diabetic kidney disease;
LGG	cis	rs66887589	0.967	rs3775842	chr4:120427732	G/A	cg09307838	chr4:120376055	NA	0.48	8.32	0.36	9.72e-16	Diastolic blood pressure;
LGG	cis	rs5769765	0.817	rs9616212	chr22:50317687	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.12	0.31	4.26e-12	Schizophrenia;
LGG	trans	rs61931739	0.500	rs7309421	chr12:34553795	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.32	0.53	1.78e-34	Morning vs. evening chronotype;
LGG	cis	rs3126085	0.935	rs12408581	chr1:152175211	A/G	cg26876637	chr1:152193138	HRNR	-0.5	-7.17	-0.32	2.92e-12	Atopic dermatitis;
LGG	cis	rs7649275	1.000	rs2612033	chr3:53766026	T/C	cg21503701	chr3:53781065	CACNA1D	-0.47	-6.8	-0.3	3.23e-11	Trans fatty acid levels;
LGG	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg02187348	chr16:89574699	SPG7	0.43	6.73	0.3	4.88e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs8062405	1.000	rs56358680	chr16:28843118	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	7.73	0.34	6.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs17685	0.753	rs1637044	chr7:75703744	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs473651	0.935	rs483166	chr2:239346641	C/T	cg21699342	chr2:239360505	ASB1	-0.39	-7.49	-0.33	3.52e-13	Multiple system atrophy;
LGG	cis	rs7084402	0.967	rs7079648	chr10:60273155	C/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.59	-0.63	2.15e-53	Refractive error;
LGG	cis	rs7917772	0.532	rs10748829	chr10:104527244	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.48	-7.92	-0.35	1.75e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs68170813	0.641	rs4730248	chr7:107125939	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-9.93	-0.42	3.54e-21	Coronary artery disease;
LGG	cis	rs12200560	0.505	rs211167	chr6:97069087	T/A	cg06623918	chr6:96969491	KIAA0776	0.46	7.79	0.34	4.41e-14	Coronary heart disease;
LGG	cis	rs526231	0.543	rs34779	chr5:102452768	A/G	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg13902645	chr11:5959945	NA	-0.72	-11.59	-0.47	1.91e-27	DNA methylation (variation);
LGG	cis	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg15596359	chr8:11213517	TDH	-0.34	-7.08	-0.31	5.22e-12	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg23758822	chr17:41437982	NA	0.9	15.76	0.59	4.33e-45	Menopause (age at onset);
LGG	cis	rs7143963	0.666	rs11847989	chr14:103303514	T/C	cg23020514	chr14:103360112	TRAF3	0.43	8.69	0.37	6.31e-17	Body mass index;
LGG	cis	rs721917	0.525	rs11201011	chr10:81739920	C/A	cg25562619	chr10:81652821	NA	-0.32	-7.17	-0.32	3.07e-12	Chronic obstructive pulmonary disease;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg10207240	chr12:122356781	WDR66	0.28	8.34	0.36	8.48e-16	Mean corpuscular volume;
LGG	cis	rs3767633	0.925	rs2055539	chr1:161807866	T/C	cg09175582	chr1:161736000	ATF6	0.73	9.13	0.39	2.2e-18	IgG glycosylation;
LGG	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg26384229	chr12:38710491	ALG10B	0.7	12.95	0.52	6.16e-33	Resting heart rate;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg22398616	chr13:53314203	LECT1	0.39	8.04	0.35	7.8e-15	Lewy body disease;
LGG	cis	rs1552244	1.000	rs113134644	chr3:10086286	G/A	cg00149659	chr3:10157352	C3orf10	0.84	10.84	0.45	1.51e-24	Alzheimer's disease;
LGG	cis	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg14673194	chr17:80132900	CCDC57	0.41	7.19	0.32	2.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4730779	0.530	rs10230259	chr7:117033753	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	7.78	0.34	4.73e-14	Waist circumference;
LGG	cis	rs2221894	0.506	rs79581337	chr8:28950860	T/G	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.83	-0.34	3.37e-14	Obesity-related traits;
LGG	cis	rs2694528	0.858	rs6869454	chr5:60406172	A/G	cg11474532	chr5:59995715	DEPDC1B	0.72	7.49	0.33	3.42e-13	Parkinson's disease;
LGG	cis	rs3735485	0.800	rs10235394	chr7:45087002	G/A	cg03440944	chr7:45023329	C7orf40	-0.55	-9.4	-0.4	2.45e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs10870270	0.957	rs9971084	chr10:133788747	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.63	-12.13	-0.49	1.29e-29	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.23	-0.32	2.07e-12	Lung cancer;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs116834347	chr4:119774155	C/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg13939156	chr17:80058883	NA	0.4	7.28	0.32	1.47e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.19e-35	Anterior chamber depth;
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg26513180	chr16:89883248	FANCA	0.67	7.41	0.33	5.87e-13	Skin colour saturation;
LGG	cis	rs4268898	0.722	rs4665253	chr2:24382546	G/A	cg06627628	chr2:24431161	ITSN2	0.48	7.78	0.34	4.67e-14	Asthma;
LGG	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg03160526	chr17:80928410	B3GNTL1	0.49	7.75	0.34	5.88e-14	Glycated hemoglobin levels;
LGG	cis	rs1878931	0.624	rs37810	chr16:3451881	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.77	-12.23	-0.49	5.17e-30	Body mass index (adult);
LGG	cis	rs17253792	0.545	rs34136598	chr14:56013238	C/T	cg01858014	chr14:56050164	KTN1	-0.75	-8.99	-0.39	6.19e-18	Putamen volume;
LGG	cis	rs113835537	0.529	rs80100524	chr11:66245936	C/T	cg24851651	chr11:66362959	CCS	0.43	7.59	0.33	1.78e-13	Airway imaging phenotypes;
LGG	cis	rs4731207	0.564	rs2127972	chr7:124665545	A/T	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.56e-13	Cutaneous malignant melanoma;
LGG	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg08125733	chr17:73851984	WBP2	0.96	15.6	0.59	2.25e-44	Psoriasis;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2274273	0.624	rs7150763	chr14:55839801	A/G	cg04306507	chr14:55594613	LGALS3	0.53	12.45	0.5	6.62e-31	Protein biomarker;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg01262667	chr19:19385393	TM6SF2	0.44	10.97	0.45	4.73e-25	Tonsillectomy;
LGG	trans	rs459571	0.606	rs456793	chr9:136903683	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.44	-7.35	-0.32	9.07e-13	Platelet distribution width;
LGG	cis	rs509477	0.718	rs273346	chr18:32603056	G/T	cg23791764	chr18:32556832	MAPRE2	0.44	7.45	0.33	4.64e-13	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg25173464	chr15:68126554	NA	-0.35	-7.26	-0.32	1.62e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg26150922	chr2:100937072	LONRF2	0.56	9.84	0.42	7.25e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.28e-19	Lung cancer;
LGG	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg00071950	chr4:10020882	SLC2A9	-0.33	-6.82	-0.3	2.84e-11	Bone mineral density;
LGG	cis	rs17641971	0.708	rs10957317	chr8:49888870	C/T	cg00325661	chr8:49890786	NA	-0.53	-9.65	-0.41	3.39e-20	Blood metabolite levels;
LGG	cis	rs2120019	1.000	rs8036197	chr15:75370232	T/C	cg17294928	chr15:75287854	SCAMP5	-0.9	-16.59	-0.61	7.35e-49	Blood trace element (Zn levels);
LGG	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg27446573	chr6:127587934	RNF146	1.12	21.83	0.71	3.72e-73	Breast cancer;
LGG	cis	rs1978968	0.717	rs1072405	chr22:18406068	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.49	-9.73	-0.41	1.8e-20	Presence of antiphospholipid antibodies;
LGG	cis	rs10489167	0.920	rs12121412	chr1:41164832	G/A	cg11417323	chr1:41160271	NFYC	-0.44	-6.76	-0.3	4.05e-11	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.67e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7945705	0.875	rs11042059	chr11:8795080	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.42	8.5	0.37	2.72e-16	Hemoglobin concentration;
LGG	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.16	0.32	3.17e-12	Educational attainment;
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg17178900	chr1:205818956	PM20D1	0.42	7.36	0.32	8.68e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs4819052	0.765	rs2838868	chr21:46714641	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.75	-12.72	-0.51	5.36e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg03162506	chr22:38580953	NA	0.33	8.13	0.35	4e-15	Cutaneous nevi;
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs7133214	0.771	rs12368869	chr12:27919916	T/C	cg04279139	chr12:27925367	LOC100133893	-0.33	-7.08	-0.31	5.45e-12	Gut microbiota (functional units);
LGG	cis	rs77633900	0.772	rs2957613	chr15:76700589	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-8.11	-0.35	4.7e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs10266483	0.774	rs56055804	chr7:63870801	G/T	cg24201672	chr7:64023550	ZNF680	0.46	6.92	0.31	1.5e-11	Response to statin therapy;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg19147804	chr7:1989927	MAD1L1	-0.59	-12.03	-0.49	3.27e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg24247370	chr13:99142703	STK24	-0.39	-7.27	-0.32	1.59e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.31	3.7e-12	Life satisfaction;
LGG	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-7.38	-0.32	7.25e-13	Bone mineral density;
LGG	cis	rs1497828	0.912	rs2815231	chr1:217538165	T/G	cg04411442	chr1:217543379	NA	-0.48	-8.09	-0.35	5.11e-15	Dialysis-related mortality;
LGG	cis	rs9486715	0.659	rs9399930	chr6:96854444	G/T	cg06623918	chr6:96969491	KIAA0776	0.75	13.8	0.54	1.5e-36	Headache;
LGG	cis	rs787274	1.000	rs2645993	chr9:115536267	T/A	cg13803584	chr9:115635662	SNX30	-0.55	-7.73	-0.34	6.75e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11098499	0.954	rs11729521	chr4:120416788	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.86e-26	Corneal astigmatism;
LGG	cis	rs3849570	0.925	rs7641973	chr3:81910489	G/A	cg07356753	chr3:81810745	GBE1	-0.43	-7.01	-0.31	8.73e-12	Waist circumference;Body mass index;
LGG	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg08250081	chr4:10125330	NA	0.39	7.59	0.33	1.72e-13	Bone mineral density;
LGG	cis	rs7928758	0.943	rs77897340	chr11:134265173	C/T	cg22777979	chr11:134283252	B3GAT1	0.96	12.11	0.49	1.64e-29	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg19671926	chr4:122722719	EXOSC9	0.53	8.23	0.36	1.99e-15	Type 2 diabetes;
LGG	trans	rs561341	0.689	rs578635	chr17:30289897	A/C	cg20587970	chr11:113659929	NA	-0.86	-14.83	-0.57	5.45e-41	Hip circumference adjusted for BMI;
LGG	cis	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg25986240	chr4:9926439	SLC2A9	-0.49	-10.73	-0.45	3.89e-24	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17253792	0.822	rs77197405	chr14:56159662	T/A	cg01858014	chr14:56050164	KTN1	-0.89	-12.06	-0.49	2.65e-29	Putamen volume;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.34	6.83	0.3	2.65e-11	Schizophrenia;
LGG	cis	rs8014204	0.762	rs957345	chr14:75276079	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.49	-8.54	-0.37	1.93e-16	Caffeine consumption;
LGG	cis	rs10463554	0.963	rs34777	chr5:102452258	C/T	cg23492399	chr5:102201601	PAM	-0.5	-7.54	-0.33	2.48e-13	Parkinson's disease;
LGG	cis	rs17401966	0.838	rs4623	chr1:10366692	C/G	cg19773385	chr1:10388646	KIF1B	-0.49	-10.36	-0.43	9.58e-23	Hepatocellular carcinoma;
LGG	cis	rs7586879	0.598	rs6724772	chr2:25128730	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg11301795	chr4:187892539	NA	0.93	24.65	0.75	2.58e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4481887	0.962	rs12037921	chr1:248454167	T/G	cg00666640	chr1:248458726	OR2T12	0.6	9.72	0.41	1.83e-20	Common traits (Other);
LGG	cis	rs17678683	1.000	rs17678683	chr2:145286559	A/C	cg17751438	chr2:145275197	ZEB2	0.66	7.47	0.33	4.01e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Myocardial infarction;
LGG	cis	rs568617	0.533	rs679147	chr11:65644363	A/G	cg04055107	chr11:65626734	MUS81;CFL1	-0.67	-10.93	-0.45	6.72e-25	Crohn's disease;
LGG	cis	rs300703	0.872	rs12233077	chr2:120949	T/A	cg21211680	chr2:198530	NA	-1.21	-14.64	-0.56	3.7e-40	Blood protein levels;
LGG	cis	rs1555133	0.694	rs6141707	chr20:30995118	A/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.68	0.3	6.89e-11	Monocyte count;
LGG	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg16325326	chr1:53192061	ZYG11B	-0.72	-17.24	-0.63	8.23e-52	Monocyte count;
LGG	trans	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg26384229	chr12:38710491	ALG10B	0.76	14.12	0.55	6.89e-38	Resting heart rate;
LGG	cis	rs2180341	1.000	rs2057223	chr6:127637374	T/C	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg19147804	chr7:1989927	MAD1L1	-0.58	-11.08	-0.46	1.88e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25632114	chr8:95732714	DPY19L4	0.46	7.87	0.34	2.52e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs5756813	0.754	rs4820307	chr22:38175955	G/A	cg19894588	chr14:64061835	NA	-0.6	-9.26	-0.4	7.65e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9560113	1.000	rs9560113	chr13:112183348	A/G	cg10483660	chr13:112241077	NA	0.35	6.93	0.31	1.37e-11	Menarche (age at onset);
LGG	cis	rs7828089	0.935	rs896375	chr8:22262098	A/G	cg12081754	chr8:22256438	SLC39A14	0.72	13.72	0.54	3.56e-36	Verbal declarative memory;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg02018176	chr4:1364513	KIAA1530	0.39	8.64	0.37	9.35e-17	Obesity-related traits;
LGG	cis	rs2916247	1.000	rs28716374	chr8:93030411	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.48	-0.37	3.03e-16	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.613	rs6488174	chr12:33756569	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.83	-0.3	2.63e-11	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.562	rs11650923	chr17:29008167	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.91	-11.22	-0.46	5.14e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2224391	0.784	rs67285271	chr6:5279267	T/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.53	-7.32	-0.32	1.07e-12	Height;
LGG	cis	rs57502260	0.704	rs72936599	chr11:68320405	G/A	cg01657329	chr11:68192670	LRP5	-0.57	-7.34	-0.32	9.46e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	cg15522984	chr1:182991683	LAMC1	0.44	8.59	0.37	1.33e-16	Fuchs's corneal dystrophy;
LGG	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg13647721	chr17:30228624	UTP6	0.79	12.59	0.51	1.83e-31	Hip circumference adjusted for BMI;
LGG	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg12463550	chr7:65579703	CRCP	-0.73	-8.04	-0.35	7.48e-15	Diabetic kidney disease;
LGG	cis	rs17776563	0.959	rs1348003	chr15:89113441	G/C	cg05013243	chr15:89149849	MIR1179	-0.51	-10.33	-0.43	1.24e-22	Thyroid hormone levels;
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18252515	chr7:66147081	NA	0.45	7.52	0.33	2.95e-13	Aortic root size;
LGG	cis	rs1577917	0.740	rs2842614	chr6:86306069	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.31	-0.36	1.09e-15	Response to antipsychotic treatment;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg27219399	chr15:67835830	MAP2K5	0.33	7.12	0.31	4.28e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17833341	chr1:154947313	SHC1;CKS1B	0.47	7.71	0.34	7.77e-14	Cognitive performance;
LGG	trans	rs12431410	0.550	rs1957994	chr14:60196234	A/C	cg11162385	chr20:25604740	NANP	0.43	6.66	0.3	7.87e-11	Schizophrenia;
LGG	cis	rs2439831	0.850	rs12442129	chr15:44055856	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.2	0.39	1.2e-18	Lung cancer in ever smokers;
LGG	cis	rs9486719	1.000	rs3798289	chr6:97023632	T/C	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs12282928	0.918	rs117447853	chr11:48315758	T/G	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg21926883	chr2:100939477	LONRF2	-0.61	-13.31	-0.53	1.94e-34	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	0.797	rs11703382	chr22:18481857	C/T	cg03078520	chr22:18463400	MICAL3	-0.59	-12.14	-0.49	1.24e-29	Presence of antiphospholipid antibodies;
LGG	cis	rs10937275	1.000	rs35102841	chr3:186649683	A/G	cg24050613	chr3:186648279	ST6GAL1	0.86	8.87	0.38	1.6e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4132509	1.000	rs6429433	chr1:243857994	C/T	cg25706552	chr1:244017396	NA	0.51	8.23	0.36	1.89e-15	RR interval (heart rate);
LGG	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg03701759	chr13:99174930	STK24	-0.36	-7.06	-0.31	6.18e-12	Longevity;
LGG	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08508325	chr11:3079039	CARS	0.42	8.26	0.36	1.58e-15	Calcium levels;
LGG	cis	rs758324	0.947	rs1846650	chr5:131158767	C/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.51e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg13683864	chr3:40499215	RPL14	1.04	23.66	0.74	1e-81	Renal cell carcinoma;
LGG	cis	rs7267979	1.000	rs2474777	chr20:25272633	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.11	0.43	7.88e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2916247	0.954	rs35983766	chr8:93056882	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.41	-0.36	5.29e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.667	rs1254123	chr11:67334812	T/C	cg08925882	chr11:67350491	GSTP1	-0.35	-6.82	-0.3	2.85e-11	Mean corpuscular volume;
LGG	cis	rs12928939	0.815	rs7185575	chr16:71672569	A/G	cg08717414	chr16:71523259	ZNF19	-0.48	-7.26	-0.32	1.59e-12	Post bronchodilator FEV1;
LGG	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.47	-0.33	4e-13	Breast cancer;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg07538946	chr5:131705188	SLC22A5	0.62	7.31	0.32	1.2e-12	Rheumatoid arthritis;
LGG	cis	rs36715	1.000	rs251213	chr5:127545605	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.64	0.33	1.26e-13	Breast cancer;
LGG	cis	rs7618915	0.501	rs2289247	chr3:52727257	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.79	-0.41	1.12e-20	Bipolar disorder;
LGG	trans	rs7819412	0.558	rs11777486	chr8:10908287	C/A	cg08975724	chr8:8085496	FLJ10661	0.42	7.33	0.32	1.03e-12	Triglycerides;
LGG	cis	rs2836974	0.897	rs4817996	chr21:40525759	G/C	cg11644478	chr21:40555479	PSMG1	0.93	17.52	0.63	4.32e-53	Cognitive function;
LGG	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg17911788	chr17:44343683	NA	0.45	7.74	0.34	6.46e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10463316	0.862	rs10062928	chr5:150768355	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.11	-0.43	7.32e-22	Metabolite levels (Pyroglutamine);
LGG	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.03	0.42	1.5e-21	Morning vs. evening chronotype;
LGG	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.6	10.75	0.45	3.19e-24	Educational attainment;
LGG	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	7.42	0.33	5.75e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2243480	1.000	rs462853	chr7:65558167	G/C	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	trans	rs1941687	0.764	rs1493915	chr18:31377582	G/T	cg27147174	chr7:100797783	AP1S1	-0.56	-9.32	-0.4	4.86e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg01221209	chr5:554886	NA	-0.48	-10.11	-0.43	7.7e-22	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs11053278	chr12:34555955	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.01	0.31	8.36e-12	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.85	-15.75	-0.59	4.55e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6977660	0.714	rs4719585	chr7:19823727	C/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.08	0.42	9.56e-22	Thyroid stimulating hormone;
LGG	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg06636001	chr8:8085503	FLJ10661	0.47	8.33	0.36	8.92e-16	Monocyte count;
LGG	cis	rs7582180	0.638	rs7581011	chr2:100954659	A/G	cg08017756	chr2:100939284	LONRF2	0.3	7.26	0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.632	rs4785716	chr16:89801127	T/C	cg26513180	chr16:89883248	FANCA	0.62	11.26	0.46	3.82e-26	Vitiligo;
LGG	cis	rs1506636	1.000	rs2259457	chr7:123424350	A/G	cg03229431	chr7:123269106	ASB15	0.73	17.88	0.64	9.97e-55	Plateletcrit;Platelet count;
LGG	cis	rs2549003	1.000	rs17848418	chr5:131821188	C/T	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs240764	0.781	rs12212736	chr6:101151410	C/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.64	-0.33	1.27e-13	Neuroticism;
LGG	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg21926883	chr2:100939477	LONRF2	-0.66	-15.29	-0.58	5.1e-43	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.901	rs4974594	chr4:1300480	C/T	cg05025164	chr4:1340916	KIAA1530	-0.54	-9.51	-0.4	1.06e-19	Obesity-related traits;
LGG	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg20821713	chr7:1055600	C7orf50	-0.49	-7.51	-0.33	3.13e-13	Bronchopulmonary dysplasia;
LGG	cis	rs4962416	0.785	rs7077275	chr10:126697210	T/C	cg19266671	chr10:126712482	CTBP2	-0.28	-6.72	-0.3	5.5e-11	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1375194	0.606	rs17657783	chr2:33814590	A/G	cg04131969	chr2:33951647	MYADML	-0.57	-10.19	-0.43	3.9e-22	Response to antidepressants in depression;
LGG	cis	rs35110281	0.805	rs4818843	chr21:45006607	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.4	-0.4	2.44e-19	Mean corpuscular volume;
LGG	trans	rs3780486	1.000	rs3780486	chr9:33139453	C/T	cg20290983	chr6:43655470	MRPS18A	1.01	17.52	0.63	4.2e-53	IgG glycosylation;
LGG	cis	rs17453880	0.658	rs2964218	chr5:151957849	A/C	cg12297329	chr5:152029980	NA	-0.67	-14.55	-0.56	8.81e-40	Subjective well-being;
LGG	cis	rs73416724	0.920	rs76088627	chr6:43311851	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.43	0.36	4.37e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1451375	0.698	rs12669770	chr7:50656334	G/A	cg20336341	chr7:50628841	DDC	0.37	7.25	0.32	1.76e-12	Malaria;
LGG	trans	rs2749592	0.531	rs1208559	chr10:38221370	T/C	cg04469686	chr1:162760199	HSD17B7	0.44	7.64	0.33	1.28e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg20110707	chr11:118481992	PHLDB1	0.5	10.38	0.43	8.08e-23	Cholesterol, total;
LGG	cis	rs2247341	0.894	rs61675353	chr4:1720794	T/G	cg07465881	chr4:1713556	SLBP	-0.46	-7.35	-0.32	9.11e-13	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4474465	1.000	rs10899506	chr11:78168705	C/T	cg02023728	chr11:77925099	USP35	0.39	6.79	0.3	3.47e-11	Alzheimer's disease (survival time);
LGG	cis	rs3784262	0.740	rs1372369	chr15:58294381	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.85	-0.3	2.4e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11622475	1.000	rs12889168	chr14:104481957	A/T	cg12183467	chr14:104352244	NA	-0.41	-7.16	-0.32	3.16e-12	Bipolar disorder;
LGG	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg03576123	chr11:487126	PTDSS2	-1.22	-16.22	-0.6	3.67e-47	Body mass index;
LGG	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg00701064	chr4:6280414	WFS1	0.74	15.88	0.59	1.22e-45	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1862618	0.671	rs2591955	chr5:56244948	C/T	cg08400814	chr5:56204995	C5orf35	0.4	7.12	0.31	4.02e-12	Initial pursuit acceleration;
LGG	cis	rs3733585	0.654	rs4447863	chr4:9938969	T/C	cg08250081	chr4:10125330	NA	-0.36	-7.07	-0.31	5.71e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.62	-0.37	1.04e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg05335186	chr13:53173507	NA	0.59	13.17	0.52	7.5e-34	Lewy body disease;
LGG	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg20848291	chr7:100343083	ZAN	0.67	9.85	0.42	6.48e-21	Other erythrocyte phenotypes;
LGG	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.41	-8.76	-0.38	3.61e-17	Restless legs syndrome;
LGG	cis	rs2404602	0.692	rs35077207	chr15:76935306	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	cis	rs986417	1.000	rs1254286	chr14:60858300	T/C	cg27398547	chr14:60952738	C14orf39	-0.67	-6.73	-0.3	5.16e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7717393	1.000	rs72798928	chr5:155790471	G/A	cg04435420	chr5:155754009	SGCD	0.97	11.12	0.46	1.23e-25	Egg allergy;
LGG	cis	rs11966931	1.000	rs6920062	chr6:108108201	A/T	cg04749840	chr6:108095067	SCML4	0.42	7.13	0.31	3.77e-12	Neutrophil percentage of white cells;
LGG	cis	rs992157	0.835	rs6729058	chr2:219148369	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.26	-0.43	2.24e-22	Colorectal cancer;
LGG	cis	rs6580649	0.883	rs7967762	chr12:48420214	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.67	-0.3	7.12e-11	Lung cancer;
LGG	cis	rs295137	0.799	rs4145969	chr2:201139961	C/T	cg23649088	chr2:200775458	C2orf69	-0.43	-7.55	-0.33	2.28e-13	Asthma (bronchodilator response);
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg07243736	chr16:783730	NARFL	0.4	6.79	0.3	3.39e-11	Height;
LGG	cis	rs2304069	0.909	rs2544931	chr5:149367837	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.62	-8.14	-0.35	3.65e-15	HIV-1 control;
LGG	cis	rs7267979	1.000	rs2257985	chr20:25269743	G/T	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7638995	0.701	rs34550101	chr3:69185670	C/T	cg26574240	chr3:69171822	LMOD3	-0.71	-8.98	-0.39	6.96e-18	Alzheimer's disease (late onset);
LGG	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs372883	0.901	rs733610	chr21:30656199	G/A	cg24692254	chr21:30365293	RNF160	-0.45	-7.94	-0.35	1.5e-14	Pancreatic cancer;
LGG	cis	rs7666738	0.830	rs13110903	chr4:98946373	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs35264875	1.000	rs7110274	chr11:68842704	A/G	cg01403660	chr11:68851641	TPCN2	0.49	6.96	0.31	1.18e-11	Blond vs. brown hair color;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.72	0.54	3.4e-36	Obesity-related traits;
LGG	cis	rs35538253	0.522	rs12934297	chr16:72022821	A/G	cg08717414	chr16:71523259	ZNF19	-0.74	-8.14	-0.35	3.61e-15	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7133214	0.771	rs11049140	chr12:27929501	G/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.91	-0.31	1.58e-11	Gut microbiota (functional units);
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	cis	rs1348850	0.793	rs13000048	chr2:178337089	C/A	cg27490568	chr2:178487706	NA	0.48	9.46	0.4	1.51e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.7	12.82	0.51	1.99e-32	Hip circumference adjusted for BMI;
LGG	cis	rs9715521	0.867	rs7437815	chr4:59826005	T/C	cg11281224	chr4:60001000	NA	-0.42	-7.08	-0.31	5.47e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1256061	0.603	rs1256045	chr14:64729760	A/C	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7044106	0.887	rs1359328	chr9:123370822	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.72	11.36	0.47	1.49e-26	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg06850241	chr22:41845214	NA	-0.43	-6.8	-0.3	3.24e-11	Vitiligo;
LGG	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg20302533	chr7:39170763	POU6F2	0.43	10.02	0.42	1.57e-21	IgG glycosylation;
LGG	cis	rs13191362	1.000	rs13207239	chr6:163008772	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.99e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7781557	0.640	rs66712128	chr7:102616987	T/C	cg18108683	chr7:102477205	FBXL13	-0.55	-8.43	-0.36	4.3e-16	Colorectal adenoma (advanced);
LGG	cis	rs7020830	0.571	rs7031314	chr9:37376122	A/T	cg14294708	chr9:37120828	ZCCHC7	-0.91	-15.2	-0.58	1.27e-42	Schizophrenia;
LGG	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.2e-22	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.08	0.49	2.09e-29	Prudent dietary pattern;
LGG	cis	rs2247341	0.928	rs2290011	chr4:1746229	G/T	cg07465881	chr4:1713556	SLBP	-0.45	-7.05	-0.31	6.62e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs3770081	1.000	rs78646493	chr2:86283195	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.97	-8.57	-0.37	1.52e-16	Facial emotion recognition (sad faces);
LGG	cis	rs10851411	0.559	rs62019322	chr15:42897374	T/C	cg21293051	chr15:42870591	STARD9	0.54	7.64	0.33	1.26e-13	Glucose homeostasis traits;
LGG	cis	rs61990749	0.597	rs72685264	chr14:78152998	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.02	-0.31	7.75e-12	Fibroblast growth factor basic levels;
LGG	cis	rs6496932	0.802	rs8038403	chr15:85856595	G/T	cg19183879	chr15:85880815	NA	0.42	6.74	0.3	4.79e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs6693567	0.565	rs696615	chr1:150338988	A/C	cg15654264	chr1:150340011	RPRD2	0.33	6.76	0.3	4.26e-11	Migraine;
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg24829409	chr8:58192753	C8orf71	-0.66	-8.51	-0.37	2.39e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.747	rs7650703	chr3:160851639	T/C	cg04691961	chr3:161091175	C3orf57	-0.54	-11.74	-0.48	5.07e-28	Morning vs. evening chronotype;
LGG	cis	rs10927875	0.619	rs7546589	chr1:16129530	A/G	cg21385522	chr1:16154831	NA	-0.72	-14.55	-0.56	8.76e-40	Dilated cardiomyopathy;
LGG	cis	rs477895	0.713	rs12575642	chr11:63979643	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.32	0.47	2.24e-26	Mean platelet volume;
LGG	cis	rs9457247	0.663	rs1894603	chr6:167434686	C/T	cg07741184	chr6:167504864	NA	-0.39	-8.54	-0.37	1.96e-16	Crohn's disease;
LGG	cis	rs2071403	0.509	rs55980998	chr2:1408999	T/A	cg06500727	chr2:1417164	TPO	-0.6	-12.14	-0.49	1.23e-29	Thyroid peroxidase antibody positivity;
LGG	trans	rs9467711	0.651	rs2237228	chr6:26104630	C/T	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.22	-0.32	2.12e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11608355	0.515	rs12826754	chr12:109923244	A/G	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs7223966	1.000	rs7217982	chr17:61832150	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.61	-0.33	1.6e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24378470	chr17:9478950	WDR16;STX8	0.46	7.67	0.34	1.03e-13	Cognitive performance;
LGG	cis	rs875971	0.895	rs6460278	chr7:65662736	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.79	-0.3	3.37e-11	Aortic root size;
LGG	cis	rs9354308	0.764	rs1353877	chr6:66569619	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs7659604	0.539	rs3217771	chr4:122739483	G/A	cg19748678	chr4:122722346	EXOSC9	0.68	13.84	0.54	1.02e-36	Type 2 diabetes;
LGG	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg07570687	chr10:102243282	WNT8B	0.42	6.95	0.31	1.22e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs992157	0.735	rs13430006	chr2:219113089	A/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-10.1	-0.42	8.11e-22	Colorectal cancer;
LGG	cis	rs2120243	0.874	rs1840680	chr3:157156029	A/G	cg01018701	chr3:157155998	VEPH1;PTX3	0.34	7.27	0.32	1.51e-12	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs8141529	0.711	rs5752797	chr22:29179998	C/T	cg15103426	chr22:29168792	CCDC117	0.59	7.69	0.34	8.76e-14	Lymphocyte counts;
LGG	cis	rs4538187	1.000	rs6755646	chr2:64091533	A/G	cg02541582	chr2:64069798	UGP2	0.61	14.46	0.56	2.26e-39	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg23782820	chr8:58130467	NA	0.43	6.68	0.3	6.82e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg13047869	chr3:10149882	C3orf24	0.53	8.99	0.39	6.44e-18	Alzheimer's disease;
LGG	cis	rs9318086	0.712	rs1886970	chr13:24440498	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	0.5	9.71	0.41	2.06e-20	Myopia (pathological);
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg11360546	chr7:1094263	C7orf50	-0.42	-7.58	-0.33	1.84e-13	Longevity;Endometriosis;
LGG	trans	rs7824557	0.564	rs11781637	chr8:11214972	C/T	cg16141378	chr3:129829833	LOC729375	0.34	7.52	0.33	2.8e-13	Retinal vascular caliber;
LGG	cis	rs1862618	0.853	rs252915	chr5:56121754	C/T	cg17809284	chr5:56205270	C5orf35	0.54	8.87	0.38	1.61e-17	Initial pursuit acceleration;
LGG	cis	rs2013441	1.000	rs4924809	chr17:20044673	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.15	-0.49	1.09e-29	Response to antipsychotic treatment;
LGG	cis	rs6977660	1.000	rs2892940	chr7:19794750	G/A	cg07541023	chr7:19748670	TWISTNB	0.49	7.61	0.33	1.56e-13	Thyroid stimulating hormone;
LGG	cis	rs4722166	0.630	rs12537614	chr7:22789551	C/G	cg05265849	chr7:22767390	IL6	0.36	7.2	0.32	2.49e-12	Lung cancer;
LGG	cis	rs826838	1.000	rs10875717	chr12:38911174	T/C	cg26384229	chr12:38710491	ALG10B	1.06	28.23	0.8	1.09e-102	Heart rate;
LGG	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2880765	0.743	rs7168345	chr15:86013601	A/G	cg13263323	chr15:86062960	AKAP13	0.35	7.07	0.31	5.76e-12	Coronary artery disease;
LGG	cis	rs10504229	0.817	rs35207430	chr8:58167614	G/A	cg02725872	chr8:58115012	NA	-0.81	-11.64	-0.48	1.23e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	10.06	0.42	1.14e-21	Bipolar disorder;
LGG	cis	rs10463554	0.892	rs11952337	chr5:102263747	G/C	cg23492399	chr5:102201601	PAM	-0.53	-8.17	-0.35	3.03e-15	Parkinson's disease;
LGG	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg05535760	chr7:792225	HEATR2	0.97	14.63	0.56	3.95e-40	Cerebrospinal P-tau181p levels;
LGG	trans	rs61931739	0.534	rs4539411	chr12:34014807	T/C	cg26384229	chr12:38710491	ALG10B	0.74	15.04	0.57	6.31e-42	Morning vs. evening chronotype;
LGG	cis	rs7315438	0.512	rs1391710	chr12:115941658	A/T	cg18639984	chr12:115943877	NA	0.41	9.03	0.39	4.49e-18	Colorectal cancer;
LGG	cis	rs870825	0.929	rs72689269	chr4:185592085	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	19.01	0.66	5.58e-60	Blood protein levels;
LGG	cis	rs4076764	1.000	rs6683181	chr1:163417077	C/T	cg06092702	chr1:163392909	NA	-0.46	-8.14	-0.35	3.77e-15	Motion sickness;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg05165339	chr4:1420672	NA	-0.27	-6.91	-0.31	1.59e-11	Obesity-related traits;
LGG	cis	rs754466	0.651	rs11002317	chr10:79617648	G/A	cg17075019	chr10:79541650	NA	-0.94	-19.98	-0.68	1.73e-64	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.68e-13	Lung cancer;
LGG	cis	rs7824557	0.545	rs34482136	chr8:11227885	C/T	cg15596359	chr8:11213517	TDH	0.43	8.67	0.37	7.23e-17	Retinal vascular caliber;
LGG	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg02822958	chr2:46747628	ATP6V1E2	-0.41	-7.22	-0.32	2.21e-12	HDL cholesterol;
LGG	cis	rs3742264	0.656	rs9534265	chr13:46547022	A/C	cg15192986	chr13:46630673	CPB2	-0.36	-6.9	-0.31	1.71e-11	Blood protein levels;
LGG	cis	rs12780845	0.540	rs10490959	chr10:17230836	A/T	cg01003015	chr10:17271136	VIM	-0.44	-7.53	-0.33	2.74e-13	Homocysteine levels;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg04234412	chr22:24373322	LOC391322	0.75	15.28	0.58	5.61e-43	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg05556477	chr5:131705319	SLC22A5	0.81	9.8	0.41	9.82e-21	Rheumatoid arthritis;
LGG	cis	rs11168854	0.656	rs7969967	chr12:49512017	A/G	cg24176009	chr12:49580217	TUBA1A	-0.6	-11.54	-0.47	2.95e-27	Body mass index;
LGG	cis	rs35306767	0.951	rs61833265	chr10:990143	C/T	cg20503657	chr10:835505	NA	0.64	8.82	0.38	2.28e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs240764	0.612	rs9373504	chr6:100941037	A/G	cg21058520	chr6:100914733	NA	0.48	8.42	0.36	4.92e-16	Neuroticism;
LGG	cis	rs2463822	0.858	rs2513037	chr11:62084822	A/T	cg06239285	chr11:62104954	ASRGL1	-1.17	-16.52	-0.61	1.56e-48	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs10489202	0.608	rs10918827	chr1:168077044	A/G	cg24449463	chr1:168025552	DCAF6	0.57	10.15	0.43	5.32e-22	Schizophrenia;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.65	-0.3	8.46e-11	Iron status biomarkers;
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg08835221	chr22:38071607	LGALS1	-0.28	-7.78	-0.34	4.67e-14	Fat distribution (HIV);
LGG	cis	rs963731	0.649	rs75712619	chr2:39357262	G/C	cg04010122	chr2:39346883	SOS1	0.95	7.73	0.34	6.98e-14	Corticobasal degeneration;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg23758822	chr17:41437982	NA	0.86	15.12	0.58	2.77e-42	Menopause (age at onset);
LGG	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.45	-0.33	4.63e-13	Obesity-related traits;
LGG	cis	rs2535633	0.631	rs2257216	chr3:52968726	T/C	cg11645453	chr3:52864694	ITIH4	-0.48	-7.86	-0.34	2.78e-14	Body mass index;
LGG	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19738812	chr7:99102438	ZKSCAN5	0.49	8.33	0.36	9.39e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs4006360	0.574	rs35944108	chr17:39238561	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.4	-0.47	1.09e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.13	-0.35	3.97e-15	Monocyte count;
LGG	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg04492858	chr10:133558786	NA	0.43	8.89	0.38	1.33e-17	Survival in rectal cancer;
LGG	cis	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg18252515	chr7:66147081	NA	-1.41	-20.61	-0.69	1.84e-67	Diabetic kidney disease;
LGG	cis	rs561341	0.882	rs28649357	chr17:30367190	A/G	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.14	-0.43	5.89e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7100689	0.646	rs10788562	chr10:82072310	C/T	cg01528321	chr10:82214614	TSPAN14	-0.82	-14.75	-0.57	1.21e-40	Post bronchodilator FEV1;
LGG	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg05623727	chr3:50126028	RBM5	-0.37	-8.12	-0.35	4.36e-15	Intelligence (multi-trait analysis);
LGG	trans	rs6787172	0.652	rs827132	chr3:158014894	T/A	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs3087591	0.801	rs2012535	chr17:29561391	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.7	-14.75	-0.57	1.23e-40	Hip circumference;
LGG	cis	rs651907	0.535	rs13094753	chr3:101525082	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.98	10.61	0.44	1.11e-23	Diabetic retinopathy;
LGG	trans	rs61931739	0.534	rs12831685	chr12:34038392	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.64	0.56	3.65e-40	Morning vs. evening chronotype;
LGG	cis	rs17767392	0.914	rs28859432	chr14:72010693	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.28	-0.32	1.48e-12	Mitral valve prolapse;
LGG	cis	rs3126085	0.935	rs1390490	chr1:152161354	T/C	cg26876637	chr1:152193138	HRNR	0.53	8.28	0.36	1.3e-15	Atopic dermatitis;
LGG	cis	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.15	-0.32	3.37e-12	Joint mobility (Beighton score);
LGG	cis	rs72901758	0.696	rs72909029	chr17:76249451	A/G	cg26068271	chr17:76253126	NA	0.51	10.69	0.44	5.69e-24	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs3857067	0.806	rs4693001	chr4:95115097	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs1401999	0.714	rs1000002	chr3:183635768	A/G	cg05044414	chr3:183734942	ABCC5	-0.56	-11.25	-0.46	4.18e-26	Anterior chamber depth;
LGG	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2718058	0.589	rs10258880	chr7:37793033	C/T	cg24998770	chr7:37888106	TXNDC3	-0.41	-6.96	-0.31	1.21e-11	Alzheimer's disease (late onset);
LGG	cis	rs6582630	0.519	rs8186881	chr12:38310285	A/G	cg26384229	chr12:38710491	ALG10B	0.92	20.65	0.69	1.22e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28595532	0.920	rs28797314	chr4:119783044	A/G	cg21605333	chr4:119757512	SEC24D	1.48	14.95	0.57	1.65e-41	Cannabis dependence symptom count;
LGG	cis	rs9611519	0.780	rs2235850	chr22:41657626	C/T	cg06634786	chr22:41940651	POLR3H	-0.51	-8.62	-0.37	1.07e-16	Neuroticism;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.39	0.32	7.09e-13	Tonsillectomy;
LGG	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg05491587	chr18:77659695	KCNG2	0.39	7.18	0.32	2.78e-12	Schizophrenia;
LGG	cis	rs8177253	0.965	rs8177260	chr3:133480458	T/A	cg11941060	chr3:133502564	NA	-0.48	-8.19	-0.36	2.59e-15	Iron status biomarkers;
LGG	cis	rs9397585	0.857	rs9371666	chr6:153387288	G/A	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.28e-38	Body mass index;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20819397	chr9:123964132	RAB14	0.38	6.85	0.3	2.33e-11	Obesity-related traits;
LGG	cis	rs9921222	1.000	rs10794639	chr16:377367	A/G	cg07915516	chr16:377344	AXIN1	0.35	10.61	0.44	1.09e-23	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9747201	1.000	rs9303023	chr17:80175920	C/T	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs16854884	0.657	rs34683397	chr3:143723559	C/T	cg06585982	chr3:143692056	C3orf58	0.57	9.64	0.41	3.56e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs1957429	0.522	rs57319601	chr14:65415743	C/T	cg23373153	chr14:65346875	NA	-0.93	-9.74	-0.41	1.67e-20	Pediatric areal bone mineral density (radius);
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg04503457	chr17:41445688	NA	-0.4	-9.94	-0.42	3.13e-21	Menopause (age at onset);
LGG	cis	rs61931739	0.517	rs860950	chr12:34104376	C/G	cg06521331	chr12:34319734	NA	-0.61	-11.54	-0.47	3e-27	Morning vs. evening chronotype;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.88	0.42	5.21e-21	Tonsillectomy;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.81	0.82	3.5e-114	Prudent dietary pattern;
LGG	trans	rs9929218	0.906	rs10852450	chr16:68749529	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-15.52	-0.58	4.68e-44	Colorectal cancer;
LGG	cis	rs9583531	0.600	rs4773241	chr13:111363021	A/G	cg15841412	chr13:111365552	ING1	0.48	7.38	0.32	7.55e-13	Coronary artery disease;
LGG	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-12.99	-0.52	4.18e-33	Schizophrenia;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-9.7	-0.41	2.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.63	-0.33	1.39e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3816183	1.000	rs2278580	chr2:43020841	T/C	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.24e-18	Hypospadias;
LGG	cis	rs35306767	0.715	rs11253539	chr10:1011347	G/A	cg26597838	chr10:835615	NA	0.54	7.07	0.31	5.62e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg05335186	chr13:53173507	NA	0.43	8.57	0.37	1.6e-16	Lewy body disease;
LGG	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs11758351	0.500	rs74974409	chr6:26194402	A/G	cg02612650	chr6:26195910	NA	0.88	6.85	0.3	2.4e-11	Gout;Renal underexcretion gout;
LGG	cis	rs6076065	0.548	rs1112819	chr20:23323987	A/G	cg11657817	chr20:23433608	CST11	0.37	7.08	0.31	5.29e-12	Facial morphology (factor 15, philtrum width);
LGG	trans	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs2290402	0.536	rs73207791	chr4:865941	A/G	cg09237302	chr4:906077	GAK	-0.44	-7.48	-0.33	3.81e-13	Type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14580567	chr4:145567271	HHIP	0.39	6.91	0.31	1.61e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg00405596	chr8:11794950	NA	-0.6	-10.53	-0.44	2.21e-23	Monocyte count;
LGG	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg06766960	chr11:133703094	NA	-0.55	-11.01	-0.46	3.34e-25	Childhood ear infection;
LGG	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg15704280	chr7:45808275	SEPT13	0.47	7.7	0.34	8.19e-14	HDL cholesterol;
LGG	cis	rs7216064	1.000	rs9897982	chr17:65879592	G/T	cg12091567	chr17:66097778	LOC651250	-0.63	-9.26	-0.4	7.41e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07988820	chr12:82153109	PPFIA2	0.59	8.68	0.37	6.69e-17	Resting heart rate;
LGG	cis	rs1801251	1.000	rs6717841	chr2:233590255	C/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	5.23e-19	Coronary artery disease;
LGG	cis	rs7084402	1.000	rs1346301	chr10:60267310	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.74	-0.64	4.16e-54	Refractive error;
LGG	cis	rs13191362	1.000	rs73035021	chr6:163000716	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.99	-8.39	-0.36	5.77e-16	Facial emotion recognition (sad faces);
LGG	cis	rs1059312	1.000	rs7302634	chr12:129279931	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.37	-0.63	1.99e-52	Systemic lupus erythematosus;
LGG	cis	rs787274	1.000	rs1361720	chr9:115535579	G/A	cg13803584	chr9:115635662	SNX30	-0.55	-7.68	-0.34	9.24e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4665809	0.652	rs2241739	chr2:26411894	C/T	cg08470875	chr2:26401718	FAM59B	-0.39	-7.77	-0.34	5.14e-14	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.580	rs9378556	chr6:8514695	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.14	0.43	5.86e-22	Motion sickness;
LGG	cis	rs9479482	1.000	rs9479481	chr6:150357944	A/G	cg03788504	chr6:150331562	NA	-0.59	-13.22	-0.52	4.62e-34	Alopecia areata;
LGG	cis	rs9527	0.590	rs7897663	chr10:104905604	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.75	-0.3	4.37e-11	Arsenic metabolism;
LGG	trans	rs9929218	1.000	rs2113199	chr16:68814502	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.19	-0.52	5.96e-34	Colorectal cancer;
LGG	trans	rs61931739	0.649	rs2263218	chr12:33729679	C/G	cg26384229	chr12:38710491	ALG10B	0.48	8.59	0.37	1.35e-16	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.49	-0.33	3.51e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6988985	0.658	rs28674937	chr8:143938532	G/A	cg10324643	chr8:143916377	GML	0.39	7.78	0.34	4.61e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.44	-0.4	1.82e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs12101539	chr15:45650666	C/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs1555895	0.576	rs4229	chr10:856918	A/T	cg09361094	chr10:834503	NA	-0.29	-7.59	-0.33	1.78e-13	Survival in rectal cancer;
LGG	cis	rs7582720	0.945	rs72932722	chr2:203647598	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.35	0.4	3.9e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs12118280	0.612	rs591141	chr1:108694894	A/G	cg11967332	chr1:108735228	SLC25A24	0.43	7.31	0.32	1.18e-12	Myeloid white cell count;
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.81	-12.21	-0.49	6.14e-30	Alzheimer's disease;
LGG	cis	rs6429082	0.623	rs7547849	chr1:235564254	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.7	-11.85	-0.48	1.85e-28	Adiposity;
LGG	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg06360820	chr2:242988706	NA	-0.92	-12.17	-0.49	9.14e-30	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg26677194	chr12:130822605	PIWIL1	0.57	10.18	0.43	4.27e-22	Menopause (age at onset);
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg13094338	chr20:62258937	GMEB2	-0.36	-6.75	-0.3	4.41e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	0.945	rs6974282	chr7:100098295	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.06	0.66	3.1e-60	Platelet count;
LGG	cis	rs8133932	1.000	rs8133932	chr21:47211085	C/T	cg11214348	chr21:47283868	PCBP3	-0.42	-7.0	-0.31	8.81e-12	Schizophrenia;
LGG	cis	rs4356975	0.563	rs12513195	chr4:69972086	T/G	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs1451375	0.617	rs1376524	chr7:50563582	G/A	cg20336341	chr7:50628841	DDC	-0.43	-7.45	-0.33	4.57e-13	Malaria;
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg22907277	chr7:1156413	C7orf50	0.46	8.02	0.35	8.58e-15	Longevity;Endometriosis;
LGG	cis	rs6912958	0.874	rs9294381	chr6:88152681	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.61	-0.44	1.09e-23	Monocyte percentage of white cells;
LGG	cis	rs7681440	0.933	rs10005233	chr4:90743331	C/T	cg15133208	chr4:90757351	SNCA	-0.37	-8.5	-0.37	2.54e-16	Dementia with Lewy bodies;
LGG	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg13114125	chr14:105738426	BRF1	-0.86	-17.39	-0.63	1.73e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7819412	0.669	rs6601568	chr8:11073402	G/A	cg21775007	chr8:11205619	TDH	-0.53	-8.49	-0.37	2.78e-16	Triglycerides;
LGG	cis	rs60695258	0.550	rs4693800	chr4:87915620	C/G	cg11209507	chr4:87813803	C4orf36	-0.48	-8.17	-0.36	2.88e-15	Hematocrit;
LGG	cis	rs72781680	1.000	rs17711825	chr2:24124578	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.47	0.4	1.47e-19	Lymphocyte counts;
LGG	cis	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs2204008	0.775	rs2387809	chr12:38363338	T/A	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Bladder cancer;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg05025164	chr4:1340916	KIAA1530	0.49	8.52	0.37	2.32e-16	Obesity-related traits;
LGG	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg14829360	chr17:73884958	NA	-0.83	-15.22	-0.58	1.04e-42	Psoriasis;
LGG	cis	rs9457247	0.646	rs239934	chr6:167412048	G/A	cg07741184	chr6:167504864	NA	0.35	7.58	0.33	1.87e-13	Crohn's disease;
LGG	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Aortic root size;
LGG	cis	rs1953600	0.805	rs2819947	chr10:81947757	T/C	cg04850286	chr10:81895943	PLAC9	0.43	9.47	0.4	1.42e-19	Sarcoidosis;
LGG	cis	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.47	-0.44	3.51e-23	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.680	rs73073296	chr3:42028074	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4731207	0.698	rs2040926	chr7:124457295	C/G	cg05630886	chr7:124431682	NA	-0.34	-7.91	-0.35	1.91e-14	Cutaneous malignant melanoma;
LGG	cis	rs1799949	0.965	rs34616041	chr17:41188786	G/A	cg12708336	chr17:41446283	NA	-0.31	-6.92	-0.31	1.47e-11	Menopause (age at onset);
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg07120314	chr15:79043507	NA	-0.72	-16.25	-0.6	2.49e-47	Coronary artery disease or large artery stroke;
LGG	cis	rs4481887	0.708	rs6587463	chr1:248544452	G/C	cg00666640	chr1:248458726	OR2T12	0.54	8.97	0.38	7.67e-18	Common traits (Other);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg02083376	chr11:44120437	EXT2	-0.42	-7.02	-0.31	7.74e-12	Apolipoprotein A-IV levels;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg16507663	chr6:150244633	RAET1G	0.41	7.73	0.34	6.7e-14	Lung cancer;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg15242686	chr22:24348715	GSTTP1	0.42	7.69	0.34	9.12e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg05484376	chr2:27715224	FNDC4	0.47	10.24	0.43	2.45e-22	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08219700	chr8:58056026	NA	0.47	7.05	0.31	6.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2885056	0.800	rs8105074	chr19:10708692	A/G	cg04833646	chr19:10679720	CDKN2D	0.95	14.14	0.55	5.32e-38	Red cell distribution width;
LGG	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg22535103	chr8:58192502	C8orf71	-0.47	-7.45	-0.33	4.48e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1564892	1.000	rs1564892	chr12:104445742	A/G	cg14987745	chr12:104360022	TDG	0.47	6.86	0.3	2.16e-11	Corneal structure;
LGG	cis	rs139371	0.742	rs139318	chr22:39500932	G/A	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.93	-0.31	1.43e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs10949834	0.817	rs6460071	chr7:73497196	G/A	cg07137043	chr7:73588983	EIF4H	-0.58	-6.99	-0.31	9.88e-12	Verbal memory performance (residualized delayed recall change);
LGG	trans	rs13128441	0.528	rs13115405	chr4:5185925	C/T	cg26099876	chr8:141644609	EIF2C2	0.56	8.67	0.37	7.49e-17	Celiac disease;
LGG	cis	rs9473924	0.542	rs9473923	chr6:50833565	A/T	cg14470998	chr6:50812995	TFAP2B	0.68	8.3	0.36	1.12e-15	Body mass index;
LGG	cis	rs6963495	0.872	rs73190193	chr7:105164852	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg03060546	chr3:49711283	APEH	-0.62	-10.24	-0.43	2.5e-22	Educational attainment (college completion);
LGG	cis	rs4642101	0.640	rs9877049	chr3:12821231	A/G	cg05775895	chr3:12838266	CAND2	0.79	15.67	0.59	1.06e-44	QRS complex (12-leadsum);
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg05025164	chr4:1340916	KIAA1530	0.86	16.91	0.62	2.64e-50	Longevity;
LGG	cis	rs9398803	0.865	rs9385399	chr6:126759033	A/C	cg19875578	chr6:126661172	C6orf173	-0.52	-9.37	-0.4	3.13e-19	Male-pattern baldness;
LGG	cis	rs1185460	0.565	rs657685	chr11:118912982	G/C	cg23280166	chr11:118938394	VPS11	-0.43	-7.39	-0.32	7.02e-13	Coronary artery disease;
LGG	cis	rs752010	0.662	rs10890154	chr1:42106740	C/T	cg06885757	chr1:42089581	HIVEP3	0.52	11.7	0.48	6.88e-28	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs4918072	0.798	rs2067831	chr10:105643223	G/C	cg11005552	chr10:105648138	OBFC1	0.72	12.09	0.49	1.87e-29	Coronary artery disease;
LGG	cis	rs11225247	0.881	rs11225235	chr11:102247361	G/A	cg06323957	chr11:102217781	BIRC2	0.83	7.21	0.32	2.26e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9875589	0.509	rs7648345	chr3:14039901	G/A	cg19554555	chr3:13937349	NA	-0.54	-9.77	-0.41	1.28e-20	Ovarian reserve;
LGG	cis	rs4774899	0.752	rs2733185	chr15:57361347	G/A	cg08128148	chr15:57256372	TCF12	-0.28	-6.81	-0.3	3.12e-11	Urinary tract infection frequency;
LGG	cis	rs2692947	0.537	rs11682182	chr2:96378210	A/G	cg06850509	chr2:96314847	NA	-0.37	-6.93	-0.31	1.45e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7000551	0.725	rs4871998	chr8:22308150	A/T	cg12081754	chr8:22256438	SLC39A14	0.7	13.92	0.54	5.02e-37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg02487422	chr3:49467188	NICN1	0.44	7.09	0.31	4.96e-12	Resting heart rate;
LGG	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.49	0.33	3.51e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg11266682	chr4:10021025	SLC2A9	-0.48	-9.27	-0.4	6.85e-19	Bone mineral density;
LGG	cis	rs1620921	0.625	rs9458045	chr6:161262083	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3768617	0.510	rs6424884	chr1:183065904	C/T	cg07245641	chr1:182991651	LAMC1	0.43	9.83	0.42	7.91e-21	Fuchs's corneal dystrophy;
LGG	cis	rs7119038	0.509	rs11216964	chr11:118581895	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.81	0.3	3.08e-11	Sjögren's syndrome;
LGG	cis	rs9596863	0.747	rs9568899	chr13:54317473	A/G	ch.13.53330881F	chr13:54432880	NA	0.5	6.92	0.31	1.53e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07677032	chr17:61819896	STRADA	0.67	12.44	0.5	7.33e-31	Prudent dietary pattern;
LGG	cis	rs4718428	0.672	rs4718412	chr7:66286867	C/T	cg13147721	chr7:65941812	NA	0.44	6.89	0.31	1.81e-11	Corneal structure;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg15352829	chr14:105391018	PLD4	0.47	11.51	0.47	3.99e-27	Rheumatoid arthritis;
LGG	cis	rs35264875	0.950	rs35337391	chr11:68854012	A/G	cg23845249	chr11:68861649	NA	0.45	8.09	0.35	5.36e-15	Blond vs. brown hair color;
LGG	cis	rs17270561	0.887	rs9358870	chr6:25719210	T/C	cg17691542	chr6:26056736	HIST1H1C	0.78	11.07	0.46	2.01e-25	Iron status biomarkers;
LGG	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.67	-0.37	7.58e-17	Alcohol dependence;
LGG	cis	rs67311347	0.869	rs9832311	chr3:40381322	A/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.11	-0.68	4.23e-65	Renal cell carcinoma;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg00166722	chr3:10149974	C3orf24	0.54	8.91	0.38	1.15e-17	Alzheimer's disease;
LGG	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.84	18.19	0.65	3.65e-56	Menarche (age at onset);
LGG	cis	rs526231	0.511	rs11951374	chr5:102355798	C/A	cg23492399	chr5:102201601	PAM	-0.54	-8.02	-0.35	8.98e-15	Primary biliary cholangitis;
LGG	cis	rs1862618	0.853	rs860580	chr5:56149429	G/T	cg08400814	chr5:56204995	C5orf35	0.47	7.65	0.33	1.21e-13	Initial pursuit acceleration;
LGG	cis	rs3820068	0.705	rs4646092	chr1:15821673	C/T	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs6964587	1.000	rs61244255	chr7:91751662	C/T	cg17063962	chr7:91808500	NA	0.51	9.18	0.39	1.41e-18	Breast cancer;
LGG	cis	rs2386661	0.547	rs57893347	chr10:5646191	G/A	cg12223502	chr10:5658492	NA	-0.37	-7.07	-0.31	5.83e-12	Breast cancer;
LGG	cis	rs57502260	0.704	rs12286536	chr11:68290234	C/G	cg01657329	chr11:68192670	LRP5	-0.57	-7.22	-0.32	2.19e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs9467773	0.526	rs9348710	chr6:26360486	A/C	cg09904177	chr6:26538194	HMGN4	-0.47	-8.41	-0.36	5.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg12046867	chr14:103022105	NA	0.72	11.25	0.46	4.01e-26	Platelet count;
LGG	cis	rs13191362	1.000	rs34066731	chr6:163011047	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11920090	0.675	rs28374787	chr3:170761547	A/G	cg09710316	chr3:170744871	SLC2A2	0.65	7.71	0.34	7.87e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2439831	0.850	rs28707214	chr15:44131623	G/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.71	0.45	4.8e-24	Lung cancer in ever smokers;
LGG	cis	rs3219090	1.000	rs3219090	chr1:226564691	A/G	cg17127702	chr1:226594323	PARP1	-0.38	-12.05	-0.49	2.96e-29	Melanoma;
LGG	trans	rs61931739	0.500	rs34061369	chr12:34519283	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs4740619	1.000	rs4741524	chr9:15634249	A/T	cg14451791	chr9:16040625	NA	-0.41	-10.52	-0.44	2.44e-23	Body mass index;
LGG	cis	rs763121	0.819	rs5757133	chr22:38947835	A/G	cg06022373	chr22:39101656	GTPBP1	-0.82	-16.39	-0.61	6.18e-48	Menopause (age at onset);
LGG	cis	rs10819861	0.679	rs10819868	chr9:98871378	C/T	cg14508093	chr9:98862825	NA	0.29	6.77	0.3	3.92e-11	Electrocardiographic traits;
LGG	cis	rs11628318	0.853	rs7155171	chr14:103031845	C/T	cg01864069	chr14:103024347	NA	-0.73	-12.12	-0.49	1.51e-29	Platelet count;
LGG	cis	rs9611565	0.532	rs4401299	chr22:42156517	A/G	cg03806693	chr22:41940476	POLR3H	0.89	14.86	0.57	4.02e-41	Vitiligo;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg25937216	chr8:58172855	NA	-0.57	-9.14	-0.39	2e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.830	rs1337735	chr6:126771024	T/A	cg19875578	chr6:126661172	C6orf173	0.57	10.41	0.44	5.91e-23	Male-pattern baldness;
LGG	cis	rs11920090	0.722	rs56145901	chr3:170648260	G/T	cg09710316	chr3:170744871	SLC2A2	0.64	7.51	0.33	3.03e-13	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4642101	0.511	rs9809596	chr3:12840513	C/G	cg05775895	chr3:12838266	CAND2	0.78	15.31	0.58	4.15e-43	QRS complex (12-leadsum);
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09771049	chr17:66031798	KPNA2	0.41	6.95	0.31	1.26e-11	Lung adenocarcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04849129	chr2:191513396	NAB1	0.49	7.26	0.32	1.59e-12	Gut microbiome composition (summer);
LGG	cis	rs4474465	1.000	rs7928933	chr11:78193921	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.23	-0.36	1.88e-15	Alzheimer's disease (survival time);
LGG	cis	rs11203032	0.831	rs11203011	chr10:90931178	A/C	cg16672925	chr10:90967113	CH25H	0.71	10.15	0.43	5.55e-22	Heart failure;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.28e-14	Lung cancer;
LGG	cis	rs7582180	0.838	rs13024601	chr2:100902032	C/T	cg05692746	chr2:100937584	LONRF2	-0.57	-9.46	-0.4	1.59e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9921222	0.509	rs3743883	chr16:404750	T/C	cg04481126	chr16:423872	TMEM8A	0.37	7.1	0.31	4.84e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs2594989	0.831	rs7356051	chr3:11566288	A/C	cg01796438	chr3:11312864	ATG7	0.52	7.15	0.32	3.4e-12	Circulating chemerin levels;
LGG	cis	rs7017914	0.967	rs6993115	chr8:71699183	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs568617	1.000	rs641018	chr11:65655393	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.51	6.99	0.31	9.41e-12	Crohn's disease;
LGG	cis	rs4846580	0.622	rs1416005	chr1:219908728	T/C	cg08034750	chr1:219919793	NA	0.41	7.26	0.32	1.61e-12	Total body bone mineral density;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.78	-0.3	3.78e-11	Height;
LGG	cis	rs17270561	0.636	rs7754814	chr6:25745243	A/T	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.48e-12	Iron status biomarkers;
LGG	cis	rs2204008	0.720	rs11170774	chr12:38021722	C/T	cg13010199	chr12:38710504	ALG10B	-0.61	-12.82	-0.51	2.01e-32	Bladder cancer;
LGG	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg17757837	chr7:157058334	UBE3C	-0.78	-15.91	-0.59	8.62e-46	Body mass index;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg09359103	chr1:154839909	KCNN3	0.52	10.76	0.45	2.9e-24	Prostate cancer;
LGG	cis	rs72781680	1.000	rs115861480	chr2:24129464	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	10.1	0.42	8.39e-22	Lymphocyte counts;
LGG	cis	rs3099143	0.901	rs1813479	chr15:77168646	T/C	cg21673338	chr15:77095150	SCAPER	0.65	10.31	0.43	1.43e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg12826209	chr6:26865740	GUSBL1	0.8	9.01	0.39	5.54e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7312933	0.558	rs11181483	chr12:42798384	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.18	0.36	2.72e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs8060686	0.641	rs28508024	chr16:68126606	T/C	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.66e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg11984989	chr7:158649758	WDR60	0.95	20.78	0.69	3.01e-68	Height;
LGG	cis	rs11650494	0.710	rs2119935	chr17:47471334	T/C	cg08112188	chr17:47440006	ZNF652	1.2	13.19	0.52	5.72e-34	Prostate cancer;
LGG	cis	rs6866614	0.627	rs27437	chr5:131436961	A/G	cg07395648	chr5:131743802	NA	-0.38	-8.22	-0.36	2.08e-15	Perceived unattractiveness to mosquitoes;
LGG	trans	rs1972460	0.506	rs62012050	chr15:82532274	T/G	cg04831495	chr15:85060580	GOLGA6L5	-0.44	-8.65	-0.37	8.72e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg23950597	chr19:37808831	NA	0.53	7.6	0.33	1.71e-13	Coronary artery calcification;
LGG	cis	rs4237845	0.537	rs12426201	chr12:58259752	C/T	cg00677455	chr12:58241039	CTDSP2	0.39	7.02	0.31	7.76e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.681	rs28578454	chr15:43603032	G/A	cg15269541	chr15:43626905	ADAL	-0.41	-6.95	-0.31	1.23e-11	Lung cancer in ever smokers;
LGG	cis	rs4665809	0.590	rs13387855	chr2:26420708	T/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.12	-0.39	2.35e-18	Gut microbiome composition (summer);
LGG	cis	rs1580019	0.563	rs13244332	chr7:32537679	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.44	7.04	0.31	6.97e-12	Cognitive ability;
LGG	cis	rs2070433	0.539	rs2839312	chr21:47958225	T/C	cg12379764	chr21:47803548	PCNT	0.7	12.15	0.49	1.15e-29	Lymphocyte counts;
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg06925179	chr17:43578568	NA	0.37	9.3	0.4	5.54e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg23782820	chr8:58130467	NA	0.57	8.43	0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.513	rs12313652	chr12:38665412	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	trans	rs7395662	1.000	rs10838912	chr11:48496477	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.94	-0.35	1.55e-14	HDL cholesterol;
LGG	cis	rs9303280	0.806	rs11078927	chr17:38064405	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.83	-0.38	2.2e-17	Self-reported allergy;
LGG	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg10664184	chr19:17420304	DDA1	0.55	8.44	0.37	4.14e-16	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.6e-17	Prudent dietary pattern;
LGG	cis	rs17711722	0.727	rs35850374	chr7:65357776	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.62e-20	Calcium levels;
LGG	cis	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg05623727	chr3:50126028	RBM5	0.33	7.18	0.32	2.72e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	5.99e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28735056	0.591	rs2277724	chr18:77694294	C/A	cg09441152	chr18:77712293	PQLC1	0.41	6.93	0.31	1.39e-11	Schizophrenia;
LGG	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14298792	chr15:30685198	CHRFAM7A	0.53	7.93	0.35	1.67e-14	Huntington's disease progression;
LGG	cis	rs3815700	1.000	rs10407204	chr19:33097353	C/T	cg02997394	chr19:33096574	ANKRD27	0.9	13.59	0.53	1.24e-35	Eosinophilic esophagitis;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg26384229	chr12:38710491	ALG10B	0.92	20.78	0.69	3.01e-68	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09755102	chr1:33283495	S100PBP;YARS	0.4	7.08	0.31	5.42e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg22968622	chr17:43663579	NA	1.08	20.88	0.7	1.02e-68	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1829883	0.748	rs1916598	chr5:98743288	G/A	cg08333243	chr5:99726346	NA	0.34	6.68	0.3	6.77e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7107174	0.901	rs2511162	chr11:77927101	A/G	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	5.99e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs35740288	0.822	rs11630179	chr15:86282934	G/A	cg04173714	chr15:86211321	AKAP13	0.42	7.1	0.31	4.8e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.47	0.47	5.83e-27	Mood instability;
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6912958	0.559	rs499373	chr6:88042062	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.7	13.23	0.52	3.88e-34	Monocyte percentage of white cells;
LGG	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11644478	chr21:40555479	PSMG1	0.88	16.39	0.61	6.39e-48	Cognitive function;
LGG	cis	rs9611519	0.964	rs4820428	chr22:41537589	C/T	cg03806693	chr22:41940476	POLR3H	0.53	8.22	0.36	2.08e-15	Neuroticism;
LGG	cis	rs1707322	1.000	rs785497	chr1:46591903	G/C	cg03146154	chr1:46216737	IPP	-0.54	-9.41	-0.4	2.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg21775007	chr8:11205619	TDH	-0.42	-6.94	-0.31	1.31e-11	Mood instability;
LGG	cis	rs16854884	0.837	rs13062793	chr3:143808387	A/G	cg06585982	chr3:143692056	C3orf58	0.55	8.88	0.38	1.45e-17	Economic and political preferences (feminism/equality);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16977799	chr11:1785547	CTSD;HCCA2	0.44	6.88	0.3	1.93e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg16339924	chr4:17578868	LAP3	0.67	11.47	0.47	5.45e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8067545	0.611	rs8071274	chr17:20216928	T/C	cg09818912	chr17:20140352	CYTSB	0.3	7.04	0.31	7.01e-12	Schizophrenia;
LGG	trans	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.65	-0.3	8.32e-11	Triglycerides;
LGG	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.57	-0.33	2.04e-13	Iron status biomarkers;
LGG	trans	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg22232500	chr2:134024266	NCKAP5	0.69	9.66	0.41	3.19e-20	Bipolar disorder;
LGG	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.18	-0.43	4.14e-22	Height;
LGG	cis	rs9818758	0.607	rs73084135	chr3:49272218	A/G	cg00383909	chr3:49044727	WDR6	1.12	13.62	0.53	9.27e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg06558623	chr16:89946397	TCF25	0.89	11.66	0.48	1.04e-27	Skin colour saturation;
LGG	cis	rs12188164	1.000	rs72717414	chr5:429818	C/G	cg00976097	chr5:421733	AHRR	-0.43	-7.16	-0.32	3.17e-12	Cystic fibrosis severity;
LGG	cis	rs2201728	0.739	rs13147646	chr4:100148447	C/A	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs2153535	0.580	rs7753192	chr6:8482637	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.49	0.5	4.66e-31	Motion sickness;
LGG	trans	rs17807624	1.000	rs17807624	chr8:11463015	A/G	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.09	-0.35	5.1e-15	Systemic lupus erythematosus;
LGG	cis	rs2742417	1.000	rs938362	chr3:45746365	T/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6866344	0.570	rs1079487	chr5:178136005	G/A	cg03877680	chr5:178157825	ZNF354A	0.82	14.09	0.55	9.09e-38	Neutrophil percentage of white cells;
LGG	cis	rs7598759	0.679	rs6437018	chr2:232327691	A/C	cg19187155	chr2:232395269	NMUR1	0.42	7.59	0.33	1.82e-13	Noise-induced hearing loss;
LGG	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg19773385	chr1:10388646	KIF1B	-0.48	-9.77	-0.41	1.28e-20	Hepatocellular carcinoma;
LGG	cis	rs929596	0.958	rs17862873	chr2:234646722	A/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.78	-12.43	-0.5	8.26e-31	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg18876405	chr7:65276391	NA	0.68	13.01	0.52	3.23e-33	Calcium levels;
LGG	cis	rs2032447	0.765	rs6942072	chr6:26014987	A/G	cg03517284	chr6:25882590	NA	-0.61	-11.48	-0.47	5.16e-27	Intelligence (multi-trait analysis);
LGG	cis	rs9522267	0.737	rs9515448	chr13:112229526	A/T	cg10483660	chr13:112241077	NA	-0.39	-8.21	-0.36	2.2e-15	Hepatitis;
LGG	cis	rs2795502	0.938	rs3121324	chr10:43379515	C/T	cg20628663	chr10:43360327	NA	0.39	8.43	0.36	4.52e-16	Blood protein levels;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25072359	chr17:41440525	NA	0.53	10.43	0.44	5.16e-23	Menopause (age at onset);
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	6.92e-48	Intelligence (multi-trait analysis);
LGG	trans	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.75	-12.03	-0.49	3.52e-29	Obesity-related traits;
LGG	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg16576597	chr16:28551801	NUPR1	0.38	8.92	0.38	1.13e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7617773	1.000	rs6771889	chr3:48194326	C/T	cg11946769	chr3:48343235	NME6	-0.54	-8.5	-0.37	2.68e-16	Coronary artery disease;
LGG	cis	rs7615952	0.576	rs17523380	chr3:125802874	C/T	cg06494592	chr3:125709126	NA	-0.49	-6.86	-0.3	2.2e-11	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.68	-0.37	6.8e-17	Systemic lupus erythematosus;
LGG	trans	rs4942242	0.663	rs9525812	chr13:44200099	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-8.86	-0.38	1.79e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs57590327	0.555	rs3755713	chr3:81811224	A/G	cg07356753	chr3:81810745	GBE1	-0.45	-6.86	-0.3	2.23e-11	Extraversion;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.38	6.77	0.3	3.94e-11	Schizophrenia;
LGG	cis	rs9636252	0.851	rs12465727	chr2:9263876	C/T	cg20341998	chr2:9276514	NA	0.38	6.91	0.31	1.6e-11	IgG glycosylation;
LGG	cis	rs68170813	0.559	rs78553765	chr7:106930787	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.58	-0.44	1.42e-23	Coronary artery disease;
LGG	cis	rs240764	0.717	rs6907444	chr6:101163606	G/T	cg09795085	chr6:101329169	ASCC3	-0.44	-7.54	-0.33	2.57e-13	Neuroticism;
LGG	cis	rs10911232	0.507	rs10797817	chr1:182999136	G/T	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs3781663	0.526	rs6592468	chr11:70019047	G/A	cg06393558	chr11:69982916	ANO1	-0.4	-7.7	-0.34	8.46e-14	Survival in rectal cancer;
LGG	cis	rs4566357	0.521	rs78411533	chr2:227910807	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.11	-0.39	2.48e-18	Coronary artery disease;
LGG	cis	rs80130819	0.515	rs1635536	chr12:48385945	A/G	cg24011408	chr12:48396354	COL2A1	0.62	7.34	0.32	9.51e-13	Prostate cancer;
LGG	cis	rs283228	0.761	rs2787559	chr6:101783727	T/G	cg27451362	chr6:101846650	GRIK2	0.53	8.91	0.38	1.16e-17	Coenzyme Q10 levels;
LGG	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.73	-0.38	4.52e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.89	-0.3	1.88e-11	Iron status biomarkers;
LGG	cis	rs6708331	0.517	rs12992553	chr2:70360262	A/G	cg01613454	chr2:70366299	NA	0.56	11.26	0.46	3.69e-26	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs77372450	0.636	rs6860257	chr5:156995869	G/A	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs9880211	1.000	rs9883189	chr3:136289466	T/C	cg21827317	chr3:136751795	NA	-0.49	-7.28	-0.32	1.44e-12	Body mass index;Height;
LGG	cis	rs58904263	1	rs58904263	chr20:30401406	A/AG	cg21427119	chr20:30132790	HM13	-0.42	-7.11	-0.31	4.43e-12	Monocyte count;
LGG	cis	rs10744422	1.000	rs10847869	chr12:123328359	C/G	cg25930673	chr12:123319894	HIP1R	-0.71	-9.28	-0.4	6.3e-19	Schizophrenia;
LGG	cis	rs3816183	0.687	rs893727	chr2:43056139	T/G	cg14631114	chr2:43023945	NA	0.44	7.99	0.35	1.08e-14	Hypospadias;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17767392	0.871	rs35468256	chr14:71839524	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.0	0.39	6e-18	Mitral valve prolapse;
LGG	trans	rs9393777	0.844	rs72839477	chr6:27327000	C/T	cg06606381	chr12:133084897	FBRSL1	-1.27	-11.3	-0.46	2.59e-26	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.628	rs72726702	chr14:71733320	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.89	-0.34	2.18e-14	Mitral valve prolapse;
LGG	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg24110177	chr3:50126178	RBM5	0.61	11.07	0.46	2.02e-25	Body mass index;
LGG	cis	rs9911578	1.000	rs172565	chr17:56808996	A/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.01	-0.42	1.77e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.02	0.46	3.03e-25	Lymphocyte counts;
LGG	cis	rs10463316	0.817	rs1810083	chr5:150776807	A/G	cg03212797	chr5:150827313	SLC36A1	0.56	9.54	0.41	8.36e-20	Metabolite levels (Pyroglutamine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19300632	chr2:55746645	CCDC104	0.4	6.78	0.3	3.74e-11	Cognitive performance;
LGG	cis	rs72945132	0.882	rs7118156	chr11:70142922	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.94	0.45	6.46e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10802521	chr3:52805072	NEK4	-0.41	-6.88	-0.3	1.89e-11	Bipolar disorder;
LGG	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg14820908	chr5:178986412	RUFY1	0.4	6.92	0.31	1.48e-11	Lung cancer;
LGG	cis	rs7552404	0.727	rs4949677	chr1:76266662	T/A	cg22875332	chr1:76189707	ACADM	0.57	8.6	0.37	1.24e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.45	0.4	1.69e-19	Bipolar disorder;
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg20607798	chr8:58055168	NA	0.57	6.87	0.3	2.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg18200150	chr17:30822561	MYO1D	0.78	18.05	0.64	1.54e-55	Schizophrenia;
LGG	cis	rs7681440	1.000	rs1471483	chr4:90754292	A/G	cg20003494	chr4:90757398	SNCA	-0.41	-8.11	-0.35	4.59e-15	Dementia with Lewy bodies;
LGG	cis	rs11719291	0.833	rs13074318	chr3:48816725	C/T	cg00383909	chr3:49044727	WDR6	1.12	13.64	0.54	7.91e-36	Cognitive function;
LGG	trans	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg27411982	chr8:10470053	RP1L1	-0.38	-6.65	-0.3	8.14e-11	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06624832	chr17:72772340	TMEM104;NAT9	0.5	7.38	0.32	7.21e-13	Gut microbiome composition (summer);
LGG	cis	rs7927592	0.913	rs10896347	chr11:68353127	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs877282	0.945	rs11253390	chr10:788678	A/G	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs589448	0.967	rs2617835	chr12:69753420	C/A	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4356932	1.000	rs12233806	chr4:76984263	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.94	9.85	0.42	6.66e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.5	2.13e-30	Lymphocyte counts;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg02951883	chr7:2050386	MAD1L1	-0.72	-14.27	-0.55	1.49e-38	Schizophrenia;
LGG	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg06550200	chr5:1325588	CLPTM1L	0.62	10.93	0.45	6.7e-25	Lung cancer;
LGG	cis	rs10463316	0.894	rs13357969	chr5:150751557	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2760061	0.819	rs3094914	chr1:228206934	C/T	cg02753203	chr1:228287806	NA	0.76	14.49	0.56	1.72e-39	Diastolic blood pressure;
LGG	cis	rs9911578	0.967	rs9894274	chr17:56977919	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.82	0.59	2.27e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg03433033	chr1:76189801	ACADM	0.82	14.97	0.57	1.34e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8042849	1	rs8042849	chr15:78817929	C/T	cg18825076	chr15:78729989	IREB2	0.48	7.9	0.34	2e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Parental lifespan;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg18279126	chr7:2041391	MAD1L1	0.33	7.08	0.31	5.47e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7937612	0.965	rs7932037	chr11:120259430	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.8	-0.51	2.44e-32	Intraocular pressure;
LGG	trans	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg15556689	chr8:8085844	FLJ10661	0.48	8.45	0.37	3.91e-16	Retinal vascular caliber;
LGG	cis	rs1408799	0.720	rs13289304	chr9:12746337	G/A	cg05274944	chr9:12693694	TYRP1	0.34	8.0	0.35	1.01e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg13902645	chr11:5959945	NA	-0.69	-11.08	-0.46	1.79e-25	DNA methylation (variation);
LGG	cis	rs12477438	0.520	rs12052986	chr2:99994960	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.72	-0.3	5.31e-11	Chronic sinus infection;
LGG	cis	rs2046867	0.818	rs1502758	chr3:72865126	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9815354	0.904	rs7647561	chr3:41848627	T/A	cg03022575	chr3:42003672	ULK4	0.65	8.32	0.36	9.85e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6598955	0.724	rs7547520	chr1:26592310	C/T	cg04990556	chr1:26633338	UBXN11	-0.68	-14.0	-0.55	2.1e-37	Obesity-related traits;
LGG	cis	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	cis	rs826838	1.000	rs11168676	chr12:38977304	A/G	cg26384229	chr12:38710491	ALG10B	1.05	28.21	0.8	1.28e-102	Heart rate;
LGG	cis	rs2201728	0.967	rs13117371	chr4:100222067	C/T	cg07219303	chr4:100140905	ADH6	-0.4	-8.22	-0.36	1.99e-15	Cardiac Troponin-T levels;
LGG	cis	rs12286929	0.609	rs7479259	chr11:115090715	T/A	cg04055981	chr11:115044050	NA	0.36	6.69	0.3	6.65e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28830936	1.000	rs9672360	chr15:41912411	T/C	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.67	-0.3	7.28e-11	Diastolic blood pressure;
LGG	cis	rs28595532	0.920	rs115878132	chr4:119756239	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs7959452	0.901	rs1384	chr12:69747834	C/T	cg11871910	chr12:69753446	YEATS4	0.76	15.93	0.59	7.52e-46	Blood protein levels;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.43	-0.33	5.29e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg22232500	chr2:134024266	NCKAP5	0.57	8.06	0.35	6.43e-15	Bipolar disorder;
LGG	trans	rs7615952	0.800	rs13086460	chr3:125646417	C/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	cis	rs9399137	0.507	rs11754021	chr6:135308375	A/G	cg22676075	chr6:135203613	NA	0.43	7.38	0.32	7.39e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs757081	0.648	rs7940253	chr11:17280596	G/A	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.58	-0.33	1.93e-13	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.87	0.42	5.56e-21	Prudent dietary pattern;
LGG	cis	rs7717393	0.786	rs6889255	chr5:155792114	G/T	cg12904904	chr5:155754151	SGCD	0.67	7.71	0.34	7.59e-14	Egg allergy;
LGG	trans	rs13191038	1	rs13191038	chr6:28482917	T/C	cg01620082	chr3:125678407	NA	-1.08	-10.25	-0.43	2.39e-22	Urinary tract infection frequency;
LGG	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg09818912	chr17:20140352	CYTSB	-0.31	-7.32	-0.32	1.12e-12	Obesity-related traits;
LGG	cis	rs7267979	0.844	rs869358	chr20:25374674	A/G	cg06421707	chr20:25228305	PYGB	-0.43	-8.87	-0.38	1.59e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg08999081	chr20:33150536	PIGU	0.32	7.46	0.33	4.36e-13	Coronary artery disease;
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	8.06	0.35	6.56e-15	Personality dimensions;
LGG	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg13798912	chr7:905769	UNC84A	0.57	7.08	0.31	5.51e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Body mass index;
LGG	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg22916017	chr11:64110731	CCDC88B	0.47	9.42	0.4	2.22e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs62238980	0.614	rs4821015	chr22:32402549	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs7737355	1.000	rs2549018	chr5:130698949	C/T	cg06307176	chr5:131281290	NA	-0.51	-8.55	-0.37	1.85e-16	Life satisfaction;
LGG	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.73	0.45	3.87e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7552404	0.691	rs5745449	chr1:76344711	A/T	cg03433033	chr1:76189801	ACADM	-0.65	-9.32	-0.4	4.88e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7267979	1.000	rs34645895	chr20:25368373	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2658782	0.826	rs2925355	chr11:93090887	T/C	cg15737290	chr11:93063684	CCDC67	0.55	8.08	0.35	5.68e-15	Pulmonary function decline;
LGG	cis	rs12188164	0.686	rs72711365	chr5:416672	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.81	0.3	2.95e-11	Cystic fibrosis severity;
LGG	cis	rs10189230	0.967	rs10498113	chr2:222352629	C/T	cg14652038	chr2:222343519	EPHA4	0.59	12.43	0.5	8.02e-31	Urate levels in lean individuals;
LGG	cis	rs963731	0.579	rs2123882	chr2:39247856	C/T	cg04010122	chr2:39346883	SOS1	-0.74	-7.51	-0.33	3.01e-13	Corticobasal degeneration;
LGG	trans	rs4332037	0.707	rs4721096	chr7:1877311	T/C	cg22232500	chr2:134024266	NCKAP5	-0.56	-7.82	-0.34	3.56e-14	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg13009111	chr11:71350975	NA	0.36	7.82	0.34	3.5e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs714031	0.872	rs3788576	chr22:40071894	G/A	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.67	-0.56	2.65e-40	Schizophrenia;
LGG	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg24848339	chr3:12840334	CAND2	-0.4	-8.7	-0.37	5.96e-17	QRS complex (12-leadsum);
LGG	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg00990874	chr7:1149470	C7orf50	-0.63	-9.14	-0.39	2.02e-18	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.610	rs6987118	chr8:58147851	G/T	cg26174226	chr8:58114915	NA	-0.53	-7.9	-0.34	2.03e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10911232	0.507	rs4442336	chr1:182982538	T/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09285771	chr14:35761165	PSMA6	-0.41	-7.0	-0.31	8.78e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.41	-0.4	2.34e-19	Triglycerides;
LGG	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.3	-0.32	1.25e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4774899	0.752	rs1820995	chr15:57332971	A/G	cg08128148	chr15:57256372	TCF12	0.29	7.01	0.31	8.25e-12	Urinary tract infection frequency;
LGG	cis	rs4660214	0.666	rs950805	chr1:39705458	A/C	cg18385671	chr1:39797026	MACF1	-0.46	-9.49	-0.4	1.27e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2032447	0.714	rs199726	chr6:25953360	G/A	cg07061783	chr6:25882402	NA	-0.46	-7.9	-0.34	2.02e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12615966	1.000	rs12620555	chr2:105379115	T/C	cg16465502	chr2:105461796	NA	0.88	10.6	0.44	1.16e-23	Pancreatic cancer;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs9790314	0.967	rs457272	chr3:161096746	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-10.58	-0.44	1.36e-23	Morning vs. evening chronotype;
LGG	trans	rs7937682	0.562	rs519850	chr11:111376888	A/T	cg18187862	chr3:45730750	SACM1L	0.45	7.52	0.33	2.83e-13	Primary sclerosing cholangitis;
LGG	trans	rs2727020	0.595	rs10769583	chr11:49483193	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.64	-0.48	1.17e-27	Coronary artery disease;
LGG	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg13770153	chr20:60521292	NA	-0.42	-7.01	-0.31	8.52e-12	Body mass index;
LGG	cis	rs7843479	0.965	rs11785657	chr8:21859485	G/A	cg17168535	chr8:21777572	XPO7	0.59	9.57	0.41	6.42e-20	Mean corpuscular volume;
LGG	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg08250081	chr4:10125330	NA	0.38	7.57	0.33	2.01e-13	Bone mineral density;
LGG	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg15556689	chr8:8085844	FLJ10661	0.49	8.76	0.38	3.77e-17	Neuroticism;
LGG	cis	rs11864453	0.826	rs2074626	chr16:72139184	C/A	cg23815491	chr16:72088622	HP	0.53	11.62	0.48	1.39e-27	Fibrinogen levels;
LGG	cis	rs7843479	0.965	rs13269198	chr8:21823025	G/A	cg17168535	chr8:21777572	XPO7	0.61	9.99	0.42	2.15e-21	Mean corpuscular volume;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg20061378	chr4:1791585	NA	-0.41	-7.09	-0.31	5.2e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4242434	0.854	rs4872007	chr8:22538879	G/A	cg00599393	chr8:22457479	C8orf58	0.44	7.97	0.35	1.22e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2760061	0.819	rs708111	chr1:228191365	G/A	cg02753203	chr1:228287806	NA	0.76	14.83	0.57	5.19e-41	Diastolic blood pressure;
LGG	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-8.5	-0.37	2.64e-16	Subjective well-being;
LGG	cis	rs7937682	0.575	rs7114617	chr11:111768173	A/T	cg22437258	chr11:111473054	SIK2	-0.42	-7.01	-0.31	8.56e-12	Primary sclerosing cholangitis;
LGG	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg21401794	chr1:90099060	LRRC8C	0.57	12.14	0.49	1.26e-29	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs1355223	0.902	rs680727	chr11:34704446	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.43	7.26	0.32	1.61e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07962882	chr19:1117289	SBNO2	0.4	7.26	0.32	1.61e-12	Menarche (age at onset);
LGG	cis	rs7523273	0.606	rs2761433	chr1:207917361	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.85	0.48	1.74e-28	Schizophrenia;
LGG	cis	rs3813359	0.545	rs6927351	chr6:130550964	C/T	cg23281432	chr6:130554730	NA	0.47	6.72	0.3	5.32e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs12230513	0.732	rs60683621	chr12:55863224	C/G	cg19537932	chr12:55886519	OR6C68	-0.61	-10.99	-0.45	3.97e-25	Contrast sensitivity;
LGG	cis	rs757110	0.803	rs7928810	chr11:17372443	G/T	cg15432903	chr11:17409602	KCNJ11	0.8	16.66	0.61	3.65e-49	Type 2 diabetes;
LGG	cis	rs2717559	0.515	rs55720963	chr8:143895957	T/A	cg06565975	chr8:143823917	SLURP1	-0.33	-8.09	-0.35	5.1e-15	Urinary tract infection frequency;
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.75	-0.48	4.45e-28	Personality dimensions;
LGG	trans	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11599315	1.000	rs11599315	chr10:1343017	C/T	cg27336068	chr10:1336103	ADARB2	-0.35	-7.22	-0.32	2.13e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9462027	0.628	rs11759151	chr6:34747603	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg02725872	chr8:58115012	NA	-0.84	-12.02	-0.49	3.74e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs1728785	1.000	rs1170445	chr16:68573064	G/T	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs12153243	0.714	rs3901620	chr5:142911019	C/A	cg13907255	chr5:142895549	NA	-0.5	-8.74	-0.38	4.43e-17	Migraine;
LGG	cis	rs9557207	0.760	rs34637058	chr13:100049880	G/T	cg24509225	chr13:100037070	UBAC2	0.62	10.57	0.44	1.6e-23	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs71403859	0.730	rs12447672	chr16:71715131	G/A	cg08717414	chr16:71523259	ZNF19	-1.07	-13.47	-0.53	4.11e-35	Post bronchodilator FEV1;
LGG	cis	rs1793639	0.606	rs1793631	chr11:131942817	G/A	cg13908476	chr11:131942942	NTM	0.7	14.03	0.55	1.57e-37	Myopia;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg13206674	chr6:150067644	NUP43	0.61	13.77	0.54	2.05e-36	Lung cancer;
LGG	cis	rs7100689	0.753	rs2185426	chr10:82120887	G/A	cg01528321	chr10:82214614	TSPAN14	0.94	16.7	0.61	2.37e-49	Post bronchodilator FEV1;
LGG	cis	rs795544	0.608	rs1502048	chr5:13788282	C/T	cg07548982	chr5:13769939	DNAH5	0.4	7.43	0.33	5.22e-13	Corneal astigmatism;
LGG	cis	rs3858526	0.834	rs10839169	chr11:6003190	C/G	cg13902645	chr11:5959945	NA	-0.64	-9.97	-0.42	2.47e-21	DNA methylation (variation);
LGG	trans	rs12579753	0.871	rs12822050	chr12:82183041	C/T	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.65e-14	Resting heart rate;
LGG	cis	rs7208859	0.623	rs8081299	chr17:29104296	G/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.29	0.32	1.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs921968	0.510	rs591573	chr2:219478193	C/T	cg10223061	chr2:219282414	VIL1	-0.3	-6.74	-0.3	4.77e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs888194	0.544	rs2196612	chr12:109849535	A/G	cg19025524	chr12:109796872	NA	-0.55	-11.22	-0.46	5.09e-26	Neuroticism;
LGG	cis	rs72901758	0.661	rs56683270	chr17:76247827	T/C	cg26068271	chr17:76253126	NA	0.46	10.42	0.44	5.58e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs10911232	0.507	rs3935384	chr1:183028970	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg07537917	chr2:241836409	C2orf54	-0.39	-7.8	-0.34	4.14e-14	Urinary metabolites;
LGG	cis	rs10504229	0.516	rs11781671	chr8:57992733	T/C	cg02725872	chr8:58115012	NA	-0.53	-8.55	-0.37	1.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg00732059	chr16:71740210	PHLPP2	-0.62	-10.22	-0.43	3.03e-22	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs4332037	0.851	rs73050128	chr7:1961882	C/A	cg22232500	chr2:134024266	NCKAP5	0.71	9.89	0.42	4.67e-21	Bipolar disorder;
LGG	cis	rs13191362	1.000	rs13204013	chr6:163002480	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11627756	0.801	rs4906237	chr14:103077649	T/G	cg12046867	chr14:103022105	NA	-0.44	-8.12	-0.35	4.15e-15	Mean platelet volume;
LGG	cis	rs12579753	1.000	rs17692461	chr12:82171755	C/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-10.86	-0.45	1.22e-24	Resting heart rate;
LGG	cis	rs4780401	0.728	rs8191335	chr16:11771353	C/A	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.3	-0.32	1.23e-12	Rheumatoid arthritis;
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.71	-0.3	5.63e-11	Vitiligo;
LGG	cis	rs7829975	0.542	rs7844374	chr8:8798684	A/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.68	-0.3	6.86e-11	Mood instability;
LGG	cis	rs57143961	1	rs57143961	chr19:16533225	C/CT	cg10248733	chr19:16607483	C19orf44;CALR3	-0.54	-7.07	-0.31	5.58e-12	Lymphocyte percentage of white cells;
LGG	cis	rs7818345	1.000	rs6981898	chr8:19305705	A/G	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.66	0.3	7.65e-11	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08494300	chr11:93474945	TAF1D;C11orf54	-0.45	-6.81	-0.3	2.99e-11	Pancreatic cancer;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg21782813	chr7:2030301	MAD1L1	0.49	12.09	0.49	2.01e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.83	0.3	2.74e-11	Parkinson's disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09563244	chr17:71161926	SSTR2	-0.46	-7.27	-0.32	1.5e-12	Pancreatic cancer;
LGG	cis	rs10131894	0.611	rs174995	chr14:75434183	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-10.09	-0.42	9.21e-22	Coronary artery disease;
LGG	cis	rs4737010	0.644	rs552904	chr8:41610114	C/T	cg17182837	chr8:41585554	ANK1	0.45	6.89	0.31	1.81e-11	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7666738	0.716	rs6827474	chr4:99089683	T/G	cg05340658	chr4:99064831	C4orf37	0.43	7.1	0.31	4.78e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4665809	0.590	rs11897162	chr2:26503654	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.06	19.76	0.68	1.82e-63	Gut microbiome composition (summer);
LGG	cis	rs988958	0.565	rs35411295	chr2:42236631	T/A	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg23280166	chr11:118938394	VPS11	-0.45	-7.64	-0.33	1.26e-13	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs875971	0.545	rs10950025	chr7:65623933	G/A	cg11764359	chr7:65958608	NA	0.63	9.75	0.41	1.44e-20	Aortic root size;
LGG	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.31	0.32	1.16e-12	Total cholesterol levels;
LGG	cis	rs6032067	0.641	rs74174934	chr20:43761331	T/G	cg10761708	chr20:43804764	PI3	0.69	10.18	0.43	4.18e-22	Blood protein levels;
LGG	cis	rs638893	1.000	rs113641235	chr11:118700264	C/T	cg22253036	chr11:118662786	DDX6	-0.42	-6.69	-0.3	6.64e-11	Vitiligo;
LGG	cis	rs950776	0.506	rs12915366	chr15:78831753	G/A	cg17108064	chr15:78857060	CHRNA5	0.47	10.07	0.42	1.07e-21	Sudden cardiac arrest;
LGG	cis	rs79149102	0.579	rs76900720	chr15:75348895	A/T	cg17294928	chr15:75287854	SCAMP5	-0.84	-8.84	-0.38	1.99e-17	Lung cancer;
LGG	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	12.14	0.49	1.26e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg27446573	chr6:127587934	RNF146	0.91	17.16	0.62	1.91e-51	Breast cancer;
LGG	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg23815491	chr16:72088622	HP	0.5	11.31	0.47	2.31e-26	Fibrinogen levels;
LGG	cis	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg00405596	chr8:11794950	NA	-0.46	-7.67	-0.34	1.05e-13	Triglycerides;
LGG	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg02187348	chr16:89574699	SPG7	0.56	9.2	0.39	1.18e-18	Multiple myeloma (IgH translocation);
LGG	cis	rs11608355	0.618	rs7958220	chr12:109830980	T/C	cg19025524	chr12:109796872	NA	-0.58	-12.9	-0.51	9.35e-33	Neuroticism;
LGG	cis	rs7208859	0.673	rs79541516	chr17:29240583	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.03	-0.39	4.52e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2084898	1.000	rs79007113	chr11:120039835	G/A	cg07435449	chr11:120005650	TRIM29	-0.67	-7.13	-0.31	3.91e-12	Stroke (pediatric);
LGG	cis	rs8044868	0.530	rs9928157	chr16:72117073	T/C	cg23815491	chr16:72088622	HP	0.38	8.3	0.36	1.16e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6963495	0.818	rs73190133	chr7:105147821	G/C	cg19920283	chr7:105172520	RINT1	0.6	7.9	0.34	2e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7954584	0.531	rs1154514	chr12:122374888	C/T	cg22618164	chr12:122356400	WDR66	0.37	10.82	0.45	1.85e-24	Mean corpuscular volume;
LGG	cis	rs74781061	0.929	rs9672559	chr15:74991336	G/A	cg02384859	chr15:74862662	ARID3B	-0.33	-6.68	-0.3	6.94e-11	Endometriosis;
LGG	cis	rs10463554	0.963	rs1011454	chr5:102368255	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.69	-0.34	8.65e-14	Parkinson's disease;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.46	0.37	3.48e-16	Obesity-related traits;
LGG	cis	rs7264396	0.690	rs2425172	chr20:34443893	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.38	0.32	7.25e-13	Total cholesterol levels;
LGG	cis	rs12210905	0.687	rs72843622	chr6:27161152	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.46	-0.33	4.27e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	trans	rs3960554	0.599	rs56090527	chr7:75762125	A/C	cg19862616	chr7:65841803	NCRNA00174	0.86	12.55	0.5	2.54e-31	Eotaxin levels;
LGG	trans	rs9467711	0.606	rs12173854	chr6:26371679	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4073582	0.595	rs708471	chr11:65931008	A/G	cg16950941	chr11:66035639	RAB1B	0.55	10.22	0.43	2.96e-22	Gout;
LGG	cis	rs804280	0.542	rs35647515	chr8:11791629	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.57	-0.33	2.05e-13	Myopia (pathological);
LGG	trans	rs7819412	0.645	rs10156356	chr8:11046209	T/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.25	-0.32	1.77e-12	Triglycerides;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.93	0.35	1.7e-14	Personality dimensions;
LGG	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg00319359	chr11:70116639	PPFIA1	0.73	7.82	0.34	3.66e-14	Coronary artery disease;
LGG	cis	rs7584330	0.826	rs72620825	chr2:238381243	G/A	cg16989719	chr2:238392110	NA	-0.37	-7.28	-0.32	1.48e-12	Prostate cancer;
LGG	cis	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg15763984	chr4:1342303	KIAA1530	0.38	6.73	0.3	5.01e-11	Obesity-related traits;
LGG	cis	rs920590	0.573	rs4392917	chr8:19680635	G/C	cg03894339	chr8:19674705	INTS10	-0.54	-9.2	-0.39	1.25e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.94	-0.35	1.55e-14	Schizophrenia;
LGG	cis	rs36071027	0.615	rs13159303	chr5:158421063	A/G	cg04248271	chr5:158524404	EBF1	0.41	7.3	0.32	1.23e-12	Carotid intima media thickness;
LGG	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	2.07e-31	Motion sickness;
LGG	cis	rs4819052	0.851	rs2838848	chr21:46671017	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.77	-0.41	1.22e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg02463440	chr8:22132932	PIWIL2	0.49	10.83	0.45	1.64e-24	Hypertriglyceridemia;
LGG	cis	rs4689642	0.507	rs10031101	chr4:7222476	G/C	cg21353189	chr4:7228343	SORCS2	0.33	7.13	0.31	3.8e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs9300255	0.620	rs1716173	chr12:123660721	A/T	cg00376283	chr12:123451042	ABCB9	0.62	9.39	0.4	2.75e-19	Neutrophil percentage of white cells;
LGG	cis	rs79349575	0.687	rs12602179	chr17:47010034	G/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs10979	1.000	rs9376761	chr6:143887165	G/A	cg25407410	chr6:143891975	LOC285740	-0.71	-12.29	-0.5	2.94e-30	Hypospadias;
LGG	cis	rs9403521	1.000	rs9403521	chr6:143994199	C/T	cg18240653	chr6:144019428	PHACTR2	0.65	10.12	0.43	6.75e-22	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.61e-14	Lung cancer;
LGG	cis	rs2860975	0.936	rs7904000	chr10:96767858	A/T	cg09036531	chr10:96991505	NA	-0.52	-9.31	-0.4	5.05e-19	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs17376456	1.000	rs66978370	chr5:93553633	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.44	0.61	3.58e-48	Diabetic retinopathy;
LGG	cis	rs7712401	0.601	rs35858098	chr5:122334365	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs6502050	0.835	rs7502548	chr17:80087569	T/C	cg13939156	chr17:80058883	NA	0.47	9.14	0.39	1.98e-18	Life satisfaction;
LGG	cis	rs2070488	1.000	rs762317	chr3:38497659	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.19	0.65	3.66e-56	Electrocardiographic conduction measures;
LGG	cis	rs1865760	0.516	rs9295684	chr6:26069669	T/C	cg03264133	chr6:25882463	NA	-0.38	-6.74	-0.3	4.69e-11	Height;
LGG	cis	rs4731207	0.698	rs10271687	chr7:124493731	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.93	-12.28	-0.5	3.49e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg19507638	chr5:93509721	C5orf36	0.41	6.81	0.3	3.07e-11	Diabetic retinopathy;
LGG	cis	rs3742264	0.656	rs9316177	chr13:46561811	A/C	cg15192986	chr13:46630673	CPB2	-0.36	-6.95	-0.31	1.26e-11	Blood protein levels;
LGG	cis	rs950169	1.000	rs12915234	chr15:84758301	G/A	cg03959625	chr15:84868606	LOC388152	0.56	8.76	0.38	3.77e-17	Schizophrenia;
LGG	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg23788917	chr6:8435910	SLC35B3	0.54	9.23	0.39	1.01e-18	Motion sickness;
LGG	cis	rs9303280	0.806	rs10852936	chr17:38031714	C/T	cg17467752	chr17:38218738	THRA	-0.44	-7.09	-0.31	5.03e-12	Self-reported allergy;
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg08677398	chr8:58056175	NA	0.45	7.49	0.33	3.5e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs873946	0.504	rs3829132	chr10:134579044	A/C	cg13271783	chr10:134563150	INPP5A	-0.52	-8.23	-0.36	1.94e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1003719	0.707	rs9976360	chr21:38587860	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.85	-0.57	4.67e-41	Eye color traits;
LGG	cis	rs3859192	0.599	rs2302777	chr17:38179492	A/G	cg17467752	chr17:38218738	THRA	-0.58	-9.83	-0.42	7.61e-21	White blood cell count;
LGG	cis	rs3733585	0.673	rs7377578	chr4:9952775	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg05165339	chr4:1420672	NA	0.31	8.04	0.35	7.58e-15	Obesity-related traits;
LGG	cis	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg04990556	chr1:26633338	UBXN11	0.58	8.31	0.36	1.08e-15	Obesity-related traits;
LGG	cis	rs3762637	1.000	rs28497203	chr3:122231819	T/C	cg24169773	chr3:122142474	KPNA1	-0.6	-10.17	-0.43	4.44e-22	LDL cholesterol levels;
LGG	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-15.62	-0.59	1.82e-44	Chronic sinus infection;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14723344	chr6:97285662	GPR63	0.57	6.68	0.3	6.68e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6882046	0.513	rs1081158	chr5:88004616	C/T	cg22951263	chr5:87985283	NA	-0.52	-9.76	-0.41	1.42e-20	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.65	10.79	0.45	2.22e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4538187	0.599	rs2919222	chr2:64293274	C/T	cg02541582	chr2:64069798	UGP2	-0.45	-11.8	-0.48	2.89e-28	Systolic blood pressure;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg11645453	chr3:52864694	ITIH4	0.4	6.83	0.3	2.76e-11	Bipolar disorder;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg04025307	chr7:1156635	C7orf50	0.88	19.12	0.66	1.78e-60	Longevity;Endometriosis;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs453301	0.682	rs2929308	chr8:9084121	T/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.45	-0.44	4.48e-23	Joint mobility (Beighton score);
LGG	cis	rs950169	0.922	rs11633075	chr15:85113972	C/A	cg24253500	chr15:84953950	NA	0.59	10.91	0.45	8.37e-25	Schizophrenia;
LGG	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg15325629	chr6:28072465	NA	1.04	7.83	0.34	3.46e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7580658	0.521	rs7605733	chr2:127931787	T/G	cg10021288	chr2:128175891	PROC	-0.42	-7.87	-0.34	2.45e-14	Protein C levels;
LGG	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg16127683	chr15:40268777	EIF2AK4	-0.91	-9.9	-0.42	4.47e-21	Corneal curvature;
LGG	cis	rs4363385	0.818	rs2651413	chr1:153012068	T/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	trans	rs12339094	0.527	rs9410635	chr9:90415664	G/A	cg24436365	chr6:63940138	NA	0.46	6.65	0.3	8.5e-11	Smoking quantity;
LGG	cis	rs757081	0.648	rs214923	chr11:17237080	G/C	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.77	-0.34	5.13e-14	Systolic blood pressure;
LGG	cis	rs1023500	0.505	rs134889	chr22:42674350	A/T	cg05082376	chr22:42548792	NA	-0.39	-8.37	-0.36	6.66e-16	Schizophrenia;
LGG	cis	rs7829975	0.871	rs572307	chr8:8578811	T/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.16	-0.35	3.23e-15	Mood instability;
LGG	cis	rs4789452	0.774	rs67129266	chr17:75381103	A/G	cg06761530	chr17:75373219	SEPT9	-0.37	-6.98	-0.31	1e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs6835098	0.962	rs10027704	chr4:174083107	T/C	cg08422745	chr4:174089978	GALNT7	-0.84	-15.28	-0.58	5.66e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs12681288	0.676	rs2701927	chr8:995886	G/A	cg15309053	chr8:964076	NA	0.39	7.77	0.34	5.15e-14	Schizophrenia;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.19	0.32	2.65e-12	Prudent dietary pattern;
LGG	cis	rs9815354	0.812	rs12108049	chr3:41958161	A/G	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.37e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13191362	1.000	rs13210756	chr6:163009030	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg07870213	chr5:140052090	DND1	0.93	17.62	0.63	1.45e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05360402	chr5:110848191	STARD4	0.46	7.23	0.32	1.99e-12	Gut microbiome composition (summer);
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg03175030	chr11:2018143	H19;MIR675	-0.58	-11.03	-0.46	2.77e-25	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs57221529	0.766	rs4081847	chr5:574072	C/T	cg11887960	chr12:57824829	NA	0.6	7.42	0.33	5.73e-13	Lung disease severity in cystic fibrosis;
LGG	trans	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg13565492	chr6:43139072	SRF	-0.58	-7.64	-0.33	1.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9650657	0.836	rs2898252	chr8:10604164	T/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.74	-0.3	4.73e-11	Neuroticism;
LGG	cis	rs9354308	0.764	rs9360164	chr6:66584033	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg01988459	chr11:68622903	NA	-0.62	-12.43	-0.5	8.5e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs929596	0.531	rs2741021	chr2:234511883	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.5	7.76	0.34	5.48e-14	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4363385	0.747	rs1984198	chr1:152958584	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	trans	rs9467711	0.606	rs9379854	chr6:26362854	T/C	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4689388	0.750	rs10755148	chr4:6295064	A/G	cg00701064	chr4:6280414	WFS1	0.71	14.64	0.56	3.63e-40	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg14541582	chr5:601475	NA	-0.68	-10.66	-0.44	7.01e-24	Obesity-related traits;
LGG	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.1	-0.72	1.92e-74	Height;
LGG	cis	rs2188561	0.697	rs13224313	chr7:107382352	G/T	cg16793755	chr7:107334138	SLC26A4	0.39	6.99	0.31	9.56e-12	Alcohol consumption;
LGG	trans	rs9929218	0.551	rs2296406	chr16:68721340	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	1.14	33.16	0.84	2.34e-124	Colorectal cancer;
LGG	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	cis	rs590121	0.876	rs681390	chr11:75274630	T/C	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.49	-0.37	2.86e-16	Coronary artery disease;
LGG	cis	rs968451	0.813	rs5757614	chr22:39717554	G/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	12.1	0.49	1.75e-29	Primary biliary cholangitis;
LGG	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.33	0.65	8.02e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7177699	0.526	rs7165042	chr15:79123338	C/G	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs854765	0.547	rs2955377	chr17:17932818	G/A	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.46	0.58	8.99e-44	Total body bone mineral density;
LGG	cis	rs796364	0.806	rs79725795	chr2:201083534	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	trans	rs1814175	0.817	rs10839465	chr11:49981554	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.46	-0.5	5.94e-31	Height;
LGG	cis	rs4969178	0.620	rs7219625	chr17:76390080	C/T	cg02836325	chr17:76403955	PGS1	-0.81	-17.55	-0.63	2.97e-53	HDL cholesterol levels;
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg05313129	chr8:58192883	C8orf71	-0.82	-12.3	-0.5	2.71e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg02030672	chr11:45687055	CHST1	0.5	8.88	0.38	1.51e-17	Obesity-related traits;
LGG	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.23	0.55	2.22e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4788570	0.697	rs9635524	chr16:71804956	C/G	cg06353428	chr16:71660113	MARVELD3	1.26	20.52	0.69	5.03e-67	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	0.736	rs10899550	chr11:78256078	G/A	cg02023728	chr11:77925099	USP35	-0.39	-6.87	-0.3	2.13e-11	Alzheimer's disease (survival time);
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg06916706	chr16:4465613	CORO7	-0.87	-15.28	-0.58	5.69e-43	Schizophrenia;
LGG	trans	rs6787172	0.623	rs9847460	chr3:158154206	T/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs4819052	0.655	rs2330102	chr21:46690968	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.65	0.3	8.2e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.16	-0.52	8.2e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs6959268	chr7:65812966	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.0	-0.31	8.95e-12	Aortic root size;
LGG	trans	rs7824557	0.583	rs4448232	chr8:11231354	G/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.57	-0.33	2.06e-13	Retinal vascular caliber;
LGG	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg11252792	chr3:125932053	NA	-0.54	-11.18	-0.46	7.79e-26	Metabolite levels;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25172604	chr17:41446521	NA	-0.32	-7.29	-0.32	1.35e-12	Menopause (age at onset);
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg00684032	chr4:1343700	KIAA1530	0.43	8.35	0.36	8.2e-16	Obesity-related traits;
LGG	cis	rs9811920	0.570	rs1021102	chr3:99603780	T/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs4474465	0.850	rs7938257	chr11:78224908	A/G	cg27205649	chr11:78285834	NARS2	0.49	8.14	0.35	3.67e-15	Alzheimer's disease (survival time);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg21782813	chr7:2030301	MAD1L1	0.46	11.02	0.46	3.11e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	0.608	rs3732962	chr3:10048951	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.46	0.5	6.16e-31	Alzheimer's disease;
LGG	trans	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.25	0.46	3.85e-26	Corneal astigmatism;
LGG	cis	rs1577917	0.655	rs12203963	chr6:86223316	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.94	0.35	1.59e-14	Response to antipsychotic treatment;
LGG	cis	rs9300255	0.722	rs34997336	chr12:123829116	G/A	cg00376283	chr12:123451042	ABCB9	-0.56	-8.63	-0.37	9.59e-17	Neutrophil percentage of white cells;
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00166722	chr3:10149974	C3orf24	0.54	9.15	0.39	1.86e-18	Alzheimer's disease;
LGG	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg22875332	chr1:76189707	ACADM	0.61	10.66	0.44	7.34e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17102423	0.589	rs4899162	chr14:65614126	G/T	cg11161011	chr14:65562177	MAX	-0.67	-11.95	-0.49	6.89e-29	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09747578	chr1:46769076	LRRC41;UQCRH	0.46	7.93	0.35	1.69e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9814567	1.000	rs4974493	chr3:134219993	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.91	-0.51	8.87e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.38	-0.36	6.26e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs12949688	0.967	rs12949028	chr17:55825470	A/C	cg12582317	chr17:55822272	NA	0.68	19.34	0.67	1.66e-61	Schizophrenia;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg04503457	chr17:41445688	NA	-0.39	-8.97	-0.38	7.22e-18	Menopause (age at onset);
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg10189774	chr4:17578691	LAP3	0.4	7.24	0.32	1.83e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7808935	0.789	rs2040668	chr7:27958773	G/T	cg22168087	chr7:27702803	HIBADH	-0.69	-9.6	-0.41	4.9e-20	Prostate cancer;
LGG	cis	rs6964587	1.000	rs9691325	chr7:91731047	G/A	cg17063962	chr7:91808500	NA	0.47	8.37	0.36	6.93e-16	Breast cancer;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg24397884	chr7:158709396	WDR60	-1.13	-17.38	-0.63	1.98e-52	Height;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg05665937	chr4:1216051	CTBP1	0.48	8.37	0.36	6.91e-16	Obesity-related traits;
LGG	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg19455335	chr8:22457658	C8orf58	-0.39	-8.02	-0.35	8.97e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504073	0.565	rs35282337	chr8:49920994	G/A	cg00325661	chr8:49890786	NA	0.8	16.25	0.6	2.62e-47	Blood metabolite ratios;
LGG	trans	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg27523141	chr10:43048294	ZNF37B	0.39	7.55	0.33	2.29e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15553911	chr19:54641084	CNOT3	-0.48	-7.3	-0.32	1.24e-12	Systemic lupus erythematosus;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg04008888	chr11:68622739	NA	-0.55	-11.99	-0.49	4.89e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9534288	0.730	rs2148412	chr13:46595849	C/T	cg15192986	chr13:46630673	CPB2	-0.57	-12.37	-0.5	1.43e-30	Blood protein levels;
LGG	cis	rs644799	0.965	rs534488	chr11:95562327	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg08645402	chr16:4508243	NA	0.5	9.61	0.41	4.52e-20	Schizophrenia;
LGG	cis	rs2573652	0.722	rs11636047	chr15:100543341	A/G	cg14911520	chr15:100542628	ADAMTS17	-0.29	-7.14	-0.31	3.72e-12	Height;
LGG	cis	rs11074306	0.543	rs28755910	chr15:28068319	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.38	-7.2	-0.32	2.53e-12	Personality dimensions;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg27400746	chr16:89904261	SPIRE2	-1.09	-16.49	-0.61	2.24e-48	Skin colour saturation;
LGG	cis	rs6665290	0.904	rs1045286	chr1:227179037	A/C	cg05696931	chr1:227175867	NA	0.4	7.78	0.34	4.83e-14	Myeloid white cell count;
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs763014	0.966	rs4144003	chr16:645968	C/T	cg04911050	chr16:677664	RAB40C	0.34	6.78	0.3	3.58e-11	Height;
LGG	cis	rs2073300	0.609	rs17830281	chr20:23350525	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs5769765	0.955	rs8139758	chr22:50261123	G/T	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg16606324	chr3:10149918	C3orf24	0.54	6.96	0.31	1.15e-11	Alzheimer's disease;
LGG	cis	rs5758659	0.622	rs6519298	chr22:42364997	C/T	cg15128208	chr22:42549153	NA	-0.4	-7.71	-0.34	7.55e-14	Cognitive function;
LGG	cis	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg00409905	chr10:38381863	ZNF37A	0.59	10.17	0.43	4.47e-22	Extrinsic epigenetic age acceleration;
LGG	cis	rs2066819	1.000	rs76151170	chr12:56659320	C/T	cg26714650	chr12:56694279	CS	-1.58	-16.22	-0.6	3.61e-47	Psoriasis vulgaris;
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.5	-0.4	1.11e-19	Triglycerides;
LGG	cis	rs2072499	0.900	rs2248080	chr1:156195971	T/A	cg24450063	chr1:156163899	SLC25A44	1.13	23.99	0.74	3.08e-83	Testicular germ cell tumor;
LGG	cis	rs9309473	1.000	rs10496191	chr2:73673798	C/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.54	-0.33	2.52e-13	Metabolite levels;
LGG	cis	rs7633770	0.735	rs12491236	chr3:46688481	C/T	cg11219411	chr3:46661640	NA	-0.54	-12.23	-0.49	5.27e-30	Coronary artery disease;
LGG	cis	rs4845570	0.749	rs11576810	chr1:151712201	C/G	cg07092448	chr1:151763213	TDRKH	-1.06	-14.98	-0.57	1.2e-41	Coronary artery disease;
LGG	cis	rs1152591	0.562	rs1272715	chr14:64651989	A/T	cg21174375	chr14:64681225	SYNE2	0.42	7.73	0.34	6.65e-14	Atrial fibrillation;
LGG	cis	rs2354432	0.891	rs2165743	chr1:146690319	C/T	cg25205988	chr1:146714368	CHD1L	1.32	16.61	0.61	5.97e-49	Mitochondrial DNA levels;
LGG	cis	rs9926296	0.605	rs3743859	chr16:89846050	A/G	cg07440826	chr16:89882328	FANCA	0.26	7.0	0.31	9.23e-12	Vitiligo;
LGG	cis	rs7177699	0.557	rs4433781	chr15:79121835	A/T	cg00540400	chr15:79124168	NA	-0.54	-11.43	-0.47	7.77e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.02e-18	Electroencephalogram traits;
LGG	cis	rs2270450	0.614	rs1362932	chr6:46716079	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.25	-0.43	2.3e-22	Hashimoto thyroiditis versus Graves' disease;
LGG	trans	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg26043149	chr18:55253948	FECH	-0.45	-7.36	-0.32	8.44e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg23649088	chr2:200775458	C2orf69	-0.52	-8.04	-0.35	7.33e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs6748734	1.000	rs7604393	chr2:241825034	T/G	cg26818257	chr2:241905806	NA	0.39	7.45	0.33	4.61e-13	Urinary metabolites;
LGG	cis	rs4680	0.737	rs3810595	chr22:19949644	G/C	cg23601416	chr22:19950040	COMT	-0.47	-11.72	-0.48	6.03e-28	Blood metabolite levels;
LGG	cis	rs17102423	0.788	rs11158575	chr14:65581665	T/C	cg16583315	chr14:65563665	MAX	-0.36	-6.72	-0.3	5.38e-11	Obesity-related traits;
LGG	cis	rs2370759	1.000	rs76467481	chr10:32610740	T/G	cg01819863	chr10:32635814	EPC1	1.07	14.7	0.56	2.04e-40	Sexual dysfunction (female);
LGG	cis	rs6065	0.529	rs1056626	chr17:4931553	G/T	cg01912298	chr17:4872499	CAMTA2;SPAG7	-0.47	-6.99	-0.31	9.87e-12	Platelet count;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg00800038	chr16:89945340	TCF25	-0.67	-8.87	-0.38	1.55e-17	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20119106	chr7:153750421	DPP6	0.47	8.04	0.35	7.5e-15	Gut microbiome composition (summer);
LGG	cis	rs8177253	0.829	rs9882812	chr3:133506127	A/G	cg12373951	chr3:133503437	NA	0.45	7.9	0.34	1.98e-14	Iron status biomarkers;
LGG	cis	rs36093844	0.706	rs79907592	chr11:85558067	G/A	cg16165120	chr11:85566439	CCDC83	-0.46	-7.32	-0.32	1.11e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs7572733	0.840	rs10497807	chr2:198585087	C/G	cg00792783	chr2:198669748	PLCL1	-0.44	-7.5	-0.33	3.37e-13	Dermatomyositis;
LGG	cis	rs9397585	0.791	rs9384070	chr6:153373230	G/C	cg17707550	chr6:153380415	RGS17	0.62	14.5	0.56	1.52e-39	Body mass index;
LGG	cis	rs3091242	0.933	rs35530120	chr1:25785451	A/G	cg02931644	chr1:25747376	RHCE	-0.42	-9.22	-0.39	1.05e-18	Erythrocyte sedimentation rate;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09375338	chr21:35445901	SLC5A3;MRPS6	0.46	7.37	0.32	8.15e-13	Hip circumference;
LGG	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.08	0.42	9.92e-22	Iron status biomarkers;
LGG	cis	rs6430585	0.583	rs2304371	chr2:136561557	A/G	cg07169764	chr2:136633963	MCM6	1.13	21.3	0.7	1.17e-70	Corneal structure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12891498	chr12:117319246	HRK	0.41	6.87	0.3	2.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs34179822	chr3:10140017	A/G	cg13047869	chr3:10149882	C3orf24	0.55	9.41	0.4	2.3e-19	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.7	0.69	7.19e-68	Alzheimer's disease;
LGG	trans	rs941408	0.963	rs2537855	chr19:2806574	A/G	cg22153745	chr1:153894579	GATAD2B	-0.67	-10.76	-0.45	3.03e-24	Total cholesterol levels;
LGG	cis	rs11122272	0.667	rs2244992	chr1:231537220	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs7044106	0.762	rs1158554	chr9:123400898	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.28e-29	Hip circumference adjusted for BMI;
LGG	cis	rs4788570	0.584	rs6499528	chr16:71672762	T/C	cg06353428	chr16:71660113	MARVELD3	1.28	21.19	0.7	3.63e-70	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs1981799	chr7:65955559	T/C	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs11622475	1.000	rs2236247	chr14:104378087	C/T	cg20488157	chr14:104394430	TDRD9	0.5	8.17	0.36	2.93e-15	Bipolar disorder;
LGG	cis	rs4950322	0.518	rs56151278	chr1:146589003	T/C	cg22381352	chr1:146742008	CHD1L	-0.45	-7.6	-0.33	1.7e-13	Protein quantitative trait loci;
LGG	cis	rs2635047	1.000	rs2635045	chr18:44668417	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.62	0.41	4.34e-20	Educational attainment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21374864	chr9:132586569	TOR1A	0.43	6.88	0.3	2.01e-11	Cognitive performance;
LGG	cis	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg24134504	chr18:76639479	NA	-0.47	-8.24	-0.36	1.81e-15	Obesity-related traits;
LGG	cis	rs896543	0.702	rs6715324	chr2:237495510	C/T	cg25295825	chr2:237489920	CXCR7	0.91	13.88	0.54	6.98e-37	Alcohol dependence (age at onset);
LGG	cis	rs10540	0.908	rs12792111	chr11:520921	G/C	cg03576123	chr11:487126	PTDSS2	-1.21	-14.91	-0.57	2.51e-41	Body mass index;
LGG	cis	rs4819052	0.851	rs1999335	chr21:46670613	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.11	0.52	1.32e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.43	-7.18	-0.32	2.74e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs6500637	0.580	rs2660243	chr16:4941397	A/G	cg08329684	chr16:4932620	PPL	-0.49	-9.23	-0.39	9.79e-19	Cancer;
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg07167872	chr1:205819463	PM20D1	0.66	13.72	0.54	3.43e-36	Menarche (age at onset);
LGG	cis	rs71403859	0.502	rs71403847	chr16:71468226	T/C	cg08717414	chr16:71523259	ZNF19	-1.31	-16.75	-0.61	1.46e-49	Post bronchodilator FEV1;
LGG	cis	rs9926296	0.585	rs6500441	chr16:89828669	C/G	cg27121462	chr16:89883253	FANCA	0.62	11.27	0.46	3.43e-26	Vitiligo;
LGG	cis	rs6764363	0.775	rs17016536	chr3:308912	A/C	cg02057681	chr3:285234	CHL1	0.39	7.07	0.31	5.56e-12	Sudden cardiac arrest;
LGG	cis	rs11785400	0.793	rs4736362	chr8:143741381	G/A	cg10596483	chr8:143751796	JRK	0.51	8.03	0.35	8.21e-15	Schizophrenia;
LGG	cis	rs7586879	0.616	rs13410999	chr2:25097939	T/C	cg04586622	chr2:25135609	ADCY3	0.44	11.76	0.48	4.12e-28	Body mass index;
LGG	cis	rs4731207	0.698	rs4463363	chr7:124513770	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.923	rs9766037	chr6:149938057	A/C	cg07701084	chr6:150067640	NUP43	0.68	12.87	0.51	1.34e-32	Lung cancer;
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-9.75	-0.41	1.54e-20	Tonsillectomy;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg01879757	chr17:41196368	BRCA1	-0.46	-9.3	-0.4	5.78e-19	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg08280861	chr8:58055591	NA	0.53	6.96	0.31	1.17e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9503598	0.636	rs6596976	chr6:3466022	C/T	cg00476032	chr6:3446245	SLC22A23	0.55	11.34	0.47	1.8e-26	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs2495754	chr10:102324812	C/T	cg11040518	chr10:102331378	NA	-0.4	-7.26	-0.32	1.64e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg02725872	chr8:58115012	NA	-0.98	-13.09	-0.52	1.53e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs13392177	0.684	rs6720449	chr2:219080978	G/A	cg04731861	chr2:219085781	ARPC2	0.5	12.7	0.51	6.31e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10836402	chr12:31226622	DDX11	0.48	7.25	0.32	1.74e-12	Gut microbiome composition (summer);
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.94	-15.01	-0.57	8.65e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs877282	0.755	rs2790388	chr10:786084	T/C	cg22713356	chr15:30763199	NA	0.5	7.94	0.35	1.6e-14	Uric acid levels;
LGG	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23221052	chr5:179740743	GFPT2	0.62	11.48	0.47	5.11e-27	Height;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg06916706	chr16:4465613	CORO7	-0.84	-14.28	-0.55	1.3e-38	Schizophrenia;
LGG	cis	rs9815354	1.000	rs9857175	chr3:41822054	T/G	cg03022575	chr3:42003672	ULK4	0.62	8.07	0.35	6.23e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs244731	0.959	rs6872021	chr5:176610012	G/A	cg17509989	chr5:176798049	RGS14	-0.58	-8.2	-0.36	2.46e-15	Urate levels in lean individuals;
LGG	cis	rs2028299	0.959	rs12594808	chr15:90400884	A/G	cg23731826	chr15:90371692	NA	0.34	7.96	0.35	1.38e-14	Type 2 diabetes;
LGG	cis	rs7312933	0.558	rs3747560	chr12:42719890	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.83	-0.34	3.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs774359	0.830	rs2453554	chr9:27561800	C/T	cg14173147	chr9:27528300	MOBKL2B	0.44	8.02	0.35	8.56e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs6540556	0.954	rs10489342	chr1:209935778	A/G	cg23920097	chr1:209922102	NA	-0.45	-8.0	-0.35	1.01e-14	Red blood cell count;
LGG	cis	rs74781061	0.929	rs2068982	chr15:74915888	A/G	cg02384859	chr15:74862662	ARID3B	0.33	6.81	0.3	3.05e-11	Endometriosis;
LGG	cis	rs6088580	0.634	rs4911418	chr20:32994257	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs2050392	0.767	rs10763786	chr10:30693567	G/C	cg25182066	chr10:30743637	MAP3K8	0.61	12.32	0.5	2.26e-30	Inflammatory bowel disease;
LGG	cis	rs3858526	0.584	rs10769276	chr11:5868020	G/T	cg25319279	chr11:5960081	NA	-0.44	-7.37	-0.32	8.03e-13	DNA methylation (variation);
LGG	cis	rs7666738	0.830	rs6532715	chr4:99016792	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12824058	0.831	rs12320318	chr12:130812335	T/C	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs2562456	0.874	rs9304986	chr19:21682062	G/A	cg00806126	chr19:22604979	ZNF98	0.63	9.3	0.4	5.6e-19	Pain;
LGG	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.96	0.45	5.2e-25	Parkinson's disease;
LGG	cis	rs6121246	0.909	rs6119725	chr20:30385557	G/T	cg04935436	chr20:30431758	NA	0.41	7.19	0.32	2.64e-12	Mean corpuscular hemoglobin;
LGG	cis	rs17376456	0.877	rs2085960	chr5:93399934	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-11.77	-0.48	3.7e-28	Prudent dietary pattern;
LGG	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.55	-8.37	-0.36	7.01e-16	Blood protein levels;
LGG	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg16339924	chr4:17578868	LAP3	0.64	10.75	0.45	3.36e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg00898013	chr13:113819073	PROZ	-0.42	-8.7	-0.38	5.65e-17	Platelet distribution width;
LGG	cis	rs7647973	0.580	rs4955432	chr3:49266772	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.52	-8.34	-0.36	8.38e-16	Menarche (age at onset);
LGG	cis	rs9513627	1.000	rs9517758	chr13:100179397	T/A	cg15490075	chr13:100150979	NA	0.63	6.71	0.3	5.64e-11	Obesity-related traits;
LGG	cis	rs9818758	0.607	rs35283189	chr3:49113668	T/C	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22256960	chr15:77711686	NA	0.43	6.93	0.31	1.41e-11	Cognitive performance;
LGG	cis	rs12477438	0.798	rs6740035	chr2:99576578	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs7617773	0.817	rs11710861	chr3:48297560	C/T	cg11946769	chr3:48343235	NME6	0.63	10.44	0.44	4.68e-23	Coronary artery disease;
LGG	cis	rs668210	0.793	rs1204011	chr11:65741086	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-9.48	-0.4	1.34e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3768617	0.565	rs4652775	chr1:183061825	A/T	cg15522984	chr1:182991683	LAMC1	0.44	8.74	0.38	4.36e-17	Fuchs's corneal dystrophy;
LGG	cis	rs8072100	0.676	rs9908049	chr17:45502096	G/C	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	6e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11628318	0.617	rs11626481	chr14:103086356	A/G	cg01864069	chr14:103024347	NA	-0.7	-9.83	-0.42	7.87e-21	Platelet count;
LGG	cis	rs9814567	1.000	rs9883753	chr3:134247231	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.38	-0.53	9.07e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9393692	0.905	rs1125000	chr6:26287256	C/T	cg15665833	chr6:26285013	NA	0.39	7.42	0.33	5.48e-13	Educational attainment;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg11878867	chr6:150167359	LRP11	0.48	9.77	0.41	1.3e-20	Lung cancer;
LGG	cis	rs9815354	0.812	rs73830532	chr3:41898814	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2242116	0.796	rs7623898	chr3:46974172	C/T	cg27129171	chr3:47204927	SETD2	-0.72	-12.52	-0.5	3.55e-31	Birth weight;
LGG	cis	rs11214589	0.747	rs10502172	chr11:113199146	C/T	cg14159747	chr11:113255604	NA	0.29	7.83	0.34	3.29e-14	Neuroticism;
LGG	cis	rs270601	0.866	rs460271	chr5:131630062	C/G	cg07395648	chr5:131743802	NA	-0.49	-9.78	-0.41	1.19e-20	Acylcarnitine levels;
LGG	cis	rs2576037	0.583	rs9916891	chr18:44493521	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.65	0.44	7.44e-24	Personality dimensions;
LGG	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg14210321	chr2:106509881	NCK2	-0.53	-9.14	-0.39	1.93e-18	Addiction;
LGG	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg02297831	chr4:17616191	MED28	0.5	9.37	0.4	3.15e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.28	-0.43	1.75e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs926938	0.527	rs11084	chr1:115537933	A/G	cg12756093	chr1:115239321	AMPD1	0.42	7.97	0.35	1.27e-14	Autism;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg20295408	chr7:1910781	MAD1L1	-0.41	-6.68	-0.3	6.71e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs597539	0.521	rs7943745	chr11:68605828	A/G	cg21963583	chr11:68658836	MRPL21	-0.37	-6.74	-0.3	4.74e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.47	-0.4	1.49e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.58	0.37	1.4e-16	Neuroticism;
LGG	cis	rs2294015	1.000	rs2294015	chr8:124696867	C/T	cg07200421	chr8:124693396	ANXA13	0.37	8.08	0.35	5.87e-15	Event-related brain oscillations;
LGG	cis	rs1348850	0.958	rs1545364	chr2:178462882	G/T	cg27490568	chr2:178487706	NA	0.47	9.22	0.39	1.04e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2760061	0.599	rs849903	chr1:228137659	T/C	cg18477163	chr1:228402036	OBSCN	-0.27	-7.22	-0.32	2.17e-12	Diastolic blood pressure;
LGG	cis	rs6582630	0.519	rs8189561	chr12:38296178	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.64e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1816752	0.905	rs9511249	chr13:24999595	G/A	cg22771759	chr13:24902376	NA	0.42	7.21	0.32	2.34e-12	Obesity-related traits;
LGG	cis	rs990171	0.913	rs10190555	chr2:102994056	A/G	cg05295703	chr2:102895712	NA	-0.57	-10.03	-0.42	1.46e-21	Lymphocyte counts;
LGG	cis	rs35110281	0.744	rs162398	chr21:44949285	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.07e-17	Mean corpuscular volume;
LGG	cis	rs9863	0.931	rs7955815	chr12:124432706	C/T	cg13487667	chr12:124434373	CCDC92	-0.38	-7.44	-0.33	4.89e-13	White blood cell count;
LGG	cis	rs4660214	0.666	rs4660550	chr1:39688459	A/T	cg18385671	chr1:39797026	MACF1	-0.46	-10.05	-0.42	1.23e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg11878867	chr6:150167359	LRP11	0.46	7.95	0.35	1.46e-14	Lung cancer;
LGG	cis	rs3812831	0.661	rs2987458	chr13:114919835	A/G	cg08824895	chr13:115047677	UPF3A	0.43	7.25	0.32	1.75e-12	Schizophrenia;
LGG	cis	rs11877825	0.826	rs1893228	chr18:10578872	C/T	cg07277756	chr18:10589357	NA	0.58	10.42	0.44	5.63e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs473651	0.935	rs482775	chr2:239335403	G/C	cg21699342	chr2:239360505	ASB1	0.41	7.78	0.34	4.74e-14	Multiple system atrophy;
LGG	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg18850127	chr7:39170497	POU6F2	0.64	16.35	0.6	9.69e-48	IgG glycosylation;
LGG	trans	rs9354308	0.764	rs1938118	chr6:66568876	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs3768617	0.706	rs10797801	chr1:182971965	G/T	cg07245641	chr1:182991651	LAMC1	0.31	6.81	0.3	2.97e-11	Fuchs's corneal dystrophy;
LGG	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.7	0.48	6.7e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2276314	0.857	rs9304155	chr18:33585710	A/C	cg05985134	chr18:33552581	C18orf21	0.64	10.05	0.42	1.25e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs698833	0.926	rs786622	chr2:44606598	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	6.8	0.3	3.24e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7208859	0.673	rs12103759	chr17:29235687	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs17504614	0.634	rs72838711	chr2:51061510	T/C	cg23851515	chr2:51057218	NRXN1	0.46	7.48	0.33	3.79e-13	Educational attainment (years of education);
LGG	trans	rs800082	0.501	rs9873732	chr3:144191665	C/T	cg24215973	chr2:240111563	HDAC4	0.41	7.22	0.32	2.18e-12	Smoking behavior;
LGG	cis	rs13217239	0.646	rs10946898	chr6:27003884	T/C	cg12292205	chr6:26970375	C6orf41	0.56	10.99	0.45	3.94e-25	Schizophrenia;
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7444	0.941	rs5749493	chr22:21939687	C/A	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs6964587	1.000	rs10264666	chr7:91578639	G/A	cg17063962	chr7:91808500	NA	-0.5	-8.75	-0.38	4.11e-17	Breast cancer;
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.78	-0.3	3.76e-11	Height;
LGG	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg05973401	chr12:123451056	ABCB9	0.48	8.07	0.35	6.23e-15	Platelet count;
LGG	cis	rs9912468	0.555	rs4791079	chr17:64209540	A/C	cg19474267	chr17:64306194	PRKCA	-0.68	-13.58	-0.53	1.33e-35	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs3760047	0.668	rs2858922	chr16:207218	G/A	cg25425005	chr16:202905	HBZ	-0.62	-10.06	-0.42	1.14e-21	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4671458	1.000	rs4671459	chr2:63392872	A/C	cg17519650	chr2:63277830	OTX1	-0.65	-8.04	-0.35	7.71e-15	Subjective well-being;
LGG	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs12893668	0.514	rs3212090	chr14:104168863	C/T	cg24130564	chr14:104152367	KLC1	-0.38	-6.86	-0.3	2.19e-11	Reticulocyte count;
LGG	cis	rs11650494	0.831	rs8065389	chr17:47456064	G/T	cg08112188	chr17:47440006	ZNF652	-1.23	-14.81	-0.57	6.74e-41	Prostate cancer;
LGG	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg25664220	chr3:72788482	NA	-0.33	-9.42	-0.4	2.16e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg06637938	chr14:75390232	RPS6KL1	0.58	10.82	0.45	1.71e-24	Height;
LGG	cis	rs2635047	0.967	rs2684843	chr18:44726260	T/A	cg19077165	chr18:44547161	KATNAL2	-0.47	-8.18	-0.36	2.69e-15	Educational attainment;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.12e-19	Alzheimer's disease;
LGG	trans	rs35110281	0.806	rs1454649	chr21:45032982	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.14	0.49	1.23e-29	Mean corpuscular volume;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg18379455	chr17:41446167	NA	0.32	7.8	0.34	4.02e-14	Menopause (age at onset);
LGG	cis	rs9858542	0.953	rs11710037	chr3:49675334	C/G	cg07274523	chr3:49395745	GPX1	0.55	9.1	0.39	2.78e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs75059851	0.756	rs7122746	chr11:133838808	A/G	cg20042908	chr11:133852938	NA	-0.78	-14.69	-0.56	2.3e-40	Schizophrenia;
LGG	cis	rs6724607	1.000	rs11680758	chr2:191446268	T/G	cg27211696	chr2:191398769	TMEM194B	0.4	9.43	0.4	1.96e-19	Pulse pressure;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	cis	rs782590	0.807	rs782572	chr2:55912120	T/C	cg18811423	chr2:55921094	PNPT1	0.94	22.87	0.73	4.85e-78	Metabolic syndrome;
LGG	cis	rs6088580	0.634	rs9789792	chr20:32957709	G/A	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.29	-0.36	1.23e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6840360	0.582	rs2709827	chr4:152331252	G/C	cg17217059	chr4:152329364	FAM160A1	0.19	6.67	0.3	7.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18036763	chr22:45404910	PHF21B	0.53	9.09	0.39	2.93e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs11673344	0.764	rs569371	chr19:37453997	A/G	cg04415599	chr19:37464508	NA	-0.35	-6.77	-0.3	4.01e-11	Obesity-related traits;
LGG	cis	rs969413	0.624	rs9914093	chr17:79260653	C/G	cg25342872	chr17:79175132	AZI1	-0.47	-7.94	-0.35	1.52e-14	Frontotemporal dementia;
LGG	cis	rs4917300	0.647	rs4917223	chr8:143115548	C/T	cg06573787	chr8:143070187	NA	0.46	7.92	0.35	1.72e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg15664640	chr17:80829946	TBCD	-0.65	-9.63	-0.41	3.99e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs1784581	1.000	rs1615717	chr6:162400612	C/T	cg17173639	chr6:162384350	PARK2	-0.84	-21.05	-0.7	1.62e-69	Itch intensity from mosquito bite;
LGG	cis	rs4356932	1.000	rs6819597	chr4:76957171	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.76	0.59	4.34e-45	Lung cancer;
LGG	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg10189774	chr4:17578691	LAP3	0.42	7.29	0.32	1.36e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs929354	1.000	rs8101	chr7:157061474	A/G	cg00092383	chr7:157075207	NA	0.43	7.53	0.33	2.6e-13	Body mass index;
LGG	cis	rs17767392	0.918	rs35094946	chr14:71752790	T/C	cg02058870	chr14:72053146	SIPA1L1	0.44	9.04	0.39	4.21e-18	Mitral valve prolapse;
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg16339924	chr4:17578868	LAP3	0.63	11.01	0.46	3.33e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9914988	0.943	rs2242345	chr17:27185827	C/T	cg20469991	chr17:27169893	C17orf63	0.58	7.23	0.32	2.01e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs561341	1.000	rs550264	chr17:30317540	G/T	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs6489882	0.807	rs1859334	chr12:113367332	C/T	cg25319449	chr12:113376135	OAS3	-0.43	-7.71	-0.34	7.84e-14	Chronic lymphocytic leukemia;
LGG	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg15556689	chr8:8085844	FLJ10661	-0.5	-8.66	-0.37	7.65e-17	Retinal vascular caliber;
LGG	cis	rs9910055	0.529	rs368328	chr17:42170289	G/A	cg13607699	chr17:42295918	UBTF	-0.42	-6.71	-0.3	5.6e-11	Total body bone mineral density;
LGG	cis	rs1045902	0.967	rs10207625	chr2:73464808	T/C	cg01422370	chr2:73384389	NA	0.47	9.01	0.39	5.64e-18	Intelligence (multi-trait analysis);
LGG	cis	rs11645898	0.687	rs11075919	chr16:72106906	T/C	cg14768367	chr16:72042858	DHODH	-0.65	-9.17	-0.39	1.56e-18	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16924120	chr12:118814149	SUDS3	0.45	6.85	0.3	2.29e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.1	-0.31	4.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs858239	0.600	rs2072369	chr7:23146189	A/G	cg23682824	chr7:23144976	KLHL7	0.45	7.68	0.34	9.35e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg02158880	chr13:53174818	NA	0.68	15.31	0.58	4.26e-43	Lewy body disease;
LGG	cis	rs35306767	0.903	rs13377166	chr10:886259	G/A	cg20503657	chr10:835505	NA	0.76	10.5	0.44	2.81e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg14673194	chr17:80132900	CCDC57	0.43	7.59	0.33	1.77e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	trans	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.67	-9.58	-0.41	5.95e-20	Ulcerative colitis;
LGG	cis	rs9814567	0.928	rs6768323	chr3:134268737	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4665809	0.590	rs4665840	chr2:26444962	C/T	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg15103426	chr22:29168792	CCDC117	0.73	11.79	0.48	3.17e-28	Lymphocyte counts;
LGG	cis	rs2019137	0.936	rs3811059	chr2:113962071	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.69	-12.47	-0.5	5.89e-31	Lymphocyte counts;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg22618164	chr12:122356400	WDR66	0.42	13.33	0.53	1.58e-34	Mean corpuscular volume;
LGG	cis	rs4722166	0.630	rs13311199	chr7:22789793	A/C	cg05265849	chr7:22767390	IL6	0.42	7.95	0.35	1.39e-14	Lung cancer;
LGG	cis	rs3096299	0.606	rs8052103	chr16:89541243	A/T	cg05484508	chr16:89589025	SPG7	-0.52	-8.12	-0.35	4.33e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs55823223	0.564	rs9894009	chr17:73850414	C/T	cg14829360	chr17:73884958	NA	-0.81	-14.98	-0.57	1.17e-41	Psoriasis;
LGG	cis	rs9443645	0.527	rs9359360	chr6:79702796	C/T	cg18132916	chr6:79620363	NA	-0.26	-6.93	-0.31	1.42e-11	Intelligence (multi-trait analysis);
LGG	trans	rs3942852	0.868	rs58407618	chr11:48104167	T/G	cg03929089	chr4:120376271	NA	-0.62	-7.77	-0.34	5.18e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9902453	0.845	rs3115101	chr17:28041627	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	14.05	0.55	1.33e-37	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs56114371	0.777	rs200482	chr6:27773904	G/A	cg01620082	chr3:125678407	NA	-0.83	-9.75	-0.41	1.45e-20	Breast cancer;
LGG	cis	rs769267	0.896	rs2074298	chr19:19377716	C/G	cg01262667	chr19:19385393	TM6SF2	0.47	11.73	0.48	5.42e-28	Tonsillectomy;
LGG	cis	rs9549367	0.789	rs7317558	chr13:113893625	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-13.99	-0.55	2.38e-37	Platelet distribution width;
LGG	trans	rs1814175	0.935	rs7925863	chr11:49615802	C/A	cg15704280	chr7:45808275	SEPT13	-1.06	-24.03	-0.74	2.06e-83	Height;
LGG	cis	rs3806843	1.000	rs10477033	chr5:140169603	G/C	cg19875535	chr5:140030758	IK	0.5	10.26	0.43	2.14e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs7444	0.941	rs140499	chr22:21927231	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.47	7.17	0.32	2.97e-12	Renal function-related traits (BUN);
LGG	cis	rs504918	0.874	rs595616	chr3:124089182	G/C	cg05766129	chr3:123988013	KALRN	0.37	6.76	0.3	4.19e-11	Schizophrenia;
LGG	cis	rs77633900	0.772	rs2948703	chr15:76711751	A/G	cg21673338	chr15:77095150	SCAPER	-0.63	-8.28	-0.36	1.36e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs981844	0.712	rs1012029	chr4:154749233	C/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs2576037	0.526	rs1539878	chr18:44523004	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.34	-6.66	-0.3	7.64e-11	Personality dimensions;
LGG	cis	rs7106204	0.609	rs16912369	chr11:24297601	C/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.5	0.33	3.36e-13	Lung cancer;
LGG	cis	rs8077889	0.869	rs11713	chr17:41845824	A/G	cg26893861	chr17:41843967	DUSP3	-0.88	-15.09	-0.57	3.89e-42	Triglycerides;
LGG	cis	rs67478160	0.643	rs876002	chr14:104239697	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-7.56	-0.33	2.21e-13	Schizophrenia;
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	cis	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.86	0.54	8.71e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg20887711	chr4:1340912	KIAA1530	-0.75	-15.42	-0.58	1.37e-43	Obesity-related traits;
LGG	cis	rs1881396	0.945	rs1881397	chr2:27832285	A/G	cg27432699	chr2:27873401	GPN1	0.52	8.03	0.35	8.04e-15	Nonalcoholic fatty liver disease;
LGG	cis	rs12701220	0.894	rs2141274	chr7:1034717	G/A	cg20821713	chr7:1055600	C7orf50	-0.52	-8.32	-0.36	9.93e-16	Bronchopulmonary dysplasia;
LGG	cis	rs2228479	0.850	rs11647174	chr16:89958538	G/A	cg04287289	chr16:89883240	FANCA	0.77	7.55	0.33	2.39e-13	Skin colour saturation;
LGG	cis	rs9611565	0.512	rs4820444	chr22:42202606	A/G	cg06634786	chr22:41940651	POLR3H	0.76	12.02	0.49	3.62e-29	Vitiligo;
LGG	cis	rs9296092	0.560	rs9469505	chr6:33527348	A/G	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs3749237	0.576	rs62259939	chr3:49386047	G/A	cg07636037	chr3:49044803	WDR6	0.6	10.25	0.43	2.29e-22	Resting heart rate;
LGG	cis	rs4936894	0.500	rs4936912	chr11:124140466	T/G	cg27160556	chr11:124181099	OR8D1	-0.47	-10.85	-0.45	1.32e-24	Aging (time to death);
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.64	0.41	3.71e-20	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25352856	chr1:180472145	ACBD6	0.47	7.46	0.33	4.19e-13	Cognitive performance;
LGG	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.7	0.56	1.95e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10484885	0.824	rs28372875	chr6:90529343	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.82	-0.45	1.81e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7539542	0.556	rs6692075	chr1:202881302	C/T	cg19681188	chr1:202830198	LOC148709	0.51	8.55	0.37	1.82e-16	Mean platelet volume;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03647317	chr4:187891568	NA	-0.42	-8.93	-0.38	1.01e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4722585	0.533	rs2158359	chr7:26193309	A/C	cg07876897	chr7:26191696	NFE2L3	-0.35	-7.05	-0.31	6.48e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs2439831	0.850	rs11070408	chr15:44034788	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.62	0.44	9.61e-24	Lung cancer in ever smokers;
LGG	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06108461	chr20:60628389	TAF4	-0.77	-14.06	-0.55	1.2e-37	Body mass index;
LGG	trans	rs2204008	0.570	rs12318341	chr12:38251087	T/C	cg06521331	chr12:34319734	NA	0.44	7.99	0.35	1.09e-14	Bladder cancer;
LGG	cis	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg25427524	chr10:38739819	LOC399744	-0.67	-12.43	-0.5	8.29e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs2531992	0.800	rs2907272	chr16:4019350	C/T	cg05927578	chr16:4029543	ADCY9	0.66	10.23	0.43	2.77e-22	Waist circumference;
LGG	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg26384229	chr12:38710491	ALG10B	-0.69	-13.87	-0.54	8.11e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.46	-0.56	2.25e-39	Bipolar disorder and schizophrenia;
LGG	cis	rs936229	0.749	rs6495127	chr15:75194490	C/T	cg10253484	chr15:75165896	SCAMP2	-0.68	-11.1	-0.46	1.49e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.93	-0.35	1.61e-14	Total body bone mineral density;
LGG	cis	rs41271473	0.687	rs7535661	chr1:228887667	C/T	cg00850481	chr1:228891306	NA	-0.6	-12.36	-0.5	1.55e-30	Chronic lymphocytic leukemia;
LGG	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg06453172	chr10:134556979	INPP5A	-0.59	-8.8	-0.38	2.66e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7503807	0.515	rs34863264	chr17:78655312	C/T	cg06872548	chr17:78716983	RPTOR	0.37	6.87	0.3	2.02e-11	Obesity;
LGG	cis	rs7937890	0.967	rs963212	chr11:14324732	A/G	cg02251663	chr11:14281053	SPON1	0.31	7.43	0.33	5.13e-13	Mitochondrial DNA levels;
LGG	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg14088196	chr11:70211408	PPFIA1	0.76	11.15	0.46	9.38e-26	Coronary artery disease;
LGG	cis	rs730775	0.505	rs325004	chr6:44270365	C/G	cg21130236	chr6:44246755	TMEM151B	-0.34	-7.44	-0.33	5.09e-13	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.41	-0.36	5.19e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.958	rs10873246	chr14:72153693	A/G	cg13720639	chr14:72061746	SIPA1L1	0.39	8.36	0.36	7.58e-16	Mitral valve prolapse;
LGG	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.51e-15	Common traits (Other);
LGG	cis	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg26695010	chr11:65641043	EFEMP2	0.5	8.36	0.36	7.21e-16	DNA methylation (variation);
LGG	cis	rs72772090	0.634	rs10515246	chr5:96099265	A/G	cg00188032	chr5:96141721	ERAP1	0.52	7.22	0.32	2.17e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7177699	0.526	rs7182529	chr15:79123631	T/C	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.58e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg23782820	chr8:58130467	NA	0.44	6.72	0.3	5.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs209489	0.892	rs76203304	chr6:53129261	G/A	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs4789693	0.809	rs8071692	chr17:80392333	G/A	cg04308225	chr17:80449738	NA	0.56	7.9	0.34	2.02e-14	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26306683	chr17:18585705	ZNF286B	0.48	9.13	0.39	2.06e-18	Educational attainment (years of education);
LGG	cis	rs6582630	0.598	rs11182207	chr12:38477514	T/C	cg26384229	chr12:38710491	ALG10B	-0.66	-13.24	-0.52	3.83e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg26384229	chr12:38710491	ALG10B	0.94	22.23	0.72	4.86e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9303280	0.901	rs869402	chr17:38068043	C/T	cg00129232	chr17:37814104	STARD3	-0.39	-7.24	-0.32	1.87e-12	Self-reported allergy;
LGG	cis	rs6032067	0.636	rs6032095	chr20:43913255	A/T	cg10761708	chr20:43804764	PI3	-0.58	-9.09	-0.39	3e-18	Blood protein levels;
LGG	trans	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg16141378	chr3:129829833	LOC729375	0.39	8.6	0.37	1.23e-16	Mood instability;
LGG	cis	rs12210905	0.688	rs12209174	chr6:27443952	G/A	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg05484508	chr16:89589025	SPG7	0.43	6.83	0.3	2.66e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs3749237	0.595	rs1464566	chr3:49459376	T/C	cg03060546	chr3:49711283	APEH	0.74	13.17	0.52	6.9e-34	Resting heart rate;
LGG	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg02427764	chr11:65769310	BANF1;EIF1AD	0.47	7.99	0.35	1.09e-14	Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg05861140	chr6:150128134	PCMT1	-0.39	-8.74	-0.38	4.42e-17	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07267656	chr12:56616060	RNF41	0.48	7.27	0.32	1.5e-12	Gut microbiome composition (summer);
LGG	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.47e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.12	-0.39	2.35e-18	Body mass index;
LGG	cis	rs10791097	0.678	rs10894272	chr11:130731081	A/G	cg12179176	chr11:130786555	SNX19	0.76	14.61	0.56	5.19e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6063312	0.935	rs6066827	chr20:47341005	T/C	cg18078177	chr20:47281410	PREX1	0.77	9.29	0.4	6.22e-19	Tonometry;
LGG	cis	rs559928	0.606	rs11231710	chr11:63925743	A/G	cg24687543	chr11:63912206	MACROD1	0.61	8.58	0.37	1.42e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs11064837	0.504	rs11064845	chr12:120051929	C/G	cg25937854	chr12:120150414	CIT	0.59	10.13	0.43	6.58e-22	Schizophrenia;
LGG	cis	rs12477438	0.501	rs12613624	chr2:99732741	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-15.43	-0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs11885103	0.746	rs2685242	chr2:595125	A/C	cg21195176	chr2:593345	NA	0.4	7.66	0.34	1.1e-13	Heschl's gyrus morphology;
LGG	cis	rs10929925	0.966	rs1880801	chr2:6149904	C/T	cg00493617	chr2:6141445	NA	0.32	7.24	0.32	1.85e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs4746818	0.818	rs10823302	chr10:70895418	G/T	cg11621586	chr10:70884670	VPS26A	1.19	23.03	0.73	8.55e-79	Left atrial antero-posterior diameter;
LGG	cis	rs2494938	0.730	rs205515	chr6:40514185	A/G	cg14084896	chr6:40530702	LRFN2	-0.32	-7.25	-0.32	1.72e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg10596483	chr8:143751796	JRK	-0.47	-6.73	-0.3	5.14e-11	Urinary tract infection frequency;
LGG	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg23594656	chr7:65796392	TPST1	-0.37	-8.16	-0.35	3.25e-15	Aortic root size;
LGG	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg08859206	chr1:53392774	SCP2	-0.34	-6.68	-0.3	6.69e-11	Monocyte count;
LGG	cis	rs6547741	1.000	rs10165098	chr2:27796526	C/T	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.83	-0.48	2.07e-28	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.737	rs175049	chr14:75481368	C/T	cg11812906	chr14:75593930	NEK9	-0.44	-7.96	-0.35	1.32e-14	Height;
LGG	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg12463550	chr7:65579703	CRCP	0.73	8.12	0.35	4.2e-15	Diabetic kidney disease;
LGG	cis	rs9783347	1.000	rs59150578	chr11:18340862	G/A	cg15585147	chr11:18324498	HPS5	0.43	8.97	0.38	7.25e-18	Pancreatic cancer;
LGG	cis	rs611744	0.647	rs1448150	chr8:109276161	T/C	cg21045802	chr8:109455806	TTC35	0.53	9.95	0.42	2.8e-21	Dupuytren's disease;
LGG	cis	rs240764	0.755	rs12206564	chr6:100987009	A/G	cg21058520	chr6:100914733	NA	0.39	6.82	0.3	2.86e-11	Neuroticism;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00933542	chr6:150070202	PCMT1	0.38	6.96	0.31	1.18e-11	Lung cancer;
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.35	-0.32	8.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504073	0.647	rs11785310	chr8:50025035	G/A	cg00325661	chr8:49890786	NA	0.74	14.24	0.55	2.08e-38	Blood metabolite ratios;
LGG	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.35	-0.5	1.71e-30	Height;
LGG	cis	rs17345786	1.000	rs55641278	chr3:101290577	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	8.95	0.38	8.68e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7618501	0.540	rs11130241	chr3:50131459	A/T	cg05623727	chr3:50126028	RBM5	-0.37	-8.13	-0.35	3.9e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.935	rs7621551	chr3:10114205	C/T	cg00149659	chr3:10157352	C3orf10	0.85	10.75	0.45	3.4e-24	Alzheimer's disease;
LGG	cis	rs8016982	0.611	rs8008870	chr14:81709374	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	19.54	0.67	1.95e-62	Schizophrenia;
LGG	cis	rs7584330	0.822	rs13390494	chr2:238388792	G/A	cg16989719	chr2:238392110	NA	-0.35	-7.66	-0.34	1.13e-13	Prostate cancer;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.47	0.5	5.92e-31	Obesity-related traits;
LGG	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6988985	0.791	rs11781816	chr8:143997795	C/T	cg10324643	chr8:143916377	GML	-0.38	-7.53	-0.33	2.62e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7567389	0.568	rs7568070	chr2:127953054	A/C	cg11380483	chr2:127933992	NA	0.57	10.31	0.43	1.39e-22	Self-rated health;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg11494091	chr17:61959527	GH2	-1.03	-26.12	-0.77	4.26e-93	Prudent dietary pattern;
LGG	cis	rs9640161	0.617	rs73170169	chr7:150008036	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.76	-15.36	-0.58	2.42e-43	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg21605986	chr5:175788725	KIAA1191	0.44	7.48	0.33	3.73e-13	Bipolar disorder;
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg14789911	chr21:47582049	C21orf56	0.46	7.5	0.33	3.22e-13	Testicular germ cell tumor;
LGG	cis	rs9807841	0.568	rs3859514	chr19:10748820	T/C	cg17710535	chr19:10819994	QTRT1	0.44	7.04	0.31	7.17e-12	Inflammatory skin disease;
LGG	cis	rs6694672	1.000	rs1115246	chr1:197037449	A/G	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.1	-0.39	2.65e-18	Personality dimensions;
LGG	cis	rs208520	0.690	rs3843513	chr6:66836797	A/G	cg07460842	chr6:66804631	NA	-0.97	-18.2	-0.65	3.3e-56	Exhaled nitric oxide output;
LGG	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.9	-0.34	2.02e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7666738	0.830	rs1426672	chr4:98923984	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7766436	0.885	rs5010014	chr6:22587299	A/G	cg13666174	chr6:22585274	NA	-0.51	-11.93	-0.48	8.78e-29	Coronary artery disease;
LGG	cis	rs7582180	0.838	rs6754867	chr2:100895081	A/G	cg21926883	chr2:100939477	LONRF2	0.43	8.35	0.36	7.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs10244797	chr7:124571684	C/T	cg05630886	chr7:124431682	NA	-0.3	-7.0	-0.31	8.91e-12	Cutaneous malignant melanoma;
LGG	cis	rs2046867	0.862	rs11922794	chr3:72813582	G/C	cg25664220	chr3:72788482	NA	-0.32	-8.93	-0.38	9.97e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7937682	0.575	rs10789851	chr11:111750955	G/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs2404602	0.608	rs12439484	chr15:76602937	A/C	cg22467129	chr15:76604101	ETFA	-0.41	-6.87	-0.3	2.13e-11	Blood metabolite levels;
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.2e-48	Intelligence (multi-trait analysis);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13610241	chr3:184032169	EIF4G1	0.38	6.83	0.3	2.64e-11	Obesity-related traits;
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg07701084	chr6:150067640	NUP43	-0.48	-7.32	-0.32	1.12e-12	Lung cancer;
LGG	cis	rs7940866	0.903	rs1433980	chr11:130870956	A/G	cg12179176	chr11:130786555	SNX19	0.69	12.8	0.51	2.46e-32	Schizophrenia;
LGG	cis	rs953387	1.000	rs4954566	chr2:136901513	A/G	cg05194412	chr2:137003533	NA	0.31	6.65	0.3	8.37e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs3096299	0.933	rs889576	chr16:89429653	A/G	cg08822215	chr16:89438651	ANKRD11	0.38	7.18	0.32	2.82e-12	Multiple myeloma (IgH translocation);
LGG	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.77	-0.38	3.47e-17	Triglycerides;
LGG	cis	rs2180341	0.782	rs4897214	chr6:127723625	G/T	cg24812749	chr6:127587940	RNF146	0.7	11.51	0.47	3.87e-27	Breast cancer;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg15971980	chr6:150254442	NA	0.44	7.1	0.31	4.59e-12	Lung cancer;
LGG	cis	rs12282928	1.000	rs10838858	chr11:48301755	C/T	cg26585981	chr11:48327164	OR4S1	-0.45	-7.25	-0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg27286069	chr11:118481882	PHLDB1	0.54	10.38	0.43	8.12e-23	Cholesterol, total;
LGG	trans	rs1814175	0.817	rs1851858	chr11:49855638	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.19	-0.78	5.26e-98	Height;
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg26617929	chr16:1858877	NA	-0.61	-8.61	-0.37	1.13e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg19223190	chr17:80058835	NA	-0.45	-8.7	-0.38	5.65e-17	Life satisfaction;
LGG	cis	rs909674	0.690	rs5750825	chr22:39831278	A/G	cg04986931	chr22:39850128	NA	0.4	9.0	0.39	5.98e-18	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16281248	chr11:64014554	PPP1R14B	0.51	8.29	0.36	1.25e-15	Cognitive performance;
LGG	cis	rs950776	0.518	rs1979907	chr15:78842239	T/C	cg06917634	chr15:78832804	PSMA4	-0.82	-17.35	-0.63	2.48e-52	Sudden cardiac arrest;
LGG	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.32	-0.32	1.09e-12	Refractive error;
LGG	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg17145862	chr1:211918768	LPGAT1	0.8	17.17	0.62	1.73e-51	Leprosy;
LGG	cis	rs9467711	0.606	rs67509210	chr6:26354100	G/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.12	-0.46	1.23e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs13190036	1.000	rs71601344	chr5:176633493	G/A	cg06733329	chr5:176740039	MXD3	0.48	6.72	0.3	5.4e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg03709012	chr19:19516395	GATAD2A	1.05	17.13	0.62	2.71e-51	Nonalcoholic fatty liver disease;
LGG	cis	rs11628318	0.614	rs4906254	chr14:103209153	C/T	cg01864069	chr14:103024347	NA	-0.44	-7.56	-0.33	2.19e-13	Platelet count;
LGG	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.21e-15	Monocyte count;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs7172689	0.908	rs28440856	chr15:81557459	C/G	cg11808699	chr15:81528661	IL16	-0.49	-9.91	-0.42	4e-21	Inattentive symptoms;
LGG	cis	rs7937682	0.921	rs11213940	chr11:111433927	C/A	cg08305652	chr11:111469057	NA	0.41	8.09	0.35	5.23e-15	Primary sclerosing cholangitis;
LGG	cis	rs8027181	0.617	rs28827493	chr15:73083121	G/A	cg02923145	chr15:73089643	NA	-0.44	-8.27	-0.36	1.45e-15	Triglyceride levels;
LGG	cis	rs6089584	0.888	rs6089623	chr20:60615759	A/G	cg06108461	chr20:60628389	TAF4	-1.02	-20.15	-0.68	2.75e-65	Body mass index;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg11584989	chr19:19387371	SF4	0.4	7.25	0.32	1.81e-12	Tonsillectomy;
LGG	cis	rs11690935	0.959	rs12692974	chr2:172663256	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.04	-0.77	1e-92	Schizophrenia;
LGG	cis	rs1065852	0.526	rs59993856	chr22:42403980	C/T	cg15128208	chr22:42549153	NA	0.41	7.07	0.31	5.81e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.74	-0.45	3.56e-24	Neuroticism;
LGG	cis	rs193541	0.555	rs2438151	chr5:122199197	A/G	cg19412675	chr5:122181750	SNX24	0.54	8.55	0.37	1.81e-16	Glucose homeostasis traits;
LGG	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.01e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.32e-16	Life satisfaction;
LGG	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg16339924	chr4:17578868	LAP3	-0.5	-8.34	-0.36	8.72e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs977987	0.836	rs4888376	chr16:75322573	T/C	cg03315344	chr16:75512273	CHST6	0.48	9.66	0.41	3.02e-20	Dupuytren's disease;
LGG	cis	rs919433	0.680	rs2244271	chr2:198286581	C/T	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.27e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2952156	0.959	rs2941504	chr17:37830900	A/G	cg00129232	chr17:37814104	STARD3	-0.68	-13.35	-0.53	1.3e-34	Asthma;
LGG	cis	rs826838	0.904	rs11612004	chr12:39204282	G/A	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.44e-42	Heart rate;
LGG	cis	rs11225247	1.000	rs78704392	chr11:102308053	G/A	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1790761	0.587	rs4930431	chr11:67294308	C/T	cg23188684	chr11:67383651	NA	-0.43	-7.33	-0.32	1.02e-12	Mean corpuscular volume;
LGG	cis	rs11098499	0.954	rs66506550	chr4:120371445	T/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs62400317	0.793	rs12210230	chr6:45344854	T/A	cg18551225	chr6:44695536	NA	-0.62	-10.09	-0.42	9.25e-22	Total body bone mineral density;
LGG	cis	rs947211	1.000	rs947211	chr1:205752665	A/G	cg11965913	chr1:205819406	PM20D1	0.43	6.8	0.3	3.33e-11	Parkinson's disease;
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg14689365	chr7:158441557	NCAPG2	0.62	10.29	0.43	1.73e-22	Height;
LGG	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.81	-0.3	3.09e-11	Intelligence (multi-trait analysis);
LGG	cis	rs807029	0.533	rs2295716	chr10:102744214	T/C	cg04662943	chr10:102668895	NA	0.47	6.95	0.31	1.21e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	1.000	rs12152515	chr3:10143976	C/T	cg16606324	chr3:10149918	C3orf24	0.55	7.29	0.32	1.32e-12	Alzheimer's disease;
LGG	cis	rs17767392	1.000	rs7142180	chr14:71759895	T/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs6088580	0.634	rs6088471	chr20:32932643	C/A	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.36	-0.36	7.6e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2249625	0.545	rs2496488	chr6:72875985	A/T	cg27608224	chr6:72922399	RIMS1	0.32	7.27	0.32	1.58e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg06470251	chr20:60548479	NA	0.53	8.44	0.37	4e-16	Body mass index;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg22218512	chr12:52308278	ACVRL1	0.39	6.98	0.31	1.04e-11	Electrocardiographic conduction measures;
LGG	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9815354	0.812	rs73071344	chr3:41827062	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.36	0.4	3.41e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1475911	1.000	rs2839466	chr21:43512324	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	0.43	7.78	0.34	4.77e-14	IgG glycosylation;
LGG	cis	rs9357271	1.000	rs9394494	chr6:38351981	C/T	cg07362130	chr6:38359646	BTBD9	-0.47	-10.76	-0.45	2.95e-24	Restless legs syndrome;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.81	0.41	8.91e-21	Prudent dietary pattern;
LGG	trans	rs9467711	0.606	rs13212985	chr6:26609989	G/C	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.32	-0.32	1.08e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg07701084	chr6:150067640	NUP43	0.48	7.64	0.33	1.27e-13	Testicular germ cell tumor;
LGG	cis	rs2635047	0.565	rs2571004	chr18:44710302	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.68	0.34	9.66e-14	Educational attainment;
LGG	cis	rs8072100	0.713	rs9895776	chr17:45486003	A/G	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23803311	chr5:147763284	FBXO38	0.44	7.42	0.33	5.56e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7582720	1.000	rs79633844	chr2:203683990	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.67	0.41	2.81e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs72945132	0.769	rs3781645	chr11:70190374	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs7100689	0.577	rs7901663	chr10:82153488	C/G	cg01528321	chr10:82214614	TSPAN14	0.87	15.77	0.59	3.75e-45	Post bronchodilator FEV1;
LGG	cis	rs1552244	0.882	rs67895180	chr3:10026079	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs1497828	0.956	rs2815235	chr1:217540910	C/T	cg04411442	chr1:217543379	NA	-0.48	-8.24	-0.36	1.85e-15	Dialysis-related mortality;
LGG	cis	rs2836974	0.568	rs2142111	chr21:40549289	G/C	cg06238570	chr21:40685208	BRWD1	0.51	8.42	0.36	4.68e-16	Cognitive function;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg11764359	chr7:65958608	NA	0.73	13.2	0.52	5.46e-34	Aortic root size;
LGG	cis	rs7084402	0.967	rs7078900	chr10:60273430	G/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.59	-0.63	2.15e-53	Refractive error;
LGG	cis	rs2797160	1.000	rs1935774	chr6:125996661	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.69	0.34	8.99e-14	Endometrial cancer;
LGG	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg08344181	chr3:125677491	NA	-0.76	-7.54	-0.33	2.46e-13	Squamous cell lung carcinoma;
LGG	cis	rs4650994	0.525	rs4993304	chr1:178535144	A/G	cg12486710	chr1:178512616	C1orf220	0.51	10.56	0.44	1.74e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs9393777	0.513	rs13190754	chr6:26587406	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	12.23	0.49	5.26e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22464182	chr2:148602625	ACVR2A	0.48	8.14	0.35	3.67e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs9309473	1.000	rs10179134	chr2:73637519	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-7.93	-0.35	1.66e-14	Metabolite levels;
LGG	trans	rs12310956	0.532	rs11052930	chr12:33964824	A/G	cg13010199	chr12:38710504	ALG10B	0.56	10.47	0.44	3.55e-23	Morning vs. evening chronotype;
LGG	cis	rs3008870	0.755	rs1570838	chr1:67403315	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.62	0.59	1.76e-44	Lymphocyte percentage of white cells;
LGG	cis	rs8141529	0.719	rs2097461	chr22:29191879	T/C	cg15103426	chr22:29168792	CCDC117	0.73	11.83	0.48	2.19e-28	Lymphocyte counts;
LGG	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg18511798	chr11:2018149	H19;MIR675	-0.7	-13.92	-0.54	5.03e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1577917	0.561	rs3087978	chr6:86388223	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.91	0.35	1.87e-14	Response to antipsychotic treatment;
LGG	cis	rs870825	0.698	rs66462315	chr4:185623917	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs2652834	1.000	rs2729783	chr15:63403316	C/T	cg05507819	chr15:63340323	TPM1	0.6	8.25	0.36	1.65e-15	HDL cholesterol;
LGG	cis	rs668210	0.793	rs622779	chr11:65744247	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.71	-9.48	-0.4	1.34e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg05084668	chr3:125655381	ALG1L	-0.6	-8.17	-0.35	2.99e-15	Blood pressure (smoking interaction);
LGG	cis	rs2153535	0.526	rs1796689	chr6:8536433	A/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	2.01e-31	Motion sickness;
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.55	0.37	1.83e-16	Bipolar disorder;
LGG	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg00405596	chr8:11794950	NA	0.64	11.41	0.47	9.3e-27	Neuroticism;
LGG	cis	rs8040855	0.542	rs2342122	chr15:85728535	C/G	cg04831495	chr15:85060580	GOLGA6L5	0.34	6.78	0.3	3.74e-11	Bulimia nervosa;
LGG	cis	rs2195525	0.572	rs948415	chr11:119217455	C/T	cg01451205	chr11:119252210	USP2	0.41	6.86	0.3	2.27e-11	Urate levels;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.01	0.31	8.24e-12	Lung cancer;
LGG	cis	rs4730779	0.534	rs9886209	chr7:117005224	A/C	cg10524701	chr7:117356490	CTTNBP2	-0.38	-7.4	-0.33	6.33e-13	Waist circumference;
LGG	cis	rs6076065	0.894	rs2243448	chr20:23378345	G/A	cg11657817	chr20:23433608	CST11	0.41	8.35	0.36	8.07e-16	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6032067	0.929	rs17424696	chr20:43810734	G/A	cg10761708	chr20:43804764	PI3	0.76	11.7	0.48	6.83e-28	Blood protein levels;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16318349	chr1:154917307	PBXIP1	-0.26	-7.07	-0.31	5.82e-12	Prostate cancer;
LGG	cis	rs72945132	0.678	rs35733235	chr11:70235595	C/T	cg00319359	chr11:70116639	PPFIA1	0.63	6.91	0.31	1.57e-11	Coronary artery disease;
LGG	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg06606381	chr12:133084897	FBRSL1	-0.7	-8.43	-0.36	4.39e-16	Depression;
LGG	cis	rs908922	0.885	rs2181173	chr1:152474866	A/T	cg20991723	chr1:152506922	NA	0.61	10.49	0.44	3.17e-23	Hair morphology;
LGG	trans	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg21775007	chr8:11205619	TDH	0.43	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs6684428	0.611	rs72904468	chr1:56366209	T/C	cg11651538	chr1:56320950	NA	-0.43	-7.77	-0.34	5.26e-14	Airflow obstruction;
LGG	cis	rs9467773	1.000	rs2255070	chr6:26501777	C/G	cg11502198	chr6:26597334	ABT1	0.54	9.3	0.4	5.47e-19	Intelligence (multi-trait analysis);
LGG	cis	rs10864907	0.614	rs10199311	chr2:113697961	C/T	cg06156847	chr2:113672199	IL1F7	-0.37	-7.41	-0.33	6.2e-13	Pulmonary function;
LGG	cis	rs28830936	0.934	rs28401754	chr15:42116903	T/C	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.04	-0.52	2.58e-33	Diastolic blood pressure;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg19901468	chr14:105411992	AHNAK2	-0.89	-19.45	-0.67	5.24e-62	Rheumatoid arthritis;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg12070911	chr6:150209640	RAET1E	0.3	7.22	0.32	2.19e-12	Lung cancer;
LGG	cis	rs7635838	0.750	rs7625680	chr3:11378069	G/A	cg00170343	chr3:11313890	ATG7	0.49	8.58	0.37	1.45e-16	HDL cholesterol;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35306767	0.761	rs11253538	chr10:1011166	C/T	cg25019033	chr10:957182	NA	-0.58	-10.93	-0.45	6.73e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs73198271	0.562	rs964773	chr8:8651314	T/C	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg08250081	chr4:10125330	NA	0.35	6.8	0.3	3.22e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4820539	1.000	rs6003518	chr22:23471533	C/T	cg14186256	chr22:23484241	RTDR1	1.0	25.78	0.77	1.52e-91	Bone mineral density;
LGG	cis	rs7107174	0.892	rs2512534	chr11:77970039	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs7551222	0.614	rs7519417	chr1:204449952	T/C	cg20240347	chr1:204465584	NA	-0.47	-8.79	-0.38	3.01e-17	Schizophrenia;
LGG	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg18681998	chr4:17616180	MED28	0.85	18.22	0.65	2.66e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg11814155	chr7:99998594	ZCWPW1	0.59	9.2	0.39	1.2e-18	Platelet count;
LGG	cis	rs920590	0.684	rs3899017	chr8:19669198	A/T	cg01411142	chr8:19674711	INTS10	0.48	7.37	0.32	7.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11098499	0.909	rs28555550	chr4:120211040	C/G	cg24375607	chr4:120327624	NA	0.62	10.19	0.43	4.02e-22	Corneal astigmatism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02949340	chr10:102820489	KAZALD1	0.43	6.96	0.31	1.2e-11	Cognitive performance;
LGG	cis	rs1577917	0.917	rs4707226	chr6:86527828	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs73787773	0.867	rs73227501	chr5:111488908	C/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.69	-8.57	-0.37	1.55e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7769051	0.522	rs57176306	chr6:133142168	C/T	cg07930552	chr6:133119739	C6orf192	1.16	10.14	0.43	6.14e-22	Type 2 diabetes nephropathy;
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg19223190	chr17:80058835	NA	0.44	8.47	0.37	3.4e-16	Life satisfaction;
LGG	cis	rs4423214	0.840	rs1790341	chr11:71177578	T/C	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs7737355	0.773	rs10040578	chr5:130950232	C/T	cg06307176	chr5:131281290	NA	-0.48	-8.09	-0.35	5.37e-15	Life satisfaction;
LGG	trans	rs1493916	0.748	rs1389535	chr18:31310416	A/G	cg04226714	chr8:49833948	SNAI2	0.46	8.17	0.35	3e-15	Life satisfaction;
LGG	cis	rs17767392	0.881	rs7140501	chr14:72023175	C/G	cg13720639	chr14:72061746	SIPA1L1	0.39	8.58	0.37	1.47e-16	Mitral valve prolapse;
LGG	cis	rs2273669	0.667	rs2145765	chr6:109296362	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.29	-0.36	1.2e-15	Prostate cancer;
LGG	cis	rs523522	0.962	rs670568	chr12:121021206	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.14	0.46	1.06e-25	High light scatter reticulocyte count;
LGG	cis	rs9462027	0.628	rs58671447	chr6:34752351	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg04568710	chr12:38710424	ALG10B	-0.39	-8.05	-0.35	7.06e-15	Morning vs. evening chronotype;
LGG	cis	rs17826219	0.561	rs4085382	chr17:29071202	T/C	cg19761014	chr17:28927070	LRRC37B2	0.6	7.59	0.33	1.74e-13	Body mass index;
LGG	cis	rs4987668	0.708	rs11979330	chr7:142636599	G/A	cg19410471	chr7:142636507	C7orf34	0.56	8.75	0.38	4.13e-17	Cancer;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg14668632	chr7:2872130	GNA12	-0.38	-7.91	-0.35	1.88e-14	Height;
LGG	trans	rs9650657	0.623	rs11250065	chr8:10600381	A/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.37	-0.32	7.75e-13	Neuroticism;
LGG	cis	rs17125944	0.615	rs7146179	chr14:53298853	A/G	cg00686598	chr14:53173677	PSMC6	-0.87	-9.16	-0.39	1.66e-18	Alzheimer's disease (late onset);
LGG	cis	rs9302635	0.513	rs7198572	chr16:72183220	G/A	cg23815491	chr16:72088622	HP	0.51	9.17	0.39	1.56e-18	Blood protein levels;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg18050959	chr15:68126178	NA	-0.38	-6.96	-0.31	1.15e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22223655	chr18:67872902	RTTN	0.47	7.94	0.35	1.59e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs11098499	0.874	rs17839089	chr4:120111069	A/G	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg12292205	chr6:26970375	C6orf41	0.69	13.16	0.52	7.98e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.92	-0.42	3.76e-21	IgG glycosylation;
LGG	cis	rs7959452	0.590	rs10878974	chr12:69781528	C/G	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg05313129	chr8:58192883	C8orf71	-0.74	-9.81	-0.41	8.95e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs12579753	0.956	rs11115038	chr12:82214660	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.84e-14	Resting heart rate;
LGG	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg19507638	chr5:93509721	C5orf36	0.42	6.88	0.3	1.92e-11	Diabetic retinopathy;
LGG	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg07537917	chr2:241836409	C2orf54	-0.41	-8.23	-0.36	1.95e-15	Urinary metabolites;
LGG	trans	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	12.63	0.51	1.3e-31	Breast cancer;
LGG	cis	rs13421350	0.579	rs13410475	chr2:173309618	C/A	cg15021238	chr2:173305865	ITGA6	-0.83	-9.74	-0.41	1.58e-20	Diabetic kidney disease;
LGG	cis	rs796364	0.664	rs4673660	chr2:200915395	C/T	cg17644776	chr2:200775616	C2orf69	0.64	8.35	0.36	7.96e-16	Schizophrenia;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs6582630	0.512	rs11181007	chr12:38266700	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.08	-0.49	2.11e-29	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg23484912	chr5:273055	PDCD6	-0.41	-7.95	-0.35	1.39e-14	Mean corpuscular volume;
LGG	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg06212747	chr3:49208901	KLHDC8B	0.67	11.51	0.47	3.86e-27	Parkinson's disease;
LGG	cis	rs7010267	0.572	rs2450083	chr8:120063542	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.66	0.37	8.19e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs4604732	0.631	rs75320597	chr1:247626751	T/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs151997	0.777	rs3846499	chr5:50254200	G/A	cg06027927	chr5:50259733	NA	0.65	11.23	0.46	4.96e-26	Callous-unemotional behaviour;
LGG	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg08470875	chr2:26401718	FAM59B	-0.37	-6.77	-0.3	4.01e-11	Gut microbiome composition (summer);
LGG	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.9	-0.31	1.75e-11	Educational attainment;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	13.0	0.52	3.66e-33	Lymphocyte counts;
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	trans	rs3780486	0.846	rs10971420	chr9:33125000	T/C	cg20290983	chr6:43655470	MRPS18A	1.11	25.2	0.76	7.03e-89	IgG glycosylation;
LGG	cis	rs8064299	0.574	rs12452204	chr17:72774128	T/C	cg25054828	chr17:72772726	NAT9;TMEM104	0.95	21.34	0.7	7.44e-71	Monocyte count;
LGG	trans	rs9329221	0.710	rs11779205	chr8:10260100	C/T	cg02002194	chr4:3960332	NA	-0.38	-6.66	-0.3	7.71e-11	Neuroticism;
LGG	cis	rs986417	0.818	rs2882601	chr14:61096879	A/T	cg27398547	chr14:60952738	C14orf39	0.67	6.94	0.31	1.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1010254	0.510	rs17113105	chr5:151712287	A/G	cg12297329	chr5:152029980	NA	-0.47	-6.81	-0.3	3.11e-11	Optic nerve measurement (cup area);
LGG	cis	rs870825	0.616	rs6814278	chr4:185644417	G/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9916302	0.718	rs10445306	chr17:37591422	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.88	-0.59	1.21e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9818758	0.607	rs35060561	chr3:49255503	T/C	cg00383909	chr3:49044727	WDR6	1.0	12.55	0.5	2.55e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg14186256	chr22:23484241	RTDR1	1.0	25.83	0.77	9.48e-92	Bone mineral density;
LGG	trans	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg07817883	chr1:32538562	TMEM39B	0.67	8.53	0.37	2.18e-16	Monocyte percentage of white cells;
LGG	trans	rs6575793	0.553	rs7140556	chr14:101036458	G/T	cg22806444	chr17:72968764	C17orf28	0.51	8.75	0.38	3.85e-17	Menarche (age at onset);
LGG	cis	rs41278232	0.920	rs7265923	chr20:62677395	G/C	cg03065311	chr20:62601662	ZNF512B	0.61	8.97	0.38	7.56e-18	Tonsillectomy;
LGG	cis	rs17767392	0.881	rs35625243	chr14:71944937	A/G	cg02058870	chr14:72053146	SIPA1L1	0.39	8.03	0.35	8.27e-15	Mitral valve prolapse;
LGG	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg03060546	chr3:49711283	APEH	-0.7	-11.73	-0.48	5.11e-28	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4493873	0.731	rs34213675	chr8:92043378	C/T	cg16814680	chr8:91681699	NA	0.5	8.22	0.36	2.1e-15	Migraine - clinic-based;
LGG	cis	rs9611565	0.512	rs2899347	chr22:42158204	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Vitiligo;
LGG	cis	rs9487094	0.813	rs34131679	chr6:109697051	C/A	cg16315928	chr6:109776240	MICAL1	0.51	8.6	0.37	1.23e-16	Height;
LGG	cis	rs875971	0.862	rs7803416	chr7:65954199	A/G	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg10295955	chr4:187884368	NA	-1.13	-31.59	-0.83	1.33e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs3857067	1.000	rs1588382	chr4:95017589	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.5	-0.33	3.3e-13	QT interval;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg21970626	chr13:21893289	NA	-0.41	-9.2	-0.39	1.25e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4727027	0.866	rs10435245	chr7:148816081	C/G	cg23583168	chr7:148888333	NA	-0.87	-16.79	-0.62	9.8e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg02002194	chr4:3960332	NA	-0.47	-8.96	-0.38	7.96e-18	Neuroticism;
LGG	cis	rs7192750	0.586	rs2288029	chr16:71917058	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs745821	0.659	rs17742008	chr18:48124763	G/T	cg18923635	chr18:48083994	NA	0.56	9.6	0.41	4.92e-20	Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg07343612	chr16:622815	PIGQ	-0.77	-15.9	-0.59	9.53e-46	Height;
LGG	cis	rs6032067	0.636	rs6104093	chr20:43908297	T/C	cg10761708	chr20:43804764	PI3	0.59	9.07	0.39	3.3e-18	Blood protein levels;
LGG	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.22	0.32	2.21e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7959452	0.590	rs11177628	chr12:69765421	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.53	-0.33	2.77e-13	Blood protein levels;
LGG	cis	rs5769707	0.605	rs9616702	chr22:50025938	A/G	cg06623630	chr22:50017776	C22orf34	-0.5	-10.12	-0.43	6.72e-22	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06361161	chr6:170151289	TCTE3;C6orf70	0.43	6.92	0.31	1.52e-11	Cognitive performance;
LGG	cis	rs4363385	0.818	rs409986	chr1:153014741	A/C	cg13444842	chr1:152974279	SPRR3	0.43	8.9	0.38	1.28e-17	Inflammatory skin disease;
LGG	cis	rs7241530	0.610	rs12455186	chr18:75893586	A/C	cg14642773	chr18:75888474	NA	0.48	9.13	0.39	2.11e-18	Educational attainment (years of education);
LGG	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.52	-9.06	-0.39	3.59e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.95	-12.35	-0.5	1.69e-30	Lung cancer in ever smokers;
LGG	cis	rs2224391	0.656	rs2875980	chr6:5289447	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.5	7.1	0.31	4.59e-12	Height;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.49	-0.37	2.74e-16	Personality dimensions;
LGG	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.47	-0.37	3.38e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg17376030	chr22:41985996	PMM1	0.41	6.74	0.3	4.86e-11	Vitiligo;
LGG	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg00990874	chr7:1149470	C7orf50	-0.71	-11.55	-0.47	2.77e-27	Bronchopulmonary dysplasia;
LGG	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg22916017	chr11:64110731	CCDC88B	0.47	9.33	0.4	4.4e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.94	-0.52	6.67e-33	Chronic sinus infection;
LGG	cis	rs1555322	0.530	rs6060341	chr20:33863633	C/T	cg17927777	chr20:33865990	NA	-0.75	-10.97	-0.45	4.62e-25	Attention deficit hyperactivity disorder;
LGG	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.5	0.5	4.19e-31	Colorectal cancer;
LGG	cis	rs870825	0.616	rs4264873	chr4:185624336	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs10883723	0.810	rs3818470	chr10:104263675	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3008870	0.755	rs6657065	chr1:67384639	T/G	cg08660285	chr1:67390436	MIER1;WDR78	0.74	15.24	0.58	8.44e-43	Lymphocyte percentage of white cells;
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg03709012	chr19:19516395	GATAD2A	-0.81	-14.93	-0.57	1.93e-41	Tonsillectomy;
LGG	cis	rs7444	0.825	rs5994638	chr22:21953276	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.99	-0.35	1.06e-14	Systemic lupus erythematosus;
LGG	cis	rs4731207	0.565	rs1994022	chr7:124580877	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1881797	1.000	rs12063141	chr1:247688343	G/A	cg18198730	chr1:247681584	NA	0.75	12.7	0.51	6.36e-32	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs5758511	0.514	rs3985938	chr22:42511727	G/T	cg15128208	chr22:42549153	NA	0.79	12.63	0.51	1.2e-31	Birth weight;
LGG	cis	rs2228479	0.717	rs17226274	chr16:89850170	C/T	cg04287289	chr16:89883240	FANCA	0.84	8.89	0.38	1.42e-17	Skin colour saturation;
LGG	cis	rs1534166	0.647	rs7355929	chr3:133514190	C/T	cg01448562	chr3:133502909	NA	0.41	6.98	0.31	1.03e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs62103177	0.810	rs62096745	chr18:77619135	A/G	cg03511173	chr18:77590860	NA	0.62	7.82	0.34	3.58e-14	Opioid sensitivity;
LGG	cis	rs7849585	0.928	rs7038554	chr9:139134981	A/G	cg14094347	chr9:139131620	QSOX2	-0.43	-9.16	-0.39	1.74e-18	Height;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs7929679	0.521	rs7122506	chr11:34786853	A/G	cg06937548	chr11:34938143	PDHX;APIP	0.42	7.15	0.32	3.41e-12	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs10895140	0.718	rs2105612	chr11:101504095	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.88	-0.3	1.98e-11	Menarche (age at onset);
LGG	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg14088196	chr11:70211408	PPFIA1	0.94	13.16	0.52	7.85e-34	Coronary artery disease;
LGG	cis	rs6815814	0.950	rs4540055	chr4:38803255	A/T	cg06935464	chr4:38784597	TLR10	0.5	7.84	0.34	3.04e-14	Breast cancer;
LGG	cis	rs7666738	0.830	rs7698771	chr4:98986479	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11997175	0.524	rs10954932	chr8:33650176	A/C	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.09e-12	Body mass index;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg05313129	chr8:58192883	C8orf71	-0.59	-7.39	-0.32	7.02e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs847649	1.000	rs28856331	chr7:102543763	T/G	cg18108683	chr7:102477205	FBXL13	-0.65	-14.37	-0.56	5.36e-39	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.89	0.54	6.77e-37	Prudent dietary pattern;
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg24397884	chr7:158709396	WDR60	0.92	20.17	0.68	2.23e-65	Height;
LGG	cis	rs344364	0.511	rs62040569	chr16:1948137	C/T	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs701145	0.585	rs1713839	chr3:153829105	A/G	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs2652834	0.851	rs1007075	chr15:63413501	A/G	cg05507819	chr15:63340323	TPM1	0.5	7.03	0.31	7.55e-12	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09537107	chr19:48897008	GRIN2D	0.43	6.84	0.3	2.58e-11	Gut microbiome composition (summer);
LGG	cis	rs854765	0.583	rs9904163	chr17:17830553	C/T	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs116095464	0.558	rs62346506	chr5:201594	T/C	cg22857025	chr5:266934	NA	-1.56	-25.51	-0.76	2.62e-90	Breast cancer;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.65	-0.3	8.23e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17152658	chr8:132916406	EFR3A	-0.4	-7.14	-0.31	3.63e-12	Menarche (age at onset);
LGG	cis	rs2832191	0.765	rs2832162	chr21:30461808	G/A	cg08807101	chr21:30365312	RNF160	0.9	18.55	0.65	7.62e-58	Dental caries;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18713687	chr3:195489789	MUC4	0.61	8.39	0.36	6.16e-16	Lung disease severity in cystic fibrosis;
LGG	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs11651000	0.817	rs11657479	chr17:45822901	T/C	cg06532163	chr17:45867833	NA	0.5	7.55	0.33	2.37e-13	IgG glycosylation;
LGG	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg15394860	chr11:2017084	H19	0.58	11.95	0.49	7.3e-29	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs561341	0.941	rs736678	chr17:30347423	G/T	cg12193833	chr17:30244370	NA	-0.29	-6.95	-0.31	1.25e-11	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.951	rs55742421	chr10:961037	A/C	cg26597838	chr10:835615	NA	0.78	10.99	0.45	3.9e-25	Eosinophil percentage of granulocytes;
LGG	trans	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.89	-0.3	1.88e-11	Common traits (Other);
LGG	cis	rs7937682	0.711	rs4938792	chr11:111420936	T/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.29	-0.32	1.37e-12	Primary sclerosing cholangitis;
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	cis	rs11764590	0.651	rs12673687	chr7:2081873	C/T	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	trans	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg06521331	chr12:34319734	NA	0.45	7.73	0.34	6.95e-14	Heart rate;
LGG	cis	rs3862030	0.503	rs10786673	chr10:104280537	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs4409675	0.956	rs4072743	chr1:28270934	T/C	cg00605270	chr1:28261552	SMPDL3B	-0.34	-7.31	-0.32	1.21e-12	Corneal astigmatism;
LGG	cis	rs4909189	1.000	rs4909189	chr7:158136986	A/T	cg06219351	chr7:158114137	PTPRN2	0.8	14.28	0.55	1.37e-38	Response to amphetamines;
LGG	cis	rs35146811	0.735	rs1727140	chr7:99815399	T/A	cg13334819	chr7:99746414	C7orf59	0.47	7.4	0.33	6.65e-13	Coronary artery disease;
LGG	cis	rs4824093	0.610	rs2208023	chr22:50249983	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.82	-7.04	-0.31	6.76e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs2730245	0.527	rs2036582	chr7:158701708	A/T	cg18245976	chr7:158708271	WDR60	-0.54	-7.16	-0.32	3.23e-12	Height;
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.01	16.5	0.61	2.01e-48	Alzheimer's disease;
LGG	cis	rs11190604	1.000	rs6584383	chr10:102303065	C/G	cg07080220	chr10:102295463	HIF1AN	0.68	11.14	0.46	1.1e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8112449	0.930	rs11085732	chr19:10533112	C/G	cg21868191	chr19:10515988	NA	-0.47	-7.9	-0.34	1.98e-14	Multiple sclerosis;Gastritis;
LGG	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg17211192	chr8:82754475	SNX16	0.77	11.92	0.48	9.29e-29	Diastolic blood pressure;
LGG	cis	rs6840360	0.571	rs17360385	chr4:152587970	C/A	cg22705602	chr4:152727874	NA	-0.32	-7.32	-0.32	1.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.571	rs7674244	chr4:152488302	T/C	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.680	rs73071354	chr3:41829186	C/A	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8177253	0.931	rs8177256	chr3:133480276	G/T	cg01448562	chr3:133502909	NA	-0.74	-13.76	-0.54	2.43e-36	Iron status biomarkers;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg09699651	chr6:150184138	LRP11	0.51	8.8	0.38	2.68e-17	Lung cancer;
LGG	cis	rs6831352	0.918	rs29001211	chr4:100051941	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.71	-0.38	5.35e-17	Alcohol dependence;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg21774281	chr1:72750124	NA	-0.34	-6.91	-0.31	1.61e-11	Pancreatic cancer;
LGG	cis	rs16866061	0.517	rs7580488	chr2:225473263	C/T	cg12698349	chr2:225449008	CUL3	0.52	8.91	0.38	1.18e-17	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.93e-31	Lymphocyte counts;
LGG	cis	rs3816183	0.626	rs6720277	chr2:42836516	A/G	cg14631114	chr2:43023945	NA	0.34	6.65	0.3	8.13e-11	Hypospadias;
LGG	cis	rs7223966	1.000	rs6504170	chr17:61709168	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.43	0.33	5.16e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11748327	0.543	rs67060329	chr5:4087292	C/T	cg01025095	chr5:4101132	NA	-0.63	-10.16	-0.43	4.87e-22	Myocardial infarction;
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg24623649	chr8:11872141	NA	-0.32	-7.6	-0.33	1.67e-13	Retinal vascular caliber;
LGG	cis	rs8114671	0.562	rs2889861	chr20:33405664	C/T	cg24642439	chr20:33292090	TP53INP2	0.44	7.05	0.31	6.68e-12	Height;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg16405210	chr4:1374714	KIAA1530	0.52	8.81	0.38	2.55e-17	Obesity-related traits;
LGG	cis	rs68170813	0.523	rs79619227	chr7:107025335	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.23	-0.43	2.86e-22	Coronary artery disease;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg01458961	chr4:102269425	PPP3CA	-0.4	-6.66	-0.3	7.79e-11	Leprosy;
LGG	cis	rs1451375	0.572	rs745042	chr7:50544138	A/G	cg14593290	chr7:50529359	DDC	-0.67	-12.11	-0.49	1.6800000000000001e-29	Malaria;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05148093	chr5:140027274	NDUFA2;IK	0.5	7.36	0.32	8.41e-13	Gut microbiome composition (summer);
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.7	-0.59	7.31e-45	Platelet count;
LGG	cis	rs3736594	0.607	rs7584462	chr2:28176056	A/T	cg27432699	chr2:27873401	GPN1	-0.44	-6.65	-0.3	8.18e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7617773	0.780	rs3731489	chr3:48228906	C/A	cg11946769	chr3:48343235	NME6	0.68	11.09	0.46	1.72e-25	Coronary artery disease;
LGG	cis	rs7980799	0.621	rs7138393	chr12:33590787	G/C	cg06521331	chr12:34319734	NA	0.39	6.7	0.3	5.92e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1005277	0.579	rs2103938	chr10:38493998	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.49	-7.87	-0.34	2.53e-14	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09774198	chr13:33160713	PDS5B	0.43	7.03	0.31	7.59e-12	Cognitive performance;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.64	-13.12	-0.52	1.21e-33	Prudent dietary pattern;
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs55863869	0.748	rs2291311	chr2:179629461	C/T	cg02880032	chr2:179629472	TTN	-0.47	-6.74	-0.3	4.8e-11	QT interval;
LGG	cis	rs972578	1.000	rs733139	chr22:43390083	A/T	cg01576275	chr22:43409880	NA	-0.23	-6.77	-0.3	3.86e-11	Mean platelet volume;
LGG	cis	rs11722228	0.522	rs7662229	chr4:10133014	A/T	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.38	-0.43	7.64e-23	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1062746	0.520	rs67174101	chr16:87328817	G/A	cg02258303	chr16:87377426	FBXO31	-0.43	-7.83	-0.34	3.37e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs7727544	0.684	rs270602	chr5:131656700	T/C	cg07395648	chr5:131743802	NA	-0.55	-12.96	-0.52	5.19e-33	Blood metabolite levels;
LGG	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg07148914	chr20:33460835	GGT7	0.52	8.79	0.38	3.04e-17	Height;
LGG	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	trans	rs11039798	1.000	rs11039904	chr11:48682597	T/A	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.6	-0.41	5.15e-20	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9371207	chr6:150179223	A/G	cg09699651	chr6:150184138	LRP11	0.54	9.46	0.4	1.59e-19	Lung cancer;
LGG	cis	rs4237845	0.513	rs7134797	chr12:58263852	C/T	cg02175503	chr12:58329896	NA	0.54	9.03	0.39	4.78e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1855769	chr6:8473095	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs867371	0.762	rs1846910	chr15:82571780	G/A	cg00614314	chr15:82944287	LOC80154	0.64	10.63	0.44	9.09e-24	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs76070545	0.551	rs28550135	chr8:104217939	A/G	cg03923813	chr8:104230441	BAALC	-1.17	-12.79	-0.51	2.83e-32	Alzheimer disease and age of onset;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg07234876	chr8:600039	NA	1.2	11.86	0.48	1.56e-28	IgG glycosylation;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11168618	0.846	rs11168599	chr12:48879951	A/C	cg24011408	chr12:48396354	COL2A1	0.48	7.89	0.34	2.18e-14	Adiponectin levels;
LGG	cis	rs9902453	1.000	rs4075623	chr17:28386526	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs6558530	0.692	rs6981804	chr8:1700284	C/A	cg25947184	chr8:1697459	NA	0.48	8.21	0.36	2.18e-15	Systolic blood pressure;
LGG	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg12179176	chr11:130786555	SNX19	0.84	17.68	0.63	8.06e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2836974	0.899	rs2836957	chr21:40623134	T/C	cg17971929	chr21:40555470	PSMG1	0.86	17.01	0.62	9.3e-51	Cognitive function;
LGG	cis	rs3087591	0.960	rs2905883	chr17:29550141	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.41	0.56	3.69e-39	Hip circumference;
LGG	cis	rs9393813	0.967	rs1883403	chr6:27350329	G/A	cg18711553	chr6:27366782	ZNF391	-0.53	-9.78	-0.41	1.18e-20	Bipolar disorder;
LGG	cis	rs11864453	0.826	rs2074627	chr16:72136769	C/T	cg23815491	chr16:72088622	HP	0.53	11.75	0.48	4.56e-28	Fibrinogen levels;
LGG	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg10760299	chr15:45669010	GATM	0.41	7.86	0.34	2.71e-14	Homoarginine levels;
LGG	cis	rs2742417	1.000	rs2742389	chr3:45756683	G/C	cg04837898	chr3:45731254	SACM1L	-0.38	-7.56	-0.33	2.21e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9790314	0.747	rs1599378	chr3:160874511	A/C	cg03342759	chr3:160939853	NMD3	-0.57	-9.69	-0.41	2.51e-20	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg14926445	chr8:58193284	C8orf71	-0.92	-12.7	-0.51	6.77e-32	Developmental language disorder (linguistic errors);
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.64	-0.44	8.2e-24	Neuroticism;
LGG	cis	rs2282802	0.685	rs7717576	chr5:139623591	G/A	cg26211634	chr5:139558579	C5orf32	0.33	7.32	0.32	1.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.538	rs9535880	chr13:52706143	G/A	cg05335186	chr13:53173507	NA	0.43	8.56	0.37	1.73e-16	Lewy body disease;
LGG	cis	rs2066819	1.000	rs77120931	chr12:56646213	A/C	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs12618769	0.597	rs4850879	chr2:99113082	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg23625390	chr15:77176239	SCAPER	0.69	13.62	0.53	9.08e-36	Blood metabolite levels;
LGG	cis	rs3749237	0.595	rs10865955	chr3:49499829	G/A	cg06212747	chr3:49208901	KLHDC8B	0.44	7.08	0.31	5.54e-12	Resting heart rate;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg24101359	chr6:42928495	GNMT	0.56	16.64	0.61	4.49e-49	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg02002194	chr4:3960332	NA	0.47	8.75	0.38	4e-17	Retinal vascular caliber;
LGG	trans	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg10756647	chr7:56101905	PSPH	0.84	9.71	0.41	2.06e-20	Diabetic kidney disease;
LGG	trans	rs35110281	0.627	rs7282704	chr21:44966253	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.25	0.49	4.42e-30	Mean corpuscular volume;
LGG	cis	rs2274273	0.624	rs7150234	chr14:55802181	A/G	cg04306507	chr14:55594613	LGALS3	0.54	12.66	0.51	9.29e-32	Protein biomarker;
LGG	trans	rs7726839	0.561	rs4957049	chr5:579080	C/A	cg25482853	chr8:67687455	SGK3	0.84	11.06	0.46	2.19e-25	Obesity-related traits;
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15320075	chr8:145703422	NA	0.8	15.89	0.59	1.11e-45	Age at first birth;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg25866889	chr13:114914595	NA	-0.36	-7.12	-0.31	4.13e-12	Schizophrenia;
LGG	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg22517653	chr1:2918612	NA	-0.5	-7.01	-0.31	8.74e-12	Plateletcrit;
LGG	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	cis	rs6426558	0.537	rs6699828	chr1:227274591	T/C	cg10327440	chr1:227177885	CDC42BPA	0.61	10.24	0.43	2.52e-22	Neutrophil percentage of white cells;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg24250549	chr1:154909240	PMVK	0.66	11.76	0.48	3.97e-28	Prostate cancer;
LGG	cis	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07988820	chr12:82153109	PPFIA2	-0.79	-12.47	-0.5	5.68e-31	Resting heart rate;
LGG	cis	rs62045849	0.557	rs6500532	chr16:89174133	A/C	cg08015503	chr16:89190385	ACSF3	-0.65	-7.21	-0.32	2.37e-12	Red blood cell count;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg02781704	chr3:194033517	NA	0.4	6.81	0.3	3.08e-11	Corneal astigmatism;
LGG	cis	rs7085104	0.572	rs284856	chr10:104574329	A/T	cg04362960	chr10:104952993	NT5C2	-0.46	-8.3	-0.36	1.17e-15	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs876084	0.505	rs4407921	chr8:121156585	C/T	cg06265175	chr8:121136014	COL14A1	0.46	9.2	0.39	1.21e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14655855	chr9:13278626	NA	0.45	7.19	0.32	2.64e-12	Cognitive performance;
LGG	cis	rs3762637	1.000	rs7615930	chr3:122125750	G/T	cg24169773	chr3:122142474	KPNA1	-0.56	-9.44	-0.4	1.81e-19	LDL cholesterol levels;
LGG	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg26384229	chr12:38710491	ALG10B	0.61	11.9	0.48	1.17e-28	Morning vs. evening chronotype;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10878170	chr12:12764498	CREBL2	0.43	6.67	0.3	7.15e-11	Gut microbiome composition (summer);
LGG	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg09060608	chr5:178986726	RUFY1	0.44	7.02	0.31	7.76e-12	Lung cancer;
LGG	cis	rs2710642	0.925	rs72807578	chr2:63008044	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-7.04	-0.31	6.79e-12	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs4363385	0.782	rs4845336	chr1:153003853	C/T	cg13444842	chr1:152974279	SPRR3	-0.41	-8.41	-0.36	5.31e-16	Inflammatory skin disease;
LGG	cis	rs2721195	1.000	rs11542372	chr8:145677089	G/A	cg08302650	chr8:145750040	LRRC24;LRRC14	0.35	7.46	0.33	4.28e-13	Age at first birth;
LGG	cis	rs72945132	0.882	rs11235755	chr11:70136323	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.17	-0.49	9e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.632	rs4936800	chr11:111734097	T/A	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg05313129	chr8:58192883	C8orf71	-0.79	-12.38	-0.5	1.36e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg22398616	chr13:53314203	LECT1	-0.5	-10.68	-0.44	6.11e-24	Lewy body disease;
LGG	cis	rs8077889	1.000	rs2079005	chr17:41865627	T/G	cg26893861	chr17:41843967	DUSP3	0.96	16.44	0.61	3.51e-48	Triglycerides;
LGG	cis	rs12220238	0.841	rs10824212	chr10:76371068	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.64	8.01	0.35	9.13e-15	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg03929089	chr4:120376271	NA	-1.03	-24.12	-0.75	7.23e-84	Height;
LGG	cis	rs10504229	0.683	rs59528137	chr8:58138565	C/T	cg08677398	chr8:58056175	NA	0.58	8.85	0.38	1.86e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4315565	0.764	rs11900784	chr2:69272496	A/T	cg13358873	chr2:69271042	ANTXR1	-0.52	-8.46	-0.37	3.66e-16	Height;
LGG	cis	rs9557207	0.950	rs9557194	chr13:99952290	A/G	cg24509225	chr13:100037070	UBAC2	0.69	12.43	0.5	8.48e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg01420254	chr6:26195488	NA	0.88	11.79	0.48	3.22e-28	Gout;Renal underexcretion gout;
LGG	cis	rs9322193	0.566	rs4870118	chr6:150245013	G/A	cg16507663	chr6:150244633	RAET1G	-0.46	-7.3	-0.32	1.26e-12	Lung cancer;
LGG	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg10760299	chr15:45669010	GATM	0.41	8.07	0.35	6.04e-15	Homoarginine levels;
LGG	cis	rs1957429	0.614	rs78603758	chr14:65396648	C/G	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.89	-0.34	2.2e-14	Initial pursuit acceleration;
LGG	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.92	0.31	1.48e-11	Neuroticism;
LGG	cis	rs3824949	1.000	rs3824949	chr11:5701409	C/G	cg05265258	chr11:5705995	TRIM5	-0.37	-7.61	-0.33	1.58e-13	Mean platelet volume;
LGG	cis	rs17818399	0.817	rs17767994	chr2:46860079	G/T	cg26688816	chr2:46740690	ATP6V1E2	0.53	9.07	0.39	3.36e-18	Height;
LGG	cis	rs13720	0.556	rs151335	chr20:57579950	A/G	cg23907860	chr20:57583709	CTSZ	-0.49	-7.45	-0.33	4.51e-13	Platelet distribution width;
LGG	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg08344181	chr3:125677491	NA	0.79	7.98	0.35	1.14e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12431410	0.892	rs727690	chr14:60157360	A/G	cg07950296	chr14:60194823	RTN1	-0.37	-6.99	-0.31	9.73e-12	Schizophrenia;
LGG	cis	rs4481887	0.888	rs4525076	chr1:248456876	T/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.56	-0.41	6.84e-20	Common traits (Other);
LGG	trans	rs3942852	0.868	rs6485808	chr11:48109151	A/G	cg15704280	chr7:45808275	SEPT13	-0.64	-8.07	-0.35	6.2e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6909430	0.901	rs66779961	chr6:98563749	C/T	cg12860156	chr6:98744658	NA	-0.44	-7.46	-0.33	4.42e-13	Quantitative traits;
LGG	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.82	-0.3	2.9e-11	Mood instability;
LGG	cis	rs4889855	0.614	rs7208670	chr17:78494220	T/G	cg16591659	chr17:78472290	NA	-0.41	-9.31	-0.4	5.16e-19	Fractional excretion of uric acid;
LGG	trans	rs9951602	0.512	rs4799246	chr18:76653417	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.65	0.54	6.88e-36	Obesity-related traits;
LGG	cis	rs754466	0.580	rs2579177	chr10:79529245	C/T	cg17075019	chr10:79541650	NA	-0.96	-20.07	-0.68	6.69e-65	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4474465	0.850	rs10793323	chr11:78244170	C/T	cg02023728	chr11:77925099	USP35	-0.39	-7.05	-0.31	6.61e-12	Alzheimer's disease (survival time);
LGG	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg26076054	chr5:421317	AHRR	-0.45	-7.56	-0.33	2.11e-13	Cystic fibrosis severity;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.76	-0.38	3.79e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07236718	chr8:30242935	RBPMS	0.43	7.65	0.33	1.2e-13	Cognitive performance;
LGG	cis	rs6087990	0.899	rs4911107	chr20:31374991	G/A	cg13636640	chr20:31349939	DNMT3B	0.97	21.11	0.7	8.94e-70	Ulcerative colitis;
LGG	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg10792982	chr14:105748885	BRF1	0.54	10.88	0.45	1.05e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg15665833	chr6:26285013	NA	0.41	7.79	0.34	4.43e-14	Educational attainment;
LGG	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg08861369	chr16:85671714	KIAA0182	0.45	6.99	0.31	9.53e-12	Platelet distribution width;
LGG	cis	rs9916302	0.904	rs801419	chr17:37466327	A/G	cg07936489	chr17:37558343	FBXL20	0.83	15.39	0.58	1.84e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs17767392	0.958	rs722633	chr14:71898788	T/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	2.8e-18	Mitral valve prolapse;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.49	-0.37	2.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs193541	0.545	rs12518979	chr5:122181787	G/T	cg19412675	chr5:122181750	SNX24	-0.5	-8.15	-0.35	3.47e-15	Glucose homeostasis traits;
LGG	cis	rs240764	0.717	rs1039031	chr6:101161812	A/G	cg09795085	chr6:101329169	ASCC3	0.44	7.48	0.33	3.67e-13	Neuroticism;
LGG	cis	rs12477438	0.520	rs11689265	chr2:99799267	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.27	38.07	0.87	1.06e-144	Chronic sinus infection;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.1	0.31	4.86e-12	Longevity;
LGG	cis	rs1008375	0.932	rs6835077	chr4:17653285	A/T	cg02297831	chr4:17616191	MED28	0.46	8.33	0.36	9.1e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6754311	0.731	rs7569057	chr2:136583958	A/C	cg07169764	chr2:136633963	MCM6	0.78	13.29	0.53	2.35e-34	Mosquito bite size;
LGG	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	9.03	0.39	4.62e-18	Eosinophil percentage of white cells;
LGG	cis	rs2404602	0.684	rs12437981	chr15:76842401	A/G	cg23625390	chr15:77176239	SCAPER	-0.71	-13.81	-0.54	1.41e-36	Blood metabolite levels;
LGG	cis	rs372883	0.600	rs1153276	chr21:30661694	T/C	cg08807101	chr21:30365312	RNF160	-0.61	-10.18	-0.43	4.39e-22	Pancreatic cancer;
LGG	cis	rs1185460	1.000	rs1784305	chr11:118942048	G/A	cg23280166	chr11:118938394	VPS11	0.6	11.03	0.46	2.79e-25	Coronary artery disease;
LGG	cis	rs10892173	0.566	rs10892174	chr11:117672565	A/C	cg07621104	chr11:117668040	DSCAML1	0.65	9.19	0.39	1.31e-18	Myopia;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg23034840	chr1:205782522	SLC41A1	0.78	12.16	0.49	9.91e-30	Prostate-specific antigen levels;
LGG	cis	rs79349575	0.749	rs318093	chr17:46989354	A/G	cg22482690	chr17:47019901	SNF8	0.36	6.99	0.31	9.67e-12	Type 2 diabetes;
LGG	cis	rs282587	0.530	rs428853	chr13:113387222	T/C	cg04656015	chr13:113407548	ATP11A	0.42	6.69	0.3	6.5500000000000006e-11	Glycated hemoglobin levels;
LGG	cis	rs2708977	0.901	rs2579505	chr2:97167962	T/C	cg01950434	chr2:97203154	ARID5A	-0.61	-9.75	-0.41	1.51e-20	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2594989	0.778	rs6801721	chr3:11470267	T/C	cg01796438	chr3:11312864	ATG7	-0.56	-7.56	-0.33	2.23e-13	Circulating chemerin levels;
LGG	cis	rs10186029	0.680	rs10179425	chr2:213978441	T/C	cg08319019	chr2:214017104	IKZF2	0.46	8.04	0.35	7.32e-15	Systemic sclerosis;
LGG	cis	rs9467773	0.901	rs1407045	chr6:26476155	A/G	cg11502198	chr6:26597334	ABT1	0.56	9.55	0.41	7.39e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.65e-15	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.06e-17	Menopause (age at onset);
LGG	trans	rs4427176	0.507	rs7006785	chr8:9580970	T/C	cg16141378	chr3:129829833	LOC729375	0.35	6.79	0.3	3.45e-11	Mosquito bite size;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.26	-0.32	1.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.615	rs3914894	chr12:38480280	C/T	cg26384229	chr12:38710491	ALG10B	-0.67	-13.31	-0.53	1.83e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9443645	0.901	rs9352686	chr6:79758223	T/G	cg18132916	chr6:79620363	NA	-0.31	-8.33	-0.36	9.01e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17433780	0.808	rs12122780	chr1:89508916	T/C	cg09516651	chr1:89888402	LOC400759	0.77	18.59	0.65	5.03e-58	Carotid intima media thickness;
LGG	cis	rs7267979	1.000	rs6050631	chr20:25431749	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.14	0.43	6.11e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.93	-0.31	1.4e-11	Height;
LGG	cis	rs1008375	0.966	rs10939755	chr4:17693755	T/C	cg16339924	chr4:17578868	LAP3	0.5	8.37	0.36	7.12e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8078723	0.690	rs56326707	chr17:38130139	C/T	cg17467752	chr17:38218738	THRA	0.59	10.8	0.45	2.12e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs13191362	1.000	rs73035012	chr6:162997279	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs15676	0.947	rs1572912	chr9:131565554	T/C	cg04621255	chr9:131581398	ENDOG	0.39	6.82	0.3	2.93e-11	Blood metabolite levels;
LGG	cis	rs6542838	0.611	rs6742047	chr2:99531460	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.82	-0.3	2.8e-11	Fear of minor pain;
LGG	cis	rs7289126	1.000	rs5750571	chr22:38640312	A/G	cg25457927	chr22:38595422	NA	-0.32	-7.83	-0.34	3.44e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg02018176	chr4:1364513	KIAA1530	0.51	11.99	0.49	4.91e-29	Obesity-related traits;
LGG	cis	rs1008375	0.932	rs11941874	chr4:17666416	C/T	cg18681998	chr4:17616180	MED28	-0.84	-17.6	-0.63	1.78e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg08742575	chr21:47604166	C21orf56	0.49	8.36	0.36	7.56e-16	Testicular germ cell tumor;
LGG	cis	rs897984	0.568	rs56083427	chr16:30881298	C/T	cg00531865	chr16:30841666	NA	-0.53	-10.01	-0.42	1.78e-21	Dementia with Lewy bodies;
LGG	cis	rs10883723	0.810	rs10786669	chr10:104256094	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs12579753	0.912	rs4417392	chr12:82158722	C/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.47	-0.5	5.65e-31	Resting heart rate;
LGG	cis	rs6502050	0.835	rs6502065	chr17:80095642	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.34e-16	Life satisfaction;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.79	0.38	2.85e-17	Alzheimer's disease;
LGG	cis	rs9768139	0.708	rs11771764	chr7:158119871	A/G	cg06219351	chr7:158114137	PTPRN2	-0.75	-14.64	-0.56	3.89e-40	Calcium levels;
LGG	cis	rs9463078	0.547	rs764397	chr6:44710771	C/A	cg25276700	chr6:44698697	NA	0.4	8.01	0.35	9.21e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg03517284	chr6:25882590	NA	-0.69	-13.33	-0.53	1.54e-34	Blood metabolite levels;
LGG	cis	rs367615	0.704	rs72804385	chr5:108848143	T/C	cg17395555	chr5:108820864	NA	0.85	15.33	0.58	3.31e-43	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7219021	0.961	rs9901447	chr17:46872346	C/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.69	-0.3	6.44e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs13191362	0.935	rs116735807	chr6:163010615	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.91	10.47	0.44	3.7e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-7.31	-0.32	1.15e-12	Schizophrenia;
LGG	trans	rs35110281	0.807	rs9984002	chr21:45061501	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.2	0.49	6.83e-30	Mean corpuscular volume;
LGG	cis	rs4642101	0.618	rs7612317	chr3:12820558	C/T	cg24848339	chr3:12840334	CAND2	0.45	10.85	0.45	1.39e-24	QRS complex (12-leadsum);
LGG	cis	rs7264396	0.673	rs2425163	chr20:34432670	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.45	0.33	4.74e-13	Total cholesterol levels;
LGG	trans	rs35110281	0.782	rs6518309	chr21:45047992	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	10.32	0.43	1.35e-22	Mean corpuscular volume;
LGG	cis	rs73086581	0.568	rs6084541	chr20:3962731	G/A	cg02187196	chr20:3869020	PANK2	-0.45	-7.0	-0.31	8.78e-12	Response to antidepressants in depression;
LGG	cis	rs7580658	0.963	rs12991768	chr2:128146245	A/G	cg10021288	chr2:128175891	PROC	-0.66	-13.45	-0.53	4.65e-35	Protein C levels;
LGG	cis	rs61990749	0.544	rs7151211	chr14:78151901	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.15	-0.32	3.38e-12	Fibroblast growth factor basic levels;
LGG	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.65e-12	Blood metabolite levels;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg18446336	chr7:2847575	GNA12	-0.31	-7.19	-0.32	2.58e-12	Height;
LGG	cis	rs561341	1.000	rs4795668	chr17:30244554	G/A	cg12193833	chr17:30244370	NA	-0.28	-7.0	-0.31	8.76e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6028335	0.610	rs12624452	chr20:37554781	G/T	cg16355469	chr20:37678765	NA	0.53	6.97	0.31	1.13e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs73416724	1.000	rs70953670	chr6:43264895	C/A	cg26312998	chr6:43337775	ZNF318	0.59	7.99	0.35	1.07e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.33	-0.6	1.13e-47	Calcium levels;
LGG	cis	rs539514	0.690	rs585233	chr13:76317973	A/G	cg04757411	chr13:76259545	LMO7	0.27	6.93	0.31	1.42e-11	Type 1 diabetes;
LGG	cis	rs713587	0.520	rs522806	chr2:25316584	C/A	cg04586622	chr2:25135609	ADCY3	-0.31	-7.87	-0.34	2.61e-14	Body mass index in non-asthmatics;
LGG	cis	rs7945718	0.621	rs6485977	chr11:12678387	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.17	0.32	2.94e-12	Educational attainment (years of education);
LGG	cis	rs12643440	0.538	rs62296722	chr4:17140970	T/G	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs10088262	0.540	rs6988602	chr8:124788502	C/T	cg02993010	chr8:124780839	FAM91A1	0.77	11.25	0.46	4.04e-26	Pancreatic cancer;
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.69	-0.41	2.47e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg26384229	chr12:38710491	ALG10B	0.86	18.54	0.65	8.22e-58	Morning vs. evening chronotype;
LGG	cis	rs1881797	0.872	rs2141544	chr1:247690800	A/G	cg21399703	chr1:247681439	NA	0.63	11.7	0.48	6.86e-28	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4423214	1.000	rs1981412	chr11:71138710	T/C	cg05163923	chr11:71159392	DHCR7	0.71	13.69	0.54	4.46e-36	Vitamin D levels;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg00364696	chr7:1142433	C7orf50	-0.39	-7.58	-0.33	1.92e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2070488	0.965	rs2366119	chr3:38484453	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.09	0.64	9.97e-56	Electrocardiographic conduction measures;
LGG	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg17133734	chr15:86042851	AKAP13	0.3	7.15	0.32	3.4e-12	Interstitial lung disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg03810365	chr4:83293920	HNRNPD	-0.42	-7.0	-0.31	9.24e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs2188554	0.675	rs916728	chr7:116991701	A/G	cg10524701	chr7:117356490	CTTNBP2	0.38	7.45	0.33	4.68e-13	Esophageal adenocarcinoma;
LGG	trans	rs12579753	1.000	rs11115015	chr12:82174543	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.57	-0.33	2.08e-13	Resting heart rate;
LGG	cis	rs9914988	0.943	rs9915673	chr17:27132893	G/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg12708336	chr17:41446283	NA	-0.33	-7.89	-0.34	2.19e-14	Menopause (age at onset);
LGG	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.94e-13	Neuroticism;
LGG	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg24692254	chr21:30365293	RNF160	-0.56	-8.1	-0.35	4.9e-15	Cognitive test performance;
LGG	cis	rs62238980	0.614	rs77621610	chr22:32503278	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs2730245	0.527	rs712199	chr7:158662250	A/G	cg24397884	chr7:158709396	WDR60	1.03	15.84	0.59	1.86e-45	Height;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg22337132	chr13:27826092	RPL21;RPL21P28	-0.4	-6.72	-0.3	5.34e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3857067	0.967	rs1841925	chr4:95035175	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.82	-0.34	3.5e-14	QT interval;
LGG	cis	rs834603	0.575	rs834592	chr7:47474328	T/C	cg23694490	chr7:47445681	TNS3	-0.41	-11.79	-0.48	3.09e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg18357526	chr6:26021779	HIST1H4A	0.47	7.89	0.34	2.16e-14	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04730665	chr2:236403704	AGAP1	0.46	7.42	0.33	5.76e-13	Cognitive performance;
LGG	cis	rs796364	0.760	rs2881594	chr2:201026183	T/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.22	-0.36	2.1e-15	Schizophrenia;
LGG	cis	rs7737355	0.947	rs3776005	chr5:130879003	T/C	cg06307176	chr5:131281290	NA	0.56	9.36	0.4	3.4e-19	Life satisfaction;
LGG	trans	rs8002861	0.765	rs12868462	chr13:44453480	C/T	cg17145862	chr1:211918768	LPGAT1	-0.93	-21.88	-0.71	2.08e-73	Leprosy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11039808	chr5:77591002	AP3B1	-0.41	-6.75	-0.3	4.35e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1298637	1.000	rs1108989	chr1:53929463	A/T	cg10892335	chr1:53966318	NA	-0.48	-8.87	-0.38	1.58e-17	Nicotine use;
LGG	cis	rs11971779	0.715	rs7787398	chr7:139061846	A/G	cg07862535	chr7:139043722	LUC7L2	0.5	8.15	0.35	3.37e-15	Diisocyanate-induced asthma;
LGG	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg15704280	chr7:45808275	SEPT13	-0.76	-8.77	-0.38	3.32e-17	Axial length;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18440474	chr2:175869653	CHN1	0.41	6.72	0.3	5.44e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.5	0.44	2.83e-23	Prudent dietary pattern;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.34	0.4	4.06e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs55665837	0.961	rs12795972	chr11:14443775	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.86e-17	Vitamin D levels;
LGG	cis	rs35306767	0.903	rs17159970	chr10:935601	T/C	cg20503657	chr10:835505	NA	0.76	10.32	0.43	1.29e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg27189623	chr16:705930	WDR90	0.4	7.75	0.34	5.72e-14	Height;
LGG	cis	rs6696846	0.791	rs11240352	chr1:205051711	C/G	cg00857998	chr1:205179979	DSTYK	-0.59	-9.64	-0.41	3.6e-20	Red blood cell count;
LGG	cis	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg09021430	chr5:549028	NA	-0.7	-9.02	-0.39	5.06e-18	Ulcerative colitis;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg04267008	chr7:1944627	MAD1L1	-0.7	-12.26	-0.49	4.11e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs75804782	0.641	rs3769125	chr2:239349562	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-6.66	-0.3	7.58e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg26384229	chr12:38710491	ALG10B	0.76	15.72	0.59	6.25e-45	Morning vs. evening chronotype;
LGG	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg26116260	chr4:7069785	GRPEL1	-0.84	-8.65	-0.37	8.38e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17539620	0.506	rs62432749	chr6:154839219	G/A	cg17771515	chr6:154831774	CNKSR3	0.62	7.63	0.33	1.4e-13	Lipoprotein (a) levels;
LGG	cis	rs1318772	0.932	rs34554590	chr5:112892277	A/G	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.8	0.3	3.31e-11	Longevity;
LGG	trans	rs12517041	1.000	rs1428617	chr5:23260918	A/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.8	-0.38	2.8e-17	Calcium levels;
LGG	cis	rs2075371	0.863	rs1646638	chr7:134008706	T/C	cg20476274	chr7:133979776	SLC35B4	0.7	13.33	0.53	1.57e-34	Mean platelet volume;
LGG	cis	rs8072100	0.967	rs2317826	chr17:45730899	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-12.79	-0.51	2.65e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs61931739	0.517	rs11513277	chr12:34074799	G/T	cg13010199	chr12:38710504	ALG10B	0.57	10.75	0.45	3.25e-24	Morning vs. evening chronotype;
LGG	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.13	19.67	0.67	4.57e-63	Smoking behavior;
LGG	cis	rs12898370	0.561	rs34129891	chr15:77481210	T/C	cg17802220	chr15:77601643	NA	-0.46	-7.0	-0.31	8.88e-12	Risky sexual behaviors (alcohol dependence interaction);
LGG	cis	rs903263	0.601	rs12405120	chr1:84556523	C/T	cg10977910	chr1:84465055	TTLL7	-0.42	-7.35	-0.32	8.79e-13	Breast cancer (male);
LGG	cis	rs9916302	0.752	rs676882	chr17:37433424	A/T	cg07936489	chr17:37558343	FBXL20	0.97	13.89	0.54	6.48e-37	Glomerular filtration rate (creatinine);
LGG	cis	rs4242434	0.672	rs10099266	chr8:22484268	C/G	cg03733263	chr8:22462867	KIAA1967	0.99	23.87	0.74	1.09e-82	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6088580	0.668	rs1205337	chr20:32926041	T/A	cg08999081	chr20:33150536	PIGU	-0.4	-10.03	-0.42	1.5e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs4319547	0.695	rs10846746	chr12:122868696	C/T	cg05707623	chr12:122985044	ZCCHC8	0.66	9.76	0.41	1.38e-20	Body mass index;
LGG	cis	rs2201728	0.739	rs71612675	chr4:100141968	G/A	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg02733842	chr7:1102375	C7orf50	0.43	6.84	0.3	2.57e-11	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs77633900	0.614	rs2468113	chr15:76851421	G/C	cg21673338	chr15:77095150	SCAPER	-0.64	-9.26	-0.4	7.54e-19	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg12877253	chr3:19992400	RAB5A	-0.33	-7.06	-0.31	6.23e-12	Post-traumatic stress disorder;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.48	0.33	3.77e-13	Schizophrenia;
LGG	cis	rs4631830	0.832	rs2337711	chr10:51504604	C/T	cg10326726	chr10:51549505	MSMB	0.72	14.7	0.56	2e-40	Prostate-specific antigen levels;
LGG	cis	rs9462027	1.000	rs6457792	chr6:34764443	C/T	cg07306190	chr6:34760872	UHRF1BP1	0.45	8.38	0.36	6.22e-16	Systemic lupus erythematosus;
LGG	cis	rs10929925	0.966	rs78203080	chr2:6160160	T/C	cg00493617	chr2:6141445	NA	0.32	7.13	0.31	3.91e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs239198	0.521	rs9377241	chr6:101334265	C/T	cg09795085	chr6:101329169	ASCC3	0.43	7.0	0.31	9.09e-12	Menarche (age at onset);
LGG	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1.02e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg20887711	chr4:1340912	KIAA1530	0.61	11.69	0.48	7.68e-28	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1658429	chr10:60330422	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg16141378	chr3:129829833	LOC729375	0.35	7.72	0.34	7.23e-14	Retinal vascular caliber;
LGG	cis	rs2549003	1.000	rs2070728	chr5:131819977	C/T	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.84e-12	Bipolar disorder;
LGG	cis	rs8017423	0.904	rs11848894	chr14:90723660	C/A	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.32	0.36	1e-15	Neuroticism;
LGG	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.74	0.34	6.34e-14	Homoarginine levels;
LGG	cis	rs921968	0.643	rs1055816	chr2:219501328	G/A	cg01130898	chr2:219473002	PLCD4	-0.41	-7.05	-0.31	6.55e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.61	-0.37	1.12e-16	Platelet distribution width;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.93	0.54	4.24e-37	Lung cancer;
LGG	cis	rs9912468	0.525	rs4790914	chr17:64209278	C/G	cg19474267	chr17:64306194	PRKCA	-0.71	-13.99	-0.55	2.47e-37	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs12493885	0.505	rs357489	chr3:153884517	A/T	cg12800244	chr3:153838788	SGEF	0.76	11.89	0.48	1.2e-28	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg19508488	chr2:152266495	RIF1	-0.62	-11.1	-0.46	1.49e-25	Lung cancer;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg11584989	chr19:19387371	SF4	0.41	7.31	0.32	1.16e-12	Tonsillectomy;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14159672	chr1:205819179	PM20D1	0.77	16.48	0.61	2.4e-48	Menarche (age at onset);
LGG	cis	rs6834538	0.965	rs1580476	chr4:113493365	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.55	8.87	0.38	1.54e-17	Free thyroxine concentration;
LGG	cis	rs7662987	0.517	rs1154410	chr4:100006645	A/G	cg12011299	chr4:100065546	ADH4	0.4	7.72	0.34	7.07e-14	Smoking initiation;
LGG	trans	rs7819412	0.775	rs6601564	chr8:10982051	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.01	-0.31	8.52e-12	Triglycerides;
LGG	cis	rs17270561	0.609	rs4711100	chr6:25741954	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs67478160	0.619	rs55824307	chr14:104271207	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21701531	chr2:145275199	ZEB2	0.52	7.72	0.34	7.41e-14	Gut microbiome composition (summer);
LGG	cis	rs6500395	1.000	rs1486411	chr16:48587083	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.89	0.38	1.32e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4665809	0.556	rs6730311	chr2:26419474	C/T	cg22920501	chr2:26401640	FAM59B	-0.45	-9.35	-0.4	3.87e-19	Gut microbiome composition (summer);
LGG	cis	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2273669	0.667	rs12374597	chr6:109346184	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs41005	1.000	rs41007	chr2:8109043	A/G	cg03155496	chr2:8117019	LOC339788	-0.88	-19.35	-0.67	1.41e-61	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs2798269	0.604	rs7325693	chr13:22163211	G/C	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.37	-0.32	8.1e-13	PR segment;
LGG	cis	rs10463554	0.892	rs3776874	chr5:102282317	C/T	cg23492399	chr5:102201601	PAM	-0.56	-8.56	-0.37	1.68e-16	Parkinson's disease;
LGG	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg15212455	chr7:39170539	POU6F2	0.51	11.97	0.49	5.8e-29	IgG glycosylation;
LGG	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg06766960	chr11:133703094	NA	-0.59	-11.65	-0.48	1.1e-27	Childhood ear infection;
LGG	cis	rs1552244	1.000	rs6764068	chr3:10153842	A/G	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.66e-18	Alzheimer's disease;
LGG	cis	rs6032067	0.777	rs17332620	chr20:43777506	C/T	cg10761708	chr20:43804764	PI3	0.75	11.87	0.48	1.48e-28	Blood protein levels;
LGG	cis	rs10463554	1.000	rs12659870	chr5:102336571	T/C	cg23492399	chr5:102201601	PAM	-0.52	-8.1	-0.35	5.07e-15	Parkinson's disease;
LGG	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg08344181	chr3:125677491	NA	-0.85	-8.48	-0.37	3.03e-16	Urinary tract infection frequency;
LGG	cis	rs11098499	0.532	rs12512646	chr4:120585733	G/A	cg24375607	chr4:120327624	NA	0.62	10.39	0.43	7.1e-23	Corneal astigmatism;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg13736514	chr6:26305472	NA	-0.44	-9.17	-0.39	1.51e-18	Educational attainment;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.51	-0.61	1.79e-48	Intelligence (multi-trait analysis);
LGG	cis	rs13065560	0.594	rs4336049	chr3:38922068	G/A	cg01426195	chr3:39028469	NA	-0.49	-10.28	-0.43	1.83e-22	Interleukin-18 levels;
LGG	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.7	-0.3	6.09e-11	Menopause (age at onset);
LGG	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.83	-0.34	3.36e-14	Triglycerides;
LGG	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.97	0.31	1.08e-11	Total cholesterol levels;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23043119	chr5:110848575	STARD4	0.42	6.73	0.3	4.9e-11	Cognitive performance;
LGG	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg05044414	chr3:183734942	ABCC5	0.56	11.42	0.47	8.54e-27	Anterior chamber depth;
LGG	cis	rs2267708	0.509	rs6959972	chr7:124617108	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.93	-0.31	1.41e-11	Chronic lymphocytic leukemia;
LGG	cis	rs1008375	1.000	rs28501187	chr4:17643620	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4237845	0.586	rs4760174	chr12:58320436	G/A	cg02175503	chr12:58329896	NA	0.85	17.53	0.63	3.98e-53	Intelligence (multi-trait analysis);
LGG	cis	rs9517313	0.707	rs9517298	chr13:99095003	C/T	cg07423050	chr13:99094983	FARP1	-0.69	-13.69	-0.54	4.67e-36	Neuroticism;
LGG	cis	rs10927875	0.929	rs4661674	chr1:16296039	A/G	cg21385522	chr1:16154831	NA	-0.82	-15.48	-0.58	7.57e-44	Dilated cardiomyopathy;
LGG	trans	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.11	-0.35	4.56e-15	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09984370	chr19:37178943	ZNF567	0.41	6.83	0.3	2.71e-11	Cognitive performance;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs7512552	0.839	rs11577843	chr1:150398258	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2921073	0.510	rs2976944	chr8:8270914	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.15	0.35	3.45e-15	Parkinson's disease;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.41	-0.4	2.24e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1816752	0.905	rs9511264	chr13:25012217	C/T	cg02811702	chr13:24901961	NA	-0.39	-7.49	-0.33	3.47e-13	Obesity-related traits;
LGG	trans	rs877282	0.945	rs877280	chr10:771599	C/T	cg22713356	chr15:30763199	NA	0.57	8.59	0.37	1.34e-16	Uric acid levels;
LGG	cis	rs988958	0.526	rs60056083	chr2:42242928	A/T	cg19376973	chr2:42229025	NA	0.67	9.55	0.41	7.29e-20	Hypospadias;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.15e-12	Lung cancer;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg18402987	chr7:1209562	NA	0.65	9.0	0.39	5.74e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg10360139	chr7:1886902	MAD1L1	-0.42	-7.59	-0.33	1.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs55728055	0.661	rs62237765	chr22:31956981	A/G	cg15162869	chr22:32027605	PISD	-0.75	-7.74	-0.34	6.25e-14	Age-related hearing impairment;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03517284	chr6:25882590	NA	-0.85	-16.47	-0.61	2.77e-48	Intelligence (multi-trait analysis);
LGG	cis	rs3820928	1.000	rs2396433	chr2:227772502	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.72e-12	Pulmonary function;
LGG	cis	rs701145	0.643	rs357488	chr3:153885006	A/G	cg17054900	chr3:154042577	DHX36	0.85	10.0	0.42	1.94e-21	Coronary artery disease;
LGG	trans	rs11250098	0.503	rs13270870	chr8:10770782	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.0	-0.39	5.64e-18	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg12708336	chr17:41446283	NA	-0.32	-7.37	-0.32	7.8e-13	Menopause (age at onset);
LGG	cis	rs72949976	0.606	rs1922797	chr2:214027642	G/A	cg08319019	chr2:214017104	IKZF2	0.63	11.72	0.48	5.91e-28	Lung cancer;Squamous cell lung carcinoma;
LGG	trans	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg10840412	chr1:235813424	GNG4	0.53	7.41	0.33	5.99e-13	Bipolar disorder;
LGG	cis	rs35740288	1.000	rs17577449	chr15:86297185	G/A	cg04173714	chr15:86211321	AKAP13	0.4	7.05	0.31	6.64e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs1814175	0.740	rs10839439	chr11:49918240	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.8	-0.78	3.38e-96	Height;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.51	-9.87	-0.42	5.53e-21	Prudent dietary pattern;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.19e-16	Alzheimer's disease;
LGG	cis	rs10214930	0.647	rs11767188	chr7:27571945	A/G	cg22168087	chr7:27702803	HIBADH	0.45	6.76	0.3	4.11e-11	Hypospadias;
LGG	cis	rs7172689	0.908	rs7181247	chr15:81560077	A/G	cg11808699	chr15:81528661	IL16	-0.47	-9.74	-0.41	1.68e-20	Inattentive symptoms;
LGG	cis	rs2463822	1.000	rs7481995	chr11:62129312	G/C	cg06239285	chr11:62104954	ASRGL1	1.15	15.87	0.59	1.39e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs7567389	0.504	rs41280570	chr2:128176230	C/T	cg10021288	chr2:128175891	PROC	0.37	6.68	0.3	6.97e-11	Self-rated health;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.49	-0.53	3.16e-35	Personality dimensions;
LGG	cis	rs11096990	0.892	rs6531696	chr4:39191754	A/G	cg24403649	chr4:39172243	NA	-0.46	-7.68	-0.34	9.31e-14	Cognitive function;
LGG	cis	rs10465746	0.935	rs12410617	chr1:84379461	G/C	cg10977910	chr1:84465055	TTLL7	0.51	9.45	0.4	1.64e-19	Obesity-related traits;
LGG	cis	rs12421382	1.000	rs12421382	chr11:109378071	C/T	cg15948088	chr11:109293068	C11orf87	0.62	10.63	0.44	9.37e-24	Schizophrenia;
LGG	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg20026190	chr17:76395443	PGS1	0.42	7.26	0.32	1.69e-12	HDL cholesterol levels;
LGG	cis	rs9462027	0.561	rs3798348	chr6:34771892	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs1568889	0.838	rs10835283	chr11:28214985	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	18.98	0.66	7.62e-60	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg21775007	chr8:11205619	TDH	-0.57	-9.41	-0.4	2.34e-19	Neuroticism;
LGG	cis	rs907683	0.584	rs2854903	chr2:220288979	C/T	cg15015639	chr2:220282977	DES	-0.35	-10.1	-0.42	8.42e-22	Resting heart rate;
LGG	cis	rs12282928	0.918	rs1503186	chr11:48244307	A/G	cg26585981	chr11:48327164	OR4S1	-0.43	-6.88	-0.3	1.96e-11	Migraine - clinic-based;
LGG	cis	rs67311347	0.544	rs9821440	chr3:40342347	T/C	cg13683864	chr3:40499215	RPL14	-0.81	-16.03	-0.6	2.65e-46	Renal cell carcinoma;
LGG	cis	rs2235642	0.893	rs8051295	chr16:1588087	A/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.43	10.42	0.44	5.49e-23	Coronary artery disease;
LGG	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg09038676	chr11:67351608	GSTP1	0.36	7.06	0.31	5.97e-12	Mean corpuscular volume;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg02725872	chr8:58115012	NA	-0.85	-11.54	-0.47	2.86e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.791	rs28858828	chr4:98950442	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.43	7.05	0.31	6.43e-12	Tonsillectomy;
LGG	cis	rs4732038	0.739	rs73164857	chr7:134237294	A/G	cg06906464	chr7:134288099	NA	-0.47	-11.01	-0.46	3.41e-25	Longevity;
LGG	cis	rs4819052	0.885	rs9980676	chr21:46665430	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.14	0.39	1.95e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs977987	0.806	rs2903033	chr16:75389606	T/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.7	0.41	2.31e-20	Joint mobility (Beighton score);
LGG	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs12200782	1.000	rs12200782	chr6:26403036	C/G	cg11502198	chr6:26597334	ABT1	-0.85	-7.16	-0.32	3.2e-12	Small cell lung carcinoma;
LGG	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg15823100	chr22:32027580	PISD	-0.74	-8.43	-0.36	4.54e-16	Age-related hearing impairment;
LGG	cis	rs7923609	1.000	rs10761723	chr10:64955581	C/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.79	-0.3	3.52e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs41563	0.674	rs2192932	chr7:104653265	A/G	cg03782966	chr7:104585482	NA	-0.31	-6.71	-0.3	5.66e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2708977	0.730	rs596069	chr2:97076642	C/T	cg01950434	chr2:97203154	ARID5A	0.49	7.65	0.34	1.16e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2645694	0.533	rs2645681	chr4:77820949	G/A	cg06046430	chr4:77819534	ANKRD56	0.56	11.36	0.47	1.49e-26	Emphysema distribution in smoking;
LGG	cis	rs7084402	1.000	rs6481402	chr10:60268977	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.87	-0.64	1.07e-54	Refractive error;
LGG	cis	rs1003719	0.715	rs2835657	chr21:38565064	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.75	-14.38	-0.56	5.15e-39	Eye color traits;
LGG	cis	rs7674212	0.510	rs55715738	chr4:104130189	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-7.11	-0.31	4.51e-12	Type 2 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg15563057	chr5:139493612	PURA	0.39	6.73	0.3	5.04e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg04553112	chr3:125709451	NA	-0.54	-6.87	-0.3	2.03e-11	Blood pressure (smoking interaction);
LGG	cis	rs888194	0.898	rs10850379	chr12:110002777	A/G	cg19025524	chr12:109796872	NA	0.35	6.88	0.3	1.9e-11	Neuroticism;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg23064060	chr3:129159190	IFT122;MBD4	-0.39	-6.72	-0.3	5.42e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs9784649	1.000	rs11738315	chr5:24967891	T/C	cg08600765	chr20:34638493	LOC647979	-0.57	-7.41	-0.33	5.98e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7084402	0.967	rs1658425	chr10:60331547	G/C	cg09696939	chr10:60272079	BICC1	-0.36	-6.96	-0.31	1.18e-11	Refractive error;
LGG	cis	rs4730250	0.595	rs7789500	chr7:106915723	A/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.68	-0.37	6.9e-17	Osteoarthritis;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs7824557	0.564	rs2572394	chr8:11235393	A/G	cg21775007	chr8:11205619	TDH	-0.77	-13.36	-0.53	1.1e-34	Retinal vascular caliber;
LGG	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15025054	chr1:212964885	TATDN3;NSL1	0.49	7.5	0.33	3.18e-13	Gut microbiome composition (summer);
LGG	cis	rs6964587	1.000	rs6974607	chr7:91750116	G/A	cg17063962	chr7:91808500	NA	0.52	9.33	0.4	4.57e-19	Breast cancer;
LGG	trans	rs9354308	0.764	rs9360167	chr6:66591357	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.26	-0.32	1.67e-12	Inflammatory bowel disease;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs2470578	0.792	rs2060625	chr3:17339152	G/T	cg20981856	chr3:17787350	NA	0.37	7.13	0.31	3.85e-12	Schizophrenia;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg16524936	chr4:1340807	KIAA1530	-0.49	-8.11	-0.35	4.46e-15	Longevity;
LGG	cis	rs561341	0.769	rs559228	chr17:30294527	T/C	cg13647721	chr17:30228624	UTP6	0.64	7.98	0.35	1.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4665809	0.590	rs1865324	chr2:26417533	C/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.16	-0.39	1.75e-18	Gut microbiome composition (summer);
LGG	cis	rs36093844	0.948	rs56271770	chr11:85548400	C/T	cg16165120	chr11:85566439	CCDC83	-0.38	-6.84	-0.3	2.52e-11	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs950169	0.960	rs35159785	chr15:84804014	G/A	cg24253500	chr15:84953950	NA	0.57	10.06	0.42	1.14e-21	Schizophrenia;
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.54e-21	Lung cancer;
LGG	cis	rs4642101	1.000	rs4642101	chr3:12842223	T/G	cg24848339	chr3:12840334	CAND2	0.35	7.52	0.33	2.82e-13	QRS complex (12-leadsum);
LGG	cis	rs4730250	0.707	rs257387	chr7:106808480	G/A	cg02696742	chr7:106810147	HBP1	-0.83	-11.57	-0.47	2.25e-27	Osteoarthritis;
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg16680214	chr1:154839983	KCNN3	-0.46	-9.09	-0.39	2.89e-18	Prostate cancer;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg19143629	chr17:61920732	SMARCD2	0.4	6.78	0.3	3.6e-11	Prudent dietary pattern;
LGG	cis	rs7851660	0.874	rs1955143	chr9:100634579	A/T	cg13688889	chr9:100608707	NA	-0.58	-11.61	-0.47	1.65e-27	Strep throat;
LGG	cis	rs992157	0.835	rs13031757	chr2:219151926	T/C	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	9.29e-26	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg19774624	chr17:42201019	HDAC5	0.61	10.52	0.44	2.35e-23	Total body bone mineral density;
LGG	trans	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.72	-0.34	7.04e-14	Heart rate;
LGG	cis	rs60695258	0.550	rs340636	chr4:87930760	T/G	cg01323104	chr4:87958903	AFF1	-0.24	-6.94	-0.31	1.36e-11	Hematocrit;
LGG	cis	rs12449964	0.515	rs9899364	chr17:17567112	G/A	cg05444541	chr17:17804740	TOM1L2	0.35	7.26	0.32	1.63e-12	Coronary artery disease or ischemic stroke;
LGG	cis	rs11105298	0.891	rs10858864	chr12:89846230	C/T	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1961456	0.542	rs75501607	chr8:18244753	C/T	cg18736775	chr8:18248649	NAT2	-0.72	-11.95	-0.49	7.16e-29	Total cholesterol levels;
LGG	cis	rs3008870	0.755	rs1925409	chr1:67365089	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-0.67	-13.83	-0.54	1.2e-36	Lymphocyte percentage of white cells;
LGG	cis	rs11711311	0.747	rs11928590	chr3:113343478	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.13	-0.31	3.98e-12	IgG glycosylation;
LGG	cis	rs477692	0.549	rs7098548	chr10:131455028	A/G	cg05714579	chr10:131428358	MGMT	-0.5	-9.31	-0.4	5.13e-19	Response to temozolomide;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-11.33	-0.47	2.01e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg06634786	chr22:41940651	POLR3H	0.76	12.13	0.49	1.32e-29	Vitiligo;
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs3820928	0.874	rs4675130	chr2:227827740	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.68	-0.34	9.48e-14	Pulmonary function;
LGG	cis	rs4689388	0.581	rs1801212	chr4:6302519	C/T	cg00701064	chr4:6280414	WFS1	0.58	10.28	0.43	1.75e-22	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12670798	0.547	rs6461583	chr7:21616867	G/C	cg04471919	chr7:21584483	DNAH11	0.29	6.76	0.3	4.24e-11	Total cholesterol levels;Cholesterol, total;LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs17092148	1.000	rs6058117	chr20:33366905	A/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs28595532	0.920	rs114684527	chr4:119749252	G/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg09359103	chr1:154839909	KCNN3	-0.51	-10.71	-0.45	4.48e-24	Prostate cancer;
LGG	trans	rs853679	0.882	rs9380069	chr6:28203300	A/G	cg01620082	chr3:125678407	NA	-0.69	-8.21	-0.36	2.15e-15	Depression;
LGG	cis	rs7582720	1.000	rs7560547	chr2:203757916	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs826838	1.000	rs11183214	chr12:38692938	C/T	cg13010199	chr12:38710504	ALG10B	0.77	16.54	0.61	1.31e-48	Heart rate;
LGG	cis	rs10493773	1.000	rs10493773	chr1:86125753	C/T	cg17807903	chr1:86174739	ZNHIT6	0.53	8.51	0.37	2.39e-16	Urate levels in overweight individuals;
LGG	cis	rs10940138	0.830	rs4976136	chr5:67206148	G/C	ch.5.1281357F	chr5:67228439	NA	0.78	13.66	0.54	5.94e-36	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs10163485	chr17:80110750	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs10911232	0.507	rs4651137	chr1:182994300	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.74	0.41	1.64e-20	Hypertriglyceridemia;
LGG	cis	rs17102423	0.559	rs11627382	chr14:65480208	A/G	cg11161011	chr14:65562177	MAX	-0.69	-11.64	-0.48	1.17e-27	Obesity-related traits;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs919433	0.617	rs13018267	chr2:198545592	G/C	cg00792783	chr2:198669748	PLCL1	-0.62	-9.79	-0.41	1.08e-20	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs1007190	0.881	rs16939676	chr17:42976347	C/A	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	cis	rs950776	0.518	rs28438420	chr15:78836288	A/T	cg17108064	chr15:78857060	CHRNA5	-0.49	-10.97	-0.45	4.69e-25	Sudden cardiac arrest;
LGG	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg12395012	chr8:11607386	GATA4	-0.4	-7.32	-0.32	1.11e-12	Neuroticism;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg02127607	chr17:61920694	SMARCD2	0.49	8.95	0.38	8.44e-18	Prudent dietary pattern;
LGG	cis	rs4474465	0.850	rs10793329	chr11:78265655	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.83	-0.3	2.7e-11	Alzheimer's disease (survival time);
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg24642844	chr7:1081250	C7orf50	-0.76	-9.77	-0.41	1.28e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7267979	0.868	rs6138550	chr20:25223430	C/T	cg08601574	chr20:25228251	PYGB	0.33	6.71	0.3	5.85e-11	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs12410462	0.551	rs4384237	chr1:227868554	G/T	cg23173402	chr1:227635558	NA	0.35	6.65	0.3	8.38e-11	Major depressive disorder;
LGG	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg00701064	chr4:6280414	WFS1	0.59	10.69	0.44	5.49e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.75	-0.68	1.89e-63	Height;
LGG	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg06917634	chr15:78832804	PSMA4	0.65	11.7	0.48	7.24e-28	Sudden cardiac arrest;
LGG	cis	rs12519773	0.526	rs4242240	chr5:92517203	A/G	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	cis	rs12476592	0.602	rs262504	chr2:63861235	C/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.84	-0.3	2.58e-11	Childhood ear infection;
LGG	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.83	-0.34	3.37e-14	HDL cholesterol;
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg23782820	chr8:58130467	NA	0.44	7.0	0.31	9.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7385804	0.796	rs2432930	chr7:100299024	A/G	cg20848291	chr7:100343083	ZAN	0.45	7.14	0.31	3.67e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs78487399	0.808	rs6544668	chr2:43732488	T/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs637571	0.522	rs11227368	chr11:65740370	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.47	7.95	0.35	1.49e-14	Eosinophil percentage of white cells;
LGG	cis	rs9354308	0.868	rs6907911	chr6:66555683	A/G	cg07460842	chr6:66804631	NA	-0.49	-8.47	-0.37	3.31e-16	Metabolite levels;
LGG	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-7.22	-0.32	2.19e-12	Hip circumference adjusted for BMI;
LGG	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg13647721	chr17:30228624	UTP6	0.78	10.24	0.43	2.64e-22	Hip circumference adjusted for BMI;
LGG	cis	rs2072438	0.503	rs2146838	chr9:123876305	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.51	-9.31	-0.4	5.21e-19	Rheumatoid arthritis;
LGG	cis	rs765787	0.530	rs55920042	chr15:45541577	G/A	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.41	-0.36	5.05e-16	IgG glycosylation;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.51e-30	Lung cancer;
LGG	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.09	18.01	0.64	2.43e-55	Smoking behavior;
LGG	cis	rs6459788	0.605	rs887628	chr7:157237589	G/A	cg06271696	chr7:157225062	NA	-0.56	-11.7	-0.48	7.31e-28	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg20673091	chr1:2541236	MMEL1	0.77	18.1	0.64	9.01e-56	Ulcerative colitis;
LGG	cis	rs7444	0.941	rs73166632	chr22:21946173	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.7	-0.34	8.36e-14	Systemic lupus erythematosus;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg11298680	chr1:28559461	DNAJC8	0.42	6.92	0.31	1.52e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4740619	0.716	rs13287834	chr9:15779336	G/A	cg14451791	chr9:16040625	NA	0.33	8.36	0.36	7.48e-16	Body mass index;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg04025307	chr7:1156635	C7orf50	0.78	10.91	0.45	8.1e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg19635926	chr16:89946313	TCF25	0.7	8.36	0.36	7.56e-16	Skin colour saturation;
LGG	cis	rs6121246	0.529	rs750144	chr20:30179027	C/T	cg18721089	chr20:30220636	NA	0.51	7.73	0.34	6.96e-14	Mean corpuscular hemoglobin;
LGG	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg13147721	chr7:65941812	NA	-0.72	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	cis	rs7267979	0.932	rs6138600	chr20:25521346	A/T	cg06421707	chr20:25228305	PYGB	0.47	9.93	0.42	3.45e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9389248	0.728	rs1022491	chr6:135259366	C/T	cg22676075	chr6:135203613	NA	-0.44	-7.61	-0.33	1.51e-13	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.85	17.59	0.63	2.09e-53	Personality dimensions;
LGG	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg24375607	chr4:120327624	NA	-0.65	-10.51	-0.44	2.49e-23	Corneal astigmatism;
LGG	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.26e-11	Self-reported allergy;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg20110707	chr11:118481992	PHLDB1	-0.49	-9.72	-0.41	1.85e-20	Cholesterol, total;
LGG	cis	rs28588043	0.938	rs28664840	chr1:170978598	G/T	cg03458344	chr1:170964477	C1orf129	-0.51	-7.47	-0.33	3.97e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg04293180	chr8:144700367	TSTA3	0.89	6.83	0.3	2.72e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs7551222	0.716	rs11240751	chr1:204462050	A/G	cg20240347	chr1:204465584	NA	-0.54	-10.23	-0.43	2.67e-22	Schizophrenia;
LGG	cis	rs1941023	0.584	rs2014121	chr11:60156297	T/C	cg08716584	chr11:60157161	MS4A7	-0.44	-8.94	-0.38	9.33e-18	Congenital heart disease (maternal effect);
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg04824913	chr4:887549	GAK	0.47	8.14	0.35	3.64e-15	Sjögren's syndrome;
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg22398616	chr13:53314203	LECT1	-0.45	-9.28	-0.4	6.35e-19	Lewy body disease;
LGG	cis	rs3903072	0.528	rs35138525	chr11:65576470	C/T	cg26695010	chr11:65641043	EFEMP2	-0.42	-6.69	-0.3	6.28e-11	Breast cancer;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.65	0.37	8.22e-17	Prudent dietary pattern;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg13206674	chr6:150067644	NUP43	0.64	14.4	0.56	4.01e-39	Lung cancer;
LGG	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg13683864	chr3:40499215	RPL14	-0.85	-16.44	-0.61	3.76e-48	Renal cell carcinoma;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	ch.2.79376880R	chr2:79523372	NA	0.47	6.79	0.3	3.41e-11	Apolipoprotein A-IV levels;
LGG	cis	rs1005277	0.505	rs200931	chr10:38128434	A/C	cg25427524	chr10:38739819	LOC399744	-0.68	-13.53	-0.53	2.13e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs12666575	0.504	rs10226475	chr7:2226162	A/G	cg05863683	chr7:1912471	MAD1L1	0.34	6.76	0.3	4.14e-11	Schizophrenia;
LGG	cis	rs36071027	0.577	rs6862399	chr5:158441675	G/T	cg18496440	chr5:158532302	NA	0.41	6.84	0.3	2.45e-11	Carotid intima media thickness;
LGG	trans	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg22232500	chr2:134024266	NCKAP5	0.6	8.08	0.35	5.68e-15	Bipolar disorder;
LGG	cis	rs2816316	1.000	rs2816315	chr1:192536886	C/T	cg02586212	chr1:192544902	RGS1	0.46	9.28	0.4	6.52e-19	Celiac disease;
LGG	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg27489772	chr12:121021490	NA	0.58	7.7	0.34	8.27e-14	Type 1 diabetes nephropathy;
LGG	cis	rs13191362	0.935	rs34141091	chr6:162953893	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.26	0.4	7.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.57	-7.96	-0.35	1.38e-14	Schizophrenia;
LGG	cis	rs7010267	0.776	rs4407910	chr8:119917117	A/G	cg17171407	chr8:119960777	TNFRSF11B	-0.38	-9.86	-0.42	6.27e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs9393777	0.528	rs7745603	chr6:27090404	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-8.84	-0.38	2.08e-17	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs2170276	chr4:120485824	A/C	cg09307838	chr4:120376055	NA	0.79	13.21	0.52	5.02e-34	Corneal astigmatism;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg22535103	chr8:58192502	C8orf71	-0.99	-15.16	-0.58	1.99e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2760061	0.819	rs1745416	chr1:228204497	G/A	cg18477163	chr1:228402036	OBSCN	0.25	6.68	0.3	6.99e-11	Diastolic blood pressure;
LGG	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.49	-8.44	-0.37	4.17e-16	Menarche (age at onset);
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg13013644	chr5:502571	SLC9A3	-0.34	-6.76	-0.3	4.1e-11	Cystic fibrosis severity;
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg08888203	chr3:10149979	C3orf24	0.56	8.06	0.35	6.56e-15	Alzheimer's disease;
LGG	cis	rs7020830	0.898	rs308521	chr9:37367094	T/C	cg14294708	chr9:37120828	ZCCHC7	1.08	27.14	0.78	9.42e-98	Schizophrenia;
LGG	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	26.91	0.78	9.89e-97	Height;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg16405210	chr4:1374714	KIAA1530	0.53	9.38	0.4	2.84e-19	Obesity-related traits;
LGG	cis	rs714031	0.900	rs5757762	chr22:40064581	C/T	cg21377881	chr22:40064566	CACNA1I	-0.62	-14.74	-0.57	1.42e-40	Schizophrenia;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs854765	0.547	rs6502633	chr17:17941037	G/C	cg04398451	chr17:18023971	MYO15A	-0.74	-15.53	-0.59	4.56e-44	Total body bone mineral density;
LGG	trans	rs12517041	1.000	rs7737671	chr5:23288400	C/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs11690935	0.851	rs10174055	chr2:172858214	C/T	cg21435375	chr2:172878103	MAP1D	-0.35	-7.87	-0.34	2.6e-14	Schizophrenia;
LGG	cis	rs9920506	0.536	rs11072768	chr15:78929478	A/C	cg07120314	chr15:79043507	NA	-0.46	-8.45	-0.37	3.88e-16	Post bronchodilator FEV1;
LGG	trans	rs3733585	0.806	rs7375599	chr4:9954918	C/T	cg26043149	chr18:55253948	FECH	0.39	6.65	0.3	8.53e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19037304	chr7:19812760	TMEM196	0.42	6.84	0.3	2.57e-11	Cognitive performance;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.25	-0.32	1.7e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11997175	0.670	rs34985841	chr8:33661889	C/A	ch.8.33884649F	chr8:33765107	NA	0.4	7.57	0.33	1.97e-13	Body mass index;
LGG	cis	rs17401966	0.838	rs12738317	chr1:10419663	C/T	cg15208524	chr1:10270712	KIF1B	0.42	7.32	0.32	1.08e-12	Hepatocellular carcinoma;
LGG	trans	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg02030672	chr11:45687055	CHST1	-0.5	-9.16	-0.39	1.73e-18	Obesity-related traits;
LGG	cis	rs9644630	1.000	rs4921657	chr8:19370867	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.57	16.26	0.6	2.26e-47	Oropharynx cancer;
LGG	cis	rs2011503	0.597	rs8103992	chr19:19665643	A/C	cg11584989	chr19:19387371	SF4	-0.64	-10.28	-0.43	1.79e-22	Bipolar disorder;
LGG	cis	rs4808199	0.895	rs4808194	chr19:19435680	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.54	0.33	2.49e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs4969178	0.965	rs938350	chr17:76399552	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.49	-0.56	1.6e-39	HDL cholesterol levels;
LGG	cis	rs17776563	0.504	rs1470109	chr15:89153673	A/G	cg05013243	chr15:89149849	MIR1179	-0.33	-6.71	-0.3	5.79e-11	Thyroid hormone levels;
LGG	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg06697600	chr4:7070879	GRPEL1	0.52	8.2	0.36	2.47e-15	Monocyte percentage of white cells;
LGG	cis	rs17683430	0.702	rs75351557	chr22:32416688	A/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs17253792	0.598	rs71413578	chr14:56018651	T/C	cg01858014	chr14:56050164	KTN1	-0.76	-9.36	-0.4	3.37e-19	Putamen volume;
LGG	cis	rs7928758	0.887	rs79256507	chr11:134263728	C/A	cg15243474	chr11:134282918	B3GAT1	1.28	15.44	0.58	1.14e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6502050	0.835	rs66932937	chr17:80116803	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.12	-0.31	4.17e-12	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.45	0.33	4.66e-13	Rheumatoid arthritis;
LGG	cis	rs6763768	0.606	rs7649323	chr3:53332706	C/G	cg16894138	chr3:53270350	TKT	0.42	8.02	0.35	8.61e-15	Bacterial meningitis;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg13010199	chr12:38710504	ALG10B	-0.49	-9.21	-0.39	1.11e-18	Morning vs. evening chronotype;
LGG	cis	rs11764590	0.715	rs9969125	chr7:2088460	C/T	cg06789500	chr7:2109450	MAD1L1	-0.31	-6.8	-0.3	3.33e-11	Neuroticism;
LGG	cis	rs3806933	0.522	rs12521169	chr5:110448313	G/A	cg04022379	chr5:110408740	TSLP	0.45	7.84	0.34	3.05e-14	Eosinophilic esophagitis;
LGG	cis	rs55794721	0.509	rs7554255	chr1:25778106	C/T	cg23205692	chr1:25664452	TMEM50A	0.48	10.08	0.42	9.93e-22	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs1552244	0.882	rs6443276	chr3:10008905	C/A	cg00149659	chr3:10157352	C3orf10	0.73	9.25	0.39	8.18e-19	Alzheimer's disease;
LGG	cis	rs4478137	0.839	rs3967763	chr4:164239273	G/C	cg06758707	chr4:164254230	NPY1R	0.71	12.73	0.51	4.89e-32	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-9.06	-0.39	3.56e-18	Prostate cancer;
LGG	cis	rs9875589	0.509	rs1488375	chr3:14061563	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	10.02	0.42	1.67e-21	Ovarian reserve;
LGG	cis	rs77633900	0.614	rs280014	chr15:76986890	A/G	cg21673338	chr15:77095150	SCAPER	-0.65	-10.36	-0.43	9.46e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.58	-0.41	6.07e-20	Response to amphetamines;
LGG	cis	rs11650494	0.908	rs77488129	chr17:47448970	G/A	cg08112188	chr17:47440006	ZNF652	1.33	15.77	0.59	3.59e-45	Prostate cancer;
LGG	cis	rs59918340	0.692	rs6983780	chr8:142231944	G/A	cg03653399	chr8:142233436	SLC45A4	0.42	8.32	0.36	1.01e-15	Immature fraction of reticulocytes;
LGG	cis	rs9303401	0.625	rs34963822	chr17:56988424	C/A	cg25039879	chr17:56429692	SUPT4H1	0.65	9.11	0.39	2.56e-18	Cognitive test performance;
LGG	trans	rs5756813	0.661	rs2071910	chr22:38204259	C/T	cg19894588	chr14:64061835	NA	-0.64	-10.13	-0.43	6.67e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9325144	0.600	rs6582630	chr12:38743508	A/G	cg26384229	chr12:38710491	ALG10B	-0.74	-14.69	-0.56	2.18e-40	Morning vs. evening chronotype;
LGG	cis	rs6754311	0.681	rs4954493	chr2:136609975	T/C	cg07169764	chr2:136633963	MCM6	-0.77	-13.17	-0.52	7.23e-34	Mosquito bite size;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs7927997	0.746	rs7110818	chr11:76292575	C/T	cg17647271	chr11:76299819	NA	-0.41	-7.28	-0.32	1.4e-12	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs990171	0.955	rs6720564	chr2:103079297	T/C	cg05295703	chr2:102895712	NA	-0.51	-9.0	-0.39	5.88e-18	Lymphocyte counts;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg11062466	chr8:58055876	NA	0.55	8.91	0.38	1.14e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.869	rs7793946	chr7:91520628	T/C	cg17063962	chr7:91808500	NA	-0.41	-7.12	-0.31	4.15e-12	Breast cancer;
LGG	cis	rs2172802	0.924	rs11941524	chr4:62446484	A/G	cg04118610	chr4:62707027	LPHN3	-0.47	-7.33	-0.32	1.06e-12	Partial epilepsies;
LGG	cis	rs17227506	0.583	rs11779680	chr8:13483883	T/C	cg03566418	chr8:13424080	C8orf48	0.55	8.21	0.36	2.29e-15	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.63	0.37	9.82e-17	Neuroticism;
LGG	cis	rs9815354	0.953	rs1717034	chr3:41955913	A/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.72e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6674970	0.966	rs4512652	chr1:151115690	G/C	cg11822372	chr1:151115635	SEMA6C	0.5	8.8	0.38	2.69e-17	Childhood ear infection;
LGG	cis	rs6988985	0.728	rs3753121	chr8:143926380	C/T	cg10324643	chr8:143916377	GML	-0.4	-8.0	-0.35	1.03e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9326248	1.000	rs664971	chr11:117070857	A/G	cg20608306	chr11:116969690	SIK3	-0.32	-8.41	-0.36	5e-16	Blood protein levels;
LGG	cis	rs1505368	0.837	rs10167244	chr2:213281310	A/G	cg16329650	chr2:213403929	ERBB4	0.4	6.88	0.3	2e-11	Symmetrical dimethylarginine levels;
LGG	trans	rs9467711	0.606	rs2073530	chr6:26375243	T/C	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs77372450	0.636	rs11465226	chr5:157003651	G/T	cg25387487	chr5:157003181	ADAM19	0.59	7.48	0.33	3.64e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg02127607	chr17:61920694	SMARCD2	-0.41	-7.1	-0.31	4.73e-12	Prudent dietary pattern;
LGG	cis	rs7129556	0.775	rs17752006	chr11:77393993	G/C	cg12586386	chr11:77299805	AQP11	0.44	7.22	0.32	2.17e-12	Weight loss (gastric bypass surgery);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27562717	chr20:30193180	ID1	0.4	6.65	0.3	8.48e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs240764	0.853	rs1875400	chr6:101020968	T/C	cg09795085	chr6:101329169	ASCC3	-0.41	-6.88	-0.3	1.98e-11	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23818046	chr5:64859282	CENPK;PPWD1	0.43	7.17	0.32	3.06e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs9354308	0.764	rs9283821	chr6:66596125	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg05091796	chr16:4465799	CORO7	-0.77	-12.59	-0.51	1.82e-31	Schizophrenia;
LGG	cis	rs912057	0.526	rs746453	chr6:6734221	C/A	cg06612196	chr6:6737390	NA	0.5	11.18	0.46	7.56e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg02175503	chr12:58329896	NA	0.56	9.29	0.4	5.84e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg19847130	chr8:10466454	RP1L1	0.32	7.03	0.31	7.54e-12	Neuroticism;
LGG	cis	rs988958	0.526	rs13424176	chr2:42239532	A/G	cg27252766	chr2:42229092	NA	0.47	6.72	0.3	5.28e-11	Hypospadias;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11245990	chr11:68621969	NA	0.38	8.24	0.36	1.83e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7226408	0.857	rs2121023	chr18:34488414	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4746818	1.000	rs10823301	chr10:70885875	G/A	cg11621586	chr10:70884670	VPS26A	1.17	22.75	0.73	1.85e-77	Left atrial antero-posterior diameter;
LGG	cis	rs9311474	0.629	rs7636227	chr3:52566682	G/A	cg18404041	chr3:52824283	ITIH1	-0.39	-7.29	-0.32	1.33e-12	Electroencephalogram traits;
LGG	trans	rs6787172	0.702	rs1730007	chr3:158016997	T/C	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg14926445	chr8:58193284	C8orf71	-0.76	-10.2	-0.43	3.45e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.782	rs192466	chr9:15585395	A/G	cg14451791	chr9:16040625	NA	-0.33	-8.34	-0.36	8.62e-16	Body mass index;
LGG	cis	rs832540	0.866	rs832579	chr5:56164943	A/G	cg12654349	chr5:56205094	C5orf35	-0.37	-6.67	-0.3	7.39e-11	Coronary artery disease;
LGG	cis	rs11628318	0.660	rs35258120	chr14:103058769	G/A	cg01864069	chr14:103024347	NA	-0.6	-9.09	-0.39	2.93e-18	Platelet count;
LGG	cis	rs9814567	0.806	rs2293293	chr3:134322742	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.15	-0.46	1.02e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7646881	0.812	rs59957986	chr3:158458913	G/A	cg19483011	chr3:158453295	NA	-0.6	-7.97	-0.35	1.22e-14	Tetralogy of Fallot;
LGG	cis	rs12586317	0.547	rs10130773	chr14:35445299	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.63	-0.33	1.33e-13	Psoriasis;
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.62	-10.41	-0.44	5.89e-23	Tonsillectomy;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg04156016	chr5:1868137	NA	0.32	7.01	0.31	8.27e-12	Cardiovascular disease risk factors;
LGG	cis	rs9517320	0.515	rs9556969	chr13:99195948	T/C	cg07423050	chr13:99094983	FARP1	-0.55	-10.67	-0.44	6.69e-24	Longevity;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs17286411	0.777	rs4788569	chr16:71914785	A/G	cg06353428	chr16:71660113	MARVELD3	0.41	7.35	0.32	9.18e-13	Blood protein levels;
LGG	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.16e-19	Bone mineral density;
LGG	cis	rs9467773	0.620	rs2494716	chr6:26662736	T/C	cg09904177	chr6:26538194	HMGN4	0.66	13.51	0.53	2.67e-35	Intelligence (multi-trait analysis);
LGG	cis	rs1122794	1.000	rs1122794	chr16:309155	A/C	cg25425005	chr16:202905	HBZ	0.41	6.71	0.3	5.61e-11	Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs9467773	0.620	rs2451732	chr6:26622904	A/T	cg09904177	chr6:26538194	HMGN4	-0.67	-13.83	-0.54	1.18e-36	Intelligence (multi-trait analysis);
LGG	cis	rs447735	0.566	rs258337	chr16:89720710	T/A	cg04240660	chr16:89714849	CHMP1A	-0.42	-7.37	-0.32	8.12e-13	Hemoglobin concentration;
LGG	cis	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg07777115	chr5:623756	CEP72	-0.52	-7.01	-0.31	8.47e-12	Obesity-related traits;
LGG	cis	rs2842992	0.673	rs6930904	chr6:160217433	T/A	cg11366901	chr6:160182831	ACAT2	1.07	16.29	0.6	1.67e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7582720	1.000	rs75324925	chr2:203698300	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs28735056	1.000	rs56197868	chr18:77636077	C/T	cg20368463	chr18:77673604	PQLC1	-0.49	-8.32	-0.36	9.86e-16	Schizophrenia;
LGG	cis	rs4965869	0.866	rs4965865	chr15:101975597	C/T	cg12371147	chr15:101978424	PCSK6	-0.43	-7.72	-0.34	7.2e-14	Platelet-derived growth factor BB levels;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg13395646	chr4:1353034	KIAA1530	-0.65	-11.37	-0.47	1.35e-26	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.06	0.6	1.78e-46	Lung cancer;
LGG	cis	rs12681287	0.577	rs13257414	chr8:87494138	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.72	-0.34	7.24e-14	Caudate activity during reward;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg08677398	chr8:58056175	NA	0.47	7.34	0.32	9.44e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg05941027	chr17:61774174	LIMD2	0.37	9.64	0.41	3.75e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg08621203	chr6:150244597	RAET1G	0.41	6.97	0.31	1.1e-11	Lung cancer;
LGG	cis	rs651907	0.557	rs59596156	chr3:101394217	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.94	0.57	1.74e-41	Colorectal cancer;
LGG	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg16447950	chr5:562315	NA	-0.5	-8.26	-0.36	1.6e-15	Ulcerative colitis;
LGG	cis	rs6089584	0.566	rs11699442	chr20:60623268	A/G	cg06470251	chr20:60548479	NA	0.41	7.19	0.32	2.55e-12	Body mass index;
LGG	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg00343986	chr7:65444356	GUSB	0.48	8.35	0.36	7.96e-16	Aortic root size;
LGG	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.56	-0.53	1.71e-35	Response to antipsychotic treatment;
LGG	cis	rs4493873	0.869	rs57987672	chr8:92119197	T/A	cg16814680	chr8:91681699	NA	0.45	6.93	0.31	1.38e-11	Migraine - clinic-based;
LGG	cis	rs2074193	0.569	rs61927895	chr12:47775402	T/A	cg02516419	chr12:47771422	NA	0.58	8.63	0.37	1.02e-16	Migraine with aura;
LGG	cis	rs2153535	0.580	rs7742689	chr6:8452433	C/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs6694672	0.717	rs7539642	chr1:197063841	A/G	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02994645	chr8:30891371	WRN;PURG	-0.48	-6.67	-0.3	7.43e-11	Lung cancer in ever smokers;
LGG	cis	rs9878978	0.928	rs17786873	chr3:2485728	A/T	cg21928760	chr3:2462534	CNTN4	0.4	8.77	0.38	3.32e-17	Blood pressure (smoking interaction);
LGG	trans	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.07	-0.39	3.47e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs936229	0.813	rs72730503	chr15:75086386	G/A	cg14664628	chr15:75095509	CSK	-1.13	-25.11	-0.76	1.83e-88	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs12517041	0.572	rs3919638	chr5:23303287	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.32	-0.47	2.13e-26	Calcium levels;
LGG	trans	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg02002194	chr4:3960332	NA	0.49	9.19	0.39	1.35e-18	Mood instability;
LGG	cis	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.88	0.48	1.29e-28	Rheumatoid arthritis;
LGG	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	13.72	0.54	3.35e-36	IgG glycosylation;
LGG	cis	rs4727027	0.901	rs6944781	chr7:148829566	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.66	0.3	7.64e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs80130819	0.591	rs3803182	chr12:48398223	G/A	cg24011408	chr12:48396354	COL2A1	0.74	7.99	0.35	1.08e-14	Prostate cancer;
LGG	cis	rs8051149	0.625	rs876987	chr16:87882209	A/G	cg02614661	chr16:87878292	SLC7A5	-0.37	-7.12	-0.31	4.19e-12	Blood metabolite levels;
LGG	cis	rs924607	0.966	rs1709554	chr5:637443	A/G	cg07001201	chr5:642380	CEP72	-0.41	-6.8	-0.3	3.16e-11	Vincristine-induced peripheral neuropathy in acute lymphoblastic leukemia;
LGG	cis	rs6496044	0.568	rs12899946	chr15:86066082	C/T	cg13263323	chr15:86062960	AKAP13	-0.37	-8.2	-0.36	2.32e-15	Interstitial lung disease;
LGG	cis	rs9527	0.569	rs10786730	chr10:104724200	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.88	-0.3	1.96e-11	Arsenic metabolism;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.42	-0.44	5.47e-23	Triglycerides;
LGG	cis	rs67133203	0.898	rs11169682	chr12:51432114	A/G	cg14688905	chr12:51403056	SLC11A2	0.73	11.09	0.46	1.73e-25	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg11062466	chr8:58055876	NA	0.62	9.84	0.42	7.26e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg18854424	chr1:2615690	NA	0.34	6.79	0.3	3.37e-11	Ulcerative colitis;
LGG	cis	rs96067	0.805	rs7522400	chr1:36613380	A/G	cg24686825	chr1:36642396	MAP7D1	-0.39	-7.06	-0.31	6.04e-12	Corneal structure;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg14159672	chr1:205819179	PM20D1	0.75	16.06	0.6	1.88e-46	Menarche (age at onset);
LGG	cis	rs9768139	0.512	rs1121014	chr7:158081769	T/C	cg25566285	chr7:158114605	PTPRN2	-0.43	-7.21	-0.32	2.31e-12	Calcium levels;
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg23985595	chr17:80112537	CCDC57	0.42	8.09	0.35	5.29e-15	Life satisfaction;
LGG	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs6089584	0.526	rs6089316	chr20:60627552	C/T	cg13770153	chr20:60521292	NA	-0.49	-8.11	-0.35	4.47e-15	Body mass index;
LGG	cis	rs62238980	0.614	rs78354020	chr22:32394259	A/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs908922	0.676	rs11205018	chr1:152496249	T/G	cg09873164	chr1:152488093	CRCT1	0.63	15.37	0.58	2.15e-43	Hair morphology;
LGG	cis	rs10911232	0.542	rs12128323	chr1:183050087	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03452623	chr4:187889614	NA	-1.04	-29.67	-0.81	3.77e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg08742575	chr21:47604166	C21orf56	0.48	8.09	0.35	5.41e-15	Testicular germ cell tumor;
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg17202724	chr17:61916730	SMARCD2	0.61	14.6	0.56	5.71e-40	Prudent dietary pattern;
LGG	cis	rs4423214	0.879	rs1792277	chr11:71138918	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-11.3	-0.46	2.6e-26	Vitamin D levels;
LGG	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg26850624	chr5:429559	AHRR	-0.34	-6.98	-0.31	9.98e-12	Cystic fibrosis severity;
LGG	cis	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs12579753	0.871	rs35801863	chr12:82238818	A/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.02	-0.46	3.14e-25	Resting heart rate;
LGG	cis	rs25645	0.830	rs4072639	chr17:38189049	G/A	cg17467752	chr17:38218738	THRA	-0.64	-11.14	-0.46	1.05e-25	Myeloid white cell count;
LGG	cis	rs2046867	0.862	rs62251653	chr3:72811827	C/T	cg25664220	chr3:72788482	NA	-0.32	-8.73	-0.38	4.57e-17	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg03929089	chr4:120376271	NA	-0.69	-10.78	-0.45	2.5300000000000002e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12229367	chr17:55822335	NA	0.45	8.63	0.37	9.89e-17	Schizophrenia;
LGG	cis	rs9549367	0.713	rs3024776	chr13:113827075	A/G	cg00898013	chr13:113819073	PROZ	0.51	10.08	0.42	9.5e-22	Platelet distribution width;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.17e-14	Total body bone mineral density;
LGG	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg07541023	chr7:19748670	TWISTNB	0.78	10.53	0.44	2.16e-23	Thyroid stimulating hormone;
LGG	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.01	0.64	2.41e-55	Refractive error;
LGG	trans	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg25214090	chr10:38739885	LOC399744	0.69	12.32	0.5	2.23e-30	Corneal astigmatism;
LGG	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg00426182	chr6:28072559	NA	0.91	6.74	0.3	4.73e-11	Hip circumference adjusted for BMI;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg13150344	chr11:67889062	CHKA	0.66	7.37	0.32	8.11e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	1.000	rs1622208	chr1:46498375	A/G	cg03146154	chr1:46216737	IPP	-0.53	-9.92	-0.42	3.69e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg24829409	chr8:58192753	C8orf71	-0.65	-9.1	-0.39	2.62e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg06022373	chr22:39101656	GTPBP1	0.91	19.1	0.66	2.18e-60	Menopause (age at onset);
LGG	cis	rs7208859	0.673	rs9909497	chr17:29173228	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2067615	0.524	rs10778503	chr12:107090616	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.79	0.51	2.79e-32	Heart rate;
LGG	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg26677194	chr12:130822605	PIWIL1	0.57	10.19	0.43	3.74e-22	Menopause (age at onset);
LGG	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg22437258	chr11:111473054	SIK2	0.56	9.76	0.41	1.39e-20	Primary sclerosing cholangitis;
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs9880211	0.846	rs73230043	chr3:136407159	G/T	cg21827317	chr3:136751795	NA	-0.48	-7.19	-0.32	2.61e-12	Body mass index;Height;
LGG	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg07615347	chr10:60278583	BICC1	0.61	16.99	0.62	1.19e-50	Refractive error;
LGG	cis	rs4665809	0.590	rs962217	chr2:26438276	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs931812	0.895	rs4734016	chr8:101910071	C/T	cg20993868	chr7:22813445	NA	0.71	13.45	0.53	4.66e-35	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2204008	0.775	rs3900361	chr12:38238936	A/G	cg13010199	chr12:38710504	ALG10B	-0.65	-13.33	-0.53	1.52e-34	Bladder cancer;
LGG	cis	rs6665290	0.669	rs34267809	chr1:227176162	C/G	cg05696931	chr1:227175867	NA	-0.42	-8.51	-0.37	2.44e-16	Myeloid white cell count;
LGG	cis	rs713587	0.967	rs10182458	chr2:25150641	A/G	cg04586622	chr2:25135609	ADCY3	0.44	11.95	0.49	7.08e-29	Body mass index in non-asthmatics;
LGG	cis	rs4478137	0.824	rs4057791	chr4:164225132	A/C	cg06758707	chr4:164254230	NPY1R	0.73	13.32	0.53	1.74e-34	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs1814175	0.817	rs6486046	chr11:49997017	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.72	-0.78	7.68e-96	Height;
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg15133208	chr4:90757351	SNCA	-0.4	-9.1	-0.39	2.69e-18	Dementia with Lewy bodies;
LGG	cis	rs58688157	0.960	rs11246213	chr11:612967	A/G	cg16486109	chr11:613632	IRF7	0.41	7.39	0.32	6.77e-13	Systemic lupus erythematosus;
LGG	cis	rs10861342	1.000	rs11112394	chr12:105551570	C/T	cg23923672	chr12:105501055	KIAA1033	-0.8	-7.08	-0.31	5.47e-12	IgG glycosylation;
LGG	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.96	0.49	6.59e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2404602	0.735	rs2280306	chr15:76652258	C/G	cg15268244	chr15:77196840	NA	0.43	9.41	0.4	2.25e-19	Blood metabolite levels;
LGG	cis	rs4727027	0.769	rs10952797	chr7:148816722	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.75	0.3	4.33e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs4622507	0.618	rs35742891	chr16:55064051	A/C	cg09947736	chr16:55091198	NA	0.78	11.37	0.47	1.32e-26	Social communication problems;
LGG	cis	rs4959677	0.698	rs9503199	chr6:2485468	C/T	cg23817096	chr6:1620687	NA	0.35	8.6	0.37	1.21e-16	Orthostatic hypotension;
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg07580895	chr4:1043494	NA	0.32	7.4	0.33	6.26e-13	Recombination rate (males);
LGG	cis	rs6089829	0.962	rs6062778	chr20:61663959	A/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7267979	1.000	rs2500443	chr20:25331442	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.26	-0.43	2.09e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg18252515	chr7:66147081	NA	-1.04	-14.97	-0.57	1.33e-41	Diabetic kidney disease;
LGG	cis	rs526231	0.543	rs34379	chr5:102398698	C/T	cg23492399	chr5:102201601	PAM	0.55	8.1	0.35	4.75e-15	Primary biliary cholangitis;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg19524238	chr7:2802976	GNA12	0.4	9.07	0.39	3.44e-18	Height;
LGG	cis	rs3741151	0.572	rs12290623	chr11:73121872	C/G	cg17517138	chr11:73019481	ARHGEF17	0.73	7.8	0.34	4.14e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	trans	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg06606381	chr12:133084897	FBRSL1	-0.7	-7.0	-0.31	9.19e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs523522	0.962	rs9040	chr12:120900274	C/T	cg27279351	chr12:120934652	DYNLL1	0.77	12.19	0.49	8.1e-30	High light scatter reticulocyte count;
LGG	cis	rs4780401	0.703	rs7193637	chr16:11764920	C/T	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.33	-0.32	1.02e-12	Rheumatoid arthritis;
LGG	cis	rs17270561	0.609	rs1937127	chr6:25769872	G/T	cg16482183	chr6:26056742	HIST1H1C	-0.56	-9.16	-0.39	1.68e-18	Iron status biomarkers;
LGG	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg06850241	chr22:41845214	NA	-0.42	-6.83	-0.3	2.71e-11	Vitiligo;
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.25	-39.57	-0.88	1.18e-150	Myeloid white cell count;
LGG	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg01657329	chr11:68192670	LRP5	0.57	10.8	0.45	2.19e-24	Total body bone mineral density;
LGG	cis	rs7247513	0.964	rs8105902	chr19:12718351	G/A	cg01871581	chr19:12707946	ZNF490	-0.42	-8.6	-0.37	1.27e-16	Bipolar disorder;
LGG	cis	rs490234	0.841	rs950534	chr9:128225881	C/G	cg14078157	chr9:128172775	NA	-0.4	-7.52	-0.33	2.79e-13	Mean arterial pressure;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg20308403	chr7:2120281	MAD1L1	0.32	6.85	0.3	2.43e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6860806	0.507	rs270615	chr5:131641573	G/C	cg07395648	chr5:131743802	NA	-0.5	-10.01	-0.42	1.74e-21	Breast cancer;
LGG	trans	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.09	-0.39	2.97e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs8073645	chr17:80110957	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs8060686	0.641	rs7190079	chr16:68073834	G/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7715811	1.000	rs13436952	chr5:13773993	A/G	cg07548982	chr5:13769939	DNAH5	-0.47	-9.95	-0.42	2.94e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg21775007	chr8:11205619	TDH	-0.56	-9.25	-0.39	8.53e-19	Triglycerides;
LGG	cis	rs12410462	1.000	rs12407171	chr1:227642282	G/A	cg23173402	chr1:227635558	NA	0.63	10.43	0.44	4.99e-23	Major depressive disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12482825	chr16:75034148	ZNRF1	0.45	6.75	0.3	4.55e-11	Gut microbiome composition (summer);
LGG	cis	rs9807841	0.670	rs8107719	chr19:10804389	T/C	cg17710535	chr19:10819994	QTRT1	0.45	6.96	0.31	1.15e-11	Inflammatory skin disease;
LGG	cis	rs2797369	0.882	rs1775644	chr6:101615409	T/C	cg27451362	chr6:101846650	GRIK2	-0.77	-10.33	-0.43	1.15e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg13699009	chr12:122356056	WDR66	-0.55	-14.84	-0.57	4.84e-41	Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs6831352	0.819	rs1154401	chr4:100009738	G/C	cg12011299	chr4:100065546	ADH4	0.43	8.89	0.38	1.39e-17	Alcohol dependence;
LGG	cis	rs56399783	0.901	rs73049362	chr7:2826822	G/A	cg19731401	chr7:2775893	GNA12	0.36	7.39	0.32	7.01e-13	Childhood ear infection;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12446722	chr1:226374380	ACBD3	-0.46	-7.33	-0.32	1.03e-12	Pancreatic cancer;
LGG	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg08859206	chr1:53392774	SCP2	-0.43	-8.59	-0.37	1.36e-16	Monocyte count;
LGG	cis	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg24375607	chr4:120327624	NA	0.59	9.6	0.41	5.13e-20	Corneal astigmatism;
LGG	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	cis	rs9470366	0.816	rs1321311	chr6:36622900	C/A	cg08179530	chr6:36648295	CDKN1A	0.61	9.0	0.39	5.73e-18	QRS duration;
LGG	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg08677398	chr8:58056175	NA	0.46	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs727505	0.954	rs55768077	chr7:124663216	A/G	cg23710748	chr7:124431027	NA	-0.51	-9.37	-0.4	3.1400000000000002e-19	Lewy body disease;
LGG	cis	rs873946	0.648	rs12766166	chr10:134556403	G/C	cg13271783	chr10:134563150	INPP5A	-0.58	-8.56	-0.37	1.62e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs644799	1.000	rs623191	chr11:95548359	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7635838	0.785	rs2606735	chr3:11400714	A/C	cg00170343	chr3:11313890	ATG7	0.48	7.94	0.35	1.55e-14	HDL cholesterol;
LGG	cis	rs6834538	0.597	rs1486865	chr4:113465651	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.78	0.38	3.1e-17	Free thyroxine concentration;
LGG	cis	rs9291683	0.645	rs11557743	chr4:10118377	C/G	cg00071950	chr4:10020882	SLC2A9	-0.35	-7.2	-0.32	2.47e-12	Bone mineral density;
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs2439831	0.850	rs16977798	chr15:44151948	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.15	0.43	5.42e-22	Lung cancer in ever smokers;
LGG	trans	rs7826238	0.517	rs35144760	chr8:8361723	A/G	cg16141378	chr3:129829833	LOC729375	0.45	9.46	0.4	1.58e-19	Systolic blood pressure;
LGG	cis	rs950169	1.000	rs79318564	chr15:84786150	G/A	cg24253500	chr15:84953950	NA	0.6	10.99	0.45	4.1e-25	Schizophrenia;
LGG	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg20608306	chr11:116969690	SIK3	0.42	13.08	0.52	1.72e-33	Blood protein levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24695950	chr2:162364264	NA	0.37	6.72	0.3	5.51e-11	Menarche (age at onset);
LGG	cis	rs7527798	0.592	rs11118360	chr1:207858586	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-7.14	-0.32	3.55e-12	Erythrocyte sedimentation rate;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg15971980	chr6:150254442	NA	0.46	8.61	0.37	1.12e-16	Lung cancer;
LGG	cis	rs6754311	0.552	rs1030765	chr2:136553188	A/T	cg07169764	chr2:136633963	MCM6	-0.81	-14.48	-0.56	1.82e-39	Mosquito bite size;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-12.52	-0.5	3.7e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.933	rs4470197	chr17:28464474	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.79	0.51	2.71e-32	Coffee consumption (cups per day);
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.87	-0.34	2.47e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg11366901	chr6:160182831	ACAT2	0.86	14.13	0.55	6.23e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg20892847	chr12:58011875	NA	-0.41	-8.74	-0.38	4.21e-17	Multiple sclerosis;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.07e-11	Menopause (age at onset);
LGG	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg10223061	chr2:219282414	VIL1	-0.34	-6.65	-0.3	8.3e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs2120243	0.539	rs2305622	chr3:157122504	C/T	cg24825693	chr3:157122686	VEPH1	-0.59	-13.58	-0.53	1.34e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs910316	0.967	rs175479	chr14:75561871	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.93	-0.45	6.61e-25	Height;
LGG	cis	rs147499554	1	rs147499554	chr15:78900650	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-7.04	-0.31	6.96e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg15556689	chr8:8085844	FLJ10661	-0.52	-9.35	-0.4	3.9e-19	Neuroticism;
LGG	cis	rs3849046	0.810	rs11957778	chr5:137917826	G/A	cg10920316	chr5:137946599	NA	-0.47	-7.65	-0.33	1.19e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg12395012	chr8:11607386	GATA4	0.37	7.03	0.31	7.5e-12	Neuroticism;
LGG	cis	rs13191362	1.000	rs35723993	chr6:163008197	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.835	rs3088177	chr17:80111724	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.76	-0.34	5.54e-14	Life satisfaction;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg00631329	chr6:26305371	NA	-0.52	-9.8	-0.41	9.81e-21	Educational attainment;
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.42	-0.53	6.35e-35	Schizophrenia;
LGG	cis	rs7617773	0.780	rs35778847	chr3:48346985	G/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg16284684	chr7:1164063	C7orf50	0.35	6.72	0.3	5.22e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	0.966	rs2302393	chr4:17654341	G/A	cg18681998	chr4:17616180	MED28	0.86	19.73	0.68	2.51e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9796	0.689	rs8032195	chr15:41448790	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.59	-0.41	5.41e-20	Menopause (age at onset);
LGG	cis	rs4740619	0.905	rs12057012	chr9:15798256	T/C	cg14451791	chr9:16040625	NA	-0.4	-10.3	-0.43	1.52e-22	Body mass index;
LGG	cis	rs7843479	0.582	rs13439690	chr8:21778082	T/C	cg17168535	chr8:21777572	XPO7	0.83	16.13	0.6	9.08e-47	Mean corpuscular volume;
LGG	cis	rs4642101	0.640	rs2305398	chr3:12856856	A/G	cg24848339	chr3:12840334	CAND2	0.37	8.15	0.35	3.47e-15	QRS complex (12-leadsum);
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.87e-21	Aortic root size;
LGG	cis	rs1552244	0.882	rs3755782	chr3:10029305	T/C	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs9796	0.649	rs8035828	chr15:41467287	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.86	-0.42	6.07e-21	Menopause (age at onset);
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.17	-0.32	2.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4727027	0.865	rs13236754	chr7:148845773	G/A	cg23583168	chr7:148888333	NA	-0.88	-17.11	-0.62	3.38e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs1994135	0.715	rs11052742	chr12:33692290	A/C	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.13e-16	Resting heart rate;
LGG	cis	rs4555082	0.750	rs2816650	chr14:105708343	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.39	-0.32	6.74e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22140378	chr20:5891760	CHGB	0.45	7.29	0.32	1.31e-12	Gut microbiome composition (summer);
LGG	cis	rs8044868	0.606	rs7189591	chr16:72099011	G/T	cg06353428	chr16:71660113	MARVELD3	0.4	6.66	0.3	7.96e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg14829155	chr15:31115871	NA	-0.58	-10.13	-0.43	6.63e-22	Huntington's disease progression;
LGG	cis	rs3771570	0.901	rs73006381	chr2:242406654	G/C	cg21155796	chr2:242212141	HDLBP	0.73	9.56	0.41	7.07e-20	Prostate cancer;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg21775007	chr8:11205619	TDH	-0.49	-7.87	-0.34	2.51e-14	Neuroticism;
LGG	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg25919922	chr13:100150906	NA	-0.74	-7.6	-0.33	1.69e-13	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	9.09e-16	Personality dimensions;
LGG	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.75	-0.45	3.22e-24	Height;
LGG	cis	rs2878628	0.650	rs56098033	chr3:52758571	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.07e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg19761014	chr17:28927070	LRRC37B2	0.61	7.34	0.32	9.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12540874	0.522	rs4947641	chr7:50489038	C/T	cg04490037	chr7:50633773	DDC	0.3	6.66	0.3	7.98e-11	Systemic sclerosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25658980	chr19:49955004	ALDH16A1;PIH1D1	0.43	7.15	0.32	3.46e-12	Cognitive performance;
LGG	cis	rs561341	1.000	rs530209	chr17:30315287	A/G	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1185460	0.547	rs666741	chr11:118911350	A/C	cg12636538	chr11:118901039	SLC37A4	-0.67	-14.38	-0.56	4.94e-39	Coronary artery disease;
LGG	cis	rs3741404	0.609	rs641378	chr11:63869493	T/C	cg18225595	chr11:63971243	STIP1	0.48	9.3	0.4	5.57e-19	Platelet count;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.67	-0.37	7.54e-17	Personality dimensions;
LGG	cis	rs9894429	1.000	rs3935543	chr17:79579874	T/C	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs975722	0.531	rs10249419	chr7:117381806	A/T	cg10524701	chr7:117356490	CTTNBP2	0.43	8.72	0.38	4.9e-17	Coronary artery disease;
LGG	cis	rs58688157	0.960	rs12422022	chr11:613192	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs9303401	0.659	rs7225896	chr17:56637337	T/C	cg25039879	chr17:56429692	SUPT4H1	0.64	8.99	0.39	6.51e-18	Cognitive test performance;
LGG	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs2549003	0.870	rs61175929	chr5:131821548	C/G	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs7264396	0.779	rs2425162	chr20:34429974	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-6.85	-0.3	2.4e-11	Total cholesterol levels;
LGG	trans	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg06521331	chr12:34319734	NA	0.47	8.28	0.36	1.32e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.660	rs801192	chr7:66031952	C/G	cg11764359	chr7:65958608	NA	-0.63	-10.81	-0.45	1.97e-24	Aortic root size;
LGG	cis	rs698833	0.506	rs713448	chr2:44504877	T/C	cg00619915	chr2:44497795	NA	-0.6	-8.88	-0.38	1.52e-17	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7833790	0.724	rs12676336	chr8:82771008	C/T	cg17211192	chr8:82754475	SNX16	0.72	11.99	0.49	4.98e-29	Diastolic blood pressure;
LGG	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11583043	0.667	rs873760	chr1:101540561	C/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.93	0.31	1.39e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs4776059	0.550	rs8032394	chr15:52868032	G/A	cg22715398	chr15:52968154	KIAA1370	-0.5	-7.16	-0.32	3.27e-12	Schizophrenia;
LGG	cis	rs2237234	0.848	rs2237235	chr6:26391395	A/G	cg09904177	chr6:26538194	HMGN4	-0.55	-7.63	-0.33	1.36e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8060686	0.641	rs113162813	chr16:68038969	A/G	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.66	-0.3	7.66e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4849845	0.678	rs3896632	chr2:121023496	C/T	cg15425061	chr2:121036351	RALB	0.37	6.82	0.3	2.79e-11	Mean platelet volume;
LGG	cis	rs7617773	0.780	rs13090538	chr3:48370769	A/C	cg11946769	chr3:48343235	NME6	0.71	11.96	0.49	6.73e-29	Coronary artery disease;
LGG	cis	rs10089	1.000	rs17164310	chr5:127493679	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.15	0.46	9.76e-26	Ileal carcinoids;
LGG	cis	rs7819412	0.595	rs4841500	chr8:10988275	A/G	cg21775007	chr8:11205619	TDH	-0.52	-8.59	-0.37	1.37e-16	Triglycerides;
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	9.25	0.39	8.44e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.07	0.31	5.57e-12	Menopause (age at onset);
LGG	trans	rs7819412	0.594	rs17724226	chr8:10968926	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.23	-0.32	2.07e-12	Triglycerides;
LGG	cis	rs2153535	0.580	rs1932284	chr6:8477694	A/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.66e-22	Motion sickness;
LGG	trans	rs11098499	0.863	rs13140409	chr4:120503460	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.44e-27	Corneal astigmatism;
LGG	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.22	0.39	1.09e-18	Diabetic retinopathy;
LGG	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9302635	0.513	rs7184169	chr16:72152933	C/T	cg23815491	chr16:72088622	HP	0.51	9.46	0.4	1.54e-19	Blood protein levels;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.76	0.66	8.49e-59	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05654648	chr3:49977408	RBM6	0.42	6.89	0.3	1.84e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9300255	0.568	rs1790102	chr12:123704890	G/A	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs9393692	0.875	rs2142703	chr6:26289605	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.98	-0.42	2.17e-21	Educational attainment;
LGG	cis	rs9902453	0.904	rs4547389	chr17:28364768	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs1552244	0.554	rs3732963	chr3:10048885	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.46	0.5	6.16e-31	Alzheimer's disease;
LGG	cis	rs4740619	0.935	rs10756696	chr9:15725282	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.15	-0.43	5.66e-22	Body mass index;
LGG	cis	rs7267979	1.000	rs2500448	chr20:25404027	A/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.31e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs933688	1.000	rs6862125	chr5:90724598	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.16	20.17	0.68	2.21e-65	Smoking behavior;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg21548813	chr6:291882	DUSP22	-0.74	-13.24	-0.52	3.6e-34	Menopause (age at onset);
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg23302884	chr18:44338147	ST8SIA5	-0.36	-7.02	-0.31	7.79e-12	Personality dimensions;
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg26752003	chr8:145688521	CYHR1	-0.53	-11.12	-0.46	1.28e-25	Age at first birth;
LGG	cis	rs1348850	0.526	rs6433672	chr2:178378175	G/T	cg27490568	chr2:178487706	NA	0.85	15.02	0.57	8.29e-42	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12949688	0.601	rs4793573	chr17:55834533	C/T	cg12582317	chr17:55822272	NA	0.43	9.74	0.41	1.66e-20	Schizophrenia;
LGG	cis	rs6964587	1.000	rs12536529	chr7:91684086	C/T	cg17063962	chr7:91808500	NA	-0.48	-8.48	-0.37	2.98e-16	Breast cancer;
LGG	cis	rs7193541	0.662	rs8058133	chr16:74657485	A/T	cg01733217	chr16:74700730	RFWD3	1.1	33.73	0.84	8.44e-127	Multiple myeloma;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg25072359	chr17:41440525	NA	0.53	10.2	0.43	3.57e-22	Menopause (age at onset);
LGG	cis	rs7737355	0.812	rs6596008	chr5:130603119	C/T	cg06307176	chr5:131281290	NA	-0.45	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs926938	0.618	rs1286560	chr1:115375930	C/T	cg12756093	chr1:115239321	AMPD1	-0.48	-8.98	-0.39	6.86e-18	Autism;
LGG	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg22437258	chr11:111473054	SIK2	0.55	9.62	0.41	4.43e-20	Primary sclerosing cholangitis;
LGG	cis	rs9926296	0.529	rs7195906	chr16:89806347	A/T	cg27121462	chr16:89883253	FANCA	0.62	11.19	0.46	6.74e-26	Vitiligo;
LGG	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg08250081	chr4:10125330	NA	0.44	8.63	0.37	1.02e-16	Bone mineral density;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.38	7.25	0.32	1.78e-12	Schizophrenia;
LGG	cis	rs2075371	0.796	rs12672752	chr7:134007382	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	13.24	0.52	3.84e-34	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg07677032	chr17:61819896	STRADA	0.66	12.32	0.5	2.39e-30	Prudent dietary pattern;
LGG	cis	rs1978968	0.826	rs5992946	chr22:18466111	G/T	cg03078520	chr22:18463400	MICAL3	-0.71	-14.41	-0.56	3.7e-39	Presence of antiphospholipid antibodies;
LGG	cis	rs9300255	0.664	rs28372579	chr12:123881176	A/G	cg00376283	chr12:123451042	ABCB9	-0.53	-7.88	-0.34	2.4e-14	Neutrophil percentage of white cells;
LGG	trans	rs2727020	0.729	rs685789	chr11:49241228	G/A	cg03929089	chr4:120376271	NA	0.86	17.4	0.63	1.53e-52	Coronary artery disease;
LGG	cis	rs7923609	0.500	rs35403056	chr10:65338410	G/A	cg02276361	chr10:65351566	REEP3	-0.34	-7.15	-0.32	3.31e-12	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.55e-15	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.89e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs853679	0.517	rs9393895	chr6:28127621	T/C	cg23281280	chr6:28129359	ZNF389	0.38	6.66	0.3	7.77e-11	Depression;
LGG	cis	rs910316	1.000	rs4903281	chr14:75554361	G/C	cg08847533	chr14:75593920	NEK9	0.63	12.12	0.49	1.52e-29	Height;
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg09448879	chr15:79043637	NA	-0.56	-14.49	-0.56	1.72e-39	Coronary artery disease or large artery stroke;
LGG	cis	rs2798269	1.000	rs11841562	chr13:22111521	C/A	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.91	-0.31	1.65e-11	PR segment;
LGG	cis	rs5760092	0.755	rs6003959	chr22:24264395	C/T	cg24846343	chr22:24311635	DDTL	-0.48	-7.36	-0.32	8.26e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs238295	0.846	rs6053528	chr20:5582598	G/T	cg24001556	chr20:5591874	RP5-1022P6.2	-0.43	-6.67	-0.3	7.22e-11	Occipital cortical area (total cortical area interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09414773	chr4:41992992	SLC30A9	0.49	7.32	0.32	1.11e-12	Gut microbiome composition (summer);
LGG	cis	rs17604090	0.793	rs17150667	chr7:29689338	G/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.85	-0.34	2.96e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.508	rs1558184	chr16:89842374	T/G	cg07648498	chr16:89883185	FANCA	0.39	6.66	0.3	7.78e-11	Vitiligo;
LGG	cis	rs6580649	1.000	rs7305954	chr12:48403530	C/T	cg24011408	chr12:48396354	COL2A1	0.65	8.37	0.36	6.66e-16	Lung cancer;
LGG	cis	rs3617	0.539	rs9825369	chr3:52953311	T/C	cg11645453	chr3:52864694	ITIH4	-0.45	-7.49	-0.33	3.41e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg26309111	chr7:23720005	C7orf46	0.35	7.15	0.32	3.52e-12	Schizophrenia;
LGG	cis	rs7226408	0.857	rs11662124	chr18:34728434	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.08	-0.31	5.24e-12	Obesity-related traits;
LGG	cis	rs3206736	0.548	rs1559959	chr7:35074367	A/G	cg13400248	chr7:35225412	NA	0.55	9.41	0.4	2.24e-19	Diastolic blood pressure;
LGG	trans	rs61931739	0.500	rs11053212	chr12:34466116	T/G	cg26384229	chr12:38710491	ALG10B	0.97	21.57	0.71	6.3e-72	Morning vs. evening chronotype;
LGG	cis	rs4561483	0.799	rs33635	chr16:11991944	C/T	cg08843971	chr16:11963173	GSPT1	-0.63	-15.35	-0.58	2.77e-43	Testicular germ cell tumor;
LGG	cis	rs10819861	0.679	rs4743525	chr9:98849009	A/G	cg14508093	chr9:98862825	NA	-0.3	-7.06	-0.31	5.98e-12	Electrocardiographic traits;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	4.08e-20	Schizophrenia;
LGG	cis	rs72634258	0.842	rs6577463	chr1:8169485	T/G	cg00042356	chr1:8021962	PARK7	-0.56	-7.89	-0.34	2.25e-14	Inflammatory bowel disease;
LGG	cis	rs1620921	0.625	rs2489961	chr6:161261383	T/G	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7572733	1.000	rs11683222	chr2:198884028	C/G	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs6502050	0.835	rs4789751	chr17:80092373	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.27	-0.4	7.36e-19	Life satisfaction;
LGG	cis	rs2072499	0.778	rs2842868	chr1:156196407	A/C	cg24450063	chr1:156163899	SLC25A44	1.0	17.47	0.63	7.03e-53	Testicular germ cell tumor;
LGG	cis	rs1318772	0.935	rs26989	chr5:112782791	C/T	cg12552261	chr5:112820674	MCC	-0.7	-7.89	-0.34	2.21e-14	F-cell distribution;
LGG	cis	rs6547631	0.595	rs34702373	chr2:85927404	C/T	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.59e-22	Blood protein levels;
LGG	cis	rs17767392	0.958	rs8014349	chr14:72046496	C/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.26	0.36	1.57e-15	Mitral valve prolapse;
LGG	cis	rs6952808	0.792	rs2056478	chr7:1953897	C/T	cg05863683	chr7:1912471	MAD1L1	0.46	8.91	0.38	1.14e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2115630	1.000	rs1030863	chr15:85282635	C/T	cg12501888	chr15:85177176	SCAND2	-0.41	-6.93	-0.31	1.42e-11	P wave terminal force;
LGG	cis	rs9911578	0.935	rs2302189	chr17:56584205	A/C	cg05425664	chr17:57184151	TRIM37	0.6	9.46	0.4	1.58e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg13206674	chr6:150067644	NUP43	-0.46	-8.08	-0.35	5.5e-15	Lung cancer;
LGG	trans	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg18187862	chr3:45730750	SACM1L	-0.45	-7.43	-0.33	5.34e-13	Primary sclerosing cholangitis;
LGG	cis	rs7659604	0.676	rs4077102	chr4:122699830	A/G	cg05802129	chr4:122689817	NA	-0.4	-6.7	-0.3	6.16e-11	Type 2 diabetes;
LGG	cis	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg04568710	chr12:38710424	ALG10B	0.4	8.53	0.37	2.17e-16	Morning vs. evening chronotype;
LGG	cis	rs796364	0.806	rs79333757	chr2:200915716	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg15596359	chr8:11213517	TDH	-0.41	-8.56	-0.37	1.62e-16	Retinal vascular caliber;
LGG	cis	rs741702	0.890	rs2967897	chr19:13031210	T/C	cg11738485	chr19:12877000	HOOK2	0.43	6.85	0.3	2.41e-11	Red blood cell traits;
LGG	cis	rs7937682	0.632	rs11823089	chr11:111673539	A/G	cg22437258	chr11:111473054	SIK2	-0.42	-6.9	-0.31	1.75e-11	Primary sclerosing cholangitis;
LGG	cis	rs3785574	0.962	rs16947051	chr17:61790917	G/C	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2.03e-21	Height;
LGG	cis	rs13191362	0.872	rs73017702	chr6:163257695	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.73	8.05	0.35	7.29e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-7.0	-0.31	9.08e-12	Schizophrenia;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg01262667	chr19:19385393	TM6SF2	0.41	9.66	0.41	3.12e-20	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09524907	chr8:56014406	XKR4	0.5	8.14	0.35	3.56e-15	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.567	rs6058203	chr20:30198979	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.68	-0.34	9.63e-14	Mean corpuscular hemoglobin;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg22963979	chr7:1858916	MAD1L1	-0.4	-7.84	-0.34	3.21e-14	Schizophrenia;
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg16141378	chr3:129829833	LOC729375	-0.44	-10.66	-0.44	7.15e-24	Mood instability;
LGG	cis	rs12724450	0.793	rs34609268	chr1:150477840	G/C	cg03818307	chr1:150480534	ECM1	0.51	6.7	0.3	6e-11	Blood protein levels;
LGG	cis	rs9470366	0.848	rs66761782	chr6:36636080	T/C	cg08179530	chr6:36648295	CDKN1A	0.63	9.31	0.4	5.35e-19	QRS duration;
LGG	cis	rs7617773	0.784	rs11715799	chr3:48255220	A/G	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	cis	rs7236492	0.935	rs77865749	chr18:77216756	G/A	cg15644404	chr18:77186268	NFATC1	-0.81	-9.94	-0.42	3.24e-21	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7208859	0.673	rs216420	chr17:28938508	C/T	cg19761014	chr17:28927070	LRRC37B2	0.69	8.69	0.37	6.49e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2303319	0.786	rs62194491	chr2:162205061	A/G	cg13806767	chr2:162164127	PSMD14	-0.66	-7.79	-0.34	4.49e-14	Cognitive function;
LGG	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg11366901	chr6:160182831	ACAT2	0.91	14.73	0.56	1.46e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9611565	0.649	rs5751144	chr22:42128097	A/G	cg17376030	chr22:41985996	PMM1	0.56	9.26	0.4	7.9e-19	Vitiligo;
LGG	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg04398451	chr17:18023971	MYO15A	-0.83	-18.31	-0.65	9.8e-57	Total body bone mineral density;
LGG	cis	rs4888262	0.564	rs6564147	chr16:74622586	G/A	cg01733217	chr16:74700730	RFWD3	0.88	17.99	0.64	2.93e-55	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg05941027	chr17:61774174	LIMD2	0.38	9.64	0.41	3.67e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6764363	0.527	rs115329276	chr3:282338	T/A	cg02057681	chr3:285234	CHL1	-0.42	-7.37	-0.32	7.69e-13	Sudden cardiac arrest;
LGG	cis	rs4851254	0.920	rs11123816	chr2:100783653	G/A	cg17356467	chr2:100759845	AFF3	0.4	6.95	0.31	1.26e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.2	0.32	2.37e-12	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.35	-0.36	7.83e-16	Triglycerides;
LGG	cis	rs977987	0.835	rs4888380	chr16:75347690	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.09	0.42	8.87e-22	Dupuytren's disease;
LGG	cis	rs7937890	0.681	rs4756784	chr11:14270904	G/A	cg22961513	chr11:14280813	SPON1	0.35	8.25	0.36	1.61e-15	Mitochondrial DNA levels;
LGG	cis	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg00262122	chr8:11665843	FDFT1	-0.42	-6.78	-0.3	3.78e-11	Monocyte count;
LGG	cis	rs10751667	0.666	rs7944815	chr11:959776	C/T	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.61e-15	Alzheimer's disease (late onset);
LGG	cis	rs3806843	0.778	rs2531346	chr5:140126139	T/G	cg19875535	chr5:140030758	IK	-0.54	-11.1	-0.46	1.49e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.31	0.43	1.38e-22	Prudent dietary pattern;
LGG	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22496380	chr5:211416	CCDC127	-1.22	-17.54	-0.63	3.62e-53	Breast cancer;
LGG	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22496380	chr5:211416	CCDC127	-1.35	-18.66	-0.66	2.4e-58	Breast cancer;
LGG	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg09085632	chr11:111637200	PPP2R1B	1.08	22.82	0.73	9e-78	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg16524936	chr4:1340807	KIAA1530	-0.5	-7.69	-0.34	8.84e-14	Obesity-related traits;
LGG	cis	rs11225247	0.881	rs12792649	chr11:102220279	T/C	cg06323957	chr11:102217781	BIRC2	0.83	7.06	0.31	5.96e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs3820881	0.516	rs17531743	chr2:201245404	G/A	cg23516759	chr2:201153734	NA	-0.69	-9.59	-0.41	5.65e-20	Chickenpox;
LGG	cis	rs1018836	0.608	rs1033348	chr8:91464169	C/G	cg16814680	chr8:91681699	NA	-0.6	-10.06	-0.42	1.14e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg04568710	chr12:38710424	ALG10B	-0.42	-9.22	-0.39	1.08e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.75	-0.34	5.83e-14	Total cholesterol levels;
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg00290607	chr11:67383545	NA	0.65	12.55	0.5	2.64e-31	Mean corpuscular volume;
LGG	cis	rs972578	0.715	rs2413722	chr22:43198934	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.88e-11	Mean platelet volume;
LGG	cis	rs7166081	1.000	rs35008245	chr15:67614967	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.12	-0.31	4.28e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.87	-0.42	5.45e-21	Morning vs. evening chronotype;
LGG	cis	rs1263173	0.566	rs4225	chr11:116703671	G/T	cg20608306	chr11:116969690	SIK3	0.41	12.86	0.51	1.41e-32	HDL cholesterol;
LGG	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg07777115	chr5:623756	CEP72	-0.56	-7.06	-0.31	6.22e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7312933	0.966	rs6582375	chr12:42423185	A/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.68	0.3	7.05e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7226408	0.600	rs10164233	chr18:34515576	G/A	cg15022739	chr18:34823045	BRUNOL4	0.41	8.83	0.38	2.2e-17	Obesity-related traits;
LGG	cis	rs7765175	0.775	rs6900728	chr6:113675986	T/G	cg26552650	chr6:113682475	NA	0.33	7.3	0.32	1.25e-12	Coronary artery calcification;
LGG	cis	rs10875746	0.579	rs10875778	chr12:48624655	T/C	cg24011408	chr12:48396354	COL2A1	-0.58	-7.54	-0.33	2.56e-13	Longevity (90 years and older);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.95	-0.38	8.7e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs727505	0.909	rs7810427	chr7:124645103	C/T	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs911263	0.603	rs2180770	chr14:68773353	G/A	cg18825221	chr14:68749962	RAD51L1	0.38	8.23	0.36	1.89e-15	Primary biliary cholangitis;
LGG	trans	rs3206736	0.548	rs1559959	chr7:35074367	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.04	0.31	6.85e-12	Diastolic blood pressure;
LGG	cis	rs4481887	0.893	rs9651175	chr1:248446888	G/T	cg01631408	chr1:248437212	OR2T33	-0.54	-10.04	-0.42	1.32e-21	Common traits (Other);
LGG	cis	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.48	-0.33	3.87e-13	Mood instability;
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg00543991	chr22:32367038	NA	0.78	8.52	0.37	2.21e-16	Childhood ear infection;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.49	-0.37	2.93e-16	Menopause (age at onset);
LGG	cis	rs12360000	0.832	rs12761504	chr10:1907561	C/A	cg26364871	chr10:1889757	NA	-0.71	-13.66	-0.54	6.48e-36	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg19507638	chr5:93509721	C5orf36	-0.7	-9.75	-0.41	1.54e-20	Diabetic retinopathy;
LGG	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.94	0.45	6.18e-25	Bone mineral density;
LGG	cis	rs1218582	0.682	rs12144978	chr1:154850445	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.49	9.82	0.42	8.62e-21	Prostate cancer;
LGG	cis	rs9354308	0.764	rs2351717	chr6:66585982	A/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg16606324	chr3:10149918	C3orf24	0.54	7.11	0.31	4.51e-12	Alzheimer's disease;
LGG	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17539620	0.624	rs62432751	chr6:154841027	A/G	cg17771515	chr6:154831774	CNKSR3	0.62	7.56	0.33	2.16e-13	Lipoprotein (a) levels;
LGG	cis	rs11648796	0.757	rs763206	chr16:770103	C/G	cg27144592	chr16:783916	NARFL	0.8	14.07	0.55	1.1e-37	Height;
LGG	cis	rs847649	0.767	rs11972261	chr7:102641244	T/G	cg18108683	chr7:102477205	FBXL13	0.57	12.07	0.49	2.29e-29	Morning vs. evening chronotype;
LGG	cis	rs887829	0.569	rs4663963	chr2:234650193	T/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.41	-0.36	5.3e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs6142618	0.562	rs2377416	chr20:30757374	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs9560113	1.000	rs4773387	chr13:112180955	T/C	cg14154082	chr13:112174009	NA	0.42	9.24	0.39	9.01e-19	Menarche (age at onset);
LGG	cis	rs4696584	0.816	rs1490652	chr4:155407089	G/A	cg04517429	chr4:155413618	DCHS2	-0.33	-7.5	-0.33	3.37e-13	Folding of antihelix;
LGG	trans	rs2562456	0.752	rs279809	chr19:21467531	T/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.18	-0.32	2.85e-12	Pain;
LGG	cis	rs12451471	0.637	rs12452616	chr17:78090081	A/G	cg24585782	chr17:78113791	EIF4A3	0.49	8.13	0.35	4.08e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1799949	1.000	rs34534709	chr17:41302940	C/G	cg23758822	chr17:41437982	NA	0.9	15.88	0.59	1.2e-45	Menopause (age at onset);
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg22044901	chr15:68126292	NA	-0.42	-7.87	-0.34	2.5e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs765787	0.530	rs11854294	chr15:45527996	A/G	cg24006582	chr15:45444508	DUOX1	-0.67	-12.76	-0.51	3.8e-32	Uric acid levels;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg12708336	chr17:41446283	NA	-0.3	-6.94	-0.31	1.33e-11	Menopause (age at onset);
LGG	cis	rs9487051	0.714	rs6903695	chr6:109631422	C/G	cg21918786	chr6:109611834	NA	0.49	9.21	0.39	1.15e-18	Reticulocyte fraction of red cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18718425	chr11:67397920	NUDT8	0.46	6.66	0.3	7.99e-11	Gut microbiome composition (summer);
LGG	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg05526886	chr2:227700861	RHBDD1	-0.41	-7.23	-0.32	2.04e-12	Pulmonary function;
LGG	cis	rs7582180	0.629	rs2309796	chr2:100954385	C/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7241530	0.662	rs67266500	chr18:75907596	C/T	cg14642773	chr18:75888474	NA	0.46	8.98	0.39	7.03e-18	Educational attainment (years of education);
LGG	cis	rs2075671	0.903	rs11520986	chr7:100276994	A/G	cg21055462	chr7:100276975	NA	0.46	9.88	0.42	5.3e-21	Other erythrocyte phenotypes;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27574168	chr18:54318782	WDR7	-0.44	-6.71	-0.3	5.85e-11	Systemic lupus erythematosus;
LGG	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg23221052	chr5:179740743	GFPT2	-0.62	-10.74	-0.45	3.41e-24	Height;
LGG	cis	rs6693567	0.565	rs2264417	chr1:150368501	C/T	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs9399137	0.507	rs11757723	chr6:135291293	C/T	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-15.99	-0.6	3.67e-46	Longevity;
LGG	cis	rs4288356	1	rs4288356	chr8:141055724	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.31	-7.68	-0.34	9.37e-14	Pulse pressure;
LGG	cis	rs1046896	0.514	rs9894705	chr17:80823758	A/C	cg10935494	chr17:80760059	TBCD	0.4	6.86	0.3	2.27e-11	Glycated hemoglobin levels;
LGG	cis	rs1957429	0.520	rs72625644	chr14:65342282	A/T	cg23373153	chr14:65346875	NA	-0.96	-9.42	-0.4	2.18e-19	Pediatric areal bone mineral density (radius);
LGG	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.49	-9.76	-0.41	1.39e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs2243480	1.000	rs451396	chr7:65484074	T/A	cg12463550	chr7:65579703	CRCP	0.76	8.21	0.36	2.17e-15	Diabetic kidney disease;
LGG	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.71	7.42	0.33	5.53e-13	Initial pursuit acceleration;
LGG	cis	rs10267417	0.603	rs12669215	chr7:19933427	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs2820315	0.965	rs8028	chr1:201865763	A/G	cg10061532	chr1:201886748	LMOD1	-0.34	-6.97	-0.31	1.1e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg07234876	chr8:600039	NA	-0.96	-8.81	-0.38	2.59e-17	IgG glycosylation;
LGG	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg14673194	chr17:80132900	CCDC57	-0.45	-8.27	-0.36	1.48e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2289583	0.500	rs67168917	chr15:75391494	G/T	cg17294928	chr15:75287854	SCAMP5	-0.54	-9.87	-0.42	5.7e-21	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.501	rs3733045	chr3:52643307	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.83	-0.42	7.6e-21	Bipolar disorder;
LGG	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg23594656	chr7:65796392	TPST1	0.38	8.44	0.37	4.04e-16	Aortic root size;
LGG	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg19507638	chr5:93509721	C5orf36	-0.7	-9.79	-0.41	1.06e-20	Diabetic retinopathy;
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg06108461	chr20:60628389	TAF4	-0.67	-9.59	-0.41	5.62e-20	Obesity-related traits;
LGG	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs950776	0.518	rs12906284	chr15:78825105	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs9905704	0.671	rs28709536	chr17:57008912	C/A	cg05425664	chr17:57184151	TRIM37	-0.44	-7.0	-0.31	9.08e-12	Testicular germ cell tumor;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg23758822	chr17:41437982	NA	0.86	15.72	0.59	6.43e-45	Menopause (age at onset);
LGG	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	cg07245641	chr1:182991651	LAMC1	0.39	8.99	0.39	6.35e-18	Colorectal cancer;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg08677398	chr8:58056175	NA	0.58	8.8	0.38	2.75e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs8062405	1.000	rs72793811	chr16:28839392	G/A	cg16576597	chr16:28551801	NUPR1	0.31	6.96	0.31	1.21e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7192750	0.586	rs4788570	chr16:71920144	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.55	0.44	1.85e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7940866	0.903	rs7942900	chr11:130839244	G/A	cg12179176	chr11:130786555	SNX19	0.73	13.55	0.53	1.82e-35	Schizophrenia;
LGG	cis	rs4742903	0.935	rs9775540	chr9:106977722	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.2	0.36	2.46e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6547741	1.000	rs6706610	chr2:27778091	G/A	cg22903471	chr2:27725779	GCKR	0.38	8.62	0.37	1.06e-16	Oral cavity cancer;
LGG	cis	rs2455601	0.766	rs1109304	chr11:8955455	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.76	-13.42	-0.53	6.39e-35	Schizophrenia;
LGG	cis	rs17376456	0.825	rs10036024	chr5:93074804	C/A	cg25358565	chr5:93447407	FAM172A	1.28	14.93	0.57	1.89e-41	Diabetic retinopathy;
LGG	cis	rs7044106	0.708	rs10760113	chr9:123474050	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.53	0.61	1.42e-48	Hip circumference adjusted for BMI;
LGG	cis	rs11216435	0.512	rs2276343	chr11:117375596	G/A	cg27161313	chr11:117392002	DSCAML1	-0.43	-7.18	-0.32	2.83e-12	Menarche (age at onset);
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs1372520	0.684	rs2737030	chr4:90710099	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-7.74	-0.34	6.22e-14	Neuroticism;
LGG	trans	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.12e-11	Retinal vascular caliber;
LGG	cis	rs17739167	0.550	rs1426890	chr15:42226125	G/A	cg20935245	chr15:42234343	EHD4	0.46	8.85	0.38	1.89e-17	Monocyte count;
LGG	cis	rs644799	0.526	rs534973	chr11:95633624	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.65	11.28	0.46	3.11e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2180341	0.618	rs6683	chr6:127610021	G/A	cg27446573	chr6:127587934	RNF146	0.73	13.16	0.52	7.75e-34	Breast cancer;
LGG	cis	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg09307838	chr4:120376055	NA	0.82	13.92	0.54	4.9e-37	Corneal astigmatism;
LGG	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.38	-6.7	-0.3	5.91e-11	Body mass index;
LGG	cis	rs9790314	1.000	rs6765269	chr3:160948542	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-11.58	-0.47	2.06e-27	Morning vs. evening chronotype;
LGG	cis	rs9581857	0.725	rs1924074	chr13:28015387	C/G	cg01674679	chr13:27998804	GTF3A	0.66	7.72	0.34	7.35e-14	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs13191362	0.935	rs35942036	chr6:163163297	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.04	0.31	7.15e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg20607798	chr8:58055168	NA	0.66	7.45	0.33	4.51e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4926298	1.000	rs931068	chr19:13158678	A/G	cg04657146	chr19:12876947	HOOK2	-0.41	-6.88	-0.3	1.95e-11	Bipolar disorder;
LGG	cis	rs17767392	0.792	rs61991249	chr14:71869546	G/C	cg02058870	chr14:72053146	SIPA1L1	0.39	8.11	0.35	4.56e-15	Mitral valve prolapse;
LGG	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg06640241	chr16:89574553	SPG7	0.88	16.06	0.6	1.91e-46	Multiple myeloma (IgH translocation);
LGG	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg08875078	chr22:50639485	SELO	0.47	7.01	0.31	8.64e-12	Late-onset Alzheimer's disease;
LGG	cis	rs877282	1.000	rs12773872	chr10:771939	T/C	cg17470449	chr10:769945	NA	0.64	8.09	0.35	5.42e-15	Uric acid levels;
LGG	cis	rs988958	0.600	rs7587291	chr2:42247668	T/A	cg27252766	chr2:42229092	NA	0.56	8.15	0.35	3.35e-15	Hypospadias;
LGG	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg14835575	chr10:16859367	RSU1	0.38	7.52	0.33	2.84e-13	Platelet distribution width;
LGG	cis	rs7814319	0.561	rs7815834	chr8:97272144	T/A	cg20787634	chr8:97240163	UQCRB	-0.68	-13.73	-0.54	3e-36	Lung function (FVC);
LGG	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs12477438	0.520	rs12621007	chr2:99791946	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	25.79	0.77	1.41e-91	Chronic sinus infection;
LGG	cis	rs4950322	0.570	rs111370771	chr1:146733077	A/G	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs992157	1.000	rs10932766	chr2:219122090	G/A	cg00012203	chr2:219082015	ARPC2	0.8	15.14	0.58	2.41e-42	Colorectal cancer;
LGG	cis	rs8072100	0.713	rs8074451	chr17:45477573	C/T	cg08085267	chr17:45401833	C17orf57	-0.5	-9.23	-0.39	9.81e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9303401	0.659	rs34275691	chr17:56736640	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs8064024	0.650	rs3813749	chr16:4919127	T/C	cg04440724	chr16:4920505	UBN1	-0.56	-12.42	-0.5	9.16e-31	Cancer;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs1983891	0.874	rs1326322	chr6:41512462	G/T	cg20194872	chr6:41519635	FOXP4	0.59	10.27	0.43	2.04e-22	Prostate cancer;
LGG	cis	rs9443645	0.901	rs9443622	chr6:79582790	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.52e-17	Intelligence (multi-trait analysis);
LGG	cis	rs994014	0.612	rs4693234	chr4:82241943	A/G	cg07938847	chr4:82126349	PRKG2	-0.3	-7.32	-0.32	1.08e-12	Height;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg27165867	chr14:105738592	BRF1	-0.47	-8.12	-0.35	4.36e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.07	-0.42	1.06e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.925	rs56134734	chr11:116833055	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.04e-12	Subjective well-being;
LGG	cis	rs950776	0.706	rs11636753	chr15:78928946	G/T	cg06917634	chr15:78832804	PSMA4	0.57	10.01	0.42	1.68e-21	Sudden cardiac arrest;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	15.26	0.58	6.79e-43	Tonsillectomy;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1010254	0.510	rs55726523	chr5:151756407	C/T	cg08593883	chr5:151785301	NMUR2	-0.44	-6.71	-0.3	5.6e-11	Optic nerve measurement (cup area);
LGG	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.7	-13.96	-0.54	3.2e-37	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs3780486	0.846	rs12554995	chr9:33132044	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	25.09	0.76	2.42e-88	IgG glycosylation;
LGG	cis	rs11690935	0.788	rs10201053	chr2:172889558	A/G	cg21435375	chr2:172878103	MAP1D	-0.33	-7.8	-0.34	4.28e-14	Schizophrenia;
LGG	cis	rs11096990	0.855	rs2167494	chr4:39216221	C/T	cg24403649	chr4:39172243	NA	-0.47	-7.62	-0.33	1.47e-13	Cognitive function;
LGG	cis	rs9783347	0.714	rs10832918	chr11:18335684	A/G	cg15585147	chr11:18324498	HPS5	-0.35	-7.98	-0.35	1.17e-14	Pancreatic cancer;
LGG	cis	rs7312933	0.558	rs7965743	chr12:42736822	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.49	-7.79	-0.34	4.55e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12893668	0.572	rs1606	chr14:104161281	G/A	cg23335576	chr14:104009727	NA	0.42	7.24	0.32	1.84e-12	Reticulocyte count;
LGG	cis	rs9487094	0.553	rs13191995	chr6:109966460	C/A	cg16315928	chr6:109776240	MICAL1	0.49	7.6	0.33	1.7e-13	Height;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.76	-0.38	3.57e-17	Menopause (age at onset);
LGG	cis	rs2933343	0.679	rs789229	chr3:128602526	C/T	cg11901034	chr3:128598214	ACAD9	-0.44	-6.7	-0.3	6.18e-11	IgG glycosylation;
LGG	cis	rs13421350	0.579	rs16860397	chr2:173308194	A/C	cg15021238	chr2:173305865	ITGA6	0.77	8.86	0.38	1.69e-17	Diabetic kidney disease;
LGG	trans	rs61931739	0.500	rs10772163	chr12:34532950	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.82e-14	Lung cancer;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs7236492	0.688	rs76247824	chr18:77186287	G/A	cg15532942	chr18:77220712	NFATC1	0.45	7.27	0.32	1.54e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs868036	0.718	rs922494	chr15:68120644	T/C	cg22044901	chr15:68126292	NA	-0.41	-7.12	-0.31	4.03e-12	Restless legs syndrome;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg11644478	chr21:40555479	PSMG1	-0.59	-10.0	-0.42	1.89e-21	Menarche (age at onset);
LGG	cis	rs9875589	0.509	rs2731305	chr3:14081342	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.73	0.41	1.79e-20	Ovarian reserve;
LGG	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg03970086	chr16:88974840	CBFA2T3	0.44	8.94	0.38	9.42e-18	Social autistic-like traits;
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg07120314	chr15:79043507	NA	-0.73	-17.19	-0.62	1.41e-51	Coronary artery disease or large artery stroke;
LGG	cis	rs9583531	0.660	rs34523940	chr13:111350205	C/T	cg24331049	chr13:111365604	ING1	-0.71	-7.26	-0.32	1.67e-12	Coronary artery disease;
LGG	cis	rs7107174	1.000	rs7116611	chr11:78030046	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs2112347	0.502	rs34342	chr5:74934213	A/C	cg19683494	chr5:74908142	NA	-0.57	-7.97	-0.35	1.29e-14	Body mass index (joint analysis main effects and smoking interaction);Waist circumference;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Hip circumference;Body mass index;Body mass index in physically active individuals;Obesity;
LGG	cis	rs4730250	0.707	rs6946931	chr7:106788621	G/T	cg02696742	chr7:106810147	HBP1	-0.77	-10.89	-0.45	9.58e-25	Osteoarthritis;
LGG	cis	rs11785400	0.731	rs4644221	chr8:143736984	C/T	cg10596483	chr8:143751796	JRK	-0.54	-8.62	-0.37	1.05e-16	Schizophrenia;
LGG	cis	rs2836974	0.965	rs9941894	chr21:40634058	C/T	cg11890956	chr21:40555474	PSMG1	1.15	26.93	0.78	8.1e-97	Cognitive function;
LGG	cis	rs34977459	1	rs34977459	chr22:21932653	GA/G	cg05046821	chr22:21984468	YDJC	-0.37	-6.8	-0.3	3.3e-11	Mean corpuscular hemoglobin;
LGG	cis	rs2386661	0.704	rs2386650	chr10:5678058	G/A	cg26603656	chr10:5671107	NA	0.39	7.67	0.34	9.91e-14	Breast cancer;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.28e-12	Prudent dietary pattern;
LGG	cis	rs11690935	0.959	rs10204502	chr2:172588866	C/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11264213	0.901	rs581459	chr1:36375110	C/T	cg27506609	chr1:36549197	TEKT2	0.61	7.54	0.33	2.5e-13	Schizophrenia;
LGG	cis	rs9815354	1.000	rs1716668	chr3:41907850	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.26	0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg00933542	chr6:150070202	PCMT1	0.4	7.19	0.32	2.54e-12	Lung cancer;
LGG	cis	rs139371	0.516	rs139291	chr22:39496199	A/G	cg17972162	chr22:39496387	APOBEC3H	-0.27	-6.86	-0.3	2.23e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs1620921	0.870	rs62436729	chr6:161210806	T/A	cg01280913	chr6:161186852	NA	-0.37	-7.65	-0.33	1.21e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9527	0.590	rs7917650	chr10:104937100	G/C	cg04362960	chr10:104952993	NT5C2	0.57	10.5	0.44	2.84e-23	Arsenic metabolism;
LGG	cis	rs2594989	0.945	rs2594969	chr3:11353399	C/G	cg01796438	chr3:11312864	ATG7	-0.56	-7.8	-0.34	4.2e-14	Circulating chemerin levels;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.9	0.31	1.69e-11	Lung cancer;
LGG	cis	rs1008375	0.864	rs4698196	chr4:17574735	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.12	0.31	4.07e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7590720	0.819	rs6435931	chr2:216892754	C/G	cg12620499	chr2:216877984	MREG	0.83	17.28	0.63	5.33e-52	Alcohol dependence;
LGG	cis	rs36051895	0.530	rs4425810	chr9:5222208	A/G	cg02405213	chr9:5042618	JAK2	-0.67	-12.12	-0.49	1.49e-29	Pediatric autoimmune diseases;
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg16885296	chr6:26284938	NA	0.41	8.92	0.38	1.11e-17	Educational attainment;
LGG	cis	rs4689388	0.926	rs9998835	chr4:6293237	C/G	cg25554036	chr4:6271136	WFS1	0.62	11.61	0.47	1.64e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs796364	0.806	rs56216998	chr2:200944333	G/T	cg17644776	chr2:200775616	C2orf69	-0.59	-6.78	-0.3	3.63e-11	Schizophrenia;
LGG	cis	rs2549003	1.000	rs2070731	chr5:131819798	T/C	cg00578828	chr5:131826934	IRF1	0.4	7.23	0.32	2.03e-12	Asthma (sex interaction);
LGG	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg10523679	chr1:76189770	ACADM	0.8	13.64	0.54	7.49e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11650494	0.908	rs78208413	chr17:47398282	G/A	cg08112188	chr17:47440006	ZNF652	1.33	15.68	0.59	9.63e-45	Prostate cancer;
LGG	cis	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg00405596	chr8:11794950	NA	0.64	11.14	0.46	1.03e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8141529	0.732	rs5762784	chr22:29171298	C/T	cg02153584	chr22:29168773	CCDC117	0.71	12.25	0.49	4.33e-30	Lymphocyte counts;
LGG	cis	rs2046867	0.862	rs6766747	chr3:72856551	T/C	cg26655873	chr3:72818019	SHQ1	0.36	7.08	0.31	5.26e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6541297	1.000	rs7543050	chr1:230278291	C/G	cg05784532	chr1:230284198	GALNT2	0.51	8.8	0.38	2.7e-17	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs16976116	0.901	rs28499113	chr15:55503621	T/C	cg11288833	chr15:55489084	RSL24D1	0.57	7.64	0.33	1.23e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.61	0.33	1.58e-13	Electroencephalogram traits;
LGG	cis	rs1059312	1.000	rs12814773	chr12:129280786	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.8	-18.0	-0.64	2.57e-55	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg12310025	chr6:25882481	NA	0.43	7.93	0.35	1.62e-14	Height;
LGG	cis	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.85	-0.3	2.3e-11	Mood instability;
LGG	cis	rs35146811	0.696	rs1727124	chr7:99804104	T/G	cg13334819	chr7:99746414	C7orf59	0.45	6.94	0.31	1.34e-11	Coronary artery disease;
LGG	cis	rs35740288	0.770	rs1157519	chr15:86161658	T/G	cg07943548	chr15:86304357	KLHL25	-0.32	-6.66	-0.3	7.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs747782	0.591	rs79476064	chr11:47721312	G/A	cg15704280	chr7:45808275	SEPT13	0.63	6.85	0.3	2.31e-11	Intraocular pressure;
LGG	cis	rs138249	0.867	rs138226	chr22:50556787	A/G	cg18875453	chr22:50517795	MLC1	0.26	6.67	0.3	7.1e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.77	0.38	3.5e-17	Vitiligo;
LGG	cis	rs17428076	0.918	rs55864623	chr2:172748690	A/G	cg21435375	chr2:172878103	MAP1D	0.46	9.63	0.41	4.11e-20	Myopia;
LGG	cis	rs17767392	0.881	rs67489015	chr14:71964521	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.12	-0.39	2.27e-18	Mitral valve prolapse;
LGG	cis	rs5758659	0.716	rs5758661	chr22:42624445	A/C	cg15128208	chr22:42549153	NA	-0.5	-9.99	-0.42	2.15e-21	Cognitive function;
LGG	cis	rs4622507	0.618	rs34202549	chr16:55070391	G/A	cg09947736	chr16:55091198	NA	0.77	11.65	0.48	1.12e-27	Social communication problems;
LGG	trans	rs6828577	0.626	rs17642633	chr4:119412100	A/G	cg26518628	chr1:97050305	NA	-0.51	-8.2	-0.36	2.35e-15	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg00800038	chr16:89945340	TCF25	-0.7	-8.21	-0.36	2.22e-15	Skin colour saturation;
LGG	cis	rs2066819	1.000	rs79101914	chr12:56729739	A/G	cg26714650	chr12:56694279	CS	-1.59	-16.13	-0.6	8.71e-47	Psoriasis vulgaris;
LGG	cis	rs8053891	0.507	rs66553600	chr16:72028198	G/C	cg01557791	chr16:72042693	DHODH	-0.4	-6.69	-0.3	6.64e-11	Coronary artery disease;
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg06969265	chr17:73775802	H3F3B	0.51	6.99	0.31	9.35e-12	Psoriasis;
LGG	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.18	0.32	2.73e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg20363699	chr7:23626180	CLK2P	-0.29	-6.89	-0.31	1.79e-11	Schizophrenia;
LGG	cis	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg18129748	chr3:49941408	MST1R	0.22	6.88	0.3	1.93e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9911578	0.835	rs1990008	chr17:56459408	C/G	cg05425664	chr17:57184151	TRIM37	0.59	9.34	0.4	4.04e-19	Intelligence (multi-trait analysis);
LGG	cis	rs704010	0.647	rs704007	chr10:80842827	G/T	cg17823346	chr10:80848143	ZMIZ1	0.28	6.72	0.3	5.19e-11	Breast cancer;
LGG	cis	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg21775007	chr8:11205619	TDH	-0.77	-13.3	-0.53	2.05e-34	Retinal vascular caliber;
LGG	cis	rs858239	0.570	rs10271613	chr7:23162586	G/A	cg23682824	chr7:23144976	KLHL7	0.44	7.41	0.33	6.06e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg19761014	chr17:28927070	LRRC37B2	0.66	7.77	0.34	5.15e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11971779	0.588	rs6972408	chr7:139071474	T/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9486715	1.000	rs7752277	chr6:97065131	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-9.3	-0.4	5.78e-19	Headache;
LGG	cis	rs908922	0.651	rs564107	chr1:152519295	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.34	0.58	3.23e-43	Hair morphology;
LGG	cis	rs55788414	0.932	rs35326835	chr16:81190413	T/C	cg06400318	chr16:81190750	PKD1L2	-1.14	-12.8	-0.51	2.54e-32	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs870825	0.929	rs10003354	chr4:185589782	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	18.85	0.66	3.22e-59	Blood protein levels;
LGG	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg07005078	chr4:17578674	LAP3	0.38	7.03	0.31	7.66e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9399137	0.507	rs4896128	chr6:135349756	A/G	cg22676075	chr6:135203613	NA	-0.42	-7.43	-0.33	5.34e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs3820928	0.874	rs1917127	chr2:227895125	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.46e-13	Pulmonary function;
LGG	cis	rs6429082	0.818	rs696248	chr1:235668511	C/A	cg26050004	chr1:235667680	B3GALNT2	0.62	10.21	0.43	3.38e-22	Adiposity;
LGG	cis	rs2013441	1.000	rs3850784	chr17:20185030	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.75e-21	Schizophrenia;
LGG	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg04568710	chr12:38710424	ALG10B	0.33	6.98	0.31	1e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9644630	0.696	rs7828025	chr8:19314693	A/G	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.81	-0.41	9.03e-21	Oropharynx cancer;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.08	-0.52	1.78e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg02466173	chr16:30829666	NA	-0.63	-12.63	-0.51	1.27e-31	Dementia with Lewy bodies;
LGG	trans	rs2562456	0.793	rs11672341	chr19:21507304	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	cis	rs741702	0.928	rs1010222	chr19:13048608	A/G	cg11738485	chr19:12877000	HOOK2	0.46	7.28	0.32	1.46e-12	Red blood cell traits;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg02951883	chr7:2050386	MAD1L1	0.71	14.16	0.55	4.34e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs1348850	0.574	rs11691740	chr2:178445161	A/G	cg23306229	chr2:178417860	TTC30B	-0.6	-7.55	-0.33	2.29e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6088590	0.561	rs6088528	chr20:33156742	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.64	0.41	3.62e-20	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg05941027	chr17:61774174	LIMD2	0.37	9.48	0.4	1.29e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2271404	0.506	rs10197366	chr2:111996785	C/T	cg23466623	chr2:111982296	NA	-0.35	-6.69	-0.3	6.41e-11	Atopic dermatitis;
LGG	cis	rs4851266	0.966	rs10496345	chr2:100817619	T/G	cg21926883	chr2:100939477	LONRF2	-0.43	-7.67	-0.34	1.03e-13	Educational attainment;
LGG	cis	rs6502050	0.835	rs12938965	chr17:80128646	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs2652834	0.904	rs2937859	chr15:63366282	C/T	cg05507819	chr15:63340323	TPM1	0.62	8.36	0.36	7.27e-16	HDL cholesterol;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg13206674	chr6:150067644	NUP43	0.61	13.35	0.53	1.27e-34	Lung cancer;
LGG	cis	rs2730245	1.000	rs2252502	chr7:158738634	G/C	cg23730037	chr7:158596552	ESYT2	0.39	6.77	0.3	3.92e-11	Height;
LGG	cis	rs9926296	0.586	rs1800359	chr16:89805261	A/G	cg26513180	chr16:89883248	FANCA	0.59	10.4	0.44	6.38e-23	Vitiligo;
LGG	cis	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg16141378	chr3:129829833	LOC729375	-0.48	-12.23	-0.49	5.49e-30	Mood instability;
LGG	cis	rs9398803	0.965	rs17754780	chr6:126664333	C/T	cg19875578	chr6:126661172	C6orf173	0.57	10.32	0.43	1.35e-22	Male-pattern baldness;
LGG	cis	rs34172651	0.583	rs200541	chr16:24733141	A/G	cg00339695	chr16:24857497	SLC5A11	-0.4	-6.77	-0.3	3.85e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg15268244	chr15:77196840	NA	0.47	10.14	0.43	5.72e-22	Blood metabolite levels;
LGG	cis	rs4664304	0.966	rs1397707	chr2:160760972	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.22	-0.32	2.19e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs55633855	0.516	rs72970468	chr11:88151729	G/A	cg08522340	chr11:88068493	CTSC	-0.4	-7.16	-0.32	3.15e-12	Body mass index;
LGG	cis	rs58688157	0.960	rs1051390	chr11:613165	G/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.01e-19	Systemic lupus erythematosus;
LGG	cis	rs2832077	1.000	rs12329875	chr21:30137796	C/T	cg24692254	chr21:30365293	RNF160	-0.56	-8.37	-0.36	6.88e-16	Cognitive test performance;
LGG	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.74	0.61	1.65e-49	Anterior chamber depth;
LGG	cis	rs7617480	0.648	rs6796790	chr3:48780317	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	7.07	0.31	5.6e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs7833790	0.777	rs10958042	chr8:82678393	G/T	cg23324259	chr8:82754387	SNX16	-0.43	-6.88	-0.3	1.97e-11	Diastolic blood pressure;
LGG	cis	rs10479542	0.929	rs7718673	chr5:178980009	C/T	cg09060608	chr5:178986726	RUFY1	-0.5	-8.82	-0.38	2.42e-17	Lung cancer;
LGG	cis	rs9457247	1.000	rs2769352	chr6:167378619	A/G	cg07741184	chr6:167504864	NA	-0.32	-7.12	-0.31	4.24e-12	Crohn's disease;
LGG	cis	rs12949688	0.967	rs12451753	chr17:55822214	T/A	cg12582317	chr17:55822272	NA	0.69	20.05	0.68	7.8e-65	Schizophrenia;
LGG	cis	rs7529073	0.545	rs340884	chr1:214145389	T/C	cg05052969	chr1:214156842	NA	-0.53	-10.48	-0.44	3.45e-23	Schizophrenia;
LGG	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.47	0.65	1.81e-57	Platelet count;
LGG	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.21	-0.39	1.11e-18	Blood metabolite levels;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg00684032	chr4:1343700	KIAA1530	0.5	9.94	0.42	3.07e-21	Obesity-related traits;
LGG	trans	rs73198271	0.722	rs488566	chr8:8639575	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.79	0.3	3.54e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7582180	0.715	rs920270	chr2:100917961	T/C	cg14675211	chr2:100938903	LONRF2	0.64	11.2	0.46	6.09e-26	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.817	rs239216	chr6:101147892	T/G	cg09795085	chr6:101329169	ASCC3	0.45	7.64	0.33	1.27e-13	Neuroticism;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.601	rs4140584	chr6:8540614	C/G	cg23788917	chr6:8435910	SLC35B3	-0.53	-9.09	-0.39	3.01e-18	Motion sickness;
LGG	cis	rs10504229	0.775	rs17805110	chr8:58161439	C/G	cg14926445	chr8:58193284	C8orf71	0.86	11.44	0.47	7.25e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.47	0.33	3.9e-13	Menopause (age at onset);
LGG	cis	rs4950322	0.570	rs4301678	chr1:146733564	C/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg22551357	chr5:81046408	SSBP2	-0.42	-7.08	-0.31	5.24e-12	Brain structure;
LGG	cis	rs10865397	0.506	rs60764301	chr2:73384850	G/A	cg20246863	chr2:73402720	NA	-0.27	-6.87	-0.3	2.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.87e-17	Lung cancer;
LGG	cis	rs8032158	0.702	rs11630780	chr15:56128445	G/T	cg05129572	chr15:56138634	NEDD4	0.38	6.74	0.3	4.65e-11	Keloid;
LGG	cis	rs12155623	0.504	rs10808736	chr8:49873039	C/A	cg22283653	chr8:49824208	NA	0.62	11.93	0.48	8.33e-29	Sudden cardiac arrest;
LGG	cis	rs7582720	0.943	rs72928610	chr2:203838961	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6456156	0.774	rs9347175	chr6:167527644	A/T	cg07741184	chr6:167504864	NA	-0.31	-7.05	-0.31	6.35e-12	Primary biliary cholangitis;
LGG	trans	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.42	-0.36	4.6e-16	Retinal vascular caliber;
LGG	cis	rs7572733	0.935	rs1369511	chr2:198746115	G/C	cg00792783	chr2:198669748	PLCL1	0.49	8.43	0.36	4.58e-16	Dermatomyositis;
LGG	cis	rs638893	1.000	rs28827279	chr11:118700763	T/C	cg22253036	chr11:118662786	DDX6	0.43	7.31	0.32	1.19e-12	Vitiligo;
LGG	cis	rs67478160	0.643	rs2887282	chr14:104280734	A/G	cg26031613	chr14:104095156	KLC1	-0.46	-7.5	-0.33	3.32e-13	Schizophrenia;
LGG	cis	rs2119480	0.701	rs1193458	chr13:111302922	T/C	cg16216153	chr13:111290848	CARKD	-0.35	-6.81	-0.3	3e-11	Diastolic blood pressure;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.81	-0.3	3.06e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.659	rs12948133	chr17:56673602	T/C	cg25039879	chr17:56429692	SUPT4H1	0.65	9.17	0.39	1.51e-18	Cognitive test performance;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg02985366	chr16:32360428	NA	-0.44	-6.79	-0.3	3.4e-11	Menopause (age at onset);
LGG	cis	rs950169	0.580	rs62021208	chr15:85196244	G/A	cg03959625	chr15:84868606	LOC388152	0.48	7.13	0.31	3.77e-12	Schizophrenia;
LGG	cis	rs13314892	0.728	rs62252233	chr3:69890439	A/G	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg01028140	chr2:1542097	TPO	-0.52	-8.23	-0.36	1.9e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.39	0.32	6.72e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12824058	0.831	rs4759451	chr12:130812739	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg21605333	chr4:119757512	SEC24D	1.39	12.82	0.51	2.04e-32	Cannabis dependence symptom count;
LGG	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg08847533	chr14:75593920	NEK9	-0.54	-10.24	-0.43	2.47e-22	Height;
LGG	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs7937682	0.889	rs1784785	chr11:111483306	A/G	cg08305652	chr11:111469057	NA	-0.44	-9.05	-0.39	4.12e-18	Primary sclerosing cholangitis;
LGG	cis	rs78487399	0.808	rs17030800	chr2:43671003	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs1580019	0.961	rs4255041	chr7:32496383	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs7566780	0.661	rs3934617	chr2:16703448	T/C	cg09580478	chr2:16689509	NA	0.45	6.86	0.3	2.15e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs1865760	0.566	rs2794720	chr6:26087202	G/C	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.61	0.33	1.58e-13	Retinal vascular caliber;
LGG	cis	rs4561483	0.583	rs1019813	chr16:11940829	C/T	cg08843971	chr16:11963173	GSPT1	0.54	12.91	0.51	8.56e-33	Testicular germ cell tumor;
LGG	cis	rs17376456	1.000	rs59472588	chr5:93511981	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.97	10.62	0.44	1e-23	Diabetic retinopathy;
LGG	cis	rs6089584	0.566	rs12373885	chr20:60556393	A/C	cg06470251	chr20:60548479	NA	0.47	8.29	0.36	1.21e-15	Body mass index;
LGG	cis	rs10504229	0.906	rs114810777	chr8:58185298	A/G	cg02725872	chr8:58115012	NA	-0.76	-10.82	-0.45	1.82e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg01017244	chr2:74357527	NA	0.48	8.23	0.36	1.93e-15	Gestational age at birth (maternal effect);
LGG	cis	rs9810089	0.814	rs864437	chr3:136119909	C/G	cg21827317	chr3:136751795	NA	0.45	7.9	0.34	2.06e-14	Gestational age at birth (child effect);
LGG	cis	rs34638952	0.577	rs8076604	chr17:27438469	G/A	cg13672501	chr17:27410685	MYO18A	-0.4	-7.2	-0.32	2.52e-12	Sitting height ratio;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg06873352	chr17:61820015	STRADA	-0.74	-14.01	-0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs3740909	1.000	rs74975990	chr11:125884728	A/C	cg24940576	chr11:125904314	CDON	-0.48	-7.53	-0.33	2.63e-13	Blood protein levels;
LGG	cis	rs7953508	0.506	rs10777530	chr12:93961110	C/T	cg18151635	chr12:93972918	NA	-0.57	-10.8	-0.45	2.1e-24	Pubertal anthropometrics;
LGG	cis	rs28595532	0.920	rs115046587	chr4:119779604	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg01059449	chr18:44338099	ST8SIA5	0.36	7.6	0.33	1.7e-13	Personality dimensions;
LGG	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg11494091	chr17:61959527	GH2	0.59	10.02	0.42	1.65e-21	Height;
LGG	cis	rs9616064	0.506	rs737135	chr22:47061791	C/T	cg25730555	chr22:47059586	GRAMD4	0.48	8.72	0.38	5.08e-17	Urate levels in obese individuals;
LGG	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg15736062	chr7:158136485	PTPRN2	-0.39	-7.54	-0.33	2.49e-13	Calcium levels;
LGG	cis	rs367943	0.634	rs6891281	chr5:112960014	G/A	cg12552261	chr5:112820674	MCC	0.51	8.91	0.38	1.21e-17	Type 2 diabetes;
LGG	cis	rs10504229	0.610	rs6993531	chr8:58147283	A/G	cg23782820	chr8:58130467	NA	0.51	7.81	0.34	3.85e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg22437258	chr11:111473054	SIK2	0.56	9.8	0.41	9.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg08885076	chr2:99613938	TSGA10	-0.51	-10.64	-0.44	8.78e-24	Chronic sinus infection;
LGG	cis	rs9467711	0.591	rs13207673	chr6:25901133	C/T	cg21479132	chr6:26055353	NA	0.84	7.56	0.33	2.24e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11677416	1.000	rs59674541	chr2:113553824	A/T	cg27083787	chr2:113543245	IL1A	0.51	8.53	0.37	2.13e-16	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg02002194	chr4:3960332	NA	-0.4	-7.05	-0.31	6.46e-12	Retinal vascular caliber;
LGG	cis	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.19	-0.32	2.54e-12	Mood instability;
LGG	cis	rs3820928	0.605	rs2228555	chr2:227872995	C/T	cg11843606	chr2:227700838	RHBDD1	0.56	10.35	0.43	1.05e-22	Pulmonary function;
LGG	trans	rs853679	0.546	rs13214023	chr6:28332141	A/G	cg08344181	chr3:125677491	NA	0.71	7.95	0.35	1.39e-14	Depression;
LGG	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg15556689	chr8:8085844	FLJ10661	0.41	7.02	0.31	7.84e-12	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg04287289	chr16:89883240	FANCA	0.76	7.67	0.34	1.04e-13	Skin colour saturation;
LGG	cis	rs9921222	0.521	rs62032884	chr16:363415	C/T	cg26944245	chr16:421049	TMEM8A;MRPL28	0.43	6.87	0.3	2.04e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs3742264	0.656	rs1409436	chr13:46614650	T/C	cg15192986	chr13:46630673	CPB2	-0.38	-7.26	-0.32	1.6e-12	Blood protein levels;
LGG	cis	rs4478037	0.822	rs4441606	chr3:33146365	G/A	cg19404215	chr3:33155277	CRTAP	1.01	11.41	0.47	9.2e-27	Major depressive disorder;
LGG	cis	rs9398803	0.687	rs6911485	chr6:126975115	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.7	0.41	2.27e-20	Male-pattern baldness;
LGG	cis	rs6693567	0.565	rs3754214	chr1:150478623	T/C	cg15654264	chr1:150340011	RPRD2	0.33	6.7	0.3	6.07e-11	Migraine;
LGG	cis	rs854037	0.595	rs34511346	chr5:57173603	T/C	cg08523694	chr5:57076192	NA	0.51	6.8	0.3	3.24e-11	Birth weight;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.03	-0.6	2.48e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7833790	0.963	rs2400473	chr8:82703403	C/T	cg23324259	chr8:82754387	SNX16	-0.47	-7.69	-0.34	8.91e-14	Diastolic blood pressure;
LGG	cis	rs1620921	0.563	rs28488549	chr6:161266035	A/G	cg01280913	chr6:161186852	NA	-0.37	-7.44	-0.33	5.01e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1552244	0.748	rs113890152	chr3:10085986	A/G	cg13047869	chr3:10149882	C3orf24	0.54	9.11	0.39	2.47e-18	Alzheimer's disease;
LGG	cis	rs2201728	0.702	rs13117459	chr4:100178092	T/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg12935359	chr14:103987150	CKB	0.4	6.67	0.3	7.33e-11	Body mass index;
LGG	cis	rs1577917	0.793	rs9362245	chr6:86496320	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-10.74	-0.45	3.51e-24	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.19	-0.32	2.61e-12	Lung cancer;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14893161	chr1:205819251	PM20D1	0.88	20.55	0.69	3.55e-67	Menarche (age at onset);
LGG	cis	rs11252926	0.562	rs11252792	chr10:544369	G/A	cg08603382	chr10:743973	NA	-0.4	-7.43	-0.33	5.35e-13	Psychosis in Alzheimer's disease;
LGG	trans	rs11650494	0.706	rs76778410	chr17:47459877	A/T	cg11430096	chr6:110968061	CDK19	0.7	7.13	0.31	3.95e-12	Prostate cancer;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg22535103	chr8:58192502	C8orf71	-0.76	-10.41	-0.44	6.09e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	0.544	rs9864601	chr3:40345318	C/T	cg13683864	chr3:40499215	RPL14	-0.82	-16.33	-0.6	1.16e-47	Renal cell carcinoma;
LGG	cis	rs7107174	1.000	rs2510039	chr11:77944480	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.12e-13	Testicular germ cell tumor;
LGG	cis	rs1003719	0.715	rs2835653	chr21:38558636	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.08	-0.57	4.13e-42	Eye color traits;
LGG	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.61	-0.51	1.46e-31	Cognitive function;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07157834	chr1:205819609	PM20D1	0.73	16.44	0.61	3.74e-48	Menarche (age at onset);
LGG	cis	rs12142240	0.698	rs17361791	chr1:46812519	A/G	cg14993813	chr1:46806288	NSUN4	-0.55	-9.12	-0.39	2.39e-18	Menopause (age at onset);
LGG	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg04568710	chr12:38710424	ALG10B	0.35	7.22	0.32	2.21e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs703842	1.000	rs703842	chr12:58162739	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	-0.46	-7.46	-0.33	4.2e-13	Multiple sclerosis;
LGG	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.694	rs7285041	chr22:41829149	G/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.01	-0.39	5.47e-18	Vitiligo;
LGG	cis	rs72781680	0.716	rs72788206	chr2:24084989	T/C	cg08917208	chr2:24149416	ATAD2B	0.65	8.61	0.37	1.13e-16	Lymphocyte counts;
LGG	cis	rs6088580	0.668	rs1205340	chr20:32923871	G/A	cg08999081	chr20:33150536	PIGU	-0.39	-9.71	-0.41	2e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs60695258	0.550	rs4693798	chr4:87914288	G/C	cg01323104	chr4:87958903	AFF1	-0.24	-6.76	-0.3	4.26e-11	Hematocrit;
LGG	cis	rs7264396	0.635	rs6060710	chr20:34536055	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.75	0.34	5.9e-14	Total cholesterol levels;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.31	0.32	1.18e-12	Menopause (age at onset);
LGG	trans	rs7824557	0.614	rs17741537	chr8:11213092	A/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.67	0.34	1.01e-13	Retinal vascular caliber;
LGG	trans	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg25214090	chr10:38739885	LOC399744	0.68	12.02	0.49	3.89e-29	Corneal astigmatism;
LGG	cis	rs735860	0.712	rs6909592	chr6:53163090	C/G	cg10236188	chr6:53219634	NA	0.41	7.98	0.35	1.17e-14	Glaucoma;
LGG	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg20040747	chr15:74715105	SEMA7A	0.39	7.48	0.33	3.78e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs17221829	1.000	rs17221829	chr11:89466732	A/C	cg02982614	chr11:89391479	FOLH1B	0.33	7.11	0.31	4.56e-12	Anxiety in major depressive disorder;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.74	0.41	1.58e-20	Prudent dietary pattern;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg04166393	chr7:2884313	GNA12	0.46	9.24	0.39	9.13e-19	Height;
LGG	cis	rs60180747	0.909	rs78921612	chr15:66826037	G/A	cg07575407	chr15:66541975	MEGF11	0.37	6.91	0.31	1.61e-11	Testicular germ cell tumor;
LGG	cis	rs11966931	0.711	rs1518525	chr6:108110126	G/T	cg04749840	chr6:108095067	SCML4	0.46	9.19	0.39	1.28e-18	Neutrophil percentage of white cells;
LGG	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.86	-0.3	2.16e-11	Neuroticism;
LGG	trans	rs61931739	0.517	rs1843735	chr12:34047389	C/G	cg13010199	chr12:38710504	ALG10B	0.51	9.94	0.42	3.08e-21	Morning vs. evening chronotype;
LGG	trans	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.53	0.33	2.64e-13	Mood instability;
LGG	cis	rs11785400	0.762	rs2280880	chr8:143721929	C/A	cg10596483	chr8:143751796	JRK	0.5	7.62	0.33	1.47e-13	Schizophrenia;
LGG	cis	rs3785574	0.962	rs2727331	chr17:61926990	G/T	cg06873352	chr17:61820015	STRADA	0.48	7.4	0.33	6.61e-13	Height;
LGG	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg05692746	chr2:100937584	LONRF2	-0.64	-11.61	-0.47	1.65e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs6840360	0.533	rs13121190	chr4:152729072	T/G	cg22705602	chr4:152727874	NA	0.34	8.34	0.36	8.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11586313	0.649	rs61815701	chr1:152887412	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-7.97	-0.35	1.28e-14	Vitamin D levels;
LGG	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg04568710	chr12:38710424	ALG10B	0.4	8.37	0.36	6.78e-16	Morning vs. evening chronotype;
LGG	cis	rs72717009	0.778	rs9427400	chr1:161477204	C/T	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs2795502	1.000	rs2795497	chr10:43339475	C/A	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs952623	0.649	rs13242896	chr7:39070062	A/G	cg18850127	chr7:39170497	POU6F2	0.35	8.14	0.35	3.59e-15	Intelligence (multi-trait analysis);
LGG	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg00383909	chr3:49044727	WDR6	0.57	8.11	0.35	4.46e-15	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LGG	cis	rs16866061	1.000	rs11694987	chr2:225397409	C/G	cg12698349	chr2:225449008	CUL3	0.9	18.03	0.64	1.87e-55	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs4481887	0.927	rs4537599	chr1:248508741	G/A	cg13385794	chr1:248469461	NA	0.5	8.2	0.36	2.39e-15	Common traits (Other);
LGG	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg02153584	chr22:29168773	CCDC117	0.7	11.77	0.48	3.72e-28	Lymphocyte counts;
LGG	cis	rs4665809	0.590	rs35656275	chr2:26494695	G/C	cg08470875	chr2:26401718	FAM59B	0.42	8.05	0.35	6.9e-15	Gut microbiome composition (summer);
LGG	cis	rs977987	0.736	rs4888392	chr16:75412262	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.75	0.3	4.32e-11	Dupuytren's disease;
LGG	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg11477892	chr4:106580295	NA	-0.41	-6.93	-0.31	1.38e-11	Post bronchodilator FEV1;
LGG	trans	rs7829975	0.582	rs448231	chr8:8790059	A/T	cg16141378	chr3:129829833	LOC729375	0.3	6.67	0.3	7.44e-11	Mood instability;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg16680214	chr1:154839983	KCNN3	-0.47	-9.47	-0.4	1.44e-19	Prostate cancer;
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg07005078	chr4:17578674	LAP3	0.39	7.08	0.31	5.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7824557	0.606	rs1435277	chr8:11196970	C/T	cg21775007	chr8:11205619	TDH	0.81	14.85	0.57	4.3e-41	Retinal vascular caliber;
LGG	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg19077165	chr18:44547161	KATNAL2	-0.54	-9.36	-0.4	3.42e-19	Educational attainment;
LGG	trans	rs1499614	1.000	rs60326618	chr7:66166358	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs1941023	0.503	rs4528348	chr11:60129505	C/G	cg08716584	chr11:60157161	MS4A7	-0.41	-8.18	-0.36	2.82e-15	Congenital heart disease (maternal effect);
LGG	trans	rs208520	0.779	rs208451	chr6:66906155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-14.32	-0.55	8.83e-39	Exhaled nitric oxide output;
LGG	cis	rs7737355	0.812	rs10078640	chr5:131071246	C/G	cg06307176	chr5:131281290	NA	0.53	8.73	0.38	4.51e-17	Life satisfaction;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.79	-0.34	4.45e-14	Life satisfaction;
LGG	cis	rs61990749	0.544	rs176979	chr14:78198072	A/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs1865760	0.865	rs9393677	chr6:25945815	G/A	cg03517284	chr6:25882590	NA	-0.38	-6.85	-0.3	2.34e-11	Height;
LGG	cis	rs4330281	0.608	rs2470580	chr3:17367746	T/C	cg20981856	chr3:17787350	NA	0.36	6.91	0.31	1.59e-11	Schizophrenia;
LGG	cis	rs17767392	0.632	rs4902917	chr14:71656692	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.19	-0.32	2.7e-12	Mitral valve prolapse;
LGG	cis	rs7255436	0.965	rs62117510	chr19:8452613	T/G	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.68	-0.3	6.78e-11	HDL cholesterol;
LGG	trans	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.03	-0.39	4.82e-18	Bladder cancer;
LGG	cis	rs1620921	0.505	rs4708881	chr6:161203159	C/T	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg11062466	chr8:58055876	NA	0.54	8.76	0.38	3.66e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg23752985	chr2:85803571	VAMP8	0.4	7.74	0.34	6.4e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6568686	0.786	rs2146459	chr6:111815963	T/C	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg14101638	chr12:121416612	HNF1A	0.35	7.47	0.33	4.12e-13	N-glycan levels;
LGG	trans	rs7618501	1.000	rs7431106	chr3:49808374	G/A	cg21582582	chr3:182698605	DCUN1D1	0.52	9.64	0.41	3.56e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs17376456	0.825	rs10051878	chr5:93064164	T/G	cg19507638	chr5:93509721	C5orf36	-0.65	-9.1	-0.39	2.6e-18	Diabetic retinopathy;
LGG	cis	rs10267417	0.535	rs6960579	chr7:19869364	A/G	cg05791153	chr7:19748676	TWISTNB	0.62	7.99	0.35	1.12e-14	Night sleep phenotypes;
LGG	cis	rs3747547	0.818	rs16934640	chr9:37943164	C/T	cg13774184	chr9:37916125	SHB	-0.73	-8.24	-0.36	1.74e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7107174	0.892	rs11237477	chr11:78095069	A/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.25	-0.32	1.81e-12	Testicular germ cell tumor;
LGG	cis	rs801193	0.569	rs2013908	chr7:66121069	A/T	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs12579753	0.692	rs7397373	chr12:82300010	C/A	cg07988820	chr12:82153109	PPFIA2	-0.5	-7.3	-0.32	1.29e-12	Resting heart rate;
LGG	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg07636037	chr3:49044803	WDR6	0.9	15.85	0.59	1.71e-45	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs875971	0.862	rs2420611	chr7:65999320	A/G	cg23594656	chr7:65796392	TPST1	-0.42	-9.26	-0.4	7.64e-19	Aortic root size;
LGG	cis	rs490234	0.676	rs4838263	chr9:128225199	G/A	cg14078157	chr9:128172775	NA	-0.53	-10.01	-0.42	1.7e-21	Mean arterial pressure;
LGG	cis	rs2268241	0.938	rs9978223	chr21:34770358	G/A	cg14850771	chr21:34775459	IFNGR2	0.82	10.08	0.42	9.89e-22	Obesity-related traits;
LGG	cis	rs4242434	0.927	rs13271626	chr8:22467760	C/G	cg00599393	chr8:22457479	C8orf58	-0.47	-8.71	-0.38	5.55e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs752010	0.902	rs60743712	chr1:42076629	G/A	cg06885757	chr1:42089581	HIVEP3	0.59	13.87	0.54	7.8e-37	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9880211	0.800	rs115050567	chr3:136515659	G/C	cg21827317	chr3:136751795	NA	-0.49	-7.13	-0.31	3.79e-12	Body mass index;Height;
LGG	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg25664220	chr3:72788482	NA	-0.32	-9.05	-0.39	3.91e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10191773	0.535	rs56048537	chr2:113078467	G/T	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-9.35	-0.4	3.61e-19	Yeast infection;
LGG	trans	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg02002194	chr4:3960332	NA	0.44	6.98	0.31	9.97e-12	Cervical cancer;
LGG	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.62e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg16141378	chr3:129829833	LOC729375	-0.41	-9.86	-0.42	6.08e-21	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs13191362	1.000	rs13193282	chr6:163015442	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.1	0.35	4.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.44	4.55e-23	Bipolar disorder;
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.44e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7538876	0.935	rs6586542	chr1:17763566	C/G	cg10329579	chr1:17754830	RCC2	0.54	11.02	0.46	3.03e-25	Basal cell carcinoma;
LGG	cis	rs644799	1.000	rs516551	chr11:95588626	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.8	0.34	4.08e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg14893161	chr1:205819251	PM20D1	0.95	24.19	0.75	3.48e-84	Menarche (age at onset);
LGG	cis	rs4242434	0.889	rs4592028	chr8:22449484	T/C	cg02227867	chr8:22457446	C8orf58	-0.43	-8.14	-0.35	3.72e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11650494	0.710	rs8066722	chr17:47475007	A/G	cg08112188	chr17:47440006	ZNF652	-1.07	-12.12	-0.49	1.53e-29	Prostate cancer;
LGG	cis	rs4950322	0.570	rs17356240	chr1:146741537	G/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs9517320	0.534	rs4772088	chr13:99138270	T/G	cg07423050	chr13:99094983	FARP1	-0.56	-10.84	-0.45	1.46e-24	Longevity;
LGG	cis	rs2018055	0.618	rs36045731	chr6:117791163	A/C	cg14611402	chr6:117803162	DCBLD1	0.3	8.91	0.38	1.19e-17	Diastolic blood pressure;
LGG	cis	rs1729951	0.575	rs16844362	chr3:136704008	T/C	cg12473912	chr3:136751656	NA	0.43	7.57	0.33	2e-13	Neuroticism;
LGG	cis	rs67311347	0.544	rs6804545	chr3:40354040	G/C	cg13683864	chr3:40499215	RPL14	-0.79	-15.18	-0.58	1.51e-42	Renal cell carcinoma;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	trans	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg25214090	chr10:38739885	LOC399744	0.63	11.45	0.47	6.6e-27	Corneal astigmatism;
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg01765077	chr12:122356316	WDR66	0.28	7.73	0.34	6.67e-14	Mean corpuscular volume;
LGG	cis	rs12291225	0.585	rs10832242	chr11:14340504	C/T	cg19336497	chr11:14380999	RRAS2	0.63	13.67	0.54	5.87e-36	Sense of smell;
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg10852096	chr15:79043040	NA	0.3	7.56	0.33	2.12e-13	Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs7103648	0.695	rs7933019	chr11:47509137	G/C	cg20307385	chr11:47447363	PSMC3	0.87	18.7	0.66	1.59e-58	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg26668828	chr6:292823	DUSP22	-0.7	-12.22	-0.49	6.13e-30	Menopause (age at onset);
LGG	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.09	-0.46	1.63e-25	Mean platelet volume;
LGG	cis	rs2229238	0.868	rs72999422	chr1:154514942	G/A	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.06	-0.39	3.72e-18	Response to antipsychotic treatment;
LGG	cis	rs7107174	1.000	rs1567890	chr11:78101700	T/C	cg02023728	chr11:77925099	USP35	0.45	7.78	0.34	4.84e-14	Testicular germ cell tumor;
LGG	cis	rs9322193	0.962	rs12175575	chr6:150084487	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs8078723	1.000	rs4795416	chr17:38158133	C/T	cg17467752	chr17:38218738	THRA	0.74	13.9	0.54	6.07e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.74	-0.3	4.68e-11	Height;
LGG	cis	rs1348850	0.574	rs10195917	chr2:178443121	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-7.18	-0.32	2.74e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg23202291	chr11:1979235	NA	-0.38	-7.3	-0.32	1.23e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs12048904	0.533	rs1590580	chr1:101292668	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.52	9.75	0.41	1.49e-20	Multiple sclerosis;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08677398	chr8:58056175	NA	0.58	8.85	0.38	1.86e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.96	-0.38	8.28e-18	Aortic root size;
LGG	cis	rs13191362	1.000	rs67747005	chr6:163150845	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	11.1	0.46	1.48e-25	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg02030672	chr11:45687055	CHST1	0.5	8.88	0.38	1.51e-17	Obesity-related traits;
LGG	cis	rs875971	0.577	rs34888281	chr7:65585771	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.35	-0.43	1.02e-22	Aortic root size;
LGG	cis	rs10927875	0.632	rs10927864	chr1:16165661	C/G	cg07117364	chr1:16154769	NA	-0.48	-9.15	-0.39	1.81e-18	Dilated cardiomyopathy;
LGG	trans	rs7980799	0.682	rs1447873	chr12:33615236	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.09	-0.35	5.35e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01532694	chr8:8243576	NA	-0.49	-7.08	-0.31	5.53e-12	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13713052	chr3:122102218	FAM162A;CCDC58	0.5	8.4	0.36	5.46e-16	Gut microbiome composition (summer);
LGG	cis	rs28374715	0.532	rs11854820	chr15:41676526	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.03e-133	Ulcerative colitis;
LGG	trans	rs11098499	0.954	rs10017543	chr4:120321420	G/A	cg25214090	chr10:38739885	LOC399744	0.72	12.63	0.51	1.2e-31	Corneal astigmatism;
LGG	cis	rs8141529	0.529	rs2267131	chr22:29190471	T/C	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.32e-12	Lymphocyte counts;
LGG	cis	rs952623	0.501	rs12670003	chr7:39083653	G/A	cg10621924	chr7:39171070	POU6F2	0.33	6.9	0.31	1.74e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7264396	0.790	rs1040695	chr20:34244829	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.18	0.32	2.87e-12	Total cholesterol levels;
LGG	cis	rs2576037	0.526	rs607780	chr18:44417456	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.67e-11	Personality dimensions;
LGG	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg22681709	chr2:178499509	PDE11A	0.52	7.71	0.34	7.51e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg18350739	chr11:68623251	NA	-0.83	-20.83	-0.7	1.72e-68	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg27189623	chr16:705930	WDR90	0.4	7.69	0.34	8.72e-14	Height;
LGG	trans	rs1814175	0.616	rs4881723	chr11:49788566	G/T	cg03929089	chr4:120376271	NA	-0.95	-19.94	-0.68	2.55e-64	Height;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg06656553	chr16:89960601	TCF25	-0.61	-6.83	-0.3	2.72e-11	Skin colour saturation;
LGG	cis	rs17253792	0.822	rs76819679	chr14:56134672	C/G	cg01858014	chr14:56050164	KTN1	-0.89	-12.05	-0.49	2.94e-29	Putamen volume;
LGG	cis	rs1577917	1.000	rs35797755	chr6:86706554	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.29	-0.53	2.3e-34	Response to antipsychotic treatment;
LGG	cis	rs17321999	1.000	rs4952115	chr2:30478386	G/T	cg05247661	chr2:30472410	LBH	0.55	8.96	0.38	8.26e-18	Systemic lupus erythematosus;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg07120314	chr15:79043507	NA	0.69	14.59	0.56	6.25e-40	Coronary artery disease or large artery stroke;
LGG	trans	rs4843747	0.671	rs4075598	chr16:88107512	T/C	cg26811252	chr16:29126840	RRN3P2	0.67	10.26	0.43	2.19e-22	Menopause (age at onset);
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.82	-0.34	3.73e-14	Neuroticism;
LGG	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg05874882	chr4:1763078	NA	-0.48	-6.83	-0.3	2.69e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs7166081	1.000	rs9806377	chr15:67612062	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.8	-0.3	3.28e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1783925	1.000	rs1615640	chr11:125308076	C/G	cg03464685	chr11:125439445	EI24	0.6	9.69	0.41	2.45e-20	Formal thought disorder in schizophrenia;
LGG	cis	rs9814567	1.000	rs9289478	chr3:134268619	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.39	-0.53	8.69e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4919087	0.715	rs793524	chr10:99024572	A/G	cg25902810	chr10:99078978	FRAT1	-0.44	-7.49	-0.33	3.42e-13	Monocyte count;
LGG	cis	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg02503808	chr4:7069936	GRPEL1	-0.83	-11.76	-0.48	4.01e-28	Monocyte percentage of white cells;
LGG	cis	rs2688419	0.588	rs55652823	chr3:23087440	T/A	cg00327796	chr3:23032191	NA	-0.41	-7.56	-0.33	2.22e-13	Type 2 diabetes;
LGG	cis	rs2650000	0.798	rs2701175	chr12:121391671	C/A	cg02403541	chr12:121454288	C12orf43	-0.55	-9.01	-0.39	5.38e-18	Metabolic traits;LDL cholesterol;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11074306	0.561	rs28562254	chr15:28068226	A/G	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs9783347	0.961	rs4150653	chr11:18374782	G/A	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.37	-0.32	7.79e-13	Pancreatic cancer;
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6466055	0.739	rs6943183	chr7:104819479	T/C	cg04380332	chr7:105027541	SRPK2	-0.38	-7.15	-0.32	3.42e-12	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	0.47	7.77	0.34	5.27e-14	Cognitive performance;
LGG	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg11965913	chr1:205819406	PM20D1	-0.41	-6.89	-0.31	1.78e-11	Menarche (age at onset);
LGG	cis	rs11112613	0.762	rs17037308	chr12:105949847	T/G	cg03607813	chr12:105948248	NA	0.64	11.25	0.46	4.14e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02899788	chr1:47133675	ATPAF1	0.41	7.08	0.31	5.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12210905	0.764	rs72835248	chr6:26931817	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.19	-0.36	2.5e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7937682	0.855	rs11213985	chr11:111581521	C/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.67	-0.41	2.81e-20	Primary sclerosing cholangitis;
LGG	cis	rs6582630	0.533	rs11504406	chr12:38334580	C/T	cg26384229	chr12:38710491	ALG10B	-0.63	-12.13	-0.49	1.33e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4851266	0.898	rs2309812	chr2:100869702	C/T	cg21926883	chr2:100939477	LONRF2	-0.47	-8.5	-0.37	2.62e-16	Educational attainment;
LGG	cis	rs1707322	0.721	rs7519900	chr1:46234947	C/T	cg03146154	chr1:46216737	IPP	0.58	10.58	0.44	1.39e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs13102973	0.682	rs7691622	chr4:135889689	T/C	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs7726839	0.540	rs7434	chr5:660804	A/G	cg14541582	chr5:601475	NA	0.71	11.05	0.46	2.26e-25	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1030877	0.960	rs3792047	chr2:105901553	A/G	cg02079111	chr2:105885981	TGFBRAP1	-0.71	-13.42	-0.53	6.4e-35	Obesity-related traits;
LGG	cis	rs10791097	0.642	rs7107568	chr11:130779668	T/C	cg12179176	chr11:130786555	SNX19	0.96	21.83	0.71	3.84e-73	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2717559	0.522	rs2585159	chr8:143875817	G/A	cg06565975	chr8:143823917	SLURP1	0.29	6.86	0.3	2.26e-11	Urinary tract infection frequency;
LGG	cis	rs6735179	0.607	rs10185594	chr2:1746661	G/A	cg20311673	chr2:1746207	PXDN	-0.39	-6.74	-0.3	4.87e-11	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	cis	rs7107174	1.000	rs7941617	chr11:78021146	C/T	cg02023728	chr11:77925099	USP35	0.45	8.06	0.35	6.42e-15	Testicular germ cell tumor;
LGG	cis	rs2762353	0.935	rs3799340	chr6:25762646	C/T	cg03264133	chr6:25882463	NA	0.54	9.99	0.42	2.04e-21	Blood metabolite levels;
LGG	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg22771759	chr13:24902376	NA	0.43	7.33	0.32	1.05e-12	Obesity-related traits;
LGG	cis	rs57221529	0.709	rs72707024	chr5:667915	G/A	cg14541582	chr5:601475	NA	-0.7	-9.85	-0.42	6.4e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs765787	0.530	rs28733848	chr15:45516047	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs3806843	0.897	rs2531338	chr5:140136957	A/T	cg19875535	chr5:140030758	IK	-0.52	-10.71	-0.45	4.8e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg19077165	chr18:44547161	KATNAL2	0.53	9.64	0.41	3.62e-20	Personality dimensions;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg16507663	chr6:150244633	RAET1G	-0.47	-8.95	-0.38	8.74e-18	Lung cancer;
LGG	trans	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.07	-0.42	1.08e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6714710	0.603	rs717417	chr2:98416850	T/G	cg26665480	chr2:98280029	ACTR1B	0.64	10.35	0.43	9.74e-23	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg00006948	chr4:1768889	NA	-0.49	-6.86	-0.3	2.16e-11	Bladder cancer;Urinary bladder cancer;
LGG	trans	rs877282	0.898	rs12359731	chr10:759497	A/G	cg22713356	chr15:30763199	NA	0.48	7.54	0.33	2.52e-13	Uric acid levels;
LGG	cis	rs6450176	1.000	rs67473746	chr5:53296730	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.4	-0.47	1.02e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs10089	0.953	rs1432615	chr5:127395371	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.44	0.47	7.49e-27	Ileal carcinoids;
LGG	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	10.88	0.45	1.02e-24	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01423368	chr11:76155379	C11orf30	0.44	7.19	0.32	2.53e-12	Gut microbiome composition (summer);
LGG	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg20821713	chr7:1055600	C7orf50	-0.41	-7.95	-0.35	1.48e-14	Longevity;Endometriosis;
LGG	trans	rs9818758	0.607	rs9855123	chr3:49229457	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-6.78	-0.3	3.74e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.72	-0.45	4.39e-24	Bladder cancer;
LGG	cis	rs981844	0.890	rs62325113	chr4:154692555	A/G	cg14289246	chr4:154710475	SFRP2	0.74	12.01	0.49	4.14e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs2721195	1.000	rs2721195	chr8:145677011	T/C	cg17328964	chr8:145687451	CYHR1	0.67	12.83	0.51	1.85e-32	Age at first birth;
LGG	cis	rs4481887	1.000	rs10888356	chr1:248465044	C/T	cg01631408	chr1:248437212	OR2T33	0.53	9.72	0.41	1.87e-20	Common traits (Other);
LGG	cis	rs138249	0.898	rs138227	chr22:50556815	A/G	cg07310406	chr22:50524374	MLC1	0.41	8.14	0.35	3.68e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	trans	rs11039798	0.588	rs6485869	chr11:48576903	G/T	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.9e-22	Axial length;
LGG	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs7465272	0.530	rs10103161	chr8:143738571	A/G	cg24634471	chr8:143751801	JRK	0.5	7.79	0.34	4.31e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs10896135	0.526	rs484262	chr11:66399681	C/T	cg24851651	chr11:66362959	CCS	-0.39	-7.21	-0.32	2.33e-12	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.96	0.54	3.36e-37	Prudent dietary pattern;
LGG	cis	rs1816752	0.905	rs7400631	chr13:24990065	A/G	cg02811702	chr13:24901961	NA	0.4	7.45	0.33	4.67e-13	Obesity-related traits;
LGG	cis	rs4474465	0.790	rs4544031	chr11:78265403	G/C	cg27205649	chr11:78285834	NARS2	0.52	8.93	0.38	1.04e-17	Alzheimer's disease (survival time);
LGG	cis	rs4330281	0.630	rs4408889	chr3:17730418	T/C	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs6840360	0.642	rs7682837	chr4:152427686	C/T	cg17217059	chr4:152329364	FAM160A1	0.21	7.2	0.32	2.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.541	rs485975	chr2:219374250	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs882632	0.668	rs35929540	chr2:29297068	C/T	cg23429306	chr2:29287725	C2orf71	0.4	7.99	0.35	1.05e-14	Major depressive disorder;
LGG	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs8180040	0.620	rs2305635	chr3:47043622	G/A	cg16586182	chr3:47516702	SCAP	0.73	13.12	0.52	1.15e-33	Colorectal cancer;
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg14346243	chr4:90757452	SNCA	-0.4	-8.08	-0.35	5.62e-15	Dementia with Lewy bodies;
LGG	cis	rs11190604	1.000	rs1054399	chr10:102312565	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	12.09	0.49	2.02e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9644630	0.841	rs3185	chr8:19328959	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.55	-14.59	-0.56	6.14e-40	Oropharynx cancer;
LGG	cis	rs9916302	0.904	rs9905432	chr17:37555918	C/A	cg00129232	chr17:37814104	STARD3	0.6	11.29	0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs826838	1.000	rs4575342	chr12:38663831	G/A	cg13010199	chr12:38710504	ALG10B	0.76	16.24	0.6	2.86e-47	Heart rate;
LGG	cis	rs754466	0.580	rs10824577	chr10:79577408	G/C	cg17075019	chr10:79541650	NA	-0.98	-22.15	-0.72	1.13e-74	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg21395723	chr22:39101663	GTPBP1	-0.37	-6.66	-0.3	7.85e-11	Menopause (age at onset);
LGG	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2276314	0.947	rs4799831	chr18:33554775	A/G	cg05985134	chr18:33552581	C18orf21	0.66	10.38	0.43	7.75e-23	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs6456156	0.586	rs1358882	chr6:167467101	G/A	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs8048589	0.615	rs34098770	chr16:12237812	G/A	cg02910054	chr16:12241554	SNX29	0.64	9.47	0.4	1.45e-19	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs7666738	0.830	rs13118892	chr4:98968497	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	9.73e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg10580341	chr11:889148	CHID1	-0.38	-6.88	-0.3	1.93e-11	Mean platelet volume;
LGG	trans	rs1814175	0.817	rs10769641	chr11:49960141	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	cis	rs17604090	0.756	rs113829432	chr7:29725069	C/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.37	-0.32	7.85e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs908922	0.676	rs10888491	chr1:152492622	A/G	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	cis	rs7106204	0.562	rs7109606	chr11:24251314	G/T	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2153535	0.580	rs6597337	chr6:8531652	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.44e-21	Motion sickness;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg13206674	chr6:150067644	NUP43	0.41	8.82	0.38	2.3e-17	Testicular germ cell tumor;
LGG	cis	rs6724607	1.000	rs13006708	chr2:191471428	G/A	cg20818283	chr2:191399100	TMEM194B	-0.3	-7.15	-0.32	3.3e-12	Pulse pressure;
LGG	cis	rs28595532	0.844	rs115573749	chr4:119756848	T/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs10492096	0.947	rs61918020	chr12:6605514	C/T	cg13857086	chr12:6580257	VAMP1	0.51	7.3	0.32	1.29e-12	Hip geometry;
LGG	cis	rs1577917	1.000	rs7760207	chr6:86721700	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.17e-33	Response to antipsychotic treatment;
LGG	cis	rs10779751	0.922	rs2746638	chr1:11278125	T/C	cg08854313	chr1:11322531	MTOR	0.74	16.63	0.61	4.73e-49	Body mass index;
LGG	cis	rs7481584	0.847	rs1468102	chr11:3004526	C/G	cg25174290	chr11:3078921	CARS	-0.44	-7.68	-0.34	9.85e-14	Calcium levels;
LGG	cis	rs6032067	1.000	rs6032065	chr20:43855649	C/T	cg10761708	chr20:43804764	PI3	0.76	11.76	0.48	4.2e-28	Blood protein levels;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17711722	0.727	rs1880555	chr7:65432567	T/C	cg00343986	chr7:65444356	GUSB	0.49	8.66	0.37	7.84e-17	Calcium levels;
LGG	cis	rs7618915	0.501	rs9917834	chr3:52634619	A/C	cg18404041	chr3:52824283	ITIH1	-0.52	-10.05	-0.42	1.29e-21	Bipolar disorder;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg01238044	chr22:24384105	GSTT1	-0.42	-7.09	-0.31	4.93e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs8060686	0.565	rs11555011	chr16:68088485	A/G	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.65	-0.3	8.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs6787172	0.728	rs827106	chr3:158078063	A/G	cg23275840	chr4:47708675	CORIN	0.39	8.11	0.35	4.65e-15	Subjective well-being;
LGG	cis	rs72781680	1.000	rs72796327	chr2:24140372	T/C	cg08917208	chr2:24149416	ATAD2B	0.93	10.15	0.43	5.25e-22	Lymphocyte counts;
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.63e-13	Alzheimer's disease;
LGG	cis	rs2013441	1.000	rs2703794	chr17:20073338	T/C	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs9880211	0.898	rs73231903	chr3:136561625	T/A	cg21827317	chr3:136751795	NA	-0.5	-7.37	-0.32	7.79e-13	Body mass index;Height;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.59	10.39	0.43	7.43e-23	Obesity-related traits;
LGG	cis	rs3806843	0.518	rs2569191	chr5:140013903	C/T	cg19875535	chr5:140030758	IK	-0.43	-8.38	-0.36	6.58e-16	Depressive symptoms (multi-trait analysis);
LGG	cis	rs13102973	0.965	rs4280794	chr4:135857174	T/C	cg14419869	chr4:135874104	NA	0.57	10.85	0.45	1.41e-24	Subjective well-being;
LGG	cis	rs2797160	1.000	rs1418642	chr6:125999768	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.37	-0.32	7.77e-13	Endometrial cancer;
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg12395012	chr8:11607386	GATA4	0.39	6.95	0.31	1.27e-11	Triglycerides;
LGG	cis	rs7726839	0.540	rs4957081	chr5:646418	G/C	cg07777115	chr5:623756	CEP72	-0.63	-8.2	-0.36	2.35e-15	Obesity-related traits;
LGG	cis	rs12681288	0.862	rs2600493	chr8:1024970	A/G	cg08648136	chr8:956695	NA	0.33	6.96	0.31	1.2e-11	Schizophrenia;
LGG	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg26384229	chr12:38710491	ALG10B	-0.76	-15.1	-0.57	3.55e-42	Morning vs. evening chronotype;
LGG	cis	rs6088580	0.524	rs2378251	chr20:33276750	C/T	cg08999081	chr20:33150536	PIGU	-0.3	-7.19	-0.32	2.69e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg03929089	chr4:120376271	NA	0.69	9.5	0.4	1.1e-19	Axial length;
LGG	cis	rs17270561	0.609	rs4712963	chr6:25740502	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.27	0.36	1.46e-15	Iron status biomarkers;
LGG	cis	rs992157	0.710	rs56364928	chr2:219059058	G/A	cg04731861	chr2:219085781	ARPC2	-0.5	-12.75	-0.51	4.21e-32	Colorectal cancer;
LGG	cis	rs10782582	0.593	rs11163904	chr1:76121208	A/G	cg03433033	chr1:76189801	ACADM	0.43	7.07	0.31	5.89e-12	Daytime sleep phenotypes;
LGG	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg15395560	chr15:45543142	SLC28A2	0.41	6.76	0.3	4.04e-11	Glomerular filtration rate;
LGG	cis	rs4363385	0.510	rs1500937	chr1:153045483	G/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.22	-0.39	1.07e-18	Inflammatory skin disease;
LGG	cis	rs74781061	0.932	rs74025818	chr15:74910628	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.15	-0.32	3.44e-12	Endometriosis;
LGG	trans	rs6787172	0.702	rs13066362	chr3:158009477	A/G	cg23275840	chr4:47708675	CORIN	0.4	8.41	0.36	5.25e-16	Subjective well-being;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg26338869	chr17:61819248	STRADA	0.59	9.93	0.42	3.35e-21	Prudent dietary pattern;
LGG	cis	rs11168187	0.843	rs7967336	chr12:48119016	C/G	cg12761788	chr12:48120090	P11	0.51	8.86	0.38	1.77e-17	Vertical cup-disc ratio;
LGG	cis	rs1733410	0.504	rs11181874	chr12:37912890	C/A	cg04568710	chr12:38710424	ALG10B	-0.35	-7.47	-0.33	4.04e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2832077	0.506	rs10222093	chr21:30163518	T/C	cg08807101	chr21:30365312	RNF160	-0.61	-9.76	-0.41	1.34e-20	Cognitive test performance;
LGG	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg27147174	chr7:100797783	AP1S1	-0.65	-12.01	-0.49	4.21e-29	Life satisfaction;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg15948088	chr11:109293068	C11orf87	0.55	9.1	0.39	2.62e-18	Schizophrenia;
LGG	cis	rs7223966	1.000	rs6504171	chr17:61710010	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.7	11.89	0.48	1.27e-28	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7444	0.941	rs5998599	chr22:21941981	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-6.87	-0.3	2.1e-11	Systemic lupus erythematosus;
LGG	trans	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg22153745	chr1:153894579	GATAD2B	-0.65	-10.57	-0.44	1.55e-23	Total cholesterol levels;
LGG	cis	rs2708377	0.858	rs55748583	chr12:11139712	T/C	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.45	6.73	0.3	5.05e-11	Bitter taste perception;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg26431298	chr1:156737036	PRCC	-0.4	-6.72	-0.3	5.41e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9560113	0.960	rs953260	chr13:112173685	C/T	cg14952266	chr13:112191215	NA	-0.42	-7.65	-0.34	1.15e-13	Menarche (age at onset);
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg05861140	chr6:150128134	PCMT1	-0.3	-6.94	-0.31	1.29e-11	Testicular germ cell tumor;
LGG	cis	rs12479064	0.724	rs3087403	chr2:100058870	C/T	cg08885076	chr2:99613938	TSGA10	-0.4	-7.37	-0.32	7.74e-13	Chronic sinus infection;
LGG	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg16482183	chr6:26056742	HIST1H1C	0.92	13.81	0.54	1.39e-36	Iron status biomarkers;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07677032	chr17:61819896	STRADA	0.69	12.79	0.51	2.86e-32	Prudent dietary pattern;
LGG	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.13	-0.35	3.83e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg03929089	chr4:120376271	NA	0.74	8.62	0.37	1.06e-16	Axial length;
LGG	cis	rs4363385	0.693	rs689008	chr1:153047100	G/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs2228479	0.850	rs11639788	chr16:89807543	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.1	-0.35	5.04e-15	Skin colour saturation;
LGG	cis	rs10823500	0.748	rs2394668	chr10:71943951	G/A	cg02100629	chr10:71892760	AIFM2	-0.3	-7.16	-0.32	3.13e-12	Blood protein levels;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg07362569	chr17:61921086	SMARCD2	-0.47	-9.0	-0.39	5.69e-18	Prudent dietary pattern;
LGG	cis	rs7667	0.881	rs12034426	chr1:19750871	C/A	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.38	-6.69	-0.3	6.38e-11	Crohn's disease and psoriasis;
LGG	trans	rs7395662	0.591	rs4882233	chr11:48739653	A/G	cg00717180	chr2:96193071	NA	-0.47	-8.86	-0.38	1.71e-17	HDL cholesterol;
LGG	cis	rs753955	0.592	rs1324972	chr13:24348159	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.41	7.31	0.32	1.18e-12	Lung cancer;
LGG	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs9649465	0.934	rs7799354	chr7:123269819	A/G	cg03229431	chr7:123269106	ASB15	-0.43	-9.66	-0.41	3.11e-20	Migraine;
LGG	cis	rs453301	0.719	rs34004903	chr8:8892604	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.96	-0.31	1.19e-11	Joint mobility (Beighton score);
LGG	cis	rs7552404	0.731	rs6699682	chr1:76340123	A/G	cg22875332	chr1:76189707	ACADM	-0.59	-8.79	-0.38	3e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4799461	0.837	rs7244667	chr18:35126708	C/T	cg27332583	chr18:35150602	NA	-0.55	-11.13	-0.46	1.12e-25	Neuroticism;
LGG	cis	rs6500395	0.962	rs1564980	chr16:48651377	A/T	cg04672837	chr16:48644449	N4BP1	0.55	8.93	0.38	9.7e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9393692	0.645	rs11756673	chr6:26323505	A/G	cg13736514	chr6:26305472	NA	-0.49	-9.88	-0.42	5.12e-21	Educational attainment;
LGG	trans	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg06606381	chr12:133084897	FBRSL1	-0.75	-7.43	-0.33	5.25e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs42648	0.869	rs3810890	chr7:89908833	G/T	cg25739043	chr7:89950458	NA	-0.44	-9.28	-0.4	6.58e-19	Homocysteine levels;
LGG	cis	rs3806843	0.607	rs246060	chr5:140324749	T/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3126085	1.000	rs12567463	chr1:152180128	T/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.88	-0.34	2.4e-14	Atopic dermatitis;
LGG	cis	rs6142618	0.562	rs4911547	chr20:30733473	A/G	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs6500602	0.855	rs2304631	chr16:4475868	A/T	cg19168338	chr16:4465731	CORO7	-1.12	-24.41	-0.75	3.46e-85	Schizophrenia;
LGG	cis	rs12210905	0.748	rs6901225	chr6:26670491	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.87	-0.34	2.53e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4731207	0.698	rs1468378	chr7:124458359	C/A	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs7107174	1.000	rs2512533	chr11:77968674	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	trans	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg07211511	chr3:129823064	LOC729375	-1.38	-22.04	-0.72	3.89e-74	Blood pressure (smoking interaction);
LGG	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-11.09	-0.46	1.64e-25	Height;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.39	7.82	0.34	3.72e-14	Schizophrenia;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.83	-0.38	2.25e-17	Lung cancer;
LGG	cis	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg12458913	chr13:53173898	NA	0.56	10.0	0.42	1.96e-21	Lewy body disease;
LGG	cis	rs9322193	0.926	rs9285525	chr6:150122389	C/G	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs8072100	1.000	rs11650372	chr17:45721795	G/A	cg19784903	chr17:45786737	TBKBP1	-0.33	-7.2	-0.32	2.41e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.57	9.44	0.4	1.83e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9815354	0.812	rs113300894	chr3:41984243	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs881375	0.867	rs6478487	chr9:123672777	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	trans	rs7246760	0.867	rs34648216	chr19:9850690	T/A	cg02900749	chr2:68251473	NA	-1.07	-11.46	-0.47	6.15e-27	Pursuit maintenance gain;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	7.76e-17	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25409748	chr1:205744748	RAB7L1	0.41	6.9	0.31	1.67e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1707322	0.821	rs11211182	chr1:46240170	G/A	cg03146154	chr1:46216737	IPP	0.58	10.18	0.43	4.08e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11771526	0.892	rs62457540	chr7:32372199	A/G	cg27511599	chr7:32358540	NA	0.64	7.12	0.31	4.18e-12	Body mass index;
LGG	cis	rs17221829	0.733	rs4753223	chr11:89360653	A/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs11608355	0.576	rs1477117	chr12:109888779	A/G	cg05360138	chr12:110035743	NA	-0.78	-10.9	-0.45	8.97e-25	Neuroticism;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs933688	1.000	rs889213	chr5:90682151	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.04e-42	Menopause (age at onset);
LGG	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.65	-0.41	3.28e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7927592	0.913	rs59056571	chr11:68272973	T/G	cg20283391	chr11:68216788	NA	-0.52	-8.41	-0.36	5.08e-16	Total body bone mineral density;
LGG	cis	rs834603	0.547	rs1704966	chr7:47469948	G/A	cg09696706	chr7:47479511	TNS3	0.35	7.83	0.34	3.25e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6598955	0.627	rs6684875	chr1:26567044	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.24e-15	Obesity-related traits;
LGG	cis	rs11112613	0.775	rs7959699	chr12:105959848	C/A	cg03607813	chr12:105948248	NA	0.54	9.36	0.4	3.57e-19	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs17376456	0.877	rs12374470	chr5:93481046	A/G	cg25358565	chr5:93447407	FAM172A	1.4	17.18	0.62	1.51e-51	Diabetic retinopathy;
LGG	cis	rs9341835	0.741	rs6929702	chr6:64144114	T/C	cg00787780	chr6:64151745	NA	0.4	7.28	0.32	1.42e-12	Schizophrenia;
LGG	cis	rs1577917	0.681	rs4707211	chr6:86232710	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.86	0.34	2.72e-14	Response to antipsychotic treatment;
LGG	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg15596359	chr8:11213517	TDH	0.34	6.86	0.3	2.15e-11	Retinal vascular caliber;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs801193	0.569	rs3846973	chr7:66120035	T/C	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs10256972	0.605	rs10251094	chr7:1017083	G/C	cg08137085	chr7:1117540	C7orf50	0.37	6.73	0.3	5.16e-11	Longevity;Endometriosis;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.75	0.38	3.99e-17	Prudent dietary pattern;
LGG	cis	rs9604529	0.759	rs77777032	chr13:114625889	T/C	cg04826882	chr13:114838756	RASA3	-0.55	-7.81	-0.34	3.85e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13191362	1.000	rs13207671	chr6:162979056	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.77	8.17	0.35	3.04e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12364882	chr19:1941705	CSNK1G2	0.45	7.04	0.31	6.91e-12	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00166722	chr3:10149974	C3orf24	0.52	8.8	0.38	2.77e-17	Alzheimer's disease;
LGG	cis	rs4563143	0.675	rs56293553	chr19:29270455	A/G	cg14983838	chr19:29218262	NA	0.7	11.28	0.46	3.14e-26	Methadone dose in opioid dependence;
LGG	cis	rs9611565	0.546	rs34077262	chr22:42061639	A/G	cg03806693	chr22:41940476	POLR3H	0.99	16.79	0.62	9.23e-50	Vitiligo;
LGG	cis	rs3816788	0.837	rs6557640	chr8:21771731	A/T	cg17168535	chr8:21777572	XPO7	0.71	13.61	0.53	1.03e-35	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.502	rs4309219	chr12:38293584	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.58	0.33	1.85e-13	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21336547	chr19:15490553	AKAP8	0.46	6.8	0.3	3.19e-11	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.666	rs12759434	chr1:26607123	C/T	cg04990556	chr1:26633338	UBXN11	-0.68	-14.18	-0.55	3.58e-38	Obesity-related traits;
LGG	trans	rs1814175	0.645	rs10444311	chr11:49986906	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.96	-0.6	5.01e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9486715	1.000	rs6905568	chr6:97066382	T/C	cg06623918	chr6:96969491	KIAA0776	-0.74	-14.18	-0.55	3.77e-38	Headache;
LGG	cis	rs2836974	0.644	rs61300849	chr21:40680194	G/A	cg11890956	chr21:40555474	PSMG1	-0.98	-20.99	-0.7	3.01e-69	Cognitive function;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.85	0.34	2.85e-14	Lung cancer;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg21911579	chr5:131705225	SLC22A5	0.67	7.44	0.33	4.97e-13	Rheumatoid arthritis;
LGG	cis	rs4700695	0.719	rs27046	chr5:65439964	G/C	cg21114390	chr5:65439923	SFRS12	-0.72	-10.51	-0.44	2.48e-23	Facial morphology (factor 19);
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg06654118	chr4:1303317	MAEA	0.47	8.2	0.36	2.45e-15	Obesity-related traits;
LGG	cis	rs3091242	0.904	rs6661533	chr1:25771715	A/G	cg27572855	chr1:25598939	RHD	0.52	11.73	0.48	5.26e-28	Erythrocyte sedimentation rate;
LGG	trans	rs2018683	0.707	rs4722875	chr7:28969632	A/G	cg19402173	chr7:128379420	CALU	-0.53	-9.21	-0.39	1.14e-18	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23986671	chr21:28339262	ADAMTS5	0.46	7.4	0.33	6.64e-13	Cognitive performance;
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg03264133	chr6:25882463	NA	0.5	9.2	0.39	1.22e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs4372295	chr1:248464871	G/T	cg00666640	chr1:248458726	OR2T12	0.61	9.95	0.42	2.82e-21	Common traits (Other);
LGG	cis	rs801193	0.613	rs2659900	chr7:66184443	G/C	cg11764359	chr7:65958608	NA	0.78	14.6	0.56	5.64e-40	Aortic root size;
LGG	cis	rs12410462	1.000	rs76233861	chr1:227673909	G/A	cg21459583	chr1:227974177	NA	0.45	7.02	0.31	8.08e-12	Major depressive disorder;
LGG	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs2413583	0.591	rs75026781	chr22:39720821	T/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.72	0.34	7.11e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg19774624	chr17:42201019	HDAC5	0.57	8.23	0.36	1.88e-15	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs1218582	0.596	rs11264275	chr1:154825270	G/T	cg03351412	chr1:154909251	PMVK	-0.47	-8.26	-0.36	1.51e-15	Prostate cancer;
LGG	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg05793240	chr7:2802953	GNA12	0.34	7.71	0.34	7.58e-14	Height;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg02725872	chr8:58115012	NA	-0.91	-12.08	-0.49	2.18e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs12580194	0.593	rs61957943	chr12:55749330	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.71	-0.41	2e-20	Cancer;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg08975724	chr8:8085496	FLJ10661	0.5	9.77	0.41	1.3e-20	Neuroticism;
LGG	cis	rs9325144	0.560	rs10785586	chr12:38676197	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.28	-0.4	6.76e-19	Morning vs. evening chronotype;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg05518471	chr10:2006740	NA	0.35	6.88	0.3	1.97e-11	Electrocardiographic conduction measures;
LGG	cis	rs910316	1.000	rs4899546	chr14:75594946	G/C	cg08847533	chr14:75593920	NEK9	0.62	12.07	0.49	2.44e-29	Height;
LGG	cis	rs9381107	0.505	rs9369420	chr6:9486467	A/G	cg14735645	chr6:9486422	NA	0.52	10.1	0.42	8.11e-22	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4474465	0.915	rs7128449	chr11:78206760	G/A	cg27205649	chr11:78285834	NARS2	0.48	8.26	0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs35306767	0.668	rs72760914	chr10:1070952	A/G	cg20503657	chr10:835505	NA	0.49	6.78	0.3	3.7e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.93e-31	Lymphocyte counts;
LGG	cis	rs875971	1.000	rs9986696	chr7:65704576	C/A	cg18876405	chr7:65276391	NA	-0.55	-9.75	-0.41	1.45e-20	Aortic root size;
LGG	cis	rs59918340	0.764	rs4961338	chr8:142230192	C/T	cg23750338	chr8:142222470	SLC45A4	-0.6	-12.67	-0.51	8.25e-32	Immature fraction of reticulocytes;
LGG	cis	rs9527	0.590	rs726010	chr10:104841977	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.58	0.44	1.39e-23	Arsenic metabolism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03314080	chr2:178129903	NFE2L2	0.41	6.99	0.31	9.4e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg10661904	chr17:79619235	PDE6G	-0.51	-10.55	-0.44	1.88e-23	Eye color traits;
LGG	cis	rs9902453	0.817	rs2729449	chr17:28089751	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.83	-0.54	1.17e-36	Coffee consumption (cups per day);
LGG	cis	rs888194	0.966	rs6606725	chr12:109905368	C/A	cg08884029	chr12:110012500	MVK;MMAB	-0.36	-7.43	-0.33	5.18e-13	Neuroticism;
LGG	trans	rs2204008	0.505	rs11182550	chr12:38570061	A/T	cg06521331	chr12:34319734	NA	-0.4	-7.08	-0.31	5.51e-12	Bladder cancer;
LGG	cis	rs12541335	0.639	rs11135995	chr8:22200148	C/T	cg02463440	chr8:22132932	PIWIL2	-0.51	-11.4	-0.47	1.1e-26	Hypertriglyceridemia;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.81e-17	Lung cancer;
LGG	trans	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	11.03	0.46	2.75e-25	Lewy body disease;
LGG	trans	rs6825911	0.672	rs4834497	chr4:111360689	C/T	cg10580549	chr19:53101634	ZNF137	0.45	7.07	0.31	5.78e-12	Blood pressure;
LGG	cis	rs4356932	1.000	rs10014049	chr4:76953532	C/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg26116260	chr4:7069785	GRPEL1	-1.07	-15.98	-0.6	4.45e-46	Monocyte percentage of white cells;
LGG	cis	rs4330281	0.647	rs9848610	chr3:17419843	A/G	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.5e-11	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25846022	chr1:78444909	FUBP1	0.51	8.44	0.37	4.25e-16	Cognitive performance;
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.26	0.55	1.68e-38	Platelet count;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs950169	0.649	rs12905952	chr15:84691261	G/A	cg24253500	chr15:84953950	NA	0.47	7.47	0.33	4e-13	Schizophrenia;
LGG	cis	rs2486288	0.656	rs7171312	chr15:45570225	C/G	cg26924012	chr15:45694286	SPATA5L1	-0.62	-10.82	-0.45	1.81e-24	Glomerular filtration rate;
LGG	cis	rs10504229	0.593	rs7000752	chr8:58026980	C/G	cg24829409	chr8:58192753	C8orf71	-0.61	-8.32	-0.36	1.03e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7085104	0.684	rs7092690	chr10:104609365	T/C	cg04362960	chr10:104952993	NT5C2	0.48	8.91	0.38	1.16e-17	Immature fraction of reticulocytes;Schizophrenia;
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg21775007	chr8:11205619	TDH	0.45	7.35	0.32	8.87e-13	Mood instability;
LGG	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg07520158	chr7:32535189	LSM5;AVL9	0.58	9.88	0.42	4.96e-21	Cognitive ability;
LGG	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12493885	0.818	rs73160504	chr3:153773384	C/T	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg19318889	chr4:1322082	MAEA	-0.39	-6.93	-0.31	1.44e-11	Obesity-related traits;
LGG	cis	rs9398803	0.830	rs1159619	chr6:126801144	C/A	cg19875578	chr6:126661172	C6orf173	0.57	10.35	0.43	9.93e-23	Male-pattern baldness;
LGG	cis	rs3749237	0.595	rs17650792	chr3:49390250	A/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.04	0.31	7.16e-12	Resting heart rate;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg12946880	chr3:66023876	MAGI1	-0.39	-6.78	-0.3	3.76e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.526	rs4309960	chr5:151971852	A/G	cg10931792	chr5:152022470	NA	0.38	8.25	0.36	1.68e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg02002194	chr4:3960332	NA	0.39	7.1	0.31	4.63e-12	Neuroticism;
LGG	trans	rs61931739	0.534	rs1844526	chr12:34102780	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs308971	0.656	rs307610	chr3:12064555	C/T	cg15873301	chr3:12045459	SYN2	0.54	7.8	0.34	4.2e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs4937291	0.966	rs10891346	chr11:112203992	T/A	cg12822818	chr11:112096781	PTS	-0.43	-6.67	-0.3	7.1e-11	Interleukin-18 levels;
LGG	cis	rs10540	0.730	rs61877766	chr11:512973	T/G	cg19913688	chr11:428466	ANO9	-0.68	-8.31	-0.36	1.1e-15	Body mass index;
LGG	cis	rs7811142	1.000	rs76913697	chr7:100002772	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	21.21	0.7	2.89e-70	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02957990	chr2:86333310	PTCD3;POLR1A	0.46	6.79	0.3	3.49e-11	Gut microbiome composition (summer);
LGG	trans	rs7615952	0.673	rs9289270	chr3:125636979	A/T	cg07211511	chr3:129823064	LOC729375	-1.3	-16.02	-0.6	2.94e-46	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs10206020	0.921	rs72776300	chr2:1571152	A/G	cg26248373	chr2:1572462	NA	-0.89	-15.04	-0.57	6.36e-42	IgG glycosylation;
LGG	cis	rs4268898	0.662	rs55661701	chr2:24400769	A/C	cg06627628	chr2:24431161	ITSN2	-0.78	-12.33	-0.5	2.12e-30	Asthma;
LGG	trans	rs9693857	0.520	rs4841163	chr8:9366178	C/G	cg21775007	chr8:11205619	TDH	0.45	6.71	0.3	5.87e-11	Systolic blood pressure;
LGG	cis	rs56397034	1	rs56397034	chr19:13000550	G/C	cg23899408	chr19:12877188	HOOK2	-0.48	-7.84	-0.34	3.13e-14	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg07460842	chr6:66804631	NA	-1.11	-28.51	-0.8	5.46e-104	Exhaled nitric oxide output;
LGG	cis	rs2073300	1.000	rs6132622	chr20:23442240	A/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.42	-7.06	-0.31	5.94e-12	Longevity;
LGG	cis	rs8016982	0.674	rs759939	chr14:81663453	G/C	cg01989461	chr14:81687754	GTF2A1	0.78	19.47	0.67	4.04e-62	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26098650	chr11:120207939	ARHGEF12	0.46	7.21	0.32	2.23e-12	Gut microbiome composition (summer);
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg12070911	chr6:150209640	RAET1E	0.27	6.98	0.31	1.05e-11	Testicular germ cell tumor;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg13012494	chr21:47604986	C21orf56	0.61	9.63	0.41	3.81e-20	Testicular germ cell tumor;
LGG	cis	rs11122272	0.735	rs2572254	chr1:231512593	T/C	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.25e-13	Hemoglobin concentration;
LGG	cis	rs36715	1.000	rs36705	chr5:127554486	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.48	7.63	0.33	1.34e-13	Breast cancer;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg01673284	chr16:4527211	HMOX2	0.33	6.91	0.31	1.58e-11	Schizophrenia;
LGG	cis	rs7264396	0.690	rs2425175	chr20:34445563	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.38	0.32	7.25e-13	Total cholesterol levels;
LGG	cis	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.67	-0.51	8.5e-32	Uric acid levels;
LGG	cis	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg20368463	chr18:77673604	PQLC1	0.56	7.41	0.33	6.21e-13	Opioid sensitivity;
LGG	trans	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-12.77	-0.51	3.24e-32	Obesity-related traits;
LGG	cis	rs4948275	0.773	rs1902429	chr10:63277075	G/A	cg03237606	chr10:63212265	TMEM26	-0.37	-6.7	-0.3	6.21e-11	Night sleep phenotypes;
LGG	cis	rs11148252	0.774	rs9596649	chr13:52934610	A/G	cg00495681	chr13:53174319	NA	-0.69	-13.26	-0.52	2.98e-34	Lewy body disease;
LGG	cis	rs2637030	0.559	rs2607501	chr5:52989545	A/T	cg06476337	chr5:52856530	NDUFS4	0.44	6.9	0.31	1.66e-11	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs368123	0.924	rs373294	chr6:160721221	A/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs8067545	0.611	rs7222984	chr17:20019694	A/C	cg13482628	chr17:19912719	NA	0.54	10.27	0.43	1.91e-22	Schizophrenia;
LGG	cis	rs4330281	0.669	rs9823767	chr3:17615737	A/G	cg20981856	chr3:17787350	NA	0.4	7.28	0.32	1.45e-12	Schizophrenia;
LGG	cis	rs3796352	1.000	rs3806692	chr3:53080987	C/G	cg12962167	chr3:53033115	SFMBT1	0.68	7.11	0.31	4.46e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs58785573	0.504	rs11947292	chr4:38634749	A/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.49	8.19	0.36	2.56e-15	Lymphocyte percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23833352	chr13:77553666	NA	-0.38	-7.01	-0.31	8.58e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1949733	0.543	rs62287446	chr4:8535988	G/A	cg11789530	chr4:8429930	ACOX3	-0.53	-8.67	-0.37	7.28e-17	Response to antineoplastic agents;
LGG	trans	rs75804782	0.630	rs56304316	chr2:239253266	C/A	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs875971	0.862	rs10274883	chr7:66116091	C/T	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs11148252	0.514	rs3818422	chr13:52719214	C/T	cg02158880	chr13:53174818	NA	-0.36	-6.78	-0.3	3.66e-11	Lewy body disease;
LGG	cis	rs4481887	1.000	rs4457616	chr1:248492198	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.77	0.41	1.29e-20	Common traits (Other);
LGG	cis	rs6840360	0.901	rs6826799	chr4:152455700	G/A	cg17217059	chr4:152329364	FAM160A1	0.21	7.23	0.32	2.06e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17428076	0.794	rs72890841	chr2:172838596	A/G	cg21435375	chr2:172878103	MAP1D	0.41	7.58	0.33	1.92e-13	Myopia;
LGG	cis	rs12368653	0.557	rs903067	chr12:58011857	G/A	cg00700412	chr12:58011837	NA	-0.49	-10.39	-0.43	7.25e-23	Multiple sclerosis;
LGG	cis	rs4262150	0.764	rs2961756	chr5:151936155	T/A	cg12297329	chr5:152029980	NA	-0.69	-13.13	-0.52	1.08e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs7647973	0.593	rs28535523	chr3:49848414	C/T	cg21659725	chr3:3221576	CRBN	0.58	7.69	0.34	9.08e-14	Menarche (age at onset);
LGG	cis	rs9790314	0.846	rs7652267	chr3:160998497	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-12.15	-0.49	1.1e-29	Morning vs. evening chronotype;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.21	0.32	2.33e-12	Height;
LGG	cis	rs2916247	0.954	rs11991256	chr8:93077207	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.37	-7.49	-0.33	3.59e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.45	-0.33	4.74e-13	Menopause (age at onset);
LGG	cis	rs60843830	0.661	rs55987018	chr2:106655	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.32	0.4	4.63e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg09408571	chr1:101003634	GPR88	0.28	7.02	0.31	8.02e-12	Breast cancer;
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2952156	0.883	rs1495100	chr17:37832279	C/T	cg07936489	chr17:37558343	FBXL20	-0.49	-8.3	-0.36	1.14e-15	Asthma;
LGG	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg00761968	chr13:53314142	LECT1	-0.39	-8.12	-0.35	4.11e-15	Lewy body disease;
LGG	cis	rs8067287	0.749	rs62065427	chr17:16831560	C/T	cg26910001	chr17:16838321	NA	-0.49	-8.96	-0.38	7.94e-18	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02887248	chr8:11659961	FDFT1	0.45	6.7	0.3	6.1e-11	Gut microbiome composition (summer);
LGG	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg00204512	chr16:28754710	NA	0.25	6.91	0.31	1.64e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9467711	0.591	rs9467635	chr6:25909166	A/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.71	-0.3	5.57e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs151997	0.962	rs27271	chr5:50183369	A/G	cg06027927	chr5:50259733	NA	0.68	11.09	0.46	1.66e-25	Callous-unemotional behaviour;
LGG	cis	rs9534288	0.797	rs9534283	chr13:46589256	C/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.26	-0.52	2.99e-34	Blood protein levels;
LGG	cis	rs4906332	1.000	rs2065018	chr14:103879187	C/T	cg26031613	chr14:104095156	KLC1	0.51	7.88	0.34	2.32e-14	Coronary artery disease;
LGG	cis	rs875971	0.706	rs1643374	chr7:65872682	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	9.92	0.42	3.68e-21	Aortic root size;
LGG	cis	rs6598955	0.543	rs17163720	chr1:26549399	A/G	cg04990556	chr1:26633338	UBXN11	-0.73	-11.0	-0.46	3.6e-25	Obesity-related traits;
LGG	cis	rs6692729	0.966	rs6426547	chr1:227004367	A/G	cg08708961	chr1:227070630	PSEN2	-0.28	-7.13	-0.31	3.92e-12	Electrodermal activity;
LGG	cis	rs6963495	0.615	rs1728645	chr7:105205115	A/G	cg19920283	chr7:105172520	RINT1	0.48	6.95	0.31	1.24e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	trans	rs11088226	0.681	rs11702499	chr21:33938565	C/T	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg10546459	chr2:36825355	FEZ2	0.48	7.18	0.32	2.84e-12	Height;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.5	0.56	1.52e-39	Tonsillectomy;
LGG	cis	rs889398	0.741	rs6499268	chr16:69906529	G/A	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.88	-0.3	1.9e-11	Body mass index;
LGG	cis	rs4731207	0.596	rs10252579	chr7:124637106	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.86	-0.3	2.19e-11	Cutaneous malignant melanoma;
LGG	cis	rs7192380	0.737	rs7204433	chr16:69589924	A/G	cg00738113	chr16:70207722	CLEC18C	-0.31	-8.47	-0.37	3.35e-16	Sjögren's syndrome;
LGG	cis	rs1129187	0.805	rs1053539	chr6:42903766	T/G	cg05552183	chr6:42928497	GNMT	0.38	11.17	0.46	7.85e-26	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	13.59	0.53	1.2e-35	Platelet count;
LGG	trans	rs9467711	0.606	rs2072803	chr6:26392515	G/C	cg08344181	chr3:125677491	NA	-0.61	-6.91	-0.31	1.59e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.27e-12	Morning vs. evening chronotype;
LGG	cis	rs763121	0.853	rs5750633	chr22:38993467	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.23	0.65	2.3e-56	Menopause (age at onset);
LGG	cis	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.68	-0.3	6.86e-11	Mood instability;
LGG	cis	rs2860975	0.620	rs1934953	chr10:96797470	A/G	cg09036531	chr10:96991505	NA	0.46	8.03	0.35	8.29e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs727505	0.563	rs73227531	chr7:124800221	T/A	cg23710748	chr7:124431027	NA	-0.44	-8.4	-0.36	5.34e-16	Lewy body disease;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg20887711	chr4:1340912	KIAA1530	0.59	11.51	0.47	4.08e-27	Longevity;
LGG	cis	rs6456156	1.000	rs6911766	chr6:167523170	T/G	cg07741184	chr6:167504864	NA	-0.33	-7.37	-0.32	7.9e-13	Primary biliary cholangitis;
LGG	cis	rs4631830	0.720	rs4935573	chr10:51504385	A/G	cg16070123	chr10:51489643	NA	0.41	7.53	0.33	2.63e-13	Prostate-specific antigen levels;
LGG	cis	rs7208859	0.623	rs9890862	chr17:29125450	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg26617929	chr16:1858877	NA	0.67	9.31	0.4	5.23e-19	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg18050959	chr15:68126178	NA	-0.38	-7.21	-0.32	2.26e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs11875185	0.510	rs78497163	chr18:55635155	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs12310956	0.532	rs10844719	chr12:33987714	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.86	0.42	6.17e-21	Morning vs. evening chronotype;
LGG	cis	rs3087591	0.821	rs1034705	chr17:29536133	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.67	-14.06	-0.55	1.15e-37	Hip circumference;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9896933	0.832	rs77512810	chr17:80804589	C/T	cg19500275	chr17:80737654	TBCD	0.52	7.02	0.31	8.01e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs6951245	0.554	rs11544331	chr7:1131411	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.59	-11.1	-0.46	1.55e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.52	-8.3	-0.36	1.13e-15	Longevity;
LGG	cis	rs981844	0.712	rs1563461	chr4:154751913	C/T	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03183877	chr10:27444699	YME1L1;MASTL	0.45	6.77	0.3	3.91e-11	Gut microbiome composition (summer);
LGG	cis	rs151997	0.962	rs27272	chr5:50181865	A/G	cg06027927	chr5:50259733	NA	0.68	11.19	0.46	7.15e-26	Callous-unemotional behaviour;
LGG	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs12682352	0.579	rs7006589	chr8:8668486	A/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.44	-0.4	1.88e-19	Neuroticism;
LGG	cis	rs4363385	0.747	rs6684188	chr1:152974285	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.37e-18	Inflammatory skin disease;
LGG	cis	rs12681287	0.604	rs13279589	chr8:87477723	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.46e-14	Caudate activity during reward;
LGG	trans	rs7395662	1.000	rs6485875	chr11:48581034	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs908922	0.676	rs1053590	chr1:152488428	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.15	-0.55	4.82e-38	Hair morphology;
LGG	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs832540	1.000	rs252913	chr5:56195846	C/T	cg14703610	chr5:56206110	C5orf35	-0.44	-7.67	-0.34	1.06e-13	Coronary artery disease;
LGG	cis	rs2486288	0.586	rs12909883	chr15:45572054	G/C	cg26924012	chr15:45694286	SPATA5L1	-0.64	-11.12	-0.46	1.33e-25	Glomerular filtration rate;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg22398616	chr13:53314203	LECT1	-0.55	-12.06	-0.49	2.62e-29	Lewy body disease;
LGG	cis	rs6089584	1.000	rs6089584	chr20:60564086	G/C	cg12751644	chr20:60527061	NA	-0.3	-7.03	-0.31	7.54e-12	Body mass index;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.34	-0.5	1.98e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.58	9.64	0.41	3.52e-20	Blood protein levels;
LGG	trans	rs7395662	0.750	rs10838985	chr11:48645085	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	1.99e-13	HDL cholesterol;
LGG	trans	rs1814175	0.781	rs12286395	chr11:49954062	C/G	cg15704280	chr7:45808275	SEPT13	-1.08	-26.96	-0.78	6.05e-97	Height;
LGG	trans	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg18335740	chr13:41363409	SLC25A15	0.56	10.8	0.45	2.2e-24	Lewy body disease;
LGG	trans	rs826838	1.000	rs826838	chr12:39106731	C/T	cg06521331	chr12:34319734	NA	0.42	7.54	0.33	2.42e-13	Heart rate;
LGG	cis	rs12615966	1.000	rs61424916	chr2:105390188	C/A	cg16465502	chr2:105461796	NA	0.89	10.83	0.45	1.6e-24	Pancreatic cancer;
LGG	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg06606381	chr12:133084897	FBRSL1	0.71	8.31	0.36	1.06e-15	Depression;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg26174226	chr8:58114915	NA	-0.52	-7.7	-0.34	8.2e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.83	0.51	1.82e-32	Prudent dietary pattern;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg01754028	chr2:159825833	TANC1	0.51	7.52	0.33	2.93e-13	Breast cancer;
LGG	cis	rs7444	0.941	rs181362	chr22:21932068	C/T	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	cis	rs1218582	0.596	rs906595	chr1:154822907	C/T	cg24250549	chr1:154909240	PMVK	0.53	9.5	0.4	1.09e-19	Prostate cancer;
LGG	cis	rs9287719	0.781	rs12472807	chr2:10781605	G/A	cg02196655	chr2:10830764	NOL10	-0.47	-8.17	-0.35	3.02e-15	Prostate cancer;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.58	-0.44	1.47e-23	Prostate cancer;
LGG	cis	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.05	-0.46	2.38e-25	Resting heart rate;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg11062466	chr8:58055876	NA	0.58	9.08	0.39	3.2e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs12618769	0.652	rs17506535	chr2:99222834	G/C	cg18455616	chr2:99124870	INPP4A	0.27	7.78	0.34	4.91e-14	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.33	-0.4	4.4e-19	Lung cancer;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg19223190	chr17:80058835	NA	0.44	8.52	0.37	2.21e-16	Life satisfaction;
LGG	cis	rs7107174	0.892	rs11237450	chr11:78023356	C/A	cg02023728	chr11:77925099	USP35	0.43	7.27	0.32	1.55e-12	Testicular germ cell tumor;
LGG	cis	rs2732480	0.557	rs2732441	chr12:48723324	C/G	cg21466736	chr12:48725269	NA	-0.4	-8.03	-0.35	7.98e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs4363385	0.818	rs572821	chr1:153008276	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs834603	0.575	rs1534137	chr7:47482719	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.93	0.35	1.65e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs67133203	0.851	rs12824225	chr12:51462145	G/C	cg14688905	chr12:51403056	SLC11A2	0.71	10.68	0.44	5.81e-24	Urinary tract infection frequency;
LGG	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg26338869	chr17:61819248	STRADA	-0.47	-7.69	-0.34	9.09e-14	Prudent dietary pattern;
LGG	cis	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg04455712	chr21:45112962	RRP1B	0.54	10.06	0.42	1.14e-21	Mean corpuscular volume;
LGG	cis	rs727563	0.562	rs5758458	chr22:42154132	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6504108	0.624	rs12947089	chr17:46237990	A/G	cg02219949	chr17:45927392	SP6	0.43	7.92	0.35	1.78e-14	Body mass index;
LGG	cis	rs9549367	0.789	rs9549705	chr13:113888425	T/C	cg00898013	chr13:113819073	PROZ	-0.45	-8.68	-0.37	6.72e-17	Platelet distribution width;
LGG	cis	rs42648	0.748	rs10225744	chr7:89946003	T/C	cg25739043	chr7:89950458	NA	-0.36	-7.66	-0.34	1.1e-13	Homocysteine levels;
LGG	cis	rs8053891	0.906	rs28714527	chr16:71997862	C/G	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.66	-0.3	7.62e-11	Coronary artery disease;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg13047869	chr3:10149882	C3orf24	-0.53	-8.99	-0.39	6.22e-18	Alzheimer's disease;
LGG	cis	rs1707322	0.681	rs12048866	chr1:46117492	T/G	cg03146154	chr1:46216737	IPP	0.55	10.76	0.45	2.87e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	7.06	0.31	6.21e-12	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs208520	0.690	rs207082	chr6:66773796	G/A	cg07460842	chr6:66804631	NA	-0.96	-17.8	-0.64	2.2e-54	Exhaled nitric oxide output;
LGG	cis	rs2072499	0.966	rs2853641	chr1:156181770	A/G	cg25208724	chr1:156163844	SLC25A44	1.17	26.36	0.77	3.53e-94	Testicular germ cell tumor;
LGG	cis	rs2742417	1.000	rs2742406	chr3:45760600	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2.07e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg21775007	chr8:11205619	TDH	0.76	13.21	0.52	4.77e-34	Retinal vascular caliber;
LGG	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.47	-8.02	-0.35	8.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7928758	1.000	rs28402124	chr11:134280521	T/C	cg22777979	chr11:134283252	B3GAT1	0.85	10.84	0.45	1.44e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs10883723	0.775	rs2296579	chr10:104241375	A/G	cg05096777	chr10:104283225	SUFU	0.32	7.01	0.31	8.26e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1978968	0.640	rs2083882	chr22:18395241	C/T	cg03078520	chr22:18463400	MICAL3	0.44	8.43	0.36	4.52e-16	Presence of antiphospholipid antibodies;
LGG	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg00204512	chr16:28754710	NA	0.25	6.92	0.31	1.53e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12421382	0.593	rs2357793	chr11:109389353	A/T	cg15948088	chr11:109293068	C11orf87	0.46	8.32	0.36	9.59e-16	Schizophrenia;
LGG	cis	rs3741404	0.620	rs12787945	chr11:63977546	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	14.41	0.56	3.83e-39	Platelet count;
LGG	cis	rs131805	1.000	rs131816	chr22:50957462	C/T	cg05418105	chr22:50981406	NA	-0.62	-9.79	-0.41	1.09e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg14829155	chr15:31115871	NA	0.67	11.31	0.47	2.31e-26	Huntington's disease progression;
LGG	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg05874882	chr4:1763078	NA	-0.48	-6.78	-0.3	3.57e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg06074448	chr4:187884817	NA	0.59	12.66	0.51	9.64e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs994014	0.572	rs1452370	chr4:82247219	T/C	cg07938847	chr4:82126349	PRKG2	-0.29	-7.04	-0.31	6.89e-12	Height;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg19168338	chr16:4465731	CORO7	-0.91	-17.72	-0.64	5.28e-54	Schizophrenia;
LGG	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg13072238	chr3:49761600	GMPPB	-0.55	-6.88	-0.3	1.98e-11	Menarche (age at onset);
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.17	-0.32	2.98e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.98	-0.42	2.25e-21	Platelet count;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg19223190	chr17:80058835	NA	0.43	8.27	0.36	1.43e-15	Life satisfaction;
LGG	cis	rs9815354	1.000	rs28702390	chr3:41889920	C/A	cg03022575	chr3:42003672	ULK4	0.73	9.19	0.39	1.34e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg17911788	chr17:44343683	NA	-0.6	-9.16	-0.39	1.65e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17296441	chr20:62284078	STMN3	0.45	6.66	0.3	7.98e-11	Gut microbiome composition (summer);
LGG	cis	rs6800768	0.533	rs7628378	chr3:24128154	A/T	cg10674438	chr3:24145617	LOC152024	-0.32	-6.69	-0.3	6.39e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7998202	0.614	rs423117	chr13:113346107	C/T	cg17218041	chr13:113365319	ATP11A	0.44	7.19	0.32	2.64e-12	Glycated hemoglobin levels;
LGG	cis	rs12410462	0.579	rs77529417	chr1:227547895	T/C	cg23173402	chr1:227635558	NA	0.49	8.39	0.36	5.92e-16	Major depressive disorder;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16346588	chr10:242978	ZMYND11	0.39	6.77	0.3	3.99e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs55871839	0.559	rs7834158	chr8:59843813	C/A	cg07426533	chr8:59803705	TOX	0.59	12.46	0.5	6.37e-31	Pneumonia;
LGG	cis	rs873946	0.586	rs3793686	chr10:134569559	A/G	cg27297192	chr10:134578999	INPP5A	0.33	7.39	0.32	6.74e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3540	0.553	rs4031431	chr15:90990782	G/T	cg22089800	chr15:90895588	ZNF774	0.69	12.58	0.5	2.03e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs10540	0.541	rs7482356	chr11:437088	T/C	cg03576123	chr11:487126	PTDSS2	0.92	13.43	0.53	5.64e-35	Body mass index;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12548227	chr7:6144298	USP42	0.39	6.65	0.3	8.28e-11	Bipolar disorder;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	cis	rs41271951	0.512	rs76649628	chr1:151041851	A/G	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	cis	rs8067545	0.750	rs6587215	chr17:19980779	G/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.43e-11	Schizophrenia;
LGG	cis	rs36051895	0.658	rs7030260	chr9:5008070	C/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.33	-0.58	3.29e-43	Pediatric autoimmune diseases;
LGG	cis	rs6121246	0.633	rs6060986	chr20:30426297	G/A	cg21427119	chr20:30132790	HM13	-0.38	-6.99	-0.31	9.9e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7617773	0.779	rs3731487	chr3:48229624	C/T	cg11946769	chr3:48343235	NME6	0.68	11.09	0.46	1.72e-25	Coronary artery disease;
LGG	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.35	0.4	3.63e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs3780486	0.846	rs6476399	chr9:33123013	A/G	cg04842962	chr6:43655489	MRPS18A	1.12	24.41	0.75	3.46e-85	IgG glycosylation;
LGG	cis	rs208520	0.874	rs208481	chr6:66922636	A/G	cg07460842	chr6:66804631	NA	-0.92	-15.92	-0.59	8.27e-46	Exhaled nitric oxide output;
LGG	cis	rs929354	0.772	rs3802126	chr7:156970281	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	trans	rs3780486	0.846	rs10124479	chr9:33136233	T/G	cg20290983	chr6:43655470	MRPS18A	1.12	24.95	0.76	1.02e-87	IgG glycosylation;
LGG	cis	rs9878978	0.722	rs35014764	chr3:2460600	A/G	cg21928760	chr3:2462534	CNTN4	0.47	9.01	0.39	5.51e-18	Blood pressure (smoking interaction);
LGG	cis	rs7011192	0.793	rs11774104	chr8:10526434	C/G	cg17329886	chr8:10513629	RP1L1	-0.61	-7.7	-0.34	8.4e-14	Suicide;
LGG	cis	rs836589	0.506	rs10209860	chr2:173562488	G/A	cg06468108	chr2:173539091	NA	-0.47	-6.77	-0.3	3.87e-11	Erectile dysfunction in type 1 diabetes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26852602	chr15:83735291	BTBD1	0.4	6.76	0.3	4.14e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00689492	chr4:1303491	MAEA	0.51	8.93	0.38	9.99e-18	Obesity-related traits;
LGG	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg06636001	chr8:8085503	FLJ10661	0.42	7.33	0.32	1.02e-12	Retinal vascular caliber;
LGG	cis	rs2204008	0.715	rs11514342	chr12:38236710	T/A	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs1062746	0.711	rs2303763	chr16:87376605	C/T	cg02258303	chr16:87377426	FBXO31	0.6	11.85	0.48	1.82e-28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs9788682	1.000	rs61204066	chr15:78815298	G/A	cg06917634	chr15:78832804	PSMA4	-0.64	-9.71	-0.41	2.09e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs11098499	0.954	rs28685688	chr4:120420334	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08109568	chr15:31115862	NA	-0.59	-10.02	-0.42	1.55e-21	Huntington's disease progression;
LGG	cis	rs7193541	0.694	rs3896277	chr16:74480694	A/T	cg01733217	chr16:74700730	RFWD3	0.86	19.06	0.66	3.31e-60	Multiple myeloma;
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg27121462	chr16:89883253	FANCA	0.62	11.34	0.47	1.85e-26	Vitiligo;
LGG	cis	rs7635838	0.686	rs347588	chr3:11287504	C/T	cg00170343	chr3:11313890	ATG7	0.57	9.49	0.4	1.21e-19	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20123891	chr17:47653646	NXPH3	0.45	6.79	0.3	3.48e-11	Gut microbiome composition (summer);
LGG	cis	rs2073499	0.748	rs2859580	chr3:50194644	G/A	cg03645007	chr3:50255295	SLC38A3	-0.61	-6.83	-0.3	2.72e-11	Schizophrenia;
LGG	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15128208	chr22:42549153	NA	0.39	7.6	0.33	1.71e-13	Cognitive function;
LGG	cis	rs10504229	1.000	rs114312649	chr8:58182539	C/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs6062509	0.839	rs3859579	chr20:62301795	A/G	cg27236539	chr20:62289627	RTEL1	0.49	7.32	0.32	1.1e-12	Prostate cancer;
LGG	cis	rs116095464	1.000	rs6555160	chr5:311669	A/G	cg22496380	chr5:211416	CCDC127	0.98	9.71	0.41	1.99e-20	Breast cancer;
LGG	cis	rs11229555	0.645	rs4367960	chr11:58194961	C/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg11161011	chr14:65562177	MAX	0.65	12.74	0.51	4.56e-32	Obesity-related traits;
LGG	cis	rs10875746	0.729	rs11168355	chr12:48410978	A/G	cg24011408	chr12:48396354	COL2A1	0.49	6.66	0.3	7.87e-11	Longevity (90 years and older);
LGG	cis	rs3768617	0.624	rs34105373	chr1:183098387	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.36	6.94	0.31	1.32e-11	Fuchs's corneal dystrophy;
LGG	cis	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg08930214	chr7:62859557	LOC100287834	0.45	7.58	0.33	1.93e-13	Obesity-related traits;
LGG	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.9	-0.34	2.07e-14	Morning vs. evening chronotype;
LGG	cis	rs4006360	0.657	rs7225713	chr17:39252092	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.25	-0.46	4.01e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg16141378	chr3:129829833	LOC729375	-0.4	-9.44	-0.4	1.78e-19	Triglycerides;
LGG	cis	rs7552404	1.000	rs2133134	chr1:76179587	G/A	cg22875332	chr1:76189707	ACADM	0.6	9.41	0.4	2.27e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg00933542	chr6:150070202	PCMT1	0.37	6.65	0.3	8.45e-11	Lung cancer;
LGG	cis	rs2013441	0.965	rs8068720	chr17:20214171	G/T	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs9646397	chr17:80083534	G/A	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg18379455	chr17:41446167	NA	-0.33	-7.59	-0.33	1.78e-13	Menopause (age at onset);
LGG	cis	rs2070488	0.775	rs11926767	chr3:38527913	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-14.7	-0.56	1.93e-40	Electrocardiographic conduction measures;
LGG	cis	rs35306767	0.623	rs36062650	chr10:1142571	T/C	cg25019033	chr10:957182	NA	-0.42	-7.98	-0.35	1.14e-14	Eosinophil percentage of granulocytes;
LGG	cis	rs62244186	0.711	rs6778410	chr3:44743993	C/T	cg02073558	chr3:44770973	ZNF501	0.72	14.23	0.55	2.22e-38	Depressive symptoms;
LGG	cis	rs10463554	0.927	rs34373	chr5:102404294	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs6708331	0.517	rs11890741	chr2:70360506	T/C	cg01613454	chr2:70366299	NA	0.56	11.26	0.46	3.69e-26	Obesity-related traits;
LGG	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.35	-7.04	-0.31	7.17e-12	Bipolar disorder;
LGG	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg14416269	chr4:6271139	WFS1	0.46	8.06	0.35	6.48e-15	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1816752	0.806	rs3816218	chr13:25017171	A/G	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs7149337	0.836	rs4901087	chr14:51668499	T/C	cg23942311	chr14:51606299	NA	0.32	7.02	0.31	7.72e-12	Cancer;
LGG	cis	rs228769	0.543	rs170634	chr17:42175821	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.46	-8.01	-0.35	9.71e-15	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs75920871	1.000	rs7125788	chr11:116883396	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.04	-0.31	6.99e-12	Subjective well-being;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg14391382	chr7:866102	UNC84A	0.53	9.2	0.39	1.26e-18	Subjective well-being;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.93	0.35	1.62e-14	Lung cancer;
LGG	cis	rs7928758	0.943	rs11824649	chr11:134279352	T/C	cg25213107	chr11:134282864	B3GAT1	0.98	11.62	0.48	1.49e-27	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs490234	0.871	rs13288032	chr9:128255582	T/A	cg14078157	chr9:128172775	NA	-0.48	-9.1	-0.39	2.64e-18	Mean arterial pressure;
LGG	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg14541582	chr5:601475	NA	-0.69	-10.89	-0.45	9.94e-25	Obesity-related traits;
LGG	cis	rs1375194	0.582	rs13391166	chr2:33805314	C/T	cg04131969	chr2:33951647	MYADML	0.59	10.35	0.43	9.95e-23	Response to antidepressants in depression;
LGG	cis	rs875971	0.965	rs6971509	chr7:65714970	G/T	cg12463550	chr7:65579703	CRCP	-0.52	-8.69	-0.37	6.37e-17	Aortic root size;
LGG	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg24692254	chr21:30365293	RNF160	0.97	24.92	0.76	1.45e-87	Dental caries;
LGG	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg15596359	chr8:11213517	TDH	-0.34	-6.88	-0.3	1.99e-11	Retinal vascular caliber;
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg14668632	chr7:2872130	GNA12	-0.36	-7.44	-0.33	4.88e-13	Height;
LGG	cis	rs9906944	0.707	rs12942084	chr17:47114392	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.88	-0.3	1.99e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs7106204	0.686	rs12803558	chr11:24288205	C/A	ch.11.24196551F	chr11:24239977	NA	0.85	9.24	0.39	8.85e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs8180040	0.654	rs13078131	chr3:47204939	G/T	cg16586182	chr3:47516702	SCAP	-0.8	-15.37	-0.58	2.31e-43	Colorectal cancer;
LGG	cis	rs7267979	1.000	rs6107045	chr20:25441936	G/A	cg06421707	chr20:25228305	PYGB	0.46	9.89	0.42	4.92e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7011049	0.908	rs79560601	chr8:53853614	C/T	cg26025543	chr8:53854495	NA	0.75	9.92	0.42	3.73e-21	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg20607798	chr8:58055168	NA	0.69	7.8	0.34	4.02e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg19913688	chr11:428466	ANO9	-0.71	-8.95	-0.38	8.45e-18	Body mass index;
LGG	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg11812906	chr14:75593930	NEK9	-0.46	-8.08	-0.35	5.76e-15	Height;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg18876405	chr7:65276391	NA	-0.53	-9.4	-0.4	2.58e-19	Aortic root size;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.24	0.36	1.82e-15	Schizophrenia;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg07870213	chr5:140052090	DND1	0.94	17.79	0.64	2.42e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg04568710	chr12:38710424	ALG10B	0.35	7.28	0.32	1.44e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg23422044	chr7:1970798	MAD1L1	-0.6	-9.14	-0.39	2.01e-18	Neuroticism;
LGG	cis	rs9322193	0.923	rs7767622	chr6:150002902	T/C	cg08621203	chr6:150244597	RAET1G	0.46	7.95	0.35	1.45e-14	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00993799	chr7:104653126	LOC100216545	0.41	6.86	0.3	2.17e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9479482	0.967	rs3860823	chr6:150356526	A/G	cg16395133	chr6:150326394	RAET1K	0.26	6.76	0.3	4.21e-11	Alopecia areata;
LGG	cis	rs3764563	0.877	rs4019751	chr19:15740716	T/G	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.36	-0.36	7.5e-16	Inflammatory biomarkers;
LGG	cis	rs9814567	1.000	rs6800862	chr3:134228628	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.46e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.72	0.3	5.37e-11	Educational attainment;
LGG	trans	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg17712092	chr4:129076599	LARP1B	0.74	14.18	0.55	3.61e-38	Eosinophil percentage of white cells;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg19500098	chr13:21900506	NA	0.4	7.85	0.34	2.93e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7923837	0.713	rs10882099	chr10:94460650	T/C	cg25093409	chr10:94429542	NA	0.53	10.76	0.45	3.01e-24	Body mass index;Multiple sclerosis;
LGG	trans	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg13565492	chr6:43139072	SRF	-0.74	-8.99	-0.39	6.13e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7188861	0.768	rs243315	chr16:11385011	C/T	cg01510278	chr16:11456238	NA	0.31	7.27	0.32	1.57e-12	HDL cholesterol;
LGG	cis	rs11771526	0.786	rs11768318	chr7:32372965	T/G	cg13207630	chr7:32358064	NA	0.8	7.92	0.35	1.81e-14	Body mass index;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg00933542	chr6:150070202	PCMT1	0.41	7.4	0.33	6.55e-13	Lung cancer;
LGG	trans	rs11088226	0.681	rs74779447	chr21:33929013	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	12.36	0.5	1.59e-30	Gastritis;
LGG	cis	rs926938	0.563	rs360642	chr1:115425429	C/G	cg12756093	chr1:115239321	AMPD1	0.44	8.38	0.36	6.39e-16	Autism;
LGG	cis	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg19847130	chr8:10466454	RP1L1	-0.32	-6.94	-0.31	1.29e-11	Neuroticism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00101895	chr6:108279135	SEC63	0.46	7.89	0.34	2.23e-14	Parental extreme longevity (95 years and older);
LGG	cis	rs7011049	0.749	rs117000605	chr8:53864529	T/G	cg26025543	chr8:53854495	NA	0.6	8.39	0.36	6.01e-16	Systolic blood pressure;
LGG	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg07777115	chr5:623756	CEP72	-0.6	-7.52	-0.33	2.87e-13	Obesity-related traits;
LGG	cis	rs2267681	0.544	rs10237429	chr7:139528596	C/G	cg14116596	chr7:139528673	TBXAS1	0.32	7.1	0.31	4.83e-12	Cervical cancer;
LGG	cis	rs370915	0.542	rs1895844	chr4:187833759	C/T	cg19519643	chr4:187840862	NA	-0.65	-13.61	-0.53	9.94e-36	Gout;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21618713	chr4:153701330	ARFIP1;TIGD4	0.42	6.99	0.31	9.34e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg23306229	chr2:178417860	TTC30B	0.72	8.49	0.37	2.77e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7582180	0.602	rs7585582	chr2:100998030	G/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.48	-0.47	5.35e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg04568710	chr12:38710424	ALG10B	0.36	7.77	0.34	5.01e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4664308	1.000	rs6719686	chr2:160908292	T/G	cg03641300	chr2:160917029	PLA2R1	-0.86	-18.04	-0.64	1.81e-55	Idiopathic membranous nephropathy;
LGG	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg05623727	chr3:50126028	RBM5	0.34	7.34	0.32	9.97e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg05534807	chr11:75379613	MAP6	0.42	7.24	0.32	1.88e-12	Body mass index;
LGG	trans	rs9747201	0.962	rs11656153	chr17:80072950	G/A	cg07393940	chr7:158741817	NA	-0.61	-11.22	-0.46	5.38e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9419702	0.538	rs4074772	chr10:133540006	A/T	cg04492858	chr10:133558786	NA	0.35	6.64	0.3	8.57e-11	Survival in rectal cancer;
LGG	cis	rs6686643	0.762	rs61800372	chr1:165611981	T/C	cg19407955	chr1:165599744	MGST3	-0.62	-8.93	-0.38	1.03e-17	Total ventricular volume;
LGG	cis	rs7828089	0.935	rs1568569	chr8:22249943	T/G	cg12081754	chr8:22256438	SLC39A14	0.76	15.14	0.58	2.3e-42	Verbal declarative memory;
LGG	cis	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg21775007	chr8:11205619	TDH	0.81	14.37	0.56	5.73e-39	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1658427	chr10:60331504	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.3	-0.32	1.25e-12	Refractive error;
LGG	cis	rs62238980	0.614	rs117002438	chr22:32371395	G/A	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs12135191	0.711	rs56176877	chr1:236491088	A/T	cg21399712	chr1:236511386	NA	-0.43	-8.09	-0.35	5.25e-15	Urate levels (BMI interaction);
LGG	cis	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg16400903	chr5:693638	TPPP	0.48	7.11	0.31	4.33e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.21	-0.49	6.21e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs975722	0.614	rs213943	chr7:117173230	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.79	0.41	1.04e-20	Coronary artery disease;
LGG	cis	rs7727544	0.735	rs272881	chr5:131669264	G/A	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.25e-34	Blood metabolite levels;
LGG	cis	rs11190604	1.000	rs2489047	chr10:102347028	A/G	cg07570687	chr10:102243282	WNT8B	0.39	6.72	0.3	5.28e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11608355	0.545	rs4766475	chr12:109908373	G/A	cg05360138	chr12:110035743	NA	0.84	12.02	0.49	3.87e-29	Neuroticism;
LGG	cis	rs7511006	0.895	rs5771270	chr22:50682865	G/A	cg08875078	chr22:50639485	SELO	0.44	7.13	0.31	3.8e-12	Obesity-related traits;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.82	0.51	2.14e-32	Prudent dietary pattern;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg22963979	chr7:1858916	MAD1L1	-0.49	-10.25	-0.43	2.32e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7089973	0.872	rs7923295	chr10:116625159	C/G	cg08188268	chr10:116634841	FAM160B1	-0.35	-7.7	-0.34	8.09e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.92	-0.42	3.72e-21	Platelet count;
LGG	cis	rs1218582	0.772	rs2174507	chr1:154887949	C/T	cg09359103	chr1:154839909	KCNN3	-0.51	-10.52	-0.44	2.4e-23	Prostate cancer;
LGG	cis	rs9914988	0.943	rs7217547	chr17:27106872	C/G	cg20469991	chr17:27169893	C17orf63	-0.53	-6.71	-0.3	5.69e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs807029	0.533	rs3740487	chr10:102750783	C/A	cg04662943	chr10:102668895	NA	0.47	6.91	0.31	1.59e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1882538	0.564	rs12707090	chr7:133115163	G/A	cg10665199	chr7:133106180	EXOC4	0.59	9.8	0.41	1.03e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.607	rs656652	chr11:67343957	C/T	cg08355456	chr11:67383691	NA	0.5	8.58	0.37	1.47e-16	Mean corpuscular volume;
LGG	cis	rs11758351	1.000	rs111596617	chr6:26191678	A/T	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs6558530	0.615	rs12674711	chr8:1699608	A/G	cg25947184	chr8:1697459	NA	0.47	8.33	0.36	8.99e-16	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg11878867	chr6:150167359	LRP11	-0.53	-10.93	-0.45	6.99e-25	Lung cancer;
LGG	cis	rs9814567	1.000	rs1917130	chr3:134313773	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.95	0.52	5.82e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12220238	0.841	rs11000942	chr10:76025256	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.69	8.85	0.38	1.82e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs283228	0.678	rs1415946	chr6:101846343	T/C	cg27451362	chr6:101846650	GRIK2	0.69	11.14	0.46	1.06e-25	Coenzyme Q10 levels;
LGG	cis	rs9462027	0.628	rs9469863	chr6:34739649	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs17209837	1.000	rs17209837	chr7:87124822	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-11.59	-0.47	1.95e-27	Gallbladder cancer;
LGG	cis	rs11650494	0.710	rs57030023	chr17:47468546	T/A	cg08112188	chr17:47440006	ZNF652	1.2	13.23	0.52	4.05e-34	Prostate cancer;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg23324259	chr8:82754387	SNX16	0.44	7.07	0.31	5.57e-12	Diastolic blood pressure;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg19168338	chr16:4465731	CORO7	-0.74	-13.76	-0.54	2.38e-36	Schizophrenia;
LGG	cis	rs9660992	0.639	rs1151786	chr1:205227760	G/C	cg21545522	chr1:205238299	TMCC2	0.49	8.99	0.39	6.26e-18	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs3942852	0.806	rs10769316	chr11:48119745	C/G	cg15704280	chr7:45808275	SEPT13	-0.66	-9.24	-0.39	8.63e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2244613	0.882	rs1974708	chr16:55793837	T/C	cg27396498	chr16:55794478	CES4	0.44	8.73	0.38	4.65e-17	Response to dabigatran etexilate treatment;
LGG	cis	rs9287719	0.967	rs10929688	chr2:10756650	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.6	-0.41	4.86e-20	Aortic root size;
LGG	cis	rs11229555	0.645	rs11229459	chr11:58208025	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs597539	0.652	rs584108	chr11:68630282	A/T	cg18350739	chr11:68623251	NA	0.89	23.07	0.73	5.99e-79	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs11586313	0.506	rs6671493	chr1:152870341	A/G	cg13444842	chr1:152974279	SPRR3	-0.39	-7.53	-0.33	2.64e-13	Vitamin D levels;
LGG	cis	rs128738	0.500	rs2077380	chr5:131568617	C/T	cg05556477	chr5:131705319	SLC22A5	-0.47	-6.92	-0.31	1.48e-11	Giant cell arteritis;
LGG	cis	rs6502050	0.529	rs35585236	chr17:80116641	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.84	-0.42	7.17e-21	Life satisfaction;
LGG	cis	rs12950390	0.853	rs11079790	chr17:45853626	G/A	cg24803719	chr17:45855879	NA	-0.3	-8.64	-0.37	9.26e-17	IgG glycosylation;
LGG	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg08847335	chr10:891726	LARP4B	-0.47	-8.49	-0.37	2.88e-16	Eosinophil percentage of granulocytes;
LGG	trans	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.26	-0.32	1.69e-12	Monocyte count;
LGG	cis	rs4423214	1.000	rs909217	chr11:71146577	G/A	cg05163923	chr11:71159392	DHCR7	0.69	13.16	0.52	7.62e-34	Vitamin D levels;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg03528353	chr17:61819722	STRADA	0.45	7.32	0.32	1.14e-12	Prudent dietary pattern;
LGG	cis	rs3126085	0.935	rs1858479	chr1:152294823	A/T	cg26876637	chr1:152193138	HRNR	-0.51	-8.02	-0.35	8.96e-15	Atopic dermatitis;
LGG	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07648498	chr16:89883185	FANCA	0.4	6.87	0.3	2.14e-11	Vitiligo;
LGG	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.26	0.4	7.82e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7089973	0.836	rs7895551	chr10:116625481	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs61931739	0.500	rs11053248	chr12:34518011	G/A	cg26384229	chr12:38710491	ALG10B	0.97	21.48	0.71	1.58e-71	Morning vs. evening chronotype;
LGG	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg06360820	chr2:242988706	NA	-0.9	-11.97	-0.49	6e-29	Obesity-related traits;
LGG	cis	rs2797160	1.000	rs13328298	chr6:126016580	G/A	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg08677398	chr8:58056175	NA	0.44	7.36	0.32	8.38e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.818	rs423692	chr1:153005681	T/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg05313129	chr8:58192883	C8orf71	-0.59	-7.44	-0.33	4.88e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg17340268	chr14:105411764	AHNAK2	0.38	7.21	0.32	2.28e-12	Rheumatoid arthritis;
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	-0.54	-9.71	-0.41	2.03e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs240764	0.612	rs241819	chr6:100910798	G/A	cg21058520	chr6:100914733	NA	0.46	8.02	0.35	8.56e-15	Neuroticism;
LGG	cis	rs11651000	0.625	rs11079786	chr17:45805916	A/G	cg24803719	chr17:45855879	NA	0.25	6.82	0.3	2.85e-11	IgG glycosylation;
LGG	cis	rs4919687	0.514	rs3850699	chr10:104414221	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.43	-7.02	-0.31	7.87e-12	Colorectal cancer;
LGG	cis	rs17208368	0.628	rs4784471	chr16:55092849	G/A	cg11181171	chr16:55090946	NA	0.47	7.78	0.34	4.91e-14	Hypospadias;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs4595586	0.525	rs73096109	chr12:39355720	C/A	cg13010199	chr12:38710504	ALG10B	0.48	8.52	0.37	2.28e-16	Morning vs. evening chronotype;
LGG	cis	rs1707322	0.717	rs10890345	chr1:46213927	C/T	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.41e-11	Depression;
LGG	cis	rs4650994	1.000	rs10913572	chr1:178526718	C/T	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10870270	0.957	rs7074604	chr10:133740373	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.47	-0.5	5.88e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11098499	0.863	rs10004484	chr4:120442428	C/T	cg09307838	chr4:120376055	NA	0.77	12.85	0.51	1.62e-32	Corneal astigmatism;
LGG	cis	rs2836974	0.863	rs8132333	chr21:40527900	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.65	0.82	1.7e-113	Cognitive function;
LGG	cis	rs6547741	0.935	rs56001553	chr2:27859926	C/T	cg27432699	chr2:27873401	GPN1	-0.71	-14.39	-0.56	4.43e-39	Oral cavity cancer;
LGG	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg20368463	chr18:77673604	PQLC1	-0.47	-8.34	-0.36	8.55e-16	Schizophrenia;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7904368	0.568	rs10752061	chr10:16853900	A/G	cg22980697	chr10:16874865	CUBN	0.42	7.52	0.33	2.95e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs4917300	0.605	rs10108708	chr8:143102886	A/G	cg26003909	chr8:143102224	NA	-0.4	-8.74	-0.38	4.35e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs12517041	1.000	rs6874000	chr5:23304235	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.79	11.88	0.48	1.34e-28	Calcium levels;
LGG	cis	rs11191205	0.686	rs10786644	chr10:103396646	C/T	cg15320455	chr10:103880129	LDB1	0.48	6.96	0.31	1.15e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg06606381	chr12:133084897	FBRSL1	-1.1	-8.83	-0.38	2.09e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg02931644	chr1:25747376	RHCE	0.43	9.5	0.4	1.11e-19	Erythrocyte sedimentation rate;
LGG	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg12163867	chr12:51592794	POU6F1	-0.4	-8.54	-0.37	1.93e-16	Cisplatin-induced ototoxicity;
LGG	trans	rs6787172	0.622	rs6774676	chr3:158093041	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.24	0.39	8.77e-19	Diabetic retinopathy;
LGG	trans	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs10504229	0.906	rs2270607	chr8:58194699	A/G	cg05313129	chr8:58192883	C8orf71	-0.79	-11.86	-0.48	1.6e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.507	rs199741	chr6:25931577	A/G	cg03264133	chr6:25882463	NA	-0.89	-16.73	-0.61	1.66e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1867631	1.000	rs11208927	chr1:67089561	T/C	cg13052034	chr1:66999238	SGIP1	0.47	9.29	0.4	5.82e-19	Menopause (age at onset);
LGG	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg09307838	chr4:120376055	NA	0.8	13.38	0.53	9.47e-35	Corneal astigmatism;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.3e-13	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs77324143	chr22:32401957	C/T	cg00543991	chr22:32367038	NA	0.8	8.9	0.38	1.28e-17	Childhood ear infection;
LGG	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg24011408	chr12:48396354	COL2A1	0.52	8.31	0.36	1.09e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs8062405	0.755	rs62031607	chr16:28631530	A/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.49	0.37	2.82e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg01625945	chr7:157512322	PTPRN2	0.33	6.82	0.3	2.86e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.66e-12	Triglycerides;
LGG	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg12439423	chr8:41522721	ANK1	0.46	8.59	0.37	1.36e-16	Type 2 diabetes;
LGG	cis	rs3816183	0.585	rs13027020	chr2:42865441	G/A	cg14631114	chr2:43023945	NA	0.34	6.82	0.3	2.78e-11	Hypospadias;
LGG	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg13010199	chr12:38710504	ALG10B	-0.52	-10.15	-0.43	5.26e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1920116	0.778	rs4352416	chr3:169554084	G/A	cg08193579	chr3:169529701	LRRC34	0.42	7.4	0.33	6.55e-13	Glioma (high-grade);
LGG	cis	rs4740619	0.782	rs770524	chr9:15577549	G/C	cg14451791	chr9:16040625	NA	-0.34	-8.57	-0.37	1.6e-16	Body mass index;
LGG	cis	rs11785400	0.793	rs13248524	chr8:143739343	T/C	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.64e-14	Schizophrenia;
LGG	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg02733842	chr7:1102375	C7orf50	-0.5	-7.72	-0.34	7.36e-14	Bronchopulmonary dysplasia;
LGG	cis	rs7208859	0.623	rs8067338	chr17:29102345	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1620921	0.875	rs1652455	chr6:161210349	C/G	cg01280913	chr6:161186852	NA	-0.38	-7.73	-0.34	6.78e-14	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2953145	0.545	rs2975751	chr2:241521135	G/A	cg07929629	chr2:241523174	NA	0.64	10.87	0.45	1.16e-24	Bipolar disorder;
LGG	cis	rs644799	1.000	rs494829	chr11:95571750	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10048158	0.528	rs8073418	chr17:64247672	A/C	cg19474267	chr17:64306194	PRKCA	-0.63	-12.18	-0.49	8.34e-30	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs36051895	0.632	rs11790841	chr9:5166273	G/C	cg02405213	chr9:5042618	JAK2	-0.77	-13.56	-0.53	1.64e-35	Pediatric autoimmune diseases;
LGG	cis	rs12220238	0.818	rs16931294	chr10:75999169	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.79	11.72	0.48	5.94e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4787491	0.679	rs7204852	chr16:30040178	C/G	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.13e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9916302	0.706	rs9908131	chr17:37520449	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.92e-16	Glomerular filtration rate (creatinine);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19080138	chr7:35734733	HERPUD2	0.39	6.65	0.3	8.29e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg16316162	chr8:144660157	NAPRT1	0.75	6.81	0.3	3.06e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs9381107	0.932	rs9380624	chr6:9418725	A/C	cg14735645	chr6:9486422	NA	-0.41	-6.91	-0.31	1.65e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2153535	0.504	rs9405393	chr6:8467432	G/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs4363385	0.667	rs78426057	chr1:152964528	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.8	-0.38	2.67e-17	Inflammatory skin disease;
LGG	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg08949735	chr16:89699720	DPEP1	-0.37	-7.58	-0.33	1.88e-13	Hemoglobin concentration;
LGG	cis	rs7582180	0.681	rs6754176	chr2:100995691	C/T	cg26150922	chr2:100937072	LONRF2	-0.59	-11.46	-0.47	6.19e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4654899	0.802	rs10493004	chr1:21442736	T/C	cg05370193	chr1:21551575	ECE1	0.29	6.72	0.3	5.33e-11	Superior frontal gyrus grey matter volume;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26517889	chr13:25497356	CENPJ	0.46	7.38	0.32	7.4e-13	Cognitive performance;
LGG	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg20913747	chr6:44695427	NA	-0.54	-8.14	-0.35	3.76e-15	Total body bone mineral density;
LGG	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg03909863	chr11:638404	DRD4	-0.41	-6.7	-0.3	5.93e-11	Systemic lupus erythematosus;
LGG	cis	rs6500395	1.000	rs3919552	chr16:48716328	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg22398616	chr13:53314203	LECT1	-0.34	-6.76	-0.3	4.15e-11	Lewy body disease;
LGG	cis	rs741702	0.928	rs10451496	chr19:13017876	C/T	cg23899408	chr19:12877188	HOOK2	-0.48	-7.74	-0.34	6.45e-14	Red blood cell traits;
LGG	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg18154014	chr19:37997991	ZNF793	-0.59	-10.35	-0.43	9.94e-23	Coronary artery calcification;
LGG	cis	rs1385374	0.858	rs11059930	chr12:129297860	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.64e-13	Prudent dietary pattern;
LGG	cis	rs6120849	0.901	rs6058194	chr20:33739831	G/A	cg24642439	chr20:33292090	TP53INP2	0.51	6.95	0.31	1.25e-11	Protein C levels;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	cis	rs4665809	0.567	rs6546848	chr2:26444414	G/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs4077515	0.934	rs3829111	chr9:139269483	G/A	cg21253087	chr9:139290292	SNAPC4	0.35	7.1	0.31	4.86e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11157436	0.602	rs12587826	chr14:22634201	A/G	cg00994629	chr14:22694547	NA	0.33	7.13	0.31	3.98e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2905347	0.529	rs2961292	chr7:22683137	C/T	cg18045685	chr7:22629474	NA	-0.73	-15.9	-0.59	9.58e-46	Major depression and alcohol dependence;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg05313129	chr8:58192883	C8orf71	-0.68	-9.82	-0.42	8.45e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	cg07245641	chr1:182991651	LAMC1	0.39	8.94	0.38	9.31e-18	Colorectal cancer;
LGG	cis	rs7100689	0.577	rs2185427	chr10:82056667	G/T	cg01528321	chr10:82214614	TSPAN14	-0.77	-13.38	-0.53	9.66e-35	Post bronchodilator FEV1;
LGG	cis	rs9549367	0.804	rs9549704	chr13:113885187	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.01	-0.35	9.17e-15	Platelet distribution width;
LGG	trans	rs11098499	0.863	rs2306457	chr4:120472839	T/A	cg25214090	chr10:38739885	LOC399744	0.66	11.65	0.48	1.1e-27	Corneal astigmatism;
LGG	cis	rs77633900	0.772	rs172244	chr15:76722769	A/T	cg21673338	chr15:77095150	SCAPER	-0.63	-8.28	-0.36	1.36e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs6141769	0.542	rs6058819	chr20:31303942	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.8	-0.3	3.32e-11	Subjective well-being;
LGG	cis	rs12477438	0.539	rs3791212	chr2:99982201	G/T	cg23527387	chr2:100056660	REV1	0.44	9.78	0.41	1.21e-20	Chronic sinus infection;
LGG	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg25174290	chr11:3078921	CARS	-0.53	-9.72	-0.41	1.92e-20	Calcium levels;
LGG	cis	rs9463078	0.585	rs718112	chr6:44859451	T/G	cg25276700	chr6:44698697	NA	0.34	7.14	0.31	3.69e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11105298	0.891	rs10777162	chr12:89830523	A/G	cg00757033	chr12:89920650	WDR51B	0.61	8.63	0.37	1.02e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10751667	0.666	rs7124480	chr11:971601	G/A	cg22143635	chr11:980567	AP2A2	0.44	8.1	0.35	5.01e-15	Alzheimer's disease (late onset);
LGG	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg11247378	chr22:39784982	NA	-0.31	-8.82	-0.38	2.41e-17	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13423282	chr19:19174731	SLC25A42	0.43	6.83	0.3	2.7e-11	Cognitive performance;
LGG	trans	rs7819412	0.805	rs2409710	chr8:10979821	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.48	-0.4	1.31e-19	Triglycerides;
LGG	cis	rs80282103	0.867	rs74117668	chr10:1076620	C/T	cg08668510	chr10:1095578	IDI1	0.76	7.78	0.34	4.75e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg18876405	chr7:65276391	NA	-0.49	-8.81	-0.38	2.56e-17	Aortic root size;
LGG	cis	rs1847202	0.592	rs13073005	chr3:72951007	C/T	cg25664220	chr3:72788482	NA	-0.25	-7.32	-0.32	1.13e-12	Motion sickness;
LGG	cis	rs4474465	1.000	rs10899525	chr11:78201454	T/G	cg27205649	chr11:78285834	NARS2	-0.48	-8.26	-0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs763121	0.962	rs5757135	chr22:38952573	C/T	cg06022373	chr22:39101656	GTPBP1	0.79	15.9	0.59	9.54e-46	Menopause (age at onset);
LGG	cis	rs75920871	0.925	rs61903418	chr11:116956665	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs7618915	0.547	rs62253700	chr3:52625019	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	5.05e-12	Bipolar disorder;
LGG	cis	rs780096	0.506	rs2288155	chr2:27714526	T/C	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs611744	0.604	rs13248461	chr8:109285833	C/T	cg18478394	chr8:109455254	TTC35	0.44	8.82	0.38	2.32e-17	Dupuytren's disease;
LGG	cis	rs7089973	0.872	rs3180654	chr10:116615045	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.68	0.34	9.66e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07869135	chr8:123794843	ZHX2	0.51	7.78	0.34	4.72e-14	Gut microbiome composition (summer);
LGG	cis	rs2188561	0.666	rs13231387	chr7:107389979	C/T	cg16793755	chr7:107334138	SLC26A4	0.41	7.2	0.32	2.53e-12	Alcohol consumption;
LGG	cis	rs12145833	0.538	rs10754798	chr1:243309958	A/G	cg02356786	chr1:243265016	LOC731275	-0.58	-6.79	-0.3	3.39e-11	Obesity (early onset extreme);
LGG	cis	rs4423214	0.798	rs12224205	chr11:71180992	A/G	cg05163923	chr11:71159392	DHCR7	-0.65	-11.28	-0.46	3.16e-26	Vitamin D levels;
LGG	cis	rs36715	1.000	rs36697	chr5:127549613	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	7.44	0.33	4.84e-13	Breast cancer;
LGG	cis	rs4478858	0.735	rs3806255	chr1:31791578	A/G	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.27e-11	Alcohol dependence;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	trans	rs9354308	0.764	rs4476812	chr6:66594554	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.4	6.89	0.3	1.88e-11	Metabolite levels;
LGG	cis	rs10789491	1.000	rs1890473	chr1:47149794	C/T	cg15501359	chr1:47185051	KIAA0494	0.66	13.5	0.53	3.03e-35	Response to hepatitis C treatment;
LGG	cis	rs17067123	0.614	rs72712845	chr4:180060896	C/A	cg26610307	chr4:180072759	NA	-0.49	-6.89	-0.3	1.86e-11	Response to hepatitis C treatment;
LGG	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg11984989	chr7:158649758	WDR60	0.88	8.93	0.38	9.81e-18	Hippocampal volume;
LGG	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg05169099	chr5:481640	SLC9A3	0.46	6.82	0.3	2.86e-11	Fat distribution (HIV);
LGG	cis	rs3812831	0.695	rs913526	chr13:114928946	G/C	cg08824895	chr13:115047677	UPF3A	0.42	7.06	0.31	5.97e-12	Schizophrenia;
LGG	cis	rs6674970	1.000	rs6674970	chr1:151116279	C/T	cg03258749	chr1:151040405	MLLT11	-0.45	-8.16	-0.35	3.13e-15	Childhood ear infection;
LGG	trans	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg01620082	chr3:125678407	NA	-0.64	-6.9	-0.31	1.76e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6430585	0.528	rs586964	chr2:136652491	G/A	cg07169764	chr2:136633963	MCM6	1.25	22.72	0.73	2.57e-77	Corneal structure;
LGG	cis	rs4006360	0.657	rs72625994	chr17:39253749	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.18	-0.46	7.23e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs755249	0.567	rs2296172	chr1:39835817	A/G	cg18385671	chr1:39797026	MACF1	0.44	7.62	0.33	1.46e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7613875	0.620	rs3774734	chr3:50108792	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.4	-6.85	-0.3	2.3e-11	Body mass index;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.27	-0.36	1.45e-15	Lymphocyte counts;
LGG	cis	rs12618769	0.597	rs17504774	chr2:99135627	A/G	cg18455616	chr2:99124870	INPP4A	-0.29	-8.53	-0.37	2.15e-16	Bipolar disorder;
LGG	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.5	-0.33	3.38e-13	Testicular germ cell tumor;
LGG	cis	rs4604732	0.631	rs11490200	chr1:247625915	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2404602	0.622	rs11632365	chr15:77139080	G/A	cg23625390	chr15:77176239	SCAPER	-0.72	-12.7	-0.51	6.77e-32	Blood metabolite levels;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg26174226	chr8:58114915	NA	-0.44	-6.89	-0.3	1.88e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.26	-0.32	1.67e-12	Menopause (age at onset);
LGG	cis	rs7189020	0.701	rs9788833	chr16:292772	T/C	cg25425005	chr16:202905	HBZ	-0.36	-6.91	-0.31	1.62e-11	Mean corpuscular volume;
LGG	trans	rs17685	0.712	rs4732578	chr7:75721532	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.97	0.77	2.03e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2299587	0.786	rs3886397	chr8:17880625	C/T	cg18067069	chr8:17937731	ASAH1	-0.29	-6.83	-0.3	2.72e-11	Economic and political preferences;
LGG	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg04568710	chr12:38710424	ALG10B	0.34	7.15	0.32	3.33e-12	Morning vs. evening chronotype;
LGG	cis	rs1577917	0.727	rs2758840	chr6:86304625	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.31	-0.63	4.09e-52	Response to antipsychotic treatment;
LGG	cis	rs113835537	0.529	rs2305533	chr11:66298623	A/C	cg24851651	chr11:66362959	CCS	0.45	7.77	0.34	5.26e-14	Airway imaging phenotypes;
LGG	cis	rs548181	0.736	rs540723	chr11:125489621	A/G	cg03464685	chr11:125439445	EI24	1.33	20.07	0.68	6.39e-65	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs875971	0.660	rs28698552	chr7:66005018	A/G	cg11764359	chr7:65958608	NA	0.63	10.81	0.45	1.96e-24	Aortic root size;
LGG	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg03433033	chr1:76189801	ACADM	0.75	12.09	0.49	1.88e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9796	0.558	rs7166905	chr15:41514876	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.58	-10.16	-0.43	4.85e-22	Menopause (age at onset);
LGG	cis	rs1843834	0.539	rs6713629	chr2:225410973	A/T	cg12698349	chr2:225449008	CUL3	0.69	11.7	0.48	7.09e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs9611565	0.512	rs5758439	chr22:42131762	C/T	cg03806693	chr22:41940476	POLR3H	1.04	17.73	0.64	4.63e-54	Vitiligo;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs56176327	0.532	rs9849038	chr3:49771990	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.62	-0.33	1.48e-13	Intelligence (multi-trait analysis);
LGG	cis	rs62380364	0.565	rs617944	chr5:88057915	T/C	cg22951263	chr5:87985283	NA	-0.54	-10.04	-0.42	1.36e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6120849	0.754	rs17319032	chr20:33643296	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs637571	0.546	rs10791827	chr11:65596546	C/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-7.86	-0.34	2.69e-14	Eosinophil percentage of white cells;
LGG	cis	rs910187	0.571	rs3746490	chr20:45801712	G/A	cg27589058	chr20:45804311	EYA2	-0.38	-10.13	-0.43	6.58e-22	Migraine;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.35	0.32	9.12e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs116095464	0.558	rs6555055	chr5:226160	A/C	cg22857025	chr5:266934	NA	-1.51	-26.49	-0.78	8.66e-95	Breast cancer;
LGG	cis	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.16	-0.35	3.25e-15	Ulcerative colitis;
LGG	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg12658694	chr1:38397304	INPP5B	0.54	12.5	0.5	4.11e-31	Coronary artery disease;
LGG	cis	rs7582180	0.764	rs12999779	chr2:100924321	T/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	1.000	rs12506395	chr4:120185094	C/T	cg25214090	chr10:38739885	LOC399744	0.64	11.53	0.47	3.32e-27	Corneal astigmatism;
LGG	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg14675211	chr2:100938903	LONRF2	0.47	7.29	0.32	1.37e-12	Intelligence (multi-trait analysis);
LGG	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg18200150	chr17:30822561	MYO1D	0.48	8.98	0.39	6.73e-18	Schizophrenia;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg26656751	chr17:43910226	CRHR1	0.48	8.87	0.38	1.54e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1322639	0.542	rs9689153	chr6:169586825	T/C	cg03254818	chr6:169586852	NA	-0.55	-7.83	-0.34	3.3e-14	Pulse pressure;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg11494091	chr17:61959527	GH2	-1.1	-29.72	-0.81	2.31e-109	Prudent dietary pattern;
LGG	cis	rs7923609	0.561	rs2195594	chr10:65319321	G/A	cg02276361	chr10:65351566	REEP3	-0.31	-6.94	-0.31	1.37e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs17776563	0.593	rs10852104	chr15:89141756	G/C	cg05013243	chr15:89149849	MIR1179	-0.34	-7.07	-0.31	5.84e-12	Thyroid hormone levels;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg19168338	chr16:4465731	CORO7	-0.94	-19.32	-0.67	2.02e-61	Schizophrenia;
LGG	cis	rs9543976	1.000	rs8192762	chr13:76176680	A/T	cg01531495	chr13:76123901	UCHL3	0.63	7.61	0.33	1.58e-13	Diabetic retinopathy;
LGG	cis	rs368123	0.924	rs444989	chr6:160707751	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.14	-0.31	3.75e-12	Waist circumference;
LGG	cis	rs2204008	0.540	rs1672425	chr12:38122842	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.87	-0.45	1.19e-24	Bladder cancer;
LGG	cis	rs17253792	0.822	rs113649689	chr14:56088065	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07677032	chr17:61819896	STRADA	0.68	12.82	0.51	2.07e-32	Prudent dietary pattern;
LGG	cis	rs68170813	0.652	rs116894096	chr7:107178477	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-8.34	-0.36	8.83e-16	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17187183	chr4:55093834	PDGFRA	0.41	6.97	0.31	1.08e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9303401	0.659	rs17822837	chr17:56737838	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.97	0.54	2.99e-37	Cognitive test performance;
LGG	cis	rs6868223	0.617	rs4242082	chr5:33649637	C/T	cg10594543	chr5:33649717	ADAMTS12	0.65	15.22	0.58	1.02e-42	Mortality in heart failure;
LGG	trans	rs656319	0.607	rs12156030	chr8:10097522	C/G	cg02002194	chr4:3960332	NA	0.43	7.41	0.33	5.96e-13	Myopia (pathological);
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.33	-6.76	-0.3	4.1e-11	Schizophrenia;
LGG	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg00976097	chr5:421733	AHRR	-0.43	-7.17	-0.32	3.01e-12	Cystic fibrosis severity;
LGG	cis	rs6977660	1.000	rs4719584	chr7:19823388	T/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.5	0.33	3.27e-13	Thyroid stimulating hormone;
LGG	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg03606772	chr1:152487856	CRCT1	0.31	7.37	0.32	8.07e-13	Hair morphology;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09995631	chr15:28393738	HERC2	-0.35	-6.99	-0.31	9.79e-12	Bipolar disorder;
LGG	trans	rs7615952	0.515	rs7630575	chr3:125682330	A/G	cg07211511	chr3:129823064	LOC729375	-0.78	-11.26	-0.46	3.78e-26	Blood pressure (smoking interaction);
LGG	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg07636037	chr3:49044803	WDR6	0.92	17.05	0.62	5.91e-51	Menarche (age at onset);
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg16141378	chr3:129829833	LOC729375	0.37	8.09	0.35	5.35e-15	Retinal vascular caliber;
LGG	trans	rs10838798	0.563	rs11039516	chr11:48124157	T/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.79	-0.3	3.49e-11	Height;
LGG	cis	rs807669	0.903	rs2800974	chr22:19168087	C/T	cg02655711	chr22:19163373	SLC25A1	0.78	16.15	0.6	7.47e-47	Metabolite levels;
LGG	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs6961069	0.777	rs4545029	chr7:80252518	T/G	cg04458919	chr7:80252533	CD36	0.28	6.73	0.3	4.95e-11	Platelet count;
LGG	cis	rs9322193	0.923	rs2880436	chr6:150180259	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.85	0.38	1.84e-17	Lung cancer;
LGG	trans	rs9388451	0.591	rs1268792	chr6:126042124	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.44	7.8	0.34	4.24e-14	Brugada syndrome;
LGG	cis	rs3735485	0.800	rs10235447	chr7:45087208	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.41	-0.4	2.29e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs875971	0.862	rs2088655	chr7:65795711	T/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs6694672	0.764	rs877897	chr1:197103975	G/A	cg13682187	chr1:196946512	CFHR5	0.49	6.89	0.3	1.88e-11	Asthma;
LGG	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.65	0.41	3.28e-20	Mean corpuscular volume;
LGG	cis	rs6728642	1.000	rs60608738	chr2:97608085	G/A	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.59	-0.33	1.73e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs10870270	1.000	rs4880263	chr10:133787629	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.8	-0.51	2.51e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs2075371	0.932	rs1862052	chr7:133981227	G/A	cg20476274	chr7:133979776	SLC35B4	0.72	13.64	0.54	7.85e-36	Mean platelet volume;
LGG	cis	rs2635047	0.967	rs7242978	chr18:44633424	G/T	cg19077165	chr18:44547161	KATNAL2	0.52	9.17	0.39	1.53e-18	Educational attainment;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg16507663	chr6:150244633	RAET1G	0.47	8.88	0.38	1.53e-17	Lung cancer;
LGG	cis	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg24308560	chr3:49941425	MST1R	-0.22	-6.73	-0.3	5.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12681288	0.792	rs4735972	chr8:998618	A/C	cg04851639	chr8:1020857	NA	-0.41	-9.04	-0.39	4.24e-18	Schizophrenia;
LGG	cis	rs977987	0.800	rs11645329	chr16:75336679	C/G	cg03315344	chr16:75512273	CHST6	0.48	9.7	0.41	2.31e-20	Dupuytren's disease;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.82	-0.59	2.34e-45	Tonsillectomy;
LGG	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.99	0.31	9.49e-12	Educational attainment;
LGG	trans	rs61931739	0.534	rs12371021	chr12:34062252	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.58e-45	Morning vs. evening chronotype;
LGG	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg11494091	chr17:61959527	GH2	0.52	8.38	0.36	6.62e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg18050959	chr15:68126178	NA	-0.37	-6.89	-0.3	1.82e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.736	rs12548025	chr8:10260921	A/T	cg06636001	chr8:8085503	FLJ10661	0.41	6.92	0.31	1.5e-11	Neuroticism;
LGG	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg05639522	chr1:247681581	NA	0.64	10.64	0.44	8.61e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg23782820	chr8:58130467	NA	0.46	6.67	0.3	7.37e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9393175	chr6:149998723	A/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.89	-0.3	1.89e-11	Lung cancer;
LGG	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg16400903	chr5:693638	TPPP	0.45	6.92	0.31	1.55e-11	Obesity-related traits;
LGG	cis	rs67311347	1.000	rs4973997	chr3:40460145	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-20.06	-0.68	6.91e-65	Renal cell carcinoma;
LGG	cis	rs8062405	1.000	rs56404918	chr16:28846840	T/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2836974	0.897	rs2836933	chr21:40564202	C/G	cg11890956	chr21:40555474	PSMG1	1.19	30.56	0.82	4.45e-113	Cognitive function;
LGG	cis	rs10883723	0.810	rs2296590	chr10:104262628	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.89e-19	Life satisfaction;
LGG	cis	rs11190604	0.943	rs11190574	chr10:102234331	T/C	cg07080220	chr10:102295463	HIF1AN	0.62	10.55	0.44	1.82e-23	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1107366	0.722	rs1992855	chr3:125909669	C/T	cg11252792	chr3:125932053	NA	-0.6	-12.01	-0.49	4e-29	Metabolite levels;
LGG	cis	rs6495122	0.501	rs7167261	chr15:75343807	T/C	cg14664628	chr15:75095509	CSK	0.48	9.17	0.39	1.52e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7584330	0.666	rs60671275	chr2:238374318	C/A	cg16989719	chr2:238392110	NA	-0.35	-7.01	-0.31	8.52e-12	Prostate cancer;
LGG	cis	rs2717559	0.522	rs2585160	chr8:143875204	G/A	cg06565975	chr8:143823917	SLURP1	0.28	6.78	0.3	3.63e-11	Urinary tract infection frequency;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg01114163	chr5:1856713	NA	-0.42	-7.32	-0.32	1.12e-12	Cardiovascular disease risk factors;
LGG	cis	rs6866344	0.697	rs72812613	chr5:178135257	G/A	cg10224037	chr5:178157518	ZNF354A	0.73	11.26	0.46	3.76e-26	Neutrophil percentage of white cells;
LGG	cis	rs701145	0.585	rs1713852	chr3:153795487	C/G	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs1801251	0.778	rs2592115	chr2:233736349	C/T	cg08000102	chr2:233561755	GIGYF2	-0.41	-6.76	-0.3	4.16e-11	Coronary artery disease;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.75	-0.54	2.64e-36	Tonsillectomy;
LGG	cis	rs9583531	0.689	rs6492308	chr13:111377829	T/C	cg24331049	chr13:111365604	ING1	0.82	14.6	0.56	5.75e-40	Coronary artery disease;
LGG	cis	rs11630290	0.592	rs1039818	chr15:64155296	A/G	cg12036633	chr15:63758958	NA	0.49	7.11	0.31	4.37e-12	Iris characteristics;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.6	-0.59	2.23e-44	Rheumatoid arthritis;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg00405596	chr8:11794950	NA	-0.46	-7.61	-0.33	1.58e-13	Neuroticism;
LGG	cis	rs1983891	0.651	rs4714489	chr6:41552429	G/A	cg20194872	chr6:41519635	FOXP4	0.47	7.8	0.34	4.18e-14	Prostate cancer;
LGG	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.53	0.33	2.76e-13	Myopia (pathological);
LGG	cis	rs12477438	0.765	rs9710648	chr2:99673129	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs6840360	0.550	rs12651635	chr4:152557786	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.64	-0.33	1.3e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6087990	0.965	rs2424903	chr20:31349315	C/T	cg13636640	chr20:31349939	DNMT3B	1.01	22.12	0.72	1.6e-74	Ulcerative colitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04041942	chr8:28747613	INTS9;HMBOX1	0.48	8.05	0.35	7.22e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04569364	chr19:57922590	ZNF17	0.53	8.49	0.37	2.82e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg24829409	chr8:58192753	C8orf71	-0.8	-13.02	-0.52	3.06e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10929925	0.902	rs58496220	chr2:6156882	A/T	cg00493617	chr2:6141445	NA	0.32	7.35	0.32	8.92e-13	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs4843747	0.671	rs28465438	chr16:88103714	G/A	cg06374794	chr16:88002281	BANP	0.46	8.58	0.37	1.42e-16	Menopause (age at onset);
LGG	cis	rs2153535	0.547	rs9502720	chr6:8541362	C/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.48	0.44	3.38e-23	Motion sickness;
LGG	cis	rs2204008	0.744	rs11495519	chr12:38060546	C/A	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs3741151	1.000	rs3741151	chr11:73020846	G/T	cg17517138	chr11:73019481	ARHGEF17	1.08	10.92	0.45	7.54e-25	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs6692729	0.814	rs2246221	chr1:227075402	C/T	cg08708961	chr1:227070630	PSEN2	0.27	6.93	0.31	1.38e-11	Electrodermal activity;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.41	-6.71	-0.3	5.85e-11	Lung cancer;
LGG	cis	rs1561176	0.783	rs1124175	chr7:155015124	A/C	cg25063631	chr7:155025500	NA	0.54	7.89	0.34	2.17e-14	Personality dimensions;
LGG	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.61	-0.33	1.53e-13	Total cholesterol levels;
LGG	cis	rs7106204	0.534	rs7928616	chr11:24296060	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	13.7	0.54	4.2e-36	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs10462794	0.853	rs4701907	chr5:4503738	G/A	cg18482690	chr5:4511582	NA	-0.43	-7.25	-0.32	1.79e-12	DNA methylation (variation);
LGG	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg13385794	chr1:248469461	NA	0.44	8.05	0.35	7.28e-15	Common traits (Other);
LGG	cis	rs7507204	0.572	rs7246730	chr19:3419781	A/G	cg08380311	chr19:3435252	NFIC	-0.79	-13.84	-0.54	1.07e-36	Height;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg16482183	chr6:26056742	HIST1H1C	0.52	9.25	0.39	8.49e-19	Height;
LGG	cis	rs4423214	0.840	rs1792229	chr11:71179395	A/G	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.71e-25	Vitamin D levels;
LGG	cis	rs2456568	0.548	rs1607402	chr11:93660732	T/G	cg26875233	chr11:93583750	C11orf90	-0.43	-8.35	-0.36	7.94e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs875971	0.502	rs1796227	chr7:66087019	G/C	cg11764359	chr7:65958608	NA	-0.63	-9.52	-0.4	9.74e-20	Aortic root size;
LGG	cis	rs28655083	0.843	rs1502433	chr16:77087101	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	0.52	8.55	0.37	1.85e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9868809	0.881	rs2276850	chr3:48669648	G/A	cg00383909	chr3:49044727	WDR6	0.83	9.59	0.41	5.61e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9905704	0.647	rs2108435	chr17:57102133	T/C	cg12560992	chr17:57184187	TRIM37	-0.52	-8.53	-0.37	2.12e-16	Testicular germ cell tumor;
LGG	cis	rs56775891	0.537	rs7236339	chr18:77579773	C/T	cg13263691	chr18:77568018	NA	0.6	8.46	0.37	3.42e-16	Schizophrenia;
LGG	cis	rs2730245	0.527	rs62475645	chr7:158656825	G/A	cg18245976	chr7:158708271	WDR60	-0.55	-7.12	-0.31	4.1e-12	Height;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg13197285	chr1:38156324	C1orf109	0.42	6.9	0.31	1.69e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.32	0.4	4.71e-19	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16515820	chr3:114866447	ZBTB20	0.48	7.68	0.34	9.82e-14	Gut microbiome composition (summer);
LGG	trans	rs937213	0.781	rs28893849	chr15:40296928	T/A	cg22705835	chr10:65332833	REEP3	-0.42	-7.04	-0.31	6.9e-12	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs1577917	0.665	rs4304137	chr6:86217448	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.93	0.48	8.44e-29	Response to antipsychotic treatment;
LGG	cis	rs3816183	1.000	rs11124892	chr2:43014304	C/A	cg14631114	chr2:43023945	NA	0.51	9.68	0.41	2.68e-20	Hypospadias;
LGG	cis	rs4716602	0.633	rs10249382	chr7:156159349	G/T	cg16983916	chr7:156159713	NA	-0.49	-9.53	-0.41	8.75e-20	Anti-saccade response;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg21724239	chr8:58056113	NA	0.51	7.69	0.34	8.72e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.819	rs1059592	chr8:22477778	G/A	cg19455335	chr8:22457658	C8orf58	-0.41	-8.37	-0.36	7e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6495122	0.546	rs34965545	chr15:75281132	C/T	cg09165964	chr15:75287851	SCAMP5	0.69	13.25	0.52	3.46e-34	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs3857536	0.730	rs6455092	chr6:66961914	T/C	cg07460842	chr6:66804631	NA	-0.45	-7.5	-0.33	3.36e-13	Blood trace element (Cu levels);
LGG	cis	rs10782582	0.617	rs1846233	chr1:76159354	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.96	-0.31	1.2e-11	Daytime sleep phenotypes;
LGG	cis	rs2839186	0.605	rs2839170	chr21:47671305	A/G	cg11766577	chr21:47581405	C21orf56	-0.41	-6.84	-0.3	2.47e-11	Testicular germ cell tumor;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14460708	chr3:172428874	NCEH1	0.4	6.66	0.3	7.68e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs6988985	0.530	rs3819497	chr8:143924052	C/T	cg10324643	chr8:143916377	GML	0.4	8.3	0.36	1.17e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs476633	0.708	rs8031159	chr15:41445199	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-11.62	-0.48	1.44e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs8072100	0.811	rs1912483	chr17:45443494	A/G	cg25173405	chr17:45401733	C17orf57	-0.52	-8.85	-0.38	1.83e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4665809	0.590	rs35615763	chr2:26468778	C/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs7267979	0.899	rs442834	chr20:25458096	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.1	0.42	8.35e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg27471124	chr11:109292789	C11orf87	0.56	10.66	0.44	7.32e-24	Schizophrenia;
LGG	cis	rs4555082	0.830	rs2255575	chr14:105727251	T/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.17	-0.32	2.9e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs60843830	1.000	rs11553746	chr2:272203	C/T	cg12623918	chr2:306882	NA	0.53	9.81	0.41	8.89e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25025968	chr11:4116056	RRM1	0.45	7.51	0.33	3.01e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs72792276	1.000	rs72794379	chr5:127464965	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	6.75	0.3	4.57e-11	Red cell distribution width;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.94	-0.35	1.53e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2013441	0.795	rs6587064	chr17:20207884	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.95	-0.31	1.28e-11	Obesity-related traits;
LGG	cis	rs13191362	0.872	rs56404230	chr6:163252863	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.69	7.76	0.34	5.33e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs897080	0.514	rs1067376	chr2:44648361	A/G	cg00619915	chr2:44497795	NA	-0.5	-6.92	-0.31	1.52e-11	Height;
LGG	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.44	-8.07	-0.35	5.94e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.39	9.2	0.39	1.21e-18	Schizophrenia;
LGG	cis	rs9560113	1.000	rs9555805	chr13:112179765	C/T	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.13	-0.78	1.01e-97	Primary sclerosing cholangitis;
LGG	cis	rs9517320	1.000	rs7996093	chr13:99133092	T/C	cg07423050	chr13:99094983	FARP1	0.41	8.31	0.36	1.09e-15	Longevity;
LGG	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg23029597	chr12:123009494	RSRC2	-0.51	-8.97	-0.38	7.37e-18	Body mass index;
LGG	cis	rs7975161	0.938	rs4964271	chr12:104652441	T/C	cg25273343	chr12:104657179	TXNRD1	-0.77	-10.43	-0.44	5.3e-23	Toenail selenium levels;
LGG	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg08847335	chr10:891726	LARP4B	-0.55	-9.06	-0.39	3.57e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.45	6.91	0.31	1.6e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.1e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9636252	0.887	rs13415243	chr2:9267504	T/C	cg20341998	chr2:9276514	NA	0.38	7.2	0.32	2.46e-12	IgG glycosylation;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs11773661	chr7:100073069	G/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs4696584	1.000	rs4696584	chr4:155397517	A/G	cg13738195	chr4:155413469	DCHS2	0.37	7.55	0.33	2.27e-13	Folding of antihelix;
LGG	cis	rs9457247	0.602	rs4710175	chr6:167467800	A/G	cg07741184	chr6:167504864	NA	0.46	10.47	0.44	3.78e-23	Crohn's disease;
LGG	cis	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg22857025	chr5:266934	NA	-1.51	-26.63	-0.78	1.86e-95	Breast cancer;
LGG	cis	rs6582630	0.555	rs11182148	chr12:38464883	A/C	cg13010199	chr12:38710504	ALG10B	0.68	14.18	0.55	3.65e-38	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9650657	0.530	rs6982381	chr8:10952500	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.01	-0.39	5.4e-18	Neuroticism;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg06178942	chr8:29120351	KIF13B	-0.39	-6.75	-0.3	4.4e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7100689	0.577	rs9420349	chr10:82031160	T/C	cg01528321	chr10:82214614	TSPAN14	0.79	13.81	0.54	1.46e-36	Post bronchodilator FEV1;
LGG	cis	rs11098499	0.863	rs3822190	chr4:120428098	G/A	cg24375607	chr4:120327624	NA	0.67	10.9	0.45	8.81e-25	Corneal astigmatism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14037413	chr11:9482594	ZNF143	0.39	6.98	0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs67311347	1.000	rs2085115	chr3:40497540	G/T	cg13683864	chr3:40499215	RPL14	-1.14	-26.65	-0.78	1.51e-95	Renal cell carcinoma;
LGG	cis	rs867371	0.929	rs1045508	chr15:82449906	A/C	cg00614314	chr15:82944287	LOC80154	-0.59	-10.11	-0.43	7.3e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg06634786	chr22:41940651	POLR3H	-0.74	-12.07	-0.49	2.37e-29	Vitiligo;
LGG	cis	rs2016266	0.806	rs11170494	chr12:53665164	C/A	cg04065151	chr12:53682969	ESPL1	-0.59	-10.02	-0.42	1.61e-21	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs11098499	0.913	rs11098496	chr4:120167466	C/G	cg25214090	chr10:38739885	LOC399744	0.64	11.57	0.47	2.26e-27	Corneal astigmatism;
LGG	cis	rs5743618	0.537	rs11096955	chr4:38776107	G/T	cg06935464	chr4:38784597	TLR10	-0.39	-7.02	-0.31	7.73e-12	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg16414030	chr3:133502952	NA	-0.48	-7.99	-0.35	1.07e-14	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg08621203	chr6:150244597	RAET1G	0.46	7.95	0.35	1.41e-14	Lung cancer;
LGG	cis	rs11098499	0.863	rs6858777	chr4:120475966	A/G	cg09307838	chr4:120376055	NA	0.8	13.32	0.53	1.63e-34	Corneal astigmatism;
LGG	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg05444541	chr17:17804740	TOM1L2	-0.7	-16.6	-0.61	6.72e-49	Total body bone mineral density;
LGG	cis	rs3820068	0.608	rs10927831	chr1:16028373	T/G	cg05660106	chr1:15850417	CASP9	0.76	14.24	0.55	1.98e-38	Systolic blood pressure;
LGG	cis	rs2153535	0.601	rs1855768	chr6:8472969	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs7106204	0.686	rs12791623	chr11:24277924	A/T	ch.11.24196551F	chr11:24239977	NA	0.75	8.01	0.35	9.65e-15	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6546537	1.000	rs17036866	chr2:69857711	T/C	cg10773587	chr2:69614142	GFPT1	-0.49	-8.17	-0.35	3e-15	Serum thyroid-stimulating hormone levels;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg11473876	chr11:109292803	C11orf87	0.48	9.48	0.4	1.34e-19	Schizophrenia;
LGG	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg10621924	chr7:39171070	POU6F2	0.4	8.09	0.35	5.3e-15	IgG glycosylation;
LGG	cis	rs503734	0.666	rs16843927	chr3:101231368	T/G	cg27318481	chr3:100970896	IMPG2	0.36	7.2	0.32	2.44e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg06212747	chr3:49208901	KLHDC8B	0.71	12.15	0.49	1.17e-29	Parkinson's disease;
LGG	cis	rs6963495	0.818	rs711430	chr7:105167969	A/G	cg21420622	chr7:105162941	PUS7	-0.45	-7.09	-0.31	5.09e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs2075371	0.933	rs1833474	chr7:133958240	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg00689492	chr4:1303491	MAEA	0.52	8.63	0.37	9.83e-17	Obesity-related traits;
LGG	cis	rs6784615	0.590	rs9846089	chr3:52529773	T/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.53	-0.33	2.67e-13	Waist-hip ratio;
LGG	cis	rs10871290	1.000	rs10871290	chr16:74472696	C/T	cg01733217	chr16:74700730	RFWD3	-0.68	-12.92	-0.51	8.12e-33	Breast cancer;
LGG	trans	rs1459104	1.000	rs34091524	chr11:55329896	A/G	cg15704280	chr7:45808275	SEPT13	0.67	6.66	0.3	7.62e-11	Body mass index;
LGG	cis	rs10465746	0.901	rs17534614	chr1:84383079	G/A	cg10977910	chr1:84465055	TTLL7	0.52	9.42	0.4	2.12e-19	Obesity-related traits;
LGG	trans	rs9929218	1.000	rs28549017	chr16:68758828	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.45	-0.56	2.51e-39	Colorectal cancer;
LGG	cis	rs139371	0.585	rs139358	chr22:39513530	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.28	-7.22	-0.32	2.21e-12	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs9911578	0.835	rs9904993	chr17:56468569	G/T	cg12560992	chr17:57184187	TRIM37	-0.8	-13.56	-0.53	1.69e-35	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.77	-8.98	-0.39	6.69e-18	Lung cancer in ever smokers;
LGG	cis	rs11098499	0.644	rs3986377	chr4:120260270	G/A	cg09307838	chr4:120376055	NA	0.67	11.64	0.48	1.23e-27	Corneal astigmatism;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg11050988	chr7:1952600	MAD1L1	-0.31	-6.99	-0.31	9.85e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-27.16	-0.78	7.18e-98	Primary sclerosing cholangitis;
LGG	cis	rs9811920	0.799	rs9832134	chr3:99836722	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.17	0.35	3.04e-15	Axial length;
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg18681998	chr4:17616180	MED28	0.86	18.7	0.66	1.47e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.39e-19	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13980007	chr1:61547494	NFIA	0.35	6.81	0.3	3.03e-11	Gut microbiome composition (summer);
LGG	cis	rs4665809	1.000	rs4665299	chr2:26256840	A/C	cg22920501	chr2:26401640	FAM59B	-0.41	-8.0	-0.35	9.82e-15	Gut microbiome composition (summer);
LGG	cis	rs17270561	0.609	rs4131670	chr6:25738619	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.34	-0.32	9.66e-13	Iron status biomarkers;
LGG	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg13147721	chr7:65941812	NA	-0.72	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	cis	rs7927592	0.913	rs4988291	chr11:68381607	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.65	-0.3	8.08e-11	Neuroticism;
LGG	cis	rs4629180	0.630	rs10188189	chr2:102127926	A/G	cg16435561	chr2:102091048	RFX8	0.45	8.34	0.36	8.45e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs9357271	0.956	rs1983605	chr6:38355940	T/A	cg07362130	chr6:38359646	BTBD9	-0.44	-9.92	-0.42	3.72e-21	Restless legs syndrome;
LGG	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg03806693	chr22:41940476	POLR3H	-1.05	-17.76	-0.64	3.55e-54	Vitiligo;
LGG	cis	rs9894429	0.789	rs7502346	chr17:79603741	T/C	cg10661904	chr17:79619235	PDE6G	-0.4	-7.98	-0.35	1.18e-14	Eye color traits;
LGG	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg03929089	chr4:120376271	NA	-0.51	-8.44	-0.37	4.06e-16	Height;
LGG	cis	rs2130392	0.702	rs12108497	chr4:185571557	C/T	cg21366198	chr4:185655624	MLF1IP	-0.44	-7.55	-0.33	2.34e-13	Kawasaki disease;
LGG	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.21e-17	Aortic root size;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg20887711	chr4:1340912	KIAA1530	-0.94	-21.26	-0.7	1.69e-70	Longevity;
LGG	cis	rs12368653	0.591	rs1552842	chr12:58012163	A/G	cg20892847	chr12:58011875	NA	-0.41	-8.67	-0.37	7.26e-17	Multiple sclerosis;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg09699651	chr6:150184138	LRP11	0.5	9.04	0.39	4.44e-18	Lung cancer;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg04025307	chr7:1156635	C7orf50	0.72	10.14	0.43	6.13e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4332037	0.539	rs55773130	chr7:2070554	T/C	cg22232500	chr2:134024266	NCKAP5	0.57	8.04	0.35	7.83e-15	Bipolar disorder;
LGG	trans	rs11039798	0.841	rs11500573	chr11:48713900	T/G	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.68	-0.3	7.01e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.902	rs1649016	chr10:60288540	T/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.47	-0.33	3.9e-13	Refractive error;
LGG	cis	rs4900538	0.927	rs1190547	chr14:102905087	G/C	cg18135206	chr14:102964638	TECPR2	-0.82	-16.28	-0.6	1.99e-47	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2247341	0.928	rs2290011	chr4:1746229	G/T	cg05026014	chr4:1749153	NA	-0.33	-9.29	-0.4	6.2e-19	Hip circumference adjusted for BMI;Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19744773	chr1:22110159	USP48	0.53	8.3	0.36	1.14e-15	Gut microbiome composition (summer);
LGG	cis	rs6964587	1.000	rs12666179	chr7:91574110	T/C	cg17063962	chr7:91808500	NA	-0.5	-8.8	-0.38	2.79e-17	Breast cancer;
LGG	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg20991723	chr1:152506922	NA	-0.7	-14.15	-0.55	4.89e-38	Hair morphology;
LGG	cis	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg12486710	chr1:178512616	C1orf220	0.51	10.56	0.44	1.74e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.73	12.72	0.51	5.32e-32	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.41e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg12438819	chr7:158236134	PTPRN2	0.32	8.53	0.37	2.08e-16	Obesity-related traits;
LGG	trans	rs12579753	1.000	rs11115030	chr12:82203021	A/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.73	-0.34	6.75e-14	Resting heart rate;
LGG	cis	rs4901847	0.562	rs3829765	chr14:58605790	G/A	cg15908186	chr14:58618357	C14orf37	0.69	12.79	0.51	2.88e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1475718	0.526	rs10881586	chr9:137122724	C/T	cg21243944	chr9:137118148	NA	-0.3	-7.64	-0.33	1.22e-13	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs798554	0.660	rs798480	chr7:2805597	G/T	cg05793240	chr7:2802953	GNA12	0.32	7.94	0.35	1.56e-14	Height;
LGG	cis	rs7000551	0.606	rs3802199	chr8:22267385	A/G	cg13512537	chr8:22265999	SLC39A14	-0.46	-7.34	-0.32	9.99e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs66573146	0.831	rs56300156	chr4:6990813	G/C	cg00086871	chr4:6988644	TBC1D14	1.06	9.65	0.41	3.3e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2228479	0.681	rs7196840	chr16:89959647	A/G	cg19635926	chr16:89946313	TCF25	0.7	8.36	0.36	7.5e-16	Skin colour saturation;
LGG	cis	rs477692	0.673	rs10829600	chr10:131322051	G/C	cg05714579	chr10:131428358	MGMT	0.45	8.55	0.37	1.82e-16	Response to temozolomide;
LGG	cis	rs7444	0.825	rs2256609	chr22:21925017	A/G	cg22858872	chr22:21984481	YDJC	-0.37	-6.73	-0.3	4.94e-11	Systemic lupus erythematosus;
LGG	cis	rs7312933	0.558	rs55702525	chr12:42814309	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.2	-0.36	2.4e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg00405596	chr8:11794950	NA	0.4	6.66	0.3	7.8e-11	Joint mobility (Beighton score);
LGG	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg04883260	chr20:61718941	NA	0.3	6.65	0.3	8.03e-11	Body mass index;
LGG	cis	rs12893668	0.703	rs12894729	chr14:104035292	G/A	cg23335576	chr14:104009727	NA	0.48	8.27	0.36	1.38e-15	Reticulocyte count;
LGG	cis	rs4746818	0.901	rs4746816	chr10:70874866	G/T	cg11621586	chr10:70884670	VPS26A	1.12	16.13	0.6	8.97e-47	Left atrial antero-posterior diameter;
LGG	cis	rs9527	0.590	rs10883820	chr10:104764661	A/C	cg04362960	chr10:104952993	NT5C2	-0.56	-10.67	-0.44	6.72e-24	Arsenic metabolism;
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.78	-0.41	1.16e-20	Systolic blood pressure;
LGG	cis	rs1670533	1.000	rs652063	chr4:1084137	T/C	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.31e-26	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.935	rs9911794	chr17:28349466	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs1348850	0.567	rs12994392	chr2:178536640	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.61	-0.37	1.15e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs77106637	0.929	rs1059000	chr11:72504972	G/C	cg03878208	chr11:72483293	STARD10	0.52	7.23	0.32	2.02e-12	Type 2 diabetes;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg04267008	chr7:1944627	MAD1L1	-0.66	-10.71	-0.45	4.42e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs1210638	0.545	rs6518507	chr22:18976479	C/G	cg14259594	chr22:18958660	DGCR5	-0.66	-12.13	-0.49	1.41e-29	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs732765	1.000	rs10134885	chr14:75373475	C/T	cg06637938	chr14:75390232	RPS6KL1	0.5	6.95	0.31	1.26e-11	Non-small cell lung cancer;
LGG	cis	rs7552167	0.925	rs78312791	chr1:24513613	C/A	cg01960748	chr1:24522592	NA	0.52	7.91	0.35	1.92e-14	Psoriasis vulgaris;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs877282	0.898	rs11253341	chr10:765008	G/C	cg22713356	chr15:30763199	NA	0.52	7.68	0.34	9.24e-14	Uric acid levels;
LGG	cis	rs3820928	0.874	rs6718057	chr2:227834349	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.52e-14	Pulmonary function;
LGG	trans	rs1493916	0.905	rs34165207	chr18:31400153	G/A	cg04226714	chr8:49833948	SNAI2	-0.48	-8.41	-0.36	5.22e-16	Life satisfaction;
LGG	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg15212455	chr7:39170539	POU6F2	0.4	9.21	0.39	1.11e-18	IgG glycosylation;
LGG	cis	rs3768617	0.510	rs1886500	chr1:183095048	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6546537	0.562	rs7565783	chr2:69750113	C/T	cg10773587	chr2:69614142	GFPT1	-0.53	-9.52	-0.4	9.67e-20	Serum thyroid-stimulating hormone levels;
LGG	cis	rs798554	0.679	rs1614791	chr7:2888057	G/T	cg19717773	chr7:2847554	GNA12	-0.32	-6.9	-0.31	1.74e-11	Height;
LGG	cis	rs1355223	0.583	rs2915179	chr11:34871943	C/T	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-7.09	-0.31	5.01e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg21132104	chr15:45694354	SPATA5L1	-0.65	-9.25	-0.4	8.01e-19	Homoarginine levels;
LGG	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg27279351	chr12:120934652	DYNLL1	0.8	13.04	0.52	2.5e-33	High light scatter reticulocyte count;
LGG	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg00409905	chr10:38381863	ZNF37A	0.67	13.56	0.53	1.62e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs35306767	0.761	rs11253540	chr10:1011958	C/T	cg20503657	chr10:835505	NA	-0.55	-7.35	-0.32	9.04e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs7226408	0.857	rs72885296	chr18:34451891	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs4006360	0.575	rs404154	chr17:39315341	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.62	-13.91	-0.54	5.14e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs2742417	1.000	rs2742422	chr3:45732820	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7607369	0.526	rs4674322	chr2:219513782	C/T	cg01130898	chr2:219473002	PLCD4	-0.46	-6.85	-0.3	2.41e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs919433	0.680	rs699319	chr2:198281776	C/A	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9787249	0.957	rs7547787	chr1:40220806	C/T	cg02773041	chr1:40204384	PPIE	0.5	9.3	0.4	5.73e-19	Blood protein levels;
LGG	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg19773385	chr1:10388646	KIF1B	-0.45	-9.51	-0.4	1.03e-19	Hepatocellular carcinoma;
LGG	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.26	-0.4	7.43e-19	Retinal vascular caliber;
LGG	cis	rs17401966	0.931	rs12753426	chr1:10372110	T/C	cg15208524	chr1:10270712	KIF1B	0.43	7.29	0.32	1.37e-12	Hepatocellular carcinoma;
LGG	cis	rs17767392	1.000	rs61991203	chr14:71767841	C/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.95	-0.38	8.92e-18	Longevity;Endometriosis;
LGG	cis	rs801193	1.000	rs13239306	chr7:66136017	T/G	cg18876405	chr7:65276391	NA	-0.58	-10.42	-0.44	5.65e-23	Aortic root size;
LGG	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.49	8.84	0.38	2.01e-17	Resistin levels;
LGG	cis	rs35146811	0.735	rs11764176	chr7:99786964	G/T	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06850548	chr1:151138564	LYSMD1;SCNM1	0.42	6.75	0.3	4.37e-11	Cognitive performance;
LGG	trans	rs1908814	0.516	rs10113042	chr8:11793178	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	Neuroticism;
LGG	cis	rs12410462	0.748	rs1495853	chr1:227657336	A/G	cg04117972	chr1:227635322	NA	-0.6	-10.13	-0.43	6.6e-22	Major depressive disorder;
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg13607699	chr17:42295918	UBTF	-0.56	-9.28	-0.4	6.33e-19	Total body bone mineral density;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.49	-0.33	3.51e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11923054	chr4:4250051	TMEM128	0.47	6.98	0.31	1.02e-11	Gut microbiome composition (summer);
LGG	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06470251	chr20:60548479	NA	0.48	8.3	0.36	1.15e-15	Body mass index;
LGG	cis	rs2729354	0.817	rs2649667	chr11:57270509	A/C	cg24343310	chr11:57249947	NA	0.42	8.02	0.35	8.44e-15	Blood protein levels;
LGG	cis	rs2075371	0.933	rs2544181	chr7:133944934	C/T	cg11752832	chr7:134001865	SLC35B4	0.58	10.38	0.43	8.02e-23	Mean platelet volume;
LGG	cis	rs3780378	0.935	rs2230724	chr9:5081780	G/A	cg02405213	chr9:5042618	JAK2	-0.49	-8.48	-0.37	2.96e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg06108461	chr20:60628389	TAF4	-0.99	-19.52	-0.67	2.39e-62	Body mass index;
LGG	cis	rs7017914	0.967	rs13254801	chr8:71688984	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg19774624	chr17:42201019	HDAC5	-0.93	-19.92	-0.68	3.07e-64	Total body bone mineral density;
LGG	cis	rs1345301	0.518	rs56238602	chr2:102863095	G/T	cg05295703	chr2:102895712	NA	0.48	9.57	0.41	6.2e-20	Waist circumference;
LGG	cis	rs60843830	0.928	rs2306060	chr2:230912	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.98	0.57	1.19e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs8017423	0.967	rs7150093	chr14:90724661	C/T	cg04374321	chr14:90722782	PSMC1	-0.88	-18.76	-0.66	8.03e-59	Mortality in heart failure;
LGG	cis	rs736801	0.521	rs41525648	chr5:131827775	A/G	cg21138405	chr5:131827807	IRF1	-0.36	-9.51	-0.4	1.09e-19	Breast cancer;Mosquito bite size;
LGG	cis	rs3087591	0.960	rs1801052	chr17:29508775	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.51	0.56	1.38e-39	Hip circumference;
LGG	cis	rs6964587	0.621	rs38799	chr7:92045139	C/T	cg17063962	chr7:91808500	NA	-0.42	-7.39	-0.32	7.1e-13	Breast cancer;
LGG	cis	rs3762637	1.000	rs72958458	chr3:122185549	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01320969	chr11:67980788	SUV420H1	0.58	6.67	0.3	7.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg27205649	chr11:78285834	NARS2	0.47	8.07	0.35	6.06e-15	Alzheimer's disease (survival time);
LGG	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg03517284	chr6:25882590	NA	0.43	7.07	0.31	5.59e-12	Iron status biomarkers;
LGG	cis	rs7945705	0.967	rs7123861	chr11:8892323	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.54	0.47	3.05e-27	Hemoglobin concentration;
LGG	cis	rs11718455	0.920	rs4682927	chr3:44033299	C/A	cg21419209	chr3:44054225	NA	-0.43	-6.98	-0.31	1e-11	Coronary artery disease;
LGG	cis	rs981844	0.775	rs62324020	chr4:154763851	G/A	cg14289246	chr4:154710475	SFRP2	0.67	11.1	0.46	1.53e-25	Response to statins (LDL cholesterol change);
LGG	trans	rs1459104	0.866	rs12787024	chr11:54883667	C/T	cg03929089	chr4:120376271	NA	0.72	6.97	0.31	1.08e-11	Body mass index;
LGG	cis	rs9311474	0.581	rs13621	chr3:52558133	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.65	0.33	1.17e-13	Electroencephalogram traits;
LGG	cis	rs61931739	0.500	rs11053197	chr12:34441949	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.73	-0.41	1.75e-20	Morning vs. evening chronotype;
LGG	cis	rs6750047	0.585	rs4670234	chr2:38272477	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	7.21	0.32	2.3e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs3126085	0.935	rs2184950	chr1:152272776	T/C	cg26876637	chr1:152193138	HRNR	-0.51	-8.08	-0.35	5.85e-15	Atopic dermatitis;
LGG	cis	rs12478296	0.792	rs6740738	chr2:243007368	A/C	cg18898632	chr2:242989856	NA	-0.73	-9.13	-0.39	2.1e-18	Obesity-related traits;
LGG	cis	rs3617	0.573	rs12492391	chr3:52912296	C/A	cg11645453	chr3:52864694	ITIH4	0.45	7.7	0.34	8.21e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs12497850	0.829	rs12636030	chr3:49182237	A/G	cg07636037	chr3:49044803	WDR6	1.07	25.01	0.76	5.7e-88	Parkinson's disease;
LGG	cis	rs9291683	0.632	rs12508991	chr4:10041104	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs74781061	0.872	rs4886598	chr15:74776782	T/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.23	-0.32	2e-12	Endometriosis;
LGG	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg19413766	chr7:29689036	LOC646762	0.52	7.44	0.33	4.96e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs12477438	0.798	rs1453561	chr2:99613924	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.85	-15.08	-0.57	4.35e-42	Chronic sinus infection;
LGG	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg22563815	chr15:78856949	CHRNA5	0.31	7.51	0.33	3.01e-13	Sudden cardiac arrest;
LGG	cis	rs2439831	0.850	rs3862142	chr15:44064806	A/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.14	0.39	1.9e-18	Lung cancer in ever smokers;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.37	-9.93	-0.42	3.51e-21	IgG glycosylation;
LGG	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs875971	0.545	rs11767262	chr7:65767224	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.58	0.44	1.47e-23	Aortic root size;
LGG	cis	rs6547631	0.622	rs4832185	chr2:85928814	T/A	cg19805943	chr2:85933069	NA	0.32	6.78	0.3	3.68e-11	Blood protein levels;
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg23262073	chr20:60523788	NA	0.61	9.63	0.41	3.95e-20	Obesity-related traits;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	20.49	0.69	6.74e-67	Alzheimer's disease;
LGG	trans	rs3780486	0.629	rs10971439	chr9:33180813	C/T	cg04842962	chr6:43655489	MRPS18A	-0.81	-10.92	-0.45	7.58e-25	IgG glycosylation;
LGG	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.68	-0.34	9.54e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937890	0.559	rs2597187	chr11:14517019	C/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.74e-14	Mitochondrial DNA levels;
LGG	cis	rs28595532	0.841	rs115725150	chr4:119768647	T/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1003719	0.654	rs764175	chr21:38517058	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.34	-0.58	3.19e-43	Eye color traits;
LGG	cis	rs10493773	0.928	rs12751296	chr1:86176968	G/A	cg17807903	chr1:86174739	ZNHIT6	-0.6	-10.03	-0.42	1.52e-21	Urate levels in overweight individuals;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg14092988	chr3:52407081	DNAH1	-0.31	-8.17	-0.35	3.04e-15	Bipolar disorder;
LGG	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	20.33	0.69	3.9e-66	Gut microbiome composition (summer);
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00631329	chr6:26305371	NA	-0.53	-9.5	-0.4	1.14e-19	Educational attainment;
LGG	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg17108064	chr15:78857060	CHRNA5	-0.41	-8.31	-0.36	1.07e-15	Sudden cardiac arrest;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13537196	chr9:15553060	C9orf93	0.49	8.03	0.35	7.92e-15	Cognitive performance;
LGG	cis	rs6784615	1.000	rs71297394	chr3:52393472	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.68	7.41	0.33	6.01e-13	Waist-hip ratio;
LGG	cis	rs67311347	0.911	rs6776044	chr3:40377503	T/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.29	-0.69	5.75e-66	Renal cell carcinoma;
LGG	cis	rs12310956	0.510	rs11612987	chr12:33879130	T/C	cg06521331	chr12:34319734	NA	-0.38	-6.68	-0.3	6.89e-11	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs7079756	chr10:102302105	G/A	cg07570687	chr10:102243282	WNT8B	0.41	6.88	0.3	1.91e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg27572855	chr1:25598939	RHD	0.49	10.94	0.45	6.31e-25	Erythrocyte sedimentation rate;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.39	-0.4	2.84e-19	Life satisfaction;
LGG	cis	rs6502050	0.871	rs8066970	chr17:80076051	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg04990556	chr1:26633338	UBXN11	0.6	8.06	0.35	6.45e-15	Obesity-related traits;
LGG	cis	rs2797369	0.882	rs4470856	chr6:101614466	C/A	cg27451362	chr6:101846650	GRIK2	-0.77	-10.33	-0.43	1.15e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs9916302	0.706	rs8069074	chr17:37685401	C/T	cg07936489	chr17:37558343	FBXL20	0.98	15.22	0.58	1.01e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs2239815	0.515	rs9625595	chr22:29238913	C/T	cg02153584	chr22:29168773	CCDC117	0.59	7.13	0.31	3.86e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs2067615	0.542	rs4346064	chr12:107081599	C/A	cg15890332	chr12:107067104	RFX4	0.43	12.6	0.51	1.66e-31	Heart rate;
LGG	cis	rs79149102	0.579	rs7168638	chr15:75280826	T/C	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.68	-0.37	7.03e-17	Lung cancer;
LGG	cis	rs1466045	0.636	rs7103109	chr11:3144199	C/T	cg01418188	chr11:3145609	OSBPL5	-0.32	-7.76	-0.34	5.48e-14	Cisplatin-induced ototoxicity;
LGG	cis	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg00405596	chr8:11794950	NA	0.42	7.17	0.32	2.9e-12	Morning vs. evening chronotype;
LGG	cis	rs7727544	0.526	rs4705908	chr5:131347520	G/A	cg07395648	chr5:131743802	NA	-0.42	-9.1	-0.39	2.67e-18	Blood metabolite levels;
LGG	cis	rs1165205	0.558	rs793144	chr6:25879321	C/T	cg15691649	chr6:25882328	NA	-0.39	-6.76	-0.3	4.16e-11	Urate levels;
LGG	trans	rs6787172	0.622	rs28578723	chr3:158095220	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.34	-0.32	9.89e-13	Subjective well-being;
LGG	cis	rs6142618	0.523	rs4911087	chr20:30844536	G/A	cg00028034	chr20:30779307	TSPYL3	0.36	7.68	0.34	9.76e-14	Inflammatory bowel disease;
LGG	cis	rs10791323	0.604	rs2853115	chr11:133707908	C/T	cg06766960	chr11:133703094	NA	0.58	11.75	0.48	4.52e-28	Childhood ear infection;
LGG	cis	rs6500395	0.962	rs989070	chr16:48602243	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs61931739	0.517	rs12816252	chr12:34067693	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	8.77e-26	Morning vs. evening chronotype;
LGG	cis	rs7590368	0.961	rs2357815	chr2:10959769	C/T	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs9398803	0.698	rs1262553	chr6:127078785	T/C	cg19875578	chr6:126661172	C6orf173	-0.51	-9.29	-0.4	5.96e-19	Male-pattern baldness;
LGG	cis	rs3849570	1.000	rs3849570	chr3:81792112	C/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.95	-0.35	1.43e-14	Waist circumference;Body mass index;
LGG	cis	rs4730250	0.554	rs17428504	chr7:106914944	T/C	cg02696742	chr7:106810147	HBP1	-0.69	-8.89	-0.38	1.36e-17	Osteoarthritis;
LGG	cis	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg12923728	chr3:195709715	SDHAP1	0.59	11.16	0.46	8.78e-26	Bronchopulmonary dysplasia;
LGG	cis	rs9880211	1.000	rs9812579	chr3:136151250	A/G	cg21827317	chr3:136751795	NA	-0.49	-7.15	-0.32	3.3e-12	Body mass index;Height;
LGG	cis	rs9357271	0.955	rs9369057	chr6:38374766	T/A	cg07362130	chr6:38359646	BTBD9	-0.45	-9.56	-0.41	7.09e-20	Restless legs syndrome;
LGG	trans	rs73191547	0.771	rs11787363	chr8:10043355	C/T	cg16141378	chr3:129829833	LOC729375	-0.3	-6.71	-0.3	5.72e-11	Schizophrenia;
LGG	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.2	-0.36	2.33e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.05	0.55	1.31e-37	Obesity-related traits;
LGG	cis	rs9810089	0.843	rs681783	chr3:136035303	C/T	cg21827317	chr3:136751795	NA	0.47	8.3	0.36	1.14e-15	Gestational age at birth (child effect);
LGG	cis	rs6840360	0.615	rs6535822	chr4:152679722	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.18	-0.43	4.27e-22	Intelligence (multi-trait analysis);
LGG	cis	rs13082711	0.911	rs17682229	chr3:27443067	T/C	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs972578	0.668	rs8136252	chr22:43237276	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.79	-0.3	3.5e-11	Mean platelet volume;
LGG	trans	rs9329221	0.617	rs615632	chr8:9796321	C/T	cg21775007	chr8:11205619	TDH	-0.5	-7.99	-0.35	1.08e-14	Neuroticism;
LGG	cis	rs10463554	0.857	rs3776873	chr5:102282472	T/A	cg23492399	chr5:102201601	PAM	-0.56	-8.56	-0.37	1.68e-16	Parkinson's disease;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.15	-0.39	1.88e-18	Personality dimensions;
LGG	cis	rs9633740	1.000	rs7097656	chr10:82250831	T/C	cg01528321	chr10:82214614	TSPAN14	1.04	16.3	0.6	1.53e-47	Post bronchodilator FEV1;
LGG	trans	rs11039798	0.565	rs7118675	chr11:48532063	C/A	cg03929089	chr4:120376271	NA	0.69	9.45	0.4	1.68e-19	Axial length;
LGG	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg25486957	chr4:152246857	NA	-0.49	-8.09	-0.35	5.39e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4253772	0.591	rs6519993	chr22:46656479	A/G	cg24881330	chr22:46731750	TRMU	0.69	8.61	0.37	1.18e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.69	-0.41	2.43e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg25214090	chr10:38739885	LOC399744	0.56	10.24	0.43	2.49e-22	Corneal astigmatism;
LGG	cis	rs422249	0.819	rs174611	chr11:61627881	T/C	cg19610905	chr11:61596333	FADS2	-0.55	-7.89	-0.34	2.15e-14	Trans fatty acid levels;
LGG	cis	rs4478858	0.735	rs10914360	chr1:31817476	G/A	cg19084893	chr1:31688959	NA	0.32	6.67	0.3	7.21e-11	Alcohol dependence;
LGG	cis	rs4820539	1.000	rs4822357	chr22:23473231	A/G	cg21100191	chr22:23484243	RTDR1	1.0	22.66	0.73	4.65e-77	Bone mineral density;
LGG	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg14541582	chr5:601475	NA	-0.57	-9.16	-0.39	1.71e-18	Ulcerative colitis;
LGG	cis	rs2249694	1.000	rs4512750	chr10:135358664	A/G	cg20169779	chr10:135381914	SYCE1	0.52	7.87	0.34	2.45e-14	Obesity-related traits;
LGG	cis	rs2451279	0.565	rs2485365	chr6:159512373	G/A	cg01046905	chr6:159515345	NA	0.33	6.86	0.3	2.19e-11	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg16141378	chr3:129829833	LOC729375	-0.38	-8.8	-0.38	2.72e-17	Retinal vascular caliber;
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.5	-0.44	2.79e-23	Triglycerides;
LGG	cis	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg03060546	chr3:49711283	APEH	-0.62	-10.31	-0.43	1.36e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7605378	1.000	rs7577763	chr2:200681753	C/T	cg17644776	chr2:200775616	C2orf69	0.53	8.5	0.37	2.58e-16	Osteoporosis;
LGG	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg13902645	chr11:5959945	NA	-0.75	-11.42	-0.47	9.18e-27	DNA methylation (variation);
LGG	cis	rs7582180	0.764	rs1530028	chr2:100927910	A/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.69	-0.3	6.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11792861	1.000	rs11792861	chr9:111809295	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.42	0.4	2.15e-19	Menarche (age at onset);
LGG	cis	rs8072100	0.840	rs9912311	chr17:45547132	T/C	cg08085267	chr17:45401833	C17orf57	-0.53	-10.45	-0.44	4.37e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15447669	chr2:234160727	ATG16L1	0.45	6.89	0.3	1.87e-11	Gut microbiome composition (summer);
LGG	cis	rs992157	0.661	rs10171839	chr2:219051314	C/T	cg04731861	chr2:219085781	ARPC2	-0.48	-12.13	-0.49	1.38e-29	Colorectal cancer;
LGG	cis	rs853679	0.517	rs9368551	chr6:28061792	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7953249	0.656	rs2178463	chr12:121389721	A/G	cg14101638	chr12:121416612	HNF1A	-0.44	-9.6	-0.41	4.94e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs4474465	1.000	rs7395344	chr11:78202388	A/G	cg27205649	chr11:78285834	NARS2	-0.48	-8.26	-0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs76419734	0.510	rs2193856	chr4:106742958	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.63	-0.33	1.32e-13	Post bronchodilator FEV1;
LGG	cis	rs67311347	0.955	rs4974067	chr3:40374551	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.68	0.3	6.85e-11	Renal cell carcinoma;
LGG	cis	rs919433	0.680	rs2124317	chr2:198477606	G/A	cg00792783	chr2:198669748	PLCL1	0.51	7.99	0.35	1.11e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs4423214	1.000	rs4944062	chr11:71187294	G/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.72e-33	Vitamin D levels;
LGG	cis	rs56283067	0.887	rs10948171	chr6:44761028	C/T	cg20913747	chr6:44695427	NA	-0.67	-11.31	-0.47	2.35e-26	Total body bone mineral density;
LGG	cis	rs2354432	0.556	rs72710311	chr1:146698256	A/G	cg25205988	chr1:146714368	CHD1L	-1.44	-13.68	-0.54	5.09e-36	Mitochondrial DNA levels;
LGG	cis	rs514406	0.683	rs10157120	chr1:53210888	A/G	cg16325326	chr1:53192061	ZYG11B	0.89	23.65	0.74	1.13e-81	Monocyte count;
LGG	cis	rs35123781	0.696	rs7703195	chr5:139071632	G/A	cg21230503	chr5:139085173	NA	0.36	8.44	0.36	4.24e-16	Schizophrenia;
LGG	cis	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg00990874	chr7:1149470	C7orf50	-0.69	-11.44	-0.47	7.34e-27	Bronchopulmonary dysplasia;
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg09307838	chr4:120376055	NA	0.54	8.97	0.38	7.54e-18	Diastolic blood pressure;
LGG	cis	rs9479482	0.935	rs9479507	chr6:150366514	T/G	cg06889755	chr6:150326021	RAET1K	-0.39	-7.94	-0.35	1.51e-14	Alopecia areata;
LGG	cis	rs77741769	0.571	rs3883901	chr12:121256520	A/G	cg02419362	chr12:121203948	SPPL3	0.53	9.15	0.39	1.88e-18	Mean corpuscular volume;
LGG	cis	rs9921222	0.656	rs12719801	chr16:381141	C/T	cg07915516	chr16:377344	AXIN1	0.29	7.76	0.34	5.5e-14	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs8177253	0.511	rs9830001	chr3:133433470	A/G	cg08048268	chr3:133502702	NA	0.4	7.09	0.31	5.15e-12	Iron status biomarkers;
LGG	cis	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg13647721	chr17:30228624	UTP6	0.63	7.82	0.34	3.49e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9788721	0.630	rs77681598	chr15:78906103	C/A	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.38	-0.32	7.54e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs887829	0.569	rs4294999	chr2:234635467	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.43	-7.92	-0.35	1.82e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs9393022	chr6:8466588	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg12501888	chr15:85177176	SCAND2	-0.49	-8.1	-0.35	5.05e-15	P wave terminal force;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg26769984	chr7:1090371	C7orf50	0.41	8.17	0.35	3.07e-15	Bronchopulmonary dysplasia;
LGG	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg05234568	chr11:5960015	NA	-0.64	-10.19	-0.43	4.03e-22	DNA methylation (variation);
LGG	cis	rs9921222	0.509	rs2301522	chr16:359953	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	-0.52	-9.09	-0.39	2.85e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7119038	0.509	rs11216960	chr11:118577873	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.83	0.3	2.6e-11	Sjögren's syndrome;
LGG	cis	rs765787	0.530	rs12592055	chr15:45514477	C/T	cg25801113	chr15:45476975	SHF	-0.87	-18.83	-0.66	3.81e-59	Uric acid levels;
LGG	cis	rs12540874	0.698	rs12718574	chr7:50573848	G/C	cg00647317	chr7:50633725	DDC	0.38	9.19	0.39	1.35e-18	Systemic sclerosis;
LGG	cis	rs7107174	1.000	rs2511170	chr11:77980582	A/G	cg02023728	chr11:77925099	USP35	0.44	7.69	0.34	8.68e-14	Testicular germ cell tumor;
LGG	trans	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg11693508	chr17:37793320	STARD3	-0.62	-9.13	-0.39	2.07e-18	Bipolar disorder;
LGG	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg13385794	chr1:248469461	NA	0.49	8.35	0.36	8.06e-16	Common traits (Other);
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg22907277	chr7:1156413	C7orf50	0.63	11.64	0.48	1.17e-27	Longevity;Endometriosis;
LGG	cis	rs7929679	0.602	rs10742326	chr11:34810010	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.81	0.3	3.03e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.27	-0.58	6.54e-43	Prudent dietary pattern;
LGG	cis	rs7444	0.941	rs738128	chr22:21971010	G/A	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg02187348	chr16:89574699	SPG7	0.47	7.67	0.34	1.01e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg01238044	chr22:24384105	GSTT1	-0.45	-7.85	-0.34	2.82e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs79057730	0.599	rs6951032	chr7:794092	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.19	0.32	2.57e-12	Initial pursuit acceleration;
LGG	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg09998033	chr7:158218633	PTPRN2	0.46	8.39	0.36	5.84e-16	Obesity-related traits;
LGG	cis	rs17401966	1.000	rs60743860	chr1:10442926	G/C	cg15208524	chr1:10270712	KIF1B	0.44	7.27	0.32	1.57e-12	Hepatocellular carcinoma;
LGG	cis	rs7107174	1.000	rs10899467	chr11:78014057	G/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.65	-0.33	1.2e-13	Testicular germ cell tumor;
LGG	cis	rs936229	0.813	rs4886619	chr15:75106138	C/T	cg14664628	chr15:75095509	CSK	-1.14	-27.83	-0.79	6.66e-101	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs8067545	0.750	rs9915758	chr17:19964775	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.72	-0.3	5.45e-11	Schizophrenia;
LGG	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.81	-0.45	1.87e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg01657329	chr11:68192670	LRP5	0.57	10.74	0.45	3.71e-24	Total body bone mineral density;
LGG	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg04226714	chr8:49833948	SNAI2	-0.47	-8.4	-0.36	5.36e-16	Life satisfaction;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7843479	0.965	rs1484162	chr8:21831385	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.12	0.43	7.11e-22	Mean corpuscular volume;
LGG	cis	rs3857067	1.000	rs12502725	chr4:94999873	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.55	-0.33	2.27e-13	QT interval;
LGG	trans	rs35110281	0.667	rs914197	chr21:45117439	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.81	0.41	9.09e-21	Mean corpuscular volume;
LGG	cis	rs5750830	0.649	rs5750820	chr22:39825322	T/G	cg04986931	chr22:39850128	NA	0.34	7.79	0.34	4.55e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.591	rs11039858	chr11:48611651	C/T	cg00717180	chr2:96193071	NA	-0.45	-8.1	-0.35	4.81e-15	HDL cholesterol;
LGG	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg25237894	chr2:233734115	C2orf82	0.65	12.46	0.5	6.34e-31	Coronary artery disease;
LGG	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg00405596	chr8:11794950	NA	0.41	6.98	0.31	1.04e-11	Mood instability;
LGG	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg08822215	chr16:89438651	ANKRD11	-0.4	-7.6	-0.33	1.66e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg19143629	chr17:61920732	SMARCD2	-0.42	-7.23	-0.32	1.99e-12	Prudent dietary pattern;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg08565409	chr2:24270541	C2orf44	-0.44	-7.19	-0.32	2.69e-12	Electrocardiographic conduction measures;
LGG	cis	rs12479064	0.724	rs28369945	chr2:100080928	C/G	cg08885076	chr2:99613938	TSGA10	-0.44	-7.99	-0.35	1.05e-14	Chronic sinus infection;
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.27	-0.46	3.22e-26	Neuroticism;
LGG	cis	rs7483296	0.705	rs2513645	chr11:115423876	A/G	cg02820646	chr11:115398838	NA	0.4	6.93	0.31	1.44e-11	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs4862307	0.836	rs4862304	chr4:184996607	C/T	cg06737308	chr4:185021514	ENPP6	0.41	7.27	0.32	1.57e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg21926883	chr2:100939477	LONRF2	-0.7	-16.99	-0.62	1.18e-50	Intelligence (multi-trait analysis);
LGG	cis	rs1044826	0.642	rs6771831	chr3:139177585	C/T	cg15131784	chr3:139108705	COPB2	0.43	7.07	0.31	5.69e-12	Obesity-related traits;
LGG	cis	rs9326248	0.539	rs7120565	chr11:117042949	T/C	cg20608306	chr11:116969690	SIK3	0.36	10.71	0.45	4.54e-24	Blood protein levels;
LGG	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	trans	rs3942852	0.568	rs10838800	chr11:48094879	C/T	cg03929089	chr4:120376271	NA	-0.69	-10.83	-0.45	1.6e-24	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg08344181	chr3:125677491	NA	-0.66	-7.86	-0.34	2.78e-14	Depression;
LGG	cis	rs7010267	0.543	rs6469796	chr8:120018042	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.89	0.38	1.39e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03713592	chr11:72463424	ARAP1	0.4	7.55	0.33	2.34e-13	Type 2 diabetes;
LGG	cis	rs9916302	0.904	rs9898773	chr17:37532507	C/G	cg07936489	chr17:37558343	FBXL20	0.85	16.01	0.6	3.05e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs17253792	0.822	rs75763956	chr14:56071176	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs6461049	0.766	rs10256077	chr7:2171450	C/T	cg21782813	chr7:2030301	MAD1L1	-0.39	-9.31	-0.4	5.18e-19	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11770909	chr7:1086716	G/A	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	5e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2832191	0.671	rs2409332	chr21:30512779	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-10.52	-0.44	2.38e-23	Dental caries;
LGG	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg26597838	chr10:835615	NA	0.95	13.04	0.52	2.46e-33	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02155754	chr12:7053564	C12orf57	0.49	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	trans	rs66887589	0.807	rs7694483	chr4:120405929	T/A	cg25214090	chr10:38739885	LOC399744	0.38	6.99	0.31	9.47e-12	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.19	0.32	2.67e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg13385794	chr1:248469461	NA	0.49	8.45	0.37	3.81e-16	Common traits (Other);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14150915	chr11:66056828	YIF1A	-0.51	-7.59	-0.33	1.8e-13	Systemic lupus erythematosus;
LGG	cis	rs6686842	0.536	rs10493093	chr1:41702186	A/G	cg02290550	chr1:41487317	SLFNL1	0.32	6.66	0.3	7.76e-11	Height;
LGG	trans	rs1814175	0.715	rs11040586	chr11:49858432	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.14	-0.49	1.24e-29	Height;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg22044901	chr15:68126292	NA	-0.42	-7.88	-0.34	2.37e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1422110	0.572	rs6884343	chr5:85444051	G/T	cg01787110	chr1:109008453	NBPF6	0.64	11.17	0.46	8.48e-26	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11168351	0.926	rs10875719	chr12:48411158	T/C	cg24011408	chr12:48396354	COL2A1	0.61	10.33	0.43	1.21e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs981844	0.775	rs921884	chr4:154753059	G/A	cg14289246	chr4:154710475	SFRP2	-0.62	-10.4	-0.44	6.7e-23	Response to statins (LDL cholesterol change);
LGG	cis	rs3771570	1.000	rs62193207	chr2:242318501	G/C	cg21155796	chr2:242212141	HDLBP	0.74	9.75	0.41	1.46e-20	Prostate cancer;
LGG	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	1.000	rs12441433	chr15:76816015	G/A	cg15268244	chr15:77196840	NA	-0.34	-7.53	-0.33	2.75e-13	Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7769051	0.522	rs6569852	chr6:133108333	C/A	cg22852734	chr6:133119734	C6orf192	1.32	10.47	0.44	3.75e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7599312	0.586	rs4404217	chr2:213385817	G/A	cg20637307	chr2:213403960	ERBB4	0.5	8.77	0.38	3.43e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9308731	0.863	rs17558117	chr2:111940996	A/T	cg19992207	chr2:111874495	ACOXL	-0.38	-6.9	-0.31	1.7e-11	Chronic lymphocytic leukemia;
LGG	cis	rs10895140	0.756	rs2508249	chr11:101493911	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05557255	chr11:2422385	TSSC4	0.49	7.9	0.34	2.09e-14	Cognitive performance;
LGG	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg01765077	chr12:122356316	WDR66	0.29	8.06	0.35	6.72e-15	Mean corpuscular volume;
LGG	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg23583168	chr7:148888333	NA	-0.68	-10.68	-0.44	5.86e-24	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs35160687	0.901	rs12472390	chr2:86475083	T/C	cg10973622	chr2:86423274	IMMT	0.41	7.15	0.32	3.32e-12	Night sleep phenotypes;
LGG	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21014159	chr11:117668035	DSCAML1	0.5	7.53	0.33	2.72e-13	Myopia;
LGG	cis	rs8072100	0.539	rs36043200	chr17:45629406	G/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.32	0.32	1.13e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2028299	1.000	rs8031576	chr15:90380214	C/A	cg23731826	chr15:90371692	NA	0.37	8.63	0.37	1.01e-16	Type 2 diabetes;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.5	-0.37	2.66e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs56804039	1.000	rs67611618	chr8:8380939	T/C	cg02002194	chr4:3960332	NA	0.44	6.98	0.31	9.97e-12	Cervical cancer;
LGG	cis	rs7928758	0.945	rs7108756	chr11:134280860	C/A	cg15243474	chr11:134282918	B3GAT1	1.03	14.19	0.55	3.45e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2235642	0.717	rs2236269	chr16:1652614	T/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.39	9.34	0.4	4.01e-19	Coronary artery disease;
LGG	cis	rs12476592	0.602	rs10865340	chr2:63824049	C/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.73	-0.3	5.16e-11	Childhood ear infection;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg14196790	chr5:131705035	SLC22A5	0.62	7.83	0.34	3.35e-14	Rheumatoid arthritis;
LGG	cis	rs11105298	0.891	rs12228177	chr12:89862030	G/T	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9527	0.590	rs7912517	chr10:104905529	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.87	-0.3	2.14e-11	Arsenic metabolism;
LGG	cis	rs11711311	0.712	rs10804510	chr3:113340700	T/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.74	0.48	4.95e-28	IgG glycosylation;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.65	0.37	8.5e-17	Obesity-related traits;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.53	0.56	1.13e-39	Platelet count;
LGG	cis	rs9807841	0.670	rs2569512	chr19:10790162	A/G	cg17710535	chr19:10819994	QTRT1	0.44	6.79	0.3	3.51e-11	Inflammatory skin disease;
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.33	6.73	0.3	5.04e-11	Aortic root size;
LGG	cis	rs116095464	0.558	rs2288459	chr5:231143	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.55	-0.63	3e-53	Breast cancer;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg00149659	chr3:10157352	C3orf10	0.84	10.23	0.43	2.8e-22	Alzheimer's disease;
LGG	cis	rs9596837	0.514	rs2785821	chr13:54272104	C/T	ch.13.53330881F	chr13:54432880	NA	0.42	6.91	0.31	1.66e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs4740619	0.846	rs10810422	chr9:15654475	C/T	cg14451791	chr9:16040625	NA	0.35	9.11	0.39	2.41e-18	Body mass index;
LGG	cis	rs653465	0.739	rs11129262	chr3:27143287	C/G	cg02860705	chr3:27208620	NA	-0.4	-7.69	-0.34	8.82e-14	Breast cancer (early onset);
LGG	trans	rs17685	0.664	rs9801113	chr7:75792031	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.51e-30	Lung cancer;
LGG	cis	rs7224668	0.564	rs9894535	chr17:79252917	A/G	cg03823431	chr17:79229385	SLC38A10	0.36	7.45	0.33	4.7e-13	IgG glycosylation;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7432375	0.901	rs4038587	chr3:136381368	A/C	cg21827317	chr3:136751795	NA	-0.47	-8.55	-0.37	1.76e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1348850	0.914	rs12693120	chr2:178283288	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-8.58	-0.37	1.44e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3820928	1.000	rs7561378	chr2:227772248	T/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.72e-12	Pulmonary function;
LGG	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg27624424	chr6:160112604	SOD2	0.65	9.41	0.4	2.41e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7666738	0.830	rs7657982	chr4:99044015	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.58e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg01171360	chr6:293285	DUSP22	-0.41	-6.91	-0.31	1.65e-11	Menopause (age at onset);
LGG	cis	rs898097	0.812	rs72859941	chr17:80837459	G/A	cg22432760	chr17:80829718	TBCD	0.4	6.91	0.31	1.56e-11	Breast cancer;
LGG	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg06028605	chr16:24865363	SLC5A11	0.48	7.79	0.34	4.51e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7619833	0.719	rs1352943	chr3:27368875	C/G	cg02860705	chr3:27208620	NA	-0.42	-7.92	-0.35	1.81e-14	Breast cancer;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs2235649	0.833	rs9929262	chr16:1851928	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-7.03	-0.31	7.29e-12	Blood metabolite levels;
LGG	cis	rs1552244	1.000	rs4269070	chr3:10126083	C/G	cg00149659	chr3:10157352	C3orf10	0.82	10.62	0.44	9.9e-24	Alzheimer's disease;
LGG	cis	rs887829	0.569	rs4663965	chr2:234650604	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.48	-8.63	-0.37	1.03e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4891159	0.584	rs2848958	chr18:74157068	C/T	cg24786174	chr18:74118243	ZNF516	0.65	15.69	0.59	8.42e-45	Longevity;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs11165623	0.585	rs6698447	chr1:96999473	C/T	cg10631902	chr5:14652156	NA	-0.45	-9.38	-0.4	2.86e-19	Hip circumference;Waist circumference;
LGG	cis	rs870825	0.549	rs28579266	chr4:185627262	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs6502050	0.805	rs6502057	chr17:80082060	A/G	cg23985595	chr17:80112537	CCDC57	0.48	9.63	0.41	4.09e-20	Life satisfaction;
LGG	cis	rs12220238	0.915	rs75467340	chr10:75907318	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.05	0.46	2.38e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03264133	chr6:25882463	NA	-0.88	-16.43	-0.61	3.8e-48	Intelligence (multi-trait analysis);
LGG	cis	rs986417	0.786	rs76632048	chr14:60846934	G/A	cg27398547	chr14:60952738	C14orf39	-0.71	-6.87	-0.3	2.01e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23009452	chr2:25264872	EFR3B	0.46	6.84	0.3	2.56e-11	Gut microbiome composition (summer);
LGG	trans	rs6011368	0.607	rs6062363	chr20:62912463	C/T	cg13869341	chr1:15865	WASH5P	0.61	11.03	0.46	2.77e-25	Clozapine-induced cytotoxicity;
LGG	cis	rs4819052	0.635	rs2838808	chr21:46621106	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.51	8.08	0.35	5.74e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7208859	0.623	rs11658022	chr17:29085359	A/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.26	0.32	1.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs796364	1.000	rs281783	chr2:200751582	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg02725872	chr8:58115012	NA	-1.07	-15.09	-0.57	4.02e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2415984	0.622	rs7156466	chr14:46933384	A/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.1	-0.42	8.4e-22	Number of children ever born;
LGG	cis	rs870825	0.746	rs1107908	chr4:185620113	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs3785574	0.962	rs114027117	chr17:61939935	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.13	25.67	0.77	5.18e-91	Height;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg15691649	chr6:25882328	NA	-0.42	-7.12	-0.31	4.14e-12	Urate levels;
LGG	cis	rs4604732	0.631	rs74154673	chr1:247625629	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs798554	0.634	rs6970963	chr7:2821271	C/T	cg13628971	chr7:2884303	GNA12	0.32	6.67	0.3	7.48e-11	Height;
LGG	cis	rs9916302	0.861	rs4795377	chr17:37669056	C/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.4	-0.58	1.69e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs12410462	0.681	rs115959512	chr1:227599578	T/C	cg23173402	chr1:227635558	NA	0.65	9.49	0.4	1.24e-19	Major depressive disorder;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg05868516	chr6:26286170	HIST1H4H	0.46	7.98	0.35	1.17e-14	Educational attainment;
LGG	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg10167378	chr1:228756711	NA	0.52	8.93	0.38	1.05e-17	Chronic lymphocytic leukemia;
LGG	cis	rs929354	1.000	rs1182389	chr7:157038803	C/T	cg00092383	chr7:157075207	NA	-0.43	-7.57	-0.33	2.05e-13	Body mass index;
LGG	cis	rs10861342	1.000	rs11112390	chr12:105542200	A/C	cg23923672	chr12:105501055	KIAA1033	0.83	7.85	0.34	2.96e-14	IgG glycosylation;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15218456	chr17:25289681	NA	0.38	6.91	0.31	1.66e-11	Menarche (age at onset);
LGG	cis	rs1682825	1.000	rs12634167	chr3:10780100	G/A	cg23512531	chr3:10780469	NA	0.61	7.96	0.35	1.37e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.21	-0.32	2.34e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2040771	0.804	rs1091013	chr22:19248587	C/T	cg02655711	chr22:19163373	SLC25A1	0.45	7.94	0.35	1.55e-14	Metabolite levels (small molecules and protein measures);
LGG	cis	rs9595066	1.000	rs4942281	chr13:44708126	C/T	cg04068111	chr13:44716778	NA	-0.57	-8.11	-0.35	4.64e-15	Schizophrenia;
LGG	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg02297831	chr4:17616191	MED28	0.49	9.23	0.39	9.34e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg06346307	chr22:19949965	COMT	-0.48	-12.6	-0.51	1.68e-31	Blood metabolite levels;
LGG	trans	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg03709012	chr19:19516395	GATAD2A	-0.85	-17.13	-0.62	2.57e-51	Tonsillectomy;
LGG	cis	rs11585357	0.793	rs11588418	chr1:17616445	A/G	cg08277548	chr1:17600880	PADI3	-0.71	-7.93	-0.35	1.67e-14	Hair shape;
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs4975709	0.544	rs4975748	chr5:1866025	G/A	cg15595755	chr5:1867978	NA	0.54	10.26	0.43	2.19e-22	Cardiovascular disease risk factors;
LGG	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs4774830	0.661	rs12443357	chr15:56305980	C/T	cg24530489	chr15:56299380	NA	-0.83	-7.46	-0.33	4.4e-13	Delta-5 desaturase activity;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg18350739	chr11:68623251	NA	-0.89	-22.53	-0.72	1.95e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2749592	0.505	rs7915670	chr10:37870212	T/C	cg25427524	chr10:38739819	LOC399744	0.46	8.67	0.37	7.53e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg02725872	chr8:58115012	NA	-0.84	-12.11	-0.49	1.61e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg07685180	chr8:600429	NA	0.83	8.58	0.37	1.4e-16	IgG glycosylation;
LGG	cis	rs17039065	1.000	rs7435183	chr4:109383566	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	7.05	0.31	6.68e-12	Gut microbiome composition (summer);
LGG	cis	rs9880211	0.948	rs9813691	chr3:136260722	T/G	cg21827317	chr3:136751795	NA	-0.49	-7.21	-0.32	2.23e-12	Body mass index;Height;
LGG	cis	rs739401	0.611	rs494427	chr11:3048140	A/G	cg05729581	chr11:3078854	CARS	-0.55	-9.69	-0.41	2.43e-20	Longevity;
LGG	cis	rs12579753	0.667	rs7397307	chr12:82300161	G/T	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.24	-0.32	1.87e-12	Resting heart rate;
LGG	cis	rs6547741	0.967	rs4665999	chr2:27834444	T/C	cg22903471	chr2:27725779	GCKR	0.38	8.58	0.37	1.45e-16	Oral cavity cancer;
LGG	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg07636037	chr3:49044803	WDR6	1.09	27.51	0.79	1.87e-99	Parkinson's disease;
LGG	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs7208859	0.623	rs9894709	chr17:29078454	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs13215691	chr6:150113802	T/C	cg07701084	chr6:150067640	NUP43	0.64	12.09	0.49	2.03e-29	Lung cancer;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg02733842	chr7:1102375	C7orf50	0.58	8.81	0.38	2.5e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.46	-0.4	1.55e-19	Life satisfaction;
LGG	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg24110177	chr3:50126178	RBM5	0.47	7.9	0.34	1.99e-14	Menarche (age at onset);
LGG	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg08470875	chr2:26401718	FAM59B	-0.41	-8.04	-0.35	7.57e-15	Gut microbiome composition (summer);
LGG	cis	rs10540	1.000	rs35874808	chr11:506442	G/T	cg03352830	chr11:487213	PTDSS2	0.85	10.77	0.45	2.72e-24	Body mass index;
LGG	cis	rs9810089	0.527	rs590198	chr3:135953729	G/A	cg12473912	chr3:136751656	NA	0.48	8.44	0.37	4.06e-16	Gestational age at birth (child effect);
LGG	cis	rs4731207	0.596	rs7806807	chr7:124611300	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7572733	0.555	rs6434954	chr2:198929716	T/C	cg00792783	chr2:198669748	PLCL1	0.6	9.41	0.4	2.34e-19	Dermatomyositis;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.05e-17	Menopause (age at onset);
LGG	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg26384229	chr12:38710491	ALG10B	0.98	22.67	0.73	4.19e-77	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2455601	0.744	rs2568085	chr11:8975748	G/T	cg21881798	chr11:8931708	C11orf17;ST5	0.52	9.11	0.39	2.57e-18	Schizophrenia;
LGG	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg17691542	chr6:26056736	HIST1H1C	0.7	11.45	0.47	6.9e-27	Height;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg25811766	chr13:21894605	NA	0.71	12.56	0.5	2.52e-31	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3733418	0.860	rs13142064	chr4:165943549	G/A	cg10852876	chr4:165953100	TRIM60	-0.48	-6.85	-0.3	2.33e-11	Obesity-related traits;
LGG	cis	rs774359	0.750	rs2477521	chr9:27509945	A/G	cg14173147	chr9:27528300	MOBKL2B	0.45	8.64	0.37	9.06e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg12293132	chr7:23720668	C7orf46	0.38	8.89	0.38	1.34e-17	Schizophrenia;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.42	0.33	5.67e-13	Prudent dietary pattern;
LGG	cis	rs17253792	0.822	rs10147431	chr14:56091841	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs1124376	0.816	rs3828352	chr3:20191973	A/T	cg05072819	chr3:20081367	KAT2B	0.56	7.82	0.34	3.57e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4776059	1.000	rs17614559	chr15:52878719	G/A	cg22715398	chr15:52968154	KIAA1370	-0.46	-7.55	-0.33	2.4e-13	Schizophrenia;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.51e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs61656020	1	rs61656020	chr16:1882221	C/G	cg26897989	chr16:1907736	C16orf73	-0.91	-15.49	-0.58	6.73e-44	Ankle injury;
LGG	cis	rs12780845	0.540	rs10904903	chr10:17238336	T/A	cg01003015	chr10:17271136	VIM	-0.44	-7.45	-0.33	4.56e-13	Homocysteine levels;
LGG	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg21466736	chr12:48725269	NA	-0.39	-7.89	-0.34	2.21e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7301016	0.901	rs12369961	chr12:62966584	C/T	cg11441379	chr12:63026424	NA	0.63	8.92	0.38	1.12e-17	IgG glycosylation;
LGG	trans	rs11250097	0.549	rs11778177	chr8:11310362	C/T	cg16141378	chr3:129829833	LOC729375	0.35	7.76	0.34	5.3e-14	Neuroticism;
LGG	cis	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.91	-0.35	1.86e-14	Joint mobility (Beighton score);
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg16301924	chr13:53314226	LECT1	-0.46	-9.05	-0.39	3.99e-18	Lewy body disease;
LGG	cis	rs7683537	0.554	rs55830081	chr4:185666477	A/C	cg04058563	chr4:185651563	MLF1IP	0.82	13.76	0.54	2.26e-36	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg06475006	chr16:89985975	MC1R	-0.58	-6.8	-0.3	3.16e-11	Skin colour saturation;
LGG	cis	rs12580194	0.593	rs60230359	chr12:55736550	T/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.03e-21	Cancer;
LGG	cis	rs910316	0.712	rs175074	chr14:75504454	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.59	-0.41	5.64e-20	Height;
LGG	cis	rs9457247	0.967	rs428805	chr6:167403132	C/A	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg15596359	chr8:11213517	TDH	0.33	6.7	0.3	6.05e-11	Neuroticism;
LGG	cis	rs13314892	0.764	rs62252219	chr3:69882748	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.44e-14	QRS complex (12-leadsum);
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.44	7.49	0.33	3.51e-13	Bipolar disorder;
LGG	cis	rs3870371	1.000	rs3870371	chr8:122697132	C/A	cg15679747	chr8:122755315	NA	-0.35	-6.75	-0.3	4.39e-11	Periodontal disease-related phenotypes;
LGG	cis	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	9.25	0.39	8.56e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12220238	0.778	rs10824216	chr10:76409210	C/G	cg19889307	chr10:75911429	ADK;AP3M1	0.6	7.74	0.34	6.33e-14	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2836950	0.565	rs2836926	chr21:40536790	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-12.44	-0.5	7.8e-31	Menarche (age at onset);
LGG	cis	rs28595532	0.920	rs114168088	chr4:119772666	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21813546	chr1:182808991	DHX9	0.45	6.83	0.3	2.74e-11	Gut microbiome composition (summer);
LGG	cis	rs7712401	0.601	rs246308	chr5:122270090	G/T	cg19412675	chr5:122181750	SNX24	0.43	7.24	0.32	1.86e-12	Mean platelet volume;
LGG	cis	rs6912958	0.712	rs9444526	chr6:88326402	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.71	-0.38	5.28e-17	Monocyte percentage of white cells;
LGG	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs151349	0.714	rs6026647	chr20:57606791	C/T	cg23907860	chr20:57583709	CTSZ	-0.37	-6.96	-0.31	1.2e-11	Platelet distribution width;
LGG	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.51	0.53	2.56e-35	HIV-1 control;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22478328	chr22:32340140	C22orf24;YWHAH	0.51	7.62	0.33	1.44e-13	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.563	rs12914005	chr15:76765667	A/G	cg23625390	chr15:77176239	SCAPER	0.39	7.32	0.32	1.08e-12	Blood metabolite levels;
LGG	cis	rs4975616	0.771	rs3816659	chr5:1317820	A/G	cg07493874	chr5:1342172	CLPTM1L	0.85	16.75	0.61	1.34e-49	Lung cancer;
LGG	cis	rs1153858	1.000	rs56669689	chr15:45637729	A/C	cg10760299	chr15:45669010	GATM	0.4	8.01	0.35	9.16e-15	Homoarginine levels;
LGG	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.74	0.41	1.68e-20	Primary sclerosing cholangitis;
LGG	cis	rs9358372	0.964	rs9348444	chr6:20809794	A/T	cg13405222	chr6:20811065	CDKAL1	-0.71	-15.71	-0.59	7.03e-45	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg09699651	chr6:150184138	LRP11	0.53	9.57	0.41	6.36e-20	Lung cancer;
LGG	cis	rs2180341	0.920	rs7756880	chr6:127683999	A/T	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.12e-12	Height;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg19168338	chr16:4465731	CORO7	-0.74	-13.66	-0.54	6.31e-36	Schizophrenia;
LGG	cis	rs2742417	0.624	rs2673068	chr3:45768981	G/A	cg04837898	chr3:45731254	SACM1L	-0.46	-9.25	-0.39	8.45e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg20003494	chr4:90757398	SNCA	-0.44	-8.7	-0.38	5.65e-17	Dementia with Lewy bodies;
LGG	cis	rs7586879	0.828	rs13428789	chr2:25087643	C/T	cg04586622	chr2:25135609	ADCY3	0.37	9.1	0.39	2.77e-18	Body mass index;
LGG	cis	rs929354	0.772	rs1182364	chr7:157017912	T/C	cg00092383	chr7:157075207	NA	0.39	6.8	0.3	3.16e-11	Body mass index;
LGG	cis	rs11239187	0.512	rs11239151	chr10:45067297	T/C	cg03916630	chr10:45065415	NA	0.35	8.45	0.37	3.87e-16	Body mass index;
LGG	cis	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg18252515	chr7:66147081	NA	-1.36	-14.78	-0.57	8.84e-41	Gout;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	trans	rs6825911	0.638	rs1996603	chr4:111378362	G/A	cg10580549	chr19:53101634	ZNF137	0.54	6.82	0.3	2.81e-11	Blood pressure;
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	0.851	rs10201430	chr2:172813241	T/C	cg13550731	chr2:172543902	DYNC1I2	-0.88	-19.62	-0.67	8.4e-63	Schizophrenia;
LGG	cis	rs7917772	0.582	rs4917976	chr10:104360518	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-11.49	-0.47	4.7e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.4	0.63	1.49e-52	Obesity-related traits;
LGG	cis	rs4689592	0.503	rs3857180	chr4:7073899	T/G	cg02503808	chr4:7069936	GRPEL1	-1.0	-13.93	-0.54	4.46e-37	Monocyte percentage of white cells;
LGG	cis	rs73001065	0.818	rs16996185	chr19:19720788	G/T	cg03709012	chr19:19516395	GATAD2A	-0.73	-6.81	-0.3	3.01e-11	LDL cholesterol;
LGG	cis	rs1806153	0.611	rs7936522	chr11:31839182	C/G	cg11990419	chr11:31841155	NA	0.35	8.02	0.35	8.62e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18432924	chr14:50359459	ARF6	-0.4	-6.67	-0.3	7.4e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs427394	0.802	rs274721	chr5:6719164	C/T	cg10857441	chr5:6722123	POLS	-0.27	-6.68	-0.3	6.71e-11	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs117586262	chr22:32406424	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs2124969	0.548	rs62175391	chr2:161022588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.18	-0.39	1.39e-18	Waist circumference adjusted for body mass index;
LGG	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg03929089	chr4:120376271	NA	-1.04	-24.69	-0.75	1.64e-86	Height;
LGG	cis	rs9611565	0.649	rs202614	chr22:41822150	A/C	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.44e-16	Vitiligo;
LGG	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg27398817	chr8:82754497	SNX16	-0.73	-11.31	-0.47	2.28e-26	Diastolic blood pressure;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs6988985	0.818	rs3802230	chr8:143992864	C/A	cg10324643	chr8:143916377	GML	0.42	8.64	0.37	9.21e-17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg13206674	chr6:150067644	NUP43	0.64	13.2	0.52	5.47e-34	Lung cancer;
LGG	cis	rs3112255	0.647	rs10175405	chr2:101319712	G/T	cg01042948	chr2:101319752	NA	-0.42	-7.18	-0.32	2.78e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg12045294	chr17:78518616	RPTOR	-0.49	-7.51	-0.33	3.15e-13	Glycated hemoglobin levels;
LGG	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg04935436	chr20:30431758	NA	0.41	7.21	0.32	2.24e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4853012	0.838	rs59570457	chr2:74344282	T/C	cg19729930	chr2:74357872	NA	0.53	11.45	0.47	6.56e-27	Gestational age at birth (maternal effect);
LGG	cis	rs782590	0.764	rs935177	chr2:55826761	C/G	cg18811423	chr2:55921094	PNPT1	0.82	17.71	0.64	5.78e-54	Metabolic syndrome;
LGG	cis	rs7727544	0.544	rs55722650	chr5:131607300	C/T	cg07395648	chr5:131743802	NA	-0.53	-11.21	-0.46	5.68e-26	Blood metabolite levels;
LGG	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7296418	0.922	rs1727293	chr12:123648032	C/T	cg00376283	chr12:123451042	ABCB9	0.67	12.32	0.5	2.39e-30	Platelet count;
LGG	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg19913688	chr11:428466	ANO9	-0.7	-8.52	-0.37	2.18e-16	Body mass index;
LGG	cis	rs3741798	1.000	rs61922028	chr12:12487096	A/C	cg08615371	chr12:12503544	MANSC1	0.59	6.8	0.3	3.26e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6540556	0.637	rs12060922	chr1:209904433	G/A	cg23920097	chr1:209922102	NA	-0.44	-7.3	-0.32	1.23e-12	Red blood cell count;
LGG	cis	rs4650994	0.525	rs2493858	chr1:178541210	A/G	cg19399532	chr1:178512495	C1orf220	0.54	10.88	0.45	1.03e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9303401	0.538	rs2240259	chr17:56458129	A/C	cg25039879	chr17:56429692	SUPT4H1	0.77	11.39	0.47	1.13e-26	Cognitive test performance;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19060382	chr12:104324997	LOC253724;HSP90B1	0.45	7.31	0.32	1.21e-12	Cognitive performance;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg11062466	chr8:58055876	NA	0.62	9.84	0.42	7.26e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs73001065	0.901	rs73004959	chr19:19711139	C/T	cg03709012	chr19:19516395	GATAD2A	0.8	6.96	0.31	1.16e-11	LDL cholesterol;
LGG	cis	rs11644362	1.000	rs12930743	chr16:12984136	G/C	cg06890432	chr16:12997467	SHISA9	-0.32	-6.91	-0.31	1.57e-11	Positive affect;Subjective well-being;
LGG	cis	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg21775007	chr8:11205619	TDH	-0.47	-7.42	-0.33	5.63e-13	Morning vs. evening chronotype;
LGG	cis	rs7598759	0.527	rs12987949	chr2:232367511	A/G	cg19187155	chr2:232395269	NMUR1	0.53	9.93	0.42	3.43e-21	Noise-induced hearing loss;
LGG	cis	rs2115630	0.691	rs61322921	chr15:85163638	T/C	cg11189052	chr15:85197271	WDR73	-0.5	-8.16	-0.35	3.13e-15	P wave terminal force;
LGG	cis	rs4144027	0.818	rs881057	chr14:104354258	T/G	cg26031613	chr14:104095156	KLC1	0.46	7.49	0.33	3.64e-13	Blood metabolite levels;
LGG	cis	rs12200782	0.929	rs116018523	chr6:26357234	T/C	cg11502198	chr6:26597334	ABT1	-0.76	-6.82	-0.3	2.77e-11	Small cell lung carcinoma;
LGG	cis	rs958025	1	rs958025	chr15:78759348	C/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.04	-0.35	7.35e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.16e-13	Dupuytren's disease;
LGG	cis	rs3741151	0.773	rs73544729	chr11:73183418	G/T	cg17517138	chr11:73019481	ARHGEF17	0.9	8.89	0.38	1.42e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.82	-0.45	1.77e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs12220238	1.000	rs10824075	chr10:75880254	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.72	0.48	6.04e-28	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs1493916	0.601	rs7237379	chr18:31322540	C/T	cg04226714	chr8:49833948	SNAI2	0.46	8.03	0.35	8.26e-15	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg12436631	chr1:155007014	DCST1;DCST2	0.44	8.8	0.38	2.72e-17	Prostate cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07344492	chr5:132947192	FSTL4	0.38	7.08	0.31	5.34e-12	Bipolar disorder;
LGG	trans	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg11441553	chr12:57614120	NXPH4	-0.61	-7.61	-0.33	1.58e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7100689	0.646	rs4601708	chr10:82119583	G/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg15133208	chr4:90757351	SNCA	-0.35	-7.75	-0.34	5.78e-14	Dementia with Lewy bodies;
LGG	cis	rs10464366	0.571	rs13233049	chr7:39187536	C/T	cg21665744	chr7:39171113	POU6F2	0.43	8.88	0.38	1.45e-17	IgG glycosylation;
LGG	cis	rs4665809	0.652	rs7585891	chr2:26403766	G/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.04	-0.39	4.2e-18	Gut microbiome composition (summer);
LGG	cis	rs6456156	0.716	rs6905911	chr6:167521624	C/T	cg07741184	chr6:167504864	NA	0.39	8.17	0.35	2.96e-15	Primary biliary cholangitis;
LGG	cis	rs35110281	0.591	rs86139	chr21:44932802	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.54	0.37	1.95e-16	Mean corpuscular volume;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00149659	chr3:10157352	C3orf10	1.17	13.74	0.54	2.96e-36	Alzheimer's disease;
LGG	cis	rs244293	0.760	rs4794547	chr17:53011172	A/G	cg19360675	chr17:53046073	COX11;STXBP4	-0.41	-6.81	-0.3	2.98e-11	Menarche (age at onset);
LGG	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.19	0.49	7.69e-30	Lung cancer in ever smokers;
LGG	cis	rs4917300	0.549	rs902819	chr8:143098548	C/T	cg26003909	chr8:143102224	NA	-0.41	-8.99	-0.39	6.21e-18	Amyotrophic lateral sclerosis;
LGG	trans	rs11992162	0.933	rs10108075	chr8:11832079	A/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.7	0.34	8.07e-14	Monocyte count;
LGG	cis	rs834603	0.518	rs834605	chr7:47450456	T/C	cg23694490	chr7:47445681	TNS3	-0.44	-12.8	-0.51	2.42e-32	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg06637938	chr14:75390232	RPS6KL1	0.59	10.75	0.45	3.33e-24	Height;
LGG	cis	rs10214930	0.625	rs2391453	chr7:27690587	T/C	cg22168087	chr7:27702803	HIBADH	0.45	6.67	0.3	7.31e-11	Hypospadias;
LGG	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg09855544	chr8:135498122	ZFAT	0.46	7.8	0.34	4.1e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.18	-0.43	4.11e-22	Obesity-related traits;
LGG	cis	rs7765175	0.631	rs9481341	chr6:113664182	G/A	cg26552650	chr6:113682475	NA	0.34	7.66	0.34	1.07e-13	Coronary artery calcification;
LGG	cis	rs760805	1.000	rs7517302	chr1:25254317	C/T	cg03961551	chr1:25251730	RUNX3	0.46	11.94	0.49	7.59e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9910055	0.676	rs11079983	chr17:42198170	C/T	cg13607699	chr17:42295918	UBTF	0.63	10.89	0.45	9.55e-25	Total body bone mineral density;
LGG	trans	rs9329221	0.538	rs2272597	chr8:10100524	A/C	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.29	-0.32	1.36e-12	Neuroticism;
LGG	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs9992101	0.645	rs6857452	chr4:77317124	C/T	cg17010112	chr4:77227123	STBD1	0.44	8.86	0.38	1.77e-17	Creatinine levels;
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg12042659	chr19:58951599	ZNF132	-0.43	-8.76	-0.38	3.71e-17	Uric acid clearance;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13995374	chr19:13056470	RAD23A	-0.46	-7.6	-0.33	1.67e-13	Pancreatic cancer;
LGG	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg19729930	chr2:74357872	NA	0.53	11.31	0.47	2.35e-26	Gestational age at birth (maternal effect);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25671651	chr2:203776787	ALS2CR8;WDR12	0.51	7.75	0.34	6.05e-14	Gut microbiome composition (summer);
LGG	cis	rs12618769	0.597	rs72821943	chr2:99141640	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs4319547	0.506	rs2062488	chr12:122804256	C/T	cg05707623	chr12:122985044	ZCCHC8	0.49	7.39	0.32	6.96e-13	Body mass index;
LGG	cis	rs2455799	0.613	rs2470536	chr3:15715156	G/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.9	-0.34	1.98e-14	Mean platelet volume;
LGG	cis	rs8133932	0.906	rs78288391	chr21:47114310	A/G	cg11214348	chr21:47283868	PCBP3	-0.43	-7.25	-0.32	1.82e-12	Schizophrenia;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9460578	0.508	rs10806925	chr6:20819976	C/T	cg13405222	chr6:20811065	CDKAL1	0.79	17.74	0.64	4.27e-54	Breast cancer;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg00830817	chr11:109293614	C11orf87	-0.4	-6.78	-0.3	3.75e-11	Schizophrenia;
LGG	cis	rs3741404	0.560	rs2875748	chr11:63915537	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.73	-13.33	-0.53	1.56e-34	Platelet count;
LGG	cis	rs28374715	0.532	rs3204853	chr15:41689166	C/A	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.03e-133	Ulcerative colitis;
LGG	trans	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg19894588	chr14:64061835	NA	-0.64	-10.21	-0.43	3.18e-22	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs7395662	0.818	rs2200181	chr11:48413175	C/G	cg15704280	chr7:45808275	SEPT13	-0.46	-7.4	-0.33	6.47e-13	HDL cholesterol;
LGG	cis	rs4493873	0.869	rs6471265	chr8:92099848	T/G	cg16814680	chr8:91681699	NA	0.44	6.86	0.3	2.17e-11	Migraine - clinic-based;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg03395511	chr6:291903	DUSP22	-0.69	-11.79	-0.48	3.14e-28	Menopause (age at onset);
LGG	cis	rs13177180	0.523	rs187682	chr5:114905276	G/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.37	-0.32	8.04e-13	Conotruncal heart defects (inherited effects);
LGG	cis	rs4242434	0.757	rs2280104	chr8:22525980	C/T	cg19455335	chr8:22457658	C8orf58	-0.43	-8.66	-0.37	7.98e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6784615	0.744	rs3821838	chr3:52489049	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.49	-0.33	3.42e-13	Waist-hip ratio;
LGG	trans	rs57221529	0.709	rs72703090	chr5:598314	C/T	cg27053975	chr1:166958233	MAEL	-0.47	-6.65	-0.3	8.18e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg06719900	chr11:109292894	C11orf87	0.49	8.75	0.38	4.07e-17	Schizophrenia;
LGG	cis	rs9314323	0.535	rs1055479	chr8:26240646	A/G	cg11498726	chr8:26250323	BNIP3L	-0.47	-10.2	-0.43	3.53e-22	Red cell distribution width;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.529	rs228748	chr17:42174390	G/A	cg16434002	chr17:42200994	HDAC5	0.46	8.19	0.36	2.6e-15	Total body bone mineral density;
LGG	cis	rs11711311	0.955	rs78029398	chr3:113421321	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.76	-0.34	5.37e-14	IgG glycosylation;
LGG	trans	rs7395662	0.963	rs9666932	chr11:48726240	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs3540	0.960	rs8030299	chr15:91026459	G/A	cg22089800	chr15:90895588	ZNF774	0.51	7.95	0.35	1.4e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4478858	0.660	rs10798844	chr1:31819128	A/G	cg19084893	chr1:31688959	NA	0.32	6.71	0.3	5.8e-11	Alcohol dependence;
LGG	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.67	-11.44	-0.47	7.12e-27	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10819861	0.547	rs10760781	chr9:98872831	G/A	cg14508093	chr9:98862825	NA	0.3	6.88	0.3	1.97e-11	Electrocardiographic traits;
LGG	cis	rs5758659	0.682	rs133306	chr22:42396150	G/A	cg15128208	chr22:42549153	NA	-0.37	-7.51	-0.33	3.1e-13	Cognitive function;
LGG	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg00198680	chr16:28758506	NA	0.29	7.26	0.32	1.65e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-7.06	-0.31	6.2e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07570687	chr10:102243282	WNT8B	0.43	7.29	0.32	1.35e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11122272	0.705	rs2572260	chr1:231486189	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.06	-0.31	6.05e-12	Hemoglobin concentration;
LGG	cis	rs9462027	0.628	rs7739003	chr6:34800329	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs4665809	0.590	rs4665319	chr2:26424583	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.02	-19.63	-0.67	7.12e-63	Gut microbiome composition (summer);
LGG	cis	rs977987	0.778	rs4887821	chr16:75398574	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	cis	rs765787	0.530	rs1706837	chr15:45519036	A/G	cg25801113	chr15:45476975	SHF	0.86	19.68	0.67	4.14e-63	Uric acid levels;
LGG	cis	rs2067615	0.599	rs12369214	chr12:107198611	G/A	cg15890332	chr12:107067104	RFX4	0.4	11.57	0.47	2.29e-27	Heart rate;
LGG	cis	rs2303745	0.589	rs7246262	chr19:17392483	C/G	cg10664184	chr19:17420304	DDA1	0.56	8.6	0.37	1.23e-16	Systemic lupus erythematosus;
LGG	cis	rs6459788	0.527	rs6980250	chr7:157228710	C/T	cg04198125	chr7:157211777	NA	0.42	7.83	0.34	3.36e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6840360	0.615	rs62329085	chr4:152470237	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.48	-0.33	3.87e-13	Intelligence (multi-trait analysis);
LGG	cis	rs548181	0.736	rs497344	chr11:125470524	T/C	cg03464685	chr11:125439445	EI24	1.31	19.5	0.67	2.9e-62	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs986417	1.000	rs2093212	chr14:60843322	G/A	cg27398547	chr14:60952738	C14orf39	-0.7	-6.8	-0.3	3.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2832191	0.791	rs7283853	chr21:30498515	G/A	cg24692254	chr21:30365293	RNF160	-0.94	-24.06	-0.75	1.42e-83	Dental caries;
LGG	cis	rs79349575	0.679	rs9894239	chr17:46997959	C/T	cg22482690	chr17:47019901	SNF8	-0.34	-6.68	-0.3	6.66e-11	Type 2 diabetes;
LGG	cis	rs12210905	1.000	rs12205628	chr6:27225959	C/A	cg11502198	chr6:26597334	ABT1	-0.87	-6.66	-0.3	7.67e-11	Hip circumference adjusted for BMI;
LGG	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg11871910	chr12:69753446	YEATS4	1.05	28.85	0.8	1.64e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.72	0.41	1.93e-20	Height;
LGG	cis	rs60780116	1	rs60780116	chr4:185708807	T/C	cg04058563	chr4:185651563	MLF1IP	0.68	10.43	0.44	5.13e-23	Type 2 diabetes;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg27532560	chr4:187881888	NA	-0.6	-13.49	-0.53	3.18e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.13e-43	Menopause (age at onset);
LGG	cis	rs208520	0.690	rs12213928	chr6:66762978	G/A	cg07460842	chr6:66804631	NA	0.96	18.02	0.64	2.11e-55	Exhaled nitric oxide output;
LGG	cis	rs6582630	0.555	rs11181053	chr12:38271364	T/C	cg04568710	chr12:38710424	ALG10B	-0.4	-8.88	-0.38	1.43e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3780486	0.505	rs10813959	chr9:33166234	C/T	cg13443165	chr9:33130375	B4GALT1	0.55	10.54	0.44	2.06e-23	IgG glycosylation;
LGG	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg12463550	chr7:65579703	CRCP	0.75	7.95	0.35	1.43e-14	Gout;
LGG	cis	rs9815354	0.680	rs73073301	chr3:42028777	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg05425664	chr17:57184151	TRIM37	0.58	9.01	0.39	5.49e-18	Intelligence (multi-trait analysis);
LGG	trans	rs10838798	0.501	rs2270994	chr11:48157869	T/C	cg15704280	chr7:45808275	SEPT13	-0.44	-6.71	-0.3	5.56e-11	Height;
LGG	cis	rs523522	0.962	rs7488320	chr12:120981630	G/T	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.15e-25	High light scatter reticulocyte count;
LGG	cis	rs7166081	1.000	rs8031500	chr15:67519040	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.72	-0.3	5.32e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1577917	1.000	rs12199784	chr6:86726808	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.17e-33	Response to antipsychotic treatment;
LGG	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg16583315	chr14:65563665	MAX	-0.36	-6.81	-0.3	2.95e-11	Obesity-related traits;
LGG	cis	rs7084783	0.538	rs7067892	chr10:105339698	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.5	8.64	0.37	9.15e-17	Fear of pain;
LGG	cis	rs2455799	0.573	rs2470539	chr3:15717844	C/T	cg16303742	chr3:15540471	COLQ	-0.39	-7.85	-0.34	2.87e-14	Mean platelet volume;
LGG	cis	rs7084402	0.967	rs1649039	chr10:60330041	C/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.24	-0.32	1.83e-12	Refractive error;
LGG	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs2576037	0.899	rs2576035	chr18:44587654	C/T	cg19077165	chr18:44547161	KATNAL2	0.51	9.04	0.39	4.25e-18	Personality dimensions;
LGG	cis	rs9517320	0.967	rs9517337	chr13:99181647	A/C	cg07423050	chr13:99094983	FARP1	0.43	8.73	0.38	4.74e-17	Longevity;
LGG	cis	rs1003719	0.667	rs28666643	chr21:38455999	T/G	cg10648535	chr21:38446584	PIGP;TTC3	0.72	13.22	0.52	4.52e-34	Eye color traits;
LGG	cis	rs12477438	0.520	rs2969379	chr2:99776686	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	25.75	0.77	2.07e-91	Chronic sinus infection;
LGG	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.48	0.56	1.75e-39	Cognitive test performance;
LGG	cis	rs10048158	0.530	rs72837185	chr17:64201520	G/A	cg19474267	chr17:64306194	PRKCA	0.63	12.64	0.51	1.12e-31	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs3820928	1.000	rs6752707	chr2:227766822	C/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.38	-0.32	7.47e-13	Pulmonary function;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg04911050	chr16:677664	RAB40C	0.35	6.96	0.31	1.17e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19269201	chr1:109969547	PSMA5	0.45	7.65	0.33	1.16e-13	Gut microbiome composition (summer);
LGG	cis	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg13147721	chr7:65941812	NA	0.84	9.32	0.4	4.85e-19	Diabetic kidney disease;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg23978390	chr7:1156363	C7orf50	0.56	9.64	0.41	3.72e-20	Longevity;Endometriosis;
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg02158880	chr13:53174818	NA	0.37	6.94	0.31	1.35e-11	Lewy body disease;
LGG	cis	rs780096	0.506	rs72819512	chr2:27614449	G/A	cg22903471	chr2:27725779	GCKR	-0.58	-13.36	-0.53	1.17e-34	Total body bone mineral density;
LGG	cis	rs977987	0.931	rs8057084	chr16:75492706	G/T	cg07303275	chr16:75499416	TMEM170A	-0.42	-7.51	-0.33	3.17e-13	Dupuytren's disease;
LGG	cis	rs9611565	0.592	rs5751139	chr22:42099981	G/C	cg06634786	chr22:41940651	POLR3H	0.77	12.18	0.49	8.26e-30	Vitiligo;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg09263875	chr16:632152	PIGQ	0.66	13.25	0.52	3.46e-34	Height;
LGG	cis	rs41271473	0.687	rs2295256	chr1:228874049	C/T	cg00850481	chr1:228891306	NA	-0.57	-11.52	-0.47	3.51e-27	Chronic lymphocytic leukemia;
LGG	cis	rs2224391	0.628	rs2773318	chr6:5258843	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-7.52	-0.33	2.85e-13	Height;
LGG	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.98	-0.35	1.15e-14	Myopia (pathological);
LGG	cis	rs1045714	0.895	rs73043182	chr7:2646005	C/T	cg14042143	chr7:2646782	IQCE	0.8	12.45	0.5	6.83e-31	Urate levels in lean individuals;
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.9	-0.38	1.22e-17	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg11995313	chr8:8860691	ERI1	0.45	7.67	0.34	1.05e-13	Joint mobility (Beighton score);
LGG	cis	rs3858526	0.834	rs7125244	chr11:5980359	T/C	cg25319279	chr11:5960081	NA	-0.55	-8.49	-0.37	2.8e-16	DNA methylation (variation);
LGG	cis	rs7904985	0.813	rs1077092	chr10:88101391	G/A	cg07322936	chr10:88137208	NA	-0.51	-7.8	-0.34	4.1e-14	Barrett's esophagus;
LGG	cis	rs2204008	0.729	rs2892365	chr12:38446760	G/C	cg26384229	chr12:38710491	ALG10B	-0.86	-19.67	-0.67	4.52e-63	Bladder cancer;
LGG	cis	rs950027	0.596	rs2467865	chr15:45638307	T/C	cg26924012	chr15:45694286	SPATA5L1	0.68	12.42	0.5	9.17e-31	Response to fenofibrate (adiponectin levels);
LGG	cis	rs711245	0.573	rs11899523	chr2:36800918	T/C	cg09467607	chr2:36825704	FEZ2	0.52	10.07	0.42	1.1e-21	Height;
LGG	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg22563815	chr15:78856949	CHRNA5	0.31	7.74	0.34	6.3e-14	Sudden cardiac arrest;
LGG	cis	rs2070433	0.752	rs2839220	chr21:47774330	G/C	cg12379764	chr21:47803548	PCNT	0.66	9.02	0.39	5.17e-18	Lymphocyte counts;
LGG	cis	rs4731207	0.698	rs10156168	chr7:124494410	G/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.52e-12	Schizophrenia;
LGG	trans	rs11098499	0.954	rs9993199	chr4:120392873	A/G	cg25214090	chr10:38739885	LOC399744	-0.69	-12.36	-0.5	1.54e-30	Corneal astigmatism;
LGG	cis	rs1983170	0.778	rs906241	chr1:92012154	G/T	cg25838465	chr1:92012736	NA	-0.5	-7.87	-0.34	2.46e-14	Eosinophil percentage of white cells;
LGG	cis	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg24110177	chr3:50126178	RBM5	-0.45	-7.25	-0.32	1.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.853	rs6596024	chr5:130769785	A/C	cg06307176	chr5:131281290	NA	0.5	8.53	0.37	2.08e-16	Life satisfaction;
LGG	cis	rs9790314	0.875	rs7615592	chr3:160981548	A/C	cg03342759	chr3:160939853	NMD3	-0.65	-11.71	-0.48	6.26e-28	Morning vs. evening chronotype;
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg18446336	chr7:2847575	GNA12	-0.28	-6.66	-0.3	8.01e-11	Height;
LGG	cis	rs7959452	0.562	rs10878975	chr12:69782044	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs2247341	0.965	rs11730727	chr4:1738313	T/C	cg07465881	chr4:1713556	SLBP	-0.44	-6.92	-0.31	1.53e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs17301259	0.548	rs2519953	chr7:88402008	T/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.33	-7.14	-0.32	3.58e-12	Heschl's gyrus morphology;
LGG	cis	rs7589342	0.839	rs12997003	chr2:106436413	C/T	cg16077055	chr2:106428750	NCK2	0.32	8.41	0.36	5.12e-16	Addiction;
LGG	cis	rs6547741	0.935	rs6547738	chr2:27852637	A/G	cg22903471	chr2:27725779	GCKR	0.37	8.37	0.36	6.88e-16	Oral cavity cancer;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.09	30.03	0.81	9.57e-111	Prudent dietary pattern;
LGG	cis	rs7561149	0.580	rs36051007	chr2:179545859	C/T	cg12089249	chr2:179345200	MIR548N;PLEKHA3	0.45	6.84	0.3	2.5e-11	QT interval;
LGG	cis	rs926392	0.572	rs6129159	chr20:37675011	A/T	cg16355469	chr20:37678765	NA	0.62	9.98	0.42	2.32e-21	Dialysis-related mortality;
LGG	cis	rs4363385	0.510	rs6661063	chr1:153036048	C/A	cg13444842	chr1:152974279	SPRR3	-0.47	-9.36	-0.4	3.47e-19	Inflammatory skin disease;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg02054479	chr16:20911997	LYRM1;DCUN1D3	-0.45	-7.02	-0.31	7.7e-12	Coronary artery disease;
LGG	cis	rs9309711	0.922	rs13399524	chr2:3480206	C/G	cg10845886	chr2:3471009	TTC15	-0.64	-12.73	-0.51	4.79e-32	Neurofibrillary tangles;
LGG	cis	rs6502050	0.835	rs6502070	chr17:80112634	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9682041	0.696	rs10936626	chr3:170095019	G/A	cg11886554	chr3:170076028	SKIL	0.64	8.36	0.36	7.55e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs4900538	0.819	rs72700604	chr14:102882307	G/A	cg18135206	chr14:102964638	TECPR2	-0.68	-12.38	-0.5	1.31e-30	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2204008	0.624	rs2320449	chr12:38224190	T/C	cg26384229	chr12:38710491	ALG10B	0.97	21.79	0.71	5.61e-73	Bladder cancer;
LGG	cis	rs77633900	0.614	rs2439992	chr15:76863023	T/G	cg21673338	chr15:77095150	SCAPER	-0.66	-10.43	-0.44	4.95e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9847710	0.791	rs6808387	chr3:53079732	C/T	cg14092988	chr3:52407081	DNAH1	0.25	6.77	0.3	3.93e-11	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01869405	chr19:33166228	ANKRD27;RGS9BP	0.4	6.79	0.3	3.42e-11	Gut microbiome composition (summer);
LGG	trans	rs2727020	1.000	rs2727020	chr11:49111407	C/G	cg15704280	chr7:45808275	SEPT13	0.82	14.41	0.56	3.63e-39	Coronary artery disease;
LGG	cis	rs6988985	0.728	rs1114761	chr8:143928956	C/T	cg10324643	chr8:143916377	GML	-0.41	-8.1	-0.35	4.89e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9858542	0.953	rs9859556	chr3:49455986	G/T	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.87e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11096990	0.819	rs2435528	chr4:39157536	A/G	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs62344088	0.590	rs62346174	chr5:296308	C/A	cg22857025	chr5:266934	NA	-1.39	-11.35	-0.47	1.71e-26	Asthma (childhood onset);
LGG	cis	rs941408	1.000	rs941407	chr19:2812153	A/G	cg06609049	chr19:2785107	THOP1	0.61	9.46	0.4	1.5700000000000001e-19	Total cholesterol levels;
LGG	cis	rs6500602	0.592	rs3747585	chr16:4519140	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	6.71	0.3	5.54e-11	Schizophrenia;
LGG	cis	rs6582630	0.519	rs10880576	chr12:38497693	T/C	cg26384229	chr12:38710491	ALG10B	0.92	21.45	0.71	2.25e-71	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2576037	0.796	rs2576038	chr18:44582200	C/G	cg23302884	chr18:44338147	ST8SIA5	0.35	6.93	0.31	1.38e-11	Personality dimensions;
LGG	cis	rs1124376	1.000	rs10084714	chr3:20183332	T/C	cg05072819	chr3:20081367	KAT2B	0.59	7.81	0.34	3.87e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.03	-0.39	4.75e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4538187	0.585	rs2969395	chr2:64253741	A/T	cg14150252	chr2:64069583	UGP2	0.43	7.78	0.34	4.77e-14	Systolic blood pressure;
LGG	cis	rs9976767	0.637	rs9984108	chr21:43825628	T/G	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.42	-0.53	6.45e-35	Type 1 diabetes;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.41	0.36	5.22e-16	Prudent dietary pattern;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06028808	chr11:68637592	NA	0.74	12.65	0.51	1.01e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg13010199	chr12:38710504	ALG10B	0.46	8.93	0.38	1.03e-17	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	8.22	0.36	1.99e-15	Diabetic retinopathy;
LGG	cis	rs8018808	0.967	rs4903579	chr14:77850940	T/A	cg20045696	chr14:77926864	AHSA1	-0.41	-6.91	-0.31	1.63e-11	Myeloid white cell count;
LGG	cis	rs2795502	0.938	rs2744085	chr10:43341976	C/T	cg20628663	chr10:43360327	NA	0.41	8.47	0.37	3.17e-16	Blood protein levels;
LGG	cis	rs9911578	1.000	rs9898626	chr17:56698219	C/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs10991814	1.000	rs16907277	chr9:93972658	A/G	cg14446406	chr9:93919335	NA	-0.76	-8.3	-0.36	1.11e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs4629710	0.592	rs4424112	chr6:131563788	C/T	cg12606694	chr6:131520996	AKAP7	0.51	8.33	0.36	9.12e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs8017423	0.900	rs7141887	chr14:90705364	G/T	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.73e-57	Mortality in heart failure;
LGG	cis	rs10824796	0.584	rs61844300	chr10:54520160	C/A	cg27418851	chr10:54531653	MBL2	-0.46	-7.98	-0.35	1.19e-14	Blood protein levels;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg13126279	chr21:47581558	C21orf56	-0.53	-9.48	-0.4	1.37e-19	Testicular germ cell tumor;
LGG	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg16339924	chr4:17578868	LAP3	0.59	10.31	0.43	1.45e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4639966	0.836	rs11217018	chr11:118635364	T/C	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg00717180	chr2:96193071	NA	0.42	7.39	0.32	6.88e-13	HDL cholesterol;
LGG	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg07636037	chr3:49044803	WDR6	1.02	23.22	0.73	1.12e-79	Parkinson's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06869971	chr15:69706519	KIF23	0.42	6.83	0.3	2.71e-11	Cognitive performance;
LGG	cis	rs12188164	0.965	rs72717435	chr5:448202	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.64	0.33	1.3e-13	Cystic fibrosis severity;
LGG	cis	rs10927875	0.722	rs6660685	chr1:16346988	A/G	cg22431228	chr1:16359049	CLCNKA	-0.45	-7.39	-0.32	6.92e-13	Dilated cardiomyopathy;
LGG	trans	rs526821	0.532	rs578067	chr11:55313690	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.65	-0.3	8.11e-11	Pediatric bone mineral density (spine);
LGG	cis	rs10463554	0.963	rs26253	chr5:102556967	T/C	cg23492399	chr5:102201601	PAM	-0.5	-7.37	-0.32	7.89e-13	Parkinson's disease;
LGG	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg12419862	chr22:24373484	LOC391322	0.87	13.14	0.52	9.63e-34	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs4665809	0.652	rs2384360	chr2:26405016	C/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.05	-0.39	3.88e-18	Gut microbiome composition (summer);
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	cis	rs13191362	1.000	rs36007635	chr6:163009335	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.51	-9.79	-0.41	1.05e-20	Coronary artery disease;
LGG	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg09696939	chr10:60272079	BICC1	0.37	7.3	0.32	1.25e-12	Refractive error;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06183820	chr6:2972097	SERPINB6	0.34	6.73	0.3	5.15e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg27523141	chr10:43048294	ZNF37B	0.39	7.55	0.33	2.27e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg07511668	chr11:68622177	NA	0.5	9.28	0.4	6.58e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.895	rs4145009	chr7:65726615	T/C	cg18252515	chr7:66147081	NA	0.42	6.8	0.3	3.31e-11	Aortic root size;
LGG	cis	rs9790314	0.582	rs11922752	chr3:160600599	G/C	cg03342759	chr3:160939853	NMD3	0.45	7.48	0.33	3.65e-13	Morning vs. evening chronotype;
LGG	cis	rs8016982	0.633	rs7141288	chr14:81710232	C/A	cg01989461	chr14:81687754	GTF2A1	0.8	19.11	0.66	1.82e-60	Schizophrenia;
LGG	trans	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08862035	chr2:2617432	NA	0.42	6.8	0.3	3.31e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg05793240	chr7:2802953	GNA12	-0.33	-7.62	-0.33	1.47e-13	Height;
LGG	cis	rs1620921	0.594	rs2465855	chr6:161270619	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1847505	0.609	rs1504418	chr13:61459644	A/G	cg25164009	chr13:61490935	NA	0.59	9.04	0.39	4.26e-18	Polychlorinated biphenyl levels;
LGG	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg17809284	chr5:56205270	C5orf35	-0.55	-8.91	-0.38	1.14e-17	Initial pursuit acceleration;
LGG	cis	rs9878978	1.000	rs62233805	chr3:2474385	T/G	cg21928760	chr3:2462534	CNTN4	0.41	8.98	0.39	7.03e-18	Blood pressure (smoking interaction);
LGG	cis	rs36051895	0.603	rs1590804	chr9:5177573	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.48	0.33	3.83e-13	Lung cancer;
LGG	cis	rs3096299	0.933	rs3114848	chr16:89452771	G/A	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.57	-0.33	2.07e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs950776	0.518	rs11636131	chr15:78821606	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg10523679	chr1:76189770	ACADM	0.76	14.38	0.56	4.95e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11718455	0.920	rs13084408	chr3:44008967	G/A	cg21419209	chr3:44054225	NA	-0.41	-6.8	-0.3	3.14e-11	Coronary artery disease;
LGG	cis	rs28680850	1.000	rs28680850	chr8:1373720	G/A	cg27134251	chr8:1365049	NA	-0.43	-6.72	-0.3	5.27e-11	Triglycerides;
LGG	cis	rs637571	0.522	rs1786175	chr11:65754808	G/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.86	-0.38	1.77e-17	Eosinophil percentage of white cells;
LGG	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	7.94	0.35	1.51e-14	Menarche (age at onset);
LGG	cis	rs9611519	0.929	rs9611469	chr22:41433319	T/C	cg03806693	chr22:41940476	POLR3H	-0.53	-7.92	-0.35	1.83e-14	Neuroticism;
LGG	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg08603382	chr10:743973	NA	-0.42	-7.62	-0.33	1.4e-13	Psychosis in Alzheimer's disease;
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg06925179	chr17:43578568	NA	-0.31	-8.16	-0.35	3.12e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs765787	0.530	rs11070451	chr15:45533541	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-7.16	-0.32	3.13e-12	Height;
LGG	cis	rs62064224	0.614	rs8065246	chr17:30682274	T/C	cg18200150	chr17:30822561	MYO1D	0.48	9.2	0.39	1.21e-18	Schizophrenia;
LGG	cis	rs12220238	1.000	rs7905536	chr10:75997209	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.58	0.47	2.09e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs72792276	0.908	rs3828656	chr5:127487535	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.66	7.14	0.32	3.52e-12	Red cell distribution width;
LGG	cis	rs55728055	0.661	rs7286496	chr22:31983760	G/A	cg15823100	chr22:32027580	PISD	-0.81	-9.04	-0.39	4.35e-18	Age-related hearing impairment;
LGG	cis	rs9733	0.593	rs10888384	chr1:150574256	C/T	cg13175981	chr1:150552382	MCL1	0.58	9.93	0.42	3.53e-21	Tonsillectomy;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg16301924	chr13:53314226	LECT1	-0.45	-9.01	-0.39	5.24e-18	Lewy body disease;
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.11	0.39	2.56e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg16724585	chr3:197361211	NA	-0.46	-8.12	-0.35	4.2e-15	Pancreatic cancer;
LGG	cis	rs77106637	1.000	rs77106637	chr11:72478320	G/A	cg03713592	chr11:72463424	ARAP1	0.41	7.36	0.32	8.71e-13	Type 2 diabetes;
LGG	cis	rs1552244	0.700	rs9833566	chr3:9981671	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	16.61	0.61	6.42e-49	Alzheimer's disease;
LGG	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg06470251	chr20:60548479	NA	0.5	8.37	0.36	6.71e-16	Body mass index;
LGG	trans	rs6952808	0.624	rs60137119	chr7:2083664	A/G	cg24247370	chr13:99142703	STK24	-0.37	-6.9	-0.31	1.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs908922	0.676	rs498184	chr1:152501423	G/C	cg20991723	chr1:152506922	NA	-0.7	-14.11	-0.55	7.02e-38	Hair morphology;
LGG	cis	rs7618501	0.602	rs2526754	chr3:50125996	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.8	-0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.602	rs10096194	chr8:11207672	C/G	cg21775007	chr8:11205619	TDH	0.81	14.2	0.55	3.16e-38	Retinal vascular caliber;
LGG	cis	rs1816752	0.783	rs9507333	chr13:24978310	G/A	cg22771759	chr13:24902376	NA	0.41	6.78	0.3	3.57e-11	Obesity-related traits;
LGG	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.57	-0.33	2.08e-13	Retinal vascular caliber;
LGG	cis	rs2635047	0.530	rs4986228	chr18:44595259	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.55	9.23	0.39	9.36e-19	Educational attainment;
LGG	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Lung cancer in ever smokers;
LGG	cis	rs2033732	0.673	rs1437510	chr8:85065019	A/G	cg05716166	chr8:85095498	RALYL	0.44	7.01	0.31	8.55e-12	Body mass index;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.58	0.33	1.91e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1978968	1.000	rs1110659	chr22:18444675	T/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg15145296	chr3:125709740	NA	-0.58	-7.45	-0.33	4.71e-13	Blood pressure (smoking interaction);
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.75	13.94	0.54	4.09e-37	Obesity-related traits;
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.51	0.4	1.07e-19	Height;
LGG	cis	rs1862618	0.754	rs252899	chr5:56188569	G/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.77	-0.34	5.03e-14	Initial pursuit acceleration;
LGG	cis	rs8133932	0.654	rs10854475	chr21:47332749	A/G	cg11214348	chr21:47283868	PCBP3	0.45	8.07	0.35	6.26e-15	Schizophrenia;
LGG	cis	rs6694672	0.867	rs1332662	chr1:197108427	A/G	cg13682187	chr1:196946512	CFHR5	0.5	7.08	0.31	5.35e-12	Asthma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05958702	chr16:30960101	FBXL19;ORAI3	0.5	7.45	0.33	4.62e-13	Gut microbiome composition (summer);
LGG	cis	rs2073499	1.000	rs77217288	chr3:50393676	G/A	cg03645007	chr3:50255295	SLC38A3	0.61	6.68	0.3	6.66e-11	Schizophrenia;
LGG	cis	rs4595586	0.545	rs4142846	chr12:39395140	C/T	cg26384229	chr12:38710491	ALG10B	0.52	9.27	0.4	6.91e-19	Morning vs. evening chronotype;
LGG	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg14416269	chr4:6271139	WFS1	0.45	7.32	0.32	1.12e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.52	9.05	0.39	4.08e-18	Menarche (age at onset);
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg10950524	chr7:2139216	MAD1L1	0.31	6.71	0.3	5.65e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg13939156	chr17:80058883	NA	-0.41	-7.15	-0.32	3.44e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg04842962	chr6:43655489	MRPS18A	1.01	16.68	0.61	2.92e-49	IgG glycosylation;
LGG	cis	rs1693575	0.624	rs1693571	chr8:101678349	A/T	cg06874326	chr8:101662790	SNX31	-0.36	-7.24	-0.32	1.85e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs11018904	0.906	rs11603498	chr11:89928783	C/A	cg27158573	chr11:89632121	NA	-0.42	-7.54	-0.33	2.5e-13	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg06606381	chr12:133084897	FBRSL1	-1.2	-11.4	-0.47	1.03e-26	Depression;
LGG	cis	rs2732480	0.577	rs2732481	chr12:48736985	T/G	cg24011408	chr12:48396354	COL2A1	0.5	7.87	0.34	2.48e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs1555895	0.568	rs4097329	chr10:844839	T/C	cg09361094	chr10:834503	NA	-0.29	-7.7	-0.34	8.21e-14	Survival in rectal cancer;
LGG	cis	rs972578	0.818	rs5751399	chr22:43285309	C/T	cg01576275	chr22:43409880	NA	-0.23	-7.14	-0.31	3.68e-12	Mean platelet volume;
LGG	cis	rs9911578	0.935	rs9911753	chr17:56983174	G/A	cg12560992	chr17:57184187	TRIM37	0.83	14.84	0.57	5.13e-41	Intelligence (multi-trait analysis);
LGG	cis	rs55665837	1.000	rs10832254	chr11:14434698	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.91	-0.38	1.16e-17	Vitamin D levels;
LGG	cis	rs7222240	1.000	rs7222240	chr17:43136195	G/A	cg24806326	chr17:43207588	PLCD3	0.45	7.52	0.33	2.91e-13	Craniofacial microsomia;
LGG	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.49	8.08	0.35	5.88e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11123170	0.543	rs35222158	chr2:113986629	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.49	7.33	0.32	1.03e-12	Renal function-related traits (BUN);
LGG	cis	rs6976053	0.846	rs4729618	chr7:100501126	C/T	cg03098644	chr7:100410630	EPHB4	-0.41	-7.43	-0.33	5.41e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg18351406	chr4:77819688	ANKRD56	0.47	8.13	0.35	4.03e-15	Emphysema distribution in smoking;
LGG	cis	rs6088580	0.634	rs6120642	chr20:33012531	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.75	-0.41	1.52e-20	Life satisfaction;
LGG	cis	rs314370	0.951	rs17881696	chr7:100493359	G/A	cg10426581	chr7:100472382	SRRT	0.53	7.28	0.32	1.45e-12	Resting heart rate;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg09699651	chr6:150184138	LRP11	0.48	8.63	0.37	9.71e-17	Lung cancer;
LGG	cis	rs6582630	0.519	rs11181998	chr12:38439970	C/A	cg26384229	chr12:38710491	ALG10B	0.94	21.7	0.71	1.46e-72	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg19539972	chr4:7069911	GRPEL1	-0.79	-10.57	-0.44	1.51e-23	Monocyte percentage of white cells;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02714710	chr16:30457337	SEPHS2	0.44	7.47	0.33	4.11e-13	Bipolar disorder;
LGG	cis	rs9583531	0.714	rs79483970	chr13:111342298	G/A	cg24331049	chr13:111365604	ING1	-0.73	-7.41	-0.33	6.13e-13	Coronary artery disease;
LGG	trans	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.38	-0.32	7.3e-13	Monocyte count;
LGG	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg19774624	chr17:42201019	HDAC5	0.65	11.41	0.47	9.37e-27	Total body bone mineral density;
LGG	cis	rs308971	0.611	rs387152	chr3:12076032	G/C	cg22839075	chr3:12045461	SYN2	0.46	6.68	0.3	6.84e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs9611565	0.512	rs2899349	chr22:42164660	T/C	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg22878388	chr2:105853796	NA	-0.48	-9.02	-0.39	4.99e-18	Type 2 diabetes;
LGG	trans	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.46	0.44	3.98e-23	Mean corpuscular volume;
LGG	cis	rs6977660	0.507	rs72591448	chr7:19775298	C/T	cg07541023	chr7:19748670	TWISTNB	0.79	10.58	0.44	1.44e-23	Thyroid stimulating hormone;
LGG	trans	rs9929218	0.954	rs10163398	chr16:68823124	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	cis	rs1552244	1.000	rs7615646	chr3:10089773	A/C	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs11785400	0.793	rs4430071	chr8:143737680	T/C	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs1577917	0.545	rs1832070	chr6:86483172	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.48	7.98	0.35	1.13e-14	Response to antipsychotic treatment;
LGG	cis	rs4409675	0.576	rs6703851	chr1:28237556	G/A	cg23691781	chr1:28212827	C1orf38	0.4	10.22	0.43	3.14e-22	Corneal astigmatism;
LGG	cis	rs7998202	0.667	rs282587	chr13:113351662	G/A	cg02820901	chr13:113351484	ATP11A	0.61	7.33	0.32	1.03e-12	Glycated hemoglobin levels;
LGG	trans	rs8073060	0.586	rs225303	chr17:33922149	A/G	cg19694781	chr19:47549865	TMEM160	1.13	18.26	0.65	1.6e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs17376456	1.000	rs17376207	chr5:93545524	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.84	-9.05	-0.39	4.08e-18	Diabetic retinopathy;
LGG	cis	rs2587949	0.615	rs980205	chr3:4197710	T/A	cg16519197	chr3:4211558	NA	0.34	7.11	0.31	4.41e-12	Periodontitis (DPAL);
LGG	cis	rs1048238	0.818	rs945421	chr1:16345393	T/C	cg22431228	chr1:16359049	CLCNKA	-0.53	-9.26	-0.4	7.4e-19	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.25	-0.32	1.75e-12	Lung cancer;
LGG	cis	rs2404602	0.684	rs12591622	chr15:76930655	A/T	cg15268244	chr15:77196840	NA	0.48	10.24	0.43	2.54e-22	Blood metabolite levels;
LGG	cis	rs62244186	0.535	rs59726036	chr3:44850074	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.46	8.18	0.36	2.82e-15	Depressive symptoms;
LGG	cis	rs9715521	0.691	rs60007977	chr4:59847637	T/C	cg11281224	chr4:60001000	NA	-0.51	-8.44	-0.37	4.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7945718	0.935	rs1609442	chr11:12795418	T/A	cg25843174	chr11:12811716	TEAD1	0.42	8.74	0.38	4.47e-17	Educational attainment (years of education);
LGG	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg18351406	chr4:77819688	ANKRD56	0.47	8.07	0.35	6.08e-15	Emphysema distribution in smoking;
LGG	cis	rs73001065	0.818	rs73004966	chr19:19716558	C/T	cg03709012	chr19:19516395	GATAD2A	0.76	6.98	0.31	1.01e-11	LDL cholesterol;
LGG	cis	rs12901789	1	rs12901789	chr15:67562214	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.08	-0.31	5.23e-12	Total body bone mineral density;
LGG	cis	rs988958	0.679	rs10171410	chr2:42224842	A/G	cg27428208	chr2:42229179	NA	0.55	9.24	0.39	8.83e-19	Hypospadias;
LGG	cis	rs7089973	0.604	rs2181563	chr10:116604344	T/C	cg03647239	chr10:116582469	FAM160B1	0.43	7.72	0.34	7.34e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs17001868	0.568	rs9611311	chr22:40733951	T/C	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs12410462	0.581	rs12402691	chr1:227543693	G/A	cg23173402	chr1:227635558	NA	0.5	8.56	0.37	1.67e-16	Major depressive disorder;
LGG	cis	rs10504229	1.000	rs116444534	chr8:58181915	A/G	cg08677398	chr8:58056175	NA	0.44	7.39	0.32	6.97e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg20991723	chr1:152506922	NA	-0.65	-12.51	-0.5	3.86e-31	Hair morphology;
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.33	-0.32	1.02e-12	Life satisfaction;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs920590	1.000	rs920590	chr8:19651161	A/G	cg03894339	chr8:19674705	INTS10	0.49	8.03	0.35	8.16e-15	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1005277	0.579	rs2505237	chr10:38438898	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs62238980	0.614	rs2006867	chr22:32384307	C/T	cg00543991	chr22:32367038	NA	0.8	8.9	0.38	1.27e-17	Childhood ear infection;
LGG	cis	rs6952808	0.792	rs12536062	chr7:1958672	G/A	cg00106254	chr7:1943704	MAD1L1	-0.48	-8.26	-0.36	1.56e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs17221829	0.668	rs12364732	chr11:89374054	T/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg04824913	chr4:887549	GAK	0.43	7.34	0.32	9.38e-13	Sjögren's syndrome;
LGG	cis	rs6477694	1.000	rs6477694	chr9:111932342	C/T	cg14171727	chr9:111936775	EPB41L4B	-0.33	-7.63	-0.33	1.37e-13	Body mass index;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg14338887	chr6:42928500	GNMT	0.28	8.97	0.38	7.53e-18	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9863	0.861	rs12298484	chr12:124418674	C/T	cg13487667	chr12:124434373	CCDC92	-0.37	-7.26	-0.32	1.66e-12	White blood cell count;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg00933542	chr6:150070202	PCMT1	-0.39	-7.08	-0.31	5.26e-12	Lung cancer;
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	trans	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.18e-13	Heart rate;
LGG	cis	rs2643217	0.855	rs1874250	chr15:38985379	T/A	cg10631289	chr15:39006617	NA	-0.41	-6.7	-0.3	5.97e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7100689	0.646	rs10736347	chr10:82134465	G/A	cg01528321	chr10:82214614	TSPAN14	0.87	15.42	0.58	1.31e-43	Post bronchodilator FEV1;
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	7.33e-43	Height;
LGG	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.04	0.52	2.52e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4481887	0.741	rs11485458	chr1:248569050	A/G	cg00666640	chr1:248458726	OR2T12	0.54	8.78	0.38	3.11e-17	Common traits (Other);
LGG	cis	rs17102423	0.963	rs35002541	chr14:65598704	G/A	cg11161011	chr14:65562177	MAX	-0.65	-12.22	-0.49	6.06e-30	Obesity-related traits;
LGG	cis	rs12410462	0.551	rs903694	chr1:227733005	C/G	cg23173402	chr1:227635558	NA	0.36	6.89	0.3	1.86e-11	Major depressive disorder;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg16268157	chr7:99778414	STAG3	-0.5	-8.37	-0.36	7.02e-16	Lung function (FEV1/FVC);
LGG	cis	rs5821446	1	rs5821446	chr17:65962538	A/AT	cg12091567	chr17:66097778	LOC651250	0.61	9.04	0.39	4.15e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs6728642	1.000	rs17037402	chr2:98014883	C/T	cg26665480	chr2:98280029	ACTR1B	-0.68	-6.74	-0.3	4.73e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs4253772	0.530	rs11090865	chr22:46731689	G/T	cg00784671	chr22:46762841	CELSR1	-0.58	-7.26	-0.32	1.61e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs367943	0.966	rs348932	chr5:112812457	G/A	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	trans	rs9354308	0.838	rs9360156	chr6:66553074	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.14	-0.35	3.66e-15	Metabolite levels;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.34	0.36	8.45e-16	Lung cancer;
LGG	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg13010199	chr12:38710504	ALG10B	0.71	14.99	0.57	1.09e-41	Heart rate;
LGG	cis	rs929596	0.793	rs2741044	chr2:234579368	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-10.27	-0.43	1.94e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs171408	0.843	rs355141	chr3:8622983	T/A	cg03557445	chr3:8615444	LOH3CR2A	-0.47	-8.21	-0.36	2.24e-15	Mitral valve prolapse;
LGG	cis	rs12468557	0.798	rs6750325	chr2:211501333	G/T	cg07063745	chr2:211341572	LANCL1;CPS1	-0.42	-7.37	-0.32	7.92e-13	Body mass index in asthmatics;
LGG	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg06392426	chr19:10676186	KRI1	0.72	12.12	0.49	1.55e-29	Red cell distribution width;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.14	-0.46	1.08e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs56114371	0.530	rs9348774	chr6:27688930	C/T	cg06606381	chr12:133084897	FBRSL1	-0.5	-6.68	-0.3	7e-11	Breast cancer;
LGG	cis	rs1008375	0.966	rs6449330	chr4:17703949	C/T	cg18681998	chr4:17616180	MED28	-0.73	-15.03	-0.57	7.2e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12908161	1.000	rs56864281	chr15:85357649	C/A	cg03959625	chr15:84868606	LOC388152	0.49	7.07	0.31	5.84e-12	Schizophrenia;
LGG	cis	rs9326248	0.861	rs11216172	chr11:116749878	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.51	7.13	0.31	3.78e-12	Blood protein levels;
LGG	cis	rs7166081	1.000	rs12915085	chr15:67522138	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.92	-0.31	1.5e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs950776	0.518	rs1504545	chr15:78818471	C/G	cg16751781	chr15:78858589	CHRNA5	-0.46	-9.22	-0.39	1.04e-18	Sudden cardiac arrest;
LGG	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg26384229	chr12:38710491	ALG10B	-0.67	-13.47	-0.53	3.83e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9443189	0.774	rs2647405	chr6:76450023	C/T	cg01950844	chr6:76311363	SENP6	-0.53	-6.98	-0.31	1.01e-11	Prostate cancer;
LGG	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg08773314	chr2:239334832	ASB1	0.43	8.24	0.36	1.78e-15	Multiple system atrophy;
LGG	cis	rs875971	0.522	rs10807697	chr7:65416170	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.43	0.44	5.3e-23	Aortic root size;
LGG	cis	rs3768617	0.510	rs12086466	chr1:183075778	C/T	cg07928641	chr1:182991847	LAMC1	-0.43	-8.65	-0.37	8.37e-17	Fuchs's corneal dystrophy;
LGG	cis	rs8180040	0.966	rs11719877	chr3:47425473	C/T	cg27129171	chr3:47204927	SETD2	0.77	15.02	0.57	8.21e-42	Colorectal cancer;
LGG	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg08589960	chr16:83986755	OSGIN1	-0.45	-6.83	-0.3	2.73e-11	Pursuit maintenance gain;
LGG	cis	rs12477438	0.748	rs10200974	chr2:99675227	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs9972944	0.902	rs10512503	chr17:63772066	G/A	cg07283582	chr17:63770753	CCDC46	0.43	8.34	0.36	8.32e-16	Total body bone mineral density;
LGG	cis	rs2502399	0.865	rs7771878	chr6:113508224	C/A	cg20413948	chr6:113544930	NA	0.3	6.94	0.31	1.35e-11	Plasma clusterin levels;
LGG	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg21926883	chr2:100939477	LONRF2	-0.48	-9.41	-0.4	2.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs35176054	0.558	rs11592714	chr10:105511647	C/T	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.91	-0.31	1.59e-11	Atrial fibrillation;
LGG	cis	rs701145	0.585	rs1727947	chr3:153879467	C/T	cg17054900	chr3:154042577	DHX36	0.75	9.25	0.39	8.37e-19	Coronary artery disease;
LGG	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg06885757	chr1:42089581	HIVEP3	-0.53	-11.96	-0.49	6.22e-29	Airway imaging phenotypes;
LGG	cis	rs78487399	0.520	rs7609256	chr2:43672499	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs12545912	0.866	rs10903318	chr8:9585483	A/T	cg16141378	chr3:129829833	LOC729375	0.34	6.7	0.3	6.15e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2243480	1.000	rs35820085	chr7:65442758	C/T	cg13147721	chr7:65941812	NA	-0.78	-9.54	-0.41	8.07e-20	Diabetic kidney disease;
LGG	cis	rs2071403	0.509	rs55750095	chr2:1409098	C/A	cg06500727	chr2:1417164	TPO	-0.6	-12.03	-0.49	3.34e-29	Thyroid peroxidase antibody positivity;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.67	12.59	0.51	1.77e-31	Obesity-related traits;
LGG	cis	rs9354308	0.764	rs9363476	chr6:66589140	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg19554555	chr3:13937349	NA	-0.56	-10.18	-0.43	4.16e-22	Ovarian reserve;
LGG	cis	rs2730245	0.527	rs1188971	chr7:158664463	G/T	cg18245976	chr7:158708271	WDR60	-0.56	-7.2	-0.32	2.45e-12	Height;
LGG	cis	rs2153535	0.580	rs6926759	chr6:8456176	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.63e-18	Motion sickness;
LGG	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.76	-0.78	4.91e-96	Height;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg03761291	chr16:3868188	CREBBP	-0.43	-8.11	-0.35	4.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.68	13.29	0.53	2.33e-34	Total body bone mineral density;
LGG	cis	rs826838	0.616	rs4418873	chr12:38625473	C/A	cg04568710	chr12:38710424	ALG10B	0.38	8.26	0.36	1.6e-15	Heart rate;
LGG	cis	rs1355223	0.583	rs1828298	chr11:34870439	A/G	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-7.13	-0.31	3.79e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg06917634	chr15:78832804	PSMA4	0.5	7.77	0.34	5.13e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2228479	0.717	rs12917681	chr16:89810941	C/A	cg19635926	chr16:89946313	TCF25	0.68	7.43	0.33	5.38e-13	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22538323	chr7:27702700	HIBADH	0.51	7.74	0.34	6.27e-14	Gut microbiome composition (summer);
LGG	cis	rs875971	0.830	rs6950137	chr7:65976610	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.48	0.37	3.03e-16	Aortic root size;
LGG	cis	rs2371030	0.965	rs1024896	chr2:211593938	C/T	cg18417063	chr2:211583084	NA	-0.64	-12.32	-0.5	2.37e-30	Non-small cell lung cancer;
LGG	cis	rs11700980	0.636	rs2832138	chr21:30284123	G/A	cg08807101	chr21:30365312	RNF160	-0.61	-6.79	-0.3	3.43e-11	QRS complex (12-leadsum);
LGG	cis	rs6674970	1.000	rs61819219	chr1:151084375	C/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.47	-7.09	-0.31	4.96e-12	Childhood ear infection;
LGG	cis	rs79349575	0.756	rs3848460	chr17:47047114	A/G	cg16584676	chr17:46985605	UBE2Z	-0.45	-7.86	-0.34	2.67e-14	Type 2 diabetes;
LGG	cis	rs10791323	0.633	rs2171006	chr11:133728323	T/C	cg00579200	chr11:133705235	NA	-0.57	-11.12	-0.46	1.26e-25	Childhood ear infection;
LGG	cis	rs875971	0.929	rs10950041	chr7:65973875	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.21e-17	Aortic root size;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg19006130	chr11:118478252	PHLDB1	0.51	8.91	0.38	1.21e-17	Systemic lupus erythematosus;
LGG	cis	rs1775148	1	rs1775148	chr1:205757824	C/T	cg26354017	chr1:205819088	PM20D1	0.54	10.14	0.43	5.84e-22	Prostate cancer;
LGG	cis	rs4788570	0.686	rs9937511	chr16:71815913	C/T	cg06353428	chr16:71660113	MARVELD3	1.26	19.81	0.68	1.04e-63	Intelligence (multi-trait analysis);
LGG	trans	rs208515	0.525	rs10455593	chr6:66691341	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.11	0.62	3.22e-51	Exhaled nitric oxide levels;
LGG	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00631329	chr6:26305371	NA	-0.54	-9.5	-0.4	1.15e-19	Educational attainment;
LGG	cis	rs7726839	0.507	rs60068988	chr5:597668	T/C	cg09021430	chr5:549028	NA	-0.69	-9.65	-0.41	3.44e-20	Obesity-related traits;
LGG	cis	rs2978263	0.627	rs6468391	chr8:30408241	C/T	cg05780722	chr8:30327988	RBPMS	-0.34	-6.69	-0.3	6.63e-11	Cognitive performance;
LGG	cis	rs6121246	0.909	rs6060821	chr20:30294034	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.59	0.51	1.83e-31	Mean corpuscular hemoglobin;
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg06634786	chr22:41940651	POLR3H	-0.76	-12.17	-0.49	9.61e-30	Vitiligo;
LGG	cis	rs7119	0.651	rs17394732	chr15:77835657	A/G	cg10437265	chr15:77819839	NA	-0.25	-6.96	-0.31	1.17e-11	Type 2 diabetes;
LGG	cis	rs72781680	0.898	rs56179550	chr2:23934867	C/T	cg08917208	chr2:24149416	ATAD2B	0.86	9.24	0.39	8.88e-19	Lymphocyte counts;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg16507663	chr6:150244633	RAET1G	0.5	10.25	0.43	2.42e-22	Testicular germ cell tumor;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg23302884	chr18:44338147	ST8SIA5	0.35	6.78	0.3	3.65e-11	Personality dimensions;
LGG	cis	rs908922	0.676	rs4240887	chr1:152530510	C/T	cg20991723	chr1:152506922	NA	0.7	14.41	0.56	3.65e-39	Hair morphology;
LGG	cis	rs6547631	0.622	rs61191323	chr2:85928631	G/A	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.68e-11	Blood protein levels;
LGG	cis	rs7928758	0.887	rs76369658	chr11:134268110	C/T	cg25213107	chr11:134282864	B3GAT1	1.22	14.6	0.56	5.61e-40	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs11150038	0.826	rs2735409	chr16:78051531	A/T	cg04733911	chr16:78082701	NA	0.63	8.63	0.37	9.76e-17	Colorectal or endometrial cancer;
LGG	cis	rs2549003	0.966	rs2706385	chr5:131831766	T/G	cg00578828	chr5:131826934	IRF1	-0.41	-7.32	-0.32	1.08e-12	Asthma (sex interaction);
LGG	cis	rs67311347	1.000	rs9835219	chr3:40424093	C/T	cg13683864	chr3:40499215	RPL14	-1.1	-24.26	-0.75	1.69e-84	Renal cell carcinoma;
LGG	cis	rs9462027	0.628	rs9469887	chr6:34758940	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-12.05	-0.49	2.89e-29	Personality dimensions;
LGG	cis	rs6665290	0.904	rs1045290	chr1:227178700	A/G	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs13082711	0.522	rs551621	chr3:27336325	G/C	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg16339924	chr4:17578868	LAP3	0.6	10.41	0.44	5.85e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2470578	0.792	rs2733510	chr3:17263805	C/T	cg20981856	chr3:17787350	NA	0.36	6.9	0.31	1.68e-11	Schizophrenia;
LGG	cis	rs9604529	0.557	rs61967979	chr13:114743190	C/T	cg03343631	chr13:114764489	RASA3	-0.58	-8.08	-0.35	5.65e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg12432903	chr7:1882776	MAD1L1	0.49	8.66	0.37	7.85e-17	Bipolar disorder;
LGG	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.44	-8.34	-0.36	8.38e-16	Multiple sclerosis;
LGG	cis	rs9303401	1.000	rs6503882	chr17:56915761	T/C	cg12560992	chr17:57184187	TRIM37	0.47	7.07	0.31	5.77e-12	Cognitive test performance;
LGG	cis	rs6840360	0.571	rs62327268	chr4:152522326	T/A	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12980942	0.591	rs2304231	chr19:41762670	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.56	7.29	0.32	1.39e-12	Coronary artery disease;
LGG	cis	rs10751667	0.666	rs7395321	chr11:940280	C/T	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs2415984	0.579	rs61993339	chr14:46969266	G/A	cg14871534	chr14:47121158	RPL10L	-0.59	-10.29	-0.43	1.63e-22	Number of children ever born;
LGG	cis	rs9611565	0.512	rs5751145	chr22:42133552	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.8	-0.45	2.07e-24	Vitiligo;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.82	-0.54	1.23e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12478296	1.000	rs55732177	chr2:243040006	C/T	cg06360820	chr2:242988706	NA	-0.89	-11.5	-0.47	4.38e-27	Obesity-related traits;
LGG	cis	rs9549367	0.789	rs2302754	chr13:113898385	C/T	cg00898013	chr13:113819073	PROZ	0.42	8.46	0.37	3.46e-16	Platelet distribution width;
LGG	cis	rs6735179	0.837	rs6548058	chr2:1775108	T/A	cg10160682	chr2:1713001	PXDN	-0.47	-7.43	-0.33	5.23e-13	Response to antipsychotic treatment;
LGG	cis	rs60180747	1.000	rs60180747	chr15:66663261	A/C	cg07575407	chr15:66541975	MEGF11	0.37	7.49	0.33	3.54e-13	Testicular germ cell tumor;
LGG	cis	rs12681288	0.550	rs72507624	chr8:961324	G/A	cg04851639	chr8:1020857	NA	-0.36	-7.46	-0.33	4.42e-13	Schizophrenia;
LGG	cis	rs9880211	0.706	rs67382287	chr3:136380459	C/T	cg21827317	chr3:136751795	NA	-0.47	-6.87	-0.3	2.12e-11	Body mass index;Height;
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.26	-0.7	1.77e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19719120	chr19:12780479	MORG1;C19orf56	-0.5	-7.33	-0.32	1.02e-12	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg08280861	chr8:58055591	NA	0.53	6.88	0.3	1.95e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3741151	0.773	rs73542938	chr11:73103012	G/C	cg17517138	chr11:73019481	ARHGEF17	0.9	8.75	0.38	3.88e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs13424612	1.000	rs4149547	chr2:240933308	C/T	cg01812947	chr2:240904978	NDUFA10	0.43	7.21	0.32	2.37e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs61931739	0.620	rs7979562	chr12:33707023	C/T	cg06521331	chr12:34319734	NA	0.4	6.95	0.31	1.24e-11	Morning vs. evening chronotype;
LGG	cis	rs7618915	1.000	rs3852064	chr3:52349412	G/T	cg14092988	chr3:52407081	DNAH1	0.42	11.24	0.46	4.41e-26	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg02733842	chr7:1102375	C7orf50	0.7	10.44	0.44	4.6e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4319547	0.956	rs10847179	chr12:123040985	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.4	-0.4	2.55e-19	Body mass index;
LGG	trans	rs7395662	0.864	rs11039917	chr11:48695428	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.09	-0.31	4.89e-12	HDL cholesterol;
LGG	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.95	-0.38	8.74e-18	Aortic root size;
LGG	cis	rs2594989	1.000	rs2594967	chr3:11349748	T/G	cg01796438	chr3:11312864	ATG7	-0.57	-7.8	-0.34	4.26e-14	Circulating chemerin levels;
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg23982607	chr1:1823379	GNB1	-0.59	-12.69	-0.51	7.33e-32	Body mass index;
LGG	cis	rs9487094	0.689	rs699700	chr6:109688731	C/A	cg01125227	chr6:109776195	MICAL1	0.43	7.77	0.34	5.2e-14	Height;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg19626725	chr5:178986131	RUFY1	0.45	7.43	0.33	5.46e-13	Lung cancer;
LGG	cis	rs10979	0.679	rs2275345	chr6:143872960	G/A	cg25407410	chr6:143891975	LOC285740	-0.6	-9.61	-0.41	4.48e-20	Hypospadias;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg02725872	chr8:58115012	NA	-0.79	-11.24	-0.46	4.42e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg05044414	chr3:183734942	ABCC5	0.56	10.92	0.45	7.43e-25	Anterior chamber depth;
LGG	cis	rs7552404	0.924	rs1251075	chr1:76190569	C/G	cg10523679	chr1:76189770	ACADM	0.78	15.1	0.57	3.62e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9487094	0.666	rs746794	chr6:109712737	G/C	cg01125227	chr6:109776195	MICAL1	0.38	6.67	0.3	7.24e-11	Height;
LGG	cis	rs1577917	1.000	rs791856	chr6:86681841	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.65	11.38	0.47	1.3e-26	Response to antipsychotic treatment;
LGG	cis	rs9858542	1.000	rs13316695	chr3:49684917	C/G	cg07274523	chr3:49395745	GPX1	0.55	9.09	0.39	3.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9783347	1.000	rs4150612	chr11:18364358	G/T	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.99e-18	Pancreatic cancer;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg02462569	chr6:150064036	NUP43	-0.38	-7.99	-0.35	1.11e-14	Lung cancer;
LGG	cis	rs4538187	0.547	rs12713498	chr2:64112428	C/T	cg02541582	chr2:64069798	UGP2	0.41	10.01	0.42	1.8e-21	Systolic blood pressure;
LGG	cis	rs4732038	0.510	rs61022470	chr7:134275558	C/G	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs9992101	0.612	rs1876535	chr4:77296600	T/C	cg17010112	chr4:77227123	STBD1	-0.46	-9.38	-0.4	3.01e-19	Creatinine levels;
LGG	cis	rs12643440	0.538	rs6843399	chr4:17140263	A/G	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg15948088	chr11:109293068	C11orf87	0.5	8.61	0.37	1.16e-16	Schizophrenia;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-8.89	-0.38	1.34e-17	Dementia with Lewy bodies;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04139300	chr20:40247070	CHD6	0.48	8.09	0.35	5.26e-15	Cognitive performance;
LGG	cis	rs6964587	0.934	rs6973792	chr7:91749798	C/A	cg17063962	chr7:91808500	NA	0.51	9.2	0.39	1.27e-18	Breast cancer;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg20453264	chr5:131705742	SLC22A5	0.61	7.76	0.34	5.39e-14	Rheumatoid arthritis;
LGG	cis	rs929596	0.639	rs7571915	chr2:234586574	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.62	-10.74	-0.45	3.7e-24	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4799461	0.740	rs7506216	chr18:35125862	C/T	cg27332583	chr18:35150602	NA	0.61	12.62	0.51	1.37e-31	Neuroticism;
LGG	trans	rs116095464	1.000	rs10069360	chr5:351615	A/G	cg00938859	chr5:1591904	SDHAP3	0.66	6.83	0.3	2.73e-11	Breast cancer;
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.65	0.33	1.16e-13	Joint mobility (Beighton score);
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.93	-0.35	1.61e-14	Total body bone mineral density;
LGG	trans	rs2562456	0.833	rs4334427	chr19:21520892	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs7107174	1.000	rs2292573	chr11:78053139	A/G	cg02023728	chr11:77925099	USP35	0.47	8.27	0.36	1.44e-15	Testicular germ cell tumor;
LGG	trans	rs7395662	1.000	rs7395662	chr11:48518893	C/T	cg00717180	chr2:96193071	NA	0.43	7.66	0.34	1.07e-13	HDL cholesterol;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg02951883	chr7:2050386	MAD1L1	-0.79	-17.01	-0.62	9.13e-51	Bipolar disorder and schizophrenia;
LGG	cis	rs4938330	0.608	rs12418744	chr11:117084537	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.59	-0.33	1.73e-13	Blood protein levels;
LGG	cis	rs9747201	0.963	rs9747989	chr17:80176092	A/G	cg14673194	chr17:80132900	CCDC57	-0.39	-7.1	-0.31	4.78e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9916302	0.904	rs9944411	chr17:37483599	T/C	cg07936489	chr17:37558343	FBXL20	0.84	15.57	0.59	2.96e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs17641971	0.684	rs12680366	chr8:49930674	T/C	cg00325661	chr8:49890786	NA	0.52	9.43	0.4	1.93e-19	Blood metabolite levels;
LGG	cis	rs7264396	0.790	rs11697903	chr20:34272224	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.52	7.64	0.33	1.3e-13	Total cholesterol levels;
LGG	cis	rs2229238	0.911	rs61559765	chr1:154518349	T/C	cg10237817	chr1:154519846	TDRD10	0.35	7.08	0.31	5.4e-12	Coronary heart disease;
LGG	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg17644776	chr2:200775616	C2orf69	-0.61	-7.13	-0.31	3.87e-12	Schizophrenia;
LGG	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg22563815	chr15:78856949	CHRNA5	-0.28	-6.96	-0.31	1.15e-11	Sudden cardiac arrest;
LGG	trans	rs7824557	0.602	rs10110557	chr8:11207508	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.82	0.3	2.81e-11	Retinal vascular caliber;
LGG	cis	rs3806843	0.576	rs246047	chr5:140328337	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs35771425	0.564	rs11119713	chr1:211421514	G/A	cg10512769	chr1:211675356	NA	-0.6	-8.02	-0.35	8.69e-15	Educational attainment (years of education);
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-6.82	-0.3	2.9e-11	Schizophrenia;
LGG	cis	rs7929679	0.602	rs10836312	chr11:34810443	T/C	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.8	0.3	3.17e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs57221529	0.766	rs4245972	chr5:578572	A/G	cg09021430	chr5:549028	NA	-0.72	-10.01	-0.42	1.79e-21	Lung disease severity in cystic fibrosis;
LGG	cis	rs6598955	0.756	rs10902723	chr1:26568542	T/C	cg04990556	chr1:26633338	UBXN11	-0.69	-13.97	-0.54	2.98e-37	Obesity-related traits;
LGG	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.51	-0.4	1.02e-19	Neuroticism;
LGG	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg22771759	chr13:24902376	NA	0.41	6.95	0.31	1.24e-11	Obesity-related traits;
LGG	cis	rs6665290	0.669	rs3795445	chr1:227180947	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.15	-32.18	-0.83	3.75e-120	Myeloid white cell count;
LGG	cis	rs2067615	0.507	rs1922432	chr12:107077232	G/A	cg15890332	chr12:107067104	RFX4	0.44	12.53	0.5	3.12e-31	Heart rate;
LGG	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.91	-0.35	1.9e-14	Mood instability;
LGG	cis	rs6840360	0.869	rs55668815	chr4:152473828	C/G	cg17217059	chr4:152329364	FAM160A1	0.2	6.69	0.3	6.37e-11	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.65	-0.54	6.74e-36	Tonsillectomy;
LGG	cis	rs7659604	1.000	rs7659943	chr4:122665560	C/T	cg20573242	chr4:122745356	CCNA2	0.41	7.46	0.33	4.18e-13	Type 2 diabetes;
LGG	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg07541023	chr7:19748670	TWISTNB	0.61	8.34	0.36	8.38e-16	Thyroid stimulating hormone;
LGG	cis	rs8027181	0.617	rs12438864	chr15:73095668	T/C	cg02923145	chr15:73089643	NA	0.44	8.35	0.36	7.72e-16	Triglyceride levels;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg24101359	chr6:42928495	GNMT	0.53	14.97	0.57	1.39e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1862618	0.713	rs832549	chr5:56183542	C/T	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.13	0.55	6.32e-38	Tonsillectomy;
LGG	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg26818257	chr2:241905806	NA	0.38	7.45	0.33	4.66e-13	Urinary metabolites;
LGG	cis	rs3820068	0.603	rs1122387	chr1:15947282	T/C	cg05660106	chr1:15850417	CASP9	0.84	16.78	0.61	1.04e-49	Systolic blood pressure;
LGG	cis	rs4713118	0.513	rs156734	chr6:28007357	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.8	-0.3	3.26e-11	Parkinson's disease;
LGG	cis	rs9611565	0.546	rs5758430	chr22:42109844	G/T	cg06481639	chr22:41940642	POLR3H	0.5	7.07	0.31	5.9e-12	Vitiligo;
LGG	cis	rs9547692	1.000	rs527929	chr13:37478506	C/T	cg01493522	chr13:37497338	NA	-0.48	-8.2	-0.36	2.34e-15	Coronary artery disease;
LGG	cis	rs4819052	0.851	rs3673	chr21:46681775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.37	0.5	1.45e-30	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2274273	0.682	rs1187876	chr14:55495199	A/T	cg04306507	chr14:55594613	LGALS3	-0.43	-10.66	-0.44	7.16e-24	Protein biomarker;
LGG	cis	rs2415984	0.783	rs61993307	chr14:46952034	C/T	cg14871534	chr14:47121158	RPL10L	-0.39	-6.69	-0.3	6.5e-11	Number of children ever born;
LGG	cis	rs2576037	0.526	rs11082562	chr18:44522671	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.4	-7.97	-0.35	1.24e-14	Personality dimensions;
LGG	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg06885757	chr1:42089581	HIVEP3	0.6	12.2	0.49	7.08e-30	Airway imaging phenotypes;
LGG	cis	rs240764	0.680	rs12209777	chr6:101156639	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.93	-0.35	1.69e-14	Neuroticism;
LGG	cis	rs6951245	0.515	rs73257955	chr7:1007014	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.76	8.51	0.37	2.39e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.679	rs1596142	chr8:58032406	G/A	cg11062466	chr8:58055876	NA	0.44	7.3	0.32	1.25e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.779	rs78589800	chr6:25883500	C/G	cg17691542	chr6:26056736	HIST1H1C	0.87	13.86	0.54	8.54e-37	Iron status biomarkers;
LGG	cis	rs7091068	0.522	rs10882323	chr10:95483280	T/C	cg20715218	chr10:95462985	C10orf4	0.67	11.15	0.46	9.88e-26	Urinary tract infection frequency;
LGG	cis	rs950776	0.642	rs7178007	chr15:78965254	G/A	cg06917634	chr15:78832804	PSMA4	0.47	7.77	0.34	5.22e-14	Sudden cardiac arrest;
LGG	trans	rs3749237	0.964	rs1799843	chr3:49849723	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.14	0.39	1.99e-18	Resting heart rate;
LGG	cis	rs9858542	0.537	rs4410472	chr3:49329090	A/T	cg03060546	chr3:49711283	APEH	-0.55	-7.23	-0.32	1.96e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3820928	0.874	rs6707265	chr2:227849255	T/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.86	-0.34	2.78e-14	Pulmonary function;
LGG	cis	rs7589342	0.895	rs11901644	chr2:106432113	T/G	cg14210321	chr2:106509881	NCK2	-0.51	-8.85	-0.38	1.89e-17	Addiction;
LGG	cis	rs9948	0.655	rs2314399	chr2:97442390	G/A	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.55e-13	Erectile dysfunction and prostate cancer treatment;
LGG	trans	rs2048656	0.535	rs2014514	chr8:9647196	A/T	cg06636001	chr8:8085503	FLJ10661	0.39	7.11	0.31	4.56e-12	Schizophrenia;
LGG	cis	rs4665809	0.589	rs4665841	chr2:26448950	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.05	-20.61	-0.69	1.85e-67	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.74	-13.54	-0.53	1.99e-35	Obesity-related traits;
LGG	cis	rs853679	0.517	rs35193936	chr6:28076270	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs2153535	0.580	rs986060	chr6:8465428	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs11225247	0.772	rs34104132	chr11:102232160	T/G	cg06323957	chr11:102217781	BIRC2	0.8	7.49	0.33	3.58e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs5750830	0.649	rs4821895	chr22:39823015	A/G	cg11247378	chr22:39784982	NA	-0.3	-8.71	-0.38	5.55e-17	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.59	11.87	0.48	1.42e-28	IgG glycosylation;
LGG	cis	rs7959452	0.590	rs56054057	chr12:69775972	C/T	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs10193935	0.901	rs13384323	chr2:42631346	C/T	cg27598129	chr2:42591480	NA	-0.65	-9.79	-0.41	1.1e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2840044	0.534	rs167691	chr17:33885826	G/A	cg05299278	chr17:33885742	SLFN14	0.45	8.97	0.38	7.53e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs7267979	0.738	rs2892409	chr20:25638138	C/T	cg06421707	chr20:25228305	PYGB	0.37	7.81	0.34	3.9e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg26174226	chr8:58114915	NA	-0.5	-7.43	-0.33	5.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7077256	0.504	rs35693916	chr10:65134282	T/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10267417	0.603	rs10248506	chr7:19905674	T/A	cg05791153	chr7:19748676	TWISTNB	0.56	7.32	0.32	1.1e-12	Night sleep phenotypes;
LGG	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg16329197	chr12:53359506	NA	-0.65	-11.1	-0.46	1.56e-25	Cancer (pleiotropy);
LGG	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg23625390	chr15:77176239	SCAPER	-0.71	-13.76	-0.54	2.41e-36	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs208520	0.690	rs207112	chr6:66792092	C/T	cg07460842	chr6:66804631	NA	-0.98	-18.39	-0.65	4.3e-57	Exhaled nitric oxide output;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.87	0.3	2.09e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg06808227	chr14:105710500	BRF1	-0.63	-11.32	-0.47	2.13e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg14912033	chr15:79043428	NA	-0.41	-10.57	-0.44	1.5e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs3820068	0.581	rs61056912	chr1:15926296	A/G	cg05660106	chr1:15850417	CASP9	0.83	16.87	0.62	4.12e-50	Systolic blood pressure;
LGG	trans	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg18187862	chr3:45730750	SACM1L	0.68	10.93	0.45	6.66e-25	Primary sclerosing cholangitis;
LGG	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.92	-0.31	1.5e-11	Systolic blood pressure;
LGG	cis	rs870825	0.616	rs28636679	chr4:185627481	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.71	0.73	2.88e-77	Blood protein levels;
LGG	cis	rs1949733	0.675	rs2688235	chr4:8450546	T/C	cg13073564	chr4:8508604	NA	-0.53	-10.91	-0.45	8.43e-25	Response to antineoplastic agents;
LGG	cis	rs9324022	0.790	rs7156824	chr14:101171480	C/A	cg18089426	chr14:101175970	NA	0.71	11.23	0.46	4.67e-26	Plateletcrit;
LGG	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg19077165	chr18:44547161	KATNAL2	0.4	6.82	0.3	2.85e-11	Educational attainment;
LGG	cis	rs4702718	0.616	rs267972	chr5:10727639	G/A	cg14521931	chr5:10832172	NA	-0.43	-8.09	-0.35	5.12e-15	Obesity-related traits;
LGG	cis	rs3791406	0.963	rs3791408	chr2:240030591	C/T	cg14550559	chr2:240039617	HDAC4	-0.45	-8.02	-0.35	8.7e-15	Skin aging (microtopography measurement);
LGG	cis	rs11098499	0.954	rs10031665	chr4:120422852	T/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs8180040	1.000	rs811115	chr3:47322133	C/T	cg16586182	chr3:47516702	SCAP	-0.76	-15.06	-0.57	5.06e-42	Colorectal cancer;
LGG	cis	rs740474	1.000	rs740474	chr5:140925362	A/G	cg00076195	chr5:140892677	NA	-0.48	-8.77	-0.38	3.51e-17	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2404602	0.684	rs4886816	chr15:76874707	A/C	cg23625390	chr15:77176239	SCAPER	-0.76	-15.44	-0.58	1.06e-43	Blood metabolite levels;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1784581	0.855	rs1893101	chr6:162384371	G/C	cg17173639	chr6:162384350	PARK2	-0.88	-22.93	-0.73	2.62e-78	Itch intensity from mosquito bite;
LGG	cis	rs2073300	0.609	rs6137927	chr20:23372513	A/G	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4434138	0.683	rs13063160	chr3:52602274	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.65	0.3	8.06e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14535006	chr20:18448030	C20orf12;POLR3F	0.43	6.83	0.3	2.72e-11	Cognitive performance;
LGG	cis	rs9880211	0.752	rs67145204	chr3:136328665	G/C	cg21827317	chr3:136751795	NA	-0.46	-6.71	-0.3	5.61e-11	Body mass index;Height;
LGG	cis	rs4631830	0.863	rs10826125	chr10:51530505	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.34	-0.32	9.44e-13	Prostate-specific antigen levels;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg09264619	chr17:80180166	NA	0.37	7.34	0.32	9.93e-13	Life satisfaction;
LGG	cis	rs4684776	1.000	rs4684069	chr3:11437543	T/C	cg24705426	chr3:11550659	ATG7	-0.41	-7.52	-0.33	2.78e-13	Small vessel stroke;
LGG	trans	rs826838	0.935	rs11169547	chr12:39185625	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.7	-0.34	8.32e-14	Heart rate;
LGG	trans	rs2048656	0.524	rs13263409	chr8:9536256	A/C	cg16141378	chr3:129829833	LOC729375	0.34	7.19	0.32	2.63e-12	Schizophrenia;
LGG	cis	rs12410462	1.000	rs1587158	chr1:227658753	G/A	cg23173402	chr1:227635558	NA	-0.52	-9.09	-0.39	2.89e-18	Major depressive disorder;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg03188948	chr7:1209495	NA	0.43	7.71	0.34	7.98e-14	Longevity;Endometriosis;
LGG	cis	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-7.39	-0.32	6.77e-13	Triglycerides;
LGG	cis	rs7582180	0.700	rs11685401	chr2:100976685	A/G	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	5e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg06197492	chr11:2016605	H19	0.52	10.73	0.45	3.89e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs8180040	0.966	rs11705957	chr3:47443262	T/G	cg27129171	chr3:47204927	SETD2	-0.79	-15.3	-0.58	4.5e-43	Colorectal cancer;
LGG	cis	rs11690935	0.959	rs973889	chr2:172579954	A/G	cg21435375	chr2:172878103	MAP1D	-0.3	-6.73	-0.3	4.89e-11	Schizophrenia;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg16507663	chr6:150244633	RAET1G	0.43	8.15	0.35	3.39e-15	Lung cancer;
LGG	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg23730037	chr7:158596552	ESYT2	-0.4	-6.74	-0.3	4.61e-11	Height;
LGG	cis	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg06521331	chr12:34319734	NA	0.4	6.86	0.3	2.26e-11	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg03929089	chr4:120376271	NA	-0.53	-8.97	-0.38	7.18e-18	HDL cholesterol;
LGG	cis	rs367943	0.966	rs364738	chr5:112808329	A/G	cg27587195	chr5:112824172	MCC	-0.46	-7.38	-0.32	7.34e-13	Type 2 diabetes;
LGG	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg24130564	chr14:104152367	KLC1	-0.38	-6.97	-0.31	1.07e-11	Reticulocyte count;
LGG	cis	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs17092148	1.000	rs910871	chr20:33333208	C/A	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs12580194	0.593	rs56677471	chr12:55749967	T/A	cg19537932	chr12:55886519	OR6C68	-0.54	-9.71	-0.41	2e-20	Cancer;
LGG	cis	rs3825932	0.961	rs10400877	chr15:79234378	A/T	cg25744700	chr15:79237217	CTSH	0.34	6.68	0.3	7.02e-11	Type 1 diabetes;
LGG	cis	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg24623649	chr8:11872141	NA	0.3	6.9	0.31	1.71e-11	Myopia (pathological);
LGG	cis	rs698833	0.848	rs696596	chr2:44718058	G/A	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.75	0.3	4.35e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs953387	0.824	rs4954578	chr2:136958593	T/C	cg07169764	chr2:136633963	MCM6	0.53	8.81	0.38	2.48e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg26174226	chr8:58114915	NA	-0.58	-7.89	-0.34	2.26e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg22563226	chr4:39639380	C4orf34	0.5	6.71	0.3	5.68e-11	Apolipoprotein A-IV levels;
LGG	cis	rs457717	0.730	rs2455215	chr5:75948799	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.81	0.3	2.99e-11	Hearing impairment;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20073412	chr11:131560558	NTM	0.44	7.42	0.33	5.83e-13	Pancreatic cancer;
LGG	cis	rs1185460	0.547	rs34150933	chr11:118911039	C/T	cg23280166	chr11:118938394	VPS11	-0.46	-7.97	-0.35	1.22e-14	Coronary artery disease;
LGG	cis	rs881375	0.678	rs2416804	chr9:123676396	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.47	-8.56	-0.37	1.68e-16	Rheumatoid arthritis;
LGG	cis	rs798554	0.679	rs1636249	chr7:2884283	T/G	cg13628971	chr7:2884303	GNA12	0.55	11.89	0.48	1.23e-28	Height;
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg14675211	chr2:100938903	LONRF2	0.62	10.79	0.45	2.27e-24	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg05665937	chr4:1216051	CTBP1	0.37	6.78	0.3	3.6e-11	Longevity;
LGG	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.4	-0.33	6.54e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4704187	0.663	rs4404659	chr5:74422119	T/C	cg03227963	chr5:74354835	NA	0.31	6.75	0.3	4.4e-11	Response to amphetamines;
LGG	cis	rs28595532	0.920	rs115090549	chr4:119753554	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg08400814	chr5:56204995	C5orf35	-0.47	-7.49	-0.33	3.48e-13	Initial pursuit acceleration;
LGG	cis	rs11877825	0.826	rs4121956	chr18:10569930	C/T	cg07277756	chr18:10589357	NA	0.58	10.76	0.45	2.9e-24	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.21	0.43	3.22e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8141529	0.692	rs2239828	chr22:29358802	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-9.34	-0.4	3.91e-19	Lymphocyte counts;
LGG	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg17211192	chr8:82754475	SNX16	-0.74	-12.45	-0.5	7.11e-31	Diastolic blood pressure;
LGG	cis	rs727505	0.721	rs55890146	chr7:124755461	A/T	cg23710748	chr7:124431027	NA	-0.43	-8.17	-0.35	3.02e-15	Lewy body disease;
LGG	cis	rs1348850	0.651	rs4893931	chr2:178228212	T/C	cg22681709	chr2:178499509	PDE11A	-0.4	-7.7	-0.34	8.18e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7662987	0.517	rs2924580	chr4:100032168	C/G	cg12011299	chr4:100065546	ADH4	0.4	7.83	0.34	3.33e-14	Smoking initiation;
LGG	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg19824325	chr16:58548873	SETD6	1.23	11.21	0.46	5.86e-26	Schizophrenia;
LGG	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg08603382	chr10:743973	NA	-0.4	-7.35	-0.32	8.75e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.38	0.32	7.23e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2290405	0.527	rs4690329	chr4:931385	T/A	cg24922022	chr4:827675	NA	0.41	8.42	0.36	4.73e-16	Systemic sclerosis;
LGG	cis	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg00071950	chr4:10020882	SLC2A9	0.33	6.83	0.3	2.64e-11	Bone mineral density;
LGG	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg13010199	chr12:38710504	ALG10B	0.69	14.08	0.55	9.82e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8072100	0.840	rs9900360	chr17:45491979	C/T	cg25173405	chr17:45401733	C17orf57	-0.49	-8.5	-0.37	2.54e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2120243	0.598	rs1500916	chr3:157088042	C/G	cg24825693	chr3:157122686	VEPH1	-0.49	-10.68	-0.44	6.22e-24	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs74781061	0.929	rs79600165	chr15:74940991	G/A	cg02384859	chr15:74862662	ARID3B	-0.33	-6.68	-0.3	7e-11	Endometriosis;
LGG	trans	rs561341	1.000	rs2344312	chr17:30243583	G/T	cg20587970	chr11:113659929	NA	-1.13	-19.51	-0.67	2.48e-62	Hip circumference adjusted for BMI;
LGG	cis	rs317689	0.918	rs581911	chr12:69738293	C/T	cg14784868	chr12:69753453	YEATS4	0.68	10.68	0.44	6.08e-24	Response to diuretic therapy;
LGG	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14829155	chr15:31115871	NA	-0.58	-10.08	-0.42	9.66e-22	Huntington's disease progression;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	2.89e-12	Menopause (age at onset);
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs56804039	1.000	rs67180327	chr8:8380754	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-6.69	-0.3	6.3e-11	Cervical cancer;
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg14196790	chr5:131705035	SLC22A5	-0.61	-7.78	-0.34	4.86e-14	Rheumatoid arthritis;
LGG	cis	rs7208859	0.614	rs73265646	chr17:29244023	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.27	-0.32	1.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.63	-10.79	-0.45	2.35e-24	Obesity-related traits;
LGG	cis	rs3206736	0.548	rs328940	chr7:35050364	G/A	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.63e-19	Diastolic blood pressure;
LGG	trans	rs1814175	0.586	rs2866862	chr11:49954588	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.76	-16.86	-0.62	4.39e-50	Height;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs11079511	chr17:61858537	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.43	-0.33	5.11e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.958	rs2100109	chr6:86544926	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.01	-0.39	5.46e-18	Response to antipsychotic treatment;
LGG	cis	rs870825	0.616	rs6852082	chr4:185645783	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs727505	0.607	rs67680878	chr7:124787381	G/A	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg22491629	chr6:157744540	C6orf35	-0.98	-13.66	-0.54	6.26e-36	Hemostatic factors and hematological phenotypes;
LGG	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg08885076	chr2:99613938	TSGA10	0.43	9.23	0.39	9.84e-19	Chronic sinus infection;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.0	0.46	3.73e-25	Tonsillectomy;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg02018176	chr4:1364513	KIAA1530	0.65	16.09	0.6	1.4e-46	Longevity;
LGG	cis	rs79149102	0.579	rs6495142	chr15:75320166	C/T	cg17294928	chr15:75287854	SCAMP5	-0.8	-8.85	-0.38	1.9e-17	Lung cancer;
LGG	cis	rs78456975	0.527	rs11901028	chr2:1557972	A/G	cg12573674	chr2:1569213	NA	-0.63	-9.7	-0.41	2.23e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg22535103	chr8:58192502	C8orf71	-0.58	-9.78	-0.41	1.14e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	0.966	rs2278685	chr15:57548473	C/T	cg08128148	chr15:57256372	TCF12	-0.32	-7.42	-0.33	5.79e-13	Urinary tract infection frequency;
LGG	cis	rs2404602	0.532	rs206205	chr15:76736091	T/G	cg23625390	chr15:77176239	SCAPER	0.54	11.07	0.46	1.94e-25	Blood metabolite levels;
LGG	cis	rs988958	0.565	rs12712820	chr2:42236370	C/T	cg27428208	chr2:42229179	NA	0.49	7.73	0.34	6.78e-14	Hypospadias;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.57	-9.06	-0.39	3.58e-18	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs12210905	0.688	rs10456051	chr6:27463436	T/C	cg10122326	chr6:28072925	NA	0.95	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;
LGG	cis	rs920590	0.758	rs35896770	chr8:19665616	G/C	cg01411142	chr8:19674711	INTS10	0.47	7.37	0.32	7.95e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg05025164	chr4:1340916	KIAA1530	0.55	9.75	0.41	1.46e-20	Obesity-related traits;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.7	0.41	2.32e-20	Skin colour saturation;
LGG	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg08949735	chr16:89699720	DPEP1	-0.49	-9.91	-0.42	4.03e-21	Vitiligo;
LGG	cis	rs7044106	0.708	rs10984992	chr9:123473416	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.32	0.32	1.12e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11711311	0.955	rs9866806	chr3:113379865	C/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.66	-13.53	-0.53	2.23e-35	IgG glycosylation;
LGG	cis	rs6977660	1.000	rs7779902	chr7:19803491	G/A	cg05791153	chr7:19748676	TWISTNB	0.55	8.39	0.36	6.1e-16	Thyroid stimulating hormone;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26149167	chr19:16187889	TPM4	0.44	7.14	0.31	3.54e-12	Cognitive performance;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.76	-0.34	5.31e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13392177	0.660	rs12988046	chr2:219073804	A/G	cg00012203	chr2:219082015	ARPC2	-0.7	-12.86	-0.51	1.38e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs11628318	0.572	rs7142319	chr14:103119425	C/T	cg12046867	chr14:103022105	NA	0.41	7.75	0.34	5.69e-14	Platelet count;
LGG	cis	rs9300255	0.722	rs12298826	chr12:123829028	A/G	cg00376283	chr12:123451042	ABCB9	-0.56	-8.63	-0.37	9.59e-17	Neutrophil percentage of white cells;
LGG	cis	rs1577917	0.739	rs6922	chr6:86205323	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.67	11.93	0.48	8.47e-29	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg13206674	chr6:150067644	NUP43	0.62	13.94	0.54	3.84e-37	Lung cancer;
LGG	trans	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs72925845	0.524	rs690791	chr17:76426177	C/T	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs61906588	0.595	rs494200	chr11:116352697	C/T	cg12564567	chr11:116371188	NA	-0.38	-7.03	-0.31	7.26e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs1670533	0.932	rs13106586	chr4:1054182	G/A	cg27284194	chr4:1044797	NA	0.55	9.83	0.42	7.7e-21	Recombination rate (females);
LGG	cis	rs6988985	0.728	rs10105643	chr8:143957886	A/C	cg10324643	chr8:143916377	GML	0.4	7.92	0.35	1.74e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs283228	0.535	rs2852503	chr6:101842189	A/T	cg02011392	chr6:101847541	GRIK2	-0.57	-8.34	-0.36	8.53e-16	Coenzyme Q10 levels;
LGG	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.23	-0.36	1.92e-15	Triglycerides;
LGG	trans	rs2727020	0.558	rs1164675	chr11:49325972	C/T	cg03929089	chr4:120376271	NA	0.88	16.73	0.61	1.71e-49	Coronary artery disease;
LGG	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	trans	rs6598955	0.671	rs10902735	chr1:26617936	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.56	-0.5	2.44e-31	Obesity-related traits;
LGG	cis	rs6087990	0.806	rs910085	chr20:31383353	T/G	cg13636640	chr20:31349939	DNMT3B	0.94	19.77	0.68	1.57e-63	Ulcerative colitis;
LGG	cis	rs2880765	0.835	rs4536419	chr15:86039471	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.3	-0.32	1.28e-12	Coronary artery disease;
LGG	cis	rs17270561	0.636	rs2070642	chr6:25831212	G/A	cg03517284	chr6:25882590	NA	-0.43	-6.95	-0.31	1.27e-11	Iron status biomarkers;
LGG	cis	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg12826209	chr6:26865740	GUSBL1	0.81	6.89	0.3	1.82e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8031584	0.678	rs4779497	chr15:31151365	T/A	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.12	-0.35	4.17e-15	Huntington's disease progression;
LGG	cis	rs11711311	1.000	rs2566970	chr3:113462123	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.64	-12.73	-0.51	4.74e-32	IgG glycosylation;
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs8180040	0.903	rs6791842	chr3:47279810	T/C	cg16586182	chr3:47516702	SCAP	-0.79	-15.41	-0.58	1.45e-43	Colorectal cancer;
LGG	cis	rs67311347	0.956	rs6771527	chr3:40506548	T/C	cg24209194	chr3:40518798	ZNF619	-0.44	-7.04	-0.31	7.09e-12	Renal cell carcinoma;
LGG	cis	rs7927592	0.913	rs3824850	chr11:68341873	A/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs3816183	0.585	rs2037884	chr2:42878172	T/C	cg14631114	chr2:43023945	NA	0.36	6.85	0.3	2.31e-11	Hypospadias;
LGG	cis	rs4474465	0.850	rs7122676	chr11:78268525	A/G	cg02023728	chr11:77925099	USP35	-0.37	-6.7	-0.3	6.07e-11	Alzheimer's disease (survival time);
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs7712401	0.562	rs30053	chr5:122303643	C/G	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs7928758	0.943	rs2360225	chr11:134265254	A/G	cg25213107	chr11:134282864	B3GAT1	1.19	14.22	0.55	2.36e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06383546	chr7:27779483	TAX1BP1	0.39	6.68	0.3	7.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6882046	0.513	rs194225	chr5:88001186	A/G	cg22951263	chr5:87985283	NA	-0.55	-10.12	-0.43	6.85e-22	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg15556689	chr8:8085844	FLJ10661	0.45	8.04	0.35	7.32e-15	Neuroticism;
LGG	cis	rs9296092	0.517	rs56043172	chr6:33522363	T/G	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg21479132	chr6:26055353	NA	0.81	7.14	0.31	3.62e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg12310025	chr6:25882481	NA	-0.54	-10.37	-0.43	8.64e-23	Blood metabolite levels;
LGG	cis	rs3857536	0.730	rs4710585	chr6:66967579	C/T	cg07460842	chr6:66804631	NA	-0.43	-7.2	-0.32	2.49e-12	Blood trace element (Cu levels);
LGG	cis	rs620875	1.000	rs644819	chr11:126851767	T/C	cg06504925	chr11:126872760	NA	-0.54	-7.58	-0.33	1.86e-13	Response to antipsychotic treatment;
LGG	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26306683	chr17:18585705	ZNF286B	0.46	8.7	0.37	5.84e-17	Educational attainment (years of education);
LGG	cis	rs11148252	0.740	rs9536052	chr13:52960709	C/G	cg22398616	chr13:53314203	LECT1	0.41	8.4	0.36	5.65e-16	Lewy body disease;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs4843747	0.749	rs13333619	chr16:88072076	C/T	cg06374794	chr16:88002281	BANP	0.48	8.74	0.38	4.22e-17	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10041390	chr10:89623018	PTEN;KILLIN	0.41	6.94	0.31	1.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs975739	0.872	rs1146930	chr13:78366895	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	3.98e-11	Hair color;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24415849	chr2:74406079	MOBKL1B	0.44	6.94	0.31	1.29e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00578252	chr1:36916159	OSCP1	0.33	7.04	0.31	6.88e-12	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.877	rs17083455	chr5:93446380	A/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.23e-20	Diabetic retinopathy;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.91	0.42	3.96e-21	Schizophrenia;
LGG	cis	rs492146	0.740	rs1032418	chr6:52834957	A/T	cg24393602	chr6:52860404	GSTA4	0.4	6.79	0.3	3.56e-11	Epilepsy (remission after treatment);
LGG	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg00383909	chr3:49044727	WDR6	0.44	7.28	0.32	1.4e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7824557	0.564	rs2437152	chr8:11235497	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.38	-0.36	6.45e-16	Retinal vascular caliber;
LGG	cis	rs7432375	0.901	rs9836231	chr3:136414321	C/T	cg21827317	chr3:136751795	NA	-0.47	-8.48	-0.37	3.04e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500395	1.000	rs1115758	chr16:48599609	T/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2933343	0.649	rs789216	chr3:128594503	A/C	cg11901034	chr3:128598214	ACAD9	-0.47	-7.09	-0.31	4.89e-12	IgG glycosylation;
LGG	trans	rs9929218	0.953	rs9939049	chr16:68812301	A/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.75	-0.51	4.13e-32	Colorectal cancer;
LGG	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg25427524	chr10:38739819	LOC399744	0.69	14.07	0.55	1.15e-37	Extrinsic epigenetic age acceleration;
LGG	cis	rs975722	0.967	rs2402229	chr7:117342229	G/T	cg10524701	chr7:117356490	CTTNBP2	0.51	11.58	0.47	2.16e-27	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19935505	chr3:33482718	UBP1	0.43	7.02	0.31	7.78e-12	Cognitive performance;
LGG	cis	rs8067545	0.611	rs2703803	chr17:20107069	G/T	cg09818912	chr17:20140352	CYTSB	0.32	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs847649	0.548	rs10953380	chr7:102747149	C/G	cg18108683	chr7:102477205	FBXL13	0.54	11.07	0.46	1.99e-25	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg02951883	chr7:2050386	MAD1L1	0.73	14.91	0.57	2.44e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	0.57	10.77	0.45	2.69e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs57221529	0.766	rs72706610	chr5:561111	G/A	cg07777115	chr5:623756	CEP72	-0.57	-7.17	-0.32	3.04e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs6951245	1.000	rs78158942	chr7:1090440	G/T	cg18402987	chr7:1209562	NA	0.68	9.38	0.4	2.96e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3126085	0.935	rs10888467	chr1:152171707	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.98	0.38	7.08e-18	Atopic dermatitis;
LGG	cis	rs78456975	1.000	rs13392535	chr2:1542634	G/T	cg01028140	chr2:1542097	TPO	-0.56	-8.41	-0.36	5.26e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7208859	0.623	rs73269988	chr17:29118145	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs59918340	0.936	rs6982449	chr8:142234642	T/C	cg23750338	chr8:142222470	SLC45A4	-0.44	-9.0	-0.39	5.87e-18	Immature fraction of reticulocytes;
LGG	cis	rs7527798	0.592	rs1323722	chr1:207823405	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-6.94	-0.31	1.29e-11	Erythrocyte sedimentation rate;
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.96	-0.54	3.38e-37	Alzheimer's disease;
LGG	cis	rs881375	0.967	rs758959	chr9:123676699	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.2	0.39	1.19e-18	Rheumatoid arthritis;
LGG	trans	rs61931739	0.534	rs4001713	chr12:34154195	A/C	cg26384229	chr12:38710491	ALG10B	-0.83	-16.24	-0.6	2.78e-47	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.764	rs9363476	chr6:66589140	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg20120463	chr17:44301886	NA	-0.46	-7.0	-0.31	8.78e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.79	-0.34	4.42e-14	Systolic blood pressure;
LGG	cis	rs899997	0.862	rs8043123	chr15:78973393	C/T	cg10852096	chr15:79043040	NA	0.26	6.84	0.3	2.59e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs936229	1.000	rs936228	chr15:75132164	T/C	cg14664628	chr15:75095509	CSK	-1.01	-21.59	-0.71	5.07e-72	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2204008	0.701	rs3898237	chr12:38219714	A/G	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.55	2.46e-37	Bladder cancer;
LGG	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg26031613	chr14:104095156	KLC1	1.14	26.59	0.78	3.04e-95	Body mass index;
LGG	cis	rs61990749	0.597	rs11623088	chr14:78137735	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.17	-0.32	3.02e-12	Fibroblast growth factor basic levels;
LGG	cis	rs1461503	0.934	rs930982	chr11:122834378	C/T	cg27398637	chr11:122830231	C11orf63	-0.69	-14.07	-0.55	1.12e-37	Menarche (age at onset);
LGG	trans	rs4713118	0.581	rs200504	chr6:27785820	T/C	cg06606381	chr12:133084897	FBRSL1	-0.56	-7.54	-0.33	2.54e-13	Parkinson's disease;
LGG	cis	rs1975974	0.539	rs58796614	chr17:21733767	C/T	cg18423549	chr17:21743878	NA	-0.51	-7.81	-0.34	3.74e-14	Psoriasis;
LGG	cis	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg22857025	chr5:266934	NA	-1.49	-26.4	-0.78	2.28e-94	Breast cancer;
LGG	cis	rs36051895	0.623	rs10283473	chr9:5244708	C/A	cg02405213	chr9:5042618	JAK2	-0.73	-12.44	-0.5	7.71e-31	Pediatric autoimmune diseases;
LGG	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	14.27	0.55	1.58e-38	Nonalcoholic fatty liver disease;
LGG	cis	rs10883723	0.810	rs2296586	chr10:104245575	C/T	cg05096777	chr10:104283225	SUFU	0.31	6.68	0.3	7.08e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs875971	0.798	rs7789615	chr7:65878661	A/G	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs4650994	0.544	rs6682815	chr1:178501109	T/C	cg12486710	chr1:178512616	C1orf220	0.51	10.76	0.45	3.02e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs17030434	1.000	rs732680	chr4:154725211	G/A	cg14289246	chr4:154710475	SFRP2	-0.73	-11.1	-0.46	1.52e-25	Electrocardiographic conduction measures;
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.48	-0.44	3.47e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.627	rs6442059	chr3:47187075	C/G	cg27129171	chr3:47204927	SETD2	0.82	14.92	0.57	2.3e-41	Colorectal cancer;
LGG	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg21100191	chr22:23484243	RTDR1	-0.87	-17.27	-0.63	5.99e-52	Bone mineral density;
LGG	cis	rs9644630	0.870	rs4244453	chr8:19359711	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.61	17.58	0.63	2.33e-53	Oropharynx cancer;
LGG	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs76693355	0.512	rs11217878	chr11:120340383	G/A	cg15690696	chr11:120217718	ARHGEF12	-0.44	-6.93	-0.31	1.37e-11	Intraocular pressure;
LGG	trans	rs10877945	1.000	rs4763049	chr12:63431918	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	0.35	6.68	0.3	6.96e-11	Obesity-related traits;
LGG	cis	rs7552404	0.691	rs1770890	chr1:76401117	A/G	cg22875332	chr1:76189707	ACADM	-0.6	-9.16	-0.39	1.7e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg21775007	chr8:11205619	TDH	-0.52	-8.17	-0.35	3.06e-15	Triglycerides;
LGG	cis	rs7666738	0.830	rs11944107	chr4:98931638	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9447004	0.584	rs7747167	chr6:74430673	T/G	cg03006477	chr6:74432658	CD109	0.29	7.47	0.33	3.97e-13	Blood protein levels;Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02767759	chr16:30366751	CD2BP2	0.56	8.83	0.38	2.11e-17	Gut microbiome composition (summer);
LGG	cis	rs3857067	1.000	rs899134	chr4:95019675	C/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg21775007	chr8:11205619	TDH	-0.72	-12.51	-0.5	3.89e-31	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs17270561	0.609	rs9358877	chr6:25739228	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09698166	chr20:21106763	PLK1S1	0.44	6.72	0.3	5.2e-11	Gut microbiome composition (summer);
LGG	cis	rs7301016	1.000	rs10877857	chr12:62872211	C/T	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs7166081	1.000	rs2033783	chr15:67507768	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.3	-6.82	-0.3	2.87e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9467711	0.659	rs35555795	chr6:26509382	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.1	-0.31	4.69e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7395662	0.804	rs8186428	chr11:48734677	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.69	-0.34	9.04e-14	HDL cholesterol;
LGG	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg27624424	chr6:160112604	SOD2	0.69	10.09	0.42	8.66e-22	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.67	-0.41	2.95e-20	Bladder cancer;
LGG	cis	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08380311	chr19:3435252	NFIC	0.82	12.6	0.51	1.59e-31	Height;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.79	-0.34	4.42e-14	Neuroticism;
LGG	cis	rs4363385	0.747	rs3737867	chr1:152976474	A/C	cg13444842	chr1:152974279	SPRR3	-0.44	-8.87	-0.38	1.6e-17	Inflammatory skin disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02627747	chr6:49431433	CENPQ;MUT	0.39	6.68	0.3	6.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs916888	0.738	rs199515	chr17:44856641	C/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.61	-9.57	-0.41	6.26e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06634786	chr22:41940651	POLR3H	0.75	11.71	0.48	6.28e-28	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	trans	rs73198271	0.813	rs17697237	chr8:8615874	A/C	cg16141378	chr3:129829833	LOC729375	-0.34	-6.73	-0.3	5.06e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1129187	0.755	rs2274514	chr6:42934500	C/T	cg24101359	chr6:42928495	GNMT	0.52	14.95	0.57	1.6e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg11812906	chr14:75593930	NEK9	-0.52	-9.65	-0.41	3.48e-20	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13934093	chr19:4458039	UBXN6	0.45	7.3	0.32	1.3e-12	Cognitive performance;
LGG	cis	rs11098499	0.754	rs7672372	chr4:120248406	A/G	cg09307838	chr4:120376055	NA	0.73	12.51	0.5	3.98e-31	Corneal astigmatism;
LGG	cis	rs6121246	0.529	rs6060118	chr20:30171209	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.38	0.36	6.31e-16	Mean corpuscular hemoglobin;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs76419734	0.558	rs10030620	chr4:106574536	A/G	cg24545054	chr4:106630052	GSTCD;INTS12	0.63	9.58	0.41	5.8e-20	Post bronchodilator FEV1;
LGG	cis	rs11864453	1.000	rs7185407	chr16:72034957	A/T	cg23815491	chr16:72088622	HP	-0.49	-10.82	-0.45	1.84e-24	Fibrinogen levels;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg14789911	chr21:47582049	C21orf56	0.49	8.67	0.37	7.19e-17	Testicular germ cell tumor;
LGG	cis	rs1801251	0.963	rs7562712	chr2:233606580	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.33	0.4	4.25e-19	Coronary artery disease;
LGG	cis	rs367615	0.704	rs11747622	chr5:108844720	G/A	cg17395555	chr5:108820864	NA	0.87	15.86	0.59	1.53e-45	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11169552	0.510	rs4131769	chr12:50952022	A/G	cg12884762	chr12:50931848	DIP2B	-0.41	-7.77	-0.34	4.96e-14	Colorectal cancer;
LGG	cis	rs765787	0.530	rs2433228	chr15:45515371	A/C	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs7666738	0.791	rs1405766	chr4:98965389	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs61931739	0.534	rs10844800	chr12:34230734	A/G	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.38e-45	Morning vs. evening chronotype;
LGG	cis	rs1862618	0.853	rs252921	chr5:56137787	G/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.48	-0.44	3.31e-23	Initial pursuit acceleration;
LGG	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg05623727	chr3:50126028	RBM5	0.32	7.0	0.31	9.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs870825	0.860	rs72703526	chr4:185605676	A/T	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	cis	rs7000551	0.689	rs2122878	chr8:22311916	T/C	cg12081754	chr8:22256438	SLC39A14	0.68	13.27	0.52	2.87e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11252926	0.545	rs11252693	chr10:532139	A/G	cg16386425	chr10:429943	DIP2C	-0.35	-6.97	-0.31	1.09e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg26031613	chr14:104095156	KLC1	1.18	29.46	0.81	3.08e-108	Body mass index;
LGG	cis	rs1153858	0.621	rs1719237	chr15:45579822	G/A	cg26924012	chr15:45694286	SPATA5L1	0.9	16.3	0.6	1.57e-47	Homoarginine levels;
LGG	cis	rs1185460	0.508	rs7942757	chr11:118903651	G/A	cg24687335	chr11:118901407	SLC37A4	-0.62	-11.22	-0.46	5.31e-26	Coronary artery disease;
LGG	cis	rs10865541	0.935	rs4971502	chr2:3414029	A/G	cg11642891	chr2:3452563	TTC15	-0.43	-8.48	-0.37	3.16e-16	Obesity-related traits;
LGG	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg10935138	chr17:73851978	WBP2	0.72	10.5	0.44	2.82e-23	Psoriasis;
LGG	cis	rs17818399	0.502	rs1451152	chr2:46800150	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.0	0.31	8.81e-12	Height;
LGG	trans	rs12517041	1.000	rs35670742	chr5:23281811	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.95	-0.45	5.5e-25	Calcium levels;
LGG	trans	rs57221529	0.600	rs11750269	chr5:666270	G/A	cg25482853	chr8:67687455	SGK3	0.96	11.77	0.48	3.86e-28	Lung disease severity in cystic fibrosis;
LGG	trans	rs7819412	0.522	rs4841497	chr8:10985140	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.62	-0.33	1.46e-13	Triglycerides;
LGG	cis	rs227808	0.704	rs9463007	chr6:44639723	C/A	cg18551225	chr6:44695536	NA	0.48	6.88	0.3	1.89e-11	Male-pattern baldness;
LGG	cis	rs870825	0.655	rs2017101	chr4:185637381	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs7226408	0.857	rs72890579	chr18:34626456	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.34	-0.32	9.43e-13	Obesity-related traits;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg22072935	chr14:105399595	NA	0.51	9.85	0.42	6.76e-21	Rheumatoid arthritis;
LGG	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.79e-68	Diabetic kidney disease;
LGG	cis	rs611744	0.507	rs2121900	chr8:109333542	T/C	cg21045802	chr8:109455806	TTC35	0.54	9.73	0.41	1.82e-20	Dupuytren's disease;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg00149659	chr3:10157352	C3orf10	0.83	10.79	0.45	2.21e-24	Alzheimer's disease;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg11584989	chr19:19387371	SF4	-0.42	-7.51	-0.33	3.1e-13	Tonsillectomy;
LGG	cis	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg09307838	chr4:120376055	NA	0.78	12.73	0.51	4.88e-32	Corneal astigmatism;
LGG	cis	rs3820068	0.705	rs58424111	chr1:15868470	A/C	cg05660106	chr1:15850417	CASP9	1.14	26.91	0.78	9.73e-97	Systolic blood pressure;
LGG	cis	rs7647973	0.731	rs13084037	chr3:49214066	G/A	cg06212747	chr3:49208901	KLHDC8B	0.63	9.37	0.4	3.19e-19	Menarche (age at onset);
LGG	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg18252515	chr7:66147081	NA	-1.41	-20.58	-0.69	2.5e-67	Diabetic kidney disease;
LGG	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg13902645	chr11:5959945	NA	0.75	14.19	0.55	3.32e-38	DNA methylation (variation);
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg03452623	chr4:187889614	NA	-1.05	-31.91	-0.83	5.36e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12200560	0.505	rs211172	chr6:97070691	C/A	cg06623918	chr6:96969491	KIAA0776	0.46	7.78	0.34	4.8e-14	Coronary heart disease;
LGG	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs17001868	0.568	rs9611310	chr22:40733777	A/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs17433780	0.836	rs17434342	chr1:89505742	C/G	cg09516651	chr1:89888402	LOC400759	-0.73	-16.83	-0.62	5.93e-50	Carotid intima media thickness;
LGG	cis	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg24375607	chr4:120327624	NA	-0.68	-11.09	-0.46	1.65e-25	Corneal astigmatism;
LGG	cis	rs6430585	0.528	rs309123	chr2:136761175	C/G	cg07169764	chr2:136633963	MCM6	1.23	24.35	0.75	6.63e-85	Corneal structure;
LGG	trans	rs6089829	0.962	rs2277769	chr20:61666805	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.14	0.31	3.72e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg03098644	chr7:100410630	EPHB4	0.48	7.16	0.32	3.26e-12	Other erythrocyte phenotypes;
LGG	cis	rs9811920	0.660	rs7619512	chr3:99729132	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-7.3	-0.32	1.3e-12	Axial length;
LGG	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs977987	0.866	rs17696831	chr16:75493298	C/G	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.09e-28	Dupuytren's disease;
LGG	trans	rs2548003	0.518	rs1833823	chr5:28741723	A/G	cg12623145	chr2:97778927	ANKRD36	0.47	6.65	0.3	8.4e-11	Hip geometry;
LGG	cis	rs2996428	0.667	rs16824230	chr1:3766240	A/G	cg10555106	chr1:3691387	LOC388588	0.36	8.17	0.36	2.88e-15	Red cell distribution width;
LGG	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg15454534	chr1:248569605	OR2T1	0.38	7.01	0.31	8.58e-12	Common traits (Other);
LGG	cis	rs67478160	0.643	rs4900594	chr14:104251006	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.52	-0.33	2.84e-13	Schizophrenia;
LGG	cis	rs921968	0.509	rs832813	chr2:219354569	T/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.32	-0.32	1.14e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg02487422	chr3:49467188	NICN1	0.4	6.87	0.3	2.14e-11	Menarche (age at onset);
LGG	cis	rs7523273	0.606	rs2488254	chr1:207941539	A/G	cg22525895	chr1:207977042	MIR29B2	0.61	11.96	0.49	6.63e-29	Schizophrenia;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg26174226	chr8:58114915	NA	-0.56	-7.71	-0.34	7.5e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9513627	1.000	rs7985908	chr13:100186218	T/C	cg25919922	chr13:100150906	NA	0.73	7.75	0.34	5.96e-14	Obesity-related traits;
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	11.19	0.46	6.99e-26	Total body bone mineral density;
LGG	cis	rs8062405	0.723	rs12445744	chr16:28588395	A/C	cg16576597	chr16:28551801	NUPR1	0.43	10.14	0.43	5.88e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9303280	0.806	rs12232497	chr17:38040119	T/C	cg19468946	chr17:37922297	IKZF3	-0.45	-8.0	-0.35	1e-14	Self-reported allergy;
LGG	cis	rs807029	0.577	rs7903239	chr10:102758337	G/T	cg04662943	chr10:102668895	NA	0.47	6.67	0.3	7.27e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1843834	0.539	rs6749402	chr2:225443901	T/G	cg22509189	chr2:225307070	NA	-0.61	-9.89	-0.42	4.84e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs2046867	0.818	rs17010215	chr3:72886965	A/G	cg26655873	chr3:72818019	SHQ1	0.37	7.12	0.31	4.02e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9733	0.744	rs2039590	chr1:150813315	G/A	cg13175981	chr1:150552382	MCL1	0.54	8.77	0.38	3.45e-17	Tonsillectomy;
LGG	cis	rs875971	0.522	rs7784623	chr7:65395034	T/G	cg00343986	chr7:65444356	GUSB	0.49	8.62	0.37	1.03e-16	Aortic root size;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1552244	0.554	rs7638846	chr3:10048601	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.75	0.51	4.02e-32	Alzheimer's disease;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg04863758	chr4:1303710	MAEA	0.41	7.24	0.32	1.86e-12	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg19223190	chr17:80058835	NA	0.43	8.28	0.36	1.29e-15	Life satisfaction;
LGG	trans	rs853679	0.607	rs67662114	chr6:27932301	G/A	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	cis	rs16866061	1.000	rs72974203	chr2:225408430	G/A	cg12698349	chr2:225449008	CUL3	0.92	19.24	0.67	4.82e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg00149659	chr3:10157352	C3orf10	0.83	10.81	0.45	2.02e-24	Alzheimer's disease;
LGG	cis	rs7095944	0.582	rs10901823	chr10:126488660	C/T	cg08799069	chr10:126477246	METTL10	-0.44	-9.92	-0.42	3.72e-21	Asthma;
LGG	cis	rs1348850	0.914	rs9789582	chr2:178330173	C/G	cg27490568	chr2:178487706	NA	0.51	10.04	0.42	1.4e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.659	rs4822036	chr22:41936019	A/G	cg06634786	chr22:41940651	POLR3H	-0.77	-12.5	-0.5	4.09e-31	Vitiligo;
LGG	cis	rs10861342	0.892	rs11112378	chr12:105514033	A/G	cg23923672	chr12:105501055	KIAA1033	0.78	7.01	0.31	8.28e-12	IgG glycosylation;
LGG	cis	rs6540556	0.954	rs6685077	chr1:209933331	A/G	cg23920097	chr1:209922102	NA	-0.45	-8.02	-0.35	8.93e-15	Red blood cell count;
LGG	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg09307838	chr4:120376055	NA	0.82	13.76	0.54	2.4e-36	Corneal astigmatism;
LGG	cis	rs7666738	0.830	rs7664051	chr4:98766970	C/G	cg05340658	chr4:99064831	C4orf37	0.48	7.78	0.34	4.73e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2282802	0.685	rs13177186	chr5:139640476	A/G	cg26211634	chr5:139558579	C5orf32	0.34	7.58	0.33	1.91e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.78	0.45	2.45e-24	Personality dimensions;
LGG	cis	rs171408	0.842	rs355132	chr3:8612576	G/A	cg03557445	chr3:8615444	LOH3CR2A	-0.5	-8.91	-0.38	1.14e-17	Mitral valve prolapse;
LGG	cis	rs6693567	0.545	rs2275246	chr1:150460168	A/G	cg15654264	chr1:150340011	RPRD2	0.33	6.75	0.3	4.46e-11	Migraine;
LGG	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.01	0.52	3.44e-33	Lung cancer in ever smokers;
LGG	trans	rs208520	0.837	rs208467	chr6:66914837	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.37	-0.58	2.23e-43	Exhaled nitric oxide output;
LGG	cis	rs2228479	0.702	rs17233868	chr16:89803629	C/T	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.06	-0.35	6.55e-15	Skin colour saturation;
LGG	cis	rs2836974	0.605	rs2836971	chr21:40652040	A/C	cg06238570	chr21:40685208	BRWD1	-0.52	-8.73	-0.38	4.65e-17	Cognitive function;
LGG	cis	rs4474465	1.000	rs10899514	chr11:78172695	A/G	cg27205649	chr11:78285834	NARS2	-0.5	-8.58	-0.37	1.48e-16	Alzheimer's disease (survival time);
LGG	cis	rs8017423	0.608	rs12589866	chr14:90820977	T/C	cg04374321	chr14:90722782	PSMC1	-0.65	-12.88	-0.51	1.2e-32	Mortality in heart failure;
LGG	cis	rs780096	0.546	rs715326	chr2:27725761	A/G	cg02592271	chr2:27665507	KRTCAP3	0.29	7.34	0.32	9.99e-13	Total body bone mineral density;
LGG	cis	rs16976116	0.901	rs3179664	chr15:55496853	G/A	cg11288833	chr15:55489084	RSL24D1	0.53	7.25	0.32	1.78e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9633740	0.578	rs11185951	chr10:82301536	G/C	cg01528321	chr10:82214614	TSPAN14	-0.92	-11.09	-0.46	1.71e-25	Post bronchodilator FEV1;
LGG	cis	rs7666738	0.830	rs7684646	chr4:99071062	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.45e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.12	-0.39	2.33e-18	Personality dimensions;
LGG	cis	rs7582180	0.652	rs11123830	chr2:100974747	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.76e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs56399783	0.901	rs55767077	chr7:2774608	C/T	cg19731401	chr7:2775893	GNA12	0.37	7.35	0.32	9.17e-13	Childhood ear infection;
LGG	cis	rs72945132	1.000	rs7938912	chr11:70114885	C/T	cg00319359	chr11:70116639	PPFIA1	0.69	7.38	0.32	7.45e-13	Coronary artery disease;
LGG	cis	rs8067545	0.611	rs4925090	chr17:20066631	C/T	cg09818912	chr17:20140352	CYTSB	-0.32	-7.53	-0.33	2.71e-13	Schizophrenia;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg02475777	chr4:1388615	CRIPAK	0.42	7.76	0.34	5.47e-14	Longevity;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg11608241	chr8:8085544	FLJ10661	-0.31	-7.09	-0.31	5.1e-12	Triglycerides;
LGG	cis	rs453301	0.653	rs11784393	chr8:8903134	C/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.77	0.34	4.97e-14	Joint mobility (Beighton score);
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg08925882	chr11:67350491	GSTP1	-0.34	-6.67	-0.3	7.44e-11	Mean corpuscular volume;
LGG	cis	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg22437258	chr11:111473054	SIK2	-0.54	-9.05	-0.39	4.01e-18	Primary sclerosing cholangitis;
LGG	cis	rs7666738	0.830	rs4441757	chr4:98927059	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4917300	0.650	rs4917266	chr8:143070168	T/A	cg06573787	chr8:143070187	NA	0.75	15.65	0.59	1.34e-44	Amyotrophic lateral sclerosis;
LGG	cis	rs6977660	1.000	rs7791038	chr7:19798833	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	7.85	0.34	2.96e-14	Thyroid stimulating hormone;
LGG	cis	rs7851660	0.901	rs2401639	chr9:100607837	T/C	cg13688889	chr9:100608707	NA	-0.69	-14.61	-0.56	5.17e-40	Strep throat;
LGG	cis	rs2718058	0.630	rs2722227	chr7:37858610	G/A	cg15028436	chr7:37888078	TXNDC3	0.52	8.2	0.36	2.31e-15	Alzheimer's disease (late onset);
LGG	trans	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.09	-0.35	5.3e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.54e-12	Retinal vascular caliber;
LGG	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg18131467	chr2:239335373	ASB1	1.02	23.49	0.74	6.43e-81	Multiple system atrophy;
LGG	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.79	0.54	1.73e-36	Colorectal cancer;
LGG	cis	rs11229555	0.645	rs61905183	chr11:58228463	T/A	cg15696309	chr11:58395628	NA	-0.96	-15.5	-0.58	5.72e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg05623727	chr3:50126028	RBM5	-0.38	-8.32	-0.36	9.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.95	-0.42	2.8e-21	Bipolar disorder;
LGG	trans	rs7824557	0.767	rs1897950	chr8:11169551	C/A	cg02002194	chr4:3960332	NA	-0.52	-9.8	-0.41	1.01e-20	Retinal vascular caliber;
LGG	cis	rs881375	0.702	rs3761847	chr9:123690239	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.51	0.4	1.02e-19	Rheumatoid arthritis;
LGG	cis	rs62064224	0.589	rs8069673	chr17:30661250	C/T	cg25809561	chr17:30822961	MYO1D	-0.38	-9.09	-0.39	2.88e-18	Schizophrenia;
LGG	cis	rs1153858	0.621	rs2687512	chr15:45581495	T/C	cg21132104	chr15:45694354	SPATA5L1	-0.67	-9.47	-0.4	1.44e-19	Homoarginine levels;
LGG	cis	rs7945705	0.967	rs10769973	chr11:8928615	C/G	cg21881798	chr11:8931708	C11orf17;ST5	0.52	11.14	0.46	1.08e-25	Hemoglobin concentration;
LGG	cis	rs3733585	0.664	rs28602527	chr4:9958327	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs113835537	0.529	rs17496250	chr11:66270774	C/G	cg24851651	chr11:66362959	CCS	0.44	7.47	0.33	3.93e-13	Airway imaging phenotypes;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	cis	rs7512552	0.839	rs1625468	chr1:150321486	G/A	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2361718	0.900	rs8081698	chr17:78104212	G/A	cg09238746	chr17:78121135	EIF4A3	-0.54	-9.81	-0.41	9.16e-21	Yeast infection;
LGG	cis	rs16854884	0.657	rs35877644	chr3:143701755	A/G	cg06585982	chr3:143692056	C3orf58	0.64	11.21	0.46	5.55e-26	Economic and political preferences (feminism/equality);
LGG	cis	rs2088885	1.000	rs957130	chr3:170975442	T/C	cg18052528	chr3:170975382	TNIK	-0.28	-6.84	-0.3	2.45e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs2404602	0.583	rs2139190	chr15:76555539	G/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.93	-0.31	1.38e-11	Blood metabolite levels;
LGG	cis	rs7107174	1.000	rs2450131	chr11:77944568	A/C	cg27205649	chr11:78285834	NARS2	-0.48	-7.64	-0.33	1.27e-13	Testicular germ cell tumor;
LGG	cis	rs372883	0.648	rs368322	chr21:30717151	C/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.91	-0.42	4.11e-21	Pancreatic cancer;
LGG	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg04733989	chr22:42467013	NAGA	-0.59	-10.65	-0.44	7.45e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg05941027	chr17:61774174	LIMD2	0.36	9.05	0.39	4.06e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7524258	0.868	rs6693725	chr1:7307810	G/T	cg07173049	chr1:7289937	CAMTA1	0.71	16.51	0.61	1.76e-48	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs17125944	0.686	rs2357946	chr14:53345266	G/C	cg00686598	chr14:53173677	PSMC6	-0.65	-7.1	-0.31	4.79e-12	Alzheimer's disease (late onset);
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg24575275	chr7:1094737	C7orf50	-0.42	-8.22	-0.36	2.13e-15	Longevity;Endometriosis;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg12692727	chr7:1102344	C7orf50	0.49	6.82	0.3	2.77e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg24623649	chr8:11872141	NA	-0.29	-7.09	-0.31	5.08e-12	Neuroticism;
LGG	cis	rs4242434	0.672	rs7846476	chr8:22479461	T/C	cg19455335	chr8:22457658	C8orf58	-0.37	-7.53	-0.33	2.71e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.63	18.26	0.65	1.74e-56	Oropharynx cancer;
LGG	cis	rs908922	0.651	rs4240886	chr1:152530396	A/T	cg09873164	chr1:152488093	CRCT1	-0.61	-14.89	-0.57	3.05e-41	Hair morphology;
LGG	cis	rs3096299	0.874	rs3102342	chr16:89451575	T/C	cg02187348	chr16:89574699	SPG7	0.47	7.57	0.33	2.08e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs9393692	0.905	rs9366649	chr6:26329103	A/T	cg15665833	chr6:26285013	NA	-0.35	-6.68	-0.3	6.75e-11	Educational attainment;
LGG	cis	rs11785693	0.862	rs11774044	chr8:4988035	C/G	cg26367366	chr8:4980734	NA	0.99	15.82	0.59	2.26e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs68170813	0.559	rs78064065	chr7:106967440	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-10.27	-0.43	2.07e-22	Coronary artery disease;
LGG	cis	rs4718428	0.705	rs68168107	chr7:66255238	G/A	cg18252515	chr7:66147081	NA	-0.75	-12.01	-0.49	3.93e-29	Corneal structure;
LGG	cis	rs7236492	0.572	rs78124041	chr18:77181489	G/A	cg15532942	chr18:77220712	NFATC1	0.53	7.79	0.34	4.35e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4242434	0.699	rs878053	chr8:22483849	T/C	cg00599393	chr8:22457479	C8orf58	-0.42	-7.72	-0.34	7.27e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2303319	0.892	rs16845742	chr2:162127034	T/G	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs4474465	1.000	rs6592780	chr11:78199888	C/G	cg27205649	chr11:78285834	NARS2	-0.48	-8.26	-0.36	1.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg11905131	chr22:24372483	LOC391322	-0.45	-8.18	-0.36	2.73e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7264396	0.561	rs6058388	chr20:34571846	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.5	-0.33	3.23e-13	Total cholesterol levels;
LGG	cis	rs73198271	0.562	rs17631022	chr8:8662197	G/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.28	0.36	1.29e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs151997	1.000	rs251043	chr5:50215997	A/G	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs736408	0.609	rs13095332	chr3:52787242	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.05	-0.31	6.62e-12	Bipolar disorder;
LGG	cis	rs7264396	0.635	rs6060696	chr20:34522060	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.25	0.32	1.72e-12	Total cholesterol levels;
LGG	cis	rs7000551	0.581	rs11136030	chr8:22254235	C/T	cg13512537	chr8:22265999	SLC39A14	-0.45	-7.33	-0.32	1.01e-12	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10979	0.894	rs6924940	chr6:143906183	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-11.6	-0.47	1.67e-27	Hypospadias;
LGG	cis	rs7326068	0.610	rs7995798	chr13:21338432	C/T	cg04906043	chr13:21280425	IL17D	-0.5	-7.91	-0.35	1.85e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg08508325	chr11:3079039	CARS	0.39	7.19	0.32	2.59e-12	Calcium levels;
LGG	cis	rs7927771	0.864	rs112060627	chr11:47426956	G/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.51	-0.44	2.68e-23	Subjective well-being;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs3741151	0.881	rs73542929	chr11:73094539	G/T	cg17517138	chr11:73019481	ARHGEF17	0.97	9.34	0.4	3.93e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28735056	0.660	rs12454454	chr18:77674634	C/T	cg20368463	chr18:77673604	PQLC1	-0.61	-11.63	-0.48	1.33e-27	Schizophrenia;
LGG	cis	rs262150	0.501	rs1017034	chr7:158820460	A/G	cg19418458	chr7:158789849	NA	-0.51	-10.59	-0.44	1.29e-23	Facial morphology (factor 20);
LGG	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg09517075	chr8:22133004	PIWIL2	0.43	9.48	0.4	1.29e-19	Hypertriglyceridemia;
LGG	cis	rs78456975	0.941	rs11886649	chr2:1567757	A/G	cg26248373	chr2:1572462	NA	-0.7	-9.14	-0.39	2.01e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2117029	0.555	rs2047101	chr12:49497643	T/A	cg24176009	chr12:49580217	TUBA1A	0.56	10.56	0.44	1.63e-23	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.733	rs12421173	chr11:89384488	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.2e-18	Anxiety in major depressive disorder;
LGG	cis	rs12681287	0.888	rs2976201	chr8:87335937	T/C	cg27223183	chr8:87520930	FAM82B	-0.44	-6.71	-0.3	5.73e-11	Caudate activity during reward;
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	trans	rs6446298	0.738	rs6446296	chr3:49838052	G/A	cg21659725	chr3:3221576	CRBN	0.53	7.94	0.35	1.52e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7166081	1.000	rs12898685	chr15:67525772	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.736	rs11658040	chr17:80059891	C/T	cg10505658	chr17:80084571	CCDC57	0.34	6.76	0.3	4.14e-11	Life satisfaction;
LGG	cis	rs6460942	1.000	rs62448568	chr7:12407445	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.85	-0.3	2.38e-11	Coronary artery disease;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg10056627	chr6:42928773	GNMT	0.25	6.88	0.3	1.98e-11	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg19399532	chr1:178512495	C1orf220	0.54	10.89	0.45	9.86e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg16850897	chr7:100343110	ZAN	-0.55	-7.52	-0.33	2.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg07636037	chr3:49044803	WDR6	0.6	10.57	0.44	1.52e-23	Resting heart rate;
LGG	cis	rs1387259	0.570	rs12368659	chr12:48562299	C/A	cg24011408	chr12:48396354	COL2A1	0.57	9.44	0.4	1.88e-19	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs4356932	0.967	rs4241581	chr4:76962055	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs4417704	0.551	rs10169544	chr2:241899356	A/C	cg26818257	chr2:241905806	NA	0.49	10.82	0.45	1.77e-24	Joint mobility (Beighton score);
LGG	cis	rs1816854	0.938	rs11182280	chr12:44209584	T/C	cg00106942	chr12:44200524	TWF1	0.42	6.68	0.3	6.98e-11	Inflammatory bowel disease;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08280861	chr8:58055591	NA	0.55	6.9	0.31	1.67e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11608355	0.545	rs11066737	chr12:109904792	A/G	cg05360138	chr12:110035743	NA	-0.86	-12.29	-0.5	3.12e-30	Neuroticism;
LGG	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.81	0.59	2.6e-45	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg24110177	chr3:50126178	RBM5	-0.54	-9.91	-0.42	3.93e-21	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20078939	chr11:33060711	TCP11L1	0.44	7.19	0.32	2.64e-12	Cognitive performance;
LGG	cis	rs3806843	0.576	rs246072	chr5:140320426	C/T	cg19875535	chr5:140030758	IK	0.37	7.37	0.32	8.17e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs881375	0.678	rs10739581	chr9:123696871	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.49	0.4	1.26e-19	Rheumatoid arthritis;
LGG	cis	rs1371867	0.817	rs1660315	chr8:101332956	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg01570182	chr17:44337453	NA	-0.66	-10.96	-0.45	5.11e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg18245976	chr7:158708271	WDR60	0.61	8.04	0.35	7.44e-15	Height;
LGG	cis	rs10463554	0.963	rs1595553	chr5:102378868	A/C	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs1847505	0.563	rs3127044	chr13:61400468	G/C	cg25164009	chr13:61490935	NA	-0.57	-9.24	-0.39	9.28e-19	Polychlorinated biphenyl levels;
LGG	cis	rs6693567	0.516	rs3850844	chr1:150413940	G/T	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.87e-11	Migraine;
LGG	cis	rs79349575	0.783	rs17708633	chr17:47011620	C/G	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs10463554	0.963	rs34773	chr5:102450576	C/G	cg23492399	chr5:102201601	PAM	-0.5	-7.57	-0.33	1.98e-13	Parkinson's disease;
LGG	trans	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.85	0.3	2.35e-11	Retinal vascular caliber;
LGG	cis	rs2730245	0.527	rs2527205	chr7:158706393	G/T	cg14689365	chr7:158441557	NCAPG2	-0.54	-6.76	-0.3	4.29e-11	Height;
LGG	cis	rs7444	0.941	rs12158299	chr22:21979584	C/T	cg11654148	chr22:21984483	YDJC	-0.38	-7.34	-0.32	9.86e-13	Systemic lupus erythematosus;
LGG	cis	rs9486719	0.843	rs3860231	chr6:97036563	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.64	-0.33	1.25e-13	Migraine;Coronary artery disease;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg00495681	chr13:53174319	NA	-0.51	-9.23	-0.39	9.63e-19	Lewy body disease;
LGG	cis	rs589448	0.867	rs623853	chr12:69753830	G/A	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4148087	0.505	rs1893590	chr21:43619595	A/C	cg08841829	chr21:43638893	ABCG1	-0.4	-7.06	-0.31	6.22e-12	Eating disorder in bipolar disorder;
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.58e-12	Bipolar disorder;
LGG	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.76	-0.61	1.34e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11971779	0.616	rs6467836	chr7:139023517	C/G	cg07862535	chr7:139043722	LUC7L2	0.41	6.76	0.3	4.13e-11	Diisocyanate-induced asthma;
LGG	cis	rs9309473	1.000	rs7598419	chr2:73798223	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-7.91	-0.34	1.93e-14	Metabolite levels;
LGG	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg24634471	chr8:143751801	JRK	0.49	7.54	0.33	2.58e-13	Schizophrenia;
LGG	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.73	-0.34	6.69e-14	Retinal vascular caliber;
LGG	cis	rs4959677	0.935	rs4959676	chr6:2495566	G/A	cg20147862	chr6:2634573	C6orf195	-0.38	-8.32	-0.36	9.99e-16	Orthostatic hypotension;
LGG	cis	rs433852	0.718	rs550455	chr19:49136515	A/G	cg06530960	chr19:49140787	SEC1;DBP	-0.53	-9.47	-0.4	1.4e-19	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.43	0.4	2.02e-19	Colorectal cancer;
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg05896524	chr21:47604654	C21orf56	0.55	9.62	0.41	4.4e-20	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.56	0.33	2.2e-13	Lung cancer;
LGG	cis	rs9487094	1.000	rs36035949	chr6:109736614	G/A	cg16315928	chr6:109776240	MICAL1	0.49	8.26	0.36	1.56e-15	Height;
LGG	cis	rs3820928	0.839	rs12470666	chr2:227876525	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.61	-0.33	1.59e-13	Pulmonary function;
LGG	cis	rs1387259	0.758	rs2634670	chr12:48771877	G/A	cg21466736	chr12:48725269	NA	-0.36	-7.07	-0.31	5.76e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs10752881	0.967	rs6695837	chr1:182991462	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg17802220	chr15:77601643	NA	-0.54	-12.13	-0.49	1.3e-29	Type 2 diabetes;
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.72	0.3	5.34e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.34	-8.08	-0.35	5.62e-15	Schizophrenia;
LGG	cis	rs1408799	0.682	rs13288558	chr9:12612529	A/G	cg05274944	chr9:12693694	TYRP1	0.32	7.41	0.33	5.94e-13	Eye color;Blue vs. green eyes;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09484580	chr10:87898628	GRID1	0.38	6.78	0.3	3.58e-11	Pancreatic cancer;
LGG	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg02273617	chr15:68117586	LBXCOR1	0.31	7.25	0.32	1.79e-12	Motion sickness;
LGG	trans	rs9858542	0.953	rs7648841	chr3:49416825	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.48	-0.44	3.46e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9611565	0.649	rs2064189	chr22:42127999	A/G	cg03806693	chr22:41940476	POLR3H	0.89	14.88	0.57	3.39e-41	Vitiligo;
LGG	cis	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg18252515	chr7:66147081	NA	-0.41	-6.92	-0.31	1.52e-11	Aortic root size;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg05896524	chr21:47604654	C21orf56	0.55	9.93	0.42	3.52e-21	Testicular germ cell tumor;
LGG	cis	rs6071166	0.772	rs6071180	chr20:37340089	C/G	cg10737118	chr20:37354790	SLC32A1	-0.43	-7.98	-0.35	1.17e-14	circulating leptin levels adjusted for BMI;circulating leptin levels;
LGG	cis	rs1200821	0.529	rs2505707	chr10:37801254	T/C	cg00409905	chr10:38381863	ZNF37A	-0.44	-8.43	-0.36	4.26e-16	Hemostatic factors and hematological phenotypes;
LGG	cis	rs60871478	0.786	rs55899111	chr7:827843	C/G	cg05535760	chr7:792225	HEATR2	-0.97	-14.49	-0.56	1.59e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg26924012	chr15:45694286	SPATA5L1	0.87	15.36	0.58	2.57e-43	Homoarginine levels;
LGG	cis	rs7202877	0.610	rs11149814	chr16:75332981	T/C	cg03315344	chr16:75512273	CHST6	0.51	6.98	0.31	1.03e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg01152986	chr16:58549298	SETD6	0.84	7.37	0.32	7.71e-13	Schizophrenia;
LGG	cis	rs4664308	1.000	rs6707458	chr2:160914540	G/T	cg03641300	chr2:160917029	PLA2R1	-0.85	-17.81	-0.64	1.92e-54	Idiopathic membranous nephropathy;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.25	-0.4	8.07e-19	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12972275	chr4:122722461	EXOSC9	0.42	6.8	0.3	3.25e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17227506	0.805	rs1585983	chr8:13439157	C/G	cg03566418	chr8:13424080	C8orf48	0.44	6.87	0.3	2.12e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22174410	chr3:42641766	NKTR	0.44	7.28	0.32	1.46e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.35	-0.43	9.97e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs972578	0.905	rs9623736	chr22:43406673	A/G	cg01576275	chr22:43409880	NA	-0.24	-7.13	-0.31	3.93e-12	Mean platelet volume;
LGG	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	cis	rs9828933	0.752	rs832192	chr3:63853423	T/C	cg17941049	chr3:63904683	ATXN7	-0.71	-7.55	-0.33	2.33e-13	Type 2 diabetes;
LGG	cis	rs1862618	0.853	rs832584	chr5:56179212	A/G	cg17809284	chr5:56205270	C5orf35	0.53	8.78	0.38	3.21e-17	Initial pursuit acceleration;
LGG	cis	rs9303401	0.659	rs7216648	chr17:56790858	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs2455799	0.613	rs7617039	chr3:15800740	A/G	cg16303742	chr3:15540471	COLQ	0.41	8.13	0.35	3.94e-15	Mean platelet volume;
LGG	cis	rs79149102	0.579	rs79916508	chr15:75373721	A/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-7.99	-0.35	1.08e-14	Lung cancer;
LGG	cis	rs861020	0.771	rs629150	chr1:209998467	C/T	cg23166289	chr1:210001082	C1orf107	0.37	7.2	0.32	2.43e-12	Orofacial clefts;
LGG	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg25703541	chr22:24373054	LOC391322	0.93	14.25	0.55	1.9e-38	S-phenylmercapturic acid levels in smokers;
LGG	trans	rs9354308	0.868	rs9345692	chr6:66544714	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20829347	chr13:112720927	SOX1	0.4	7.03	0.31	7.32e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7666738	0.715	rs116787789	chr4:98718720	G/A	cg05340658	chr4:99064831	C4orf37	0.46	7.55	0.33	2.28e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	6.76	0.3	4.27e-11	Schizophrenia;
LGG	cis	rs28595532	0.920	rs114696063	chr4:119760624	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs3782089	1.000	rs1194337	chr11:65259471	C/T	cg21890820	chr11:65308645	LTBP3	0.58	6.95	0.31	1.25e-11	Height;
LGG	cis	rs12477438	0.520	rs11692699	chr2:99730657	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.81	0.64	2.01e-54	Chronic sinus infection;
LGG	cis	rs10463554	0.963	rs26261	chr5:102545693	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.54	-0.33	2.53e-13	Parkinson's disease;
LGG	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg18511798	chr11:2018149	H19;MIR675	0.52	10.37	0.43	8.52e-23	DNA methylation (variation);
LGG	cis	rs1865760	0.568	rs2032450	chr6:25993114	C/G	cg03264133	chr6:25882463	NA	-0.41	-7.18	-0.32	2.77e-12	Height;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg00409905	chr10:38381863	ZNF37A	0.64	11.96	0.49	6.2e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs7923837	0.687	rs1977833	chr10:94463945	G/A	cg25093409	chr10:94429542	NA	0.52	10.44	0.44	4.64e-23	Body mass index;Multiple sclerosis;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg00290607	chr11:67383545	NA	0.65	12.55	0.5	2.64e-31	Mean corpuscular volume;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs9357271	1.000	rs9296248	chr6:38358834	C/T	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	cis	rs2153535	0.580	rs7450817	chr6:8481421	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg00080972	chr5:178986291	RUFY1	0.42	7.26	0.32	1.67e-12	Lung cancer;
LGG	cis	rs8180040	0.966	rs11716763	chr3:47518266	C/T	cg16586182	chr3:47516702	SCAP	0.77	15.39	0.58	1.87e-43	Colorectal cancer;
LGG	cis	rs2051211	0.947	rs73065216	chr3:38524194	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-9.35	-0.4	3.67e-19	QRS duration;
LGG	cis	rs2635047	0.624	rs2289036	chr18:44595809	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.58	-10.21	-0.43	3.43e-22	Educational attainment;
LGG	cis	rs10791323	0.569	rs11533204	chr11:133743644	A/G	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08703520	chr19:58978336	ZNF324	-0.51	-7.38	-0.32	7.25e-13	Systemic lupus erythematosus;
LGG	cis	rs8067545	0.516	rs11869258	chr17:20206898	G/A	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.42e-22	Schizophrenia;
LGG	cis	rs28374715	0.662	rs513280	chr15:41482800	T/C	cg18705301	chr15:41695430	NDUFAF1	0.99	17.74	0.64	4.31e-54	Ulcerative colitis;
LGG	cis	rs7833790	0.636	rs12544174	chr8:82731477	G/A	cg06027949	chr8:82754900	SNX16	-0.55	-8.54	-0.37	1.9e-16	Diastolic blood pressure;
LGG	cis	rs7928758	0.887	rs80021729	chr11:134263734	A/C	cg25213107	chr11:134282864	B3GAT1	1.26	14.05	0.55	1.37e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs8002861	0.846	rs12428314	chr13:44476011	C/T	cg17145862	chr1:211918768	LPGAT1	-0.87	-19.96	-0.68	2.14e-64	Leprosy;
LGG	cis	rs910316	0.687	rs175059	chr14:75490667	T/C	cg11812906	chr14:75593930	NEK9	-0.46	-8.3	-0.36	1.17e-15	Height;
LGG	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.63	0.33	1.39e-13	Colorectal cancer;
LGG	cis	rs61990749	0.597	rs176980	chr14:78198449	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.25	-0.32	1.82e-12	Fibroblast growth factor basic levels;
LGG	cis	rs847649	1.000	rs1100046	chr7:102549295	T/A	cg18108683	chr7:102477205	FBXL13	-0.65	-14.34	-0.55	7.2e-39	Morning vs. evening chronotype;
LGG	cis	rs15676	0.947	rs2280842	chr9:131585808	C/G	cg04621255	chr9:131581398	ENDOG	-0.39	-6.98	-0.31	1.01e-11	Blood metabolite levels;
LGG	trans	rs11088226	1.000	rs11701627	chr21:33927794	T/A	cg09050820	chr6:167586206	TCP10L2	0.66	9.77	0.41	1.3e-20	Gastritis;
LGG	cis	rs367615	0.550	rs10060801	chr5:108881782	A/G	cg17395555	chr5:108820864	NA	0.68	12.34	0.5	1.86e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg20913747	chr6:44695427	NA	-0.67	-12.05	-0.49	2.73e-29	Total body bone mineral density;
LGG	cis	rs10754283	0.967	rs1953821	chr1:90107098	C/G	cg21401794	chr1:90099060	LRRC8C	0.49	9.03	0.39	4.83e-18	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs62400317	0.859	rs56337964	chr6:45039786	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.55e-22	Total body bone mineral density;
LGG	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.8e-12	Diabetic retinopathy;
LGG	cis	rs78487399	0.808	rs12104615	chr2:43676938	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs2251666	0.514	rs75256268	chr16:4880908	T/C	cg04440724	chr16:4920505	UBN1	-0.62	-9.0	-0.39	5.76e-18	Cancer;
LGG	cis	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg19847130	chr8:10466454	RP1L1	-0.32	-6.82	-0.3	2.9e-11	Neuroticism;
LGG	cis	rs10493773	1.000	rs10493774	chr1:86137963	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.59	-9.75	-0.41	1.45e-20	Urate levels in overweight individuals;
LGG	cis	rs1927702	0.706	rs13298936	chr9:16015576	C/G	cg14451791	chr9:16040625	NA	0.29	7.05	0.31	6.73e-12	Body mass index;
LGG	cis	rs4242434	0.672	rs3758041	chr8:22486987	A/G	cg03733263	chr8:22462867	KIAA1967	0.97	23.29	0.73	5.59e-80	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs17689437	0.671	rs1177648	chr16:68598007	A/G	cg02972257	chr16:68554789	NA	-0.43	-7.09	-0.31	5.03e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.22e-44	Lung cancer;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg08645402	chr16:4508243	NA	0.48	8.64	0.37	9.28e-17	Schizophrenia;
LGG	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.89	-13.13	-0.52	1.02e-33	Schizophrenia;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.64	-0.41	3.7799999999999997e-20	Triglycerides;
LGG	cis	rs77106637	0.860	rs7129793	chr11:72455885	C/T	cg03713592	chr11:72463424	ARAP1	0.45	7.65	0.33	1.2e-13	Type 2 diabetes;
LGG	cis	rs7412746	0.658	rs2864869	chr1:150734655	G/A	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.31e-11	Melanoma;
LGG	cis	rs12421382	0.592	rs2029297	chr11:109465968	A/G	cg11473876	chr11:109292803	C11orf87	0.47	9.19	0.39	1.37e-18	Schizophrenia;
LGG	cis	rs1348850	0.560	rs13019660	chr2:178498214	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.72	-0.34	7.28e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg19812747	chr11:111475976	SIK2	0.5	10.45	0.44	4.48e-23	Primary sclerosing cholangitis;
LGG	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.67	-11.64	-0.48	1.23e-27	Height;
LGG	cis	rs17376456	0.877	rs17374627	chr5:93296306	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-9.38	-0.4	3.02e-19	Diabetic retinopathy;
LGG	cis	rs1707322	0.721	rs4609469	chr1:46117185	C/T	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2404602	0.662	rs908817	chr15:76639191	G/A	cg23625390	chr15:77176239	SCAPER	-0.66	-13.25	-0.52	3.34e-34	Blood metabolite levels;
LGG	cis	rs12765878	0.967	rs10883941	chr10:105650782	C/T	cg11005552	chr10:105648138	OBFC1	1.03	27.18	0.78	5.76e-98	Coronary artery disease;
LGG	cis	rs9640161	0.789	rs1464752	chr7:150021284	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.77	-16.07	-0.6	1.77e-46	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs12762955	0.561	rs10752022	chr10:1043798	C/T	cg18964960	chr10:1102726	WDR37	-0.45	-6.65	-0.3	8.54e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs9902453	0.904	rs12952179	chr17:28412687	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.18	-0.52	6.78e-34	Coffee consumption (cups per day);
LGG	cis	rs11148252	0.774	rs9536066	chr13:52983981	A/G	cg02158880	chr13:53174818	NA	0.44	8.74	0.38	4.41e-17	Lewy body disease;
LGG	cis	rs77372450	0.636	rs10066519	chr5:157017429	A/G	cg25387487	chr5:157003181	ADAM19	-0.57	-7.16	-0.32	3.24e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg03806693	chr22:41940476	POLR3H	1.09	19.75	0.68	1.95e-63	Vitiligo;
LGG	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg10189774	chr4:17578691	LAP3	0.4	6.96	0.31	1.16e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11018904	0.768	rs35389990	chr11:89978683	T/C	cg16176437	chr11:89678848	NA	0.47	6.94	0.31	1.31e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35740288	0.857	rs3803506	chr15:86290940	A/C	cg07943548	chr15:86304357	KLHL25	-0.36	-7.0	-0.31	9.3e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9372253	1.000	rs9374170	chr6:110712991	A/G	cg01119278	chr6:110721349	DDO	-0.31	-7.33	-0.32	1.03e-12	Platelet distribution width;
LGG	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg13385794	chr1:248469461	NA	0.45	8.13	0.35	4.09e-15	Common traits (Other);
LGG	cis	rs4315565	0.541	rs12464309	chr2:69284111	G/T	cg13358873	chr2:69271042	ANTXR1	0.45	6.81	0.3	2.97e-11	Height;
LGG	cis	rs13102973	0.867	rs11722699	chr4:135907871	G/T	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.83e-15	Subjective well-being;
LGG	cis	rs2154319	0.887	rs9439035	chr1:41540265	T/C	cg02290550	chr1:41487317	SLFNL1	-0.5	-9.02	-0.39	5.03e-18	Height;
LGG	cis	rs7681440	0.647	rs1442133	chr4:90819195	C/T	cg20003494	chr4:90757398	SNCA	-0.34	-6.7	-0.3	6.21e-11	Dementia with Lewy bodies;
LGG	cis	rs4481887	0.741	rs6587462	chr1:248539094	C/T	cg13385794	chr1:248469461	NA	-0.45	-8.01	-0.35	9.56e-15	Common traits (Other);
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.64	-0.41	3.63e-20	Lung cancer;
LGG	cis	rs28595532	0.920	rs114928651	chr4:119734194	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs881375	0.967	rs2270231	chr9:123650982	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.98	0.49	5.27e-29	Rheumatoid arthritis;
LGG	trans	rs36715	0.951	rs36698	chr5:127549749	T/A	cg16011800	chr17:1958478	HIC1	-0.45	-6.71	-0.3	5.76e-11	Breast cancer;
LGG	trans	rs9467711	0.591	rs35335639	chr6:26038681	C/G	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.97	-0.31	1.09e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs67311347	1.000	rs28707772	chr3:40504666	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.43	-0.78	1.54e-94	Renal cell carcinoma;
LGG	trans	rs6601327	0.641	rs11782886	chr8:9587891	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.68	-0.34	9.41e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs9929218	1.000	rs4500718	chr16:68754312	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.83	-14.37	-0.56	5.72e-39	Colorectal cancer;
LGG	cis	rs9923856	0.614	rs7203459	chr16:11230703	T/C	cg16765268	chr16:11229200	CLEC16A	0.37	6.9	0.31	1.69e-11	Atopic dermatitis;Adult asthma;
LGG	cis	rs12431410	0.584	rs12882475	chr14:60228055	T/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.26	-0.32	1.67e-12	Schizophrenia;
LGG	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.58	0.37	1.43e-16	Lung cancer;
LGG	cis	rs497273	0.511	rs1151862	chr12:121331285	G/A	cg02419362	chr12:121203948	SPPL3	-0.48	-8.45	-0.37	3.75e-16	Systemic lupus erythematosus;
LGG	cis	rs12476592	0.516	rs6546002	chr2:63593829	A/C	cg17519650	chr2:63277830	OTX1	-0.52	-7.94	-0.35	1.53e-14	Childhood ear infection;
LGG	cis	rs1003719	0.680	rs2835630	chr21:38521842	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.76	-14.77	-0.57	1.02e-40	Eye color traits;
LGG	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg10847948	chr11:71163743	NADSYN1	-0.68	-13.22	-0.52	4.42e-34	Vitamin D levels;
LGG	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-8.61	-0.37	1.14e-16	Calcium levels;
LGG	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg06917634	chr15:78832804	PSMA4	-0.52	-8.11	-0.35	4.6e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg27624424	chr6:160112604	SOD2	0.66	9.39	0.4	2.76e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.77	-0.45	2.77e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02690350	chr17:27620209	NUFIP2	0.49	8.02	0.35	8.93e-15	Cognitive performance;
LGG	cis	rs1046896	0.607	rs12449739	chr17:80683420	G/A	cg08200770	chr17:80723486	TBCD	-0.45	-8.42	-0.36	4.75e-16	Glycated hemoglobin levels;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	trans	rs11976180	1.000	rs2371244	chr7:143757611	A/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.83	-0.3	2.72e-11	Obesity-related traits;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13732083	chr21:47605072	C21orf56	-0.52	-8.43	-0.36	4.52e-16	Testicular germ cell tumor;
LGG	cis	rs2213920	0.620	rs7852799	chr9:118188696	T/C	cg13918206	chr9:118159781	DEC1	0.63	8.87	0.38	1.6e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg12560992	chr17:57184187	TRIM37	-0.73	-11.58	-0.47	2.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs10081290	chr7:124575508	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs3806843	1.000	rs10477034	chr5:140169730	A/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	trans	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-10.1	-0.42	8.48e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7084402	1.000	rs6481401	chr10:60268880	A/C	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.25e-13	Refractive error;
LGG	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg23845249	chr11:68861649	NA	0.44	7.81	0.34	3.77e-14	Blond vs. brown hair color;
LGG	cis	rs6908034	0.607	rs12526109	chr6:19820089	C/A	cg02682789	chr6:19804855	NA	0.9	8.42	0.36	4.78e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.57	-9.59	-0.41	5.51e-20	Longevity;
LGG	cis	rs362296	0.698	rs362279	chr4:3260072	G/A	cg06533319	chr4:3265114	C4orf44	0.51	10.03	0.42	1.54e-21	Parental longevity (mother's age at death);
LGG	trans	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg18187862	chr3:45730750	SACM1L	0.65	10.85	0.45	1.39e-24	Primary sclerosing cholangitis;
LGG	cis	rs5753037	0.585	rs249396	chr22:30213972	T/G	cg01021169	chr22:30184971	ASCC2	-0.41	-8.26	-0.36	1.5e-15	Type 1 diabetes;
LGG	cis	rs62238980	0.614	rs76474221	chr22:32415212	C/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs798554	0.660	rs2527692	chr7:2856533	G/A	cg19524238	chr7:2802976	GNA12	0.33	7.92	0.35	1.81e-14	Height;
LGG	cis	rs10824796	0.638	rs61844298	chr10:54516758	A/G	cg27418851	chr10:54531653	MBL2	-0.46	-7.69	-0.34	9.02e-14	Blood protein levels;
LGG	cis	rs3126085	0.935	rs7533529	chr1:152176871	T/C	cg26876637	chr1:152193138	HRNR	0.54	8.83	0.38	2.23e-17	Atopic dermatitis;
LGG	cis	rs4975709	1.000	rs2279588	chr5:1878021	G/A	cg07747251	chr5:1868357	NA	0.43	7.35	0.32	8.86e-13	Cardiovascular disease risk factors;
LGG	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg08847335	chr10:891726	LARP4B	-0.49	-8.83	-0.38	2.22e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg14664628	chr15:75095509	CSK	-1.14	-27.83	-0.79	6.66e-101	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs853679	0.607	rs35902873	chr6:28058949	G/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	trans	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs11971779	0.680	rs7808740	chr7:139028955	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.92	0.31	1.47e-11	Diisocyanate-induced asthma;
LGG	cis	rs9878978	0.691	rs34078497	chr3:2437657	G/A	cg21928760	chr3:2462534	CNTN4	0.39	7.77	0.34	5.23e-14	Blood pressure (smoking interaction);
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg00701064	chr4:6280414	WFS1	0.75	17.19	0.62	1.34e-51	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs360798	0.532	rs1553832	chr2:63013515	C/G	cg17519650	chr2:63277830	OTX1	-0.46	-7.54	-0.33	2.53e-13	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.22e-31	Prudent dietary pattern;
LGG	cis	rs12908161	1.000	rs35960805	chr15:85343980	T/G	cg03959625	chr15:84868606	LOC388152	0.48	7.03	0.31	7.38e-12	Schizophrenia;
LGG	cis	rs6088580	0.543	rs13042351	chr20:33238573	G/A	cg08999081	chr20:33150536	PIGU	-0.31	-7.26	-0.32	1.64e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs13260300	0.572	rs7824069	chr8:75522602	A/C	cg22993706	chr8:75542856	NA	0.41	8.14	0.35	3.62e-15	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs2862064	0.818	rs4704840	chr5:156484648	G/C	cg12943317	chr5:156479607	HAVCR1	-0.88	-10.83	-0.45	1.69e-24	Platelet count;
LGG	cis	rs4950322	0.580	rs972368	chr1:146582724	C/G	cg22381352	chr1:146742008	CHD1L	-0.44	-7.5	-0.33	3.37e-13	Protein quantitative trait loci;
LGG	cis	rs7264396	0.790	rs6058288	chr20:34228680	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.42	7.6	0.33	1.62e-13	Total cholesterol levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01993413	chr14:21979151	METTL3	0.41	6.83	0.3	2.7e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	1.000	rs6704930	chr2:26325705	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg05342682	chr7:94953680	PON1	-0.31	-7.13	-0.31	3.96e-12	Paraoxonase activity;
LGG	cis	rs7617773	0.817	rs34225441	chr3:48308891	T/A	cg11946769	chr3:48343235	NME6	0.69	11.51	0.47	3.75e-27	Coronary artery disease;
LGG	cis	rs11758351	1.000	rs79868973	chr6:26189312	C/G	cg06951627	chr6:26196580	NA	0.53	8.15	0.35	3.34e-15	Gout;Renal underexcretion gout;
LGG	cis	rs7940866	0.817	rs961491	chr11:130866090	G/T	cg12179176	chr11:130786555	SNX19	0.75	13.98	0.54	2.67e-37	Schizophrenia;
LGG	trans	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.74	-0.34	6.2e-14	Joint mobility (Beighton score);
LGG	cis	rs1408799	0.750	rs10756386	chr9:12621004	C/G	cg05274944	chr9:12693694	TYRP1	0.32	7.4	0.33	6.43e-13	Eye color;Blue vs. green eyes;
LGG	trans	rs7246760	0.618	rs73008109	chr19:9734056	C/T	cg02900749	chr2:68251473	NA	-0.98	-9.86	-0.42	6.13e-21	Pursuit maintenance gain;
LGG	cis	rs4926611	0.863	rs7542387	chr1:54078923	A/G	cg23596471	chr1:54105337	GLIS1	0.42	8.17	0.36	2.9e-15	Hand grip strength;
LGG	cis	rs7296418	0.885	rs1051434	chr12:123641200	C/T	cg00376283	chr12:123451042	ABCB9	0.67	12.32	0.5	2.4e-30	Platelet count;
LGG	cis	rs1348850	0.526	rs6718769	chr2:178450909	T/C	cg27490568	chr2:178487706	NA	0.73	12.91	0.51	8.42e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs950776	0.648	rs57945453	chr15:78862845	C/T	cg17108064	chr15:78857060	CHRNA5	0.45	9.38	0.4	2.9e-19	Sudden cardiac arrest;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.97e-12	Prudent dietary pattern;
LGG	cis	rs11098499	0.874	rs6826823	chr4:120112098	G/C	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs6445975	0.666	rs9822328	chr3:58407837	T/C	cg24175188	chr3:58374923	PXK	-0.56	-9.13	-0.39	2.11e-18	Systemic lupus erythematosus;
LGG	cis	rs2201728	0.714	rs13103321	chr4:100220240	G/T	cg07219303	chr4:100140905	ADH6	-0.36	-6.73	-0.3	4.89e-11	Cardiac Troponin-T levels;
LGG	cis	rs7166081	1.000	rs58074225	chr15:67545892	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.81	-0.3	3.12e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4819052	0.851	rs2838834	chr21:46665208	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.41	0.53	7.02e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11252926	0.604	rs12359454	chr10:568081	T/C	cg08603382	chr10:743973	NA	-0.49	-9.42	-0.4	2.23e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs644799	1.000	rs509720	chr11:95562771	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs2204008	0.557	rs11520191	chr12:38197057	T/A	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.35e-17	Bladder cancer;
LGG	cis	rs1801251	1.000	rs4973055	chr2:233720283	G/T	cg25237894	chr2:233734115	C2orf82	-0.66	-12.45	-0.5	6.6e-31	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.37e-16	Lung cancer;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16680214	chr1:154839983	KCNN3	-0.48	-8.98	-0.38	7.07e-18	Prostate cancer;
LGG	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	cis	rs4639966	0.836	rs73001486	chr11:118629364	G/A	cg19182353	chr11:118479428	PHLDB1	-0.53	-8.76	-0.38	3.57e-17	Systemic lupus erythematosus;
LGG	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs9560113	0.764	rs1177401	chr13:112173067	T/C	cg10483660	chr13:112241077	NA	-0.37	-7.27	-0.32	1.51e-12	Menarche (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04364194	chr1:202114085	ARL8A	-0.51	-7.58	-0.33	1.95e-13	Systemic lupus erythematosus;
LGG	cis	rs12912251	1.000	rs12916379	chr15:38991520	A/G	cg10631289	chr15:39006617	NA	0.36	6.76	0.3	4.24e-11	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs1552244	0.572	rs17032440	chr3:10169819	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	0.88	11.77	0.48	3.64e-28	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs55633605	chr4:119761589	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs4671458	0.948	rs12478442	chr2:63556365	A/G	cg17519650	chr2:63277830	OTX1	0.6	7.65	0.34	1.14e-13	Subjective well-being;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg05025164	chr4:1340916	KIAA1530	-0.58	-10.21	-0.43	3.27e-22	Obesity-related traits;
LGG	cis	rs12368653	0.666	rs701007	chr12:58113416	C/A	cg12615879	chr12:58013172	SLC26A10	0.33	7.31	0.32	1.17e-12	Multiple sclerosis;
LGG	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg13770153	chr20:60521292	NA	-0.47	-7.55	-0.33	2.36e-13	Body mass index;
LGG	cis	rs9583531	0.628	rs9521914	chr13:111382231	C/A	cg24331049	chr13:111365604	ING1	0.8	13.78	0.54	1.85e-36	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs1820518	chr15:45694579	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.05	0.35	7.14e-15	Homoarginine levels;
LGG	cis	rs9747201	0.962	rs6502062	chr17:80086177	T/G	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.35	-0.32	8.94e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2486288	0.656	rs11632920	chr15:45551264	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.0	-0.42	1.91e-21	Glomerular filtration rate;
LGG	cis	rs17376456	0.504	rs6898507	chr5:93082343	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs3764563	0.799	rs2017776	chr19:15698229	T/C	cg20725493	chr19:15740067	CYP4F8	0.58	6.82	0.3	2.77e-11	Inflammatory biomarkers;
LGG	cis	rs7267979	0.764	rs2474767	chr20:25246733	T/C	cg06421707	chr20:25228305	PYGB	0.44	9.24	0.39	9.12e-19	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13191362	1.000	rs13209100	chr6:163159350	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.41	0.36	5.31e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2290416	0.892	rs3793369	chr8:144664335	G/A	cg15537850	chr8:144661051	NAPRT1	0.94	7.41	0.33	6.11e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2280018	0.609	rs2941253	chr16:15173746	G/A	cg27102117	chr16:15229624	NA	0.63	12.4	0.5	1.11e-30	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg19635926	chr16:89946313	TCF25	0.71	7.98	0.35	1.13e-14	Skin colour saturation;
LGG	cis	rs7618915	0.524	rs35249778	chr3:52661640	G/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.31	-0.32	1.21e-12	Bipolar disorder;
LGG	cis	rs2180341	0.961	rs7774468	chr6:127592501	G/C	cg24812749	chr6:127587940	RNF146	0.96	15.91	0.59	8.37e-46	Breast cancer;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.09	-0.42	8.78e-22	Obesity-related traits;
LGG	cis	rs74417235	0.610	rs35212808	chr5:154057808	A/G	cg08754654	chr5:154026448	NA	0.53	10.86	0.45	1.22e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs13082711	0.554	rs34066402	chr3:27387987	G/A	cg02860705	chr3:27208620	NA	0.91	16.37	0.61	7.29e-48	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.32	0.4	4.64e-19	Height;
LGG	cis	rs7113874	0.524	rs10769921	chr11:8621143	G/A	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.69e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9467711	0.591	rs13195692	chr6:26044373	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.74	0.34	6.47e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.36	0.36	7.3e-16	Bipolar disorder;
LGG	cis	rs10197940	0.662	rs2432945	chr2:152278414	T/C	cg19508488	chr2:152266495	RIF1	0.57	10.45	0.44	4.45e-23	Lung cancer;
LGG	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.46	0.5	6.1e-31	Colorectal cancer;
LGG	cis	rs11252926	0.605	rs10904075	chr10:425667	A/G	cg19334176	chr10:443029	DIP2C	0.24	6.78	0.3	3.58e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.76	0.34	5.57e-14	Lung cancer;
LGG	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	7.38	0.32	7.38e-13	Educational attainment;
LGG	cis	rs7220401	0.789	rs3760456	chr17:27948844	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-12.15	-0.49	1.13e-29	Coronary artery disease;
LGG	cis	rs6430585	1.000	rs6732236	chr2:136501509	T/G	cg07169764	chr2:136633963	MCM6	0.99	18.68	0.66	1.99e-58	Corneal structure;
LGG	trans	rs7939886	0.920	rs4612826	chr11:55948005	C/A	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs12188164	0.582	rs72700694	chr5:483267	T/C	cg21972741	chr5:435613	AHRR	0.47	7.36	0.32	8.53e-13	Cystic fibrosis severity;
LGG	cis	rs4926298	0.926	rs8111617	chr19:13191461	C/T	cg04657146	chr19:12876947	HOOK2	-0.41	-6.76	-0.3	4.25e-11	Bipolar disorder;
LGG	cis	rs727505	1.000	rs10228201	chr7:124449895	A/G	cg23710748	chr7:124431027	NA	-0.53	-10.13	-0.43	6.5600000000000005e-22	Lewy body disease;
LGG	cis	rs875971	0.862	rs6960446	chr7:65733259	A/G	cg11764359	chr7:65958608	NA	-0.73	-12.87	-0.51	1.29e-32	Aortic root size;
LGG	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg25801113	chr15:45476975	SHF	0.88	20.14	0.68	2.84e-65	Uric acid levels;
LGG	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.47	-9.47	-0.4	1.39e-19	Calcium levels;
LGG	cis	rs1577917	0.740	rs6926049	chr6:86266133	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.26	0.63	6.71e-52	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.520	rs7602923	chr2:99990375	A/G	cg23527387	chr2:100056660	REV1	0.44	9.76	0.41	1.37e-20	Chronic sinus infection;
LGG	cis	rs2270450	0.650	rs9296510	chr6:46713805	C/T	cg10156739	chr6:46714674	LOC100287718	0.47	10.36	0.43	9.42e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg07943548	chr15:86304357	KLHL25	0.34	6.77	0.3	3.8e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-12.79	-0.51	2.67e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4731207	0.724	rs10257255	chr7:124479678	C/T	cg05630886	chr7:124431682	NA	0.34	7.99	0.35	1.11e-14	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.9	-0.42	4.24e-21	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11072887	chr6:37322624	RNF8	0.51	8.41	0.36	5.1e-16	Cognitive performance;
LGG	cis	rs4253772	0.592	rs1807600	chr22:46644640	A/G	cg24881330	chr22:46731750	TRMU	0.59	7.53	0.33	2.6e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg10847948	chr11:71163743	NADSYN1	-0.59	-8.76	-0.38	3.75e-17	Vitamin D levels;
LGG	cis	rs2235642	0.893	rs2076442	chr16:1591112	G/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.43	10.61	0.44	1.14e-23	Coronary artery disease;
LGG	cis	rs738322	0.967	rs133013	chr22:38570912	C/T	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs6840360	0.642	rs7680236	chr4:152409601	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12136530	0.593	rs12404783	chr1:19735885	A/C	cg17081867	chr1:19768096	CAPZB	-0.32	-6.75	-0.3	4.32e-11	Lead levels in blood;
LGG	cis	rs9486719	1.000	rs12212614	chr6:97036466	T/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.8	-0.3	3.21e-11	Migraine;Coronary artery disease;
LGG	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg12011299	chr4:100065546	ADH4	-0.42	-8.08	-0.35	5.67e-15	Alcohol dependence;
LGG	cis	rs9549367	0.713	rs4907599	chr13:113861441	C/T	cg18105134	chr13:113819100	PROZ	0.7	14.97	0.57	1.38e-41	Platelet distribution width;
LGG	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg20387954	chr3:183756860	HTR3D	0.41	7.64	0.33	1.28e-13	Anterior chamber depth;
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.79	-0.34	4.45e-14	Total body bone mineral density;
LGG	cis	rs2576037	0.501	rs8089938	chr18:44459497	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.04	0.35	7.72e-15	Personality dimensions;
LGG	cis	rs4561483	0.549	rs33657	chr16:11969724	G/C	cg08843971	chr16:11963173	GSPT1	-0.64	-16.45	-0.61	3.29e-48	Testicular germ cell tumor;
LGG	cis	rs2635047	0.638	rs2289133	chr18:44602249	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.51	8.8	0.38	2.78e-17	Educational attainment;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg13732083	chr21:47605072	C21orf56	0.46	7.73	0.34	6.85e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.36	7.93	0.35	1.69e-14	Schizophrenia;
LGG	cis	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs6547741	1.000	rs4665381	chr2:27757150	A/C	cg27432699	chr2:27873401	GPN1	0.69	13.99	0.54	2.52e-37	Oral cavity cancer;
LGG	cis	rs2084898	1.000	rs2084897	chr11:120026600	C/T	cg13907859	chr11:120009124	TRIM29	0.85	12.01	0.49	4.06e-29	Stroke (pediatric);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08862778	chr1:11322643	MTOR	0.57	9.85	0.42	6.72e-21	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg13880726	chr7:1868755	MAD1L1	0.41	7.32	0.32	1.12e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.28	0.32	1.45e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg17202724	chr17:61916730	SMARCD2	-0.63	-15.27	-0.58	6.12e-43	Prudent dietary pattern;
LGG	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg18198730	chr1:247681584	NA	0.73	12.54	0.5	3.05e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4819052	0.851	rs7275870	chr21:46671214	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.13	0.52	1.09e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17122278	0.929	rs7126175	chr11:118450875	C/T	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.14e-11	Total cholesterol levels;
LGG	cis	rs1682825	1.000	rs55695942	chr3:10768609	G/A	cg23512531	chr3:10780469	NA	0.58	8.06	0.35	6.5e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs35740288	0.539	rs34362339	chr15:86337628	C/T	cg04173714	chr15:86211321	AKAP13	0.41	6.95	0.31	1.26e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17321999	1.000	rs7604484	chr2:30491556	T/G	cg05247661	chr2:30472410	LBH	0.53	8.27	0.36	1.42e-15	Systemic lupus erythematosus;
LGG	cis	rs11203032	0.831	rs2863216	chr10:90941937	C/T	cg16672925	chr10:90967113	CH25H	0.75	11.18	0.46	7.27e-26	Heart failure;
LGG	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.05	-0.39	4.09e-18	Triglycerides;
LGG	cis	rs7666738	0.830	rs13138063	chr4:99050438	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg23594656	chr7:65796392	TPST1	0.36	8.08	0.35	5.48e-15	Aortic root size;
LGG	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg26384229	chr12:38710491	ALG10B	-0.73	-13.91	-0.54	5.54e-37	Morning vs. evening chronotype;
LGG	cis	rs208520	0.779	rs208446	chr6:66903515	T/C	cg07460842	chr6:66804631	NA	-0.93	-15.1	-0.57	3.38e-42	Exhaled nitric oxide output;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.45	7.65	0.34	1.14e-13	Longevity;
LGG	cis	rs9308731	1.000	rs9308731	chr2:111908262	G/A	cg26001287	chr2:111877753	BCL2L11	-0.38	-7.75	-0.34	5.9e-14	Chronic lymphocytic leukemia;
LGG	cis	rs12410462	0.502	rs78101727	chr1:227732069	C/T	cg23173402	chr1:227635558	NA	0.67	9.59	0.41	5.64e-20	Major depressive disorder;
LGG	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg04607235	chr12:12878440	APOLD1	-0.54	-7.87	-0.34	2.53e-14	Systemic lupus erythematosus;
LGG	cis	rs11148252	0.514	rs9526843	chr13:52730056	C/T	cg16301924	chr13:53314226	LECT1	-0.42	-7.87	-0.34	2.49e-14	Lewy body disease;
LGG	cis	rs1018836	0.923	rs2187982	chr8:91556317	G/T	cg16814680	chr8:91681699	NA	-0.82	-15.69	-0.59	8.71e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.24	-0.32	1.82e-12	Neuroticism;
LGG	cis	rs559928	1.000	rs559928	chr11:64150370	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.55	-7.27	-0.32	1.5e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.67	0.3	7.29e-11	Parkinson's disease;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.5	-0.53	3.06e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs1018836	0.828	rs7014967	chr8:91557843	G/T	cg16814680	chr8:91681699	NA	-0.73	-13.21	-0.52	4.97e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs1348850	0.526	rs2293475	chr2:178407897	C/T	cg27490568	chr2:178487706	NA	-0.79	-13.65	-0.54	6.52e-36	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06470251	chr20:60548479	NA	0.41	7.14	0.31	3.61e-12	Body mass index;
LGG	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg13647721	chr17:30228624	UTP6	0.58	7.48	0.33	3.72e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7617773	0.817	rs35414021	chr3:48293524	G/C	cg11946769	chr3:48343235	NME6	0.69	11.37	0.47	1.33e-26	Coronary artery disease;
LGG	cis	rs4862750	0.874	rs6553027	chr4:187875777	T/C	cg27532560	chr4:187881888	NA	-0.59	-12.93	-0.52	7.23e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg25894440	chr7:65020034	NA	-0.63	-6.67	-0.3	7.32e-11	Diabetic kidney disease;
LGG	cis	rs7155454	0.901	rs7148590	chr14:65473196	G/A	cg26396452	chr14:65542826	MAX	0.36	6.79	0.3	3.5e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10115490	chr5:56111596	MAP3K1	-0.45	-6.8	-0.3	3.16e-11	Pancreatic cancer;
LGG	cis	rs36051895	0.589	rs6476948	chr9:5204404	C/T	cg02405213	chr9:5042618	JAK2	-0.73	-13.28	-0.53	2.59e-34	Pediatric autoimmune diseases;
LGG	cis	rs60871478	1.000	rs34086011	chr7:805430	C/T	cg05535760	chr7:792225	HEATR2	0.78	12.49	0.5	4.91e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs17125944	0.505	rs75194546	chr14:53212069	A/C	cg13660082	chr14:53194042	PSMC6	-0.56	-7.77	-0.34	5.01e-14	Alzheimer's disease (late onset);
LGG	cis	rs10911251	0.528	rs10911266	chr1:183115097	C/T	cg07928641	chr1:182991847	LAMC1	0.46	8.92	0.38	1.06e-17	Colorectal cancer;
LGG	trans	rs7395662	0.791	rs11040136	chr11:48939791	T/G	cg15704280	chr7:45808275	SEPT13	0.48	7.93	0.35	1.61e-14	HDL cholesterol;
LGG	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.19	-0.39	1.37e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs4147929	0.553	rs4147936	chr19:1065197	G/C	cg05372495	chr19:1063624	ABCA7	-0.55	-8.94	-0.38	9.12e-18	Alzheimer's disease (late onset);
LGG	cis	rs8067545	0.750	rs4570919	chr17:20000815	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.8	-0.3	3.32e-11	Schizophrenia;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4663969	0.839	rs17862866	chr2:234610912	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.45	-8.38	-0.36	6.28e-16	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs963731	0.649	rs6716101	chr2:39188510	A/G	cg04010122	chr2:39346883	SOS1	-0.79	-7.01	-0.31	8.73e-12	Corticobasal degeneration;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-6.74	-0.3	4.69e-11	Lung cancer;
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs2587949	0.593	rs1444050	chr3:4200077	C/A	cg16519197	chr3:4211558	NA	0.33	6.98	0.31	1.06e-11	Periodontitis (DPAL);
LGG	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg02574844	chr11:5959923	NA	-0.54	-8.77	-0.38	3.53e-17	DNA methylation (variation);
LGG	cis	rs721399	1.000	rs4244446	chr8:18262518	C/T	cg18736775	chr8:18248649	NAT2	0.5	8.83	0.38	2.1e-17	Blood metabolite levels;
LGG	cis	rs6088580	0.634	rs6059835	chr20:33020141	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs60843830	1.000	rs62114548	chr2:274672	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.4	0.56	4.23e-39	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg08085267	chr17:45401833	C17orf57	-0.62	-12.22	-0.49	5.74e-30	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.36	-0.36	7.28e-16	Life satisfaction;
LGG	cis	rs2404602	0.669	rs17464903	chr15:77195486	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.22e-19	Blood metabolite levels;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg01570182	chr17:44337453	NA	0.71	11.86	0.48	1.63e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg04008888	chr11:68622739	NA	-0.31	-6.79	-0.3	3.46e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1005277	0.579	rs2505194	chr10:38393881	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.24	-0.32	1.94e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.77	-0.3	3.88e-11	Mean platelet volume;
LGG	cis	rs6066825	0.644	rs6019380	chr20:47318845	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.07	0.35	5.97e-15	Colorectal cancer;
LGG	trans	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.39	8.14	0.35	3.65e-15	Obesity-related traits;
LGG	cis	rs2180341	0.782	rs4487601	chr6:127723521	A/G	cg27446573	chr6:127587934	RNF146	0.9	17.11	0.62	3.38e-51	Breast cancer;
LGG	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.07	0.42	1.08e-21	Dupuytren's disease;
LGG	cis	rs1401999	0.898	rs4148561	chr3:183726379	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.16	0.6	6.61e-47	Anterior chamber depth;
LGG	cis	rs12519773	0.576	rs1496337	chr5:92411293	C/T	cg18783429	chr5:92414398	NA	0.31	7.45	0.33	4.61e-13	Migraine;
LGG	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.49	0.33	3.5e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs910316	1.000	rs12879542	chr14:75507525	C/T	cg11812906	chr14:75593930	NEK9	0.53	9.7	0.41	2.27e-20	Height;
LGG	trans	rs17685	0.753	rs4732595	chr7:75755139	A/G	cg19862616	chr7:65841803	NCRNA00174	1.08	25.92	0.77	3.61e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg22907277	chr7:1156413	C7orf50	0.63	11.41	0.47	9.74e-27	Longevity;Endometriosis;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.52	-0.44	2.35e-23	Total body bone mineral density;
LGG	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.76	-0.38	3.84e-17	Triglycerides;
LGG	cis	rs11711311	1.000	rs12497716	chr3:113453258	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.23	0.52	3.87e-34	IgG glycosylation;
LGG	cis	rs4974559	0.744	rs10024529	chr4:1363886	G/A	cg02980000	chr4:1222292	CTBP1	0.79	8.75	0.38	3.92e-17	Systolic blood pressure;
LGG	cis	rs13102973	0.614	rs56199725	chr4:135873448	T/C	cg14419869	chr4:135874104	NA	-0.49	-8.42	-0.36	4.93e-16	Subjective well-being;
LGG	cis	rs713587	0.563	rs11686663	chr2:25107759	C/T	cg04586622	chr2:25135609	ADCY3	0.43	11.59	0.47	1.82e-27	Body mass index in non-asthmatics;
LGG	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg09307838	chr4:120376055	NA	0.68	11.74	0.48	4.89e-28	Educational attainment;
LGG	cis	rs11608355	0.515	rs6606727	chr12:109941450	T/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.718	rs1599383	chr3:160829820	T/C	cg04691961	chr3:161091175	C3orf57	-0.52	-11.36	-0.47	1.48e-26	Morning vs. evening chronotype;
LGG	cis	rs887829	0.569	rs4148326	chr2:234673462	T/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.41	-7.6	-0.33	1.7e-13	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg21775007	chr8:11205619	TDH	-0.5	-8.15	-0.35	3.31e-15	Neuroticism;
LGG	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg13010199	chr12:38710504	ALG10B	0.7	14.31	0.55	9.98e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.82	0.59	2.3e-45	Lung cancer;
LGG	cis	rs1506636	0.962	rs10273985	chr7:123309538	A/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs17767392	0.958	rs12892512	chr14:71983296	G/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.13	0.39	2.12e-18	Mitral valve prolapse;
LGG	cis	rs4566357	0.595	rs10201538	chr2:227914449	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.09	-0.39	2.93e-18	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7818345	0.540	rs4623445	chr8:19347184	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.43	10.04	0.42	1.38e-21	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg00830817	chr11:109293614	C11orf87	0.43	6.94	0.31	1.37e-11	Schizophrenia;
LGG	cis	rs60871478	1.000	rs35488064	chr7:812722	G/C	cg05535760	chr7:792225	HEATR2	0.79	12.65	0.51	1.03e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs77686669	1	rs77686669	chr7:99744572	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.56	8.67	0.37	7.3e-17	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg15971980	chr6:150254442	NA	0.46	9.15	0.39	1.87e-18	Testicular germ cell tumor;
LGG	cis	rs7172689	0.909	rs58607573	chr15:81542671	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.63	-0.44	9.32e-24	Inattentive symptoms;
LGG	cis	rs7829975	0.633	rs2979181	chr8:8323088	A/T	cg14979609	chr8:8086686	FLJ10661	-0.3	-7.64	-0.33	1.28e-13	Mood instability;
LGG	trans	rs1032833	0.732	rs6433766	chr2:180037793	G/C	cg23654767	chr2:101192981	PDCL3	0.55	7.09	0.31	5.02e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2717559	0.561	rs7841267	chr8:143881683	A/C	cg06565975	chr8:143823917	SLURP1	-0.29	-7.09	-0.31	4.95e-12	Urinary tract infection frequency;
LGG	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2635047	1.000	rs9304341	chr18:44670263	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.19	0.32	2.59e-12	Educational attainment;
LGG	trans	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg26384229	chr12:38710491	ALG10B	0.6	11.22	0.46	5.45e-26	Morning vs. evening chronotype;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg01758870	chr7:23719630	C7orf46	-0.31	-6.92	-0.31	1.5e-11	Schizophrenia;
LGG	trans	rs9784649	0.760	rs17403440	chr5:25054004	C/T	cg11038491	chr20:34638489	LOC647979	-0.7	-10.2	-0.43	3.73e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-6.92	-0.31	1.52e-11	Systemic lupus erythematosus;
LGG	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs6723226	0.750	rs10182170	chr2:32704186	G/A	cg02381751	chr2:32503542	YIPF4	0.68	11.76	0.48	4.07e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2624839	0.704	rs2624833	chr3:50212512	G/T	cg05623727	chr3:50126028	RBM5	0.35	6.71	0.3	5.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg17644776	chr2:200775616	C2orf69	-0.67	-9.2	-0.39	1.25e-18	Schizophrenia;
LGG	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg08400814	chr5:56204995	C5orf35	-0.47	-7.53	-0.33	2.76e-13	Initial pursuit acceleration;
LGG	cis	rs11190604	0.767	rs10509743	chr10:102190406	C/T	cg07570687	chr10:102243282	WNT8B	0.4	7.27	0.32	1.57e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4642101	0.824	rs3889514	chr3:12844072	T/C	cg05775895	chr3:12838266	CAND2	0.69	12.77	0.51	3.3e-32	QRS complex (12-leadsum);
LGG	cis	rs760805	1.000	rs11249204	chr1:25261740	C/T	cg03961551	chr1:25251730	RUNX3	-0.47	-12.1	-0.49	1.85e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9287719	0.934	rs6727884	chr2:10757557	C/T	cg02196655	chr2:10830764	NOL10	0.44	7.46	0.33	4.39e-13	Prostate cancer;
LGG	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.3e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs950169	0.724	rs11632668	chr15:84948687	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.16e-17	Schizophrenia;
LGG	cis	rs9923856	0.614	rs2241099	chr16:11225064	C/G	cg16765268	chr16:11229200	CLEC16A	0.37	6.8	0.3	3.31e-11	Atopic dermatitis;Adult asthma;
LGG	cis	rs41271473	0.948	rs17437060	chr1:228822374	C/T	cg16512390	chr1:228756714	NA	0.5	6.69	0.3	6.31e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg03264133	chr6:25882463	NA	-0.38	-6.66	-0.3	7.76e-11	Height;
LGG	cis	rs3858526	0.523	rs10769289	chr11:5886607	C/T	cg13902645	chr11:5959945	NA	-0.68	-11.81	-0.48	2.61e-28	DNA methylation (variation);
LGG	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11890956	chr21:40555474	PSMG1	1.17	29.22	0.81	3.69e-107	Cognitive function;
LGG	cis	rs2204008	0.540	rs3908193	chr12:38410907	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.29	-0.4	6.01e-19	Bladder cancer;
LGG	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg11995313	chr8:8860691	ERI1	0.46	7.81	0.34	3.88e-14	Joint mobility (Beighton score);
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17401966	0.931	rs912961	chr1:10356848	A/G	cg15208524	chr1:10270712	KIF1B	0.44	7.67	0.34	1.05e-13	Hepatocellular carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14099293	chr6:38607245	BTBD9	0.47	6.9	0.31	1.75e-11	Gut microbiome composition (summer);
LGG	cis	rs11673344	0.864	rs2562587	chr19:37510259	C/T	cg27390819	chr19:37464633	NA	-0.37	-6.65	-0.3	8.17e-11	Obesity-related traits;
LGG	cis	rs875971	1.000	rs55962648	chr7:65625751	C/G	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.39e-16	Aortic root size;
LGG	cis	rs6089584	0.888	rs6061981	chr20:60618973	T/C	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.94	-0.31	1.35e-11	Neuroticism;
LGG	cis	rs208520	1.000	rs12191598	chr6:66983962	T/C	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs7336332	0.800	rs9805452	chr13:28047908	C/T	cg01674679	chr13:27998804	GTF3A	-0.54	-7.64	-0.33	1.28e-13	Weight;
LGG	cis	rs62238980	0.522	rs117390331	chr22:32461489	T/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg08989290	chr16:615782	NHLRC4	0.32	6.66	0.3	7.72e-11	Height;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg17178900	chr1:205818956	PM20D1	0.58	13.06	0.52	2.03e-33	Menarche (age at onset);
LGG	cis	rs1799949	0.602	rs8176235	chr17:41219560	C/T	cg25072359	chr17:41440525	NA	0.47	7.67	0.34	1.06e-13	Menopause (age at onset);
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.52	0.47	3.53e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs5758511	0.680	rs1107553	chr22:42667473	A/G	cg15128208	chr22:42549153	NA	0.73	11.56	0.47	2.5e-27	Birth weight;
LGG	cis	rs858239	0.601	rs4599714	chr7:23168801	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.09	0.31	5.1e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.19e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg15440763	chr7:158190612	PTPRN2	0.54	11.54	0.47	2.98e-27	Obesity-related traits;
LGG	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg23306229	chr2:178417860	TTC30B	-0.71	-8.51	-0.37	2.45e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9560113	1.000	rs11620313	chr13:112179363	G/A	cg14952266	chr13:112191215	NA	-0.41	-7.55	-0.33	2.42e-13	Menarche (age at onset);
LGG	cis	rs3733585	0.699	rs7435196	chr4:9967556	A/C	cg08250081	chr4:10125330	NA	-0.37	-7.16	-0.32	3.25e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1153858	0.848	rs9806699	chr15:45740392	G/A	cg21132104	chr15:45694354	SPATA5L1	0.6	8.52	0.37	2.32e-16	Homoarginine levels;
LGG	trans	rs61931739	0.635	rs1405024	chr12:33937939	A/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.47	-0.37	3.19e-16	Morning vs. evening chronotype;
LGG	cis	rs9902453	0.765	rs2628191	chr17:28051140	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.16	-0.55	4.39e-38	Coffee consumption (cups per day);
LGG	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.37	6.71	0.3	5.61e-11	IgG glycosylation;
LGG	cis	rs12220238	0.915	rs11001014	chr10:76128832	A/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.71	-8.96	-0.38	7.72e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18404041	chr3:52824283	ITIH1	-0.39	-7.34	-0.32	9.93e-13	Electroencephalogram traits;
LGG	cis	rs2762353	0.639	rs566530	chr6:25878361	T/C	cg18357526	chr6:26021779	HIST1H4A	0.56	9.58	0.41	6.01e-20	Blood metabolite levels;
LGG	cis	rs4481887	0.927	rs4460676	chr1:248431781	G/A	cg00666640	chr1:248458726	OR2T12	0.6	9.53	0.4	9.2e-20	Common traits (Other);
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.27e-12	Bipolar disorder;
LGG	cis	rs557514	1.000	rs557514	chr1:182404684	A/G	cg26135716	chr1:182360902	GLUL	0.42	6.98	0.31	1.06e-11	Common carotid intima-media thickness;
LGG	trans	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg06636001	chr8:8085503	FLJ10661	0.49	8.91	0.38	1.16e-17	Retinal vascular caliber;
LGG	cis	rs300703	0.678	rs423643	chr2:199648	A/C	cg24565620	chr2:194026	NA	-0.69	-10.46	-0.44	4.12e-23	Blood protein levels;
LGG	cis	rs3008870	0.958	rs12131222	chr1:67438535	A/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.04	-0.35	7.69e-15	HDL cholesterol;
LGG	cis	rs35160687	0.644	rs4832265	chr2:86488265	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.9	0.31	1.74e-11	Night sleep phenotypes;
LGG	cis	rs929843	1	rs929843	chr16:70045748	A/C	cg09409435	chr16:70099608	PDXDC2	0.89	14.99	0.57	1.04e-41	Menarche (age at onset);
LGG	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-8.45	-0.37	3.75e-16	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg16141378	chr3:129829833	LOC729375	0.36	7.77	0.34	4.98e-14	Retinal vascular caliber;
LGG	trans	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.54	0.44	2.08e-23	Lewy body disease;
LGG	trans	rs7181230	0.885	rs28736699	chr15:40347435	A/C	cg22705835	chr10:65332833	REEP3	-0.62	-10.17	-0.43	4.67e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs2032447	0.839	rs199751	chr6:26015583	T/C	cg03264133	chr6:25882463	NA	-0.67	-12.3	-0.5	2.75e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg21775007	chr8:11205619	TDH	0.45	7.44	0.33	5.03e-13	Mood instability;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01973725	chr5:80608537	RNU5E;RNU5D;ZCCHC9	-0.59	-7.0	-0.31	8.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg07701084	chr6:150067640	NUP43	0.61	11.3	0.47	2.47e-26	Lung cancer;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.29e-23	Prudent dietary pattern;
LGG	cis	rs539514	0.550	rs2328956	chr13:76294595	G/A	cg04757411	chr13:76259545	LMO7	-0.27	-7.07	-0.31	5.75e-12	Type 1 diabetes;
LGG	cis	rs826838	1.000	rs9795768	chr12:39012479	T/C	cg13010199	chr12:38710504	ALG10B	0.75	15.74	0.59	4.92e-45	Heart rate;
LGG	cis	rs4642101	0.824	rs9835677	chr3:12845158	G/A	cg05775895	chr3:12838266	CAND2	0.69	12.67	0.51	8.53e-32	QRS complex (12-leadsum);
LGG	cis	rs35740288	0.787	rs11635418	chr15:86244178	C/G	cg07943548	chr15:86304357	KLHL25	-0.37	-7.12	-0.31	4.07e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9290065	0.519	rs10936216	chr3:160698314	G/C	cg03342759	chr3:160939853	NMD3	-0.54	-9.23	-0.39	9.7e-19	Kawasaki disease;
LGG	cis	rs9322193	0.962	rs9767122	chr6:150104689	T/G	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	4.96e-31	Lung cancer;
LGG	cis	rs12360000	0.830	rs11250863	chr10:1912417	T/A	cg26364871	chr10:1889757	NA	-0.72	-13.63	-0.54	8.07e-36	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs208520	0.690	rs3899423	chr6:66835285	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.11	-0.62	3.27e-51	Exhaled nitric oxide output;
LGG	cis	rs2204008	0.685	rs4556621	chr12:38187236	C/A	cg26384229	chr12:38710491	ALG10B	0.97	22.03	0.72	4.21e-74	Bladder cancer;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.87	0.51	1.28e-32	Prudent dietary pattern;
LGG	cis	rs7408868	1.000	rs7408868	chr19:15285679	G/C	cg14696996	chr19:15285081	NOTCH3	1.03	12.33	0.5	2.18e-30	Pulse pressure;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg11965913	chr1:205819406	PM20D1	-0.68	-14.55	-0.56	9.48e-40	Monocyte percentage of white cells;
LGG	cis	rs7923609	0.967	rs10761752	chr10:65160321	T/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.86e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9291683	0.595	rs35501905	chr4:10053431	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.08e-11	Bone mineral density;
LGG	cis	rs6580649	0.941	rs1859441	chr12:48423233	C/T	cg24011408	chr12:48396354	COL2A1	-0.56	-6.92	-0.31	1.55e-11	Lung cancer;
LGG	trans	rs4942242	1.000	rs7335094	chr13:44223936	T/C	cg19169023	chr15:41853346	TYRO3	-0.32	-6.81	-0.3	2.99e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs796364	0.951	rs6722092	chr2:201059371	G/T	cg23649088	chr2:200775458	C2orf69	0.57	8.46	0.37	3.47e-16	Schizophrenia;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2463822	1.000	rs2513749	chr11:62105391	C/T	cg06239285	chr11:62104954	ASRGL1	1.13	15.88	0.59	1.25e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs757081	0.667	rs17561348	chr11:17161615	C/T	cg15432903	chr11:17409602	KCNJ11	0.54	9.0	0.39	5.71e-18	Systolic blood pressure;
LGG	cis	rs9878978	0.722	rs35000138	chr3:2437233	C/T	cg21928760	chr3:2462534	CNTN4	0.46	8.88	0.38	1.49e-17	Blood pressure (smoking interaction);
LGG	cis	rs2712184	0.660	rs10164732	chr2:217645669	A/T	cg05032264	chr2:217675019	NA	0.41	9.1	0.39	2.63e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg19671926	chr4:122722719	EXOSC9	0.53	8.14	0.35	3.79e-15	Type 2 diabetes;
LGG	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg07928641	chr1:182991847	LAMC1	0.49	10.0	0.42	1.85e-21	Colorectal cancer;
LGG	cis	rs826838	0.616	rs10880738	chr12:38617762	C/T	cg13010199	chr12:38710504	ALG10B	-0.55	-11.04	-0.46	2.6e-25	Heart rate;
LGG	cis	rs2282300	0.653	rs67745574	chr11:30234839	C/T	cg25418670	chr11:30344373	C11orf46	-0.57	-7.76	-0.34	5.49e-14	Morning vs. evening chronotype;
LGG	cis	rs9902453	1.000	rs57411618	chr17:28273052	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.64	0.54	7.51e-36	Coffee consumption (cups per day);
LGG	cis	rs7264396	0.635	rs6060703	chr20:34529906	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.05	-0.31	6.39e-12	Total cholesterol levels;
LGG	cis	rs9309473	0.607	rs10196402	chr2:73572081	A/C	cg20560298	chr2:73613845	ALMS1	-0.46	-8.41	-0.36	5.13e-16	Metabolite levels;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.68	0.3	6.95e-11	Alzheimer's disease;
LGG	cis	rs994014	0.572	rs1452366	chr4:82252467	G/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.83	-0.3	2.64e-11	Height;
LGG	cis	rs11711311	1.000	rs9809850	chr3:113429010	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.11	0.55	7.2e-38	IgG glycosylation;
LGG	cis	rs4330281	0.626	rs9883518	chr3:17485883	T/C	cg20981856	chr3:17787350	NA	0.35	6.74	0.3	4.87e-11	Schizophrenia;
LGG	cis	rs2243480	0.908	rs313822	chr7:65573939	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.61	-0.69	1.84e-67	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25326283	chr20:44509818	ZSWIM1	0.5	7.51	0.33	3.1e-13	Gut microbiome composition (summer);
LGG	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg23131131	chr22:24373011	LOC391322	0.49	8.04	0.35	7.78e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15596359	chr8:11213517	TDH	0.42	8.7	0.37	5.71e-17	Retinal vascular caliber;
LGG	cis	rs8072100	0.754	rs8081717	chr17:45653921	T/A	cg08085267	chr17:45401833	C17orf57	0.62	12.8	0.51	2.45e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg19847130	chr8:10466454	RP1L1	0.3	6.7	0.3	6.23e-11	Joint mobility (Beighton score);
LGG	cis	rs476633	0.708	rs3986303	chr15:41443179	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.72	-11.7	-0.48	7.15e-28	Glomerular filtration rate (creatinine);
LGG	trans	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.61	-0.33	1.59e-13	Joint mobility (Beighton score);
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-9.07	-0.39	3.42e-18	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg12654349	chr5:56205094	C5orf35	-0.62	-9.78	-0.41	1.15e-20	Initial pursuit acceleration;
LGG	cis	rs561341	0.700	rs2074101	chr17:30228656	G/A	cg00745463	chr17:30367425	LRRC37B	-0.46	-7.17	-0.32	2.92e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4242434	0.927	rs3735894	chr8:22454826	A/G	cg03733263	chr8:22462867	KIAA1967	1.09	28.42	0.8	1.53e-103	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6694672	0.850	rs4915156	chr1:197062820	A/T	cg13682187	chr1:196946512	CFHR5	0.51	7.1	0.31	4.85e-12	Asthma;
LGG	cis	rs1005277	0.505	rs13503	chr10:38239843	C/A	cg18963800	chr10:38644991	HSD17B7P2	0.44	7.28	0.32	1.41e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10540	1.000	rs35255804	chr11:492617	G/A	cg03352830	chr11:487213	PTDSS2	0.87	11.24	0.46	4.24e-26	Body mass index;
LGG	cis	rs9513627	0.920	rs73556201	chr13:100128753	C/G	cg15490075	chr13:100150979	NA	-0.69	-7.22	-0.32	2.17e-12	Obesity-related traits;
LGG	cis	rs12477438	0.559	rs6733285	chr2:99725575	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.74	15.4	0.58	1.63e-43	Chronic sinus infection;
LGG	cis	rs801193	1.000	rs7782320	chr7:66177098	C/T	cg00343986	chr7:65444356	GUSB	0.4	6.87	0.3	2.06e-11	Aortic root size;
LGG	cis	rs1949733	0.554	rs4259044	chr4:8536188	A/G	cg11789530	chr4:8429930	ACOX3	-0.51	-8.4	-0.36	5.52e-16	Response to antineoplastic agents;
LGG	cis	rs283228	1.000	rs2518175	chr6:101813085	A/T	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs2275620	0.966	rs6583969	chr10:96826245	G/A	cg09036531	chr10:96991505	NA	-0.42	-7.31	-0.32	1.17e-12	Gout;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg20607798	chr8:58055168	NA	0.67	7.39	0.32	7.05e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg19980929	chr12:42632907	YAF2	0.36	8.06	0.35	6.66e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6088580	0.524	rs6142210	chr20:33223012	C/T	cg07148914	chr20:33460835	GGT7	-0.52	-8.44	-0.37	4.02e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.3	-0.36	1.13e-15	Total body bone mineral density;
LGG	cis	rs7208859	0.623	rs11657369	chr17:29136468	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4604732	0.603	rs10925051	chr1:247641834	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.51	8.48	0.37	3.12e-16	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2985684	0.901	rs7146248	chr14:50112067	C/T	cg04989706	chr14:50066350	PPIL5	-0.52	-8.1	-0.35	5.08e-15	Carotid intima media thickness;
LGG	cis	rs997295	0.529	rs12592315	chr15:68040266	A/G	cg08079166	chr15:68083412	MAP2K5	-0.3	-6.65	-0.3	8.42e-11	Motion sickness;
LGG	cis	rs9790314	0.663	rs10513559	chr3:160667465	G/A	cg03342759	chr3:160939853	NMD3	0.45	7.57	0.33	1.98e-13	Morning vs. evening chronotype;
LGG	cis	rs941873	0.805	rs10762860	chr10:81117794	C/G	cg09469691	chr10:81107165	PPIF	0.56	9.64	0.41	3.75e-20	Height;
LGG	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.28	-0.36	1.33e-15	Body mass index;
LGG	cis	rs7681440	0.746	rs1442134	chr4:90819154	A/G	cg14346243	chr4:90757452	SNCA	-0.35	-7.05	-0.31	6.46e-12	Dementia with Lewy bodies;
LGG	cis	rs11122272	0.735	rs2739506	chr1:231529183	T/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs9527	0.590	rs34104646	chr10:104896078	T/A	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs9398803	0.865	rs1538171	chr6:126752884	C/G	cg19875578	chr6:126661172	C6orf173	0.58	10.57	0.44	1.49e-23	Male-pattern baldness;
LGG	cis	rs3820928	0.692	rs2396434	chr2:227775223	G/T	cg11843606	chr2:227700838	RHBDD1	-0.56	-10.39	-0.43	7.13e-23	Pulmonary function;
LGG	cis	rs17826219	0.636	rs8080829	chr17:29058730	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.36	0.32	8.46e-13	Body mass index;
LGG	cis	rs7267979	0.844	rs6083845	chr20:25388090	G/C	cg06421707	chr20:25228305	PYGB	-0.43	-9.0	-0.39	5.84e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1580019	0.885	rs4460270	chr7:32496450	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs11168618	0.626	rs2731094	chr12:48881661	C/T	cg24011408	chr12:48396354	COL2A1	-0.42	-6.68	-0.3	6.96e-11	Adiponectin levels;
LGG	cis	rs9879311	0.522	rs6442169	chr3:10430862	A/G	cg21387009	chr3:10280255	IRAK2	-0.39	-6.71	-0.3	5.69e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4253772	0.744	rs4253760	chr22:46622384	T/G	cg24881330	chr22:46731750	TRMU	0.58	7.22	0.32	2.22e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1801251	0.964	rs12472839	chr2:233559615	A/G	cg25237894	chr2:233734115	C2orf82	0.63	11.51	0.47	4.09e-27	Coronary artery disease;
LGG	trans	rs61931739	0.500	rs11052966	chr12:34019826	C/T	cg13010199	chr12:38710504	ALG10B	0.52	10.06	0.42	1.13e-21	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg16507663	chr6:150244633	RAET1G	0.51	10.24	0.43	2.53e-22	Testicular germ cell tumor;
LGG	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg08400814	chr5:56204995	C5orf35	-0.42	-6.87	-0.3	2.05e-11	Initial pursuit acceleration;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg24829409	chr8:58192753	C8orf71	-0.89	-13.53	-0.53	2.31e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg14403583	chr14:105418241	AHNAK2	0.74	15.17	0.58	1.8e-42	Rheumatoid arthritis;
LGG	trans	rs11088226	1.000	rs11088226	chr21:33925531	C/G	cg09050820	chr6:167586206	TCP10L2	0.67	9.62	0.41	4.13e-20	Gastritis;
LGG	cis	rs7712401	0.601	rs4555798	chr5:122332114	C/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs6500602	0.627	rs1641866	chr16:4593040	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.39	7.93	0.35	1.65e-14	Schizophrenia;
LGG	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg02733842	chr7:1102375	C7orf50	-0.45	-6.92	-0.31	1.5e-11	Bronchopulmonary dysplasia;
LGG	cis	rs9921222	1.000	rs9921222	chr16:375782	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.38	-6.91	-0.31	1.56e-11	Bone mineral density (spine);Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09233161	chr9:37079712	NA	0.47	6.85	0.3	2.3e-11	Gut microbiome composition (summer);
LGG	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg01620082	chr3:125678407	NA	-0.99	-9.71	-0.41	2.01e-20	Depression;
LGG	cis	rs2836950	0.762	rs8134638	chr21:40644170	T/C	cg11644478	chr21:40555479	PSMG1	-0.56	-9.02	-0.39	5.06e-18	Menarche (age at onset);
LGG	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-15.62	-0.59	1.82e-44	Chronic sinus infection;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg08677398	chr8:58056175	NA	0.47	6.9	0.31	1.69e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12545912	0.710	rs10903317	chr8:9555907	A/C	cg16141378	chr3:129829833	LOC729375	0.33	6.91	0.31	1.59e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg16680214	chr1:154839983	KCNN3	-0.44	-8.52	-0.37	2.2e-16	Prostate cancer;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg05368731	chr17:41323189	NBR1	0.9	17.77	0.64	3.19e-54	Menopause (age at onset);
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg14092988	chr3:52407081	DNAH1	-0.3	-8.11	-0.35	4.71e-15	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.05	0.39	3.98e-18	Alzheimer's disease;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	13.9	0.54	6.12e-37	Platelet count;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg14196790	chr5:131705035	SLC22A5	0.56	7.05	0.31	6.66e-12	Rheumatoid arthritis;
LGG	cis	rs561341	1.000	rs484175	chr17:30309041	G/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg24523585	chr13:49821926	CDADC1	0.39	6.81	0.3	3.09e-11	Bilirubin levels;
LGG	cis	rs2380220	0.516	rs7748108	chr6:96008082	T/C	cg04719120	chr6:96025338	MANEA	0.5	7.67	0.34	1.06e-13	Behavioural disinhibition (generation interaction);
LGG	trans	rs9393777	0.513	rs6904071	chr6:27047256	G/A	cg06606381	chr12:133084897	FBRSL1	-0.59	-7.07	-0.31	5.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg13114125	chr14:105738426	BRF1	-0.83	-16.28	-0.6	1.82e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg07308232	chr7:1071921	C7orf50	-0.52	-9.8	-0.41	9.71e-21	Longevity;Endometriosis;
LGG	cis	rs11264213	0.901	rs67641270	chr1:36413329	T/C	cg27506609	chr1:36549197	TEKT2	0.66	8.33	0.36	9e-16	Schizophrenia;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg23034840	chr1:205782522	SLC41A1	0.54	8.73	0.38	4.72e-17	Menarche (age at onset);
LGG	cis	rs7512552	0.839	rs1694385	chr1:150377960	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg22509189	chr2:225307070	NA	0.61	9.68	0.41	2.67e-20	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs5769707	0.604	rs1018814	chr22:50036900	T/C	cg06623630	chr22:50017776	C22orf34	-0.5	-10.05	-0.42	1.24e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs988958	0.958	rs13001171	chr2:42279071	C/T	cg27252766	chr2:42229092	NA	0.47	7.73	0.34	6.83e-14	Hypospadias;
LGG	cis	rs67311347	1.000	rs11714912	chr3:40494065	A/G	cg13683864	chr3:40499215	RPL14	1.01	21.69	0.71	1.72e-72	Renal cell carcinoma;
LGG	cis	rs6840360	0.571	rs6811676	chr4:152562726	T/C	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	1.000	rs9747668	chr17:80161081	A/G	cg13939156	chr17:80058883	NA	-0.39	-7.08	-0.31	5.26e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.47	0.69	8.81e-67	Platelet count;
LGG	cis	rs11098499	0.739	rs9884728	chr4:120127079	C/T	cg09307838	chr4:120376055	NA	-0.59	-9.53	-0.41	8.74e-20	Corneal astigmatism;
LGG	cis	rs9952991	0.599	rs12968719	chr18:12879466	G/A	cg23598886	chr18:12777645	NA	-0.56	-6.7	-0.3	6.05e-11	Inflammatory skin disease;
LGG	cis	rs4589502	0.800	rs2035150	chr15:67201794	A/C	cg09911534	chr15:67153556	NA	0.5	6.91	0.31	1.6e-11	Lung cancer (smoking interaction);
LGG	cis	rs796364	0.806	rs203765	chr2:200903020	G/A	cg23649088	chr2:200775458	C2orf69	-0.57	-7.03	-0.31	7.36e-12	Schizophrenia;
LGG	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.41	-7.39	-0.32	6.9e-13	Colorectal cancer;
LGG	cis	rs8017423	0.586	rs2896134	chr14:90831293	G/A	cg04374321	chr14:90722782	PSMC1	-0.63	-12.3	-0.5	2.69e-30	Mortality in heart failure;
LGG	cis	rs1371867	0.875	rs962452	chr8:101331369	G/A	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs597583	0.806	rs1940039	chr11:117393102	C/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.39	-0.36	5.76e-16	Putamen volume;
LGG	cis	rs1865760	0.602	rs9467662	chr6:26021327	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.12	0.43	6.75e-22	Height;
LGG	cis	rs2669010	1.000	rs2632233	chr12:76992831	G/A	cg14998926	chr12:77026162	NA	-0.38	-6.82	-0.3	2.9100000000000002e-11	Systemic lupus erythematosus;
LGG	cis	rs877282	0.755	rs11253399	chr10:790030	T/A	cg17470449	chr10:769945	NA	0.53	6.96	0.31	1.14e-11	Uric acid levels;
LGG	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg00599393	chr8:22457479	C8orf58	-0.43	-7.83	-0.34	3.31e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1401999	0.668	rs6806313	chr3:183642152	G/C	cg20387954	chr3:183756860	HTR3D	0.49	9.75	0.41	1.53e-20	Anterior chamber depth;
LGG	cis	rs11608355	0.515	rs7971160	chr12:109946751	T/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs9297145	0.761	rs62473005	chr7:98742510	G/C	cg05967295	chr7:98741636	SMURF1	0.92	15.17	0.58	1.76e-42	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg16141378	chr3:129829833	LOC729375	-0.35	-8.32	-0.36	1.02e-15	Monocyte count;
LGG	cis	rs7166081	1.000	rs8030620	chr15:67620665	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.12	-0.31	4.28e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg12219531	chr12:120966889	COQ5	0.68	11.19	0.46	6.86e-26	High light scatter reticulocyte count;
LGG	cis	rs9649465	0.967	rs13244694	chr7:123329879	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.81	-0.38	2.61e-17	Migraine;
LGG	cis	rs9611565	0.659	rs9611604	chr22:41916001	C/G	cg06850241	chr22:41845214	NA	-0.46	-7.01	-0.31	8.24e-12	Vitiligo;
LGG	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.54	-0.56	1.03e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg12432903	chr7:1882776	MAD1L1	0.45	7.05	0.31	6.57e-12	Bipolar disorder;
LGG	cis	rs7827545	0.701	rs6577655	chr8:135593725	C/T	cg17885191	chr8:135476712	NA	0.49	7.8	0.34	4.25e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg26666090	chr16:58549219	SETD6	1.13	10.05	0.42	1.3e-21	Schizophrenia;
LGG	cis	rs3806843	0.576	rs246043	chr5:140330924	G/A	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19717773	chr7:2847554	GNA12	-0.32	-6.67	-0.3	7.17e-11	Height;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs721917	0.525	rs2246111	chr10:81689741	G/T	cg25562619	chr10:81652821	NA	-0.34	-7.65	-0.33	1.21e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg24829409	chr8:58192753	C8orf71	-0.8	-11.39	-0.47	1.16e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24165667	chr5:71616247	PTCD2;MRPS27	0.51	8.01	0.35	9.33e-15	Gut microbiome composition (summer);
LGG	cis	rs911555	0.755	rs2756132	chr14:103967820	C/G	cg24130564	chr14:104152367	KLC1	0.38	7.2	0.32	2.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs113835537	0.529	rs57691879	chr11:66236604	C/T	cg24851651	chr11:66362959	CCS	0.43	7.58	0.33	1.97e-13	Airway imaging phenotypes;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.36	6.8	0.3	3.3e-11	Schizophrenia;
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg03517284	chr6:25882590	NA	-0.39	-7.01	-0.31	8.5e-12	Height;
LGG	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.1	0.46	1.46e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg05091796	chr16:4465799	CORO7	-0.82	-13.73	-0.54	3.05e-36	Schizophrenia;
LGG	cis	rs6500602	0.727	rs4786510	chr16:4571247	A/G	cg08645402	chr16:4508243	NA	0.51	9.8	0.41	1.01e-20	Schizophrenia;
LGG	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.72	-0.3	5.28e-11	Electroencephalogram traits;
LGG	cis	rs1506636	0.962	rs7811830	chr7:123320183	G/C	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg24623649	chr8:11872141	NA	-0.29	-6.82	-0.3	2.84e-11	Systolic blood pressure;
LGG	cis	rs9534288	0.699	rs1409433	chr13:46655501	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.4	-0.56	4.09e-39	Blood protein levels;
LGG	cis	rs9397585	0.857	rs9479485	chr6:153368756	C/T	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs1355223	0.867	rs3818514	chr11:34680053	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.77	-0.3	3.9e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4774830	0.744	rs62046390	chr15:56308506	G/A	cg05129572	chr15:56138634	NEDD4	0.75	7.16	0.32	3.16e-12	Delta-5 desaturase activity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20791839	chr3:53926047	SELK	0.47	8.01	0.35	9.17e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs736408	0.812	rs2071506	chr3:52826276	T/C	cg14092988	chr3:52407081	DNAH1	0.33	8.77	0.38	3.38e-17	Bipolar disorder;
LGG	trans	rs1814175	0.669	rs11040473	chr11:49703813	C/T	cg15704280	chr7:45808275	SEPT13	-0.86	-16.97	-0.62	1.43e-50	Height;
LGG	cis	rs1552244	1.000	rs7631678	chr3:10078816	T/G	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	cis	rs6754311	0.593	rs313522	chr2:136430866	T/A	cg07169764	chr2:136633963	MCM6	0.75	13.1	0.52	1.4e-33	Mosquito bite size;
LGG	cis	rs1847202	0.859	rs6771288	chr3:72939471	A/G	cg25664220	chr3:72788482	NA	-0.24	-7.55	-0.33	2.4e-13	Motion sickness;
LGG	cis	rs977987	0.864	rs37593	chr16:75496907	T/C	cg03315344	chr16:75512273	CHST6	-0.57	-11.16	-0.46	8.79e-26	Dupuytren's disease;
LGG	cis	rs9368481	0.761	rs3931464	chr6:26939856	C/A	cg12292205	chr6:26970375	C6orf41	0.73	14.19	0.55	3.37e-38	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17453880	0.712	rs7733573	chr5:152048219	C/T	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	trans	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.39	-0.36	5.73e-16	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.05	0.42	1.24e-21	Motion sickness;
LGG	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg13010199	chr12:38710504	ALG10B	-0.55	-11.05	-0.46	2.44e-25	Heart rate;
LGG	cis	rs6940638	0.688	rs7764984	chr6:27034181	A/G	cg12826209	chr6:26865740	GUSBL1	0.44	7.21	0.32	2.34e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.553	rs11973507	chr7:139099461	A/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs2204008	0.837	rs7974888	chr12:37945215	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.41	0.33	6.25e-13	Bladder cancer;
LGG	cis	rs908922	0.676	rs12129646	chr1:152518816	C/T	cg03606772	chr1:152487856	CRCT1	0.3	7.06	0.31	6.13e-12	Hair morphology;
LGG	cis	rs7824557	0.578	rs2060458	chr8:11212811	C/A	cg15596359	chr8:11213517	TDH	-0.4	-8.03	-0.35	7.99e-15	Retinal vascular caliber;
LGG	cis	rs11191205	0.644	rs12354716	chr10:103386775	C/A	cg15320455	chr10:103880129	LDB1	0.48	6.95	0.31	1.22e-11	Intelligence (multi-trait analysis);
LGG	trans	rs12579753	0.917	rs71466033	chr12:82242187	C/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.9e-14	Resting heart rate;
LGG	cis	rs9462027	0.630	rs2744943	chr6:34643179	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.67e-24	Systemic lupus erythematosus;
LGG	cis	rs2072499	0.865	rs2758603	chr1:156198994	T/C	cg25208724	chr1:156163844	SLC25A44	1.11	22.96	0.73	1.91e-78	Testicular germ cell tumor;
LGG	cis	rs2201728	0.739	rs34713251	chr4:100142078	G/A	cg07219303	chr4:100140905	ADH6	-0.38	-7.02	-0.31	7.82e-12	Cardiac Troponin-T levels;
LGG	cis	rs6580649	0.941	rs4760618	chr12:48434767	G/A	cg24011408	chr12:48396354	COL2A1	-0.57	-7.05	-0.31	6.44e-12	Lung cancer;
LGG	cis	rs113835537	0.529	rs60358007	chr11:66222353	G/A	cg24851651	chr11:66362959	CCS	0.43	7.36	0.32	8.6e-13	Airway imaging phenotypes;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg01879757	chr17:41196368	BRCA1	-0.45	-9.1	-0.39	2.75e-18	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02994863	chr1:64059297	PGM1	0.39	7.05	0.31	6.35e-12	Obesity-related traits;
LGG	cis	rs2180341	1.000	rs13218061	chr6:127653758	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs9393777	0.557	rs7759741	chr6:27241043	C/T	cg12292205	chr6:26970375	C6orf41	-0.63	-9.57	-0.41	6.54e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.63	0.41	3.9e-20	Height;
LGG	cis	rs3790455	0.610	rs1171548	chr1:156471998	G/T	cg14087168	chr1:156450669	MEF2D	-0.66	-9.6	-0.41	5.16e-20	Migraine;
LGG	trans	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg07211511	chr3:129823064	LOC729375	-0.66	-9.09	-0.39	2.82e-18	Blood pressure (smoking interaction);
LGG	cis	rs368123	1.000	rs28458334	chr6:160753363	G/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.28	-0.32	1.44e-12	Waist circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03965620	chr10:12238232	CDC123;NUDT5	0.45	6.9	0.31	1.72e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.676	rs11680660	chr2:100931738	G/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.09	-0.31	4.97e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7474896	0.559	rs2738185	chr10:38247736	G/A	cg25427524	chr10:38739819	LOC399744	0.52	7.64	0.33	1.27e-13	Obesity (extreme);
LGG	cis	rs514406	0.825	rs3863643	chr1:53224577	C/T	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.44	0.37	4.19e-16	Tonsillectomy;
LGG	cis	rs4689642	0.507	rs4689645	chr4:7221434	T/C	cg21353189	chr4:7228343	SORCS2	0.33	7.11	0.31	4.33e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg20309703	chr11:118481025	PHLDB1	-0.56	-10.36	-0.43	9.01e-23	Cholesterol, total;
LGG	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg09873164	chr1:152488093	CRCT1	0.54	10.99	0.45	4.02e-25	Hair morphology;
LGG	cis	rs1003719	0.788	rs61701101	chr21:38450317	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs4555082	0.957	rs2735818	chr14:105714751	A/G	cg10792982	chr14:105748885	BRF1	0.55	10.93	0.45	6.57e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.26	-0.32	1.69e-12	Life satisfaction;
LGG	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg25174290	chr11:3078921	CARS	-0.48	-8.3	-0.36	1.17e-15	Calcium levels;
LGG	cis	rs9944715	0.954	rs8084827	chr18:43747028	C/T	cg26436583	chr18:43649176	PSTPIP2	0.39	7.2	0.32	2.43e-12	Red cell distribution width;Mean corpuscular volume;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08871016	chr21:45079232	HSF2BP;RRP1B	-0.47	-7.04	-0.31	6.91e-12	Systemic lupus erythematosus;
LGG	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.99	0.35	1.05e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs8177253	1.000	rs6762719	chr3:133480817	A/G	cg11941060	chr3:133502564	NA	-0.49	-8.35	-0.36	7.99e-16	Iron status biomarkers;
LGG	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.33	0.55	8.14e-39	Exhaled nitric oxide output;
LGG	cis	rs2131877	0.956	rs58381781	chr3:194872824	T/C	cg07250128	chr3:194833983	C3orf21	0.41	7.58	0.33	1.88e-13	Non-small cell lung cancer;
LGG	trans	rs11098499	0.789	rs10212719	chr4:120254437	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.58e-25	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04145065	chr4:40057559	N4BP2;LOC344967	0.44	7.07	0.31	5.66e-12	Cognitive performance;
LGG	cis	rs60843830	1.000	rs3791223	chr2:222336	T/C	cg04617936	chr2:214353	NA	-0.39	-7.29	-0.32	1.33e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2028299	1.000	rs1371135	chr15:90391270	T/C	cg23731826	chr15:90371692	NA	0.37	8.89	0.38	1.35e-17	Type 2 diabetes;
LGG	cis	rs9682041	0.696	rs10936627	chr3:170104406	C/T	cg11886554	chr3:170076028	SKIL	0.65	8.43	0.36	4.56e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs35771425	0.507	rs6540681	chr1:211493573	A/G	cg10512769	chr1:211675356	NA	0.67	9.96	0.42	2.75e-21	Educational attainment (years of education);
LGG	cis	rs4731207	0.596	rs10264288	chr7:124574527	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.52e-13	Cutaneous malignant melanoma;
LGG	cis	rs11676348	0.935	rs4674248	chr2:218960131	T/C	cg00012203	chr2:219082015	ARPC2	-0.5	-8.78	-0.38	3.18e-17	Ulcerative colitis;
LGG	cis	rs561341	0.700	rs79272796	chr17:30226974	T/C	cg00745463	chr17:30367425	LRRC37B	-0.46	-7.15	-0.32	3.35e-12	Hip circumference adjusted for BMI;
LGG	cis	rs17767392	0.958	rs4902938	chr14:72014778	T/C	cg13720639	chr14:72061746	SIPA1L1	0.4	8.8	0.38	2.82e-17	Mitral valve prolapse;
LGG	cis	rs9325144	0.505	rs7955162	chr12:38711658	G/A	cg13010199	chr12:38710504	ALG10B	0.73	16.26	0.6	2.44e-47	Morning vs. evening chronotype;
LGG	trans	rs10028773	0.600	rs4001390	chr4:120265783	G/C	cg25214090	chr10:38739885	LOC399744	0.56	10.38	0.43	7.62e-23	Educational attainment;
LGG	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg16262614	chr3:133464971	TF	0.47	8.71	0.38	5.36e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs7727544	0.684	rs272874	chr5:131675046	A/G	cg24060327	chr5:131705240	SLC22A5	0.43	6.94	0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs12681288	0.862	rs2004701	chr8:1022287	A/G	cg04851639	chr8:1020857	NA	-0.43	-9.35	-0.4	3.79e-19	Schizophrenia;
LGG	cis	rs6735179	0.601	rs114382205	chr2:1747539	G/A	cg20570797	chr2:1712800	PXDN	-0.46	-7.99	-0.35	1.1e-14	Response to antipsychotic treatment;
LGG	cis	rs78456975	0.607	rs73909625	chr2:1541934	A/G	cg01028140	chr2:1542097	TPO	-0.56	-8.41	-0.36	5.26e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1816752	0.905	rs7995909	chr13:25013297	T/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.28	-0.32	1.42e-12	Bipolar disorder;
LGG	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.34	0.36	8.73e-16	Aortic root size;
LGG	cis	rs35740288	0.770	rs17635450	chr15:86199049	C/G	cg04173714	chr15:86211321	AKAP13	-0.53	-8.46	-0.37	3.53e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg12310025	chr6:25882481	NA	0.42	7.65	0.33	1.2e-13	Height;
LGG	cis	rs4917300	0.650	rs4917267	chr8:143070882	T/A	cg06573787	chr8:143070187	NA	0.76	15.72	0.59	6.26e-45	Amyotrophic lateral sclerosis;
LGG	cis	rs4742903	0.875	rs10820609	chr9:106907332	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.21	0.36	2.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6840360	0.615	rs7669761	chr4:152609304	G/A	cg22705602	chr4:152727874	NA	-0.38	-9.49	-0.4	1.19e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1143633	0.615	rs11687403	chr2:113643638	G/A	cg06156847	chr2:113672199	IL1F7	0.38	7.49	0.33	3.59e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7267979	0.789	rs6083820	chr20:25354178	G/A	cg06421707	chr20:25228305	PYGB	-0.38	-7.91	-0.35	1.87e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg02002194	chr4:3960332	NA	-0.39	-7.15	-0.32	3.33e-12	Neuroticism;
LGG	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg16230307	chr14:35515116	FAM177A1	0.91	13.07	0.52	1.95e-33	Psoriasis;
LGG	cis	rs2665103	0.715	rs16973457	chr15:82563991	C/T	cg00614314	chr15:82944287	LOC80154	0.46	7.86	0.34	2.7e-14	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.573	rs7925419	chr11:49231859	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.38	-7.24	-0.32	1.92e-12	Coronary artery disease;
LGG	cis	rs7580658	0.864	rs10928761	chr2:128003247	C/T	cg10021288	chr2:128175891	PROC	-0.62	-12.79	-0.51	2.72e-32	Protein C levels;
LGG	cis	rs2456568	0.802	rs7101791	chr11:93638998	A/G	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs12143943	0.866	rs4252713	chr1:204510528	G/A	cg20240347	chr1:204465584	NA	-0.35	-7.54	-0.33	2.51e-13	Cognitive performance;
LGG	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg15704280	chr7:45808275	SEPT13	0.85	8.82	0.38	2.37e-17	Myopia (pathological);
LGG	cis	rs754466	0.651	rs2004382	chr10:79650351	G/C	cg17075019	chr10:79541650	NA	-0.94	-18.79	-0.66	5.66e-59	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg14668632	chr7:2872130	GNA12	-0.36	-7.15	-0.32	3.43e-12	Height;
LGG	cis	rs9463078	0.605	rs17339124	chr6:44942577	C/G	cg25276700	chr6:44698697	NA	0.34	7.04	0.31	6.79e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.33	-0.36	9.17e-16	Diabetic kidney disease;
LGG	cis	rs7172689	0.862	rs113569519	chr15:81563619	T/A	cg11808699	chr15:81528661	IL16	-0.45	-9.42	-0.4	2.12e-19	Inattentive symptoms;
LGG	cis	rs929596	0.785	rs17864701	chr2:234652717	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.76	-13.43	-0.53	6.09e-35	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs6502050	0.799	rs4789680	chr17:80100547	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs453301	0.686	rs11785819	chr8:8870378	T/G	cg02002194	chr4:3960332	NA	0.39	7.24	0.32	1.87e-12	Joint mobility (Beighton score);
LGG	cis	rs2070488	1.000	rs7373805	chr3:38455439	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.37	0.63	1.99e-52	Electrocardiographic conduction measures;
LGG	cis	rs4808199	0.895	rs6511036	chr19:19582651	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.57	0.63	2.65e-53	Nonalcoholic fatty liver disease;
LGG	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.74	0.34	6.48e-14	Neuroticism;
LGG	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg05890377	chr2:74357713	NA	0.48	9.69	0.41	2.48e-20	Gestational age at birth (maternal effect);
LGG	cis	rs887829	0.570	rs10175809	chr2:234596865	T/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10911457	0.701	rs10911469	chr1:183888858	C/T	cg18131582	chr1:183912305	GLT25D2	0.27	6.67	0.3	7.2e-11	High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs317689	0.658	rs479971	chr12:69672471	A/G	cg20891283	chr12:69753455	YEATS4	0.46	7.0	0.31	8.99e-12	Response to diuretic therapy;
LGG	cis	rs6430585	0.528	rs499483	chr2:136652524	G/A	cg07169764	chr2:136633963	MCM6	1.25	22.72	0.73	2.57e-77	Corneal structure;
LGG	cis	rs7546	0.501	rs12102426	chr16:4922450	T/G	cg04440724	chr16:4920505	UBN1	-0.61	-13.55	-0.53	1.84e-35	Cancer;
LGG	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg22535103	chr8:58192502	C8orf71	-0.77	-10.34	-0.43	1.12e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1801251	0.727	rs13029336	chr2:233569935	A/G	cg25237894	chr2:233734115	C2orf82	-0.51	-9.7	-0.41	2.28e-20	Coronary artery disease;
LGG	cis	rs870825	0.860	rs2696052	chr4:185604356	G/A	cg04058563	chr4:185651563	MLF1IP	-0.97	-18.92	-0.66	1.51e-59	Blood protein levels;
LGG	cis	rs7582720	1.000	rs77230711	chr2:203805552	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9443645	0.901	rs7767100	chr6:79810533	A/C	cg18132916	chr6:79620363	NA	-0.31	-8.25	-0.36	1.67e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11574514	1.000	rs16957590	chr16:67934725	C/T	cg09738193	chr16:67926317	PSKH1	0.73	6.79	0.3	3.42e-11	Crohn's disease;
LGG	cis	rs3219090	1.000	rs2048424	chr1:226583007	G/C	cg17127702	chr1:226594323	PARP1	0.38	12.09	0.49	1.89e-29	Melanoma;
LGG	cis	rs9287719	0.967	rs6748036	chr2:10717489	C/T	cg02196655	chr2:10830764	NOL10	-0.43	-7.35	-0.32	9.25e-13	Prostate cancer;
LGG	cis	rs10791323	0.628	rs1893850	chr11:133705356	T/C	cg00579200	chr11:133705235	NA	-0.6	-11.65	-0.48	1.13e-27	Childhood ear infection;
LGG	cis	rs10949834	1.000	rs10949834	chr7:73480569	G/A	cg07137043	chr7:73588983	EIF4H	-0.67	-7.38	-0.32	7.49e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs769267	0.931	rs2965197	chr19:19470910	C/T	cg11584989	chr19:19387371	SF4	-0.41	-7.28	-0.32	1.44e-12	Tonsillectomy;
LGG	cis	rs796364	0.756	rs2949006	chr2:200715388	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.82	0.45	1.84e-24	Schizophrenia;
LGG	cis	rs79976124	0.800	rs6918860	chr6:66637741	G/C	cg07460842	chr6:66804631	NA	0.73	12.59	0.51	1.78e-31	Type 2 diabetes;
LGG	cis	rs2298450	0.717	rs62232368	chr21:37626011	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-7.97	-0.35	1.23e-14	Schizophrenia;
LGG	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.15	0.52	9.04e-34	Bladder cancer;
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg08355456	chr11:67383691	NA	0.5	8.01	0.35	9.19e-15	Mean corpuscular volume;
LGG	cis	rs72949976	0.646	rs1441169	chr2:214033530	A/G	cg08319019	chr2:214017104	IKZF2	0.62	11.56	0.47	2.54e-27	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs644799	0.542	rs10831416	chr11:95467220	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.74	13.76	0.54	2.37e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs116095464	0.510	rs7723883	chr5:270798	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs6502050	0.835	rs4789754	chr17:80091941	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.25	-0.36	1.63e-15	Life satisfaction;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-20.01	-0.68	1.15e-64	Prudent dietary pattern;
LGG	cis	rs6496932	0.802	rs10163187	chr15:85870518	C/T	cg19183879	chr15:85880815	NA	0.42	6.79	0.3	3.43e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs10489202	0.683	rs4657730	chr1:168072738	A/T	cg24449463	chr1:168025552	DCAF6	-0.57	-10.22	-0.43	2.99e-22	Schizophrenia;
LGG	cis	rs4262150	0.672	rs17113833	chr5:152344526	A/T	cg12297329	chr5:152029980	NA	-0.55	-8.76	-0.38	3.82e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg06697600	chr4:7070879	GRPEL1	0.38	6.72	0.3	5.38e-11	Monocyte percentage of white cells;
LGG	trans	rs11098499	0.730	rs12505735	chr4:120532956	G/T	cg25214090	chr10:38739885	LOC399744	0.61	10.72	0.45	4.21e-24	Corneal astigmatism;
LGG	cis	rs701145	0.537	rs2695845	chr3:153881836	G/A	cg12800244	chr3:153838788	SGEF	0.78	8.34	0.36	8.54e-16	Coronary artery disease;
LGG	cis	rs17711722	0.701	rs781145	chr7:65440370	A/C	cg11764359	chr7:65958608	NA	0.56	9.37	0.4	3.19e-19	Calcium levels;
LGG	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.22	-0.36	2.07e-15	Retinal vascular caliber;
LGG	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg21665744	chr7:39171113	POU6F2	0.39	8.03	0.35	7.88e-15	IgG glycosylation;
LGG	cis	rs8044868	0.512	rs12935266	chr16:72157000	C/G	cg23815491	chr16:72088622	HP	0.37	7.87	0.34	2.5e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	trans	rs1814175	0.647	rs4881649	chr11:49845560	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.44	-0.4	1.76e-19	Height;
LGG	cis	rs4731207	0.596	rs4507709	chr7:124651533	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.34	0.47	1.75e-26	Bipolar disorder;
LGG	cis	rs66573146	1.000	rs56074877	chr4:6990374	C/T	cg00086871	chr4:6988644	TBC1D14	1.06	9.65	0.41	3.3e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs963731	0.522	rs7607509	chr2:39285372	A/G	cg04010122	chr2:39346883	SOS1	-0.7	-7.66	-0.34	1.1e-13	Corticobasal degeneration;
LGG	cis	rs1153858	0.621	rs2413769	chr15:45561868	A/C	cg21132104	chr15:45694354	SPATA5L1	0.64	9.13	0.39	2.2e-18	Homoarginine levels;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg00495681	chr13:53174319	NA	-0.57	-10.46	-0.44	3.8e-23	Lewy body disease;
LGG	cis	rs7192750	0.586	rs4788449	chr16:71931219	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.79	0.45	2.33e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg19507638	chr5:93509721	C5orf36	-0.73	-10.06	-0.42	1.17e-21	Diabetic retinopathy;
LGG	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.7	0.3	6e-11	Bone mineral density;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs79057730	0.599	rs35928068	chr7:805363	G/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.27	0.36	1.44e-15	Initial pursuit acceleration;
LGG	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.3	0.43	1.49e-22	Diabetic retinopathy;
LGG	trans	rs6089829	0.962	rs9679865	chr20:61666132	C/G	cg23505145	chr19:12996616	KLF1	0.41	7.34	0.32	9.54e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3771570	0.901	rs62190410	chr2:242410621	C/T	cg21155796	chr2:242212141	HDLBP	0.7	9.33	0.4	4.41e-19	Prostate cancer;
LGG	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg09461388	chr22:46763229	CELSR1	-0.67	-7.09	-0.31	4.96e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1555895	0.622	rs7703	chr10:858394	C/T	cg10556349	chr10:835070	NA	-0.31	-7.74	-0.34	6.09e-14	Survival in rectal cancer;
LGG	cis	rs7712401	0.601	rs13185741	chr5:122338010	A/G	cg19412675	chr5:122181750	SNX24	-0.41	-6.67	-0.3	7.09e-11	Mean platelet volume;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs888194	0.690	rs2058805	chr12:109998591	T/C	cg19025524	chr12:109796872	NA	-0.35	-6.96	-0.31	1.15e-11	Neuroticism;
LGG	trans	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	6.68	0.3	6.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6817170	0.617	rs9999331	chr4:154379959	T/C	cg07229402	chr4:154369277	NA	0.35	7.02	0.31	8.09e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26630902	chr16:15692851	KIAA0430	0.44	7.45	0.33	4.75e-13	Pancreatic cancer;
LGG	cis	rs9325144	0.555	rs2387847	chr12:38687434	C/T	cg13010199	chr12:38710504	ALG10B	0.6	12.05	0.49	2.81e-29	Morning vs. evening chronotype;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04071446	chr10:115933849	C10orf118	0.4	7.14	0.31	3.72e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7681440	0.874	rs7687945	chr4:90764699	C/T	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg13732083	chr21:47605072	C21orf56	0.49	8.46	0.37	3.41e-16	Testicular germ cell tumor;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg14893161	chr1:205819251	PM20D1	-0.58	-11.06	-0.46	2.21e-25	Menarche (age at onset);
LGG	cis	rs11718455	1.000	rs6762022	chr3:44055917	C/G	cg21419209	chr3:44054225	NA	-0.45	-7.12	-0.31	4.22e-12	Coronary artery disease;
LGG	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg13852791	chr20:30311386	BCL2L1	0.66	8.81	0.38	2.45e-17	Mean corpuscular hemoglobin;
LGG	trans	rs7937682	0.562	rs7938620	chr11:111366844	G/A	cg18187862	chr3:45730750	SACM1L	-0.44	-7.47	-0.33	4.03e-13	Primary sclerosing cholangitis;
LGG	cis	rs12410462	0.901	rs16847844	chr1:227638110	A/G	cg04117972	chr1:227635322	NA	0.67	11.0	0.46	3.6e-25	Major depressive disorder;
LGG	cis	rs35110281	0.715	rs969060	chr21:45080852	T/G	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.58	-0.41	5.75e-20	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116559327	chr4:119754526	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg06917634	chr15:78832804	PSMA4	-0.68	-13.47	-0.53	3.79e-35	Sudden cardiac arrest;
LGG	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.84	0.3	2.46e-11	Menarche (age at onset);
LGG	cis	rs875971	0.545	rs11770063	chr7:65783016	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.84	0.45	1.5e-24	Aortic root size;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg00657871	chr1:85156634	SSX2IP	0.4	6.75	0.3	4.41e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	20.16	0.68	2.46e-65	Platelet count;
LGG	cis	rs10484885	0.775	rs72919985	chr6:90534641	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.81	-0.45	1.97e-24	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18272543	chr7:27779524	TAX1BP1	0.45	7.44	0.33	4.97e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg16606324	chr3:10149918	C3orf24	0.6	6.91	0.31	1.61e-11	Alzheimer's disease;
LGG	cis	rs1881797	0.932	rs2387038	chr1:247674919	G/A	cg18198730	chr1:247681584	NA	0.75	12.09	0.49	1.93e-29	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg20607798	chr8:58055168	NA	0.69	7.79	0.34	4.52e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.774	rs11249893	chr8:8700851	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.54	0.33	2.56e-13	Mood instability;
LGG	cis	rs9611565	0.918	rs9538	chr22:41755857	G/T	cg06634786	chr22:41940651	POLR3H	-0.74	-12.11	-0.49	1.7e-29	Vitiligo;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.88	-0.3	1.98e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7781557	1.000	rs17135875	chr7:102519031	T/C	cg18108683	chr7:102477205	FBXL13	-0.47	-7.45	-0.33	4.73e-13	Colorectal adenoma (advanced);
LGG	cis	rs12410462	0.591	rs66491073	chr1:227782721	A/C	cg04117972	chr1:227635322	NA	0.45	8.34	0.36	8.29e-16	Major depressive disorder;
LGG	cis	rs2916247	0.908	rs7005983	chr8:93167589	G/A	cg10183463	chr8:93005414	RUNX1T1	0.35	7.04	0.31	6.89e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12484590	chr1:156475177	NA	0.52	8.09	0.35	5.31e-15	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg00405596	chr8:11794950	NA	-0.41	-6.78	-0.3	3.59e-11	Neuroticism;
LGG	cis	rs13191362	0.935	rs66923841	chr6:163177317	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.93	9.48	0.4	1.37e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs826838	0.935	rs3886109	chr12:39189243	C/T	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.44e-42	Heart rate;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs7279011	chr21:46655995	G/A	cg06618935	chr21:46677482	NA	-0.47	-9.16	-0.39	1.62e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9393777	0.546	rs9366673	chr6:26893329	C/G	cg12292205	chr6:26970375	C6orf41	-0.54	-7.69	-0.34	9.07e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.918	rs34071486	chr4:100051087	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.84	-0.3	2.46e-11	Total body bone mineral density;
LGG	trans	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs6456156	0.716	rs6905876	chr6:167521562	C/T	cg07741184	chr6:167504864	NA	0.39	8.23	0.36	1.96e-15	Primary biliary cholangitis;
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg10295955	chr4:187884368	NA	1.13	31.15	0.82	1.13e-115	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7507204	0.906	rs1860323	chr19:3424799	G/C	cg08380311	chr19:3435252	NFIC	0.81	12.31	0.5	2.47e-30	Height;
LGG	cis	rs3784262	0.669	rs7171261	chr15:58356855	C/G	cg12031962	chr15:58353849	ALDH1A2	0.31	6.69	0.3	6.57e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7819412	0.775	rs2001329	chr8:10986859	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.19	-0.32	2.62e-12	Triglycerides;
LGG	cis	rs12540874	0.698	rs10899736	chr7:50546925	C/T	cg04490037	chr7:50633773	DDC	0.33	7.31	0.32	1.21e-12	Systemic sclerosis;
LGG	trans	rs17685	0.535	rs41299460	chr7:75600951	G/A	cg19862616	chr7:65841803	NCRNA00174	0.56	9.54	0.41	8.25e-20	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9899728	0.539	rs11077772	chr17:73035698	C/T	cg27626185	chr17:73056755	KCTD2	-1.05	-12.39	-0.5	1.23e-30	Alzheimer's disease or small vessel stroke;
LGG	cis	rs10911251	0.528	rs2093982	chr1:183094191	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Colorectal cancer;
LGG	cis	rs2133450	0.712	rs9811489	chr3:7370789	G/A	cg19930620	chr3:7340148	GRM7	-0.36	-7.8	-0.34	4.13e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs7904368	0.659	rs3740169	chr10:16873547	C/T	cg22980697	chr10:16874865	CUBN	0.51	8.96	0.38	7.92e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs2046867	0.908	rs1106310	chr3:72818902	A/T	cg25664220	chr3:72788482	NA	0.33	9.42	0.4	2.18e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg05552183	chr6:42928497	GNMT	0.39	11.41	0.47	9.23e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2952156	0.652	rs11869286	chr17:37813856	C/G	cg00129232	chr17:37814104	STARD3	-0.79	-17.38	-0.63	1.89e-52	Asthma;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.41e-31	Lung cancer;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs283228	1.000	rs2787557	chr6:101786676	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.98	0.38	7.09e-18	Coenzyme Q10 levels;
LGG	cis	rs965513	1.000	rs925489	chr9:100546600	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.75	-0.41	1.54e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg01842473	chr11:617407	IRF7;MUPCDH	-0.55	-7.48	-0.33	3.7e-13	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs4330281	0.647	rs34297417	chr3:17728287	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs4147929	0.532	rs4147932	chr19:1064485	C/T	cg05372495	chr19:1063624	ABCA7	-0.56	-9.23	-0.39	9.62e-19	Alzheimer's disease (late onset);
LGG	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg27476859	chr7:2772710	GNA12	0.52	10.27	0.43	2e-22	Height;
LGG	cis	rs35160687	0.787	rs10186289	chr2:86512988	G/A	cg10973622	chr2:86423274	IMMT	0.45	8.13	0.35	3.97e-15	Night sleep phenotypes;
LGG	cis	rs7760949	0.852	rs9475800	chr6:13932230	A/G	cg27413430	chr6:13925136	RNF182	0.48	7.23	0.32	1.95e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs453301	0.624	rs2915251	chr8:8867411	G/C	cg27411982	chr8:10470053	RP1L1	0.46	7.9	0.34	2.01e-14	Joint mobility (Beighton score);
LGG	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg12386194	chr3:101231763	SENP7	0.47	8.34	0.36	8.77e-16	Colorectal cancer;
LGG	cis	rs9815354	0.812	rs57809229	chr3:41840162	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3820928	0.605	rs6748311	chr2:227792530	T/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-10.65	-0.44	8.04e-24	Pulmonary function;
LGG	cis	rs929354	0.742	rs1182396	chr7:157031831	A/C	cg05182265	chr7:156933206	UBE3C	0.36	7.4	0.33	6.51e-13	Body mass index;
LGG	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14373873	chr11:113211441	TTC12	0.55	12.05	0.49	2.8e-29	Neuroticism;
LGG	cis	rs9549367	0.774	rs9549364	chr13:113903745	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs2898279	0.815	rs4581006	chr8:11305365	A/G	cg26274995	chr8:11302983	FAM167A	0.49	9.87	0.42	5.78e-21	Small cell lung carcinoma;
LGG	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg24692254	chr21:30365293	RNF160	-0.58	-8.54	-0.37	1.95e-16	Cognitive test performance;
LGG	cis	rs2204008	0.806	rs3922574	chr12:38329069	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.77	0.3	4.02e-11	Bladder cancer;
LGG	cis	rs774359	0.750	rs812858	chr9:27545467	C/T	cg21249376	chr9:27528432	MOBKL2B	0.43	7.41	0.33	5.96e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs2905347	0.726	rs2961294	chr7:22695031	T/C	cg18045685	chr7:22629474	NA	-0.69	-14.52	-0.56	1.21e-39	Major depression and alcohol dependence;
LGG	cis	rs798554	0.721	rs2527680	chr7:2892361	C/T	cg13628971	chr7:2884303	GNA12	0.55	11.37	0.47	1.35e-26	Height;
LGG	cis	rs6120849	0.901	rs6060266	chr20:33733078	T/C	cg24642439	chr20:33292090	TP53INP2	0.49	6.68	0.3	6.75e-11	Protein C levels;
LGG	cis	rs4664304	0.966	rs7601374	chr2:160754050	T/C	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.33	-0.32	1.06e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4356203	0.870	rs12286505	chr11:17163725	G/A	cg15432903	chr11:17409602	KCNJ11	0.38	7.26	0.32	1.67e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs853679	0.546	rs34546986	chr6:28362309	G/A	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Depression;
LGG	cis	rs10504130	0.569	rs11785467	chr8:52675668	A/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2046867	0.908	rs67967166	chr3:72794198	A/G	cg25664220	chr3:72788482	NA	-0.32	-8.95	-0.38	8.76e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7208859	0.623	rs59029591	chr17:29235746	A/C	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs651907	0.557	rs7612283	chr3:101434919	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.22	-0.32	2.13e-12	Colorectal cancer;
LGG	cis	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg00745463	chr17:30367425	LRRC37B	-0.66	-9.53	-0.4	9.18e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7833790	0.654	rs7835342	chr8:82698092	A/G	cg06027949	chr8:82754900	SNX16	-0.47	-7.47	-0.33	3.93e-13	Diastolic blood pressure;
LGG	cis	rs8072100	0.688	rs8075843	chr17:45442363	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-9.93	-0.42	3.41e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11748327	0.580	rs10063823	chr5:4011811	T/C	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.27e-12	Myocardial infarction;
LGG	cis	rs1966248	0.543	rs12203224	chr6:134101494	G/T	cg25632230	chr6:134101081	NA	-0.34	-7.53	-0.33	2.65e-13	Coronary artery disease;
LGG	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9560113	0.509	rs28608633	chr13:112206880	G/A	cg15979348	chr13:112237479	NA	0.42	6.99	0.31	9.51e-12	Menarche (age at onset);
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg26513180	chr16:89883248	FANCA	0.68	7.56	0.33	2.25e-13	Skin colour saturation;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1371867	0.775	rs6511	chr8:101252680	T/C	cg06636551	chr8:101224915	SPAG1	0.48	8.76	0.38	3.63e-17	Atrioventricular conduction;
LGG	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs801193	0.805	rs12532355	chr7:66070584	C/G	cg18252515	chr7:66147081	NA	0.41	7.07	0.31	5.78e-12	Aortic root size;
LGG	cis	rs2204008	0.619	rs11178987	chr12:38201258	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.44	-0.44	4.69e-23	Bladder cancer;
LGG	cis	rs10771431	0.935	rs1117735	chr12:9372728	G/A	cg08997352	chr12:9597637	DDX12	-0.67	-13.03	-0.52	2.73e-33	Breast size;
LGG	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg17809284	chr5:56205270	C5orf35	-0.56	-9.11	-0.39	2.54e-18	Initial pursuit acceleration;
LGG	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg26384229	chr12:38710491	ALG10B	-0.6	-10.87	-0.45	1.17e-24	Morning vs. evening chronotype;
LGG	cis	rs4730250	0.669	rs6466160	chr7:106793175	T/A	cg02696742	chr7:106810147	HBP1	0.79	11.12	0.46	1.24e-25	Osteoarthritis;
LGG	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.63	0.72	6.44e-77	Breast cancer;
LGG	cis	rs2066819	0.818	rs773652	chr12:56674766	G/A	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.66e-11	Psoriasis vulgaris;
LGG	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg06138931	chr13:21896616	NA	0.46	7.76	0.34	5.37e-14	White matter hyperintensity burden;
LGG	cis	rs868036	1.000	rs8037262	chr15:68108572	C/T	cg05925327	chr15:68127851	NA	-0.38	-8.84	-0.38	2.05e-17	Restless legs syndrome;
LGG	cis	rs11190604	1.000	rs11190551	chr10:102204734	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03399598	chr4:174091002	GALNT7	0.56	8.83	0.38	2.14e-17	Gut microbiome composition (summer);
LGG	cis	rs2730245	0.618	rs859781	chr7:158661758	G/A	cg14689365	chr7:158441557	NCAPG2	0.6	9.93	0.42	3.5e-21	Height;
LGG	cis	rs11649653	0.502	rs4889490	chr16:30823047	A/C	cg00531865	chr16:30841666	NA	-0.45	-9.65	-0.41	3.37e-20	Triglycerides;
LGG	cis	rs938554	0.744	rs13129697	chr4:9926967	T/G	cg25986240	chr4:9926439	SLC2A9	0.4	7.68	0.34	9.66e-14	Blood metabolite levels;
LGG	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.53	-0.63	3.9e-53	Breast cancer;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	7.96	0.35	1.33e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1978968	0.912	rs28478894	chr22:18454600	G/A	cg03078520	chr22:18463400	MICAL3	-0.71	-14.99	-0.57	1.09e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs4731207	0.698	rs10954049	chr7:124535450	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs9814567	0.752	rs9848254	chr3:134330374	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg22681709	chr2:178499509	PDE11A	-0.46	-7.11	-0.31	4.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06942064	chr1:208417143	PLXNA2	0.46	7.57	0.33	2.05e-13	Cognitive performance;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.43	-0.36	4.31e-16	Prudent dietary pattern;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg10207240	chr12:122356781	WDR66	0.24	7.42	0.33	5.56e-13	Mean corpuscular volume;
LGG	cis	rs13191362	0.872	rs67712738	chr6:163245768	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.75	0.34	5.96e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2548003	1.000	rs1423291	chr5:28743348	C/T	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs9354308	0.764	rs9294665	chr6:66598299	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs9611565	0.765	rs132921	chr22:41812044	G/A	cg17376030	chr22:41985996	PMM1	-0.48	-7.77	-0.34	4.93e-14	Vitiligo;
LGG	cis	rs1978968	0.763	rs13055106	chr22:18465208	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.66	-13.63	-0.54	8.44e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs7582720	1.000	rs77931721	chr2:203763076	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg22681709	chr2:178499509	PDE11A	0.47	7.27	0.32	1.52e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg05313129	chr8:58192883	C8orf71	-0.64	-8.3	-0.36	1.18e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg12463550	chr7:65579703	CRCP	0.81	8.7	0.37	5.87e-17	Diabetic kidney disease;
LGG	trans	rs7395662	0.890	rs11039806	chr11:48547716	T/A	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	5.92e-13	HDL cholesterol;
LGG	cis	rs12893668	0.572	rs11540512	chr14:104147377	C/T	cg24130564	chr14:104152367	KLC1	-0.39	-7.12	-0.31	4.16e-12	Reticulocyte count;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg24623649	chr8:11872141	NA	-0.3	-6.82	-0.3	2.8e-11	Triglycerides;
LGG	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg04691961	chr3:161091175	C3orf57	-0.41	-8.53	-0.37	2.08e-16	Morning vs. evening chronotype;
LGG	trans	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg18187862	chr3:45730750	SACM1L	0.64	10.59	0.44	1.32e-23	Primary sclerosing cholangitis;
LGG	cis	rs9467773	0.620	rs2451738	chr6:26618459	A/T	cg11502198	chr6:26597334	ABT1	-0.69	-12.47	-0.5	5.69e-31	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.57	-9.69	-0.41	2.4e-20	Height;
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg00490583	chr16:1843685	IGFALS	-0.41	-7.05	-0.31	6.44e-12	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1.05e-12	Neuroticism;
LGG	cis	rs6951245	1.000	rs77702926	chr7:1088838	G/A	cg24642844	chr7:1081250	C7orf50	-0.83	-13.92	-0.54	4.67e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs561341	0.714	rs111760509	chr17:30304320	A/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.51	-0.44	2.69e-23	Hip circumference adjusted for BMI;
LGG	cis	rs283228	0.535	rs2852507	chr6:101844253	G/A	cg02011392	chr6:101847541	GRIK2	0.51	7.31	0.32	1.16e-12	Coenzyme Q10 levels;
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.68	12.31	0.5	2.61e-30	Obesity-related traits;
LGG	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg12386194	chr3:101231763	SENP7	0.56	9.51	0.4	1e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg07936489	chr17:37558343	FBXL20	-0.98	-15.22	-0.58	1.01e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.34	-0.4	4.21e-19	Lung cancer;
LGG	cis	rs11105298	0.891	rs10858851	chr12:89830870	C/T	cg00757033	chr12:89920650	WDR51B	0.63	8.93	0.38	1.02e-17	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17376456	0.825	rs13171131	chr5:93223028	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs4665809	0.838	rs2243834	chr2:26357748	A/C	cg22920501	chr2:26401640	FAM59B	0.39	7.76	0.34	5.38e-14	Gut microbiome composition (summer);
LGG	cis	rs7011049	1.000	rs4521776	chr8:53838833	G/C	cg26025543	chr8:53854495	NA	0.75	9.95	0.42	2.9e-21	Systolic blood pressure;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.97	0.84	1.49e-123	Prudent dietary pattern;
LGG	trans	rs7824557	0.602	rs11784544	chr8:11204503	G/C	cg02002194	chr4:3960332	NA	-0.39	-6.96	-0.31	1.15e-11	Retinal vascular caliber;
LGG	trans	rs9354308	0.746	rs9360157	chr6:66555811	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-7.85	-0.34	2.88e-14	Metabolite levels;
LGG	cis	rs943466	1.000	rs7755323	chr6:33761159	A/G	cg07519485	chr6:33762594	MLN	0.54	11.2	0.46	6.03e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs9644630	0.930	rs7005075	chr8:19367452	G/C	cg06699216	chr8:19333253	CSGALNACT1	0.49	11.4	0.47	1.03e-26	Oropharynx cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20565741	chr17:27920051	ANKRD13B	0.45	6.68	0.3	7.03e-11	Gut microbiome composition (summer);
LGG	cis	rs7618501	0.633	rs2008877	chr3:50162291	T/G	cg05623727	chr3:50126028	RBM5	-0.36	-7.67	-0.34	1.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.63	-0.37	1.02e-16	Menopause (age at onset);
LGG	cis	rs6502050	0.805	rs7406858	chr17:80080623	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs1904096	0.506	rs28701470	chr4:95167088	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.57	-10.55	-0.44	1.83e-23	Type 2 diabetes;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg09634481	chr6:45345446	RUNX2;SUPT3H	-0.46	-7.69	-0.34	8.84e-14	Brain structure;
LGG	cis	rs34311866	0.577	rs11736181	chr4:877412	C/T	cg07828340	chr4:882639	GAK	0.6	7.41	0.33	6.11e-13	Parkinson's disease;
LGG	cis	rs10504229	1.000	rs111915672	chr8:58191665	T/C	cg08677398	chr8:58056175	NA	0.43	6.84	0.3	2.56e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs782590	0.818	rs2627765	chr2:55883317	G/T	cg18811423	chr2:55921094	PNPT1	0.88	18.65	0.66	2.52e-58	Metabolic syndrome;
LGG	cis	rs4819052	0.679	rs2236450	chr21:46702553	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.68	0.44	5.78e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11608355	0.515	rs4766606	chr12:109934390	C/G	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg13047869	chr3:10149882	C3orf24	0.47	7.92	0.35	1.74e-14	Alzheimer's disease;
LGG	cis	rs35306767	0.714	rs66797613	chr10:1090469	C/T	cg20503657	chr10:835505	NA	0.53	6.94	0.31	1.34e-11	Eosinophil percentage of granulocytes;
LGG	trans	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg06521331	chr12:34319734	NA	-0.54	-9.42	-0.4	2.21e-19	Bladder cancer;
LGG	cis	rs7241530	0.717	rs28612511	chr18:75889196	T/G	cg14642773	chr18:75888474	NA	0.46	9.38	0.4	2.9e-19	Educational attainment (years of education);
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg17499041	chr6:35310257	PPARD	-0.39	-6.84	-0.3	2.53e-11	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15541040	chr2:3486749	NA	0.49	8.9	0.38	1.28e-17	Neurofibrillary tangles;
LGG	cis	rs1784581	0.855	rs1790002	chr6:162384397	G/T	cg17173639	chr6:162384350	PARK2	-0.89	-23.14	-0.73	2.88e-79	Itch intensity from mosquito bite;
LGG	cis	rs597539	0.652	rs516425	chr11:68715675	G/A	cg04772025	chr11:68637568	NA	0.72	12.75	0.51	3.93e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg12923728	chr3:195709715	SDHAP1	-0.8	-15.09	-0.57	4.01e-42	Pancreatic cancer;
LGG	cis	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg19847130	chr8:10466454	RP1L1	-0.32	-6.92	-0.31	1.51e-11	Myopia (pathological);
LGG	trans	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg21659725	chr3:3221576	CRBN	0.55	7.47	0.33	4.09e-13	Menarche (age at onset);
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-7.05	-0.31	6.45e-12	Obesity-related traits;
LGG	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg25358565	chr5:93447407	FAM172A	1.34	16.26	0.6	2.26e-47	Diabetic retinopathy;
LGG	cis	rs7223966	1.000	rs11870797	chr17:61804622	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4665809	1.000	rs6546767	chr2:26328746	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs9325144	0.647	rs11168104	chr12:38857616	G/T	cg13010199	chr12:38710504	ALG10B	-0.56	-10.62	-0.44	1.03e-23	Morning vs. evening chronotype;
LGG	cis	rs40363	0.645	rs40447	chr16:3514841	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.44	-6.7	-0.3	5.99e-11	Tuberculosis;
LGG	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg17376030	chr22:41985996	PMM1	0.56	9.02	0.39	5.11e-18	Vitiligo;
LGG	cis	rs548181	0.736	rs543389	chr11:125464841	A/G	cg03464685	chr11:125439445	EI24	1.36	19.79	0.68	1.3e-63	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.31e-21	Prudent dietary pattern;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.67	-0.3	7.28e-11	Aortic root size;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg14926445	chr8:58193284	C8orf71	0.88	11.61	0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs6598955	0.724	rs869683	chr1:26570993	T/A	cg04990556	chr1:26633338	UBXN11	-0.69	-14.09	-0.55	8.72e-38	Obesity-related traits;
LGG	cis	rs853679	0.517	rs9357065	chr6:28129580	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	trans	rs2562456	0.833	rs1781872	chr19:21477403	T/G	cg00806126	chr19:22604979	ZNF98	-0.56	-7.54	-0.33	2.53e-13	Pain;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg11859384	chr17:80120422	CCDC57	0.44	7.73	0.34	6.61e-14	Life satisfaction;
LGG	cis	rs2228479	0.618	rs72477006	chr16:89950299	G/C	cg00800038	chr16:89945340	TCF25	-0.69	-9.07	-0.39	3.38e-18	Skin colour saturation;
LGG	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.95	-0.31	1.22e-11	Educational attainment;
LGG	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs7122539	0.506	rs11227625	chr11:66684151	T/G	cg24851651	chr11:66362959	CCS	0.36	7.02	0.31	7.77e-12	HIV-1 susceptibility;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg12790134	chr8:67578787	VCPIP1	0.42	7.29	0.32	1.37e-12	Bipolar disorder;
LGG	cis	rs2074193	0.627	rs61927894	chr12:47775057	A/G	cg02516419	chr12:47771422	NA	0.73	10.81	0.45	1.89e-24	Migraine with aura;
LGG	cis	rs11122272	0.735	rs2790876	chr1:231536033	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.12	-0.46	1.24e-25	Hemoglobin concentration;
LGG	trans	rs7939886	0.920	rs59300271	chr11:55961792	G/A	cg03929089	chr4:120376271	NA	0.73	6.79	0.3	3.52e-11	Myopia (pathological);
LGG	cis	rs2180341	0.618	rs12529077	chr6:127634244	G/T	cg27446573	chr6:127587934	RNF146	0.73	13.37	0.53	1.04e-34	Breast cancer;
LGG	cis	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg24846343	chr22:24311635	DDTL	-0.48	-7.51	-0.33	3.04e-13	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg04568710	chr12:38710424	ALG10B	-0.39	-8.24	-0.36	1.85e-15	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs13173952	chr5:93307557	A/T	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs933688	1.000	rs12655973	chr5:90736537	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	19.97	0.68	1.85e-64	Smoking behavior;
LGG	cis	rs765787	0.530	rs2554456	chr15:45521138	A/C	cg25801113	chr15:45476975	SHF	0.87	19.95	0.68	2.35e-64	Uric acid levels;
LGG	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs4478137	0.501	rs9764	chr4:164245405	A/G	cg06758707	chr4:164254230	NPY1R	-0.53	-7.8	-0.34	4.12e-14	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7617773	0.817	rs35456569	chr3:48250899	T/A	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg02725872	chr8:58115012	NA	-0.98	-13.22	-0.52	4.5e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	1.000	rs12126434	chr1:182988414	A/G	cg07245641	chr1:182991651	LAMC1	-0.42	-9.66	-0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs9790314	0.637	rs778654	chr3:160716078	G/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.36	-0.4	3.38e-19	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.500	rs10844848	chr12:34409705	A/C	cg13010199	chr12:38710504	ALG10B	0.69	13.45	0.53	4.77e-35	Morning vs. evening chronotype;
LGG	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.92	0.35	1.81e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg21665744	chr7:39171113	POU6F2	0.38	7.34	0.32	9.38e-13	IgG glycosylation;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg10056627	chr6:42928773	GNMT	0.26	7.12	0.31	4.1e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6600671	1.000	rs4844607	chr1:121184059	C/T	cg00646200	chr1:148855367	NA	-0.54	-10.62	-0.44	9.68e-24	Hip geometry;
LGG	cis	rs6912958	0.781	rs7761814	chr6:88188309	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.5	-0.37	2.57e-16	Monocyte percentage of white cells;
LGG	cis	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg22496380	chr5:211416	CCDC127	-1.34	-18.64	-0.65	3e-58	Breast cancer;
LGG	trans	rs17685	0.796	rs3757594	chr7:75678644	G/A	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.84	-0.77	7.9e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.46	-0.33	4.24e-13	Lung cancer;
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg01943577	chr7:158741284	NA	-0.45	-8.35	-0.36	7.87e-16	Height;
LGG	cis	rs2880765	0.835	rs4280192	chr15:86043020	G/A	cg17133734	chr15:86042851	AKAP13	-0.28	-6.77	-0.3	3.88e-11	Coronary artery disease;
LGG	cis	rs11650494	0.831	rs7216993	chr17:47454263	A/G	cg08112188	chr17:47440006	ZNF652	1.09	13.4	0.53	8.2e-35	Prostate cancer;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg00495681	chr13:53174319	NA	0.85	18.92	0.66	1.51e-59	Lewy body disease;
LGG	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.87	-0.34	2.6e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9359856	0.510	rs2768940	chr6:90436319	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.86	-13.28	-0.53	2.39e-34	Bipolar disorder;
LGG	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2243480	1.000	rs778679	chr7:65840911	A/G	cg18252515	chr7:66147081	NA	-1.44	-20.91	-0.7	7.19e-69	Diabetic kidney disease;
LGG	cis	rs6598955	0.671	rs17163866	chr1:26648088	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.18	0.36	2.72e-15	Obesity-related traits;
LGG	cis	rs10493773	0.775	rs12738010	chr1:86102575	A/C	cg17807903	chr1:86174739	ZNHIT6	0.65	12.97	0.52	4.72e-33	Urate levels in overweight individuals;
LGG	cis	rs7089973	0.604	rs11819372	chr10:116594934	A/G	cg08188268	chr10:116634841	FAM160B1	0.3	6.69	0.3	6.52e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6554196	0.508	rs3819386	chr4:55527374	T/C	cg18836493	chr4:55524333	KIT	-0.44	-8.13	-0.35	3.98e-15	Monocyte count;
LGG	cis	rs1577917	0.740	rs9353320	chr6:86244848	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.49	8.55	0.37	1.77e-16	Response to antipsychotic treatment;
LGG	cis	rs9325144	0.678	rs7315271	chr12:39164731	A/G	cg04568710	chr12:38710424	ALG10B	-0.33	-6.83	-0.3	2.63e-11	Morning vs. evening chronotype;
LGG	cis	rs9905704	0.647	rs9901655	chr17:56987142	G/A	cg12560992	chr17:57184187	TRIM37	0.52	8.29	0.36	1.2e-15	Testicular germ cell tumor;
LGG	cis	rs780096	0.587	rs4665969	chr2:27574953	C/T	cg27432699	chr2:27873401	GPN1	0.52	9.12	0.39	2.29e-18	Total body bone mineral density;
LGG	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg25486957	chr4:152246857	NA	-0.48	-8.06	-0.35	6.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.35	8.14	0.35	3.72e-15	Schizophrenia;
LGG	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-26.61	-0.78	2.46e-95	Renal cell carcinoma;
LGG	cis	rs11064837	0.504	rs10774508	chr12:120070106	G/A	cg25937854	chr12:120150414	CIT	-0.6	-10.55	-0.44	1.89e-23	Schizophrenia;
LGG	cis	rs3743104	0.534	rs11854391	chr15:33022582	A/T	cg07179000	chr15:33023586	GREM1	-0.47	-8.75	-0.38	4.06e-17	Hypospadias;
LGG	cis	rs8062405	0.965	rs62037363	chr16:28865042	T/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12477438	0.871	rs62156364	chr2:99695097	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-11.63	-0.48	1.31e-27	Chronic sinus infection;
LGG	cis	rs4148087	0.929	rs915845	chr21:43635438	T/G	cg10192877	chr21:43641690	ABCG1	-0.4	-7.1	-0.31	4.74e-12	Eating disorder in bipolar disorder;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27482856	chr7:99214447	ZNF498	-0.41	-6.72	-0.3	5.41e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg02158880	chr13:53174818	NA	-0.4	-7.85	-0.34	2.85e-14	Lewy body disease;
LGG	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg27633287	chr12:130766243	NA	-0.43	-7.49	-0.33	3.44e-13	Menopause (age at onset);
LGG	cis	rs653465	0.621	rs10865811	chr3:27135957	G/A	cg02860705	chr3:27208620	NA	-0.38	-7.4	-0.33	6.68e-13	Breast cancer (early onset);
LGG	trans	rs7824557	0.602	rs7834139	chr8:11206363	C/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.21	0.32	2.36e-12	Retinal vascular caliber;
LGG	trans	rs1459104	0.641	rs4454742	chr11:54840592	A/T	cg03929089	chr4:120376271	NA	0.7	6.91	0.31	1.62e-11	Body mass index;
LGG	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs8180040	0.676	rs66564457	chr3:47020072	G/A	cg27129171	chr3:47204927	SETD2	0.81	14.95	0.57	1.68e-41	Colorectal cancer;
LGG	cis	rs367615	0.552	rs2963024	chr5:108730773	C/T	cg17395555	chr5:108820864	NA	-0.71	-11.6	-0.47	1.74e-27	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs7395662	0.794	rs11511967	chr11:48820453	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.23	-0.36	1.88e-15	HDL cholesterol;
LGG	cis	rs3850699	0.926	rs7094325	chr10:104429746	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.79	-0.3	3.41e-11	Prostate cancer;
LGG	cis	rs2404602	1.000	rs1117367	chr15:76872330	A/C	cg22467129	chr15:76604101	ETFA	-0.47	-7.93	-0.35	1.69e-14	Blood metabolite levels;
LGG	cis	rs2133450	0.967	rs62234950	chr3:7335338	T/G	cg19930620	chr3:7340148	GRM7	-0.4	-8.69	-0.37	6.29e-17	Early response to risperidone in schizophrenia;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg11965913	chr1:205819406	PM20D1	0.83	18.32	0.65	8.82e-57	Menarche (age at onset);
LGG	cis	rs11098499	0.955	rs1511015	chr4:120170473	A/C	cg24375607	chr4:120327624	NA	0.61	10.16	0.43	4.94e-22	Corneal astigmatism;
LGG	cis	rs7914558	1.000	rs10748838	chr10:104943986	T/A	cg04362960	chr10:104952993	NT5C2	0.56	10.68	0.44	5.97e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg00012203	chr2:219082015	ARPC2	0.78	14.89	0.57	2.94e-41	Colorectal cancer;
LGG	cis	rs4474465	0.850	rs4245460	chr11:78258147	G/C	cg27205649	chr11:78285834	NARS2	0.52	8.76	0.38	3.6e-17	Alzheimer's disease (survival time);
LGG	cis	rs9916302	0.605	rs2879258	chr17:37399379	G/T	cg00129232	chr17:37814104	STARD3	-0.59	-8.18	-0.36	2.84e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg11062466	chr8:58055876	NA	0.43	6.8	0.3	3.17e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.554	rs7111711	chr11:49557880	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.64	-11.01	-0.46	3.22e-25	Coronary artery disease;
LGG	cis	rs7959452	0.684	rs11177615	chr12:69754189	G/A	cg11871910	chr12:69753446	YEATS4	0.93	21.84	0.71	3.45e-73	Blood protein levels;
LGG	cis	rs2228479	0.702	rs62056100	chr16:89939753	C/T	cg26513180	chr16:89883248	FANCA	0.89	8.55	0.37	1.86e-16	Skin colour saturation;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg08742575	chr21:47604166	C21orf56	0.55	9.98	0.42	2.29e-21	Testicular germ cell tumor;
LGG	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg16577123	chr5:140027231	NDUFA2;IK	0.42	6.68	0.3	6.88e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4925325	0.876	rs6089560	chr20:60517325	T/G	cg13770153	chr20:60521292	NA	-1.14	-21.4	-0.71	3.86e-71	Obesity-related traits;
LGG	cis	rs13002735	1	rs13002735	chr2:232268884	A/C	cg11378575	chr2:232265004	B3GNT7	0.57	8.94	0.38	9.33e-18	Resting heart rate;
LGG	cis	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg07234876	chr8:600039	NA	0.99	9.89	0.42	4.64e-21	IgG glycosylation;
LGG	cis	rs975739	0.966	rs1279403	chr13:78391757	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.7	0.3	6.01e-11	Hair color;
LGG	trans	rs3857536	0.679	rs1964856	chr6:66952886	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.43	-7.15	-0.32	3.41e-12	Blood trace element (Cu levels);
LGG	cis	rs6489882	0.867	rs4767032	chr12:113363077	T/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.18e-13	Chronic lymphocytic leukemia;
LGG	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs12479064	0.724	rs112900993	chr2:99948805	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.78	-0.38	3.08e-17	Chronic sinus infection;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg09699651	chr6:150184138	LRP11	0.51	8.85	0.38	1.87e-17	Lung cancer;
LGG	trans	rs637571	0.615	rs10160792	chr11:65667149	C/G	cg17712092	chr4:129076599	LARP1B	0.89	18.86	0.66	2.75e-59	Eosinophil percentage of white cells;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg22535103	chr8:58192502	C8orf71	-0.74	-9.3	-0.4	5.47e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.714	rs2051540	chr6:25947197	T/C	cg12310025	chr6:25882481	NA	-0.68	-12.93	-0.51	7.51e-33	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg03433033	chr1:76189801	ACADM	-0.62	-9.12	-0.39	2.39e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs67311347	1.000	rs11707278	chr3:40487075	A/T	cg24209194	chr3:40518798	ZNF619	0.43	6.66	0.3	7.93e-11	Renal cell carcinoma;
LGG	cis	rs1008375	1.000	rs10012335	chr4:17628630	C/G	cg15017067	chr4:17643749	FAM184B	0.3	6.91	0.31	1.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg27110132	chr16:3661765	BTBD12	0.77	7.34	0.32	9.74e-13	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs62025270	0.688	rs62025298	chr15:86317152	T/C	cg25843651	chr15:86329602	KLHL25	0.63	10.17	0.43	4.45e-22	Idiopathic pulmonary fibrosis;
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.09	0.31	4.95e-12	Retinal vascular caliber;
LGG	cis	rs7166081	1.000	rs12594234	chr15:67596154	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs75920871	1.000	rs10892044	chr11:116766899	C/T	cg20608306	chr11:116969690	SIK3	0.32	6.84	0.3	2.53e-11	Subjective well-being;
LGG	cis	rs9467711	0.722	rs13201782	chr6:26651053	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	6.7	0.3	6.03e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12643440	0.504	rs16894581	chr4:17186933	A/G	cg22650099	chr4:17144496	NA	-0.49	-8.03	-0.35	7.98e-15	Metabolite levels (Pyroglutamine);
LGG	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.48	7.96	0.35	1.3e-14	Osteoporosis;
LGG	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg12373951	chr3:133503437	NA	0.43	7.84	0.34	3.11e-14	Iron status biomarkers;
LGG	cis	rs9788721	0.592	rs28564957	chr15:78906107	C/A	cg06917634	chr15:78832804	PSMA4	-0.66	-12.55	-0.5	2.72e-31	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg06212747	chr3:49208901	KLHDC8B	0.62	10.32	0.43	1.28e-22	Parkinson's disease;
LGG	cis	rs952623	0.649	rs6462887	chr7:39067636	A/G	cg20302533	chr7:39170763	POU6F2	0.32	7.68	0.34	9.76e-14	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs2911713	chr2:27640980	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.88	-0.3	2.01e-11	Total body bone mineral density;
LGG	cis	rs11098499	0.775	rs67281037	chr4:120281157	G/C	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs56161922	0.908	rs55689175	chr1:207859699	G/C	cg09557387	chr1:207818395	CR1L	0.94	9.47	0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs3749237	0.595	rs4855859	chr3:49526300	C/T	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.6e-35	Resting heart rate;
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg18876405	chr7:65276391	NA	-0.5	-8.86	-0.38	1.79e-17	Aortic root size;
LGG	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg17077180	chr1:38461687	NA	-0.5	-12.46	-0.5	6.1e-31	Coronary artery disease;
LGG	cis	rs990171	1.000	rs10197284	chr2:102982703	G/A	cg05295703	chr2:102895712	NA	-0.56	-9.67	-0.41	2.76e-20	Lymphocyte counts;
LGG	trans	rs6582630	0.519	rs11514056	chr12:38284001	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.65	-0.41	3.28e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10927875	1.000	rs10927875	chr1:16299312	A/G	cg21385522	chr1:16154831	NA	0.8	15.54	0.59	4.17e-44	Dilated cardiomyopathy;
LGG	trans	rs57221529	0.713	rs56328416	chr5:591138	G/A	cg25482853	chr8:67687455	SGK3	0.99	12.66	0.51	9.13e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs9326248	0.581	rs7106437	chr11:116992076	T/C	cg20608306	chr11:116969690	SIK3	0.41	12.8	0.51	2.57e-32	Blood protein levels;
LGG	trans	rs4843747	0.671	rs72818540	chr16:88078988	C/T	cg26811252	chr16:29126840	RRN3P2	0.71	11.13	0.46	1.14e-25	Menopause (age at onset);
LGG	cis	rs3126085	0.825	rs10788830	chr1:152206898	A/C	cg26876637	chr1:152193138	HRNR	0.56	9.19	0.39	1.3e-18	Atopic dermatitis;
LGG	cis	rs416603	0.901	rs149597	chr16:11343942	C/G	cg00044050	chr16:11439710	C16orf75	-0.53	-8.86	-0.38	1.67e-17	Type 1 diabetes;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.9	0.31	1.77e-11	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.02e-20	Diabetic retinopathy;
LGG	cis	rs9911578	0.967	rs1588322	chr17:56990099	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-9.99	-0.42	2.09e-21	Intelligence (multi-trait analysis);
LGG	cis	rs4740619	0.745	rs4472620	chr9:15941439	A/G	cg14451791	chr9:16040625	NA	-0.39	-9.6	-0.41	4.87e-20	Body mass index;
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg16141378	chr3:129829833	LOC729375	0.41	9.63	0.41	3.84e-20	Neuroticism;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.33	0.55	7.9e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3762637	1.000	rs78381804	chr3:122222262	A/T	cg24169773	chr3:122142474	KPNA1	-0.6	-10.2	-0.43	3.63e-22	LDL cholesterol levels;
LGG	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.91	0.45	8.06e-25	Corneal astigmatism;
LGG	cis	rs9878978	0.722	rs2055481	chr3:2446925	T/A	cg21928760	chr3:2462534	CNTN4	0.39	7.76	0.34	5.49e-14	Blood pressure (smoking interaction);
LGG	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg15556689	chr8:8085844	FLJ10661	-0.45	-8.17	-0.36	2.9e-15	Mood instability;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.35	0.61	8.8e-48	Obesity-related traits;
LGG	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg18479299	chr3:125709523	NA	-0.58	-7.39	-0.32	6.93e-13	Blood pressure (smoking interaction);
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg20887711	chr4:1340912	KIAA1530	0.61	11.93	0.48	8.29e-29	Obesity-related traits;
LGG	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	7.72	0.34	7.4e-14	Cognitive test performance;
LGG	cis	rs9611565	0.512	rs2050031	chr22:42152266	A/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.64	-0.44	8.31e-24	Vitiligo;
LGG	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg06606381	chr12:133084897	FBRSL1	-1.15	-10.64	-0.44	8.52e-24	Intelligence (multi-trait analysis);
LGG	cis	rs990171	1.000	rs6753717	chr2:102993161	A/C	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.33e-21	Lymphocyte counts;
LGG	cis	rs10504073	0.669	rs57085792	chr8:50018355	T/C	cg00325661	chr8:49890786	NA	0.7	13.75	0.54	2.65e-36	Blood metabolite ratios;
LGG	trans	rs853679	0.546	rs200949	chr6:27835435	A/G	cg08344181	chr3:125677491	NA	-0.56	-6.85	-0.3	2.37e-11	Depression;
LGG	cis	rs7928758	0.887	rs80021729	chr11:134263734	A/C	cg15243474	chr11:134282918	B3GAT1	1.28	15.44	0.58	1.14e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2276314	1.000	rs9304153	chr18:33562150	T/C	cg05985134	chr18:33552581	C18orf21	0.64	9.96	0.42	2.65e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.3	0.43	1.48e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7998202	0.667	rs282577	chr13:113358838	G/A	cg02820901	chr13:113351484	ATP11A	0.55	6.7	0.3	6.03e-11	Glycated hemoglobin levels;
LGG	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.16e-14	HDL cholesterol;
LGG	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg05793240	chr7:2802953	GNA12	0.33	7.41	0.33	5.97e-13	Height;
LGG	cis	rs561341	0.883	rs7406056	chr17:30220224	C/T	cg13647721	chr17:30228624	UTP6	0.77	10.18	0.43	4.1e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7267979	0.844	rs1555330	chr20:25232097	A/C	cg06421707	chr20:25228305	PYGB	0.54	12.2	0.49	7.06e-30	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1978968	0.956	rs12159837	chr22:18447491	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.35	-0.5	1.72e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg11859384	chr17:80120422	CCDC57	0.39	6.79	0.3	3.51e-11	Life satisfaction;
LGG	cis	rs7666738	0.791	rs10856934	chr4:99010844	A/G	cg05340658	chr4:99064831	C4orf37	-0.51	-8.51	-0.37	2.35e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs16912285	0.685	rs16912402	chr11:24313135	C/G	ch.11.24196551F	chr11:24239977	NA	0.88	9.61	0.41	4.81e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.71	-0.3	5.68e-11	Height;
LGG	cis	rs7216064	1.000	rs4791212	chr17:65975385	C/T	cg12091567	chr17:66097778	LOC651250	-0.62	-9.28	-0.4	6.32e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.87	-0.34	2.52e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2836950	0.565	rs2836931	chr21:40546569	T/G	cg11890956	chr21:40555474	PSMG1	-0.75	-12.91	-0.51	8.95e-33	Menarche (age at onset);
LGG	cis	rs4727027	0.870	rs11525060	chr7:148801091	G/A	cg23583168	chr7:148888333	NA	-0.84	-15.79	-0.59	2.95e-45	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9815354	0.812	rs7629767	chr3:42043509	T/G	cg03022575	chr3:42003672	ULK4	0.66	7.89	0.34	2.15e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7937682	1.000	rs7128353	chr11:111538875	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.15	-26.08	-0.77	6.62e-93	Primary sclerosing cholangitis;
LGG	cis	rs9611519	0.780	rs9611546	chr22:41698542	C/G	cg06634786	chr22:41940651	POLR3H	-0.57	-9.44	-0.4	1.87e-19	Neuroticism;
LGG	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg06212747	chr3:49208901	KLHDC8B	0.51	7.96	0.35	1.38e-14	Menarche (age at onset);
LGG	cis	rs4072980	0.545	rs16824518	chr1:38415315	A/C	cg12658694	chr1:38397304	INPP5B	-0.53	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	trans	rs7980799	0.716	rs1351683	chr12:33598563	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-11.65	-0.48	1.08e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs4481887	1.000	rs4589143	chr1:248470446	A/G	cg13385794	chr1:248469461	NA	0.49	8.19	0.36	2.51e-15	Common traits (Other);
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg22433210	chr17:43662623	NA	-0.63	-10.83	-0.45	1.62e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12541335	0.639	rs3923439	chr8:22170079	G/A	cg02463440	chr8:22132932	PIWIL2	0.49	10.82	0.45	1.76e-24	Hypertriglyceridemia;
LGG	cis	rs7818345	0.534	rs34221121	chr8:19319625	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	7.51	0.33	3.1400000000000003e-13	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14086659	chr2:95787933	MRPS5	0.43	7.12	0.31	4.04e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg14541582	chr5:601475	NA	-0.7	-10.86	-0.45	1.28e-24	Obesity-related traits;
LGG	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg13902645	chr11:5959945	NA	-0.66	-10.08	-0.42	9.92e-22	DNA methylation (variation);
LGG	cis	rs62079673	0.527	rs9788998	chr17:80605644	A/G	cg13639189	chr17:80606880	WDR45L	0.43	7.54	0.33	2.45e-13	Breast cancer;
LGG	cis	rs16976116	0.951	rs3809540	chr15:55489412	A/C	cg11288833	chr15:55489084	RSL24D1	0.55	7.68	0.34	9.65e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.6	0.41	5.24e-20	Mean corpuscular volume;
LGG	cis	rs6735179	0.565	rs736870	chr2:1748702	T/C	cg08534653	chr2:1747700	PXDN	0.5	7.5	0.33	3.35e-13	Response to antipsychotic treatment;
LGG	cis	rs4740619	0.544	rs9406536	chr9:15815030	G/A	cg14451791	chr9:16040625	NA	0.32	7.93	0.35	1.61e-14	Body mass index;
LGG	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg07274523	chr3:49395745	GPX1	-0.54	-8.83	-0.38	2.16e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-10.09	-0.42	8.79e-22	Mood instability;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg21226059	chr5:178986404	RUFY1	0.5	8.6	0.37	1.25e-16	Lung cancer;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.39	-0.32	7.09e-13	Lung cancer;
LGG	cis	rs832540	0.931	rs33319	chr5:56206675	C/A	cg14703610	chr5:56206110	C5orf35	0.47	8.1	0.35	4.82e-15	Coronary artery disease;
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	trans	rs9650657	0.737	rs2409669	chr8:10623969	A/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.68	-0.3	6.79e-11	Neuroticism;
LGG	cis	rs6933660	0.745	rs3778608	chr6:151738131	A/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-12.34	-0.5	1.98e-30	Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs9820598	chr3:10117912	C/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg24829409	chr8:58192753	C8orf71	-0.84	-13.27	-0.52	2.8e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg26338869	chr17:61819248	STRADA	0.57	9.43	0.4	2.02e-19	Prudent dietary pattern;
LGG	cis	rs751728	0.626	rs6457741	chr6:33756026	C/T	cg07519485	chr6:33762594	MLN	-0.29	-6.67	-0.3	7.18e-11	Crohn's disease;
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.513	rs556442	chr11:68192690	G/A	cg16797656	chr11:68205561	LRP5	-0.56	-10.25	-0.43	2.38e-22	Total body bone mineral density;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg04287289	chr16:89883240	FANCA	0.83	8.95	0.38	8.67e-18	Skin colour saturation;
LGG	cis	rs6784615	1.000	rs35982798	chr3:52383340	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.68	7.42	0.33	5.54e-13	Waist-hip ratio;
LGG	cis	rs11627756	0.958	rs4906238	chr14:103077702	G/A	cg12046867	chr14:103022105	NA	-0.4	-7.52	-0.33	2.93e-13	Mean platelet volume;
LGG	cis	rs62064224	0.714	rs11657299	chr17:30634951	G/A	cg25809561	chr17:30822961	MYO1D	0.34	8.02	0.35	8.71e-15	Schizophrenia;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7660520	0.524	rs4862101	chr4:183733177	T/C	cg25287198	chr4:183728479	NA	0.48	7.67	0.34	1.03e-13	Pediatric autoimmune diseases;
LGG	cis	rs2742417	0.603	rs2742458	chr3:45767602	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.65e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4774830	0.744	rs77377502	chr15:56307889	A/G	cg05129572	chr15:56138634	NEDD4	0.75	7.17	0.32	2.93e-12	Delta-5 desaturase activity;
LGG	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg20336341	chr7:50628841	DDC	-0.43	-7.59	-0.33	1.8e-13	Malaria;
LGG	cis	rs6586163	0.509	rs2031610	chr10:90754487	T/C	cg03111039	chr10:90751583	FAS;ACTA2	0.75	14.64	0.56	3.61e-40	Chronic lymphocytic leukemia;
LGG	cis	rs7100689	0.725	rs2487074	chr10:82064104	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	15.93	0.59	7.5e-46	Post bronchodilator FEV1;
LGG	cis	rs2451279	0.565	rs2451255	chr6:159510816	A/C	cg01046905	chr6:159515345	NA	0.33	7.05	0.31	6.36e-12	Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;
LGG	cis	rs68170813	0.559	rs75203426	chr7:107017589	G/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.29	-0.43	1.63e-22	Coronary artery disease;
LGG	cis	rs7226408	0.857	rs10502666	chr18:34423393	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.97	-0.31	1.08e-11	Obesity-related traits;
LGG	cis	rs2013441	1.000	rs2034109	chr17:20196633	C/T	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6e-11	Obesity-related traits;
LGG	cis	rs12210905	0.688	rs72845027	chr6:27528199	T/C	cg10122326	chr6:28072925	NA	0.94	7.23	0.32	1.96e-12	Hip circumference adjusted for BMI;
LGG	trans	rs7395662	0.929	rs11493665	chr11:48721035	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.64e-13	HDL cholesterol;
LGG	cis	rs9635726	0.638	rs2952155	chr17:37861718	T/C	cg00129232	chr17:37814104	STARD3	-0.62	-11.03	-0.46	2.85e-25	Primary biliary cholangitis;
LGG	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.87	0.3	2.03e-11	Resting heart rate;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg00933542	chr6:150070202	PCMT1	0.38	6.99	0.31	9.4e-12	Lung cancer;
LGG	cis	rs1010254	0.510	rs72806363	chr5:151686969	C/G	cg12297329	chr5:152029980	NA	-0.48	-7.0	-0.31	9.09e-12	Optic nerve measurement (cup area);
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	18.98	0.66	7.39e-60	Platelet count;
LGG	cis	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg21479132	chr6:26055353	NA	0.82	8.08	0.35	5.56e-15	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6601327	0.606	rs13268319	chr8:9579249	C/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	8.98e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs59918340	0.728	rs6987335	chr8:142235358	T/G	cg03653399	chr8:142233436	SLC45A4	-0.41	-7.84	-0.34	3.18e-14	Immature fraction of reticulocytes;
LGG	cis	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.69	-0.34	8.79e-14	Mood instability;
LGG	cis	rs7582180	0.629	rs4851308	chr2:100971865	C/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	7.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9788721	0.836	rs17483721	chr15:78733731	C/T	cg18825076	chr15:78729989	IREB2	0.58	9.63	0.41	4.12e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9811920	0.638	rs2452321	chr3:99638836	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.52	8.97	0.38	7.32e-18	Axial length;
LGG	cis	rs28386778	0.897	rs2584642	chr17:61942427	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.12	0.35	4.19e-15	Prudent dietary pattern;
LGG	cis	rs9463078	0.683	rs1418433	chr6:44752568	C/T	cg25276700	chr6:44698697	NA	0.41	8.64	0.37	8.96e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg02574844	chr11:5959923	NA	-0.55	-8.53	-0.37	2.18e-16	DNA methylation (variation);
LGG	cis	rs9926296	0.744	rs6860	chr16:89711120	C/T	cg04287289	chr16:89883240	FANCA	-0.44	-7.78	-0.34	4.73e-14	Vitiligo;
LGG	cis	rs977987	0.750	rs4888406	chr16:75432334	G/T	cg03315344	chr16:75512273	CHST6	0.51	10.27	0.43	2.01e-22	Dupuytren's disease;
LGG	cis	rs2282802	0.685	rs35214989	chr5:139636127	T/C	cg26211634	chr5:139558579	C5orf32	0.34	7.54	0.33	2.58e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4853012	0.838	rs61521879	chr2:74346208	T/C	cg20891558	chr2:74357851	NA	0.49	9.53	0.41	8.75e-20	Gestational age at birth (maternal effect);
LGG	cis	rs10929925	0.931	rs2091378	chr2:6145081	C/G	cg00493617	chr2:6141445	NA	0.31	6.85	0.3	2.41e-11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg05535760	chr7:792225	HEATR2	0.76	12.29	0.5	2.94e-30	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg26174226	chr8:58114915	NA	-0.57	-7.67	-0.34	1.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.754	rs6673768	chr1:182983396	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.06e-11	Fuchs's corneal dystrophy;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22168489	chr12:122356033	WDR66	0.41	9.3	0.4	5.77e-19	Mean corpuscular volume;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg15242686	chr22:24348715	GSTTP1	0.4	7.72	0.34	7.38e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg23594656	chr7:65796392	TPST1	0.39	8.3	0.36	1.13e-15	Aortic root size;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	cis	rs16976116	0.901	rs28714578	chr15:55491121	G/A	cg11288833	chr15:55489084	RSL24D1	0.57	7.71	0.34	7.86e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.78	0.45	2.47e-24	Diabetic retinopathy;
LGG	cis	rs7829975	0.539	rs940031	chr8:8546848	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.05	-0.35	7.2e-15	Mood instability;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.24e-18	Lung cancer;
LGG	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg14675211	chr2:100938903	LONRF2	0.48	7.3	0.32	1.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs68121641	chr3:10165845	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg07701084	chr6:150067640	NUP43	0.71	13.9	0.54	5.92e-37	Lung cancer;
LGG	cis	rs2224391	0.628	rs2753237	chr6:5252675	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.49	-0.33	3.53e-13	Height;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg04267008	chr7:1944627	MAD1L1	-0.55	-9.43	-0.4	1.97e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	1.000	rs348957	chr5:112821178	C/T	cg27587195	chr5:112824172	MCC	0.46	7.38	0.32	7.24e-13	Type 2 diabetes;
LGG	cis	rs988958	0.565	rs35411295	chr2:42236631	T/A	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg04080417	chr5:1859792	NA	-0.53	-8.68	-0.37	7.01e-17	Cardiovascular disease risk factors;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.7	-0.3	6.09e-11	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg19729930	chr2:74357872	NA	0.54	11.73	0.48	5.2e-28	Gestational age at birth (maternal effect);
LGG	cis	rs72772090	0.539	rs3334	chr5:96115085	G/C	cg00188032	chr5:96141721	ERAP1	0.55	7.31	0.32	1.21e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6835098	1.000	rs1054497	chr4:174089048	A/T	cg08422745	chr4:174089978	GALNT7	0.85	15.3	0.58	4.57e-43	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs657075	0.595	rs35724182	chr5:131580301	C/T	cg06968155	chr5:131705112	SLC22A5	0.53	6.65	0.3	8.07e-11	Rheumatoid arthritis;
LGG	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg12751644	chr20:60527061	NA	-0.3	-6.75	-0.3	4.54e-11	Body mass index;
LGG	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg14983838	chr19:29218262	NA	0.71	11.43	0.47	8.31e-27	Methadone dose in opioid dependence;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg00933542	chr6:150070202	PCMT1	0.39	7.06	0.31	6.27e-12	Lung cancer;
LGG	cis	rs988958	0.567	rs11899374	chr2:42220752	G/T	cg19376973	chr2:42229025	NA	0.67	10.11	0.43	7.81e-22	Hypospadias;
LGG	cis	rs4430311	0.723	rs897959	chr1:243897774	C/T	cg25706552	chr1:244017396	NA	-0.65	-15.92	-0.59	7.94e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1707322	0.721	rs10789471	chr1:46215619	G/A	cg03146154	chr1:46216737	IPP	0.56	10.7	0.45	5.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.83	-0.48	2.09e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs950776	1.000	rs950776	chr15:78926018	A/G	cg06917634	chr15:78832804	PSMA4	0.7	13.15	0.52	9.19e-34	Sudden cardiac arrest;
LGG	cis	rs9581857	0.685	rs60787915	chr13:28022298	C/T	cg01674679	chr13:27998804	GTF3A	-0.59	-7.19	-0.32	2.68e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs4660214	0.666	rs598415	chr1:39832407	T/C	cg18385671	chr1:39797026	MACF1	0.47	9.8	0.41	9.76e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.78	0.38	3.25e-17	Longevity;
LGG	cis	rs11098499	0.863	rs7657849	chr4:120455494	T/C	cg09307838	chr4:120376055	NA	0.8	13.14	0.52	9.94e-34	Corneal astigmatism;
LGG	cis	rs694739	0.628	rs538147	chr11:64129722	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.79	15.22	0.58	1.03e-42	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs738321	0.701	rs11703601	chr22:38598041	C/T	cg03162506	chr22:38580953	NA	0.39	9.29	0.4	6.2800000000000005e-19	Breast cancer;
LGG	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg13114125	chr14:105738426	BRF1	-0.85	-15.96	-0.6	5.17e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg21782813	chr7:2030301	MAD1L1	0.51	12.49	0.5	4.65e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs9479482	0.967	rs1853664	chr6:150355266	A/G	cg03788504	chr6:150331562	NA	-0.56	-12.59	-0.51	1.75e-31	Alopecia areata;
LGG	cis	rs8067545	0.641	rs1479129	chr17:19845769	A/G	cg04132472	chr17:19861366	AKAP10	0.26	7.15	0.32	3.42e-12	Schizophrenia;
LGG	cis	rs921968	0.643	rs6708683	chr2:219504503	G/A	cg01130898	chr2:219473002	PLCD4	-0.41	-7.05	-0.31	6.6e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7539542	0.556	rs3820152	chr1:202878492	A/T	cg19681188	chr1:202830198	LOC148709	-0.51	-8.44	-0.37	4e-16	Mean platelet volume;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg11494091	chr17:61959527	GH2	1.01	24.72	0.75	1.2e-86	Prudent dietary pattern;
LGG	cis	rs7582180	0.764	rs13001423	chr2:100925340	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs6462411	0.877	rs1962785	chr7:3919542	C/G	cg18022346	chr7:3920534	SDK1	-0.35	-6.74	-0.3	4.58e-11	Quantitative traits;
LGG	cis	rs9308731	1.000	rs1980045	chr2:111904541	A/G	cg18081430	chr2:111878091	BCL2L11	-0.31	-6.76	-0.3	4.15e-11	Chronic lymphocytic leukemia;
LGG	cis	rs2764980	1.000	rs2764980	chr10:3284007	C/T	cg20244327	chr10:3283946	NA	0.32	8.59	0.37	1.31e-16	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs12318506	0.826	rs11180452	chr12:75693881	G/T	cg04728562	chr12:75699417	CAPS2	-1.17	-9.72	-0.41	1.8899999999999998e-20	Coronary artery calcification;
LGG	cis	rs537930	0.560	rs31204	chr5:134351797	A/G	cg24576358	chr5:134350122	NA	0.32	7.19	0.32	2.66e-12	Height;
LGG	cis	rs2013441	1.000	rs2526464	chr17:20075052	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs12410462	0.591	rs2453682	chr1:227710381	T/C	cg04117972	chr1:227635322	NA	0.46	8.35	0.36	7.99e-16	Major depressive disorder;
LGG	cis	rs3741151	0.773	rs17310361	chr11:73233724	T/C	cg17517138	chr11:73019481	ARHGEF17	0.8	7.79	0.34	4.54e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1941023	0.503	rs4939349	chr11:60135880	G/A	cg08716584	chr11:60157161	MS4A7	-0.42	-8.39	-0.36	5.92e-16	Congenital heart disease (maternal effect);
LGG	cis	rs12230513	0.732	rs61547125	chr12:55814082	C/G	cg19537932	chr12:55886519	OR6C68	-0.59	-10.79	-0.45	2.34e-24	Contrast sensitivity;
LGG	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.22	-0.36	1.99e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs734999	0.588	rs2764842	chr1:2529192	A/G	cg15627072	chr1:2432621	PLCH2	-0.38	-8.39	-0.36	6.04e-16	Ulcerative colitis;
LGG	cis	rs11997175	0.716	rs7460818	chr8:33816362	A/G	ch.8.33884649F	chr8:33765107	NA	0.41	7.87	0.34	2.46e-14	Body mass index;
LGG	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg18876405	chr7:65276391	NA	0.67	12.92	0.51	7.92e-33	Aortic root size;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg13206674	chr6:150067644	NUP43	0.66	14.87	0.57	3.5e-41	Lung cancer;
LGG	cis	rs9972944	0.729	rs62065062	chr17:63777383	G/A	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.41e-14	Total body bone mineral density;
LGG	cis	rs7618915	0.501	rs6804145	chr3:52694198	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.54e-14	Bipolar disorder;
LGG	cis	rs76070545	0.636	rs28615644	chr8:104220123	A/G	cg03923813	chr8:104230441	BAALC	-1.19	-12.81	-0.51	2.3e-32	Alzheimer disease and age of onset;
LGG	cis	rs2172802	0.659	rs4484334	chr4:62499841	C/T	cg04118610	chr4:62707027	LPHN3	0.61	10.71	0.45	4.47e-24	Partial epilepsies;
LGG	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.04	0.52	2.62e-33	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11245443	chr6:26199702	HIST1H3D;HIST1H2BF;HIST1H2AD	0.39	6.65	0.3	8.32e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs4843747	0.671	rs28679286	chr16:88106307	C/T	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.14	0.43	6.13e-22	Height;
LGG	cis	rs73086581	0.947	rs17287577	chr20:3966254	C/T	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs2898290	0.622	rs17799486	chr8:11340494	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.82	-0.3	2.88e-11	Systolic blood pressure;
LGG	trans	rs2727020	0.553	rs3907576	chr11:49536639	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.3	-0.7	1.13e-70	Coronary artery disease;
LGG	cis	rs4731207	0.698	rs7778956	chr7:124527733	C/T	cg05630886	chr7:124431682	NA	-0.35	-8.41	-0.36	5.15e-16	Cutaneous malignant melanoma;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.49	0.37	2.89e-16	Schizophrenia;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08280861	chr8:58055591	NA	0.67	11.68	0.48	8.3e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.709	rs272852	chr5:131688767	G/A	cg07395648	chr5:131743802	NA	-0.55	-13.14	-0.52	9.83e-34	Blood metabolite levels;
LGG	cis	rs2276314	0.857	rs59649576	chr18:33616075	G/T	cg19628046	chr18:33552617	C18orf21	0.51	7.54	0.33	2.58e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9872999	1	rs9872999	chr3:133457514	C/T	cg24879335	chr3:133465180	TF	0.45	7.38	0.32	7.62e-13	Iron status biomarkers;
LGG	cis	rs208520	0.955	rs9453664	chr6:66976079	A/C	cg07460842	chr6:66804631	NA	0.9	14.8	0.57	7.18e-41	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg22535103	chr8:58192502	C8orf71	-0.84	-10.81	-0.45	1.95e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	1.000	rs4862751	chr4:187904050	G/A	cg22105103	chr4:187893119	NA	0.54	10.32	0.43	1.31e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs798554	0.644	rs1639040	chr7:2884116	G/T	cg19717773	chr7:2847554	GNA12	-0.32	-6.86	-0.3	2.28e-11	Height;
LGG	cis	rs644799	0.687	rs3748252	chr11:95519195	A/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.85	-17.6	-0.63	1.8e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg00495681	chr13:53174319	NA	-0.45	-7.46	-0.33	4.34e-13	Lewy body disease;
LGG	cis	rs9902453	0.904	rs9900112	chr17:28282910	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.06	0.55	1.17e-37	Coffee consumption (cups per day);
LGG	cis	rs765787	0.530	rs2413780	chr15:45538866	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs2032447	0.714	rs199734	chr6:25940393	G/C	cg03517284	chr6:25882590	NA	-0.71	-13.67	-0.54	5.6e-36	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.51	8.24	0.36	1.76e-15	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg17470184	chr11:118478236	PHLDB1	-0.42	-7.22	-0.32	2.14e-12	Cholesterol, total;
LGG	cis	rs11122272	0.735	rs973253	chr1:231520874	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs1577917	0.958	rs11752180	chr6:86573165	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.18	-0.49	8.86e-30	Response to antipsychotic treatment;
LGG	cis	rs7937890	0.559	rs2575830	chr11:14485602	C/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs2456568	0.548	rs10466335	chr11:93663820	G/C	cg26875233	chr11:93583750	C11orf90	-0.44	-8.6	-0.37	1.27e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg02733842	chr7:1102375	C7orf50	-0.44	-7.27	-0.32	1.55e-12	Bronchopulmonary dysplasia;
LGG	cis	rs11864453	0.713	rs7191127	chr16:72123992	G/T	cg01557791	chr16:72042693	DHODH	-0.51	-9.36	-0.4	3.54e-19	Fibrinogen levels;
LGG	cis	rs9462027	0.606	rs205260	chr6:34563958	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.55	-0.44	1.81e-23	Systemic lupus erythematosus;
LGG	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg04374321	chr14:90722782	PSMC1	0.49	8.2	0.36	2.34e-15	Longevity;
LGG	trans	rs8129326	0.664	rs13047294	chr21:35783445	G/A	cg07474852	chr4:123073612	NA	0.5	8.93	0.38	9.74e-18	Cancer;
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg13732083	chr21:47605072	C21orf56	0.46	7.74	0.34	6.13e-14	Testicular germ cell tumor;
LGG	trans	rs9650657	0.648	rs6601512	chr8:10585596	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.48	-0.33	3.86e-13	Neuroticism;
LGG	cis	rs1728785	0.901	rs1170444	chr16:68573287	T/C	cg02972257	chr16:68554789	NA	-0.55	-8.29	-0.36	1.22e-15	Ulcerative colitis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg20618610	chr11:58830857	NA	0.37	6.74	0.3	4.6e-11	Menarche (age at onset);
LGG	cis	rs62064224	0.589	rs4523973	chr17:30809455	G/A	cg25809561	chr17:30822961	MYO1D	0.39	9.3	0.4	5.71e-19	Schizophrenia;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.26	0.4	7.83e-19	Bipolar disorder;
LGG	cis	rs12282928	1.000	rs7106648	chr11:48283292	A/T	cg26585981	chr11:48327164	OR4S1	-0.43	-7.04	-0.31	7.14e-12	Migraine - clinic-based;
LGG	cis	rs11158026	0.757	rs56164809	chr14:55400212	A/G	cg04306507	chr14:55594613	LGALS3	0.31	6.69	0.3	6.33e-11	Parkinson's disease;
LGG	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg27286337	chr10:134555280	INPP5A	0.84	12.09	0.49	1.93e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg24642844	chr7:1081250	C7orf50	-0.55	-8.94	-0.38	9.56e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.66	-0.44	6.84e-24	Lung cancer;
LGG	cis	rs2033732	0.673	rs1550211	chr8:85057571	G/A	cg05716166	chr8:85095498	RALYL	0.42	6.67	0.3	7.3e-11	Body mass index;
LGG	trans	rs2190422	0.678	rs2190421	chr7:103072330	T/C	cg21537297	chr8:144298583	GPIHBP1	-0.4	-6.77	-0.3	3.99e-11	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.591	rs11039766	chr11:48488715	T/C	cg03929089	chr4:120376271	NA	-0.55	-9.31	-0.4	5.32e-19	HDL cholesterol;
LGG	cis	rs1790761	0.667	rs658768	chr11:67337808	G/A	cg24690094	chr11:67383802	NA	0.51	9.19	0.39	1.35e-18	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.7	0.41	2.17e-20	Prudent dietary pattern;
LGG	trans	rs931812	0.535	rs3105452	chr8:101943618	A/G	cg20993868	chr7:22813445	NA	0.39	7.36	0.32	8.71e-13	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs758324	0.773	rs630044	chr5:131258378	G/T	cg06307176	chr5:131281290	NA	0.54	8.92	0.38	1.1e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs7829975	0.742	rs7832968	chr8:8652889	G/A	cg21775007	chr8:11205619	TDH	0.48	8.04	0.35	7.76e-15	Mood instability;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg02127607	chr17:61920694	SMARCD2	-0.39	-6.85	-0.3	2.34e-11	Prudent dietary pattern;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11786005	chr6:170863399	PSMB1;TBP	0.5	8.02	0.35	8.65e-15	Cognitive performance;
LGG	cis	rs11150038	0.536	rs2464764	chr16:78046054	C/G	cg04733911	chr16:78082701	NA	-0.68	-11.36	-0.47	1.47e-26	Colorectal or endometrial cancer;
LGG	cis	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg00806245	chr18:76673096	NA	-0.66	-8.36	-0.36	7.32e-16	Obesity-related traits;
LGG	cis	rs7949030	0.780	rs3017666	chr11:62404417	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-12.63	-0.51	1.21e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.53	-0.37	2.03e-16	Neuroticism;
LGG	cis	rs9814567	1.000	rs9876658	chr3:134179453	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	12.48	0.5	5.13e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9815354	0.812	rs73073371	chr3:41843443	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs926938	0.527	rs360584	chr1:115463181	G/A	cg12756093	chr1:115239321	AMPD1	0.44	8.22	0.36	2.11e-15	Autism;
LGG	cis	rs769267	0.930	rs4808959	chr19:19572108	T/G	cg03709012	chr19:19516395	GATAD2A	0.84	16.93	0.62	2.07e-50	Tonsillectomy;
LGG	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg01043669	chr3:72786069	NA	0.42	7.06	0.31	6.04e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3857067	1.000	rs899133	chr4:95019609	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.49	-0.33	3.53e-13	QT interval;
LGG	cis	rs736801	0.780	rs2188962	chr5:131770805	C/T	cg21138405	chr5:131827807	IRF1	-0.29	-7.02	-0.31	8.16e-12	Breast cancer;Mosquito bite size;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.98	-0.42	2.16e-21	Joint mobility (Beighton score);
LGG	cis	rs4538187	1.000	rs6715992	chr2:64085344	C/T	cg19915305	chr2:64069682	UGP2	0.68	15.66	0.59	1.18e-44	Systolic blood pressure;
LGG	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.73	13.48	0.53	3.66e-35	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02099313	chr1:231114956	TTC13;ARV1	0.47	7.37	0.32	8.01e-13	Gut microbiome composition (summer);
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs798554	0.704	rs798512	chr7:2782592	C/G	cg05793240	chr7:2802953	GNA12	0.31	7.45	0.33	4.65e-13	Height;
LGG	cis	rs6088580	0.634	rs1205334	chr20:32930369	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.21	-0.36	2.29e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs3781663	0.581	rs10793018	chr11:70004396	G/A	cg06393558	chr11:69982916	ANO1	-0.41	-7.81	-0.34	3.91e-14	Survival in rectal cancer;
LGG	cis	rs12348691	0.503	rs7849834	chr9:100606188	T/C	cg13688889	chr9:100608707	NA	-0.83	-16.18	-0.6	5.35e-47	Alopecia areata;
LGG	cis	rs1707322	1.000	rs4539075	chr1:46358010	C/T	cg03146154	chr1:46216737	IPP	0.54	10.33	0.43	1.22e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg16507663	chr6:150244633	RAET1G	0.45	8.47	0.37	3.17e-16	Lung cancer;
LGG	trans	rs28793375	1	rs28793375	chr8:41415618	C/T	cg01970784	chr8:10191983	MSRA	0.58	6.79	0.3	3.45e-11	Interleukin-7 levels;Interleukin-5 levels;
LGG	cis	rs7107174	1.000	rs55825352	chr11:78034424	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.63	-0.33	1.3e-13	Testicular germ cell tumor;
LGG	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.09	0.39	2.88e-18	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13085065	chr19:41769941	HNRNPUL1	0.45	6.75	0.3	4.57e-11	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.76	-0.45	2.87e-24	Lung cancer;
LGG	cis	rs7084402	0.967	rs1427222	chr10:60290970	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.09	0.64	1.06e-55	Refractive error;
LGG	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg23231163	chr10:75533350	FUT11	-0.4	-6.73	-0.3	5.03e-11	Inflammatory bowel disease;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.39e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12580194	0.593	rs66516917	chr12:55749131	T/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.7	-0.41	2.27e-20	Cancer;
LGG	cis	rs526231	0.697	rs168820	chr5:102642673	G/A	cg23492399	chr5:102201601	PAM	-0.58	-7.61	-0.33	1.59e-13	Primary biliary cholangitis;
LGG	cis	rs79387448	0.592	rs6728945	chr2:102986471	T/C	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.98	-0.31	1.02e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2075371	0.933	rs1868785	chr7:133945855	G/C	cg20476274	chr7:133979776	SLC35B4	0.72	13.87	0.54	8.13e-37	Mean platelet volume;
LGG	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg08847533	chr14:75593920	NEK9	-0.53	-9.86	-0.42	6.03e-21	Height;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1865760	0.588	rs9467658	chr6:26010881	T/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.29	0.4	5.92e-19	Height;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg08280861	chr8:58055591	NA	0.58	9.99	0.42	2.03e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.817	rs2321333	chr17:28140857	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.21	0.55	2.64e-38	Coffee consumption (cups per day);
LGG	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg05169160	chr2:178484487	TTC30A	0.34	6.64	0.3	8.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg25811766	chr13:21894605	NA	0.58	7.64	0.33	1.29e-13	White matter hyperintensity burden;
LGG	cis	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	trans	rs11250098	0.548	rs7837038	chr8:10783074	G/A	cg02002194	chr4:3960332	NA	0.38	6.83	0.3	2.67e-11	Morning vs. evening chronotype;
LGG	cis	rs5769765	1.000	rs5769760	chr22:50259696	A/G	cg02269571	chr22:50332266	NA	0.63	10.05	0.42	1.25e-21	Schizophrenia;
LGG	cis	rs6163	0.588	rs10786706	chr10:104500659	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-7.44	-0.33	4.83e-13	Waist circumference;Hip circumference;
LGG	cis	rs76419734	0.510	rs2553463	chr4:106730663	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.53	-7.5	-0.33	3.35e-13	Post bronchodilator FEV1;
LGG	cis	rs1008375	0.932	rs2302394	chr4:17641188	A/G	cg02297831	chr4:17616191	MED28	0.46	8.33	0.36	9.29e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3762637	0.941	rs9289192	chr3:122076115	C/G	cg24169773	chr3:122142474	KPNA1	-0.56	-8.9	-0.38	1.32e-17	LDL cholesterol levels;
LGG	trans	rs12310956	0.532	rs11052948	chr12:33981973	T/C	cg26384229	chr12:38710491	ALG10B	0.81	15.99	0.6	3.93e-46	Morning vs. evening chronotype;
LGG	cis	rs2011503	0.769	rs72999059	chr19:19378245	A/C	cg01262667	chr19:19385393	TM6SF2	0.35	6.76	0.3	4.21e-11	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00648153	chr6:74364149	SLC17A5	0.43	7.52	0.33	2.86e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3780486	0.505	rs10813958	chr9:33165985	A/G	cg13443165	chr9:33130375	B4GALT1	-0.57	-11.09	-0.46	1.6e-25	IgG glycosylation;
LGG	cis	rs7751419	0.651	rs12198923	chr6:39094988	C/G	cg08089693	chr6:39098871	NA	-0.43	-7.72	-0.34	7.18e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs6089584	0.627	rs6089303	chr20:60565797	G/A	cg06108461	chr20:60628389	TAF4	-0.61	-10.61	-0.44	1.13e-23	Body mass index;
LGG	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg05444541	chr17:17804740	TOM1L2	0.69	16.47	0.61	2.76e-48	Total body bone mineral density;
LGG	cis	rs35306767	0.668	rs12784928	chr10:1083617	A/C	cg25019033	chr10:957182	NA	-0.46	-8.83	-0.38	2.2e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs4474465	1.000	rs4944202	chr11:78189558	T/C	cg27205649	chr11:78285834	NARS2	-0.49	-8.21	-0.36	2.25e-15	Alzheimer's disease (survival time);
LGG	cis	rs5756813	0.754	rs15691	chr22:38172380	C/A	cg24232236	chr22:38142998	TRIOBP	0.39	7.39	0.32	6.97e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.23	0.36	1.97e-15	Schizophrenia;
LGG	trans	rs4561483	0.624	rs2288547	chr16:11935436	C/T	cg18993626	chr8:74463939	STAU2	-0.36	-6.75	-0.3	4.5e-11	Testicular germ cell tumor;
LGG	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg18795169	chr1:18902165	NA	-1.06	-34.39	-0.85	1.39e-129	Urate levels in lean individuals;
LGG	trans	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.77	0.34	5.05e-14	Monocyte count;
LGG	cis	rs714031	0.934	rs4820386	chr22:40068051	C/T	cg21377881	chr22:40064566	CACNA1I	-0.62	-14.76	-0.57	1.1e-40	Schizophrenia;
LGG	cis	rs11676348	0.818	rs6436031	chr2:218979259	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-10.08	-0.42	9.9e-22	Ulcerative colitis;
LGG	trans	rs9858542	0.953	rs71324979	chr3:49619651	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.07	-0.42	1.04e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg13047869	chr3:10149882	C3orf24	0.55	9.34	0.4	4.05e-19	Alzheimer's disease;
LGG	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg16583315	chr14:65563665	MAX	-0.43	-8.75	-0.38	4.14e-17	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04798930	chr2:37193060	STRN	0.45	7.69	0.34	8.89e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs139371	0.652	rs139337	chr22:39505461	C/T	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.71	-0.3	5.55e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs4771450	0.962	rs2026181	chr13:103969099	C/T	cg02987523	chr13:103978230	NA	-0.32	-7.05	-0.31	6.57e-12	Uric acid levels;
LGG	cis	rs28647808	0.881	rs4549850	chr9:136265239	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs9880211	0.752	rs13062352	chr3:136464762	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.31	1.77e-11	Body mass index;Height;
LGG	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg15733309	chr7:157513707	PTPRN2	0.61	14.57	0.56	7.37e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	trans	rs208515	0.525	rs12191500	chr6:66668681	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	16.99	0.62	1.16e-50	Exhaled nitric oxide levels;
LGG	cis	rs6952808	0.636	rs73048162	chr7:1949328	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	8.99	0.39	6.48e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs2727020	0.521	rs7107178	chr11:49526668	G/A	cg15704280	chr7:45808275	SEPT13	0.87	13.75	0.54	2.55e-36	Coronary artery disease;
LGG	cis	rs9326248	0.501	rs4938351	chr11:117022352	A/C	cg01368799	chr11:117014884	PAFAH1B2	0.75	13.66	0.54	6.46e-36	Blood protein levels;
LGG	cis	rs3126085	0.867	rs36033453	chr1:152221226	T/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.35	-0.36	8.1e-16	Atopic dermatitis;
LGG	cis	rs57590327	0.503	rs11711024	chr3:81910207	T/C	cg07356753	chr3:81810745	GBE1	-0.45	-7.23	-0.32	2.01e-12	Extraversion;
LGG	cis	rs2476847	0.815	rs2476846	chr6:551352	A/G	cg13471009	chr6:564609	EXOC2	-0.37	-7.87	-0.34	2.48e-14	Inflammatory skin disease;
LGG	trans	rs8002861	0.905	rs12429722	chr13:44412466	T/A	cg17145862	chr1:211918768	LPGAT1	-0.91	-21.2	-0.7	3.16e-70	Leprosy;
LGG	cis	rs2227564	0.649	rs2948689	chr10:75657860	A/G	cg00564723	chr10:75632066	CAMK2G	-0.47	-9.35	-0.4	3.78e-19	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs5760092	0.572	rs738806	chr22:24234172	A/G	cg04234412	chr22:24373322	LOC391322	-0.57	-9.27	-0.4	7.17e-19	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs765787	1.000	rs765787	chr15:45500047	C/T	cg24006582	chr15:45444508	DUOX1	-0.48	-6.74	-0.3	4.87e-11	Uric acid levels;
LGG	cis	rs977987	0.933	rs4888431	chr16:75500699	G/T	cg03315344	chr16:75512273	CHST6	0.58	11.62	0.48	1.46e-27	Dupuytren's disease;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg08461457	chr11:2027003	NA	0.39	7.49	0.33	3.54e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg01585723	chr16:33734837	NA	0.46	8.17	0.35	2.91e-15	Menopause (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03745386	chr12:29534188	ERGIC2	-0.49	-7.28	-0.32	1.49e-12	Systemic lupus erythematosus;
LGG	cis	rs1008375	0.932	rs964012	chr4:17619184	A/G	cg18681998	chr4:17616180	MED28	0.86	18.15	0.64	5.37e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9583531	0.657	rs7318291	chr13:111352460	C/T	cg15841412	chr13:111365552	ING1	-0.45	-6.81	-0.3	3.13e-11	Coronary artery disease;
LGG	cis	rs2243480	0.908	rs1532573	chr7:65798802	A/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.33	-0.36	9.17e-16	Diabetic kidney disease;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg14004847	chr7:1930337	MAD1L1	-0.54	-8.87	-0.38	1.61e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg15764593	chr10:829463	NA	-0.64	-9.83	-0.42	7.99e-21	Uric acid levels;
LGG	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg27165867	chr14:105738592	BRF1	-0.46	-7.48	-0.33	3.85e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg12473912	chr3:136751656	NA	0.41	6.87	0.3	2.1e-11	Gestational age at birth (child effect);
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg02725872	chr8:58115012	NA	-0.92	-11.94	-0.49	7.77e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs637571	0.522	rs1151512	chr11:65757533	G/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.88	-0.38	1.44e-17	Eosinophil percentage of white cells;
LGG	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.05	-0.6	2.1e-46	Platelet count;
LGG	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg16325326	chr1:53192061	ZYG11B	-0.76	-18.31	-0.65	9.77e-57	Monocyte count;
LGG	cis	rs870825	0.655	rs72703561	chr4:185630890	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.91	0.38	1.15e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9309473	0.950	rs6546859	chr2:73842055	C/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.46e-14	Metabolite levels;
LGG	trans	rs1814175	0.616	rs10839388	chr11:49842603	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.55	-0.71	7.16e-72	Height;
LGG	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs17270561	0.609	rs2000350	chr6:25763154	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg00745463	chr17:30367425	LRRC37B	-0.79	-10.97	-0.45	4.93e-25	Hip circumference adjusted for BMI;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg24503407	chr1:205819492	PM20D1	-0.41	-7.12	-0.31	4.16e-12	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00177013	chr20:62339100	ARFRP1;ZGPAT	0.47	7.39	0.32	7.06e-13	Gut microbiome composition (summer);
LGG	cis	rs3096299	0.685	rs4785676	chr16:89553624	T/C	cg06640241	chr16:89574553	SPG7	0.95	18.24	0.65	2.14e-56	Multiple myeloma (IgH translocation);
LGG	cis	rs2839186	0.934	rs4819221	chr21:47695417	G/T	cg13126279	chr21:47581558	C21orf56	0.49	8.57	0.37	1.55e-16	Testicular germ cell tumor;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg18279126	chr7:2041391	MAD1L1	0.34	7.2	0.32	2.44e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11168854	0.595	rs11168857	chr12:49490309	A/G	cg24176009	chr12:49580217	TUBA1A	0.56	10.37	0.43	8.67e-23	Body mass index;
LGG	cis	rs11585357	0.842	rs72633804	chr1:17617024	T/C	cg08277548	chr1:17600880	PADI3	-0.73	-8.15	-0.35	3.4e-15	Hair shape;
LGG	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs283228	0.550	rs646273	chr6:101784844	G/A	cg27451362	chr6:101846650	GRIK2	1.02	15.37	0.58	2.35e-43	Coenzyme Q10 levels;
LGG	trans	rs7618501	0.633	rs11130234	chr3:50024758	G/T	cg21659725	chr3:3221576	CRBN	0.66	12.4	0.5	1.06e-30	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg00343986	chr7:65444356	GUSB	-0.48	-8.47	-0.37	3.16e-16	Aortic root size;
LGG	cis	rs6121246	0.559	rs6060621	chr20:30261562	G/C	cg13852791	chr20:30311386	BCL2L1	0.95	18.69	0.66	1.71e-58	Mean corpuscular hemoglobin;
LGG	cis	rs7647973	0.769	rs4974081	chr3:49070499	A/G	cg07636037	chr3:49044803	WDR6	-0.9	-16.7	-0.61	2.4e-49	Menarche (age at onset);
LGG	cis	rs10214930	0.697	rs1052741	chr7:27565161	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.92	0.31	1.53e-11	Hypospadias;
LGG	trans	rs45509595	0.659	rs390764	chr6:27782535	C/T	cg01620082	chr3:125678407	NA	-0.83	-9.35	-0.4	3.68e-19	Breast cancer;
LGG	cis	rs4665809	0.793	rs6546715	chr2:26261520	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.7	-0.34	8.34e-14	Gut microbiome composition (summer);
LGG	trans	rs6825911	0.669	rs10001506	chr4:111374275	G/A	cg10580549	chr19:53101634	ZNF137	0.46	7.1	0.31	4.63e-12	Blood pressure;
LGG	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.13e-42	Aortic root size;
LGG	cis	rs60871478	1.000	rs62432250	chr7:801792	C/G	cg04727924	chr7:799746	HEATR2	-0.48	-7.61	-0.33	1.52e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05025164	chr4:1340916	KIAA1530	-0.7	-13.24	-0.52	3.65e-34	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22224769	chr1:68150929	GADD45A	0.48	7.34	0.32	9.61e-13	Gut microbiome composition (summer);
LGG	trans	rs453301	0.658	rs12114954	chr8:8904862	T/G	cg16141378	chr3:129829833	LOC729375	0.36	8.38	0.36	6.45e-16	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs67895971	chr8:58177994	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs3809863	0.602	rs2317677	chr17:45393407	G/A	cg08085267	chr17:45401833	C17orf57	-0.71	-13.88	-0.54	7e-37	Glaucoma (primary open-angle);
LGG	cis	rs56235845	0.964	rs4075958	chr5:176784512	A/G	cg06060754	chr5:176797920	RGS14	-0.45	-7.49	-0.33	3.52e-13	Hemoglobin concentration;Hematocrit;
LGG	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg27129171	chr3:47204927	SETD2	0.81	14.98	0.57	1.21e-41	Colorectal cancer;
LGG	cis	rs9894429	0.572	rs112417725	chr17:79578219	A/G	cg10661904	chr17:79619235	PDE6G	0.49	10.09	0.42	9.02e-22	Eye color traits;
LGG	trans	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg05926928	chr17:57297772	GDPD1	1.36	21.89	0.71	1.99e-73	Opioid sensitivity;
LGG	cis	rs11148252	0.538	rs2296348	chr13:52710136	T/G	cg02158880	chr13:53174818	NA	0.35	6.67	0.3	7.51e-11	Lewy body disease;
LGG	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg17158414	chr2:27665306	KRTCAP3	-0.3	-7.76	-0.34	5.31e-14	Total body bone mineral density;
LGG	cis	rs2735413	0.711	rs12921476	chr16:78079846	G/C	cg04733911	chr16:78082701	NA	-0.75	-16.21	-0.6	3.81e-47	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs12949688	0.935	rs9893344	chr17:55826114	G/A	cg12582317	chr17:55822272	NA	0.63	16.73	0.61	1.75e-49	Schizophrenia;
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg07005078	chr4:17578674	LAP3	0.39	7.08	0.31	5.44e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg04733989	chr22:42467013	NAGA	0.51	8.61	0.37	1.17e-16	Schizophrenia;
LGG	cis	rs1218582	0.741	rs2335407	chr1:154843347	A/G	cg03351412	chr1:154909251	PMVK	-0.65	-12.26	-0.5	3.86e-30	Prostate cancer;
LGG	cis	rs3820928	1.000	rs3820928	chr2:227773466	A/G	cg11843606	chr2:227700838	RHBDD1	-0.42	-7.14	-0.31	3.6e-12	Pulmonary function;
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs9388451	0.839	rs1811852	chr6:126071575	G/C	cg05901451	chr6:126070800	HEY2	-0.83	-17.91	-0.64	6.95e-55	Brugada syndrome;
LGG	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.94	-0.31	1.32e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg06481639	chr22:41940642	POLR3H	-0.63	-9.18	-0.39	1.48e-18	Vitiligo;
LGG	cis	rs2708240	1.000	rs2708255	chr7:147587614	C/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-7.02	-0.31	7.71e-12	QT interval (drug interaction);
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg21724239	chr8:58056113	NA	0.57	8.26	0.36	1.5e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	1.000	rs2071298	chr6:25914901	G/A	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs8072100	0.817	rs7213086	chr17:45752310	C/G	cg08085267	chr17:45401833	C17orf57	-0.51	-9.55	-0.41	7.61e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs774359	0.732	rs7019847	chr9:27491397	G/A	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.33	-0.36	9.35e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs12142240	0.698	rs41294476	chr1:46818374	C/A	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs11748327	0.580	rs6555240	chr5:4008320	A/G	cg01025095	chr5:4101132	NA	-0.42	-6.78	-0.3	3.67e-11	Myocardial infarction;
LGG	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg17376030	chr22:41985996	PMM1	-0.57	-8.94	-0.38	9.07e-18	Vitiligo;
LGG	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg03161606	chr19:29218774	NA	0.69	10.98	0.45	4.44e-25	Methadone dose in opioid dependence;
LGG	cis	rs10773046	0.740	rs10773045	chr12:124351666	A/G	cg18594669	chr12:124364423	DNAH10	0.34	6.78	0.3	3.68e-11	Osteoarthritis (hip);
LGG	cis	rs12701220	0.655	rs34696066	chr7:1140919	C/T	cg26769984	chr7:1090371	C7orf50	0.44	7.74	0.34	6.4e-14	Bronchopulmonary dysplasia;
LGG	cis	rs2213920	0.679	rs4978638	chr9:118232778	G/C	cg13918206	chr9:118159781	DEC1	0.54	7.29	0.32	1.36e-12	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs12230513	0.732	rs61956358	chr12:55852286	G/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.93	-0.45	6.76e-25	Contrast sensitivity;
LGG	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.21e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg13282195	chr8:144660772	NAPRT1	-0.75	-8.41	-0.36	4.98e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg11494091	chr17:61959527	GH2	1.04	26.63	0.78	2.03e-95	Prudent dietary pattern;
LGG	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg18404041	chr3:52824283	ITIH1	-0.57	-10.95	-0.45	5.62e-25	Bipolar disorder;
LGG	cis	rs10504229	0.906	rs58559296	chr8:58171714	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs796364	0.906	rs6740981	chr2:201060216	T/C	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.26e-17	Schizophrenia;
LGG	cis	rs9796	0.689	rs13329537	chr15:41449211	C/G	cg18705301	chr15:41695430	NDUFAF1	0.55	9.25	0.39	8.24e-19	Menopause (age at onset);
LGG	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.96	0.49	6.68e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12580194	0.593	rs61957937	chr12:55746850	G/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4065321	0.609	rs8075668	chr17:38137623	C/T	cg17467752	chr17:38218738	THRA	-0.54	-9.36	-0.4	3.51e-19	White blood cell count (basophil);White blood cell count;
LGG	cis	rs6466055	0.777	rs10281886	chr7:104835888	T/C	cg04380332	chr7:105027541	SRPK2	-0.37	-6.97	-0.31	1.1e-11	Schizophrenia;
LGG	cis	rs6951245	0.872	rs76161580	chr7:1100307	G/T	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6988985	0.728	rs1134095	chr8:143954290	A/G	cg10324643	chr8:143916377	GML	-0.39	-7.94	-0.35	1.53e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9863	0.896	rs7307053	chr12:124494540	A/G	cg13487667	chr12:124434373	CCDC92	0.37	7.48	0.33	3.69e-13	White blood cell count;
LGG	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg01620082	chr3:125678407	NA	-0.97	-9.48	-0.4	1.36e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.625	rs3820945	chr2:99105156	G/A	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg20387954	chr3:183756860	HTR3D	0.71	14.28	0.55	1.35e-38	Anterior chamber depth;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11287851	chr11:119187772	MCAM	0.41	6.76	0.3	4.1e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2735413	0.632	rs11864652	chr16:78094008	A/T	cg04733911	chr16:78082701	NA	0.67	11.09	0.46	1.65e-25	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4262150	0.883	rs4484413	chr5:152165140	A/T	cg12297329	chr5:152029980	NA	-0.7	-12.92	-0.51	8.02e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.57	0.33	2.04e-13	Personality dimensions;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27326856	chr19:37663410	ZNF585A	0.43	6.98	0.31	1.06e-11	Cognitive performance;
LGG	cis	rs13260300	0.657	rs2553714	chr8:75498177	C/T	cg22993706	chr8:75542856	NA	0.37	6.99	0.31	9.51e-12	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	trans	rs55821297	0.590	rs6533520	chr4:111387806	T/C	cg10580549	chr19:53101634	ZNF137	0.56	7.03	0.31	7.25e-12	Iris color (a* coordinate);
LGG	cis	rs1451375	0.669	rs10274172	chr7:50637575	G/A	cg00647317	chr7:50633725	DDC	0.33	7.49	0.33	3.47e-13	Malaria;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg18350739	chr11:68623251	NA	-0.87	-22.22	-0.72	5.67e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10791323	0.572	rs10791334	chr11:133735810	A/C	cg06766960	chr11:133703094	NA	-0.55	-10.71	-0.45	4.8e-24	Childhood ear infection;
LGG	cis	rs834603	0.575	rs834609	chr7:47456846	T/C	cg23694490	chr7:47445681	TNS3	-0.42	-12.18	-0.49	8.45e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs4073582	0.555	rs521109	chr11:66030948	G/A	cg16950941	chr11:66035639	RAB1B	0.56	10.49	0.44	2.95e-23	Gout;
LGG	cis	rs9467773	0.620	rs2504599	chr6:26641060	C/T	cg09904177	chr6:26538194	HMGN4	0.67	14.01	0.55	1.99e-37	Intelligence (multi-trait analysis);
LGG	cis	rs1878931	0.501	rs9302871	chr16:3415512	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	0.81	13.99	0.55	2.4e-37	Body mass index (adult);
LGG	cis	rs10936602	0.500	rs10049456	chr3:169563523	T/G	cg00832555	chr3:169529716	LRRC34	0.36	7.13	0.31	4e-12	Renal cell carcinoma;
LGG	cis	rs9322193	0.923	rs2151913	chr6:150130642	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.32e-11	Lung cancer;
LGG	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg23029597	chr12:123009494	RSRC2	-0.87	-16.73	-0.61	1.84e-49	Body mass index;
LGG	cis	rs6795744	0.634	rs17290567	chr3:14042447	A/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.48	-7.04	-0.31	6.9e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7618915	0.571	rs34954168	chr3:52612159	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.4	9.23e-20	Bipolar disorder;
LGG	cis	rs78456975	1.000	rs10208340	chr2:1563100	G/A	cg26248373	chr2:1572462	NA	-0.69	-8.76	-0.38	3.72e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg08888203	chr3:10149979	C3orf24	0.57	9.84	0.42	7.38e-21	Alzheimer's disease;
LGG	cis	rs3740540	0.530	rs4297414	chr10:126292116	T/G	cg04949429	chr10:126290192	LHPP	0.58	11.16	0.46	8.93e-26	Obesity-related traits;Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9534288	0.659	rs2146882	chr13:46668111	A/G	cg15192986	chr13:46630673	CPB2	-0.67	-13.99	-0.55	2.44e-37	Blood protein levels;
LGG	cis	rs514406	0.505	rs416968	chr1:53183513	A/G	cg24675658	chr1:53192096	ZYG11B	-0.54	-11.48	-0.47	5.22e-27	Monocyte count;
LGG	cis	rs1552244	0.935	rs7649243	chr3:10089470	T/A	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03120789	chr1:20208808	OTUD3	0.47	7.17	0.32	2.93e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.799	rs4482345	chr17:80152919	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs4936894	0.500	rs10893165	chr11:124077170	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.09	-0.42	8.85e-22	Aging (time to death);
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.62	0.37	1.06e-16	Bipolar disorder;
LGG	cis	rs72781680	1.000	rs7588286	chr2:24071427	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.61e-20	Lymphocyte counts;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00290607	chr11:67383545	NA	-0.67	-13.25	-0.52	3.45e-34	Mean corpuscular volume;
LGG	cis	rs2204008	0.677	rs1581356	chr12:38391467	T/C	cg26384229	chr12:38710491	ALG10B	0.91	19.15	0.66	1.18e-60	Bladder cancer;
LGG	cis	rs9581857	0.547	rs4612914	chr13:28049128	A/G	cg01674679	chr13:27998804	GTF3A	-0.64	-7.43	-0.33	5.16e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs9399137	0.507	rs4594969	chr6:135285586	A/T	cg24558204	chr6:135376177	HBS1L	0.62	10.53	0.44	2.22e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9309473	0.898	rs28879089	chr2:73812886	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.3	-0.32	1.27e-12	Metabolite levels;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.764	rs115986119	chr4:119767785	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.82e-22	Cannabis dependence symptom count;
LGG	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg08847533	chr14:75593920	NEK9	0.53	9.99	0.42	2.01e-21	Height;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg15147215	chr3:52552868	STAB1	-0.38	-7.18	-0.32	2.85e-12	Bipolar disorder;
LGG	cis	rs9381107	0.649	rs2206546	chr6:9487663	T/C	cg14735645	chr6:9486422	NA	-0.39	-6.99	-0.31	9.63e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2243480	0.522	rs431168	chr7:65511604	G/T	cg25894440	chr7:65020034	NA	-0.78	-7.05	-0.31	6.69e-12	Diabetic kidney disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03284175	chr1:146643471	PRKAB2	0.38	6.66	0.3	7.76e-11	Bilirubin levels;
LGG	cis	rs2479724	0.868	rs2249703	chr6:41814760	A/G	cg17623882	chr6:41773611	USP49	-0.52	-9.32	-0.4	4.61e-19	Menarche (age at onset);
LGG	cis	rs9487094	0.670	rs12214639	chr6:109897617	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	5.88e-17	IgG glycosylation;
LGG	cis	rs881375	0.631	rs2416808	chr9:123706283	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.39	0.5	1.15e-30	Rheumatoid arthritis;
LGG	cis	rs17453880	0.929	rs4958322	chr5:152020639	A/G	cg12297329	chr5:152029980	NA	-0.9	-23.82	-0.74	1.89e-82	Subjective well-being;
LGG	cis	rs4642101	0.561	rs4560285	chr3:12809066	G/A	cg05775895	chr3:12838266	CAND2	0.57	9.73	0.41	1.74e-20	QRS complex (12-leadsum);
LGG	trans	rs5756813	0.754	rs5750495	chr22:38179120	T/A	cg19894588	chr14:64061835	NA	0.61	9.39	0.4	2.74e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg10802521	chr3:52805072	NEK4	-0.4	-6.93	-0.31	1.39e-11	Bipolar disorder;
LGG	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg12091567	chr17:66097778	LOC651250	0.63	10.52	0.44	2.37e-23	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9649465	1.000	rs1468656	chr7:123375505	G/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	trans	rs7829975	0.573	rs7842359	chr8:8797078	T/G	cg16141378	chr3:129829833	LOC729375	0.34	7.75	0.34	5.72e-14	Mood instability;
LGG	cis	rs11577318	0.853	rs4333841	chr1:26631927	T/C	cg04990556	chr1:26633338	UBXN11	-0.48	-8.03	-0.35	8.4e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2239547	0.657	rs6445539	chr3:52874296	G/A	cg11645453	chr3:52864694	ITIH4	0.71	11.06	0.46	2.11e-25	Schizophrenia;
LGG	cis	rs968451	1.000	rs17000962	chr22:39680187	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.83	11.09	0.46	1.65e-25	Primary biliary cholangitis;
LGG	trans	rs11722228	0.521	rs12501336	chr4:10137351	G/A	cg26043149	chr18:55253948	FECH	1.0	18.82	0.66	4.42e-59	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2153535	0.580	rs4365970	chr6:8453813	C/T	cg21535247	chr6:8435926	SLC35B3	-0.58	-9.85	-0.42	6.79e-21	Motion sickness;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg04861929	chr11:109293070	C11orf87	0.52	9.73	0.41	1.74e-20	Schizophrenia;
LGG	cis	rs11792861	0.781	rs72607158	chr9:111763010	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.05	0.42	1.28e-21	Menarche (age at onset);
LGG	cis	rs7717393	0.786	rs72813885	chr5:155763166	A/G	cg04435420	chr5:155754009	SGCD	0.75	9.26	0.4	7.67e-19	Egg allergy;
LGG	cis	rs473651	0.935	rs1103770	chr2:239339281	G/C	cg18131467	chr2:239335373	ASB1	0.89	15.87	0.59	1.29e-45	Multiple system atrophy;
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg11764359	chr7:65958608	NA	-0.73	-12.99	-0.52	4.05e-33	Aortic root size;
LGG	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg03929089	chr4:120376271	NA	-0.81	-15.64	-0.59	1.46e-44	Height;
LGG	cis	rs1620921	0.625	rs67613705	chr6:161265155	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.31	-0.32	1.15e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg00334542	chr7:100209784	MOSPD3	-0.61	-8.51	-0.37	2.41e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.921	rs6002333	chr22:41719469	C/T	cg03806693	chr22:41940476	POLR3H	-0.92	-15.77	-0.59	3.81e-45	Vitiligo;
LGG	cis	rs7769051	0.522	rs6934155	chr6:133124021	C/T	cg22852734	chr6:133119734	C6orf192	1.31	10.34	0.43	1.11e-22	Type 2 diabetes nephropathy;
LGG	cis	rs9389248	0.690	rs2064101	chr6:135250530	G/A	cg22676075	chr6:135203613	NA	-0.5	-8.58	-0.37	1.42e-16	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg22398616	chr13:53314203	LECT1	-0.35	-7.05	-0.31	6.36e-12	Lewy body disease;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.27	0.6	2.19e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9747201	0.832	rs4072580	chr17:80160337	A/C	cg21453758	chr17:80185943	SLC16A3	0.35	7.48	0.33	3.69e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6815814	0.950	rs3924112	chr4:38795810	C/T	cg06935464	chr4:38784597	TLR10	0.61	8.32	0.36	9.79e-16	Breast cancer;
LGG	trans	rs7395662	0.963	rs10769382	chr11:48590415	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02404933	chr17:79995793	DCXR	-0.5	-7.43	-0.33	5.21e-13	Systemic lupus erythematosus;
LGG	trans	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.34	0.32	9.63e-13	Neuroticism;
LGG	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg08250081	chr4:10125330	NA	-0.35	-6.76	-0.3	4.22e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.67	-0.34	1.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs36051895	0.659	rs72701605	chr9:5062056	G/A	cg02405213	chr9:5042618	JAK2	-0.82	-15.2	-0.58	1.25e-42	Pediatric autoimmune diseases;
LGG	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg11584989	chr19:19387371	SF4	0.73	12.18	0.49	8.75e-30	Bipolar disorder;
LGG	trans	rs7980799	0.689	rs4142890	chr12:33446630	C/G	cg26384229	chr12:38710491	ALG10B	-0.4	-6.68	-0.3	7.02e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2242116	0.900	rs4683300	chr3:46934292	C/A	cg02527881	chr3:46936655	PTH1R	-0.39	-9.65	-0.41	3.28e-20	Birth weight;
LGG	cis	rs6951245	0.515	rs78461900	chr7:1007033	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.95	-12.45	-0.5	7.01e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1371867	0.875	rs1788184	chr8:101335106	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.61	-0.37	1.13e-16	Atrioventricular conduction;
LGG	cis	rs4740619	0.669	rs7869624	chr9:15760822	C/T	cg14451791	chr9:16040625	NA	0.35	8.9	0.38	1.3e-17	Body mass index;
LGG	trans	rs9467711	1.000	rs6903015	chr6:26322526	A/G	cg06606381	chr12:133084897	FBRSL1	-0.63	-7.09	-0.31	5.14e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg16611736	chr16:25123254	LCMT1	0.39	6.89	0.3	1.83e-11	Bilirubin levels;
LGG	cis	rs3820068	0.603	rs72645900	chr1:15931980	A/T	cg05660106	chr1:15850417	CASP9	0.83	16.84	0.62	5.33e-50	Systolic blood pressure;
LGG	trans	rs2727020	0.675	rs7929401	chr11:49350832	C/A	cg15704280	chr7:45808275	SEPT13	-0.8	-12.04	-0.49	3.04e-29	Coronary artery disease;
LGG	cis	rs7945718	0.621	rs4514397	chr11:12689768	G/T	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs798554	0.629	rs2533875	chr7:2882829	G/A	cg19524238	chr7:2802976	GNA12	0.33	8.04	0.35	7.79e-15	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15046935	chr19:45595006	NA	0.4	6.68	0.3	6.68e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10892173	0.566	rs10892175	chr11:117674355	G/A	cg07621104	chr11:117668040	DSCAML1	0.64	9.02	0.39	4.96e-18	Myopia;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9640161	0.830	rs17173702	chr7:150068605	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.81	-0.41	8.8e-21	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg03929089	chr4:120376271	NA	-0.92	-17.27	-0.63	6.28e-52	Height;
LGG	cis	rs2832191	0.967	rs3787660	chr21:30520907	C/T	cg24692254	chr21:30365293	RNF160	0.86	19.56	0.67	1.59e-62	Dental caries;
LGG	cis	rs12477438	0.520	rs13004491	chr2:99738008	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs6964587	1.000	rs1859113	chr7:91679887	T/C	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.75e-16	Breast cancer;
LGG	cis	rs798554	1.000	rs798540	chr7:2764130	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-6.83	-0.3	2.76e-11	Height;
LGG	cis	rs11098499	0.663	rs9996501	chr4:120238918	C/A	cg09307838	chr4:120376055	NA	0.73	12.4	0.5	1.09e-30	Corneal astigmatism;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg03709012	chr19:19516395	GATAD2A	0.77	14.36	0.56	5.99e-39	Tonsillectomy;
LGG	cis	rs2832191	0.791	rs4817270	chr21:30480368	G/A	cg24692254	chr21:30365293	RNF160	-0.96	-24.74	-0.75	9.56e-87	Dental caries;
LGG	cis	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs457717	0.730	rs2252231	chr5:75948474	T/C	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.73	0.3	4.94e-11	Hearing impairment;
LGG	cis	rs7918232	0.941	rs788220	chr10:27447205	T/C	cg14442939	chr10:27389572	ANKRD26	-0.75	-11.25	-0.46	3.89e-26	Breast cancer;
LGG	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.97	0.45	4.83e-25	Morning vs. evening chronotype;
LGG	cis	rs11630290	0.592	rs8028348	chr15:64156465	A/G	cg12036633	chr15:63758958	NA	0.5	7.19	0.32	2.64e-12	Iris characteristics;
LGG	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg23933602	chr10:16859644	RSU1	0.66	9.5	0.4	1.12e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1577917	1.000	rs13217384	chr6:86720000	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.45	-0.4	1.65e-19	Response to antipsychotic treatment;
LGG	trans	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg20587970	chr11:113659929	NA	-1.36	-24.22	-0.75	2.62e-84	Hip circumference adjusted for BMI;
LGG	cis	rs4256922	1.000	rs4078160	chr10:52565940	A/C	cg12289553	chr10:52500425	ASAH2B	-0.42	-6.66	-0.3	7.67e-11	Urate levels in lean individuals;
LGG	cis	rs9916302	0.660	rs4795379	chr17:37674683	T/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.66	-0.37	7.91e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs9733	0.744	rs3754211	chr1:150951857	G/A	cg13175981	chr1:150552382	MCL1	-0.46	-7.24	-0.32	1.94e-12	Tonsillectomy;
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.81	-0.34	3.73e-14	Systolic blood pressure;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs6460942	0.915	rs62448621	chr7:12459941	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-7.25	-0.32	1.75e-12	Coronary artery disease;
LGG	cis	rs317689	0.718	rs645026	chr12:69757931	G/A	cg20891283	chr12:69753455	YEATS4	0.81	13.19	0.52	6e-34	Response to diuretic therapy;
LGG	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg14019146	chr3:50243930	SLC38A3	0.34	7.34	0.32	9.86e-13	Menarche (age at onset);
LGG	cis	rs2303745	0.841	rs10409801	chr19:17407415	A/G	cg04248312	chr19:17393744	ANKLE1	-0.6	-8.12	-0.35	4.13e-15	Systemic lupus erythematosus;
LGG	trans	rs12517041	1.000	rs6452112	chr5:23313498	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg21171335	chr12:122356390	WDR66	0.29	8.4	0.36	5.58e-16	Mean corpuscular volume;
LGG	cis	rs2011503	0.739	rs8108659	chr19:19680738	T/A	cg11584989	chr19:19387371	SF4	-0.62	-9.7	-0.41	2.33e-20	Bipolar disorder;
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs16976116	0.901	rs28433503	chr15:55499857	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs950169	1.000	rs12903820	chr15:84723820	A/G	cg24253500	chr15:84953950	NA	0.59	10.7	0.45	5.11e-24	Schizophrenia;
LGG	cis	rs57221529	0.766	rs58015612	chr5:580665	A/T	cg01221209	chr5:554886	NA	-0.48	-7.09	-0.31	4.97e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg08280861	chr8:58055591	NA	0.52	6.98	0.31	1.01e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg15971980	chr6:150254442	NA	0.44	8.32	0.36	9.68e-16	Lung cancer;
LGG	cis	rs73086581	0.524	rs2253977	chr20:3939140	A/G	cg02187196	chr20:3869020	PANK2	-0.45	-7.25	-0.32	1.77e-12	Response to antidepressants in depression;
LGG	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.89	0.38	1.39e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9894429	0.966	rs6565605	chr17:79589359	C/T	cg18240062	chr17:79603768	NPLOC4	0.75	14.0	0.55	2.21e-37	Eye color traits;
LGG	cis	rs9911578	1.000	rs304296	chr17:56834229	G/T	cg12560992	chr17:57184187	TRIM37	0.88	15.71	0.59	7.21e-45	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs8078723	0.933	rs4794822	chr17:38156712	C/T	cg17467752	chr17:38218738	THRA	0.73	13.8	0.54	1.5e-36	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	trans	rs12517041	1.000	rs6879795	chr5:23305275	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.8	-11.97	-0.49	5.93e-29	Calcium levels;
LGG	cis	rs9341808	0.935	rs9343974	chr6:80924645	A/G	cg08355045	chr6:80787529	NA	0.39	7.72	0.34	7.36e-14	Sitting height ratio;
LGG	cis	rs7932354	0.666	rs6485696	chr11:46842045	C/T	cg03339077	chr11:47165057	C11orf49	-0.44	-8.03	-0.35	8.13e-15	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg13802316	chr11:70253460	CTTN	-0.59	-7.55	-0.33	2.36e-13	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs9646412	chr17:41425893	A/T	cg01879757	chr17:41196368	BRCA1	-0.42	-8.44	-0.37	4e-16	Menopause (age at onset);
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg11050988	chr7:1952600	MAD1L1	-0.3	-7.24	-0.32	1.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg11642891	chr2:3452563	TTC15	-0.47	-9.48	-0.4	1.37e-19	Obesity-related traits;
LGG	trans	rs7980799	0.935	rs7294492	chr12:33548530	C/T	cg13010199	chr12:38710504	ALG10B	-0.37	-6.73	-0.3	5.1e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.34	-8.75	-0.38	4.04e-17	IgG glycosylation;
LGG	trans	rs1814175	0.669	rs12364577	chr11:49707361	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.49	-9.43	-0.4	1.97e-19	Height;
LGG	cis	rs1577917	1.000	rs9647603	chr6:86639341	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs9309473	0.687	rs6546827	chr2:73606493	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-8.58	-0.37	1.44e-16	Metabolite levels;
LGG	cis	rs3087591	0.690	rs12103621	chr17:29607235	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.71	-14.02	-0.55	1.82e-37	Hip circumference;
LGG	cis	rs72945132	0.882	rs12289915	chr11:70131956	G/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs35555954	chr17:80122438	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07279963	chr3:61546526	PTPRG	0.41	6.79	0.3	3.45e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs9393777	0.920	rs72839445	chr6:27249686	G/A	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.1	-0.46	1.51e-25	Intelligence (multi-trait analysis);
LGG	cis	rs877282	0.583	rs10904566	chr10:821662	C/G	cg01169559	chr10:831247	NA	0.53	9.34	0.4	4.05e-19	Uric acid levels;
LGG	cis	rs1552244	1.000	rs67134728	chr3:10151431	G/C	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg20368463	chr18:77673604	PQLC1	0.6	7.67	0.34	1.01e-13	Opioid sensitivity;
LGG	cis	rs1843834	0.574	rs6436499	chr2:225456551	A/T	cg12698349	chr2:225449008	CUL3	0.71	11.64	0.48	1.23e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg07777115	chr5:623756	CEP72	-0.63	-8.26	-0.36	1.49e-15	Obesity-related traits;
LGG	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg25272121	chr1:152190972	HRNR	-0.42	-8.46	-0.37	3.6e-16	Inflammatory skin disease;
LGG	cis	rs853679	0.517	rs4713152	chr6:28137454	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs4919694	0.615	rs78384860	chr10:105003019	G/T	cg04362960	chr10:104952993	NT5C2	1.02	12.87	0.51	1.25e-32	Arsenic metabolism;
LGG	cis	rs7666738	0.861	rs28821920	chr4:98962743	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9914544	1.000	rs1737944	chr17:18840433	G/A	cg26378065	chr17:18585709	ZNF286B	0.48	8.79	0.38	2.9e-17	Educational attainment (years of education);
LGG	cis	rs2084898	1.000	rs2084898	chr11:120026748	C/T	cg07435449	chr11:120005650	TRIM29	-0.63	-7.31	-0.32	1.17e-12	Stroke (pediatric);
LGG	cis	rs11986414	1	rs11986414	chr8:1746950	A/G	cg22756942	chr8:1746360	NA	0.63	9.47	0.4	1.4e-19	Gaucher disease severity;
LGG	cis	rs116095464	0.614	rs62344292	chr5:244630	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.81	-0.64	1.95e-54	Breast cancer;
LGG	cis	rs6582630	0.502	rs1915395	chr12:38420726	A/G	cg26384229	chr12:38710491	ALG10B	0.99	23.11	0.73	3.83e-79	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs138857	0.515	rs9616373	chr22:50308597	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.92	-10.28	-0.43	1.81e-22	Mean platelet volume;
LGG	cis	rs72945132	0.882	rs10466703	chr11:70218548	C/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.23	0.52	4.17e-34	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07946583	chr12:77158144	ZDHHC17	0.49	7.35	0.32	8.94e-13	Gut microbiome composition (summer);
LGG	cis	rs3741151	0.773	rs6592526	chr11:73208911	C/T	cg17517138	chr11:73019481	ARHGEF17	0.85	8.17	0.36	2.93e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.79	0.54	1.73e-36	Colorectal cancer;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg10935494	chr17:80760059	TBCD	-0.38	-6.74	-0.3	4.69e-11	Glycated hemoglobin levels;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08925882	chr11:67350491	GSTP1	-0.34	-6.8	-0.3	3.19e-11	Mean corpuscular volume;
LGG	cis	rs4919087	0.705	rs701812	chr10:98975413	A/G	cg25902810	chr10:99078978	FRAT1	-0.42	-7.38	-0.32	7.32e-13	Monocyte count;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg16405210	chr4:1374714	KIAA1530	0.5	8.47	0.37	3.28e-16	Obesity-related traits;
LGG	cis	rs9399135	0.967	rs4896120	chr6:135293512	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.41	0.4	2.41e-19	Red blood cell count;
LGG	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	cis	rs42648	0.870	rs7783199	chr7:89999305	G/A	cg25739043	chr7:89950458	NA	0.38	7.97	0.35	1.24e-14	Homocysteine levels;
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg26554054	chr8:600488	NA	0.92	9.73	0.41	1.8e-20	IgG glycosylation;
LGG	cis	rs881375	1.000	rs10760121	chr9:123647915	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.76	0.48	4.19e-28	Rheumatoid arthritis;
LGG	cis	rs1018836	0.608	rs1033347	chr8:91464137	G/A	cg16814680	chr8:91681699	NA	-0.6	-10.07	-0.42	1.05e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.45	0.44	4.43e-23	Diabetic retinopathy;
LGG	cis	rs4684776	0.867	rs13084898	chr3:11334276	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.7	-0.37	6e-17	Small vessel stroke;
LGG	cis	rs2032447	0.520	rs198818	chr6:26125711	A/C	cg12310025	chr6:25882481	NA	0.49	9.04	0.39	4.21e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.889	rs11785755	chr8:22453223	C/A	cg02227867	chr8:22457446	C8orf58	-0.43	-8.0	-0.35	1.04e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg08888203	chr3:10149979	C3orf24	0.54	8.68	0.37	6.98e-17	Alzheimer's disease;
LGG	trans	rs11875185	0.510	rs79004903	chr18:55600521	A/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs61931739	1.000	rs12298806	chr12:34036528	C/G	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs9911578	1.000	rs8079774	chr17:56908188	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.75	0.59	4.71e-45	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.967	rs11656855	chr17:45714655	C/T	cg08085267	chr17:45401833	C17orf57	0.58	11.59	0.47	1.87e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9354308	0.933	rs10455586	chr6:66571498	T/C	cg07460842	chr6:66804631	NA	0.57	9.53	0.4	9.08e-20	Metabolite levels;
LGG	trans	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg02002194	chr4:3960332	NA	0.4	7.19	0.32	2.62e-12	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01221716	chr6:26421570	BTN2A3	0.44	6.7	0.3	6.05e-11	Gut microbiome composition (summer);
LGG	cis	rs2836974	0.897	rs3945	chr21:40566067	A/G	cg11644478	chr21:40555479	PSMG1	0.9	16.88	0.62	3.72e-50	Cognitive function;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg04160749	chr8:58172571	NA	-0.47	-7.17	-0.32	3.03e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7818382	0.967	rs7812465	chr8:96050557	C/T	cg16049864	chr8:95962084	TP53INP1	0.31	6.7	0.3	6.16e-11	Alzheimer's disease (late onset);
LGG	cis	rs3768617	0.811	rs6674729	chr1:183059143	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.82	0.3	2.83e-11	Fuchs's corneal dystrophy;
LGG	trans	rs7980799	0.682	rs1601005	chr12:33634658	A/G	cg26384229	chr12:38710491	ALG10B	-0.66	-12.15	-0.49	1.16e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9296092	0.538	rs115770720	chr6:33517032	A/T	cg13560919	chr6:33536144	NA	-1.05	-21.66	-0.71	2.2e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs6121246	0.909	rs6060870	chr20:30303299	C/T	cg04935436	chr20:30431758	NA	0.41	7.26	0.32	1.7e-12	Mean corpuscular hemoglobin;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11368578	chr7:150754936	CDK5	0.4	6.75	0.3	4.48e-11	Bipolar disorder;
LGG	cis	rs921968	0.541	rs72965126	chr2:219330189	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.28	0.32	1.4e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6763768	0.606	rs4687573	chr3:53292090	C/T	cg16894138	chr3:53270350	TKT	0.39	7.42	0.33	5.52e-13	Bacterial meningitis;
LGG	cis	rs920590	0.641	rs2035889	chr8:19634087	T/A	cg01411142	chr8:19674711	INTS10	0.45	7.0	0.31	8.91e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4862307	0.836	rs4643860	chr4:184997945	T/C	cg06737308	chr4:185021514	ENPP6	-0.43	-7.46	-0.33	4.22e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	trans	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.42	8.84	0.38	2.03e-17	Aortic root size;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17604090	0.793	rs17150667	chr7:29689338	G/T	cg12658982	chr7:29603541	PRR15	-0.36	-6.79	-0.3	3.35e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4246949	0.671	rs3808965	chr10:125519977	T/C	cg12769705	chr10:125521557	CPXM2	-0.32	-6.82	-0.3	2.87e-11	Ulcerative colitis;
LGG	cis	rs10791097	0.694	rs7106973	chr11:130758113	G/A	cg12179176	chr11:130786555	SNX19	0.84	17.38	0.63	1.86e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7220401	0.512	rs71371126	chr17:28002642	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.64	-10.83	-0.45	1.63e-24	Coronary artery disease;
LGG	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg13010199	chr12:38710504	ALG10B	0.63	12.78	0.51	3.13e-32	Morning vs. evening chronotype;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24220383	chr17:73511862	CASKIN2;TSEN54	0.43	7.01	0.31	8.43e-12	Cognitive performance;
LGG	cis	rs17854409	1.000	rs17854409	chr20:61491494	T/C	cg06598544	chr20:61472147	COL9A3	-0.92	-10.34	-0.43	1.1e-22	Obesity-related traits;
LGG	cis	rs8016982	0.855	rs10149681	chr14:81686319	G/A	cg01989461	chr14:81687754	GTF2A1	0.64	12.62	0.51	1.36e-31	Schizophrenia;
LGG	cis	rs4268898	0.717	rs2543662	chr2:24443271	G/T	cg06627628	chr2:24431161	ITSN2	0.72	11.94	0.49	8.12e-29	Asthma;
LGG	cis	rs13191362	1.000	rs35754151	chr6:163074867	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.8	0.3	3.23e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.63	-0.54	8.52e-36	Schizophrenia;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg11878867	chr6:150167359	LRP11	-0.39	-8.22	-0.36	2.12e-15	Testicular germ cell tumor;
LGG	cis	rs10256972	0.521	rs10280960	chr7:1103697	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.35	-6.87	-0.3	2.11e-11	Longevity;Endometriosis;
LGG	cis	rs11630290	0.592	rs4777332	chr15:64158112	A/G	cg12036633	chr15:63758958	NA	0.48	7.0	0.31	8.79e-12	Iris characteristics;
LGG	cis	rs6500602	0.701	rs4785969	chr16:4536934	A/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.33	7.33	0.32	1.03e-12	Schizophrenia;
LGG	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg15269541	chr15:43626905	ADAL	-0.41	-6.91	-0.31	1.58e-11	Lung cancer in ever smokers;
LGG	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg08400814	chr5:56204995	C5orf35	-0.38	-6.69	-0.3	6.42e-11	Coronary artery disease;
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.07	-0.31	5.7e-12	Triglycerides;
LGG	cis	rs780096	0.526	rs780102	chr2:27659491	T/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg11494091	chr17:61959527	GH2	-0.73	-12.84	-0.51	1.73e-32	Height;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg13206674	chr6:150067644	NUP43	0.67	15.58	0.59	2.62e-44	Lung cancer;
LGG	cis	rs62400317	0.762	rs12193264	chr6:44930793	T/C	cg20913747	chr6:44695427	NA	-0.66	-11.2	-0.46	6.22e-26	Total body bone mineral density;
LGG	cis	rs2028414	0.512	rs2247712	chr14:105359827	T/C	cg11813489	chr14:105363835	NA	-0.45	-8.73	-0.38	4.55e-17	IgG glycosylation;
LGG	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg00825309	chr19:58991885	ZNF446	-0.44	-8.04	-0.35	7.57e-15	Uric acid clearance;
LGG	cis	rs9815354	0.951	rs12492599	chr3:42005734	C/A	cg03022575	chr3:42003672	ULK4	-0.65	-8.38	-0.36	6.51e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07362569	chr17:61921086	SMARCD2	-0.43	-7.94	-0.35	1.5e-14	Prudent dietary pattern;
LGG	cis	rs10463554	0.892	rs66759661	chr5:102261598	A/T	cg23492399	chr5:102201601	PAM	-0.55	-8.51	-0.37	2.36e-16	Parkinson's disease;
LGG	cis	rs2916247	0.788	rs1973258	chr8:93121262	A/G	cg10183463	chr8:93005414	RUNX1T1	0.4	8.23	0.36	1.87e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	0.525	rs4665324	chr2:26447147	A/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs1451375	1.000	rs10247443	chr7:50620586	G/A	cg00647317	chr7:50633725	DDC	-0.34	-7.58	-0.33	1.89e-13	Malaria;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg20887711	chr4:1340912	KIAA1530	0.46	8.02	0.35	8.97e-15	Obesity-related traits;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg00166722	chr3:10149974	C3orf24	0.48	8.05	0.35	7.11e-15	Alzheimer's disease;
LGG	cis	rs875971	0.545	rs316316	chr7:65614257	C/T	cg11764359	chr7:65958608	NA	-0.63	-9.75	-0.41	1.44e-20	Aortic root size;
LGG	cis	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg24375607	chr4:120327624	NA	-0.66	-10.8	-0.45	2.06e-24	Corneal astigmatism;
LGG	cis	rs12410462	0.681	rs4486420	chr1:227572321	T/A	cg04117972	chr1:227635322	NA	0.72	11.2	0.46	6.29e-26	Major depressive disorder;
LGG	cis	rs1109114	0.934	rs58203769	chr5:148618708	A/G	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.44	-0.58	1.11e-43	Body mass index;
LGG	cis	rs12545109	0.800	rs1467123	chr8:57418870	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs1877316	chr17:61766880	C/A	cg18032289	chr17:61959525	GH2	-0.4	-6.92	-0.31	1.54e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg02743256	chr7:2109353	MAD1L1	-0.35	-7.06	-0.31	6.24e-12	Bipolar disorder;
LGG	cis	rs4075765	0.764	rs55639114	chr11:26264858	T/C	cg19182008	chr11:26298241	NA	0.99	8.79	0.38	3e-17	Cannabis dependence symptom count;
LGG	cis	rs8067545	0.563	rs3850780	chr17:20181902	A/C	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3e-13	Schizophrenia;
LGG	cis	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	2.97e-22	Corneal astigmatism;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	6.99	0.31	9.82e-12	Longevity;
LGG	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs11785693	0.909	rs62489557	chr8:4968371	A/G	cg26367366	chr8:4980734	NA	1.02	15.29	0.58	5.27e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs908922	0.584	rs10888500	chr1:152532749	G/A	cg20991723	chr1:152506922	NA	-0.71	-14.3	-0.55	1.12e-38	Hair morphology;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27562717	chr20:30193180	ID1	0.44	7.0	0.31	9.13e-12	Cognitive performance;
LGG	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.17	0.35	3.02e-15	Diabetic kidney disease;
LGG	cis	rs17039065	1.000	rs59671813	chr4:109393618	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.84	0.3	2.45e-11	Gut microbiome composition (summer);
LGG	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.75	-0.41	1.45e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg11878867	chr6:150167359	LRP11	-0.47	-9.76	-0.41	1.41e-20	Lung cancer;
LGG	cis	rs888194	0.738	rs1001382	chr12:109974931	T/C	cg08884029	chr12:110012500	MVK;MMAB	-0.33	-6.69	-0.3	6.39e-11	Neuroticism;
LGG	cis	rs56399783	0.901	rs73049305	chr7:2778755	C/T	cg19731401	chr7:2775893	GNA12	0.38	7.66	0.34	1.1e-13	Childhood ear infection;
LGG	cis	rs10743315	0.557	rs78983750	chr12:19284967	C/T	cg02471346	chr12:19282374	PLEKHA5	0.82	7.12	0.31	4.02e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg06028808	chr11:68637592	NA	0.7	12.09	0.49	2e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1816854	1.000	rs10880570	chr12:44202465	A/T	cg00106942	chr12:44200524	TWF1	-0.44	-6.66	-0.3	7.69e-11	Inflammatory bowel disease;
LGG	cis	rs2694528	0.844	rs2169256	chr5:60062668	C/T	cg11474532	chr5:59995715	DEPDC1B	0.73	7.81	0.34	3.74e-14	Parkinson's disease;
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.36	6.98	0.31	1.04e-11	Schizophrenia;
LGG	cis	rs7646881	0.812	rs79303235	chr3:158444793	C/T	cg19483011	chr3:158453295	NA	-0.58	-7.79	-0.34	4.35e-14	Tetralogy of Fallot;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs9790314	1.000	rs336591	chr3:161078080	A/G	cg04691961	chr3:161091175	C3orf57	-0.66	-15.99	-0.6	3.88e-46	Morning vs. evening chronotype;
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs6840360	0.571	rs7692700	chr4:152552797	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.5	-0.37	2.72e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3126085	0.935	rs10888466	chr1:152166223	A/C	cg26876637	chr1:152193138	HRNR	-0.55	-9.08	-0.39	3.06e-18	Atopic dermatitis;
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg03351412	chr1:154909251	PMVK	0.56	9.68	0.41	2.54e-20	Prostate cancer;
LGG	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg22676075	chr6:135203613	NA	0.4	7.06	0.31	6.29e-12	Red blood cell count;
LGG	cis	rs2361718	0.564	rs2304844	chr17:78084507	G/C	cg21238619	chr17:78079768	GAA	-0.49	-9.52	-0.4	9.44e-20	Yeast infection;
LGG	cis	rs8067287	0.554	rs56035746	chr17:16841433	C/T	cg26910001	chr17:16838321	NA	-0.5	-9.44	-0.4	1.88e-19	Diabetic kidney disease;
LGG	cis	rs1372520	0.684	rs1811442	chr4:90747751	C/T	cg15133208	chr4:90757351	SNCA	-0.41	-8.41	-0.36	5.18e-16	Neuroticism;
LGG	cis	rs911263	0.603	rs11158728	chr14:68762205	G/T	cg18825221	chr14:68749962	RAD51L1	0.38	8.26	0.36	1.57e-15	Primary biliary cholangitis;
LGG	trans	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg27523141	chr10:43048294	ZNF37B	0.32	6.71	0.3	5.55e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg11905131	chr22:24372483	LOC391322	-0.46	-7.77	-0.34	5.06e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12410462	0.581	rs112572966	chr1:227553905	C/T	cg23173402	chr1:227635558	NA	0.45	7.64	0.33	1.28e-13	Major depressive disorder;
LGG	cis	rs1008375	1.000	rs56974987	chr4:17627856	G/A	cg02297831	chr4:17616191	MED28	0.5	9.45	0.4	1.67e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4363385	0.597	rs55667413	chr1:152976849	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.2	-0.39	1.19e-18	Inflammatory skin disease;
LGG	cis	rs10504229	1.000	rs76944716	chr8:58191643	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-12.82	-0.51	1.97e-32	Developmental language disorder (linguistic errors);
LGG	trans	rs9784649	1.000	rs7702197	chr5:24975778	A/G	cg08600765	chr20:34638493	LOC647979	0.55	7.09	0.31	5.16e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4423214	0.650	rs2186777	chr11:71219803	C/A	cg10847948	chr11:71163743	NADSYN1	-0.56	-9.67	-0.41	2.95e-20	Vitamin D levels;
LGG	cis	rs2404602	0.967	rs12148805	chr15:76800659	G/A	cg15268244	chr15:77196840	NA	-0.34	-7.46	-0.33	4.19e-13	Blood metabolite levels;
LGG	cis	rs9910055	0.530	rs2269906	chr17:42294337	G/T	cg19774624	chr17:42201019	HDAC5	0.57	10.15	0.43	5.27e-22	Total body bone mineral density;
LGG	cis	rs875971	0.862	rs3926380	chr7:66080645	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.98	-0.31	1.02e-11	Aortic root size;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg06848047	chr4:90757629	SNCA	-0.42	-8.03	-0.35	8.2e-15	Dementia with Lewy bodies;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22968622	chr17:43663579	NA	0.85	14.97	0.57	1.39e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs1982963	0.901	rs1566131	chr14:52514684	G/A	cg05884192	chr14:52515736	NID2	-0.34	-7.62	-0.33	1.48e-13	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4950322	0.570	rs72691054	chr1:146749611	T/C	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs7107174	1.000	rs12270434	chr11:78103300	G/A	cg27205649	chr11:78285834	NARS2	-0.44	-7.26	-0.32	1.62e-12	Testicular germ cell tumor;
LGG	trans	rs984440	0.542	rs1073348	chr8:139082730	T/C	cg03334052	chr1:168888044	NA	0.34	6.76	0.3	4.12e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	0.688	rs72845232	chr6:27428126	T/G	cg00426182	chr6:28072559	NA	0.94	7.01	0.31	8.62e-12	Hip circumference adjusted for BMI;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg19015582	chr11:75946767	NA	0.43	7.02	0.31	7.79e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7208859	0.623	rs56812022	chr17:29068733	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs910187	0.678	rs3818013	chr20:45816639	A/G	cg27589058	chr20:45804311	EYA2	-0.35	-9.05	-0.39	4.09e-18	Migraine;
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg02353165	chr6:42928485	GNMT	0.41	11.92	0.48	9.02e-29	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs870825	0.929	rs55746424	chr4:185589603	C/T	cg04058563	chr4:185651563	MLF1IP	1.07	19.46	0.67	4.37e-62	Blood protein levels;
LGG	cis	rs3749237	0.595	rs4855873	chr3:49459114	A/C	cg03060546	chr3:49711283	APEH	0.74	13.19	0.52	6.13e-34	Resting heart rate;
LGG	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.73	0.41	1.8e-20	Menopause (age at onset);
LGG	trans	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg08975724	chr8:8085496	FLJ10661	0.43	8.15	0.35	3.49e-15	Neuroticism;
LGG	trans	rs9650657	0.655	rs4841434	chr8:10586123	T/C	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.69	-0.3	6.28e-11	Neuroticism;
LGG	cis	rs9308433	0.643	rs955920	chr1:214464309	G/A	cg06198575	chr1:214491504	SMYD2	0.46	6.68	0.3	6.92e-11	IgG glycosylation;
LGG	cis	rs6840360	0.555	rs4554052	chr4:152726610	T/C	cg22705602	chr4:152727874	NA	0.37	9.18	0.39	1.45e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.692	rs35195096	chr15:76938447	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.22	-0.32	2.17e-12	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24695828	chr19:36980257	ZNF566	0.46	7.41	0.33	5.98e-13	Cognitive performance;
LGG	cis	rs12493885	0.505	rs357489	chr3:153884517	A/T	cg07365816	chr3:153839000	SGEF	0.49	7.22	0.32	2.12e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.22	-0.32	2.19e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7818345	0.569	rs4317590	chr8:19357642	A/G	cg01280390	chr8:19363452	CSGALNACT1	0.45	10.81	0.45	2e-24	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg08484992	chr16:88977278	CBFA2T3	0.32	6.96	0.31	1.19e-11	Social autistic-like traits;
LGG	cis	rs12410462	0.591	rs16847991	chr1:227791096	A/G	cg23173402	chr1:227635558	NA	0.37	7.1	0.31	4.67e-12	Major depressive disorder;
LGG	cis	rs9443645	0.901	rs4421161	chr6:79564219	A/G	cg18132916	chr6:79620363	NA	0.31	8.35	0.36	8.22e-16	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg01988459	chr11:68622903	NA	-0.61	-12.47	-0.5	5.52e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg06028808	chr11:68637592	NA	0.73	11.96	0.49	6.56e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7927771	0.864	rs3781627	chr11:47441472	T/A	cg20307385	chr11:47447363	PSMC3	0.57	10.03	0.42	1.49e-21	Subjective well-being;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.58	8.09	0.35	5.37e-15	Lung function (FEV1/FVC);
LGG	cis	rs1865760	1.000	rs3752421	chr6:25918688	G/A	cg16482183	chr6:26056742	HIST1H1C	0.52	9.32	0.4	4.91e-19	Height;
LGG	cis	rs9467711	0.651	rs17587597	chr6:25986451	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.77	0.3	3.93e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.65e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg21055462	chr7:100276975	NA	0.39	7.68	0.34	9.26e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs208520	1.000	rs208520	chr6:66952828	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.19	-0.55	3.28e-38	Exhaled nitric oxide output;
LGG	trans	rs2921036	0.545	rs4840975	chr8:8363258	C/T	cg16141378	chr3:129829833	LOC729375	0.4	8.53	0.37	2.14e-16	Neuroticism;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.45	-9.04	-0.39	4.24e-18	Schizophrenia;
LGG	cis	rs5756813	0.727	rs58765732	chr22:38160794	A/C	cg19171272	chr22:38449367	NA	0.4	6.92	0.31	1.49e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3858526	0.920	rs11039698	chr11:5950907	C/T	cg25319279	chr11:5960081	NA	-0.57	-8.78	-0.38	3.22e-17	DNA methylation (variation);
LGG	cis	rs11191205	0.644	rs74926559	chr10:103378309	G/A	cg15320455	chr10:103880129	LDB1	0.51	7.45	0.33	4.67e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7178909	0.835	rs12437459	chr15:90420773	A/C	cg19708238	chr15:90437601	AP3S2	0.4	6.7	0.3	5.97e-11	Common traits (Other);
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg14004847	chr7:1930337	MAD1L1	0.53	9.73	0.41	1.72e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg20891283	chr12:69753455	YEATS4	1.08	28.83	0.8	2.01e-105	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg11890956	chr21:40555474	PSMG1	-1.04	-20.94	-0.7	5.47e-69	Cognitive function;
LGG	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg22875332	chr1:76189707	ACADM	0.6	10.31	0.43	1.46e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs66887589	0.837	rs6534135	chr4:120406302	A/G	cg09307838	chr4:120376055	NA	0.49	8.46	0.37	3.53e-16	Diastolic blood pressure;
LGG	cis	rs9303401	0.659	rs3809724	chr17:57061238	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.4	0.56	4.2e-39	Cognitive test performance;
LGG	cis	rs17253792	0.822	rs75351812	chr14:56082192	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs9487094	0.961	rs1923725	chr6:109708888	T/G	cg16315928	chr6:109776240	MICAL1	0.53	9.13	0.39	2.15e-18	Height;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00972603	chr1:28655503	MED18	-0.42	-7.48	-0.33	3.76e-13	Pancreatic cancer;
LGG	cis	rs2635047	0.638	rs2668784	chr18:44711391	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.88	0.3	1.96e-11	Educational attainment;
LGG	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	trans	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7385804	0.761	rs1734910	chr7:100309544	A/G	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.93e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs1008375	1.000	rs1974624	chr4:17650281	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.17	0.32	3.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9443645	0.527	rs4706746	chr6:79674176	G/A	cg18132916	chr6:79620363	NA	-0.28	-7.29	-0.32	1.38e-12	Intelligence (multi-trait analysis);
LGG	trans	rs12599106	0.818	rs17723574	chr16:34602945	C/G	cg15383120	chr6:291909	DUSP22	-0.43	-7.38	-0.32	7.5e-13	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs8017423	0.935	rs12880102	chr14:90793526	G/T	cg04374321	chr14:90722782	PSMC1	-0.86	-17.48	-0.63	6.55e-53	Mortality in heart failure;
LGG	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs12482904	0.607	rs11203202	chr21:43825357	C/G	cg23042151	chr21:43824109	UBASH3A	-0.53	-10.58	-0.44	1.47e-23	Vitiligo;
LGG	cis	rs5771225	0.505	rs5771111	chr22:50695946	C/G	cg16473166	chr22:50639996	SELO	0.63	9.48	0.4	1.34e-19	Late-onset Alzheimer's disease;
LGG	cis	rs72848980	1.000	rs72848976	chr10:105312536	G/A	cg00126946	chr10:105363258	SH3PXD2A	0.49	7.42	0.33	5.78e-13	White matter hyperintensity burden;
LGG	cis	rs10256972	0.626	rs62433138	chr7:1050877	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-8.9	-0.38	1.29e-17	Longevity;Endometriosis;
LGG	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	9.57	0.41	6.21e-20	Aortic root size;
LGG	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg24209194	chr3:40518798	ZNF619	-0.43	-6.96	-0.31	1.16e-11	Renal cell carcinoma;
LGG	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg07511668	chr11:68622177	NA	0.51	9.77	0.41	1.24e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.16e-25	Aortic root size;
LGG	cis	rs6840360	0.554	rs62329088	chr4:152471289	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg08219700	chr8:58056026	NA	0.47	7.05	0.31	6.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6831352	1.000	rs1126670	chr4:100052733	C/A	cg12011299	chr4:100065546	ADH4	0.45	9.24	0.39	9.28e-19	Alcohol dependence;
LGG	cis	rs9486719	0.843	rs2499797	chr6:96848669	C/T	cg06623918	chr6:96969491	KIAA0776	0.73	9.65	0.41	3.5e-20	Migraine;Coronary artery disease;
LGG	trans	rs17685	0.712	rs60721456	chr7:75743820	T/A	cg19862616	chr7:65841803	NCRNA00174	1.05	23.82	0.74	1.96e-82	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	trans	rs11650494	0.908	rs77247327	chr17:47411493	T/C	cg11430096	chr6:110968061	CDK19	0.68	7.1	0.31	4.76e-12	Prostate cancer;
LGG	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg06360820	chr2:242988706	NA	-0.96	-11.89	-0.48	1.25e-28	Obesity-related traits;
LGG	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg03929089	chr4:120376271	NA	-0.56	-9.95	-0.42	2.85e-21	HDL cholesterol;
LGG	cis	rs7241530	0.662	rs7244039	chr18:75906601	T/C	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs3858526	0.834	rs7113548	chr11:5989293	G/A	cg25319279	chr11:5960081	NA	-0.55	-8.56	-0.37	1.73e-16	DNA methylation (variation);
LGG	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg25986240	chr4:9926439	SLC2A9	0.39	7.73	0.34	6.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs721917	0.525	rs7903576	chr10:81741142	A/G	cg25562619	chr10:81652821	NA	-0.33	-7.13	-0.31	3.77e-12	Chronic obstructive pulmonary disease;
LGG	cis	rs1499614	1.000	rs2659903	chr7:66180931	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg14703610	chr5:56206110	C5orf35	0.45	7.77	0.34	5.17e-14	Coronary artery disease;
LGG	cis	rs2273669	0.667	rs11751295	chr6:109334458	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs11651000	0.857	rs57171311	chr17:45826168	A/G	cg06532163	chr17:45867833	NA	0.54	8.24	0.36	1.79e-15	IgG glycosylation;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17513182	chr1:153894941	GATAD2B	-0.43	-6.86	-0.3	2.16e-11	Pancreatic cancer;
LGG	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg16141378	chr3:129829833	LOC729375	0.36	8.11	0.35	4.59e-15	Triglycerides;
LGG	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg18681998	chr4:17616180	MED28	0.86	19.73	0.68	2.51e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62238980	0.614	rs976915	chr22:32428445	A/G	cg00543991	chr22:32367038	NA	0.78	8.57	0.37	1.51e-16	Childhood ear infection;
LGG	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg21798802	chr22:38057573	PDXP	0.4	8.59	0.37	1.34e-16	Fat distribution (HIV);
LGG	cis	rs12477438	0.765	rs6754843	chr2:99680485	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs7208859	0.623	rs11652631	chr17:29060766	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.46	-8.81	-0.38	2.61e-17	Height;
LGG	cis	rs9487094	1.000	rs9487094	chr6:109742015	G/A	cg16315928	chr6:109776240	MICAL1	0.47	7.96	0.35	1.35e-14	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19300632	chr2:55746645	CCDC104	0.4	7.08	0.31	5.54e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9486715	0.867	rs2499774	chr6:97006581	C/G	cg18709589	chr6:96969512	KIAA0776	-0.44	-8.71	-0.38	5.39e-17	Headache;
LGG	trans	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg18187862	chr3:45730750	SACM1L	0.65	10.74	0.45	3.44e-24	Primary sclerosing cholangitis;
LGG	cis	rs7928758	0.943	rs79449985	chr11:134265121	C/T	cg15243474	chr11:134282918	B3GAT1	1.16	15.24	0.58	8.91e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs798502	0.522	rs7790322	chr7:2830498	C/T	cg13628971	chr7:2884303	GNA12	0.38	7.72	0.34	7.15e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.5	-0.37	2.68e-16	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg00800038	chr16:89945340	TCF25	-0.71	-8.59	-0.37	1.32e-16	Skin colour saturation;
LGG	cis	rs9467773	0.595	rs7767847	chr6:26597893	A/T	cg09904177	chr6:26538194	HMGN4	0.68	13.95	0.54	3.56e-37	Intelligence (multi-trait analysis);
LGG	trans	rs6575793	0.512	rs6575791	chr14:101029203	A/G	cg22806444	chr17:72968764	C17orf28	-0.48	-8.36	-0.36	7.14e-16	Menarche (age at onset);
LGG	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg20573242	chr4:122745356	CCNA2	-0.46	-8.54	-0.37	1.89e-16	Type 2 diabetes;
LGG	cis	rs9858542	0.903	rs11917431	chr3:49644012	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.37	0.4	3.23e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1023500	0.551	rs4822076	chr22:42364057	C/T	cg04733989	chr22:42467013	NAGA	0.49	7.58	0.33	1.85e-13	Schizophrenia;
LGG	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.51	-6.99	-0.31	9.54e-12	Crohn's disease;
LGG	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg08600765	chr20:34638493	LOC647979	-0.57	-7.42	-0.33	5.8e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12617538	chr9:69786570	NA	0.43	7.99	0.35	1.11e-14	Menarche (age at onset);
LGG	cis	rs1348850	0.526	rs9288003	chr2:178446572	T/G	cg23306229	chr2:178417860	TTC30B	0.62	7.65	0.34	1.16e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs736408	0.648	rs3774354	chr3:52817675	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.72	-0.45	4.13e-24	Bipolar disorder;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg19980929	chr12:42632907	YAF2	0.39	8.88	0.38	1.53e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7712401	0.623	rs30044	chr5:122272080	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs7737355	0.812	rs10076930	chr5:130764037	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.81	-0.38	2.62e-17	Life satisfaction;
LGG	cis	rs11690935	0.959	rs1474074	chr2:172659852	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.4	-0.78	2.17e-94	Schizophrenia;
LGG	cis	rs77372450	0.636	rs10066998	chr5:157008510	G/A	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs4478137	0.501	rs28437702	chr4:164231410	C/T	cg06758707	chr4:164254230	NPY1R	-0.55	-8.1	-0.35	4.93e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs4662945	0.603	rs2406981	chr2:130305487	A/G	cg05962382	chr2:130345044	NA	-0.48	-8.15	-0.35	3.44e-15	Response to cytidine analogues (gemcitabine);
LGG	cis	rs368123	1.000	rs405137	chr6:160731591	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs600231	0.577	rs35826299	chr11:65240964	T/C	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.65	-0.37	8.55e-17	Bone mineral density;
LGG	cis	rs2180341	0.538	rs11154402	chr6:127711932	C/A	cg24812749	chr6:127587940	RNF146	0.53	8.75	0.38	4.04e-17	Breast cancer;
LGG	cis	rs67133203	0.851	rs11831810	chr12:51464251	C/T	cg14688905	chr12:51403056	SLC11A2	0.7	10.59	0.44	1.34e-23	Urinary tract infection frequency;
LGG	cis	rs9473924	0.542	rs2857506	chr6:50800308	C/T	cg14470998	chr6:50812995	TFAP2B	0.67	8.24	0.36	1.79e-15	Body mass index;
LGG	cis	rs7107174	1.000	rs10899465	chr11:78013588	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs1372520	0.684	rs1442148	chr4:90748846	T/A	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs73086581	0.898	rs11906452	chr20:3981559	A/G	cg02187196	chr20:3869020	PANK2	0.74	10.45	0.44	4.21e-23	Response to antidepressants in depression;
LGG	cis	rs908922	0.676	rs528427	chr1:152511507	G/C	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	trans	rs7944735	0.578	rs7949985	chr11:48062449	C/T	cg15704280	chr7:45808275	SEPT13	0.71	7.28	0.32	1.42e-12	Intraocular pressure;
LGG	cis	rs8005745	0.614	rs2301108	chr14:62197464	C/T	cg01748970	chr14:62088363	NA	0.86	10.22	0.43	2.91e-22	Select biomarker traits;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-9.7	-0.41	2.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs3820068	0.580	rs61169376	chr1:16003832	A/G	cg05660106	chr1:15850417	CASP9	0.76	13.95	0.54	3.5e-37	Systolic blood pressure;
LGG	trans	rs45509595	0.749	rs401763	chr6:27782528	T/C	cg08344181	chr3:125677491	NA	-0.68	-7.84	-0.34	3.19e-14	Breast cancer;
LGG	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg12046867	chr14:103022105	NA	-0.8	-15.54	-0.59	4.15e-44	Platelet count;
LGG	trans	rs877282	0.945	rs11253398	chr10:790012	T/C	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.7	-14.56	-0.56	8.55e-40	Obesity-related traits;
LGG	cis	rs9875589	0.509	rs2129888	chr3:14013826	A/T	cg19554555	chr3:13937349	NA	-0.55	-9.69	-0.41	2.43e-20	Ovarian reserve;
LGG	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg00292662	chr22:38071168	LGALS1	0.65	14.86	0.57	4e-41	Fat distribution (HIV);
LGG	cis	rs3087591	0.922	rs2953013	chr17:29496343	A/C	cg24425628	chr17:29625626	OMG;NF1	-0.69	-13.74	-0.54	2.88e-36	Hip circumference;
LGG	cis	rs9611565	0.659	rs1569516	chr22:41910244	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-9.24	-0.39	9.16e-19	Vitiligo;
LGG	cis	rs826838	0.935	rs7301104	chr12:39182821	C/T	cg13010199	chr12:38710504	ALG10B	0.72	15.05	0.57	5.76e-42	Heart rate;
LGG	trans	rs35110281	0.627	rs6518268	chr21:44967448	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.26	0.5	3.98e-30	Mean corpuscular volume;
LGG	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg06212747	chr3:49208901	KLHDC8B	0.48	7.39	0.32	6.85e-13	Menarche (age at onset);
LGG	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg13939156	chr17:80058883	NA	0.47	8.23	0.36	1.89e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs7267979	1.000	rs6050617	chr20:25421648	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1801251	1.000	rs35212961	chr2:233582762	C/T	cg08000102	chr2:233561755	GIGYF2	0.59	9.58	0.41	6.04e-20	Coronary artery disease;
LGG	cis	rs6963495	0.818	rs6961863	chr7:105180953	C/T	cg19920283	chr7:105172520	RINT1	0.62	8.31	0.36	1.09e-15	Bipolar disorder (body mass index interaction);
LGG	trans	rs1814175	0.791	rs10769593	chr11:49616217	T/C	cg15704280	chr7:45808275	SEPT13	-1.06	-24.79	-0.76	6.03e-87	Height;
LGG	cis	rs4330281	0.669	rs10510478	chr3:17730282	A/G	cg20981856	chr3:17787350	NA	-0.37	-6.9	-0.31	1.75e-11	Schizophrenia;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.89	-0.42	4.83e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs57221529	0.766	rs4957053	chr5:575927	T/C	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs747782	0.646	rs3847503	chr11:47464519	G/A	cg15704280	chr7:45808275	SEPT13	0.62	6.75	0.3	4.44e-11	Intraocular pressure;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg08621203	chr6:150244597	RAET1G	0.44	7.05	0.31	6.5e-12	Lung cancer;
LGG	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	12.22	0.49	5.98e-30	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg06951627	chr6:26196580	NA	0.47	6.87	0.3	2.02e-11	Gout;Renal underexcretion gout;
LGG	cis	rs9362426	1.000	rs9294377	chr6:88084839	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	10.02	0.42	1.55e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs1008375	0.932	rs12500947	chr4:17603424	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.75	0.3	4.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2243480	1.000	rs56291018	chr7:65390339	G/A	cg10756647	chr7:56101905	PSPH	0.84	9.88	0.42	5.27e-21	Diabetic kidney disease;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4774899	1.000	rs2111891	chr15:57243872	A/G	cg08128148	chr15:57256372	TCF12	-0.34	-8.02	-0.35	8.67e-15	Urinary tract infection frequency;
LGG	cis	rs9309473	0.555	rs2901437	chr2:73597024	T/G	cg20560298	chr2:73613845	ALMS1	-0.46	-8.31	-0.36	1.08e-15	Metabolite levels;
LGG	cis	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg13443165	chr9:33130375	B4GALT1	-0.59	-11.5	-0.47	4.36e-27	IgG glycosylation;
LGG	cis	rs10267417	0.603	rs6966428	chr7:19891587	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	7.45	0.33	4.46e-13	Night sleep phenotypes;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg09021430	chr5:549028	NA	-0.72	-10.11	-0.43	7.65e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs11785400	0.793	rs4371985	chr8:143737279	C/T	cg24634471	chr8:143751801	JRK	0.46	7.0	0.31	9.03e-12	Schizophrenia;
LGG	cis	rs637571	0.512	rs660118	chr11:65735174	G/C	cg26695010	chr11:65641043	EFEMP2	-0.51	-8.5	-0.37	2.67e-16	Eosinophil percentage of white cells;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg25703541	chr22:24373054	LOC391322	-0.91	-18.14	-0.64	6.08e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11214589	0.875	rs10891540	chr11:113239082	A/G	cg14159747	chr11:113255604	NA	-0.31	-8.56	-0.37	1.66e-16	Neuroticism;
LGG	trans	rs1005277	0.528	rs2057228	chr10:38515766	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs208520	0.526	rs6913344	chr6:66754285	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.1	-27.46	-0.79	3.04e-99	Exhaled nitric oxide output;
LGG	cis	rs9522267	1.000	rs9522266	chr13:112195456	C/T	cg10483660	chr13:112241077	NA	-0.37	-7.43	-0.33	5.44e-13	Hepatitis;
LGG	cis	rs2251260	1.000	rs2251260	chr14:62023767	C/T	cg23386212	chr14:62041363	NA	-0.6	-9.04	-0.39	4.26e-18	Yeast infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19864851	chr10:75503847	SEC24C	0.44	6.73	0.3	5.01e-11	Gut microbiome composition (summer);
LGG	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.76	0.34	5.4e-14	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs4363385	0.776	rs1890284	chr1:152942190	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.31	-0.36	1.07e-15	Inflammatory skin disease;
LGG	cis	rs2228479	0.717	rs1007932	chr16:89838541	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-9.04	-0.39	4.44e-18	Skin colour saturation;
LGG	cis	rs4919087	0.962	rs10786324	chr10:99054387	A/G	cg25902810	chr10:99078978	FRAT1	0.51	9.54	0.41	8.15e-20	Monocyte count;
LGG	cis	rs6952808	0.825	rs4236277	chr7:1942270	C/T	cg04267008	chr7:1944627	MAD1L1	-0.73	-12.91	-0.51	8.82e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.817	rs1705772	chr12:34174756	G/A	cg26384229	chr12:38710491	ALG10B	0.63	12.17	0.49	9.52e-30	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.830	rs17027216	chr4:99009152	G/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs897080	0.515	rs1067343	chr2:44621042	A/G	cg00619915	chr2:44497795	NA	-0.48	-6.8	-0.3	3.24e-11	Height;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg18402987	chr7:1209562	NA	0.71	9.6	0.41	5.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg08305652	chr11:111469057	NA	-0.39	-7.55	-0.33	2.28e-13	Primary sclerosing cholangitis;
LGG	cis	rs4363385	0.669	rs2937264	chr1:153011026	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs1843834	0.858	rs2047136	chr2:225511361	A/T	cg22455342	chr2:225449267	CUL3	0.6	10.36	0.43	8.92e-23	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs747650	0.892	rs7111764	chr11:47233209	G/A	cg03339077	chr11:47165057	C11orf49	-0.53	-10.14	-0.43	6.11e-22	Acne (severe);
LGG	cis	rs7599312	0.534	rs7607373	chr2:213409719	G/A	cg16329650	chr2:213403929	ERBB4	0.77	16.55	0.61	1.12e-48	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs9815354	1.000	rs2371623	chr3:41761083	T/C	cg03022575	chr3:42003672	ULK4	0.59	7.48	0.33	3.73e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs568617	0.767	rs2231884	chr11:65656564	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-6.89	-0.31	1.79e-11	Crohn's disease;
LGG	cis	rs17039065	1.000	rs72889363	chr4:109383406	T/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.98	0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs7226408	0.544	rs170452	chr18:34698731	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.12	-0.39	2.37e-18	Obesity-related traits;
LGG	cis	rs7937682	0.924	rs7938360	chr11:111539875	A/G	cg22437258	chr11:111473054	SIK2	0.57	9.78	0.41	1.13e-20	Primary sclerosing cholangitis;
LGG	cis	rs17321999	0.904	rs72787719	chr2:30474359	G/A	cg05247661	chr2:30472410	LBH	0.62	9.93	0.42	3.3e-21	Systemic lupus erythematosus;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.18	-0.46	7.29e-26	IgG glycosylation;
LGG	cis	rs9359856	0.564	rs17292425	chr6:90372128	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.82	-0.42	8.61e-21	Bipolar disorder;
LGG	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	trans	rs11088226	0.681	rs11700671	chr21:33938621	T/A	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg13770153	chr20:60521292	NA	1.09	19.67	0.67	4.87e-63	Obesity-related traits;
LGG	cis	rs457717	0.511	rs6867296	chr5:75932382	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	-0.34	-6.66	-0.3	7.84e-11	Hearing impairment;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02625641	chr15:59041175	ADAM10	0.41	7.23	0.32	1.99e-12	Bilirubin levels;
LGG	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg03162506	chr22:38580953	NA	0.37	9.52	0.4	9.55e-20	Cutaneous nevi;
LGG	cis	rs8067545	0.611	rs2013443	chr17:20023109	G/C	cg09818912	chr17:20140352	CYTSB	-0.34	-7.91	-0.35	1.87e-14	Schizophrenia;
LGG	cis	rs875971	0.825	rs1000464	chr7:65777909	G/C	cg23594656	chr7:65796392	TPST1	0.4	9.0	0.39	6.07e-18	Aortic root size;
LGG	cis	rs7659604	1.000	rs28532673	chr4:122664323	A/G	cg19748678	chr4:122722346	EXOSC9	-0.54	-10.6	-0.44	1.24e-23	Type 2 diabetes;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.47	-0.33	4.15e-13	Schizophrenia;
LGG	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg03517284	chr6:25882590	NA	0.51	9.39	0.4	2.67e-19	Blood metabolite levels;
LGG	cis	rs7618501	0.633	rs4688758	chr3:50028385	G/A	cg18129748	chr3:49941408	MST1R	0.22	6.93	0.31	1.4e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg00204512	chr16:28754710	NA	0.25	7.15	0.32	3.45e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.11e-22	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01555122	chr2:55276516	RTN4	0.43	6.86	0.3	2.24e-11	Cognitive performance;
LGG	cis	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg14979609	chr8:8086686	FLJ10661	-0.28	-6.92	-0.31	1.54e-11	Neuroticism;
LGG	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg24642439	chr20:33292090	TP53INP2	0.46	7.13	0.31	3.78e-12	Height;
LGG	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	cis	rs13082711	0.554	rs674798	chr3:27332302	G/T	cg02860705	chr3:27208620	NA	0.6	11.48	0.47	5.17e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4538187	0.518	rs781516	chr2:64276576	A/G	cg02541582	chr2:64069798	UGP2	0.46	12.09	0.49	1.97e-29	Systolic blood pressure;
LGG	cis	rs950776	0.545	rs28444683	chr15:78984507	C/A	cg07120314	chr15:79043507	NA	-0.42	-8.19	-0.36	2.57e-15	Sudden cardiac arrest;
LGG	cis	rs2153535	0.541	rs4637688	chr6:8446501	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.95	0.38	8.85e-18	Motion sickness;
LGG	cis	rs1318772	0.932	rs348934	chr5:112833108	C/A	cg12552261	chr5:112820674	MCC	-0.69	-7.48	-0.33	3.8e-13	F-cell distribution;
LGG	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg25664220	chr3:72788482	NA	-0.33	-8.96	-0.38	8.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg26396452	chr14:65542826	MAX	0.49	10.28	0.43	1.78e-22	Obesity-related traits;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	7.53	0.33	2.75e-13	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs7702521	chr5:93484579	G/T	cg21475434	chr5:93447410	FAM172A	0.72	7.3	0.32	1.27e-12	Diabetic retinopathy;
LGG	cis	rs514024	0.700	rs555022	chr9:130491726	T/C	cg13643465	chr9:130375613	STXBP1	0.59	11.11	0.46	1.35e-25	Eating disorders (purging via substances);
LGG	cis	rs60180747	1.000	rs11631625	chr15:66608731	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.53	9.29	0.4	6.25e-19	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.68	-0.34	9.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg20891283	chr12:69753455	YEATS4	-0.77	-12.33	-0.5	2.06e-30	Response to diuretic therapy;
LGG	cis	rs11700980	0.551	rs56000932	chr21:30116268	G/A	cg24692254	chr21:30365293	RNF160	-0.49	-6.76	-0.3	4.07e-11	QRS complex (12-leadsum);
LGG	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg00857998	chr1:205179979	DSTYK	0.47	6.75	0.3	4.5e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg08508337	chr8:144660607	NAPRT1	0.86	6.71	0.3	5.83e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs2952156	0.684	rs11658786	chr17:37815899	G/A	cg00129232	chr17:37814104	STARD3	-0.8	-17.5	-0.63	5.09e-53	Asthma;
LGG	cis	rs1862618	0.802	rs7733041	chr5:56107377	A/C	cg12654349	chr5:56205094	C5orf35	-0.63	-9.73	-0.41	1.81e-20	Initial pursuit acceleration;
LGG	cis	rs7558370	0.737	rs77681530	chr2:3712062	C/G	cg14882966	chr2:3699353	NA	0.77	7.11	0.31	4.49e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs11098499	0.874	rs12502503	chr4:120116255	C/T	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg08499158	chr17:42289980	UBTF	0.53	9.93	0.42	3.41e-21	Total body bone mineral density;
LGG	cis	rs1124376	1.000	rs17006623	chr3:20161043	G/T	cg05072819	chr3:20081367	KAT2B	0.62	8.31	0.36	1.1e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg16006296	chr10:38738647	LOC399744	0.34	6.69	0.3	6.53e-11	Diastolic blood pressure;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg23978390	chr7:1156363	C7orf50	0.45	7.58	0.33	1.89e-13	Longevity;Endometriosis;
LGG	cis	rs3096299	0.685	rs4785675	chr16:89539974	T/C	cg05484508	chr16:89589025	SPG7	0.46	7.43	0.33	5.34e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs35164067	0.662	rs11666164	chr19:10576270	C/T	cg21868191	chr19:10515988	NA	-0.55	-7.45	-0.33	4.75e-13	Inflammatory bowel disease;
LGG	cis	rs1862618	0.802	rs4389648	chr5:56103602	A/G	cg12654349	chr5:56205094	C5orf35	-0.67	-10.53	-0.44	2.17e-23	Initial pursuit acceleration;
LGG	cis	rs2836950	0.545	rs2297256	chr21:40558421	C/T	cg17971929	chr21:40555470	PSMG1	-0.53	-8.89	-0.38	1.4e-17	Menarche (age at onset);
LGG	trans	rs10506458	0.915	rs998505	chr12:63400018	C/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-22.01	-0.72	5.18e-74	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4740619	0.716	rs10962156	chr9:15781267	T/G	cg14451791	chr9:16040625	NA	0.32	8.01	0.35	9.21e-15	Body mass index;
LGG	cis	rs1461503	0.900	rs10892935	chr11:122838590	C/T	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs721917	0.506	rs927452	chr10:81652266	C/T	cg25562619	chr10:81652821	NA	-0.35	-8.19	-0.36	2.61e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs4642101	0.855	rs9836128	chr3:12845426	G/C	cg05775895	chr3:12838266	CAND2	0.69	12.67	0.51	8.53e-32	QRS complex (12-leadsum);
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.95	-0.42	2.91e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1499614	1.000	rs1882655	chr7:66147057	T/C	cg13147721	chr7:65941812	NA	0.82	10.09	0.42	8.89e-22	Gout;
LGG	cis	rs9354308	0.868	rs9363460	chr6:66557539	C/A	cg07460842	chr6:66804631	NA	-0.47	-7.92	-0.35	1.8e-14	Metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04332545	chr22:30988090	PES1	0.42	6.91	0.31	1.66e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2836950	0.501	rs4818019	chr21:40694456	T/A	cg17971929	chr21:40555470	PSMG1	-0.53	-9.0	-0.39	5.72e-18	Menarche (age at onset);
LGG	cis	rs78366141	0.536	rs76806573	chr4:89682729	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	8.49	0.37	2.88e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1552244	1.000	rs3895942	chr3:10108745	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg00409905	chr10:38381863	ZNF37A	0.44	8.36	0.36	7.56e-16	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg19635926	chr16:89946313	TCF25	0.69	8.32	0.36	9.92e-16	Skin colour saturation;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs10773046	0.740	rs1317312	chr12:124364131	G/C	cg18594669	chr12:124364423	DNAH10	0.33	6.71	0.3	5.56e-11	Osteoarthritis (hip);
LGG	cis	rs6502050	0.731	rs4789730	chr17:80145983	T/A	cg13939156	chr17:80058883	NA	-0.45	-8.8	-0.38	2.63e-17	Life satisfaction;
LGG	cis	rs2412459	0.831	rs6492924	chr15:40272391	G/A	cg22077389	chr15:40226273	EIF2AK4	-0.58	-7.04	-0.31	7.07e-12	Response to haloperidol in psychosis;
LGG	cis	rs4423214	0.592	rs10898223	chr11:71219264	G/A	cg05163923	chr11:71159392	DHCR7	-0.56	-8.24	-0.36	1.76e-15	Vitamin D levels;
LGG	trans	rs6956675	0.915	rs6977279	chr7:62630625	C/G	cg01314568	chr7:57830625	NA	-0.48	-7.82	-0.34	3.49e-14	Obesity-related traits;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.05	0.46	2.43e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.15	-0.43	5.4e-22	Morning vs. evening chronotype;
LGG	cis	rs12476592	0.543	rs262470	chr2:63830559	C/T	cg17519650	chr2:63277830	OTX1	-0.43	-6.72	-0.3	5.48e-11	Childhood ear infection;
LGG	cis	rs734999	0.967	rs4486391	chr1:2513055	A/T	cg20673091	chr1:2541236	MMEL1	0.58	13.46	0.53	4.47e-35	Ulcerative colitis;
LGG	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg06481639	chr22:41940642	POLR3H	-0.52	-7.31	-0.32	1.15e-12	Vitiligo;
LGG	cis	rs17767392	0.958	rs56407721	chr14:71963503	T/C	cg02058870	chr14:72053146	SIPA1L1	0.46	9.08	0.39	3.08e-18	Mitral valve prolapse;
LGG	cis	rs6920372	0.708	rs13198852	chr6:110068322	C/T	cg16315928	chr6:109776240	MICAL1	0.43	7.46	0.33	4.41e-13	Height;
LGG	cis	rs1881797	1.000	rs12071797	chr1:247686871	A/G	cg05639522	chr1:247681581	NA	0.62	10.36	0.43	9.31e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8051149	0.625	rs876987	chr16:87882209	A/G	cg01412419	chr16:87856264	NA	0.45	8.57	0.37	1.51e-16	Blood metabolite levels;
LGG	cis	rs6901004	0.805	rs354532	chr6:111548813	C/T	cg15721981	chr6:111408429	SLC16A10	-0.38	-6.88	-0.3	1.97e-11	Blood metabolite levels;
LGG	trans	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg06521331	chr12:34319734	NA	0.51	9.37	0.4	3.29e-19	Morning vs. evening chronotype;
LGG	cis	rs921968	0.541	rs10205073	chr2:219412784	C/A	cg01130898	chr2:219473002	PLCD4	0.42	7.3	0.32	1.28e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6834538	0.858	rs6816782	chr4:113559353	T/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	8.42	0.36	4.79e-16	Free thyroxine concentration;
LGG	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs6933660	0.800	rs9383893	chr6:151757327	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.64	-0.37	9e-17	Menarche (age at onset);
LGG	cis	rs8133932	0.701	rs6518258	chr21:47281829	C/T	cg11214348	chr21:47283868	PCBP3	0.44	7.91	0.34	1.98e-14	Schizophrenia;
LGG	cis	rs10489202	0.644	rs11584210	chr1:167846853	A/G	cg24449463	chr1:168025552	DCAF6	-0.51	-6.96	-0.31	1.14e-11	Schizophrenia;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg08024992	chr7:2133441	MAD1L1	0.37	7.18	0.32	2.79e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.42	-0.33	5.82e-13	Restless legs syndrome;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg07511668	chr11:68622177	NA	0.51	9.46	0.4	1.56e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2276314	0.857	rs4799408	chr18:33588982	C/T	cg05985134	chr18:33552581	C18orf21	-0.62	-9.82	-0.42	8.53e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg08297393	chr2:100937505	LONRF2	-0.52	-8.93	-0.38	1e-17	Intelligence (multi-trait analysis);
LGG	cis	rs12681287	0.640	rs7017706	chr8:87480890	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs13191362	0.507	rs6936804	chr6:163069424	A/T	cg21926612	chr6:163149169	PACRG;PARK2	-0.59	-8.18	-0.36	2.68e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs919433	0.713	rs10178946	chr2:198463090	G/T	cg00792783	chr2:198669748	PLCL1	0.52	8.17	0.35	3.02e-15	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Myopia (pathological);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04226542	chr12:64173449	TMEM5	0.45	7.73	0.34	6.56e-14	Menarche (age at onset);
LGG	cis	rs801193	0.569	rs11772819	chr7:66217970	T/C	cg23594656	chr7:65796392	TPST1	-0.37	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs3845702	0.736	rs2367990	chr2:180843126	C/T	cg01881094	chr2:180872142	CWC22	-1.25	-16.87	-0.62	3.8300000000000002e-50	Schizophrenia;
LGG	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.38	0.53	9.56e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.26	-0.58	7.28e-43	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg05861140	chr6:150128134	PCMT1	-0.32	-7.23	-0.32	1.99e-12	Testicular germ cell tumor;
LGG	cis	rs1534166	0.647	rs1464937	chr3:133536655	C/G	cg08048268	chr3:133502702	NA	0.37	6.72	0.3	5.44e-11	Alcohol consumption (transferrin glycosylation);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00155397	chr1:240775160	GREM2	-0.48	-7.51	-0.33	3.17e-13	Systemic lupus erythematosus;
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	4.08e-20	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25096440	chr11:9482398	ZNF143	0.55	8.52	0.37	2.23e-16	Gut microbiome composition (summer);
LGG	cis	rs921968	0.541	rs7601872	chr2:219319885	C/G	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.98e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.29	-0.4	5.95e-19	Life satisfaction;
LGG	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs7927592	0.956	rs12271290	chr11:68326236	A/G	cg01657329	chr11:68192670	LRP5	0.48	8.41	0.36	5.18e-16	Total body bone mineral density;
LGG	cis	rs7264396	0.790	rs10211771	chr20:34219994	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.81	0.34	3.82e-14	Total cholesterol levels;
LGG	cis	rs67133203	0.904	rs12366476	chr12:51359963	C/G	cg14688905	chr12:51403056	SLC11A2	0.79	11.96	0.49	6.48e-29	Urinary tract infection frequency;
LGG	cis	rs17102423	0.559	rs11624169	chr14:65481710	C/G	cg11161011	chr14:65562177	MAX	-0.76	-12.4	-0.5	1.12e-30	Obesity-related traits;
LGG	trans	rs853679	1.000	rs853685	chr6:28288785	C/T	cg08344181	chr3:125677491	NA	-0.54	-7.22	-0.32	2.14e-12	Depression;
LGG	cis	rs10504130	0.569	rs10958305	chr8:52819024	T/C	cg24946253	chr8:52722146	PXDNL	-0.45	-6.65	-0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2573652	0.722	rs11636084	chr15:100543394	A/G	cg14911520	chr15:100542628	ADAMTS17	-0.29	-7.14	-0.31	3.72e-12	Height;
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18099408	chr3:52552593	STAB1	-0.33	-6.89	-0.3	1.85e-11	Bipolar disorder;
LGG	cis	rs41271473	0.800	rs12133951	chr1:228791179	A/C	cg16512390	chr1:228756714	NA	0.54	6.98	0.31	1.05e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7208859	0.524	rs59913838	chr17:29101563	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg24692254	chr21:30365293	RNF160	-0.7	-13.1	-0.52	1.45e-33	Cognitive test performance;
LGG	trans	rs11976180	1.000	rs2951353	chr7:143761116	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs3733585	0.673	rs6840802	chr4:9965633	C/G	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.79	-0.34	4.4e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10335659	chr2:99757356	C2orf15;TSGA10	-0.47	-7.01	-0.31	8.66e-12	Systemic lupus erythematosus;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg03647317	chr4:187891568	NA	-0.42	-8.97	-0.38	7.41e-18	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2727020	0.595	rs11040416	chr11:49566429	C/T	cg03929089	chr4:120376271	NA	-0.98	-21.62	-0.71	3.64e-72	Coronary artery disease;
LGG	cis	rs943466	1.000	rs6933174	chr6:33751003	G/A	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	1.99e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs1348850	0.914	rs4893961	chr2:178411075	A/G	cg27490568	chr2:178487706	NA	0.47	9.27	0.4	7e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg13206674	chr6:150067644	NUP43	0.64	14.4	0.56	4.01e-39	Lung cancer;
LGG	cis	rs916888	0.610	rs199436	chr17:44789285	C/T	cg01570182	chr17:44337453	NA	-0.51	-9.36	-0.4	3.55e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.41	0.58	1.52e-43	Lung cancer;
LGG	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg22643751	chr7:855365	UNC84A	0.44	7.54	0.33	2.48e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg13206674	chr6:150067644	NUP43	0.65	14.69	0.56	2.29e-40	Lung cancer;
LGG	cis	rs950169	0.922	rs4338765	chr15:84916836	G/T	cg03959625	chr15:84868606	LOC388152	0.55	8.7	0.38	5.63e-17	Schizophrenia;
LGG	cis	rs977987	0.806	rs7188231	chr16:75436561	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.29	0.43	1.61e-22	Dupuytren's disease;
LGG	cis	rs12210905	1.000	rs9368498	chr6:27254006	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-6.81	-0.3	3.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7173743	0.518	rs12899452	chr15:79112550	T/A	cg00540400	chr15:79124168	NA	0.53	11.18	0.46	7.23e-26	Coronary artery disease;
LGG	cis	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg19847130	chr8:10466454	RP1L1	0.31	6.73	0.3	4.96e-11	Neuroticism;
LGG	cis	rs782590	0.935	rs782606	chr2:55886602	T/C	cg18811423	chr2:55921094	PNPT1	0.9	20.92	0.7	7.05e-69	Metabolic syndrome;
LGG	cis	rs350251	0.934	rs183008	chr16:12201691	C/T	cg02910054	chr16:12241554	SNX29	-0.46	-8.66	-0.37	8.08e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4950322	0.570	rs72692914	chr1:146774637	T/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs7917772	0.560	rs11595170	chr10:104339851	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.59	-11.44	-0.47	7.03e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7020830	0.898	rs12000309	chr9:37230844	G/A	cg14294708	chr9:37120828	ZCCHC7	1.19	34.78	0.85	3.12e-131	Schizophrenia;
LGG	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs4788815	0.562	rs12926041	chr16:71978645	G/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.72	0.45	4.3e-24	Metabolite levels;
LGG	cis	rs11229555	1.000	rs12808544	chr11:58373221	C/A	cg15696309	chr11:58395628	NA	-0.98	-17.31	-0.63	3.94e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17102423	0.654	rs8015921	chr14:65523015	G/A	cg16583315	chr14:65563665	MAX	-0.4	-8.07	-0.35	6e-15	Obesity-related traits;
LGG	trans	rs17685	0.712	rs6976236	chr7:75741087	G/T	cg19862616	chr7:65841803	NCRNA00174	1.08	25.9	0.77	4.44e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs2820315	0.867	rs2819351	chr1:201885157	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.88	0.3	1.92e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs11122272	0.675	rs1416913	chr1:231533206	A/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs3785574	0.962	rs7215915	chr17:61828385	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.56	0.79	1.09e-99	Height;
LGG	cis	rs11644362	1.000	rs12934970	chr16:12988077	G/C	cg08528231	chr16:12997261	SHISA9	-0.33	-6.73	-0.3	5.08e-11	Positive affect;Subjective well-being;
LGG	cis	rs17227506	0.679	rs35274434	chr8:13438099	G/A	cg03566418	chr8:13424080	C8orf48	0.63	9.92	0.42	3.66e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg11764359	chr7:65958608	NA	-0.56	-9.38	-0.4	2.9e-19	Aortic root size;
LGG	cis	rs6450176	0.909	rs6884760	chr5:53293077	T/A	ch.5.1024479R	chr5:53302184	ARL15	-0.67	-11.06	-0.46	2.23e-25	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg08222618	chr4:941054	TMEM175	0.77	16.57	0.61	9.26e-49	Sjögren's syndrome;
LGG	cis	rs11587400	0.679	rs6537836	chr1:115108923	T/C	cg12756093	chr1:115239321	AMPD1	0.38	6.68	0.3	7.02e-11	Autism;
LGG	trans	rs9467711	0.591	rs76091509	chr6:26706602	T/A	cg08344181	chr3:125677491	NA	-0.88	-7.45	-0.33	4.67e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs637571	0.522	rs606978	chr11:65711517	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	7.23	0.32	2.04e-12	Eosinophil percentage of white cells;
LGG	cis	rs6977660	1.000	rs6943114	chr7:19818354	G/T	cg05791153	chr7:19748676	TWISTNB	0.59	8.86	0.38	1.76e-17	Thyroid stimulating hormone;
LGG	trans	rs1814175	0.935	rs11040465	chr11:49689323	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.33	-0.47	1.98e-26	Height;
LGG	cis	rs7940866	0.903	rs2324316	chr11:130872353	G/T	cg12179176	chr11:130786555	SNX19	0.71	12.82	0.51	2.05e-32	Schizophrenia;
LGG	cis	rs9640161	0.789	rs11767409	chr7:150058043	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.6	-11.13	-0.46	1.19e-25	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg15309053	chr8:964076	NA	0.43	9.2	0.39	1.2e-18	Schizophrenia;
LGG	cis	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg12395012	chr8:11607386	GATA4	0.4	7.02	0.31	7.75e-12	Retinal vascular caliber;
LGG	cis	rs11105298	0.891	rs11105299	chr12:89877943	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.3	-0.4	5.79e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg11764359	chr7:65958608	NA	0.79	14.74	0.57	1.42e-40	Aortic root size;
LGG	cis	rs67478160	0.619	rs11160761	chr14:104254856	A/T	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.32e-13	Schizophrenia;
LGG	cis	rs704795	0.867	rs7566052	chr2:27628635	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.71	-0.3	5.85e-11	Menopause (age at onset);
LGG	cis	rs7639513	0.767	rs9861472	chr3:12707776	A/T	cg23032965	chr3:12705835	RAF1	-0.85	-16.8	-0.62	8.72e-50	Itch intensity from mosquito bite;
LGG	cis	rs894344	0.650	rs55675081	chr8:135582032	C/A	cg09855544	chr8:135498122	ZFAT	0.42	7.58	0.33	1.92e-13	Systolic blood pressure;
LGG	cis	rs151997	0.962	rs32482	chr5:50207118	T/C	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg15971980	chr6:150254442	NA	0.44	8.37	0.36	6.95e-16	Lung cancer;
LGG	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.07	-0.35	6.1e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6500637	0.558	rs11076856	chr16:4949815	A/G	cg08329684	chr16:4932620	PPL	-0.55	-12.45	-0.5	6.65e-31	Cancer;
LGG	cis	rs11190604	1.000	rs10883496	chr10:102221931	T/C	cg07570687	chr10:102243282	WNT8B	0.44	7.63	0.33	1.36e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3093024	1.000	rs3093024	chr6:167532793	C/T	cg07741184	chr6:167504864	NA	0.33	7.64	0.33	1.25e-13	Rheumatoid arthritis;
LGG	cis	rs2629540	0.847	rs11245342	chr10:126414084	C/T	cg08799069	chr10:126477246	METTL10	0.64	12.94	0.52	6.83e-33	Cocaine dependence;
LGG	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg11887960	chr12:57824829	NA	0.6	7.33	0.32	1.07e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg21724239	chr8:58056113	NA	0.59	9.14	0.39	1.94e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9354308	0.764	rs4422602	chr6:66615447	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.68	-0.3	7.09e-11	Metabolite levels;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg14092988	chr3:52407081	DNAH1	0.3	8.03	0.35	8e-15	Bipolar disorder;
LGG	cis	rs78487399	0.710	rs80100685	chr2:43650413	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.02e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs372883	0.583	rs117214	chr21:30720834	A/G	cg24692254	chr21:30365293	RNF160	0.57	10.7	0.45	4.84e-24	Pancreatic cancer;
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg07157834	chr1:205819609	PM20D1	0.73	16.63	0.61	5.03e-49	Menarche (age at onset);
LGG	cis	rs35123781	0.696	rs4912756	chr5:139070780	A/T	cg10513866	chr5:139070639	NA	0.4	7.89	0.34	2.26e-14	Schizophrenia;
LGG	cis	rs6088590	1.000	rs6120748	chr20:33458284	T/G	cg06115741	chr20:33292138	TP53INP2	0.57	9.04	0.39	4.15e-18	Coronary artery disease;
LGG	trans	rs7944735	0.517	rs12274550	chr11:48196752	C/A	cg03929089	chr4:120376271	NA	0.7	7.6	0.33	1.69e-13	Intraocular pressure;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.36	0.32	8.57e-13	Prudent dietary pattern;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7246760	0.748	rs113505247	chr19:9725671	C/T	cg16876255	chr19:9731953	ZNF561	0.87	7.76	0.34	5.52e-14	Pursuit maintenance gain;
LGG	cis	rs4242434	0.819	rs720745	chr8:22471147	G/T	cg00599393	chr8:22457479	C8orf58	-0.43	-7.91	-0.35	1.86e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9300255	0.602	rs1727314	chr12:123640664	C/A	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	cis	rs2204008	0.805	rs11180825	chr12:38242916	G/T	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs2286885	1.000	rs10733678	chr9:129242280	G/A	cg14319473	chr9:129242481	FAM125B	0.45	8.49	0.37	2.85e-16	Intraocular pressure;
LGG	cis	rs9807989	0.507	rs4851577	chr2:103028921	T/C	cg03938978	chr2:103052716	IL18RAP	0.4	9.27	0.4	7.2e-19	Asthma;
LGG	cis	rs10046574	0.561	rs10226494	chr7:135214412	C/G	cg27474649	chr7:135195673	CNOT4	0.68	8.89	0.38	1.36e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1865760	0.516	rs9379819	chr6:26049819	A/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.06e-14	Height;
LGG	cis	rs7551222	0.752	rs4951407	chr1:204558070	G/T	cg20240347	chr1:204465584	NA	0.5	9.77	0.41	1.29e-20	Schizophrenia;
LGG	cis	rs1577917	0.876	rs1582127	chr6:86697204	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.71e-20	Response to antipsychotic treatment;
LGG	cis	rs4253772	0.530	rs11704350	chr22:46671507	C/T	cg09461388	chr22:46763229	CELSR1	-0.7	-7.14	-0.31	3.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs3096299	0.606	rs4785573	chr16:89565403	A/G	cg02187348	chr16:89574699	SPG7	0.52	7.95	0.35	1.45e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg13628971	chr7:2884303	GNA12	0.51	10.19	0.43	3.78e-22	Height;
LGG	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg16386425	chr10:429943	DIP2C	0.39	7.39	0.32	7.14e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.503	rs7914389	chr10:104295402	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs34172651	0.517	rs34172679	chr16:24840381	C/T	cg02428538	chr16:24856791	SLC5A11	-0.68	-10.39	-0.43	7.23e-23	Intelligence (multi-trait analysis);
LGG	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.33	0.32	1.05e-12	Neuroticism;
LGG	cis	rs4595586	0.545	rs12828790	chr12:39401043	G/A	cg26384229	chr12:38710491	ALG10B	0.61	10.86	0.45	1.28e-24	Morning vs. evening chronotype;
LGG	cis	rs4474465	0.915	rs12277503	chr11:78140373	A/C	cg02023728	chr11:77925099	USP35	0.41	7.1	0.31	4.69e-12	Alzheimer's disease (survival time);
LGG	trans	rs7824557	0.767	rs17797443	chr8:11164012	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.04	0.42	1.4e-21	Retinal vascular caliber;
LGG	cis	rs2836974	0.584	rs7276774	chr21:40628725	T/G	cg17971929	chr21:40555470	PSMG1	-0.72	-13.73	-0.54	3.16e-36	Cognitive function;
LGG	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.04	-0.39	4.27e-18	Neuroticism;
LGG	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg09021430	chr5:549028	NA	-0.72	-9.87	-0.42	5.61e-21	Obesity-related traits;
LGG	cis	rs17122278	1.000	rs10892243	chr11:118441846	T/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.7	-0.3	6.17e-11	Total cholesterol levels;
LGG	trans	rs9354352	0.935	rs9345749	chr6:66699892	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-11.59	-0.47	1.83e-27	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs116095464	0.558	rs7703803	chr5:292311	A/G	cg22857025	chr5:266934	NA	-1.52	-26.32	-0.77	4.95e-94	Breast cancer;
LGG	cis	rs8053891	1.000	rs8053891	chr16:71997789	A/C	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.66	-0.3	7.62e-11	Coronary artery disease;
LGG	cis	rs9906944	0.898	rs9909861	chr17:47079416	C/A	cg09029085	chr17:47094198	IGF2BP1	0.33	8.88	0.38	1.44e-17	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg24642439	chr20:33292090	TP53INP2	0.82	15.36	0.58	2.59e-43	Coronary artery disease;
LGG	cis	rs9818758	0.607	rs13077498	chr3:49313978	C/T	cg00383909	chr3:49044727	WDR6	1.01	12.54	0.5	3.02e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7580658	0.963	rs867304	chr2:128078488	G/A	cg10021288	chr2:128175891	PROC	-0.64	-13.41	-0.53	7.38e-35	Protein C levels;
LGG	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg02836325	chr17:76403955	PGS1	-0.7	-14.27	-0.55	1.47e-38	HDL cholesterol levels;
LGG	cis	rs490647	0.652	rs537958	chr1:37254301	A/G	cg24672014	chr1:37203461	NA	0.35	7.41	0.33	5.9e-13	Neuroticism;
LGG	cis	rs4851254	0.660	rs59447631	chr2:100691493	T/C	cg17356467	chr2:100759845	AFF3	0.46	7.43	0.33	5.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.57	-0.33	2.01e-13	Initial pursuit acceleration;
LGG	cis	rs17711722	0.565	rs73372653	chr7:65442795	A/T	cg18876405	chr7:65276391	NA	0.45	7.9	0.34	1.99e-14	Calcium levels;
LGG	cis	rs12282928	0.885	rs1503176	chr11:48269191	C/T	cg26585981	chr11:48327164	OR4S1	-0.43	-7.09	-0.31	5.18e-12	Migraine - clinic-based;
LGG	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	9.53	0.41	8.58e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9311474	0.507	rs6787154	chr3:52784416	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.96	0.35	1.34e-14	Electroencephalogram traits;
LGG	cis	rs651907	0.557	rs35117343	chr3:101445126	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.42e-12	Colorectal cancer;
LGG	cis	rs941873	0.869	rs7917610	chr10:81117237	T/C	cg09469691	chr10:81107165	PPIF	0.63	11.2	0.46	6.02e-26	Height;
LGG	cis	rs9815354	1.000	rs9875107	chr3:41822313	A/T	cg03022575	chr3:42003672	ULK4	0.61	7.94	0.35	1.59e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4481887	0.676	rs28684663	chr1:248548325	T/C	cg13385794	chr1:248469461	NA	0.42	7.63	0.33	1.33e-13	Common traits (Other);
LGG	cis	rs2242116	0.796	rs4683296	chr3:46973820	G/C	cg16586182	chr3:47516702	SCAP	0.57	9.72	0.41	1.88e-20	Birth weight;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-8.1	-0.35	4.77e-15	Life satisfaction;
LGG	cis	rs9393692	0.557	rs12665035	chr6:26275649	T/C	cg00631329	chr6:26305371	NA	-0.44	-7.19	-0.32	2.65e-12	Educational attainment;
LGG	cis	rs61931739	0.534	rs1384860	chr12:34045388	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs9325144	0.560	rs10785573	chr12:38654166	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	cis	rs10155981	0.510	rs28661240	chr7:22594075	G/A	cg05062323	chr7:22590069	NA	-0.75	-9.29	-0.4	6.2800000000000005e-19	Bilirubin levels;
LGG	cis	rs1862618	0.853	rs6450409	chr5:56101399	A/G	cg08400814	chr5:56204995	C5orf35	-0.41	-6.69	-0.3	6.35e-11	Initial pursuit acceleration;
LGG	cis	rs2412459	0.611	rs4924402	chr15:40245754	C/T	cg21830797	chr15:40226279	EIF2AK4	-0.6	-7.99	-0.35	1.12e-14	Response to haloperidol in psychosis;
LGG	cis	rs9783347	0.621	rs10832923	chr11:18391237	G/C	cg15585147	chr11:18324498	HPS5	0.31	7.07	0.31	5.65e-12	Pancreatic cancer;
LGG	cis	rs55871839	0.708	rs4738732	chr8:59809943	A/G	cg07426533	chr8:59803705	TOX	0.58	13.22	0.52	4.61e-34	Pneumonia;
LGG	cis	rs67311347	0.911	rs58282210	chr3:40417943	C/T	cg13683864	chr3:40499215	RPL14	-1.0	-20.52	-0.69	4.86e-67	Renal cell carcinoma;
LGG	cis	rs3206736	0.728	rs17800067	chr7:35120352	C/A	cg13400248	chr7:35225412	NA	0.44	8.09	0.35	5.29e-15	Diastolic blood pressure;
LGG	cis	rs1728785	1.000	rs1170426	chr16:68603798	C/T	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs638893	0.898	rs530646	chr11:118701668	A/G	cg22253036	chr11:118662786	DDX6	0.42	7.11	0.31	4.52e-12	Vitiligo;
LGG	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg05084668	chr3:125655381	ALG1L	-0.54	-7.29	-0.32	1.33e-12	Blood pressure (smoking interaction);
LGG	cis	rs9783347	0.890	rs11024634	chr11:18392074	G/A	cg15585147	chr11:18324498	HPS5	0.44	9.19	0.39	1.38e-18	Pancreatic cancer;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg11473876	chr11:109292803	C11orf87	0.48	9.48	0.4	1.34e-19	Schizophrenia;
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.41	-0.33	5.9e-13	Height;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.26	0.32	1.63e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs57927100	0.734	rs1436138	chr17:75316880	A/G	cg15401418	chr17:75316383	SEPT9	0.3	7.27	0.32	1.54e-12	Systolic blood pressure;
LGG	cis	rs516946	1.000	rs3802316	chr8:41528228	G/C	cg19441908	chr8:41529140	ANK1	0.43	7.52	0.33	2.83e-13	Type 2 diabetes;
LGG	cis	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg05084668	chr3:125655381	ALG1L	-0.56	-7.62	-0.33	1.48e-13	Blood pressure (smoking interaction);
LGG	cis	rs2075371	0.796	rs1646645	chr7:134012232	G/T	cg20476274	chr7:133979776	SLC35B4	-0.68	-13.04	-0.52	2.48e-33	Mean platelet volume;
LGG	cis	rs7223966	0.960	rs2854222	chr17:61939015	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.47	-0.37	3.31e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4771450	0.924	rs4772542	chr13:103971316	C/T	cg02987523	chr13:103978230	NA	-0.32	-6.85	-0.3	2.33e-11	Uric acid levels;
LGG	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg04731861	chr2:219085781	ARPC2	0.29	7.0	0.31	9.25e-12	Ulcerative colitis;
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-9.2	-0.39	1.26e-18	Vitiligo;
LGG	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg21459583	chr1:227974177	NA	0.46	7.07	0.31	5.76e-12	Major depressive disorder;
LGG	cis	rs2760061	0.569	rs621631	chr1:228114728	A/G	cg18477163	chr1:228402036	OBSCN	-0.26	-6.98	-0.31	1.03e-11	Diastolic blood pressure;
LGG	cis	rs55665837	0.559	rs9667144	chr11:14421101	C/T	cg19336497	chr11:14380999	RRAS2	0.53	10.66	0.44	7.17e-24	Vitamin D levels;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	trans	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg02002194	chr4:3960332	NA	0.4	7.39	0.32	6.95e-13	Mood instability;
LGG	cis	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg26695010	chr11:65641043	EFEMP2	0.63	11.4	0.47	1.01e-26	Eosinophil percentage of white cells;
LGG	cis	rs4665809	1.000	rs11126364	chr2:26314515	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	cis	rs6598955	0.671	rs8564	chr1:26605069	T/C	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.53	-9.42	-0.4	2.09e-19	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs5756813	0.688	rs5995498	chr22:38196573	T/G	cg19894588	chr14:64061835	NA	-0.64	-10.23	-0.43	2.8e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg19875535	chr5:140030758	IK	-0.57	-11.69	-0.48	7.72e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.98	-0.35	1.16e-14	Total body bone mineral density;
LGG	cis	rs9290065	0.622	rs11705811	chr3:160643787	C/T	cg04691961	chr3:161091175	C3orf57	-0.39	-8.01	-0.35	9.5e-15	Kawasaki disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19492446	chr18:35145650	BRUNOL4	0.5	8.5	0.37	2.59e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.49	7.4	0.33	6.25e-13	Bitter taste perception;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg15971980	chr6:150254442	NA	0.45	8.58	0.37	1.47e-16	Lung cancer;
LGG	cis	rs757278	0.608	rs6977789	chr7:117342771	A/G	cg10524701	chr7:117356490	CTTNBP2	0.46	8.25	0.36	1.66e-15	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs35264875	1.000	rs72919430	chr11:68829817	G/T	cg01403660	chr11:68851641	TPCN2	0.53	7.36	0.32	8.49e-13	Blond vs. brown hair color;
LGG	cis	rs17739167	0.550	rs17687976	chr15:42234824	A/G	cg20935245	chr15:42234343	EHD4	-0.45	-8.4	-0.36	5.53e-16	Monocyte count;
LGG	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg06634786	chr22:41940651	POLR3H	0.67	10.9	0.45	8.67e-25	Cannabis dependence symptom count;
LGG	cis	rs60871478	0.730	rs62432226	chr7:792973	T/C	cg13798912	chr7:905769	UNC84A	0.54	6.91	0.31	1.64e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs9463078	0.715	rs1557143	chr6:44756415	T/C	cg25276700	chr6:44698697	NA	0.43	9.12	0.39	2.39e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs738322	0.555	rs5750549	chr22:38547172	C/T	cg25457927	chr22:38595422	NA	-0.45	-10.98	-0.45	4.25e-25	Cutaneous nevi;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.14	-0.35	3.77e-15	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.84e-13	Menopause (age at onset);
LGG	cis	rs7582180	0.764	rs11691684	chr2:100921776	T/A	cg14675211	chr2:100938903	LONRF2	0.66	11.39	0.47	1.19e-26	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.714	rs660652	chr15:78887832	A/G	cg06917634	chr15:78832804	PSMA4	-0.68	-12.58	-0.5	2.06e-31	Sudden cardiac arrest;
LGG	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10463554	0.892	rs17154860	chr5:102291145	C/T	cg23492399	chr5:102201601	PAM	-0.54	-8.41	-0.36	5.27e-16	Parkinson's disease;
LGG	cis	rs7432375	0.578	rs17366234	chr3:136577085	C/T	cg21827317	chr3:136751795	NA	0.53	9.34	0.4	3.94e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg08219700	chr8:58056026	NA	-0.44	-6.93	-0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	trans	rs116095464	0.558	rs7356561	chr5:284381	G/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs875971	0.522	rs781144	chr7:65440344	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	10.22	0.43	3.06e-22	Aortic root size;
LGG	trans	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.28	0.36	1.34e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs72945132	0.882	rs66627443	chr11:70199036	C/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs1881396	0.945	rs62141291	chr2:27784034	C/T	cg27432699	chr2:27873401	GPN1	0.56	8.5	0.37	2.53e-16	Nonalcoholic fatty liver disease;
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.71	0.41	2.12e-20	Bipolar disorder;
LGG	cis	rs35306767	0.909	rs12264390	chr10:959111	T/C	cg26597838	chr10:835615	NA	0.64	9.47	0.4	1.41e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4671458	0.948	rs17474666	chr2:63420517	T/C	cg17519650	chr2:63277830	OTX1	-0.65	-8.15	-0.35	3.4e-15	Subjective well-being;
LGG	cis	rs12410462	0.636	rs2644154	chr1:227703888	G/A	cg04117972	chr1:227635322	NA	0.46	8.32	0.36	9.61e-16	Major depressive disorder;
LGG	cis	rs9300255	0.537	rs2695482	chr12:123623174	C/T	cg00376283	chr12:123451042	ABCB9	0.65	10.63	0.44	9.57e-24	Neutrophil percentage of white cells;
LGG	cis	rs763121	0.853	rs6001173	chr22:39015302	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.17	0.65	4.17e-56	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg21724239	chr8:58056113	NA	0.63	9.24	0.39	8.92e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4690686	0.500	rs12498752	chr4:177265451	T/C	cg17059388	chr4:177262070	NA	1.03	24.11	0.75	8.15e-84	Essential tremor;
LGG	trans	rs61931739	0.793	rs609886	chr12:34138160	T/G	cg26384229	chr12:38710491	ALG10B	0.67	12.99	0.52	4.11e-33	Morning vs. evening chronotype;
LGG	cis	rs758324	0.540	rs31481	chr5:131397202	A/G	cg06307176	chr5:131281290	NA	0.45	6.7	0.3	6.22e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg23422044	chr7:1970798	MAD1L1	-0.46	-8.32	-0.36	9.98e-16	Neuroticism;
LGG	cis	rs1577917	1.000	rs884841	chr6:86680300	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-12.84	-0.51	1.65e-32	Response to antipsychotic treatment;
LGG	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg21926883	chr2:100939477	LONRF2	-0.68	-15.97	-0.6	4.56e-46	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg21453758	chr17:80185943	SLC16A3	0.33	6.91	0.31	1.56e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	10.89	0.45	9.75e-25	Schizophrenia;
LGG	cis	rs7089973	0.872	rs60820172	chr10:116625891	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.54	0.33	2.43e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9443645	0.527	rs7756996	chr6:79509367	A/C	cg18132916	chr6:79620363	NA	-0.27	-7.07	-0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs1860469	chr7:66106875	A/G	cg12463550	chr7:65579703	CRCP	-0.46	-7.1	-0.31	4.63e-12	Aortic root size;
LGG	cis	rs4805272	0.512	rs12373558	chr19:29337692	A/G	cg12756686	chr19:29218302	NA	0.62	8.38	0.36	6.31e-16	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg27411982	chr8:10470053	RP1L1	-0.47	-8.07	-0.35	6.32e-15	Retinal vascular caliber;
LGG	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg02002194	chr4:3960332	NA	-0.42	-7.5	-0.33	3.28e-13	Neuroticism;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16219491	chr6:26197733	HIST1H3D	-0.42	-6.65	-0.3	8.07e-11	Body fat percentage;
LGG	cis	rs2342371	0.756	rs12637868	chr3:196106754	G/A	cg15048948	chr3:196158458	UBXN7	0.62	10.65	0.44	8.04e-24	Fat distribution (HIV);
LGG	cis	rs2797160	1.000	rs2747724	chr6:126004935	G/A	cg05901451	chr6:126070800	HEY2	-0.44	-7.31	-0.32	1.18e-12	Endometrial cancer;
LGG	cis	rs2354432	0.556	rs34602039	chr1:146850972	G/A	cg25205988	chr1:146714368	CHD1L	-1.24	-11.72	-0.48	5.88e-28	Mitochondrial DNA levels;
LGG	cis	rs7412746	0.658	rs11582281	chr1:150826831	T/C	cg15448220	chr1:150897856	SETDB1	0.39	7.25	0.32	1.75e-12	Melanoma;
LGG	cis	rs41342147	0.591	rs11554054	chr2:242254867	C/G	cg10173475	chr2:242152697	ANO7	-0.57	-8.63	-0.37	1.01e-16	Vitiligo;
LGG	cis	rs209489	0.892	rs2294857	chr6:53159090	G/T	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1966248	0.570	rs12204363	chr6:134098184	T/C	cg25632230	chr6:134101081	NA	-0.34	-7.53	-0.33	2.75e-13	Coronary artery disease;
LGG	cis	rs3815700	1.000	rs10404211	chr19:33093565	C/T	cg02997394	chr19:33096574	ANKRD27	0.87	12.04	0.49	3.03e-29	Eosinophilic esophagitis;
LGG	cis	rs8014204	0.836	rs8021280	chr14:75290018	C/G	cg06637938	chr14:75390232	RPS6KL1	0.78	15.64	0.59	1.44e-44	Caffeine consumption;
LGG	trans	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg13565492	chr6:43139072	SRF	-0.74	-9.15	-0.39	1.85e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23043968	chr1:119682730	WARS2	0.41	7.28	0.32	1.42e-12	Menarche (age at onset);
LGG	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg01206211	chr2:36825736	FEZ2	-0.48	-9.77	-0.41	1.27e-20	Height;
LGG	cis	rs2120019	0.938	rs8033925	chr15:75311959	A/G	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.47	-0.65	1.75e-57	Blood trace element (Zn levels);
LGG	cis	rs7959452	0.590	rs7968629	chr12:69782857	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	trans	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg21659725	chr3:3221576	CRBN	0.54	9.37	0.4	3.28e-19	Body mass index;
LGG	cis	rs4356932	1.000	rs6532163	chr4:76983618	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg11812906	chr14:75593930	NEK9	-0.46	-8.57	-0.37	1.57e-16	Height;
LGG	cis	rs6732160	0.588	rs13390460	chr2:73371476	G/A	cg01422370	chr2:73384389	NA	0.56	9.77	0.41	1.23e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4689642	0.507	rs4689087	chr4:7222086	T/C	cg21353189	chr4:7228343	SORCS2	0.32	6.72	0.3	5.31e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	cis	rs9974653	1	rs9974653	chr21:40741846	A/C	cg13500489	chr21:40813570	LCA5L	0.44	6.92	0.31	1.54e-11	Platelet count;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs10493773	1.000	rs7523292	chr1:86134992	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.54	-8.86	-0.38	1.7e-17	Urate levels in overweight individuals;
LGG	cis	rs60695258	0.963	rs3775228	chr4:87985166	C/T	cg21988461	chr4:88008667	AFF1	0.25	6.7	0.3	6.02e-11	Hematocrit;
LGG	cis	rs9596863	0.950	rs6561749	chr13:54435195	G/C	ch.13.53330881F	chr13:54432880	NA	-0.49	-7.02	-0.31	7.78e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg22963979	chr7:1858916	MAD1L1	0.4	7.82	0.34	3.7e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00495681	chr13:53174319	NA	0.51	9.05	0.39	4e-18	Lewy body disease;
LGG	cis	rs7546668	0.652	rs12691551	chr1:15907908	C/G	cg18192808	chr1:15853278	DNAJC16	0.35	7.28	0.32	1.41e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs68170813	0.559	rs3801959	chr7:106955666	A/G	cg02696742	chr7:106810147	HBP1	-0.76	-10.79	-0.45	2.3e-24	Coronary artery disease;
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26076054	chr5:421317	AHRR	-0.53	-8.82	-0.38	2.41e-17	Cystic fibrosis severity;
LGG	cis	rs981844	0.712	rs1037652	chr4:154746565	C/T	cg14289246	chr4:154710475	SFRP2	0.56	9.83	0.42	7.96e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs7312774	0.867	rs10492213	chr12:107295841	A/T	cg16260113	chr12:107380972	MTERFD3	-0.63	-6.71	-0.3	5.75e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs735860	0.737	rs2397139	chr6:53150804	C/G	cg10236188	chr6:53219634	NA	-0.39	-7.78	-0.34	4.81e-14	Glaucoma;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg06094111	chr12:56709459	CNPY2	0.38	6.69	0.3	6.37e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs774359	0.789	rs2440619	chr9:27514323	G/A	cg21249376	chr9:27528432	MOBKL2B	0.46	8.8	0.38	2.67e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs1816752	0.935	rs3816219	chr13:25017133	C/T	cg22771759	chr13:24902376	NA	0.45	7.57	0.33	2.02e-13	Obesity-related traits;
LGG	cis	rs939658	0.805	rs11635757	chr15:79432737	T/C	cg17916960	chr15:79447300	NA	-0.68	-13.2	-0.52	5.47e-34	Refractive error;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06656553	chr16:89960601	TCF25	-0.72	-7.1	-0.31	4.6e-12	Skin colour saturation;
LGG	cis	rs9487094	0.626	rs3799849	chr6:110036763	C/A	cg16315928	chr6:109776240	MICAL1	0.47	8.06	0.35	6.38e-15	Height;
LGG	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg02002194	chr4:3960332	NA	-0.49	-8.97	-0.38	7.17e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13082711	0.871	rs34209332	chr3:27434061	A/T	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg14835575	chr10:16859367	RSU1	0.83	15.68	0.59	9.37e-45	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.25	0.7	1.92e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3126085	0.935	rs11204976	chr1:152273777	C/T	cg26876637	chr1:152193138	HRNR	-0.51	-7.92	-0.35	1.82e-14	Atopic dermatitis;
LGG	cis	rs806215	0.547	rs806169	chr7:127300668	C/G	cg25922125	chr7:127225783	GCC1	0.52	7.61	0.33	1.56e-13	Type 2 diabetes;
LGG	cis	rs17039065	0.920	rs58424294	chr4:109420427	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs7829975	0.514	rs2920991	chr8:8259117	T/A	cg06636001	chr8:8085503	FLJ10661	0.53	10.16	0.43	4.89e-22	Mood instability;
LGG	cis	rs2249694	0.520	rs7911139	chr10:135323525	T/C	cg20169779	chr10:135381914	SYCE1	-0.55	-7.53	-0.33	2.7e-13	Obesity-related traits;
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg04008888	chr11:68622739	NA	0.34	7.63	0.33	1.3e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.9	-0.45	8.53e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg12042659	chr19:58951599	ZNF132	0.36	7.36	0.32	8.23e-13	Uric acid clearance;
LGG	cis	rs1355223	0.902	rs1901831	chr11:34725175	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.7	-0.3	6.1e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs11976180	1.000	rs2961144	chr7:143747870	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	0.37	6.71	0.3	5.56e-11	Obesity-related traits;
LGG	cis	rs888194	0.690	rs736344	chr12:110001195	A/G	cg19025524	chr12:109796872	NA	-0.35	-7.1	-0.31	4.8e-12	Neuroticism;
LGG	cis	rs2236267	0.726	rs4904428	chr14:88610516	T/C	cg18078958	chr14:88630771	NA	-0.34	-7.8	-0.34	4.29e-14	Food antigen IgG levels;
LGG	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg11764359	chr7:65958608	NA	0.72	12.79	0.51	2.8e-32	Aortic root size;
LGG	cis	rs4629180	1.000	rs908133	chr2:102092374	A/C	cg16435561	chr2:102091048	RFX8	0.41	6.92	0.31	1.49e-11	Chronic rhinosinusitis with nasal polyps;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01949938	chr7:72300047	SBDSP;TYW1B	0.48	7.12	0.31	4.19e-12	Gut microbiome composition (summer);
LGG	cis	rs1065852	0.510	rs5758666	chr22:42632833	G/A	cg15128208	chr22:42549153	NA	0.49	8.28	0.36	1.35e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7647973	0.925	rs4955421	chr3:49218888	G/A	cg07636037	chr3:49044803	WDR6	0.78	13.92	0.54	4.9e-37	Menarche (age at onset);
LGG	cis	rs7927771	0.965	rs12364432	chr11:47902883	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.54	-0.37	2e-16	Subjective well-being;
LGG	cis	rs988958	0.675	rs7576689	chr2:42218358	C/T	cg27252766	chr2:42229092	NA	0.57	8.83	0.38	2.16e-17	Hypospadias;
LGG	cis	rs4319547	1.000	rs7309390	chr12:123110422	A/G	cg23029597	chr12:123009494	RSRC2	-0.92	-18.31	-0.65	1.03e-56	Body mass index;
LGG	cis	rs4077515	1.000	rs11145763	chr9:139263596	A/C	cg21253087	chr9:139290292	SNAPC4	0.35	7.07	0.31	5.59e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2274273	0.901	rs10140801	chr14:55730404	C/T	cg04306507	chr14:55594613	LGALS3	0.6	16.63	0.61	5.22e-49	Protein biomarker;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg27177954	chr22:41601126	L3MBTL2	-0.37	-6.93	-0.31	1.39e-11	Iris color (L* coordinate);
LGG	cis	rs7727544	0.548	rs2069614	chr5:131407601	T/C	cg07395648	chr5:131743802	NA	-0.4	-8.69	-0.37	6.48e-17	Blood metabolite levels;
LGG	cis	rs12681288	0.823	rs2701909	chr8:1003057	A/G	cg04851639	chr8:1020857	NA	-0.42	-9.21	-0.39	1.15e-18	Schizophrenia;
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg19539972	chr4:7069911	GRPEL1	0.77	11.26	0.46	3.57e-26	Monocyte percentage of white cells;
LGG	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.1	-0.35	4.8e-15	Coronary artery disease;
LGG	cis	rs611744	0.647	rs2594357	chr8:109255989	A/G	cg18478394	chr8:109455254	TTC35	0.41	8.03	0.35	7.9e-15	Dupuytren's disease;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	19.99	0.68	1.54e-64	Alzheimer's disease;
LGG	cis	rs875971	0.929	rs4122249	chr7:65920936	T/C	cg23594656	chr7:65796392	TPST1	-0.4	-8.93	-0.38	9.91e-18	Aortic root size;
LGG	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg26248373	chr2:1572462	NA	-0.72	-9.49	-0.4	1.18e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11628318	0.715	rs1815262	chr14:103056926	C/T	cg23461800	chr14:103021989	NA	-0.53	-8.65	-0.37	8.31e-17	Platelet count;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg22907277	chr7:1156413	C7orf50	0.7	8.78	0.38	3.12e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg16096631	chr1:42092165	HIVEP3	0.7	18.38	0.65	4.76e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg24098013	chr12:12878779	APOLD1	0.51	8.39	0.36	5.78e-16	Lymphocyte counts;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01773306	chr2:85555458	TGOLN2	0.39	6.69	0.3	6.45e-11	Body mass index;
LGG	cis	rs9660992	0.710	rs1172138	chr1:205246019	G/A	cg21545522	chr1:205238299	TMCC2	0.48	8.48	0.37	2.94e-16	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs8018808	0.935	rs8018711	chr14:77921749	G/A	cg20045696	chr14:77926864	AHSA1	0.4	6.67	0.3	7.29e-11	Myeloid white cell count;
LGG	cis	rs9768139	0.733	rs35016950	chr7:158118710	C/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.9	-0.34	2e-14	Calcium levels;
LGG	cis	rs13102973	0.863	rs13129178	chr4:135858219	A/C	cg14419869	chr4:135874104	NA	0.57	10.89	0.45	9.36e-25	Subjective well-being;
LGG	cis	rs710216	0.843	rs710220	chr1:43415346	G/T	cg03128534	chr1:43423976	SLC2A1	0.43	7.11	0.31	4.3e-12	Red cell distribution width;
LGG	cis	rs6500395	1.000	rs12447645	chr16:48694440	A/G	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7216064	0.628	rs62084702	chr17:66043157	C/T	cg12091567	chr17:66097778	LOC651250	0.79	13.08	0.52	1.68e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9814567	1.000	rs6806417	chr3:134211446	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.4	0.53	7.63e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7223966	1.000	rs112143304	chr17:61822401	T/A	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.61	-0.37	1.17e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8180040	0.726	rs11130112	chr3:47024495	G/T	cg27129171	chr3:47204927	SETD2	0.82	15.3	0.58	4.58e-43	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11011602	chr9:136215029	SNORD24;MED22;RPL7A	0.45	7.71	0.34	7.58e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs360798	0.532	rs1022110	chr2:63046039	T/G	cg17519650	chr2:63277830	OTX1	-0.45	-7.37	-0.32	8.07e-13	Coronary artery disease;
LGG	trans	rs12579753	1.000	rs11115047	chr12:82232773	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.76	-0.34	5.41e-14	Resting heart rate;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.19	0.62	1.4e-51	Obesity-related traits;
LGG	cis	rs11410354	1	rs11410354	chr11:442472	C/CT	cg03352830	chr11:487213	PTDSS2	-0.64	-9.05	-0.39	4.01e-18	Breast cancer;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg14926717	chr14:62583919	FLJ43390	-0.36	-6.98	-0.31	1.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.840	rs2234052	chr22:41777241	A/G	cg06850241	chr22:41845214	NA	-0.42	-6.84	-0.3	2.5e-11	Vitiligo;
LGG	cis	rs8054556	0.669	rs9972866	chr16:30018982	C/G	cg06326092	chr16:30034487	C16orf92	0.36	7.08	0.31	5.42e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12477438	1.000	rs73963398	chr2:99887025	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.82	-12.88	-0.51	1.12e-32	Chronic sinus infection;
LGG	cis	rs2011503	0.941	rs10422893	chr19:19372185	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.36	7.25	0.32	1.82e-12	Bipolar disorder;
LGG	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg17108064	chr15:78857060	CHRNA5	0.44	9.61	0.41	4.8e-20	Sudden cardiac arrest;
LGG	cis	rs72781680	0.898	rs10490751	chr2:24001356	A/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	trans	rs2243480	0.708	rs13242216	chr7:65898277	T/C	cg10756647	chr7:56101905	PSPH	0.8	9.33	0.4	4.26e-19	Diabetic kidney disease;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs889312	0.532	rs16886181	chr5:56029243	T/C	cg27303933	chr5:56029418	NA	0.32	6.8	0.3	3.22e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Corneal astigmatism;
LGG	cis	rs11630290	0.628	rs17774754	chr15:64126156	C/T	cg12036633	chr15:63758958	NA	-0.6	-7.05	-0.31	6.69e-12	Iris characteristics;
LGG	cis	rs11167764	1.000	rs7722567	chr5:141483178	C/T	cg08523384	chr5:141488047	NDFIP1	-0.37	-6.95	-0.31	1.25e-11	Crohn's disease;
LGG	cis	rs17534004	0.920	rs71436424	chr13:31481030	C/G	cg00367615	chr13:31480979	C13orf33	0.35	6.9	0.31	1.68e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs7712401	0.560	rs13168225	chr5:122347264	C/T	cg19412675	chr5:122181750	SNX24	-0.5	-8.0	-0.35	9.8e-15	Mean platelet volume;
LGG	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg21775007	chr8:11205619	TDH	0.45	7.41	0.33	6.24e-13	Neuroticism;
LGG	cis	rs7945705	0.747	rs1980428	chr11:9010497	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.66	0.48	1e-27	Hemoglobin concentration;
LGG	cis	rs1062177	0.901	rs1549622	chr5:151266049	A/G	cg00977110	chr5:151150581	G3BP1	0.46	6.99	0.31	9.76e-12	Preschool internalizing problems;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.7	-0.59	7.31e-45	Platelet count;
LGG	cis	rs6546537	0.550	rs6546531	chr2:69779963	C/A	cg10773587	chr2:69614142	GFPT1	-0.44	-7.62	-0.33	1.4e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs3735485	0.760	rs9639905	chr7:45057743	A/G	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs8072100	0.790	rs34200664	chr17:45744652	C/T	cg08085267	chr17:45401833	C17orf57	0.52	9.64	0.41	3.6e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7000551	0.725	rs2443496	chr8:22365788	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	12.39	0.5	1.23e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8060686	0.641	rs1125333	chr16:68227566	C/A	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs172166	0.694	rs2791332	chr6:28108788	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.47	-6.84	-0.3	2.52e-11	Cardiac Troponin-T levels;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.14	-0.35	3.62e-15	Skin colour saturation;
LGG	cis	rs9326248	0.520	rs6589602	chr11:117037065	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.76	13.86	0.54	8.59e-37	Blood protein levels;
LGG	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18876405	chr7:65276391	NA	-0.6	-11.0	-0.46	3.64e-25	Aortic root size;
LGG	cis	rs490234	0.702	rs13287071	chr9:128268224	T/C	cg14078157	chr9:128172775	NA	-0.54	-10.25	-0.43	2.31e-22	Mean arterial pressure;
LGG	cis	rs4631830	0.540	rs2843562	chr10:51496796	A/G	cg16070123	chr10:51489643	NA	0.51	9.95	0.42	2.98e-21	Prostate-specific antigen levels;
LGG	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg24112000	chr20:60950667	NA	-0.4	-7.95	-0.35	1.48e-14	Colorectal cancer;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg11905131	chr22:24372483	LOC391322	-0.42	-7.31	-0.32	1.19e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.46	-0.37	3.58e-16	Obesity-related traits;
LGG	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg19812747	chr11:111475976	SIK2	0.35	6.69	0.3	6.62e-11	Primary sclerosing cholangitis;
LGG	cis	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg21775007	chr8:11205619	TDH	0.53	8.78	0.38	3.21e-17	Triglycerides;
LGG	cis	rs9467773	0.534	rs34453863	chr6:26628005	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.16	0.49	1.03e-29	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.541	rs10200507	chr2:219335944	C/A	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9381107	0.505	rs9394957	chr6:9484928	C/G	cg14735645	chr6:9486422	NA	-0.53	-10.2	-0.43	3.51e-22	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7395662	0.895	rs3903506	chr11:48718513	G/A	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs16837677	1.000	rs16837672	chr1:156774021	G/A	cg14991358	chr1:156767203	PRCC	0.76	7.66	0.34	1.11e-13	Sjögren's syndrome;
LGG	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg25817165	chr18:72167213	CNDP2	-0.64	-12.97	-0.52	5.1e-33	Refractive error;
LGG	cis	rs2204008	0.744	rs11514073	chr12:38399553	A/C	cg26384229	chr12:38710491	ALG10B	0.97	21.07	0.7	1.29e-69	Bladder cancer;
LGG	trans	rs7923837	0.687	rs2185756	chr10:94430497	A/C	cg27639046	chr2:171608303	NA	-0.36	-7.14	-0.31	3.65e-12	Body mass index;Multiple sclerosis;
LGG	trans	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg18187862	chr3:45730750	SACM1L	0.58	9.55	0.41	7.28e-20	Primary sclerosing cholangitis;
LGG	trans	rs75804782	0.521	rs55915157	chr2:239424273	T/C	cg01134436	chr17:81009848	B3GNTL1	0.74	8.27	0.36	1.48e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.8	16.32	0.6	1.26e-47	Lymphocyte counts;
LGG	cis	rs1957429	0.520	rs72625637	chr14:65307705	G/A	cg23373153	chr14:65346875	NA	-0.88	-8.7	-0.37	5.81e-17	Pediatric areal bone mineral density (radius);
LGG	cis	rs10871290	0.650	rs2288054	chr16:74491733	A/G	cg01733217	chr16:74700730	RFWD3	0.72	12.89	0.51	1.11e-32	Breast cancer;
LGG	cis	rs17253792	0.822	rs8007065	chr14:56081272	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs981844	0.712	rs4616729	chr4:154746900	T/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs7633857	0.532	rs9858335	chr3:160760146	A/G	cg04691961	chr3:161091175	C3orf57	-0.41	-8.38	-0.36	6.53e-16	Educational attainment (years of education);
LGG	cis	rs9443645	0.838	rs946022	chr6:79672133	G/T	cg18132916	chr6:79620363	NA	-0.31	-8.56	-0.37	1.69e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg27400746	chr16:89904261	SPIRE2	-1.05	-15.41	-0.58	1.53e-43	Skin colour saturation;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg12458913	chr13:53173898	NA	0.63	12.28	0.5	3.4e-30	Lewy body disease;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg01238044	chr22:24384105	GSTT1	-0.45	-7.83	-0.34	3.47e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6912958	0.559	rs1201409	chr6:88055264	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.11	0.52	1.31e-33	Monocyte percentage of white cells;
LGG	cis	rs6743376	0.556	rs3820738	chr2:113819439	A/G	cg05949173	chr2:113825882	IL1F10	0.5	9.69	0.41	2.39e-20	Inflammatory biomarkers;
LGG	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg09137382	chr11:130731461	NA	0.36	6.85	0.3	2.3e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs896854	0.967	rs10956933	chr8:95967688	C/G	cg13393036	chr8:95962371	TP53INP1	-0.27	-7.16	-0.32	3.12e-12	Type 2 diabetes;
LGG	trans	rs6575793	0.532	rs12433699	chr14:101035546	C/G	cg22806444	chr17:72968764	C17orf28	0.53	9.01	0.39	5.46e-18	Menarche (age at onset);
LGG	cis	rs7843479	0.506	rs7818430	chr8:21798429	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.16	0.6	6.41e-47	Mean corpuscular volume;
LGG	cis	rs1865760	0.827	rs9295681	chr6:25944117	T/G	cg17691542	chr6:26056736	HIST1H1C	0.54	9.68	0.41	2.75e-20	Height;
LGG	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg02002194	chr4:3960332	NA	0.44	7.86	0.34	2.81e-14	Retinal vascular caliber;
LGG	cis	rs559928	0.553	rs4930168	chr11:64173058	A/G	cg26318627	chr11:63887540	MACROD1	-0.39	-7.17	-0.32	3.03e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg07636037	chr3:49044803	WDR6	0.76	13.56	0.53	1.62e-35	Menarche (age at onset);
LGG	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg22643751	chr7:855365	UNC84A	0.36	6.96	0.31	1.16e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6690583	0.524	rs12030837	chr1:85519383	A/G	cg22153463	chr1:85462885	MCOLN2	-0.66	-7.69	-0.34	8.83e-14	Serum sulfate level;
LGG	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg11984989	chr7:158649758	WDR60	-0.96	-19.86	-0.68	6.08e-64	Height;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.47e-14	Obesity-related traits;
LGG	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22618164	chr12:122356400	WDR66	-0.32	-8.93	-0.38	1.03e-17	Mean corpuscular volume;
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg13047869	chr3:10149882	C3orf24	0.48	7.99	0.35	1.11e-14	Alzheimer's disease;
LGG	cis	rs738321	0.757	rs4821748	chr22:38541936	G/A	cg03162506	chr22:38580953	NA	0.4	9.78	0.41	1.14e-20	Breast cancer;
LGG	cis	rs1865760	0.566	rs2051544	chr6:26071093	C/T	cg18357526	chr6:26021779	HIST1H4A	0.47	7.84	0.34	3.08e-14	Height;
LGG	cis	rs6831352	0.918	rs17218162	chr4:100056060	G/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs7208859	0.623	rs73267858	chr17:29059737	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.88	-10.84	-0.45	1.53e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg07636037	chr3:49044803	WDR6	1.09	25.5	0.76	2.93e-90	Parkinson's disease;
LGG	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.46e-12	HDL cholesterol;
LGG	cis	rs3768617	0.510	rs4651139	chr1:183091963	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.23	-0.36	1.9e-15	Life satisfaction;
LGG	cis	rs2346177	0.844	rs4953365	chr2:46644946	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.5	-9.21	-0.39	1.18e-18	HDL cholesterol;
LGG	trans	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.31	-0.36	1.04e-15	Triglycerides;
LGG	cis	rs6578185	0.810	rs11784198	chr8:142448360	C/T	cg07762003	chr8:142452454	FLJ43860	-0.66	-13.42	-0.53	6.56e-35	Endometriosis;
LGG	cis	rs9322193	0.607	rs9371228	chr6:150243113	G/A	cg11878867	chr6:150167359	LRP11	0.46	7.92	0.35	1.79e-14	Lung cancer;
LGG	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg20608306	chr11:116969690	SIK3	0.43	13.42	0.53	6.33e-35	Blood protein levels;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs62064224	0.791	rs2344977	chr17:30720573	C/G	cg18200150	chr17:30822561	MYO1D	0.78	17.36	0.63	2.38e-52	Schizophrenia;
LGG	cis	rs933688	0.877	rs1477349	chr5:90707773	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs597583	0.664	rs3819210	chr11:117389517	A/G	cg27161313	chr11:117392002	DSCAML1	-0.57	-9.29	-0.4	6e-19	Putamen volume;
LGG	trans	rs7395662	1.000	rs7938880	chr11:48642154	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.02	-0.35	8.96e-15	HDL cholesterol;
LGG	cis	rs6831352	0.918	rs29001209	chr4:100052340	C/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs9287719	0.967	rs7355649	chr2:10748094	C/A	cg02196655	chr2:10830764	NOL10	-0.43	-7.29	-0.32	1.36e-12	Prostate cancer;
LGG	cis	rs7598759	0.712	rs12991636	chr2:232333666	T/C	cg19187155	chr2:232395269	NMUR1	0.43	7.85	0.34	2.84e-14	Noise-induced hearing loss;
LGG	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg02891314	chr5:179741120	GFPT2	-0.64	-11.67	-0.48	8.99e-28	Height;
LGG	trans	rs66887589	0.837	rs7661498	chr4:120408108	T/C	cg25214090	chr10:38739885	LOC399744	0.38	6.96	0.31	1.15e-11	Diastolic blood pressure;
LGG	cis	rs8031584	0.560	rs7171208	chr15:31198929	A/G	cg08109568	chr15:31115862	NA	0.45	8.15	0.35	3.54e-15	Huntington's disease progression;
LGG	cis	rs7635838	0.684	rs2606757	chr3:11358163	T/A	cg00170343	chr3:11313890	ATG7	0.51	8.77	0.38	3.55e-17	HDL cholesterol;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg19635926	chr16:89946313	TCF25	0.79	8.1	0.35	5.04e-15	Skin colour saturation;
LGG	cis	rs3008870	1.000	rs2985818	chr1:67398916	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.03	22.99	0.73	1.39e-78	Lymphocyte percentage of white cells;
LGG	cis	rs112591243	0.570	rs77436553	chr21:47759343	G/A	cg10657630	chr21:48055338	PRMT2	0.86	6.87	0.3	2.1e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs2019137	0.905	rs2276561	chr2:113956371	G/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.35	-0.43	1.03e-22	Lymphocyte counts;
LGG	cis	rs16866061	0.515	rs11695326	chr2:225415134	A/G	cg22455342	chr2:225449267	CUL3	0.44	7.36	0.32	8.37e-13	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg15557168	chr22:42548783	NA	-0.47	-10.3	-0.43	1.6e-22	Schizophrenia;
LGG	cis	rs17270561	0.608	rs9358875	chr6:25738008	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.19	-0.32	2.53e-12	Iron status biomarkers;
LGG	cis	rs68170813	0.570	rs7794915	chr7:106849393	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-8.75	-0.38	3.95e-17	Coronary artery disease;
LGG	cis	rs6796502	0.541	rs28440083	chr3:46881986	A/G	cg23231268	chr3:46792462	NA	-0.6	-8.01	-0.35	9.56e-15	Breast cancer;
LGG	cis	rs9291683	0.669	rs887733	chr4:10183108	T/C	cg08250081	chr4:10125330	NA	-0.38	-7.21	-0.32	2.32e-12	Bone mineral density;
LGG	cis	rs4665809	1.000	rs6749855	chr2:26255263	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-13.29	-0.53	2.32e-34	Gut microbiome composition (summer);
LGG	cis	rs16957091	0.909	rs12907826	chr15:43017081	G/A	cg07484255	chr15:43025164	CDAN1	-0.48	-6.67	-0.3	7.27e-11	MGMT methylation in smokers;
LGG	cis	rs2201728	0.902	rs12498658	chr4:100237821	G/A	cg07219303	chr4:100140905	ADH6	-0.4	-8.23	-0.36	1.93e-15	Cardiac Troponin-T levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05353415	chr7:42276004	GLI3	0.49	8.08	0.35	5.78e-15	Gut microbiome composition (summer);
LGG	cis	rs908922	0.676	rs11205032	chr1:152527690	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.71	0.56	1.83e-40	Hair morphology;
LGG	cis	rs10193935	0.901	rs222464	chr2:42643889	C/T	cg27598129	chr2:42591480	NA	-0.67	-9.94	-0.42	3.23e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7084402	0.934	rs1658453	chr10:60309602	T/C	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-16.29	-0.6	1.81e-47	Platelet count;
LGG	cis	rs7659604	0.540	rs34445121	chr4:122710889	G/A	cg20573242	chr4:122745356	CCNA2	-0.46	-7.99	-0.35	1.07e-14	Type 2 diabetes;
LGG	trans	rs1814175	0.817	rs7483795	chr11:49704930	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-27.03	-0.78	3.05e-97	Height;
LGG	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg00599393	chr8:22457479	C8orf58	0.47	8.57	0.37	1.54e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10463316	0.608	rs7700423	chr5:150769155	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-9.91	-0.42	3.96e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs9560113	0.881	rs9560111	chr13:112181289	C/T	cg14952266	chr13:112191215	NA	-0.41	-7.5	-0.33	3.18e-13	Menarche (age at onset);
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03647317	chr4:187891568	NA	-0.41	-8.63	-0.37	1.01e-16	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.9	0.31	1.71e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07362569	chr17:61921086	SMARCD2	-0.51	-9.88	-0.42	5.07e-21	Prudent dietary pattern;
LGG	cis	rs597539	0.652	rs10792001	chr11:68637737	G/C	cg01988459	chr11:68622903	NA	-0.62	-12.57	-0.5	2.17e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11148252	0.716	rs2760772	chr13:52780373	C/G	cg05335186	chr13:53173507	NA	0.39	7.75	0.34	5.8e-14	Lewy body disease;
LGG	cis	rs6076065	0.925	rs2281430	chr20:23399314	T/C	cg11657817	chr20:23433608	CST11	0.34	6.67	0.3	7.46e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs853679	0.546	rs200995	chr6:27813694	C/T	cg08344181	chr3:125677491	NA	0.65	7.66	0.34	1.11e-13	Depression;
LGG	trans	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.81	-0.38	2.53e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.29	-0.43	1.69e-22	Chronic sinus infection;
LGG	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg25008857	chr14:105974488	NA	0.56	9.76	0.41	1.34e-20	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs4689592	0.554	rs66925245	chr4:7071999	C/T	cg06697600	chr4:7070879	GRPEL1	0.52	7.96	0.35	1.37e-14	Monocyte percentage of white cells;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg08355353	chr1:113217657	MOV10	-0.41	-6.88	-0.3	1.91e-11	Pancreatic cancer;
LGG	cis	rs17221829	0.965	rs1967075	chr11:89447256	A/G	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.68	-0.34	9.5e-14	Anxiety in major depressive disorder;
LGG	cis	rs2239815	0.515	rs9625591	chr22:29232564	A/G	cg15103426	chr22:29168792	CCDC117	0.66	7.76	0.34	5.4e-14	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg26897989	chr16:1907736	C16orf73	-0.82	-13.81	-0.54	1.37e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2070488	1.000	rs1841777	chr3:38484819	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.03	0.64	1.83e-55	Electrocardiographic conduction measures;
LGG	cis	rs11150038	0.536	rs2735405	chr16:78048809	T/C	cg04733911	chr16:78082701	NA	-0.67	-11.16	-0.46	9.23e-26	Colorectal or endometrial cancer;
LGG	cis	rs75920871	0.528	rs7128772	chr11:116889411	T/A	cg01368799	chr11:117014884	PAFAH1B2	-0.5	-7.31	-0.32	1.22e-12	Subjective well-being;
LGG	cis	rs9309711	0.961	rs11675119	chr2:3476422	C/A	cg10845886	chr2:3471009	TTC15	-0.74	-14.88	-0.57	3.22e-41	Neurofibrillary tangles;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24478630	chr2:74692696	MOGS	-0.41	-6.72	-0.3	5.46e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6952808	0.792	rs4721184	chr7:1950784	T/C	cg13880726	chr7:1868755	MAD1L1	0.38	6.65	0.3	8.23e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	0.649	rs255866	chr5:112748532	A/T	cg12552261	chr5:112820674	MCC	0.57	10.49	0.44	3.1e-23	Type 2 diabetes;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg07959490	chr17:80112427	CCDC57	0.46	9.22	0.39	1.06e-18	Life satisfaction;
LGG	cis	rs6582630	0.519	rs11495376	chr12:38284957	A/C	cg26384229	chr12:38710491	ALG10B	0.91	20.52	0.69	4.79e-67	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg15556689	chr8:8085844	FLJ10661	0.4	7.26	0.32	1.61e-12	Monocyte count;
LGG	cis	rs992157	0.796	rs55680399	chr2:219160621	T/C	cg00012203	chr2:219082015	ARPC2	0.66	11.98	0.49	5.48e-29	Colorectal cancer;
LGG	cis	rs3768617	0.528	rs2027082	chr1:183084608	C/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.68	-0.37	6.64e-17	Eosinophil percentage of white cells;
LGG	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg00717180	chr2:96193071	NA	-0.43	-7.66	-0.34	1.08e-13	HDL cholesterol;
LGG	cis	rs709400	1.000	rs6593	chr14:104163282	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.35	-0.36	8.22e-16	Body mass index;
LGG	cis	rs7766436	0.885	rs13211957	chr6:22573415	C/T	cg13666174	chr6:22585274	NA	-0.52	-11.88	-0.48	1.37e-28	Coronary artery disease;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.01	0.42	1.72e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg10483660	chr13:112241077	NA	0.36	7.05	0.31	6.51e-12	Menarche (age at onset);
LGG	cis	rs2587949	0.615	rs1444061	chr3:4222709	G/A	cg16519197	chr3:4211558	NA	0.32	6.75	0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs769267	0.930	rs747050	chr19:19584987	C/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.24	0.43	2.46e-22	Tonsillectomy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20089077	chr19:37569736	ZNF420	0.45	7.52	0.33	2.8e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg19774624	chr17:42201019	HDAC5	0.95	20.69	0.69	7.77e-68	Total body bone mineral density;
LGG	cis	rs6740322	0.748	rs6544635	chr2:43486704	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.69	-10.9	-0.45	8.78e-25	Coronary artery disease;
LGG	cis	rs9611565	0.729	rs202654	chr22:41841034	G/A	cg06481639	chr22:41940642	POLR3H	0.5	7.62	0.33	1.46e-13	Vitiligo;
LGG	cis	rs7681423	1.000	rs7659024	chr4:155520930	G/A	cg20735720	chr4:155535218	FGG	-0.58	-10.39	-0.43	7.45e-23	Fibrinogen;
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg18681998	chr4:17616180	MED28	0.85	18.91	0.66	1.63e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8016982	0.609	rs8009519	chr14:81702503	C/G	cg01989461	chr14:81687754	GTF2A1	0.81	20.11	0.68	4.35e-65	Schizophrenia;
LGG	trans	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg26043149	chr18:55253948	FECH	0.47	7.78	0.34	4.93e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg21782813	chr7:2030301	MAD1L1	0.46	11.07	0.46	1.98e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	1.000	rs565007	chr15:43716641	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.87	10.84	0.45	1.45e-24	Lung cancer in ever smokers;
LGG	trans	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg07817883	chr1:32538562	TMEM39B	-0.68	-9.62	-0.41	4.2e-20	Monocyte percentage of white cells;
LGG	cis	rs372883	0.967	rs2832290	chr21:30728863	C/T	cg24692254	chr21:30365293	RNF160	-0.45	-7.58	-0.33	1.92e-13	Pancreatic cancer;
LGG	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg13959647	chr9:123605229	PSMD5;LOC253039	0.42	6.67	0.3	7.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6088580	0.634	rs4142007	chr20:32990050	G/T	cg08999081	chr20:33150536	PIGU	-0.39	-9.71	-0.41	2.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6132905	0.520	rs2422824	chr20:2647370	C/T	cg01629329	chr20:2633258	NOP56;MIR1292	-0.44	-7.92	-0.35	1.73e-14	Mumps;
LGG	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg03469862	chr11:68924853	NA	0.46	7.07	0.31	5.85e-12	Blond vs. brown hair color;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg20119798	chr7:94954144	PON1	-0.41	-8.91	-0.38	1.18e-17	Paraoxonase activity;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg21775007	chr8:11205619	TDH	0.84	15.61	0.59	1.92e-44	Retinal vascular caliber;
LGG	cis	rs11792861	0.926	rs72607171	chr9:111837776	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.56	0.41	6.8e-20	Menarche (age at onset);
LGG	cis	rs12190007	0.514	rs2984462	chr6:169843903	A/T	cg15038512	chr6:170123185	PHF10	-0.46	-8.63	-0.37	9.56e-17	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg21605333	chr4:119757512	SEC24D	1.48	14.95	0.57	1.65e-41	Cannabis dependence symptom count;
LGG	cis	rs751728	0.664	rs2296744	chr6:33740382	G/A	cg25922239	chr6:33757077	LEMD2	0.42	7.16	0.32	3.12e-12	Crohn's disease;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg21970626	chr13:21893289	NA	-0.46	-10.11	-0.43	7.87e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2640806	0.505	rs11996832	chr8:97365812	G/A	cg22138393	chr8:97340270	PTDSS1	0.28	7.27	0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg11366901	chr6:160182831	ACAT2	1.01	15.28	0.58	5.4e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4363385	0.747	rs946101	chr1:152972032	C/T	cg13444842	chr1:152974279	SPRR3	0.44	9.04	0.39	4.36e-18	Inflammatory skin disease;
LGG	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg00071950	chr4:10020882	SLC2A9	0.34	6.81	0.3	2.95e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg23621652	chr2:207630148	FASTKD2;MDH1B	-0.34	-6.67	-0.3	7.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs41271473	0.950	rs72751907	chr1:228867648	C/T	cg00850481	chr1:228891306	NA	-0.51	-8.74	-0.38	4.18e-17	Chronic lymphocytic leukemia;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg23302884	chr18:44338147	ST8SIA5	0.38	7.64	0.33	1.23e-13	Personality dimensions;
LGG	cis	rs1816752	1.000	rs1816752	chr13:24980949	A/G	cg22771759	chr13:24902376	NA	0.44	7.33	0.32	1.04e-12	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.23	-0.43	2.87e-22	Lung cancer;
LGG	cis	rs4953318	0.619	rs10198247	chr2:46362677	C/T	cg12428440	chr2:46370979	PRKCE	-0.5	-9.24	-0.39	8.91e-19	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs899997	0.906	rs1809415	chr15:79028201	C/T	cg07120314	chr15:79043507	NA	0.72	14.22	0.55	2.42e-38	Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	trans	rs208520	0.837	rs208488	chr6:66926902	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-15.56	-0.59	3.1e-44	Exhaled nitric oxide output;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg06413043	chr12:125576309	AACS	0.35	6.8	0.3	3.25e-11	Migraine with aura;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg17887936	chr1:154540354	CHRNB2	0.45	6.81	0.3	2.98e-11	Emphysema imaging phenotypes;
LGG	trans	rs9409565	0.586	rs9409547	chr9:97212196	A/C	cg05679027	chr9:99775184	HIATL2	-0.46	-7.06	-0.31	6.13e-12	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9479482	1.000	rs9479482	chr6:150358012	T/C	cg06889755	chr6:150326021	RAET1K	-0.4	-8.28	-0.36	1.37e-15	Alopecia areata;
LGG	cis	rs10504229	0.683	rs7838958	chr8:58136968	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs5001130	chr6:8442298	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	1.03e-17	Motion sickness;
LGG	cis	rs2576037	0.526	rs642897	chr18:44396917	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.43	-0.47	8.34e-27	Personality dimensions;
LGG	cis	rs975739	1.000	rs1158097	chr13:78386375	T/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.44	-0.37	3.95e-16	Tonsillectomy;
LGG	cis	rs7215564	0.908	rs2316067	chr17:78659720	C/T	cg16980736	chr17:78789706	RPTOR	-0.6	-8.08	-0.35	5.66e-15	Myopia (pathological);
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.23	0.49	5.13e-30	Prudent dietary pattern;
LGG	trans	rs73198271	0.603	rs570364	chr8:8593638	G/T	cg16141378	chr3:129829833	LOC729375	0.35	6.86	0.3	2.24e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg20887711	chr4:1340912	KIAA1530	0.48	8.64	0.37	9.19e-17	Obesity-related traits;
LGG	cis	rs55794721	0.509	rs6699896	chr1:25762902	A/T	cg23205692	chr1:25664452	TMEM50A	0.49	10.37	0.43	8.39e-23	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs7811142	0.830	rs75636500	chr7:99947657	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	18.98	0.66	8.01e-60	Platelet count;
LGG	cis	rs2243480	0.803	rs160649	chr7:65543199	C/T	cg13147721	chr7:65941812	NA	-0.81	-9.7	-0.41	2.23e-20	Diabetic kidney disease;
LGG	cis	rs751728	1.000	rs3793079	chr6:33767788	T/A	cg25922239	chr6:33757077	LEMD2	0.71	12.49	0.5	4.72e-31	Crohn's disease;
LGG	cis	rs2576037	0.526	rs4890703	chr18:44522037	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.77	15.13	0.58	2.55e-42	Personality dimensions;
LGG	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg14186256	chr22:23484241	RTDR1	0.93	22.88	0.73	4.34e-78	Bone mineral density;
LGG	cis	rs9486719	1.000	rs6921291	chr6:97066242	C/T	cg18709589	chr6:96969512	KIAA0776	-0.51	-7.78	-0.34	4.81e-14	Migraine;Coronary artery disease;
LGG	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	6.25e-15	Retinal vascular caliber;
LGG	cis	rs9916302	0.706	rs8078599	chr17:37518660	C/T	cg00129232	chr17:37814104	STARD3	0.58	8.43	0.36	4.3e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs6138458	0.961	rs227625	chr20:24911618	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	trans	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-11.23	-0.46	4.67e-26	Brugada syndrome;
LGG	cis	rs503734	0.666	rs7628681	chr3:101265823	T/G	cg27318481	chr3:100970896	IMPG2	0.36	7.19	0.32	2.69e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12155623	0.619	rs870397	chr8:49861225	C/T	cg22283653	chr8:49824208	NA	0.51	9.58	0.41	5.92e-20	Sudden cardiac arrest;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.67	-0.34	1.04e-13	Personality dimensions;
LGG	cis	rs60871478	0.579	rs56109762	chr7:925967	G/A	cg10204951	chr7:910479	UNC84A	-0.57	-7.24	-0.32	1.87e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs1799949	0.859	rs11657004	chr17:41442751	A/G	cg01879757	chr17:41196368	BRCA1	-0.4	-8.32	-0.36	9.68e-16	Menopause (age at onset);
LGG	trans	rs116095464	0.764	rs10069197	chr5:230822	G/C	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg03517284	chr6:25882590	NA	-0.64	-12.17	-0.49	9.68e-30	Intelligence (multi-trait analysis);
LGG	cis	rs72925845	0.577	rs691277	chr17:76429761	G/C	cg03830375	chr17:76426088	DNAH17	0.5	7.09	0.31	4.99e-12	Triglycerides;
LGG	cis	rs597583	0.715	rs4938400	chr11:117399604	C/A	cg27161313	chr11:117392002	DSCAML1	-0.63	-10.04	-0.42	1.32e-21	Putamen volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19061982	chr2:113299409	POLR1B	0.48	7.13	0.31	3.8e-12	Gut microbiome composition (summer);
LGG	cis	rs17767392	0.881	rs12881957	chr14:71909854	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.84	0.38	2e-17	Mitral valve prolapse;
LGG	trans	rs7395662	0.791	rs4347396	chr11:48895929	T/C	cg03929089	chr4:120376271	NA	0.44	7.16	0.32	3.21e-12	HDL cholesterol;
LGG	cis	rs6138458	0.701	rs6138474	chr20:25012427	T/A	cg26195577	chr20:24973756	C20orf3	0.89	16.01	0.6	3.29e-46	Blood protein levels;
LGG	cis	rs1865760	0.566	rs2858993	chr6:26087856	T/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.92	0.42	3.64e-21	Height;
LGG	cis	rs2115630	0.691	rs2292462	chr15:85200754	G/T	cg11189052	chr15:85197271	WDR73	-0.49	-8.0	-0.35	9.83e-15	P wave terminal force;
LGG	cis	rs1620921	0.563	rs2465861	chr6:161261486	T/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg11890956	chr21:40555474	PSMG1	1.21	31.01	0.82	4.36e-115	Cognitive function;
LGG	cis	rs115344852	0.585	rs1016069	chr6:28440418	T/A	cg13525197	chr6:28411240	ZSCAN23	-0.49	-7.21	-0.32	2.25e-12	Epithelial ovarian cancer;
LGG	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg08648136	chr8:956695	NA	0.36	7.57	0.33	2.04e-13	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg27597069	chr6:37321822	RNF8	-0.51	-7.41	-0.33	6.12e-13	Systemic lupus erythematosus;
LGG	cis	rs3126085	0.515	rs10788835	chr1:152330945	T/C	cg26876637	chr1:152193138	HRNR	-0.44	-6.81	-0.3	3.01e-11	Atopic dermatitis;
LGG	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg07005078	chr4:17578674	LAP3	0.37	6.88	0.3	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9650657	0.506	rs7823296	chr8:10778546	A/G	cg02002194	chr4:3960332	NA	0.42	7.74	0.34	6.29e-14	Neuroticism;
LGG	cis	rs910316	0.967	rs10246	chr14:75544470	T/A	cg06637938	chr14:75390232	RPS6KL1	0.59	10.93	0.45	6.83e-25	Height;
LGG	cis	rs9311474	0.607	rs4475032	chr3:52560021	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-9.06	-0.39	3.75e-18	Electroencephalogram traits;
LGG	cis	rs3784262	0.669	rs1063666	chr15:58246602	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.06	-0.31	6.15e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1497828	0.871	rs2815238	chr1:217543384	T/A	cg04411442	chr1:217543379	NA	0.5	8.39	0.36	5.96e-16	Dialysis-related mortality;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.67	-0.41	2.98e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4936891	0.577	rs4565912	chr11:123904395	A/G	cg22125253	chr11:123886957	OR10G4	-0.54	-9.14	-0.39	2.04e-18	Male fertility;
LGG	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.81	-0.41	9.42e-21	Systolic blood pressure;
LGG	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.08	0.39	3.18e-18	Breast cancer;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06028808	chr11:68637592	NA	0.72	12.34	0.5	2e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-6.79	-0.3	3.49e-11	Lung cancer;
LGG	cis	rs3762637	1.000	rs9858558	chr3:122139742	G/A	cg24169773	chr3:122142474	KPNA1	-0.6	-10.15	-0.43	5.33e-22	LDL cholesterol levels;
LGG	cis	rs4430311	0.723	rs1973284	chr1:243856681	A/G	cg25706552	chr1:244017396	NA	-0.64	-15.18	-0.58	1.58e-42	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs643506	1.000	rs643506	chr11:111636627	T/G	cg09085632	chr11:111637200	PPP2R1B	0.58	9.29	0.4	5.82e-19	Breast cancer;
LGG	cis	rs12824058	0.737	rs11060829	chr12:130814996	G/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.69	0.41	2.49e-20	Menopause (age at onset);
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg23034840	chr1:205782522	SLC41A1	-0.49	-7.83	-0.34	3.35e-14	Menarche (age at onset);
LGG	cis	rs11626933	0.885	rs28517514	chr14:90788709	G/A	cg04374321	chr14:90722782	PSMC1	0.42	7.09	0.31	5.18e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg26656751	chr17:43910226	CRHR1	-0.33	-6.77	-0.3	3.95e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs778371	0.676	rs17164	chr2:233593499	C/T	cg08000102	chr2:233561755	GIGYF2	0.67	11.06	0.46	2.26e-25	Schizophrenia;
LGG	cis	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg21775007	chr8:11205619	TDH	-0.78	-13.98	-0.54	2.78e-37	Retinal vascular caliber;
LGG	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.91	-16.3	-0.6	1.57e-47	Homoarginine levels;
LGG	cis	rs1008375	0.932	rs4235390	chr4:17696378	G/T	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs61931739	0.534	rs4547187	chr12:34041259	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.9	-0.48	1.09e-28	Morning vs. evening chronotype;
LGG	trans	rs7647973	0.710	rs11130208	chr3:49615624	G/T	cg21659725	chr3:3221576	CRBN	-0.59	-7.6	-0.33	1.66e-13	Menarche (age at onset);
LGG	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg11871910	chr12:69753446	YEATS4	0.92	22.12	0.72	1.57e-74	Blood protein levels;
LGG	cis	rs7615952	0.599	rs6803160	chr3:125709554	G/T	cg04553112	chr3:125709451	NA	-0.55	-7.0	-0.31	9.29e-12	Blood pressure (smoking interaction);
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.63	-0.33	1.37e-13	Personality dimensions;
LGG	cis	rs2898290	0.593	rs2199690	chr8:11339616	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.11	-0.31	4.31e-12	Systolic blood pressure;
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg18099408	chr3:52552593	STAB1	-0.34	-6.76	-0.3	4.16e-11	Bipolar disorder;
LGG	cis	rs56146971	0.714	rs79810056	chr14:91852929	A/G	cg14409461	chr14:91925021	SMEK1	-0.42	-6.97	-0.31	1.06e-11	Alzheimer disease and age of onset;
LGG	cis	rs7208859	0.673	rs9891413	chr17:29208209	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs56124677	chr4:119772213	C/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs4722166	0.695	rs56061963	chr7:22800397	T/C	cg05265849	chr7:22767390	IL6	0.37	7.2	0.32	2.39e-12	Lung cancer;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.14	0.55	5.24e-38	Platelet count;
LGG	cis	rs7909791	0.809	rs12570462	chr10:105613329	A/G	cg11005552	chr10:105648138	OBFC1	-0.63	-9.63	-0.41	3.86e-20	White matter hyperintensity burden;
LGG	cis	rs537930	0.925	rs2431150	chr5:134348146	G/C	cg24576358	chr5:134350122	NA	0.46	9.41	0.4	2.39e-19	Height;
LGG	cis	rs9393777	0.623	rs9348719	chr6:26470032	T/C	cg12826209	chr6:26865740	GUSBL1	0.83	11.77	0.48	3.81e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg08305652	chr11:111469057	NA	-0.43	-8.48	-0.37	3.05e-16	Primary sclerosing cholangitis;
LGG	cis	rs8017423	0.569	rs10141476	chr14:90823351	C/T	cg04374321	chr14:90722782	PSMC1	-0.64	-12.83	-0.51	1.91e-32	Mortality in heart failure;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-9.63	-0.41	3.88e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg05868516	chr6:26286170	HIST1H4H	0.47	8.12	0.35	4.29e-15	Educational attainment;
LGG	cis	rs1355223	0.545	rs7111695	chr11:34874906	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.34	-0.36	8.35e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg26384229	chr12:38710491	ALG10B	0.92	20.58	0.69	2.5e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs668210	0.793	rs645571	chr11:65752852	A/T	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.7	-9.28	-0.4	6.43e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs209489	0.892	rs17544187	chr6:53131343	T/G	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs61931739	0.500	rs7306435	chr12:34482933	A/G	cg13010199	chr12:38710504	ALG10B	-0.69	-13.52	-0.53	2.5e-35	Morning vs. evening chronotype;
LGG	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg02487422	chr3:49467188	NICN1	-0.52	-9.42	-0.4	2.14e-19	Resting heart rate;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.47	-0.58	7.99e-44	Platelet count;
LGG	trans	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg01620082	chr3:125678407	NA	-0.85	-7.29	-0.32	1.33e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7493	0.853	rs6973380	chr7:95043523	C/T	cg17330251	chr7:94953956	PON1	-0.43	-8.14	-0.35	3.64e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs1814175	0.588	rs10839463	chr11:49971643	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.72	-0.61	2.02e-49	Height;
LGG	cis	rs7223966	1.000	rs2665826	chr17:61944924	A/G	cg05941027	chr17:61774174	LIMD2	0.33	8.36	0.36	7.46e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4237845	0.537	rs11172369	chr12:58280592	T/C	cg00677455	chr12:58241039	CTDSP2	0.38	6.89	0.31	1.77e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.53	-9.13	-0.39	2.06e-18	Obesity-related traits;
LGG	cis	rs2836974	0.831	rs2836964	chr21:40631006	T/C	cg11890956	chr21:40555474	PSMG1	1.18	30.85	0.82	2.21e-114	Cognitive function;
LGG	cis	rs1801251	1.000	rs6738386	chr2:233602028	T/C	cg08000102	chr2:233561755	GIGYF2	0.56	9.25	0.4	8e-19	Coronary artery disease;
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg20821713	chr7:1055600	C7orf50	-0.46	-6.71	-0.3	5.66e-11	Bronchopulmonary dysplasia;
LGG	cis	rs3096299	1.000	rs3096299	chr16:89448663	G/A	cg06640241	chr16:89574553	SPG7	0.68	11.5	0.47	4.31e-27	Multiple myeloma (IgH translocation);
LGG	cis	rs78456975	0.527	rs11886696	chr2:1567841	A/G	cg12573674	chr2:1569213	NA	-0.62	-9.35	-0.4	3.86e-19	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs11098499	0.866	rs13125526	chr4:120288019	G/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9948	0.881	rs3731941	chr2:97476219	A/G	cg01990225	chr2:97406019	LMAN2L	-0.65	-6.81	-0.3	3.05e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs10794720	0.748	rs11250275	chr10:1171823	A/G	cg08668510	chr10:1095578	IDI1	-0.72	-7.05	-0.31	6.53e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg00814883	chr7:100076585	TSC22D4	-0.74	-10.82	-0.45	1.71e-24	Platelet count;
LGG	cis	rs62238980	0.614	rs4821020	chr22:32414089	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs9503598	0.636	rs6596978	chr6:3468878	C/T	cg00476032	chr6:3446245	SLC22A23	0.54	10.98	0.45	4.19e-25	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs757110	0.933	rs4148646	chr11:17415190	C/G	cg15432903	chr11:17409602	KCNJ11	0.86	16.83	0.62	6.32e-50	Type 2 diabetes;
LGG	cis	rs11676855	0.893	rs6431329	chr2:235934338	C/T	cg14917874	chr2:235941519	SH3BP4	0.53	9.83	0.42	7.9e-21	Dialysis-related mortality;
LGG	cis	rs7789940	0.951	rs73140055	chr7:75975777	A/T	cg10167463	chr7:75959203	YWHAG	-0.47	-7.85	-0.34	2.88e-14	Multiple sclerosis;
LGG	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs1994135	0.594	rs10772096	chr12:33732869	A/G	cg06521331	chr12:34319734	NA	-0.45	-7.79	-0.34	4.29e-14	Resting heart rate;
LGG	trans	rs116095464	0.614	rs10067482	chr5:219328	T/G	cg00938859	chr5:1591904	SDHAP3	0.88	13.08	0.52	1.67e-33	Breast cancer;
LGG	cis	rs12824058	0.831	rs12322456	chr12:130813594	A/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.73	0.41	1.8e-20	Menopause (age at onset);
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.5	0.5	4.35e-31	Obesity-related traits;
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.82	0.3	2.89e-11	Aortic root size;
LGG	cis	rs12824058	0.678	rs11614163	chr12:130814621	C/G	cg26677194	chr12:130822605	PIWIL1	0.57	9.86	0.42	5.85e-21	Menopause (age at onset);
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.34	-0.47	1.8e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg23815491	chr16:72088622	HP	0.44	7.34	0.32	9.88e-13	Coronary artery disease;
LGG	cis	rs4969178	0.645	rs4490057	chr17:76375095	C/T	cg20026190	chr17:76395443	PGS1	-0.44	-7.46	-0.33	4.22e-13	HDL cholesterol levels;
LGG	cis	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg05623727	chr3:50126028	RBM5	0.36	6.76	0.3	4.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg11878867	chr6:150167359	LRP11	-0.5	-10.28	-0.43	1.87e-22	Lung cancer;
LGG	cis	rs2463822	0.583	rs11600383	chr11:62060451	A/G	cg06239285	chr11:62104954	ASRGL1	0.9	11.68	0.48	8.78e-28	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2404602	0.692	rs55676827	chr15:76961716	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.39e-12	Blood metabolite levels;
LGG	cis	rs2832191	0.791	rs2832196	chr21:30497412	G/A	cg08807101	chr21:30365312	RNF160	-0.82	-16.77	-0.61	1.1e-49	Dental caries;
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg16590910	chr6:42928470	GNMT	0.42	11.89	0.48	1.24e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs929354	0.772	rs2023975	chr7:157012096	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.36	-0.32	8.29e-13	Body mass index;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg13206674	chr6:150067644	NUP43	0.41	8.6	0.37	1.2e-16	Lung cancer;
LGG	cis	rs8064299	0.597	rs4789097	chr17:72781208	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.98	-23.18	-0.73	1.77e-79	Monocyte count;
LGG	cis	rs11997175	0.846	rs34860600	chr8:33761566	C/A	ch.8.33884649F	chr8:33765107	NA	0.43	8.14	0.35	3.63e-15	Body mass index;
LGG	cis	rs6582630	0.519	rs11520262	chr12:38333051	A/G	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.63e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10911363	0.659	rs6669960	chr1:183436577	C/G	cg23894439	chr1:183413866	NA	-0.5	-9.33	-0.4	4.42e-19	Systemic lupus erythematosus;
LGG	cis	rs11748327	0.920	rs55988212	chr5:4057889	A/G	cg01025095	chr5:4101132	NA	-0.57	-9.28	-0.4	6.29e-19	Myocardial infarction;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08142263	chr19:17420206	DDA1	0.4	6.68	0.3	6.96e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.51	-0.33	3.11e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10779751	0.762	rs6540965	chr1:11325521	C/G	cg08854313	chr1:11322531	MTOR	-0.67	-14.43	-0.56	3.15e-39	Body mass index;
LGG	cis	rs10865541	0.967	rs6755327	chr2:3397281	T/C	cg11642891	chr2:3452563	TTC15	-0.45	-8.88	-0.38	1.48e-17	Obesity-related traits;
LGG	cis	rs12286929	0.702	rs11215419	chr11:115081810	A/T	cg04055981	chr11:115044050	NA	0.38	7.03	0.31	7.63e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	9.2	0.39	1.26e-18	Schizophrenia;
LGG	cis	rs8114671	0.562	rs6087651	chr20:33518353	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.26e-17	Height;
LGG	cis	rs17401966	0.540	rs6682868	chr1:10454773	C/T	cg19773385	chr1:10388646	KIF1B	0.36	8.19	0.36	2.58e-15	Hepatocellular carcinoma;
LGG	cis	rs6459804	0.588	rs78762416	chr7:157511142	G/A	cg15733309	chr7:157513707	PTPRN2	0.78	17.9	0.64	7.37e-55	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-19.46	-0.67	4.47e-62	Gut microbiome composition (summer);
LGG	cis	rs9650657	0.529	rs10108618	chr8:10953092	A/G	cg15596359	chr8:11213517	TDH	0.32	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs28595532	0.920	rs114792862	chr4:119759938	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs6840360	0.550	rs6535806	chr4:152483906	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg05890377	chr2:74357713	NA	0.52	9.87	0.42	5.76e-21	Gestational age at birth (maternal effect);
LGG	cis	rs11098499	0.954	rs7687843	chr4:120421211	C/T	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs875971	0.545	rs316323	chr7:65610989	C/T	cg11764359	chr7:65958608	NA	-0.64	-9.82	-0.42	8.38e-21	Aortic root size;
LGG	cis	rs1862618	0.671	rs2255726	chr5:56243128	T/C	cg12654349	chr5:56205094	C5orf35	0.57	9.87	0.42	5.39e-21	Initial pursuit acceleration;
LGG	trans	rs7246760	0.867	rs35416342	chr19:9779058	A/G	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.11e-21	Lung cancer;
LGG	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg13147721	chr7:65941812	NA	0.84	10.18	0.43	4.21e-22	Diabetic kidney disease;
LGG	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.35	-0.32	8.82e-13	Initial pursuit acceleration;
LGG	cis	rs9863	0.861	rs11835839	chr12:124431049	G/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.04	-0.31	7.01e-12	White blood cell count;
LGG	cis	rs155076	0.711	rs4769158	chr13:21881975	T/C	cg06138931	chr13:21896616	NA	0.51	8.49	0.37	2.91e-16	White matter hyperintensity burden;
LGG	trans	rs1814175	0.616	rs847641	chr11:49919261	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	cis	rs7523273	0.606	rs12401619	chr1:207976276	G/C	cg22525895	chr1:207977042	MIR29B2	-0.64	-12.66	-0.51	9.79e-32	Schizophrenia;
LGG	cis	rs11874712	0.931	rs8095031	chr18:43666861	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs7566780	0.548	rs11889461	chr2:16700727	A/G	cg09580478	chr2:16689509	NA	0.46	7.28	0.32	1.47e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs5758511	0.680	rs5758681	chr22:42645091	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.47	7.76	0.34	5.62e-14	Birth weight;
LGG	cis	rs887829	0.641	rs10197460	chr2:234589190	G/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.5	-0.37	2.6e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs10876993	0.855	rs1678520	chr12:58049319	C/G	cg18357645	chr12:58087776	OS9	0.69	12.25	0.49	4.61e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs2839186	0.609	rs2839189	chr21:47694357	C/T	cg12379764	chr21:47803548	PCNT	0.66	10.53	0.44	2.2e-23	Testicular germ cell tumor;
LGG	cis	rs10911232	0.507	rs10911195	chr1:182993438	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.23e-21	Hypertriglyceridemia;
LGG	cis	rs3816183	0.680	rs7585445	chr2:43083070	C/T	cg14631114	chr2:43023945	NA	0.45	8.04	0.35	7.4e-15	Hypospadias;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16927796	chr22:29886713	NEFH	-0.65	-7.81	-0.34	3.82e-14	Intelligence (multi-trait analysis);
LGG	cis	rs472402	0.580	rs11738248	chr5:6657494	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.42	-6.71	-0.3	5.57e-11	Response to amphetamines;
LGG	cis	rs1577917	1.000	rs12209127	chr6:86724427	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.15	-0.43	5.42e-22	Response to antipsychotic treatment;
LGG	cis	rs7166081	1.000	rs8038652	chr15:67552064	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.79	-0.3	3.47e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3849046	0.817	rs6596438	chr5:137905448	T/G	cg10920316	chr5:137946599	NA	0.43	6.99	0.31	9.88e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg02487422	chr3:49467188	NICN1	0.39	6.8	0.3	3.29e-11	Menarche (age at onset);
LGG	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.98	-0.35	1.19e-14	Monocyte count;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs1847202	0.826	rs11925587	chr3:72952227	A/G	cg25664220	chr3:72788482	NA	0.23	6.83	0.3	2.71e-11	Motion sickness;
LGG	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs826838	0.967	rs1684415	chr12:39130099	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs4262150	0.846	rs72797296	chr5:152044445	G/A	cg12297329	chr5:152029980	NA	-0.82	-15.97	-0.6	4.59e-46	Bipolar disorder and schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03909821	chr3:150422049	FAM194A	-0.49	-7.29	-0.32	1.39e-12	Systemic lupus erythematosus;
LGG	cis	rs7572733	0.534	rs13026569	chr2:198783330	C/G	cg00792783	chr2:198669748	PLCL1	-0.68	-11.05	-0.46	2.39e-25	Dermatomyositis;
LGG	cis	rs1129187	0.967	rs11752813	chr6:42928017	C/G	cg02353165	chr6:42928485	GNMT	0.52	16.09	0.6	1.4300000000000001e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs367943	0.712	rs9326889	chr5:112731438	A/G	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.29e-23	Type 2 diabetes;
LGG	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg04568710	chr12:38710424	ALG10B	0.35	7.38	0.32	7.22e-13	Bladder cancer;
LGG	cis	rs1021993	0.545	rs7548184	chr1:209531600	C/T	cg24446417	chr1:209558027	NA	-0.72	-10.67	-0.44	6.31e-24	Gut microbiome composition (winter);
LGG	cis	rs657075	0.584	rs71583479	chr5:131692152	A/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18830721	chr4:83821700	THAP9	-0.47	-6.89	-0.3	1.81e-11	Systemic lupus erythematosus;
LGG	cis	rs854765	0.547	rs2955372	chr17:17970229	T/C	cg05444541	chr17:17804740	TOM1L2	0.69	16.39	0.61	6.09e-48	Total body bone mineral density;
LGG	cis	rs4363385	1.000	rs10888527	chr1:153001363	G/T	cg07796016	chr1:152779584	LCE1C	0.43	7.34	0.32	9.94e-13	Inflammatory skin disease;
LGG	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg02503808	chr4:7069936	GRPEL1	0.94	13.12	0.52	1.19e-33	Monocyte percentage of white cells;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg21724239	chr8:58056113	NA	0.61	9.12	0.39	2.22e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.625	rs11040006	chr11:48774302	G/A	cg15704280	chr7:45808275	SEPT13	0.49	7.94	0.35	1.57e-14	HDL cholesterol;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.85	0.42	6.78e-21	Height;
LGG	cis	rs9297145	0.585	rs13235218	chr7:98785080	C/T	cg05967295	chr7:98741636	SMURF1	-0.63	-11.09	-0.46	1.68e-25	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg18511798	chr11:2018149	H19;MIR675	0.41	7.64	0.33	1.25e-13	DNA methylation (variation);
LGG	cis	rs6912958	0.535	rs1753153	chr6:88032834	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.71	13.27	0.52	2.82e-34	Monocyte percentage of white cells;
LGG	cis	rs6087990	0.899	rs4911262	chr20:31393352	G/A	cg13636640	chr20:31349939	DNMT3B	0.98	21.57	0.71	6.22e-72	Ulcerative colitis;
LGG	cis	rs2594989	0.670	rs9845397	chr3:11470263	C/T	cg01796438	chr3:11312864	ATG7	-0.56	-7.56	-0.33	2.23e-13	Circulating chemerin levels;
LGG	cis	rs6580649	1.000	rs9805048	chr12:48403692	C/T	cg24011408	chr12:48396354	COL2A1	0.65	8.37	0.36	6.66e-16	Lung cancer;
LGG	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg06453172	chr10:134556979	INPP5A	-0.51	-7.82	-0.34	3.65e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.35	-8.19	-0.36	2.48e-15	Schizophrenia;
LGG	cis	rs6964587	0.620	rs6967588	chr7:91643402	G/T	cg17063962	chr7:91808500	NA	0.49	9.21	0.39	1.18e-18	Breast cancer;
LGG	cis	rs7630877	0.719	rs1524514	chr3:179673066	T/C	cg18765712	chr3:179670323	PEX5L	0.44	7.04	0.31	6.88e-12	Type 2 diabetes;
LGG	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.6	0.33	1.64e-13	Neuroticism;
LGG	cis	rs1451375	1.000	rs4452748	chr7:50625056	A/C	cg20336341	chr7:50628841	DDC	-0.38	-7.23	-0.32	1.96e-12	Malaria;
LGG	cis	rs1385374	0.858	rs10847697	chr12:129299385	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	6.92	0.31	1.49e-11	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg05368731	chr17:41323189	NBR1	0.94	18.66	0.66	2.28e-58	Menopause (age at onset);
LGG	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg03342759	chr3:160939853	NMD3	0.63	11.15	0.46	9.64e-26	Morning vs. evening chronotype;
LGG	cis	rs4731207	0.698	rs6960683	chr7:124530368	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs3540	0.574	rs2601205	chr15:90961813	A/G	cg22089800	chr15:90895588	ZNF774	0.68	12.35	0.5	1.79e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs10078	0.571	rs2671890	chr5:456457	A/G	cg24955955	chr5:415729	AHRR	0.81	10.87	0.45	1.2e-24	Fat distribution (HIV);
LGG	cis	rs933688	0.532	rs997737	chr5:90567031	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.57	-7.21	-0.32	2.24e-12	Smoking behavior;
LGG	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.23e-56	White matter hyperintensity burden;
LGG	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg15454534	chr1:248569605	OR2T1	0.38	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg20607798	chr8:58055168	NA	0.68	7.7	0.34	8.4e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg08355456	chr11:67383691	NA	0.49	8.41	0.36	5.25e-16	Mean corpuscular volume;
LGG	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg05753993	chr18:77199432	NFATC1	0.36	6.78	0.3	3.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6669919	0.653	rs10863908	chr1:211685097	G/A	cg10512769	chr1:211675356	NA	-0.69	-14.47	-0.56	2.12e-39	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07243700	chr1:100731457	RTCD1	0.4	7.08	0.31	5.26e-12	Gut microbiome composition (summer);
LGG	cis	rs8062405	1.000	rs62036620	chr16:28833097	A/G	cg09754948	chr16:28834200	ATXN2L	0.5	7.93	0.35	1.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4889855	0.614	rs6565694	chr17:78501101	T/C	cg16591659	chr17:78472290	NA	-0.4	-9.1	-0.39	2.6e-18	Fractional excretion of uric acid;
LGG	cis	rs7511006	1.000	rs7511006	chr22:50676259	T/C	cg16473166	chr22:50639996	SELO	0.58	9.78	0.41	1.2e-20	Obesity-related traits;
LGG	cis	rs1580019	0.563	rs764483	chr7:32578150	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.08	26.95	0.78	6.84e-97	Cognitive ability;
LGG	cis	rs78456975	0.506	rs10206900	chr2:1552841	T/C	cg26248373	chr2:1572462	NA	-0.89	-14.5	-0.56	1.57e-39	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7944584	0.588	rs2697923	chr11:47363215	G/T	cg20307385	chr11:47447363	PSMC3	-0.66	-13.3	-0.53	2.03e-34	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4671458	0.626	rs75934274	chr2:63748815	T/G	cg17519650	chr2:63277830	OTX1	-0.54	-7.25	-0.32	1.73e-12	Subjective well-being;
LGG	cis	rs864537	0.646	rs1723016	chr1:167433056	T/C	cg09179987	chr1:167433047	CD247	0.46	10.55	0.44	1.84e-23	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs10489202	0.608	rs35059151	chr1:168079393	C/A	cg24449463	chr1:168025552	DCAF6	-0.56	-10.03	-0.42	1.47e-21	Schizophrenia;
LGG	trans	rs12517041	1.000	rs6859293	chr5:23312935	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.8	-0.48	2.79e-28	Calcium levels;
LGG	cis	rs4555082	0.874	rs2816620	chr14:105732704	G/T	cg10792982	chr14:105748885	BRF1	0.67	13.16	0.52	7.88e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg07120314	chr15:79043507	NA	-0.77	-19.23	-0.67	5.09e-61	Coronary artery disease or large artery stroke;
LGG	cis	rs10751667	0.714	rs7933889	chr11:972270	C/T	cg22143635	chr11:980567	AP2A2	0.45	8.26	0.36	1.52e-15	Alzheimer's disease (late onset);
LGG	cis	rs9325144	0.600	rs10748442	chr12:38732939	A/T	cg04568710	chr12:38710424	ALG10B	0.4	8.46	0.37	3.65e-16	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg04287289	chr16:89883240	FANCA	0.9	8.75	0.38	4.1e-17	Skin colour saturation;
LGG	cis	rs1008375	1.000	rs2315556	chr4:17670861	T/C	cg18681998	chr4:17616180	MED28	0.82	18.22	0.65	2.57e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.38e-12	Vitiligo;
LGG	cis	rs2346160	0.867	rs2989555	chr6:167704244	C/T	cg20683250	chr6:167653907	NA	-0.42	-6.88	-0.3	1.98e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9783347	1.000	rs10734259	chr11:18314865	A/G	cg15585147	chr11:18324498	HPS5	0.44	9.2	0.39	1.24e-18	Pancreatic cancer;
LGG	cis	rs1552244	0.872	rs115331527	chr3:10154504	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.09	0.39	2.95e-18	Alzheimer's disease;
LGG	cis	rs524281	0.647	rs2302883	chr11:65824994	T/C	cg16950941	chr11:66035639	RAB1B	-0.53	-8.43	-0.36	4.38e-16	Electroencephalogram traits;
LGG	cis	rs2153535	0.584	rs9502721	chr6:8541379	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.58	0.5	2.1e-31	Motion sickness;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg11859384	chr17:80120422	CCDC57	0.45	7.84	0.34	3.17e-14	Life satisfaction;
LGG	cis	rs12545109	1.000	rs2217957	chr8:57313360	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.92	-0.31	1.53e-11	Obesity-related traits;
LGG	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg05768032	chr16:30646687	NA	0.42	7.13	0.31	3.83e-12	Multiple myeloma;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg00306905	chr10:121356070	TIAL1	0.45	7.45	0.33	4.55e-13	Corneal astigmatism;
LGG	cis	rs4481887	0.861	rs4497248	chr1:248450525	T/C	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.58e-15	Common traits (Other);
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.55	0.47	2.66e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.862	rs6955837	chr7:66043142	C/T	cg11764359	chr7:65958608	NA	-0.74	-13.25	-0.52	3.26e-34	Aortic root size;
LGG	cis	rs13314892	0.728	rs74956589	chr3:69886006	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.87	-0.34	2.49e-14	QRS complex (12-leadsum);
LGG	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg08885076	chr2:99613938	TSGA10	-0.43	-8.15	-0.35	3.55e-15	Chronic sinus infection;
LGG	cis	rs78366141	0.649	rs76884708	chr4:89692043	G/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.24	0.36	1.77e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7552404	1.000	rs12126607	chr1:76217097	G/A	cg03433033	chr1:76189801	ACADM	0.77	13.25	0.52	3.27e-34	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4974559	0.895	rs28493051	chr4:1331030	A/C	cg02980000	chr4:1222292	CTBP1	0.67	9.92	0.42	3.8e-21	Systolic blood pressure;
LGG	cis	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg27411982	chr8:10470053	RP1L1	0.42	7.31	0.32	1.17e-12	Neuroticism;
LGG	cis	rs6450176	0.625	rs3822499	chr5:53289459	C/G	ch.5.1024479R	chr5:53302184	ARL15	-0.86	-13.62	-0.53	9.21e-36	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.28	-0.32	1.47e-12	HDL cholesterol;
LGG	cis	rs2404602	0.692	rs7174673	chr15:77071998	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.78	-0.3	3.68e-11	Blood metabolite levels;
LGG	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg11317459	chr13:21872234	NA	-1.19	-19.52	-0.67	2.25e-62	White matter hyperintensity burden;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg13736514	chr6:26305472	NA	-0.45	-9.4	-0.4	2.54e-19	Educational attainment;
LGG	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.93	0.42	3.46e-21	Height;
LGG	cis	rs910187	0.678	rs3818009	chr20:45816514	C/T	cg27589058	chr20:45804311	EYA2	-0.34	-9.03	-0.39	4.54e-18	Migraine;
LGG	cis	rs1552244	1.000	rs66838678	chr3:10150350	G/A	cg13047869	chr3:10149882	C3orf24	0.54	9.03	0.39	4.68e-18	Alzheimer's disease;
LGG	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Colorectal cancer;
LGG	cis	rs9303401	0.592	rs66583824	chr17:56639853	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs11112613	0.653	rs941101	chr12:105937098	T/G	cg03607813	chr12:105948248	NA	0.63	10.54	0.44	2.03e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs7395662	0.677	rs10839110	chr11:48839960	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.03	-0.35	8.24e-15	HDL cholesterol;
LGG	cis	rs6540556	0.768	rs6692012	chr1:209935490	A/G	cg23920097	chr1:209922102	NA	-0.45	-8.0	-0.35	1.01e-14	Red blood cell count;
LGG	cis	rs7953508	0.506	rs2200160	chr12:93963873	C/T	cg18151635	chr12:93972918	NA	-0.56	-10.58	-0.44	1.37e-23	Pubertal anthropometrics;
LGG	cis	rs703842	0.616	rs4760332	chr12:58222672	A/C	cg00677455	chr12:58241039	CTDSP2	-0.42	-7.56	-0.33	2.11e-13	Multiple sclerosis;
LGG	cis	rs17221829	0.733	rs11018689	chr11:89367791	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs7208859	0.623	rs3752021	chr17:29111043	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3540	0.512	rs3862437	chr15:91084632	A/G	cg22089800	chr15:90895588	ZNF774	-0.66	-12.2	-0.49	7e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs8062405	0.754	rs3859172	chr16:28566158	G/T	cg00198680	chr16:28758506	NA	0.3	7.54	0.33	2.55e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4819052	0.679	rs8132135	chr21:46694782	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.4	6.65	0.3	8.2e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7552404	0.691	rs61770550	chr1:76366966	C/T	cg22875332	chr1:76189707	ACADM	0.59	8.77	0.38	3.42e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9325144	0.625	rs11534879	chr12:38968165	A/G	cg26384229	chr12:38710491	ALG10B	-0.73	-13.86	-0.54	8.45e-37	Morning vs. evening chronotype;
LGG	cis	rs1609391	0.567	rs835633	chr3:136676496	T/C	cg12473912	chr3:136751656	NA	0.43	7.64	0.33	1.29e-13	Neuroticism;
LGG	cis	rs7044106	0.762	rs10760110	chr9:123412563	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.85	-16.56	-0.61	1.05e-48	Hip circumference adjusted for BMI;
LGG	cis	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg19847130	chr8:10466454	RP1L1	0.35	7.31	0.32	1.15e-12	Neuroticism;
LGG	trans	rs2562456	0.793	rs73537884	chr19:21504710	A/G	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.28	-0.53	2.44e-34	Alzheimer's disease;
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00292662	chr22:38071168	LGALS1	0.89	23.96	0.74	4.09e-83	Fat distribution (HIV);
LGG	trans	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg16141378	chr3:129829833	LOC729375	0.45	10.65	0.44	7.69e-24	Mood instability;
LGG	cis	rs2708240	0.967	rs2710098	chr7:147574672	G/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs240764	0.635	rs7773043	chr6:100921115	G/A	cg21058520	chr6:100914733	NA	0.45	7.97	0.35	1.25e-14	Neuroticism;
LGG	cis	rs17092148	0.652	rs4911154	chr20:32996101	A/G	cg12302830	chr20:33297742	TP53INP2	-0.4	-6.66	-0.3	7.98e-11	Neuroticism;
LGG	cis	rs10155981	0.510	rs10255241	chr7:22593806	C/T	cg05062323	chr7:22590069	NA	-0.79	-9.84	-0.42	7.42e-21	Bilirubin levels;
LGG	cis	rs9818758	0.607	rs9880088	chr3:49178990	G/A	cg00383909	chr3:49044727	WDR6	1.01	12.61	0.51	1.57e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs72945132	0.825	rs2298411	chr11:70206046	G/A	cg14191688	chr11:70257035	CTTN	0.55	7.94	0.35	1.52e-14	Coronary artery disease;
LGG	trans	rs8002861	0.935	rs1822969	chr13:44418164	G/A	cg17145862	chr1:211918768	LPGAT1	0.98	25.48	0.76	3.72e-90	Leprosy;
LGG	cis	rs5769765	1.000	rs5769764	chr22:50270784	G/A	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg02002194	chr4:3960332	NA	0.38	6.73	0.3	5e-11	Neuroticism;
LGG	trans	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.37	-0.36	6.69e-16	Breast cancer;
LGG	trans	rs453301	0.658	rs9650616	chr8:8869199	T/G	cg16141378	chr3:129829833	LOC729375	0.33	7.43	0.33	5.16e-13	Joint mobility (Beighton score);
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg08645402	chr16:4508243	NA	0.48	8.16	0.35	3.14e-15	Schizophrenia;
LGG	cis	rs4740619	0.846	rs7046351	chr9:15664421	T/A	cg14451791	chr9:16040625	NA	0.34	8.81	0.38	2.58e-17	Body mass index;
LGG	cis	rs2267681	0.603	rs2267679	chr7:139539218	C/T	cg14116596	chr7:139528673	TBXAS1	0.33	7.34	0.32	9.64e-13	Cervical cancer;
LGG	cis	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg13010199	chr12:38710504	ALG10B	0.65	13.3	0.53	2.02e-34	Bladder cancer;
LGG	cis	rs61931739	0.929	rs10844740	chr12:34067930	C/T	cg06521331	chr12:34319734	NA	0.42	7.65	0.33	1.2e-13	Morning vs. evening chronotype;
LGG	cis	rs3750082	0.632	rs7811630	chr7:32960718	C/A	cg08946731	chr7:32981826	RP9P	0.47	6.99	0.31	9.91e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs10088262	0.527	rs3911939	chr8:124793744	T/G	cg15047889	chr8:124780837	FAM91A1	-0.52	-7.26	-0.32	1.63e-12	Pancreatic cancer;
LGG	cis	rs2652834	0.851	rs2729823	chr15:63420660	A/G	cg05507819	chr15:63340323	TPM1	0.51	7.15	0.32	3.38e-12	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.32	-0.32	1.13e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7819412	0.668	rs920047	chr8:11087475	C/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.14	-0.31	3.74e-12	Triglycerides;
LGG	trans	rs9858542	0.953	rs9841110	chr3:49492481	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.46	-0.37	3.41e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1008375	1.000	rs12648232	chr4:17612537	C/T	cg04450456	chr4:17643702	FAM184B	-0.32	-6.9	-0.31	1.68e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4132509	1.000	rs10927043	chr1:243762208	C/T	cg25706552	chr1:244017396	NA	0.51	8.22	0.36	2.07e-15	RR interval (heart rate);
LGG	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.57	-9.63	-0.41	3.94e-20	Blood metabolite levels;
LGG	cis	rs651907	0.535	rs17412601	chr3:101499275	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.64	0.51	1.12e-31	Colorectal cancer;
LGG	cis	rs6582630	0.555	rs10880611	chr12:38509316	C/G	cg13010199	chr12:38710504	ALG10B	0.7	14.76	0.57	1.06e-40	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs9815354	0.812	rs73069390	chr3:41785513	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.1	0.39	2.7e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1920116	0.778	rs11717389	chr3:169566247	T/C	cg08193579	chr3:169529701	LRRC34	0.42	7.35	0.32	9.33e-13	Glioma (high-grade);
LGG	cis	rs9790314	0.875	rs55688744	chr3:160944222	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.2	-0.49	6.81e-30	Morning vs. evening chronotype;
LGG	cis	rs72772090	0.539	rs11748519	chr5:96119328	C/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9513627	1.000	rs6491511	chr13:100198717	C/A	cg25919922	chr13:100150906	NA	0.74	7.67	0.34	9.98e-14	Obesity-related traits;
LGG	cis	rs5742933	0.857	rs2289226	chr2:190526205	A/G	cg04003228	chr2:190539410	ANKAR	0.55	8.01	0.35	9.6e-15	Ferritin levels;
LGG	cis	rs2732480	0.500	rs12829841	chr12:48628739	A/G	cg21466736	chr12:48725269	NA	-0.37	-7.43	-0.33	5.14e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.42	-0.4	2.17e-19	Lung cancer;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg16507663	chr6:150244633	RAET1G	-0.43	-8.11	-0.35	4.61e-15	Lung cancer;
LGG	cis	rs4731207	0.596	rs2402763	chr7:124709732	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.12	-0.31	4.26e-12	Cutaneous malignant melanoma;
LGG	cis	rs7927771	0.542	rs6485775	chr11:47773518	A/G	cg20307385	chr11:47447363	PSMC3	-0.56	-10.84	-0.45	1.51e-24	Subjective well-being;
LGG	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg13009111	chr11:71350975	NA	0.35	7.76	0.34	5.33e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2732480	0.557	rs2634682	chr12:48732943	T/C	cg21466736	chr12:48725269	NA	-0.4	-8.04	-0.35	7.57e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs939658	0.728	rs12904323	chr15:79412583	A/C	cg17916960	chr15:79447300	NA	-0.63	-12.0	-0.49	4.68e-29	Refractive error;
LGG	cis	rs1005277	0.557	rs2983338	chr10:38550734	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.23	-0.32	1.96e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03183872	chr20:3140552	FASTKD5;UBOX5	0.48	7.84	0.34	3.14e-14	Cognitive performance;
LGG	cis	rs3219090	0.886	rs2377013	chr1:226600665	C/A	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	trans	rs1493916	0.837	rs9952002	chr18:31414314	C/G	cg04226714	chr8:49833948	SNAI2	-0.44	-7.94	-0.35	1.5e-14	Life satisfaction;
LGG	cis	rs1267303	0.675	rs2476164	chr1:46985274	T/C	cg25110126	chr1:46999211	NA	-0.51	-8.49	-0.37	2.75e-16	Monobrow;
LGG	cis	rs3087591	0.887	rs1013946	chr17:29530350	A/C	cg24425628	chr17:29625626	OMG;NF1	0.69	14.45	0.56	2.6e-39	Hip circumference;
LGG	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs10791323	0.604	rs2257010	chr11:133712348	G/A	cg06766960	chr11:133703094	NA	-0.56	-10.88	-0.45	1.07e-24	Childhood ear infection;
LGG	cis	rs9616064	0.531	rs66909472	chr22:47050210	G/A	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.87	-0.3	2.06e-11	Urate levels in obese individuals;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg04287289	chr16:89883240	FANCA	0.88	8.38	0.36	6.51e-16	Skin colour saturation;
LGG	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg05890377	chr2:74357713	NA	-0.41	-7.64	-0.33	1.25e-13	Gestational age at birth (maternal effect);
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs2058338	chr4:17678600	A/G	cg02297831	chr4:17616191	MED28	-0.51	-9.75	-0.41	1.48e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9354308	0.714	rs9294668	chr6:66598877	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs3008870	1.000	rs912797	chr1:67413478	A/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.35	0.74	2.84e-80	Lymphocyte percentage of white cells;
LGG	cis	rs2018055	0.644	rs13195673	chr6:117801639	A/G	cg14611402	chr6:117803162	DCBLD1	0.3	8.88	0.38	1.44e-17	Diastolic blood pressure;
LGG	cis	rs988958	0.526	rs2119171	chr2:42254637	T/G	cg19376973	chr2:42229025	NA	0.63	9.4	0.4	2.6e-19	Hypospadias;
LGG	cis	rs477692	0.905	rs563859	chr10:131417586	T/C	cg05714579	chr10:131428358	MGMT	0.67	14.32	0.55	9.25e-39	Response to temozolomide;
LGG	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg03342759	chr3:160939853	NMD3	0.44	7.29	0.32	1.35e-12	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg17376030	chr22:41985996	PMM1	-0.56	-9.09	-0.39	2.96e-18	Vitiligo;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg11062466	chr8:58055876	NA	0.47	8.17	0.36	2.92e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9329289	0.510	rs35854428	chr10:2554280	T/C	cg15501526	chr10:2543763	NA	0.48	9.07	0.39	3.46e-18	Age-related hearing impairment;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs875971	1.000	rs6961717	chr7:65587537	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.54	0.37	1.91e-16	Aortic root size;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4.2e-19	Life satisfaction;
LGG	cis	rs12701220	0.901	rs12701708	chr7:1090333	C/T	cg20821713	chr7:1055600	C7orf50	-0.51	-8.17	-0.35	2.98e-15	Bronchopulmonary dysplasia;
LGG	cis	rs4901847	0.868	rs8008786	chr14:58546110	C/A	cg15908186	chr14:58618357	C14orf37	0.52	9.15	0.39	1.87e-18	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17453880	0.890	rs11167585	chr5:152029577	A/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs11792861	0.926	rs58795279	chr9:111851902	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.45	0.4	1.68e-19	Menarche (age at onset);
LGG	cis	rs1045714	0.895	rs61729413	chr7:2646796	G/A	cg14042143	chr7:2646782	IQCE	0.8	12.45	0.5	6.83e-31	Urate levels in lean individuals;
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg21248554	chr2:27665150	KRTCAP3	0.25	6.69	0.3	6.29e-11	Total body bone mineral density;
LGG	trans	rs9393777	0.920	rs34953377	chr6:27381660	T/C	cg08344181	chr3:125677491	NA	-0.8	-8.05	-0.35	7.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11159840	0.588	rs10782474	chr14:88597021	C/T	cg18078958	chr14:88630771	NA	-0.28	-6.67	-0.3	7.26e-11	Left ventricular obstructive tract defect (inherited effect);
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg00976097	chr5:421733	AHRR	-0.47	-7.71	-0.34	7.92e-14	Cystic fibrosis severity;
LGG	cis	rs7107174	1.000	rs10899458	chr11:78007451	A/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25976786	chr12:53662079	ESPL1	0.39	6.76	0.3	4.17e-11	Bipolar disorder;
LGG	cis	rs2290159	0.752	rs3773352	chr3:12651982	G/C	cg23032965	chr3:12705835	RAF1	0.67	9.72	0.41	1.97e-20	Cholesterol, total;
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07343612	chr16:622815	PIGQ	-0.76	-15.73	-0.59	5.55e-45	Height;
LGG	cis	rs4819052	0.851	rs13047104	chr21:46673562	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.88	0.38	1.43e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg20578329	chr17:80767326	TBCD	-0.73	-11.44	-0.47	7.41e-27	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs644799	1.000	rs527899	chr11:95529242	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.66	-0.37	8.2e-17	Blood pressure (smoking interaction);
LGG	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.7	-0.34	8.12e-14	Calcium levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00239003	chr19:45458398	CLPTM1	0.42	6.71	0.3	5.72e-11	Cognitive performance;
LGG	trans	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg02030672	chr11:45687055	CHST1	0.5	8.85	0.38	1.8e-17	Obesity-related traits;
LGG	trans	rs2727020	0.729	rs10742932	chr11:49173234	T/C	cg03929089	chr4:120376271	NA	-0.87	-17.35	-0.63	2.58e-52	Coronary artery disease;
LGG	cis	rs2179367	0.959	rs237034	chr6:149711862	A/T	cg14343457	chr6:149716235	MAP3K7IP2	-0.8	-11.74	-0.48	5.02e-28	Dupuytren's disease;
LGG	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg05775895	chr3:12838266	CAND2	0.64	11.41	0.47	9.9e-27	QRS complex (12-leadsum);
LGG	cis	rs2576037	0.583	rs4890698	chr18:44489725	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.8	-0.38	2.74e-17	Personality dimensions;
LGG	cis	rs2668423	0.960	rs2668427	chr19:1372132	C/T	cg02639931	chr19:1387894	NDUFS7	-0.83	-14.26	-0.55	1.59e-38	Nonalcoholic fatty liver disease;
LGG	cis	rs453301	0.538	rs7830804	chr8:8970762	G/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.79	-0.3	3.41e-11	Joint mobility (Beighton score);
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.12	-0.46	1.25e-25	Obesity-related traits;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg19673125	chr6:150240577	RAET1G	0.37	9.07	0.39	3.42e-18	Testicular germ cell tumor;
LGG	cis	rs7572644	0.680	rs12465012	chr2:28028191	C/T	cg27432699	chr2:27873401	GPN1	0.48	7.02	0.31	7.76e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs6121246	0.697	rs45557936	chr20:30226690	G/A	cg13852791	chr20:30311386	BCL2L1	0.69	10.22	0.43	3.14e-22	Mean corpuscular hemoglobin;
LGG	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg23205692	chr1:25664452	TMEM50A	-0.48	-10.12	-0.43	6.74e-22	Erythrocyte sedimentation rate;
LGG	cis	rs1519814	1.000	rs1519814	chr8:121115024	T/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.41	-0.47	9.52e-27	Breast cancer;
LGG	cis	rs1570884	0.516	rs7330830	chr13:50167929	T/A	cg08779649	chr13:50194554	NA	0.36	9.09	0.39	2.98e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7647973	1.000	rs3448	chr3:49396751	T/C	cg06212747	chr3:49208901	KLHDC8B	0.49	7.7	0.34	8.31e-14	Menarche (age at onset);
LGG	cis	rs11971779	0.648	rs4732367	chr7:139028102	A/C	cg07862535	chr7:139043722	LUC7L2	0.41	6.77	0.3	3.92e-11	Diisocyanate-induced asthma;
LGG	cis	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.7	-0.3	6.11e-11	Triglycerides;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg05896524	chr21:47604654	C21orf56	0.55	9.62	0.41	4.38e-20	Testicular germ cell tumor;
LGG	cis	rs12612619	0.579	rs6753540	chr2:27080134	G/A	cg12045002	chr2:27069975	DPYSL5	-0.32	-7.02	-0.31	7.99e-12	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs36051895	0.623	rs7027871	chr9:5236822	C/G	cg02405213	chr9:5042618	JAK2	0.77	13.74	0.54	2.76e-36	Pediatric autoimmune diseases;
LGG	cis	rs9467773	0.587	rs3208733	chr6:26414425	C/T	cg09904177	chr6:26538194	HMGN4	-0.44	-7.91	-0.34	1.95e-14	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.37	-0.56	5.71e-39	Tonsillectomy;
LGG	cis	rs2361718	0.501	rs12944619	chr17:78144109	T/C	cg21238619	chr17:78079768	GAA	-0.49	-9.05	-0.39	3.87e-18	Yeast infection;
LGG	cis	rs72781680	0.898	rs12620558	chr2:23936022	G/A	cg08917208	chr2:24149416	ATAD2B	0.86	9.24	0.39	8.88e-19	Lymphocyte counts;
LGG	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.77	0.41	1.27e-20	Hypertriglyceridemia;
LGG	cis	rs17376456	1.000	rs13185608	chr5:93509688	T/G	cg21475434	chr5:93447410	FAM172A	0.73	7.38	0.32	7.28e-13	Diabetic retinopathy;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg11878867	chr6:150167359	LRP11	-0.39	-8.15	-0.35	3.55e-15	Testicular germ cell tumor;
LGG	cis	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg24375607	chr4:120327624	NA	0.55	9.91	0.42	4.07e-21	Corneal astigmatism;
LGG	cis	rs2576037	1.000	rs2576037	chr18:44585420	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.48	7.98	0.35	1.14e-14	Personality dimensions;
LGG	cis	rs11758351	0.925	rs10452600	chr6:26192502	C/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs2732480	0.523	rs34286639	chr12:48629044	C/T	cg24011408	chr12:48396354	COL2A1	0.52	8.31	0.36	1.09e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs9291683	0.935	rs1860911	chr4:10275057	C/T	cg26043149	chr18:55253948	FECH	0.44	7.58	0.33	1.87e-13	Bone mineral density;
LGG	cis	rs2074585	0.517	rs11637971	chr15:91079863	A/C	cg22089800	chr15:90895588	ZNF774	-0.52	-8.68	-0.37	6.72e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7927771	0.864	rs7107726	chr11:47429245	T/A	cg20307385	chr11:47447363	PSMC3	-0.58	-10.51	-0.44	2.68e-23	Subjective well-being;
LGG	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.55	-0.33	2.35e-13	IgG glycosylation;
LGG	cis	rs3219090	0.924	rs1828445	chr1:226601401	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.34	0.5	1.85e-30	Melanoma;
LGG	cis	rs4788570	0.566	rs8056735	chr16:71502483	A/G	cg06353428	chr16:71660113	MARVELD3	-0.86	-12.0	-0.49	4.57e-29	Intelligence (multi-trait analysis);
LGG	cis	rs4901847	0.678	rs8022677	chr14:58557349	T/C	cg15908186	chr14:58618357	C14orf37	0.41	7.14	0.31	3.61e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01423820	chr14:77228690	VASH1	0.55	9.47	0.4	1.43e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs2251381	0.722	rs2251278	chr21:30529234	A/G	cg24692254	chr21:30365293	RNF160	0.83	17.09	0.62	3.88e-51	Selective IgA deficiency;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg22604940	chr3:20227925	SGOL1	-0.43	-6.82	-0.3	2.9100000000000002e-11	Coronary artery disease;
LGG	cis	rs10979	1.000	rs9496673	chr6:143885393	C/G	cg25407410	chr6:143891975	LOC285740	-0.71	-12.51	-0.5	3.85e-31	Hypospadias;
LGG	cis	rs9649465	1.000	rs3807635	chr7:123382152	A/C	cg03229431	chr7:123269106	ASB15	-0.39	-8.62	-0.37	1.04e-16	Migraine;
LGG	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg01324343	chr3:183735012	ABCC5	-0.65	-12.8	-0.51	2.61e-32	Anterior chamber depth;
LGG	cis	rs737693	1.000	rs72983508	chr11:102727409	C/A	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1322639	0.614	rs6903921	chr6:169563957	C/T	cg03254818	chr6:169586852	NA	0.52	8.06	0.35	6.52e-15	Pulse pressure;
LGG	cis	rs7928758	0.943	rs7929612	chr11:134268634	C/T	cg15243474	chr11:134282918	B3GAT1	1.13	15.11	0.57	3.05e-42	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.77e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs12210905	1.000	rs12205921	chr6:27113540	G/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs3816183	0.720	rs2119020	chr2:43064334	T/A	cg14631114	chr2:43023945	NA	0.45	8.13	0.35	4.08e-15	Hypospadias;
LGG	cis	rs4704846	1.000	rs6555851	chr5:156539271	G/A	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	trans	rs62103177	0.810	rs62103192	chr18:77629050	A/T	cg05926928	chr17:57297772	GDPD1	1.36	21.6	0.71	4.56e-72	Opioid sensitivity;
LGG	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg21479132	chr6:26055353	NA	0.8	7.29	0.32	1.32e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.32	0.36	1.02e-15	Tonsillectomy;
LGG	cis	rs10901296	0.660	rs2772033	chr9:133757080	G/A	cg13397898	chr9:133768931	QRFP	0.42	8.14	0.35	3.68e-15	Bilirubin levels;
LGG	cis	rs9942416	0.650	rs2640646	chr5:74977458	A/T	cg19683494	chr5:74908142	NA	-0.44	-6.89	-0.31	1.78e-11	Age-related disease endophenotypes;
LGG	cis	rs2072499	0.865	rs2758608	chr1:156202860	A/T	cg25208724	chr1:156163844	SLC25A44	1.07	22.24	0.72	4.28e-75	Testicular germ cell tumor;
LGG	cis	rs11098499	0.657	rs71614442	chr4:120379346	C/T	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg15017067	chr4:17643749	FAM184B	0.31	7.23	0.32	2.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.699	rs12498956	chr4:9950705	G/T	cg08250081	chr4:10125330	NA	-0.37	-7.2	-0.32	2.43e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg19077165	chr18:44547161	KATNAL2	-0.59	-10.95	-0.45	5.6e-25	Personality dimensions;
LGG	cis	rs368123	1.000	rs649587	chr6:160718374	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs34172651	0.917	rs6497760	chr16:24806535	G/A	cg00339695	chr16:24857497	SLC5A11	0.34	6.79	0.3	3.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg11266682	chr4:10021025	SLC2A9	0.53	10.61	0.44	1.11e-23	Bone mineral density;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg05036130	chr6:150231994	NA	0.34	6.74	0.3	4.69e-11	Testicular germ cell tumor;
LGG	cis	rs7219021	0.705	rs1962412	chr17:46970259	T/C	cg16584676	chr17:46985605	UBE2Z	0.44	7.26	0.32	1.61e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs3820068	0.581	rs78175477	chr1:15948091	C/G	cg05660106	chr1:15850417	CASP9	0.84	16.78	0.61	1.04e-49	Systolic blood pressure;
LGG	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg07395648	chr5:131743802	NA	-0.42	-9.21	-0.39	1.16e-18	Blood metabolite levels;
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.41e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.58	-0.37	1.46e-16	Bone mineral density;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03191532	chr2:237032664	AGAP1	0.38	6.95	0.31	1.23e-11	Electrocardiographic conduction measures;
LGG	cis	rs1552244	1.000	rs112509186	chr3:10156533	A/G	cg08888203	chr3:10149979	C3orf24	0.56	9.43	0.4	2.04e-19	Alzheimer's disease;
LGG	cis	rs7590720	1.000	rs4674058	chr2:216909368	A/G	cg12620499	chr2:216877984	MREG	0.75	13.67	0.54	5.49e-36	Alcohol dependence;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-0.96	-12.64	-0.51	1.14e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg07061783	chr6:25882402	NA	-0.6	-9.77	-0.41	1.22e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3762637	0.941	rs75344200	chr3:122073421	C/T	cg24169773	chr3:122142474	KPNA1	-0.56	-8.83	-0.38	2.13e-17	LDL cholesterol levels;
LGG	cis	rs765787	0.530	rs12323957	chr15:45490773	C/T	cg25801113	chr15:45476975	SHF	-0.89	-19.62	-0.67	8.45e-63	Uric acid levels;
LGG	cis	rs6460942	0.915	rs17541242	chr7:12459068	A/G	cg06484146	chr7:12443880	VWDE	-0.4	-7.25	-0.32	1.75e-12	Coronary artery disease;
LGG	cis	rs9513627	0.915	rs73556179	chr13:100122009	G/A	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs9902453	0.934	rs11080120	chr17:28507021	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.52	0.53	2.49e-35	Coffee consumption (cups per day);
LGG	cis	rs4713118	0.527	rs35949862	chr6:28115367	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Parkinson's disease;
LGG	cis	rs7582180	0.591	rs62148360	chr2:101006319	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.12	-0.49	1.47e-29	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.859	rs10948212	chr6:45156933	A/C	cg18551225	chr6:44695536	NA	-0.62	-9.94	-0.42	3.19e-21	Total body bone mineral density;
LGG	cis	rs736408	0.677	rs1042779	chr3:52821011	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.53	9.16	0.39	1.73e-18	Bipolar disorder;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.74	0.34	6.27e-14	Height;
LGG	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg13271783	chr10:134563150	INPP5A	-0.5	-7.69	-0.34	9.17e-14	Migraine;
LGG	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg10483660	chr13:112241077	NA	-0.36	-7.78	-0.34	4.63e-14	Hepatitis;
LGG	cis	rs868036	1.000	rs4633663	chr15:68106378	G/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs1650123	0.932	rs703627	chr12:104037293	T/A	cg23227824	chr12:103980017	STAB2	0.33	7.41	0.33	6e-13	IgG glycosylation;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg14092988	chr3:52407081	DNAH1	0.29	7.88	0.34	2.37e-14	Electroencephalogram traits;
LGG	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.68e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1978968	0.956	rs7291155	chr22:18444599	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs9393692	0.620	rs9366650	chr6:26335997	G/A	cg13736514	chr6:26305472	NA	-0.47	-9.15	-0.39	1.85e-18	Educational attainment;
LGG	cis	rs6087771	0.642	rs6060411	chr20:30222139	T/C	cg13852791	chr20:30311386	BCL2L1	0.82	13.14	0.52	9.74e-34	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2836974	0.897	rs1984022	chr21:40596085	G/A	cg11890956	chr21:40555474	PSMG1	1.19	29.85	0.81	5.65e-110	Cognitive function;
LGG	cis	rs709400	0.663	rs2273703	chr14:103918029	C/G	cg12935359	chr14:103987150	CKB	-0.4	-6.74	-0.3	4.74e-11	Body mass index;
LGG	cis	rs7827545	1.000	rs6578232	chr8:135565690	G/A	cg09855544	chr8:135498122	ZFAT	0.46	7.81	0.34	3.8e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs8017423	0.967	rs8021881	chr14:90722276	T/C	cg04374321	chr14:90722782	PSMC1	0.89	19.08	0.66	2.56e-60	Mortality in heart failure;
LGG	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg17971929	chr21:40555470	PSMG1	0.89	17.44	0.63	9.64e-53	Cognitive function;
LGG	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.54	-0.33	2.59e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7555523	0.887	rs4657476	chr1:165732661	A/G	cg24409356	chr1:165738333	TMCO1	-0.76	-9.21	-0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs7208859	0.623	rs11657662	chr17:29076347	A/G	cg01831904	chr17:28903510	LRRC37B2	0.81	9.91	0.42	4.15e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7944735	0.567	rs77684932	chr11:48024893	A/G	cg03929089	chr4:120376271	NA	0.7	7.02	0.31	7.87e-12	Intraocular pressure;
LGG	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg16400903	chr5:693638	TPPP	0.46	6.86	0.3	2.16e-11	Obesity-related traits;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.74	0.51	4.23e-32	Prudent dietary pattern;
LGG	cis	rs7216064	0.953	rs11868959	chr17:65840810	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.76	-0.38	3.77e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4595586	0.545	rs12820138	chr12:39357049	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.64	0.33	1.23e-13	Morning vs. evening chronotype;
LGG	cis	rs283228	0.550	rs2787580	chr6:101817317	T/C	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs11711311	0.955	rs12634241	chr3:113397685	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.44	-0.33	4.85e-13	IgG glycosylation;
LGG	cis	rs4665809	0.590	rs4665313	chr2:26415897	A/G	cg08470875	chr2:26401718	FAM59B	-0.43	-8.33	-0.36	9.49e-16	Gut microbiome composition (summer);
LGG	cis	rs67478160	0.595	rs12433109	chr14:104196607	G/A	cg26031613	chr14:104095156	KLC1	-0.52	-8.71	-0.38	5.56e-17	Schizophrenia;
LGG	cis	rs490234	0.902	rs7853181	chr9:128223024	C/T	cg14078157	chr9:128172775	NA	0.37	6.79	0.3	3.55e-11	Mean arterial pressure;
LGG	trans	rs1814175	0.647	rs61306292	chr11:49856040	G/C	cg15704280	chr7:45808275	SEPT13	-1.09	-27.08	-0.78	1.71e-97	Height;
LGG	cis	rs2836974	0.605	rs2836988	chr21:40707975	A/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.31	-0.36	1.08e-15	Cognitive function;
LGG	trans	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg02002194	chr4:3960332	NA	0.41	7.36	0.32	8.6e-13	Neuroticism;
LGG	cis	rs1881396	0.947	rs4666010	chr2:27878686	T/C	cg27432699	chr2:27873401	GPN1	0.59	9.06	0.39	3.69e-18	Nonalcoholic fatty liver disease;
LGG	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg04287289	chr16:89883240	FANCA	-0.44	-7.88	-0.34	2.4e-14	Vitiligo;
LGG	cis	rs7666738	0.791	rs34790496	chr4:98930516	C/T	cg05340658	chr4:99064831	C4orf37	0.48	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6089829	0.851	rs6089827	chr20:61668845	C/T	cg23505145	chr19:12996616	KLF1	0.41	7.36	0.32	8.36e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg25706552	chr1:244017396	NA	0.56	8.9	0.38	1.28e-17	RR interval (heart rate);
LGG	cis	rs35306767	0.761	rs11253537	chr10:1010735	G/A	cg20503657	chr10:835505	NA	0.56	7.36	0.32	8.2e-13	Eosinophil percentage of granulocytes;
LGG	cis	rs12971120	0.891	rs3794955	chr18:72174827	C/T	cg26446133	chr18:72167187	CNDP2	-0.67	-13.37	-0.53	1.04e-34	Refractive error;
LGG	cis	rs2862064	1.000	rs7731951	chr5:156449685	A/T	cg12943317	chr5:156479607	HAVCR1	0.84	10.33	0.43	1.16e-22	Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14941457	chr2:219824293	CDK5R2	0.63	10.05	0.42	1.24e-21	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	8.06e-24	Lung cancer;
LGG	trans	rs7944735	0.507	rs7396592	chr11:48100837	T/C	cg15704280	chr7:45808275	SEPT13	-0.69	-9.86	-0.42	6.23e-21	Intraocular pressure;
LGG	cis	rs7833790	0.654	rs6415652	chr8:82702257	G/A	cg17211192	chr8:82754475	SNX16	-0.68	-11.52	-0.47	3.44e-27	Diastolic blood pressure;
LGG	cis	rs7084402	0.967	rs1658435	chr10:60327527	A/G	cg07615347	chr10:60278583	BICC1	0.62	17.82	0.64	1.89e-54	Refractive error;
LGG	cis	rs3008870	0.755	rs2815368	chr1:67500778	C/T	cg02640540	chr1:67518911	SLC35D1	0.36	6.98	0.31	1.01e-11	Lymphocyte percentage of white cells;
LGG	cis	rs17453880	0.856	rs11953465	chr5:151960536	A/G	cg10931792	chr5:152022470	NA	0.38	8.2	0.36	2.32e-15	Subjective well-being;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg10189774	chr4:17578691	LAP3	0.37	6.73	0.3	5.18e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs62025270	0.632	rs55981798	chr15:86144100	C/G	cg25843651	chr15:86329602	KLHL25	0.54	8.14	0.35	3.73e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs72781680	0.898	rs17509001	chr2:24021231	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs6088580	0.634	rs13041646	chr20:33082881	T/A	cg08999081	chr20:33150536	PIGU	0.39	9.73	0.41	1.73e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1797081	0.967	rs811912	chr10:16859618	G/C	cg22980697	chr10:16874865	CUBN	0.38	7.25	0.32	1.76e-12	Platelet distribution width;
LGG	cis	rs9467160	1.000	rs6922631	chr6:24438734	G/A	cg20631270	chr6:24437470	GPLD1	0.54	7.7	0.34	8.27e-14	Liver enzyme levels;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.17	0.32	2.95e-12	Lung cancer;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-9.75	-0.41	1.54e-20	Lung cancer;
LGG	cis	rs11874712	0.527	rs9807399	chr18:43640714	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.66	-16.07	-0.6	1.66e-46	Migraine - clinic-based;
LGG	cis	rs932287	0.666	rs10840161	chr11:9053824	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.41	8.47	0.37	3.28e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.46	9.18	0.39	1.46e-18	Colorectal cancer;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg21782813	chr7:2030301	MAD1L1	-0.47	-11.28	-0.46	3.12e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs16854884	0.657	rs1979910	chr3:143710268	A/C	cg06585982	chr3:143692056	C3orf58	0.65	11.52	0.47	3.52e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs2479724	0.935	rs1887718	chr6:41857691	C/T	cg17623882	chr6:41773611	USP49	-0.52	-9.28	-0.4	6.38e-19	Menarche (age at onset);
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg24107021	chr13:96297058	DZIP1	-0.43	-6.69	-0.3	6.56e-11	Alzheimer's disease (survival time);
LGG	cis	rs55871839	0.559	rs1448549	chr8:59836138	C/T	cg07426533	chr8:59803705	TOX	0.6	12.5	0.5	4.38e-31	Pneumonia;
LGG	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg02073558	chr3:44770973	ZNF501	0.84	17.89	0.64	8.29e-55	Depressive symptoms;
LGG	cis	rs4969178	0.930	rs12601079	chr17:76400329	G/A	cg20026190	chr17:76395443	PGS1	0.56	9.9	0.42	4.31e-21	HDL cholesterol levels;
LGG	cis	rs28595532	0.920	rs56342843	chr4:119765070	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs17376456	1.000	rs34068652	chr5:93563319	G/A	cg21475434	chr5:93447410	FAM172A	0.72	7.28	0.32	1.48e-12	Diabetic retinopathy;
LGG	cis	rs1799949	0.930	rs4584865	chr17:41424919	C/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.57	-0.37	1.56e-16	Menopause (age at onset);
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.67	-0.37	7.58e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2535633	0.631	rs2710313	chr3:52969529	T/A	cg11645453	chr3:52864694	ITIH4	-0.49	-8.17	-0.36	2.94e-15	Body mass index;
LGG	trans	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg27523141	chr10:43048294	ZNF37B	0.41	8.05	0.35	6.97e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs3768617	0.510	rs10458355	chr1:183063993	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11673391	chr1:10459052	PGD	0.42	7.12	0.31	4.18e-12	Bipolar disorder;
LGG	cis	rs4555082	0.834	rs11849607	chr14:105745383	G/A	cg06808227	chr14:105710500	BRF1	-0.64	-11.05	-0.46	2.41e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg25338242	chr13:114786047	RASA3	0.4	7.24	0.32	1.92e-12	Schizophrenia;
LGG	cis	rs773506	0.628	rs10820836	chr9:93928329	A/G	cg14446406	chr9:93919335	NA	0.64	11.29	0.46	2.74e-26	Type 2 diabetes nephropathy;
LGG	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06634786	chr22:41940651	POLR3H	-0.69	-11.43	-0.47	7.89e-27	Vitiligo;
LGG	cis	rs7937682	0.737	rs679032	chr11:111423286	G/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-18.15	-0.64	5.21e-56	Primary sclerosing cholangitis;
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg00166722	chr3:10149974	C3orf24	0.57	8.08	0.35	5.77e-15	Alzheimer's disease;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg04166393	chr7:2884313	GNA12	0.46	8.65	0.37	8.84e-17	Height;
LGG	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.28	0.4	6.39e-19	Colorectal cancer;
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg23188684	chr11:67383651	NA	-0.51	-8.2	-0.36	2.3e-15	Mean corpuscular volume;
LGG	cis	rs7241530	0.595	rs8094118	chr18:75914266	T/G	cg14642773	chr18:75888474	NA	0.43	8.14	0.35	3.59e-15	Educational attainment (years of education);
LGG	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.02	0.42	1.56e-21	Cognitive ability;
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.5	8.88	0.38	1.48e-17	Longevity;
LGG	trans	rs8002861	0.905	rs12875768	chr13:44428305	C/T	cg12856521	chr11:46389249	DGKZ	-0.4	-6.87	-0.3	2.04e-11	Leprosy;
LGG	cis	rs1881797	1.000	rs67977965	chr1:247687835	G/A	cg21399703	chr1:247681439	NA	0.63	11.27	0.46	3.27e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2247341	0.965	rs2854920	chr4:1715349	C/T	cg08446824	chr4:1720184	TMEM129	-0.69	-13.1	-0.52	1.46e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs12048904	0.619	rs10783153	chr1:101328230	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.83	18.07	0.64	1.33e-55	Multiple sclerosis;
LGG	cis	rs950169	0.763	rs35372971	chr15:84941795	G/A	cg03959625	chr15:84868606	LOC388152	0.55	8.47	0.37	3.3e-16	Schizophrenia;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.68	-0.3	6.94e-11	Menopause (age at onset);
LGG	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg06481639	chr22:41940642	POLR3H	-0.54	-8.04	-0.35	7.43e-15	Vitiligo;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05214690	chr5:178772203	ADAMTS2	0.42	6.65	0.3	8.37e-11	Hip circumference;
LGG	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg02574844	chr11:5959923	NA	-0.57	-9.56	-0.41	6.71e-20	DNA methylation (variation);
LGG	cis	rs2404602	0.716	rs12594577	chr15:76828793	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.97	-0.31	1.09e-11	Blood metabolite levels;
LGG	trans	rs2727020	0.521	rs4980445	chr11:49570183	C/T	cg03929089	chr4:120376271	NA	-0.83	-13.38	-0.53	9.82e-35	Coronary artery disease;
LGG	cis	rs6076065	0.723	rs4813493	chr20:23367373	G/C	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg18252515	chr7:66147081	NA	0.4	6.88	0.3	1.92e-11	Aortic root size;
LGG	cis	rs7084402	0.967	rs1303970	chr10:60298477	G/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.65	4.72e-56	Refractive error;
LGG	cis	rs9457247	1.000	rs393558	chr6:167397750	A/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9467711	0.591	rs13214280	chr6:26008620	C/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.38	0.32	7.64e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2737618	0.674	rs2258280	chr1:200097648	G/A	cg21825944	chr1:200113062	NR5A2	-0.61	-11.73	-0.48	5.28e-28	Uric acid levels;
LGG	cis	rs9325144	0.647	rs3759139	chr12:39087609	G/A	cg26384229	chr12:38710491	ALG10B	-0.72	-13.47	-0.53	4.1e-35	Morning vs. evening chronotype;
LGG	trans	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.3	-0.36	1.16e-15	Neuroticism;
LGG	cis	rs752010	0.523	rs943376	chr1:42122117	A/G	cg16096631	chr1:42092165	HIVEP3	0.58	13.72	0.54	3.57e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17376456	0.825	rs10054903	chr5:93281491	C/A	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg04568710	chr12:38710424	ALG10B	0.4	8.45	0.37	3.72e-16	Morning vs. evening chronotype;
LGG	cis	rs758324	0.947	rs1875177	chr5:131202625	T/C	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	3.01e-19	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg06521331	chr12:34319734	NA	0.44	7.88	0.34	2.33e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1042058	0.565	rs650110	chr10:30753132	A/G	cg25182066	chr10:30743637	MAP3K8	-0.66	-14.17	-0.55	4.22e-38	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg13206674	chr6:150067644	NUP43	0.69	15.89	0.59	1.05e-45	Lung cancer;
LGG	cis	rs807029	0.533	rs722435	chr10:102745062	G/T	cg04662943	chr10:102668895	NA	0.46	6.84	0.3	2.6e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7011049	0.915	rs67767021	chr8:53860855	A/G	cg26025543	chr8:53854495	NA	0.62	8.76	0.38	3.65e-17	Systolic blood pressure;
LGG	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.54	9.32	0.4	4.64e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9354308	0.764	rs1938066	chr6:66608424	T/G	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.53e-11	Metabolite levels;
LGG	cis	rs17125944	0.505	rs77690283	chr14:53233320	C/G	cg13660082	chr14:53194042	PSMC6	-0.55	-7.82	-0.34	3.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs870825	0.929	rs72689262	chr4:185590950	C/G	cg04058563	chr4:185651563	MLF1IP	1.03	18.86	0.66	2.81e-59	Blood protein levels;
LGG	cis	rs2028299	1.000	rs12910992	chr15:90372465	C/T	cg23731826	chr15:90371692	NA	0.38	9.03	0.39	4.76e-18	Type 2 diabetes;
LGG	cis	rs16854884	1.000	rs17668478	chr3:143794370	G/A	cg06585982	chr3:143692056	C3orf58	0.53	8.17	0.36	2.93e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs9309473	0.948	rs7566385	chr2:73756817	G/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.9	-0.34	2.11e-14	Metabolite levels;
LGG	cis	rs4595586	0.545	rs7970307	chr12:39380760	A/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs7129556	0.737	rs7950873	chr11:77412851	A/G	cg12586386	chr11:77299805	AQP11	0.45	7.09	0.31	4.97e-12	Weight loss (gastric bypass surgery);
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01341218	chr17:43662625	NA	0.96	17.09	0.62	3.91e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7582180	0.817	rs1437967	chr2:100929072	C/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.74	-0.41	1.61e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1949733	1.000	rs2688223	chr4:8471398	T/C	cg11789530	chr4:8429930	ACOX3	0.87	17.04	0.62	6.45e-51	Response to antineoplastic agents;
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg06719900	chr11:109292894	C11orf87	0.51	9.0	0.39	5.85e-18	Schizophrenia;
LGG	trans	rs7824557	0.568	rs35747588	chr8:11206627	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.91	-0.31	1.62e-11	Retinal vascular caliber;
LGG	cis	rs9467773	1.000	rs12526680	chr6:26550954	A/G	cg09904177	chr6:26538194	HMGN4	0.75	16.77	0.61	1.18e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7551222	0.646	rs4951382	chr1:204451495	T/C	cg20240347	chr1:204465584	NA	-0.49	-9.13	-0.39	2.11e-18	Schizophrenia;
LGG	cis	rs559928	1.000	rs72924202	chr11:64133228	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.63	7.8	0.34	4.21e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6976053	0.846	rs314378	chr7:100458795	T/C	cg03098644	chr7:100410630	EPHB4	-0.43	-7.79	-0.34	4.34e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs35306767	0.855	rs61830932	chr10:934183	T/C	cg26597838	chr10:835615	NA	0.75	10.22	0.43	3.07e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6964587	0.869	rs11769726	chr7:91485231	A/G	cg17063962	chr7:91808500	NA	-0.4	-6.89	-0.3	1.88e-11	Breast cancer;
LGG	cis	rs2307022	0.566	rs2035869	chr16:68386754	A/G	cg07273125	chr16:68295692	NA	0.43	9.49	0.4	1.21e-19	Body mass index;
LGG	trans	rs7819412	0.560	rs13265553	chr8:10989057	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.48	-0.33	3.75e-13	Triglycerides;
LGG	cis	rs9462027	0.675	rs34657938	chr6:34801631	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs6062788	0.524	rs6122360	chr20:61698520	G/A	cg04970637	chr20:61718950	NA	-0.27	-6.66	-0.3	7.73e-11	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03754076	chr1:232766254	NA	0.42	6.75	0.3	4.41e-11	Cognitive performance;
LGG	cis	rs7647973	0.580	rs35218722	chr3:49275805	A/G	cg07636037	chr3:49044803	WDR6	0.94	20.32	0.69	4.34e-66	Menarche (age at onset);
LGG	trans	rs208520	0.608	rs3846803	chr6:66805743	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs9948	0.655	rs62152785	chr2:97459403	A/T	cg01990225	chr2:97406019	LMAN2L	-0.65	-6.71	-0.3	5.57e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs10479542	0.630	rs6879664	chr5:178974576	T/G	cg21226059	chr5:178986404	RUFY1	0.46	7.32	0.32	1.11e-12	Lung cancer;
LGG	trans	rs3808502	0.526	rs11985709	chr8:11423083	A/C	cg16141378	chr3:129829833	LOC729375	0.41	9.47	0.4	1.42e-19	Neuroticism;
LGG	cis	rs10791097	0.694	rs7940027	chr11:130745591	A/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7937612	0.897	rs7126413	chr11:120207405	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.5	-11.64	-0.48	1.18e-27	Intraocular pressure;
LGG	cis	rs3733585	0.673	rs9994266	chr4:9954450	C/T	cg08250081	chr4:10125330	NA	-0.38	-7.26	-0.32	1.68e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.82	0.38	2.29e-17	Platelet count;
LGG	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.38	0.43	7.74e-23	Diabetic retinopathy;
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.02	-0.42	1.56e-21	Joint mobility (Beighton score);
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg04863758	chr4:1303710	MAEA	0.45	7.73	0.34	6.94e-14	Obesity-related traits;
LGG	cis	rs2013441	0.613	rs12451841	chr17:20004875	G/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.68	-0.3	6.89e-11	Obesity-related traits;
LGG	cis	rs79911532	0.515	rs80171070	chr7:75636868	T/C	cg15148918	chr7:75625777	STYXL1	-0.7	-7.84	-0.34	3.14e-14	Mononucleosis;
LGG	cis	rs67460515	0.596	rs35589595	chr3:160930984	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-12.17	-0.49	9.69e-30	Parkinson's disease;
LGG	cis	rs42648	0.748	rs6972119	chr7:89894008	T/C	cg25739043	chr7:89950458	NA	-0.35	-7.39	-0.32	6.73e-13	Homocysteine levels;
LGG	cis	rs67133203	0.904	rs12369278	chr12:51331300	C/A	cg14688905	chr12:51403056	SLC11A2	0.73	10.77	0.45	2.64e-24	Urinary tract infection frequency;
LGG	cis	rs55986470	0.630	rs116252536	chr2:239394268	T/C	cg18131467	chr2:239335373	ASB1	-0.54	-7.22	-0.32	2.11e-12	Chronotype;
LGG	cis	rs9976767	0.932	rs9981707	chr21:43827829	T/C	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.88	-0.42	5.02e-21	Type 1 diabetes;
LGG	cis	rs17221829	0.528	rs4561217	chr11:89375265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.51	13.32	0.53	1.69e-34	Tonsillectomy;
LGG	cis	rs6694672	0.867	rs1759006	chr1:197031664	T/C	cg13682187	chr1:196946512	CFHR5	0.51	6.94	0.31	1.37e-11	Asthma;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg02985366	chr16:32360428	NA	0.45	7.03	0.31	7.39e-12	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs116903413	chr22:32398342	C/T	cg00543991	chr22:32367038	NA	0.78	8.69	0.37	6.21e-17	Childhood ear infection;
LGG	cis	rs920590	1.000	rs6995371	chr8:19650268	A/G	cg03894339	chr8:19674705	INTS10	0.51	8.54	0.37	1.89e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg02002194	chr4:3960332	NA	-0.5	-9.27	-0.4	6.91e-19	Myopia (pathological);
LGG	cis	rs7568458	0.905	rs6714709	chr2:85756375	C/G	cg23752985	chr2:85803571	VAMP8	0.43	8.45	0.37	3.77e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8141529	0.748	rs715531	chr22:29282679	A/G	cg15103426	chr22:29168792	CCDC117	0.62	9.56	0.41	6.9e-20	Lymphocyte counts;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg16507663	chr6:150244633	RAET1G	0.47	8.9	0.38	1.29e-17	Lung cancer;
LGG	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg11812906	chr14:75593930	NEK9	0.54	10.03	0.42	1.5e-21	Height;
LGG	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg12463550	chr7:65579703	CRCP	0.51	8.56	0.37	1.63e-16	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09306365	chr3:61547944	PTPRG	0.42	6.68	0.3	6.96e-11	Cognitive performance;
LGG	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg06598544	chr20:61472147	COL9A3	-0.9	-10.19	-0.43	3.87e-22	Obesity-related traits;
LGG	cis	rs4689642	1.000	rs10937792	chr4:7215861	C/T	cg21353189	chr4:7228343	SORCS2	0.3	7.5	0.33	3.31e-13	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg04025307	chr7:1156635	C7orf50	0.55	10.15	0.43	5.64e-22	Longevity;Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08047338	chr2:75873982	MRPL19	0.47	6.82	0.3	2.84e-11	Gut microbiome composition (summer);
LGG	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.88	-0.45	1.03e-24	Hemoglobin concentration;
LGG	cis	rs9487094	0.670	rs6911700	chr6:109997294	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.73	0.34	6.59e-14	Height;
LGG	cis	rs4363385	0.747	rs1611760	chr1:152957573	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.21	-0.39	1.17e-18	Inflammatory skin disease;
LGG	cis	rs79349575	0.749	rs46521	chr17:46988529	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs7615952	0.609	rs13088451	chr3:125553499	G/C	cg05084668	chr3:125655381	ALG1L	-0.72	-8.88	-0.38	1.49e-17	Blood pressure (smoking interaction);
LGG	cis	rs12220238	0.818	rs115350439	chr10:75899365	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.28	0.46	3.1e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9916302	0.706	rs1877030	chr17:37740161	T/C	cg07936489	chr17:37558343	FBXL20	-1.01	-14.02	-0.55	1.85e-37	Glomerular filtration rate (creatinine);
LGG	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg06238570	chr21:40685208	BRWD1	-0.52	-8.14	-0.35	3.69e-15	Cognitive function;
LGG	trans	rs11722228	0.508	rs3822246	chr4:10094698	G/A	cg26043149	chr18:55253948	FECH	0.95	16.48	0.61	2.26e-48	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg02002194	chr4:3960332	NA	0.44	8.04	0.35	7.63e-15	Triglycerides;
LGG	cis	rs9325144	0.647	rs11169258	chr12:39113040	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-9.97	-0.42	2.35e-21	Morning vs. evening chronotype;
LGG	cis	rs2282802	0.711	rs11168018	chr5:139700608	T/A	cg26211634	chr5:139558579	C5orf32	-0.33	-7.17	-0.32	2.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs62025270	0.688	rs17576534	chr15:86285740	C/T	cg25843651	chr15:86329602	KLHL25	0.58	8.91	0.38	1.19e-17	Idiopathic pulmonary fibrosis;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.11	-0.31	4.5e-12	Neuroticism;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg06719900	chr11:109292894	C11orf87	0.44	8.34	0.36	8.72e-16	Schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11975718	chr4:84377034	HELQ;MRPS18C	-0.47	-6.79	-0.3	3.4e-11	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs10950032	chr7:65738591	C/A	cg18252515	chr7:66147081	NA	1.43	20.67	0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs7618915	0.508	rs11717043	chr3:52656092	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.69	0.41	2.41e-20	Bipolar disorder;
LGG	cis	rs2180341	1.000	rs6903878	chr6:127638600	C/G	cg27446573	chr6:127587934	RNF146	1.14	22.68	0.73	3.9e-77	Breast cancer;
LGG	cis	rs1577917	0.917	rs2084293	chr6:86566002	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	cis	rs4242434	0.927	rs2291231	chr8:22463912	C/T	cg19455335	chr8:22457658	C8orf58	-0.46	-9.54	-0.41	8e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs930421	0.502	rs2278582	chr2:42989444	A/G	cg14631114	chr2:43023945	NA	0.42	8.94	0.38	9.03e-18	Attention deficit hyperactivity disorder;
LGG	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.765	rs4374423	chr2:99662348	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs898097	0.841	rs8074284	chr17:80909967	G/A	cg15369054	chr17:80825471	TBCD	-0.51	-8.94	-0.38	9.02e-18	Breast cancer;
LGG	cis	rs4557101	0.625	rs6800926	chr3:73534976	G/A	cg24173753	chr3:73529447	PDZRN3	0.37	7.78	0.34	4.87e-14	QT interval;
LGG	cis	rs2602381	0.599	rs6761246	chr2:234603439	A/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.38	-6.76	-0.3	4.13e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs9399137	0.507	rs13209780	chr6:135344795	G/C	cg24558204	chr6:135376177	HBS1L	0.61	10.8	0.45	2.14e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs801193	1.000	rs7783924	chr7:66209057	A/C	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs2346177	0.844	rs34791442	chr2:46655169	T/C	cg02822958	chr2:46747628	ATP6V1E2	0.43	7.37	0.32	7.74e-13	HDL cholesterol;
LGG	cis	rs66716358	0.773	rs7118653	chr11:44327797	T/C	cg16977035	chr11:44330474	ALX4	0.38	10.06	0.42	1.17e-21	Monobrow;
LGG	cis	rs10779751	0.881	rs2744820	chr1:11365015	G/A	cg08854313	chr1:11322531	MTOR	-0.76	-14.88	-0.57	3.37e-41	Body mass index;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg04008888	chr11:68622739	NA	-0.56	-11.46	-0.47	6.3e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg08999081	chr20:33150536	PIGU	0.39	9.73	0.41	1.73e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg06521331	chr12:34319734	NA	-0.44	-7.87	-0.34	2.5e-14	Heart rate;
LGG	cis	rs13082711	0.911	rs923941	chr3:27458914	A/G	cg02860705	chr3:27208620	NA	0.73	13.17	0.52	7.03e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	1e-35	Lung cancer;
LGG	cis	rs8060686	0.563	rs118005841	chr16:68157562	A/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.58	-0.33	1.96e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.72	0.3	5.26e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11168187	0.843	rs3764020	chr12:48120132	C/T	cg12761788	chr12:48120090	P11	0.51	8.76	0.38	3.58e-17	Vertical cup-disc ratio;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs990171	0.913	rs4851009	chr2:103055644	G/A	cg05295703	chr2:102895712	NA	-0.53	-9.21	-0.39	1.15e-18	Lymphocyte counts;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.69	-0.34	8.98e-14	Lung cancer;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg11766577	chr21:47581405	C21orf56	-0.48	-8.24	-0.36	1.8e-15	Testicular germ cell tumor;
LGG	cis	rs1348850	0.872	rs2084233	chr2:178331206	G/A	cg27490568	chr2:178487706	NA	0.51	10.07	0.42	1.07e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7666738	0.791	rs10017624	chr4:98984009	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1552244	0.554	rs6762702	chr3:10055789	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.9	-0.45	8.67e-25	Alzheimer's disease;
LGG	cis	rs2342371	0.848	rs12632592	chr3:196219365	G/A	cg15048948	chr3:196158458	UBXN7	0.42	6.96	0.31	1.15e-11	Fat distribution (HIV);
LGG	cis	rs67311347	0.594	rs12629111	chr3:40285351	T/C	cg13683864	chr3:40499215	RPL14	-0.81	-15.69	-0.59	8.33e-45	Renal cell carcinoma;
LGG	trans	rs1493916	1.000	rs990882	chr18:31398180	T/G	cg04226714	chr8:49833948	SNAI2	-0.48	-8.61	-0.37	1.17e-16	Life satisfaction;
LGG	cis	rs7937612	1.000	rs7104639	chr11:120239456	C/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.4e-32	Intraocular pressure;
LGG	cis	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg24375607	chr4:120327624	NA	0.67	11.0	0.46	3.52e-25	Corneal astigmatism;
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg09256448	chr16:638327	NA	0.37	6.65	0.3	8.42e-11	Height;
LGG	cis	rs9815354	1.000	rs9834098	chr3:41833493	A/G	cg03022575	chr3:42003672	ULK4	0.65	8.39	0.36	5.73e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12824058	0.831	rs7299065	chr12:130809661	A/T	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	cis	rs6582630	0.533	rs4103689	chr12:38702980	A/C	cg04568710	chr12:38710424	ALG10B	0.4	8.61	0.37	1.13e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.68e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4474465	0.833	rs10899540	chr11:78245549	T/A	cg27205649	chr11:78285834	NARS2	0.51	8.82	0.38	2.27e-17	Alzheimer's disease (survival time);
LGG	cis	rs12681288	0.645	rs2600509	chr8:989022	C/G	cg04851639	chr8:1020857	NA	0.41	8.47	0.37	3.23e-16	Schizophrenia;
LGG	cis	rs6032067	0.929	rs6017510	chr20:43831785	A/G	cg10761708	chr20:43804764	PI3	0.76	11.82	0.48	2.37e-28	Blood protein levels;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg15049968	chr18:44337910	ST8SIA5	-0.38	-6.93	-0.31	1.41e-11	Personality dimensions;
LGG	cis	rs7851660	0.935	rs10818124	chr9:100603008	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.56	-0.56	8.14e-40	Strep throat;
LGG	cis	rs9810089	0.900	rs480162	chr3:136068695	A/T	cg21827317	chr3:136751795	NA	0.43	7.47	0.33	4.12e-13	Gestational age at birth (child effect);
LGG	trans	rs12439619	0.530	rs28883606	chr15:82509054	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-8.33	-0.36	9.18e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg01879757	chr17:41196368	BRCA1	-0.45	-7.98	-0.35	1.16e-14	Menopause (age at onset);
LGG	cis	rs10911232	0.524	rs4487994	chr1:182982173	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Hypertriglyceridemia;
LGG	cis	rs6964587	0.967	rs4729015	chr7:91561592	T/G	cg17063962	chr7:91808500	NA	-0.49	-8.68	-0.37	6.57e-17	Breast cancer;
LGG	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.54	-8.89	-0.38	1.33e-17	Blood metabolite levels;
LGG	cis	rs4936891	0.542	rs10790620	chr11:123863989	C/T	cg22125253	chr11:123886957	OR10G4	-0.45	-7.88	-0.34	2.39e-14	Male fertility;
LGG	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg07636037	chr3:49044803	WDR6	0.7	11.16	0.46	9.05e-26	Menarche (age at onset);
LGG	cis	rs7503807	0.664	rs9913181	chr17:78573872	A/C	cg18469159	chr17:78755841	RPTOR	-0.41	-7.76	-0.34	5.47e-14	Obesity;
LGG	cis	rs1949733	1.000	rs2688233	chr4:8491885	T/C	cg11789530	chr4:8429930	ACOX3	0.88	17.49	0.63	5.75e-53	Response to antineoplastic agents;
LGG	cis	rs4820539	1.000	rs2267003	chr22:23457098	A/G	cg21100191	chr22:23484243	RTDR1	0.95	21.05	0.7	1.7e-69	Bone mineral density;
LGG	cis	rs344364	0.511	rs2982455	chr16:1950498	T/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.08	-0.31	5.52e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs947211	1.000	rs823144	chr1:205744546	C/A	cg26354017	chr1:205819088	PM20D1	0.47	7.72	0.34	7.28e-14	Parkinson's disease;
LGG	cis	rs365132	0.967	rs58279426	chr5:176448139	T/C	cg16309518	chr5:176445507	NA	-0.56	-12.44	-0.5	7.82e-31	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs888194	0.725	rs2241210	chr12:109950144	A/G	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-6.68	-0.3	7.02e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg16507663	chr6:150244633	RAET1G	0.43	8.08	0.35	5.78e-15	Lung cancer;
LGG	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg13010199	chr12:38710504	ALG10B	0.63	13.24	0.52	3.77e-34	Bladder cancer;
LGG	cis	rs2735413	0.563	rs72800915	chr16:78055777	C/T	cg04733911	chr16:78082701	NA	0.57	7.49	0.33	3.44e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6502050	0.835	rs6502067	chr17:80111205	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg23533926	chr12:111358616	MYL2	-0.42	-6.91	-0.31	1.57e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg22433210	chr17:43662623	NA	0.92	15.33	0.58	3.46e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs873946	0.504	rs4880275	chr10:134576552	C/T	cg26818010	chr10:134567672	INPP5A	-0.59	-9.3	-0.4	5.4e-19	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7129220	0.588	rs61878581	chr11:10083808	C/T	cg01453529	chr11:10209919	SBF2	-0.44	-7.05	-0.31	6.36e-12	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg00129232	chr17:37814104	STARD3	-0.8	-17.47	-0.63	7.32e-53	Asthma;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.69	-12.81	-0.51	2.2e-32	Longevity;Endometriosis;
LGG	cis	rs11077773	1.000	rs11077773	chr17:73060073	C/T	cg27626185	chr17:73056755	KCTD2	0.88	11.71	0.48	6.41e-28	Information processing speed;
LGG	cis	rs9894429	0.690	rs11869779	chr17:79570067	C/T	cg10661904	chr17:79619235	PDE6G	0.41	8.15	0.35	3.4e-15	Eye color traits;
LGG	trans	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.98	0.45	4.29e-25	Lewy body disease;
LGG	cis	rs9322193	0.923	rs10782318	chr6:150075273	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.87	-0.38	1.58e-17	Lung cancer;
LGG	cis	rs6951245	0.572	rs73264010	chr7:1040477	T/C	cg02733842	chr7:1102375	C7orf50	0.67	8.0	0.35	9.72e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4727027	0.635	rs12111923	chr7:148885877	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.62	8.85	0.38	1.88e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2115630	0.653	rs61394864	chr15:85170174	T/C	cg12501888	chr15:85177176	SCAND2	-0.55	-9.11	-0.39	2.58e-18	P wave terminal force;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25187227	chr4:40058080	N4BP2;LOC344967	0.41	6.92	0.31	1.53e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6547741	0.904	rs1528403	chr2:27846645	C/G	cg22903471	chr2:27725779	GCKR	0.39	8.75	0.38	4e-17	Oral cavity cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10243787	chr22:19419481	HIRA;MRPL40	0.47	7.07	0.31	5.79e-12	Gut microbiome composition (summer);
LGG	cis	rs7336332	0.598	rs10220056	chr13:28003781	T/G	cg01674679	chr13:27998804	GTF3A	-0.67	-8.57	-0.37	1.56e-16	Weight;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg08645402	chr16:4508243	NA	0.46	7.86	0.34	2.71e-14	Schizophrenia;
LGG	cis	rs875971	0.825	rs1129531	chr7:65619104	C/T	cg11764359	chr7:65958608	NA	-0.74	-12.94	-0.52	6.84e-33	Aortic root size;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13872356	chr11:62341519	EEF1G	-0.47	-6.81	-0.3	3.04e-11	Systemic lupus erythematosus;
LGG	cis	rs7071206	1.000	rs7071206	chr10:79401316	C/T	cg07817648	chr10:79422355	NA	0.67	12.97	0.52	5.18e-33	Bone mineral density;
LGG	cis	rs11098499	0.955	rs11931312	chr4:120159023	T/C	cg09307838	chr4:120376055	NA	0.72	12.16	0.49	1.06e-29	Corneal astigmatism;
LGG	cis	rs735539	0.521	rs2147347	chr13:21410468	C/T	cg04906043	chr13:21280425	IL17D	-0.51	-7.87	-0.34	2.52e-14	Dental caries;
LGG	cis	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.41	6.68	0.3	7e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg09021430	chr5:549028	NA	-0.68	-9.59	-0.41	5.38e-20	Obesity-related traits;
LGG	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.2	-0.49	6.84e-30	HDL cholesterol;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.53	-0.53	2.19e-35	Schizophrenia;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg06873352	chr17:61820015	STRADA	0.74	13.85	0.54	1e-36	Prudent dietary pattern;
LGG	cis	rs2635047	0.875	rs2635040	chr18:44640972	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	10.32	0.43	1.28e-22	Educational attainment;
LGG	cis	rs2836974	0.899	rs6517514	chr21:40527095	G/T	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs7662987	0.517	rs3018047	chr4:100014510	C/T	cg12011299	chr4:100065546	ADH4	-0.38	-7.35	-0.32	9.07e-13	Smoking initiation;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.27	0.32	1.51e-12	Menopause (age at onset);
LGG	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg10253484	chr15:75165896	SCAMP2	-0.5	-8.02	-0.35	8.68e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9479482	1.000	rs5017316	chr6:150333489	A/T	cg07549998	chr6:150325970	RAET1K	-0.37	-7.23	-0.32	1.96e-12	Alopecia areata;
LGG	cis	rs6466055	0.669	rs10953468	chr7:104741842	A/T	cg03782966	chr7:104585482	NA	0.31	6.66	0.3	7.92e-11	Schizophrenia;
LGG	cis	rs283228	0.502	rs2852500	chr6:101841721	C/A	cg27451362	chr6:101846650	GRIK2	0.94	14.44	0.56	2.82e-39	Coenzyme Q10 levels;
LGG	cis	rs7923609	0.967	rs7896783	chr10:65162153	G/A	cg08743896	chr10:65200160	JMJD1C	-0.29	-6.66	-0.3	7.99e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs208520	0.690	rs207081	chr6:66773742	A/G	cg07460842	chr6:66804631	NA	-0.96	-17.86	-0.64	1.19e-54	Exhaled nitric oxide output;
LGG	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs514406	0.861	rs551435	chr1:53260537	G/T	cg24675658	chr1:53192096	ZYG11B	0.48	9.69	0.41	2.42e-20	Monocyte count;
LGG	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg09754948	chr16:28834200	ATXN2L	-0.47	-7.63	-0.33	1.39e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs8073060	0.855	rs12150450	chr17:33868896	A/T	cg19694781	chr19:47549865	TMEM160	0.65	10.5	0.44	2.73e-23	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs35491132	1	rs35491132	chr6:27527227	GT/G	cg01620082	chr3:125678407	NA	-1.0	-9.66	-0.41	3.04e-20	Urinary tract infection frequency;
LGG	cis	rs533581	0.866	rs502258	chr16:88968547	G/A	cg03970086	chr16:88974840	CBFA2T3	0.42	7.92	0.35	1.75e-14	Social autistic-like traits;
LGG	cis	rs7216064	0.636	rs4638	chr17:66039350	A/G	cg12091567	chr17:66097778	LOC651250	0.79	13.04	0.52	2.6e-33	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs7668874	0.731	rs1594438	chr4:116816387	C/T	cg21553154	chr22:36784489	MYH9	0.44	6.8	0.3	3.29e-11	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg06951627	chr6:26196580	NA	0.45	6.7	0.3	6.22e-11	Gout;Renal underexcretion gout;
LGG	cis	rs17286411	0.750	rs11075910	chr16:71936733	A/G	cg03805757	chr16:71968109	PKD1L3	0.34	7.07	0.31	5.84e-12	Blood protein levels;
LGG	cis	rs11718455	1.000	rs1012410	chr3:44053516	G/C	cg21419209	chr3:44054225	NA	-0.45	-7.24	-0.32	1.89e-12	Coronary artery disease;
LGG	cis	rs972578	0.765	rs2002595	chr22:43296051	C/A	cg01576275	chr22:43409880	NA	-0.22	-6.75	-0.3	4.34e-11	Mean platelet volume;
LGG	cis	rs28386778	1.000	rs2665810	chr17:61970210	C/G	cg07362569	chr17:61921086	SMARCD2	0.48	9.17	0.39	1.51e-18	Prudent dietary pattern;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.45	7.57	0.33	2.08e-13	Longevity;
LGG	cis	rs6061231	0.505	rs62199217	chr20:60929539	G/A	cg06026331	chr20:60912101	LAMA5	0.72	12.53	0.5	3.07e-31	Colorectal cancer;
LGG	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg21644426	chr2:191273491	MFSD6	0.59	10.18	0.43	4.18e-22	Pulse pressure;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.46	0.53	4.41e-35	Prudent dietary pattern;
LGG	cis	rs3784262	0.904	rs3784263	chr15:58253062	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.23	-0.36	1.97e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs28735056	0.609	rs4799099	chr18:77639585	A/G	cg20368463	chr18:77673604	PQLC1	0.66	13.54	0.53	2.09e-35	Schizophrenia;
LGG	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.91	0.35	1.85e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11875185	0.510	rs75354634	chr18:55605977	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.79	-0.38	3.01e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08169394	chr17:11143830	SHISA6	0.39	6.73	0.3	5.17e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.71e-21	Bipolar disorder;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00761968	chr13:53314142	LECT1	-0.37	-7.92	-0.35	1.82e-14	Lewy body disease;
LGG	trans	rs62458065	0.640	rs79619897	chr7:32514819	C/T	cg00845942	chr12:64062724	DPY19L2	-0.57	-7.4	-0.33	6.45e-13	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg24250549	chr1:154909240	PMVK	0.74	15.16	0.58	1.98e-42	Prostate cancer;
LGG	cis	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	6.82	0.3	2.9100000000000002e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9547692	0.877	rs9652258	chr13:37476123	G/C	cg01493522	chr13:37497338	NA	-0.5	-8.37	-0.36	6.66e-16	Coronary artery disease;
LGG	cis	rs7010267	0.570	rs4495458	chr8:120042780	G/T	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.86	0.38	1.77e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs9486715	0.838	rs7452350	chr6:96883326	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs1707322	0.721	rs10789468	chr1:46124558	A/G	cg03146154	chr1:46216737	IPP	0.55	10.81	0.45	1.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.97	0.35	1.26e-14	Lung cancer;
LGG	cis	rs35146811	0.735	rs1061230	chr7:99807265	G/A	cg22906224	chr7:99728672	NA	-0.57	-9.39	-0.4	2.64e-19	Coronary artery disease;
LGG	cis	rs225245	0.791	rs720774	chr17:34017453	T/G	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs11750568	0.967	rs931619	chr5:178514729	C/T	cg10208897	chr5:178548229	ADAMTS2	-0.43	-7.04	-0.31	7.19e-12	Height;
LGG	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-13.62	-0.53	9.16e-36	Morning vs. evening chronotype;
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg24503407	chr1:205819492	PM20D1	0.48	8.08	0.35	5.66e-15	Parkinson's disease;
LGG	cis	rs16937	0.711	rs10900462	chr1:205153312	A/G	cg00889227	chr1:205173544	DSTYK	0.31	7.65	0.33	1.21e-13	Schizophrenia;
LGG	cis	rs1552244	0.938	rs9873794	chr3:10074153	T/G	cg13047869	chr3:10149882	C3orf24	0.53	8.9	0.38	1.32e-17	Alzheimer's disease;
LGG	cis	rs9359856	0.564	rs7682	chr6:90352862	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.52	-0.4	9.44e-20	Bipolar disorder;
LGG	cis	rs7412746	0.658	rs11581757	chr1:150892244	A/G	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.64e-13	Melanoma;
LGG	trans	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg16141378	chr3:129829833	LOC729375	0.3	6.72	0.3	5.3e-11	Joint mobility (Beighton score);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17800473	chr17:31255522	TMEM98	0.41	6.69	0.3	6.37e-11	Gut microbiome composition (summer);
LGG	cis	rs42648	0.693	rs2106274	chr7:89880548	C/T	cg25739043	chr7:89950458	NA	-0.34	-6.93	-0.31	1.39e-11	Homocysteine levels;
LGG	cis	rs992157	0.560	rs10932763	chr2:219085863	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.53	-8.83	-0.38	2.16e-17	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs122898	chr17:28905254	C/T	cg13385521	chr17:29058706	SUZ12P	-0.88	-10.03	-0.42	1.44e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7975161	0.753	rs7972034	chr12:104640881	G/T	cg25273343	chr12:104657179	TXNRD1	-0.74	-7.28	-0.32	1.47e-12	Toenail selenium levels;
LGG	trans	rs7395662	0.593	rs8188975	chr11:48891877	A/G	cg00717180	chr2:96193071	NA	0.41	7.31	0.32	1.17e-12	HDL cholesterol;
LGG	cis	rs9768139	0.733	rs13309408	chr7:158122261	C/T	cg02855558	chr7:158107723	PTPRN2	-0.38	-6.83	-0.3	2.73e-11	Calcium levels;
LGG	cis	rs10504073	0.584	rs11778863	chr8:49954893	C/T	cg00325661	chr8:49890786	NA	0.79	15.39	0.58	1.81e-43	Blood metabolite ratios;
LGG	cis	rs7551222	0.716	rs6679717	chr1:204560677	A/G	cg20240347	chr1:204465584	NA	-0.44	-8.46	-0.37	3.42e-16	Schizophrenia;
LGG	cis	rs1865760	0.892	rs2328903	chr6:25935765	T/C	cg17691542	chr6:26056736	HIST1H1C	0.56	9.96	0.42	2.64e-21	Height;
LGG	cis	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.54	-0.33	2.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs638893	0.588	rs529717	chr11:118640081	A/G	cg13782932	chr11:118662891	DDX6	0.37	6.8	0.3	3.25e-11	Vitiligo;
LGG	cis	rs7937682	0.883	rs568038	chr11:111432161	A/C	cg19812747	chr11:111475976	SIK2	0.5	10.18	0.43	4.34e-22	Primary sclerosing cholangitis;
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg02524346	chr8:600233	NA	1.14	11.39	0.47	1.12e-26	IgG glycosylation;
LGG	cis	rs9868809	0.505	rs9877685	chr3:48748588	C/T	cg00383909	chr3:49044727	WDR6	0.92	11.43	0.47	8.27e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.94	-0.31	1.31e-11	Blood metabolite levels;
LGG	cis	rs7659604	0.728	rs3924987	chr4:122689784	G/T	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.56	-0.47	2.54e-27	Type 2 diabetes;
LGG	cis	rs9303280	0.936	rs12950209	chr17:38049102	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-9.17	-0.39	1.5e-18	Self-reported allergy;
LGG	cis	rs16912285	0.688	rs7126291	chr11:24312936	A/C	ch.11.24196551F	chr11:24239977	NA	0.89	13.49	0.53	3.27e-35	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg02002194	chr4:3960332	NA	-0.37	-6.82	-0.3	2.79e-11	Retinal vascular caliber;
LGG	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg10513866	chr5:139070639	NA	0.4	7.87	0.34	2.54e-14	Schizophrenia;
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg04013166	chr16:89971882	TCF25	-0.5	-6.68	-0.3	6.83e-11	Skin colour saturation;
LGG	cis	rs9790314	0.663	rs13098884	chr3:160687386	A/G	cg04691961	chr3:161091175	C3orf57	0.43	9.16	0.39	1.63e-18	Morning vs. evening chronotype;
LGG	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg13770153	chr20:60521292	NA	-0.42	-6.85	-0.3	2.33e-11	Body mass index;
LGG	cis	rs4740619	0.619	rs10810521	chr9:16031471	C/G	cg14451791	chr9:16040625	NA	-0.42	-11.06	-0.46	2.08e-25	Body mass index;
LGG	trans	rs11992162	0.597	rs6996342	chr8:11784541	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.4	0.33	6.32e-13	Monocyte count;
LGG	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62244186	0.541	rs3804583	chr3:44884647	G/T	cg15225532	chr3:44803084	KIF15;KIAA1143	0.42	7.34	0.32	9.59e-13	Depressive symptoms;
LGG	cis	rs4423214	0.840	rs1790340	chr11:71182589	T/C	cg10847948	chr11:71163743	NADSYN1	0.62	10.6	0.44	1.22e-23	Vitamin D levels;
LGG	cis	rs7177699	0.557	rs7403714	chr15:79118650	C/T	cg00540400	chr15:79124168	NA	-0.54	-11.32	-0.47	2.08e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02048674	chr19:49991517	RPL13AP5;RPL13A	0.43	7.5	0.33	3.4e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs774359	0.830	rs2814707	chr9:27536397	C/T	cg21249376	chr9:27528432	MOBKL2B	0.44	8.13	0.35	4.05e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs8062405	0.964	rs11860513	chr16:28825420	C/T	cg07382826	chr16:28625726	SULT1A1	0.34	7.22	0.32	2.17e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs17032396	chr3:10153559	A/G	cg00166722	chr3:10149974	C3orf24	-0.54	-8.96	-0.38	7.98e-18	Alzheimer's disease;
LGG	cis	rs3785574	0.638	rs2854182	chr17:61969062	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.09	24.59	0.75	4.9400000000000004e-86	Height;
LGG	cis	rs3733585	0.605	rs56178126	chr4:10123581	C/T	cg08250081	chr4:10125330	NA	-0.48	-9.32	-0.4	4.88e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9287719	0.967	rs2010080	chr2:10736552	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	trans	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg25214090	chr10:38739885	LOC399744	0.71	12.65	0.51	1.05e-31	Corneal astigmatism;
LGG	cis	rs7814319	0.966	rs10112328	chr8:97254372	C/T	cg20787634	chr8:97240163	UQCRB	0.75	17.93	0.64	5.7e-55	Lung function (FVC);
LGG	cis	rs2562456	0.755	rs2650773	chr19:21644088	A/G	cg00806126	chr19:22604979	ZNF98	0.57	8.09	0.35	5.19e-15	Pain;
LGG	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg03128945	chr5:622914	CEP72	-0.42	-7.32	-0.32	1.09e-12	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs35449999	chr6:163023465	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.71	0.34	7.58e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg10057126	chr4:77819792	ANKRD56	0.37	6.95	0.31	1.23e-11	Emphysema distribution in smoking;
LGG	cis	rs2635047	0.519	rs2668771	chr18:44775897	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.77	0.3	3.88e-11	Educational attainment;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.59	-0.37	1.38e-16	Prudent dietary pattern;
LGG	cis	rs1797081	1.000	rs2603807	chr10:16872797	A/G	cg22980697	chr10:16874865	CUBN	0.37	7.13	0.31	3.82e-12	Platelet distribution width;
LGG	trans	rs1005277	0.522	rs289649	chr10:37975384	T/C	cg27523141	chr10:43048294	ZNF37B	0.33	6.95	0.31	1.27e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17767392	0.958	rs34169215	chr14:72011148	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.8	-0.38	2.82e-17	Mitral valve prolapse;
LGG	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg24375607	chr4:120327624	NA	0.67	10.79	0.45	2.27e-24	Corneal astigmatism;
LGG	cis	rs17818399	0.781	rs34449783	chr2:46863555	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-9.57	-0.41	6.25e-20	Height;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg07243736	chr16:783730	NARFL	0.42	7.26	0.32	1.65e-12	Height;
LGG	cis	rs10489202	0.608	rs10800334	chr1:168075613	T/C	cg24449463	chr1:168025552	DCAF6	-0.56	-10.01	-0.42	1.77e-21	Schizophrenia;
LGG	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg07061783	chr6:25882402	NA	-0.39	-7.02	-0.31	8.18e-12	Blood metabolite levels;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg11168104	chr5:1857477	NA	-0.4	-6.86	-0.3	2.23e-11	Cardiovascular disease risk factors;
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.78	-0.3	3.57e-11	Menopause (age at onset);
LGG	cis	rs4363385	0.667	rs454186	chr1:153049149	C/T	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg02503808	chr4:7069936	GRPEL1	0.91	14.15	0.55	4.93e-38	Monocyte percentage of white cells;
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg07747251	chr5:1868357	NA	0.46	9.38	0.4	2.9e-19	Cardiovascular disease risk factors;
LGG	cis	rs3008870	0.583	rs11208978	chr1:67442210	C/T	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-18.56	-0.65	6.57e-58	Lymphocyte percentage of white cells;
LGG	cis	rs2285947	0.503	rs12700287	chr7:21612620	C/G	cg04471919	chr7:21584483	DNAH11	-0.36	-8.54	-0.37	2.02e-16	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs7937682	0.632	rs57414412	chr11:111769431	G/A	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.69	-12.57	-0.5	2.11e-31	Obesity-related traits;
LGG	cis	rs7572263	0.916	rs12995124	chr2:209057014	G/C	cg00164906	chr2:209055251	C2orf80	-0.55	-8.44	-0.37	4.22e-16	Glioma;Non-glioblastoma glioma;
LGG	cis	rs6502050	0.835	rs7405738	chr17:80084227	A/G	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs67311347	0.544	rs9833640	chr3:40354941	T/A	cg13683864	chr3:40499215	RPL14	-0.8	-15.74	-0.59	4.83e-45	Renal cell carcinoma;
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg20003494	chr4:90757398	SNCA	-0.4	-7.9	-0.34	2.03e-14	Dementia with Lewy bodies;
LGG	cis	rs912057	0.609	rs1294431	chr6:6745003	G/C	cg06612196	chr6:6737390	NA	0.5	10.74	0.45	3.64e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.45	0.47	6.73e-27	Bipolar disorder;
LGG	cis	rs1318772	1.000	rs446272	chr5:112801861	A/G	cg12552261	chr5:112820674	MCC	-0.71	-7.93	-0.35	1.69e-14	F-cell distribution;
LGG	cis	rs2594989	1.000	rs388407	chr3:11320709	C/T	cg01796438	chr3:11312864	ATG7	-0.61	-8.46	-0.37	3.64e-16	Circulating chemerin levels;
LGG	cis	rs897984	0.609	rs35468353	chr16:31056433	A/G	cg00531865	chr16:30841666	NA	-0.49	-10.23	-0.43	2.77e-22	Dementia with Lewy bodies;
LGG	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg05729581	chr11:3078854	CARS	-0.55	-9.58	-0.41	6.11e-20	Longevity;
LGG	cis	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.07e-25	Resting heart rate;
LGG	trans	rs656319	0.559	rs17689037	chr8:9974858	C/T	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.68	-0.3	7e-11	Myopia (pathological);
LGG	cis	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg06521331	chr12:34319734	NA	-0.63	-11.42	-0.47	8.68e-27	Morning vs. evening chronotype;
LGG	cis	rs2274273	0.774	rs9323278	chr14:55541574	C/G	cg04306507	chr14:55594613	LGALS3	0.44	10.85	0.45	1.32e-24	Protein biomarker;
LGG	cis	rs4642101	0.793	rs3889513	chr3:12844070	G/A	cg24848339	chr3:12840334	CAND2	0.38	8.61	0.37	1.18e-16	QRS complex (12-leadsum);
LGG	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.57	-0.33	2.07e-13	Testicular germ cell tumor;
LGG	cis	rs2916247	1.000	rs7825562	chr8:93022696	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.33	-0.36	9.1e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10876993	0.890	rs115106209	chr12:58059331	G/A	cg18357645	chr12:58087776	OS9	0.71	13.08	0.52	1.69e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs2760061	0.846	rs3094912	chr1:228209815	T/A	cg01200585	chr1:228362443	C1orf69	0.46	8.07	0.35	6.16e-15	Diastolic blood pressure;
LGG	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14829155	chr15:31115871	NA	0.67	11.58	0.47	2.02e-27	Huntington's disease progression;
LGG	cis	rs2275620	1.000	rs1891071	chr10:96805371	C/T	cg09036531	chr10:96991505	NA	-0.41	-7.27	-0.32	1.56e-12	Gout;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25427524	chr10:38739819	LOC399744	-0.63	-11.56	-0.47	2.38e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	1.000	rs2218803	chr3:161047973	T/G	cg04691961	chr3:161091175	C3orf57	-0.62	-14.52	-0.56	1.22e-39	Morning vs. evening chronotype;
LGG	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg11502198	chr6:26597334	ABT1	-0.86	-6.66	-0.3	7.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs7618915	0.547	rs3755806	chr3:52643685	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.57	-9.74	-0.41	1.57e-20	Bipolar disorder;
LGG	cis	rs1008375	0.931	rs2315558	chr4:17674558	C/A	cg02297831	chr4:17616191	MED28	0.52	10.03	0.42	1.54e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12681288	0.550	rs12549204	chr8:959085	G/T	cg04851639	chr8:1020857	NA	-0.33	-6.9	-0.31	1.72e-11	Schizophrenia;
LGG	cis	rs9463078	0.764	rs10948194	chr6:44951990	A/C	cg25276700	chr6:44698697	NA	-0.4	-8.45	-0.37	3.71e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6456156	0.586	rs12213683	chr6:167460718	G/A	cg07741184	chr6:167504864	NA	0.4	9.03	0.39	4.5e-18	Primary biliary cholangitis;
LGG	cis	rs908922	0.676	rs525960	chr1:152497866	T/A	cg20991723	chr1:152506922	NA	-0.73	-15.0	-0.57	9.89e-42	Hair morphology;
LGG	trans	rs61931739	0.649	rs1068864	chr12:33733119	A/C	cg26384229	chr12:38710491	ALG10B	0.48	8.63	0.37	9.6e-17	Morning vs. evening chronotype;
LGG	cis	rs10479542	0.766	rs2411380	chr5:178973780	T/C	cg12542080	chr5:178950795	NA	0.3	6.76	0.3	4.2e-11	Lung cancer;
LGG	cis	rs7503807	1.000	rs7503807	chr17:78591111	G/T	cg06872548	chr17:78716983	RPTOR	-0.43	-10.62	-0.44	9.97e-24	Obesity;
LGG	cis	rs17023223	0.537	rs4508058	chr1:119684250	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-9.15	-0.39	1.87e-18	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs7633770	0.786	rs4683256	chr3:46683617	T/G	cg11219411	chr3:46661640	NA	0.59	14.09	0.55	9.38e-38	Coronary artery disease;
LGG	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg27297192	chr10:134578999	INPP5A	0.3	7.34	0.32	9.76e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9486719	1.000	rs12530462	chr6:97053514	C/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-7.23	-0.32	2e-12	Migraine;Coronary artery disease;
LGG	cis	rs500492	0.542	rs400354	chr16:1074526	T/G	cg08273874	chr16:1060765	NA	-0.57	-8.16	-0.35	3.11e-15	Polycystic ovary syndrome;
LGG	cis	rs6952808	0.656	rs73048919	chr7:2103637	C/A	cg04267008	chr7:1944627	MAD1L1	-0.67	-11.62	-0.48	1.44e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs503734	0.502	rs513154	chr3:100953212	T/G	cg27318481	chr3:100970896	IMPG2	-0.57	-13.13	-0.52	1.09e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2997447	0.688	rs3008431	chr1:26371281	A/G	cg19633962	chr1:26362018	EXTL1	-0.6	-8.33	-0.36	8.93e-16	QRS complex (12-leadsum);
LGG	cis	rs826838	1.000	rs10506122	chr12:38699232	A/G	cg26384229	chr12:38710491	ALG10B	1.07	28.51	0.8	6e-104	Heart rate;
LGG	cis	rs17039065	0.920	rs12507588	chr4:109448257	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.63	7.77	0.34	4.98e-14	Gut microbiome composition (summer);
LGG	cis	rs500492	0.508	rs2744147	chr16:1073146	C/G	cg08273874	chr16:1060765	NA	-0.52	-7.71	-0.34	7.57e-14	Polycystic ovary syndrome;
LGG	cis	rs9796	0.689	rs7180494	chr15:41451841	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.46	-0.4	1.5700000000000001e-19	Menopause (age at onset);
LGG	cis	rs35306767	0.903	rs12769873	chr10:936526	G/T	cg20503657	chr10:835505	NA	0.75	10.48	0.44	3.3e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs11001765	0.530	rs10824410	chr10:78132087	C/G	cg16072382	chr10:78096093	C10orf11	0.5	6.79	0.3	3.55e-11	Chin dimples;
LGG	cis	rs8177179	0.967	rs4443173	chr3:133439378	A/G	cg24879335	chr3:133465180	TF	0.44	7.27	0.32	1.51e-12	Iron status biomarkers (transferrin levels);
LGG	cis	rs7249142	0.549	rs539	chr19:19287802	A/G	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	5.95e-17	IgG glycosylation;
LGG	cis	rs947474	0.517	rs11258303	chr10:6405534	C/A	cg19837174	chr10:6389707	NA	0.49	7.4	0.33	6.41e-13	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs7927771	0.839	rs3817334	chr11:47650993	C/T	cg20307385	chr11:47447363	PSMC3	-0.39	-6.92	-0.31	1.53e-11	Subjective well-being;
LGG	cis	rs847649	0.842	rs4729873	chr7:102731781	G/A	cg18108683	chr7:102477205	FBXL13	0.56	11.76	0.48	4.08e-28	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.77	0.34	5.03e-14	Lung cancer;
LGG	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.93	-0.31	1.44e-11	Mood instability;
LGG	cis	rs1008375	0.966	rs2010053	chr4:17583806	A/C	cg07005078	chr4:17578674	LAP3	0.38	6.97	0.31	1.1e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7659604	0.540	rs11934307	chr4:122677514	G/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs10911232	0.507	rs10752890	chr1:183021910	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs4642101	0.793	rs13086170	chr3:12832604	G/C	cg24848339	chr3:12840334	CAND2	0.42	9.74	0.41	1.56e-20	QRS complex (12-leadsum);
LGG	trans	rs4942242	0.640	rs9533571	chr13:44230136	C/T	cg19169023	chr15:41853346	TYRO3	-0.45	-8.9	-0.38	1.27e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.22e-15	Bipolar disorder;
LGG	cis	rs8017423	0.967	rs4900030	chr14:90689813	T/A	cg04374321	chr14:90722782	PSMC1	0.87	18.41	0.65	3.29e-57	Mortality in heart failure;
LGG	cis	rs3931020	0.530	rs12125889	chr1:75241971	A/G	cg10128416	chr1:75198403	TYW3;CRYZ	0.38	6.73	0.3	4.97e-11	Resistin levels;
LGG	cis	rs370915	0.542	rs1425953	chr4:187833652	A/C	cg19519643	chr4:187840862	NA	-0.63	-12.97	-0.52	4.99e-33	Gout;
LGG	trans	rs7395662	0.963	rs10454482	chr11:48754977	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.99	-0.35	1.06e-14	HDL cholesterol;
LGG	cis	rs858239	0.669	rs1618339	chr7:23229774	T/C	cg23682824	chr7:23144976	KLHL7	0.42	7.23	0.32	2.06e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4481887	0.927	rs7521689	chr1:248435831	G/T	cg00666640	chr1:248458726	OR2T12	0.6	9.49	0.4	1.24e-19	Common traits (Other);
LGG	cis	rs1729951	0.545	rs1097288	chr3:136693721	C/T	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg06634786	chr22:41940651	POLR3H	-0.81	-13.06	-0.52	1.99e-33	Vitiligo;
LGG	cis	rs4851266	0.765	rs11123821	chr2:100871189	A/C	cg21926883	chr2:100939477	LONRF2	-0.46	-8.1	-0.35	5.09e-15	Educational attainment;
LGG	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.48	0.37	3.14e-16	Mood instability;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.88e-21	Prudent dietary pattern;
LGG	cis	rs185694	1.000	rs202082	chr13:30881026	G/A	cg07600127	chr13:30881527	KATNAL1	-0.54	-6.94	-0.31	1.29e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.31	-0.4	5.14e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108043	0.543	rs62306480	chr4:87922069	C/A	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07570687	chr10:102243282	WNT8B	0.41	6.68	0.3	6.86e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3813359	0.545	rs62431209	chr6:130556308	G/A	cg23281432	chr6:130554730	NA	0.5	6.79	0.3	3.5e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg16141378	chr3:129829833	LOC729375	-0.46	-10.83	-0.45	1.59e-24	Triglycerides;
LGG	cis	rs7216064	1.000	rs60432293	chr17:65860407	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg20040747	chr15:74715105	SEMA7A	-0.41	-8.89	-0.38	1.34e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.19e-18	Neuroticism;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.23	0.55	2.25e-38	Obesity-related traits;
LGG	cis	rs2404602	0.622	rs11632670	chr15:76974055	A/G	cg15268244	chr15:77196840	NA	0.47	10.15	0.43	5.53e-22	Blood metabolite levels;
LGG	trans	rs7395662	1.000	rs10838917	chr11:48503127	G/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.87	-0.34	2.52e-14	HDL cholesterol;
LGG	cis	rs60843830	1.000	rs2290911	chr2:224919	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.51	8.56	0.37	1.72e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2270927	0.510	rs4352583	chr5:75576716	A/G	cg13563193	chr19:33072644	PDCD5	0.83	10.03	0.42	1.44e-21	Mean corpuscular volume;
LGG	cis	rs3126085	0.515	rs11204984	chr1:152331987	T/C	cg26876637	chr1:152193138	HRNR	-0.44	-6.81	-0.3	3.01e-11	Atopic dermatitis;
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg00800038	chr16:89945340	TCF25	-0.62	-8.78	-0.38	3.13e-17	Skin colour saturation;
LGG	cis	rs6088580	0.634	rs1890000	chr20:32968312	G/T	cg08999081	chr20:33150536	PIGU	-0.4	-10.21	-0.43	3.25e-22	Glomerular filtration rate (creatinine);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22969287	chr11:16760677	C11orf58	-0.5	-7.53	-0.33	2.64e-13	Systemic lupus erythematosus;
LGG	cis	rs4974559	0.895	rs10018133	chr4:1338246	C/T	cg02980000	chr4:1222292	CTBP1	0.66	7.9	0.34	2.03e-14	Systolic blood pressure;
LGG	cis	rs11967485	0.686	rs62435784	chr6:157132612	C/G	cg23222435	chr6:157204239	ARID1B	-0.77	-6.91	-0.31	1.59e-11	Calcium levels;
LGG	cis	rs2721195	0.719	rs4925811	chr8:145802447	G/T	cg11211951	chr8:145729740	GPT	-0.52	-12.49	-0.5	4.86e-31	Age at first birth;
LGG	cis	rs9611519	0.780	rs2235852	chr22:41661154	G/T	cg06634786	chr22:41940651	POLR3H	-0.43	-7.14	-0.31	3.68e-12	Neuroticism;
LGG	cis	rs7659604	0.967	rs34949254	chr4:122664344	G/A	cg19748678	chr4:122722346	EXOSC9	0.53	10.4	0.44	6.54e-23	Type 2 diabetes;
LGG	trans	rs7618501	0.521	rs2883059	chr3:49902160	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.5	-0.33	3.3e-13	Intelligence (multi-trait analysis);
LGG	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg10840412	chr1:235813424	GNG4	0.66	8.82	0.38	2.31e-17	Bipolar disorder;
LGG	cis	rs42648	0.596	rs194507	chr7:89843560	A/C	cg25739043	chr7:89950458	NA	0.33	6.95	0.31	1.26e-11	Homocysteine levels;
LGG	cis	rs916888	0.647	rs199449	chr17:44808902	G/A	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.48	8.31	0.36	1.07e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1816854	0.872	rs11182275	chr12:44206289	T/G	cg20956634	chr12:44200518	TWF1	0.44	6.7	0.3	5.91e-11	Inflammatory bowel disease;
LGG	cis	rs28595532	0.920	rs114094671	chr4:119753540	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.580	rs2327061	chr6:8447231	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs9910055	0.529	rs228766	chr17:42186813	A/G	cg19774624	chr17:42201019	HDAC5	0.64	11.27	0.46	3.41e-26	Total body bone mineral density;
LGG	cis	rs4409675	0.576	rs10794507	chr1:28216072	T/C	cg23691781	chr1:28212827	C1orf38	0.4	10.89	0.45	9.76e-25	Corneal astigmatism;
LGG	cis	rs6735179	0.688	rs2382563	chr2:1763599	T/C	cg10160682	chr2:1713001	PXDN	-0.55	-9.9	-0.42	4.49e-21	Response to antipsychotic treatment;
LGG	cis	rs7786877	0.723	rs7812235	chr7:100211486	G/C	cg03098644	chr7:100410630	EPHB4	0.47	6.69	0.3	6.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.6	0.65	4.5e-58	Menopause (age at onset);
LGG	cis	rs9359856	0.550	rs1179905	chr6:90322922	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.7	-10.42	-0.44	5.59e-23	Bipolar disorder;
LGG	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg07541023	chr7:19748670	TWISTNB	0.58	8.38	0.36	6.33e-16	Thyroid stimulating hormone;
LGG	cis	rs7769051	0.522	rs7761207	chr6:133110430	G/A	cg07930552	chr6:133119739	C6orf192	1.15	10.6	0.44	1.22e-23	Type 2 diabetes nephropathy;
LGG	cis	rs6546324	0.540	rs4671811	chr2:67827416	G/A	cg18237512	chr2:67827392	NA	-0.4	-7.15	-0.32	3.35e-12	Endometriosis;
LGG	cis	rs9942416	0.660	rs66493518	chr5:74990125	G/C	cg19683494	chr5:74908142	NA	0.44	6.86	0.3	2.21e-11	Age-related disease endophenotypes;
LGG	cis	rs2798269	0.902	rs2798280	chr13:22112853	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.07	-0.31	5.71e-12	PR segment;
LGG	cis	rs2836974	0.653	rs8130556	chr21:40516872	C/T	cg11644478	chr21:40555479	PSMG1	0.91	16.42	0.61	4.55e-48	Cognitive function;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.69	0.48	7.85e-28	IgG glycosylation;
LGG	cis	rs72772090	0.539	rs55773007	chr5:96124918	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.32	0.32	1.09e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1865760	1.000	rs3799372	chr6:25922311	A/G	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	trans	rs7944735	0.507	rs7934659	chr11:48066374	C/T	cg15704280	chr7:45808275	SEPT13	0.71	10.12	0.43	7.02e-22	Intraocular pressure;
LGG	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg12373951	chr3:133503437	NA	0.4	7.1	0.31	4.75e-12	Iron status biomarkers;
LGG	cis	rs7819412	0.668	rs2409715	chr8:11010136	A/T	cg27411982	chr8:10470053	RP1L1	-0.43	-7.06	-0.31	6.12e-12	Triglycerides;
LGG	cis	rs10504229	0.679	rs72649132	chr8:58054615	G/A	cg08280861	chr8:58055591	NA	0.63	7.76	0.34	5.38e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2117029	0.521	rs6580702	chr12:49563266	A/G	cg24176009	chr12:49580217	TUBA1A	0.63	12.25	0.49	4.51e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs10883502	chr10:102238343	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.06	0.46	2.16e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg02931644	chr1:25747376	RHCE	0.44	10.01	0.42	1.8e-21	Erythrocyte sedimentation rate;
LGG	cis	rs888194	0.568	rs10850141	chr12:109876128	C/T	cg19025524	chr12:109796872	NA	-0.38	-7.11	-0.31	4.36e-12	Neuroticism;
LGG	cis	rs9863	0.861	rs11057397	chr12:124419728	C/T	cg13487667	chr12:124434373	CCDC92	-0.36	-7.2	-0.32	2.38e-12	White blood cell count;
LGG	cis	rs9457247	1.000	rs409356	chr6:167405226	T/A	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs12451471	0.559	rs34746710	chr17:78079224	G/A	cg06718696	chr17:78121285	EIF4A3	0.89	14.4	0.56	4.24e-39	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7937682	0.889	rs551825	chr11:111480116	C/G	cg08305652	chr11:111469057	NA	-0.44	-9.05	-0.39	4.12e-18	Primary sclerosing cholangitis;
LGG	cis	rs3617	0.532	rs9836499	chr3:52904524	G/T	cg11645453	chr3:52864694	ITIH4	-0.45	-7.58	-0.33	1.85e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs368123	1.000	rs510615	chr6:160722449	G/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs9649465	1.000	rs10228367	chr7:123370903	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	cis	rs7617773	0.780	rs35411187	chr3:48360017	C/G	cg11946769	chr3:48343235	NME6	0.71	11.94	0.49	7.5e-29	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs74251568	chr16:89903416	A/C	cg26513180	chr16:89883248	FANCA	0.97	9.15	0.39	1.78e-18	Skin colour saturation;
LGG	cis	rs881375	0.678	rs1930782	chr9:123687905	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.68	0.41	2.61e-20	Rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs6741773	chr2:99738962	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.26	0.63	6.59e-52	Chronic sinus infection;
LGG	cis	rs9326248	0.559	rs476399	chr11:116733728	T/C	cg20608306	chr11:116969690	SIK3	0.4	12.93	0.51	7.58e-33	Blood protein levels;
LGG	trans	rs11039798	0.588	rs11039855	chr11:48610091	A/G	cg15704280	chr7:45808275	SEPT13	0.73	10.0	0.42	1.87e-21	Axial length;
LGG	cis	rs7584262	0.653	rs10210654	chr2:42264686	G/A	cg27428208	chr2:42229179	NA	0.5	7.45	0.33	4.65e-13	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10620501	chr8:37620046	PROSC	0.47	7.66	0.34	1.07e-13	Cognitive performance;
LGG	cis	rs8177253	0.763	rs8177224	chr3:133474003	C/G	cg16414030	chr3:133502952	NA	0.52	8.47	0.37	3.31e-16	Iron status biomarkers;
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.18	0.39	1.38e-18	Bipolar disorder;
LGG	cis	rs12477438	0.520	rs2632276	chr2:99779655	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	23.98	0.74	3.51e-83	Chronic sinus infection;
LGG	cis	rs4006360	0.610	rs7503043	chr17:39295561	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.14	-0.46	1.03e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.8	0.38	2.76e-17	Mood instability;
LGG	cis	rs4730250	0.708	rs3801965	chr7:106825628	G/T	cg02696742	chr7:106810147	HBP1	-0.77	-11.01	-0.46	3.22e-25	Osteoarthritis;
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg13047869	chr3:10149882	C3orf24	0.49	8.12	0.35	4.14e-15	Alzheimer's disease;
LGG	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg23601095	chr6:26197514	HIST1H3D	0.69	8.39	0.36	6.13e-16	Gout;Renal underexcretion gout;
LGG	cis	rs1348850	0.914	rs3813259	chr2:178257214	G/A	cg22681709	chr2:178499509	PDE11A	-0.44	-8.09	-0.35	5.27e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17270561	0.578	rs76182885	chr6:25904085	G/C	cg17691542	chr6:26056736	HIST1H1C	1.09	17.7	0.64	6.44e-54	Iron status biomarkers;
LGG	cis	rs992157	0.560	rs1514132	chr2:219084082	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.52	-8.69	-0.37	6.2e-17	Colorectal cancer;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	9.98	0.42	2.19e-21	Personality dimensions;
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg11764359	chr7:65958608	NA	-0.73	-13.03	-0.52	2.7e-33	Aortic root size;
LGG	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.49	-0.33	3.6e-13	Retinal vascular caliber;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.19	-0.32	2.56e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7582180	0.903	rs7607170	chr2:100903008	C/G	cg26150922	chr2:100937072	LONRF2	-0.53	-9.39	-0.4	2.82e-19	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.15	-0.35	3.36e-15	Neuroticism;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg04863758	chr4:1303710	MAEA	0.45	7.8	0.34	4.15e-14	Obesity-related traits;
LGG	cis	rs953387	0.910	rs59869505	chr2:136932321	A/C	cg07169764	chr2:136633963	MCM6	0.54	8.85	0.38	1.88e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg02018176	chr4:1364513	KIAA1530	0.42	9.38	0.4	2.88e-19	Obesity-related traits;
LGG	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg22676075	chr6:135203613	NA	0.43	7.43	0.33	5.38e-13	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs526231	0.543	rs6881225	chr5:102307592	T/C	cg23492399	chr5:102201601	PAM	-0.62	-9.4	-0.4	2.61e-19	Primary biliary cholangitis;
LGG	cis	rs6725041	0.547	rs59096325	chr2:213203853	C/T	cg16329650	chr2:213403929	ERBB4	-0.38	-6.71	-0.3	5.85e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs10779751	1.000	rs6679878	chr1:11306882	A/G	cg08854313	chr1:11322531	MTOR	0.75	16.65	0.61	4.15e-49	Body mass index;
LGG	cis	rs694739	0.734	rs663743	chr11:64107735	G/A	cg22916017	chr11:64110731	CCDC88B	0.49	9.69	0.41	2.37e-20	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.3	0.5	2.77e-30	Prudent dietary pattern;
LGG	cis	rs8053891	0.502	rs34679758	chr16:71995427	A/G	cg04254540	chr16:71951199	KIAA0174	-0.77	-9.85	-0.42	6.54e-21	Coronary artery disease;
LGG	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg18188782	chr20:61659543	NA	0.39	6.71	0.3	5.68e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1697139	0.967	rs1705396	chr5:66510876	T/C	cg11553311	chr5:66541588	NA	0.38	8.29	0.36	1.27e-15	Breast cancer;
LGG	trans	rs9354308	0.764	rs9354320	chr6:66583901	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.69	-0.41	2.52e-20	Lung cancer;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg22535103	chr8:58192502	C8orf71	-0.89	-12.35	-0.5	1.79e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4746818	1.000	rs7909631	chr10:70918676	C/T	cg11621586	chr10:70884670	VPS26A	1.19	21.94	0.71	1.07e-73	Left atrial antero-posterior diameter;
LGG	trans	rs877282	0.838	rs11253373	chr10:774857	A/G	cg22713356	chr15:30763199	NA	0.57	8.63	0.37	1.01e-16	Uric acid levels;
LGG	cis	rs1552244	1.000	rs17032299	chr3:10087638	C/T	cg08888203	chr3:10149979	C3orf24	0.59	9.93	0.42	3.49e-21	Alzheimer's disease;
LGG	cis	rs240764	0.658	rs10872628	chr6:101176349	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.73	-0.34	6.6e-14	Neuroticism;
LGG	cis	rs8180040	0.654	rs11714373	chr3:47214817	G/A	cg27129171	chr3:47204927	SETD2	-0.82	-15.03	-0.57	7.57e-42	Colorectal cancer;
LGG	cis	rs7914558	0.933	rs2066323	chr10:104871361	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.38	0.43	8.11e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4664308	0.967	rs17831329	chr2:160915819	T/C	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.17	-0.65	4.18e-56	Idiopathic membranous nephropathy;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg07959490	chr17:80112427	CCDC57	0.47	9.28	0.4	6.65e-19	Life satisfaction;
LGG	cis	rs67311347	1.000	rs28434528	chr3:40484893	A/G	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	cis	rs5769765	1.000	rs5770742	chr22:50270309	T/C	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg24690094	chr11:67383802	NA	-0.55	-10.28	-0.43	1.86e-22	Mean corpuscular volume;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.71	-0.38	5.55e-17	Menopause (age at onset);
LGG	cis	rs17604090	0.938	rs68158127	chr7:29684698	A/G	cg19413766	chr7:29689036	LOC646762	-0.62	-7.77	-0.34	5.14e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.7	-0.34	8.34e-14	Blood trace element (Cu levels);
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg07167872	chr1:205819463	PM20D1	0.6	12.27	0.5	3.54e-30	Menarche (age at onset);
LGG	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg00531865	chr16:30841666	NA	-0.52	-10.72	-0.45	4.29e-24	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg05556477	chr5:131705319	SLC22A5	0.83	10.09	0.42	9.02e-22	Rheumatoid arthritis;
LGG	cis	rs10752881	1.000	rs12028732	chr1:182985525	G/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs3106136	0.967	rs2087170	chr4:95162960	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.1	-0.35	4.8e-15	Capecitabine sensitivity;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20141549	chr3:51534298	VPRBP	-0.43	-7.11	-0.31	4.41e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1008375	0.800	rs28754811	chr4:17612312	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.8	0.3	3.17e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg15704280	chr7:45808275	SEPT13	-0.86	-13.17	-0.52	7.31e-34	Coronary artery disease;
LGG	cis	rs240764	0.853	rs4461738	chr6:100977940	T/C	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.52e-12	Neuroticism;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg18538332	chr22:24372958	LOC391322	-0.45	-7.46	-0.33	4.26e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9463078	0.801	rs9395079	chr6:45154433	C/T	cg25276700	chr6:44698697	NA	-0.38	-7.79	-0.34	4.54e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9325144	0.581	rs2730929	chr12:38942739	T/C	cg26384229	chr12:38710491	ALG10B	-0.84	-17.45	-0.63	8.77e-53	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg14675211	chr2:100938903	LONRF2	0.48	7.4	0.33	6.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs67460515	0.892	rs4856756	chr3:160999414	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.69	-0.41	2.43e-20	Parkinson's disease;
LGG	cis	rs1881797	1.000	rs10925069	chr1:247681313	C/T	cg11166453	chr1:247681781	NA	-0.66	-10.28	-0.43	1.89e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg03929089	chr4:120376271	NA	0.84	8.71	0.38	5.6e-17	Myopia (pathological);
LGG	cis	rs644799	0.965	rs10831426	chr11:95505888	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3782089	0.546	rs76146604	chr11:65277512	G/T	cg00206168	chr11:65308501	LTBP3	0.71	7.62	0.33	1.47e-13	Height;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	trans	rs208520	0.955	rs28684412	chr6:66979430	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs4731207	0.596	rs6971179	chr7:124592351	G/A	cg05630886	chr7:124431682	NA	-0.29	-6.71	-0.3	5.54e-11	Cutaneous malignant melanoma;
LGG	cis	rs6964587	1.000	rs926192	chr7:91671853	C/A	cg17063962	chr7:91808500	NA	0.49	8.69	0.37	6.38e-17	Breast cancer;
LGG	cis	rs9916302	0.560	rs3764352	chr17:37790939	C/T	cg00129232	chr17:37814104	STARD3	-0.78	-14.03	-0.55	1.62e-37	Glomerular filtration rate (creatinine);
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.97e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9814567	0.712	rs9838119	chr3:134331980	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4919087	0.715	rs946981	chr10:98995076	A/G	cg25902810	chr10:99078978	FRAT1	-0.43	-7.28	-0.32	1.41e-12	Monocyte count;
LGG	cis	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.68	11.98	0.49	5.41e-29	Obesity-related traits;
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg02127607	chr17:61920694	SMARCD2	0.46	8.36	0.36	7.42e-16	Prudent dietary pattern;
LGG	cis	rs6918586	0.658	rs198828	chr6:26119459	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.79	-0.41	1.1e-20	Schizophrenia;
LGG	cis	rs13314892	0.840	rs62250978	chr3:69840659	T/C	cg17445875	chr3:69859618	MITF	-0.38	-7.46	-0.33	4.27e-13	QRS complex (12-leadsum);
LGG	cis	rs6088580	0.524	rs1853056	chr20:33262058	C/T	cg07148914	chr20:33460835	GGT7	-0.49	-8.02	-0.35	8.65e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs1883415	0.534	rs760906	chr6:24479845	C/T	cg20631270	chr6:24437470	GPLD1	-0.5	-8.64	-0.37	9.29e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2243480	0.901	rs73148097	chr7:65431787	A/C	cg12463550	chr7:65579703	CRCP	0.73	8.02	0.35	8.57e-15	Diabetic kidney disease;
LGG	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg11584989	chr19:19387371	SF4	0.74	12.17	0.49	9.05e-30	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.82	0.54	1.33e-36	Lung cancer;
LGG	cis	rs1322639	0.614	rs6937001	chr6:169565086	C/T	cg04662567	chr6:169592167	NA	0.79	11.34	0.47	1.74e-26	Pulse pressure;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg05941027	chr17:61774174	LIMD2	0.35	9.05	0.39	4.09e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1129187	0.755	rs9471986	chr6:42944127	A/G	cg24101359	chr6:42928495	GNMT	0.51	14.35	0.55	6.55e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.7	0.34	8.21e-14	Educational attainment;
LGG	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg08677398	chr8:58056175	NA	0.46	7.37	0.32	7.85e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2289583	0.642	rs55798479	chr15:75392210	C/T	cg14664628	chr15:75095509	CSK	0.51	9.08	0.39	3.03e-18	Systemic lupus erythematosus;
LGG	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg00745463	chr17:30367425	LRRC37B	0.54	7.22	0.32	2.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1707322	0.717	rs2275086	chr1:46085879	C/G	cg03146154	chr1:46216737	IPP	-0.57	-11.38	-0.47	1.29e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg03517284	chr6:25882590	NA	-0.53	-10.09	-0.42	9.28e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs4911259	0.552	rs6058925	chr20:31465374	G/A	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.67	-0.48	8.79e-28	Inflammatory bowel disease;
LGG	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-10.11	-0.43	7.52e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.82	0.42	8.4e-21	Tonsillectomy;
LGG	cis	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.54	0.41	8.12e-20	Mean corpuscular volume;
LGG	trans	rs1814175	0.645	rs1722000	chr11:49917928	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg06026331	chr20:60912101	LAMA5	0.48	8.85	0.38	1.82e-17	Colorectal cancer;
LGG	cis	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg23422044	chr7:1970798	MAD1L1	-0.62	-10.73	-0.45	3.74e-24	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs8176323	chr17:41195711	G/C	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs4988958	0.565	rs885088	chr2:103039044	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.48e-19	Asthma (childhood onset);
LGG	cis	rs9287719	0.967	rs7566767	chr2:10754663	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9863	0.931	rs34180676	chr12:124431519	C/T	cg13487667	chr12:124434373	CCDC92	-0.38	-7.44	-0.33	4.89e-13	White blood cell count;
LGG	trans	rs61931739	0.500	rs11053207	chr12:34459827	A/G	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg27400746	chr16:89904261	SPIRE2	-0.84	-13.65	-0.54	6.65e-36	Skin colour saturation;
LGG	cis	rs78487399	0.808	rs17030925	chr2:43713808	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.81	-0.3	2.98e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs4774899	1.000	rs11858471	chr15:57262769	T/A	cg08128148	chr15:57256372	TCF12	-0.34	-8.26	-0.36	1.6e-15	Urinary tract infection frequency;
LGG	trans	rs11039798	0.920	rs9667596	chr11:48691193	T/C	cg15704280	chr7:45808275	SEPT13	0.76	8.76	0.38	3.78e-17	Axial length;
LGG	cis	rs77633900	0.772	rs387321	chr15:76743565	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.45	-0.37	3.86e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg00166722	chr3:10149974	C3orf24	0.52	8.8	0.38	2.77e-17	Alzheimer's disease;
LGG	cis	rs742614	0.533	rs2626547	chr20:32404921	G/A	cg06304546	chr20:32448765	NA	-0.69	-13.86	-0.54	9.05e-37	Stearic acid (18:0) levels;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg13206674	chr6:150067644	NUP43	0.65	14.64	0.56	3.53e-40	Lung cancer;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg10302505	chr8:128748092	MYC	-0.41	-6.65	-0.3	8.08e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs6828577	0.729	rs35604604	chr4:119421152	C/A	cg26518628	chr1:97050305	NA	-0.55	-8.76	-0.38	3.83e-17	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs2243480	1.000	rs313832	chr7:65550891	G/T	cg18252515	chr7:66147081	NA	-1.38	-19.63	-0.67	7.29e-63	Diabetic kidney disease;
LGG	trans	rs75804782	0.630	rs74404946	chr2:239300772	C/G	cg01134436	chr17:81009848	B3GNTL1	0.78	6.75	0.3	4.31e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3735485	0.760	rs4724347	chr7:45059112	G/T	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9649465	0.935	rs3815458	chr7:123304323	A/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.96	-0.38	8.13e-18	Migraine;
LGG	cis	rs1799949	1.000	rs2037075	chr17:41305826	G/T	cg18379455	chr17:41446167	NA	-0.32	-7.35	-0.32	8.92e-13	Menopause (age at onset);
LGG	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg14829360	chr17:73884958	NA	-0.8	-14.82	-0.57	6.21e-41	Psoriasis;
LGG	cis	rs4604732	0.631	rs75600450	chr1:247625492	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.69e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs2404602	0.583	rs12592501	chr15:76554790	C/A	cg23625390	chr15:77176239	SCAPER	0.42	7.87	0.34	2.58e-14	Blood metabolite levels;
LGG	cis	rs4973397	0.774	rs12998237	chr2:232276651	T/C	cg11378575	chr2:232265004	B3GNT7	0.58	10.06	0.42	1.2e-21	Anti-saccade response;
LGG	cis	rs875971	1.000	rs4718344	chr7:65874381	C/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg00938859	chr5:1591904	SDHAP3	-0.89	-13.09	-0.52	1.61e-33	Breast cancer;
LGG	trans	rs6089829	1.000	rs62207535	chr20:61669187	A/G	cg23505145	chr19:12996616	KLF1	0.39	6.84	0.3	2.52e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs950169	0.845	rs4502182	chr15:84923520	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	4.95e-17	Schizophrenia;
LGG	cis	rs2439831	0.867	rs2412778	chr15:43660982	A/G	cg15269541	chr15:43626905	ADAL	-0.41	-7.06	-0.31	6.23e-12	Lung cancer in ever smokers;
LGG	trans	rs9467711	0.606	rs9379900	chr6:26603811	A/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.51	-0.4	1.03e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg05556477	chr5:131705319	SLC22A5	0.85	10.19	0.43	3.8e-22	Rheumatoid arthritis;
LGG	cis	rs4917300	0.606	rs6583564	chr8:143114363	G/T	cg06573787	chr8:143070187	NA	0.6	10.02	0.42	1.57e-21	Amyotrophic lateral sclerosis;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg00177290	chr1:110161285	AMPD2	-0.38	-6.78	-0.3	3.66e-11	Apolipoprotein A-IV levels;
LGG	cis	rs4478037	0.749	rs9850896	chr3:33140817	C/T	cg19404215	chr3:33155277	CRTAP	1.01	11.43	0.47	8.24e-27	Major depressive disorder;
LGG	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.39	7.32	0.32	1.13e-12	Colorectal cancer;
LGG	cis	rs9487094	0.670	rs4490694	chr6:109892692	A/T	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	cis	rs929354	0.713	rs1034785	chr7:157002383	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.38	-0.32	7.6e-13	Body mass index;
LGG	trans	rs984440	0.524	rs6577869	chr8:139083777	C/A	cg03334052	chr1:168888044	NA	0.34	6.87	0.3	2.08e-11	Obesity-related traits;
LGG	cis	rs1816752	0.805	rs4769353	chr13:25000456	A/G	cg22771759	chr13:24902376	NA	0.42	7.09	0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg02023728	chr11:77925099	USP35	0.44	7.66	0.34	1.11e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg05861140	chr6:150128134	PCMT1	-0.45	-10.19	-0.43	3.9e-22	Lung cancer;
LGG	cis	rs6500395	0.775	rs1968902	chr16:48663974	A/G	cg04672837	chr16:48644449	N4BP1	0.49	8.05	0.35	7.14e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs920590	0.758	rs17091534	chr8:19670651	C/T	cg03894339	chr8:19674705	INTS10	0.64	10.29	0.43	1.74e-22	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07927839	chr12:53491483	IGFBP6	0.57	8.85	0.38	1.81e-17	Gut microbiome composition (summer);
LGG	cis	rs881375	0.654	rs10760126	chr9:123662618	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.8	0.45	2.2e-24	Rheumatoid arthritis;
LGG	trans	rs2018683	1.000	rs740252	chr7:28997765	C/G	cg19402173	chr7:128379420	CALU	-0.77	-14.76	-0.57	1.08e-40	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs892961	0.932	rs7208671	chr17:75413129	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.44	0.33	4.81e-13	Menopause (age at onset);
LGG	trans	rs2243480	1.000	rs316321	chr7:65611613	G/A	cg10756647	chr7:56101905	PSPH	0.82	9.55	0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs11693319	1.000	rs11693319	chr2:179738269	C/T	cg17765952	chr2:179737173	CCDC141	0.58	9.45	0.4	1.65e-19	Blood pressure measurement (cold pressor test);
LGG	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg20891283	chr12:69753455	YEATS4	0.97	22.99	0.73	1.43e-78	Blood protein levels;
LGG	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg12463550	chr7:65579703	CRCP	0.49	8.18	0.36	2.83e-15	Aortic root size;
LGG	cis	rs7582180	0.676	rs1437969	chr2:100983482	A/C	cg05692746	chr2:100937584	LONRF2	-0.61	-11.04	-0.46	2.56e-25	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.791	rs10033211	chr4:98995624	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2153535	0.580	rs965706	chr6:8464708	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs79149102	0.579	rs7172065	chr15:75321910	C/T	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.06	-0.35	6.46e-15	Lung cancer;
LGG	cis	rs7828089	0.935	rs2293144	chr8:22262418	A/G	cg12081754	chr8:22256438	SLC39A14	0.75	14.75	0.57	1.26e-40	Verbal declarative memory;
LGG	trans	rs800082	1.000	rs28847402	chr3:144316893	C/G	cg24215973	chr2:240111563	HDAC4	-0.5	-8.72	-0.38	4.91e-17	Smoking behavior;
LGG	cis	rs1008375	0.931	rs6831211	chr4:17697009	G/A	cg16339924	chr4:17578868	LAP3	0.5	8.52	0.37	2.33e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.694	rs4822032	chr22:41925535	T/C	cg17554472	chr22:41940697	POLR3H	-0.47	-7.02	-0.31	7.73e-12	Vitiligo;
LGG	cis	rs9768139	0.708	rs896779	chr7:158113390	T/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.34	-0.32	9.85e-13	Tonsillectomy;
LGG	cis	rs11074306	0.561	rs4778184	chr15:28065033	C/T	cg26402630	chr15:28053930	OCA2	0.36	7.21	0.32	2.3e-12	Uveal melanoma;
LGG	cis	rs9646954	0.542	rs4149513	chr2:101022726	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.83	-0.48	2.22e-28	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00559939	chr2:173600969	RAPGEF4;LOC91149	0.39	6.78	0.3	3.65e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6831352	0.918	rs17218073	chr4:100055739	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs7208859	0.524	rs73263982	chr17:28920624	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.72	-9.19	-0.39	1.36e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13217239	0.646	rs7747454	chr6:27034253	T/G	cg09904177	chr6:26538194	HMGN4	-0.39	-6.97	-0.31	1.13e-11	Schizophrenia;
LGG	cis	rs950169	1.000	rs11638394	chr15:84778928	G/A	cg24253500	chr15:84953950	NA	0.59	10.94	0.45	6.1e-25	Schizophrenia;
LGG	cis	rs988958	0.567	rs11892988	chr2:42246149	C/G	cg27252766	chr2:42229092	NA	0.5	7.83	0.34	3.47e-14	Hypospadias;
LGG	trans	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg14222797	chr10:16859974	RSU1	-0.65	-7.6	-0.33	1.69e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.85	-0.3	2.41e-11	Alzheimer's disease (survival time);
LGG	cis	rs13401104	0.716	rs57014724	chr2:237127936	G/A	cg15742758	chr2:237126235	ASB18	0.48	7.86	0.34	2.68e-14	Educational attainment;
LGG	cis	rs916888	0.773	rs199533	chr17:44828931	G/A	cg15921436	chr17:44337874	NA	0.58	12.44	0.5	7.74e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7927592	0.763	rs7119422	chr11:68331154	C/T	cg01657329	chr11:68192670	LRP5	0.56	10.68	0.44	6.01e-24	Total body bone mineral density;
LGG	cis	rs2415984	0.622	rs2415997	chr14:46930446	A/C	cg14871534	chr14:47121158	RPL10L	-0.59	-10.22	-0.43	3.12e-22	Number of children ever born;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs4481887	1.000	rs4430369	chr1:248464330	A/G	cg13385794	chr1:248469461	NA	0.5	8.45	0.37	3.78e-16	Common traits (Other);
LGG	cis	rs7829975	0.577	rs940030	chr8:8546928	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.95	-0.31	1.26e-11	Mood instability;
LGG	cis	rs2033711	0.870	rs7408188	chr19:58939389	T/G	cg00825309	chr19:58991885	ZNF446	-0.46	-9.45	-0.4	1.74e-19	Uric acid clearance;
LGG	cis	rs67460515	0.563	rs11922957	chr3:160828865	A/C	cg04691961	chr3:161091175	C3orf57	-0.44	-8.33	-0.36	9.38e-16	Parkinson's disease;
LGG	trans	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs6956675	0.915	rs4717497	chr7:62645096	A/G	cg01314568	chr7:57830625	NA	-0.47	-7.71	-0.34	7.78e-14	Obesity-related traits;
LGG	cis	rs2916247	0.954	rs28707439	chr8:93070202	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.39	-0.36	6.09e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11690935	1.000	rs6757773	chr2:172549630	T/A	cg21435375	chr2:172878103	MAP1D	0.31	6.91	0.31	1.58e-11	Schizophrenia;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg12708336	chr17:41446283	NA	-0.31	-7.07	-0.31	5.83e-12	Menopause (age at onset);
LGG	cis	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.54	0.37	1.96e-16	Platelet distribution width;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.45	0.44	4.37e-23	Personality dimensions;
LGG	cis	rs35146811	0.844	rs2070215	chr7:99696797	T/C	cg22906224	chr7:99728672	NA	0.56	8.75	0.38	4.09e-17	Coronary artery disease;
LGG	cis	rs736408	0.688	rs2239551	chr3:52818579	A/G	cg11645453	chr3:52864694	ITIH4	-0.42	-7.02	-0.31	7.88e-12	Bipolar disorder;
LGG	cis	rs2120019	1.000	rs7167285	chr15:75368769	A/G	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.52	-0.67	2.34e-62	Blood trace element (Zn levels);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02343648	chr10:102133165	C10orf75	0.36	7.04	0.31	6.9e-12	Menarche (age at onset);
LGG	cis	rs11971779	0.680	rs17613690	chr7:139088401	C/T	cg07862535	chr7:139043722	LUC7L2	-0.43	-7.19	-0.32	2.61e-12	Diisocyanate-induced asthma;
LGG	cis	rs2013441	0.866	rs62067558	chr17:20025706	G/T	cg13482628	chr17:19912719	NA	0.42	7.08	0.31	5.42e-12	Obesity-related traits;
LGG	cis	rs17767392	0.918	rs17178234	chr14:71900364	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	2.8e-18	Mitral valve prolapse;
LGG	cis	rs17453880	0.890	rs61070048	chr5:151964713	A/C	cg10931792	chr5:152022470	NA	0.38	8.29	0.36	1.25e-15	Subjective well-being;
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg13959647	chr9:123605229	PSMD5;LOC253039	0.54	9.34	0.4	3.96e-19	Birth weight;
LGG	cis	rs2072499	0.750	rs57056972	chr1:156159064	C/A	cg24450063	chr1:156163899	SLC25A44	1.08	18.76	0.66	8.03e-59	Testicular germ cell tumor;
LGG	trans	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg25214090	chr10:38739885	LOC399744	0.59	10.56	0.44	1.72e-23	Corneal astigmatism;
LGG	cis	rs35306767	0.855	rs55708963	chr10:925712	C/A	cg25019033	chr10:957182	NA	-0.56	-9.45	-0.4	1.75e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs7619708	1	rs7619708	chr3:195810187	T/C	cg23484912	chr5:273055	PDCD6	-0.44	-8.06	-0.35	6.34e-15	Red cell distribution width;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg08677398	chr8:58056175	NA	0.46	7.14	0.32	3.57e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.739	rs11719306	chr3:47184182	G/A	cg27129171	chr3:47204927	SETD2	0.85	16.55	0.61	1.2e-48	Colorectal cancer;
LGG	cis	rs75059851	0.932	rs73034295	chr11:133822133	G/A	cg17703048	chr11:133852993	NA	-0.75	-12.41	-0.5	9.52e-31	Schizophrenia;
LGG	cis	rs77633900	0.614	rs2439989	chr15:76883862	G/C	cg21673338	chr15:77095150	SCAPER	-0.65	-10.07	-0.42	1.08e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs12410462	0.591	rs2644161	chr1:227706319	A/G	cg23173402	chr1:227635558	NA	-0.39	-7.29	-0.32	1.37e-12	Major depressive disorder;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg21782813	chr7:2030301	MAD1L1	0.39	9.1	0.39	2.65e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.760	rs1242198	chr1:53352016	G/A	cg16325326	chr1:53192061	ZYG11B	0.68	15.53	0.59	4.26e-44	Monocyte count;
LGG	cis	rs7646881	0.812	rs73015644	chr3:158447744	C/T	cg19483011	chr3:158453295	NA	-0.59	-7.8	-0.34	4.05e-14	Tetralogy of Fallot;
LGG	cis	rs1620921	0.622	rs73029748	chr6:161268408	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1034435	0.755	rs5767173	chr22:48892473	T/C	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.86	-0.62	4.48e-50	Late-onset Alzheimer's disease;
LGG	cis	rs9287719	0.753	rs1990613	chr2:10781975	C/T	cg02196655	chr2:10830764	NOL10	0.49	8.67	0.37	7.43e-17	Prostate cancer;
LGG	cis	rs4930103	0.935	rs2071094	chr11:2021164	G/T	cg23202291	chr11:1979235	NA	0.37	7.02	0.31	7.94e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs4417704	0.551	rs4315517	chr2:241894906	T/G	cg26818257	chr2:241905806	NA	0.5	10.98	0.45	4.52e-25	Joint mobility (Beighton score);
LGG	cis	rs1707322	1.000	rs10890375	chr1:46406581	G/A	cg03146154	chr1:46216737	IPP	0.54	10.23	0.43	2.73e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9457247	0.765	rs9457259	chr6:167444281	C/T	cg07741184	chr6:167504864	NA	0.43	9.49	0.4	1.26e-19	Crohn's disease;
LGG	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.36	-0.47	1.52e-26	Type 2 diabetes;
LGG	cis	rs12949688	0.934	rs12449409	chr17:55822467	G/A	cg12582317	chr17:55822272	NA	0.69	20.11	0.68	4.28e-65	Schizophrenia;
LGG	cis	rs2247341	1.000	rs8051	chr4:1694809	C/T	cg08629884	chr4:1719983	TMEM129	0.56	10.59	0.44	1.26e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg00405596	chr8:11794950	NA	-0.39	-6.76	-0.3	4.04e-11	Neuroticism;
LGG	cis	rs1355223	0.902	rs7121272	chr11:34752562	T/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.03	-0.31	7.4e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10504229	1.000	rs72652905	chr8:58188355	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.48	-0.5	4.99e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs7917772	0.503	rs1536308	chr10:104288777	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg08885076	chr2:99613938	TSGA10	0.43	9.3	0.4	5.52e-19	Chronic sinus infection;
LGG	cis	rs61931739	0.500	rs7296061	chr12:34435009	A/G	cg06521331	chr12:34319734	NA	0.58	10.16	0.43	4.85e-22	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg06873352	chr17:61820015	STRADA	0.72	13.35	0.53	1.3e-34	Prudent dietary pattern;
LGG	cis	rs16976116	0.851	rs11855907	chr15:55494634	A/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg16301924	chr13:53314226	LECT1	0.44	8.88	0.38	1.52e-17	Lewy body disease;
LGG	cis	rs2289583	0.544	rs1867153	chr15:75271229	C/T	cg14664628	chr15:75095509	CSK	0.59	9.88	0.42	5.14e-21	Systemic lupus erythematosus;
LGG	cis	rs7582720	1.000	rs72932786	chr2:203698737	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.37	0.69	2.63e-66	Alzheimer's disease;
LGG	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.66	-0.41	3.22e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg21972741	chr5:435613	AHRR	0.49	8.83	0.38	2.12e-17	Cystic fibrosis severity;
LGG	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg00278107	chr5:1061253	SLC12A7	0.41	7.0	0.31	9.26e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9914544	0.545	rs12937933	chr17:18770283	C/G	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.56	-0.33	2.16e-13	Educational attainment (years of education);
LGG	cis	rs6963495	1.000	rs6963495	chr7:105166853	T/C	cg19920283	chr7:105172520	RINT1	0.59	7.2	0.32	2.42e-12	Bipolar disorder (body mass index interaction);
LGG	trans	rs7965445	0.614	rs4907443	chr12:131972307	G/A	cg16675054	chr5:171616574	STK10	0.35	6.67	0.3	7.12e-11	Mortality in heart failure;
LGG	cis	rs7091068	0.754	rs1326224	chr10:95459267	C/T	cg20715218	chr10:95462985	C10orf4	0.68	10.56	0.44	1.61e-23	Urinary tract infection frequency;
LGG	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg02753203	chr1:228287806	NA	-0.63	-11.73	-0.48	5.44e-28	Diastolic blood pressure;
LGG	cis	rs2862064	0.932	rs1553319	chr5:156479001	T/A	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.59	-0.44	1.33e-23	Platelet count;
LGG	cis	rs7017914	0.902	rs35580034	chr8:71572073	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs6960043	0.601	rs12374901	chr7:15024954	C/T	cg19272540	chr7:15055459	NA	-0.32	-6.78	-0.3	3.57e-11	Type 2 diabetes;
LGG	cis	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg04861929	chr11:109293070	C11orf87	0.51	9.53	0.4	9.05e-20	Schizophrenia;
LGG	cis	rs41271473	0.500	rs4606285	chr1:228887544	G/T	cg00850481	chr1:228891306	NA	-0.62	-14.16	-0.55	4.42e-38	Chronic lymphocytic leukemia;
LGG	cis	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg25986240	chr4:9926439	SLC2A9	-0.5	-9.55	-0.41	7.45e-20	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg13939156	chr17:80058883	NA	0.49	9.64	0.41	3.54e-20	Life satisfaction;
LGG	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg11846333	chr4:119757529	SEC24D	0.75	7.03	0.31	7.3e-12	Cannabis dependence symptom count;
LGG	cis	rs7851660	0.874	rs10122541	chr9:100628268	G/A	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs9747201	0.894	rs4503854	chr17:80178696	A/T	cg13939156	chr17:80058883	NA	-0.42	-7.32	-0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2274273	0.934	rs10137307	chr14:55845185	T/C	cg04306507	chr14:55594613	LGALS3	0.6	16.41	0.61	5.14e-48	Protein biomarker;
LGG	cis	rs1109114	0.934	rs7714706	chr5:148620848	G/A	cg06539116	chr5:148597365	ABLIM3	-0.57	-14.38	-0.56	5.11e-39	Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07790826	chr11:70049435	FADD	-0.43	-6.81	-0.3	3.06e-11	Pancreatic cancer;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg23034840	chr1:205782522	SLC41A1	0.53	8.83	0.38	2.16e-17	Menarche (age at onset);
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg11211951	chr8:145729740	GPT	0.61	14.67	0.56	2.88e-40	Age at first birth;
LGG	cis	rs62400317	0.762	rs857601	chr6:44805214	G/T	cg18551225	chr6:44695536	NA	0.64	10.61	0.44	1.12e-23	Total body bone mineral density;
LGG	cis	rs283228	0.958	rs2629979	chr6:101786114	G/A	cg27451362	chr6:101846650	GRIK2	0.53	8.91	0.38	1.16e-17	Coenzyme Q10 levels;
LGG	cis	rs4262150	0.672	rs55978039	chr5:152348505	A/T	cg12297329	chr5:152029980	NA	-0.56	-8.68	-0.37	6.66e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7923837	1.000	rs10748582	chr10:94477219	A/T	cg25093409	chr10:94429542	NA	0.37	6.86	0.3	2.27e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs17491951	0.735	rs13020509	chr2:2886851	A/T	cg02105481	chr2:2853515	NA	0.44	8.96	0.38	8.22e-18	White matter integrity (bipolar disorder risk interaction);
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg12379764	chr21:47803548	PCNT	-0.5	-8.27	-0.36	1.41e-15	Testicular germ cell tumor;
LGG	cis	rs4650994	1.000	rs17361251	chr1:178520577	C/A	cg12486710	chr1:178512616	C1orf220	0.42	8.52	0.37	2.33e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4803468	0.967	rs892044	chr19:41903671	A/G	cg14132834	chr19:41945861	ATP5SL	-0.48	-9.55	-0.41	7.44e-20	Height;
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.37	-0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg00187635	chr16:83986795	OSGIN1	0.44	6.92	0.31	1.51e-11	Pursuit maintenance gain;
LGG	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg18188782	chr20:61659543	NA	0.4	6.71	0.3	5.75e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.63	0.33	1.38e-13	Lung cancer;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.77	-0.45	2.64e-24	Lung cancer;
LGG	cis	rs7824557	0.614	rs2736286	chr8:11227104	A/G	cg15596359	chr8:11213517	TDH	0.38	7.83	0.34	3.24e-14	Retinal vascular caliber;
LGG	cis	rs4409675	0.576	rs7520860	chr1:28232952	C/A	cg23691781	chr1:28212827	C1orf38	0.41	11.12	0.46	1.26e-25	Corneal astigmatism;
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg10802521	chr3:52805072	NEK4	0.4	6.98	0.31	1e-11	Electroencephalogram traits;
LGG	cis	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg11040518	chr10:102331378	NA	-0.4	-7.25	-0.32	1.77e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2797369	0.574	rs4591857	chr6:101597761	G/T	cg27451362	chr6:101846650	GRIK2	0.47	7.4	0.33	6.43e-13	Renal function-related traits (eGRFcrea);
LGG	cis	rs2880765	0.835	rs6497202	chr15:86021375	T/C	cg13263323	chr15:86062960	AKAP13	-0.36	-7.48	-0.33	3.66e-13	Coronary artery disease;
LGG	cis	rs62400317	0.859	rs10456548	chr6:45219699	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.12	-0.43	7.2e-22	Total body bone mineral density;
LGG	cis	rs7103648	0.695	rs10838726	chr11:47568344	C/G	cg20307385	chr11:47447363	PSMC3	0.87	18.64	0.65	2.84e-58	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14395634	chr11:65626208	CFL1	0.45	7.58	0.33	1.86e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6028335	0.867	rs67147849	chr20:37695241	C/T	cg16355469	chr20:37678765	NA	0.56	7.17	0.32	3.03e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs4975709	1.000	rs4975709	chr5:1877280	A/C	cg14773178	chr5:1868261	NA	0.38	7.25	0.32	1.79e-12	Cardiovascular disease risk factors;
LGG	cis	rs7089973	0.604	rs765174	chr10:116601888	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2011503	1.000	rs2965194	chr19:19460702	C/T	cg11584989	chr19:19387371	SF4	-0.76	-12.66	-0.51	9.36e-32	Bipolar disorder;
LGG	cis	rs1862618	0.671	rs2034244	chr5:56242774	T/C	cg17809284	chr5:56205270	C5orf35	0.52	9.69	0.41	2.42e-20	Initial pursuit acceleration;
LGG	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.8	-0.3	3.34e-11	Blood metabolite levels;
LGG	cis	rs709400	0.643	rs11621777	chr14:104072090	A/G	cg26031613	chr14:104095156	KLC1	1.18	29.68	0.81	3.29e-109	Body mass index;
LGG	cis	rs1729951	0.575	rs75976	chr3:136700455	G/A	cg21827317	chr3:136751795	NA	0.54	9.96	0.42	2.55e-21	Neuroticism;
LGG	cis	rs7945705	0.902	rs2016942	chr11:8938787	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.04	0.31	6.89e-12	Hemoglobin concentration;
LGG	trans	rs1814175	0.935	rs1827017	chr11:49632592	C/G	cg03929089	chr4:120376271	NA	-1.02	-22.48	-0.72	3.37e-76	Height;
LGG	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg27532318	chr7:32358331	NA	0.71	7.31	0.32	1.19e-12	Body mass index;
LGG	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.520	rs13023744	chr2:99738224	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs688020	1.000	rs673500	chr7:4229445	C/G	cg02004499	chr7:4244250	SDK1	-0.61	-11.27	-0.46	3.49e-26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;
LGG	cis	rs77372450	0.636	rs11465233	chr5:157001953	T/A	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.81e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs7923452	0.938	rs67812762	chr10:30759479	G/T	cg25182066	chr10:30743637	MAP3K8	0.45	6.71	0.3	5.87e-11	Itch intensity from mosquito bite;
LGG	cis	rs16854884	0.770	rs6784938	chr3:143817528	C/T	cg06585982	chr3:143692056	C3orf58	0.53	8.3	0.36	1.15e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs7512552	0.839	rs1260421	chr1:150357780	G/A	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9815354	0.680	rs73073285	chr3:42027566	T/G	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs193541	0.632	rs152038	chr5:122195846	G/A	cg19412675	chr5:122181750	SNX24	0.53	8.34	0.36	8.33e-16	Glucose homeostasis traits;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs10489202	0.683	rs2294817	chr1:168073601	C/A	cg24449463	chr1:168025552	DCAF6	-0.56	-10.0	-0.42	1.84e-21	Schizophrenia;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg22535103	chr8:58192502	C8orf71	-0.93	-12.81	-0.51	2.24e-32	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	cis	rs1920116	0.778	rs34194057	chr3:169549551	G/T	cg08193579	chr3:169529701	LRRC34	0.4	6.65	0.3	8.06e-11	Glioma (high-grade);
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg11360546	chr7:1094263	C7orf50	-0.38	-6.8	-0.3	3.31e-11	Longevity;Endometriosis;
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg14403583	chr14:105418241	AHNAK2	0.76	14.98	0.57	1.15e-41	Rheumatoid arthritis;
LGG	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg02269571	chr22:50332266	NA	0.45	7.39	0.32	7.09e-13	Schizophrenia;
LGG	cis	rs986417	0.818	rs4278669	chr14:60982075	T/C	cg27398547	chr14:60952738	C14orf39	0.72	7.05	0.31	6.47e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs668210	0.894	rs1786171	chr11:65769809	G/C	cg02202077	chr11:65769826	EIF1AD;BANF1	0.75	11.07	0.46	1.9e-25	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17767392	1.000	rs17178206	chr14:71880093	A/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.1	0.39	2.75e-18	Mitral valve prolapse;
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg15971980	chr6:150254442	NA	0.45	8.44	0.36	4.23e-16	Lung cancer;
LGG	cis	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	8.17	0.35	2.95e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg05484508	chr16:89589025	SPG7	0.46	7.44	0.33	4.95e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs2016266	0.784	rs10747666	chr12:53716836	G/A	cg13445358	chr12:53661749	ESPL1	-0.37	-7.17	-0.32	3.03e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4671458	0.948	rs72815377	chr2:63599530	C/T	cg17519650	chr2:63277830	OTX1	-0.61	-7.78	-0.34	4.69e-14	Subjective well-being;
LGG	cis	rs887829	0.569	rs3806597	chr2:234637569	C/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	0.42	7.88	0.34	2.32e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs6665290	0.904	rs12409428	chr1:227189969	T/C	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs875971	1.000	rs875971	chr7:65617595	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.97	-0.42	2.41e-21	Aortic root size;
LGG	cis	rs17818399	0.620	rs1080871	chr2:46854708	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.47	-8.18	-0.36	2.86e-15	Height;
LGG	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg16230307	chr14:35515116	FAM177A1	0.88	13.03	0.52	2.91e-33	Psoriasis;
LGG	cis	rs72781680	0.583	rs6731333	chr2:24113354	C/T	cg08917208	chr2:24149416	ATAD2B	0.6	7.7	0.34	8.51e-14	Lymphocyte counts;
LGG	cis	rs2694528	0.858	rs158699	chr5:60325888	T/C	cg11474532	chr5:59995715	DEPDC1B	-0.68	-7.28	-0.32	1.43e-12	Parkinson's disease;
LGG	cis	rs7133214	0.771	rs12368818	chr12:27921621	A/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.91	-0.31	1.58e-11	Gut microbiota (functional units);
LGG	trans	rs1728785	1.000	rs11075680	chr16:68565700	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs7539542	0.556	rs10753925	chr1:202854488	C/T	cg19681188	chr1:202830198	LOC148709	0.52	8.77	0.38	3.34e-17	Mean platelet volume;
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-15.42	-0.58	1.36e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	0.958	rs12202188	chr6:86562700	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.05	-0.39	4e-18	Response to antipsychotic treatment;
LGG	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.32	0.32	1.1e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs920590	0.643	rs2083641	chr8:19660217	A/C	cg03894339	chr8:19674705	INTS10	0.5	8.54	0.37	2.01e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs721917	0.506	rs2244451	chr10:81644990	G/A	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.66e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs67133203	0.659	rs224589	chr12:51399050	A/C	cg14688905	chr12:51403056	SLC11A2	-0.57	-9.53	-0.41	8.73e-20	Urinary tract infection frequency;
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg07005078	chr4:17578674	LAP3	0.38	6.87	0.3	2.05e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10463554	0.892	rs1560040	chr5:102300067	C/A	cg23492399	chr5:102201601	PAM	-0.56	-8.47	-0.37	3.26e-16	Parkinson's disease;
LGG	trans	rs4813802	0.724	rs2876052	chr20:6711572	C/T	cg01883025	chr16:30441151	DCTPP1	0.58	7.4	0.33	6.41e-13	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.967	rs2576030	chr18:44659166	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.41	7.76	0.34	5.43e-14	Educational attainment;
LGG	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg10760299	chr15:45669010	GATM	0.4	7.78	0.34	4.67e-14	Homoarginine levels;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.85	-0.38	1.92e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7659604	0.502	rs13106764	chr4:122699630	C/G	cg20573242	chr4:122745356	CCNA2	-0.47	-8.15	-0.35	3.45e-15	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12317515	chr5:74063363	GFM2;NSA2	0.48	7.14	0.31	3.54e-12	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs8075257	chr17:61728750	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.49	0.33	3.41e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg23743428	chr13:21893420	NA	-0.46	-10.47	-0.44	3.69e-23	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7267979	0.586	rs6050439	chr20:25192331	T/C	cg06421707	chr20:25228305	PYGB	0.39	8.04	0.35	7.54e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.95	0.6	5.6e-46	Lung cancer;
LGG	cis	rs10791097	0.547	rs11222371	chr11:130745719	C/T	cg12179176	chr11:130786555	SNX19	0.87	17.58	0.63	2.34e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6704644	0.932	rs11686188	chr2:234451630	C/T	cg27060346	chr2:234359958	DGKD	-0.59	-7.55	-0.33	2.36e-13	Bilirubin levels;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.79	-0.41	1.04e-20	Triglycerides;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.79	15.73	0.59	5.9e-45	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.91e-60	Menopause (age at onset);
LGG	cis	rs950776	0.667	rs57728226	chr15:78929350	G/C	cg06917634	chr15:78832804	PSMA4	0.65	11.63	0.48	1.35e-27	Sudden cardiac arrest;
LGG	cis	rs17270561	0.636	rs6456694	chr6:25712894	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.8e-14	Iron status biomarkers;
LGG	cis	rs1577917	1.000	rs955227	chr6:86651032	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.78	-13.85	-0.54	9.74e-37	Response to antipsychotic treatment;
LGG	trans	rs6601450	0.522	rs7837979	chr8:10198534	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.23	-0.36	1.94e-15	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12477438	0.765	rs10193039	chr2:99692373	A/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.89	-15.26	-0.58	6.98e-43	Chronic sinus infection;
LGG	cis	rs7715811	1.000	rs1502042	chr5:13758344	G/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.81	-0.41	8.92e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs2073499	1.000	rs2071802	chr3:50412945	A/G	cg03645007	chr3:50255295	SLC38A3	0.61	6.68	0.3	7.07e-11	Schizophrenia;
LGG	cis	rs2204008	0.639	rs7311462	chr12:38278130	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.4	-0.4	2.45e-19	Personality dimensions;
LGG	trans	rs61931739	0.534	rs10844725	chr12:34009504	C/A	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs9303401	0.659	rs12944971	chr17:56988801	A/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.97	0.38	7.66e-18	Cognitive test performance;
LGG	cis	rs9397585	0.502	rs6557273	chr6:153443159	A/G	cg12989544	chr6:153429875	RGS17	0.31	7.11	0.31	4.32e-12	Body mass index;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg26354017	chr1:205819088	PM20D1	-0.42	-7.31	-0.32	1.19e-12	Menarche (age at onset);
LGG	trans	rs6952808	0.689	rs1107591	chr7:2041638	G/A	cg24247370	chr13:99142703	STK24	-0.36	-6.75	-0.3	4.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-8.01	-0.35	9.6e-15	Life satisfaction;
LGG	cis	rs13082711	0.911	rs2370995	chr3:27428216	C/T	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.69e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs208520	0.526	rs9363522	chr6:66816642	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-31.95	-0.83	3.47e-119	Exhaled nitric oxide output;
LGG	cis	rs6977660	1.000	rs12531373	chr7:19816825	A/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	cis	rs908922	0.676	rs10788842	chr1:152514588	A/T	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-15.4	-0.58	1.61e-43	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9611565	0.504	rs5758452	chr22:42144927	G/A	cg17376030	chr22:41985996	PMM1	-0.55	-9.09	-0.39	2.91e-18	Vitiligo;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg05861140	chr6:150128134	PCMT1	-0.46	-10.61	-0.44	1.09e-23	Lung cancer;
LGG	trans	rs7829975	0.806	rs2428	chr8:8641145	C/T	cg27411982	chr8:10470053	RP1L1	0.41	7.13	0.31	3.78e-12	Mood instability;
LGG	cis	rs17453880	0.890	rs6860811	chr5:152049653	G/T	cg12297329	chr5:152029980	NA	-0.9	-23.18	-0.73	1.8e-79	Subjective well-being;
LGG	cis	rs2694528	1.000	rs11744756	chr5:60201715	C/T	cg11474532	chr5:59995715	DEPDC1B	0.71	7.36	0.32	8.48e-13	Parkinson's disease;
LGG	cis	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg04455712	chr21:45112962	RRP1B	0.52	9.84	0.42	6.98e-21	Mean corpuscular volume;
LGG	cis	rs7208859	0.673	rs9912122	chr17:29140716	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.8	-10.43	-0.44	5.24e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3806843	0.576	rs246045	chr5:140329884	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	trans	rs2562456	0.833	rs62109218	chr19:21528861	A/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs1355223	0.583	rs2956076	chr11:34874124	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.38	-7.1	-0.31	4.88e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.84	-0.42	7.11e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs2820315	0.928	rs2678210	chr1:201787940	T/C	cg10061532	chr1:201886748	LMOD1	0.35	7.15	0.32	3.45e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs7432375	0.901	rs1017882	chr3:136357705	T/C	cg21827317	chr3:136751795	NA	0.48	8.59	0.37	1.39e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2117029	0.862	rs10875915	chr12:49430094	C/T	cg24176009	chr12:49580217	TUBA1A	0.43	7.75	0.34	5.98e-14	Intelligence (multi-trait analysis);
LGG	cis	rs72717009	0.825	rs10494360	chr1:161475750	G/A	cg23840854	chr1:161414152	NA	-0.73	-8.83	-0.38	2.21e-17	Rheumatoid arthritis;
LGG	cis	rs240764	0.658	rs35967345	chr6:101187858	T/G	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs4865875	0.892	rs73126830	chr5:54071978	C/G	cg22421804	chr5:54100067	NA	-0.52	-6.92	-0.31	1.47e-11	Sense of smell;
LGG	trans	rs6582630	0.560	rs11504462	chr12:38440379	G/A	cg06521331	chr12:34319734	NA	0.45	8.04	0.35	7.84e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg00405596	chr8:11794950	NA	-0.44	-7.51	-0.33	3.08e-13	Morning vs. evening chronotype;
LGG	cis	rs2072499	0.966	rs2853643	chr1:156184831	G/A	cg25208724	chr1:156163844	SLC25A44	1.17	24.69	0.75	1.63e-86	Testicular germ cell tumor;
LGG	cis	rs2737618	0.722	rs2737680	chr1:200088559	C/A	cg21825944	chr1:200113062	NR5A2	-0.62	-12.04	-0.49	3.03e-29	Uric acid levels;
LGG	cis	rs755249	0.567	rs16825921	chr1:39649198	A/T	cg18385671	chr1:39797026	MACF1	0.44	7.16	0.32	3.16e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2075371	0.611	rs34573600	chr7:134018937	C/T	cg11752832	chr7:134001865	SLC35B4	0.5	8.32	0.36	9.770000000000001e-16	Mean platelet volume;
LGG	cis	rs4595586	0.545	rs6580888	chr12:39369704	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs1568889	0.838	rs11030220	chr11:28145769	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.23	0.67	5.37e-61	Bipolar disorder;
LGG	cis	rs789852	0.681	rs789856	chr3:194329805	T/C	cg18000598	chr3:194342907	TMEM44	-0.74	-7.68	-0.34	9.52e-14	QT interval;
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1008375	0.966	rs12509962	chr4:17680292	G/A	cg18681998	chr4:17616180	MED28	0.82	18.17	0.65	4.47e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836974	0.545	rs3167757	chr21:40714478	C/T	cg11890956	chr21:40555474	PSMG1	0.75	12.96	0.52	5.21e-33	Cognitive function;
LGG	cis	rs1978968	1.000	rs5013012	chr22:18450149	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.63	-12.78	-0.51	2.95e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg26384229	chr12:38710491	ALG10B	0.99	23.69	0.74	7.66e-82	Heart rate;
LGG	trans	rs225245	0.817	rs225299	chr17:33922742	T/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.1	-0.31	4.87e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs634534	0.622	rs624273	chr11:65712413	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.43	7.11	0.31	4.45e-12	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs561341	0.505	rs28708703	chr17:30386845	C/G	cg13647721	chr17:30228624	UTP6	0.62	7.76	0.34	5.33e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3812831	0.695	rs7983872	chr13:114944781	T/G	cg25338242	chr13:114786047	RASA3	0.41	7.4	0.33	6.37e-13	Schizophrenia;
LGG	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.18e-29	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4243971	0.516	rs6141302	chr20:30984239	G/T	cg00028034	chr20:30779307	TSPYL3	0.33	6.73	0.3	4.94e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.702	rs3789038	chr16:4546586	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.36	-8.11	-0.35	4.68e-15	Schizophrenia;
LGG	cis	rs4930103	0.591	rs11042048	chr11:1986240	C/G	cg18511798	chr11:2018149	H19;MIR675	-0.57	-10.84	-0.45	1.55e-24	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1862618	0.853	rs252910	chr5:56192983	G/A	cg03609598	chr5:56110824	MAP3K1	-0.57	-8.1	-0.35	4.99e-15	Initial pursuit acceleration;
LGG	trans	rs4718428	0.607	rs66954441	chr7:66369209	T/C	cg10756647	chr7:56101905	PSPH	0.47	7.01	0.31	8.24e-12	Corneal structure;
LGG	cis	rs11671005	0.693	rs34230465	chr19:58943576	C/G	cg13877915	chr19:58951672	ZNF132	0.6	8.36	0.36	7.47e-16	Mean platelet volume;
LGG	cis	rs1577917	0.958	rs1591438	chr6:86525214	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-14.21	-0.55	2.78e-38	Response to antipsychotic treatment;
LGG	cis	rs9910055	0.530	rs2269905	chr17:42294462	A/G	cg13607699	chr17:42295918	UBTF	0.91	18.92	0.66	1.44e-59	Total body bone mineral density;
LGG	cis	rs919433	0.680	rs2605039	chr2:198362851	C/A	cg00792783	chr2:198669748	PLCL1	0.5	7.92	0.35	1.77e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7582180	0.625	rs11892034	chr2:100938952	T/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1878931	0.501	rs9921169	chr16:3421261	A/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	13.82	0.54	1.23e-36	Body mass index (adult);
LGG	cis	rs7192750	0.538	rs28594331	chr16:71863482	C/T	cg06353428	chr16:71660113	MARVELD3	0.66	10.26	0.43	2.09e-22	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6582630	0.638	rs12423236	chr12:38548162	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.08e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4478858	0.684	rs7519766	chr1:31735512	C/A	cg19084893	chr1:31688959	NA	0.31	6.85	0.3	2.32e-11	Alcohol dependence;
LGG	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg08344181	chr3:125677491	NA	0.56	7.28	0.32	1.45e-12	Depression;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg08645402	chr16:4508243	NA	0.5	9.5	0.4	1.13e-19	Schizophrenia;
LGG	cis	rs7208859	0.673	rs11653955	chr17:29033292	C/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.53	0.44	2.24e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11771526	0.792	rs62457499	chr7:32319197	T/C	cg27532318	chr7:32358331	NA	0.73	7.43	0.33	5.29e-13	Body mass index;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg07511668	chr11:68622177	NA	0.51	9.68	0.41	2.69e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.48	0.37	3.05e-16	Personality dimensions;
LGG	trans	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg24247370	chr13:99142703	STK24	0.36	6.91	0.31	1.65e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4650994	0.524	rs2209170	chr1:178607388	C/A	cg12486710	chr1:178512616	C1orf220	-0.5	-10.18	-0.43	4.22e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1862618	0.853	rs832565	chr5:56150803	T/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.8	-0.38	2.67e-17	Initial pursuit acceleration;
LGG	cis	rs713587	0.713	rs12618252	chr2:25207950	G/A	cg04586622	chr2:25135609	ADCY3	-0.37	-9.73	-0.41	1.71e-20	Body mass index in non-asthmatics;
LGG	cis	rs28595532	0.764	rs56309519	chr4:119754158	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg19500098	chr13:21900506	NA	0.46	9.81	0.41	9.15e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6546550	0.867	rs1551374	chr2:70079633	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.89	-0.34	2.13e-14	Prevalent atrial fibrillation;
LGG	cis	rs2694528	1.000	rs929780	chr5:60189026	C/G	cg11474532	chr5:59995715	DEPDC1B	-0.68	-7.4	-0.33	6.32e-13	Parkinson's disease;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg04025307	chr7:1156635	C7orf50	0.8	16.69	0.61	2.54e-49	Longevity;Endometriosis;
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg08742575	chr21:47604166	C21orf56	-0.55	-9.22	-0.39	1.08e-18	Testicular germ cell tumor;
LGG	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.85	-0.45	1.37e-24	Vitiligo;
LGG	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg24011408	chr12:48396354	COL2A1	0.49	7.71	0.34	7.5e-14	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	1.000	rs6089581	chr20:60562394	G/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg15556689	chr8:8085844	FLJ10661	0.46	7.91	0.35	1.96e-14	Retinal vascular caliber;
LGG	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.3	-0.36	1.18e-15	Joint mobility (Beighton score);
LGG	cis	rs3733418	0.860	rs35449092	chr4:165949676	C/G	cg10852876	chr4:165953100	TRIM60	-0.52	-7.18	-0.32	2.85e-12	Obesity-related traits;
LGG	trans	rs9914544	0.545	rs2892015	chr17:18786849	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs11748327	0.881	rs12656247	chr5:4075389	C/T	cg01025095	chr5:4101132	NA	-0.6	-9.71	-0.41	2.1e-20	Myocardial infarction;
LGG	trans	rs9858542	1.000	rs1131095	chr3:49714225	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.94	-0.42	3.1e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8141529	0.764	rs8137969	chr22:29228484	G/C	cg02153584	chr22:29168773	CCDC117	0.69	11.67	0.48	9.1e-28	Lymphocyte counts;
LGG	cis	rs4423214	1.000	rs4944958	chr11:71168073	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.8	-7.03	-0.31	7.62e-12	Facial emotion recognition (sad faces);
LGG	cis	rs7582180	0.544	rs13026570	chr2:100939498	A/C	cg14675211	chr2:100938903	LONRF2	0.65	11.18	0.46	7.6e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7822232	1.000	rs7822232	chr8:145145687	A/C	cg06495924	chr8:145149574	CYC1	-0.8	-7.18	-0.32	2.73e-12	Blood metabolite levels;
LGG	cis	rs593982	0.920	rs618456	chr11:65475620	C/T	cg08755490	chr11:65554678	OVOL1	0.7	8.6	0.37	1.21e-16	Atopic dermatitis;
LGG	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg02836325	chr17:76403955	PGS1	-0.8	-17.52	-0.63	4.42e-53	HDL cholesterol levels;
LGG	cis	rs868036	0.718	rs16951275	chr15:68077168	T/C	cg05925327	chr15:68127851	NA	-0.38	-7.75	-0.34	5.99e-14	Restless legs syndrome;
LGG	cis	rs4474465	0.915	rs10128737	chr11:78186687	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.67	-0.37	7.52e-17	Alzheimer's disease (survival time);
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.16	-0.49	1.06e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.764	rs13062022	chr3:47169375	G/A	cg27129171	chr3:47204927	SETD2	0.84	16.34	0.6	9.84e-48	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03442064	chr6:41515050	FOXP4	0.5	8.42	0.36	4.68e-16	Gut microbiome composition (summer);
LGG	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg27624424	chr6:160112604	SOD2	0.65	9.66	0.41	3.13e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6121246	0.909	rs57726761	chr20:30314046	A/G	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg04287289	chr16:89883240	FANCA	0.84	8.04	0.35	7.52e-15	Skin colour saturation;
LGG	cis	rs4330281	0.647	rs6792422	chr3:17701005	A/C	cg20981856	chr3:17787350	NA	0.41	7.76	0.34	5.52e-14	Schizophrenia;
LGG	cis	rs2243480	1.000	rs10247526	chr7:65780696	T/G	cg18252515	chr7:66147081	NA	1.43	20.72	0.69	5.87e-68	Diabetic kidney disease;
LGG	cis	rs7301016	1.000	rs11174518	chr12:62902550	T/C	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.27e-17	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17301506	chr20:32700554	EIF2S2	0.41	6.91	0.31	1.58e-11	Gut microbiome composition (summer);
LGG	cis	rs6445975	0.955	rs4681845	chr3:58332496	C/T	cg24175188	chr3:58374923	PXK	0.53	9.52	0.4	9.59e-20	Systemic lupus erythematosus;
LGG	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg19468946	chr17:37922297	IKZF3	-0.44	-7.81	-0.34	3.9e-14	Self-reported allergy;
LGG	trans	rs9393777	0.920	rs41269265	chr6:27425349	T/C	cg08344181	chr3:125677491	NA	-0.8	-8.05	-0.35	7.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7568458	0.704	rs10176176	chr2:85762048	A/T	cg17127132	chr2:85788382	GGCX	0.47	8.19	0.36	2.62e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs10853191	0.558	rs11080462	chr18:10849597	A/C	cg11727592	chr13:46916922	C13orf18	-0.3	-6.92	-0.31	1.54e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs10540	1.000	rs71487292	chr11:486076	G/A	cg03352830	chr11:487213	PTDSS2	0.87	10.52	0.44	2.31e-23	Body mass index;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg20607798	chr8:58055168	NA	0.64	7.46	0.33	4.41e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6598955	0.724	rs12726972	chr1:26639634	A/G	cg04990556	chr1:26633338	UBXN11	0.71	12.68	0.51	7.45e-32	Obesity-related traits;
LGG	cis	rs1348850	0.645	rs10164417	chr2:178444130	A/G	cg27490568	chr2:178487706	NA	0.64	11.44	0.47	7.29e-27	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.69	-0.3	6.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6430585	0.528	rs895285	chr2:136710554	A/G	cg07169764	chr2:136633963	MCM6	1.23	22.62	0.72	7.26e-77	Corneal structure;
LGG	cis	rs780096	0.587	rs10205219	chr2:27568565	T/C	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.84	-0.3	2.53e-11	Total body bone mineral density;
LGG	cis	rs3768617	0.706	rs11588675	chr1:182988052	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.36	7.07	0.31	5.6e-12	Fuchs's corneal dystrophy;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01171360	chr6:293285	DUSP22	-0.58	-9.55	-0.41	7.87e-20	Menopause (age at onset);
LGG	trans	rs11098499	0.566	rs17051356	chr4:120585308	C/T	cg25214090	chr10:38739885	LOC399744	0.58	9.78	0.41	1.15e-20	Corneal astigmatism;
LGG	cis	rs73086581	0.838	rs56401022	chr20:4024281	A/G	cg02187196	chr20:3869020	PANK2	0.67	9.41	0.4	2.4e-19	Response to antidepressants in depression;
LGG	cis	rs457717	0.730	rs456572	chr5:75947256	A/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs17376456	0.877	rs9885329	chr5:93380278	G/A	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-10.47	-0.44	3.58e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10267417	0.603	rs10228558	chr7:19911915	A/G	cg05791153	chr7:19748676	TWISTNB	0.57	7.54	0.33	2.54e-13	Night sleep phenotypes;
LGG	cis	rs9902453	0.933	rs7224199	chr17:28523726	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.62	12.17	0.49	9.46e-30	Coffee consumption (cups per day);
LGG	cis	rs7711186	0.786	rs13360296	chr5:178054930	A/G	cg17371294	chr5:178012716	COL23A1	-0.65	-6.69	-0.3	6.36e-11	Urate levels in obese individuals;
LGG	cis	rs3857536	0.730	rs4710584	chr6:66953453	A/G	cg07460842	chr6:66804631	NA	-0.42	-6.87	-0.3	2.13e-11	Blood trace element (Cu levels);
LGG	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg08470875	chr2:26401718	FAM59B	-0.41	-8.04	-0.35	7.57e-15	Gut microbiome composition (summer);
LGG	cis	rs897984	0.647	rs7203999	chr16:31017554	T/C	cg02466173	chr16:30829666	NA	0.43	7.44	0.33	4.95e-13	Dementia with Lewy bodies;
LGG	cis	rs12893668	0.616	rs58033365	chr14:104030901	T/C	cg23335576	chr14:104009727	NA	0.49	8.44	0.37	4.21e-16	Reticulocyte count;
LGG	cis	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35146811	0.538	rs3823642	chr7:99796072	T/C	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg15674680	chr20:60982522	CABLES2	0.48	6.72	0.3	5.23e-11	Colorectal cancer;
LGG	cis	rs7113874	0.543	rs11041993	chr11:8596554	T/C	cg23764900	chr11:8616102	STK33	-0.38	-6.64	-0.3	8.62e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9644630	0.841	rs6984449	chr8:19327959	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.56	14.86	0.57	3.92e-41	Oropharynx cancer;
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg12310025	chr6:25882481	NA	-0.89	-19.45	-0.67	5.02e-62	Uric acid levels;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg21948465	chr5:131705150	SLC22A5	0.68	7.57	0.33	1.99e-13	Rheumatoid arthritis;
LGG	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg19468946	chr17:37922297	IKZF3	-0.45	-7.99	-0.35	1.07e-14	Self-reported allergy;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.53	-0.37	2.07e-16	Menopause (age at onset);
LGG	cis	rs9916302	0.706	rs9893735	chr17:37469858	A/C	cg07936489	chr17:37558343	FBXL20	0.99	15.36	0.58	2.5e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7481584	0.581	rs399565	chr11:3061780	C/T	cg05729581	chr11:3078854	CARS	0.41	6.71	0.3	5.56e-11	Calcium levels;
LGG	cis	rs79387448	0.638	rs11465670	chr2:103034440	A/G	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.74	-0.3	4.75e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9815354	0.812	rs73077361	chr3:41850146	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs75804782	0.521	rs58568091	chr2:239430582	G/A	cg01134436	chr17:81009848	B3GNTL1	0.78	8.54	0.37	1.98e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2236918	0.687	rs1776176	chr1:242012554	C/T	cg17736920	chr1:242011382	EXO1	0.42	7.62	0.33	1.4e-13	Menopause (age at onset);
LGG	cis	rs1124376	1.000	rs6771941	chr3:20157077	G/T	cg05072819	chr3:20081367	KAT2B	0.57	8.46	0.37	3.41e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7586879	0.520	rs6718511	chr2:25122324	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.86	0.51	1.4e-32	Body mass index;
LGG	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.62	-0.48	1.44e-27	Hemoglobin concentration;
LGG	cis	rs4363385	0.720	rs1611764	chr1:152957887	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.92	-0.38	1.12e-17	Inflammatory skin disease;
LGG	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg26597838	chr10:835615	NA	0.75	10.26	0.43	2.09e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs8031584	0.918	rs1425292	chr15:31285422	G/A	cg08109568	chr15:31115862	NA	-0.53	-9.27	-0.4	6.91e-19	Huntington's disease progression;
LGG	cis	rs9682041	0.800	rs7643085	chr3:170070371	A/G	cg11886554	chr3:170076028	SKIL	0.84	10.87	0.45	1.11e-24	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2742540	0.503	rs11042121	chr11:8932640	A/C	cg00186954	chr11:8933980	ST5;C11orf17	0.59	12.97	0.52	4.92e-33	Hematocrit;
LGG	cis	rs12908161	0.959	rs34028043	chr15:85231585	G/A	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	9.2e-12	Schizophrenia;
LGG	cis	rs34845616	0.520	rs1793680	chr11:133798762	C/T	cg17703048	chr11:133852993	NA	-0.43	-8.26	-0.36	1.55e-15	Hand grip strength;
LGG	trans	rs7395662	1.000	rs7949554	chr11:48581992	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg26513180	chr16:89883248	FANCA	0.93	20.56	0.69	3.14e-67	Vitiligo;
LGG	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.53	0.33	2.62e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs546131	0.890	rs496558	chr11:34826425	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.61	10.96	0.45	5.31e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs524281	0.861	rs11227410	chr11:65873396	G/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs2635047	0.967	rs1119005	chr18:44725605	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.92	0.38	1.07e-17	Educational attainment;
LGG	cis	rs67311347	0.910	rs7651204	chr3:40512835	C/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.06	-0.31	6.18e-12	Renal cell carcinoma;
LGG	cis	rs9300255	0.596	rs7304782	chr12:123719444	A/G	cg05973401	chr12:123451056	ABCB9	-0.5	-8.07	-0.35	6.17e-15	Neutrophil percentage of white cells;
LGG	cis	rs992157	0.710	rs10169718	chr2:219103580	C/T	cg04731861	chr2:219085781	ARPC2	0.49	12.54	0.5	2.87e-31	Colorectal cancer;
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg27432699	chr2:27873401	GPN1	-0.5	-8.58	-0.37	1.44e-16	Total body bone mineral density;
LGG	cis	rs11628318	0.614	rs62007925	chr14:103128288	G/A	cg12046867	chr14:103022105	NA	0.74	12.53	0.5	3.15e-31	Platelet count;
LGG	cis	rs2916247	0.954	rs2996056	chr8:93180247	A/C	cg10183463	chr8:93005414	RUNX1T1	0.35	7.26	0.32	1.65e-12	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.545	rs4718364	chr7:66001340	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.31	0.43	1.46e-22	Aortic root size;
LGG	cis	rs3789045	0.729	rs61817460	chr1:204543579	G/A	cg17419461	chr1:204415978	PIK3C2B	-0.47	-9.39	-0.4	2.77e-19	Educational attainment (college completion);
LGG	cis	rs965469	0.652	rs6051837	chr20:3388994	G/T	cg25506879	chr20:3388711	C20orf194	-0.49	-7.68	-0.34	9.46e-14	IFN-related cytopenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.7.2194789F	chr7:102039835	PRKRIP1	-0.47	-6.94	-0.31	1.29e-11	Systemic lupus erythematosus;
LGG	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg09307838	chr4:120376055	NA	0.79	13.09	0.52	1.62e-33	Corneal astigmatism;
LGG	cis	rs7904985	1.000	rs7904985	chr10:88116479	A/G	cg07322936	chr10:88137208	NA	0.48	7.11	0.31	4.38e-12	Barrett's esophagus;
LGG	cis	rs7119	0.717	rs11639293	chr15:77810845	T/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs2012796	0.743	rs8020575	chr14:81859521	G/A	cg02996355	chr14:81879375	NA	0.56	9.22	0.39	1.02e-18	Night sleep phenotypes;
LGG	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24229701	chr12:130821962	PIWIL1	0.46	7.89	0.34	2.14e-14	Menopause (age at onset);
LGG	cis	rs4679904	0.883	rs73875285	chr3:160213286	C/T	cg20378687	chr3:160281681	KPNA4	-0.35	-6.73	-0.3	4.99e-11	Primary biliary cholangitis;
LGG	cis	rs9951602	0.512	rs9946138	chr18:76654608	A/G	cg24134504	chr18:76639479	NA	-0.46	-8.14	-0.35	3.67e-15	Obesity-related traits;
LGG	trans	rs6952808	0.609	rs12699453	chr7:1953056	C/T	cg24247370	chr13:99142703	STK24	-0.36	-6.7	-0.3	6.02e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs17345786	0.906	rs55710435	chr3:101180330	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.55	9.37	0.4	3.12e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11203032	0.831	rs2211599	chr10:90929547	G/A	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	cis	rs2694528	0.858	rs78579471	chr5:60411282	G/A	cg11474532	chr5:59995715	DEPDC1B	0.68	7.29	0.32	1.35e-12	Parkinson's disease;
LGG	cis	rs657075	0.595	rs3749753	chr5:131587131	C/T	cg06968155	chr5:131705112	SLC22A5	0.54	6.73	0.3	4.98e-11	Rheumatoid arthritis;
LGG	cis	rs3857067	1.000	rs1904095	chr4:95012530	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.41	-7.5	-0.33	3.38e-13	QT interval;
LGG	trans	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9902453	0.765	rs2264303	chr17:28055348	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.25	-0.55	1.79e-38	Coffee consumption (cups per day);
LGG	cis	rs6882076	0.925	rs1393207	chr5:156397540	T/A	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.39	-0.47	1.14e-26	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs11608355	1.000	rs2075439	chr12:109859374	A/G	cg19025524	chr12:109796872	NA	-0.49	-9.3	-0.4	5.47e-19	Neuroticism;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.87	-0.38	1.6e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs9875081	chr3:10083935	G/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs9902453	0.740	rs1382391	chr17:28111986	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.22	-0.55	2.44e-38	Coffee consumption (cups per day);
LGG	cis	rs911119	1.000	rs3787499	chr20:23616807	G/A	cg16589663	chr20:23618590	CST3	0.47	6.72	0.3	5.39e-11	Chronic kidney disease;
LGG	cis	rs7017914	0.934	rs35109143	chr8:71577900	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs2273669	0.588	rs111773102	chr6:109306480	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.5	-0.37	2.63e-16	Prostate cancer;
LGG	cis	rs526231	0.543	rs62362884	chr5:102567455	G/A	cg23492399	chr5:102201601	PAM	-0.58	-8.34	-0.36	8.5e-16	Primary biliary cholangitis;
LGG	cis	rs7659604	0.643	rs6838881	chr4:122663616	A/T	cg19748678	chr4:122722346	EXOSC9	0.44	7.6	0.33	1.66e-13	Type 2 diabetes;
LGG	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.88	-16.95	-0.62	1.71e-50	Height;
LGG	cis	rs6089829	0.962	rs2872543	chr20:61665017	G/A	cg08564027	chr20:61660810	NA	1.02	25.47	0.76	4.35e-90	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg11707556	chr5:10655725	ANKRD33B	0.47	6.93	0.31	1.42e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2597513	0.745	rs2655232	chr3:13572140	T/C	cg24006715	chr3:13568212	NA	0.63	10.33	0.43	1.19e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg06521331	chr12:34319734	NA	0.4	6.73	0.3	4.88e-11	Morning vs. evening chronotype;
LGG	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.19e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg23782820	chr8:58130467	NA	0.53	7.42	0.33	5.78e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7944735	0.517	rs11039538	chr11:48154990	A/T	cg03929089	chr4:120376271	NA	0.68	7.09	0.31	5.1e-12	Intraocular pressure;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg14926445	chr8:58193284	C8orf71	-0.71	-8.43	-0.36	4.4e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3849570	0.922	rs3772895	chr3:81769493	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-8.04	-0.35	7.73e-15	Waist circumference;Body mass index;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg19182353	chr11:118479428	PHLDB1	0.55	10.9	0.45	9.14e-25	Cholesterol, total;
LGG	cis	rs9972944	0.627	rs28845012	chr17:63760891	G/A	cg07283582	chr17:63770753	CCDC46	-0.39	-7.64	-0.33	1.28e-13	Total body bone mineral density;
LGG	cis	rs74781061	0.860	rs1866113	chr15:74729603	T/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.71	-0.3	5.75e-11	Endometriosis;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs67311347	1.000	rs12494022	chr3:40426652	A/C	cg13683864	chr3:40499215	RPL14	-1.15	-26.09	-0.77	5.69e-93	Renal cell carcinoma;
LGG	trans	rs9650657	0.515	rs6601560	chr8:10950866	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.83	-0.38	2.15e-17	Neuroticism;
LGG	cis	rs10752881	1.000	rs6424879	chr1:182986592	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs1505368	0.781	rs4673664	chr2:213277649	T/C	cg20637307	chr2:213403960	ERBB4	0.47	8.8	0.38	2.8e-17	Symmetrical dimethylarginine levels;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18099408	chr3:52552593	STAB1	-0.37	-7.41	-0.33	5.88e-13	Electroencephalogram traits;
LGG	cis	rs847649	0.732	rs6465876	chr7:102497569	G/T	cg18108683	chr7:102477205	FBXL13	-0.65	-14.5	-0.56	1.58e-39	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.513	rs10772116	chr12:33897795	G/C	cg26384229	chr12:38710491	ALG10B	0.65	12.48	0.5	5.29e-31	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs60251075	chr5:245292	T/C	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs9486719	0.895	rs3798294	chr6:97049587	G/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.03	-0.31	7.44e-12	Migraine;Coronary artery disease;
LGG	cis	rs7572644	0.581	rs35463245	chr2:28000724	C/G	cg27432699	chr2:27873401	GPN1	0.48	7.35	0.32	9.29e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs12701220	0.744	rs10499317	chr7:1012103	C/G	cg00990874	chr7:1149470	C7orf50	-0.49	-7.5	-0.33	3.25e-13	Bronchopulmonary dysplasia;
LGG	cis	rs2880765	0.835	rs1872074	chr15:86033184	T/G	cg10818794	chr15:86012489	AKAP13	-0.38	-8.07	-0.35	5.98e-15	Coronary artery disease;
LGG	cis	rs2228479	0.618	rs17233623	chr16:89811209	C/T	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.19	-0.32	2.6e-12	Skin colour saturation;
LGG	cis	rs6784615	0.744	rs3796342	chr3:52324165	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.65	0.33	1.21e-13	Waist-hip ratio;
LGG	cis	rs17767392	0.881	rs17767686	chr14:72006744	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.01	-0.39	5.3e-18	Mitral valve prolapse;
LGG	cis	rs28595532	0.920	rs115850161	chr4:119732447	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs9929218	0.817	rs3118228	chr16:68710737	T/G	cg02972257	chr16:68554789	NA	0.46	6.79	0.3	3.46e-11	Colorectal cancer;
LGG	cis	rs3735485	0.738	rs10253578	chr7:45102058	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.58	-0.41	6.12e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7267979	0.844	rs6132824	chr20:25238173	T/C	cg06421707	chr20:25228305	PYGB	0.54	12.2	0.49	7.06e-30	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.89	-0.31	1.78e-11	Bone mineral density;
LGG	cis	rs4132509	0.947	rs10927039	chr1:243721726	C/T	cg21452805	chr1:244014465	NA	-0.57	-6.75	-0.3	4.37e-11	RR interval (heart rate);
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.52e-13	IgG glycosylation;
LGG	cis	rs7927592	0.763	rs10791982	chr11:68337664	T/G	cg16797656	chr11:68205561	LRP5	-0.51	-10.04	-0.42	1.41e-21	Total body bone mineral density;
LGG	cis	rs7077164	1.000	rs1227769	chr10:71586296	C/T	cg20696214	chr10:71583771	COL13A1	-0.4	-7.7	-0.34	8.53e-14	Non-alcoholic fatty liver disease histology (lobular);
LGG	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg09408571	chr1:101003634	GPR88	0.32	8.3	0.36	1.18e-15	Breast cancer;
LGG	cis	rs2032447	0.772	rs199754	chr6:25992309	A/G	cg03517284	chr6:25882590	NA	-0.66	-12.29	-0.5	3.17e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2063714	0.658	rs12196864	chr6:157212862	C/T	cg23222435	chr6:157204239	ARID1B	-0.63	-11.77	-0.48	3.64e-28	Sitting height ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15181807	chr11:66445392	RBM4B	0.43	6.87	0.3	2.13e-11	Gut microbiome composition (summer);
LGG	cis	rs933688	1.000	rs332544	chr5:90778848	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.06	17.23	0.63	8.96e-52	Smoking behavior;
LGG	cis	rs1957429	0.901	rs1467571	chr14:65347682	C/T	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs7618915	0.501	rs7622694	chr3:52663882	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.37	0.47	1.42e-26	Bipolar disorder;
LGG	cis	rs9583531	0.600	rs1441042	chr13:111365589	T/G	cg15841412	chr13:111365552	ING1	0.47	7.17	0.32	2.96e-12	Coronary artery disease;
LGG	cis	rs7173743	1.000	rs4438276	chr15:79138565	A/G	cg00540400	chr15:79124168	NA	-0.43	-8.68	-0.37	6.65e-17	Coronary artery disease;
LGG	cis	rs9457247	0.740	rs13195812	chr6:167443902	C/T	cg07741184	chr6:167504864	NA	0.42	9.19	0.39	1.36e-18	Crohn's disease;
LGG	trans	rs9818758	0.607	rs9850917	chr3:49286983	A/G	cg21659725	chr3:3221576	CRBN	-0.63	-6.79	-0.3	3.56e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs5769765	0.908	rs138880	chr22:50218611	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.69	-9.81	-0.41	8.91e-21	Schizophrenia;
LGG	cis	rs1062177	1.000	rs62377945	chr5:151208004	C/G	cg00977110	chr5:151150581	G3BP1	0.51	7.98	0.35	1.19e-14	Preschool internalizing problems;
LGG	trans	rs28735056	0.967	rs8091497	chr18:77632565	G/A	cg05926928	chr17:57297772	GDPD1	-0.49	-7.75	-0.34	5.76e-14	Schizophrenia;
LGG	cis	rs10504229	0.679	rs12679920	chr8:58051710	G/T	cg20607798	chr8:58055168	NA	0.62	7.17	0.32	2.89e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7539542	0.600	rs9943282	chr1:202895140	C/T	cg19681188	chr1:202830198	LOC148709	0.51	8.51	0.37	2.36e-16	Mean platelet volume;
LGG	cis	rs2404602	0.647	rs11629727	chr15:77009038	G/C	cg23625390	chr15:77176239	SCAPER	-0.69	-13.55	-0.53	1.88e-35	Blood metabolite levels;
LGG	cis	rs8062405	0.755	rs4788080	chr16:28558081	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.78	0.38	3.27e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4731207	0.596	rs1552119	chr7:124638876	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs10744422	1.000	rs936083	chr12:123338964	A/G	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	5.17e-19	Schizophrenia;
LGG	cis	rs28735056	0.904	rs62103174	chr18:77621048	A/G	cg23825213	chr18:77623475	KCNG2	-0.4	-7.17	-0.32	3.03e-12	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06920434	chr11:63607473	MARK2	0.37	6.67	0.3	7.15e-11	Obesity-related traits;
LGG	cis	rs12367572	0.663	rs1224436	chr12:45400397	C/T	cg03114573	chr12:45410052	DBX2	-0.66	-12.13	-0.49	1.35e-29	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.31	-0.36	1.04e-15	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs4459614	chr17:80086597	C/T	cg23985595	chr17:80112537	CCDC57	0.48	9.62	0.41	4.38e-20	Life satisfaction;
LGG	cis	rs4642101	0.765	rs9871991	chr3:12827525	C/A	cg24848339	chr3:12840334	CAND2	0.41	9.33	0.4	4.57e-19	QRS complex (12-leadsum);
LGG	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.32	0.32	1.13e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9926296	0.744	rs154656	chr16:89708003	T/A	cg03605463	chr16:89740564	NA	0.6	10.86	0.45	1.29e-24	Vitiligo;
LGG	cis	rs1401999	1.000	rs6443927	chr3:183718864	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.36	0.53	1.13e-34	Anterior chamber depth;
LGG	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04935121	chr11:63775413	MACROD1	0.3	7.17	0.32	3.02e-12	Pulse pressure;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg24829409	chr8:58192753	C8orf71	-0.69	-9.93	-0.42	3.53e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4696584	0.696	rs1873367	chr4:155413362	C/T	cg13738195	chr4:155413469	DCHS2	-0.37	-7.28	-0.32	1.4e-12	Folding of antihelix;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg11905131	chr22:24372483	LOC391322	-0.42	-7.44	-0.33	5.08e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4776059	0.959	rs4548810	chr15:52943814	C/T	cg22715398	chr15:52968154	KIAA1370	-0.46	-7.66	-0.34	1.09e-13	Schizophrenia;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.7e-34	Prudent dietary pattern;
LGG	cis	rs1799949	0.832	rs2070835	chr17:41174025	A/C	cg18379455	chr17:41446167	NA	-0.32	-7.1	-0.31	4.61e-12	Menopause (age at onset);
LGG	cis	rs4631830	0.832	rs11005089	chr10:51510813	C/A	cg10326726	chr10:51549505	MSMB	0.7	14.16	0.55	4.41e-38	Prostate-specific antigen levels;
LGG	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg11812906	chr14:75593930	NEK9	-0.46	-8.21	-0.36	2.25e-15	Height;
LGG	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg02002194	chr4:3960332	NA	0.43	8.13	0.35	4.01e-15	Mood instability;
LGG	cis	rs9457247	0.534	rs4710149	chr6:167386346	T/C	cg18261144	chr6:167370276	RNASET2	-0.39	-7.87	-0.34	2.51e-14	Crohn's disease;
LGG	cis	rs9486719	0.895	rs12195315	chr6:96905711	T/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs11169552	0.510	rs3935869	chr12:50964076	A/G	cg12884762	chr12:50931848	DIP2B	-0.4	-7.36	-0.32	8.2e-13	Colorectal cancer;
LGG	trans	rs7826238	0.543	rs2976908	chr8:8345774	T/G	cg16141378	chr3:129829833	LOC729375	-0.42	-9.62	-0.41	4.36e-20	Systolic blood pressure;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.26	0.4	7.65e-19	Electroencephalogram traits;
LGG	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg16339924	chr4:17578868	LAP3	0.61	10.57	0.44	1.51e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg26441486	chr22:50317300	CRELD2	0.41	6.99	0.31	9.34e-12	Schizophrenia;
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs611744	0.647	rs10106246	chr8:109268710	T/C	cg21045802	chr8:109455806	TTC35	0.53	9.97	0.42	2.53e-21	Dupuytren's disease;
LGG	cis	rs262150	0.567	rs2527177	chr7:158804737	T/C	cg19418458	chr7:158789849	NA	-0.52	-10.92	-0.45	7.2e-25	Facial morphology (factor 20);
LGG	cis	rs9467711	0.606	rs35076545	chr6:26603924	C/A	cg12826209	chr6:26865740	GUSBL1	0.78	7.51	0.33	3.01e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-14.99	-0.57	1.07e-41	Prudent dietary pattern;
LGG	cis	rs2880765	0.835	rs7162502	chr15:86044473	G/T	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs4865875	0.892	rs4290968	chr5:54098301	C/T	cg22421804	chr5:54100067	NA	0.51	7.41	0.33	6.17e-13	Sense of smell;
LGG	cis	rs2230307	0.536	rs554742	chr1:100512568	G/A	cg24955406	chr1:100503596	HIAT1	0.58	8.21	0.36	2.17e-15	Carotid intima media thickness;
LGG	cis	rs561341	0.660	rs7406043	chr17:30220152	C/G	cg13647721	chr17:30228624	UTP6	0.77	10.18	0.43	4.1e-22	Hip circumference adjusted for BMI;
LGG	cis	rs17818399	0.533	rs4384837	chr2:46789514	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.6	-10.92	-0.45	7.64e-25	Height;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24475210	chr4:6642433	MRFAP1	-0.4	-6.68	-0.3	7.03e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.55	0.44	1.77e-23	Obesity-related traits;
LGG	cis	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg13010199	chr12:38710504	ALG10B	0.78	16.58	0.61	8.63e-49	Heart rate;
LGG	cis	rs722599	1.000	rs722599	chr14:75327443	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.68	-12.57	-0.5	2.23e-31	IgG glycosylation;
LGG	cis	rs7172689	0.908	rs11637813	chr15:81561641	C/A	cg11808699	chr15:81528661	IL16	-0.46	-9.34	-0.4	3.91e-19	Inattentive symptoms;
LGG	cis	rs9291683	0.546	rs13146686	chr4:10034933	A/G	cg11266682	chr4:10021025	SLC2A9	0.5	9.8	0.41	9.56e-21	Bone mineral density;
LGG	trans	rs208520	0.526	rs2881644	chr6:66803535	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.16	32.96	0.84	1.58e-123	Exhaled nitric oxide output;
LGG	cis	rs6696846	0.777	rs2369526	chr1:205054406	C/T	cg21545522	chr1:205238299	TMCC2	0.38	7.33	0.32	1.03e-12	Red blood cell count;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg05692746	chr2:100937584	LONRF2	-0.63	-11.52	-0.47	3.73e-27	Intelligence (multi-trait analysis);
LGG	cis	rs72781680	1.000	rs72796357	chr2:24160131	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.31	0.4	5.34e-19	Lymphocyte counts;
LGG	cis	rs10819861	0.645	rs10819815	chr9:98854722	G/A	cg14508093	chr9:98862825	NA	0.3	7.16	0.32	3.16e-12	Electrocardiographic traits;
LGG	cis	rs12210905	1.000	rs12209800	chr6:27189517	C/T	cg15325629	chr6:28072465	NA	-0.83	-6.96	-0.31	1.17e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12291225	0.637	rs8570	chr11:14300759	C/G	cg22961513	chr11:14280813	SPON1	-0.29	-6.73	-0.3	4.9e-11	Sense of smell;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg13047869	chr3:10149882	C3orf24	0.53	8.76	0.38	3.65e-17	Alzheimer's disease;
LGG	cis	rs4740619	0.544	rs9407652	chr9:15827921	C/A	cg14451791	chr9:16040625	NA	0.32	7.81	0.34	4e-14	Body mass index;
LGG	cis	rs6062788	0.811	rs6011581	chr20:61698889	G/A	cg04845185	chr20:61696220	NA	-0.34	-6.71	-0.3	5.73e-11	Body mass index;
LGG	cis	rs1799949	0.965	rs11651623	chr17:41329847	G/A	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs116023344	chr4:119760263	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7646881	1.000	rs73015651	chr3:158450922	C/T	cg19483011	chr3:158453295	NA	-0.66	-9.79	-0.41	1.05e-20	Tetralogy of Fallot;
LGG	cis	rs12422267	0.536	rs12303540	chr12:132609679	A/G	cg09764611	chr12:132620959	NA	0.57	8.62	0.37	1.07e-16	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.09	-0.55	9.12e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17834180	chr10:124768240	IKZF5;ACADSB	0.43	7.26	0.32	1.64e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg13699009	chr12:122356056	WDR66	0.57	15.82	0.59	2.25e-45	Mean corpuscular volume;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg15971980	chr6:150254442	NA	0.43	7.86	0.34	2.63e-14	Lung cancer;
LGG	cis	rs2153535	0.580	rs9379215	chr6:8481225	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs950776	0.518	rs952216	chr15:78819202	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs7777484	0.534	rs2258709	chr7:2832365	C/T	cg19717773	chr7:2847554	GNA12	0.42	9.48	0.4	1.34e-19	Height;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg03452623	chr4:187889614	NA	-1.04	-29.65	-0.81	4.72e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg02631450	chr22:32366979	NA	0.94	9.1	0.39	2.78e-18	Childhood ear infection;
LGG	cis	rs7772486	0.625	rs9390355	chr6:146112942	C/T	cg23711669	chr6:146136114	FBXO30	-0.4	-6.72	-0.3	5.23e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg16339924	chr4:17578868	LAP3	0.59	10.0	0.42	1.88e-21	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg11245990	chr11:68621969	NA	0.45	9.21	0.39	1.12e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.63e-19	Diabetic retinopathy;
LGG	cis	rs4268898	0.636	rs76172309	chr2:24458911	G/C	cg06627628	chr2:24431161	ITSN2	-0.78	-12.59	-0.51	1.8e-31	Asthma;
LGG	cis	rs3096299	0.584	rs3114889	chr16:89415505	T/C	cg06640241	chr16:89574553	SPG7	0.62	10.36	0.43	8.94e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs2594989	0.943	rs9822446	chr3:11420780	C/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.09	-0.31	5.1e-12	Circulating chemerin levels;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.4	-6.75	-0.3	4.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.36	-0.36	7.63e-16	Aortic root size;
LGG	cis	rs4639966	0.836	rs11217014	chr11:118626286	T/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.59	-0.37	1.36e-16	Systemic lupus erythematosus;
LGG	cis	rs10871290	0.551	rs3863435	chr16:74465396	C/G	cg01733217	chr16:74700730	RFWD3	-0.69	-13.33	-0.53	1.51e-34	Breast cancer;
LGG	cis	rs17253792	0.545	rs17745459	chr14:56008549	T/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.42	-0.4	2.24e-19	Putamen volume;
LGG	cis	rs2276314	0.857	rs3737474	chr18:33613595	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.79	0.41	1.08e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.5	2.13e-30	Lymphocyte counts;
LGG	cis	rs7408868	1.000	rs7247835	chr19:15262844	A/G	cg14696996	chr19:15285081	NOTCH3	1.06	12.63	0.51	1.3e-31	Pulse pressure;
LGG	cis	rs12497850	0.764	rs6784111	chr3:49178846	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.49	-7.46	-0.33	4.34e-13	Parkinson's disease;
LGG	cis	rs12681366	0.659	rs2450558	chr8:95410507	T/C	cg13257157	chr8:95487014	RAD54B	-0.37	-6.76	-0.3	4.26e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.1	0.49	1.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.75	-0.41	1.49e-20	Lung cancer;
LGG	cis	rs17209837	0.607	rs4148813	chr7:87092376	A/G	cg25823085	chr7:87105416	ABCB4	0.3	7.59	0.33	1.82e-13	Gallbladder cancer;
LGG	cis	rs7811528	0.591	rs11770552	chr7:2709471	C/T	cg11411865	chr7:2701802	TTYH3	0.47	6.66	0.3	7.99e-11	Schizophrenia;
LGG	cis	rs67133203	0.904	rs12818033	chr12:51357325	T/C	cg14688905	chr12:51403056	SLC11A2	0.77	11.5	0.47	4.41e-27	Urinary tract infection frequency;
LGG	cis	rs7552404	0.690	rs12723575	chr1:76335203	T/C	cg22875332	chr1:76189707	ACADM	-0.55	-8.44	-0.37	3.98e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7312933	0.584	rs6582391	chr12:42634686	G/A	cg19980929	chr12:42632907	YAF2	0.39	8.99	0.39	6.59e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3789045	1.000	rs3789044	chr1:204589101	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.81	-0.38	2.46e-17	Educational attainment (college completion);
LGG	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.87	-17.1	-0.62	3.66e-51	Response to antipsychotic treatment;
LGG	cis	rs7568458	0.591	rs55971080	chr2:85812746	T/C	cg02493740	chr2:85810744	VAMP5	-0.4	-7.2	-0.32	2.39e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2933343	0.729	rs1680780	chr3:128612659	G/C	cg25356066	chr3:128598488	ACAD9	0.47	7.15	0.32	3.51e-12	IgG glycosylation;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg13880726	chr7:1868755	MAD1L1	0.4	7.09	0.31	5.03e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.2	0.32	2.38e-12	Obesity-related traits;
LGG	cis	rs4332037	0.754	rs62436669	chr7:1926636	G/A	cg12591125	chr7:1885375	MAD1L1	0.47	6.99	0.31	9.78e-12	Bipolar disorder;
LGG	cis	rs2455799	0.533	rs2470513	chr3:15750056	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-7.86	-0.34	2.79e-14	Mean platelet volume;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.82	-0.3	2.9100000000000002e-11	Aortic root size;
LGG	trans	rs853679	0.607	rs72846780	chr6:28119055	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs4696584	0.816	rs61270934	chr4:155400949	T/C	cg04517429	chr4:155413618	DCHS2	-0.31	-7.06	-0.31	6.33e-12	Folding of antihelix;
LGG	cis	rs7178909	0.835	rs7169019	chr15:90400364	T/G	cg19708238	chr15:90437601	AP3S2	0.4	6.65	0.3	8.06e-11	Common traits (Other);
LGG	cis	rs875971	0.862	rs12537823	chr7:65720884	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.82	0.3	2.85e-11	Aortic root size;
LGG	trans	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg26043149	chr18:55253948	FECH	-0.49	-8.28	-0.36	1.37e-15	Bone mineral density;
LGG	cis	rs7586879	0.796	rs916484	chr2:25082588	A/C	cg04586622	chr2:25135609	ADCY3	0.36	8.64	0.37	9.12e-17	Body mass index;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.73e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3206736	0.548	rs328908	chr7:35026008	C/T	cg13400248	chr7:35225412	NA	0.54	9.51	0.4	1.07e-19	Diastolic blood pressure;
LGG	cis	rs4660214	0.694	rs16866216	chr1:39674588	A/G	cg18385671	chr1:39797026	MACF1	-0.47	-9.58	-0.41	5.73e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg12935359	chr14:103987150	CKB	0.4	6.68	0.3	7.03e-11	Body mass index;
LGG	cis	rs3816183	0.615	rs6749246	chr2:43080039	A/G	cg14631114	chr2:43023945	NA	0.46	8.09	0.35	5.47e-15	Hypospadias;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg03264133	chr6:25882463	NA	-0.43	-7.64	-0.33	1.29e-13	Height;
LGG	cis	rs1451375	0.572	rs3807558	chr7:50571022	A/G	cg14593290	chr7:50529359	DDC	-0.65	-11.75	-0.48	4.63e-28	Malaria;
LGG	cis	rs3087591	1.000	rs12939853	chr17:29455021	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.25	0.55	1.92e-38	Hip circumference;
LGG	trans	rs6011368	0.540	rs6089804	chr20:62917143	T/C	cg13869341	chr1:15865	WASH5P	-0.58	-10.18	-0.43	4.25e-22	Clozapine-induced cytotoxicity;
LGG	cis	rs1949733	0.656	rs2631762	chr4:8423122	A/T	cg13073564	chr4:8508604	NA	-0.52	-10.68	-0.44	5.97e-24	Response to antineoplastic agents;
LGG	trans	rs6825911	0.543	rs2046579	chr4:111344826	G/A	cg10580549	chr19:53101634	ZNF137	0.55	7.13	0.31	3.88e-12	Blood pressure;
LGG	cis	rs6784615	0.744	rs34827613	chr3:52419291	C/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.88	0.34	2.28e-14	Waist-hip ratio;
LGG	cis	rs77633900	0.772	rs157769	chr15:76834397	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-8.26	-0.36	1.52e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs75920871	1.000	rs61905691	chr11:116880703	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs283228	0.798	rs501116	chr6:101762537	A/G	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs6752107	0.935	rs10199278	chr2:234160669	C/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.36	0.53	1.1e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1577917	1.000	rs1911553	chr6:86630892	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.72	-12.87	-0.51	1.24e-32	Response to antipsychotic treatment;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs6121246	0.567	rs6060260	chr20:30192907	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2361718	0.522	rs11867921	chr17:78121170	G/T	cg09238746	chr17:78121135	EIF4A3	-0.95	-16.51	-0.61	1.75e-48	Yeast infection;
LGG	trans	rs6601327	0.670	rs10092751	chr8:9426325	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.89	0.3	1.85e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6993813	0.843	rs4422806	chr8:120022768	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.95e-11	Bone mineral density (hip);
LGG	trans	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.54	9.24	0.39	9.23e-19	Blood metabolite levels;
LGG	trans	rs11098499	0.619	rs28502463	chr4:120257023	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12989020	chr6:157098657	ARID1B	0.42	6.9	0.31	1.77e-11	Gut microbiome composition (summer);
LGG	cis	rs9811920	0.641	rs58704213	chr3:99690331	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.42	-7.42	-0.33	5.64e-13	Axial length;
LGG	cis	rs559928	0.606	rs17773078	chr11:63906224	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.74	0.3	4.7e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg07460842	chr6:66804631	NA	0.54	8.69	0.37	6.41e-17	Metabolite levels;
LGG	cis	rs7765175	1.000	rs9488156	chr6:113665039	C/T	cg26552650	chr6:113682475	NA	-0.32	-6.97	-0.31	1.07e-11	Coronary artery calcification;
LGG	cis	rs6580649	0.941	rs1635529	chr12:48395102	T/G	cg24011408	chr12:48396354	COL2A1	0.65	7.91	0.35	1.85e-14	Lung cancer;
LGG	cis	rs7312933	0.558	rs1669886	chr12:42838240	A/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.67	-0.34	9.94e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12477438	0.520	rs8179690	chr2:99795300	A/T	cg08885076	chr2:99613938	TSGA10	-0.43	-9.24	-0.39	9.32e-19	Chronic sinus infection;
LGG	cis	rs12580194	0.593	rs59676560	chr12:55745425	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-9.31	-0.4	4.99e-19	Cancer;
LGG	cis	rs9467773	1.000	rs1884946	chr6:26545308	C/G	cg09904177	chr6:26538194	HMGN4	0.78	17.88	0.64	9.53e-55	Intelligence (multi-trait analysis);
LGG	cis	rs3540	0.960	rs2238329	chr15:91028401	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.02	0.35	8.49e-15	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs12580194	0.593	rs60142559	chr12:55719192	A/G	cg19537932	chr12:55886519	OR6C68	-0.54	-9.42	-0.4	2.15e-19	Cancer;
LGG	trans	rs7824557	0.564	rs1435275	chr8:11235735	T/C	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Retinal vascular caliber;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.93	-0.35	1.66e-14	IgG glycosylation;
LGG	cis	rs5769707	0.749	rs7286706	chr22:50058346	G/C	cg06623630	chr22:50017776	C22orf34	-0.33	-6.96	-0.31	1.14e-11	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs36051895	0.560	rs10975009	chr9:5220397	T/G	cg02405213	chr9:5042618	JAK2	-0.7	-13.09	-0.52	1.52e-33	Pediatric autoimmune diseases;
LGG	cis	rs858239	0.669	rs6461688	chr7:23116615	G/A	cg23682824	chr7:23144976	KLHL7	0.44	7.68	0.34	9.49e-14	Cerebrospinal fluid biomarker levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07052796	chr10:5708731	ASB13	0.44	6.87	0.3	2.09e-11	Gut microbiome composition (summer);
LGG	cis	rs9894429	0.789	rs35887231	chr17:79587126	G/A	cg18240062	chr17:79603768	NPLOC4	0.82	15.45	0.58	1.02e-43	Eye color traits;
LGG	cis	rs7084402	0.967	rs1649058	chr10:60317087	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs9467711	0.591	rs56294283	chr6:25976099	A/G	cg21479132	chr6:26055353	NA	0.82	7.91	0.34	1.98e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4660214	0.666	rs1984143	chr1:39756317	G/A	cg18385671	chr1:39797026	MACF1	-0.46	-9.57	-0.41	6.39e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7819412	0.660	rs7462931	chr8:10910343	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-9.85	-0.42	6.73e-21	Triglycerides;
LGG	cis	rs1707322	0.752	rs12062535	chr1:46222880	G/A	cg03146154	chr1:46216737	IPP	0.57	10.72	0.45	4.25e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2839186	0.771	rs2839155	chr21:47639992	A/G	cg11766577	chr21:47581405	C21orf56	-0.56	-10.21	-0.43	3.23e-22	Testicular germ cell tumor;
LGG	cis	rs4006360	0.560	rs3861283	chr17:39243940	C/G	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.21	-0.46	5.81e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg13013644	chr5:502571	SLC9A3	0.31	6.83	0.3	2.75e-11	Cystic fibrosis severity;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg11062466	chr8:58055876	NA	0.49	8.38	0.36	6.4e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17253792	0.545	rs35294669	chr14:56017438	T/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	trans	rs116095464	0.558	rs56127718	chr5:270273	G/T	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs6088580	0.634	rs6059890	chr20:33101653	G/C	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.03e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg07636037	chr3:49044803	WDR6	1.11	28.35	0.8	3.13e-103	Parkinson's disease;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.21	-0.52	5.06e-34	Total body bone mineral density;
LGG	cis	rs7027203	0.828	rs10761288	chr9:96609363	C/T	cg13679303	chr9:96623674	NA	-0.38	-6.71	-0.3	5.65e-11	DNA methylation (variation);
LGG	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg26384229	chr12:38710491	ALG10B	-0.75	-15.0	-0.57	1.01e-41	Morning vs. evening chronotype;
LGG	cis	rs35306767	0.761	rs11253560	chr10:1047226	T/G	cg20503657	chr10:835505	NA	0.56	7.32	0.32	1.14e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs66573146	0.634	rs56097119	chr4:7018692	C/G	cg00086871	chr4:6988644	TBC1D14	0.91	8.45	0.37	3.93e-16	Granulocyte percentage of myeloid white cells;
LGG	trans	rs2749592	0.588	rs2504144	chr10:38383525	C/T	cg17830980	chr10:43048298	ZNF37B	-0.36	-7.35	-0.32	9.1e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.61	-0.33	1.5e-13	Longevity;Endometriosis;
LGG	cis	rs9926296	0.656	rs2376881	chr16:89827011	C/G	cg03605463	chr16:89740564	NA	-0.4	-6.73	-0.3	5.12e-11	Vitiligo;
LGG	cis	rs7927771	0.524	rs11039415	chr11:47845814	A/G	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg07925687	chr3:120461082	RABL3;GTF2E1	0.39	6.69	0.3	6.53e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg14580567	chr4:145567271	HHIP	0.4	7.09	0.31	5.1e-12	Bipolar disorder;
LGG	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg15890332	chr12:107067104	RFX4	0.31	8.24	0.36	1.8e-15	Total body bone mineral density;
LGG	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg15557168	chr22:42548783	NA	-0.34	-7.81	-0.34	3.94e-14	Cognitive function;
LGG	cis	rs651907	0.557	rs3806654	chr3:101396529	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	15.02	0.57	8.14e-42	Colorectal cancer;
LGG	cis	rs208520	1.000	rs72882086	chr6:66976671	G/A	cg07460842	chr6:66804631	NA	0.9	14.83	0.57	5.65e-41	Exhaled nitric oxide output;
LGG	cis	rs6430585	0.528	rs6750549	chr2:136707480	A/G	cg07169764	chr2:136633963	MCM6	1.27	25.45	0.76	5.25e-90	Corneal structure;
LGG	cis	rs12282928	1.000	rs11039667	chr11:48326063	C/G	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18876405	chr7:65276391	NA	-0.6	-11.42	-0.47	8.63e-27	Aortic root size;
LGG	cis	rs703842	0.616	rs10783851	chr12:58231155	A/G	cg02175503	chr12:58329896	NA	-0.51	-8.22	-0.36	2.09e-15	Multiple sclerosis;
LGG	cis	rs4727027	0.901	rs12671341	chr7:148805282	T/C	cg23583168	chr7:148888333	NA	-0.85	-16.05	-0.6	2.17e-46	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11190604	0.832	rs2489041	chr10:102333635	G/C	cg07570687	chr10:102243282	WNT8B	0.45	6.98	0.31	1.04e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.5	9.57	0.41	6.26e-20	Longevity;
LGG	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg11247378	chr22:39784982	NA	-0.31	-8.98	-0.39	6.75e-18	Intelligence (multi-trait analysis);
LGG	cis	rs17162190	0.698	rs61692526	chr1:26849906	T/C	cg23229016	chr1:26872525	RPS6KA1	0.26	7.1	0.31	4.78e-12	Mean corpuscular volume;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg21782813	chr7:2030301	MAD1L1	0.48	11.01	0.46	3.27e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4073582	0.595	rs474005	chr11:66033301	C/T	cg16950941	chr11:66035639	RAB1B	0.56	10.49	0.44	2.95e-23	Gout;
LGG	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg27535305	chr1:53392650	SCP2	0.35	7.87	0.34	2.48e-14	Monocyte count;
LGG	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg06618935	chr21:46677482	NA	0.47	9.24	0.39	9.15e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9296092	0.560	rs9469500	chr6:33526196	C/T	cg13560919	chr6:33536144	NA	-1.04	-21.17	-0.7	4.79e-70	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg19318889	chr4:1322082	MAEA	-0.48	-8.31	-0.36	1.06e-15	Longevity;
LGG	cis	rs317689	0.819	rs317685	chr12:69715457	A/G	cg14784868	chr12:69753453	YEATS4	-0.44	-6.93	-0.31	1.41e-11	Response to diuretic therapy;
LGG	cis	rs4740619	0.905	rs2211323	chr9:15802264	A/C	cg14451791	chr9:16040625	NA	-0.41	-10.39	-0.43	7.42e-23	Body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03993166	chr15:101817914	SELS	-0.44	-6.86	-0.3	2.21e-11	Pancreatic cancer;
LGG	cis	rs7923837	1.000	rs1112718	chr10:94479107	A/G	cg25093409	chr10:94429542	NA	0.36	6.87	0.3	2.05e-11	Body mass index;Multiple sclerosis;
LGG	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg02254774	chr11:50257496	LOC441601	0.58	6.79	0.3	3.5e-11	Myopia (pathological);
LGG	cis	rs6088590	0.687	rs6088582	chr20:33286798	G/A	cg08999081	chr20:33150536	PIGU	0.38	9.52	0.4	9.87e-20	Coronary artery disease;
LGG	cis	rs514406	0.505	rs269287	chr1:53168842	T/C	cg24675658	chr1:53192096	ZYG11B	-0.6	-13.47	-0.53	3.85e-35	Monocyte count;
LGG	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs916888	0.821	rs199507	chr17:44858855	A/G	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.13e-12	Bipolar disorder;
LGG	cis	rs6882076	1.000	rs1501908	chr5:156398169	C/G	cg12943317	chr5:156479607	HAVCR1	0.65	11.49	0.47	4.56e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs7618915	0.547	rs2289250	chr3:52682946	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.58	-9.92	-0.42	3.58e-21	Bipolar disorder;
LGG	cis	rs17021463	0.676	rs12512832	chr4:95310216	G/T	cg11021082	chr4:95130006	SMARCAD1	0.42	7.13	0.31	3.92e-12	Testicular germ cell tumor;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg09884257	chr4:6988322	TBC1D14	-0.4	-6.79	-0.3	3.49e-11	Hematological and biochemical traits;
LGG	cis	rs4454254	0.814	rs7815937	chr8:141065441	G/A	cg05910124	chr8:141057427	TRAPPC9	-0.29	-7.0	-0.31	9.06e-12	Pulse pressure;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.52	-0.33	2.95e-13	Height;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.22	-0.49	6.04e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs7766436	0.767	rs13206434	chr6:22608883	A/G	cg13666174	chr6:22585274	NA	-0.39	-9.0	-0.39	5.98e-18	Coronary artery disease;
LGG	trans	rs2727020	0.576	rs61885308	chr11:49343363	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.39	-7.31	-0.32	1.17e-12	Coronary artery disease;
LGG	cis	rs2976388	1.000	rs2585179	chr8:143774193	G/A	cg06565975	chr8:143823917	SLURP1	-0.43	-10.86	-0.45	1.27e-24	Urinary tract infection frequency;
LGG	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.75	0.38	4.09e-17	Hypertriglyceridemia;
LGG	cis	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg24623649	chr8:11872141	NA	0.3	6.99	0.31	9.56e-12	Neuroticism;
LGG	cis	rs1577917	0.560	rs9450288	chr6:86221586	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.57	10.55	0.44	1.83e-23	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.16e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs6089829	0.925	rs6062396	chr20:61667949	T/C	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7106204	0.748	rs36092013	chr11:24211987	C/T	ch.11.24196551F	chr11:24239977	NA	1.04	16.23	0.6	3.06e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7619833	0.685	rs487930	chr3:27330335	A/C	cg02860705	chr3:27208620	NA	-0.39	-7.61	-0.33	1.55e-13	Breast cancer;
LGG	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.88	-0.38	1.5e-17	Neuroticism;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06028808	chr11:68637592	NA	0.68	11.76	0.48	4.13e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2070488	0.699	rs13064938	chr3:38440237	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.88	0.57	3.15e-41	Electrocardiographic conduction measures;
LGG	trans	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg06875740	chr19:51307921	C19orf48	-0.64	-8.02	-0.35	8.75e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg04025307	chr7:1156635	C7orf50	0.78	16.23	0.6	3.25e-47	Longevity;Endometriosis;
LGG	cis	rs3806843	0.735	rs2563335	chr5:140044292	A/C	cg19875535	chr5:140030758	IK	0.57	11.95	0.49	7.34e-29	Depressive symptoms (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18251360	chr22:20067313	DGCR8	0.44	7.08	0.31	5.26e-12	Cognitive performance;
LGG	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg24253500	chr15:84953950	NA	0.59	10.91	0.45	8.37e-25	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11897909	chr13:102570476	FGF14	0.45	7.31	0.32	1.19e-12	Gut microbiome composition (summer);
LGG	cis	rs7586879	0.639	rs2033654	chr2:25103108	C/A	cg04586622	chr2:25135609	ADCY3	0.44	11.91	0.48	1.01e-28	Body mass index;
LGG	cis	rs941873	0.868	rs2145998	chr10:81121696	T/A	cg09469691	chr10:81107165	PPIF	0.59	10.36	0.43	8.91e-23	Height;
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg02772935	chr3:125709198	NA	-0.54	-6.95	-0.31	1.25e-11	Blood pressure (smoking interaction);
LGG	cis	rs3771570	1.000	rs73004354	chr2:242356239	G/T	cg21155796	chr2:242212141	HDLBP	0.75	9.95	0.42	2.8e-21	Prostate cancer;
LGG	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg10057126	chr4:77819792	ANKRD56	0.35	6.8	0.3	3.27e-11	Emphysema distribution in smoking;
LGG	cis	rs910316	1.000	rs7147118	chr14:75610170	G/C	cg06637938	chr14:75390232	RPS6KL1	0.57	10.5	0.44	2.73e-23	Height;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06850241	chr22:41845214	NA	0.46	7.01	0.31	8.44e-12	Vitiligo;
LGG	cis	rs367615	0.506	rs2914680	chr5:108787146	A/G	cg17395555	chr5:108820864	NA	-0.79	-14.24	-0.55	2.06e-38	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs72772090	0.539	rs35898772	chr5:96179685	A/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.18	-0.36	2.68e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17270561	0.609	rs9356984	chr6:25725481	C/T	cg16482183	chr6:26056742	HIST1H1C	-0.51	-8.15	-0.35	3.55e-15	Iron status biomarkers;
LGG	trans	rs12579753	1.000	rs11613196	chr12:82173251	A/T	cg07923666	chr12:49932857	KCNH3	0.51	7.58	0.33	1.84e-13	Resting heart rate;
LGG	trans	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.69	-0.37	6.36e-17	Retinal vascular caliber;
LGG	cis	rs6912958	0.781	rs9444522	chr6:88309705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.73	-0.38	4.74e-17	Monocyte percentage of white cells;
LGG	cis	rs875971	0.893	rs62465470	chr7:65601218	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.54e-11	Aortic root size;
LGG	cis	rs8180040	0.620	rs11720139	chr3:47036756	C/G	cg27129171	chr3:47204927	SETD2	-0.8	-14.47	-0.56	2.01e-39	Colorectal cancer;
LGG	cis	rs10979	0.597	rs9403515	chr6:143908013	A/G	cg25407410	chr6:143891975	LOC285740	-0.54	-8.07	-0.35	6.26e-15	Hypospadias;
LGG	cis	rs834603	0.575	rs1799371	chr7:47467436	C/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6977660	1.000	rs714238	chr7:19803925	C/T	cg07541023	chr7:19748670	TWISTNB	0.45	6.92	0.31	1.48e-11	Thyroid stimulating hormone;
LGG	cis	rs3857067	0.806	rs6858342	chr4:95112318	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs10504130	0.660	rs6473666	chr8:52838295	A/G	cg13492337	chr8:52722140	PXDNL	-0.51	-7.69	-0.34	8.83e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs6601327	0.578	rs4075359	chr8:9487813	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.46	-0.33	4.22e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg00666640	chr1:248458726	OR2T12	0.5	8.63	0.37	9.57e-17	Common traits (Other);
LGG	cis	rs897080	0.515	rs786616	chr2:44592975	C/G	cg00619915	chr2:44497795	NA	-0.48	-6.7	-0.3	5.97e-11	Height;
LGG	cis	rs5769765	0.862	rs56377703	chr22:50306940	C/T	cg02269571	chr22:50332266	NA	-0.71	-10.87	-0.45	1.14e-24	Schizophrenia;
LGG	cis	rs7647973	0.626	rs2329021	chr3:49679072	G/A	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg02524346	chr8:600233	NA	-1.04	-10.53	-0.44	2.24e-23	IgG glycosylation;
LGG	cis	rs1008375	0.606	rs6828925	chr4:17561139	C/T	cg10189774	chr4:17578691	LAP3	0.4	7.1	0.31	4.69e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2562456	0.793	rs2650819	chr19:21638873	C/T	cg00806126	chr19:22604979	ZNF98	0.56	7.96	0.35	1.34e-14	Pain;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.63	10.81	0.45	1.99e-24	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs11053251	chr12:34520743	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs714031	0.934	rs738315	chr22:40069245	T/C	cg21377881	chr22:40064566	CACNA1I	-0.6	-14.4	-0.56	4.12e-39	Schizophrenia;
LGG	cis	rs6964587	0.869	rs6979024	chr7:91481512	T/C	cg17063962	chr7:91808500	NA	-0.4	-6.88	-0.3	1.91e-11	Breast cancer;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.06	-0.31	6.28e-12	Lung cancer;
LGG	cis	rs953387	1.000	rs950176	chr2:136898078	A/G	cg05194412	chr2:137003533	NA	-0.32	-6.9	-0.31	1.69e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs6963495	0.674	rs75880756	chr7:105163821	G/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs17209837	1.000	rs4148815	chr7:87087834	A/T	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg00149659	chr3:10157352	C3orf10	0.94	11.97	0.49	6.05e-29	Alzheimer's disease;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.39	-0.43	7.15e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9921222	0.521	rs11649255	chr16:357140	A/G	cg07915516	chr16:377344	AXIN1	0.27	6.79	0.3	3.35e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9468199	0.505	rs72847381	chr6:27873931	G/A	cg00426182	chr6:28072559	NA	0.96	7.24	0.32	1.92e-12	Parkinson's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12502403	chr11:63607025	MARK2	0.41	6.75	0.3	4.39e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.675	rs2736265	chr8:11186674	A/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.59	-0.33	1.82e-13	Retinal vascular caliber;
LGG	cis	rs4774899	0.752	rs2920264	chr15:57321065	T/C	cg08128148	chr15:57256372	TCF12	0.28	6.75	0.3	4.48e-11	Urinary tract infection frequency;
LGG	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08316775	chr2:73964643	TPRKB	0.49	7.93	0.35	1.69e-14	Cognitive performance;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg04529724	chr6:150244392	RAET1G	0.33	6.69	0.3	6.62e-11	Testicular germ cell tumor;
LGG	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg27490568	chr2:178487706	NA	0.46	9.21	0.39	1.16e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs763121	0.853	rs5750649	chr22:39036769	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.44	0.65	2.56e-57	Menopause (age at onset);
LGG	cis	rs4734806	1.000	rs57857375	chr8:105708680	G/A	cg01675814	chr8:105601641	LRP12	0.49	6.96	0.31	1.17e-11	Periodontitis (DPAL);
LGG	cis	rs1451375	0.652	rs10265930	chr7:50627449	C/T	cg14593290	chr7:50529359	DDC	0.51	8.77	0.38	3.48e-17	Malaria;
LGG	cis	rs3820068	0.581	rs72645895	chr1:15931709	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs305851	0.818	rs7761456	chr6:39768005	A/C	cg02386599	chr6:39769542	DAAM2	0.28	6.69	0.3	6.33e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-6.89	-0.3	1.89e-11	Daytime sleep phenotypes;
LGG	cis	rs10463554	0.963	rs40093	chr5:102439825	A/T	cg23492399	chr5:102201601	PAM	-0.5	-7.52	-0.33	2.8e-13	Parkinson's disease;
LGG	cis	rs1784581	0.651	rs1784589	chr6:162389571	A/G	cg17173639	chr6:162384350	PARK2	-0.76	-17.12	-0.62	2.9e-51	Itch intensity from mosquito bite;
LGG	cis	rs6840360	0.615	rs72728171	chr4:152469372	C/A	cg22705602	chr4:152727874	NA	-0.32	-7.57	-0.33	1.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs4919087	0.810	rs1572437	chr10:99029278	A/G	cg25902810	chr10:99078978	FRAT1	0.47	8.45	0.37	3.87e-16	Monocyte count;
LGG	cis	rs3784262	0.512	rs4646572	chr15:58343021	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-6.99	-0.31	9.7e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2013441	1.000	rs2703799	chr17:20085768	G/T	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs17453880	0.963	rs6863717	chr5:152027165	G/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs2235573	0.625	rs3026677	chr22:38432725	C/G	cg19171272	chr22:38449367	NA	-0.55	-10.75	-0.45	3.21e-24	Glioblastoma;Glioma;
LGG	cis	rs9517313	0.770	rs9517301	chr13:99095088	A/G	cg07423050	chr13:99094983	FARP1	-0.66	-13.45	-0.53	4.95e-35	Neuroticism;
LGG	cis	rs2729354	0.768	rs2729384	chr11:57258617	T/C	cg24343310	chr11:57249947	NA	0.42	8.14	0.35	3.74e-15	Blood protein levels;
LGG	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg26655873	chr3:72818019	SHQ1	0.33	6.87	0.3	2.13e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs975722	0.638	rs10244694	chr7:117322367	G/A	cg10524701	chr7:117356490	CTTNBP2	0.47	9.64	0.41	3.58e-20	Coronary artery disease;
LGG	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.89	-0.38	1.41e-17	Retinal vascular caliber;
LGG	cis	rs17208368	0.723	rs72802762	chr16:55091684	A/G	cg11181171	chr16:55090946	NA	0.5	7.56	0.33	2.21e-13	Hypospadias;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs6459804	1.000	rs35487364	chr7:157507765	T/C	cg24764310	chr7:157512201	PTPRN2	-0.48	-10.3	-0.43	1.53e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.731	rs9891378	chr17:80116035	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs875971	0.895	rs4718349	chr7:65909011	C/G	cg12463550	chr7:65579703	CRCP	0.51	8.56	0.37	1.63e-16	Aortic root size;
LGG	cis	rs9899728	0.539	rs57813751	chr17:73053512	C/T	cg27626185	chr17:73056755	KCTD2	-1.04	-12.33	-0.5	2.02e-30	Alzheimer's disease or small vessel stroke;
LGG	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg00745463	chr17:30367425	LRRC37B	0.48	7.07	0.31	5.89e-12	Hip circumference adjusted for BMI;
LGG	cis	rs78366141	0.649	rs6813481	chr4:89739174	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.85	7.34	0.32	9.36e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg20887711	chr4:1340912	KIAA1530	0.59	11.49	0.47	4.69e-27	Longevity;
LGG	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg23815491	chr16:72088622	HP	0.37	6.81	0.3	3.1e-11	Blood protein levels;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg25072359	chr17:41440525	NA	0.48	9.36	0.4	3.53e-19	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.54	-0.37	1.96e-16	Life satisfaction;
LGG	cis	rs6430585	0.528	rs309166	chr2:136667487	C/T	cg07169764	chr2:136633963	MCM6	1.15	20.47	0.69	9.04e-67	Corneal structure;
LGG	cis	rs6964587	1.000	rs6465343	chr7:91618208	T/C	cg17063962	chr7:91808500	NA	0.49	8.71	0.38	5.22e-17	Breast cancer;
LGG	trans	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg26043149	chr18:55253948	FECH	0.43	7.18	0.32	2.88e-12	Bone mineral density;
LGG	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg15627072	chr1:2432621	PLCH2	-0.38	-8.47	-0.37	3.34e-16	Ulcerative colitis;
LGG	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	trans	rs4942242	0.602	rs61960076	chr13:44217784	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-8.82	-0.38	2.31e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6444746	1.000	rs2008918	chr3:193499512	A/G	cg22553634	chr3:193489233	NA	-0.71	-8.47	-0.37	3.24e-16	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	trans	rs58106596	0.800	rs11693819	chr2:232566206	G/A	cg01370599	chr3:116745421	NA	0.72	10.85	0.45	1.36e-24	White blood cell count;Lymphocyte counts;
LGG	cis	rs12210905	1.000	rs72843643	chr6:27211247	G/C	cg15325629	chr6:28072465	NA	0.83	6.81	0.3	3.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg00850481	chr1:228891306	NA	-0.5	-8.65	-0.37	8.65e-17	Chronic lymphocytic leukemia;
LGG	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.67	14.18	0.55	3.7e-38	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24857609	chr8:71315397	NCOA2	0.47	7.0	0.31	8.91e-12	Gut microbiome composition (summer);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg09376854	chr10:103535775	FGF8	0.45	6.76	0.3	4.26e-11	Hip circumference;
LGG	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg00142150	chr22:38071001	LGALS1	-0.39	-6.67	-0.3	7.1e-11	Glioblastoma;Glioma;
LGG	cis	rs2841277	0.708	rs10083490	chr14:105402418	A/G	cg21017887	chr14:105400489	NA	-0.43	-8.69	-0.37	6.18e-17	Rheumatoid arthritis;
LGG	cis	rs11683229	0.852	rs35684492	chr2:63492440	A/C	cg19915305	chr2:64069682	UGP2	-0.44	-6.79	-0.3	3.53e-11	Protein quantitative trait loci;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs12824058	0.831	rs11609362	chr12:130810526	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	cis	rs12765878	1.000	rs2902639	chr10:105658588	G/C	cg11005552	chr10:105648138	OBFC1	1.04	27.28	0.79	2.07e-98	Coronary artery disease;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.27	0.32	1.57e-12	Obesity-related traits;
LGG	trans	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg06521331	chr12:34319734	NA	-0.52	-8.99	-0.39	6.22e-18	Bladder cancer;
LGG	trans	rs6940638	0.956	rs3922717	chr6:27030924	A/G	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10883723	0.810	rs7092622	chr10:104249919	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.89	0.57	2.93e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8060686	0.545	rs9922165	chr16:68181177	C/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-7.08	-0.31	5.36e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg07538946	chr5:131705188	SLC22A5	-0.64	-7.77	-0.34	5.21e-14	Rheumatoid arthritis;
LGG	cis	rs2019137	0.936	rs3828189	chr2:113954496	T/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.25	-0.43	2.42e-22	Lymphocyte counts;
LGG	cis	rs977987	0.836	rs34673655	chr16:75323559	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.74	0.3	4.79e-11	Dupuytren's disease;
LGG	cis	rs2046867	0.818	rs62251647	chr3:72805789	G/A	cg26655873	chr3:72818019	SHQ1	0.34	6.81	0.3	3.1e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1832871	0.640	rs262831	chr6:158691169	A/T	cg07215822	chr6:158701037	NA	-0.46	-8.89	-0.38	1.4e-17	Height;
LGG	cis	rs8014204	1.000	rs8014204	chr14:75322794	A/G	cg06637938	chr14:75390232	RPS6KL1	0.82	16.58	0.61	8.32e-49	Caffeine consumption;
LGG	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.3	-0.32	1.24e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs17253792	0.642	rs10483648	chr14:56104278	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs7011049	0.778	rs6994249	chr8:53866215	G/A	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs758324	0.812	rs9327621	chr5:131118943	T/C	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.41e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs8060686	0.641	rs12448677	chr16:68209741	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg11871910	chr12:69753446	YEATS4	0.66	12.97	0.52	4.98e-33	Blood protein levels;
LGG	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.3e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1843834	0.539	rs2047135	chr2:225427302	G/C	cg22455342	chr2:225449267	CUL3	0.86	15.2	0.58	1.29e-42	IgE levels in asthmatics (D.p. specific);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02569853	chr2:20251308	LAPTM4A	-0.39	-6.73	-0.3	4.93e-11	Brain structure;
LGG	cis	rs4959677	0.901	rs10458144	chr6:2479189	C/T	cg20147862	chr6:2634573	C6orf195	0.4	8.67	0.37	7.53e-17	Orthostatic hypotension;
LGG	cis	rs6840360	0.642	rs2709838	chr4:152371364	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5e-12	Intelligence (multi-trait analysis);
LGG	cis	rs504918	1.000	rs525715	chr3:124089331	G/A	cg05766129	chr3:123988013	KALRN	0.38	6.82	0.3	2.9100000000000002e-11	Schizophrenia;
LGG	trans	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg26521024	chr13:45151950	TSC22D1	0.39	6.69	0.3	6.36e-11	Dupuytren's disease;
LGG	cis	rs751728	0.687	rs4711355	chr6:33759906	G/T	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	cis	rs6732160	0.650	rs7560224	chr2:73406182	A/G	cg01422370	chr2:73384389	NA	0.49	9.34	0.4	4.03e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs422249	0.547	rs174533	chr11:61549025	G/A	cg19610905	chr11:61596333	FADS2	-0.81	-14.73	-0.56	1.55e-40	Trans fatty acid levels;
LGG	cis	rs1371867	0.875	rs1125706	chr8:101326739	T/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.85	-0.38	1.85e-17	Atrioventricular conduction;
LGG	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg08847533	chr14:75593920	NEK9	-0.61	-11.67	-0.48	9.26e-28	Height;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.4	7.09	0.31	5.19e-12	Longevity;
LGG	cis	rs258892	0.947	rs266444	chr5:72181404	C/T	cg21869765	chr5:72125136	TNPO1	0.42	7.14	0.32	3.58e-12	Small cell lung carcinoma;
LGG	cis	rs2273669	0.667	rs11752532	chr6:109335969	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs17270561	0.609	rs6941933	chr6:25745702	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.44	-0.33	4.96e-13	Iron status biomarkers;
LGG	cis	rs75804782	0.641	rs6715311	chr2:239363321	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-6.7	-0.3	6.16e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs4639966	0.512	rs7926282	chr11:118605914	A/C	cg19182353	chr11:118479428	PHLDB1	-0.55	-7.6	-0.33	1.66e-13	Systemic lupus erythematosus;
LGG	cis	rs2519796	0.509	rs471882	chr9:136825399	C/G	cg13751417	chr9:136814406	VAV2	0.44	8.11	0.35	4.57e-15	Hematocrit;Hemoglobin concentration;
LGG	cis	rs55665837	1.000	rs11023246	chr11:14536956	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.84e-17	Vitamin D levels;
LGG	cis	rs1552244	0.554	rs17050704	chr3:10045734	T/C	cg00149659	chr3:10157352	C3orf10	0.58	8.37	0.36	6.86e-16	Alzheimer's disease;
LGG	cis	rs7683537	0.887	rs4540092	chr4:185633546	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	22.73	0.73	2.39e-77	Systemic lupus erythematosus;
LGG	cis	rs4242434	0.672	rs7830206	chr8:22485375	C/T	cg00599393	chr8:22457479	C8orf58	-0.39	-7.03	-0.31	7.4e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs11098499	0.863	rs10013305	chr4:120450424	G/A	cg25214090	chr10:38739885	LOC399744	0.67	11.79	0.48	2.98e-28	Corneal astigmatism;
LGG	cis	rs3820068	0.581	rs72645881	chr1:15928203	C/T	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs1800469	1.000	rs2241714	chr19:41869392	C/T	cg09537434	chr19:41945824	ATP5SL	0.47	7.9	0.34	2.1e-14	Colorectal cancer;
LGG	cis	rs12210905	1.000	rs6902012	chr6:27243767	C/T	cg23155468	chr6:27110703	HIST1H2BK	0.59	6.74	0.3	4.85e-11	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.02	-0.57	8.06e-42	Prudent dietary pattern;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.02	0.39	5.16e-18	Platelet count;
LGG	cis	rs765787	0.530	rs28414644	chr15:45536721	G/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs7072216	0.763	rs733345	chr10:100164215	G/T	cg26618903	chr10:100175079	PYROXD2	-0.28	-7.09	-0.31	5.11e-12	Metabolite levels;
LGG	cis	rs4481887	0.861	rs6676064	chr1:248443890	G/C	cg00666640	chr1:248458726	OR2T12	0.57	8.94	0.38	9.24e-18	Common traits (Other);
LGG	cis	rs9325144	0.554	rs1906264	chr12:38739490	A/G	cg04568710	chr12:38710424	ALG10B	0.39	8.27	0.36	1.43e-15	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg11766577	chr21:47581405	C21orf56	-0.49	-8.1	-0.35	5.09e-15	Testicular germ cell tumor;
LGG	cis	rs9467773	1.000	rs9467778	chr6:26534743	T/C	cg09904177	chr6:26538194	HMGN4	0.78	18.24	0.65	2.18e-56	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06958686	chr17:61699762	MAP3K3	0.45	6.75	0.3	4.41e-11	Gut microbiome composition (summer);
LGG	cis	rs4936891	1.000	rs4936890	chr11:123914742	G/A	cg22125253	chr11:123886957	OR10G4	-0.55	-10.49	-0.44	3.06e-23	Male fertility;
LGG	cis	rs9522267	0.535	rs9522286	chr13:112230909	A/G	cg10483660	chr13:112241077	NA	-0.36	-7.78	-0.34	4.63e-14	Hepatitis;
LGG	trans	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg02002194	chr4:3960332	NA	-0.52	-10.52	-0.44	2.4e-23	Mood instability;
LGG	cis	rs875971	0.929	rs34406470	chr7:65929956	A/G	cg12463550	chr7:65579703	CRCP	0.5	8.43	0.36	4.57e-16	Aortic root size;
LGG	cis	rs4642101	0.534	rs13316229	chr3:12807371	C/T	cg05775895	chr3:12838266	CAND2	0.56	9.47	0.4	1.41e-19	QRS complex (12-leadsum);
LGG	trans	rs7395662	0.864	rs10839201	chr11:48989417	A/G	cg03929089	chr4:120376271	NA	0.44	7.58	0.33	1.84e-13	HDL cholesterol;
LGG	trans	rs11992162	0.591	rs34123222	chr8:11795349	C/T	cg02002194	chr4:3960332	NA	0.43	7.92	0.35	1.74e-14	Monocyte count;
LGG	trans	rs12517041	1.000	rs2099090	chr5:23287823	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	2.95e-25	Calcium levels;
LGG	cis	rs758324	0.773	rs4705901	chr5:131146993	T/C	cg06307176	chr5:131281290	NA	0.54	8.93	0.38	1.01e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1552244	1.000	rs6442148	chr3:10078289	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	cis	rs17208368	0.628	rs8060118	chr16:55092141	A/G	cg09947736	chr16:55091198	NA	0.66	12.58	0.5	1.95e-31	Hypospadias;
LGG	cis	rs10089	1.000	rs1560636	chr5:127447987	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	12.01	0.49	4.02e-29	Ileal carcinoids;
LGG	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg00204512	chr16:28754710	NA	-0.26	-6.86	-0.3	2.26e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg15857475	chr8:145742913	RECQL4;LRRC14	0.86	16.9	0.62	2.95e-50	Age at first birth;
LGG	cis	rs3741151	0.686	rs11822984	chr11:73261467	A/C	cg17517138	chr11:73019481	ARHGEF17	0.81	7.79	0.34	4.54e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg17644776	chr2:200775616	C2orf69	0.57	7.13	0.31	3.88e-12	Schizophrenia;
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg10207240	chr12:122356781	WDR66	0.26	7.73	0.34	6.62e-14	Mean corpuscular volume;
LGG	cis	rs36051895	0.623	rs6476957	chr9:5261324	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-13.37	-0.53	1.09e-34	Pediatric autoimmune diseases;
LGG	cis	rs4731207	0.698	rs12537161	chr7:124538590	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.49	-0.33	3.58e-13	Cutaneous malignant melanoma;
LGG	cis	rs4481887	1.000	rs4579792	chr1:248463742	C/T	cg01631408	chr1:248437212	OR2T33	0.52	9.3	0.4	5.42e-19	Common traits (Other);
LGG	trans	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.895	rs7924481	chr11:48582457	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs4764124	0.571	rs11830399	chr12:14956932	G/C	cg19759883	chr12:14956454	WBP11;C12orf60	0.56	10.47	0.44	3.54e-23	Pubertal anthropometrics;
LGG	cis	rs11676348	0.873	rs10210012	chr2:219013334	G/A	cg00012203	chr2:219082015	ARPC2	-0.49	-8.71	-0.38	5.24e-17	Ulcerative colitis;
LGG	cis	rs2117029	0.965	rs1138908	chr12:49402299	G/C	cg24176009	chr12:49580217	TUBA1A	0.43	7.76	0.34	5.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs28442244	chr6:86701236	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	9.33	0.4	4.36e-19	Response to antipsychotic treatment;
LGG	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg14829360	chr17:73884958	NA	0.53	10.23	0.43	2.73e-22	White matter hyperintensity burden;
LGG	cis	rs7786808	0.586	rs7794256	chr7:158206214	T/G	cg15440763	chr7:158190612	PTPRN2	-0.44	-9.48	-0.4	1.36e-19	Obesity-related traits;
LGG	cis	rs2153535	0.623	rs6597338	chr6:8533508	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	10.34	0.43	1.07e-22	Height;
LGG	trans	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg02030672	chr11:45687055	CHST1	0.5	8.76	0.38	3.76e-17	Obesity-related traits;
LGG	cis	rs4665809	0.652	rs10779956	chr2:26405985	A/G	cg08470875	chr2:26401718	FAM59B	-0.41	-7.97	-0.35	1.28e-14	Gut microbiome composition (summer);
LGG	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg01200585	chr1:228362443	C1orf69	-0.45	-7.98	-0.35	1.13e-14	Diastolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02994645	chr8:30891371	WRN;PURG	0.42	6.65	0.3	8.36e-11	Cognitive performance;
LGG	cis	rs3806843	0.551	rs246018	chr5:140335043	T/C	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs477692	0.569	rs10764884	chr10:131308370	G/C	cg05714579	chr10:131428358	MGMT	0.51	10.16	0.43	5.14e-22	Response to temozolomide;
LGG	cis	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg27411982	chr8:10470053	RP1L1	-0.47	-7.59	-0.33	1.77e-13	Neuroticism;
LGG	trans	rs7395662	0.963	rs7952491	chr11:48663295	T/A	cg15704280	chr7:45808275	SEPT13	-0.49	-8.09	-0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.3	-0.47	2.52e-26	Blood metabolite levels;
LGG	cis	rs9549367	0.636	rs486407	chr13:113833499	G/A	cg18105134	chr13:113819100	PROZ	0.72	15.5	0.58	6.05e-44	Platelet distribution width;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.07e-11	Menopause (age at onset);
LGG	cis	rs7529073	1.000	rs7529073	chr1:214147889	T/C	cg24083324	chr1:214162604	PROX1	-0.5	-8.91	-0.38	1.16e-17	Schizophrenia;
LGG	cis	rs1348850	0.651	rs1901826	chr2:178225266	G/A	cg22681709	chr2:178499509	PDE11A	-0.38	-7.19	-0.32	2.55e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10743315	0.557	rs17343287	chr12:19420064	T/C	cg02471346	chr12:19282374	PLEKHA5	0.8	7.45	0.33	4.62e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.572	rs28446104	chr8:8795901	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.35	-0.32	8.93e-13	Mood instability;
LGG	cis	rs9311474	0.508	rs11718420	chr3:52611413	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.68	0.3	7.04e-11	Electroencephalogram traits;
LGG	cis	rs10489167	1.000	rs10489167	chr1:41176466	A/G	cg11417323	chr1:41160271	NFYC	0.42	7.38	0.32	7.25e-13	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs78456975	0.941	rs28913033	chr2:1523194	T/C	cg01028140	chr2:1542097	TPO	-0.57	-8.51	-0.37	2.4e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7638995	0.941	rs1995664	chr3:69183004	T/C	cg26574240	chr3:69171822	LMOD3	-0.6	-9.88	-0.42	5.27e-21	Alzheimer's disease (late onset);
LGG	cis	rs72781680	0.851	rs72796397	chr2:24178211	T/A	cg08917208	chr2:24149416	ATAD2B	0.81	9.54	0.41	8.07e-20	Lymphocyte counts;
LGG	cis	rs9944715	0.906	rs7241829	chr18:43737111	G/C	cg26436583	chr18:43649176	PSTPIP2	0.42	7.8	0.34	4.1e-14	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.2	-0.39	1.25e-18	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24862861	chr10:976594	NA	0.48	7.53	0.33	2.65e-13	Gut microbiome composition (summer);
LGG	trans	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg26384229	chr12:38710491	ALG10B	0.73	14.69	0.56	2.34e-40	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg02951883	chr7:2050386	MAD1L1	-0.77	-16.16	-0.6	6.94e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg24375607	chr4:120327624	NA	0.69	11.15	0.46	1.01e-25	Corneal astigmatism;
LGG	cis	rs950776	0.518	rs12906951	chr15:78825562	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11980791	chr9:131084797	COQ4;TRUB2	0.48	7.66	0.34	1.06e-13	Cognitive performance;
LGG	cis	rs8180040	0.620	rs11917361	chr3:47070497	G/T	cg27129171	chr3:47204927	SETD2	-0.83	-15.24	-0.58	8.41e-43	Colorectal cancer;
LGG	cis	rs72772090	0.710	rs113710451	chr5:96060306	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.47	-7.06	-0.31	5.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7647973	0.566	rs57630346	chr3:49086215	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.5	8.55	0.37	1.82e-16	Menarche (age at onset);
LGG	trans	rs10506458	0.915	rs1009540	chr12:63414872	C/A	cg22491629	chr6:157744540	C6orf35	-0.95	-13.37	-0.53	1.08e-34	Hemostatic factors and hematological phenotypes;
LGG	cis	rs736408	0.677	rs678	chr3:52820981	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.27	0.36	1.4e-15	Bipolar disorder;
LGG	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg16586182	chr3:47516702	SCAP	0.75	14.32	0.55	9.32e-39	Colorectal cancer;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.56	0.47	2.53e-27	Bipolar disorder;
LGG	cis	rs4740619	0.967	rs7032755	chr9:15640025	G/T	cg14451791	chr9:16040625	NA	0.34	8.33	0.36	8.91e-16	Body mass index;
LGG	cis	rs7945705	0.967	rs34842234	chr11:8891894	G/A	cg21881798	chr11:8931708	C11orf17;ST5	0.53	11.54	0.47	3.05e-27	Hemoglobin concentration;
LGG	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg04568710	chr12:38710424	ALG10B	0.39	8.13	0.35	4.07e-15	Morning vs. evening chronotype;
LGG	cis	rs981844	1.000	rs2606328	chr4:154653864	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.59	0.47	1.98e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs3790455	0.610	rs1171561	chr1:156455898	G/A	cg14087168	chr1:156450669	MEF2D	-0.66	-10.11	-0.43	7.48e-22	Migraine;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg05025164	chr4:1340916	KIAA1530	-0.57	-10.03	-0.42	1.53e-21	Obesity-related traits;
LGG	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg23009067	chr7:2775923	GNA12	0.25	6.96	0.31	1.2e-11	Height;
LGG	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.97	0.57	1.27e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.75	0.61	1.49e-49	Personality dimensions;
LGG	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg16141378	chr3:129829833	LOC729375	0.44	10.59	0.44	1.28e-23	Mood instability;
LGG	cis	rs12893668	0.572	rs4900590	chr14:104146421	C/T	cg26031613	chr14:104095156	KLC1	-0.67	-10.78	-0.45	2.46e-24	Reticulocyte count;
LGG	cis	rs9818758	0.607	rs34326553	chr3:49134429	A/G	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs7208859	0.623	rs28556733	chr17:29083945	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9372253	1.000	rs9372253	chr6:110716136	C/T	cg01119278	chr6:110721349	DDO	-0.3	-7.31	-0.32	1.19e-12	Platelet distribution width;
LGG	cis	rs537930	0.890	rs299363	chr5:134331822	G/A	cg24576358	chr5:134350122	NA	0.47	9.47	0.4	1.47e-19	Height;
LGG	trans	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.74	0.59	4.83e-45	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.524	rs2028216	chr3:52680823	C/T	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.32	2.09e-12	Bipolar disorder;
LGG	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.28	0.46	3.12e-26	Vitamin D levels;
LGG	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg10523679	chr1:76189770	ACADM	0.82	13.97	0.54	2.97e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs3096299	0.967	rs753853	chr16:89446525	G/T	cg02187348	chr16:89574699	SPG7	0.43	6.84	0.3	2.52e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-8.42	-0.36	4.66e-16	Diabetic retinopathy;
LGG	cis	rs1862618	0.525	rs2662021	chr5:56261691	C/T	cg08400814	chr5:56204995	C5orf35	0.55	8.08	0.35	5.77e-15	Initial pursuit acceleration;
LGG	cis	rs6502050	0.865	rs8079388	chr17:80162798	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.86e-13	Life satisfaction;
LGG	cis	rs41271473	1.000	rs1062060	chr1:228880021	A/G	cg16512390	chr1:228756714	NA	-0.47	-6.69	-0.3	6.6e-11	Chronic lymphocytic leukemia;
LGG	cis	rs36071027	0.593	rs11745589	chr5:158428274	A/T	cg04248271	chr5:158524404	EBF1	0.41	7.32	0.32	1.09e-12	Carotid intima media thickness;
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg15556689	chr8:8085844	FLJ10661	0.39	6.93	0.31	1.38e-11	Monocyte count;
LGG	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg02397686	chr17:73851076	WBP2	0.61	7.95	0.35	1.45e-14	Psoriasis;
LGG	cis	rs6502050	0.799	rs4789681	chr17:80100546	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs1408224	0.657	rs7318686	chr13:47200504	G/A	cg24453118	chr13:47229927	LRCH1	-0.3	-7.02	-0.31	7.76e-12	QRS complex (12-leadsum);
LGG	cis	rs2117029	0.586	rs10875931	chr12:49573296	G/A	cg24176009	chr12:49580217	TUBA1A	0.66	12.79	0.51	2.83e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg10523679	chr1:76189770	ACADM	0.77	12.46	0.5	6.47e-31	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7659604	0.521	rs13114801	chr4:122670855	C/A	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.78	-0.34	4.75e-14	Type 2 diabetes;
LGG	cis	rs10256972	0.591	rs11766651	chr7:1161646	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.65	-11.36	-0.47	1.54e-26	Longevity;Endometriosis;
LGG	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg13010199	chr12:38710504	ALG10B	0.5	9.62	0.41	4.2e-20	Morning vs. evening chronotype;
LGG	trans	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg18335740	chr13:41363409	SLC25A15	0.51	8.98	0.39	7.06e-18	Lewy body disease;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg22535103	chr8:58192502	C8orf71	-0.72	-9.37	-0.4	3.17e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg11062466	chr8:58055876	NA	0.58	13.2	0.52	5.38e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2718058	0.606	rs2718065	chr7:37859525	A/G	cg15028436	chr7:37888078	TXNDC3	0.52	8.2	0.36	2.31e-15	Alzheimer's disease (late onset);
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.02	-0.31	7.71e-12	Bipolar disorder;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.72	-0.34	7.1e-14	Menopause (age at onset);
LGG	cis	rs2239547	0.522	rs2581801	chr3:52972907	G/T	cg11645453	chr3:52864694	ITIH4	-0.67	-10.33	-0.43	1.17e-22	Schizophrenia;
LGG	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.33	-6.77	-0.3	3.91e-11	Hemoglobin concentration;
LGG	cis	rs7615952	0.736	rs9862893	chr3:125686974	A/G	cg05084668	chr3:125655381	ALG1L	-1.12	-14.07	-0.55	1.12e-37	Blood pressure (smoking interaction);
LGG	cis	rs9322193	0.607	rs915140	chr6:150220810	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.8	0.3	3.15e-11	Lung cancer;
LGG	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg18404041	chr3:52824283	ITIH1	-0.56	-10.77	-0.45	2.83e-24	Bipolar disorder;
LGG	cis	rs344364	0.511	rs1742473	chr16:1953095	T/C	cg14074117	chr16:1909714	C16orf73	-0.51	-7.63	-0.33	1.32e-13	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs2727020	0.521	rs11040408	chr11:49534880	A/T	cg11707556	chr5:10655725	ANKRD33B	0.65	11.13	0.46	1.15e-25	Coronary artery disease;
LGG	cis	rs9486719	1.000	rs12207570	chr6:96987884	A/C	cg18709589	chr6:96969512	KIAA0776	-0.48	-7.3	-0.32	1.3e-12	Migraine;Coronary artery disease;
LGG	cis	rs3742264	0.656	rs6561274	chr13:46518096	A/G	cg15192986	chr13:46630673	CPB2	0.35	6.85	0.3	2.3e-11	Blood protein levels;
LGG	trans	rs7980799	0.772	rs6488162	chr12:33593127	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-7.71	-0.34	7.84e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6725041	0.547	rs6753945	chr2:213204574	T/C	cg16329650	chr2:213403929	ERBB4	-0.38	-6.71	-0.3	5.85e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.01	-0.6	3.11e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9976767	0.637	rs9784215	chr21:43823736	C/A	cg23042151	chr21:43824109	UBASH3A	-0.63	-13.3	-0.53	2.09e-34	Type 1 diabetes;
LGG	trans	rs11039798	0.512	rs28453037	chr11:49006929	C/A	cg15704280	chr7:45808275	SEPT13	0.73	10.21	0.43	3.18e-22	Axial length;
LGG	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg03806693	chr22:41940476	POLR3H	1.04	17.72	0.64	5.15e-54	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs7944735	0.508	rs1872167	chr11:47901269	C/T	cg15704280	chr7:45808275	SEPT13	0.62	6.81	0.3	3.1e-11	Intraocular pressure;
LGG	cis	rs950776	0.714	rs514743	chr15:78884227	A/T	cg06917634	chr15:78832804	PSMA4	-0.69	-12.86	-0.51	1.46e-32	Sudden cardiac arrest;
LGG	cis	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg06521331	chr12:34319734	NA	-0.61	-11.23	-0.46	4.79e-26	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs2120243	1.000	rs2120243	chr3:157147568	A/C	cg24825693	chr3:157122686	VEPH1	-0.38	-8.31	-0.36	1.06e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9329289	0.510	rs28579610	chr10:2546080	C/A	cg15501526	chr10:2543763	NA	0.48	9.2	0.39	1.19e-18	Age-related hearing impairment;
LGG	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.83	0.34	3.41e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11157436	0.602	rs2032441	chr14:22625615	G/A	cg00994629	chr14:22694547	NA	0.33	7.08	0.31	5.35e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7617480	0.648	rs14018	chr3:48784270	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.48	7.9	0.34	2.06e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6598955	0.543	rs6690461	chr1:26543097	T/A	cg04990556	chr1:26633338	UBXN11	0.71	10.47	0.44	3.52e-23	Obesity-related traits;
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.2e-17	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs199504	chr17:44861003	C/T	cg10053473	chr17:62856997	LRRC37A3	0.9	14.12	0.55	6.91e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs867371	0.826	rs2047678	chr15:82498198	G/A	cg00614314	chr15:82944287	LOC80154	0.48	7.67	0.34	9.89e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs9398803	0.865	rs9375439	chr6:126758540	C/G	cg19875578	chr6:126661172	C6orf173	0.58	10.56	0.44	1.65e-23	Male-pattern baldness;
LGG	cis	rs6088580	0.634	rs6087588	chr20:33066369	T/C	cg24642439	chr20:33292090	TP53INP2	0.55	9.22	0.39	1.02e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs8180040	0.966	rs878659	chr3:47500662	G/A	cg27129171	chr3:47204927	SETD2	0.79	15.35	0.58	2.88e-43	Colorectal cancer;
LGG	cis	rs10484885	0.775	rs55926724	chr6:90417450	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-12.98	-0.52	4.4e-33	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs9951602	1.000	rs7232284	chr18:76667529	A/G	cg02800362	chr5:177631904	HNRNPAB	0.79	9.78	0.41	1.12e-20	Obesity-related traits;
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.23	-0.36	1.85e-15	Neuroticism;
LGG	cis	rs9790314	0.875	rs336582	chr3:161082659	C/T	cg03342759	chr3:160939853	NMD3	-0.63	-11.14	-0.46	1.06e-25	Morning vs. evening chronotype;
LGG	cis	rs17253792	0.822	rs10133962	chr14:56066088	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs1801251	0.963	rs13011298	chr2:233612996	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.09	0.39	2.98e-18	Coronary artery disease;
LGG	cis	rs17504614	0.597	rs17569963	chr2:51077569	A/G	cg08066024	chr2:51057548	NRXN1	-0.54	-8.52	-0.37	2.2e-16	Educational attainment (years of education);
LGG	cis	rs4969178	0.931	rs3826323	chr17:76400268	C/G	cg05887092	chr17:76393375	PGS1	0.72	16.0	0.6	3.37e-46	HDL cholesterol levels;
LGG	trans	rs2739330	0.828	rs4822451	chr22:24248166	T/G	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-10.7	-0.45	5.01e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs754423	0.515	rs12436363	chr14:52544565	T/C	cg12071775	chr14:52591786	NA	-0.43	-7.11	-0.31	4.55e-12	Craniofacial microsomia;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-11.93	-0.49	8.22e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.818	rs10788853	chr1:153002231	C/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.99	-0.39	6.58e-18	Inflammatory skin disease;
LGG	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg15764593	chr10:829463	NA	-0.7	-10.51	-0.44	2.49e-23	Uric acid levels;
LGG	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg16141378	chr3:129829833	LOC729375	-0.43	-10.44	-0.44	4.71e-23	Mood instability;
LGG	cis	rs7737355	0.704	rs984616	chr5:130891101	C/T	cg06307176	chr5:131281290	NA	0.52	8.68	0.37	6.87e-17	Life satisfaction;
LGG	cis	rs8062405	1.000	rs9972693	chr16:28859802	A/G	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.74e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06850241	chr22:41845214	NA	0.45	7.08	0.31	5.43e-12	Vitiligo;
LGG	cis	rs2180341	0.920	rs4472373	chr6:127705983	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.88	0.59	1.26e-45	Breast cancer;
LGG	cis	rs6840360	0.642	rs7684462	chr4:152348422	T/G	cg17217059	chr4:152329364	FAM160A1	0.2	6.93	0.31	1.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8017423	0.647	rs4904679	chr14:90821801	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-12.84	-0.51	1.64e-32	Mortality in heart failure;
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg04013166	chr16:89971882	TCF25	0.55	7.36	0.32	8.23e-13	Skin colour saturation;
LGG	cis	rs11166927	0.594	rs4736007	chr8:140817192	A/G	cg16909799	chr8:140841666	TRAPPC9	0.46	9.1	0.39	2.72e-18	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs2346160	0.867	rs206975	chr6:167690356	A/G	cg20683250	chr6:167653907	NA	-0.42	-7.07	-0.31	5.75e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9549367	0.865	rs3861721	chr13:113906308	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.17	-0.32	2.97e-12	Iron status biomarkers;
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg11584989	chr19:19387371	SF4	0.42	7.66	0.34	1.1e-13	Tonsillectomy;
LGG	cis	rs2070433	0.756	rs9637220	chr21:47887436	T/C	cg12379764	chr21:47803548	PCNT	0.52	7.36	0.32	8.31e-13	Lymphocyte counts;
LGG	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.28	0.43	1.82e-22	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs1968374	chr5:249025	A/C	cg22857025	chr5:266934	NA	-1.54	-24.33	-0.75	7.86e-85	Breast cancer;
LGG	cis	rs798554	0.724	rs798498	chr7:2795882	T/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.49	-0.33	3.57e-13	Height;
LGG	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs2270450	0.650	rs9349374	chr6:46714598	C/T	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.57	-0.44	1.51e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs17767392	0.595	rs11850267	chr14:71657524	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.19	-0.32	2.7e-12	Mitral valve prolapse;
LGG	cis	rs1983170	1.000	rs483532	chr1:91980447	A/G	cg25838465	chr1:92012736	NA	-0.49	-7.2	-0.32	2.49e-12	Eosinophil percentage of white cells;
LGG	cis	rs6582630	0.539	rs12308081	chr12:38342881	C/G	cg04568710	chr12:38710424	ALG10B	-0.42	-8.92	-0.38	1.1e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8062405	0.824	rs62034324	chr16:28536762	T/C	cg00204512	chr16:28754710	NA	0.25	7.24	0.32	1.88e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs970548	0.738	rs61854124	chr10:46077158	T/C	cg20477318	chr10:51623047	TIMM23	0.69	8.32	0.36	9.81e-16	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg04490037	chr7:50633773	DDC	0.3	6.72	0.3	5.45e-11	Body mass index;
LGG	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg03162506	chr22:38580953	NA	0.38	9.52	0.4	9.52e-20	Cutaneous nevi;
LGG	cis	rs13082711	0.520	rs12486671	chr3:27556832	A/G	cg02860705	chr3:27208620	NA	0.57	9.81	0.41	9.19e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7635838	0.617	rs367745	chr3:11309274	T/C	cg00170343	chr3:11313890	ATG7	0.53	9.23	0.39	9.96e-19	HDL cholesterol;
LGG	cis	rs7107174	1.000	rs72931642	chr11:78037862	A/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.49	-0.33	3.4e-13	Testicular germ cell tumor;
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs679087	0.686	rs10843500	chr12:29918582	C/G	cg14258853	chr12:29935411	TMTC1	0.37	7.88	0.34	2.43e-14	Schizophrenia;
LGG	trans	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg16141378	chr3:129829833	LOC729375	0.38	8.67	0.37	7.46e-17	Joint mobility (Beighton score);
LGG	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg20735989	chr4:730612	PCGF3	-0.6	-10.45	-0.44	4.26e-23	White blood cell count;
LGG	cis	rs11250097	0.507	rs2409779	chr8:11311340	A/T	cg21775007	chr8:11205619	TDH	-0.48	-7.57	-0.33	2.01e-13	Neuroticism;
LGG	cis	rs950776	0.752	rs7182583	chr15:78899210	G/C	cg16751781	chr15:78858589	CHRNA5	0.42	7.99	0.35	1.1e-14	Sudden cardiac arrest;
LGG	cis	rs7928758	0.832	rs75190711	chr11:134269772	G/C	cg15243474	chr11:134282918	B3GAT1	1.16	15.31	0.58	4.11e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.17	0.52	7.19e-34	Coronary artery disease;
LGG	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg15556689	chr8:8085844	FLJ10661	0.45	8.06	0.35	6.78e-15	Neuroticism;
LGG	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg05444541	chr17:17804740	TOM1L2	-0.57	-12.38	-0.5	1.29e-30	Total body bone mineral density;
LGG	cis	rs7255045	0.752	rs11085822	chr19:12985576	A/G	cg07955356	chr19:12992479	DNASE2	0.41	6.89	0.31	1.79e-11	Mean corpuscular volume;
LGG	cis	rs10463554	0.892	rs34830	chr5:102444053	A/G	cg23492399	chr5:102201601	PAM	-0.52	-7.72	-0.34	7.26e-14	Parkinson's disease;
LGG	cis	rs561341	0.700	rs6505266	chr17:30225813	G/A	cg00745463	chr17:30367425	LRRC37B	-0.46	-7.25	-0.32	1.81e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2227631	0.505	rs6955537	chr7:100759727	A/G	cg18465962	chr7:100767262	NA	-0.53	-9.54	-0.41	8.09e-20	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.48	-12.02	-0.49	3.59e-29	Tonsillectomy;
LGG	cis	rs2693698	0.651	rs11160505	chr14:99683291	C/A	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.72e-28	Schizophrenia;
LGG	cis	rs2587949	0.571	rs2629247	chr3:4238709	T/C	cg16519197	chr3:4211558	NA	-0.34	-6.79	-0.3	3.4e-11	Periodontitis (DPAL);
LGG	cis	rs2282802	0.685	rs7717563	chr5:139689968	A/G	cg26211634	chr5:139558579	C5orf32	-0.34	-7.54	-0.33	2.5e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9358372	0.574	rs11751916	chr6:20795448	A/G	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.13	-0.39	2.21e-18	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2013441	1.000	rs2703789	chr17:20162923	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs12507964	chr4:120413061	T/A	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs6582630	0.502	rs7312212	chr12:38274760	T/G	cg13010199	chr12:38710504	ALG10B	0.65	13.42	0.53	6.49e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.63	0.59	1.62e-44	Nonalcoholic fatty liver disease;
LGG	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.26	-0.36	1.52e-15	Retinal vascular caliber;
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg14092988	chr3:52407081	DNAH1	0.31	8.16	0.35	3.18e-15	Bipolar disorder;
LGG	cis	rs4555082	0.957	rs8022526	chr14:105756485	A/G	cg13114125	chr14:105738426	BRF1	-0.8	-16.03	-0.6	2.48e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg21862992	chr11:68658383	NA	0.51	8.44	0.37	4.09e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8062405	0.789	rs2106480	chr16:28537971	T/C	cg16576597	chr16:28551801	NUPR1	0.38	8.94	0.38	9.06e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.19	-0.58	1.38e-42	Prudent dietary pattern;
LGG	cis	rs912057	0.671	rs1294434	chr6:6745377	G/A	cg06612196	chr6:6737390	NA	0.49	10.39	0.43	7.18e-23	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg10284592	chr11:57434942	ZDHHC5	0.44	7.22	0.32	2.17e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	cis	rs7660883	1.000	rs11946481	chr4:87984610	C/T	cg21988461	chr4:88008667	AFF1	-0.31	-8.4	-0.36	5.63e-16	HDL cholesterol levels;
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg11965913	chr1:205819406	PM20D1	-0.46	-7.24	-0.32	1.83e-12	Parkinson's disease;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg00933542	chr6:150070202	PCMT1	0.39	7.05	0.31	6.35e-12	Lung cancer;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.862	rs1167399	chr7:65561877	G/A	cg18252515	chr7:66147081	NA	0.45	7.46	0.33	4.25e-13	Aortic root size;
LGG	cis	rs9399135	0.660	rs9376072	chr6:135280519	G/C	cg24558204	chr6:135376177	HBS1L	0.54	9.56	0.41	7.1e-20	Red blood cell count;
LGG	cis	rs236352	0.576	rs6914008	chr6:36853037	T/A	cg03410223	chr6:36853544	C6orf89	0.45	8.54	0.37	2e-16	Heart rate;
LGG	cis	rs7726839	0.794	rs6883536	chr5:599274	G/A	cg14541582	chr5:601475	NA	-0.49	-8.57	-0.37	1.61e-16	Obesity-related traits;
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg11764359	chr7:65958608	NA	-0.74	-13.42	-0.53	6.39e-35	Aortic root size;
LGG	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg06634786	chr22:41940651	POLR3H	-0.68	-11.63	-0.48	1.33e-27	Vitiligo;
LGG	cis	rs13031619	1.000	rs13031619	chr2:3698371	A/G	cg01268866	chr2:3683757	COLEC11	-0.38	-6.7	-0.3	5.93e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs60871478	0.853	rs62432864	chr7:808405	T/G	cg05535760	chr7:792225	HEATR2	0.8	12.29	0.5	3.04e-30	Cerebrospinal P-tau181p levels;
LGG	cis	rs9581943	0.967	rs9579128	chr13:28481938	A/G	cg16302790	chr13:28498334	PDX1	0.5	8.44	0.37	4.13e-16	Pancreatic cancer;
LGG	trans	rs4841097	0.806	rs6992247	chr8:8948469	G/T	cg02002194	chr4:3960332	NA	-0.39	-7.15	-0.32	3.51e-12	Platelet distribution width;
LGG	cis	rs28595532	0.920	rs28837152	chr4:119782868	G/A	cg21605333	chr4:119757512	SEC24D	1.48	14.95	0.57	1.65e-41	Cannabis dependence symptom count;
LGG	trans	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg10840412	chr1:235813424	GNG4	0.65	8.7	0.37	5.95e-17	Bipolar disorder;
LGG	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.53	8.86	0.38	1.69e-17	Eosinophil percentage of white cells;
LGG	cis	rs12421382	0.614	rs12420249	chr11:109390254	T/G	cg00830817	chr11:109293614	C11orf87	0.4	6.88	0.3	2.01e-11	Schizophrenia;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg06916706	chr16:4465613	CORO7	-0.84	-14.45	-0.56	2.37e-39	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16162927	chr6:136610857	BCLAF1	0.45	7.33	0.32	1.02e-12	Cognitive performance;
LGG	cis	rs4474465	0.646	rs7936011	chr11:78275931	G/T	cg27205649	chr11:78285834	NARS2	0.59	11.0	0.46	3.53e-25	Alzheimer's disease (survival time);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg12105765	chr3:183947332	VWA5B2	0.6	6.8	0.3	3.25e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10751667	0.643	rs10794352	chr11:946294	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.95	0.35	1.44e-14	Alzheimer's disease (late onset);
LGG	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg27165867	chr14:105738592	BRF1	-0.47	-7.49	-0.33	3.55e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs3206736	0.548	rs1649221	chr7:34987758	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.14	0.31	3.73e-12	Diastolic blood pressure;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.18	-0.39	1.39e-18	Personality dimensions;
LGG	cis	rs6582630	0.555	rs11181684	chr12:38388000	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.69	0.3	6.66e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.662	rs448725	chr7:65514628	A/G	cg11764359	chr7:65958608	NA	0.69	12.16	0.49	1.04e-29	Aortic root size;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	12.15	0.49	1.08e-29	Prudent dietary pattern;
LGG	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg25817165	chr18:72167213	CNDP2	-0.64	-13.68	-0.54	5.27e-36	Refractive error;
LGG	cis	rs1538970	0.924	rs3790582	chr1:45887288	T/C	cg05343316	chr1:45956843	TESK2	0.73	12.12	0.49	1.52e-29	Platelet count;
LGG	cis	rs2594989	0.943	rs7349536	chr3:11442503	C/T	cg01796438	chr3:11312864	ATG7	0.49	6.93	0.31	1.38e-11	Circulating chemerin levels;
LGG	cis	rs7666738	0.830	rs35939134	chr4:98980311	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7843479	1.000	rs10503715	chr8:21850687	G/A	cg17168535	chr8:21777572	XPO7	0.58	9.49	0.4	1.25e-19	Mean corpuscular volume;
LGG	cis	rs4363385	0.747	rs4845508	chr1:152968421	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.02	-0.39	4.84e-18	Inflammatory skin disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02573089	chr17:57233042	PRR11;SKA2	-0.46	-6.79	-0.3	3.54e-11	Systemic lupus erythematosus;
LGG	cis	rs2072499	0.833	rs2251636	chr1:156202809	G/C	cg25208724	chr1:156163844	SLC25A44	1.12	25.03	0.76	4.35e-88	Testicular germ cell tumor;
LGG	cis	rs7017914	0.967	rs11989553	chr8:71640899	A/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg18402987	chr7:1209562	NA	0.4	7.45	0.33	4.67e-13	Longevity;Endometriosis;
LGG	cis	rs853679	0.517	rs9380055	chr6:28081629	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.57	10.49	0.44	3.04e-23	Total body bone mineral density;
LGG	cis	rs972578	0.791	rs2179259	chr22:43405068	G/A	cg01576275	chr22:43409880	NA	-0.26	-7.73	-0.34	6.97e-14	Mean platelet volume;
LGG	cis	rs721399	0.539	rs10089958	chr8:18269343	A/G	cg18736775	chr8:18248649	NAT2	-0.75	-11.22	-0.46	5.35e-26	Blood metabolite levels;
LGG	cis	rs926938	0.527	rs2335954	chr1:115534151	C/T	cg12756093	chr1:115239321	AMPD1	-0.43	-7.75	-0.34	5.88e-14	Autism;
LGG	cis	rs1018836	0.923	rs7812970	chr8:91541229	G/A	cg16814680	chr8:91681699	NA	-0.79	-14.43	-0.56	3.1e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7481584	0.624	rs436580	chr11:3063961	T/G	cg08468577	chr11:2973342	NAP1L4	-0.32	-6.69	-0.3	6.38e-11	Calcium levels;
LGG	cis	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.25	-0.32	1.76e-12	Mood instability;
LGG	trans	rs7980799	0.635	rs11052619	chr12:33480199	C/T	cg26384229	chr12:38710491	ALG10B	-0.4	-6.81	-0.3	2.99e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs1459104	0.866	rs67929427	chr11:54824182	C/T	cg03929089	chr4:120376271	NA	0.7	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs4696584	0.816	rs4150	chr4:155405919	C/T	cg13738195	chr4:155413469	DCHS2	0.4	8.34	0.36	8.83e-16	Folding of antihelix;
LGG	cis	rs12586317	0.514	rs74590021	chr14:35490113	T/G	cg16230307	chr14:35515116	FAM177A1	0.92	13.62	0.53	8.85e-36	Psoriasis;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00166722	chr3:10149974	C3orf24	0.54	8.93	0.38	1.02e-17	Alzheimer's disease;
LGG	cis	rs2346177	0.605	rs7556828	chr2:46663172	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.63	12.31	0.5	2.58e-30	HDL cholesterol;
LGG	cis	rs1044826	0.642	rs6799312	chr3:139211932	C/T	cg15131784	chr3:139108705	COPB2	0.41	6.85	0.3	2.35e-11	Obesity-related traits;
LGG	cis	rs9467711	0.606	rs9366656	chr6:26434630	T/C	cg12826209	chr6:26865740	GUSBL1	0.79	8.17	0.35	2.95e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs68170813	0.559	rs2249043	chr7:106960515	C/T	cg02696742	chr7:106810147	HBP1	-0.73	-10.39	-0.43	7.38e-23	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.62	0.59	1.72e-44	Lung cancer;
LGG	cis	rs9788682	0.947	rs7169584	chr15:78822660	A/T	cg24631222	chr15:78858424	CHRNA5	0.48	7.3	0.32	1.28e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7166081	1.000	rs12916403	chr15:67591665	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs755249	0.567	rs67886352	chr1:39708703	G/A	cg18385671	chr1:39797026	MACF1	0.44	7.2	0.32	2.45e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs757081	0.547	rs11024220	chr11:17274534	G/A	cg15432903	chr11:17409602	KCNJ11	-0.43	-7.95	-0.35	1.44e-14	Systolic blood pressure;
LGG	cis	rs77669868	0.929	rs3782007	chr11:114066438	A/G	cg01914181	chr11:114070210	ZBTB16	-0.65	-8.39	-0.36	5.76e-16	Monocyte percentage of white cells;
LGG	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.17	-0.32	2.9e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17604090	1.000	rs73297441	chr7:29684363	T/C	cg19413766	chr7:29689036	LOC646762	-0.63	-7.96	-0.35	1.32e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs1837494	0.566	rs12694587	chr2:223892312	T/C	cg02552189	chr2:223891284	NA	-0.47	-8.94	-0.38	9.6e-18	Oropharynx cancer;
LGG	cis	rs17428076	0.918	rs62183765	chr2:172832024	G/T	cg21435375	chr2:172878103	MAP1D	0.45	9.69	0.41	2.47e-20	Myopia;
LGG	cis	rs10504229	0.775	rs55825382	chr8:58157605	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs35828828	chr17:56718205	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.83	0.57	5.44e-41	Cognitive test performance;
LGG	cis	rs10463554	0.824	rs34818	chr5:102436111	T/A	cg23492399	chr5:102201601	PAM	-0.51	-7.62	-0.33	1.45e-13	Parkinson's disease;
LGG	cis	rs62103177	0.564	rs2115996	chr18:77701007	C/G	cg03511173	chr18:77590860	NA	0.55	6.73	0.3	4.96e-11	Opioid sensitivity;
LGG	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9398803	0.713	rs4621657	chr6:126896227	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.38	0.4	2.96e-19	Male-pattern baldness;
LGG	cis	rs2594989	0.831	rs9840982	chr3:11564940	C/A	cg01796438	chr3:11312864	ATG7	0.55	7.45	0.33	4.48e-13	Circulating chemerin levels;
LGG	cis	rs7568458	0.905	rs6739015	chr2:85755357	A/G	cg23752985	chr2:85803571	VAMP8	0.42	8.35	0.36	7.72e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs477692	0.673	rs556253	chr10:131355781	G/A	cg05714579	chr10:131428358	MGMT	0.43	8.14	0.35	3.77e-15	Response to temozolomide;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg19143629	chr17:61920732	SMARCD2	-0.42	-7.23	-0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs875971	0.660	rs10272357	chr7:66063074	G/A	cg18876405	chr7:65276391	NA	-0.64	-11.91	-0.48	1.05e-28	Aortic root size;
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.76	-0.34	5.53e-14	Life satisfaction;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg22398616	chr13:53314203	LECT1	-0.46	-9.0	-0.39	5.8e-18	Lewy body disease;
LGG	cis	rs11148252	0.840	rs56304200	chr13:52781763	T/A	cg12458913	chr13:53173898	NA	0.61	11.8	0.48	2.85e-28	Lewy body disease;
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.17	-0.39	1.6e-18	Menopause (age at onset);
LGG	cis	rs12615966	0.872	rs72830429	chr2:105367977	T/C	cg16465502	chr2:105461796	NA	0.88	10.03	0.42	1.43e-21	Pancreatic cancer;
LGG	cis	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg21775007	chr8:11205619	TDH	0.54	8.99	0.39	6.27e-18	Neuroticism;
LGG	cis	rs41271473	0.898	rs3738073	chr1:228871693	C/T	cg10167378	chr1:228756711	NA	0.56	7.99	0.35	1.11e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2594989	1.000	rs2594986	chr3:11330964	G/A	cg01796438	chr3:11312864	ATG7	-0.6	-8.37	-0.36	6.66e-16	Circulating chemerin levels;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.4e-28	Tonsillectomy;
LGG	cis	rs514406	0.607	rs1930305	chr1:53195481	G/T	cg16325326	chr1:53192061	ZYG11B	-0.91	-25.63	-0.77	7.69e-91	Monocyte count;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.19	-0.32	2.56e-12	Dementia with Lewy bodies;
LGG	cis	rs11098499	0.722	rs7673476	chr4:120248683	C/T	cg09307838	chr4:120376055	NA	0.66	11.52	0.47	3.7e-27	Corneal astigmatism;
LGG	cis	rs7582180	0.568	rs10186134	chr2:100939501	T/A	cg14675211	chr2:100938903	LONRF2	0.63	11.06	0.46	2.12e-25	Intelligence (multi-trait analysis);
LGG	cis	rs2012796	0.785	rs61986593	chr14:81840659	G/A	cg02996355	chr14:81879375	NA	0.6	9.97	0.42	2.45e-21	Night sleep phenotypes;
LGG	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg19717773	chr7:2847554	GNA12	-0.44	-10.3	-0.43	1.5e-22	Height;
LGG	cis	rs701145	0.537	rs1713855	chr3:153847833	T/C	cg12800244	chr3:153838788	SGEF	0.8	8.69	0.37	6.52e-17	Coronary artery disease;
LGG	cis	rs7551222	0.752	rs4951400	chr1:204534571	C/G	cg18851795	chr1:204543875	NA	-0.35	-6.69	-0.3	6.57e-11	Schizophrenia;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg02733842	chr7:1102375	C7orf50	0.68	10.21	0.43	3.19e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs8073060	0.505	rs225276	chr17:33973034	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs1008375	1.000	rs28480159	chr4:17685707	A/C	cg04450456	chr4:17643702	FAM184B	0.31	6.76	0.3	4.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg04287289	chr16:89883240	FANCA	0.74	7.9	0.34	2.07e-14	Skin colour saturation;
LGG	cis	rs6840360	0.530	rs12645029	chr4:152650032	T/C	cg25486957	chr4:152246857	NA	-0.5	-7.85	-0.34	2.97e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.861	rs10788778	chr1:248481551	T/C	cg13385794	chr1:248469461	NA	0.49	8.14	0.35	3.68e-15	Common traits (Other);
LGG	cis	rs7223966	0.921	rs2727300	chr17:61965398	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	6.99	0.31	9.71e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.39	7.72	0.34	7.02e-14	Schizophrenia;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6032067	1.000	rs35284867	chr20:43845836	A/T	cg10761708	chr20:43804764	PI3	0.76	11.79	0.48	3.06e-28	Blood protein levels;
LGG	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg27532318	chr7:32358331	NA	0.73	7.4	0.33	6.35e-13	Body mass index;
LGG	cis	rs3820928	1.000	rs3820927	chr2:227779191	C/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.43	-0.33	5.17e-13	Pulmonary function;
LGG	cis	rs73416724	0.925	rs112053368	chr6:43382960	C/A	cg26312998	chr6:43337775	ZNF318	0.6	8.43	0.36	4.27e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9287719	0.967	rs715247	chr2:10736291	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg00204512	chr16:28754710	NA	0.24	6.99	0.31	9.48e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs36715	1.000	rs36702	chr5:127552723	A/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.47	7.46	0.33	4.21e-13	Breast cancer;
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.06	-0.31	6.01e-12	Obesity;
LGG	trans	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg02002194	chr4:3960332	NA	0.46	8.92	0.38	1.11e-17	Mood instability;
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.39e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72945132	0.882	rs7928686	chr11:70134528	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg11494091	chr17:61959527	GH2	-0.47	-7.06	-0.31	5.96e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2088885	1.000	rs4894463	chr3:170981313	A/C	cg18052528	chr3:170975382	TNIK	-0.27	-6.75	-0.3	4.44e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg21545522	chr1:205238299	TMCC2	0.38	7.23	0.32	1.95e-12	Red blood cell count;
LGG	trans	rs7618501	0.603	rs72942333	chr3:49986118	T/C	cg21659725	chr3:3221576	CRBN	0.66	12.3	0.5	2.91e-30	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24054938	chr1:153651301	NPR1	-0.45	-7.0	-0.31	9.01e-12	Pancreatic cancer;
LGG	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg10596483	chr8:143751796	JRK	0.58	9.62	0.41	4.15e-20	Schizophrenia;
LGG	cis	rs2228479	0.764	rs11641201	chr16:89983276	T/C	cg03036210	chr16:89904091	SPIRE2	-0.54	-7.61	-0.33	1.5700000000000001e-13	Skin colour saturation;
LGG	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg09845145	chr15:78292470	TBC1D2B	0.62	9.7	0.41	2.18e-20	Coronary artery disease or large artery stroke;
LGG	cis	rs1965732	0.588	rs13385033	chr2:3715071	C/T	cg15327641	chr2:3715039	ALLC	0.33	7.24	0.32	1.91e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1018697	1.000	rs7073114	chr10:104555651	C/T	cg04362960	chr10:104952993	NT5C2	0.49	9.12	0.39	2.22e-18	Colorectal adenoma (advanced);
LGG	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg03929089	chr4:120376271	NA	-0.86	-13.46	-0.53	4.32e-35	Coronary artery disease;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs4423214	1.000	rs12789751	chr11:71164471	G/A	cg05163923	chr11:71159392	DHCR7	0.71	13.73	0.54	3.03e-36	Vitamin D levels;
LGG	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg02574844	chr11:5959923	NA	-0.59	-9.15	-0.39	1.87e-18	DNA methylation (variation);
LGG	cis	rs4302748	0.909	rs1882062	chr7:36188719	C/T	cg24442661	chr7:36192818	EEPD1	0.54	7.06	0.31	6.11e-12	Platelet count;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25517755	chr10:38738941	LOC399744	-0.37	-6.71	-0.3	5.76e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9596863	1.000	rs7995218	chr13:54427874	C/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.0	0.31	9.08e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg26116260	chr4:7069785	GRPEL1	-0.8	-7.19	-0.32	2.57e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs308971	0.563	rs307611	chr3:12063344	G/C	cg22839075	chr3:12045461	SYN2	0.51	6.65	0.3	8.08e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs2694528	0.858	rs158918	chr5:60242121	A/T	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.4	-0.33	6.5e-13	Parkinson's disease;
LGG	cis	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.47e-14	Mononucleosis;
LGG	cis	rs7618501	0.501	rs35275715	chr3:49959148	A/G	cg05623727	chr3:50126028	RBM5	0.39	8.51	0.37	2.42e-16	Intelligence (multi-trait analysis);
LGG	trans	rs9354308	0.764	rs9453475	chr6:66603657	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs9325144	0.671	rs7306605	chr12:38730471	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.67	0.56	2.71e-40	Morning vs. evening chronotype;
LGG	cis	rs6735179	0.729	rs2382561	chr2:1763501	C/T	cg08534653	chr2:1747700	PXDN	0.43	6.73	0.3	5.14e-11	Response to antipsychotic treatment;
LGG	cis	rs4478037	0.642	rs77202692	chr3:33115776	A/C	cg19404215	chr3:33155277	CRTAP	0.76	9.46	0.4	1.55e-19	Major depressive disorder;
LGG	cis	rs62064224	0.614	rs4795700	chr17:30763794	A/G	cg18200150	chr17:30822561	MYO1D	0.5	9.62	0.41	4.42e-20	Schizophrenia;
LGG	cis	rs208515	0.525	rs10944859	chr6:66665197	A/G	cg07460842	chr6:66804631	NA	0.94	16.94	0.62	2.02e-50	Exhaled nitric oxide levels;
LGG	cis	rs1552244	0.766	rs34232505	chr3:10186216	T/A	cg00166722	chr3:10149974	C3orf24	0.49	7.96	0.35	1.38e-14	Alzheimer's disease;
LGG	cis	rs4727443	0.866	rs13238380	chr7:99629061	C/T	cg12813108	chr7:99719912	CNPY4	-0.58	-11.41	-0.47	9.58e-27	Interstitial lung disease;
LGG	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg09307838	chr4:120376055	NA	-0.8	-13.31	-0.53	1.91e-34	Corneal astigmatism;
LGG	cis	rs7106204	0.534	rs16912429	chr11:24344410	T/C	ch.11.24196551F	chr11:24239977	NA	0.81	8.61	0.37	1.14e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4665809	0.652	rs4665832	chr2:26404775	A/G	cg22920501	chr2:26401640	FAM59B	-0.44	-9.05	-0.39	3.88e-18	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.33	0.32	1.02e-12	Skin colour saturation;
LGG	cis	rs7572733	1.000	rs2196172	chr2:198889893	T/G	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs7647973	0.710	rs6446285	chr3:49626306	G/A	cg07636037	chr3:49044803	WDR6	0.56	7.2	0.32	2.41e-12	Menarche (age at onset);
LGG	cis	rs7818345	0.967	rs35029660	chr8:19308126	T/C	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.66	0.3	7.92e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs3806843	0.766	rs801176	chr5:140087010	A/G	cg19875535	chr5:140030758	IK	0.53	10.76	0.45	2.96e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2204008	0.502	rs2387275	chr12:38142836	G/A	cg26384229	chr12:38710491	ALG10B	0.96	20.76	0.69	3.82e-68	Bladder cancer;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg12310025	chr6:25882481	NA	-0.44	-7.9	-0.34	2.09e-14	Height;
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg22168489	chr12:122356033	WDR66	0.45	11.03	0.46	2.73e-25	Mean corpuscular volume;
LGG	cis	rs17384381	1.000	rs12140935	chr1:85855716	G/A	cg16011679	chr1:85725395	C1orf52	0.6	10.5	0.44	2.77e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-7.77	-0.34	5.17e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3820068	0.603	rs72645887	chr1:15929905	G/C	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07685180	chr8:600429	NA	1.02	10.39	0.43	7.3e-23	IgG glycosylation;
LGG	cis	rs8114671	0.967	rs4911478	chr20:33782625	A/C	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.47	-0.33	4.1e-13	Height;
LGG	cis	rs4909189	1.000	rs11764065	chr7:158135974	T/C	cg06219351	chr7:158114137	PTPRN2	-0.82	-14.18	-0.55	3.61e-38	Response to amphetamines;
LGG	cis	rs3820928	0.874	rs2229813	chr2:227892720	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.43	-0.33	5.4e-13	Pulmonary function;
LGG	cis	rs11074306	0.561	rs6497242	chr15:28072568	T/C	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs1843834	0.539	rs10177898	chr2:225437552	C/T	cg22509189	chr2:225307070	NA	-0.62	-10.03	-0.42	1.43e-21	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	9.01	0.39	5.62e-18	Lung function (FEV1/FVC);
LGG	cis	rs11792861	0.926	rs10512391	chr9:111809530	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.57	8.83	0.38	2.13e-17	Menarche (age at onset);
LGG	cis	rs763121	0.853	rs5757208	chr22:39049230	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs2708240	0.936	rs2538981	chr7:147582251	A/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	2.96e-11	QT interval (drug interaction);
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg26578617	chr4:90757533	SNCA	-0.44	-8.72	-0.38	4.97e-17	Dementia with Lewy bodies;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.63	-11.92	-0.48	9.53e-29	Obesity-related traits;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg05335186	chr13:53173507	NA	0.57	12.52	0.5	3.55e-31	Lewy body disease;
LGG	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.62	0.51	1.42e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs738322	0.753	rs2267372	chr22:38598234	A/G	cg25457927	chr22:38595422	NA	0.5	13.09	0.52	1.54e-33	Cutaneous nevi;
LGG	cis	rs778371	0.915	rs748002	chr2:233757679	G/A	cg08000102	chr2:233561755	GIGYF2	-0.65	-10.06	-0.42	1.11e-21	Schizophrenia;
LGG	cis	rs4948496	0.754	rs6479782	chr10:63806809	T/C	cg14789659	chr10:63809073	ARID5B	0.39	7.43	0.33	5.46e-13	Systemic lupus erythematosus;
LGG	cis	rs57920188	0.703	rs3813810	chr1:4088339	G/T	cg20703997	chr1:4087676	NA	0.46	6.68	0.3	6.68e-11	Interleukin-17 levels;
LGG	cis	rs9322193	0.923	rs10782315	chr6:150064229	T/C	cg00933542	chr6:150070202	PCMT1	0.4	7.27	0.32	1.59e-12	Lung cancer;
LGG	cis	rs7208859	0.673	rs78799101	chr17:29215160	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.73	-8.66	-0.37	7.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg00495681	chr13:53174319	NA	-0.58	-10.6	-0.44	1.16e-23	Lewy body disease;
LGG	cis	rs910316	0.789	rs175444	chr14:75601782	G/C	cg08847533	chr14:75593920	NEK9	-0.53	-9.97	-0.42	2.39e-21	Height;
LGG	cis	rs561341	0.825	rs2008368	chr17:30347397	T/C	cg13647721	chr17:30228624	UTP6	0.64	8.04	0.35	7.66e-15	Hip circumference adjusted for BMI;
LGG	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.05	-0.46	2.34e-25	Coronary artery disease;
LGG	trans	rs12517041	0.938	rs4701357	chr5:23263746	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.94	-0.38	9.69e-18	Calcium levels;
LGG	cis	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg09021430	chr5:549028	NA	-0.69	-9.86	-0.42	6.16e-21	Obesity-related traits;
LGG	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg18225595	chr11:63971243	STIP1	-0.59	-7.8	-0.34	4.14e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4243830	1.000	rs11809957	chr1:6584420	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	11.33	0.47	1.9e-26	Body mass index;
LGG	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg12011299	chr4:100065546	ADH4	0.4	7.86	0.34	2.79e-14	Smoking initiation;
LGG	cis	rs7959452	0.527	rs4761157	chr12:69780907	A/G	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22682162	chr6:97731065	MIR548H3;C6orf167	0.44	7.31	0.32	1.15e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11122272	0.735	rs2491408	chr1:231519248	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs1577917	0.696	rs10806334	chr6:86439329	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-12.43	-0.5	8.18e-31	Response to antipsychotic treatment;
LGG	cis	rs7635838	0.596	rs347598	chr3:11258289	G/C	cg00170343	chr3:11313890	ATG7	0.44	7.59	0.33	1.83e-13	HDL cholesterol;
LGG	cis	rs17767392	0.958	rs12885344	chr14:72003224	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.28	-0.4	6.46e-19	Mitral valve prolapse;
LGG	cis	rs524281	1.000	rs547087	chr11:65846264	A/G	cg14541915	chr11:65894463	PACS1	-0.31	-7.14	-0.31	3.68e-12	Electroencephalogram traits;
LGG	cis	rs9467773	0.620	rs2494700	chr6:26631306	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs1497828	0.956	rs2818976	chr1:217548956	A/C	cg04411442	chr1:217543379	NA	0.48	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	cis	rs7208859	0.524	rs73988172	chr17:29086332	A/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs644799	1.000	rs487609	chr11:95588102	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.87	0.54	7.83e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1978968	1.000	rs5992135	chr22:18447114	C/T	cg03078520	chr22:18463400	MICAL3	-0.61	-12.33	-0.5	2.14e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs6467136	0.539	rs4731365	chr7:127082497	A/G	cg25922125	chr7:127225783	GCC1	0.44	6.8	0.3	3.24e-11	Type 2 diabetes;
LGG	cis	rs7558370	0.737	rs77200948	chr2:3710169	C/T	cg20720597	chr2:3699334	NA	0.76	7.09	0.31	4.99e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg04362960	chr10:104952993	NT5C2	-0.5	-8.32	-0.36	9.87e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7301826	1.000	rs10744482	chr12:131298195	C/T	cg11011512	chr12:131303247	STX2	0.34	7.43	0.33	5.22e-13	Plasma plasminogen activator levels;
LGG	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg16482183	chr6:26056742	HIST1H1C	0.69	11.77	0.48	3.87e-28	Iron status biomarkers;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg00689492	chr4:1303491	MAEA	-0.45	-7.58	-0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs7226408	0.857	rs12185461	chr18:34492036	A/G	cg15022739	chr18:34823045	BRUNOL4	0.42	6.71	0.3	5.53e-11	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs3087502	chr7:99955364	G/A	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.01	-0.42	1.79e-21	Platelet count;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.25	-0.39	8.55e-19	Triglycerides;
LGG	cis	rs899997	1.000	rs7182567	chr15:79045054	A/G	cg17734273	chr15:78292508	TBC1D2B	-0.38	-9.41	-0.4	2.4e-19	Coronary artery disease or large artery stroke;
LGG	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg19500275	chr17:80737654	TBCD	-0.45	-6.68	-0.3	7.01e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs17209837	0.915	rs17149637	chr7:87085209	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-12.78	-0.51	3.16e-32	Gallbladder cancer;
LGG	cis	rs12911832	0.701	rs452698	chr15:59105571	A/G	cg05156742	chr15:59063176	FAM63B	0.65	12.06	0.49	2.5e-29	Schizophrenia;
LGG	cis	rs801193	1.000	rs4717310	chr7:66161007	C/T	cg00343986	chr7:65444356	GUSB	0.4	6.82	0.3	2.93e-11	Aortic root size;
LGG	cis	rs17401966	0.537	rs3748575	chr1:10342352	C/T	cg19773385	chr1:10388646	KIF1B	-0.32	-7.01	-0.31	8.68e-12	Hepatocellular carcinoma;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.27	-0.32	1.51e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.38	-0.36	6.51e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs875971	1.000	rs7792762	chr7:66004138	T/C	cg18876405	chr7:65276391	NA	0.54	9.8	0.41	9.69e-21	Aortic root size;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.31	0.55	9.95e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs514406	0.667	rs10788942	chr1:53210521	A/T	cg24675658	chr1:53192096	ZYG11B	0.62	13.42	0.53	6.69e-35	Monocyte count;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13012494	chr21:47604986	C21orf56	0.51	8.73	0.38	4.74e-17	Testicular germ cell tumor;
LGG	cis	rs360798	0.532	rs189671	chr2:62959308	T/A	cg17519650	chr2:63277830	OTX1	-0.45	-7.17	-0.32	3.06e-12	Coronary artery disease;
LGG	cis	rs4262150	0.764	rs2961765	chr5:151931175	C/T	cg12297329	chr5:152029980	NA	-0.69	-13.13	-0.52	1.08e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09771049	chr17:66031798	KPNA2	0.41	6.76	0.3	4.25e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg21775007	chr8:11205619	TDH	-0.51	-8.16	-0.35	3.18e-15	Retinal vascular caliber;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg06112835	chr11:68658793	MRPL21	0.58	9.66	0.41	3.02e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs209489	0.681	rs16883629	chr6:53112652	A/G	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs986417	0.892	rs74060153	chr14:60794488	T/A	cg27398547	chr14:60952738	C14orf39	-0.71	-6.79	-0.3	3.36e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs483180	0.859	rs478093	chr1:120255126	C/T	cg19096424	chr1:120255104	PHGDH	-0.84	-14.76	-0.57	1.12e-40	Macular telangiectasia type 2;
LGG	cis	rs11264213	0.901	rs11263830	chr1:36345798	C/T	cg27506609	chr1:36549197	TEKT2	0.68	8.11	0.35	4.43e-15	Schizophrenia;
LGG	cis	rs67460515	0.859	rs7610800	chr3:161002582	C/T	cg03342759	chr3:160939853	NMD3	-0.77	-13.86	-0.54	8.74e-37	Parkinson's disease;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.39	6.77	0.3	3.85e-11	Schizophrenia;
LGG	cis	rs1994135	0.715	rs10844624	chr12:33691010	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.38	-0.36	6.25e-16	Resting heart rate;
LGG	cis	rs12618769	0.597	rs7593615	chr2:99030598	C/A	cg18455616	chr2:99124870	INPP4A	0.3	8.78	0.38	3.2e-17	Bipolar disorder;
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs2235642	0.750	rs2859310	chr16:1656765	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	-0.39	-9.34	-0.4	4.15e-19	Coronary artery disease;
LGG	cis	rs6912958	0.559	rs451829	chr6:88041919	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.09	0.52	1.53e-33	Monocyte percentage of white cells;
LGG	cis	rs524281	0.861	rs1862005	chr11:65863402	T/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.66	-0.3	7.55e-11	Electroencephalogram traits;
LGG	cis	rs853679	0.517	rs4711164	chr6:28115156	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	trans	rs61931739	0.782	rs1197569	chr12:34186733	A/T	cg13010199	chr12:38710504	ALG10B	0.44	8.53	0.37	2.15e-16	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.87	-9.41	-0.4	2.34e-19	Diabetic retinopathy;
LGG	cis	rs10504229	0.679	rs2317991	chr8:58035080	C/T	cg11062466	chr8:58055876	NA	-0.42	-7.06	-0.31	6.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	0.571	rs6700047	chr1:178508742	G/A	cg12486710	chr1:178512616	C1orf220	-0.34	-6.71	-0.3	5.8e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4538187	0.851	rs11674020	chr2:64134894	G/A	cg02541582	chr2:64069798	UGP2	-0.62	-14.68	-0.56	2.44e-40	Systolic blood pressure;
LGG	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg26076054	chr5:421317	AHRR	0.43	7.88	0.34	2.37e-14	Cystic fibrosis severity;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg22044901	chr15:68126292	NA	-0.43	-8.04	-0.35	7.56e-15	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs67311347	1.000	rs4973878	chr3:40407565	C/T	cg13683864	chr3:40499215	RPL14	-0.98	-20.17	-0.68	2.19e-65	Renal cell carcinoma;
LGG	cis	rs6500602	0.826	rs11076831	chr16:4460133	A/G	cg06916706	chr16:4465613	CORO7	1.16	24.08	0.75	1.15e-83	Schizophrenia;
LGG	cis	rs9291683	0.588	rs3756236	chr4:10013463	T/A	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.04e-11	Bone mineral density;
LGG	cis	rs79349575	0.685	rs1124829	chr17:46967797	C/A	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.07e-14	Type 2 diabetes;
LGG	trans	rs1997103	0.863	rs2140916	chr7:55403154	A/C	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs12681287	0.604	rs41469550	chr8:87406544	G/T	cg27223183	chr8:87520930	FAM82B	0.5	7.75	0.34	5.7e-14	Caudate activity during reward;
LGG	trans	rs12517041	1.000	rs2099091	chr5:23295532	T/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs2901331	0.533	rs17392884	chr2:125425451	A/G	cg07771321	chr2:125368595	CNTNAP5	-0.43	-7.42	-0.33	5.54e-13	Response to statin therapy;
LGG	cis	rs9733	0.503	rs7556451	chr1:150913142	A/G	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Tonsillectomy;
LGG	cis	rs7586879	0.687	rs11892869	chr2:25096692	A/T	cg04586622	chr2:25135609	ADCY3	0.44	11.76	0.48	4.12e-28	Body mass index;
LGG	cis	rs9393813	0.626	rs2235232	chr6:27326863	G/A	cg18711553	chr6:27366782	ZNF391	0.5	9.71	0.41	2.14e-20	Bipolar disorder;
LGG	cis	rs4718428	0.672	rs12530806	chr7:66390724	A/G	cg12165864	chr7:66369176	NA	-0.57	-9.09	-0.39	2.95e-18	Corneal structure;
LGG	cis	rs727505	1.000	rs7806680	chr7:124433079	G/A	cg23710748	chr7:124431027	NA	-0.5	-9.53	-0.4	8.84e-20	Lewy body disease;
LGG	cis	rs3008870	1.000	rs3008853	chr1:67385488	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs6060960	0.502	rs15817	chr20:30193538	A/G	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs12049351	0.774	rs4148760	chr1:229673934	G/C	cg13547644	chr1:229569608	ACTA1	0.28	6.66	0.3	7.9e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg18252515	chr7:66147081	NA	-0.4	-6.81	-0.3	2.98e-11	Aortic root size;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12726277	chr7:973190	ADAP1	0.36	6.91	0.31	1.57e-11	Menarche (age at onset);
LGG	cis	rs7647973	1.000	rs1464569	chr3:49460350	A/G	cg07636037	chr3:49044803	WDR6	0.79	14.07	0.55	1.09e-37	Menarche (age at onset);
LGG	cis	rs11190604	0.806	rs11190510	chr10:102157175	G/A	cg07080220	chr10:102295463	HIF1AN	0.57	9.81	0.41	8.79e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9611565	0.512	rs132784	chr22:42052363	G/A	cg06634786	chr22:41940651	POLR3H	0.76	11.78	0.48	3.5e-28	Vitiligo;
LGG	cis	rs9473924	0.542	rs55648125	chr6:50816718	A/G	cg14470998	chr6:50812995	TFAP2B	0.68	7.42	0.33	5.76e-13	Body mass index;
LGG	cis	rs3747547	0.818	rs3827518	chr9:37948432	C/T	cg13774184	chr9:37916125	SHB	-0.61	-7.14	-0.31	3.71e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs35160687	0.623	rs2276625	chr2:86481835	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.39	-7.18	-0.32	2.79e-12	Night sleep phenotypes;
LGG	cis	rs1620921	0.505	rs9458030	chr6:161209985	G/A	cg01280913	chr6:161186852	NA	-0.51	-10.72	-0.45	4.38e-24	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2273669	0.667	rs77936298	chr6:109350616	A/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs6868223	0.797	rs6862337	chr5:33659825	A/T	cg10594543	chr5:33649717	ADAMTS12	0.61	13.51	0.53	2.8e-35	Mortality in heart failure;
LGG	cis	rs1994135	0.647	rs67243558	chr12:33695383	T/C	cg06521331	chr12:34319734	NA	-0.53	-8.78	-0.38	3.13e-17	Resting heart rate;
LGG	cis	rs4631830	0.900	rs11006274	chr10:51540291	C/T	cg10326726	chr10:51549505	MSMB	0.67	13.78	0.54	1.94e-36	Prostate-specific antigen levels;
LGG	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg27432699	chr2:27873401	GPN1	-0.43	-7.1	-0.31	4.85e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg12458913	chr13:53173898	NA	1.0	25.31	0.76	2.17e-89	Lewy body disease;
LGG	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg18854424	chr1:2615690	NA	-0.35	-7.35	-0.32	9.06e-13	Ulcerative colitis;
LGG	cis	rs4929949	0.901	rs4475924	chr11:8620009	T/C	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.69e-11	Body mass index;
LGG	cis	rs72781680	0.566	rs55987381	chr2:23900938	T/C	cg08917208	chr2:24149416	ATAD2B	0.59	7.11	0.31	4.46e-12	Lymphocyte counts;
LGG	cis	rs11785400	1.000	rs11776301	chr8:143737142	A/G	cg10596483	chr8:143751796	JRK	0.57	9.35	0.4	3.86e-19	Schizophrenia;
LGG	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg25019033	chr10:957182	NA	-0.53	-9.69	-0.41	2.53e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs6141769	0.542	rs28456308	chr20:31273747	C/T	cg13636640	chr20:31349939	DNMT3B	-0.47	-6.94	-0.31	1.35e-11	Subjective well-being;
LGG	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg23649088	chr2:200775458	C2orf69	-0.59	-7.84	-0.34	3.16e-14	Schizophrenia;
LGG	cis	rs9560113	0.597	rs947170	chr13:112241062	G/A	cg15979348	chr13:112237479	NA	-0.47	-8.05	-0.35	7.05e-15	Menarche (age at onset);
LGG	cis	rs910316	1.000	rs8003506	chr14:75586288	A/C	cg08847533	chr14:75593920	NEK9	-0.62	-11.39	-0.47	1.13e-26	Height;
LGG	trans	rs4332037	0.722	rs4719331	chr7:1914679	A/C	cg10840412	chr1:235813424	GNG4	0.56	7.38	0.32	7.39e-13	Bipolar disorder;
LGG	cis	rs10911251	0.528	rs10911265	chr1:183115071	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.56	0.37	1.72e-16	Colorectal cancer;
LGG	cis	rs11239187	0.543	rs11239154	chr10:45073400	C/A	cg03916630	chr10:45065415	NA	0.35	8.48	0.37	2.95e-16	Body mass index;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1062177	1.000	rs72802204	chr5:151183183	T/C	cg00977110	chr5:151150581	G3BP1	0.5	7.99	0.35	1.1e-14	Preschool internalizing problems;
LGG	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg03929089	chr4:120376271	NA	-0.53	-9.0	-0.39	5.78e-18	HDL cholesterol;
LGG	cis	rs9926296	0.632	rs1800286	chr16:89869761	T/C	cg23057051	chr16:89984268	MC1R	-0.38	-7.28	-0.32	1.43e-12	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06176410	chr17:1733445	RPA1;SMYD4	0.47	6.84	0.3	2.59e-11	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.958	rs884842	chr6:86680397	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.34	-0.4	4.02e-19	Response to antipsychotic treatment;
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.78	-0.41	1.16e-20	Systolic blood pressure;
LGG	trans	rs3858145	0.588	rs736535	chr10:70043916	G/A	cg04882175	chr6:131122610	NA	-0.57	-8.14	-0.35	3.57e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs2204008	0.591	rs11495396	chr12:38380182	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.11	0.31	4.4e-12	Bladder cancer;
LGG	cis	rs7572733	0.935	rs10192466	chr2:198738019	G/A	cg00792783	chr2:198669748	PLCL1	0.49	8.48	0.37	2.96e-16	Dermatomyositis;
LGG	cis	rs7582180	0.614	rs3748930	chr2:101010082	G/C	cg26150922	chr2:100937072	LONRF2	-0.59	-11.55	-0.47	2.78e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs9972944	0.902	rs9972956	chr17:63771092	T/C	cg07283582	chr17:63770753	CCDC46	0.44	8.75	0.38	4.04e-17	Total body bone mineral density;
LGG	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg23324259	chr8:82754387	SNX16	-0.46	-7.46	-0.33	4.26e-13	Diastolic blood pressure;
LGG	cis	rs2153535	0.580	rs2225765	chr6:8481785	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06811360	chr17:8089327	NA	0.38	6.67	0.3	7.46e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg11301795	chr4:187892539	NA	-0.95	-25.01	-0.76	5.76e-88	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg16141378	chr3:129829833	LOC729375	-0.42	-10.01	-0.42	1.72e-21	Mood instability;
LGG	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg06360820	chr2:242988706	NA	-0.93	-11.59	-0.47	1.98e-27	Obesity-related traits;
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00166722	chr3:10149974	C3orf24	0.56	8.1	0.35	4.75e-15	Alzheimer's disease;
LGG	cis	rs5015933	0.801	rs2416961	chr9:128140357	C/T	cg14078157	chr9:128172775	NA	-0.35	-6.74	-0.3	4.77e-11	Body mass index;
LGG	cis	rs9868809	0.881	rs7620853	chr3:48666503	G/A	cg00383909	chr3:49044727	WDR6	0.81	9.3	0.4	5.7e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs503734	0.935	rs13089177	chr3:100968048	C/T	cg27318481	chr3:100970896	IMPG2	-0.37	-7.92	-0.35	1.84e-14	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg24623649	chr8:11872141	NA	-0.32	-7.82	-0.34	3.5e-14	Neuroticism;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg05665937	chr4:1216051	CTBP1	0.54	10.0	0.42	1.86e-21	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg02297831	chr4:17616191	MED28	0.45	8.32	0.36	1.02e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6541297	1.000	rs1997947	chr1:230283764	A/G	cg05784532	chr1:230284198	GALNT2	-0.52	-9.24	-0.39	9.17e-19	Coronary artery disease;
LGG	cis	rs5758511	0.680	rs5758692	chr22:42669029	T/A	cg15128208	chr22:42549153	NA	0.75	11.74	0.48	5.04e-28	Birth weight;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg26155939	chr18:44337853	ST8SIA5	0.37	6.84	0.3	2.53e-11	Personality dimensions;
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg18258770	chr4:90757814	SNCA	0.39	7.02	0.31	8.15e-12	Dementia with Lewy bodies;
LGG	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07570687	chr10:102243282	WNT8B	0.4	7.53	0.33	2.69e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4253772	0.551	rs9615936	chr22:46686328	C/G	cg09461388	chr22:46763229	CELSR1	-0.63	-6.77	-0.3	3.81e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1008375	0.966	rs7675735	chr4:17587137	T/A	cg10189774	chr4:17578691	LAP3	0.41	7.44	0.33	5.06e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1577917	0.771	rs2842608	chr6:86295858	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-11.38	-0.47	1.25e-26	Response to antipsychotic treatment;
LGG	cis	rs9916302	0.851	rs2338795	chr17:37399364	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.48	-0.58	6.99e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.85	0.34	2.83e-14	Bipolar disorder;
LGG	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg27661571	chr11:113659931	NA	-0.65	-9.31	-0.4	5.27e-19	Hip circumference adjusted for BMI;
LGG	trans	rs9467711	0.591	rs9461219	chr6:25836927	C/G	cg06606381	chr12:133084897	FBRSL1	0.73	6.86	0.3	2.21e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg08250081	chr4:10125330	NA	0.6	11.1	0.46	1.48e-25	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg02002194	chr4:3960332	NA	0.42	7.83	0.34	3.3e-14	Neuroticism;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg19318889	chr4:1322082	MAEA	0.46	8.03	0.35	8.25e-15	Longevity;
LGG	cis	rs7044106	0.791	rs7043969	chr9:123493989	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	18.07	0.64	1.22e-55	Hip circumference adjusted for BMI;
LGG	cis	rs6815814	0.731	rs11735251	chr4:38773057	T/A	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.71	0.3	5.59e-11	Schizophrenia;
LGG	cis	rs1003719	0.680	rs2835621	chr21:38510616	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.0	-0.57	1e-41	Eye color traits;
LGG	cis	rs7246760	1.000	rs56754106	chr19:9937789	T/A	cg16876255	chr19:9731953	ZNF561	0.78	7.18	0.32	2.73e-12	Pursuit maintenance gain;
LGG	cis	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg21775007	chr8:11205619	TDH	0.62	10.21	0.43	3.32e-22	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.09e-11	Total body bone mineral density;
LGG	cis	rs2463822	0.925	rs1528730	chr11:62081181	A/C	cg06239285	chr11:62104954	ASRGL1	1.13	15.47	0.58	8.2e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg23583168	chr7:148888333	NA	-0.85	-16.19	-0.6	4.92e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs9902453	0.765	rs1531553	chr17:28066752	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.72	-14.48	-0.56	1.84e-39	Coffee consumption (cups per day);
LGG	cis	rs7681440	0.904	rs3806789	chr4:90759556	C/T	cg20003494	chr4:90757398	SNCA	-0.43	-8.56	-0.37	1.72e-16	Dementia with Lewy bodies;
LGG	cis	rs9649465	0.561	rs609953	chr7:123422444	T/A	cg03229431	chr7:123269106	ASB15	0.61	13.99	0.55	2.44e-37	Migraine;
LGG	cis	rs2282802	0.660	rs2436390	chr5:139586501	G/A	cg26211634	chr5:139558579	C5orf32	-0.34	-7.54	-0.33	2.46e-13	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs3784262	0.669	rs12912093	chr15:58332583	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.71	-0.3	5.7e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6582630	0.593	rs11182590	chr12:38574274	A/T	cg26384229	chr12:38710491	ALG10B	0.77	15.98	0.6	4.1e-46	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11771526	0.786	rs4342492	chr7:32394075	A/C	cg13207630	chr7:32358064	NA	0.67	6.75	0.3	4.57e-11	Body mass index;
LGG	cis	rs7312933	0.533	rs3747557	chr12:42717961	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.1	-0.35	4.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs17604090	0.877	rs28516764	chr7:29685245	T/G	cg19413766	chr7:29689036	LOC646762	-0.63	-7.96	-0.35	1.32e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs12950390	0.853	rs4794107	chr17:45843159	T/G	cg06532163	chr17:45867833	NA	0.54	9.04	0.39	4.34e-18	IgG glycosylation;
LGG	cis	rs9815354	0.812	rs113772069	chr3:41933389	T/C	cg03022575	chr3:42003672	ULK4	0.82	9.5	0.4	1.11e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9290065	0.519	rs7626904	chr3:160672427	C/T	cg03342759	chr3:160939853	NMD3	-0.52	-8.78	-0.38	3.12e-17	Kawasaki disease;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg21970626	chr13:21893289	NA	-0.47	-10.16	-0.43	4.95e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs9460578	0.537	rs7752140	chr6:20813765	C/T	cg13405222	chr6:20811065	CDKAL1	0.78	17.66	0.63	9.4e-54	Breast cancer;
LGG	cis	rs2303745	0.589	rs751599	chr19:17396549	A/G	cg10664184	chr19:17420304	DDA1	0.55	8.37	0.36	6.89e-16	Systemic lupus erythematosus;
LGG	cis	rs7580658	0.637	rs9636236	chr2:127982941	G/A	cg10021288	chr2:128175891	PROC	-0.61	-12.16	-0.49	9.97e-30	Protein C levels;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg07685180	chr8:600429	NA	1.04	10.63	0.44	9.37e-24	IgG glycosylation;
LGG	cis	rs992157	0.798	rs2382819	chr2:219155909	G/T	cg04731861	chr2:219085781	ARPC2	0.45	10.82	0.45	1.84e-24	Colorectal cancer;
LGG	trans	rs2243480	1.000	rs313798	chr7:65493031	A/G	cg10756647	chr7:56101905	PSPH	0.84	9.86	0.42	6.24e-21	Diabetic kidney disease;
LGG	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg12463550	chr7:65579703	CRCP	0.77	8.31	0.36	1.08e-15	Diabetic kidney disease;
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg16885296	chr6:26284938	NA	0.4	8.71	0.38	5.39e-17	Educational attainment;
LGG	cis	rs2404602	0.679	rs12900494	chr15:76912504	A/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.7	-0.3	6.04e-11	Blood metabolite levels;
LGG	cis	rs11690935	1.000	rs11678984	chr2:172535848	T/G	cg13550731	chr2:172543902	DYNC1I2	1.04	26.55	0.78	4.64e-95	Schizophrenia;
LGG	cis	rs7975161	0.638	rs4592489	chr12:104619699	C/T	cg25273343	chr12:104657179	TXNRD1	-0.61	-9.43	-0.4	2e-19	Toenail selenium levels;
LGG	cis	rs7000551	0.681	rs2461488	chr8:22371858	G/A	cg12081754	chr8:22256438	SLC39A14	0.68	13.16	0.52	7.86e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg00717180	chr2:96193071	NA	-0.46	-8.3	-0.36	1.19e-15	HDL cholesterol;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.7	-0.37	5.88e-17	IgG glycosylation;
LGG	cis	rs6981523	0.566	rs34162231	chr8:11003088	A/T	cg27411982	chr8:10470053	RP1L1	-0.43	-6.92	-0.31	1.52e-11	Neuroticism;
LGG	cis	rs9479482	0.935	rs563278	chr6:150364427	G/C	cg06889755	chr6:150326021	RAET1K	-0.4	-8.3	-0.36	1.14e-15	Alopecia areata;
LGG	cis	rs7814319	0.727	rs3808386	chr8:97273543	G/A	cg20787634	chr8:97240163	UQCRB	-0.69	-13.92	-0.54	4.84e-37	Lung function (FVC);
LGG	trans	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg12395012	chr8:11607386	GATA4	-0.4	-7.57	-0.33	2.1e-13	Mood instability;
LGG	cis	rs2361718	1.000	rs2361718	chr17:78103466	C/T	cg27427491	chr17:78079615	GAA	-0.32	-8.39	-0.36	6.05e-16	Yeast infection;
LGG	cis	rs7572733	0.555	rs700671	chr2:198690001	T/C	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs10463554	0.853	rs246907	chr5:102566278	A/T	cg23492399	chr5:102201601	PAM	-0.52	-7.62	-0.33	1.43e-13	Parkinson's disease;
LGG	cis	rs7737355	0.947	rs10478980	chr5:130618247	C/T	cg06307176	chr5:131281290	NA	0.51	8.57	0.37	1.52e-16	Life satisfaction;
LGG	cis	rs4650994	0.507	rs56229230	chr1:178526563	G/A	cg12486710	chr1:178512616	C1orf220	0.51	10.56	0.44	1.74e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13065560	0.560	rs4491835	chr3:39005889	T/C	cg01426195	chr3:39028469	NA	-0.46	-8.85	-0.38	1.82e-17	Interleukin-18 levels;
LGG	cis	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg12463550	chr7:65579703	CRCP	0.73	8.3	0.36	1.11e-15	Diabetic kidney disease;
LGG	cis	rs870825	0.860	rs56180712	chr4:185600223	A/G	cg04058563	chr4:185651563	MLF1IP	1.08	20.51	0.69	5.61e-67	Blood protein levels;
LGG	cis	rs4774830	0.744	rs60931351	chr15:56305541	A/T	cg05129572	chr15:56138634	NEDD4	0.71	6.9	0.31	1.75e-11	Delta-5 desaturase activity;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg14926445	chr8:58193284	C8orf71	-0.82	-9.85	-0.42	6.68e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.559	rs11851589	chr14:71651679	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.96	-0.31	1.17e-11	Mitral valve prolapse;
LGG	cis	rs561341	1.000	rs521919	chr17:30298039	G/T	cg00745463	chr17:30367425	LRRC37B	-0.7	-10.31	-0.43	1.4e-22	Hip circumference adjusted for BMI;
LGG	cis	rs3820928	0.874	rs10207404	chr2:227794420	T/C	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.71	-0.34	7.97e-14	Pulmonary function;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08645402	chr16:4508243	NA	-0.42	-7.68	-0.34	9.39e-14	Schizophrenia;
LGG	cis	rs4262150	0.883	rs11949473	chr5:152151759	A/C	cg12297329	chr5:152029980	NA	-0.7	-13.14	-0.52	1e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs67385638	1.000	rs72872548	chr11:5289139	C/A	cg12559170	chr11:5275217	HBG2	0.59	13.59	0.53	1.25e-35	Hemoglobin levels;
LGG	cis	rs4262150	0.883	rs72802883	chr5:152246607	A/C	cg12297329	chr5:152029980	NA	-0.66	-12.47	-0.5	5.85e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs2119480	0.731	rs378399	chr13:111308040	G/C	cg16216153	chr13:111290848	CARKD	-0.34	-6.71	-0.3	5.56e-11	Diastolic blood pressure;
LGG	cis	rs9309473	1.000	rs1534471	chr2:73647508	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.71	-0.34	7.95e-14	Metabolite levels;
LGG	cis	rs17453880	0.895	rs7730088	chr5:152028536	T/G	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.47e-82	Subjective well-being;
LGG	cis	rs1719271	0.831	rs12441708	chr15:65164930	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.49	-6.65	-0.3	8.17e-11	Platelet count;
LGG	cis	rs9547996	0.959	rs9548003	chr13:38233206	A/G	cg17979426	chr13:38220150	TRPC4	-0.43	-8.62	-0.37	1.08e-16	Diastolic blood pressure;
LGG	cis	rs9388451	0.537	rs1739383	chr6:126098915	G/T	cg05901451	chr6:126070800	HEY2	-0.68	-12.85	-0.51	1.61e-32	Brugada syndrome;
LGG	cis	rs1015291	0.708	rs1388692	chr12:20008682	A/G	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs9810089	0.868	rs4630889	chr3:136278251	T/C	cg21827317	chr3:136751795	NA	0.48	8.71	0.38	5.52e-17	Gestational age at birth (child effect);
LGG	cis	rs9357271	1.000	rs7749685	chr6:38357890	T/C	cg07362130	chr6:38359646	BTBD9	-0.43	-9.88	-0.42	5.27e-21	Restless legs syndrome;
LGG	cis	rs3781663	0.500	rs7931752	chr11:70022846	T/C	cg06393558	chr11:69982916	ANO1	-0.39	-7.67	-0.34	1e-13	Survival in rectal cancer;
LGG	cis	rs73198271	0.681	rs11987924	chr8:8649972	T/C	cg01851573	chr8:8652454	MFHAS1	0.38	6.81	0.3	2.99e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs1010254	0.510	rs80091187	chr5:151694855	T/C	cg12297329	chr5:152029980	NA	-0.47	-6.88	-0.3	1.9e-11	Optic nerve measurement (cup area);
LGG	cis	rs3857747	0.827	rs4236367	chr7:40457271	G/A	cg00420559	chr7:40367873	C7orf10	-0.38	-7.86	-0.34	2.76e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs11148252	0.740	rs7981050	chr13:52755149	C/T	cg12458913	chr13:53173898	NA	0.53	9.83	0.42	7.71e-21	Lewy body disease;
LGG	cis	rs72781680	0.898	rs55657921	chr2:24008091	C/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs1728785	0.681	rs4783649	chr16:68558467	G/A	cg02972257	chr16:68554789	NA	0.65	9.28	0.4	6.52e-19	Ulcerative colitis;
LGG	cis	rs873946	0.586	rs12783078	chr10:134569706	C/T	cg27286337	chr10:134555280	INPP5A	0.84	12.01	0.49	4.22e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9611565	0.512	rs139560	chr22:42194962	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-7.81	-0.34	3.87e-14	Vitiligo;
LGG	cis	rs1218582	0.740	rs1977879	chr1:154879743	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.54	-0.33	2.54e-13	Prostate cancer;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	trans	rs6561151	0.681	rs17571812	chr13:44472462	G/A	cg12856521	chr11:46389249	DGKZ	0.98	14.42	0.56	3.5e-39	Crohn's disease;
LGG	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.84	-0.3	2.54e-11	Electroencephalogram traits;
LGG	cis	rs35740288	0.822	rs2306225	chr15:86227952	A/G	cg07943548	chr15:86304357	KLHL25	-0.36	-7.01	-0.31	8.34e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6594499	0.872	rs13178997	chr5:110444249	G/T	cg04022379	chr5:110408740	TSLP	0.4	7.44	0.33	4.79e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7646881	0.767	rs58152433	chr3:158456640	A/G	cg19483011	chr3:158453295	NA	-0.58	-7.82	-0.34	3.69e-14	Tetralogy of Fallot;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.83e-17	Lung cancer;
LGG	trans	rs35110281	0.744	rs230646	chr21:44918788	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.96	0.42	2.73e-21	Mean corpuscular volume;
LGG	cis	rs9287719	0.967	rs6755548	chr2:10746126	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs2236267	0.726	rs2295740	chr14:88602804	G/C	cg18078958	chr14:88630771	NA	0.32	7.3	0.32	1.22e-12	Food antigen IgG levels;
LGG	cis	rs4780805	0.564	rs8045821	chr16:19397943	C/T	cg13639881	chr16:19421817	TMC5	0.67	11.11	0.46	1.35e-25	Sleep duration;
LGG	cis	rs1707322	0.721	rs4431884	chr1:46101323	C/T	cg03146154	chr1:46216737	IPP	0.57	11.01	0.46	3.42e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10504229	0.683	rs10504224	chr8:58143735	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-9.9	-0.42	4.43e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.606	rs1581358	chr12:38391582	G/T	cg13010199	chr12:38710504	ALG10B	0.72	13.91	0.54	5.42e-37	Bladder cancer;
LGG	trans	rs11875185	0.510	rs11875874	chr18:55628174	A/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.85	-0.38	1.91e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs929596	0.728	rs6744284	chr2:234625297	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.65	-11.4	-0.47	1.05e-26	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs853679	0.607	rs36101351	chr6:27943369	C/T	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	cis	rs17030434	0.911	rs17030490	chr4:154738340	C/T	cg14289246	chr4:154710475	SFRP2	-0.69	-10.89	-0.45	9.38e-25	Electrocardiographic conduction measures;
LGG	cis	rs17376456	0.877	rs7728736	chr5:93404277	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.25	0.43	2.35e-22	Diabetic retinopathy;
LGG	cis	rs875971	0.862	rs6952182	chr7:65683317	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.82	-0.3	2.9100000000000002e-11	Aortic root size;
LGG	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg20673091	chr1:2541236	MMEL1	0.77	18.44	0.65	2.43e-57	Ulcerative colitis;
LGG	cis	rs477692	0.967	rs496692	chr10:131429100	C/T	cg05714579	chr10:131428358	MGMT	0.56	11.55	0.47	2.84e-27	Response to temozolomide;
LGG	cis	rs7103648	0.545	rs6485795	chr11:47929846	G/A	cg20307385	chr11:47447363	PSMC3	0.8	16.01	0.6	3.15e-46	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs131777	0.577	rs5770928	chr22:51029091	G/C	cg25309564	chr22:51001381	C22orf41	0.62	9.63	0.41	4.05e-20	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg21963583	chr11:68658836	MRPL21	0.61	10.54	0.44	2e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.3	-0.43	1.52e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2916247	0.954	rs7015301	chr8:93173941	C/T	cg10183463	chr8:93005414	RUNX1T1	0.35	7.0	0.31	8.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs283228	0.550	rs2518327	chr6:101813309	T/G	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs6964587	1.000	rs11982213	chr7:91722966	A/G	cg17063962	chr7:91808500	NA	0.47	8.39	0.36	6.13e-16	Breast cancer;
LGG	cis	rs977987	0.778	rs4888409	chr16:75436231	A/T	cg03315344	chr16:75512273	CHST6	0.5	10.08	0.42	9.91e-22	Dupuytren's disease;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	cis	rs2235573	0.638	rs742396	chr22:38452254	C/G	cg10587741	chr22:38071170	LGALS1	-0.33	-6.77	-0.3	3.88e-11	Glioblastoma;Glioma;
LGG	trans	rs12310956	0.532	rs10772114	chr12:33853970	G/A	cg13010199	chr12:38710504	ALG10B	0.46	8.64	0.37	9.22e-17	Morning vs. evening chronotype;
LGG	cis	rs968451	0.906	rs12628367	chr22:39717104	A/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	12.1	0.49	1.75e-29	Primary biliary cholangitis;
LGG	cis	rs9611565	0.681	rs132918	chr22:41808350	C/T	cg17376030	chr22:41985996	PMM1	-0.48	-7.77	-0.34	4.93e-14	Vitiligo;
LGG	cis	rs6500395	0.962	rs868792	chr16:48640632	T/C	cg04672837	chr16:48644449	N4BP1	0.55	9.11	0.39	2.53e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10905065	1.000	rs7913067	chr10:5787305	C/T	cg11519256	chr10:5708881	ASB13	0.43	7.68	0.34	9.38e-14	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.690	rs12204512	chr6:66710486	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.62	0.63	1.49e-53	Exhaled nitric oxide output;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg01758870	chr7:23719630	C7orf46	0.31	6.99	0.31	9.86e-12	Schizophrenia;
LGG	cis	rs4262150	0.726	rs4958560	chr5:151929836	A/G	cg12297329	chr5:152029980	NA	-0.73	-13.93	-0.54	4.55e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs1008375	0.932	rs6449317	chr4:17631253	T/C	cg18681998	chr4:17616180	MED28	0.86	18.17	0.65	4.28e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg14154082	chr13:112174009	NA	0.41	9.05	0.39	3.97e-18	Menarche (age at onset);
LGG	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg27286337	chr10:134555280	INPP5A	0.89	13.27	0.52	2.84e-34	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs123509	0.687	rs17238972	chr3:42819975	C/G	cg12982090	chr3:42733453	KBTBD5	-0.91	-14.23	-0.55	2.26e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs6840360	0.642	rs1470281	chr4:152431552	A/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.33	0.32	1.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12765878	0.603	rs2475216	chr10:105660651	G/A	cg11005552	chr10:105648138	OBFC1	-0.73	-13.0	-0.52	3.81e-33	Coronary artery disease;
LGG	cis	rs8133932	0.701	rs2150454	chr21:47288142	T/C	cg13695288	chr21:47294981	PCBP3	-0.37	-7.41	-0.33	6.03e-13	Schizophrenia;
LGG	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg08330972	chr4:2403930	ZFYVE28	0.99	10.07	0.42	1.04e-21	Influenza A (H1N1) severity;
LGG	cis	rs60871478	0.685	rs34421533	chr7:816638	A/G	cg13798912	chr7:905769	UNC84A	0.57	6.97	0.31	1.11e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01782790	chr1:163393050	NA	0.37	7.65	0.33	1.2e-13	Menarche (age at onset);
LGG	cis	rs13191362	0.810	rs13209784	chr6:162961274	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.16	0.39	1.7e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11039798	0.925	rs12277669	chr11:48925316	A/T	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.49	-10.68	-0.44	6.17e-24	Aortic root size;
LGG	cis	rs72615157	0.628	rs7801070	chr7:99847147	T/G	cg16268157	chr7:99778414	STAG3	-0.43	-6.92	-0.31	1.49e-11	Lung function (FEV1/FVC);
LGG	cis	rs9381040	0.674	rs4711657	chr6:41162715	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-7.69	-0.34	9.04e-14	Alzheimer's disease (late onset);
LGG	cis	rs357618	0.897	rs165362	chr5:150863087	T/G	cg03212797	chr5:150827313	SLC36A1	-0.45	-7.3	-0.32	1.28e-12	Basophil percentage of white cells;
LGG	cis	rs875971	0.545	rs73142265	chr7:65699497	G/A	cg11764359	chr7:65958608	NA	0.62	9.2	0.39	1.24e-18	Aortic root size;
LGG	cis	rs9487094	0.922	rs13204102	chr6:109938944	C/A	cg01125227	chr6:109776195	MICAL1	0.51	8.74	0.38	4.42e-17	Height;
LGG	cis	rs66691851	0.504	rs863930	chr3:135949737	T/G	cg12473912	chr3:136751656	NA	0.48	8.41	0.36	5.18e-16	Neuroticism;Schizophrenia;
LGG	cis	rs6708331	0.517	rs9989836	chr2:70342727	G/A	cg01613454	chr2:70366299	NA	0.54	10.77	0.45	2.83e-24	Obesity-related traits;
LGG	cis	rs7267979	0.932	rs13040655	chr20:25582197	C/T	cg06421707	chr20:25228305	PYGB	0.47	9.81	0.41	9.46e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.73	13.97	0.54	2.98e-37	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs12499324	chr4:120393786	C/T	cg09307838	chr4:120376055	NA	0.81	13.55	0.53	1.76e-35	Corneal astigmatism;
LGG	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg24558204	chr6:135376177	HBS1L	0.62	10.73	0.45	4.03e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.8	-0.3	3.33e-11	Morning vs. evening chronotype;
LGG	cis	rs7617773	1.000	rs7617773	chr3:48193515	C/T	cg11946769	chr3:48343235	NME6	-0.55	-8.69	-0.37	6.36e-17	Coronary artery disease;
LGG	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg20991723	chr1:152506922	NA	0.69	13.8	0.54	1.51e-36	Hair morphology;
LGG	cis	rs8180040	0.783	rs11710121	chr3:47351501	T/G	cg27129171	chr3:47204927	SETD2	-0.77	-13.81	-0.54	1.42e-36	Colorectal cancer;
LGG	cis	rs2075671	0.903	rs4727459	chr7:100276821	T/C	cg21055462	chr7:100276975	NA	0.46	9.88	0.42	5.3e-21	Other erythrocyte phenotypes;
LGG	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg06636001	chr8:8085503	FLJ10661	0.58	11.71	0.48	6.12e-28	Mood instability;
LGG	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg08305652	chr11:111469057	NA	0.39	7.57	0.33	2.01e-13	Primary sclerosing cholangitis;
LGG	cis	rs7666738	0.830	rs11097608	chr4:99011693	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.31	0.36	1.07e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6121246	0.559	rs6121172	chr20:30296095	A/C	cg13852791	chr20:30311386	BCL2L1	0.95	19.02	0.66	5.17e-60	Mean corpuscular hemoglobin;
LGG	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg24006582	chr15:45444508	DUOX1	0.66	12.26	0.49	4.17e-30	Uric acid levels;
LGG	cis	rs10256972	0.527	rs28671326	chr7:1174973	G/A	cg18402987	chr7:1209562	NA	0.39	6.95	0.31	1.27e-11	Longevity;Endometriosis;
LGG	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs7106204	0.534	rs16912285	chr11:24252528	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	9.49	0.4	1.22e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9911578	0.935	rs302873	chr17:56769481	C/G	cg12560992	chr17:57184187	TRIM37	0.88	15.54	0.59	3.92e-44	Intelligence (multi-trait analysis);
LGG	cis	rs9914988	0.943	rs4794838	chr17:27131095	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.73	0.41	1.69e-20	Bipolar disorder;
LGG	cis	rs73086581	0.592	rs6037702	chr20:3936392	G/A	cg02187196	chr20:3869020	PANK2	-0.48	-7.47	-0.33	3.91e-13	Response to antidepressants in depression;
LGG	cis	rs1568889	1.000	rs11603799	chr11:28196488	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.78	0.57	8.74e-41	Bipolar disorder;
LGG	cis	rs9715521	0.900	rs4860450	chr4:59827819	G/A	cg11281224	chr4:60001000	NA	-0.43	-7.11	-0.31	4.5e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg08645402	chr16:4508243	NA	0.51	9.72	0.41	1.96e-20	Schizophrenia;
LGG	cis	rs861020	0.677	rs2049998	chr1:210031154	C/T	cg09163369	chr1:210001066	C1orf107	-0.41	-7.31	-0.32	1.15e-12	Orofacial clefts;
LGG	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg04362960	chr10:104952993	NT5C2	0.48	7.88	0.34	2.42e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs62027291	0.654	rs62028181	chr15:77006293	A/G	cg23625390	chr15:77176239	SCAPER	-0.65	-7.35	-0.32	8.88e-13	Plateletcrit;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08225642	chr2:133173643	GPR39	0.42	6.67	0.3	7.19e-11	Gut microbiome composition (summer);
LGG	cis	rs6500395	0.708	rs9930644	chr16:48555929	G/C	cg04672837	chr16:48644449	N4BP1	0.45	7.65	0.34	1.15e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11614062	1.000	rs11614062	chr12:93956672	A/T	cg18151635	chr12:93972918	NA	-0.55	-9.14	-0.39	1.97e-18	Height;
LGG	cis	rs2880765	0.743	rs8039049	chr15:86007629	A/G	cg13263323	chr15:86062960	AKAP13	-0.35	-7.2	-0.32	2.38e-12	Coronary artery disease;
LGG	cis	rs975722	0.603	rs2518873	chr7:117217721	C/T	cg10524701	chr7:117356490	CTTNBP2	0.46	9.83	0.42	7.77e-21	Coronary artery disease;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.8	-0.34	4.08e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6120849	0.754	rs1885117	chr20:33600740	C/T	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.39e-11	Protein C levels;
LGG	cis	rs2228479	0.850	rs62054611	chr16:89817017	T/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs514406	0.584	rs7524702	chr1:53197830	G/A	cg24675658	chr1:53192096	ZYG11B	0.62	13.12	0.52	1.16e-33	Monocyte count;
LGG	cis	rs112591243	0.685	rs2839366	chr21:48026443	A/T	cg10657630	chr21:48055338	PRMT2	-0.87	-7.7	-0.34	8.53e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04845077	chr9:34126958	DCAF12	-0.46	-6.68	-0.3	6.78e-11	Systemic lupus erythematosus;
LGG	cis	rs62238980	0.614	rs79110727	chr22:32377455	A/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs9354308	0.753	rs10455590	chr6:66598194	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.76	-0.3	4.26e-11	Metabolite levels;
LGG	cis	rs74781061	0.860	rs6495101	chr15:74742752	T/A	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs853679	0.542	rs2295594	chr6:28053097	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.73	-0.3	5.14e-11	Menarche (age at onset);
LGG	cis	rs4555082	0.874	rs2816612	chr14:105723103	C/T	cg13114125	chr14:105738426	BRF1	-0.86	-16.19	-0.6	4.94e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs58688157	0.960	rs60870990	chr11:613742	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.5	-0.4	1.14e-19	Systemic lupus erythematosus;
LGG	cis	rs7667	0.841	rs12027702	chr1:19747103	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.4	-6.95	-0.31	1.22e-11	Crohn's disease and psoriasis;
LGG	cis	rs9457247	0.663	rs9457258	chr6:167444254	T/C	cg07741184	chr6:167504864	NA	0.4	8.77	0.38	3.34e-17	Crohn's disease;
LGG	cis	rs12447804	0.645	rs12599591	chr16:58115491	C/T	cg03859792	chr16:58121049	NA	0.64	10.04	0.42	1.42e-21	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2842992	0.724	rs2273823	chr6:160211485	T/C	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9534288	0.700	rs57192057	chr13:46592327	C/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.31	-0.53	1.86e-34	Blood protein levels;
LGG	cis	rs11514810	1.000	rs4385385	chr7:1431125	T/C	cg24899294	chr7:1481343	MICALL2	-0.73	-8.43	-0.36	4.53e-16	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs1023500	0.596	rs5751204	chr22:42433801	C/T	cg04733989	chr22:42467013	NAGA	0.59	10.02	0.42	1.6e-21	Schizophrenia;
LGG	cis	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg00405596	chr8:11794950	NA	-0.39	-6.76	-0.3	4.11e-11	Neuroticism;
LGG	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg08930214	chr7:62859557	LOC100287834	0.45	7.32	0.32	1.13e-12	Obesity-related traits;
LGG	cis	rs4409675	0.576	rs7536088	chr1:28234325	A/G	cg23691781	chr1:28212827	C1orf38	0.37	9.22	0.39	1.03e-18	Corneal astigmatism;
LGG	cis	rs6502050	0.842	rs6502053	chr17:80066714	C/T	cg23985595	chr17:80112537	CCDC57	0.46	9.19	0.39	1.33e-18	Life satisfaction;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg10569807	chr12:25404368	KRAS	-0.37	-7.44	-0.33	5.02e-13	Iris color (L* coordinate);
LGG	cis	rs2276314	0.857	rs28651028	chr18:33638910	G/A	cg05985134	chr18:33552581	C18orf21	0.63	10.01	0.42	1.81e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.29	-0.32	1.33e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg06046430	chr4:77819534	ANKRD56	0.55	11.27	0.46	3.37e-26	Emphysema distribution in smoking;
LGG	cis	rs4689388	0.824	rs114669221	chr4:6301459	G/A	cg25554036	chr4:6271136	WFS1	0.61	11.64	0.48	1.24e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4417704	0.551	rs12479396	chr2:241889171	G/A	cg14055004	chr2:241860995	NA	0.28	7.62	0.33	1.41e-13	Joint mobility (Beighton score);
LGG	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg05234568	chr11:5960015	NA	-0.74	-12.1	-0.49	1.75e-29	DNA methylation (variation);
LGG	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg04935436	chr20:30431758	NA	0.41	7.21	0.32	2.24e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg18379455	chr17:41446167	NA	-0.31	-7.07	-0.31	5.68e-12	Menopause (age at onset);
LGG	cis	rs952623	0.501	rs11972294	chr7:39085743	A/G	cg20302533	chr7:39170763	POU6F2	0.35	8.25	0.36	1.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4731207	0.596	rs10228686	chr7:124663086	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.08	-0.31	5.26e-12	Cutaneous malignant melanoma;
LGG	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs10870270	1.000	rs4880246	chr10:133764064	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.61	-0.53	1.06e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg13385521	chr17:29058706	SUZ12P	0.9	10.23	0.43	2.69e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6907340	0.517	rs9465533	chr6:19801708	C/A	cg02682789	chr6:19804855	NA	0.53	7.74	0.34	6.34e-14	Endometriosis;
LGG	cis	rs11785400	0.793	rs34875149	chr8:143736131	G/A	cg24634471	chr8:143751801	JRK	0.5	7.74	0.34	6.48e-14	Schizophrenia;
LGG	cis	rs7241530	0.595	rs4799015	chr18:75913716	A/G	cg14642773	chr18:75888474	NA	0.43	8.07	0.35	6.31e-15	Educational attainment (years of education);
LGG	cis	rs6087990	0.806	rs910084	chr20:31379665	C/T	cg13636640	chr20:31349939	DNMT3B	0.93	19.52	0.67	2.27e-62	Ulcerative colitis;
LGG	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg15432903	chr11:17409602	KCNJ11	0.81	16.62	0.61	5.29e-49	Type 2 diabetes;
LGG	cis	rs9926296	0.607	rs2079672	chr16:89884917	A/G	cg26513180	chr16:89883248	FANCA	-0.66	-12.81	-0.51	2.3e-32	Vitiligo;
LGG	trans	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg24247370	chr13:99142703	STK24	-0.37	-6.82	-0.3	2.85e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.86	-0.38	1.67e-17	Cognitive function;
LGG	cis	rs9790314	1.000	rs336567	chr3:161073046	A/G	cg03342759	chr3:160939853	NMD3	-0.63	-11.28	-0.46	2.98e-26	Morning vs. evening chronotype;
LGG	cis	rs12586317	0.508	rs8015350	chr14:35635230	A/T	cg05294307	chr14:35346193	BAZ1A	-0.35	-6.67	-0.3	7.31e-11	Psoriasis;
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs6504173	chr17:61735056	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.75	0.34	5.89e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg17830980	chr10:43048298	ZNF37B	0.62	14.48	0.56	1.84e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs11122272	0.735	rs2790892	chr1:231512771	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7107174	0.892	rs1007837	chr11:77941076	A/G	cg02023728	chr11:77925099	USP35	0.42	7.59	0.33	1.75e-13	Testicular germ cell tumor;
LGG	cis	rs10489167	1.000	rs9438945	chr1:41139584	C/G	cg11417323	chr1:41160271	NFYC	0.52	7.14	0.32	3.55e-12	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs801193	1.000	rs2707850	chr7:66203870	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.38e-19	Aortic root size;
LGG	cis	rs2354432	0.556	rs12568866	chr1:146718430	A/C	cg25205988	chr1:146714368	CHD1L	-1.45	-15.29	-0.58	4.99e-43	Mitochondrial DNA levels;
LGG	cis	rs6809651	0.524	rs12638263	chr3:185795855	A/C	cg00760338	chr3:185826511	ETV5	-0.87	-14.14	-0.55	5.34e-38	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	9.21	0.39	1.11e-18	Obesity-related traits;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07939768	chr17:27621433	NUFIP2	-0.46	-6.8	-0.3	3.22e-11	Systemic lupus erythematosus;
LGG	trans	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg02002194	chr4:3960332	NA	-0.46	-8.59	-0.37	1.36e-16	Joint mobility (Beighton score);
LGG	cis	rs6582630	0.555	rs7301250	chr12:38596244	G/T	cg04568710	chr12:38710424	ALG10B	0.33	6.79	0.3	3.43e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.23	0.36	1.92e-15	Thyroid stimulating hormone;
LGG	cis	rs68149176	0.772	rs61527026	chr16:87878783	C/G	cg00025439	chr16:87856450	NA	-0.45	-6.82	-0.3	2.78e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs1046896	0.586	rs9897951	chr17:80810662	T/C	cg12045294	chr17:78518616	RPTOR	-0.46	-7.15	-0.32	3.32e-12	Glycated hemoglobin levels;
LGG	cis	rs17534004	1.000	rs34538248	chr13:31468796	A/C	cg00367615	chr13:31480979	C13orf33	0.34	6.96	0.31	1.2e-11	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.32	-0.4	4.75e-19	Life satisfaction;
LGG	cis	rs4731207	0.596	rs6466982	chr7:124656788	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs1595825	0.891	rs73056823	chr2:198769788	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-6.97	-0.31	1.1e-11	Ulcerative colitis;
LGG	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.58	-9.99	-0.42	2.04e-21	Colorectal cancer;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg05863683	chr7:1912471	MAD1L1	0.43	8.37	0.36	6.92e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.77	-0.38	3.5e-17	Menopause (age at onset);
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs2224391	0.628	rs2773309	chr6:5248916	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.43	-0.33	5.2e-13	Height;
LGG	cis	rs4481887	0.676	rs7524978	chr1:248527319	A/T	cg00666640	chr1:248458726	OR2T12	0.49	8.4	0.36	5.59e-16	Common traits (Other);
LGG	cis	rs504918	1.000	rs17312336	chr3:124081180	A/G	cg05766129	chr3:123988013	KALRN	0.39	7.16	0.32	3.2e-12	Schizophrenia;
LGG	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.67	0.51	8.42e-32	Mean corpuscular hemoglobin;
LGG	cis	rs9768139	0.708	rs11769028	chr7:158113881	G/A	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	trans	rs561341	1.000	rs548957	chr17:30302411	G/A	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs912057	0.965	rs1294409	chr6:6738355	A/G	cg06612196	chr6:6737390	NA	-0.44	-8.82	-0.38	2.32e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs747782	0.527	rs12289516	chr11:48234680	G/A	cg15704280	chr7:45808275	SEPT13	0.73	7.96	0.35	1.32e-14	Intraocular pressure;
LGG	cis	rs9534288	0.797	rs6561280	chr13:46583691	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.41	0.47	9.29e-27	Electroencephalogram traits;
LGG	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg06917634	chr15:78832804	PSMA4	-0.72	-14.13	-0.55	5.81e-38	Sudden cardiac arrest;
LGG	cis	rs6772849	0.662	rs12494372	chr3:128401693	A/C	cg08795948	chr3:128337044	NA	0.63	10.0	0.42	1.95e-21	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs4148883	0.629	rs10009145	chr4:100047929	G/A	cg13256891	chr4:100009986	ADH5	0.38	6.74	0.3	4.64e-11	Alcohol dependence;
LGG	cis	rs75920871	0.623	rs56016514	chr11:116961588	G/A	cg20608306	chr11:116969690	SIK3	-0.34	-8.01	-0.35	9.14e-15	Subjective well-being;
LGG	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg11279151	chr3:101281821	RG9MTD1	0.42	7.49	0.33	3.63e-13	Colorectal cancer;
LGG	cis	rs6951245	0.572	rs73265918	chr7:1056809	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.84	-10.88	-0.45	1.05e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22522985	chr1:52485971	TXNDC12	0.42	7.17	0.32	2.94e-12	Pancreatic cancer;
LGG	cis	rs62238980	0.614	rs80272272	chr22:32475924	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs8180040	0.932	rs1531875	chr3:47452786	G/A	cg27129171	chr3:47204927	SETD2	0.77	15.02	0.57	8.21e-42	Colorectal cancer;
LGG	cis	rs6784615	0.744	rs419752	chr3:52429665	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.88	0.34	2.28e-14	Waist-hip ratio;
LGG	trans	rs3942852	0.774	rs11039519	chr11:48130094	G/C	cg03929089	chr4:120376271	NA	-0.64	-9.09	-0.39	2.87e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.64	0.41	3.71e-20	Bipolar disorder;
LGG	cis	rs12142240	0.698	rs6695043	chr1:46844530	A/G	cg00530320	chr1:46809349	NSUN4	-0.45	-8.44	-0.37	4e-16	Menopause (age at onset);
LGG	cis	rs1873147	0.569	rs8029221	chr15:63308583	C/T	cg12160578	chr15:63334699	TPM1	0.57	7.92	0.35	1.78e-14	Orofacial clefts;
LGG	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.82	0.34	3.65e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs4262150	0.883	rs12188079	chr5:152201527	T/C	cg12297329	chr5:152029980	NA	-0.67	-12.48	-0.5	5.23e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.58e-15	Colorectal cancer;
LGG	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg02463440	chr8:22132932	PIWIL2	0.49	10.83	0.45	1.67e-24	Hypertriglyceridemia;
LGG	cis	rs17776563	0.593	rs10852105	chr15:89141792	A/G	cg05013243	chr15:89149849	MIR1179	-0.34	-7.07	-0.31	5.84e-12	Thyroid hormone levels;
LGG	cis	rs4954585	0.683	rs4452212	chr2:137015991	G/A	cg05194412	chr2:137003533	NA	0.38	8.23	0.36	1.9e-15	Colorectal cancer;
LGG	cis	rs780096	0.526	rs780106	chr2:27681598	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs4330281	0.765	rs7645459	chr3:17808236	C/G	cg20981856	chr3:17787350	NA	-0.39	-7.12	-0.31	4.05e-12	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2797369	0.571	rs6924821	chr6:101509688	C/T	cg27451362	chr6:101846650	GRIK2	-0.73	-10.65	-0.44	8.06e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs6735179	0.532	rs6756670	chr2:1761496	A/G	cg08534653	chr2:1747700	PXDN	0.48	7.51	0.33	3.06e-13	Response to antipsychotic treatment;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.28	0.36	1.3e-15	Tonsillectomy;
LGG	cis	rs2652834	0.851	rs9302231	chr15:63427394	G/A	cg05507819	chr15:63340323	TPM1	0.5	7.12	0.31	4.27e-12	HDL cholesterol;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg18252515	chr7:66147081	NA	-1.41	-20.28	-0.69	6.73e-66	Diabetic kidney disease;
LGG	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg14784868	chr12:69753453	YEATS4	1.01	24.12	0.75	7.19e-84	Cerebrospinal fluid biomarker levels;
LGG	cis	rs34891900	0.507	rs2587084	chr22:18140644	T/G	cg19898043	chr22:18121309	BCL2L13	0.55	9.1	0.39	2.78e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg12751644	chr20:60527061	NA	-0.29	-6.9	-0.31	1.75e-11	Body mass index;
LGG	cis	rs77956314	0.515	rs12299065	chr12:117442304	A/G	cg02017074	chr12:117425053	FBXW8	0.55	7.58	0.33	1.94e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs61931739	0.500	rs7955247	chr12:34126580	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.46	3.63e-26	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Bone mineral density;
LGG	cis	rs7177699	0.525	rs7166770	chr15:79113568	A/G	cg00540400	chr15:79124168	NA	0.53	11.23	0.46	4.79e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs17401966	0.931	rs12137880	chr1:10388620	T/C	cg19773385	chr1:10388646	KIF1B	-0.49	-10.51	-0.44	2.5e-23	Hepatocellular carcinoma;
LGG	cis	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-11.01	-0.46	3.45e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg02462569	chr6:150064036	NUP43	-0.38	-8.08	-0.35	5.62e-15	Lung cancer;
LGG	cis	rs17373728	0.739	rs6472896	chr8:76190315	A/C	cg07016329	chr8:76221503	NA	-0.62	-11.55	-0.47	2.84e-27	Diabetic kidney disease;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg07677032	chr17:61819896	STRADA	0.67	12.4	0.5	1.08e-30	Prudent dietary pattern;
LGG	cis	rs9912468	0.966	rs9303504	chr17:64315366	G/C	cg19474267	chr17:64306194	PRKCA	-0.97	-28.04	-0.79	7.55e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs4680	1.000	rs165656	chr22:19948863	C/G	cg22546130	chr22:19950026	COMT	-0.34	-8.3	-0.36	1.12e-15	Blood metabolite levels;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.93	13.73	0.54	3.05e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	8.22	0.36	2e-15	Schizophrenia;
LGG	cis	rs943466	1.000	rs55775340	chr6:33751784	C/G	cg07519485	chr6:33762594	MLN	0.55	11.36	0.47	1.53e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs17102423	0.723	rs8181939	chr14:65555758	G/A	cg26396452	chr14:65542826	MAX	0.42	8.41	0.36	5.14e-16	Obesity-related traits;
LGG	cis	rs11644362	1.000	rs35325771	chr16:12985138	A/C	cg08528231	chr16:12997261	SHISA9	-0.33	-6.66	-0.3	7.66e-11	Positive affect;Subjective well-being;
LGG	cis	rs2346177	0.816	rs74179078	chr2:46654651	T/A	cg26688816	chr2:46740690	ATP6V1E2	-0.58	-10.68	-0.44	5.86e-24	HDL cholesterol;
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs9527	0.545	rs7095304	chr10:104954795	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.85	0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-7.96	-0.35	1.38e-14	Obesity-related traits;
LGG	trans	rs1814175	0.645	rs1818895	chr11:50031523	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs1417569	0.517	rs2994627	chr10:31200884	C/T	cg00428179	chr10:31322131	ZNF438	-0.37	-8.68	-0.37	6.79e-17	Tuberculosis;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.32	-6.84	-0.3	2.53e-11	Schizophrenia;
LGG	cis	rs62045844	0.536	rs9940965	chr16:89180664	C/G	cg08015503	chr16:89190385	ACSF3	-0.63	-7.2	-0.32	2.43e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2735413	0.670	rs4522431	chr16:78111152	C/T	cg04733911	chr16:78082701	NA	0.63	10.22	0.43	2.94e-22	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1801251	0.964	rs6748027	chr2:233629552	T/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.31	0.4	4.96e-19	Coronary artery disease;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs1143633	0.579	rs3811042	chr2:113670834	G/A	cg06771106	chr2:113671356	IL1F7	0.38	7.39	0.32	7.13e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg17644776	chr2:200775616	C2orf69	-0.57	-7.13	-0.31	3.81e-12	Schizophrenia;
LGG	cis	rs13102973	0.931	rs116199858	chr4:135847256	G/C	cg14419869	chr4:135874104	NA	0.57	10.71	0.45	4.63e-24	Subjective well-being;
LGG	cis	rs4689388	0.856	rs3200	chr4:6304878	C/T	cg00701064	chr4:6280414	WFS1	0.71	15.76	0.59	4.05e-45	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg10505658	chr17:80084571	CCDC57	0.42	8.5	0.37	2.63e-16	Life satisfaction;
LGG	cis	rs6032067	0.777	rs116517830	chr20:43784872	G/A	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.1	-0.35	4.76e-15	Neuroticism;
LGG	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg18240062	chr17:79603768	NPLOC4	0.61	10.27	0.43	2.03e-22	Eye color traits;
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg23758822	chr17:41437982	NA	0.87	12.86	0.51	1.36e-32	Menopause (age at onset);
LGG	cis	rs6598955	0.671	rs7544	chr1:26607726	T/G	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs11105298	0.891	rs11105302	chr12:89891366	A/G	cg00757033	chr12:89920650	WDR51B	-0.59	-8.95	-0.38	8.49e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1847505	0.562	rs79109903	chr13:61453746	A/T	cg25164009	chr13:61490935	NA	0.58	9.97	0.42	2.5e-21	Polychlorinated biphenyl levels;
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg00149659	chr3:10157352	C3orf10	0.8	9.66	0.41	3.17e-20	Alzheimer's disease;
LGG	trans	rs9302065	0.681	rs9524903	chr13:95963565	A/G	cg19955956	chr7:72299837	SBDSP;TYW1B	0.42	7.68	0.34	9.34e-14	Blood metabolite levels;
LGG	cis	rs5750830	0.621	rs743838	chr22:39824707	T/G	cg11247378	chr22:39784982	NA	-0.32	-9.04	-0.39	4.38e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg11062466	chr8:58055876	NA	0.51	8.62	0.37	1.04e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7011049	0.841	rs116352923	chr8:53870151	G/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg12560992	chr17:57184187	TRIM37	0.92	16.36	0.61	8.37e-48	Intelligence (multi-trait analysis);
LGG	cis	rs773506	0.933	rs773514	chr9:93981649	G/A	cg14446406	chr9:93919335	NA	0.44	8.33	0.36	9.03e-16	Type 2 diabetes nephropathy;
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.68	9.24	0.39	9.27e-19	Lung function (FEV1/FVC);
LGG	cis	rs7586879	0.593	rs11689546	chr2:25130451	A/G	cg04586622	chr2:25135609	ADCY3	0.47	12.99	0.52	3.92e-33	Body mass index;
LGG	cis	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg12486710	chr1:178512616	C1orf220	-0.51	-10.56	-0.44	1.72e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4950322	0.748	rs17360812	chr1:146826720	C/T	cg22381352	chr1:146742008	CHD1L	0.48	7.72	0.34	7.11e-14	Protein quantitative trait loci;
LGG	cis	rs4820294	0.669	rs12628135	chr22:38065655	A/G	cg00142150	chr22:38071001	LGALS1	0.68	13.03	0.52	2.76e-33	Fat distribution (HIV);
LGG	cis	rs13314892	0.764	rs1549745	chr3:69851305	T/C	cg17445875	chr3:69859618	MITF	-0.4	-7.74	-0.34	6.2e-14	QRS complex (12-leadsum);
LGG	cis	rs4727027	0.782	rs10245343	chr7:148796333	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	8.75	0.38	4.1e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs13191362	0.872	rs35443919	chr6:163055804	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.9	0.31	1.74e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11039798	0.925	rs6485831	chr11:48455031	A/T	cg15704280	chr7:45808275	SEPT13	0.76	8.97	0.38	7.49e-18	Axial length;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg18253101	chr19:709325	PALM	0.46	6.85	0.3	2.41e-11	Hip circumference;
LGG	cis	rs1862618	0.573	rs2034245	chr5:56243685	T/C	cg12402800	chr5:56204917	C5orf35	0.43	6.68	0.3	6.76e-11	Initial pursuit acceleration;
LGG	cis	rs11122272	0.735	rs2474630	chr1:231535335	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs12956009	0.518	rs953291	chr18:44870499	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.32	0.32	1.1e-12	Educational attainment (years of education);
LGG	cis	rs4780401	0.728	rs8191288	chr16:11765614	G/A	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.29	-0.32	1.39e-12	Rheumatoid arthritis;
LGG	trans	rs853679	1.000	rs853679	chr6:28296863	C/A	cg08344181	chr3:125677491	NA	-0.52	-7.12	-0.31	4.22e-12	Depression;
LGG	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg19847130	chr8:10466454	RP1L1	0.33	7.21	0.32	2.31e-12	Neuroticism;
LGG	cis	rs3780378	0.870	rs2149556	chr9:5059440	C/T	cg02405213	chr9:5042618	JAK2	-0.54	-9.83	-0.42	7.91e-21	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.87e-16	Tonsillectomy;
LGG	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg11764359	chr7:65958608	NA	-0.76	-13.31	-0.53	1.93e-34	Aortic root size;
LGG	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.09e-19	Common traits (Other);
LGG	cis	rs11098499	0.863	rs10030660	chr4:120436704	G/A	cg24375607	chr4:120327624	NA	0.65	10.52	0.44	2.39e-23	Corneal astigmatism;
LGG	cis	rs17209837	0.607	rs1473152	chr7:87080350	A/C	cg25823085	chr7:87105416	ABCB4	0.3	7.4	0.33	6.54e-13	Gallbladder cancer;
LGG	cis	rs9324022	0.580	rs10151519	chr14:101175798	G/A	cg18089426	chr14:101175970	NA	0.68	12.91	0.51	8.92e-33	Plateletcrit;
LGG	cis	rs68170813	0.559	rs3815148	chr7:106938420	G/T	cg02696742	chr7:106810147	HBP1	0.69	10.43	0.44	5.16e-23	Coronary artery disease;
LGG	cis	rs2439831	1.000	rs537115	chr15:43729948	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.08	0.49	2.15e-29	Lung cancer in ever smokers;
LGG	trans	rs9650657	0.770	rs6601529	chr8:10670550	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.22	-0.32	2.2e-12	Neuroticism;
LGG	cis	rs7586879	0.593	rs6733224	chr2:25130907	C/T	cg04586622	chr2:25135609	ADCY3	-0.48	-13.18	-0.52	6.47e-34	Body mass index;
LGG	cis	rs8056893	0.523	rs4783620	chr16:68359408	G/C	cg07273125	chr16:68295692	NA	0.39	8.61	0.37	1.18e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.78	-0.41	1.2e-20	Mean corpuscular volume;
LGG	cis	rs1707322	0.821	rs10749857	chr1:46248143	C/T	cg03146154	chr1:46216737	IPP	0.58	10.34	0.43	1.14e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11190604	0.767	rs872290	chr10:102198879	G/A	cg07080220	chr10:102295463	HIF1AN	0.58	10.1	0.42	8.11e-22	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17376456	0.696	rs6860390	chr5:93494731	G/T	cg19507638	chr5:93509721	C5orf36	0.43	7.43	0.33	5.4e-13	Diabetic retinopathy;
LGG	cis	rs72781680	0.821	rs72790304	chr2:24108557	G/A	cg08917208	chr2:24149416	ATAD2B	0.72	8.9	0.38	1.26e-17	Lymphocyte counts;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg23034840	chr1:205782522	SLC41A1	0.49	7.94	0.35	1.51e-14	Menarche (age at onset);
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg24112000	chr20:60950667	NA	-0.35	-7.97	-0.35	1.27e-14	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00510787	chr6:151772946	C6orf211;RMND1	0.47	7.57	0.33	1.98e-13	Cognitive performance;
LGG	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg13173536	chr2:3403300	TTC15	-0.35	-7.2	-0.32	2.45e-12	Obesity-related traits;
LGG	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg11644478	chr21:40555479	PSMG1	-0.61	-10.16	-0.43	5.13e-22	Menarche (age at onset);
LGG	trans	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg24247370	chr13:99142703	STK24	-0.42	-7.59	-0.33	1.79e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs3870371	1.000	rs4327433	chr8:122694160	C/T	cg15679747	chr8:122755315	NA	-0.35	-6.82	-0.3	2.77e-11	Periodontal disease-related phenotypes;
LGG	cis	rs721917	0.544	rs9325567	chr10:81659578	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	trans	rs1997103	0.954	rs2177807	chr7:55391002	G/T	cg20935933	chr6:143382018	AIG1	-0.52	-8.61	-0.37	1.13e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg08645402	chr16:4508243	NA	0.51	9.83	0.42	7.5e-21	Schizophrenia;
LGG	cis	rs6938	0.618	rs11638130	chr15:75183935	G/A	cg17294928	chr15:75287854	SCAMP5	0.66	12.33	0.5	2.19e-30	Breast cancer;
LGG	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.91	0.31	1.61e-11	Acne (severe);
LGG	cis	rs7666738	0.830	rs28867087	chr4:98880349	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.3	0.36	1.19e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17767392	1.000	rs35260692	chr14:71831665	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.25	-0.39	8.45e-19	Mitral valve prolapse;
LGG	cis	rs9303280	0.901	rs2952140	chr17:37928059	C/T	cg00129232	chr17:37814104	STARD3	0.46	8.7	0.37	5.85e-17	Self-reported allergy;
LGG	cis	rs17345786	1.000	rs11715368	chr3:101336380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.64	-10.78	-0.45	2.58e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-8.95	-0.38	8.93e-18	Life satisfaction;
LGG	cis	rs3796352	1.000	rs35576914	chr3:53092270	G/A	cg12962167	chr3:53033115	SFMBT1	0.8	7.94	0.35	1.56e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg27129171	chr3:47204927	SETD2	0.85	16.36	0.61	7.99e-48	Colorectal cancer;
LGG	cis	rs6840360	0.571	rs6833814	chr4:152539679	A/G	cg22705602	chr4:152727874	NA	-0.33	-7.94	-0.35	1.58e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11018904	0.817	rs11601793	chr11:89946354	T/G	cg27158573	chr11:89632121	NA	-0.42	-7.62	-0.33	1.45e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.822	rs9992360	chr4:98937123	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.918	rs7689753	chr4:100055575	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs2354432	0.607	rs6694347	chr1:146751140	T/C	cg25205988	chr1:146714368	CHD1L	-1.48	-15.1	-0.57	3.56e-42	Mitochondrial DNA levels;
LGG	cis	rs13102973	0.682	rs11938038	chr4:135894258	T/C	cg14419869	chr4:135874104	NA	0.47	7.92	0.35	1.73e-14	Subjective well-being;
LGG	cis	rs6748734	1.000	rs6724662	chr2:241831560	A/G	cg07537917	chr2:241836409	C2orf54	-0.42	-8.17	-0.36	2.9e-15	Urinary metabolites;
LGG	cis	rs35110281	0.667	rs2838354	chr21:45119857	T/C	cg04455712	chr21:45112962	RRP1B	0.54	10.11	0.43	7.36e-22	Mean corpuscular volume;
LGG	cis	rs367943	1.000	rs348960	chr5:112820651	C/A	cg27587195	chr5:112824172	MCC	0.46	7.38	0.32	7.24e-13	Type 2 diabetes;
LGG	cis	rs8077889	0.871	rs72836549	chr17:41904360	G/T	cg26893861	chr17:41843967	DUSP3	0.94	15.79	0.59	3.06e-45	Triglycerides;
LGG	cis	rs3126085	0.935	rs11589587	chr1:152184129	T/C	cg26876637	chr1:152193138	HRNR	-0.48	-6.9	-0.31	1.71e-11	Atopic dermatitis;
LGG	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs2548003	1.000	rs1833824	chr5:28741740	T/C	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg20608306	chr11:116969690	SIK3	0.41	12.83	0.51	1.93e-32	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05716316	chr15:78799689	AGPHD1	0.48	7.18	0.32	2.81e-12	Gut microbiome composition (summer);
LGG	trans	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.48e-28	Corneal astigmatism;
LGG	trans	rs11722228	0.522	rs77691548	chr4:10136115	T/G	cg26043149	chr18:55253948	FECH	1.0	18.56	0.65	7e-58	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7615952	0.546	rs2922171	chr3:125343193	C/T	cg21696256	chr3:125484277	NA	-0.46	-6.87	-0.3	2.02e-11	Blood pressure (smoking interaction);
LGG	cis	rs9611565	0.694	rs202641	chr22:41833116	C/T	cg06850241	chr22:41845214	NA	0.43	7.07	0.31	5.74e-12	Vitiligo;
LGG	cis	rs9768139	0.733	rs12698208	chr7:158117575	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.44	-0.33	4.94e-13	Calcium levels;
LGG	cis	rs2404602	0.569	rs283793	chr15:76774752	G/A	cg23625390	chr15:77176239	SCAPER	0.57	10.22	0.43	3.13e-22	Blood metabolite levels;
LGG	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg21775007	chr8:11205619	TDH	0.46	7.44	0.33	4.94e-13	Mood instability;
LGG	cis	rs523522	0.923	rs10774553	chr12:120954984	T/C	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg09818912	chr17:20140352	CYTSB	0.33	7.67	0.34	1.01e-13	Schizophrenia;
LGG	trans	rs1973993	0.561	rs3862908	chr1:96987042	G/A	cg10631902	chr5:14652156	NA	-0.38	-7.1	-0.31	4.65e-12	Weight;
LGG	cis	rs9325144	0.681	rs7957376	chr12:39096518	C/T	cg13010199	chr12:38710504	ALG10B	0.48	7.27	0.32	1.53e-12	Morning vs. evening chronotype;
LGG	cis	rs9783347	1.000	rs4150612	chr11:18364358	G/T	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.32	-0.32	1.12e-12	Pancreatic cancer;
LGG	cis	rs4268898	0.865	rs13021828	chr2:24439276	G/C	cg06627628	chr2:24431161	ITSN2	-0.55	-9.45	-0.4	1.75e-19	Asthma;
LGG	cis	rs11877825	0.826	rs9676161	chr18:10571439	G/A	cg25239095	chr18:10589360	NA	0.49	9.0	0.39	6.02e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg06636001	chr8:8085503	FLJ10661	0.44	8.01	0.35	9.09e-15	Mood instability;
LGG	cis	rs6502050	0.835	rs7213172	chr17:80085703	G/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.88	-0.38	1.53e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.736	rs11250002	chr8:10257041	T/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.88	0.3	1.9e-11	Neuroticism;
LGG	cis	rs6815814	0.904	rs67712706	chr4:38820616	A/G	cg06935464	chr4:38784597	TLR10	0.54	7.48	0.33	3.77e-13	Breast cancer;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11072887	chr6:37322624	RNF8	-0.46	-6.8	-0.3	3.23e-11	Systemic lupus erythematosus;
LGG	cis	rs2439831	0.867	rs2245176	chr15:43750762	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.62	-0.33	1.45e-13	Lung cancer in ever smokers;
LGG	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg05280133	chr15:45670068	GATM;LOC145663	-0.41	-7.12	-0.31	4.02e-12	Homoarginine levels;
LGG	cis	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg24375607	chr4:120327624	NA	0.67	11.16	0.46	9.18e-26	Corneal astigmatism;
LGG	cis	rs2072732	0.861	rs6679678	chr1:2950594	T/C	cg22517653	chr1:2918612	NA	-0.44	-6.98	-0.31	1.03e-11	Plateletcrit;
LGG	cis	rs9457247	0.902	rs34560498	chr6:167395862	A/G	cg07741184	chr6:167504864	NA	0.32	7.08	0.31	5.53e-12	Crohn's disease;
LGG	cis	rs4849845	0.653	rs3933618	chr2:121035552	T/G	cg15425061	chr2:121036351	RALB	0.38	7.02	0.31	7.83e-12	Mean platelet volume;
LGG	cis	rs4808199	0.894	rs10418051	chr19:19397789	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.23	0.32	1.96e-12	Nonalcoholic fatty liver disease;
LGG	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.87e-26	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.572	rs3774208	chr3:10164722	T/G	cg08888203	chr3:10149979	C3orf24	0.56	7.99	0.35	1.1e-14	Alzheimer's disease;
LGG	cis	rs7582720	1.000	rs72932558	chr2:203847325	C/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7582180	0.629	rs893416	chr2:100957443	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.5e-30	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg00684032	chr4:1343700	KIAA1530	0.42	8.2	0.36	2.32e-15	Obesity-related traits;
LGG	cis	rs2694528	0.858	rs75646569	chr5:60345424	T/G	cg11474532	chr5:59995715	DEPDC1B	0.68	7.28	0.32	1.43e-12	Parkinson's disease;
LGG	cis	rs4478858	0.698	rs11802155	chr1:31805012	T/C	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs875971	0.522	rs4718285	chr7:65292005	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.63	0.44	8.86e-24	Aortic root size;
LGG	cis	rs2797160	1.000	rs1739380	chr6:126012858	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.45	0.33	4.62e-13	Endometrial cancer;
LGG	cis	rs9467160	1.000	rs9461012	chr6:24441844	A/G	cg20631270	chr6:24437470	GPLD1	-0.54	-7.85	-0.34	2.94e-14	Liver enzyme levels;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.91e-22	Menopause (age at onset);
LGG	cis	rs721917	0.506	rs2758538	chr10:81652803	A/G	cg25562619	chr10:81652821	NA	-0.33	-7.58	-0.33	1.91e-13	Chronic obstructive pulmonary disease;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01516881	chr6:292596	DUSP22	-0.69	-11.62	-0.48	1.43e-27	Menopause (age at onset);
LGG	cis	rs7584262	1.000	rs7584262	chr2:42250549	C/T	cg27252766	chr2:42229092	NA	0.53	8.27	0.36	1.46e-15	Bone mineral density;
LGG	cis	rs7568458	0.905	rs10187424	chr2:85794297	T/C	cg17127132	chr2:85788382	GGCX	0.46	8.06	0.35	6.58e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17102423	0.963	rs11626496	chr14:65600981	C/G	cg11161011	chr14:65562177	MAX	-0.64	-11.85	-0.48	1.73e-28	Obesity-related traits;
LGG	cis	rs3733585	0.673	rs4459990	chr4:9954005	T/C	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2797160	1.000	rs77678056	chr6:126019738	A/G	cg05901451	chr6:126070800	HEY2	0.45	7.54	0.33	2.56e-13	Endometrial cancer;
LGG	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.08	-0.35	5.49e-15	Neuroticism;
LGG	cis	rs1014246	0.848	rs10787715	chr10:118459571	C/T	cg14919929	chr10:118506882	NA	0.61	11.45	0.47	6.73e-27	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs8060686	0.641	rs3743735	chr16:68119555	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4417704	0.551	rs13009903	chr2:241900756	A/G	cg05025159	chr2:241905733	NA	0.52	10.73	0.45	3.99e-24	Joint mobility (Beighton score);
LGG	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg26818257	chr2:241905806	NA	-0.37	-6.98	-0.31	1.05e-11	Urinary metabolites;
LGG	trans	rs116095464	0.510	rs7714944	chr5:231765	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.23	-0.36	1.87e-15	Breast cancer;
LGG	trans	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg16141378	chr3:129829833	LOC729375	0.45	10.38	0.43	7.7e-23	Mood instability;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg05091796	chr16:4465799	CORO7	-0.79	-13.65	-0.54	7e-36	Schizophrenia;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg13880726	chr7:1868755	MAD1L1	0.41	7.32	0.32	1.12e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg07606381	chr6:8435919	SLC35B3	-0.99	-16.46	-0.61	2.81e-48	Motion sickness;
LGG	cis	rs7949566	0.676	rs752805	chr11:126293285	A/T	cg05055844	chr11:126275997	ST3GAL4	0.33	6.89	0.31	1.78e-11	Platelet distribution width;Mean platelet volume;
LGG	cis	rs787274	1.000	rs947609	chr9:115516562	A/G	cg13803584	chr9:115635662	SNX30	-0.58	-7.35	-0.32	9.32e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9368481	0.569	rs6907403	chr6:26877297	A/C	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17604090	0.818	rs28390296	chr7:29687091	C/T	cg19413766	chr7:29689036	LOC646762	-0.62	-7.94	-0.35	1.59e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg13009111	chr11:71350975	NA	0.33	7.17	0.32	2.99e-12	Monocyte count;
LGG	cis	rs854037	0.698	rs16887407	chr5:57072852	G/T	cg08523694	chr5:57076192	NA	0.51	7.12	0.31	4.03e-12	Birth weight;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg15049968	chr18:44337910	ST8SIA5	-0.39	-7.0	-0.31	8.79e-12	Personality dimensions;
LGG	cis	rs2046867	0.818	rs62249861	chr3:72867779	A/G	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.56	0.33	2.21e-13	Retinal vascular caliber;
LGG	cis	rs9300255	0.596	rs10734901	chr12:123743447	G/A	cg05973401	chr12:123451056	ABCB9	0.51	8.14	0.35	3.68e-15	Neutrophil percentage of white cells;
LGG	cis	rs60871478	0.636	rs10245785	chr7:894422	T/C	cg13798912	chr7:905769	UNC84A	-0.58	-7.2	-0.32	2.45e-12	Cerebrospinal P-tau181p levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07547781	chr6:127664470	ECHDC1	0.42	6.88	0.3	1.94e-11	Cognitive performance;
LGG	cis	rs11711311	1.000	rs9811200	chr3:113531180	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	13.78	0.54	1.83e-36	IgG glycosylation;
LGG	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.36	0.36	7.53e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg11752832	chr7:134001865	SLC35B4	0.61	11.21	0.46	5.57e-26	Mean platelet volume;
LGG	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg08400814	chr5:56204995	C5orf35	-0.47	-7.45	-0.33	4.77e-13	Initial pursuit acceleration;
LGG	trans	rs561341	1.000	rs555629	chr17:30294136	T/C	cg20587970	chr11:113659929	NA	-1.34	-24.01	-0.74	2.48e-83	Hip circumference adjusted for BMI;
LGG	cis	rs1018836	1.000	rs1018836	chr8:91570362	A/G	cg16814680	chr8:91681699	NA	-0.72	-12.77	-0.51	3.32e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.27	-0.36	1.47e-15	Educational attainment (years of education);
LGG	cis	rs7107174	0.892	rs2512529	chr11:77977351	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.67	-0.34	1.02e-13	Testicular germ cell tumor;
LGG	cis	rs2718058	0.583	rs2722248	chr7:37845286	G/T	cg15028436	chr7:37888078	TXNDC3	0.52	8.2	0.36	2.31e-15	Alzheimer's disease (late onset);
LGG	cis	rs2862064	1.000	rs1354163	chr5:156420703	C/T	cg12943317	chr5:156479607	HAVCR1	-0.86	-10.54	-0.44	2.04e-23	Platelet count;
LGG	trans	rs6787172	0.677	rs827163	chr3:158022891	T/C	cg23275840	chr4:47708675	CORIN	0.4	8.72	0.38	4.83e-17	Subjective well-being;
LGG	cis	rs12210905	1.000	rs12201498	chr6:27030084	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg05665937	chr4:1216051	CTBP1	0.49	8.9	0.38	1.25e-17	Obesity-related traits;
LGG	cis	rs9926296	0.572	rs2079671	chr16:89884981	T/C	cg26513180	chr16:89883248	FANCA	0.66	12.86	0.51	1.37e-32	Vitiligo;
LGG	cis	rs10504229	0.773	rs1874373	chr8:58194423	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.66	-0.54	6.16e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.536	rs3800274	chr6:151759192	T/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.5	-7.45	-0.33	4.7e-13	Menarche (age at onset);
LGG	trans	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs11166927	0.594	rs7828992	chr8:140826670	A/G	cg16909799	chr8:140841666	TRAPPC9	-0.64	-13.79	-0.54	1.72e-36	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs9300255	0.510	rs1790133	chr12:123698518	T/G	cg00376283	chr12:123451042	ABCB9	0.64	10.17	0.43	4.56e-22	Neutrophil percentage of white cells;
LGG	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.64	0.33	1.22e-13	Cystic fibrosis severity;
LGG	cis	rs3096299	0.900	rs3114867	chr16:89428967	A/C	cg06640241	chr16:89574553	SPG7	0.72	12.72	0.51	5.39e-32	Multiple myeloma (IgH translocation);
LGG	cis	rs6754311	0.678	rs309181	chr2:136614813	C/G	cg07169764	chr2:136633963	MCM6	-0.77	-13.08	-0.52	1.77e-33	Mosquito bite size;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.21	0.32	2.27e-12	Schizophrenia;
LGG	cis	rs8072100	0.935	rs78551919	chr17:45626002	A/C	cg25173405	chr17:45401733	C17orf57	0.48	8.34	0.36	8.35e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4474465	1.000	rs4474465	chr11:78204380	C/T	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.92e-11	Alzheimer's disease (survival time);
LGG	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg08704250	chr15:31115839	NA	-0.42	-7.25	-0.32	1.7e-12	Huntington's disease progression;
LGG	trans	rs7395662	1.000	rs7121460	chr11:48545232	C/A	cg03929089	chr4:120376271	NA	-0.43	-6.96	-0.31	1.17e-11	HDL cholesterol;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-6.87	-0.3	2.09e-11	Lung cancer;
LGG	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	trans	rs9329221	0.683	rs555200	chr8:9888729	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.1	-0.35	5.06e-15	Neuroticism;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.41	8.51	0.37	2.42e-16	Prostate cancer;
LGG	cis	rs11771526	0.901	rs1530823	chr7:32311420	G/T	cg13207630	chr7:32358064	NA	-0.64	-6.93	-0.31	1.44e-11	Body mass index;
LGG	cis	rs2067615	0.579	rs10778510	chr12:107162965	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-11.93	-0.48	8.52e-29	Heart rate;
LGG	cis	rs72781680	1.000	rs61739076	chr2:24149439	G/A	cg08917208	chr2:24149416	ATAD2B	0.94	10.2	0.43	3.71e-22	Lymphocyte counts;
LGG	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg15145296	chr3:125709740	NA	-0.6	-7.69	-0.34	9.17e-14	Blood pressure (smoking interaction);
LGG	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg23649088	chr2:200775458	C2orf69	-0.41	-7.01	-0.31	8.68e-12	QT interval;
LGG	cis	rs611744	0.647	rs2859813	chr8:109263497	G/A	cg21045802	chr8:109455806	TTC35	0.52	9.81	0.41	8.85e-21	Dupuytren's disease;
LGG	cis	rs8072100	0.905	rs9895274	chr17:45539117	C/T	cg08085267	chr17:45401833	C17orf57	-0.63	-13.01	-0.52	3.52e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg04166393	chr7:2884313	GNA12	0.47	9.02	0.39	5.07e-18	Height;
LGG	cis	rs10992471	0.729	rs7042335	chr9:95122547	C/T	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.1	-0.31	4.58e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg05484508	chr16:89589025	SPG7	0.56	9.84	0.42	7.26e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs9611565	0.559	rs5751160	chr22:42175695	A/G	cg03806693	chr22:41940476	POLR3H	1.05	17.65	0.63	1.14e-53	Vitiligo;
LGG	cis	rs6466055	0.777	rs10238507	chr7:104807207	G/T	cg04380332	chr7:105027541	SRPK2	0.37	7.03	0.31	7.51e-12	Schizophrenia;
LGG	cis	rs3857747	0.895	rs6462979	chr7:40401376	G/A	cg00420559	chr7:40367873	C7orf10	-0.4	-8.07	-0.35	6.3e-15	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs55788414	0.872	rs12102958	chr16:81186207	T/A	cg06400318	chr16:81190750	PKD1L2	-0.91	-11.09	-0.46	1.64e-25	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs9952991	0.941	rs34920518	chr18:12783086	A/G	cg23544223	chr18:12777786	NA	-0.6	-8.93	-0.38	9.78e-18	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11044724	chr2:7005733	CMPK2	0.43	6.95	0.31	1.23e-11	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.518	rs10786679	chr10:104315667	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.66	11.4	0.47	1.04e-26	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6430585	0.528	rs6743537	chr2:136702601	C/T	cg07169764	chr2:136633963	MCM6	1.14	20.02	0.68	1.15e-64	Corneal structure;
LGG	cis	rs6061231	0.793	rs6061512	chr20:60976929	G/A	cg15674680	chr20:60982522	CABLES2	0.48	6.72	0.3	5.23e-11	Colorectal cancer;
LGG	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.79	-0.3	3.55e-11	Cutaneous nevi;
LGG	cis	rs12049351	0.774	rs4148757	chr1:229693846	A/C	cg13547644	chr1:229569608	ACTA1	0.28	6.73	0.3	4.91e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs3785574	0.962	rs62077512	chr17:61851435	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.3	0.4	5.58e-19	Height;
LGG	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg02631450	chr22:32366979	NA	0.81	8.43	0.36	4.42e-16	Childhood ear infection;
LGG	cis	rs7524258	0.903	rs4908450	chr1:7292756	T/C	cg07173049	chr1:7289937	CAMTA1	0.78	19.42	0.67	6.95e-62	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs8135665	0.625	rs8142185	chr22:38451080	A/C	cg19171272	chr22:38449367	NA	-0.45	-8.26	-0.36	1.57e-15	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs1865760	1.000	rs7739966	chr6:25906040	T/C	cg03517284	chr6:25882590	NA	-0.41	-7.4	-0.33	6.57e-13	Height;
LGG	cis	rs13126513	0.519	rs959247	chr4:100556984	A/G	cg05468953	chr4:100565104	NA	0.42	8.23	0.36	1.89e-15	Metabolite levels (MHPG);
LGG	trans	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg13565492	chr6:43139072	SRF	-0.72	-8.87	-0.38	1.61e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg05044414	chr3:183734942	ABCC5	0.76	16.73	0.61	1.76e-49	Anterior chamber depth;
LGG	cis	rs7084402	0.935	rs12264028	chr10:60278140	C/T	cg09696939	chr10:60272079	BICC1	0.37	7.33	0.32	1.06e-12	Refractive error;
LGG	cis	rs735396	0.770	rs1169314	chr12:121443116	A/G	cg02403541	chr12:121454288	C12orf43	0.64	10.24	0.43	2.61e-22	N-glycan levels;
LGG	cis	rs12325245	0.536	rs34129245	chr16:58588191	A/G	cg01472538	chr16:58549086	SETD6	0.98	8.84	0.38	2.07e-17	Schizophrenia;
LGG	cis	rs7226408	0.857	rs72888908	chr18:34517789	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg14829155	chr15:31115871	NA	0.48	8.36	0.36	7.45e-16	Huntington's disease progression;
LGG	cis	rs11169552	0.510	rs10783376	chr12:50981249	C/G	cg12884762	chr12:50931848	DIP2B	-0.41	-7.72	-0.34	7.25e-14	Colorectal cancer;
LGG	trans	rs916888	0.779	rs199498	chr17:44865603	A/G	cg22433210	chr17:43662623	NA	0.66	10.37	0.43	8.61e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8177253	0.665	rs9869257	chr3:133451412	G/T	cg16414030	chr3:133502952	NA	-0.49	-7.98	-0.35	1.18e-14	Iron status biomarkers;
LGG	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg26811252	chr16:29126840	RRN3P2	0.75	11.8	0.48	2.69e-28	Menopause (age at onset);
LGG	cis	rs295140	0.605	rs1436164	chr2:201158411	C/T	cg17644776	chr2:200775616	C2orf69	-0.44	-7.28	-0.32	1.41e-12	QT interval;
LGG	cis	rs8049040	0.547	rs12934168	chr16:71436778	C/T	cg06353428	chr16:71660113	MARVELD3	-0.47	-7.29	-0.32	1.34e-12	Blood protein levels;
LGG	cis	rs752010	0.695	rs11210509	chr1:42109311	A/G	cg06885757	chr1:42089581	HIVEP3	0.55	11.86	0.48	1.58e-28	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs10504229	0.775	rs72650876	chr8:58161638	G/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11627756	0.958	rs2146430	chr14:103071825	G/T	cg12046867	chr14:103022105	NA	-0.41	-7.92	-0.35	1.75e-14	Mean platelet volume;
LGG	trans	rs9784649	1.000	rs56004901	chr5:24998968	A/G	cg11038491	chr20:34638489	LOC647979	-0.6	-7.85	-0.34	2.82e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1801251	1.000	rs7558609	chr2:233700379	C/T	cg08000102	chr2:233561755	GIGYF2	0.58	9.42	0.4	2.19e-19	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs28447324	chr11:50046629	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.71	-15.65	-0.59	1.23e-44	Height;
LGG	cis	rs7975161	1.000	rs7975161	chr12:104645405	C/T	cg25273343	chr12:104657179	TXNRD1	0.75	10.16	0.43	5.18e-22	Toenail selenium levels;
LGG	cis	rs9880211	0.699	rs34804893	chr3:136339970	G/A	cg21827317	chr3:136751795	NA	-0.47	-6.82	-0.3	2.9100000000000002e-11	Body mass index;Height;
LGG	cis	rs2066819	1.000	rs35526714	chr12:56634639	G/C	cg26714650	chr12:56694279	CS	-1.57	-14.91	-0.57	2.37e-41	Psoriasis vulgaris;
LGG	cis	rs2115630	0.936	rs11073663	chr15:85260268	A/G	cg12501888	chr15:85177176	SCAND2	-0.42	-6.85	-0.3	2.37e-11	P wave terminal force;
LGG	cis	rs6444746	1.000	rs904881	chr3:193506621	G/T	cg22553634	chr3:193489233	NA	-0.68	-8.02	-0.35	8.49e-15	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs7236492	0.572	rs34712138	chr18:77179833	G/A	cg05753993	chr18:77199432	NFATC1	0.41	6.77	0.3	3.8e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs2250402	0.510	rs6492926	chr15:40325829	T/G	cg01081584	chr15:40268610	EIF2AK4	-0.95	-10.22	-0.43	3.08e-22	Corneal curvature;
LGG	cis	rs9894429	0.646	rs12603868	chr17:79618834	G/C	cg10661904	chr17:79619235	PDE6G	-0.52	-10.58	-0.44	1.36e-23	Eye color traits;
LGG	cis	rs2797160	1.000	rs1739349	chr6:126014984	G/C	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs7241530	0.636	rs4799270	chr18:75898528	G/T	cg14642773	chr18:75888474	NA	0.47	8.97	0.38	7.24e-18	Educational attainment (years of education);
LGG	cis	rs3790455	1.000	rs6700679	chr1:156442956	C/T	cg14087168	chr1:156450669	MEF2D	0.48	7.99	0.35	1.1e-14	Migraine;
LGG	cis	rs9649465	0.967	rs6966470	chr7:123299855	C/T	cg03229431	chr7:123269106	ASB15	0.42	9.23	0.39	9.94e-19	Migraine;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.4e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8060686	0.641	rs9932251	chr16:68131732	G/A	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.07	-0.31	5.66e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4253772	0.637	rs36125344	chr22:46655779	G/C	cg00784671	chr22:46762841	CELSR1	-0.56	-6.65	-0.3	8.46e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs1829883	0.898	rs2461990	chr5:98793519	G/A	cg08333243	chr5:99726346	NA	-0.36	-6.7	-0.3	6.21e-11	Hemostatic factors and hematological phenotypes;
LGG	trans	rs9393777	0.778	rs4452638	chr6:27229265	A/G	cg06606381	chr12:133084897	FBRSL1	0.92	9.74	0.41	1.65e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg06917763	chr7:130033247	NA	0.36	7.78	0.34	4.83e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs55665837	0.519	rs1451677	chr11:14746012	A/C	cg18937875	chr11:14930189	NA	-0.48	-7.77	-0.34	5.13e-14	Vitamin D levels;
LGG	cis	rs975722	0.516	rs7357267	chr7:117023912	T/G	cg10524701	chr7:117356490	CTTNBP2	0.41	8.85	0.38	1.82e-17	Coronary artery disease;
LGG	cis	rs6461049	0.519	rs3778992	chr7:2175313	C/G	cg14004847	chr7:1930337	MAD1L1	-0.57	-10.24	-0.43	2.48e-22	Schizophrenia;
LGG	cis	rs4950322	0.517	rs114823926	chr1:146753478	A/T	cg22381352	chr1:146742008	CHD1L	-0.52	-8.5	-0.37	2.62e-16	Protein quantitative trait loci;
LGG	cis	rs7582180	0.663	rs930374	chr2:100962700	A/G	cg08297393	chr2:100937505	LONRF2	-0.53	-10.07	-0.42	1.1e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17030434	1.000	rs10026531	chr4:154727070	C/T	cg14289246	chr4:154710475	SFRP2	-0.72	-11.45	-0.47	6.79e-27	Electrocardiographic conduction measures;
LGG	cis	rs35146811	0.735	rs1043915	chr7:99799845	T/A	cg22906224	chr7:99728672	NA	0.57	9.45	0.4	1.66e-19	Coronary artery disease;
LGG	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg18709589	chr6:96969512	KIAA0776	0.43	8.55	0.37	1.82e-16	Headache;
LGG	cis	rs13217239	0.646	rs11756275	chr6:27007113	A/C	cg12292205	chr6:26970375	C6orf41	-0.55	-10.83	-0.45	1.69e-24	Schizophrenia;
LGG	trans	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg13009111	chr11:71350975	NA	0.34	7.54	0.33	2.56e-13	Retinal vascular caliber;
LGG	cis	rs4356932	1.000	rs4484329	chr4:76978692	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs703842	1.000	rs10877013	chr12:58165085	C/T	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	7.74	0.34	6.12e-14	Multiple sclerosis;
LGG	cis	rs7737355	0.898	rs26007	chr5:131006356	T/A	cg06307176	chr5:131281290	NA	0.57	9.39	0.4	2.76e-19	Life satisfaction;
LGG	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg26597838	chr10:835615	NA	0.53	6.87	0.3	2.05e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs11098499	0.954	rs11722872	chr4:120233030	G/C	cg09307838	chr4:120376055	NA	0.79	12.95	0.52	5.73e-33	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.652	rs4851311	chr2:100980398	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.64	-0.48	1.23e-27	Intelligence (multi-trait analysis);
LGG	cis	rs910316	1.000	rs9805979	chr14:75566209	G/A	cg06637938	chr14:75390232	RPS6KL1	0.58	10.67	0.44	6.78e-24	Height;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.79	0.59	3.06e-45	Platelet count;
LGG	cis	rs5769765	0.704	rs138837	chr22:50180714	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.59	-8.51	-0.37	2.35e-16	Schizophrenia;
LGG	cis	rs763121	0.819	rs138700	chr22:39129999	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	17.78	0.64	2.77e-54	Menopause (age at onset);
LGG	cis	rs2286885	1.000	rs4837093	chr9:129254443	G/A	cg14319473	chr9:129242481	FAM125B	0.46	8.63	0.37	9.86e-17	Intraocular pressure;
LGG	cis	rs453301	0.509	rs7000323	chr8:8792273	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.3	-0.32	1.27e-12	Joint mobility (Beighton score);
LGG	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-11.43	-0.47	8.24e-27	Height;
LGG	cis	rs7208859	0.623	rs73269916	chr17:29096326	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4740619	0.870	rs7860755	chr9:15795602	C/G	cg14451791	chr9:16040625	NA	-0.35	-8.85	-0.38	1.81e-17	Body mass index;
LGG	cis	rs877282	0.891	rs12767043	chr10:797943	C/T	cg17470449	chr10:769945	NA	0.62	7.72	0.34	7.03e-14	Uric acid levels;
LGG	cis	rs1348850	0.750	rs55792594	chr2:178496468	C/T	cg27490568	chr2:178487706	NA	0.56	10.99	0.45	4.12e-25	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1620921	0.711	rs1652465	chr6:161248552	T/A	cg01280913	chr6:161186852	NA	-0.34	-7.07	-0.31	5.76e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7215564	0.908	rs57778244	chr17:78653798	T/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs9398803	0.835	rs4897182	chr6:126755642	A/C	cg19875578	chr6:126661172	C6orf173	0.56	10.13	0.43	6.59e-22	Male-pattern baldness;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2760061	0.598	rs849904	chr1:228137145	G/C	cg01200585	chr1:228362443	C1orf69	-0.43	-7.54	-0.33	2.52e-13	Diastolic blood pressure;
LGG	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg27478167	chr7:817139	HEATR2	-0.44	-7.04	-0.31	7.13e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs17826219	0.706	rs57698184	chr17:29064918	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.5	-0.44	2.81e-23	Body mass index;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.41	-0.47	1.01e-26	Triglycerides;
LGG	cis	rs10791097	0.694	rs11222370	chr11:130744767	T/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.76e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7100689	0.577	rs10749550	chr10:82031197	A/G	cg01528321	chr10:82214614	TSPAN14	0.81	14.06	0.55	1.18e-37	Post bronchodilator FEV1;
LGG	cis	rs8114671	0.836	rs6141526	chr20:33615255	G/T	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.43	-0.36	4.41e-16	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15977246	chr14:93799786	KIAA1409;BTBD7	0.54	8.12	0.35	4.3e-15	Gut microbiome composition (summer);
LGG	cis	rs2229238	0.911	rs6681207	chr1:154517217	T/C	cg10237817	chr1:154519846	TDRD10	0.34	6.83	0.3	2.64e-11	Coronary heart disease;
LGG	cis	rs1358748	0.522	rs1321153	chr1:67584824	T/C	cg02640540	chr1:67518911	SLC35D1	0.55	6.68	0.3	6.86e-11	Tuberculosis;
LGG	cis	rs7666738	0.800	rs1559858	chr4:99024075	A/G	cg05340658	chr4:99064831	C4orf37	0.48	7.93	0.35	1.71e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.55	-0.33	2.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.660	rs10950044	chr7:66042976	A/G	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.18e-29	Aortic root size;
LGG	cis	rs2762353	0.806	rs6909187	chr6:25785925	C/T	cg03264133	chr6:25882463	NA	0.53	9.72	0.41	1.91e-20	Blood metabolite levels;
LGG	cis	rs7191439	0.584	rs7193436	chr16:88748736	T/C	cg02389323	chr16:88786976	FAM38A	0.87	8.47	0.37	3.39e-16	Plateletcrit;
LGG	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.48	-7.77	-0.34	5.04e-14	Mean platelet volume;
LGG	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg00599393	chr8:22457479	C8orf58	-0.42	-7.64	-0.33	1.28e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9783347	0.826	rs4757645	chr11:18393845	C/G	cg03595886	chr11:18357587	GTF2H1	0.37	7.64	0.33	1.29e-13	Pancreatic cancer;
LGG	cis	rs854572	0.870	rs757158	chr7:94955528	C/T	cg17330251	chr7:94953956	PON1	-0.58	-14.74	-0.57	1.35e-40	Paraoxonase activity;
LGG	cis	rs9549367	0.789	rs7338235	chr13:113888687	T/C	cg00898013	chr13:113819073	PROZ	-0.44	-8.64	-0.37	9.02e-17	Platelet distribution width;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.85	0.38	1.93e-17	Platelet count;
LGG	cis	rs6456156	0.792	rs10946215	chr6:167516181	A/G	cg07741184	chr6:167504864	NA	-0.42	-9.05	-0.39	3.92e-18	Primary biliary cholangitis;
LGG	trans	rs61931739	0.513	rs1608908	chr12:33895389	C/A	cg26384229	chr12:38710491	ALG10B	0.65	12.53	0.5	3.15e-31	Morning vs. evening chronotype;
LGG	cis	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg24692254	chr21:30365293	RNF160	0.69	12.68	0.51	7.87e-32	Cognitive test performance;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs6456156	0.565	rs6456153	chr6:167472167	T/C	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Primary biliary cholangitis;
LGG	cis	rs9814567	0.752	rs13098546	chr3:134333161	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.58	0.44	1.36e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9303401	0.659	rs34468504	chr17:56648277	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs944802	0.639	rs7022662	chr9:22147715	C/G	cg00491127	chr9:22154101	NA	0.43	6.79	0.3	3.48e-11	White blood cell count;
LGG	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs6787172	0.702	rs827180	chr3:157966191	C/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs60843830	1.000	rs58461606	chr2:267367	G/T	cg12623918	chr2:306882	NA	0.52	9.72	0.41	1.83e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs4731207	0.596	rs1481339	chr7:124708237	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.37	-0.32	7.82e-13	Cutaneous malignant melanoma;
LGG	cis	rs3740909	1.000	rs76619396	chr11:125884904	G/A	cg24940576	chr11:125904314	CDON	-0.48	-7.53	-0.33	2.63e-13	Blood protein levels;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg16359550	chr11:109292809	C11orf87	0.4	7.93	0.35	1.64e-14	Schizophrenia;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg21724239	chr8:58056113	NA	0.61	9.03	0.39	4.56e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg08621203	chr6:150244597	RAET1G	0.39	6.72	0.3	5.37e-11	Lung cancer;
LGG	cis	rs45430	0.928	rs398206	chr21:42742036	C/A	cg06102954	chr21:42741788	MX2	0.41	7.56	0.33	2.16e-13	Melanoma;
LGG	cis	rs9311474	0.508	rs6786919	chr3:52599789	A/G	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.88e-14	Electroencephalogram traits;
LGG	trans	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs6752107	0.503	rs13002340	chr2:234234959	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	8.33	0.36	8.98e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg17376030	chr22:41985996	PMM1	0.57	8.86	0.38	1.79e-17	Vitiligo;
LGG	cis	rs2404602	0.591	rs11635162	chr15:76951105	C/T	cg15268244	chr15:77196840	NA	0.43	8.34	0.36	8.61e-16	Blood metabolite levels;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.64	-0.37	9.25e-17	Lung cancer;
LGG	trans	rs4427176	0.507	rs7462055	chr8:9578531	C/G	cg16141378	chr3:129829833	LOC729375	0.34	6.76	0.3	4.18e-11	Mosquito bite size;
LGG	cis	rs6663390	0.510	rs12566127	chr1:208070646	C/T	cg03990033	chr1:208084030	CD34	0.62	7.85	0.34	2.85e-14	Facial morphology (factor 18);
LGG	cis	rs41005	0.967	rs6753101	chr2:8104849	G/T	cg03155496	chr2:8117019	LOC339788	-0.87	-19.04	-0.66	3.89e-60	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs7143963	1.000	rs12588749	chr14:103330873	C/T	cg23020514	chr14:103360112	TRAF3	0.51	9.88	0.42	5.12e-21	Body mass index;
LGG	cis	rs10463554	0.927	rs6862616	chr5:102246038	T/C	cg23492399	chr5:102201601	PAM	-0.54	-8.29	-0.36	1.23e-15	Parkinson's disease;
LGG	cis	rs9326248	1.000	rs10790175	chr11:117034729	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.6	8.97	0.38	7.14e-18	Blood protein levels;
LGG	cis	rs2153535	0.580	rs1932285	chr6:8477719	T/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.34e-31	Motion sickness;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20887711	chr4:1340912	KIAA1530	0.59	11.57	0.47	2.23e-27	Longevity;
LGG	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg17971929	chr21:40555470	PSMG1	-0.85	-16.58	-0.61	8.58e-49	Cognitive function;
LGG	trans	rs61931739	0.613	rs1525898	chr12:33904445	G/T	cg13010199	chr12:38710504	ALG10B	0.44	8.35	0.36	7.94e-16	Morning vs. evening chronotype;
LGG	cis	rs5758659	0.622	rs5758527	chr22:42375761	T/G	cg15557168	chr22:42548783	NA	-0.33	-7.49	-0.33	3.54e-13	Cognitive function;
LGG	cis	rs17376456	0.877	rs10476596	chr5:93367074	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.96	-10.49	-0.44	3e-23	Diabetic retinopathy;
LGG	cis	rs7552404	0.924	rs7544117	chr1:76158246	A/G	cg03433033	chr1:76189801	ACADM	0.81	15.06	0.57	5.32e-42	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6831352	0.918	rs29001224	chr4:100047373	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs6938	0.596	rs11630918	chr15:75155896	C/T	cg17294928	chr15:75287854	SCAMP5	0.65	11.91	0.48	1.06e-28	Breast cancer;
LGG	trans	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg13565492	chr6:43139072	SRF	-0.68	-8.92	-0.38	1.07e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg15038512	chr6:170123185	PHF10	0.51	6.73	0.3	4.91e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg20302533	chr7:39170763	POU6F2	0.49	11.55	0.47	2.74e-27	IgG glycosylation;
LGG	cis	rs7681440	0.874	rs1442154	chr4:90775761	C/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.27e-22	Tonsillectomy;
LGG	cis	rs4930103	0.782	rs10840167	chr11:2022023	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.73	-14.92	-0.57	2.26e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7173389	0.530	rs6495062	chr15:73682691	T/C	cg01796676	chr15:73680284	NA	0.5	9.43	0.4	2.02e-19	Resting heart rate;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00367659	chr17:33288544	CCT6B;ZNF830	0.4	7.08	0.31	5.35e-12	Bilirubin levels;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg14926445	chr8:58193284	C8orf71	-0.73	-9.22	-0.39	1.05e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6540556	0.954	rs3753606	chr1:209937212	C/T	cg23920097	chr1:209922102	NA	0.43	7.74	0.34	6.12e-14	Red blood cell count;
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs9901112	chr17:61730617	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.32	-0.32	1.1e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9486715	0.790	rs2971602	chr6:97022468	C/T	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.27	-0.6	2.18e-47	Headache;
LGG	cis	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg26384229	chr12:38710491	ALG10B	0.94	22.22	0.72	5.52e-75	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2985684	1.000	rs2224949	chr14:50096560	A/G	cg02151108	chr14:50098012	C14orf104	0.47	10.14	0.43	5.87e-22	Carotid intima media thickness;
LGG	cis	rs9388451	0.531	rs9401850	chr6:126151000	T/G	cg05901451	chr6:126070800	HEY2	-0.58	-10.43	-0.44	5.24e-23	Brugada syndrome;
LGG	cis	rs7267979	1.000	rs422844	chr20:25445591	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4319547	0.656	rs10773075	chr12:122814236	G/A	cg23029597	chr12:123009494	RSRC2	-0.9	-16.8	-0.62	8.43e-50	Body mass index;
LGG	cis	rs7914558	1.000	rs12780843	chr10:104769335	G/C	cg04362960	chr10:104952993	NT5C2	0.53	10.13	0.43	6.18e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1552244	1.000	rs7611218	chr3:10063960	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.12	0.39	2.24e-18	Alzheimer's disease;
LGG	cis	rs9811920	0.638	rs793503	chr3:99588070	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.51	8.83	0.38	2.23e-17	Axial length;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.52	-0.37	2.34e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg15394860	chr11:2017084	H19	0.65	14.4	0.56	3.98e-39	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.17e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs853679	0.517	rs17711344	chr6:28077602	A/G	cg18032046	chr6:28092343	ZSCAN16	0.57	7.59	0.33	1.75e-13	Depression;
LGG	cis	rs1707322	0.686	rs61784833	chr1:46233772	T/C	cg03146154	chr1:46216737	IPP	0.58	10.75	0.45	3.18e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7395662	0.591	rs7482521	chr11:48609735	G/A	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	1.94e-11	HDL cholesterol;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg13482628	chr17:19912719	NA	0.6	11.86	0.48	1.55e-28	Schizophrenia;
LGG	cis	rs807669	0.934	rs1780643	chr22:19191725	T/C	cg02655711	chr22:19163373	SLC25A1	0.77	15.63	0.59	1.56e-44	Metabolite levels;
LGG	cis	rs7566780	0.516	rs7567636	chr2:16664016	A/C	cg09580478	chr2:16689509	NA	0.43	6.7	0.3	6.06e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs7590368	0.774	rs3932106	chr2:10916408	C/T	cg15705551	chr2:10952987	PDIA6	0.59	8.23	0.36	1.9e-15	Educational attainment (years of education);
LGG	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.26	-0.32	1.7e-12	Hemoglobin concentration;
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg24687543	chr11:63912206	MACROD1	0.52	7.66	0.34	1.11e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg10621924	chr7:39171070	POU6F2	0.45	9.12	0.39	2.29e-18	IgG glycosylation;
LGG	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg16325326	chr1:53192061	ZYG11B	0.73	16.82	0.62	6.53e-50	Monocyte count;
LGG	cis	rs17001868	0.568	rs55769635	chr22:40790101	G/A	cg07138101	chr22:40742427	ADSL	0.66	8.63	0.37	9.94e-17	Mammographic density (dense area);
LGG	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	8.8	0.38	2.75e-17	Mean corpuscular volume;
LGG	trans	rs11098499	0.644	rs10012252	chr4:120559139	T/C	cg25214090	chr10:38739885	LOC399744	0.57	10.34	0.43	1.13e-22	Corneal astigmatism;
LGG	cis	rs62400317	0.762	rs12208332	chr6:44903221	C/T	cg20913747	chr6:44695427	NA	-0.66	-11.25	-0.46	4.09e-26	Total body bone mineral density;
LGG	cis	rs35110281	0.626	rs162389	chr21:44936227	T/C	cg04455712	chr21:45112962	RRP1B	0.46	8.85	0.38	1.87e-17	Mean corpuscular volume;
LGG	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg27411982	chr8:10470053	RP1L1	0.43	7.42	0.33	5.8e-13	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg08280861	chr8:58055591	NA	0.51	6.77	0.3	4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.701	rs10880260	chr12:42561398	A/G	cg19980929	chr12:42632907	YAF2	0.37	8.19	0.36	2.64e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs977987	0.815	rs1364078	chr16:75396881	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.36	0.43	9.54e-23	Dupuytren's disease;
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg08499158	chr17:42289980	UBTF	-0.6	-11.44	-0.47	7.39e-27	Total body bone mineral density;
LGG	cis	rs3087591	0.708	rs35109242	chr17:29649223	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	cis	rs2421770	0.532	rs3103239	chr11:35352117	A/C	cg10331829	chr11:35343789	SLC1A2	-0.34	-7.62	-0.33	1.43e-13	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs921968	0.643	rs589967	chr2:219445165	T/C	cg01130898	chr2:219473002	PLCD4	-0.39	-6.69	-0.3	6.41e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6062788	0.524	rs6122360	chr20:61698520	G/A	cg04883260	chr20:61718941	NA	-0.43	-9.64	-0.41	3.57e-20	Body mass index;
LGG	cis	rs2243480	1.000	rs78803505	chr7:65382572	A/T	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs62244186	0.566	rs55852922	chr3:44826188	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	0.45	7.91	0.35	1.9e-14	Depressive symptoms;
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg01069141	chr11:67398826	TBX10;NUDT8	0.42	8.32	0.36	9.71e-16	Mean corpuscular volume;
LGG	cis	rs7762018	1.000	rs11961560	chr6:170130121	T/C	cg17545662	chr6:170176663	C6orf70	0.69	8.68	0.37	6.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs12517041	1.000	rs34694473	chr5:23311661	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.24	-0.46	4.24e-26	Calcium levels;
LGG	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.72e-21	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7944735	0.817	rs6485784	chr11:47832260	C/T	cg15704280	chr7:45808275	SEPT13	0.62	7.87	0.34	2.52e-14	Intraocular pressure;
LGG	cis	rs4930103	0.935	rs4929987	chr11:2028591	C/G	cg18511798	chr11:2018149	H19;MIR675	-0.75	-14.84	-0.57	4.99e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	13.06	0.52	2.01e-33	Cognitive test performance;
LGG	cis	rs4566357	0.615	rs12328876	chr2:227918899	G/T	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.93e-18	Coronary artery disease;
LGG	cis	rs10231759	0.583	rs55649631	chr7:150512828	A/C	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.36	8.17	0.35	2.98e-15	Height;
LGG	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg06917634	chr15:78832804	PSMA4	0.69	13.59	0.53	1.22e-35	Sudden cardiac arrest;
LGG	cis	rs1799949	0.536	rs4793227	chr17:41412250	A/C	cg04503457	chr17:41445688	NA	-0.4	-9.83	-0.42	7.86e-21	Menopause (age at onset);
LGG	cis	rs1784581	0.588	rs4131681	chr6:162422167	T/G	cg17173639	chr6:162384350	PARK2	0.64	13.5	0.53	2.92e-35	Itch intensity from mosquito bite;
LGG	cis	rs1153858	1.000	rs12595087	chr15:45655232	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs59104589	0.959	rs3771555	chr2:242322680	C/T	cg10021735	chr2:242295487	FARP2	-0.4	-7.35	-0.32	8.93e-13	Fibrinogen levels;
LGG	cis	rs7927592	0.956	rs12274114	chr11:68255577	A/C	cg16797656	chr11:68205561	LRP5	0.4	6.99	0.31	9.55e-12	Total body bone mineral density;
LGG	cis	rs1372520	0.577	rs2737021	chr4:90739992	T/A	cg15133208	chr4:90757351	SNCA	-0.4	-8.21	-0.36	2.25e-15	Neuroticism;
LGG	trans	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg25214090	chr10:38739885	LOC399744	0.68	12.22	0.49	5.6e-30	Corneal astigmatism;
LGG	cis	rs7027203	0.828	rs4344139	chr9:96600298	T/C	cg13679303	chr9:96623674	NA	-0.39	-6.89	-0.3	1.85e-11	DNA methylation (variation);
LGG	cis	rs4880487	0.888	rs10794730	chr10:1247022	C/T	cg03183215	chr10:1252341	ADARB2	-0.71	-16.56	-0.61	1.08e-48	Migraine;
LGG	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg04617936	chr2:214353	NA	-0.41	-7.52	-0.33	2.95e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9460578	0.634	rs12215519	chr6:20800635	G/C	cg13405222	chr6:20811065	CDKAL1	0.65	11.52	0.47	3.64e-27	Breast cancer;
LGG	cis	rs6502050	0.835	rs62078306	chr17:80085341	A/G	cg11859384	chr17:80120422	CCDC57	0.46	8.02	0.35	8.59e-15	Life satisfaction;
LGG	cis	rs11722228	0.549	rs41268389	chr4:10099277	G/A	cg08250081	chr4:10125330	NA	0.67	12.34	0.5	1.9e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9814567	1.000	rs9819532	chr3:134288644	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg19524238	chr7:2802976	GNA12	0.36	8.25	0.36	1.69e-15	Height;
LGG	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.45e-13	HDL cholesterol;
LGG	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg18876405	chr7:65276391	NA	-0.6	-11.4	-0.47	1.01e-26	Aortic root size;
LGG	cis	rs7917772	0.503	rs11191326	chr10:104302959	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.37	0.32	8.02e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs992157	0.737	rs3731860	chr2:219156979	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.6	-9.83	-0.42	7.92e-21	Colorectal cancer;
LGG	cis	rs13082711	0.911	rs11716531	chr3:27457208	G/A	cg02860705	chr3:27208620	NA	0.74	13.24	0.52	3.78e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4423214	1.000	rs732934	chr11:71186476	G/A	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.12	-0.52	1.14e-33	Vitamin D levels;
LGG	cis	rs7119	0.717	rs11634174	chr15:77811232	A/T	cg10437265	chr15:77819839	NA	0.25	7.08	0.31	5.23e-12	Type 2 diabetes;
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg18379455	chr17:41446167	NA	-0.32	-7.41	-0.33	5.88e-13	Menopause (age at onset);
LGG	trans	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.87	0.3	2.1e-11	Retinal vascular caliber;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg22605179	chr22:29664171	EWSR1;RHBDD3	0.4	6.67	0.3	7.26e-11	Body mass index;
LGG	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.44	-0.33	5.09e-13	Testicular germ cell tumor;
LGG	cis	rs9463078	0.845	rs1360196	chr6:44952642	G/A	cg25276700	chr6:44698697	NA	-0.37	-7.85	-0.34	2.88e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg02800362	chr5:177631904	HNRNPAB	0.77	13.32	0.53	1.66e-34	Obesity-related traits;
LGG	cis	rs28595532	0.720	rs72670231	chr4:119312908	C/T	cg21605333	chr4:119757512	SEC24D	0.89	8.37	0.36	6.95e-16	Cannabis dependence symptom count;
LGG	cis	rs10504229	1.000	rs59549824	chr8:58186205	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs873946	0.648	rs3750578	chr10:134563366	A/G	cg13271783	chr10:134563150	INPP5A	-0.55	-8.22	-0.36	2.05e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.09	-0.35	5.13e-15	IgG glycosylation;
LGG	cis	rs651907	0.640	rs771578	chr3:101613434	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	8.39	0.36	5.9e-16	Colorectal cancer;
LGG	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.77	0.34	4.99e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg02353165	chr6:42928485	GNMT	0.47	14.16	0.55	4.29e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11864453	0.713	rs3764312	chr16:72125733	A/C	cg23815491	chr16:72088622	HP	0.51	11.56	0.47	2.46e-27	Fibrinogen levels;
LGG	cis	rs13102973	0.932	rs13112935	chr4:135829379	T/C	cg14419869	chr4:135874104	NA	0.54	9.84	0.42	7.14e-21	Subjective well-being;
LGG	cis	rs225245	0.782	rs225272	chr17:33969911	T/C	cg05299278	chr17:33885742	SLFN14	0.43	8.24	0.36	1.78e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12478296	0.901	rs6731775	chr2:242999443	T/C	cg18898632	chr2:242989856	NA	-0.73	-8.78	-0.38	3.28e-17	Obesity-related traits;
LGG	cis	rs12579753	0.917	rs10862361	chr12:82197946	T/C	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs17539620	0.534	rs76931320	chr6:154833508	G/A	cg17771515	chr6:154831774	CNKSR3	0.62	7.6	0.33	1.64e-13	Lipoprotein (a) levels;
LGG	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.94e-20	Colorectal cancer;
LGG	cis	rs7084402	1.000	rs36097682	chr10:60269738	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	cis	rs868036	0.718	rs28587941	chr15:68122509	T/C	cg22044901	chr15:68126292	NA	-0.39	-6.72	-0.3	5.21e-11	Restless legs syndrome;
LGG	cis	rs2842992	0.830	rs2025190	chr6:160138241	C/T	cg11366901	chr6:160182831	ACAT2	1.05	17.02	0.62	8.19e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.29	-0.6	1.68e-47	Skin colour saturation;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg25072359	chr17:41440525	NA	0.51	10.0	0.42	1.83e-21	Menopause (age at onset);
LGG	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.22e-45	HDL cholesterol levels;
LGG	trans	rs2727020	0.617	rs1917311	chr11:49422665	C/T	cg03929089	chr4:120376271	NA	-0.96	-20.4	-0.69	1.88e-66	Coronary artery disease;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg13732083	chr21:47605072	C21orf56	0.55	9.66	0.41	3.08e-20	Testicular germ cell tumor;
LGG	cis	rs4919044	0.808	rs1339820	chr10:94818382	A/C	cg05127821	chr10:94822908	CYP26C1	0.48	8.05	0.35	7.22e-15	Coronary artery disease;
LGG	cis	rs7086627	0.515	rs11202957	chr10:82209592	A/G	cg00277334	chr10:82204260	NA	-0.52	-12.53	-0.5	3.34e-31	Post bronchodilator FEV1;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04008888	chr11:68622739	NA	-0.54	-11.63	-0.48	1.32e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9640161	0.702	rs3735175	chr7:150020457	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.59	-0.59	2.37e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg14926445	chr8:58193284	C8orf71	-0.93	-13.06	-0.52	2.14e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.7	0.56	2.06e-40	Cognitive test performance;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg13206674	chr6:150067644	NUP43	0.64	14.5	0.56	1.5e-39	Lung cancer;
LGG	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg25883020	chr8:41504993	NKX6-3	0.33	7.27	0.32	1.58e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs7904368	0.951	rs7074647	chr10:16855455	T/C	cg23933602	chr10:16859644	RSU1	0.66	10.02	0.42	1.59e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6952808	0.575	rs2056479	chr7:1954273	G/A	cg21782813	chr7:2030301	MAD1L1	0.37	8.52	0.37	2.34e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.09e-17	Mean corpuscular volume;
LGG	cis	rs2762353	0.538	rs35670731	chr6:25728235	C/T	cg03264133	chr6:25882463	NA	0.74	14.2	0.55	3.14e-38	Blood metabolite levels;
LGG	trans	rs11098499	0.697	rs28458294	chr4:120238924	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.62e-25	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg14668632	chr7:2872130	GNA12	-0.37	-7.46	-0.33	4.28e-13	Height;
LGG	cis	rs10267417	0.535	rs6946403	chr7:19861549	C/T	cg05791153	chr7:19748676	TWISTNB	0.58	7.47	0.33	3.93e-13	Night sleep phenotypes;
LGG	cis	rs56283067	0.578	rs72862930	chr6:45361883	C/T	cg18551225	chr6:44695536	NA	-0.59	-8.7	-0.37	5.72e-17	Total body bone mineral density;
LGG	cis	rs11696845	0.712	rs6130685	chr20:43366730	T/G	cg25301532	chr20:43378953	KCNK15	0.45	11.02	0.46	3.21e-25	Obesity-related traits;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	ch.6.143706070F	chr6:143664377	NA	-0.48	-7.77	-0.34	5.14e-14	Body fat percentage;
LGG	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg00543991	chr22:32367038	NA	0.74	8.53	0.37	2.03e-16	Childhood ear infection;
LGG	trans	rs4332037	0.707	rs73046323	chr7:1882795	G/A	cg10840412	chr1:235813424	GNG4	0.54	7.48	0.33	3.65e-13	Bipolar disorder;
LGG	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg11764359	chr7:65958608	NA	0.8	15.09	0.57	3.74e-42	Aortic root size;
LGG	cis	rs28595532	0.920	rs17325017	chr4:119774607	A/G	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs35110281	0.807	rs2838325	chr21:45014284	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.53	-9.5	-0.4	1.14e-19	Mean corpuscular volume;
LGG	cis	rs9788682	1.000	rs12441426	chr15:78812329	T/C	cg24631222	chr15:78858424	CHRNA5	0.49	7.42	0.33	5.69e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg05802129	chr4:122689817	NA	0.44	6.81	0.3	3.08e-11	Type 2 diabetes;
LGG	trans	rs11039798	0.588	rs666165	chr11:48457439	C/T	cg15704280	chr7:45808275	SEPT13	-0.71	-9.76	-0.41	1.38e-20	Axial length;
LGG	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.57	-0.37	1.56e-16	Platelet distribution width;
LGG	trans	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg27661571	chr11:113659931	NA	0.47	6.78	0.3	3.56e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10791097	0.694	rs1893018	chr11:130756632	T/C	cg12179176	chr11:130786555	SNX19	0.84	17.36	0.63	2.4e-52	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg13010199	chr12:38710504	ALG10B	-0.48	-9.24	-0.39	9.13e-19	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg16041611	chr6:43139680	SRF	-0.44	-7.27	-0.32	1.56e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs240110	0.539	rs6934256	chr6:101338728	G/A	cg09795085	chr6:101329169	ASCC3	0.47	7.74	0.34	6.39e-14	Neuroticism;
LGG	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg19508488	chr2:152266495	RIF1	0.61	11.07	0.46	1.96e-25	Lung cancer;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg24503407	chr1:205819492	PM20D1	-0.8	-18.42	-0.65	2.98e-57	Menarche (age at onset);
LGG	cis	rs4919694	1.000	rs12257941	chr10:104833161	C/T	cg04362960	chr10:104952993	NT5C2	1.06	15.51	0.58	5.26e-44	Arsenic metabolism;
LGG	cis	rs798554	0.686	rs2644298	chr7:2858448	G/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.89	-0.38	1.39e-17	Height;
LGG	cis	rs1729951	0.546	rs12054408	chr3:136677645	T/C	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	5.86e-21	Neuroticism;
LGG	cis	rs10504229	0.593	rs11781042	chr8:57993056	A/T	cg11062466	chr8:58055876	NA	0.44	6.95	0.31	1.28e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3106136	0.934	rs4693004	chr4:95168456	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.1	-0.35	4.81e-15	Capecitabine sensitivity;
LGG	cis	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.963	rs4882146	chr11:48660169	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.33	-0.32	1.01e-12	HDL cholesterol;
LGG	cis	rs28830936	1.000	rs112896623	chr15:42001845	C/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.76	-0.3	4.05e-11	Diastolic blood pressure;
LGG	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg09237302	chr4:906077	GAK	-0.46	-7.84	-0.34	3.21e-14	Type 2 diabetes;
LGG	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg08344181	chr3:125677491	NA	-0.83	-7.74	-0.34	6.49e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7737355	0.947	rs6882552	chr5:130841493	A/G	cg06307176	chr5:131281290	NA	0.55	9.26	0.4	7.7e-19	Life satisfaction;
LGG	cis	rs4665809	0.887	rs2384324	chr2:26354239	A/G	cg08470875	chr2:26401718	FAM59B	-0.37	-6.8	-0.3	3.14e-11	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg19847130	chr8:10466454	RP1L1	-0.31	-6.78	-0.3	3.6e-11	Mood instability;
LGG	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg06697600	chr4:7070879	GRPEL1	0.52	8.01	0.35	9.23e-15	Monocyte percentage of white cells;
LGG	cis	rs3096299	0.967	rs3102341	chr16:89450744	G/A	cg06640241	chr16:89574553	SPG7	0.73	12.51	0.5	3.86e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg27490568	chr2:178487706	NA	0.81	14.29	0.55	1.25e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs963731	0.649	rs2305516	chr2:39198966	C/T	cg04010122	chr2:39346883	SOS1	0.78	6.91	0.31	1.57e-11	Corticobasal degeneration;
LGG	cis	rs6141769	0.542	rs12480157	chr20:31262920	A/G	cg13636640	chr20:31349939	DNMT3B	-0.47	-7.11	-0.31	4.46e-12	Subjective well-being;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg19147804	chr7:1989927	MAD1L1	-0.48	-9.44	-0.4	1.89e-19	Schizophrenia;
LGG	cis	rs12200782	1.000	rs72844495	chr6:26610640	T/C	cg11502198	chr6:26597334	ABT1	-0.88	-7.51	-0.33	3.1400000000000003e-13	Small cell lung carcinoma;
LGG	cis	rs6956675	0.915	rs4285375	chr7:62650353	C/T	cg08930214	chr7:62859557	LOC100287834	0.45	7.62	0.33	1.4e-13	Obesity-related traits;
LGG	cis	rs11758351	0.587	rs16891456	chr6:26234127	T/C	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs17102423	0.755	rs7161394	chr14:65563309	G/T	cg11161011	chr14:65562177	MAX	-0.78	-15.88	-0.59	1.26e-45	Obesity-related traits;
LGG	cis	rs11630290	1.000	rs72750986	chr15:63996338	C/A	cg12036633	chr15:63758958	NA	-0.64	-8.75	-0.38	4.11e-17	Iris characteristics;
LGG	cis	rs7474896	0.515	rs2749582	chr10:38275284	A/G	cg00409905	chr10:38381863	ZNF37A	0.47	7.04	0.31	7.1e-12	Obesity (extreme);
LGG	cis	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-11.8	-0.48	2.84e-28	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2602381	0.599	rs4583459	chr2:234593374	G/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.38	-6.76	-0.3	4.11e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs4665809	0.941	rs3177055	chr2:26359315	G/A	cg08470875	chr2:26401718	FAM59B	-0.37	-6.86	-0.3	2.29e-11	Gut microbiome composition (summer);
LGG	trans	rs4843747	0.803	rs72818522	chr16:88059144	C/T	cg26811252	chr16:29126840	RRN3P2	0.7	10.74	0.45	3.4e-24	Menopause (age at onset);
LGG	cis	rs6121246	0.909	rs7354225	chr20:30296881	C/T	cg04935436	chr20:30431758	NA	0.43	7.4	0.33	6.57e-13	Mean corpuscular hemoglobin;
LGG	trans	rs11227306	0.902	rs625652	chr11:65641931	T/A	cg17712092	chr4:129076599	LARP1B	-0.57	-10.12	-0.43	7.28e-22	DNA methylation (variation);
LGG	cis	rs113835537	0.597	rs3825065	chr11:66311011	A/G	cg24851651	chr11:66362959	CCS	0.46	7.85	0.34	2.83e-14	Airway imaging phenotypes;
LGG	cis	rs3859192	0.539	rs2305481	chr17:38138624	G/A	cg17467752	chr17:38218738	THRA	-0.6	-9.78	-0.41	1.19e-20	White blood cell count;
LGG	cis	rs9547996	0.959	rs9532095	chr13:38251689	T/G	cg17979426	chr13:38220150	TRPC4	-0.41	-8.04	-0.35	7.48e-15	Diastolic blood pressure;
LGG	cis	rs9427116	0.502	rs903323	chr1:154572228	A/G	cg11650704	chr1:154556575	ADAR	0.49	9.72	0.41	1.97e-20	Blood protein levels;
LGG	cis	rs6977660	0.660	rs10269891	chr7:19816063	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs989128	0.642	rs873839	chr17:48631857	G/A	cg20467136	chr17:48638190	CACNA1G	0.48	6.8	0.3	3.34e-11	Type 2 diabetes;
LGG	cis	rs597539	0.503	rs7131462	chr11:68610143	G/A	cg01988459	chr11:68622903	NA	0.41	8.45	0.37	3.84e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17209837	0.607	rs4148811	chr7:87101486	T/G	cg25823085	chr7:87105416	ABCB4	0.3	7.41	0.33	6.04e-13	Gallbladder cancer;
LGG	cis	rs7267979	0.868	rs6138546	chr20:25216534	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.56	0.44	1.64e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4740619	0.688	rs1927698	chr9:15934144	T/G	cg14451791	chr9:16040625	NA	-0.41	-10.15	-0.43	5.34e-22	Body mass index;
LGG	cis	rs7618915	1.000	rs7618915	chr3:52279594	G/A	cg18404041	chr3:52824283	ITIH1	-0.43	-7.63	-0.33	1.36e-13	Bipolar disorder;
LGG	cis	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg26384229	chr12:38710491	ALG10B	0.95	21.39	0.7	4.4e-71	Bladder cancer;
LGG	cis	rs7588746	0.868	rs12104649	chr2:201128832	C/T	cg17644776	chr2:200775616	C2orf69	-0.5	-7.26	-0.32	1.7e-12	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs4073582	0.595	rs801739	chr11:65922589	A/G	cg16950941	chr11:66035639	RAB1B	0.55	10.28	0.43	1.86e-22	Gout;
LGG	cis	rs2404602	0.583	rs4381566	chr15:76589262	A/G	cg22467129	chr15:76604101	ETFA	-0.41	-6.76	-0.3	4.06e-11	Blood metabolite levels;
LGG	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs4740619	0.935	rs10810399	chr9:15562879	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.33	-0.43	1.23e-22	Body mass index;
LGG	cis	rs898097	0.690	rs3785520	chr17:80895745	T/C	cg15664640	chr17:80829946	TBCD	0.72	12.71	0.51	5.99e-32	Breast cancer;
LGG	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg02487422	chr3:49467188	NICN1	0.58	10.71	0.45	4.66e-24	Resting heart rate;
LGG	cis	rs1577917	0.958	rs11756510	chr6:86699794	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.98	-0.42	2.19e-21	Response to antipsychotic treatment;
LGG	cis	rs62025270	0.649	rs12148610	chr15:86245928	A/G	cg25843651	chr15:86329602	KLHL25	0.56	8.55	0.37	1.77e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs12478296	0.786	rs28802397	chr2:243049730	G/A	cg06360820	chr2:242988706	NA	-0.91	-11.57	-0.47	2.2e-27	Obesity-related traits;
LGG	cis	rs7766436	0.524	rs66992531	chr6:22511065	T/C	cg13666174	chr6:22585274	NA	-0.43	-8.4	-0.36	5.43e-16	Coronary artery disease;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg05665937	chr4:1216051	CTBP1	0.44	7.97	0.35	1.23e-14	Obesity-related traits;
LGG	cis	rs2718058	0.630	rs2718045	chr7:37795438	C/G	cg15028436	chr7:37888078	TXNDC3	-0.49	-7.93	-0.35	1.7e-14	Alzheimer's disease (late onset);
LGG	cis	rs9747201	0.963	rs4789729	chr17:80146089	G/A	cg09264619	chr17:80180166	NA	-0.5	-10.02	-0.42	1.56e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1010254	0.510	rs72808345	chr5:151759695	G/A	cg08593883	chr5:151785301	NMUR2	-0.45	-6.89	-0.3	1.83e-11	Optic nerve measurement (cup area);
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	trans	rs11875185	0.510	rs17754534	chr18:55596126	C/G	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs17376456	0.877	rs12153788	chr5:93405437	A/G	cg25358565	chr5:93447407	FAM172A	1.36	16.72	0.61	1.94e-49	Diabetic retinopathy;
LGG	trans	rs9388451	0.874	rs3734634	chr6:126111800	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.51	-9.23	-0.39	9.96e-19	Brugada syndrome;
LGG	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.8	14.9	0.57	2.68e-41	Subjective well-being;
LGG	cis	rs6429082	0.875	rs4659524	chr1:235583354	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.46	-7.64	-0.33	1.22e-13	Adiposity;
LGG	cis	rs1577917	0.681	rs4348284	chr6:86350394	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.26	-0.46	3.53e-26	Response to antipsychotic treatment;
LGG	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg00343986	chr7:65444356	GUSB	0.42	7.21	0.32	2.34e-12	Aortic root size;
LGG	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg27476859	chr7:2772710	GNA12	0.52	10.13	0.43	6.62e-22	Height;
LGG	cis	rs7605378	0.528	rs1704190	chr2:200760629	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	7.75	0.34	5.82e-14	Osteoporosis;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg26174226	chr8:58114915	NA	-0.6	-8.19	-0.36	2.66e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg14926445	chr8:58193284	C8orf71	0.92	12.6	0.51	1.69e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs734999	0.545	rs7368072	chr1:2556125	C/T	cg20673091	chr1:2541236	MMEL1	0.75	18.11	0.64	8.15e-56	Ulcerative colitis;
LGG	cis	rs9303401	0.659	rs56162835	chr17:56687315	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs600231	0.719	rs7114809	chr11:65251444	A/G	cg17120908	chr11:65337727	SSSCA1	-0.52	-9.25	-0.39	8.54e-19	Bone mineral density;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg08621203	chr6:150244597	RAET1G	0.4	6.77	0.3	3.93e-11	Lung cancer;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg10295955	chr4:187884368	NA	1.14	30.3	0.82	6.01e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3771570	1.000	rs62193175	chr2:242284405	G/A	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg02825527	chr7:2087843	MAD1L1	-0.36	-7.22	-0.32	2.16e-12	Neuroticism;
LGG	trans	rs1814175	0.645	rs12364337	chr11:49942580	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs11148252	0.557	rs9536223	chr13:53233194	A/T	cg05335186	chr13:53173507	NA	0.75	18.82	0.66	4.4e-59	Lewy body disease;
LGG	cis	rs6032067	0.641	rs6017495	chr20:43756955	G/A	cg10761708	chr20:43804764	PI3	0.71	10.42	0.44	5.73e-23	Blood protein levels;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.86	-0.48	1.56e-28	Obesity-related traits;
LGG	cis	rs7917772	0.503	rs10748825	chr10:104293609	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10744422	1.000	rs3852536	chr12:123333824	C/T	cg25930673	chr12:123319894	HIP1R	-0.74	-9.31	-0.4	4.96e-19	Schizophrenia;
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01570182	chr17:44337453	NA	0.71	11.48	0.47	4.98e-27	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4853012	0.887	rs6737314	chr2:74339586	A/G	cg20891558	chr2:74357851	NA	0.45	8.19	0.36	2.52e-15	Gestational age at birth (maternal effect);
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs4737010	0.536	rs6474365	chr8:41662940	G/T	cg17182837	chr8:41585554	ANK1	-0.55	-7.87	-0.34	2.46e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg02725872	chr8:58115012	NA	-0.66	-9.11	-0.39	2.41e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg10840412	chr1:235813424	GNG4	0.52	7.0	0.31	9.25e-12	Bipolar disorder;
LGG	cis	rs9611565	0.765	rs132915	chr22:41805782	T/C	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05935374	chr11:82782929	RAB30	0.42	6.92	0.31	1.48e-11	Gut microbiome composition (summer);
LGG	cis	rs9398803	0.865	rs9401883	chr6:126797111	A/G	cg19875578	chr6:126661172	C6orf173	0.58	10.51	0.44	2.48e-23	Male-pattern baldness;
LGG	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg17971929	chr21:40555470	PSMG1	-0.53	-8.96	-0.38	8.08e-18	Menarche (age at onset);
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.71	0.45	4.67e-24	Personality dimensions;
LGG	cis	rs208520	0.526	rs9354370	chr6:66808209	C/T	cg07460842	chr6:66804631	NA	1.14	31.68	0.83	5.3e-118	Exhaled nitric oxide output;
LGG	trans	rs7937682	0.575	rs7127010	chr11:111770782	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs9815354	0.812	rs116393551	chr3:41865476	G/A	cg03022575	chr3:42003672	ULK4	0.83	9.64	0.41	3.59e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.29	-0.53	2.17e-34	Alzheimer's disease;
LGG	cis	rs988958	0.526	rs12712830	chr2:42252955	T/G	cg27428208	chr2:42229179	NA	0.48	7.58	0.33	1.91e-13	Hypospadias;
LGG	cis	rs7928758	0.945	rs28378882	chr11:134280503	G/T	cg25213107	chr11:134282864	B3GAT1	0.98	11.51	0.47	4.02e-27	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs2562456	0.793	rs62110424	chr19:21599637	A/C	cg00806126	chr19:22604979	ZNF98	-0.58	-7.71	-0.34	7.58e-14	Pain;
LGG	cis	rs9326248	0.569	rs11216161	chr11:116721201	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.54	6.74	0.3	4.78e-11	Blood protein levels;
LGG	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg11494091	chr17:61959527	GH2	0.6	9.99	0.42	2.09e-21	Height;
LGG	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg09795085	chr6:101329169	ASCC3	-0.43	-7.3	-0.32	1.29e-12	Neuroticism;
LGG	cis	rs9472414	0.510	rs609699	chr6:44705266	G/A	cg20913747	chr6:44695427	NA	0.46	7.61	0.33	1.59e-13	Height;
LGG	cis	rs2195525	0.572	rs10790290	chr11:119218542	T/C	cg01451205	chr11:119252210	USP2	0.41	6.87	0.3	2.08e-11	Urate levels;
LGG	cis	rs73001065	0.688	rs59148799	chr19:19484008	A/G	cg03709012	chr19:19516395	GATAD2A	0.95	10.91	0.45	8.34e-25	LDL cholesterol;
LGG	trans	rs12310956	0.510	rs1825903	chr12:33870437	G/C	cg13010199	chr12:38710504	ALG10B	0.46	8.79	0.38	3.06e-17	Morning vs. evening chronotype;
LGG	cis	rs4555082	0.957	rs2816629	chr14:105737261	G/A	cg13114125	chr14:105738426	BRF1	-0.87	-17.37	-0.63	2.13e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7607369	0.648	rs7559490	chr2:219656867	A/T	cg01130898	chr2:219473002	PLCD4	0.41	6.73	0.3	5.01e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09341008	chr10:64576118	EGR2	0.42	7.14	0.31	3.58e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs992157	0.710	rs13026485	chr2:219057984	C/T	cg00012203	chr2:219082015	ARPC2	-0.81	-16.23	-0.6	3.05e-47	Colorectal cancer;
LGG	cis	rs16854884	0.586	rs6795008	chr3:143738421	A/G	cg06585982	chr3:143692056	C3orf58	0.68	12.34	0.5	1.84e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg26818010	chr10:134567672	INPP5A	-0.72	-11.05	-0.46	2.28e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6963495	0.818	rs1721498	chr7:105178819	A/C	cg21420622	chr7:105162941	PUS7	0.46	7.18	0.32	2.78e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs10870270	1.000	rs11146354	chr10:133774757	A/G	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.64	-0.51	1.19e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs34467563	0.872	rs56138709	chr8:97357453	C/A	cg22138393	chr8:97340270	PTDSS1	0.3	6.68	0.3	6.76e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.81	15.94	0.6	6.76e-46	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1577917	1.000	rs10944161	chr6:86630376	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	4.98e-20	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg05665937	chr4:1216051	CTBP1	0.65	12.45	0.5	6.77e-31	Obesity-related traits;
LGG	cis	rs10540	1.000	rs116101630	chr11:506826	G/C	cg19913688	chr11:428466	ANO9	-0.62	-7.78	-0.34	4.64e-14	Body mass index;
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg02158880	chr13:53174818	NA	0.46	9.44	0.4	1.86e-19	Lewy body disease;
LGG	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03635649	chr5:41510801	PLCXD3	0.42	6.66	0.3	7.83e-11	Gut microbiome composition (summer);
LGG	cis	rs9633740	0.545	rs2343306	chr10:82230146	A/G	cg01528321	chr10:82214614	TSPAN14	-1.11	-19.57	-0.67	1.34e-62	Post bronchodilator FEV1;
LGG	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg08847335	chr10:891726	LARP4B	-0.49	-8.75	-0.38	3.89e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs5769765	0.954	rs5769762	chr22:50264042	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs4973397	0.810	rs12999051	chr2:232276992	T/A	cg11378575	chr2:232265004	B3GNT7	0.56	9.86	0.42	6.2e-21	Anti-saccade response;
LGG	cis	rs908922	0.676	rs491077	chr1:152519570	C/A	cg09873164	chr1:152488093	CRCT1	0.63	15.34	0.58	3.23e-43	Hair morphology;
LGG	cis	rs6032067	0.852	rs17424751	chr20:43814622	T/C	cg10761708	chr20:43804764	PI3	0.76	11.93	0.49	8.26e-29	Blood protein levels;
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg16920238	chr17:80076378	CCDC57	0.32	7.28	0.32	1.43e-12	Life satisfaction;
LGG	cis	rs11628318	0.614	rs11847932	chr14:103185435	T/G	cg23461800	chr14:103021989	NA	0.49	7.5	0.33	3.37e-13	Platelet count;
LGG	cis	rs4774899	1.000	rs12909016	chr15:57518557	G/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.1	-0.31	4.71e-12	Urinary tract infection frequency;
LGG	cis	rs2486288	0.656	rs6493144	chr15:45573489	C/G	cg26924012	chr15:45694286	SPATA5L1	0.63	10.99	0.45	4.12e-25	Glomerular filtration rate;
LGG	cis	rs116095464	0.558	rs9312956	chr5:201812	T/C	cg22857025	chr5:266934	NA	-1.56	-25.53	-0.76	2.22e-90	Breast cancer;
LGG	cis	rs66573146	0.539	rs56659624	chr4:7069377	G/C	cg02503808	chr4:7069936	GRPEL1	-0.94	-8.72	-0.38	5.13e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs873946	0.586	rs12774727	chr10:134569910	T/C	cg26818010	chr10:134567672	INPP5A	-0.77	-11.82	-0.48	2.41e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs561341	1.000	rs506766	chr17:30289659	T/C	cg20587970	chr11:113659929	NA	-1.34	-22.75	-0.73	1.74e-77	Hip circumference adjusted for BMI;
LGG	cis	rs11168187	0.891	rs1235152	chr12:48104746	G/C	cg12761788	chr12:48120090	P11	-0.5	-8.35	-0.36	7.77e-16	Vertical cup-disc ratio;
LGG	cis	rs72945132	1.000	rs72945132	chr11:70113901	G/C	cg14191688	chr11:70257035	CTTN	0.58	7.94	0.35	1.52e-14	Coronary artery disease;
LGG	cis	rs694739	0.628	rs10897487	chr11:64140704	C/T	cg22916017	chr11:64110731	CCDC88B	0.47	9.45	0.4	1.66e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg15556689	chr8:8085844	FLJ10661	0.51	8.92	0.38	1.08e-17	Retinal vascular caliber;
LGG	trans	rs7944735	0.507	rs7114598	chr11:48101766	C/T	cg15704280	chr7:45808275	SEPT13	0.67	9.5	0.4	1.17e-19	Intraocular pressure;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg11494091	chr17:61959527	GH2	0.59	9.59	0.41	5.61e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8067545	0.641	rs169412	chr17:19851875	G/T	cg04132472	chr17:19861366	AKAP10	0.26	7.15	0.32	3.36e-12	Schizophrenia;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg02158880	chr13:53174818	NA	0.41	8.14	0.35	3.56e-15	Lewy body disease;
LGG	cis	rs6089829	0.962	rs2277768	chr20:61666823	T/C	cg03213289	chr20:61660250	NA	0.66	14.56	0.56	7.9e-40	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs62120679	0.552	rs730417	chr19:2317666	T/C	cg07474816	chr19:2321113	NA	-0.46	-7.51	-0.33	3.01e-13	Parkinson's disease;
LGG	cis	rs1953600	0.870	rs2789695	chr10:81946840	C/T	cg04850286	chr10:81895943	PLAC9	0.44	9.79	0.41	1.09e-20	Sarcoidosis;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.73	0.69	5.22e-68	Platelet count;
LGG	cis	rs4253772	0.591	rs9627324	chr22:46656511	A/G	cg24881330	chr22:46731750	TRMU	0.69	8.61	0.37	1.18e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2273669	0.667	rs17070139	chr6:109358345	C/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.73e-16	Prostate cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25365783	chr7:108166722	PNPLA8	0.42	6.89	0.3	1.84e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs651907	0.557	rs3806653	chr3:101396972	T/C	cg12386194	chr3:101231763	SENP7	0.45	8.01	0.35	9.16e-15	Colorectal cancer;
LGG	cis	rs11229555	0.645	rs61889554	chr11:58424081	C/A	cg15696309	chr11:58395628	NA	-0.89	-11.93	-0.48	8.41e-29	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2412208	0.755	rs10864263	chr1:7068025	C/T	cg20434152	chr1:7120926	CAMTA1	-0.44	-8.68	-0.37	6.97e-17	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs6964587	1.000	rs6951972	chr7:91689446	T/G	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	2.96e-16	Breast cancer;
LGG	trans	rs7395662	1.000	rs4929903	chr11:48913332	T/G	cg00717180	chr2:96193071	NA	-0.45	-8.32	-0.36	9.98e-16	HDL cholesterol;
LGG	cis	rs8051149	0.688	rs55776570	chr16:87869516	C/G	cg01412419	chr16:87856264	NA	0.61	10.12	0.43	6.74e-22	Blood metabolite levels;
LGG	cis	rs8180040	0.966	rs13075233	chr3:47420627	T/C	cg16586182	chr3:47516702	SCAP	-0.78	-15.94	-0.6	6.2e-46	Colorectal cancer;
LGG	cis	rs13191362	1.000	rs35017019	chr6:162982581	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.95	10.45	0.44	4.4e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg25004347	chr4:1352787	KIAA1530	-0.38	-6.74	-0.3	4.79e-11	Obesity-related traits;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	20.12	0.68	3.72e-65	Longevity;
LGG	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg13010199	chr12:38710504	ALG10B	0.56	11.12	0.46	1.24e-25	Heart rate;
LGG	cis	rs8067545	0.611	rs2703777	chr17:20138891	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.03e-13	Schizophrenia;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg19223190	chr17:80058835	NA	-0.44	-8.47	-0.37	3.16e-16	Life satisfaction;
LGG	cis	rs7264396	0.790	rs8125090	chr20:34360015	C/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.53	7.59	0.33	1.82e-13	Total cholesterol levels;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg04861929	chr11:109293070	C11orf87	0.51	9.41	0.4	2.31e-19	Schizophrenia;
LGG	cis	rs12704876	0.509	rs10257162	chr7:96343642	T/C	cg03808172	chr7:96339361	SHFM1	0.54	9.53	0.4	9.15e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9368481	0.546	rs12664610	chr6:26885031	G/A	cg12292205	chr6:26970375	C6orf41	0.69	13.14	0.52	9.9e-34	Autism spectrum disorder or schizophrenia;
LGG	trans	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.22	0.43	2.9e-22	Myopia (pathological);
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.25	-0.32	1.78e-12	Menopause (age at onset);
LGG	trans	rs1005277	0.505	rs200910	chr10:38108176	C/T	cg27523141	chr10:43048294	ZNF37B	0.37	7.61	0.33	1.56e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg09754948	chr16:28834200	ATXN2L	0.49	7.61	0.33	1.56e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9596837	0.514	rs7320587	chr13:54201004	G/T	ch.13.53330881F	chr13:54432880	NA	0.44	7.24	0.32	1.86e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg10523679	chr1:76189770	ACADM	0.69	11.08	0.46	1.84e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1018836	0.923	rs9694450	chr8:91618292	G/A	cg16814680	chr8:91681699	NA	-0.85	-15.99	-0.6	3.7e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg11814155	chr7:99998594	ZCWPW1	0.58	8.75	0.38	4.06e-17	Platelet count;
LGG	cis	rs2224391	0.628	rs2773316	chr6:5254448	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.44	-0.33	4.94e-13	Height;
LGG	cis	rs10484885	0.571	rs17708151	chr6:90632293	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.6	-0.33	1.69e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs138544659	1	rs138544659	chr15:78900701	T/G	cg18825076	chr15:78729989	IREB2	-0.44	-7.04	-0.31	6.96e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema distribution in smoking;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs858239	0.601	rs10224327	chr7:23161820	T/C	cg23682824	chr7:23144976	KLHL7	0.43	7.32	0.32	1.11e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg02023728	chr11:77925099	USP35	-0.44	-7.46	-0.33	4.42e-13	Testicular germ cell tumor;
LGG	cis	rs774359	0.797	rs7041409	chr9:27487221	T/C	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.11	-0.35	4.49e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs2133450	0.717	rs9812897	chr3:7277163	C/G	cg19930620	chr3:7340148	GRM7	-0.35	-7.51	-0.33	3.16e-13	Early response to risperidone in schizophrenia;
LGG	trans	rs9467711	0.651	rs34043431	chr6:25875084	T/C	cg08344181	chr3:125677491	NA	-0.76	-6.79	-0.3	3.39e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6032067	0.714	rs6094110	chr20:43864889	T/C	cg10761708	chr20:43804764	PI3	0.57	8.76	0.38	3.76e-17	Blood protein levels;
LGG	cis	rs2730245	0.527	rs2527194	chr7:158732959	G/A	cg14689365	chr7:158441557	NCAPG2	-0.56	-6.9	-0.31	1.73e-11	Height;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8060686	0.641	rs76646352	chr16:68044797	C/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs9650657	0.769	rs2116094	chr8:10598822	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.19	-0.32	2.68e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23216184	chr22:20068322	DGCR8	0.49	7.34	0.32	9.7e-13	Gut microbiome composition (summer);
LGG	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg02743256	chr7:2109353	MAD1L1	-0.4	-7.57	-0.33	2.01e-13	Neuroticism;
LGG	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg05677249	chr15:77158041	SCAPER	-0.31	-6.69	-0.3	6.39e-11	Blood metabolite levels;
LGG	cis	rs73227498	0.618	rs7720344	chr5:111491581	T/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.48	-6.74	-0.3	4.84e-11	Thyroid cancer;
LGG	cis	rs3889237	0.965	rs9896349	chr17:64784410	A/T	cg09655520	chr17:64786064	PRKCA	-0.44	-9.26	-0.4	7.8e-19	Height;
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.27	0.4	7.33e-19	Height;
LGG	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg26318627	chr11:63887540	MACROD1	-0.38	-6.86	-0.3	2.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.92	-0.35	1.73e-14	Myeloid white cell count;
LGG	cis	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg12395012	chr8:11607386	GATA4	-0.38	-6.95	-0.31	1.25e-11	Retinal vascular caliber;
LGG	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg08508325	chr11:3079039	CARS	-0.6	-12.98	-0.52	4.48e-33	Longevity;
LGG	cis	rs11168187	0.843	rs12819759	chr12:48115086	T/G	cg12761788	chr12:48120090	P11	0.5	8.72	0.38	4.91e-17	Vertical cup-disc ratio;
LGG	cis	rs35740288	0.752	rs11635956	chr15:86279928	G/A	cg04173714	chr15:86211321	AKAP13	0.42	7.1	0.31	4.62e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12638871	chr3:127842906	RUVBL1	0.46	7.05	0.31	6.6e-12	Gut microbiome composition (summer);
LGG	cis	rs6547631	0.622	rs1437742	chr2:85924899	T/A	cg19805943	chr2:85933069	NA	0.32	6.73	0.3	5.17e-11	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02234479	chr17:16342158	NCRNA00188;SNORD49B;SNORD49A	0.44	7.16	0.32	3.2e-12	Cognitive performance;
LGG	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg05342682	chr7:94953680	PON1	0.31	6.97	0.31	1.13e-11	Paraoxonase activity;
LGG	cis	rs826838	1.000	rs826892	chr12:39100790	T/C	cg13010199	chr12:38710504	ALG10B	-0.62	-13.29	-0.53	2.38e-34	Heart rate;
LGG	cis	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs2221559	chr11:48707973	A/G	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs6138458	1.000	rs227624	chr20:24911562	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs992157	0.710	rs7569907	chr2:219070551	C/T	cg04731861	chr2:219085781	ARPC2	-0.49	-12.6	-0.51	1.65e-31	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg02002194	chr4:3960332	NA	0.52	10.28	0.43	1.82e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7647973	1.000	rs12583	chr3:49571462	G/T	cg06212747	chr3:49208901	KLHDC8B	-0.52	-7.88	-0.34	2.31e-14	Menarche (age at onset);
LGG	cis	rs1847202	0.787	rs13071878	chr3:72951084	G/A	cg25664220	chr3:72788482	NA	-0.25	-7.32	-0.32	1.13e-12	Motion sickness;
LGG	cis	rs11098499	0.657	rs10434028	chr4:120294464	T/G	cg24375607	chr4:120327624	NA	0.57	9.18	0.39	1.49e-18	Corneal astigmatism;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.04	-0.52	2.44e-33	Alzheimer's disease;
LGG	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg02023728	chr11:77925099	USP35	-0.4	-7.01	-0.31	8.31e-12	Alzheimer's disease (survival time);
LGG	cis	rs2070488	0.662	rs6599202	chr3:38480651	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.66	11.74	0.48	4.99e-28	Electrocardiographic conduction measures;
LGG	cis	rs7647973	0.710	rs1491983	chr3:49639803	G/T	cg03060546	chr3:49711283	APEH	0.6	7.9	0.34	2.11e-14	Menarche (age at onset);
LGG	cis	rs225245	0.765	rs226428	chr17:34049950	C/T	cg05299278	chr17:33885742	SLFN14	-0.42	-7.99	-0.35	1.09e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6489882	0.902	rs1156361	chr12:113375983	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.33	-0.32	1.03e-12	Chronic lymphocytic leukemia;
LGG	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg02951883	chr7:2050386	MAD1L1	0.44	6.93	0.31	1.42e-11	Neuroticism;
LGG	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg21399703	chr1:247681439	NA	0.67	11.87	0.48	1.42e-28	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2836950	0.772	rs62222988	chr21:40569508	T/C	cg17971929	chr21:40555470	PSMG1	-0.49	-8.0	-0.35	1.01e-14	Menarche (age at onset);
LGG	cis	rs17125944	0.615	rs12590862	chr14:53297008	A/G	cg00686598	chr14:53173677	PSMC6	-0.84	-8.92	-0.38	1.07e-17	Alzheimer's disease (late onset);
LGG	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.13e-34	IgG glycosylation;
LGG	cis	rs6089584	0.854	rs6061985	chr20:60622362	T/C	cg13770153	chr20:60521292	NA	-0.54	-8.57	-0.37	1.52e-16	Body mass index;
LGG	cis	rs1348850	0.632	rs11678875	chr2:178509068	A/G	cg22681709	chr2:178499509	PDE11A	-0.52	-9.53	-0.4	8.88e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.4	-6.82	-0.3	2.86e-11	Total body bone mineral density;
LGG	cis	rs8060686	0.641	rs111632263	chr16:68233122	T/A	cg09117114	chr16:67998030	SLC12A4	-0.39	-6.72	-0.3	5.24e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs3774749	0.565	rs2624839	chr3:50202231	T/C	cg21659725	chr3:3221576	CRBN	0.5	8.19	0.36	2.65e-15	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.710	rs1059306	chr6:86388109	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.9	17.86	0.64	1.23e-54	Response to antipsychotic treatment;
LGG	cis	rs7312933	0.533	rs11181499	chr12:42818761	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	8.15	0.35	3.51e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3857536	0.654	rs9342541	chr6:66977595	G/A	cg07460842	chr6:66804631	NA	-0.44	-7.14	-0.31	3.67e-12	Blood trace element (Cu levels);
LGG	cis	rs11203032	0.831	rs10887922	chr10:90930236	G/A	cg16672925	chr10:90967113	CH25H	0.75	10.79	0.45	2.22e-24	Heart failure;
LGG	cis	rs79349575	0.756	rs62078385	chr17:47045009	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.18	0.36	2.68e-15	Type 2 diabetes;
LGG	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg06558623	chr16:89946397	TCF25	1.07	13.14	0.52	9.43e-34	Skin colour saturation;
LGG	cis	rs3768617	0.510	rs7518957	chr1:183093028	A/T	cg15522984	chr1:182991683	LAMC1	-0.46	-9.25	-0.4	8.1e-19	Fuchs's corneal dystrophy;
LGG	trans	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg05926928	chr17:57297772	GDPD1	-1.05	-13.89	-0.54	6.57e-37	Opioid sensitivity;
LGG	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg14912033	chr15:79043428	NA	0.35	7.68	0.34	9.57e-14	Coronary artery disease or large artery stroke;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15527401	chr19:59071099	UBE2M;LOC100131691	0.46	7.12	0.31	4.15e-12	Gut microbiome composition (summer);
LGG	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg21138405	chr5:131827807	IRF1	0.28	6.75	0.3	4.31e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs12450239	0.778	rs12940455	chr17:77441124	C/T	cg07832143	chr17:77435199	HRNBP3	0.45	8.63	0.37	9.66e-17	Body mass index;
LGG	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg06027949	chr8:82754900	SNX16	-0.49	-6.85	-0.3	2.39e-11	Diastolic blood pressure;
LGG	cis	rs657075	0.697	rs3792883	chr5:131651181	G/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs9911578	0.935	rs7218105	chr17:57041119	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	5.17e-45	Intelligence (multi-trait analysis);
LGG	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg10664184	chr19:17420304	DDA1	0.56	8.62	0.37	1.11e-16	Systemic lupus erythematosus;
LGG	cis	rs1451375	0.712	rs11974297	chr7:50618260	A/G	cg00647317	chr7:50633725	DDC	-0.35	-8.0	-0.35	9.78e-15	Malaria;
LGG	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-8.56	-0.37	1.64e-16	Life satisfaction;
LGG	cis	rs4953318	0.619	rs35744969	chr2:46353140	C/A	cg12428440	chr2:46370979	PRKCE	0.49	8.9	0.38	1.28e-17	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	trans	rs7246760	1.000	rs28802413	chr19:9901617	T/C	cg02900749	chr2:68251473	NA	-1.03	-11.43	-0.47	7.69e-27	Pursuit maintenance gain;
LGG	cis	rs10875746	0.669	rs10783244	chr12:48664989	A/C	cg24011408	chr12:48396354	COL2A1	-0.57	-7.43	-0.33	5.4e-13	Longevity (90 years and older);
LGG	cis	rs503425	1.000	rs503425	chr11:118692727	C/T	cg19182353	chr11:118479428	PHLDB1	0.46	6.7	0.3	6.06e-11	Systemic lupus erythematosus;
LGG	cis	rs11098499	0.954	rs6857105	chr4:120222298	C/G	cg09307838	chr4:120376055	NA	0.75	11.9	0.48	1.11e-28	Corneal astigmatism;
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg14500267	chr11:67383377	NA	0.46	8.55	0.37	1.86e-16	Mean corpuscular volume;
LGG	trans	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.14	-0.46	1.08e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.37	-6.66	-0.3	7.81e-11	Restless legs syndrome;
LGG	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg14088196	chr11:70211408	PPFIA1	0.94	13.24	0.52	3.72e-34	Coronary artery disease;
LGG	cis	rs8017423	0.935	rs4904661	chr14:90729332	T/C	cg04374321	chr14:90722782	PSMC1	0.91	19.63	0.67	7.42e-63	Mortality in heart failure;
LGG	cis	rs17039065	0.920	rs1562973	chr4:109408138	G/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.05	0.31	6.35e-12	Gut microbiome composition (summer);
LGG	cis	rs67478160	0.583	rs12879612	chr14:104233618	T/A	cg26031613	chr14:104095156	KLC1	-0.46	-7.54	-0.33	2.45e-13	Schizophrenia;
LGG	cis	rs6754311	0.550	rs10173394	chr2:136522675	C/T	cg07169764	chr2:136633963	MCM6	-0.78	-13.77	-0.54	2.2e-36	Mosquito bite size;
LGG	cis	rs1015291	0.680	rs1352903	chr12:19994758	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.17	-0.32	2.94e-12	Diastolic blood pressure;
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg02524346	chr8:600233	NA	1.08	10.54	0.44	1.93e-23	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03322749	chr9:125026979	RBM18;MRRF	0.44	6.7	0.3	6.09e-11	Gut microbiome composition (summer);
LGG	cis	rs1401999	1.000	rs1533684	chr3:183635815	A/G	cg01324343	chr3:183735012	ABCC5	0.84	17.74	0.64	3.99e-54	Anterior chamber depth;
LGG	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.59	-0.37	1.31e-16	Aortic root size;
LGG	cis	rs4919044	1.000	rs17108042	chr10:94770488	A/C	cg05127821	chr10:94822908	CYP26C1	-0.51	-7.77	-0.34	5.04e-14	Coronary artery disease;
LGG	cis	rs68170813	0.559	rs10953536	chr7:107021691	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.03	-0.42	1.48e-21	Coronary artery disease;
LGG	cis	rs752010	0.841	rs6661784	chr1:42080312	A/T	cg16096631	chr1:42092165	HIVEP3	0.72	19.72	0.68	2.87e-63	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3820928	1.000	rs6723774	chr2:227770592	C/T	cg11843606	chr2:227700838	RHBDD1	0.43	7.26	0.32	1.59e-12	Pulmonary function;
LGG	cis	rs7927592	0.763	rs10896327	chr11:68235275	G/C	cg01657329	chr11:68192670	LRP5	-0.56	-10.48	-0.44	3.37e-23	Total body bone mineral density;
LGG	cis	rs9914988	0.943	rs4794839	chr17:27131393	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.81	-0.38	2.44e-17	HDL cholesterol;
LGG	cis	rs10991814	1.000	rs2387099	chr9:93985824	A/G	cg14446406	chr9:93919335	NA	-0.61	-7.01	-0.31	8.35e-12	Neutrophil percentage of granulocytes;
LGG	trans	rs6956675	0.957	rs28541324	chr7:62608767	G/A	cg01314568	chr7:57830625	NA	-0.5	-7.86	-0.34	2.81e-14	Obesity-related traits;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg21782813	chr7:2030301	MAD1L1	0.4	9.46	0.4	1.54e-19	Schizophrenia;
LGG	cis	rs4595586	0.967	rs11169807	chr12:39244161	A/G	cg26384229	chr12:38710491	ALG10B	0.43	7.76	0.34	5.59e-14	Morning vs. evening chronotype;
LGG	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg21827317	chr3:136751795	NA	0.53	10.01	0.42	1.71e-21	Neuroticism;
LGG	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.67	0.3	7.3e-11	Cognitive ability;
LGG	cis	rs13191362	0.507	rs2510207	chr6:163086592	T/C	cg06582575	chr6:163149167	PACRG;PARK2	-0.54	-7.13	-0.31	3.89e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7084402	0.935	rs1649068	chr10:60304864	A/C	cg09696939	chr10:60272079	BICC1	-0.36	-7.09	-0.31	4.97e-12	Refractive error;
LGG	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.49	0.4	1.23e-19	Birth weight;
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.45e-12	Bipolar disorder;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.79	-0.3	3.36e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.862	rs10950033	chr7:65739673	A/G	cg18252515	chr7:66147081	NA	0.42	7.09	0.31	5.02e-12	Aortic root size;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg16507663	chr6:150244633	RAET1G	0.47	8.92	0.38	1.11e-17	Lung cancer;
LGG	cis	rs9815354	1.000	rs1716669	chr3:41908681	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.19	0.36	2.53e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs875971	0.660	rs801193	chr7:66030612	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.6	-0.41	5.03e-20	Aortic root size;
LGG	cis	rs2832191	1.000	rs2832185	chr21:30483761	C/G	cg24692254	chr21:30365293	RNF160	-0.87	-19.91	-0.68	3.72e-64	Dental caries;
LGG	cis	rs644799	0.544	rs1254935	chr11:95631470	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.69	13.24	0.52	3.7e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11122272	0.735	rs2250719	chr1:231486208	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.06	-0.31	6.05e-12	Hemoglobin concentration;
LGG	cis	rs2073300	1.000	rs6137966	chr20:23444359	A/T	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13217239	0.646	rs7451149	chr6:27057518	A/G	cg12292205	chr6:26970375	C6orf41	-0.55	-10.72	-0.45	4.35e-24	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg09699651	chr6:150184138	LRP11	0.51	8.97	0.38	7.37e-18	Lung cancer;
LGG	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	12.81	0.51	2.34e-32	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg13736514	chr6:26305472	NA	0.46	9.17	0.39	1.5e-18	Educational attainment;
LGG	cis	rs6952808	0.692	rs11773316	chr7:2027354	C/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.04	-0.42	1.41e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg16680214	chr1:154839983	KCNN3	-0.47	-9.35	-0.4	3.63e-19	Prostate cancer;
LGG	cis	rs7954584	0.551	rs1169072	chr12:122401501	C/T	cg22618164	chr12:122356400	WDR66	-0.42	-13.19	-0.52	5.96e-34	Mean corpuscular volume;
LGG	cis	rs17166499	0.803	rs73070141	chr7:12897219	A/G	cg12945054	chr7:12841881	NA	-0.7	-7.5	-0.33	3.36e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg11764359	chr7:65958608	NA	0.79	14.79	0.57	8.03e-41	Aortic root size;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg08621203	chr6:150244597	RAET1G	0.45	7.73	0.34	6.72e-14	Lung cancer;
LGG	cis	rs4147929	0.532	rs4147930	chr19:1064193	G/A	cg12082025	chr19:1064218	ABCA7	-0.46	-7.04	-0.31	6.91e-12	Alzheimer's disease (late onset);
LGG	cis	rs6772849	0.930	rs55987729	chr3:128340110	T/C	cg08795948	chr3:128337044	NA	0.66	11.27	0.46	3.36e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg11634705	chr7:873449	UNC84A	0.42	7.33	0.32	1e-12	Subjective well-being;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg17976065	chr17:15902694	ZSWIM7;TTC19	0.41	6.66	0.3	7.58e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs990171	0.955	rs1573895	chr2:102982876	T/C	cg05295703	chr2:102895712	NA	-0.56	-9.67	-0.41	2.76e-20	Lymphocyte counts;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	8.5	0.37	2.65e-16	Longevity;
LGG	cis	rs2067615	0.524	rs4964186	chr12:107080235	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.86	0.51	1.45e-32	Heart rate;
LGG	cis	rs2247341	0.928	rs2854916	chr4:1721348	G/A	cg05026014	chr4:1749153	NA	-0.34	-9.54	-0.41	8.28e-20	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9436116	1	rs9436116	chr1:150454724	G/T	cg15654264	chr1:150340011	RPRD2	0.33	6.77	0.3	3.87e-11	Morning vs. evening chronotype;
LGG	cis	rs9325144	0.600	rs12227663	chr12:38734922	C/T	cg26384229	chr12:38710491	ALG10B	-0.75	-14.43	-0.56	3.07e-39	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg19812747	chr11:111475976	SIK2	-0.43	-8.63	-0.37	1.01e-16	Primary sclerosing cholangitis;
LGG	trans	rs7395662	1.000	rs4882120	chr11:48573529	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg27523141	chr10:43048294	ZNF37B	-0.42	-8.5	-0.37	2.58e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs7107174	1.000	rs2511177	chr11:77922960	C/T	cg02023728	chr11:77925099	USP35	0.43	7.71	0.34	7.82e-14	Testicular germ cell tumor;
LGG	cis	rs1018836	0.884	rs9643307	chr8:91625257	A/C	cg16814680	chr8:91681699	NA	-0.84	-15.72	-0.59	6.06e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg00383909	chr3:49044727	WDR6	0.46	7.31	0.32	1.18e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8053891	0.756	rs35800852	chr16:72002105	G/T	cg09427745	chr16:71932006	KIAA0174	-0.38	-6.79	-0.3	3.49e-11	Coronary artery disease;
LGG	trans	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg01620082	chr3:125678407	NA	-0.74	-7.36	-0.32	8.25e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18058532	chr11:31832710	PAX6	0.47	6.96	0.31	1.17e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.713	rs9461229	chr6:25992279	G/T	cg12310025	chr6:25882481	NA	-0.4	-7.17	-0.32	2.92e-12	Height;
LGG	cis	rs4253772	0.591	rs7286155	chr22:46714735	A/G	cg00784671	chr22:46762841	CELSR1	-0.56	-7.0	-0.31	8.9e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12477438	0.520	rs720229	chr2:99704273	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.01	0.35	9.29e-15	Chronic sinus infection;
LGG	cis	rs4925386	0.959	rs6121989	chr20:60916713	A/T	cg06026331	chr20:60912101	LAMA5	-0.5	-9.4	-0.4	2.48e-19	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6598955	0.671	rs6686100	chr1:26617338	G/C	cg04990556	chr1:26633338	UBXN11	0.58	7.95	0.35	1.43e-14	Obesity-related traits;
LGG	cis	rs4950322	0.570	rs4950401	chr1:146791289	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs1728785	0.892	rs4783562	chr16:68562963	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.34	-0.36	8.78e-16	Ulcerative colitis;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg00166722	chr3:10149974	C3orf24	0.55	9.15	0.39	1.87e-18	Alzheimer's disease;
LGG	cis	rs258892	0.947	rs17606	chr5:72184098	C/T	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.11e-11	Small cell lung carcinoma;
LGG	cis	rs2712184	0.756	rs2541388	chr2:217664284	A/G	cg05032264	chr2:217675019	NA	0.42	9.27	0.4	7.07e-19	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg17150306	chr7:855575	UNC84A	0.35	7.25	0.32	1.79e-12	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg07701084	chr6:150067640	NUP43	0.68	12.79	0.51	2.67e-32	Lung cancer;
LGG	cis	rs6500395	1.000	rs9931737	chr16:48623539	C/T	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2624839	0.639	rs2526389	chr3:50192826	C/T	cg14019146	chr3:50243930	SLC38A3	-0.43	-8.81	-0.38	2.49e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.502	rs10880388	chr12:38401341	A/T	cg04568710	chr12:38710424	ALG10B	0.35	7.25	0.32	1.75e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.22	-0.36	2.05e-15	Life satisfaction;
LGG	cis	rs1062746	0.545	rs3815947	chr16:87359648	C/T	cg02258303	chr16:87377426	FBXO31	-0.41	-7.14	-0.32	3.55e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs7089973	0.604	rs11196924	chr10:116571796	A/C	cg08188268	chr10:116634841	FAM160B1	-0.34	-7.25	-0.32	1.74e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6860806	0.507	rs156322	chr5:131653925	C/T	cg07395648	chr5:131743802	NA	-0.48	-9.8	-0.41	1e-20	Breast cancer;
LGG	cis	rs42648	0.837	rs3761804	chr7:89915338	C/T	cg25739043	chr7:89950458	NA	-0.39	-8.46	-0.37	3.53e-16	Homocysteine levels;
LGG	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg20336341	chr7:50628841	DDC	0.44	8.38	0.36	6.59e-16	Malaria;
LGG	cis	rs7103648	0.669	rs7927445	chr11:47780754	G/T	cg20307385	chr11:47447363	PSMC3	0.81	16.48	0.61	2.27e-48	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs9788721	0.836	rs72738732	chr15:78752188	C/G	cg18825076	chr15:78729989	IREB2	-0.61	-9.79	-0.41	1.06e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg27476859	chr7:2772710	GNA12	0.46	8.94	0.38	9.22e-18	Height;
LGG	cis	rs10504229	0.775	rs17805146	chr8:58161484	G/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1572438	0.811	rs6916756	chr6:880467	G/A	cg21062780	chr6:887772	NA	0.36	6.76	0.3	4.26e-11	Aging;
LGG	trans	rs7395662	1.000	rs7931984	chr11:48580835	T/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs4332037	0.539	rs11762545	chr7:2060775	C/T	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.08	-0.46	1.76e-25	Bipolar disorder;
LGG	trans	rs7395662	0.791	rs12273724	chr11:48845710	G/A	cg15704280	chr7:45808275	SEPT13	0.5	8.19	0.36	2.61e-15	HDL cholesterol;
LGG	cis	rs7319311	0.565	rs7991436	chr13:111026440	G/A	cg06243866	chr13:111019493	COL4A2	0.46	6.83	0.3	2.66e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg18511798	chr11:2018149	H19;MIR675	-0.7	-13.62	-0.53	9.03e-36	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg20236831	chr1:1259679	GLTPD1;CPSF3L	-0.37	-6.69	-0.3	6.31e-11	Pancreatic cancer;
LGG	cis	rs9747201	0.925	rs7209621	chr17:80057099	C/T	cg21453758	chr17:80185943	SLC16A3	-0.34	-6.98	-0.31	1.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9650657	0.571	rs4840512	chr8:10596825	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.48	-0.33	3.87e-13	Neuroticism;
LGG	cis	rs365132	0.791	rs55954117	chr5:176454075	A/G	cg16309518	chr5:176445507	NA	-0.51	-11.21	-0.46	5.78e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs11971779	0.616	rs11771715	chr7:139027496	T/C	cg07862535	chr7:139043722	LUC7L2	0.41	6.75	0.3	4.51e-11	Diisocyanate-induced asthma;
LGG	trans	rs7395662	0.963	rs9667588	chr11:48730337	C/T	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs7927592	0.956	rs12281742	chr11:68303629	C/T	cg16797656	chr11:68205561	LRP5	-0.4	-7.16	-0.32	3.1e-12	Total body bone mineral density;
LGG	cis	rs17286411	0.787	rs1834036	chr16:71972060	G/A	cg03805757	chr16:71968109	PKD1L3	0.34	7.02	0.31	7.78e-12	Blood protein levels;
LGG	cis	rs11098499	0.909	rs28714195	chr4:120316950	A/T	cg24375607	chr4:120327624	NA	0.67	10.97	0.45	4.7e-25	Corneal astigmatism;
LGG	cis	rs9783347	1.000	rs9783386	chr11:18386625	G/A	cg15585147	chr11:18324498	HPS5	0.42	8.54	0.37	1.97e-16	Pancreatic cancer;
LGG	cis	rs2188561	0.697	rs10808154	chr7:107386396	G/A	cg16793755	chr7:107334138	SLC26A4	0.41	7.21	0.32	2.26e-12	Alcohol consumption;
LGG	cis	rs7503807	0.515	rs12946206	chr17:78687270	G/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs1978968	0.701	rs9618179	chr22:18476909	C/T	cg03078520	chr22:18463400	MICAL3	-0.53	-10.8	-0.45	2.07e-24	Presence of antiphospholipid antibodies;
LGG	cis	rs7851660	0.967	rs3021526	chr9:100617021	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.8	0.34	4.18e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg08188268	chr10:116634841	FAM160B1	0.31	6.69	0.3	6.4e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg03517284	chr6:25882590	NA	-0.62	-11.74	-0.48	4.97e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7590720	1.000	rs934154	chr2:216901933	C/T	cg12620499	chr2:216877984	MREG	0.77	14.16	0.55	4.32e-38	Alcohol dependence;
LGG	cis	rs10754283	0.934	rs1934043	chr1:90106645	C/T	cg06121193	chr1:90282411	NA	-0.37	-7.25	-0.32	1.71e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6547741	1.000	rs1080060	chr2:27768808	T/A	cg22903471	chr2:27725779	GCKR	0.38	8.62	0.37	1.06e-16	Oral cavity cancer;
LGG	cis	rs12586317	0.620	rs10145433	chr14:35583333	G/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.48	-0.33	3.74e-13	Psoriasis;
LGG	trans	rs35110281	0.591	rs162369	chr21:44931965	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.76	0.41	1.38e-20	Mean corpuscular volume;
LGG	cis	rs17401966	0.931	rs2276100	chr1:10394536	C/G	cg19773385	chr1:10388646	KIF1B	-0.48	-10.24	-0.43	2.63e-22	Hepatocellular carcinoma;
LGG	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.39	0.5	1.15e-30	Rheumatoid arthritis;
LGG	cis	rs12971120	0.891	rs2303463	chr18:72168608	G/A	cg25817165	chr18:72167213	CNDP2	-0.66	-13.5	-0.53	2.98e-35	Refractive error;
LGG	cis	rs9314323	0.862	rs3808580	chr8:26250296	C/T	cg11498726	chr8:26250323	BNIP3L	0.56	11.85	0.48	1.72e-28	Red cell distribution width;
LGG	cis	rs755249	0.567	rs72661965	chr1:39846590	A/C	cg18385671	chr1:39797026	MACF1	0.44	7.65	0.34	1.17e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2573652	0.722	rs11858932	chr15:100542763	G/A	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.46	-0.33	4.27e-13	Height;
LGG	cis	rs7166081	1.000	rs7182798	chr15:67535212	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.99	-0.31	9.42e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4731207	0.570	rs1600738	chr7:124639549	G/T	cg05630886	chr7:124431682	NA	-0.29	-6.69	-0.3	6.28e-11	Cutaneous malignant melanoma;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg27400746	chr16:89904261	SPIRE2	-0.77	-12.59	-0.51	1.77e-31	Skin colour saturation;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg01769037	chr6:15246613	JARID2	0.72	7.05	0.31	6.59e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg03188948	chr7:1209495	NA	0.67	8.66	0.37	8.16e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12579753	0.872	rs34415838	chr12:82122078	T/C	cg07923666	chr12:49932857	KCNH3	-0.5	-7.71	-0.34	7.9e-14	Resting heart rate;
LGG	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg14092571	chr14:90743983	NA	-0.81	-16.39	-0.61	5.89e-48	Gut microbiota (bacterial taxa);
LGG	cis	rs4660214	0.666	rs1180384	chr1:39892774	T/C	cg18385671	chr1:39797026	MACF1	0.47	9.69	0.41	2.5e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3733346	0.553	rs11729289	chr4:939206	G/A	cg23939001	chr4:940644	TMEM175	0.71	17.88	0.64	9.74e-55	Sjögren's syndrome;
LGG	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg09060608	chr5:178986726	RUFY1	-0.42	-6.85	-0.3	2.39e-11	Lung cancer;
LGG	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg25986240	chr4:9926439	SLC2A9	-0.46	-9.6	-0.41	4.96e-20	Bone mineral density;
LGG	cis	rs9863	0.931	rs6488914	chr12:124447841	C/G	cg13487667	chr12:124434373	CCDC92	0.38	7.51	0.33	3.12e-13	White blood cell count;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs7618501	0.521	rs6774354	chr3:49961780	G/A	cg24110177	chr3:50126178	RBM5	-0.59	-10.8	-0.45	2.11e-24	Intelligence (multi-trait analysis);
LGG	trans	rs78049276	0.688	rs80157433	chr4:148370548	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.55	-7.24	-0.32	1.93e-12	Pulse pressure;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg24250549	chr1:154909240	PMVK	0.75	15.46	0.58	9.24e-44	Prostate cancer;
LGG	cis	rs780094	0.544	rs780110	chr2:27685388	G/A	cg22903471	chr2:27725779	GCKR	-0.54	-11.96	-0.49	6.45e-29	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs807029	0.577	rs11190786	chr10:102757442	A/G	cg04662943	chr10:102668895	NA	0.47	6.77	0.3	3.86e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7264396	0.790	rs6060530	chr20:34227663	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.28	0.32	1.4e-12	Total cholesterol levels;
LGG	cis	rs7246760	0.867	rs57943754	chr19:9841283	G/A	cg16876255	chr19:9731953	ZNF561	0.72	6.9	0.31	1.73e-11	Pursuit maintenance gain;
LGG	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg02886208	chr11:14281011	SPON1	0.53	11.62	0.48	1.41e-27	Mitochondrial DNA levels;
LGG	trans	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg20587970	chr11:113659929	NA	1.06	15.99	0.6	3.68e-46	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	0.965	rs11657883	chr17:41330024	T/C	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg16141378	chr3:129829833	LOC729375	-0.54	-13.4	-0.53	7.67e-35	Neuroticism;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg09426994	chr11:118478258	PHLDB1	0.43	7.87	0.34	2.57e-14	Cholesterol, total;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.92	0.31	1.54e-11	Lung cancer;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg26513180	chr16:89883248	FANCA	0.72	8.09	0.35	5.25e-15	Skin colour saturation;
LGG	trans	rs7746199	0.736	rs13202295	chr6:27698837	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04004882	chr2:215674386	BARD1	0.54	7.85	0.34	3e-14	Neuroblastoma;
LGG	cis	rs10911232	0.507	rs7515822	chr1:183037803	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Hypertriglyceridemia;
LGG	trans	rs61931739	0.736	rs7314457	chr12:34454301	G/A	cg13010199	chr12:38710504	ALG10B	0.57	11.66	0.48	1.01e-27	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs478647	chr11:68700424	C/T	cg21862992	chr11:68658383	NA	0.51	8.54	0.37	2e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.58	-0.33	1.88e-13	Mood instability;
LGG	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg00405596	chr8:11794950	NA	-0.46	-7.75	-0.34	5.92e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg16606324	chr3:10149918	C3orf24	0.6	6.91	0.31	1.61e-11	Alzheimer's disease;
LGG	cis	rs61931739	0.649	rs815045	chr12:33722057	C/G	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs6142618	0.562	rs3746604	chr20:30779130	T/C	cg00028034	chr20:30779307	TSPYL3	0.37	8.0	0.35	1.03e-14	Inflammatory bowel disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00427086	chr15:52861396	ARPP19	0.48	8.09	0.35	5.21e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2346160	1.000	rs4709159	chr6:167664918	C/T	cg20683250	chr6:167653907	NA	-0.45	-7.41	-0.33	6.13e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs2516739	1.000	rs2516740	chr16:2097110	A/C	cg04515572	chr16:2107413	TSC2	-0.42	-7.01	-0.31	8.22e-12	Longevity;
LGG	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg26924012	chr15:45694286	SPATA5L1	1.02	20.51	0.69	5.35e-67	Homoarginine levels;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.59	-0.33	1.72e-13	Prostate cancer;
LGG	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg14456004	chr13:21872349	NA	-1.16	-18.4	-0.65	3.76e-57	White matter hyperintensity burden;
LGG	cis	rs9427116	0.502	rs7531982	chr1:154596122	A/T	cg11650704	chr1:154556575	ADAR	-0.5	-9.84	-0.42	7.4e-21	Blood protein levels;
LGG	cis	rs7095944	1.000	rs7095944	chr10:126302936	A/G	cg08799069	chr10:126477246	METTL10	-0.34	-7.36	-0.32	8.71e-13	Asthma;
LGG	cis	rs2204008	0.754	rs11514074	chr12:38401128	C/T	cg13010199	chr12:38710504	ALG10B	0.72	14.53	0.56	1.15e-39	Bladder cancer;
LGG	cis	rs4555082	0.834	rs2735822	chr14:105712734	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.48	-0.33	3.85e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2072732	0.821	rs12033401	chr1:2944086	C/T	cg08733933	chr1:2954429	NA	-0.46	-8.88	-0.38	1.51e-17	Plateletcrit;
LGG	trans	rs8002861	0.619	rs9562516	chr13:44431738	T/C	cg17145862	chr1:211918768	LPGAT1	0.77	15.97	0.6	4.9e-46	Leprosy;
LGG	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.96	0.49	6.25e-29	Rheumatoid arthritis;
LGG	trans	rs11719291	0.833	rs73080361	chr3:48832146	G/A	cg21659725	chr3:3221576	CRBN	-0.72	-6.71	-0.3	5.75e-11	Cognitive function;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg25442928	chr22:47069558	GRAMD4	0.37	6.75	0.3	4.42e-11	Pancreatic cancer;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00166722	chr3:10149974	C3orf24	0.5	8.41	0.36	5.1e-16	Alzheimer's disease;
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.18	0.32	2.71e-12	Height;
LGG	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg07615347	chr10:60278583	BICC1	0.56	13.85	0.54	9.36e-37	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09437885	chr19:19754475	GMIP	0.44	6.72	0.3	5.51e-11	Gut microbiome composition (summer);
LGG	trans	rs9409565	0.826	rs9409767	chr9:97228524	T/C	cg05679027	chr9:99775184	HIATL2	-0.49	-8.08	-0.35	5.77e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs12549902	0.966	rs4317621	chr8:41516581	A/G	cg25883020	chr8:41504993	NKX6-3	0.33	7.19	0.32	2.54e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	trans	rs7824557	0.564	rs2736293	chr8:11234613	T/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	cis	rs60180747	1.000	rs112914414	chr15:66833344	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.64	11.33	0.47	1.97e-26	Testicular germ cell tumor;
LGG	cis	rs16854884	0.582	rs35211123	chr3:143640171	A/T	cg06585982	chr3:143692056	C3orf58	0.66	11.49	0.47	4.72e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs3540	0.960	rs8030390	chr15:90943471	C/T	cg22089800	chr15:90895588	ZNF774	0.5	7.59	0.33	1.82e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.8	-0.3	3.34e-11	Personality dimensions;
LGG	cis	rs589448	0.538	rs622656	chr12:69753595	C/T	cg11871910	chr12:69753446	YEATS4	0.85	15.87	0.59	1.3e-45	Cerebrospinal fluid biomarker levels;
LGG	cis	rs116095464	0.558	rs62344345	chr5:257420	C/T	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs7618915	0.547	rs12486847	chr3:52691112	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.34e-23	Bipolar disorder;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg00745248	chr2:20101788	TTC32	0.41	6.85	0.3	2.33e-11	Prudent dietary pattern;
LGG	cis	rs58688157	0.705	rs12419720	chr11:598205	C/G	cg02461776	chr11:598696	PHRF1	0.54	8.68	0.37	6.86e-17	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.42	7.78	0.34	4.92e-14	Schizophrenia;
LGG	cis	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg21775007	chr8:11205619	TDH	-0.48	-7.25	-0.32	1.78e-12	Neuroticism;
LGG	trans	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg16141378	chr3:129829833	LOC729375	0.34	7.75	0.34	5.8e-14	Joint mobility (Beighton score);
LGG	cis	rs17221829	0.932	rs4753236	chr11:89448147	C/T	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.89	-0.34	2.27e-14	Anxiety in major depressive disorder;
LGG	cis	rs6450176	1.000	rs3776702	chr5:53305419	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.71	-11.61	-0.47	1.59e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6748734	0.947	rs6752787	chr2:241840647	G/A	cg07537917	chr2:241836409	C2orf54	-0.39	-7.34	-0.32	9.7e-13	Urinary metabolites;
LGG	cis	rs11148252	0.711	rs61957304	chr13:52798423	G/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.32	-0.4	4.62e-19	Lewy body disease;
LGG	cis	rs10791097	0.967	rs1944142	chr11:130717440	C/T	cg12179176	chr11:130786555	SNX19	0.7	12.94	0.52	6.83e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.18	0.52	6.45e-34	Obesity-related traits;
LGG	cis	rs600550	0.551	rs12792791	chr11:60082497	G/A	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.75	-0.34	5.96e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs528418	0.592	rs6926799	chr6:145700019	A/G	cg03642472	chr6:145670687	NA	0.59	7.85	0.34	2.87e-14	Methadone dose in opioid dependence;
LGG	cis	rs79387448	0.638	rs13405222	chr2:102981891	T/C	cg20060108	chr2:102954350	IL1RL1	-0.43	-6.72	-0.3	5.51e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg15971980	chr6:150254442	NA	0.43	6.92	0.31	1.48e-11	Lung cancer;
LGG	cis	rs939658	0.805	rs8024813	chr15:79427260	A/G	cg17916960	chr15:79447300	NA	-0.67	-13.27	-0.52	2.79e-34	Refractive error;
LGG	cis	rs2046867	0.661	rs6790583	chr3:72901701	G/T	cg01043669	chr3:72786069	NA	0.38	6.65	0.3	8.29e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs17666538	0.710	rs7834337	chr8:655828	A/G	cg02524346	chr8:600233	NA	1.17	11.52	0.47	3.49e-27	IgG glycosylation;
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg20887711	chr4:1340912	KIAA1530	0.49	8.82	0.38	2.3e-17	Obesity-related traits;
LGG	cis	rs9943753	0.508	rs2075433	chr12:109833920	A/G	cg19025524	chr12:109796872	NA	-0.54	-11.71	-0.48	6.3e-28	HDL cholesterol;
LGG	cis	rs12701220	0.504	rs12702092	chr7:1145868	G/A	cg26769984	chr7:1090371	C7orf50	0.46	7.58	0.33	1.88e-13	Bronchopulmonary dysplasia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08793459	chr17:57784647	PTRH2;TMEM49	0.52	9.03	0.39	4.79e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs9473924	0.505	rs9463663	chr6:50902266	G/A	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.35	-0.4	3.77e-19	Blood metabolite levels;
LGG	cis	rs7819412	0.502	rs11777918	chr8:11036919	A/G	cg21775007	chr8:11205619	TDH	0.49	7.71	0.34	7.66e-14	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17371436	chr19:3185547	NCLN	0.47	6.86	0.3	2.25e-11	Gut microbiome composition (summer);
LGG	cis	rs113835537	0.529	rs3741360	chr11:66300348	A/G	cg24851651	chr11:66362959	CCS	0.46	7.93	0.35	1.71e-14	Airway imaging phenotypes;
LGG	cis	rs972578	0.765	rs8142102	chr22:43312615	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.66	-0.3	7.89e-11	Mean platelet volume;
LGG	cis	rs1010254	0.559	rs72808330	chr5:151746569	A/G	cg12297329	chr5:152029980	NA	-0.47	-6.77	-0.3	3.88e-11	Optic nerve measurement (cup area);
LGG	cis	rs780096	0.587	rs6743819	chr2:27567407	G/T	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.82	-0.34	3.7e-14	Total body bone mineral density;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.69	0.37	6.48e-17	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg21132104	chr15:45694354	SPATA5L1	0.7	10.37	0.43	8.87e-23	Homoarginine levels;
LGG	cis	rs7166081	1.000	rs3743347	chr15:67547301	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.18	-0.32	2.79e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs35952432	1	rs35952432	chr6:28074901	C/T	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Lung cancer;
LGG	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg15440763	chr7:158190612	PTPRN2	0.43	8.8	0.38	2.66e-17	Obesity-related traits;
LGG	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg00531865	chr16:30841666	NA	-0.48	-10.09	-0.42	8.74e-22	Dementia with Lewy bodies;
LGG	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs4919694	1.000	rs78214351	chr10:104822688	A/G	cg04362960	chr10:104952993	NT5C2	1.07	15.54	0.59	3.95e-44	Arsenic metabolism;
LGG	cis	rs1348850	0.793	rs6736390	chr2:178480314	T/C	cg27490568	chr2:178487706	NA	0.54	10.76	0.45	3.11e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11644478	chr21:40555479	PSMG1	0.83	14.65	0.56	3.31e-40	Cognitive function;
LGG	cis	rs6546537	0.911	rs4852898	chr2:69872797	C/T	cg10773587	chr2:69614142	GFPT1	-0.47	-7.74	-0.34	6.22e-14	Serum thyroid-stimulating hormone levels;
LGG	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg21226059	chr5:178986404	RUFY1	0.46	8.31	0.36	1.06e-15	Lung cancer;
LGG	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg19445457	chr11:5799446	OR52N5	0.39	6.72	0.3	5.21e-11	DNA methylation (variation);
LGG	cis	rs2797160	1.000	rs2211419	chr6:125995533	C/T	cg05901451	chr6:126070800	HEY2	0.43	7.27	0.32	1.5e-12	Endometrial cancer;
LGG	cis	rs17345786	0.861	rs17402964	chr3:101067945	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.55	8.14	0.35	3.64e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11105298	0.838	rs4842488	chr12:89881564	C/G	cg00757033	chr12:89920650	WDR51B	0.65	9.39	0.4	2.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs1465370	0.682	rs2268382	chr7:130027037	A/C	cg06917763	chr7:130033247	NA	0.36	7.86	0.34	2.75e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs4450131	0.898	rs3824804	chr10:126326606	C/T	cg08799069	chr10:126477246	METTL10	-0.31	-6.77	-0.3	4.03e-11	White blood cell count (basophil);
LGG	cis	rs55665837	0.540	rs7938266	chr11:14709324	A/G	cg18937875	chr11:14930189	NA	-0.49	-8.02	-0.35	8.86e-15	Vitamin D levels;
LGG	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg06827562	chr3:125932279	NA	0.83	20.54	0.69	4.1e-67	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg07142201	chr11:109293216	C11orf87	0.54	9.63	0.41	3.85e-20	Schizophrenia;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg13880726	chr7:1868755	MAD1L1	0.41	7.32	0.32	1.11e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs67460515	0.892	rs10513564	chr3:161059762	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-9.63	-0.41	3.96e-20	Parkinson's disease;
LGG	cis	rs9952991	0.622	rs16939895	chr18:12821903	C/T	cg23598886	chr18:12777645	NA	-0.47	-6.65	-0.3	8.47e-11	Inflammatory skin disease;
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	trans	rs11875185	0.510	rs77992382	chr18:55593630	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7927592	0.701	rs12226585	chr11:68257861	A/T	cg16797656	chr11:68205561	LRP5	-0.51	-9.81	-0.41	9.16e-21	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.18e-11	Bladder cancer;
LGG	cis	rs988958	0.526	rs36036427	chr2:42252889	G/A	cg19376973	chr2:42229025	NA	0.63	9.48	0.4	1.28e-19	Hypospadias;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg05863683	chr7:1912471	MAD1L1	0.43	8.38	0.36	6.5e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9788682	1.000	rs2036534	chr15:78826948	T/C	cg06917634	chr15:78832804	PSMA4	-0.64	-9.68	-0.41	2.7e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9341835	0.518	rs2622293	chr6:64218491	T/C	cg00787780	chr6:64151745	NA	-0.39	-6.91	-0.31	1.59e-11	Schizophrenia;
LGG	cis	rs2980439	0.557	rs2976876	chr8:8318850	T/C	cg06636001	chr8:8085503	FLJ10661	0.56	10.87	0.45	1.16e-24	Neuroticism;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg14926445	chr8:58193284	C8orf71	-0.69	-9.16	-0.39	1.67e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs2235649	0.663	rs12596160	chr16:1848784	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.9	-0.31	1.72e-11	Blood metabolite levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24539604	chr2:191184750	HIBCH	0.36	6.65	0.3	8.24e-11	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.31	-0.5	2.52e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs2029213	0.523	rs3773745	chr3:53270424	A/G	cg16894138	chr3:53270350	TKT	-0.5	-10.18	-0.43	4.39e-22	Heart rate;
LGG	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.5	8.3	0.36	1.15e-15	Bipolar disorder;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.42	-0.44	5.47e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg26384229	chr12:38710491	ALG10B	0.99	23.27	0.73	7.12e-80	Bladder cancer;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.61	10.66	0.44	7.41e-24	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs113823909	chr8:58170635	A/G	cg02725872	chr8:58115012	NA	-0.75	-10.46	-0.44	4.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.506	rs1728922	chr2:27644464	A/C	cg22903471	chr2:27725779	GCKR	-0.56	-12.75	-0.51	3.89e-32	Total body bone mineral density;
LGG	cis	rs4665809	0.818	rs35413760	chr2:26267137	C/A	cg22920501	chr2:26401640	FAM59B	0.41	7.67	0.34	1.02e-13	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.683	rs3105738	chr8:9889914	A/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.07	-0.35	6.32e-15	Neuroticism;
LGG	cis	rs2439831	0.850	rs7181039	chr15:44179112	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	1.01	10.66	0.44	7.33e-24	Lung cancer in ever smokers;
LGG	cis	rs10089	1.000	rs3805607	chr5:127477418	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.78	0.48	3.35e-28	Ileal carcinoids;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.7e-36	Lung cancer;
LGG	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg00376283	chr12:123451042	ABCB9	0.63	10.28	0.43	1.79e-22	Neutrophil percentage of white cells;
LGG	cis	rs4771450	0.924	rs9582685	chr13:103974766	A/C	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs4262150	0.774	rs17453740	chr5:151976143	A/G	cg12297329	chr5:152029980	NA	-0.81	-15.84	-0.59	1.83e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs34467563	0.669	rs17709595	chr8:97389774	A/G	cg22138393	chr8:97340270	PTDSS1	-0.29	-7.04	-0.31	6.84e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs870825	0.616	rs745656	chr4:185637523	C/T	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg23782820	chr8:58130467	NA	0.57	8.37	0.36	6.67e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.05	0.39	4.05e-18	Obesity-related traits;
LGG	cis	rs4356932	1.000	rs4580676	chr4:76953295	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs4262150	0.810	rs72799113	chr5:152055862	G/T	cg12297329	chr5:152029980	NA	-0.79	-14.99	-0.57	1.09e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.86	-0.34	2.69e-14	Life satisfaction;
LGG	cis	rs11764590	0.666	rs7787359	chr7:2090849	A/G	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.53	-0.37	2.11e-16	Neuroticism;
LGG	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg18129748	chr3:49941408	MST1R	0.22	7.16	0.32	3.21e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs4793234	chr17:41436183	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.47	0.33	4e-13	Menopause (age at onset);
LGG	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg00198680	chr16:28758506	NA	-0.28	-7.12	-0.31	4.06e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs8002861	0.967	rs7999434	chr13:44482961	T/C	cg17145862	chr1:211918768	LPGAT1	0.95	24.16	0.75	5.08e-84	Leprosy;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg24642844	chr7:1081250	C7orf50	-0.85	-14.18	-0.55	3.57e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4356932	1.000	rs4637430	chr4:76962223	G/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs7395662	0.819	rs1473579	chr11:48901553	A/G	cg00717180	chr2:96193071	NA	-0.46	-8.44	-0.37	4.13e-16	HDL cholesterol;
LGG	cis	rs6028335	0.610	rs1130247	chr20:37581437	A/G	cg16355469	chr20:37678765	NA	0.55	7.39	0.32	6.83e-13	Alcohol and nicotine co-dependence;
LGG	cis	rs9397585	0.599	rs828925	chr6:153409860	C/G	cg17707550	chr6:153380415	RGS17	-0.42	-9.51	-0.4	1.02e-19	Body mass index;
LGG	trans	rs3010562	0.872	rs6938463	chr6:167757981	G/A	cg13679164	chr6:161258479	NA	-0.42	-7.22	-0.32	2.22e-12	Gut microbiome composition (summer and winter);
LGG	cis	rs12724450	0.793	rs11806171	chr1:150310827	A/C	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10413281	chr14:21979401	METTL3	0.41	6.87	0.3	2.09e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6787391	0.933	rs9862943	chr3:4746621	A/T	cg11584376	chr3:4789075	ITPR1	-0.34	-6.99	-0.31	9.59e-12	Breast cancer;
LGG	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg06951627	chr6:26196580	NA	0.45	6.7	0.3	6.22e-11	Gout;Renal underexcretion gout;
LGG	cis	rs6121246	0.909	rs6060960	chr20:30394517	G/T	cg21427119	chr20:30132790	HM13	0.42	7.17	0.32	3.06e-12	Mean corpuscular hemoglobin;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18536802	chr5:112043188	APC	0.42	7.05	0.31	6.35e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6450176	0.597	rs1541682	chr5:53304401	C/T	ch.5.1024479R	chr5:53302184	ARL15	-1.07	-16.07	-0.6	1.7e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg12293132	chr7:23720668	C7orf46	-0.37	-8.84	-0.38	2e-17	Schizophrenia;
LGG	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.64	0.41	3.73e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs561341	0.941	rs7215147	chr17:30266711	G/A	cg20587970	chr11:113659929	NA	-1.16	-20.39	-0.69	2.13e-66	Hip circumference adjusted for BMI;
LGG	cis	rs367943	0.712	rs1607159	chr5:112681044	C/A	cg12552261	chr5:112820674	MCC	0.54	9.77	0.41	1.28e-20	Type 2 diabetes;
LGG	cis	rs4750440	0.702	rs4748066	chr10:14029313	A/T	cg00551146	chr10:14014579	FRMD4A	-0.27	-6.67	-0.3	7.12e-11	Adiponectin levels;
LGG	cis	rs798554	0.757	rs2533878	chr7:2878707	A/G	cg19524238	chr7:2802976	GNA12	-0.37	-8.6	-0.37	1.26e-16	Height;
LGG	cis	rs7107174	1.000	rs2510051	chr11:77981171	A/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	trans	rs4819388	0.789	rs4568033	chr21:45649778	A/G	cg17383793	chr5:52405638	MOCS2	0.44	6.89	0.3	1.8e-11	Celiac disease;
LGG	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.09	-0.64	1.02e-55	Refractive error;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg13939156	chr17:80058883	NA	-0.46	-9.03	-0.39	4.51e-18	Life satisfaction;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12541335	0.639	rs4872468	chr8:22179844	G/C	cg09517075	chr8:22133004	PIWIL2	0.43	9.46	0.4	1.56e-19	Hypertriglyceridemia;
LGG	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg07936489	chr17:37558343	FBXL20	-0.7	-12.21	-0.49	6.66e-30	Glomerular filtration rate (creatinine);
LGG	cis	rs1371867	0.875	rs1660311	chr8:101330579	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg00343986	chr7:65444356	GUSB	-0.39	-6.66	-0.3	7.81e-11	Aortic root size;
LGG	cis	rs2074977	0.550	rs11085020	chr19:3446107	C/T	cg08380311	chr19:3435252	NFIC	-0.64	-11.39	-0.47	1.11e-26	Height;
LGG	cis	rs7666738	0.830	rs1349757	chr4:99058763	C/G	cg05340658	chr4:99064831	C4orf37	0.48	8.01	0.35	9.18e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10911232	0.507	rs10797814	chr1:182990929	C/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs9640161	0.830	rs7800196	chr7:150061534	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.54	-10.06	-0.42	1.18e-21	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2439831	0.850	rs11856795	chr15:44160582	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.78	0.45	2.45e-24	Lung cancer in ever smokers;
LGG	cis	rs7727544	0.526	rs17516457	chr5:131590387	T/C	cg07395648	chr5:131743802	NA	-0.52	-10.89	-0.45	9.95e-25	Blood metabolite levels;
LGG	cis	rs3768617	0.811	rs12138049	chr1:182979546	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.06e-11	Fuchs's corneal dystrophy;
LGG	cis	rs972578	0.521	rs2413725	chr22:43202339	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.72	-0.3	5.21e-11	Mean platelet volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00810945	chr16:21964237	UQCRC2	0.49	7.92	0.35	1.82e-14	Gut microbiome composition (summer);
LGG	cis	rs9911578	1.000	rs9915935	chr17:56843048	A/G	cg12560992	chr17:57184187	TRIM37	0.88	15.7	0.59	7.56e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6460942	0.915	rs17444141	chr7:12460971	T/G	cg06484146	chr7:12443880	VWDE	-0.4	-7.15	-0.32	3.35e-12	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.17e-12	Lung cancer;
LGG	cis	rs4950322	0.570	rs78681047	chr1:146792732	G/A	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs11722228	0.549	rs56146302	chr4:10081052	C/T	cg25986240	chr4:9926439	SLC2A9	-0.57	-10.64	-0.44	8.26e-24	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs988958	0.567	rs2165239	chr2:42254356	C/T	cg27252766	chr2:42229092	NA	0.51	7.94	0.35	1.55e-14	Hypospadias;
LGG	cis	rs4851266	1.000	rs6750097	chr2:100836885	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	trans	rs6825911	0.638	rs6814283	chr4:111388265	T/C	cg10580549	chr19:53101634	ZNF137	0.51	6.86	0.3	2.2e-11	Blood pressure;
LGG	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg18245976	chr7:158708271	WDR60	0.44	7.47	0.33	4.04e-13	Height;
LGG	cis	rs9308433	0.529	rs4655336	chr1:214499667	A/C	cg06198575	chr1:214491504	SMYD2	0.51	7.79	0.34	4.59e-14	IgG glycosylation;
LGG	cis	rs2415984	0.579	rs12147928	chr14:46972569	C/T	cg14871534	chr14:47121158	RPL10L	0.56	10.0	0.42	1.84e-21	Number of children ever born;
LGG	cis	rs2298450	0.575	rs2268299	chr21:37660161	G/A	cg02919814	chr21:37666008	DOPEY2	-0.45	-8.95	-0.38	8.86e-18	Schizophrenia;
LGG	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg19812747	chr11:111475976	SIK2	-0.47	-9.43	-0.4	1.99e-19	Primary sclerosing cholangitis;
LGG	cis	rs10489202	0.583	rs203782	chr1:167882386	A/G	cg24449463	chr1:168025552	DCAF6	0.57	9.77	0.41	1.31e-20	Schizophrenia;
LGG	cis	rs9972944	0.729	rs10083870	chr17:63773272	C/T	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs9815354	1.000	rs1716696	chr3:41935811	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.26	0.49	4.14e-30	Prudent dietary pattern;
LGG	cis	rs10752881	0.967	rs6695746	chr1:182991355	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.34	0.53	1.39e-34	Tonsillectomy;
LGG	cis	rs3770081	1.000	rs17584578	chr2:86307624	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	-0.64	-6.89	-0.31	1.8e-11	Facial emotion recognition (sad faces);
LGG	cis	rs2239547	0.657	rs2276817	chr3:52860936	C/T	cg11645453	chr3:52864694	ITIH4	0.72	11.24	0.46	4.56e-26	Schizophrenia;
LGG	cis	rs6988985	0.765	rs62525057	chr8:143976023	T/C	cg10324643	chr8:143916377	GML	0.41	8.12	0.35	4.23e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs1577917	0.958	rs12193904	chr6:86452703	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.68	-0.56	2.44e-40	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg08219700	chr8:58056026	NA	0.47	7.26	0.32	1.68e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7172689	1.000	rs72746132	chr15:81537940	G/A	cg11808699	chr15:81528661	IL16	-0.51	-10.19	-0.43	3.74e-22	Inattentive symptoms;
LGG	cis	rs868036	0.609	rs13329413	chr15:68097126	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.37	-6.73	-0.3	5e-11	Restless legs syndrome;
LGG	cis	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	trans	rs116095464	0.558	rs28729548	chr5:229025	C/T	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs7538876	0.935	rs11577822	chr1:17754608	T/G	cg10329579	chr1:17754830	RCC2	-0.55	-10.65	-0.44	7.57e-24	Basal cell carcinoma;
LGG	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg24060327	chr5:131705240	SLC22A5	0.49	8.64	0.37	9.5e-17	Blood metabolite levels;
LGG	trans	rs12310956	0.532	rs1352211	chr12:33983132	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.88	0.57	3.22e-41	Morning vs. evening chronotype;
LGG	cis	rs4921915	0.598	rs4646243	chr8:18247609	T/C	cg18736775	chr8:18248649	NAT2	-0.77	-11.23	-0.46	4.72e-26	Iron status biomarkers (transferrin levels);
LGG	cis	rs2952156	0.920	rs9303274	chr17:37836353	T/C	cg00129232	chr17:37814104	STARD3	-0.75	-16.5	-0.61	1.88e-48	Asthma;
LGG	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.3	-0.5	2.74e-30	Cognitive function;
LGG	trans	rs11098499	0.863	rs3775858	chr4:120486028	A/G	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.88e-27	Corneal astigmatism;
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg26318627	chr11:63887540	MACROD1	-0.46	-6.78	-0.3	3.74e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	1.000	rs67913746	chr8:58177825	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs10884984	0.874	rs11195161	chr10:112279568	C/G	cg18756771	chr10:112261994	DUSP5	0.67	11.26	0.46	3.74e-26	Facial morphology (factor 22);
LGG	cis	rs68170813	0.652	rs17404067	chr7:107168119	G/T	cg02696742	chr7:106810147	HBP1	-0.62	-7.78	-0.34	4.62e-14	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs4718315	chr7:65648541	T/C	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs77633900	0.881	rs1875883	chr15:76638231	C/T	cg21673338	chr15:77095150	SCAPER	-0.62	-7.95	-0.35	1.47e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg27398817	chr8:82754497	SNX16	-0.71	-10.98	-0.45	4.55e-25	Diastolic blood pressure;
LGG	cis	rs2224391	0.628	rs766340	chr6:5243521	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.3	-0.32	1.3e-12	Height;
LGG	cis	rs4363385	0.617	rs5010885	chr1:152973141	C/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.17	-0.39	1.55e-18	Inflammatory skin disease;
LGG	cis	rs12681288	0.645	rs35040046	chr8:989973	C/T	cg15309053	chr8:964076	NA	0.39	7.69	0.34	8.76e-14	Schizophrenia;
LGG	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-13.6	-0.53	1.11e-35	Bladder cancer;
LGG	cis	rs7247513	0.930	rs28368916	chr19:12701577	T/G	cg01871581	chr19:12707946	ZNF490	-0.46	-9.48	-0.4	1.33e-19	Bipolar disorder;
LGG	cis	rs4356932	1.000	rs10000130	chr4:76939335	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.41	-6.9	-0.31	1.72e-11	Blood protein levels;
LGG	cis	rs975722	0.577	rs213946	chr7:117191283	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	9.63	0.41	4.11e-20	Coronary artery disease;
LGG	trans	rs6787172	0.622	rs9870731	chr3:158117844	G/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs7828089	0.542	rs7332050	chr8:22265294	G/T	cg12081754	chr8:22256438	SLC39A14	0.94	20.01	0.68	1.16e-64	Verbal declarative memory;
LGG	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.66	-12.24	-0.49	4.78e-30	Menarche (age at onset);
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.589	rs17492549	chr9:5202830	A/C	cg02405213	chr9:5042618	JAK2	-0.77	-12.95	-0.52	6.12e-33	Pediatric autoimmune diseases;
LGG	cis	rs12220238	1.000	rs10824106	chr10:75958408	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.81	-11.12	-0.46	1.25e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11690935	0.959	rs10803863	chr2:172535337	T/C	cg21435375	chr2:172878103	MAP1D	0.3	6.74	0.3	4.59e-11	Schizophrenia;
LGG	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg12011299	chr4:100065546	ADH4	0.43	8.61	0.37	1.15e-16	Alcohol dependence;
LGG	cis	rs1552244	0.515	rs28853661	chr3:10177659	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.9	12.98	0.52	4.57e-33	Alzheimer's disease;
LGG	cis	rs7805747	0.961	rs73158188	chr7:151415233	C/T	cg17611936	chr7:151411526	PRKAG2	0.48	7.0	0.31	8.97e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	trans	rs75804782	0.641	rs72985397	chr2:239341354	A/G	cg01134436	chr17:81009848	B3GNTL1	0.83	8.74	0.38	4.46e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs701145	0.585	rs9839821	chr3:153796323	G/A	cg17054900	chr3:154042577	DHX36	0.79	9.42	0.4	2.15e-19	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.99	-0.31	9.8e-12	Lung cancer;
LGG	cis	rs6502050	0.835	rs12600852	chr17:80104593	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg04935436	chr20:30431758	NA	0.43	7.43	0.33	5.32e-13	Mean corpuscular hemoglobin;
LGG	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-11.93	-0.48	8.8e-29	Chronic sinus infection;
LGG	cis	rs611744	0.647	rs1609472	chr8:109269232	T/G	cg18478394	chr8:109455254	TTC35	0.43	8.51	0.37	2.38e-16	Dupuytren's disease;
LGG	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.52	-0.33	2.8e-13	Mean corpuscular hemoglobin;
LGG	cis	rs988958	0.526	rs34006080	chr2:42239736	T/C	cg19376973	chr2:42229025	NA	0.63	9.43	0.4	1.97e-19	Hypospadias;
LGG	cis	rs17102423	0.731	rs942629	chr14:65539318	A/G	cg16583315	chr14:65563665	MAX	-0.4	-8.37	-0.36	6.76e-16	Obesity-related traits;
LGG	cis	rs4474465	0.688	rs4275650	chr11:78284822	T/A	cg27205649	chr11:78285834	NARS2	0.59	11.02	0.46	2.98e-25	Alzheimer's disease (survival time);
LGG	cis	rs6500395	1.000	rs1120276	chr16:48598517	C/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg09873164	chr1:152488093	CRCT1	-0.62	-15.14	-0.58	2.47e-42	Hair morphology;
LGG	cis	rs3106136	0.967	rs8026	chr4:95212185	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	4.01e-15	Capecitabine sensitivity;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg00106254	chr7:1943704	MAD1L1	-0.51	-8.99	-0.39	6.45e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4650994	0.544	rs10798613	chr1:178500022	C/T	cg19399532	chr1:178512495	C1orf220	0.57	11.58	0.47	2.14e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg17034360	chr1:68629032	GPR177	0.35	6.65	0.3	8.17e-11	Menarche (age at onset);
LGG	trans	rs9329221	0.512	rs7843924	chr8:9976540	C/T	cg02002194	chr4:3960332	NA	-0.41	-7.63	-0.33	1.37e-13	Neuroticism;
LGG	trans	rs826838	0.967	rs1486345	chr12:39131677	G/A	cg06521331	chr12:34319734	NA	0.43	7.73	0.34	6.88e-14	Heart rate;
LGG	cis	rs9462027	0.628	rs7752522	chr6:34760583	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.27e-25	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs3770081	1.000	rs12622009	chr2:86248325	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.77	-6.88	-0.3	1.9e-11	Facial emotion recognition (sad faces);
LGG	cis	rs736801	0.704	rs56399423	chr5:131672657	T/C	cg07395648	chr5:131743802	NA	-0.55	-11.72	-0.48	5.92e-28	Breast cancer;Mosquito bite size;
LGG	cis	rs35306767	0.671	rs11253473	chr10:906826	A/G	cg25019033	chr10:957182	NA	-0.56	-10.08	-0.42	9.84e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7267979	1.000	rs2257991	chr20:25270339	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.73e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.16	-0.32	3.14e-12	Bipolar disorder;
LGG	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg08048268	chr3:133502702	NA	0.6	11.13	0.46	1.19e-25	Iron status biomarkers;
LGG	cis	rs6977660	1.000	rs35784097	chr7:19818848	A/G	cg07541023	chr7:19748670	TWISTNB	0.48	7.44	0.33	4.79e-13	Thyroid stimulating hormone;
LGG	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.85	-0.3	2.41e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg18850127	chr7:39170497	POU6F2	0.64	16.26	0.6	2.28e-47	IgG glycosylation;
LGG	cis	rs7584330	0.910	rs72620830	chr2:238396985	C/T	cg16989719	chr2:238392110	NA	-0.32	-7.03	-0.31	7.26e-12	Prostate cancer;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg03452623	chr4:187889614	NA	-1.04	-31.6	-0.83	1.21e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs61931739	0.591	rs1608907	chr12:33945435	A/G	cg06521331	chr12:34319734	NA	-0.4	-7.07	-0.31	5.66e-12	Morning vs. evening chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16000967	chr3:120068640	LRRC58	0.47	8.01	0.35	9.67e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11722228	0.522	rs12504600	chr4:10067138	C/A	cg25986240	chr4:9926439	SLC2A9	-0.53	-9.88	-0.42	5.25e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10504229	1.000	rs17217082	chr8:58180918	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs988958	0.530	rs6724482	chr2:42236010	A/C	cg27252766	chr2:42229092	NA	0.52	7.48	0.33	3.73e-13	Hypospadias;
LGG	trans	rs11039798	0.623	rs7294273	chr11:48705374	T/C	cg03929089	chr4:120376271	NA	0.71	9.81	0.41	8.94e-21	Axial length;
LGG	cis	rs2963155	0.518	rs1438732	chr5:142756266	G/C	cg17617527	chr5:142782415	NR3C1	0.96	12.07	0.49	2.44e-29	Breast cancer;
LGG	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg24209194	chr3:40518798	ZNF619	0.46	7.21	0.32	2.26e-12	Renal cell carcinoma;
LGG	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg13852791	chr20:30311386	BCL2L1	0.64	8.29	0.36	1.26e-15	Mean corpuscular hemoglobin;
LGG	cis	rs11792861	0.926	rs72607170	chr9:111836941	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.57	0.41	6.22e-20	Menarche (age at onset);
LGG	cis	rs4819052	0.851	rs1056101	chr21:46678702	C/G	cg06618935	chr21:46677482	NA	-0.44	-8.53	-0.37	2.07e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2985684	1.000	rs2147712	chr14:50091684	G/A	cg04989706	chr14:50066350	PPIL5	-0.52	-8.23	-0.36	1.97e-15	Carotid intima media thickness;
LGG	cis	rs3796352	1.000	rs36090694	chr3:53010742	T/C	cg12962167	chr3:53033115	SFMBT1	0.79	8.13	0.35	3.99e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2594989	0.943	rs2442780	chr3:11510568	A/G	cg01796438	chr3:11312864	ATG7	-0.52	-7.17	-0.32	2.97e-12	Circulating chemerin levels;
LGG	cis	rs3736594	0.513	rs2384627	chr2:27774449	G/A	cg27432699	chr2:27873401	GPN1	0.57	8.52	0.37	2.26e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1519814	1.000	rs4504680	chr8:121132175	T/C	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	trans	rs6561151	0.681	rs2325088	chr13:44424063	T/C	cg17145862	chr1:211918768	LPGAT1	0.69	10.79	0.45	2.39e-24	Crohn's disease;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.84	-0.42	7.33e-21	Lung cancer;
LGG	cis	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg06521331	chr12:34319734	NA	-0.58	-9.98	-0.42	2.25e-21	Morning vs. evening chronotype;
LGG	cis	rs7954584	0.616	rs10743186	chr12:122356436	C/T	cg21171335	chr12:122356390	WDR66	0.29	8.4	0.36	5.42e-16	Mean corpuscular volume;
LGG	cis	rs727563	0.569	rs73178647	chr22:41964168	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.68	-0.34	9.51e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs870825	0.616	rs7681824	chr4:185617525	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.71	0.73	2.88e-77	Blood protein levels;
LGG	cis	rs6964587	0.626	rs2269810	chr7:91508837	T/C	cg17063962	chr7:91808500	NA	-0.43	-7.77	-0.34	5.03e-14	Breast cancer;
LGG	cis	rs7737355	0.812	rs6896132	chr5:130773561	C/G	cg06307176	chr5:131281290	NA	0.5	8.27	0.36	1.39e-15	Life satisfaction;
LGG	cis	rs6582630	0.555	rs35284307	chr12:38509999	T/G	cg04568710	chr12:38710424	ALG10B	0.36	7.44	0.33	4.79e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7615952	0.673	rs115942855	chr3:125601960	G/A	cg05084668	chr3:125655381	ALG1L	-1.17	-13.01	-0.52	3.42e-33	Blood pressure (smoking interaction);
LGG	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg16586182	chr3:47516702	SCAP	0.74	13.54	0.53	2e-35	Colorectal cancer;
LGG	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg08648136	chr8:956695	NA	0.37	7.73	0.34	6.57e-14	Schizophrenia;
LGG	trans	rs3206736	0.548	rs328904	chr7:35021176	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.21	0.32	2.27e-12	Diastolic blood pressure;
LGG	cis	rs12449000	1	rs12449000	chr16:89872970	T/C	cg07648498	chr16:89883185	FANCA	0.43	7.17	0.32	2.89e-12	Schizophrenia;
LGG	cis	rs9644630	0.932	rs4921653	chr8:19359853	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.51	-12.43	-0.5	8.16e-31	Oropharynx cancer;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.12	0.55	6.74e-38	Prudent dietary pattern;
LGG	cis	rs2228479	0.764	rs7186976	chr16:89961593	A/G	cg00800038	chr16:89945340	TCF25	-0.61	-8.5	-0.37	2.67e-16	Skin colour saturation;
LGG	cis	rs6582630	0.562	rs35080195	chr12:38310866	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.5	-0.44	2.69e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9912468	1.000	rs9910355	chr17:64315205	A/C	cg19474267	chr17:64306194	PRKCA	-0.97	-28.04	-0.79	7.55e-102	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg18350739	chr11:68623251	NA	-0.84	-21.45	-0.71	2.11e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs780096	0.526	rs3845686	chr2:27655447	T/G	cg05484376	chr2:27715224	FNDC4	0.47	10.14	0.43	5.8e-22	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs56394721	chr3:10150795	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.66	-0.37	7.65e-17	Systolic blood pressure;
LGG	trans	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.34	0.53	1.37e-34	Bladder cancer;
LGG	trans	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg08344181	chr3:125677491	NA	0.61	7.03	0.31	7.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs735539	0.521	rs7984503	chr13:21448486	T/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.26	-0.32	1.67e-12	Dental caries;
LGG	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg09754948	chr16:28834200	ATXN2L	0.42	6.71	0.3	5.87e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg05692746	chr2:100937584	LONRF2	-0.63	-11.6	-0.47	1.8e-27	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.545	rs67688847	chr7:65626051	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.57e-23	Aortic root size;
LGG	cis	rs10791097	0.967	rs6590512	chr11:130717916	A/G	cg12179176	chr11:130786555	SNX19	-0.71	-13.09	-0.52	1.59e-33	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9810089	0.903	rs7432375	chr3:136288405	G/A	cg12473912	chr3:136751656	NA	0.39	6.75	0.3	4.45e-11	Gestational age at birth (child effect);
LGG	trans	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.82	-0.42	8.29e-21	Triglycerides;
LGG	cis	rs4731207	0.596	rs1011723	chr7:124605261	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs2018683	0.770	rs10951208	chr7:29022504	G/T	cg19402173	chr7:128379420	CALU	-0.68	-12.28	-0.5	3.4e-30	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs897984	0.762	rs7204459	chr16:30984212	G/A	cg00531865	chr16:30841666	NA	0.54	11.28	0.46	3.06e-26	Dementia with Lewy bodies;
LGG	cis	rs1018836	0.828	rs10956730	chr8:91597428	T/G	cg16814680	chr8:91681699	NA	-0.77	-14.17	-0.55	4.16e-38	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12464483	0.591	rs67686878	chr2:30895044	C/T	cg17749961	chr2:30669863	LCLAT1	0.76	10.27	0.43	2.03e-22	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.49	-8.49	-0.37	2.8e-16	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03150279	chr9:127905984	SCAI	0.47	6.81	0.3	2.98e-11	Gut microbiome composition (summer);
LGG	cis	rs17666538	0.792	rs1979174	chr8:592274	C/A	cg13264159	chr8:625131	ERICH1	-0.94	-9.77	-0.41	1.29e-20	IgG glycosylation;
LGG	cis	rs4959677	0.689	rs1772977	chr6:2502900	T/C	cg20147862	chr6:2634573	C6orf195	-0.38	-8.43	-0.36	4.31e-16	Orthostatic hypotension;
LGG	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg08344181	chr3:125677491	NA	-0.65	-7.35	-0.32	8.91e-13	Depression;
LGG	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02711726	chr17:80685570	FN3KRP	-0.54	-9.47	-0.4	1.48e-19	Glycated hemoglobin levels;
LGG	cis	rs3106136	0.967	rs2171381	chr4:95224768	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.07	-0.35	6.07e-15	Capecitabine sensitivity;
LGG	cis	rs55871839	0.640	rs4738734	chr8:59814330	A/T	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs796364	0.951	rs12996313	chr2:200997916	C/T	cg17644776	chr2:200775616	C2orf69	-0.6	-7.48	-0.33	3.73e-13	Schizophrenia;
LGG	trans	rs57221529	0.766	rs72706608	chr5:559203	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs56150431	chr4:119764786	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs877282	0.838	rs34778553	chr10:796865	T/C	cg17470449	chr10:769945	NA	0.62	7.7	0.34	8.4e-14	Uric acid levels;
LGG	cis	rs875971	1.000	rs6958277	chr7:65979349	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.73	-0.38	4.64e-17	Aortic root size;
LGG	trans	rs1728785	0.901	rs8050289	chr16:68566976	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs6582630	0.538	rs7971292	chr12:38498151	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.77	-0.45	2.72e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7681440	0.647	rs11941682	chr4:90804316	T/G	cg26578617	chr4:90757533	SNCA	-0.36	-7.05	-0.31	6.36e-12	Dementia with Lewy bodies;
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.13	-0.43	6.24e-22	Lung cancer;
LGG	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg04362960	chr10:104952993	NT5C2	0.57	10.5	0.44	2.84e-23	Arsenic metabolism;
LGG	trans	rs6582630	0.502	rs11520279	chr12:38360871	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9649465	0.967	rs2286831	chr7:123303477	A/G	cg03229431	chr7:123269106	ASB15	-0.41	-8.95	-0.38	8.47e-18	Migraine;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09413933	chr21:30397036	USP16	0.41	6.82	0.3	2.9e-11	Bipolar disorder;
LGG	cis	rs6963495	0.932	rs55700120	chr7:105148460	G/T	cg19920283	chr7:105172520	RINT1	0.6	7.85	0.34	2.86e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4727443	0.866	rs13243708	chr7:99616291	T/C	cg12813108	chr7:99719912	CNPY4	-0.58	-11.29	-0.46	2.89e-26	Interstitial lung disease;
LGG	cis	rs61931739	0.517	rs1843737	chr12:34015305	A/G	cg06521331	chr12:34319734	NA	-0.6	-11.52	-0.47	3.56e-27	Morning vs. evening chronotype;
LGG	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	trans	rs9784649	1.000	rs56205870	chr5:24958870	A/G	cg08600765	chr20:34638493	LOC647979	-0.58	-7.43	-0.33	5.12e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs62244186	0.715	rs10212378	chr3:44667286	C/G	cg02073558	chr3:44770973	ZNF501	0.7	13.39	0.53	8.25e-35	Depressive symptoms;
LGG	cis	rs11771526	0.901	rs11773754	chr7:32304801	A/G	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21582582	chr3:182698605	DCUN1D1	-0.42	-7.02	-0.31	7.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7246760	0.867	rs66464474	chr19:9795149	T/C	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs9467160	0.520	rs2753910	chr6:24442473	C/T	cg20631270	chr6:24437470	GPLD1	-0.52	-9.18	-0.39	1.41e-18	Liver enzyme levels;
LGG	cis	rs11966931	0.711	rs2139084	chr6:108136860	T/G	cg04749840	chr6:108095067	SCML4	-0.46	-9.34	-0.4	4.15e-19	Neutrophil percentage of white cells;
LGG	trans	rs9354308	0.868	rs9345695	chr6:66554270	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-8.47	-0.37	3.23e-16	Metabolite levels;
LGG	cis	rs7572733	0.935	rs1105078	chr2:198807885	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.2	0.36	2.36e-15	Dermatomyositis;
LGG	cis	rs1620921	0.967	rs1247558	chr6:161190199	A/G	cg01280913	chr6:161186852	NA	-0.33	-6.8	-0.3	3.23e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg05368731	chr17:41323189	NBR1	-0.86	-16.7	-0.61	2.31e-49	Menopause (age at onset);
LGG	cis	rs3219090	0.962	rs1397550	chr1:226601242	C/T	cg17127702	chr1:226594323	PARP1	-0.38	-12.38	-0.5	1.28e-30	Melanoma;
LGG	cis	rs35123781	1.000	rs650446	chr5:139054510	T/A	cg21230503	chr5:139085173	NA	0.31	7.32	0.32	1.13e-12	Schizophrenia;
LGG	trans	rs17685	0.672	rs55807301	chr7:75807401	C/A	cg19862616	chr7:65841803	NCRNA00174	1.05	24.24	0.75	2.13e-84	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg06916706	chr16:4465613	CORO7	-1.13	-22.3	-0.72	2.41e-75	Schizophrenia;
LGG	cis	rs477692	1.000	rs577227	chr10:131404528	C/T	cg05714579	chr10:131428358	MGMT	0.54	11.0	0.46	3.73e-25	Response to temozolomide;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg19901468	chr14:105411992	AHNAK2	-0.88	-18.6	-0.65	4.59e-58	Rheumatoid arthritis;
LGG	cis	rs7917772	0.636	rs4919674	chr10:104522226	T/C	cg04362960	chr10:104952993	NT5C2	0.48	7.99	0.35	1.05e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2120243	0.539	rs722484	chr3:157100627	C/T	cg24825693	chr3:157122686	VEPH1	-0.57	-13.24	-0.52	3.68e-34	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00349776	chr1:165414189	RXRG	0.42	7.03	0.31	7.48e-12	Cognitive performance;
LGG	cis	rs11971779	0.680	rs6962186	chr7:139034806	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	20.07	0.68	6.08e-65	Platelet count;
LGG	trans	rs11039798	0.698	rs78553793	chr11:48947336	C/A	cg15704280	chr7:45808275	SEPT13	0.73	7.68	0.34	9.4e-14	Axial length;
LGG	trans	rs6582630	0.585	rs12422588	chr12:38478675	C/T	cg06521331	chr12:34319734	NA	0.43	7.83	0.34	3.39e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9549260	0.755	rs7324319	chr13:41233505	G/C	cg21288729	chr13:41239152	FOXO1	0.33	6.65	0.3	8.34e-11	Red blood cell count;
LGG	cis	rs2742417	1.000	rs2742379	chr3:45787835	G/A	cg04837898	chr3:45731254	SACM1L	-0.34	-6.67	-0.3	7.35e-11	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.14	0.49	1.23e-29	Mean corpuscular volume;
LGG	cis	rs7106204	0.534	rs16912411	chr11:24320444	A/T	ch.11.24196551F	chr11:24239977	NA	0.83	8.61	0.37	1.18e-16	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg24450063	chr1:156163899	SLC25A44	1.06	18.03	0.64	1.85e-55	Testicular germ cell tumor;
LGG	cis	rs7666738	0.830	rs4699601	chr4:99034429	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.45	0.37	3.75e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	8.99	0.39	6.35e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7084402	0.967	rs12259990	chr10:60297574	A/G	cg09696939	chr10:60272079	BICC1	0.36	6.96	0.31	1.15e-11	Refractive error;
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg01341218	chr17:43662625	NA	0.9	15.3	0.58	4.59e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7827545	1.000	rs7463007	chr8:135567143	C/T	cg09855544	chr8:135498122	ZFAT	0.46	7.85	0.34	3.01e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs7824557	0.527	rs2572369	chr8:11238597	C/T	cg15596359	chr8:11213517	TDH	0.42	8.68	0.37	6.85e-17	Retinal vascular caliber;
LGG	cis	rs7932354	0.502	rs7118546	chr11:47087128	C/G	cg03339077	chr11:47165057	C11orf49	-0.54	-10.16	-0.43	5.14e-22	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs9814567	1.000	rs9863786	chr3:134247203	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.76	0.3	4.27e-11	Neuroticism;
LGG	cis	rs36071027	0.615	rs13159303	chr5:158421063	A/G	cg00594129	chr5:158524270	EBF1	0.45	8.08	0.35	5.64e-15	Carotid intima media thickness;
LGG	cis	rs151997	0.962	rs27612	chr5:50179120	G/A	cg06027927	chr5:50259733	NA	0.68	11.19	0.46	7.15e-26	Callous-unemotional behaviour;
LGG	cis	rs2708977	1.000	rs13029764	chr2:97328874	C/T	cg01950434	chr2:97203154	ARID5A	-0.55	-8.64	-0.37	9.08e-17	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	0.945	rs6978739	chr7:100098680	C/G	cg11814155	chr7:99998594	ZCWPW1	0.61	9.18	0.39	1.43e-18	Platelet count;
LGG	cis	rs5758659	0.714	rs2413668	chr22:42505841	G/A	cg15128208	chr22:42549153	NA	0.49	10.06	0.42	1.12e-21	Cognitive function;
LGG	cis	rs6831352	0.918	rs17218560	chr4:100060794	C/T	cg13256891	chr4:100009986	ADH5	0.53	9.19	0.39	1.38e-18	Alcohol dependence;
LGG	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	cis	rs2652834	0.950	rs2729801	chr15:63381095	A/G	cg05507819	chr15:63340323	TPM1	0.53	6.99	0.31	9.42e-12	HDL cholesterol;
LGG	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg16400903	chr5:693638	TPPP	0.43	6.66	0.3	7.67e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg16141378	chr3:129829833	LOC729375	0.3	6.79	0.3	3.5e-11	Neuroticism;
LGG	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg03517284	chr6:25882590	NA	-0.45	-7.84	-0.34	3.22e-14	Height;
LGG	cis	rs12682352	0.715	rs332039	chr8:8723651	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	9.11	0.39	2.51e-18	Neuroticism;
LGG	cis	rs7091068	0.518	rs726817	chr10:95459817	C/T	cg20715218	chr10:95462985	C10orf4	0.68	12.14	0.49	1.21e-29	Urinary tract infection frequency;
LGG	cis	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg19847130	chr8:10466454	RP1L1	-0.32	-6.82	-0.3	2.92e-11	Neuroticism;
LGG	cis	rs9486719	1.000	rs11153067	chr6:97039421	A/T	cg06623918	chr6:96969491	KIAA0776	0.76	10.81	0.45	1.89e-24	Migraine;Coronary artery disease;
LGG	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg11812906	chr14:75593930	NEK9	-0.53	-9.47	-0.4	1.48e-19	Height;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02475777	chr4:1388615	CRIPAK	0.41	7.58	0.33	1.87e-13	Longevity;
LGG	cis	rs12325245	0.536	rs34737210	chr16:58549262	T/C	cg01152986	chr16:58549298	SETD6	0.84	7.31	0.32	1.15e-12	Schizophrenia;
LGG	cis	rs981844	1.000	rs2118862	chr4:154657782	A/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs1801251	0.711	rs778368	chr2:233745333	G/C	cg25237894	chr2:233734115	C2orf82	-0.7	-14.74	-0.57	1.3e-40	Coronary artery disease;
LGG	cis	rs7953508	0.711	rs3825198	chr12:93977465	T/A	cg18151635	chr12:93972918	NA	-0.45	-8.08	-0.35	5.54e-15	Pubertal anthropometrics;
LGG	cis	rs838147	0.844	rs8104897	chr19:49249814	C/A	cg13540341	chr19:49222985	MAMSTR	0.44	10.48	0.44	3.23e-23	Dietary macronutrient intake;
LGG	cis	rs9399137	0.507	rs4451150	chr6:135279063	T/G	cg22676075	chr6:135203613	NA	0.46	8.05	0.35	7.03e-15	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs4851266	0.865	rs11123818	chr2:100867308	G/A	cg21926883	chr2:100939477	LONRF2	-0.47	-8.5	-0.37	2.62e-16	Educational attainment;
LGG	cis	rs2594989	1.000	rs2606752	chr3:11360170	A/G	cg01796438	chr3:11312864	ATG7	-0.58	-7.86	-0.34	2.81e-14	Circulating chemerin levels;
LGG	cis	rs7447593	0.518	rs4074995	chr5:176797343	C/T	cg16006841	chr5:176797999	RGS14	0.59	9.66	0.41	3.12e-20	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs6502050	0.799	rs4132775	chr17:80155412	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs6952808	0.595	rs3800917	chr7:2167939	A/G	cg22963979	chr7:1858916	MAD1L1	0.41	8.14	0.35	3.64e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs903263	0.601	rs10493750	chr1:84562265	C/T	cg10977910	chr1:84465055	TTLL7	-0.42	-7.52	-0.33	2.92e-13	Breast cancer (male);
LGG	cis	rs9611565	0.840	rs3788584	chr22:41779073	T/A	cg06481639	chr22:41940642	POLR3H	-0.54	-8.03	-0.35	7.89e-15	Vitiligo;
LGG	cis	rs929354	1.000	rs1182452	chr7:157053618	G/A	cg00092383	chr7:157075207	NA	0.4	7.05	0.31	6.62e-12	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07520141	chr5:10564205	ANKRD33B	0.48	7.23	0.32	1.95e-12	Gut microbiome composition (summer);
LGG	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg26031613	chr14:104095156	KLC1	1.14	27.35	0.79	9.62e-99	Body mass index;
LGG	cis	rs9807841	0.723	rs1965767	chr19:10860215	T/C	cg17710535	chr19:10819994	QTRT1	0.49	8.23	0.36	1.87e-15	Inflammatory skin disease;
LGG	cis	rs1843834	0.898	rs2014887	chr2:225520082	A/G	cg22455342	chr2:225449267	CUL3	0.59	10.1	0.42	8.5e-22	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs10504229	0.728	rs56180705	chr8:58149734	T/C	cg08219700	chr8:58056026	NA	0.43	6.85	0.3	2.4e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9649465	0.807	rs11770249	chr7:123286412	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.8	-0.38	2.63e-17	Migraine;
LGG	cis	rs10464366	0.798	rs6945380	chr7:39115215	C/T	cg20302533	chr7:39170763	POU6F2	0.47	11.06	0.46	2.14e-25	IgG glycosylation;
LGG	cis	rs7659604	0.605	rs2071486	chr4:122740162	C/T	cg20573242	chr4:122745356	CCNA2	0.6	11.73	0.48	5.16e-28	Type 2 diabetes;
LGG	cis	rs240764	0.782	rs12216199	chr6:101152723	C/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.64	-0.33	1.27e-13	Neuroticism;
LGG	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg25358565	chr5:93447407	FAM172A	1.27	15.62	0.59	1.68e-44	Diabetic retinopathy;
LGG	cis	rs61884328	0.777	rs17790336	chr11:47127549	G/T	cg03339077	chr11:47165057	C11orf49	0.63	6.84	0.3	2.5e-11	Total body bone mineral density (age over 60);
LGG	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg00745463	chr17:30367425	LRRC37B	-0.64	-9.54	-0.41	8.27e-20	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.526	rs10803912	chr2:178407176	A/C	cg23306229	chr2:178417860	TTC30B	-0.72	-8.7	-0.37	5.71e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs875971	1.000	rs6957199	chr7:65978519	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs3126085	0.867	rs12748016	chr1:152197235	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.35	-0.36	8.05e-16	Atopic dermatitis;
LGG	cis	rs9308731	1.000	rs9308731	chr2:111908262	G/A	cg19992207	chr2:111874495	ACOXL	-0.39	-7.2	-0.32	2.47e-12	Chronic lymphocytic leukemia;
LGG	trans	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg10122326	chr6:28072925	NA	1.04	8.11	0.35	4.66e-15	Parkinson's disease;
LGG	cis	rs2576037	0.583	rs487386	chr18:44377004	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.68	0.44	5.78e-24	Personality dimensions;
LGG	cis	rs3767633	0.925	rs2499855	chr1:161929761	C/T	cg09175582	chr1:161736000	ATF6	0.73	8.91	0.38	1.18e-17	IgG glycosylation;
LGG	cis	rs2797369	0.713	rs4455678	chr6:101568672	C/G	cg27451362	chr6:101846650	GRIK2	-0.84	-11.2	-0.46	6.29e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg24110177	chr3:50126178	RBM5	0.59	10.86	0.45	1.22e-24	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg23957911	chr4:2758084	TNIP2	-0.45	-7.03	-0.31	7.64e-12	Pancreatic cancer;
LGG	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg18551225	chr6:44695536	NA	-0.68	-11.29	-0.46	2.92e-26	Total body bone mineral density;
LGG	cis	rs28595532	1.000	rs11931194	chr4:119631160	C/T	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs4808199	0.894	rs9304960	chr19:19465529	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.32	0.32	1.1e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg02524346	chr8:600233	NA	0.89	9.69	0.41	2.41e-20	IgG glycosylation;
LGG	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg27129171	chr3:47204927	SETD2	0.79	15.15	0.58	2.17e-42	Colorectal cancer;
LGG	cis	rs113835537	0.529	rs11227510	chr11:66281220	T/C	cg24851651	chr11:66362959	CCS	0.44	7.58	0.33	1.89e-13	Airway imaging phenotypes;
LGG	cis	rs7027203	0.828	rs4744287	chr9:96585567	A/G	cg13679303	chr9:96623674	NA	0.37	6.78	0.3	3.64e-11	DNA methylation (variation);
LGG	cis	rs6735179	0.648	rs6706107	chr2:1761661	C/A	cg10160682	chr2:1713001	PXDN	-0.53	-9.51	-0.4	1.08e-19	Response to antipsychotic treatment;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg16208672	chr14:51134997	SAV1	0.41	6.86	0.3	2.28e-11	Hip circumference;
LGG	cis	rs11649653	0.502	rs62057232	chr16:30820866	T/C	cg02466173	chr16:30829666	NA	0.42	8.05	0.35	6.87e-15	Triglycerides;
LGG	cis	rs2304069	0.819	rs10875553	chr5:149374932	T/C	cg12661370	chr5:149340060	SLC26A2	0.49	6.71	0.3	5.71e-11	HIV-1 control;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg21542922	chr4:187680768	NA	0.4	6.87	0.3	2.1e-11	Electrocardiographic conduction measures;
LGG	cis	rs1346	0.552	rs10791821	chr11:65368323	A/G	cg17120908	chr11:65337727	SSSCA1	0.45	6.91	0.31	1.58e-11	Vertical cup-disc ratio;Optic cup area;
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	cis	rs1408224	0.626	rs6561323	chr13:47185601	C/T	cg24453118	chr13:47229927	LRCH1	0.29	6.86	0.3	2.19e-11	QRS complex (12-leadsum);
LGG	cis	rs9858542	0.953	rs9837341	chr3:49664767	A/G	cg03060546	chr3:49711283	APEH	-0.66	-11.09	-0.46	1.73e-25	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs2832077	0.527	rs2832116	chr21:30228368	C/A	cg14791747	chr16:20752902	THUMPD1	0.56	10.31	0.43	1.43e-22	Cognitive test performance;
LGG	cis	rs504918	0.934	rs10511423	chr3:124078870	A/C	cg05766129	chr3:123988013	KALRN	-0.38	-6.95	-0.31	1.23e-11	Schizophrenia;
LGG	cis	rs8180040	0.966	rs2101247	chr3:47494303	G/A	cg16586182	chr3:47516702	SCAP	0.77	15.39	0.58	1.86e-43	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16221875	chr6:21588597	NA	0.42	6.83	0.3	2.76e-11	Gut microbiome composition (summer);
LGG	cis	rs25645	0.502	rs7223318	chr17:38108553	G/C	cg17467752	chr17:38218738	THRA	0.45	6.95	0.31	1.22e-11	Myeloid white cell count;
LGG	cis	rs950027	0.620	rs1145084	chr15:45675440	G/A	cg26924012	chr15:45694286	SPATA5L1	0.68	12.04	0.49	3.2e-29	Response to fenofibrate (adiponectin levels);
LGG	cis	rs10174077	0.687	rs10172023	chr2:152476028	C/G	cg19508488	chr2:152266495	RIF1	0.49	7.85	0.34	2.95e-14	Squamous cell lung carcinoma;
LGG	cis	rs45544231	0.569	rs1362546	chr16:52549935	C/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.79	-0.3	3.44e-11	Restless legs syndrome;
LGG	cis	rs6489882	0.867	rs4767031	chr12:113362751	C/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.36	-0.32	8.61e-13	Chronic lymphocytic leukemia;
LGG	cis	rs965513	1.000	rs7864322	chr9:100548934	C/T	cg13688889	chr9:100608707	NA	-0.53	-9.69	-0.41	2.52e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs760805	0.932	rs1005734	chr1:25262022	C/A	cg22509179	chr1:25234806	RUNX3	-0.67	-14.15	-0.55	5.19e-38	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8014204	0.604	rs2159906	chr14:75390912	G/T	cg06637938	chr14:75390232	RPS6KL1	1.09	27.88	0.79	3.95e-101	Caffeine consumption;
LGG	cis	rs72634258	0.554	rs4908694	chr1:7850898	C/T	cg26816564	chr1:7831052	VAMP3	0.79	12.51	0.5	3.96e-31	Inflammatory bowel disease;
LGG	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	15.54	0.59	3.97e-44	Mean platelet volume;
LGG	cis	rs8180040	1.000	rs1024037	chr3:47318449	C/A	cg16586182	chr3:47516702	SCAP	0.78	15.48	0.58	7.72e-44	Colorectal cancer;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg01988459	chr11:68622903	NA	-0.63	-12.68	-0.51	8.08e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2455799	0.613	rs13060772	chr3:15896795	C/T	cg16303742	chr3:15540471	COLQ	-0.4	-7.83	-0.34	3.35e-14	Mean platelet volume;
LGG	trans	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.88	-0.42	5.02e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.04	-0.35	7.35e-15	Neuroticism;
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg26513180	chr16:89883248	FANCA	0.94	20.97	0.7	4e-69	Vitiligo;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.01e-20	Lung cancer;
LGG	cis	rs1552244	0.882	rs55962400	chr3:10044457	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.17	0.62	1.69e-51	Alzheimer's disease;
LGG	cis	rs701145	0.585	rs1632688	chr3:153874139	C/A	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs4925386	0.840	rs6143024	chr20:60914229	A/G	cg24112000	chr20:60950667	NA	-0.4	-7.89	-0.34	2.26e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs10791097	0.694	rs10160281	chr11:130742788	T/C	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.06e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.4	7.95	0.35	1.47e-14	Prostate cancer;
LGG	cis	rs2486288	0.656	rs11632724	chr15:45550791	G/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	trans	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg02002194	chr4:3960332	NA	-0.46	-8.76	-0.38	3.58e-17	Systolic blood pressure;
LGG	trans	rs9747201	0.925	rs11867806	chr17:80072049	A/G	cg07393940	chr7:158741817	NA	-0.61	-11.12	-0.46	1.29e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs3942852	0.806	rs10734562	chr11:48128189	A/T	cg03929089	chr4:120376271	NA	0.65	9.17	0.39	1.56e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4716602	0.596	rs12698432	chr7:156158719	C/G	cg16983916	chr7:156159713	NA	0.48	9.53	0.4	8.91e-20	Anti-saccade response;
LGG	cis	rs13082711	0.911	rs7640929	chr3:27513944	C/A	cg02860705	chr3:27208620	NA	0.69	12.23	0.49	5.37e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11123610	0.520	rs59726279	chr2:3718655	A/G	cg26344334	chr2:3718215	ALLC	-0.48	-8.34	-0.36	8.6e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1348850	0.574	rs4893835	chr2:178442592	T/C	cg27490568	chr2:178487706	NA	0.69	12.2	0.49	7.19e-30	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11168854	0.651	rs12227770	chr12:49576848	T/A	cg24176009	chr12:49580217	TUBA1A	0.64	12.37	0.5	1.47e-30	Body mass index;
LGG	cis	rs6938	0.597	rs4886641	chr15:75228655	C/A	cg17294928	chr15:75287854	SCAMP5	0.7	13.02	0.52	2.96e-33	Breast cancer;
LGG	cis	rs9311474	0.508	rs4687546	chr3:52605943	T/A	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.54e-12	Electroencephalogram traits;
LGG	cis	rs4642101	0.662	rs1969154	chr3:12829156	A/G	cg05775895	chr3:12838266	CAND2	0.62	11.0	0.46	3.74e-25	QRS complex (12-leadsum);
LGG	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg26396452	chr14:65542826	MAX	0.43	8.45	0.37	3.77e-16	Obesity-related traits;
LGG	cis	rs9916302	0.851	rs7225096	chr17:37664443	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9790314	0.967	rs1382427	chr3:161032576	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.31	-0.47	2.41e-26	Morning vs. evening chronotype;
LGG	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg14664628	chr15:75095509	CSK	-0.8	-16.17	-0.6	6.09e-47	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs1816752	0.683	rs7330532	chr13:25017591	C/T	cg02811702	chr13:24901961	NA	0.4	7.51	0.33	3.07e-13	Obesity-related traits;
LGG	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg14664628	chr15:75095509	CSK	-0.54	-10.5	-0.44	2.73e-23	Breast cancer;
LGG	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.51	-0.53	2.65e-35	Response to antipsychotic treatment;
LGG	cis	rs9487094	0.778	rs13214717	chr6:109894354	C/A	cg16315928	chr6:109776240	MICAL1	0.52	8.57	0.37	1.54e-16	Height;
LGG	cis	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg21479132	chr6:26055353	NA	0.8	7.5	0.33	3.28e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg03847636	chr4:7070632	GRPEL1	-0.48	-6.98	-0.31	1.04e-11	Monocyte percentage of white cells;
LGG	trans	rs7647973	0.626	rs4855849	chr3:49653378	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	trans	rs11992162	0.636	rs11250182	chr8:11807576	A/T	cg13009111	chr11:71350975	NA	-0.33	-7.31	-0.32	1.21e-12	Monocyte count;
LGG	cis	rs9517320	0.534	rs61971163	chr13:99188883	G/A	cg03701759	chr13:99174930	STK24	-0.37	-7.12	-0.31	4.03e-12	Longevity;
LGG	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs2131877	0.830	rs7616009	chr3:194881756	G/A	cg07250128	chr3:194833983	C3orf21	0.44	7.49	0.33	3.53e-13	Non-small cell lung cancer;
LGG	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg24848339	chr3:12840334	CAND2	0.38	8.06	0.35	6.36e-15	QRS complex (12-leadsum);
LGG	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg08344181	chr3:125677491	NA	-0.66	-7.72	-0.34	7.37e-14	Breast cancer;
LGG	trans	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg22232500	chr2:134024266	NCKAP5	0.61	8.3	0.36	1.13e-15	Bipolar disorder;
LGG	cis	rs7914558	1.000	rs12255047	chr10:104760752	G/A	cg04362960	chr10:104952993	NT5C2	0.53	10.18	0.43	4.29e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs12101261	0.580	rs8003515	chr14:81446242	G/C	cg06600135	chr14:81408086	NA	0.39	7.47	0.33	4e-13	Graves' disease;
LGG	cis	rs12477438	0.508	rs2516832	chr2:99771268	G/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs4601790	0.601	rs12801636	chr11:65391317	C/T	cg27068330	chr11:65405492	SIPA1	0.42	7.01	0.31	8.62e-12	Blood pressure (age interaction);
LGG	cis	rs9341808	0.527	rs7453746	chr6:80810013	T/G	cg08355045	chr6:80787529	NA	0.46	9.34	0.4	4.14e-19	Sitting height ratio;
LGG	cis	rs7084402	0.967	rs1658479	chr10:60289398	C/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	8.01e-13	Refractive error;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg08208917	chr15:42565872	GANC;TMEM87A	0.4	6.8	0.3	3.29e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9309473	1.000	rs6707722	chr2:73654363	G/A	cg20560298	chr2:73613845	ALMS1	-0.45	-7.46	-0.33	4.22e-13	Metabolite levels;
LGG	cis	rs72781680	0.948	rs72796385	chr2:24170360	T/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.65	0.41	3.42e-20	Lymphocyte counts;
LGG	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.1	26.0	0.77	1.45e-92	Height;
LGG	cis	rs79146658	0.736	rs4637162	chr2:179736012	T/C	cg17765952	chr2:179737173	CCDC141	0.59	8.86	0.38	1.75e-17	Diastolic blood pressure;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg11841349	chr3:9791615	OGG1	-0.43	-6.8	-0.3	3.26e-11	Height;
LGG	cis	rs60871478	1.000	rs4720917	chr7:806998	C/G	cg05535760	chr7:792225	HEATR2	0.79	12.67	0.51	8.73e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs1059312	0.808	rs4760537	chr12:129301299	C/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.34	8.62	0.37	1.04e-16	Systemic lupus erythematosus;
LGG	cis	rs4731207	0.698	rs4377885	chr7:124533680	A/G	cg05630886	chr7:124431682	NA	0.32	7.43	0.33	5.12e-13	Cutaneous malignant melanoma;
LGG	cis	rs35146811	0.735	rs7811662	chr7:99792608	A/G	cg22906224	chr7:99728672	NA	0.56	9.26	0.4	7.89e-19	Coronary artery disease;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7219021	0.811	rs3959442	chr17:46894377	A/C	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.66	-0.3	7.63e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs4804815	0.780	rs75533704	chr19:7840557	G/T	cg00970558	chr19:7854469	CLEC4GP1	0.65	9.81	0.41	9.18e-21	Neutrophil count;
LGG	cis	rs5758659	0.504	rs133367	chr22:42463366	A/G	cg15557168	chr22:42548783	NA	0.33	7.52	0.33	2.83e-13	Cognitive function;
LGG	cis	rs2836974	0.623	rs34240248	chr21:40685239	A/G	cg22974920	chr21:40686053	BRWD1	-0.43	-6.95	-0.31	1.26e-11	Cognitive function;
LGG	cis	rs6495122	0.699	rs1378942	chr15:75077367	A/C	cg14664628	chr15:75095509	CSK	0.79	16.02	0.6	2.84e-46	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs656319	0.629	rs10111315	chr8:9865588	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.48	0.33	3.73e-13	Myopia (pathological);
LGG	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs2075371	0.865	rs2544172	chr7:133931338	T/C	cg20476274	chr7:133979776	SLC35B4	0.72	14.2	0.55	2.95e-38	Mean platelet volume;
LGG	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg09117114	chr16:67998030	SLC12A4	-0.37	-6.65	-0.3	8.1e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg04772025	chr11:68637568	NA	0.77	13.86	0.54	8.44e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7819412	0.634	rs6987767	chr8:10910066	T/C	cg16141378	chr3:129829833	LOC729375	-0.39	-8.45	-0.37	3.88e-16	Triglycerides;
LGG	cis	rs17767392	0.595	rs7150921	chr14:71657290	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.19	-0.32	2.7e-12	Mitral valve prolapse;
LGG	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg05234568	chr11:5960015	NA	-0.68	-12.27	-0.5	3.74e-30	DNA methylation (variation);
LGG	cis	rs2952156	0.959	rs2941503	chr17:37828745	A/G	cg00129232	chr17:37814104	STARD3	-0.69	-14.3	-0.55	1.11e-38	Asthma;
LGG	cis	rs780096	0.545	rs2280737	chr2:27589810	A/G	cg27432699	chr2:27873401	GPN1	-0.49	-8.52	-0.37	2.33e-16	Total body bone mineral density;
LGG	cis	rs6461049	0.765	rs3800908	chr7:2159437	C/T	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.82	-0.54	1.32e-36	Schizophrenia;
LGG	cis	rs10991814	0.764	rs75828717	chr9:93964907	T/A	cg14446406	chr9:93919335	NA	-0.75	-8.29	-0.36	1.27e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs9611565	0.525	rs1883827	chr22:41703579	A/G	cg03806693	chr22:41940476	POLR3H	-0.74	-12.31	-0.5	2.57e-30	Vitiligo;
LGG	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg18876405	chr7:65276391	NA	-0.63	-11.61	-0.47	1.59e-27	Cotinine glucuronidation;
LGG	cis	rs7712401	0.601	rs1990890	chr5:122182970	C/T	cg19412675	chr5:122181750	SNX24	0.4	6.7	0.3	5.91e-11	Mean platelet volume;
LGG	cis	rs11739663	0.553	rs60444023	chr5:586340	A/C	cg16447950	chr5:562315	NA	-0.52	-8.54	-0.37	1.9e-16	Ulcerative colitis;
LGG	cis	rs4595586	0.679	rs4768473	chr12:39326256	A/G	cg13010199	chr12:38710504	ALG10B	0.36	6.78	0.3	3.78e-11	Morning vs. evening chronotype;
LGG	cis	rs9815354	1.000	rs7648578	chr3:41858731	C/T	cg03022575	chr3:42003672	ULK4	0.63	8.19	0.36	2.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg02297831	chr4:17616191	MED28	0.5	9.24	0.39	8.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19601447	chr10:135192230	PAOX	0.47	7.06	0.31	6.19e-12	Gut microbiome composition (summer);
LGG	cis	rs12282928	1.000	rs11039671	chr11:48332985	G/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs2708240	0.875	rs2710120	chr7:147572711	A/G	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.68	-0.3	6.73e-11	QT interval (drug interaction);
LGG	cis	rs4820294	1.000	rs41280035	chr22:38054038	A/G	cg21798802	chr22:38057573	PDXP	0.61	14.07	0.55	1.09e-37	Fat distribution (HIV);
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs16976116	0.901	rs28535372	chr15:55500602	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2816062	0.813	rs2745318	chr1:18895844	C/T	cg18795169	chr1:18902165	NA	1.05	34.71	0.85	6.22e-131	Urate levels in lean individuals;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg26174226	chr8:58114915	NA	-0.53	-7.46	-0.33	4.33e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.933	rs9303628	chr17:28527228	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	12.7	0.51	6.5e-32	Coffee consumption (cups per day);
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg14092988	chr3:52407081	DNAH1	0.32	8.47	0.37	3.26e-16	Bipolar disorder;
LGG	cis	rs67133203	0.799	rs67259551	chr12:51378701	C/T	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4727027	0.901	rs10952792	chr7:148760501	C/T	cg23583168	chr7:148888333	NA	-0.83	-15.64	-0.59	1.46e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.6	0.41	5.2e-20	Skin colour saturation;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.73	-0.83	3.35e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6502050	0.835	rs8071425	chr17:80117335	C/T	cg13939156	chr17:80058883	NA	0.46	9.04	0.39	4.32e-18	Life satisfaction;
LGG	cis	rs8133932	0.701	rs7276114	chr21:47301187	C/T	cg13695288	chr21:47294981	PCBP3	0.36	7.22	0.32	2.17e-12	Schizophrenia;
LGG	cis	rs854037	0.670	rs4323195	chr5:57140747	T/C	cg08523694	chr5:57076192	NA	0.55	7.92	0.35	1.78e-14	Birth weight;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg13012494	chr21:47604986	C21orf56	0.49	8.21	0.36	2.21e-15	Testicular germ cell tumor;
LGG	cis	rs6942756	0.531	rs7800983	chr7:128971130	C/T	cg02491457	chr7:128862824	NA	0.49	9.0	0.39	5.68e-18	White matter hyperintensity burden;
LGG	cis	rs17001868	0.568	rs17001846	chr22:40744053	A/G	cg07138101	chr22:40742427	ADSL	0.66	8.54	0.37	1.91e-16	Mammographic density (dense area);
LGG	cis	rs589448	0.933	rs523398	chr12:69752775	C/T	cg14784868	chr12:69753453	YEATS4	1.01	24.12	0.75	7.19e-84	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3784262	0.692	rs4646590	chr15:58303137	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.76	-0.3	4.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg05861140	chr6:150128134	PCMT1	-0.29	-6.69	-0.3	6.36e-11	Testicular germ cell tumor;
LGG	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.66	0.37	7.7e-17	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18656765	chr4:159644664	PPID	0.52	7.83	0.34	3.29e-14	Gut microbiome composition (summer);
LGG	cis	rs6976053	0.935	rs314376	chr7:100457356	A/G	cg03098644	chr7:100410630	EPHB4	-0.4	-7.05	-0.31	6.49e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs72945132	0.882	rs72949078	chr11:70217708	T/C	cg14088196	chr11:70211408	PPFIA1	0.96	13.28	0.53	2.43e-34	Coronary artery disease;
LGG	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg25706281	chr1:46860511	FAAH	-0.31	-7.28	-0.32	1.49e-12	Menopause (age at onset);
LGG	cis	rs714515	0.934	rs2227199	chr1:172359780	A/G	cg01573306	chr1:172330400	DNM3	0.33	7.32	0.32	1.07e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs853679	0.607	rs33932084	chr6:28268824	A/G	cg01620082	chr3:125678407	NA	-1.05	-10.51	-0.44	2.52e-23	Depression;
LGG	cis	rs3742264	0.656	rs1080107	chr13:46516959	C/A	cg15192986	chr13:46630673	CPB2	-0.35	-6.8	-0.3	3.33e-11	Blood protein levels;
LGG	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.96	-0.54	3.35e-37	Gut microbiome composition (summer);
LGG	cis	rs10779751	0.770	rs11121691	chr1:11181327	C/T	cg08854313	chr1:11322531	MTOR	-0.71	-14.38	-0.56	5.12e-39	Body mass index;
LGG	cis	rs7241530	0.610	rs12455126	chr18:75893273	A/G	cg14642773	chr18:75888474	NA	0.48	9.42	0.4	2.16e-19	Educational attainment (years of education);
LGG	cis	rs350251	0.833	rs350272	chr16:12234773	A/C	cg02910054	chr16:12241554	SNX29	-0.5	-9.68	-0.41	2.72e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg00717180	chr2:96193071	NA	-0.49	-8.97	-0.38	7.58e-18	Coronary artery disease;
LGG	cis	rs7638909	0.512	rs7645178	chr3:38597558	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.47	-7.98	-0.35	1.17e-14	Electrocardiographic conduction measures;
LGG	cis	rs283228	0.920	rs1933356	chr6:101837672	C/T	cg27451362	chr6:101846650	GRIK2	0.57	9.73	0.41	1.74e-20	Coenzyme Q10 levels;
LGG	cis	rs6909430	0.731	rs9375247	chr6:98607366	A/G	cg12860156	chr6:98744658	NA	-0.39	-6.93	-0.31	1.41e-11	Quantitative traits;
LGG	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.72	-13.33	-0.53	1.52e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.11	0.35	4.45e-15	HIV-1 control;
LGG	cis	rs9309473	0.898	rs6546851	chr2:73833283	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.3e-14	Metabolite levels;
LGG	trans	rs9657904	0.951	rs7629357	chr3:105570818	C/G	cg14088669	chr1:158435396	OR10K1	-0.4	-6.8	-0.3	3.27e-11	Multiple sclerosis;
LGG	cis	rs6963495	0.818	rs73190158	chr7:105153943	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7607369	0.580	rs7568196	chr2:219652373	G/A	cg01130898	chr2:219473002	PLCD4	0.42	6.87	0.3	2.04e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs28386778	0.897	rs2665832	chr17:61912261	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs807029	0.533	rs2863095	chr10:102746503	C/T	cg04662943	chr10:102668895	NA	0.46	6.78	0.3	3.63e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs28830936	1.000	rs4923905	chr15:41909889	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.65	-0.51	9.93e-32	Diastolic blood pressure;
LGG	cis	rs283228	0.617	rs2852553	chr6:101768437	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs11792861	0.888	rs11794648	chr9:111829792	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.62	10.03	0.42	1.51e-21	Menarche (age at onset);
LGG	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg13298116	chr11:62369859	EML3;MTA2	-0.59	-13.74	-0.54	2.91e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4771450	0.962	rs4394937	chr13:103970382	T/C	cg02987523	chr13:103978230	NA	-0.32	-6.85	-0.3	2.33e-11	Uric acid levels;
LGG	cis	rs4819052	1.000	rs2838847	chr21:46670958	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.34	0.43	1.1e-22	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7786877	0.723	rs6969584	chr7:100209747	A/C	cg20848291	chr7:100343083	ZAN	-0.6	-8.18	-0.36	2.82e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1218582	0.744	rs6674853	chr1:154892753	G/C	cg09359103	chr1:154839909	KCNN3	-0.52	-10.57	-0.44	1.49e-23	Prostate cancer;
LGG	cis	rs1790761	0.806	rs1638557	chr11:67215988	C/G	cg00290607	chr11:67383545	NA	-0.51	-9.19	-0.39	1.33e-18	Mean corpuscular volume;
LGG	cis	rs1577917	0.958	rs2324839	chr6:86536942	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00149659	chr3:10157352	C3orf10	0.72	9.05	0.39	3.89e-18	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05598539	chr7:128695331	TNPO3;LOC286016	0.56	8.81	0.38	2.6e-17	Gut microbiome composition (summer);
LGG	cis	rs2456568	0.741	rs10831137	chr11:93636912	C/T	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.47e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12681366	0.734	rs6991077	chr8:95387805	C/T	cg13257157	chr8:95487014	RAD54B	0.38	6.78	0.3	3.58e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs10838798	0.504	rs11039673	chr11:48335156	G/A	cg15704280	chr7:45808275	SEPT13	-0.55	-9.13	-0.39	2.08e-18	Height;
LGG	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg05973401	chr12:123451056	ABCB9	0.48	7.25	0.32	1.81e-12	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs9457247	1.000	rs932644	chr6:167404187	A/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs774359	0.797	rs7864595	chr9:27495572	C/A	cg21249376	chr9:27528432	MOBKL2B	-0.42	-8.73	-0.38	4.58e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.65	-0.34	1.17e-13	Neuroticism;
LGG	cis	rs9783347	0.621	rs3802967	chr11:18344064	T/C	cg15585147	chr11:18324498	HPS5	0.31	6.94	0.31	1.36e-11	Pancreatic cancer;
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg15017067	chr4:17643749	FAM184B	0.3	6.66	0.3	7.83e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7503807	0.967	rs12947696	chr17:78596793	C/T	cg09596252	chr17:78655493	RPTOR	0.42	7.45	0.33	4.55e-13	Obesity;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.43	-0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3820068	0.580	rs34426856	chr1:16006315	C/T	cg05660106	chr1:15850417	CASP9	0.72	13.01	0.52	3.41e-33	Systolic blood pressure;
LGG	cis	rs7937682	0.961	rs4936682	chr11:111629743	T/G	cg22437258	chr11:111473054	SIK2	-0.52	-8.86	-0.38	1.73e-17	Primary sclerosing cholangitis;
LGG	cis	rs17253792	0.545	rs35418987	chr14:56017407	T/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs17641971	0.645	rs10504073	chr8:50024944	C/T	cg00325661	chr8:49890786	NA	0.56	10.56	0.44	1.74e-23	Blood metabolite levels;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg00864171	chr11:67383662	NA	0.55	9.56	0.41	7.18e-20	Mean corpuscular volume;
LGG	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg19700328	chr14:106028568	NA	-0.64	-10.33	-0.43	1.18e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	ch.17.1008464R	chr17:37630567	CDK12	0.4	7.07	0.31	5.87e-12	Bipolar disorder;
LGG	cis	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg09085632	chr11:111637200	PPP2R1B	-0.74	-13.67	-0.54	5.7e-36	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.21	0.36	2.25e-15	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg15971980	chr6:150254442	NA	0.44	8.36	0.36	7.14e-16	Lung cancer;
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.5	-0.56	1.58e-39	Tonsillectomy;
LGG	cis	rs4253772	0.591	rs739165	chr22:46684528	C/T	cg09461388	chr22:46763229	CELSR1	-0.7	-7.24	-0.32	1.92e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11675119	0.517	rs12619851	chr2:3492747	T/C	cg10845886	chr2:3471009	TTC15	-0.46	-8.84	-0.38	1.94e-17	Neurofibrillary tangles;
LGG	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.8e-12	HDL cholesterol;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg06638463	chr19:10530633	PDE4A	0.42	7.49	0.33	3.44e-13	Obesity-related traits;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.59	-10.3	-0.43	1.52e-22	Longevity;Endometriosis;
LGG	cis	rs7829975	0.871	rs777709	chr8:8583872	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.71	-0.38	5.42e-17	Mood instability;
LGG	cis	rs10979	0.557	rs9376767	chr6:143909380	G/A	cg25407410	chr6:143891975	LOC285740	-0.56	-8.24	-0.36	1.8e-15	Hypospadias;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs711245	0.863	rs848607	chr2:36770192	G/A	cg01206211	chr2:36825736	FEZ2	0.41	7.8	0.34	4.07e-14	Height;
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.74	0.38	4.26e-17	Morning vs. evening chronotype;
LGG	cis	rs10789491	1.000	rs1258061	chr1:47105000	G/A	cg15501359	chr1:47185051	KIAA0494	-0.74	-14.33	-0.55	8.39e-39	Response to hepatitis C treatment;
LGG	cis	rs17270561	0.609	rs7746609	chr6:25727996	C/T	cg12310025	chr6:25882481	NA	0.46	7.85	0.34	3e-14	Iron status biomarkers;
LGG	cis	rs4936891	0.599	rs729775	chr11:123910401	C/A	cg22125253	chr11:123886957	OR10G4	-0.54	-9.25	-0.39	8.55e-19	Male fertility;
LGG	cis	rs17208368	0.628	rs8060014	chr16:55092421	C/T	cg11181171	chr16:55090946	NA	0.45	7.36	0.32	8.64e-13	Hypospadias;
LGG	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.37	0.36	6.81e-16	Mood instability;
LGG	cis	rs2797369	0.713	rs943910	chr6:101576535	G/T	cg27451362	chr6:101846650	GRIK2	0.81	10.88	0.45	1.06e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs67311347	1.000	rs4973998	chr3:40460352	C/T	cg13683864	chr3:40499215	RPL14	-1.14	-26.35	-0.77	3.62e-94	Renal cell carcinoma;
LGG	trans	rs6601327	0.540	rs4841225	chr8:9669164	T/A	cg16141378	chr3:129829833	LOC729375	0.33	7.38	0.32	7.32e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs193541	0.593	rs154517	chr5:122189825	A/T	cg19412675	chr5:122181750	SNX24	0.51	8.18	0.36	2.69e-15	Glucose homeostasis traits;
LGG	cis	rs4006360	0.537	rs12602811	chr17:39245273	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.5e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1124376	0.832	rs6793985	chr3:20136485	T/C	cg05072819	chr3:20081367	KAT2B	0.6	8.09	0.35	5.29e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11719291	0.915	rs11557629	chr3:48732223	G/A	cg00383909	chr3:49044727	WDR6	0.9	11.22	0.46	5.15e-26	Cognitive function;
LGG	cis	rs5769765	0.955	rs2319465	chr22:50265784	A/C	cg26441486	chr22:50317300	CRELD2	-0.42	-7.56	-0.33	2.22e-13	Schizophrenia;
LGG	cis	rs4975616	0.773	rs414965	chr5:1324121	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.86	-17.41	-0.63	1.3e-52	Lung cancer;
LGG	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.13	-0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-9.02	-0.39	5.07e-18	Response to antipsychotic treatment;
LGG	cis	rs4538187	0.547	rs12713498	chr2:64112428	C/T	cg19915305	chr2:64069682	UGP2	0.45	10.15	0.43	5.34e-22	Systolic blood pressure;
LGG	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.54e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg03733263	chr8:22462867	KIAA1967	-0.94	-20.7	-0.69	7.47e-68	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg26897989	chr16:1907736	C16orf73	-0.85	-13.94	-0.54	4.02e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7666738	0.830	rs13102369	chr4:99045912	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.84	-0.45	1.46e-24	Systolic blood pressure;
LGG	cis	rs10256972	0.591	rs6950319	chr7:1161324	A/G	cg03188948	chr7:1209495	NA	0.4	6.99	0.31	9.77e-12	Longevity;Endometriosis;
LGG	cis	rs1003719	0.788	rs2835597	chr21:38466539	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.6	7.05	0.31	6.61e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7192750	0.652	rs152828	chr16:72123886	T/C	cg14768367	chr16:72042858	DHODH	0.75	8.34	0.36	8.82e-16	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7959452	0.590	rs11177644	chr12:69785748	A/G	cg14784868	chr12:69753453	YEATS4	0.91	20.24	0.69	1.01e-65	Blood protein levels;
LGG	cis	rs7267979	1.000	rs6138575	chr20:25438952	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.18	0.43	4.27e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.91	0.45	7.76e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg13047869	chr3:10149882	C3orf24	0.54	9.09	0.39	2.91e-18	Alzheimer's disease;
LGG	cis	rs9788721	0.836	rs2656052	chr15:78740932	A/C	cg18825076	chr15:78729989	IREB2	-0.55	-9.19	-0.39	1.36e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg18851795	chr1:204543875	NA	-0.36	-6.73	-0.3	4.97e-11	Schizophrenia;
LGG	cis	rs526231	0.578	rs34786	chr5:102458113	C/G	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs12476592	0.516	rs6717060	chr2:63568608	G/A	cg17519650	chr2:63277830	OTX1	-0.51	-7.89	-0.34	2.15e-14	Childhood ear infection;
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4262150	0.846	rs4958573	chr5:152091739	G/A	cg12297329	chr5:152029980	NA	-0.79	-14.64	-0.56	3.79e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg20821713	chr7:1055600	C7orf50	-0.41	-7.92	-0.35	1.79e-14	Longevity;Endometriosis;
LGG	cis	rs9911578	0.900	rs8067264	chr17:57182793	G/C	cg05425664	chr17:57184151	TRIM37	-0.71	-11.65	-0.48	1.15e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7444	0.941	rs5749485	chr22:21938224	A/C	cg22858872	chr22:21984481	YDJC	-0.35	-6.77	-0.3	3.94e-11	Systemic lupus erythematosus;
LGG	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.27	0.36	1.47e-15	Neuroticism;
LGG	cis	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg18188782	chr20:61659543	NA	0.39	6.71	0.3	5.68e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28386778	0.897	rs896064	chr17:61860932	C/T	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg15971980	chr6:150254442	NA	0.43	7.22	0.32	2.1e-12	Lung cancer;
LGG	cis	rs1476670	0.710	rs753637	chr1:44508927	A/G	cg09470012	chr1:44509516	NA	0.43	8.43	0.36	4.35e-16	Eotaxin levels;
LGG	cis	rs55823223	0.564	rs4572466	chr17:73846314	A/C	cg08125733	chr17:73851984	WBP2	0.72	11.33	0.47	1.89e-26	Psoriasis;
LGG	cis	rs2859741	0.967	rs494157	chr1:37512995	C/T	cg09363841	chr1:37513479	NA	0.63	15.82	0.59	2.19e-45	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs9790314	0.582	rs13071909	chr3:160604864	A/G	cg03342759	chr3:160939853	NMD3	0.45	7.57	0.33	1.97e-13	Morning vs. evening chronotype;
LGG	cis	rs7829975	0.688	rs7827182	chr8:8380471	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	11.62	0.48	1.43e-27	Mood instability;
LGG	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg07636037	chr3:49044803	WDR6	0.61	10.57	0.44	1.49e-23	Resting heart rate;
LGG	cis	rs9487094	0.670	rs12193719	chr6:109910254	C/G	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.34e-15	Height;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08104402	chr16:1663436	IFT140;CRAMP1L	0.42	6.68	0.3	6.71e-11	Cognitive performance;
LGG	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.31	0.36	1.08e-15	Diabetic kidney disease;
LGG	trans	rs62344088	0.590	rs6889904	chr5:177264	A/C	cg00938859	chr5:1591904	SDHAP3	0.77	6.87	0.3	2.11e-11	Asthma (childhood onset);
LGG	cis	rs12908161	1.000	rs4643294	chr15:85250253	C/T	cg24253500	chr15:84953950	NA	0.42	7.02	0.31	7.99e-12	Schizophrenia;
LGG	trans	rs7395662	0.500	rs10838984	chr11:48640485	C/T	cg03929089	chr4:120376271	NA	-0.57	-9.86	-0.42	5.9e-21	HDL cholesterol;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg27476859	chr7:2772710	GNA12	0.46	8.87	0.38	1.61e-17	Height;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.61	0.41	4.82e-20	Longevity;
LGG	cis	rs208520	0.526	rs1385219	chr6:66754476	C/T	cg07460842	chr6:66804631	NA	1.11	29.34	0.81	1.13e-107	Exhaled nitric oxide output;
LGG	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg08717414	chr16:71523259	ZNF19	-0.47	-7.25	-0.32	1.75e-12	Post bronchodilator FEV1;
LGG	cis	rs67460515	0.563	rs6772723	chr3:160895074	C/G	cg04691961	chr3:161091175	C3orf57	-0.45	-8.42	-0.36	4.88e-16	Parkinson's disease;
LGG	cis	rs58649573	0.509	rs4836955	chr9:126788469	G/A	cg14112217	chr9:126806003	NA	0.4	8.0	0.35	9.9e-15	Post-traumatic stress disorder;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg22907277	chr7:1156413	C7orf50	0.71	13.32	0.53	1.63e-34	Longevity;Endometriosis;
LGG	cis	rs11229555	0.645	rs11229445	chr11:58199458	G/A	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4363385	0.818	rs4845335	chr1:152993955	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.92	-0.38	1.08e-17	Inflammatory skin disease;
LGG	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg09021430	chr5:549028	NA	-0.69	-9.64	-0.41	3.71e-20	Obesity-related traits;
LGG	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.42	-6.72	-0.3	5.42e-11	Carotid intima media thickness;
LGG	cis	rs6918586	0.658	rs198837	chr6:26113398	A/T	cg18357526	chr6:26021779	HIST1H4A	0.56	9.73	0.41	1.69e-20	Schizophrenia;
LGG	cis	rs17270561	0.609	rs9348692	chr6:25720812	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.44	-0.33	4.84e-13	Iron status biomarkers;
LGG	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg03929089	chr4:120376271	NA	-1.01	-21.75	-0.71	8.55e-73	Height;
LGG	cis	rs7618915	0.501	rs11714030	chr3:52765882	C/T	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.67e-15	Bipolar disorder;
LGG	cis	rs4356203	0.905	rs594034	chr11:17222380	G/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.31	-0.32	1.16e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs6840360	0.837	rs13146981	chr4:152720703	T/C	cg22705602	chr4:152727874	NA	0.27	6.7	0.3	6.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	0.872	rs7112608	chr11:34699269	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.31	-0.32	1.18e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg02951883	chr7:2050386	MAD1L1	-0.64	-12.05	-0.49	2.91e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs736801	0.569	rs11748193	chr5:131725329	A/T	cg07395648	chr5:131743802	NA	-0.59	-13.01	-0.52	3.34e-33	Breast cancer;Mosquito bite size;
LGG	cis	rs769267	0.896	rs2315610	chr19:19597240	T/C	cg11584989	chr19:19387371	SF4	0.39	7.15	0.32	3.5e-12	Tonsillectomy;
LGG	cis	rs6714710	0.580	rs13032265	chr2:98409565	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.49	0.4	1.22e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs1401999	0.899	rs2313211	chr3:183738626	T/A	cg01324343	chr3:183735012	ABCC5	0.89	18.34	0.65	7.42e-57	Anterior chamber depth;
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.94	-0.31	1.33e-11	Aortic root size;
LGG	cis	rs933688	1.000	rs12651840	chr5:90729592	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.12	0.68	3.87e-65	Smoking behavior;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.58	-11.64	-0.48	1.2100000000000001e-27	Obesity-related traits;
LGG	cis	rs11074306	0.521	rs17674169	chr15:28071302	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg05941027	chr17:61774174	LIMD2	0.38	9.76	0.41	1.37e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg08125733	chr17:73851984	WBP2	0.7	10.96	0.45	5.09e-25	Psoriasis;
LGG	cis	rs7618915	0.501	rs2336146	chr3:52626646	A/G	cg14092988	chr3:52407081	DNAH1	0.3	8.09	0.35	5.24e-15	Bipolar disorder;
LGG	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg13010199	chr12:38710504	ALG10B	-0.55	-11.04	-0.46	2.6e-25	Heart rate;
LGG	cis	rs12477438	0.765	rs6750876	chr2:99679673	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs72991	0.639	rs1529579	chr11:121235871	G/T	cg27192990	chr6:129479024	LAMA2	-0.6	-9.62	-0.41	4.31e-20	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7681440	0.835	rs6839608	chr4:90805493	T/C	cg20003494	chr4:90757398	SNCA	-0.41	-8.04	-0.35	7.61e-15	Dementia with Lewy bodies;
LGG	cis	rs6445975	0.667	rs34532954	chr3:58243594	C/A	cg24175188	chr3:58374923	PXK	0.39	7.22	0.32	2.1e-12	Systemic lupus erythematosus;
LGG	cis	rs7945718	0.875	rs9888181	chr11:12782781	G/A	cg25843174	chr11:12811716	TEAD1	0.4	8.25	0.36	1.67e-15	Educational attainment (years of education);
LGG	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg13271783	chr10:134563150	INPP5A	0.56	8.48	0.37	2.99e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13190924	chr15:44084524	SERF2	-0.45	-6.95	-0.31	1.24e-11	Pancreatic cancer;
LGG	cis	rs1552244	0.882	rs28366039	chr3:10028988	C/A	cg08888203	chr3:10149979	C3orf24	0.52	8.55	0.37	1.74e-16	Alzheimer's disease;
LGG	cis	rs9399135	0.967	rs12526055	chr6:135325918	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.55	0.41	7.79e-20	Red blood cell count;
LGG	cis	rs1005277	0.541	rs2472177	chr10:38384015	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-7.35	-0.32	8.91e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg21775007	chr8:11205619	TDH	-0.46	-7.63	-0.33	1.31e-13	Mood instability;
LGG	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg10189774	chr4:17578691	LAP3	0.4	7.01	0.31	8.52e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg23205692	chr1:25664452	TMEM50A	0.48	10.33	0.43	1.22e-22	Erythrocyte sedimentation rate;
LGG	cis	rs597583	0.951	rs636530	chr11:117421858	C/T	cg27161313	chr11:117392002	DSCAML1	0.41	7.01	0.31	8.65e-12	Putamen volume;
LGG	cis	rs875971	0.545	rs1638735	chr7:66095738	C/T	cg11764359	chr7:65958608	NA	0.71	10.07	0.42	1.07e-21	Aortic root size;
LGG	cis	rs3106136	0.967	rs66581998	chr4:95196901	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.45	-8.01	-0.35	9.64e-15	Capecitabine sensitivity;
LGG	trans	rs9329221	0.655	rs4316191	chr8:10259229	G/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.72	-0.3	5.47e-11	Neuroticism;
LGG	cis	rs12824058	0.831	rs4759653	chr12:130812604	T/C	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.51e-14	Menopause (age at onset);
LGG	cis	rs2051211	0.895	rs2300670	chr3:38555815	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.58	-9.0	-0.39	5.96e-18	QRS duration;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg07701084	chr6:150067640	NUP43	0.61	11.38	0.47	1.25e-26	Lung cancer;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg24497897	chr11:65658826	CCDC85B	0.39	6.68	0.3	6.73e-11	Body mass index;
LGG	cis	rs651907	0.565	rs2925323	chr3:101658926	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.38	6.93	0.31	1.44e-11	Colorectal cancer;
LGG	cis	rs868036	0.958	rs3784709	chr15:68072275	C/T	cg05925327	chr15:68127851	NA	-0.37	-8.45	-0.37	3.94e-16	Restless legs syndrome;
LGG	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg13147721	chr7:65941812	NA	-0.73	-9.13	-0.39	2.16e-18	Diabetic kidney disease;
LGG	cis	rs11098499	0.780	rs10013652	chr4:120292256	A/G	cg09307838	chr4:120376055	NA	0.72	12.08	0.49	2.17e-29	Corneal astigmatism;
LGG	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg11644478	chr21:40555479	PSMG1	0.87	15.66	0.59	1.2e-44	Cognitive function;
LGG	cis	rs1153858	1.000	rs66714503	chr15:45648038	G/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	trans	rs7395662	0.819	rs12269855	chr11:48778652	C/G	cg03929089	chr4:120376271	NA	-0.43	-7.03	-0.31	7.39e-12	HDL cholesterol;
LGG	cis	rs6541297	1.000	rs2352723	chr1:230291868	C/T	cg05784532	chr1:230284198	GALNT2	-0.55	-9.09	-0.39	2.85e-18	Coronary artery disease;
LGG	cis	rs780096	0.546	rs715325	chr2:27725572	C/A	cg22903471	chr2:27725779	GCKR	-0.58	-13.5	-0.53	2.84e-35	Total body bone mineral density;
LGG	cis	rs9296092	0.500	rs9461885	chr6:33521069	G/T	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs17376456	0.597	rs10064158	chr5:93095186	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs6489785	1.000	rs6489785	chr12:121363724	C/T	cg02419362	chr12:121203948	SPPL3	-0.45	-7.37	-0.32	7.88e-13	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs2470578	0.792	rs2733491	chr3:17308965	G/A	cg20981856	chr3:17787350	NA	0.35	6.76	0.3	4.29e-11	Schizophrenia;
LGG	trans	rs9914544	0.545	rs2386404	chr17:18769349	T/C	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.54	-0.33	2.51e-13	Educational attainment (years of education);
LGG	cis	rs2836950	0.565	rs8130320	chr21:40580258	C/T	cg17971929	chr21:40555470	PSMG1	-0.54	-9.24	-0.39	8.79e-19	Menarche (age at onset);
LGG	cis	rs10751667	0.857	rs7481221	chr11:966813	G/A	cg11406765	chr11:980039	AP2A2	-0.69	-7.53	-0.33	2.73e-13	Alzheimer's disease (late onset);
LGG	cis	rs11098499	0.954	rs56270433	chr4:120406030	C/T	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs9527	0.544	rs3781280	chr10:104863843	T/G	cg04362960	chr10:104952993	NT5C2	0.55	10.19	0.43	3.91e-22	Arsenic metabolism;
LGG	cis	rs877282	0.583	rs7072970	chr10:822757	G/A	cg01169559	chr10:831247	NA	0.53	9.35	0.4	3.68e-19	Uric acid levels;
LGG	cis	rs1008375	0.931	rs6449328	chr4:17700474	C/T	cg18681998	chr4:17616180	MED28	0.73	14.94	0.57	1.87e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg23302884	chr18:44338147	ST8SIA5	0.36	6.97	0.31	1.12e-11	Personality dimensions;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12468850	chr8:21767224	DOK2	0.35	6.72	0.3	5.21e-11	Pancreatic cancer;
LGG	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg13114125	chr14:105738426	BRF1	-0.84	-16.52	-0.61	1.6e-48	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10895140	0.718	rs10750610	chr11:101518419	T/C	cg23650423	chr11:101454676	TRPC6	-0.43	-6.82	-0.3	2.89e-11	Menarche (age at onset);
LGG	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg22437258	chr11:111473054	SIK2	0.54	9.54	0.41	8.01e-20	Primary sclerosing cholangitis;
LGG	cis	rs2404602	0.647	rs35710279	chr15:77082234	T/A	cg23625390	chr15:77176239	SCAPER	-0.75	-14.9	-0.57	2.83e-41	Blood metabolite levels;
LGG	cis	rs9926296	0.607	rs11076629	chr16:89875259	T/C	cg23057051	chr16:89984268	MC1R	-0.36	-7.14	-0.31	3.71e-12	Vitiligo;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg27532560	chr4:187881888	NA	-0.6	-12.98	-0.52	4.4e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs16837677	0.655	rs4661058	chr1:156730599	C/T	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs832540	0.898	rs331498	chr5:56249842	C/G	cg14703610	chr5:56206110	C5orf35	-0.46	-7.95	-0.35	1.48e-14	Coronary artery disease;
LGG	cis	rs7945705	0.967	rs56316046	chr11:8876598	G/T	cg00186954	chr11:8933980	ST5;C11orf17	0.37	7.48	0.33	3.69e-13	Hemoglobin concentration;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg16301924	chr13:53314226	LECT1	-0.48	-10.12	-0.43	6.83e-22	Lewy body disease;
LGG	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg21644426	chr2:191273491	MFSD6	-0.57	-10.02	-0.42	1.55e-21	Pulse pressure;
LGG	cis	rs1775715	0.737	rs1419171	chr10:32214831	C/A	cg14930904	chr10:32216787	ARHGAP12	0.35	6.66	0.3	7.99e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs10504229	0.683	rs11785260	chr8:58132906	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs2211420	chr6:125995549	A/G	cg05901451	chr6:126070800	HEY2	-0.42	-7.06	-0.31	6.1e-12	Endometrial cancer;
LGG	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.24	0.39	9.22e-19	Diabetic retinopathy;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.27	-0.36	1.48e-15	Life satisfaction;
LGG	cis	rs6772849	1.000	rs2713605	chr3:128307460	A/T	cg08795948	chr3:128337044	NA	0.53	8.76	0.38	3.83e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs738322	0.901	rs132941	chr22:38545942	T/C	cg03162506	chr22:38580953	NA	0.34	8.78	0.38	3.18e-17	Cutaneous nevi;
LGG	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg09238746	chr17:78121135	EIF4A3	0.89	15.65	0.59	1.3e-44	Yeast infection;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg05165339	chr4:1420672	NA	-0.35	-9.01	-0.39	5.37e-18	Longevity;
LGG	trans	rs6076960	0.622	rs6054063	chr20:6262992	C/A	cg21095983	chr6:86352623	SYNCRIP	0.54	9.95	0.42	2.88e-21	Smooth-surface caries;
LGG	cis	rs12477438	0.798	rs2084987	chr2:99587885	C/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.2	-0.49	7.02e-30	Chronic sinus infection;
LGG	cis	rs6728642	0.908	rs9973669	chr2:97679094	T/C	cg26665480	chr2:98280029	ACTR1B	-0.67	-7.87	-0.34	2.62e-14	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs7904985	0.961	rs12355013	chr10:88114538	A/G	cg07322936	chr10:88137208	NA	0.48	7.25	0.32	1.78e-12	Barrett's esophagus;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2273669	0.915	rs1887414	chr6:109292736	C/T	cg05315195	chr6:109294784	ARMC2	0.54	8.04	0.35	7.84e-15	Prostate cancer;
LGG	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.54e-24	Aortic root size;
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg04703951	chr17:43578652	NA	-0.29	-6.67	-0.3	7.24e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs516946	1.000	rs3802315	chr8:41528178	G/T	cg01678292	chr8:41522873	ANK1	0.35	8.05	0.35	6.91e-15	Type 2 diabetes;
LGG	cis	rs910316	1.000	rs10136948	chr14:75511075	C/T	cg11812906	chr14:75593930	NEK9	0.53	9.87	0.42	5.52e-21	Height;
LGG	cis	rs9467711	0.606	rs34622023	chr6:26362119	A/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.83	-14.51	-0.56	1.42e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg03511173	chr18:77590860	NA	0.43	7.28	0.32	1.4e-12	Schizophrenia;
LGG	cis	rs12780845	0.540	rs7096079	chr10:17180675	A/C	cg01003015	chr10:17271136	VIM	-0.44	-7.53	-0.33	2.76e-13	Homocysteine levels;
LGG	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.58	0.53	1.38e-35	Breast cancer;
LGG	cis	rs11651000	0.857	rs11658383	chr17:45842354	A/C	cg24803719	chr17:45855879	NA	-0.27	-6.9	-0.31	1.77e-11	IgG glycosylation;
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs738321	0.757	rs2235345	chr22:38518177	C/T	cg03162506	chr22:38580953	NA	0.39	9.29	0.4	6.22e-19	Breast cancer;
LGG	cis	rs7617773	0.539	rs2017858	chr3:48382282	G/T	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs2033317	chr2:26477650	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.07	21.13	0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs709400	0.663	rs7152202	chr14:103886757	A/G	cg26031613	chr14:104095156	KLC1	0.79	14.04	0.55	1.45e-37	Body mass index;
LGG	trans	rs1941687	0.797	rs7228309	chr18:31412519	A/G	cg27147174	chr7:100797783	AP1S1	0.53	8.93	0.38	1.03e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs12142240	0.698	rs6659228	chr1:46811027	C/G	cg14993813	chr1:46806288	NSUN4	-0.54	-8.81	-0.38	2.48e-17	Menopause (age at onset);
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg09699651	chr6:150184138	LRP11	0.54	9.71	0.41	2.11e-20	Lung cancer;
LGG	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg18240062	chr17:79603768	NPLOC4	0.81	15.43	0.58	1.23e-43	Eye color traits;
LGG	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg25801113	chr15:45476975	SHF	0.88	20.26	0.69	8.23e-66	Uric acid levels;
LGG	cis	rs41271473	1.000	rs4641285	chr1:228878663	G/A	cg00850481	chr1:228891306	NA	-0.5	-8.66	-0.37	8.02e-17	Chronic lymphocytic leukemia;
LGG	cis	rs9640161	0.830	rs76741564	chr7:150059529	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.57	-10.54	-0.44	1.92e-23	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.67	-0.37	7.17e-17	Personality dimensions;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.89	0.66	1.96e-59	Menopause (age at onset);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg16604136	chr1:163291493	NUF2	0.41	6.79	0.3	3.36e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6500602	0.701	rs8053770	chr16:4539030	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.36	6.78	0.3	3.63e-11	Schizophrenia;
LGG	cis	rs6502050	0.799	rs6502066	chr17:80103737	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs757081	0.658	rs214101	chr11:17289354	A/G	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.18	-0.32	2.84e-12	Systolic blood pressure;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg19223190	chr17:80058835	NA	0.43	8.37	0.36	6.99e-16	Life satisfaction;
LGG	cis	rs7208859	0.623	rs55814012	chr17:29077697	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg16141378	chr3:129829833	LOC729375	-0.43	-10.5	-0.44	2.69e-23	Mood instability;
LGG	cis	rs7572733	0.935	rs2880389	chr2:198801707	T/C	cg00792783	chr2:198669748	PLCL1	0.48	7.97	0.35	1.23e-14	Dermatomyositis;
LGG	cis	rs9650657	0.562	rs10090444	chr8:10745469	C/G	cg27411982	chr8:10470053	RP1L1	0.46	7.8	0.34	4.06e-14	Neuroticism;
LGG	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6500602	0.826	rs7205189	chr16:4460114	A/G	cg02048412	chr16:4421654	VASN;CORO7	0.28	7.03	0.31	7.44e-12	Schizophrenia;
LGG	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg08847533	chr14:75593920	NEK9	-0.58	-11.01	-0.46	3.44e-25	Height;
LGG	cis	rs2404602	0.692	rs36070630	chr15:76949259	T/C	cg22467129	chr15:76604101	ETFA	-0.44	-7.34	-0.32	9.94e-13	Blood metabolite levels;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg01879757	chr17:41196368	BRCA1	-0.4	-8.19	-0.36	2.61e-15	Menopause (age at onset);
LGG	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.63	-0.44	9.25e-24	Total body bone mineral density;
LGG	cis	rs10089	0.953	rs4836359	chr5:127385518	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.44	0.47	7.49e-27	Ileal carcinoids;
LGG	cis	rs300774	1.000	rs300692	chr2:181415	C/T	cg21211680	chr2:198530	NA	-0.55	-7.06	-0.31	6.09e-12	Suicide attempts in bipolar disorder;
LGG	trans	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg07817883	chr1:32538562	TMEM39B	1.44	13.58	0.53	1.38e-35	Granulocyte percentage of myeloid white cells;
LGG	trans	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg16141378	chr3:129829833	LOC729375	0.39	9.0	0.39	5.81e-18	Morning vs. evening chronotype;
LGG	cis	rs1801251	1.000	rs1022330	chr2:233577330	G/A	cg25237894	chr2:233734115	C2orf82	0.65	12.33	0.5	2.07e-30	Coronary artery disease;
LGG	cis	rs7580658	0.963	rs4233583	chr2:128060068	C/A	cg10021288	chr2:128175891	PROC	-0.64	-13.28	-0.53	2.51e-34	Protein C levels;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg05859214	chr5:133337475	VDAC1	-0.44	-6.74	-0.3	4.59e-11	Apolipoprotein A-IV levels;
LGG	cis	rs9467773	0.626	rs6935803	chr6:26350495	A/G	cg09904177	chr6:26538194	HMGN4	-0.46	-8.3	-0.36	1.17e-15	Intelligence (multi-trait analysis);
LGG	trans	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg10756647	chr7:56101905	PSPH	0.45	6.68	0.3	6.71e-11	Corneal structure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06932451	chr19:36869880	NA	0.41	6.97	0.31	1.12e-11	Cognitive performance;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg12419862	chr22:24373484	LOC391322	0.99	21.33	0.7	8.28e-71	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs6887276	0.538	rs35897671	chr5:127349745	C/T	cg16011800	chr17:1958478	HIC1	0.42	6.92	0.31	1.5e-11	Height;
LGG	cis	rs2032447	0.714	rs175319	chr6:25956172	A/G	cg18357526	chr6:26021779	HIST1H4A	0.87	15.82	0.59	2.28e-45	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.650	rs657913	chr8:9882575	G/T	cg21775007	chr8:11205619	TDH	-0.44	-6.97	-0.31	1.08e-11	Neuroticism;
LGG	cis	rs7949030	0.626	rs11231154	chr11:62362293	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.08	0.57	4.54e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg17644776	chr2:200775616	C2orf69	-0.67	-8.34	-0.36	8.4e-16	Schizophrenia;
LGG	cis	rs11148252	0.683	rs9536006	chr13:52887707	T/G	cg12458913	chr13:53173898	NA	0.62	11.96	0.49	6.26e-29	Lewy body disease;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg26354017	chr1:205819088	PM20D1	-0.55	-10.58	-0.44	1.47e-23	Menarche (age at onset);
LGG	cis	rs9522267	0.535	rs7326875	chr13:112236231	C/T	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.66	13.45	0.53	4.93e-35	Prudent dietary pattern;
LGG	cis	rs9807841	0.670	rs8102380	chr19:10801185	G/A	cg17710535	chr19:10819994	QTRT1	0.45	6.94	0.31	1.35e-11	Inflammatory skin disease;
LGG	cis	rs4262150	0.883	rs72799151	chr5:152110837	C/A	cg12297329	chr5:152029980	NA	-0.7	-12.9	-0.51	9.38e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23604584	chr13:50367114	KPNA3	0.45	7.3	0.32	1.26e-12	Cognitive performance;
LGG	cis	rs17169635	0.879	rs7798969	chr7:134547679	G/T	cg02516134	chr7:134575187	CALD1	-0.39	-7.95	-0.35	1.4e-14	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg11062466	chr8:58055876	NA	0.5	8.52	0.37	2.19e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17433780	0.504	rs1409150	chr1:89473175	A/G	cg09516651	chr1:89888402	LOC400759	0.56	12.64	0.51	1.13e-31	Carotid intima media thickness;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11645453	chr3:52864694	ITIH4	0.4	6.66	0.3	7.94e-11	Bipolar disorder;
LGG	cis	rs3813359	0.545	rs1932113	chr6:130555422	C/T	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4538187	1.000	rs13431781	chr2:64086372	A/G	cg14150252	chr2:64069583	UGP2	0.5	10.02	0.42	1.67e-21	Systolic blood pressure;
LGG	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.74	-0.3	4.78e-11	Triglycerides;
LGG	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.14	0.31	3.65e-12	Resting heart rate;
LGG	cis	rs16944613	0.528	rs6416554	chr15:91138290	T/C	cg26821196	chr15:91095069	CRTC3	0.5	7.13	0.31	3.79e-12	Colorectal cancer;
LGG	cis	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.04	-0.31	7.17e-12	Morning vs. evening chronotype;
LGG	cis	rs1728785	0.892	rs4783648	chr16:68558334	C/T	cg02972257	chr16:68554789	NA	0.65	9.16	0.39	1.72e-18	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04786791	chr1:218458496	RRP15	0.47	7.26	0.32	1.61e-12	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.802	rs194058	chr5:56188977	G/A	cg12654349	chr5:56205094	C5orf35	-0.69	-10.67	-0.44	6.49e-24	Initial pursuit acceleration;
LGG	cis	rs4689642	0.718	rs62289707	chr4:7224978	T/C	cg21353189	chr4:7228343	SORCS2	0.39	9.07	0.39	3.34e-18	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs9467711	0.606	rs1977	chr6:26377546	A/G	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg27286069	chr11:118481882	PHLDB1	-0.37	-6.81	-0.3	3.04e-11	Glioma;
LGG	cis	rs9457247	0.624	rs9457260	chr6:167466665	C/T	cg07741184	chr6:167504864	NA	0.44	10.07	0.42	1.03e-21	Crohn's disease;
LGG	trans	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg07211511	chr3:129823064	LOC729375	-0.66	-9.16	-0.39	1.64e-18	Blood pressure (smoking interaction);
LGG	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-10.54	-0.44	2.0500000000000001e-23	Depression;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg24642844	chr7:1081250	C7orf50	-0.72	-13.01	-0.52	3.36e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3771570	1.000	rs17386695	chr2:242379751	A/G	cg21155796	chr2:242212141	HDLBP	-0.76	-10.19	-0.43	3.86e-22	Prostate cancer;
LGG	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.95	10.85	0.45	1.39e-24	Lung cancer in ever smokers;
LGG	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	8.86e-19	Diabetic retinopathy;
LGG	cis	rs3857536	0.605	rs36040831	chr6:66876588	G/A	cg07460842	chr6:66804631	NA	-0.67	-12.64	-0.51	1.15e-31	Blood trace element (Cu levels);
LGG	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg22348356	chr13:114891224	RASA3	0.44	8.93	0.38	1e-17	Schizophrenia;
LGG	cis	rs11864453	0.793	rs7197453	chr16:72079127	G/C	cg01557791	chr16:72042693	DHODH	-0.63	-11.24	-0.46	4.49e-26	Fibrinogen levels;
LGG	cis	rs2708240	0.936	rs2538976	chr7:147585819	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.73	-0.3	5.07e-11	QT interval (drug interaction);
LGG	cis	rs283228	0.550	rs646273	chr6:101784844	G/A	cg02011392	chr6:101847541	GRIK2	0.53	7.25	0.32	1.73e-12	Coenzyme Q10 levels;
LGG	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-16.06	-0.6	1.79e-46	Calcium levels;
LGG	cis	rs975739	0.695	rs1537067	chr13:78581501	A/G	cg07847733	chr13:78271382	SLAIN1	0.45	7.77	0.34	4.99e-14	Hair color;
LGG	cis	rs644799	1.000	rs593665	chr11:95574302	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8180040	0.764	rs2132173	chr3:47247060	C/T	cg22292345	chr3:47051533	LOC100129354	-0.28	-6.75	-0.3	4.47e-11	Colorectal cancer;
LGG	cis	rs7666738	0.677	rs13120306	chr4:99036099	A/T	cg05340658	chr4:99064831	C4orf37	0.48	7.8	0.34	4.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11920090	0.789	rs6774307	chr3:170759494	T/C	cg09710316	chr3:170744871	SLC2A2	0.71	8.51	0.37	2.46e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs877282	0.947	rs957642	chr10:773966	C/T	cg17470449	chr10:769945	NA	0.62	7.98	0.35	1.14e-14	Uric acid levels;
LGG	cis	rs7572733	0.534	rs2060488	chr2:198751637	T/G	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.82	-0.59	2.26e-45	Height;
LGG	cis	rs2797369	0.550	rs2764273	chr6:101660659	G/T	cg27451362	chr6:101846650	GRIK2	0.48	7.45	0.33	4.65e-13	Renal function-related traits (eGRFcrea);
LGG	trans	rs11039798	0.925	rs7929225	chr11:48931739	G/C	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs4132509	0.948	rs12136624	chr1:243981611	C/A	cg21452805	chr1:244014465	NA	0.67	7.99	0.35	1.08e-14	RR interval (heart rate);
LGG	cis	rs11148252	0.819	rs7336679	chr13:53043333	G/A	cg16301924	chr13:53314226	LECT1	-0.48	-10.06	-0.42	1.19e-21	Lewy body disease;
LGG	cis	rs8067287	0.688	rs11652843	chr17:16843250	A/C	cg26910001	chr17:16838321	NA	-0.45	-8.81	-0.38	2.44e-17	Diabetic kidney disease;
LGG	cis	rs1865760	0.566	rs1539183	chr6:26075051	G/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.96	0.35	1.32e-14	Height;
LGG	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.81	-9.54	-0.41	8e-20	Response to haloperidol in psychosis;
LGG	cis	rs4774830	1.000	rs12439559	chr15:56118175	G/T	cg05129572	chr15:56138634	NEDD4	-0.89	-7.93	-0.35	1.6e-14	Delta-5 desaturase activity;
LGG	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-7.02	-0.31	8.19e-12	Uric acid levels;
LGG	cis	rs60695258	0.517	rs867196	chr4:87971600	G/C	cg11209507	chr4:87813803	C4orf36	0.46	7.89	0.34	2.27e-14	Hematocrit;
LGG	cis	rs2120243	0.508	rs1456106	chr3:157123456	T/C	cg24825693	chr3:157122686	VEPH1	-0.59	-13.63	-0.54	8.58e-36	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6759839	0.716	rs6531114	chr2:16617781	T/C	cg09580478	chr2:16689509	NA	0.47	7.22	0.32	2.09e-12	Mean platelet volume;
LGG	cis	rs12042938	0.622	rs58403453	chr1:231813438	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	8.62	0.37	1.1e-16	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg06374794	chr16:88002281	BANP	0.47	8.57	0.37	1.59e-16	Menopause (age at onset);
LGG	cis	rs9549367	0.789	rs34568744	chr13:113894564	G/T	cg18105134	chr13:113819100	PROZ	-0.69	-14.15	-0.55	5.16e-38	Platelet distribution width;
LGG	cis	rs73787773	0.668	rs59043064	chr5:111491066	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.67	-8.53	-0.37	2.03e-16	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.45	8.37	0.36	6.68e-16	Longevity;
LGG	cis	rs35306767	0.855	rs56222464	chr10:867535	C/G	cg25019033	chr10:957182	NA	-0.53	-9.07	-0.39	3.44e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9783347	1.000	rs4150564	chr11:18355308	G/A	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs1801251	0.963	rs283481	chr2:233648091	A/G	cg08000102	chr2:233561755	GIGYF2	0.6	9.81	0.41	9.32e-21	Coronary artery disease;
LGG	cis	rs4988958	0.527	rs6756161	chr2:103048417	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.52	0.4	9.77e-20	Asthma (childhood onset);
LGG	cis	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.91	-0.38	1.18e-17	Mean corpuscular volume;
LGG	cis	rs11098499	0.863	rs13134665	chr4:120426430	T/C	cg09307838	chr4:120376055	NA	0.81	13.48	0.53	3.49e-35	Corneal astigmatism;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07640605	chr10:38146342	ZNF248	-0.36	-6.84	-0.3	2.56e-11	Brain structure;
LGG	cis	rs10791323	0.628	rs2853117	chr11:133705266	T/G	cg00579200	chr11:133705235	NA	-0.6	-11.65	-0.48	1.13e-27	Childhood ear infection;
LGG	cis	rs9796	0.717	rs476633	chr15:41392134	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-9.9	-0.42	4.5e-21	Menopause (age at onset);
LGG	cis	rs8141529	1.000	rs8141529	chr22:29269692	A/G	cg15103426	chr22:29168792	CCDC117	0.67	9.9	0.42	4.42e-21	Lymphocyte counts;
LGG	cis	rs5850	0.557	rs10270788	chr7:23189000	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.84	0.3	2.46e-11	Blood protein levels;
LGG	cis	rs6840360	0.615	rs1561916	chr4:152479234	C/T	cg22705602	chr4:152727874	NA	-0.31	-7.47	-0.33	4.09e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17221829	0.702	rs12360859	chr11:89359887	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.05	-0.39	3.97e-18	Anxiety in major depressive disorder;
LGG	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg05623727	chr3:50126028	RBM5	0.44	9.53	0.4	8.83e-20	Body mass index;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs650950	0.528	rs646660	chr11:35528452	C/T	cg07562458	chr1:224622430	WDR26	0.39	6.95	0.31	1.22e-11	Bronchopulmonary dysplasia;
LGG	cis	rs2204008	0.806	rs1589382	chr12:38408565	T/A	cg26384229	chr12:38710491	ALG10B	0.94	21.39	0.7	4.43e-71	Bladder cancer;
LGG	cis	rs7615952	0.599	rs2270986	chr3:125701099	T/C	cg15145296	chr3:125709740	NA	-0.63	-8.21	-0.36	2.18e-15	Blood pressure (smoking interaction);
LGG	cis	rs35164067	0.853	rs12983921	chr19:10547226	C/T	cg21868191	chr19:10515988	NA	-0.53	-7.64	-0.33	1.29e-13	Inflammatory bowel disease;
LGG	cis	rs870825	0.929	rs55880126	chr4:185591237	T/G	cg04058563	chr4:185651563	MLF1IP	1.07	19.62	0.67	8.25e-63	Blood protein levels;
LGG	cis	rs9916302	0.706	rs439537	chr17:37734482	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-8.72	-0.38	5.13e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs911186	0.509	rs6934329	chr6:27158033	A/G	cg12292205	chr6:26970375	C6orf41	-0.62	-8.52	-0.37	2.23e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.27	-0.32	1.57e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	cg07245641	chr1:182991651	LAMC1	0.4	8.85	0.38	1.83e-17	Fuchs's corneal dystrophy;
LGG	cis	rs826838	1.000	rs826886	chr12:39095797	A/G	cg13010199	chr12:38710504	ALG10B	0.62	13.1	0.52	1.4e-33	Heart rate;
LGG	cis	rs7619833	0.592	rs6551179	chr3:27236385	C/T	cg02860705	chr3:27208620	NA	0.41	8.03	0.35	8.13e-15	Breast cancer;
LGG	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg27489772	chr12:121021490	NA	-0.55	-7.48	-0.33	3.7e-13	Type 1 diabetes nephropathy;
LGG	cis	rs6800768	0.663	rs12492765	chr3:24091865	C/T	cg10674438	chr3:24145617	LOC152024	-0.49	-8.75	-0.38	4.09e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs656319	0.513	rs3885723	chr8:9991661	A/C	cg16141378	chr3:129829833	LOC729375	0.33	7.13	0.31	3.86e-12	Myopia (pathological);
LGG	cis	rs7010267	0.716	rs3134065	chr8:119959921	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.96	0.35	1.38e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.91	-0.38	1.14e-17	Menopause (age at onset);
LGG	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg16751781	chr15:78858589	CHRNA5	0.44	8.79	0.38	3.01e-17	Sudden cardiac arrest;
LGG	cis	rs977987	0.806	rs1895490	chr16:75392806	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	trans	rs1814175	0.692	rs1851873	chr11:49937767	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.88	-0.34	2.34e-14	Height;
LGG	cis	rs6450176	1.000	rs4334836	chr5:53300835	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg04568710	chr12:38710424	ALG10B	-0.42	-9.32	-0.4	4.93e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11112613	0.762	rs17037312	chr12:105950085	C/T	cg03607813	chr12:105948248	NA	0.63	11.22	0.46	5.42e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg22493809	chr1:120838387	FAM72B	0.41	6.99	0.31	9.81e-12	Bipolar disorder;
LGG	cis	rs6960043	0.738	rs10266209	chr7:15058691	C/T	cg19272540	chr7:15055459	NA	-0.39	-8.62	-0.37	1.03e-16	Type 2 diabetes;
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg04450456	chr4:17643702	FAM184B	0.32	6.84	0.3	2.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17608500	chr1:154955711	FLAD1	0.51	8.33	0.36	9.31e-16	Gut microbiome composition (summer);
LGG	cis	rs7589342	0.801	rs13031068	chr2:106455021	A/G	cg14210321	chr2:106509881	NCK2	-0.52	-9.1	-0.39	2.63e-18	Addiction;
LGG	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs11920090	0.860	rs55641619	chr3:170740599	A/G	cg09710316	chr3:170744871	SLC2A2	0.63	8.56	0.37	1.68e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs6866344	0.697	rs62392833	chr5:178135452	T/A	cg03877680	chr5:178157825	ZNF354A	0.76	12.2	0.49	6.94e-30	Neutrophil percentage of white cells;
LGG	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.52	-0.4	9.62e-20	Diabetic retinopathy;
LGG	cis	rs2842992	0.715	rs2277073	chr6:160182749	G/A	cg27624424	chr6:160112604	SOD2	0.66	9.64	0.41	3.8e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	10.32	0.43	1.34e-22	Parkinson's disease;
LGG	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg09029085	chr17:47094198	IGF2BP1	0.3	8.12	0.35	4.23e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs2173063	0.764	rs117719037	chr15:93125324	T/C	cg07052004	chr15:93132129	NA	0.68	7.04	0.31	6.99e-12	Subcutaneous adipose tissue;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.62	-0.44	1e-23	Lung cancer;
LGG	cis	rs9462027	0.583	rs912716	chr6:34715761	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.53	-0.47	3.34e-27	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.02	-0.46	3.05e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	9.04e-26	Morning vs. evening chronotype;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg09217309	chr6:150244204	RAET1G	0.44	8.16	0.35	3.14e-15	Testicular germ cell tumor;
LGG	cis	rs77741769	0.553	rs12372231	chr12:121351729	T/A	cg02419362	chr12:121203948	SPPL3	0.55	9.64	0.41	3.74e-20	Mean corpuscular volume;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg00990874	chr7:1149470	C7orf50	-0.5	-8.74	-0.38	4.42e-17	Bronchopulmonary dysplasia;
LGG	cis	rs131656	1	rs131656	chr22:21917450	G/A	cg22858872	chr22:21984481	YDJC	-0.36	-6.67	-0.3	7.44e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6997458	0.785	rs1389245	chr8:86352388	C/T	cg02393479	chr8:86352350	CA3	0.31	6.88	0.3	1.96e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs868036	0.681	rs9920643	chr15:68104314	C/T	cg22044901	chr15:68126292	NA	-0.4	-6.78	-0.3	3.71e-11	Restless legs syndrome;
LGG	cis	rs67311347	0.955	rs60554147	chr3:40472503	T/C	cg13683864	chr3:40499215	RPL14	-0.98	-20.15	-0.68	2.58e-65	Renal cell carcinoma;
LGG	cis	rs9398803	0.661	rs9375449	chr6:126963807	T/C	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg02002194	chr4:3960332	NA	0.41	7.52	0.33	2.86e-13	Neuroticism;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.38	-0.43	7.82e-23	Lung cancer;
LGG	cis	rs1670533	1.000	rs7669399	chr4:1058478	T/G	cg27284194	chr4:1044797	NA	0.55	9.81	0.41	8.99e-21	Recombination rate (females);
LGG	cis	rs10979	0.965	rs34373782	chr6:143888258	A/G	cg25407410	chr6:143891975	LOC285740	-0.72	-12.41	-0.5	9.83e-31	Hypospadias;
LGG	cis	rs2798269	0.966	rs2798272	chr13:22136766	C/G	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg20573242	chr4:122745356	CCNA2	-0.43	-7.91	-0.34	1.94e-14	Type 2 diabetes;
LGG	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg12373951	chr3:133503437	NA	-0.39	-6.98	-0.31	1e-11	Iron status biomarkers;
LGG	cis	rs9790314	0.718	rs6774635	chr3:160847908	A/G	cg04691961	chr3:161091175	C3orf57	-0.54	-11.74	-0.48	5.07e-28	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.728	rs72650852	chr8:58150463	G/A	cg21724239	chr8:58056113	NA	0.59	9.07	0.39	3.47e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg15556689	chr8:8085844	FLJ10661	0.43	7.32	0.32	1.09e-12	Retinal vascular caliber;
LGG	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg00198680	chr16:28758506	NA	-0.29	-7.06	-0.31	6e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs910187	0.605	rs6066224	chr20:45806632	T/A	cg27589058	chr20:45804311	EYA2	-0.38	-10.01	-0.42	1.81e-21	Migraine;
LGG	cis	rs698813	0.637	rs7579841	chr2:44498887	T/A	cg00619915	chr2:44497795	NA	-0.6	-8.58	-0.37	1.42e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	4.15e-21	Electroencephalogram traits;
LGG	cis	rs5769707	0.681	rs1107514	chr22:50042383	T/C	cg20744362	chr22:50050164	C22orf34	0.43	7.36	0.32	8.47e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6938	0.534	rs7495739	chr15:75185670	C/T	cg10253484	chr15:75165896	SCAMP2	0.43	7.37	0.32	8.08e-13	Breast cancer;
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg08280861	chr8:58055591	NA	0.58	9.88	0.42	5.34e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.78	17.12	0.62	3e-51	Obesity-related traits;
LGG	cis	rs769267	0.899	rs3934667	chr19:19431423	T/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.31	-0.43	1.46e-22	Tonsillectomy;
LGG	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg05163923	chr11:71159392	DHCR7	-0.63	-11.24	-0.46	4.49e-26	Vitamin D levels;
LGG	cis	rs28386778	0.734	rs7210724	chr17:61799198	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11956761	chr1:99730221	LPPR4	0.43	7.13	0.31	3.83e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.69	-0.56	2.17e-40	Platelet count;
LGG	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.02	0.57	8.36e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7851660	0.809	rs7034249	chr9:100653821	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.76	-0.51	3.55e-32	Strep throat;
LGG	cis	rs1153858	1.000	rs1346268	chr15:45673029	T/C	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	trans	rs79911532	0.515	rs78827697	chr7:75687725	C/G	cg19862616	chr7:65841803	NCRNA00174	0.76	8.02	0.35	8.59e-15	Mononucleosis;
LGG	cis	rs1451375	0.617	rs10276473	chr7:50612997	A/C	cg20336341	chr7:50628841	DDC	-0.43	-7.75	-0.34	5.75e-14	Malaria;
LGG	cis	rs41271473	1.000	rs4391638	chr1:228878481	A/C	cg00850481	chr1:228891306	NA	-0.5	-8.64	-0.37	9.09e-17	Chronic lymphocytic leukemia;
LGG	cis	rs910187	0.678	rs6122564	chr20:45814745	A/C	cg27589058	chr20:45804311	EYA2	-0.35	-9.14	-0.39	2.01e-18	Migraine;
LGG	trans	rs34787248	1	rs34787248	chr6:28197886	C/T	cg06606381	chr12:133084897	FBRSL1	-0.65	-8.38	-0.36	6.59e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg13880726	chr7:1868755	MAD1L1	0.46	8.06	0.35	6.79e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.51	-0.44	2.66e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs57221529	0.766	rs56350081	chr5:583198	G/A	cg14541582	chr5:601475	NA	-0.71	-11.11	-0.46	1.34e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	10.32	0.43	1.27e-22	Lung cancer in ever smokers;
LGG	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.72	-13.57	-0.53	1.5e-35	Hip circumference adjusted for BMI;
LGG	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg10057126	chr4:77819792	ANKRD56	0.36	6.98	0.31	1.06e-11	Emphysema distribution in smoking;
LGG	cis	rs6088590	1.000	rs2378256	chr20:33292127	G/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.51	0.58	5.37e-44	Coronary artery disease;
LGG	trans	rs9944715	0.954	rs8094706	chr18:43770146	A/G	cg01718231	chr17:29326311	RNF135	-0.41	-6.69	-0.3	6.59e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg19942237	chr7:29603211	PRR15	-0.28	-6.74	-0.3	4.74e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4987668	0.708	rs6947073	chr7:142637062	C/G	cg19410471	chr7:142636507	C7orf34	0.5	8.03	0.35	8.12e-15	Cancer;
LGG	cis	rs7075426	0.512	rs9633738	chr10:88183796	T/A	cg07322936	chr10:88137208	NA	-0.5	-7.82	-0.34	3.56e-14	Migraine without aura;
LGG	cis	rs7647973	0.580	rs7652746	chr3:49262307	C/T	cg07636037	chr3:49044803	WDR6	-0.95	-20.17	-0.68	2.07e-65	Menarche (age at onset);
LGG	cis	rs6586163	0.527	rs3740286	chr10:90751340	A/G	cg03111039	chr10:90751583	FAS;ACTA2	0.76	14.91	0.57	2.42e-41	Chronic lymphocytic leukemia;
LGG	trans	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg18187862	chr3:45730750	SACM1L	-0.43	-6.98	-0.31	1.02e-11	Primary sclerosing cholangitis;
LGG	cis	rs6964587	1.000	rs2188155	chr7:91599825	A/C	cg17063962	chr7:91808500	NA	0.48	8.52	0.37	2.29e-16	Breast cancer;
LGG	cis	rs6582630	0.519	rs11609739	chr12:38547969	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.67	0.3	7.23e-11	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg06636001	chr8:8085503	FLJ10661	0.54	10.29	0.43	1.73e-22	Neuroticism;
LGG	cis	rs9911578	1.000	rs391370	chr17:56675050	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.65	0.59	1.34e-44	Intelligence (multi-trait analysis);
LGG	cis	rs7737355	0.812	rs10054168	chr5:130788698	C/T	cg06307176	chr5:131281290	NA	-0.52	-8.73	-0.38	4.63e-17	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01221484	chr19:58920079	ZNF584	0.46	7.04	0.31	6.91e-12	Gut microbiome composition (summer);
LGG	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg05294307	chr14:35346193	BAZ1A	-0.4	-7.61	-0.33	1.5700000000000001e-13	Psoriasis;
LGG	cis	rs3096299	0.933	rs2965939	chr16:89493043	G/A	cg08822215	chr16:89438651	ANKRD11	-0.36	-6.9	-0.31	1.74e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs1408799	0.679	rs10491743	chr9:12760920	C/T	cg05274944	chr9:12693694	TYRP1	0.36	8.46	0.37	3.66e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs2204008	0.713	rs2320522	chr12:38251438	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs2075371	1.000	rs1862050	chr7:133980999	T/C	cg20476274	chr7:133979776	SLC35B4	0.79	15.8	0.59	2.64e-45	Mean platelet volume;
LGG	cis	rs4950322	0.570	rs72691097	chr1:146771388	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg16141378	chr3:129829833	LOC729375	0.4	9.22	0.39	1.04e-18	Triglycerides;
LGG	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.23	-0.36	1.88e-15	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27598621	chr11:125034439	PKNOX2	0.45	6.94	0.31	1.37e-11	Gut microbiome composition (summer);
LGG	cis	rs7100689	0.646	rs1934693	chr10:82125650	T/C	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.683	rs2088217	chr8:58113124	C/T	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs920590	0.758	rs1826420	chr8:19664878	G/T	cg03894339	chr8:19674705	INTS10	0.64	10.4	0.44	6.35e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12049351	0.612	rs10916486	chr1:229609461	A/G	cg13547644	chr1:229569608	ACTA1	0.32	6.99	0.31	9.65e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs7020830	0.505	rs12553878	chr9:37095705	C/T	cg14294708	chr9:37120828	ZCCHC7	0.78	15.12	0.57	2.96e-42	Schizophrenia;
LGG	cis	rs4689388	0.926	rs1801214	chr4:6303022	C/T	cg25554036	chr4:6271136	WFS1	0.61	11.4	0.47	1.1e-26	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11971779	0.941	rs4732368	chr7:139034207	A/C	cg07862535	chr7:139043722	LUC7L2	0.67	10.13	0.43	6.34e-22	Diisocyanate-induced asthma;
LGG	cis	rs10870270	1.000	rs11146338	chr10:133770291	C/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.61	-0.53	1.06e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs10479542	0.929	rs10074573	chr5:178976966	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.42	-6.84	-0.3	2.5e-11	Lung cancer;
LGG	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg06092702	chr1:163392909	NA	-0.47	-8.36	-0.36	7.17e-16	Motion sickness;
LGG	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.11	-0.46	1.43e-25	Mean platelet volume;
LGG	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg03929089	chr4:120376271	NA	0.65	8.35	0.36	8.26e-16	D-dimer levels;
LGG	cis	rs738321	0.694	rs4821749	chr22:38542074	A/G	cg25457927	chr22:38595422	NA	-0.4	-9.5	-0.4	1.09e-19	Breast cancer;
LGG	cis	rs2243480	1.000	rs316304	chr7:65616894	T/C	cg13147721	chr7:65941812	NA	-0.84	-10.16	-0.43	4.94e-22	Diabetic kidney disease;
LGG	cis	rs968451	0.865	rs12627970	chr22:39721745	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	12.1	0.49	1.75e-29	Primary biliary cholangitis;
LGG	cis	rs912057	1.000	rs1294407	chr6:6738103	C/G	cg06612196	chr6:6737390	NA	0.44	8.76	0.38	3.66e-17	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs3960554	0.932	rs76873475	chr7:75829199	C/A	cg19862616	chr7:65841803	NCRNA00174	0.85	11.81	0.48	2.61e-28	Eotaxin levels;
LGG	cis	rs10504229	1.000	rs66796009	chr8:58174529	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs67397200	0.632	rs11666308	chr19:17437744	T/C	cg04248312	chr19:17393744	ANKLE1	-0.37	-7.02	-0.31	7.87e-12	Breast cancer;Breast Cancer in BRCA1 mutation carriers;Breast cancer (estrogen-receptor negative);
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.6	10.26	0.43	2.18e-22	Total body bone mineral density;
LGG	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs75920871	0.528	rs12279066	chr11:116913909	C/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.27	-0.43	2.01e-22	Subjective well-being;
LGG	cis	rs2404602	0.684	rs157759	chr15:76846990	T/A	cg23625390	chr15:77176239	SCAPER	0.7	13.75	0.54	2.54e-36	Blood metabolite levels;
LGG	cis	rs5756391	0.782	rs5756389	chr22:37290547	A/T	cg21209356	chr22:37319042	CSF2RB	0.35	7.99	0.35	1.04e-14	Itch intensity from mosquito bite adjusted by bite size;
LGG	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-9.06	-0.39	3.54e-18	Retinal vascular caliber;
LGG	cis	rs3741151	0.686	rs7123985	chr11:73260463	A/C	cg17517138	chr11:73019481	ARHGEF17	0.68	7.07	0.31	5.8e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2070677	0.935	rs11101880	chr10:135412888	T/C	cg20169779	chr10:135381914	SYCE1	-1.02	-13.24	-0.52	3.6e-34	Gout;
LGG	cis	rs6540556	0.954	rs643118	chr1:209934841	C/T	cg23920097	chr1:209922102	NA	-0.44	-7.93	-0.35	1.64e-14	Red blood cell count;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg04071446	chr10:115933849	C10orf118	-0.45	-7.44	-0.33	4.85e-13	Coronary artery disease;
LGG	cis	rs9487094	0.670	rs34928881	chr6:109848049	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.77	0.34	5.06e-14	Height;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg08621203	chr6:150244597	RAET1G	0.51	9.5	0.4	1.13e-19	Testicular germ cell tumor;
LGG	cis	rs992157	0.560	rs6436047	chr2:219108913	A/C	cg04731861	chr2:219085781	ARPC2	-0.52	-13.43	-0.53	6.09e-35	Colorectal cancer;
LGG	cis	rs10479542	0.896	rs10078712	chr5:178978805	C/T	cg09060608	chr5:178986726	RUFY1	-0.5	-8.82	-0.38	2.33e-17	Lung cancer;
LGG	cis	rs12541335	0.590	rs11136002	chr8:22217082	C/T	cg02463440	chr8:22132932	PIWIL2	0.48	10.84	0.45	1.52e-24	Hypertriglyceridemia;
LGG	cis	rs4704187	0.687	rs4340901	chr5:74404905	C/T	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.47	-0.44	3.52e-23	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.24	-0.36	1.82e-15	Schizophrenia;
LGG	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg03806693	chr22:41940476	POLR3H	-1.08	-17.28	-0.63	5.32e-52	Vitiligo;
LGG	trans	rs116095464	0.558	rs6555056	chr5:226222	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.25	0.52	3.2e-34	Breast cancer;
LGG	cis	rs7106204	0.620	rs35008727	chr11:24258035	A/T	ch.11.24196551F	chr11:24239977	NA	0.86	9.48	0.4	1.34e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs561341	0.556	rs2470269	chr17:30406949	T/C	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.58	-0.37	1.5e-16	Hip circumference adjusted for BMI;
LGG	cis	rs7539542	0.516	rs10920517	chr1:202856469	A/T	cg19681188	chr1:202830198	LOC148709	0.53	8.69	0.37	6.33e-17	Mean platelet volume;
LGG	cis	rs10504229	0.679	rs10504217	chr8:58037522	A/G	cg14926445	chr8:58193284	C8orf71	-0.68	-8.98	-0.39	6.75e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	1.000	rs34569561	chr3:52287293	T/C	cg14092988	chr3:52407081	DNAH1	0.43	11.66	0.48	9.95e-28	Bipolar disorder;
LGG	cis	rs8078723	0.668	rs56030650	chr17:38131187	C/A	cg17467752	chr17:38218738	THRA	0.6	10.99	0.45	4.12e-25	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.94	-0.31	1.32e-11	Lung cancer;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg13126279	chr21:47581558	C21orf56	-0.47	-8.24	-0.36	1.83e-15	Testicular germ cell tumor;
LGG	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Myopia (pathological);
LGG	cis	rs1129187	0.755	rs3293	chr6:42938377	G/T	cg02353165	chr6:42928485	GNMT	0.47	14.29	0.55	1.2e-38	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.28	0.53	2.48e-34	Morning vs. evening chronotype;
LGG	cis	rs12367572	0.965	rs10748405	chr12:45321341	C/G	cg03114573	chr12:45410052	DBX2	-0.54	-9.14	-0.39	2.03e-18	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg03517284	chr6:25882590	NA	-0.4	-7.1	-0.31	4.87e-12	Height;
LGG	cis	rs2730245	0.527	rs842700	chr7:158697565	G/A	cg14689365	chr7:158441557	NCAPG2	0.55	6.75	0.3	4.52e-11	Height;
LGG	trans	rs34421088	0.585	rs10101661	chr8:11593504	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.0	-0.31	9.26e-12	Neuroticism;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg03188948	chr7:1209495	NA	0.64	8.25	0.36	1.66e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12971120	0.838	rs3794950	chr18:72182965	G/A	cg25817165	chr18:72167213	CNDP2	-0.64	-12.74	-0.51	4.51e-32	Refractive error;
LGG	cis	rs4843185	0.637	rs4143866	chr16:85716366	A/G	cg26571870	chr16:85723150	GINS2	-0.42	-7.53	-0.33	2.74e-13	Platelet distribution width;
LGG	cis	rs774359	0.732	rs7019847	chr9:27491397	G/A	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.31	-0.36	1.07e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs6450176	1.000	rs9687611	chr5:53300288	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs11148252	0.904	rs3892337	chr13:53029485	C/G	cg12458913	chr13:53173898	NA	0.75	15.63	0.59	1.61e-44	Lewy body disease;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg02462569	chr6:150064036	NUP43	-0.35	-7.37	-0.32	7.97e-13	Lung cancer;
LGG	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg19761014	chr17:28927070	LRRC37B2	0.64	7.52	0.33	2.91e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs950027	0.549	rs9920634	chr15:45596546	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.74	-0.41	1.56e-20	Response to fenofibrate (adiponectin levels);
LGG	trans	rs9325144	0.555	rs1825806	chr12:38692547	G/A	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.83e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.748	rs79658522	chr7:1095877	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6450176	0.538	rs12186486	chr5:53306549	T/A	ch.5.1024479R	chr5:53302184	ARL15	-1.03	-16.04	-0.6	2.21e-46	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2188554	0.675	rs6466610	chr7:117012774	T/C	cg10524701	chr7:117356490	CTTNBP2	0.39	7.59	0.33	1.73e-13	Esophageal adenocarcinoma;
LGG	cis	rs1927790	0.667	rs7981845	chr13:96942533	C/T	cg02571835	chr13:96230311	CLDN10	-0.36	-7.2	-0.32	2.51e-12	Body mass index;
LGG	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg08704250	chr15:31115839	NA	-0.43	-7.94	-0.35	1.59e-14	Huntington's disease progression;
LGG	cis	rs3862030	0.839	rs2274351	chr10:104264107	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.54	-10.13	-0.43	6.22e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	trans	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.78	-0.41	1.21e-20	Systolic blood pressure;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10254974	chr17:16342133	NCRNA00188;SNORD49B;SNORD49A	-0.46	-7.44	-0.33	4.81e-13	Body fat percentage;
LGG	cis	rs7077256	0.564	rs12785227	chr10:65262685	A/G	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs6121246	0.529	rs6058152	chr20:30178107	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	8.49	0.37	2.93e-16	Mean corpuscular hemoglobin;
LGG	cis	rs17092148	0.887	rs6059919	chr20:33151545	G/T	cg12302830	chr20:33297742	TP53INP2	-0.44	-6.92	-0.31	1.52e-11	Neuroticism;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg22907277	chr7:1156413	C7orf50	0.84	14.98	0.57	1.17e-41	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28489187	0.667	rs233114	chr1:85786957	T/G	cg16011679	chr1:85725395	C1orf52	0.35	6.65	0.3	8.53e-11	Asymmetrical dimethylarginine levels;Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.65	-0.44	7.82e-24	Platelet count;
LGG	cis	rs2836974	0.565	rs2836939	chr21:40578546	C/T	cg11890956	chr21:40555474	PSMG1	0.97	14.45	0.56	2.38e-39	Cognitive function;
LGG	cis	rs4538187	1.000	rs11676710	chr2:64173754	A/G	cg02541582	chr2:64069798	UGP2	-0.62	-14.64	-0.56	3.53e-40	Systolic blood pressure;
LGG	cis	rs12956009	0.518	rs3902716	chr18:44889441	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.51	0.33	3.11e-13	Educational attainment (years of education);
LGG	cis	rs701145	0.585	rs357498	chr3:153945495	G/A	cg17054900	chr3:154042577	DHX36	0.94	10.33	0.43	1.18e-22	Coronary artery disease;
LGG	cis	rs12681288	0.712	rs2600488	chr8:1021266	A/C	cg08648136	chr8:956695	NA	0.33	6.78	0.3	3.71e-11	Schizophrenia;
LGG	cis	rs6554196	0.508	rs999021	chr4:55524533	C/G	cg18836493	chr4:55524333	KIT	-0.43	-7.93	-0.35	1.64e-14	Monocyte count;
LGG	cis	rs10463316	0.894	rs954341	chr5:150751855	G/A	cg03212797	chr5:150827313	SLC36A1	-0.61	-10.66	-0.44	7.1e-24	Metabolite levels (Pyroglutamine);
LGG	cis	rs9322193	0.962	rs2275046	chr6:150157001	A/G	cg16507663	chr6:150244633	RAET1G	0.43	7.98	0.35	1.16e-14	Lung cancer;
LGG	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg18105134	chr13:113819100	PROZ	-0.69	-14.27	-0.55	1.47e-38	Platelet distribution width;
LGG	cis	rs3096299	0.967	rs28689480	chr16:89460093	T/C	cg08822215	chr16:89438651	ANKRD11	-0.4	-7.68	-0.34	9.32e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs1577917	0.958	rs11755048	chr6:86514334	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-13.9	-0.54	5.94e-37	Response to antipsychotic treatment;
LGG	cis	rs853679	0.517	rs9380059	chr6:28132358	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs11651000	0.857	rs56172120	chr17:45824904	G/A	cg24803719	chr17:45855879	NA	-0.26	-6.78	-0.3	3.73e-11	IgG glycosylation;
LGG	cis	rs2952156	0.959	rs11653998	chr17:37877447	C/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.75	-0.34	5.97e-14	Asthma;
LGG	cis	rs736801	0.780	rs12521868	chr5:131784393	A/C	cg07395648	chr5:131743802	NA	0.52	10.89	0.45	9.44e-25	Breast cancer;Mosquito bite size;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.540	rs1283306	chr12:38153778	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.55	-0.44	1.78e-23	Bladder cancer;
LGG	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg18225595	chr11:63971243	STIP1	-0.46	-9.01	-0.39	5.29e-18	Platelet count;
LGG	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg05784532	chr1:230284198	GALNT2	0.52	9.21	0.39	1.11e-18	Coronary artery disease;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg11878867	chr6:150167359	LRP11	-0.47	-8.2	-0.36	2.37e-15	Lung cancer;
LGG	cis	rs1577917	0.771	rs2842602	chr6:86331887	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-11.59	-0.47	1.93e-27	Response to antipsychotic treatment;
LGG	cis	rs4561483	0.831	rs33621	chr16:12008513	G/A	cg08843971	chr16:11963173	GSPT1	-0.64	-15.77	-0.59	3.57e-45	Testicular germ cell tumor;
LGG	cis	rs787274	1.000	rs2645991	chr9:115519035	T/C	cg13803584	chr9:115635662	SNX30	-0.58	-7.42	-0.33	5.53e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs977987	0.835	rs11641532	chr16:75329480	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.83	0.42	8.06e-21	Dupuytren's disease;
LGG	cis	rs7927592	0.956	rs11228269	chr11:68289796	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.34	-0.36	8.81e-16	Total body bone mineral density;
LGG	trans	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs5758659	0.714	rs133376	chr22:42466905	C/T	cg15557168	chr22:42548783	NA	-0.36	-8.08	-0.35	5.52e-15	Cognitive function;
LGG	cis	rs8133932	0.701	rs3788228	chr21:47307669	G/A	cg13695288	chr21:47294981	PCBP3	-0.36	-7.22	-0.32	2.12e-12	Schizophrenia;
LGG	cis	rs2213920	0.679	rs4979523	chr9:118177550	G/A	cg13918206	chr9:118159781	DEC1	0.63	8.93	0.38	1e-17	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs9303401	0.659	rs62081314	chr17:56778328	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	15.0	0.57	9.38e-42	Cognitive test performance;
LGG	cis	rs1865760	0.929	rs9467646	chr6:25957408	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.8	-0.34	4.19e-14	Height;
LGG	cis	rs9790314	0.663	rs7632423	chr3:160738728	A/G	cg03342759	chr3:160939853	NMD3	0.45	7.65	0.34	1.17e-13	Morning vs. evening chronotype;
LGG	cis	rs42648	0.869	rs10234301	chr7:89918278	T/C	cg25739043	chr7:89950458	NA	-0.44	-9.39	-0.4	2.68e-19	Homocysteine levels;
LGG	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg06636001	chr8:8085503	FLJ10661	0.44	7.66	0.34	1.13e-13	Retinal vascular caliber;
LGG	cis	rs3008870	1.000	rs17497828	chr1:67452322	G/A	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.75	-0.3	4.57e-11	Lymphocyte percentage of white cells;
LGG	trans	rs2243480	0.666	rs1880311	chr7:65276752	G/C	cg10756647	chr7:56101905	PSPH	-0.86	-9.37	-0.4	3.18e-19	Diabetic kidney disease;
LGG	cis	rs4319547	0.695	rs11836188	chr12:122865507	T/C	cg23029597	chr12:123009494	RSRC2	0.93	17.24	0.63	8.17e-52	Body mass index;
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.85	-0.38	1.89e-17	Bipolar disorder;
LGG	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg18551225	chr6:44695536	NA	-0.62	-10.29	-0.43	1.67e-22	Total body bone mineral density;
LGG	trans	rs9467711	0.790	rs34107459	chr6:26328353	T/C	cg01620082	chr3:125678407	NA	-0.89	-8.23	-0.36	1.85e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg27542038	chr10:14027202	FRMD4A	0.66	12.78	0.51	3.13e-32	Adiponectin levels;
LGG	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg03264133	chr6:25882463	NA	-0.41	-7.24	-0.32	1.89e-12	Height;
LGG	cis	rs3741151	0.686	rs1938777	chr11:73122340	A/G	cg17517138	chr11:73019481	ARHGEF17	0.75	8.13	0.35	3.91e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2247341	0.965	rs2854920	chr4:1715349	C/T	cg07465881	chr4:1713556	SLBP	-0.5	-7.97	-0.35	1.29e-14	Hip circumference adjusted for BMI;Height;
LGG	cis	rs10504229	1.000	rs67243305	chr8:58174958	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.04	-0.6	2.2e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.39	0.4	2.64e-19	Neuroticism;
LGG	trans	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg13010199	chr12:38710504	ALG10B	0.47	8.47	0.37	3.19e-16	Resting heart rate;
LGG	cis	rs1799949	1.000	rs1973646	chr17:41310495	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.02	-0.39	5.1e-18	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs1034273	chr6:8468145	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg22601191	chr20:60968625	CABLES2	0.46	8.61	0.37	1.15e-16	Colorectal cancer;
LGG	cis	rs6500602	0.598	rs3859155	chr16:4593741	A/C	cg06916706	chr16:4465613	CORO7	0.7	11.92	0.48	9.53e-29	Schizophrenia;
LGG	cis	rs34172651	0.583	rs4787649	chr16:24700215	C/T	cg02428538	chr16:24856791	SLC5A11	0.57	9.13	0.39	2.21e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	1.000	rs690316	chr15:43737880	C/A	cg15269541	chr15:43626905	ADAL	-0.42	-7.18	-0.32	2.77e-12	Lung cancer in ever smokers;
LGG	cis	rs8114671	0.562	rs2076667	chr20:33506964	G/A	cg07148914	chr20:33460835	GGT7	0.53	8.89	0.38	1.4e-17	Height;
LGG	cis	rs2871865	0.620	rs1573891	chr15:99186488	G/C	cg03437748	chr15:99193247	IGF1R	0.65	7.71	0.34	7.76e-14	Height;
LGG	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg21053147	chr12:120880522	NA	-0.56	-8.31	-0.36	1.08e-15	Type 1 diabetes nephropathy;
LGG	cis	rs1707322	1.000	rs4660905	chr1:46461587	C/T	cg03146154	chr1:46216737	IPP	-0.53	-9.99	-0.42	2.14e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4332037	0.851	rs34040190	chr7:1920356	G/A	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.58	-0.37	1.45e-16	Bipolar disorder;
LGG	cis	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg21775007	chr8:11205619	TDH	-0.77	-13.27	-0.52	2.7200000000000002e-34	Retinal vascular caliber;
LGG	cis	rs1552244	1.000	rs6414438	chr3:10073824	G/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-14.04	-0.55	1.51e-37	Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg02725872	chr8:58115012	NA	-0.78	-11.2	-0.46	6.48e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs17221829	0.710	rs1844198	chr11:89388187	T/C	cg02982614	chr11:89391479	FOLH1B	-0.4	-8.96	-0.38	7.75e-18	Anxiety in major depressive disorder;
LGG	cis	rs75920871	0.748	rs7946219	chr11:116962759	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-8.02	-0.35	8.83e-15	Subjective well-being;
LGG	cis	rs2415984	0.579	rs4485263	chr14:46967552	A/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.18	-0.43	4.4e-22	Number of children ever born;
LGG	cis	rs4642101	0.793	rs12714880	chr3:12832101	G/A	cg24848339	chr3:12840334	CAND2	0.43	10.11	0.43	7.6e-22	QRS complex (12-leadsum);
LGG	cis	rs7572263	0.528	rs13387151	chr2:209074635	A/C	cg00164906	chr2:209055251	C2orf80	0.5	7.78	0.34	4.72e-14	Glioma;Non-glioblastoma glioma;
LGG	cis	rs2075371	1.000	rs2544218	chr7:133992315	C/A	cg11752832	chr7:134001865	SLC35B4	0.63	11.54	0.47	3.11e-27	Mean platelet volume;
LGG	cis	rs35306767	0.903	rs35957139	chr10:884889	C/T	cg08847335	chr10:891726	LARP4B	-0.53	-9.0	-0.39	5.96e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs11190604	1.000	rs10883510	chr10:102297018	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.48	0.47	5.1e-27	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs61931739	0.534	rs10844767	chr12:34152368	C/G	cg26384229	chr12:38710491	ALG10B	0.82	16.5	0.61	1.97e-48	Morning vs. evening chronotype;
LGG	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg08859206	chr1:53392774	SCP2	0.48	9.38	0.4	3.04e-19	Monocyte count;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs9393777	0.920	rs13207689	chr6:27369704	C/G	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.27	-0.46	3.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9547996	0.842	rs1028728	chr13:38173816	A/T	cg17979426	chr13:38220150	TRPC4	-0.36	-6.91	-0.31	1.58e-11	Diastolic blood pressure;
LGG	trans	rs6563199	0.522	rs7335775	chr13:81370189	C/T	cg05370988	chr3:186500739	EIF4A2	-0.42	-6.73	-0.3	4.99e-11	Height;
LGG	cis	rs972578	0.875	rs4822250	chr22:43409058	C/A	cg01576275	chr22:43409880	NA	-0.24	-7.05	-0.31	6.5e-12	Mean platelet volume;
LGG	cis	rs4774899	1.000	rs1462156	chr15:57503423	A/G	cg08128148	chr15:57256372	TCF12	-0.29	-6.88	-0.3	2e-11	Urinary tract infection frequency;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs17376456	0.877	rs17315943	chr5:93442830	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-10.1	-0.43	8.03e-22	Diabetic retinopathy;
LGG	cis	rs7932354	0.502	rs10769244	chr11:47182368	A/G	cg03339077	chr11:47165057	C11orf49	0.54	10.15	0.43	5.66e-22	Bone mineral density (hip);Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25261764	chr18:55288998	NARS	0.43	6.9	0.31	1.75e-11	Cognitive performance;
LGG	cis	rs4604732	0.631	rs11490201	chr1:247626262	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.89	0.38	1.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs6964587	1.000	rs55745934	chr7:91670998	T/C	cg17063962	chr7:91808500	NA	0.49	8.59	0.37	1.34e-16	Breast cancer;
LGG	cis	rs453301	0.686	rs11785634	chr8:8892597	G/T	cg11995313	chr8:8860691	ERI1	0.46	7.76	0.34	5.63e-14	Joint mobility (Beighton score);
LGG	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg10911889	chr6:126070802	HEY2	0.46	8.06	0.35	6.49e-15	Brugada syndrome;
LGG	cis	rs2439831	0.702	rs495175	chr15:43798684	C/G	cg15269541	chr15:43626905	ADAL	-0.42	-7.09	-0.31	5.15e-12	Lung cancer in ever smokers;
LGG	cis	rs9875589	0.509	rs1906538	chr3:14014169	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.49	10.13	0.43	6.33e-22	Ovarian reserve;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg00106254	chr7:1943704	MAD1L1	-0.45	-7.81	-0.34	3.82e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg15586420	chr15:90294517	MESP1	0.39	6.84	0.3	2.44e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg19006130	chr11:118478252	PHLDB1	-0.41	-7.0	-0.31	8.79e-12	Cholesterol, total;
LGG	cis	rs4308124	0.708	rs10178095	chr2:111972516	C/T	cg04571233	chr2:111982156	NA	-0.6	-9.85	-0.42	6.38e-21	Vitiligo;
LGG	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.57	-10.66	-0.44	7.37e-24	Total body bone mineral density;
LGG	trans	rs8002861	0.664	rs9533686	chr13:44468494	A/G	cg17145862	chr1:211918768	LPGAT1	0.8	17.48	0.63	6.51e-53	Leprosy;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.84	-0.42	7.17e-21	Life satisfaction;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg03727229	chr11:118479170	PHLDB1	0.4	6.73	0.3	5.19e-11	Cholesterol, total;
LGG	cis	rs7582720	1.000	rs72936862	chr2:203786812	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg26384229	chr12:38710491	ALG10B	0.59	11.13	0.46	1.12e-25	Morning vs. evening chronotype;
LGG	cis	rs963731	0.649	rs297151	chr2:39326511	A/C	cg04010122	chr2:39346883	SOS1	-0.82	-8.07	-0.35	6.01e-15	Corticobasal degeneration;
LGG	trans	rs11650494	0.901	rs74659133	chr17:47336931	C/T	cg11430096	chr6:110968061	CDK19	0.65	6.81	0.3	3.09e-11	Prostate cancer;
LGG	cis	rs2066819	1.000	rs1274493	chr12:56682371	C/T	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.66e-11	Psoriasis vulgaris;
LGG	cis	rs1953600	0.668	rs751740	chr10:81912179	T/C	cg04850286	chr10:81895943	PLAC9	0.34	7.53	0.33	2.59e-13	Sarcoidosis;
LGG	cis	rs2204008	0.837	rs11168341	chr12:37961951	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.32	0.55	9.52e-39	Bladder cancer;
LGG	cis	rs3784262	0.527	rs1441815	chr15:58274229	A/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.65	-0.3	8.45e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs910316	0.934	rs4903278	chr14:75535019	C/A	cg08847533	chr14:75593920	NEK9	0.61	11.9	0.48	1.17e-28	Height;
LGG	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg09417038	chr21:47716443	C21orf57	0.35	7.12	0.31	4.06e-12	Testicular germ cell tumor;
LGG	cis	rs881375	0.678	rs10818488	chr9:123705087	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.83	0.48	2.15e-28	Rheumatoid arthritis;
LGG	trans	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg25482853	chr8:67687455	SGK3	0.84	11.28	0.46	3.21e-26	Obesity-related traits;
LGG	cis	rs12079745	0.793	rs12073439	chr1:169284482	A/G	cg09363564	chr1:169337483	NME7;BLZF1	-0.89	-6.88	-0.3	1.93e-11	QT interval;
LGG	cis	rs1620921	0.935	rs783171	chr6:161173610	A/G	cg01280913	chr6:161186852	NA	-0.35	-7.36	-0.32	8.18e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2153535	0.601	rs4960414	chr6:8438541	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.27e-18	Motion sickness;
LGG	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg25427524	chr10:38739819	LOC399744	-0.67	-13.56	-0.53	1.64e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	1.000	rs58608483	chr8:58195269	T/G	cg08677398	chr8:58056175	NA	0.42	6.87	0.3	2.04e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg13256891	chr4:100009986	ADH5	0.56	9.61	0.41	4.58e-20	Smoking initiation;
LGG	cis	rs1256531	0.661	rs55793205	chr14:66017517	T/C	cg15999311	chr14:65749247	NA	0.79	6.91	0.31	1.61e-11	Conduct disorder (symptom count);
LGG	cis	rs916888	0.821	rs415430	chr17:44859144	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg22907277	chr7:1156413	C7orf50	0.62	11.5	0.47	4.24e-27	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg22907277	chr7:1156413	C7orf50	0.7	8.76	0.38	3.72e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs250677	0.958	rs43147	chr5:148417103	C/G	cg18129178	chr5:148520854	ABLIM3	0.41	7.1	0.31	4.67e-12	Breast cancer;
LGG	cis	rs6577655	0.517	rs2315835	chr8:135589854	A/G	cg17885191	chr8:135476712	NA	0.59	8.85	0.38	1.87e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg12045294	chr17:78518616	RPTOR	-0.47	-7.28	-0.32	1.44e-12	Glycated hemoglobin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25826596	chr17:34891243	MYO19;PIGW	0.49	7.41	0.33	5.9e-13	Gut microbiome composition (summer);
LGG	cis	rs12464559	0.522	rs7583148	chr2:152620986	C/T	cg01189475	chr2:152685088	ARL5A	0.74	7.52	0.33	2.92e-13	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs7647973	0.626	rs1586827	chr3:49671224	T/C	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	cis	rs367943	0.966	rs348945	chr5:112822889	C/T	cg27587195	chr5:112824172	MCC	-0.46	-7.43	-0.33	5.33e-13	Type 2 diabetes;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs4731207	0.698	rs2158677	chr7:124443966	T/C	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs3020736	0.500	rs5996109	chr22:42493098	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72720396	0.789	rs12022460	chr1:91202257	A/G	cg13456504	chr1:91191583	NA	-0.51	-8.32	-0.36	9.99e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11623869	0.772	rs12587310	chr14:103907286	G/A	cg26031613	chr14:104095156	KLC1	-0.8	-14.01	-0.55	1.98e-37	Bone mineral density;
LGG	cis	rs73081554	0.505	rs6807387	chr3:58456719	T/C	cg24175188	chr3:58374923	PXK	-0.53	-8.01	-0.35	9.44e-15	Rheumatoid arthritis;
LGG	trans	rs2018683	0.707	rs4722878	chr7:28973031	C/T	cg19402173	chr7:128379420	CALU	-0.53	-9.24	-0.39	8.65e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.42	-0.4	2.13e-19	Retinal vascular caliber;
LGG	trans	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-13.06	-0.52	2.08e-33	Intelligence (multi-trait analysis);
LGG	cis	rs7086627	0.515	rs7088877	chr10:82208860	C/G	cg00277334	chr10:82204260	NA	-0.53	-12.83	-0.51	1.8e-32	Post bronchodilator FEV1;
LGG	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg15823100	chr22:32027580	PISD	-0.81	-9.04	-0.39	4.35e-18	Age-related hearing impairment;
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.58	10.76	0.45	2.96e-24	Total body bone mineral density;
LGG	cis	rs7075426	0.905	rs10887612	chr10:88213946	T/C	cg07322936	chr10:88137208	NA	0.42	7.29	0.32	1.32e-12	Migraine without aura;
LGG	cis	rs611744	0.647	rs7016198	chr8:109262752	G/A	cg21045802	chr8:109455806	TTC35	0.52	9.88	0.42	5.21e-21	Dupuytren's disease;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg12310025	chr6:25882481	NA	0.52	9.73	0.41	1.76e-20	Blood metabolite levels;
LGG	cis	rs7399018	0.739	rs7399073	chr12:51614050	C/A	cg12163867	chr12:51592794	POU6F1	-0.45	-9.75	-0.41	1.53e-20	Cisplatin-induced ototoxicity;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.39e-19	Life satisfaction;
LGG	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg02428538	chr16:24856791	SLC5A11	0.71	11.02	0.46	3e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg21782813	chr7:2030301	MAD1L1	0.54	13.89	0.54	6.23e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs763121	0.853	rs9306329	chr22:39072454	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs1577917	0.917	rs1584273	chr6:86524577	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.9	-0.38	1.26e-17	Response to antipsychotic treatment;
LGG	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg16339924	chr4:17578868	LAP3	0.69	11.91	0.48	9.91e-29	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7819412	0.539	rs11250131	chr8:11251175	C/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.8	-0.3	3.18e-11	Triglycerides;
LGG	cis	rs4332037	0.539	rs55790766	chr7:2021248	C/T	cg02951883	chr7:2050386	MAD1L1	0.46	6.67	0.3	7.19e-11	Bipolar disorder;
LGG	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg26818010	chr10:134567672	INPP5A	-0.77	-11.82	-0.48	2.3e-28	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg04287289	chr16:89883240	FANCA	0.74	7.88	0.34	2.31e-14	Skin colour saturation;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.55	-7.14	-0.31	3.67e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs896854	0.875	rs4735333	chr8:95955074	G/A	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.87	-0.38	1.62e-17	Type 2 diabetes;
LGG	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11644478	chr21:40555479	PSMG1	0.92	18.07	0.64	1.22e-55	Cognitive function;
LGG	cis	rs4319547	1.000	rs1392236	chr12:123074890	C/G	cg23029597	chr12:123009494	RSRC2	-0.96	-18.7	-0.66	1.59e-58	Body mass index;
LGG	cis	rs921968	0.643	rs613539	chr2:219455967	G/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.06	-0.31	6.29e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs17169635	0.601	rs1377297	chr7:134546119	A/C	cg02516134	chr7:134575187	CALD1	-0.33	-7.37	-0.32	7.83e-13	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg07701084	chr6:150067640	NUP43	0.69	12.92	0.51	8.28e-33	Lung cancer;
LGG	cis	rs2798269	0.902	rs1359190	chr13:22096611	T/G	cg18095732	chr13:22033692	ZDHHC20	-0.42	-7.13	-0.31	3.86e-12	PR segment;
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg16339924	chr4:17578868	LAP3	0.66	11.09	0.46	1.59e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9354308	0.714	rs9342512	chr6:66589763	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.36e-11	Metabolite levels;
LGG	cis	rs870825	0.616	rs28445002	chr4:185648977	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs7408868	0.563	rs10404382	chr19:15301389	C/A	cg14696996	chr19:15285081	NOTCH3	0.87	11.14	0.46	1.07e-25	Pulse pressure;
LGG	cis	rs55788414	0.932	rs9940095	chr16:81182108	A/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs1978968	0.956	rs1110661	chr22:18444734	C/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.43	-0.5	8.09e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg09476347	chr16:613343	C16orf11	-0.38	-6.96	-0.31	1.2e-11	Height;
LGG	cis	rs7666738	0.830	rs4492007	chr4:98959848	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs734999	0.545	rs28532547	chr1:2561286	T/G	cg18854424	chr1:2615690	NA	-0.35	-7.45	-0.33	4.48e-13	Ulcerative colitis;
LGG	cis	rs4629710	0.592	rs4310080	chr6:131538377	T/G	cg12606694	chr6:131520996	AKAP7	0.51	8.36	0.36	7.33e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs4332037	0.539	rs4719416	chr7:2106608	G/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.57	-0.47	2.31e-27	Bipolar disorder;
LGG	cis	rs11122272	0.735	rs2749711	chr1:231537543	G/A	cg10503236	chr1:231470652	EXOC8	-0.36	-7.01	-0.31	8.49e-12	Hemoglobin concentration;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg16606324	chr3:10149918	C3orf24	0.55	7.3	0.32	1.23e-12	Alzheimer's disease;
LGG	cis	rs151234	0.800	rs231974	chr16:28540322	A/T	cg01378222	chr16:28622494	SULT1A1	-0.67	-8.64	-0.37	9.36e-17	Platelet distribution width;
LGG	cis	rs832540	0.898	rs702680	chr5:56220382	T/C	cg12654349	chr5:56205094	C5orf35	-0.41	-7.44	-0.33	4.83e-13	Coronary artery disease;
LGG	cis	rs12586317	0.883	rs4982254	chr14:35755737	C/T	cg16230307	chr14:35515116	FAM177A1	0.6	8.79	0.38	3.01e-17	Psoriasis;
LGG	cis	rs12681287	0.547	rs9942793	chr8:87509091	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	cis	rs9902453	0.845	rs7218113	chr17:28372130	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs7011049	1.000	rs28867471	chr8:53838179	C/T	cg26025543	chr8:53854495	NA	0.75	9.98	0.42	2.29e-21	Systolic blood pressure;
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg26554054	chr8:600488	NA	1.18	11.96	0.49	6.4e-29	IgG glycosylation;
LGG	cis	rs6088580	0.524	rs6088552	chr20:33226491	A/G	cg07148914	chr20:33460835	GGT7	-0.51	-8.22	-0.36	2.07e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs12701220	0.655	rs6463317	chr7:1159243	G/A	cg02733842	chr7:1102375	C7orf50	-0.43	-7.26	-0.32	1.6e-12	Bronchopulmonary dysplasia;
LGG	cis	rs4555082	0.834	rs11622165	chr14:105759761	C/A	cg13114125	chr14:105738426	BRF1	-0.85	-15.73	-0.59	5.93e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11583043	0.708	rs3861736	chr1:101532657	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.37	0.36	6.85e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs13191362	1.000	rs13220181	chr6:163004401	T/A	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs853679	0.517	rs9380058	chr6:28127444	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg19168338	chr16:4465731	CORO7	-0.72	-13.44	-0.53	5.34e-35	Schizophrenia;
LGG	cis	rs7216064	1.000	rs6504555	chr17:65940727	A/G	cg12091567	chr17:66097778	LOC651250	0.63	9.08	0.39	3.23e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9914544	0.564	rs1859083	chr17:18843306	C/T	cg26378065	chr17:18585709	ZNF286B	-0.5	-9.64	-0.41	3.54e-20	Educational attainment (years of education);
LGG	cis	rs1620921	0.681	rs1247541	chr6:161253485	T/C	cg01280913	chr6:161186852	NA	-0.34	-6.98	-0.31	1.02e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3784262	0.739	rs1530293	chr15:58210398	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.35	-7.31	-0.32	1.16e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1620921	0.594	rs13220254	chr6:161269958	T/C	cg01280913	chr6:161186852	NA	-0.35	-7.1	-0.31	4.62e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs765787	0.530	rs12913123	chr15:45516425	C/T	cg24006582	chr15:45444508	DUOX1	0.66	12.05	0.49	2.95e-29	Uric acid levels;
LGG	cis	rs7149242	0.500	rs10144381	chr14:101173297	C/T	cg18089426	chr14:101175970	NA	0.43	9.48	0.4	1.28e-19	Platelet count;
LGG	cis	rs9811920	0.609	rs4479633	chr3:99654510	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.07	-0.39	3.44e-18	Axial length;
LGG	cis	rs1008375	0.932	rs4698627	chr4:17605959	T/C	cg16339924	chr4:17578868	LAP3	0.65	11.18	0.46	7.3e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.862	rs11760844	chr7:65739883	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.62	-0.37	1.05e-16	Aortic root size;
LGG	cis	rs9463078	0.845	rs2396425	chr6:45177025	A/G	cg25276700	chr6:44698697	NA	-0.41	-8.48	-0.37	3.01e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs875971	0.862	rs11763189	chr7:65983529	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs7945705	0.935	rs2568061	chr11:8886260	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.17	-0.49	9.64e-30	Hemoglobin concentration;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.35	6.67	0.3	7.36e-11	Schizophrenia;
LGG	cis	rs701145	0.585	rs1609205	chr3:153793923	G/A	cg17054900	chr3:154042577	DHX36	0.78	9.2	0.39	1.19e-18	Coronary artery disease;
LGG	cis	rs128738	0.505	rs13190293	chr5:131566926	A/T	cg05556477	chr5:131705319	SLC22A5	0.46	6.75	0.3	4.53e-11	Giant cell arteritis;
LGG	cis	rs898097	0.578	rs8069697	chr17:80908110	T/C	cg15664640	chr17:80829946	TBCD	0.57	11.45	0.47	6.7399999999999993e-27	Breast cancer;
LGG	cis	rs7100689	0.646	rs6585946	chr10:82118292	G/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg19717773	chr7:2847554	GNA12	-0.36	-8.19	-0.36	2.54e-15	Height;
LGG	cis	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg06521331	chr12:34319734	NA	-0.4	-7.06	-0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs8177253	1.000	rs8177240	chr3:133477701	T/G	cg16414030	chr3:133502952	NA	-0.59	-10.13	-0.43	6.22e-22	Iron status biomarkers;
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.4	-0.44	6.54e-23	Bipolar disorder;
LGG	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.67	-0.34	9.95e-14	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs10518331	chr4:120323595	C/T	cg09307838	chr4:120376055	NA	0.81	13.52	0.53	2.53e-35	Corneal astigmatism;
LGG	cis	rs571497	0.697	rs62128260	chr19:7833876	T/A	cg00970558	chr19:7854469	CLEC4GP1	0.65	7.14	0.31	3.66e-12	Monocyte count;
LGG	cis	rs7666738	0.830	rs3896704	chr4:99034252	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.45	0.37	3.75e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs258892	0.895	rs9293442	chr5:72055595	T/C	cg21869765	chr5:72125136	TNPO1	-0.42	-6.65	-0.3	8.43e-11	Small cell lung carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23570261	chr2:128284252	IWS1	0.46	7.71	0.34	7.76e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7582180	0.764	rs7425449	chr2:100928393	A/G	cg05692746	chr2:100937584	LONRF2	-0.63	-11.33	-0.47	1.89e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg07157834	chr1:205819609	PM20D1	0.45	7.43	0.33	5.19e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2635047	0.811	rs12957869	chr18:44786869	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.59	0.33	1.75e-13	Educational attainment;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg15272186	chr6:29709610	LOC285830	-0.54	-6.76	-0.3	4.05e-11	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.66	-11.02	-0.46	3.19e-25	Coronary artery disease;
LGG	cis	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg26384229	chr12:38710491	ALG10B	0.96	21.01	0.7	2.62e-69	Bladder cancer;
LGG	cis	rs12724450	0.793	rs12759551	chr1:150395663	C/T	cg03818307	chr1:150480534	ECM1	0.5	7.16	0.32	3.23e-12	Blood protein levels;
LGG	cis	rs854037	0.698	rs10037009	chr5:57051724	C/T	cg08523694	chr5:57076192	NA	0.5	7.19	0.32	2.59e-12	Birth weight;
LGG	cis	rs9534288	0.699	rs2296642	chr13:46656669	A/G	cg15192986	chr13:46630673	CPB2	-0.7	-14.4	-0.56	4.09e-39	Blood protein levels;
LGG	trans	rs61931739	0.534	rs11053073	chr12:34202412	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.96e-46	Morning vs. evening chronotype;
LGG	cis	rs13102973	0.867	rs4429776	chr4:135883394	G/T	cg14419869	chr4:135874104	NA	0.47	8.59	0.37	1.3e-16	Subjective well-being;
LGG	cis	rs9547692	1.000	rs9547692	chr13:37473243	A/C	cg02985381	chr13:37494744	SMAD9	0.73	12.89	0.51	1.03e-32	Coronary artery disease;
LGG	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg02002194	chr4:3960332	NA	0.43	7.64	0.33	1.26e-13	Retinal vascular caliber;
LGG	cis	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg13010199	chr12:38710504	ALG10B	-0.51	-9.91	-0.42	4.04e-21	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.46	-0.56	2.34e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg06532163	chr17:45867833	NA	0.55	9.3	0.4	5.63e-19	IgG glycosylation;
LGG	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.61	10.73	0.45	3.83e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2732480	0.577	rs2732479	chr12:48736260	A/C	cg21466736	chr12:48725269	NA	-0.39	-7.79	-0.34	4.34e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg06521331	chr12:34319734	NA	-0.65	-12.7	-0.51	6.6e-32	Morning vs. evening chronotype;
LGG	cis	rs4789378	1.000	rs4789378	chr17:74930366	C/T	cg02841895	chr17:74942714	MGAT5B	0.35	7.3	0.32	1.3e-12	Colorectal or endometrial cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15115510	chr20:33872603	EIF6	0.42	6.74	0.3	4.87e-11	Cognitive performance;
LGG	cis	rs7618915	0.851	rs34228726	chr3:52322797	A/G	cg14092988	chr3:52407081	DNAH1	0.43	11.49	0.47	4.6e-27	Bipolar disorder;
LGG	cis	rs9790314	0.846	rs4560315	chr3:160982132	G/T	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs4684776	1.000	rs12637318	chr3:11474823	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.11	-0.35	4.73e-15	Small vessel stroke;
LGG	cis	rs7202877	0.610	rs3851735	chr16:75372092	A/G	cg03315344	chr16:75512273	CHST6	0.51	6.87	0.3	2.08e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg12253571	chr8:8283032	NA	-0.32	-7.01	-0.31	8.64e-12	Mood instability;
LGG	cis	rs2836974	0.863	rs12483216	chr21:40539614	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.85	0.64	1.32e-54	Cognitive function;
LGG	cis	rs9443645	0.901	rs9361451	chr6:79555055	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs16957091	0.909	rs2280048	chr15:43011297	C/A	cg07484255	chr15:43025164	CDAN1	-0.48	-6.87	-0.3	2.08e-11	MGMT methylation in smokers;
LGG	cis	rs11608355	0.810	rs2217971	chr12:109857666	G/C	cg19025524	chr12:109796872	NA	-0.41	-6.86	-0.3	2.26e-11	Neuroticism;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg25319279	chr11:5960081	NA	-0.57	-8.49	-0.37	2.87e-16	DNA methylation (variation);
LGG	cis	rs28830936	1.000	rs17677199	chr15:41954613	C/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.33	-6.79	-0.3	3.4e-11	Diastolic blood pressure;
LGG	cis	rs10782582	0.593	rs17585530	chr1:76134990	G/A	cg10523679	chr1:76189770	ACADM	-0.42	-6.74	-0.3	4.63e-11	Daytime sleep phenotypes;
LGG	cis	rs17270561	0.609	rs9379786	chr6:25730255	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs7765175	0.674	rs9400614	chr6:113680516	C/T	cg26552650	chr6:113682475	NA	0.34	7.34	0.32	9.67e-13	Coronary artery calcification;
LGG	cis	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg05491587	chr18:77659695	KCNG2	-0.42	-7.49	-0.33	3.42e-13	Schizophrenia;
LGG	trans	rs9467711	0.606	rs68112369	chr6:26365759	T/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.95e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg04772025	chr11:68637568	NA	0.74	13.0	0.52	3.53e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.79	-0.34	4.45e-14	Obesity-related traits;
LGG	cis	rs6840360	0.615	rs4696094	chr4:152465501	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.5	-0.33	3.23e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3741798	1.000	rs78807762	chr12:12484136	G/A	cg08615371	chr12:12503544	MANSC1	0.59	6.67	0.3	7.52e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19524238	chr7:2802976	GNA12	0.39	9.0	0.39	5.84e-18	Height;
LGG	cis	rs11250464	0.736	rs5015512	chr10:1411923	T/C	cg08668359	chr10:1443807	ADARB2	0.65	12.25	0.49	4.6e-30	Radiation response;
LGG	cis	rs7226408	0.857	rs72894317	chr18:34706241	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08883955	chr16:11945066	RSL1D1	0.42	6.84	0.3	2.54e-11	Cognitive performance;
LGG	cis	rs9583531	0.600	rs6492305	chr13:111361400	C/T	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	cis	rs60180747	0.909	rs78135660	chr15:66769029	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.6	10.01	0.42	1.79e-21	Testicular germ cell tumor;
LGG	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.37	0.32	7.78e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.02	0.52	3e-33	Tonsillectomy;
LGG	cis	rs1153858	1.000	rs16952714	chr15:45650358	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs7648466	0.544	rs2172247	chr3:46214670	T/C	cg13144783	chr3:46249795	CCR1	-0.62	-13.52	-0.53	2.33e-35	Eotaxin levels;
LGG	cis	rs801193	0.967	rs34356500	chr7:66236607	G/T	cg18252515	chr7:66147081	NA	-0.42	-7.18	-0.32	2.75e-12	Aortic root size;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg00689492	chr4:1303491	MAEA	0.5	8.5	0.37	2.64e-16	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg04863758	chr4:1303710	MAEA	0.43	7.39	0.32	6.72e-13	Obesity-related traits;
LGG	cis	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg04568710	chr12:38710424	ALG10B	-0.33	-7.1	-0.31	4.76e-12	Bladder cancer;
LGG	cis	rs11166927	0.904	rs7835774	chr8:140819234	G/A	cg16909799	chr8:140841666	TRAPPC9	0.55	11.51	0.47	3.89e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs4969178	0.931	rs6501208	chr17:76395038	A/T	cg02836325	chr17:76403955	PGS1	-0.72	-14.62	-0.56	4.73e-40	HDL cholesterol levels;
LGG	cis	rs7681423	0.951	rs6050	chr4:155507590	C/T	cg20735720	chr4:155535218	FGG	0.54	9.43	0.4	1.93e-19	Fibrinogen;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.09	-0.35	5.27e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2479106	0.727	rs2159793	chr9:126701763	T/C	cg16191174	chr9:126692580	DENND1A	0.55	8.01	0.35	9.3e-15	Polycystic ovary syndrome;
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg22907277	chr7:1156413	C7orf50	0.66	8.51	0.37	2.36e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2836974	0.899	rs34433511	chr21:40618883	A/C	cg11644478	chr21:40555479	PSMG1	0.91	17.69	0.64	7.04e-54	Cognitive function;
LGG	cis	rs12791968	0.765	rs2279359	chr11:44999605	A/G	cg11846598	chr11:44996168	LOC221122	0.58	9.77	0.41	1.23e-20	Inhibitory control;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg00864171	chr11:67383662	NA	0.55	9.47	0.4	1.49e-19	Mean corpuscular volume;
LGG	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs6500602	0.701	rs4786508	chr16:4568043	G/A	cg06916706	chr16:4465613	CORO7	-0.89	-15.64	-0.59	1.36e-44	Schizophrenia;
LGG	cis	rs2073300	0.609	rs6137910	chr20:23346515	C/G	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1577917	0.958	rs12213431	chr6:86500956	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-11.93	-0.48	8.32e-29	Response to antipsychotic treatment;
LGG	cis	rs7582720	0.943	rs115130739	chr2:203725677	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg21926883	chr2:100939477	LONRF2	-0.68	-16.0	-0.6	3.36e-46	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg00166722	chr3:10149974	C3orf24	0.49	8.25	0.36	1.65e-15	Alzheimer's disease;
LGG	cis	rs7737355	0.773	rs3776006	chr5:130875538	C/T	cg06307176	chr5:131281290	NA	0.51	8.6	0.37	1.29e-16	Life satisfaction;
LGG	cis	rs1021993	0.545	rs58017268	chr1:209540074	C/T	cg24446417	chr1:209558027	NA	-0.73	-10.89	-0.45	1e-24	Gut microbiome composition (winter);
LGG	cis	rs7666738	0.791	rs13127542	chr4:98949159	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1620921	0.563	rs12196112	chr6:161264064	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6868223	0.617	rs12152898	chr5:33645597	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.65	0.59	1.23e-44	Mortality in heart failure;
LGG	trans	rs7916697	0.540	rs4551651	chr10:70024529	A/G	cg04882175	chr6:131122610	NA	-0.44	-6.88	-0.3	1.96e-11	Optic disc area;
LGG	cis	rs950776	0.518	rs12591557	chr15:78811732	A/G	cg16751781	chr15:78858589	CHRNA5	0.47	9.2	0.39	1.24e-18	Sudden cardiac arrest;
LGG	cis	rs2731664	0.792	rs179809	chr5:176865329	T/G	cg23176889	chr5:176863531	GRK6	-0.64	-12.19	-0.49	7.8e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1801251	0.963	rs7591176	chr2:233581803	C/A	cg08000102	chr2:233561755	GIGYF2	0.58	9.5	0.4	1.12e-19	Coronary artery disease;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg00294572	chr6:26285232	NA	0.42	7.82	0.34	3.73e-14	Educational attainment;
LGG	cis	rs7071206	0.947	rs4979905	chr10:79416367	C/T	cg07817648	chr10:79422355	NA	-0.77	-14.53	-0.56	1.17e-39	Bone mineral density;
LGG	cis	rs986417	1.000	rs2351176	chr14:61073731	A/T	cg27398547	chr14:60952738	C14orf39	0.75	6.93	0.31	1.4e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg16386425	chr10:429943	DIP2C	-0.46	-9.25	-0.39	8.57e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.49	-7.03	-0.31	7.66e-12	Menarche (age at onset);
LGG	trans	rs9329221	0.868	rs7831557	chr8:10280228	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.36	-0.4	3.48e-19	Neuroticism;
LGG	cis	rs10463554	0.963	rs13340364	chr5:102339110	G/A	cg23492399	chr5:102201601	PAM	-0.51	-7.64	-0.33	1.24e-13	Parkinson's disease;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.64	-11.34	-0.47	1.74e-26	Renal function-related traits (BUN);
LGG	cis	rs77972916	0.536	rs11679731	chr2:43589064	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-7.77	-0.34	4.93e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15369054	chr17:80825471	TBCD	0.44	8.09	0.35	5.12e-15	Breast cancer;
LGG	cis	rs1218582	0.741	rs10908447	chr1:154869742	C/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.74	-0.45	3.47e-24	Prostate cancer;
LGG	cis	rs78456975	0.527	rs10206020	chr2:1557927	A/G	cg26248373	chr2:1572462	NA	-0.87	-14.55	-0.56	8.85e-40	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs28655083	0.509	rs664408	chr16:77104820	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	0.44	7.51	0.33	3.12e-13	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg02988316	chr9:504774	KANK1	-0.4	-6.8	-0.3	3.18e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs7727544	0.660	rs2631361	chr5:131707380	C/A	cg24060327	chr5:131705240	SLC22A5	0.48	8.25	0.36	1.68e-15	Blood metabolite levels;
LGG	cis	rs61990749	0.597	rs759808	chr14:78250845	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.02	0.31	8.1e-12	Fibroblast growth factor basic levels;
LGG	cis	rs17253792	0.822	rs75555677	chr14:56096429	G/A	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.51e-31	Putamen volume;
LGG	cis	rs4566357	0.615	rs10198214	chr2:227913314	A/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.06	-0.39	3.55e-18	Coronary artery disease;
LGG	cis	rs4917300	0.967	rs2201177	chr8:143119176	T/C	cg06573787	chr8:143070187	NA	0.49	8.9	0.38	1.25e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs459571	0.916	rs467303	chr9:136904835	C/T	cg13789015	chr9:136890014	NCRNA00094	0.59	11.05	0.46	2.3e-25	Platelet distribution width;
LGG	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.14	-0.35	3.77e-15	Height;
LGG	trans	rs11148252	0.712	rs61957257	chr13:52769702	G/A	cg18335740	chr13:41363409	SLC25A15	0.64	12.65	0.51	1.07e-31	Lewy body disease;
LGG	cis	rs6582630	0.638	rs12425379	chr12:38523705	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.82	-0.45	1.79e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7918232	0.505	rs788221	chr10:27442247	G/C	cg14442939	chr10:27389572	ANKRD26	-0.71	-9.03	-0.39	4.52e-18	Breast cancer;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg24829409	chr8:58192753	C8orf71	-0.48	-8.33	-0.36	9.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.525	rs11613788	chr12:39390710	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs6964587	0.967	rs2188153	chr7:91595117	G/T	cg17063962	chr7:91808500	NA	0.48	8.54	0.37	1.93e-16	Breast cancer;
LGG	cis	rs1163251	0.902	rs640195	chr1:120217650	T/A	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.26e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6456042	1.000	rs3127420	chr6:166538548	T/C	cg11088901	chr6:166572345	T	-0.34	-7.24	-0.32	1.93e-12	Asthma;
LGG	trans	rs7939886	0.920	rs4489763	chr11:55944474	G/A	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs4595586	0.545	rs3914595	chr12:39388530	G/T	cg13010199	chr12:38710504	ALG10B	0.42	7.48	0.33	3.79e-13	Morning vs. evening chronotype;
LGG	cis	rs9906944	0.545	rs1994969	chr17:47080431	G/T	cg10950924	chr17:47092072	IGF2BP1	-0.51	-9.89	-0.42	4.83e-21	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.21	-0.49	6.49e-30	Extrinsic epigenetic age acceleration;
LGG	trans	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg18187862	chr3:45730750	SACM1L	0.64	10.59	0.44	1.32e-23	Primary sclerosing cholangitis;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.8	14.79	0.57	8.59e-41	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs16912285	0.539	rs11027824	chr11:24368141	A/G	ch.11.24196551F	chr11:24239977	NA	0.65	7.22	0.32	2.16e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs8114671	0.836	rs6120778	chr20:33565169	T/C	cg24642439	chr20:33292090	TP53INP2	0.51	8.32	0.36	9.88e-16	Height;
LGG	cis	rs4919087	0.962	rs10882891	chr10:99059645	C/A	cg25902810	chr10:99078978	FRAT1	0.53	9.98	0.42	2.32e-21	Monocyte count;
LGG	cis	rs10911232	0.524	rs10911229	chr1:183050368	C/G	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.98	0.39	6.65e-18	Hypertriglyceridemia;
LGG	cis	rs10080237	0.564	rs2490224	chr6:80809833	G/A	cg08355045	chr6:80787529	NA	0.4	7.95	0.35	1.48e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs8179	0.645	rs17766836	chr7:92258961	C/T	cg15732164	chr7:92237376	CDK6	-0.52	-9.82	-0.42	8.57e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs4474465	0.688	rs4277140	chr11:78285096	G/T	cg27205649	chr11:78285834	NARS2	-0.6	-11.21	-0.46	5.78e-26	Alzheimer's disease (survival time);
LGG	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg19717773	chr7:2847554	GNA12	-0.38	-8.81	-0.38	2.47e-17	Height;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg21970626	chr13:21893289	NA	-0.4	-9.21	-0.39	1.17e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-11.55	-0.47	2.71e-27	Brugada syndrome;
LGG	cis	rs7648466	0.592	rs7616215	chr3:46205686	A/G	cg12441928	chr3:46249985	CCR1	0.45	8.82	0.38	2.32e-17	Eotaxin levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21552867	chr2:84686507	SUCLG1	0.45	7.11	0.31	4.3e-12	Cognitive performance;
LGG	cis	rs9291683	0.552	rs17187075	chr4:9990328	G/C	cg08250081	chr4:10125330	NA	0.38	7.4	0.33	6.48e-13	Bone mineral density;
LGG	cis	rs1691799	0.799	rs10784525	chr12:66772766	G/A	cg16791601	chr12:66731901	HELB	-0.65	-14.99	-0.57	1.1e-41	White blood cell count (basophil);
LGG	trans	rs9467711	1.000	rs6923139	chr6:26313348	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-7.01	-0.31	8.3e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg13264159	chr8:625131	ERICH1	-0.75	-8.47	-0.37	3.19e-16	IgG glycosylation;
LGG	trans	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.9e-13	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs8176273	chr17:41211653	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.18	-0.32	2.77e-12	Menopause (age at onset);
LGG	cis	rs6445975	0.715	rs13320332	chr3:58268344	A/T	cg24175188	chr3:58374923	PXK	0.4	7.31	0.32	1.19e-12	Systemic lupus erythematosus;
LGG	cis	rs757081	0.658	rs190046	chr11:17293356	T/C	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.45	-0.33	4.75e-13	Systolic blood pressure;
LGG	cis	rs4132509	0.744	rs12021907	chr1:243995640	A/G	cg21452805	chr1:244014465	NA	-0.87	-8.84	-0.38	2.08e-17	RR interval (heart rate);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	8.86	0.38	1.71e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2652822	0.530	rs7165016	chr15:63439590	T/A	cg02713581	chr15:63449717	RPS27L	0.42	6.68	0.3	6.66e-11	Metabolic traits;
LGG	cis	rs9543976	0.623	rs8192756	chr13:76164938	C/T	cg12827798	chr13:76122768	UCHL3	-0.44	-6.76	-0.3	4.2e-11	Diabetic retinopathy;
LGG	trans	rs225245	0.755	rs7217565	chr17:34024707	C/A	cg19694781	chr19:47549865	TMEM160	-0.42	-7.14	-0.31	3.63e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7726839	0.574	rs11134148	chr5:637107	C/T	cg09021430	chr5:549028	NA	-0.68	-9.46	-0.4	1.5e-19	Obesity-related traits;
LGG	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs526231	0.543	rs152134	chr5:102512447	C/G	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.61e-16	Primary biliary cholangitis;
LGG	cis	rs2762353	0.808	rs1184803	chr6:25834658	T/C	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	trans	rs3857536	0.813	rs7743965	chr6:66941346	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs2559856	1.000	rs2559858	chr12:102089300	A/G	cg12924262	chr12:102091054	CHPT1	0.66	13.31	0.53	1.93e-34	Blood protein levels;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg21724239	chr8:58056113	NA	0.55	7.8	0.34	4.12e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs11166927	0.967	rs56343024	chr8:140803580	G/A	cg16909799	chr8:140841666	TRAPPC9	0.59	12.42	0.5	9.42e-31	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs3820068	0.705	rs4646087	chr1:15822404	A/G	cg05660106	chr1:15850417	CASP9	1.11	26.82	0.78	2.77e-96	Systolic blood pressure;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg04450456	chr4:17643702	FAM184B	0.31	6.71	0.3	5.81e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs7241530	0.662	rs7237276	chr18:75907694	C/T	cg14642773	chr18:75888474	NA	0.48	9.36	0.4	3.36e-19	Educational attainment (years of education);
LGG	trans	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.53	-8.58	-0.37	1.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs889398	0.617	rs4985447	chr16:69885166	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.72	-0.34	7.22e-14	Body mass index;
LGG	trans	rs7939886	0.920	rs17150096	chr11:55902996	C/T	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs75804782	0.521	rs56365531	chr2:239458456	C/T	cg18131467	chr2:239335373	ASB1	-0.66	-7.72	-0.34	7.09e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2243480	1.000	rs7787230	chr7:65629099	G/A	cg18252515	chr7:66147081	NA	1.44	20.8	0.7	2.34e-68	Diabetic kidney disease;
LGG	cis	rs6956675	0.534	rs1806453	chr7:62641533	A/G	cg08930214	chr7:62859557	LOC100287834	-0.39	-7.13	-0.31	3.84e-12	Obesity-related traits;
LGG	cis	rs10982213	0.830	rs10739412	chr9:117183166	A/G	cg00969271	chr9:117093052	ORM2	0.41	7.06	0.31	6.29e-12	Interleukin-6 levels;
LGG	cis	rs12135191	0.967	rs12742042	chr1:236461620	A/G	cg21399712	chr1:236511386	NA	-0.39	-7.53	-0.33	2.62e-13	Urate levels (BMI interaction);
LGG	cis	rs13421350	0.579	rs115112210	chr2:173318179	G/T	cg15021238	chr2:173305865	ITGA6	-0.84	-9.64	-0.41	3.54e-20	Diabetic kidney disease;
LGG	cis	rs11098499	0.866	rs6847778	chr4:120293582	A/G	cg09307838	chr4:120376055	NA	0.73	12.16	0.49	1.07e-29	Corneal astigmatism;
LGG	cis	rs2735413	0.914	rs12448754	chr16:78066747	T/C	cg04733911	chr16:78082701	NA	-0.76	-17.38	-0.63	1.94e-52	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs9611565	0.659	rs28623192	chr22:41940524	A/G	cg06850241	chr22:41845214	NA	-0.44	-6.79	-0.3	3.55e-11	Vitiligo;
LGG	trans	rs2178146	0.609	rs4843957	chr16:86470046	C/G	cg06401414	chr8:141599436	EIF2C2	-0.24	-6.76	-0.3	4.09e-11	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);Esophageal adenocarcinoma;
LGG	cis	rs9581857	0.615	rs61622854	chr13:28023194	T/A	cg01674679	chr13:27998804	GTF3A	-0.63	-7.48	-0.33	3.66e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs12477438	0.798	rs6705821	chr2:99602832	T/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.2	-0.49	6.88e-30	Chronic sinus infection;
LGG	cis	rs6840360	1.000	rs4696109	chr4:152668785	A/C	cg22705602	chr4:152727874	NA	-0.28	-6.94	-0.31	1.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg17545662	chr6:170176663	C6orf70	0.7	12.11	0.49	1.63e-29	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03647317	chr4:187891568	NA	-0.41	-8.9	-0.38	1.25e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg01262667	chr19:19385393	TM6SF2	0.45	11.36	0.47	1.5e-26	Tonsillectomy;
LGG	cis	rs3762637	1.000	rs12630576	chr3:122139517	A/C	cg24169773	chr3:122142474	KPNA1	-0.61	-10.48	-0.44	3.42e-23	LDL cholesterol levels;
LGG	cis	rs9810089	0.872	rs527888	chr3:136031358	G/C	cg21827317	chr3:136751795	NA	0.45	7.86	0.34	2.73e-14	Gestational age at birth (child effect);
LGG	cis	rs2576037	0.796	rs2247021	chr18:44578794	A/C	cg19077165	chr18:44547161	KATNAL2	-0.53	-9.62	-0.41	4.44e-20	Personality dimensions;
LGG	cis	rs2274273	0.870	rs946059	chr14:55847466	A/G	cg04306507	chr14:55594613	LGALS3	0.63	18.01	0.64	2.48e-55	Protein biomarker;
LGG	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg21775007	chr8:11205619	TDH	-0.55	-8.92	-0.38	1.09e-17	Neuroticism;
LGG	cis	rs7727544	0.606	rs72795121	chr5:131638324	T/A	cg07395648	chr5:131743802	NA	-0.43	-9.19	-0.39	1.34e-18	Blood metabolite levels;
LGG	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg19761014	chr17:28927070	LRRC37B2	0.57	7.17	0.32	3.02e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	1.000	rs11974264	chr7:65647582	C/G	cg12463550	chr7:65579703	CRCP	-0.52	-8.66	-0.37	7.76e-17	Aortic root size;
LGG	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg00599393	chr8:22457479	C8orf58	0.42	7.59	0.33	1.79e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs10193935	0.901	rs10170082	chr2:42623452	T/C	cg27598129	chr2:42591480	NA	-0.65	-9.81	-0.41	9.29e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.557	rs1250097	chr4:1238338	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.48	-0.5	5.03e-31	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs9824585	chr3:10114802	T/C	cg08888203	chr3:10149979	C3orf24	0.54	9.23	0.39	9.49e-19	Alzheimer's disease;
LGG	cis	rs6500395	0.925	rs6500396	chr16:48625458	A/T	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8133932	0.654	rs375254	chr21:47337151	T/A	cg11214348	chr21:47283868	PCBP3	-0.45	-7.98	-0.35	1.17e-14	Schizophrenia;
LGG	cis	rs240764	0.619	rs9399641	chr6:101100783	T/C	cg09795085	chr6:101329169	ASCC3	0.41	6.89	0.3	1.82e-11	Neuroticism;
LGG	cis	rs7017914	0.967	rs7018381	chr8:71670117	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs9527	0.590	rs10883829	chr10:104840635	T/C	cg04362960	chr10:104952993	NT5C2	0.57	10.8	0.45	2.08e-24	Arsenic metabolism;
LGG	cis	rs7923609	0.967	rs7909269	chr10:65177766	G/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.67e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.21	-0.43	3.2e-22	Total cholesterol levels;
LGG	cis	rs9303401	0.659	rs12602389	chr17:56779778	G/A	cg25039879	chr17:56429692	SUPT4H1	0.64	8.96	0.38	7.82e-18	Cognitive test performance;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.53	0.37	2.14e-16	Prudent dietary pattern;
LGG	cis	rs6582630	0.539	rs4882324	chr12:38499180	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.83	-0.45	1.68e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9650657	0.524	rs10088408	chr8:10817197	C/T	cg19847130	chr8:10466454	RP1L1	0.32	6.77	0.3	3.99e-11	Neuroticism;
LGG	cis	rs10504229	1.000	rs68076606	chr8:58191271	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs7507204	0.530	rs4807470	chr19:3443470	A/T	cg08382705	chr11:45687319	CHST1	-0.64	-11.41	-0.47	9.57e-27	Height;
LGG	cis	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg07460842	chr6:66804631	NA	-0.89	-16.78	-0.61	1.02e-49	Exhaled nitric oxide output;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.44	6.75	0.3	4.38e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg22947322	chr17:47091978	IGF2BP1	-0.45	-7.92	-0.35	1.82e-14	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs4538187	0.802	rs35480874	chr2:64221458	T/C	cg19915305	chr2:64069682	UGP2	-0.68	-15.34	-0.58	3e-43	Systolic blood pressure;
LGG	cis	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg21775007	chr8:11205619	TDH	-0.51	-7.94	-0.35	1.52e-14	Triglycerides;
LGG	cis	rs4917300	0.566	rs1388799	chr8:143100593	A/G	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.29e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg24829409	chr8:58192753	C8orf71	-0.8	-13.01	-0.52	3.28e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs561341	1.000	rs117029332	chr17:30266085	C/G	cg27661571	chr11:113659931	NA	-0.7	-9.54	-0.41	8.15e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1499614	1.000	rs2707838	chr7:66159201	C/T	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs9297145	1.000	rs9297145	chr7:98759117	A/C	cg05967295	chr7:98741636	SMURF1	0.97	19.08	0.66	2.52e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs2730245	1.000	rs2657345	chr7:158744169	T/C	cg24397884	chr7:158709396	WDR60	-1.04	-23.25	-0.73	8.16e-80	Height;
LGG	cis	rs138249	0.898	rs84504	chr22:50559247	G/A	cg18875453	chr22:50517795	MLC1	0.26	6.73	0.3	5.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs2204008	0.774	rs10400552	chr12:38393577	C/G	cg13010199	chr12:38710504	ALG10B	0.7	14.09	0.55	8.62e-38	Bladder cancer;
LGG	cis	rs1707322	1.000	rs11211200	chr1:46288352	A/G	cg03146154	chr1:46216737	IPP	0.53	9.84	0.42	6.86e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2839186	0.585	rs2839154	chr21:47637760	C/T	cg13012494	chr21:47604986	C21orf56	-0.49	-7.83	-0.34	3.26e-14	Testicular germ cell tumor;
LGG	cis	rs7937682	0.883	rs11213941	chr11:111434094	T/C	cg19812747	chr11:111475976	SIK2	0.5	10.52	0.44	2.44e-23	Primary sclerosing cholangitis;
LGG	cis	rs6993813	0.837	rs7004052	chr8:120031029	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs597539	0.690	rs497149	chr11:68626639	A/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.91	0.59	8.41e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs561341	1.000	rs4795670	chr17:30244839	T/C	cg20587970	chr11:113659929	NA	-1.2	-21.12	-0.7	7.37e-70	Hip circumference adjusted for BMI;
LGG	cis	rs9393777	0.778	rs74689501	chr6:26887821	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	7.28	0.32	1.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs113153120	chr3:10156398	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.01	-0.55	2e-37	Alzheimer's disease;
LGG	cis	rs3818285	0.556	rs2084607	chr10:111681411	C/T	cg00817464	chr10:111662876	XPNPEP1	0.55	10.36	0.43	9.11e-23	Superior crus of antihelix expression;
LGG	cis	rs10028773	0.568	rs6838457	chr4:120267367	A/G	cg24375607	chr4:120327624	NA	0.53	9.04	0.39	4.46e-18	Educational attainment;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs686320	0.667	rs694520	chr11:65247130	G/A	cg17392047	chr11:65247138	NA	0.72	6.65	0.3	8.32e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05557255	chr11:2422385	TSSC4	0.5	8.41	0.36	5.2e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs614226	1.000	rs580016	chr12:120933977	T/C	cg21053147	chr12:120880522	NA	0.61	9.12	0.39	2.29e-18	Type 1 diabetes nephropathy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10927271	chr22:46610313	PPARA	-0.44	-7.82	-0.34	3.52e-14	Cognitive performance;
LGG	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.69	7.65	0.34	1.14e-13	Mean platelet volume;
LGG	cis	rs9517320	0.967	rs9517317	chr13:99125711	G/C	cg07423050	chr13:99094983	FARP1	0.4	8.29	0.36	1.23e-15	Longevity;
LGG	cis	rs4950928	0.887	rs7556099	chr1:203166198	C/G	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.92	-0.35	1.84e-14	YKL-40 levels;
LGG	cis	rs28595532	0.920	rs115530096	chr4:119760512	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-9.34	-0.4	3.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs79839061	0.518	rs11734537	chr4:869174	A/G	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.550	rs11723438	chr4:152531801	C/T	cg25486957	chr4:152246857	NA	0.5	8.35	0.36	7.93e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs7414273	chr1:183075017	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg09754948	chr16:28834200	ATXN2L	0.42	6.8	0.3	3.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6502050	0.769	rs8068708	chr17:80120424	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.5	-0.4	1.1e-19	Life satisfaction;
LGG	cis	rs67460515	0.563	rs68166680	chr3:160829735	T/A	cg03342759	chr3:160939853	NMD3	-0.72	-11.91	-0.48	1.01e-28	Parkinson's disease;
LGG	cis	rs1665650	0.957	rs7086870	chr10:118486260	G/A	cg14919929	chr10:118506882	NA	-0.47	-8.1	-0.35	4.83e-15	Colorectal cancer;
LGG	cis	rs912057	0.671	rs1294433	chr6:6745163	G/A	cg06612196	chr6:6737390	NA	0.49	10.62	0.44	9.8599999999999993e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs944722	0.967	rs2297511	chr17:26091227	C/T	cg07704981	chr17:26127537	NOS2	-0.48	-8.44	-0.37	4.01e-16	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	trans	rs7819412	0.595	rs10503416	chr8:10987553	C/T	cg16141378	chr3:129829833	LOC729375	-0.31	-7.01	-0.31	8.68e-12	Triglycerides;
LGG	cis	rs7762018	0.607	rs80267898	chr6:170040306	G/A	cg19338460	chr6:170058176	WDR27	-0.88	-9.39	-0.4	2.73e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4731207	0.596	rs10275346	chr7:124610346	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs2732480	0.500	rs11168464	chr12:48602115	C/T	cg21466736	chr12:48725269	NA	-0.36	-7.31	-0.32	1.15e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs79387448	0.655	rs3771167	chr2:102986188	A/G	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.88	-0.3	2.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs55823223	0.564	rs12103594	chr17:73855279	C/T	cg10935138	chr17:73851978	WBP2	0.51	7.33	0.32	1.04e-12	Psoriasis;
LGG	cis	rs4750440	0.523	rs4565800	chr10:14032326	G/C	cg00551146	chr10:14014579	FRMD4A	0.3	7.14	0.32	3.59e-12	Adiponectin levels;
LGG	cis	rs6752107	0.503	rs2304776	chr2:234227693	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.48	8.29	0.36	1.23e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6547631	0.592	rs2070966	chr2:85922860	G/T	cg24620635	chr2:85921963	GNLY	0.49	9.61	0.41	4.69e-20	Blood protein levels;
LGG	cis	rs9992101	0.645	rs61402764	chr4:77327339	C/T	cg17010112	chr4:77227123	STBD1	-0.45	-9.28	-0.4	6.45e-19	Creatinine levels;
LGG	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg03342759	chr3:160939853	NMD3	-0.67	-11.08	-0.46	1.85e-25	Parkinson's disease;
LGG	cis	rs1909881	0.688	rs1039393	chr8:96505493	G/T	cg04203453	chr8:96504381	NA	-1.09	-18.65	-0.65	2.63e-58	Obesity-related traits;
LGG	cis	rs490234	0.934	rs4837018	chr9:128275991	A/G	cg14078157	chr9:128172775	NA	-0.4	-7.49	-0.33	3.52e-13	Mean arterial pressure;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.71	-0.41	2.15e-20	Triglycerides;
LGG	cis	rs7193541	0.965	rs7199068	chr16:74698263	C/G	cg01733217	chr16:74700730	RFWD3	0.91	21.34	0.7	7.63e-71	Multiple myeloma;
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.46	-0.37	3.62e-16	IgG glycosylation;
LGG	cis	rs11700980	0.551	rs56066604	chr21:30116217	A/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs6831352	0.918	rs13113166	chr4:100050528	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs3755397	1	rs3755397	chr2:242294913	A/G	cg10173475	chr2:242152697	ANO7	-0.68	-7.7	-0.34	8.15e-14	Chronic lymphocytic leukemia;Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;Eosinophil percentage of white cells;
LGG	cis	rs1023500	0.573	rs2269524	chr22:42475703	T/G	cg04733989	chr22:42467013	NAGA	-0.59	-10.7	-0.45	5.21e-24	Schizophrenia;
LGG	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg24397884	chr7:158709396	WDR60	1.11	16.98	0.62	1.21e-50	Height;
LGG	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg03264133	chr6:25882463	NA	0.46	7.98	0.35	1.12e-14	Blood metabolite levels;
LGG	cis	rs897984	0.609	rs17839567	chr16:31057945	A/G	cg00531865	chr16:30841666	NA	-0.49	-10.17	-0.43	4.77e-22	Dementia with Lewy bodies;
LGG	cis	rs4819052	0.851	rs7279182	chr21:46656112	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.72	12.6	0.51	1.69e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg06360820	chr2:242988706	NA	-0.94	-12.41	-0.5	1.03e-30	Obesity-related traits;
LGG	cis	rs7617773	0.780	rs7645425	chr3:48362369	A/T	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs2288073	0.965	rs13395596	chr2:24410738	T/C	cg26838691	chr2:24397539	C2orf84	-0.48	-6.79	-0.3	3.4e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg14283194	chr7:91763737	CYP51A1	0.42	7.21	0.32	2.34e-12	Lung adenocarcinoma;
LGG	cis	rs6840360	0.615	rs12647462	chr4:152607278	C/T	cg22705602	chr4:152727874	NA	-0.37	-9.15	-0.39	1.85e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9880211	0.898	rs1052620	chr3:136574521	C/T	cg21827317	chr3:136751795	NA	-0.51	-7.41	-0.33	5.85e-13	Body mass index;Height;
LGG	cis	rs6964587	0.933	rs28671255	chr7:91770705	A/G	cg17063962	chr7:91808500	NA	0.53	9.76	0.41	1.38e-20	Breast cancer;
LGG	cis	rs483180	0.512	rs594400	chr1:120214275	G/T	cg19096424	chr1:120255104	PHGDH	-0.6	-10.77	-0.45	2.83e-24	Macular telangiectasia type 2;
LGG	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.65	-0.67	6.1e-63	Height;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.27	-0.36	1.38e-15	Life satisfaction;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg16507663	chr6:150244633	RAET1G	-0.5	-10.29	-0.43	1.69e-22	Testicular germ cell tumor;
LGG	cis	rs12788925	0.504	rs7124873	chr11:102803476	A/G	cg19620758	chr11:102826565	MMP13	-0.43	-8.51	-0.37	2.49e-16	Coronary artery disease;
LGG	trans	rs208520	1.000	rs208536	chr6:66963440	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.88	-14.32	-0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs4862307	0.836	rs6829678	chr4:185001631	C/T	cg06737308	chr4:185021514	ENPP6	-0.4	-7.01	-0.31	8.28e-12	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs7215564	0.558	rs4889876	chr17:78657071	T/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.32	-0.36	9.89e-16	Myopia (pathological);
LGG	trans	rs3206736	0.529	rs1649225	chr7:34991676	C/A	cg14337134	chr7:102920323	DPY19L2P2	0.4	7.14	0.31	3.73e-12	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01729820	chr17:17585298	RAI1	0.44	6.76	0.3	4.23e-11	Gut microbiome composition (summer);
LGG	cis	rs4700695	0.841	rs417152	chr5:65316205	G/A	cg21114390	chr5:65439923	SFRS12	0.59	7.35	0.32	8.86e-13	Facial morphology (factor 19);
LGG	trans	rs3960554	0.800	rs112463197	chr7:75622912	C/T	cg19862616	chr7:65841803	NCRNA00174	0.88	12.26	0.5	4.04e-30	Eotaxin levels;
LGG	cis	rs4696584	0.755	rs17031728	chr4:155412581	C/G	cg13738195	chr4:155413469	DCHS2	-0.38	-7.44	-0.33	4.82e-13	Folding of antihelix;
LGG	trans	rs9467711	0.606	rs35307327	chr6:26370474	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs611744	0.647	rs615126	chr8:109247619	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	trans	rs2243480	1.000	rs1546059	chr7:65654709	C/A	cg10756647	chr7:56101905	PSPH	-0.8	-9.24	-0.39	9.32e-19	Diabetic kidney disease;
LGG	cis	rs1163251	0.837	rs595283	chr1:120247887	C/G	cg19096424	chr1:120255104	PHGDH	-0.71	-12.37	-0.5	1.48e-30	Blood metabolite levels;
LGG	cis	rs240764	0.635	rs2071826	chr6:100928357	G/A	cg21058520	chr6:100914733	NA	0.48	8.4	0.36	5.53e-16	Neuroticism;
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10802521	chr3:52805072	NEK4	-0.45	-7.65	-0.33	1.2e-13	Bipolar disorder;
LGG	cis	rs8060686	0.641	rs9938553	chr16:68183064	T/A	cg27539214	chr16:67997921	SLC12A4	-0.45	-7.08	-0.31	5.36e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs17401966	1.000	rs12734551	chr1:10391536	A/C	cg15208524	chr1:10270712	KIF1B	0.44	7.5	0.33	3.27e-13	Hepatocellular carcinoma;
LGG	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.51	-10.03	-0.42	1.52e-21	Coronary artery disease;
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs9354308	0.764	rs9351534	chr6:66603183	G/T	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs7681440	0.746	rs10001067	chr4:90818216	C/G	cg18258770	chr4:90757814	SNCA	-0.37	-6.81	-0.3	3.08e-11	Dementia with Lewy bodies;
LGG	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg24110177	chr3:50126178	RBM5	0.57	10.54	0.44	1.99e-23	Intelligence (multi-trait analysis);
LGG	cis	rs11074306	0.561	rs8037478	chr15:28076829	A/G	cg26402630	chr15:28053930	OCA2	0.36	7.26	0.32	1.66e-12	Uveal melanoma;
LGG	cis	rs12410462	0.582	rs12408978	chr1:227596235	A/T	cg21459583	chr1:227974177	NA	-0.48	-7.32	-0.32	1.13e-12	Major depressive disorder;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.98	0.35	1.16e-14	Lung cancer;
LGG	cis	rs1256061	0.624	rs1152582	chr14:64692630	G/C	cg23250157	chr14:64679961	SYNE2	0.38	6.82	0.3	2.88e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7512552	0.803	rs2454286	chr1:150355538	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7166081	0.950	rs35322464	chr15:67511490	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.84	-0.3	2.44e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1465370	0.682	rs6972781	chr7:130023179	A/G	cg06917763	chr7:130033247	NA	0.35	7.58	0.33	1.9e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs6866344	0.697	rs17184344	chr5:178129281	A/G	cg10224037	chr5:178157518	ZNF354A	0.74	11.51	0.47	3.84e-27	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.83	0.51	1.86e-32	Prudent dietary pattern;
LGG	cis	rs6728642	0.831	rs10496325	chr2:97683329	C/T	cg26665480	chr2:98280029	ACTR1B	0.69	8.19	0.36	2.54e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs34638952	0.577	rs923638	chr17:27453301	T/A	cg27392559	chr17:27410759	MYO18A	-0.37	-7.08	-0.31	5.41e-12	Sitting height ratio;
LGG	cis	rs7208859	0.573	rs7223803	chr17:29077193	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg06521331	chr12:34319734	NA	-0.61	-11.21	-0.46	5.54e-26	Morning vs. evening chronotype;
LGG	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.62	-0.33	1.43e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1862618	0.525	rs2662016	chr5:56269047	A/G	cg12402800	chr5:56204917	C5orf35	0.46	6.91	0.31	1.6e-11	Initial pursuit acceleration;
LGG	cis	rs7615952	0.576	rs12497295	chr3:125818650	G/A	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs7917772	0.636	rs2250580	chr10:104505687	C/G	cg04362960	chr10:104952993	NT5C2	-0.45	-7.44	-0.33	5.09e-13	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9487051	0.807	rs7748641	chr6:109592381	C/T	cg21918786	chr6:109611834	NA	-0.42	-7.77	-0.34	4.96e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9341808	0.718	rs2322630	chr6:80841033	A/G	cg08355045	chr6:80787529	NA	0.41	7.92	0.35	1.75e-14	Sitting height ratio;
LGG	cis	rs2243480	1.000	rs465359	chr7:65558164	C/T	cg12463550	chr7:65579703	CRCP	0.78	8.78	0.38	3.21e-17	Diabetic kidney disease;
LGG	cis	rs17818399	0.781	rs12105006	chr2:46862586	C/T	cg26688816	chr2:46740690	ATP6V1E2	0.53	9.11	0.39	2.4e-18	Height;
LGG	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg25809561	chr17:30822961	MYO1D	0.39	8.99	0.39	6.44e-18	Schizophrenia;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.48	10.38	0.43	7.51e-23	Aortic root size;
LGG	trans	rs61931739	0.534	rs1211286	chr12:34135581	T/C	cg13010199	chr12:38710504	ALG10B	0.54	10.55	0.44	1.91e-23	Morning vs. evening chronotype;
LGG	cis	rs17384381	1.000	rs12140170	chr1:85849723	G/A	cg16011679	chr1:85725395	C1orf52	0.6	10.48	0.44	3.32e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7666738	0.822	rs28367231	chr4:98845726	G/T	cg05340658	chr4:99064831	C4orf37	0.47	7.7	0.34	8.05e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs4714291	0.925	rs847784	chr6:40053272	A/G	cg02267698	chr19:7991119	CTXN1	0.6	9.45	0.4	1.64e-19	Strep throat;
LGG	cis	rs2251381	0.778	rs722013	chr21:30549245	G/T	cg08807101	chr21:30365312	RNF160	0.76	13.68	0.54	5.12e-36	Selective IgA deficiency;
LGG	cis	rs308971	0.563	rs394945	chr3:12075117	T/C	cg22839075	chr3:12045461	SYN2	0.51	6.67	0.3	7.24e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg24955955	chr5:415729	AHRR	0.71	10.0	0.42	1.95e-21	Fat distribution (HIV);
LGG	cis	rs6982240	0.514	rs10089212	chr8:142265380	T/A	cg20799268	chr8:142275649	NA	-0.25	-6.96	-0.31	1.17e-11	Tonsillectomy;
LGG	trans	rs9467711	0.538	rs35942482	chr6:26444938	T/A	cg08344181	chr3:125677491	NA	-0.63	-7.1	-0.31	4.63e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.39	0.56	4.38e-39	Platelet count;
LGG	trans	rs116095464	0.558	rs10067021	chr5:221490	C/T	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs12210905	0.688	rs12189640	chr6:27474657	T/C	cg00426182	chr6:28072559	NA	0.93	6.96	0.31	1.21e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg08677398	chr8:58056175	NA	0.62	13.79	0.54	1.73e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs2227564	0.620	rs4746148	chr10:75534488	C/T	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.88	-0.42	5.03e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs147649347	1	rs147649347	chr2:24210076	GATAA/G	cg08917208	chr2:24149416	ATAD2B	0.91	10.04	0.42	1.33e-21	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2386661	0.547	rs11259742	chr10:5647078	C/T	cg12223502	chr10:5658492	NA	-0.34	-6.77	-0.3	3.88e-11	Breast cancer;
LGG	trans	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg10756647	chr7:56101905	PSPH	0.84	9.88	0.42	5.27e-21	Diabetic kidney disease;
LGG	trans	rs7395662	0.963	rs6485900	chr11:48637415	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.86	-0.34	2.66e-14	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.53	-0.37	2.06e-16	Lung cancer;
LGG	cis	rs494459	0.838	rs2510897	chr11:118644582	A/C	cg20110707	chr11:118481992	PHLDB1	0.31	6.69	0.3	6.64e-11	Height;
LGG	cis	rs4740619	0.716	rs1927697	chr9:15934102	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.13	-0.43	6.5e-22	Body mass index;
LGG	cis	rs10274279	0.660	rs10278007	chr7:157372906	C/G	cg09270525	chr7:157391030	PTPRN2	0.84	13.49	0.53	3.26e-35	Myopia (pathological);
LGG	cis	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg13939156	chr17:80058883	NA	-0.4	-7.07	-0.31	5.64e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.02	0.57	8.07e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2120019	0.935	rs12591119	chr15:75355944	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-19.43	-0.67	5.92e-62	Blood trace element (Zn levels);
LGG	cis	rs7615952	0.800	rs12489350	chr3:125644116	T/C	cg05084668	chr3:125655381	ALG1L	-0.87	-10.78	-0.45	2.54e-24	Blood pressure (smoking interaction);
LGG	cis	rs9549367	0.713	rs56002882	chr13:113830694	T/C	cg18105134	chr13:113819100	PROZ	-0.8	-16.79	-0.62	9.37e-50	Platelet distribution width;
LGG	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.48e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg02002194	chr4:3960332	NA	0.42	7.86	0.34	2.72e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs56399783	0.901	rs73051415	chr7:2850643	C/T	cg19731401	chr7:2775893	GNA12	0.37	7.4	0.33	6.3e-13	Childhood ear infection;
LGG	cis	rs854765	0.583	rs28428991	chr17:17827649	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.67	13.28	0.53	2.56e-34	Total body bone mineral density;
LGG	cis	rs2645694	0.626	rs2703129	chr4:77818548	T/C	cg10057126	chr4:77819792	ANKRD56	0.37	6.99	0.31	9.63e-12	Emphysema distribution in smoking;
LGG	cis	rs17021463	0.673	rs35898424	chr4:95289278	A/G	cg11021082	chr4:95130006	SMARCAD1	0.4	6.83	0.3	2.61e-11	Testicular germ cell tumor;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.65	0.54	7.1e-36	Obesity-related traits;
LGG	cis	rs13191362	1.000	rs55847707	chr6:163003414	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs908922	0.566	rs12144049	chr1:152440910	C/T	cg09873164	chr1:152488093	CRCT1	0.38	7.11	0.31	4.46e-12	Hair morphology;
LGG	trans	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.99	-0.31	9.66e-12	Triglycerides;
LGG	trans	rs853679	0.585	rs201001	chr6:27808899	T/C	cg06606381	chr12:133084897	FBRSL1	-0.55	-7.41	-0.33	6.21e-13	Depression;
LGG	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg02228329	chr11:64053129	BAD;GPR137	-0.63	-11.42	-0.47	8.42e-27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs9354308	0.764	rs9354311	chr6:66568384	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs6879260	1.000	rs1035411	chr5:179729519	A/G	cg13944838	chr5:179740914	GFPT2	-0.7	-12.83	-0.51	1.89e-32	Height;
LGG	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg08048268	chr3:133502702	NA	-0.43	-7.66	-0.34	1.07e-13	Iron status biomarkers;
LGG	cis	rs6495122	0.501	rs8039755	chr15:75337426	T/C	cg09165964	chr15:75287851	SCAMP5	-0.56	-10.61	-0.44	1.13e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2694528	0.844	rs2219333	chr5:60049119	T/C	cg11474532	chr5:59995715	DEPDC1B	0.73	7.81	0.34	3.95e-14	Parkinson's disease;
LGG	cis	rs9467711	0.591	rs10484433	chr6:26030492	G/T	cg21479132	chr6:26055353	NA	0.75	7.58	0.33	1.91e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3206736	0.548	rs328896	chr7:35017222	A/G	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.19e-19	Diastolic blood pressure;
LGG	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg16576597	chr16:28551801	NUPR1	0.3	6.67	0.3	7.23e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12477438	0.765	rs28648058	chr2:99696417	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.38	-0.58	2.1e-43	Chronic sinus infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05300158	chr4:140477727	SETD7	0.44	7.29	0.32	1.35e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg01966878	chr4:90757139	SNCA	0.33	6.64	0.3	8.56e-11	Dementia with Lewy bodies;
LGG	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg17809284	chr5:56205270	C5orf35	-0.53	-8.7	-0.37	5.91e-17	Type 2 diabetes;
LGG	cis	rs9462027	0.628	rs9469886	chr6:34758824	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs8177253	0.665	rs6774822	chr3:133442012	G/T	cg01448562	chr3:133502909	NA	-0.52	-8.83	-0.38	2.18e-17	Iron status biomarkers;
LGG	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg11644478	chr21:40555479	PSMG1	-0.9	-17.04	-0.62	6.8e-51	Cognitive function;
LGG	cis	rs8005677	0.828	rs57822749	chr14:23409967	G/A	cg25600027	chr14:23388339	RBM23	-0.42	-7.13	-0.31	3.76e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs16854884	0.770	rs4450810	chr3:143809091	C/A	cg06585982	chr3:143692056	C3orf58	0.56	9.25	0.39	8.53e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg06115741	chr20:33292138	TP53INP2	0.5	8.23	0.36	1.87e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6977660	0.714	rs4721827	chr7:19825655	A/G	cg07541023	chr7:19748670	TWISTNB	0.57	7.77	0.34	5.1e-14	Thyroid stimulating hormone;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	14.88	0.57	3.34e-41	Obesity-related traits;
LGG	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.77	0.3	3.91e-11	Cognitive ability;
LGG	cis	rs4363385	0.509	rs11581802	chr1:152936164	G/A	cg13444842	chr1:152974279	SPRR3	-0.48	-9.65	-0.41	3.47e-20	Inflammatory skin disease;
LGG	cis	rs7107174	1.000	rs2510055	chr11:77961912	C/T	cg02023728	chr11:77925099	USP35	0.44	7.61	0.33	1.58e-13	Testicular germ cell tumor;
LGG	cis	rs2075671	0.903	rs62482250	chr7:100266057	C/T	cg20848291	chr7:100343083	ZAN	-0.66	-9.5	-0.4	1.13e-19	Other erythrocyte phenotypes;
LGG	cis	rs972578	0.677	rs7287107	chr22:43262513	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.92	-0.31	1.5e-11	Mean platelet volume;
LGG	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.1	-0.35	4.88e-15	Response to antipsychotic treatment;
LGG	cis	rs782590	1.000	rs782590	chr2:55843413	C/T	cg18811423	chr2:55921094	PNPT1	0.89	20.44	0.69	1.24e-66	Metabolic syndrome;
LGG	cis	rs3741151	0.686	rs12291233	chr11:73272946	T/G	cg17517138	chr11:73019481	ARHGEF17	0.67	7.01	0.31	8.52e-12	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs116095464	0.558	rs56298907	chr5:283280	C/A	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs4704846	1.000	rs4704853	chr5:156536876	A/G	cg12943317	chr5:156479607	HAVCR1	-0.58	-7.63	-0.33	1.37e-13	Blood protein levels;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg06221963	chr1:154839813	KCNN3	-0.52	-10.5	-0.44	2.72e-23	Prostate cancer;
LGG	cis	rs1577917	0.958	rs1816937	chr6:86557251	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs9341835	0.584	rs2622286	chr6:64150067	A/T	cg00787780	chr6:64151745	NA	0.44	8.12	0.35	4.32e-15	Schizophrenia;
LGG	cis	rs8062405	0.929	rs11864750	chr16:28875204	A/T	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg12310025	chr6:25882481	NA	-0.43	-7.79	-0.34	4.5e-14	Height;
LGG	cis	rs8141529	0.719	rs132561	chr22:29351179	C/T	cg15103426	chr22:29168792	CCDC117	-0.61	-9.37	-0.4	3.08e-19	Lymphocyte counts;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg14893161	chr1:205819251	PM20D1	0.88	20.55	0.69	3.55e-67	Menarche (age at onset);
LGG	cis	rs4076764	0.957	rs4443867	chr1:163434917	T/C	cg06092702	chr1:163392909	NA	-0.47	-8.44	-0.37	4.17e-16	Motion sickness;
LGG	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.94	-0.52	6.72e-33	Alzheimer's disease;
LGG	trans	rs2204008	0.537	rs28680519	chr12:38502946	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.01	-0.39	5.55e-18	Bladder cancer;
LGG	cis	rs908922	0.676	rs477621	chr1:152486252	T/C	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.43e-45	Hair morphology;
LGG	cis	rs2236267	0.726	rs12431598	chr14:88630812	G/A	cg02175263	chr14:88627849	NA	-0.31	-6.86	-0.3	2.26e-11	Food antigen IgG levels;
LGG	cis	rs2439831	0.867	rs496584	chr15:43831923	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.93	10.85	0.45	1.38e-24	Lung cancer in ever smokers;
LGG	cis	rs7503807	0.935	rs62068348	chr17:78608575	T/C	cg06872548	chr17:78716983	RPTOR	0.45	10.87	0.45	1.11e-24	Obesity;
LGG	cis	rs7143963	0.943	rs7156339	chr14:103366698	C/T	cg23020514	chr14:103360112	TRAF3	0.47	8.78	0.38	3.18e-17	Body mass index;
LGG	cis	rs62025270	0.688	rs12148571	chr15:86267393	G/A	cg25843651	chr15:86329602	KLHL25	0.57	8.89	0.38	1.41e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs61884328	0.777	rs61897784	chr11:47154514	A/G	cg03339077	chr11:47165057	C11orf49	0.68	7.02	0.31	7.94e-12	Total body bone mineral density (age over 60);
LGG	cis	rs2354432	0.607	rs6703847	chr1:146669444	G/A	cg25205988	chr1:146714368	CHD1L	1.06	9.3	0.4	5.51e-19	Mitochondrial DNA levels;
LGG	cis	rs11122272	0.735	rs2790890	chr1:231514567	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.43	-0.33	5.25e-13	Hemoglobin concentration;
LGG	cis	rs559928	0.606	rs1011219	chr11:63973396	A/G	cg02228329	chr11:64053129	BAD;GPR137	-0.56	-6.81	-0.3	3.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4740619	0.774	rs10756720	chr9:15919177	A/G	cg14451791	chr9:16040625	NA	0.34	8.21	0.36	2.26e-15	Body mass index;
LGG	cis	rs9611519	0.754	rs4820435	chr22:41652846	G/T	cg03806693	chr22:41940476	POLR3H	-0.69	-11.32	-0.47	2.13e-26	Neuroticism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06937024	chr6:35695489	FKBP5;LOC285847	-0.45	-6.99	-0.31	9.94e-12	Pancreatic cancer;
LGG	cis	rs9814567	1.000	rs9829092	chr3:134229866	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.15	-0.52	8.81e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4076764	0.958	rs11580702	chr1:163385523	C/G	cg24596788	chr1:163392923	NA	-0.72	-13.84	-0.54	1.02e-36	Motion sickness;
LGG	cis	rs34929064	0.881	rs7802442	chr7:22736446	A/C	cg18045685	chr7:22629474	NA	0.43	7.65	0.33	1.17e-13	Major depression and alcohol dependence;
LGG	cis	rs968451	0.789	rs1569500	chr22:39683515	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	13.93	0.54	4.37e-37	Primary biliary cholangitis;
LGG	cis	rs1568889	1.000	rs16917735	chr11:28119980	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	-0.75	-13.95	-0.54	3.62e-37	Bipolar disorder;
LGG	cis	rs881375	1.000	rs1953126	chr9:123640500	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.68	0.48	8.3e-28	Rheumatoid arthritis;
LGG	trans	rs6601327	0.635	rs10112972	chr8:9655218	T/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.02	-0.31	7.88e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4595586	0.545	rs9669705	chr12:39374459	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs7576782	chr2:42218378	C/A	cg27428208	chr2:42229179	NA	0.53	8.21	0.36	2.24e-15	Hypospadias;
LGG	cis	rs12295403	0.691	rs12808592	chr11:18677315	G/A	cg09201001	chr11:18656081	SPTY2D1	0.39	6.64	0.3	8.59e-11	Ovarian reserve;
LGG	cis	rs4731207	0.596	rs7799712	chr7:124649717	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg26174226	chr8:58114915	NA	-0.52	-7.52	-0.33	2.89e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg14926445	chr8:58193284	C8orf71	-0.8	-9.74	-0.41	1.63e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg03517284	chr6:25882590	NA	-0.81	-15.5	-0.58	5.81e-44	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18239851	chr1:70671762	SFRS11;LRRC40	0.42	7.14	0.31	3.53e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.39	-0.43	7.13e-23	Triglycerides;
LGG	trans	rs12517041	1.000	rs1428623	chr5:23286659	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs9309711	0.666	rs6723126	chr2:3484500	T/C	cg15506890	chr2:3487001	NA	-0.55	-10.66	-0.44	7.04e-24	Neurofibrillary tangles;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg07511668	chr11:68622177	NA	0.48	9.15	0.39	1.75e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg04156016	chr5:1868137	NA	0.32	7.21	0.32	2.36e-12	Cardiovascular disease risk factors;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	12.7	0.51	6.68e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.647	rs34103231	chr15:76912690	A/G	cg15268244	chr15:77196840	NA	0.48	10.31	0.43	1.44e-22	Blood metabolite levels;
LGG	cis	rs4481887	0.893	rs7538645	chr1:248478137	C/T	cg13385794	chr1:248469461	NA	0.5	8.37	0.36	6.76e-16	Common traits (Other);
LGG	cis	rs11785400	0.793	rs4736366	chr8:143742413	C/T	cg10596483	chr8:143751796	JRK	0.54	8.39	0.36	5.98e-16	Schizophrenia;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg27532560	chr4:187881888	NA	0.6	12.86	0.51	1.39e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs72781680	0.898	rs72786286	chr2:24074659	T/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.02	0.39	5.03e-18	Lymphocyte counts;
LGG	cis	rs9325144	0.534	rs1973293	chr12:38679575	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.86	0.48	1.62e-28	Morning vs. evening chronotype;
LGG	trans	rs9951602	0.512	rs7234283	chr18:76640552	T/G	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs7671752	chr4:17661398	C/T	cg04450456	chr4:17643702	FAM184B	0.31	6.82	0.3	2.78e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12586317	0.576	rs10146445	chr14:35631553	C/T	cg05294307	chr14:35346193	BAZ1A	-0.38	-7.23	-0.32	2e-12	Psoriasis;
LGG	trans	rs11650494	0.908	rs75904857	chr17:47370449	T/G	cg11430096	chr6:110968061	CDK19	0.67	7.01	0.31	8.66e-12	Prostate cancer;
LGG	trans	rs61931739	1.000	rs12305700	chr12:34036332	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.21	-0.36	2.22e-15	Morning vs. evening chronotype;
LGG	cis	rs1707322	1.000	rs785504	chr1:46595696	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.52	-0.4	9.26e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg14541582	chr5:601475	NA	-0.7	-11.02	-0.46	3.05e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs9464760	0.527	rs13194276	chr6:15158452	G/C	cg15799072	chr6:15248335	JARID2	0.62	8.02	0.35	8.57e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs7937682	0.632	rs4935811	chr11:111679262	C/T	cg22437258	chr11:111473054	SIK2	-0.42	-6.9	-0.31	1.75e-11	Primary sclerosing cholangitis;
LGG	cis	rs6750795	0.569	rs1797387	chr2:232414692	A/G	cg19187155	chr2:232395269	NMUR1	0.49	9.3	0.4	5.46e-19	Height;
LGG	cis	rs12210905	1.000	rs9393796	chr6:27226965	T/G	cg15325629	chr6:28072465	NA	0.71	6.71	0.3	5.68e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg24623649	chr8:11872141	NA	0.3	6.9	0.31	1.67e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs1823913	0.614	rs1947457	chr2:192163696	C/T	cg25785477	chr4:130014987	SCLT1;C4orf33	0.64	6.76	0.3	4.24e-11	Obesity-related traits;
LGG	cis	rs12908161	0.959	rs1051168	chr15:85200520	G/T	cg24253500	chr15:84953950	NA	0.42	7.03	0.31	7.24e-12	Schizophrenia;
LGG	cis	rs7580658	0.963	rs12463451	chr2:128053883	C/T	cg10021288	chr2:128175891	PROC	-0.64	-13.28	-0.53	2.57e-34	Protein C levels;
LGG	cis	rs988958	0.675	rs56140445	chr2:42230317	G/C	cg27252766	chr2:42229092	NA	0.54	8.46	0.37	3.65e-16	Hypospadias;
LGG	cis	rs9308433	0.529	rs9430133	chr1:214496313	C/T	cg06198575	chr1:214491504	SMYD2	0.51	7.77	0.34	5.13e-14	IgG glycosylation;
LGG	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.97	-0.31	1.13e-11	Type 2 diabetes;
LGG	cis	rs220324	0.954	rs467589	chr21:43582763	C/T	cg08841829	chr21:43638893	ABCG1	0.42	6.87	0.3	2.07e-11	Idiopathic osteonecrosis of the femoral head;
LGG	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg06606381	chr12:133084897	FBRSL1	-0.98	-10.45	-0.44	4.33e-23	Depression;
LGG	cis	rs12291225	0.877	rs11023160	chr11:14264225	T/A	cg19336497	chr11:14380999	RRAS2	-0.47	-8.61	-0.37	1.13e-16	Sense of smell;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.5	-0.4	1.18e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.929	rs515857	chr1:53336859	A/G	cg24675658	chr1:53192096	ZYG11B	-0.47	-8.48	-0.37	3.06e-16	Monocyte count;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	20.07	0.68	6.63e-65	Platelet count;
LGG	cis	rs644799	0.544	rs56298021	chr11:95545113	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.68	13.2	0.52	5.17e-34	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg20991723	chr1:152506922	NA	-0.71	-14.48	-0.56	1.9e-39	Hair morphology;
LGG	trans	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs208520	0.565	rs1385222	chr6:66753013	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	1.09	27.54	0.79	1.42e-99	Exhaled nitric oxide output;
LGG	cis	rs12519773	0.611	rs6873704	chr5:92490864	A/C	cg18783429	chr5:92414398	NA	0.27	6.65	0.3	8.2e-11	Migraine;
LGG	cis	rs769267	0.895	rs2916069	chr19:19520358	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.37	0.36	7.07e-16	Tonsillectomy;
LGG	cis	rs2228479	0.850	rs62052711	chr16:89855100	C/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs9547996	0.879	rs61957469	chr13:38133006	C/T	cg13634560	chr13:38173852	POSTN	-0.35	-7.08	-0.31	5.25e-12	Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.93	-0.42	3.33e-21	Lung cancer;
LGG	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg17971929	chr21:40555470	PSMG1	0.89	17.57	0.63	2.49e-53	Cognitive function;
LGG	cis	rs490234	0.702	rs35129945	chr9:128320134	C/T	cg14078157	chr9:128172775	NA	-0.54	-10.27	-0.43	1.96e-22	Mean arterial pressure;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.11	-0.49	1.6800000000000001e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs4650994	0.816	rs2811303	chr1:178595646	G/T	cg12486710	chr1:178512616	C1orf220	-0.4	-8.05	-0.35	7.25e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs741702	0.928	rs2293683	chr19:13039284	A/G	cg11738485	chr19:12877000	HOOK2	0.43	6.75	0.3	4.32e-11	Red blood cell traits;
LGG	cis	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg21605333	chr4:119757512	SEC24D	0.72	8.21	0.36	2.3e-15	Cannabis dependence symptom count;
LGG	cis	rs7264396	0.635	rs6121073	chr20:34457513	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.06	0.31	6.2e-12	Total cholesterol levels;
LGG	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18252515	chr7:66147081	NA	-0.49	-8.01	-0.35	9.43e-15	Aortic root size;
LGG	cis	rs950776	0.593	rs680244	chr15:78871288	T/C	cg16751781	chr15:78858589	CHRNA5	-0.42	-8.46	-0.37	3.54e-16	Sudden cardiac arrest;
LGG	cis	rs738322	1.000	rs738322	chr22:38569006	A/G	cg25457927	chr22:38595422	NA	-0.42	-10.72	-0.45	4.24e-24	Cutaneous nevi;
LGG	cis	rs559928	1.000	rs72926038	chr11:64142391	G/C	cg05555928	chr11:63887634	MACROD1	-0.63	-9.05	-0.39	3.95e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7727544	0.684	rs274561	chr5:131719228	A/C	cg24060327	chr5:131705240	SLC22A5	-0.48	-8.17	-0.35	3.02e-15	Blood metabolite levels;
LGG	trans	rs61931739	0.534	rs4931783	chr12:34115322	G/A	cg26384229	chr12:38710491	ALG10B	0.82	16.46	0.61	2.95e-48	Morning vs. evening chronotype;
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.11	-0.31	4.4e-12	Bipolar disorder;
LGG	cis	rs1865760	0.865	rs9393678	chr6:25945819	C/T	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.69e-13	Height;
LGG	cis	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	8.87	0.38	1.6e-17	Mood instability;
LGG	trans	rs8105895	1.000	rs62112917	chr19:22226580	C/T	cg19945060	chr8:41508779	NA	0.45	6.7	0.3	5.93e-11	Body mass index (change over time);
LGG	cis	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg24375607	chr4:120327624	NA	0.68	11.12	0.46	1.24e-25	Corneal astigmatism;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07697189	chr5:171766855	SH3PXD2B	0.38	6.85	0.3	2.39e-11	Menarche (age at onset);
LGG	cis	rs2576037	0.526	rs2257027	chr18:44566990	A/T	cg23302884	chr18:44338147	ST8SIA5	0.39	7.69	0.34	8.91e-14	Personality dimensions;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.48	-0.4	1.38e-19	Lung cancer;
LGG	cis	rs11098499	0.954	rs13145352	chr4:120409963	C/T	cg24375607	chr4:120327624	NA	-0.71	-11.34	-0.47	1.72e-26	Corneal astigmatism;
LGG	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg13852791	chr20:30311386	BCL2L1	0.77	12.5	0.5	4.43e-31	Mean corpuscular hemoglobin;
LGG	cis	rs2247341	0.965	rs13138643	chr4:1740675	G/A	cg07465881	chr4:1713556	SLBP	-0.44	-6.95	-0.31	1.27e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9354308	0.764	rs1938100	chr6:66599919	T/G	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	cis	rs1218582	0.682	rs12046459	chr1:154912017	A/C	cg24250549	chr1:154909240	PMVK	0.75	14.87	0.57	3.73e-41	Prostate cancer;
LGG	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg15557168	chr22:42548783	NA	0.41	8.65	0.37	8.3e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs3733585	0.673	rs4314284	chr4:9956096	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.85	-0.34	2.83e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9467773	0.620	rs9295701	chr6:26627508	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.3e-32	Intelligence (multi-trait analysis);
LGG	cis	rs12431410	0.584	rs17096618	chr14:60244191	C/G	cg07950296	chr14:60194823	RTN1	-0.38	-7.35	-0.32	9.33e-13	Schizophrenia;
LGG	cis	rs4689642	0.756	rs4689091	chr4:7226892	G/A	cg21353189	chr4:7228343	SORCS2	0.38	8.92	0.38	1.09e-17	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg23625390	chr15:77176239	SCAPER	-0.76	-15.37	-0.58	2.22e-43	Blood metabolite levels;
LGG	cis	rs9325144	0.534	rs4882283	chr12:38710249	C/T	cg13010199	chr12:38710504	ALG10B	0.62	12.38	0.5	1.32e-30	Morning vs. evening chronotype;
LGG	cis	rs9303280	0.806	rs9909593	chr17:37970149	C/T	cg17467752	chr17:38218738	THRA	0.43	6.99	0.31	9.63e-12	Self-reported allergy;
LGG	cis	rs2204008	0.713	rs11173567	chr12:38089375	T/C	cg26384229	chr12:38710491	ALG10B	0.88	19.39	0.67	9.67e-62	Bladder cancer;
LGG	cis	rs7584262	0.737	rs7578091	chr2:42243480	G/C	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Bone mineral density;
LGG	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg12855166	chr17:30846586	MYO1D	0.38	6.92	0.31	1.54e-11	Schizophrenia;
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg04166393	chr7:2884313	GNA12	0.45	8.63	0.37	1.02e-16	Height;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	7.88	0.34	2.34e-14	Schizophrenia;
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.53	0.33	2.71e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6912958	0.703	rs12207825	chr6:88098292	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.61	11.14	0.46	1.07e-25	Monocyte percentage of white cells;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	12.82	0.51	1.99e-32	Obesity-related traits;
LGG	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	1.99e-19	Diabetic retinopathy;
LGG	cis	rs7932354	0.528	rs7946709	chr11:47100796	G/T	cg03339077	chr11:47165057	C11orf49	-0.53	-9.87	-0.42	5.65e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs2742417	0.624	rs2673029	chr3:45758867	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.46	-0.4	1.56e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg02462569	chr6:150064036	NUP43	-0.37	-7.8	-0.34	4.03e-14	Lung cancer;
LGG	cis	rs870825	0.616	rs6552805	chr4:185637894	C/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	cis	rs736408	0.716	rs2239549	chr3:52823126	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.81	0.34	3.87e-14	Bipolar disorder;
LGG	cis	rs7607369	0.626	rs4672892	chr2:219278630	A/G	cg10223061	chr2:219282414	VIL1	0.34	7.29	0.32	1.31e-12	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs73198271	0.653	rs10087742	chr8:8660474	A/G	cg01851573	chr8:8652454	MFHAS1	0.36	6.72	0.3	5.25e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4664304	0.802	rs3749114	chr2:160832996	A/T	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.45	-0.37	3.72e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs796364	0.806	rs6743396	chr2:200860138	T/C	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.4e-12	Schizophrenia;
LGG	cis	rs7940866	0.740	rs2162060	chr11:130830763	A/G	cg12179176	chr11:130786555	SNX19	0.74	14.02	0.55	1.79e-37	Schizophrenia;
LGG	cis	rs367615	0.918	rs17161895	chr5:108855831	T/G	cg17395555	chr5:108820864	NA	0.64	8.95	0.38	8.91e-18	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14725858	chr5:36241190	C5orf33	0.44	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs7786808	0.741	rs11767875	chr7:158228923	A/G	cg15440763	chr7:158190612	PTPRN2	0.43	8.84	0.38	2.06e-17	Obesity-related traits;
LGG	cis	rs6429082	0.902	rs704708	chr1:235620134	T/C	cg26050004	chr1:235667680	B3GALNT2	0.45	7.5	0.33	3.32e-13	Adiposity;
LGG	cis	rs7524258	0.835	rs75096060	chr1:7270248	G/C	cg07173049	chr1:7289937	CAMTA1	0.7	16.96	0.62	1.61e-50	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.68	0.34	9.3e-14	Prostate cancer;
LGG	cis	rs17641971	0.684	rs4873310	chr8:49990006	A/T	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	cis	rs7107174	1.000	rs2510040	chr11:77944548	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.56	-0.33	2.14e-13	Testicular germ cell tumor;
LGG	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg10523679	chr1:76189770	ACADM	0.76	12.1	0.49	1.81e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs1908814	0.516	rs56102998	chr8:11796675	G/A	cg02002194	chr4:3960332	NA	-0.49	-9.22	-0.39	1.03e-18	Neuroticism;
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg10189774	chr4:17578691	LAP3	0.42	7.39	0.32	6.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618915	0.547	rs11177	chr3:52721305	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	4.93e-12	Bipolar disorder;
LGG	cis	rs929354	0.742	rs886677	chr7:157003782	T/A	cg17757837	chr7:157058334	UBE3C	0.77	15.63	0.59	1.5e-44	Body mass index;
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.78	-0.48	3.34e-28	Intelligence (multi-trait analysis);
LGG	cis	rs3857067	0.806	rs17302467	chr4:95112056	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs3008870	1.000	rs1925412	chr1:67405057	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.0	0.73	1.26e-78	Lymphocyte percentage of white cells;
LGG	cis	rs12479064	0.724	rs11885942	chr2:100004165	A/G	cg08885076	chr2:99613938	TSGA10	-0.44	-8.15	-0.35	3.34e-15	Chronic sinus infection;
LGG	cis	rs9549367	0.789	rs9549695	chr13:113874814	A/G	cg00898013	chr13:113819073	PROZ	0.4	7.97	0.35	1.27e-14	Platelet distribution width;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg02725872	chr8:58115012	NA	-0.88	-11.96	-0.49	6.26e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs6462411	0.938	rs2007554	chr7:3919822	A/G	cg18022346	chr7:3920534	SDK1	-0.35	-6.65	-0.3	8.19e-11	Quantitative traits;
LGG	cis	rs9790314	0.967	rs10804790	chr3:161039300	T/A	cg04691961	chr3:161091175	C3orf57	-0.63	-14.84	-0.57	4.79e-41	Morning vs. evening chronotype;
LGG	cis	rs868036	1.000	rs3784719	chr15:68098180	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs504918	0.676	rs1025957	chr3:124061080	A/G	cg05766129	chr3:123988013	KALRN	-0.4	-7.27	-0.32	1.57e-12	Schizophrenia;
LGG	cis	rs2549003	1.000	rs7735073	chr5:131815357	G/A	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.93e-22	Asthma (sex interaction);
LGG	cis	rs4242434	0.698	rs10104039	chr8:22538384	A/G	cg00599393	chr8:22457479	C8orf58	0.39	7.07	0.31	5.62e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg21171335	chr12:122356390	WDR66	0.28	7.56	0.33	2.16e-13	Mean corpuscular volume;
LGG	cis	rs887829	0.570	rs7608175	chr2:234599089	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	0.48	8.3	0.36	1.15e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4671458	1.000	rs12473894	chr2:63376570	C/T	cg17519650	chr2:63277830	OTX1	-0.62	-7.78	-0.34	4.74e-14	Subjective well-being;
LGG	cis	rs6693567	0.565	rs11205371	chr1:150398510	A/G	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs2243480	1.000	rs316329	chr7:65608416	A/C	cg18252515	chr7:66147081	NA	-1.39	-20.07	-0.68	6.69e-65	Diabetic kidney disease;
LGG	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg19442545	chr10:75533431	FUT11	-0.46	-7.48	-0.33	3.76e-13	Inflammatory bowel disease;
LGG	cis	rs611744	0.870	rs613179	chr8:109166006	G/A	cg21045802	chr8:109455806	TTC35	0.39	6.96	0.31	1.15e-11	Dupuytren's disease;
LGG	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg13147721	chr7:65941812	NA	-0.81	-9.61	-0.41	4.53e-20	Diabetic kidney disease;
LGG	trans	rs58106596	0.660	rs13398149	chr2:232564881	A/C	cg01370599	chr3:116745421	NA	0.61	7.84	0.34	3.11e-14	White blood cell count;Lymphocyte counts;
LGG	cis	rs9326248	0.861	rs7120449	chr11:117042899	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.62	7.96	0.35	1.3e-14	Blood protein levels;
LGG	cis	rs9287719	0.839	rs12692415	chr2:10745474	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg05025164	chr4:1340916	KIAA1530	0.44	7.58	0.33	1.88e-13	Obesity-related traits;
LGG	cis	rs4132509	1.000	rs4553169	chr1:243900640	G/A	cg21452805	chr1:244014465	NA	0.64	7.55	0.33	2.35e-13	RR interval (heart rate);
LGG	cis	rs9910055	0.659	rs7214540	chr17:42256604	A/G	cg19774624	chr17:42201019	HDAC5	-0.93	-19.92	-0.68	3.07e-64	Total body bone mineral density;
LGG	cis	rs7044106	0.762	rs3904197	chr9:123480378	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.71	0.61	2.19e-49	Hip circumference adjusted for BMI;
LGG	cis	rs17376456	0.877	rs9314092	chr5:93326362	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.81	8.94	0.38	9.58e-18	Diabetic retinopathy;
LGG	cis	rs2842992	0.724	rs9347340	chr6:160188891	C/T	cg11366901	chr6:160182831	ACAT2	-0.91	-14.8	-0.57	7.55e-41	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.13e-95	Breast cancer;
LGG	cis	rs881375	0.967	rs1930781	chr9:123687834	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.15	0.39	1.77e-18	Rheumatoid arthritis;
LGG	cis	rs7829975	0.714	rs11777085	chr8:8672429	G/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.72	0.41	1.86e-20	Mood instability;
LGG	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg20744362	chr22:50050164	C22orf34	0.39	7.53	0.33	2.74e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs8114671	0.836	rs6058154	chr20:33585834	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.18	-0.36	2.69e-15	Height;
LGG	cis	rs6800768	0.633	rs62255804	chr3:24149034	G/A	cg10674438	chr3:24145617	LOC152024	-0.53	-9.5	-0.4	1.11e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7226408	0.857	rs72894323	chr18:34710125	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg16339924	chr4:17578868	LAP3	0.59	10.22	0.43	2.94e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4478858	0.735	rs11583123	chr1:31751772	T/C	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.54e-11	Alcohol dependence;
LGG	cis	rs367943	0.547	rs11241218	chr5:112958258	T/C	cg12552261	chr5:112820674	MCC	0.53	9.31	0.4	5.08e-19	Type 2 diabetes;
LGG	cis	rs908922	0.702	rs569232	chr1:152526643	A/G	cg09873164	chr1:152488093	CRCT1	0.59	13.74	0.54	2.91e-36	Hair morphology;
LGG	cis	rs4481887	0.893	rs1339991	chr1:248509363	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.93	0.38	9.93e-18	Common traits (Other);
LGG	cis	rs2404602	0.692	rs3110382	chr15:77148688	G/A	cg22467129	chr15:76604101	ETFA	0.42	7.07	0.31	5.73e-12	Blood metabolite levels;
LGG	trans	rs4650994	0.905	rs12753251	chr1:178529898	G/A	cg05059571	chr16:84539110	KIAA1609	-0.43	-7.95	-0.35	1.46e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs5769765	0.825	rs9616780	chr22:50292763	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.24e-13	Schizophrenia;
LGG	cis	rs10883723	0.810	rs17782574	chr10:104279394	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.14	0.55	5.71e-38	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg26384229	chr12:38710491	ALG10B	0.83	16.67	0.61	3.31e-49	Morning vs. evening chronotype;
LGG	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg11707556	chr5:10655725	ANKRD33B	-0.55	-10.69	-0.44	5.33e-24	Coronary artery disease;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg08645402	chr16:4508243	NA	0.5	9.5	0.4	1.13e-19	Schizophrenia;
LGG	cis	rs963731	0.649	rs2278914	chr2:39218552	G/A	cg04010122	chr2:39346883	SOS1	-0.76	-6.66	-0.3	7.97e-11	Corticobasal degeneration;
LGG	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.42	6.65	0.3	8.06e-11	Hip circumference adjusted for BMI;
LGG	cis	rs503734	0.666	rs2682386	chr3:101068873	C/T	cg27318481	chr3:100970896	IMPG2	-0.35	-6.99	-0.31	9.34e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.19	-0.32	2.62e-12	Fear of minor pain;
LGG	cis	rs60871478	0.636	rs4721600	chr7:871728	C/T	cg13798912	chr7:905769	UNC84A	-0.58	-7.37	-0.32	8.17e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs1451375	0.617	rs896307	chr7:50569060	T/C	cg14593290	chr7:50529359	DDC	-0.65	-11.8	-0.48	2.79e-28	Malaria;
LGG	cis	rs17270561	0.609	rs12663099	chr6:25739518	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs933688	1.000	rs2367353	chr5:90686568	G/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.54	0.63	3.32e-53	Smoking behavior;
LGG	cis	rs35110281	0.563	rs162371	chr21:44931489	G/T	cg04455712	chr21:45112962	RRP1B	0.46	8.61	0.37	1.18e-16	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03347828	chr17:7739579	NA	0.53	8.17	0.35	3.04e-15	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg05091796	chr16:4465799	CORO7	-1.04	-19.04	-0.66	4.09e-60	Schizophrenia;
LGG	cis	rs9368481	0.645	rs10456350	chr6:26975581	A/C	cg18867708	chr6:26865862	GUSBL1	0.44	7.33	0.32	1.01e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7100689	0.646	rs2050824	chr10:82123563	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs12153243	0.675	rs17401501	chr5:142894711	G/A	cg13907255	chr5:142895549	NA	-0.5	-8.85	-0.38	1.92e-17	Migraine;
LGG	cis	rs1109114	0.816	rs2918265	chr5:148610276	C/A	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.89	-0.59	1.11e-45	Body mass index;
LGG	cis	rs6665290	0.904	rs2297416	chr1:227172935	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-44.15	-0.9	4.73e-168	Myeloid white cell count;
LGG	cis	rs7737355	0.812	rs7729787	chr5:131066577	A/C	cg06307176	chr5:131281290	NA	0.5	8.35	0.36	7.78e-16	Life satisfaction;
LGG	cis	rs9916302	0.904	rs1619021	chr17:37739274	G/A	cg07936489	chr17:37558343	FBXL20	-0.83	-14.6	-0.56	5.46e-40	Glomerular filtration rate (creatinine);
LGG	cis	rs8072100	0.713	rs4968228	chr17:45497548	T/C	cg25173405	chr17:45401733	C17orf57	-0.53	-9.05	-0.39	3.93e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6088580	0.634	rs6120644	chr20:33023810	G/A	cg24642439	chr20:33292090	TP53INP2	0.57	9.61	0.41	4.83e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs17221829	0.626	rs2931188	chr11:89355428	A/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-8.82	-0.38	2.34e-17	Anxiety in major depressive disorder;
LGG	cis	rs240764	0.635	rs6901854	chr6:100932291	C/T	cg21058520	chr6:100914733	NA	0.48	8.33	0.36	9.22e-16	Neuroticism;
LGG	cis	rs2197308	0.565	rs12809769	chr12:37909968	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.81e-75	Morning vs. evening chronotype;
LGG	cis	rs1882538	0.512	rs13241734	chr7:133122742	C/G	cg10665199	chr7:133106180	EXOC4	0.59	9.7	0.41	2.19e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.47	-0.53	4.04e-35	Retinal vascular caliber;
LGG	cis	rs17504614	0.591	rs66703491	chr2:51063307	C/T	cg23851515	chr2:51057218	NRXN1	0.48	7.82	0.34	3.71e-14	Educational attainment (years of education);
LGG	cis	rs74417235	0.684	rs13179358	chr5:154059746	C/A	cg08754654	chr5:154026448	NA	0.53	10.83	0.45	1.56e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs13217239	0.646	rs9379956	chr6:27033735	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-11.09	-0.46	1.64e-25	Schizophrenia;
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.8e-33	Aortic root size;
LGG	trans	rs61931739	0.559	rs4385974	chr12:34313128	G/C	cg13010199	chr12:38710504	ALG10B	0.47	8.89	0.38	1.33e-17	Morning vs. evening chronotype;
LGG	cis	rs250677	0.687	rs250674	chr5:148438597	A/G	cg18129178	chr5:148520854	ABLIM3	0.45	7.38	0.32	7.32e-13	Breast cancer;
LGG	cis	rs7226408	0.600	rs323296	chr18:34665702	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.16	-0.39	1.7e-18	Obesity-related traits;
LGG	cis	rs4730779	0.545	rs6949974	chr7:117225159	C/T	cg10524701	chr7:117356490	CTTNBP2	0.38	7.48	0.33	3.86e-13	Waist circumference;
LGG	trans	rs7829975	0.510	rs2979160	chr8:8307666	A/G	cg02002194	chr4:3960332	NA	-0.5	-9.55	-0.41	7.74e-20	Mood instability;
LGG	cis	rs896854	1.000	rs13255935	chr8:95965685	C/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.26	-0.4	7.64e-19	Type 2 diabetes;
LGG	cis	rs42648	0.667	rs2157793	chr7:89880354	C/G	cg25739043	chr7:89950458	NA	-0.34	-6.93	-0.31	1.39e-11	Homocysteine levels;
LGG	cis	rs1005277	0.589	rs2749624	chr10:38529865	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.47	-0.33	4.07e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.825	rs10072232	chr5:93398890	G/A	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	cis	rs17001868	0.568	rs3788578	chr22:40742921	C/T	cg07138101	chr22:40742427	ADSL	0.68	8.82	0.38	2.32e-17	Mammographic density (dense area);
LGG	trans	rs7829975	0.517	rs12542733	chr8:8824858	G/T	cg02002194	chr4:3960332	NA	0.36	7.08	0.31	5.32e-12	Mood instability;
LGG	cis	rs9527	0.590	rs11191572	chr10:104893137	A/G	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs75920871	0.528	rs2513097	chr11:116836212	A/G	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-7.22	-0.32	2.19e-12	Subjective well-being;
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.19	0.46	7.05e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.78	0.51	3e-32	Prudent dietary pattern;
LGG	cis	rs793571	0.523	rs12439457	chr15:58982390	T/C	cg05156742	chr15:59063176	FAM63B	0.57	9.69	0.41	2.53e-20	Schizophrenia;
LGG	cis	rs72945132	0.882	rs7945389	chr11:70158876	C/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	trans	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg07461501	chr17:79650226	HGS;ARL16	0.52	9.78	0.41	1.13e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg01988459	chr11:68622903	NA	-0.64	-12.66	-0.51	9.26e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1497828	0.956	rs2810787	chr1:217549038	A/G	cg04411442	chr1:217543379	NA	0.48	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	cis	rs4740619	0.967	rs12340969	chr9:15645713	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.46	-0.44	3.86e-23	Body mass index;
LGG	cis	rs155076	1.000	rs484365	chr13:21845944	G/T	cg11317459	chr13:21872234	NA	-1.18	-19.46	-0.67	4.49e-62	White matter hyperintensity burden;
LGG	cis	rs12615966	0.932	rs1947308	chr2:105391930	G/A	cg16465502	chr2:105461796	NA	0.88	10.6	0.44	1.16e-23	Pancreatic cancer;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12049351	0.507	rs10916484	chr1:229601673	G/A	cg13547644	chr1:229569608	ACTA1	0.32	7.1	0.31	4.59e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.6	9.52	0.4	9.53e-20	Renal function-related traits (BUN);
LGG	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg03806693	chr22:41940476	POLR3H	-1.15	-21.94	-0.71	1.08e-73	Vitiligo;
LGG	cis	rs7827545	1.000	rs4909481	chr8:135564555	A/G	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs7236492	0.810	rs9957497	chr18:77227217	A/G	cg15532942	chr18:77220712	NFATC1	0.42	6.87	0.3	2.05e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7811142	0.943	rs11769886	chr7:99998607	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.28	-0.43	1.87e-22	Platelet count;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg09477492	chr1:156737114	PRCC	0.72	6.87	0.3	2.08e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs28699126	0.504	rs1056632	chr2:26512733	T/G	cg22920501	chr2:26401640	FAM59B	0.47	9.48	0.4	1.35e-19	Mean corpuscular hemoglobin;
LGG	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg23422044	chr7:1970798	MAD1L1	-0.5	-9.35	-0.4	3.68e-19	Neuroticism;
LGG	cis	rs6582630	0.638	rs12831496	chr12:38552604	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-13.35	-0.53	1.24e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9487051	0.735	rs351756	chr6:109538773	A/G	cg21918786	chr6:109611834	NA	0.42	7.73	0.34	6.8e-14	Reticulocyte fraction of red cells;
LGG	trans	rs8002861	0.875	rs12428432	chr13:44464043	A/G	cg12856521	chr11:46389249	DGKZ	-0.42	-7.23	-0.32	2.05e-12	Leprosy;
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg07120314	chr15:79043507	NA	-0.67	-15.1	-0.57	3.55e-42	Coronary artery disease or large artery stroke;
LGG	cis	rs7659604	0.537	rs6823818	chr4:122731699	G/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.27e-27	Type 2 diabetes;
LGG	cis	rs10489202	1.000	rs12408205	chr1:167982332	A/G	cg24449463	chr1:168025552	DCAF6	-0.61	-10.02	-0.42	1.56e-21	Schizophrenia;
LGG	cis	rs2599510	0.840	rs466146	chr2:32539236	A/C	cg02381751	chr2:32503542	YIPF4	0.49	8.05	0.35	7.3e-15	Interleukin-18 levels;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.43	0.44	5.08e-23	Prudent dietary pattern;
LGG	cis	rs564799	0.931	rs2366643	chr3:159736485	T/C	cg04855961	chr3:159719849	NA	-0.27	-7.47	-0.33	4.02e-13	Systemic lupus erythematosus;
LGG	cis	rs644799	0.710	rs10831429	chr11:95508524	C/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.26	0.58	6.89e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2880765	0.835	rs7174323	chr15:86049719	A/C	cg13263323	chr15:86062960	AKAP13	-0.34	-7.16	-0.32	3.22e-12	Coronary artery disease;
LGG	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg20503657	chr10:835505	NA	0.75	10.3	0.43	1.48e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs3806843	0.735	rs801180	chr5:140092903	G/T	cg19875535	chr5:140030758	IK	-0.57	-11.85	-0.48	1.73e-28	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg06875740	chr19:51307921	C19orf48	-0.62	-7.99	-0.35	1.11e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1348850	0.526	rs4243389	chr2:178379783	G/C	cg23306229	chr2:178417860	TTC30B	0.72	8.76	0.38	3.67e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs3540	0.597	rs4620932	chr15:91036569	G/A	cg22089800	chr15:90895588	ZNF774	0.68	12.45	0.5	7.09e-31	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4919694	1.000	rs4917379	chr10:104752831	A/T	cg04362960	chr10:104952993	NT5C2	1.07	15.17	0.58	1.68e-42	Arsenic metabolism;
LGG	trans	rs7937682	0.558	rs7113067	chr11:111692182	G/A	cg18187862	chr3:45730750	SACM1L	-0.59	-9.54	-0.41	8.34e-20	Primary sclerosing cholangitis;
LGG	cis	rs7107174	1.000	rs7107174	chr11:77997936	C/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs6500602	0.893	rs4785962	chr16:4484328	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.38	6.69	0.3	6.28e-11	Schizophrenia;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg00166722	chr3:10149974	C3orf24	0.5	8.57	0.37	1.52e-16	Alzheimer's disease;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg21724239	chr8:58056113	NA	0.49	7.33	0.32	1.01e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7172689	0.862	rs28453231	chr15:81554899	G/C	cg11808699	chr15:81528661	IL16	-0.51	-10.81	-0.45	1.97e-24	Inattentive symptoms;
LGG	cis	rs763121	0.853	rs5757204	chr22:39046700	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs7264396	0.790	rs6121020	chr20:34252006	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.61	-0.33	1.53e-13	Total cholesterol levels;
LGG	cis	rs1055129	0.560	rs2305913	chr17:73922941	T/C	cg08125733	chr17:73851984	WBP2	0.42	7.18	0.32	2.78e-12	White matter hyperintensity burden;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg01262667	chr19:19385393	TM6SF2	0.44	10.62	0.44	9.85e-24	Tonsillectomy;
LGG	cis	rs370915	0.928	rs433477	chr4:187814866	C/G	cg19519643	chr4:187840862	NA	0.41	7.54	0.33	2.51e-13	Gout;
LGG	cis	rs11096990	0.855	rs11730771	chr4:39222407	C/T	cg24403649	chr4:39172243	NA	-0.45	-7.39	-0.32	6.92e-13	Cognitive function;
LGG	cis	rs9814567	0.806	rs1880374	chr3:134322113	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg05091796	chr16:4465799	CORO7	-0.81	-13.74	-0.54	2.73e-36	Schizophrenia;
LGG	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg15017067	chr4:17643749	FAM184B	0.3	6.99	0.31	9.48e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1163251	0.837	rs2764886	chr1:120241771	C/T	cg19096424	chr1:120255104	PHGDH	0.66	11.96	0.49	6.47e-29	Blood metabolite levels;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.85	-0.38	1.93e-17	Menopause (age at onset);
LGG	cis	rs4356975	0.563	rs12505466	chr4:69985662	A/T	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs2742417	0.967	rs1534875	chr3:45741043	T/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs68170813	0.559	rs78888729	chr7:106940957	G/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.55	-0.44	1.88e-23	Coronary artery disease;
LGG	cis	rs11252926	0.625	rs7903876	chr10:482678	T/C	cg18196295	chr10:418757	DIP2C	-0.51	-9.67	-0.41	2.9e-20	Psychosis in Alzheimer's disease;
LGG	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.24	-0.36	1.73e-15	Neuroticism;
LGG	cis	rs1355223	0.902	rs836467	chr11:34737432	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.89	-0.3	1.83e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2404602	0.716	rs17362383	chr15:76650702	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.29	-0.32	1.37e-12	Blood metabolite levels;
LGG	cis	rs12445022	0.632	rs12920915	chr16:87577521	C/T	cg08031982	chr16:87577539	NA	0.38	9.54	0.41	8.05e-20	Small vessel stroke;Systemic juvenile idiopathic arthritis;
LGG	cis	rs6988985	0.728	rs4310186	chr8:143956247	C/G	cg10324643	chr8:143916377	GML	-0.38	-7.58	-0.33	1.97e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs185694	1.000	rs1099860	chr13:30883168	C/T	cg07600127	chr13:30881527	KATNAL1	-0.54	-7.07	-0.31	5.68e-12	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7927592	0.513	rs607887	chr11:68196961	C/T	cg01657329	chr11:68192670	LRP5	-0.6	-10.81	-0.45	1.86e-24	Total body bone mineral density;
LGG	cis	rs4888262	0.526	rs4887777	chr16:74637821	A/G	cg01733217	chr16:74700730	RFWD3	0.89	18.21	0.65	2.89e-56	Testicular germ cell tumor;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg00495681	chr13:53174319	NA	0.58	10.74	0.45	3.53e-24	Lewy body disease;
LGG	cis	rs757978	0.810	rs35319025	chr2:242402463	C/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.64	-7.12	-0.31	4.08e-12	Chronic lymphocytic leukemia;
LGG	cis	rs7927771	1.000	rs12363232	chr11:47623890	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.71	-0.38	5.47e-17	Subjective well-being;
LGG	cis	rs6489882	0.703	rs10850096	chr12:113360786	T/C	cg25319449	chr12:113376135	OAS3	-0.37	-6.7	-0.3	6.06e-11	Chronic lymphocytic leukemia;
LGG	trans	rs2727020	0.567	rs1164687	chr11:49290669	G/A	cg11707556	chr5:10655725	ANKRD33B	0.38	6.78	0.3	3.77e-11	Coronary artery disease;
LGG	cis	rs10823500	0.777	rs10762348	chr10:71952322	C/A	cg02100629	chr10:71892760	AIFM2	-0.29	-6.97	-0.31	1.13e-11	Blood protein levels;
LGG	cis	rs7208859	0.673	rs11658344	chr17:29207745	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06634786	chr22:41940651	POLR3H	0.78	12.41	0.5	9.51e-31	Vitiligo;
LGG	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg06606381	chr12:133084897	FBRSL1	-1.26	-11.91	-0.48	1.04e-28	Depression;
LGG	cis	rs7555523	1.000	rs7555523	chr1:165718979	C/A	cg24409356	chr1:165738333	TMCO1	0.76	9.2	0.39	1.2e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg07332563	chr6:291687	DUSP22	-0.58	-9.71	-0.41	2.05e-20	Menopause (age at onset);
LGG	cis	rs9916302	0.904	rs4794813	chr17:37670994	A/T	cg07936489	chr17:37558343	FBXL20	-0.83	-15.25	-0.58	8.01e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg13206674	chr6:150067644	NUP43	0.68	15.66	0.59	1.22e-44	Lung cancer;
LGG	cis	rs6121246	0.954	rs6058470	chr20:30416827	A/T	cg13852791	chr20:30311386	BCL2L1	0.79	12.8	0.51	2.41e-32	Mean corpuscular hemoglobin;
LGG	cis	rs2073300	0.609	rs6137919	chr20:23363163	T/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2439831	0.850	rs28513374	chr15:44125495	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.51	0.4	1.08e-19	Lung cancer in ever smokers;
LGG	cis	rs10791323	0.569	rs329664	chr11:133754975	G/T	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs8020289	1.000	rs8020289	chr14:77293520	A/G	cg23436960	chr14:77239540	VASH1	0.26	6.67	0.3	7.5e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	trans	rs6787172	0.622	rs12629587	chr3:158108932	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.46	-0.33	4.36e-13	Subjective well-being;
LGG	cis	rs709400	0.663	rs1028613	chr14:103888324	G/A	cg26031613	chr14:104095156	KLC1	0.78	13.39	0.53	8.67e-35	Body mass index;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs755500	chr17:37409865	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.51	-0.47	3.74e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs939658	1.000	rs17175798	chr15:79463960	A/G	cg17916960	chr15:79447300	NA	0.63	12.55	0.5	2.68e-31	Refractive error;
LGG	cis	rs1816752	0.905	rs3818938	chr13:25029083	C/T	cg22771759	chr13:24902376	NA	0.41	6.88	0.3	2.01e-11	Obesity-related traits;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg19147804	chr7:1989927	MAD1L1	-0.43	-8.44	-0.37	4.16e-16	Schizophrenia;
LGG	cis	rs3799378	0.582	rs1796518	chr6:26388672	C/T	cg09904177	chr6:26538194	HMGN4	-0.42	-7.24	-0.32	1.87e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg23758822	chr17:41437982	NA	-0.86	-15.44	-0.58	1.12e-43	Menopause (age at onset);
LGG	cis	rs7927592	0.913	rs3740631	chr11:68341722	T/G	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs17376456	0.825	rs10038831	chr5:93124115	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.49e-24	Diabetic retinopathy;
LGG	cis	rs4319547	0.695	rs7301515	chr12:122949673	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.71	-10.3	-0.43	1.53e-22	Body mass index;
LGG	cis	rs8064024	0.719	rs17137286	chr16:4852892	G/C	cg04440724	chr16:4920505	UBN1	-0.43	-8.97	-0.38	7.14e-18	Cancer;
LGG	cis	rs2273669	0.667	rs11153147	chr6:109304058	A/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.48	-0.37	3.07e-16	Prostate cancer;
LGG	cis	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05901451	chr6:126070800	HEY2	-0.68	-12.91	-0.51	8.67e-33	Brugada syndrome;
LGG	cis	rs10231759	0.583	rs35792015	chr7:150513841	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.38	8.4	0.36	5.66e-16	Height;
LGG	cis	rs12200782	1.000	rs10456330	chr6:26436692	C/T	cg11502198	chr6:26597334	ABT1	-0.83	-6.81	-0.3	3.07e-11	Small cell lung carcinoma;
LGG	cis	rs5756813	0.661	rs2285178	chr22:38205989	T/C	cg24232236	chr22:38142998	TRIOBP	0.35	6.83	0.3	2.68e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs7011049	0.915	rs7823407	chr8:53870460	C/G	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs5756813	0.727	rs4239889	chr22:38140352	T/G	cg19171272	chr22:38449367	NA	0.4	6.79	0.3	3.44e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs17376456	0.825	rs17314762	chr5:93231200	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.84	0.59	1.75e-45	Diabetic retinopathy;
LGG	cis	rs12476592	0.602	rs262508	chr2:63885280	G/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs4631830	0.832	rs1585378	chr10:51523213	A/T	cg10326726	chr10:51549505	MSMB	-0.69	-14.43	-0.56	3.12e-39	Prostate-specific antigen levels;
LGG	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs6601327	0.613	rs12682175	chr8:9479161	A/G	cg16141378	chr3:129829833	LOC729375	0.35	7.69	0.34	9.19e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7940866	0.774	rs10466547	chr11:130823576	T/C	cg12179176	chr11:130786555	SNX19	0.75	14.35	0.55	6.92e-39	Schizophrenia;
LGG	trans	rs1941687	0.765	rs11877423	chr18:31390368	G/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg21775007	chr8:11205619	TDH	0.52	8.68	0.37	7e-17	Triglycerides;
LGG	cis	rs362272	0.525	rs2471347	chr4:3044435	A/G	cg13731523	chr4:3047190	NA	0.42	9.93	0.42	3.5e-21	Serum sulfate level;
LGG	cis	rs4417704	0.551	rs13009903	chr2:241900756	A/G	cg26818257	chr2:241905806	NA	0.49	10.79	0.45	2.31e-24	Joint mobility (Beighton score);
LGG	cis	rs11123170	0.529	rs1015755	chr2:113968307	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.55	7.94	0.35	1.59e-14	Renal function-related traits (BUN);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15573334	chr6:52860341	GSTA4	0.47	7.02	0.31	8.07e-12	Gut microbiome composition (summer);
LGG	trans	rs7824557	0.614	rs2736277	chr8:11218893	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.14	-0.35	3.69e-15	Retinal vascular caliber;
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00142150	chr22:38071001	LGALS1	0.92	19.76	0.68	1.8e-63	Fat distribution (HIV);
LGG	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg14893161	chr1:205819251	PM20D1	0.47	7.63	0.33	1.34e-13	Parkinson's disease;
LGG	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg22676075	chr6:135203613	NA	0.36	6.66	0.3	7.71e-11	Red blood cell count;
LGG	cis	rs6088590	0.930	rs6120723	chr20:33364655	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	15.39	0.58	1.8e-43	Coronary artery disease;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-11.06	-0.46	2.22e-25	IgG glycosylation;
LGG	trans	rs12579753	0.827	rs7958100	chr12:82200782	G/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.78	-0.34	4.91e-14	Resting heart rate;
LGG	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg12310025	chr6:25882481	NA	-0.72	-14.23	-0.55	2.2e-38	Blood metabolite levels;
LGG	cis	rs6554196	0.686	rs723585	chr4:55503194	A/G	cg18836493	chr4:55524333	KIT	-0.4	-7.59	-0.33	1.76e-13	Monocyte count;
LGG	cis	rs9944715	0.954	rs13381496	chr18:43747390	A/C	cg26436583	chr18:43649176	PSTPIP2	0.37	6.9	0.31	1.71e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2075371	0.933	rs431306	chr7:133955974	A/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs17253792	0.822	rs10150498	chr14:56064124	G/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs4774830	0.744	rs62046397	chr15:56321302	G/A	cg05129572	chr15:56138634	NEDD4	0.73	6.99	0.31	9.75e-12	Delta-5 desaturase activity;
LGG	cis	rs9815354	0.951	rs6793520	chr3:41865289	C/G	cg03022575	chr3:42003672	ULK4	0.68	8.7	0.37	5.68e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	7.96	0.35	1.37e-14	Red cell distribution width;
LGG	cis	rs13421350	0.688	rs7564416	chr2:173322326	G/A	cg15021238	chr2:173305865	ITGA6	-0.44	-7.46	-0.33	4.33e-13	Diabetic kidney disease;
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.18	-0.32	2.82e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg12193833	chr17:30244370	NA	-0.29	-6.94	-0.31	1.31e-11	Hip circumference adjusted for BMI;
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg02397686	chr17:73851076	WBP2	0.42	6.78	0.3	3.77e-11	Psoriasis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19280121	chr17:21117780	TMEM11	0.5	7.67	0.34	1.05e-13	Gut microbiome composition (summer);
LGG	cis	rs2572431	0.505	rs13269118	chr8:11247814	G/A	cg21775007	chr8:11205619	TDH	0.65	10.48	0.44	3.28e-23	Neuroticism;
LGG	cis	rs755249	0.508	rs586057	chr1:39858794	G/C	cg18385671	chr1:39797026	MACF1	0.47	9.72	0.41	1.94e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1010254	0.510	rs72806385	chr5:151704007	G/A	cg12297329	chr5:152029980	NA	-0.47	-6.89	-0.3	1.82e-11	Optic nerve measurement (cup area);
LGG	cis	rs2658782	0.901	rs11604909	chr11:93218355	C/G	cg15737290	chr11:93063684	CCDC67	0.51	7.5	0.33	3.29e-13	Pulmonary function decline;
LGG	cis	rs10915437	0.566	rs9426494	chr1:4206288	C/T	cg27165836	chr1:4193882	NA	-0.37	-7.28	-0.32	1.41e-12	Migraine - clinic-based;
LGG	cis	rs4704846	1.000	rs919745	chr5:156531279	A/G	cg12943317	chr5:156479607	HAVCR1	0.55	7.27	0.32	1.53e-12	Blood protein levels;
LGG	cis	rs12431410	0.584	rs10498490	chr14:60241437	A/G	cg07950296	chr14:60194823	RTN1	-0.38	-7.43	-0.33	5.28e-13	Schizophrenia;
LGG	cis	rs67311347	1.000	rs9860162	chr3:40403875	C/T	cg13683864	chr3:40499215	RPL14	-0.99	-20.18	-0.68	1.93e-65	Renal cell carcinoma;
LGG	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg07636037	chr3:49044803	WDR6	1.05	23.99	0.74	2.92e-83	Parkinson's disease;
LGG	cis	rs11711311	0.911	rs9817327	chr3:113478500	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.31	0.55	9.79e-39	IgG glycosylation;
LGG	trans	rs9929218	0.906	rs34565494	chr16:68741769	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.89	-15.95	-0.6	5.92e-46	Colorectal cancer;
LGG	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.44	0.58	1.11e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs2318144	chr8:58114743	G/A	cg24829409	chr8:58192753	C8orf71	-0.77	-10.43	-0.44	5.19e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.66e-25	Intelligence (multi-trait analysis);
LGG	trans	rs9354308	0.764	rs9283822	chr6:66596203	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.82	-0.3	2.78e-11	Metabolite levels;
LGG	cis	rs17102423	0.594	rs1998688	chr14:65562306	C/G	cg26396452	chr14:65542826	MAX	-0.46	-9.52	-0.4	9.33e-20	Obesity-related traits;
LGG	cis	rs10479542	0.784	rs4701132	chr5:178985270	A/G	cg19626725	chr5:178986131	RUFY1	-0.48	-7.41	-0.33	6.24e-13	Lung cancer;
LGG	cis	rs1971762	0.545	rs876252	chr12:54071422	A/G	cg06632207	chr12:54070931	ATP5G2	0.24	7.29	0.32	1.33e-12	Height;
LGG	cis	rs6960043	0.791	rs2191346	chr7:15053878	C/G	cg19272540	chr7:15055459	NA	-0.31	-7.02	-0.31	7.99e-12	Type 2 diabetes;
LGG	cis	rs7572733	0.935	rs6434946	chr2:198798497	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.2	0.36	2.36e-15	Dermatomyositis;
LGG	cis	rs7980687	0.638	rs7299943	chr12:123593485	A/T	cg00376283	chr12:123451042	ABCB9	0.64	10.21	0.43	3.27e-22	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs1862618	0.853	rs832582	chr5:56177743	G/A	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs10845606	1.000	rs10845609	chr12:12838920	T/A	cg09462578	chr12:12878428	APOLD1	-0.52	-7.26	-0.32	1.6e-12	Systemic lupus erythematosus;
LGG	cis	rs1003719	0.788	rs13050757	chr21:38465345	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs1797081	0.561	rs2603795	chr10:16860256	A/G	cg23933602	chr10:16859644	RSU1	0.74	13.91	0.54	5.35e-37	Platelet distribution width;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14319473	chr9:129242481	FAM125B	0.43	7.15	0.32	3.34e-12	Pancreatic cancer;
LGG	cis	rs4665809	0.617	rs930263	chr2:26402594	G/C	cg22920501	chr2:26401640	FAM59B	-0.42	-8.77	-0.38	3.46e-17	Gut microbiome composition (summer);
LGG	cis	rs9863	0.828	rs4765127	chr12:124460167	G/T	cg13487667	chr12:124434373	CCDC92	-0.35	-7.09	-0.31	4.96e-12	White blood cell count;
LGG	cis	rs798554	0.679	rs1639066	chr7:2892972	A/G	cg04166393	chr7:2884313	GNA12	0.46	9.07	0.39	3.32e-18	Height;
LGG	cis	rs739401	0.611	rs401707	chr11:3050965	T/C	cg08508325	chr11:3079039	CARS	-0.6	-12.99	-0.52	4.23e-33	Longevity;
LGG	cis	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg27129171	chr3:47204927	SETD2	0.79	15.33	0.58	3.53e-43	Colorectal cancer;
LGG	cis	rs116095464	0.558	rs55838121	chr5:266890	G/A	cg22857025	chr5:266934	NA	-1.47	-24.95	-0.76	1.1e-87	Breast cancer;
LGG	cis	rs3747547	0.818	rs67198935	chr9:37932797	T/G	cg13774184	chr9:37916125	SHB	-0.72	-8.72	-0.38	5.13e-17	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs1983891	0.742	rs9367109	chr6:41562530	A/G	cg20194872	chr6:41519635	FOXP4	0.49	8.59	0.37	1.34e-16	Prostate cancer;
LGG	cis	rs9309473	0.607	rs7604588	chr2:73571417	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-8.3	-0.36	1.18e-15	Metabolite levels;
LGG	cis	rs10861342	1.000	rs11112398	chr12:105572967	A/G	cg23923672	chr12:105501055	KIAA1033	0.8	7.22	0.32	2.08e-12	IgG glycosylation;
LGG	cis	rs13064447	0.845	rs58411770	chr3:12773868	C/T	cg23032965	chr3:12705835	RAF1	-0.48	-7.22	-0.32	2.19e-12	Major depression and alcohol dependence;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.34	7.35	0.32	8.91e-13	Schizophrenia;
LGG	cis	rs7208859	0.623	rs9897728	chr17:29108804	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg14101638	chr12:121416612	HNF1A	0.39	7.99	0.35	1.05e-14	N-glycan levels;
LGG	cis	rs1957429	0.901	rs3813423	chr14:65347475	C/A	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs61989804	0.826	rs6573597	chr14:65720883	C/T	cg15999311	chr14:65749247	NA	0.63	6.77	0.3	3.91e-11	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	Neuroticism;
LGG	cis	rs1865760	0.622	rs9295685	chr6:26071725	G/C	cg12310025	chr6:25882481	NA	-0.39	-6.94	-0.31	1.37e-11	Height;
LGG	cis	rs6686643	1.000	rs959617	chr1:165616881	C/G	cg19407955	chr1:165599744	MGST3	-0.59	-8.71	-0.38	5.54e-17	Total ventricular volume;
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg22535103	chr8:58192502	C8orf71	-0.72	-9.84	-0.42	7.36e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg00666640	chr1:248458726	OR2T12	-0.54	-8.62	-0.37	1.07e-16	Common traits (Other);
LGG	cis	rs6951245	1.000	rs74887741	chr7:1110658	G/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.39	0.56	4.47e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg06481639	chr22:41940642	POLR3H	0.51	7.62	0.33	1.42e-13	Vitiligo;
LGG	cis	rs8062405	0.755	rs2077031	chr16:28603168	T/A	cg16576597	chr16:28551801	NUPR1	0.44	10.15	0.43	5.39e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6456156	0.774	rs968333	chr6:167526198	A/T	cg07741184	chr6:167504864	NA	0.33	7.33	0.32	1.03e-12	Primary biliary cholangitis;
LGG	cis	rs9354308	0.764	rs9294661	chr6:66595971	A/C	cg07460842	chr6:66804631	NA	-0.4	-6.93	-0.31	1.37e-11	Metabolite levels;
LGG	cis	rs12282928	1.000	rs12294937	chr11:48337466	T/C	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg00409905	chr10:38381863	ZNF37A	0.64	12.21	0.49	6.4e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05901451	chr6:126070800	HEY2	0.83	17.72	0.64	5.15e-54	Brugada syndrome;
LGG	cis	rs9902453	0.817	rs17226179	chr17:28168573	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.6	0.53	1.13e-35	Coffee consumption (cups per day);
LGG	cis	rs2285947	0.901	rs2285943	chr7:21582963	G/T	cg04471919	chr7:21584483	DNAH11	0.5	13.72	0.54	3.55e-36	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs8031584	0.958	rs1043742	chr15:31232581	A/C	cg19680485	chr15:31195859	MTMR15	-0.47	-7.68	-0.34	9.65e-14	Huntington's disease progression;
LGG	cis	rs2635047	1.000	rs2684826	chr18:44679147	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.23	0.39	9.45e-19	Educational attainment;
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg22398616	chr13:53314203	LECT1	-0.35	-6.95	-0.31	1.21e-11	Lewy body disease;
LGG	cis	rs9467603	1.000	rs9461216	chr6:25808743	A/T	cg21479132	chr6:26055353	NA	0.74	6.67	0.3	7.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.932	rs6449315	chr4:17590219	A/G	cg18681998	chr4:17616180	MED28	0.8	16.62	0.61	5.26e-49	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg18567174	chr15:68126065	LBXCOR1	0.39	7.6	0.33	1.61e-13	Obesity;
LGG	cis	rs897984	0.542	rs7294	chr16:31102321	A/G	cg00531865	chr16:30841666	NA	0.47	9.51	0.4	1e-19	Dementia with Lewy bodies;
LGG	cis	rs758324	0.947	rs559971	chr5:131316164	A/G	cg06307176	chr5:131281290	NA	0.56	9.12	0.39	2.38e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs897080	0.515	rs1067336	chr2:44625876	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.73	-0.3	5.07e-11	Height;
LGG	cis	rs9513627	0.833	rs112671387	chr13:100123073	A/G	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs7107174	0.892	rs2510042	chr11:77923665	C/T	cg02023728	chr11:77925099	USP35	0.45	7.83	0.34	3.46e-14	Testicular germ cell tumor;
LGG	cis	rs10214930	0.697	rs3925338	chr7:27593439	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.86	0.3	2.21e-11	Hypospadias;
LGG	cis	rs9487094	0.813	rs6920962	chr6:109724490	A/T	cg16315928	chr6:109776240	MICAL1	0.44	7.4	0.33	6.61e-13	Height;
LGG	cis	rs6963495	0.818	rs73190161	chr7:105156871	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs9393692	0.846	rs9366651	chr6:26336696	G/T	cg13736514	chr6:26305472	NA	-0.47	-9.63	-0.41	4.06e-20	Educational attainment;
LGG	trans	rs11875185	0.510	rs75426909	chr18:55650062	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.12	-0.39	2.29e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7246760	0.867	rs3859512	chr19:9932831	C/T	cg16876255	chr19:9731953	ZNF561	0.78	7.21	0.32	2.25e-12	Pursuit maintenance gain;
LGG	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	9.09e-48	Intelligence (multi-trait analysis);
LGG	cis	rs10492096	0.947	rs10774435	chr12:6616120	G/T	cg13857086	chr12:6580257	VAMP1	0.48	6.99	0.31	9.72e-12	Hip geometry;
LGG	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs3768617	0.510	rs10752900	chr1:183086238	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.47	-9.48	-0.4	1.33e-19	Personality dimensions;
LGG	cis	rs7927592	0.763	rs2513277	chr11:68360887	T/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.79	-0.45	2.27e-24	Total body bone mineral density;
LGG	cis	rs17301259	0.548	rs2538888	chr7:88320260	A/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.67	-0.3	7.33e-11	Heschl's gyrus morphology;
LGG	cis	rs6500602	0.793	rs4785964	chr16:4484613	A/G	cg05091796	chr16:4465799	CORO7	-1.02	-18.08	-0.64	1.18e-55	Schizophrenia;
LGG	cis	rs9910055	0.659	rs8079310	chr17:42270291	A/G	cg16434002	chr17:42200994	HDAC5	-0.57	-10.43	-0.44	4.98e-23	Total body bone mineral density;
LGG	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04146151	chr16:2155961	PKD1	-0.51	-8.65	-0.37	8.75e-17	Triglycerides;
LGG	cis	rs4561483	0.583	rs11645213	chr16:11942924	C/A	cg08843971	chr16:11963173	GSPT1	0.54	12.96	0.52	5.28e-33	Testicular germ cell tumor;
LGG	cis	rs9894429	0.816	rs7406040	chr17:79597583	A/C	cg18240062	chr17:79603768	NPLOC4	0.81	15.28	0.58	5.74e-43	Eye color traits;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg14196790	chr5:131705035	SLC22A5	-0.54	-6.89	-0.3	1.88e-11	Rheumatoid arthritis;
LGG	cis	rs7582180	0.868	rs6542924	chr2:100893113	A/C	cg04143929	chr2:100879511	NA	0.53	7.77	0.34	4.98e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg00599393	chr8:22457479	C8orf58	-0.43	-7.87	-0.34	2.48e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs11583043	1.000	rs7541397	chr1:101322866	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.45	-8.63	-0.37	9.88e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg05059571	chr16:84539110	KIAA1609	0.51	9.55	0.41	7.36e-20	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg13010199	chr12:38710504	ALG10B	-0.54	-9.99	-0.42	2.02e-21	Morning vs. evening chronotype;
LGG	cis	rs3099143	1.000	rs35645941	chr15:77140302	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-10.89	-0.45	9.55e-25	Recalcitrant atopic dermatitis;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06642177	chr6:134496341	SGK1	0.43	7.07	0.31	5.64e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2072732	0.756	rs12041634	chr1:2951034	A/T	cg22517653	chr1:2918612	NA	-0.44	-6.98	-0.31	1.03e-11	Plateletcrit;
LGG	cis	rs11148252	0.846	rs7985262	chr13:52997161	C/T	cg12458913	chr13:53173898	NA	0.63	12.28	0.5	3.4e-30	Lewy body disease;
LGG	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.14	-0.31	3.69e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs78487399	0.808	rs12105786	chr2:43676433	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs9467711	0.559	rs9348721	chr6:26485573	A/G	cg06606381	chr12:133084897	FBRSL1	-0.84	-8.73	-0.38	4.53e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.7	-0.3	6.2e-11	Coronary artery disease;
LGG	cis	rs6540556	0.954	rs6540555	chr1:209936571	A/G	cg23920097	chr1:209922102	NA	-0.45	-8.0	-0.35	9.88e-15	Red blood cell count;
LGG	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg17294928	chr15:75287854	SCAMP5	0.56	10.26	0.43	2.25e-22	Breast cancer;
LGG	cis	rs11771526	0.901	rs62457472	chr7:32306885	A/G	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg16359550	chr11:109292809	C11orf87	0.4	7.88	0.34	2.44e-14	Schizophrenia;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.96	0.6	5.39e-46	Lung cancer;
LGG	cis	rs6831352	0.840	rs29001223	chr4:100047433	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.77e-17	Alcohol dependence;
LGG	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.31	0.36	1.1e-15	Thyroid stimulating hormone;
LGG	cis	rs4740619	0.819	rs169342	chr9:15613838	T/A	cg14451791	chr9:16040625	NA	-0.34	-8.7	-0.37	5.93e-17	Body mass index;
LGG	cis	rs7833790	0.685	rs13255262	chr8:82728024	T/G	cg17211192	chr8:82754475	SNX16	-0.74	-12.45	-0.5	7.11e-31	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg06873352	chr17:61820015	STRADA	-0.74	-13.89	-0.54	6.25e-37	Prudent dietary pattern;
LGG	cis	rs559928	0.597	rs2186572	chr11:63895887	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.77	0.3	3.95e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg15665833	chr6:26285013	NA	0.38	7.5	0.33	3.31e-13	Educational attainment;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg13395646	chr4:1353034	KIAA1530	-0.43	-7.32	-0.32	1.12e-12	Obesity-related traits;
LGG	cis	rs1909881	1.000	rs1909881	chr8:96515888	A/G	cg04203453	chr8:96504381	NA	-1.08	-18.36	-0.65	5.69e-57	Obesity-related traits;
LGG	cis	rs9314323	0.862	rs7813520	chr8:26263260	C/T	cg11498726	chr8:26250323	BNIP3L	-0.56	-11.83	-0.48	2.11e-28	Red cell distribution width;
LGG	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16346588	chr10:242978	ZMYND11	0.39	6.79	0.3	3.51e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg16339924	chr4:17578868	LAP3	-0.52	-8.56	-0.37	1.67e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7928758	0.778	rs1866767	chr11:134274763	A/G	cg25213107	chr11:134282864	B3GAT1	-1.09	-13.31	-0.53	1.96e-34	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs9393777	0.841	rs67092078	chr6:27054772	G/A	cg01620082	chr3:125678407	NA	-0.99	-9.46	-0.4	1.5700000000000001e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	cis	rs2933343	0.951	rs789218	chr3:128592670	G/A	cg25356066	chr3:128598488	ACAD9	0.46	6.78	0.3	3.74e-11	IgG glycosylation;
LGG	cis	rs1218582	0.772	rs6683557	chr1:154852307	C/G	cg09359103	chr1:154839909	KCNN3	-0.51	-10.61	-0.44	1.11e-23	Prostate cancer;
LGG	trans	rs1997103	1.000	rs6951294	chr7:55400835	C/T	cg20935933	chr6:143382018	AIG1	0.58	9.02	0.39	4.99e-18	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs7181230	0.848	rs62004114	chr15:40333355	C/G	cg22705835	chr10:65332833	REEP3	-0.61	-9.92	-0.42	3.55e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs12956009	0.583	rs1115360	chr18:44894550	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.4e-12	Educational attainment (years of education);
LGG	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg20608306	chr11:116969690	SIK3	0.33	8.74	0.38	4.27e-17	Blood protein levels;
LGG	cis	rs1532815	1.000	rs1532815	chr1:165180089	A/T	cg03428399	chr1:165174748	LMX1A	-0.55	-11.63	-0.48	1.29e-27	Response to acetaminophen (hepatotoxicity);
LGG	cis	rs1707322	0.752	rs4660313	chr1:46110841	A/G	cg03146154	chr1:46216737	IPP	-0.55	-10.66	-0.44	6.97e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2573652	0.722	rs11630930	chr15:100544145	G/T	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.28	-0.32	1.47e-12	Height;
LGG	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg06636001	chr8:8085503	FLJ10661	0.53	9.7	0.41	2.31e-20	Neuroticism;
LGG	cis	rs6541297	1.000	rs6541297	chr1:230283506	G/A	cg20703242	chr1:230279135	GALNT2	0.37	7.58	0.33	1.91e-13	Coronary artery disease;
LGG	cis	rs644799	1.000	rs627568	chr11:95569253	A/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.95	20.32	0.69	4.12e-66	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4417704	0.577	rs7591322	chr2:241900403	T/C	cg26818257	chr2:241905806	NA	0.5	10.91	0.45	8.36e-25	Joint mobility (Beighton score);
LGG	cis	rs7100689	0.646	rs1340374	chr10:82129114	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg13114125	chr14:105738426	BRF1	-0.85	-16.01	-0.6	3.16e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg04772025	chr11:68637568	NA	0.75	13.2	0.52	5.47e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9522267	0.535	rs9522303	chr13:112237301	T/C	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	trans	rs1814175	0.591	rs11040589	chr11:49862449	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg27147174	chr7:100797783	AP1S1	-0.7	-13.22	-0.52	4.56e-34	Life satisfaction;
LGG	cis	rs11657217	0.638	rs4313839	chr17:77698619	C/T	cg06901238	chr17:77706717	ENPP7	-0.47	-10.16	-0.43	4.91e-22	Diastolic blood pressure response to hydrochlorothiazide in hypertension;
LGG	cis	rs3126085	0.935	rs12045496	chr1:152253910	A/G	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs7737355	1.000	rs27873	chr5:130731151	T/C	cg06307176	chr5:131281290	NA	-0.49	-8.09	-0.35	5.44e-15	Life satisfaction;
LGG	cis	rs6748734	1.000	rs6748734	chr2:241837452	A/G	cg07537917	chr2:241836409	C2orf54	-0.4	-7.79	-0.34	4.44e-14	Urinary metabolites;
LGG	cis	rs1682825	0.858	rs6795031	chr3:10763012	C/T	cg23512531	chr3:10780469	NA	-0.56	-7.86	-0.34	2.73e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg09699651	chr6:150184138	LRP11	0.47	8.36	0.36	7.26e-16	Lung cancer;
LGG	cis	rs4321325	0.536	rs10198483	chr2:127934102	G/A	cg11380483	chr2:127933992	NA	0.81	14.37	0.56	5.42e-39	Protein C levels;
LGG	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg00631329	chr6:26305371	NA	-0.44	-7.19	-0.32	2.56e-12	Educational attainment;
LGG	cis	rs3087591	0.960	rs2953000	chr17:29509791	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.45	0.56	2.46e-39	Hip circumference;
LGG	trans	rs7178375	1.000	rs7178375	chr15:31215935	C/T	cg04373760	chr16:53404718	NA	0.53	8.09	0.35	5.2e-15	Hypertriglyceridemia;
LGG	cis	rs9916302	0.904	rs600010	chr17:37433517	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7129556	0.520	rs4366508	chr11:77274999	C/T	cg12586386	chr11:77299805	AQP11	0.39	6.87	0.3	2.1e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs4689592	0.513	rs4689586	chr4:7067413	A/G	cg26116260	chr4:7069785	GRPEL1	1.15	22.53	0.72	2.05e-76	Monocyte percentage of white cells;
LGG	cis	rs9303401	0.659	rs7210432	chr17:56668170	C/T	cg25039879	chr17:56429692	SUPT4H1	0.65	9.24	0.39	9.2e-19	Cognitive test performance;
LGG	cis	rs2153535	0.580	rs2225766	chr6:8481833	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.15	0.43	5.64e-22	Motion sickness;
LGG	cis	rs6121246	0.583	rs28815498	chr20:30351560	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs921968	0.643	rs535830	chr2:219372233	C/G	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16405210	chr4:1374714	KIAA1530	-0.53	-9.32	-0.4	4.58e-19	Longevity;
LGG	cis	rs739401	0.572	rs384490	chr11:3078885	A/C	cg05729581	chr11:3078854	CARS	-0.57	-10.06	-0.42	1.16e-21	Longevity;
LGG	cis	rs17270561	0.666	rs4712971	chr6:25771900	T/C	cg03264133	chr6:25882463	NA	-0.45	-7.09	-0.31	4.91e-12	Iron status biomarkers;
LGG	cis	rs9880211	0.898	rs9870825	chr3:136065720	C/A	cg21827317	chr3:136751795	NA	-0.48	-7.03	-0.31	7.46e-12	Body mass index;Height;
LGG	cis	rs7619833	0.620	rs1445108	chr3:27231558	G/A	cg02860705	chr3:27208620	NA	0.41	8.03	0.35	8.13e-15	Breast cancer;
LGG	cis	rs9462027	0.628	rs2814992	chr6:34617144	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.55	-0.44	1.85e-23	Systemic lupus erythematosus;
LGG	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.52	0.37	2.23e-16	Height;
LGG	trans	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg06521331	chr12:34319734	NA	-0.4	-7.08	-0.31	5.49e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6835098	1.000	rs2332654	chr4:174088399	C/T	cg08422745	chr4:174089978	GALNT7	-0.87	-15.59	-0.59	2.35e-44	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs1552244	0.882	rs13084194	chr3:10031492	T/A	cg00166722	chr3:10149974	C3orf24	0.54	8.92	0.38	1.05e-17	Alzheimer's disease;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.61	-10.47	-0.44	3.7e-23	Obesity-related traits;
LGG	cis	rs7617773	0.817	rs3731534	chr3:48211777	C/T	cg11946769	chr3:48343235	NME6	0.68	11.24	0.46	4.3e-26	Coronary artery disease;
LGG	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg20735989	chr4:730612	PCGF3	-0.6	-10.54	-0.44	2e-23	White blood cell count;
LGG	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg15162869	chr22:32027605	PISD	0.65	6.88	0.3	1.89e-11	Age-related hearing impairment;
LGG	cis	rs1620921	0.711	rs1629794	chr6:161246303	G/A	cg01280913	chr6:161186852	NA	-0.34	-7.0	-0.31	9.29e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6089829	0.962	rs57684920	chr20:61662639	G/A	cg08564027	chr20:61660810	NA	-1.04	-25.47	-0.76	4.06e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7202877	0.706	rs1540	chr16:75481185	G/C	cg03315344	chr16:75512273	CHST6	-0.52	-6.67	-0.3	7.09e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs17102423	0.594	rs8010213	chr14:65552182	C/T	cg26396452	chr14:65542826	MAX	0.48	9.99	0.42	2.15e-21	Obesity-related traits;
LGG	cis	rs6426558	0.537	rs10799381	chr1:227239746	G/T	cg10327440	chr1:227177885	CDC42BPA	0.62	10.38	0.43	7.53e-23	Neutrophil percentage of white cells;
LGG	cis	rs9325144	0.624	rs10783329	chr12:39113951	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.03	-0.42	1.49e-21	Morning vs. evening chronotype;
LGG	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg06417478	chr19:12876846	HOOK2	0.41	6.79	0.3	3.39e-11	Red blood cell traits;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.15	-0.39	1.79e-18	Life satisfaction;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03029616	chr21:31986034	KRTAP6-1	0.46	7.63	0.33	1.39e-13	Pancreatic cancer;
LGG	cis	rs11098499	0.863	rs7669520	chr4:120515278	T/C	cg09307838	chr4:120376055	NA	0.8	13.36	0.53	1.2e-34	Corneal astigmatism;
LGG	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	7.95	0.35	1.4e-14	Iron status biomarkers;
LGG	cis	rs17345786	0.861	rs11711808	chr3:101235101	T/C	cg12386194	chr3:101231763	SENP7	0.74	12.8	0.51	2.45e-32	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7552404	0.731	rs17650138	chr1:76398887	C/T	cg10523679	chr1:76189770	ACADM	-0.79	-10.86	-0.45	1.2e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9557207	0.950	rs1927729	chr13:99955798	A/G	cg24509225	chr13:100037070	UBAC2	0.7	12.64	0.51	1.16e-31	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg00701064	chr4:6280414	WFS1	0.77	17.56	0.63	2.69e-53	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06873352	chr17:61820015	STRADA	0.74	14.0	0.55	2.22e-37	Prudent dietary pattern;
LGG	cis	rs9486719	1.000	rs12208884	chr6:96885572	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	trans	rs36715	1.000	rs251212	chr5:127545910	G/A	cg16011800	chr17:1958478	HIC1	-0.46	-6.72	-0.3	5.38e-11	Breast cancer;
LGG	cis	rs9557207	1.000	rs12857217	chr13:99916436	C/T	cg24509225	chr13:100037070	UBAC2	0.66	11.95	0.49	6.84e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs763121	0.853	rs3827357	chr22:39079413	A/G	cg21395723	chr22:39101663	GTPBP1	0.38	6.66	0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs61931739	0.500	rs11053242	chr12:34511625	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.96	-0.42	2.63e-21	Morning vs. evening chronotype;
LGG	cis	rs929596	0.614	rs10929302	chr2:234665782	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.75	-13.43	-0.53	5.62e-35	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg12070911	chr6:150209640	RAET1E	0.31	7.64	0.33	1.24e-13	Lung cancer;
LGG	trans	rs853679	0.546	rs2232423	chr6:28366151	A/G	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs11605924	0.901	rs6485644	chr11:45855998	C/T	ch.11.939596F	chr11:45881766	CRY2	-0.47	-7.83	-0.34	3.28e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03506944	chr4:154074021	TRIM2	0.45	7.53	0.33	2.75e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7582180	0.591	rs12991577	chr2:101010867	C/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.66	-0.48	1.03e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1021993	0.545	rs79212878	chr1:209547417	G/A	cg24446417	chr1:209558027	NA	-0.74	-11.08	-0.46	1.86e-25	Gut microbiome composition (winter);
LGG	cis	rs60180747	0.863	rs11635184	chr15:66714743	A/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	11.13	0.46	1.2e-25	Testicular germ cell tumor;
LGG	cis	rs9912468	0.646	rs56152251	chr17:64280153	G/A	cg19474267	chr17:64306194	PRKCA	0.92	22.28	0.72	2.76e-75	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.08e-11	Neuroticism;
LGG	cis	rs9644630	0.841	rs4292704	chr8:19329303	G/C	cg06699216	chr8:19333253	CSGALNACT1	-0.53	-12.7	-0.51	6.34e-32	Oropharynx cancer;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg06074448	chr4:187884817	NA	-0.58	-12.78	-0.51	2.94e-32	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-8.1	-0.35	5e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10850519	0.744	rs9971756	chr12:115948940	G/A	cg18639984	chr12:115943877	NA	-0.41	-8.91	-0.38	1.15e-17	Diastolic blood pressure;
LGG	trans	rs1814175	0.626	rs1722008	chr11:49897676	A/T	cg03929089	chr4:120376271	NA	-1.03	-24.24	-0.75	2.05e-84	Height;
LGG	cis	rs11112613	0.713	rs73184084	chr12:105952615	T/A	cg03607813	chr12:105948248	NA	0.59	10.85	0.45	1.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs2439831	1.000	rs561863	chr15:43761352	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg21775007	chr8:11205619	TDH	0.44	6.83	0.3	2.66e-11	Neuroticism;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg15485101	chr11:133734466	NA	0.61	10.69	0.45	5.31e-24	Childhood ear infection;
LGG	cis	rs9682041	1.000	rs9682041	chr3:170091902	C/T	cg11886554	chr3:170076028	SKIL	1.0	12.11	0.49	1.59e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	trans	rs28735056	1.000	rs4798922	chr18:77628953	G/C	cg05926928	chr17:57297772	GDPD1	-0.5	-7.88	-0.34	2.31e-14	Schizophrenia;
LGG	cis	rs1018836	0.608	rs1015994	chr8:91465011	T/C	cg16814680	chr8:91681699	NA	-0.59	-9.93	-0.42	3.39e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2204008	0.837	rs7301679	chr12:37989629	T/C	cg26384229	chr12:38710491	ALG10B	-0.8	-17.56	-0.63	2.97e-53	Bladder cancer;
LGG	cis	rs2412459	1.000	rs8023482	chr15:40307095	A/C	cg20255370	chr15:40268687	EIF2AK4	-0.92	-9.91	-0.42	3.85e-21	Response to haloperidol in psychosis;
LGG	cis	rs986417	0.901	rs1950312	chr14:60989784	A/G	cg27398547	chr14:60952738	C14orf39	-0.7	-6.96	-0.31	1.2e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12908161	1.000	rs35524990	chr15:85258203	T/C	cg24253500	chr15:84953950	NA	0.42	7.02	0.31	7.99e-12	Schizophrenia;
LGG	cis	rs184065563	1	rs184065563	chr6:45144224	G/A	cg18551225	chr6:44695536	NA	-0.61	-10.11	-0.43	7.69e-22	Total body bone mineral density (age over 60);Total body bone mineral density;
LGG	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Myopia (pathological);
LGG	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg10189774	chr4:17578691	LAP3	0.42	7.27	0.32	1.54e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.92	-0.31	1.55e-11	Lung cancer;
LGG	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg21775007	chr8:11205619	TDH	0.53	8.77	0.38	3.56e-17	Neuroticism;
LGG	cis	rs11785400	0.928	rs2280878	chr8:143722366	G/A	cg24634471	chr8:143751801	JRK	0.52	8.08	0.35	5.84e-15	Schizophrenia;
LGG	trans	rs11098499	0.863	rs1383533	chr4:120434576	G/A	cg25214090	chr10:38739885	LOC399744	0.65	11.42	0.47	8.92e-27	Corneal astigmatism;
LGG	cis	rs2836974	0.897	rs2836928	chr21:40543320	C/T	cg17971929	chr21:40555470	PSMG1	0.88	16.81	0.62	7.75e-50	Cognitive function;
LGG	cis	rs6456042	0.893	rs3127441	chr6:166562854	T/C	cg11088901	chr6:166572345	T	-0.37	-7.72	-0.34	7e-14	Asthma;
LGG	cis	rs7666738	0.830	rs4699577	chr4:98846513	G/A	cg05340658	chr4:99064831	C4orf37	0.49	8.14	0.35	3.68e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12618769	0.597	rs10199199	chr2:99061834	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.59e-16	Bipolar disorder;
LGG	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg03060546	chr3:49711283	APEH	0.61	9.33	0.4	4.4e-19	Resting heart rate;
LGG	cis	rs981844	0.712	rs2405208	chr4:154755774	T/C	cg14289246	chr4:154710475	SFRP2	-0.56	-9.63	-0.41	4.07e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs60871478	0.635	rs4311567	chr7:792295	T/C	cg22643751	chr7:855365	UNC84A	0.42	7.49	0.33	3.42e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs7659604	0.605	rs67772833	chr4:122723106	G/A	cg19748678	chr4:122722346	EXOSC9	0.63	12.7	0.51	6.28e-32	Type 2 diabetes;
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06028808	chr11:68637592	NA	-0.71	-12.32	-0.5	2.29e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3762637	0.943	rs72960447	chr3:122235105	G/A	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	cis	rs350251	0.899	rs1704116	chr16:12209658	A/G	cg02910054	chr16:12241554	SNX29	0.44	8.14	0.35	3.61e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12780845	0.522	rs7900703	chr10:17237617	T/C	cg01003015	chr10:17271136	VIM	-0.44	-7.5	-0.33	3.27e-13	Homocysteine levels;
LGG	cis	rs1978968	0.957	rs55865752	chr22:18444227	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.34	-0.5	1.9e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs9527	0.571	rs3740400	chr10:104629465	T/G	cg04362960	chr10:104952993	NT5C2	0.55	10.2	0.43	3.7e-22	Arsenic metabolism;
LGG	cis	rs9300255	0.566	rs10744150	chr12:123721614	A/C	cg00376283	chr12:123451042	ABCB9	0.67	11.6	0.47	1.77e-27	Neutrophil percentage of white cells;
LGG	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg20503657	chr10:835505	NA	0.75	10.23	0.43	2.85e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs4481887	0.927	rs4350233	chr1:248489994	G/A	cg00666640	chr1:248458726	OR2T12	0.57	9.15	0.39	1.78e-18	Common traits (Other);
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg10056627	chr6:42928773	GNMT	0.25	6.98	0.31	1.03e-11	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7100689	0.577	rs2282367	chr10:82040346	A/G	cg01528321	chr10:82214614	TSPAN14	0.8	13.88	0.54	7.29e-37	Post bronchodilator FEV1;
LGG	cis	rs6748734	1.000	rs4675868	chr2:241828542	A/C	cg26818257	chr2:241905806	NA	0.39	7.4	0.33	6.51e-13	Urinary metabolites;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.32	0.53	1.65e-34	Obesity-related traits;
LGG	cis	rs60180747	1.000	rs11071896	chr15:66821250	A/G	cg07575407	chr15:66541975	MEGF11	0.34	6.71	0.3	5.63e-11	Testicular germ cell tumor;
LGG	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg01448562	chr3:133502909	NA	-0.81	-15.61	-0.59	1.87e-44	Iron status biomarkers;
LGG	cis	rs2298450	0.717	rs8126481	chr21:37614781	G/T	cg02919814	chr21:37666008	DOPEY2	-0.41	-7.69	-0.34	8.73e-14	Schizophrenia;
LGG	cis	rs8060686	0.641	rs116821144	chr16:68081341	A/G	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.17e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10865541	0.869	rs4318418	chr2:3393289	A/C	cg11642891	chr2:3452563	TTC15	-0.39	-7.47	-0.33	4.02e-13	Obesity-related traits;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06932451	chr19:36869880	NA	-0.4	-7.13	-0.31	3.85e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs780096	0.506	rs1647285	chr2:27714511	A/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs240764	0.604	rs9373590	chr6:101212001	A/T	cg09795085	chr6:101329169	ASCC3	0.48	8.18	0.36	2.81e-15	Neuroticism;
LGG	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	-0.47	-8.2	-0.36	2.31e-15	Body mass index;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.44	-0.33	4.85e-13	Bipolar disorder;
LGG	cis	rs12681288	0.676	rs935820	chr8:1022168	A/G	cg04851639	chr8:1020857	NA	-0.42	-8.88	-0.38	1.49e-17	Schizophrenia;
LGG	cis	rs1971762	0.712	rs7302232	chr12:53965423	A/T	cg06632207	chr12:54070931	ATP5G2	0.22	6.87	0.3	2.07e-11	Height;
LGG	cis	rs2635047	0.682	rs9960932	chr18:44792445	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.54	0.33	2.46e-13	Educational attainment;
LGG	cis	rs12410462	1.000	rs80168344	chr1:227655804	C/T	cg21459583	chr1:227974177	NA	0.46	7.1	0.31	4.75e-12	Major depressive disorder;
LGG	cis	rs7647973	0.626	rs62262672	chr3:49655927	T/A	cg03060546	chr3:49711283	APEH	-0.63	-8.41	-0.36	5.05e-16	Menarche (age at onset);
LGG	cis	rs6665290	0.835	rs11578479	chr1:227210888	A/T	cg05696931	chr1:227175867	NA	-0.4	-7.81	-0.34	3.99e-14	Myeloid white cell count;
LGG	trans	rs1814175	0.616	rs28417656	chr11:50040152	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs28735056	1.000	rs59183289	chr18:77631198	A/G	cg20368463	chr18:77673604	PQLC1	-0.5	-9.02	-0.39	5.13e-18	Schizophrenia;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.01	0.31	8.48e-12	Lung cancer;
LGG	cis	rs9460578	0.537	rs9460563	chr6:20825018	T/C	cg13405222	chr6:20811065	CDKAL1	0.76	17.27	0.63	6.07e-52	Breast cancer;
LGG	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg16141378	chr3:129829833	LOC729375	0.36	8.22	0.36	2e-15	Neuroticism;
LGG	cis	rs4481887	0.927	rs10888344	chr1:248446655	T/C	cg00666640	chr1:248458726	OR2T12	0.57	9.27	0.4	6.94e-19	Common traits (Other);
LGG	cis	rs2439831	0.850	rs60883262	chr15:44076503	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.61	0.44	1.12e-23	Lung cancer in ever smokers;
LGG	cis	rs1499614	1.000	rs1638731	chr7:66144679	C/T	cg13147721	chr7:65941812	NA	-0.82	-10.09	-0.42	8.89e-22	Gout;
LGG	cis	rs77633900	0.772	rs157789	chr15:76805703	T/A	cg21673338	chr15:77095150	SCAPER	-0.63	-8.11	-0.35	4.62e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2652834	1.000	rs7181141	chr15:63398552	A/G	cg05507819	chr15:63340323	TPM1	0.58	7.74	0.34	6.17e-14	HDL cholesterol;
LGG	cis	rs1153858	1.000	rs66939267	chr15:45676902	T/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.88e-12	Blood metabolite levels;
LGG	cis	rs2762353	0.595	rs13194155	chr6:25755508	C/T	cg03517284	chr6:25882590	NA	0.66	12.87	0.51	1.33e-32	Blood metabolite levels;
LGG	cis	rs1165472	0.755	rs12566150	chr1:56160904	C/G	cg11523071	chr1:56160889	NA	-0.61	-13.97	-0.54	2.88e-37	Paclitaxel-induced neuropathy;
LGG	cis	rs73001065	0.636	rs10415849	chr19:19505087	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.85	0.45	1.39e-24	LDL cholesterol;
LGG	trans	rs12310956	0.510	rs10129020	chr12:33858936	T/G	cg26384229	chr12:38710491	ALG10B	0.66	12.57	0.5	2.14e-31	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.7	-0.37	5.98e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs61989804	0.590	rs4902384	chr14:65764734	G/T	cg15999311	chr14:65749247	NA	0.82	8.29	0.36	1.26e-15	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg22431228	chr1:16359049	CLCNKA	-0.51	-9.88	-0.42	5.28e-21	Dilated cardiomyopathy;
LGG	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-9.58	-0.41	6.18e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6598163	0.700	rs12813179	chr12:132302228	C/G	cg04876069	chr12:132293656	NA	-0.35	-6.7	-0.3	6.25e-11	Migraine;
LGG	trans	rs17685	0.712	rs10235738	chr7:75773460	G/A	cg19862616	chr7:65841803	NCRNA00174	1.06	24.81	0.76	4.83e-87	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg24375607	chr4:120327624	NA	0.68	11.13	0.46	1.12e-25	Corneal astigmatism;
LGG	cis	rs2276314	0.947	rs16967319	chr18:33573525	A/G	cg05985134	chr18:33552581	C18orf21	0.64	9.95	0.42	2.89e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.61	11.72	0.48	5.62e-28	Longevity;
LGG	cis	rs523522	0.962	rs2168319	chr12:120933217	C/T	cg27279351	chr12:120934652	DYNLL1	0.78	12.51	0.5	4.02e-31	High light scatter reticulocyte count;
LGG	cis	rs7635838	0.859	rs9826803	chr3:11461863	G/A	cg00170343	chr3:11313890	ATG7	0.43	7.05	0.31	6.36e-12	HDL cholesterol;
LGG	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg13010199	chr12:38710504	ALG10B	-0.57	-10.81	-0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs9810089	0.903	rs10935185	chr3:136290529	C/G	cg12473912	chr3:136751656	NA	0.39	6.75	0.3	4.45e-11	Gestational age at birth (child effect);
LGG	cis	rs12195424	0.730	rs77627159	chr6:56308904	G/T	cg07152817	chr6:56299822	NA	-0.98	-9.58	-0.41	5.82e-20	Cerebrospinal fluid clusterin levels;
LGG	cis	rs11971779	0.793	rs4732366	chr7:139027845	G/C	cg07862535	chr7:139043722	LUC7L2	0.5	8.09	0.35	5.28e-15	Diisocyanate-induced asthma;
LGG	cis	rs28735056	0.846	rs12958903	chr18:77628996	A/G	cg20368463	chr18:77673604	PQLC1	0.42	7.37	0.32	7.86e-13	Schizophrenia;
LGG	cis	rs7250872	0.647	rs7259484	chr19:1813207	A/G	cg18850929	chr19:1828978	REXO1	0.45	7.22	0.32	2.19e-12	Bipolar disorder;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg14196790	chr5:131705035	SLC22A5	0.6	7.62	0.33	1.46e-13	Rheumatoid arthritis;
LGG	cis	rs11148252	0.668	rs6561658	chr13:52734151	T/A	cg12458913	chr13:53173898	NA	0.53	9.17	0.39	1.5e-18	Lewy body disease;
LGG	cis	rs3771570	0.579	rs62190373	chr2:242388685	G/A	cg21155796	chr2:242212141	HDLBP	0.74	9.86	0.42	6.21e-21	Prostate cancer;
LGG	cis	rs3770081	0.793	rs60719866	chr2:86284378	A/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.67	7.21	0.32	2.37e-12	Facial emotion recognition (sad faces);
LGG	cis	rs3858526	0.523	rs10769287	chr11:5884845	T/C	cg13902645	chr11:5959945	NA	-0.69	-11.76	-0.48	4.02e-28	DNA methylation (variation);
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg05316309	chr22:43011028	POLDIP3;RNU12	0.37	6.93	0.31	1.46e-11	Eye color traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08905358	chr2:109065694	GCC2	0.48	6.92	0.31	1.47e-11	Gut microbiome composition (summer);
LGG	cis	rs868036	0.681	rs4776976	chr15:68103291	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.43	-0.36	4.39e-16	Restless legs syndrome;
LGG	cis	rs6032067	1.000	rs6017519	chr20:43854677	C/T	cg10761708	chr20:43804764	PI3	0.75	11.7	0.48	7.05e-28	Blood protein levels;
LGG	cis	rs765787	0.530	rs28815867	chr15:45526805	G/C	cg25801113	chr15:45476975	SHF	0.87	19.81	0.68	1e-63	Uric acid levels;
LGG	cis	rs7712401	0.623	rs538424	chr5:122228763	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.97	0.31	1.13e-11	Mean platelet volume;
LGG	cis	rs7312774	0.618	rs7979117	chr12:107345883	C/T	cg16260113	chr12:107380972	MTERFD3	0.94	8.75	0.38	3.87e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs780096	0.546	rs6547626	chr2:27646770	C/T	cg05484376	chr2:27715224	FNDC4	0.46	9.96	0.42	2.7e-21	Total body bone mineral density;
LGG	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg07636037	chr3:49044803	WDR6	0.91	16.8	0.62	8.81e-50	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs888194	0.738	rs1001382	chr12:109974931	T/C	cg19025524	chr12:109796872	NA	-0.36	-7.21	-0.32	2.25e-12	Neuroticism;
LGG	cis	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg19847130	chr8:10466454	RP1L1	-0.35	-7.6	-0.33	1.7e-13	Neuroticism;
LGG	cis	rs1055129	0.560	rs9302994	chr17:73906934	G/A	cg14829360	chr17:73884958	NA	-0.53	-10.09	-0.42	8.88e-22	White matter hyperintensity burden;
LGG	cis	rs9290065	0.519	rs7616249	chr3:160679422	T/C	cg03342759	chr3:160939853	NMD3	-0.51	-8.54	-0.37	1.89e-16	Kawasaki disease;
LGG	cis	rs6430585	0.583	rs79176913	chr2:136638113	C/A	cg07169764	chr2:136633963	MCM6	1.3	27.55	0.79	1.21e-99	Corneal structure;
LGG	cis	rs55665837	1.000	rs55665837	chr11:14495049	C/T	cg19336497	chr11:14380999	RRAS2	-0.45	-8.82	-0.38	2.26e-17	Vitamin D levels;
LGG	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg11366901	chr6:160182831	ACAT2	1.06	16.25	0.6	2.65e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs116095464	0.558	rs55833259	chr5:286728	G/A	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	cis	rs919433	0.679	rs6719832	chr2:198533369	C/T	cg00792783	chr2:198669748	PLCL1	-0.55	-9.03	-0.39	4.67e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs10227331	0.934	rs2302447	chr7:157295985	A/T	cg06076350	chr7:157294107	NA	0.36	6.85	0.3	2.3e-11	Inattentive symptoms;
LGG	cis	rs208520	0.690	rs12201219	chr6:66748862	A/T	cg07460842	chr6:66804631	NA	0.96	17.94	0.64	5.27e-55	Exhaled nitric oxide output;
LGG	cis	rs6867032	0.527	rs1017924	chr5:1976187	C/T	cg26168224	chr5:2018326	NA	0.92	13.81	0.54	1.43e-36	Gut microbiome composition (winter);
LGG	trans	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg13698153	chr12:118541722	VSIG10	0.4	6.73	0.3	5.07e-11	Vitiligo;
LGG	cis	rs6089584	0.888	rs6061973	chr20:60610870	C/T	cg13770153	chr20:60521292	NA	-0.54	-8.58	-0.37	1.46e-16	Body mass index;
LGG	cis	rs6840360	0.509	rs62327273	chr4:152547594	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.85e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.724	rs10400308	chr11:48891246	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.86	-0.34	2.76e-14	HDL cholesterol;
LGG	cis	rs6762477	0.748	rs2073726	chr3:50223593	T/A	cg14019146	chr3:50243930	SLC38A3	0.34	7.3	0.32	1.29e-12	Menarche (age at onset);
LGG	cis	rs4356203	0.905	rs6486352	chr11:17172370	A/T	cg15432903	chr11:17409602	KCNJ11	0.38	7.26	0.32	1.66e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg06618935	chr21:46677482	NA	-0.53	-9.39	-0.4	2.67e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11250097	0.549	rs11784897	chr8:11310442	G/A	cg21775007	chr8:11205619	TDH	-0.47	-7.52	-0.33	2.88e-13	Neuroticism;
LGG	cis	rs3749237	0.595	rs4955412	chr3:49418168	A/C	cg02487422	chr3:49467188	NICN1	0.57	10.62	0.44	1.04e-23	Resting heart rate;
LGG	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.13	0.31	3.77e-12	Prudent dietary pattern;
LGG	cis	rs7707921	0.522	rs9293290	chr5:81474225	A/T	cg15871215	chr5:81402204	ATG10	-0.31	-7.04	-0.31	7.1e-12	Breast cancer;
LGG	cis	rs9322193	1.000	rs58189451	chr6:149921388	G/A	cg09699651	chr6:150184138	LRP11	0.46	7.93	0.35	1.69e-14	Lung cancer;
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	18.58	0.65	5.3e-58	Platelet count;
LGG	trans	rs4332037	0.805	rs10278591	chr7:1921362	A/G	cg11693508	chr17:37793320	STARD3	-0.59	-8.8	-0.38	2.74e-17	Bipolar disorder;
LGG	cis	rs2839186	0.771	rs2280957	chr21:47642272	A/G	cg08742575	chr21:47604166	C21orf56	-0.55	-9.96	-0.42	2.55e-21	Testicular germ cell tumor;
LGG	cis	rs6834538	0.965	rs4834294	chr4:113529020	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.55	8.76	0.38	3.59e-17	Free thyroxine concentration;
LGG	cis	rs7927771	0.931	rs4752801	chr11:47907641	A/G	cg20307385	chr11:47447363	PSMC3	-0.52	-9.22	-0.39	1.01e-18	Subjective well-being;
LGG	cis	rs472402	0.623	rs7707877	chr5:6635946	C/G	cg08700190	chr5:6636046	SRD5A1	-0.36	-7.76	-0.34	5.59e-14	Response to amphetamines;
LGG	cis	rs4356203	0.870	rs11024208	chr11:17259979	G/A	cg15432903	chr11:17409602	KCNJ11	-0.4	-7.53	-0.33	2.75e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs4803455	0.565	rs11083616	chr19:41865643	A/G	cg09537434	chr19:41945824	ATP5SL	0.65	11.79	0.48	2.96e-28	Migraine;Coronary artery disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg11081185	chr11:208423	RIC8A;BET1L	0.41	6.97	0.31	1.07e-11	Body mass index;
LGG	cis	rs477895	0.629	rs7130030	chr11:63933733	T/G	cg04317338	chr11:64019027	PLCB3	0.66	8.21	0.36	2.2e-15	Mean platelet volume;
LGG	cis	rs9902453	0.967	rs4533341	chr17:28495672	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.26	0.52	2.95e-34	Coffee consumption (cups per day);
LGG	cis	rs11098499	0.754	rs17595608	chr4:120250506	C/T	cg24375607	chr4:120327624	NA	0.61	10.27	0.43	2.01e-22	Corneal astigmatism;
LGG	cis	rs2576037	0.583	rs892586	chr18:44560429	C/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.53	8.98	0.39	6.98e-18	Personality dimensions;
LGG	cis	rs9790314	1.000	rs336543	chr3:161061080	C/T	cg04691961	chr3:161091175	C3orf57	0.63	15.04	0.57	6.66e-42	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.559	rs132768	chr22:42013523	C/A	cg03806693	chr22:41940476	POLR3H	1.05	17.74	0.64	4.31e-54	Vitiligo;
LGG	cis	rs4774830	0.744	rs62046386	chr15:56305252	G/A	cg05129572	chr15:56138634	NEDD4	0.71	6.9	0.31	1.75e-11	Delta-5 desaturase activity;
LGG	cis	rs7106204	1.000	rs35876423	chr11:24214859	G/T	ch.11.24196551F	chr11:24239977	NA	0.97	12.43	0.5	8.38e-31	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.68	12.31	0.5	2.61e-30	Obesity-related traits;
LGG	cis	rs9818758	0.607	rs55873331	chr3:49597055	C/T	cg00383909	chr3:49044727	WDR6	1.11	13.18	0.52	6.3e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg09307838	chr4:120376055	NA	0.81	13.59	0.53	1.19e-35	Corneal astigmatism;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.46	0.58	8.66e-44	Platelet count;
LGG	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg00129232	chr17:37814104	STARD3	0.48	9.02	0.39	5.18e-18	Self-reported allergy;
LGG	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17376030	chr22:41985996	PMM1	0.54	8.58	0.37	1.48e-16	Vitiligo;
LGG	cis	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg21775007	chr8:11205619	TDH	-0.44	-7.23	-0.32	2.06e-12	Systolic blood pressure;
LGG	cis	rs6460942	0.841	rs62448597	chr7:12449110	G/C	cg06484146	chr7:12443880	VWDE	-0.41	-7.22	-0.32	2.15e-12	Coronary artery disease;
LGG	trans	rs1005277	0.602	rs1740743	chr10:38519222	C/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs9487051	0.836	rs9400270	chr6:109607488	G/A	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg01585723	chr16:33734837	NA	0.47	8.14	0.35	3.72e-15	Menopause (age at onset);
LGG	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg16141378	chr3:129829833	LOC729375	0.33	7.45	0.33	4.47e-13	Triglycerides;
LGG	cis	rs4481887	0.790	rs4382760	chr1:248422343	A/C	cg13385794	chr1:248469461	NA	-0.43	-7.1	-0.31	4.75e-12	Common traits (Other);
LGG	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg13010199	chr12:38710504	ALG10B	0.63	12.68	0.51	7.62e-32	Morning vs. evening chronotype;
LGG	cis	rs2013441	1.000	rs17686839	chr17:20039171	A/G	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg17971929	chr21:40555470	PSMG1	0.54	9.07	0.39	3.43e-18	Menarche (age at onset);
LGG	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg13607699	chr17:42295918	UBTF	-0.41	-6.65	-0.3	8.47e-11	Total body bone mineral density;
LGG	cis	rs62244186	0.659	rs9311358	chr3:44538748	C/G	cg02073558	chr3:44770973	ZNF501	0.68	12.67	0.51	8.84e-32	Depressive symptoms;
LGG	cis	rs12780845	0.522	rs10904895	chr10:17220609	C/G	cg01003015	chr10:17271136	VIM	-0.45	-7.67	-0.34	1.01e-13	Homocysteine levels;
LGG	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg11584989	chr19:19387371	SF4	-0.41	-7.28	-0.32	1.46e-12	Tonsillectomy;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.31	-0.36	1.07e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs8141529	0.778	rs7287806	chr22:29213011	G/A	cg02153584	chr22:29168773	CCDC117	0.69	11.53	0.47	3.14e-27	Lymphocyte counts;
LGG	cis	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg26384229	chr12:38710491	ALG10B	0.84	18.51	0.65	1.19e-57	Bladder cancer;
LGG	cis	rs7945718	0.805	rs11022510	chr11:12833262	G/A	cg25843174	chr11:12811716	TEAD1	0.37	7.44	0.33	4.98e-13	Educational attainment (years of education);
LGG	cis	rs4242434	0.672	rs900266	chr8:22485295	A/T	cg19455335	chr8:22457658	C8orf58	-0.39	-8.11	-0.35	4.6e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg02002194	chr4:3960332	NA	-0.48	-8.84	-0.38	2.05e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs67133203	0.579	rs1038526	chr12:51484145	T/C	cg14688905	chr12:51403056	SLC11A2	-0.52	-8.78	-0.38	3.22e-17	Urinary tract infection frequency;
LGG	cis	rs3806843	1.000	rs6898939	chr5:140169355	C/A	cg19875535	chr5:140030758	IK	0.51	10.67	0.44	6.5e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs910316	1.000	rs4903284	chr14:75592483	G/C	cg08847533	chr14:75593920	NEK9	0.62	11.88	0.48	1.4e-28	Height;
LGG	cis	rs2762353	0.718	rs1184804	chr6:25868226	T/C	cg07061783	chr6:25882402	NA	-0.39	-7.0	-0.31	8.99e-12	Blood metabolite levels;
LGG	cis	rs7615952	1.000	rs7616044	chr3:125649354	G/C	cg05084668	chr3:125655381	ALG1L	-0.87	-11.02	-0.46	2.95e-25	Blood pressure (smoking interaction);
LGG	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-7.52	-0.33	2.86e-13	Bronchopulmonary dysplasia;
LGG	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg22643751	chr7:855365	UNC84A	-0.43	-7.51	-0.33	3e-13	Cerebrospinal P-tau181p levels;
LGG	trans	rs9650657	0.836	rs1073913	chr8:10611708	A/C	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.07	-0.31	5.62e-12	Neuroticism;
LGG	trans	rs3206736	0.548	rs17793874	chr7:35065558	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.29	0.32	1.35e-12	Diastolic blood pressure;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.88	-0.34	2.42e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.76	-0.38	3.82e-17	Life satisfaction;
LGG	cis	rs67311347	0.544	rs9877105	chr3:40333366	T/C	cg13683864	chr3:40499215	RPL14	-0.82	-16.46	-0.61	2.86e-48	Renal cell carcinoma;
LGG	trans	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.18	0.43	4.08e-22	Retinal vascular caliber;
LGG	cis	rs4356203	0.783	rs7113964	chr11:17255921	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.76e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17953633	chr17:34957751	MRM1	0.44	6.99	0.31	9.56e-12	Gut microbiome composition (summer);
LGG	cis	rs950169	0.580	rs36126054	chr15:85177723	T/G	cg24253500	chr15:84953950	NA	0.41	6.96	0.31	1.18e-11	Schizophrenia;
LGG	cis	rs12579753	0.667	rs7485761	chr12:82301259	C/G	cg07988820	chr12:82153109	PPFIA2	-0.49	-7.24	-0.32	1.87e-12	Resting heart rate;
LGG	cis	rs7582180	0.663	rs2053263	chr2:100971407	A/G	cg14675211	chr2:100938903	LONRF2	0.62	10.97	0.45	4.69e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg02462569	chr6:150064036	NUP43	-0.4	-8.5	-0.37	2.63e-16	Lung cancer;
LGG	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg17691542	chr6:26056736	HIST1H1C	0.64	10.46	0.44	3.91e-23	Iron status biomarkers;
LGG	cis	rs11098499	0.863	rs11098531	chr4:120465001	G/A	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.09e-25	Corneal astigmatism;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.39	0.56	4.47e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.97	0.49	6.09e-29	Hip circumference adjusted for BMI;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg00713939	chr8:144660590	NAPRT1	-0.73	-8.36	-0.36	7.14e-16	Attention deficit hyperactivity disorder;
LGG	cis	rs15676	1.000	rs15676	chr9:131572027	A/G	cg04621255	chr9:131581398	ENDOG	0.39	6.96	0.31	1.15e-11	Blood metabolite levels;
LGG	cis	rs7927771	0.832	rs7940536	chr11:47395240	G/A	cg20307385	chr11:47447363	PSMC3	0.57	10.49	0.44	3.17e-23	Subjective well-being;
LGG	cis	rs7267979	0.966	rs6050567	chr20:25354561	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg02428538	chr16:24856791	SLC5A11	0.72	10.96	0.45	5.17e-25	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg13395646	chr4:1353034	KIAA1530	0.49	8.32	0.36	1.02e-15	Obesity-related traits;
LGG	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-12.8	-0.51	2.6e-32	Response to antipsychotic treatment;
LGG	cis	rs7208859	0.673	rs11657270	chr17:29214387	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.76	0.38	3.75e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg22963979	chr7:1858916	MAD1L1	-0.49	-10.22	-0.43	3.11e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs2980439	0.525	rs2945238	chr8:8170136	A/C	cg08975724	chr8:8085496	FLJ10661	0.42	8.13	0.35	3.82e-15	Neuroticism;
LGG	cis	rs826838	0.616	rs4619214	chr12:38614704	C/A	cg26384229	chr12:38710491	ALG10B	0.71	14.49	0.56	1.61e-39	Heart rate;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	5.87e-19	Fuchs's corneal dystrophy;
LGG	trans	rs11088226	0.581	rs1967870	chr21:33882858	A/G	cg09050820	chr6:167586206	TCP10L2	0.49	7.97	0.35	1.22e-14	Gastritis;
LGG	cis	rs6988985	0.560	rs7826809	chr8:143925609	C/T	cg10324643	chr8:143916377	GML	0.45	9.25	0.39	8.41e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg03929089	chr4:120376271	NA	-0.43	-6.94	-0.31	1.3e-11	HDL cholesterol;
LGG	cis	rs7762018	0.607	rs75521584	chr6:170051595	T/C	cg19338460	chr6:170058176	WDR27	-0.83	-8.57	-0.37	1.51e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12410462	0.515	rs1845760	chr1:227714702	A/C	cg23173402	chr1:227635558	NA	-0.36	-6.87	-0.3	2.15e-11	Major depressive disorder;
LGG	cis	rs7617480	0.587	rs9311431	chr3:48848787	T/A	cg07636037	chr3:49044803	WDR6	0.9	16.29	0.6	1.68e-47	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs858239	0.669	rs12539467	chr7:23115859	A/G	cg23682824	chr7:23144976	KLHL7	0.45	7.84	0.34	3.2e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.72	-0.56	1.64e-40	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs35160687	0.644	rs4832274	chr2:86529084	C/G	cg10973622	chr2:86423274	IMMT	-0.39	-6.89	-0.31	1.8e-11	Night sleep phenotypes;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.6	0.65	4.5e-58	Menopause (age at onset);
LGG	cis	rs4727027	0.901	rs34201592	chr7:148842403	C/G	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.55e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7954584	0.520	rs1169096	chr12:122465836	G/C	cg22618164	chr12:122356400	WDR66	-0.31	-8.5	-0.37	2.54e-16	Mean corpuscular volume;
LGG	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg27476859	chr7:2772710	GNA12	0.5	9.77	0.41	1.31e-20	Height;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg04503457	chr17:41445688	NA	-0.4	-9.95	-0.42	2.8e-21	Menopause (age at onset);
LGG	cis	rs9393692	0.645	rs766406	chr6:26319588	G/T	cg16885296	chr6:26284938	NA	0.4	8.28	0.36	1.36e-15	Educational attainment;
LGG	cis	rs12220238	0.915	rs10824148	chr10:76078014	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.88	0.38	1.44e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs2933343	0.621	rs789249	chr3:128578453	T/C	cg11901034	chr3:128598214	ACAD9	-0.45	-6.82	-0.3	2.92e-11	IgG glycosylation;
LGG	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg09021430	chr5:549028	NA	-0.69	-9.52	-0.4	9.4e-20	Obesity-related traits;
LGG	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10851411	0.657	rs1048571	chr15:42862024	A/G	cg21293051	chr15:42870591	STARD9	0.5	7.19	0.32	2.67e-12	Glucose homeostasis traits;
LGG	cis	rs9926296	0.509	rs2159113	chr16:89832083	C/T	cg27121462	chr16:89883253	FANCA	0.46	7.41	0.33	5.88e-13	Vitiligo;
LGG	cis	rs7918232	0.941	rs7907988	chr10:27444344	T/G	cg14240646	chr10:27532245	ACBD5	-0.74	-10.35	-0.43	1.02e-22	Breast cancer;
LGG	cis	rs11123610	0.520	rs11682697	chr2:3721127	A/G	cg26344334	chr2:3718215	ALLC	-0.49	-8.34	-0.36	8.55e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9287719	0.967	rs759402	chr2:10729554	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs208515	0.560	rs207084	chr6:66776966	T/C	cg07460842	chr6:66804631	NA	-1.09	-27.36	-0.79	9e-99	Exhaled nitric oxide levels;
LGG	cis	rs7044106	0.762	rs1547267	chr9:123408736	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.22	0.32	2.09e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4742903	0.967	rs7048372	chr9:106859738	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.5e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs4689388	0.926	rs4416547	chr4:6293967	G/A	cg14416269	chr4:6271139	WFS1	0.51	9.34	0.4	4.12e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs727505	0.564	rs4731236	chr7:124827236	G/T	cg23710748	chr7:124431027	NA	-0.44	-8.44	-0.37	4.12e-16	Lewy body disease;
LGG	cis	rs7959452	0.719	rs57954211	chr12:69748397	C/A	cg22834771	chr12:69754056	YEATS4	-0.42	-7.22	-0.32	2.2e-12	Blood protein levels;
LGG	cis	rs7215564	0.908	rs56078934	chr17:78658849	A/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.32	-0.36	9.89e-16	Myopia (pathological);
LGG	cis	rs4262150	0.810	rs17566146	chr5:152088959	C/G	cg12297329	chr5:152029980	NA	-0.73	-13.62	-0.53	9.46e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.4	0.4	2.42e-19	Gout;Renal underexcretion gout;
LGG	cis	rs10865541	1.000	rs10165099	chr2:3402591	T/C	cg11642891	chr2:3452563	TTC15	-0.42	-8.09	-0.35	5.18e-15	Obesity-related traits;
LGG	cis	rs7851660	0.809	rs7048255	chr9:100665698	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	trans	rs1814175	0.817	rs10839401	chr11:49876144	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.11	-0.49	1.65e-29	Height;
LGG	cis	rs1348850	0.918	rs4893966	chr2:178470138	A/G	cg27490568	chr2:178487706	NA	0.47	9.25	0.4	8.05e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4731207	0.565	rs6977613	chr7:124681791	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.42	-0.33	5.54e-13	Cutaneous malignant melanoma;
LGG	cis	rs528418	0.592	rs6935932	chr6:145678634	A/G	cg03642472	chr6:145670687	NA	0.57	7.41	0.33	5.84e-13	Methadone dose in opioid dependence;
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.85	0.34	2.9e-14	Schizophrenia;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.1	0.64	8.82e-56	Personality dimensions;
LGG	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.08	-0.35	5.58e-15	Bone mineral density;
LGG	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg11890956	chr21:40555474	PSMG1	-0.95	-19.14	-0.66	1.44e-60	Cognitive function;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.5	-0.4	1.11e-19	Monocyte percentage of white cells;
LGG	cis	rs1552244	0.882	rs68153882	chr3:10013110	T/C	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.05	-0.39	4.09e-18	Obesity-related traits;
LGG	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg11266682	chr4:10021025	SLC2A9	-0.44	-8.15	-0.35	3.36e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28374715	0.681	rs7162231	chr15:41591859	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.28	-29.79	-0.81	1.11e-109	Ulcerative colitis;
LGG	cis	rs78456975	0.574	rs13412980	chr2:1545231	C/A	cg12573674	chr2:1569213	NA	-0.59	-8.13	-0.35	4.11e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9815354	0.812	rs17216919	chr3:41888938	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2839186	0.739	rs7282763	chr21:47696800	C/T	cg11766577	chr21:47581405	C21orf56	-0.48	-8.57	-0.37	1.58e-16	Testicular germ cell tumor;
LGG	cis	rs5750830	0.649	rs5750822	chr22:39826788	C/T	cg04986931	chr22:39850128	NA	0.36	8.19	0.36	2.57e-15	Intelligence (multi-trait analysis);
LGG	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg07882059	chr11:68924751	NA	0.42	7.38	0.32	7.31e-13	Blond vs. brown hair color;
LGG	cis	rs7208859	0.623	rs9915566	chr17:29132158	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.14	-0.35	3.69e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6951245	1.000	rs78523927	chr7:1089458	T/C	cg04025307	chr7:1156635	C7orf50	0.65	8.47	0.37	3.3e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04008888	chr11:68622739	NA	0.51	11.18	0.46	7.28e-26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9329221	0.682	rs6982308	chr8:10193772	C/G	cg02002194	chr4:3960332	NA	0.48	9.09	0.39	3.02e-18	Neuroticism;
LGG	cis	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg13010199	chr12:38710504	ALG10B	-0.51	-10.15	-0.43	5.53e-22	Bladder cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg14428767	chr6:149867359	PPIL4	0.43	6.92	0.31	1.47e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7174348	1	rs7174348	chr15:78792439	G/A	cg06917634	chr15:78832804	PSMA4	-0.52	-7.92	-0.35	1.75e-14	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.98	-0.31	1.05e-11	Retinal vascular caliber;
LGG	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg16751781	chr15:78858589	CHRNA5	-0.37	-6.83	-0.3	2.67e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs4942242	0.663	rs9525815	chr13:44223692	T/C	cg19169023	chr15:41853346	TYRO3	-0.45	-8.81	-0.38	2.48e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs736408	0.546	rs3733046	chr3:52621627	C/T	cg11645453	chr3:52864694	ITIH4	0.4	6.74	0.3	4.69e-11	Bipolar disorder;
LGG	cis	rs6547631	0.622	rs1866141	chr2:85925386	T/C	cg19805943	chr2:85933069	NA	0.32	6.73	0.3	5.17e-11	Blood protein levels;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.26	0.36	1.53e-15	Prudent dietary pattern;
LGG	cis	rs3820068	0.603	rs7536654	chr1:15989141	C/G	cg05660106	chr1:15850417	CASP9	0.83	17.36	0.63	2.21e-52	Systolic blood pressure;
LGG	cis	rs2762353	0.935	rs3757130	chr6:25770866	C/T	cg12310025	chr6:25882481	NA	0.5	9.28	0.4	6.47e-19	Blood metabolite levels;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	cis	rs597539	0.690	rs647661	chr11:68625875	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.36	0.58	2.38e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12447804	0.645	rs12447745	chr16:58117833	T/C	cg03859792	chr16:58121049	NA	0.6	9.09	0.39	3.01e-18	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9527	0.571	rs7096249	chr10:104618524	G/A	cg04362960	chr10:104952993	NT5C2	0.53	9.65	0.41	3.4e-20	Arsenic metabolism;
LGG	cis	rs10193935	0.792	rs10204778	chr2:42498121	G/T	cg27598129	chr2:42591480	NA	-0.64	-9.71	-0.41	2.09e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8053891	0.855	rs6499553	chr16:71996715	C/T	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.79	-0.3	3.54e-11	Coronary artery disease;
LGG	cis	rs6815814	0.898	rs5743592	chr4:38803063	A/G	cg06935464	chr4:38784597	TLR10	0.61	8.34	0.36	8.47e-16	Breast cancer;
LGG	cis	rs6061231	0.556	rs6121571	chr20:60977323	T/G	cg22601191	chr20:60968625	CABLES2	0.44	8.24	0.36	1.72e-15	Colorectal cancer;
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg20120463	chr17:44301886	NA	-0.47	-7.34	-0.32	9.41e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3806843	0.576	rs246009	chr5:140338069	A/G	cg19875535	chr5:140030758	IK	-0.38	-7.56	-0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg06873352	chr17:61820015	STRADA	0.73	13.6	0.53	1.08e-35	Prudent dietary pattern;
LGG	cis	rs17376456	0.877	rs12374488	chr5:93481407	A/G	cg19507638	chr5:93509721	C5orf36	-0.73	-9.97	-0.42	2.42e-21	Diabetic retinopathy;
LGG	cis	rs9611565	0.649	rs738422	chr22:42123399	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.12	-0.39	2.26e-18	Vitiligo;
LGG	cis	rs7666738	0.830	rs35560671	chr4:99069095	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs870825	0.616	rs79884757	chr4:185621454	A/G	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg02254774	chr11:50257496	LOC441601	0.57	6.72	0.3	5.3e-11	Myopia (pathological);
LGG	cis	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.06e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs6582630	0.555	rs11182193	chr12:38474090	C/G	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7226408	0.857	rs10502667	chr18:34482449	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs9611565	0.580	rs5758449	chr22:42140160	C/T	cg03806693	chr22:41940476	POLR3H	0.89	14.9	0.57	2.66e-41	Vitiligo;
LGG	cis	rs597583	0.806	rs4938397	chr11:117392337	G/T	cg27161313	chr11:117392002	DSCAML1	-0.51	-8.32	-0.36	9.83e-16	Putamen volume;
LGG	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.85	10.59	0.44	1.29e-23	Lung cancer in ever smokers;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.41	-7.88	-0.34	2.44e-14	Personality dimensions;
LGG	cis	rs17539620	0.624	rs62432743	chr6:154836214	T/G	cg17771515	chr6:154831774	CNKSR3	0.61	7.49	0.33	3.44e-13	Lipoprotein (a) levels;
LGG	cis	rs372883	0.901	rs13048365	chr21:30740394	T/C	cg24692254	chr21:30365293	RNF160	0.44	7.7	0.34	8.38e-14	Pancreatic cancer;
LGG	cis	rs4734806	1.000	rs13251577	chr8:105713738	A/G	cg01675814	chr8:105601641	LRP12	-0.5	-6.9	-0.31	1.76e-11	Periodontitis (DPAL);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg09699651	chr6:150184138	LRP11	0.53	9.55	0.41	7.46e-20	Lung cancer;
LGG	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-11.41	-0.47	9.29e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs9560113	0.922	rs4773377	chr13:112174152	G/C	cg10483660	chr13:112241077	NA	0.34	6.77	0.3	3.87e-11	Menarche (age at onset);
LGG	cis	rs9926296	0.572	rs8046872	chr16:89841552	T/C	cg03605463	chr16:89740564	NA	-0.39	-6.77	-0.3	3.97e-11	Vitiligo;
LGG	cis	rs2797369	0.656	rs2770331	chr6:101585854	G/T	cg27451362	chr6:101846650	GRIK2	0.83	11.44	0.47	7.46e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs73086581	1.000	rs73086510	chr20:3922131	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.46	0.47	6.39e-27	Response to antidepressants in depression;
LGG	cis	rs9399137	0.507	rs13064	chr6:135287533	A/G	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg02725872	chr8:58115012	NA	-0.76	-10.91	-0.45	8.07e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs57024841	0.500	rs10116414	chr9:139831696	C/T	cg00693599	chr9:139836323	FBXW5	0.42	7.33	0.32	1.03e-12	Beta-trace protein levels;
LGG	cis	rs2046867	0.908	rs868336	chr3:72818165	A/C	cg26655873	chr3:72818019	SHQ1	0.36	7.37	0.32	7.77e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7726839	0.561	rs56410216	chr5:583216	C/A	cg07777115	chr5:623756	CEP72	-0.52	-7.01	-0.31	8.47e-12	Obesity-related traits;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg17663101	chr3:49131524	QRICH1	-0.47	-6.94	-0.31	1.32e-11	Pancreatic cancer;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	17.66	0.63	9.34e-54	Platelet count;
LGG	cis	rs9457247	0.508	rs6902119	chr6:167505791	T/C	cg07741184	chr6:167504864	NA	0.37	8.76	0.38	3.68e-17	Crohn's disease;
LGG	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg17971929	chr21:40555470	PSMG1	0.87	17.36	0.63	2.21e-52	Cognitive function;
LGG	cis	rs2120243	0.539	rs9857875	chr3:157078897	C/T	cg24825693	chr3:157122686	VEPH1	-0.51	-11.2	-0.46	6.51e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs78487399	0.808	rs74365854	chr2:43661482	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	14.55	0.56	8.99e-40	Platelet count;
LGG	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg11764359	chr7:65958608	NA	0.77	14.4	0.56	4.05e-39	Aortic root size;
LGG	cis	rs959260	0.528	rs9909443	chr17:73308346	C/T	cg14668889	chr17:73230827	NUP85	0.56	9.26	0.4	7.73e-19	Systemic lupus erythematosus;
LGG	trans	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg10756647	chr7:56101905	PSPH	0.83	9.79	0.41	1.05e-20	Diabetic kidney disease;
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.817	rs240110	chr6:101059629	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.41	0.33	5.94e-13	Neuroticism;
LGG	cis	rs9534288	0.797	rs9534287	chr13:46603926	A/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.49e-34	Blood protein levels;
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg15537850	chr8:144661051	NAPRT1	0.99	7.53	0.33	2.71e-13	Attention deficit hyperactivity disorder;
LGG	trans	rs12310956	0.510	rs10844690	chr12:33854752	C/A	cg26384229	chr12:38710491	ALG10B	0.63	12.14	0.49	1.18e-29	Morning vs. evening chronotype;
LGG	trans	rs2562456	0.833	rs11671609	chr19:21525571	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs10991814	0.841	rs7029087	chr9:94061633	A/G	cg14446406	chr9:93919335	NA	-0.69	-7.8	-0.34	4.02e-14	Neutrophil percentage of granulocytes;
LGG	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg05677249	chr15:77158041	SCAPER	-0.31	-6.75	-0.3	4.43e-11	Blood metabolite levels;
LGG	cis	rs9303401	0.614	rs34920953	chr17:56589406	G/A	cg25039879	chr17:56429692	SUPT4H1	0.66	9.23	0.39	9.75e-19	Cognitive test performance;
LGG	cis	rs921968	0.541	rs7603816	chr2:219396255	C/T	cg01130898	chr2:219473002	PLCD4	0.42	7.3	0.32	1.28e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.58	10.1	0.42	8.27e-22	Birth weight;
LGG	cis	rs34172651	0.517	rs2303084	chr16:24834581	G/C	cg06028605	chr16:24865363	SLC5A11	0.5	8.28	0.36	1.33e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg02002194	chr4:3960332	NA	0.36	6.68	0.3	6.9e-11	Mood instability;
LGG	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg03476357	chr21:30257390	N6AMT1	-0.52	-7.75	-0.34	5.89e-14	Cognitive test performance;
LGG	cis	rs6761276	0.727	rs6743376	chr2:113832333	C/A	cg05949173	chr2:113825882	IL1F10	0.38	7.0	0.31	8.77e-12	Protein quantitative trait loci;
LGG	cis	rs6088590	1.000	rs2180276	chr20:33360785	T/A	cg24642439	chr20:33292090	TP53INP2	0.83	15.32	0.58	3.62e-43	Coronary artery disease;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.11	-0.57	3.1e-42	Platelet count;
LGG	cis	rs7474896	0.583	rs34185758	chr10:37990854	T/C	cg25427524	chr10:38739819	LOC399744	-0.45	-6.75	-0.3	4.37e-11	Obesity (extreme);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04729594	chr2:33172444	LTBP1	0.43	7.92	0.35	1.74e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs17209837	0.607	rs17149644	chr7:87086218	T/C	cg25823085	chr7:87105416	ABCB4	0.3	7.43	0.33	5.35e-13	Gallbladder cancer;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs72945132	0.882	rs67093918	chr11:70198999	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	cis	rs2180341	1.000	rs6569478	chr6:127598619	G/A	cg24812749	chr6:127587940	RNF146	0.97	16.06	0.6	1.86e-46	Breast cancer;
LGG	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg03476357	chr21:30257390	N6AMT1	-0.44	-7.36	-0.32	8.23e-13	Cognitive test performance;
LGG	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.03	26.38	0.77	2.77e-94	Chronic sinus infection;
LGG	cis	rs9611565	0.694	rs202622	chr22:41825342	T/G	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-9.75	-0.41	1.49e-20	Personality dimensions;
LGG	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg17077180	chr1:38461687	NA	-0.55	-14.06	-0.55	1.25e-37	Coronary artery disease;
LGG	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg11764359	chr7:65958608	NA	0.8	14.96	0.57	1.43e-41	Aortic root size;
LGG	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-16.76	-0.61	1.28e-49	Vitiligo;
LGG	cis	rs6459788	0.693	rs35146559	chr7:157238557	G/A	cg05333889	chr7:157238977	NA	-0.52	-9.94	-0.42	3.19e-21	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs427394	0.743	rs274716	chr5:6722289	T/C	cg10857441	chr5:6722123	POLS	-0.3	-7.06	-0.31	6.22e-12	Menopause (age at onset);
LGG	cis	rs514406	0.861	rs7513052	chr1:53241360	C/T	cg24675658	chr1:53192096	ZYG11B	0.49	10.07	0.42	1.08e-21	Monocyte count;
LGG	cis	rs2905347	0.726	rs2961294	chr7:22695031	T/C	cg23521230	chr7:22704884	NA	0.39	7.1	0.31	4.67e-12	Major depression and alcohol dependence;
LGG	cis	rs2688608	0.588	rs10128205	chr10:75469648	C/G	cg19442545	chr10:75533431	FUT11	-0.45	-7.36	-0.32	8.42e-13	Inflammatory bowel disease;
LGG	cis	rs7168592	1.000	rs28576902	chr15:101725618	A/C	cg24254196	chr15:101719523	CHSY1	0.62	6.99	0.31	9.95e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs8005677	1.000	rs2295683	chr14:23388382	A/C	cg01529538	chr14:23388837	RBM23	0.37	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg09699651	chr6:150184138	LRP11	0.47	8.3	0.36	1.15e-15	Lung cancer;
LGG	cis	rs1552244	1.000	rs33917318	chr3:10067797	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.39	0.69	2.06e-66	Alzheimer's disease;
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.97	-0.31	1.12e-11	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs7998202	0.614	rs282573	chr13:113362105	G/A	cg17218041	chr13:113365319	ATP11A	-0.44	-7.18	-0.32	2.84e-12	Glycated hemoglobin levels;
LGG	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg04568710	chr12:38710424	ALG10B	-0.34	-7.08	-0.31	5.41e-12	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.569	rs6881815	chr5:93105666	A/G	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg11360546	chr7:1094263	C7orf50	-0.39	-7.14	-0.32	3.52e-12	Longevity;Endometriosis;
LGG	cis	rs9527	0.590	rs1926029	chr10:104855670	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.17	-0.32	2.9e-12	Arsenic metabolism;
LGG	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg19455335	chr8:22457658	C8orf58	-0.39	-8.06	-0.35	6.7e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.65	-11.03	-0.46	2.86e-25	Coronary artery disease;
LGG	cis	rs61931739	0.500	rs3922568	chr12:34560107	A/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	cis	rs7811142	1.000	rs112317829	chr7:100043173	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs7666738	0.830	rs10025174	chr4:98914172	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7089973	0.624	rs11196940	chr10:116593791	T/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.26	0.32	1.63e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9322193	0.926	rs2342860	chr6:150098777	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg26384229	chr12:38710491	ALG10B	-0.62	-11.3	-0.46	2.51e-26	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11969893	0.737	rs1358758	chr6:101411891	T/C	cg12253828	chr6:101329408	ASCC3	0.97	8.44	0.37	4.09e-16	Economic and political preferences (immigration/crime);
LGG	cis	rs7786808	0.705	rs1377373	chr7:158215549	A/C	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.84	-0.34	3.04e-14	Obesity-related traits;
LGG	cis	rs11599315	0.757	rs11250392	chr10:1342543	T/C	cg01270228	chr10:1369114	ADARB2	0.6	10.68	0.44	5.88e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7011049	1.000	rs113124539	chr8:53854321	G/A	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs10875746	0.551	rs3185921	chr12:48734731	C/T	cg24011408	chr12:48396354	COL2A1	-0.56	-7.13	-0.31	3.91e-12	Longevity (90 years and older);
LGG	trans	rs9393777	0.920	rs67859638	chr6:27357978	A/G	cg01620082	chr3:125678407	NA	-1.05	-9.87	-0.42	5.69e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.770	rs11121695	chr1:11229515	G/A	cg08854313	chr1:11322531	MTOR	-0.71	-14.58	-0.56	6.44e-40	Body mass index;
LGG	cis	rs62400317	0.762	rs12212190	chr6:44926271	T/C	cg20913747	chr6:44695427	NA	-0.65	-11.21	-0.46	5.99e-26	Total body bone mineral density;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.36e-18	Height;
LGG	cis	rs7267979	0.816	rs6076358	chr20:25519403	G/T	cg06421707	chr20:25228305	PYGB	-0.43	-9.0	-0.39	5.84e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9462027	0.628	rs2744944	chr6:34658080	A/C	cg07306190	chr6:34760872	UHRF1BP1	0.51	10.25	0.43	2.41e-22	Systemic lupus erythematosus;
LGG	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	cis	rs6138458	0.626	rs6138473	chr20:25012155	A/G	cg26195577	chr20:24973756	C20orf3	-0.87	-16.09	-0.6	1.39e-46	Blood protein levels;
LGG	cis	rs1580019	0.563	rs4723169	chr7:32567577	G/A	cg06133097	chr7:32552212	AVL9	-0.4	-7.61	-0.33	1.59e-13	Cognitive ability;
LGG	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg01620082	chr3:125678407	NA	-1.02	-9.24	-0.39	8.88e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg10852222	chr5:149380144	HMGXB3;TIGD6	-0.6	-7.88	-0.34	2.37e-14	HIV-1 control;
LGG	cis	rs757110	0.745	rs10734252	chr11:17404839	G/A	cg15432903	chr11:17409602	KCNJ11	0.83	17.78	0.64	2.84e-54	Type 2 diabetes;
LGG	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs10791323	0.569	rs1119852	chr11:133743022	C/A	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs9486719	0.947	rs2472908	chr6:96875998	A/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02625641	chr15:59041175	ADAM10	0.46	7.53	0.33	2.63e-13	Cognitive performance;
LGG	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg22348356	chr13:114891224	RASA3	0.4	7.74	0.34	6.22e-14	Schizophrenia;
LGG	cis	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg11905131	chr22:24372483	LOC391322	-0.44	-7.85	-0.34	2.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg14191688	chr11:70257035	CTTN	0.6	8.49	0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs6840360	0.571	rs11932059	chr4:152524496	G/A	cg25486957	chr4:152246857	NA	-0.49	-8.11	-0.35	4.43e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9393692	0.620	rs9358916	chr6:26283185	G/A	cg13736514	chr6:26305472	NA	-0.45	-9.02	-0.39	5.15e-18	Educational attainment;
LGG	cis	rs17345786	0.798	rs1609159	chr3:101275902	A/C	cg12386194	chr3:101231763	SENP7	0.6	10.7	0.45	5.14e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12091966	0.632	rs4388693	chr1:231220364	G/A	cg26538035	chr1:231178722	NA	0.35	6.72	0.3	5.34e-11	Interleukin-4 levels;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.46	8.01	0.35	9.09e-15	Longevity;
LGG	cis	rs8049040	0.609	rs7188858	chr16:71468895	T/C	cg08717414	chr16:71523259	ZNF19	-0.53	-8.49	-0.37	2.86e-16	Blood protein levels;
LGG	cis	rs1318772	0.932	rs67382821	chr5:112902324	C/G	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	cis	rs9534288	0.699	rs1467665	chr13:46662919	C/T	cg15192986	chr13:46630673	CPB2	-0.68	-14.03	-0.55	1.66e-37	Blood protein levels;
LGG	trans	rs7395662	1.000	rs6485903	chr11:48639004	G/A	cg00717180	chr2:96193071	NA	-0.44	-7.64	-0.33	1.23e-13	HDL cholesterol;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg04703951	chr17:43578652	NA	-0.36	-7.46	-0.33	4.45e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg03264133	chr6:25882463	NA	-0.87	-16.5	-0.61	1.96e-48	Intelligence (multi-trait analysis);
LGG	cis	rs854765	0.647	rs741782	chr17:18019712	T/C	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.88	-0.51	1.14e-32	Total body bone mineral density;
LGG	cis	rs798554	0.591	rs1182156	chr7:2901084	G/T	cg27476859	chr7:2772710	GNA12	0.47	9.04	0.39	4.45e-18	Height;
LGG	cis	rs4595586	0.545	rs11615634	chr12:39364704	A/C	cg26384229	chr12:38710491	ALG10B	0.59	10.93	0.45	6.93e-25	Morning vs. evening chronotype;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg23302884	chr18:44338147	ST8SIA5	0.46	9.1	0.39	2.71e-18	Personality dimensions;
LGG	cis	rs2742417	0.603	rs2742456	chr3:45767176	C/T	cg04837898	chr3:45731254	SACM1L	-0.48	-9.52	-0.4	9.54e-20	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg21775007	chr8:11205619	TDH	0.44	6.84	0.3	2.44e-11	Morning vs. evening chronotype;
LGG	cis	rs4764487	0.735	rs3181291	chr12:6341499	C/T	cg08284733	chr12:6341482	CD9	0.37	10.18	0.43	4.41e-22	Mean platelet volume;
LGG	cis	rs79349575	0.783	rs12453374	chr17:46994846	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs459571	0.916	rs109536	chr9:136889987	G/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.72	-12.36	-0.5	1.62e-30	Platelet distribution width;
LGG	cis	rs258892	0.895	rs13174766	chr5:72057135	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.74	-0.3	4.77e-11	Small cell lung carcinoma;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg26656751	chr17:43910226	CRHR1	-0.43	-7.9	-0.34	2.05e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1847202	1.000	rs7634188	chr3:72941289	A/G	cg25664220	chr3:72788482	NA	0.24	7.37	0.32	7.76e-13	Motion sickness;
LGG	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg15841412	chr13:111365552	ING1	-0.44	-6.99	-0.31	9.49e-12	Coronary artery disease;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg24829409	chr8:58192753	C8orf71	-0.62	-8.26	-0.36	1.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg10802521	chr3:52805072	NEK4	-0.45	-7.78	-0.34	4.61e-14	Bipolar disorder;
LGG	cis	rs36093844	0.706	rs7102361	chr11:85560139	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.34	-0.32	9.83e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs1552244	0.572	rs3894321	chr3:10168892	A/C	cg00166722	chr3:10149974	C3orf24	0.54	8.08	0.35	5.49e-15	Alzheimer's disease;
LGG	cis	rs9814567	1.000	rs62271515	chr3:134300507	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2227564	0.649	rs2242258	chr10:75607168	T/C	cg00564723	chr10:75632066	CAMK2G	0.51	10.91	0.45	8.39e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11098499	1.000	rs3749591	chr4:120214030	T/G	cg09307838	chr4:120376055	NA	0.71	11.4	0.47	1.03e-26	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs4869812	chr6:149990583	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.96	0.54	3.1e-37	Lung cancer;
LGG	cis	rs941408	0.890	rs1640269	chr19:2793194	A/C	cg06609049	chr19:2785107	THOP1	0.66	10.23	0.43	2.74e-22	Total cholesterol levels;
LGG	cis	rs459571	0.920	rs2520094	chr9:136919985	A/T	cg13789015	chr9:136890014	NCRNA00094	0.56	10.53	0.44	2.18e-23	Platelet distribution width;
LGG	cis	rs295140	1.000	rs10931897	chr2:201162520	T/C	cg25099087	chr2:201172481	SPATS2L	0.27	6.71	0.3	5.66e-11	QT interval;
LGG	cis	rs9926296	0.605	rs886952	chr16:89836781	G/A	cg07440826	chr16:89882328	FANCA	-0.26	-7.05	-0.31	6.51e-12	Vitiligo;
LGG	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.26	0.32	1.61e-12	Electroencephalogram traits;
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg04287289	chr16:89883240	FANCA	0.84	8.04	0.35	7.52e-15	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg12070911	chr6:150209640	RAET1E	0.31	7.69	0.34	9.01e-14	Lung cancer;
LGG	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.74e-14	Neuroticism;
LGG	cis	rs2470578	0.792	rs2733488	chr3:17315496	T/C	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg05861140	chr6:150128134	PCMT1	-0.46	-10.61	-0.44	1.13e-23	Lung cancer;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.26	0.4	7.56e-19	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06976977	chr4:73935744	COX18	0.45	6.85	0.3	2.4e-11	Gut microbiome composition (summer);
LGG	cis	rs6694672	0.867	rs4915379	chr1:197161428	A/G	cg13682187	chr1:196946512	CFHR5	0.47	6.72	0.3	5.37e-11	Asthma;
LGG	cis	rs2735413	0.564	rs2344492	chr16:78096226	C/T	cg04733911	chr16:78082701	NA	0.63	8.96	0.38	7.77e-18	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1682825	0.858	rs1434608	chr3:10760942	C/T	cg23512531	chr3:10780469	NA	-0.56	-7.49	-0.33	3.47e-13	Economic and political preferences (feminism/equality);
LGG	cis	rs7666738	0.830	rs35915560	chr4:98978649	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1355223	0.583	rs2956074	chr11:34864880	T/C	cg24088639	chr11:34937564	PDHX;APIP	-0.42	-7.52	-0.33	2.85e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg08704250	chr15:31115839	NA	-0.35	-6.71	-0.3	5.75e-11	Huntington's disease progression;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg09914581	chr2:11606494	E2F6	-0.43	-7.39	-0.32	6.8e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2072732	0.821	rs58265521	chr1:2943398	C/A	cg22517653	chr1:2918612	NA	-0.5	-7.01	-0.31	8.74e-12	Plateletcrit;
LGG	cis	rs17504614	0.634	rs66477617	chr2:51053587	C/G	cg23851515	chr2:51057218	NRXN1	0.48	7.86	0.34	2.77e-14	Educational attainment (years of education);
LGG	cis	rs4417704	0.551	rs10169006	chr2:241898824	A/G	cg14055004	chr2:241860995	NA	0.27	7.07	0.31	5.67e-12	Joint mobility (Beighton score);
LGG	cis	rs9303401	0.625	rs10515159	chr17:56802693	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23780514	chr18:71959249	CYB5A	0.56	8.28	0.36	1.38e-15	Gut microbiome composition (summer);
LGG	cis	rs4665809	0.549	rs17527979	chr2:26428132	A/G	cg08470875	chr2:26401718	FAM59B	-0.41	-7.76	-0.34	5.4e-14	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.757	rs7924526	chr11:49267043	G/A	cg03929089	chr4:120376271	NA	0.79	13.89	0.54	6.29e-37	Coronary artery disease;
LGG	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg00405596	chr8:11794950	NA	0.63	10.96	0.45	5.39e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg12654349	chr5:56205094	C5orf35	-0.68	-10.69	-0.44	5.54e-24	Initial pursuit acceleration;
LGG	cis	rs7208859	0.573	rs73267865	chr17:29064204	C/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs875971	0.755	rs10228885	chr7:65780529	C/G	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg06558623	chr16:89946397	TCF25	1.16	14.96	0.57	1.45e-41	Skin colour saturation;
LGG	cis	rs4740619	0.740	rs7019143	chr9:15769014	C/A	cg14451791	chr9:16040625	NA	0.33	8.54	0.37	1.97e-16	Body mass index;
LGG	cis	rs7712401	0.601	rs185009	chr5:122273767	A/G	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs2439831	0.867	rs2251844	chr15:43836478	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	10.76	0.45	3.07e-24	Lung cancer in ever smokers;
LGG	cis	rs9611565	0.921	rs8137373	chr22:41729216	A/G	cg06481639	chr22:41940642	POLR3H	0.5	7.48	0.33	3.72e-13	Vitiligo;
LGG	trans	rs8002861	0.905	rs9525869	chr13:44467210	A/G	cg12856521	chr11:46389249	DGKZ	0.41	7.09	0.31	5.12e-12	Leprosy;
LGG	cis	rs854765	0.547	rs2955370	chr17:17966945	C/T	cg04398451	chr17:18023971	MYO15A	0.74	15.5	0.58	5.77e-44	Total body bone mineral density;
LGG	cis	rs472402	0.623	rs8192133	chr5:6636645	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-7.03	-0.31	7.24e-12	Response to amphetamines;
LGG	cis	rs10504229	0.728	rs17804720	chr8:58154565	T/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs17301259	0.548	rs2905213	chr7:88398193	T/G	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.31	-6.87	-0.3	2.04e-11	Heschl's gyrus morphology;
LGG	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg21132104	chr15:45694354	SPATA5L1	0.72	11.01	0.46	3.43e-25	Homoarginine levels;
LGG	cis	rs9880211	1.000	rs4038586	chr3:136363291	T/C	cg21827317	chr3:136751795	NA	-0.49	-7.29	-0.32	1.32e-12	Body mass index;Height;
LGG	trans	rs7937682	0.921	rs10789841	chr11:111469582	T/C	cg18187862	chr3:45730750	SACM1L	-0.57	-9.02	-0.39	4.86e-18	Primary sclerosing cholangitis;
LGG	cis	rs4076764	0.914	rs10753614	chr1:163365903	C/T	cg24596788	chr1:163392923	NA	0.7	13.33	0.53	1.48e-34	Motion sickness;
LGG	cis	rs5758511	0.680	rs5758684	chr22:42649509	C/T	cg15128208	chr22:42549153	NA	0.75	11.5	0.47	4.15e-27	Birth weight;
LGG	cis	rs2013441	1.000	rs11871827	chr17:20215905	C/G	cg13482628	chr17:19912719	NA	-0.51	-9.26	-0.4	7.85e-19	Obesity-related traits;
LGG	cis	rs3858526	0.523	rs10838749	chr11:5884246	A/G	cg13902645	chr11:5959945	NA	-0.67	-11.54	-0.47	2.86e-27	DNA methylation (variation);
LGG	cis	rs9322193	0.886	rs9718079	chr6:149967083	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.02	-0.31	7.96e-12	Lung cancer;
LGG	cis	rs7552404	1.000	rs6593585	chr1:76140273	G/A	cg10523679	chr1:76189770	ACADM	0.81	14.89	0.57	2.92e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg06074448	chr4:187884817	NA	0.53	10.96	0.45	5.36e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2075371	0.966	rs1619682	chr7:133996703	T/G	cg20476274	chr7:133979776	SLC35B4	0.76	14.94	0.57	1.78e-41	Mean platelet volume;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16265078	chr11:85955426	EED	0.59	6.75	0.3	4.41e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.904	rs1966916	chr17:37425238	T/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.93	-0.31	1.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg07538946	chr5:131705188	SLC22A5	0.68	7.8	0.34	4.03e-14	Rheumatoid arthritis;
LGG	cis	rs8072100	0.840	rs1912482	chr17:45454883	G/A	cg25173405	chr17:45401733	C17orf57	-0.49	-8.53	-0.37	2.04e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs617791	0.530	rs55947178	chr11:65754230	G/A	cg26695010	chr11:65641043	EFEMP2	0.46	7.19	0.32	2.68e-12	Breast cancer;
LGG	trans	rs9784649	1.000	rs55806673	chr5:24957298	A/G	cg08600765	chr20:34638493	LOC647979	-0.55	-7.2	-0.32	2.42e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3780378	0.875	rs2031906	chr9:5087495	C/T	cg02405213	chr9:5042618	JAK2	-0.52	-9.13	-0.39	2.19e-18	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs11885103	0.692	rs2724920	chr2:554750	C/G	cg21195176	chr2:593345	NA	0.4	7.43	0.33	5.39e-13	Heschl's gyrus morphology;
LGG	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg21926883	chr2:100939477	LONRF2	0.6	12.83	0.51	1.8e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9398803	0.589	rs853965	chr6:127036174	C/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.66	-0.41	3.15e-20	Male-pattern baldness;
LGG	cis	rs4561483	0.583	rs62038798	chr16:12001569	C/T	cg08843971	chr16:11963173	GSPT1	0.59	14.76	0.57	1.16e-40	Testicular germ cell tumor;
LGG	cis	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.14	-0.35	3.79e-15	Joint mobility (Beighton score);
LGG	cis	rs4356932	0.967	rs4432767	chr4:76981312	A/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs10904887	1.000	rs10904887	chr10:17188641	T/C	cg01003015	chr10:17271136	VIM	-0.45	-7.37	-0.32	8.04e-13	Telomere length;
LGG	cis	rs4566357	1.000	rs6436650	chr2:227925097	C/T	cg11843606	chr2:227700838	RHBDD1	-0.41	-7.21	-0.32	2.26e-12	Coronary artery disease;
LGG	cis	rs6088580	0.634	rs6059856	chr20:33057954	G/C	cg06115741	chr20:33292138	TP53INP2	0.5	8.17	0.36	2.86e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg08677398	chr8:58056175	NA	0.58	8.85	0.38	1.86e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs847851	1.000	rs1535001	chr6:34927280	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.36	-6.65	-0.3	8.45e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1008375	0.897	rs1006723	chr4:17618524	G/A	cg18681998	chr4:17616180	MED28	0.9	19.74	0.68	2.28e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7215564	0.818	rs4889776	chr17:78592385	C/T	cg16980736	chr17:78789706	RPTOR	-0.67	-8.58	-0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs17221829	0.574	rs2773245	chr11:89372626	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.15	-0.39	1.83e-18	Anxiety in major depressive disorder;
LGG	trans	rs2278034	0.578	rs881753	chr3:195606770	C/T	cg16724585	chr3:197361211	NA	0.39	7.23	0.32	2e-12	Bronchopulmonary dysplasia;
LGG	cis	rs28595532	0.920	rs56104443	chr4:119752052	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9393692	0.620	rs9357005	chr6:26336838	C/A	cg00631329	chr6:26305371	NA	-0.46	-7.68	-0.34	9.59e-14	Educational attainment;
LGG	cis	rs4700695	0.614	rs251285	chr5:65211137	A/T	cg21114390	chr5:65439923	SFRS12	0.6	7.02	0.31	7.86e-12	Facial morphology (factor 19);
LGG	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.61	-0.44	1.07e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs875971	1.000	rs778722	chr7:65844828	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs798554	0.679	rs798499	chr7:2792013	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-8.46	-0.37	3.44e-16	Height;
LGG	cis	rs6977660	1.000	rs10275322	chr7:19821220	C/T	cg07541023	chr7:19748670	TWISTNB	0.48	7.53	0.33	2.69e-13	Thyroid stimulating hormone;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.08	-0.35	5.51e-15	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23812325	chr4:56915719	NA	0.45	6.66	0.3	7.93e-11	Gut microbiome composition (summer);
LGG	cis	rs738322	0.804	rs4821743	chr22:38514906	A/G	cg25457927	chr22:38595422	NA	-0.35	-8.31	-0.36	1.09e-15	Cutaneous nevi;
LGG	cis	rs897984	0.683	rs8050330	chr16:30824970	C/T	cg02466173	chr16:30829666	NA	-0.64	-12.81	-0.51	2.32e-32	Dementia with Lewy bodies;
LGG	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg13877915	chr19:58951672	ZNF132	0.98	25.18	0.76	9.08e-89	Uric acid clearance;
LGG	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-10.57	-0.44	1.58e-23	Aortic root size;
LGG	cis	rs9322193	0.962	rs4816	chr6:150114745	G/A	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs7539542	0.556	rs1539357	chr1:202878454	T/A	cg19681188	chr1:202830198	LOC148709	0.51	8.55	0.37	1.82e-16	Mean platelet volume;
LGG	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg13073564	chr4:8508604	NA	0.42	7.2	0.32	2.45e-12	Response to antineoplastic agents;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-9.79	-0.41	1.04e-20	Lung cancer;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg07685180	chr8:600429	NA	-1.12	-9.63	-0.41	3.87e-20	IgG glycosylation;
LGG	cis	rs2640806	0.645	rs7824505	chr8:97330691	G/T	cg22138393	chr8:97340270	PTDSS1	0.31	8.21	0.36	2.23e-15	Obesity-related traits;
LGG	cis	rs7020830	0.898	rs997318	chr9:37364094	C/T	cg14294708	chr9:37120828	ZCCHC7	1.16	32.63	0.83	4.23e-122	Schizophrenia;
LGG	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	7.83	0.34	3.42e-14	Electroencephalogram traits;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.6	-10.13	-0.43	6.41e-22	Obesity-related traits;
LGG	cis	rs847577	0.609	rs34320230	chr7:97785500	C/T	cg13397024	chr7:97797637	LMTK2	-0.35	-6.69	-0.3	6.37e-11	Breast cancer;
LGG	trans	rs9650657	0.593	rs1968401	chr8:10615383	C/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.76	-0.3	4.11e-11	Neuroticism;
LGG	cis	rs3857536	0.741	rs2097679	chr6:66937994	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs3857536	0.813	rs6455091	chr6:66949127	C/G	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg04369109	chr6:150039330	LATS1	-0.43	-7.13	-0.31	3.77e-12	Lung cancer;
LGG	trans	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.55	9.44	0.4	1.85e-19	Mean corpuscular volume;
LGG	cis	rs7582180	0.700	rs11685293	chr2:100976502	A/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	5.01e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10895140	0.681	rs7119712	chr11:101427771	G/A	cg23650423	chr11:101454676	TRPC6	0.43	6.67	0.3	7.54e-11	Menarche (age at onset);
LGG	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg09596252	chr17:78655493	RPTOR	0.45	8.05	0.35	7.11e-15	Obesity;
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.48	-0.44	3.33e-23	Bipolar disorder;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.84	0.3	2.56e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11971779	0.680	rs2355786	chr7:139065622	A/C	cg07862535	chr7:139043722	LUC7L2	-0.44	-7.28	-0.32	1.48e-12	Diisocyanate-induced asthma;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12949688	0.967	rs12451748	chr17:55822171	T/C	cg12582317	chr17:55822272	NA	0.69	20.11	0.68	4.21e-65	Schizophrenia;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.0	-0.52	3.57e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs1499614	1.000	rs1267817	chr7:66110040	G/T	cg18252515	chr7:66147081	NA	-1.37	-18.76	-0.66	7.91e-59	Gout;
LGG	trans	rs3960554	0.932	rs4728614	chr7:75841589	A/G	cg19862616	chr7:65841803	NCRNA00174	-0.8	-11.43	-0.47	8.1e-27	Eotaxin levels;
LGG	cis	rs3857536	0.642	rs7755840	chr6:66891913	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs4555082	1.000	rs7146683	chr14:105759385	A/G	cg27165867	chr14:105738592	BRF1	-0.44	-7.49	-0.33	3.51e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg12573674	chr2:1569213	NA	-0.65	-10.04	-0.42	1.38e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs56283067	0.887	rs9463042	chr6:44770527	T/C	cg18551225	chr6:44695536	NA	-0.65	-10.83	-0.45	1.64e-24	Total body bone mineral density;
LGG	cis	rs755249	1.000	rs4660293	chr1:40028180	C/T	cg18385671	chr1:39797026	MACF1	-0.37	-7.04	-0.31	7.02e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7619833	0.504	rs6771541	chr3:27526516	C/T	cg02860705	chr3:27208620	NA	0.39	7.43	0.33	5.39e-13	Breast cancer;
LGG	cis	rs4906332	0.782	rs7161305	chr14:104002234	G/A	cg23335576	chr14:104009727	NA	0.51	8.06	0.35	6.62e-15	Coronary artery disease;
LGG	cis	rs7927771	1.000	rs12421210	chr11:47779586	C/T	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.5e-17	Subjective well-being;
LGG	trans	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.21	-0.39	1.14e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs12477438	0.798	rs7570657	chr2:99654281	G/C	cg08885076	chr2:99613938	TSGA10	-0.5	-10.51	-0.44	2.62e-23	Chronic sinus infection;
LGG	cis	rs11758351	1.000	rs11755210	chr6:26202768	C/T	cg06951627	chr6:26196580	NA	0.52	7.85	0.34	2.91e-14	Gout;Renal underexcretion gout;
LGG	cis	rs4731207	0.698	rs4728010	chr7:124481420	T/A	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg22907277	chr7:1156413	C7orf50	0.44	7.55	0.33	2.29e-13	Longevity;Endometriosis;
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.97	0.35	1.23e-14	Obesity-related traits;
LGG	trans	rs453301	0.653	rs2956244	chr8:8885166	A/G	cg02002194	chr4:3960332	NA	-0.46	-8.59	-0.37	1.36e-16	Joint mobility (Beighton score);
LGG	cis	rs17270561	0.609	rs9358883	chr6:25755515	A/G	cg16482183	chr6:26056742	HIST1H1C	0.52	8.2	0.36	2.43e-15	Iron status biomarkers;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg03264133	chr6:25882463	NA	-0.5	-9.22	-0.39	1.01e-18	Height;
LGG	cis	rs155076	1.000	rs261430	chr13:21865242	C/T	cg11317459	chr13:21872234	NA	-1.23	-20.44	-0.69	1.23e-66	White matter hyperintensity burden;
LGG	cis	rs7084402	0.967	rs1658418	chr10:60333003	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.81	0.64	1.9e-54	Refractive error;
LGG	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg18898632	chr2:242989856	NA	-0.8	-9.91	-0.42	4.18e-21	Obesity-related traits;
LGG	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	14.0	0.55	2.26e-37	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7188861	0.813	rs1541701	chr16:11445640	G/A	cg01510278	chr16:11456238	NA	-0.33	-7.76	-0.34	5.61e-14	HDL cholesterol;
LGG	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg00343986	chr7:65444356	GUSB	-0.41	-7.09	-0.31	5.05e-12	Aortic root size;
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00166722	chr3:10149974	C3orf24	0.57	8.13	0.35	3.95e-15	Alzheimer's disease;
LGG	cis	rs6732160	0.517	rs10189791	chr2:73397699	G/A	cg01422370	chr2:73384389	NA	0.57	9.64	0.41	3.65e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11971779	0.680	rs2355783	chr7:139075879	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs6951245	1.000	rs76214082	chr7:1102097	T/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.68	-0.44	5.86e-24	Platelet count;
LGG	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs703842	0.642	rs11536137	chr12:58056426	C/A	cg18357645	chr12:58087776	OS9	-0.55	-8.12	-0.35	4.26e-15	Multiple sclerosis;
LGG	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg25174290	chr11:3078921	CARS	0.74	15.45	0.58	9.61e-44	Longevity;
LGG	cis	rs734999	0.545	rs7368105	chr1:2556548	C/T	cg18854424	chr1:2615690	NA	0.36	7.64	0.33	1.28e-13	Ulcerative colitis;
LGG	cis	rs9487051	0.735	rs396000	chr6:109519611	A/G	cg21918786	chr6:109611834	NA	0.4	7.49	0.33	3.41e-13	Reticulocyte fraction of red cells;
LGG	cis	rs7177699	0.557	rs4389112	chr15:79122099	G/A	cg00540400	chr15:79124168	NA	-0.51	-10.63	-0.44	9e-24	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs9462027	0.628	rs9462026	chr6:34797033	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.21	-0.46	5.64e-26	Systemic lupus erythematosus;
LGG	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg03891598	chr16:83986782	OSGIN1	0.54	8.73	0.38	4.78e-17	Pursuit maintenance gain;
LGG	cis	rs12188164	0.897	rs55932239	chr5:423906	G/A	cg26076054	chr5:421317	AHRR	-0.48	-7.93	-0.35	1.61e-14	Cystic fibrosis severity;
LGG	cis	rs1355223	0.867	rs7943363	chr11:34691134	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.02	-0.31	7.86e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs698833	0.852	rs698823	chr2:44720947	C/T	cg18685995	chr2:44588913	PREPL;C2orf34	0.44	6.87	0.3	2.12e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs10540	0.908	rs71487293	chr11:486414	G/A	cg03576123	chr11:487126	PTDSS2	-1.31	-17.38	-0.63	1.98e-52	Body mass index;
LGG	cis	rs9399135	0.636	rs7749106	chr6:135268142	G/A	cg22676075	chr6:135203613	NA	0.39	6.76	0.3	4.17e-11	Red blood cell count;
LGG	cis	rs963731	0.579	rs72909662	chr2:39335328	C/T	cg04010122	chr2:39346883	SOS1	0.77	7.21	0.32	2.33e-12	Corticobasal degeneration;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg05863683	chr7:1912471	MAD1L1	0.4	7.81	0.34	3.98e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg24110177	chr3:50126178	RBM5	0.61	11.08	0.46	1.86e-25	Body mass index;
LGG	cis	rs7605378	0.752	rs769960	chr2:200710706	G/T	cg17644776	chr2:200775616	C2orf69	-0.62	-10.54	-0.44	1.91e-23	Osteoporosis;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg19812747	chr11:111475976	SIK2	-0.5	-10.67	-0.44	6.37e-24	Primary sclerosing cholangitis;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.539	rs11982455	chr7:1911458	A/C	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.08	-0.31	5.36e-12	Bipolar disorder;
LGG	cis	rs9303401	0.614	rs34941454	chr17:57102742	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.84	13.75	0.54	2.61e-36	Cognitive test performance;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.58e-11	Lung cancer;
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg13607699	chr17:42295918	UBTF	0.73	12.32	0.5	2.31e-30	Total body bone mineral density;
LGG	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg06225923	chr16:88797506	FAM38A	-0.53	-7.84	-0.34	3.03e-14	Autism spectrum disorder-related traits;
LGG	cis	rs7107174	1.000	rs4128206	chr11:78015952	A/C	cg02023728	chr11:77925099	USP35	0.44	7.75	0.34	5.78e-14	Testicular germ cell tumor;
LGG	cis	rs36051895	0.623	rs11506668	chr9:5252789	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-11.99	-0.49	5.08e-29	Pediatric autoimmune diseases;
LGG	trans	rs116095464	0.558	rs59113266	chr5:279965	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs9381040	0.655	rs4140578	chr6:41041829	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.17	-0.32	2.95e-12	Alzheimer's disease (late onset);
LGG	cis	rs7503807	0.967	rs7215486	chr17:78612034	C/T	cg06872548	chr17:78716983	RPTOR	0.45	10.82	0.45	1.71e-24	Obesity;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg06719900	chr11:109292894	C11orf87	0.45	8.39	0.36	6.05e-16	Schizophrenia;
LGG	cis	rs9596863	1.000	rs1155438	chr13:54460544	G/T	ch.13.53330881F	chr13:54432880	NA	-0.52	-7.34	-0.32	9.94e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Electroencephalogram traits;
LGG	cis	rs9487094	0.885	rs1590306	chr6:109680950	G/A	cg01125227	chr6:109776195	MICAL1	0.52	8.93	0.38	9.8e-18	Height;
LGG	trans	rs853679	0.760	rs967005	chr6:28210688	C/T	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.94	-0.35	1.58e-14	Depression;
LGG	cis	rs9427116	0.531	rs35504625	chr1:154599778	C/G	cg11650704	chr1:154556575	ADAR	-0.49	-9.69	-0.41	2.38e-20	Blood protein levels;
LGG	cis	rs1185460	1.000	rs1799993	chr11:118958127	A/C	cg23280166	chr11:118938394	VPS11	-0.52	-9.45	-0.4	1.65e-19	Coronary artery disease;
LGG	cis	rs2404602	0.655	rs4886824	chr15:76969256	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.44e-11	Blood metabolite levels;
LGG	cis	rs4242434	0.819	rs6558173	chr8:22492103	A/C	cg00599393	chr8:22457479	C8orf58	0.45	8.26	0.36	1.51e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs921968	0.541	rs12987171	chr2:219327030	G/C	cg01130898	chr2:219473002	PLCD4	-0.42	-7.25	-0.32	1.72e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.78	-0.45	2.49e-24	Vitiligo;
LGG	cis	rs17767392	0.918	rs35822724	chr14:71776934	C/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.12	0.39	2.39e-18	Mitral valve prolapse;
LGG	trans	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg25214090	chr10:38739885	LOC399744	0.62	10.98	0.45	4.28e-25	Corneal astigmatism;
LGG	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-14.09	-0.55	9.3e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs10256972	0.706	rs4285396	chr7:1123738	A/G	cg18402987	chr7:1209562	NA	0.41	7.39	0.32	7e-13	Longevity;Endometriosis;
LGG	trans	rs7819412	0.540	rs11777355	chr8:11044689	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.94	-0.31	1.3e-11	Triglycerides;
LGG	cis	rs975739	0.695	rs7319342	chr13:78523484	C/T	cg07847733	chr13:78271382	SLAIN1	0.41	7.08	0.31	5.29e-12	Hair color;
LGG	cis	rs5771225	0.544	rs1555048	chr22:50688348	A/G	cg16473166	chr22:50639996	SELO	0.61	9.44	0.4	1.87e-19	Late-onset Alzheimer's disease;
LGG	cis	rs3806933	0.522	rs12515367	chr5:110447853	A/G	cg04022379	chr5:110408740	TSLP	0.48	7.98	0.35	1.15e-14	Eosinophilic esophagitis;
LGG	cis	rs6669919	0.553	rs12568639	chr1:211675300	G/A	cg10512769	chr1:211675356	NA	-0.94	-24.24	-0.75	2.02e-84	Intelligence (multi-trait analysis);
LGG	cis	rs9357271	1.000	rs9369055	chr6:38361176	A/T	cg07362130	chr6:38359646	BTBD9	0.48	10.93	0.45	6.55e-25	Restless legs syndrome;
LGG	cis	rs701145	0.938	rs355776	chr3:154035626	A/T	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg16270222	chr17:41446396	NA	-0.31	-7.47	-0.33	4.08e-13	Menopause (age at onset);
LGG	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg03929089	chr4:120376271	NA	-0.63	-11.18	-0.46	7.37e-26	Height;
LGG	cis	rs11098499	0.954	rs71614438	chr4:120371252	G/A	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs7786877	0.626	rs11767547	chr7:100221635	C/T	cg20848291	chr7:100343083	ZAN	-0.61	-8.5	-0.37	2.57e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs986417	1.000	rs2351175	chr14:61066730	C/T	cg27398547	chr14:60952738	C14orf39	0.75	7.04	0.31	7.06e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.18e-26	Personality dimensions;
LGG	cis	rs62158211	0.908	rs62158169	chr2:114081827	C/T	cg17784749	chr2:114082611	LOC440839	0.61	8.37	0.36	7.03e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg04013166	chr16:89971882	TCF25	0.54	7.22	0.32	2.12e-12	Skin colour saturation;
LGG	cis	rs7582180	0.739	rs11123824	chr2:100924029	G/A	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11599315	0.507	rs12220554	chr10:1341852	C/T	cg09624528	chr10:1369823	ADARB2	0.55	10.78	0.45	2.49e-24	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs308971	0.563	rs2618402	chr3:12039799	A/C	cg15873301	chr3:12045459	SYN2	-0.5	-6.8	-0.3	3.19e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg03735888	chr19:58951602	ZNF132	0.41	8.23	0.36	1.94e-15	Uric acid clearance;
LGG	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	cg07245641	chr1:182991651	LAMC1	0.4	8.99	0.39	6.18e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4660306	1.000	rs4660306	chr1:45978675	C/T	cg04700938	chr1:45965449	CCDC163P;MMACHC	0.37	6.8	0.3	3.22e-11	Homocysteine levels;
LGG	cis	rs3784262	0.740	rs2044071	chr15:58270804	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.06	-0.31	6.09e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs12042938	0.507	rs1765775	chr1:231731446	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.78	-15.32	-0.58	3.79e-43	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs2247341	0.965	rs3752747	chr4:1737108	C/T	cg08629884	chr4:1719983	TMEM129	-0.56	-10.79	-0.45	2.3e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.569	rs7736892	chr5:93205597	G/A	cg19507638	chr5:93509721	C5orf36	0.42	6.9	0.31	1.75e-11	Diabetic retinopathy;
LGG	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg03342759	chr3:160939853	NMD3	-0.62	-10.83	-0.45	1.6e-24	Morning vs. evening chronotype;
LGG	trans	rs7937682	0.883	rs553632	chr11:111462897	C/T	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-12.62	-0.51	1.41e-31	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02938179	chr5:173042890	BOD1	0.42	6.81	0.3	2.95e-11	Cognitive performance;
LGG	cis	rs73086581	1.000	rs6037708	chr20:3961253	C/G	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	cis	rs11191205	0.686	rs61382490	chr10:103454402	A/T	cg15320455	chr10:103880129	LDB1	0.53	7.69	0.34	8.9e-14	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs2982452	chr16:1949511	G/A	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504073	0.584	rs55795863	chr8:49898055	A/G	cg00325661	chr8:49890786	NA	0.82	16.48	0.61	2.39e-48	Blood metabolite ratios;
LGG	cis	rs9325144	0.647	rs11168741	chr12:38989120	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.95	-0.54	3.47e-37	Morning vs. evening chronotype;
LGG	cis	rs7584330	0.910	rs6713555	chr2:238398182	A/G	cg16989719	chr2:238392110	NA	0.33	7.01	0.31	8.34e-12	Prostate cancer;
LGG	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg08344181	chr3:125677491	NA	-0.79	-7.01	-0.31	8.62e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6121246	0.529	rs6060210	chr20:30187681	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	trans	rs3780486	0.846	rs10813948	chr9:33121570	G/A	cg20290983	chr6:43655470	MRPS18A	1.1	24.54	0.75	8.64e-86	IgG glycosylation;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	8.54	0.37	1.94e-16	Schizophrenia;
LGG	cis	rs9381107	0.722	rs11753684	chr6:9450092	A/G	cg14735645	chr6:9486422	NA	-0.42	-7.22	-0.32	2.2e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4740619	0.967	rs7049176	chr9:15677427	T/C	cg14451791	chr9:16040625	NA	-0.36	-9.22	-0.39	1.06e-18	Body mass index;
LGG	cis	rs1577917	0.958	rs7382798	chr6:86559834	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.16	-0.39	1.68e-18	Response to antipsychotic treatment;
LGG	cis	rs1847202	0.762	rs13093504	chr3:72949855	T/C	cg25664220	chr3:72788482	NA	-0.25	-7.28	-0.32	1.47e-12	Motion sickness;
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs151997	0.629	rs27288	chr5:50194920	T/A	cg06027927	chr5:50259733	NA	0.61	10.31	0.43	1.42e-22	Callous-unemotional behaviour;
LGG	trans	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg21659725	chr3:3221576	CRBN	0.58	8.68	0.37	6.65e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.850	rs3097773	chr15:43893072	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	-0.81	-9.18	-0.39	1.45e-18	Lung cancer in ever smokers;
LGG	cis	rs7000551	0.508	rs11780977	chr8:22245028	G/A	cg13512537	chr8:22265999	SLC39A14	-0.43	-6.81	-0.3	2.97e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17376456	0.825	rs10064368	chr5:93266396	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs66573146	0.831	rs56031152	chr4:6973832	C/A	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03647317	chr4:187891568	NA	-0.42	-9.27	-0.4	7.11e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1008375	0.574	rs7670135	chr4:17566221	G/T	cg18681998	chr4:17616180	MED28	0.74	14.49	0.56	1.65e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg13009111	chr11:71350975	NA	-0.31	-6.92	-0.31	1.48e-11	Systolic blood pressure;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09699651	chr6:150184138	LRP11	0.55	10.53	0.44	2.15e-23	Lung cancer;
LGG	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg13271783	chr10:134563150	INPP5A	-0.59	-8.68	-0.37	6.83e-17	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.754	rs9991959	chr4:120253773	C/T	cg24375607	chr4:120327624	NA	-0.61	-10.4	-0.44	6.56e-23	Corneal astigmatism;
LGG	cis	rs300703	0.872	rs428697	chr2:213302	G/A	cg24565620	chr2:194026	NA	-0.74	-9.88	-0.42	4.94e-21	Blood protein levels;
LGG	cis	rs981844	1.000	rs2606341	chr4:154658702	T/C	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg01557791	chr16:72042693	DHODH	-0.39	-7.04	-0.31	7.08e-12	Fibrinogen levels;
LGG	cis	rs3741151	0.773	rs73548693	chr11:73286637	G/A	cg17517138	chr11:73019481	ARHGEF17	0.84	8.02	0.35	8.93e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs4950322	0.547	rs61838945	chr1:146583059	G/T	cg22381352	chr1:146742008	CHD1L	-0.43	-7.37	-0.32	7.79e-13	Protein quantitative trait loci;
LGG	cis	rs17641971	0.899	rs818557	chr8:49984515	G/C	cg00325661	chr8:49890786	NA	-0.5	-8.52	-0.37	2.19e-16	Blood metabolite levels;
LGG	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs876084	0.505	rs35529075	chr8:121143623	C/G	cg06265175	chr8:121136014	COL14A1	0.46	9.23	0.39	9.76e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs801193	0.935	rs2286683	chr7:66129843	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs7617773	0.746	rs4371540	chr3:48353543	G/A	cg11946769	chr3:48343235	NME6	0.72	12.02	0.49	3.57e-29	Coronary artery disease;
LGG	cis	rs368123	1.000	rs406151	chr6:160717711	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.15	-0.32	3.3e-12	Waist circumference;
LGG	cis	rs847649	0.731	rs13222980	chr7:102703898	A/G	cg18108683	chr7:102477205	FBXL13	0.55	11.22	0.46	5.21e-26	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.540	rs289638	chr10:37923731	G/A	cg00409905	chr10:38381863	ZNF37A	-0.62	-12.46	-0.5	6.09e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs4664308	0.935	rs58354887	chr2:160927112	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.83	-0.64	1.56e-54	Idiopathic membranous nephropathy;
LGG	cis	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg19847130	chr8:10466454	RP1L1	0.35	7.83	0.34	3.26e-14	Neuroticism;
LGG	cis	rs2717559	0.683	rs2717611	chr8:143879927	C/T	cg06565975	chr8:143823917	SLURP1	-0.31	-8.24	-0.36	1.83e-15	Urinary tract infection frequency;
LGG	cis	rs9660992	0.626	rs1172113	chr1:205226288	T/C	cg21545522	chr1:205238299	TMCC2	0.41	7.73	0.34	6.75e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9311474	0.629	rs13081028	chr3:52555316	G/A	cg15147215	chr3:52552868	STAB1	-0.45	-9.0	-0.39	5.91e-18	Electroencephalogram traits;
LGG	cis	rs11971779	0.793	rs11772447	chr7:139033589	T/G	cg07862535	chr7:139043722	LUC7L2	0.5	8.21	0.36	2.24e-15	Diisocyanate-induced asthma;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-11.08	-0.46	1.89e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6120849	0.663	rs6088662	chr20:33547633	A/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.79	0.3	3.4e-11	Protein C levels;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.67e-11	Menopause (age at onset);
LGG	cis	rs73787773	0.644	rs17134156	chr5:111481737	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.58	-7.57	-0.33	2.08e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg02071572	chr4:1403502	NA	0.42	7.15	0.32	3.3e-12	Longevity;
LGG	cis	rs1055129	0.655	rs7223416	chr17:73836162	C/G	cg14829360	chr17:73884958	NA	-0.43	-7.79	-0.34	4.55e-14	White matter hyperintensity burden;
LGG	cis	rs7226408	0.802	rs72887095	chr18:34508949	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg08499158	chr17:42289980	UBTF	-0.58	-11.19	-0.46	6.79e-26	Total body bone mineral density;
LGG	trans	rs61931739	0.534	rs11052983	chr12:34045787	C/A	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs1620921	0.563	rs1806449	chr6:161280932	G/T	cg01280913	chr6:161186852	NA	-0.37	-7.64	-0.33	1.23e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1465370	0.692	rs2402996	chr7:130017003	C/T	cg25718383	chr7:130020096	CPA1	0.32	8.42	0.36	4.83e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12182343	chr17:75955921	NA	0.4	6.79	0.3	3.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs367943	1.000	rs367943	chr5:112809728	C/T	cg27587195	chr5:112824172	MCC	0.46	7.37	0.32	8.02e-13	Type 2 diabetes;
LGG	cis	rs6815814	0.904	rs73236629	chr4:38825449	G/T	cg06935464	chr4:38784597	TLR10	0.57	7.71	0.34	7.91e-14	Breast cancer;
LGG	cis	rs7927771	0.507	rs10838759	chr11:47785347	T/C	cg20307385	chr11:47447363	PSMC3	0.56	10.99	0.45	4.16e-25	Subjective well-being;
LGG	cis	rs17672112	1.000	rs12196997	chr6:101187165	C/A	cg27451362	chr6:101846650	GRIK2	0.69	8.8	0.38	2.66e-17	Putamen volume;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.28	0.46	3.03e-26	Tonsillectomy;
LGG	cis	rs9329289	0.603	rs2458698	chr10:2548452	C/T	cg18171855	chr10:2543474	NA	0.45	8.05	0.35	7.22e-15	Age-related hearing impairment;
LGG	cis	rs2274273	0.901	rs112870553	chr14:55790062	T/G	cg04306507	chr14:55594613	LGALS3	0.64	18.04	0.64	1.78e-55	Protein biomarker;
LGG	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.28e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg13012494	chr21:47604986	C21orf56	0.62	10.37	0.43	8.41e-23	Testicular germ cell tumor;
LGG	cis	rs4732038	0.739	rs11984091	chr7:134257938	A/G	cg06906464	chr7:134288099	NA	-0.48	-11.52	-0.47	3.67e-27	Longevity;
LGG	cis	rs79349575	0.783	rs12601858	chr17:47017477	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs4237845	0.788	rs6581157	chr12:58288793	C/T	cg02175503	chr12:58329896	NA	0.61	10.76	0.45	2.95e-24	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.586	rs11657161	chr17:20180715	A/G	cg09818912	chr17:20140352	CYTSB	0.32	7.6	0.33	1.62e-13	Schizophrenia;
LGG	cis	rs3087591	0.960	rs8067021	chr17:29555078	T/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.41	-0.56	3.69e-39	Hip circumference;
LGG	cis	rs61931739	0.629	rs708146	chr12:33731808	C/G	cg06521331	chr12:34319734	NA	-0.41	-7.06	-0.31	6.32e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.68	-0.54	5.04e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1816752	0.905	rs6490928	chr13:25014059	T/C	cg22771759	chr13:24902376	NA	0.42	7.14	0.31	3.6e-12	Obesity-related traits;
LGG	cis	rs13177180	0.588	rs256956	chr5:114877022	C/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.32	-6.85	-0.3	2.36e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs7188861	0.768	rs1646025	chr16:11379938	A/G	cg01510278	chr16:11456238	NA	0.3	7.25	0.32	1.81e-12	HDL cholesterol;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	9.05	0.39	3.95e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7914558	0.966	rs10786727	chr10:104698523	G/A	cg04362960	chr10:104952993	NT5C2	0.54	10.24	0.43	2.55e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs2832077	0.527	rs2250141	chr21:30241984	A/T	cg14791747	chr16:20752902	THUMPD1	-0.51	-9.09	-0.39	2.87e-18	Cognitive test performance;
LGG	cis	rs7166081	1.000	rs3743349	chr15:67652097	G/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.78	-0.3	3.78e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.07	0.49	2.34e-29	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg00933542	chr6:150070202	PCMT1	0.39	7.11	0.31	4.44e-12	Lung cancer;
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs9321453	1.000	rs9376037	chr6:134775037	C/G	cg08754004	chr6:134775465	NA	-0.45	-6.77	-0.3	3.85e-11	Urate levels;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1218582	0.772	rs6656435	chr1:154876869	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.65	-0.44	7.64e-24	Prostate cancer;
LGG	cis	rs6495122	0.532	rs2472304	chr15:75044238	G/A	cg10253484	chr15:75165896	SCAMP2	-0.47	-7.49	-0.33	3.6e-13	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs7216064	1.000	rs3935969	chr17:65881959	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.46e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9547996	0.879	rs2209230	chr13:38187158	A/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.65e-11	Diastolic blood pressure;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07025343	chr14:77606922	ZDHHC22	0.4	6.74	0.3	4.68e-11	Bipolar disorder;
LGG	cis	rs6956675	0.915	rs4717501	chr7:62652936	C/T	cg08930214	chr7:62859557	LOC100287834	0.42	7.11	0.31	4.37e-12	Obesity-related traits;
LGG	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg13010199	chr12:38710504	ALG10B	0.53	10.38	0.43	7.59e-23	Bladder cancer;
LGG	cis	rs7618915	0.547	rs4687636	chr3:52633929	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.45	0.37	3.86e-16	Bipolar disorder;
LGG	cis	rs4478037	0.915	rs4578976	chr3:33146189	C/T	cg19404215	chr3:33155277	CRTAP	1.01	11.41	0.47	9.2e-27	Major depressive disorder;
LGG	cis	rs329648	1.000	rs329648	chr11:133765367	A/G	cg15485101	chr11:133734466	NA	0.45	7.13	0.31	3.87e-12	Parkinson's disease;
LGG	cis	rs4512344	0.509	rs2409784	chr8:11396856	G/T	cg24623649	chr8:11872141	NA	-0.29	-6.97	-0.31	1.13e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9443189	0.570	rs7755068	chr6:76405700	A/G	cg01950844	chr6:76311363	SENP6	0.76	10.04	0.42	1.39e-21	Prostate cancer;
LGG	cis	rs6582630	0.519	rs8186992	chr12:38325848	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.75	0.3	4.33e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9487094	0.626	rs4141930	chr6:110060818	C/T	cg01125227	chr6:109776195	MICAL1	0.42	7.41	0.33	6.03e-13	Height;
LGG	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg27572855	chr1:25598939	RHD	0.52	11.73	0.48	5.24e-28	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs5753037	0.504	rs140114	chr22:30133881	C/T	cg01021169	chr22:30184971	ASCC2	-0.38	-7.45	-0.33	4.57e-13	Type 1 diabetes;
LGG	cis	rs867371	0.896	rs6495647	chr15:82537049	C/G	cg00614314	chr15:82944287	LOC80154	0.6	10.13	0.43	6.67e-22	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg18225595	chr11:63971243	STIP1	0.54	7.28	0.32	1.44e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg01879757	chr17:41196368	BRCA1	-0.45	-8.94	-0.38	9.15e-18	Menopause (age at onset);
LGG	cis	rs9896933	0.775	rs79299098	chr17:80830944	G/A	cg15369054	chr17:80825471	TBCD	0.51	6.82	0.3	2.89e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg03213289	chr20:61660250	NA	0.66	14.44	0.56	2.67e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs561341	0.714	rs7218466	chr17:30263314	A/G	cg13647721	chr17:30228624	UTP6	0.65	8.73	0.38	4.78e-17	Hip circumference adjusted for BMI;
LGG	cis	rs926392	0.547	rs6129161	chr20:37678327	T/G	cg16355469	chr20:37678765	NA	0.63	9.89	0.42	4.63e-21	Dialysis-related mortality;
LGG	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.74	-0.41	1.65e-20	Retinal vascular caliber;
LGG	trans	rs800082	0.668	rs6805395	chr3:144292116	T/C	cg24215973	chr2:240111563	HDAC4	-0.64	-12.6	-0.51	1.61e-31	Smoking behavior;
LGG	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg19847130	chr8:10466454	RP1L1	0.31	6.72	0.3	5.5e-11	Neuroticism;
LGG	cis	rs2415984	0.811	rs4424814	chr14:46813895	C/G	cg14871534	chr14:47121158	RPL10L	-0.41	-6.66	-0.3	7.78e-11	Number of children ever born;
LGG	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg11266682	chr4:10021025	SLC2A9	0.51	10.02	0.42	1.66e-21	Bone mineral density;
LGG	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.28e-30	Height;
LGG	cis	rs36051895	0.659	rs62541540	chr9:5040080	A/G	cg02405213	chr9:5042618	JAK2	-0.83	-15.43	-0.58	1.17e-43	Pediatric autoimmune diseases;
LGG	cis	rs2617583	0.967	rs2652509	chr5:1448247	A/G	cg07151155	chr5:1473589	LPCAT1	-0.36	-7.06	-0.31	6.18e-12	Breast cancer;
LGG	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg12292205	chr6:26970375	C6orf41	0.75	14.9	0.57	2.59e-41	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1015291	0.708	rs1586839	chr12:19998176	C/A	cg25401612	chr12:20009446	NA	-0.34	-7.24	-0.32	1.87e-12	Diastolic blood pressure;
LGG	cis	rs11190604	1.000	rs11190592	chr10:102291059	T/C	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg03709012	chr19:19516395	GATAD2A	0.93	14.9	0.57	2.7e-41	Nonalcoholic fatty liver disease;
LGG	cis	rs9487051	0.872	rs9386789	chr6:109603218	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.87	-0.38	1.57e-17	Reticulocyte fraction of red cells;
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg04013166	chr16:89971882	TCF25	0.54	7.34	0.32	9.37e-13	Skin colour saturation;
LGG	cis	rs7648466	0.592	rs4683184	chr3:46187707	G/A	cg13144783	chr3:46249795	CCR1	-0.62	-13.29	-0.53	2.3e-34	Eotaxin levels;
LGG	cis	rs7267979	0.966	rs2257705	chr20:25264664	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04578738	chr17:34136331	TAF15	0.49	8.03	0.35	7.96e-15	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-16.18	-0.6	5.54e-47	Intelligence (multi-trait analysis);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg13219564	chr2:46926944	SOCS5	-0.38	-6.7	-0.3	6.01e-11	Brain structure;
LGG	cis	rs7264396	0.836	rs6058282	chr20:34212590	T/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.26	0.32	1.64e-12	Total cholesterol levels;
LGG	cis	rs35740288	0.770	rs17570529	chr15:86125607	A/T	cg04173714	chr15:86211321	AKAP13	0.47	8.35	0.36	7.99e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10267417	0.603	rs12666448	chr7:19859119	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	7.5	0.33	3.38e-13	Night sleep phenotypes;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg05941027	chr17:61774174	LIMD2	0.34	8.43	0.36	4.57e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.958	rs10944137	chr6:86454314	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.84	-14.96	-0.57	1.39e-41	Response to antipsychotic treatment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21254083	chr11:119598909	PVRL1	0.49	7.22	0.32	2.21e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.93	-0.31	1.45e-11	Lung cancer;
LGG	cis	rs10214930	0.647	rs2391438	chr7:27570173	C/A	cg22168087	chr7:27702803	HIBADH	0.46	7.0	0.31	8.99e-12	Hypospadias;
LGG	cis	rs7937890	0.869	rs2915404	chr11:14404825	A/G	cg02886208	chr11:14281011	SPON1	-0.43	-8.7	-0.37	5.75e-17	Mitochondrial DNA levels;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg14926445	chr8:58193284	C8orf71	0.7	9.01	0.39	5.58e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1847505	0.609	rs76153604	chr13:61493971	C/G	cg25164009	chr13:61490935	NA	0.57	8.88	0.38	1.48e-17	Polychlorinated biphenyl levels;
LGG	cis	rs2154319	0.887	rs10489522	chr1:41504442	T/A	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.98	-0.39	7.04e-18	Height;
LGG	cis	rs62238980	0.614	rs733908	chr22:32462505	C/T	cg02631450	chr22:32366979	NA	0.92	9.15	0.39	1.81e-18	Childhood ear infection;
LGG	cis	rs916888	0.610	rs199536	chr17:44820425	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.47	-8.02	-0.35	8.43e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3816788	0.620	rs11783414	chr8:21773384	A/G	cg17168535	chr8:21777572	XPO7	-0.69	-12.95	-0.52	5.9e-33	Lung cancer in ever smokers;
LGG	cis	rs7666738	0.830	rs2903150	chr4:99027184	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17221829	0.521	rs11018654	chr11:89317497	C/T	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.27	-0.36	1.46e-15	Anxiety in major depressive disorder;
LGG	cis	rs7208859	0.673	rs9907197	chr17:29018263	C/T	cg13385521	chr17:29058706	SUZ12P	0.88	10.39	0.43	7.01e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6546550	0.935	rs1377995	chr2:70064155	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.0	-0.35	1.01e-14	Prevalent atrial fibrillation;
LGG	cis	rs1816752	0.870	rs9511261	chr13:25012018	C/T	cg02811702	chr13:24901961	NA	0.4	7.54	0.33	2.48e-13	Obesity-related traits;
LGG	cis	rs1816752	0.875	rs8001187	chr13:24976414	G/A	cg02811702	chr13:24901961	NA	0.41	7.34	0.32	9.91e-13	Obesity-related traits;
LGG	cis	rs920590	0.679	rs4577973	chr8:19658017	A/G	cg03894339	chr8:19674705	INTS10	0.45	7.7	0.34	8.15e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg25986240	chr4:9926439	SLC2A9	0.33	6.77	0.3	3.86e-11	Bone mineral density;
LGG	cis	rs67460515	1.000	rs67460515	chr3:161068566	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-10.16	-0.43	5.17e-22	Parkinson's disease;
LGG	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.48	7.11	0.31	4.55e-12	Cystic fibrosis severity;
LGG	cis	rs1552244	1.000	rs7622966	chr3:10139833	C/T	cg13047869	chr3:10149882	C3orf24	0.56	9.49	0.4	1.21e-19	Alzheimer's disease;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs72945132	0.882	rs17853270	chr11:70200529	C/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.58	-0.33	1.84e-13	Coronary artery disease;
LGG	cis	rs12701220	0.895	rs12534778	chr7:1065861	C/T	cg26769984	chr7:1090371	C7orf50	-0.52	-9.14	-0.39	1.94e-18	Bronchopulmonary dysplasia;
LGG	cis	rs12220238	1.000	rs111704178	chr10:75957251	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7208859	0.623	rs11656844	chr17:29060597	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.77	0.45	2.84e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.13	0.6	8.94e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg09217309	chr6:150244204	RAET1G	0.47	8.54	0.37	2e-16	Testicular germ cell tumor;
LGG	cis	rs4819052	0.808	rs2246697	chr21:46689999	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.78	13.75	0.54	2.54e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3020736	0.500	rs1801311	chr22:42486723	G/A	cg05082376	chr22:42548792	NA	0.37	7.7	0.34	8.45e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg17788362	chr6:86352627	SYNCRIP	0.45	7.75	0.34	5.9e-14	Smooth-surface caries;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.89	0.59	1.08e-45	Lung cancer;
LGG	cis	rs75920871	0.557	rs7123336	chr11:116782819	T/C	cg20608306	chr11:116969690	SIK3	-0.4	-10.53	-0.44	2.11e-23	Subjective well-being;
LGG	trans	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg19847130	chr8:10466454	RP1L1	-0.31	-6.81	-0.3	3.03e-11	Mood instability;
LGG	cis	rs938554	0.558	rs4697701	chr4:9946095	C/T	cg25986240	chr4:9926439	SLC2A9	0.37	7.31	0.32	1.15e-12	Blood metabolite levels;
LGG	cis	rs4776059	1.000	rs11070907	chr15:52924231	G/T	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.74	-0.34	6.13e-14	Schizophrenia;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs2235642	0.928	rs2076435	chr16:1607574	C/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	10.09	0.42	8.94e-22	Coronary artery disease;
LGG	cis	rs11229555	1.000	rs12787765	chr11:58400686	G/A	cg15696309	chr11:58395628	NA	-0.98	-17.52	-0.63	4.36e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs344364	0.511	rs2917519	chr16:1950479	C/A	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.08	-0.31	5.52e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs60871478	0.636	rs4276575	chr7:900035	C/T	cg22643751	chr7:855365	UNC84A	-0.4	-7.22	-0.32	2.15e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg13397898	chr9:133768931	QRFP	0.35	8.87	0.38	1.58e-17	Response to amphetamines;
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	trans	rs6076960	0.652	rs6085441	chr20:6211383	A/G	cg17788362	chr6:86352627	SYNCRIP	0.5	8.8	0.38	2.8e-17	Smooth-surface caries;
LGG	cis	rs7481584	0.669	rs12793371	chr11:3034709	A/G	cg25174290	chr11:3078921	CARS	-0.5	-8.98	-0.39	6.76e-18	Calcium levels;
LGG	cis	rs2153535	0.580	rs9406161	chr6:8466144	G/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2645694	0.651	rs2703144	chr4:77830505	C/G	cg10057126	chr4:77819792	ANKRD56	0.35	6.67	0.3	7.4e-11	Emphysema distribution in smoking;
LGG	cis	rs2290159	0.571	rs7637392	chr3:12696433	A/G	cg23032965	chr3:12705835	RAF1	0.67	9.64	0.41	3.61e-20	Cholesterol, total;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg06916706	chr16:4465613	CORO7	-0.71	-12.24	-0.49	4.84e-30	Schizophrenia;
LGG	cis	rs7267979	0.966	rs2261720	chr20:25260641	T/G	cg06421707	chr20:25228305	PYGB	0.47	10.22	0.43	2.96e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg16507663	chr6:150244633	RAET1G	0.41	6.96	0.31	1.18e-11	Testicular germ cell tumor;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg02725872	chr8:58115012	NA	-0.75	-10.46	-0.44	4.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.530	rs61815714	chr1:152921380	C/T	cg13444842	chr1:152974279	SPRR3	-0.48	-9.59	-0.41	5.6e-20	Inflammatory skin disease;
LGG	cis	rs1552244	0.554	rs2272119	chr3:10049352	A/G	cg00149659	chr3:10157352	C3orf10	0.58	8.26	0.36	1.51e-15	Alzheimer's disease;
LGG	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.24e-14	HDL cholesterol;
LGG	cis	rs763121	0.853	rs2413544	chr22:39059404	A/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.48	0.63	6.84e-53	Menopause (age at onset);
LGG	cis	rs12618769	0.597	rs6753515	chr2:99128965	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1982963	0.950	rs2645750	chr14:52502792	C/A	cg05884192	chr14:52515736	NID2	-0.34	-7.29	-0.32	1.38e-12	Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.19	0.62	1.34e-51	Alzheimer's disease;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg13628971	chr7:2884303	GNA12	0.54	11.39	0.47	1.17e-26	Height;
LGG	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg16751781	chr15:78858589	CHRNA5	-0.38	-6.65	-0.3	8.45e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs8062405	0.824	rs4788085	chr16:28535003	A/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.71	0.3	5.75e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6500395	1.000	rs11647048	chr16:48623227	T/G	cg04672837	chr16:48644449	N4BP1	0.53	8.61	0.37	1.13e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1552244	0.938	rs66915020	chr3:10110174	A/G	cg16606324	chr3:10149918	C3orf24	0.53	6.99	0.31	9.62e-12	Alzheimer's disease;
LGG	cis	rs1451375	0.583	rs3807556	chr7:50610536	G/A	cg14593290	chr7:50529359	DDC	0.65	11.74	0.48	5.06e-28	Malaria;
LGG	cis	rs7512552	0.839	rs1694369	chr1:150351101	A/G	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9952991	0.883	rs2542147	chr18:12775851	G/T	cg23544223	chr18:12777786	NA	0.61	9.26	0.4	7.39e-19	Inflammatory skin disease;
LGG	cis	rs9291683	0.588	rs3796829	chr4:10019138	C/G	cg16147221	chr4:10020634	SLC2A9	0.36	6.76	0.3	4.09e-11	Bone mineral density;
LGG	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg14993813	chr1:46806288	NSUN4	-0.55	-9.16	-0.39	1.69e-18	Menopause (age at onset);
LGG	cis	rs11158026	0.757	rs7157085	chr14:55444746	G/A	cg04306507	chr14:55594613	LGALS3	0.31	7.14	0.32	3.55e-12	Parkinson's disease;
LGG	trans	rs3206736	0.548	rs328939	chr7:35050227	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg19077165	chr18:44547161	KATNAL2	0.66	12.25	0.49	4.5e-30	Personality dimensions;
LGG	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.94	0.38	9.19e-18	Colorectal cancer;
LGG	trans	rs28595532	0.720	rs72670224	chr4:119301885	G/T	cg26518628	chr1:97050305	NA	-0.81	-7.07	-0.31	5.64e-12	Cannabis dependence symptom count;
LGG	trans	rs2929451	0.566	rs17658270	chr8:9153619	C/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.03	-0.31	7.59e-12	Nose size;
LGG	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg26384229	chr12:38710491	ALG10B	0.97	22.22	0.72	5.54e-75	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03517284	chr6:25882590	NA	0.66	12.76	0.51	3.77e-32	Blood metabolite levels;
LGG	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.42	0.33	5.58e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs951366	0.617	rs823075	chr1:205774897	C/T	cg07157834	chr1:205819609	PM20D1	0.82	20.13	0.68	3.45e-65	Menarche (age at onset);
LGG	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.43	7.82	0.34	3.58e-14	Total cholesterol levels;
LGG	cis	rs4555082	0.874	rs2245329	chr14:105719181	T/C	cg27165867	chr14:105738592	BRF1	-0.46	-7.62	-0.33	1.45e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12950390	0.814	rs4794099	chr17:45838358	T/C	cg24803719	chr17:45855879	NA	-0.3	-8.4	-0.36	5.51e-16	IgG glycosylation;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg11050988	chr7:1952600	MAD1L1	-0.34	-7.96	-0.35	1.39e-14	Schizophrenia;
LGG	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.47	0.33	3.97e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.93	0.35	1.62e-14	Coronary artery disease;
LGG	cis	rs2016266	0.502	rs7137242	chr12:53638882	C/T	cg04065151	chr12:53682969	ESPL1	-0.83	-16.58	-0.61	7.97e-49	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg05044414	chr3:183734942	ABCC5	0.76	16.86	0.62	4.61e-50	Anterior chamber depth;
LGG	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg08999081	chr20:33150536	PIGU	0.31	7.25	0.32	1.73e-12	Coronary artery disease;
LGG	cis	rs35110281	0.622	rs9977258	chr21:44976485	G/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.77	-0.34	5.01e-14	Mean corpuscular volume;
LGG	cis	rs4538187	0.585	rs2969395	chr2:64253741	A/T	cg19915305	chr2:64069682	UGP2	0.61	12.29	0.5	3.04e-30	Systolic blood pressure;
LGG	cis	rs9326248	0.520	rs74830	chr11:117090558	C/T	cg20608306	chr11:116969690	SIK3	-0.35	-10.44	-0.44	4.71e-23	Blood protein levels;
LGG	cis	rs208520	1.000	rs208527	chr6:66957209	A/C	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs2282300	0.739	rs1933343	chr11:30310992	T/C	cg25418670	chr11:30344373	C11orf46	0.56	7.89	0.34	2.16e-14	Morning vs. evening chronotype;
LGG	cis	rs7143963	0.943	rs12586226	chr14:103251003	A/G	cg23020514	chr14:103360112	TRAF3	-0.52	-9.56	-0.41	6.84e-20	Body mass index;
LGG	cis	rs6582630	0.599	rs11181807	chr12:38403763	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.47	-0.44	3.55e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.49	-0.4	1.18e-19	Schizophrenia;
LGG	cis	rs17711722	0.510	rs73142128	chr7:65331109	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	16.3	0.6	1.5e-47	Calcium levels;
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg14159672	chr1:205819179	PM20D1	0.42	6.69	0.3	6.32e-11	Parkinson's disease;
LGG	cis	rs17451754	0.626	rs213979	chr7:117248234	T/G	cg10524701	chr7:117356490	CTTNBP2	0.45	7.87	0.34	2.51e-14	Barrett's esophagus  or Esophageal adenocarcinoma;
LGG	cis	rs6840360	0.554	rs6849111	chr4:152708874	T/C	cg22705602	chr4:152727874	NA	-0.4	-10.21	-0.43	3.23e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.593	rs2156676	chr11:133715791	G/C	cg06766960	chr11:133703094	NA	-0.58	-11.41	-0.47	9.78e-27	Childhood ear infection;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs3768617	0.706	rs6678517	chr1:183002639	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.8	0.3	3.2e-11	Fuchs's corneal dystrophy;
LGG	trans	rs11039798	0.841	rs7950737	chr11:48590678	T/G	cg15704280	chr7:45808275	SEPT13	0.77	9.01	0.39	5.55e-18	Axial length;
LGG	cis	rs9486719	0.741	rs2049927	chr6:96848958	C/G	cg06623918	chr6:96969491	KIAA0776	-0.74	-10.02	-0.42	1.59e-21	Migraine;Coronary artery disease;
LGG	cis	rs4820539	1.000	rs4822360	chr22:23482460	A/G	cg21100191	chr22:23484243	RTDR1	0.96	21.92	0.71	1.42e-73	Bone mineral density;
LGG	trans	rs7618501	0.966	rs2352974	chr3:49890613	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.6	11.02	0.46	3.11e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11074306	0.561	rs9806561	chr15:28073054	C/T	cg26402630	chr15:28053930	OCA2	0.35	6.96	0.31	1.14e-11	Uveal melanoma;
LGG	cis	rs736408	0.509	rs13083798	chr3:52649748	A/G	cg14092988	chr3:52407081	DNAH1	0.25	6.84	0.3	2.6e-11	Bipolar disorder;
LGG	cis	rs745080	0.519	rs34773814	chr14:52965329	A/G	cg23333723	chr14:53022898	GPR137C	-0.4	-8.07	-0.35	6.04e-15	Orofacial clefts;
LGG	cis	rs514406	0.505	rs835609	chr1:53170494	T/C	cg24675658	chr1:53192096	ZYG11B	-0.61	-13.52	-0.53	2.39e-35	Monocyte count;
LGG	cis	rs11997175	0.600	rs4739590	chr8:33802686	A/G	ch.8.33884649F	chr8:33765107	NA	0.35	6.86	0.3	2.17e-11	Body mass index;
LGG	cis	rs738322	0.935	rs75387	chr22:38572057	C/T	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs4555082	0.834	rs2735817	chr14:105717796	A/G	cg13114125	chr14:105738426	BRF1	0.83	16.03	0.6	2.67e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1595825	0.891	rs1016883	chr2:198881668	A/G	cg00982548	chr2:198649783	BOLL	0.51	6.84	0.3	2.56e-11	Ulcerative colitis;
LGG	cis	rs4974559	0.793	rs10025954	chr4:1351382	C/T	cg02980000	chr4:1222292	CTBP1	0.66	8.09	0.35	5.34e-15	Systolic blood pressure;
LGG	cis	rs910316	0.935	rs175422	chr14:75627319	T/A	cg06637938	chr14:75390232	RPS6KL1	-0.58	-10.55	-0.44	1.79e-23	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00699235	chr12:49962218	MCRS1	0.51	8.11	0.35	4.56e-15	Gut microbiome composition (summer);
LGG	cis	rs7582720	0.943	rs72926799	chr2:203828192	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7582720	1.000	rs72926786	chr2:203816494	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4650994	0.544	rs4075631	chr1:178506594	C/A	cg19399532	chr1:178512495	C1orf220	0.56	11.48	0.47	5.25e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs12410462	0.579	rs115037090	chr1:227666191	A/G	cg04117972	chr1:227635322	NA	0.88	13.55	0.53	1.8e-35	Major depressive disorder;
LGG	cis	rs988958	0.876	rs11902166	chr2:42282829	A/C	cg19376973	chr2:42229025	NA	-0.55	-8.61	-0.37	1.12e-16	Hypospadias;
LGG	cis	rs826838	0.510	rs17523988	chr12:39222785	A/C	cg26384229	chr12:38710491	ALG10B	0.86	16.78	0.61	1.07e-49	Heart rate;
LGG	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg18252515	chr7:66147081	NA	0.4	6.88	0.3	1.9e-11	Aortic root size;
LGG	trans	rs3808502	0.563	rs10098664	chr8:11417493	T/C	cg08975724	chr8:8085496	FLJ10661	0.49	9.57	0.41	6.24e-20	Neuroticism;
LGG	cis	rs3008870	1.000	rs2755250	chr1:67495283	A/G	cg08660285	chr1:67390436	MIER1;WDR78	0.98	22.44	0.72	4.96e-76	Lymphocyte percentage of white cells;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs6565180	0.926	rs12446288	chr16:30388709	A/G	cg17640201	chr16:30407289	ZNF48	0.89	18.56	0.65	6.75e-58	Tonsillectomy;
LGG	cis	rs240764	0.853	rs12191199	chr6:101008093	C/T	cg09795085	chr6:101329169	ASCC3	-0.41	-6.88	-0.3	1.95e-11	Neuroticism;
LGG	cis	rs6500395	0.962	rs9934626	chr16:48602761	G/C	cg04672837	chr16:48644449	N4BP1	0.53	8.59	0.37	1.37e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3858526	0.959	rs10838797	chr11:5920977	A/G	cg13902645	chr11:5959945	NA	-0.72	-11.24	-0.46	4.52e-26	DNA methylation (variation);
LGG	cis	rs2762353	0.779	rs1408273	chr6:25840946	C/T	cg03517284	chr6:25882590	NA	0.48	9.11	0.39	2.58e-18	Blood metabolite levels;
LGG	cis	rs740474	0.652	rs251022	chr5:140892643	T/C	cg00076195	chr5:140892677	NA	0.54	10.4	0.44	6.68e-23	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs8060686	0.641	rs111227007	chr16:68093138	T/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.6	-0.33	1.67e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs73191547	0.615	rs10089666	chr8:10083040	A/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.41	0.33	5.87e-13	Schizophrenia;
LGG	cis	rs17539620	0.624	rs871069	chr6:154837578	A/C	cg17771515	chr6:154831774	CNKSR3	0.62	7.63	0.33	1.4e-13	Lipoprotein (a) levels;
LGG	cis	rs7172689	0.954	rs72744156	chr15:81526279	C/T	cg11808699	chr15:81528661	IL16	-0.46	-9.33	-0.4	4.32e-19	Inattentive symptoms;
LGG	cis	rs7811142	1.000	rs4463351	chr7:100078226	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs7927592	0.731	rs488381	chr11:68291693	G/A	cg01657329	chr11:68192670	LRP5	0.56	10.59	0.44	1.34e-23	Total body bone mineral density;
LGG	cis	rs7044106	0.708	rs920745	chr9:123429943	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.61	0.61	6.09e-49	Hip circumference adjusted for BMI;
LGG	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg08975724	chr8:8085496	FLJ10661	0.43	7.8	0.34	4.23e-14	Retinal vascular caliber;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg22980697	chr10:16874865	CUBN	0.39	7.56	0.33	2.16e-13	Platelet distribution width;
LGG	cis	rs503341	0.756	rs11231591	chr11:63587986	G/T	cg04850017	chr11:63683019	RCOR2	0.32	8.03	0.35	8.06e-15	Pulse pressure;
LGG	cis	rs600550	0.588	rs11230248	chr11:60085893	T/C	cg05040360	chr11:60102449	MS4A6E	-0.35	-7.66	-0.34	1.12e-13	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs1552244	0.882	rs17050672	chr3:10025463	G/A	cg08888203	chr3:10149979	C3orf24	0.55	9.01	0.39	5.23e-18	Alzheimer's disease;
LGG	cis	rs8064299	0.597	rs2053748	chr17:72775911	A/G	cg25054828	chr17:72772726	NAT9;TMEM104	-0.94	-20.88	-0.7	1.07e-68	Monocyte count;
LGG	trans	rs804280	0.542	rs34117651	chr8:11791617	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Myopia (pathological);
LGG	cis	rs2732480	0.538	rs1387259	chr12:48703522	C/T	cg21466736	chr12:48725269	NA	0.38	7.57	0.33	2.06e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs35176054	0.730	rs11592832	chr10:105512186	C/T	cg00730670	chr10:105510713	SH3PXD2A	-0.51	-6.91	-0.31	1.59e-11	Atrial fibrillation;
LGG	cis	rs28595532	0.920	rs115860482	chr4:119759546	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25807061	chr7:74306919	PMS2L5;STAG3L2	-0.45	-6.76	-0.3	4.11e-11	Systemic lupus erythematosus;
LGG	cis	rs9467773	0.583	rs1021373	chr6:26632457	G/A	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.01e-31	Intelligence (multi-trait analysis);
LGG	cis	rs6088590	0.582	rs6059909	chr20:33139691	C/A	cg24642439	chr20:33292090	TP53INP2	0.56	9.3	0.4	5.67e-19	Coronary artery disease;
LGG	cis	rs9467711	0.651	rs34116162	chr6:25937652	G/A	cg21479132	chr6:26055353	NA	0.85	7.43	0.33	5.33e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17376456	0.569	rs7732578	chr5:93410244	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.56	-7.96	-0.35	1.33e-14	Diabetic retinopathy;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg18350739	chr11:68623251	NA	-0.86	-21.84	-0.71	3.33e-73	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7129556	1.000	rs7129556	chr11:77300048	A/G	cg12586386	chr11:77299805	AQP11	-0.51	-8.45	-0.37	3.88e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	cis	rs2439831	0.702	rs7171750	chr15:44025858	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.32	0.4	4.65e-19	Lung cancer in ever smokers;
LGG	cis	rs7226408	0.739	rs115893729	chr18:34343144	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.82	-0.3	2.77e-11	Obesity-related traits;
LGG	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg17757837	chr7:157058334	UBE3C	0.78	15.99	0.6	3.83e-46	Body mass index;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.42	8.7	0.37	5.92e-17	Schizophrenia;
LGG	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.61	0.33	1.53e-13	Electroencephalogram traits;
LGG	cis	rs2243480	1.000	rs313809	chr7:65499983	G/A	cg13147721	chr7:65941812	NA	-0.82	-9.79	-0.41	1.09e-20	Diabetic kidney disease;
LGG	trans	rs10802346	0.514	rs5024440	chr1:246372608	G/C	cg22732515	chr19:44031385	ETHE1	0.54	9.44	0.4	1.89e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg04000281	chr11:63949212	NA	-0.43	-8.14	-0.35	3.75e-15	Platelet count;
LGG	cis	rs6693567	0.565	rs3754217	chr1:150480373	G/T	cg15654264	chr1:150340011	RPRD2	0.33	6.72	0.3	5.48e-11	Migraine;
LGG	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg03517284	chr6:25882590	NA	-0.55	-10.47	-0.44	3.7e-23	Blood metabolite levels;
LGG	cis	rs9807989	0.507	rs1420105	chr2:103035119	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.57	0.41	6.52e-20	Asthma;
LGG	cis	rs7786877	0.680	rs28584500	chr7:100216341	G/A	cg03098644	chr7:100410630	EPHB4	0.48	7.08	0.31	5.54e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs2160869	chr3:10079255	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg20913747	chr6:44695427	NA	-0.68	-12.03	-0.49	3.52e-29	Total body bone mineral density;
LGG	cis	rs35146811	1.000	rs35146811	chr7:99720994	A/C	cg22906224	chr7:99728672	NA	0.6	9.86	0.42	5.82e-21	Coronary artery disease;
LGG	cis	rs3858526	0.523	rs10769290	chr11:5886947	T/A	cg25319279	chr11:5960081	NA	-0.48	-8.05	-0.35	7.01e-15	DNA methylation (variation);
LGG	cis	rs950169	1.000	rs1848093	chr15:84755527	G/C	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-15.87	-0.59	1.35e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs7617773	0.780	rs35297486	chr3:48378147	T/A	cg11946769	chr3:48343235	NME6	0.71	11.7	0.48	6.76e-28	Coronary artery disease;
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg23730037	chr7:158596552	ESYT2	-0.41	-6.94	-0.31	1.35e-11	Height;
LGG	cis	rs8014204	0.762	rs8016389	chr14:75287554	T/C	cg06637938	chr14:75390232	RPS6KL1	0.65	11.9	0.48	1.14e-28	Caffeine consumption;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs2133450	0.508	rs17047073	chr3:7349612	A/G	cg19930620	chr3:7340148	GRM7	-0.43	-9.58	-0.41	5.77e-20	Early response to risperidone in schizophrenia;
LGG	cis	rs11148252	0.510	rs7337430	chr13:52584244	C/T	cg05335186	chr13:53173507	NA	0.38	7.18	0.32	2.8e-12	Lewy body disease;
LGG	cis	rs2735413	0.918	rs12918959	chr16:78081719	T/C	cg04733911	chr16:78082701	NA	-0.78	-18.77	-0.66	7.27e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs61931739	0.927	rs12315970	chr12:34038535	A/G	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.06	0.6	1.83e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2070488	0.775	rs7644530	chr3:38558316	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.73	-14.34	-0.55	7.72e-39	Electrocardiographic conduction measures;
LGG	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.41	-0.44	6.05e-23	Depression;
LGG	cis	rs61931739	0.534	rs11053049	chr12:34164537	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs11148252	0.811	rs9535895	chr13:52765847	G/A	cg22398616	chr13:53314203	LECT1	-0.45	-9.3	-0.4	5.66e-19	Lewy body disease;
LGG	cis	rs12497850	0.897	rs9681717	chr3:48872998	A/G	cg07636037	chr3:49044803	WDR6	1.09	27.18	0.78	6.12e-98	Parkinson's disease;
LGG	trans	rs9354308	0.764	rs4710543	chr6:66584671	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg24642844	chr7:1081250	C7orf50	-0.81	-13.56	-0.53	1.59e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.36	4.24e-16	Bipolar disorder;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg19223190	chr17:80058835	NA	0.44	8.49	0.37	2.77e-16	Life satisfaction;
LGG	cis	rs9878978	0.722	rs13064421	chr3:2447525	G/A	cg21928760	chr3:2462534	CNTN4	0.39	7.76	0.34	5.49e-14	Blood pressure (smoking interaction);
LGG	cis	rs4295623	0.531	rs2898295	chr8:11595969	C/T	cg21775007	chr8:11205619	TDH	-0.43	-7.07	-0.31	5.87e-12	Morning vs. evening chronotype;
LGG	cis	rs76917914	0.820	rs3739670	chr9:100819192	C/T	cg03040243	chr9:100819229	NANS	0.48	6.69	0.3	6.5500000000000006e-11	Immature fraction of reticulocytes;
LGG	cis	rs12738007	0.967	rs34380016	chr1:29558230	A/G	cg11747820	chr1:29584023	PTPRU	-0.33	-7.59	-0.33	1.81e-13	Schizophrenia;
LGG	cis	rs12477438	0.520	rs11123762	chr2:99727789	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs2204008	0.846	rs2030416	chr12:38465118	A/G	cg13010199	chr12:38710504	ALG10B	-0.64	-13.61	-0.53	1e-35	Bladder cancer;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.5	-8.35	-0.36	7.96e-16	Longevity;Endometriosis;
LGG	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	trans	rs7613875	0.641	rs6793528	chr3:50100188	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.8	-0.3	3.3e-11	Body mass index;
LGG	cis	rs10893109	0.517	rs7925715	chr11:123780926	A/T	cg12387464	chr11:123775935	OR8D4	0.4	8.69	0.37	6.23e-17	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg20887711	chr4:1340912	KIAA1530	0.48	8.25	0.36	1.6e-15	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs11738115	chr5:96113072	A/T	cg00188032	chr5:96141721	ERAP1	-0.53	-7.02	-0.31	7.82e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4622507	0.773	rs62034614	chr16:55046548	A/G	cg09947736	chr16:55091198	NA	0.59	10.13	0.43	6.54e-22	Social communication problems;
LGG	cis	rs6668534	0.904	rs1340976	chr1:161661489	C/A	cg26156167	chr1:161582651	NA	0.38	6.66	0.3	7.65e-11	Blood protein levels;
LGG	cis	rs7493	1.000	rs6968305	chr7:95042529	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.24	-0.36	1.8e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6684428	0.610	rs12123610	chr1:56312992	A/T	cg11651538	chr1:56320950	NA	0.63	10.52	0.44	2.45e-23	Airflow obstruction;
LGG	cis	rs201673768	1	rs201673768	chr12:48699606	TGTTTTGTTTTG/T	cg24011408	chr12:48396354	COL2A1	0.7	11.85	0.48	1.84e-28	Platelet count;
LGG	cis	rs10504229	0.679	rs56040464	chr8:58131603	G/A	cg26174226	chr8:58114915	NA	-0.6	-8.62	-0.37	1.08e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.545	rs1375796	chr12:39410592	G/T	cg13010199	chr12:38710504	ALG10B	0.45	8.05	0.35	7.12e-15	Morning vs. evening chronotype;
LGG	cis	rs2124969	0.548	rs72982036	chr2:161031590	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.19	-0.39	1.29e-18	Waist circumference adjusted for body mass index;
LGG	cis	rs12476592	0.602	rs262524	chr2:63892727	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs77372450	0.636	rs6875939	chr5:156994466	A/G	cg25387487	chr5:157003181	ADAM19	-0.59	-7.34	-0.32	9.38e-13	Bipolar disorder (body mass index interaction);
LGG	cis	rs61931739	0.500	rs7313094	chr12:34457508	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.41	1.79e-20	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg05861140	chr6:150128134	PCMT1	-0.44	-10.15	-0.43	5.24e-22	Lung cancer;
LGG	cis	rs7614311	0.636	rs73117059	chr3:63916028	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.7	-0.34	8.35e-14	Lung function (FVC);Lung function (FEV1);
LGG	trans	rs1814175	0.645	rs28627251	chr11:50048125	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.73	-0.68	2.52e-63	Height;
LGG	cis	rs10754283	0.934	rs10493829	chr1:90117833	T/C	cg06121193	chr1:90282411	NA	-0.38	-7.3	-0.32	1.3e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg12773197	chr13:112238673	NA	0.36	7.17	0.32	3e-12	Hepatitis;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg11494091	chr17:61959527	GH2	0.99	24.01	0.74	2.39e-83	Prudent dietary pattern;
LGG	cis	rs17209837	0.607	rs45478299	chr7:87111321	G/A	cg25823085	chr7:87105416	ABCB4	0.3	7.4	0.33	6.54e-13	Gallbladder cancer;
LGG	cis	rs10875746	0.551	rs10875799	chr12:48740879	C/A	cg24011408	chr12:48396354	COL2A1	-0.55	-7.1	-0.31	4.77e-12	Longevity (90 years and older);
LGG	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	Neuroticism;
LGG	trans	rs1945213	0.694	rs7116741	chr11:55862620	C/T	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7940866	0.834	rs2324315	chr11:130839772	C/G	cg12179176	chr11:130786555	SNX19	0.72	13.35	0.53	1.32e-34	Schizophrenia;
LGG	cis	rs929354	0.742	rs3808317	chr7:156944460	A/G	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08730330	chr17:61904790	PSMC5;FTSJ3	0.42	6.91	0.31	1.63e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs975722	0.646	rs43028	chr7:117105581	T/C	cg10524701	chr7:117356490	CTTNBP2	0.42	9.32	0.4	4.75e-19	Coronary artery disease;
LGG	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg10792982	chr14:105748885	BRF1	0.68	13.49	0.53	3.17e-35	Mean platelet volume;Platelet distribution width;
LGG	cis	rs8060686	0.641	rs7193935	chr16:68071147	C/T	cg27539214	chr16:67997921	SLC12A4	-0.43	-6.89	-0.3	1.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7618501	0.521	rs2352984	chr3:49948728	T/C	cg21659725	chr3:3221576	CRBN	0.55	9.68	0.41	2.56e-20	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.960	rs1013947	chr17:29530362	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.45	0.56	2.6e-39	Hip circumference;
LGG	cis	rs8062405	0.824	rs4788083	chr16:28545449	A/G	cg09754948	chr16:28834200	ATXN2L	0.44	7.09	0.31	5.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3771570	1.000	rs62193171	chr2:242276523	C/A	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs17376456	0.877	rs10076052	chr5:93317762	C/T	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs755249	0.567	rs1537817	chr1:39639653	A/G	cg18385671	chr1:39797026	MACF1	-0.43	-8.31	-0.36	1.07e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg07393940	chr7:158741817	NA	-0.58	-10.7	-0.45	4.88e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs758324	0.617	rs9717078	chr5:131170891	G/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1018836	0.828	rs7008172	chr8:91551613	C/T	cg16814680	chr8:91681699	NA	-0.71	-12.6	-0.51	1.74e-31	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg01988459	chr11:68622903	NA	0.59	12.08	0.49	2.11e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs67311347	0.866	rs1454491	chr3:40352647	C/G	cg24209194	chr3:40518798	ZNF619	0.42	6.78	0.3	3.78e-11	Renal cell carcinoma;
LGG	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg16141378	chr3:129829833	LOC729375	0.36	8.2	0.36	2.42e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1348850	0.874	rs952746	chr2:178306584	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-9.13	-0.39	2.17e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7319311	1.000	rs7320755	chr13:111031092	C/G	cg06243866	chr13:111019493	COL4A2	-0.48	-8.63	-0.37	9.57e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.53	0.4	9.23e-20	Monocyte count;
LGG	cis	rs2153904	0.793	rs1891091	chr1:205661418	A/G	cg23034840	chr1:205782522	SLC41A1	0.65	7.18	0.32	2.73e-12	Prostate-specific antigen levels;
LGG	cis	rs876084	0.505	rs62526984	chr8:121128068	A/G	cg06265175	chr8:121136014	COL14A1	0.48	9.65	0.41	3.37e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1023500	0.505	rs134888	chr22:42674281	C/T	cg17050807	chr22:42548356	NA	-0.38	-7.42	-0.33	5.76e-13	Schizophrenia;
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.8e-14	Personality dimensions;
LGG	cis	rs9859260	0.744	rs557527	chr3:195780709	G/A	cg02975922	chr3:195473998	MUC4	0.45	7.14	0.31	3.63e-12	Mean corpuscular volume;
LGG	cis	rs9397585	0.667	rs9371672	chr6:153422140	C/G	cg12989544	chr6:153429875	RGS17	0.31	6.82	0.3	2.85e-11	Body mass index;
LGG	cis	rs10504229	0.683	rs56235637	chr8:58106008	T/C	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg04731861	chr2:219085781	ARPC2	-0.43	-10.45	-0.44	4.16e-23	Colorectal cancer;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.76	14.65	0.56	3.47e-40	Obesity-related traits;
LGG	trans	rs853679	0.607	rs67101035	chr6:27798887	C/G	cg01620082	chr3:125678407	NA	-1.04	-9.97	-0.42	2.47e-21	Depression;
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg05556477	chr5:131705319	SLC22A5	0.77	9.16	0.39	1.7e-18	Rheumatoid arthritis;
LGG	cis	rs12493885	0.769	rs11711982	chr3:153756867	A/G	cg17054900	chr3:154042577	DHX36	-0.63	-7.99	-0.35	1.11e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12220238	1.000	rs10824114	chr10:75970503	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.41	0.47	9.8e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs7937682	0.632	rs11214015	chr11:111719417	A/T	cg18187862	chr3:45730750	SACM1L	0.59	9.55	0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs7551222	0.752	rs2369244	chr1:204515299	C/G	cg18851795	chr1:204543875	NA	0.35	6.68	0.3	6.67e-11	Schizophrenia;
LGG	trans	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.52	-0.4	9.56e-20	Bladder cancer;
LGG	cis	rs6426558	0.537	rs2813950	chr1:227426072	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.55	-9.34	-0.4	4.02e-19	Neutrophil percentage of white cells;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.56	-9.38	-0.4	2.97e-19	Longevity;Endometriosis;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg05313129	chr8:58192883	C8orf71	-0.68	-8.74	-0.38	4.32e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2976388	1.000	rs2920292	chr8:143765699	A/G	cg06565975	chr8:143823917	SLURP1	-0.41	-10.52	-0.44	2.4e-23	Urinary tract infection frequency;
LGG	cis	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.97	-0.45	4.8e-25	Heart rate;
LGG	cis	rs9910055	0.762	rs2240226	chr17:42266218	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.51	9.13	0.39	2.08e-18	Total body bone mineral density;
LGG	cis	rs9894429	1.000	rs7213129	chr17:79581573	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs12580194	0.593	rs12579346	chr12:55786856	A/G	cg19537932	chr12:55886519	OR6C68	-0.56	-10.24	-0.43	2.52e-22	Cancer;
LGG	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg05084668	chr3:125655381	ALG1L	-0.59	-8.12	-0.35	4.37e-15	Blood pressure (smoking interaction);
LGG	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg16325326	chr1:53192061	ZYG11B	0.63	13.45	0.53	4.9e-35	Monocyte count;
LGG	cis	rs7091068	0.518	rs4919436	chr10:95461475	C/T	cg20715218	chr10:95462985	C10orf4	0.68	12.14	0.49	1.21e-29	Urinary tract infection frequency;
LGG	cis	rs7927592	0.956	rs6591341	chr11:68335478	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.63	-0.37	9.9e-17	Total body bone mineral density;
LGG	cis	rs7726839	0.540	rs4957083	chr5:659343	T/C	cg16400903	chr5:693638	TPPP	0.46	6.86	0.3	2.16e-11	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs6822679	chr4:120402702	A/C	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs8114671	0.804	rs6088666	chr20:33564570	A/G	cg07148914	chr20:33460835	GGT7	0.5	8.28	0.36	1.32e-15	Height;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.21	-0.32	2.32e-12	Lung cancer;
LGG	cis	rs6546537	0.550	rs72837959	chr2:69780762	C/T	cg10773587	chr2:69614142	GFPT1	-0.44	-7.62	-0.33	1.4e-13	Serum thyroid-stimulating hormone levels;
LGG	trans	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-7.98	-0.35	1.18e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg08564027	chr20:61660810	NA	1.02	25.54	0.76	1.95e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7582180	0.614	rs2241809	chr2:101014363	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.0	0.49	4.47e-29	Intelligence (multi-trait analysis);
LGG	cis	rs526231	0.575	rs10463990	chr5:102317418	G/A	cg23492399	chr5:102201601	PAM	-0.62	-9.26	-0.4	7.74e-19	Primary biliary cholangitis;
LGG	cis	rs3806843	0.771	rs801174	chr5:140112712	C/T	cg19875535	chr5:140030758	IK	-0.58	-11.84	-0.48	2e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4466137	0.868	rs4703962	chr5:82999808	A/G	cg16102102	chr5:83017553	HAPLN1	-0.61	-11.17	-0.46	8.3e-26	Prostate cancer;
LGG	cis	rs11169552	0.543	rs11169481	chr12:50926485	C/A	cg12884762	chr12:50931848	DIP2B	-0.4	-7.64	-0.33	1.25e-13	Colorectal cancer;
LGG	cis	rs12410462	0.892	rs35341041	chr1:227653885	G/A	cg04117972	chr1:227635322	NA	0.73	11.79	0.48	3.1e-28	Major depressive disorder;
LGG	cis	rs2201728	0.967	rs34397848	chr4:100147247	A/G	cg07219303	chr4:100140905	ADH6	-0.42	-8.35	-0.36	8.24e-16	Cardiac Troponin-T levels;
LGG	cis	rs801193	0.935	rs2659916	chr7:66151352	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.76	0.38	3.61e-17	Aortic root size;
LGG	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg01864069	chr14:103024347	NA	-0.68	-9.57	-0.41	6.59e-20	Platelet count;
LGG	cis	rs12949688	0.967	rs12950062	chr17:55825534	G/A	cg12229367	chr17:55822335	NA	0.46	8.83	0.38	2.11e-17	Schizophrenia;
LGG	cis	rs12701220	0.500	rs6463224	chr7:1140418	C/A	cg26769984	chr7:1090371	C7orf50	0.41	6.86	0.3	2.27e-11	Bronchopulmonary dysplasia;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs2762353	0.935	rs1359232	chr6:25809716	C/A	cg12310025	chr6:25882481	NA	0.53	10.21	0.43	3.27e-22	Blood metabolite levels;
LGG	cis	rs875971	1.000	rs1363055	chr7:65943275	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	trans	rs11039798	1.000	rs6485856	chr11:48556298	G/C	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.18e-17	Axial length;
LGG	cis	rs10851478	0.529	rs9920722	chr15:49735112	C/T	cg08060515	chr15:49448048	GALK2;COPS2	-0.4	-7.21	-0.32	2.36e-12	Oral cavity cancer;
LGG	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg11366901	chr6:160182831	ACAT2	1.05	15.97	0.6	4.76e-46	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1997103	1.000	rs2331068	chr7:55408220	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7618915	0.571	rs34115864	chr3:52612178	A/G	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.36	4.24e-16	Bipolar disorder;
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg07243736	chr16:783730	NARFL	0.39	6.81	0.3	2.95e-11	Height;
LGG	cis	rs73082363	0.609	rs73082357	chr3:49083566	G/A	cg19401529	chr3:49056140	DALRD3	0.75	8.16	0.35	3.23e-15	Coronary artery disease;
LGG	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg00129232	chr17:37814104	STARD3	-0.49	-8.98	-0.39	6.93e-18	Self-reported allergy;
LGG	cis	rs2028299	0.879	rs8034631	chr15:90422665	A/T	cg23731826	chr15:90371692	NA	0.35	8.38	0.36	6.61e-16	Type 2 diabetes;
LGG	trans	rs10802346	0.545	rs10924568	chr1:246385482	C/A	cg22732515	chr19:44031385	ETHE1	0.54	9.37	0.4	3.1e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs283228	0.528	rs1928071	chr6:101580699	C/G	cg27451362	chr6:101846650	GRIK2	0.59	8.68	0.37	6.96e-17	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.593	rs58647001	chr8:58025132	G/A	cg14926445	chr8:58193284	C8orf71	-0.63	-8.0	-0.35	1.01e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.56	0.41	6.98e-20	Bone mineral density;
LGG	cis	rs17767294	0.708	rs72848752	chr6:27878268	A/C	cg00426182	chr6:28072559	NA	0.96	7.24	0.32	1.92e-12	Parkinson's disease;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.79	0.54	1.82e-36	Prudent dietary pattern;
LGG	cis	rs7918232	0.943	rs6482593	chr10:27371437	A/G	cg14240646	chr10:27532245	ACBD5	-0.76	-11.12	-0.46	1.28e-25	Breast cancer;
LGG	cis	rs240764	0.658	rs2050549	chr6:101216645	A/G	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs11239187	0.586	rs1585913	chr10:45117976	G/A	cg03916630	chr10:45065415	NA	0.29	6.72	0.3	5.4e-11	Body mass index;
LGG	cis	rs5758659	0.904	rs134877	chr22:42662371	C/T	cg15128208	chr22:42549153	NA	-0.43	-8.52	-0.37	2.22e-16	Cognitive function;
LGG	trans	rs8002861	0.810	rs7334812	chr13:44445538	C/T	cg17145862	chr1:211918768	LPGAT1	0.98	25.03	0.76	4.44e-88	Leprosy;
LGG	cis	rs798554	0.836	rs13243214	chr7:2817455	G/T	cg13628971	chr7:2884303	GNA12	0.49	9.64	0.41	3.59e-20	Height;
LGG	cis	rs1018836	0.628	rs35816262	chr8:91511017	C/G	cg16814680	chr8:91681699	NA	-0.7	-11.89	-0.48	1.22e-28	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9807989	0.507	rs4851571	chr2:103019000	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs963731	0.579	rs6544186	chr2:39226271	A/C	cg04010122	chr2:39346883	SOS1	-0.69	-7.19	-0.32	2.66e-12	Corticobasal degeneration;
LGG	cis	rs12980942	0.591	rs2304232	chr19:41762525	A/G	cg25627403	chr19:41769009	HNRNPUL1	0.58	7.67	0.34	1.05e-13	Coronary artery disease;
LGG	cis	rs9522267	0.535	rs7329118	chr13:112232693	C/T	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.98e-25	Hepatitis;
LGG	cis	rs4748857	0.947	rs7084042	chr10:23509719	T/C	cg12804278	chr10:23633326	C10orf67	0.39	6.65	0.3	8.27e-11	Systemic lupus erythematosus;
LGG	cis	rs10276381	0.786	rs28430601	chr7:28238811	A/G	cg23620719	chr7:28220237	JAZF1	0.83	10.05	0.42	1.29e-21	Crohn's disease;
LGG	cis	rs11997175	1.000	rs6468203	chr8:33749572	T/A	ch.8.33884649F	chr8:33765107	NA	0.37	6.7	0.3	5.98e-11	Body mass index;
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg26116260	chr4:7069785	GRPEL1	1.15	22.53	0.72	2.05e-76	Monocyte percentage of white cells;
LGG	cis	rs7226408	0.625	rs9949826	chr18:34547897	C/T	cg15022739	chr18:34823045	BRUNOL4	0.42	9.05	0.39	3.87e-18	Obesity-related traits;
LGG	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg10518543	chr12:38710700	ALG10B	0.41	6.71	0.3	5.68e-11	Morning vs. evening chronotype;
LGG	cis	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg08975724	chr8:8085496	FLJ10661	0.51	10.25	0.43	2.37e-22	Neuroticism;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.897	rs2836944	chr21:40593539	G/A	cg11644478	chr21:40555479	PSMG1	0.92	18.08	0.64	1.12e-55	Cognitive function;
LGG	cis	rs7523273	0.925	rs2745977	chr1:208017360	C/A	cg22525895	chr1:207977042	MIR29B2	-0.6	-11.19	-0.46	6.58e-26	Schizophrenia;
LGG	cis	rs1580019	0.563	rs13225132	chr7:32800975	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.55	9.2	0.39	1.22e-18	Cognitive ability;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-11.13	-0.46	1.14e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs3091242	0.933	rs11249251	chr1:25770188	C/G	cg23205692	chr1:25664452	TMEM50A	0.44	9.16	0.39	1.66e-18	Erythrocyte sedimentation rate;
LGG	cis	rs9443645	0.869	rs7762022	chr6:79502859	C/A	cg18132916	chr6:79620363	NA	-0.31	-8.4	-0.36	5.56e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg13395646	chr4:1353034	KIAA1530	0.48	8.13	0.35	4.02e-15	Obesity-related traits;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.45	7.91	0.35	1.91e-14	Longevity;
LGG	cis	rs599083	0.590	rs661988	chr11:68189251	T/G	cg16797656	chr11:68205561	LRP5	0.44	6.78	0.3	3.63e-11	Bone mineral density (spine);
LGG	cis	rs9916302	0.706	rs9906612	chr17:37547631	A/C	cg00129232	chr17:37814104	STARD3	0.56	8.44	0.37	4.14e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs2243480	0.803	rs36127118	chr7:65565505	A/G	cg13147721	chr7:65941812	NA	-0.81	-10.23	-0.43	2.86e-22	Diabetic kidney disease;
LGG	cis	rs950169	0.580	rs11634322	chr15:85172209	C/T	cg24253500	chr15:84953950	NA	0.44	7.33	0.32	1.01e-12	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs3741404	0.609	rs651855	chr11:63870810	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.4	8.0	0.35	1e-14	Platelet count;
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg16606324	chr3:10149918	C3orf24	0.6	6.86	0.3	2.28e-11	Alzheimer's disease;
LGG	cis	rs3020736	0.500	rs2839708	chr22:42500745	A/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg04503457	chr17:41445688	NA	-0.39	-9.23	-0.39	9.39e-19	Menopause (age at onset);
LGG	cis	rs8072100	0.738	rs9895509	chr17:45549618	A/T	cg08085267	chr17:45401833	C17orf57	0.49	9.15	0.39	1.78e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs714031	0.730	rs5757766	chr22:40069490	T/C	cg21377881	chr22:40064566	CACNA1I	-0.6	-14.4	-0.56	4.12e-39	Schizophrenia;
LGG	cis	rs7660883	0.897	rs342454	chr4:88021500	T/A	cg21988461	chr4:88008667	AFF1	0.34	9.8	0.41	1e-20	HDL cholesterol levels;
LGG	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg13232821	chr7:50628718	DDC	0.36	7.13	0.31	3.91e-12	Malaria;
LGG	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.81	0.3	3.06e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg11965913	chr1:205819406	PM20D1	0.85	18.49	0.65	1.37e-57	Menarche (age at onset);
LGG	trans	rs783540	0.872	rs2678445	chr15:83246141	T/A	cg16105309	chr15:79090380	ADAMTS7	0.42	7.24	0.32	1.83e-12	Schizophrenia;
LGG	cis	rs7927592	0.913	rs67947146	chr11:68314980	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs4851266	1.000	rs1465801	chr2:100836060	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs2289583	0.642	rs11635266	chr15:75386649	T/C	cg14664628	chr15:75095509	CSK	0.51	8.96	0.38	8.2e-18	Systemic lupus erythematosus;
LGG	cis	rs2154319	1.000	rs2154319	chr1:41745770	A/G	cg02290550	chr1:41487317	SLFNL1	0.45	7.97	0.35	1.25e-14	Height;
LGG	cis	rs7508	0.668	rs7834136	chr8:17922396	C/T	cg18067069	chr8:17937731	ASAH1	0.38	9.0	0.39	5.97e-18	Atrial fibrillation;
LGG	trans	rs1814175	0.654	rs7482446	chr11:49779020	A/G	cg03929089	chr4:120376271	NA	-1.05	-24.77	-0.75	7.54e-87	Height;
LGG	trans	rs7618501	0.633	rs12485600	chr3:50025530	A/G	cg21659725	chr3:3221576	CRBN	0.66	12.43	0.5	8.47e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg06634786	chr22:41940651	POLR3H	-0.83	-13.42	-0.53	6.47e-35	Vitiligo;
LGG	trans	rs208520	0.661	rs207111	chr6:66792513	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.41	-0.65	3.35e-57	Exhaled nitric oxide output;
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg12395012	chr8:11607386	GATA4	0.39	7.24	0.32	1.9e-12	Mood instability;
LGG	cis	rs3820928	0.933	rs1429267	chr2:227767593	G/C	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.38	-0.32	7.47e-13	Pulmonary function;
LGG	cis	rs6502050	0.871	rs11870632	chr17:80075406	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.37	0.4	3.25e-19	Life satisfaction;
LGG	cis	rs9463078	0.625	rs12190513	chr6:44920679	A/T	cg25276700	chr6:44698697	NA	0.33	6.94	0.31	1.33e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7226408	0.857	rs72885287	chr18:34446659	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg11766577	chr21:47581405	C21orf56	-0.59	-10.83	-0.45	1.67e-24	Testicular germ cell tumor;
LGG	cis	rs3747547	0.892	rs11789186	chr9:37975114	A/C	cg13774184	chr9:37916125	SHB	-0.68	-7.07	-0.31	5.59e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.594	rs1957948	chr14:65542629	A/G	cg16583315	chr14:65563665	MAX	0.44	8.96	0.38	8.01e-18	Obesity-related traits;
LGG	cis	rs9875589	0.915	rs13097822	chr3:13969396	T/A	cg19554555	chr3:13937349	NA	0.75	14.3	0.55	1.08e-38	Ovarian reserve;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.79	-0.3	3.53e-11	Obesity-related traits;
LGG	cis	rs17767392	0.958	rs2332638	chr14:72028915	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.83	-0.42	7.45e-21	Mitral valve prolapse;
LGG	cis	rs10991814	0.920	rs16907323	chr9:94025459	A/G	cg14446406	chr9:93919335	NA	-0.66	-7.4	-0.33	6.57e-13	Neutrophil percentage of granulocytes;
LGG	cis	rs11645898	0.687	rs72787058	chr16:72105084	C/T	cg14768367	chr16:72042858	DHODH	-0.69	-9.4	-0.4	2.54e-19	Blood protein levels;
LGG	cis	rs950776	0.722	rs471889	chr15:78870235	T/C	cg06917634	chr15:78832804	PSMA4	-0.65	-12.1	-0.49	1.82e-29	Sudden cardiac arrest;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.5	-0.33	3.28e-13	Prostate cancer;
LGG	cis	rs977987	1.000	rs977985	chr16:75506947	C/G	cg07303275	chr16:75499416	TMEM170A	0.41	7.31	0.32	1.16e-12	Dupuytren's disease;
LGG	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	trans	rs1493916	0.606	rs10432168	chr18:31312106	T/C	cg04226714	chr8:49833948	SNAI2	-0.44	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs6121246	0.909	rs1994251	chr20:30287328	T/G	cg13852791	chr20:30311386	BCL2L1	0.78	12.61	0.51	1.58e-31	Mean corpuscular hemoglobin;
LGG	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs753778	0.602	rs9792	chr8:142205237	C/T	cg18755752	chr8:142205143	DENND3	0.53	10.91	0.45	8.02e-25	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg08470875	chr2:26401718	FAM59B	-0.37	-6.84	-0.3	2.45e-11	Gut microbiome composition (summer);
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg05793240	chr7:2802953	GNA12	0.33	7.92	0.35	1.77e-14	Height;
LGG	cis	rs10936602	0.539	rs28688695	chr3:169554781	A/G	cg00832555	chr3:169529716	LRRC34	0.35	7.12	0.31	4.08e-12	Renal cell carcinoma;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.74	-0.3	4.69e-11	Aortic root size;
LGG	cis	rs9300255	0.602	rs2851450	chr12:123703501	C/T	cg05973401	chr12:123451056	ABCB9	0.5	7.55	0.33	2.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs60695258	0.550	rs388401	chr4:87974415	C/G	cg11209507	chr4:87813803	C4orf36	-0.45	-7.56	-0.33	2.18e-13	Hematocrit;
LGG	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg27587195	chr5:112824172	MCC	0.46	7.38	0.32	7.24e-13	Type 2 diabetes;
LGG	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg14673194	chr17:80132900	CCDC57	0.47	8.45	0.37	3.69e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9399135	0.967	rs4637662	chr6:135298158	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.53e-19	Red blood cell count;
LGG	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg11584989	chr19:19387371	SF4	0.7	11.56	0.47	2.56e-27	Bipolar disorder;
LGG	cis	rs3087591	0.887	rs7503395	chr17:29440554	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.24	0.55	2.02e-38	Hip circumference;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.7	-0.37	5.84e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg24623649	chr8:11872141	NA	-0.3	-7.07	-0.31	5.87e-12	Triglycerides;
LGG	cis	rs227833	0.560	rs227808	chr6:44666915	T/C	cg18551225	chr6:44695536	NA	-0.49	-6.7	-0.3	6.18e-11	Monobrow;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg03188948	chr7:1209495	NA	0.42	7.44	0.33	5.03e-13	Longevity;Endometriosis;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg20607798	chr8:58055168	NA	0.64	7.13	0.31	3.98e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7202877	0.706	rs1074961	chr16:75389484	C/T	cg03315344	chr16:75512273	CHST6	0.53	7.42	0.33	5.81e-13	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg24250549	chr1:154909240	PMVK	0.7	13.81	0.54	1.46e-36	Prostate cancer;
LGG	cis	rs1371614	0.523	rs4665924	chr2:27139305	T/C	cg12045002	chr2:27069975	DPYSL5	-0.34	-7.16	-0.32	3.18e-12	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	-0.66	-11.32	-0.47	2.21e-26	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg13939156	chr17:80058883	NA	-0.45	-8.59	-0.37	1.3e-16	Life satisfaction;
LGG	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg13013644	chr5:502571	SLC9A3	0.32	7.09	0.31	4.96e-12	Cystic fibrosis severity;
LGG	cis	rs2117029	0.619	rs11168862	chr12:49505958	A/G	cg24176009	chr12:49580217	TUBA1A	0.6	11.52	0.47	3.67e-27	Intelligence (multi-trait analysis);
LGG	trans	rs2524005	1.000	rs2524005	chr6:29899677	C/T	cg06606381	chr12:133084897	FBRSL1	-0.64	-8.87	-0.38	1.58e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs701145	0.878	rs187357	chr3:153958876	C/A	cg17054900	chr3:154042577	DHX36	0.97	12.06	0.49	2.66e-29	Coronary artery disease;
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.47	9.3	0.4	5.54e-19	Personality dimensions;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg11245990	chr11:68621969	NA	0.42	8.99	0.39	6.34e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs561341	0.943	rs508566	chr17:30289861	G/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.54	-0.44	2e-23	Hip circumference adjusted for BMI;
LGG	cis	rs1555895	0.566	rs11253451	chr10:852885	C/T	cg09361094	chr10:834503	NA	-0.29	-7.59	-0.33	1.79e-13	Survival in rectal cancer;
LGG	trans	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs7267979	0.866	rs2424698	chr20:25256106	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.14	0.43	5.76e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg05896524	chr21:47604654	C21orf56	0.64	11.7	0.48	7.26e-28	Testicular germ cell tumor;
LGG	cis	rs11074306	0.543	rs8041183	chr15:28072895	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg09359103	chr1:154839909	KCNN3	-0.52	-10.64	-0.44	8.52e-24	Prostate cancer;
LGG	cis	rs854037	0.698	rs35497805	chr5:57079833	A/G	cg08523694	chr5:57076192	NA	0.62	7.52	0.33	2.91e-13	Birth weight;
LGG	cis	rs2008905	1	rs2008905	chr11:17184623	C/T	cg15432903	chr11:17409602	KCNJ11	0.38	6.91	0.31	1.59e-11	Schizophrenia;
LGG	cis	rs11718455	1.000	rs9854785	chr3:44031295	A/G	cg21419209	chr3:44054225	NA	-0.43	-6.98	-0.31	1e-11	Coronary artery disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02276695	chr19:19774628	ATP13A1	0.42	6.91	0.31	1.58e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1005277	0.691	rs2474558	chr10:38486141	A/C	cg17830980	chr10:43048298	ZNF37B	0.56	11.69	0.48	7.69e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs3806843	0.864	rs2531343	chr5:140129346	A/G	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg20607798	chr8:58055168	NA	-0.59	-7.0	-0.31	9.18e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3888647	0.622	rs4758618	chr11:2995186	A/T	cg05729581	chr11:3078854	CARS	-0.5	-8.44	-0.37	4.17e-16	Type 2 diabetes;
LGG	cis	rs9902453	0.967	rs12449783	chr17:28527653	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	12.73	0.51	4.67e-32	Coffee consumption (cups per day);
LGG	cis	rs4363385	0.720	rs9325996	chr1:152965347	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.06	-0.39	3.56e-18	Inflammatory skin disease;
LGG	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.3e-11	Aortic root size;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.37	0.43	8.23e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg13802316	chr11:70253460	CTTN	-0.59	-7.63	-0.33	1.35e-13	Coronary artery disease;
LGG	cis	rs61990749	0.597	rs13379065	chr14:78141295	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.19	-0.32	2.66e-12	Fibroblast growth factor basic levels;
LGG	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.05	11.32	0.47	2.15e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28588043	1.000	rs7882102	chr1:170985569	C/T	cg03458344	chr1:170964477	C1orf129	-0.49	-7.36	-0.32	8.46e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg13550731	chr2:172543902	DYNC1I2	-0.98	-22.54	-0.72	1.77e-76	Schizophrenia;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	4.15e-21	Electroencephalogram traits;
LGG	cis	rs1552244	1.000	rs3826	chr3:10141065	T/G	cg00149659	chr3:10157352	C3orf10	0.83	10.84	0.45	1.54e-24	Alzheimer's disease;
LGG	cis	rs8180040	0.835	rs6780013	chr3:47452118	G/A	cg27129171	chr3:47204927	SETD2	-0.75	-13.36	-0.53	1.17e-34	Colorectal cancer;
LGG	cis	rs597539	0.652	rs1249474	chr11:68654774	C/T	cg18350739	chr11:68623251	NA	-0.78	-19.2	-0.67	7.15e-61	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582180	0.629	rs74177696	chr2:100938481	C/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4561483	0.798	rs456325	chr16:12012562	C/G	cg08843971	chr16:11963173	GSPT1	-0.64	-15.72	-0.59	6.12e-45	Testicular germ cell tumor;
LGG	cis	rs8005677	1.000	rs8005677	chr14:23376678	T/C	cg01529538	chr14:23388837	RBM23	0.37	6.77	0.3	3.84e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs13136462	chr4:120543173	C/T	cg01244601	chr4:120671846	NA	-0.36	-7.01	-0.31	8.39e-12	Corneal astigmatism;
LGG	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.31	-0.79	1.52e-98	Primary sclerosing cholangitis;
LGG	cis	rs9682041	0.696	rs9872796	chr3:170099393	T/G	cg11886554	chr3:170076028	SKIL	1.02	12.14	0.49	1.24e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs910316	0.967	rs4903293	chr14:75656568	A/G	cg11812906	chr14:75593930	NEK9	-0.54	-9.89	-0.42	4.69e-21	Height;
LGG	cis	rs7107174	1.000	rs10899489	chr11:78095373	G/T	cg02023728	chr11:77925099	USP35	0.44	7.64	0.33	1.24e-13	Testicular germ cell tumor;
LGG	cis	rs3820928	0.874	rs7423610	chr2:227836262	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.52e-14	Pulmonary function;
LGG	cis	rs3806843	0.766	rs2530239	chr5:140062547	C/T	cg19875535	chr5:140030758	IK	-0.53	-10.92	-0.45	7.51e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9322193	0.607	rs12209310	chr6:150226018	G/A	cg07701084	chr6:150067640	NUP43	0.49	7.44	0.33	4.89e-13	Lung cancer;
LGG	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg27572855	chr1:25598939	RHD	0.49	10.89	0.45	9.89e-25	Erythrocyte sedimentation rate;
LGG	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg06022373	chr22:39101656	GTPBP1	0.89	18.11	0.64	8.26e-56	Menopause (age at onset);
LGG	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg04362960	chr10:104952993	NT5C2	-0.56	-10.44	-0.44	4.63e-23	Arsenic metabolism;
LGG	trans	rs9409565	0.826	rs9409550	chr9:97223294	C/G	cg05679027	chr9:99775184	HIATL2	-0.48	-7.92	-0.35	1.79e-14	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg16405210	chr4:1374714	KIAA1530	0.51	8.57	0.37	1.53e-16	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs7746199	0.736	rs13202291	chr6:27698857	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs5769707	0.749	rs8137251	chr22:50036669	G/A	cg06623630	chr22:50017776	C22orf34	-0.47	-9.55	-0.41	7.44e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs899997	0.773	rs62010525	chr15:78968310	C/G	cg14912033	chr15:79043428	NA	0.34	6.99	0.31	9.54e-12	Coronary artery disease or large artery stroke;
LGG	cis	rs2120243	0.647	rs1456099	chr3:157146307	A/T	cg24825693	chr3:157122686	VEPH1	0.37	7.65	0.33	1.21e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.75	-0.34	5.68e-14	Personality dimensions;
LGG	cis	rs1552244	0.554	rs34391585	chr3:9999208	G/C	cg00149659	chr3:10157352	C3orf10	0.55	8.17	0.35	2.97e-15	Alzheimer's disease;
LGG	cis	rs10751667	0.666	rs7395488	chr11:954111	T/C	cg22143635	chr11:980567	AP2A2	0.44	8.25	0.36	1.67e-15	Alzheimer's disease (late onset);
LGG	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg21972741	chr5:435613	AHRR	0.49	8.85	0.38	1.8e-17	Cystic fibrosis severity;
LGG	cis	rs73110464	0.609	rs727266	chr12:53356411	C/T	cg14581129	chr12:53358946	NA	-0.32	-7.38	-0.32	7.5e-13	Cancer (pleiotropy);
LGG	cis	rs6450176	1.000	rs7736354	chr5:53297591	C/T	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.53	-0.47	3.39e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs778371	0.676	rs921055	chr2:233697337	A/C	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.2	-0.46	6.42e-26	Schizophrenia;
LGG	cis	rs4780401	0.755	rs8191297	chr16:11766986	T/C	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.32	-0.32	1.12e-12	Rheumatoid arthritis;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.48	-0.37	3.02e-16	Personality dimensions;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg11245990	chr11:68621969	NA	0.4	8.55	0.37	1.83e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11969893	0.850	rs9485417	chr6:101300038	C/T	cg12253828	chr6:101329408	ASCC3	-1.23	-10.39	-0.43	7.23e-23	Economic and political preferences (immigration/crime);
LGG	cis	rs6430585	0.583	rs111837148	chr2:136612036	G/A	cg07169764	chr2:136633963	MCM6	1.3	26.9	0.78	1.11e-96	Corneal structure;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.65e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.88	-0.3	1.99e-11	Retinal vascular caliber;
LGG	cis	rs9381040	0.626	rs2272986	chr6:41037778	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.38	-7.17	-0.32	2.95e-12	Alzheimer's disease (late onset);
LGG	cis	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg21775007	chr8:11205619	TDH	-0.51	-8.17	-0.36	2.95e-15	Triglycerides;
LGG	cis	rs2880765	0.743	rs8032488	chr15:86012768	T/C	cg13263323	chr15:86062960	AKAP13	-0.36	-7.32	-0.32	1.07e-12	Coronary artery disease;
LGG	cis	rs5758511	0.573	rs4501042	chr22:42245763	C/T	cg15128208	chr22:42549153	NA	-0.44	-7.5	-0.33	3.24e-13	Birth weight;
LGG	cis	rs4680	1.000	rs4633	chr22:19950235	C/T	cg22546130	chr22:19950026	COMT	0.35	8.51	0.37	2.38e-16	Blood metabolite levels;
LGG	cis	rs13217239	0.585	rs114919438	chr6:26963792	T/C	cg12292205	chr6:26970375	C6orf41	-0.56	-11.3	-0.46	2.61e-26	Schizophrenia;
LGG	cis	rs67460515	0.892	rs73026974	chr3:160963231	A/C	cg03342759	chr3:160939853	NMD3	-0.77	-13.82	-0.54	1.35e-36	Parkinson's disease;
LGG	cis	rs9916302	0.904	rs7223331	chr17:37482930	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.51	0.47	4.01e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7215564	0.818	rs1531946	chr17:78630807	G/A	cg06153925	chr17:78755379	RPTOR	0.41	7.0	0.31	9.19e-12	Myopia (pathological);
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg18761221	chr20:60518478	NA	0.54	8.66	0.37	7.68e-17	Obesity-related traits;
LGG	cis	rs10170846	0.893	rs10932967	chr2:223544111	C/T	cg25565276	chr2:223520875	FARSB	0.63	10.8	0.45	2.12e-24	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg14541582	chr5:601475	NA	-0.69	-10.89	-0.45	9.94e-25	Obesity-related traits;
LGG	cis	rs972578	0.791	rs738538	chr22:43281879	A/G	cg01576275	chr22:43409880	NA	-0.24	-7.21	-0.32	2.33e-12	Mean platelet volume;
LGG	cis	rs4839827	1	rs4839827	chr6:96853967	C/T	cg06623918	chr6:96969491	KIAA0776	0.5	8.88	0.38	1.47e-17	Migraine;
LGG	cis	rs2018055	0.618	rs722359	chr6:117792878	T/C	cg14611402	chr6:117803162	DCBLD1	0.3	8.63	0.37	9.81e-17	Diastolic blood pressure;
LGG	cis	rs8053891	0.756	rs12708922	chr16:72001629	A/G	cg09427745	chr16:71932006	KIAA0174	-0.37	-6.74	-0.3	4.7e-11	Coronary artery disease;
LGG	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg12923728	chr3:195709715	SDHAP1	0.56	9.47	0.4	1.41e-19	Mean corpuscular volume;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg16507663	chr6:150244633	RAET1G	0.44	7.17	0.32	2.92e-12	Lung cancer;
LGG	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06470251	chr20:60548479	NA	0.41	7.18	0.32	2.75e-12	Body mass index;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.1	0.6	1.19e-46	Lung cancer;
LGG	cis	rs7267979	0.966	rs7270835	chr20:25435067	C/T	cg06421707	chr20:25228305	PYGB	0.47	9.98	0.42	2.15e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg19143629	chr17:61920732	SMARCD2	-0.41	-6.94	-0.31	1.37e-11	Prudent dietary pattern;
LGG	cis	rs17767392	0.914	rs35613269	chr14:71887814	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	trans	rs561341	1.000	rs473356	chr17:30321762	G/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs4901847	0.679	rs11626913	chr14:58564594	C/T	cg15908186	chr14:58618357	C14orf37	0.46	8.0	0.35	9.95e-15	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7937682	0.593	rs1944117	chr11:111351184	T/C	cg09085632	chr11:111637200	PPP2R1B	0.6	10.19	0.43	3.85e-22	Primary sclerosing cholangitis;
LGG	cis	rs12497850	0.866	rs6791234	chr3:48996137	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.83	-0.3	2.63e-11	Parkinson's disease;
LGG	cis	rs36051895	0.623	rs72703608	chr9:5258127	A/G	cg02405213	chr9:5042618	JAK2	-0.75	-12.36	-0.5	1.53e-30	Pediatric autoimmune diseases;
LGG	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.75	8.27	0.36	1.44e-15	Initial pursuit acceleration;
LGG	cis	rs2762353	0.779	rs1165182	chr6:25837829	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.15	-0.46	9.81e-26	Blood metabolite levels;
LGG	cis	rs2643217	0.953	rs1495188	chr15:38995250	T/A	cg10631289	chr15:39006617	NA	-0.43	-7.43	-0.33	5.39e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg25922239	chr6:33757077	LEMD2	0.42	7.14	0.32	3.6e-12	Crohn's disease;
LGG	trans	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg02002194	chr4:3960332	NA	0.38	7.13	0.31	3.99e-12	Joint mobility (Beighton score);
LGG	cis	rs9303401	0.704	rs7359501	chr17:56641200	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.43	7.33	0.32	1.04e-12	Cognitive test performance;
LGG	cis	rs3736594	0.546	rs6734059	chr2:27808154	C/T	cg27432699	chr2:27873401	GPN1	-0.56	-8.5	-0.37	2.53e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9811920	0.965	rs9837131	chr3:99854514	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.3	0.36	1.14e-15	Axial length;
LGG	cis	rs7474896	0.559	rs1208645	chr10:38132087	C/T	cg25427524	chr10:38739819	LOC399744	0.51	7.51	0.33	3.11e-13	Obesity (extreme);
LGG	cis	rs12190007	0.547	rs1018559	chr6:169854176	A/G	cg15038512	chr6:170123185	PHF10	-0.45	-8.58	-0.37	1.41e-16	Obesity-related traits;
LGG	cis	rs10028773	0.700	rs7690338	chr4:120256468	C/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.89e-21	Educational attainment;
LGG	cis	rs4740619	0.590	rs10810519	chr9:16029411	G/C	cg14451791	chr9:16040625	NA	-0.42	-11.23	-0.46	4.83e-26	Body mass index;
LGG	cis	rs4481887	0.617	rs28719164	chr1:248543802	T/G	cg01631408	chr1:248437212	OR2T33	-0.36	-6.74	-0.3	4.79e-11	Common traits (Other);
LGG	cis	rs7267979	1.000	rs3002702	chr20:25268920	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.29	0.43	1.72e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs208520	0.690	rs12198745	chr6:66722598	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.74	0.64	4.35e-54	Exhaled nitric oxide output;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg27189623	chr16:705930	WDR90	0.41	7.95	0.35	1.47e-14	Height;
LGG	cis	rs7208859	0.673	rs11649765	chr17:29233888	T/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7072216	0.763	rs7091709	chr10:100167605	G/A	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.24	-0.32	1.87e-12	Metabolite levels;
LGG	cis	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg24308560	chr3:49941425	MST1R	-0.22	-6.8	-0.3	3.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.88e-12	Life satisfaction;
LGG	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg06481639	chr22:41940642	POLR3H	0.5	7.01	0.31	8.31e-12	Vitiligo;
LGG	cis	rs1005277	0.579	rs2505197	chr10:38393310	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg00933542	chr6:150070202	PCMT1	0.38	7.04	0.31	6.9e-12	Lung cancer;
LGG	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg08975724	chr8:8085496	FLJ10661	0.44	8.46	0.37	3.58e-16	Mood instability;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-7.67	-0.34	9.93e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs10752881	1.000	rs12753817	chr1:182970337	A/T	cg07928641	chr1:182991847	LAMC1	0.46	9.66	0.41	3e-20	Colorectal cancer;
LGG	cis	rs7223966	0.961	rs17631394	chr17:61646000	A/G	cg17202724	chr17:61916730	SMARCD2	0.38	7.33	0.32	1.03e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs34734847	0.750	rs3914	chr12:121174899	T/C	cg21892295	chr12:121157589	UNC119B	-0.39	-7.39	-0.32	6.81e-13	Mean corpuscular volume;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg06221963	chr1:154839813	KCNN3	-0.52	-11.0	-0.46	3.79e-25	Prostate cancer;
LGG	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg10621924	chr7:39171070	POU6F2	0.48	10.01	0.42	1.72e-21	IgG glycosylation;
LGG	cis	rs7191700	0.578	rs243324	chr16:11354970	A/G	cg00044050	chr16:11439710	C16orf75	0.57	9.65	0.41	3.47e-20	Multiple sclerosis;
LGG	cis	rs1218582	0.710	rs4845685	chr1:154878300	C/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.13	-0.39	2.09e-18	Prostate cancer;
LGG	cis	rs2463822	0.844	rs1919359	chr11:62055703	A/G	cg06239285	chr11:62104954	ASRGL1	1.17	14.13	0.55	5.83e-38	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs975722	0.671	rs213937	chr7:117185071	T/C	cg10524701	chr7:117356490	CTTNBP2	0.44	9.62	0.41	4.4e-20	Coronary artery disease;
LGG	cis	rs709400	0.604	rs7158144	chr14:103887615	A/G	cg26031613	chr14:104095156	KLC1	0.78	13.39	0.53	8.67e-35	Body mass index;
LGG	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg03929089	chr4:120376271	NA	-0.44	-7.06	-0.31	6.13e-12	HDL cholesterol;
LGG	cis	rs6977660	1.000	rs34367208	chr7:19818811	T/G	cg07541023	chr7:19748670	TWISTNB	0.47	7.34	0.32	9.87e-13	Thyroid stimulating hormone;
LGG	cis	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg00405596	chr8:11794950	NA	-0.61	-10.59	-0.44	1.32e-23	Monocyte count;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.49	0.33	3.59e-13	Schizophrenia;
LGG	cis	rs9790314	0.632	rs778645	chr3:160707459	A/T	cg04691961	chr3:161091175	C3orf57	-0.43	-9.23	-0.39	1.01e-18	Morning vs. evening chronotype;
LGG	cis	rs6977660	1.000	rs10260360	chr7:19792824	T/C	cg07541023	chr7:19748670	TWISTNB	0.44	6.73	0.3	5.07e-11	Thyroid stimulating hormone;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg11905131	chr22:24372483	LOC391322	-0.4	-6.99	-0.31	9.8e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.5	0.44	2.86e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2227564	0.620	rs4746143	chr10:75477298	A/G	cg00564723	chr10:75632066	CAMK2G	-0.48	-10.06	-0.42	1.14e-21	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs36071027	0.615	rs56176059	chr5:158414823	T/C	cg04248271	chr5:158524404	EBF1	0.41	7.29	0.32	1.34e-12	Carotid intima media thickness;
LGG	cis	rs7582180	0.607	rs1530029	chr2:100968205	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.14	0.49	1.2e-29	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.661	rs10015965	chr4:120268237	A/G	cg24375607	chr4:120327624	NA	0.52	8.87	0.38	1.55e-17	Corneal astigmatism;
LGG	cis	rs367943	0.799	rs13154055	chr5:112971516	A/T	cg12552261	chr5:112820674	MCC	0.58	10.04	0.42	1.36e-21	Type 2 diabetes;
LGG	cis	rs11971779	0.715	rs55714903	chr7:139074590	T/C	cg07862535	chr7:139043722	LUC7L2	0.5	8.14	0.35	3.71e-15	Diisocyanate-induced asthma;
LGG	cis	rs7107174	0.901	rs4944199	chr11:78122779	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.13	-0.31	3.83e-12	Testicular germ cell tumor;
LGG	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.19	-0.32	2.69e-12	Retinal vascular caliber;
LGG	cis	rs4315565	0.614	rs6546475	chr2:69275428	C/G	cg13358873	chr2:69271042	ANTXR1	0.52	7.43	0.33	5.21e-13	Height;
LGG	cis	rs3796352	1.000	rs11710292	chr3:53117798	T/C	cg12962167	chr3:53033115	SFMBT1	0.78	8.16	0.35	3.17e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-0.74	-16.37	-0.61	7.44e-48	Lymphocyte percentage of white cells;
LGG	cis	rs9326248	0.539	rs10892058	chr11:116876621	C/T	cg20608306	chr11:116969690	SIK3	0.4	12.61	0.51	1.45e-31	Blood protein levels;
LGG	cis	rs9611519	0.894	rs9611486	chr22:41458784	C/G	cg03806693	chr22:41940476	POLR3H	-0.54	-8.17	-0.35	2.96e-15	Neuroticism;
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.77	-0.34	5.05e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg00953403	chr17:74099816	EXOC7	0.42	7.06	0.31	6.06e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs2842992	0.830	rs2758313	chr6:160154099	C/G	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.34	0.32	9.67e-13	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4743820	0.651	rs4744036	chr9:93932466	G/A	cg14446406	chr9:93919335	NA	0.82	13.89	0.54	6.36e-37	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg05625103	chr10:2543513	NA	0.41	7.75	0.34	5.9e-14	Age-related hearing impairment;
LGG	cis	rs7666738	0.791	rs34437628	chr4:99029232	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg27490568	chr2:178487706	NA	0.52	10.16	0.43	4.97e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2412459	0.536	rs7173301	chr15:40269843	C/T	cg16127683	chr15:40268777	EIF2AK4	0.66	9.96	0.42	2.6e-21	Response to haloperidol in psychosis;
LGG	trans	rs7824557	0.564	rs12550129	chr8:11233917	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.2	0.36	2.37e-15	Retinal vascular caliber;
LGG	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10884984	0.874	rs55798624	chr10:112283147	C/T	cg18756771	chr10:112261994	DUSP5	0.67	11.09	0.46	1.6e-25	Facial morphology (factor 22);
LGG	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.42	-0.53	6.42e-35	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.777	rs6502058	chr17:80082500	A/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs6831352	0.918	rs29001203	chr4:100053091	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.52	-0.37	2.2e-16	Alcohol dependence;
LGG	cis	rs4356932	0.935	rs115828298	chr4:76967941	G/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	5.17e-11	Blood protein levels;
LGG	cis	rs8072100	0.666	rs9913014	chr17:45460189	C/T	cg08085267	chr17:45401833	C17orf57	-0.5	-9.28	-0.4	6.33e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7106204	0.748	rs6484032	chr11:24237153	C/A	ch.11.24196551F	chr11:24239977	NA	1.01	16.38	0.61	6.64e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9611565	0.840	rs2234059	chr22:41777913	T/C	cg03806693	chr22:41940476	POLR3H	-0.98	-17.46	-0.63	7.93e-53	Vitiligo;
LGG	cis	rs2224391	0.628	rs2773319	chr6:5258941	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.52	6.94	0.31	1.34e-11	Height;
LGG	cis	rs2802728	0.881	rs2039838	chr1:243582314	A/G	cg05593162	chr1:243577377	SDCCAG8	-0.49	-6.79	-0.3	3.44e-11	Toenail selenium levels;
LGG	trans	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg06521331	chr12:34319734	NA	0.44	7.91	0.35	1.9e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8017423	0.967	rs4904662	chr14:90729427	G/A	cg04374321	chr14:90722782	PSMC1	0.9	19.49	0.67	3.31e-62	Mortality in heart failure;
LGG	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.01	0.52	3.44e-33	Lung cancer in ever smokers;
LGG	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.22	-0.46	5.1e-26	Lung cancer;
LGG	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg12591125	chr7:1885375	MAD1L1	0.48	7.5	0.33	3.39e-13	Bipolar disorder;
LGG	cis	rs4076764	0.958	rs11584957	chr1:163392937	C/T	cg06092702	chr1:163392909	NA	-0.48	-8.55	-0.37	1.83e-16	Motion sickness;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.6	10.2	0.43	3.56e-22	Longevity;
LGG	cis	rs4466137	0.794	rs975595	chr5:83010095	G/A	cg15083037	chr5:83017644	HAPLN1	-0.35	-7.04	-0.31	7.02e-12	Prostate cancer;
LGG	cis	rs1904096	0.506	rs4693378	chr4:95168552	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.95	-0.45	5.64e-25	Type 2 diabetes;
LGG	cis	rs7773004	1.000	rs7773004	chr6:26267755	A/G	cg13736514	chr6:26305472	NA	-0.42	-8.41	-0.36	5.28e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs9911578	0.874	rs302874	chr17:56767996	A/G	cg12560992	chr17:57184187	TRIM37	0.82	13.86	0.54	8.99e-37	Intelligence (multi-trait analysis);
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg16339924	chr4:17578868	LAP3	-0.62	-10.9	-0.45	8.54e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10857712	0.754	rs1052582	chr10:135233840	C/G	cg00491522	chr10:135256596	NA	0.52	8.23	0.36	1.85e-15	Systemic lupus erythematosus;
LGG	cis	rs11690935	0.851	rs9808259	chr2:172648974	C/T	cg21435375	chr2:172878103	MAP1D	-0.32	-7.24	-0.32	1.82e-12	Schizophrenia;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg07791516	chr6:150247246	NA	0.32	7.07	0.31	5.76e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs7826238	0.539	rs2945891	chr8:8155475	C/T	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.67	-0.3	7.16e-11	Systolic blood pressure;
LGG	cis	rs9814567	1.000	rs1880376	chr3:134270347	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg21775007	chr8:11205619	TDH	-0.58	-9.72	-0.41	1.86e-20	Retinal vascular caliber;
LGG	cis	rs8083786	1	rs8083786	chr18:12881361	A/G	cg23598886	chr18:12777645	NA	-0.53	-7.58	-0.33	1.87e-13	Rheumatoid arthritis;
LGG	cis	rs2952156	1.000	rs2643194	chr17:37853048	C/T	cg00129232	chr17:37814104	STARD3	-0.68	-13.58	-0.53	1.36e-35	Asthma;
LGG	cis	rs1790761	0.967	rs1628442	chr11:67238632	C/T	cg00864171	chr11:67383662	NA	-0.44	-7.21	-0.32	2.33e-12	Mean corpuscular volume;
LGG	cis	rs7937682	0.961	rs552387	chr11:111490047	T/G	cg19812747	chr11:111475976	SIK2	-0.49	-10.25	-0.43	2.3e-22	Primary sclerosing cholangitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24503272	chr6:160210831	MRPL18;TCP1	0.4	6.66	0.3	7.62e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.556	rs4665314	chr2:26415912	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.12	-0.7	8.17e-70	Gut microbiome composition (summer);
LGG	cis	rs6138458	1.000	rs227631	chr20:24913653	A/G	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs96067	0.528	rs274131	chr1:36582925	C/T	cg27506609	chr1:36549197	TEKT2	-0.55	-6.95	-0.31	1.23e-11	Corneal structure;
LGG	cis	rs12142240	0.692	rs7529674	chr1:46818508	T/C	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs2204008	0.837	rs2387317	chr12:38235319	T/C	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.79	-0.34	4.36e-14	Skin colour saturation;
LGG	trans	rs1493916	0.837	rs1493908	chr18:31411700	G/A	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg14004847	chr7:1930337	MAD1L1	0.57	9.96	0.42	2.56e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg01864069	chr14:103024347	NA	-0.68	-9.87	-0.42	5.39e-21	Platelet count;
LGG	cis	rs17270561	0.609	rs3922699	chr6:25734969	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs9549367	0.569	rs3024719	chr13:113814225	G/A	cg00898013	chr13:113819073	PROZ	-0.45	-7.71	-0.34	7.93e-14	Platelet distribution width;
LGG	cis	rs10940138	0.830	rs62369638	chr5:67235576	C/G	ch.5.1281357F	chr5:67228439	NA	0.73	12.56	0.5	2.51e-31	Menarche (age at onset);
LGG	cis	rs924043	0.500	rs12527357	chr6:170397916	T/C	cg00389036	chr6:170409598	NA	0.56	7.06	0.31	6.32e-12	Type 1 diabetes;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg07701084	chr6:150067640	NUP43	0.66	11.68	0.48	8.19e-28	Lung cancer;
LGG	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg07636037	chr3:49044803	WDR6	0.6	10.55	0.44	1.82e-23	Resting heart rate;
LGG	cis	rs3741404	0.825	rs7111753	chr11:63942189	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.48	0.33	3.72e-13	Platelet count;
LGG	cis	rs704	0.752	rs6505079	chr17:26718177	T/A	cg10342447	chr17:26645325	TMEM97	-0.39	-7.02	-0.31	8.15e-12	Osteoprotegerin levels;
LGG	cis	rs4820294	1.000	rs739139	chr22:38067011	C/G	cg08835221	chr22:38071607	LGALS1	0.27	7.55	0.33	2.4e-13	Fat distribution (HIV);
LGG	cis	rs7000551	0.689	rs2469753	chr8:22383225	T/C	cg12081754	chr8:22256438	SLC39A14	0.64	11.95	0.49	7.45e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11645453	chr3:52864694	ITIH4	0.39	6.65	0.3	8.06e-11	Electroencephalogram traits;
LGG	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg19784903	chr17:45786737	TBKBP1	-0.32	-6.78	-0.3	3.57e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4363385	0.747	rs6665575	chr1:152960506	G/A	cg13444842	chr1:152974279	SPRR3	-0.45	-9.2	-0.39	1.27e-18	Inflammatory skin disease;
LGG	cis	rs854765	0.647	rs6502637	chr17:17986098	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.88	0.54	7e-37	Total body bone mineral density;
LGG	cis	rs9462027	0.651	rs34493158	chr6:34753339	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.36	-0.47	1.54e-26	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg23758822	chr17:41437982	NA	0.85	14.6	0.56	5.35e-40	Menopause (age at onset);
LGG	cis	rs9359856	0.564	rs72915918	chr6:90430792	G/C	cg13799429	chr6:90582589	CASP8AP2	-0.77	-9.97	-0.42	2.48e-21	Bipolar disorder;
LGG	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14154082	chr13:112174009	NA	-0.43	-9.48	-0.4	1.29e-19	Menarche (age at onset);
LGG	cis	rs4794202	0.629	rs59111282	chr17:45902414	G/T	cg02219949	chr17:45927392	SP6	0.56	6.8	0.3	3.28e-11	Alzheimer's disease (cognitive decline);
LGG	cis	rs6834538	0.597	rs4833414	chr4:113469913	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.78	0.38	3.1e-17	Free thyroxine concentration;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg19168338	chr16:4465731	CORO7	0.89	16.31	0.6	1.41e-47	Schizophrenia;
LGG	cis	rs7208859	0.623	rs73271869	chr17:29152221	G/A	cg13385521	chr17:29058706	SUZ12P	0.84	9.65	0.41	3.48e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg20916646	chr4:852691	GAK	0.62	10.49	0.44	2.97e-23	Sjögren's syndrome;
LGG	cis	rs1005224	0.782	rs34882722	chr14:76153896	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-6.98	-0.31	1.02e-11	Large artery stroke;
LGG	cis	rs701145	0.585	rs896013	chr3:153863873	A/G	cg12800244	chr3:153838788	SGEF	0.77	8.47	0.37	3.18e-16	Coronary artery disease;
LGG	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg06046430	chr4:77819534	ANKRD56	0.56	11.3	0.46	2.65e-26	Emphysema distribution in smoking;
LGG	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs561341	0.783	rs512698	chr17:30292507	G/T	cg13647721	chr17:30228624	UTP6	0.64	7.98	0.35	1.16e-14	Hip circumference adjusted for BMI;
LGG	cis	rs72843166	0.545	rs72839491	chr17:61029908	A/G	cg06641342	chr17:61514920	CYB561	0.46	7.17	0.32	2.96e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9467773	0.596	rs2494693	chr6:26619226	T/C	cg09904177	chr6:26538194	HMGN4	0.67	13.93	0.54	4.36e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2415984	0.622	rs61993301	chr14:46949667	C/T	cg14871534	chr14:47121158	RPL10L	-0.58	-10.15	-0.43	5.4e-22	Number of children ever born;
LGG	cis	rs9300255	0.722	rs1060105	chr12:123806219	C/T	cg05973401	chr12:123451056	ABCB9	-0.46	-6.68	-0.3	6.69e-11	Neutrophil percentage of white cells;
LGG	cis	rs926938	0.527	rs360685	chr1:115499795	G/C	cg12756093	chr1:115239321	AMPD1	0.42	7.89	0.34	2.27e-14	Autism;
LGG	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg03970086	chr16:88974840	CBFA2T3	0.4	7.71	0.34	8.01e-14	Social autistic-like traits;
LGG	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg20608306	chr11:116969690	SIK3	0.35	9.01	0.39	5.33e-18	Blood protein levels;
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.35e-16	Life satisfaction;
LGG	cis	rs11148252	0.846	rs9379	chr13:53050479	G/A	cg16301924	chr13:53314226	LECT1	-0.48	-10.1	-0.42	8.14e-22	Lewy body disease;
LGG	cis	rs8180040	0.966	rs11710322	chr3:47331136	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-15.65	-0.59	1.26e-44	Colorectal cancer;
LGG	cis	rs1055129	0.560	rs3682	chr17:73942150	A/G	cg08125733	chr17:73851984	WBP2	0.42	7.02	0.31	8.01e-12	White matter hyperintensity burden;
LGG	cis	rs56399783	0.614	rs55776032	chr7:2762255	T/C	cg19731401	chr7:2775893	GNA12	0.37	7.32	0.32	1.1e-12	Childhood ear infection;
LGG	cis	rs11785693	1.000	rs11785693	chr8:4976913	A/T	cg26367366	chr8:4980734	NA	0.54	7.84	0.34	3.11e-14	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs909674	0.524	rs5750821	chr22:39825492	A/T	cg04986931	chr22:39850128	NA	0.34	7.95	0.35	1.49e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs11785693	0.862	rs62491202	chr8:5001470	C/A	cg26367366	chr8:4980734	NA	1.0	14.63	0.56	4.1e-40	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-8.16	-0.35	3.08e-15	Schizophrenia;
LGG	trans	rs3857536	0.813	rs7768944	chr6:66951088	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.71	0.54	3.77e-36	Bladder cancer;
LGG	cis	rs9308731	0.644	rs1837369	chr2:111874276	C/T	cg19992207	chr2:111874495	ACOXL	-0.36	-6.74	-0.3	4.81e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11650776	1	rs11650776	chr17:37641402	G/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.43	-0.58	1.21e-43	Lung function (FEV1);
LGG	cis	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.48	-0.33	3.84e-13	Joint mobility (Beighton score);
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg14159672	chr1:205819179	PM20D1	-0.75	-15.58	-0.59	2.53e-44	Menarche (age at onset);
LGG	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.63	0.51	1.3e-31	Hip circumference adjusted for BMI;
LGG	trans	rs8073060	0.586	rs72829922	chr17:34044809	G/A	cg19694781	chr19:47549865	TMEM160	1.16	17.64	0.63	1.17e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg12386194	chr3:101231763	SENP7	0.7	12.1	0.49	1.75e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs8127571	0.551	rs2838986	chr21:47145374	C/T	cg11214348	chr21:47283868	PCBP3	0.44	6.87	0.3	2.12e-11	Immune reponse to smallpox (secreted IFN-alpha);
LGG	cis	rs950776	0.518	rs8025429	chr15:78836362	G/A	cg06917634	chr15:78832804	PSMA4	-0.83	-17.56	-0.63	2.76e-53	Sudden cardiac arrest;
LGG	cis	rs1865760	0.566	rs9379825	chr6:26083871	C/A	cg16482183	chr6:26056742	HIST1H1C	0.55	9.91	0.42	3.86e-21	Height;
LGG	cis	rs7711186	0.786	rs4077796	chr5:178052597	C/T	cg17371294	chr5:178012716	COL23A1	-0.67	-6.91	-0.31	1.62e-11	Urate levels in obese individuals;
LGG	cis	rs8141529	0.719	rs5762880	chr22:29287816	T/G	cg02153584	chr22:29168773	CCDC117	0.6	9.52	0.4	9.55e-20	Lymphocyte counts;
LGG	trans	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg02002194	chr4:3960332	NA	-0.42	-7.91	-0.35	1.86e-14	Mood instability;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg25785477	chr4:130014987	SCLT1;C4orf33	0.42	7.04	0.31	6.81e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1978968	0.717	rs8139578	chr22:18468208	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.64	-13.43	-0.53	5.75e-35	Presence of antiphospholipid antibodies;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg03528353	chr17:61819722	STRADA	0.44	7.42	0.33	5.67e-13	Prudent dietary pattern;
LGG	cis	rs854765	0.647	rs854809	chr17:18006539	C/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.79	-0.51	2.87e-32	Total body bone mineral density;
LGG	cis	rs9790314	0.586	rs16832246	chr3:161109916	A/G	cg04691961	chr3:161091175	C3orf57	0.41	8.35	0.36	7.78e-16	Morning vs. evening chronotype;
LGG	cis	rs9947295	0.649	rs73401826	chr18:11783442	A/C	cg14735704	chr18:11749182	GNAL	0.47	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	cis	rs73787773	0.867	rs73787778	chr5:111477958	G/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.66	-8.12	-0.35	4.13e-15	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs5756813	0.688	rs2413483	chr22:38127950	C/T	cg24232236	chr22:38142998	TRIOBP	0.38	7.37	0.32	7.84e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	0.66	8.53	0.37	2.18e-16	Lung function (FEV1/FVC);
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg18379455	chr17:41446167	NA	-0.33	-7.82	-0.34	3.58e-14	Menopause (age at onset);
LGG	cis	rs12549902	0.966	rs12544241	chr8:41514888	G/A	cg21772509	chr8:41503840	NKX6-3	0.86	19.04	0.66	4e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs1941023	0.503	rs10750936	chr11:60144180	G/A	cg08716584	chr11:60157161	MS4A7	-0.43	-8.49	-0.37	2.85e-16	Congenital heart disease (maternal effect);
LGG	cis	rs2836974	0.644	rs11088471	chr21:40699313	A/G	cg11644478	chr21:40555479	PSMG1	-0.71	-12.61	-0.51	1.51e-31	Cognitive function;
LGG	trans	rs9929218	0.539	rs1125557	chr16:68809599	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	18.49	0.65	1.46e-57	Colorectal cancer;
LGG	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.88	0.34	2.34e-14	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.46	-0.4	1.55e-19	Triglycerides;
LGG	cis	rs727505	1.000	rs68091803	chr7:124526331	C/T	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg27426351	chr10:43362370	NA	-0.55	-7.83	-0.34	3.42e-14	Blood protein levels;
LGG	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg08603382	chr10:743973	NA	0.39	7.22	0.32	2.16e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs6582630	0.519	rs10880629	chr12:38533611	T/G	cg26384229	chr12:38710491	ALG10B	0.93	21.87	0.71	2.52e-73	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23747904	chr2:120301847	PCDP1	0.47	7.96	0.35	1.31e-14	Cognitive performance;
LGG	cis	rs1822534	0.510	rs310752	chr3:12272683	G/A	cg20888142	chr3:12045662	SYN2	0.37	6.91	0.31	1.65e-11	Plateletcrit;Lymphocyte counts;White blood cell count;
LGG	trans	rs10838798	0.504	rs11039627	chr11:48293931	C/T	cg03929089	chr4:120376271	NA	-0.5	-8.22	-0.36	2.09e-15	Height;
LGG	trans	rs6582630	0.519	rs11514078	chr12:38408817	G/C	cg06521331	chr12:34319734	NA	-0.52	-9.07	-0.39	3.54e-18	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs637571	0.522	rs12797319	chr11:65735672	G/A	cg17712092	chr4:129076599	LARP1B	0.74	14.19	0.55	3.38e-38	Eosinophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08558449	chr16:57023715	NLRC5	0.5	7.31	0.32	1.15e-12	Gut microbiome composition (summer);
LGG	cis	rs11630290	1.000	rs72750990	chr15:64005333	C/T	cg12036633	chr15:63758958	NA	-0.63	-8.7	-0.37	6.03e-17	Iris characteristics;
LGG	cis	rs988958	0.675	rs12712815	chr2:42224021	A/G	cg27252766	chr2:42229092	NA	0.56	8.83	0.38	2.22e-17	Hypospadias;
LGG	cis	rs4423214	0.959	rs12793224	chr11:71168710	G/A	cg05163923	chr11:71159392	DHCR7	0.72	14.08	0.55	1.03e-37	Vitamin D levels;
LGG	cis	rs7814319	0.838	rs4537274	chr8:97232665	A/G	cg20787634	chr8:97240163	UQCRB	-0.71	-15.56	-0.59	3.16e-44	Lung function (FVC);
LGG	cis	rs787274	0.543	rs10759590	chr9:115610567	G/C	cg13803584	chr9:115635662	SNX30	-0.66	-7.91	-0.35	1.88e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2130392	1.000	rs873686	chr4:185638876	A/G	cg21366198	chr4:185655624	MLF1IP	0.41	6.97	0.31	1.11e-11	Kawasaki disease;
LGG	cis	rs4622507	0.566	rs936879	chr16:55078450	G/A	cg09947736	chr16:55091198	NA	0.81	12.84	0.51	1.65e-32	Social communication problems;
LGG	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.94e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10504130	0.569	rs60153173	chr8:52690624	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7208859	0.673	rs11656845	chr17:29206164	G/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg13647721	chr17:30228624	UTP6	0.69	8.0	0.35	9.85e-15	Hip circumference adjusted for BMI;
LGG	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14952266	chr13:112191215	NA	-0.41	-7.5	-0.33	3.38e-13	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.65e-54	Menopause (age at onset);
LGG	cis	rs2120019	0.608	rs4886414	chr15:75308650	C/T	cg17294928	chr15:75287854	SCAMP5	1.0	19.28	0.67	3e-61	Blood trace element (Zn levels);
LGG	cis	rs4689388	0.926	rs9998519	chr4:6292909	C/T	cg00701064	chr4:6280414	WFS1	0.74	16.58	0.61	8.17e-49	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9549367	0.789	rs9549699	chr13:113878263	T/A	cg18105134	chr13:113819100	PROZ	-0.69	-13.96	-0.54	3.34e-37	Platelet distribution width;
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.38	-0.53	9.53e-35	Alzheimer's disease;
LGG	trans	rs9354308	0.764	rs9351530	chr6:66589648	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs2737618	0.722	rs2821333	chr1:200093253	A/C	cg21825944	chr1:200113062	NR5A2	-0.61	-11.93	-0.48	8.82e-29	Uric acid levels;
LGG	cis	rs8028313	0.630	rs28565266	chr15:67938011	C/G	cg18567174	chr15:68126065	LBXCOR1	-0.4	-7.64	-0.33	1.24e-13	Obesity;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg03727229	chr11:118479170	PHLDB1	0.37	6.7	0.3	6.16e-11	Cholesterol, total;
LGG	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs7681440	0.647	rs11941110	chr4:90819569	T/C	cg06848047	chr4:90757629	SNCA	-0.35	-6.67	-0.3	7.44e-11	Dementia with Lewy bodies;
LGG	cis	rs16912285	0.892	rs76549901	chr11:24335849	G/A	ch.11.24196551F	chr11:24239977	NA	0.82	8.64	0.37	9.25e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs736408	0.608	rs6445534	chr3:52743384	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.84e-12	Bipolar disorder;
LGG	cis	rs10504229	0.906	rs116341227	chr8:58190532	G/C	cg11062466	chr8:58055876	NA	0.48	8.26	0.36	1.49e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg15557168	chr22:42548783	NA	0.39	8.44	0.37	4e-16	Schizophrenia;
LGG	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	9.22	0.39	1.02e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs71403859	0.803	rs7203606	chr16:71590511	A/C	cg08717414	chr16:71523259	ZNF19	-1.18	-16.21	-0.6	3.94e-47	Post bronchodilator FEV1;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.74	-0.64	4.39e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs2243480	1.000	rs58669269	chr7:65951953	T/C	cg12463550	chr7:65579703	CRCP	0.77	8.29	0.36	1.24e-15	Diabetic kidney disease;
LGG	cis	rs10256972	0.552	rs2960837	chr7:1203957	A/G	cg18402987	chr7:1209562	NA	0.4	7.53	0.33	2.73e-13	Longevity;Endometriosis;
LGG	cis	rs7020830	0.931	rs13295115	chr9:37157964	T/G	cg14294708	chr9:37120828	ZCCHC7	1.2	33.53	0.84	5.92e-126	Schizophrenia;
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.93	-0.38	1.04e-17	Neuroticism;
LGG	cis	rs7119	0.717	rs35268067	chr15:77753688	C/G	cg05673287	chr15:77411982	SGK269	-0.44	-9.48	-0.4	1.28e-19	Type 2 diabetes;
LGG	cis	rs5015933	0.902	rs7872015	chr9:128131133	C/G	cg14078157	chr9:128172775	NA	-0.35	-6.69	-0.3	6.26e-11	Body mass index;
LGG	cis	rs11885103	0.791	rs2724898	chr2:587948	G/C	cg21195176	chr2:593345	NA	0.41	7.82	0.34	3.51e-14	Heschl's gyrus morphology;
LGG	cis	rs473651	1.000	rs473651	chr2:239335401	A/C	cg18131467	chr2:239335373	ASB1	1.02	23.73	0.74	4.92e-82	Multiple system atrophy;
LGG	cis	rs283228	0.535	rs687697	chr6:101721893	T/C	cg27451362	chr6:101846650	GRIK2	0.92	13.13	0.52	1.1e-33	Coenzyme Q10 levels;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.6	10.4	0.44	6.32e-23	Obesity-related traits;
LGG	cis	rs988958	0.530	rs12996334	chr2:42218684	G/A	cg27428208	chr2:42229179	NA	0.52	8.07	0.35	6.05e-15	Hypospadias;
LGG	cis	rs4689388	0.926	rs11725500	chr4:6293919	C/G	cg14416269	chr4:6271139	WFS1	0.51	9.34	0.4	4.12e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.92	-0.48	9.79e-29	Testicular germ cell tumor;
LGG	cis	rs1620921	0.505	rs9456586	chr6:161207643	G/A	cg01280913	chr6:161186852	NA	-0.51	-10.75	-0.45	3.35e-24	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2243480	1.000	rs1499614	chr7:65730798	A/T	cg18252515	chr7:66147081	NA	-1.4	-20.29	-0.69	6.13e-66	Diabetic kidney disease;
LGG	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg00717180	chr2:96193071	NA	-0.42	-7.54	-0.33	2.44e-13	Height;
LGG	cis	rs2836974	0.897	rs6517513	chr21:40526878	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs16854884	0.657	rs35067746	chr3:143747147	T/A	cg06585982	chr3:143692056	C3orf58	0.61	10.6	0.44	1.22e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs6582630	0.622	rs11831595	chr12:38511489	C/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.38	-0.4	2.97e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs11761941	chr7:1097183	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	9.64	0.41	3.77e-20	Longevity;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07659893	chr17:61819838	STRADA	-0.47	-7.92	-0.35	1.75e-14	Prudent dietary pattern;
LGG	cis	rs877282	0.898	rs11253350	chr10:765968	G/A	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.05e-11	Uric acid levels;
LGG	cis	rs1034435	0.755	rs6007871	chr22:48894392	C/G	cg05992904	chr22:48892994	FAM19A5	-0.8	-16.61	-0.61	6.04e-49	Late-onset Alzheimer's disease;
LGG	cis	rs72781680	0.821	rs1022346	chr2:24127849	T/C	cg08917208	chr2:24149416	ATAD2B	0.66	8.62	0.37	1.05e-16	Lymphocyte counts;
LGG	cis	rs4665809	0.590	rs2289019	chr2:26420809	G/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.27	-0.36	1.39e-15	Gut microbiome composition (summer);
LGG	cis	rs16870629	1.000	rs16870629	chr5:1015063	C/T	cg07267674	chr5:1049712	NA	-0.58	-10.61	-0.44	1.11e-23	QT interval;
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.54	-0.33	2.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg24631222	chr15:78858424	CHRNA5	0.46	7.06	0.31	6.11e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.44	-0.37	3.95e-16	Prudent dietary pattern;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg04861929	chr11:109293070	C11orf87	0.52	9.59	0.41	5.31e-20	Schizophrenia;
LGG	cis	rs938554	0.876	rs6449139	chr4:9934111	A/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.11	0.31	4.34e-12	Blood metabolite levels;
LGG	cis	rs17508449	0.547	rs55646484	chr1:114398774	C/A	cg26035817	chr1:114414802	PTPN22	-0.46	-6.75	-0.3	4.33e-11	Leprosy;
LGG	trans	rs6787172	0.651	rs6441195	chr3:158151746	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	8.91e-13	Subjective well-being;
LGG	cis	rs1577917	0.917	rs2218594	chr6:86543766	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.21	-0.49	6.3e-30	Response to antipsychotic treatment;
LGG	cis	rs2153535	0.601	rs2143353	chr6:8530111	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.56e-22	Motion sickness;
LGG	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg13647721	chr17:30228624	UTP6	0.6	7.72	0.34	7.01e-14	Hip circumference adjusted for BMI;
LGG	cis	rs8031584	0.697	rs798080	chr15:31122169	T/C	cg08109568	chr15:31115862	NA	0.6	10.28	0.43	1.85e-22	Huntington's disease progression;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg17202724	chr17:61916730	SMARCD2	-0.6	-14.58	-0.56	6.99e-40	Prudent dietary pattern;
LGG	trans	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg06437703	chr8:37914619	EIF4EBP1	-0.65	-11.67	-0.48	8.85e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6724607	1.000	rs4321393	chr2:191452899	G/T	cg20818283	chr2:191399100	TMEM194B	0.3	7.18	0.32	2.74e-12	Pulse pressure;
LGG	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.67	-0.3	7.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs4740619	0.819	rs10962126	chr9:15723336	C/T	cg14451791	chr9:16040625	NA	0.34	8.85	0.38	1.85e-17	Body mass index;
LGG	cis	rs11628318	0.588	rs12185065	chr14:103074636	A/C	cg12046867	chr14:103022105	NA	0.43	8.74	0.38	4.47e-17	Platelet count;
LGG	cis	rs1707322	0.648	rs4439382	chr1:46150805	C/T	cg03146154	chr1:46216737	IPP	0.55	10.26	0.43	2.19e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4819052	0.807	rs1075788	chr21:46666564	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.85	0.38	1.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs116095464	0.558	rs6878087	chr5:223117	C/T	cg22496380	chr5:211416	CCDC127	0.99	13.59	0.53	1.26e-35	Breast cancer;
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg19635926	chr16:89946313	TCF25	0.69	6.77	0.3	3.87e-11	Skin colour saturation;
LGG	cis	rs62238980	0.614	rs17682385	chr22:32387572	C/T	cg02631450	chr22:32366979	NA	1.01	9.71	0.41	2.06e-20	Childhood ear infection;
LGG	cis	rs283228	0.833	rs283208	chr6:101729346	A/C	cg27451362	chr6:101846650	GRIK2	0.51	8.09	0.35	5.13e-15	Coenzyme Q10 levels;
LGG	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.05	-0.35	7.03e-15	Retinal vascular caliber;
LGG	cis	rs12410462	0.551	rs6693348	chr1:227719467	C/G	cg23173402	chr1:227635558	NA	-0.35	-6.68	-0.3	6.78e-11	Major depressive disorder;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1461503	0.934	rs7113330	chr11:122843358	C/T	cg27398637	chr11:122830231	C11orf63	-0.67	-13.34	-0.53	1.3600000000000001e-34	Menarche (age at onset);
LGG	trans	rs225245	0.782	rs321618	chr17:33912404	A/G	cg19694781	chr19:47549865	TMEM160	-0.41	-7.08	-0.31	5.47e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs1048238	0.506	rs7552077	chr1:16196759	A/G	cg21385522	chr1:16154831	NA	0.56	10.39	0.43	7.31e-23	Systolic blood pressure;
LGG	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg05234568	chr11:5960015	NA	-0.49	-8.52	-0.37	2.3e-16	DNA methylation (variation);
LGG	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg17971929	chr21:40555470	PSMG1	0.87	17.36	0.63	2.21e-52	Cognitive function;
LGG	cis	rs11105298	0.891	rs10858902	chr12:89927789	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.27	-0.4	6.97e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs597583	0.664	rs4936384	chr11:117398591	C/T	cg27161313	chr11:117392002	DSCAML1	-0.5	-8.16	-0.35	3.15e-15	Putamen volume;
LGG	cis	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg24110177	chr3:50126178	RBM5	0.61	11.22	0.46	5.22e-26	Body mass index;
LGG	cis	rs2404602	0.716	rs67204011	chr15:76846555	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	cis	rs2303745	0.589	rs1965717	chr19:17398559	C/T	cg04248312	chr19:17393744	ANKLE1	-0.66	-10.87	-0.45	1.19e-24	Systemic lupus erythematosus;
LGG	cis	rs17767392	0.846	rs4899394	chr14:71773497	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.83	-0.38	2.25e-17	Mitral valve prolapse;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg07677032	chr17:61819896	STRADA	0.65	11.79	0.48	3.07e-28	Prudent dietary pattern;
LGG	cis	rs6456156	0.846	rs204293	chr6:167514481	T/C	cg07741184	chr6:167504864	NA	0.34	7.71	0.34	7.93e-14	Primary biliary cholangitis;
LGG	cis	rs3806843	0.735	rs778596	chr5:140037272	G/A	cg19875535	chr5:140030758	IK	-0.57	-11.9	-0.48	1.17e-28	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9911578	0.835	rs3744093	chr17:56492800	T/C	cg12560992	chr17:57184187	TRIM37	-0.81	-13.52	-0.53	2.33e-35	Intelligence (multi-trait analysis);
LGG	cis	rs2832191	0.791	rs2832197	chr21:30497790	T/C	cg08807101	chr21:30365312	RNF160	-0.82	-16.77	-0.61	1.1e-49	Dental caries;
LGG	cis	rs8067545	0.611	rs733794	chr17:20157957	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.15	-0.43	5.66e-22	Schizophrenia;
LGG	cis	rs12586317	0.511	rs113770696	chr14:35444383	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.44	0.53	5.56e-35	Psoriasis;
LGG	cis	rs4704846	0.556	rs2862719	chr5:156500629	A/G	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.92	-0.35	1.78e-14	Blood protein levels;
LGG	cis	rs10819861	0.645	rs10739800	chr9:98853170	C/A	cg14508093	chr9:98862825	NA	0.3	7.21	0.32	2.26e-12	Electrocardiographic traits;
LGG	cis	rs2404602	0.692	rs2120108	chr15:76869929	G/T	cg22467129	chr15:76604101	ETFA	0.42	6.93	0.31	1.4e-11	Blood metabolite levels;
LGG	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg23649088	chr2:200775458	C2orf69	-0.45	-7.65	-0.33	1.21e-13	QT interval;
LGG	cis	rs2645694	0.626	rs2703143	chr4:77830441	A/G	cg10057126	chr4:77819792	ANKRD56	0.35	6.67	0.3	7.4e-11	Emphysema distribution in smoking;
LGG	cis	rs6784615	1.000	rs34628357	chr3:52362580	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.73	0.34	6.6e-14	Waist-hip ratio;
LGG	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg27523141	chr10:43048294	ZNF37B	0.38	7.49	0.33	3.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2635047	0.601	rs2576057	chr18:44644127	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.6	0.37	1.26e-16	Educational attainment;
LGG	cis	rs6598955	0.640	rs4233460	chr1:26633387	A/G	cg04990556	chr1:26633338	UBXN11	-0.71	-14.59	-0.56	5.91e-40	Obesity-related traits;
LGG	cis	rs910187	0.571	rs6512428	chr20:45807822	T/C	cg27589058	chr20:45804311	EYA2	-0.36	-9.4	-0.4	2.58e-19	Migraine;
LGG	cis	rs9790314	0.637	rs778649	chr3:160709377	C/T	cg03342759	chr3:160939853	NMD3	-0.44	-7.47	-0.33	3.99e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg24829409	chr8:58192753	C8orf71	-0.79	-10.61	-0.44	1.09e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.520	rs11123764	chr2:99750677	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.36	0.63	2.36e-52	Chronic sinus infection;
LGG	cis	rs7618915	0.547	rs6768697	chr3:52703615	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.19	-0.32	2.68e-12	Bipolar disorder;
LGG	cis	rs35306767	0.953	rs11253517	chr10:970524	A/G	cg26597838	chr10:835615	NA	-0.61	-9.13	-0.39	2.13e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.69	12.74	0.51	4.23e-32	Obesity-related traits;
LGG	cis	rs1953600	0.870	rs2789690	chr10:81938204	G/T	cg04850286	chr10:81895943	PLAC9	0.44	9.81	0.41	8.85e-21	Sarcoidosis;
LGG	trans	rs1459104	0.866	rs28873990	chr11:54812748	G/A	cg15704280	chr7:45808275	SEPT13	0.77	7.62	0.33	1.43e-13	Body mass index;
LGG	cis	rs35160687	0.814	rs6547673	chr2:86528938	A/G	cg10973622	chr2:86423274	IMMT	0.46	8.18	0.36	2.8e-15	Night sleep phenotypes;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.76	0.54	2.35e-36	Obesity-related traits;
LGG	trans	rs73198271	0.565	rs575895	chr8:8594247	G/A	cg16141378	chr3:129829833	LOC729375	0.34	6.86	0.3	2.28e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs11203032	0.831	rs4399251	chr10:90943634	A/C	cg16672925	chr10:90967113	CH25H	0.75	11.23	0.46	4.91e-26	Heart failure;
LGG	cis	rs4788570	0.547	rs7202479	chr16:71759679	A/C	cg06353428	chr16:71660113	MARVELD3	1.26	21.43	0.71	2.89e-71	Intelligence (multi-trait analysis);
LGG	cis	rs7511006	1.000	rs7364173	chr22:50681029	C/T	cg08875078	chr22:50639485	SELO	-0.45	-7.38	-0.32	7.35e-13	Obesity-related traits;
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.16	0.39	1.63e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7666738	0.830	rs6854994	chr4:98977624	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs883565	0.569	rs784513	chr3:39164915	G/A	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs758324	0.561	rs407204	chr5:131327465	C/G	cg06307176	chr5:131281290	NA	0.45	6.77	0.3	3.96e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7216064	1.000	rs9913471	chr17:65874495	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.47e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg15971980	chr6:150254442	NA	0.41	7.22	0.32	2.14e-12	Lung cancer;
LGG	cis	rs4538187	0.950	rs11691987	chr2:64147999	T/C	cg02541582	chr2:64069798	UGP2	-0.62	-14.64	-0.56	3.75e-40	Systolic blood pressure;
LGG	cis	rs10895140	0.709	rs1938840	chr11:101485915	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg24375607	chr4:120327624	NA	0.54	9.22	0.39	1.08e-18	Corneal astigmatism;
LGG	cis	rs7635838	0.565	rs346067	chr3:11252095	T/C	cg00170343	chr3:11313890	ATG7	0.43	7.34	0.32	9.76e-13	HDL cholesterol;
LGG	cis	rs9910055	1.000	rs9910055	chr17:42283037	C/T	cg19774624	chr17:42201019	HDAC5	-0.82	-14.64	-0.56	3.77e-40	Total body bone mineral density;
LGG	cis	rs13177180	0.769	rs6878790	chr5:114882201	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.39	-8.5	-0.37	2.72e-16	Conotruncal heart defects (inherited effects);
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs9325144	0.752	rs12300353	chr12:39154492	G/C	cg04568710	chr12:38710424	ALG10B	-0.36	-7.32	-0.32	1.07e-12	Morning vs. evening chronotype;
LGG	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg19539972	chr4:7069911	GRPEL1	-0.76	-10.2	-0.43	3.64e-22	Monocyte percentage of white cells;
LGG	cis	rs8017423	0.967	rs55894943	chr14:90714799	A/G	cg04374321	chr14:90722782	PSMC1	0.86	18.14	0.64	5.81e-56	Mortality in heart failure;
LGG	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs1847505	0.609	rs7327571	chr13:61487601	C/G	cg25164009	chr13:61490935	NA	-0.58	-8.99	-0.39	6.17e-18	Polychlorinated biphenyl levels;
LGG	cis	rs11677416	0.961	rs1894399	chr2:113540177	C/T	cg27083787	chr2:113543245	IL1A	0.53	8.85	0.38	1.93e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg16208657	chr15:68119293	LBXCOR1	-0.34	-6.66	-0.3	7.57e-11	Obesity;
LGG	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.5	11.67	0.48	8.79e-28	Oropharynx cancer;
LGG	cis	rs9397585	0.857	rs6910440	chr6:153372108	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.69	0.56	2.25e-40	Body mass index;
LGG	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	1.000	rs12363179	chr11:111568091	G/A	cg09085632	chr11:111637200	PPP2R1B	1.18	25.8	0.77	1.29e-91	Primary sclerosing cholangitis;
LGG	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.31	0.4	5.22e-19	Height;
LGG	cis	rs6831352	0.879	rs56222233	chr4:100069627	T/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg24829409	chr8:58192753	C8orf71	-0.67	-9.72	-0.41	1.93e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.04	0.52	2.62e-33	Menopause (age at onset);
LGG	cis	rs283228	0.535	rs2852509	chr6:101844515	A/G	cg02011392	chr6:101847541	GRIK2	0.5	7.24	0.32	1.89e-12	Coenzyme Q10 levels;
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs9300255	0.510	rs1727322	chr12:123699520	A/G	cg05973401	chr12:123451056	ABCB9	0.48	6.93	0.31	1.41e-11	Neutrophil percentage of white cells;
LGG	cis	rs4430311	0.964	rs2953331	chr1:244024268	A/G	cg25706552	chr1:244017396	NA	-0.66	-17.1	-0.62	3.7e-51	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs11628318	0.515	rs11850580	chr14:103156586	C/T	cg12046867	chr14:103022105	NA	0.43	8.01	0.35	9.7e-15	Platelet count;
LGG	cis	rs875971	0.895	rs6460300	chr7:65952924	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs780096	0.565	rs10169261	chr2:27727314	C/T	cg22903471	chr2:27725779	GCKR	-0.58	-13.2	-0.52	5.33e-34	Total body bone mineral density;
LGG	cis	rs12477438	0.677	rs12475034	chr2:99699464	A/G	cg08885076	chr2:99613938	TSGA10	-0.6	-11.54	-0.47	2.9e-27	Chronic sinus infection;
LGG	cis	rs7247513	0.639	rs12984441	chr19:12760287	A/C	cg01871581	chr19:12707946	ZNF490	-0.41	-8.23	-0.36	1.91e-15	Bipolar disorder;
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs79387448	0.638	rs6741230	chr2:103069631	C/T	cg20060108	chr2:102954350	IL1RL1	-0.45	-6.88	-0.3	1.89e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25072359	chr17:41440525	NA	0.53	9.88	0.42	5.12e-21	Menopause (age at onset);
LGG	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.37	-0.5	1.42e-30	Height;
LGG	cis	rs7617773	0.963	rs9822496	chr3:48181333	T/C	cg11946769	chr3:48343235	NME6	0.5	8.01	0.35	9.61e-15	Coronary artery disease;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.49	-9.72	-0.41	1.84e-20	Personality dimensions;
LGG	cis	rs13401104	0.716	rs12185623	chr2:237128932	G/C	cg15742758	chr2:237126235	ASB18	0.47	7.82	0.34	3.66e-14	Educational attainment;
LGG	cis	rs7208859	0.623	rs7208088	chr17:29143667	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.82	0.48	2.45e-28	Resting heart rate;
LGG	cis	rs12681288	0.676	rs7011999	chr8:1008446	A/G	cg04851639	chr8:1020857	NA	-0.44	-8.9	-0.38	1.31e-17	Schizophrenia;
LGG	cis	rs11577318	0.853	rs4450008	chr1:26643860	C/A	cg10402321	chr1:26617780	UBXN11	-0.47	-8.12	-0.35	4.15e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs67460515	0.529	rs11712713	chr3:160852471	A/G	cg04691961	chr3:161091175	C3orf57	-0.43	-8.68	-0.37	6.64e-17	Parkinson's disease;
LGG	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg00092383	chr7:157075207	NA	0.38	6.71	0.3	5.84e-11	Body mass index;
LGG	cis	rs7215564	0.908	rs9900687	chr17:78739721	C/T	cg16980736	chr17:78789706	RPTOR	0.59	8.06	0.35	6.76e-15	Myopia (pathological);
LGG	cis	rs1707322	1.000	rs34446427	chr1:46417655	A/C	cg03146154	chr1:46216737	IPP	0.53	10.13	0.43	6.49e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs28374715	0.783	rs11630656	chr15:41570909	T/G	cg18705301	chr15:41695430	NDUFAF1	-1.28	-27.89	-0.79	3.51e-101	Ulcerative colitis;
LGG	cis	rs10832963	0.924	rs10500834	chr11:18638712	A/T	cg09201001	chr11:18656081	SPTY2D1	0.99	21.23	0.7	2.26e-70	Breast cancer;
LGG	cis	rs300774	0.925	rs441469	chr2:129028	C/T	cg04617936	chr2:214353	NA	-0.51	-7.87	-0.34	2.48e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs1552244	1.000	rs4260416	chr3:10125283	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.19	0.39	1.29e-18	Alzheimer's disease;
LGG	cis	rs1385374	0.698	rs2170988	chr12:129290876	A/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs11157436	0.602	rs17255440	chr14:22635193	T/C	cg00994629	chr14:22694547	NA	0.33	7.2	0.32	2.52e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs7584330	0.737	rs10445707	chr2:238368751	A/G	cg16989719	chr2:238392110	NA	-0.33	-7.01	-0.31	8.42e-12	Prostate cancer;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg17830980	chr10:43048298	ZNF37B	-0.6	-13.47	-0.53	3.99e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	0.789	rs1968752	chr16:28631585	G/T	cg00198680	chr16:28758506	NA	0.29	7.05	0.31	6.64e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg22920501	chr2:26401640	FAM59B	-0.42	-8.8	-0.38	2.79e-17	Gut microbiome composition (summer);
LGG	trans	rs853679	0.607	rs35098436	chr6:28134221	T/C	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs12431204	0.838	rs9548085	chr13:38439356	T/C	cg23307680	chr13:38443104	TRPC4	0.4	6.94	0.31	1.35e-11	Schizophrenia;
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg20607798	chr8:58055168	NA	0.72	8.12	0.35	4.3e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg27373749	chr11:63775612	MACROD1	0.39	8.87	0.38	1.63e-17	Schizophrenia;
LGG	cis	rs10463554	0.927	rs154369	chr5:102406844	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs7000551	0.689	rs6996872	chr8:22316753	T/C	cg12081754	chr8:22256438	SLC39A14	0.69	13.53	0.53	2.17e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.83	-0.45	1.61e-24	Triglycerides;
LGG	cis	rs1046896	0.553	rs1044661	chr17:80901020	G/A	cg03160526	chr17:80928410	B3GNTL1	0.53	8.47	0.37	3.26e-16	Glycated hemoglobin levels;
LGG	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg25554036	chr4:6271136	WFS1	0.53	8.83	0.38	2.1e-17	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10078	0.515	rs1053299	chr5:470760	G/A	cg05169099	chr5:481640	SLC9A3	0.46	6.85	0.3	2.42e-11	Fat distribution (HIV);
LGG	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.03e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72781680	0.950	rs72796343	chr2:24147631	G/A	cg08917208	chr2:24149416	ATAD2B	0.93	10.05	0.42	1.22e-21	Lymphocyte counts;
LGG	cis	rs4481887	0.741	rs11485458	chr1:248569050	A/G	cg01631408	chr1:248437212	OR2T33	-0.4	-7.11	-0.31	4.48e-12	Common traits (Other);
LGG	cis	rs62238980	0.614	rs117486425	chr22:32441850	A/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.1	0.31	4.79e-12	Lung cancer;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg04450456	chr4:17643702	FAM184B	0.31	6.73	0.3	4.97e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg00319359	chr11:70116639	PPFIA1	0.63	6.91	0.31	1.57e-11	Coronary artery disease;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg19357499	chr8:144660631	NAPRT1	0.92	7.05	0.31	6.37e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.35	-0.32	8.84e-13	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.737	rs10481445	chr8:11109269	T/C	cg06636001	chr8:8085503	FLJ10661	-0.62	-11.75	-0.48	4.41e-28	Retinal vascular caliber;
LGG	cis	rs7122539	0.768	rs7931485	chr11:66578635	G/A	cg01599099	chr11:66649832	PC	0.4	8.1	0.35	4.94e-15	HIV-1 susceptibility;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg25072359	chr17:41440525	NA	0.52	10.33	0.43	1.16e-22	Menopause (age at onset);
LGG	cis	rs4819052	0.765	rs2838852	chr21:46677037	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.03	0.52	2.73e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7077256	0.542	rs72831023	chr10:65056620	T/C	cg02276361	chr10:65351566	REEP3	-0.33	-6.79	-0.3	3.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12908161	1.000	rs12911736	chr15:85240008	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.18	0.32	2.85e-12	Schizophrenia;
LGG	cis	rs703842	0.560	rs11533604	chr12:58047713	G/A	cg18357645	chr12:58087776	OS9	-0.55	-8.13	-0.35	3.96e-15	Multiple sclerosis;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.93	-0.52	7.04e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.23	0.55	2.25e-38	Obesity-related traits;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg18350739	chr11:68623251	NA	-0.87	-22.15	-0.72	1.16e-74	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg18424134	chr6:126068038	NA	0.21	6.67	0.3	7.28e-11	Brugada syndrome;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19568834	chr20:34252926	CPNE1;RBM12	0.45	7.19	0.32	2.55e-12	Cognitive performance;
LGG	cis	rs72945132	0.882	rs113472486	chr11:70194945	C/G	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.31e-14	Coronary artery disease;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg07959490	chr17:80112427	CCDC57	-0.45	-8.39	-0.36	5.75e-16	Life satisfaction;
LGG	cis	rs11098499	0.754	rs10518300	chr4:120249499	G/T	cg09307838	chr4:120376055	NA	-0.67	-10.77	-0.45	2.64e-24	Corneal astigmatism;
LGG	cis	rs701145	0.585	rs1727953	chr3:153871392	G/T	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.52	-0.37	2.25e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7252981	0.632	rs11878202	chr19:19744079	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.38	-8.51	-0.37	2.51e-16	Perceived unattractiveness to mosquitoes;
LGG	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.45	-0.37	3.73e-16	Blood metabolite levels;
LGG	trans	rs1005277	0.522	rs9417256	chr10:37976990	A/G	cg27523141	chr10:43048294	ZNF37B	0.34	7.17	0.32	2.91e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4742903	0.904	rs1507514	chr9:106986114	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.24	0.36	1.76e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs66573146	1.000	rs55833486	chr4:6978729	C/A	cg07817883	chr1:32538562	TMEM39B	1.26	11.94	0.49	7.69e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs935334	0.935	rs6574279	chr14:76663938	A/T	cg14073839	chr14:76668648	C14orf118	-0.42	-7.01	-0.31	8.63e-12	Blood pressure;
LGG	cis	rs7166081	1.000	rs16950804	chr15:67554479	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg05861140	chr6:150128134	PCMT1	-0.32	-7.23	-0.32	1.96e-12	Testicular germ cell tumor;
LGG	trans	rs7824557	0.564	rs2572399	chr8:11234520	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.84	0.34	3.17e-14	Retinal vascular caliber;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4417704	0.551	rs4430951	chr2:241894333	G/A	cg14055004	chr2:241860995	NA	0.28	7.35	0.32	9.34e-13	Joint mobility (Beighton score);
LGG	cis	rs972578	0.765	rs5758988	chr22:43249093	T/C	cg01576275	chr22:43409880	NA	-0.23	-7.04	-0.31	6.86e-12	Mean platelet volume;
LGG	cis	rs2404602	0.716	rs8030411	chr15:76699855	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.08	0.39	3.04e-18	Blood metabolite levels;
LGG	trans	rs615632	0.570	rs17734541	chr8:9708433	A/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.29	0.32	1.35e-12	Neuroticism;
LGG	cis	rs11583043	0.958	rs12746722	chr1:101464789	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.39	0.36	5.81e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs806215	1.000	rs327512	chr7:127257251	G/A	cg25922125	chr7:127225783	GCC1	0.67	9.8	0.41	1.01e-20	Type 2 diabetes;
LGG	trans	rs11875185	0.510	rs79393671	chr18:55647348	G/A	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3813567	0.759	rs12594550	chr15:78959037	C/G	cg09448879	chr15:79043637	NA	-0.43	-7.59	-0.33	1.79e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7503807	0.967	rs8064502	chr17:78562434	C/A	cg09596252	chr17:78655493	RPTOR	0.46	8.04	0.35	7.81e-15	Obesity;
LGG	cis	rs9503598	0.543	rs913536	chr6:3432608	G/A	cg00476032	chr6:3446245	SLC22A23	-0.37	-7.01	-0.31	8.39e-12	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs620875	1.000	rs620875	chr11:126859157	A/C	cg06504925	chr11:126872760	NA	-0.54	-7.52	-0.33	2.82e-13	Response to antipsychotic treatment;
LGG	cis	rs9527	0.615	rs10883800	chr10:104671212	A/C	cg04362960	chr10:104952993	NT5C2	0.55	10.03	0.42	1.51e-21	Arsenic metabolism;
LGG	cis	rs6582630	0.504	rs4882367	chr12:38330878	A/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.66	-0.37	8.09e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7829975	0.539	rs883647	chr8:8569724	G/A	cg02002194	chr4:3960332	NA	0.4	7.11	0.31	4.45e-12	Mood instability;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.73	-0.41	1.74e-20	Lung cancer;
LGG	cis	rs7586879	0.828	rs1077641	chr2:25123665	G/A	cg04586622	chr2:25135609	ADCY3	0.38	9.51	0.4	1.06e-19	Body mass index;
LGG	cis	rs755249	0.567	rs41270807	chr1:39801815	A/C	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.55e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1109114	0.816	rs2918268	chr5:148606756	A/G	cg06539116	chr5:148597365	ABLIM3	-0.6	-15.28	-0.58	5.59e-43	Body mass index;
LGG	cis	rs679087	0.932	rs721617	chr12:29934586	C/T	cg14258853	chr12:29935411	TMTC1	0.43	8.65	0.37	8.61e-17	Schizophrenia;
LGG	cis	rs10893109	0.517	rs7926767	chr11:123777536	A/G	cg12387464	chr11:123775935	OR8D4	-0.39	-8.52	-0.37	2.35e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs9303401	0.573	rs34717648	chr17:56886624	T/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.85e-18	Cognitive test performance;
LGG	cis	rs7666738	0.830	rs10470894	chr4:99039107	G/A	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4746818	0.688	rs951718	chr10:70928044	A/G	cg11621586	chr10:70884670	VPS26A	1.19	21.99	0.71	6.58e-74	Left atrial antero-posterior diameter;
LGG	trans	rs3206736	0.548	rs328925	chr7:35037327	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	trans	rs6787172	0.783	rs12496767	chr3:158179237	C/A	cg23275840	chr4:47708675	CORIN	-0.33	-6.72	-0.3	5.35e-11	Subjective well-being;
LGG	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.33	0.32	1.04e-12	Hip circumference adjusted for BMI;
LGG	cis	rs60695258	0.550	rs388401	chr4:87974415	C/G	cg01323104	chr4:87958903	AFF1	-0.25	-7.05	-0.31	6.71e-12	Hematocrit;
LGG	cis	rs7000551	0.725	rs2461483	chr8:22386479	C/T	cg12081754	chr8:22256438	SLC39A14	0.67	12.38	0.5	1.37e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg21095983	chr6:86352623	SYNCRIP	0.57	10.62	0.44	1.05e-23	Smooth-surface caries;
LGG	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.98	10.1	0.42	8.25e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	0.522	rs1880556	chr7:65432544	T/C	cg00343986	chr7:65444356	GUSB	0.49	8.7	0.37	5.82e-17	Aortic root size;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg19524238	chr7:2802976	GNA12	0.36	8.65	0.37	8.84e-17	Height;
LGG	trans	rs7395662	0.963	rs8189397	chr11:48711870	A/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg11062466	chr8:58055876	NA	0.63	9.8	0.41	1.03e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.840	rs3915420	chr4:1260337	T/C	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg21775007	chr8:11205619	TDH	-0.52	-8.35	-0.36	7.95e-16	Triglycerides;
LGG	trans	rs116095464	0.614	rs28736753	chr5:274081	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.33	-0.36	9.24e-16	Breast cancer;
LGG	cis	rs908922	0.584	rs71626721	chr1:152532745	A/G	cg20991723	chr1:152506922	NA	-0.7	-14.32	-0.55	8.93e-39	Hair morphology;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26887465	chr16:284511	ITFG3	-0.43	-6.92	-0.31	1.55e-11	Pancreatic cancer;
LGG	cis	rs12210905	0.925	rs11961181	chr6:26994163	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.04e-13	Hip circumference adjusted for BMI;
LGG	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg02002194	chr4:3960332	NA	0.4	6.91	0.31	1.63e-11	Triglycerides;
LGG	cis	rs4665809	0.531	rs10199898	chr2:26445485	T/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs807669	0.903	rs807666	chr22:19160549	C/T	cg02655711	chr22:19163373	SLC25A1	0.79	16.15	0.6	7.67e-47	Metabolite levels;
LGG	trans	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	cis	rs3008870	0.959	rs4655658	chr1:67389608	C/T	cg08660285	chr1:67390436	MIER1;WDR78	1.02	22.58	0.72	1.2e-76	Lymphocyte percentage of white cells;
LGG	cis	rs769267	0.930	rs10422819	chr19:19643028	C/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	9.53	0.4	9.24e-20	Tonsillectomy;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg10295955	chr4:187884368	NA	-1.15	-30.73	-0.82	7.77e-114	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs593531	0.524	rs634608	chr11:74084729	G/A	cg18195628	chr11:73498948	MRPL48	-0.4	-6.72	-0.3	5.36e-11	Neuroticism;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.57	0.33	2.05e-13	Lung cancer;
LGG	cis	rs2797160	0.935	rs12717178	chr6:126016499	G/A	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.82e-13	Endometrial cancer;
LGG	cis	rs75920871	0.528	rs1241655	chr11:116837808	G/T	cg01368799	chr11:117014884	PAFAH1B2	-0.49	-7.22	-0.32	2.19e-12	Subjective well-being;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg06873352	chr17:61820015	STRADA	-0.67	-11.92	-0.48	9.03e-29	Prudent dietary pattern;
LGG	cis	rs727505	1.000	rs56321835	chr7:124529622	T/C	cg23710748	chr7:124431027	NA	-0.52	-9.79	-0.41	1.07e-20	Lewy body disease;
LGG	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg06481639	chr22:41940642	POLR3H	0.54	7.69	0.34	8.99e-14	Vitiligo;
LGG	trans	rs1997103	1.000	rs10263552	chr7:55404747	C/T	cg20935933	chr6:143382018	AIG1	0.56	8.64	0.37	8.99e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7584262	0.740	rs13414536	chr2:42245179	T/C	cg27428208	chr2:42229179	NA	0.48	7.53	0.33	2.68e-13	Bone mineral density;
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.95	0.35	1.4e-14	Bipolar disorder;
LGG	trans	rs7395662	0.929	rs7952580	chr11:48595206	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.22	-0.32	2.09e-12	HDL cholesterol;
LGG	cis	rs9611565	0.512	rs139571	chr22:42214238	G/A	cg06481639	chr22:41940642	POLR3H	-0.56	-7.83	-0.34	3.38e-14	Vitiligo;
LGG	cis	rs11764590	0.715	rs11760737	chr7:2104055	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-6.68	-0.3	6.71e-11	Neuroticism;
LGG	cis	rs74781061	0.860	rs4077703	chr15:74762162	G/A	cg02384859	chr15:74862662	ARID3B	-0.35	-7.18	-0.32	2.77e-12	Endometriosis;
LGG	cis	rs17209837	0.607	rs10452936	chr7:87094306	C/A	cg25823085	chr7:87105416	ABCB4	0.3	7.53	0.33	2.66e-13	Gallbladder cancer;
LGG	cis	rs7044106	0.762	rs7044226	chr9:123466328	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.21	0.6	3.78e-47	Hip circumference adjusted for BMI;
LGG	cis	rs459571	0.629	rs441233	chr9:136876021	A/G	cg13789015	chr9:136890014	NCRNA00094	-0.49	-8.96	-0.38	7.82e-18	Platelet distribution width;
LGG	cis	rs651907	0.557	rs7651404	chr3:101393294	C/A	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.55	-0.33	2.32e-13	Colorectal cancer;
LGG	cis	rs727505	1.000	rs28702851	chr7:124442991	G/A	cg23710748	chr7:124431027	NA	-0.55	-10.51	-0.44	2.54e-23	Lewy body disease;
LGG	cis	rs9581857	0.685	rs9319373	chr13:28042835	A/G	cg01674679	chr13:27998804	GTF3A	-0.66	-7.59	-0.33	1.8e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs1552244	0.572	rs6785976	chr3:10168647	A/G	cg00166722	chr3:10149974	C3orf24	0.57	8.19	0.36	2.54e-15	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16706631	chr6:26204823	HIST1H4E	0.45	7.54	0.33	2.42e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs4851254	0.961	rs7583067	chr2:100796850	C/T	cg17356467	chr2:100759845	AFF3	0.4	7.05	0.31	6.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.74e-12	Lung cancer;
LGG	cis	rs10186029	0.676	rs10932464	chr2:213968315	T/A	cg08319019	chr2:214017104	IKZF2	0.47	8.28	0.36	1.29e-15	Systemic sclerosis;
LGG	cis	rs79057730	0.527	rs35316052	chr7:802954	C/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.68	7.5	0.33	3.25e-13	Initial pursuit acceleration;
LGG	cis	rs7707921	0.602	rs10514231	chr5:81307412	C/T	cg15871215	chr5:81402204	ATG10	0.31	6.79	0.3	3.34e-11	Breast cancer;
LGG	cis	rs12210905	1.000	rs12209393	chr6:27085073	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs950776	0.518	rs12907169	chr15:78825498	G/C	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs17767392	0.846	rs35151594	chr14:71808583	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.36	-0.36	7.35e-16	Mitral valve prolapse;
LGG	cis	rs2836974	0.555	rs35909862	chr21:40621158	G/A	cg11644478	chr21:40555479	PSMG1	-0.75	-13.81	-0.54	1.43e-36	Cognitive function;
LGG	cis	rs9900497	0.569	rs2072327	chr17:19651482	G/T	cg00516966	chr17:19651653	ALDH3A1	-0.49	-12.94	-0.52	6.28e-33	Response to paliperidone in schizophrenia (CGI-S score);
LGG	trans	rs12517041	1.000	rs1428620	chr5:23283138	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs12791968	0.765	rs17181389	chr11:44996996	G/T	cg11846598	chr11:44996168	LOC221122	-0.6	-9.93	-0.42	3.48e-21	Inhibitory control;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg19223190	chr17:80058835	NA	0.44	8.42	0.36	4.76e-16	Life satisfaction;
LGG	cis	rs7618915	0.547	rs6762813	chr3:52726695	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.09	-0.31	4.93e-12	Bipolar disorder;
LGG	cis	rs1046896	0.520	rs8074086	chr17:80818460	A/C	cg03160526	chr17:80928410	B3GNTL1	0.5	7.89	0.34	2.21e-14	Glycated hemoglobin levels;
LGG	cis	rs4742903	0.967	rs10820610	chr9:106907819	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.22	0.36	2.01e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7762018	0.655	rs11966349	chr6:170162537	A/G	cg19338460	chr6:170058176	WDR27	0.69	9.67	0.41	2.86e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs12310956	0.510	rs7965329	chr12:33868199	C/A	cg13010199	chr12:38710504	ALG10B	0.46	8.81	0.38	2.57e-17	Morning vs. evening chronotype;
LGG	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg23845249	chr11:68861649	NA	0.44	7.85	0.34	2.89e-14	Blond vs. brown hair color;
LGG	cis	rs9596863	0.851	rs7981543	chr13:54313476	A/G	ch.13.53330881F	chr13:54432880	NA	-0.49	-6.76	-0.3	4.12e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs11098499	0.738	rs10026493	chr4:120384194	C/G	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs9486719	1.000	rs11752584	chr6:96884952	C/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg03188948	chr7:1209495	NA	0.64	8.26	0.36	1.58e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.35	0.32	8.79e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11105298	0.891	rs10858871	chr12:89871613	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.52	-0.4	9.93e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs11997175	0.574	rs4733453	chr8:33650745	A/G	ch.8.33884649F	chr8:33765107	NA	0.39	7.27	0.32	1.59e-12	Body mass index;
LGG	cis	rs7945705	0.791	rs10769958	chr11:8815115	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.38	-7.77	-0.34	5.21e-14	Hemoglobin concentration;
LGG	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg06453172	chr10:134556979	INPP5A	-0.5	-7.71	-0.34	7.68e-14	Migraine;
LGG	cis	rs7481584	0.624	rs80871	chr11:3049843	A/C	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	cis	rs7712401	0.601	rs36180885	chr5:122356403	C/A	cg19412675	chr5:122181750	SNX24	-0.48	-7.74	-0.34	6.34e-14	Mean platelet volume;
LGG	trans	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg02030672	chr11:45687055	CHST1	-0.52	-9.36	-0.4	3.53e-19	Obesity-related traits;
LGG	cis	rs8061903	0.804	rs718566	chr16:9415351	C/T	cg03762483	chr16:10274847	GRIN2A	-0.39	-6.99	-0.31	9.53e-12	HIV-1 viral setpoint;
LGG	trans	rs7980799	0.649	rs2084391	chr12:33655419	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.0	-0.35	1.01e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6540556	0.769	rs6540553	chr1:209929044	C/G	cg05527609	chr1:210001259	C1orf107	-0.49	-6.77	-0.3	3.86e-11	Red blood cell count;
LGG	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17253792	0.732	rs79014965	chr14:56117551	T/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.11	-0.49	1.56e-29	Putamen volume;
LGG	cis	rs3820928	0.845	rs4234065	chr2:227882006	C/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.66	-0.34	1.06e-13	Pulmonary function;
LGG	cis	rs7727544	0.631	rs13357280	chr5:131600187	A/G	cg07395648	chr5:131743802	NA	-0.44	-9.4	-0.4	2.59e-19	Blood metabolite levels;
LGG	cis	rs7737355	0.812	rs10515455	chr5:130878789	C/T	cg06307176	chr5:131281290	NA	0.52	8.65	0.37	8.71e-17	Life satisfaction;
LGG	cis	rs4764487	0.760	rs733700	chr12:6337974	A/G	cg08284733	chr12:6341482	CD9	0.37	9.96	0.42	2.63e-21	Mean platelet volume;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg08621203	chr6:150244597	RAET1G	0.51	9.68	0.41	2.56e-20	Testicular germ cell tumor;
LGG	cis	rs4680	0.737	rs6269	chr22:19949952	A/G	cg22546130	chr22:19950026	COMT	-0.45	-10.58	-0.44	1.47e-23	Blood metabolite levels;
LGG	cis	rs9911578	1.000	rs12453459	chr17:56624291	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.9	-0.59	9.77e-46	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02847575	chr16:30382517	TBC1D10B	0.46	6.93	0.31	1.41e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09610735	chr10:22609918	BMI1	0.42	6.68	0.3	6.79e-11	Gut microbiome composition (summer);
LGG	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.04	-0.42	1.34e-21	Aortic root size;
LGG	cis	rs7463659	1.000	rs7836944	chr8:135436202	A/G	cg17885191	chr8:135476712	NA	0.44	7.64	0.33	1.28e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg00864171	chr11:67383662	NA	-0.57	-10.11	-0.43	7.89e-22	Mean corpuscular volume;
LGG	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg10818794	chr15:86012489	AKAP13	-0.31	-6.73	-0.3	4.98e-11	Interstitial lung disease;
LGG	cis	rs3820068	0.603	rs927207	chr1:15990552	A/G	cg05660106	chr1:15850417	CASP9	0.84	16.23	0.6	3.27e-47	Systolic blood pressure;
LGG	cis	rs4423214	1.000	rs12790558	chr11:71170905	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.16	-0.52	7.87e-34	Vitamin D levels;
LGG	cis	rs2032447	0.670	rs198820	chr6:26124243	G/A	cg18357526	chr6:26021779	HIST1H4A	-0.76	-14.27	-0.55	1.52e-38	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.527	rs34259385	chr8:10325456	C/T	cg02002194	chr4:3960332	NA	0.39	6.78	0.3	3.73e-11	Neuroticism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02234820	chr1:85358327	LPAR3	0.36	6.72	0.3	5.27e-11	Obesity-related traits;
LGG	cis	rs79149102	0.579	rs74023935	chr15:75359184	T/C	cg17294928	chr15:75287854	SCAMP5	-0.77	-8.35	-0.36	7.97e-16	Lung cancer;
LGG	cis	rs3862030	0.720	rs11191295	chr10:104231054	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.13e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs17208368	0.628	rs12444201	chr16:55093998	A/G	cg09947736	chr16:55091198	NA	-0.67	-12.84	-0.51	1.67e-32	Hypospadias;
LGG	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg15627072	chr1:2432621	PLCH2	0.37	8.28	0.36	1.3e-15	Ulcerative colitis;
LGG	cis	rs6495122	0.699	rs3784789	chr15:75082552	C/G	cg17294928	chr15:75287854	SCAMP5	0.41	6.72	0.3	5.21e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9914988	0.887	rs9895625	chr17:27108516	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.79	-0.41	1.05e-20	Triglycerides;
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.2	-0.36	2.43e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs8031584	1.000	rs12906054	chr15:31292023	A/C	cg19680485	chr15:31195859	MTMR15	-0.45	-6.93	-0.31	1.46e-11	Huntington's disease progression;
LGG	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg19455335	chr8:22457658	C8orf58	-0.44	-9.01	-0.39	5.35e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs155076	1.000	rs564685	chr13:21846879	A/G	cg14456004	chr13:21872349	NA	-1.16	-18.31	-0.65	9.59e-57	White matter hyperintensity burden;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.5	0.37	2.6e-16	Platelet count;
LGG	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg13770153	chr20:60521292	NA	-0.48	-7.83	-0.34	3.45e-14	Body mass index;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.16	-20.78	-0.69	3.21e-68	Alzheimer's disease;
LGG	cis	rs6738485	0.531	rs72819612	chr2:106846316	T/C	cg16099169	chr2:106886729	NA	-0.38	-7.77	-0.34	5.29e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LGG	cis	rs6665290	0.558	rs1319103	chr1:227219314	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.81	-14.56	-0.56	8.06e-40	Myeloid white cell count;
LGG	cis	rs11150038	0.623	rs28684973	chr16:78015886	A/C	cg04733911	chr16:78082701	NA	0.56	7.2	0.32	2.46e-12	Colorectal or endometrial cancer;
LGG	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg14703610	chr5:56206110	C5orf35	0.4	7.0	0.31	9.04e-12	Breast cancer;Breast cancer (early onset);
LGG	cis	rs73416724	1.000	rs78567061	chr6:43293446	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.74e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7819412	0.522	rs4642600	chr8:11013025	C/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.08	-0.35	5.85e-15	Triglycerides;
LGG	cis	rs12579753	0.917	rs7972839	chr12:82178920	C/T	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.81	-0.45	1.95e-24	Resting heart rate;
LGG	cis	rs6500395	0.962	rs9937134	chr16:48577683	T/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.47	8.85	0.38	1.91e-17	Obesity-related traits;
LGG	cis	rs7512552	0.839	rs834232	chr1:150354682	T/C	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2228479	0.850	rs11649510	chr16:89851004	A/G	cg26513180	chr16:89883248	FANCA	1.02	9.75	0.41	1.48e-20	Skin colour saturation;
LGG	trans	rs8073060	0.586	rs225257	chr17:33956625	G/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg14789911	chr21:47582049	C21orf56	-0.45	-7.43	-0.33	5.15e-13	Testicular germ cell tumor;
LGG	cis	rs3741404	0.825	rs2845597	chr11:63954370	G/A	cg04000281	chr11:63949212	NA	-0.41	-7.98	-0.35	1.19e-14	Platelet count;
LGG	cis	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs138249	0.934	rs138234	chr22:50560372	C/T	cg18875453	chr22:50517795	MLC1	0.26	6.73	0.3	5.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg05793240	chr7:2802953	GNA12	0.3	7.31	0.32	1.17e-12	Height;
LGG	cis	rs6062302	0.548	rs4809310	chr20:62228745	G/A	cg16989086	chr20:62203971	PRIC285	0.49	7.13	0.31	3.97e-12	Glioblastoma;
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.66	8.77	0.38	3.35e-17	Lung function (FEV1/FVC);
LGG	cis	rs10489202	1.000	rs10489202	chr1:167903079	A/C	cg24449463	chr1:168025552	DCAF6	0.61	9.91	0.42	3.98e-21	Schizophrenia;
LGG	trans	rs9929218	0.529	rs11640736	chr16:68738324	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.93	20.95	0.7	5.08e-69	Colorectal cancer;
LGG	cis	rs4704846	1.000	rs1036200	chr5:156531865	A/G	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.4	-0.33	6.3e-13	Blood protein levels;
LGG	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg10661904	chr17:79619235	PDE6G	0.42	8.53	0.37	2.03e-16	Eye color traits;
LGG	cis	rs11229555	0.645	rs12802960	chr11:58174775	T/C	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg04008888	chr11:68622739	NA	-0.54	-11.14	-0.46	1.06e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7444	0.941	rs181366	chr22:21933780	C/T	cg05046821	chr22:21984468	YDJC	-0.38	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	cis	rs939658	0.935	rs34859518	chr15:79450422	A/G	cg17916960	chr15:79447300	NA	-0.62	-12.1	-0.49	1.87e-29	Refractive error;
LGG	cis	rs12476592	0.602	rs174485	chr2:63857402	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.78	-0.3	3.68e-11	Childhood ear infection;
LGG	trans	rs9354308	0.727	rs9363468	chr6:66566692	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.88	-0.3	1.98e-11	Metabolite levels;
LGG	cis	rs972578	0.668	rs9607961	chr22:43232818	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.89	-0.3	1.84e-11	Mean platelet volume;
LGG	cis	rs735396	1.000	rs1169306	chr12:121438311	C/T	cg14101638	chr12:121416612	HNF1A	0.36	7.42	0.33	5.64e-13	N-glycan levels;
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg12813108	chr7:99719912	CNPY4	-0.52	-7.92	-0.35	1.78e-14	Lung function (FEV1/FVC);
LGG	cis	rs17102423	0.530	rs4902357	chr14:65542067	C/G	cg26396452	chr14:65542826	MAX	0.47	10.01	0.42	1.81e-21	Obesity-related traits;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg06916706	chr16:4465613	CORO7	-0.9	-16.22	-0.6	3.72e-47	Schizophrenia;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg05665937	chr4:1216051	CTBP1	0.61	11.38	0.47	1.21e-26	Obesity-related traits;
LGG	cis	rs7493	0.806	rs17876090	chr7:95053404	A/T	cg17330251	chr7:94953956	PON1	-0.44	-8.33	-0.36	9.52e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg20887711	chr4:1340912	KIAA1530	0.5	9.19	0.39	1.36e-18	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg10056627	chr6:42928773	GNMT	0.26	7.13	0.31	3.98e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs9393777	0.920	rs35716472	chr6:27406607	C/G	cg06606381	chr12:133084897	FBRSL1	-1.11	-10.65	-0.44	7.53e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4478858	0.698	rs7543348	chr1:31804805	A/C	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs2236918	1.000	rs1635512	chr1:242024500	A/G	cg17736920	chr1:242011382	EXO1	-0.53	-9.53	-0.41	8.73e-20	Menopause (age at onset);
LGG	cis	rs73198271	0.562	rs75525911	chr8:8659359	C/A	cg01851573	chr8:8652454	MFHAS1	0.52	8.36	0.36	7.34e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs2133450	0.717	rs34684786	chr3:7371272	G/A	cg19930620	chr3:7340148	GRM7	-0.37	-7.89	-0.34	2.27e-14	Early response to risperidone in schizophrenia;
LGG	trans	rs1814175	0.765	rs1794141	chr11:49914135	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.3.55501R	chr3:3184210	TRNT1	-0.47	-6.98	-0.31	1.01e-11	Systemic lupus erythematosus;
LGG	cis	rs2013441	0.932	rs3850782	chr17:20181940	A/C	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs1878931	0.726	rs3843728	chr16:3448251	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	1.03	23.98	0.74	3.47e-83	Body mass index (adult);
LGG	cis	rs3862435	0.572	rs2589967	chr15:90907876	T/C	cg22089800	chr15:90895588	ZNF774	0.53	6.67	0.3	7.29e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg06850241	chr22:41845214	NA	-0.44	-6.83	-0.3	2.67e-11	Vitiligo;
LGG	cis	rs11225247	0.772	rs34296997	chr11:102238607	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.34	0.32	9.89e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg11062466	chr8:58055876	NA	0.5	8.08	0.35	5.81e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs72827839	0.846	rs16953461	chr17:46261736	G/T	cg02219949	chr17:45927392	SP6	-0.53	-8.08	-0.35	5.59e-15	Ease of getting up in the morning;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.81	16.16	0.6	6.37e-47	Obesity-related traits;
LGG	cis	rs2303319	1.000	rs62188122	chr2:162240407	T/A	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	cis	rs938554	0.744	rs938558	chr4:9939205	G/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.43	-0.36	4.4e-16	Blood metabolite levels;
LGG	cis	rs920590	0.879	rs67391684	chr8:19654642	A/T	cg01411142	chr8:19674711	INTS10	0.47	7.53	0.33	2.7e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10937275	0.623	rs35166820	chr3:186646140	C/T	cg26193484	chr3:186648175	ST6GAL1	0.9	9.25	0.39	8.51e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg19183879	chr15:85880815	NA	0.39	6.96	0.31	1.17e-11	Bulimia nervosa;
LGG	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg02002194	chr4:3960332	NA	0.43	7.62	0.33	1.42e-13	Retinal vascular caliber;
LGG	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.76	-0.3	4.15e-11	Bone mineral density;
LGG	cis	rs17376456	0.825	rs10052662	chr5:93271385	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg12923728	chr3:195709715	SDHAP1	-0.77	-14.48	-0.56	1.79e-39	Pancreatic cancer;
LGG	cis	rs2635047	0.935	rs1398218	chr18:44745721	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.37	-6.89	-0.3	1.88e-11	Educational attainment;
LGG	trans	rs61931739	0.500	rs11053213	chr12:34466395	G/T	cg26384229	chr12:38710491	ALG10B	0.97	21.57	0.71	6.3e-72	Morning vs. evening chronotype;
LGG	cis	rs3087591	0.708	rs2854305	chr17:29647003	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.35	0.5	1.68e-30	Hip circumference;
LGG	cis	rs2764208	0.550	rs3736896	chr6:34735883	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.46	-7.94	-0.35	1.57e-14	Systemic lupus erythematosus;
LGG	cis	rs12410462	0.551	rs12096675	chr1:227839384	C/T	cg04117972	chr1:227635322	NA	0.43	7.97	0.35	1.28e-14	Major depressive disorder;
LGG	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg15921436	chr17:44337874	NA	0.45	10.41	0.44	5.95e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg07511668	chr11:68622177	NA	0.51	9.4	0.4	2.45e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2404602	0.583	rs12913096	chr15:76551852	C/T	cg23625390	chr15:77176239	SCAPER	0.41	7.71	0.34	7.81e-14	Blood metabolite levels;
LGG	cis	rs477895	0.653	rs34089806	chr11:63887987	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.44	0.47	7.26e-27	Mean platelet volume;
LGG	cis	rs10504229	1.000	rs112284078	chr8:58191640	A/G	cg24829409	chr8:58192753	C8orf71	-0.89	-13.72	-0.54	3.37e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg03576123	chr11:487126	PTDSS2	-0.49	-6.7	-0.3	6.08e-11	Systemic lupus erythematosus;
LGG	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg11317459	chr13:21872234	NA	-1.19	-19.52	-0.67	2.25e-62	White matter hyperintensity burden;
LGG	cis	rs2063714	0.967	rs913971	chr6:157197802	C/T	cg23222435	chr6:157204239	ARID1B	-0.61	-11.41	-0.47	9.32e-27	Sitting height ratio;
LGG	cis	rs2412459	1.000	rs2279581	chr15:40300092	A/G	cg01081584	chr15:40268610	EIF2AK4	-0.76	-8.69	-0.37	6.31e-17	Response to haloperidol in psychosis;
LGG	cis	rs61008539	0.893	rs4719460	chr7:859610	C/T	cg00934597	chr7:893267	UNC84A	0.52	8.74	0.38	4.31e-17	Perceived unattractiveness to mosquitoes;
LGG	cis	rs9640161	0.830	rs17173681	chr7:150059414	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.56	10.35	0.43	9.68e-23	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1949733	1.000	rs6447875	chr4:8503206	T/C	cg11789530	chr4:8429930	ACOX3	0.88	17.48	0.63	6.44e-53	Response to antineoplastic agents;
LGG	cis	rs5769707	0.605	rs2071900	chr22:50052175	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.49	-0.4	1.24e-19	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs2243480	0.711	rs2420172	chr7:65635341	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	6.91e-19	Diabetic kidney disease;
LGG	cis	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg12826209	chr6:26865740	GUSBL1	-0.75	-8.07	-0.35	6.13e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.26	0.52	3.09e-34	Prudent dietary pattern;
LGG	trans	rs330071	0.515	rs12545193	chr8:9251880	G/A	cg15556689	chr8:8085844	FLJ10661	0.38	6.72	0.3	5.42e-11	Acne (severe);
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7507204	0.723	rs12982194	chr19:3411947	G/A	cg08382705	chr11:45687319	CHST1	-0.5	-6.93	-0.31	1.43e-11	Height;
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg02002194	chr4:3960332	NA	0.41	7.74	0.34	6.15e-14	Morning vs. evening chronotype;
LGG	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611519	0.602	rs8138520	chr22:41412928	A/G	cg03806693	chr22:41940476	POLR3H	-0.46	-7.49	-0.33	3.54e-13	Neuroticism;
LGG	cis	rs7619833	0.593	rs7626742	chr3:27268398	G/T	cg02860705	chr3:27208620	NA	0.41	7.69	0.34	9.21e-14	Breast cancer;
LGG	cis	rs9322193	0.923	rs9689599	chr6:149953109	A/C	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg22963979	chr7:1858916	MAD1L1	-0.49	-9.7	-0.41	2.18e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs9341835	0.530	rs7742595	chr6:64161733	C/T	cg00787780	chr6:64151745	NA	0.41	7.22	0.32	2.15e-12	Schizophrenia;
LGG	cis	rs9359856	0.510	rs4235839	chr6:90472410	A/G	cg13799429	chr6:90582589	CASP8AP2	0.86	13.4	0.53	7.83e-35	Bipolar disorder;
LGG	trans	rs7819412	0.775	rs2898257	chr8:10935368	A/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.68	-0.41	2.61e-20	Triglycerides;
LGG	trans	rs9291683	0.610	rs993173	chr4:10323935	T/C	cg26043149	chr18:55253948	FECH	-0.44	-7.4	-0.33	6.37e-13	Bone mineral density;
LGG	cis	rs1577917	0.958	rs10455448	chr6:86533611	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.18	-0.49	8.18e-30	Response to antipsychotic treatment;
LGG	cis	rs1669338	0.507	rs4685609	chr3:3202279	T/C	cg16797762	chr3:3221439	CRBN	-0.98	-12.95	-0.52	6.21e-33	White matter integrity;
LGG	cis	rs7493	0.950	rs17879277	chr7:95030632	A/C	cg08461772	chr7:95026248	PON3	0.39	8.19	0.36	2.51e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs116095464	0.558	rs113796397	chr5:246503	A/G	cg00938859	chr5:1591904	SDHAP3	0.89	12.76	0.51	3.73e-32	Breast cancer;
LGG	cis	rs4595586	0.545	rs11615584	chr12:39409350	C/G	cg26384229	chr12:38710491	ALG10B	0.66	11.9	0.48	1.09e-28	Morning vs. evening chronotype;
LGG	cis	rs9902453	1.000	rs7207021	chr17:28400516	C/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.36	-0.53	1.11e-34	Coffee consumption (cups per day);
LGG	cis	rs3820068	0.705	rs11587541	chr1:15899478	T/C	cg05660106	chr1:15850417	CASP9	1.12	23.93	0.74	5.5e-83	Systolic blood pressure;
LGG	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	7.87	0.34	2.56e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg11995313	chr8:8860691	ERI1	0.44	7.42	0.33	5.71e-13	Joint mobility (Beighton score);
LGG	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg27411982	chr8:10470053	RP1L1	0.4	7.01	0.31	8.61e-12	Mood instability;
LGG	trans	rs61931739	0.500	rs4436630	chr12:34394200	C/T	cg26384229	chr12:38710491	ALG10B	0.86	18.54	0.65	8.22e-58	Morning vs. evening chronotype;
LGG	trans	rs10435719	0.867	rs34465618	chr8:11791356	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4538187	1.000	rs4233930	chr2:64077305	C/G	cg02541582	chr2:64069798	UGP2	0.56	13.26	0.52	3.03e-34	Systolic blood pressure;
LGG	cis	rs7171869	1	rs7171869	chr15:78900909	A/G	cg06917634	chr15:78832804	PSMA4	0.5	7.85	0.34	3.02e-14	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs9325144	0.647	rs12227834	chr12:38849246	G/C	cg04568710	chr12:38710424	ALG10B	-0.39	-8.07	-0.35	5.96e-15	Morning vs. evening chronotype;
LGG	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg18252515	chr7:66147081	NA	-0.74	-11.52	-0.47	3.61e-27	Corneal structure;
LGG	cis	rs8056064	0.744	rs12600161	chr16:82779603	T/C	cg08271366	chr16:82816457	CDH13	-0.44	-7.25	-0.32	1.76e-12	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs5769707	0.967	rs17182154	chr22:49990470	A/G	cg06623630	chr22:50017776	C22orf34	-0.32	-6.66	-0.3	7.85e-11	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs4474465	0.790	rs7481910	chr11:78264202	G/C	cg02023728	chr11:77925099	USP35	-0.38	-6.82	-0.3	2.83e-11	Alzheimer's disease (survival time);
LGG	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.46	-8.75	-0.38	4e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7493	0.755	rs116306774	chr7:95016976	G/A	cg17330251	chr7:94953956	PON1	-0.45	-8.55	-0.37	1.86e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs1577917	0.917	rs35038582	chr6:86721305	T/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.17e-33	Response to antipsychotic treatment;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg24690094	chr11:67383802	NA	0.5	9.14	0.39	2e-18	Mean corpuscular volume;
LGG	cis	rs801193	1.000	rs2055682	chr7:66260289	A/G	cg11764359	chr7:65958608	NA	0.62	10.4	0.44	6.43e-23	Aortic root size;
LGG	cis	rs4665809	0.878	rs6720312	chr2:26364934	A/G	cg22920501	chr2:26401640	FAM59B	0.42	8.5	0.37	2.53e-16	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	9.13e-13	Lung cancer;
LGG	cis	rs8031584	0.541	rs1983459	chr15:31208749	C/T	cg14829155	chr15:31115871	NA	-0.49	-8.64	-0.37	9.51e-17	Huntington's disease progression;
LGG	trans	rs9409565	0.559	rs7044227	chr9:97067592	T/A	cg05679027	chr9:99775184	HIATL2	0.47	7.36	0.32	8.27e-13	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs1568889	0.667	rs7123947	chr11:28399908	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.62	10.18	0.43	4.19e-22	Bipolar disorder;
LGG	cis	rs7811417	0.505	rs1473119	chr7:21564835	A/G	cg23045935	chr7:21583304	DNAH11	-0.37	-7.81	-0.34	3.96e-14	Schizophrenia;
LGG	cis	rs9462027	0.628	rs9469899	chr6:34793124	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.58	-0.44	1.43e-23	Systemic lupus erythematosus;
LGG	trans	rs6601450	0.519	rs34906836	chr8:10288992	C/A	cg06636001	chr8:8085503	FLJ10661	0.43	7.41	0.33	6.02e-13	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7098414	0.511	rs7899545	chr10:82150635	G/C	cg00277334	chr10:82204260	NA	-0.35	-7.76	-0.34	5.62e-14	Post bronchodilator FEV1;
LGG	cis	rs12477438	0.798	rs12473029	chr2:99637961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.87	-16.0	-0.6	3.33e-46	Chronic sinus infection;
LGG	cis	rs12200782	1.000	rs12195971	chr6:26460424	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.6	-7.36	-0.32	8.61e-13	Small cell lung carcinoma;
LGG	cis	rs7572733	0.534	rs1518363	chr2:198810131	C/T	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs4742903	0.967	rs4743689	chr9:106909300	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.18	0.36	2.72e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs745821	0.701	rs753327	chr18:48108003	T/C	cg18923635	chr18:48083994	NA	-0.42	-7.54	-0.33	2.57e-13	Diastolic blood pressure;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg23978390	chr7:1156363	C7orf50	0.53	8.7	0.37	5.82e-17	Longevity;Endometriosis;
LGG	cis	rs2153535	0.560	rs2210798	chr6:8481522	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs4268898	0.662	rs2303297	chr2:24432937	C/T	cg06627628	chr2:24431161	ITSN2	-0.79	-12.85	-0.51	1.57e-32	Asthma;
LGG	cis	rs950169	0.922	rs4842941	chr15:84831312	G/C	cg03959625	chr15:84868606	LOC388152	-0.55	-8.71	-0.38	5.36e-17	Schizophrenia;
LGG	cis	rs12291225	0.645	rs3763950	chr11:14278049	T/A	cg02886208	chr11:14281011	SPON1	-0.36	-6.98	-0.31	1.03e-11	Sense of smell;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg13206674	chr6:150067644	NUP43	0.65	14.65	0.56	3.2e-40	Lung cancer;
LGG	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg15921436	chr17:44337874	NA	0.51	11.19	0.46	6.78e-26	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6547631	0.622	rs10203826	chr2:85926190	A/C	cg24620635	chr2:85921963	GNLY	0.5	10.22	0.43	2.92e-22	Blood protein levels;
LGG	cis	rs504918	0.554	rs4234218	chr3:123961210	C/G	cg05766129	chr3:123988013	KALRN	0.46	7.94	0.35	1.55e-14	Schizophrenia;
LGG	trans	rs61931739	0.500	rs10844844	chr12:34380350	G/T	cg13010199	chr12:38710504	ALG10B	0.64	12.23	0.49	5.34e-30	Morning vs. evening chronotype;
LGG	cis	rs3750450	0.672	rs7858727	chr9:111936128	C/A	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.04	-0.35	7.81e-15	Low vWF levels;
LGG	trans	rs2197308	0.606	rs2218397	chr12:38278307	C/T	cg06521331	chr12:34319734	NA	0.43	7.67	0.34	1.02e-13	Morning vs. evening chronotype;
LGG	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg08648136	chr8:956695	NA	0.45	9.75	0.41	1.44e-20	Schizophrenia;
LGG	cis	rs11264213	0.901	rs631202	chr1:36449099	G/C	cg27506609	chr1:36549197	TEKT2	0.83	8.63	0.37	9.65e-17	Schizophrenia;
LGG	trans	rs9329221	0.537	rs2062332	chr8:9980024	G/A	cg08975724	chr8:8085496	FLJ10661	0.39	7.46	0.33	4.29e-13	Neuroticism;
LGG	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg06138931	chr13:21896616	NA	0.51	8.58	0.37	1.43e-16	White matter hyperintensity burden;
LGG	cis	rs4555082	0.834	rs2816653	chr14:105713973	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.47	-0.47	5.67e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9467711	0.591	rs13206501	chr6:26110148	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.69	0.34	8.67e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12136530	0.774	rs4911996	chr1:19765205	C/G	cg17081867	chr1:19768096	CAPZB	0.36	8.25	0.36	1.62e-15	Lead levels in blood;
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.04	0.42	1.33e-21	Height;
LGG	cis	rs1348850	0.632	rs13008833	chr2:178514439	G/C	cg22681709	chr2:178499509	PDE11A	-0.52	-9.45	-0.4	1.73e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg15704280	chr7:45808275	SEPT13	-1.07	-27.07	-0.78	1.8299999999999999e-97	Height;
LGG	cis	rs1125355	0.690	rs72937289	chr2:159627512	C/A	cg02251393	chr2:159651559	DAPL1	0.41	7.9	0.34	2.09e-14	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24095088	chr6:160210874	MRPL18;TCP1	0.43	7.69	0.34	9.21e-14	Obesity-related traits;
LGG	cis	rs9914988	0.943	rs59461345	chr17:27151852	G/T	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs1062746	0.502	rs11649601	chr16:87339220	G/C	cg02258303	chr16:87377426	FBXO31	-0.43	-8.13	-0.35	3.83e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15743833	chr17:6376638	PITPNM3	0.47	6.92	0.31	1.46e-11	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.593	rs7620848	chr3:49828021	G/C	cg03060546	chr3:49711283	APEH	-0.61	-8.41	-0.36	5.26e-16	Menarche (age at onset);
LGG	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.93	-0.42	3.28e-21	Gout;
LGG	trans	rs11039798	0.920	rs12292685	chr11:48571032	G/T	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.6e-16	Axial length;
LGG	cis	rs7017914	0.935	rs6472551	chr8:71781849	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.82	-0.3	2.87e-11	Bone mineral density;
LGG	trans	rs1814175	0.867	rs7926002	chr11:49616018	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.82	-0.45	1.72e-24	Height;
LGG	cis	rs9300255	0.679	rs4759420	chr12:123794871	G/C	cg00376283	chr12:123451042	ABCB9	0.56	8.63	0.37	9.92e-17	Neutrophil percentage of white cells;
LGG	cis	rs2739330	0.796	rs2154594	chr22:24254055	A/G	cg24846343	chr22:24311635	DDTL	-0.6	-11.88	-0.48	1.3e-28	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs8002861	0.934	rs9533685	chr13:44468331	A/G	cg17145862	chr1:211918768	LPGAT1	0.99	26.08	0.77	6.54e-93	Leprosy;
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg19774624	chr17:42201019	HDAC5	0.78	14.44	0.56	2.84e-39	Total body bone mineral density;
LGG	cis	rs514406	0.861	rs503015	chr1:53254456	T/C	cg24675658	chr1:53192096	ZYG11B	0.48	9.69	0.41	2.42e-20	Monocyte count;
LGG	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg02227867	chr8:22457446	C8orf58	0.46	8.65	0.37	8.8e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg05082376	chr22:42548792	NA	-0.37	-7.31	-0.32	1.19e-12	Schizophrenia;
LGG	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.59	-0.51	1.75e-31	Chronic sinus infection;
LGG	cis	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg24375607	chr4:120327624	NA	0.59	10.03	0.42	1.51e-21	Corneal astigmatism;
LGG	trans	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.28	-0.36	1.34e-15	Triglycerides;
LGG	cis	rs368123	0.686	rs2774226	chr6:160700386	G/A	cg19643109	chr6:160697625	NA	-0.39	-8.36	-0.36	7.62e-16	Waist circumference;
LGG	cis	rs7100689	0.542	rs10887869	chr10:82194689	A/G	cg00277334	chr10:82204260	NA	-0.38	-8.22	-0.36	2.04e-15	Post bronchodilator FEV1;
LGG	cis	rs56397034	1	rs56397034	chr19:13000550	G/C	cg11738485	chr19:12877000	HOOK2	-0.46	-7.46	-0.33	4.25e-13	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs3813567	0.702	rs7164665	chr15:78953919	T/C	cg05914723	chr15:78953907	NA	0.49	7.02	0.31	8.13e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7666738	0.830	rs4292342	chr4:98959870	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.3e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088590	1.000	rs6120708	chr20:33335526	G/A	cg08999081	chr20:33150536	PIGU	0.32	7.43	0.33	5.24e-13	Coronary artery disease;
LGG	cis	rs11671005	0.735	rs56292587	chr19:58919066	A/T	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs6430585	0.878	rs9677760	chr2:136538939	T/A	cg07169764	chr2:136633963	MCM6	-1.0	-19.02	-0.66	4.99e-60	Corneal structure;
LGG	cis	rs1552244	0.882	rs56125067	chr3:9984130	T/G	cg08888203	chr3:10149979	C3orf24	0.52	8.61	0.37	1.18e-16	Alzheimer's disease;
LGG	trans	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg13010199	chr12:38710504	ALG10B	0.57	10.61	0.44	1.11e-23	Morning vs. evening chronotype;
LGG	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg00376283	chr12:123451042	ABCB9	0.63	9.93	0.42	3.33e-21	Neutrophil percentage of white cells;
LGG	cis	rs12421382	0.659	rs56410856	chr11:109382455	T/G	cg11473876	chr11:109292803	C11orf87	0.48	9.47	0.4	1.43e-19	Schizophrenia;
LGG	cis	rs8177179	0.967	rs6782434	chr3:133438834	C/G	cg24879335	chr3:133465180	TF	0.45	7.41	0.33	5.99e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg21926883	chr2:100939477	LONRF2	0.5	9.55	0.41	7.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.817	rs8142561	chr22:50291750	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.64	0.33	1.24e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14574726	chr11:809735	RPLP2	0.47	7.1	0.31	4.64e-12	Gut microbiome composition (summer);
LGG	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs798554	0.797	rs1182184	chr7:2872446	G/A	cg04166393	chr7:2884313	GNA12	0.48	9.21	0.39	1.11e-18	Height;
LGG	cis	rs3784262	0.631	rs6493980	chr15:58352290	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.93	-0.31	1.46e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4629710	0.538	rs11754401	chr6:131582197	G/A	cg12606694	chr6:131520996	AKAP7	0.53	8.57	0.37	1.54e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs1552244	0.882	rs34706481	chr3:10004123	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.81	0.38	2.58e-17	Alzheimer's disease;
LGG	cis	rs7647973	0.516	rs4499638	chr3:49202782	C/G	cg18654377	chr3:49208889	KLHDC8B	-0.51	-8.05	-0.35	6.94e-15	Menarche (age at onset);
LGG	cis	rs9878978	1.000	rs2174019	chr3:2472667	A/G	cg21928760	chr3:2462534	CNTN4	0.4	8.8	0.38	2.77e-17	Blood pressure (smoking interaction);
LGG	trans	rs10802346	0.545	rs1770012	chr1:246426405	A/G	cg13514129	chr1:39547527	MACF1	0.68	12.57	0.5	2.31e-31	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs9868809	0.881	rs2276852	chr3:48666923	A/G	cg00383909	chr3:49044727	WDR6	0.76	9.07	0.39	3.36e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11885103	0.647	rs2685244	chr2:553264	A/G	cg21195176	chr2:593345	NA	0.41	7.4	0.33	6.2800000000000005e-13	Heschl's gyrus morphology;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg05279229	chr7:1896384	MAD1L1	-0.39	-7.05	-0.31	6.38e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.6	0.51	1.67e-31	Colorectal cancer;
LGG	cis	rs9467773	0.967	rs6932865	chr6:26540166	C/A	cg09904177	chr6:26538194	HMGN4	0.78	18.03	0.64	1.96e-55	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.31	-7.95	-0.35	1.47e-14	Total body bone mineral density;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg02725872	chr8:58115012	NA	-0.76	-11.34	-0.47	1.8e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.583	rs6905113	chr6:101209368	A/G	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01510332	chr19:59087201	MGC2752	0.44	6.9	0.31	1.68e-11	Gut microbiome composition (summer);
LGG	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg17644776	chr2:200775616	C2orf69	0.57	7.13	0.31	3.81e-12	Schizophrenia;
LGG	cis	rs9311474	0.581	rs4687626	chr3:52569098	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.5	0.33	3.23e-13	Electroencephalogram traits;
LGG	cis	rs1278769	0.786	rs7998551	chr13:113540649	G/T	cg00823993	chr13:113535758	ATP11A	0.7	10.42	0.44	5.36e-23	Interstitial lung disease;
LGG	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg12179176	chr11:130786555	SNX19	0.75	14.48	0.56	1.77e-39	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs926938	0.563	rs360655	chr1:115447867	T/C	cg12756093	chr1:115239321	AMPD1	0.46	8.61	0.37	1.12e-16	Autism;
LGG	cis	rs9325144	0.505	rs1906262	chr12:38653605	A/G	cg26384229	chr12:38710491	ALG10B	0.88	19.86	0.68	6.07e-64	Morning vs. evening chronotype;
LGG	cis	rs1994135	0.654	rs1447872	chr12:33718343	C/A	cg06521331	chr12:34319734	NA	-0.51	-8.4	-0.36	5.67e-16	Resting heart rate;
LGG	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg01420254	chr6:26195488	NA	-0.9	-11.5	-0.47	4.25e-27	Gout;Renal underexcretion gout;
LGG	cis	rs35306767	0.715	rs12772979	chr10:1034412	C/T	cg20503657	chr10:835505	NA	0.56	7.14	0.31	3.73e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs9916302	0.731	rs11868030	chr17:37650332	A/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.75	-0.59	4.44e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs1559088	0.948	rs2019603	chr19:33577367	C/T	cg17764715	chr19:33622953	WDR88	-0.53	-9.27	-0.4	7.36e-19	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7659604	0.702	rs6826506	chr4:122710865	T/G	cg19748678	chr4:122722346	EXOSC9	0.68	13.53	0.53	2.14e-35	Type 2 diabetes;
LGG	cis	rs28386778	0.863	rs4968661	chr17:61796306	A/G	cg07677032	chr17:61819896	STRADA	0.66	12.08	0.49	2.07e-29	Prudent dietary pattern;
LGG	cis	rs920590	0.721	rs61180388	chr8:19670214	G/C	cg01411142	chr8:19674711	INTS10	0.46	7.18	0.32	2.76e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.73e-33	Prudent dietary pattern;
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-7.24	-0.32	1.83e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg03477792	chr4:77819574	ANKRD56	0.53	9.25	0.39	8.6e-19	Emphysema distribution in smoking;
LGG	cis	rs11711311	1.000	rs11719303	chr3:113494524	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.64	-0.33	1.3e-13	IgG glycosylation;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg26354017	chr1:205819088	PM20D1	0.87	20.81	0.7	2.23e-68	Menarche (age at onset);
LGG	cis	rs875971	1.000	rs1540651	chr7:65650121	C/T	cg23594656	chr7:65796392	TPST1	0.39	8.49	0.37	2.91e-16	Aortic root size;
LGG	cis	rs11148252	0.514	rs2296347	chr13:52728423	A/C	cg02158880	chr13:53174818	NA	-0.37	-6.83	-0.3	2.76e-11	Lewy body disease;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs73036520	0.846	rs17356664	chr19:45740771	C/T	cg20198684	chr19:45742032	NA	0.31	7.37	0.32	8.12e-13	Monocyte percentage of white cells;
LGG	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg08847533	chr14:75593920	NEK9	0.63	12.2	0.49	7.25e-30	Height;
LGG	cis	rs4604732	0.536	rs76191272	chr1:247628055	A/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.14	0.39	1.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg18379455	chr17:41446167	NA	-0.33	-7.45	-0.33	4.72e-13	Menopause (age at onset);
LGG	cis	rs2762353	0.902	rs3799344	chr6:25786993	C/T	cg03517284	chr6:25882590	NA	0.49	9.18	0.39	1.4e-18	Blood metabolite levels;
LGG	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg27411982	chr8:10470053	RP1L1	0.46	7.48	0.33	3.78e-13	Neuroticism;
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg07157834	chr1:205819609	PM20D1	0.44	8.77	0.38	3.5e-17	Menarche (age at onset);
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.33	0.43	1.18e-22	Prudent dietary pattern;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg08677398	chr8:58056175	NA	0.56	9.08	0.39	3.15e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.57	0.33	2.09e-13	Systolic blood pressure;
LGG	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg08847533	chr14:75593920	NEK9	-0.55	-10.21	-0.43	3.29e-22	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18543035	chr10:8374526	NA	0.52	8.73	0.38	4.72e-17	Gut microbiome composition (summer);
LGG	cis	rs9768139	0.935	rs7800718	chr7:158121878	G/A	cg15736062	chr7:158136485	PTPRN2	0.36	7.11	0.31	4.56e-12	Calcium levels;
LGG	cis	rs3733585	0.699	rs7683283	chr4:9969974	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.66	0.34	1.11e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9911578	1.000	rs302859	chr17:56693132	C/T	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg15145296	chr3:125709740	NA	-0.6	-7.76	-0.34	5.32e-14	Blood pressure (smoking interaction);
LGG	cis	rs4730779	0.571	rs39322	chr7:116969162	G/A	cg10524701	chr7:117356490	CTTNBP2	0.37	7.24	0.32	1.83e-12	Waist circumference;
LGG	trans	rs2562456	0.793	rs3853837	chr19:21601974	C/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs9921222	0.632	rs11649268	chr16:398643	A/C	cg26944245	chr16:421049	TMEM8A;MRPL28	0.54	9.28	0.4	6.6e-19	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs931127	1.000	rs931127	chr11:65405300	G/A	cg01640437	chr11:65405484	SIPA1	0.33	6.86	0.3	2.19e-11	Systemic lupus erythematosus;
LGG	cis	rs4650994	0.525	rs4650996	chr1:178517365	A/G	cg12486710	chr1:178512616	C1orf220	0.51	10.56	0.44	1.74e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.32	-0.53	1.65e-34	Personality dimensions;
LGG	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.05	0.52	2.33e-33	Coronary artery disease;
LGG	cis	rs782590	0.687	rs62165255	chr2:55932585	G/A	cg18811423	chr2:55921094	PNPT1	0.94	21.89	0.71	2.01e-73	Metabolic syndrome;
LGG	trans	rs61931739	0.500	rs12829125	chr12:34314789	A/G	cg13010199	chr12:38710504	ALG10B	0.59	11.2	0.46	6.22e-26	Morning vs. evening chronotype;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01341218	chr17:43662625	NA	0.96	17.02	0.62	8.42e-51	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3784262	0.669	rs4646609	chr15:58274989	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.9	-0.31	1.7e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9325144	0.505	rs10785560	chr12:38636622	C/T	cg26384229	chr12:38710491	ALG10B	0.89	19.88	0.68	5.14e-64	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg02733842	chr7:1102375	C7orf50	0.64	9.72	0.41	1.92e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg06873352	chr17:61820015	STRADA	-0.72	-13.64	-0.54	7.27e-36	Prudent dietary pattern;
LGG	cis	rs950776	0.593	rs588765	chr15:78865425	T/C	cg17108064	chr15:78857060	CHRNA5	-0.46	-9.96	-0.42	2.7e-21	Sudden cardiac arrest;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.2	-0.32	2.52e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.52	0.4	9.29e-20	Obesity-related traits;
LGG	trans	rs7980799	0.682	rs1384599	chr12:33624579	G/A	cg26384229	chr12:38710491	ALG10B	-0.65	-11.96	-0.49	6.7200000000000006e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7107174	0.901	rs10899493	chr11:78117534	T/C	cg02023728	chr11:77925099	USP35	0.42	7.64	0.33	1.28e-13	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs2190808	chr16:89840856	C/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.99	-0.35	1.08e-14	Skin colour saturation;
LGG	cis	rs992157	0.560	rs7578940	chr2:219083318	G/T	cg04731861	chr2:219085781	ARPC2	0.52	13.55	0.53	1.82e-35	Colorectal cancer;
LGG	cis	rs9322193	0.504	rs7771014	chr6:150205446	T/A	cg07701084	chr6:150067640	NUP43	0.43	7.92	0.35	1.78e-14	Lung cancer;
LGG	cis	rs7582180	0.809	rs7590008	chr2:100894115	T/C	cg08297393	chr2:100937505	LONRF2	-0.45	-7.34	-0.32	9.63e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4700695	0.614	rs153374	chr5:65424875	A/G	cg21114390	chr5:65439923	SFRS12	0.71	7.83	0.34	3.29e-14	Facial morphology (factor 19);
LGG	cis	rs1801251	0.711	rs778339	chr2:233739678	T/C	cg25237894	chr2:233734115	C2orf82	-0.72	-15.23	-0.58	9.32e-43	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs12451216	chr17:20025840	C/A	cg13482628	chr17:19912719	NA	0.49	9.13	0.39	2.06e-18	Obesity-related traits;
LGG	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg01346077	chr3:125931526	NA	0.6	14.43	0.56	2.93e-39	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs7727544	0.716	rs7701414	chr5:131585958	A/G	cg07395648	chr5:131743802	NA	-0.43	-9.23	-0.39	9.37e-19	Blood metabolite levels;
LGG	cis	rs637571	0.522	rs493899	chr11:65747952	A/C	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.81	0.34	3.73e-14	Eosinophil percentage of white cells;
LGG	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.96	-0.42	2.58e-21	Schizophrenia;
LGG	cis	rs1577917	1.000	rs10455455	chr6:86670214	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.38	-0.43	7.83e-23	Response to antipsychotic treatment;
LGG	cis	rs8133932	0.768	rs73907803	chr21:47044516	C/T	cg11214348	chr21:47283868	PCBP3	-0.41	-6.79	-0.3	3.39e-11	Schizophrenia;
LGG	cis	rs3768617	0.510	rs3768629	chr1:183074582	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.38	0.4	2.98e-19	Fuchs's corneal dystrophy;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg04832318	chr3:185303823	SENP2	0.38	6.8	0.3	3.22e-11	Bipolar disorder;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg20295408	chr7:1910781	MAD1L1	-0.45	-7.85	-0.34	2.83e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg15574263	chr11:911693	CHID1	-0.43	-7.26	-0.32	1.68e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6500395	1.000	rs7198773	chr16:48606091	T/C	cg04672837	chr16:48644449	N4BP1	0.56	9.31	0.4	5.12e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.96	0.35	1.3e-14	Personality dimensions;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.78	0.34	4.7e-14	Schizophrenia;
LGG	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs2153535	0.505	rs1737583	chr6:8536812	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.06	0.39	3.78e-18	Motion sickness;
LGG	cis	rs7193541	0.662	rs8063458	chr16:74469121	G/T	cg01733217	chr16:74700730	RFWD3	-0.88	-19.47	-0.67	3.99e-62	Multiple myeloma;
LGG	cis	rs3820928	0.605	rs10186145	chr2:227781150	A/G	cg05526886	chr2:227700861	RHBDD1	-0.42	-7.47	-0.33	3.91e-13	Pulmonary function;
LGG	cis	rs6500395	1.000	rs7202551	chr16:48728984	A/G	cg04672837	chr16:48644449	N4BP1	-0.53	-8.59	-0.37	1.36e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12497850	0.931	rs9846123	chr3:49088112	C/T	cg18654377	chr3:49208889	KLHDC8B	0.45	6.89	0.3	1.87e-11	Parkinson's disease;
LGG	cis	rs877282	0.945	rs34367686	chr10:791868	G/C	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	trans	rs800082	0.690	rs2717392	chr3:144280080	T/C	cg24215973	chr2:240111563	HDAC4	0.59	11.23	0.46	4.77e-26	Smoking behavior;
LGG	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.58	-0.44	1.36e-23	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.560	rs3021497	chr8:10996089	A/G	cg16141378	chr3:129829833	LOC729375	0.33	6.71	0.3	5.76e-11	Triglycerides;
LGG	cis	rs9948	0.529	rs62156208	chr2:97383686	A/G	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.47	-0.33	4.06e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg17127132	chr2:85788382	GGCX	0.48	8.33	0.36	9.48e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs910316	1.000	rs12897094	chr14:75579416	C/T	cg06637938	chr14:75390232	RPS6KL1	0.58	10.7	0.45	4.95e-24	Height;
LGG	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg02931644	chr1:25747376	RHCE	0.41	9.07	0.39	3.41e-18	Erythrocyte sedimentation rate;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg09217309	chr6:150244204	RAET1G	0.44	8.05	0.35	6.84e-15	Testicular germ cell tumor;
LGG	cis	rs7095944	0.614	rs61872084	chr10:126439062	C/T	cg08799069	chr10:126477246	METTL10	-0.48	-10.79	-0.45	2.25e-24	Asthma;
LGG	cis	rs4950322	0.518	rs4950306	chr1:146589420	C/G	cg22381352	chr1:146742008	CHD1L	-0.45	-7.6	-0.33	1.7e-13	Protein quantitative trait loci;
LGG	cis	rs6712932	1.000	rs1978821	chr2:105833235	C/T	cg22878388	chr2:105853796	NA	-0.44	-8.06	-0.35	6.42e-15	Type 2 diabetes;
LGG	cis	rs300774	0.800	rs406427	chr2:146263	C/A	cg04617936	chr2:214353	NA	-0.49	-7.4	-0.33	6.5e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs897984	0.762	rs4889604	chr16:30985994	G/T	cg00531865	chr16:30841666	NA	0.54	11.28	0.46	3.06e-26	Dementia with Lewy bodies;
LGG	cis	rs751728	0.965	rs4713683	chr6:33757550	C/G	cg25922239	chr6:33757077	LEMD2	0.67	11.02	0.46	3.2e-25	Crohn's disease;
LGG	cis	rs6121246	0.909	rs6060812	chr20:30292803	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.63	0.51	1.29e-31	Mean corpuscular hemoglobin;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg15971980	chr6:150254442	NA	0.46	8.59	0.37	1.34e-16	Lung cancer;
LGG	cis	rs10463554	0.963	rs17154953	chr5:102355261	A/G	cg23492399	chr5:102201601	PAM	-0.49	-7.4	-0.33	6.45e-13	Parkinson's disease;
LGG	cis	rs7914558	0.902	rs3736922	chr10:104850632	A/G	cg04362960	chr10:104952993	NT5C2	-0.51	-9.47	-0.4	1.4e-19	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg00071950	chr4:10020882	SLC2A9	0.43	8.82	0.38	2.29e-17	Bone mineral density;
LGG	cis	rs6089584	1.000	rs6089591	chr20:60570548	A/C	cg06470251	chr20:60548479	NA	0.52	9.22	0.39	1.06e-18	Body mass index;
LGG	cis	rs4731207	0.698	rs34618371	chr7:124496170	C/T	cg05630886	chr7:124431682	NA	-0.34	-7.91	-0.35	1.88e-14	Cutaneous malignant melanoma;
LGG	cis	rs4589502	0.800	rs4147433	chr15:67201152	G/A	cg18595228	chr15:67193261	NA	-0.49	-6.75	-0.3	4.36e-11	Lung cancer (smoking interaction);
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg00405596	chr8:11794950	NA	0.41	6.88	0.3	1.99e-11	Mood instability;
LGG	cis	rs7666738	0.830	rs28444709	chr4:99028496	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.45e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg24692254	chr21:30365293	RNF160	-0.59	-8.8	-0.38	2.8e-17	Cognitive test performance;
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg16482183	chr6:26056742	HIST1H1C	0.42	7.21	0.32	2.22e-12	Height;
LGG	cis	rs1008375	0.863	rs2058336	chr4:17608299	T/C	cg10189774	chr4:17578691	LAP3	0.42	7.53	0.33	2.75e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg09699651	chr6:150184138	LRP11	0.5	8.67	0.37	7.07e-17	Lung cancer;
LGG	cis	rs4423214	0.592	rs10898193	chr11:71197083	A/G	cg05163923	chr11:71159392	DHCR7	0.57	8.26	0.36	1.55e-15	Vitamin D levels;
LGG	cis	rs9611565	0.694	rs202613	chr22:41821993	C/A	cg17376030	chr22:41985996	PMM1	-0.56	-8.95	-0.38	8.62e-18	Vitiligo;
LGG	cis	rs3820928	0.934	rs4675117	chr2:227769794	A/G	cg11843606	chr2:227700838	RHBDD1	0.44	7.25	0.32	1.76e-12	Pulmonary function;
LGG	cis	rs7223966	1.000	rs2013288	chr17:61785904	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.47	-0.37	3.21e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs988958	0.526	rs12712828	chr2:42244795	T/G	cg19376973	chr2:42229025	NA	0.64	9.52	0.4	9.47e-20	Hypospadias;
LGG	cis	rs9611565	0.694	rs202618	chr22:41822856	A/G	cg06850241	chr22:41845214	NA	0.45	7.11	0.31	4.32e-12	Vitiligo;
LGG	cis	rs9902453	0.740	rs2617884	chr17:28120430	G/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg22857025	chr5:266934	NA	-1.49	-25.91	-0.77	3.75e-92	Breast cancer;
LGG	cis	rs6977660	0.714	rs6976972	chr7:19818315	C/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs2953174	0.786	rs2975749	chr2:241519093	A/G	cg07929629	chr2:241523174	NA	0.56	6.85	0.3	2.3e-11	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.59e-12	Lung cancer;
LGG	trans	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg13009111	chr11:71350975	NA	-0.32	-6.86	-0.3	2.22e-11	Monocyte count;
LGG	cis	rs1023500	0.573	rs133378	chr22:42467695	G/C	cg05082376	chr22:42548792	NA	-0.36	-7.55	-0.33	2.34e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg24829409	chr8:58192753	C8orf71	-0.87	-13.72	-0.54	3.36e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs12618769	0.652	rs13402379	chr2:99209314	G/A	cg18455616	chr2:99124870	INPP4A	0.27	7.73	0.34	6.8e-14	Bipolar disorder;
LGG	cis	rs11166927	0.904	rs7836476	chr8:140819035	C/T	cg16909799	chr8:140841666	TRAPPC9	0.55	11.52	0.47	3.67e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	trans	rs877282	0.898	rs12356744	chr10:757477	G/C	cg22713356	chr15:30763199	NA	0.48	7.24	0.32	1.93e-12	Uric acid levels;
LGG	trans	rs61931739	0.500	rs7306334	chr12:34482900	A/G	cg26384229	chr12:38710491	ALG10B	-0.96	-21.25	-0.7	1.9e-70	Morning vs. evening chronotype;
LGG	cis	rs834603	0.546	rs1704973	chr7:47483705	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.84	0.34	3.05e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.24	0.49	4.75e-30	Prudent dietary pattern;
LGG	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	16.83	0.62	6.25e-50	Subjective well-being;
LGG	cis	rs6500395	1.000	rs1039340	chr16:48574637	A/C	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3008870	0.583	rs2147838	chr1:67399466	T/C	cg11518657	chr1:67396239	MIER1	0.48	7.22	0.32	2.18e-12	Lymphocyte percentage of white cells;
LGG	cis	rs6547741	1.000	rs6718128	chr2:27833752	A/G	cg27432699	chr2:27873401	GPN1	-0.69	-14.05	-0.55	1.31e-37	Oral cavity cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg18036763	chr22:45404910	PHF21B	0.47	7.99	0.35	1.11e-14	Bipolar disorder;
LGG	cis	rs9814567	1.000	rs9835204	chr3:134261342	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg26043149	chr18:55253948	FECH	0.41	6.75	0.3	4.41e-11	Bone mineral density;
LGG	cis	rs7666738	0.830	rs969049	chr4:98988857	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	8.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2131877	0.956	rs60023213	chr3:194870505	A/T	cg07250128	chr3:194833983	C3orf21	0.4	7.55	0.33	2.3e-13	Non-small cell lung cancer;
LGG	trans	rs35110281	0.715	rs2838320	chr21:44995037	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.65	0.48	1.08e-27	Mean corpuscular volume;
LGG	trans	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg00170343	chr3:11313890	ATG7	0.53	6.77	0.3	3.89e-11	Circulating chemerin levels;
LGG	cis	rs7829975	0.593	rs2979241	chr8:8303353	G/C	cg14979609	chr8:8086686	FLJ10661	-0.31	-8.07	-0.35	5.92e-15	Mood instability;
LGG	cis	rs72772090	0.539	rs72775807	chr5:96179761	C/T	cg00188032	chr5:96141721	ERAP1	0.55	7.17	0.32	2.94e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10463316	0.894	rs3905511	chr5:150768204	G/A	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.18	-0.43	4.4e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg17294928	chr15:75287854	SCAMP5	-0.95	-17.06	-0.62	5.41e-51	Blood trace element (Zn levels);
LGG	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg00376283	chr12:123451042	ABCB9	0.63	10.19	0.43	3.9e-22	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7618915	0.501	rs62253740	chr3:52684128	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.33	-0.32	1.04e-12	Bipolar disorder;
LGG	cis	rs832540	0.669	rs173764	chr5:56198920	C/T	cg08400814	chr5:56204995	C5orf35	-0.38	-6.75	-0.3	4.47e-11	Coronary artery disease;
LGG	cis	rs2721195	1.000	rs6599530	chr8:145677418	C/G	cg15857475	chr8:145742913	RECQL4;LRRC14	-0.8	-15.58	-0.59	2.51e-44	Age at first birth;
LGG	cis	rs28655083	0.956	rs11863953	chr16:77065710	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.51	-8.04	-0.35	7.4e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.38	-0.36	6.2e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2290402	0.536	rs56253935	chr4:853871	A/T	cg09237302	chr4:906077	GAK	-0.45	-7.56	-0.33	2.17e-13	Type 2 diabetes;
LGG	cis	rs7089973	0.836	rs12765350	chr10:116635305	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.45e-14	Obesity-related traits;
LGG	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.58	-0.33	1.88e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7223966	0.921	rs2006123	chr17:61958669	G/T	cg05941027	chr17:61774174	LIMD2	0.34	8.46	0.37	3.6e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2072732	0.861	rs4576609	chr1:2938265	C/T	cg08733933	chr1:2954429	NA	-0.44	-8.56	-0.37	1.69e-16	Plateletcrit;
LGG	cis	rs9522267	0.535	rs2039916	chr13:112238863	A/C	cg14952266	chr13:112191215	NA	0.5	10.57	0.44	1.49e-23	Hepatitis;
LGG	trans	rs9987353	0.518	rs4841110	chr8:9086023	C/T	cg06636001	chr8:8085503	FLJ10661	0.39	6.98	0.31	1.02e-11	Recombination measurement;
LGG	cis	rs10884984	0.802	rs1889568	chr10:112263030	C/T	cg18756771	chr10:112261994	DUSP5	-0.7	-13.25	-0.52	3.26e-34	Facial morphology (factor 22);
LGG	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg08344181	chr3:125677491	NA	-0.87	-8.58	-0.37	1.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11771526	0.686	rs28399034	chr7:32272898	A/G	cg27532318	chr7:32358331	NA	0.65	6.9	0.31	1.74e-11	Body mass index;
LGG	cis	rs4330281	0.626	rs9880971	chr3:17624579	C/A	cg20981856	chr3:17787350	NA	0.4	7.49	0.33	3.43e-13	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03211936	chr1:16134184	UQCRHL	-0.38	-6.89	-0.3	1.83e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4363385	0.747	rs1415971	chr1:152965779	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.3e-18	Inflammatory skin disease;
LGG	cis	rs1920116	0.778	rs16854453	chr3:169559234	G/A	cg08193579	chr3:169529701	LRRC34	0.4	6.97	0.31	1.11e-11	Glioma (high-grade);
LGG	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.48	-9.31	-0.4	5.24e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs11586313	0.597	rs1590931	chr1:152861866	C/T	cg13444842	chr1:152974279	SPRR3	-0.38	-7.2	-0.32	2.51e-12	Vitamin D levels;
LGG	cis	rs933688	1.000	rs6867219	chr5:90718008	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	16.46	0.61	3.04e-48	Smoking behavior;
LGG	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.97	0.31	1.06e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2730245	0.563	rs2709857	chr7:158685257	T/C	cg11984989	chr7:158649758	WDR60	1.04	23.85	0.74	1.4e-82	Height;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.43	-0.33	5.35e-13	Neuroticism;
LGG	trans	rs7746199	0.736	rs6904596	chr6:27491299	G/A	cg08344181	chr3:125677491	NA	-0.76	-8.2	-0.36	2.39e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.659	rs56364401	chr22:41951243	T/G	cg17554472	chr22:41940697	POLR3H	-0.47	-6.66	-0.3	7.56e-11	Vitiligo;
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg10295955	chr4:187884368	NA	-1.16	-31.1	-0.82	1.86e-115	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6963495	0.606	rs6969426	chr7:105147150	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.88	0.34	2.44e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6840360	0.642	rs2053566	chr4:152445831	A/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.3	0.32	1.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6450176	1.000	rs6450176	chr5:53298025	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.47	-0.47	5.67e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs503734	0.629	rs2317700	chr3:101143166	T/C	cg27318481	chr3:100970896	IMPG2	0.35	7.2	0.32	2.47e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11771526	0.901	rs17161124	chr7:32307324	A/T	cg13207630	chr7:32358064	NA	-0.59	-6.75	-0.3	4.42e-11	Body mass index;
LGG	trans	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg18335740	chr13:41363409	SLC25A15	0.66	13.39	0.53	8.8e-35	Lewy body disease;
LGG	cis	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.39	-0.36	6.05e-16	Bipolar disorder;
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg02002194	chr4:3960332	NA	0.51	9.73	0.41	1.78e-20	Neuroticism;
LGG	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs4356932	1.000	rs8878	chr4:76942300	C/T	cg25799590	chr4:76943062	CXCL10;ART3	0.4	6.77	0.3	3.94e-11	Blood protein levels;
LGG	trans	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg04469686	chr1:162760199	HSD17B7	0.43	7.06	0.31	6.33e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1348850	0.526	rs78587445	chr2:178461339	G/T	cg22681709	chr2:178499509	PDE11A	0.48	6.65	0.3	8.19e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs61931739	0.500	rs12809868	chr12:34464905	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	cis	rs6504108	0.602	rs7219967	chr17:46294074	G/T	cg02219949	chr17:45927392	SP6	0.43	8.03	0.35	8.4e-15	Body mass index;
LGG	cis	rs3812831	0.654	rs367312	chr13:114930195	G/A	cg25338242	chr13:114786047	RASA3	0.39	7.19	0.32	2.7e-12	Schizophrenia;
LGG	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.38	-0.32	7.63e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs698813	0.604	rs4953077	chr2:44481207	C/T	cg00619915	chr2:44497795	NA	-0.59	-8.69	-0.37	6.32e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs7928758	0.887	rs80021729	chr11:134263734	A/C	cg22777979	chr11:134283252	B3GAT1	1.03	12.26	0.5	4.04e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs16854884	0.657	rs10513235	chr3:143698664	T/C	cg06585982	chr3:143692056	C3orf58	0.61	10.3	0.43	1.59e-22	Economic and political preferences (feminism/equality);
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg01988459	chr11:68622903	NA	-0.64	-12.55	-0.5	2.56e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7829975	0.660	rs10093926	chr8:8549020	A/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.22	-0.39	1.07e-18	Mood instability;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16405210	chr4:1374714	KIAA1530	-0.52	-9.18	-0.39	1.41e-18	Longevity;
LGG	trans	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.8	-0.34	4.15e-14	Neuroticism;
LGG	cis	rs757278	0.552	rs4730793	chr7:117311117	C/T	cg10524701	chr7:117356490	CTTNBP2	0.42	7.53	0.33	2.72e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs10808265	0.567	rs7803585	chr7:132262702	C/G	cg05950570	chr7:132261418	PLXNA4	0.53	9.93	0.42	3.46e-21	Pulmonary function decline;
LGG	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.33	-0.47	1.93e-26	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.59	-11.58	-0.47	2.06e-27	Height;
LGG	cis	rs10463316	0.894	rs4099169	chr5:150766526	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.3	-0.43	1.55e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02018176	chr4:1364513	KIAA1530	0.49	11.99	0.49	4.89e-29	Longevity;
LGG	cis	rs7580658	0.895	rs4662580	chr2:128102806	C/A	cg10021288	chr2:128175891	PROC	-0.63	-12.87	-0.51	1.27e-32	Protein C levels;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg16270222	chr17:41446396	NA	-0.29	-6.67	-0.3	7.23e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg14926445	chr8:58193284	C8orf71	-0.84	-12.01	-0.49	4.06e-29	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.564	rs10503415	chr8:10983921	C/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.18	-0.32	2.89e-12	Triglycerides;
LGG	cis	rs56775891	1.000	rs34945223	chr18:77575871	A/G	cg13263691	chr18:77568018	NA	0.83	14.61	0.56	4.79e-40	Schizophrenia;
LGG	cis	rs763014	0.932	rs2384974	chr16:651279	C/G	cg27189623	chr16:705930	WDR90	0.4	7.77	0.34	4.97e-14	Height;
LGG	cis	rs2236918	0.710	rs2526702	chr1:242017983	G/A	cg17736920	chr1:242011382	EXO1	0.39	7.09	0.31	4.98e-12	Menopause (age at onset);
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg26174226	chr8:58114915	NA	-0.5	-6.99	-0.31	9.38e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9443645	0.869	rs9361467	chr6:79621098	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.57	-0.37	1.5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7119	0.717	rs8032071	chr15:77745762	C/T	cg05673287	chr15:77411982	SGK269	0.45	9.09	0.39	2.9e-18	Type 2 diabetes;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs4804815	0.697	rs73008237	chr19:7841188	T/C	cg09310891	chr19:7854403	CLEC4GP1	0.54	8.35	0.36	7.92e-16	Neutrophil count;
LGG	cis	rs6882046	0.513	rs587490	chr5:88032522	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.42	-0.44	5.79e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs870825	0.616	rs4416519	chr4:185639502	T/C	cg04058563	chr4:185651563	MLF1IP	1.04	22.83	0.73	7.36e-78	Blood protein levels;
LGG	trans	rs79976124	0.837	rs10455591	chr6:66650584	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.27	0.5	3.79e-30	Type 2 diabetes;
LGG	cis	rs10504229	0.516	rs58244172	chr8:57987805	G/A	cg14926445	chr8:58193284	C8orf71	-0.45	-7.02	-0.31	7.84e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.96	-0.38	7.75e-18	Schizophrenia;
LGG	cis	rs2013441	1.000	rs1561974	chr17:20196144	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6e-11	Obesity-related traits;
LGG	cis	rs992157	1.000	rs736730	chr2:219120255	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.34	0.47	1.78e-26	Colorectal cancer;
LGG	cis	rs9611565	0.512	rs964899	chr22:42142386	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.83	0.34	3.45e-14	Vitiligo;
LGG	trans	rs6601327	0.641	rs11778555	chr8:9587574	C/T	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs208520	0.633	rs7738469	chr6:66807446	T/C	cg07460842	chr6:66804631	NA	-0.98	-18.63	-0.65	3.39e-58	Exhaled nitric oxide output;
LGG	cis	rs5753037	0.640	rs131260	chr22:30132964	A/C	cg01021169	chr22:30184971	ASCC2	-0.34	-6.66	-0.3	7.65e-11	Type 1 diabetes;
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg26554054	chr8:600488	NA	0.95	9.98	0.42	2.27e-21	IgG glycosylation;
LGG	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.38	-0.32	7.5e-13	Body mass index;
LGG	cis	rs504918	0.588	rs34251299	chr3:124029086	A/G	cg05766129	chr3:123988013	KALRN	-0.58	-10.14	-0.43	6e-22	Schizophrenia;
LGG	cis	rs2576037	0.526	rs2571027	chr18:44561516	C/G	cg19077165	chr18:44547161	KATNAL2	0.58	10.83	0.45	1.57e-24	Personality dimensions;
LGG	cis	rs7781557	0.640	rs6465886	chr7:102614137	C/A	cg18108683	chr7:102477205	FBXL13	-0.54	-8.15	-0.35	3.35e-15	Colorectal adenoma (advanced);
LGG	cis	rs12586317	0.576	rs72664862	chr14:35641572	C/T	cg16230307	chr14:35515116	FAM177A1	0.38	6.65	0.3	8.4e-11	Psoriasis;
LGG	cis	rs796364	0.806	rs12616905	chr2:201007764	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.53	-0.41	8.61e-20	Schizophrenia;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg16270222	chr17:41446396	NA	0.3	7.31	0.32	1.15e-12	Menopause (age at onset);
LGG	cis	rs9900972	0.851	rs62077283	chr17:76868135	T/C	cg00961940	chr17:76876995	TIMP2	0.46	8.49	0.37	2.75e-16	Obesity-related traits;
LGG	cis	rs7122539	0.646	rs2187041	chr11:66534516	T/C	cg01599099	chr11:66649832	PC	0.48	9.8	0.41	1.03e-20	HIV-1 susceptibility;
LGG	cis	rs6582630	0.615	rs11182380	chr12:38511735	G/T	cg26384229	chr12:38710491	ALG10B	-0.67	-13.34	-0.53	1.38e-34	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg21153622	chr11:89784906	NA	-0.41	-6.99	-0.31	9.57e-12	HDL cholesterol;
LGG	cis	rs16854884	0.657	rs35085196	chr3:143712210	C/T	cg06585982	chr3:143692056	C3orf58	0.65	11.52	0.47	3.52e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs9902453	0.808	rs76039587	chr17:28233760	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.59	0.53	1.24e-35	Coffee consumption (cups per day);
LGG	cis	rs15676	0.853	rs2259043	chr9:131607921	A/G	cg04621255	chr9:131581398	ENDOG	-0.41	-7.08	-0.31	5.43e-12	Blood metabolite levels;
LGG	trans	rs7824557	0.569	rs35418978	chr8:11186453	T/C	cg02002194	chr4:3960332	NA	-0.39	-7.23	-0.32	2.06e-12	Retinal vascular caliber;
LGG	cis	rs2067615	0.524	rs10467029	chr12:107078448	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.97	0.52	5.07e-33	Heart rate;
LGG	trans	rs2834485	0.816	rs1547356	chr21:35822572	C/T	cg07474852	chr4:123073612	NA	0.62	10.22	0.43	2.91e-22	Cancer;
LGG	cis	rs4319547	0.695	rs113841747	chr12:122886088	G/T	cg05707623	chr12:122985044	ZCCHC8	0.66	9.76	0.41	1.4e-20	Body mass index;
LGG	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg02931644	chr1:25747376	RHCE	0.42	9.36	0.4	3.34e-19	Erythrocyte sedimentation rate;
LGG	cis	rs9397585	0.857	rs6914676	chr6:153386932	C/G	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.28e-38	Body mass index;
LGG	cis	rs7408868	0.908	rs2074619	chr19:15276919	G/A	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs75920871	0.925	rs4938333	chr11:116930888	A/G	cg20608306	chr11:116969690	SIK3	-0.33	-7.0	-0.31	9.19e-12	Subjective well-being;
LGG	cis	rs847649	0.842	rs1608651	chr7:102624192	C/T	cg18108683	chr7:102477205	FBXL13	0.58	12.23	0.49	5.11e-30	Morning vs. evening chronotype;
LGG	cis	rs4481887	0.741	rs7417519	chr1:248550370	C/T	cg15454534	chr1:248569605	OR2T1	-0.36	-6.68	-0.3	6.8e-11	Common traits (Other);
LGG	cis	rs7503807	0.515	rs1485330	chr17:78640822	G/A	cg18469159	chr17:78755841	RPTOR	-0.66	-11.44	-0.47	7.06e-27	Obesity;
LGG	cis	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs17221829	0.733	rs10830299	chr11:89362670	C/T	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs1691799	0.899	rs1168299	chr12:66736074	C/G	cg16791601	chr12:66731901	HELB	-0.67	-15.89	-0.59	1.12e-45	White blood cell count (basophil);
LGG	cis	rs7527798	0.571	rs11118237	chr1:207818719	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-6.98	-0.31	1.05e-11	Erythrocyte sedimentation rate;
LGG	cis	rs12643440	0.538	rs1581402	chr4:17139877	T/A	cg22650099	chr4:17144496	NA	-0.5	-8.52	-0.37	2.34e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs4332037	0.539	rs34809719	chr7:2028968	G/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.77	-0.3	3.93e-11	Bipolar disorder;
LGG	trans	rs6600671	1.000	rs4844381	chr1:121184898	C/T	cg00340584	chr1:149512963	NA	-0.27	-7.62	-0.33	1.4e-13	Hip geometry;
LGG	trans	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.16	-32.53	-0.83	1.08e-121	Exhaled nitric oxide output;
LGG	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg08305652	chr11:111469057	NA	0.44	8.35	0.36	7.99e-16	Primary sclerosing cholangitis;
LGG	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg04568710	chr12:38710424	ALG10B	0.4	8.31	0.36	1.07e-15	Morning vs. evening chronotype;
LGG	cis	rs17030434	0.906	rs12643219	chr4:154670798	T/C	cg14289246	chr4:154710475	SFRP2	-0.71	-11.07	-0.46	1.95e-25	Electrocardiographic conduction measures;
LGG	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg02631450	chr22:32366979	NA	0.96	9.36	0.4	3.54e-19	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26912688	chr1:176176562	RFWD2	0.5	7.59	0.33	1.83e-13	Gut microbiome composition (summer);
LGG	cis	rs17767392	0.681	rs7146169	chr14:71684656	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.33	-6.84	-0.3	2.58e-11	Mitral valve prolapse;
LGG	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg14993813	chr1:46806288	NSUN4	-0.51	-7.95	-0.35	1.46e-14	Menopause (age at onset);
LGG	cis	rs7712401	0.584	rs4836382	chr5:122376641	G/A	cg19412675	chr5:122181750	SNX24	0.46	7.52	0.33	2.83e-13	Mean platelet volume;
LGG	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.89	0.34	2.26e-14	Multiple myeloma (hyperdiploidy);
LGG	trans	rs6446298	1.000	rs6446298	chr3:49860854	T/C	cg21659725	chr3:3221576	CRBN	0.65	10.98	0.45	4.34e-25	Intelligence (multi-trait analysis);
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg26668828	chr6:292823	DUSP22	-0.53	-9.28	-0.4	6.68e-19	Menopause (age at onset);
LGG	cis	rs5769765	1.000	rs1033665	chr22:50252127	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.11	-0.43	7.86e-22	Schizophrenia;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-12.23	-0.49	5.13e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs9325144	0.555	rs4882284	chr12:38710459	C/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.6	-0.37	1.23e-16	Morning vs. evening chronotype;
LGG	cis	rs4631830	0.900	rs10763576	chr10:51538813	A/T	cg10326726	chr10:51549505	MSMB	-0.69	-14.18	-0.55	3.69e-38	Prostate-specific antigen levels;
LGG	cis	rs12478296	0.786	rs13409307	chr2:242995499	G/C	cg06360820	chr2:242988706	NA	-0.96	-12.5	-0.5	4.23e-31	Obesity-related traits;
LGG	cis	rs34929064	0.671	rs34198632	chr7:22743801	G/A	cg18045685	chr7:22629474	NA	0.51	6.97	0.31	1.07e-11	Major depression and alcohol dependence;
LGG	cis	rs2070488	0.775	rs961179	chr3:38509618	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.76	0.57	1.16e-40	Electrocardiographic conduction measures;
LGG	cis	rs7552404	0.727	rs7521344	chr1:76318325	C/T	cg22875332	chr1:76189707	ACADM	-0.53	-8.1	-0.35	4.81e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs131777	0.708	rs131749	chr22:51024624	C/T	cg05418105	chr22:50981406	NA	0.61	10.38	0.43	7.56e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	trans	rs8002861	0.641	rs6561148	chr13:44426269	C/T	cg12856521	chr11:46389249	DGKZ	0.54	9.58	0.41	5.72e-20	Leprosy;
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg09913183	chr17:42254507	C17orf65;ASB16	0.61	11.4	0.47	1.03e-26	Total body bone mineral density;
LGG	cis	rs7551222	0.749	rs4951409	chr1:204560990	A/T	cg20240347	chr1:204465584	NA	-0.47	-9.15	-0.39	1.85e-18	Schizophrenia;
LGG	cis	rs9311474	0.607	rs4687625	chr3:52563718	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.73	0.34	6.74e-14	Electroencephalogram traits;
LGG	cis	rs6540556	0.769	rs7521461	chr1:209926207	C/G	cg23920097	chr1:209922102	NA	-0.49	-8.73	-0.38	4.77e-17	Red blood cell count;
LGG	cis	rs963731	0.522	rs13031871	chr2:39252851	T/G	cg04010122	chr2:39346883	SOS1	-0.72	-7.38	-0.32	7.56e-13	Corticobasal degeneration;
LGG	cis	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8016982	0.633	rs7160342	chr14:81713427	G/C	cg01989461	chr14:81687754	GTF2A1	0.79	18.83	0.66	3.63e-59	Schizophrenia;
LGG	cis	rs10463316	0.894	rs10476769	chr5:150763970	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.19	-0.43	3.78e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg07511668	chr11:68622177	NA	0.48	9.09	0.39	2.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.87	0.42	5.62e-21	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11064206	chr12:123459532	OGFOD2;ABCB9	0.5	7.82	0.34	3.67e-14	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg00800038	chr16:89945340	TCF25	-0.69	-7.92	-0.35	1.76e-14	Skin colour saturation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04025889	chr20:32891089	AHCY	0.44	6.67	0.3	7.46e-11	Gut microbiome composition (summer);
LGG	cis	rs826838	0.620	rs11614695	chr12:39331847	C/T	cg13010199	chr12:38710504	ALG10B	0.62	12.17	0.49	9.39e-30	Heart rate;
LGG	cis	rs57590327	0.528	rs7642112	chr3:81674927	C/T	cg07356753	chr3:81810745	GBE1	-0.49	-7.44	-0.33	4.97e-13	Extraversion;
LGG	cis	rs7208859	0.524	rs11653605	chr17:29088385	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7945404	0.548	rs10750188	chr11:121230246	A/C	cg27192990	chr6:129479024	LAMA2	-0.56	-8.1	-0.35	4.88e-15	QT interval;
LGG	trans	rs11976180	1.000	rs2961132	chr7:143768128	A/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.4	-7.2	-0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs1793639	0.606	rs1793636	chr11:131934926	G/C	cg13908476	chr11:131942942	NTM	0.68	13.9	0.54	5.77e-37	Myopia;
LGG	cis	rs533581	0.866	rs562812	chr16:88970944	G/A	cg08484992	chr16:88977278	CBFA2T3	0.3	6.73	0.3	5e-11	Social autistic-like traits;
LGG	trans	rs8073060	0.545	rs3859282	chr17:34006111	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs754466	0.580	rs10824576	chr10:79566040	G/C	cg17075019	chr10:79541650	NA	-0.93	-20.11	-0.68	4.13e-65	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs898097	0.845	rs7213006	chr17:80899928	T/C	cg15664640	chr17:80829946	TBCD	0.6	11.1	0.46	1.5e-25	Breast cancer;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.3	-0.32	1.3e-12	Lung cancer;
LGG	cis	rs9611565	0.802	rs4822028	chr22:41789408	A/G	cg06481639	chr22:41940642	POLR3H	-0.5	-7.57	-0.33	2.1e-13	Vitiligo;
LGG	cis	rs3925075	1.000	rs4411512	chr16:31347445	C/T	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs870825	0.616	rs61653735	chr4:185630025	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	trans	rs7824557	0.583	rs2263511	chr8:11233318	A/C	cg02002194	chr4:3960332	NA	0.44	7.93	0.35	1.69e-14	Retinal vascular caliber;
LGG	cis	rs7264396	0.690	rs2425165	chr20:34438059	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.42	0.33	5.59e-13	Total cholesterol levels;
LGG	cis	rs709400	0.663	rs62007718	chr14:103940436	G/A	cg26031613	chr14:104095156	KLC1	0.8	13.98	0.54	2.66e-37	Body mass index;
LGG	cis	rs975722	1.000	rs7777807	chr7:117348905	C/T	cg10524701	chr7:117356490	CTTNBP2	0.51	11.63	0.48	1.27e-27	Coronary artery disease;
LGG	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg10621924	chr7:39171070	POU6F2	0.48	9.97	0.42	2.36e-21	IgG glycosylation;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs283228	0.517	rs1832416	chr6:101807024	T/A	cg27451362	chr6:101846650	GRIK2	0.96	14.64	0.56	3.53e-40	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.897	rs7212196	chr17:61834981	T/C	cg07677032	chr17:61819896	STRADA	0.68	12.59	0.5	1.87e-31	Prudent dietary pattern;
LGG	cis	rs9916302	0.904	rs585961	chr17:37444036	G/A	cg07936489	chr17:37558343	FBXL20	0.85	16.06	0.6	1.93e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.61	0.51	1.55e-31	Motion sickness;
LGG	cis	rs9560113	1.000	rs9560107	chr13:112180146	G/A	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs2463822	1.000	rs118049526	chr11:62107508	C/T	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.35	-0.58	2.77e-43	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs57046232	0.552	rs6076987	chr20:6351417	A/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.86	0.3	2.22e-11	Colorectal cancer;
LGG	cis	rs2839186	0.619	rs55689527	chr21:47622727	A/G	cg14789911	chr21:47582049	C21orf56	-0.45	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg10053473	chr17:62856997	LRRC37A3	-0.94	-15.02	-0.57	7.92e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17270561	0.541	rs12192932	chr6:25911502	A/G	cg17042849	chr6:26104293	HIST1H4C	-0.52	-6.71	-0.3	5.83e-11	Iron status biomarkers;
LGG	cis	rs6460942	0.915	rs62448602	chr7:12457145	T/G	cg06484146	chr7:12443880	VWDE	-0.4	-6.97	-0.31	1.12e-11	Coronary artery disease;
LGG	cis	rs7937682	0.593	rs1944111	chr11:111364432	G/C	cg09085632	chr11:111637200	PPP2R1B	0.67	11.19	0.46	6.72e-26	Primary sclerosing cholangitis;
LGG	cis	rs13191362	0.938	rs13208970	chr6:163006368	G/T	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.85	0.34	2.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg15174905	chr19:19281255	LOC729991-MEF2B;MEF2B	-0.33	-8.45	-0.37	3.91e-16	IgG glycosylation;
LGG	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg13010199	chr12:38710504	ALG10B	-0.55	-10.25	-0.43	2.32e-22	Morning vs. evening chronotype;
LGG	cis	rs4746818	0.818	rs7076011	chr10:70900430	T/C	cg11621586	chr10:70884670	VPS26A	1.18	21.7	0.71	1.5299999999999999e-72	Left atrial antero-posterior diameter;
LGG	cis	rs9858542	1.000	rs9836291	chr3:49697459	G/A	cg07274523	chr3:49395745	GPX1	0.55	9.02	0.39	5.07e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg08250081	chr4:10125330	NA	-0.35	-6.68	-0.3	7.07e-11	Bone mineral density;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.37	-0.5	1.39e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9457247	1.000	rs376551	chr6:167384923	G/A	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.44e-12	Crohn's disease;
LGG	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.13	-0.31	3.98e-12	Blood metabolite levels;
LGG	cis	rs8062405	0.965	rs7359397	chr16:28885659	C/T	cg09754948	chr16:28834200	ATXN2L	0.47	7.35	0.32	9.13e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs877426	0.555	rs7988568	chr13:114826751	C/T	cg00571178	chr13:114841904	RASA3	-0.55	-9.69	-0.41	2.52e-20	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs765787	0.530	rs4238376	chr15:45541887	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.95	-12.58	-0.5	1.99e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg14338887	chr6:42928500	GNMT	0.28	8.97	0.38	7.53e-18	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04008888	chr11:68622739	NA	-0.57	-11.89	-0.48	1.22e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs870825	0.860	rs28799091	chr4:185598594	G/A	cg04058563	chr4:185651563	MLF1IP	1.04	20.72	0.69	5.75e-68	Blood protein levels;
LGG	cis	rs3020736	0.500	rs6002623	chr22:42513761	G/A	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72945132	0.882	rs56368270	chr11:70162590	A/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.82	0.34	3.66e-14	Coronary artery disease;
LGG	cis	rs7949030	0.754	rs36104523	chr11:62395740	A/T	cg11742103	chr11:62369870	EML3;MTA2	-0.54	-12.65	-0.51	1.07e-31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2439831	1.000	rs2256764	chr15:43735763	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-6.81	-0.3	3.04e-11	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg15971980	chr6:150254442	NA	0.45	8.55	0.37	1.87e-16	Lung cancer;
LGG	cis	rs1401999	0.966	rs2037379	chr3:183650330	T/C	cg20387954	chr3:183756860	HTR3D	0.66	13.36	0.53	1.11e-34	Anterior chamber depth;
LGG	cis	rs28735056	0.904	rs11520415	chr18:77620620	C/T	cg03511173	chr18:77590860	NA	0.42	7.15	0.32	3.42e-12	Schizophrenia;
LGG	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg03160526	chr17:80928410	B3GNTL1	0.53	8.56	0.37	1.69e-16	Glycated hemoglobin levels;
LGG	cis	rs1577917	0.958	rs10944168	chr6:86680156	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.94	-0.42	3.03e-21	Response to antipsychotic treatment;
LGG	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs57590327	0.503	rs1464790	chr3:81852923	A/T	cg07356753	chr3:81810745	GBE1	0.49	7.87	0.34	2.46e-14	Extraversion;
LGG	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg08446824	chr4:1720184	TMEM129	-0.64	-11.69	-0.48	7.56e-28	Hip circumference adjusted for BMI;Height;
LGG	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg06640241	chr16:89574553	SPG7	0.83	14.58	0.56	7.08e-40	Multiple myeloma (IgH translocation);
LGG	cis	rs3126085	0.673	rs3126089	chr1:152306187	T/A	cg26876637	chr1:152193138	HRNR	-0.52	-7.97	-0.35	1.21e-14	Atopic dermatitis;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09118169	chr16:1833616	NUBP2;SPSB3	0.44	7.4	0.33	6.52e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs12780845	0.540	rs11254423	chr10:17218346	G/A	cg01003015	chr10:17271136	VIM	-0.45	-7.52	-0.33	2.93e-13	Homocysteine levels;
LGG	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg18129748	chr3:49941408	MST1R	-0.21	-6.69	-0.3	6.65e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.918	rs17817958	chr4:100061245	A/C	cg13256891	chr4:100009986	ADH5	0.56	9.15	0.39	1.76e-18	Alcohol dependence;
LGG	cis	rs6665290	0.904	rs3768425	chr1:227178127	A/G	cg05696931	chr1:227175867	NA	-0.41	-8.03	-0.35	7.95e-15	Myeloid white cell count;
LGG	cis	rs2463822	1.000	rs2463822	chr11:62103420	T/C	cg06239285	chr11:62104954	ASRGL1	1.14	15.63	0.59	1.52e-44	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.64	-0.56	3.79e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs3820068	0.608	rs2057304	chr1:16017710	A/G	cg05660106	chr1:15850417	CASP9	0.76	14.01	0.55	2.03e-37	Systolic blood pressure;
LGG	cis	rs5758659	0.652	rs133303	chr22:42395242	C/G	cg15128208	chr22:42549153	NA	-0.39	-7.86	-0.34	2.75e-14	Cognitive function;
LGG	cis	rs1341267	0.529	rs6492721	chr13:95258944	A/G	cg18412871	chr13:95254051	GPR180	-0.51	-8.53	-0.37	2.13e-16	Triglyceride levels;
LGG	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12893428	chr3:195717962	SDHAP1	0.51	10.67	0.44	6.32e-24	Pancreatic cancer;
LGG	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.94	-11.81	-0.48	2.64e-28	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs61931739	0.500	rs9795938	chr12:34587739	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.08	-0.31	5.41e-12	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs11774585	chr8:58132685	G/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs67366981	0.925	rs56753733	chr14:77713930	A/C	cg22824376	chr14:77648248	TMEM63C	0.6	6.77	0.3	3.9e-11	Obsessive-compulsive symptoms;
LGG	cis	rs17102423	0.806	rs4902362	chr14:65582755	G/A	cg11161011	chr14:65562177	MAX	0.59	10.77	0.45	2.66e-24	Obesity-related traits;
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg00142150	chr22:38071001	LGALS1	0.92	19.7	0.68	3.4e-63	Fat distribution (HIV);
LGG	cis	rs7173389	1.000	rs7164883	chr15:73652174	A/G	cg01796676	chr15:73680284	NA	0.5	8.36	0.36	7.5e-16	Resting heart rate;
LGG	cis	rs7949030	0.653	rs17773169	chr11:62318530	G/T	cg11742103	chr11:62369870	EML3;MTA2	0.62	15.46	0.58	9.12e-44	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg23758822	chr17:41437982	NA	0.87	15.43	0.58	1.28e-43	Menopause (age at onset);
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	cis	rs7551222	0.634	rs12139477	chr1:204553104	A/C	cg20240347	chr1:204465584	NA	-0.49	-9.8	-0.41	9.53e-21	Schizophrenia;
LGG	cis	rs4635969	1.000	rs4635969	chr5:1308552	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.62	-8.51	-0.37	2.46e-16	Testicular germ cell tumor;Testicular germ cell cancer;
LGG	cis	rs2836974	0.932	rs6517527	chr21:40581751	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.3	0.63	4.41e-52	Cognitive function;
LGG	cis	rs6933660	0.676	rs3757316	chr6:151774339	A/G	cg02564969	chr6:151773285	C6orf211;RMND1	-0.45	-7.52	-0.33	2.89e-13	Menarche (age at onset);
LGG	cis	rs7937682	0.883	rs1612013	chr11:111456293	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.15	-0.72	1.23e-74	Primary sclerosing cholangitis;
LGG	cis	rs10752881	1.000	rs10752881	chr1:182973491	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs8048589	0.615	rs34598762	chr16:12234958	A/G	cg02910054	chr16:12241554	SNX29	0.64	9.69	0.41	2.53e-20	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs17376456	0.877	rs10060462	chr5:93455073	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.31	0.43	1.37e-22	Diabetic retinopathy;
LGG	cis	rs9300255	0.602	rs1716164	chr12:123663660	G/A	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.86e-22	Neutrophil percentage of white cells;
LGG	cis	rs3738772	0.633	rs919958	chr1:110053148	C/G	cg08367326	chr1:110052010	AMIGO1	-0.43	-8.61	-0.37	1.13e-16	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg02725872	chr8:58115012	NA	-0.8	-11.76	-0.48	4.1e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs11626933	0.959	rs2149649	chr14:90774974	A/G	cg14092571	chr14:90743983	NA	0.76	15.73	0.59	5.5e-45	Gut microbiota (bacterial taxa);
LGG	cis	rs9473924	0.542	rs9296645	chr6:50831194	A/G	cg14470998	chr6:50812995	TFAP2B	0.68	7.96	0.35	1.31e-14	Body mass index;
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg27411982	chr8:10470053	RP1L1	0.41	7.12	0.31	4.17e-12	Systolic blood pressure;
LGG	cis	rs11711311	0.911	rs3773681	chr3:113523901	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.1	0.55	8.18e-38	IgG glycosylation;
LGG	cis	rs6762	0.748	rs28735718	chr11:839629	A/G	cg10580341	chr11:889148	CHID1	-0.38	-6.98	-0.31	1.04e-11	Mean platelet volume;
LGG	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.63	-0.44	9.54e-24	Morning vs. evening chronotype;
LGG	cis	rs13082711	0.539	rs383135	chr3:27555866	A/G	cg02860705	chr3:27208620	NA	-0.57	-9.81	-0.41	9.19e-21	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9393692	0.905	rs9379843	chr6:26289435	A/G	cg13736514	chr6:26305472	NA	-0.47	-9.83	-0.42	7.84e-21	Educational attainment;
LGG	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg27490568	chr2:178487706	NA	0.51	9.95	0.42	2.95e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs240764	0.658	rs12210255	chr6:101187540	G/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.32	-0.36	1.01e-15	Neuroticism;
LGG	cis	rs7944584	0.563	rs61895112	chr11:47560433	T/C	cg20307385	chr11:47447363	PSMC3	0.85	16.9	0.62	2.9e-50	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg17691542	chr6:26056736	HIST1H1C	0.61	10.06	0.42	1.11e-21	Iron status biomarkers;
LGG	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.74	-9.61	-0.41	4.8e-20	Schizophrenia;
LGG	cis	rs9303401	0.659	rs12602808	chr17:56698420	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs6800768	0.658	rs7630879	chr3:24128336	A/G	cg10674438	chr3:24145617	LOC152024	-0.33	-6.86	-0.3	2.27e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.729	rs2413647	chr22:41907148	G/A	cg06634786	chr22:41940651	POLR3H	-0.81	-13.06	-0.52	2.17e-33	Vitiligo;
LGG	cis	rs4631830	0.900	rs9787697	chr10:51533376	C/T	cg10326726	chr10:51549505	MSMB	-0.7	-14.51	-0.56	1.31e-39	Prostate-specific antigen levels;
LGG	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg20243285	chr1:44584518	KLF17	0.33	7.39	0.32	7.14e-13	Menarche (age at onset);
LGG	cis	rs2439831	0.681	rs2278859	chr15:43632960	A/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.2e-13	Lung cancer in ever smokers;
LGG	cis	rs7172689	0.819	rs8040740	chr15:81574388	A/C	cg11808699	chr15:81528661	IL16	-0.46	-9.32	-0.4	4.62e-19	Inattentive symptoms;
LGG	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg27411982	chr8:10470053	RP1L1	-0.45	-7.76	-0.34	5.61e-14	Triglycerides;
LGG	trans	rs1814175	0.817	rs10769618	chr11:49822336	A/G	cg03929089	chr4:120376271	NA	-1.04	-24.49	-0.75	1.45e-85	Height;
LGG	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.44	-0.37	4.07e-16	Height;
LGG	cis	rs2228479	0.850	rs45567439	chr16:89814604	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs1467026	0.606	rs9814180	chr3:12818386	A/G	cg05775895	chr3:12838266	CAND2	0.72	13.91	0.54	5.17e-37	P wave duration;
LGG	cis	rs1552244	1.000	rs13319597	chr3:10126312	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	-1.15	-20.39	-0.69	2.07e-66	Alzheimer's disease;
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs2708377	0.858	rs115781584	chr12:11304560	C/T	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.48	7.3	0.32	1.22e-12	Bitter taste perception;
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg18357526	chr6:26021779	HIST1H4A	0.57	9.24	0.39	8.98e-19	Blood metabolite levels;
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	trans	rs9467711	0.606	rs2073529	chr6:26375159	C/T	cg08344181	chr3:125677491	NA	0.57	6.67	0.3	7.16e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2562456	0.792	rs2562398	chr19:21722949	A/G	cg25042112	chr7:64838748	ZNF92	0.47	6.69	0.3	6.37e-11	Pain;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14928991	chr14:61448281	TRMT5;SLC38A6	0.49	8.12	0.35	4.3e-15	Cognitive performance;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg24497897	chr11:65658826	CCDC85B	0.4	6.85	0.3	2.42e-11	Bipolar disorder;
LGG	cis	rs4740619	0.544	rs9406541	chr9:15827572	T/C	cg14451791	chr9:16040625	NA	0.32	7.81	0.34	4e-14	Body mass index;
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg10760299	chr15:45669010	GATM	-0.41	-8.07	-0.35	6.01e-15	Homoarginine levels;
LGG	cis	rs988958	0.565	rs12712819	chr2:42236349	A/G	cg19376973	chr2:42229025	NA	0.63	9.32	0.4	4.95e-19	Hypospadias;
LGG	cis	rs300774	0.858	rs444497	chr2:123332	C/G	cg04617936	chr2:214353	NA	-0.49	-7.37	-0.32	7.97e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs8060686	0.621	rs35432211	chr16:68095449	T/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.6	-0.33	1.67e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.32	0.32	1.09e-12	Retinal vascular caliber;
LGG	cis	rs2832191	1.000	rs2832190	chr21:30488226	G/A	cg24692254	chr21:30365293	RNF160	-0.87	-20.0	-0.68	1.32e-64	Dental caries;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg22535103	chr8:58192502	C8orf71	-1.01	-15.9	-0.59	1e-45	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14328230	chr19:17830207	MAP1S	0.45	7.06	0.31	6.02e-12	Gut microbiome composition (summer);
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg09448879	chr15:79043637	NA	-0.55	-13.91	-0.54	5.36e-37	Coronary artery disease or large artery stroke;
LGG	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg00701064	chr4:6280414	WFS1	0.75	17.41	0.63	1.31e-52	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg05556477	chr5:131705319	SLC22A5	0.81	9.81	0.41	9.35e-21	Rheumatoid arthritis;
LGG	cis	rs2228479	0.850	rs17233567	chr16:89813821	G/A	cg19635926	chr16:89946313	TCF25	0.73	7.14	0.32	3.54e-12	Skin colour saturation;
LGG	cis	rs3858704	0.517	rs7297186	chr12:111778178	C/T	cg10833066	chr12:111807467	FAM109A	-0.36	-6.67	-0.3	7.54e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs9583531	0.600	rs4773240	chr13:111360585	G/A	cg24331049	chr13:111365604	ING1	0.89	16.56	0.61	1.06e-48	Coronary artery disease;
LGG	trans	rs208520	0.690	rs12213581	chr6:66735818	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.68	0.63	7.72e-54	Exhaled nitric oxide output;
LGG	cis	rs780096	0.526	rs1260342	chr2:27663416	G/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	trans	rs7395662	0.781	rs11499902	chr11:48742731	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.94	-0.35	1.52e-14	HDL cholesterol;
LGG	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg00490583	chr16:1843685	IGFALS	0.51	8.84	0.38	2.03e-17	Insulin-like growth factors;
LGG	cis	rs344364	0.511	rs1742472	chr16:1953040	A/G	cg00490583	chr16:1843685	IGFALS	-0.42	-7.25	-0.32	1.8e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg13443165	chr9:33130375	B4GALT1	-0.58	-11.36	-0.47	1.56e-26	IgG glycosylation;
LGG	cis	rs1728785	0.792	rs1111502	chr16:68581209	A/G	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg00409905	chr10:38381863	ZNF37A	-0.62	-12.66	-0.51	9.51e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs7143963	0.636	rs28372031	chr14:103335242	T/C	cg23020514	chr14:103360112	TRAF3	0.41	8.51	0.37	2.45e-16	Body mass index;
LGG	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg17376030	chr22:41985996	PMM1	-0.63	-10.14	-0.43	5.98e-22	Vitiligo;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.91	0.38	1.21e-17	Schizophrenia;
LGG	trans	rs7618501	1.000	rs3811696	chr3:49761605	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs1878931	0.580	rs4578649	chr16:3407258	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.93	-20.04	-0.68	8.77e-65	Body mass index (adult);
LGG	cis	rs4774830	0.744	rs62046392	chr15:56312554	C/G	cg24530489	chr15:56299380	NA	-0.86	-7.87	-0.34	2.48e-14	Delta-5 desaturase activity;
LGG	trans	rs2727020	0.521	rs10839296	chr11:49537617	T/C	cg15704280	chr7:45808275	SEPT13	0.87	13.63	0.54	8.3e-36	Coronary artery disease;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00566492	chr22:39096679	JOSD1	0.45	6.66	0.3	7.83e-11	Hip circumference;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg13009111	chr11:71350975	NA	0.3	6.79	0.3	3.47e-11	Joint mobility (Beighton score);
LGG	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg18225595	chr11:63971243	STIP1	0.48	9.3	0.4	5.57e-19	Platelet count;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg05861140	chr6:150128134	PCMT1	-0.4	-8.88	-0.38	1.5e-17	Lung cancer;
LGG	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.34	0.47	1.77e-26	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16153388	chr8:748422	NA	0.31	6.85	0.3	2.35e-11	Menarche (age at onset);
LGG	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg13147721	chr7:65941812	NA	-0.81	-9.61	-0.41	4.53e-20	Diabetic kidney disease;
LGG	cis	rs4731207	0.698	rs10085793	chr7:124484166	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg21132104	chr15:45694354	SPATA5L1	0.73	11.06	0.46	2.24e-25	Homoarginine levels;
LGG	cis	rs4731207	0.671	rs6466949	chr7:124444900	T/C	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg12310025	chr6:25882481	NA	-0.43	-7.75	-0.34	5.77e-14	Height;
LGG	cis	rs11758351	0.500	rs75551401	chr6:26185387	T/C	cg01420254	chr6:26195488	NA	0.97	7.39	0.32	7.13e-13	Gout;Renal underexcretion gout;
LGG	cis	rs2836950	0.509	rs11088466	chr21:40580017	T/A	cg11890956	chr21:40555474	PSMG1	-0.71	-12.42	-0.5	9.33e-31	Menarche (age at onset);
LGG	cis	rs740474	0.707	rs251019	chr5:140899784	G/C	cg00076195	chr5:140892677	NA	0.49	8.21	0.36	2.29e-15	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs868036	0.718	rs2241420	chr15:68082816	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.38	-0.36	6.42e-16	Restless legs syndrome;
LGG	cis	rs727505	0.721	rs67817822	chr7:124769572	A/G	cg23710748	chr7:124431027	NA	-0.43	-8.31	-0.36	1.09e-15	Lewy body disease;
LGG	cis	rs7512552	0.966	rs1122967	chr1:150258838	C/G	cg15654264	chr1:150340011	RPRD2	-0.43	-8.76	-0.38	3.67e-17	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg22535103	chr8:58192502	C8orf71	-0.77	-9.57	-0.41	6.33e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg14893161	chr1:205819251	PM20D1	1.01	27.34	0.79	1.11e-98	Menarche (age at onset);
LGG	cis	rs9790314	0.690	rs9860738	chr3:160843290	G/A	cg03342759	chr3:160939853	NMD3	-0.6	-10.97	-0.45	4.88e-25	Morning vs. evening chronotype;
LGG	cis	rs4380275	1.000	rs4359695	chr2:774214	G/C	cg14072418	chr2:740025	NA	-0.41	-7.63	-0.33	1.32e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs17767392	0.670	rs61989257	chr14:71730470	C/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.12	-0.35	4.32e-15	Mitral valve prolapse;
LGG	cis	rs362272	0.502	rs2798298	chr4:3036602	G/A	cg02566259	chr4:3043199	NA	0.35	8.68	0.37	6.56e-17	Serum sulfate level;
LGG	cis	rs6087990	0.806	rs4911257	chr20:31359574	T/C	cg13636640	chr20:31349939	DNMT3B	0.94	19.65	0.67	6.01e-63	Ulcerative colitis;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg08793459	chr17:57784647	PTRH2;TMEM49	-0.4	-6.81	-0.3	3.1e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs975722	0.736	rs2246450	chr7:117240668	A/T	cg10524701	chr7:117356490	CTTNBP2	0.45	8.94	0.38	9.08e-18	Coronary artery disease;
LGG	cis	rs9372253	1.000	rs9384740	chr6:110716207	G/A	cg01119278	chr6:110721349	DDO	-0.3	-7.3	-0.32	1.28e-12	Platelet distribution width;
LGG	cis	rs1949733	0.701	rs2631735	chr4:8476118	A/G	cg11789530	chr4:8429930	ACOX3	0.72	13.51	0.53	2.78e-35	Response to antineoplastic agents;
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg22535103	chr8:58192502	C8orf71	-0.87	-11.15	-0.46	9.71e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.19	0.39	1.31e-18	Height;
LGG	cis	rs2540226	0.655	rs2160199	chr2:39930191	A/G	cg18968196	chr2:39892502	TMEM178	0.27	7.26	0.32	1.67e-12	Personality dimensions;
LGG	cis	rs61931739	0.500	rs11053140	chr12:34316122	T/C	cg06521331	chr12:34319734	NA	-0.66	-12.24	-0.49	4.76e-30	Morning vs. evening chronotype;
LGG	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg08564027	chr20:61660810	NA	1.02	25.73	0.77	2.59e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs240764	0.612	rs7751526	chr6:100949822	A/G	cg21058520	chr6:100914733	NA	0.47	8.24	0.36	1.73e-15	Neuroticism;
LGG	cis	rs62103177	0.810	rs62103187	chr18:77627633	G/C	cg20368463	chr18:77673604	PQLC1	0.57	7.47	0.33	3.89e-13	Opioid sensitivity;
LGG	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg17376030	chr22:41985996	PMM1	0.55	8.77	0.38	3.5e-17	Vitiligo;
LGG	cis	rs2239547	0.522	rs9842974	chr3:53011050	C/A	cg11645453	chr3:52864694	ITIH4	0.68	10.53	0.44	2.17e-23	Schizophrenia;
LGG	trans	rs2243480	1.000	rs186378	chr7:65582058	A/C	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.18e-19	Diabetic kidney disease;
LGG	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg16414030	chr3:133502952	NA	0.65	11.72	0.48	5.75e-28	Iron status biomarkers;
LGG	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27511599	chr7:32358540	NA	0.63	6.76	0.3	4.06e-11	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10308682	chr20:5931622	MCM8;TRMT6	0.45	7.18	0.32	2.86e-12	Gut microbiome composition (summer);
LGG	trans	rs1493916	0.837	rs4997493	chr18:31407302	C/T	cg04226714	chr8:49833948	SNAI2	-0.44	-7.95	-0.35	1.39e-14	Life satisfaction;
LGG	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.92	0.54	4.67e-37	Total body bone mineral density;
LGG	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.19	0.39	1.29e-18	Blood metabolite levels;
LGG	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg02002194	chr4:3960332	NA	-0.45	-8.02	-0.35	8.63e-15	Triglycerides;
LGG	cis	rs1005277	0.563	rs2505215	chr10:38481273	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.49	-7.82	-0.34	3.56e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	0.593	rs2811297	chr1:178551472	C/T	cg12486710	chr1:178512616	C1orf220	-0.34	-6.65	-0.3	8.07e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.59	-0.41	5.63e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.86	0.3	2.23e-11	Lung cancer;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.44	-0.33	4.79e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.651	rs2420596	chr7:65915983	T/C	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.73e-18	Aortic root size;
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4799461	1.000	rs4799461	chr18:35185858	C/T	cg27332583	chr18:35150602	NA	0.55	10.98	0.45	4.55e-25	Neuroticism;
LGG	cis	rs740474	0.533	rs3844598	chr5:140992235	A/G	cg00076195	chr5:140892677	NA	0.42	7.5	0.33	3.33e-13	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs937213	0.712	rs2279580	chr15:40300214	G/C	cg22705835	chr10:65332833	REEP3	-0.46	-8.24	-0.36	1.78e-15	Endometrial cancer;Endometrial endometrioid carcinoma;
LGG	cis	rs2916247	0.908	rs9657006	chr8:93178242	A/C	cg10183463	chr8:93005414	RUNX1T1	0.35	7.2	0.32	2.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2115536	0.692	rs6495451	chr15:80164053	C/T	cg00225070	chr15:80189496	MTHFS	0.39	7.46	0.33	4.31e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4642101	0.824	rs3889515	chr3:12844112	G/C	cg24848339	chr3:12840334	CAND2	0.38	8.61	0.37	1.18e-16	QRS complex (12-leadsum);
LGG	cis	rs7552404	0.924	rs1146580	chr1:76209935	T/C	cg22875332	chr1:76189707	ACADM	0.58	10.25	0.43	2.37e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4332037	0.539	rs868754	chr7:2033780	G/C	cg02825527	chr7:2087843	MAD1L1	-0.44	-7.73	-0.34	6.86e-14	Bipolar disorder;
LGG	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg25427524	chr10:38739819	LOC399744	0.7	14.32	0.55	8.86e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2235649	0.833	rs7189070	chr16:1850813	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.21e-11	Blood metabolite levels;
LGG	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg02503808	chr4:7069936	GRPEL1	0.42	6.87	0.3	2.03e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.49	11.42	0.47	8.63e-27	Oropharynx cancer;
LGG	cis	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg04455712	chr21:45112962	RRP1B	-0.45	-8.35	-0.36	7.74e-16	Mean corpuscular volume;
LGG	cis	rs62064224	0.818	rs35677406	chr17:30665005	T/C	cg12855166	chr17:30846586	MYO1D	0.38	6.79	0.3	3.37e-11	Schizophrenia;
LGG	cis	rs2688608	0.901	rs2675671	chr10:75632760	C/T	cg23231163	chr10:75533350	FUT11	-0.39	-6.83	-0.3	2.75e-11	Inflammatory bowel disease;
LGG	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.94	0.42	3.24e-21	Diabetic retinopathy;
LGG	cis	rs651907	0.557	rs11712748	chr3:101383562	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.23	0.36	1.86e-15	Colorectal cancer;
LGG	cis	rs8014204	0.816	rs11159107	chr14:75341266	C/A	cg06637938	chr14:75390232	RPS6KL1	-0.68	-12.45	-0.5	6.8e-31	Caffeine consumption;
LGG	cis	rs6582630	0.538	rs8189550	chr12:38333058	T/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.05	-0.49	2.94e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9326248	0.954	rs4938349	chr11:117021923	C/T	cg11861562	chr11:117069780	TAGLN	0.25	6.76	0.3	4.08e-11	Blood protein levels;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg11062466	chr8:58055876	NA	0.48	8.29	0.36	1.23e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg22358067	chr17:16797159	NA	0.51	7.29	0.32	1.38e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733346	0.590	rs6848199	chr4:940838	C/T	cg20814179	chr4:940893	TMEM175	0.55	11.49	0.47	4.56e-27	Sjögren's syndrome;
LGG	cis	rs6938	0.534	rs1133322	chr15:75212357	A/G	cg09165964	chr15:75287851	SCAMP5	0.58	10.97	0.45	4.97e-25	Breast cancer;
LGG	cis	rs2439831	0.867	rs2584702	chr15:43684914	C/A	cg15269541	chr15:43626905	ADAL	-0.45	-7.73	-0.34	6.59e-14	Lung cancer in ever smokers;
LGG	cis	rs9487094	0.710	rs10499052	chr6:109885475	G/A	cg16315928	chr6:109776240	MICAL1	0.49	7.73	0.34	6.75e-14	Height;
LGG	cis	rs9902453	0.967	rs1906451	chr17:28515479	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.66	13.03	0.52	2.75e-33	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.620	rs4412193	chr6:26338056	A/G	cg00631329	chr6:26305371	NA	-0.46	-7.69	-0.34	9.14e-14	Educational attainment;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	trans	rs1941687	0.669	rs7243220	chr18:31408110	T/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.82	-0.38	2.43e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6121246	0.529	rs6120862	chr20:30199459	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.68	-0.34	9.63e-14	Mean corpuscular hemoglobin;
LGG	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.81	-0.45	1.97e-24	Aortic root size;
LGG	cis	rs8005677	0.828	rs12589539	chr14:23396680	A/G	cg01529538	chr14:23388837	RBM23	0.36	6.8	0.3	3.25e-11	Cognitive ability (multi-trait analysis);
LGG	trans	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg25214090	chr10:38739885	LOC399744	0.63	11.23	0.46	4.96e-26	Corneal astigmatism;
LGG	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg25919922	chr13:100150906	NA	-0.73	-7.54	-0.33	2.46e-13	Obesity-related traits;
LGG	cis	rs9522267	0.535	rs4644738	chr13:112235995	G/A	cg14952266	chr13:112191215	NA	0.52	10.93	0.45	6.84e-25	Hepatitis;
LGG	cis	rs7044106	0.762	rs10760107	chr9:123383630	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.65	11.73	0.48	5.43e-28	Hip circumference adjusted for BMI;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03584380	chr10:114206433	VTI1A;ZDHHC6	-0.45	-6.66	-0.3	7.78e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs858239	0.730	rs858290	chr7:23248036	A/G	cg23682824	chr7:23144976	KLHL7	0.4	6.85	0.3	2.29e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg18538332	chr22:24372958	LOC391322	-0.48	-7.74	-0.34	6.3e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg21659725	chr3:3221576	CRBN	-0.64	-6.9	-0.31	1.77e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg05793240	chr7:2802953	GNA12	0.31	7.06	0.31	6.15e-12	Height;
LGG	cis	rs2645694	0.626	rs2703136	chr4:77828957	T/A	cg18351406	chr4:77819688	ANKRD56	0.46	7.9	0.34	1.98e-14	Emphysema distribution in smoking;
LGG	cis	rs7727544	0.735	rs2631370	chr5:131703776	T/C	cg24060327	chr5:131705240	SLC22A5	0.5	8.67	0.37	7.4e-17	Blood metabolite levels;
LGG	cis	rs6539288	0.677	rs7315989	chr12:107339788	A/G	cg26297688	chr12:107349093	C12orf23	-0.38	-7.06	-0.31	5.95e-12	Total body bone mineral density;
LGG	cis	rs3768617	0.528	rs4651144	chr1:183097421	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg25338242	chr13:114786047	RASA3	0.45	6.89	0.31	1.8e-11	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs7301826	0.934	rs10848212	chr12:131322000	C/G	cg11011512	chr12:131303247	STX2	-0.32	-6.89	-0.31	1.78e-11	Plasma plasminogen activator levels;
LGG	cis	rs6908034	0.607	rs113592672	chr6:19806063	G/C	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2346177	0.542	rs13020043	chr2:46698431	A/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	9.22	0.39	1.06e-18	HDL cholesterol;
LGG	cis	rs74781061	0.929	rs8028163	chr15:74822701	C/T	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg05555928	chr11:63887634	MACROD1	-0.38	-6.93	-0.31	1.42e-11	Platelet count;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg18402987	chr7:1209562	NA	0.61	8.65	0.37	8.82e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.64e-13	Dementia with Lewy bodies;
LGG	cis	rs4631830	0.720	rs2125770	chr10:51514824	T/C	cg10326726	chr10:51549505	MSMB	-0.62	-12.26	-0.5	3.88e-30	Prostate-specific antigen levels;
LGG	cis	rs10504229	1.000	rs59708460	chr8:58196526	G/A	cg24829409	chr8:58192753	C8orf71	-0.89	-13.53	-0.53	2.11e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg12751644	chr20:60527061	NA	-0.29	-6.69	-0.3	6.52e-11	Body mass index;
LGG	cis	rs1707322	0.721	rs11211158	chr1:46132850	C/G	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg12293132	chr7:23720668	C7orf46	0.35	8.13	0.35	3.84e-15	Schizophrenia;
LGG	cis	rs951366	0.576	rs11240561	chr1:205712957	T/G	cg14893161	chr1:205819251	PM20D1	-0.44	-7.57	-0.33	1.97e-13	Menarche (age at onset);
LGG	cis	rs10751667	0.666	rs4072741	chr11:976565	T/C	cg22143635	chr11:980567	AP2A2	0.45	8.3	0.36	1.14e-15	Alzheimer's disease (late onset);
LGG	cis	rs7179456	0.547	rs6494036	chr15:59015961	A/T	cg05156742	chr15:59063176	FAM63B	0.58	9.0	0.39	5.79e-18	Asperger disorder;
LGG	cis	rs61776719	0.875	rs10890238	chr1:38445654	A/T	cg17077180	chr1:38461687	NA	0.52	13.28	0.53	2.43e-34	Coronary artery disease;
LGG	cis	rs2549003	1.000	rs6894655	chr5:131818649	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.3e-22	Asthma (sex interaction);
LGG	cis	rs11628318	0.853	rs4906226	chr14:103027359	C/T	cg01864069	chr14:103024347	NA	-0.74	-12.17	-0.49	9.32e-30	Platelet count;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg11765430	chr4:331396	ZNF141	0.42	7.14	0.31	3.52e-12	Lung adenocarcinoma;
LGG	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg15704280	chr7:45808275	SEPT13	0.5	8.17	0.35	2.94e-15	HDL cholesterol;
LGG	cis	rs7208859	0.623	rs9895785	chr17:29107708	C/T	cg19761014	chr17:28927070	LRRC37B2	-0.63	-7.48	-0.33	3.88e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7166081	1.000	rs4776913	chr15:67580356	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	trans	rs2562456	0.793	rs11667392	chr19:21472608	T/C	cg00806126	chr19:22604979	ZNF98	-0.56	-7.33	-0.32	1.04e-12	Pain;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg06654118	chr4:1303317	MAEA	0.48	8.07	0.35	6.16e-15	Obesity-related traits;
LGG	cis	rs9549367	0.789	rs12869947	chr13:113896156	A/G	cg18105134	chr13:113819100	PROZ	-0.69	-14.07	-0.55	1.08e-37	Platelet distribution width;
LGG	cis	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01570182	chr17:44337453	NA	0.58	9.97	0.42	2.49e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs561341	1.000	rs55959993	chr17:30254771	C/G	cg20587970	chr11:113659929	NA	-1.36	-24.15	-0.75	5.62e-84	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.68	-0.56	2.5e-40	Prudent dietary pattern;
LGG	cis	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg15038512	chr6:170123185	PHF10	0.52	6.81	0.3	3.02e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9329221	0.651	rs2975648	chr8:10135976	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.62	0.37	1.06e-16	Neuroticism;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg04160749	chr8:58172571	NA	-0.51	-7.99	-0.35	1.11e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs72772090	0.634	rs17401901	chr5:96091925	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.91	-0.38	1.19e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9858542	0.953	rs9853683	chr3:49512588	A/G	cg03060546	chr3:49711283	APEH	-0.63	-10.36	-0.43	9.64e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22704520	chr2:200820451	C2orf60;C2orf47	0.39	6.94	0.31	1.33e-11	Obesity-related traits;
LGG	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg24881330	chr22:46731750	TRMU	0.71	7.21	0.32	2.27e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6840360	0.571	rs4696279	chr4:152560449	G/A	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11890956	chr21:40555474	PSMG1	-0.74	-12.88	-0.51	1.19e-32	Menarche (age at onset);
LGG	cis	rs806215	0.547	rs56185520	chr7:127364310	A/G	cg25922125	chr7:127225783	GCC1	-0.5	-7.26	-0.32	1.69e-12	Type 2 diabetes;
LGG	cis	rs1003719	0.715	rs2835613	chr21:38496883	A/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.8	-15.76	-0.59	4.15e-45	Eye color traits;
LGG	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.78e-12	Aortic root size;
LGG	cis	rs28386778	0.562	rs721575	chr17:61782920	A/G	cg11494091	chr17:61959527	GH2	-0.91	-20.48	-0.69	7.96e-67	Prudent dietary pattern;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg09264619	chr17:80180166	NA	-0.39	-7.77	-0.34	5.04e-14	Life satisfaction;
LGG	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg08975724	chr8:8085496	FLJ10661	0.51	9.53	0.4	9.03e-20	Red cell distribution width;
LGG	cis	rs4918072	0.797	rs7071685	chr10:105696383	T/C	cg11005552	chr10:105648138	OBFC1	0.48	7.77	0.34	5.25e-14	Coronary artery disease;
LGG	cis	rs6450176	1.000	rs1445887	chr5:53299376	A/T	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2640806	0.505	rs28375708	chr8:97369057	C/G	cg22138393	chr8:97340270	PTDSS1	0.28	6.93	0.31	1.44e-11	Obesity-related traits;
LGG	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg11764359	chr7:65958608	NA	-0.58	-9.89	-0.42	4.87e-21	Aortic root size;
LGG	cis	rs9894429	0.816	rs9747093	chr17:79584280	G/A	cg18240062	chr17:79603768	NPLOC4	0.74	13.76	0.54	2.31e-36	Eye color traits;
LGG	trans	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.73	-0.41	1.71e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.567	rs7551791	chr1:153024267	A/T	cg13444842	chr1:152974279	SPRR3	-0.49	-9.84	-0.42	7.3e-21	Inflammatory skin disease;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs4740619	0.836	rs4740628	chr9:15888333	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.19	-0.43	4.02e-22	Body mass index;
LGG	trans	rs34034104	1.000	rs34034104	chr15:40725033	C/A	cg01027929	chr7:26241406	HNRNPA2B1;CBX3	-0.53	-7.67	-0.34	1.03e-13	Itch intensity from mosquito bite adjusted by bite size;Itch intensity from mosquito bite;
LGG	cis	rs6089584	0.507	rs6061990	chr20:60628429	T/G	cg13770153	chr20:60521292	NA	-0.48	-7.85	-0.34	2.97e-14	Body mass index;
LGG	cis	rs372883	0.506	rs2832300	chr21:30749315	A/G	cg08807101	chr21:30365312	RNF160	0.54	8.94	0.38	9.28e-18	Pancreatic cancer;
LGG	cis	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg25427524	chr10:38739819	LOC399744	-0.66	-13.42	-0.53	6.18e-35	Extrinsic epigenetic age acceleration;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg26258108	chr2:232329189	NCL	0.4	6.76	0.3	4.25e-11	Body mass index;
LGG	cis	rs7811142	0.775	rs1636980	chr7:99938864	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	0.97	14.76	0.57	1.08e-40	Platelet count;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13445258	chr3:128369860	RPN1	0.5	8.02	0.35	8.84e-15	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs4730250	0.707	rs3729876	chr7:106786952	T/C	cg02696742	chr7:106810147	HBP1	0.77	10.59	0.44	1.25e-23	Osteoarthritis;
LGG	cis	rs4819052	0.851	rs9753963	chr21:46661437	G/A	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.53e-14	Blood trace element (Cu levels);
LGG	trans	rs7615952	0.512	rs4679430	chr3:125357893	T/C	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07623022	chr16:18801545	RPS15A	0.44	7.03	0.31	7.58e-12	Cognitive performance;
LGG	cis	rs2235642	0.533	rs2076436	chr16:1608082	A/G	cg04525384	chr16:1557733	TELO2	0.42	6.72	0.3	5.34e-11	Coronary artery disease;
LGG	cis	rs2730245	0.645	rs4909282	chr7:158699797	T/C	cg11984989	chr7:158649758	WDR60	1.03	23.68	0.74	8.01e-82	Height;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg05368731	chr17:41323189	NBR1	0.95	18.95	0.66	1.02e-59	Menopause (age at onset);
LGG	cis	rs7623687	0.892	rs73074830	chr3:49577017	A/C	cg19401529	chr3:49056140	DALRD3	0.7	7.82	0.34	3.65e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs939658	0.805	rs2010524	chr15:79435825	G/T	cg17916960	chr15:79447300	NA	-0.67	-13.08	-0.52	1.8e-33	Refractive error;
LGG	cis	rs899997	1.000	rs7182993	chr15:79045014	G/A	cg17734273	chr15:78292508	TBC1D2B	-0.38	-9.49	-0.4	1.19e-19	Coronary artery disease or large artery stroke;
LGG	cis	rs8177179	0.967	rs4287912	chr3:133437778	A/G	cg16262614	chr3:133464971	TF	0.47	8.77	0.38	3.44e-17	Iron status biomarkers (transferrin levels);
LGG	cis	rs4689388	0.750	rs12642481	chr4:6301058	G/A	cg00701064	chr4:6280414	WFS1	0.65	12.97	0.52	4.85e-33	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg12070911	chr6:150209640	RAET1E	0.3	7.66	0.34	1.11e-13	Testicular germ cell tumor;
LGG	cis	rs2070997	0.816	rs6597643	chr9:133725830	C/T	cg13397898	chr9:133768931	QRFP	-0.34	-7.13	-0.31	4.01e-12	Response to amphetamines;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.46	0.33	4.43e-13	Tonsillectomy;
LGG	trans	rs12339094	0.860	rs9410966	chr9:90407826	G/A	cg24436365	chr6:63940138	NA	0.42	6.93	0.31	1.41e-11	Smoking quantity;
LGG	cis	rs11583043	0.957	rs6577223	chr1:101499750	G/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.06	0.35	6.38e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs910316	1.000	rs10138183	chr14:75615227	T/C	cg11812906	chr14:75593930	NEK9	0.56	10.39	0.43	7.13e-23	Height;
LGG	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg21775007	chr8:11205619	TDH	0.48	8.14	0.35	3.62e-15	Mood instability;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.94e-18	Menopause (age at onset);
LGG	cis	rs3816183	1.000	rs893731	chr2:43015432	T/C	cg27299406	chr2:43020013	HAAO	-0.28	-6.84	-0.3	2.59e-11	Hypospadias;
LGG	trans	rs61931739	0.500	rs11053222	chr12:34481100	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.25	0.7	1.9e-70	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg08250081	chr4:10125330	NA	-0.46	-9.06	-0.39	3.57e-18	Bone mineral density;
LGG	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg18681998	chr4:17616180	MED28	0.87	20.21	0.68	1.37e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12143943	0.834	rs10900598	chr1:204525568	G/T	cg20240347	chr1:204465584	NA	-0.34	-7.47	-0.33	3.89e-13	Cognitive performance;
LGG	trans	rs9914544	0.505	rs4924774	chr17:18794920	A/C	cg21372672	chr17:16614065	CCDC144A	-0.38	-8.17	-0.35	2.9e-15	Educational attainment (years of education);
LGG	cis	rs10875746	0.551	rs12322347	chr12:48707698	T/G	cg24011408	chr12:48396354	COL2A1	-0.56	-7.21	-0.32	2.32e-12	Longevity (90 years and older);
LGG	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg13072238	chr3:49761600	GMPPB	-0.55	-6.88	-0.3	1.98e-11	Menarche (age at onset);
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.94	-0.38	9.45e-18	Lung cancer;
LGG	cis	rs734999	0.967	rs10752745	chr1:2507938	A/G	cg05697835	chr1:2722811	NA	0.29	6.73	0.3	4.99e-11	Ulcerative colitis;
LGG	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg04727924	chr7:799746	HEATR2	-0.48	-7.75	-0.34	5.96e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg22535103	chr8:58192502	C8orf71	-0.89	-12.37	-0.5	1.41e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8014204	0.566	rs9441	chr14:75128425	G/A	cg06637938	chr14:75390232	RPS6KL1	0.65	11.85	0.48	1.7e-28	Caffeine consumption;
LGG	cis	rs6834538	0.737	rs923236	chr4:113429600	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.48	6.94	0.31	1.33e-11	Free thyroxine concentration;
LGG	cis	rs16867321	0.588	rs2368175	chr2:181493763	G/C	cg23363182	chr2:181467187	NA	-0.43	-8.36	-0.36	7.21e-16	Obesity;
LGG	trans	rs28595532	0.545	rs72677057	chr4:119264162	A/T	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs4716602	0.513	rs13237220	chr7:156169727	G/A	cg04090468	chr7:156181990	NA	-0.9	-12.98	-0.52	4.58e-33	Anti-saccade response;
LGG	trans	rs9354308	0.933	rs2814131	chr6:66562051	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.05	0.42	1.27e-21	Metabolite levels;
LGG	cis	rs1005224	0.895	rs6574252	chr14:76141834	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-7.0	-0.31	9.02e-12	Large artery stroke;
LGG	cis	rs4969178	0.895	rs2292640	chr17:76396610	G/A	cg02836325	chr17:76403955	PGS1	-0.72	-14.45	-0.56	2.45e-39	HDL cholesterol levels;
LGG	cis	rs9486719	0.947	rs9398072	chr6:96911304	T/C	cg06623918	chr6:96969491	KIAA0776	0.72	10.74	0.45	3.69e-24	Migraine;Coronary artery disease;
LGG	cis	rs4363385	0.525	rs11205138	chr1:152890568	G/A	cg07796016	chr1:152779584	LCE1C	-0.62	-10.37	-0.43	8.45e-23	Inflammatory skin disease;
LGG	cis	rs3820928	1.000	rs10210763	chr2:227776029	G/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.25	-0.32	1.72e-12	Pulmonary function;
LGG	cis	rs798554	0.671	rs1182195	chr7:2868730	A/G	cg27476859	chr7:2772710	GNA12	0.49	9.17	0.39	1.54e-18	Height;
LGG	cis	rs2204008	0.715	rs11495369	chr12:38238673	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs2463822	0.844	rs7104149	chr11:62171627	A/G	cg06239285	chr11:62104954	ASRGL1	-1.12	-14.85	-0.57	4.35e-41	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.46	6.72	0.3	5.34e-11	Schizophrenia;
LGG	cis	rs2153535	0.580	rs7741403	chr6:8530578	C/T	cg21535247	chr6:8435926	SLC35B3	-0.59	-10.24	-0.43	2.63e-22	Motion sickness;
LGG	cis	rs963731	0.649	rs6756184	chr2:39256877	G/A	cg04010122	chr2:39346883	SOS1	-0.82	-7.11	-0.31	4.48e-12	Corticobasal degeneration;
LGG	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.63	-8.11	-0.35	4.67e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg09033563	chr22:24373618	LOC391322	-0.51	-8.34	-0.36	8.57e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1032833	0.732	rs17363323	chr2:179996977	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs77106637	1.000	rs76793820	chr11:72619860	G/A	cg03878208	chr11:72483293	STARD10	0.51	7.15	0.32	3.3e-12	Type 2 diabetes;
LGG	cis	rs1152591	0.811	rs1255984	chr14:64654431	C/T	cg21174375	chr14:64681225	SYNE2	-0.35	-6.65	-0.3	8.17e-11	Atrial fibrillation;
LGG	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg15704280	chr7:45808275	SEPT13	-0.54	-9.14	-0.39	2.04e-18	Height;
LGG	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg22875332	chr1:76189707	ACADM	0.62	10.5	0.44	2.77e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2549003	0.966	rs10065633	chr5:131816716	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.37e-22	Asthma (sex interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24448245	chr7:66461718	SBDS;TYW1	0.52	8.3	0.36	1.15e-15	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg09264619	chr17:80180166	NA	0.34	6.89	0.31	1.79e-11	Life satisfaction;
LGG	cis	rs2274273	0.840	rs10142448	chr14:55838108	G/T	cg04306507	chr14:55594613	LGALS3	-0.6	-16.26	-0.6	2.41e-47	Protein biomarker;
LGG	cis	rs11864453	0.647	rs10492814	chr16:72126514	G/A	cg01557791	chr16:72042693	DHODH	-0.45	-8.24	-0.36	1.79e-15	Fibrinogen levels;
LGG	cis	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg22857025	chr5:266934	NA	-1.34	-13.38	-0.53	9.77e-35	Breast cancer;
LGG	cis	rs763121	0.819	rs5757161	chr22:38990662	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	16.92	0.62	2.42e-50	Menopause (age at onset);
LGG	cis	rs2841277	0.712	rs2841280	chr14:105393556	G/C	cg14403583	chr14:105418241	AHNAK2	0.77	15.42	0.58	1.41e-43	Rheumatoid arthritis;
LGG	cis	rs2197308	0.765	rs68029712	chr12:37906585	T/G	cg26384229	chr12:38710491	ALG10B	0.97	22.16	0.72	1.08e-74	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg05165339	chr4:1420672	NA	0.34	8.54	0.37	1.88e-16	Longevity;
LGG	cis	rs796364	0.806	rs4673634	chr2:200863349	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.84	10.02	0.42	1.6e-21	Schizophrenia;
LGG	cis	rs17122278	1.000	rs11216912	chr11:118452334	G/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.14e-11	Total cholesterol levels;
LGG	trans	rs7395662	0.963	rs4882002	chr11:48546731	A/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.98	-0.35	1.14e-14	HDL cholesterol;
LGG	cis	rs7089973	0.604	rs2420067	chr10:116590348	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.25	0.32	1.72e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7301826	0.610	rs7961690	chr12:131296880	G/T	cg11011512	chr12:131303247	STX2	-0.4	-8.39	-0.36	6.03e-16	Plasma plasminogen activator levels;
LGG	cis	rs990171	1.000	rs4851588	chr2:103073505	C/G	cg05295703	chr2:102895712	NA	-0.51	-8.93	-0.38	1.02e-17	Lymphocyte counts;
LGG	cis	rs975739	1.000	rs1279399	chr13:78379199	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	4e-11	Hair color;
LGG	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.21	-0.49	6.19e-30	Depression;
LGG	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg19336497	chr11:14380999	RRAS2	-0.35	-6.92	-0.31	1.49e-11	Mitochondrial DNA levels;
LGG	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.37	-0.32	7.87e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs17217047	chr8:58180296	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.14e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg19761014	chr17:28927070	LRRC37B2	0.67	7.86	0.34	2.73e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg04568710	chr12:38710424	ALG10B	-0.34	-7.16	-0.32	3.24e-12	Morning vs. evening chronotype;
LGG	cis	rs1843834	0.721	rs6436507	chr2:225598242	T/A	cg22455342	chr2:225449267	CUL3	0.47	7.98	0.35	1.12e-14	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg01145232	chr6:150245071	RAET1G	0.5	9.32	0.4	4.9e-19	Lung cancer;
LGG	cis	rs9646954	0.542	rs11674830	chr2:101024735	A/G	cg14675211	chr2:100938903	LONRF2	0.67	12.21	0.49	6.64e-30	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg15556689	chr8:8085844	FLJ10661	0.47	8.14	0.35	3.56e-15	Retinal vascular caliber;
LGG	trans	rs3942852	0.774	rs1039481	chr11:48182237	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.74e-21	Diabetic retinopathy;
LGG	cis	rs7937682	1.000	rs505372	chr11:111507189	A/C	cg08305652	chr11:111469057	NA	-0.44	-8.6	-0.37	1.27e-16	Primary sclerosing cholangitis;
LGG	cis	rs2692947	0.673	rs2692894	chr2:96784934	T/G	cg22654517	chr2:96458247	NA	-0.36	-7.48	-0.33	3.81e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg03929089	chr4:120376271	NA	0.68	7.4	0.33	6.68e-13	Intraocular pressure;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg12708336	chr17:41446283	NA	-0.31	-6.94	-0.31	1.37e-11	Menopause (age at onset);
LGG	cis	rs4788570	0.697	rs6499540	chr16:71822250	A/C	cg06353428	chr16:71660113	MARVELD3	1.27	20.46	0.69	9.34e-67	Intelligence (multi-trait analysis);
LGG	cis	rs11229555	0.645	rs36019763	chr11:58232283	G/T	cg15696309	chr11:58395628	NA	-0.96	-15.5	-0.58	5.72e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4689388	0.926	rs4689391	chr4:6280449	G/A	cg14416269	chr4:6271139	WFS1	0.54	10.04	0.42	1.4e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.14	-0.31	3.73e-12	Neuroticism;
LGG	cis	rs7829975	0.582	rs6983150	chr8:8792426	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.05	-0.35	6.99e-15	Mood instability;
LGG	cis	rs7726839	0.540	rs3792720	chr5:643028	T/G	cg09021430	chr5:549028	NA	-0.68	-9.44	-0.4	1.81e-19	Obesity-related traits;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg18402987	chr7:1209562	NA	0.39	7.05	0.31	6.42e-12	Longevity;Endometriosis;
LGG	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg10661904	chr17:79619235	PDE6G	-0.4	-8.13	-0.35	4.09e-15	Eye color traits;
LGG	cis	rs60180747	1.000	rs74581464	chr15:66760980	T/A	cg07575407	chr15:66541975	MEGF11	0.34	6.68	0.3	6.79e-11	Testicular germ cell tumor;
LGG	cis	rs6496044	0.568	rs6496049	chr15:86069205	C/G	cg13263323	chr15:86062960	AKAP13	-0.39	-8.45	-0.37	3.84e-16	Interstitial lung disease;
LGG	cis	rs2836974	0.931	rs2735306	chr21:40713134	A/G	cg17971929	chr21:40555470	PSMG1	-0.78	-13.97	-0.54	2.89e-37	Cognitive function;
LGG	cis	rs4731207	0.623	rs34865746	chr7:124639919	T/A	cg05630886	chr7:124431682	NA	-0.29	-6.72	-0.3	5.32e-11	Cutaneous malignant melanoma;
LGG	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.76	14.44	0.56	2.88e-39	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs6840360	0.642	rs7657670	chr4:152353375	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	4.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs883565	0.740	rs6796837	chr3:39076188	C/T	cg01426195	chr3:39028469	NA	-0.71	-16.0	-0.6	3.44e-46	Handedness;
LGG	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.22	0.52	4.65e-34	Colorectal cancer;
LGG	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg18567174	chr15:68126065	LBXCOR1	-0.37	-7.21	-0.32	2.3e-12	Obesity;
LGG	cis	rs7945705	0.747	rs2568020	chr11:8994715	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.42	-0.36	4.67e-16	Hemoglobin concentration;
LGG	cis	rs372883	1.000	rs372883	chr21:30717737	A/G	cg24692254	chr21:30365293	RNF160	-0.43	-7.36	-0.32	8.49e-13	Pancreatic cancer;
LGG	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	trans	rs9650657	0.513	rs7005884	chr8:10796472	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.38	-0.36	6.28e-16	Neuroticism;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14364474	chr18:11821957	GNAL	-0.53	-6.76	-0.3	4.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.943	rs28578163	chr7:100044754	A/G	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.6e-15	Bone mineral density;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.98	-0.42	2.28e-21	Lung cancer;
LGG	cis	rs4481887	0.573	rs10888329	chr1:248404654	C/T	cg00666640	chr1:248458726	OR2T12	-0.47	-7.15	-0.32	3.51e-12	Common traits (Other);
LGG	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs11785400	0.762	rs9694556	chr8:143727841	A/G	cg10596483	chr8:143751796	JRK	0.51	7.98	0.35	1.12e-14	Schizophrenia;
LGG	cis	rs657075	0.697	rs3792879	chr5:131644835	T/C	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs4700695	0.841	rs27569	chr5:65373419	C/T	cg21114390	chr5:65439923	SFRS12	-0.56	-7.04	-0.31	6.83e-12	Facial morphology (factor 19);
LGG	cis	rs651907	0.557	rs3094296	chr3:101400167	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.38	-6.73	-0.3	5.09e-11	Colorectal cancer;
LGG	cis	rs62158211	0.955	rs7556815	chr2:114085785	G/A	cg17784749	chr2:114082611	LOC440839	0.61	8.52	0.37	2.34e-16	Sleep duration (oversleepers vs undersleepers);Sleep traits (multi-trait analysis);Sleep duration;
LGG	cis	rs2282300	0.739	rs7925340	chr11:30280408	A/C	cg25418670	chr11:30344373	C11orf46	0.56	7.79	0.34	4.53e-14	Morning vs. evening chronotype;
LGG	cis	rs4919694	0.572	rs12261294	chr10:104934952	C/T	cg04362960	chr10:104952993	NT5C2	0.89	13.43	0.53	5.89e-35	Arsenic metabolism;
LGG	cis	rs7937682	0.814	rs1784788	chr11:111486136	T/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.68	-0.44	6.18e-24	Primary sclerosing cholangitis;
LGG	cis	rs2070488	0.965	rs7433277	chr3:38529818	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.03	0.64	1.97e-55	Electrocardiographic conduction measures;
LGG	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.92	-0.42	3.65e-21	Retinal vascular caliber;
LGG	cis	rs2470578	0.792	rs2733507	chr3:17270795	T/C	cg20981856	chr3:17787350	NA	0.35	6.7	0.3	5.99e-11	Schizophrenia;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg07362569	chr17:61921086	SMARCD2	0.49	9.55	0.41	7.31e-20	Prudent dietary pattern;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14337668	chr9:99883682	NA	0.38	6.95	0.31	1.26e-11	Menarche (age at onset);
LGG	cis	rs12738007	0.933	rs6426352	chr1:29470843	G/C	cg01115565	chr1:29584222	PTPRU	-0.26	-7.18	-0.32	2.79e-12	Schizophrenia;
LGG	cis	rs4481887	0.962	rs6587452	chr1:248485931	C/T	cg00666640	chr1:248458726	OR2T12	0.61	9.76	0.41	1.37e-20	Common traits (Other);
LGG	trans	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.62	-0.48	1.42e-27	Neuroticism;
LGG	cis	rs7208859	0.573	rs73267872	chr17:29067207	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs116095464	0.558	rs13357299	chr5:242211	T/C	cg22857025	chr5:266934	NA	-1.48	-25.85	-0.77	7.68e-92	Breast cancer;
LGG	cis	rs1784581	0.546	rs1954917	chr6:162447490	C/T	cg17173639	chr6:162384350	PARK2	0.66	13.92	0.54	4.68e-37	Itch intensity from mosquito bite;
LGG	cis	rs2274273	0.870	rs4366639	chr14:55790516	T/G	cg04306507	chr14:55594613	LGALS3	0.62	17.17	0.62	1.69e-51	Protein biomarker;
LGG	cis	rs6582630	0.519	rs1851121	chr12:38389467	T/C	cg13010199	chr12:38710504	ALG10B	0.7	14.27	0.55	1.44e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9291683	0.655	rs35750364	chr4:10049049	T/C	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.63e-15	Bone mineral density;
LGG	cis	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg21775007	chr8:11205619	TDH	-0.45	-7.07	-0.31	5.9e-12	Neuroticism;
LGG	trans	rs61931739	0.534	rs10844840	chr12:34364517	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.21	0.52	4.86e-34	Morning vs. evening chronotype;
LGG	cis	rs990171	0.955	rs4851008	chr2:103026611	G/C	cg05295703	chr2:102895712	NA	-0.55	-9.67	-0.41	2.82e-20	Lymphocyte counts;
LGG	cis	rs12458462	0.509	rs3786241	chr18:77494328	A/C	cg11879182	chr18:77439856	CTDP1	0.5	8.59	0.37	1.3e-16	Monocyte count;
LGG	cis	rs721399	0.568	rs13254811	chr8:18273018	A/G	cg18736775	chr8:18248649	NAT2	-0.71	-10.85	-0.45	1.38e-24	Blood metabolite levels;
LGG	trans	rs503734	0.502	rs571391	chr3:100963154	C/T	cg21204139	chr1:64669336	UBE2U	0.3	6.97	0.31	1.11e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.51	-9.04	-0.39	4.21e-18	Longevity;
LGG	cis	rs1776421	0.760	rs61768412	chr1:53901450	C/G	cg10892335	chr1:53966318	NA	0.87	13.77	0.54	2.1e-36	PR interval in Tripanosoma cruzi seropositivity;
LGG	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.51	7.16	0.32	3.11e-12	Birth weight;
LGG	cis	rs4639966	0.569	rs603486	chr11:118587347	A/G	cg15558759	chr11:118478939	PHLDB1	0.42	7.42	0.33	5.55e-13	Systemic lupus erythematosus;
LGG	cis	rs62064224	0.702	rs2302277	chr17:30791509	C/G	cg18200150	chr17:30822561	MYO1D	0.84	20.38	0.69	2.28e-66	Schizophrenia;
LGG	cis	rs7599312	0.532	rs16848751	chr2:213389346	A/G	cg20637307	chr2:213403960	ERBB4	0.46	8.03	0.35	7.91e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs9393777	0.844	rs35909544	chr6:27163456	G/A	cg08344181	chr3:125677491	NA	-0.64	-7.43	-0.33	5.16e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg17971929	chr21:40555470	PSMG1	0.85	16.5	0.61	1.86e-48	Cognitive function;
LGG	cis	rs6089584	0.526	rs6089619	chr20:60610916	C/T	cg13770153	chr20:60521292	NA	-0.45	-7.56	-0.33	2.14e-13	Body mass index;
LGG	cis	rs12143943	0.966	rs6669246	chr1:204557561	A/G	cg20240347	chr1:204465584	NA	-0.33	-7.19	-0.32	2.59e-12	Cognitive performance;
LGG	cis	rs9443645	0.901	rs1572585	chr6:79690576	C/T	cg18132916	chr6:79620363	NA	-0.31	-8.49	-0.37	2.83e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7726839	0.540	rs61580655	chr5:597564	A/G	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.25e-11	Obesity-related traits;
LGG	cis	rs10936602	0.520	rs28525288	chr3:169554872	A/G	cg00832555	chr3:169529716	LRRC34	0.35	7.12	0.31	4.08e-12	Renal cell carcinoma;
LGG	cis	rs6748734	0.947	rs6752787	chr2:241840647	G/A	cg26818257	chr2:241905806	NA	0.38	7.03	0.31	7.33e-12	Urinary metabolites;
LGG	cis	rs67460515	0.563	rs13256	chr3:160796505	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-7.81	-0.34	3.84e-14	Parkinson's disease;
LGG	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.41	-0.78	2.02e-94	Schizophrenia;
LGG	cis	rs36051895	0.695	rs62541534	chr9:5028921	C/G	cg02405213	chr9:5042618	JAK2	-0.83	-15.28	-0.58	5.4e-43	Pediatric autoimmune diseases;
LGG	cis	rs7084402	0.967	rs1658493	chr10:60281090	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	8e-55	Refractive error;
LGG	cis	rs7020830	0.858	rs13293465	chr9:37127678	C/T	cg14294708	chr9:37120828	ZCCHC7	1.19	31.98	0.83	2.75e-119	Schizophrenia;
LGG	cis	rs798766	1.000	rs2305188	chr4:1739592	A/G	cg05874882	chr4:1763078	NA	-0.48	-6.79	-0.3	3.54e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs6444746	1.000	rs1797849	chr3:193511570	C/T	cg22553634	chr3:193489233	NA	-0.69	-8.18	-0.36	2.71e-15	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs559928	0.606	rs55970968	chr11:63961433	C/T	cg24687543	chr11:63912206	MACROD1	0.61	8.6	0.37	1.2e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17221829	0.733	rs11018726	chr11:89413265	T/C	cg02982614	chr11:89391479	FOLH1B	-0.38	-8.53	-0.37	2.14e-16	Anxiety in major depressive disorder;
LGG	cis	rs7223966	0.584	rs76957877	chr17:61621330	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.5	7.55	0.33	2.34e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08280861	chr8:58055591	NA	0.6	7.76	0.34	5.54e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2901460	0.509	rs6750080	chr2:62071542	C/T	cg02183531	chr2:62113199	CCT4	-0.46	-8.05	-0.35	6.9e-15	Mean corpuscular volume;
LGG	cis	rs714515	0.900	rs9425291	chr1:172312769	A/G	cg01573306	chr1:172330400	DNM3	0.35	7.88	0.34	2.36e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs7493	0.755	rs13223537	chr7:94966167	C/T	cg08461772	chr7:95026248	PON3	-0.4	-8.48	-0.37	3.11e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7715806	0.500	rs72633982	chr5:75001321	C/T	cg19683494	chr5:74908142	NA	0.52	6.94	0.31	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.787	rs7222326	chr17:80057272	T/C	cg19223190	chr17:80058835	NA	-0.48	-9.71	-0.41	2.14e-20	Life satisfaction;
LGG	cis	rs1790761	0.967	rs10274	chr11:67202826	G/A	cg14500267	chr11:67383377	NA	-0.38	-6.93	-0.31	1.38e-11	Mean corpuscular volume;
LGG	cis	rs12282928	0.670	rs7941311	chr11:48225839	G/A	cg26585981	chr11:48327164	OR4S1	-0.4	-7.02	-0.31	7.71e-12	Migraine - clinic-based;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg24250549	chr1:154909240	PMVK	0.73	14.3	0.55	1.14e-38	Prostate cancer;
LGG	cis	rs477895	0.713	rs11600867	chr11:63972052	T/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.87	11.47	0.47	5.44e-27	Mean platelet volume;
LGG	cis	rs6938	0.596	rs11072511	chr15:75159433	A/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.09	-0.31	4.96e-12	Breast cancer;
LGG	cis	rs755249	1.000	rs2293476	chr1:40036847	C/G	cg18385671	chr1:39797026	MACF1	-0.36	-6.68	-0.3	7.06e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6500602	0.826	rs9932461	chr16:4454170	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.42	-7.68	-0.34	9.47e-14	Schizophrenia;
LGG	cis	rs10937275	0.623	rs34421968	chr3:186645080	T/C	cg24050613	chr3:186648279	ST6GAL1	0.85	8.86	0.38	1.71e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13082711	0.911	rs17682751	chr3:27497027	C/T	cg02860705	chr3:27208620	NA	-0.73	-13.18	-0.52	6.56e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs17854409	0.881	rs68066790	chr20:61487150	T/A	cg05147244	chr20:61493195	TCFL5	0.76	7.42	0.33	5.5e-13	Obesity-related traits;
LGG	cis	rs12681366	0.614	rs2921387	chr8:95458337	G/C	cg13257157	chr8:95487014	RAD54B	0.38	7.02	0.31	8.02e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs2760061	0.626	rs592736	chr1:228116831	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.79	-0.34	4.51e-14	Diastolic blood pressure;
LGG	cis	rs11758351	1.000	rs17598927	chr6:26184640	C/G	cg06951627	chr6:26196580	NA	-0.54	-7.86	-0.34	2.72e-14	Gout;Renal underexcretion gout;
LGG	trans	rs12579753	0.879	rs11115008	chr12:82164859	C/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.76	-0.34	5.44e-14	Resting heart rate;
LGG	cis	rs8062405	0.755	rs62034358	chr16:28587597	G/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.9	0.38	1.28e-17	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9905704	0.647	rs11079367	chr17:57009024	A/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.0	-0.31	9.08e-12	Testicular germ cell tumor;
LGG	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.19	-0.46	6.68e-26	Mean platelet volume;
LGG	cis	rs8017423	0.967	rs59006192	chr14:90706456	C/T	cg04374321	chr14:90722782	PSMC1	0.87	18.47	0.65	1.73e-57	Mortality in heart failure;
LGG	trans	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg10840412	chr1:235813424	GNG4	-0.6	-8.24	-0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs4148883	0.603	rs1893883	chr4:100124716	C/G	cg12011299	chr4:100065546	ADH4	0.34	7.3	0.32	1.3e-12	Alcohol dependence;
LGG	cis	rs13088318	0.615	rs28565548	chr3:101230663	T/G	cg27318481	chr3:100970896	IMPG2	0.35	7.06	0.31	6.29e-12	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7980799	0.649	rs2389215	chr12:33649457	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-7.99	-0.35	1.1e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs17253792	0.659	rs34330219	chr14:56017375	G/A	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	cis	rs6815814	0.898	rs1106956	chr4:38889811	A/G	cg06935464	chr4:38784597	TLR10	0.55	7.84	0.34	3.06e-14	Breast cancer;
LGG	cis	rs1348850	0.958	rs10930801	chr2:178459861	G/A	cg27490568	chr2:178487706	NA	0.46	8.85	0.38	1.84e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8062405	0.964	rs78613234	chr16:28839425	T/C	cg07382826	chr16:28625726	SULT1A1	0.35	7.35	0.32	9.16e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28595532	0.920	rs114243409	chr4:119756585	C/A	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs2587949	0.615	rs1994270	chr3:4232535	C/A	cg16519197	chr3:4211558	NA	-0.33	-6.82	-0.3	2.79e-11	Periodontitis (DPAL);
LGG	cis	rs709400	0.633	rs3783395	chr14:103895020	T/C	cg26031613	chr14:104095156	KLC1	0.78	13.84	0.54	1.01e-36	Body mass index;
LGG	cis	rs57502260	0.573	rs11228295	chr11:68388588	C/G	cg16797656	chr11:68205561	LRP5	0.44	7.12	0.31	4.16e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs1883415	0.553	rs760907	chr6:24479873	T/C	cg20631270	chr6:24437470	GPLD1	0.49	8.52	0.37	2.19e-16	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9549367	0.774	rs9549696	chr13:113875062	C/T	cg18105134	chr13:113819100	PROZ	-0.72	-14.34	-0.55	7.7e-39	Platelet distribution width;
LGG	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	trans	rs7395662	0.963	rs6485865	chr11:48575989	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.27	-0.32	1.5e-12	HDL cholesterol;
LGG	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs62103177	0.810	rs62103175	chr18:77622467	C/T	cg20368463	chr18:77673604	PQLC1	0.57	7.49	0.33	3.55e-13	Opioid sensitivity;
LGG	cis	rs41271951	0.512	rs12068365	chr1:151015868	G/A	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.07	-0.31	5.88e-12	Blood protein levels;
LGG	cis	rs708547	0.581	rs6554400	chr4:57805306	A/C	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.46	-7.7	-0.34	8.59e-14	Response to bleomycin (chromatid breaks);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05745317	chr6:27441043	ZNF184	0.47	7.68	0.34	9.74e-14	Cognitive performance;
LGG	cis	rs3749237	0.595	rs4855839	chr3:49507847	G/A	cg03060546	chr3:49711283	APEH	0.74	13.18	0.52	6.57e-34	Resting heart rate;
LGG	cis	rs875971	0.505	rs2462573	chr7:65507392	C/T	cg18876405	chr7:65276391	NA	-0.67	-12.54	-0.5	2.99e-31	Aortic root size;
LGG	cis	rs11191270	0.590	rs12569901	chr10:104025410	C/G	cg15320455	chr10:103880129	LDB1	0.65	8.43	0.36	4.4e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg01017244	chr2:74357527	NA	0.5	9.41	0.4	2.4e-19	Gestational age at birth (maternal effect);
LGG	cis	rs9796	0.621	rs2928142	chr15:41470449	T/C	cg18705301	chr15:41695430	NDUFAF1	0.58	9.96	0.42	2.7e-21	Menopause (age at onset);
LGG	cis	rs9379850	0.730	rs9393738	chr6:26620658	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	12.15	0.49	1.17e-29	Intelligence (multi-trait analysis);
LGG	cis	rs11190604	1.000	rs11190601	chr10:102296730	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.46	0.33	4.24e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9926296	0.533	rs12102290	chr16:89812617	C/T	cg27121462	chr16:89883253	FANCA	0.62	11.34	0.47	1.85e-26	Vitiligo;
LGG	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg07382826	chr16:28625726	SULT1A1	0.42	8.99	0.39	6.36e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs644799	0.710	rs3748253	chr11:95519506	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.9	0.64	7.77e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg02574844	chr11:5959923	NA	-0.56	-9.03	-0.39	4.59e-18	DNA methylation (variation);
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg09845145	chr15:78292470	TBC1D2B	0.62	12.01	0.49	4.09e-29	Coronary artery disease or large artery stroke;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.4	7.84	0.34	3.12e-14	Schizophrenia;
LGG	cis	rs75920871	0.528	rs11216245	chr11:116913202	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.45	-0.33	4.75e-13	Subjective well-being;
LGG	cis	rs17767392	0.958	rs7144829	chr14:72066456	G/A	cg13720639	chr14:72061746	SIPA1L1	0.39	8.25	0.36	1.64e-15	Mitral valve prolapse;
LGG	cis	rs6547741	0.935	rs4666004	chr2:27855052	T/A	cg27432699	chr2:27873401	GPN1	0.68	14.01	0.55	2.08e-37	Oral cavity cancer;
LGG	cis	rs10911363	0.615	rs12024309	chr1:183419981	A/G	cg09173681	chr1:183549694	NCF2	-0.37	-8.31	-0.36	1.04e-15	Systemic lupus erythematosus;
LGG	cis	rs6558530	0.666	rs7845723	chr8:1697086	T/G	cg25947184	chr8:1697459	NA	0.47	8.24	0.36	1.75e-15	Systolic blood pressure;
LGG	cis	rs503734	0.502	rs348880	chr3:100981426	A/G	cg27318481	chr3:100970896	IMPG2	-0.57	-12.82	-0.51	2.07e-32	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9858542	0.953	rs4625	chr3:49572140	A/G	cg07274523	chr3:49395745	GPX1	0.58	9.74	0.41	1.57e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7208859	0.673	rs9889968	chr17:29220128	C/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs778371	0.723	rs12993791	chr2:233690082	C/T	cg08000102	chr2:233561755	GIGYF2	-0.69	-11.15	-0.46	9.47e-26	Schizophrenia;
LGG	trans	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg02002194	chr4:3960332	NA	0.38	7.0	0.31	8.96e-12	Joint mobility (Beighton score);
LGG	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg02975922	chr3:195473998	MUC4	-0.54	-8.98	-0.39	6.82e-18	Pancreatic cancer;
LGG	cis	rs16976116	0.951	rs12385963	chr15:55482851	A/G	cg11288833	chr15:55489084	RSL24D1	0.54	7.44	0.33	4.9e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12893668	0.673	rs2296482	chr14:104029819	T/G	cg23335576	chr14:104009727	NA	0.49	8.51	0.37	2.37e-16	Reticulocyte count;
LGG	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg17182837	chr8:41585554	ANK1	0.52	7.7	0.34	8.26e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7481584	0.624	rs449466	chr11:3047603	C/T	cg08508325	chr11:3079039	CARS	0.43	8.34	0.36	8.56e-16	Calcium levels;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg19673125	chr6:150240577	RAET1G	0.37	9.07	0.39	3.41e-18	Testicular germ cell tumor;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg02158880	chr13:53174818	NA	0.68	15.78	0.59	3.41e-45	Lewy body disease;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg12379764	chr21:47803548	PCNT	0.5	8.23	0.36	1.91e-15	Testicular germ cell tumor;
LGG	cis	rs10028187	0.822	rs2016847	chr4:154402835	C/T	cg24020152	chr4:154419554	KIAA0922	0.46	9.85	0.42	6.38e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs6500602	0.727	rs7193136	chr16:4580034	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.7	0.41	2.19e-20	Schizophrenia;
LGG	cis	rs637571	0.528	rs11602769	chr11:65594139	T/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.74	-0.34	6.3e-14	Eosinophil percentage of white cells;
LGG	trans	rs12517041	1.000	rs6898560	chr5:23312968	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs6866344	0.570	rs1071881	chr5:178135917	C/T	cg03877680	chr5:178157825	ZNF354A	0.82	14.06	0.55	1.23e-37	Neutrophil percentage of white cells;
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1005224	0.889	rs12717566	chr14:76147507	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-6.68	-0.3	6.73e-11	Large artery stroke;
LGG	cis	rs9640161	0.789	rs6964110	chr7:150041836	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.69	-14.79	-0.57	8.35e-41	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1348850	0.747	rs1047884	chr2:178488281	C/G	cg22681709	chr2:178499509	PDE11A	-0.48	-8.67	-0.37	7.58e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4865169	0.560	rs1277311	chr4:57902761	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.47	7.97	0.35	1.21e-14	Breast cancer;
LGG	cis	rs3053386	1	rs3053386	chr6:2488337	C/CAA	cg20147862	chr6:2634573	C6orf195	-0.38	-8.25	-0.36	1.66e-15	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs853679	0.517	rs9357063	chr6:28060005	G/A	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	trans	rs2727020	0.553	rs3862350	chr11:49595912	A/C	cg15704280	chr7:45808275	SEPT13	-1.01	-21.64	-0.71	3e-72	Coronary artery disease;
LGG	cis	rs9296092	0.517	rs7743178	chr6:33470462	G/A	cg13560919	chr6:33536144	NA	-0.92	-16.58	-0.61	8.08e-49	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs67311347	0.956	rs7640228	chr3:40516190	G/A	cg13683864	chr3:40499215	RPL14	1.15	29.04	0.8	2.3e-106	Renal cell carcinoma;
LGG	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg19812747	chr11:111475976	SIK2	-0.46	-9.34	-0.4	4.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs2180341	0.824	rs9321076	chr6:127655614	G/A	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs35110281	0.774	rs141521	chr21:44963686	G/A	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.91	-0.38	1.15e-17	Mean corpuscular volume;
LGG	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg09640425	chr7:158790006	NA	-0.4	-7.42	-0.33	5.56e-13	Facial morphology (factor 20);
LGG	cis	rs2032447	0.802	rs12346	chr6:26097046	T/C	cg12310025	chr6:25882481	NA	-0.61	-11.48	-0.47	5.16e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg00684032	chr4:1343700	KIAA1530	0.38	6.68	0.3	6.73e-11	Longevity;
LGG	cis	rs7507204	0.723	rs12610998	chr19:3413653	T/C	cg08380311	chr19:3435252	NFIC	0.82	12.0	0.49	4.4e-29	Height;
LGG	cis	rs7923609	1.000	rs4399232	chr10:64999490	C/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.76	-0.3	4.2e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6062302	0.522	rs2872810	chr20:62241931	C/T	cg16989086	chr20:62203971	PRIC285	-0.48	-7.11	-0.31	4.4e-12	Glioblastoma;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs12701220	0.894	rs10263252	chr7:1049949	G/A	cg02733842	chr7:1102375	C7orf50	-0.48	-7.77	-0.34	5.28e-14	Bronchopulmonary dysplasia;
LGG	cis	rs72781680	0.821	rs2176265	chr2:24158638	C/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.73	0.38	4.68e-17	Lymphocyte counts;
LGG	cis	rs9322193	0.926	rs952166	chr6:150119910	A/T	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.66e-11	Lung cancer;
LGG	cis	rs922692	1.000	rs11638372	chr15:78983559	A/G	cg00540400	chr15:79124168	NA	0.33	6.66	0.3	7.83e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs17504614	0.648	rs78864136	chr2:51080916	T/A	cg23851515	chr2:51057218	NRXN1	0.67	8.13	0.35	3.88e-15	Educational attainment (years of education);
LGG	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg23625390	chr15:77176239	SCAPER	-0.48	-9.46	-0.4	1.61e-19	Blood metabolite levels;
LGG	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg17230874	chr3:125932073	NA	0.59	11.76	0.48	3.97e-28	Metabolite levels;
LGG	cis	rs11920090	0.932	rs11923694	chr3:170717426	A/G	cg09710316	chr3:170744871	SLC2A2	0.6	8.45	0.37	3.92e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs3204270	0.639	rs79193599	chr17:79651490	C/A	cg18367735	chr17:79674897	NA	0.6	7.7	0.34	8.16e-14	Dental caries;
LGG	cis	rs988958	0.600	rs10189068	chr2:42247361	G/A	cg19376973	chr2:42229025	NA	0.63	9.83	0.42	7.77e-21	Hypospadias;
LGG	cis	rs7647973	1.000	rs62259947	chr3:49439924	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	-0.39	-6.66	-0.3	7.98e-11	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4740619	0.933	rs2382534	chr9:15713090	A/G	cg14451791	chr9:16040625	NA	-0.37	-9.42	-0.4	2.08e-19	Body mass index;
LGG	cis	rs6502050	0.765	rs6502075	chr17:80121813	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6580649	0.941	rs7296913	chr12:48488920	G/A	cg24011408	chr12:48396354	COL2A1	-0.54	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs35306767	0.903	rs4522091	chr10:874116	G/T	cg26597838	chr10:835615	NA	0.76	10.57	0.44	1.55e-23	Eosinophil percentage of granulocytes;
LGG	trans	rs2727020	0.734	rs1164663	chr11:49294723	A/T	cg11707556	chr5:10655725	ANKRD33B	0.58	10.24	0.43	2.59e-22	Coronary artery disease;
LGG	cis	rs8114671	0.527	rs6088650	chr20:33514465	C/T	cg07148914	chr20:33460835	GGT7	-0.53	-8.88	-0.38	1.46e-17	Height;
LGG	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21659725	chr3:3221576	CRBN	0.55	9.58	0.41	5.74e-20	Intelligence (multi-trait analysis);
LGG	trans	rs826838	1.000	rs11168505	chr12:38939057	A/T	cg06521331	chr12:34319734	NA	0.47	8.22	0.36	2.13e-15	Heart rate;
LGG	cis	rs9549367	0.789	rs7994324	chr13:113906497	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.66	-0.37	8.17e-17	Platelet distribution width;
LGG	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg19761014	chr17:28927070	LRRC37B2	0.63	7.67	0.34	1.01e-13	Body mass index;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs936229	0.511	rs12591513	chr15:75102714	G/A	cg14664628	chr15:75095509	CSK	-0.8	-16.61	-0.61	6.02e-49	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs11039798	0.511	rs717896	chr11:48375335	G/T	cg03929089	chr4:120376271	NA	-0.69	-9.48	-0.4	1.29e-19	Axial length;
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	14.37	0.56	5.7e-39	Platelet count;
LGG	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.17	-0.32	3.07e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2439831	0.850	rs10163054	chr15:44047638	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.64	0.44	8.58e-24	Lung cancer in ever smokers;
LGG	cis	rs2046867	0.862	rs35178407	chr3:72799703	C/T	cg26655873	chr3:72818019	SHQ1	0.35	7.04	0.31	6.88e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs457717	0.706	rs2455213	chr5:75944993	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.3	6.71	0.3	5.79e-11	Hearing impairment;
LGG	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.664	rs11150736	chr17:78613507	C/T	cg18469159	chr17:78755841	RPTOR	-0.39	-7.32	-0.32	1.08e-12	Obesity;
LGG	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg06481639	chr22:41940642	POLR3H	0.58	8.44	0.37	4.15e-16	Vitiligo;
LGG	cis	rs657075	0.697	rs71583486	chr5:131719689	G/T	cg17951613	chr5:131705445	SLC22A5	0.64	7.25	0.32	1.75e-12	Rheumatoid arthritis;
LGG	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.37	-0.32	8e-13	Neuroticism;
LGG	trans	rs2948294	0.588	rs7011221	chr8:8114246	C/T	cg16141378	chr3:129829833	LOC729375	-0.48	-10.92	-0.45	7.55e-25	Red cell distribution width;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg19717773	chr7:2847554	GNA12	-0.34	-6.98	-0.31	1e-11	Height;
LGG	cis	rs950169	0.960	rs12905475	chr15:84800495	G/A	cg24253500	chr15:84953950	NA	0.56	9.77	0.41	1.25e-20	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg06601766	chr17:61851465	DDX42;CCDC47	-0.43	-7.06	-0.31	6.03e-12	Prudent dietary pattern;
LGG	cis	rs4481887	0.927	rs12044126	chr1:248481952	T/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs963731	0.649	rs2123876	chr2:39255873	C/G	cg04010122	chr2:39346883	SOS1	-0.87	-7.43	-0.33	5.29e-13	Corticobasal degeneration;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.83	-0.42	7.63e-21	Personality dimensions;
LGG	cis	rs9397585	0.833	rs6927884	chr6:153397429	T/A	cg17707550	chr6:153380415	RGS17	0.51	11.19	0.46	6.65e-26	Body mass index;
LGG	trans	rs72991	0.793	rs10790438	chr11:121226192	T/C	cg27192990	chr6:129479024	LAMA2	-0.43	-7.19	-0.32	2.66e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2030746	0.899	rs3843846	chr2:121311799	G/A	cg03661458	chr2:121334411	NA	-0.29	-6.76	-0.3	4.13e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	trans	rs9329221	0.537	rs6995859	chr8:9975709	T/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.7	-0.37	6.03e-17	Neuroticism;
LGG	cis	rs79911532	0.515	rs10226745	chr7:75843603	C/T	cg15148918	chr7:75625777	STYXL1	-0.59	-6.95	-0.31	1.27e-11	Mononucleosis;
LGG	trans	rs916888	0.773	rs199448	chr17:44809001	A/G	cg07870213	chr5:140052090	DND1	0.93	17.48	0.63	6.4e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7666738	0.830	rs35213297	chr4:98984049	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.86	0.34	2.79e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs853679	0.517	rs9380060	chr6:28132603	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg15369054	chr17:80825471	TBCD	0.59	10.74	0.45	3.69e-24	Breast cancer;
LGG	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.39e-12	Blood metabolite levels;
LGG	cis	rs1059312	0.808	rs12831705	chr12:129294905	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.35	8.87	0.38	1.6e-17	Systemic lupus erythematosus;
LGG	trans	rs116095464	0.558	rs2162870	chr5:228129	G/A	cg00938859	chr5:1591904	SDHAP3	0.88	13.05	0.52	2.29e-33	Breast cancer;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2213920	0.679	rs4979536	chr9:118213738	C/T	cg13918206	chr9:118159781	DEC1	0.62	8.6	0.37	1.27e-16	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs3858526	0.642	rs10838783	chr11:5900282	T/G	cg02574844	chr11:5959923	NA	-0.57	-8.83	-0.38	2.15e-17	DNA methylation (variation);
LGG	cis	rs4072980	0.524	rs28477803	chr1:38398694	C/T	cg26528311	chr1:38462546	FHL3	0.32	7.97	0.35	1.22e-14	Coronary artery disease;
LGG	cis	rs1843834	0.505	rs940317	chr2:225358118	C/T	cg12698349	chr2:225449008	CUL3	0.69	11.67	0.48	9.44e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs13108904	0.934	rs13115173	chr4:1316824	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.68	12.58	0.5	1.96e-31	Obesity-related traits;
LGG	cis	rs7635838	0.617	rs2606731	chr3:11291615	A/C	cg00170343	chr3:11313890	ATG7	0.52	9.09	0.39	2.93e-18	HDL cholesterol;
LGG	cis	rs72945132	0.882	rs1061328	chr11:70185325	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.21	0.36	2.25e-15	Coronary artery disease;
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg08888203	chr3:10149979	C3orf24	0.55	9.01	0.39	5.3e-18	Alzheimer's disease;
LGG	cis	rs1003719	0.762	rs3787786	chr21:38463436	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg16482183	chr6:26056742	HIST1H1C	-0.53	-9.43	-0.4	2.01e-19	Height;
LGG	cis	rs6743226	0.603	rs62186408	chr2:242235651	A/G	cg10021735	chr2:242295487	FARP2	0.4	6.96	0.31	1.2e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs6964587	0.773	rs13223564	chr7:91932666	A/G	cg17063962	chr7:91808500	NA	0.47	8.14	0.35	3.65e-15	Breast cancer;
LGG	cis	rs10754283	0.967	rs1317864	chr1:90105448	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	12.21	0.49	6.37e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	15.09	0.57	3.91e-42	Platelet count;
LGG	cis	rs3820068	0.603	rs6429767	chr1:15963334	G/A	cg05660106	chr1:15850417	CASP9	0.83	16.72	0.61	1.94e-49	Systolic blood pressure;
LGG	cis	rs9503598	0.636	rs7745968	chr6:3467745	G/T	cg00476032	chr6:3446245	SLC22A23	0.53	10.81	0.45	1.9e-24	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	trans	rs6076960	0.682	rs6054065	chr20:6267920	G/A	cg24759859	chr6:86352639	SYNCRIP	0.42	7.03	0.31	7.48e-12	Smooth-surface caries;
LGG	cis	rs898097	0.737	rs3785521	chr17:80895769	A/G	cg15664640	chr17:80829946	TBCD	0.78	14.78	0.57	9.11e-41	Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09319946	chr13:25497353	CENPJ	0.43	6.81	0.3	3.01e-11	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10460130	chr2:242625978	DTYMK	0.44	7.63	0.33	1.31e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6835098	1.000	rs1054496	chr4:174089080	A/G	cg08422745	chr4:174089978	GALNT7	-0.85	-14.83	-0.57	5.23e-41	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg09324608	chr17:30823087	MYO1D	0.29	7.02	0.31	7.79e-12	Schizophrenia;
LGG	cis	rs10504229	0.906	rs111838497	chr8:58185620	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg06521331	chr12:34319734	NA	0.45	8.05	0.35	6.96e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg26513180	chr16:89883248	FANCA	0.71	8.1	0.35	4.82e-15	Skin colour saturation;
LGG	cis	rs2832077	0.506	rs2832088	chr21:30158620	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-11.03	-0.46	2.76e-25	Cognitive test performance;
LGG	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg14019146	chr3:50243930	SLC38A3	0.32	6.81	0.3	3.11e-11	Body mass index;
LGG	cis	rs4332037	0.722	rs7788921	chr7:1915282	C/A	cg24189917	chr7:1970923	MAD1L1	-0.52	-7.57	-0.33	1.97e-13	Bipolar disorder;
LGG	cis	rs6728642	0.908	rs7588921	chr2:98021001	C/T	cg26665480	chr2:98280029	ACTR1B	-0.71	-8.42	-0.36	4.72e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9916302	0.861	rs10491129	chr17:37461643	T/G	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	3.01e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs11577318	0.853	rs7416513	chr1:26647949	G/C	cg07461501	chr17:79650226	HGS;ARL16	0.53	9.82	0.42	8.17e-21	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6940638	0.688	rs9393790	chr6:27114052	A/C	cg12826209	chr6:26865740	GUSBL1	-0.43	-7.14	-0.31	3.62e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2652834	0.851	rs4633662	chr15:63424286	G/A	cg05507819	chr15:63340323	TPM1	0.5	7.1	0.31	4.6e-12	HDL cholesterol;
LGG	cis	rs72945132	0.825	rs7941965	chr11:70213182	T/C	cg00319359	chr11:70116639	PPFIA1	0.76	8.39	0.36	6.1e-16	Coronary artery disease;
LGG	cis	rs360798	0.512	rs6739804	chr2:63269604	T/C	cg17519650	chr2:63277830	OTX1	0.58	9.51	0.4	1.07e-19	Coronary artery disease;
LGG	cis	rs7945705	0.869	rs4909952	chr11:8963946	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.35	7.19	0.32	2.59e-12	Hemoglobin concentration;
LGG	cis	rs504918	0.502	rs76996118	chr3:124025129	C/A	cg05766129	chr3:123988013	KALRN	-0.57	-10.06	-0.42	1.15e-21	Schizophrenia;
LGG	cis	rs7552404	1.000	rs4949872	chr1:76131392	C/G	cg22875332	chr1:76189707	ACADM	0.59	9.26	0.4	7.79e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7188861	0.813	rs12596260	chr16:11398265	T/G	cg01510278	chr16:11456238	NA	0.31	7.38	0.32	7.57e-13	HDL cholesterol;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg14926445	chr8:58193284	C8orf71	-0.73	-9.29	-0.4	6.02e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs490234	0.718	rs2047502	chr9:128178894	C/A	cg14078157	chr9:128172775	NA	-0.51	-9.43	-0.4	1.96e-19	Mean arterial pressure;
LGG	cis	rs2274273	0.870	rs67514154	chr14:55767382	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.32	0.63	3.51e-52	Protein biomarker;
LGG	trans	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg11608241	chr8:8085544	FLJ10661	-0.33	-7.45	-0.33	4.7e-13	Neuroticism;
LGG	trans	rs853679	0.882	rs9393908	chr6:28190830	T/A	cg01620082	chr3:125678407	NA	-0.69	-7.7	-0.34	8.39e-14	Depression;
LGG	cis	rs6787391	0.897	rs3828435	chr3:4743267	G/C	cg11584376	chr3:4789075	ITPR1	-0.34	-7.16	-0.32	3.2e-12	Breast cancer;
LGG	cis	rs7647973	1.000	rs2177268	chr3:49439725	A/T	cg07636037	chr3:49044803	WDR6	-0.76	-13.57	-0.53	1.48e-35	Menarche (age at onset);
LGG	cis	rs2594989	0.943	rs2442769	chr3:11491086	A/G	cg01796438	chr3:11312864	ATG7	0.52	6.84	0.3	2.5e-11	Circulating chemerin levels;
LGG	cis	rs757081	0.643	rs665311	chr11:17206740	A/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.0	-0.39	5.95e-18	Systolic blood pressure;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg13692902	chr5:34915868	BRIX1;RAD1	-0.44	-6.83	-0.3	2.61e-11	Pancreatic cancer;
LGG	cis	rs1534166	0.647	rs9876158	chr3:133508300	T/C	cg01448562	chr3:133502909	NA	0.41	7.09	0.31	5.09e-12	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs7589342	0.929	rs12053259	chr2:106428720	G/A	cg14210321	chr2:106509881	NCK2	-0.51	-8.84	-0.38	2.03e-17	Addiction;
LGG	cis	rs9894429	1.000	rs35435780	chr17:79579602	G/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.01	-0.31	8.64e-12	Neuroticism;
LGG	cis	rs240764	0.658	rs705585	chr6:101262409	A/G	cg09795085	chr6:101329169	ASCC3	0.45	7.53	0.33	2.74e-13	Neuroticism;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.17	0.36	2.93e-15	Lung cancer;
LGG	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg03477792	chr4:77819574	ANKRD56	0.52	9.08	0.39	3.14e-18	Emphysema distribution in smoking;
LGG	cis	rs9894429	0.646	rs7217415	chr17:79618252	G/A	cg10661904	chr17:79619235	PDE6G	-0.5	-9.81	-0.41	9.08e-21	Eye color traits;
LGG	cis	rs6977660	0.562	rs2189566	chr7:19768960	G/A	cg07541023	chr7:19748670	TWISTNB	0.78	10.63	0.44	9.51e-24	Thyroid stimulating hormone;
LGG	cis	rs6582630	0.519	rs11495699	chr12:38286219	G/T	cg26384229	chr12:38710491	ALG10B	0.98	21.99	0.71	6.82e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07791516	chr6:150247246	NA	0.33	7.21	0.32	2.28e-12	Testicular germ cell tumor;
LGG	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.74	0.3	4.79e-11	Dupuytren's disease;
LGG	cis	rs1847202	0.517	rs13062803	chr3:72951840	T/A	cg25664220	chr3:72788482	NA	-0.25	-7.32	-0.32	1.13e-12	Motion sickness;
LGG	cis	rs1008375	1.000	rs4698641	chr4:17642630	C/T	cg04450456	chr4:17643702	FAM184B	0.33	7.47	0.33	4e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs36071027	0.577	rs11747844	chr5:158441176	A/T	cg00594129	chr5:158524270	EBF1	-0.46	-8.23	-0.36	1.89e-15	Carotid intima media thickness;
LGG	cis	rs4650994	0.593	rs12735140	chr1:178544218	C/A	cg19399532	chr1:178512495	C1orf220	-0.39	-7.37	-0.32	8.02e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs3540	0.960	rs28539372	chr15:91021412	T/A	cg22089800	chr15:90895588	ZNF774	0.5	7.66	0.34	1.06e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs3820928	0.874	rs13423714	chr2:227896652	C/G	cg11843606	chr2:227700838	RHBDD1	0.46	7.91	0.34	1.97e-14	Pulmonary function;
LGG	cis	rs6028335	0.867	rs61387464	chr20:37715912	C/T	cg16355469	chr20:37678765	NA	0.56	7.08	0.31	5.49e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs8016982	0.633	rs4363794	chr14:81674327	C/A	cg01989461	chr14:81687754	GTF2A1	0.75	17.48	0.63	6.46e-53	Schizophrenia;
LGG	cis	rs9611565	0.512	rs964898	chr22:42142306	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-7.68	-0.34	9.73e-14	Vitiligo;
LGG	cis	rs1816752	0.905	rs6490929	chr13:25014252	G/A	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	trans	rs941408	0.515	rs1736188	chr19:2782368	A/G	cg22153745	chr1:153894579	GATAD2B	-0.59	-8.68	-0.37	7.02e-17	Total cholesterol levels;
LGG	cis	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg24110177	chr3:50126178	RBM5	-0.57	-8.95	-0.38	8.37e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9527	0.590	rs10883818	chr10:104759586	A/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.81	-0.3	3.07e-11	Arsenic metabolism;
LGG	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg20991723	chr1:152506922	NA	-0.71	-14.39	-0.56	4.56e-39	Hair morphology;
LGG	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg13385794	chr1:248469461	NA	0.47	7.51	0.33	3.08e-13	Common traits (Other);
LGG	cis	rs2274273	0.624	rs7147247	chr14:55777713	A/T	cg04306507	chr14:55594613	LGALS3	0.52	12.05	0.49	2.81e-29	Protein biomarker;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg07959490	chr17:80112427	CCDC57	0.47	9.23	0.39	9.53e-19	Life satisfaction;
LGG	cis	rs9815354	1.000	rs9830469	chr3:41762535	A/G	cg03022575	chr3:42003672	ULK4	0.59	7.54	0.33	2.42e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.63e-15	Bone mineral density;
LGG	cis	rs1577917	1.000	rs10455158	chr6:86672825	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.58	-0.41	5.84e-20	Response to antipsychotic treatment;
LGG	cis	rs193541	0.632	rs7735618	chr5:122176245	C/G	cg19412675	chr5:122181750	SNX24	0.52	8.28	0.36	1.29e-15	Glucose homeostasis traits;
LGG	cis	rs3857536	0.673	rs7759888	chr6:66891922	T/C	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	trans	rs7939886	0.920	rs11227808	chr11:56070347	A/T	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.57	0.37	1.56e-16	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs6991035	chr8:58183374	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7301016	0.846	rs12369751	chr12:63031133	G/C	cg01804193	chr12:63026212	NA	0.55	7.13	0.31	3.86e-12	IgG glycosylation;
LGG	cis	rs9400467	0.537	rs73530952	chr6:111486242	G/A	cg15721981	chr6:111408429	SLC16A10	0.59	7.16	0.32	3.27e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs6502050	0.731	rs9892653	chr17:80100191	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg06028808	chr11:68637592	NA	0.73	12.37	0.5	1.41e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7223966	0.883	rs2727317	chr17:61961302	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.72	0.3	5.34e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7954584	0.567	rs1169071	chr12:122390084	G/T	cg01765077	chr12:122356316	WDR66	0.27	7.37	0.32	8.07e-13	Mean corpuscular volume;
LGG	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14373873	chr11:113211441	TTC12	0.42	8.68	0.37	6.6e-17	Neuroticism;
LGG	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs79349575	0.729	rs62075824	chr17:46986679	A/G	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.98e-11	Type 2 diabetes;
LGG	cis	rs36051895	0.659	rs12336577	chr9:5063690	T/A	cg02405213	chr9:5042618	JAK2	-0.82	-15.84	-0.59	1.8e-45	Pediatric autoimmune diseases;
LGG	cis	rs9972944	0.729	rs7222147	chr17:63774100	C/T	cg07283582	chr17:63770753	CCDC46	0.4	7.72	0.34	7.15e-14	Total body bone mineral density;
LGG	cis	rs13191362	1.000	rs35575481	chr6:163007746	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.84	0.34	3.18e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2797369	0.883	rs2764269	chr6:101692731	A/C	cg27451362	chr6:101846650	GRIK2	0.79	10.57	0.44	1.6e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg17376030	chr22:41985996	PMM1	-0.59	-9.61	-0.41	4.79e-20	Vitiligo;
LGG	cis	rs12368653	1.000	rs12368653	chr12:58133256	A/G	cg02175503	chr12:58329896	NA	0.56	9.9	0.42	4.51e-21	Multiple sclerosis;
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg14338887	chr6:42928500	GNMT	0.31	10.2	0.43	3.46e-22	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs873946	0.517	rs2803990	chr10:134560340	A/G	cg27297192	chr10:134578999	INPP5A	0.27	6.79	0.3	3.51e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4563143	0.647	rs73029014	chr19:29257655	G/C	cg04546413	chr19:29218101	NA	0.75	12.65	0.51	1.04e-31	Methadone dose in opioid dependence;
LGG	cis	rs9457247	1.000	rs10946198	chr6:167404432	C/T	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs7742824	0.879	rs7769540	chr6:44062899	G/C	cg04074908	chr6:44101190	TMEM63B	0.57	11.52	0.47	3.59e-27	Major depressive disorder;
LGG	cis	rs9902453	0.899	rs1979572	chr17:28511978	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.86	0.51	1.37e-32	Coffee consumption (cups per day);
LGG	cis	rs1552244	0.808	rs17032306	chr3:10091399	C/G	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs1878931	0.501	rs37800	chr16:3423648	T/G	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.82	-14.27	-0.55	1.53e-38	Body mass index (adult);
LGG	cis	rs9325144	0.505	rs6582691	chr12:38806894	T/C	cg13010199	chr12:38710504	ALG10B	-0.69	-14.36	-0.56	5.96e-39	Morning vs. evening chronotype;
LGG	cis	rs6495122	0.501	rs7163636	chr15:75346760	C/T	cg17294928	chr15:75287854	SCAMP5	0.56	10.39	0.43	7.32e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs4731207	0.507	rs10954052	chr7:124586811	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs9976767	0.637	rs9325635	chr21:43823289	G/A	cg23042151	chr21:43824109	UBASH3A	-0.62	-13.11	-0.52	1.31e-33	Type 1 diabetes;
LGG	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg00166722	chr3:10149974	C3orf24	0.36	6.92	0.31	1.49e-11	Alzheimer's disease;
LGG	cis	rs12142240	0.698	rs17357759	chr1:46832534	A/G	cg00530320	chr1:46809349	NSUN4	0.42	7.6	0.33	1.69e-13	Menopause (age at onset);
LGG	cis	rs36093844	0.660	rs1445500	chr11:85542482	A/C	cg16165120	chr11:85566439	CCDC83	-0.45	-7.07	-0.31	5.8e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs1577917	0.687	rs13197828	chr6:86805630	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.66	-0.37	7.75e-17	Response to antipsychotic treatment;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg25724323	chr2:58478735	NA	0.42	7.46	0.33	4.38e-13	Menarche (age at onset);
LGG	cis	rs514406	0.825	rs7523761	chr1:53250915	T/C	cg08859206	chr1:53392774	SCP2	0.34	6.81	0.3	3.09e-11	Monocyte count;
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg13628971	chr7:2884303	GNA12	0.34	7.01	0.31	8.28e-12	Height;
LGG	cis	rs367943	0.688	rs1464163	chr5:112691815	A/G	cg12552261	chr5:112820674	MCC	0.56	10.01	0.42	1.73e-21	Type 2 diabetes;
LGG	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	trans	rs9354308	0.678	rs2000384	chr6:66597429	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg02725872	chr8:58115012	NA	-0.74	-10.32	-0.43	1.33e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3857536	0.740	rs9354392	chr6:66894555	G/T	cg07460842	chr6:66804631	NA	-0.48	-8.26	-0.36	1.53e-15	Blood trace element (Cu levels);
LGG	cis	rs17655565	1.000	rs2276399	chr12:52705269	G/A	cg02645295	chr12:52705424	NA	-0.66	-9.16	-0.39	1.73e-18	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg06636001	chr8:8085503	FLJ10661	-0.6	-11.5	-0.47	4.17e-27	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg00830817	chr11:109293614	C11orf87	0.41	7.0	0.31	9.08e-12	Schizophrenia;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg08621203	chr6:150244597	RAET1G	0.46	7.88	0.34	2.32e-14	Lung cancer;
LGG	cis	rs4919087	0.620	rs793518	chr10:98986970	C/T	cg25902810	chr10:99078978	FRAT1	-0.41	-6.76	-0.3	4.22e-11	Monocyte count;
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg08280861	chr8:58055591	NA	0.71	7.6	0.33	1.68e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6938	0.618	rs62029167	chr15:75228350	G/A	cg14664628	chr15:75095509	CSK	-0.54	-10.29	-0.43	1.68e-22	Breast cancer;
LGG	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg00129232	chr17:37814104	STARD3	-0.48	-8.86	-0.38	1.74e-17	Self-reported allergy;
LGG	trans	rs208520	0.586	rs208442	chr6:66900618	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.69	-11.85	-0.48	1.77e-28	Exhaled nitric oxide output;
LGG	cis	rs10865541	0.778	rs10779975	chr2:3420032	A/G	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.42e-11	Obesity-related traits;
LGG	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg23335576	chr14:104009727	NA	0.47	8.19	0.36	2.56e-15	Reticulocyte count;
LGG	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg24642439	chr20:33292090	TP53INP2	0.82	14.48	0.56	1.82e-39	Coronary artery disease;
LGG	cis	rs2245008	0.774	rs253136	chr16:83979601	A/C	cg07978099	chr16:83986941	OSGIN1	-0.54	-8.74	-0.38	4.43e-17	Pursuit maintenance gain;
LGG	cis	rs10744422	1.000	rs10744422	chr12:123336789	T/C	cg25930673	chr12:123319894	HIP1R	-0.76	-9.33	-0.4	4.25e-19	Schizophrenia;
LGG	cis	rs2294693	0.945	rs9369255	chr6:40989503	T/C	cg14769373	chr6:40998127	UNC5CL	-0.41	-6.74	-0.3	4.75e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg14784868	chr12:69753453	YEATS4	-0.74	-14.84	-0.57	4.85e-41	Blood protein levels;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg04025307	chr7:1156635	C7orf50	0.83	15.07	0.57	4.69e-42	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs886427	0.517	rs739716	chr16:2986431	T/C	cg27042294	chr16:2982532	FLYWCH1	0.39	6.89	0.3	1.88e-11	Metabolic syndrome;
LGG	cis	rs559928	0.606	rs78038516	chr11:63978067	C/G	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.25e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs9784649	0.760	rs17343923	chr5:25052414	G/A	cg08600765	chr20:34638493	LOC647979	-0.74	-10.48	-0.44	3.29e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs61931739	0.534	rs10844816	chr12:34248533	C/A	cg13010199	chr12:38710504	ALG10B	0.56	10.55	0.44	1.88e-23	Morning vs. evening chronotype;
LGG	cis	rs7582180	0.903	rs13013891	chr2:100896110	T/C	cg05692746	chr2:100937584	LONRF2	-0.59	-9.67	-0.41	2.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4474465	0.850	rs6592789	chr11:78246767	G/C	cg27205649	chr11:78285834	NARS2	0.51	8.79	0.38	3.01e-17	Alzheimer's disease (survival time);
LGG	cis	rs7267979	0.966	rs2145126	chr20:25263648	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs800082	0.690	rs800081	chr3:144339980	C/T	cg24215973	chr2:240111563	HDAC4	0.62	11.83	0.48	2.16e-28	Smoking behavior;
LGG	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	trans	rs9650657	0.571	rs11783247	chr8:10788875	C/T	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.57	-0.41	6.33e-20	Neuroticism;
LGG	trans	rs853679	1.000	rs7740487	chr6:28216486	C/G	cg06606381	chr12:133084897	FBRSL1	-0.73	-8.5	-0.37	2.63e-16	Depression;
LGG	trans	rs9914544	0.564	rs11548434	chr17:18761508	G/A	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.56	-0.33	2.2e-13	Educational attainment (years of education);
LGG	trans	rs6582630	0.547	rs1589388	chr12:38416025	C/T	cg06521331	chr12:34319734	NA	0.44	8.0	0.35	1.02e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs847577	0.748	rs940430	chr7:97716540	A/G	cg13397024	chr7:97797637	LMTK2	-0.36	-6.88	-0.3	2.01e-11	Breast cancer;
LGG	cis	rs2916247	0.908	rs6471318	chr8:93086731	C/G	cg10183463	chr8:93005414	RUNX1T1	0.38	7.73	0.34	6.7e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9886651	0.869	rs11779374	chr8:128792310	G/A	cg24514600	chr8:128805414	PVT1	-0.54	-12.12	-0.49	1.43e-29	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.29	-0.32	1.34e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	0.692	rs1471780	chr15:77026526	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.89	-0.31	1.79e-11	Blood metabolite levels;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg08302650	chr8:145750040	LRRC24;LRRC14	0.35	6.98	0.31	1.05e-11	Age at first birth;
LGG	cis	rs9311474	0.508	rs6788887	chr3:52605005	T/C	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Electroencephalogram traits;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.76	0.41	1.39e-20	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27480539	chr19:16770792	TMEM38A;C19orf42	0.45	7.0	0.31	8.91e-12	Gut microbiome composition (summer);
LGG	cis	rs8072100	1.000	rs4375701	chr17:45712218	C/T	cg19784903	chr17:45786737	TBKBP1	-0.32	-7.07	-0.31	5.86e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4776059	1.000	rs11858743	chr15:52936330	G/A	cg22715398	chr15:52968154	KIAA1370	-0.47	-7.78	-0.34	4.79e-14	Schizophrenia;
LGG	cis	rs2404602	0.735	rs4886805	chr15:76739384	A/G	cg15268244	chr15:77196840	NA	-0.45	-9.9	-0.42	4.25e-21	Blood metabolite levels;
LGG	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg13010199	chr12:38710504	ALG10B	0.75	15.99	0.6	3.98e-46	Heart rate;
LGG	cis	rs2280018	0.963	rs12928424	chr16:15150773	C/G	cg07549590	chr16:15018862	NA	-0.45	-8.1	-0.35	4.94e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.55	-0.63	3e-53	Breast cancer;
LGG	cis	rs35146811	0.735	rs1727133	chr7:99812870	C/T	cg22906224	chr7:99728672	NA	-0.58	-9.64	-0.41	3.73e-20	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2304069	0.817	rs216132	chr5:149431259	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.75	-11.79	-0.48	3.02e-28	HIV-1 control;
LGG	cis	rs2072499	0.833	rs2251847	chr1:156204047	G/A	cg24450063	chr1:156163899	SLC25A44	1.04	21.46	0.71	1.93e-71	Testicular germ cell tumor;
LGG	trans	rs853679	0.607	rs34218844	chr6:28290647	T/C	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	cis	rs8180040	1.000	rs295442	chr3:47335881	A/C	cg16586182	chr3:47516702	SCAP	-0.78	-15.12	-0.57	2.92e-42	Colorectal cancer;
LGG	cis	rs473651	0.904	rs62196716	chr2:239356977	C/G	cg18131467	chr2:239335373	ASB1	1.03	23.69	0.74	7.89e-82	Multiple system atrophy;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-8.71	-0.38	5.62e-17	Menopause (age at onset);
LGG	cis	rs2046867	0.644	rs56947804	chr3:72788435	T/C	cg25664220	chr3:72788482	NA	-0.32	-9.06	-0.39	3.59e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg10756647	chr7:56101905	PSPH	0.71	9.13	0.39	2.06e-18	Diabetic kidney disease;
LGG	cis	rs6784615	1.000	rs498778	chr3:52453893	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	-0.7	-7.72	-0.34	7.29e-14	Waist-hip ratio;
LGG	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg25945732	chr2:264204	ACP1;SH3YL1	0.82	15.47	0.58	8.32e-44	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7215564	0.509	rs61750765	chr17:78519519	T/C	cg16980736	chr17:78789706	RPTOR	-0.56	-7.79	-0.34	4.44e-14	Myopia (pathological);
LGG	cis	rs11252926	0.537	rs4554800	chr10:458477	G/T	cg08603382	chr10:743973	NA	-0.41	-7.65	-0.34	1.17e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs614226	0.744	rs787832	chr12:120986801	A/G	cg21053147	chr12:120880522	NA	-0.54	-8.04	-0.35	7.58e-15	Type 1 diabetes nephropathy;
LGG	cis	rs7264396	0.790	rs6060541	chr20:34248066	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.44	0.33	5.05e-13	Total cholesterol levels;
LGG	cis	rs769267	0.929	rs2905431	chr19:19482882	G/A	cg01262667	chr19:19385393	TM6SF2	-0.45	-11.44	-0.47	7.4e-27	Tonsillectomy;
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg26897989	chr16:1907736	C16orf73	-0.82	-13.81	-0.54	1.37e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs240764	0.658	rs7740006	chr6:101220432	T/C	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs8028313	0.630	rs12438118	chr15:67951150	A/C	cg24231037	chr15:68117551	LBXCOR1	0.37	8.28	0.36	1.35e-15	Obesity;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg13206674	chr6:150067644	NUP43	0.65	14.63	0.56	4.02e-40	Lung cancer;
LGG	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg15704280	chr7:45808275	SEPT13	-0.49	-8.09	-0.35	5.4e-15	HDL cholesterol;
LGG	cis	rs780096	0.565	rs8179252	chr2:27746832	A/C	cg02592271	chr2:27665507	KRTCAP3	-0.3	-8.01	-0.35	9.05e-15	Total body bone mineral density;
LGG	cis	rs1355223	0.506	rs1509659	chr11:34865133	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.41	-0.36	5.08e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4862750	0.872	rs56389997	chr4:187894796	A/C	cg27532560	chr4:187881888	NA	-0.59	-12.81	-0.51	2.31e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1552244	0.935	rs35148833	chr3:10116937	C/A	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs7511006	1.000	rs5771109	chr22:50678571	T/C	cg16473166	chr22:50639996	SELO	0.59	9.88	0.42	5.22e-21	Obesity-related traits;
LGG	cis	rs9296092	0.560	rs62407569	chr6:33538865	A/G	cg13560919	chr6:33536144	NA	-1.05	-21.28	-0.7	1.32e-70	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg23758822	chr17:41437982	NA	0.9	15.9	0.59	9.66e-46	Menopause (age at onset);
LGG	cis	rs757081	0.667	rs34724588	chr11:17137581	T/C	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.87	-0.38	1.59e-17	Systolic blood pressure;
LGG	cis	rs13082711	0.911	rs2172298	chr3:27425611	T/C	cg02860705	chr3:27208620	NA	0.71	13.0	0.52	3.69e-33	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7572733	0.935	rs1607376	chr2:198827914	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.3	0.36	1.18e-15	Dermatomyositis;
LGG	trans	rs916888	0.610	rs199436	chr17:44789285	C/T	cg07870213	chr5:140052090	DND1	-0.69	-13.45	-0.53	4.62e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7827545	1.000	rs4909911	chr8:135565255	G/A	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs62400317	0.859	rs12203558	chr6:45244423	C/G	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs6977660	0.619	rs10271639	chr7:19779604	G/A	cg07541023	chr7:19748670	TWISTNB	0.52	7.98	0.35	1.18e-14	Thyroid stimulating hormone;
LGG	cis	rs3820928	0.839	rs13398103	chr2:227859693	T/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.48	-0.33	3.68e-13	Pulmonary function;
LGG	cis	rs1506636	1.000	rs60689684	chr7:123370403	C/T	cg03229431	chr7:123269106	ASB15	0.72	17.06	0.62	5.28e-51	Plateletcrit;Platelet count;
LGG	cis	rs13088645	0.532	rs12695612	chr3:134161824	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.49	8.36	0.36	7.15e-16	Coronary artery disease;
LGG	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.05	0.35	7.14e-15	Homoarginine levels;
LGG	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.09	0.35	5.3e-15	Neuroticism;
LGG	cis	rs977987	0.778	rs8057849	chr16:75443816	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg02977157	chr20:13765764	C20orf7;ESF1	-0.38	-6.73	-0.3	4.99e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs2640806	0.505	rs13265799	chr8:97360472	C/G	cg22138393	chr8:97340270	PTDSS1	0.28	7.09	0.31	5.06e-12	Obesity-related traits;
LGG	cis	rs1729951	0.575	rs16844326	chr3:136678385	G/C	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	6.24e-21	Neuroticism;
LGG	cis	rs6582630	0.576	rs4882258	chr12:38453686	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.18	-0.39	1.44e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.56	10.04	0.42	1.35e-21	Longevity;
LGG	cis	rs12421382	0.616	rs2357795	chr11:109381135	C/T	cg15948088	chr11:109293068	C11orf87	0.5	8.75	0.38	4.14e-17	Schizophrenia;
LGG	cis	rs763014	1.000	rs763014	chr16:675680	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.53	0.53	2.11e-35	Height;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg22535103	chr8:58192502	C8orf71	0.9	12.51	0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.917	rs9284148	chr11:5973185	G/C	cg13902645	chr11:5959945	NA	-0.74	-11.33	-0.47	1.97e-26	DNA methylation (variation);
LGG	cis	rs4639966	0.797	rs68097885	chr11:118596444	G/A	cg20309703	chr11:118481025	PHLDB1	-0.51	-7.34	-0.32	9.38e-13	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9790314	0.521	rs1376122	chr3:161087857	A/G	cg04691961	chr3:161091175	C3orf57	-0.53	-11.31	-0.47	2.37e-26	Morning vs. evening chronotype;
LGG	cis	rs11758351	1.000	rs1341759	chr6:26195502	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs73086581	1.000	rs73086508	chr20:3921715	C/T	cg02187196	chr20:3869020	PANK2	0.82	11.46	0.47	6.39e-27	Response to antidepressants in depression;
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.32	-6.86	-0.3	2.29e-11	Personality dimensions;
LGG	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.15	0.32	3.45e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg05368731	chr17:41323189	NBR1	0.95	18.5	0.65	1.23e-57	Menopause (age at onset);
LGG	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg16141378	chr3:129829833	LOC729375	0.39	8.54	0.37	1.94e-16	Neuroticism;
LGG	cis	rs765787	0.530	rs2413784	chr15:45530516	A/C	cg25801113	chr15:45476975	SHF	0.87	19.89	0.68	4.48e-64	Uric acid levels;
LGG	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.52	-0.33	2.9e-13	Coronary artery disease;
LGG	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg05163923	chr11:71159392	DHCR7	-0.63	-10.87	-0.45	1.18e-24	Vitamin D levels;
LGG	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg26924012	chr15:45694286	SPATA5L1	1.04	21.4	0.71	3.69e-71	Homoarginine levels;
LGG	trans	rs3858145	0.588	rs2305083	chr10:70044937	C/A	cg04882175	chr6:131122610	NA	-0.57	-8.11	-0.35	4.73e-15	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	cis	rs10189230	0.967	rs1367241	chr2:222353413	G/A	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.85e-32	Urate levels in lean individuals;
LGG	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.08	-0.46	1.88e-25	Hemoglobin concentration;
LGG	cis	rs950776	0.518	rs12902493	chr15:78819275	C/G	cg06917634	chr15:78832804	PSMA4	0.83	17.7	0.64	6.47e-54	Sudden cardiac arrest;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg07701084	chr6:150067640	NUP43	0.69	12.37	0.5	1.41e-30	Lung cancer;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg05665937	chr4:1216051	CTBP1	0.5	9.17	0.39	1.57e-18	Obesity-related traits;
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg15691649	chr6:25882328	NA	-0.39	-6.86	-0.3	2.16e-11	Uric acid levels;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.66	-0.37	7.73e-17	Personality dimensions;
LGG	trans	rs1493916	0.807	rs10775455	chr18:31310761	A/C	cg27147174	chr7:100797783	AP1S1	-0.63	-11.28	-0.46	2.95e-26	Life satisfaction;
LGG	cis	rs425535	0.653	rs416176	chr4:74826269	G/T	cg01447579	chr4:74847100	PF4	0.55	6.67	0.3	7.09e-11	Blood protein levels;
LGG	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.7	-0.37	5.86e-17	Alcohol dependence;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.85	0.42	6.62e-21	Skin colour saturation;
LGG	cis	rs10504229	0.683	rs882429	chr8:58129292	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs16942000	chr15:45633003	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.16	0.72	1.07e-74	Homoarginine levels;
LGG	cis	rs60871478	1.000	rs34761279	chr7:794471	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.86	0.3	2.15e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs4845570	1.000	rs3811415	chr1:151763767	C/T	cg07092448	chr1:151763213	TDRKH	-1.15	-17.42	-0.63	1.25e-52	Coronary artery disease;
LGG	cis	rs7727544	0.904	rs58835386	chr5:131600559	A/G	cg07395648	chr5:131743802	NA	-0.52	-11.91	-0.48	1.01e-28	Blood metabolite levels;
LGG	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-9.78	-0.41	1.17e-20	Response to antipsychotic treatment;
LGG	cis	rs5756391	0.546	rs1807546	chr22:37311425	A/C	cg21209356	chr22:37319042	CSF2RB	0.4	9.11	0.39	2.46e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1865760	0.929	rs9358896	chr6:25943197	C/A	cg03264133	chr6:25882463	NA	-0.41	-7.15	-0.32	3.3e-12	Height;
LGG	cis	rs6502050	0.698	rs36043222	chr17:80117822	G/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs7937612	1.000	rs10892566	chr11:120241923	T/C	cg24566217	chr11:120254723	ARHGEF12	-0.54	-12.93	-0.52	7.14e-33	Intraocular pressure;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.65	-0.44	7.5e-24	Longevity;Endometriosis;
LGG	trans	rs783540	0.967	rs1145173	chr15:83223425	A/G	cg16105309	chr15:79090380	ADAMTS7	0.45	7.84	0.34	3.08e-14	Schizophrenia;
LGG	trans	rs7819412	0.691	rs73198970	chr8:11040216	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.99	-0.35	1.08e-14	Triglycerides;
LGG	cis	rs7927771	1.000	rs4752797	chr11:47874364	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-7.95	-0.35	1.39e-14	Subjective well-being;
LGG	cis	rs2404602	0.536	rs1587381	chr15:76769620	G/A	cg26408565	chr15:76604113	ETFA	-0.4	-6.87	-0.3	2.14e-11	Blood metabolite levels;
LGG	cis	rs72781680	0.756	rs2551337	chr2:24006886	C/T	cg08917208	chr2:24149416	ATAD2B	0.64	8.23	0.36	1.98e-15	Lymphocyte counts;
LGG	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs7766436	0.687	rs10485012	chr6:22607026	A/C	cg13666174	chr6:22585274	NA	-0.38	-8.88	-0.38	1.44e-17	Coronary artery disease;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg05692746	chr2:100937584	LONRF2	-0.65	-11.85	-0.48	1.81e-28	Intelligence (multi-trait analysis);
LGG	cis	rs12422267	0.536	rs7976530	chr12:132609140	C/T	cg08270023	chr12:132619174	NA	-0.43	-7.13	-0.31	3.87e-12	Plasma amyloid beta peptide concentrations (ABx-40);
LGG	cis	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs1994135	0.647	rs66542958	chr12:33695385	T/G	cg13010199	chr12:38710504	ALG10B	0.54	9.52	0.4	9.43e-20	Resting heart rate;
LGG	cis	rs11997175	0.574	rs4389890	chr8:33658018	C/T	ch.8.33884649F	chr8:33765107	NA	0.39	7.19	0.32	2.59e-12	Body mass index;
LGG	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg13770153	chr20:60521292	NA	-0.51	-8.22	-0.36	2.11e-15	Body mass index;
LGG	cis	rs9788333	0.707	rs12584557	chr13:21886171	C/A	cg13903179	chr13:21900392	NA	0.45	8.51	0.37	2.52e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg00745463	chr17:30367425	LRRC37B	0.48	7.07	0.31	5.89e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs801193	1.000	rs10234018	chr7:66146284	A/T	cg11764359	chr7:65958608	NA	-0.62	-10.56	-0.44	1.73e-23	Aortic root size;
LGG	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg22517653	chr1:2918612	NA	-0.43	-6.87	-0.3	2.1e-11	Plateletcrit;
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.46e-16	Life satisfaction;
LGG	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg09085632	chr11:111637200	PPP2R1B	0.85	15.32	0.58	3.67e-43	Primary sclerosing cholangitis;
LGG	trans	rs12579753	0.879	rs11115007	chr12:82164673	A/T	cg07923666	chr12:49932857	KCNH3	-0.48	-7.48	-0.33	3.83e-13	Resting heart rate;
LGG	cis	rs754466	0.958	rs11002341	chr10:79701363	A/C	cg17075019	chr10:79541650	NA	-0.8	-13.51	-0.53	2.62e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs968567	0.501	rs174553	chr11:61575158	A/G	cg19610905	chr11:61596333	FADS2	-0.8	-14.73	-0.56	1.53e-40	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.39	-0.36	5.75e-16	Neuroticism;
LGG	cis	rs7249142	0.562	rs10854009	chr19:19284705	A/C	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.82	-0.42	8.23e-21	IgG glycosylation;
LGG	trans	rs2197308	0.605	rs2387437	chr12:37919367	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.15e-20	Morning vs. evening chronotype;
LGG	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg09754948	chr16:28834200	ATXN2L	0.42	6.71	0.3	5.56e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7223966	1.000	rs56383601	chr17:61929968	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.28	0.32	1.42e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8180040	0.545	rs9311403	chr3:47138878	T/C	cg27129171	chr3:47204927	SETD2	0.82	15.03	0.57	7.5e-42	Colorectal cancer;
LGG	cis	rs6993813	0.872	rs10505351	chr8:120033998	C/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs1865760	0.625	rs9393681	chr6:26008260	A/G	cg18357526	chr6:26021779	HIST1H4A	0.49	8.32	0.36	9.93e-16	Height;
LGG	trans	rs3808502	0.585	rs4549730	chr8:11239078	T/G	cg02002194	chr4:3960332	NA	0.42	7.58	0.33	1.85e-13	Neuroticism;
LGG	trans	rs9914544	0.524	rs8071147	chr17:18790678	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03264133	chr6:25882463	NA	-0.53	-9.99	-0.42	2.04e-21	Blood metabolite levels;
LGG	cis	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg06636001	chr8:8085503	FLJ10661	0.67	13.43	0.53	5.74e-35	Neuroticism;
LGG	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg16395133	chr6:150326394	RAET1K	0.27	6.77	0.3	4e-11	Alopecia areata;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs10484885	0.887	rs17764308	chr6:90602268	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.81	-11.29	-0.46	2.93e-26	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6430585	0.528	rs309120	chr2:136708787	G/C	cg07169764	chr2:136633963	MCM6	1.14	20.28	0.69	6.98e-66	Corneal structure;
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs61990749	0.597	rs1477262	chr14:78226653	G/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.02	0.31	7.73e-12	Fibroblast growth factor basic levels;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg01114163	chr5:1856713	NA	-0.39	-6.77	-0.3	3.91e-11	Cardiovascular disease risk factors;
LGG	trans	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg21582582	chr3:182698605	DCUN1D1	0.52	9.74	0.41	1.59e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.892	rs32842	chr5:102478002	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.54	-0.33	2.47e-13	Parkinson's disease;
LGG	cis	rs1385374	0.642	rs10847691	chr12:129287449	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	6.87	0.3	2.08e-11	Systemic lupus erythematosus;
LGG	cis	rs9807989	0.507	rs6710034	chr2:103023678	G/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs1797081	1.000	rs1797081	chr10:16874565	A/G	cg22980697	chr10:16874865	CUBN	0.37	7.09	0.31	5.21e-12	Platelet distribution width;
LGG	cis	rs7937682	1.000	rs7937682	chr11:111579939	C/G	cg22437258	chr11:111473054	SIK2	0.59	9.83	0.42	7.69e-21	Primary sclerosing cholangitis;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13012494	chr21:47604986	C21orf56	0.55	9.64	0.41	3.55e-20	Testicular germ cell tumor;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg16920238	chr17:80076378	CCDC57	-0.33	-7.35	-0.32	8.91e-13	Life satisfaction;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	trans	rs2562456	0.833	rs62109223	chr19:21532393	C/T	cg00806126	chr19:22604979	ZNF98	-0.58	-7.63	-0.33	1.39e-13	Pain;
LGG	cis	rs58688157	0.705	rs11539530	chr11:609353	G/A	cg16486109	chr11:613632	IRF7	0.42	7.03	0.31	7.36e-12	Systemic lupus erythematosus;
LGG	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg21659725	chr3:3221576	CRBN	0.54	9.43	0.4	2.04e-19	Body mass index;
LGG	cis	rs4478858	0.684	rs16834336	chr1:31751512	G/A	cg19084893	chr1:31688959	NA	0.31	6.67	0.3	7.54e-11	Alcohol dependence;
LGG	cis	rs17208368	0.723	rs4784469	chr16:55090609	T/A	cg11181171	chr16:55090946	NA	0.47	7.04	0.31	6.95e-12	Hypospadias;
LGG	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg00426182	chr6:28072559	NA	0.93	6.96	0.31	1.21e-11	Hip circumference adjusted for BMI;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11698762	chr2:74648964	WDR54	0.51	7.84	0.34	3.14e-14	Gut microbiome composition (summer);
LGG	cis	rs2734839	0.964	rs2734833	chr11:113292920	G/A	cg14159747	chr11:113255604	NA	0.27	7.13	0.31	3.86e-12	Information processing speed;
LGG	cis	rs911555	0.755	rs4143998	chr14:103955247	T/C	cg24130564	chr14:104152367	KLC1	-0.39	-7.19	-0.32	2.59e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs3008870	1.000	rs12137403	chr1:67437043	C/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.73	-0.3	5e-11	Lymphocyte percentage of white cells;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg06371346	chr10:52283680	SGMS1	-0.35	-6.67	-0.3	7.44e-11	Apolipoprotein A-IV levels;
LGG	cis	rs17401966	0.838	rs912963	chr1:10348042	C/T	cg19773385	chr1:10388646	KIF1B	-0.46	-9.84	-0.42	7.29e-21	Hepatocellular carcinoma;
LGG	cis	rs7312774	0.748	rs1861746	chr12:107301518	G/A	cg16260113	chr12:107380972	MTERFD3	0.65	6.85	0.3	2.4e-11	Severe influenza A (H1N1) infection;
LGG	cis	rs9611565	0.765	rs132909	chr22:41802031	G/A	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	cis	rs6977940	0.818	rs73033457	chr7:2899235	C/A	cg19731401	chr7:2775893	GNA12	0.37	6.9	0.31	1.73e-11	White matter integrity;
LGG	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg22044901	chr15:68126292	NA	-0.44	-7.23	-0.32	2.05e-12	Restless legs syndrome;
LGG	cis	rs3106136	0.967	rs13135934	chr4:95207688	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.13	-0.35	4.01e-15	Capecitabine sensitivity;
LGG	cis	rs1552244	1.000	rs7651058	chr3:10066964	C/T	cg00149659	chr3:10157352	C3orf10	0.84	10.61	0.44	1.1e-23	Alzheimer's disease;
LGG	cis	rs7917772	0.503	rs10883732	chr10:104293461	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs4555082	1.000	rs7146012	chr14:105757566	G/A	cg27165867	chr14:105738592	BRF1	-0.45	-7.75	-0.34	5.81e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11696845	0.966	rs6073535	chr20:43373859	T/C	cg25301532	chr20:43378953	KCNK15	0.35	7.66	0.34	1.11e-13	Obesity-related traits;
LGG	cis	rs10173297	0.686	rs62108696	chr2:3707852	T/C	cg14882966	chr2:3699353	NA	0.59	7.48	0.33	3.89e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs933688	0.938	rs6869048	chr5:90664322	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.53	0.67	2.08e-62	Smoking behavior;
LGG	cis	rs4808199	0.895	rs12981405	chr19:19651577	C/T	cg03709012	chr19:19516395	GATAD2A	1.06	15.13	0.58	2.52e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs10823500	0.748	rs7072230	chr10:71978144	A/G	cg02100629	chr10:71892760	AIFM2	-0.29	-6.88	-0.3	1.96e-11	Blood protein levels;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg02158880	chr13:53174818	NA	0.37	7.0	0.31	9.18e-12	Lewy body disease;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.79	-0.3	3.48e-11	Neuroticism;
LGG	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.45	0.37	3.84e-16	Diabetic retinopathy;
LGG	cis	rs368123	1.000	rs622624	chr6:160716932	G/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.27	-0.32	1.57e-12	Waist circumference;
LGG	cis	rs2046867	0.661	rs7637050	chr3:72910790	A/C	cg25664220	chr3:72788482	NA	-0.28	-8.1	-0.35	4.78e-15	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg20453264	chr5:131705742	SLC22A5	0.62	7.97	0.35	1.26e-14	Rheumatoid arthritis;
LGG	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg12856521	chr11:46389249	DGKZ	-0.5	-9.06	-0.39	3.78e-18	Leprosy;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg03740221	chr16:89603733	SPG7	-0.3	-7.36	-0.32	8.41e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26480543	chr19:55629279	PPP1R12C	0.55	8.42	0.36	4.63e-16	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs916888	0.610	rs199446	chr17:44813169	G/A	cg17911788	chr17:44343683	NA	-0.47	-7.98	-0.35	1.13e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7326068	0.524	rs7998500	chr13:21159000	A/G	cg04906043	chr13:21280425	IL17D	-0.4	-6.95	-0.31	1.24e-11	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs67311347	0.956	rs13066971	chr3:40462510	A/T	cg13683864	chr3:40499215	RPL14	1.04	23.25	0.73	8.77e-80	Renal cell carcinoma;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg08677398	chr8:58056175	NA	0.51	7.89	0.34	2.25e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.559	rs79026644	chr7:107031803	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.46	-0.44	4.04e-23	Coronary artery disease;
LGG	cis	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.31	0.55	1.03e-38	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7618501	1.000	rs3749240	chr3:49750188	T/A	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.73	-0.41	1.71e-20	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.572	rs3894322	chr3:10168965	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.12	15.12	0.57	3.02e-42	Alzheimer's disease;
LGG	cis	rs1461503	0.900	rs7102462	chr11:122828767	C/G	cg27398637	chr11:122830231	C11orf63	-0.74	-15.23	-0.58	9.62e-43	Menarche (age at onset);
LGG	cis	rs34172651	0.876	rs7186893	chr16:24806420	G/T	cg00339695	chr16:24857497	SLC5A11	0.34	6.79	0.3	3.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs881375	0.967	rs2416805	chr9:123676482	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.96	0.49	6.25e-29	Rheumatoid arthritis;
LGG	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-11.06	-0.46	2.26e-25	Chronic sinus infection;
LGG	cis	rs4740619	0.819	rs2663300	chr9:15583444	G/C	cg14451791	chr9:16040625	NA	-0.35	-9.1	-0.39	2.6e-18	Body mass index;
LGG	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg08222618	chr4:941054	TMEM175	0.7	13.4	0.53	7.7e-35	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs796364	1.000	rs769949	chr2:200729558	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs208520	0.690	rs12202401	chr6:66760544	A/G	cg07460842	chr6:66804631	NA	0.96	18.02	0.64	2.24e-55	Exhaled nitric oxide output;
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.03	-0.31	7.61e-12	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22167839	chr7:35840133	SEPT7	0.41	6.91	0.31	1.61e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9308731	0.966	rs1877331	chr2:111906510	G/A	cg19992207	chr2:111874495	ACOXL	-0.39	-7.24	-0.32	1.83e-12	Chronic lymphocytic leukemia;
LGG	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs1552244	0.554	rs7349576	chr3:10050893	T/C	cg00149659	chr3:10157352	C3orf10	0.59	8.35	0.36	7.75e-16	Alzheimer's disease;
LGG	cis	rs1949733	1.000	rs3103072	chr4:8508431	C/T	cg11789530	chr4:8429930	ACOX3	-0.86	-17.01	-0.62	9.39e-51	Response to antineoplastic agents;
LGG	cis	rs365132	0.905	rs353463	chr5:176403170	A/C	cg16309518	chr5:176445507	NA	-0.51	-11.21	-0.46	5.51e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs853679	0.517	rs9295761	chr6:28147987	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	9.16e-14	Depression;
LGG	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg22398616	chr13:53314203	LECT1	0.44	8.54	0.37	1.95e-16	Lewy body disease;
LGG	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs7159888	0.577	rs1269068	chr14:65767333	A/G	cg15999311	chr14:65749247	NA	-0.45	-7.89	-0.34	2.15e-14	IgG glycosylation;N-glycan levels;
LGG	cis	rs3789045	0.560	rs1107339	chr1:204411942	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.59	-10.78	-0.45	2.41e-24	Educational attainment (college completion);
LGG	cis	rs7552404	1.000	rs9662166	chr1:76235906	C/A	cg03433033	chr1:76189801	ACADM	0.75	12.09	0.49	1.93e-29	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7927592	0.913	rs10896329	chr11:68250029	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.2	-0.36	2.31e-15	Total body bone mineral density;
LGG	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg19824325	chr16:58548873	SETD6	1.22	11.06	0.46	2.08e-25	Schizophrenia;
LGG	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg02002194	chr4:3960332	NA	0.52	9.86	0.42	5.94e-21	Retinal vascular caliber;
LGG	cis	rs9814567	0.752	rs13075117	chr3:134329535	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.61	10.53	0.44	2.09e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6964587	1.000	rs9690778	chr7:91735299	A/G	cg17063962	chr7:91808500	NA	0.5	9.09	0.39	2.89e-18	Breast cancer;
LGG	trans	rs941408	0.515	rs1736193	chr19:2785273	G/C	cg19676328	chr12:49525230	TUBA1B	-0.55	-8.03	-0.35	7.96e-15	Total cholesterol levels;
LGG	cis	rs611744	0.935	rs679077	chr8:109244742	G/T	cg21045802	chr8:109455806	TTC35	0.38	6.79	0.3	3.38e-11	Dupuytren's disease;
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg07308232	chr7:1071921	C7orf50	-0.68	-13.61	-0.53	1.03e-35	Longevity;Endometriosis;
LGG	cis	rs6121246	0.909	rs6058450	chr20:30343911	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	12.69	0.51	6.98e-32	Mean corpuscular hemoglobin;
LGG	cis	rs4622507	0.821	rs12927600	chr16:55045947	C/A	cg09947736	chr16:55091198	NA	0.62	10.2	0.43	3.45e-22	Social communication problems;
LGG	cis	rs11252926	0.545	rs1551508	chr10:555469	A/G	cg16386425	chr10:429943	DIP2C	-0.37	-7.43	-0.33	5.31e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs16854884	0.657	rs62269895	chr3:143749085	C/G	cg06585982	chr3:143692056	C3orf58	0.61	10.62	0.44	9.8599999999999993e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs657075	0.757	rs3805665	chr5:131644718	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs2795502	0.882	rs2744095	chr10:43337949	A/T	cg27426351	chr10:43362370	NA	-0.53	-7.44	-0.33	5.09e-13	Blood protein levels;
LGG	cis	rs908922	0.676	rs4112786	chr1:152532872	T/A	cg20991723	chr1:152506922	NA	-0.7	-14.4	-0.56	4.27e-39	Hair morphology;
LGG	cis	rs9815354	0.680	rs73073288	chr3:42027637	G/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs888194	0.544	rs7316486	chr12:109849540	A/G	cg19025524	chr12:109796872	NA	-0.52	-10.37	-0.43	8.26e-23	Neuroticism;
LGG	trans	rs7762018	0.660	rs78181018	chr6:170096652	A/C	cg06875740	chr19:51307921	C19orf48	-0.67	-6.73	-0.3	5.17e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1865760	0.532	rs9295687	chr6:26082710	T/C	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg22920501	chr2:26401640	FAM59B	-0.4	-8.01	-0.35	9.71e-15	Gut microbiome composition (summer);
LGG	cis	rs950776	0.518	rs4887062	chr15:78837801	G/A	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.67	-0.3	7.24e-11	Sudden cardiac arrest;
LGG	cis	rs9611565	0.570	rs12159188	chr22:42121125	A/T	cg06634786	chr22:41940651	POLR3H	0.67	10.94	0.45	6.13e-25	Vitiligo;
LGG	trans	rs2727020	0.521	rs11040377	chr11:49474346	T/C	cg15704280	chr7:45808275	SEPT13	-0.75	-13.76	-0.54	2.28e-36	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11877825	0.865	rs34956381	chr18:10571021	G/A	cg25239095	chr18:10589360	NA	0.48	8.95	0.38	8.72e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg12573674	chr2:1569213	NA	-0.62	-9.15	-0.39	1.76e-18	IgG glycosylation;
LGG	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.22	0.39	1.07e-18	Rheumatoid arthritis;
LGG	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg09021430	chr5:549028	NA	-0.75	-10.52	-0.44	2.3e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs137603	0.966	rs137585	chr22:39683444	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.48	-7.97	-0.35	1.23e-14	Primary biliary cholangitis;
LGG	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg00579200	chr11:133705235	NA	-0.58	-11.15	-0.46	9.97e-26	Childhood ear infection;
LGG	cis	rs7582180	0.629	rs12617779	chr2:100937707	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.702	rs28699233	chr15:44122866	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	8.65	0.37	8.25e-17	Lung cancer in ever smokers;
LGG	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs1577917	0.682	rs6935918	chr6:86283575	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.33	0.36	9e-16	Response to antipsychotic treatment;
LGG	cis	rs9359856	0.673	rs1179901	chr6:90321196	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.83	-0.34	3.28e-14	Bipolar disorder;
LGG	cis	rs6450176	0.633	rs25858	chr5:53339518	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.7	-0.48	7.11e-28	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	0.5	8.5	0.37	2.62e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs7615952	0.866	rs6438949	chr3:125650064	G/C	cg07211511	chr3:129823064	LOC729375	-1.28	-19.85	-0.68	7.11e-64	Blood pressure (smoking interaction);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg12292947	chr7:47343625	TNS3	-0.34	-7.23	-0.32	2.02e-12	Corneal astigmatism;
LGG	cis	rs1420338	0.967	rs10272282	chr7:34172073	C/T	cg01275685	chr7:34179230	BMPER	-0.5	-8.88	-0.38	1.51e-17	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs4363385	0.765	rs3806221	chr1:153002555	G/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	cis	rs36715	0.904	rs36701	chr5:127552529	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.45	7.06	0.31	6.24e-12	Breast cancer;
LGG	cis	rs10901296	0.702	rs11244178	chr9:133766008	C/T	cg03924115	chr9:133768966	QRFP	-0.44	-6.7	-0.3	6.02e-11	Bilirubin levels;
LGG	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg16096631	chr1:42092165	HIVEP3	0.6	14.7	0.56	1.94e-40	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs72945132	0.562	rs7951959	chr11:70234272	A/G	cg14191688	chr11:70257035	CTTN	0.56	8.42	0.36	4.84e-16	Coronary artery disease;
LGG	trans	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.95	-0.31	1.28e-11	Joint mobility (Beighton score);
LGG	cis	rs4819052	0.851	rs35064782	chr21:46674360	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.0	0.52	3.85e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6840360	0.571	rs17275536	chr4:152498625	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.39	-0.36	5.81e-16	Intelligence (multi-trait analysis);
LGG	trans	rs6575793	0.512	rs6575791	chr14:101029203	A/G	cg09399377	chr6:136611038	BCLAF1	-0.47	-7.47	-0.33	3.94e-13	Menarche (age at onset);
LGG	cis	rs1419980	0.673	rs4883421	chr12:7774028	A/G	cg10578777	chr12:7781093	NA	0.59	7.97	0.35	1.25e-14	HDL cholesterol levels;
LGG	cis	rs2282300	0.739	rs1222219	chr11:30344345	G/C	cg25418670	chr11:30344373	C11orf46	-0.57	-7.91	-0.35	1.85e-14	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs61884328	0.777	rs17790420	chr11:47169555	G/A	cg03339077	chr11:47165057	C11orf49	0.62	6.66	0.3	7.63e-11	Total body bone mineral density (age over 60);
LGG	cis	rs3762637	1.000	rs9882100	chr3:122169908	T/C	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs10504229	0.593	rs17192845	chr8:58053339	C/T	cg02725872	chr8:58115012	NA	-0.97	-12.73	-0.51	4.94e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs11693319	1.000	rs67113930	chr2:179741348	A/G	cg17765952	chr2:179737173	CCDC141	0.58	9.45	0.4	1.65e-19	Blood pressure measurement (cold pressor test);
LGG	cis	rs1847505	0.562	rs1606647	chr13:61416304	A/G	cg25164009	chr13:61490935	NA	0.56	9.42	0.4	2.17e-19	Polychlorinated biphenyl levels;
LGG	cis	rs686320	0.667	rs550015	chr11:65186348	A/G	cg17392047	chr11:65247138	NA	-0.54	-6.96	-0.31	1.14e-11	Hip circumference adjusted for BMI;
LGG	cis	rs3820068	0.705	rs4646077	chr1:15827136	C/T	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs1580019	0.562	rs4720064	chr7:32559638	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.97	0.31	1.11e-11	Cognitive ability;
LGG	cis	rs35306767	0.953	rs1539174	chr10:974870	C/G	cg25019033	chr10:957182	NA	-0.6	-12.54	-0.5	3.02e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs10256972	0.616	rs7806746	chr7:1075573	A/C	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.12	-0.39	2.24e-18	Longevity;Endometriosis;
LGG	cis	rs8005677	1.000	rs4982709	chr14:23394699	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-6.92	-0.31	1.51e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs914187	1.000	rs914187	chr21:42619749	A/G	cg21268422	chr21:42620091	BACE2	0.7	14.01	0.55	1.91e-37	Body mass index;
LGG	cis	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg04455712	chr21:45112962	RRP1B	0.48	9.12	0.39	2.36e-18	Mean corpuscular volume;
LGG	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.9	-0.31	1.77e-11	Hip circumference adjusted for BMI;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.93	-0.38	1.01e-17	Lymphocyte counts;
LGG	cis	rs6732160	0.619	rs12105975	chr2:73406049	T/A	cg01422370	chr2:73384389	NA	0.49	9.26	0.4	7.88e-19	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.5	9.42	0.4	2.11e-19	Obesity-related traits;
LGG	cis	rs3813567	0.759	rs12148319	chr15:78956192	A/G	cg05914723	chr15:78953907	NA	0.49	6.99	0.31	9.73e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg12458913	chr13:53173898	NA	0.56	10.1	0.42	8.15e-22	Lewy body disease;
LGG	cis	rs877282	0.898	rs10904547	chr10:766283	C/T	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.02e-11	Uric acid levels;
LGG	cis	rs2839186	0.564	rs4819215	chr21:47623573	G/A	cg12379764	chr21:47803548	PCNT	-0.51	-8.35	-0.36	7.87e-16	Testicular germ cell tumor;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.62	-11.91	-0.48	1.01e-28	Obesity-related traits;
LGG	cis	rs2901331	0.533	rs2174252	chr2:125418292	C/T	cg07771321	chr2:125368595	CNTNAP5	-0.46	-8.04	-0.35	7.54e-15	Response to statin therapy;
LGG	cis	rs6426558	0.537	rs2670462	chr1:227432923	C/G	cg10327440	chr1:227177885	CDC42BPA	-0.62	-10.2	-0.43	3.64e-22	Neutrophil percentage of white cells;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26149167	chr19:16187889	TPM4	0.42	6.82	0.3	2.8e-11	Menarche (age at onset);
LGG	cis	rs6909430	1.000	rs9372768	chr6:98671543	C/G	cg12860156	chr6:98744658	NA	-0.44	-7.39	-0.32	6.75e-13	Quantitative traits;
LGG	cis	rs12282928	1.000	rs10769339	chr11:48294296	T/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.65e-12	Migraine - clinic-based;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg02951883	chr7:2050386	MAD1L1	-0.65	-12.22	-0.49	5.61e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs73416724	1.000	rs17209407	chr6:43358362	A/G	cg26312998	chr6:43337775	ZNF318	0.59	8.43	0.36	4.32e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs75804782	0.641	rs2340870	chr2:239356026	C/T	cg01134436	chr17:81009848	B3GNTL1	0.84	8.83	0.38	2.25e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs12477438	0.834	rs6757019	chr2:99676936	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs1519814	1.000	rs4871045	chr8:121167814	T/C	cg22335954	chr8:121166405	COL14A1	-0.55	-11.1	-0.46	1.46e-25	Breast cancer;
LGG	cis	rs7762018	1.000	rs6923339	chr6:170128033	T/A	cg19338460	chr6:170058176	WDR27	-0.64	-8.59	-0.37	1.35e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg24829409	chr8:58192753	C8orf71	-0.78	-11.25	-0.46	3.97e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs3764563	1.000	rs8107240	chr19:15737392	A/G	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.36	-0.36	7.5e-16	Inflammatory biomarkers;
LGG	cis	rs11608355	0.515	rs11611011	chr12:109936948	C/T	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs11711311	0.866	rs13313893	chr3:113400856	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.42	0.53	6.42e-35	IgG glycosylation;
LGG	cis	rs2730245	0.527	rs62476462	chr7:158686619	A/G	cg14689365	chr7:158441557	NCAPG2	0.54	6.69	0.3	6.6e-11	Height;
LGG	cis	rs2274273	0.564	rs10140164	chr14:55406123	A/G	cg04306507	chr14:55594613	LGALS3	0.33	7.84	0.34	3.04e-14	Protein biomarker;
LGG	cis	rs769267	0.896	rs7250893	chr19:19625547	A/G	cg03709012	chr19:19516395	GATAD2A	0.84	16.83	0.62	6.17e-50	Tonsillectomy;
LGG	cis	rs17655565	1.000	rs60696802	chr12:52693176	C/T	cg08257133	chr12:52711352	KRT83	0.53	7.31	0.32	1.19e-12	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs2180341	0.814	rs9321085	chr6:127735361	T/C	cg24812749	chr6:127587940	RNF146	0.7	11.18	0.46	7.77e-26	Breast cancer;
LGG	cis	rs4268898	0.610	rs55860688	chr2:24451534	T/C	cg06627628	chr2:24431161	ITSN2	-0.77	-12.51	-0.5	3.85e-31	Asthma;
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.33	0.36	9.43e-16	Schizophrenia;
LGG	cis	rs9611565	0.649	rs5758344	chr22:41817685	G/A	cg03806693	chr22:41940476	POLR3H	1.08	19.59	0.67	1.06e-62	Vitiligo;
LGG	cis	rs1790761	0.505	rs7941395	chr11:67347417	A/G	cg09038676	chr11:67351608	GSTP1	0.36	7.06	0.31	5.97e-12	Mean corpuscular volume;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7107174	1.000	rs2510047	chr11:77988668	C/T	cg02023728	chr11:77925099	USP35	-0.44	-7.7	-0.34	8.05e-14	Testicular germ cell tumor;
LGG	cis	rs9303280	0.806	rs8069176	chr17:38057197	G/A	cg00129232	chr17:37814104	STARD3	-0.46	-8.38	-0.36	6.33e-16	Self-reported allergy;
LGG	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg26039829	chr8:22132926	PIWIL2	0.53	12.33	0.5	2.01e-30	Hypertriglyceridemia;
LGG	cis	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.66	-0.74	1.07e-81	Primary sclerosing cholangitis;
LGG	cis	rs1348850	0.632	rs10167783	chr2:178519041	G/A	cg27490568	chr2:178487706	NA	0.53	10.37	0.43	8.37e-23	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg08975724	chr8:8085496	FLJ10661	-0.49	-9.31	-0.4	5.26e-19	Triglycerides;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.51	-0.44	2.52e-23	IgG glycosylation;
LGG	cis	rs17401966	0.838	rs10492971	chr1:10342975	G/A	cg15208524	chr1:10270712	KIF1B	0.44	7.87	0.34	2.51e-14	Hepatocellular carcinoma;
LGG	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg13939156	chr17:80058883	NA	-0.4	-7.19	-0.32	2.6e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg06521331	chr12:34319734	NA	0.43	7.32	0.32	1.09e-12	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.562	rs9379211	chr6:8463927	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9815354	1.000	rs6763829	chr3:41897046	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7727544	0.606	rs11950562	chr5:131652529	A/C	cg24060327	chr5:131705240	SLC22A5	-0.42	-7.04	-0.31	7.06e-12	Blood metabolite levels;
LGG	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.37	-0.4	3.28e-19	Height;
LGG	cis	rs9811920	0.683	rs813218	chr3:99592596	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.43	7.51	0.33	3.16e-13	Axial length;
LGG	cis	rs240764	0.658	rs12174806	chr6:101219581	C/T	cg21058520	chr6:100914733	NA	0.39	6.78	0.3	3.74e-11	Neuroticism;
LGG	cis	rs9457247	0.765	rs9457251	chr6:167426707	T/C	cg07741184	chr6:167504864	NA	0.41	9.18	0.39	1.39e-18	Crohn's disease;
LGG	cis	rs1185460	0.546	rs592190	chr11:118955314	G/A	cg23280166	chr11:118938394	VPS11	-0.46	-7.84	-0.34	3.19e-14	Coronary artery disease;
LGG	cis	rs9393692	0.537	rs2393594	chr6:26316289	G/C	cg00631329	chr6:26305371	NA	-0.46	-7.68	-0.34	9.57e-14	Educational attainment;
LGG	cis	rs3733346	0.553	rs10008187	chr4:941017	C/T	cg08222618	chr4:941054	TMEM175	0.81	19.63	0.67	6.87e-63	Sjögren's syndrome;
LGG	trans	rs1962073	0.529	rs13258627	chr8:10274578	T/C	cg02002194	chr4:3960332	NA	-0.39	-6.66	-0.3	7.86e-11	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);
LGG	trans	rs6952808	1.000	rs6954673	chr7:1886937	C/T	cg24247370	chr13:99142703	STK24	-0.42	-7.59	-0.33	1.79e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs7939886	0.920	rs77391761	chr11:55814896	G/C	cg15704280	chr7:45808275	SEPT13	0.87	9.09	0.39	2.83e-18	Myopia (pathological);
LGG	cis	rs477692	1.000	rs473771	chr10:131408155	A/C	cg05714579	chr10:131428358	MGMT	0.56	11.41	0.47	9.95e-27	Response to temozolomide;
LGG	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs477895	1.000	rs2286614	chr11:64068310	C/T	cg22916017	chr11:64110731	CCDC88B	-0.49	-6.72	-0.3	5.45e-11	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs7820302	chr8:58142502	C/T	cg05313129	chr8:58192883	C8orf71	-0.71	-10.07	-0.42	1.1e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs5769707	0.609	rs2007024	chr22:49988815	C/T	cg06623630	chr22:50017776	C22orf34	-0.44	-8.97	-0.38	7.36e-18	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04730665	chr2:236403704	AGAP1	-0.41	-6.81	-0.3	3.11e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10754283	0.967	rs4658130	chr1:90113447	G/C	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7226408	0.600	rs7230559	chr18:34525019	T/C	cg15022739	chr18:34823045	BRUNOL4	0.41	8.82	0.38	2.32e-17	Obesity-related traits;
LGG	cis	rs763121	0.853	rs2072796	chr22:39064230	A/G	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs12282928	0.807	rs4980429	chr11:48298148	G/A	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg14664628	chr15:75095509	CSK	-0.56	-10.79	-0.45	2.21e-24	Breast cancer;
LGG	cis	rs7666738	0.830	rs7694889	chr4:98855596	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4789693	0.546	rs7220204	chr17:80376130	T/A	cg04308225	chr17:80449738	NA	0.48	7.46	0.33	4.31e-13	Glucocorticoid-induced osteonecrosis;
LGG	trans	rs2018683	0.700	rs13227954	chr7:29017188	A/C	cg19402173	chr7:128379420	CALU	0.7	12.1	0.49	1.84e-29	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs2836974	0.899	rs114399588	chr21:40653958	G/A	cg11644478	chr21:40555479	PSMG1	0.89	16.84	0.62	5.63e-50	Cognitive function;
LGG	cis	rs66573146	0.808	rs55942328	chr4:6990960	T/G	cg26116260	chr4:7069785	GRPEL1	-0.82	-7.4	-0.33	6.52e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9462027	0.651	rs4259246	chr6:34803947	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.29	-0.46	2.71e-26	Systemic lupus erythematosus;
LGG	cis	rs13082711	0.911	rs77037289	chr3:27512971	C/T	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.22e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6502050	0.723	rs8077209	chr17:80163221	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.62	-0.33	1.41e-13	Life satisfaction;
LGG	cis	rs12497850	1.000	rs6788650	chr3:48749543	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.86	0.3	2.21e-11	Parkinson's disease;
LGG	cis	rs4891159	0.527	rs689642	chr18:74119120	A/C	cg24786174	chr18:74118243	ZNF516	0.69	17.38	0.63	1.91e-52	Longevity;
LGG	cis	rs5017598	1.000	rs5017598	chr6:169211494	A/G	cg05672967	chr6:169256475	NA	0.56	8.82	0.38	2.32e-17	Pediatric bone mineral density (femoral neck);Pediatric bone mineral density (hip);
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg11878867	chr6:150167359	LRP11	-0.47	-9.78	-0.41	1.21e-20	Lung cancer;
LGG	cis	rs6752107	0.782	rs12692254	chr2:234161211	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.31	0.53	1.96e-34	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg05539622	chr2:73298971	SFXN5	-0.39	-6.91	-0.31	1.57e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs3008870	0.755	rs1024230	chr1:67512920	A/C	cg02640540	chr1:67518911	SLC35D1	0.58	11.64	0.48	1.24e-27	Lymphocyte percentage of white cells;
LGG	cis	rs240764	0.853	rs10457809	chr6:100984400	C/T	cg21058520	chr6:100914733	NA	0.42	7.19	0.32	2.59e-12	Neuroticism;
LGG	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06481639	chr22:41940642	POLR3H	0.59	8.55	0.37	1.86e-16	Vitiligo;
LGG	cis	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.51	-0.33	3.13e-13	Morning vs. evening chronotype;
LGG	cis	rs701145	0.938	rs701135	chr3:154065455	C/G	cg17054900	chr3:154042577	DHX36	0.99	12.36	0.5	1.63e-30	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs8176269	chr17:41213626	G/T	cg12708336	chr17:41446283	NA	-0.3	-6.97	-0.31	1.09e-11	Menopause (age at onset);
LGG	cis	rs67311347	1.000	rs9865348	chr3:40397658	A/C	cg13683864	chr3:40499215	RPL14	-0.99	-20.17	-0.68	2.23e-65	Renal cell carcinoma;
LGG	cis	rs3820928	0.935	rs113195824	chr2:227769139	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.38	-0.32	7.56e-13	Pulmonary function;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13765646	chr4:47708509	CORIN	0.39	6.85	0.3	2.42e-11	Menarche (age at onset);
LGG	cis	rs1978968	0.797	rs11703382	chr22:18481857	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.58	-11.94	-0.49	8.13e-29	Presence of antiphospholipid antibodies;
LGG	cis	rs847649	0.694	rs11770319	chr7:102770170	C/G	cg18108683	chr7:102477205	FBXL13	0.55	11.43	0.47	8.16e-27	Morning vs. evening chronotype;
LGG	cis	rs4665809	0.589	rs4665842	chr2:26448954	A/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs7949030	1.000	rs7949030	chr11:62394881	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.52	12.25	0.49	4.42e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6089829	0.925	rs13041507	chr20:61666180	T/C	cg08045932	chr20:61659980	NA	0.6	13.13	0.52	1.02e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2228479	0.702	rs62056092	chr16:89930426	A/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.45	-0.61	3.27e-48	Skin colour saturation;
LGG	cis	rs11650494	0.516	rs9907942	chr17:47513891	C/T	cg08112188	chr17:47440006	ZNF652	0.95	10.38	0.43	7.61e-23	Prostate cancer;
LGG	cis	rs1008375	0.932	rs13134570	chr4:17692863	C/T	cg18681998	chr4:17616180	MED28	-0.75	-14.97	-0.57	1.38e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1153858	1.000	rs4775907	chr15:45638647	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.75	0.34	5.92e-14	Homoarginine levels;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.09	17.83	0.64	1.66e-54	Platelet count;
LGG	cis	rs372883	0.648	rs1153291	chr21:30689070	G/T	cg24692254	chr21:30365293	RNF160	-0.56	-10.17	-0.43	4.54e-22	Pancreatic cancer;
LGG	cis	rs17666538	0.585	rs1669615	chr8:616665	T/C	cg13264159	chr8:625131	ERICH1	-1.04	-12.13	-0.49	1.39e-29	IgG glycosylation;
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg19524238	chr7:2802976	GNA12	0.37	8.73	0.38	4.75e-17	Height;
LGG	cis	rs11190604	1.000	rs7090431	chr10:102261753	A/G	cg07080220	chr10:102295463	HIF1AN	0.69	11.82	0.48	2.37e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7927592	0.913	rs7102898	chr11:68328870	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs2236267	0.726	rs1940551	chr14:88603859	T/C	cg02175263	chr14:88627849	NA	0.31	6.97	0.31	1.09e-11	Food antigen IgG levels;
LGG	cis	rs1005277	0.522	rs9418276	chr10:37940116	G/T	cg25427524	chr10:38739819	LOC399744	-0.62	-12.56	-0.5	2.32e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs4481887	0.927	rs7524700	chr1:248472816	A/G	cg01631408	chr1:248437212	OR2T33	-0.51	-9.29	-0.4	5.81e-19	Common traits (Other);
LGG	cis	rs11214589	0.774	rs877137	chr11:113256330	C/T	cg14159747	chr11:113255604	NA	0.32	8.67	0.37	7.34e-17	Neuroticism;
LGG	cis	rs4721295	0.546	rs1637766	chr7:2204400	G/A	cg00106254	chr7:1943704	MAD1L1	0.43	7.85	0.34	2.81e-14	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.88	-0.42	5.19e-21	Response to antipsychotic treatment;
LGG	cis	rs4330281	0.647	rs6577622	chr3:17724339	C/T	cg20981856	chr3:17787350	NA	0.4	7.66	0.34	1.13e-13	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27417846	chr2:88927289	EIF2AK3	0.44	7.29	0.32	1.37e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs13314892	0.881	rs58244283	chr3:69827001	T/A	cg17445875	chr3:69859618	MITF	-0.35	-7.15	-0.32	3.39e-12	QRS complex (12-leadsum);
LGG	cis	rs908922	0.676	rs1001834	chr1:152495940	C/A	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	cis	rs2836974	0.829	rs34227163	chr21:40551943	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.9	0.64	7.4e-55	Cognitive function;
LGG	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg25173405	chr17:45401733	C17orf57	0.48	8.41	0.36	5.1e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	1.000	rs77120900	chr8:58170368	C/T	cg08677398	chr8:58056175	NA	0.46	7.5	0.33	3.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4561483	0.549	rs154149	chr16:11956118	T/A	cg08843971	chr16:11963173	GSPT1	-0.61	-15.29	-0.58	5.3e-43	Testicular germ cell tumor;
LGG	cis	rs7538876	0.903	rs6675912	chr1:17769290	T/G	cg10329579	chr1:17754830	RCC2	-0.55	-10.55	-0.44	1.78e-23	Basal cell carcinoma;
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg27121462	chr16:89883253	FANCA	0.62	11.68	0.48	8.32e-28	Vitiligo;
LGG	cis	rs9972944	0.651	rs1819910	chr17:63814576	C/A	cg07283582	chr17:63770753	CCDC46	-0.38	-6.91	-0.31	1.57e-11	Total body bone mineral density;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg23131131	chr22:24373011	LOC391322	-0.47	-7.73	-0.34	6.57e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg18110333	chr6:292329	DUSP22	-0.7	-11.96	-0.49	6.58e-29	Menopause (age at onset);
LGG	cis	rs9611565	0.527	rs73178638	chr22:41942904	T/C	cg17376030	chr22:41985996	PMM1	0.6	9.34	0.4	4.19e-19	Vitiligo;
LGG	cis	rs6732160	0.845	rs6546805	chr2:73386115	G/T	cg01422370	chr2:73384389	NA	0.52	10.27	0.43	2e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs3892820	chr18:44479558	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.63	-0.33	1.35e-13	Personality dimensions;
LGG	cis	rs7084402	0.967	rs7098326	chr10:60276906	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.41	0.33	6.24e-13	Refractive error;
LGG	cis	rs11096990	0.855	rs2566172	chr4:39152563	G/A	cg24403649	chr4:39172243	NA	-0.49	-7.89	-0.34	2.26e-14	Cognitive function;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg19617948	chr20:30135124	HM13;PSIMCT-1	-0.37	-6.68	-0.3	7.08e-11	Lung adenocarcinoma;
LGG	cis	rs6540556	0.723	rs10863785	chr1:209908876	C/T	cg05527609	chr1:210001259	C1orf107	0.5	6.77	0.3	3.97e-11	Red blood cell count;
LGG	trans	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg08975724	chr8:8085496	FLJ10661	0.42	8.19	0.36	2.58e-15	Monocyte count;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg07786668	chr16:73092391	ZFHX3	0.43	7.23	0.32	2.03e-12	Body mass index;
LGG	cis	rs3784262	1.000	rs12903551	chr15:58268372	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.26	-0.36	1.57e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7781557	0.638	rs55781834	chr7:102572433	A/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.1	-0.35	5.06e-15	Colorectal adenoma (advanced);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08171195	chr1:155214570	GBA	0.46	6.75	0.3	4.48e-11	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08770590	chr10:112064742	SMNDC1	-0.46	-6.81	-0.3	2.96e-11	Gut microbiome composition (summer);
LGG	cis	rs1568889	0.877	rs1384903	chr11:28124359	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.7	10.96	0.45	5.25e-25	Bipolar disorder;
LGG	cis	rs4849845	0.637	rs13022486	chr2:121038611	C/T	cg15425061	chr2:121036351	RALB	0.37	6.89	0.3	1.84e-11	Mean platelet volume;
LGG	cis	rs9788682	1.000	rs35212593	chr15:78831826	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-9.76	-0.41	1.34e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg19006130	chr11:118478252	PHLDB1	0.4	7.09	0.31	5.01e-12	Cholesterol, total;
LGG	cis	rs889398	0.741	rs6499269	chr16:69908918	T/C	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.9	-0.31	1.71e-11	Body mass index;
LGG	trans	rs61931739	0.534	rs11053016	chr12:34104372	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs910316	1.000	rs12588240	chr14:75612083	C/A	cg11812906	chr14:75593930	NEK9	0.54	10.13	0.43	6.3e-22	Height;
LGG	cis	rs9790314	0.664	rs723757	chr3:160645435	C/T	cg04691961	chr3:161091175	C3orf57	0.43	9.16	0.39	1.64e-18	Morning vs. evening chronotype;
LGG	trans	rs28735056	0.933	rs499260	chr18:77589689	G/A	cg05926928	chr17:57297772	GDPD1	-0.48	-7.6	-0.33	1.68e-13	Schizophrenia;
LGG	trans	rs61931739	0.500	rs56056630	chr12:34543465	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs7819412	0.838	rs3021494	chr8:10983534	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.32	-0.32	1.11e-12	Triglycerides;
LGG	trans	rs2204008	0.744	rs11181337	chr12:38322083	C/A	cg06521331	chr12:34319734	NA	-0.53	-9.64	-0.41	3.77e-20	Bladder cancer;
LGG	cis	rs7474896	0.583	rs10764144	chr10:37975732	G/C	cg00409905	chr10:38381863	ZNF37A	-0.46	-7.43	-0.33	5.39e-13	Obesity (extreme);
LGG	cis	rs4423214	0.592	rs7120029	chr11:71198957	G/A	cg05163923	chr11:71159392	DHCR7	-0.58	-8.36	-0.36	7.46e-16	Vitamin D levels;
LGG	cis	rs644799	1.000	rs693597	chr11:95589629	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.47	7.91	0.34	1.93e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2832191	1.000	rs6516891	chr21:30483070	C/T	cg24692254	chr21:30365293	RNF160	-0.87	-20.05	-0.68	8.13e-65	Dental caries;
LGG	cis	rs7523273	0.565	rs1359147	chr1:207886150	C/T	cg22525895	chr1:207977042	MIR29B2	0.46	8.67	0.37	7.36e-17	Schizophrenia;
LGG	cis	rs2070677	0.935	rs4300354	chr10:135415890	C/T	cg20169779	chr10:135381914	SYCE1	-0.99	-12.87	-0.51	1.34e-32	Gout;
LGG	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	cis	rs589448	0.538	rs683790	chr12:69751434	T/G	cg14784868	chr12:69753453	YEATS4	0.75	12.7	0.51	6.18e-32	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.97	-0.31	1.06e-11	Bipolar disorder;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg05025164	chr4:1340916	KIAA1530	0.45	7.42	0.33	5.49e-13	Obesity-related traits;
LGG	cis	rs6598163	0.517	rs11246827	chr12:132296423	G/A	cg07389463	chr12:132296394	NA	0.61	14.11	0.55	7.06e-38	Migraine;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07185584	chr20:19997881	NAA20	0.52	7.84	0.34	3.02e-14	Gut microbiome composition (summer);
LGG	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.41	0.53	6.86e-35	Anterior chamber depth;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	trans	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg27411982	chr8:10470053	RP1L1	0.47	8.01	0.35	9.42e-15	Joint mobility (Beighton score);
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg26668828	chr6:292823	DUSP22	-0.69	-12.13	-0.49	1.38e-29	Menopause (age at onset);
LGG	cis	rs9660992	0.573	rs7531256	chr1:205191202	T/G	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg07751222	chr4:102268245	PPP3CA	-0.35	-6.74	-0.3	4.66e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.2	-0.39	1.28e-18	Neuroticism;
LGG	cis	rs10766496	0.778	rs60836767	chr11:18736571	T/C	cg02515468	chr11:18743222	IGSF22	-0.46	-7.54	-0.33	2.5e-13	Diabetic kidney disease;
LGG	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg01403660	chr11:68851641	TPCN2	0.52	7.27	0.32	1.55e-12	Blond vs. brown hair color;
LGG	cis	rs2985684	0.895	rs4900940	chr14:50075310	A/C	cg04989706	chr14:50066350	PPIL5	-0.55	-8.58	-0.37	1.48e-16	Carotid intima media thickness;
LGG	cis	rs672059	1.000	rs3120034	chr1:183167051	A/G	cg07928641	chr1:182991847	LAMC1	0.34	6.83	0.3	2.69e-11	Hypertriglyceridemia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg17408647	chr7:43769049	C7orf44	0.41	6.87	0.3	2.05e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs763014	1.000	rs8054842	chr16:672799	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.68	-0.59	9.59e-45	Height;
LGG	cis	rs6582630	0.519	rs12372510	chr12:38293074	T/C	cg26384229	chr12:38710491	ALG10B	0.9	19.85	0.68	6.59e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs757081	0.667	rs3950680	chr11:17138666	G/A	cg15432903	chr11:17409602	KCNJ11	-0.54	-8.87	-0.38	1.59e-17	Systolic blood pressure;
LGG	cis	rs546131	0.928	rs552627	chr11:34826680	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.61	10.86	0.45	1.22e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs897984	0.806	rs10782002	chr16:30946506	A/G	cg00531865	chr16:30841666	NA	0.56	12.05	0.49	2.81e-29	Dementia with Lewy bodies;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.74	0.34	6.12e-14	Rheumatoid arthritis;
LGG	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg03909863	chr11:638404	DRD4	-0.41	-6.86	-0.3	2.24e-11	Systemic lupus erythematosus;
LGG	cis	rs7044106	0.791	rs735109	chr9:123488879	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	0.42	6.71	0.3	5.57e-11	Hip circumference adjusted for BMI;
LGG	cis	rs514406	0.505	rs7543239	chr1:53162416	A/G	cg24675658	chr1:53192096	ZYG11B	-0.6	-13.22	-0.52	4.4e-34	Monocyte count;
LGG	trans	rs3780486	0.846	rs3780490	chr9:33129839	A/G	cg20290983	chr6:43655470	MRPS18A	1.12	24.98	0.76	7.49e-88	IgG glycosylation;
LGG	cis	rs8014204	0.967	rs4903266	chr14:75344941	C/G	cg03030879	chr14:75389066	RPS6KL1	0.38	6.92	0.31	1.47e-11	Caffeine consumption;
LGG	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg27454842	chr22:32027588	PISD	-0.6	-6.85	-0.3	2.33e-11	Age-related hearing impairment;
LGG	cis	rs757081	0.667	rs12577525	chr11:17260116	G/A	cg15432903	chr11:17409602	KCNJ11	-0.55	-9.11	-0.39	2.43e-18	Systolic blood pressure;
LGG	cis	rs6489882	0.867	rs4766664	chr12:113362997	T/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.36	-0.32	8.61e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.38	-0.32	7.3e-13	Lung cancer;
LGG	cis	rs7122539	0.646	rs714766	chr11:66535323	A/G	cg01599099	chr11:66649832	PC	0.48	9.8	0.41	1.03e-20	HIV-1 susceptibility;
LGG	cis	rs875971	0.862	rs1968126	chr7:66057004	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-10.98	-0.45	4.53e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	8.51	0.37	2.52e-16	Bone mineral density;
LGG	trans	rs73198271	0.632	rs57281209	chr8:8602795	C/T	cg16141378	chr3:129829833	LOC729375	0.36	7.02	0.31	7.89e-12	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03132911	chr5:75698732	IQGAP2	0.42	6.76	0.3	4.07e-11	Cognitive performance;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs2033732	0.706	rs4740000	chr8:85075376	G/T	cg05716166	chr8:85095498	RALYL	0.45	7.22	0.32	2.11e-12	Body mass index;
LGG	cis	rs1552244	0.882	rs3755783	chr3:10029289	A/G	cg00149659	chr3:10157352	C3orf10	0.74	8.98	0.39	6.76e-18	Alzheimer's disease;
LGG	cis	rs1620921	0.967	rs1084658	chr6:161180477	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.48	-0.33	3.73e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2290402	0.536	rs2279175	chr4:852013	G/A	cg09237302	chr4:906077	GAK	-0.44	-7.53	-0.33	2.63e-13	Type 2 diabetes;
LGG	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg13147721	chr7:65941812	NA	-0.47	-7.38	-0.32	7.39e-13	Corneal structure;
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.2	0.52	5.63e-34	Prudent dietary pattern;
LGG	cis	rs2594989	0.943	rs2454508	chr3:11493232	T/C	cg01796438	chr3:11312864	ATG7	-0.53	-7.27	-0.32	1.5e-12	Circulating chemerin levels;
LGG	cis	rs10256972	0.621	rs10951594	chr7:1088607	C/G	cg18402987	chr7:1209562	NA	0.38	7.0	0.31	9.09e-12	Longevity;Endometriosis;
LGG	cis	rs7091068	0.662	rs829106	chr10:95441742	G/T	cg20715218	chr10:95462985	C10orf4	0.63	9.39	0.4	2.71e-19	Urinary tract infection frequency;
LGG	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg03762349	chr15:79060523	ADAMTS7	0.32	6.99	0.31	9.53e-12	Sudden cardiac arrest;
LGG	cis	rs7786877	0.508	rs11765509	chr7:100310990	T/G	cg21055462	chr7:100276975	NA	0.44	9.1	0.39	2.68e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg06654118	chr4:1303317	MAEA	0.48	8.05	0.35	6.9e-15	Obesity-related traits;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg12458913	chr13:53173898	NA	-0.54	-10.12	-0.43	7.27e-22	Lewy body disease;
LGG	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg06532163	chr17:45867833	NA	0.55	9.31	0.4	5.18e-19	IgG glycosylation;
LGG	cis	rs721917	0.506	rs2819100	chr10:81696919	G/A	cg25562619	chr10:81652821	NA	-0.34	-7.67	-0.34	1.01e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs11098499	0.722	rs10025925	chr4:120271744	A/T	cg09307838	chr4:120376055	NA	0.66	11.26	0.46	3.71e-26	Corneal astigmatism;
LGG	cis	rs972578	0.791	rs3091382	chr22:43291095	C/T	cg01576275	chr22:43409880	NA	-0.24	-7.26	-0.32	1.67e-12	Mean platelet volume;
LGG	cis	rs806321	0.534	rs1269281	chr13:50890538	A/C	cg10393508	chr13:50950265	NA	-0.34	-8.69	-0.37	6.31e-17	Multiple sclerosis;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.94	-0.54	3.94e-37	Alzheimer's disease;
LGG	cis	rs897984	0.762	rs897986	chr16:30980902	T/C	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.24e-15	Dementia with Lewy bodies;
LGG	cis	rs988958	0.635	rs9309078	chr2:42249890	C/G	cg19376973	chr2:42229025	NA	0.62	9.72	0.41	1.83e-20	Hypospadias;
LGG	cis	rs17270561	0.609	rs3778272	chr6:25767661	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs13095912	0.778	rs7651346	chr3:185300395	G/A	cg11274856	chr3:185301563	NA	0.5	8.07	0.35	6.07e-15	Systolic blood pressure;
LGG	cis	rs1801251	0.964	rs12997185	chr2:233560587	A/T	cg25237894	chr2:233734115	C2orf82	0.62	11.08	0.46	1.77e-25	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs117432936	chr22:32382309	G/T	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs7011049	1.000	rs72640850	chr8:53836681	A/C	cg26025543	chr8:53854495	NA	0.74	9.9	0.42	4.48e-21	Systolic blood pressure;
LGG	cis	rs12042938	0.622	rs61707606	chr1:231813446	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.52	8.62	0.37	1.1e-16	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs933688	1.000	rs1964292	chr5:90743608	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs611744	0.905	rs408506	chr8:109154233	A/C	cg21045802	chr8:109455806	TTC35	-0.38	-6.69	-0.3	6.46e-11	Dupuytren's disease;
LGG	cis	rs9875589	0.509	rs4047237	chr3:14012861	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.55	11.37	0.47	1.39e-26	Ovarian reserve;
LGG	cis	rs17253792	0.749	rs79713967	chr14:56124186	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	trans	rs6582630	0.537	rs66855609	chr12:38299029	T/C	cg06521331	chr12:34319734	NA	-0.51	-9.46	-0.4	1.61e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2173063	1.000	rs78159701	chr15:93126039	G/C	cg07052004	chr15:93132129	NA	0.65	6.77	0.3	4e-11	Subcutaneous adipose tissue;
LGG	cis	rs2153535	0.580	rs6921964	chr6:8446395	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.54	0.5	2.94e-31	Motion sickness;
LGG	cis	rs10479542	1.000	rs10479542	chr5:178981241	T/A	cg19626725	chr5:178986131	RUFY1	0.45	7.45	0.33	4.56e-13	Lung cancer;
LGG	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	cis	rs6547631	0.622	rs10206121	chr2:85930169	T/A	cg19805943	chr2:85933069	NA	0.32	6.74	0.3	4.68e-11	Blood protein levels;
LGG	cis	rs801193	1.000	rs3778909	chr7:66255646	G/C	cg18876405	chr7:65276391	NA	0.6	10.99	0.45	4.11e-25	Aortic root size;
LGG	cis	rs4356203	0.870	rs7935219	chr11:17168187	G/C	cg15432903	chr11:17409602	KCNJ11	0.39	7.28	0.32	1.45e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs2486288	0.656	rs11632651	chr15:45550838	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.88	-0.42	5.06e-21	Glomerular filtration rate;
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.91	-0.31	1.6e-11	Bipolar disorder;
LGG	cis	rs2046867	0.818	rs62249879	chr3:72917171	A/G	cg25664220	chr3:72788482	NA	-0.29	-7.89	-0.34	2.23e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9863	0.804	rs80270210	chr12:124447397	G/T	cg13487667	chr12:124434373	CCDC92	-0.41	-7.85	-0.34	2.96e-14	White blood cell count;
LGG	cis	rs3749237	0.537	rs4459909	chr3:49469217	T/C	cg03060546	chr3:49711283	APEH	0.73	13.1	0.52	1.4e-33	Resting heart rate;
LGG	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.92	-0.74	6.2e-83	Primary sclerosing cholangitis;
LGG	cis	rs2153535	0.580	rs6902001	chr6:8477055	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg20821713	chr7:1055600	C7orf50	-0.34	-6.71	-0.3	5.77e-11	Longevity;Endometriosis;
LGG	trans	rs12579753	0.810	rs1922565	chr12:82135348	T/C	cg07923666	chr12:49932857	KCNH3	-0.51	-8.09	-0.35	5.33e-15	Resting heart rate;
LGG	cis	rs753778	0.667	rs10103731	chr8:142206068	C/T	cg18755752	chr8:142205143	DENND3	-0.49	-9.93	-0.42	3.37e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9640161	0.830	rs3757423	chr7:150067714	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	0.52	10.1	0.42	8.38e-22	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.729	rs1917325	chr11:49370004	G/A	cg03929089	chr4:120376271	NA	-0.9	-18.23	-0.65	2.28e-56	Coronary artery disease;
LGG	cis	rs778371	1.000	rs11535	chr2:233743532	G/C	cg25237894	chr2:233734115	C2orf82	-0.46	-7.8	-0.34	4.26e-14	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02339298	chr21:33984905	C21orf59	0.39	6.78	0.3	3.59e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4330281	0.669	rs6577643	chr3:17766697	C/G	cg20981856	chr3:17787350	NA	-0.37	-6.84	-0.3	2.55e-11	Schizophrenia;
LGG	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg13770153	chr20:60521292	NA	-0.52	-8.22	-0.36	2.12e-15	Body mass index;
LGG	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.53	-8.54	-0.37	2.01e-16	Menarche (age at onset);
LGG	trans	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg16141378	chr3:129829833	LOC729375	-0.42	-9.67	-0.41	2.76e-20	Neuroticism;
LGG	cis	rs1348850	0.634	rs2293471	chr2:178487729	T/G	cg27490568	chr2:178487706	NA	0.76	14.09	0.55	8.71e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1949733	0.598	rs16842480	chr4:8535621	G/T	cg11789530	chr4:8429930	ACOX3	-0.65	-10.57	-0.44	1.6e-23	Response to antineoplastic agents;
LGG	cis	rs780096	0.526	rs13472	chr2:27600239	G/A	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.8	-0.34	4.15e-14	Total body bone mineral density;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07243736	chr16:783730	NARFL	0.42	7.21	0.32	2.22e-12	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19875216	chr3:133524841	SRPRB	0.5	7.35	0.32	8.91e-13	Gut microbiome composition (summer);
LGG	trans	rs12517041	1.000	rs10052994	chr5:23292784	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.99	-0.45	3.87e-25	Calcium levels;
LGG	cis	rs8114671	0.869	rs6060199	chr20:33654773	A/G	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs62400317	0.859	rs6919873	chr6:45159336	A/G	cg18551225	chr6:44695536	NA	-0.62	-10.17	-0.43	4.75e-22	Total body bone mineral density;
LGG	cis	rs4819052	0.679	rs2255761	chr21:46683622	A/G	cg06618935	chr21:46677482	NA	-0.36	-7.15	-0.32	3.3e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2235642	0.893	rs2076445	chr16:1592266	A/T	cg09025071	chr16:1593152	IFT140;TMEM204	0.42	10.33	0.43	1.16e-22	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs79497892	chr22:32434359	C/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs832540	0.931	rs832529	chr5:56229288	C/T	cg14703610	chr5:56206110	C5orf35	0.46	7.99	0.35	1.12e-14	Coronary artery disease;
LGG	cis	rs9715521	0.775	rs67846233	chr4:59848576	G/A	cg11281224	chr4:60001000	NA	-0.5	-8.46	-0.37	3.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11608355	0.545	rs7316375	chr12:109906998	G/C	cg05360138	chr12:110035743	NA	0.84	12.16	0.49	1.05e-29	Neuroticism;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.559	rs17427158	chr7:106824259	G/T	cg02696742	chr7:106810147	HBP1	-0.77	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	cis	rs9640161	0.742	rs11983355	chr7:150016697	A/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.32	-0.58	3.63e-43	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.39	-0.36	5.81e-16	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2415984	0.622	rs61993302	chr14:46949684	C/T	cg14871534	chr14:47121158	RPL10L	-0.57	-10.09	-0.42	8.65e-22	Number of children ever born;
LGG	cis	rs3768617	0.510	rs10797844	chr1:183082067	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.34	0.32	9.85e-13	Tonsillectomy;
LGG	trans	rs9929218	0.529	rs11075694	chr16:68730366	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	25.07	0.76	2.85e-88	Colorectal cancer;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg08621203	chr6:150244597	RAET1G	-0.45	-6.78	-0.3	3.66e-11	Lung cancer;
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg06558623	chr16:89946397	TCF25	1.16	14.82	0.57	6.25e-41	Skin colour saturation;
LGG	cis	rs7646881	0.953	rs73015657	chr3:158451932	G/A	cg19483011	chr3:158453295	NA	-0.66	-9.89	-0.42	4.83e-21	Tetralogy of Fallot;
LGG	cis	rs7829975	0.714	rs59046059	chr8:8670736	C/A	cg08975724	chr8:8085496	FLJ10661	0.43	8.35	0.36	8.19e-16	Mood instability;
LGG	cis	rs7949030	0.626	rs71490390	chr11:62329185	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.31	0.6	1.33e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1949733	0.655	rs2631736	chr4:8478421	C/G	cg13073564	chr4:8508604	NA	0.53	10.85	0.45	1.41e-24	Response to antineoplastic agents;
LGG	cis	rs617791	0.669	rs4994056	chr11:65750997	G/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.8	0.34	4.28e-14	Breast cancer;
LGG	cis	rs9309473	0.607	rs4641966	chr2:73590806	G/A	cg20560298	chr2:73613845	ALMS1	-0.49	-8.85	-0.38	1.87e-17	Metabolite levels;
LGG	trans	rs17685	0.587	rs1623759	chr7:75724679	A/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.85	0.77	7.24e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs17270561	0.609	rs9358871	chr6:25726675	G/A	cg03517284	chr6:25882590	NA	-0.43	-6.94	-0.31	1.33e-11	Iron status biomarkers;
LGG	trans	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg02002194	chr4:3960332	NA	-0.45	-8.77	-0.38	3.33e-17	Mood instability;
LGG	cis	rs9329221	0.905	rs4841329	chr8:10253098	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.17	-0.35	2.98e-15	Neuroticism;
LGG	cis	rs4481887	0.893	rs1339992	chr1:248509182	G/A	cg13385794	chr1:248469461	NA	0.46	7.79	0.34	4.5e-14	Common traits (Other);
LGG	cis	rs9527	0.615	rs1556960	chr10:104726673	A/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.88	-0.3	1.96e-11	Arsenic metabolism;
LGG	cis	rs60180747	1.000	rs74634457	chr15:66835704	A/G	cg07575407	chr15:66541975	MEGF11	0.34	6.75	0.3	4.33e-11	Testicular germ cell tumor;
LGG	cis	rs6460942	1.000	rs62448566	chr7:12403662	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.87	-0.3	2.08e-11	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg15971980	chr6:150254442	NA	0.45	8.42	0.36	4.61e-16	Lung cancer;
LGG	cis	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg04369109	chr6:150039330	LATS1	-0.41	-6.93	-0.31	1.46e-11	Lung cancer;
LGG	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg13647721	chr17:30228624	UTP6	0.77	10.23	0.43	2.89e-22	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.545	rs67397473	chr7:65633305	A/G	cg11764359	chr7:65958608	NA	0.64	9.89	0.42	4.69e-21	Aortic root size;
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg02002194	chr4:3960332	NA	0.45	8.46	0.37	3.65e-16	Neuroticism;
LGG	cis	rs7267979	0.903	rs6132819	chr20:25218618	C/G	cg06421707	chr20:25228305	PYGB	0.47	10.34	0.43	1.14e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg01191920	chr7:158217561	PTPRN2	-0.73	-15.7	-0.59	7.48e-45	Obesity-related traits;
LGG	cis	rs9358372	0.537	rs12661145	chr6:20791537	A/T	cg13405222	chr6:20811065	CDKAL1	0.62	13.36	0.53	1.11e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs875971	0.862	rs778720	chr7:65846275	A/C	cg23594656	chr7:65796392	TPST1	0.4	8.75	0.38	3.93e-17	Aortic root size;
LGG	cis	rs6665290	0.904	rs9727512	chr1:227185375	G/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.95	-0.91	1.35e-174	Myeloid white cell count;
LGG	cis	rs709400	0.859	rs7693	chr14:104023704	C/T	cg26031613	chr14:104095156	KLC1	1.15	25.38	0.76	1.14e-89	Body mass index;
LGG	cis	rs3735485	0.800	rs1294965	chr7:45071861	C/A	cg03440944	chr7:45023329	C7orf40	0.55	9.39	0.4	2.69e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs240764	0.817	rs239221	chr6:101113085	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	5.01e-14	Neuroticism;
LGG	cis	rs1506636	1.000	rs1506636	chr7:123317140	C/T	cg03229431	chr7:123269106	ASB15	0.7	17.19	0.62	1.33e-51	Plateletcrit;Platelet count;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg20887711	chr4:1340912	KIAA1530	0.94	21.13	0.7	6.69e-70	Longevity;
LGG	cis	rs10464366	0.544	rs34866559	chr7:39166071	G/A	cg21665744	chr7:39171113	POU6F2	0.43	8.87	0.38	1.57e-17	IgG glycosylation;
LGG	cis	rs6977660	0.507	rs4721822	chr7:19771693	T/C	cg07541023	chr7:19748670	TWISTNB	0.79	10.66	0.44	7.23e-24	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg14926445	chr8:58193284	C8orf71	-0.89	-11.42	-0.47	8.86e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs6831352	0.725	rs2602846	chr4:100025151	T/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Alcohol dependence;
LGG	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg27446573	chr6:127587934	RNF146	1.09	20.95	0.7	4.94e-69	Breast cancer;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg04025307	chr7:1156635	C7orf50	0.59	11.06	0.46	2.11e-25	Longevity;Endometriosis;
LGG	cis	rs17021463	0.872	rs10856909	chr4:95268748	C/G	cg11021082	chr4:95130006	SMARCAD1	0.46	8.27	0.36	1.43e-15	Testicular germ cell tumor;
LGG	cis	rs10743315	0.557	rs74465549	chr12:19344365	A/C	cg02471346	chr12:19282374	PLEKHA5	0.86	8.39	0.36	5.98e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07085476	chr11:82867879	PCF11	0.44	6.94	0.31	1.35e-11	Cognitive performance;
LGG	cis	rs62400317	0.762	rs11961316	chr6:45029598	T/C	cg20913747	chr6:44695427	NA	-0.57	-8.56	-0.37	1.64e-16	Total body bone mineral density;
LGG	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg22980697	chr10:16874865	CUBN	0.57	9.3	0.4	5.53e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs7572733	0.840	rs6743671	chr2:198563642	T/C	cg00792783	chr2:198669748	PLCL1	-0.44	-7.51	-0.33	3e-13	Dermatomyositis;
LGG	cis	rs2302729	0.929	rs7136355	chr12:2783476	T/C	cg19945202	chr12:2788847	CACNA1C	-0.78	-11.25	-0.46	4.03e-26	Sleep quality;
LGG	cis	rs1153858	1.000	rs11070453	chr15:45645154	C/G	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	trans	rs13086611	1	rs13086611	chr3:49385417	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.14	-0.35	3.73e-15	Educational attainment;
LGG	trans	rs11875185	0.510	rs74764573	chr18:55639455	G/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs755249	0.510	rs613511	chr1:39833473	C/T	cg18385671	chr1:39797026	MACF1	0.47	9.97	0.42	2.52e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9291683	0.609	rs34709913	chr4:10028955	T/C	cg00071950	chr4:10020882	SLC2A9	0.45	9.4	0.4	2.49e-19	Bone mineral density;
LGG	cis	rs4808199	0.901	rs12973258	chr19:19488718	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.29	0.32	1.32e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg01043669	chr3:72786069	NA	0.43	7.05	0.31	6.6e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs2404602	0.622	rs11637296	chr15:77207885	C/A	cg15268244	chr15:77196840	NA	0.48	9.92	0.42	3.8e-21	Blood metabolite levels;
LGG	trans	rs1814175	0.509	rs60698301	chr11:49877672	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.59	-0.61	7.81e-49	Height;
LGG	trans	rs853679	0.882	rs9380064	chr6:28143118	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.51	-0.4	1.02e-19	Depression;
LGG	cis	rs3099143	1.000	rs2629034	chr15:77042240	G/A	cg21673338	chr15:77095150	SCAPER	-0.67	-10.47	-0.44	3.62e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg14683738	chr19:37701593	ZNF585B	-0.39	-6.69	-0.3	6.44e-11	Coronary artery calcification;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.8	0.41	9.73e-21	Lymphocyte counts;
LGG	cis	rs9354308	0.764	rs2105453	chr6:66601978	G/C	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg02002194	chr4:3960332	NA	-0.55	-10.63	-0.44	9.35e-24	Neuroticism;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg01145232	chr6:150245071	RAET1G	0.32	6.67	0.3	7.4e-11	Testicular germ cell tumor;
LGG	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg03959625	chr15:84868606	LOC388152	0.6	9.4	0.4	2.52e-19	Schizophrenia;
LGG	cis	rs3761218	1.000	rs3761219	chr20:3776368	T/C	cg25011176	chr20:3776985	CDC25B	-0.49	-7.55	-0.33	2.27e-13	Bipolar disorder;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs6542838	0.588	rs4851175	chr2:99530118	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.4	-6.82	-0.3	2.8e-11	Fear of minor pain;
LGG	cis	rs9899728	0.764	rs7219493	chr17:73044188	T/C	cg27626185	chr17:73056755	KCTD2	-0.68	-9.0	-0.39	6.05e-18	Alzheimer's disease or small vessel stroke;
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.3	-0.43	1.56e-22	Total body bone mineral density;
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-10.9	-0.45	8.8e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10516465	chr14:102695515	RAGE	0.38	6.89	0.3	1.88e-11	Electrocardiographic conduction measures;
LGG	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.25	-0.32	1.81e-12	Triglycerides;
LGG	cis	rs6500602	1.000	rs11648292	chr16:4462897	C/A	cg08645402	chr16:4508243	NA	0.47	8.44	0.37	4.01e-16	Schizophrenia;
LGG	cis	rs28595532	0.920	rs17324807	chr4:119770638	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg09359103	chr1:154839909	KCNN3	0.35	6.73	0.3	4.89e-11	Prostate cancer;
LGG	cis	rs1594829	0.535	rs11784209	chr8:26170246	T/C	cg11498726	chr8:26250323	BNIP3L	-0.39	-8.65	-0.37	8.5e-17	Height;
LGG	trans	rs6787172	0.702	rs2682406	chr3:158026489	T/A	cg23275840	chr4:47708675	CORIN	0.41	8.89	0.38	1.33e-17	Subjective well-being;
LGG	cis	rs2249694	0.922	rs8192780	chr10:135354125	T/G	cg20169779	chr10:135381914	SYCE1	0.5	7.66	0.34	1.07e-13	Obesity-related traits;
LGG	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg02503808	chr4:7069936	GRPEL1	0.88	13.56	0.53	1.64e-35	Monocyte percentage of white cells;
LGG	cis	rs7786808	0.530	rs7785656	chr7:158184164	C/G	cg12438819	chr7:158236134	PTPRN2	0.26	6.77	0.3	3.94e-11	Obesity-related traits;
LGG	cis	rs9611565	0.659	rs73178641	chr22:41952075	A/T	cg17554472	chr22:41940697	POLR3H	-0.49	-6.86	-0.3	2.25e-11	Vitiligo;
LGG	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	7.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg00701064	chr4:6280414	WFS1	0.74	16.54	0.61	1.26e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs600550	0.588	rs11230239	chr11:60072149	C/T	cg05040360	chr11:60102449	MS4A6E	-0.38	-8.26	-0.36	1.52e-15	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04935121	chr11:63775413	MACROD1	0.3	7.14	0.31	3.71e-12	Pulse pressure;
LGG	cis	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg09044154	chr16:88155775	NA	-0.5	-7.51	-0.33	3.02e-13	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs72841536	chr6:26378288	T/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2046867	0.818	rs17690720	chr3:72866030	T/C	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg05863683	chr7:1912471	MAD1L1	0.46	8.83	0.38	2.12e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22747643	chr7:1499391	MICALL2	-0.43	-6.97	-0.31	1.08e-11	Pancreatic cancer;
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs950169	0.922	rs11630760	chr15:85113337	G/T	cg03959625	chr15:84868606	LOC388152	0.57	9.03	0.39	4.55e-18	Schizophrenia;
LGG	cis	rs7166081	1.000	rs12594234	chr15:67596154	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4919087	0.892	rs2065861	chr10:99004608	C/T	cg25902810	chr10:99078978	FRAT1	0.51	9.6	0.41	5.14e-20	Monocyte count;
LGG	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26734620	chr12:56694298	CS	0.75	6.77	0.3	3.88e-11	Psoriasis vulgaris;
LGG	cis	rs10267417	0.603	rs10239480	chr7:19882806	T/A	cg05791153	chr7:19748676	TWISTNB	0.64	8.28	0.36	1.35e-15	Night sleep phenotypes;
LGG	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg13802316	chr11:70253460	CTTN	-0.57	-7.34	-0.32	9.61e-13	Coronary artery disease;
LGG	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.89	-0.3	1.86e-11	Triglycerides;
LGG	cis	rs12701220	0.894	rs34712249	chr7:1036634	C/T	cg26769984	chr7:1090371	C7orf50	0.53	9.42	0.4	2.22e-19	Bronchopulmonary dysplasia;
LGG	cis	rs62380364	0.602	rs448809	chr5:88005828	G/T	cg22951263	chr5:87985283	NA	-0.54	-10.02	-0.42	1.55e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8177253	0.761	rs35332919	chr3:133519002	T/A	cg08048268	chr3:133502702	NA	-0.69	-13.7	-0.54	4e-36	Iron status biomarkers;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.78	-0.3	3.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs12618769	0.601	rs56118505	chr2:99139832	T/G	cg18455616	chr2:99124870	INPP4A	0.29	8.49	0.37	2.87e-16	Bipolar disorder;
LGG	cis	rs17666538	0.535	rs1669658	chr8:607380	A/G	cg13264159	chr8:625131	ERICH1	-0.99	-11.28	-0.46	3.13e-26	IgG glycosylation;
LGG	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.04	-0.31	6.96e-12	Monocyte percentage of white cells;
LGG	cis	rs17209837	0.607	rs1014283	chr7:87076587	C/A	cg00919237	chr7:87102261	ABCB4	-0.75	-14.38	-0.56	5.24e-39	Gallbladder cancer;
LGG	cis	rs60180747	1.000	rs79350921	chr15:66801937	G/T	cg07575407	chr15:66541975	MEGF11	0.35	6.95	0.31	1.25e-11	Testicular germ cell tumor;
LGG	cis	rs7107174	0.579	rs10793299	chr11:78018954	T/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6840360	0.615	rs4696095	chr4:152467243	A/G	cg25486957	chr4:152246857	NA	-0.52	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	cis	rs9384488	0.524	rs7755448	chr6:157028615	T/C	cg05282260	chr6:156983263	NA	-0.47	-7.4	-0.33	6.58e-13	Alzheimer's disease biomarkers;
LGG	cis	rs10540	1.000	rs61876336	chr11:489537	C/T	cg03576123	chr11:487126	PTDSS2	-1.31	-17.43	-0.63	1.07e-52	Body mass index;
LGG	cis	rs736408	0.562	rs2072390	chr3:52780509	A/T	cg14092988	chr3:52407081	DNAH1	0.29	7.64	0.33	1.24e-13	Bipolar disorder;
LGG	trans	rs10435719	0.867	rs62493601	chr8:11788307	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.92	0.38	1.08e-17	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.66	-0.48	9.76e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2204008	0.621	rs7302846	chr12:38072979	A/C	cg26384229	chr12:38710491	ALG10B	0.72	14.25	0.55	1.88e-38	Bladder cancer;
LGG	cis	rs1008375	0.932	rs10009933	chr4:17670107	A/C	cg02297831	chr4:17616191	MED28	0.47	8.52	0.37	2.22e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg01458961	chr4:102269425	PPP3CA	0.38	6.78	0.3	3.61e-11	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26236440	chr2:113341947	CHCHD5	0.43	7.08	0.31	5.33e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg09699651	chr6:150184138	LRP11	0.56	10.71	0.45	4.68e-24	Testicular germ cell tumor;
LGG	cis	rs7561149	0.646	rs6433735	chr2:179690233	C/T	cg17765952	chr2:179737173	CCDC141	-0.41	-9.3	-0.4	5.67e-19	QT interval;
LGG	cis	rs4321325	0.733	rs74707659	chr2:127945469	T/C	cg11380483	chr2:127933992	NA	0.67	8.94	0.38	9.09e-18	Protein C levels;
LGG	cis	rs714515	0.511	rs9425301	chr1:172363815	A/C	cg01573306	chr1:172330400	DNM3	0.42	9.35	0.4	3.75e-19	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.5	-0.37	2.67e-16	Morning vs. evening chronotype;
LGG	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg24623649	chr8:11872141	NA	0.3	7.01	0.31	8.62e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7712401	0.601	rs187405	chr5:122294995	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs9796	0.870	rs3986311	chr15:41264339	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.31	-0.36	1.09e-15	Menopause (age at onset);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg16330517	chr18:43913699	RNF165	-0.41	-7.35	-0.32	8.93e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.758	rs11980081	chr7:1069372	T/C	cg24575275	chr7:1094737	C7orf50	-0.39	-7.28	-0.32	1.42e-12	Longevity;Endometriosis;
LGG	cis	rs638893	0.528	rs521910	chr11:118610629	C/T	cg13782932	chr11:118662891	DDX6	-0.37	-6.84	-0.3	2.44e-11	Vitiligo;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.44	-0.37	4.19e-16	Life satisfaction;
LGG	cis	rs9611565	0.649	rs79005	chr22:41835544	G/A	cg06850241	chr22:41845214	NA	0.44	7.1	0.31	4.66e-12	Vitiligo;
LGG	cis	rs6076065	0.775	rs761723	chr20:23330720	A/G	cg12633918	chr20:23549525	CST9L	-0.33	-6.65	-0.3	8.05e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs7086627	0.515	rs10887901	chr10:82210581	G/A	cg03293884	chr10:82215075	TSPAN14	-0.43	-8.66	-0.37	8.09e-17	Post bronchodilator FEV1;
LGG	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg00290607	chr11:67383545	NA	-0.5	-8.91	-0.38	1.15e-17	Mean corpuscular volume;
LGG	cis	rs2032447	0.531	rs428469	chr6:25898624	G/A	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.55	-8.5	-0.37	2.56e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7020830	0.861	rs2291589	chr9:37079661	T/G	cg14294708	chr9:37120828	ZCCHC7	1.15	32.91	0.84	2.62e-123	Schizophrenia;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.86	-0.59	1.51e-45	Height;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg24829409	chr8:58192753	C8orf71	-0.79	-12.94	-0.52	6.86e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.502	rs4315813	chr4:122674866	G/A	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	cis	rs34929064	0.918	rs2961300	chr7:22708784	C/G	cg18045685	chr7:22629474	NA	-0.57	-10.57	-0.44	1.48e-23	Major depression and alcohol dependence;
LGG	cis	rs62238980	0.614	rs74925531	chr22:32417582	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg21972741	chr5:435613	AHRR	0.49	8.81	0.38	2.6e-17	Cystic fibrosis severity;
LGG	cis	rs526231	0.543	rs26820	chr5:102528092	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.39	-0.36	5.72e-16	Primary biliary cholangitis;
LGG	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg06766960	chr11:133703094	NA	-0.52	-10.27	-0.43	1.99e-22	Childhood ear infection;
LGG	cis	rs11718455	0.920	rs34909426	chr3:44000472	G/A	cg21419209	chr3:44054225	NA	-0.4	-6.69	-0.3	6.56e-11	Coronary artery disease;
LGG	cis	rs2298450	0.717	rs9974041	chr21:37634873	G/A	cg02919814	chr21:37666008	DOPEY2	-0.43	-7.83	-0.34	3.26e-14	Schizophrenia;
LGG	cis	rs644799	0.965	rs607039	chr11:95547086	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg08975724	chr8:8085496	FLJ10661	0.41	7.67	0.34	9.94e-14	Neuroticism;
LGG	cis	rs651907	0.557	rs17411983	chr3:101399126	A/G	cg12386194	chr3:101231763	SENP7	-0.45	-7.99	-0.35	1.07e-14	Colorectal cancer;
LGG	cis	rs6429082	0.738	rs2131921	chr1:235705157	C/T	cg26050004	chr1:235667680	B3GALNT2	0.56	8.53	0.37	2.05e-16	Adiposity;
LGG	cis	rs427394	0.772	rs274689	chr5:6736215	G/C	cg10857441	chr5:6722123	POLS	-0.28	-6.92	-0.31	1.47e-11	Menopause (age at onset);
LGG	cis	rs7751419	0.651	rs59030947	chr6:39094731	C/T	cg08089693	chr6:39098871	NA	-0.43	-7.73	-0.34	6.81e-14	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg02725872	chr8:58115012	NA	-0.86	-11.91	-0.48	1.04e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.5	-0.37	2.64e-16	Retinal vascular caliber;
LGG	cis	rs2535633	0.602	rs6801235	chr3:53009595	T/C	cg11645453	chr3:52864694	ITIH4	0.49	8.23	0.36	1.87e-15	Body mass index;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg07157834	chr1:205819609	PM20D1	0.74	16.66	0.61	3.47e-49	Menarche (age at onset);
LGG	cis	rs7598759	0.712	rs6740474	chr2:232331831	A/G	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.49e-14	Noise-induced hearing loss;
LGG	cis	rs1729951	0.575	rs1682357	chr3:136692009	G/A	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs6997458	0.741	rs1496530	chr8:86255898	C/T	cg02393479	chr8:86352350	CA3	-0.32	-6.99	-0.31	9.54e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11874712	0.931	rs35507656	chr18:43652541	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.92	-0.45	7.41e-25	Migraine - clinic-based;
LGG	cis	rs593982	0.920	rs10896044	chr11:65554680	C/G	cg08755490	chr11:65554678	OVOL1	0.75	11.32	0.47	2.21e-26	Atopic dermatitis;
LGG	cis	rs7647973	1.000	rs11719762	chr3:49409002	G/C	cg06212747	chr3:49208901	KLHDC8B	0.51	7.97	0.35	1.26e-14	Menarche (age at onset);
LGG	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg19468946	chr17:37922297	IKZF3	-0.45	-8.03	-0.35	8.41e-15	Self-reported allergy;
LGG	trans	rs7939886	0.920	rs11227917	chr11:56095322	T/C	cg15704280	chr7:45808275	SEPT13	0.8	7.23	0.32	1.97e-12	Myopia (pathological);
LGG	cis	rs7017914	0.967	rs6982406	chr8:71654608	T/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.76	-0.3	4.09e-11	Bone mineral density;
LGG	cis	rs9560113	1.000	rs9555806	chr13:112179954	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs1559088	0.749	rs10405757	chr19:33616526	C/A	cg03563238	chr19:33554763	RHPN2	-0.44	-9.96	-0.42	2.68e-21	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs9640161	0.742	rs2108852	chr7:150019628	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.55	-0.59	3.73e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs2153535	0.580	rs9379216	chr6:8481235	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	17.08	0.62	4.3e-51	Hip circumference adjusted for BMI;
LGG	trans	rs35110281	0.807	rs9976441	chr21:45046591	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.1	0.42	8.2e-22	Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg02002194	chr4:3960332	NA	0.45	8.29	0.36	1.21e-15	Triglycerides;
LGG	cis	rs9487051	0.714	rs6927569	chr6:109621494	T/C	cg21918786	chr6:109611834	NA	-0.49	-9.19	-0.39	1.35e-18	Reticulocyte fraction of red cells;
LGG	cis	rs9815354	0.638	rs73073302	chr3:42029879	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg08112188	chr17:47440006	ZNF652	1.26	13.39	0.53	8.61e-35	Prostate cancer;
LGG	cis	rs12367572	0.796	rs7979141	chr12:45282630	A/T	cg03114573	chr12:45410052	DBX2	-0.52	-8.92	-0.38	1.12e-17	Gut microbiome composition (summer);
LGG	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg03891598	chr16:83986782	OSGIN1	0.62	9.7	0.41	2.22e-20	Pursuit maintenance gain;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.59	-0.44	1.32e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs763014	0.898	rs8050792	chr16:656033	T/C	cg27189623	chr16:705930	WDR90	0.4	7.54	0.33	2.52e-13	Height;
LGG	cis	rs7551345	0.851	rs10914330	chr1:31691577	A/C	cg20941758	chr1:31673023	NA	-0.32	-6.86	-0.3	2.2e-11	Schizophrenia;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg05556477	chr5:131705319	SLC22A5	-0.8	-9.59	-0.41	5.57e-20	Rheumatoid arthritis;
LGG	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.84	-0.34	3.12e-14	Retinal vascular caliber;
LGG	trans	rs9354308	0.838	rs9354305	chr6:66542891	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.28	-0.36	1.29e-15	Metabolite levels;
LGG	trans	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2204008	0.840	rs3892363	chr12:38479487	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Bladder cancer;
LGG	trans	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg22358067	chr17:16797159	NA	0.5	7.14	0.31	3.68e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs910316	0.737	rs175080	chr14:75513828	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-8.68	-0.37	6.68e-17	Height;
LGG	trans	rs2243480	0.901	rs778693	chr7:65872345	T/G	cg10756647	chr7:56101905	PSPH	0.8	9.39	0.4	2.64e-19	Diabetic kidney disease;
LGG	cis	rs9467711	0.790	rs66488313	chr6:26631568	G/T	cg12826209	chr6:26865740	GUSBL1	0.76	6.7	0.3	6.03e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19524238	chr7:2802976	GNA12	-0.3	-7.19	-0.32	2.62e-12	Height;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.43	-0.36	4.52e-16	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.54	-0.41	8.13e-20	Lung cancer;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg05335186	chr13:53173507	NA	-0.44	-9.01	-0.39	5.41e-18	Lewy body disease;
LGG	trans	rs6582630	0.555	rs35186318	chr12:38295822	C/T	cg06521331	chr12:34319734	NA	0.44	7.86	0.34	2.74e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg24687543	chr11:63912206	MACROD1	0.52	7.74	0.34	6.38e-14	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg13206674	chr6:150067644	NUP43	0.66	13.74	0.54	2.97e-36	Lung cancer;
LGG	cis	rs908922	0.676	rs6587686	chr1:152528948	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.41	-0.56	3.65e-39	Hair morphology;
LGG	cis	rs7143963	0.945	rs72702792	chr14:103279303	A/G	cg23020514	chr14:103360112	TRAF3	0.51	9.66	0.41	3.22e-20	Body mass index;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg12458913	chr13:53173898	NA	0.54	10.02	0.42	1.67e-21	Lewy body disease;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg16405210	chr4:1374714	KIAA1530	0.66	11.8	0.48	2.7e-28	Obesity-related traits;
LGG	cis	rs4262150	0.883	rs72804781	chr5:152314450	T/C	cg12297329	chr5:152029980	NA	-0.62	-11.3	-0.46	2.64e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.742	rs208454	chr6:66907783	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-14.32	-0.55	8.83e-39	Exhaled nitric oxide output;
LGG	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg15212455	chr7:39170539	POU6F2	0.41	9.69	0.41	2.42e-20	IgG glycosylation;
LGG	cis	rs11758351	0.500	rs16891404	chr6:26203970	G/A	cg02612650	chr6:26195910	NA	0.87	6.75	0.3	4.47e-11	Gout;Renal underexcretion gout;
LGG	cis	rs11105298	0.891	rs10858889	chr12:89902604	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.45	-0.4	1.71e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs8079658	1.000	rs17695630	chr17:63801593	G/C	cg18091269	chr17:63822838	CCDC46	-0.4	-6.73	-0.3	4.88e-11	Post bronchodilator FEV1;
LGG	cis	rs9879311	0.866	rs775017	chr3:10398964	T/C	cg21387009	chr3:10280255	IRAK2	-0.4	-7.45	-0.33	4.52e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs2033711	0.870	rs11669741	chr19:58960481	C/T	cg03735888	chr19:58951602	ZNF132	-0.51	-10.31	-0.43	1.43e-22	Uric acid clearance;
LGG	cis	rs1552244	0.608	rs7615408	chr3:10000186	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.42	-0.44	5.75e-23	Alzheimer's disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg03507199	chr6:107811876	SOBP	0.44	7.45	0.33	4.6e-13	Bipolar disorder;
LGG	cis	rs10904908	0.733	rs191693	chr10:17331115	G/A	cg01003015	chr10:17271136	VIM	0.48	7.76	0.34	5.34e-14	Total cholesterol levels;Cholesterol, total;
LGG	trans	rs7395662	0.963	rs11039826	chr11:48572398	G/A	cg15704280	chr7:45808275	SEPT13	-0.49	-8.02	-0.35	8.64e-15	HDL cholesterol;
LGG	cis	rs7954584	0.635	rs3847694	chr12:122325820	A/G	cg22168489	chr12:122356033	WDR66	0.42	10.04	0.42	1.33e-21	Mean corpuscular volume;
LGG	cis	rs2832191	0.716	rs1543652	chr21:30448000	G/C	cg24692254	chr21:30365293	RNF160	1.04	29.58	0.81	9.38e-109	Dental caries;
LGG	cis	rs847649	0.731	rs7785272	chr7:102671023	A/G	cg18108683	chr7:102477205	FBXL13	-0.55	-11.1	-0.46	1.45e-25	Morning vs. evening chronotype;
LGG	cis	rs1355223	0.573	rs1097403	chr11:34730083	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.45	7.12	0.31	4.08e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.6	-0.37	1.22e-16	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.55e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2985684	0.948	rs4900925	chr14:50012325	A/G	cg04989706	chr14:50066350	PPIL5	0.61	9.36	0.4	3.55e-19	Carotid intima media thickness;
LGG	trans	rs11098499	1.000	rs6849889	chr4:120186348	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.7	0.48	6.86e-28	Corneal astigmatism;
LGG	cis	rs9771228	0.931	rs10264177	chr7:32370862	A/G	cg27532318	chr7:32358331	NA	0.43	6.83	0.3	2.62e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs559928	0.947	rs12417275	chr11:64143774	A/C	cg18225595	chr11:63971243	STIP1	0.47	6.78	0.3	3.69e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6977660	0.652	rs4721826	chr7:19823804	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.43	0.44	5.09e-23	Thyroid stimulating hormone;
LGG	cis	rs9381040	0.655	rs9394756	chr6:41016183	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.17	-0.32	3.06e-12	Alzheimer's disease (late onset);
LGG	cis	rs208520	0.690	rs2144081	chr6:66824972	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.47	-0.65	1.75e-57	Exhaled nitric oxide output;
LGG	cis	rs12476592	0.602	rs6736029	chr2:63789170	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg11890956	chr21:40555474	PSMG1	1.21	30.65	0.82	1.79e-113	Cognitive function;
LGG	cis	rs8062405	1.000	rs55719896	chr16:28846866	G/A	cg09754948	chr16:28834200	ATXN2L	0.48	7.7	0.34	8.14e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12431410	0.892	rs12885453	chr14:60160565	G/A	cg07950296	chr14:60194823	RTN1	0.38	7.14	0.31	3.75e-12	Schizophrenia;
LGG	trans	rs208515	0.556	rs12201658	chr6:66678457	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.93	17.09	0.62	4.15e-51	Exhaled nitric oxide levels;
LGG	cis	rs2479724	0.776	rs2250428	chr6:41832772	T/A	cg17623882	chr6:41773611	USP49	-0.5	-8.88	-0.38	1.43e-17	Menarche (age at onset);
LGG	cis	rs55728055	0.661	rs55894054	chr22:31976299	T/C	cg15162869	chr22:32027605	PISD	-0.76	-7.83	-0.34	3.42e-14	Age-related hearing impairment;
LGG	cis	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-8.7	-0.37	5.67e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg08045932	chr20:61659980	NA	0.6	13.16	0.52	8.01e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.07	-0.42	1.1e-21	Lung cancer;
LGG	trans	rs330048	0.561	rs1825100	chr8:9146270	C/T	cg02002194	chr4:3960332	NA	0.42	7.42	0.33	5.81e-13	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg25072359	chr17:41440525	NA	0.52	9.9	0.42	4.45e-21	Menopause (age at onset);
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg20887711	chr4:1340912	KIAA1530	0.7	14.58	0.56	7.05e-40	Longevity;
LGG	cis	rs9486715	0.867	rs9486181	chr6:96868132	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs3816183	0.958	rs4328684	chr2:43025741	A/G	cg14631114	chr2:43023945	NA	0.49	9.25	0.39	8.19e-19	Hypospadias;
LGG	cis	rs11122272	0.525	rs61835222	chr1:231537917	C/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.41	-0.33	6.03e-13	Hemoglobin concentration;
LGG	cis	rs929354	0.707	rs1182445	chr7:157024428	C/G	cg17757837	chr7:157058334	UBE3C	-0.78	-15.94	-0.6	6.35e-46	Body mass index;
LGG	cis	rs79349575	0.783	rs61576918	chr17:46985593	A/C	cg22482690	chr17:47019901	SNF8	0.35	6.87	0.3	2.13e-11	Type 2 diabetes;
LGG	cis	rs3762637	0.882	rs72958418	chr3:122160373	G/C	cg24169773	chr3:122142474	KPNA1	-0.63	-10.9	-0.45	8.88e-25	LDL cholesterol levels;
LGG	cis	rs8053891	0.756	rs9925462	chr16:72000195	C/G	cg09427745	chr16:71932006	KIAA0174	-0.38	-7.0	-0.31	9.12e-12	Coronary artery disease;
LGG	cis	rs4959677	0.868	rs7747066	chr6:2490587	A/G	cg23817096	chr6:1620687	NA	-0.31	-7.32	-0.32	1.08e-12	Orthostatic hypotension;
LGG	cis	rs1799949	1.000	rs8176202	chr17:41230228	G/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.65	-0.37	8.56e-17	Menopause (age at onset);
LGG	cis	rs2130392	0.926	rs7679215	chr4:185635311	C/T	cg21366198	chr4:185655624	MLF1IP	0.45	8.16	0.35	3.25e-15	Kawasaki disease;
LGG	cis	rs6669919	0.653	rs6674367	chr1:211685413	C/T	cg10512769	chr1:211675356	NA	-0.69	-14.43	-0.56	3.03e-39	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	0.752	rs4955547	chr3:134334975	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.8	-0.45	2.16e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs67311347	1.000	rs2276871	chr3:40499273	C/T	cg24209194	chr3:40518798	ZNF619	0.44	7.06	0.31	6.19e-12	Renal cell carcinoma;
LGG	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.73	0.75	1.14e-86	Chronic sinus infection;
LGG	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	1.000	rs58275763	chr3:10143274	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs6121246	0.567	rs6120937	chr20:30219721	C/T	cg18721089	chr20:30220636	NA	-0.5	-7.5	-0.33	3.37e-13	Mean corpuscular hemoglobin;
LGG	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.606	rs10112585	chr8:8795030	A/T	cg16141378	chr3:129829833	LOC729375	0.34	7.83	0.34	3.26e-14	Mood instability;
LGG	trans	rs2727020	0.615	rs10128582	chr11:49447424	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.47	-0.71	1.87e-71	Coronary artery disease;
LGG	cis	rs1801251	0.778	rs709934	chr2:233733352	A/G	cg08000102	chr2:233561755	GIGYF2	-0.43	-7.11	-0.31	4.51e-12	Coronary artery disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22164177	chr12:117013718	MAP1LC3B2	0.4	7.42	0.33	5.82e-13	Menarche (age at onset);
LGG	cis	rs3858526	0.959	rs11039540	chr11:5928334	C/T	cg02574844	chr11:5959923	NA	-0.56	-8.83	-0.38	2.25e-17	DNA methylation (variation);
LGG	cis	rs524281	0.861	rs4013917	chr11:65926185	A/G	cg16950941	chr11:66035639	RAB1B	-0.45	-6.65	-0.3	8.3e-11	Electroencephalogram traits;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg03575163	chr10:104503671	C10orf26	0.42	6.75	0.3	4.31e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs11169552	0.510	rs12580051	chr12:51045072	T/A	cg12884762	chr12:50931848	DIP2B	-0.39	-7.32	-0.32	1.11e-12	Colorectal cancer;
LGG	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg20991723	chr1:152506922	NA	0.7	14.41	0.56	3.65e-39	Hair morphology;
LGG	cis	rs8180040	0.701	rs12491473	chr3:46989904	G/A	cg27129171	chr3:47204927	SETD2	-0.84	-16.08	-0.6	1.58e-46	Colorectal cancer;
LGG	trans	rs853679	1.000	rs6905391	chr6:28262686	G/A	cg08344181	chr3:125677491	NA	-0.54	-7.28	-0.32	1.43e-12	Depression;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.34	6.95	0.31	1.28e-11	Schizophrenia;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg19223190	chr17:80058835	NA	0.43	8.22	0.36	2.11e-15	Life satisfaction;
LGG	cis	rs11190604	0.767	rs3829162	chr10:102172752	T/G	cg07570687	chr10:102243282	WNT8B	0.4	7.06	0.31	6.3e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4911259	0.552	rs13037833	chr20:31459562	C/T	cg13636640	chr20:31349939	DNMT3B	-0.64	-11.61	-0.47	1.65e-27	Inflammatory bowel disease;
LGG	cis	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg15556689	chr8:8085844	FLJ10661	0.4	7.29	0.32	1.39e-12	Mood instability;
LGG	cis	rs62432291	0.681	rs436277	chr6:159634142	G/A	cg14500486	chr6:159655392	FNDC1	0.66	7.21	0.32	2.37e-12	Joint mobility (Beighton score);
LGG	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.3	0.43	1.49e-22	Diabetic retinopathy;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00290607	chr11:67383545	NA	0.57	11.12	0.46	1.22e-25	Mean corpuscular volume;
LGG	cis	rs875971	1.000	rs2420168	chr7:65630631	C/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.61	-0.37	1.18e-16	Aortic root size;
LGG	cis	rs561341	0.843	rs879945	chr17:30242796	G/A	cg00745463	chr17:30367425	LRRC37B	-0.61	-9.33	-0.4	4.42e-19	Hip circumference adjusted for BMI;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05525867	chr15:75661090	MAN2C1	0.46	7.82	0.34	3.72e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg27411982	chr8:10470053	RP1L1	-0.42	-6.87	-0.3	2.08e-11	Neuroticism;
LGG	cis	rs7927592	0.672	rs10501398	chr11:68331715	C/G	cg16797656	chr11:68205561	LRP5	-0.51	-9.86	-0.42	5.9e-21	Total body bone mineral density;
LGG	cis	rs13102973	0.674	rs11730572	chr4:135885397	C/T	cg14419869	chr4:135874104	NA	0.47	7.96	0.35	1.37e-14	Subjective well-being;
LGG	cis	rs1949733	0.816	rs2631746	chr4:8490934	C/T	cg11789530	chr4:8429930	ACOX3	-0.79	-15.78	-0.59	3.24e-45	Response to antineoplastic agents;
LGG	cis	rs11700980	0.551	rs8132111	chr21:30117206	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs12210905	0.841	rs72839470	chr6:27309304	T/A	cg15325629	chr6:28072465	NA	0.92	7.03	0.31	7.52e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6500395	1.000	rs1872655	chr16:48670883	A/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs35110281	0.776	rs2838338	chr21:45075582	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.78	0.48	3.32e-28	Mean corpuscular volume;
LGG	trans	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg24247370	chr13:99142703	STK24	-0.4	-7.48	-0.33	3.85e-13	Testicular germ cell tumor;
LGG	cis	rs7580658	0.680	rs12468304	chr2:128193812	A/G	cg10021288	chr2:128175891	PROC	0.66	13.65	0.54	7.02e-36	Protein C levels;
LGG	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg24088639	chr11:34937564	PDHX;APIP	-0.41	-7.34	-0.32	9.97e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7077256	0.526	rs56206255	chr10:65201076	G/A	cg02276361	chr10:65351566	REEP3	-0.34	-6.96	-0.31	1.18e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7558370	0.737	rs17017879	chr2:3713658	C/G	cg17046650	chr2:3699563	NA	0.89	8.85	0.38	1.81e-17	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg20891558	chr2:74357851	NA	0.5	9.63	0.41	3.86e-20	Gestational age at birth (maternal effect);
LGG	cis	rs6952808	0.723	rs60995052	chr7:2030007	G/C	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.6	-0.47	1.71e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs1153858	1.000	rs2114501	chr15:45670316	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs6500395	1.000	rs2111243	chr16:48724897	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.95	-0.38	8.51e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4253772	0.550	rs9615949	chr22:46722531	C/T	cg09461388	chr22:46763229	CELSR1	-0.68	-7.06	-0.31	5.96e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs228437	0.913	rs11154779	chr6:134909194	T/C	cg24504307	chr6:134963096	NA	0.37	6.79	0.3	3.5e-11	Melanoma;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg12310025	chr6:25882481	NA	-0.44	-8.06	-0.35	6.59e-15	Height;
LGG	cis	rs9905704	0.881	rs302846	chr17:56687536	T/A	cg12560992	chr17:57184187	TRIM37	0.45	6.7	0.3	5.95e-11	Testicular germ cell tumor;
LGG	cis	rs981844	0.712	rs4292309	chr4:154745178	C/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.8	-0.41	9.82e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs10489202	0.683	rs202260	chr1:167956167	G/T	cg24449463	chr1:168025552	DCAF6	-0.59	-10.43	-0.44	5.13e-23	Schizophrenia;
LGG	cis	rs7582180	0.739	rs4851292	chr2:100924761	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs9486715	1.000	rs9373985	chr6:97063522	C/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.38	-0.4	3.02e-19	Headache;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg22188945	chr17:2304408	MNT	0.45	6.66	0.3	7.82e-11	Hip circumference;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00295835	chr11:113644563	ZW10	0.51	7.65	0.33	1.22e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.57e-22	Motion sickness;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg04627240	chr19:42746847	GSK3A	0.74	7.09	0.31	5.17e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs6088580	0.634	rs6088508	chr20:33060081	A/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.66	0.41	3.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs10791097	0.690	rs12284487	chr11:130729705	T/C	cg09137382	chr11:130731461	NA	0.41	7.81	0.34	3.89e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4921915	0.598	rs55686478	chr8:18250375	G/A	cg18736775	chr8:18248649	NAT2	-0.78	-11.25	-0.46	3.88e-26	Iron status biomarkers (transferrin levels);
LGG	cis	rs7084402	0.967	rs1658491	chr10:60281354	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.4e-13	Refractive error;
LGG	cis	rs11700980	0.551	rs34161405	chr21:30113840	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs2012796	0.785	rs61986599	chr14:81860917	G/A	cg02996355	chr14:81879375	NA	0.58	9.53	0.4	8.92e-20	Night sleep phenotypes;
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-6.99	-0.31	9.9e-12	Bipolar disorder;
LGG	cis	rs2730245	1.000	rs6965685	chr7:158726462	C/T	cg24397884	chr7:158709396	WDR60	1.06	25.47	0.76	4.15e-90	Height;
LGG	cis	rs10504229	0.610	rs6999661	chr8:58127391	C/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs115706007	chr4:119733638	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg09426994	chr11:118478258	PHLDB1	0.54	9.89	0.42	4.64e-21	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs7840100	chr8:58036662	T/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.0	-0.42	1.9e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs35160687	0.644	rs1863056	chr2:86491245	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.99	0.31	9.6e-12	Night sleep phenotypes;
LGG	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	28.06	0.79	6.13e-102	Height;
LGG	cis	rs8179	0.645	rs11767704	chr7:92256375	C/T	cg15732164	chr7:92237376	CDK6	-0.53	-9.93	-0.42	3.48e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs6088590	1.000	rs28542147	chr20:33376323	G/A	cg24642439	chr20:33292090	TP53INP2	0.83	15.37	0.58	2.16e-43	Coronary artery disease;
LGG	cis	rs8072100	0.905	rs11651766	chr17:45574931	G/T	cg25173405	chr17:45401733	C17orf57	-0.5	-8.79	-0.38	3.04e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6942756	1.000	rs2718084	chr7:128897342	T/C	cg02491457	chr7:128862824	NA	0.73	13.72	0.54	3.39e-36	White matter hyperintensity burden;
LGG	cis	rs9916302	0.861	rs11078912	chr17:37671490	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.82	-0.59	2.34e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg13206674	chr6:150067644	NUP43	0.64	13.37	0.53	1.07e-34	Lung cancer;
LGG	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg02788857	chr8:22132959	PIWIL2	0.49	11.35	0.47	1.6e-26	Hypertriglyceridemia;
LGG	cis	rs7106204	0.609	rs12801799	chr11:24300630	A/T	ch.11.24196551F	chr11:24239977	NA	0.89	10.01	0.42	1.74e-21	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4650994	0.509	rs7519794	chr1:178542390	G/T	cg19399532	chr1:178512495	C1orf220	-0.4	-7.5	-0.33	3.22e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg05279229	chr7:1896384	MAD1L1	-0.38	-6.84	-0.3	2.57e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4862750	0.872	rs6852907	chr4:187897094	A/C	cg03452623	chr4:187889614	NA	-1.04	-29.44	-0.81	3.74e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg10460130	chr2:242625978	DTYMK	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs7757666	chr6:25902626	T/C	cg03517284	chr6:25882590	NA	-0.41	-7.34	-0.32	9.36e-13	Height;
LGG	cis	rs6547741	1.000	rs2384654	chr2:27847364	C/T	cg27432699	chr2:27873401	GPN1	0.7	14.3	0.55	1.14e-38	Oral cavity cancer;
LGG	cis	rs7444	0.941	rs73166619	chr22:21930093	C/T	cg15846791	chr22:21984385	YDJC	-0.47	-7.12	-0.31	4.05e-12	Systemic lupus erythematosus;
LGG	cis	rs9470366	0.545	rs4713999	chr6:36633069	A/G	cg08179530	chr6:36648295	CDKN1A	-0.63	-10.76	-0.45	2.86e-24	QRS duration;
LGG	trans	rs1493916	0.870	rs7235698	chr18:31382486	A/G	cg27147174	chr7:100797783	AP1S1	-0.68	-12.93	-0.52	7.46e-33	Life satisfaction;
LGG	cis	rs72781680	0.665	rs2953028	chr2:24068126	T/C	cg08917208	chr2:24149416	ATAD2B	0.63	8.25	0.36	1.69e-15	Lymphocyte counts;
LGG	cis	rs3736594	0.513	rs62141278	chr2:27768381	C/T	cg27432699	chr2:27873401	GPN1	0.56	8.51	0.37	2.39e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.45e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2018055	0.644	rs62433108	chr6:117804797	T/G	cg14611402	chr6:117803162	DCBLD1	0.29	8.35	0.36	8.2e-16	Diastolic blood pressure;
LGG	cis	rs765787	0.530	rs1706832	chr15:45517173	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.64	-0.51	1.18e-31	Uric acid levels;
LGG	cis	rs10895140	0.756	rs11224830	chr11:101412927	G/A	cg04553838	chr11:101454733	TRPC6	0.43	6.69	0.3	6.32e-11	Menarche (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00586367	chr8:74790437	UBE2W	-0.46	-7.05	-0.31	6.53e-12	Systemic lupus erythematosus;
LGG	cis	rs4740619	0.836	rs10810455	chr9:15866156	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.8	-0.41	9.92e-21	Body mass index;
LGG	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg09307838	chr4:120376055	NA	0.73	12.15	0.49	1.13e-29	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs6999984	chr8:58115079	G/A	cg11062466	chr8:58055876	NA	0.54	8.84	0.38	1.97e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12048904	0.619	rs12239082	chr1:101330077	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.55	-9.9	-0.42	4.19e-21	Multiple sclerosis;
LGG	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.49	7.82	0.34	3.58e-14	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1465370	0.720	rs1558917	chr7:130028723	C/T	cg04743876	chr7:130013617	NA	0.36	8.09	0.35	5.26e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs28830936	0.510	rs12440605	chr15:42102285	A/G	cg17847044	chr15:42102381	MAPKBP1	0.79	27.23	0.78	3.41e-98	Diastolic blood pressure;
LGG	cis	rs4722166	0.508	rs2069832	chr7:22767433	A/G	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	9.38e-16	Lung cancer;
LGG	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.98	0.39	6.98e-18	Common traits (Other);
LGG	cis	rs2204008	0.744	rs11182316	chr12:38499552	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.92	0.31	1.54e-11	Bladder cancer;
LGG	cis	rs516946	0.797	rs11995075	chr8:41534068	T/C	cg21772509	chr8:41503840	NKX6-3	-0.72	-10.9	-0.45	8.51e-25	Type 2 diabetes;
LGG	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg15674680	chr20:60982522	CABLES2	0.49	6.76	0.3	4.1e-11	Colorectal cancer;
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.29	-0.32	1.32e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00933542	chr6:150070202	PCMT1	0.4	7.29	0.32	1.35e-12	Lung cancer;
LGG	cis	rs1552244	0.572	rs6783705	chr3:10164783	A/G	cg13047869	chr3:10149882	C3orf24	0.6	8.56	0.37	1.69e-16	Alzheimer's disease;
LGG	trans	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.06	-0.35	6.72e-15	Bone mineral density;
LGG	cis	rs7166081	1.000	rs4776909	chr15:67542349	T/A	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.18	-0.32	2.72e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs11748327	0.580	rs11745500	chr5:4006143	G/C	cg01025095	chr5:4101132	NA	-0.44	-7.04	-0.31	6.95e-12	Myocardial infarction;
LGG	cis	rs9790314	0.967	rs463928	chr3:161087734	A/T	cg04691961	chr3:161091175	C3orf57	-0.7	-17.26	-0.63	6.71e-52	Morning vs. evening chronotype;
LGG	cis	rs12210905	0.688	rs57075114	chr6:27491169	T/G	cg10122326	chr6:28072925	NA	1.04	7.9	0.34	2.04e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12282928	1.000	rs1503183	chr11:48259296	C/T	cg26585981	chr11:48327164	OR4S1	-0.43	-6.96	-0.31	1.19e-11	Migraine - clinic-based;
LGG	trans	rs66573146	0.656	rs41410847	chr4:6957332	C/T	cg07817883	chr1:32538562	TMEM39B	1.12	11.69	0.48	7.83e-28	Granulocyte percentage of myeloid white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06432462	chr9:80646879	GNAQ	0.45	7.41	0.33	6.11e-13	Cognitive performance;
LGG	cis	rs950776	0.752	rs2869546	chr15:78907345	C/T	cg06917634	chr15:78832804	PSMA4	-0.69	-12.77	-0.51	3.28e-32	Sudden cardiac arrest;
LGG	cis	rs2180341	0.960	rs1543432	chr6:127698018	T/C	cg27446573	chr6:127587934	RNF146	1.13	22.33	0.72	1.64e-75	Breast cancer;
LGG	cis	rs780096	0.546	rs1260320	chr2:27722416	A/G	cg27432699	chr2:27873401	GPN1	0.48	8.32	0.36	9.94e-16	Total body bone mineral density;
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.24	0.46	4.45e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13191362	1.000	rs35044651	chr6:163004142	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.89	10.3	0.43	1.49e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs17428076	0.793	rs12622772	chr2:172625737	T/C	cg21435375	chr2:172878103	MAP1D	0.41	8.98	0.39	6.9e-18	Myopia;
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.58	9.99	0.42	2e-21	Birth weight;
LGG	cis	rs769267	0.930	rs9917108	chr19:19572785	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.25	0.43	2.34e-22	Tonsillectomy;
LGG	trans	rs7939886	0.920	rs11227428	chr11:55941972	C/G	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs644799	1.000	rs2508289	chr11:95624669	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.37	0.32	8.05e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs11657120	chr17:61857218	G/A	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.07e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.920	rs1337842	chr6:86675097	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.81	-0.34	3.91e-14	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	9.37	0.4	3.13e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg14191688	chr11:70257035	CTTN	0.5	7.16	0.32	3.22e-12	Coronary artery disease;
LGG	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.94e-31	Motion sickness;
LGG	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg16680214	chr1:154839983	KCNN3	-0.36	-6.75	-0.3	4.34e-11	Prostate cancer;
LGG	cis	rs11608355	0.515	rs11609630	chr12:109918934	C/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg22968622	chr17:43663579	NA	0.79	15.34	0.58	3.09e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7226408	0.857	rs72888928	chr18:34531073	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs1816752	0.905	rs9511242	chr13:24993399	G/A	cg22771759	chr13:24902376	NA	0.43	7.3	0.32	1.22e-12	Obesity-related traits;
LGG	cis	rs9633740	0.578	rs7084416	chr10:82304297	G/A	cg01528321	chr10:82214614	TSPAN14	-0.85	-10.56	-0.44	1.63e-23	Post bronchodilator FEV1;
LGG	cis	rs9322193	0.884	rs62439837	chr6:149991516	G/T	cg12070911	chr6:150209640	RAET1E	0.31	7.4	0.33	6.48e-13	Lung cancer;
LGG	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg26138144	chr22:38071188	LGALS1	0.68	15.51	0.58	5.21e-44	Fat distribution (HIV);
LGG	cis	rs876084	0.505	rs10216978	chr8:121105620	C/A	cg06265175	chr8:121136014	COL14A1	0.47	9.59	0.41	5.31e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11628318	0.713	rs4900543	chr14:103029024	T/C	cg23461800	chr14:103021989	NA	-0.58	-10.55	-0.44	1.78e-23	Platelet count;
LGG	trans	rs783540	0.934	rs36109438	chr15:83264459	T/G	cg16105309	chr15:79090380	ADAMTS7	0.42	7.36	0.32	8.19e-13	Schizophrenia;
LGG	cis	rs7945705	0.776	rs2316865	chr11:8815470	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.43	8.7	0.37	5.75e-17	Hemoglobin concentration;
LGG	cis	rs4747241	0.626	rs9415061	chr10:74081183	G/T	cg25082487	chr10:74091975	NA	0.38	7.07	0.31	5.7e-12	Heschl's gyrus morphology;
LGG	trans	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg16141378	chr3:129829833	LOC729375	-0.33	-7.3	-0.32	1.3e-12	Mean corpuscular volume;
LGG	cis	rs7737355	0.773	rs28852	chr5:131027842	A/C	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.31e-17	Life satisfaction;
LGG	cis	rs990171	0.913	rs2272128	chr2:103039929	G/A	cg05295703	chr2:102895712	NA	-0.55	-9.69	-0.41	2.53e-20	Lymphocyte counts;
LGG	cis	rs10911232	0.507	rs12037623	chr1:183000148	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs9815354	0.680	rs79239400	chr3:42030249	C/A	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3857067	0.806	rs17374832	chr4:95114394	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.54	-0.47	2.9e-27	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11785400	0.793	rs11785376	chr8:143730412	C/T	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	4.01e-13	Schizophrenia;
LGG	cis	rs6840360	0.667	rs4266275	chr4:152348064	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.06	0.31	6.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1538970	1.000	rs4660852	chr1:45848931	A/C	cg05343316	chr1:45956843	TESK2	-0.69	-11.57	-0.47	2.35e-27	Platelet count;
LGG	cis	rs3742264	0.615	rs4941536	chr13:46523444	A/G	cg15192986	chr13:46630673	CPB2	-0.35	-6.67	-0.3	7.32e-11	Blood protein levels;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10911251	0.527	rs1537520	chr1:183084229	C/T	cg15522984	chr1:182991683	LAMC1	0.46	8.97	0.38	7.31e-18	Colorectal cancer;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.52	-0.5	3.56e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs2535633	0.631	rs2336670	chr3:52998504	T/G	cg11645453	chr3:52864694	ITIH4	-0.48	-7.89	-0.34	2.25e-14	Body mass index;
LGG	cis	rs12477438	0.501	rs6715321	chr2:100109001	A/G	cg23527387	chr2:100056660	REV1	-0.42	-9.41	-0.4	2.33e-19	Chronic sinus infection;
LGG	cis	rs8180040	0.966	rs17784882	chr3:47544003	C/A	cg27129171	chr3:47204927	SETD2	-0.79	-15.2	-0.58	1.27e-42	Colorectal cancer;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg05665937	chr4:1216051	CTBP1	0.56	10.34	0.43	1.09e-22	Obesity-related traits;
LGG	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg26655873	chr3:72818019	SHQ1	0.34	7.08	0.31	5.38e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7465272	1.000	rs35868630	chr8:143685933	G/A	cg10104451	chr8:143696006	ARC	-0.75	-11.09	-0.46	1.66e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg07362569	chr17:61921086	SMARCD2	0.49	9.55	0.41	7.31e-20	Prudent dietary pattern;
LGG	trans	rs208520	0.661	rs150263	chr6:66777620	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.87	-0.64	1.09e-54	Exhaled nitric oxide output;
LGG	cis	rs12497850	0.931	rs7647813	chr3:48833348	G/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.89	0.45	1e-24	Parkinson's disease;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg11050988	chr7:1952600	MAD1L1	-0.34	-8.04	-0.35	7.31e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg20587970	chr11:113659929	NA	-1.3	-24.25	-0.75	1.8e-84	Hip circumference adjusted for BMI;
LGG	cis	rs1210638	0.575	rs11703200	chr22:18959169	G/A	cg12798833	chr22:18958832	DGCR5	0.89	15.33	0.58	3.46e-43	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg17541922	chr11:86511813	PRSS23	0.42	7.16	0.32	3.23e-12	Corneal astigmatism;
LGG	cis	rs9303401	0.614	rs12947982	chr17:57140301	A/G	cg25039879	chr17:56429692	SUPT4H1	0.56	8.02	0.35	8.64e-15	Cognitive test performance;
LGG	cis	rs2594989	0.887	rs7632902	chr3:11476884	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.46	-0.33	4.38e-13	Circulating chemerin levels;
LGG	cis	rs975210	0.790	rs74021482	chr15:70355123	C/G	cg01666796	chr15:70364327	TLE3	-0.53	-7.1	-0.31	4.63e-12	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs10197940	0.624	rs6724796	chr2:152412813	C/T	cg06191203	chr2:152266755	RIF1	-0.46	-8.07	-0.35	6.03e-15	Lung cancer;
LGG	trans	rs2797160	0.651	rs6939969	chr6:126034563	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.46	8.04	0.35	7.52e-15	Endometrial cancer;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg12419862	chr22:24373484	LOC391322	-0.87	-17.56	-0.63	2.96e-53	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg26850624	chr5:429559	AHRR	-0.29	-6.77	-0.3	3.93e-11	Cystic fibrosis severity;
LGG	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26850624	chr5:429559	AHRR	-0.37	-8.13	-0.35	3.94e-15	Cystic fibrosis severity;
LGG	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.46	2.61e-26	Bipolar disorder;
LGG	trans	rs9354308	0.738	rs9453473	chr6:66599132	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.9	-0.31	1.73e-11	Metabolite levels;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9379850	1.000	rs9379850	chr6:26343057	C/G	cg12826209	chr6:26865740	GUSBL1	0.83	10.02	0.42	1.57e-21	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23260255	chr3:187871479	LPP	0.44	7.22	0.32	2.16e-12	Gut microbiome composition (summer);
LGG	cis	rs1816752	0.875	rs17384871	chr13:25059097	T/C	cg22771759	chr13:24902376	NA	0.42	7.19	0.32	2.62e-12	Obesity-related traits;
LGG	trans	rs5756813	0.646	rs3788528	chr22:38146433	T/C	cg19894588	chr14:64061835	NA	0.44	7.4	0.33	6.32e-13	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7618915	0.547	rs11130314	chr3:52697082	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.21	-0.32	2.25e-12	Bipolar disorder;
LGG	cis	rs4308124	0.679	rs7600458	chr2:111963590	G/C	cg04571233	chr2:111982156	NA	-0.6	-9.84	-0.42	6.95e-21	Vitiligo;
LGG	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.41	-0.33	6.16e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs61931739	0.534	rs4086956	chr12:34105047	A/T	cg06521331	chr12:34319734	NA	-0.61	-11.54	-0.47	3e-27	Morning vs. evening chronotype;
LGG	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg24253500	chr15:84953950	NA	0.42	6.96	0.31	1.2e-11	Schizophrenia;
LGG	cis	rs6752107	1.000	rs6431654	chr2:234161769	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.44	8.18	0.36	2.73e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3762637	1.000	rs55853677	chr3:122140616	G/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.56	-0.44	1.71e-23	LDL cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22029275	chr13:25745784	FAM123A	0.51	7.79	0.34	4.46e-14	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg11494091	chr17:61959527	GH2	-1.0	-24.28	-0.75	1.33e-84	Prudent dietary pattern;
LGG	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.64	-0.37	9.42e-17	Joint mobility (Beighton score);
LGG	cis	rs4538187	0.851	rs11674020	chr2:64134894	G/A	cg19915305	chr2:64069682	UGP2	-0.69	-15.78	-0.59	3.34e-45	Systolic blood pressure;
LGG	cis	rs9902453	1.000	rs4575590	chr17:28361969	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs6940638	0.956	rs12203454	chr6:27031100	C/T	cg09904177	chr6:26538194	HMGN4	-0.52	-7.26	-0.32	1.67e-12	Intelligence (multi-trait analysis);
LGG	cis	rs782590	0.537	rs12619903	chr2:55884106	T/A	cg18811423	chr2:55921094	PNPT1	-0.68	-11.28	-0.46	3.11e-26	Metabolic syndrome;
LGG	cis	rs2063714	1.000	rs2063714	chr6:157195980	C/G	cg23222435	chr6:157204239	ARID1B	-0.65	-12.51	-0.5	3.96e-31	Sitting height ratio;
LGG	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg00325661	chr8:49890786	NA	-0.45	-7.85	-0.34	2.82e-14	Sudden cardiac arrest;
LGG	cis	rs9325144	0.560	rs7304568	chr12:38632408	G/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.63	-0.61	5.22e-49	Morning vs. evening chronotype;
LGG	cis	rs2282526	0.587	rs91424	chr21:44921161	A/G	cg04455712	chr21:45112962	RRP1B	-0.45	-7.92	-0.35	1.75e-14	Mean corpuscular hemoglobin;
LGG	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.24	-0.36	1.84e-15	Alzheimer's disease (survival time);
LGG	cis	rs7712401	0.562	rs30052	chr5:122305009	A/T	cg19412675	chr5:122181750	SNX24	0.41	6.79	0.3	3.54e-11	Mean platelet volume;
LGG	cis	rs9398803	0.865	rs9375442	chr6:126803137	A/C	cg19875578	chr6:126661172	C6orf173	0.55	10.03	0.42	1.53e-21	Male-pattern baldness;
LGG	cis	rs5771225	0.544	rs67157296	chr22:50672877	T/C	cg16473166	chr22:50639996	SELO	0.73	11.19	0.46	6.94e-26	Late-onset Alzheimer's disease;
LGG	cis	rs155076	0.666	rs2015241	chr13:21888254	A/G	cg06138931	chr13:21896616	NA	0.54	8.87	0.38	1.66e-17	White matter hyperintensity burden;
LGG	cis	rs7923609	1.000	rs10761727	chr10:64995493	C/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.76	-0.3	4.25e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg01191920	chr7:158217561	PTPRN2	0.91	24.48	0.75	1.55e-85	Obesity-related traits;
LGG	cis	rs2354432	0.556	rs4295925	chr1:146857335	T/C	cg25205988	chr1:146714368	CHD1L	1.19	11.63	0.48	1.29e-27	Mitochondrial DNA levels;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg02725872	chr8:58115012	NA	-0.93	-12.32	-0.5	2.21e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6752107	0.791	rs3792106	chr2:234190740	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.41	7.18	0.32	2.85e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg13880726	chr7:1868755	MAD1L1	0.41	7.24	0.32	1.86e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.57	-0.44	1.48e-23	Lung cancer;
LGG	trans	rs1964356	0.967	rs2953802	chr8:8851881	G/A	cg02002194	chr4:3960332	NA	-0.4	-7.28	-0.32	1.4e-12	Mean corpuscular volume;
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg11764359	chr7:65958608	NA	0.74	13.39	0.53	8.69e-35	Aortic root size;
LGG	cis	rs4750440	0.671	rs1809305	chr10:14026780	G/A	cg00551146	chr10:14014579	FRMD4A	0.3	7.21	0.32	2.34e-12	Adiponectin levels;
LGG	cis	rs7103648	0.897	rs3758675	chr11:47400602	G/A	cg20307385	chr11:47447363	PSMC3	0.92	20.5	0.69	6.54e-67	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs7267979	1.000	rs4813563	chr20:25365340	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4808199	0.948	rs757000	chr19:19448301	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.32	0.32	1.1e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs2404602	0.692	rs67010831	chr15:76965308	T/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.74	-0.3	4.77e-11	Blood metabolite levels;
LGG	trans	rs1997103	1.000	rs6973450	chr7:55396537	A/G	cg20935933	chr6:143382018	AIG1	0.59	9.1	0.39	2.74e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4919044	1.000	rs17108036	chr10:94766779	C/G	cg05127821	chr10:94822908	CYP26C1	-0.51	-7.82	-0.34	3.56e-14	Coronary artery disease;
LGG	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg24812749	chr6:127587940	RNF146	0.66	11.23	0.46	5e-26	Breast cancer;
LGG	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504130	0.542	rs1589079	chr8:52836299	T/C	cg24946253	chr8:52722146	PXDNL	-0.5	-8.21	-0.36	2.27e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs1499614	0.522	rs13247442	chr7:66188858	T/C	cg10756647	chr7:56101905	PSPH	0.76	7.38	0.32	7.46e-13	Gout;
LGG	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg09467607	chr2:36825704	FEZ2	0.63	13.24	0.52	3.62e-34	Height;
LGG	cis	rs752010	0.806	rs943375	chr1:42092152	A/G	cg16096631	chr1:42092165	HIVEP3	0.8	24.64	0.75	2.86e-86	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg26513180	chr16:89883248	FANCA	0.94	21.76	0.71	8.08e-73	Vitiligo;
LGG	cis	rs7326068	0.576	rs34880311	chr13:21329255	A/T	cg04906043	chr13:21280425	IL17D	-0.44	-7.12	-0.31	4.15e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs7937682	0.632	rs10891297	chr11:111770150	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs1797081	0.967	rs780633	chr10:16863161	C/T	cg23933602	chr10:16859644	RSU1	1.01	26.99	0.78	4.38e-97	Platelet distribution width;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.45	-7.78	-0.34	4.63e-14	Obesity-related traits;
LGG	cis	rs17125944	0.505	rs10483618	chr14:53203590	T/C	cg13660082	chr14:53194042	PSMC6	-0.56	-7.97	-0.35	1.24e-14	Alzheimer's disease (late onset);
LGG	cis	rs6951245	0.872	rs57068908	chr7:1060084	A/C	cg24642844	chr7:1081250	C7orf50	-0.74	-12.46	-0.5	6.23e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg22906224	chr7:99728672	NA	0.55	8.94	0.38	9.65e-18	Coronary artery disease;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06873352	chr17:61820015	STRADA	0.73	13.73	0.54	3.12e-36	Prudent dietary pattern;
LGG	cis	rs1465370	0.720	rs3823579	chr7:130017374	T/C	cg06917763	chr7:130033247	NA	0.33	7.23	0.32	2.02e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs561341	0.739	rs7213369	chr17:30211878	G/A	cg27661571	chr11:113659931	NA	0.47	6.78	0.3	3.56e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	0.608	rs2302786	chr3:9979660	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.35	-0.43	1.01e-22	Alzheimer's disease;
LGG	cis	rs9460578	0.673	rs9465925	chr6:20882544	C/T	cg13405222	chr6:20811065	CDKAL1	0.66	11.77	0.48	3.73e-28	Breast cancer;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.28	-0.36	1.32e-15	Lymphocyte counts;
LGG	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06108461	chr20:60628389	TAF4	-0.74	-13.42	-0.53	6.37e-35	Body mass index;
LGG	cis	rs13108904	0.935	rs1732100	chr4:1281761	C/T	cg00684032	chr4:1343700	KIAA1530	-0.47	-9.16	-0.39	1.75e-18	Obesity-related traits;
LGG	trans	rs7944735	0.690	rs7927682	chr11:47947658	T/C	cg15704280	chr7:45808275	SEPT13	0.69	8.24	0.36	1.77e-15	Intraocular pressure;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-10.78	-0.45	2.5300000000000002e-24	Lung cancer;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg13628971	chr7:2884303	GNA12	0.5	10.11	0.43	7.79e-22	Height;
LGG	cis	rs11864453	0.645	rs7194668	chr16:72128207	G/C	cg23815491	chr16:72088622	HP	0.42	9.28	0.4	6.51e-19	Fibrinogen levels;
LGG	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg27478167	chr7:817139	HEATR2	-0.48	-6.94	-0.31	1.33e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7681440	0.804	rs1442135	chr4:90819093	C/T	cg15133208	chr4:90757351	SNCA	0.35	7.75	0.34	5.95e-14	Dementia with Lewy bodies;
LGG	cis	rs7615952	0.599	rs6438955	chr3:125730333	C/A	cg15145296	chr3:125709740	NA	-0.59	-7.68	-0.34	9.7e-14	Blood pressure (smoking interaction);
LGG	cis	rs7928758	1.000	rs28402124	chr11:134280521	T/C	cg15243474	chr11:134282918	B3GAT1	1.05	13.44	0.53	5.28e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4423214	0.592	rs10898211	chr11:71210677	T/C	cg10847948	chr11:71163743	NADSYN1	0.58	8.73	0.38	4.6e-17	Vitamin D levels;
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg18446336	chr7:2847575	GNA12	-0.29	-6.92	-0.31	1.54e-11	Height;
LGG	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg14416269	chr4:6271139	WFS1	0.46	7.67	0.34	1.03e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.79	0.3	3.54e-11	Longevity;
LGG	cis	rs8180040	0.900	rs10865946	chr3:47425060	T/G	cg16586182	chr3:47516702	SCAP	-0.78	-15.62	-0.59	1.77e-44	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs9895684	chr17:29242600	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.23	-0.32	2.06e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs3733585	0.563	rs881971	chr4:9930962	A/G	cg26043149	chr18:55253948	FECH	-0.4	-6.84	-0.3	2.52e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11190604	1.000	rs4604805	chr10:102261409	C/G	cg07570687	chr10:102243282	WNT8B	0.42	7.33	0.32	1.04e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4731207	0.570	rs2086505	chr7:124664157	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.97	-0.31	1.09e-11	Cutaneous malignant melanoma;
LGG	cis	rs4481887	0.927	rs4405158	chr1:248490647	A/C	cg01631408	chr1:248437212	OR2T33	-0.53	-9.48	-0.4	1.31e-19	Common traits (Other);
LGG	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg27511599	chr7:32358540	NA	0.57	6.73	0.3	5.05e-11	Body mass index;
LGG	cis	rs9291683	0.679	rs2241483	chr4:10099831	A/G	cg08250081	chr4:10125330	NA	-0.34	-6.69	-0.3	6.47e-11	Bone mineral density;
LGG	cis	rs12421382	0.659	rs57978015	chr11:109385473	T/C	cg04861929	chr11:109293070	C11orf87	0.56	10.09	0.42	8.66e-22	Schizophrenia;
LGG	trans	rs35110281	0.811	rs2838337	chr21:45072621	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.12	0.49	1.49e-29	Mean corpuscular volume;
LGG	cis	rs11628318	0.570	rs4906231	chr14:103062227	T/C	cg01864069	chr14:103024347	NA	-0.68	-9.87	-0.42	5.39e-21	Platelet count;
LGG	cis	rs2120243	0.621	rs7634847	chr3:157159145	A/G	cg24825693	chr3:157122686	VEPH1	-0.39	-8.26	-0.36	1.57e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs12517041	1.000	rs1428627	chr5:23309212	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	cis	rs35123781	1.000	rs599946	chr5:139057461	A/G	cg21230503	chr5:139085173	NA	0.31	7.41	0.33	6.08e-13	Schizophrenia;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.88e-11	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg00409905	chr10:38381863	ZNF37A	0.65	12.62	0.51	1.43e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.37e-12	Lung cancer;
LGG	cis	rs6500602	0.727	rs3761681	chr16:4566857	C/T	cg01673284	chr16:4527211	HMOX2	0.33	6.92	0.31	1.49e-11	Schizophrenia;
LGG	cis	rs1550582	1.000	rs16905157	chr8:135519964	C/T	cg17885191	chr8:135476712	NA	0.67	10.5	0.44	2.82e-23	Educational attainment;
LGG	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg07382826	chr16:28625726	SULT1A1	0.36	7.39	0.32	6.92e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9921222	0.565	rs10903014	chr16:377623	A/G	cg00101154	chr16:420108	MRPL28	-0.62	-10.78	-0.45	2.56e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs757278	0.896	rs10258815	chr7:117401398	G/A	cg10524701	chr7:117356490	CTTNBP2	0.35	6.93	0.31	1.39e-11	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.79	0.41	1.11e-20	Mean corpuscular volume;
LGG	cis	rs7827545	0.961	rs4909482	chr8:135564786	G/T	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs12153243	0.714	rs17402447	chr5:142916732	G/T	cg13907255	chr5:142895549	NA	0.5	8.84	0.38	1.96e-17	Migraine;
LGG	cis	rs6061231	0.724	rs1570027	chr20:60968596	A/G	cg22601191	chr20:60968625	CABLES2	0.58	10.13	0.43	6.18e-22	Colorectal cancer;
LGG	cis	rs2742417	1.000	rs767280	chr3:45771601	C/G	cg04837898	chr3:45731254	SACM1L	-0.36	-7.04	-0.31	7.04e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs7980799	0.682	rs1601006	chr12:33629519	C/T	cg13010199	chr12:38710504	ALG10B	-0.43	-7.79	-0.34	4.45e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg17145862	chr1:211918768	LPGAT1	0.97	24.89	0.76	2.05e-87	Leprosy;
LGG	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	12.9	0.51	9.21e-33	Response to antipsychotic treatment;
LGG	cis	rs1465370	0.711	rs2302823	chr7:130008159	A/G	cg25718383	chr7:130020096	CPA1	0.29	7.07	0.31	5.81e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg02503808	chr4:7069936	GRPEL1	-0.97	-13.7	-0.54	4.29e-36	Monocyte percentage of white cells;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01089589	chr2:10920095	ATP6V1C2	0.41	6.67	0.3	7.23e-11	Pancreatic cancer;
LGG	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg10518543	chr12:38710700	ALG10B	0.42	6.8	0.3	3.19e-11	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.958	rs1548067	chr2:178462914	C/T	cg22681709	chr2:178499509	PDE11A	-0.42	-7.83	-0.34	3.43e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg05784532	chr1:230284198	GALNT2	-0.55	-9.09	-0.39	2.85e-18	Coronary artery disease;
LGG	cis	rs8133932	0.736	rs4819159	chr21:47285605	A/G	cg11214348	chr21:47283868	PCBP3	0.44	7.99	0.35	1.1e-14	Schizophrenia;
LGG	cis	rs2013441	1.000	rs2158473	chr17:20139090	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs769267	0.965	rs2074299	chr19:19380646	T/C	cg11584989	chr19:19387371	SF4	0.44	7.93	0.35	1.67e-14	Tonsillectomy;
LGG	cis	rs2243480	1.000	rs6460260	chr7:65215455	T/C	cg18252515	chr7:66147081	NA	1.32	18.42	0.65	3.11e-57	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg04503457	chr17:41445688	NA	0.35	8.39	0.36	5.88e-16	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11496811	chr1:181058973	IER5	0.45	7.35	0.32	9.07e-13	Cognitive performance;
LGG	cis	rs1790761	0.967	rs1476792	chr11:67196237	A/G	cg14500267	chr11:67383377	NA	-0.38	-7.05	-0.31	6.74e-12	Mean corpuscular volume;
LGG	cis	rs910316	1.000	rs1047418	chr14:75605792	A/G	cg08847533	chr14:75593920	NEK9	0.62	11.87	0.48	1.5e-28	Height;
LGG	cis	rs4862307	0.808	rs6817858	chr4:185000321	G/A	cg06737308	chr4:185021514	ENPP6	-0.4	-6.95	-0.31	1.22e-11	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	trans	rs6582630	0.537	rs1851124	chr12:38516404	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.87	-0.38	1.54e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9863	0.828	rs56041971	chr12:124480866	G/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.12	-0.31	4.09e-12	White blood cell count;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg19635926	chr16:89946313	TCF25	0.81	9.09	0.39	2.93e-18	Skin colour saturation;
LGG	cis	rs9341835	0.510	rs7745873	chr6:64165853	A/G	cg00787780	chr6:64151745	NA	0.42	7.25	0.32	1.79e-12	Schizophrenia;
LGG	cis	rs1882538	0.503	rs1345938	chr7:133137867	C/T	cg10665199	chr7:133106180	EXOC4	-0.54	-9.18	-0.39	1.47e-18	Intelligence (multi-trait analysis);
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.39	-0.43	6.99e-23	Triglycerides;
LGG	cis	rs4481887	0.830	rs10888341	chr1:248441995	T/C	cg13385794	chr1:248469461	NA	0.5	8.31	0.36	1.07e-15	Common traits (Other);
LGG	cis	rs17376456	0.877	rs10052428	chr5:93476530	T/C	cg19507638	chr5:93509721	C5orf36	-0.72	-9.95	-0.42	2.89e-21	Diabetic retinopathy;
LGG	cis	rs3849046	0.680	rs13165665	chr5:137946500	A/G	cg10920316	chr5:137946599	NA	-0.44	-7.11	-0.31	4.44e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7904368	0.707	rs12253979	chr10:16853415	T/C	cg14835575	chr10:16859367	RSU1	0.79	14.49	0.56	1.71e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs1577917	0.771	rs2758844	chr6:86330115	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.67	-11.88	-0.48	1.4e-28	Response to antipsychotic treatment;
LGG	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.7	-0.34	8.11e-14	Restless legs syndrome;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2486288	0.656	rs7167146	chr15:45571386	A/G	cg26924012	chr15:45694286	SPATA5L1	0.63	10.94	0.45	6.07e-25	Glomerular filtration rate;
LGG	cis	rs7681440	0.647	rs6824979	chr4:90819407	C/G	cg26578617	chr4:90757533	SNCA	0.35	7.02	0.31	7.82e-12	Dementia with Lewy bodies;
LGG	cis	rs2373794	0.614	rs423177	chr2:40379296	A/G	cg17740179	chr2:40377776	SLC8A1	0.76	9.62	0.41	4.33e-20	Asthma;
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.87	0.34	2.47e-14	Lung cancer;
LGG	cis	rs7715806	0.500	rs4703676	chr5:74979866	G/C	cg19683494	chr5:74908142	NA	0.52	6.86	0.3	2.24e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1355223	0.902	rs12801509	chr11:34747336	G/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-6.76	-0.3	4.12e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg03576123	chr11:487126	PTDSS2	-1.21	-15.41	-0.58	1.43e-43	Body mass index;
LGG	cis	rs8135665	0.625	rs34385006	chr22:38450291	C/T	cg13116946	chr22:38479732	SLC16A8	0.53	8.69	0.37	6.32e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs11098499	0.866	rs12501602	chr4:120287935	A/T	cg24375607	chr4:120327624	NA	0.57	9.38	0.4	2.9e-19	Corneal astigmatism;
LGG	cis	rs8014204	0.901	rs2080087	chr14:75365062	C/T	cg06637938	chr14:75390232	RPS6KL1	0.85	17.42	0.63	1.27e-52	Caffeine consumption;
LGG	cis	rs73081554	0.611	rs35975336	chr3:58451634	G/A	cg24175188	chr3:58374923	PXK	0.55	7.37	0.32	7.73e-13	Rheumatoid arthritis;
LGG	cis	rs1348850	0.958	rs4528793	chr2:178464271	C/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.91	-0.34	1.92e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg01765077	chr12:122356316	WDR66	-0.26	-6.72	-0.3	5.41e-11	Mean corpuscular volume;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.6	-0.37	1.28e-16	Menopause (age at onset);
LGG	cis	rs34172651	0.517	rs189919	chr16:24737741	G/A	cg06028605	chr16:24865363	SLC5A11	-0.47	-7.7	-0.34	8.32e-14	Intelligence (multi-trait analysis);
LGG	cis	rs55788414	0.527	rs2873368	chr16:81184208	C/G	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg00684032	chr4:1343700	KIAA1530	0.68	14.24	0.55	2.04e-38	Obesity-related traits;
LGG	cis	rs7481584	1.000	rs3814964	chr11:2999507	G/T	cg08508325	chr11:3079039	CARS	0.39	7.1	0.31	4.72e-12	Calcium levels;
LGG	trans	rs11098499	0.532	rs4504231	chr4:120586891	G/A	cg25214090	chr10:38739885	LOC399744	0.57	9.9	0.42	4.46e-21	Corneal astigmatism;
LGG	cis	rs3749237	0.595	rs35701831	chr3:49515000	A/C	cg07636037	chr3:49044803	WDR6	0.6	10.48	0.44	3.25e-23	Resting heart rate;
LGG	cis	rs1707322	1.000	rs785510	chr1:46528618	T/C	cg03146154	chr1:46216737	IPP	-0.53	-9.64	-0.41	3.69e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs8048589	0.642	rs8062015	chr16:12176879	G/A	cg02910054	chr16:12241554	SNX29	0.41	6.78	0.3	3.63e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.8	0.3	3.18e-11	Parkinson's disease;
LGG	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg01181863	chr3:195395398	SDHAP2	-0.73	-12.27	-0.5	3.68e-30	Pancreatic cancer;
LGG	cis	rs7584262	0.573	rs11891679	chr2:42275726	C/G	cg19376973	chr2:42229025	NA	0.53	8.35	0.36	8.13e-16	Bone mineral density;
LGG	cis	rs9522267	0.643	rs9522279	chr13:112221296	C/T	cg10483660	chr13:112241077	NA	-0.37	-7.8	-0.34	4.09e-14	Hepatitis;
LGG	cis	rs9912468	0.901	rs67828405	chr17:64324384	C/T	cg19474267	chr17:64306194	PRKCA	0.94	25.38	0.76	1.04e-89	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs17767392	0.958	rs2877729	chr14:71887868	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	1.02e-17	Mitral valve prolapse;
LGG	cis	rs4538187	1.000	rs11676710	chr2:64173754	A/G	cg14150252	chr2:64069583	UGP2	-0.51	-10.06	-0.42	1.14e-21	Systolic blood pressure;
LGG	cis	rs3126085	0.935	rs3126094	chr1:152308243	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.58	-0.37	1.41e-16	Atopic dermatitis;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.26	-0.43	2.16e-22	Lung cancer;
LGG	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg25358565	chr5:93447407	FAM172A	-0.83	-11.41	-0.47	9.5e-27	Diabetic retinopathy;
LGG	cis	rs2236293	0.899	rs1885372	chr9:35838030	A/G	cg12876594	chr9:35791798	NPR2	0.37	6.96	0.31	1.14e-11	Blood protein levels;
LGG	cis	rs453301	0.522	rs1964356	chr8:8853270	G/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.27	0.4	7.13e-19	Joint mobility (Beighton score);
LGG	trans	rs61931739	0.517	rs56308002	chr12:34016021	C/G	cg13010199	chr12:38710504	ALG10B	0.57	10.73	0.45	4e-24	Morning vs. evening chronotype;
LGG	cis	rs8017423	0.967	rs55962513	chr14:90729460	C/G	cg04374321	chr14:90722782	PSMC1	0.9	19.49	0.67	3.31e-62	Mortality in heart failure;
LGG	cis	rs11235843	0.602	rs7106773	chr11:73383174	C/G	cg18195628	chr11:73498948	MRPL48	-0.51	-7.17	-0.32	2.96e-12	Hand grip strength;
LGG	cis	rs1007190	0.881	rs9909048	chr17:42973517	G/C	cg15406952	chr17:42872593	NA	1.09	14.13	0.55	5.86e-38	DNA methylation (variation);
LGG	cis	rs12410462	0.581	rs7541809	chr1:227547299	G/A	cg04117972	chr1:227635322	NA	0.57	9.37	0.4	3.12e-19	Major depressive disorder;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.43	0.47	8.11e-27	Electroencephalogram traits;
LGG	cis	rs7786808	0.552	rs2878456	chr7:158182129	A/T	cg12438819	chr7:158236134	PTPRN2	0.32	8.11	0.35	4.43e-15	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.7	-0.41	2.33e-20	Lung cancer;
LGG	cis	rs7953249	0.656	rs1732391	chr12:121392341	C/T	cg14101638	chr12:121416612	HNF1A	-0.45	-9.8	-0.41	9.9e-21	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs1847505	0.593	rs3127045	chr13:61401233	C/T	cg25164009	chr13:61490935	NA	-0.57	-9.04	-0.39	4.29e-18	Polychlorinated biphenyl levels;
LGG	cis	rs7208859	0.623	rs56378576	chr17:29010120	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.67	-8.0	-0.35	1e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg04863758	chr4:1303710	MAEA	0.42	7.24	0.32	1.9e-12	Obesity-related traits;
LGG	cis	rs853679	0.517	rs4713135	chr6:28039586	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.45	-0.33	4.63e-13	Depression;
LGG	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg08048268	chr3:133502702	NA	-0.6	-11.23	-0.46	4.91e-26	Iron status biomarkers;
LGG	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg03929089	chr4:120376271	NA	-0.64	-8.91	-0.38	1.17e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9788721	0.902	rs114205691	chr15:78901113	C/T	cg18825076	chr15:78729989	IREB2	-0.44	-7.04	-0.31	6.96e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs151349	1.000	rs108727	chr20:57584890	C/T	cg23907860	chr20:57583709	CTSZ	0.45	9.46	0.4	1.62e-19	Platelet distribution width;
LGG	cis	rs12188164	0.620	rs1043356	chr5:480948	C/T	cg21972741	chr5:435613	AHRR	-0.46	-7.12	-0.31	4.14e-12	Cystic fibrosis severity;
LGG	trans	rs853679	0.607	rs13217619	chr6:28306671	T/C	cg08344181	chr3:125677491	NA	-0.91	-9.3	-0.4	5.71e-19	Depression;
LGG	cis	rs908922	0.627	rs11590073	chr1:152500810	C/T	cg20991723	chr1:152506922	NA	-0.73	-15.0	-0.57	9.89e-42	Hair morphology;
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg08297393	chr2:100937505	LONRF2	-0.54	-10.12	-0.43	7.18e-22	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.853	rs4821811	chr22:39075145	C/T	cg21395723	chr22:39101663	GTPBP1	0.38	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs9863	0.828	rs4765541	chr12:124465995	T/C	cg13487667	chr12:124434373	CCDC92	-0.34	-6.86	-0.3	2.17e-11	White blood cell count;
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg10505658	chr17:80084571	CCDC57	0.41	8.45	0.37	3.82e-16	Life satisfaction;
LGG	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg16586182	chr3:47516702	SCAP	-0.76	-13.95	-0.54	3.68e-37	Colorectal cancer;
LGG	cis	rs7155454	1.000	rs12435835	chr14:65499909	T/G	cg11161011	chr14:65562177	MAX	-0.43	-7.07	-0.31	5.57e-12	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs12993904	0.501	rs2693830	chr2:6159255	C/A	cg00493617	chr2:6141445	NA	0.32	7.37	0.32	8.02e-13	Clozapine-induced agranulocytosis;
LGG	cis	rs3204270	0.530	rs57707013	chr17:79635281	C/T	cg18367735	chr17:79674897	NA	0.54	7.49	0.33	3.53e-13	Dental caries;
LGG	cis	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg24623649	chr8:11872141	NA	-0.34	-7.95	-0.35	1.45e-14	Triglycerides;
LGG	cis	rs7811142	0.830	rs61735533	chr7:99955866	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.57	0.67	1.39e-62	Platelet count;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg01494348	chr8:144660395	NAPRT1	0.93	7.41	0.33	6.01e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs55728055	0.661	rs73162106	chr22:32034875	A/G	cg15823100	chr22:32027580	PISD	-0.72	-8.23	-0.36	1.89e-15	Age-related hearing impairment;
LGG	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg21055462	chr7:100276975	NA	-0.44	-9.36	-0.4	3.4e-19	Other erythrocyte phenotypes;
LGG	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.78	-0.3	3.57e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2439831	1.000	rs28666488	chr15:43741090	G/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.18e-13	Lung cancer in ever smokers;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00631329	chr6:26305371	NA	-0.52	-9.26	-0.4	7.45e-19	Educational attainment;
LGG	cis	rs10489202	0.612	rs3820401	chr1:168074753	T/C	cg24449463	chr1:168025552	DCAF6	-0.57	-10.14	-0.43	5.88e-22	Schizophrenia;
LGG	cis	rs6748734	0.581	rs10207380	chr2:241860911	A/G	cg26818257	chr2:241905806	NA	0.51	10.78	0.45	2.59e-24	Urinary metabolites;
LGG	trans	rs1814175	0.817	rs7950856	chr11:49976394	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.71	-0.75	1.43e-86	Height;
LGG	cis	rs17666538	1.000	rs61064968	chr8:587933	T/C	cg07685180	chr8:600429	NA	-1.19	-10.28	-0.43	1.89e-22	IgG glycosylation;
LGG	cis	rs7582180	0.903	rs2309826	chr2:100905274	C/A	cg08297393	chr2:100937505	LONRF2	-0.53	-9.26	-0.4	7.42e-19	Intelligence (multi-trait analysis);
LGG	cis	rs975739	0.868	rs5351	chr13:78475313	C/T	cg07847733	chr13:78271382	SLAIN1	-0.39	-6.73	-0.3	5.15e-11	Hair color;
LGG	cis	rs2243480	1.000	rs4718316	chr7:65648731	A/G	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	cis	rs2013441	1.000	rs2703780	chr17:20143672	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs9467160	0.734	rs35901848	chr6:24443640	G/A	cg20631270	chr6:24437470	GPLD1	0.55	8.55	0.37	1.75e-16	Liver enzyme levels;
LGG	cis	rs7119	0.931	rs59418918	chr15:77833110	A/C	cg17802220	chr15:77601643	NA	-0.34	-7.25	-0.32	1.79e-12	Type 2 diabetes;
LGG	cis	rs4481887	0.927	rs9651177	chr1:248445702	A/G	cg01631408	chr1:248437212	OR2T33	-0.49	-9.42	-0.4	2.2e-19	Common traits (Other);
LGG	cis	rs7216064	0.953	rs9890629	chr17:65871559	G/A	cg12091567	chr17:66097778	LOC651250	-0.61	-8.9	-0.38	1.23e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14580567	chr4:145567271	HHIP	0.38	6.93	0.31	1.4e-11	Bilirubin levels;
LGG	trans	rs1005277	0.579	rs2472175	chr10:38382901	T/G	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.95	-0.31	1.25e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	1.000	rs6914463	chr6:86653415	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.51	-8.6	-0.37	1.25e-16	Response to antipsychotic treatment;
LGG	trans	rs2243480	1.000	rs11538349	chr7:65421871	C/T	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs2737618	0.651	rs2816976	chr1:200081021	A/T	cg21825944	chr1:200113062	NR5A2	-0.59	-11.46	-0.47	6.36e-27	Uric acid levels;
LGG	cis	rs67311347	0.910	rs13089215	chr3:40495894	T/C	cg13683864	chr3:40499215	RPL14	1.0	20.19	0.68	1.79e-65	Renal cell carcinoma;
LGG	cis	rs9322193	0.962	rs1413655	chr6:150142951	A/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.67	-0.3	7.46e-11	Lung cancer;
LGG	cis	rs7226408	0.532	rs323328	chr18:34723643	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.39	-8.48	-0.37	2.97e-16	Obesity-related traits;
LGG	cis	rs2985684	0.841	rs12894785	chr14:50049755	G/C	cg02151108	chr14:50098012	C14orf104	-0.43	-9.19	-0.39	1.36e-18	Carotid intima media thickness;
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26897989	chr16:1907736	C16orf73	-0.82	-13.84	-0.54	1.05e-36	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs765787	0.530	rs4270107	chr15:45535350	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg05096777	chr10:104283225	SUFU	0.32	7.14	0.31	3.63e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11098499	0.954	rs3890049	chr4:120326283	T/A	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.43e-26	Corneal astigmatism;
LGG	cis	rs1976403	0.633	rs1697422	chr1:21821897	T/C	cg20417195	chr1:21767127	NBPF3	0.43	7.73	0.34	6.8e-14	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs2980436	1	rs2980436	chr8:8092025	A/G	cg16141378	chr3:129829833	LOC729375	0.6	15.9	0.59	9.88e-46	Schizophrenia;
LGG	cis	rs12731740	1.000	rs67006021	chr1:208021328	C/T	cg22525895	chr1:207977042	MIR29B2	-0.65	-7.45	-0.33	4.67e-13	Biomedical quantitative traits;
LGG	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg21775007	chr8:11205619	TDH	0.43	6.68	0.3	6.87e-11	Myopia (pathological);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg19143629	chr17:61920732	SMARCD2	0.4	6.85	0.3	2.29e-11	Prudent dietary pattern;
LGG	cis	rs10267417	0.603	rs2892957	chr7:19952910	T/A	cg05791153	chr7:19748676	TWISTNB	0.52	6.82	0.3	2.89e-11	Night sleep phenotypes;
LGG	cis	rs1595825	0.891	rs76450397	chr2:198786112	T/C	cg00982548	chr2:198649783	BOLL	-0.52	-7.05	-0.31	6.65e-12	Ulcerative colitis;
LGG	cis	rs6579956	0.517	rs34814004	chr5:152065716	C/T	cg12297329	chr5:152029980	NA	0.44	7.22	0.32	2.17e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3106136	0.967	rs12499309	chr4:95171284	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.29	-0.36	1.2e-15	Capecitabine sensitivity;
LGG	cis	rs10791097	0.694	rs6590520	chr11:130747386	C/G	cg12179176	chr11:130786555	SNX19	0.84	17.73	0.64	4.68e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs11229555	0.645	rs10896774	chr11:58175837	T/G	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12765878	0.812	rs2475214	chr10:105660986	T/C	cg11005552	chr10:105648138	OBFC1	-0.82	-16.42	-0.61	4.56e-48	Coronary artery disease;
LGG	cis	rs12893668	0.542	rs12884809	chr14:104095320	G/A	cg23335576	chr14:104009727	NA	0.45	7.96	0.35	1.31e-14	Reticulocyte count;
LGG	cis	rs870825	0.860	rs60523653	chr4:185604676	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg16339924	chr4:17578868	LAP3	0.63	10.84	0.45	1.55e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3733585	0.699	rs13328050	chr4:9951120	G/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.73	-0.34	6.76e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg11441553	chr12:57614120	NXPH4	-0.59	-7.47	-0.33	4.1e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.825	rs34592268	chr5:93232751	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.36	0.43	9.08e-23	Diabetic retinopathy;
LGG	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg23788917	chr6:8435910	SLC35B3	-0.52	-8.9	-0.38	1.28e-17	Motion sickness;
LGG	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg03806693	chr22:41940476	POLR3H	-1.15	-21.94	-0.71	1.08e-73	Vitiligo;
LGG	cis	rs9916302	0.706	rs584377	chr17:37460128	G/A	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg17911788	chr17:44343683	NA	0.6	9.18	0.39	1.43e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs7084402	0.967	rs7921371	chr10:60330531	G/C	cg09696939	chr10:60272079	BICC1	0.35	6.85	0.3	2.38e-11	Refractive error;
LGG	cis	rs9815354	0.812	rs73077360	chr3:41850054	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1650123	0.677	rs703615	chr12:104019152	T/A	cg23227824	chr12:103980017	STAB2	0.36	8.51	0.37	2.45e-16	IgG glycosylation;
LGG	cis	rs2486288	0.656	rs8041702	chr15:45547093	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.21	-0.43	3.4e-22	Glomerular filtration rate;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14993530	chr1:245027115	HNRNPU	0.58	6.72	0.3	5.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.866	rs10518329	chr4:120401835	A/G	cg09307838	chr4:120376055	NA	0.75	12.82	0.51	2.06e-32	Corneal astigmatism;
LGG	cis	rs2117029	0.521	rs1039225	chr12:49582692	A/C	cg24176009	chr12:49580217	TUBA1A	0.6	11.58	0.47	2.17e-27	Intelligence (multi-trait analysis);
LGG	cis	rs868036	0.609	rs2127163	chr15:68090842	C/T	cg18567174	chr15:68126065	LBXCOR1	-0.39	-6.98	-0.31	1.01e-11	Restless legs syndrome;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg04503457	chr17:41445688	NA	-0.4	-9.42	-0.4	2.14e-19	Menopause (age at onset);
LGG	cis	rs17122278	1.000	rs57438673	chr11:118459039	G/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.68	-0.3	6.81e-11	Total cholesterol levels;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs1696756	0.759	rs1298563	chr17:77834703	G/A	cg00646381	chr17:77835854	NA	0.4	6.94	0.31	1.33e-11	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg13047869	chr3:10149882	C3orf24	0.55	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs13427251	0.868	rs1901284	chr2:100146040	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.52	9.64	0.41	3.79e-20	Chronic sinus infection;
LGG	cis	rs801193	0.844	rs2244022	chr7:66202430	A/G	cg11764359	chr7:65958608	NA	0.54	9.34	0.4	4.2e-19	Aortic root size;
LGG	cis	rs17221829	0.521	rs10741306	chr11:89313629	A/T	cg02982614	chr11:89391479	FOLH1B	-0.37	-8.41	-0.36	5.01e-16	Anxiety in major depressive disorder;
LGG	cis	rs2067615	0.579	rs4385986	chr12:107133775	C/T	cg15890332	chr12:107067104	RFX4	0.41	12.2	0.49	6.76e-30	Heart rate;
LGG	trans	rs7618501	0.966	rs13063621	chr3:49821625	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.92	0.51	7.73e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg13010199	chr12:38710504	ALG10B	0.58	11.27	0.46	3.36e-26	Morning vs. evening chronotype;
LGG	cis	rs6834538	0.928	rs10434015	chr4:113401363	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.3	0.36	1.11e-15	Free thyroxine concentration;
LGG	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.48e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4319547	0.688	rs10744287	chr12:123077485	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.44	-6.95	-0.31	1.29e-11	Body mass index;
LGG	cis	rs600231	0.708	rs1784100	chr11:65249227	T/C	cg17120908	chr11:65337727	SSSCA1	-0.51	-9.07	-0.39	3.33e-18	Bone mineral density;
LGG	cis	rs801193	1.000	rs1553610	chr7:66197233	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.73	-0.3	5.04e-11	Aortic root size;
LGG	cis	rs782590	0.683	rs782633	chr2:55898203	A/G	cg18811423	chr2:55921094	PNPT1	0.92	22.13	0.72	1.52e-74	Metabolic syndrome;
LGG	cis	rs13260300	0.614	rs1582725	chr8:75532966	A/G	cg22993706	chr8:75542856	NA	0.41	7.93	0.35	1.67e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs3820928	0.904	rs60906902	chr2:227760034	C/T	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.3	-0.32	1.27e-12	Pulmonary function;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg04234412	chr22:24373322	LOC391322	-0.77	-16.85	-0.62	4.9e-50	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.58	0.33	1.86e-13	Cystic fibrosis severity;
LGG	cis	rs7089973	0.966	rs36089581	chr10:116623059	G/C	cg08188268	chr10:116634841	FAM160B1	0.32	6.75	0.3	4.33e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11098499	0.865	rs10032158	chr4:120391632	C/T	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs7945705	0.738	rs11042067	chr11:8815453	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.34	-6.86	-0.3	2.22e-11	Hemoglobin concentration;
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg08677398	chr8:58056175	NA	0.44	7.4	0.33	6.46e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4356975	0.563	rs11933459	chr4:69981763	A/G	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg18099408	chr3:52552593	STAB1	0.35	7.09	0.31	5.03e-12	Bipolar disorder;
LGG	trans	rs543686	0.770	rs4923765	chr15:35052405	A/G	cg00755064	chr7:23749991	STK31	0.37	6.73	0.3	5.12e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1461503	0.966	rs10892936	chr11:122841720	G/A	cg27398637	chr11:122830231	C11orf63	-0.71	-13.79	-0.54	1.66e-36	Menarche (age at onset);
LGG	cis	rs4481887	1.000	rs7517319	chr1:248466408	C/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs6582630	0.576	rs2222345	chr12:38356020	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.19	-0.49	7.67e-30	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7666738	0.830	rs13124689	chr4:98961182	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62238980	0.522	rs45462396	chr22:32545789	C/T	cg00543991	chr22:32367038	NA	0.77	8.65	0.37	8.29e-17	Childhood ear infection;
LGG	cis	rs7954584	0.635	rs7137218	chr12:122342877	G/T	cg22618164	chr12:122356400	WDR66	0.4	12.43	0.5	8.51e-31	Mean corpuscular volume;
LGG	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.34	0.43	1.12e-22	Diabetic retinopathy;
LGG	cis	rs755249	0.567	rs17264671	chr1:39818052	A/C	cg18385671	chr1:39797026	MACF1	0.43	7.32	0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs883565	0.612	rs784512	chr3:39165110	G/T	cg01426195	chr3:39028469	NA	0.65	14.08	0.55	1.02e-37	Handedness;
LGG	cis	rs975722	0.500	rs10254610	chr7:117406238	G/A	cg10524701	chr7:117356490	CTTNBP2	0.37	7.18	0.32	2.77e-12	Coronary artery disease;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Body mass index;
LGG	cis	rs67311347	1.000	rs9874006	chr3:40471596	G/A	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	cis	rs2282300	0.739	rs10835648	chr11:30320506	A/G	cg25418670	chr11:30344373	C11orf46	0.53	7.5	0.33	3.37e-13	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.88e-11	Aortic root size;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg23782820	chr8:58130467	NA	0.58	8.63	0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7615952	0.599	rs1875683	chr3:125732481	C/G	cg05084668	chr3:125655381	ALG1L	-0.57	-7.65	-0.34	1.16e-13	Blood pressure (smoking interaction);
LGG	cis	rs10892173	0.846	rs12790243	chr11:117678543	C/T	cg21640587	chr11:117668038	DSCAML1	0.47	7.83	0.34	3.32e-14	Myopia;
LGG	cis	rs504918	1.000	rs7646556	chr3:124085029	T/C	cg05766129	chr3:123988013	KALRN	-0.39	-7.0	-0.31	8.81e-12	Schizophrenia;
LGG	cis	rs9807989	0.507	rs1420094	chr2:103015687	C/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs295140	0.605	rs159320	chr2:201187775	A/G	cg17644776	chr2:200775616	C2orf69	0.44	7.49	0.33	3.53e-13	QT interval;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg24829409	chr8:58192753	C8orf71	-0.64	-9.01	-0.39	5.49e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6429082	0.744	rs903347	chr1:235586613	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.6	-10.15	-0.43	5.46e-22	Adiposity;
LGG	cis	rs7301016	0.901	rs7975109	chr12:62941643	C/T	cg11441379	chr12:63026424	NA	0.62	8.63	0.37	9.58e-17	IgG glycosylation;
LGG	cis	rs1030877	0.515	rs2576741	chr2:105897964	T/C	cg02079111	chr2:105885981	TGFBRAP1	0.64	10.21	0.43	3.23e-22	Obesity-related traits;
LGG	cis	rs1816752	0.905	rs2000153	chr13:24979890	G/A	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.28e-12	Obesity-related traits;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg19147804	chr7:1989927	MAD1L1	-0.52	-9.7	-0.41	2.22e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	1.000	rs67006488	chr3:10152993	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.24e-18	Alzheimer's disease;
LGG	cis	rs875971	0.898	rs6977501	chr7:65693342	T/C	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.93e-21	Aortic root size;
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.4	-0.33	6.34e-13	Neuroticism;
LGG	cis	rs11190604	1.000	rs11190540	chr10:102202629	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.45	0.47	6.84e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg13010199	chr12:38710504	ALG10B	0.76	16.27	0.6	2.21e-47	Heart rate;
LGG	cis	rs7568458	0.510	rs10206961	chr2:85814984	C/T	cg02493740	chr2:85810744	VAMP5	-0.39	-6.85	-0.3	2.31e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.06	-0.39	3.73e-18	Menopause (age at onset);
LGG	cis	rs6696846	0.905	rs11240349	chr1:205041015	G/A	cg00857998	chr1:205179979	DSTYK	0.53	8.55	0.37	1.82e-16	Red blood cell count;
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg11584989	chr19:19387371	SF4	0.4	7.2	0.32	2.4e-12	Tonsillectomy;
LGG	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg12395012	chr8:11607386	GATA4	-0.41	-7.35	-0.32	9.02e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs3099143	0.901	rs28405838	chr15:77226053	C/G	cg21673338	chr15:77095150	SCAPER	-0.65	-9.25	-0.39	8.56e-19	Recalcitrant atopic dermatitis;
LGG	cis	rs1355223	0.583	rs1553757	chr11:34867089	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.75	14.69	0.56	2.29e-40	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg04733989	chr22:42467013	NAGA	0.5	8.37	0.36	7.07e-16	Schizophrenia;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.47e-27	Rheumatoid arthritis;
LGG	cis	rs9303401	0.659	rs11079357	chr17:56902778	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.95	0.57	1.56e-41	Cognitive test performance;
LGG	cis	rs7924176	0.564	rs11000920	chr10:75968201	T/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.86	-0.3	2.23e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs7000551	0.689	rs4872000	chr8:22337323	G/T	cg12081754	chr8:22256438	SLC39A14	0.69	13.24	0.52	3.74e-34	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs77106637	1.000	rs11602858	chr11:72615069	C/G	cg03878208	chr11:72483293	STARD10	0.51	7.18	0.32	2.84e-12	Type 2 diabetes;
LGG	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg18252515	chr7:66147081	NA	0.42	7.0	0.31	8.91e-12	Aortic root size;
LGG	cis	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg12432903	chr7:1882776	MAD1L1	0.55	8.28	0.36	1.31e-15	Bipolar disorder;
LGG	cis	rs867371	0.964	rs7169961	chr15:82478929	C/T	cg00614314	chr15:82944287	LOC80154	0.59	9.76	0.41	1.35e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg25172604	chr17:41446521	NA	-0.31	-7.18	-0.32	2.83e-12	Menopause (age at onset);
LGG	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg17927777	chr20:33865990	NA	0.71	9.42	0.4	2.08e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs7027203	0.828	rs4744291	chr9:96598297	A/G	cg13679303	chr9:96623674	NA	-0.39	-6.89	-0.3	1.85e-11	DNA methylation (variation);
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg10207240	chr12:122356781	WDR66	0.27	8.23	0.36	1.91e-15	Mean corpuscular volume;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21963583	chr11:68658836	MRPL21	0.6	10.44	0.44	4.5e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs35110281	0.501	rs162378	chr21:44925905	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.49	-8.14	-0.35	3.79e-15	Mean corpuscular volume;
LGG	cis	rs10237118	0.915	rs6464833	chr7:140227293	C/T	cg09787580	chr7:140227335	DENND2A	-0.72	-9.06	-0.39	3.8e-18	Optic nerve measurement (cup area);
LGG	cis	rs4474465	0.833	rs7934912	chr11:78218556	A/T	cg27205649	chr11:78285834	NARS2	0.47	8.11	0.35	4.56e-15	Alzheimer's disease (survival time);
LGG	trans	rs7395662	1.000	rs4882016	chr11:48570125	G/A	cg15704280	chr7:45808275	SEPT13	-0.51	-8.25	-0.36	1.63e-15	HDL cholesterol;
LGG	cis	rs6908034	0.607	rs12529148	chr6:19806797	G/C	cg02682789	chr6:19804855	NA	0.91	8.61	0.37	1.19e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs3808502	0.527	rs2736374	chr8:11113828	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-6.77	-0.3	3.83e-11	Neuroticism;
LGG	cis	rs262150	0.574	rs2730272	chr7:158798622	G/C	cg19418458	chr7:158789849	NA	-0.55	-11.58	-0.47	2.1e-27	Facial morphology (factor 20);
LGG	cis	rs9325144	0.881	rs56344858	chr12:39180935	A/G	cg04568710	chr12:38710424	ALG10B	-0.34	-6.71	-0.3	5.66e-11	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs6449323	chr4:17683916	A/T	cg02297831	chr4:17616191	MED28	0.46	8.68	0.37	6.82e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg01191920	chr7:158217561	PTPRN2	-0.72	-16.42	-0.61	4.52e-48	Obesity-related traits;
LGG	cis	rs2573652	0.722	rs11852383	chr15:100542765	C/T	cg14911520	chr15:100542628	ADAMTS17	-0.3	-7.42	-0.33	5.61e-13	Height;
LGG	cis	rs4808199	0.948	rs2023883	chr19:19405480	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	7.21	0.32	2.25e-12	Nonalcoholic fatty liver disease;
LGG	trans	rs75804782	0.521	rs56120037	chr2:239398464	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.6	0.37	1.2e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.86	17.83	0.64	1.68e-54	Personality dimensions;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.59	-0.33	1.8e-13	Height;
LGG	cis	rs2976388	0.556	rs10956985	chr8:143818750	C/A	cg10596483	chr8:143751796	JRK	-0.47	-6.65	-0.3	8.2e-11	Urinary tract infection frequency;
LGG	cis	rs80282103	0.618	rs7100114	chr10:1110231	A/G	cg08668510	chr10:1095578	IDI1	0.76	8.27	0.36	1.4e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9463078	0.625	rs538801	chr6:44875762	A/T	cg25276700	chr6:44698697	NA	0.33	6.91	0.31	1.62e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9303401	0.659	rs17822908	chr17:56801778	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.22	0.58	1.06e-42	Cognitive test performance;
LGG	cis	rs7829975	0.514	rs2979151	chr8:8258019	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.05	-0.42	1.23e-21	Mood instability;
LGG	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg11494091	chr17:61959527	GH2	0.6	10.03	0.42	1.44e-21	Height;
LGG	cis	rs7084402	0.967	rs1649092	chr10:60289389	A/T	cg09696939	chr10:60272079	BICC1	-0.36	-7.08	-0.31	5.5e-12	Refractive error;
LGG	cis	rs6867032	1.000	rs4413568	chr5:2016894	A/G	cg26168224	chr5:2018326	NA	1.3	32.0	0.83	2.17e-119	Gut microbiome composition (winter);
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.69	-0.37	6.44e-17	Menopause (age at onset);
LGG	cis	rs2645694	0.651	rs2703128	chr4:77819187	C/G	cg10057126	chr4:77819792	ANKRD56	0.37	7.01	0.31	8.6e-12	Emphysema distribution in smoking;
LGG	cis	rs2074193	0.627	rs11183923	chr12:47774811	A/C	cg02516419	chr12:47771422	NA	-0.73	-10.74	-0.45	3.46e-24	Migraine with aura;
LGG	trans	rs3779273	0.748	rs4236580	chr7:77835256	T/C	cg05596911	chr5:118502651	DMXL1	-0.52	-12.1	-0.49	1.81e-29	Body mass index;
LGG	cis	rs11758351	1.000	rs11754744	chr6:26202605	G/A	cg01420254	chr6:26195488	NA	0.88	11.69	0.48	7.89e-28	Gout;Renal underexcretion gout;
LGG	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs6909430	1.000	rs6909430	chr6:98739774	A/G	cg12860156	chr6:98744658	NA	-0.49	-8.54	-0.37	1.95e-16	Quantitative traits;
LGG	cis	rs35160687	0.712	rs1863057	chr2:86502101	C/T	cg10973622	chr2:86423274	IMMT	-0.41	-7.18	-0.32	2.77e-12	Night sleep phenotypes;
LGG	cis	rs7582720	1.000	rs114110842	chr2:203823400	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg20119798	chr7:94954144	PON1	-0.38	-7.79	-0.34	4.29e-14	Paraoxonase activity;
LGG	cis	rs3796352	1.000	rs7625448	chr3:53120766	C/A	cg12962167	chr3:53033115	SFMBT1	0.64	7.05	0.31	6.59e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9527	0.535	rs4917999	chr10:104963051	C/G	cg04362960	chr10:104952993	NT5C2	-0.56	-10.1	-0.42	8.57e-22	Arsenic metabolism;
LGG	cis	rs6831352	0.589	rs1133483	chr4:100023923	G/C	cg12011299	chr4:100065546	ADH4	0.53	12.32	0.5	2.31e-30	Alcohol dependence;
LGG	cis	rs796364	0.587	rs7588746	chr2:200986345	A/G	cg17644776	chr2:200775616	C2orf69	0.53	7.3	0.32	1.29e-12	Schizophrenia;
LGG	cis	rs1552244	1.000	rs7626117	chr3:10140671	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.72	-12.51	-0.5	3.9e-31	Alzheimer's disease;
LGG	trans	rs7824557	0.707	rs3808518	chr8:11143272	A/C	cg16141378	chr3:129829833	LOC729375	0.38	8.55	0.37	1.74e-16	Retinal vascular caliber;
LGG	cis	rs4262150	0.803	rs72799145	chr5:152102663	C/T	cg12297329	chr5:152029980	NA	-0.75	-13.57	-0.53	1.55e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.75	-0.38	4.07e-17	Response to antipsychotic treatment;
LGG	cis	rs17253792	0.822	rs78922774	chr14:56115302	T/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs2270450	0.650	rs34405250	chr6:46695911	A/G	cg10156739	chr6:46714674	LOC100287718	-0.44	-9.27	-0.4	7.33e-19	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.25	0.55	1.78e-38	Bladder cancer;
LGG	trans	rs9858542	1.000	rs3197999	chr3:49721532	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.32	-0.32	1.08e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7524258	0.868	rs2412153	chr1:7272412	C/T	cg07173049	chr1:7289937	CAMTA1	0.71	17.03	0.62	7.26e-51	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs10089	1.000	rs4836370	chr5:127499224	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	12.05	0.49	2.86e-29	Ileal carcinoids;
LGG	cis	rs6032067	0.929	rs13039213	chr20:43805712	A/C	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs9900497	0.536	rs4646785	chr17:19651902	A/G	cg15323506	chr17:19619410	SLC47A2	-0.44	-7.4	-0.33	6.44e-13	Response to paliperidone in schizophrenia (CGI-S score);
LGG	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg25173405	chr17:45401733	C17orf57	-0.56	-9.44	-0.4	1.9e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs9291683	0.588	rs2240724	chr4:10021290	G/C	cg26043149	chr18:55253948	FECH	0.4	6.65	0.3	8.32e-11	Bone mineral density;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	2.03e-57	Platelet count;
LGG	cis	rs10876993	0.789	rs1689600	chr12:58049645	A/T	cg18357645	chr12:58087776	OS9	0.68	12.15	0.49	1.16e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs68170813	0.641	rs79434636	chr7:107105656	A/C	cg02696742	chr7:106810147	HBP1	-0.73	-9.86	-0.42	5.98e-21	Coronary artery disease;
LGG	cis	rs10936602	0.527	rs9814802	chr3:169532377	A/G	cg00832555	chr3:169529716	LRRC34	0.35	7.31	0.32	1.2e-12	Renal cell carcinoma;
LGG	cis	rs11758351	0.500	rs79697629	chr6:26196512	A/G	cg03181300	chr6:26195995	NA	0.87	6.67	0.3	7.09e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2273669	0.667	rs12195848	chr6:109279105	A/C	cg05315195	chr6:109294784	ARMC2	-0.59	-7.64	-0.33	1.25e-13	Prostate cancer;
LGG	cis	rs1129187	0.902	rs6907751	chr6:42944850	C/T	cg13397359	chr6:42928475	GNMT	0.67	20.19	0.68	1.73e-65	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6694672	1.000	rs1759007	chr1:197027606	C/T	cg13682187	chr1:196946512	CFHR5	-0.48	-6.95	-0.31	1.27e-11	Asthma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19553056	chr4:142142166	ZNF330	0.48	7.37	0.32	7.94e-13	Gut microbiome composition (summer);
LGG	trans	rs1814175	0.676	rs1721999	chr11:49917372	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs9837602	0.529	rs1688774	chr3:99521108	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.43	-0.36	4.55e-16	Breast cancer;
LGG	cis	rs986417	1.000	rs1955699	chr14:61045989	A/G	cg27398547	chr14:60952738	C14orf39	0.77	7.49	0.33	3.59e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs67311347	1.000	rs73080165	chr3:40533062	G/T	cg13683864	chr3:40499215	RPL14	-1.08	-23.46	-0.74	8.84e-81	Renal cell carcinoma;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.64e-36	Lung cancer;
LGG	cis	rs2640806	0.505	rs7835247	chr8:97363868	T/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.15	0.32	3.31e-12	Obesity-related traits;
LGG	cis	rs7124681	0.584	rs4752792	chr11:47815702	G/A	cg20307385	chr11:47447363	PSMC3	-0.55	-10.8	-0.45	2.13e-24	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.79	0.34	4.59e-14	Joint mobility (Beighton score);
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.38	-0.32	7.32e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2658782	0.724	rs1563445	chr11:93246042	A/G	cg15737290	chr11:93063684	CCDC67	0.45	6.74	0.3	4.6e-11	Pulmonary function decline;
LGG	cis	rs12200560	0.505	rs211176	chr6:97073821	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.72	0.34	7.4e-14	Coronary heart disease;
LGG	trans	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.72	-12.93	-0.52	7.11e-33	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs35110281	0.687	rs4819284	chr21:45084548	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.52	9.12	0.39	2.31e-18	Mean corpuscular volume;
LGG	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.99	-0.35	1.06e-14	HDL cholesterol;
LGG	cis	rs9911578	0.835	rs10853006	chr17:56489076	G/A	cg05425664	chr17:57184151	TRIM37	0.57	8.99	0.39	6.55e-18	Intelligence (multi-trait analysis);
LGG	cis	rs897984	0.760	rs11076	chr16:30995528	A/G	cg00531865	chr16:30841666	NA	0.54	11.46	0.47	6.16e-27	Dementia with Lewy bodies;
LGG	cis	rs7208859	0.725	rs7342938	chr17:29189830	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.72	-9.2	-0.39	1.24e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8017423	0.967	rs4900033	chr14:90701963	C/A	cg04374321	chr14:90722782	PSMC1	0.87	18.21	0.65	2.73e-56	Mortality in heart failure;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	10.72	0.45	4.22e-24	Obesity-related traits;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg05603623	chr19:8008081	TIMM44	-0.42	-6.74	-0.3	4.7e-11	Body fat mass;
LGG	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg04691961	chr3:161091175	C3orf57	-0.68	-16.36	-0.61	8.21e-48	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg08742575	chr21:47604166	C21orf56	0.56	10.15	0.43	5.48e-22	Testicular germ cell tumor;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs9549260	0.755	rs2755214	chr13:41149345	T/G	cg21288729	chr13:41239152	FOXO1	0.34	6.75	0.3	4.46e-11	Red blood cell count;
LGG	cis	rs9393692	0.905	rs7769028	chr6:26267568	C/T	cg00631329	chr6:26305371	NA	-0.51	-9.21	-0.39	1.1e-18	Educational attainment;
LGG	cis	rs9322193	0.923	rs9767652	chr6:150055638	A/T	cg11878867	chr6:150167359	LRP11	-0.53	-10.99	-0.45	4.16e-25	Lung cancer;
LGG	cis	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg04025307	chr7:1156635	C7orf50	0.55	7.87	0.34	2.59e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11771526	0.892	rs62457534	chr7:32357652	G/A	cg27532318	chr7:32358331	NA	0.88	8.29	0.36	1.25e-15	Body mass index;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.97	0.35	1.29e-14	Personality dimensions;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1754541	0.956	rs17417619	chr1:101628924	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-6.76	-0.3	4.17e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs7582180	0.629	rs6736576	chr2:100950854	C/T	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.04e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg16920238	chr17:80076378	CCDC57	-0.31	-7.07	-0.31	5.88e-12	Life satisfaction;
LGG	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs11771526	0.901	rs17161086	chr7:32294254	A/G	cg13207630	chr7:32358064	NA	-0.66	-7.12	-0.31	4.19e-12	Body mass index;
LGG	cis	rs4430311	0.536	rs10927055	chr1:243815781	A/G	cg25706552	chr1:244017396	NA	-0.63	-15.49	-0.58	6.94e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10193935	1.000	rs12618105	chr2:42414146	T/G	cg27598129	chr2:42591480	NA	-0.64	-9.41	-0.4	2.35e-19	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg03929089	chr4:120376271	NA	-0.86	-13.66	-0.54	6.37e-36	Height;
LGG	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg14490972	chr6:43484812	POLR1C;YIPF3	0.42	7.17	0.32	2.9e-12	Body mass index;
LGG	cis	rs8032158	0.963	rs1912398	chr15:56159103	T/G	cg02198044	chr15:56286336	NEDD4	-0.68	-11.78	-0.48	3.27e-28	Keloid;
LGG	cis	rs7945705	0.747	rs11042150	chr11:9010819	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.62	-0.48	1.41e-27	Hemoglobin concentration;
LGG	cis	rs8180040	0.654	rs62246451	chr3:47211632	C/T	cg16586182	chr3:47516702	SCAP	0.74	13.38	0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg15268244	chr15:77196840	NA	0.47	10.12	0.43	7.23e-22	Blood metabolite levels;
LGG	cis	rs2404602	0.967	rs7167613	chr15:77041192	C/A	cg23625390	chr15:77176239	SCAPER	0.51	10.26	0.43	2.12e-22	Blood metabolite levels;
LGG	trans	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg05926928	chr17:57297772	GDPD1	-0.53	-8.73	-0.38	4.6e-17	Schizophrenia;
LGG	cis	rs36051895	0.530	rs10115208	chr9:5229353	T/C	cg02405213	chr9:5042618	JAK2	-0.71	-12.95	-0.52	6.06e-33	Pediatric autoimmune diseases;
LGG	cis	rs11874712	0.712	rs2578183	chr18:43676720	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.21	-0.39	1.13e-18	Migraine - clinic-based;
LGG	cis	rs55894132	1	rs55894132	chr14:23408837	C/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.39	-0.33	6.69e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9302635	0.678	rs8054585	chr16:72225314	G/A	cg23815491	chr16:72088622	HP	0.47	9.01	0.39	5.58e-18	Blood protein levels;
LGG	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg14683738	chr19:37701593	ZNF585B	-0.42	-6.89	-0.31	1.82e-11	Coronary artery calcification;
LGG	cis	rs62064224	0.593	rs916663	chr17:30835833	A/C	cg12855166	chr17:30846586	MYO1D	-0.44	-7.89	-0.34	2.16e-14	Schizophrenia;
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg22753661	chr15:79092743	ADAMTS7	0.4	6.92	0.31	1.53e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.17	0.62	1.69e-51	Alzheimer's disease;
LGG	cis	rs17539620	0.624	rs62432737	chr6:154834772	G/A	cg17771515	chr6:154831774	CNKSR3	0.63	8.0	0.35	1.03e-14	Lipoprotein (a) levels;
LGG	cis	rs7659604	0.967	rs28529384	chr4:122664215	T/C	cg19748678	chr4:122722346	EXOSC9	0.52	10.25	0.43	2.38e-22	Type 2 diabetes;
LGG	cis	rs17445240	1.000	rs78506209	chr2:3699715	G/A	cg14882966	chr2:3699353	NA	0.89	9.13	0.39	2.11e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg01191920	chr7:158217561	PTPRN2	0.7	15.17	0.58	1.82e-42	Obesity-related traits;
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg12395012	chr8:11607386	GATA4	-0.38	-7.18	-0.32	2.79e-12	Neuroticism;
LGG	cis	rs7249142	0.562	rs10418053	chr19:19287164	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.29	-7.46	-0.33	4.26e-13	IgG glycosylation;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg00221070	chr5:63255805	NA	-0.36	-6.71	-0.3	5.61e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12551746	chr3:132136984	DNAJC13	0.45	6.88	0.3	1.97e-11	Gut microbiome composition (summer);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg00431236	chr2:264988	ACP1;SH3YL1	0.41	7.33	0.32	1.06e-12	Bilirubin levels;
LGG	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg14088196	chr11:70211408	PPFIA1	0.91	12.68	0.51	7.8e-32	Coronary artery disease;
LGG	cis	rs314370	0.855	rs76181418	chr7:100494960	G/T	cg10426581	chr7:100472382	SRRT	0.53	7.28	0.32	1.45e-12	Resting heart rate;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg24829409	chr8:58192753	C8orf71	-0.82	-13.21	-0.52	4.78e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.799	rs28376857	chr17:80104351	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1707322	1.000	rs785465	chr1:46522577	G/T	cg03146154	chr1:46216737	IPP	0.54	9.92	0.42	3.78e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg02297831	chr4:17616191	MED28	0.45	7.85	0.34	2.9e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6748734	1.000	rs4675874	chr2:241819796	A/G	cg04034577	chr2:241836375	C2orf54	0.51	10.64	0.44	8.57e-24	Urinary metabolites;
LGG	cis	rs5758511	0.514	rs9607885	chr22:42578596	T/C	cg15128208	chr22:42549153	NA	0.76	11.91	0.48	1.08e-28	Birth weight;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs561341	0.830	rs2301765	chr17:30202056	T/A	cg12193833	chr17:30244370	NA	0.28	6.99	0.31	9.6e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4713118	0.513	rs149945	chr6:28002853	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-6.76	-0.3	4.24e-11	Parkinson's disease;
LGG	cis	rs9522267	0.535	rs9515454	chr13:112236885	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg09044154	chr16:88155775	NA	-0.48	-7.26	-0.32	1.63e-12	Menopause (age at onset);
LGG	cis	rs1008375	1.000	rs4698651	chr4:17694223	A/G	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.34e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.95e-13	Joint mobility (Beighton score);
LGG	cis	rs2243480	1.000	rs160652	chr7:65538431	A/G	cg13147721	chr7:65941812	NA	-0.81	-9.65	-0.41	3.48e-20	Diabetic kidney disease;
LGG	cis	rs4481887	0.927	rs4390208	chr1:248472211	C/T	cg13385794	chr1:248469461	NA	0.48	8.26	0.36	1.52e-15	Common traits (Other);
LGG	cis	rs9309711	0.666	rs4321399	chr2:3481659	G/A	cg10845886	chr2:3471009	TTC15	-0.49	-9.9	-0.42	4.4e-21	Neurofibrillary tangles;
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg10802521	chr3:52805072	NEK4	0.42	7.27	0.32	1.52e-12	Bipolar disorder;
LGG	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg08999081	chr20:33150536	PIGU	0.38	9.42	0.4	2.07e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg11764359	chr7:65958608	NA	-0.73	-12.47	-0.5	5.66e-31	Aortic root size;
LGG	cis	rs8060686	0.641	rs57408712	chr16:68242573	G/C	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.5700000000000001e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg13732083	chr21:47605072	C21orf56	-0.49	-8.53	-0.37	2.13e-16	Testicular germ cell tumor;
LGG	cis	rs9914544	0.591	rs9900052	chr17:18699398	G/A	cg26378065	chr17:18585709	ZNF286B	0.41	7.77	0.34	5.17e-14	Educational attainment (years of education);
LGG	cis	rs4330281	0.647	rs7617683	chr3:17728919	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.49	-0.33	3.48e-13	Schizophrenia;
LGG	cis	rs870825	0.616	rs7680835	chr4:185652992	C/G	cg04058563	chr4:185651563	MLF1IP	-1.0	-22.1	-0.72	2.05e-74	Blood protein levels;
LGG	cis	rs61931739	0.500	rs11524949	chr12:34435551	C/T	cg06521331	chr12:34319734	NA	-0.58	-9.89	-0.42	4.66e-21	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs1932280	chr6:8473654	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs10771431	1.000	rs11611670	chr12:9385535	C/T	cg00504896	chr12:9437009	LOC642846	-0.62	-13.23	-0.52	4.11e-34	Breast size;
LGG	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.37	-0.32	7.89e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.897	rs2836929	chr21:40543811	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.61	0.63	1.75e-53	Cognitive function;
LGG	trans	rs3857536	0.741	rs4710582	chr6:66939984	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg01620082	chr3:125678407	NA	-0.99	-9.14	-0.39	2.02e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.44	6.85	0.3	2.33e-11	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg08888203	chr3:10149979	C3orf24	0.55	9.26	0.4	7.7e-19	Alzheimer's disease;
LGG	trans	rs35110281	0.591	rs162366	chr21:44935383	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.54	-9.61	-0.41	4.59e-20	Mean corpuscular volume;
LGG	cis	rs745821	0.701	rs73959980	chr18:48124420	T/G	cg18923635	chr18:48083994	NA	0.46	8.16	0.35	3.2e-15	Diastolic blood pressure;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2282300	0.702	rs2211018	chr11:30330079	C/T	cg06241208	chr11:30344200	C11orf46	0.51	6.68	0.3	7.01e-11	Morning vs. evening chronotype;
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg06873352	chr17:61820015	STRADA	0.48	7.5	0.33	3.23e-13	Height;
LGG	cis	rs10464366	0.843	rs12701691	chr7:39090177	T/G	cg15212455	chr7:39170539	POU6F2	0.36	8.11	0.35	4.59e-15	IgG glycosylation;
LGG	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg25019033	chr10:957182	NA	-0.54	-9.77	-0.41	1.23e-20	Eosinophil percentage of granulocytes;
LGG	trans	rs2898290	0.622	rs1600250	chr8:11345425	A/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.66	-0.37	7.67e-17	Systolic blood pressure;
LGG	cis	rs1497828	0.956	rs3122364	chr1:217540360	A/G	cg04411442	chr1:217543379	NA	-0.48	-8.24	-0.36	1.85e-15	Dialysis-related mortality;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04071427	chr10:70091481	HNRNPH3;PBLD	0.43	7.28	0.32	1.47e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg21782813	chr7:2030301	MAD1L1	0.39	8.99	0.39	6.48e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1451375	1.000	rs1451374	chr7:50622653	G/A	cg20336341	chr7:50628841	DDC	0.37	7.2	0.32	2.43e-12	Malaria;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17290332	chr10:14880008	CDNF;HSPA14	0.43	7.52	0.33	2.82e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6866344	0.697	rs11748495	chr5:178130000	A/G	cg10224037	chr5:178157518	ZNF354A	-0.76	-11.72	-0.48	5.59e-28	Neutrophil percentage of white cells;
LGG	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg03689076	chr20:33865952	NA	-0.64	-9.15	-0.39	1.84e-18	Attention deficit hyperactivity disorder;
LGG	trans	rs61931739	0.853	rs11053002	chr12:34083499	T/C	cg13010199	chr12:38710504	ALG10B	-0.47	-9.05	-0.39	3.96e-18	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg08219700	chr8:58056026	NA	0.47	7.24	0.32	1.87e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs5758659	0.652	rs133300	chr22:42389839	A/G	cg15557168	chr22:42548783	NA	-0.34	-7.55	-0.33	2.41e-13	Cognitive function;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg15971980	chr6:150254442	NA	0.45	8.4	0.36	5.44e-16	Lung cancer;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg20308403	chr7:2120281	MAD1L1	0.33	7.07	0.31	5.6e-12	Schizophrenia;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.22	-0.32	2.08e-12	Bipolar disorder;
LGG	cis	rs60871478	1.000	rs62432242	chr7:797715	G/A	cg05535760	chr7:792225	HEATR2	0.77	12.35	0.5	1.79e-30	Cerebrospinal P-tau181p levels;
LGG	cis	rs7618915	0.547	rs12487591	chr3:52642936	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.17	-0.32	3e-12	Bipolar disorder;
LGG	cis	rs6539288	0.745	rs2041895	chr12:107350088	C/G	cg26297688	chr12:107349093	C12orf23	-0.37	-7.15	-0.32	3.37e-12	Total body bone mineral density;
LGG	cis	rs2842992	0.915	rs1967802	chr6:160097791	G/A	cg27624424	chr6:160112604	SOD2	0.71	10.49	0.44	3.13e-23	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs61931739	0.500	rs34287388	chr12:34444626	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs1829883	1.000	rs2511973	chr5:98807871	T/A	cg08333243	chr5:99726346	NA	-0.4	-7.77	-0.34	5.15e-14	Hemostatic factors and hematological phenotypes;
LGG	cis	rs3857067	0.772	rs4692999	chr4:95107644	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.35	1.87e-14	QT interval;
LGG	cis	rs4742903	0.935	rs1580014	chr9:106933625	A/C	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.16e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs919433	0.713	rs6719729	chr2:198480072	G/A	cg00792783	chr2:198669748	PLCL1	0.51	7.99	0.35	1.11e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.2	0.43	3.71e-22	Motion sickness;
LGG	cis	rs350251	0.865	rs350271	chr16:12235372	A/G	cg02910054	chr16:12241554	SNX29	0.46	8.52	0.37	2.23e-16	Intelligence (multi-trait analysis);
LGG	cis	rs8027181	0.617	rs11072389	chr15:73088483	C/T	cg01955962	chr15:73089536	NA	-0.4	-6.79	-0.3	3.47e-11	Triglyceride levels;
LGG	cis	rs597539	0.652	rs668576	chr11:68668208	A/G	cg04772025	chr11:68637568	NA	0.75	13.15	0.52	8.41e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs950169	1.000	rs1911155	chr15:84787635	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.82	0.38	2.42e-17	Schizophrenia;
LGG	cis	rs6121246	0.529	rs6060174	chr20:30183538	G/A	cg21427119	chr20:30132790	HM13	-0.58	-9.04	-0.39	4.37e-18	Mean corpuscular hemoglobin;
LGG	cis	rs11645898	0.748	rs3852785	chr16:72198642	G/A	cg14768367	chr16:72042858	DHODH	-0.81	-10.61	-0.44	1.06e-23	Blood protein levels;
LGG	cis	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg03060546	chr3:49711283	APEH	-0.62	-8.32	-0.36	9.64e-16	Menarche (age at onset);
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg04369109	chr6:150039330	LATS1	-0.4	-6.75	-0.3	4.44e-11	Lung cancer;
LGG	cis	rs7250872	0.540	rs12460791	chr19:1842919	A/G	cg18850929	chr19:1828978	REXO1	0.5	7.94	0.35	1.57e-14	Bipolar disorder;
LGG	cis	rs951366	0.538	rs56276813	chr1:205730573	G/T	cg14893161	chr1:205819251	PM20D1	-0.44	-7.47	-0.33	3.89e-13	Menarche (age at onset);
LGG	cis	rs12458462	0.892	rs35928863	chr18:77438956	A/G	cg11879182	chr18:77439856	CTDP1	0.81	15.28	0.58	5.69e-43	Monocyte count;
LGG	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.17e-21	Diabetic kidney disease;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.25	-0.32	1.82e-12	Bipolar disorder;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9309473	0.950	rs6740766	chr2:73780913	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs875971	0.964	rs2277911	chr7:65958625	T/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.64	-0.37	8.9e-17	Aortic root size;
LGG	cis	rs875971	1.000	rs1981798	chr7:65954903	G/T	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs1451375	0.652	rs7803440	chr7:50625632	C/T	cg14593290	chr7:50529359	DDC	0.5	8.75	0.38	3.86e-17	Malaria;
LGG	cis	rs1218582	0.711	rs4845677	chr1:154838050	C/T	cg03351412	chr1:154909251	PMVK	0.65	12.25	0.49	4.56e-30	Prostate cancer;
LGG	cis	rs9457247	0.602	rs12208359	chr6:167458455	G/A	cg07741184	chr6:167504864	NA	0.42	9.45	0.4	1.66e-19	Crohn's disease;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg00031303	chr3:195681400	NA	0.53	8.43	0.36	4.48e-16	Pancreatic cancer;
LGG	cis	rs9287719	0.967	rs6432112	chr2:10744874	A/G	cg02196655	chr2:10830764	NOL10	0.43	7.43	0.33	5.13e-13	Prostate cancer;
LGG	cis	rs6964587	0.626	rs10280301	chr7:91524258	A/T	cg17063962	chr7:91808500	NA	-0.44	-7.98	-0.35	1.14e-14	Breast cancer;
LGG	cis	rs8141529	0.636	rs5762799	chr22:29187380	G/T	cg15103426	chr22:29168792	CCDC117	0.6	7.87	0.34	2.49e-14	Lymphocyte counts;
LGG	cis	rs60843830	0.964	rs7584915	chr2:264227	G/A	cg04617936	chr2:214353	NA	-0.39	-7.36	-0.32	8.31e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10876993	0.672	rs2640611	chr12:58037757	T/A	cg18357645	chr12:58087776	OS9	0.67	12.08	0.49	2.09e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs793571	0.590	rs442495	chr15:59022615	T/C	cg05156742	chr15:59063176	FAM63B	0.6	10.11	0.43	7.78e-22	Schizophrenia;
LGG	cis	rs61990749	0.597	rs6574402	chr14:78267950	C/A	cg02301378	chr14:78227641	SNW1;C14orf178	0.6	7.11	0.31	4.53e-12	Fibroblast growth factor basic levels;
LGG	cis	rs2762353	0.935	rs1183200	chr6:25818646	G/C	cg03517284	chr6:25882590	NA	-0.51	-9.62	-0.41	4.2e-20	Blood metabolite levels;
LGG	cis	rs36051895	0.632	rs7040806	chr9:5174782	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-15.6	-0.59	2.19e-44	Pediatric autoimmune diseases;
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg13264159	chr8:625131	ERICH1	0.96	11.51	0.47	3.92e-27	IgG glycosylation;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.57	0.33	2.01e-13	Schizophrenia;
LGG	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg05535760	chr7:792225	HEATR2	0.79	12.73	0.51	4.8e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg27110132	chr16:3661765	BTBD12	-0.44	-7.29	-0.32	1.33e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs79146658	0.646	rs4894055	chr2:179714675	C/T	cg17765952	chr2:179737173	CCDC141	-0.58	-8.44	-0.37	4.18e-16	Diastolic blood pressure;
LGG	cis	rs854765	0.547	rs4072739	chr17:17884660	G/A	cg05444541	chr17:17804740	TOM1L2	-0.66	-14.87	-0.57	3.66e-41	Total body bone mineral density;
LGG	trans	rs1814175	0.817	rs1794164	chr11:49899610	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.86	-0.78	1.79e-96	Height;
LGG	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg13263323	chr15:86062960	AKAP13	-0.39	-8.43	-0.36	4.31e-16	Interstitial lung disease;
LGG	cis	rs7829975	0.511	rs2976906	chr8:8342415	A/T	cg08975724	chr8:8085496	FLJ10661	0.36	6.75	0.3	4.51e-11	Mood instability;
LGG	cis	rs868036	0.718	rs4776982	chr15:68114974	C/T	cg22044901	chr15:68126292	NA	0.4	6.79	0.3	3.54e-11	Restless legs syndrome;
LGG	cis	rs41271473	0.526	rs10916343	chr1:228727961	C/T	cg10167378	chr1:228756711	NA	0.71	9.48	0.4	1.3e-19	Chronic lymphocytic leukemia;
LGG	cis	rs3820068	0.705	rs72643701	chr1:15866219	G/A	cg05660106	chr1:15850417	CASP9	1.1	25.38	0.76	1.13e-89	Systolic blood pressure;
LGG	cis	rs875971	0.789	rs7808013	chr7:66071196	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.02	-0.31	8.06e-12	Aortic root size;
LGG	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg00198680	chr16:28758506	NA	0.28	6.89	0.3	1.84e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4789452	1.000	rs7216382	chr17:75374578	T/C	cg06761530	chr17:75373219	SEPT9	-0.38	-7.44	-0.33	5.02e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs7582180	0.629	rs11123826	chr2:100936276	G/T	cg05692746	chr2:100937584	LONRF2	0.67	12.49	0.5	4.71e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9948	0.881	rs1317911	chr2:97488698	T/G	cg26665480	chr2:98280029	ACTR1B	-0.68	-7.27	-0.32	1.51e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.61	-11.05	-0.46	2.3e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg13147721	chr7:65941812	NA	-0.79	-9.62	-0.41	4.37e-20	Diabetic kidney disease;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg02292450	chr8:114389388	CSMD3	0.63	6.93	0.31	1.42e-11	Airflow obstruction;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg22105103	chr4:187893119	NA	-0.56	-10.55	-0.44	1.8e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg20891283	chr12:69753455	YEATS4	0.75	14.66	0.56	2.95e-40	Blood protein levels;
LGG	cis	rs7786808	0.608	rs6978352	chr7:158209802	T/C	cg15440763	chr7:158190612	PTPRN2	-0.43	-9.18	-0.39	1.47e-18	Obesity-related traits;
LGG	trans	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg19862616	chr7:65841803	NCRNA00174	0.76	8.02	0.35	8.59e-15	Mononucleosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16944159	chr2:62132759	COMMD1	0.56	9.0	0.39	6e-18	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs12594857	chr15:45667178	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs1577917	0.740	rs2758843	chr6:86328431	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-12.5	-0.5	4.16e-31	Response to antipsychotic treatment;
LGG	cis	rs7223966	1.000	rs9903903	chr17:61762044	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.71	0.34	7.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10979	0.931	rs9484771	chr6:143896897	T/A	cg25407410	chr6:143891975	LOC285740	-0.73	-12.64	-0.51	1.11e-31	Hypospadias;
LGG	cis	rs61906588	0.595	rs493308	chr11:116352789	C/T	cg12564567	chr11:116371188	NA	-0.38	-6.99	-0.31	9.87e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs7851660	0.805	rs7038998	chr9:100662396	C/G	cg13688889	chr9:100608707	NA	-0.63	-12.58	-0.5	1.98e-31	Strep throat;
LGG	cis	rs11190604	1.000	rs10883504	chr10:102280687	G/A	cg07570687	chr10:102243282	WNT8B	0.44	7.36	0.32	8.22e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4742903	0.904	rs7038714	chr9:106992930	T/G	cg14250997	chr9:106856677	SMC2	0.38	7.76	0.34	5.58e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24917645	chr20:3801318	C20orf29	0.52	8.09	0.35	5.38e-15	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg23306229	chr2:178417860	TTC30B	0.72	8.66	0.37	7.96e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs896854	0.967	rs1320164	chr8:95960767	G/A	cg16049864	chr8:95962084	TP53INP1	-0.42	-9.16	-0.39	1.68e-18	Type 2 diabetes;
LGG	cis	rs6541297	0.699	rs966333	chr1:230305477	T/C	cg05784532	chr1:230284198	GALNT2	0.47	6.73	0.3	5.08e-11	Coronary artery disease;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	9.86	0.42	6.02e-21	Obesity-related traits;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg27471124	chr11:109292789	C11orf87	0.51	9.85	0.42	6.42e-21	Schizophrenia;
LGG	cis	rs427394	0.632	rs2279656	chr5:6737576	G/A	cg15145174	chr5:6755386	POLS	-0.44	-8.1	-0.35	4.75e-15	Menopause (age at onset);
LGG	trans	rs9291683	0.507	rs3775940	chr4:10025163	A/T	cg26043149	chr18:55253948	FECH	0.42	7.06	0.31	6.26e-12	Bone mineral density;
LGG	cis	rs73086581	1.000	rs73084594	chr20:3916380	T/G	cg02187196	chr20:3869020	PANK2	0.81	11.13	0.46	1.15e-25	Response to antidepressants in depression;
LGG	cis	rs7918232	0.574	rs10458708	chr10:27455605	C/T	cg14240646	chr10:27532245	ACBD5	-0.89	-17.3	-0.63	4.2e-52	Breast cancer;
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.32e-13	Life satisfaction;
LGG	cis	rs8177179	0.666	rs4075352	chr3:133468012	A/G	cg08048268	chr3:133502702	NA	-0.4	-6.7	-0.3	6.1e-11	Iron status biomarkers (transferrin levels);
LGG	cis	rs8013055	0.846	rs10139744	chr14:105974696	G/A	cg25008857	chr14:105974488	NA	0.59	9.95	0.42	2.82e-21	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs7503807	0.515	rs12453880	chr17:78637655	A/G	cg18469159	chr17:78755841	RPTOR	-0.66	-11.08	-0.46	1.83e-25	Obesity;
LGG	cis	rs4918072	0.793	rs7099625	chr10:105703798	A/G	cg11005552	chr10:105648138	OBFC1	-0.47	-7.51	-0.33	2.99e-13	Coronary artery disease;
LGG	cis	rs4740619	0.716	rs7467207	chr9:15746302	G/A	cg14451791	chr9:16040625	NA	0.33	8.54	0.37	1.88e-16	Body mass index;
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg16141378	chr3:129829833	LOC729375	-0.42	-9.94	-0.42	3e-21	Mood instability;
LGG	cis	rs34929064	1.000	rs6942430	chr7:22724644	A/G	cg18045685	chr7:22629474	NA	0.56	8.87	0.38	1.57e-17	Major depression and alcohol dependence;
LGG	cis	rs2976388	1.000	rs2920294	chr8:143765326	C/G	cg06565975	chr8:143823917	SLURP1	-0.41	-10.36	-0.43	9.31e-23	Urinary tract infection frequency;
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	cis	rs1707322	1.000	rs6672115	chr1:46272879	T/C	cg03146154	chr1:46216737	IPP	0.54	10.21	0.43	3.25e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9560113	1.000	rs2104790	chr13:112177412	C/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs61990749	0.544	rs3759728	chr14:78230159	A/T	cg02301378	chr14:78227641	SNW1;C14orf178	0.58	7.29	0.32	1.32e-12	Fibroblast growth factor basic levels;
LGG	cis	rs7179456	0.567	rs72745027	chr15:59094329	A/G	cg05156742	chr15:59063176	FAM63B	-0.65	-11.95	-0.49	7.12e-29	Asperger disorder;
LGG	cis	rs4253772	0.591	rs11704586	chr22:46685274	T/C	cg00784671	chr22:46762841	CELSR1	-0.62	-7.33	-0.32	1.03e-12	LDL cholesterol;Cholesterol, total;
LGG	trans	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	10.45	0.44	4.43e-23	Mean corpuscular volume;
LGG	cis	rs9640161	0.830	rs17173703	chr7:150068620	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.55	-9.81	-0.41	8.8e-21	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs2228479	0.850	rs2238532	chr16:89863672	T/C	cg00800038	chr16:89945340	TCF25	-0.69	-7.75	-0.34	5.68e-14	Skin colour saturation;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	trans	rs9329221	0.539	rs35060302	chr8:10264771	C/G	cg02002194	chr4:3960332	NA	-0.38	-6.65	-0.3	8.33e-11	Neuroticism;
LGG	trans	rs12517041	1.000	rs35561495	chr5:23309925	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	cis	rs9611565	0.559	rs7290990	chr22:41964357	C/A	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.38e-12	Vitiligo;
LGG	cis	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg04455712	chr21:45112962	RRP1B	0.55	10.44	0.44	4.62e-23	Mean corpuscular volume;
LGG	cis	rs6815814	0.731	rs4504265	chr4:38773865	G/T	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg20607798	chr8:58055168	NA	0.6	7.18	0.32	2.83e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17001868	0.568	rs742140	chr22:40781586	G/A	cg07138101	chr22:40742427	ADSL	0.7	9.09	0.39	2.92e-18	Mammographic density (dense area);
LGG	cis	rs6088580	0.524	rs2889855	chr20:33276853	A/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.95	-0.31	1.28e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs11608355	1.000	rs11066591	chr12:109880523	G/A	cg19025524	chr12:109796872	NA	-0.48	-9.03	-0.39	4.8e-18	Neuroticism;
LGG	cis	rs11645898	0.748	rs72787042	chr16:72067522	A/G	cg14768367	chr16:72042858	DHODH	-0.89	-11.84	-0.48	2.03e-28	Blood protein levels;
LGG	trans	rs7819412	0.522	rs10101329	chr8:10990672	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.75	0.3	4.51e-11	Triglycerides;
LGG	cis	rs9467773	0.596	rs62396201	chr6:26668216	G/A	cg09904177	chr6:26538194	HMGN4	0.64	12.76	0.51	3.52e-32	Intelligence (multi-trait analysis);
LGG	cis	rs3760776	1.000	rs3760776	chr19:5839746	C/T	cg25387410	chr19:5844109	FUT3	-0.54	-7.11	-0.31	4.32e-12	N-glycan levels;Tumor biomarkers;Vitamin B12 levels;
LGG	cis	rs9611565	0.512	rs5996063	chr22:42168767	G/A	cg17376030	chr22:41985996	PMM1	-0.67	-10.69	-0.44	5.67e-24	Vitiligo;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00933542	chr6:150070202	PCMT1	0.4	7.27	0.32	1.59e-12	Lung cancer;
LGG	cis	rs834603	0.546	rs1704969	chr7:47467787	A/G	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6704768	0.545	rs5004510	chr2:233679275	A/C	cg08000102	chr2:233561755	GIGYF2	-0.68	-11.03	-0.46	2.87e-25	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.83	-0.51	1.84e-32	Menarche (age at onset);
LGG	cis	rs782590	0.774	rs782637	chr2:55894247	T/C	cg18811423	chr2:55921094	PNPT1	0.92	22.07	0.72	2.78e-74	Metabolic syndrome;
LGG	cis	rs35146811	0.806	rs1534310	chr7:99699169	A/T	cg22906224	chr7:99728672	NA	0.57	9.18	0.39	1.47e-18	Coronary artery disease;
LGG	cis	rs11722228	1.000	rs6823877	chr4:9921931	T/C	cg25986240	chr4:9926439	SLC2A9	0.7	16.28	0.6	1.97e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg05941027	chr17:61774174	LIMD2	0.37	9.63	0.41	4.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1580019	0.539	rs11769109	chr7:32571352	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.42	6.77	0.3	3.91e-11	Cognitive ability;
LGG	cis	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg04990556	chr1:26633338	UBXN11	0.59	7.77	0.34	5.03e-14	Obesity-related traits;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg01238044	chr22:24384105	GSTT1	-0.41	-7.07	-0.31	5.76e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg26513180	chr16:89883248	FANCA	0.98	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	cis	rs17767392	0.846	rs68073803	chr14:71757679	C/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.11	0.39	2.43e-18	Mitral valve prolapse;
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.28	-0.43	1.88e-22	Bipolar disorder;
LGG	trans	rs7980799	0.618	rs1482983	chr12:33690326	A/C	cg26384229	chr12:38710491	ALG10B	0.68	12.39	0.5	1.19e-30	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9549367	0.673	rs3024735	chr13:113819513	G/A	cg00898013	chr13:113819073	PROZ	-0.5	-9.97	-0.42	2.4e-21	Platelet distribution width;
LGG	cis	rs1129187	0.755	rs4714638	chr6:42917017	A/G	cg13397359	chr6:42928475	GNMT	0.58	15.73	0.59	5.67e-45	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7216064	0.953	rs4790905	chr17:65863350	C/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.86	-0.38	1.76e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs72781680	0.898	rs72798041	chr2:23953076	T/C	cg08917208	chr2:24149416	ATAD2B	0.89	9.29	0.4	5.86e-19	Lymphocyte counts;
LGG	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.61	-0.63	1.61e-53	Bladder cancer;
LGG	cis	rs9291683	0.679	rs13137795	chr4:10051506	G/A	cg08250081	chr4:10125330	NA	0.41	8.14	0.35	3.75e-15	Bone mineral density;
LGG	cis	rs3087591	0.580	rs3815156	chr17:29685150	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.61	-8.97	-0.38	7.56e-18	Hip circumference;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg00761968	chr13:53314142	LECT1	-0.38	-7.96	-0.35	1.32e-14	Lewy body disease;
LGG	cis	rs2070433	0.752	rs60290737	chr21:47837630	C/A	cg12379764	chr21:47803548	PCNT	0.67	9.32	0.4	4.68e-19	Lymphocyte counts;
LGG	cis	rs13217239	0.646	rs12527111	chr6:27006475	C/T	cg12292205	chr6:26970375	C6orf41	0.56	10.87	0.45	1.11e-24	Schizophrenia;
LGG	cis	rs12497850	1.000	rs12493578	chr3:48730116	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.62	-10.11	-0.43	7.3e-22	Parkinson's disease;
LGG	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	cis	rs1707322	1.000	rs10890372	chr1:46391020	T/G	cg03146154	chr1:46216737	IPP	0.54	10.12	0.43	6.9e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg19336497	chr11:14380999	RRAS2	-0.57	-11.55	-0.47	2.71e-27	Sense of smell;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-10.85	-0.45	1.37e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9303401	1.000	rs6503877	chr17:56841948	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.44	0.44	4.76e-23	Cognitive test performance;
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-7.67	-0.34	9.94e-14	IgG glycosylation;
LGG	cis	rs9880211	1.000	rs35899944	chr3:136229057	G/A	cg21827317	chr3:136751795	NA	-0.49	-7.3	-0.32	1.24e-12	Body mass index;Height;
LGG	cis	rs4731207	0.698	rs10228376	chr7:124493743	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.35	-0.4	3.89e-19	Life satisfaction;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.68	-12.61	-0.51	1.53e-31	Obesity-related traits;
LGG	cis	rs1401999	1.000	rs939338	chr3:183704068	A/G	cg01324343	chr3:183735012	ABCC5	-0.86	-18.23	-0.65	2.33e-56	Anterior chamber depth;
LGG	cis	rs157093	0.957	rs157094	chr20:56253021	A/G	cg04055238	chr20:56251166	PMEPA1	0.48	8.39	0.36	5.75e-16	Verbal declarative memory;
LGG	cis	rs7252981	0.632	rs880090	chr19:19740729	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	9.3	0.4	5.57e-19	Perceived unattractiveness to mosquitoes;
LGG	cis	rs972578	0.791	rs8135830	chr22:43316232	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	cis	rs1847202	1.000	rs7610496	chr3:72926390	A/G	cg25664220	chr3:72788482	NA	-0.25	-7.66	-0.34	1.08e-13	Motion sickness;
LGG	cis	rs4906332	1.000	rs12147655	chr14:103850906	G/C	cg26031613	chr14:104095156	KLC1	-0.53	-8.06	-0.35	6.68e-15	Coronary artery disease;
LGG	cis	rs4819052	0.807	rs28715237	chr21:46673768	C/G	cg06618935	chr21:46677482	NA	-0.49	-9.64	-0.41	3.57e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16868751	chr10:96162146	TBC1D12	0.5	8.12	0.35	4.36e-15	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.717	rs11644967	chr16:89806614	T/A	cg03036210	chr16:89904091	SPIRE2	-0.59	-7.84	-0.34	3.22e-14	Skin colour saturation;
LGG	cis	rs7619833	0.620	rs7620772	chr3:27238349	C/G	cg02860705	chr3:27208620	NA	0.41	7.97	0.35	1.22e-14	Breast cancer;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.41	0.4	2.31e-19	Lung cancer;
LGG	cis	rs459571	0.715	rs401826	chr9:136890591	C/T	cg13789015	chr9:136890014	NCRNA00094	0.6	11.05	0.46	2.27e-25	Platelet distribution width;
LGG	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg18252515	chr7:66147081	NA	1.43	20.48	0.69	7.66e-67	Diabetic kidney disease;
LGG	cis	rs7552167	0.925	rs11249020	chr1:24512804	A/G	cg01960748	chr1:24522592	NA	-0.51	-7.61	-0.33	1.56e-13	Psoriasis vulgaris;
LGG	cis	rs3617	0.573	rs62253583	chr3:52928334	G/A	cg11645453	chr3:52864694	ITIH4	-0.46	-7.78	-0.34	4.82e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1862618	0.853	rs6885541	chr5:56110857	G/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	cis	rs4144027	0.935	rs8008020	chr14:104355883	T/C	cg26031613	chr14:104095156	KLC1	0.47	7.51	0.33	3.05e-13	Blood metabolite levels;
LGG	cis	rs8180040	0.676	rs1108301	chr3:47029426	G/A	cg27129171	chr3:47204927	SETD2	-0.83	-15.26	-0.58	6.77e-43	Colorectal cancer;
LGG	cis	rs7512552	0.839	rs17596326	chr1:150433819	A/G	cg15654264	chr1:150340011	RPRD2	0.46	9.32	0.4	4.59e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs10838798	0.523	rs11039593	chr11:48240112	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.21e-14	Height;
LGG	trans	rs9393777	0.623	rs9366658	chr6:26469866	G/A	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.73	-0.3	5.1e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.62e-12	Menopause (age at onset);
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.7	0.34	8.4e-14	Systolic blood pressure;
LGG	cis	rs72781680	0.679	rs718138	chr2:23976324	G/A	cg08917208	chr2:24149416	ATAD2B	0.65	8.52	0.37	2.27e-16	Lymphocyte counts;
LGG	cis	rs6831352	1.000	rs1126673	chr4:100045616	C/T	cg13256891	chr4:100009986	ADH5	0.55	9.7	0.41	2.17e-20	Alcohol dependence;
LGG	cis	rs1451375	0.698	rs1813214	chr7:50637525	A/G	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs10751667	0.621	rs11246345	chr11:934924	T/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs11585357	0.947	rs11585119	chr1:17605792	C/A	cg08277548	chr1:17600880	PADI3	-0.79	-9.24	-0.39	8.78e-19	Hair shape;
LGG	cis	rs6840360	0.571	rs11931934	chr4:152552082	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.49	-0.33	3.43e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.13	0.43	6.44e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9326248	1.000	rs664082	chr11:117071070	C/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	8.83	0.38	2.11e-17	Blood protein levels;
LGG	trans	rs11165623	0.792	rs9437609	chr1:96977961	A/C	cg10631902	chr5:14652156	NA	-0.56	-12.03	-0.49	3.53e-29	Hip circumference;Waist circumference;
LGG	cis	rs6088580	0.634	rs2378134	chr20:32938085	C/T	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.58	-0.41	6.09e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg21095983	chr6:86352623	SYNCRIP	0.59	10.74	0.45	3.6e-24	Smooth-surface caries;
LGG	cis	rs16937	0.711	rs11240382	chr1:205168569	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.66	-0.34	1.12e-13	Schizophrenia;
LGG	cis	rs1927790	0.759	rs12583996	chr13:96991702	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.94	-0.31	1.33e-11	Body mass index;
LGG	cis	rs11168618	0.776	rs7955785	chr12:48862538	T/A	cg24011408	chr12:48396354	COL2A1	0.49	8.02	0.35	8.64e-15	Adiponectin levels;
LGG	cis	rs9443645	0.527	rs10943588	chr6:79510994	A/C	cg18132916	chr6:79620363	NA	-0.27	-7.12	-0.31	4.13e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8048589	0.898	rs3851011	chr16:12192472	C/A	cg02910054	chr16:12241554	SNX29	0.42	6.79	0.3	3.55e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.38	-7.45	-0.33	4.56e-13	Schizophrenia;
LGG	cis	rs4774830	0.744	rs7167999	chr15:56167667	T/C	cg05129572	chr15:56138634	NEDD4	-0.89	-8.04	-0.35	7.49e-15	Delta-5 desaturase activity;
LGG	cis	rs7215564	0.908	rs35374347	chr17:78642244	C/T	cg16980736	chr17:78789706	RPTOR	-0.71	-9.31	-0.4	5.13e-19	Myopia (pathological);
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.59	8.78	0.38	3.09e-17	Renal function-related traits (BUN);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-10.04	-0.42	1.35e-21	Lung cancer;
LGG	cis	rs13040088	1.000	rs910831	chr20:61558775	T/C	cg23096297	chr20:61557774	DIDO1	0.87	11.99	0.49	4.87e-29	Menopause (age at onset);
LGG	trans	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.38	-0.36	6.22e-16	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg00495681	chr13:53174319	NA	0.46	7.67	0.34	9.97e-14	Lewy body disease;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.68	-0.41	2.64e-20	Neuroticism;
LGG	cis	rs13102973	0.931	rs12499856	chr4:135868573	C/T	cg14419869	chr4:135874104	NA	0.58	10.95	0.45	5.91e-25	Subjective well-being;
LGG	cis	rs62238980	0.614	rs117655982	chr22:32461141	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2018055	0.644	rs13211956	chr6:117801732	T/G	cg14611402	chr6:117803162	DCBLD1	0.3	8.88	0.38	1.44e-17	Diastolic blood pressure;
LGG	cis	rs8038465	0.622	rs710086	chr15:73877001	C/T	cg15420318	chr15:73925796	NPTN	0.5	8.5	0.37	2.64e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9309711	0.506	rs9284794	chr2:3492052	G/A	cg15506890	chr2:3487001	NA	-0.52	-10.17	-0.43	4.78e-22	Neurofibrillary tangles;
LGG	cis	rs5769765	0.908	rs9616376	chr22:50310829	A/G	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	cis	rs3747547	0.818	rs7023756	chr9:37946629	A/G	cg13774184	chr9:37916125	SHB	-0.75	-8.49	-0.37	2.9e-16	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs3815700	1.000	rs8104328	chr19:33094371	G/A	cg02997394	chr19:33096574	ANKRD27	0.88	13.06	0.52	2.04e-33	Eosinophilic esophagitis;
LGG	cis	rs4820294	0.669	rs1894532	chr22:38059750	T/C	cg10587741	chr22:38071170	LGALS1	0.59	13.77	0.54	2.06e-36	Fat distribution (HIV);
LGG	cis	rs12477438	0.501	rs1451246	chr2:100064283	C/A	cg23527387	chr2:100056660	REV1	0.42	9.48	0.4	1.29e-19	Chronic sinus infection;
LGG	cis	rs10479542	0.683	rs7380706	chr5:178961872	C/T	cg21226059	chr5:178986404	RUFY1	0.39	6.83	0.3	2.63e-11	Lung cancer;
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg22398616	chr13:53314203	LECT1	0.53	11.7	0.48	7.18e-28	Lewy body disease;
LGG	cis	rs2735413	0.564	rs73578735	chr16:78104936	C/G	cg04733911	chr16:78082701	NA	0.59	8.14	0.35	3.58e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg11693508	chr17:37793320	STARD3	0.54	7.59	0.33	1.72e-13	Bipolar disorder;
LGG	trans	rs1945213	0.659	rs17149979	chr11:55840862	A/G	cg15704280	chr7:45808275	SEPT13	0.89	12.6	0.51	1.73e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3858526	0.642	rs55732658	chr11:5894602	A/C	cg13902645	chr11:5959945	NA	-0.64	-9.87	-0.42	5.71e-21	DNA methylation (variation);
LGG	cis	rs9868809	0.505	rs11719291	chr3:48735706	A/G	cg00383909	chr3:49044727	WDR6	0.9	11.17	0.46	8.3e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg22907277	chr7:1156413	C7orf50	0.61	9.96	0.42	2.59e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23740310	chr12:12878752	APOLD1	0.48	7.08	0.31	5.47e-12	Gut microbiome composition (summer);
LGG	cis	rs2013441	0.508	rs4925078	chr17:19982473	A/G	cg09818912	chr17:20140352	CYTSB	0.3	6.67	0.3	7.47e-11	Obesity-related traits;
LGG	trans	rs459571	0.959	rs416390	chr9:136908549	C/G	cg09836344	chr4:1243392	C4orf42;CTBP1	0.68	11.65	0.48	1.11e-27	Platelet distribution width;
LGG	cis	rs9287719	0.967	rs759403	chr2:10729897	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs17401966	1.000	rs7530167	chr1:10453374	A/G	cg15208524	chr1:10270712	KIF1B	0.42	6.9	0.31	1.74e-11	Hepatocellular carcinoma;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.63	-0.48	1.34e-27	Personality dimensions;
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg14092988	chr3:52407081	DNAH1	0.31	8.2	0.36	2.34e-15	Bipolar disorder;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg01673284	chr16:4527211	HMOX2	0.34	6.79	0.3	3.52e-11	Schizophrenia;
LGG	trans	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg06521331	chr12:34319734	NA	-0.53	-9.72	-0.41	1.87e-20	Bladder cancer;
LGG	cis	rs13421350	0.579	rs74461567	chr2:173327823	C/T	cg15021238	chr2:173305865	ITGA6	-0.82	-9.16	-0.39	1.75e-18	Diabetic kidney disease;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg05368731	chr17:41323189	NBR1	0.98	19.06	0.66	3.1e-60	Menopause (age at onset);
LGG	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	2.02e-18	Blood metabolite levels;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	18.98	0.66	8.07e-60	Platelet count;
LGG	trans	rs9951602	0.512	rs8085719	chr18:76649111	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.6	0.53	1.14e-35	Obesity-related traits;
LGG	cis	rs1577917	0.666	rs6454471	chr6:86214456	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.88	17.33	0.63	3.17e-52	Response to antipsychotic treatment;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05051152	chr8:124408913	ATAD2	0.38	6.76	0.3	4.25e-11	Obesity-related traits;
LGG	cis	rs12618769	0.597	rs3769741	chr2:99068204	G/T	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.92	0.31	1.54e-11	Cognitive ability;
LGG	cis	rs4819052	0.851	rs7281263	chr21:46695606	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.35	0.4	3.84e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17504614	0.648	rs10490173	chr2:51085669	A/T	cg23851515	chr2:51057218	NRXN1	0.62	7.81	0.34	4e-14	Educational attainment (years of education);
LGG	cis	rs7590368	0.640	rs72779433	chr2:10946986	C/T	cg15705551	chr2:10952987	PDIA6	0.57	7.41	0.33	6e-13	Educational attainment (years of education);
LGG	cis	rs12682352	0.602	rs13260419	chr8:8675176	A/G	cg08975724	chr8:8085496	FLJ10661	0.37	6.76	0.3	4.28e-11	Neuroticism;
LGG	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	12.7	0.51	6.74e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs4578248	chr1:248434069	G/A	cg01631408	chr1:248437212	OR2T33	-0.56	-10.19	-0.43	3.77e-22	Common traits (Other);
LGG	cis	rs10937275	1.000	rs10937275	chr3:186650790	A/G	cg13419791	chr3:186648285	ST6GAL1	-0.78	-8.01	-0.35	9.17e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg07142201	chr11:109293216	C11orf87	0.51	9.25	0.4	8.13e-19	Schizophrenia;
LGG	cis	rs6577655	0.517	rs4909294	chr8:135588020	C/T	cg17885191	chr8:135476712	NA	0.58	8.59	0.37	1.33e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs769267	0.895	rs1858999	chr19:19497669	C/G	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.16	-0.46	8.86e-26	Tonsillectomy;
LGG	cis	rs7945718	0.621	rs11022465	chr11:12686139	C/T	cg25843174	chr11:12811716	TEAD1	-0.33	-6.97	-0.31	1.09e-11	Educational attainment (years of education);
LGG	cis	rs769267	0.930	rs892021	chr19:19613480	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	16.89	0.62	3.11e-50	Tonsillectomy;
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg02524346	chr8:600233	NA	-1.1	-11.29	-0.46	2.72e-26	IgG glycosylation;
LGG	cis	rs344364	0.511	rs62040571	chr16:1948514	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg15394860	chr11:2017084	H19	0.6	13.23	0.52	4.12e-34	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2236267	0.693	rs8008120	chr14:88622367	A/C	cg18078958	chr14:88630771	NA	-0.31	-7.34	-0.32	9.8e-13	Food antigen IgG levels;
LGG	cis	rs17345786	1.000	rs58907984	chr3:101305170	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.52	9.06	0.39	3.59e-18	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6076960	0.652	rs3905171	chr20:6211177	T/C	cg17788362	chr6:86352627	SYNCRIP	0.5	8.7	0.37	5.66e-17	Smooth-surface caries;
LGG	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg07549998	chr6:150325970	RAET1K	-0.38	-7.25	-0.32	1.76e-12	Alopecia areata;
LGG	cis	rs9291683	0.546	rs13120348	chr4:10053155	C/G	cg00071950	chr4:10020882	SLC2A9	-0.39	-7.87	-0.34	2.54e-14	Bone mineral density;
LGG	cis	rs2370759	0.945	rs3740237	chr10:32557592	G/C	cg01819863	chr10:32635814	EPC1	1.05	12.49	0.5	4.62e-31	Sexual dysfunction (female);
LGG	cis	rs7113874	0.524	rs10769925	chr11:8623585	C/T	cg23764900	chr11:8616102	STK33	0.39	6.83	0.3	2.71e-11	Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs546131	0.820	rs744841	chr11:34857667	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.59	10.84	0.45	1.49e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs589448	0.902	rs2603090	chr12:69777188	G/A	cg14784868	chr12:69753453	YEATS4	1.0	23.89	0.74	8.97e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7833790	1.000	rs7833790	chr8:82731157	T/C	cg27398817	chr8:82754497	SNX16	-0.79	-11.59	-0.47	1.93e-27	Diastolic blood pressure;
LGG	cis	rs6138458	0.887	rs227622	chr20:24910597	T/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs922107	0.967	rs12752582	chr1:90019713	G/T	cg01128109	chr1:89989507	LRRC8B	-0.32	-7.27	-0.32	1.53e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel + carboplatin);
LGG	cis	rs6951245	0.572	rs73265911	chr7:1055363	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	9.06	0.39	3.77e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.798	rs1530996	chr2:99584079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.59	-0.51	1.8e-31	Chronic sinus infection;
LGG	cis	rs55788414	0.932	rs729265	chr16:81183600	G/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	6.07e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs8056893	0.842	rs4783553	chr16:68365955	A/G	cg07273125	chr16:68295692	NA	-0.39	-7.46	-0.33	4.17e-13	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg00343986	chr7:65444356	GUSB	-0.42	-7.21	-0.32	2.27e-12	Aortic root size;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03627896	chr16:30934334	NCRNA00095	-0.49	-7.15	-0.32	3.41e-12	Systemic lupus erythematosus;
LGG	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22496380	chr5:211416	CCDC127	-1.22	-17.01	-0.62	9.49e-51	Breast cancer;
LGG	cis	rs1865760	0.929	rs1816546	chr6:25938252	C/T	cg03517284	chr6:25882590	NA	-0.38	-6.73	-0.3	4.92e-11	Height;
LGG	cis	rs2290416	0.892	rs62522168	chr8:144679776	G/A	cg01494348	chr8:144660395	NAPRT1	0.96	7.42	0.33	5.47e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2046867	0.908	rs9811830	chr3:72809591	A/G	cg25664220	chr3:72788482	NA	-0.32	-8.97	-0.38	7.59e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg07362569	chr17:61921086	SMARCD2	-0.5	-9.45	-0.4	1.74e-19	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs11763414	chr7:100016844	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.8	0.69	2.58e-68	Platelet count;
LGG	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg08648136	chr8:956695	NA	0.38	7.73	0.34	6.6e-14	Schizophrenia;
LGG	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg08085267	chr17:45401833	C17orf57	0.62	12.8	0.51	2.45e-32	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4917300	0.626	rs28375965	chr8:143103882	A/G	cg06573787	chr8:143070187	NA	0.49	8.44	0.37	4.13e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs9303280	0.806	rs12936409	chr17:38043649	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.16	-0.32	3.2e-12	Self-reported allergy;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg11062466	chr8:58055876	NA	0.6	9.78	0.41	1.15e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs7937682	0.924	rs10891283	chr11:111527672	A/G	cg18187862	chr3:45730750	SACM1L	0.66	10.96	0.45	5.15e-25	Primary sclerosing cholangitis;
LGG	cis	rs2071426	0.710	rs11188145	chr10:96791277	T/G	cg09036531	chr10:96991505	NA	-0.4	-6.77	-0.3	3.94e-11	Blood metabolite levels;
LGG	cis	rs13108904	0.846	rs12643212	chr4:1224948	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.66	11.57	0.47	2.18e-27	Obesity-related traits;
LGG	cis	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg27411982	chr8:10470053	RP1L1	0.45	7.3	0.32	1.26e-12	Neuroticism;
LGG	cis	rs3008870	1.000	rs2985822	chr1:67404910	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.09	0.73	4.54e-79	Lymphocyte percentage of white cells;
LGG	cis	rs2228479	0.867	rs35542367	chr16:89965825	G/C	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.7	-0.59	8e-45	Skin colour saturation;
LGG	cis	rs9834373	0.614	rs4560262	chr3:78502283	A/G	cg06138941	chr3:78371609	NA	-0.46	-8.59	-0.37	1.32e-16	Protein quantitative trait loci;
LGG	cis	rs951366	0.789	rs823152	chr1:205736285	G/A	cg14159672	chr1:205819179	PM20D1	0.79	17.49	0.63	5.64e-53	Menarche (age at onset);
LGG	cis	rs9796	0.700	rs2305656	chr15:41279519	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.25	-0.43	2.33e-22	Menopause (age at onset);
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg19635926	chr16:89946313	TCF25	0.63	7.39	0.32	7.11e-13	Skin colour saturation;
LGG	cis	rs3796619	0.961	rs62294748	chr4:1082999	G/A	cg21130718	chr4:1044621	NA	0.39	7.53	0.33	2.7e-13	Recombination rate (males);
LGG	cis	rs1153858	1.000	rs4774578	chr15:45646051	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs10870270	0.913	rs115236491	chr10:133766855	T/G	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.62	-0.53	9.44e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs35740288	0.539	rs11634553	chr15:86336611	G/A	cg04173714	chr15:86211321	AKAP13	0.41	6.95	0.31	1.26e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs853679	0.599	rs13193295	chr6:28003228	C/G	cg08344181	chr3:125677491	NA	-0.85	-8.59	-0.37	1.35e-16	Depression;
LGG	cis	rs2764208	0.576	rs2764199	chr6:34706982	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.47	-8.48	-0.37	3.01e-16	Systemic lupus erythematosus;
LGG	cis	rs2050392	0.894	rs303430	chr10:30706235	C/A	cg25182066	chr10:30743637	MAP3K8	-0.51	-10.6	-0.44	1.21e-23	Inflammatory bowel disease;
LGG	cis	rs3796352	1.000	rs1346719	chr3:53077372	A/G	cg12962167	chr3:53033115	SFMBT1	0.63	6.77	0.3	4.04e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg07791516	chr6:150247246	NA	0.37	6.76	0.3	4.15e-11	Lung cancer;
LGG	cis	rs10504130	0.569	rs4436115	chr8:52674492	G/A	cg22653915	chr8:52722023	PXDNL	-0.42	-6.71	-0.3	5.67e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg04025307	chr7:1156635	C7orf50	0.71	10.01	0.42	1.76e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg26338869	chr17:61819248	STRADA	-0.57	-9.52	-0.4	9.89e-20	Prudent dietary pattern;
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg18404041	chr3:52824283	ITIH1	0.51	9.91	0.42	3.95e-21	Bipolar disorder;
LGG	trans	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.52	0.44	2.38e-23	Lewy body disease;
LGG	cis	rs503734	0.629	rs9856435	chr3:101218228	C/T	cg27318481	chr3:100970896	IMPG2	0.34	6.99	0.31	9.41e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg08975724	chr8:8085496	FLJ10661	0.39	7.27	0.32	1.59e-12	Neuroticism;
LGG	cis	rs1046896	0.627	rs7225515	chr17:80795783	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.7	0.34	8.13e-14	Glycated hemoglobin levels;
LGG	cis	rs4332037	1.000	rs10240470	chr7:1949971	G/T	cg23422044	chr7:1970798	MAD1L1	0.69	11.67	0.48	9.11e-28	Bipolar disorder;
LGG	cis	rs6500395	0.962	rs1115759	chr16:48599530	A/G	cg16662043	chr16:48846231	NA	0.37	7.28	0.32	1.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1125355	0.690	rs62183662	chr2:159641579	A/G	cg02251393	chr2:159651559	DAPL1	0.42	8.76	0.38	3.81e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7044106	0.762	rs4142158	chr9:123410819	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.31	0.6	1.39e-47	Hip circumference adjusted for BMI;
LGG	cis	rs7828089	0.967	rs7828414	chr8:22264585	T/C	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.79	-0.3	3.47e-11	Verbal declarative memory;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg27471124	chr11:109292789	C11orf87	0.5	9.73	0.41	1.71e-20	Schizophrenia;
LGG	cis	rs2251260	1.000	rs2250772	chr14:62019060	G/C	cg23386212	chr14:62041363	NA	0.69	11.13	0.46	1.21e-25	Yeast infection;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.68e-123	Prudent dietary pattern;
LGG	trans	rs853679	0.769	rs17720293	chr6:28214698	C/T	cg01620082	chr3:125678407	NA	-0.82	-8.79	-0.38	2.84e-17	Depression;
LGG	trans	rs12579753	0.917	rs7132732	chr12:82206053	C/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs79149102	0.579	rs3816261	chr15:75336173	T/A	cg17294928	chr15:75287854	SCAMP5	-0.85	-8.41	-0.36	5.18e-16	Lung cancer;
LGG	cis	rs62380364	0.542	rs2457979	chr5:88039660	T/A	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.55e-23	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg26769984	chr7:1090371	C7orf50	0.42	8.27	0.36	1.39e-15	Bronchopulmonary dysplasia;
LGG	cis	rs67133203	0.554	rs454520	chr12:51410745	T/C	cg14688905	chr12:51403056	SLC11A2	-0.58	-10.04	-0.42	1.41e-21	Urinary tract infection frequency;
LGG	trans	rs1459104	0.777	rs116287458	chr11:54916623	G/A	cg15704280	chr7:45808275	SEPT13	0.78	7.74	0.34	6.5e-14	Body mass index;
LGG	trans	rs7939886	0.764	rs11227350	chr11:55912289	T/C	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs7481584	0.962	rs11024766	chr11:2984645	C/G	cg08508325	chr11:3079039	CARS	0.38	7.13	0.31	3.98e-12	Calcium levels;
LGG	trans	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs12291225	0.546	rs12795545	chr11:14355564	G/A	cg19336497	chr11:14380999	RRAS2	-0.64	-13.63	-0.54	8.35e-36	Sense of smell;
LGG	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg04568710	chr12:38710424	ALG10B	0.44	9.7	0.41	2.33e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7811142	0.943	rs66958101	chr7:100074020	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.92	-0.59	7.63e-46	Platelet count;
LGG	cis	rs12230513	1.000	rs7304684	chr12:55895538	C/T	cg19537932	chr12:55886519	OR6C68	-0.47	-7.58	-0.33	1.88e-13	Contrast sensitivity;
LGG	cis	rs9911578	0.933	rs2531726	chr17:56522533	C/T	cg05425664	chr17:57184151	TRIM37	0.59	9.22	0.39	1.07e-18	Intelligence (multi-trait analysis);
LGG	cis	rs11711311	1.000	rs9288982	chr3:113470149	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	14.04	0.55	1.54e-37	IgG glycosylation;
LGG	cis	rs9503598	0.644	rs4959240	chr6:3430674	C/T	cg00476032	chr6:3446245	SLC22A23	0.42	8.17	0.36	2.92e-15	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.602	rs1453373	chr2:178221668	G/A	cg27490568	chr2:178487706	NA	0.34	6.79	0.3	3.36e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1863824	0.625	rs10887600	chr10:88169072	C/T	cg07322936	chr10:88137208	NA	-0.52	-8.49	-0.37	2.92e-16	Schizophrenia;
LGG	cis	rs9650657	0.537	rs11250092	chr8:10786543	A/G	cg27411982	chr8:10470053	RP1L1	0.46	7.81	0.34	3.96e-14	Neuroticism;
LGG	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.8	-0.3	3.3e-11	Blood metabolite levels;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg12288994	chr5:1860383	NA	0.79	16.03	0.6	2.66e-46	Cardiovascular disease risk factors;
LGG	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg09021430	chr5:549028	NA	-0.69	-9.64	-0.41	3.71e-20	Obesity-related traits;
LGG	cis	rs57502260	0.764	rs3867143	chr11:68223074	A/G	cg01657329	chr11:68192670	LRP5	-0.58	-7.32	-0.32	1.09e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs2559856	1.000	rs2695285	chr12:102089043	G/A	cg15068132	chr12:102092402	CHPT1	-0.37	-6.77	-0.3	4.02e-11	Blood protein levels;
LGG	cis	rs75920871	0.841	rs61903430	chr11:116987342	G/C	cg20608306	chr11:116969690	SIK3	-0.32	-6.64	-0.3	8.57e-11	Subjective well-being;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg05793240	chr7:2802953	GNA12	-0.34	-7.86	-0.34	2.77e-14	Height;
LGG	trans	rs45509595	0.556	rs34409918	chr6:27685348	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Breast cancer;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.38	0.4	2.93e-19	Neuroticism;
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg08742575	chr21:47604166	C21orf56	0.49	8.34	0.36	8.72e-16	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.46	-0.33	4.46e-13	Life satisfaction;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.56	9.97	0.42	2.53e-21	Longevity;
LGG	cis	rs6993813	0.872	rs4273881	chr8:120016355	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.86	0.3	2.16e-11	Bone mineral density (hip);
LGG	cis	rs17384381	1.000	rs17388521	chr1:85897904	A/G	cg16011679	chr1:85725395	C1orf52	-0.6	-10.74	-0.45	3.43e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9926296	0.563	rs4785724	chr16:89893235	G/C	cg23057051	chr16:89984268	MC1R	-0.35	-6.69	-0.3	6.49e-11	Vitiligo;
LGG	cis	rs2839186	0.900	rs2839200	chr21:47709095	C/T	cg05896524	chr21:47604654	C21orf56	0.55	9.32	0.4	4.69e-19	Testicular germ cell tumor;
LGG	cis	rs9311474	0.629	rs11709284	chr3:52559705	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.24	0.32	1.82e-12	Electroencephalogram traits;
LGG	cis	rs61931739	0.529	rs1525900	chr12:33976652	T/G	cg06521331	chr12:34319734	NA	-0.41	-7.26	-0.32	1.69e-12	Morning vs. evening chronotype;
LGG	cis	rs711245	0.572	rs3821150	chr2:36795233	G/A	cg15105969	chr2:36825350	FEZ2	0.49	7.38	0.32	7.55e-13	Height;
LGG	cis	rs3818285	0.515	rs12258440	chr10:111676799	C/T	cg00817464	chr10:111662876	XPNPEP1	-0.57	-10.38	-0.43	8.1e-23	Superior crus of antihelix expression;
LGG	cis	rs637571	0.584	rs594689	chr11:65635559	G/A	cg04055107	chr11:65626734	MUS81;CFL1	-0.49	-7.83	-0.34	3.39e-14	Eosinophil percentage of white cells;
LGG	cis	rs7737355	0.812	rs9687376	chr5:130918037	A/C	cg06307176	chr5:131281290	NA	0.53	8.77	0.38	3.54e-17	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17151150	chr11:118977897	C2CD2L	0.5	7.92	0.35	1.75e-14	Gut microbiome composition (summer);
LGG	cis	rs6546550	0.901	rs897119	chr2:70160658	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.87	-0.34	2.56e-14	Prevalent atrial fibrillation;
LGG	cis	rs537930	0.770	rs31210	chr5:134361020	C/T	cg24576358	chr5:134350122	NA	0.37	7.14	0.31	3.69e-12	Height;
LGG	cis	rs17301259	0.564	rs10248441	chr7:88416536	T/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.01	-0.31	8.43e-12	Heschl's gyrus morphology;
LGG	cis	rs7208859	0.573	rs216442	chr17:28931197	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.3	0.43	1.49e-22	Retinal vascular caliber;
LGG	cis	rs8114671	0.562	rs6088653	chr20:33520321	T/C	cg07148914	chr20:33460835	GGT7	0.54	9.07	0.39	3.3e-18	Height;
LGG	cis	rs10927875	0.597	rs61782184	chr1:16150976	G/A	cg21385522	chr1:16154831	NA	-1.04	-25.96	-0.77	2.23e-92	Dilated cardiomyopathy;
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs9311474	0.507	rs4687644	chr3:52746541	T/G	cg14092988	chr3:52407081	DNAH1	0.29	7.88	0.34	2.29e-14	Electroencephalogram traits;
LGG	cis	rs60871478	0.588	rs73043546	chr7:857513	C/G	cg05535760	chr7:792225	HEATR2	-0.95	-12.57	-0.5	2.11e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs11239187	0.566	rs2061971	chr10:45089053	A/G	cg03916630	chr10:45065415	NA	0.36	8.5	0.37	2.72e-16	Body mass index;
LGG	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	trans	rs6787172	0.702	rs1095627	chr3:157977406	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs7493	0.853	rs35686517	chr7:95052611	G/A	cg17330251	chr7:94953956	PON1	-0.43	-8.3	-0.36	1.16e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.05	-0.31	6.48e-12	Aortic root size;
LGG	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs9527	0.615	rs4917991	chr10:104783833	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.97	-0.31	1.13e-11	Arsenic metabolism;
LGG	cis	rs270601	0.770	rs4361510	chr5:131599647	C/T	cg07395648	chr5:131743802	NA	-0.36	-7.37	-0.32	7.76e-13	Acylcarnitine levels;
LGG	cis	rs8177179	1.000	rs8177179	chr3:133463457	G/A	cg24879335	chr3:133465180	TF	0.45	7.39	0.32	6.84e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs55665837	1.000	rs2305306	chr11:14534999	T/A	cg19336497	chr11:14380999	RRAS2	-0.44	-8.6	-0.37	1.25e-16	Vitamin D levels;
LGG	trans	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg25214090	chr10:38739885	LOC399744	0.61	10.26	0.43	2.13e-22	Corneal astigmatism;
LGG	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs380904	0.519	rs12541790	chr8:144643321	A/G	cg21643262	chr8:144646939	NA	-0.53	-7.83	-0.34	3.38e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6599192	1	rs6599192	chr3:41992408	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Multiple myeloma;
LGG	cis	rs4423214	0.840	rs1540127	chr11:71179038	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	cis	rs2172802	0.629	rs1948616	chr4:62487688	A/G	cg04118610	chr4:62707027	LPHN3	-0.55	-9.51	-0.4	1.07e-19	Partial epilepsies;
LGG	cis	rs9372253	0.967	rs9400379	chr6:110713783	A/G	cg01119278	chr6:110721349	DDO	-0.3	-7.15	-0.32	3.39e-12	Platelet distribution width;
LGG	cis	rs11098499	0.954	rs7654587	chr4:120388406	C/T	cg09307838	chr4:120376055	NA	0.82	13.73	0.54	3.14e-36	Corneal astigmatism;
LGG	trans	rs7618501	0.633	rs6771546	chr3:49968572	T/C	cg21659725	chr3:3221576	CRBN	0.63	11.63	0.48	1.32e-27	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.664	rs2854308	chr17:29666539	A/G	cg24425628	chr17:29625626	OMG;NF1	0.59	12.45	0.5	6.72e-31	Hip circumference;
LGG	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg17211192	chr8:82754475	SNX16	0.78	12.08	0.49	2.09e-29	Diastolic blood pressure;
LGG	cis	rs7552404	0.889	rs2211080	chr1:76243438	G/A	cg10523679	chr1:76189770	ACADM	0.79	14.08	0.55	9.51e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs763121	0.853	rs926299	chr22:39095698	C/G	cg21395723	chr22:39101663	GTPBP1	0.38	6.69	0.3	6.38e-11	Menopause (age at onset);
LGG	cis	rs9611565	0.649	rs9623450	chr22:42175231	G/A	cg06634786	chr22:41940651	POLR3H	0.68	10.94	0.45	6.12e-25	Vitiligo;
LGG	cis	rs2276314	0.857	rs9960670	chr18:33577712	A/G	cg05985134	chr18:33552581	C18orf21	0.63	9.83	0.42	8.05e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9650657	0.803	rs13276026	chr8:10609955	G/A	cg27411982	chr8:10470053	RP1L1	-0.4	-6.72	-0.3	5.51e-11	Neuroticism;
LGG	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.77	0.38	3.47e-17	Schizophrenia;
LGG	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg21775007	chr8:11205619	TDH	0.74	12.6	0.51	1.64e-31	Retinal vascular caliber;
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg13047869	chr3:10149882	C3orf24	0.44	7.28	0.32	1.47e-12	Alzheimer's disease;
LGG	trans	rs208520	0.690	rs4386800	chr6:66755242	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.54	0.63	3.42e-53	Exhaled nitric oxide output;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.52	8.26	0.36	1.58e-15	Longevity;
LGG	cis	rs9486715	0.929	rs7775721	chr6:97056979	C/T	cg06623918	chr6:96969491	KIAA0776	-0.76	-14.65	-0.56	3.36e-40	Headache;
LGG	cis	rs28595532	0.920	rs17259173	chr4:119777232	T/C	cg11846333	chr4:119757529	SEC24D	0.85	7.36	0.32	8.48e-13	Cannabis dependence symptom count;
LGG	cis	rs10911232	0.507	rs4652769	chr1:183009196	T/C	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg13206674	chr6:150067644	NUP43	0.68	15.92	0.59	7.6e-46	Lung cancer;
LGG	cis	rs4563143	0.663	rs73025068	chr19:29238998	G/A	cg03161606	chr19:29218774	NA	0.7	11.08	0.46	1.81e-25	Methadone dose in opioid dependence;
LGG	cis	rs367615	0.704	rs17161885	chr5:108852642	A/G	cg17395555	chr5:108820864	NA	0.86	15.54	0.59	3.95e-44	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs4900069	0.764	rs12433069	chr14:91594186	A/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.43	-7.31	-0.32	1.2e-12	Resting heart rate;
LGG	cis	rs6089829	0.962	rs6089826	chr20:61668595	G/A	cg08045932	chr20:61659980	NA	0.6	13.08	0.52	1.79e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs344364	0.511	rs1657133	chr16:1950300	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg19318889	chr4:1322082	MAEA	0.46	7.9	0.34	2.03e-14	Longevity;
LGG	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.07	17.22	0.62	1.02e-51	Breast cancer;
LGG	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9303401	0.614	rs34058624	chr17:57118121	T/C	cg25039879	chr17:56429692	SUPT4H1	0.57	8.05	0.35	6.88e-15	Cognitive test performance;
LGG	cis	rs7301826	0.580	rs61938969	chr12:131316070	A/G	cg11011512	chr12:131303247	STX2	-0.39	-8.39	-0.36	5.82e-16	Plasma plasminogen activator levels;
LGG	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg03264133	chr6:25882463	NA	-0.57	-10.53	-0.44	2.13e-23	Intelligence (multi-trait analysis);
LGG	cis	rs17428076	1.000	rs17428076	chr2:172851936	C/G	cg21435375	chr2:172878103	MAP1D	-0.45	-9.79	-0.41	1.04e-20	Myopia;
LGG	cis	rs4684776	1.000	rs6762035	chr3:11423759	T/G	cg24705426	chr3:11550659	ATG7	-0.42	-7.45	-0.33	4.46e-13	Small vessel stroke;
LGG	cis	rs12893668	0.703	rs8017993	chr14:104047734	A/G	cg23335576	chr14:104009727	NA	0.47	8.34	0.36	8.37e-16	Reticulocyte count;
LGG	trans	rs459571	0.920	rs417142	chr9:136891370	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.24	-0.49	4.78e-30	Platelet distribution width;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02071572	chr4:1403502	NA	0.4	6.84	0.3	2.59e-11	Longevity;
LGG	cis	rs34172651	0.876	rs1862451	chr16:24803620	A/G	cg02428538	chr16:24856791	SLC5A11	-0.49	-8.24	-0.36	1.78e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg08045932	chr20:61659980	NA	0.6	13.0	0.52	3.71e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6694672	0.850	rs10754213	chr1:197055925	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs9831754	0.704	rs9836909	chr3:78451594	A/G	cg06138941	chr3:78371609	NA	-0.8	-15.51	-0.58	5.3e-44	Calcium levels;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg02462569	chr6:150064036	NUP43	-0.4	-8.72	-0.38	4.97e-17	Lung cancer;
LGG	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.41	-0.33	6.16e-13	Iron status biomarkers;
LGG	trans	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg22232500	chr2:134024266	NCKAP5	0.67	9.17	0.39	1.59e-18	Bipolar disorder;
LGG	cis	rs4689388	0.853	rs4293850	chr4:6292020	A/C	cg00701064	chr4:6280414	WFS1	0.71	15.35	0.58	2.68e-43	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs561341	0.831	rs11658469	chr17:30206426	T/C	cg20587970	chr11:113659929	NA	1.06	15.99	0.6	3.68e-46	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg07791516	chr6:150247246	NA	0.37	6.73	0.3	4.98e-11	Lung cancer;
LGG	cis	rs10028773	0.506	rs12374346	chr4:120281705	G/A	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Educational attainment;
LGG	cis	rs708547	0.697	rs67479587	chr4:57878884	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.51	8.46	0.37	3.55e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs7444	0.941	rs73166622	chr22:21938863	G/C	cg15846791	chr22:21984385	YDJC	-0.45	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg22535103	chr8:58192502	C8orf71	-0.83	-10.59	-0.44	1.32e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.73	-0.34	6.82e-14	Neuroticism;
LGG	cis	rs10463554	0.856	rs26427	chr5:102366783	A/C	cg23492399	chr5:102201601	PAM	0.45	6.82	0.3	2.9e-11	Parkinson's disease;
LGG	cis	rs11864453	1.000	rs7201491	chr16:72034312	G/A	cg01557791	chr16:72042693	DHODH	-0.59	-11.12	-0.46	1.31e-25	Fibrinogen levels;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18252515	chr7:66147081	NA	0.44	7.31	0.32	1.21e-12	Aortic root size;
LGG	cis	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg05623727	chr3:50126028	RBM5	-0.44	-9.68	-0.41	2.6e-20	Body mass index;
LGG	trans	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg02002194	chr4:3960332	NA	-0.53	-10.37	-0.43	8.84e-23	Mood instability;
LGG	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg07661805	chr8:143867942	LY6D	-0.3	-8.07	-0.35	6.04e-15	Urinary tract infection frequency;
LGG	cis	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg19338460	chr6:170058176	WDR27	-0.6	-8.08	-0.35	5.81e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg06634786	chr22:41940651	POLR3H	-0.55	-8.88	-0.38	1.46e-17	Neuroticism;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg18110333	chr6:292329	DUSP22	-0.7	-11.97	-0.49	6.03e-29	Menopause (age at onset);
LGG	trans	rs11875185	0.510	rs35818338	chr18:55634543	C/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.87	-11.53	-0.47	3.3699999999999996e-27	Longevity;Endometriosis;
LGG	cis	rs7769051	0.522	rs7738256	chr6:133113066	C/G	cg07930552	chr6:133119739	C6orf192	1.15	10.55	0.44	1.8e-23	Type 2 diabetes nephropathy;
LGG	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg10847948	chr11:71163743	NADSYN1	0.52	9.79	0.41	1.05e-20	Vitamin D levels;
LGG	cis	rs13102973	0.965	rs7656631	chr4:135869921	C/T	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs11583043	0.708	rs17123647	chr1:101529018	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.43	6.72	0.3	5.44e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01245787	chr4:71859630	DCK	0.47	7.63	0.33	1.34e-13	Cognitive performance;
LGG	cis	rs787274	0.557	rs912662	chr9:115669880	A/C	cg13803584	chr9:115635662	SNX30	-0.63	-6.7	-0.3	6.22e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs368123	0.750	rs560535	chr6:160720531	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.17e-12	Waist circumference;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06634786	chr22:41940651	POLR3H	-0.79	-12.79	-0.51	2.66e-32	Vitiligo;
LGG	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg03929089	chr4:120376271	NA	-0.53	-9.01	-0.39	5.52e-18	HDL cholesterol;
LGG	cis	rs1005277	0.579	rs2474587	chr10:38420666	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.23e-29	Extrinsic epigenetic age acceleration;
LGG	trans	rs6601327	0.543	rs11249948	chr8:9648686	A/G	cg12395012	chr8:11607386	GATA4	-0.37	-6.75	-0.3	4.32e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3796619	1.000	rs13146371	chr4:1082887	C/T	cg21130718	chr4:1044621	NA	0.38	7.27	0.32	1.56e-12	Recombination rate (males);
LGG	cis	rs7666738	0.830	rs28728124	chr4:99001116	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	9.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3820068	0.581	rs72645889	chr1:15930251	T/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs3087591	1.000	rs2107360	chr17:29697901	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.64	-0.56	3.75e-40	Hip circumference;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg03031660	chr17:73257791	MRPS7;GGA3	-0.46	-7.08	-0.31	5.52e-12	Coronary artery disease;
LGG	trans	rs62103177	0.713	rs62103186	chr18:77627574	G/C	cg05926928	chr17:57297772	GDPD1	1.36	21.68	0.71	1.93e-72	Opioid sensitivity;
LGG	cis	rs4713118	0.513	rs149989	chr6:27998184	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.45	-6.66	-0.3	7.7e-11	Parkinson's disease;
LGG	cis	rs28588043	0.877	rs7055894	chr1:170992809	C/T	cg03458344	chr1:170964477	C1orf129	-0.47	-7.02	-0.31	8.12e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs6066825	0.555	rs717709	chr20:47305959	G/A	cg18078177	chr20:47281410	PREX1	0.47	7.82	0.34	3.67e-14	Colorectal cancer;
LGG	cis	rs988958	0.565	rs6752691	chr2:42235581	C/T	cg19376973	chr2:42229025	NA	0.63	9.17	0.39	1.56e-18	Hypospadias;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg08965527	chr16:84178213	HSDL1;LRRC50	-0.41	-7.03	-0.31	7.61e-12	Leprosy;
LGG	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg23601095	chr6:26197514	HIST1H3D	0.72	9.19	0.39	1.3e-18	Gout;Renal underexcretion gout;
LGG	cis	rs7582180	0.614	rs6737217	chr2:101006267	T/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.69	-0.48	7.98e-28	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.658	rs4980440	chr11:49386017	C/T	cg03929089	chr4:120376271	NA	-0.95	-20.3	-0.69	5.39e-66	Coronary artery disease;
LGG	cis	rs4509693	0.943	rs6584395	chr10:102498008	G/C	cg24179445	chr10:102496915	NA	0.37	6.8	0.3	3.34e-11	Alzheimer's disease;
LGG	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg23845249	chr11:68861649	NA	0.44	7.81	0.34	3.77e-14	Blond vs. brown hair color;
LGG	cis	rs7208859	0.573	rs216443	chr17:28931871	A/G	cg19761014	chr17:28927070	LRRC37B2	0.66	7.82	0.34	3.62e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7954584	0.531	rs10840631	chr12:122373729	C/T	cg13699009	chr12:122356056	WDR66	0.58	15.73	0.59	5.88e-45	Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs11292	chr10:102313607	A/G	cg11040518	chr10:102331378	NA	-0.38	-6.92	-0.31	1.53e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7226408	0.857	rs11081988	chr18:34697833	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs36051895	0.664	rs11793659	chr9:5109707	A/G	cg02405213	chr9:5042618	JAK2	-0.8	-14.54	-0.56	1.05e-39	Pediatric autoimmune diseases;
LGG	cis	rs9815354	0.680	rs73073280	chr3:42025772	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28595532	0.920	rs114581578	chr4:119756404	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.5	0.5	4.28e-31	Obesity-related traits;
LGG	cis	rs826838	0.967	rs11169142	chr12:39085773	A/T	cg13010199	chr12:38710504	ALG10B	-0.63	-13.41	-0.53	7.18e-35	Heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00286986	chr8:124085360	WDR67	0.53	8.06	0.35	6.35e-15	Gut microbiome composition (summer);
LGG	cis	rs9291683	0.507	rs6849273	chr4:10021595	C/T	cg08250081	chr4:10125330	NA	0.42	8.34	0.36	8.47e-16	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08494300	chr11:93474945	TAF1D;C11orf54	0.45	7.21	0.32	2.34e-12	Cognitive performance;
LGG	cis	rs7923837	0.574	rs2488075	chr10:94490174	T/C	cg25093409	chr10:94429542	NA	-0.4	-7.51	-0.33	3.12e-13	Body mass index;Multiple sclerosis;
LGG	cis	rs7937682	0.921	rs11213945	chr11:111461003	A/G	cg19812747	chr11:111475976	SIK2	0.47	9.3	0.4	5.78e-19	Primary sclerosing cholangitis;
LGG	cis	rs7949030	0.596	rs11231138	chr11:62316195	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.72	17.93	0.64	5.75e-55	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs72945132	0.882	rs947812	chr11:70209169	C/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.12	0.52	1.13e-33	Coronary artery disease;
LGG	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs9486715	1.000	rs2273621	chr6:97058553	A/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.33	-0.4	4.5e-19	Headache;
LGG	cis	rs7737355	0.853	rs31586	chr5:131000696	A/G	cg06307176	chr5:131281290	NA	0.53	8.79	0.38	3e-17	Life satisfaction;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs4740619	0.647	rs4741545	chr9:15830506	T/G	cg14451791	chr9:16040625	NA	-0.36	-9.28	-0.4	6.67e-19	Body mass index;
LGG	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15664640	chr17:80829946	TBCD	-0.67	-9.02	-0.39	5e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9815354	1.000	rs9875083	chr3:41775786	T/A	cg03022575	chr3:42003672	ULK4	0.66	8.31	0.36	1.06e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1847505	0.609	rs75871412	chr13:61496028	C/G	cg25164009	chr13:61490935	NA	0.6	9.35	0.4	3.83e-19	Polychlorinated biphenyl levels;
LGG	cis	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.52	-0.33	2.84e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.77	13.62	0.53	8.93e-36	Obesity-related traits;
LGG	cis	rs11734570	0.581	rs73811716	chr4:38590773	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.41	0.36	5.02e-16	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs12325245	0.536	rs17821549	chr16:58554780	C/T	cg19824325	chr16:58548873	SETD6	1.22	11.06	0.46	2.17e-25	Schizophrenia;
LGG	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg06360820	chr2:242988706	NA	-0.9	-11.51	-0.47	3.88e-27	Obesity-related traits;
LGG	cis	rs7264396	0.790	rs6060565	chr20:34285442	C/T	cg17201900	chr20:34330562	RBM39	0.49	6.64	0.3	8.63e-11	Total cholesterol levels;
LGG	cis	rs2115536	1.000	rs2115536	chr15:80194247	C/T	cg11839771	chr15:80205821	ST20	-0.34	-7.27	-0.32	1.55e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.46	0.5	6.1e-31	Colorectal cancer;
LGG	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs6500596	0.570	rs758045	chr16:4434198	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.34	-6.65	-0.3	8.18e-11	Schizophrenia;
LGG	cis	rs11662586	1.000	rs12605316	chr18:77693600	C/T	cg20368463	chr18:77673604	PQLC1	0.49	7.86	0.34	2.71e-14	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg03929089	chr4:120376271	NA	-0.53	-9.0	-0.39	5.78e-18	HDL cholesterol;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg11062466	chr8:58055876	NA	0.48	8.25	0.36	1.67e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg03188948	chr7:1209495	NA	0.61	8.14	0.35	3.58e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03031660	chr17:73257791	MRPS7;GGA3	0.39	6.72	0.3	5.24e-11	Bilirubin levels;
LGG	cis	rs7241530	0.585	rs12956095	chr18:75890645	A/G	cg14642773	chr18:75888474	NA	0.46	9.0	0.39	5.89e-18	Educational attainment (years of education);
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg08280861	chr8:58055591	NA	0.5	6.75	0.3	4.44e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9858542	0.537	rs9874474	chr3:49326178	A/G	cg03060546	chr3:49711283	APEH	-0.53	-7.16	-0.32	3.22e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7927592	0.912	rs55767696	chr11:68375120	C/G	cg16797656	chr11:68205561	LRP5	0.4	7.09	0.31	4.99e-12	Total body bone mineral density;
LGG	cis	rs17102423	0.755	rs11625045	chr14:65549089	C/T	cg11161011	chr14:65562177	MAX	-0.79	-15.95	-0.6	6.09e-46	Obesity-related traits;
LGG	cis	rs7129556	0.775	rs623907	chr11:77501448	T/A	cg12586386	chr11:77299805	AQP11	0.45	7.4	0.33	6.52e-13	Weight loss (gastric bypass surgery);
LGG	trans	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg02002194	chr4:3960332	NA	0.38	7.03	0.31	7.67e-12	Myopia;Myopia (pathological);
LGG	cis	rs2836974	0.932	rs13048178	chr21:40561012	G/T	cg11890956	chr21:40555474	PSMG1	1.19	29.42	0.81	4.82e-108	Cognitive function;
LGG	cis	rs2230307	0.536	rs11166407	chr1:100637708	C/T	cg24955406	chr1:100503596	HIAT1	0.55	8.04	0.35	7.67e-15	Carotid intima media thickness;
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg13264159	chr8:625131	ERICH1	0.88	8.45	0.37	3.94e-16	IgG glycosylation;
LGG	cis	rs896854	0.654	rs2011566	chr8:95971921	G/A	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.42	-0.36	4.64e-16	Type 2 diabetes;
LGG	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg08508325	chr11:3079039	CARS	-0.61	-13.24	-0.52	3.61e-34	Longevity;
LGG	cis	rs7824557	0.767	rs6985146	chr8:11170721	A/C	cg21775007	chr8:11205619	TDH	0.59	9.68	0.41	2.54e-20	Retinal vascular caliber;
LGG	cis	rs17001868	0.568	rs9611314	chr22:40735798	C/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs7044106	0.734	rs12553070	chr9:123485266	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	17.48	0.63	6.43e-53	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg16920238	chr17:80076378	CCDC57	0.32	7.24	0.32	1.89e-12	Life satisfaction;
LGG	cis	rs2046867	0.862	rs75638790	chr3:72830502	C/T	cg25664220	chr3:72788482	NA	-0.34	-9.21	-0.39	1.14e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12477438	0.520	rs12052986	chr2:99994960	C/G	cg23527387	chr2:100056660	REV1	0.41	9.23	0.39	9.34e-19	Chronic sinus infection;
LGG	cis	rs6547741	1.000	rs6547740	chr2:27854369	C/T	cg22903471	chr2:27725779	GCKR	0.37	8.33	0.36	9.44e-16	Oral cavity cancer;
LGG	cis	rs2201728	0.677	rs35765787	chr4:100187513	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.89	-0.31	1.82e-11	Cardiac Troponin-T levels;
LGG	trans	rs7395662	0.791	rs7945791	chr11:48936340	C/T	cg03929089	chr4:120376271	NA	0.44	7.09	0.31	5.2e-12	HDL cholesterol;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg08621203	chr6:150244597	RAET1G	0.51	9.61	0.41	4.79e-20	Testicular germ cell tumor;
LGG	trans	rs656319	0.702	rs477860	chr8:9811765	T/C	cg02002194	chr4:3960332	NA	0.43	7.31	0.32	1.15e-12	Myopia (pathological);
LGG	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.4e-18	Motion sickness;
LGG	cis	rs7949030	1.000	rs10897289	chr11:62400016	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.56	12.39	0.5	1.25e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4917300	0.571	rs4917276	chr8:143095436	G/T	cg26003909	chr8:143102224	NA	0.36	7.34	0.32	9.81e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg13798912	chr7:905769	UNC84A	-0.57	-7.13	-0.31	3.84e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	7.01	0.31	8.58e-12	Schizophrenia;
LGG	cis	rs4740619	0.709	rs10810461	chr9:15876507	G/T	cg14451791	chr9:16040625	NA	-0.39	-9.76	-0.41	1.42e-20	Body mass index;
LGG	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg23205692	chr1:25664452	TMEM50A	0.49	10.59	0.44	1.29e-23	Erythrocyte sedimentation rate;
LGG	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg17108064	chr15:78857060	CHRNA5	-0.46	-10.0	-0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs2777491	0.574	rs1757468	chr15:41743574	T/A	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.95	-0.84	9.49e-128	Ulcerative colitis;
LGG	cis	rs2032447	0.966	rs3752416	chr6:26045929	T/C	cg03517284	chr6:25882590	NA	-0.57	-10.75	-0.45	3.13e-24	Intelligence (multi-trait analysis);
LGG	trans	rs877282	1.000	rs2004479	chr10:770854	G/A	cg22713356	chr15:30763199	NA	0.55	8.46	0.37	3.53e-16	Uric acid levels;
LGG	cis	rs7216064	1.000	rs6504543	chr17:65837659	T/C	cg12091567	chr17:66097778	LOC651250	-0.63	-9.33	-0.4	4.48e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg00367488	chr2:120020686	STEAP3	0.36	6.83	0.3	2.72e-11	Electrocardiographic conduction measures;
LGG	cis	rs2243480	1.000	rs6974723	chr7:65637939	C/T	cg13147721	chr7:65941812	NA	0.84	10.18	0.43	4.21e-22	Diabetic kidney disease;
LGG	cis	rs514406	0.861	rs503296	chr1:53283088	A/G	cg24675658	chr1:53192096	ZYG11B	0.48	9.63	0.41	4.06e-20	Monocyte count;
LGG	cis	rs35110281	0.805	rs162402	chr21:44963418	G/C	cg04455712	chr21:45112962	RRP1B	0.52	9.9	0.42	4.51e-21	Mean corpuscular volume;
LGG	cis	rs3219090	0.820	rs2570368	chr1:226605373	T/C	cg17127702	chr1:226594323	PARP1	0.38	12.33	0.5	2.01e-30	Melanoma;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg05665937	chr4:1216051	CTBP1	0.65	12.52	0.5	3.39e-31	Obesity-related traits;
LGG	cis	rs7742824	1.000	rs73429745	chr6:44101422	C/T	cg04074908	chr6:44101190	TMEM63B	0.69	13.2	0.52	5.21e-34	Major depressive disorder;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg08645402	chr16:4508243	NA	0.48	9.08	0.39	3.24e-18	Schizophrenia;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg04729594	chr2:33172444	LTBP1	-0.37	-7.05	-0.31	6.55e-12	Sexual dysfunction (SSRI/SNRI-related);
LGG	trans	rs2048656	0.605	rs13273565	chr8:9649146	T/C	cg06636001	chr8:8085503	FLJ10661	0.4	6.75	0.3	4.44e-11	Schizophrenia;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg22907277	chr7:1156413	C7orf50	0.58	7.46	0.33	4.26e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6462411	0.877	rs28533776	chr7:3914756	G/A	cg18022346	chr7:3920534	SDK1	-0.36	-6.94	-0.31	1.34e-11	Quantitative traits;
LGG	cis	rs11690935	0.959	rs35391289	chr2:172634983	A/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.86	-0.3	2.15e-11	Schizophrenia;
LGG	cis	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg14541582	chr5:601475	NA	-0.36	-7.1	-0.31	4.75e-12	Ulcerative colitis;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg06221963	chr1:154839813	KCNN3	-0.52	-10.86	-0.45	1.29e-24	Prostate cancer;
LGG	cis	rs4141404	0.604	rs2103853	chr22:31855475	T/C	cg02404636	chr22:31891804	SFI1	0.35	6.95	0.31	1.24e-11	Paclitaxel-induced neuropathy;
LGG	cis	rs7089973	0.604	rs7095816	chr10:116585109	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.37	0.32	8.08e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg07461501	chr17:79650226	HGS;ARL16	0.53	9.81	0.41	9.29e-21	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7904368	0.806	rs1130684	chr10:16859335	C/G	cg22980697	chr10:16874865	CUBN	0.57	9.12	0.39	2.32e-18	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs7786808	0.649	rs6459879	chr7:158211792	C/G	cg15440763	chr7:158190612	PTPRN2	0.43	9.26	0.4	7.4e-19	Obesity-related traits;
LGG	cis	rs1865760	0.892	rs6456705	chr6:25936056	G/A	cg17691542	chr6:26056736	HIST1H1C	0.56	10.06	0.42	1.19e-21	Height;
LGG	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg09818912	chr17:20140352	CYTSB	0.29	6.67	0.3	7.26e-11	Obesity-related traits;
LGG	cis	rs2011503	0.941	rs112253053	chr19:19425145	T/A	cg11584989	chr19:19387371	SF4	0.79	13.22	0.52	4.37e-34	Bipolar disorder;
LGG	cis	rs17376456	0.825	rs17372649	chr5:93126096	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.58	0.41	6.14e-20	Diabetic retinopathy;
LGG	cis	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg03060546	chr3:49711283	APEH	-0.67	-11.34	-0.47	1.82e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3806843	0.900	rs2337984	chr5:140136811	G/A	cg19875535	chr5:140030758	IK	-0.54	-11.2	-0.46	6.1e-26	Depressive symptoms (multi-trait analysis);
LGG	cis	rs514024	0.729	rs7852204	chr9:130373596	T/C	cg13643465	chr9:130375613	STXBP1	0.62	11.75	0.48	4.56e-28	Eating disorders (purging via substances);
LGG	cis	rs6546324	0.625	rs2861640	chr2:67794589	G/C	cg18237512	chr2:67827392	NA	-0.41	-7.39	-0.32	6.72e-13	Endometriosis;
LGG	cis	rs711245	0.748	rs2276671	chr2:36771701	C/A	cg01206211	chr2:36825736	FEZ2	0.43	7.7	0.34	8.21e-14	Height;
LGG	cis	rs17376456	0.877	rs13169675	chr5:93331284	A/G	cg25358565	chr5:93447407	FAM172A	1.35	16.44	0.61	3.48e-48	Diabetic retinopathy;
LGG	cis	rs9325144	0.647	rs870431	chr12:38953073	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-14.06	-0.55	1.18e-37	Morning vs. evening chronotype;
LGG	cis	rs7249142	0.562	rs1050544	chr19:19287901	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.25	-6.94	-0.31	1.36e-11	IgG glycosylation;
LGG	cis	rs7937682	1.000	rs11213973	chr11:111538903	A/T	cg08305652	chr11:111469057	NA	-0.43	-8.47	-0.37	3.26e-16	Primary sclerosing cholangitis;
LGG	trans	rs6011368	0.585	rs13043326	chr20:62914092	C/A	cg13869341	chr1:15865	WASH5P	0.59	10.35	0.43	9.68e-23	Clozapine-induced cytotoxicity;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	6.85e-15	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9e-20	Life satisfaction;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12712846	chr1:181058068	IER5	0.43	7.18	0.32	2.75e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4423214	0.840	rs1792227	chr11:71177412	A/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.33	0.47	1.98e-26	Vitamin D levels;
LGG	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.0	0.35	9.76e-15	HDL cholesterol;
LGG	trans	rs1728785	1.000	rs1170436	chr16:68607486	T/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	10.49	0.44	3.12e-23	Ulcerative colitis;
LGG	cis	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg12826209	chr6:26865740	GUSBL1	0.79	8.7	0.37	5.75e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10950821	0.843	rs73684577	chr7:20665781	A/G	cg21202529	chr7:20656503	ABCB5	-0.37	-6.74	-0.3	4.87e-11	Response to statin therapy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02276793	chr3:169685131	LOC100128164;SEC62	0.48	7.01	0.31	8.69e-12	Gut microbiome composition (summer);
LGG	cis	rs4631830	0.863	rs4935162	chr10:51525699	C/G	cg10326726	chr10:51549505	MSMB	-0.68	-14.12	-0.55	6.6e-38	Prostate-specific antigen levels;
LGG	cis	rs2576037	0.583	rs504668	chr18:44410749	T/C	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.58e-13	Personality dimensions;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg03188948	chr7:1209495	NA	0.48	7.81	0.34	3.97e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7572733	0.935	rs10931796	chr2:198840661	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.23	0.36	1.91e-15	Dermatomyositis;
LGG	cis	rs3008870	0.958	rs34367328	chr1:67445321	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs721917	0.506	rs7078242	chr10:81646641	C/A	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs11628318	0.525	rs10129838	chr14:103154317	T/C	cg01864069	chr14:103024347	NA	0.66	9.07	0.39	3.33e-18	Platelet count;
LGG	trans	rs7395662	0.786	rs12791074	chr11:49005023	G/A	cg03929089	chr4:120376271	NA	-0.47	-7.82	-0.34	3.71e-14	HDL cholesterol;
LGG	cis	rs4629180	0.606	rs13390891	chr2:102111943	T/C	cg16435561	chr2:102091048	RFX8	0.46	8.54	0.37	1.93e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs3749237	0.636	rs1568662	chr3:49521263	A/G	cg02487422	chr3:49467188	NICN1	0.58	10.82	0.45	1.75e-24	Resting heart rate;
LGG	cis	rs599083	0.530	rs667126	chr11:68177728	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-7.57	-0.33	1.97e-13	Bone mineral density (spine);
LGG	cis	rs6089584	0.888	rs6061966	chr20:60607936	C/G	cg13770153	chr20:60521292	NA	-0.53	-8.15	-0.35	3.41e-15	Body mass index;
LGG	cis	rs477895	0.713	rs2282490	chr11:63962152	T/C	cg04317338	chr11:64019027	PLCB3	0.67	8.24	0.36	1.78e-15	Mean platelet volume;
LGG	cis	rs16854884	0.633	rs6779321	chr3:143736676	T/C	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs4740619	0.819	rs276453	chr9:15573753	A/C	cg14451791	chr9:16040625	NA	-0.35	-9.08	-0.39	3.05e-18	Body mass index;
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.67	0.3	7.27e-11	Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22513888	chr2:63815863	MDH1;C2orf86	0.48	6.85	0.3	2.38e-11	Gut microbiome composition (summer);
LGG	cis	rs2640806	0.505	rs6997311	chr8:97366406	A/G	cg22138393	chr8:97340270	PTDSS1	-0.28	-7.44	-0.33	4.97e-13	Obesity-related traits;
LGG	cis	rs2197308	0.659	rs11181327	chr12:37903171	C/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.47	-0.33	4.04e-13	Morning vs. evening chronotype;
LGG	cis	rs9467773	0.620	rs2498351	chr6:26659642	C/T	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg17644776	chr2:200775616	C2orf69	-0.44	-7.41	-0.33	5.94e-13	QT interval;
LGG	cis	rs908922	0.676	rs2282296	chr1:152487979	C/T	cg20991723	chr1:152506922	NA	-0.73	-14.77	-0.57	1.03e-40	Hair morphology;
LGG	cis	rs9326248	0.648	rs11216257	chr11:116932561	C/T	cg11861562	chr11:117069780	TAGLN	0.29	6.89	0.3	1.83e-11	Blood protein levels;
LGG	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg06627628	chr2:24431161	ITSN2	-0.66	-10.57	-0.44	1.57e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9522267	0.535	rs9522291	chr13:112233761	T/C	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs2072499	0.966	rs1060604	chr1:156184268	T/C	cg25208724	chr1:156163844	SLC25A44	1.17	24.57	0.75	5.95e-86	Testicular germ cell tumor;
LGG	cis	rs943466	1.000	rs6933607	chr6:33743997	G/A	cg07519485	chr6:33762594	MLN	0.57	11.55	0.47	2.8e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7027203	0.828	rs3957506	chr9:96588133	C/T	cg13679303	chr9:96623674	NA	-0.38	-6.77	-0.3	4.04e-11	DNA methylation (variation);
LGG	cis	rs7103648	0.966	rs10769263	chr11:47417183	A/C	cg20307385	chr11:47447363	PSMC3	0.95	23.19	0.73	1.67e-79	Diastolic blood pressure;Systolic blood pressure;
LGG	trans	rs7819412	0.561	rs2001328	chr8:10987199	T/C	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.87	-0.34	2.5e-14	Triglycerides;
LGG	cis	rs12493885	0.769	rs11711982	chr3:153756867	A/G	cg12800244	chr3:153838788	SGEF	-0.67	-7.91	-0.35	1.89e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs3858526	0.514	rs4595572	chr11:5864045	T/G	cg05234568	chr11:5960015	NA	-0.68	-12.57	-0.5	2.21e-31	DNA methylation (variation);
LGG	trans	rs9467711	0.591	rs67844427	chr6:25931020	G/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.41	-0.33	6.22e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12477438	0.520	rs7593274	chr2:100009043	G/A	cg23527387	chr2:100056660	REV1	0.44	9.72	0.41	1.93e-20	Chronic sinus infection;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg04008888	chr11:68622739	NA	-0.55	-11.6	-0.47	1.69e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs79839061	0.732	rs73207773	chr4:827249	G/A	cg07828340	chr4:882639	GAK	0.83	7.51	0.33	3.1e-13	Intelligence (multi-trait analysis);
LGG	trans	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.07	-0.42	1.1e-21	Neuroticism;
LGG	cis	rs4006360	0.579	rs2132841	chr17:39234970	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.32	-0.47	2.12e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs283228	0.605	rs775944	chr6:101715412	C/T	cg27451362	chr6:101846650	GRIK2	0.92	13.16	0.52	7.75e-34	Coenzyme Q10 levels;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg00990874	chr7:1149470	C7orf50	-0.47	-8.23	-0.36	1.91e-15	Bronchopulmonary dysplasia;
LGG	cis	rs7666738	0.830	rs35685312	chr4:98858521	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg09085632	chr11:111637200	PPP2R1B	1.17	27.24	0.78	3.31e-98	Primary sclerosing cholangitis;
LGG	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg04568710	chr12:38710424	ALG10B	0.34	6.97	0.31	1.1e-11	Bladder cancer;
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg16195804	chr12:123717050	C12orf65	-0.4	-6.75	-0.3	4.35e-11	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg24375607	chr4:120327624	NA	0.67	11.08	0.46	1.78e-25	Corneal astigmatism;
LGG	cis	rs9814567	0.752	rs4634170	chr3:134335471	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.83	-0.45	1.64e-24	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7613875	0.580	rs6808044	chr3:50136165	A/G	cg05623727	chr3:50126028	RBM5	-0.44	-9.68	-0.41	2.6e-20	Body mass index;
LGG	cis	rs9397585	0.819	rs7749708	chr6:153375907	C/T	cg17707550	chr6:153380415	RGS17	0.61	14.1	0.55	8.16e-38	Body mass index;
LGG	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg12561776	chr17:30844705	MYO1D	-0.27	-6.91	-0.31	1.58e-11	Schizophrenia;
LGG	trans	rs7613875	0.600	rs1061474	chr3:50144951	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.43	-7.4	-0.33	6.6e-13	Body mass index;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg02725872	chr8:58115012	NA	-0.98	-13.36	-0.53	1.17e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs4356932	1.000	rs7674409	chr4:76958334	C/G	cg25799590	chr4:76943062	CXCL10;ART3	0.4	6.74	0.3	4.72e-11	Blood protein levels;
LGG	cis	rs28735056	0.935	rs72980082	chr18:77630170	G/T	cg20368463	chr18:77673604	PQLC1	-0.49	-8.75	-0.38	4.02e-17	Schizophrenia;
LGG	trans	rs12478296	0.591	rs6746311	chr2:243001279	A/G	cg01596870	chr19:55963115	NA	-0.46	-6.92	-0.31	1.56e-11	Obesity-related traits;
LGG	trans	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.79	-0.34	4.39e-14	Neuroticism;
LGG	trans	rs3779273	1.000	rs3807648	chr7:77828434	T/C	cg05596911	chr5:118502651	DMXL1	-0.43	-9.06	-0.39	3.65e-18	Body mass index;
LGG	cis	rs1408799	0.711	rs10960730	chr9:12631099	A/G	cg05274944	chr9:12693694	TYRP1	0.33	7.53	0.33	2.73e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs498872	1.000	rs498872	chr11:118477367	A/G	cg17470184	chr11:118478236	PHLDB1	-0.42	-7.69	-0.34	8.9e-14	Glioma;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg08888203	chr3:10149979	C3orf24	0.53	9.03	0.39	4.71e-18	Alzheimer's disease;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg15394860	chr11:2017084	H19	-0.43	-9.23	-0.39	9.56e-19	DNA methylation (variation);
LGG	trans	rs853679	0.882	rs9461432	chr6:28086883	T/C	cg08344181	chr3:125677491	NA	-0.65	-7.73	-0.34	6.73e-14	Depression;
LGG	cis	rs11792861	0.890	rs2900481	chr9:111831825	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.56e-19	Menarche (age at onset);
LGG	cis	rs1949733	1.000	rs1916326	chr4:8500023	G/A	cg13073564	chr4:8508604	NA	0.6	11.96	0.49	6.74e-29	Response to antineoplastic agents;
LGG	trans	rs208520	0.690	rs2797693	chr6:66868985	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.76	-0.64	3.27e-54	Exhaled nitric oxide output;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg21724239	chr8:58056113	NA	0.6	9.07	0.39	3.38e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs1945213	0.694	rs1384099	chr11:55866040	A/C	cg15704280	chr7:45808275	SEPT13	0.89	12.57	0.5	2.28e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs35306767	0.903	rs11253494	chr10:937047	C/T	cg08847335	chr10:891726	LARP4B	-0.48	-8.6	-0.37	1.2e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs3741151	0.656	rs73550316	chr11:73299799	G/A	cg17517138	chr11:73019481	ARHGEF17	0.84	8.02	0.35	8.93e-15	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11608355	0.521	rs6606703	chr12:109813665	C/T	cg19025524	chr12:109796872	NA	-0.57	-12.45	-0.5	6.82e-31	Neuroticism;
LGG	cis	rs7503807	0.905	rs9909449	chr17:78614393	A/G	cg06872548	chr17:78716983	RPTOR	0.45	11.05	0.46	2.46e-25	Obesity;
LGG	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.61	-0.37	1.12e-16	Platelet distribution width;
LGG	cis	rs1065852	0.906	rs5751232	chr22:42564304	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.34	0.32	9.78e-13	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs1707322	0.686	rs1547924	chr1:46085112	C/T	cg03146154	chr1:46216737	IPP	0.57	11.21	0.46	5.81e-26	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs3812049	0.826	rs6860245	chr5:127367998	G/C	cg16011800	chr17:1958478	HIC1	0.62	9.45	0.4	1.68e-19	Lymphocyte counts;Red cell distribution width;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg22493809	chr1:120838387	FAM72B	-0.44	-7.33	-0.32	1.05e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7945718	0.967	rs1440286	chr11:12809152	G/A	cg25843174	chr11:12811716	TEAD1	0.4	8.4	0.36	5.51e-16	Educational attainment (years of education);
LGG	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.04	-0.31	6.9e-12	Blood metabolite levels;
LGG	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	7.24	0.32	1.85e-12	Retinal vascular caliber;
LGG	cis	rs710865	0.966	rs709683	chr1:19565344	C/G	cg13387374	chr1:19411106	UBR4	0.45	8.73	0.38	4.69e-17	Brain structure;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg04166393	chr7:2884313	GNA12	0.46	8.53	0.37	2.16e-16	Height;
LGG	cis	rs3096299	0.967	rs7205785	chr16:89458984	A/G	cg08822215	chr16:89438651	ANKRD11	-0.39	-7.44	-0.33	4.85e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg25801113	chr15:45476975	SHF	0.87	19.15	0.66	1.2e-60	Uric acid levels;
LGG	cis	rs5769765	0.671	rs138833	chr22:50178917	A/G	cg02269571	chr22:50332266	NA	-0.53	-8.5	-0.37	2.54e-16	Schizophrenia;
LGG	trans	rs61931739	0.817	rs7963318	chr12:34244929	C/G	cg26384229	chr12:38710491	ALG10B	-0.61	-11.78	-0.48	3.32e-28	Morning vs. evening chronotype;
LGG	cis	rs9303401	0.614	rs7215900	chr17:56654850	A/T	cg25039879	chr17:56429692	SUPT4H1	0.64	8.8	0.38	2.65e-17	Cognitive test performance;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg05091796	chr16:4465799	CORO7	-0.61	-10.02	-0.42	1.61e-21	Schizophrenia;
LGG	cis	rs9487094	0.813	rs12528712	chr6:109660884	G/T	cg16315928	chr6:109776240	MICAL1	0.52	8.65	0.37	8.35e-17	Height;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.24	-0.32	1.86e-12	Menopause (age at onset);
LGG	cis	rs11785400	0.731	rs4294163	chr8:143730830	G/T	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.3e-14	Schizophrenia;
LGG	cis	rs4237845	0.715	rs4760340	chr12:58275176	A/T	cg02175503	chr12:58329896	NA	0.67	12.27	0.5	3.82e-30	Intelligence (multi-trait analysis);
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg21963583	chr11:68658836	MRPL21	0.58	10.01	0.42	1.72e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7667	0.812	rs12045440	chr1:19765518	G/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	0.38	6.81	0.3	3.1e-11	Crohn's disease and psoriasis;
LGG	cis	rs738322	1.000	rs4381	chr22:38570791	T/C	cg03162506	chr22:38580953	NA	0.37	9.64	0.41	3.77e-20	Cutaneous nevi;
LGG	trans	rs2832077	0.943	rs11700746	chr21:30189207	T/C	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.17e-13	Cognitive test performance;
LGG	cis	rs11920090	0.860	rs7638998	chr3:170741015	A/G	cg09710316	chr3:170744871	SLC2A2	0.63	8.56	0.37	1.68e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1451375	0.698	rs10899748	chr7:50646089	G/A	cg14593290	chr7:50529359	DDC	0.43	7.74	0.34	6.15e-14	Malaria;
LGG	cis	rs10895140	0.665	rs11224923	chr11:101520344	G/A	cg23650423	chr11:101454676	TRPC6	-0.4	-6.77	-0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs4820294	0.926	rs62236671	chr22:38069305	G/A	cg26138144	chr22:38071188	LGALS1	0.9	23.97	0.74	3.72e-83	Fat distribution (HIV);
LGG	cis	rs240764	0.579	rs240151	chr6:101067720	A/T	cg09795085	chr6:101329169	ASCC3	0.45	7.56	0.33	2.26e-13	Neuroticism;
LGG	cis	rs704795	0.902	rs11887784	chr2:27679919	A/G	cg22903471	chr2:27725779	GCKR	-0.59	-13.61	-0.53	1.06e-35	Menopause (age at onset);
LGG	cis	rs898097	0.578	rs9906163	chr17:80908174	T/C	cg15369054	chr17:80825471	TBCD	-0.39	-7.5	-0.33	3.18e-13	Breast cancer;
LGG	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg17644776	chr2:200775616	C2orf69	-0.67	-8.48	-0.37	3.05e-16	Schizophrenia;
LGG	cis	rs6868223	0.930	rs3935845	chr5:33639395	T/A	cg10594543	chr5:33649717	ADAMTS12	0.57	12.82	0.51	2.08e-32	Mortality in heart failure;
LGG	cis	rs1799949	0.929	rs799905	chr17:41277187	G/C	cg18379455	chr17:41446167	NA	-0.33	-7.76	-0.34	5.49e-14	Menopause (age at onset);
LGG	cis	rs6500395	0.963	rs4785528	chr16:48687908	A/C	cg04672837	chr16:48644449	N4BP1	-0.53	-8.84	-0.38	2e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg12310025	chr6:25882481	NA	-0.51	-9.47	-0.4	1.42e-19	Height;
LGG	cis	rs9790314	0.875	rs462514	chr3:161092809	C/T	cg04691961	chr3:161091175	C3orf57	-0.67	-15.99	-0.6	4.05e-46	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08280861	chr8:58055591	NA	0.55	7.01	0.31	8.71e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg03709012	chr19:19516395	GATAD2A	-0.84	-16.98	-0.62	1.22e-50	Tonsillectomy;
LGG	cis	rs4930103	0.935	rs4930110	chr11:2026701	G/C	cg08461457	chr11:2027003	NA	0.41	7.87	0.34	2.61e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg21775007	chr8:11205619	TDH	0.79	14.0	0.55	2.26e-37	Retinal vascular caliber;
LGG	cis	rs244899	0.904	rs168647	chr5:167912404	G/A	cg06604206	chr5:167912465	RARS	-0.56	-12.53	-0.5	3.25e-31	Response to platinum-based chemotherapy (carboplatin);
LGG	cis	rs752092	0.855	rs7171515	chr15:101769618	C/T	cg19997662	chr15:101784653	CHSY1	-0.83	-17.54	-0.63	3.52e-53	Corneal structure;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg12395012	chr8:11607386	GATA4	0.4	6.94	0.31	1.35e-11	Neuroticism;
LGG	cis	rs10267417	0.514	rs2072184	chr7:19748883	A/G	cg07541023	chr7:19748670	TWISTNB	1.06	18.27	0.65	1.55e-56	Night sleep phenotypes;
LGG	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg25703541	chr22:24373054	LOC391322	0.85	13.76	0.54	2.22e-36	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs9790314	0.740	rs4856767	chr3:161004379	C/T	cg04691961	chr3:161091175	C3orf57	-0.53	-12.2	-0.49	6.74e-30	Morning vs. evening chronotype;
LGG	cis	rs896543	0.657	rs10179774	chr2:237487588	C/T	cg25295825	chr2:237489920	CXCR7	0.79	11.33	0.47	1.97e-26	Alcohol dependence (age at onset);
LGG	cis	rs7523050	0.643	rs12741359	chr1:109400489	T/C	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	trans	rs11875185	0.510	rs113708775	chr18:55614658	T/C	cg15513957	chr14:69354734	ACTN1	-0.95	-9.2	-0.39	1.2e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs3096299	0.754	rs2965816	chr16:89514183	G/T	cg08392591	chr16:89556376	ANKRD11	-0.54	-8.62	-0.37	1.1e-16	Multiple myeloma (IgH translocation);
LGG	trans	rs9329221	0.537	rs12678800	chr8:9978940	G/A	cg16141378	chr3:129829833	LOC729375	-0.38	-8.72	-0.38	5.19e-17	Neuroticism;
LGG	cis	rs72772090	0.539	rs3333	chr5:96115111	G/A	cg00188032	chr5:96141721	ERAP1	0.55	7.21	0.32	2.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2197308	0.623	rs1672426	chr12:38118671	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.52	-0.44	2.38e-23	Morning vs. evening chronotype;
LGG	cis	rs793571	0.502	rs421829	chr15:59079902	G/C	cg05156742	chr15:59063176	FAM63B	0.66	12.33	0.5	2.12e-30	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs12451471	0.667	rs12942002	chr17:78101629	C/G	cg06718696	chr17:78121285	EIF4A3	0.89	14.38	0.56	4.96e-39	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	trans	rs3774749	0.565	rs1005678	chr3:50210289	C/G	cg21659725	chr3:3221576	CRBN	0.51	8.32	0.36	9.85e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs9322193	0.923	rs2342857	chr6:150130673	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.61e-14	Lung cancer;
LGG	cis	rs2369473	1	rs2369473	chr1:160210727	C/A	cg07195126	chr1:160370843	VANGL2	0.44	7.87	0.34	2.45e-14	Squamous cell lung carcinoma;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg11301795	chr4:187892539	NA	-0.95	-25.11	-0.76	1.96e-88	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1408799	0.695	rs4741245	chr9:12749300	A/G	cg05274944	chr9:12693694	TYRP1	0.35	8.39	0.36	6.08e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs3806843	0.771	rs2563336	chr5:140107199	A/G	cg19875535	chr5:140030758	IK	-0.59	-12.16	-0.49	9.78e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs17102423	1.000	rs4902364	chr14:65602006	G/A	cg16583315	chr14:65563665	MAX	-0.35	-6.66	-0.3	7.96e-11	Obesity-related traits;
LGG	trans	rs1814175	0.645	rs11040703	chr11:50024961	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs7129556	0.737	rs614495	chr11:77536886	T/A	cg12586386	chr11:77299805	AQP11	0.45	7.4	0.33	6.52e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs6732160	0.593	rs2288630	chr2:73457552	C/T	cg01422370	chr2:73384389	NA	0.47	8.95	0.38	8.52e-18	Intelligence (multi-trait analysis);
LGG	trans	rs1459104	0.585	rs72909604	chr11:55797131	C/A	cg15704280	chr7:45808275	SEPT13	0.69	6.95	0.31	1.22e-11	Body mass index;
LGG	trans	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.95	-0.35	1.42e-14	Neuroticism;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs240764	0.658	rs10223467	chr6:101207589	A/G	cg21058520	chr6:100914733	NA	0.39	6.73	0.3	5.18e-11	Neuroticism;
LGG	cis	rs4808199	1.000	rs12972397	chr19:19562349	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg01238044	chr22:24384105	GSTT1	-0.43	-7.29	-0.32	1.32e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4979906	1.000	rs4979786	chr10:79444965	T/C	cg07817648	chr10:79422355	NA	-0.48	-7.65	-0.34	1.16e-13	Mortality in heart failure;
LGG	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg00717180	chr2:96193071	NA	-0.48	-8.66	-0.37	7.67e-17	HDL cholesterol;
LGG	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg04287289	chr16:89883240	FANCA	0.54	9.91	0.42	3.86e-21	Vitiligo;
LGG	cis	rs7847628	0.566	rs10739575	chr9:123606101	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.63	-7.89	-0.34	2.12e-14	Birth weight;
LGG	trans	rs7246657	0.943	rs713256	chr19:37865365	C/T	cg24637308	chr11:6592297	DNHD1	0.42	6.71	0.3	5.56e-11	Coronary artery calcification;
LGG	cis	rs2290416	0.892	rs34178175	chr8:144664687	G/A	cg08508337	chr8:144660607	NAPRT1	0.89	7.19	0.32	2.63e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs28595532	0.920	rs116697254	chr4:119733603	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs17331151	0.573	rs3755801	chr3:52865798	G/A	cg04865290	chr3:52927548	TMEM110	-0.42	-7.29	-0.32	1.36e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs7191439	0.858	rs8050715	chr16:88780923	C/G	cg27087555	chr16:88793112	FAM38A	-1.42	-18.34	-0.65	6.95e-57	Plateletcrit;
LGG	cis	rs701145	0.640	rs357499	chr3:153946463	C/G	cg17054900	chr3:154042577	DHX36	0.97	10.57	0.44	1.54e-23	Coronary artery disease;
LGG	cis	rs7301826	0.651	rs12820597	chr12:131280185	T/C	cg11011512	chr12:131303247	STX2	-0.4	-8.36	-0.36	7.42e-16	Plasma plasminogen activator levels;
LGG	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg16797656	chr11:68205561	LRP5	0.4	7.22	0.32	2.19e-12	Total body bone mineral density;
LGG	cis	rs2629540	0.889	rs7476729	chr10:126428174	C/G	cg08799069	chr10:126477246	METTL10	-0.66	-12.89	-0.51	1.01e-32	Cocaine dependence;
LGG	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.89	-0.34	2.22e-14	Mean platelet volume;
LGG	cis	rs7208859	0.528	rs3764416	chr17:28900708	G/T	cg01831904	chr17:28903510	LRRC37B2	0.84	10.48	0.44	3.45e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6429082	0.783	rs291365	chr1:235688043	A/G	cg26050004	chr1:235667680	B3GALNT2	0.69	11.93	0.48	8.66e-29	Adiposity;
LGG	cis	rs7567389	0.510	rs1473623	chr2:128196220	T/C	cg10021288	chr2:128175891	PROC	-0.36	-6.86	-0.3	2.24e-11	Self-rated health;
LGG	cis	rs432925	0.600	rs379056	chr16:339291	G/C	cg06233593	chr16:337645	AXIN1	0.42	7.81	0.34	3.73e-14	Morning vs. evening chronotype;
LGG	cis	rs17453880	0.929	rs6859908	chr5:152049109	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs74781061	0.929	rs16969612	chr15:74806437	A/G	cg02384859	chr15:74862662	ARID3B	0.35	7.28	0.32	1.48e-12	Endometriosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22853526	chr1:113216965	MOV10	0.41	6.71	0.3	5.77e-11	Gut microbiome composition (summer);
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs2228479	0.541	rs9922515	chr16:89954138	G/C	cg04013166	chr16:89971882	TCF25	0.52	7.12	0.31	4.13e-12	Skin colour saturation;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg26338869	chr17:61819248	STRADA	0.58	9.61	0.41	4.63e-20	Prudent dietary pattern;
LGG	cis	rs11096990	0.613	rs4974996	chr4:39227548	C/A	cg24403649	chr4:39172243	NA	0.4	7.22	0.32	2.15e-12	Cognitive function;
LGG	cis	rs796364	0.813	rs7565417	chr2:201057491	G/A	cg23649088	chr2:200775458	C2orf69	0.59	8.77	0.38	3.57e-17	Schizophrenia;
LGG	cis	rs11864453	0.713	rs2241412	chr16:72144284	A/G	cg01557791	chr16:72042693	DHODH	-0.52	-9.57	-0.41	6.19e-20	Fibrinogen levels;
LGG	trans	rs6582630	0.519	rs7305545	chr12:38349223	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7598759	0.675	rs6727530	chr2:232332058	T/C	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.49e-14	Noise-induced hearing loss;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	trans	rs11165623	0.602	rs942904	chr1:97025708	C/T	cg10631902	chr5:14652156	NA	-0.45	-9.34	-0.4	4e-19	Hip circumference;Waist circumference;
LGG	cis	rs72634258	0.554	rs1012477	chr1:7858135	C/G	cg00042356	chr1:8021962	PARK7	-0.61	-7.62	-0.33	1.44e-13	Inflammatory bowel disease;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg05313129	chr8:58192883	C8orf71	0.62	8.6	0.37	1.23e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8067545	0.611	rs10491107	chr17:20188174	C/T	cg13482628	chr17:19912719	NA	0.53	9.96	0.42	2.55e-21	Schizophrenia;
LGG	cis	rs875971	0.522	rs6960048	chr7:65408039	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.97	-0.35	1.25e-14	Aortic root size;
LGG	cis	rs7129556	0.737	rs72949618	chr11:77464530	G/A	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.36e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs12188164	1.000	rs55842567	chr5:437586	G/A	cg26850624	chr5:429559	AHRR	-0.37	-8.13	-0.35	3.94e-15	Cystic fibrosis severity;
LGG	cis	rs921968	0.508	rs72965103	chr2:219312469	T/C	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9326248	0.813	rs4938350	chr11:117022276	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.74	0.34	6.32e-14	Blood protein levels;
LGG	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg03605463	chr16:89740564	NA	0.62	11.05	0.46	2.43e-25	Vitiligo;
LGG	cis	rs1568889	0.838	rs11030265	chr11:28296168	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.1	0.66	2.14e-60	Bipolar disorder;
LGG	cis	rs9902453	0.904	rs12939344	chr17:28328819	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.72	-0.54	3.43e-36	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20991612	chr1:43613606	FAM183A	0.44	6.76	0.3	4.1e-11	Gut microbiome composition (summer);
LGG	cis	rs1003719	0.788	rs1155785	chr21:38447939	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs36071027	0.615	rs13159303	chr5:158421063	A/G	cg18496440	chr5:158532302	NA	0.41	6.91	0.31	1.64e-11	Carotid intima media thickness;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg07677032	chr17:61819896	STRADA	0.68	12.65	0.51	1.01e-31	Prudent dietary pattern;
LGG	cis	rs11630290	0.806	rs72752906	chr15:64093465	G/T	cg12036633	chr15:63758958	NA	-0.58	-8.04	-0.35	7.45e-15	Iris characteristics;
LGG	cis	rs7619833	0.693	rs547518	chr3:27358405	A/T	cg02860705	chr3:27208620	NA	0.39	7.47	0.33	4.08e-13	Breast cancer;
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg24829409	chr8:58192753	C8orf71	-0.82	-11.42	-0.47	8.97e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg00800038	chr16:89945340	TCF25	-0.73	-8.33	-0.36	9.06e-16	Skin colour saturation;
LGG	cis	rs9549260	0.755	rs9549236	chr13:41147158	C/T	cg21288729	chr13:41239152	FOXO1	-0.36	-7.49	-0.33	3.45e-13	Red blood cell count;
LGG	cis	rs367943	0.712	rs1850407	chr5:112721569	C/A	cg12552261	chr5:112820674	MCC	0.57	10.35	0.43	1.02e-22	Type 2 diabetes;
LGG	cis	rs769267	0.965	rs1010207	chr19:19416045	T/C	cg03709012	chr19:19516395	GATAD2A	0.8	15.33	0.58	3.55e-43	Tonsillectomy;
LGG	trans	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg24247370	chr13:99142703	STK24	-0.39	-7.04	-0.31	6.81e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs910316	0.737	rs108622	chr14:75481908	A/G	cg11812906	chr14:75593930	NEK9	-0.44	-7.95	-0.35	1.42e-14	Height;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.34	-6.73	-0.3	5.09e-11	Longevity;Endometriosis;
LGG	cis	rs769267	0.930	rs2315022	chr19:19413381	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.28	0.36	1.3e-15	Tonsillectomy;
LGG	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.44	0.63	9.61e-53	Chronic sinus infection;
LGG	cis	rs1044826	0.692	rs188421	chr3:139234066	A/C	cg15131784	chr3:139108705	COPB2	-0.42	-6.79	-0.3	3.51e-11	Obesity-related traits;
LGG	cis	rs2798269	0.867	rs2761909	chr13:22116804	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.09	-0.31	5e-12	PR segment;
LGG	cis	rs4888262	0.526	rs8056718	chr16:74612030	G/C	cg01733217	chr16:74700730	RFWD3	0.85	16.9	0.62	2.92e-50	Testicular germ cell tumor;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg22105103	chr4:187893119	NA	0.55	10.13	0.43	6.46e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg06634786	chr22:41940651	POLR3H	0.78	12.27	0.5	3.6e-30	Vitiligo;
LGG	cis	rs2227564	0.649	rs2688626	chr10:75611090	G/A	cg00564723	chr10:75632066	CAMK2G	-0.53	-11.23	-0.46	5e-26	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2836974	0.897	rs2026265	chr21:40595517	G/A	cg17971929	chr21:40555470	PSMG1	0.87	17.12	0.62	3.06e-51	Cognitive function;
LGG	cis	rs10256972	0.933	rs35696159	chr7:1047194	A/G	cg07308232	chr7:1071921	C7orf50	-0.62	-11.79	-0.48	3.13e-28	Longevity;Endometriosis;
LGG	trans	rs6582630	0.555	rs11613249	chr12:38519339	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.74	-0.38	4.37e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs1862618	0.853	rs2113079	chr5:56157951	A/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.83	-0.38	2.18e-17	Initial pursuit acceleration;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg22398616	chr13:53314203	LECT1	-0.44	-8.94	-0.38	9.52e-18	Lewy body disease;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.54	0.37	1.99e-16	Lung cancer;
LGG	cis	rs7829975	0.688	rs7817376	chr8:8380530	C/T	cg14979609	chr8:8086686	FLJ10661	0.29	7.49	0.33	3.57e-13	Mood instability;
LGG	cis	rs67478160	0.634	rs2368559	chr14:104230535	C/T	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.51e-13	Schizophrenia;
LGG	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21582582	chr3:182698605	DCUN1D1	0.4	6.98	0.31	1.06e-11	Intelligence (multi-trait analysis);
LGG	cis	rs589448	0.967	rs2617834	chr12:69753365	T/C	cg11871910	chr12:69753446	YEATS4	1.05	28.53	0.8	4.82e-104	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10751667	0.666	rs10902235	chr11:938892	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.92	0.35	1.81e-14	Alzheimer's disease (late onset);
LGG	cis	rs3126085	0.877	rs2338431	chr1:152169305	A/G	cg26876637	chr1:152193138	HRNR	0.56	9.07	0.39	3.44e-18	Atopic dermatitis;
LGG	cis	rs9462027	0.606	rs7341253	chr6:34726838	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.88	-0.38	1.43e-17	Bone mineral density;
LGG	cis	rs977987	0.705	rs4888377	chr16:75325686	C/G	cg03315344	chr16:75512273	CHST6	0.5	9.52	0.4	9.6e-20	Dupuytren's disease;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg20887711	chr4:1340912	KIAA1530	0.45	7.96	0.35	1.32e-14	Obesity-related traits;
LGG	cis	rs801193	0.636	rs2659895	chr7:66196471	C/A	cg18876405	chr7:65276391	NA	0.49	8.83	0.38	2.16e-17	Aortic root size;
LGG	cis	rs11758351	1.000	rs77957229	chr6:26185226	A/G	cg01420254	chr6:26195488	NA	0.89	11.27	0.46	3.28e-26	Gout;Renal underexcretion gout;
LGG	cis	rs780096	0.526	rs13391837	chr2:27649375	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.32	-0.32	1.13e-12	Total body bone mineral density;
LGG	cis	rs9302635	0.513	rs12928732	chr16:72188683	C/T	cg23815491	chr16:72088622	HP	0.49	9.19	0.39	1.3e-18	Blood protein levels;
LGG	cis	rs6558174	0.965	rs1564595	chr8:22488939	A/G	cg03733263	chr8:22462867	KIAA1967	0.65	11.04	0.46	2.61e-25	Breast cancer;
LGG	cis	rs853679	0.517	rs4713143	chr6:28106759	A/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs10229583	0.527	rs10239440	chr7:127406049	T/C	cg25855768	chr7:127472121	SND1	-0.44	-7.35	-0.32	9.23e-13	Type 2 diabetes;
LGG	cis	rs17208368	0.628	rs4784470	chr16:55092840	T/C	cg09947736	chr16:55091198	NA	0.68	12.97	0.52	5.03e-33	Hypospadias;
LGG	cis	rs796364	0.806	rs11688168	chr2:200916004	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg22398616	chr13:53314203	LECT1	-0.49	-10.04	-0.42	1.35e-21	Lewy body disease;
LGG	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg22974920	chr21:40686053	BRWD1	-0.43	-6.93	-0.31	1.38e-11	Cognitive function;
LGG	cis	rs55728055	0.661	rs62237814	chr22:31992574	G/C	cg15823100	chr22:32027580	PISD	-0.75	-8.49	-0.37	2.79e-16	Age-related hearing impairment;
LGG	cis	rs4808199	0.895	rs8105094	chr19:19374061	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	6.92	0.31	1.55e-11	Nonalcoholic fatty liver disease;
LGG	cis	rs12216125	0.537	rs12207059	chr6:25922385	C/T	cg17691542	chr6:26056736	HIST1H1C	1.09	17.65	0.63	1.12e-53	Iron status biomarkers;
LGG	cis	rs4474465	0.850	rs10899551	chr11:78256998	A/C	cg02023728	chr11:77925099	USP35	0.38	6.83	0.3	2.7e-11	Alzheimer's disease (survival time);
LGG	cis	rs2762353	0.808	rs1185568	chr6:25834428	T/A	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg07308232	chr7:1071921	C7orf50	-0.53	-9.73	-0.41	1.69e-20	Longevity;Endometriosis;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg04369109	chr6:150039330	LATS1	-0.41	-6.81	-0.3	3.09e-11	Lung cancer;
LGG	trans	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg25214090	chr10:38739885	LOC399744	0.45	8.04	0.35	7.56e-15	Diastolic blood pressure;
LGG	cis	rs9768139	0.901	rs56113702	chr7:158117938	C/T	cg15736062	chr7:158136485	PTPRN2	0.37	7.33	0.32	1.02e-12	Calcium levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24247472	chr17:46908838	CALCOCO2	0.47	7.6	0.33	1.67e-13	Cognitive performance;
LGG	trans	rs9657904	0.813	rs2055557	chr3:105562238	T/C	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.4e-14	Multiple sclerosis;
LGG	trans	rs4942242	0.626	rs7986998	chr13:44209916	G/A	cg19169023	chr15:41853346	TYRO3	0.44	8.82	0.38	2.31e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg08999081	chr20:33150536	PIGU	0.4	10.14	0.43	5.82e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.88	0.38	1.5e-17	Longevity;
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs656319	0.585	rs13272731	chr8:9906934	C/G	cg12395012	chr8:11607386	GATA4	0.41	7.15	0.32	3.34e-12	Myopia (pathological);
LGG	cis	rs3761847	0.622	rs1323471	chr9:123826315	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.18	0.36	2.81e-15	Rheumatoid arthritis;
LGG	cis	rs9788682	0.747	rs28480606	chr15:78762313	A/G	cg06917634	chr15:78832804	PSMA4	-0.53	-8.1	-0.35	4.78e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs5769765	0.773	rs4075331	chr22:50302850	A/G	cg02269571	chr22:50332266	NA	-0.62	-10.07	-0.42	1.09e-21	Schizophrenia;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg06916706	chr16:4465613	CORO7	-0.75	-13.34	-0.53	1.43e-34	Schizophrenia;
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs5758659	1.000	rs134882	chr22:42670965	A/G	cg15557168	chr22:42548783	NA	-0.4	-8.97	-0.38	7.49e-18	Cognitive function;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09852199	chr1:203764897	ZC3H11A	0.44	7.08	0.31	5.45e-12	Cognitive performance;
LGG	cis	rs68170813	0.559	rs12533767	chr7:106860245	A/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.63	-0.44	9.37e-24	Coronary artery disease;
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg05863683	chr7:1912471	MAD1L1	0.41	8.03	0.35	7.95e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2239815	0.515	rs5762849	chr22:29238086	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.65	0.34	1.17e-13	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs4555082	0.874	rs760270	chr14:105737785	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.28	-0.32	1.47e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6445975	1.000	rs4076852	chr3:58375286	C/T	cg24175188	chr3:58374923	PXK	-0.45	-7.88	-0.34	2.35e-14	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.48	0.33	3.67e-13	Schizophrenia;
LGG	cis	rs3749237	0.576	rs3877784	chr3:49539417	C/T	cg07636037	chr3:49044803	WDR6	0.59	10.3	0.43	1.57e-22	Resting heart rate;
LGG	cis	rs2243480	1.000	rs13237037	chr7:65997882	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.23	0.36	1.99e-15	Diabetic kidney disease;
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.75	0.38	3.91e-17	Schizophrenia;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg18402987	chr7:1209562	NA	0.7	9.67	0.41	2.84e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8062405	1.000	rs55991577	chr16:28843025	C/T	cg00204512	chr16:28754710	NA	0.25	7.05	0.31	6.66e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	cis	rs6502050	0.842	rs9894129	chr17:80075700	A/G	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	cis	rs11252926	0.589	rs12359901	chr10:475068	A/G	cg16386425	chr10:429943	DIP2C	0.46	9.07	0.39	3.46e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs2067615	0.524	rs1922436	chr12:107065258	A/G	cg15890332	chr12:107067104	RFX4	0.4	11.59	0.47	1.96e-27	Heart rate;
LGG	cis	rs9868809	0.505	rs28793701	chr3:48762683	C/G	cg00383909	chr3:49044727	WDR6	0.93	11.59	0.47	1.83e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.94	-0.54	3.94e-37	Alzheimer's disease;
LGG	cis	rs28595532	0.920	rs116046128	chr4:119741990	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs7385804	0.796	rs221801	chr7:100290031	C/A	cg16850897	chr7:100343110	ZAN	0.44	7.0	0.31	8.86e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs4742903	0.584	rs10217250	chr9:106911633	A/T	cg14250997	chr9:106856677	SMC2	0.4	8.34	0.36	8.51e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs11711311	0.911	rs28577577	chr3:113447276	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.45e-38	IgG glycosylation;
LGG	cis	rs9768139	0.733	rs12698209	chr7:158117595	A/G	cg25566285	chr7:158114605	PTPRN2	-0.89	-19.95	-0.68	2.19e-64	Calcium levels;
LGG	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs977987	0.778	rs7203157	chr16:75417920	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.81	0.3	2.95e-11	Dupuytren's disease;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg11062466	chr8:58055876	NA	0.46	7.77	0.34	5.16e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12541335	0.639	rs7003478	chr8:22201123	A/G	cg02788857	chr8:22132959	PIWIL2	0.5	11.86	0.48	1.69e-28	Hypertriglyceridemia;
LGG	cis	rs875971	0.862	rs801209	chr7:66019390	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg05313129	chr8:58192883	C8orf71	-0.65	-8.55	-0.37	1.87e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.89	0.45	1e-24	Parkinson's disease;
LGG	cis	rs7044106	0.791	rs10985004	chr9:123484937	T/A	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.82	0.3	2.84e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg20607798	chr8:58055168	NA	0.63	7.32	0.32	1.12e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg09177884	chr7:1199841	ZFAND2A	-0.53	-9.06	-0.39	3.78e-18	Longevity;Endometriosis;
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg09699651	chr6:150184138	LRP11	0.51	9.03	0.39	4.5e-18	Lung cancer;
LGG	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg18850127	chr7:39170497	POU6F2	0.51	11.65	0.48	1.05e-27	IgG glycosylation;
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg08297393	chr2:100937505	LONRF2	-0.54	-10.34	-0.43	1.14e-22	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.821	rs70600	chr17:44860021	C/T	cg04703951	chr17:43578652	NA	0.38	7.66	0.34	1.11e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs4714291	0.963	rs4714293	chr6:40009566	T/C	cg02267698	chr19:7991119	CTXN1	0.58	8.99	0.39	6.25e-18	Strep throat;
LGG	cis	rs6762	0.642	rs28692469	chr11:839675	T/C	cg08498830	chr11:832797	CD151	-0.45	-7.32	-0.32	1.11e-12	Mean platelet volume;
LGG	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg15440763	chr7:158190612	PTPRN2	0.5	10.54	0.44	2.0500000000000001e-23	Obesity-related traits;
LGG	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.0	-0.52	3.62e-33	Gut microbiome composition (summer);
LGG	cis	rs9911578	1.000	rs1631237	chr17:56734695	A/G	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs75179575	chr22:32426433	C/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs4665809	1.000	rs13030858	chr2:26315451	G/A	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs2652834	0.904	rs2729826	chr15:63360446	C/G	cg05507819	chr15:63340323	TPM1	-0.6	-8.15	-0.35	3.52e-15	HDL cholesterol;
LGG	cis	rs4356932	0.871	rs4859606	chr4:76965879	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs7166081	1.000	rs8025774	chr15:67483276	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.83	-0.3	2.6e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24942186	chr3:55521373	WNT5A	0.47	7.47	0.33	4.07e-13	Cognitive performance;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg06925179	chr17:43578568	NA	0.39	9.44	0.4	1.85e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9467711	0.591	rs3734528	chr6:26022244	A/G	cg21479132	chr6:26055353	NA	0.82	8.09	0.35	5.13e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.734	rs7217625	chr17:80157766	T/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.47	-0.37	3.35e-16	Life satisfaction;
LGG	cis	rs12410462	0.636	rs2814085	chr1:227705476	T/C	cg23173402	chr1:227635558	NA	0.38	7.09	0.31	4.89e-12	Major depressive disorder;
LGG	cis	rs6976053	0.935	rs4727470	chr7:100509201	A/G	cg03098644	chr7:100410630	EPHB4	-0.39	-6.79	-0.3	3.52e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7769051	0.708	rs62426668	chr6:133225021	C/T	cg22852734	chr6:133119734	C6orf192	0.89	7.68	0.34	9.67e-14	Type 2 diabetes nephropathy;
LGG	cis	rs2976388	1.000	rs2976396	chr8:143764001	A/G	cg06565975	chr8:143823917	SLURP1	0.4	10.11	0.43	7.49e-22	Urinary tract infection frequency;
LGG	cis	rs637571	0.544	rs55704213	chr11:65730002	C/A	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.74	-0.38	4.32e-17	Eosinophil percentage of white cells;
LGG	trans	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg22358067	chr17:16797159	NA	-0.51	-6.87	-0.3	2.04e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2836974	0.565	rs34304022	chr21:40579619	G/A	cg11644478	chr21:40555479	PSMG1	0.71	9.64	0.41	3.52e-20	Cognitive function;
LGG	cis	rs10426930	0.607	rs858415	chr19:5055996	C/T	cg18473234	chr19:5097819	KDM4B	-0.41	-7.39	-0.32	7.14e-13	Monocyte percentage of white cells;
LGG	cis	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg20368463	chr18:77673604	PQLC1	0.53	6.98	0.31	1.02e-11	Opioid sensitivity;
LGG	cis	rs55665837	0.540	rs11023302	chr11:14693935	C/G	cg18937875	chr11:14930189	NA	-0.49	-8.05	-0.35	7.16e-15	Vitamin D levels;
LGG	cis	rs2013441	0.670	rs4924802	chr17:19955895	G/T	cg13482628	chr17:19912719	NA	0.53	8.75	0.38	3.85e-17	Obesity-related traits;
LGG	cis	rs2224391	1.000	rs9504369	chr6:5261575	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.11	-0.35	4.58e-15	Height;
LGG	trans	rs453301	0.686	rs6601280	chr8:8909236	A/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.75	-0.34	5.83e-14	Joint mobility (Beighton score);
LGG	cis	rs722599	0.748	rs2537824	chr14:75367349	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.6	-10.03	-0.42	1.52e-21	IgG glycosylation;
LGG	cis	rs12618769	0.597	rs3769725	chr2:99105967	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.54	0.37	2.02e-16	Bipolar disorder;
LGG	cis	rs8133932	0.701	rs3788217	chr21:47287321	T/C	cg13695288	chr21:47294981	PCBP3	-0.36	-7.35	-0.32	9.23e-13	Schizophrenia;
LGG	cis	rs6558174	0.802	rs3758040	chr8:22487087	T/C	cg03733263	chr8:22462867	KIAA1967	0.61	9.68	0.41	2.55e-20	Breast cancer;
LGG	cis	rs1971762	0.527	rs11170590	chr12:53938913	G/A	cg06632207	chr12:54070931	ATP5G2	0.21	6.76	0.3	4.2e-11	Height;
LGG	cis	rs651907	0.557	rs11711079	chr3:101386918	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.41	0.53	7.22e-35	Colorectal cancer;
LGG	trans	rs2204008	0.837	rs11180821	chr12:38242843	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.67	-0.41	2.95e-20	Bladder cancer;
LGG	cis	rs13082711	0.911	rs34098124	chr3:27451242	G/T	cg02860705	chr3:27208620	NA	0.76	13.79	0.54	1.77e-36	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs6598955	0.694	rs6659387	chr1:26634307	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.39	8.25	0.36	1.67e-15	Obesity-related traits;
LGG	cis	rs8114671	0.527	rs6060112	chr20:33489276	A/T	cg07148914	chr20:33460835	GGT7	0.59	9.73	0.41	1.7e-20	Height;
LGG	cis	rs62025270	0.632	rs6496109	chr15:86132008	C/G	cg25843651	chr15:86329602	KLHL25	0.54	8.12	0.35	4.32e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg00409905	chr10:38381863	ZNF37A	0.67	13.6	0.53	1.12e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.61	-10.42	-0.44	5.39e-23	Obesity-related traits;
LGG	cis	rs55823223	0.680	rs57287238	chr17:73850940	T/C	cg06969265	chr17:73775802	H3F3B	0.5	6.88	0.3	1.89e-11	Psoriasis;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg04267008	chr7:1944627	MAD1L1	-0.7	-12.26	-0.49	4.11e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs887829	0.588	rs7556676	chr2:234658250	A/G	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.7	-0.34	8.27e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs9443645	0.901	rs2152951	chr6:79762172	A/G	cg18132916	chr6:79620363	NA	0.31	8.47	0.37	3.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.649	rs1869513	chr2:39205315	A/G	cg04010122	chr2:39346883	SOS1	-0.76	-7.06	-0.31	6.32e-12	Corticobasal degeneration;
LGG	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg19761014	chr17:28927070	LRRC37B2	0.57	6.69	0.3	6.5e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs350251	0.837	rs1641850	chr16:12188433	C/G	cg02910054	chr16:12241554	SNX29	0.42	7.62	0.33	1.4e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg01673284	chr16:4527211	HMOX2	0.36	7.07	0.31	5.78e-12	Schizophrenia;
LGG	cis	rs7814319	0.933	rs7827095	chr8:97239126	C/T	cg20787634	chr8:97240163	UQCRB	0.74	17.49	0.63	5.75e-53	Lung function (FVC);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16422343	chr6:36564708	SFRS3	0.34	6.68	0.3	7.08e-11	Gut microbiome composition (summer);
LGG	cis	rs2013441	0.965	rs8071665	chr17:20209943	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs4141404	0.582	rs5753630	chr22:31861950	A/G	cg02404636	chr22:31891804	SFI1	0.33	6.71	0.3	5.8e-11	Paclitaxel-induced neuropathy;
LGG	cis	rs9790314	0.645	rs10936224	chr3:160902531	G/A	cg04691961	chr3:161091175	C3orf57	-0.5	-10.93	-0.45	6.52e-25	Morning vs. evening chronotype;
LGG	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.67e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02397782	chr11:75479475	DGAT2	0.47	6.83	0.3	2.67e-11	Hip circumference;
LGG	cis	rs11112613	0.713	rs68053161	chr12:105950035	G/C	cg03607813	chr12:105948248	NA	0.64	11.25	0.46	4.14e-26	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg14092988	chr3:52407081	DNAH1	0.32	8.63	0.37	9.68e-17	Bipolar disorder;
LGG	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg14191688	chr11:70257035	CTTN	0.55	8.01	0.35	9.7e-15	Coronary artery disease;
LGG	cis	rs9462027	0.651	rs13220394	chr6:34810172	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.32	-0.47	2.13e-26	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.609	rs9379785	chr6:25726213	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.67	-0.34	9.96e-14	Iron status biomarkers;
LGG	cis	rs2346177	0.875	rs2881327	chr2:46641955	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.55	-10.11	-0.43	7.7e-22	HDL cholesterol;
LGG	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg08297393	chr2:100937505	LONRF2	-0.42	-7.43	-0.33	5.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12282928	0.959	rs11039640	chr11:48307236	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs2013441	0.965	rs2703790	chr17:20163209	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09642507	chr17:27224533	FLOT2	0.48	7.07	0.31	5.83e-12	Gut microbiome composition (summer);
LGG	trans	rs11088226	0.681	rs2409456	chr21:33929374	G/A	cg09050820	chr6:167586206	TCP10L2	0.87	12.42	0.5	8.79e-31	Gastritis;
LGG	cis	rs262150	0.659	rs2730275	chr7:158793397	A/G	cg19418458	chr7:158789849	NA	-0.56	-11.57	-0.47	2.23e-27	Facial morphology (factor 20);
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.92	-0.38	1.11e-17	Neuroticism;
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg27476859	chr7:2772710	GNA12	0.42	7.14	0.32	3.58e-12	Height;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.96	-0.35	1.32e-14	Skin colour saturation;
LGG	cis	rs899997	0.773	rs7178423	chr15:78964961	T/G	cg14912033	chr15:79043428	NA	-0.34	-6.82	-0.3	2.9100000000000002e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19524238	chr7:2802976	GNA12	0.4	9.23	0.39	9.82e-19	Height;
LGG	cis	rs875971	0.862	rs13536	chr7:66019190	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg25237894	chr2:233734115	C2orf82	-0.55	-10.42	-0.44	5.38e-23	Coronary artery disease;
LGG	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg13298116	chr11:62369859	EML3;MTA2	-0.69	-17.13	-0.62	2.69e-51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs3809472	chr15:45694318	G/T	cg26924012	chr15:45694286	SPATA5L1	1.04	22.29	0.72	2.71e-75	Homoarginine levels;
LGG	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg08564027	chr20:61660810	NA	1.02	25.08	0.76	2.73e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.65e-15	Obesity-related traits;
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg13206674	chr6:150067644	NUP43	0.42	8.94	0.38	8.98e-18	Testicular germ cell tumor;
LGG	cis	rs12210905	0.688	rs72845025	chr6:27524443	G/C	cg10122326	chr6:28072925	NA	0.94	7.23	0.32	1.96e-12	Hip circumference adjusted for BMI;
LGG	cis	rs13082711	0.911	rs923940	chr3:27459341	C/G	cg02860705	chr3:27208620	NA	0.69	12.32	0.5	2.22e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10911251	0.508	rs729672	chr1:183109236	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.53	0.37	2.15e-16	Colorectal cancer;
LGG	cis	rs3820928	0.839	rs4673174	chr2:227801316	A/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	2.93e-14	Pulmonary function;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.67	-0.41	2.92e-20	Aortic root size;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.56	-0.33	2.18e-13	Life satisfaction;
LGG	cis	rs2244613	0.706	rs7200011	chr16:55794768	C/A	cg27396498	chr16:55794478	CES4	0.43	8.75	0.38	3.95e-17	Response to dabigatran etexilate treatment;
LGG	cis	rs4731207	0.596	rs1481328	chr7:124631026	C/T	cg05630886	chr7:124431682	NA	0.3	6.85	0.3	2.33e-11	Cutaneous malignant melanoma;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg24607181	chr17:41446203	NA	-0.3	-7.13	-0.31	3.98e-12	Menopause (age at onset);
LGG	cis	rs6665290	0.935	rs6704144	chr1:227201030	C/G	cg10327440	chr1:227177885	CDC42BPA	-1.13	-29.23	-0.81	3.38e-107	Myeloid white cell count;
LGG	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg07075026	chr17:47091521	IGF2BP1	-0.39	-6.92	-0.31	1.48e-11	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs9905704	0.647	rs6503892	chr17:57067086	G/A	cg12560992	chr17:57184187	TRIM37	0.54	8.67	0.37	7.39e-17	Testicular germ cell tumor;
LGG	cis	rs612683	0.735	rs3754131	chr1:100931073	A/C	cg06223162	chr1:101003688	GPR88	0.43	10.56	0.44	1.62e-23	Breast cancer;
LGG	cis	rs2576037	0.526	rs2187092	chr18:44526798	A/C	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.74	-0.3	4.86e-11	Personality dimensions;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.95e-14	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13369624	chr13:21714458	SAP18	0.54	8.33	0.36	9.28e-16	Gut microbiome composition (summer);
LGG	cis	rs2652822	0.935	rs7162825	chr15:63439186	A/G	cg02713581	chr15:63449717	RPS27L	-0.46	-7.93	-0.35	1.67e-14	Metabolic traits;
LGG	cis	rs9303401	0.703	rs9909925	chr17:57210069	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.51	-8.58	-0.37	1.44e-16	Cognitive test performance;
LGG	cis	rs6772849	0.901	rs9289330	chr3:128311067	C/G	cg08795948	chr3:128337044	NA	0.48	8.03	0.35	7.92e-15	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg06521331	chr12:34319734	NA	-0.57	-10.38	-0.43	7.87e-23	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17330983	chr14:23770641	PPP1R3E	0.52	8.01	0.35	9.23e-15	Gut microbiome composition (summer);
LGG	cis	rs4747241	0.593	rs9415064	chr10:74089364	C/T	cg25082487	chr10:74091975	NA	0.38	7.18	0.32	2.86e-12	Heschl's gyrus morphology;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg12379764	chr21:47803548	PCNT	-0.45	-7.64	-0.33	1.29e-13	Testicular germ cell tumor;
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.24	-0.36	1.77e-15	Aortic root size;
LGG	cis	rs9368481	0.569	rs10946868	chr6:26887930	A/G	cg18867708	chr6:26865862	GUSBL1	0.46	7.6	0.33	1.65e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg02657836	chr5:155109126	NA	0.33	6.81	0.3	3.08e-11	Prudent dietary pattern;
LGG	cis	rs2905347	0.757	rs1006509	chr7:22698466	C/T	cg18045685	chr7:22629474	NA	0.66	14.0	0.55	2.11e-37	Major depression and alcohol dependence;
LGG	cis	rs35110281	0.517	rs11701973	chr21:44979671	G/A	cg01579765	chr21:45077557	HSF2BP	-0.3	-6.68	-0.3	6.89e-11	Mean corpuscular volume;
LGG	cis	rs910187	0.678	rs1046667	chr20:45817255	A/C	cg27589058	chr20:45804311	EYA2	-0.36	-9.21	-0.39	1.11e-18	Migraine;
LGG	cis	rs2046867	0.818	rs62249863	chr3:72868666	G/C	cg25664220	chr3:72788482	NA	-0.33	-8.98	-0.38	7.07e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10256972	0.732	rs12701856	chr7:1107707	C/T	cg04025307	chr7:1156635	C7orf50	0.68	12.87	0.51	1.29e-32	Longevity;Endometriosis;
LGG	cis	rs8179	0.761	rs42035	chr7:92239531	A/G	cg15732164	chr7:92237376	CDK6	-0.56	-10.37	-0.43	8.41e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7681440	0.835	rs6831847	chr4:90785341	A/G	cg20003494	chr4:90757398	SNCA	0.4	7.88	0.34	2.44e-14	Dementia with Lewy bodies;
LGG	cis	rs3903072	0.528	rs7928652	chr11:65580228	A/C	cg26695010	chr11:65641043	EFEMP2	-0.43	-6.8	-0.3	3.26e-11	Breast cancer;
LGG	cis	rs2153535	0.580	rs915351	chr6:8442793	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg18357526	chr6:26021779	HIST1H4A	0.47	7.88	0.34	2.35e-14	Height;
LGG	cis	rs12701220	0.857	rs1057558	chr7:1062366	A/G	cg20821713	chr7:1055600	C7orf50	-0.48	-7.7	-0.34	8.33e-14	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	0.695	rs6569487	chr6:127726196	C/T	cg24812749	chr6:127587940	RNF146	-0.62	-10.39	-0.43	7.22e-23	Breast cancer;
LGG	cis	rs3736594	0.918	rs12471347	chr2:27981655	G/C	cg27432699	chr2:27873401	GPN1	0.56	8.93	0.38	1.01e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4888262	0.564	rs8050850	chr16:74582597	C/A	cg01733217	chr16:74700730	RFWD3	0.82	16.38	0.61	6.42e-48	Testicular germ cell tumor;
LGG	cis	rs7937612	0.931	rs34298380	chr11:120203559	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.5	-11.7	-0.48	6.84e-28	Intraocular pressure;
LGG	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg03433033	chr1:76189801	ACADM	-0.68	-9.97	-0.42	2.47e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg26354017	chr1:205819088	PM20D1	0.52	8.73	0.38	4.7e-17	Prostate-specific antigen levels;
LGG	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg11342453	chr6:26196699	NA	-0.49	-6.68	-0.3	6.87e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7666738	0.830	rs2865989	chr4:99067532	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6061231	0.798	rs2427308	chr20:60969451	C/T	cg22633769	chr20:60982531	CABLES2	0.49	6.69	0.3	6.5e-11	Colorectal cancer;
LGG	cis	rs10911232	0.507	rs6668980	chr1:183018857	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs17102423	0.760	rs2781375	chr14:65569597	A/G	cg16583315	chr14:65563665	MAX	-0.39	-7.9	-0.34	1.99e-14	Obesity-related traits;
LGG	cis	rs12701220	0.655	rs12702117	chr7:1148702	T/C	cg02733842	chr7:1102375	C7orf50	-0.44	-7.29	-0.32	1.38e-12	Bronchopulmonary dysplasia;
LGG	trans	rs9657904	0.865	rs3996189	chr3:105576911	G/A	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.39e-14	Multiple sclerosis;
LGG	cis	rs8031584	0.958	rs11293	chr15:31234981	G/A	cg19680485	chr15:31195859	MTMR15	-0.47	-7.74	-0.34	6.23e-14	Huntington's disease progression;
LGG	cis	rs2549003	0.966	rs2706386	chr5:131832687	C/T	cg21138405	chr5:131827807	IRF1	-0.38	-10.19	-0.43	4.03e-22	Asthma (sex interaction);
LGG	cis	rs3812831	0.695	rs422149	chr13:114931086	T/G	cg06611532	chr13:114900021	NA	0.28	7.21	0.32	2.34e-12	Schizophrenia;
LGG	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg15556689	chr8:8085844	FLJ10661	0.4	6.94	0.31	1.34e-11	Myopia (pathological);
LGG	cis	rs9790314	0.905	rs4518145	chr3:160950030	T/C	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs13217239	0.646	rs10946891	chr6:26973215	T/C	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Schizophrenia;
LGG	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg19748678	chr4:122722346	EXOSC9	0.67	13.43	0.53	5.96e-35	Type 2 diabetes;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg04369109	chr6:150039330	LATS1	0.41	6.76	0.3	4.23e-11	Lung cancer;
LGG	cis	rs1862618	0.853	rs3099459	chr5:56137170	G/C	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	cis	rs6956675	1.000	rs6956675	chr7:62577770	A/G	cg08930214	chr7:62859557	LOC100287834	0.46	7.61	0.33	1.53e-13	Obesity-related traits;
LGG	cis	rs6580649	0.941	rs57380031	chr12:48452237	C/T	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs17826219	0.706	rs73271850	chr17:29142140	A/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Body mass index;
LGG	cis	rs17376456	0.825	rs17372725	chr5:93135588	C/A	cg25358565	chr5:93447407	FAM172A	1.26	15.64	0.59	1.44e-44	Diabetic retinopathy;
LGG	cis	rs1003719	0.708	rs8126491	chr21:38551219	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.29	-0.58	5.1e-43	Eye color traits;
LGG	cis	rs3733585	0.631	rs4697924	chr4:10124239	A/G	cg25986240	chr4:9926439	SLC2A9	0.37	7.25	0.32	1.71e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2153535	0.541	rs1414347	chr6:8471831	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.49e-22	Motion sickness;
LGG	cis	rs4665809	0.652	rs12611790	chr2:26404221	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.06	-20.37	-0.69	2.45e-66	Gut microbiome composition (summer);
LGG	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg05044414	chr3:183734942	ABCC5	0.58	11.95	0.49	7.1e-29	Anterior chamber depth;
LGG	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg00376283	chr12:123451042	ABCB9	0.68	12.5	0.5	4.29e-31	Platelet count;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.47	-0.44	3.69e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs208520	0.690	rs207096	chr6:66797287	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.52	-0.65	1.05e-57	Exhaled nitric oxide output;
LGG	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg13147721	chr7:65941812	NA	-0.46	-6.89	-0.3	1.83e-11	Corneal structure;
LGG	cis	rs4799461	0.740	rs948536	chr18:35125314	A/G	cg27332583	chr18:35150602	NA	0.58	11.5	0.47	4.44e-27	Neuroticism;
LGG	cis	rs7666738	0.570	rs1869351	chr4:99077286	T/C	cg05340658	chr4:99064831	C4orf37	0.43	6.99	0.31	9.56e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7566780	0.693	rs725456	chr2:16661088	A/G	cg09580478	chr2:16689509	NA	0.49	7.14	0.32	3.52e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs9911578	0.967	rs2333410	chr17:57137129	G/A	cg12560992	chr17:57184187	TRIM37	-0.9	-16.11	-0.6	1.14e-46	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.563	rs917304	chr16:4440426	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	6.8	0.3	3.23e-11	Schizophrenia;
LGG	cis	rs4948275	0.773	rs2650697	chr10:63296343	A/G	cg03237606	chr10:63212265	TMEM26	-0.39	-7.04	-0.31	6.83e-12	Night sleep phenotypes;
LGG	cis	rs9640161	0.789	rs3735172	chr7:150028958	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.73	15.8	0.59	2.67e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs936229	0.690	rs2445618	chr15:75035256	T/C	cg14664628	chr15:75095509	CSK	-0.94	-18.27	-0.65	1.46e-56	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs151349	0.837	rs151350	chr20:57591634	C/G	cg23907860	chr20:57583709	CTSZ	-0.38	-7.38	-0.32	7.6e-13	Platelet distribution width;
LGG	cis	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	7.59	0.33	1.75e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6032067	0.929	rs2233898	chr20:43850525	A/G	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs9527	0.590	rs11191544	chr10:104827198	C/G	cg05308233	chr10:104796373	CNNM2	-0.32	-7.21	-0.32	2.24e-12	Arsenic metabolism;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg15971980	chr6:150254442	NA	0.45	8.37	0.36	6.68e-16	Lung cancer;
LGG	cis	rs11264213	0.901	rs6665591	chr1:36411737	A/G	cg27506609	chr1:36549197	TEKT2	0.69	8.54	0.37	1.98e-16	Schizophrenia;
LGG	cis	rs7617480	0.610	rs4955420	chr3:49208865	A/G	cg06212747	chr3:49208901	KLHDC8B	0.78	14.09	0.55	9.41e-38	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg26695010	chr11:65641043	EFEMP2	0.46	7.3	0.32	1.26e-12	Breast cancer;
LGG	cis	rs758324	0.812	rs10042334	chr5:131114979	A/T	cg06307176	chr5:131281290	NA	0.53	8.82	0.38	2.41e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs738321	0.757	rs3788536	chr22:38534209	C/T	cg25457927	chr22:38595422	NA	-0.4	-9.4	-0.4	2.46e-19	Breast cancer;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg16359550	chr11:109292809	C11orf87	0.44	8.46	0.37	3.63e-16	Schizophrenia;
LGG	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Vitiligo;
LGG	cis	rs9400467	0.537	rs78080415	chr6:111537016	T/C	cg15721981	chr6:111408429	SLC16A10	0.59	7.2	0.32	2.38e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs72772090	0.539	rs11747148	chr5:96112863	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4555082	0.874	rs2015978	chr14:105720134	G/C	cg06808227	chr14:105710500	BRF1	-0.64	-11.17	-0.46	8.46e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10865397	0.506	rs13414160	chr2:73383261	C/A	cg01422370	chr2:73384389	NA	0.53	9.82	0.42	8.69e-21	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg00745463	chr17:30367425	LRRC37B	-0.71	-10.4	-0.44	6.65e-23	Hip circumference adjusted for BMI;
LGG	cis	rs5760092	0.627	rs6519489	chr22:24261846	G/A	cg04234412	chr22:24373322	LOC391322	0.69	10.64	0.44	8.21e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs1062177	0.756	rs2915817	chr5:151115517	T/C	cg00977110	chr5:151150581	G3BP1	-0.47	-7.57	-0.33	2.02e-13	Preschool internalizing problems;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg08677398	chr8:58056175	NA	0.48	7.4	0.33	6.52e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.32	-0.32	1.13e-12	Total body bone mineral density;
LGG	cis	rs1506636	0.886	rs6466878	chr7:123272278	T/C	cg03229431	chr7:123269106	ASB15	-0.74	-18.66	-0.66	2.35e-58	Plateletcrit;Platelet count;
LGG	cis	rs2188561	0.697	rs12705421	chr7:107401429	A/G	cg16793755	chr7:107334138	SLC26A4	0.41	7.21	0.32	2.29e-12	Alcohol consumption;
LGG	cis	rs9964724	0.826	rs7237475	chr18:35167222	T/C	cg27332583	chr18:35150602	NA	-0.42	-8.99	-0.39	6.23e-18	Educational attainment (years of education);
LGG	trans	rs17685	0.712	rs869805	chr7:75688596	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs10059630	chr5:93459807	C/A	cg21475434	chr5:93447410	FAM172A	0.7	7.18	0.32	2.73e-12	Diabetic retinopathy;
LGG	cis	rs11690935	0.959	rs10184866	chr2:172608956	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.07	-26.93	-0.78	7.91e-97	Schizophrenia;
LGG	cis	rs3733585	0.605	rs4235355	chr4:10123078	C/A	cg25986240	chr4:9926439	SLC2A9	0.39	7.74	0.34	6.35e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12282928	1.000	rs1905285	chr11:48326024	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg21775007	chr8:11205619	TDH	-0.58	-9.36	-0.4	3.55e-19	Retinal vascular caliber;
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.41	-0.4	2.39e-19	Personality dimensions;
LGG	trans	rs6582630	0.519	rs8189549	chr12:38245752	A/G	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6977660	0.652	rs10486362	chr7:19755224	A/G	cg07541023	chr7:19748670	TWISTNB	-0.93	-13.47	-0.53	3.99e-35	Thyroid stimulating hormone;
LGG	cis	rs9522267	0.535	rs9522304	chr13:112237316	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.22	-0.32	2.2e-12	Hepatitis;
LGG	cis	rs9467773	0.595	rs2172007	chr6:26639777	A/C	cg09904177	chr6:26538194	HMGN4	0.62	12.15	0.49	1.11e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs4534897	chr17:41431808	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.16	-0.32	3.24e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.55	9.94	0.42	3.07e-21	Longevity;
LGG	cis	rs2204008	0.576	rs11519979	chr12:37999413	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs9790314	0.875	rs336568	chr3:161072763	G/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.43	-0.47	7.95e-27	Morning vs. evening chronotype;
LGG	cis	rs4974559	0.739	rs2335937	chr4:1321516	C/A	cg02980000	chr4:1222292	CTBP1	0.81	9.16	0.39	1.73e-18	Systolic blood pressure;
LGG	cis	rs1506636	1.000	rs2402671	chr7:123355483	T/C	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.5e-57	Plateletcrit;Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12563480	chr17:46184629	SNX11	0.43	7.33	0.32	1.04e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.2	-0.43	3.54e-22	Chronic sinus infection;
LGG	cis	rs4474465	0.688	rs7937225	chr11:78278126	T/A	cg27205649	chr11:78285834	NARS2	0.6	11.35	0.47	1.61e-26	Alzheimer's disease (survival time);
LGG	cis	rs208520	1.000	rs208523	chr6:66954195	G/C	cg07460842	chr6:66804631	NA	-0.9	-14.82	-0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs2247341	0.965	rs2854920	chr4:1715349	C/T	cg05026014	chr4:1749153	NA	-0.32	-8.9	-0.38	1.22e-17	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg27286069	chr11:118481882	PHLDB1	0.54	10.44	0.44	4.86e-23	Cholesterol, total;
LGG	cis	rs2531992	0.686	rs12922685	chr16:4028621	G/C	cg05927578	chr16:4029543	ADCY9	-0.77	-10.91	-0.45	8.09e-25	Waist circumference;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg07870213	chr5:140052090	DND1	0.69	13.48	0.53	3.45e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs10435719	0.780	rs9692662	chr8:11789863	C/T	cg13009111	chr11:71350975	NA	0.35	7.7	0.34	8.43e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11914070	0.860	rs62229144	chr22:18963205	C/T	cg14259594	chr22:18958660	DGCR5	-0.57	-9.13	-0.39	2.07e-18	Gait variability;
LGG	cis	rs6952808	0.564	rs55865401	chr7:2145720	G/C	cg11050988	chr7:1952600	MAD1L1	-0.28	-6.79	-0.3	3.39e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9788682	0.747	rs2938671	chr15:78732754	A/G	cg06917634	chr15:78832804	PSMA4	0.53	8.09	0.35	5.1e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.52	10.2	0.43	3.43e-22	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg26155939	chr18:44337853	ST8SIA5	-0.37	-6.74	-0.3	4.77e-11	Personality dimensions;
LGG	cis	rs875971	0.545	rs1065265	chr7:65841203	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	cis	rs9300255	0.664	rs7306755	chr12:123767929	G/A	cg05973401	chr12:123451056	ABCB9	-0.48	-6.91	-0.31	1.65e-11	Neutrophil percentage of white cells;
LGG	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22168489	chr12:122356033	WDR66	-0.37	-8.35	-0.36	8.01e-16	Mean corpuscular volume;
LGG	cis	rs1595825	0.838	rs73058883	chr2:198896255	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.52e-11	Ulcerative colitis;
LGG	cis	rs738322	0.935	rs4384	chr22:38572440	G/C	cg03162506	chr22:38580953	NA	0.38	9.67	0.41	2.96e-20	Cutaneous nevi;
LGG	cis	rs7000551	0.751	rs2449340	chr8:22389900	T/G	cg12081754	chr8:22256438	SLC39A14	0.69	13.06	0.52	2.02e-33	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs228769	0.673	rs228787	chr17:42099488	C/T	cg19774624	chr17:42201019	HDAC5	0.57	8.49	0.37	2.75e-16	Bone mineral density (hip);Bone mineral density (spine);
LGG	trans	rs11992162	0.591	rs4240678	chr8:11802426	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.27	-0.36	1.42e-15	Monocyte count;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg09699651	chr6:150184138	LRP11	0.53	9.17	0.39	1.52e-18	Lung cancer;
LGG	cis	rs2242663	0.558	rs11227485	chr11:66215423	C/T	cg01599099	chr11:66649832	PC	0.38	7.51	0.33	3.02e-13	Bipolar disorder;
LGG	cis	rs7107174	1.000	rs1385600	chr11:77936166	C/T	cg02023728	chr11:77925099	USP35	-0.47	-8.38	-0.36	6.3e-16	Testicular germ cell tumor;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs490234	0.588	rs34983978	chr9:128169170	G/A	cg14078157	chr9:128172775	NA	-0.61	-11.48	-0.47	5.32e-27	Mean arterial pressure;
LGG	cis	rs12230513	0.632	rs59213907	chr12:55728911	A/T	cg19537932	chr12:55886519	OR6C68	-0.56	-9.95	-0.42	2.89e-21	Contrast sensitivity;
LGG	cis	rs13082711	0.640	rs66941564	chr3:27259702	C/A	cg02860705	chr3:27208620	NA	0.92	18.35	0.65	6.34e-57	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9596863	0.634	rs2806737	chr13:54298029	C/T	ch.13.53330881F	chr13:54432880	NA	-0.45	-7.09	-0.31	5.13e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs11148252	0.574	rs9536247	chr13:53279542	T/C	cg05335186	chr13:53173507	NA	0.79	20.87	0.7	1.21e-68	Lewy body disease;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.28	-0.32	1.4e-12	Life satisfaction;
LGG	cis	rs6500602	0.702	rs4786493	chr16:4500122	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.36	0.36	7.44e-16	Schizophrenia;
LGG	cis	rs9914544	1.000	rs6502677	chr17:18803658	A/G	cg26306683	chr17:18585705	ZNF286B	0.47	8.91	0.38	1.18e-17	Educational attainment (years of education);
LGG	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg02002194	chr4:3960332	NA	0.4	7.12	0.31	4.13e-12	Joint mobility (Beighton score);
LGG	cis	rs2011503	0.882	rs113841472	chr19:19565482	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.73	0.3	4.95e-11	Bipolar disorder;
LGG	cis	rs7107174	0.688	rs11237490	chr11:78135229	C/T	cg02023728	chr11:77925099	USP35	0.44	7.55	0.33	2.34e-13	Testicular germ cell tumor;
LGG	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg21926883	chr2:100939477	LONRF2	-0.49	-9.45	-0.4	1.63e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.58	-0.37	1.39e-16	Bone mineral density;
LGG	cis	rs7432375	0.580	rs4678442	chr3:136532971	A/G	cg21827317	chr3:136751795	NA	0.43	7.81	0.34	3.92e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1941023	0.503	rs4939350	chr11:60136243	C/G	cg08716584	chr11:60157161	MS4A7	-0.42	-8.39	-0.36	5.92e-16	Congenital heart disease (maternal effect);
LGG	trans	rs7618501	1.000	rs35261599	chr3:49773236	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.91	-0.51	8.67e-33	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.562	rs2526481	chr17:20127018	T/C	cg13482628	chr17:19912719	NA	-0.53	-10.0	-0.42	1.86e-21	Schizophrenia;
LGG	cis	rs55908905	1	rs55908905	chr11:66477864	AT/A	cg01599099	chr11:66649832	PC	0.48	9.57	0.41	6.22e-20	Breast cancer;
LGG	cis	rs17376456	0.877	rs28633397	chr5:93447048	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.39	0.43	7.46e-23	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2576037	0.526	rs509647	chr18:44383675	G/T	cg01059449	chr18:44338099	ST8SIA5	-0.35	-7.61	-0.33	1.51e-13	Personality dimensions;
LGG	cis	rs9810089	0.777	rs2688601	chr3:136252601	G/A	cg21827317	chr3:136751795	NA	0.47	8.36	0.36	7.5e-16	Gestational age at birth (child effect);
LGG	cis	rs988958	0.526	rs12712828	chr2:42244795	T/G	cg27252766	chr2:42229092	NA	0.47	6.75	0.3	4.4e-11	Hypospadias;
LGG	cis	rs6541297	0.702	rs4846904	chr1:230279410	G/A	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs17504614	0.550	rs56109000	chr2:51070070	C/G	cg23851515	chr2:51057218	NRXN1	0.47	7.72	0.34	7.25e-14	Educational attainment (years of education);
LGG	cis	rs4253772	0.514	rs11704878	chr22:46714664	C/T	cg09461388	chr22:46763229	CELSR1	-0.68	-7.07	-0.31	5.81e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9916302	0.784	rs4795361	chr17:37573446	G/A	cg00129232	chr17:37814104	STARD3	-0.6	-11.29	-0.46	2.8e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg16482183	chr6:26056742	HIST1H1C	0.61	9.62	0.41	4.35e-20	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg12070911	chr6:150209640	RAET1E	0.3	7.43	0.33	5.32e-13	Lung cancer;
LGG	cis	rs992157	0.835	rs11677953	chr2:219121663	G/A	cg00012203	chr2:219082015	ARPC2	-0.7	-12.58	-0.5	2.08e-31	Colorectal cancer;
LGG	cis	rs8077889	0.917	rs72836545	chr17:41892602	A/G	cg26893861	chr17:41843967	DUSP3	0.94	15.93	0.6	6.95e-46	Triglycerides;
LGG	cis	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg27411982	chr8:10470053	RP1L1	0.45	7.81	0.34	3.88e-14	Triglycerides;
LGG	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg23625390	chr15:77176239	SCAPER	0.48	9.4	0.4	2.52e-19	Blood metabolite levels;
LGG	cis	rs7666738	0.830	rs17027090	chr4:98897923	G/T	cg05340658	chr4:99064831	C4orf37	0.47	7.76	0.34	5.32e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.965	rs2854154	chr17:61981696	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.11	-29.77	-0.81	1.38e-109	Prudent dietary pattern;
LGG	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg03342759	chr3:160939853	NMD3	-0.63	-11.15	-0.46	9.75e-26	Morning vs. evening chronotype;
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	9.07	0.39	3.4e-18	Bipolar disorder;
LGG	cis	rs4363385	0.714	rs4845329	chr1:152974454	G/C	cg13444842	chr1:152974279	SPRR3	-0.44	-9.19	-0.39	1.37e-18	Inflammatory skin disease;
LGG	cis	rs1965732	0.563	rs13390724	chr2:3721632	G/A	cg20493526	chr2:3714936	ALLC	0.45	9.81	0.41	9.46e-21	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6815814	0.950	rs56408159	chr4:38812116	T/A	cg06935464	chr4:38784597	TLR10	0.6	8.19	0.36	2.49e-15	Breast cancer;
LGG	cis	rs757081	0.667	rs1987694	chr11:17107648	G/C	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.81	-0.38	2.6e-17	Systolic blood pressure;
LGG	cis	rs4812048	1.000	rs6070696	chr20:57597645	A/G	cg23907860	chr20:57583709	CTSZ	0.46	7.09	0.31	4.89e-12	Mean platelet volume;
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg11494091	chr17:61959527	GH2	0.56	9.07	0.39	3.47e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7715811	0.956	rs5023693	chr5:13767129	T/C	cg07548982	chr5:13769939	DNAH5	-0.47	-9.69	-0.41	2.42e-20	Subclinical atherosclerosis traits (other);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16282993	chr6:26204765	HIST1H4E	-0.49	-7.11	-0.31	4.47e-12	Systemic lupus erythematosus;
LGG	cis	rs9910055	0.659	rs7212573	chr17:42254281	A/G	cg13607699	chr17:42295918	UBTF	0.54	8.96	0.38	8.25e-18	Total body bone mineral density;
LGG	cis	rs72949976	1.000	rs6747328	chr2:214032156	C/G	cg08319019	chr2:214017104	IKZF2	-0.59	-10.09	-0.42	8.63e-22	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs9926296	0.548	rs6500439	chr16:89808275	A/C	cg10011746	chr16:89865162	FANCA	-0.35	-6.66	-0.3	7.87e-11	Vitiligo;
LGG	trans	rs783540	0.900	rs783525	chr15:83284629	T/A	cg16105309	chr15:79090380	ADAMTS7	0.38	6.75	0.3	4.34e-11	Schizophrenia;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg00830817	chr11:109293614	C11orf87	0.42	6.89	0.3	1.89e-11	Schizophrenia;
LGG	cis	rs13191362	1.000	rs7764785	chr6:163009967	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1908814	0.516	rs10113062	chr8:11793249	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7173743	0.784	rs11072811	chr15:79132330	G/T	cg00540400	chr15:79124168	NA	-0.4	-8.15	-0.35	3.32e-15	Coronary artery disease;
LGG	cis	rs75920871	0.528	rs7124872	chr11:116927951	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.51	7.51	0.33	3.1e-13	Subjective well-being;
LGG	cis	rs11748327	0.959	rs11750208	chr5:4031987	C/T	cg01025095	chr5:4101132	NA	-0.56	-9.0	-0.39	5.87e-18	Myocardial infarction;
LGG	cis	rs12347191	0.500	rs973473	chr9:100620730	T/G	cg13688889	chr9:100608707	NA	-0.82	-16.07	-0.6	1.65e-46	Orofacial clefts;
LGG	cis	rs6747952	0.899	rs2121404	chr2:239083826	A/G	cg17459225	chr2:239074497	NA	0.43	7.87	0.34	2.45e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1355223	0.573	rs1361646	chr11:34746360	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.08	-0.31	5.31e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10791097	0.668	rs10791102	chr11:130744977	G/A	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6714710	0.603	rs116309486	chr2:98493359	A/G	cg26665480	chr2:98280029	ACTR1B	0.61	9.92	0.42	3.71e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs8141529	0.719	rs9625619	chr22:29272328	T/A	cg15103426	chr22:29168792	CCDC117	0.62	9.6	0.41	4.86e-20	Lymphocyte counts;
LGG	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg03959625	chr15:84868606	LOC388152	0.54	8.48	0.37	3.15e-16	Schizophrenia;
LGG	cis	rs12765878	0.934	rs11191841	chr10:105639611	C/T	cg11005552	chr10:105648138	OBFC1	-0.99	-24.63	-0.75	3.34e-86	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02551244	chr2:23608357	KLHL29	0.45	7.14	0.31	3.63e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.89	-0.42	4.9e-21	Lung cancer;
LGG	cis	rs4243830	0.850	rs12410405	chr1:6581283	C/G	cg05709478	chr1:6581295	PLEKHG5	0.43	6.89	0.31	1.77e-11	Body mass index;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12599106	0.792	rs11648801	chr16:34360980	C/T	cg07332563	chr6:291687	DUSP22	-0.4	-6.96	-0.31	1.2e-11	Menopause (age at onset);
LGG	trans	rs12310956	0.510	rs1565026	chr12:33887499	A/G	cg26384229	chr12:38710491	ALG10B	0.62	12.11	0.49	1.64e-29	Morning vs. evening chronotype;
LGG	cis	rs17092148	0.887	rs6058104	chr20:33271052	G/A	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.26	-0.32	1.68e-12	Neuroticism;
LGG	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs1408799	0.745	rs12379024	chr9:12717405	A/G	cg05274944	chr9:12693694	TYRP1	-0.35	-8.26	-0.36	1.52e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.35	-7.37	-0.32	7.79e-13	Schizophrenia;
LGG	cis	rs9300255	0.739	rs11057210	chr12:123733799	A/G	cg00376283	chr12:123451042	ABCB9	0.64	10.27	0.43	1.93e-22	Neutrophil percentage of white cells;
LGG	cis	rs7507204	0.767	rs12982509	chr19:3412057	C/T	cg08380311	chr19:3435252	NFIC	-0.81	-12.37	-0.5	1.49e-30	Height;
LGG	cis	rs1003719	0.680	rs2835629	chr21:38521660	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.55	-0.59	3.74e-44	Eye color traits;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.3	-0.32	1.26e-12	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.54	-0.41	8.13e-20	Lung cancer;
LGG	cis	rs1862618	0.526	rs2591963	chr5:56237135	T/A	cg08400814	chr5:56204995	C5orf35	0.53	8.25	0.36	1.63e-15	Initial pursuit acceleration;
LGG	cis	rs798554	0.679	rs2644281	chr7:2886748	A/G	cg14668632	chr7:2872130	GNA12	-0.33	-6.94	-0.31	1.34e-11	Height;
LGG	cis	rs10089	1.000	rs4835945	chr5:127526481	C/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.55	0.47	2.63e-27	Ileal carcinoids;
LGG	cis	rs67460515	0.563	rs4521287	chr3:160812752	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-12.03	-0.49	3.34e-29	Parkinson's disease;
LGG	cis	rs3206736	0.761	rs6462594	chr7:35190084	G/T	cg13400248	chr7:35225412	NA	0.38	7.06	0.31	6.1e-12	Diastolic blood pressure;
LGG	trans	rs28735056	0.967	rs11662248	chr18:77619009	C/T	cg05926928	chr17:57297772	GDPD1	-0.48	-7.67	-0.34	1.05e-13	Schizophrenia;
LGG	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs9300255	0.596	rs11057207	chr12:123730891	T/G	cg05973401	chr12:123451056	ABCB9	0.51	8.21	0.36	2.18e-15	Neutrophil percentage of white cells;
LGG	cis	rs2282802	0.617	rs10477348	chr5:139666906	A/T	cg26211634	chr5:139558579	C5orf32	0.33	7.2	0.32	2.39e-12	Intelligence (multi-trait analysis);
LGG	cis	rs787274	1.000	rs10733594	chr9:115552630	T/G	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg26153158	chr1:1875876	NA	-0.48	-8.97	-0.38	7.59e-18	Body mass index;
LGG	cis	rs11785693	0.862	rs11774126	chr8:4979583	A/C	cg26367366	chr8:4980734	NA	0.99	15.37	0.58	2.17e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	trans	rs2624839	0.704	rs11919418	chr3:50233215	T/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.8	0.34	4.1e-14	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.545	rs2460427	chr7:65619205	T/C	cg11764359	chr7:65958608	NA	-0.63	-9.75	-0.41	1.44e-20	Aortic root size;
LGG	cis	rs7568458	0.837	rs6547624	chr2:85802134	A/T	cg17127132	chr2:85788382	GGCX	0.46	8.17	0.35	3.03e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs981844	0.754	rs897608	chr4:154754960	C/T	cg14289246	chr4:154710475	SFRP2	0.56	9.57	0.41	6.37e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs6500602	0.893	rs6500596	chr16:4470027	G/T	cg19168338	chr16:4465731	CORO7	-1.12	-24.46	-0.75	1.98e-85	Schizophrenia;
LGG	cis	rs888194	0.690	rs888192	chr12:109995097	C/T	cg19025524	chr12:109796872	NA	0.35	6.92	0.31	1.55e-11	Neuroticism;
LGG	cis	rs9467773	1.000	rs9295695	chr6:26528250	C/T	cg09904177	chr6:26538194	HMGN4	-0.78	-17.89	-0.64	8.2e-55	Intelligence (multi-trait analysis);
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg00035636	chr13:21900591	NA	0.38	8.29	0.36	1.23e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg22907277	chr7:1156413	C7orf50	0.68	12.74	0.51	4.51e-32	Longevity;Endometriosis;
LGG	cis	rs6831352	0.734	rs2851259	chr4:100033986	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs2276314	1.000	rs4799834	chr18:33566243	T/C	cg05985134	chr18:33552581	C18orf21	0.65	10.17	0.43	4.42e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7020830	0.830	rs308499	chr9:37348059	C/G	cg14294708	chr9:37120828	ZCCHC7	1.1	28.98	0.8	4.37e-106	Schizophrenia;
LGG	cis	rs6961069	0.722	rs13438282	chr7:80262224	C/T	cg04458919	chr7:80252533	CD36	0.28	6.91	0.31	1.63e-11	Platelet count;
LGG	cis	rs11225247	1.000	rs117960807	chr11:102275262	A/C	cg06323957	chr11:102217781	BIRC2	0.8	6.79	0.3	3.39e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs736408	0.812	rs2240920	chr3:52831009	A/G	cg14092988	chr3:52407081	DNAH1	-0.31	-7.87	-0.34	2.47e-14	Bipolar disorder;
LGG	cis	rs4664308	0.810	rs59019419	chr2:161061287	G/A	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.93	-0.59	7.34e-46	Idiopathic membranous nephropathy;
LGG	trans	rs526821	0.553	rs295597	chr11:55470003	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.66	-0.3	8e-11	Pediatric bone mineral density (spine);
LGG	cis	rs6908034	0.505	rs76709285	chr6:19804330	C/G	cg02682789	chr6:19804855	NA	0.91	8.38	0.36	6.45e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06108461	chr20:60628389	TAF4	-0.85	-15.86	-0.59	1.46e-45	Body mass index;
LGG	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg20821713	chr7:1055600	C7orf50	-0.49	-7.83	-0.34	3.35e-14	Bronchopulmonary dysplasia;
LGG	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg19507638	chr5:93509721	C5orf36	-0.65	-9.32	-0.4	4.6e-19	Diabetic retinopathy;
LGG	cis	rs17655565	0.904	rs3809172	chr12:52695198	G/C	cg02645295	chr12:52705424	NA	-0.6	-8.03	-0.35	8e-15	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs2282032	0.527	rs3742666	chr14:90767860	T/C	cg14092571	chr14:90743983	NA	0.43	7.68	0.34	9.77e-14	Longevity;
LGG	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.21	-0.36	2.21e-15	Retinal vascular caliber;
LGG	cis	rs889312	0.500	rs832577	chr5:56163787	G/A	cg12654349	chr5:56205094	C5orf35	-0.37	-6.72	-0.3	5.48e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs1847202	0.793	rs13088835	chr3:72949861	A/T	cg25664220	chr3:72788482	NA	-0.25	-7.26	-0.32	1.61e-12	Motion sickness;
LGG	cis	rs2836974	0.836	rs1041440	chr21:40627325	C/T	cg06238570	chr21:40685208	BRWD1	0.44	6.86	0.3	2.25e-11	Cognitive function;
LGG	cis	rs9311474	0.607	rs28661185	chr3:52567188	G/T	cg18404041	chr3:52824283	ITIH1	-0.49	-9.09	-0.39	2.91e-18	Electroencephalogram traits;
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg11494091	chr17:61959527	GH2	0.51	8.02	0.35	8.78e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.59	-0.37	1.32e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg13545763	chr17:47755325	SPOP	-0.41	-7.11	-0.31	4.33e-12	Brain structure;
LGG	cis	rs2346177	0.580	rs7565770	chr2:46683683	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.68	-13.71	-0.54	3.83e-36	HDL cholesterol;
LGG	cis	rs986417	0.818	rs1955702	chr14:61074301	T/A	cg27398547	chr14:60952738	C14orf39	0.68	6.98	0.31	1.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.63e-24	Body mass index;
LGG	cis	rs4132509	1.000	rs10927040	chr1:243731693	T/C	cg21452805	chr1:244014465	NA	0.62	7.33	0.32	1.03e-12	RR interval (heart rate);
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg07677032	chr17:61819896	STRADA	0.66	11.55	0.47	2.67e-27	Prudent dietary pattern;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg07362569	chr17:61921086	SMARCD2	0.49	9.46	0.4	1.5e-19	Prudent dietary pattern;
LGG	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg23649088	chr2:200775458	C2orf69	0.46	8.1	0.35	5.01e-15	Systolic blood pressure;
LGG	cis	rs806215	0.813	rs2582717	chr7:127311863	A/G	cg25922125	chr7:127225783	GCC1	0.57	8.44	0.37	4.17e-16	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs176880	chr10:38401417	C/G	cg25427524	chr10:38739819	LOC399744	0.64	11.86	0.48	1.69e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs7949030	0.622	rs34894392	chr11:62374821	A/G	cg13298116	chr11:62369859	EML3;MTA2	0.7	17.18	0.62	1.53e-51	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7249142	0.549	rs2238667	chr19:19282523	G/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-10.85	-0.45	1.37e-24	IgG glycosylation;
LGG	cis	rs68170813	0.559	rs79778437	chr7:107004972	T/A	cg02696742	chr7:106810147	HBP1	-0.67	-9.56	-0.41	7.24e-20	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16203607	chr17:62500946	DDX5	0.45	7.75	0.34	5.77e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg12046867	chr14:103022105	NA	0.45	8.7	0.38	5.65e-17	Platelet count;
LGG	cis	rs9513627	1.000	rs9585075	chr13:100128634	G/A	cg15490075	chr13:100150979	NA	-0.69	-7.22	-0.32	2.17e-12	Obesity-related traits;
LGG	trans	rs79911532	0.515	rs887579	chr7:75701640	G/A	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	cis	rs11753937	0.774	rs569833	chr6:133527935	T/C	cg06181518	chr6:133562196	EYA4	0.44	7.22	0.32	2.2e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs1595825	0.735	rs2164327	chr2:198726773	C/T	cg00982548	chr2:198649783	BOLL	-0.5	-6.8	-0.3	3.23e-11	Ulcerative colitis;
LGG	cis	rs2456568	0.803	rs10831138	chr11:93640468	T/C	cg26875233	chr11:93583750	C11orf90	-0.34	-6.74	-0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6502050	0.835	rs12450189	chr17:80095128	A/C	cg11859384	chr17:80120422	CCDC57	-0.46	-8.06	-0.35	6.55e-15	Life satisfaction;
LGG	cis	rs3816183	0.959	rs2374444	chr2:43018644	A/G	cg14631114	chr2:43023945	NA	0.5	9.42	0.4	2.19e-19	Hypospadias;
LGG	cis	rs6817170	0.692	rs9760673	chr4:154372380	C/T	cg07229402	chr4:154369277	NA	0.34	6.83	0.3	2.72e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	trans	rs7246760	1.000	rs56754106	chr19:9937789	T/A	cg02900749	chr2:68251473	NA	-1.08	-11.46	-0.47	6.09e-27	Pursuit maintenance gain;
LGG	cis	rs950776	0.616	rs3743077	chr15:78894896	C/T	cg17108064	chr15:78857060	CHRNA5	0.45	9.72	0.41	1.95e-20	Sudden cardiac arrest;
LGG	cis	rs12134040	0.646	rs12734378	chr1:236511354	A/G	cg21399712	chr1:236511386	NA	0.43	8.61	0.37	1.16e-16	Urate levels (BMI interaction);
LGG	cis	rs714515	0.836	rs2001129	chr1:172333248	A/C	cg01573306	chr1:172330400	DNM3	0.35	7.85	0.34	2.84e-14	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4481887	0.927	rs10749646	chr1:248429719	A/G	cg01631408	chr1:248437212	OR2T33	0.57	10.11	0.43	7.54e-22	Common traits (Other);
LGG	cis	rs10751667	0.666	rs10902255	chr11:967268	T/C	cg22143635	chr11:980567	AP2A2	0.44	8.18	0.36	2.68e-15	Alzheimer's disease (late onset);
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg13009111	chr11:71350975	NA	0.33	7.16	0.32	3.12e-12	Monocyte count;
LGG	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	cis	rs528418	0.540	rs2876617	chr6:145699309	A/G	cg03642472	chr6:145670687	NA	0.57	7.63	0.33	1.32e-13	Methadone dose in opioid dependence;
LGG	cis	rs7819412	0.654	rs6987059	chr8:11071057	A/G	cg21775007	chr8:11205619	TDH	-0.54	-8.44	-0.37	4.01e-16	Triglycerides;
LGG	cis	rs35306767	0.903	rs12264711	chr10:929525	T/C	cg20503657	chr10:835505	NA	0.75	10.31	0.43	1.45e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg12741488	chr16:2933841	FLYWCH2	0.4	7.08	0.31	5.52e-12	Bilirubin levels;
LGG	cis	rs2718058	0.613	rs2597272	chr7:37759710	C/G	cg15028436	chr7:37888078	TXNDC3	-0.57	-8.94	-0.38	9.18e-18	Alzheimer's disease (late onset);
LGG	cis	rs7481584	0.886	rs4758621	chr11:3009640	C/T	cg25174290	chr11:3078921	CARS	0.44	7.88	0.34	2.37e-14	Calcium levels;
LGG	trans	rs9467711	0.606	rs1978	chr6:26377573	A/T	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7659604	1.000	rs6823488	chr4:122664819	A/G	cg19748678	chr4:122722346	EXOSC9	0.39	7.29	0.32	1.32e-12	Type 2 diabetes;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.99	-0.35	1.07e-14	Life satisfaction;
LGG	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg15454534	chr1:248569605	OR2T1	0.38	6.85	0.3	2.34e-11	Common traits (Other);
LGG	trans	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg06437703	chr8:37914619	EIF4EBP1	-0.62	-10.79	-0.45	2.27e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs651907	0.514	rs11706494	chr3:101509475	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs1847505	0.563	rs3127053	chr13:61412076	G/T	cg25164009	chr13:61490935	NA	-0.62	-10.14	-0.43	5.88e-22	Polychlorinated biphenyl levels;
LGG	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg06827562	chr3:125932279	NA	0.51	12.39	0.5	1.23e-30	Metabolite levels;
LGG	trans	rs7246760	0.867	rs73014087	chr19:9956366	A/G	cg02900749	chr2:68251473	NA	-1.09	-10.51	-0.44	2.68e-23	Pursuit maintenance gain;
LGG	cis	rs2270450	0.650	rs10948301	chr6:46704467	A/G	cg10156739	chr6:46714674	LOC100287718	0.48	10.6	0.44	1.15e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs6963495	0.818	rs117907809	chr7:105168472	C/A	cg21420622	chr7:105162941	PUS7	-0.44	-6.66	-0.3	7.93e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.87	0.34	2.47e-14	Lung cancer;
LGG	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg06808227	chr14:105710500	BRF1	-0.63	-10.9	-0.45	8.91e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs4330281	0.715	rs7427588	chr3:17806424	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.16	-0.32	3.16e-12	Schizophrenia;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.78	0.54	1.86e-36	Obesity-related traits;
LGG	cis	rs6547741	1.000	rs10205364	chr2:27794233	C/T	cg27432699	chr2:27873401	GPN1	0.7	14.11	0.55	7.05e-38	Oral cavity cancer;
LGG	cis	rs9911578	1.000	rs12952832	chr17:56906254	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.75	0.59	4.71e-45	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg02725872	chr8:58115012	NA	-0.84	-16.12	-0.6	1.05e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg03433033	chr1:76189801	ACADM	-0.43	-6.82	-0.3	2.92e-11	Daytime sleep phenotypes;
LGG	cis	rs3816183	0.626	rs7586943	chr2:42893139	C/T	cg14631114	chr2:43023945	NA	0.34	6.66	0.3	7.83e-11	Hypospadias;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg11494091	chr17:61959527	GH2	0.99	24.12	0.75	7.35e-84	Prudent dietary pattern;
LGG	cis	rs3748682	0.821	rs12751325	chr1:38289383	T/C	cg12658694	chr1:38397304	INPP5B	0.38	7.08	0.31	5.51e-12	Hypothyroidism;
LGG	cis	rs9611565	0.918	rs28638318	chr22:41753059	G/A	cg17376030	chr22:41985996	PMM1	0.51	8.15	0.35	3.37e-15	Vitiligo;
LGG	cis	rs62400317	0.859	rs72858517	chr6:45223467	A/C	cg18551225	chr6:44695536	NA	-0.62	-10.24	-0.43	2.5e-22	Total body bone mineral density;
LGG	cis	rs9788721	0.836	rs17483548	chr15:78730313	G/A	cg18825076	chr15:78729989	IREB2	-0.59	-9.41	-0.4	2.36e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2077654	0.822	rs4148627	chr11:17436271	G/A	cg25308976	chr11:17434268	ABCC8	0.85	10.12	0.43	7.17e-22	Gout;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02614525	chr16:75298977	BCAR1	0.43	7.33	0.32	1.02e-12	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.569	rs10750553	chr11:133740251	T/C	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	cis	rs17711722	0.653	rs2460421	chr7:65491123	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.54	-11.95	-0.49	6.82e-29	Calcium levels;
LGG	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg14768367	chr16:72042858	DHODH	0.73	8.26	0.36	1.55e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6674970	0.966	rs2091219	chr1:151012060	A/G	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.48	-7.29	-0.32	1.38e-12	Childhood ear infection;
LGG	cis	rs4975709	0.801	rs3797063	chr5:1881549	A/T	cg15595755	chr5:1867978	NA	0.43	7.5	0.33	3.22e-13	Cardiovascular disease risk factors;
LGG	cis	rs7147624	1.000	rs10135969	chr14:65982345	C/T	cg03016385	chr14:66212404	NA	-0.77	-9.7	-0.41	2.18e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2404602	0.530	rs11072614	chr15:76967205	G/A	cg15268244	chr15:77196840	NA	0.43	8.39	0.36	6.07e-16	Blood metabolite levels;
LGG	trans	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg20587970	chr11:113659929	NA	-1.05	-18.08	-0.64	1.2e-55	Hip circumference adjusted for BMI;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.33	0.4	4.57e-19	Bipolar disorder;
LGG	cis	rs4604732	0.642	rs10802514	chr1:247637749	A/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.5	8.27	0.36	1.43e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg05535760	chr7:792225	HEATR2	0.79	12.69	0.51	6.94e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs7937682	0.710	rs674230	chr11:111437887	A/G	cg19812747	chr11:111475976	SIK2	-0.5	-10.5	-0.44	2.79e-23	Primary sclerosing cholangitis;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg04080417	chr5:1859792	NA	-0.52	-8.51	-0.37	2.39e-16	Cardiovascular disease risk factors;
LGG	trans	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg26043149	chr18:55253948	FECH	0.4	6.66	0.3	7.69e-11	Bone mineral density;
LGG	cis	rs12477438	0.765	rs1453564	chr2:99564428	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.5	-0.44	2.82e-23	Chronic sinus infection;
LGG	cis	rs1577917	1.000	rs12663651	chr6:86701655	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.61	-0.41	4.49e-20	Response to antipsychotic treatment;
LGG	cis	rs2377585	0.653	rs11046806	chr12:8844322	A/G	cg03761649	chr12:8850719	RIMKLB	0.49	8.19	0.36	2.58e-15	Reticulocyte fraction of red cells;
LGG	cis	rs3735485	0.738	rs2289372	chr7:45114226	C/T	cg03440944	chr7:45023329	C7orf40	-0.56	-9.57	-0.41	6.37e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs7786808	0.615	rs4909212	chr7:158197037	G/T	cg01191920	chr7:158217561	PTPRN2	-0.77	-17.13	-0.62	2.62e-51	Obesity-related traits;
LGG	trans	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg16141378	chr3:129829833	LOC729375	0.36	7.8	0.34	4.09e-14	Triglycerides;
LGG	cis	rs7208859	0.673	rs2433	chr17:29226228	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11225247	1.000	rs57562739	chr11:102306641	G/T	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg22681709	chr2:178499509	PDE11A	-0.5	-7.11	-0.31	4.54e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1129187	0.902	rs10948059	chr6:42928461	C/T	cg05552183	chr6:42928497	GNMT	0.51	15.99	0.6	3.69e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14189758	chr20:36156486	BLCAP	0.5	8.17	0.35	2.96e-15	Cognitive performance;
LGG	cis	rs10191773	0.589	rs6761440	chr2:112959193	G/A	cg04979063	chr2:113191202	RGPD5;RGPD8	0.74	9.06	0.39	3.79e-18	Yeast infection;
LGG	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg12165864	chr7:66369176	NA	-0.57	-9.13	-0.39	2.2e-18	Corneal structure;
LGG	cis	rs6028335	0.622	rs73621984	chr20:37639209	A/G	cg16355469	chr20:37678765	NA	0.51	6.99	0.31	9.45e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.4	-0.33	6.65e-13	Life satisfaction;
LGG	trans	rs10435719	0.753	rs9694940	chr8:11789858	G/C	cg08975724	chr8:8085496	FLJ10661	0.4	7.37	0.32	7.67e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26110653	chr13:38924412	UFM1	0.44	7.06	0.31	6.1e-12	Cognitive performance;
LGG	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg15627072	chr1:2432621	PLCH2	-0.35	-7.85	-0.34	2.84e-14	Ulcerative colitis;
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg09033563	chr22:24373618	LOC391322	-0.51	-8.47	-0.37	3.2e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3733585	0.673	rs6836706	chr4:9964251	T/A	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9858542	0.537	rs34915642	chr3:49358646	G/A	cg03060546	chr3:49711283	APEH	-0.53	-7.19	-0.32	2.68e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.0	-0.31	9.28e-12	Monocyte count;
LGG	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.56	-8.91	-0.38	1.19e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs79349575	0.721	rs9904645	chr17:46969665	A/T	cg16584676	chr17:46985605	UBE2Z	0.46	7.9	0.34	2.03e-14	Type 2 diabetes;
LGG	cis	rs9863	0.861	rs7312404	chr12:124446728	A/G	cg13487667	chr12:124434373	CCDC92	-0.37	-7.43	-0.33	5.19e-13	White blood cell count;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg11494091	chr17:61959527	GH2	0.6	9.98	0.42	2.19e-21	Height;
LGG	cis	rs4481887	0.790	rs4526648	chr1:248422503	A/T	cg00666640	chr1:248458726	OR2T12	-0.52	-8.47	-0.37	3.36e-16	Common traits (Other);
LGG	cis	rs7223966	1.000	rs8074771	chr17:61735865	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	3.2e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7633770	0.710	rs34820891	chr3:46698059	A/G	cg11219411	chr3:46661640	NA	-0.53	-11.97	-0.49	6.01e-29	Coronary artery disease;
LGG	cis	rs2880765	0.677	rs7181410	chr15:86006335	A/G	cg13263323	chr15:86062960	AKAP13	0.35	7.23	0.32	2.06e-12	Coronary artery disease;
LGG	cis	rs9916302	0.706	rs7503377	chr17:37708841	A/G	cg00129232	chr17:37814104	STARD3	-0.6	-8.66	-0.37	7.9e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs6495367	0.872	rs7183818	chr15:79372413	A/G	cg17916960	chr15:79447300	NA	0.48	8.61	0.37	1.15e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs8180040	0.932	rs12489046	chr3:47527683	T/G	cg27129171	chr3:47204927	SETD2	0.79	15.33	0.58	3.53e-43	Colorectal cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg13149307	chr10:20104452	PLXDC2	0.38	7.1	0.31	4.84e-12	Obesity-related traits;
LGG	cis	rs2777491	1.000	rs316609	chr15:41743828	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.98	-20.02	-0.68	1.1e-64	Ulcerative colitis;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg21782813	chr7:2030301	MAD1L1	0.41	9.7	0.41	2.26e-20	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg14739378	chr6:46655306	TDRD6	0.37	6.99	0.31	9.56e-12	Menarche (age at onset);
LGG	trans	rs9467711	0.591	rs13202688	chr6:25993469	A/G	cg01620082	chr3:125678407	NA	-0.85	-7.42	-0.33	5.52e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07265985	chr2:220432066	OBSL1	0.44	8.25	0.36	1.61e-15	Menarche (age at onset);
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg07308232	chr7:1071921	C7orf50	-0.7	-13.7	-0.54	4.05e-36	Longevity;Endometriosis;
LGG	cis	rs28595532	1.000	rs56225646	chr4:119651217	T/C	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs7250872	0.606	rs12985022	chr19:1825401	A/G	cg18850929	chr19:1828978	REXO1	0.49	8.06	0.35	6.4e-15	Bipolar disorder;
LGG	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg01570182	chr17:44337453	NA	0.73	12.41	0.5	1e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1371867	0.846	rs1660317	chr8:101333252	G/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs2880765	0.835	rs7169429	chr15:86036648	C/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.32	-0.32	1.08e-12	Coronary artery disease;
LGG	cis	rs3764563	0.735	rs62106282	chr19:15727124	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-8.03	-0.35	7.87e-15	Inflammatory biomarkers;
LGG	cis	rs3820928	0.904	rs4439949	chr2:227764954	T/G	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.41	-0.33	6.22e-13	Pulmonary function;
LGG	cis	rs2180341	0.842	rs7739679	chr6:127545428	G/A	cg27446573	chr6:127587934	RNF146	1.06	19.02	0.66	4.95e-60	Breast cancer;
LGG	cis	rs2731664	0.792	rs652242	chr5:176873010	C/G	cg23176889	chr5:176863531	GRK6	-0.65	-12.85	-0.51	1.56e-32	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.524	rs6088568	chr20:33265971	A/C	cg07148914	chr20:33460835	GGT7	-0.5	-8.26	-0.36	1.53e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs877282	0.945	rs11253390	chr10:788678	A/G	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2692947	0.526	rs4907225	chr2:96576670	C/T	cg22654517	chr2:96458247	NA	0.38	7.59	0.33	1.76e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.53	7.99	0.35	1.11e-14	Renal function-related traits (BUN);
LGG	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.81	-12.87	-0.51	1.24e-32	Chronic sinus infection;
LGG	cis	rs3764563	1.000	rs4371280	chr19:15715768	A/C	cg20725493	chr19:15740067	CYP4F8	-0.68	-7.9	-0.34	2.12e-14	Inflammatory biomarkers;
LGG	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg06115741	chr20:33292138	TP53INP2	0.6	9.97	0.42	2.39e-21	Coronary artery disease;
LGG	cis	rs36071027	0.615	rs13189454	chr5:158410515	C/T	cg00594129	chr5:158524270	EBF1	0.44	8.02	0.35	8.99e-15	Carotid intima media thickness;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.24e-12	Lung cancer;
LGG	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg02461776	chr11:598696	PHRF1	0.54	8.5	0.37	2.59e-16	Systemic lupus erythematosus;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11975718	chr4:84377034	HELQ;MRPS18C	0.42	6.72	0.3	5.48e-11	Cognitive performance;
LGG	cis	rs12681288	0.782	rs12549337	chr8:1030187	A/G	cg04851639	chr8:1020857	NA	-0.39	-7.69	-0.34	8.99e-14	Schizophrenia;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg20607798	chr8:58055168	NA	0.67	7.66	0.34	1.13e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6582630	0.555	rs2197308	chr12:38281261	A/G	cg04568710	chr12:38710424	ALG10B	-0.41	-9.12	-0.39	2.29e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17321999	1.000	rs6732241	chr2:30479927	C/T	cg05247661	chr2:30472410	LBH	0.56	9.11	0.39	2.5e-18	Systemic lupus erythematosus;
LGG	trans	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg01620082	chr3:125678407	NA	-0.51	-6.92	-0.31	1.48e-11	Depression;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.69	-0.3	6.45e-11	Longevity;Endometriosis;
LGG	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.94	0.35	1.52e-14	Cannabis dependence symptom count;
LGG	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg00149659	chr3:10157352	C3orf10	0.58	8.46	0.37	3.43e-16	Alzheimer's disease;
LGG	cis	rs17655565	0.533	rs12301094	chr12:52707610	A/G	cg08257133	chr12:52711352	KRT83	0.65	13.66	0.54	6.38e-36	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	-0.31	-6.72	-0.3	5.2e-11	Schizophrenia;
LGG	cis	rs7765175	0.598	rs2801419	chr6:113658814	C/T	cg26552650	chr6:113682475	NA	0.33	7.41	0.33	5.9e-13	Coronary artery calcification;
LGG	cis	rs9399135	0.967	rs7763836	chr6:135362378	T/C	cg24558204	chr6:135376177	HBS1L	0.53	9.71	0.41	2.04e-20	Red blood cell count;
LGG	cis	rs9951602	0.512	rs8089108	chr18:76651361	C/T	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs708547	1.000	rs708547	chr4:57821309	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.58	8.93	0.38	9.84e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs78456975	0.506	rs6756310	chr2:1549809	A/G	cg01028140	chr2:1542097	TPO	-0.54	-9.87	-0.42	5.57e-21	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs988958	0.675	rs35531047	chr2:42220435	T/A	cg27428208	chr2:42229179	NA	0.52	9.15	0.39	1.87e-18	Hypospadias;
LGG	trans	rs2243480	0.803	rs34004500	chr7:65312178	A/T	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01911186	chr12:12765398	CREBL2	0.43	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.961	rs62259943	chr3:49425167	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.05	-0.35	6.96e-15	Menarche (age at onset);
LGG	cis	rs9910055	0.659	rs2251165	chr17:42234748	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.51	0.5	3.72e-31	Total body bone mineral density;
LGG	cis	rs1552244	1.000	rs9845756	chr3:10067548	G/C	cg13047869	chr3:10149882	C3orf24	0.54	9.01	0.39	5.31e-18	Alzheimer's disease;
LGG	cis	rs883115	1.000	rs6690184	chr1:224813400	G/C	cg01808320	chr1:224927238	CNIH3	-0.38	-6.9	-0.31	1.68e-11	Cancer;
LGG	cis	rs11122272	0.705	rs2486731	chr1:231532511	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.58	10.09	0.42	8.95e-22	Hemoglobin concentration;
LGG	trans	rs12517041	0.935	rs10061491	chr5:23296773	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.2	19.54	0.67	1.8e-62	Platelet count;
LGG	cis	rs7614311	0.731	rs17401592	chr3:63954490	A/G	cg22134162	chr3:63841271	THOC7	-0.44	-7.93	-0.35	1.61e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.62	-8.83	-0.38	2.15e-17	Lung function (FEV1/FVC);
LGG	cis	rs4774899	0.698	rs2585088	chr15:57328867	T/A	cg08128148	chr15:57256372	TCF12	0.28	6.84	0.3	2.55e-11	Urinary tract infection frequency;
LGG	cis	rs10267417	0.603	rs12333603	chr7:19907821	C/G	cg05791153	chr7:19748676	TWISTNB	-0.57	-7.28	-0.32	1.43e-12	Night sleep phenotypes;
LGG	cis	rs789852	1.000	rs789852	chr3:194327098	T/C	cg18000598	chr3:194342907	TMEM44	-0.86	-8.04	-0.35	7.32e-15	QT interval;
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-6.91	-0.31	1.62e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9905704	0.647	rs3809723	chr17:57061978	T/G	cg12560992	chr17:57184187	TRIM37	0.55	8.77	0.38	3.37e-17	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs12497850	1.000	rs12497850	chr3:48748989	G/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.86	0.3	2.21e-11	Parkinson's disease;
LGG	cis	rs875971	1.000	rs3981131	chr7:65951677	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.52	0.37	2.31e-16	Aortic root size;
LGG	cis	rs4481887	1.000	rs4244180	chr1:248471033	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.73	-0.41	1.76e-20	Common traits (Other);
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.42	-0.44	5.36e-23	IgG glycosylation;
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04781638	chr15:83240791	CPEB1	0.4	7.21	0.32	2.37e-12	Gut microbiome composition (summer);
LGG	cis	rs9534288	0.912	rs9526135	chr13:46624992	G/C	cg15192986	chr13:46630673	CPB2	-0.73	-16.04	-0.6	2.23e-46	Blood protein levels;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg26668828	chr6:292823	DUSP22	-0.51	-9.0	-0.39	5.9e-18	Menopause (age at onset);
LGG	cis	rs4077515	0.967	rs4075760	chr9:139266697	A/G	cg21253087	chr9:139290292	SNAPC4	0.35	7.02	0.31	7.86e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs57502260	1.000	rs57502260	chr11:68220905	A/G	cg01657329	chr11:68192670	LRP5	-0.56	-7.33	-0.32	1.06e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs365132	1.000	rs365132	chr5:176378574	G/T	cg16309518	chr5:176445507	NA	-0.55	-12.19	-0.49	7.91e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg13647721	chr17:30228624	UTP6	0.63	7.8	0.34	4.19e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7071206	0.853	rs114936111	chr10:79430143	G/A	cg07817648	chr10:79422355	NA	-0.64	-12.16	-0.49	1.06e-29	Bone mineral density;
LGG	cis	rs7927771	0.832	rs4752990	chr11:47410393	G/A	cg20307385	chr11:47447363	PSMC3	-0.57	-10.31	-0.43	1.42e-22	Subjective well-being;
LGG	cis	rs4862750	0.872	rs1991254	chr4:187875375	T/G	cg03452623	chr4:187889614	NA	-1.04	-29.53	-0.81	1.58e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.23	-0.49	5.29e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs6693567	0.545	rs1260403	chr1:150303666	A/G	cg15654264	chr1:150340011	RPRD2	0.33	6.74	0.3	4.75e-11	Migraine;
LGG	cis	rs1420338	0.967	rs2192874	chr7:34144916	G/A	cg01275685	chr7:34179230	BMPER	-0.5	-9.32	-0.4	4.9e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs10908907	0.955	rs6559369	chr9:92258660	G/A	cg01515543	chr9:92254510	LOC100129066	0.43	7.9	0.34	2.07e-14	Alcoholism (heaviness of drinking);
LGG	trans	rs9291683	0.655	rs55941493	chr4:10100341	G/A	cg26043149	chr18:55253948	FECH	-0.47	-8.1	-0.35	5.01e-15	Bone mineral density;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg18402987	chr7:1209562	NA	0.39	7.04	0.31	7.03e-12	Longevity;Endometriosis;
LGG	trans	rs3808502	0.526	rs36048422	chr8:11417144	T/C	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.29	-0.4	6.04e-19	Neuroticism;
LGG	cis	rs72615157	0.645	rs11771660	chr7:99851269	T/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.68	-9.8	-0.41	9.96e-21	Lung function (FEV1/FVC);
LGG	cis	rs763014	0.966	rs15564	chr16:677854	G/T	cg09263875	chr16:632152	PIGQ	0.66	13.43	0.53	5.85e-35	Height;
LGG	cis	rs7011049	0.778	rs12375305	chr8:53869051	C/T	cg26025543	chr8:53854495	NA	0.62	8.73	0.38	4.65e-17	Systolic blood pressure;
LGG	cis	rs9911578	1.000	rs9892062	chr17:56976981	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.82	0.59	2.27e-45	Intelligence (multi-trait analysis);
LGG	cis	rs240764	0.817	rs11155606	chr6:101163915	T/C	cg09795085	chr6:101329169	ASCC3	-0.46	-7.67	-0.34	1.03e-13	Neuroticism;
LGG	trans	rs9467711	0.606	rs9379899	chr6:26603015	T/A	cg08344181	chr3:125677491	NA	-0.58	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2014572	0.967	rs8106734	chr19:57763546	C/T	cg24459738	chr19:57751996	ZNF805	-0.37	-7.14	-0.31	3.6e-12	Hyperactive-impulsive symptoms;
LGG	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg24189917	chr7:1970923	MAD1L1	-0.49	-7.33	-0.32	1.04e-12	Bipolar disorder;
LGG	cis	rs17767392	0.836	rs2332640	chr14:72044547	C/T	cg13720639	chr14:72061746	SIPA1L1	0.38	8.34	0.36	8.76e-16	Mitral valve prolapse;
LGG	cis	rs9916302	0.861	rs4795376	chr17:37669043	T/C	cg00129232	chr17:37814104	STARD3	-0.6	-11.12	-0.46	1.27e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs9911578	0.692	rs412000	chr17:56709058	G/C	cg12560992	chr17:57184187	TRIM37	0.64	10.98	0.45	4.51e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.814	rs9894554	chr17:80073423	C/G	cg09264619	chr17:80180166	NA	0.35	6.92	0.31	1.46e-11	Life satisfaction;
LGG	cis	rs6815814	0.768	rs2013740	chr4:38891737	A/G	cg06935464	chr4:38784597	TLR10	0.49	7.56	0.33	2.25e-13	Breast cancer;
LGG	trans	rs12439619	0.693	rs9944185	chr15:82450268	G/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-6.71	-0.3	5.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs308971	0.611	rs387152	chr3:12076032	G/C	cg02700894	chr3:12045449	SYN2	0.49	7.06	0.31	5.95e-12	Fasting blood insulin (BMI interaction);
LGG	cis	rs7937612	0.931	rs7115714	chr11:120294861	G/A	cg24566217	chr11:120254723	ARHGEF12	-0.52	-12.17	-0.49	9.02e-30	Intraocular pressure;
LGG	cis	rs2013441	1.000	rs2189710	chr17:20078964	C/A	cg09818912	chr17:20140352	CYTSB	0.29	6.69	0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs867371	1.000	rs7173339	chr15:82467594	A/G	cg00614314	chr15:82944287	LOC80154	0.6	9.8	0.41	9.8e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs546131	1.000	rs546131	chr11:34851760	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.61	11.01	0.46	3.41e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs943466	1.000	rs11754690	chr6:33744157	G/A	cg07519485	chr6:33762594	MLN	0.57	11.55	0.47	2.8e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg19147804	chr7:1989927	MAD1L1	-0.62	-12.52	-0.5	3.48e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg02461776	chr11:598696	PHRF1	0.53	8.48	0.37	3.13e-16	Systemic lupus erythematosus;
LGG	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg26513180	chr16:89883248	FANCA	0.94	21.12	0.7	7.5e-70	Vitiligo;
LGG	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-12.64	-0.51	1.09e-31	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg21782813	chr7:2030301	MAD1L1	0.48	11.6	0.47	1.79e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.21	-0.39	1.14e-18	Triglycerides;
LGG	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg24675658	chr1:53192096	ZYG11B	0.66	13.8	0.54	1.61e-36	Monocyte count;
LGG	cis	rs1570884	0.536	rs1359541	chr13:50158939	A/G	cg08779649	chr13:50194554	NA	0.36	9.17	0.39	1.58e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06850241	chr22:41845214	NA	0.44	7.12	0.31	4.12e-12	Cannabis dependence symptom count;
LGG	cis	rs9644630	0.504	rs62496181	chr8:19318989	A/T	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.84	-0.42	7.06e-21	Oropharynx cancer;
LGG	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg08305652	chr11:111469057	NA	-0.36	-7.45	-0.33	4.61e-13	Primary sclerosing cholangitis;
LGG	cis	rs9858542	0.537	rs9864406	chr3:49352619	A/G	cg00383909	chr3:49044727	WDR6	0.56	8.05	0.35	6.94e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12724450	0.793	rs7546610	chr1:150367569	G/A	cg03818307	chr1:150480534	ECM1	0.49	7.15	0.32	3.51e-12	Blood protein levels;
LGG	cis	rs427394	0.659	rs274717	chr5:6721067	C/T	cg15145174	chr5:6755386	POLS	0.43	7.96	0.35	1.3e-14	Menopause (age at onset);
LGG	cis	rs17376456	0.877	rs17083462	chr5:93462401	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.45	0.4	1.63e-19	Diabetic retinopathy;
LGG	cis	rs7786808	0.505	rs67537656	chr7:158192646	C/T	cg09998033	chr7:158218633	PTPRN2	0.46	8.23	0.36	1.98e-15	Obesity-related traits;
LGG	trans	rs853679	0.607	rs72854513	chr6:28265954	A/T	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	cis	rs1153858	1.000	rs2467858	chr15:45711492	A/G	cg26924012	chr15:45694286	SPATA5L1	1.03	20.47	0.69	8.4e-67	Homoarginine levels;
LGG	cis	rs3749237	0.964	rs13084243	chr3:49821878	G/C	cg07636037	chr3:49044803	WDR6	0.46	7.04	0.31	7.11e-12	Resting heart rate;
LGG	cis	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg07460842	chr6:66804631	NA	0.72	12.06	0.49	2.63e-29	Type 2 diabetes;
LGG	cis	rs2742417	0.967	rs2742441	chr3:45748429	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg02574844	chr11:5959923	NA	-0.59	-9.07	-0.39	3.29e-18	DNA methylation (variation);
LGG	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg10621924	chr7:39171070	POU6F2	0.48	10.06	0.42	1.15e-21	IgG glycosylation;
LGG	trans	rs7923837	0.687	rs10882101	chr10:94462427	T/C	cg27639046	chr2:171608303	NA	-0.35	-7.04	-0.31	7.2e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs5771225	0.563	rs5771281	chr22:50693479	A/G	cg08875078	chr22:50639485	SELO	0.47	6.95	0.31	1.22e-11	Late-onset Alzheimer's disease;
LGG	cis	rs7618915	0.501	rs6617	chr3:52740182	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.33	0.47	1.94e-26	Bipolar disorder;
LGG	cis	rs9486719	1.000	rs926276	chr6:96868735	C/T	cg18709589	chr6:96969512	KIAA0776	0.44	6.84	0.3	2.44e-11	Migraine;Coronary artery disease;
LGG	cis	rs1348850	0.526	rs4144278	chr2:178412378	C/T	cg27490568	chr2:178487706	NA	0.86	14.98	0.57	1.18e-41	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg07796016	chr1:152779584	LCE1C	0.47	7.38	0.32	7.21e-13	Inflammatory skin disease;
LGG	cis	rs10267417	0.603	rs1557773	chr7:19908586	A/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-7.78	-0.34	4.69e-14	Night sleep phenotypes;
LGG	cis	rs4662945	0.603	rs13002385	chr2:130276865	T/C	cg05962382	chr2:130345044	NA	-0.47	-8.05	-0.35	7e-15	Response to cytidine analogues (gemcitabine);
LGG	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg18681998	chr4:17616180	MED28	0.86	19.69	0.68	3.72e-63	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4631830	0.832	rs2843554	chr10:51523861	G/T	cg10326726	chr10:51549505	MSMB	-0.69	-14.54	-0.56	1.01e-39	Prostate-specific antigen levels;
LGG	cis	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg19399532	chr1:178512495	C1orf220	-0.54	-10.77	-0.45	2.78e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg05665937	chr4:1216051	CTBP1	0.38	6.91	0.31	1.57e-11	Longevity;
LGG	trans	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg21775007	chr8:11205619	TDH	0.46	7.58	0.33	1.95e-13	Mood instability;
LGG	cis	rs2273669	0.667	rs12215381	chr6:109363217	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs6456156	0.819	rs7765739	chr6:167518472	C/T	cg07741184	chr6:167504864	NA	0.41	9.05	0.39	3.92e-18	Primary biliary cholangitis;
LGG	cis	rs2227564	0.533	rs3870402	chr10:75473787	A/C	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.7	-0.41	2.25e-20	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1847505	0.562	rs3861177	chr13:61446605	T/C	cg25164009	chr13:61490935	NA	0.57	9.78	0.41	1.2e-20	Polychlorinated biphenyl levels;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg00405596	chr8:11794950	NA	-0.45	-7.56	-0.33	2.12e-13	Neuroticism;
LGG	trans	rs11039798	0.588	rs11039807	chr11:48549391	T/A	cg03929089	chr4:120376271	NA	0.69	9.48	0.4	1.34e-19	Axial length;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg10207240	chr12:122356781	WDR66	0.28	8.34	0.36	8.48e-16	Mean corpuscular volume;
LGG	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg04034577	chr2:241836375	C2orf54	-0.48	-10.18	-0.43	4.15e-22	Urinary metabolites;
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg16141378	chr3:129829833	LOC729375	0.4	8.97	0.38	7.18e-18	Neuroticism;
LGG	cis	rs11690935	0.959	rs7597387	chr2:172577116	T/C	cg21435375	chr2:172878103	MAP1D	-0.3	-6.85	-0.3	2.43e-11	Schizophrenia;
LGG	cis	rs1862618	0.511	rs2591952	chr5:56120769	T/A	cg17809284	chr5:56205270	C5orf35	-0.52	-8.49	-0.37	2.87e-16	Initial pursuit acceleration;
LGG	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg13877915	chr19:58951672	ZNF132	1.0	26.76	0.78	5.19e-96	Uric acid clearance;
LGG	trans	rs7615952	1.000	rs7615952	chr3:125649403	A/C	cg07211511	chr3:129823064	LOC729375	1.33	21.14	0.7	6.16e-70	Blood pressure (smoking interaction);
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg05025164	chr4:1340916	KIAA1530	0.86	17.01	0.62	9.7e-51	Longevity;
LGG	trans	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg27411982	chr8:10470053	RP1L1	-0.42	-7.36	-0.32	8.28e-13	Mood instability;
LGG	cis	rs13098911	0.540	rs13074382	chr3:46061840	A/G	cg12691230	chr3:46064611	XCR1	-0.49	-6.82	-0.3	2.84e-11	Celiac disease;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg16507663	chr6:150244633	RAET1G	0.41	7.58	0.33	1.93e-13	Lung cancer;
LGG	cis	rs9314323	0.767	rs13271042	chr8:26190212	T/G	cg11498726	chr8:26250323	BNIP3L	-0.52	-10.6	-0.44	1.19e-23	Red cell distribution width;
LGG	cis	rs6087990	0.735	rs6119946	chr20:31329704	A/G	cg13636640	chr20:31349939	DNMT3B	-0.86	-17.62	-0.63	1.57e-53	Ulcerative colitis;
LGG	trans	rs1493916	0.748	rs4799355	chr18:31313124	G/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.55	-0.47	2.72e-27	Life satisfaction;
LGG	cis	rs910316	0.783	rs11850751	chr14:75590113	A/T	cg06637938	chr14:75390232	RPS6KL1	0.57	10.53	0.44	2.17e-23	Height;
LGG	cis	rs3768617	0.510	rs12091137	chr1:183075732	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Fuchs's corneal dystrophy;
LGG	trans	rs9914544	0.505	rs7503678	chr17:18776020	A/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs340849	0.740	rs6540809	chr1:214118343	G/A	cg05052969	chr1:214156842	NA	0.37	6.7	0.3	6.19e-11	Alzheimer's disease;
LGG	cis	rs9911578	1.000	rs2055779	chr17:57030561	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.77	0.59	3.88e-45	Intelligence (multi-trait analysis);
LGG	cis	rs755249	0.501	rs4660669	chr1:39807458	A/C	cg18385671	chr1:39797026	MACF1	-0.49	-9.77	-0.41	1.26e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1107366	0.722	rs9862438	chr3:125910381	C/T	cg01346077	chr3:125931526	NA	0.42	10.15	0.43	5.33e-22	Metabolite levels;
LGG	cis	rs765787	0.530	rs4774550	chr15:45542312	C/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	cis	rs701145	0.585	rs447429	chr3:153909946	T/C	cg12800244	chr3:153838788	SGEF	0.83	8.38	0.36	6.39e-16	Coronary artery disease;
LGG	trans	rs9467711	0.591	rs56195001	chr6:25976165	C/T	cg06606381	chr12:133084897	FBRSL1	-0.74	-7.17	-0.32	2.94e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg17554472	chr22:41940697	POLR3H	-0.46	-6.73	-0.3	4.98e-11	Vitiligo;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.58	-0.33	1.85e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs986417	0.748	rs10142927	chr14:61041956	A/G	cg27398547	chr14:60952738	C14orf39	0.65	6.86	0.3	2.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2730245	0.527	rs712197	chr7:158660846	C/G	cg24397884	chr7:158709396	WDR60	1.08	15.97	0.6	4.76e-46	Height;
LGG	cis	rs35306767	0.953	rs12354639	chr10:963681	G/A	cg08847335	chr10:891726	LARP4B	-0.36	-6.99	-0.31	9.44e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.06	-0.35	6.54e-15	Response to antipsychotic treatment;
LGG	cis	rs4538187	0.804	rs36123537	chr2:64217490	G/A	cg14150252	chr2:64069583	UGP2	-0.48	-9.52	-0.4	9.85e-20	Systolic blood pressure;
LGG	cis	rs1451375	1.000	rs1451375	chr7:50622712	A/C	cg20336341	chr7:50628841	DDC	-0.37	-7.23	-0.32	2.04e-12	Malaria;
LGG	cis	rs7107174	1.000	rs10899483	chr11:78061057	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg19223190	chr17:80058835	NA	-0.43	-8.39	-0.36	5.94e-16	Life satisfaction;
LGG	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs7824557	0.737	rs2293855	chr8:11177410	G/A	cg15596359	chr8:11213517	TDH	-0.33	-6.8	-0.3	3.33e-11	Retinal vascular caliber;
LGG	cis	rs8048589	0.660	rs11075054	chr16:12216295	C/A	cg02910054	chr16:12241554	SNX29	0.55	8.46	0.37	3.59e-16	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	trans	rs5756813	0.705	rs6000886	chr22:38176670	T/C	cg19894588	chr14:64061835	NA	0.63	10.24	0.43	2.46e-22	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.31e-14	Lung cancer;
LGG	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg04240660	chr16:89714849	CHMP1A	-0.38	-6.75	-0.3	4.43e-11	Hemoglobin concentration;
LGG	cis	rs7223966	1.000	rs8077265	chr17:61732727	A/G	cg11494091	chr17:61959527	GH2	0.56	9.12	0.39	2.38e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3820068	0.581	rs72645871	chr1:15926142	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg05425664	chr17:57184151	TRIM37	-0.68	-11.18	-0.46	7.36e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.681	rs511673	chr15:43618863	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.67	0.54	5.85e-36	Lung cancer in ever smokers;
LGG	cis	rs4555082	0.834	rs2735819	chr14:105713449	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-16.04	-0.6	2.33e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg18657643	chr3:195545456	NA	0.51	7.49	0.33	3.44e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs657075	0.697	rs3805676	chr5:131668467	G/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	trans	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.22	-0.39	1.06e-18	Neuroticism;
LGG	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg15268244	chr15:77196840	NA	0.4	8.78	0.38	3.25e-17	Blood metabolite levels;
LGG	cis	rs1153858	0.621	rs1706824	chr15:45579948	C/T	cg26924012	chr15:45694286	SPATA5L1	0.91	16.49	0.61	2.06e-48	Homoarginine levels;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	1.000	rs9989967	chr3:134238964	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.39	-0.53	8.23e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs151997	0.853	rs6882235	chr5:50260139	T/C	cg06027927	chr5:50259733	NA	0.66	11.28	0.46	2.99e-26	Callous-unemotional behaviour;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.19	-0.32	2.6e-12	Bipolar disorder;
LGG	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg04346459	chr6:41068666	NFYA;LOC221442	-0.41	-7.34	-0.32	9.89e-13	Alzheimer's disease (late onset);
LGG	cis	rs4713118	0.513	rs149942	chr6:28001610	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.46	-6.76	-0.3	4.24e-11	Parkinson's disease;
LGG	cis	rs6952808	0.692	rs10950473	chr7:1999453	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.58	-0.47	2.01e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs12765878	0.564	rs2073338	chr10:105642803	A/C	cg11005552	chr10:105648138	OBFC1	-0.73	-12.75	-0.51	4.01e-32	Coronary artery disease;
LGG	trans	rs9329221	0.617	rs483916	chr8:9793601	A/C	cg02002194	chr4:3960332	NA	0.45	8.5	0.37	2.59e-16	Neuroticism;
LGG	cis	rs7937682	0.889	rs10789844	chr11:111579109	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.17	-27.39	-0.79	6.66e-99	Primary sclerosing cholangitis;
LGG	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg09163369	chr1:210001066	C1orf107	0.39	7.01	0.31	8.38e-12	Orofacial clefts;
LGG	trans	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg06521331	chr12:34319734	NA	0.43	7.35	0.32	9.02e-13	Morning vs. evening chronotype;
LGG	cis	rs6748734	0.947	rs6752787	chr2:241840647	G/A	cg04034577	chr2:241836375	C2orf54	-0.51	-10.29	-0.43	1.62e-22	Urinary metabolites;
LGG	cis	rs11920090	0.720	rs73169739	chr3:170750018	T/C	cg09710316	chr3:170744871	SLC2A2	0.71	8.48	0.37	2.95e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs35306767	0.855	rs12770190	chr10:951262	C/T	cg20503657	chr10:835505	NA	0.71	9.08	0.39	3.03e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs3812831	0.630	rs9562129	chr13:114917152	A/G	cg06611532	chr13:114900021	NA	0.29	7.15	0.32	3.31e-12	Schizophrenia;
LGG	cis	rs7208859	0.623	rs9915546	chr17:29132144	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7192750	0.562	rs9921412	chr16:71988106	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.29e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs1465370	0.720	rs7811462	chr7:130017487	G/A	cg06917763	chr7:130033247	NA	0.33	7.23	0.32	2.02e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04592976	chr16:89984572	MC1R	0.42	6.93	0.31	1.45e-11	Cognitive performance;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.72	-0.3	5.44e-11	Menopause (age at onset);
LGG	cis	rs8018808	1.000	rs4899652	chr14:77848972	A/G	cg20045696	chr14:77926864	AHSA1	-0.41	-6.91	-0.31	1.64e-11	Myeloid white cell count;
LGG	cis	rs8025790	0.508	rs35930676	chr15:67827705	G/A	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.64	-0.33	1.25e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.36	-6.79	-0.3	3.37e-11	Schizophrenia;
LGG	cis	rs7568458	0.684	rs7608074	chr2:85809703	T/G	cg17127132	chr2:85788382	GGCX	0.52	8.3	0.36	1.16e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.18e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1801251	0.896	rs921054	chr2:233694673	G/A	cg08000102	chr2:233561755	GIGYF2	-0.5	-8.17	-0.35	2.98e-15	Coronary artery disease;
LGG	trans	rs1814175	0.645	rs28538913	chr11:50040718	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs2587949	0.638	rs2686699	chr3:4194174	G/A	cg16519197	chr3:4211558	NA	-0.35	-7.44	-0.33	4.85e-13	Periodontitis (DPAL);
LGG	cis	rs10751667	0.643	rs7394524	chr11:933865	T/C	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs701145	0.537	rs449361	chr3:153922410	T/C	cg17054900	chr3:154042577	DHX36	0.9	10.22	0.43	3.15e-22	Coronary artery disease;
LGG	cis	rs11711311	1.000	rs16861312	chr3:113492402	G/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.51e-13	IgG glycosylation;
LGG	cis	rs9354308	0.753	rs10455590	chr6:66598194	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.82	-0.3	2.84e-11	Metabolite levels;
LGG	cis	rs2404602	0.684	rs28895952	chr15:76856776	A/G	cg15268244	chr15:77196840	NA	0.48	10.23	0.43	2.88e-22	Blood metabolite levels;
LGG	cis	rs2692947	0.711	rs34639392	chr2:96508976	T/C	cg22654517	chr2:96458247	NA	0.36	7.6	0.33	1.65e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.34	-8.16	-0.35	3.16e-15	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7647973	0.961	rs6778080	chr3:49317338	C/T	cg06212747	chr3:49208901	KLHDC8B	-0.48	-7.51	-0.33	2.99e-13	Menarche (age at onset);
LGG	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg01657329	chr11:68192670	LRP5	-0.5	-8.58	-0.37	1.46e-16	Total body bone mineral density;
LGG	trans	rs72991	0.672	rs297530	chr11:121243291	T/C	cg27192990	chr6:129479024	LAMA2	-0.57	-9.26	-0.4	7.7e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7107174	0.892	rs2510038	chr11:77966034	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.4	-0.33	6.44e-13	Testicular germ cell tumor;
LGG	cis	rs13082711	0.911	rs3736312	chr3:27442336	G/A	cg02860705	chr3:27208620	NA	0.76	14.06	0.55	1.25e-37	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3096299	0.685	rs12446145	chr16:89542695	C/T	cg08392591	chr16:89556376	ANKRD11	0.61	9.77	0.41	1.31e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg27587195	chr5:112824172	MCC	-0.45	-7.21	-0.32	2.34e-12	Type 2 diabetes;
LGG	cis	rs7635838	0.617	rs184700	chr3:11293061	A/G	cg00170343	chr3:11313890	ATG7	0.48	8.17	0.36	2.9e-15	HDL cholesterol;
LGG	trans	rs7647973	0.587	rs10452032	chr3:49680973	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg00290607	chr11:67383545	NA	-0.5	-8.99	-0.39	6.5e-18	Mean corpuscular volume;
LGG	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.95	0.6	5.8e-46	Lymphocyte percentage of white cells;
LGG	cis	rs7666738	0.893	rs11729640	chr4:99052699	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2832077	0.527	rs2738953	chr21:30238363	G/C	cg03476357	chr21:30257390	N6AMT1	0.46	7.91	0.35	1.91e-14	Cognitive test performance;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.625	rs73178625	chr22:41928320	G/C	cg17554472	chr22:41940697	POLR3H	-0.5	-7.23	-0.32	2.03e-12	Vitiligo;
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg12463550	chr7:65579703	CRCP	-0.51	-8.4	-0.36	5.6e-16	Aortic root size;
LGG	cis	rs1065852	0.906	rs9611734	chr22:42502070	A/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	8.23	0.36	1.87e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs5758511	0.817	rs133291	chr22:42269628	C/T	cg15128208	chr22:42549153	NA	0.52	8.57	0.37	1.59e-16	Birth weight;
LGG	cis	rs1580019	0.844	rs1584615	chr7:32503258	G/C	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.77	0.59	3.88e-45	Cognitive ability;
LGG	cis	rs56283067	0.847	rs60328783	chr6:44693099	C/G	cg20913747	chr6:44695427	NA	-0.67	-12.0	-0.49	4.3e-29	Total body bone mineral density;
LGG	cis	rs9399137	0.507	rs11759077	chr6:135381351	A/G	cg22676075	chr6:135203613	NA	0.4	6.96	0.31	1.16e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	trans	rs75804782	0.641	rs11885523	chr2:239344263	G/A	cg01134436	chr17:81009848	B3GNTL1	0.84	8.82	0.38	2.31e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg18379455	chr17:41446167	NA	-0.33	-7.53	-0.33	2.7e-13	Menopause (age at onset);
LGG	cis	rs2280630	0.505	rs2249736	chr3:39195462	G/T	cg23654821	chr3:39188656	CSRNP1	-0.29	-8.49	-0.37	2.87e-16	Verbal declarative memory;
LGG	trans	rs72766638	0.895	rs72766630	chr9:136926791	G/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.56	-7.53	-0.33	2.74e-13	Mosquito bite size;
LGG	cis	rs875971	0.545	rs7810213	chr7:65946579	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	trans	rs11989744	0.957	rs57291069	chr8:23570211	G/T	cg03492747	chr16:86543808	FOXF1	0.52	7.82	0.34	3.52e-14	Waist-hip ratio;
LGG	cis	rs9467711	0.591	rs34791189	chr6:26035806	G/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.63	0.33	1.32e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg15627072	chr1:2432621	PLCH2	0.42	10.31	0.43	1.45e-22	Ulcerative colitis;
LGG	cis	rs10484885	0.775	rs17584945	chr6:90512776	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.85	-10.78	-0.45	2.5300000000000002e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs703842	0.616	rs10877023	chr12:58224199	C/A	cg00677455	chr12:58241039	CTDSP2	0.44	8.14	0.35	3.77e-15	Multiple sclerosis;
LGG	trans	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.82	-0.34	3.7e-14	Retinal vascular caliber;
LGG	cis	rs12230513	0.732	rs4130004	chr12:55860773	G/T	cg19537932	chr12:55886519	OR6C68	-0.61	-10.99	-0.45	3.97e-25	Contrast sensitivity;
LGG	cis	rs9296092	0.538	rs9469487	chr6:33516943	G/T	cg13560919	chr6:33536144	NA	-1.05	-21.55	-0.71	7.71e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs72945132	0.882	rs3781648	chr11:70190058	T/C	cg14191688	chr11:70257035	CTTN	0.56	8.14	0.35	3.82e-15	Coronary artery disease;
LGG	cis	rs9398803	0.723	rs853971	chr6:127066190	T/C	cg19875578	chr6:126661172	C6orf173	-0.5	-9.19	-0.39	1.34e-18	Male-pattern baldness;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg16507663	chr6:150244633	RAET1G	0.47	8.89	0.38	1.36e-17	Lung cancer;
LGG	cis	rs9814567	0.964	rs6772406	chr3:134210183	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.3	-0.53	2.07e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg17211192	chr8:82754475	SNX16	-0.74	-11.56	-0.47	2.39e-27	Diastolic blood pressure;
LGG	cis	rs3735485	0.800	rs4724343	chr7:45052133	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg12654349	chr5:56205094	C5orf35	-0.53	-8.86	-0.38	1.7e-17	Coronary artery disease;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg13395646	chr4:1353034	KIAA1530	-0.52	-9.03	-0.39	4.47e-18	Obesity-related traits;
LGG	trans	rs7829975	0.572	rs28730413	chr8:8795447	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.35	-0.32	9.06e-13	Mood instability;
LGG	cis	rs283228	0.724	rs2256350	chr6:101779244	T/G	cg27451362	chr6:101846650	GRIK2	0.63	10.43	0.44	5.01e-23	Coenzyme Q10 levels;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg17554472	chr22:41940697	POLR3H	-0.5	-6.95	-0.31	1.23e-11	Vitiligo;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg05868516	chr6:26286170	HIST1H4H	0.46	7.89	0.34	2.17e-14	Educational attainment;
LGG	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11644478	chr21:40555479	PSMG1	0.9	16.77	0.61	1.21e-49	Cognitive function;
LGG	cis	rs637571	0.544	rs56239996	chr11:65730003	A/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.74	-0.38	4.32e-17	Eosinophil percentage of white cells;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg13206674	chr6:150067644	NUP43	0.68	16.02	0.6	2.83e-46	Lung cancer;
LGG	cis	rs35306767	0.855	rs61830900	chr10:871481	C/G	cg25019033	chr10:957182	NA	-0.53	-9.07	-0.39	3.44e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs6142618	0.562	rs2235901	chr20:30720036	G/A	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18005807	chr22:18506799	MICAL3	0.54	8.61	0.37	1.17e-16	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.56	-7.61	-0.33	1.5700000000000001e-13	Diabetic retinopathy;
LGG	cis	rs62238980	0.614	rs17683471	chr22:32487815	C/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs6696846	0.765	rs4394715	chr1:205108393	T/G	cg21545522	chr1:205238299	TMCC2	0.38	7.21	0.32	2.3e-12	Red blood cell count;
LGG	cis	rs7267979	0.966	rs2387882	chr20:25378802	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg18252515	chr7:66147081	NA	-0.44	-7.67	-0.34	1.04e-13	Aortic root size;
LGG	cis	rs61524473	1	rs61524473	chr15:45646283	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Metabolite levels (small molecules and protein measures);
LGG	cis	rs2644899	0.793	rs2644916	chr19:41309211	A/G	cg24958765	chr19:41283667	RAB4B	-0.51	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs67460515	0.892	rs1382429	chr3:161015153	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-9.89	-0.42	4.76e-21	Parkinson's disease;
LGG	trans	rs970548	0.697	rs11239540	chr10:45999209	T/C	cg20477318	chr10:51623047	TIMM23	0.7	8.02	0.35	8.62e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg02733842	chr7:1102375	C7orf50	0.54	9.59	0.41	5.43e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8067545	0.641	rs2108978	chr17:19861458	C/T	cg04132472	chr17:19861366	AKAP10	0.26	7.24	0.32	1.83e-12	Schizophrenia;
LGG	cis	rs4566357	0.615	rs3769642	chr2:227917323	T/C	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.06	-0.39	3.56e-18	Coronary artery disease;
LGG	cis	rs11150038	0.590	rs17705051	chr16:78023306	A/G	cg04733911	chr16:78082701	NA	-0.7	-7.1	-0.31	4.84e-12	Colorectal or endometrial cancer;
LGG	cis	rs12618769	0.597	rs2309390	chr2:99114310	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs1451375	0.583	rs11575320	chr7:50605298	A/G	cg14593290	chr7:50529359	DDC	-0.64	-11.51	-0.47	3.95e-27	Malaria;
LGG	trans	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg21659725	chr3:3221576	CRBN	-0.58	-10.01	-0.42	1.68e-21	Body mass index;
LGG	cis	rs13108904	0.967	rs13109112	chr4:1290481	C/A	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.46	7.92	0.35	1.81e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs7226408	0.600	rs9789231	chr18:34532038	C/T	cg15022739	chr18:34823045	BRUNOL4	0.42	8.93	0.38	9.88e-18	Obesity-related traits;
LGG	cis	rs10931896	0.531	rs296801	chr2:201142812	C/T	cg17644776	chr2:200775616	C2orf69	0.48	8.14	0.35	3.75e-15	Systolic blood pressure;
LGG	cis	rs2201728	0.714	rs35979317	chr4:100150217	A/G	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	cis	rs7552404	0.727	rs61770533	chr1:76306490	C/G	cg22875332	chr1:76189707	ACADM	0.57	8.63	0.37	9.7e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11971779	0.555	rs4728466	chr7:139096365	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs7927771	0.524	rs10838740	chr11:47679980	A/G	cg20307385	chr11:47447363	PSMC3	0.56	10.73	0.45	3.91e-24	Subjective well-being;
LGG	cis	rs657075	0.640	rs13180186	chr5:131705558	G/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.71	0.3	5.71e-11	Rheumatoid arthritis;
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.13	0.43	6.55e-22	Prudent dietary pattern;
LGG	cis	rs7954584	0.626	rs10840637	chr12:122427310	A/G	cg22618164	chr12:122356400	WDR66	0.37	10.56	0.44	1.62e-23	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04432377	chr3:45017297	EXOSC7;ZDHHC3	0.48	7.68	0.34	9.64e-14	Gut microbiome composition (summer);
LGG	cis	rs2304069	0.954	rs4705409	chr5:149414899	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.88	13.55	0.53	1.86e-35	HIV-1 control;
LGG	cis	rs2228479	0.850	rs12596934	chr16:89841605	T/G	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	trans	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg24247370	chr13:99142703	STK24	-0.38	-7.07	-0.31	5.64e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2274273	0.870	rs3783650	chr14:55848972	A/C	cg04306507	chr14:55594613	LGALS3	0.63	17.87	0.64	1.01e-54	Protein biomarker;
LGG	cis	rs7546	0.504	rs2015319	chr16:4936280	C/G	cg08329684	chr16:4932620	PPL	-0.57	-12.61	-0.51	1.58e-31	Cancer;
LGG	cis	rs889398	0.742	rs12446197	chr16:69854869	A/G	cg00738113	chr16:70207722	CLEC18C	0.24	6.76	0.3	4.11e-11	Body mass index;
LGG	cis	rs7666738	0.830	rs7687315	chr4:98900613	A/G	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.04e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4728302	0.643	rs6966335	chr7:133702217	C/T	cg10665199	chr7:133106180	EXOC4	0.4	6.96	0.31	1.16e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.54	-8.95	-0.38	8.8e-18	Response to antipsychotic treatment;
LGG	cis	rs4799461	0.580	rs7506595	chr18:35189856	G/A	cg27332583	chr18:35150602	NA	0.54	8.28	0.36	1.33e-15	Neuroticism;
LGG	cis	rs5762813	0.560	rs5762823	chr22:29220758	C/G	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs10744422	0.925	rs2880678	chr12:123317099	C/T	cg25930673	chr12:123319894	HIP1R	-0.71	-9.08	-0.39	3.14e-18	Schizophrenia;
LGG	trans	rs7395662	0.687	rs11602892	chr11:48959152	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.87	-0.3	2.03e-11	HDL cholesterol;
LGG	cis	rs4665809	1.000	rs6739061	chr2:26256147	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.53e-33	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg25517755	chr10:38738941	LOC399744	0.35	6.66	0.3	7.86e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs6601327	0.606	rs9644707	chr8:9590116	A/T	cg02002194	chr4:3960332	NA	0.38	6.98	0.31	1e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3020736	0.500	rs4147641	chr22:42482502	C/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs61931739	0.500	rs10772160	chr12:34456848	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs2274273	0.870	rs8023197	chr14:55767395	G/T	cg04306507	chr14:55594613	LGALS3	0.64	18.19	0.65	3.52e-56	Protein biomarker;
LGG	cis	rs7928758	0.943	rs7948031	chr11:134269091	T/C	cg22777979	chr11:134283252	B3GAT1	0.93	12.27	0.5	3.68e-30	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7980799	0.653	rs1384598	chr12:33622899	T/A	cg06521331	chr12:34319734	NA	0.41	6.93	0.31	1.46e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs9783347	0.621	rs10766469	chr11:18323316	G/C	cg15585147	chr11:18324498	HPS5	0.31	6.99	0.31	9.66e-12	Pancreatic cancer;
LGG	cis	rs3096299	0.591	rs748940	chr16:89440757	T/A	cg08822215	chr16:89438651	ANKRD11	-0.41	-7.79	-0.34	4.47e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs7937682	0.924	rs489783	chr11:111520522	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs17604090	0.628	rs875263	chr7:29711066	T/C	cg12658982	chr7:29603541	PRR15	-0.4	-8.46	-0.37	3.54e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs3733585	0.699	rs6449176	chr4:9967843	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs55728055	0.661	rs62239172	chr22:32047941	G/A	cg01338084	chr22:32026380	PISD	1.51	12.81	0.51	2.35e-32	Age-related hearing impairment;
LGG	cis	rs10782582	0.532	rs12132503	chr1:76137762	C/G	cg03433033	chr1:76189801	ACADM	-0.44	-7.05	-0.31	6.49e-12	Daytime sleep phenotypes;
LGG	cis	rs208520	0.837	rs208498	chr6:66931560	G/A	cg07460842	chr6:66804631	NA	-0.9	-15.57	-0.59	2.94e-44	Exhaled nitric oxide output;
LGG	cis	rs9859260	0.701	rs9872347	chr3:195831237	T/C	cg03462622	chr3:195777018	TFRC	0.33	6.89	0.3	1.85e-11	Mean corpuscular volume;
LGG	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg14784868	chr12:69753453	YEATS4	0.66	11.83	0.48	2.12e-28	Response to diuretic therapy;
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg14092988	chr3:52407081	DNAH1	0.31	8.06	0.35	6.51e-15	Bipolar disorder;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg05861140	chr6:150128134	PCMT1	-0.31	-7.05	-0.31	6.61e-12	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg11494091	chr17:61959527	GH2	0.56	9.1	0.39	2.67e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg19168338	chr16:4465731	CORO7	-0.93	-18.01	-0.64	2.41e-55	Schizophrenia;
LGG	cis	rs1552244	0.935	rs41520445	chr3:10153141	A/C	cg00149659	chr3:10157352	C3orf10	-0.88	-11.31	-0.47	2.37e-26	Alzheimer's disease;
LGG	trans	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg12575136	chr18:32820987	ZNF397	0.47	8.68	0.37	6.96e-17	White blood cell count;
LGG	cis	rs12210905	1.000	rs1102557	chr6:27149794	C/A	cg23155468	chr6:27110703	HIST1H2BK	0.66	7.73	0.34	6.94e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9660992	0.512	rs12123773	chr1:205122420	C/G	cg21545522	chr1:205238299	TMCC2	0.37	7.0	0.31	8.8e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.31	0.63	3.81e-52	Intelligence (multi-trait analysis);
LGG	cis	rs12731740	0.908	rs7512286	chr1:207993102	A/G	cg22525895	chr1:207977042	MIR29B2	-0.64	-7.4	-0.33	6.56e-13	Biomedical quantitative traits;
LGG	trans	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg11693508	chr17:37793320	STARD3	0.6	8.41	0.36	5.08e-16	Bipolar disorder;
LGG	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg03060546	chr3:49711283	APEH	-0.63	-10.32	-0.43	1.35e-22	Educational attainment;
LGG	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg01191920	chr7:158217561	PTPRN2	-0.77	-17.78	-0.64	2.61e-54	Obesity-related traits;
LGG	cis	rs3936840	0.964	rs10150698	chr14:102977876	A/G	cg18135206	chr14:102964638	TECPR2	0.47	8.32	0.36	9.91e-16	Plateletcrit;
LGG	cis	rs908922	0.651	rs4845444	chr1:152530125	G/A	cg03606772	chr1:152487856	CRCT1	0.31	7.29	0.32	1.34e-12	Hair morphology;
LGG	cis	rs2762353	0.776	rs1165178	chr6:25827516	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs7444	0.941	rs140491	chr22:21922364	T/C	cg15846791	chr22:21984385	YDJC	-0.45	-6.95	-0.31	1.23e-11	Systemic lupus erythematosus;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11316940	chr10:69524027	NA	0.44	6.98	0.31	1.01e-11	Cognitive performance;
LGG	cis	rs6752107	1.000	rs10165561	chr2:234172915	G/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	8.0	0.35	1.04e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4740619	0.716	rs1970497	chr9:15776169	T/A	cg14451791	chr9:16040625	NA	0.35	8.88	0.38	1.49e-17	Body mass index;
LGG	trans	rs12579753	1.000	rs11519754	chr12:82209181	A/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	trans	rs35110281	0.667	rs2070533	chr21:45122753	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.97	0.42	2.36e-21	Mean corpuscular volume;
LGG	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg18478394	chr8:109455254	TTC35	0.41	8.1	0.35	4.75e-15	Dupuytren's disease;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.8	0.38	2.83e-17	Lung cancer;
LGG	cis	rs2404602	0.716	rs3866543	chr15:76629609	T/G	cg23625390	chr15:77176239	SCAPER	0.46	8.93	0.38	1.02e-17	Blood metabolite levels;
LGG	cis	rs9747201	1.000	rs55638685	chr17:80107566	G/C	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17808901	chr3:39093368	WDR48	0.53	8.85	0.38	1.91e-17	Gut microbiome composition (summer);
LGG	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg09021430	chr5:549028	NA	-0.69	-9.36	-0.4	3.59e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs344364	0.511	rs2982447	chr16:1947413	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	0.48	7.4	0.33	6.59e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg21475434	chr5:93447410	FAM172A	0.69	7.12	0.31	4.17e-12	Diabetic retinopathy;
LGG	cis	rs7246760	0.867	rs12461215	chr19:9782461	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg11301795	chr4:187892539	NA	-0.94	-24.88	-0.76	2.16e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1639906	0.965	rs1639908	chr7:2230644	C/G	cg20308403	chr7:2120281	MAD1L1	-0.35	-7.92	-0.35	1.82e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3008870	0.755	rs2755254	chr1:67470855	C/T	cg02640540	chr1:67518911	SLC35D1	0.38	7.55	0.33	2.3e-13	Lymphocyte percentage of white cells;
LGG	trans	rs11989744	0.956	rs35693687	chr8:23575746	A/G	cg03492747	chr16:86543808	FOXF1	0.51	7.74	0.34	6.5e-14	Waist-hip ratio;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg13939156	chr17:80058883	NA	0.49	9.65	0.41	3.29e-20	Life satisfaction;
LGG	cis	rs8017423	0.967	rs4904656	chr14:90721442	G/T	cg04374321	chr14:90722782	PSMC1	0.89	19.1	0.66	2.21e-60	Mortality in heart failure;
LGG	cis	rs4788570	0.538	rs72797713	chr16:71534208	G/A	cg06353428	chr16:71660113	MARVELD3	-1.0	-13.56	-0.53	1.66e-35	Intelligence (multi-trait analysis);
LGG	cis	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg27523141	chr10:43048294	ZNF37B	0.43	8.51	0.37	2.37e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1577917	0.883	rs12214536	chr6:86790310	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.75	-0.34	5.95e-14	Response to antipsychotic treatment;
LGG	cis	rs4891159	0.584	rs690397	chr18:74117767	C/T	cg24786174	chr18:74118243	ZNF516	0.68	17.2	0.62	1.24e-51	Longevity;
LGG	cis	rs208520	0.690	rs851468	chr6:66825875	G/A	cg07460842	chr6:66804631	NA	-0.98	-18.47	-0.65	1.75e-57	Exhaled nitric oxide output;
LGG	cis	rs17666538	0.636	rs62486234	chr8:589157	G/T	cg02524346	chr8:600233	NA	-0.94	-8.76	-0.38	3.76e-17	IgG glycosylation;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg08386886	chr17:41277274	BRCA1;NBR2	0.4	6.71	0.3	5.7e-11	Parkinson's disease (motor and cognition);
LGG	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg05692746	chr2:100937584	LONRF2	-0.59	-9.72	-0.41	1.83e-20	Intelligence (multi-trait analysis);
LGG	cis	rs994014	0.572	rs10021462	chr4:82271011	G/T	cg07938847	chr4:82126349	PRKG2	-0.28	-6.77	-0.3	3.87e-11	Height;
LGG	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.7e-18	Primary sclerosing cholangitis;
LGG	trans	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.57	-0.56	7.27e-40	Extrinsic epigenetic age acceleration;
LGG	cis	rs651907	0.557	rs12629658	chr3:101356535	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.42	0.53	6.5e-35	Colorectal cancer;
LGG	cis	rs77633900	0.614	rs280030	chr15:77026853	T/C	cg21673338	chr15:77095150	SCAPER	-0.67	-10.48	-0.44	3.23e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00166722	chr3:10149974	C3orf24	-0.52	-8.79	-0.38	2.86e-17	Alzheimer's disease;
LGG	cis	rs2153535	0.542	rs6905925	chr6:8440030	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	6.67e-18	Motion sickness;
LGG	cis	rs1862618	0.627	rs744023	chr5:56197078	C/T	cg12654349	chr5:56205094	C5orf35	-0.79	-11.44	-0.47	7.66e-27	Initial pursuit acceleration;
LGG	cis	rs6840360	0.642	rs11932398	chr4:152397554	T/G	cg17217059	chr4:152329364	FAM160A1	0.21	7.24	0.32	1.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.966	rs11953833	chr5:140155123	T/A	cg19875535	chr5:140030758	IK	0.51	10.68	0.44	6.06e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs360798	0.532	rs13013218	chr2:63011671	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-7.6	-0.33	1.62e-13	Coronary artery disease;
LGG	cis	rs4595586	0.525	rs7970652	chr12:39374873	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs9341835	0.518	rs6939983	chr6:64173216	C/T	cg00787780	chr6:64151745	NA	0.41	7.17	0.32	3.05e-12	Schizophrenia;
LGG	cis	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg05623727	chr3:50126028	RBM5	0.33	7.16	0.32	3.12e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.79	-0.48	3.11e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1014246	0.541	rs2011695	chr10:118507219	A/C	cg14919929	chr10:118506882	NA	-0.67	-14.02	-0.55	1.8e-37	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs727563	0.648	rs6002406	chr22:41965237	A/T	cg17376030	chr22:41985996	PMM1	0.66	10.27	0.43	1.94e-22	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11231629	1	rs11231629	chr11:63648573	C/T	cg18137308	chr11:63775436	MACROD1	0.38	8.85	0.38	1.89e-17	Schizophrenia;
LGG	cis	rs7551222	0.752	rs4252677	chr1:204495253	G/A	cg20240347	chr1:204465584	NA	-0.57	-11.45	-0.47	6.66e-27	Schizophrenia;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg19358568	chr6:129614126	LAMA2	0.61	6.76	0.3	4.26e-11	Airflow obstruction;
LGG	cis	rs514406	0.893	rs479569	chr1:53352407	C/T	cg24675658	chr1:53192096	ZYG11B	-0.47	-9.37	-0.4	3.25e-19	Monocyte count;
LGG	cis	rs8180040	0.966	rs13059519	chr3:47539969	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-15.36	-0.58	2.44e-43	Colorectal cancer;
LGG	cis	rs1534166	0.601	rs13324779	chr3:133510413	G/A	cg01448562	chr3:133502909	NA	0.41	6.97	0.31	1.11e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs10463316	0.779	rs6896444	chr5:150777357	T/G	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.64	-0.41	3.57e-20	Metabolite levels (Pyroglutamine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15943396	chr5:159436103	TTC1	0.47	6.78	0.3	3.68e-11	Gut microbiome composition (summer);
LGG	cis	rs12711979	0.509	rs13035992	chr2:3826597	G/A	cg17052675	chr2:3827356	NA	-0.5	-9.96	-0.42	2.71e-21	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.71	-0.34	7.5e-14	Initial pursuit acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg03031773	chr17:46970570	ATP5G1	0.42	6.81	0.3	2.98e-11	Cognitive performance;
LGG	trans	rs7829975	0.658	rs907181	chr8:8702875	T/C	cg02002194	chr4:3960332	NA	-0.38	-7.02	-0.31	8.04e-12	Mood instability;
LGG	cis	rs4430311	0.755	rs12138722	chr1:243802639	T/A	cg25706552	chr1:244017396	NA	-0.65	-15.75	-0.59	4.47e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs11976180	0.517	rs6949375	chr7:143773851	T/G	cg16807089	chr7:143582499	FAM115A	0.53	6.72	0.3	5.43e-11	Obesity-related traits;
LGG	trans	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg06521331	chr12:34319734	NA	-0.54	-9.5	-0.4	1.12e-19	Bladder cancer;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	4.95e-22	Menopause (age at onset);
LGG	cis	rs12579753	0.917	rs2401002	chr12:82215870	C/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.95	-0.45	5.73e-25	Resting heart rate;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.66	11.28	0.46	3.08e-26	Obesity-related traits;
LGG	cis	rs911119	1.000	rs6114209	chr20:23622266	G/C	cg16589663	chr20:23618590	CST3	0.47	6.72	0.3	5.44e-11	Chronic kidney disease;
LGG	cis	rs60871478	1.000	rs62432861	chr7:807649	G/A	cg04727924	chr7:799746	HEATR2	-0.47	-7.52	-0.33	2.81e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs561341	1.000	rs535151	chr17:30317405	C/T	cg13647721	chr17:30228624	UTP6	0.65	8.67	0.37	7.55e-17	Hip circumference adjusted for BMI;
LGG	cis	rs1348850	0.554	rs7595576	chr2:178371921	C/T	cg27490568	chr2:178487706	NA	0.85	15.27	0.58	6.38e-43	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2242116	0.727	rs4683298	chr3:46966387	C/G	cg02527881	chr3:46936655	PTH1R	-0.35	-8.6	-0.37	1.22e-16	Birth weight;
LGG	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.2	-0.36	2.42e-15	Retinal vascular caliber;
LGG	cis	rs2290402	0.536	rs3775127	chr4:886061	G/A	cg00846425	chr4:957561	DGKQ	-0.43	-6.8	-0.3	3.18e-11	Type 2 diabetes;
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	trans	rs1945213	0.694	rs34537090	chr11:55843285	G/C	cg11707556	chr5:10655725	ANKRD33B	0.49	7.19	0.32	2.63e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7296418	0.961	rs1727307	chr12:123575742	A/G	cg00376283	chr12:123451042	ABCB9	0.65	12.32	0.5	2.38e-30	Platelet count;
LGG	cis	rs10504073	0.647	rs4873312	chr8:49991145	A/G	cg00325661	chr8:49890786	NA	0.74	14.46	0.56	2.28e-39	Blood metabolite ratios;
LGG	trans	rs9329221	0.621	rs522483	chr8:9812969	C/G	cg21775007	chr8:11205619	TDH	-0.43	-6.68	-0.3	7.06e-11	Neuroticism;
LGG	cis	rs950027	0.620	rs1719245	chr15:45623782	T/C	cg26924012	chr15:45694286	SPATA5L1	0.66	11.73	0.48	5.25e-28	Response to fenofibrate (adiponectin levels);
LGG	cis	rs2976388	0.609	rs2244152	chr8:143784885	C/A	cg06565975	chr8:143823917	SLURP1	0.36	9.23	0.39	9.72e-19	Urinary tract infection frequency;
LGG	cis	rs963731	0.737	rs13023273	chr2:39230119	C/G	cg04010122	chr2:39346883	SOS1	-0.78	-6.74	-0.3	4.78e-11	Corticobasal degeneration;
LGG	cis	rs7044106	0.708	rs991121	chr9:123370345	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.09	0.6	1.34e-46	Hip circumference adjusted for BMI;
LGG	cis	rs8028313	0.731	rs6494678	chr15:67946247	C/T	cg16208657	chr15:68119293	LBXCOR1	-0.35	-6.85	-0.3	2.31e-11	Obesity;
LGG	cis	rs11583043	0.793	rs3903905	chr1:101420957	G/T	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	6.72	0.3	5.32e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19613905	chr15:56757180	MNS1	0.46	7.32	0.32	1.14e-12	Gut microbiome composition (summer);
LGG	cis	rs7220401	0.521	rs2292973	chr17:27893015	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.53	9.32	0.4	4.81e-19	Coronary artery disease;
LGG	cis	rs2597513	0.860	rs2731347	chr3:13568249	A/G	cg24006715	chr3:13568212	NA	0.63	10.24	0.43	2.63e-22	Hip circumference adjusted for BMI;Height;
LGG	cis	rs35740288	0.770	rs11633893	chr15:86148438	A/G	cg04173714	chr15:86211321	AKAP13	-0.46	-8.52	-0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs12477438	0.520	rs6717729	chr2:99756941	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.6	0.75	4.55e-86	Chronic sinus infection;
LGG	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.31	0.36	1.08e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9818758	0.607	rs34784192	chr3:49274823	G/T	cg00383909	chr3:49044727	WDR6	0.98	12.38	0.5	1.34e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs61931739	0.500	rs7298322	chr12:34445489	A/T	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs10267417	0.535	rs10272487	chr7:19862415	A/T	cg05791153	chr7:19748676	TWISTNB	0.59	7.35	0.32	9.13e-13	Night sleep phenotypes;
LGG	cis	rs3849570	1.000	rs3860595	chr3:81811784	A/G	cg07356753	chr3:81810745	GBE1	-0.41	-7.16	-0.32	3.18e-12	Waist circumference;Body mass index;
LGG	trans	rs7395662	1.000	rs10839171	chr11:48923034	C/A	cg00717180	chr2:96193071	NA	0.42	7.55	0.33	2.39e-13	HDL cholesterol;
LGG	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg08645402	chr16:4508243	NA	0.41	6.71	0.3	5.57e-11	Schizophrenia;
LGG	cis	rs1577917	0.655	rs2758848	chr6:86347605	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.44	-7.83	-0.34	3.44e-14	Response to antipsychotic treatment;
LGG	cis	rs10463554	0.963	rs187427	chr5:102512803	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.57	-0.33	2e-13	Parkinson's disease;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg11062466	chr8:58055876	NA	0.44	6.93	0.31	1.38e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17253792	0.822	rs10135426	chr14:56054644	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02741808	chr17:73780792	UNK	0.46	6.94	0.31	1.32e-11	Gut microbiome composition (summer);
LGG	cis	rs992157	0.735	rs13388024	chr2:219097773	A/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.58	-0.5	1.92e-31	Colorectal cancer;
LGG	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg27124370	chr19:33622961	WDR88	0.46	8.31	0.36	1.06e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.92	-0.31	1.49e-11	Monocyte percentage of white cells;
LGG	cis	rs13260300	1.000	rs2891356	chr8:75473223	A/G	cg22993706	chr8:75542856	NA	0.41	8.46	0.37	3.42e-16	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs6735179	0.603	rs736868	chr2:1748429	T/C	cg20570797	chr2:1712800	PXDN	-0.46	-7.97	-0.35	1.24e-14	Response to antipsychotic treatment;
LGG	trans	rs1941687	0.831	rs35740221	chr18:31387714	T/G	cg27147174	chr7:100797783	AP1S1	-0.54	-9.09	-0.39	2.98e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.36	0.32	8.68e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg14092988	chr3:52407081	DNAH1	0.3	8.11	0.35	4.73e-15	Electroencephalogram traits;
LGG	cis	rs68170813	0.559	rs2189501	chr7:106942766	A/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.62	-0.44	1e-23	Coronary artery disease;
LGG	cis	rs6500602	0.893	rs934888	chr16:4462832	C/T	cg08645402	chr16:4508243	NA	0.51	8.8	0.38	2.64e-17	Schizophrenia;
LGG	cis	rs898097	0.567	rs8076119	chr17:80910061	A/G	cg15369054	chr17:80825471	TBCD	-0.39	-7.21	-0.32	2.26e-12	Breast cancer;
LGG	trans	rs1997103	1.000	rs6976824	chr7:55396115	A/C	cg20935933	chr6:143382018	AIG1	0.59	9.23	0.39	9.75e-19	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7599312	0.532	rs1531788	chr2:213394320	C/T	cg16329650	chr2:213403929	ERBB4	0.48	7.94	0.35	1.5e-14	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7192750	0.538	rs11075911	chr16:71988505	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.29e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs614367	1.000	rs614367	chr11:69328764	A/G	cg08353955	chr11:69289746	NA	0.6	7.73	0.34	6.82e-14	Breast cancer;Breast cancer (early onset);
LGG	cis	rs11122272	0.735	rs2790877	chr1:231535427	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg14979609	chr8:8086686	FLJ10661	-0.29	-6.8	-0.3	3.21e-11	Neuroticism;
LGG	cis	rs10540	1.000	rs12801271	chr11:508720	C/T	cg19913688	chr11:428466	ANO9	-0.65	-8.08	-0.35	5.73e-15	Body mass index;
LGG	cis	rs8049040	0.609	rs9940485	chr16:71486105	C/T	cg06353428	chr16:71660113	MARVELD3	-0.5	-7.92	-0.35	1.81e-14	Blood protein levels;
LGG	cis	rs8062405	1.000	rs4788102	chr16:28873398	G/A	cg00204512	chr16:28754710	NA	0.26	7.31	0.32	1.16e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg05639522	chr1:247681581	NA	0.59	10.22	0.43	3.05e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs796364	0.662	rs11688415	chr2:201143409	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.61	6.97	0.31	1.09e-11	Schizophrenia;
LGG	cis	rs611744	0.573	rs1457210	chr8:109261562	A/G	cg21045802	chr8:109455806	TTC35	-0.48	-8.79	-0.38	3.03e-17	Dupuytren's disease;
LGG	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg07117364	chr1:16154769	NA	-0.53	-8.38	-0.36	6.56e-16	Dilated cardiomyopathy;
LGG	cis	rs12282928	0.959	rs1158897	chr11:48273340	T/C	cg26585981	chr11:48327164	OR4S1	-0.44	-7.19	-0.32	2.64e-12	Migraine - clinic-based;
LGG	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.8	16.9	0.62	3.04e-50	Multiple sclerosis;
LGG	cis	rs11239187	0.530	rs17408014	chr10:45065405	G/A	cg03916630	chr10:45065415	NA	0.36	8.74	0.38	4.34e-17	Body mass index;
LGG	cis	rs4862750	0.915	rs6835681	chr4:187903476	A/G	cg03647317	chr4:187891568	NA	-0.4	-8.65	-0.37	8.44e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4650994	0.789	rs2811300	chr1:178590394	T/C	cg12486710	chr1:178512616	C1orf220	-0.4	-8.02	-0.35	8.55e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2028299	0.919	rs12440156	chr15:90420673	G/A	cg23731826	chr15:90371692	NA	0.38	8.98	0.38	7.08e-18	Type 2 diabetes;
LGG	cis	rs1552244	1.000	rs113771705	chr3:10075983	T/C	cg00166722	chr3:10149974	C3orf24	0.54	9.1	0.39	2.64e-18	Alzheimer's disease;
LGG	cis	rs12286929	0.644	rs9645660	chr11:115081563	C/T	cg04055981	chr11:115044050	NA	0.37	6.99	0.31	9.92e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg06521331	chr12:34319734	NA	0.62	11.04	0.46	2.59e-25	Morning vs. evening chronotype;
LGG	trans	rs9393777	0.920	rs55834529	chr6:27072542	A/G	cg08344181	chr3:125677491	NA	-0.91	-8.65	-0.37	8.37e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6743226	0.580	rs12619620	chr2:242250094	G/A	cg10021735	chr2:242295487	FARP2	0.4	7.06	0.31	5.99e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg22857025	chr5:266934	NA	-1.3	-13.34	-0.53	1.41e-34	Breast cancer;
LGG	cis	rs17767392	0.874	rs34767050	chr14:71780957	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.08	-0.39	3.23e-18	Mitral valve prolapse;
LGG	cis	rs9527	0.590	rs7894959	chr10:104756182	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.18	0.43	4.06e-22	Arsenic metabolism;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg25703541	chr22:24373054	LOC391322	-1.07	-23.66	-0.74	1.01e-81	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9309473	1.000	rs1881245	chr2:73649928	G/A	cg20560298	chr2:73613845	ALMS1	-0.44	-7.42	-0.33	5.7e-13	Metabolite levels;
LGG	cis	rs3809863	0.646	rs9899121	chr17:45395144	C/T	cg08085267	chr17:45401833	C17orf57	-0.71	-14.04	-0.55	1.53e-37	Glaucoma (primary open-angle);
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg24829409	chr8:58192753	C8orf71	-0.72	-9.58	-0.41	5.94e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs11585357	0.895	rs72633814	chr1:17626456	T/C	cg08277548	chr1:17600880	PADI3	-0.72	-7.81	-0.34	3.75e-14	Hair shape;
LGG	cis	rs2798269	0.966	rs17679426	chr13:22122477	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.85	-0.3	2.38e-11	PR segment;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg16507663	chr6:150244633	RAET1G	0.48	9.08	0.39	3.18e-18	Lung cancer;
LGG	cis	rs929354	0.742	rs11980541	chr7:156988776	G/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	cis	rs9513627	1.000	rs3928271	chr13:100186958	G/A	cg15490075	chr13:100150979	NA	0.63	6.79	0.3	3.36e-11	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.81	0.38	2.61e-17	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15291304	chr22:41864762	PHF5A;ACO2	0.46	7.43	0.33	5.38e-13	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg21724239	chr8:58056113	NA	0.7	15.94	0.6	6.61e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6901004	0.803	rs193282	chr6:111543067	G/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.66	-0.34	1.13e-13	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs17216620	chr8:58169412	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.35	-0.5	1.67e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.686	rs34338142	chr4:17626174	T/A	cg10189774	chr4:17578691	LAP3	0.39	6.9	0.31	1.76e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.19	-0.36	2.57e-15	Bone mineral density;
LGG	trans	rs58106596	0.747	rs6731997	chr2:232560411	A/G	cg01370599	chr3:116745421	NA	0.62	9.62	0.41	4.22e-20	White blood cell count;Lymphocyte counts;
LGG	cis	rs4789693	0.679	rs7217570	chr17:80379332	G/T	cg04308225	chr17:80449738	NA	-0.48	-7.51	-0.33	3.1400000000000003e-13	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs4242434	0.747	rs6986550	chr8:22467870	T/A	cg02227867	chr8:22457446	C8orf58	-0.42	-8.12	-0.35	4.34e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1577917	0.958	rs10944144	chr6:86537755	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.63	-0.44	9.24e-24	Response to antipsychotic treatment;
LGG	cis	rs7937682	0.889	rs1784786	chr11:111486043	A/G	cg19812747	chr11:111475976	SIK2	0.51	10.78	0.45	2.59e-24	Primary sclerosing cholangitis;
LGG	cis	rs2201728	0.667	rs55812286	chr4:100182050	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	cis	rs868036	1.000	rs868037	chr15:68054996	A/G	cg08079166	chr15:68083412	MAP2K5	-0.35	-7.95	-0.35	1.44e-14	Restless legs syndrome;
LGG	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg13902645	chr11:5959945	NA	-0.71	-11.11	-0.46	1.43e-25	DNA methylation (variation);
LGG	cis	rs2013441	1.000	rs2386429	chr17:20210809	G/A	cg13482628	chr17:19912719	NA	-0.5	-9.3	-0.4	5.63e-19	Obesity-related traits;
LGG	cis	rs1249910	0.695	rs13068244	chr3:112399350	C/T	cg02954903	chr3:112359935	CCDC80	0.41	7.33	0.32	1.05e-12	Diabetic kidney disease;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.5	0.5	4.44e-31	Total body bone mineral density;
LGG	cis	rs12477438	1.000	rs1922624	chr2:99909958	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-10.78	-0.45	2.43e-24	Chronic sinus infection;
LGG	cis	rs2239815	0.515	rs6005917	chr22:29233486	A/G	cg02153584	chr22:29168773	CCDC117	0.59	7.19	0.32	2.69e-12	Esophageal cancer (squamous cell);Esophageal squamous cell carcinoma;
LGG	cis	rs7208859	0.573	rs7214313	chr17:29138596	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.54	-0.44	1.98e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.34	0.36	8.68e-16	Morning vs. evening chronotype;
LGG	cis	rs12802200	0.561	rs746708	chr11:572129	C/T	cg16486109	chr11:613632	IRF7	0.42	7.52	0.33	2.83e-13	Systemic lupus erythematosus;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09894929	chr7:8473578	NXPH1	0.4	6.67	0.3	7.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1318772	0.932	rs348935	chr5:112829601	G/A	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs28595532	0.920	rs116821181	chr4:119734892	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs7666738	0.830	rs2114426	chr4:98933130	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7937682	0.883	rs486038	chr11:111465963	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs36051895	0.664	rs3780377	chr9:5110899	T/C	cg02405213	chr9:5042618	JAK2	-0.83	-15.54	-0.59	3.8e-44	Pediatric autoimmune diseases;
LGG	cis	rs6956675	0.915	rs6965334	chr7:62645446	A/G	cg08930214	chr7:62859557	LOC100287834	0.44	7.39	0.32	6.74e-13	Obesity-related traits;
LGG	cis	rs875971	0.571	rs78668714	chr7:65939451	G/A	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs7572733	0.534	rs7604700	chr2:198718630	A/G	cg00792783	chr2:198669748	PLCL1	0.68	11.12	0.46	1.23e-25	Dermatomyositis;
LGG	cis	rs8017423	0.838	rs11845950	chr14:90723962	T/A	cg04374321	chr14:90722782	PSMC1	0.89	19.09	0.66	2.47e-60	Mortality in heart failure;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.83	-0.57	5.45e-41	Platelet count;
LGG	cis	rs1775715	0.737	rs11817598	chr10:32206259	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.75	0.3	4.31e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs9815354	0.627	rs115971784	chr3:42016146	T/C	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3749237	0.964	rs2234385	chr3:49846041	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.95	0.31	1.22e-11	Resting heart rate;
LGG	cis	rs950776	0.720	rs11633223	chr15:78935476	T/C	cg22563815	chr15:78856949	CHRNA5	0.28	6.85	0.3	2.32e-11	Sudden cardiac arrest;
LGG	cis	rs2287838	0.716	rs7245579	chr19:10000876	C/G	cg00846166	chr19:10022875	OLFM2	0.32	7.32	0.32	1.09e-12	Sleep duration;
LGG	trans	rs1814175	0.645	rs11040671	chr11:49958776	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs7959452	0.535	rs7308481	chr12:69659299	A/G	cg11871910	chr12:69753446	YEATS4	0.69	13.32	0.53	1.72e-34	Blood protein levels;
LGG	cis	rs6438424	0.521	rs10934427	chr3:117721983	T/C	cg07910724	chr3:117604411	NA	0.32	8.54	0.37	1.88e-16	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.23e-22	Diabetic retinopathy;
LGG	cis	rs1878931	0.696	rs35984213	chr16:3451030	G/A	cg26668626	chr16:3451006	ZNF174;ZNF434	1.03	23.86	0.74	1.21e-82	Body mass index (adult);
LGG	cis	rs4555082	0.874	rs56263609	chr14:105756944	C/T	cg27165867	chr14:105738592	BRF1	-0.46	-7.33	-0.32	1.01e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4538187	1.000	rs6546029	chr2:64069732	G/A	cg14150252	chr2:64069583	UGP2	0.5	9.73	0.41	1.77e-20	Systolic blood pressure;
LGG	cis	rs17102423	0.594	rs7159443	chr14:65550816	T/A	cg26396452	chr14:65542826	MAX	0.48	10.0	0.42	1.85e-21	Obesity-related traits;
LGG	cis	rs9788721	0.902	rs951266	chr15:78878541	C/T	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.48	-0.33	3.65e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1055129	0.655	rs7216615	chr17:73833910	T/C	cg08125733	chr17:73851984	WBP2	0.43	7.18	0.32	2.79e-12	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13948074	chr1:178511686	C1orf220	0.47	7.53	0.33	2.6e-13	Gut microbiome composition (summer);
LGG	cis	rs9650657	0.645	rs4841411	chr8:10521890	C/G	cg21775007	chr8:11205619	TDH	0.43	6.85	0.3	2.41e-11	Neuroticism;
LGG	trans	rs3206736	0.548	rs329233	chr7:35055831	T/C	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.09	0.31	5.19e-12	Diastolic blood pressure;
LGG	cis	rs9916302	0.904	rs4357971	chr17:37717280	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.65	-0.48	1.09e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg13282195	chr8:144660772	NAPRT1	0.98	7.59	0.33	1.83e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs2071403	0.871	rs13403150	chr2:1406059	A/G	cg06500727	chr2:1417164	TPO	-0.54	-10.37	-0.43	8.61e-23	Thyroid peroxidase antibody positivity;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg03517284	chr6:25882590	NA	-0.38	-6.85	-0.3	2.34e-11	Height;
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg05793240	chr7:2802953	GNA12	0.36	8.05	0.35	7.2e-15	Height;
LGG	cis	rs3816183	0.585	rs6544582	chr2:42873653	G/C	cg14631114	chr2:43023945	NA	0.35	6.95	0.31	1.28e-11	Hypospadias;
LGG	cis	rs3733585	0.699	rs6449177	chr4:9968050	T/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.73	-0.34	6.58e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4950322	0.570	rs2354428	chr1:146749181	T/C	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.48e-16	Obesity-related traits;
LGG	cis	rs1801251	0.896	rs4973561	chr2:233687337	C/G	cg08000102	chr2:233561755	GIGYF2	-0.52	-8.78	-0.38	3.27e-17	Coronary artery disease;
LGG	cis	rs1005224	0.889	rs9323617	chr14:76158638	A/G	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-6.87	-0.3	2.05e-11	Large artery stroke;
LGG	cis	rs2120243	0.533	rs62278578	chr3:157055867	C/T	cg24825693	chr3:157122686	VEPH1	-0.37	-8.07	-0.35	6.03e-15	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg24112000	chr20:60950667	NA	-0.37	-8.14	-0.35	3.59e-15	Colorectal cancer;
LGG	trans	rs55986470	0.817	rs72993054	chr2:239404244	C/T	cg01134436	chr17:81009848	B3GNTL1	0.78	8.63	0.37	1.01e-16	Chronotype;
LGG	trans	rs9467711	0.591	rs34351439	chr6:25833010	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.65	-0.3	8.17e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12230513	0.732	rs59438785	chr12:55811665	A/G	cg19537932	chr12:55886519	OR6C68	-0.59	-10.79	-0.45	2.34e-24	Contrast sensitivity;
LGG	cis	rs7172689	0.955	rs60831942	chr15:81556116	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.45	-0.44	4.14e-23	Inattentive symptoms;
LGG	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg14154082	chr13:112174009	NA	0.42	9.22	0.39	1.09e-18	Menarche (age at onset);
LGG	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg18252515	chr7:66147081	NA	-0.4	-6.66	-0.3	7.59e-11	Aortic root size;
LGG	cis	rs4356975	0.563	rs4508963	chr4:69984488	A/C	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs3126085	0.935	rs4421596	chr1:152181673	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs7085104	0.632	rs3781287	chr10:104595420	A/C	cg04362960	chr10:104952993	NT5C2	0.48	8.89	0.38	1.38e-17	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg21926883	chr2:100939477	LONRF2	-0.68	-16.22	-0.6	3.64e-47	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	1.000	rs8082020	chr17:29694795	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.68	-14.46	-0.56	2.24e-39	Hip circumference;
LGG	trans	rs9329221	0.532	rs2062333	chr8:9981149	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.72	0.34	7.37e-14	Neuroticism;
LGG	trans	rs7939886	0.920	rs11227670	chr11:56026737	A/C	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	trans	rs7829975	0.509	rs2945269	chr8:8115578	G/C	cg02002194	chr4:3960332	NA	-0.57	-11.46	-0.47	6.09e-27	Mood instability;
LGG	cis	rs5769765	0.671	rs138844	chr22:50184484	T/G	cg26441486	chr22:50317300	CRELD2	0.37	6.69	0.3	6.48e-11	Schizophrenia;
LGG	trans	rs7395662	0.609	rs10839190	chr11:48957008	T/C	cg00717180	chr2:96193071	NA	0.42	7.5	0.33	3.3e-13	HDL cholesterol;
LGG	cis	rs2455601	1.000	rs2455601	chr11:8899400	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-8.45	-0.37	3.87e-16	Schizophrenia;
LGG	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg13013644	chr5:502571	SLC9A3	0.32	7.21	0.32	2.26e-12	Cystic fibrosis severity;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg16301924	chr13:53314226	LECT1	-0.55	-11.88	-0.48	1.41e-28	Lewy body disease;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs911263	0.590	rs1570106	chr14:68813115	A/G	cg18825221	chr14:68749962	RAD51L1	0.41	6.9	0.31	1.77e-11	Primary biliary cholangitis;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.87	-0.38	1.63e-17	Longevity;Endometriosis;
LGG	cis	rs4631830	0.832	rs67289834	chr10:51501304	C/T	cg16070123	chr10:51489643	NA	0.39	6.81	0.3	3.05e-11	Prostate-specific antigen levels;
LGG	cis	rs28595532	0.688	rs116053430	chr4:119731375	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg07092213	chr7:1199455	ZFAND2A	-0.44	-7.44	-0.33	4.99e-13	Longevity;Endometriosis;
LGG	cis	rs6500395	0.962	rs7499213	chr16:48680597	T/C	cg16662043	chr16:48846231	NA	0.37	7.24	0.32	1.89e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2070488	1.000	rs3792527	chr3:38493212	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.19	0.65	3.66e-56	Electrocardiographic conduction measures;
LGG	cis	rs34599045	0.522	rs71626739	chr1:152906133	T/C	cg07796016	chr1:152779584	LCE1C	-0.85	-7.82	-0.34	3.6e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2153535	0.580	rs1034272	chr6:8469335	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs8133932	0.598	rs753092	chr21:47293521	C/A	cg13695288	chr21:47294981	PCBP3	-0.37	-7.44	-0.33	4.81e-13	Schizophrenia;
LGG	cis	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg06521331	chr12:34319734	NA	-0.44	-7.45	-0.33	4.62e-13	Resting heart rate;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.52	0.44	2.45e-23	Obesity-related traits;
LGG	cis	rs6582630	0.555	rs7294313	chr12:38323603	G/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.44	-0.44	4.73e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62238980	0.522	rs79257145	chr22:32545097	T/C	cg02631450	chr22:32366979	NA	0.94	9.1	0.39	2.78e-18	Childhood ear infection;
LGG	cis	rs9914988	0.887	rs28873200	chr17:27149512	A/G	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.74	-0.34	6.15e-14	Skin colour saturation;
LGG	cis	rs738322	0.555	rs5756932	chr22:38546118	C/T	cg25457927	chr22:38595422	NA	-0.42	-10.46	-0.44	3.81e-23	Cutaneous nevi;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg24503407	chr1:205819492	PM20D1	0.83	20.11	0.68	4.36e-65	Menarche (age at onset);
LGG	trans	rs9650657	0.812	rs7834466	chr8:10634805	G/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.89	-0.3	1.81e-11	Neuroticism;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.86	0.34	2.64e-14	Testicular germ cell tumor;
LGG	cis	rs1461503	0.934	rs7121840	chr11:122845360	A/G	cg27398637	chr11:122830231	C11orf63	-0.69	-13.59	-0.53	1.26e-35	Menarche (age at onset);
LGG	cis	rs66725070	1	rs66725070	chr15:58267416	GACAT/G	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.26	-0.36	1.57e-15	Barrett's esophagus;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	trans	rs1032833	0.732	rs75749465	chr2:180012005	T/C	cg23654767	chr2:101192981	PDCL3	0.72	8.59	0.37	1.34e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs11758351	0.789	rs2069020	chr6:26205500	C/T	cg01420254	chr6:26195488	NA	0.88	11.78	0.48	3.32e-28	Gout;Renal underexcretion gout;
LGG	cis	rs4481887	0.927	rs10749651	chr1:248472930	T/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.2	-0.52	5.46e-34	Aortic root size;
LGG	cis	rs753778	0.570	rs6578154	chr8:142210057	G/A	cg18755752	chr8:142205143	DENND3	-0.47	-9.53	-0.4	9.13e-20	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs988958	0.565	rs11889038	chr2:42238233	G/A	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs9911578	0.967	rs6416932	chr17:57148991	G/A	cg05425664	chr17:57184151	TRIM37	-0.7	-11.37	-0.47	1.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs10832963	1.000	rs10832962	chr11:18656271	C/T	cg20219074	chr11:18656078	SPTY2D1	0.83	15.22	0.58	1.1e-42	Breast cancer;
LGG	cis	rs760805	1.000	rs3845302	chr1:25259884	C/G	cg22509179	chr1:25234806	RUNX3	-0.65	-13.87	-0.54	7.65e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9399137	0.507	rs7772031	chr6:135259734	G/A	cg22676075	chr6:135203613	NA	-0.44	-7.58	-0.33	1.88e-13	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6871536	0.853	rs6874184	chr5:131961149	G/A	cg04303330	chr5:131992430	IL13	0.29	6.89	0.31	1.77e-11	Asthma (childhood onset);
LGG	cis	rs897080	0.552	rs1067389	chr2:44642290	G/A	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	3.93e-11	Height;
LGG	cis	rs12476592	0.602	rs7571325	chr2:63785914	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs7959452	0.640	rs10878957	chr12:69699638	G/C	cg14784868	chr12:69753453	YEATS4	0.73	13.96	0.54	3.26e-37	Blood protein levels;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg23782820	chr8:58130467	NA	0.53	7.54	0.33	2.45e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.34	0.4	4.1e-19	Platelet count;
LGG	cis	rs72945132	0.882	rs7950916	chr11:70210001	T/C	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg18644191	chr1:99730224	LPPR4	0.4	7.15	0.32	3.42e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs8031584	0.958	rs35256769	chr15:31237776	G/A	cg14298792	chr15:30685198	CHRFAM7A	-0.43	-6.69	-0.3	6.61e-11	Huntington's disease progression;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.81e-34	Prudent dietary pattern;
LGG	cis	rs2905347	0.531	rs2961289	chr7:22677755	C/T	cg23521230	chr7:22704884	NA	0.39	7.1	0.31	4.71e-12	Major depression and alcohol dependence;
LGG	trans	rs1814175	0.653	rs10839480	chr11:50034556	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.75	-0.75	9.1e-87	Height;
LGG	trans	rs4714291	1.000	rs6917453	chr6:39992386	A/G	cg02267698	chr19:7991119	CTXN1	0.53	8.01	0.35	9.33e-15	Strep throat;
LGG	cis	rs870825	0.616	rs28450662	chr4:185638900	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.63	0.72	6.95e-77	Blood protein levels;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg01059449	chr18:44338099	ST8SIA5	-0.37	-8.08	-0.35	5.82e-15	Personality dimensions;
LGG	trans	rs853679	0.607	rs61742093	chr6:27879982	A/G	cg01620082	chr3:125678407	NA	-1.01	-10.12	-0.43	6.8e-22	Depression;
LGG	trans	rs9650657	0.515	rs7820860	chr8:10950396	C/G	cg02002194	chr4:3960332	NA	0.42	7.71	0.34	7.79e-14	Neuroticism;
LGG	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg05639522	chr1:247681581	NA	0.62	7.4	0.33	6.52e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1009647	0.645	rs17742719	chr14:55855596	A/C	cg04306507	chr14:55594613	LGALS3	-0.45	-7.99	-0.35	1.07e-14	Testicular germ cell tumor;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg11814155	chr7:99998594	ZCWPW1	0.54	8.09	0.35	5.18e-15	Platelet count;
LGG	cis	rs28595532	0.920	rs115853212	chr4:119765354	C/T	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs8114671	0.562	rs1018447	chr20:33401707	A/G	cg07148914	chr20:33460835	GGT7	-0.54	-9.19	-0.39	1.29e-18	Height;
LGG	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4262150	0.667	rs4509081	chr5:152257172	A/G	cg12297329	chr5:152029980	NA	0.6	11.68	0.48	8.41e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.632	rs2839184	chr21:47689013	G/A	cg12379764	chr21:47803548	PCNT	-0.64	-9.84	-0.42	6.85e-21	Testicular germ cell tumor;
LGG	cis	rs4481887	1.000	rs11204636	chr1:248492409	A/C	cg00666640	chr1:248458726	OR2T12	-0.6	-9.73	-0.41	1.69e-20	Common traits (Other);
LGG	cis	rs72945132	0.714	rs115143889	chr11:70150122	G/T	cg14191688	chr11:70257035	CTTN	0.6	8.49	0.37	2.89e-16	Coronary artery disease;
LGG	cis	rs11214589	0.905	rs1078	chr11:113241877	C/T	cg14159747	chr11:113255604	NA	0.32	8.55	0.37	1.75e-16	Neuroticism;
LGG	cis	rs4740619	0.935	rs4740615	chr9:15574853	T/C	cg14451791	chr9:16040625	NA	-0.41	-10.69	-0.44	5.37e-24	Body mass index;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	cis	rs6993813	0.872	rs4615609	chr8:120035493	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs2762353	0.574	rs11756503	chr6:25710432	C/T	cg03517284	chr6:25882590	NA	0.69	13.29	0.53	2.21e-34	Blood metabolite levels;
LGG	cis	rs6920965	0.507	rs9385389	chr6:126215486	G/C	cg05901451	chr6:126070800	HEY2	-0.47	-7.91	-0.35	1.86e-14	High light scatter reticulocyte count;
LGG	cis	rs7267979	1.000	rs4815417	chr20:25379526	C/T	cg06421707	chr20:25228305	PYGB	-0.46	-10.09	-0.42	8.68e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9560113	0.597	rs1163644	chr13:112241223	C/T	cg10483660	chr13:112241077	NA	-0.45	-9.35	-0.4	3.79e-19	Menarche (age at onset);
LGG	cis	rs9359856	0.564	rs41273329	chr6:90393483	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.75	-0.41	1.5e-20	Bipolar disorder;
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.7e-15	Testicular germ cell tumor;
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.33	0.36	9.07e-16	Lung cancer;
LGG	cis	rs9399135	1.000	rs6569988	chr6:135352303	C/A	cg24558204	chr6:135376177	HBS1L	0.52	9.66	0.41	3.04e-20	Red blood cell count;
LGG	cis	rs877282	1.000	rs877281	chr10:771557	T/G	cg17470449	chr10:769945	NA	0.64	8.09	0.35	5.42e-15	Uric acid levels;
LGG	cis	rs4746818	1.000	rs1506770	chr10:70964357	G/A	cg11621586	chr10:70884670	VPS26A	1.11	18.93	0.66	1.27e-59	Left atrial antero-posterior diameter;
LGG	trans	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.07	0.39	3.42e-18	Resting heart rate;
LGG	cis	rs4555082	0.957	rs3000073	chr14:105729792	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-17.23	-0.63	8.86e-52	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg02951883	chr7:2050386	MAD1L1	-0.73	-14.57	-0.56	7.19e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.26	0.32	1.6e-12	Tonsillectomy;
LGG	cis	rs9878978	0.964	rs6762278	chr3:2493351	T/C	cg21928760	chr3:2462534	CNTN4	0.4	8.86	0.38	1.79e-17	Blood pressure (smoking interaction);
LGG	cis	rs4481887	0.927	rs4586010	chr1:248437568	G/A	cg13385794	chr1:248469461	NA	0.5	8.44	0.37	4.17e-16	Common traits (Other);
LGG	cis	rs12477438	0.748	rs7558239	chr2:99640581	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs9880211	0.948	rs13326151	chr3:136261744	C/T	cg21827317	chr3:136751795	NA	-0.48	-7.15	-0.32	3.31e-12	Body mass index;Height;
LGG	cis	rs28595532	0.764	rs55704595	chr4:119780607	G/A	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs12482904	1.000	rs2839511	chr21:43848521	G/A	cg23042151	chr21:43824109	UBASH3A	-0.4	-6.66	-0.3	7.99e-11	Vitiligo;
LGG	cis	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg20368463	chr18:77673604	PQLC1	0.54	7.11	0.31	4.39e-12	Opioid sensitivity;
LGG	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg15596359	chr8:11213517	TDH	-0.35	-6.95	-0.31	1.22e-11	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs7743686	chr6:8526111	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs4555082	0.681	rs28588570	chr14:105709606	A/T	cg13114125	chr14:105738426	BRF1	-0.87	-17.74	-0.64	4.17e-54	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17776563	0.614	rs55878306	chr15:89139282	A/G	cg05013243	chr15:89149849	MIR1179	-0.34	-7.02	-0.31	7.96e-12	Thyroid hormone levels;
LGG	cis	rs2249694	0.810	rs2987785	chr10:135365003	C/T	cg20169779	chr10:135381914	SYCE1	0.46	6.87	0.3	2.06e-11	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01069256	chr8:79577942	FAM164A	0.39	6.74	0.3	4.58e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2735413	0.846	rs72800943	chr16:78079555	G/A	cg04733911	chr16:78082701	NA	-0.77	-18.41	-0.65	3.45e-57	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4601821	0.635	rs12282356	chr11:113208382	A/G	cg14373873	chr11:113211441	TTC12	0.42	8.29	0.36	1.23e-15	Alcoholic chronic pancreatitis;
LGG	cis	rs4563143	0.663	rs10406794	chr19:29228056	C/T	cg12667521	chr19:29218732	NA	0.68	10.33	0.43	1.18e-22	Methadone dose in opioid dependence;
LGG	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg09696939	chr10:60272079	BICC1	0.38	7.48	0.33	3.72e-13	Refractive error;
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.84	-0.34	3.1e-14	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg17911788	chr17:44343683	NA	0.47	7.94	0.35	1.58e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10150615	chr22:24372951	LOC391322	0.41	6.65	0.3	8.15e-11	Cognitive performance;
LGG	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.12	0.35	4.17e-15	Colorectal cancer;
LGG	cis	rs7208859	0.623	rs57486336	chr17:29085731	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3735485	0.760	rs4720488	chr7:45041111	G/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.32	3.59e-12	Prudent dietary pattern;
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03264133	chr6:25882463	NA	-0.9	-19.02	-0.66	4.89e-60	Uric acid levels;
LGG	trans	rs12439619	0.846	rs62012056	chr15:82539619	A/G	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.67	-0.3	7.53e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4595586	0.563	rs11169769	chr12:39233134	C/G	cg26384229	chr12:38710491	ALG10B	0.85	16.44	0.61	3.75e-48	Morning vs. evening chronotype;
LGG	cis	rs7044106	0.708	rs1324472	chr9:123375110	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	6.92	0.31	1.53e-11	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.965	rs2965188	chr19:19522557	G/A	cg11584989	chr19:19387371	SF4	0.39	7.1	0.31	4.81e-12	Tonsillectomy;
LGG	cis	rs6964587	0.869	rs7778667	chr7:91520816	C/G	cg17063962	chr7:91808500	NA	-0.41	-7.17	-0.32	3e-12	Breast cancer;
LGG	cis	rs11971779	0.680	rs2355788	chr7:139101897	T/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs7084402	0.967	rs1593672	chr10:60294379	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.46	0.63	8.18e-53	Refractive error;
LGG	cis	rs1048238	0.506	rs7525608	chr1:16141901	A/G	cg22431228	chr1:16359049	CLCNKA	-0.38	-6.88	-0.3	1.9e-11	Systolic blood pressure;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg05025164	chr4:1340916	KIAA1530	0.42	7.19	0.32	2.66e-12	Obesity-related traits;
LGG	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.37	-0.4	3.32e-19	Calcium levels;
LGG	cis	rs1185460	0.546	rs7114961	chr11:118914388	G/C	cg24687335	chr11:118901407	SLC37A4	-0.58	-10.35	-0.43	9.93e-23	Coronary artery disease;
LGG	trans	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.5	0.4	1.18e-19	Gout;
LGG	cis	rs1552244	0.832	rs67145301	chr3:10197314	G/A	cg00149659	chr3:10157352	C3orf10	0.8	9.68	0.41	2.55e-20	Alzheimer's disease;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg24642844	chr7:1081250	C7orf50	-0.45	-8.41	-0.36	4.96e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2268241	1.000	rs2268241	chr21:34781050	G/A	cg14850771	chr21:34775459	IFNGR2	0.77	9.25	0.39	8.61e-19	Obesity-related traits;
LGG	cis	rs295140	0.565	rs295139	chr2:201159988	T/A	cg17644776	chr2:200775616	C2orf69	0.43	7.09	0.31	5e-12	QT interval;
LGG	cis	rs60843830	1.000	rs55753056	chr2:243929	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.59	0.37	1.37e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	8.97	0.38	7.19e-18	Mood instability;
LGG	cis	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg18129748	chr3:49941408	MST1R	-0.22	-6.83	-0.3	2.63e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.51	-0.33	3.08e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7786808	0.615	rs1563066	chr7:158194935	A/C	cg12438819	chr7:158236134	PTPRN2	0.32	8.21	0.36	2.3e-15	Obesity-related traits;
LGG	cis	rs8180040	1.000	rs7613282	chr3:47389409	C/T	cg27129171	chr3:47204927	SETD2	-0.81	-15.84	-0.59	1.9e-45	Colorectal cancer;
LGG	cis	rs9300255	0.537	rs1619561	chr12:123620268	G/C	cg00376283	chr12:123451042	ABCB9	0.65	10.6	0.44	1.18e-23	Neutrophil percentage of white cells;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23593986	chr20:33577678	MIR499;MYH7B	0.41	6.95	0.31	1.22e-11	Menarche (age at onset);
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg08621203	chr6:150244597	RAET1G	0.44	6.78	0.3	3.65e-11	Lung cancer;
LGG	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg12615879	chr12:58013172	SLC26A10	0.32	7.17	0.32	3.07e-12	Multiple sclerosis;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg12692727	chr7:1102344	C7orf50	0.5	6.86	0.3	2.18e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg18424134	chr6:126068038	NA	0.21	6.82	0.3	2.85e-11	Brugada syndrome;
LGG	cis	rs7586879	0.639	rs7580081	chr2:25097072	G/C	cg04586622	chr2:25135609	ADCY3	0.43	11.68	0.48	8.78e-28	Body mass index;
LGG	cis	rs35306767	0.953	rs12259801	chr10:959306	C/G	cg20503657	chr10:835505	NA	0.64	9.46	0.4	1.51e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs4936894	0.500	rs11601414	chr11:124077618	G/T	cg27160556	chr11:124181099	OR8D1	0.47	10.69	0.44	5.49e-24	Aging (time to death);
LGG	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg16096631	chr1:42092165	HIVEP3	0.76	23.11	0.73	3.88e-79	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs826838	0.967	rs1684414	chr12:39129553	A/G	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs6952808	0.609	rs4721190	chr7:1954732	A/G	cg14004847	chr7:1930337	MAD1L1	0.51	8.88	0.38	1.52e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs2777491	0.915	rs7165675	chr15:41614704	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	trans	rs7178375	1.000	rs35162264	chr15:31200683	T/A	cg04373760	chr16:53404718	NA	0.56	8.59	0.37	1.35e-16	Hypertriglyceridemia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg19010396	chr19:19431384	KIAA0892;SF4	0.4	7.15	0.32	3.4e-12	Bilirubin levels;
LGG	trans	rs11039798	0.588	rs589834	chr11:48419382	C/G	cg03929089	chr4:120376271	NA	-0.69	-9.51	-0.4	1.09e-19	Axial length;
LGG	cis	rs9583531	0.574	rs7319459	chr13:111352408	T/C	cg24331049	chr13:111365604	ING1	-0.87	-16.29	-0.6	1.64e-47	Coronary artery disease;
LGG	cis	rs6088580	0.570	rs6058057	chr20:33065283	G/A	cg08999081	chr20:33150536	PIGU	0.4	10.14	0.43	5.82e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg04267008	chr7:1944627	MAD1L1	0.62	11.06	0.46	2.19e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9557207	0.901	rs34485817	chr13:99817684	G/C	cg24509225	chr13:100037070	UBAC2	0.7	12.01	0.49	4.26e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.25	-0.43	2.37e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4969178	0.965	rs12944051	chr17:76395856	C/T	cg05887092	chr17:76393375	PGS1	-0.7	-14.88	-0.57	3.42e-41	HDL cholesterol levels;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg07167872	chr1:205819463	PM20D1	0.57	11.36	0.47	1.49e-26	Menarche (age at onset);
LGG	cis	rs6558530	0.965	rs6558535	chr8:1710632	T/C	cg08198773	chr8:1697536	NA	0.36	6.76	0.3	4.1e-11	Systolic blood pressure;
LGG	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.81	-0.34	3.94e-14	Gut microbiome composition (summer);
LGG	cis	rs4702718	0.549	rs267963	chr5:10736580	G/A	cg14521931	chr5:10832172	NA	-0.46	-8.94	-0.38	9.67e-18	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs4411311	chr12:39363612	C/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg18876405	chr7:65276391	NA	-0.55	-9.73	-0.41	1.74e-20	Aortic root size;
LGG	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg16141378	chr3:129829833	LOC729375	0.36	8.2	0.36	2.31e-15	Joint mobility (Beighton score);
LGG	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27297192	chr10:134578999	INPP5A	0.3	6.75	0.3	4.38e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9814567	1.000	rs7648990	chr3:134244390	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg18128536	chr17:47092178	IGF2BP1	-0.49	-9.45	-0.4	1.67e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg10556349	chr10:835070	NA	-0.3	-7.7	-0.34	8.37e-14	Survival in rectal cancer;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg18926786	chr6:150244388	RAET1G	0.31	6.67	0.3	7.4e-11	Testicular germ cell tumor;
LGG	cis	rs4740619	0.522	rs7019205	chr9:15823667	T/C	cg14451791	chr9:16040625	NA	0.32	8.08	0.35	5.52e-15	Body mass index;
LGG	cis	rs1023500	0.596	rs133352	chr22:42434022	C/A	cg15557168	chr22:42548783	NA	-0.39	-8.2	-0.36	2.42e-15	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10995359	chr2:30670170	LCLAT1	0.44	7.33	0.32	1.05e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.96	0.38	7.83e-18	Lung cancer;
LGG	trans	rs12579753	1.000	rs34031374	chr12:82235615	G/C	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.76e-14	Resting heart rate;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg12379764	chr21:47803548	PCNT	0.5	8.17	0.35	2.97e-15	Testicular germ cell tumor;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg23758822	chr17:41437982	NA	0.89	15.54	0.59	3.95e-44	Menopause (age at onset);
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg10505658	chr17:80084571	CCDC57	0.42	8.5	0.37	2.63e-16	Life satisfaction;
LGG	cis	rs12188164	0.515	rs2672744	chr5:411047	A/G	cg21972741	chr5:435613	AHRR	-0.42	-7.31	-0.32	1.18e-12	Cystic fibrosis severity;
LGG	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg21045802	chr8:109455806	TTC35	0.47	8.83	0.38	2.24e-17	Dupuytren's disease;
LGG	cis	rs798766	1.000	rs798754	chr4:1720757	A/G	cg00006948	chr4:1768889	NA	-0.5	-7.01	-0.31	8.45e-12	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs4253772	0.591	rs11705624	chr22:46685380	C/T	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.78e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs78487399	0.808	rs6544666	chr2:43732234	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.76	-0.3	4.24e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs10504229	0.728	rs72650867	chr8:58154912	C/T	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.91e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4302748	0.647	rs12540878	chr7:36192694	C/G	cg24442661	chr7:36192818	EEPD1	0.59	7.6	0.33	1.66e-13	Platelet count;
LGG	cis	rs9399137	0.507	rs6940878	chr6:135366309	G/A	cg22676075	chr6:135203613	NA	0.4	6.89	0.31	1.78e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs9951602	0.512	rs6506868	chr18:76642559	C/G	cg24134504	chr18:76639479	NA	-0.47	-8.24	-0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs7927592	0.956	rs11228278	chr11:68308530	G/A	cg01657329	chr11:68192670	LRP5	-0.5	-8.68	-0.37	6.57e-17	Total body bone mineral density;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.46	-7.15	-0.32	3.33e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7681440	0.904	rs6532193	chr4:90764188	G/A	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.56	-9.26	-0.4	7.95e-19	Longevity;Endometriosis;
LGG	cis	rs57221529	0.709	rs72706611	chr5:561146	C/A	cg07777115	chr5:623756	CEP72	-0.57	-7.17	-0.32	3.04e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs8180040	0.615	rs13062681	chr3:47021124	A/G	cg27129171	chr3:47204927	SETD2	0.82	15.16	0.58	2.01e-42	Colorectal cancer;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg16405210	chr4:1374714	KIAA1530	-0.66	-11.85	-0.48	1.76e-28	Longevity;
LGG	cis	rs17384381	0.953	rs12122816	chr1:85792384	C/T	cg16011679	chr1:85725395	C1orf52	0.62	10.48	0.44	3.24e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg11584989	chr19:19387371	SF4	0.42	7.65	0.33	1.17e-13	Tonsillectomy;
LGG	trans	rs11098499	0.722	rs28713555	chr4:120251995	C/T	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-7.03	-0.31	7.21e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs12410462	0.551	rs68046179	chr1:227897635	G/A	cg21459583	chr1:227974177	NA	0.37	6.78	0.3	3.79e-11	Major depressive disorder;
LGG	cis	rs28595532	0.920	rs115259971	chr4:119762654	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2075371	0.863	rs12672691	chr7:133954431	C/T	cg11752832	chr7:134001865	SLC35B4	0.57	10.15	0.43	5.46e-22	Mean platelet volume;
LGG	cis	rs8014204	0.575	rs1045430	chr14:75130235	T/G	cg06637938	chr14:75390232	RPS6KL1	0.68	12.87	0.51	1.26e-32	Caffeine consumption;
LGG	cis	rs397969	0.596	rs7209653	chr17:19882084	A/G	cg13482628	chr17:19912719	NA	0.5	8.57	0.37	1.56e-16	Platelet count;
LGG	cis	rs12586317	0.620	rs76293361	chr14:35570889	G/A	cg16230307	chr14:35515116	FAM177A1	0.88	12.97	0.52	5.04e-33	Psoriasis;
LGG	cis	rs9972944	0.651	rs9909246	chr17:63791547	C/G	cg07283582	chr17:63770753	CCDC46	-0.39	-7.08	-0.31	5.53e-12	Total body bone mineral density;
LGG	cis	rs17666538	0.585	rs1703927	chr8:613620	A/G	cg07234876	chr8:600039	NA	-1.03	-10.28	-0.43	1.75e-22	IgG glycosylation;
LGG	cis	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-10.01	-0.42	1.71e-21	Joint mobility (Beighton score);
LGG	cis	rs3862030	0.839	rs2281880	chr10:104269217	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.55	-10.34	-0.43	1.08e-22	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs651907	0.514	rs10936744	chr3:101433440	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.22	0.52	4.65e-34	Colorectal cancer;
LGG	trans	rs11098499	0.908	rs7696649	chr4:120322177	G/A	cg25214090	chr10:38739885	LOC399744	0.7	12.36	0.5	1.66e-30	Corneal astigmatism;
LGG	cis	rs2239547	0.522	rs6773040	chr3:52935428	C/A	cg11645453	chr3:52864694	ITIH4	-0.69	-10.73	-0.45	4.02e-24	Schizophrenia;
LGG	cis	rs2832077	0.943	rs2272701	chr21:30190907	C/T	cg24692254	chr21:30365293	RNF160	-0.57	-8.34	-0.36	8.46e-16	Cognitive test performance;
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.56	-0.41	6.81e-20	Schizophrenia;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.74	-13.71	-0.54	3.95e-36	Longevity;Endometriosis;
LGG	cis	rs12579753	0.879	rs1922552	chr12:82158093	G/T	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.47	-0.5	5.65e-31	Resting heart rate;
LGG	cis	rs4642101	0.824	rs9852222	chr3:12848491	G/T	cg05775895	chr3:12838266	CAND2	0.69	12.66	0.51	9.38e-32	QRS complex (12-leadsum);
LGG	cis	rs4631830	0.863	rs3101227	chr10:51520203	C/A	cg10326726	chr10:51549505	MSMB	-0.68	-14.29	-0.55	1.24e-38	Prostate-specific antigen levels;
LGG	cis	rs1552244	0.882	rs13063929	chr3:10010308	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.06	17.39	0.63	1.66e-52	Alzheimer's disease;
LGG	cis	rs8044868	0.530	rs2550868	chr16:72066072	G/A	cg06353428	chr16:71660113	MARVELD3	0.4	6.77	0.3	3.8e-11	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs4363385	0.693	rs310109	chr1:153055879	A/G	cg13444842	chr1:152974279	SPRR3	-0.4	-8.01	-0.35	9.65e-15	Inflammatory skin disease;
LGG	cis	rs7216064	1.000	rs58122682	chr17:65876915	T/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2180341	1.000	rs6910763	chr6:127630925	T/C	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.35	-0.36	7.82e-16	Neuroticism;
LGG	cis	rs7177699	0.557	rs6495333	chr15:79113215	G/A	cg00540400	chr15:79124168	NA	0.54	11.38	0.47	1.26e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6708331	0.517	rs10496178	chr2:70342815	A/G	cg01613454	chr2:70366299	NA	0.52	10.48	0.44	3.23e-23	Obesity-related traits;
LGG	cis	rs6088580	0.634	rs6059905	chr20:33126946	T/C	cg08999081	chr20:33150536	PIGU	0.41	10.14	0.43	5.76e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs61931739	0.534	rs1826144	chr12:34094272	A/G	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs7394190	0.810	rs7394178	chr10:75421580	G/A	cg07699608	chr10:75541558	CHCHD1	0.53	7.26	0.32	1.65e-12	Incident atrial fibrillation;
LGG	cis	rs9768139	0.634	rs56389048	chr7:158121368	T/A	cg25566285	chr7:158114605	PTPRN2	0.9	20.43	0.69	1.3e-66	Calcium levels;
LGG	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg18876405	chr7:65276391	NA	0.65	12.51	0.5	3.98e-31	Aortic root size;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg15971980	chr6:150254442	NA	0.45	8.46	0.37	3.47e-16	Lung cancer;
LGG	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg15145296	chr3:125709740	NA	-0.58	-7.65	-0.34	1.14e-13	Blood pressure (smoking interaction);
LGG	cis	rs12936587	0.564	rs7208561	chr17:17615528	C/T	cg05444541	chr17:17804740	TOM1L2	-0.43	-9.14	-0.39	2.01e-18	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg03806693	chr22:41940476	POLR3H	-0.8	-12.51	-0.5	3.9e-31	Vitiligo;
LGG	cis	rs13108904	0.870	rs11721789	chr4:1254414	C/A	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.39e-12	Obesity-related traits;
LGG	cis	rs16854884	0.802	rs6783329	chr3:143798454	T/G	cg06585982	chr3:143692056	C3orf58	0.56	9.4	0.4	2.62e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs1018836	0.739	rs4734247	chr8:91569144	A/G	cg16814680	chr8:91681699	NA	-0.72	-12.73	-0.51	4.92e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6121246	0.512	rs6060941	chr20:30367383	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg27400746	chr16:89904261	SPIRE2	0.98	16.72	0.61	1.9e-49	Skin colour saturation;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg14926445	chr8:58193284	C8orf71	-0.45	-7.09	-0.31	4.96e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.955	rs9616368	chr22:50303533	C/G	cg02269571	chr22:50332266	NA	-0.69	-10.71	-0.45	4.59e-24	Schizophrenia;
LGG	cis	rs17433780	0.897	rs17434151	chr1:89500526	G/T	cg09516651	chr1:89888402	LOC400759	0.77	17.45	0.63	8.98e-53	Carotid intima media thickness;
LGG	trans	rs62103177	0.733	rs62103232	chr18:77635553	G/A	cg05926928	chr17:57297772	GDPD1	1.42	22.7	0.73	2.98e-77	Opioid sensitivity;
LGG	cis	rs10489202	0.632	rs413168	chr1:168005789	C/G	cg17859187	chr1:168147929	TIPRL	0.39	6.67	0.3	7.27e-11	Schizophrenia;
LGG	cis	rs9487094	0.961	rs11967108	chr6:109675243	T/C	cg16315928	chr6:109776240	MICAL1	0.54	9.17	0.39	1.51e-18	Height;
LGG	cis	rs62064224	0.553	rs6505297	chr17:30765767	A/G	cg18200150	chr17:30822561	MYO1D	0.52	9.81	0.41	9.32e-21	Schizophrenia;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4936323	0.504	rs10891812	chr11:115096431	T/C	cg04055981	chr11:115044050	NA	0.38	7.07	0.31	5.59e-12	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs7077256	0.564	rs35479340	chr10:65329342	C/T	cg02276361	chr10:65351566	REEP3	-0.33	-6.78	-0.3	3.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9303280	0.776	rs9891174	chr17:38031802	T/A	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.49e-12	Self-reported allergy;
LGG	cis	rs963731	0.649	rs10184015	chr2:39243129	A/G	cg04010122	chr2:39346883	SOS1	-0.75	-7.88	-0.34	2.43e-14	Corticobasal degeneration;
LGG	cis	rs9393692	0.557	rs2893842	chr6:26338434	T/G	cg00631329	chr6:26305371	NA	-0.46	-7.37	-0.32	8e-13	Educational attainment;
LGG	cis	rs13118159	0.771	rs13117476	chr4:1334721	A/G	cg05165339	chr4:1420672	NA	-0.29	-7.76	-0.34	5.65e-14	Longevity;
LGG	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg12386194	chr3:101231763	SENP7	0.45	7.99	0.35	1.07e-14	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg13385521	chr17:29058706	SUZ12P	0.77	8.69	0.37	6.26e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4975709	0.610	rs1531994	chr5:1859297	T/C	cg01114163	chr5:1856713	NA	-0.41	-7.1	-0.31	4.67e-12	Cardiovascular disease risk factors;
LGG	cis	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.42	-7.04	-0.31	7.16e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1862618	0.756	rs832548	chr5:56183637	G/C	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs6938	0.618	rs1133323	chr15:75212225	C/T	cg17294928	chr15:75287854	SCAMP5	0.66	12.24	0.49	4.7e-30	Breast cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg21166781	chr9:124262344	GGTA1	-0.36	-7.16	-0.32	3.27e-12	Brain structure;
LGG	cis	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg19847130	chr8:10466454	RP1L1	0.32	6.76	0.3	4.25e-11	Triglycerides;
LGG	cis	rs9443189	0.570	rs6903124	chr6:76290079	A/C	cg01950844	chr6:76311363	SENP6	0.75	9.86	0.42	5.97e-21	Prostate cancer;
LGG	cis	rs9814567	1.000	rs7630874	chr3:134293291	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2046867	0.628	rs7356054	chr3:72912727	A/G	cg01043669	chr3:72786069	NA	0.39	6.95	0.31	1.27e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg24690094	chr11:67383802	NA	0.49	8.89	0.38	1.34e-17	Mean corpuscular volume;
LGG	cis	rs12431410	0.550	rs11847286	chr14:60209063	C/T	cg07950296	chr14:60194823	RTN1	0.37	7.06	0.31	6.12e-12	Schizophrenia;
LGG	cis	rs2014572	0.875	rs10405008	chr19:57753643	C/G	cg24459738	chr19:57751996	ZNF805	0.37	7.14	0.31	3.63e-12	Hyperactive-impulsive symptoms;
LGG	cis	rs4974559	0.740	rs11933854	chr4:1315172	G/A	cg02980000	chr4:1222292	CTBP1	0.67	9.18	0.39	1.39e-18	Systolic blood pressure;
LGG	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg00343986	chr7:65444356	GUSB	-0.39	-6.68	-0.3	6.79e-11	Aortic root size;
LGG	trans	rs62103177	0.810	rs3902996	chr18:77630571	A/G	cg14227996	chr4:17616232	MED28	0.72	8.72	0.38	5.02e-17	Opioid sensitivity;
LGG	cis	rs9473924	0.542	rs66834257	chr6:50809141	G/A	cg14470998	chr6:50812995	TFAP2B	0.66	7.91	0.35	1.9e-14	Body mass index;
LGG	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg18681998	chr4:17616180	MED28	0.86	17.84	0.64	1.42e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg12826209	chr6:26865740	GUSBL1	0.78	6.74	0.3	4.61e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9818758	0.607	rs35673421	chr3:49139406	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg00800038	chr16:89945340	TCF25	-0.67	-8.87	-0.38	1.55e-17	Skin colour saturation;
LGG	cis	rs1345301	1.000	rs13405355	chr2:102878206	C/T	cg05295703	chr2:102895712	NA	0.38	7.74	0.34	6.3e-14	Waist circumference;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg15971980	chr6:150254442	NA	0.45	8.41	0.36	5.21e-16	Lung cancer;
LGG	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg11845111	chr2:191398756	TMEM194B	-0.37	-8.23	-0.36	1.86e-15	Pulse pressure;
LGG	cis	rs7762018	0.607	rs77392231	chr6:170057634	G/A	cg19338460	chr6:170058176	WDR27	-0.85	-10.1	-0.42	8.19e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2730245	0.550	rs2657364	chr7:158683825	T/C	cg18245976	chr7:158708271	WDR60	-0.58	-10.82	-0.45	1.74e-24	Height;
LGG	cis	rs7546668	1.000	rs1129347	chr1:15817334	G/A	cg21858823	chr1:15850916	CASP9	0.4	7.45	0.33	4.49e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs7959452	0.536	rs4761237	chr12:69776461	C/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs11122272	0.735	rs2572251	chr1:231514243	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg24692254	chr21:30365293	RNF160	-0.88	-20.26	-0.69	8.59e-66	Dental caries;
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19717773	chr7:2847554	GNA12	-0.35	-7.98	-0.35	1.19e-14	Height;
LGG	trans	rs6601450	0.547	rs10105843	chr8:10197863	A/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.71	0.38	5.46e-17	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7811142	0.830	rs6948685	chr7:99970188	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.98	-14.89	-0.57	3.1e-41	Platelet count;
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6964587	0.967	rs2299235	chr7:91627500	C/T	cg17063962	chr7:91808500	NA	0.48	8.58	0.37	1.47e-16	Breast cancer;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22350171	chr1:228675139	RNF187	0.62	6.97	0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	trans	rs6561151	0.681	rs10507521	chr13:44441834	C/G	cg17145862	chr1:211918768	LPGAT1	-0.71	-10.8	-0.45	2.06e-24	Crohn's disease;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.46	-0.37	3.41e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg24812749	chr6:127587940	RNF146	0.96	15.87	0.59	1.3e-45	Breast cancer;
LGG	cis	rs4538187	1.000	rs6715992	chr2:64085344	C/T	cg14150252	chr2:64069583	UGP2	0.5	9.99	0.42	2.11e-21	Systolic blood pressure;
LGG	cis	rs7107174	1.000	rs4944195	chr11:78003499	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	trans	rs7618501	0.669	rs7634084	chr3:49949834	A/T	cg21659725	chr3:3221576	CRBN	0.63	11.68	0.48	8.61e-28	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03666973	chr2:27008764	CENPA	0.49	7.53	0.33	2.65e-13	Gut microbiome composition (summer);
LGG	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs17253792	0.822	rs75232282	chr14:56067290	G/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs240764	0.658	rs7740783	chr6:101263516	C/T	cg21058520	chr6:100914733	NA	-0.39	-6.73	-0.3	5.16e-11	Neuroticism;
LGG	cis	rs654950	0.806	rs2759251	chr1:42041749	C/G	cg06885757	chr1:42089581	HIVEP3	-0.66	-15.08	-0.57	4.25e-42	Airway imaging phenotypes;
LGG	trans	rs1728785	1.000	rs1728785	chr16:68591230	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.7	-10.79	-0.45	2.36e-24	Ulcerative colitis;
LGG	cis	rs77106637	0.932	rs2886599	chr11:72721271	C/A	cg03713592	chr11:72463424	ARAP1	0.41	7.59	0.33	1.76e-13	Type 2 diabetes;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.09	-0.31	5.2e-12	Schizophrenia;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg05279229	chr7:1896384	MAD1L1	-0.4	-7.01	-0.31	8.58e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs3796352	1.000	rs35720014	chr3:52982110	A/C	cg12962167	chr3:53033115	SFMBT1	0.77	8.08	0.35	5.68e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9814567	0.929	rs1534027	chr3:134284662	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.4	-0.53	7.96e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg02002194	chr4:3960332	NA	-0.44	-7.85	-0.34	2.97e-14	Red cell distribution width;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.39	-0.36	5.92e-16	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg20607798	chr8:58055168	NA	0.69	7.8	0.34	4.02e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-9.94	-0.42	3.14e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg09307838	chr4:120376055	NA	0.84	14.28	0.55	1.32e-38	Corneal astigmatism;
LGG	cis	rs9309473	0.579	rs6728128	chr2:73595982	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-8.58	-0.37	1.45e-16	Metabolite levels;
LGG	cis	rs9611565	0.559	rs7290991	chr22:41964361	C/G	cg06634786	chr22:41940651	POLR3H	-0.72	-11.54	-0.47	2.88e-27	Vitiligo;
LGG	trans	rs11098499	0.562	rs58583086	chr4:120556362	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-9.44	-0.4	1.87e-19	Corneal astigmatism;
LGG	cis	rs473651	0.716	rs548179	chr2:239320505	G/A	cg08773314	chr2:239334832	ASB1	0.38	7.16	0.32	3.14e-12	Multiple system atrophy;
LGG	cis	rs7246760	1.000	rs59771283	chr19:9854958	G/A	cg16876255	chr19:9731953	ZNF561	0.78	7.25	0.32	1.79e-12	Pursuit maintenance gain;
LGG	cis	rs9658691	0.607	rs9325604	chr10:90775756	A/G	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-9.03	-0.39	4.62e-18	Mosquito bite size;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.683	rs56196593	chr8:58141898	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3741404	0.791	rs7112960	chr11:63907079	A/G	cg18225595	chr11:63971243	STIP1	0.64	12.69	0.51	7.28e-32	Platelet count;
LGG	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.03	-0.35	8.39e-15	Schizophrenia;
LGG	cis	rs56283067	0.886	rs56110323	chr6:44679934	G/A	cg20913747	chr6:44695427	NA	-0.64	-11.38	-0.47	1.23e-26	Total body bone mineral density;
LGG	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg14500267	chr11:67383377	NA	0.41	7.34	0.32	9.45e-13	Mean corpuscular volume;
LGG	cis	rs2836974	0.932	rs2836953	chr21:40617483	G/A	cg11890956	chr21:40555474	PSMG1	1.17	28.34	0.8	3.41e-103	Cognitive function;
LGG	cis	rs7681440	0.904	rs6816305	chr4:90772902	C/G	cg01966878	chr4:90757139	SNCA	-0.36	-7.42	-0.33	5.71e-13	Dementia with Lewy bodies;
LGG	cis	rs9325144	0.600	rs12424410	chr12:38758035	A/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.44	-0.37	4.03e-16	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg14262678	chr6:151773367	RMND1;C6orf211	0.55	9.86	0.42	6.04e-21	Menarche (age at onset);
LGG	cis	rs1978968	0.788	rs12169946	chr22:18468105	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.62	-12.97	-0.52	4.97e-33	Presence of antiphospholipid antibodies;
LGG	cis	rs9604529	0.759	rs79192570	chr13:114625570	G/A	cg13259177	chr13:114761607	RASA3	-0.66	-8.57	-0.37	1.61e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9527	0.615	rs7073295	chr10:104672233	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.03	0.42	1.51e-21	Arsenic metabolism;
LGG	cis	rs16837677	0.571	rs75853057	chr1:156753759	G/T	cg14991358	chr1:156767203	PRCC	0.75	7.73	0.34	6.86e-14	Sjögren's syndrome;
LGG	cis	rs7524258	0.868	rs4908607	chr1:7269323	A/G	cg07173049	chr1:7289937	CAMTA1	0.71	16.97	0.62	1.38e-50	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-9.73	-0.41	1.77e-20	Lung cancer;
LGG	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.86	-0.3	2.23e-11	Monocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15408407	chr19:1438438	RPS15	0.43	6.92	0.31	1.51e-11	Cognitive performance;
LGG	cis	rs7927592	0.913	rs12283755	chr11:68371658	A/G	cg20283391	chr11:68216788	NA	-0.5	-8.16	-0.35	3.23e-15	Total body bone mineral density;
LGG	cis	rs7241530	0.560	rs12959612	chr18:75894165	C/T	cg14642773	chr18:75888474	NA	0.48	9.18	0.39	1.47e-18	Educational attainment (years of education);
LGG	cis	rs60871478	0.636	rs55663559	chr7:884057	G/A	cg13798912	chr7:905769	UNC84A	-0.57	-7.14	-0.31	3.65e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2120243	0.539	rs12638732	chr3:157113871	T/C	cg24825693	chr3:157122686	VEPH1	-0.58	-13.49	-0.53	3.16e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg27411982	chr8:10470053	RP1L1	-0.4	-6.69	-0.3	6.46e-11	Neuroticism;
LGG	cis	rs62103177	0.636	rs9958792	chr18:77627876	T/C	cg20368463	chr18:77673604	PQLC1	-0.53	-8.29	-0.36	1.28e-15	Opioid sensitivity;
LGG	trans	rs656319	0.559	rs55683917	chr8:9976479	C/G	cg16141378	chr3:129829833	LOC729375	0.34	7.6	0.33	1.66e-13	Myopia (pathological);
LGG	trans	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.46	-7.9	-0.34	2.03e-14	Mean corpuscular volume;
LGG	trans	rs12579753	0.869	rs12366921	chr12:82223024	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.78	-0.34	4.69e-14	Resting heart rate;
LGG	cis	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.04	-0.31	6.93e-12	Neuroticism;
LGG	cis	rs1790761	0.505	rs7945035	chr11:67348162	A/G	cg09038676	chr11:67351608	GSTP1	0.36	7.08	0.31	5.52e-12	Mean corpuscular volume;
LGG	cis	rs888194	0.738	rs7956788	chr12:109960962	T/C	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-6.68	-0.3	7.02e-11	Neuroticism;
LGG	cis	rs6032067	0.929	rs2233883	chr20:43835822	T/C	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs4700695	0.614	rs153387	chr5:65422236	G/A	cg21114390	chr5:65439923	SFRS12	-0.68	-6.86	-0.3	2.24e-11	Facial morphology (factor 19);
LGG	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.91	0.35	1.9e-14	Coronary artery disease;
LGG	cis	rs882300	0.934	rs1519523	chr2:136934449	A/C	cg07169764	chr2:136633963	MCM6	0.46	7.44	0.33	4.85e-13	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs9403521	1.000	rs7766510	chr6:144002291	C/G	cg18240653	chr6:144019428	PHACTR2	-0.62	-9.68	-0.41	2.69e-20	Obesity-related traits;
LGG	cis	rs2795502	1.000	rs2796575	chr10:43374911	A/G	cg20628663	chr10:43360327	NA	0.41	8.24	0.36	1.82e-15	Blood protein levels;
LGG	cis	rs2228479	0.717	rs34027607	chr16:89808939	T/C	cg04287289	chr16:89883240	FANCA	0.77	8.42	0.36	4.58e-16	Skin colour saturation;
LGG	cis	rs3849046	0.713	rs13159624	chr5:137945037	C/T	cg10920316	chr5:137946599	NA	-0.46	-7.32	-0.32	1.11e-12	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs8062405	0.964	rs9972768	chr16:28861734	A/C	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg00761968	chr13:53314142	LECT1	-0.38	-7.95	-0.35	1.39e-14	Lewy body disease;
LGG	cis	rs12291225	0.679	rs4757245	chr11:14297872	A/C	cg19336497	chr11:14380999	RRAS2	-0.57	-11.62	-0.48	1.48e-27	Sense of smell;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg22907277	chr7:1156413	C7orf50	0.8	14.52	0.56	1.25e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs75920871	0.843	rs4936363	chr11:116972935	A/G	cg20608306	chr11:116969690	SIK3	0.33	6.79	0.3	3.47e-11	Subjective well-being;
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.28	-0.43	1.83e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs10754283	0.901	rs6663526	chr1:90110862	T/C	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9790314	0.580	rs960212	chr3:161047974	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-10.88	-0.45	1.09e-24	Morning vs. evening chronotype;
LGG	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs79387448	0.701	rs3752659	chr2:103001598	A/G	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.73	-0.3	5.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg04986931	chr22:39850128	NA	0.34	7.92	0.35	1.8e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2074193	0.617	rs215376	chr12:47750875	A/C	cg02516419	chr12:47771422	NA	-0.69	-9.78	-0.41	1.21e-20	Migraine with aura;
LGG	cis	rs7827545	1.000	rs2119879	chr8:135549042	T/C	cg17885191	chr8:135476712	NA	0.42	6.74	0.3	4.69e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs910316	1.000	rs13099	chr14:75599155	G/A	cg11812906	chr14:75593930	NEK9	-0.53	-9.81	-0.41	9.44e-21	Height;
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.93	-0.31	1.44e-11	Menopause (age at onset);
LGG	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg06634786	chr22:41940651	POLR3H	0.76	12.15	0.49	1.18e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs897984	0.683	rs12926237	chr16:30837596	C/T	cg00531865	chr16:30841666	NA	0.69	16.66	0.61	3.81e-49	Dementia with Lewy bodies;
LGG	cis	rs12210905	1.000	rs7757680	chr6:27005840	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-7.43	-0.33	5.19e-13	Hip circumference adjusted for BMI;
LGG	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs7428	0.962	rs3637	chr2:85549874	A/G	cg24342717	chr2:85555507	TGOLN2	-0.47	-7.41	-0.33	5.87e-13	Ear protrusion;
LGG	cis	rs4639966	0.836	rs7130875	chr11:118613674	T/C	cg19182353	chr11:118479428	PHLDB1	-0.51	-8.38	-0.36	6.48e-16	Systemic lupus erythematosus;
LGG	cis	rs8032158	0.702	rs11630780	chr15:56128445	G/T	cg02198044	chr15:56286336	NEDD4	0.52	9.05	0.39	3.84e-18	Keloid;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24332422	chr5:112073686	APC	0.41	6.86	0.3	2.19e-11	Gut microbiome composition (summer);
LGG	cis	rs9733	0.818	rs10888388	chr1:150687296	C/T	cg13175981	chr1:150552382	MCL1	0.54	9.12	0.39	2.24e-18	Tonsillectomy;
LGG	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg06481639	chr22:41940642	POLR3H	-0.48	-7.29	-0.32	1.32e-12	Vitiligo;
LGG	cis	rs7119	0.717	rs34194537	chr15:77795761	G/A	cg05673287	chr15:77411982	SGK269	-0.45	-9.79	-0.41	1.09e-20	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12296079	chr11:61849674	NA	0.49	7.78	0.34	4.8e-14	Gut microbiome composition (summer);
LGG	cis	rs4423214	1.000	rs12791871	chr11:71164544	A/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.1	-0.52	1.45e-33	Vitamin D levels;
LGG	cis	rs9322193	0.923	rs9766004	chr6:150075499	C/T	cg02462569	chr6:150064036	NUP43	-0.42	-9.21	-0.39	1.11e-18	Lung cancer;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg10505658	chr17:80084571	CCDC57	-0.42	-8.55	-0.37	1.84e-16	Life satisfaction;
LGG	cis	rs2247341	0.965	rs2854917	chr4:1720550	T/C	cg05026014	chr4:1749153	NA	-0.33	-9.18	-0.39	1.39e-18	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8017423	0.647	rs4904677	chr14:90819245	C/T	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg22875332	chr1:76189707	ACADM	0.59	9.39	0.4	2.66e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8060686	0.641	rs73612690	chr16:68153200	G/A	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.05	-0.31	6.37e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2731664	0.765	rs2630766	chr5:176874941	A/C	cg23176889	chr5:176863531	GRK6	-0.66	-13.35	-0.53	1.31e-34	Intelligence (multi-trait analysis);
LGG	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg19913688	chr11:428466	ANO9	-0.67	-8.61	-0.37	1.19e-16	Body mass index;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs9942416	0.601	rs114547168	chr5:74991903	A/G	cg19683494	chr5:74908142	NA	0.45	7.09	0.31	5.15e-12	Age-related disease endophenotypes;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg22920501	chr2:26401640	FAM59B	0.41	7.66	0.34	1.08e-13	Gut microbiome composition (summer);
LGG	cis	rs858239	0.600	rs7784929	chr7:23124277	T/C	cg23682824	chr7:23144976	KLHL7	0.43	7.49	0.33	3.57e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27297192	chr10:134578999	INPP5A	0.31	7.19	0.32	2.59e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17534004	1.000	rs35955426	chr13:31471381	A/G	cg00367615	chr13:31480979	C13orf33	0.35	7.09	0.31	4.96e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs9901225	1	rs9901225	chr17:40755811	C/T	cg14558262	chr17:40713999	COASY	0.63	11.88	0.48	1.41e-28	Colorectal or endometrial cancer;
LGG	cis	rs2120019	0.938	rs35911108	chr15:75322179	G/A	cg17294928	chr15:75287854	SCAMP5	-0.98	-18.85	-0.66	2.94e-59	Blood trace element (Zn levels);
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg06850241	chr22:41845214	NA	0.46	7.33	0.32	1.06e-12	Vitiligo;
LGG	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg04731861	chr2:219085781	ARPC2	0.29	6.98	0.31	1.01e-11	Ulcerative colitis;
LGG	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg00677455	chr12:58241039	CTDSP2	0.39	7.31	0.32	1.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg24955955	chr5:415729	AHRR	0.81	10.82	0.45	1.71e-24	Fat distribution (HIV);
LGG	cis	rs6088580	0.634	rs6088483	chr20:32984714	T/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.66	-0.41	3.01e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1577917	1.000	rs10498958	chr6:86649705	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.78	13.96	0.54	3.18e-37	Response to antipsychotic treatment;
LGG	cis	rs7726354	0.793	rs75433101	chr5:56002070	T/A	cg27303933	chr5:56029418	NA	0.49	6.79	0.3	3.36e-11	Breast cancer (early onset);
LGG	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg22916017	chr11:64110731	CCDC88B	-0.45	-6.66	-0.3	7.66e-11	Mean platelet volume;
LGG	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg15556689	chr8:8085844	FLJ10661	0.47	8.64	0.37	8.98e-17	Mood instability;
LGG	cis	rs9322193	0.962	rs35443312	chr6:149991761	T/C	cg13206674	chr6:150067644	NUP43	0.68	15.68	0.59	9.55e-45	Lung cancer;
LGG	cis	rs9810089	0.527	rs895894	chr3:135955443	C/T	cg12473912	chr3:136751656	NA	0.48	8.38	0.36	6.47e-16	Gestational age at birth (child effect);
LGG	trans	rs7395662	0.895	rs4882238	chr11:48755540	A/G	cg00717180	chr2:96193071	NA	-0.41	-7.38	-0.32	7.46e-13	HDL cholesterol;
LGG	cis	rs16854884	1.000	rs13067695	chr3:143781054	C/T	cg06585982	chr3:143692056	C3orf58	0.53	8.24	0.36	1.81e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs2762353	0.526	rs12215823	chr6:25726074	G/C	cg17691542	chr6:26056736	HIST1H1C	0.41	6.91	0.31	1.62e-11	Blood metabolite levels;
LGG	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg01448562	chr3:133502909	NA	-0.74	-13.77	-0.54	2.14e-36	Iron status biomarkers;
LGG	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg10523679	chr1:76189770	ACADM	0.82	15.55	0.59	3.5e-44	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9944715	0.954	rs8086610	chr18:43844658	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.37	-7.11	-0.31	4.46e-12	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.27	-0.32	1.5e-12	Joint mobility (Beighton score);
LGG	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg19812747	chr11:111475976	SIK2	-0.5	-10.67	-0.44	6.37e-24	Primary sclerosing cholangitis;
LGG	cis	rs35306767	0.807	rs11253513	chr10:968450	C/T	cg08847335	chr10:891726	LARP4B	-0.36	-6.97	-0.31	1.07e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs8067545	0.720	rs9916675	chr17:19900168	A/G	cg13482628	chr17:19912719	NA	0.58	10.7	0.45	5.1e-24	Schizophrenia;
LGG	cis	rs787274	0.557	rs2182048	chr9:115668970	C/T	cg13803584	chr9:115635662	SNX30	0.72	8.44	0.37	4.08e-16	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs74781061	0.860	rs6495102	chr15:74762678	A/G	cg02384859	chr15:74862662	ARID3B	-0.35	-7.34	-0.32	9.94e-13	Endometriosis;
LGG	cis	rs990171	1.000	rs3860444	chr2:103007623	A/G	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.19e-21	Lymphocyte counts;
LGG	cis	rs9926296	0.712	rs2437957	chr16:89715648	G/A	cg08949735	chr16:89699720	DPEP1	-0.49	-10.08	-0.42	9.99e-22	Vitiligo;
LGG	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg20673091	chr1:2541236	MMEL1	-0.78	-17.7	-0.64	6.72e-54	Ulcerative colitis;
LGG	cis	rs1801251	1.000	rs13004406	chr2:233584557	A/T	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.22	-0.39	1.05e-18	Coronary artery disease;
LGG	cis	rs897984	0.609	rs12445650	chr16:31044897	G/A	cg00531865	chr16:30841666	NA	-0.51	-10.41	-0.44	6.28e-23	Dementia with Lewy bodies;
LGG	cis	rs9287719	0.674	rs11691060	chr2:10827061	T/C	cg02196655	chr2:10830764	NOL10	0.5	8.79	0.38	2.96e-17	Prostate cancer;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg26174226	chr8:58114915	NA	-0.46	-6.86	-0.3	2.24e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2629751	0.512	rs2583271	chr12:104440855	C/T	cg14987745	chr12:104360022	TDG	-0.54	-7.09	-0.31	5.14e-12	Hepatitis C induced liver fibrosis;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg24575275	chr7:1094737	C7orf50	-0.37	-7.38	-0.32	7.21e-13	Longevity;Endometriosis;
LGG	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg26944245	chr16:421049	TMEM8A;MRPL28	-0.57	-10.69	-0.44	5.5e-24	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs9863	0.828	rs12303933	chr12:124482256	T/C	cg13487667	chr12:124434373	CCDC92	-0.36	-7.28	-0.32	1.43e-12	White blood cell count;
LGG	cis	rs9341808	0.700	rs12215236	chr6:80975058	A/T	cg08355045	chr6:80787529	NA	0.39	7.52	0.33	2.87e-13	Sitting height ratio;
LGG	cis	rs9309711	0.666	rs11127429	chr2:3485224	T/G	cg15506890	chr2:3487001	NA	-0.55	-10.58	-0.44	1.36e-23	Neurofibrillary tangles;
LGG	cis	rs6993813	0.872	rs4403441	chr8:120031785	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs9682041	0.627	rs3772173	chr3:170078232	C/T	cg11886554	chr3:170076028	SKIL	0.57	7.45	0.33	4.69e-13	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs877282	0.947	rs7475589	chr10:767479	C/G	cg17470449	chr10:769945	NA	0.6	7.51	0.33	3.11e-13	Uric acid levels;
LGG	cis	rs7143963	0.636	rs7152791	chr14:103293716	C/T	cg23020514	chr14:103360112	TRAF3	0.41	8.65	0.37	8.78e-17	Body mass index;
LGG	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg09029085	chr17:47094198	IGF2BP1	0.26	6.65	0.3	8.03e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs7481584	0.624	rs369461	chr11:3061992	A/G	cg25174290	chr11:3078921	CARS	-0.53	-9.71	-0.41	2.05e-20	Calcium levels;
LGG	cis	rs9926296	0.706	rs2159115	chr16:89831819	A/G	cg26513180	chr16:89883248	FANCA	0.59	10.53	0.44	2.27e-23	Vitiligo;
LGG	cis	rs367943	0.698	rs2115208	chr5:112973994	A/G	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	trans	rs7944735	0.508	rs7124949	chr11:47825972	A/G	cg15704280	chr7:45808275	SEPT13	0.63	6.89	0.3	1.77e-11	Intraocular pressure;
LGG	cis	rs10791323	0.627	rs2723614	chr11:133705871	T/G	cg15485101	chr11:133734466	NA	0.59	10.45	0.44	4.28e-23	Childhood ear infection;
LGG	cis	rs2688482	0.512	rs3103954	chr3:195516630	G/T	cg13752114	chr3:195489708	MUC4	0.69	9.23	0.39	9.93e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs453301	0.686	rs10217044	chr8:8894752	A/G	cg11995313	chr8:8860691	ERI1	0.46	7.92	0.35	1.83e-14	Joint mobility (Beighton score);
LGG	cis	rs6795744	0.665	rs17303603	chr3:14092316	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.48	7.11	0.31	4.5e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs854765	0.603	rs4506967	chr17:17990474	A/C	cg04398451	chr17:18023971	MYO15A	-0.83	-18.31	-0.65	9.8e-57	Total body bone mineral density;
LGG	cis	rs6952808	0.609	rs4721185	chr7:1951109	T/C	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.14	-0.32	3.55e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	8.07	0.35	6.05e-15	Renal function-related traits (BUN);
LGG	cis	rs10504229	0.724	rs16922734	chr8:58111192	C/T	cg08280861	chr8:58055591	NA	0.53	6.8	0.3	3.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs62294332	chr4:9959989	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg00857998	chr1:205179979	DSTYK	0.56	8.89	0.38	1.39e-17	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg26441486	chr22:50317300	CRELD2	-0.39	-7.12	-0.31	4.08e-12	Schizophrenia;
LGG	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg21475434	chr5:93447410	FAM172A	0.75	7.45	0.33	4.69e-13	Diabetic retinopathy;
LGG	cis	rs12949688	1.000	rs886925	chr17:55817649	G/C	cg12229367	chr17:55822335	NA	0.44	8.49	0.37	2.83e-16	Schizophrenia;
LGG	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.02	0.57	7.96e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7786808	0.544	rs6971888	chr7:158193835	G/A	cg12438819	chr7:158236134	PTPRN2	-0.3	-7.92	-0.35	1.72e-14	Obesity-related traits;
LGG	cis	rs12188164	0.561	rs2721010	chr5:456915	A/G	cg26076054	chr5:421317	AHRR	0.42	7.79	0.34	4.59e-14	Cystic fibrosis severity;
LGG	cis	rs9992101	0.645	rs1828538	chr4:77288033	G/A	cg17010112	chr4:77227123	STBD1	-0.46	-9.58	-0.41	5.99e-20	Creatinine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25887850	chr20:44509743	ZSWIM1	0.49	7.5	0.33	3.35e-13	Gut microbiome composition (summer);
LGG	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg23601095	chr6:26197514	HIST1H3D	0.71	9.15	0.39	1.8e-18	Gout;Renal underexcretion gout;
LGG	cis	rs1665650	0.957	rs1638416	chr10:118494199	C/T	cg14919929	chr10:118506882	NA	0.48	8.45	0.37	3.88e-16	Colorectal cancer;
LGG	cis	rs7191700	0.601	rs243329	chr16:11352313	A/T	cg00044050	chr16:11439710	C16orf75	0.56	9.53	0.4	9.01e-20	Multiple sclerosis;
LGG	cis	rs2228479	0.850	rs57267516	chr16:89903552	G/A	cg04287289	chr16:89883240	FANCA	0.84	8.15	0.35	3.46e-15	Skin colour saturation;
LGG	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg08508325	chr11:3079039	CARS	0.38	7.09	0.31	5.18e-12	Calcium levels;
LGG	cis	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25517755	chr10:38738941	LOC399744	0.38	7.02	0.31	7.9e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2229238	0.911	rs73023349	chr1:154513440	T/C	cg10237817	chr1:154519846	TDRD10	0.35	6.98	0.31	1.04e-11	Coronary heart disease;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17882374	chr17:78041429	CCDC40	0.38	6.74	0.3	4.77e-11	Electrocardiographic conduction measures;
LGG	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg20246863	chr2:73402720	NA	-0.27	-6.8	-0.3	3.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7953508	0.750	rs7977788	chr12:93982332	G/A	cg18151635	chr12:93972918	NA	-0.47	-8.4	-0.36	5.67e-16	Pubertal anthropometrics;
LGG	cis	rs2406342	0.528	rs75536638	chr18:74499060	G/T	cg24983120	chr18:74499380	NA	0.42	7.63	0.33	1.33e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (cisplatin);
LGG	cis	rs7614311	0.636	rs3774702	chr3:63856870	G/A	cg22134162	chr3:63841271	THOC7	-0.34	-6.71	-0.3	5.71e-11	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs12681288	0.550	rs76893867	chr8:962618	G/C	cg04851639	chr8:1020857	NA	-0.34	-7.13	-0.31	3.99e-12	Schizophrenia;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg02951883	chr7:2050386	MAD1L1	-0.62	-12.02	-0.49	3.64e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs4925386	0.681	rs2427296	chr20:60927475	G/A	cg24112000	chr20:60950667	NA	-0.4	-8.11	-0.35	4.74e-15	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs2235649	0.828	rs9925354	chr16:1849866	G/A	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.86	-0.3	2.16e-11	Blood metabolite levels;
LGG	cis	rs801193	0.569	rs6951302	chr7:66132512	T/C	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	cis	rs9560113	0.960	rs4773378	chr13:112174154	G/A	cg14154082	chr13:112174009	NA	0.41	9.13	0.39	2.08e-18	Menarche (age at onset);
LGG	cis	rs514406	0.679	rs960570	chr1:53237763	A/G	cg25767906	chr1:53392781	SCP2	0.43	8.36	0.36	7.59e-16	Monocyte count;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	cis	rs2228479	0.867	rs76885005	chr16:89966668	A/G	cg03036210	chr16:89904091	SPIRE2	-0.56	-7.38	-0.32	7.2e-13	Skin colour saturation;
LGG	cis	rs7582180	0.726	rs2871340	chr2:100884117	A/C	cg14675211	chr2:100938903	LONRF2	-0.42	-6.87	-0.3	2.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.53	-0.44	2.1e-23	Lung cancer;
LGG	cis	rs9914544	0.966	rs9906795	chr17:18816740	G/A	cg26378065	chr17:18585709	ZNF286B	0.49	9.11	0.39	2.52e-18	Educational attainment (years of education);
LGG	trans	rs853679	0.607	rs71559070	chr6:28038929	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs9527	0.551	rs28606370	chr10:104670832	C/A	cg04362960	chr10:104952993	NT5C2	0.55	10.09	0.42	8.9e-22	Arsenic metabolism;
LGG	trans	rs1941687	0.732	rs3744888	chr18:31402594	A/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.82	-0.38	2.41e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11771526	0.901	rs11760534	chr7:32262966	C/T	cg13207630	chr7:32358064	NA	0.68	7.23	0.32	1.98e-12	Body mass index;
LGG	cis	rs2559856	1.000	rs2559860	chr12:102087636	C/T	cg12924262	chr12:102091054	CHPT1	0.66	13.22	0.52	4.49e-34	Blood protein levels;
LGG	cis	rs2708240	1.000	rs2708271	chr7:147574111	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.77	-0.3	4.03e-11	QT interval (drug interaction);
LGG	cis	rs4253772	0.530	rs9615958	chr22:46751122	A/G	cg00784671	chr22:46762841	CELSR1	-0.63	-7.55	-0.33	2.27e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4919087	0.590	rs61569149	chr10:99073879	A/G	cg25902810	chr10:99078978	FRAT1	-0.41	-7.11	-0.31	4.37e-12	Monocyte count;
LGG	cis	rs7717393	0.786	rs72798934	chr5:155795332	A/C	cg12904904	chr5:155754151	SGCD	0.64	7.45	0.33	4.53e-13	Egg allergy;
LGG	cis	rs9388451	0.839	rs9321054	chr6:126079968	A/G	cg05901451	chr6:126070800	HEY2	0.81	17.69	0.63	7.39e-54	Brugada syndrome;
LGG	cis	rs8141529	0.956	rs469989	chr22:29303595	G/C	cg02153584	chr22:29168773	CCDC117	-0.59	-8.89	-0.38	1.34e-17	Lymphocyte counts;
LGG	cis	rs6772849	0.930	rs9868579	chr3:128351054	C/T	cg08795948	chr3:128337044	NA	-0.66	-11.2	-0.46	6.12e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs67311347	1.000	rs13073003	chr3:40504326	C/T	cg13683864	chr3:40499215	RPL14	1.15	28.26	0.8	7.65e-103	Renal cell carcinoma;
LGG	trans	rs116095464	1.000	rs7736	chr5:314935	T/C	cg00938859	chr5:1591904	SDHAP3	0.8	8.53	0.37	2.15e-16	Breast cancer;
LGG	cis	rs62400317	0.859	rs62400293	chr6:45233580	A/T	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	trans	rs916888	0.773	rs199451	chr17:44801784	G/A	cg06925179	chr17:43578568	NA	0.42	10.02	0.42	1.68e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7726839	0.526	rs11960158	chr5:568665	C/T	cg25482853	chr8:67687455	SGK3	0.86	11.22	0.46	5.18e-26	Obesity-related traits;
LGG	cis	rs727505	1.000	rs10240673	chr7:124513050	A/G	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs56161922	0.908	rs78159416	chr1:207820375	C/A	cg09557387	chr1:207818395	CR1L	0.98	9.6	0.41	4.97e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg26656751	chr17:43910226	CRHR1	0.48	8.8	0.38	2.71e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs17270561	0.636	rs9348696	chr6:25781938	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	9.41	0.4	2.38e-19	Iron status biomarkers;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01899001	chr3:48754828	IP6K2	0.6	6.84	0.3	2.54e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13314892	0.728	rs62252229	chr3:69888407	C/G	cg17445875	chr3:69859618	MITF	-0.41	-7.96	-0.35	1.36e-14	QRS complex (12-leadsum);
LGG	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg02353165	chr6:42928485	GNMT	0.31	7.44	0.33	4.89e-13	Blood protein levels;
LGG	cis	rs208520	0.661	rs1100950	chr6:66827285	A/C	cg07460842	chr6:66804631	NA	-0.97	-18.12	-0.64	7.59e-56	Exhaled nitric oxide output;
LGG	cis	rs12451471	0.559	rs12452263	chr17:78079310	T/C	cg24585782	chr17:78113791	EIF4A3	-0.48	-8.05	-0.35	7.27e-15	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs2731664	0.756	rs2545796	chr5:176864269	T/C	cg23176889	chr5:176863531	GRK6	-0.64	-12.49	-0.5	4.8e-31	Intelligence (multi-trait analysis);
LGG	trans	rs17666538	0.636	rs10107345	chr8:603700	G/T	cg20325293	chr4:54244256	FIP1L1	-0.8	-7.83	-0.34	3.25e-14	IgG glycosylation;
LGG	cis	rs2153535	0.580	rs1115079	chr6:8449615	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.4e-31	Motion sickness;
LGG	cis	rs911263	0.603	rs11628954	chr14:68782604	C/T	cg18825221	chr14:68749962	RAD51L1	0.38	8.29	0.36	1.25e-15	Primary biliary cholangitis;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs12493885	0.585	rs61790899	chr3:153642124	C/T	cg12800244	chr3:153838788	SGEF	-0.65	-7.62	-0.33	1.42e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2718058	0.550	rs2392522	chr7:37801783	C/T	cg15028436	chr7:37888078	TXNDC3	-0.45	-7.35	-0.32	8.81e-13	Alzheimer's disease (late onset);
LGG	cis	rs875971	0.862	rs1875057	chr7:65731855	A/G	cg11764359	chr7:65958608	NA	-0.73	-12.87	-0.51	1.29e-32	Aortic root size;
LGG	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg05084668	chr3:125655381	ALG1L	-0.56	-7.53	-0.33	2.76e-13	Blood pressure (smoking interaction);
LGG	cis	rs758324	0.588	rs253944	chr5:131330054	C/G	cg06307176	chr5:131281290	NA	0.45	6.8	0.3	3.19e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs4808199	0.895	rs7252888	chr19:19628037	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.38	6.99	0.31	9.58e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg02811702	chr13:24901961	NA	0.39	7.36	0.32	8.64e-13	Obesity-related traits;
LGG	cis	rs9457247	0.740	rs10946204	chr6:167451129	T/C	cg07741184	chr6:167504864	NA	0.43	9.51	0.4	1.07e-19	Crohn's disease;
LGG	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg13482628	chr17:19912719	NA	0.5	9.33	0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs727505	1.000	rs67084428	chr7:124499388	G/T	cg23710748	chr7:124431027	NA	-0.52	-9.83	-0.42	7.64e-21	Lewy body disease;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg05861140	chr6:150128134	PCMT1	-0.36	-7.16	-0.32	3.28e-12	Testicular germ cell tumor;
LGG	cis	rs7546668	1.000	rs7546668	chr1:15855123	G/C	cg21858823	chr1:15850916	CASP9	0.38	7.11	0.31	4.29e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs782590	0.574	rs12991445	chr2:55675939	C/T	cg18811423	chr2:55921094	PNPT1	0.68	12.9	0.51	9.24e-33	Metabolic syndrome;
LGG	cis	rs6540556	0.769	rs6679405	chr1:209926468	A/C	cg05527609	chr1:210001259	C1orf107	-0.49	-6.82	-0.3	2.77e-11	Red blood cell count;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg04160749	chr8:58172571	NA	-0.51	-8.11	-0.35	4.57e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	1.000	rs13059720	chr3:134242021	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.03	0.52	2.84e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg26554054	chr8:600488	NA	1.07	10.5	0.44	2.93e-23	IgG glycosylation;
LGG	cis	rs7726839	0.561	rs11955068	chr5:582324	C/T	cg14541582	chr5:601475	NA	-0.57	-9.14	-0.39	2.03e-18	Obesity-related traits;
LGG	cis	rs7927592	0.763	rs11822059	chr11:68300822	T/G	cg16797656	chr11:68205561	LRP5	0.51	10.04	0.42	1.38e-21	Total body bone mineral density;
LGG	cis	rs7580658	0.891	rs3768866	chr2:128045415	G/A	cg10021288	chr2:128175891	PROC	-0.64	-13.29	-0.53	2.23e-34	Protein C levels;
LGG	cis	rs6500395	0.890	rs11861666	chr16:48679914	G/T	cg04672837	chr16:48644449	N4BP1	0.51	8.4	0.36	5.66e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7582180	0.652	rs11694700	chr2:100936637	C/T	cg21926883	chr2:100939477	LONRF2	-0.7	-16.6	-0.61	6.8e-49	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	1.000	rs34106666	chr6:86676258	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.34	-0.4	4.02e-19	Response to antipsychotic treatment;
LGG	trans	rs7395662	0.963	rs1857786	chr11:48967424	G/A	cg03929089	chr4:120376271	NA	-0.43	-6.99	-0.31	9.92e-12	HDL cholesterol;
LGG	cis	rs1552244	0.882	rs13074282	chr3:10024699	T/G	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs992157	0.710	rs12996912	chr2:219110555	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.21	0.43	3.32e-22	Colorectal cancer;
LGG	cis	rs9479482	0.967	rs1543547	chr6:150346532	T/C	cg07549998	chr6:150325970	RAET1K	-0.38	-7.14	-0.32	3.59e-12	Alopecia areata;
LGG	cis	rs7918232	0.830	rs7087033	chr10:27392522	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	11.46	0.47	6.22e-27	Breast cancer;
LGG	cis	rs8067545	0.516	rs4925086	chr17:20013459	A/T	cg13482628	chr17:19912719	NA	0.55	10.37	0.43	8.79e-23	Schizophrenia;
LGG	cis	rs1801251	0.929	rs10933409	chr2:233629386	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.71	0.51	6.05e-32	Coronary artery disease;
LGG	trans	rs11039571	0.588	rs61917001	chr11:48233667	G/C	cg15704280	chr7:45808275	SEPT13	0.68	8.74	0.38	4.4e-17	D-dimer levels;
LGG	cis	rs763121	0.853	rs138702	chr22:39132601	A/T	cg06022373	chr22:39101656	GTPBP1	-0.86	-17.61	-0.63	1.62e-53	Menopause (age at onset);
LGG	trans	rs7762018	0.607	rs61740334	chr6:170047902	T/A	cg06875740	chr19:51307921	C19orf48	-0.72	-6.8	-0.3	3.19e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1018836	0.608	rs2142147	chr8:91468200	A/G	cg16814680	chr8:91681699	NA	-0.59	-9.85	-0.42	6.61e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4073582	0.595	rs801736	chr11:65928430	A/T	cg14036092	chr11:66035641	RAB1B	0.45	7.74	0.34	6.3e-14	Gout;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg06221963	chr1:154839813	KCNN3	-0.52	-10.21	-0.43	3.25e-22	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05361520	chr19:7099630	NA	0.46	6.78	0.3	3.68e-11	Gut microbiome composition (summer);
LGG	cis	rs6977660	0.941	rs6953957	chr7:19820560	A/G	cg07541023	chr7:19748670	TWISTNB	0.48	7.52	0.33	2.85e-13	Thyroid stimulating hormone;
LGG	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9790314	0.905	rs1154701	chr3:161008025	T/A	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs899997	1.000	rs4887078	chr15:79011073	C/T	cg14912033	chr15:79043428	NA	-0.4	-10.22	-0.43	3.05e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs6933660	0.720	rs6913515	chr6:151753470	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.68	14.26	0.55	1.74e-38	Menarche (age at onset);
LGG	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg08862035	chr2:2617432	NA	0.42	6.96	0.31	1.14e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg02733842	chr7:1102375	C7orf50	0.61	9.58	0.41	6.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1881797	0.527	rs78398999	chr1:247686970	G/A	cg18198730	chr1:247681584	NA	0.68	7.83	0.34	3.4e-14	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11098499	0.754	rs1546503	chr4:120241167	T/C	cg09307838	chr4:120376055	NA	0.72	12.13	0.49	1.36e-29	Corneal astigmatism;
LGG	cis	rs2649	0.518	rs6494412	chr15:63856544	C/A	cg22599514	chr15:63798201	USP3	0.45	7.4	0.33	6.65e-13	Aortic root size;
LGG	cis	rs6908034	0.600	rs79733895	chr6:19799541	A/G	cg02682789	chr6:19804855	NA	0.91	8.3	0.36	1.13e-15	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs11158026	0.662	rs28481699	chr14:55406549	A/T	cg04306507	chr14:55594613	LGALS3	0.31	6.88	0.3	1.99e-11	Parkinson's disease;
LGG	cis	rs2247341	1.000	rs34049648	chr4:1697337	G/A	cg08446824	chr4:1720184	TMEM129	-0.64	-11.81	-0.48	2.51e-28	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4925166	1	rs4925166	chr17:18210810	T/G	cg08201673	chr17:18167551	SMCR7	0.42	8.58	0.37	1.48e-16	Multiple sclerosis;
LGG	cis	rs2303319	1.000	rs3769964	chr2:162207346	C/T	cg13806767	chr2:162164127	PSMD14	-0.66	-7.79	-0.34	4.49e-14	Cognitive function;
LGG	trans	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg02030672	chr11:45687055	CHST1	-0.49	-8.75	-0.38	4.05e-17	Obesity-related traits;
LGG	cis	rs77633900	0.685	rs2469556	chr15:76650148	G/A	cg21673338	chr15:77095150	SCAPER	-0.62	-8.11	-0.35	4.67e-15	Non-glioblastoma glioma;Glioma;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs28735056	0.904	rs62103183	chr18:77626564	A/G	cg05926928	chr17:57297772	GDPD1	0.58	9.46	0.4	1.52e-19	Schizophrenia;
LGG	trans	rs2574985	0.739	rs3011779	chr10:52286555	G/A	cg18558237	chr10:81444220	LOC650623	0.45	6.87	0.3	2.02e-11	Subjective well-being;
LGG	cis	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.89	-0.45	9.51e-25	Resting heart rate;
LGG	cis	rs4665809	1.000	rs3910272	chr2:26287842	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.9	-0.54	5.94e-37	Gut microbiome composition (summer);
LGG	cis	rs933688	0.532	rs11740007	chr5:90545498	C/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.54	-7.2	-0.32	2.49e-12	Smoking behavior;
LGG	cis	rs9486715	1.000	rs11153085	chr6:97066355	A/T	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.36	-0.4	3.41e-19	Headache;
LGG	cis	rs7428	0.527	rs1061782	chr2:85546615	A/G	cg24342717	chr2:85555507	TGOLN2	0.73	13.86	0.54	8.54e-37	Ear protrusion;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05961215	chr15:35280640	ZNF770	0.52	8.02	0.35	9.04e-15	Gut microbiome composition (summer);
LGG	cis	rs9868809	0.881	rs3806694	chr3:48672334	G/C	cg00383909	chr3:49044727	WDR6	0.83	9.6	0.41	4.87e-20	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs8062405	1.000	rs12444171	chr16:28845251	G/A	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.18e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2594989	0.887	rs7643330	chr3:11442093	A/G	cg01796438	chr3:11312864	ATG7	-0.51	-7.01	-0.31	8.66e-12	Circulating chemerin levels;
LGG	trans	rs853679	0.607	rs13205911	chr6:28124114	C/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs7617480	0.648	rs9864243	chr3:48982732	G/A	cg06212747	chr3:49208901	KLHDC8B	0.46	6.91	0.31	1.63e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6882046	0.513	rs2431391	chr5:88046590	C/T	cg22951263	chr5:87985283	NA	-0.56	-10.44	-0.44	4.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs7580658	0.637	rs12463909	chr2:127971738	C/G	cg10021288	chr2:128175891	PROC	0.59	11.85	0.48	1.86e-28	Protein C levels;
LGG	cis	rs9400467	0.506	rs12197149	chr6:111656067	G/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg10204951	chr7:910479	UNC84A	-0.51	-6.82	-0.3	2.85e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg19168338	chr16:4465731	CORO7	-0.72	-13.26	-0.52	3.03e-34	Schizophrenia;
LGG	cis	rs7647973	1.000	rs7619789	chr3:49476263	T/C	cg06212747	chr3:49208901	KLHDC8B	0.51	8.05	0.35	6.87e-15	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg19507638	chr5:93509721	C5orf36	-0.73	-10.1	-0.43	8.03e-22	Diabetic retinopathy;
LGG	cis	rs9463078	0.647	rs6933449	chr6:45325151	G/C	cg25276700	chr6:44698697	NA	0.32	6.75	0.3	4.42e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg01879757	chr17:41196368	BRCA1	0.4	8.16	0.35	3.21e-15	Menopause (age at onset);
LGG	cis	rs9486715	0.830	rs2475023	chr6:96996833	G/A	cg06623918	chr6:96969491	KIAA0776	-0.79	-16.16	-0.6	6.58e-47	Headache;
LGG	cis	rs526231	0.543	rs28025	chr5:102537379	A/G	cg23492399	chr5:102201601	PAM	-0.56	-8.22	-0.36	2.08e-15	Primary biliary cholangitis;
LGG	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg09873164	chr1:152488093	CRCT1	0.61	14.72	0.56	1.68e-40	Hair morphology;
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.13	-0.31	3.95e-12	Monocyte percentage of white cells;
LGG	cis	rs9394438	0.628	rs804843	chr6:37545923	A/G	cg00985040	chr6:37553208	NA	-0.37	-8.43	-0.36	4.26e-16	IgG glycosylation;
LGG	cis	rs10743315	0.557	rs17271690	chr12:19450236	A/G	cg02471346	chr12:19282374	PLEKHA5	0.83	7.78	0.34	4.67e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6121246	0.511	rs879982	chr20:30398510	A/G	cg13852791	chr20:30311386	BCL2L1	0.96	19.24	0.67	4.68e-61	Mean corpuscular hemoglobin;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg05896524	chr21:47604654	C21orf56	0.48	8.3	0.36	1.19e-15	Testicular germ cell tumor;
LGG	cis	rs7106204	0.609	rs12790279	chr11:24286221	C/G	ch.11.24196551F	chr11:24239977	NA	0.85	10.12	0.43	6.74e-22	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.66	0.54	6.46e-36	Lung cancer;
LGG	cis	rs9796	0.870	rs28479904	chr15:41268305	G/T	cg18705301	chr15:41695430	NDUFAF1	-0.48	-8.31	-0.36	1.08e-15	Menopause (age at onset);
LGG	cis	rs13102973	0.829	rs55951114	chr4:135897925	T/C	cg14419869	chr4:135874104	NA	0.45	8.2	0.36	2.38e-15	Subjective well-being;
LGG	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg06606381	chr12:133084897	FBRSL1	-1.06	-10.42	-0.44	5.58e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4144027	0.935	rs10139856	chr14:104354505	T/C	cg26031613	chr14:104095156	KLC1	0.46	7.52	0.33	2.81e-13	Blood metabolite levels;
LGG	cis	rs10865397	0.539	rs13414338	chr2:73383375	C/T	cg01422370	chr2:73384389	NA	0.53	9.77	0.41	1.24e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11209002	0.738	rs10789222	chr1:67566651	C/T	cg02640540	chr1:67518911	SLC35D1	0.57	6.91	0.31	1.66e-11	Crohn's disease;
LGG	cis	rs4642101	0.680	rs7626609	chr3:12806080	A/G	cg05775895	chr3:12838266	CAND2	-0.68	-11.82	-0.48	2.28e-28	QRS complex (12-leadsum);
LGG	cis	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg09307838	chr4:120376055	NA	0.78	12.73	0.51	4.88e-32	Corneal astigmatism;
LGG	cis	rs7927771	0.524	rs12785949	chr11:47729770	C/T	cg20307385	chr11:47447363	PSMC3	0.58	11.29	0.46	2.89e-26	Subjective well-being;
LGG	cis	rs9816226	0.591	rs6809651	chr3:185814642	G/A	cg00760338	chr3:185826511	ETV5	-0.81	-10.11	-0.43	7.53e-22	Obesity;Body mass index;
LGG	cis	rs2415984	0.622	rs10131871	chr14:46931700	A/G	cg14871534	chr14:47121158	RPL10L	0.61	10.48	0.44	3.37e-23	Number of children ever born;
LGG	cis	rs4243830	0.850	rs2063806	chr1:6610382	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.79	-12.26	-0.5	4.05e-30	Body mass index;
LGG	cis	rs3767633	0.858	rs2341468	chr1:161862312	G/A	cg09175582	chr1:161736000	ATF6	0.73	8.97	0.38	7.64e-18	IgG glycosylation;
LGG	cis	rs7523273	0.606	rs2761430	chr1:207912408	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.83	0.48	2.12e-28	Schizophrenia;
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg26554054	chr8:600488	NA	0.94	9.78	0.41	1.17e-20	IgG glycosylation;
LGG	cis	rs11074306	0.522	rs28612097	chr15:28068006	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs2816062	0.721	rs2816047	chr1:18893728	A/C	cg10574377	chr1:18908098	NA	0.35	6.94	0.31	1.29e-11	Urate levels in lean individuals;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg22907277	chr7:1156413	C7orf50	0.7	12.95	0.52	5.71e-33	Longevity;Endometriosis;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.97	-0.31	1.09e-11	Lung cancer;
LGG	cis	rs4481887	0.800	rs28680862	chr1:248515419	T/C	cg13385794	chr1:248469461	NA	0.45	7.93	0.35	1.68e-14	Common traits (Other);
LGG	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs8060686	0.641	rs13816	chr16:68055495	G/C	cg27539214	chr16:67997921	SLC12A4	-0.43	-6.92	-0.31	1.56e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg18225595	chr11:63971243	STIP1	0.64	12.03	0.49	3.25e-29	Platelet count;
LGG	cis	rs1348850	0.574	rs4893834	chr2:178442288	C/T	cg23306229	chr2:178417860	TTC30B	-0.6	-7.5	-0.33	3.27e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2243480	1.000	rs34193460	chr7:65393110	A/G	cg13147721	chr7:65941812	NA	-0.79	-9.58	-0.41	5.9e-20	Diabetic kidney disease;
LGG	cis	rs9486715	0.838	rs9486275	chr6:96901187	C/T	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10834038	chr1:27561776	WDTC1	0.34	6.8	0.3	3.15e-11	Gut microbiome composition (summer);
LGG	cis	rs7084402	1.000	rs11006169	chr10:60269326	T/A	cg09696939	chr10:60272079	BICC1	0.38	7.39	0.32	6.75e-13	Refractive error;
LGG	cis	rs9397585	0.599	rs9479502	chr6:153402698	C/T	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs6735179	0.607	rs10188708	chr2:1746032	G/C	cg10160682	chr2:1713001	PXDN	-0.58	-9.89	-0.42	4.71e-21	Response to antipsychotic treatment;
LGG	cis	rs7107174	1.000	rs10899495	chr11:78123293	C/T	cg02023728	chr11:77925099	USP35	0.44	7.77	0.34	5.21e-14	Testicular germ cell tumor;
LGG	cis	rs11874712	1.000	rs7244921	chr18:43667528	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.65	-0.44	7.67e-24	Migraine - clinic-based;
LGG	cis	rs2832191	0.550	rs66484040	chr21:30511691	G/A	cg08807101	chr21:30365312	RNF160	-0.62	-10.6	-0.44	1.18e-23	Dental caries;
LGG	cis	rs7582180	0.764	rs4635546	chr2:100921125	G/A	cg08017756	chr2:100939284	LONRF2	-0.3	-7.0	-0.31	9.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10865541	0.902	rs10206964	chr2:3425948	T/C	cg11642891	chr2:3452563	TTC15	-0.42	-8.08	-0.35	5.8e-15	Obesity-related traits;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.98	-0.42	2.2e-21	Schizophrenia;
LGG	cis	rs4731207	0.672	rs3213667	chr7:124480869	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg22643751	chr7:855365	UNC84A	0.42	7.39	0.32	6.86e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs36051895	0.623	rs3780383	chr9:5232409	G/C	cg02405213	chr9:5042618	JAK2	-0.77	-12.81	-0.51	2.34e-32	Pediatric autoimmune diseases;
LGG	cis	rs968451	0.789	rs1003643	chr22:39676494	T/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.8	13.17	0.52	7.2e-34	Primary biliary cholangitis;
LGG	cis	rs73193808	0.639	rs2832241	chr21:30552036	A/G	cg03476357	chr21:30257390	N6AMT1	0.41	6.83	0.3	2.67e-11	Coronary artery disease;
LGG	cis	rs10231759	0.583	rs4015632	chr7:150516826	A/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.37	7.95	0.35	1.43e-14	Height;
LGG	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg19766460	chr21:43528205	UMODL1;C21orf128	0.47	8.86	0.38	1.74e-17	IgG glycosylation;
LGG	cis	rs5769765	0.865	rs4824108	chr22:50271428	A/G	cg02269571	chr22:50332266	NA	0.64	10.12	0.43	6.99e-22	Schizophrenia;
LGG	cis	rs4865875	0.892	rs10066622	chr5:54104956	A/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	trans	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg23533926	chr12:111358616	MYL2	-0.4	-6.7	-0.3	6.09e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07399312	chr1:156470683	MEF2D	0.46	6.81	0.3	3e-11	Gut microbiome composition (summer);
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.31	-8.1	-0.35	5.04e-15	IgG glycosylation;
LGG	cis	rs2295359	1.000	rs4655684	chr1:67611772	A/G	cg03340356	chr1:67600835	NA	-0.32	-6.72	-0.3	5.39e-11	Psoriasis;
LGG	cis	rs6424115	1.000	rs7519554	chr1:24154566	T/A	cg15997130	chr1:24165203	NA	-0.48	-13.18	-0.52	6.64e-34	Immature fraction of reticulocytes;
LGG	cis	rs1790761	0.520	rs1551884	chr11:67399601	C/G	cg23188684	chr11:67383651	NA	-0.52	-8.25	-0.36	1.71e-15	Mean corpuscular volume;
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg10950524	chr7:2139216	MAD1L1	0.32	6.95	0.31	1.22e-11	Schizophrenia;
LGG	cis	rs8028182	0.577	rs28693593	chr15:75849776	A/C	cg20655648	chr15:75932815	IMP3	0.44	7.27	0.32	1.59e-12	Sudden cardiac arrest;
LGG	cis	rs4819052	1.000	rs2297284	chr21:46705345	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.71	10.84	0.45	1.48e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3091242	0.933	rs34006994	chr1:25780668	C/T	cg27572855	chr1:25598939	RHD	-0.49	-11.05	-0.46	2.44e-25	Erythrocyte sedimentation rate;
LGG	trans	rs7824557	0.524	rs7835318	chr8:10953874	G/A	cg11608241	chr8:8085544	FLJ10661	-0.29	-6.66	-0.3	7.99e-11	Retinal vascular caliber;
LGG	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-7.69	-0.34	9.22e-14	Inflammatory skin disease;
LGG	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.4	-0.36	5.59e-16	Retinal vascular caliber;
LGG	cis	rs1005224	0.929	rs11625260	chr14:76162293	G/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-6.75	-0.3	4.46e-11	Large artery stroke;
LGG	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	9.27	0.4	7.17e-19	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs17767392	1.000	rs34528013	chr14:71767848	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	cis	rs8064024	0.619	rs9935080	chr16:4902207	A/G	cg08329684	chr16:4932620	PPL	0.52	11.56	0.47	2.6e-27	Cancer;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg00800038	chr16:89945340	TCF25	-0.68	-7.85	-0.34	2.82e-14	Skin colour saturation;
LGG	trans	rs62103177	0.810	rs62103194	chr18:77629482	G/A	cg05926928	chr17:57297772	GDPD1	1.37	21.36	0.7	5.86e-71	Opioid sensitivity;
LGG	cis	rs763121	0.962	rs1980455	chr22:38925719	A/C	cg06022373	chr22:39101656	GTPBP1	0.8	15.78	0.59	3.41e-45	Menopause (age at onset);
LGG	cis	rs2404602	0.692	rs4641709	chr15:77047736	C/T	cg22467129	chr15:76604101	ETFA	0.42	7.03	0.31	7.42e-12	Blood metabolite levels;
LGG	cis	rs7104764	0.507	rs6598056	chr11:252283	A/G	cg00562011	chr11:252351	PSMD13	0.49	7.79	0.34	4.58e-14	Menarche (age at onset);
LGG	cis	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.95	0.31	1.25e-11	Joint mobility (Beighton score);
LGG	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.45	7.29	0.32	1.39e-12	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4731207	0.596	rs1026839	chr7:124672599	C/T	cg05630886	chr7:124431682	NA	0.31	7.14	0.32	3.54e-12	Cutaneous malignant melanoma;
LGG	cis	rs7017914	0.967	rs35115527	chr8:71643009	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs4742903	0.904	rs4743691	chr9:106931541	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs10504229	0.871	rs56048296	chr8:58163781	C/T	cg23782820	chr8:58130467	NA	0.49	7.75	0.34	5.95e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.686	rs35406700	chr8:10244593	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	6.96	0.31	1.15e-11	Neuroticism;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg05863683	chr7:1912471	MAD1L1	0.45	8.73	0.38	4.52e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs9329221	0.537	rs13282106	chr8:9981900	G/T	cg02002194	chr4:3960332	NA	-0.43	-8.07	-0.35	6.16e-15	Neuroticism;
LGG	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.81	-0.38	2.61e-17	Retinal vascular caliber;
LGG	cis	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg24375607	chr4:120327624	NA	0.58	9.85	0.42	6.73e-21	Corneal astigmatism;
LGG	cis	rs981844	0.826	rs1545604	chr4:154682733	C/T	cg14289246	chr4:154710475	SFRP2	0.67	11.4	0.47	1.01e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs7766436	0.561	rs1342206	chr6:22593676	G/A	cg13666174	chr6:22585274	NA	-0.41	-9.83	-0.42	7.51e-21	Coronary artery disease;
LGG	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.15	0.58	2.05e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4819052	0.565	rs35776291	chr21:46706142	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.41	6.75	0.3	4.32e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17221829	0.626	rs10830305	chr11:89366794	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs9457247	1.000	rs444988	chr6:167389674	A/T	cg07741184	chr6:167504864	NA	0.32	7.12	0.31	4.24e-12	Crohn's disease;
LGG	cis	rs11098499	0.954	rs10005644	chr4:120298477	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs9916302	0.904	rs9894500	chr17:37515735	G/C	cg00129232	chr17:37814104	STARD3	0.61	11.54	0.47	2.93e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4466137	0.794	rs6869296	chr5:83007333	C/G	cg15083037	chr5:83017644	HAPLN1	0.33	6.68	0.3	6.85e-11	Prostate cancer;
LGG	cis	rs9400467	0.537	rs17606672	chr6:111546833	G/C	cg15721981	chr6:111408429	SLC16A10	0.58	6.96	0.31	1.19e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg17290332	chr10:14880008	CDNF;HSPA14	-0.44	-7.1	-0.31	4.78e-12	Coronary artery disease;
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg15556689	chr8:8085844	FLJ10661	0.51	9.29	0.4	6.16e-19	Triglycerides;
LGG	cis	rs2050392	0.799	rs2907	chr10:30728250	A/G	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.99	-0.45	3.93e-25	Inflammatory bowel disease;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg20026190	chr17:76395443	PGS1	0.57	10.0	0.42	1.9e-21	HDL cholesterol levels;
LGG	trans	rs3206736	0.548	rs329236	chr7:35056266	C/A	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.32	0.32	1.12e-12	Diastolic blood pressure;
LGG	cis	rs7959452	0.535	rs1350166	chr12:69636314	G/T	cg20891283	chr12:69753455	YEATS4	0.73	13.65	0.54	6.91e-36	Blood protein levels;
LGG	cis	rs17030434	0.871	rs6847648	chr4:154729700	G/A	cg14289246	chr4:154710475	SFRP2	-0.62	-10.08	-0.42	1.01e-21	Electrocardiographic conduction measures;
LGG	cis	rs975722	0.696	rs213953	chr7:117218575	G/A	cg10524701	chr7:117356490	CTTNBP2	0.47	10.15	0.43	5.49e-22	Coronary artery disease;
LGG	cis	rs921968	0.541	rs4674314	chr2:219423520	A/G	cg01130898	chr2:219473002	PLCD4	0.42	7.14	0.32	3.53e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7106204	0.514	rs7117803	chr11:24253214	A/T	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs61192259	0.566	rs10947738	chr6:38469187	A/C	cg07362130	chr6:38359646	BTBD9	-0.34	-7.49	-0.33	3.44e-13	Restless legs syndrome;
LGG	cis	rs11748327	0.580	rs11738929	chr5:4011156	C/T	cg01025095	chr5:4101132	NA	-0.45	-7.33	-0.32	1.04e-12	Myocardial infarction;
LGG	cis	rs9790314	0.905	rs6789388	chr3:160970437	G/A	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs35432774	chr7:65393019	G/C	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	trans	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg15556689	chr8:8085844	FLJ10661	0.43	7.39	0.32	7.01e-13	Retinal vascular caliber;
LGG	cis	rs728616	0.681	rs55855057	chr10:82034729	G/A	cg27171509	chr10:82033454	MAT1A	-0.43	-6.71	-0.3	5.59e-11	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs77106637	0.932	rs74439784	chr11:72649396	A/T	cg03713592	chr11:72463424	ARAP1	0.39	7.52	0.33	2.82e-13	Type 2 diabetes;
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.46	-7.33	-0.32	1.06e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2346177	0.519	rs1597040	chr2:46673903	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-12.16	-0.49	1e-29	HDL cholesterol;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg00424166	chr6:150045504	NUP43	-0.37	-7.59	-0.33	1.84e-13	Lung cancer;
LGG	cis	rs1978968	1.000	rs5992928	chr22:18451438	A/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.61	-0.51	1.58e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg15596359	chr8:11213517	TDH	-0.42	-8.43	-0.36	4.52e-16	Retinal vascular caliber;
LGG	cis	rs62025270	0.593	rs62022926	chr15:86239492	C/T	cg25843651	chr15:86329602	KLHL25	0.57	8.62	0.37	1.04e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs1978968	1.000	rs2099945	chr22:18438642	G/C	cg03078520	chr22:18463400	MICAL3	-0.62	-12.68	-0.51	8.17e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs620875	0.920	rs1784324	chr11:126808929	G/A	cg06504925	chr11:126872760	NA	-0.58	-6.8	-0.3	3.21e-11	Response to antipsychotic treatment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16370446	chr4:15683284	LOC285550	0.42	7.04	0.31	6.82e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11169552	0.510	rs10876073	chr12:51025910	T/A	cg12884762	chr12:50931848	DIP2B	-0.41	-7.66	-0.34	1.09e-13	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09237070	chr2:75873857	MRPL19	0.47	6.97	0.31	1.08e-11	Gut microbiome composition (summer);
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21862992	chr11:68658383	NA	0.5	8.31	0.36	1.05e-15	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs867371	0.722	rs8033050	chr15:82561989	G/A	cg00614314	chr15:82944287	LOC80154	0.64	10.77	0.45	2.68e-24	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7635838	0.785	rs2594972	chr3:11397417	A/G	cg00170343	chr3:11313890	ATG7	0.5	8.27	0.36	1.4e-15	HDL cholesterol;
LGG	cis	rs7538876	0.967	rs2800696	chr1:17730238	A/T	cg10329579	chr1:17754830	RCC2	-0.48	-9.21	-0.39	1.14e-18	Basal cell carcinoma;
LGG	trans	rs7819412	0.654	rs34741518	chr8:10776860	A/C	cg16141378	chr3:129829833	LOC729375	0.4	8.84	0.38	1.94e-17	Triglycerides;
LGG	cis	rs769267	0.965	rs6511026	chr19:19391402	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.01	0.52	3.45e-33	Tonsillectomy;
LGG	cis	rs11690935	0.632	rs35854151	chr2:172657439	G/A	cg13550731	chr2:172543902	DYNC1I2	0.69	14.02	0.55	1.83e-37	Schizophrenia;
LGG	cis	rs2153535	0.601	rs9393030	chr6:8516489	C/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.12e-31	Motion sickness;
LGG	cis	rs35771425	0.642	rs3767380	chr1:211452845	A/G	cg10512769	chr1:211675356	NA	-0.44	-7.69	-0.34	8.95e-14	Educational attainment (years of education);
LGG	cis	rs7681440	0.904	rs7672979	chr4:90767873	A/G	cg15133208	chr4:90757351	SNCA	-0.38	-8.76	-0.38	3.71e-17	Dementia with Lewy bodies;
LGG	cis	rs7588746	0.544	rs2163548	chr2:201226862	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-6.78	-0.3	3.61e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs875971	0.789	rs10260426	chr7:65736042	G/T	cg23594656	chr7:65796392	TPST1	0.41	9.09	0.39	2.84e-18	Aortic root size;
LGG	cis	rs4732038	0.647	rs59136474	chr7:134252691	C/T	cg06906464	chr7:134288099	NA	-0.51	-12.11	-0.49	1.6800000000000001e-29	Longevity;
LGG	trans	rs1005277	0.579	rs2472182	chr10:38388865	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs7737355	0.812	rs31591	chr5:131005638	C/T	cg06307176	chr5:131281290	NA	0.53	8.75	0.38	4.1e-17	Life satisfaction;
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg06916706	chr16:4465613	CORO7	-0.72	-12.52	-0.5	3.4e-31	Schizophrenia;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg07142201	chr11:109293216	C11orf87	0.51	9.41	0.4	2.25e-19	Schizophrenia;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg04503457	chr17:41445688	NA	-0.38	-8.89	-0.38	1.39e-17	Menopause (age at onset);
LGG	trans	rs853679	0.607	rs13199649	chr6:27868792	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-11.64	-0.48	1.15e-27	Depression;
LGG	cis	rs941408	0.515	rs56000942	chr19:2774104	G/C	cg06609049	chr19:2785107	THOP1	1.0	14.96	0.57	1.47e-41	Total cholesterol levels;
LGG	cis	rs8180040	0.627	rs58956475	chr3:47224615	G/C	cg16586182	chr3:47516702	SCAP	0.74	13.38	0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs61008539	0.815	rs6960062	chr7:884665	A/G	cg00934597	chr7:893267	UNC84A	-0.46	-7.47	-0.33	4.13e-13	Perceived unattractiveness to mosquitoes;
LGG	cis	rs72945132	0.825	rs12287883	chr11:70122369	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	12.67	0.51	8.94e-32	Coronary artery disease;
LGG	cis	rs155076	0.711	rs4770129	chr13:21882059	T/G	cg11317459	chr13:21872234	NA	1.39	27.95	0.79	2.01e-101	White matter hyperintensity burden;
LGG	cis	rs58688157	0.705	rs12800061	chr11:587425	C/A	cg03576123	chr11:487126	PTDSS2	-0.49	-6.71	-0.3	5.83e-11	Systemic lupus erythematosus;
LGG	cis	rs1256531	0.661	rs4343192	chr14:66198856	C/G	cg15999311	chr14:65749247	NA	0.79	6.76	0.3	4.14e-11	Conduct disorder (symptom count);
LGG	cis	rs477895	0.838	rs2001003	chr11:64018687	C/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.82	10.37	0.43	8.15e-23	Mean platelet volume;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg18402987	chr7:1209562	NA	0.4	7.47	0.33	3.96e-13	Longevity;Endometriosis;
LGG	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10484885	0.536	rs57461860	chr6:90622283	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.6	-7.64	-0.33	1.22e-13	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6834538	0.597	rs2087111	chr4:113536080	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.37	0.36	6.73e-16	Free thyroxine concentration;
LGG	cis	rs9715521	0.935	rs62301184	chr4:59836168	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.34	-0.32	9.67e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7717393	0.786	rs17053462	chr5:155780558	C/T	cg04435420	chr5:155754009	SGCD	-0.7	-9.22	-0.39	1.04e-18	Egg allergy;
LGG	cis	rs4474465	0.790	rs10899541	chr11:78245573	A/G	cg02023728	chr11:77925099	USP35	0.38	6.83	0.3	2.7e-11	Alzheimer's disease (survival time);
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.5	8.69	0.37	6.26e-17	Longevity;
LGG	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg03959625	chr15:84868606	LOC388152	0.52	7.66	0.34	1.07e-13	Schizophrenia;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg21948465	chr5:131705150	SLC22A5	0.67	7.52	0.33	2.84e-13	Rheumatoid arthritis;
LGG	cis	rs4851254	0.626	rs13001783	chr2:100689652	A/T	cg17356467	chr2:100759845	AFF3	0.45	7.31	0.32	1.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17253792	0.822	rs7150841	chr14:56088986	T/C	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs6495122	0.699	rs34862454	chr15:75101530	C/T	cg20040747	chr15:74715105	SEMA7A	0.4	8.67	0.37	7.49e-17	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs12410462	0.591	rs2644144	chr1:227731867	C/G	cg23173402	chr1:227635558	NA	0.38	7.27	0.32	1.52e-12	Major depressive disorder;
LGG	cis	rs4006360	0.577	rs4986669	chr17:39250341	C/A	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27286337	chr10:134555280	INPP5A	0.87	13.69	0.54	4.54e-36	Migraine;
LGG	cis	rs9300255	0.544	rs1790100	chr12:123656725	G/T	cg05973401	chr12:123451056	ABCB9	0.5	7.48	0.33	3.85e-13	Neutrophil percentage of white cells;
LGG	cis	rs908922	0.636	rs474086	chr1:152513431	C/T	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs526231	0.575	rs55652053	chr5:102337170	T/A	cg23492399	chr5:102201601	PAM	-0.59	-9.01	-0.39	5.27e-18	Primary biliary cholangitis;
LGG	cis	rs12701220	0.568	rs7777700	chr7:1003096	C/G	cg00990874	chr7:1149470	C7orf50	-0.49	-7.27	-0.32	1.53e-12	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg05025164	chr4:1340916	KIAA1530	0.43	7.56	0.33	2.14e-13	Obesity-related traits;
LGG	cis	rs9611565	0.625	rs2076199	chr22:41903743	G/T	cg06481639	chr22:41940642	POLR3H	-0.52	-7.85	-0.34	2.98e-14	Vitiligo;
LGG	cis	rs2013441	0.613	rs9901125	chr17:20008929	A/G	cg13482628	chr17:19912719	NA	0.53	9.91	0.42	3.96e-21	Obesity-related traits;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg26354017	chr1:205819088	PM20D1	-0.51	-9.36	-0.4	3.36e-19	Menarche (age at onset);
LGG	cis	rs1799949	0.930	rs33968979	chr17:41297992	G/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.06e-17	Menopause (age at onset);
LGG	cis	rs10883723	0.810	rs3781289	chr10:104244991	G/T	cg05096777	chr10:104283225	SUFU	0.33	7.2	0.32	2.38e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1862618	0.671	rs173763	chr5:56225418	G/A	cg12654349	chr5:56205094	C5orf35	-0.58	-10.01	-0.42	1.78e-21	Initial pursuit acceleration;
LGG	cis	rs881375	0.902	rs2900180	chr9:123706382	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.01	0.39	5.6e-18	Rheumatoid arthritis;
LGG	trans	rs7618501	1.000	rs7374183	chr3:49785133	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.56	-0.69	3.42e-67	Intelligence (multi-trait analysis);
LGG	cis	rs13376709	0.636	rs12723537	chr1:243812680	G/A	cg25706552	chr1:244017396	NA	-0.63	-15.49	-0.58	6.82e-44	Schizophrenia;
LGG	cis	rs2718058	0.606	rs2722247	chr7:37869308	C/T	cg15028436	chr7:37888078	TXNDC3	-0.54	-8.68	-0.37	6.7e-17	Alzheimer's disease (late onset);
LGG	cis	rs61931739	0.534	rs2636082	chr12:34061848	T/A	cg06521331	chr12:34319734	NA	-0.63	-11.88	-0.48	1.3e-28	Morning vs. evening chronotype;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs4332037	0.906	rs62442903	chr7:1953416	G/A	cg12432903	chr7:1882776	MAD1L1	0.49	7.62	0.33	1.42e-13	Bipolar disorder;
LGG	cis	rs1865760	0.602	rs2157050	chr6:26020431	C/T	cg17691542	chr6:26056736	HIST1H1C	0.56	10.12	0.43	6.75e-22	Height;
LGG	cis	rs10884984	0.863	rs72832241	chr10:112278788	G/A	cg18756771	chr10:112261994	DUSP5	0.58	8.66	0.37	7.77e-17	Facial morphology (factor 22);
LGG	cis	rs975739	1.000	rs750192	chr13:78390743	A/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.7	0.3	6.01e-11	Hair color;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23712970	chr14:23540735	ACIN1	0.45	7.93	0.35	1.65e-14	Menarche (age at onset);
LGG	cis	rs7552404	1.000	rs28602663	chr1:76235355	C/T	cg22875332	chr1:76189707	ACADM	0.6	9.69	0.41	2.42e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4727027	0.899	rs6944096	chr7:148870026	A/G	cg23583168	chr7:148888333	NA	-0.91	-18.24	-0.65	2.13e-56	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.12	-0.31	4.27e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7949030	0.591	rs11231156	chr11:62366454	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.21	0.6	3.98e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	cg07245641	chr1:182991651	LAMC1	0.4	9.11	0.39	2.46e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7000551	0.751	rs2449338	chr8:22369232	A/G	cg12081754	chr8:22256438	SLC39A14	0.65	12.44	0.5	7.54e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs13314892	0.764	rs62251032	chr3:69865127	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs9916302	0.706	rs4795385	chr17:37733148	A/G	cg07936489	chr17:37558343	FBXL20	0.98	15.23	0.58	9.75e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs6952808	0.595	rs2398705	chr7:2164995	G/A	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.58	-0.37	1.43e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs877282	0.853	rs4579862	chr10:753298	A/C	cg22713356	chr15:30763199	NA	0.51	7.78	0.34	4.85e-14	Uric acid levels;
LGG	cis	rs7737355	0.898	rs4706030	chr5:130957486	A/G	cg06307176	chr5:131281290	NA	0.58	9.58	0.41	5.84e-20	Life satisfaction;
LGG	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg25767906	chr1:53392781	SCP2	-0.38	-7.65	-0.34	1.14e-13	Monocyte count;
LGG	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg13902645	chr11:5959945	NA	0.8	14.18	0.55	3.55e-38	DNA methylation (variation);
LGG	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg13207630	chr7:32358064	NA	0.69	7.23	0.32	1.98e-12	Body mass index;
LGG	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg07520158	chr7:32535189	LSM5;AVL9	0.6	10.15	0.43	5.25e-22	Cognitive ability;
LGG	cis	rs4740619	0.870	rs10962149	chr9:15773953	A/G	cg14451791	chr9:16040625	NA	-0.39	-10.19	-0.43	3.82e-22	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07532744	chr12:62860172	MON2	-0.54	-8.1	-0.35	4.94e-15	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs77823122	chr8:58170161	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.32	-0.5	2.4e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11608355	0.521	rs11066503	chr12:109842434	A/G	cg19025524	chr12:109796872	NA	-0.57	-12.28	-0.5	3.47e-30	Neuroticism;
LGG	cis	rs35771425	0.600	rs17188916	chr1:211457821	C/G	cg10512769	chr1:211675356	NA	-0.63	-8.47	-0.37	3.17e-16	Educational attainment (years of education);
LGG	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg24375607	chr4:120327624	NA	0.51	8.08	0.35	5.51e-15	Educational attainment;
LGG	cis	rs718857	0.689	rs1443837	chr9:106677245	G/A	cg14250997	chr9:106856677	SMC2	0.33	6.99	0.31	9.34e-12	Breast cancer;
LGG	cis	rs1348850	0.526	rs10930797	chr2:178437553	C/G	cg23306229	chr2:178417860	TTC30B	0.72	8.5	0.37	2.62e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9814567	0.964	rs6805388	chr3:134173534	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.67	-11.82	-0.48	2.27e-28	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.56	-9.37	-0.4	3.22e-19	Cognitive ability;
LGG	cis	rs6952808	0.609	rs11772205	chr7:1951236	C/T	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.08	-0.31	5.43e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4987668	0.708	rs11975216	chr7:142635313	A/G	cg19410471	chr7:142636507	C7orf34	0.57	8.89	0.38	1.33e-17	Cancer;
LGG	cis	rs11514810	1.000	rs11514810	chr7:1428476	C/T	cg01003211	chr7:1472830	NA	-0.6	-9.16	-0.39	1.67e-18	Executive inhibition (Stroop WIT and CIT) in attention deficit hyperactivity disorder;
LGG	cis	rs3862030	0.720	rs11593526	chr10:104228017	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.52	-9.81	-0.41	9.19e-21	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs7444	0.882	rs9621715	chr22:21942007	G/A	cg11654148	chr22:21984483	YDJC	-0.4	-7.8	-0.34	4.24e-14	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.636	rs1185977	chr6:25829054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.37	0.43	8.57e-23	Iron status biomarkers;
LGG	cis	rs977987	0.872	rs4887816	chr16:75319716	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.84	0.42	6.96e-21	Dupuytren's disease;
LGG	cis	rs823143	0.570	rs823082	chr1:205786935	C/T	cg14893161	chr1:205819251	PM20D1	-0.73	-16.65	-0.61	4.18e-49	Monocyte percentage of white cells;
LGG	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg08847533	chr14:75593920	NEK9	0.63	12.02	0.49	3.83e-29	Height;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.35	-0.43	9.72e-23	Bipolar disorder;
LGG	cis	rs12482904	0.836	rs9975418	chr21:43832560	A/G	cg23042151	chr21:43824109	UBASH3A	-0.42	-7.24	-0.32	1.85e-12	Vitiligo;
LGG	cis	rs2204008	0.744	rs11514071	chr12:38392076	C/T	cg26384229	chr12:38710491	ALG10B	0.92	19.58	0.67	1.22e-62	Bladder cancer;
LGG	cis	rs568617	0.953	rs1151519	chr11:65645831	G/C	cg26695010	chr11:65641043	EFEMP2	0.47	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs7617480	0.648	rs4974083	chr3:49000626	A/G	cg07636037	chr3:49044803	WDR6	0.91	16.43	0.61	3.95e-48	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs7746199	0.736	rs34573979	chr6:27480526	C/T	cg08344181	chr3:125677491	NA	-0.9	-8.76	-0.38	3.73e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1010254	0.559	rs72808310	chr5:151730307	T/C	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.71e-11	Optic nerve measurement (cup area);
LGG	trans	rs8002861	0.870	rs4942255	chr13:44451844	A/T	cg17145862	chr1:211918768	LPGAT1	-0.97	-24.24	-0.75	2.16e-84	Leprosy;
LGG	cis	rs611744	0.604	rs6469170	chr8:109305277	T/C	cg21045802	chr8:109455806	TTC35	0.57	10.79	0.45	2.21e-24	Dupuytren's disease;
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg10505658	chr17:80084571	CCDC57	-0.42	-8.55	-0.37	1.83e-16	Life satisfaction;
LGG	cis	rs7602441	0.521	rs76490718	chr2:14766139	T/C	cg06545361	chr2:14773388	FAM84A	0.78	7.11	0.31	4.45e-12	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg19635926	chr16:89946313	TCF25	0.74	7.35	0.32	9.08e-13	Skin colour saturation;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg02725872	chr8:58115012	NA	-0.76	-11.33	-0.47	1.96e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs3204270	0.500	rs62077175	chr17:79649568	G/T	cg18367735	chr17:79674897	NA	0.59	7.84	0.34	3.03e-14	Dental caries;
LGG	cis	rs1008375	1.000	rs10939750	chr4:17692422	C/G	cg18681998	chr4:17616180	MED28	0.73	14.69	0.56	2.3e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg07677032	chr17:61819896	STRADA	-0.53	-9.33	-0.4	4.57e-19	Prudent dietary pattern;
LGG	cis	rs1577917	0.739	rs2758846	chr6:86349570	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-11.3	-0.47	2.52e-26	Response to antipsychotic treatment;
LGG	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg06808227	chr14:105710500	BRF1	-0.63	-10.9	-0.45	8.91e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs17776563	0.887	rs72763817	chr15:89141238	C/G	cg05013243	chr15:89149849	MIR1179	-0.5	-10.34	-0.43	1.09e-22	Thyroid hormone levels;
LGG	cis	rs2011503	1.000	rs8110171	chr19:19560063	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.75	0.3	4.56e-11	Bipolar disorder;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg11062466	chr8:58055876	NA	0.63	10.25	0.43	2.27e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.545	rs1796217	chr7:66085918	A/G	cg11764359	chr7:65958608	NA	-0.64	-9.94	-0.42	3.03e-21	Aortic root size;
LGG	cis	rs9649465	1.000	rs2299985	chr7:123369044	T/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.87	-0.38	1.58e-17	Migraine;
LGG	cis	rs17153755	0.931	rs12677897	chr8:11612963	G/A	cg12395012	chr8:11607386	GATA4	-0.58	-10.45	-0.44	4.15e-23	Testicular germ cell tumor;
LGG	cis	rs10504229	0.953	rs72650891	chr8:58179697	T/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg06112835	chr11:68658793	MRPL21	0.59	9.81	0.41	8.98e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	cis	rs4466137	0.830	rs6886442	chr5:82973210	A/C	cg15083037	chr5:83017644	HAPLN1	0.35	7.01	0.31	8.37e-12	Prostate cancer;
LGG	cis	rs67311347	0.869	rs6790495	chr3:40366770	C/T	cg13683864	chr3:40499215	RPL14	-0.96	-19.16	-0.67	1.09e-60	Renal cell carcinoma;
LGG	cis	rs8114671	0.742	rs6058161	chr20:33620026	C/T	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs10876993	0.893	rs7979246	chr12:58092554	A/G	cg18357645	chr12:58087776	OS9	0.7	12.34	0.5	1.98e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs11190604	1.000	rs2489039	chr10:102328036	T/A	cg07570687	chr10:102243282	WNT8B	0.43	6.98	0.31	1.01e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2066819	1.000	rs2643626	chr12:56726518	C/T	cg26714650	chr12:56694279	CS	1.49	18.49	0.65	1.42e-57	Psoriasis vulgaris;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.45	0.33	4.51e-13	Schizophrenia;
LGG	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.75	-10.96	-0.45	5.04e-25	Schizophrenia;
LGG	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg18252515	chr7:66147081	NA	-0.76	-12.07	-0.49	2.45e-29	Corneal structure;
LGG	cis	rs7084402	0.902	rs1582826	chr10:60297175	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg08280861	chr8:58055591	NA	-0.54	-6.8	-0.3	3.27e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9290065	0.519	rs7644586	chr3:160674133	T/C	cg04691961	chr3:161091175	C3orf57	-0.43	-8.96	-0.38	8.12e-18	Kawasaki disease;
LGG	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg18135555	chr8:22132992	PIWIL2	0.39	10.29	0.43	1.73e-22	Hypertriglyceridemia;
LGG	cis	rs2273669	0.588	rs2145767	chr6:109296185	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.38	-0.36	6.43e-16	Prostate cancer;
LGG	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg18681998	chr4:17616180	MED28	-0.81	-17.74	-0.64	4.32e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs950169	0.922	rs62021167	chr15:85118051	T/A	cg24253500	chr15:84953950	NA	0.6	10.91	0.45	8.36e-25	Schizophrenia;
LGG	cis	rs7674212	0.541	rs17217473	chr4:104114742	A/C	cg16532752	chr4:104119610	CENPE	-0.39	-6.7	-0.3	6.02e-11	Type 2 diabetes;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg07142201	chr11:109293216	C11orf87	0.51	9.41	0.4	2.25e-19	Schizophrenia;
LGG	cis	rs4974559	0.790	rs11933855	chr4:1315183	C/T	cg02980000	chr4:1222292	CTBP1	0.66	9.08	0.39	3.22e-18	Systolic blood pressure;
LGG	cis	rs62238980	0.522	rs62238974	chr22:32568024	A/G	cg00543991	chr22:32367038	NA	0.75	9.2	0.39	1.26e-18	Childhood ear infection;
LGG	cis	rs35146811	0.625	rs2906645	chr7:99817859	A/G	cg22906224	chr7:99728672	NA	-0.57	-9.34	-0.4	3.91e-19	Coronary artery disease;
LGG	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg12667521	chr19:29218732	NA	0.62	9.39	0.4	2.77e-19	Methadone dose in opioid dependence;
LGG	cis	rs12950390	0.853	rs8078052	chr17:45859434	A/G	cg06532163	chr17:45867833	NA	0.56	9.33	0.4	4.47e-19	IgG glycosylation;
LGG	trans	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg06437703	chr8:37914619	EIF4EBP1	0.67	11.97	0.49	5.78e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2241941	0.879	rs7109418	chr11:20623007	C/T	cg18855426	chr11:20631935	SLC6A5	-0.41	-6.9	-0.31	1.67e-11	Obesity-related traits;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.74	-0.41	1.66e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs503734	0.666	rs2250611	chr3:101104186	T/G	cg27318481	chr3:100970896	IMPG2	-0.36	-7.24	-0.32	1.89e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg20607798	chr8:58055168	NA	0.69	7.73	0.34	6.94e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg00409905	chr10:38381863	ZNF37A	0.54	10.69	0.45	5.36e-24	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg09264619	chr17:80180166	NA	-0.38	-7.54	-0.33	2.51e-13	Life satisfaction;
LGG	cis	rs10540	1.000	rs35996687	chr11:458595	G/A	cg03576123	chr11:487126	PTDSS2	-1.34	-17.24	-0.63	8.06e-52	Body mass index;
LGG	cis	rs7811142	1.000	rs7787620	chr7:100089234	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.3	-0.43	1.56e-22	Platelet count;
LGG	cis	rs7572733	0.935	rs6742782	chr2:198755021	A/C	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.66e-16	Dermatomyositis;
LGG	cis	rs11157436	0.602	rs4982569	chr14:22637613	T/C	cg00994629	chr14:22694547	NA	0.33	7.13	0.31	3.78e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs10504073	0.584	rs4873306	chr8:49950369	T/C	cg00325661	chr8:49890786	NA	0.77	15.09	0.57	4.04e-42	Blood metabolite ratios;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.58	-0.33	1.94e-13	Skin colour saturation;
LGG	cis	rs13421350	0.579	rs78623829	chr2:173379230	G/A	cg15021238	chr2:173305865	ITGA6	-0.8	-8.6	-0.37	1.22e-16	Diabetic kidney disease;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg13395646	chr4:1353034	KIAA1530	-0.48	-8.3	-0.36	1.12e-15	Obesity-related traits;
LGG	cis	rs597539	0.690	rs7129960	chr11:68622456	A/G	cg06028808	chr11:68637592	NA	0.73	11.96	0.49	6.21e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs228437	1.000	rs228448	chr6:134903308	C/T	cg24504307	chr6:134963096	NA	0.39	7.51	0.33	2.99e-13	Melanoma;
LGG	cis	rs2635047	0.601	rs2576058	chr18:44641397	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.04	0.31	7.19e-12	Educational attainment;
LGG	cis	rs1580019	0.537	rs7804609	chr7:32558094	A/C	cg06133097	chr7:32552212	AVL9	-0.39	-7.31	-0.32	1.16e-12	Cognitive ability;
LGG	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg19812747	chr11:111475976	SIK2	0.48	9.5	0.4	1.13e-19	Primary sclerosing cholangitis;
LGG	cis	rs898097	0.812	rs8065641	chr17:80820259	A/G	cg15369054	chr17:80825471	TBCD	0.58	10.69	0.44	5.71e-24	Breast cancer;
LGG	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.37	-0.32	8.17e-13	Systolic blood pressure;
LGG	cis	rs2458413	0.522	rs2514657	chr8:105331215	T/C	cg23108931	chr8:105342351	NA	-0.27	-7.12	-0.31	4.21e-12	Paget's disease;
LGG	cis	rs2839186	0.868	rs2839199	chr21:47708269	T/C	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23901904	chr1:10855062	CASZ1	0.5	8.32	0.36	1.02e-15	Gut microbiome composition (summer);
LGG	cis	rs2594989	0.895	rs2606759	chr3:11349494	T/C	cg01796438	chr3:11312864	ATG7	-0.57	-7.8	-0.34	4.26e-14	Circulating chemerin levels;
LGG	cis	rs6502050	0.835	rs7207947	chr17:80145291	A/T	cg23985595	chr17:80112537	CCDC57	-0.51	-10.21	-0.43	3.2800000000000002e-22	Life satisfaction;
LGG	cis	rs1348850	0.519	rs4144275	chr2:178523368	C/T	cg22681709	chr2:178499509	PDE11A	-0.45	-8.17	-0.35	3.03e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs654950	0.875	rs633297	chr1:41985453	A/C	cg16096631	chr1:42092165	HIVEP3	0.35	7.7	0.34	8.37e-14	Airway imaging phenotypes;
LGG	cis	rs7247513	0.930	rs35275129	chr19:12716493	G/A	cg01871581	chr19:12707946	ZNF490	-0.45	-9.21	-0.39	1.15e-18	Bipolar disorder;
LGG	cis	rs17604090	0.775	rs10225523	chr7:29689735	C/A	cg19413766	chr7:29689036	LOC646762	-0.59	-7.9	-0.34	2.06e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.56	9.51	0.4	1.01e-19	Obesity-related traits;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg13630560	chr10:468051	DIP2C	0.38	7.68	0.34	9.24e-14	Electrocardiographic conduction measures;
LGG	cis	rs2836974	0.568	rs11910906	chr21:40685662	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.29	-0.5	3.18e-30	Cognitive function;
LGG	cis	rs6714710	0.603	rs11681535	chr2:98488949	G/C	cg26665480	chr2:98280029	ACTR1B	0.6	9.58	0.41	5.84e-20	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7923837	0.687	rs10882102	chr10:94466495	G/C	cg25093409	chr10:94429542	NA	0.53	10.5	0.44	2.9e-23	Body mass index;Multiple sclerosis;
LGG	cis	rs1552244	0.572	rs66514627	chr3:10166632	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.88	-0.48	1.39e-28	Alzheimer's disease;
LGG	trans	rs8073060	0.586	rs4795086	chr17:34042190	G/A	cg19694781	chr19:47549865	TMEM160	1.16	18.04	0.64	1.79e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs372883	0.506	rs2832301	chr21:30749712	G/A	cg24692254	chr21:30365293	RNF160	0.58	10.5	0.44	2.76e-23	Pancreatic cancer;
LGG	cis	rs11628318	0.660	rs8009475	chr14:103058608	A/G	cg01864069	chr14:103024347	NA	-0.68	-9.87	-0.42	5.48e-21	Platelet count;
LGG	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg24623649	chr8:11872141	NA	-0.31	-7.25	-0.32	1.74e-12	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02399570	chr3:156877196	CCNL1	-0.49	-7.2	-0.32	2.38e-12	Systemic lupus erythematosus;
LGG	cis	rs440932	0.887	rs398801	chr8:9031704	A/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.39	-0.32	6.98e-13	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs875971	0.508	rs10242423	chr7:66059175	A/G	cg18252515	chr7:66147081	NA	0.41	7.03	0.31	7.52e-12	Aortic root size;
LGG	cis	rs4780401	0.609	rs4780399	chr16:11828701	A/T	cg01061890	chr16:11836724	TXNDC11	-0.71	-13.25	-0.52	3.41e-34	Rheumatoid arthritis;
LGG	cis	rs8056893	0.523	rs1111574	chr16:68378557	G/A	cg07273125	chr16:68295692	NA	0.39	8.49	0.37	2.82e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg00409905	chr10:38381863	ZNF37A	0.66	13.35	0.53	1.29e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.07	-0.49	2.27e-29	Alzheimer's disease;
LGG	cis	rs10911232	0.507	rs10911206	chr1:183012423	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20621256	chr9:140118465	C9orf169	0.45	7.01	0.31	8.35e-12	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.512	rs117968470	chr8:58014651	C/G	cg08677398	chr8:58056175	NA	0.47	6.98	0.31	1.05e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9783347	0.600	rs10766467	chr11:18310449	T/C	cg03595886	chr11:18357587	GTF2H1	-0.48	-11.42	-0.47	8.61e-27	Pancreatic cancer;
LGG	cis	rs3820068	0.655	rs11587521	chr1:15839206	T/C	cg05660106	chr1:15850417	CASP9	1.1	27.19	0.78	5.39e-98	Systolic blood pressure;
LGG	cis	rs6032067	0.929	rs13043296	chr20:43805688	T/C	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs6762	0.719	rs28655651	chr11:837121	G/C	cg10580341	chr11:889148	CHID1	-0.39	-7.07	-0.31	5.77e-12	Mean platelet volume;
LGG	cis	rs2708240	0.666	rs2708257	chr7:147592449	C/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.34	-8.33	-0.36	9.22e-16	QT interval (drug interaction);
LGG	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.72	13.9	0.54	5.61e-37	Total body bone mineral density;
LGG	cis	rs1568889	0.838	rs1483858	chr11:28189639	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.21	0.67	6.41e-61	Bipolar disorder;
LGG	cis	rs6762477	0.748	rs3755831	chr3:50228767	G/T	cg14019146	chr3:50243930	SLC38A3	0.34	7.41	0.33	6.05e-13	Menarche (age at onset);
LGG	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg23527387	chr2:100056660	REV1	0.35	8.05	0.35	6.89e-15	Chronic sinus infection;
LGG	cis	rs3845702	1.000	rs3768837	chr2:180835792	T/A	cg01881094	chr2:180872142	CWC22	-0.91	-14.19	-0.55	3.37e-38	Schizophrenia;
LGG	cis	rs6977660	0.714	rs6945297	chr7:19814029	A/C	cg05791153	chr7:19748676	TWISTNB	0.74	10.39	0.43	7.23e-23	Thyroid stimulating hormone;
LGG	cis	rs7143963	0.636	rs941589	chr14:103341056	T/C	cg23020514	chr14:103360112	TRAF3	0.4	8.33	0.36	9.12e-16	Body mass index;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg00684032	chr4:1343700	KIAA1530	0.42	8.3	0.36	1.13e-15	Obesity-related traits;
LGG	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg00990874	chr7:1149470	C7orf50	-0.66	-9.41	-0.4	2.39e-19	Bronchopulmonary dysplasia;
LGG	cis	rs2287838	0.716	rs7254559	chr19:10003119	C/G	cg07950397	chr19:10022659	OLFM2	0.3	6.81	0.3	3e-11	Sleep duration;
LGG	trans	rs453301	0.571	rs2929453	chr8:9084341	A/G	cg02002194	chr4:3960332	NA	0.47	9.11	0.39	2.42e-18	Joint mobility (Beighton score);
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg20887711	chr4:1340912	KIAA1530	0.93	19.94	0.68	2.48e-64	Longevity;
LGG	cis	rs4595586	0.545	rs1156705	chr12:39372672	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs2455601	0.573	rs2653573	chr11:8989874	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.56	-10.27	-0.43	1.97e-22	Schizophrenia;
LGG	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg26811252	chr16:29126840	RRN3P2	0.67	10.57	0.44	1.48e-23	Menopause (age at onset);
LGG	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg26116260	chr4:7069785	GRPEL1	-0.77	-7.34	-0.32	9.76e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7193541	0.585	rs7978	chr16:74486189	T/C	cg01733217	chr16:74700730	RFWD3	-0.95	-22.63	-0.72	6.54e-77	Multiple myeloma;
LGG	cis	rs453301	0.686	rs6987107	chr8:8893581	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.12	-0.31	4.24e-12	Joint mobility (Beighton score);
LGG	cis	rs9473924	0.505	rs7745565	chr6:50860083	A/G	cg14470998	chr6:50812995	TFAP2B	0.67	8.09	0.35	5.24e-15	Body mass index;
LGG	trans	rs459571	0.959	rs455381	chr9:136905577	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.68	-11.68	-0.48	8.36e-28	Platelet distribution width;
LGG	cis	rs2276314	0.947	rs3898595	chr18:33565885	T/A	cg05985134	chr18:33552581	C18orf21	0.65	10.17	0.43	4.42e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2668423	0.922	rs266805	chr19:1376723	C/T	cg02639931	chr19:1387894	NDUFS7	-0.83	-14.93	-0.57	1.96e-41	Nonalcoholic fatty liver disease;
LGG	cis	rs765787	0.530	rs2554455	chr15:45521304	T/C	cg25801113	chr15:45476975	SHF	0.87	19.9	0.68	4.09e-64	Uric acid levels;
LGG	cis	rs709400	0.894	rs61996721	chr14:104061352	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-7.92	-0.35	1.82e-14	Body mass index;
LGG	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1034435	0.755	rs6007869	chr22:48894213	A/G	cg05992904	chr22:48892994	FAM19A5	-0.8	-16.78	-0.61	1.06e-49	Late-onset Alzheimer's disease;
LGG	cis	rs61931739	0.629	rs17637821	chr12:33701108	T/C	cg06521331	chr12:34319734	NA	0.4	6.89	0.3	1.82e-11	Morning vs. evening chronotype;
LGG	cis	rs6815814	0.950	rs5743560	chr4:38806200	G/T	cg06935464	chr4:38784597	TLR10	0.6	8.24	0.36	1.76e-15	Breast cancer;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	10.04	0.42	1.41e-21	Obesity-related traits;
LGG	cis	rs4862750	0.914	rs9998558	chr4:187874691	A/G	cg03452623	chr4:187889614	NA	-1.04	-29.57	-0.81	1.01e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4969178	0.560	rs4969182	chr17:76393030	T/C	cg05887092	chr17:76393375	PGS1	0.79	18.56	0.65	6.95e-58	HDL cholesterol levels;
LGG	cis	rs9325144	0.723	rs10161183	chr12:39182087	T/C	cg04568710	chr12:38710424	ALG10B	-0.33	-6.78	-0.3	3.61e-11	Morning vs. evening chronotype;
LGG	cis	rs7940866	0.874	rs10894290	chr11:130811049	T/G	cg12179176	chr11:130786555	SNX19	0.75	14.38	0.56	4.94e-39	Schizophrenia;
LGG	cis	rs526231	0.543	rs26525	chr5:102464923	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg13482628	chr17:19912719	NA	0.52	9.5	0.4	1.09e-19	Schizophrenia;
LGG	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs7742824	0.827	rs59842359	chr6:44105929	C/T	cg04074908	chr6:44101190	TMEM63B	0.69	13.25	0.52	3.38e-34	Major depressive disorder;
LGG	cis	rs17875496	0.665	rs11325	chr15:81601340	G/T	cg19620333	chr15:81596332	IL16	0.53	9.63	0.41	4.02e-20	Number of common colds;
LGG	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs6977660	0.598	rs72591445	chr7:19773035	G/A	cg05791153	chr7:19748676	TWISTNB	1.02	13.12	0.52	1.22e-33	Thyroid stimulating hormone;
LGG	cis	rs79349575	0.783	rs56046215	chr17:47008757	A/T	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.47e-11	Type 2 diabetes;
LGG	cis	rs8056893	0.504	rs12102971	chr16:68298024	G/C	cg07273125	chr16:68295692	NA	0.48	10.72	0.45	4.09e-24	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs908922	0.676	rs569032	chr1:152508615	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.67	0.59	1e-44	Hair morphology;
LGG	cis	rs5769707	0.609	rs135861	chr22:49998118	A/G	cg06623630	chr22:50017776	C22orf34	-0.47	-9.5	-0.4	1.13e-19	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs12579753	0.789	rs35448307	chr12:82165817	A/G	cg07923666	chr12:49932857	KCNH3	-0.51	-7.99	-0.35	1.08e-14	Resting heart rate;
LGG	cis	rs9304742	0.854	rs11084211	chr19:53460861	C/T	cg24044776	chr19:53454761	ZNF816A	-0.35	-7.55	-0.33	2.33e-13	Psoriasis;
LGG	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg09307838	chr4:120376055	NA	0.79	13.21	0.52	5.02e-34	Corneal astigmatism;
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg24642844	chr7:1081250	C7orf50	-0.66	-10.82	-0.45	1.85e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs35851103	0.627	rs6601644	chr8:11847078	G/A	cg24623649	chr8:11872141	NA	0.35	8.38	0.36	6.23e-16	Neuroticism;
LGG	cis	rs2594989	0.943	rs2454499	chr3:11500531	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.71e-13	Circulating chemerin levels;
LGG	cis	rs10895140	0.718	rs10750611	chr11:101519671	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.87	-0.3	2.13e-11	Menarche (age at onset);
LGG	cis	rs4789452	1.000	rs4789452	chr17:75372850	G/A	cg06761530	chr17:75373219	SEPT9	-0.38	-7.51	-0.33	3.08e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs9522267	0.535	rs9515447	chr13:112222303	C/T	cg10483660	chr13:112241077	NA	-0.36	-7.88	-0.34	2.31e-14	Hepatitis;
LGG	cis	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg24375607	chr4:120327624	NA	-0.67	-10.95	-0.45	5.55e-25	Corneal astigmatism;
LGG	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg18681998	chr4:17616180	MED28	0.87	20.33	0.69	3.74e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs75804782	0.572	rs72982580	chr2:239447783	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	8.56	0.37	1.62e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6426558	0.524	rs2813948	chr1:227459621	A/T	cg10327440	chr1:227177885	CDC42BPA	0.62	10.23	0.43	2.77e-22	Neutrophil percentage of white cells;
LGG	cis	rs9300255	0.596	rs1568427	chr12:123738678	A/G	cg00376283	chr12:123451042	ABCB9	0.66	11.37	0.47	1.32e-26	Neutrophil percentage of white cells;
LGG	cis	rs11229555	0.645	rs11229435	chr11:58185796	G/C	cg15696309	chr11:58395628	NA	-0.94	-15.28	-0.58	5.53e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	17.61	0.63	1.63e-53	Smoking behavior;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg06481639	chr22:41940642	POLR3H	0.51	7.72	0.34	7.02e-14	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15096432	chr1:202162128	LGR6	0.48	7.55	0.33	2.27e-13	Gut microbiome composition (summer);
LGG	cis	rs7927771	0.524	rs10742814	chr11:47554337	G/A	cg20307385	chr11:47447363	PSMC3	0.56	11.06	0.46	2.25e-25	Subjective well-being;
LGG	cis	rs858239	0.601	rs10278776	chr7:23169759	C/T	cg23682824	chr7:23144976	KLHL7	0.42	7.09	0.31	5.1e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs758324	0.588	rs253945	chr5:131330158	C/T	cg06307176	chr5:131281290	NA	0.45	6.77	0.3	3.99e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs899997	1.000	rs11072793	chr15:79006442	C/T	cg17734273	chr15:78292508	TBC1D2B	-0.34	-8.19	-0.36	2.5e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs7949030	0.688	rs2849031	chr11:62365665	G/A	cg22862634	chr11:62369728	EML3;MTA2	-0.61	-13.91	-0.54	5.59e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7939886	0.844	rs2512784	chr11:55894186	G/A	cg03929089	chr4:120376271	NA	-0.72	-7.46	-0.33	4.28e-13	Myopia (pathological);
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg09699651	chr6:150184138	LRP11	-0.51	-9.1	-0.39	2.6e-18	Lung cancer;
LGG	cis	rs7264396	0.733	rs6058305	chr20:34310757	C/G	cg17201900	chr20:34330562	RBM39	0.51	6.89	0.3	1.82e-11	Total cholesterol levels;
LGG	cis	rs7011049	0.841	rs6473776	chr8:53875125	C/G	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg07701084	chr6:150067640	NUP43	0.47	7.23	0.32	1.98e-12	Lung cancer;
LGG	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg02772935	chr3:125709198	NA	-0.53	-6.77	-0.3	3.96e-11	Blood pressure (smoking interaction);
LGG	cis	rs9394152	0.845	rs7747216	chr6:33476718	A/G	cg13560919	chr6:33536144	NA	-0.69	-12.75	-0.51	4.14e-32	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1729951	0.575	rs361242	chr3:136698330	C/G	cg12473912	chr3:136751656	NA	0.44	7.74	0.34	6.34e-14	Neuroticism;
LGG	cis	rs73416724	1.000	rs17209400	chr6:43328062	A/G	cg26312998	chr6:43337775	ZNF318	0.61	8.57	0.37	1.59e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs8072100	0.840	rs2136751	chr17:45456093	A/G	cg08085267	chr17:45401833	C17orf57	-0.54	-10.56	-0.44	1.69e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4692589	0.606	rs13127322	chr4:170935169	C/T	cg19918862	chr4:170955249	NA	0.4	7.26	0.32	1.69e-12	Anxiety disorder;
LGG	cis	rs1793639	0.967	rs1793635	chr11:131937646	A/T	cg13908476	chr11:131942942	NTM	-0.44	-9.16	-0.39	1.75e-18	Myopia;
LGG	cis	rs13191362	1.000	rs34052221	chr6:163160803	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.81	0.41	8.99e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.26e-20	Smoking initiation;
LGG	cis	rs7917772	0.560	rs7912339	chr10:104373758	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.69	0.48	7.59e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs12701220	0.541	rs12535516	chr7:1114440	C/G	cg02733842	chr7:1102375	C7orf50	-0.57	-8.72	-0.38	4.83e-17	Bronchopulmonary dysplasia;
LGG	cis	rs11155671	0.530	rs9383577	chr6:150207195	C/T	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20555477	chr9:86594889	HNRNPK;RMI1	0.39	6.96	0.31	1.15e-11	Obesity-related traits;
LGG	cis	rs7044106	0.762	rs10818471	chr9:123394045	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.17	0.6	5.99e-47	Hip circumference adjusted for BMI;
LGG	cis	rs12360000	0.510	rs4880946	chr10:1914321	A/G	cg26364871	chr10:1889757	NA	-0.51	-9.67	-0.41	2.81e-20	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs992157	0.798	rs2382818	chr2:219155907	A/T	cg04731861	chr2:219085781	ARPC2	0.45	10.82	0.45	1.84e-24	Colorectal cancer;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg07956936	chr16:72127419	TXNL4B;DHX38	0.42	6.67	0.3	7.33e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs7917772	0.505	rs61869211	chr10:104449836	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.56	9.41	0.4	2.31e-19	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.22	-0.58	1.08e-42	Prudent dietary pattern;
LGG	trans	rs11165623	0.543	rs60982887	chr1:96989155	T/G	cg10631902	chr5:14652156	NA	-0.47	-9.63	-0.41	4.05e-20	Hip circumference;Waist circumference;
LGG	cis	rs4665809	0.941	rs1470096	chr2:26311482	T/C	cg08470875	chr2:26401718	FAM59B	-0.37	-6.79	-0.3	3.36e-11	Gut microbiome composition (summer);
LGG	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg03929089	chr4:120376271	NA	-0.83	-8.74	-0.38	4.21e-17	Myopia (pathological);
LGG	cis	rs10895140	0.645	rs10219300	chr11:101431122	A/C	cg23650423	chr11:101454676	TRPC6	0.43	6.68	0.3	6.86e-11	Menarche (age at onset);
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20887711	chr4:1340912	KIAA1530	-0.91	-19.84	-0.68	7.72e-64	Longevity;
LGG	cis	rs2688419	0.565	rs2688414	chr3:23078904	T/C	cg00327796	chr3:23032191	NA	-0.35	-6.78	-0.3	3.61e-11	Type 2 diabetes;
LGG	cis	rs1552244	0.515	rs7613004	chr3:9999913	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.61	-0.44	1.05e-23	Alzheimer's disease;
LGG	cis	rs7223966	1.000	rs11658175	chr17:61923838	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.39	-0.32	6.7e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7216064	0.817	rs28609796	chr17:65855104	T/A	cg12091567	chr17:66097778	LOC651250	-0.6	-8.85	-0.38	1.92e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12788078	chr18:43546845	KIAA1632	0.43	7.27	0.32	1.49e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.45	-0.61	3.21e-48	Total body bone mineral density;
LGG	cis	rs9470366	0.527	rs10807170	chr6:36629444	C/T	cg08179530	chr6:36648295	CDKN1A	-0.65	-11.46	-0.47	6.32e-27	QRS duration;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg06719900	chr11:109292894	C11orf87	0.44	8.44	0.37	4.06e-16	Schizophrenia;
LGG	cis	rs2273669	0.667	rs28504359	chr6:109330417	C/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs4819052	1.000	rs28628220	chr21:46663741	G/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.81	12.97	0.52	5.1e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs12682352	0.652	rs3827806	chr8:8724276	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-9.22	-0.39	1.06e-18	Neuroticism;
LGG	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg05692746	chr2:100937584	LONRF2	-0.59	-9.76	-0.41	1.4e-20	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.548	rs13427522	chr2:219438359	C/T	cg02985541	chr2:219472218	PLCD4	0.29	6.7	0.3	6.05e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs7635838	0.586	rs379241	chr3:11291565	G/A	cg00170343	chr3:11313890	ATG7	0.54	9.3	0.4	5.7e-19	HDL cholesterol;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.74	0.3	4.68e-11	Schizophrenia;
LGG	cis	rs13191362	0.935	rs66507030	chr6:162953825	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.4	0.33	6.5e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs72991	0.607	rs10790445	chr11:121237372	T/G	cg27192990	chr6:129479024	LAMA2	-0.53	-7.97	-0.35	1.24e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8044868	0.586	rs7201643	chr16:72100780	C/A	cg23815491	chr16:72088622	HP	0.4	8.36	0.36	7.23e-16	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg04863758	chr4:1303710	MAEA	0.45	7.83	0.34	3.41e-14	Obesity-related traits;
LGG	cis	rs367615	0.512	rs814153	chr5:108667829	A/C	cg17395555	chr5:108820864	NA	0.76	12.27	0.5	3.67e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6754311	0.544	rs11678022	chr2:136809033	A/T	cg07169764	chr2:136633963	MCM6	-0.66	-10.89	-0.45	9.68e-25	Mosquito bite size;
LGG	cis	rs7954584	0.520	rs1169095	chr12:122465738	G/A	cg22618164	chr12:122356400	WDR66	-0.31	-8.5	-0.37	2.63e-16	Mean corpuscular volume;
LGG	cis	rs921968	0.541	rs3770214	chr2:219508988	C/T	cg01130898	chr2:219473002	PLCD4	0.48	8.35	0.36	7.96e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs9290065	0.519	rs1530636	chr3:160697442	A/G	cg03342759	chr3:160939853	NMD3	0.55	9.31	0.4	5.02e-19	Kawasaki disease;
LGG	cis	rs847577	0.748	rs13221897	chr7:97719699	G/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.88	-0.3	2.01e-11	Breast cancer;
LGG	cis	rs6582630	0.555	rs1969362	chr12:38514843	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.7	0.56	1.98e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17711722	0.523	rs313812	chr7:65505043	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.59	-13.08	-0.52	1.79e-33	Calcium levels;
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg24060327	chr5:131705240	SLC22A5	-0.6	-6.78	-0.3	3.64e-11	Rheumatoid arthritis;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7474896	0.583	rs12783272	chr10:38024885	T/G	cg25427524	chr10:38739819	LOC399744	-0.48	-6.87	-0.3	2.11e-11	Obesity (extreme);
LGG	cis	rs17102423	0.594	rs2781373	chr14:65568215	G/A	cg16583315	chr14:65563665	MAX	-0.42	-8.55	-0.37	1.82e-16	Obesity-related traits;
LGG	cis	rs6840360	0.571	rs62327278	chr4:152558790	G/C	cg22705602	chr4:152727874	NA	-0.32	-7.59	-0.33	1.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.99	-0.31	9.65e-12	Lung cancer;
LGG	cis	rs2228479	0.867	rs34272502	chr16:89949000	G/C	cg06558623	chr16:89946397	TCF25	1.17	14.93	0.57	1.98e-41	Skin colour saturation;
LGG	cis	rs6840360	0.615	rs113052419	chr4:152473008	T/C	cg22705602	chr4:152727874	NA	-0.32	-7.66	-0.34	1.12e-13	Intelligence (multi-trait analysis);
LGG	cis	rs12926788	0.689	rs1862450	chr16:24856775	A/G	cg02428538	chr16:24856791	SLC5A11	0.69	10.35	0.43	1e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg02002194	chr4:3960332	NA	0.5	9.6	0.41	5.2e-20	Neuroticism;
LGG	cis	rs561341	0.883	rs886224	chr17:30229902	T/C	cg12193833	chr17:30244370	NA	-0.28	-6.98	-0.31	1.01e-11	Hip circumference adjusted for BMI;
LGG	cis	rs11105298	0.891	rs1054807	chr12:89913419	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.58	0.41	5.71e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04193427	chr21:44395084	PKNOX1	0.51	7.43	0.33	5.35e-13	Gut microbiome composition (summer);
LGG	cis	rs2717559	0.541	rs11774054	chr8:143881976	T/C	cg06565975	chr8:143823917	SLURP1	-0.33	-8.11	-0.35	4.55e-15	Urinary tract infection frequency;
LGG	trans	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.82	-0.34	3.49e-14	Retinal vascular caliber;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.31	0.4	4.96e-19	Longevity;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.89e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs9611565	0.559	rs9611619	chr22:41986714	C/T	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Vitiligo;
LGG	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg00701064	chr4:6280414	WFS1	0.75	16.53	0.61	1.41e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs3806843	0.900	rs2261651	chr5:140136804	A/C	cg19875535	chr5:140030758	IK	-0.54	-11.03	-0.46	2.8e-25	Depressive symptoms (multi-trait analysis);
LGG	trans	rs1941687	0.797	rs6507070	chr18:31393244	C/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg21058520	chr6:100914733	NA	0.4	6.93	0.31	1.39e-11	Neuroticism;
LGG	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.37	-0.32	8e-13	HDL cholesterol;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg06197492	chr11:2016605	H19	0.5	10.14	0.43	6.03e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10911232	0.507	rs4072709	chr1:183028855	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs1915146	0.546	rs2454055	chr10:126859832	T/C	cg23000734	chr10:126850823	CTBP2	0.26	7.58	0.33	1.94e-13	Menarche (age at onset);
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg24642844	chr7:1081250	C7orf50	-0.48	-8.82	-0.38	2.36e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg21775007	chr8:11205619	TDH	-0.47	-7.32	-0.32	1.11e-12	Triglycerides;
LGG	cis	rs3008870	0.920	rs12132532	chr1:67457015	G/T	cg02640540	chr1:67518911	SLC35D1	-0.4	-7.12	-0.31	4.19e-12	Lymphocyte percentage of white cells;
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg08888203	chr3:10149979	C3orf24	0.55	9.31	0.4	5.05e-19	Alzheimer's disease;
LGG	cis	rs5769765	0.720	rs138820	chr22:50164078	A/G	cg02269571	chr22:50332266	NA	-0.48	-7.51	-0.33	3.16e-13	Schizophrenia;
LGG	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg08250081	chr4:10125330	NA	0.38	7.33	0.32	1.02e-12	Bone mineral density;
LGG	cis	rs12681288	0.823	rs6994989	chr8:1007284	C/A	cg08648136	chr8:956695	NA	0.38	7.89	0.34	2.22e-14	Schizophrenia;
LGG	cis	rs75920871	0.920	rs11216178	chr11:116766390	G/T	cg20608306	chr11:116969690	SIK3	-0.33	-6.88	-0.3	1.98e-11	Subjective well-being;
LGG	cis	rs6089584	0.888	rs6089624	chr20:60619907	C/G	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs7168592	1.000	rs56132489	chr15:101734162	C/T	cg24254196	chr15:101719523	CHSY1	-0.64	-7.24	-0.32	1.83e-12	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg05091796	chr16:4465799	CORO7	-0.87	-14.87	-0.57	3.66e-41	Schizophrenia;
LGG	cis	rs892961	0.899	rs312911	chr17:75414585	A/C	cg05865280	chr17:75406074	SEPT9	0.42	9.84	0.42	7.41e-21	Airflow obstruction;
LGG	cis	rs11096990	0.634	rs12648082	chr4:39279724	T/C	cg24403649	chr4:39172243	NA	-0.39	-6.98	-0.31	1.03e-11	Cognitive function;
LGG	cis	rs1865760	0.820	rs9348697	chr6:25890834	C/T	cg03264133	chr6:25882463	NA	-0.46	-8.01	-0.35	9.4e-15	Height;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	-0.56	-9.55	-0.41	7.63e-20	Renal function-related traits (BUN);
LGG	cis	rs9790314	1.000	rs1382426	chr3:161045933	G/A	cg04691961	chr3:161091175	C3orf57	-0.63	-14.96	-0.57	1.49e-41	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.545	rs2388175	chr12:39389217	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg23188684	chr11:67383651	NA	-0.43	-7.14	-0.32	3.58e-12	Mean corpuscular volume;
LGG	cis	rs72945132	0.882	rs17160762	chr11:70134766	A/G	cg14191688	chr11:70257035	CTTN	-0.57	-8.35	-0.36	8.11e-16	Coronary artery disease;
LGG	cis	rs42648	0.596	rs194518	chr7:89853149	G/A	cg25739043	chr7:89950458	NA	-0.34	-7.02	-0.31	7.71e-12	Homocysteine levels;
LGG	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.91	0.54	5.53e-37	Colorectal cancer;
LGG	cis	rs8062405	0.964	rs72793809	chr16:28832382	C/T	cg09754948	chr16:28834200	ATXN2L	0.5	7.93	0.35	1.69e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7937682	0.847	rs500163	chr11:111462649	T/G	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs727505	0.607	rs10464674	chr7:124791551	A/G	cg23710748	chr7:124431027	NA	-0.44	-8.49	-0.37	2.92e-16	Lewy body disease;
LGG	cis	rs71327718	1	rs71327718	chr3:125592857	C/G	cg05084668	chr3:125655381	ALG1L	-1.11	-12.4	-0.5	1.14e-30	Metabolite levels (HVA/5-HIAA ratio);
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2836974	0.932	rs8128734	chr21:40569511	G/A	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	cis	rs1010254	0.543	rs113559777	chr5:151816645	T/C	cg08593883	chr5:151785301	NMUR2	-0.45	-7.1	-0.31	4.7e-12	Optic nerve measurement (cup area);
LGG	cis	rs981844	0.885	rs62325082	chr4:154661274	A/G	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs9470366	1.000	rs9470366	chr6:36625562	C/T	cg08179530	chr6:36648295	CDKN1A	0.59	8.55	0.37	1.76e-16	QRS duration;
LGG	cis	rs933688	0.759	rs1423593	chr5:90752351	T/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.83	0.66	3.88e-59	Smoking behavior;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.86	-0.38	1.73e-17	Menopause (age at onset);
LGG	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.38	-0.32	7.6e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs694739	0.536	rs11231740	chr11:64046641	C/T	cg05555928	chr11:63887634	MACROD1	0.47	8.7	0.38	5.64e-17	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2242194	0.844	rs11264295	chr1:154987526	C/T	cg24250549	chr1:154909240	PMVK	0.4	6.76	0.3	4.17e-11	Schizophrenia;
LGG	cis	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.36	-0.4	3.39e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.529	rs228757	chr17:42164885	G/C	cg13607699	chr17:42295918	UBTF	-0.44	-7.05	-0.31	6.41e-12	Total body bone mineral density;
LGG	trans	rs629535	0.859	rs55803226	chr8:70108965	T/C	cg21567404	chr3:27674614	NA	-0.4	-6.72	-0.3	5.29e-11	Dupuytren's disease;
LGG	cis	rs12724450	0.793	rs57323357	chr1:150405010	C/G	cg03818307	chr1:150480534	ECM1	0.49	7.08	0.31	5.44e-12	Blood protein levels;
LGG	cis	rs9611565	0.729	rs505533	chr22:41864216	A/C	cg17376030	chr22:41985996	PMM1	-0.41	-6.67	-0.3	7.11e-11	Vitiligo;
LGG	cis	rs283228	0.617	rs1066380	chr6:101763121	C/T	cg02011392	chr6:101847541	GRIK2	0.53	7.32	0.32	1.07e-12	Coenzyme Q10 levels;
LGG	cis	rs6598955	0.671	rs12068212	chr1:26612935	C/T	cg04990556	chr1:26633338	UBXN11	0.58	8.05	0.35	6.8e-15	Obesity-related traits;
LGG	cis	rs10504229	0.516	rs11776524	chr8:57983246	A/G	cg22535103	chr8:58192502	C8orf71	-0.43	-7.12	-0.31	4.09e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs60733400	0.500	rs72644697	chr1:2533605	G/A	cg15627072	chr1:2432621	PLCH2	0.37	8.13	0.35	3.96e-15	Multiple sclerosis;
LGG	cis	rs7741085	1.000	rs6940887	chr6:44636390	G/A	cg18551225	chr6:44695536	NA	0.44	7.44	0.33	4.92e-13	Total body bone mineral density;
LGG	trans	rs7904321	1.000	rs7904321	chr10:64840665	C/T	cg16041611	chr6:43139680	SRF	0.4	6.68	0.3	6.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1401999	0.510	rs3749438	chr3:183705184	G/A	cg01324343	chr3:183735012	ABCC5	0.56	10.07	0.42	1.06e-21	Anterior chamber depth;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-13.94	-0.54	3.85e-37	Alzheimer's disease;
LGG	cis	rs9467711	0.651	rs72832596	chr6:25962951	C/A	cg21479132	chr6:26055353	NA	0.79	7.08	0.31	5.39e-12	Autism spectrum disorder or schizophrenia;
LGG	trans	rs10802346	0.545	rs2362252	chr1:246371574	A/C	cg22732515	chr19:44031385	ETHE1	0.55	9.39	0.4	2.74e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs35771425	0.600	rs17267561	chr1:211540941	G/A	cg10512769	chr1:211675356	NA	-0.62	-8.28	-0.36	1.33e-15	Educational attainment (years of education);
LGG	cis	rs514406	0.621	rs881198	chr1:53196440	C/T	cg24675658	chr1:53192096	ZYG11B	0.61	13.17	0.52	7.27e-34	Monocyte count;
LGG	cis	rs9815354	0.855	rs73071261	chr3:42003369	C/A	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg25358565	chr5:93447407	FAM172A	1.37	17.04	0.62	7.07e-51	Diabetic retinopathy;
LGG	cis	rs28830936	0.966	rs28680296	chr15:42121538	C/G	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.94	-0.52	6.74e-33	Diastolic blood pressure;
LGG	cis	rs867371	0.502	rs2047679	chr15:82531881	T/C	cg00614314	chr15:82944287	LOC80154	0.47	7.94	0.35	1.54e-14	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.08	-0.46	1.84e-25	Intelligence (multi-trait analysis);
LGG	trans	rs11782517	0.881	rs7845806	chr8:10110188	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-6.96	-0.31	1.15e-11	Nose size;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3780378	0.875	rs7869668	chr9:5069837	G/A	cg02405213	chr9:5042618	JAK2	-0.52	-9.26	-0.4	7.58e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03150474	chr6:10695108	C6orf52;PAK1IP1	0.42	6.98	0.31	1e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs787274	0.850	rs2645985	chr9:115510812	A/G	cg13803584	chr9:115635662	SNX30	0.58	7.33	0.32	1.02e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs78456975	1.000	rs4073861	chr2:1563611	G/A	cg26248373	chr2:1572462	NA	-0.69	-8.94	-0.38	9.41e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10504229	0.511	rs75967910	chr8:58024231	C/G	cg11062466	chr8:58055876	NA	0.53	7.96	0.35	1.35e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.606	rs7819827	chr8:8797055	G/C	cg15556689	chr8:8085844	FLJ10661	-0.38	-6.72	-0.3	5.38e-11	Mood instability;
LGG	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.49e-19	Fuchs's corneal dystrophy;
LGG	trans	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg16141378	chr3:129829833	LOC729375	0.34	7.82	0.34	3.61e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs55665837	1.000	rs10832275	chr11:14478224	A/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.8	-0.38	2.74e-17	Vitamin D levels;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg18032289	chr17:61959525	GH2	-0.4	-6.82	-0.3	2.82e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17767392	0.881	rs35620527	chr14:71915703	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.6	-0.37	1.24e-16	Mitral valve prolapse;
LGG	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.77	0.57	9.82e-41	Cognitive test performance;
LGG	cis	rs992157	1.000	rs11554825	chr2:219125809	C/T	cg00012203	chr2:219082015	ARPC2	0.78	14.85	0.57	4.56e-41	Colorectal cancer;
LGG	cis	rs208520	0.690	rs4710311	chr6:66823223	C/T	cg07460842	chr6:66804631	NA	-0.91	-17.13	-0.62	2.68e-51	Exhaled nitric oxide output;
LGG	cis	rs11864453	1.000	rs1035559	chr16:72031860	A/G	cg01557791	chr16:72042693	DHODH	-0.6	-11.19	-0.46	7.08e-26	Fibrinogen levels;
LGG	cis	rs4478858	0.735	rs6676682	chr1:31809816	C/T	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs4132509	1.000	rs1458024	chr1:243937445	G/C	cg25706552	chr1:244017396	NA	0.54	8.76	0.38	3.59e-17	RR interval (heart rate);
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.93	-0.38	1.02e-17	Lung cancer;
LGG	trans	rs9467711	0.659	rs13195509	chr6:26463660	C/T	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.47	-0.44	3.57e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg14186256	chr22:23484241	RTDR1	1.0	25.1	0.76	2.09e-88	Bone mineral density;
LGG	trans	rs7618501	0.522	rs73077175	chr3:49774658	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.7	-0.34	8.49e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs4882096	chr11:48534102	T/G	cg00717180	chr2:96193071	NA	-0.42	-7.41	-0.33	6e-13	HDL cholesterol;
LGG	cis	rs1497828	1.000	rs2818967	chr1:217568218	T/G	cg04411442	chr1:217543379	NA	0.45	7.65	0.34	1.14e-13	Dialysis-related mortality;
LGG	cis	rs8133932	0.654	rs7280405	chr21:47275611	C/T	cg13695288	chr21:47294981	PCBP3	-0.36	-7.11	-0.31	4.39e-12	Schizophrenia;
LGG	cis	rs758324	0.681	rs423957	chr5:131334131	G/C	cg06307176	chr5:131281290	NA	0.47	6.85	0.3	2.38e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2243480	1.000	rs316334	chr7:65602126	G/T	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs2439831	0.867	rs486301	chr15:43836949	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.73	0.41	1.79e-20	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.739	rs11687352	chr2:100919888	A/C	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.76e-43	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03613717	chr10:121356708	TIAL1	0.52	7.97	0.35	1.22e-14	Gut microbiome composition (summer);
LGG	cis	rs72781680	0.898	rs111460347	chr2:24018833	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.94	-0.52	6.31e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504073	0.584	rs1511368	chr8:49949523	A/T	cg00325661	chr8:49890786	NA	0.77	15.09	0.57	4.04e-42	Blood metabolite ratios;
LGG	cis	rs7084402	0.935	rs1593675	chr10:60291694	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.37	-0.32	7.85e-13	Refractive error;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	13.9	0.54	6.12e-37	Platelet count;
LGG	cis	rs7215564	0.908	rs756077	chr17:78663071	A/G	cg16980736	chr17:78789706	RPTOR	-0.61	-8.06	-0.35	6.44e-15	Myopia (pathological);
LGG	cis	rs372883	0.648	rs1153292	chr21:30689195	G/T	cg24692254	chr21:30365293	RNF160	-0.65	-11.85	-0.48	1.77e-28	Pancreatic cancer;
LGG	cis	rs17767392	1.000	rs34873919	chr14:71780741	C/T	cg02058870	chr14:72053146	SIPA1L1	0.47	9.52	0.4	9.68e-20	Mitral valve prolapse;
LGG	cis	rs7666738	0.822	rs979946	chr4:98921235	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.31e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg00938859	chr5:1591904	SDHAP3	0.89	13.14	0.52	9.22e-34	Breast cancer;
LGG	cis	rs2228479	0.850	rs2302162	chr16:89845287	A/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs3768617	0.510	rs3768618	chr1:183092491	C/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9487094	0.666	rs4946967	chr6:109678572	C/T	cg16315928	chr6:109776240	MICAL1	0.44	7.84	0.34	3.23e-14	Height;
LGG	cis	rs367943	0.698	rs12719164	chr5:112960802	A/C	cg12552261	chr5:112820674	MCC	0.53	9.6	0.41	5.04e-20	Type 2 diabetes;
LGG	cis	rs9715521	0.803	rs62301187	chr4:59840420	T/C	cg11281224	chr4:60001000	NA	-0.44	-7.33	-0.32	1.03e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7937682	0.889	rs559482	chr11:111497902	G/A	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs2274273	0.870	rs66696758	chr14:55766509	G/A	cg04306507	chr14:55594613	LGALS3	0.62	16.93	0.62	2.04e-50	Protein biomarker;
LGG	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg19539972	chr4:7069911	GRPEL1	-0.78	-10.29	-0.43	1.63e-22	Monocyte percentage of white cells;
LGG	trans	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg06606381	chr12:133084897	FBRSL1	0.77	7.36	0.32	8.53e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2832270	0.562	rs55823432	chr21:30553969	A/C	cg24692254	chr21:30365293	RNF160	-0.66	-6.68	-0.3	6.71e-11	Response to mTOR inhibitor (everolimus);
LGG	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-9.63	-0.41	3.85e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg19761014	chr17:28927070	LRRC37B2	0.67	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs7267979	1.000	rs6050599	chr20:25400240	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.5	-0.44	2.81e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg27432699	chr2:27873401	GPN1	-0.47	-8.0	-0.35	9.77e-15	Total body bone mineral density;
LGG	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg02002194	chr4:3960332	NA	0.45	8.1	0.35	4.99e-15	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.521	rs72982596	chr2:239454919	G/C	cg01134436	chr17:81009848	B3GNTL1	0.77	8.58	0.37	1.48e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2404602	0.536	rs7165025	chr15:76766434	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.07	-0.31	5.61e-12	Blood metabolite levels;
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg01114163	chr5:1856713	NA	-0.41	-7.21	-0.32	2.34e-12	Cardiovascular disease risk factors;
LGG	cis	rs1163251	0.869	rs629735	chr1:120206932	G/T	cg19096424	chr1:120255104	PHGDH	-0.59	-10.63	-0.44	9.45e-24	Blood metabolite levels;
LGG	cis	rs8180040	0.739	rs12488225	chr3:47235107	G/A	cg16586182	chr3:47516702	SCAP	-0.79	-15.32	-0.58	3.65e-43	Colorectal cancer;
LGG	cis	rs910316	1.000	rs12590452	chr14:75548756	T/C	cg08847533	chr14:75593920	NEK9	0.63	12.29	0.5	3.03e-30	Height;
LGG	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.32	-0.47	2.1e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1355223	0.506	rs7947848	chr11:34866220	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.52	-8.41	-0.36	5.08e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1552244	0.882	rs6443279	chr3:10053599	C/A	cg00166722	chr3:10149974	C3orf24	0.54	9.15	0.39	1.86e-18	Alzheimer's disease;
LGG	cis	rs3091242	0.933	rs7541095	chr1:25761291	T/C	cg09222892	chr1:25734099	RHCE	0.46	9.82	0.42	8.1899999999999992e-21	Erythrocyte sedimentation rate;
LGG	cis	rs9358372	0.787	rs12209113	chr6:20826750	C/T	cg13405222	chr6:20811065	CDKAL1	0.77	17.33	0.63	3.09e-52	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.64	-0.33	1.3e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg01879757	chr17:41196368	BRCA1	-0.41	-8.44	-0.37	4.22e-16	Menopause (age at onset);
LGG	cis	rs6977660	1.000	rs6974669	chr7:19793296	T/A	cg07541023	chr7:19748670	TWISTNB	0.49	7.61	0.33	1.54e-13	Thyroid stimulating hormone;
LGG	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg22535103	chr8:58192502	C8orf71	-0.79	-11.26	-0.46	3.76e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs36051895	0.659	rs1159782	chr9:5078117	T/C	cg02405213	chr9:5042618	JAK2	-0.84	-15.8	-0.59	2.63e-45	Pediatric autoimmune diseases;
LGG	cis	rs11874712	0.527	rs12709735	chr18:43687087	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.15	-0.39	1.89e-18	Migraine - clinic-based;
LGG	cis	rs41271473	0.526	rs10916344	chr1:228737489	C/T	cg10167378	chr1:228756711	NA	0.69	9.58	0.41	5.79e-20	Chronic lymphocytic leukemia;
LGG	cis	rs6860806	0.531	rs270607	chr5:131649186	A/G	cg07395648	chr5:131743802	NA	-0.49	-10.12	-0.43	7.08e-22	Breast cancer;
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs12368653	0.789	rs17852479	chr12:58126234	C/A	cg02175503	chr12:58329896	NA	-0.44	-7.16	-0.32	3.15e-12	Multiple sclerosis;
LGG	cis	rs1784581	0.588	rs9458428	chr6:162424579	A/G	cg17173639	chr6:162384350	PARK2	-0.64	-13.48	-0.53	3.75e-35	Itch intensity from mosquito bite;
LGG	cis	rs6502050	0.799	rs6502078	chr17:80124364	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs898097	0.544	rs6502022	chr17:80908652	C/T	cg02711726	chr17:80685570	FN3KRP	-0.39	-7.57	-0.33	2.11e-13	Breast cancer;
LGG	cis	rs72717009	0.825	rs7515174	chr1:161476949	C/G	cg12643083	chr1:161476548	FCGR2A	-0.67	-9.98	-0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs6594713	0.717	rs8180416	chr5:112868440	A/G	cg12552261	chr5:112820674	MCC	0.62	8.46	0.37	3.6e-16	Brain cytoarchitecture;
LGG	cis	rs11711311	1.000	rs9288983	chr3:113488699	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.49	0.53	3.19e-35	IgG glycosylation;
LGG	cis	rs7481584	0.624	rs428726	chr11:3046201	G/A	cg08508325	chr11:3079039	CARS	0.43	8.5	0.37	2.6e-16	Calcium levels;
LGG	cis	rs6840360	0.617	rs2724564	chr4:152349962	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.02	0.31	7.84e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9487051	0.872	rs7772602	chr6:109608661	C/G	cg21918786	chr6:109611834	NA	0.48	8.91	0.38	1.21e-17	Reticulocyte fraction of red cells;
LGG	cis	rs80282103	0.618	rs56004802	chr10:1159187	C/T	cg08668510	chr10:1095578	IDI1	0.78	7.61	0.33	1.58e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs68170813	0.559	rs10953532	chr7:106881808	C/T	cg02696742	chr7:106810147	HBP1	-0.76	-11.01	-0.46	3.45e-25	Coronary artery disease;
LGG	cis	rs1620921	0.621	rs11753103	chr6:161267086	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1577917	0.958	rs12208227	chr6:86670944	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.97	-0.42	2.41e-21	Response to antipsychotic treatment;
LGG	cis	rs9747201	0.894	rs9944398	chr17:80177439	A/G	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9402673	0.517	rs978036	chr6:135342903	C/T	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.92e-20	Reticulocyte count;High light scatter reticulocyte count;
LGG	cis	rs950169	0.881	rs34591918	chr15:84950833	C/T	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs12545109	0.765	rs2610047	chr8:57412106	T/C	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs6752107	1.000	rs3828309	chr2:234180410	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	-0.4	-7.27	-0.32	1.58e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg02018176	chr4:1364513	KIAA1530	0.41	9.24	0.39	9.24e-19	Obesity-related traits;
LGG	cis	rs7605378	0.528	rs1704191	chr2:200816393	C/A	cg17644776	chr2:200775616	C2orf69	0.71	12.69	0.51	6.99e-32	Osteoporosis;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.57e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs539514	0.627	rs9530463	chr13:76293772	C/T	cg04757411	chr13:76259545	LMO7	-0.27	-6.8	-0.3	3.31e-11	Type 1 diabetes;
LGG	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.63	0.37	9.73e-17	Systolic blood pressure;
LGG	cis	rs10744422	1.000	rs4759382	chr12:123347609	C/T	cg25930673	chr12:123319894	HIP1R	0.71	9.16	0.39	1.72e-18	Schizophrenia;
LGG	cis	rs9513627	0.833	rs112671387	chr13:100123073	A/G	cg15490075	chr13:100150979	NA	-0.67	-6.98	-0.31	1.05e-11	Obesity-related traits;
LGG	cis	rs8027181	0.617	rs12439200	chr15:73086731	A/G	cg01955962	chr15:73089536	NA	0.41	6.99	0.31	9.4e-12	Triglyceride levels;
LGG	cis	rs11190604	0.666	rs7084768	chr10:102200497	T/C	cg07570687	chr10:102243282	WNT8B	-0.43	-7.63	-0.33	1.33e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11190604	0.945	rs11190553	chr10:102207959	T/C	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs597539	0.690	rs659465	chr11:68618964	T/G	cg04772025	chr11:68637568	NA	0.75	12.57	0.5	2.29e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7011049	1.000	rs72643586	chr8:53847859	A/T	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg12923728	chr3:195709715	SDHAP1	-0.79	-15.05	-0.57	5.63e-42	Pancreatic cancer;
LGG	cis	rs12477438	0.834	rs11903311	chr2:99701807	T/C	cg08885076	chr2:99613938	TSGA10	-0.49	-10.01	-0.42	1.7e-21	Chronic sinus infection;
LGG	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg06481639	chr22:41940642	POLR3H	-0.55	-7.84	-0.34	3.21e-14	Vitiligo;
LGG	cis	rs4595586	0.545	rs12823586	chr12:39391677	C/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs4631830	0.863	rs4486572	chr10:51531805	A/G	cg16070123	chr10:51489643	NA	-0.4	-7.28	-0.32	1.4e-12	Prostate-specific antigen levels;
LGG	cis	rs4851254	0.660	rs114552491	chr2:100709533	C/T	cg17356467	chr2:100759845	AFF3	0.46	7.46	0.33	4.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3858526	0.883	rs10769333	chr11:5939685	A/T	cg02574844	chr11:5959923	NA	-0.54	-8.72	-0.38	5.1e-17	DNA methylation (variation);
LGG	cis	rs9916302	0.904	rs679995	chr17:37441679	A/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.48e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.81	0.57	6.66e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17826219	0.636	rs7221463	chr17:29080551	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.6	-0.44	1.18e-23	Body mass index;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14473050	chr2:231729718	ITM2C	0.59	6.83	0.3	2.7e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg15704280	chr7:45808275	SEPT13	0.49	8.02	0.35	8.68e-15	HDL cholesterol;
LGG	cis	rs2404602	0.692	rs4442773	chr15:77031633	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.84	-0.3	2.51e-11	Blood metabolite levels;
LGG	cis	rs897080	0.552	rs1067392	chr2:44639097	G/T	cg00619915	chr2:44497795	NA	-0.48	-6.71	-0.3	5.85e-11	Height;
LGG	cis	rs7246865	0.859	rs16981598	chr19:17204327	A/G	cg19418318	chr19:17219073	MYO9B	0.31	8.08	0.35	5.75e-15	Reticulocyte fraction of red cells;
LGG	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg15823100	chr22:32027580	PISD	-0.75	-8.52	-0.37	2.27e-16	Age-related hearing impairment;
LGG	cis	rs2688608	0.530	rs71507081	chr10:75493136	G/A	cg19442545	chr10:75533431	FUT11	-0.42	-6.92	-0.31	1.52e-11	Inflammatory bowel disease;
LGG	cis	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg24623649	chr8:11872141	NA	0.29	7.08	0.31	5.49e-12	Neuroticism;
LGG	cis	rs365132	1.000	rs2055619	chr5:176415964	A/G	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs9815354	0.953	rs6795797	chr3:41862250	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.18	0.36	2.67e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs270601	0.633	rs4535443	chr5:131572561	A/G	cg07395648	chr5:131743802	NA	-0.34	-6.71	-0.3	5.77e-11	Acylcarnitine levels;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.28	-0.4	6.74e-19	Lung cancer;
LGG	cis	rs4734806	1.000	rs13250799	chr8:105713617	A/G	cg01675814	chr8:105601641	LRP12	0.49	6.79	0.3	3.48e-11	Periodontitis (DPAL);
LGG	cis	rs2832191	0.791	rs2832178	chr21:30479858	T/G	cg24692254	chr21:30365293	RNF160	-0.97	-25.17	-0.76	1.03e-88	Dental caries;
LGG	cis	rs11626933	0.959	rs17799226	chr14:90754538	C/T	cg04374321	chr14:90722782	PSMC1	0.43	6.7	0.3	6.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6840360	0.571	rs62327275	chr4:152548238	G/T	cg25486957	chr4:152246857	NA	-0.5	-8.24	-0.36	1.77e-15	Intelligence (multi-trait analysis);
LGG	cis	rs2289583	0.573	rs34582157	chr15:75397815	A/C	cg14664628	chr15:75095509	CSK	0.52	9.0	0.39	5.71e-18	Systemic lupus erythematosus;
LGG	trans	rs1964356	0.967	rs17701675	chr8:8850633	A/G	cg27411982	chr8:10470053	RP1L1	-0.42	-7.22	-0.32	2.1e-12	Mean corpuscular volume;
LGG	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg08499158	chr17:42289980	UBTF	0.66	12.64	0.51	1.19e-31	Total body bone mineral density;
LGG	cis	rs9880192	0.516	rs2713575	chr3:128294355	A/G	cg08795948	chr3:128337044	NA	0.42	7.32	0.32	1.11e-12	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;White blood cell count;Eosinophil percentage of white cells;Eosinophil counts;Monocyte count;Monocyte-lymphocyte ratio;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg23034840	chr1:205782522	SLC41A1	-0.74	-14.2	-0.55	3.04e-38	Monocyte percentage of white cells;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg00933542	chr6:150070202	PCMT1	0.4	7.21	0.32	2.3e-12	Lung cancer;
LGG	cis	rs2274273	0.905	rs8007620	chr14:55586587	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.59	0.63	2.12e-53	Protein biomarker;
LGG	cis	rs61931739	0.621	rs843785	chr12:33729308	C/T	cg06521331	chr12:34319734	NA	0.4	6.98	0.31	1.05e-11	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.716	rs1588961	chr15:76752698	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.32	2.01e-12	Blood metabolite levels;
LGG	cis	rs9487094	0.670	rs13199135	chr6:109909842	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.34e-15	Height;
LGG	cis	rs853679	0.517	rs9380062	chr6:28137569	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg12708336	chr17:41446283	NA	-0.33	-7.96	-0.35	1.32e-14	Menopause (age at onset);
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.92e-19	Height;
LGG	cis	rs611744	0.647	rs2298603	chr8:109271426	C/T	cg18478394	chr8:109455254	TTC35	0.42	8.52	0.37	2.32e-16	Dupuytren's disease;
LGG	cis	rs7246760	0.867	rs73014056	chr19:9914120	G/A	cg16876255	chr19:9731953	ZNF561	0.81	7.07	0.31	5.76e-12	Pursuit maintenance gain;
LGG	cis	rs709400	0.894	rs10143293	chr14:104063014	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-8.07	-0.35	5.97e-15	Body mass index;
LGG	cis	rs990171	0.913	rs2075185	chr2:103070988	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.95	-0.38	8.33e-18	Lymphocyte counts;
LGG	cis	rs910316	1.000	rs12589876	chr14:75544189	G/A	cg11812906	chr14:75593930	NEK9	0.54	10.11	0.43	7.54e-22	Height;
LGG	cis	rs2282335	0.507	rs2498421	chr9:71855357	A/G	cg14075627	chr9:71863002	TJP2	0.42	7.28	0.32	1.43e-12	Renal sinus fat;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.25	-0.32	1.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.25	0.43	2.39e-22	Obesity-related traits;
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg14689365	chr7:158441557	NCAPG2	0.6	9.94	0.42	3.14e-21	Height;
LGG	cis	rs7618915	0.501	rs7611731	chr3:52692721	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.17	0.39	1.51e-18	Bipolar disorder;
LGG	cis	rs7582180	0.874	rs13031270	chr2:100896311	G/T	cg26150922	chr2:100937072	LONRF2	-0.55	-9.67	-0.41	2.95e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2235573	0.594	rs11912649	chr22:38415542	C/T	cg19171272	chr22:38449367	NA	-0.56	-11.06	-0.46	2.08e-25	Glioblastoma;Glioma;
LGG	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.47	7.71	0.34	7.75e-14	Electroencephalogram traits;
LGG	cis	rs8018808	0.902	rs8006688	chr14:77926649	G/A	cg20045696	chr14:77926864	AHSA1	0.4	6.79	0.3	3.46e-11	Myeloid white cell count;
LGG	cis	rs2304069	0.729	rs2066933	chr5:149433597	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.77	11.55	0.47	2.61e-27	HIV-1 control;
LGG	cis	rs1008375	0.898	rs4698620	chr4:17587361	C/T	cg04450456	chr4:17643702	FAM184B	0.32	6.94	0.31	1.3e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2279817	0.863	rs12023877	chr1:18025633	A/C	cg21791023	chr1:18019539	ARHGEF10L	0.64	11.6	0.47	1.73e-27	Neuroticism;
LGG	trans	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.47e-27	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs66495524	chr8:58187365	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6728642	0.561	rs58984980	chr2:97570759	T/A	cg26665480	chr2:98280029	ACTR1B	-0.68	-8.28	-0.36	1.38e-15	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs7072216	0.763	rs3814142	chr10:100171104	C/G	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.16	-0.32	3.11e-12	Metabolite levels;
LGG	cis	rs7444	0.941	rs181363	chr22:21932264	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-7.13	-0.31	3.83e-12	Systemic lupus erythematosus;
LGG	cis	rs7793919	0.764	rs6944865	chr7:4766383	A/T	cg09789173	chr7:4769017	FOXK1	0.79	17.77	0.64	3.04e-54	Mosquito bite size;
LGG	cis	rs9814567	1.000	rs4334685	chr3:134304335	T/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2204008	0.580	rs36118148	chr12:38411812	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.28	-0.4	6.54e-19	Bladder cancer;
LGG	cis	rs11711311	0.824	rs35341324	chr3:113351719	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.62	12.29	0.5	2.94e-30	IgG glycosylation;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23945273	chr4:120987944	MAD2L1	0.62	6.96	0.31	1.16e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4665809	0.941	rs41285975	chr2:26351144	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs947211	0.846	rs708726	chr1:205762139	G/T	cg14893161	chr1:205819251	PM20D1	-0.57	-9.12	-0.39	2.22e-18	Parkinson's disease;
LGG	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg24596788	chr1:163392923	NA	-0.62	-11.68	-0.48	8.57e-28	Motion sickness;
LGG	cis	rs11750568	1.000	rs11750568	chr5:178535713	A/G	cg10208897	chr5:178548229	ADAMTS2	0.43	6.93	0.31	1.43e-11	Height;
LGG	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6601327	0.575	rs7001832	chr8:9607235	C/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.09	-0.31	5.15e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs283228	0.535	rs579069	chr6:101839539	A/T	cg02011392	chr6:101847541	GRIK2	0.53	7.35	0.32	9.26e-13	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg08677398	chr8:58056175	NA	0.51	8.06	0.35	6.56e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs35146811	0.735	rs11767968	chr7:99790971	G/A	cg13334819	chr7:99746414	C7orf59	-0.45	-6.94	-0.31	1.33e-11	Coronary artery disease;
LGG	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.55	-0.37	1.78e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs72720396	1.000	rs72720396	chr1:91191582	A/G	cg13456504	chr1:91191583	NA	0.65	9.42	0.4	2.2e-19	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg06115741	chr20:33292138	TP53INP2	0.6	9.88	0.42	5.23e-21	Coronary artery disease;
LGG	cis	rs6754311	0.731	rs748841	chr2:136558157	C/T	cg07169764	chr2:136633963	MCM6	-0.74	-12.56	-0.5	2.46e-31	Mosquito bite size;
LGG	cis	rs4237845	0.537	rs2002275	chr12:58283385	A/G	cg02175503	chr12:58329896	NA	0.57	9.67	0.41	2.92e-20	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.505	rs7840347	chr8:10072350	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.4	0.36	5.72e-16	Neuroticism;
LGG	cis	rs854765	0.964	rs12950562	chr17:17995166	C/T	cg04398451	chr17:18023971	MYO15A	0.67	13.88	0.54	7.09e-37	Total body bone mineral density;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07167872	chr1:205819463	PM20D1	-0.36	-6.69	-0.3	6.28e-11	Menarche (age at onset);
LGG	cis	rs2710642	0.888	rs13418889	chr2:63079775	T/C	cg17519650	chr2:63277830	OTX1	0.47	7.75	0.34	5.99e-14	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs4076764	0.846	rs7525724	chr1:163426372	G/A	cg06092702	chr1:163392909	NA	-0.41	-7.38	-0.32	7.4e-13	Motion sickness;
LGG	cis	rs988958	0.565	rs1440095	chr2:42289666	T/C	cg27428208	chr2:42229179	NA	0.42	8.63	0.37	1e-16	Hypospadias;
LGG	trans	rs7829975	0.522	rs6601689	chr8:8172283	C/T	cg27411982	chr8:10470053	RP1L1	0.4	6.7	0.3	6.07e-11	Mood instability;
LGG	cis	rs34467563	0.500	rs7821730	chr8:97334850	A/T	cg22138393	chr8:97340270	PTDSS1	0.31	8.11	0.35	4.54e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg24503407	chr1:205819492	PM20D1	0.91	23.9	0.74	8.24e-83	Menarche (age at onset);
LGG	cis	rs9534288	0.619	rs2146881	chr13:46679598	T/C	cg15192986	chr13:46630673	CPB2	-0.7	-14.25	-0.55	1.92e-38	Blood protein levels;
LGG	cis	rs9611519	0.929	rs11090039	chr22:41496800	G/A	cg03806693	chr22:41940476	POLR3H	-0.56	-8.61	-0.37	1.13e-16	Neuroticism;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg16270222	chr17:41446396	NA	-0.29	-6.67	-0.3	7.23e-11	Menopause (age at onset);
LGG	cis	rs7829975	0.511	rs1543238	chr8:8134809	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	9.26	0.4	7.84e-19	Mood instability;
LGG	cis	rs10464366	0.560	rs11763728	chr7:39145862	C/T	cg18850127	chr7:39170497	POU6F2	0.54	13.2	0.52	5.4e-34	IgG glycosylation;
LGG	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07570687	chr10:102243282	WNT8B	0.4	7.25	0.32	1.78e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg08344181	chr3:125677491	NA	-0.79	-8.23	-0.36	1.86e-15	Lung cancer in ever smokers;
LGG	cis	rs72781680	1.000	rs72796329	chr2:24141912	G/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.57	0.41	6.62e-20	Lymphocyte counts;
LGG	cis	rs8114671	0.967	rs2093058	chr20:33791281	C/T	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.33	-0.32	1e-12	Height;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg21862992	chr11:68658383	NA	0.51	8.44	0.37	4.05e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs963731	0.579	rs1531021	chr2:39199955	C/G	cg04010122	chr2:39346883	SOS1	-0.73	-7.56	-0.33	2.17e-13	Corticobasal degeneration;
LGG	cis	rs7193541	0.825	rs4411525	chr16:74595502	A/C	cg01733217	chr16:74700730	RFWD3	0.83	18.1	0.64	9.49e-56	Multiple myeloma;
LGG	trans	rs67340775	0.541	rs200964	chr6:27866943	G/C	cg01620082	chr3:125678407	NA	-0.67	-8.55	-0.37	1.85e-16	Lung cancer in ever smokers;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg11584989	chr19:19387371	SF4	0.4	7.2	0.32	2.4e-12	Tonsillectomy;
LGG	trans	rs7819412	0.807	rs10105315	chr8:10932203	G/C	cg16141378	chr3:129829833	LOC729375	0.39	8.97	0.38	7.67e-18	Triglycerides;
LGG	cis	rs7927592	0.763	rs4340059	chr11:68362433	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.79	-0.45	2.27e-24	Total body bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25707994	chr7:157129685	DNAJB6	0.42	6.94	0.31	1.32e-11	Cognitive performance;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg24935452	chr19:1110436	SBNO2	0.38	6.65	0.3	8.53e-11	Pancreatic cancer;
LGG	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg08975724	chr8:8085496	FLJ10661	-0.44	-7.97	-0.35	1.24e-14	Retinal vascular caliber;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs7659604	0.521	rs9993206	chr4:122686957	A/G	cg19671926	chr4:122722719	EXOSC9	0.47	7.23	0.32	2e-12	Type 2 diabetes;
LGG	cis	rs8005677	0.828	rs2295682	chr14:23374862	C/T	cg25600027	chr14:23388339	RBM23	-0.42	-7.07	-0.31	5.9e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs8072100	0.967	rs4239162	chr17:45755810	G/A	cg19784903	chr17:45786737	TBKBP1	-0.35	-7.69	-0.34	9.21e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg00405596	chr8:11794950	NA	0.64	11.4	0.47	1.06e-26	Neuroticism;
LGG	cis	rs78487399	0.808	rs75126888	chr2:43664007	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs3762637	1.000	rs9878699	chr3:122194231	T/A	cg24169773	chr3:122142474	KPNA1	-0.62	-10.55	-0.44	1.78e-23	LDL cholesterol levels;
LGG	cis	rs4728302	0.643	rs2346442	chr7:133705907	A/G	cg10665199	chr7:133106180	EXOC4	-0.4	-6.79	-0.3	3.43e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.740	rs9596648	chr13:52934569	A/T	cg02158880	chr13:53174818	NA	-0.4	-7.82	-0.34	3.54e-14	Lewy body disease;
LGG	cis	rs1218582	0.772	rs4845400	chr1:154872523	C/T	cg06221963	chr1:154839813	KCNN3	-0.53	-11.08	-0.46	1.77e-25	Prostate cancer;
LGG	cis	rs2249694	0.960	rs7094588	chr10:135401586	A/G	cg20169779	chr10:135381914	SYCE1	-0.47	-7.44	-0.33	4.83e-13	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.78e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1153858	1.000	rs12593370	chr15:45617417	C/T	cg10760299	chr15:45669010	GATM	0.4	7.73	0.34	6.81e-14	Homoarginine levels;
LGG	cis	rs1978968	0.763	rs5992943	chr22:18465756	A/C	cg03078520	chr22:18463400	MICAL3	-0.66	-13.96	-0.54	3.32e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs2760061	0.819	rs1745417	chr1:228204279	C/T	cg18477163	chr1:228402036	OBSCN	0.25	6.68	0.3	6.99e-11	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26714410	chr13:45150072	TSC22D1	0.51	7.89	0.34	2.19e-14	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.14	0.72	1.26e-74	Bladder cancer;
LGG	cis	rs7959452	0.640	rs4274230	chr12:69700772	T/G	cg11871910	chr12:69753446	YEATS4	0.72	14.31	0.55	1.01e-38	Blood protein levels;
LGG	cis	rs763121	0.853	rs138709	chr22:39139216	C/G	cg06022373	chr22:39101656	GTPBP1	0.89	17.42	0.63	1.21e-52	Menopause (age at onset);
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg11965913	chr1:205819406	PM20D1	-0.83	-18.42	-0.65	2.89e-57	Menarche (age at onset);
LGG	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs62344088	0.590	rs62345236	chr5:283519	G/A	cg22496380	chr5:211416	CCDC127	-1.09	-9.85	-0.42	6.73e-21	Asthma (childhood onset);
LGG	cis	rs2841277	0.676	rs4264326	chr14:105411700	A/G	cg15352829	chr14:105391018	PLD4	-0.48	-11.51	-0.47	3.81e-27	Rheumatoid arthritis;
LGG	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg10596483	chr8:143751796	JRK	0.58	9.46	0.4	1.55e-19	Schizophrenia;
LGG	cis	rs11608355	0.515	rs56244055	chr12:109936211	G/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs3768617	0.510	rs2333620	chr1:183100555	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg11584989	chr19:19387371	SF4	-0.4	-7.3	-0.32	1.23e-12	Tonsillectomy;
LGG	cis	rs35740288	0.703	rs10520598	chr15:86173381	T/G	cg04173714	chr15:86211321	AKAP13	0.46	8.46	0.37	3.44e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05025164	chr4:1340916	KIAA1530	0.86	17.01	0.62	9.7e-51	Longevity;
LGG	cis	rs2645694	0.533	rs2703125	chr4:77819900	T/C	cg06046430	chr4:77819534	ANKRD56	0.56	11.3	0.46	2.65e-26	Emphysema distribution in smoking;
LGG	cis	rs1552244	0.554	rs2272120	chr3:10046703	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.42	0.5	8.89e-31	Alzheimer's disease;
LGG	cis	rs4538187	0.855	rs11125981	chr2:63911761	G/A	cg14150252	chr2:64069583	UGP2	-0.43	-7.71	-0.34	7.92e-14	Systolic blood pressure;
LGG	cis	rs4720575	1.000	rs4720574	chr7:47085597	A/C	cg00036614	chr7:47093842	NA	-0.49	-9.62	-0.41	4.42e-20	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs6815814	1.000	rs11722836	chr4:38811529	T/A	cg06935464	chr4:38784597	TLR10	0.6	8.19	0.36	2.49e-15	Breast cancer;
LGG	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg19761014	chr17:28927070	LRRC37B2	0.64	7.67	0.34	1.02e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8077059	1.000	rs9916043	chr17:55813260	C/T	cg12582317	chr17:55822272	NA	0.39	7.02	0.31	7.82e-12	Sex hormone-binding globulin levels;
LGG	trans	rs8056742	1.000	rs16975170	chr16:85092575	C/T	cg21573796	chr15:44394647	FRMD5	-0.41	-6.65	-0.3	8.24e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg15556689	chr8:8085844	FLJ10661	0.5	9.34	0.4	4.11e-19	Mood instability;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	7.13	0.31	3.95e-12	Prudent dietary pattern;
LGG	cis	rs9611565	0.694	rs202628	chr22:41849513	A/G	cg17376030	chr22:41985996	PMM1	0.48	7.84	0.34	3.17e-14	Vitiligo;
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg11062466	chr8:58055876	NA	0.51	7.83	0.34	3.3e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs67311347	0.544	rs12635762	chr3:40332759	C/T	cg13683864	chr3:40499215	RPL14	0.83	17.23	0.63	9.26e-52	Renal cell carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17677112	chr7:77428730	PHTF2;TMEM60	0.49	7.46	0.33	4.37e-13	Gut microbiome composition (summer);
LGG	cis	rs6496932	0.802	rs2063442	chr15:85858044	T/C	cg19183879	chr15:85880815	NA	0.42	6.74	0.3	4.76e-11	Central corneal thickness;Corneal structure;
LGG	trans	rs7829975	0.681	rs2271342	chr8:8643938	C/T	cg21775007	chr8:11205619	TDH	0.47	7.76	0.34	5.29e-14	Mood instability;
LGG	trans	rs1728785	1.000	rs7196104	chr16:68579746	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs3091242	0.933	rs926438	chr1:25753638	C/T	cg02931644	chr1:25747376	RHCE	0.42	9.54	0.41	7.96e-20	Erythrocyte sedimentation rate;
LGG	cis	rs9486715	0.867	rs4598081	chr6:96975227	A/G	cg06623918	chr6:96969491	KIAA0776	0.79	16.2	0.6	4.31e-47	Headache;
LGG	cis	rs568617	0.953	rs658938	chr11:65651830	A/G	cg26695010	chr11:65641043	EFEMP2	0.47	6.74	0.3	4.81e-11	Crohn's disease;
LGG	cis	rs2228479	0.850	rs17227263	chr16:89810598	G/A	cg03036210	chr16:89904091	SPIRE2	-0.67	-8.03	-0.35	8.31e-15	Skin colour saturation;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.85	0.38	1.92e-17	Platelet count;
LGG	cis	rs1185460	0.546	rs7114961	chr11:118914388	G/C	cg23280166	chr11:118938394	VPS11	-0.44	-7.61	-0.33	1.53e-13	Coronary artery disease;
LGG	cis	rs6977660	1.000	rs12666159	chr7:19804199	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	8.56	0.37	1.7e-16	Thyroid stimulating hormone;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.06e-12	Prudent dietary pattern;
LGG	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg06145435	chr7:1022769	CYP2W1	0.3	6.66	0.3	7.77e-11	Longevity;Endometriosis;
LGG	cis	rs17401966	0.538	rs7418410	chr1:10236402	A/G	cg19773385	chr1:10388646	KIF1B	0.37	7.83	0.34	3.37e-14	Hepatocellular carcinoma;
LGG	cis	rs875971	0.508	rs6947808	chr7:66045082	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.91	-0.45	8.03e-25	Aortic root size;
LGG	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs9788682	0.747	rs938682	chr15:78896547	A/G	cg06917634	chr15:78832804	PSMA4	-0.49	-7.74	-0.34	6.28e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs988958	0.567	rs10184755	chr2:42258948	C/T	cg27428208	chr2:42229179	NA	-0.56	-9.6	-0.41	4.92e-20	Hypospadias;
LGG	trans	rs9951602	0.850	rs56367211	chr18:76677563	G/T	cg02800362	chr5:177631904	HNRNPAB	-0.71	-9.01	-0.39	5.39e-18	Obesity-related traits;
LGG	cis	rs7192750	0.517	rs9932922	chr16:71918178	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.53	0.44	2.22e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs2030746	0.521	rs6750309	chr2:121332191	A/G	cg13274077	chr2:121334614	NA	-0.37	-9.26	-0.4	7.63e-19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs6681460	0.625	rs6696812	chr1:67100309	T/C	cg13052034	chr1:66999238	SGIP1	0.36	6.98	0.31	1.02e-11	Presence of antiphospholipid antibodies;
LGG	cis	rs67133203	0.808	rs11169712	chr12:51511152	G/A	cg14688905	chr12:51403056	SLC11A2	0.67	10.03	0.42	1.5e-21	Urinary tract infection frequency;
LGG	cis	rs2415984	0.622	rs1761026	chr14:46930139	T/C	cg14871534	chr14:47121158	RPL10L	0.57	10.06	0.42	1.17e-21	Number of children ever born;
LGG	cis	rs4780401	0.609	rs16958588	chr16:11819330	G/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.94	-0.52	6.37e-33	Rheumatoid arthritis;
LGG	cis	rs12497850	0.864	rs4521268	chr3:49137904	G/T	cg02487422	chr3:49467188	NICN1	0.42	7.09	0.31	5.06e-12	Parkinson's disease;
LGG	cis	rs1577917	1.000	rs12663690	chr6:86640162	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.57	9.47	0.4	1.41e-19	Response to antipsychotic treatment;
LGG	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg08949735	chr16:89699720	DPEP1	-0.47	-9.53	-0.4	8.9e-20	Vitiligo;
LGG	cis	rs7524258	0.903	rs6577424	chr1:7292417	C/T	cg07173049	chr1:7289937	CAMTA1	-0.77	-19.21	-0.67	6.88e-61	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1594829	0.553	rs6996531	chr8:26153455	C/A	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs10911251	0.528	rs10911248	chr1:183080564	G/A	cg15522984	chr1:182991683	LAMC1	0.46	9.24	0.39	9.19e-19	Colorectal cancer;
LGG	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg03342759	chr3:160939853	NMD3	-0.44	-7.34	-0.32	9.59e-13	Morning vs. evening chronotype;
LGG	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg11871910	chr12:69753446	YEATS4	0.72	14.46	0.56	2.19e-39	Blood protein levels;
LGG	cis	rs9457247	0.579	rs2181059	chr6:167441624	T/C	cg07741184	chr6:167504864	NA	0.4	8.77	0.38	3.34e-17	Crohn's disease;
LGG	cis	rs9322193	0.923	rs14314	chr6:150141531	A/C	cg09699651	chr6:150184138	LRP11	0.49	8.63	0.37	1.03e-16	Lung cancer;
LGG	cis	rs10927875	0.632	rs1122068	chr1:16127480	G/C	cg21385522	chr1:16154831	NA	-1.04	-25.65	-0.77	6.13e-91	Dilated cardiomyopathy;
LGG	cis	rs787274	1.000	rs10739370	chr9:115556941	A/G	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs6999351	chr8:58127227	C/T	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17453880	0.929	rs7715495	chr5:152048107	T/G	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.3	0.4	5.4e-19	Lung cancer;
LGG	cis	rs9660180	0.620	rs3817856	chr1:1663831	C/T	cg23982607	chr1:1823379	GNB1	0.39	6.86	0.3	2.28e-11	Body mass index;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg18402987	chr7:1209562	NA	0.53	8.61	0.37	1.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7572644	0.782	rs4666030	chr2:28097222	C/T	cg27432699	chr2:27873401	GPN1	0.45	6.79	0.3	3.54e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg21782813	chr7:2030301	MAD1L1	0.46	10.92	0.45	7.39e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9943753	0.525	rs7957928	chr12:109835975	C/G	cg19025524	chr12:109796872	NA	-0.54	-11.63	-0.48	1.28e-27	HDL cholesterol;
LGG	cis	rs9486715	0.867	rs926277	chr6:96868837	T/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg15320075	chr8:145703422	NA	-0.72	-13.06	-0.52	2.09e-33	Age at first birth;
LGG	cis	rs908922	0.651	rs11205035	chr1:152532832	A/G	cg09873164	chr1:152488093	CRCT1	0.61	14.84	0.57	5.18e-41	Hair morphology;
LGG	cis	rs774359	0.750	rs700791	chr9:27545960	G/T	cg21249376	chr9:27528432	MOBKL2B	0.38	6.73	0.3	5.06e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs977987	0.806	rs11640674	chr16:75394944	A/G	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs7618915	0.547	rs4687638	chr3:52651966	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.52	0.37	2.3e-16	Bipolar disorder;
LGG	cis	rs208520	1.000	rs28773210	chr6:66993566	C/T	cg07460842	chr6:66804631	NA	0.9	14.76	0.57	1.13e-40	Exhaled nitric oxide output;
LGG	cis	rs2729354	0.729	rs2581923	chr11:57249991	C/T	cg24343310	chr11:57249947	NA	0.41	8.06	0.35	6.55e-15	Blood protein levels;
LGG	cis	rs4262150	0.883	rs72804775	chr5:152303195	C/T	cg12297329	chr5:152029980	NA	-0.61	-11.05	-0.46	2.34e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	1.000	rs17040322	chr2:26351274	G/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs4851266	0.966	rs1160545	chr2:100832269	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.15	-0.35	3.38e-15	Educational attainment;
LGG	trans	rs9348721	0.673	rs9358934	chr6:26363755	G/C	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Intelligence (multi-trait analysis);
LGG	trans	rs4650994	1.000	rs4650994	chr1:178515312	A/G	cg05059571	chr16:84539110	KIAA1609	0.44	8.02	0.35	8.88e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8180040	0.966	rs4858868	chr3:47455086	G/A	cg16586182	chr3:47516702	SCAP	-0.78	-15.62	-0.59	1.77e-44	Colorectal cancer;
LGG	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg25039879	chr17:56429692	SUPT4H1	0.63	8.83	0.38	2.21e-17	Cognitive test performance;
LGG	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg24011408	chr12:48396354	COL2A1	0.52	8.31	0.36	1.11e-15	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	trans	rs61931739	0.649	rs708139	chr12:33733265	C/A	cg26384229	chr12:38710491	ALG10B	0.48	8.63	0.37	9.6e-17	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.93	-0.35	1.66e-14	Life satisfaction;
LGG	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg27411982	chr8:10470053	RP1L1	0.45	7.86	0.34	2.79e-14	Triglycerides;
LGG	cis	rs3741404	0.609	rs592271	chr11:63872029	G/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.32	0.58	3.64e-43	Platelet count;
LGG	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg04731861	chr2:219085781	ARPC2	-0.41	-9.99	-0.42	2.13e-21	Colorectal cancer;
LGG	cis	rs1790761	0.658	rs666328	chr11:67335538	G/A	cg09038676	chr11:67351608	GSTP1	-0.36	-7.18	-0.32	2.81e-12	Mean corpuscular volume;
LGG	trans	rs1814175	0.676	rs11040647	chr11:49935947	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs6582630	0.519	rs8189461	chr12:38374870	G/T	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12110303	1	rs12110303	chr5:90662839	G/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.71	0.64	6.01e-54	Breast cancer;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg16270222	chr17:41446396	NA	-0.29	-6.81	-0.3	2.99e-11	Menopause (age at onset);
LGG	cis	rs1008375	0.931	rs10019482	chr4:17578079	G/A	cg10189774	chr4:17578691	LAP3	0.41	7.48	0.33	3.87e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6977660	0.714	rs1468287	chr7:19784210	T/A	cg05791153	chr7:19748676	TWISTNB	0.74	9.87	0.42	5.75e-21	Thyroid stimulating hormone;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg16507663	chr6:150244633	RAET1G	0.41	7.61	0.33	1.52e-13	Lung cancer;
LGG	cis	rs1682825	0.615	rs350661	chr3:10779703	G/C	cg23512531	chr3:10780469	NA	-0.6	-9.83	-0.42	7.93e-21	Economic and political preferences (feminism/equality);
LGG	trans	rs330071	0.622	rs898797	chr8:9229689	C/T	cg16141378	chr3:129829833	LOC729375	-0.35	-7.65	-0.33	1.2e-13	Acne (severe);
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18876405	chr7:65276391	NA	-0.54	-9.66	-0.41	3.18e-20	Aortic root size;
LGG	cis	rs9611565	0.918	rs2281333	chr22:41749630	T/C	cg03806693	chr22:41940476	POLR3H	-0.85	-14.77	-0.57	9.77e-41	Vitiligo;
LGG	trans	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05039488	chr6:79577232	IRAK1BP1	-0.53	-9.59	-0.41	5.43e-20	Brugada syndrome;
LGG	cis	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg09307838	chr4:120376055	NA	0.8	13.4	0.53	7.73e-35	Corneal astigmatism;
LGG	cis	rs3020736	0.500	rs7364293	chr22:42506370	C/T	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.44e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg24829409	chr8:58192753	C8orf71	-0.81	-12.77	-0.51	3.41e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.500	rs13052701	chr21:47660045	A/T	cg12016809	chr21:47604291	C21orf56	0.48	7.08	0.31	5.52e-12	Testicular germ cell tumor;
LGG	trans	rs6956675	0.915	rs1608134	chr7:62653607	A/C	cg01314568	chr7:57830625	NA	-0.47	-7.78	-0.34	4.85e-14	Obesity-related traits;
LGG	cis	rs7824557	0.527	rs4631425	chr8:11239054	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.35	-0.53	1.32e-34	Retinal vascular caliber;
LGG	trans	rs7395662	1.000	rs12361812	chr11:48563104	A/G	cg15704280	chr7:45808275	SEPT13	-0.51	-8.22	-0.36	2.01e-15	HDL cholesterol;
LGG	cis	rs2862064	1.000	rs1910052	chr5:156429154	T/C	cg12943317	chr5:156479607	HAVCR1	-0.85	-10.57	-0.44	1.55e-23	Platelet count;
LGG	cis	rs1008375	0.966	rs6832414	chr4:17696866	C/G	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg08677398	chr8:58056175	NA	0.56	8.69	0.37	6.17e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs17209837	1.000	rs2302387	chr7:87092185	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-12.77	-0.51	3.19e-32	Gallbladder cancer;
LGG	trans	rs9650657	0.504	rs10093053	chr8:11037187	T/C	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.68	-0.37	6.93e-17	Neuroticism;
LGG	cis	rs2576037	0.526	rs571181	chr18:44376399	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.36	-7.96	-0.35	1.32e-14	Personality dimensions;
LGG	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg02002194	chr4:3960332	NA	-0.5	-9.34	-0.4	3.97e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1865760	0.827	rs9295680	chr6:25944103	T/C	cg17691542	chr6:26056736	HIST1H1C	0.54	9.68	0.41	2.75e-20	Height;
LGG	cis	rs4819052	0.851	rs1999333	chr21:46670401	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.56e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2117029	0.554	rs2334930	chr12:49569311	T/C	cg24176009	chr12:49580217	TUBA1A	0.66	12.78	0.51	3.07e-32	Intelligence (multi-trait analysis);
LGG	cis	rs12681366	0.663	rs1561648	chr8:95474437	C/T	cg13257157	chr8:95487014	RAD54B	0.39	6.95	0.31	1.25e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs17376456	0.877	rs7701011	chr5:93311456	G/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs6714710	0.535	rs13006932	chr2:98370698	T/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.97	0.42	2.45e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.755	rs76288834	chr7:66069802	G/A	cg11764359	chr7:65958608	NA	-0.74	-13.2	-0.52	5.21e-34	Aortic root size;
LGG	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg20891283	chr12:69753455	YEATS4	1.1	29.23	0.81	3.44e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11074306	0.561	rs74505882	chr15:28071908	C/T	cg26402630	chr15:28053930	OCA2	0.36	7.23	0.32	2.04e-12	Uveal melanoma;
LGG	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg23324259	chr8:82754387	SNX16	0.45	7.19	0.32	2.55e-12	Diastolic blood pressure;
LGG	cis	rs4006360	0.657	rs6503588	chr17:39235453	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.25	-0.46	4.12e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	trans	rs2665103	0.687	rs11633000	chr15:82561661	C/G	cg16105309	chr15:79090380	ADAMTS7	0.34	6.66	0.3	7.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9814567	1.000	rs9814567	chr3:134218557	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.73	13.07	0.52	1.85e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.58	0.41	5.8e-20	Height;
LGG	cis	rs11585357	0.557	rs17378462	chr1:17595702	C/T	cg08277548	chr1:17600880	PADI3	-0.59	-6.85	-0.3	2.37e-11	Hair shape;
LGG	cis	rs1552244	1.000	rs7628448	chr3:10146828	G/A	cg18621852	chr3:10150065	C3orf24	0.41	6.82	0.3	2.92e-11	Alzheimer's disease;
LGG	cis	rs35146811	0.589	rs1727142	chr7:99816179	T/C	cg22906224	chr7:99728672	NA	-0.56	-8.83	-0.38	2.16e-17	Coronary artery disease;
LGG	cis	rs6088580	0.609	rs6058029	chr20:32969643	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.36	2.92e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6546550	0.901	rs13015457	chr2:70125763	G/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.96	-0.35	1.33e-14	Prevalent atrial fibrillation;
LGG	cis	rs60180747	0.909	rs74956204	chr15:66794352	G/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.62	10.38	0.43	8.13e-23	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	7.81e-24	Lung cancer;
LGG	trans	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg27411982	chr8:10470053	RP1L1	0.4	6.99	0.31	9.94e-12	Mood instability;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-7.56	-0.33	2.19e-13	Life satisfaction;
LGG	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg03342759	chr3:160939853	NMD3	-0.66	-11.77	-0.48	3.6e-28	Morning vs. evening chronotype;
LGG	cis	rs2643217	1.000	rs2643217	chr15:39003763	C/T	cg10631289	chr15:39006617	NA	-0.43	-7.33	-0.32	1.05e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.825	rs58532402	chr11:70189491	C/T	cg13802316	chr11:70253460	CTTN	-0.57	-7.44	-0.33	4.81e-13	Coronary artery disease;
LGG	cis	rs1348850	0.668	rs13034886	chr2:178493301	G/T	cg23306229	chr2:178417860	TTC30B	0.53	6.89	0.31	1.77e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg05863683	chr7:1912471	MAD1L1	0.38	6.82	0.3	2.87e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1670533	1.000	rs2045068	chr4:1052212	G/A	cg27284194	chr4:1044797	NA	0.55	9.93	0.42	3.37e-21	Recombination rate (females);
LGG	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg19077165	chr18:44547161	KATNAL2	-0.61	-11.27	-0.46	3.37e-26	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11859641	chr8:22102489	POLR3D;MIR320A	0.45	6.72	0.3	5.41e-11	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.825	rs801202	chr7:66023929	C/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	trans	rs4512344	0.514	rs13255193	chr8:11309192	T/C	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.85	-0.34	2.94e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs7819412	0.511	rs2898290	chr8:11433909	T/C	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.29	-0.46	2.72e-26	Triglycerides;
LGG	trans	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.98	-0.35	1.13e-14	Triglycerides;
LGG	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19355462	chr6:15248936	JARID2	0.47	6.84	0.3	2.56e-11	Gut microbiome composition (summer);
LGG	cis	rs4689388	0.890	rs3821941	chr4:6286954	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.93	0.48	8.34e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg19847130	chr8:10466454	RP1L1	-0.31	-6.81	-0.3	3.08e-11	Mood instability;
LGG	cis	rs67366981	0.925	rs66846709	chr14:77692812	G/A	cg22824376	chr14:77648248	TMEM63C	0.69	7.49	0.33	3.44e-13	Obsessive-compulsive symptoms;
LGG	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg04705435	chr11:17411270	KCNJ11	0.42	8.34	0.36	8.67e-16	Type 2 diabetes;
LGG	cis	rs7681440	0.874	rs1442151	chr4:90775491	T/A	cg15133208	chr4:90757351	SNCA	-0.38	-8.69	-0.37	6.41e-17	Dementia with Lewy bodies;
LGG	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg00631329	chr6:26305371	NA	0.5	8.57	0.37	1.59e-16	Mosquito bite size;
LGG	cis	rs17023223	0.537	rs10923754	chr1:119668640	T/C	cg05756136	chr1:119680316	WARS2	-0.44	-8.58	-0.37	1.41e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs36051895	0.559	rs7858422	chr9:5209797	G/T	cg02405213	chr9:5042618	JAK2	-0.63	-11.28	-0.46	3.19e-26	Pediatric autoimmune diseases;
LGG	cis	rs7666738	0.830	rs9995386	chr4:98907826	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4330281	0.669	rs11708672	chr3:17703137	C/T	cg20981856	chr3:17787350	NA	-0.38	-7.09	-0.31	5.21e-12	Schizophrenia;
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.27	0.36	1.47e-15	Bipolar disorder;
LGG	cis	rs2046867	0.774	rs62249873	chr3:72907115	G/A	cg26655873	chr3:72818019	SHQ1	0.34	6.65	0.3	8.34e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg26384229	chr12:38710491	ALG10B	-0.72	-13.67	-0.54	5.55e-36	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.51e-30	Lung cancer;
LGG	cis	rs9926296	0.712	rs258330	chr16:89729574	T/G	cg08949735	chr16:89699720	DPEP1	-0.48	-9.89	-0.42	4.67e-21	Vitiligo;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg06028808	chr11:68637592	NA	0.72	12.6	0.51	1.69e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7326068	0.557	rs4331211	chr13:21125299	T/C	cg04906043	chr13:21280425	IL17D	-0.47	-7.87	-0.34	2.51e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs11722228	0.964	rs10939614	chr4:9926613	T/C	cg11266682	chr4:10021025	SLC2A9	-0.38	-6.73	-0.3	5.11e-11	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7937890	0.559	rs2597197	chr11:14489832	G/A	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg15787769	chr11:842744	TSPAN4;POLR2L	-0.49	-7.89	-0.34	2.22e-14	Mean platelet volume;
LGG	cis	rs734999	0.588	rs2843401	chr1:2528133	T/C	cg18854424	chr1:2615690	NA	-0.36	-7.24	-0.32	1.86e-12	Ulcerative colitis;
LGG	cis	rs10461617	0.592	rs6450403	chr5:56062737	A/C	cg12654349	chr5:56205094	C5orf35	-0.44	-7.54	-0.33	2.46e-13	Type 2 diabetes;
LGG	cis	rs17539620	0.624	rs74551216	chr6:154840524	T/C	cg17771515	chr6:154831774	CNKSR3	0.62	7.65	0.34	1.17e-13	Lipoprotein (a) levels;
LGG	cis	rs56283067	0.847	rs1418432	chr6:44691372	T/C	cg18551225	chr6:44695536	NA	-0.7	-12.34	-0.5	1.86e-30	Total body bone mineral density;
LGG	cis	rs4700695	0.841	rs251614	chr5:65228251	C/G	cg21114390	chr5:65439923	SFRS12	-0.58	-7.43	-0.33	5.16e-13	Facial morphology (factor 19);
LGG	cis	rs9291683	0.507	rs6827754	chr4:10018153	A/C	cg00071950	chr4:10020882	SLC2A9	-0.38	-7.67	-0.34	1.02e-13	Bone mineral density;
LGG	cis	rs8062405	1.000	rs62036616	chr16:28826307	A/G	cg16576597	chr16:28551801	NUPR1	0.31	6.93	0.31	1.38e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs1345301	0.518	rs1035131	chr2:102862641	A/C	cg05295703	chr2:102895712	NA	0.47	9.44	0.4	1.82e-19	Waist circumference;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	cg15522984	chr1:182991683	LAMC1	0.47	9.45	0.4	1.7e-19	Hypertriglyceridemia;
LGG	cis	rs7666738	0.830	rs2865979	chr4:99027137	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1153858	1.000	rs72623915	chr15:45647433	C/T	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs36051895	0.603	rs10974972	chr9:5130146	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-15.24	-0.58	8.79e-43	Pediatric autoimmune diseases;
LGG	cis	rs9435341	0.965	rs1762482	chr1:107599002	A/C	cg09367891	chr1:107599246	PRMT6	-0.59	-10.57	-0.44	1.49e-23	Facial morphology (factor 21, depth of nasal alae);
LGG	trans	rs453301	0.631	rs17700611	chr8:8793654	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.83	0.3	2.64e-11	Joint mobility (Beighton score);
LGG	trans	rs7824557	0.734	rs2293856	chr8:11177447	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	9.97	0.42	2.37e-21	Retinal vascular caliber;
LGG	cis	rs9467160	0.581	rs2817244	chr6:24464511	G/T	cg20631270	chr6:24437470	GPLD1	0.44	6.98	0.31	1.03e-11	Liver enzyme levels;
LGG	cis	rs769267	0.965	rs2074296	chr19:19373689	A/G	cg11584989	chr19:19387371	SF4	0.44	7.94	0.35	1.55e-14	Tonsillectomy;
LGG	trans	rs116095464	0.558	rs10075018	chr5:239175	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	13.04	0.52	2.41e-33	Breast cancer;
LGG	cis	rs938554	0.513	rs11943372	chr4:9999346	T/A	cg25986240	chr4:9926439	SLC2A9	-0.37	-6.86	-0.3	2.16e-11	Blood metabolite levels;
LGG	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs10752881	0.967	rs8179284	chr1:182974707	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	trans	rs2727020	0.553	rs7479975	chr11:49581964	C/G	cg03929089	chr4:120376271	NA	-0.98	-20.72	-0.69	5.63e-68	Coronary artery disease;
LGG	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg05925327	chr15:68127851	NA	-0.36	-7.48	-0.33	3.71e-13	Restless legs syndrome;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.13	-0.46	1.2e-25	IgG glycosylation;
LGG	cis	rs66573146	0.572	rs68169399	chr4:6952491	T/A	cg00086871	chr4:6988644	TBC1D14	0.84	8.31	0.36	1.03e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs367943	0.637	rs10039956	chr5:113010928	G/A	cg12552261	chr5:112820674	MCC	0.48	7.76	0.34	5.3e-14	Type 2 diabetes;
LGG	cis	rs2072732	0.821	rs58052947	chr1:2950094	T/C	cg08733933	chr1:2954429	NA	-0.37	-8.03	-0.35	8.1e-15	Plateletcrit;
LGG	cis	rs854037	0.752	rs1835874	chr5:57133250	T/C	cg08523694	chr5:57076192	NA	0.52	8.3	0.36	1.15e-15	Birth weight;
LGG	cis	rs9362426	0.708	rs4707367	chr6:88101188	A/C	cg06087457	chr6:88040249	C6orf162;GJB7	-0.41	-8.06	-0.35	6.56e-15	Depressive episodes in bipolar disorder;
LGG	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg03264133	chr6:25882463	NA	0.46	7.53	0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs7552404	1.000	rs211718	chr1:76106675	C/T	cg22875332	chr1:76189707	ACADM	0.61	10.22	0.43	3.1e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.12e-14	IgG glycosylation;
LGG	cis	rs10504229	0.679	rs7839948	chr8:58130607	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	1.000	rs13416881	chr2:1554808	G/A	cg01028140	chr2:1542097	TPO	-0.55	-8.46	-0.37	3.66e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs4722585	0.533	rs3753097	chr7:26198207	A/G	cg07876897	chr7:26191696	NFE2L3	0.35	6.98	0.31	1.03e-11	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs1348850	0.597	rs13014512	chr2:178470851	T/A	cg27490568	chr2:178487706	NA	0.89	16.24	0.6	2.95e-47	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs74781061	0.932	rs2012008	chr15:74734168	A/G	cg02384859	chr15:74862662	ARID3B	-0.33	-6.78	-0.3	3.76e-11	Endometriosis;
LGG	cis	rs12908161	1.000	rs11638290	chr15:85227636	C/T	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	9.2e-12	Schizophrenia;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg08409804	chr12:121773393	ANAPC5	0.33	6.76	0.3	4.06e-11	Parkinson's disease (motor and cognition);
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg11584989	chr19:19387371	SF4	-0.42	-7.5	-0.33	3.38e-13	Tonsillectomy;
LGG	cis	rs1862618	0.641	rs252893	chr5:56224714	T/C	cg12654349	chr5:56205094	C5orf35	-0.58	-10.01	-0.42	1.78e-21	Initial pursuit acceleration;
LGG	cis	rs11098499	0.691	rs10028773	chr4:120265259	C/G	cg09307838	chr4:120376055	NA	-0.67	-11.48	-0.47	5.03e-27	Corneal astigmatism;
LGG	trans	rs561341	1.000	rs15654	chr17:30326360	A/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg03806693	chr22:41940476	POLR3H	-1.14	-20.82	-0.7	2.02e-68	Vitiligo;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg02733842	chr7:1102375	C7orf50	0.68	10.19	0.43	3.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg26554054	chr8:600488	NA	-0.88	-9.64	-0.41	3.74e-20	IgG glycosylation;
LGG	cis	rs9815354	0.767	rs73079350	chr3:41876310	C/T	cg03022575	chr3:42003672	ULK4	0.83	9.6	0.41	5.14e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10875746	0.669	rs61941003	chr12:48619625	G/A	cg24011408	chr12:48396354	COL2A1	-0.58	-7.54	-0.33	2.56e-13	Longevity (90 years and older);
LGG	cis	rs1790761	0.967	rs12573992	chr11:67197757	A/G	cg14500267	chr11:67383377	NA	-0.38	-6.94	-0.31	1.34e-11	Mean corpuscular volume;
LGG	cis	rs7737355	0.947	rs244736	chr5:130816178	T/C	cg06307176	chr5:131281290	NA	0.55	9.17	0.39	1.6e-18	Life satisfaction;
LGG	cis	rs11885103	0.626	rs1317822	chr2:550989	T/C	cg21195176	chr2:593345	NA	0.39	7.23	0.32	1.99e-12	Heschl's gyrus morphology;
LGG	cis	rs9557207	0.802	rs2195	chr13:99783668	C/T	cg24509225	chr13:100037070	UBAC2	0.61	10.52	0.44	2.45e-23	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs8017423	0.605	rs3742673	chr14:90735707	C/T	cg04374321	chr14:90722782	PSMC1	0.6	11.76	0.48	4e-28	Mortality in heart failure;
LGG	cis	rs72772090	0.710	rs17400685	chr5:96066366	A/C	cg17330273	chr5:96107758	CAST;ERAP1	0.51	7.96	0.35	1.33e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9362426	0.608	rs9450682	chr6:88147802	A/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.47	8.96	0.38	8.16e-18	Depressive episodes in bipolar disorder;
LGG	cis	rs11190604	1.000	rs11190555	chr10:102209160	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9657904	1.000	rs6437621	chr3:105552900	T/C	cg14088669	chr1:158435396	OR10K1	-0.4	-6.79	-0.3	3.4e-11	Multiple sclerosis;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs9517320	0.515	rs1107379	chr13:99198921	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.85	-0.45	1.35e-24	Longevity;
LGG	cis	rs4538187	0.529	rs13013890	chr2:63654109	G/A	cg19915305	chr2:64069682	UGP2	-0.58	-8.53	-0.37	2.06e-16	Systolic blood pressure;
LGG	cis	rs1535500	0.967	rs11756091	chr6:39282806	G/T	cg13075951	chr6:39282393	KCNK17	0.26	6.76	0.3	4.15e-11	Type 2 diabetes;
LGG	trans	rs2235573	0.551	rs139893	chr22:38393608	G/A	cg19894588	chr14:64061835	NA	0.6	9.92	0.42	3.56e-21	Glioblastoma;Glioma;
LGG	cis	rs559928	0.947	rs10792430	chr11:64147114	T/A	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.77	0.3	3.86e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12476592	0.602	rs2166497	chr2:63800159	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs2204008	0.684	rs11514164	chr12:38036494	C/T	cg13010199	chr12:38710504	ALG10B	0.66	13.51	0.53	2.72e-35	Bladder cancer;
LGG	cis	rs11690935	0.959	rs6433314	chr2:172660971	A/G	cg21435375	chr2:172878103	MAP1D	-0.32	-7.17	-0.32	3.04e-12	Schizophrenia;
LGG	trans	rs9914544	0.689	rs8073236	chr17:18787182	C/G	cg21372672	chr17:16614065	CCDC144A	-0.43	-9.4	-0.4	2.49e-19	Educational attainment (years of education);
LGG	cis	rs10504229	0.679	rs17804870	chr8:58158071	A/G	cg05313129	chr8:58192883	C8orf71	-0.78	-8.84	-0.38	2.06e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs758324	0.716	rs27348	chr5:131407139	A/T	cg06307176	chr5:131281290	NA	-0.45	-7.22	-0.32	2.08e-12	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs2270450	0.650	rs1421380	chr6:46706271	G/A	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.49	-0.44	3.09e-23	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg09699651	chr6:150184138	LRP11	0.48	8.52	0.37	2.31e-16	Lung cancer;
LGG	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg04362960	chr10:104952993	NT5C2	0.56	10.41	0.44	6.3e-23	Arsenic metabolism;
LGG	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.56e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg12708336	chr17:41446283	NA	-0.3	-7.06	-0.31	6.3e-12	Menopause (age at onset);
LGG	cis	rs12618769	0.652	rs72823801	chr2:99235055	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.68	0.34	9.48e-14	Bipolar disorder;
LGG	cis	rs1401999	0.628	rs6798870	chr3:183740350	G/A	cg20387954	chr3:183756860	HTR3D	0.57	10.75	0.45	3.17e-24	Anterior chamber depth;
LGG	cis	rs9906944	0.707	rs11655950	chr17:47129121	C/T	cg09029085	chr17:47094198	IGF2BP1	0.3	8.13	0.35	3.87e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs10504229	1.000	rs17216957	chr8:58179893	C/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1707322	1.000	rs6657720	chr1:46386269	G/A	cg03146154	chr1:46216737	IPP	0.54	10.21	0.43	3.34e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10484885	0.878	rs72921934	chr6:90579464	T/A	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.64	-0.44	8.27e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9611565	0.765	rs202663	chr22:41812819	T/C	cg03806693	chr22:41940476	POLR3H	0.95	16.66	0.61	3.76e-49	Vitiligo;
LGG	cis	rs2180341	0.597	rs3798859	chr6:127663116	C/T	cg27446573	chr6:127587934	RNF146	0.74	13.46	0.53	4.54e-35	Breast cancer;
LGG	cis	rs28595532	0.841	rs115924581	chr4:119786333	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.83	0.34	3.47e-14	Cannabis dependence symptom count;
LGG	trans	rs2235573	0.686	rs4821735	chr22:38458969	G/C	cg19894588	chr14:64061835	NA	0.43	6.87	0.3	2.12e-11	Glioblastoma;Glioma;
LGG	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg05091796	chr16:4465799	CORO7	0.61	9.5	0.4	1.11e-19	Schizophrenia;
LGG	cis	rs4356203	0.875	rs11024136	chr11:17064397	T/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.15	-0.32	3.32e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg05335186	chr13:53173507	NA	0.47	9.05	0.39	4.07e-18	Lewy body disease;
LGG	cis	rs7084783	0.532	rs2172459	chr10:105418505	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.39	7.34	0.32	9.43e-13	Fear of pain;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.48	-0.33	3.72e-13	Systolic blood pressure;
LGG	cis	rs62400317	0.859	rs10948223	chr6:45273921	A/C	cg20913747	chr6:44695427	NA	-0.61	-10.4	-0.44	6.85e-23	Total body bone mineral density;
LGG	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.74	-13.19	-0.52	6.24e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3820928	0.874	rs1114562	chr2:227788592	T/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.83	-0.34	3.47e-14	Pulmonary function;
LGG	cis	rs7666738	0.791	rs6532725	chr4:99061479	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2133450	0.526	rs17047062	chr3:7343383	A/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.46	-0.4	1.58e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs875971	0.564	rs313804	chr7:65514622	A/G	cg23594656	chr7:65796392	TPST1	-0.32	-6.84	-0.3	2.49e-11	Aortic root size;
LGG	trans	rs7746199	0.736	rs58616630	chr6:27474715	A/G	cg01620082	chr3:125678407	NA	-1.05	-9.87	-0.42	5.69e-21	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs67460515	0.892	rs11718905	chr3:161051793	G/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.62	-0.41	4.17e-20	Parkinson's disease;
LGG	cis	rs240764	0.717	rs6916468	chr6:101160325	G/C	cg09795085	chr6:101329169	ASCC3	-0.44	-7.54	-0.33	2.57e-13	Neuroticism;
LGG	cis	rs11157436	0.560	rs2242543	chr14:22694331	G/A	cg00994629	chr14:22694547	NA	0.35	7.8	0.34	4.05e-14	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg16850897	chr7:100343110	ZAN	-0.64	-9.4	-0.4	2.59e-19	Other erythrocyte phenotypes;
LGG	cis	rs7726839	0.574	rs72707007	chr5:661856	T/C	cg01221209	chr5:554886	NA	-0.46	-6.68	-0.3	6.93e-11	Obesity-related traits;
LGG	cis	rs189798	0.807	rs330905	chr8:8993551	A/T	cg06636001	chr8:8085503	FLJ10661	0.47	7.9	0.34	2.02e-14	Myopia (pathological);
LGG	cis	rs2413583	0.591	rs17305131	chr22:39718564	T/C	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.77	0.34	4.97e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4954585	0.659	rs13018756	chr2:137008235	C/T	cg07169764	chr2:136633963	MCM6	-0.46	-7.46	-0.33	4.32e-13	Colorectal cancer;
LGG	cis	rs7084402	0.935	rs4141671	chr10:60338753	T/C	cg09696939	chr10:60272079	BICC1	0.36	7.06	0.31	5.94e-12	Refractive error;
LGG	cis	rs4788570	0.667	rs9929840	chr16:71800942	C/T	cg06353428	chr16:71660113	MARVELD3	-1.27	-19.32	-0.67	1.97e-61	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg11812906	chr14:75593930	NEK9	-0.53	-9.48	-0.4	1.38e-19	Height;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg07959490	chr17:80112427	CCDC57	-0.46	-9.04	-0.39	4.16e-18	Life satisfaction;
LGG	cis	rs9303401	0.646	rs7217845	chr17:57236900	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.48	8.14	0.35	3.75e-15	Cognitive test performance;
LGG	cis	rs6904897	0.563	rs9321479	chr6:135233909	A/G	cg24558204	chr6:135376177	HBS1L	-0.49	-8.2	-0.36	2.36e-15	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs10256972	0.621	rs2363285	chr7:1091644	C/T	cg18402987	chr7:1209562	NA	0.38	7.01	0.31	8.71e-12	Longevity;Endometriosis;
LGG	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06873352	chr17:61820015	STRADA	-0.46	-7.18	-0.32	2.78e-12	Height;
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg27532560	chr4:187881888	NA	-0.59	-12.79	-0.51	2.85e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7312933	0.703	rs12370778	chr12:42599696	T/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.22	0.32	2.21e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6815814	0.861	rs11936050	chr4:38789524	C/T	cg06935464	chr4:38784597	TLR10	0.54	8.81	0.38	2.46e-17	Breast cancer;
LGG	cis	rs7264396	0.580	rs2425173	chr20:34445142	G/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	6.72	0.3	5.36e-11	Total cholesterol levels;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.15	-0.43	5.43e-22	Lung cancer;
LGG	cis	rs899997	0.954	rs4887091	chr15:79043580	T/C	cg14912033	chr15:79043428	NA	-0.42	-10.63	-0.44	9.21e-24	Coronary artery disease or large artery stroke;
LGG	cis	rs3096299	0.900	rs4785663	chr16:89434888	G/A	cg02187348	chr16:89574699	SPG7	0.48	7.74	0.34	6.36e-14	Multiple myeloma (IgH translocation);
LGG	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg07636037	chr3:49044803	WDR6	0.82	14.27	0.55	1.49e-38	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs4819052	0.851	rs4819039	chr21:46659458	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg21775007	chr8:11205619	TDH	-0.46	-7.33	-0.32	1.02e-12	Triglycerides;
LGG	cis	rs503734	0.846	rs1507435	chr3:100921878	C/G	cg27318481	chr3:100970896	IMPG2	0.43	9.59	0.41	5.46e-20	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1904096	0.506	rs6823404	chr4:95197520	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.2	-0.46	6e-26	Type 2 diabetes;
LGG	cis	rs1843834	0.898	rs11887386	chr2:225526975	T/G	cg22455342	chr2:225449267	CUL3	0.59	10.1	0.43	8e-22	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg08601574	chr20:25228251	PYGB	0.33	6.81	0.3	3.07e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1506636	0.927	rs11983604	chr7:123329754	T/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.41	-0.65	3.36e-57	Plateletcrit;Platelet count;
LGG	trans	rs826838	1.000	rs1843881	chr12:38733706	A/G	cg06521331	chr12:34319734	NA	0.45	7.61	0.33	1.51e-13	Heart rate;
LGG	cis	rs7618915	0.501	rs13085775	chr3:52678370	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.46	0.47	6.14e-27	Bipolar disorder;
LGG	cis	rs7192750	0.586	rs12935795	chr16:71987452	G/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.72	0.45	4.18e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs6539288	0.933	rs10778513	chr12:107302183	A/G	cg15890332	chr12:107067104	RFX4	0.26	6.64	0.3	8.6e-11	Total body bone mineral density;
LGG	cis	rs801193	0.548	rs2659891	chr7:66201114	A/G	cg18252515	chr7:66147081	NA	-0.44	-7.52	-0.33	2.84e-13	Aortic root size;
LGG	trans	rs7246760	0.867	rs8102257	chr19:9830795	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.79	-0.45	2.29e-24	Pursuit maintenance gain;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg10729496	chr3:10149963	C3orf24	0.46	7.15	0.32	3.32e-12	Alzheimer's disease;
LGG	cis	rs1577917	0.958	rs13201730	chr6:86556647	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.33	-0.43	1.22e-22	Response to antipsychotic treatment;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.95	-0.35	1.45e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg11878867	chr6:150167359	LRP11	-0.52	-10.68	-0.44	5.89e-24	Lung cancer;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg23188684	chr11:67383651	NA	0.53	9.22	0.39	1.02e-18	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21826008	chr12:54674368	HNRPA1L-2;HNRNPA1;CBX5	0.46	6.81	0.3	3.12e-11	Gut microbiome composition (summer);
LGG	cis	rs722599	0.599	rs8003660	chr14:75227098	T/C	cg06637938	chr14:75390232	RPS6KL1	0.5	8.07	0.35	5.95e-15	IgG glycosylation;
LGG	cis	rs2120243	0.967	rs7648322	chr3:157143684	A/G	cg24825693	chr3:157122686	VEPH1	-0.42	-8.73	-0.38	4.6e-17	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs7444	0.941	rs2070512	chr22:21949411	A/C	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs1862618	0.573	rs185220	chr5:56205357	A/G	cg12402800	chr5:56204917	C5orf35	-0.43	-6.74	-0.3	4.67e-11	Initial pursuit acceleration;
LGG	cis	rs6089584	0.606	rs2144674	chr20:60576579	G/A	cg06108461	chr20:60628389	TAF4	-0.67	-11.69	-0.48	7.61e-28	Body mass index;
LGG	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg09307838	chr4:120376055	NA	0.72	12.42	0.5	9.42e-31	Corneal astigmatism;
LGG	cis	rs933688	1.000	rs1363839	chr5:90671274	A/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.87	17.14	0.62	2.25e-51	Smoking behavior;
LGG	cis	rs4481887	1.000	rs4244174	chr1:248467956	A/G	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs11605275	1.000	rs11603592	chr11:20023522	C/T	cg14835545	chr11:20032148	NAV2	-0.96	-10.89	-0.45	9.83e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs137887	0.935	rs137885	chr22:50463231	T/C	cg23116504	chr22:50470537	TTLL8	-0.36	-6.66	-0.3	7.65e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.37	0.32	8.11e-13	Hip circumference adjusted for BMI;
LGG	cis	rs3857747	0.792	rs10259706	chr7:40419192	T/G	cg00420559	chr7:40367873	C7orf10	0.36	7.31	0.32	1.19e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs9309473	1.000	rs7585004	chr2:73666645	C/G	cg20560298	chr2:73613845	ALMS1	-0.41	-6.81	-0.3	3.03e-11	Metabolite levels;
LGG	cis	rs9303280	0.901	rs7359623	chr17:38049589	C/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.9	-0.38	1.31e-17	Self-reported allergy;
LGG	cis	rs1497828	0.956	rs2646829	chr1:217542801	T/C	cg04411442	chr1:217543379	NA	0.48	8.15	0.35	3.48e-15	Dialysis-related mortality;
LGG	cis	rs7208859	0.623	rs76633166	chr17:29113365	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7829975	0.742	rs882462	chr8:8678530	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.59	0.41	5.41e-20	Mood instability;
LGG	cis	rs490234	0.812	rs4838268	chr9:128280315	G/T	cg14078157	chr9:128172775	NA	-0.46	-8.59	-0.37	1.32e-16	Mean arterial pressure;
LGG	cis	rs7072216	0.690	rs113195335	chr10:100175532	A/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.12	-0.31	4.16e-12	Metabolite levels;
LGG	trans	rs6561151	0.681	rs2121037	chr13:44471317	C/T	cg12856521	chr11:46389249	DGKZ	0.9	14.75	0.57	1.27e-40	Crohn's disease;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25072359	chr17:41440525	NA	0.53	10.06	0.42	1.17e-21	Menopause (age at onset);
LGG	cis	rs7937682	0.889	rs516263	chr11:111484719	A/C	cg08305652	chr11:111469057	NA	-0.44	-9.04	-0.39	4.44e-18	Primary sclerosing cholangitis;
LGG	cis	rs12421382	0.659	rs1371331	chr11:109382578	G/A	cg04861929	chr11:109293070	C11orf87	0.55	10.06	0.42	1.15e-21	Schizophrenia;
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.7	-0.34	8.46e-14	Monocyte count;
LGG	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.47	0.37	3.4e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs4788815	0.513	rs7204967	chr16:71804287	A/G	cg06353428	chr16:71660113	MARVELD3	1.25	19.69	0.68	3.94e-63	Metabolite levels;
LGG	cis	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.09	-0.35	5.22e-15	Mood instability;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.23e-11	Hair morphology;
LGG	cis	rs6089584	0.889	rs6142923	chr20:60596617	C/T	cg06470251	chr20:60548479	NA	-0.53	-8.44	-0.37	4.07e-16	Body mass index;
LGG	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg25427524	chr10:38739819	LOC399744	0.51	7.55	0.33	2.37e-13	Obesity (extreme);
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg06654118	chr4:1303317	MAEA	-0.48	-8.55	-0.37	1.77e-16	Obesity-related traits;
LGG	cis	rs4689642	0.507	rs7690968	chr4:7222781	G/A	cg21353189	chr4:7228343	SORCS2	0.34	7.16	0.32	3.23e-12	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs1957429	0.520	rs17102258	chr14:65332369	G/A	cg23373153	chr14:65346875	NA	-1.03	-11.17	-0.46	7.86e-26	Pediatric areal bone mineral density (radius);
LGG	cis	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.18e-95	Breast cancer;
LGG	cis	rs2117029	0.767	rs11614738	chr12:49424616	G/A	cg24176009	chr12:49580217	TUBA1A	0.47	8.38	0.36	6.54e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.634	rs6059892	chr20:33105766	A/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs151997	1.000	rs42415	chr5:50207442	T/A	cg06027927	chr5:50259733	NA	0.66	10.7	0.45	5.22e-24	Callous-unemotional behaviour;
LGG	cis	rs752010	0.695	rs10789407	chr1:42106538	G/T	cg06885757	chr1:42089581	HIVEP3	0.56	12.86	0.51	1.46e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.1	0.31	4.84e-12	Lung cancer;
LGG	cis	rs7618501	0.966	rs2246832	chr3:49881134	A/T	cg24110177	chr3:50126178	RBM5	-0.42	-7.16	-0.32	3.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.544	rs6675811	chr1:178499068	T/A	cg19399532	chr1:178512495	C1orf220	0.55	11.54	0.47	2.88e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11630290	0.592	rs12324556	chr15:64160951	G/A	cg12036633	chr15:63758958	NA	0.5	7.28	0.32	1.42e-12	Iris characteristics;
LGG	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg12310025	chr6:25882481	NA	-0.45	-7.34	-0.32	9.98e-13	Iron status biomarkers;
LGG	cis	rs58649573	0.552	rs3780681	chr9:126784287	T/A	cg14112217	chr9:126806003	NA	0.37	7.35	0.32	8.92e-13	Post-traumatic stress disorder;
LGG	cis	rs975722	1.000	rs6978581	chr7:117356893	A/G	cg10524701	chr7:117356490	CTTNBP2	0.52	11.99	0.49	5.02e-29	Coronary artery disease;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	12.37	0.5	1.38e-30	Prudent dietary pattern;
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg16606324	chr3:10149918	C3orf24	-0.53	-7.01	-0.31	8.44e-12	Alzheimer's disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09238957	chr16:46723420	ORC6L;VPS35	0.42	6.95	0.31	1.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7173743	0.967	rs28580532	chr15:79134724	C/T	cg00540400	chr15:79124168	NA	-0.43	-8.63	-0.37	1.02e-16	Coronary artery disease;
LGG	cis	rs2050392	0.517	rs2489847	chr10:30743673	G/A	cg25182066	chr10:30743637	MAP3K8	-0.69	-14.81	-0.57	6.83e-41	Inflammatory bowel disease;
LGG	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.64	-0.33	1.27e-13	Colorectal cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg19125715	chr8:67525489	MYBL1	0.42	6.87	0.3	2.13e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.569	rs2045020	chr5:93224466	T/C	cg25358565	chr5:93447407	FAM172A	-0.86	-11.91	-0.48	1.06e-28	Diabetic retinopathy;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg16507663	chr6:150244633	RAET1G	0.44	8.36	0.36	7.52e-16	Lung cancer;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs4006360	0.504	rs7502045	chr17:39252972	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.18	-0.46	7.29e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4474465	0.920	rs7113559	chr11:78205703	T/G	cg27205649	chr11:78285834	NARS2	0.5	8.55	0.37	1.76e-16	Alzheimer's disease (survival time);
LGG	cis	rs7923609	0.540	rs7921909	chr10:65328446	G/A	cg02276361	chr10:65351566	REEP3	-0.32	-6.99	-0.31	9.88e-12	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.24	0.69	1.06e-65	Alzheimer's disease;
LGG	trans	rs3206736	0.548	rs328900	chr7:35020280	C/T	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.21	0.32	2.27e-12	Diastolic blood pressure;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg00684032	chr4:1343700	KIAA1530	0.41	7.54	0.33	2.47e-13	Obesity-related traits;
LGG	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.24	-0.32	1.92e-12	Schizophrenia;
LGG	cis	rs6918586	1.000	rs198806	chr6:26133616	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.49	-8.12	-0.35	4.41e-15	Schizophrenia;
LGG	cis	rs7208859	0.623	rs7223209	chr17:29107220	C/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2249694	0.919	rs10857768	chr10:135402703	A/G	cg20169779	chr10:135381914	SYCE1	-0.5	-7.88	-0.34	2.43e-14	Obesity-related traits;
LGG	cis	rs11955398	0.665	rs11948543	chr5:59918937	T/C	cg02684056	chr5:59996105	DEPDC1B	0.4	6.66	0.3	7.6e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.633	rs4688755	chr3:50064424	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.45	-8.11	-0.35	4.42e-15	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.812	rs1013504	chr10:952816	T/C	cg20503657	chr10:835505	NA	0.95	11.42	0.47	8.58e-27	Eosinophil percentage of granulocytes;
LGG	cis	rs62400317	0.859	rs6920046	chr6:45159431	A/C	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9522267	0.535	rs11069899	chr13:112231553	T/C	cg10483660	chr13:112241077	NA	-0.35	-7.5	-0.33	3.24e-13	Hepatitis;
LGG	cis	rs1008375	0.931	rs6449326	chr4:17699790	G/T	cg16339924	chr4:17578868	LAP3	0.49	8.34	0.36	8.39e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2964802	0.505	rs10513058	chr5:10804383	C/T	cg14521931	chr5:10832172	NA	-0.76	-17.11	-0.62	3.12e-51	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.6	-0.37	1.26e-16	Schizophrenia;
LGG	cis	rs2668423	0.922	rs3826942	chr19:1360575	A/G	cg02639931	chr19:1387894	NDUFS7	0.8	13.02	0.52	3.02e-33	Nonalcoholic fatty liver disease;
LGG	cis	rs826838	0.616	rs10880751	chr12:38627485	C/T	cg26384229	chr12:38710491	ALG10B	0.67	13.23	0.52	3.97e-34	Heart rate;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg11050988	chr7:1952600	MAD1L1	-0.42	-10.27	-0.43	2.01e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs910187	0.605	rs6066223	chr20:45803998	A/G	cg27589058	chr20:45804311	EYA2	0.37	10.07	0.42	1.05e-21	Migraine;
LGG	cis	rs4820294	0.516	rs12484441	chr22:38097359	C/G	cg21798802	chr22:38057573	PDXP	0.46	8.68	0.37	6.99e-17	Fat distribution (HIV);
LGG	cis	rs6461049	0.800	rs3800913	chr7:2163237	A/G	cg11050988	chr7:1952600	MAD1L1	-0.35	-8.37	-0.36	6.95e-16	Schizophrenia;
LGG	cis	rs12478296	1.000	rs7603984	chr2:243047294	A/G	cg06360820	chr2:242988706	NA	-0.96	-11.88	-0.48	1.34e-28	Obesity-related traits;
LGG	cis	rs651907	1.000	rs662792	chr3:101599608	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.42	7.26	0.32	1.68e-12	Colorectal cancer;
LGG	cis	rs514406	0.755	rs11206015	chr1:53242187	T/C	cg24675658	chr1:53192096	ZYG11B	0.49	10.08	0.42	9.46e-22	Monocyte count;
LGG	cis	rs4959677	0.698	rs2325963	chr6:2479402	T/C	cg23817096	chr6:1620687	NA	-0.34	-8.32	-0.36	9.770000000000001e-16	Orthostatic hypotension;
LGG	cis	rs6747952	0.866	rs4663854	chr2:239083167	C/T	cg17459225	chr2:239074497	NA	-0.42	-7.75	-0.34	5.73e-14	Mean corpuscular hemoglobin concentration;
LGG	trans	rs7939886	0.920	rs11227212	chr11:55873334	A/G	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.38e-15	Myopia (pathological);
LGG	cis	rs6500602	0.727	rs4786516	chr16:4578641	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs4474465	0.920	rs7396701	chr11:78202699	A/C	cg27205649	chr11:78285834	NARS2	0.48	8.32	0.36	9.83e-16	Alzheimer's disease (survival time);
LGG	cis	rs4926611	0.698	rs35227000	chr1:54060016	G/C	cg23596471	chr1:54105337	GLIS1	-0.42	-8.63	-0.37	1.02e-16	Hand grip strength;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg00684032	chr4:1343700	KIAA1530	0.5	9.85	0.42	6.4e-21	Obesity-related traits;
LGG	cis	rs71335811	1	rs71335811	chr19:49130070	TC/T	cg06530960	chr19:49140787	SEC1;DBP	-0.53	-9.11	-0.39	2.51e-18	Myeloid white cell count;
LGG	cis	rs11711311	1.000	rs13061150	chr3:113506734	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.36	0.53	1.12e-34	IgG glycosylation;
LGG	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.82	12.64	0.51	1.14e-31	Cognitive test performance;
LGG	cis	rs10267417	0.535	rs117655512	chr7:19944403	T/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.78	0.3	3.77e-11	Night sleep phenotypes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg12560154	chr19:11925149	ZNF440	0.38	6.76	0.3	4.1e-11	Body mass index;
LGG	cis	rs10865541	0.967	rs6751808	chr2:3397377	A/G	cg13173536	chr2:3403300	TTC15	-0.37	-7.82	-0.34	3.56e-14	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs12594234	chr15:67596154	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.53	-0.33	2.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs854765	0.647	rs2974998	chr17:17995619	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	14.09	0.55	8.86e-38	Total body bone mineral density;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.08	-0.42	9.9700000000000009e-22	Lung cancer;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg05863683	chr7:1912471	MAD1L1	0.41	7.95	0.35	1.44e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs2304069	0.545	rs6866616	chr5:149415401	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.48	8.1	0.35	4.82e-15	HIV-1 control;
LGG	cis	rs4268898	0.636	rs72787385	chr2:24585820	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-12.36	-0.5	1.57e-30	Asthma;
LGG	cis	rs2933343	0.679	rs789254	chr3:128574593	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.64	0.3	8.56e-11	IgG glycosylation;
LGG	cis	rs1451375	0.959	rs1451373	chr7:50622606	A/G	cg00647317	chr7:50633725	DDC	-0.34	-7.64	-0.33	1.27e-13	Malaria;
LGG	trans	rs6787172	0.702	rs827094	chr3:157984410	A/C	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	cis	rs367943	0.871	rs348940	chr5:112824530	C/A	cg12552261	chr5:112820674	MCC	-0.65	-11.97	-0.49	6.17e-29	Type 2 diabetes;
LGG	cis	rs10540	0.730	rs12789735	chr11:518509	G/A	cg19913688	chr11:428466	ANO9	-0.67	-8.25	-0.36	1.63e-15	Body mass index;
LGG	cis	rs975739	0.657	rs1330911	chr13:78587551	G/A	cg07847733	chr13:78271382	SLAIN1	0.45	7.86	0.34	2.69e-14	Hair color;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg16405210	chr4:1374714	KIAA1530	0.42	7.03	0.31	7.69e-12	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16570995	chr6:37138163	PIM1	0.44	6.72	0.3	5.3e-11	Gut microbiome composition (summer);
LGG	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15664640	chr17:80829946	TBCD	-0.79	-15.58	-0.59	2.59e-44	Breast cancer;
LGG	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg00579200	chr11:133705235	NA	0.44	8.05	0.35	7.06e-15	Childhood ear infection;
LGG	trans	rs208520	0.754	rs851594	chr6:66876695	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.18	-0.62	1.54e-51	Exhaled nitric oxide output;
LGG	cis	rs9951602	0.512	rs12458828	chr18:76648522	C/T	cg24134504	chr18:76639479	NA	0.47	8.32	0.36	1.01e-15	Obesity-related traits;
LGG	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg13009111	chr11:71350975	NA	0.33	7.16	0.32	3.12e-12	Monocyte count;
LGG	cis	rs2180341	0.924	rs6930849	chr6:127630963	A/T	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg06606381	chr12:133084897	FBRSL1	-0.89	-9.53	-0.4	8.55e-20	Depression;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs12824058	0.831	rs7310433	chr12:130809289	C/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18256790	chr17:8532950	MYH10	0.42	6.85	0.3	2.38e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7227917	0.536	rs72916029	chr18:45513460	T/A	cg22195133	chr18:45534586	NA	0.77	7.02	0.31	8.02e-12	Lung cancer in ever smokers;
LGG	cis	rs7011049	1.000	rs11995106	chr8:53834768	C/T	cg26025543	chr8:53854495	NA	0.73	9.7	0.41	2.25e-20	Systolic blood pressure;
LGG	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg00343986	chr7:65444356	GUSB	-0.47	-7.94	-0.35	1.57e-14	Calcium levels;
LGG	cis	rs7937682	0.961	rs4935790	chr11:111633014	T/C	cg09085632	chr11:111637200	PPP2R1B	1.19	28.63	0.8	1.69e-104	Primary sclerosing cholangitis;
LGG	cis	rs7582180	0.629	rs4850927	chr2:100969067	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.54e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9443645	0.835	rs1044309	chr6:79646575	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.72	-0.38	5.15e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2857078	0.654	rs9896789	chr17:42314567	C/T	cg08499158	chr17:42289980	UBTF	-0.44	-7.86	-0.34	2.79e-14	Red cell distribution width;Reticulocyte count;
LGG	cis	rs6496667	0.510	rs16944405	chr15:90975517	A/G	cg22089800	chr15:90895588	ZNF774	0.52	8.67	0.37	7.39e-17	Rheumatoid arthritis;
LGG	cis	rs4363385	0.693	rs4845497	chr1:152904162	T/C	cg13444842	chr1:152974279	SPRR3	-0.39	-7.23	-0.32	2.04e-12	Inflammatory skin disease;
LGG	cis	rs1065656	0.571	rs2745170	chr16:1835231	G/T	cg26617929	chr16:1858877	NA	0.38	6.79	0.3	3.43e-11	Insulin-like growth factors;
LGG	cis	rs6952808	0.825	rs12669937	chr7:1939765	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.67	-0.37	7.18e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs11603023	0.625	rs633683	chr11:118504742	A/G	cg19182353	chr11:118479428	PHLDB1	0.5	9.78	0.41	1.21e-20	Cholesterol, total;
LGG	cis	rs17711722	0.675	rs6947132	chr7:65273495	G/A	cg11764359	chr7:65958608	NA	-0.56	-9.39	-0.4	2.73e-19	Calcium levels;
LGG	cis	rs12477438	0.520	rs11695379	chr2:99742161	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	32.99	0.84	1.22e-123	Chronic sinus infection;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12580194	0.593	rs12581959	chr12:55787311	G/A	cg19537932	chr12:55886519	OR6C68	-0.56	-10.02	-0.42	1.56e-21	Cancer;
LGG	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2156903	chr17:61937179	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.38e-17	Prudent dietary pattern;
LGG	cis	rs1909881	0.605	rs1604255	chr8:96474689	A/C	cg04203453	chr8:96504381	NA	-0.6	-11.15	-0.46	9.59e-26	Obesity-related traits;
LGG	cis	rs1552244	0.882	rs13064570	chr3:9997545	G/C	cg00166722	chr3:10149974	C3orf24	0.51	8.53	0.37	2.04e-16	Alzheimer's disease;
LGG	cis	rs9611565	0.838	rs4239894	chr22:41745548	C/G	cg03806693	chr22:41940476	POLR3H	-0.95	-16.32	-0.6	1.23e-47	Vitiligo;
LGG	cis	rs6141769	0.542	rs7360824	chr20:31315158	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.73	-0.3	5.09e-11	Subjective well-being;
LGG	cis	rs3020736	0.500	rs4147638	chr22:42487900	G/A	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.79e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.870	rs13124876	chr4:1247955	T/C	cg02018176	chr4:1364513	KIAA1530	0.38	8.45	0.37	3.71e-16	Obesity-related traits;
LGG	trans	rs11252926	0.563	rs10795103	chr10:451849	C/A	cg00953403	chr17:74099816	EXOC7	0.42	7.02	0.31	8.18e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs9849248	0.627	rs73146085	chr3:88116515	T/C	cg14530983	chr3:88190749	ZNF654	0.56	7.81	0.34	3.74e-14	Menarche (age at onset);
LGG	cis	rs17270561	0.583	rs12662869	chr6:25784481	A/C	cg12310025	chr6:25882481	NA	0.44	7.41	0.33	5.86e-13	Iron status biomarkers;
LGG	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.38	0.36	6.3e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9322193	0.962	rs35031906	chr6:149998574	T/C	cg05861140	chr6:150128134	PCMT1	-0.45	-10.29	-0.43	1.63e-22	Lung cancer;
LGG	cis	rs7223966	0.729	rs9902761	chr17:62010627	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	8.14	0.35	3.82e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17376456	0.877	rs10055741	chr5:93297187	C/T	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs4862307	0.733	rs28631204	chr4:184996363	T/G	cg06737308	chr4:185021514	ENPP6	0.42	7.35	0.32	9.02e-13	Serum dimethylarginine levels (asymmetric/symetric ratio);
LGG	cis	rs2251381	0.515	rs2832299	chr21:30749237	G/C	cg24692254	chr21:30365293	RNF160	0.58	10.5	0.44	2.82e-23	Selective IgA deficiency;
LGG	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.12	12.32	0.5	2.33e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.688	rs113940455	chr3:10014165	A/C	cg00149659	chr3:10157352	C3orf10	0.75	9.2	0.39	1.21e-18	Alzheimer's disease;
LGG	cis	rs6728642	0.572	rs7574488	chr2:97599618	T/C	cg26665480	chr2:98280029	ACTR1B	-0.86	-11.41	-0.47	9.87e-27	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	trans	rs6952808	0.743	rs4719308	chr7:1877502	T/G	cg24247370	chr13:99142703	STK24	-0.4	-7.07	-0.31	5.78e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9513627	1.000	rs4584676	chr13:100160560	A/G	cg25919922	chr13:100150906	NA	0.75	8.01	0.35	9.05e-15	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg13939156	chr17:80058883	NA	-0.46	-9.03	-0.39	4.8e-18	Life satisfaction;
LGG	cis	rs9902453	0.765	rs2729440	chr17:28106874	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.24	-0.55	1.97e-38	Coffee consumption (cups per day);
LGG	cis	rs2228479	0.572	rs62054252	chr16:89896834	G/A	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.63	-0.61	4.77e-49	Skin colour saturation;
LGG	cis	rs12681288	0.862	rs7015529	chr8:1020249	A/G	cg15309053	chr8:964076	NA	0.35	7.08	0.31	5.48e-12	Schizophrenia;
LGG	cis	rs6089584	0.507	rs28545731	chr20:60634102	C/T	cg13770153	chr20:60521292	NA	-0.46	-7.5	-0.33	3.35e-13	Body mass index;
LGG	cis	rs6582630	0.555	rs1829583	chr12:38423161	T/C	cg26384229	chr12:38710491	ALG10B	-0.86	-19.82	-0.68	9.78e-64	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1568889	0.838	rs7131053	chr11:28143312	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.23	0.67	5.47e-61	Bipolar disorder;
LGG	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg11764359	chr7:65958608	NA	-0.71	-12.74	-0.51	4.3e-32	Aortic root size;
LGG	cis	rs4776059	1.000	rs12902679	chr15:52881317	C/T	cg22715398	chr15:52968154	KIAA1370	0.53	8.02	0.35	8.76e-15	Schizophrenia;
LGG	cis	rs4629710	0.592	rs9492864	chr6:131531306	A/T	cg12606694	chr6:131520996	AKAP7	0.53	8.67	0.37	7.19e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs4253772	0.550	rs6008601	chr22:46705326	C/G	cg00784671	chr22:46762841	CELSR1	-0.58	-7.42	-0.33	5.7e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6976053	0.818	rs2571598	chr7:100489639	C/T	cg03098644	chr7:100410630	EPHB4	0.43	7.7	0.34	8.38e-14	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs514406	0.644	rs7530078	chr1:53204861	G/T	cg24675658	chr1:53192096	ZYG11B	0.6	13.08	0.52	1.78e-33	Monocyte count;
LGG	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg26039829	chr8:22132926	PIWIL2	0.54	12.41	0.5	9.66e-31	Hypertriglyceridemia;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg02127607	chr17:61920694	SMARCD2	0.49	8.83	0.38	2.25e-17	Prudent dietary pattern;
LGG	cis	rs9341808	0.718	rs10080237	chr6:80854470	T/C	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.84e-14	Sitting height ratio;
LGG	cis	rs4423214	0.879	rs1790324	chr11:71150520	A/C	cg10847948	chr11:71163743	NADSYN1	0.63	11.45	0.47	7.01e-27	Vitamin D levels;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.82	-0.48	2.38e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1620921	0.625	rs9456599	chr6:161272401	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11096990	0.855	rs2566170	chr4:39152377	T/A	cg24403649	chr4:39172243	NA	-0.48	-7.72	-0.34	7.27e-14	Cognitive function;
LGG	cis	rs9788682	1.000	rs7163730	chr15:78814681	A/G	cg24631222	chr15:78858424	CHRNA5	0.45	6.97	0.31	1.07e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4639966	0.836	rs7943039	chr11:118603030	G/A	cg20110707	chr11:118481992	PHLDB1	-0.43	-6.71	-0.3	5.64e-11	Systemic lupus erythematosus;
LGG	cis	rs807669	0.903	rs1780637	chr22:19178250	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	16.02	0.6	2.73e-46	Metabolite levels;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg05091796	chr16:4465799	CORO7	-0.84	-13.89	-0.54	6.73e-37	Schizophrenia;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.26	0.46	3.69e-26	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg02462569	chr6:150064036	NUP43	-0.35	-7.37	-0.32	7.97e-13	Lung cancer;
LGG	cis	rs6964587	0.773	rs13236026	chr7:91885873	A/G	cg17063962	chr7:91808500	NA	0.47	8.21	0.36	2.22e-15	Breast cancer;
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg06850241	chr22:41845214	NA	0.45	7.22	0.32	2.21e-12	Vitiligo;
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.8e-16	Tonsillectomy;
LGG	cis	rs1497406	0.744	rs4233540	chr1:16507384	A/G	cg20430773	chr1:16534157	ARHGEF19	-0.32	-8.24	-0.36	1.77e-15	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9790314	0.936	rs336572	chr3:161068014	G/A	cg03342759	chr3:160939853	NMD3	-0.68	-12.55	-0.5	2.64e-31	Morning vs. evening chronotype;
LGG	cis	rs873946	0.586	rs12770021	chr10:134562021	G/A	cg06453172	chr10:134556979	INPP5A	-0.56	-8.48	-0.37	3.1e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs28595532	0.920	rs116739193	chr4:119771024	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs35160687	0.901	rs7571424	chr2:86539160	A/G	cg10973622	chr2:86423274	IMMT	0.4	6.85	0.3	2.35e-11	Night sleep phenotypes;
LGG	cis	rs6544311	0.507	rs11684633	chr2:40376525	A/T	cg17740179	chr2:40377776	SLC8A1	0.38	6.68	0.3	7.08e-11	QT interval;
LGG	trans	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg03517284	chr6:25882590	NA	-0.43	-7.07	-0.31	5.71e-12	Iron status biomarkers;
LGG	cis	rs941408	1.000	rs2260416	chr19:2796355	G/A	cg06609049	chr19:2785107	THOP1	0.61	9.63	0.41	4.09e-20	Total cholesterol levels;
LGG	cis	rs4742903	0.839	rs10761016	chr9:107007721	A/T	cg14250997	chr9:106856677	SMC2	0.37	7.47	0.33	4.05e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9287719	0.967	rs6432117	chr2:10749359	G/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs2115630	0.645	rs1107179	chr15:85198362	A/C	cg11189052	chr15:85197271	WDR73	0.56	9.18	0.39	1.42e-18	P wave terminal force;
LGG	cis	rs10504229	0.906	rs67389108	chr8:58193718	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.03	-0.6	2.58e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7301826	0.627	rs73162873	chr12:131296013	A/G	cg11011512	chr12:131303247	STX2	0.41	8.94	0.38	9.6e-18	Plasma plasminogen activator levels;
LGG	cis	rs1552244	0.688	rs9875667	chr3:10180041	T/C	cg08888203	chr3:10149979	C3orf24	0.44	7.96	0.35	1.36e-14	Alzheimer's disease;
LGG	cis	rs2228479	0.850	rs62056061	chr16:89901767	G/A	cg04287289	chr16:89883240	FANCA	0.84	8.04	0.35	7.52e-15	Skin colour saturation;
LGG	cis	rs12360000	0.897	rs7921481	chr10:1898756	A/C	cg26364871	chr10:1889757	NA	0.74	14.33	0.55	7.89e-39	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg00431236	chr2:264988	ACP1;SH3YL1	-0.43	-7.09	-0.31	5.07e-12	Breast cancer;
LGG	cis	rs2018055	1.000	rs13195478	chr6:117814437	G/A	cg14611402	chr6:117803162	DCBLD1	0.3	8.18	0.36	2.69e-15	Diastolic blood pressure;
LGG	cis	rs3733585	0.699	rs6449158	chr4:9960459	T/C	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.59	-0.33	1.83e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.02	-0.46	3.04e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg02002194	chr4:3960332	NA	0.41	7.08	0.31	5.33e-12	Neuroticism;
LGG	cis	rs8031584	0.678	rs3122	chr15:31170290	A/T	cg14829155	chr15:31115871	NA	0.66	11.07	0.46	1.94e-25	Huntington's disease progression;
LGG	cis	rs634534	0.561	rs14157	chr11:65769780	T/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.75	0.34	5.98e-14	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27419330	chr2:32264583	DPY30	0.46	7.54	0.33	2.47e-13	Cognitive performance;
LGG	cis	rs947474	1.000	rs947474	chr10:6390450	A/G	cg19837174	chr10:6389707	NA	-0.6	-8.56	-0.37	1.67e-16	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs1451375	0.617	rs2329366	chr7:50544966	G/A	cg14593290	chr7:50529359	DDC	-0.65	-11.48	-0.47	5.24e-27	Malaria;
LGG	cis	rs7756236	0.521	rs6930671	chr6:36625272	T/C	cg08179530	chr6:36648295	CDKN1A	0.41	6.69	0.3	6.56e-11	QRS duration;
LGG	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg12800244	chr3:153838788	SGEF	0.79	8.35	0.36	8.27e-16	Coronary artery disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09155575	chr17:38084037	ORMDL3	0.4	6.89	0.3	1.85e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg15971980	chr6:150254442	NA	0.44	8.16	0.35	3.09e-15	Lung cancer;
LGG	cis	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg21775007	chr8:11205619	TDH	0.78	13.69	0.54	4.63e-36	Retinal vascular caliber;
LGG	cis	rs950169	0.881	rs62029596	chr15:84955434	A/G	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.62e-23	Schizophrenia;
LGG	cis	rs2249694	0.520	rs10776685	chr10:135327317	T/C	cg20169779	chr10:135381914	SYCE1	-0.55	-7.46	-0.33	4.23e-13	Obesity-related traits;
LGG	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg25174290	chr11:3078921	CARS	-0.51	-9.93	-0.42	3.44e-21	Calcium levels;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.17	-0.46	8.45e-26	Personality dimensions;
LGG	cis	rs7552404	0.727	rs1146653	chr1:76280438	A/G	cg22875332	chr1:76189707	ACADM	0.54	8.43	0.36	4.41e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9393777	0.528	rs35982103	chr6:27243134	C/T	cg12292205	chr6:26970375	C6orf41	-0.64	-9.66	-0.41	3.11e-20	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.648	rs7702	chr16:4560929	G/C	cg01673284	chr16:4527211	HMOX2	0.37	7.32	0.32	1.14e-12	Schizophrenia;
LGG	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg10513866	chr5:139070639	NA	0.4	7.41	0.33	6.11e-13	Schizophrenia;
LGG	cis	rs9309473	1.000	rs10184268	chr2:73627044	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.6	-0.33	1.71e-13	Metabolite levels;
LGG	cis	rs13191362	0.872	rs13215538	chr6:163037975	T/C	cg21926612	chr6:163149169	PACRG;PARK2	1.04	11.75	0.48	4.53e-28	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11711311	0.911	rs13321446	chr3:113522544	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.68	-0.34	9.42e-14	IgG glycosylation;
LGG	cis	rs11753937	0.774	rs519332	chr6:133571272	A/G	cg06181518	chr6:133562196	EYA4	0.43	7.36	0.32	8.68e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs2361718	0.500	rs8064429	chr17:78096187	A/C	cg21238619	chr17:78079768	GAA	-0.47	-9.36	-0.4	3.37e-19	Yeast infection;
LGG	cis	rs9640161	0.789	rs10282458	chr7:150045302	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-14.94	-0.57	1.72e-41	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg17202724	chr17:61916730	SMARCD2	-0.61	-14.71	-0.56	1.88e-40	Prudent dietary pattern;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg12379764	chr21:47803548	PCNT	-0.43	-7.37	-0.32	7.87e-13	Testicular germ cell tumor;
LGG	cis	rs1008375	0.966	rs4698638	chr4:17632988	G/C	cg02297831	chr4:17616191	MED28	0.5	9.32	0.4	4.77e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9326248	0.520	rs10892060	chr11:116881662	C/A	cg20608306	chr11:116969690	SIK3	0.41	12.58	0.5	2.05e-31	Blood protein levels;
LGG	cis	rs236352	0.504	rs6934844	chr6:36853309	C/T	cg03410223	chr6:36853544	C6orf89	0.43	7.86	0.34	2.7e-14	Heart rate;
LGG	cis	rs8133932	0.621	rs1124309	chr21:47328767	C/A	cg11214348	chr21:47283868	PCBP3	0.45	8.03	0.35	8.11e-15	Schizophrenia;
LGG	cis	rs7647973	0.577	rs6446247	chr3:49102001	A/T	cg06212747	chr3:49208901	KLHDC8B	0.47	6.99	0.31	9.69e-12	Menarche (age at onset);
LGG	cis	rs2204008	0.653	rs11182569	chr12:38572452	G/A	cg26384229	chr12:38710491	ALG10B	0.99	23.41	0.74	1.57e-80	Bladder cancer;
LGG	cis	rs6076065	0.707	rs2024746	chr20:23356862	G/A	cg11657817	chr20:23433608	CST11	0.4	8.15	0.35	3.53e-15	Facial morphology (factor 15, philtrum width);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02619135	chr3:51428440	RBM15B	0.44	6.83	0.3	2.69e-11	Gut microbiome composition (summer);
LGG	cis	rs735539	0.563	rs9579950	chr13:21347384	G/A	cg04906043	chr13:21280425	IL17D	-0.5	-7.85	-0.34	2.97e-14	Dental caries;
LGG	cis	rs1355223	0.573	rs947501	chr11:34753375	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.46	-7.24	-0.32	1.92e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.16	-0.32	3.25e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg19147804	chr7:1989927	MAD1L1	-0.44	-8.6	-0.37	1.29e-16	Schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg24942186	chr3:55521373	WNT5A	0.41	6.72	0.3	5.43e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg18357526	chr6:26021779	HIST1H4A	0.56	9.1	0.39	2.65e-18	Blood metabolite levels;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg16103275	chr6:290800	DUSP22	0.49	8.08	0.35	5.61e-15	Menopause (age at onset);
LGG	cis	rs6793245	0.845	rs4073797	chr3:38590850	A/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.53	-8.85	-0.38	1.92e-17	QT interval;
LGG	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg23324259	chr8:82754387	SNX16	-0.47	-7.57	-0.33	2.04e-13	Diastolic blood pressure;
LGG	cis	rs7786877	0.723	rs7812123	chr7:100211556	C/A	cg03098644	chr7:100410630	EPHB4	0.47	6.69	0.3	6.45e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1008375	0.931	rs10939734	chr4:17570709	C/T	cg10189774	chr4:17578691	LAP3	0.43	7.63	0.33	1.35e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg00129232	chr17:37814104	STARD3	-0.76	-16.29	-0.6	1.79e-47	Asthma;
LGG	trans	rs9929218	0.954	rs60302411	chr16:68824220	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg00424166	chr6:150045504	NUP43	-0.36	-7.48	-0.33	3.66e-13	Lung cancer;
LGG	cis	rs9611565	0.649	rs202655	chr22:41841564	G/C	cg06481639	chr22:41940642	POLR3H	0.56	8.34	0.36	8.55e-16	Vitiligo;
LGG	cis	rs55788414	0.932	rs35066366	chr16:81185280	G/A	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.11	-0.43	7.64e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7659604	0.540	rs4361412	chr4:122669403	C/T	cg19748678	chr4:122722346	EXOSC9	-0.43	-7.6	-0.33	1.7e-13	Type 2 diabetes;
LGG	cis	rs4148883	0.675	rs34511427	chr4:100105405	G/T	cg13256891	chr4:100009986	ADH5	0.38	6.79	0.3	3.35e-11	Alcohol dependence;
LGG	cis	rs41271473	1.000	rs6701241	chr1:228868477	C/G	cg16512390	chr1:228756714	NA	0.49	6.95	0.31	1.27e-11	Chronic lymphocytic leukemia;
LGG	cis	rs11122272	0.735	rs2486733	chr1:231531465	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg14456004	chr13:21872349	NA	-1.17	-18.37	-0.65	5.09e-57	White matter hyperintensity burden;
LGG	cis	rs6840360	0.615	rs58977077	chr4:152470239	T/G	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg02475777	chr4:1388615	CRIPAK	0.59	10.58	0.44	1.43e-23	Longevity;
LGG	cis	rs5758511	0.680	rs739146	chr22:42660414	A/G	cg15128208	chr22:42549153	NA	0.74	11.47	0.47	5.7e-27	Birth weight;
LGG	cis	rs875971	0.862	rs1643375	chr7:65872677	T/C	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs17221829	0.681	rs75322840	chr11:89390394	T/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.38	-0.4	3.07e-19	Anxiety in major depressive disorder;
LGG	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg24848339	chr3:12840334	CAND2	0.43	9.91	0.42	3.85e-21	QRS complex (12-leadsum);
LGG	cis	rs7681440	0.874	rs10028246	chr4:90766704	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.516	rs1866994	chr8:57990092	A/C	cg14926445	chr8:58193284	C8orf71	-0.44	-6.88	-0.3	1.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.727	rs632984	chr11:68620271	C/T	cg06028808	chr11:68637592	NA	0.73	11.86	0.48	1.62e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1729951	0.575	rs835641	chr3:136703474	G/T	cg21827317	chr3:136751795	NA	0.52	9.71	0.41	2.01e-20	Neuroticism;
LGG	cis	rs6456156	0.586	rs720325	chr6:167467349	G/T	cg07741184	chr6:167504864	NA	0.39	9.06	0.39	3.82e-18	Primary biliary cholangitis;
LGG	cis	rs61931739	0.534	rs2220547	chr12:34106255	G/A	cg06521331	chr12:34319734	NA	-0.61	-10.99	-0.45	4.12e-25	Morning vs. evening chronotype;
LGG	cis	rs9359856	0.564	rs36040566	chr6:90372574	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.82	-0.42	8.61e-21	Bipolar disorder;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg02475777	chr4:1388615	CRIPAK	-0.46	-8.48	-0.37	3e-16	Obesity-related traits;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg16405210	chr4:1374714	KIAA1530	0.86	16.26	0.6	2.43e-47	Longevity;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg17951613	chr5:131705445	SLC22A5	0.66	7.42	0.33	5.74e-13	Rheumatoid arthritis;
LGG	cis	rs7223966	1.000	rs16947014	chr17:61719032	C/T	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.84	-0.38	2.04e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg21848117	chr17:79233487	SLC38A10	0.39	6.79	0.3	3.53e-11	Menarche (age at onset);
LGG	cis	rs7172689	0.908	rs11637313	chr15:81567752	C/A	cg11808699	chr15:81528661	IL16	-0.48	-9.76	-0.41	1.33e-20	Inattentive symptoms;
LGG	cis	rs28386778	0.897	rs57108948	chr17:61802378	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.69e-123	Prudent dietary pattern;
LGG	cis	rs3796352	1.000	rs7622420	chr3:53111069	A/G	cg12962167	chr3:53033115	SFMBT1	0.65	7.21	0.32	2.33e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg05925327	chr15:68127851	NA	-0.37	-7.57	-0.33	2.08e-13	Restless legs syndrome;
LGG	trans	rs3942852	0.696	rs4597030	chr11:48176573	G/A	cg03929089	chr4:120376271	NA	-0.68	-9.96	-0.42	2.71e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9309473	1.000	rs7572722	chr2:73724675	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.82	-0.34	3.49e-14	Metabolite levels;
LGG	cis	rs7829975	0.684	rs546603	chr8:8595838	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.03	-0.39	4.79e-18	Mood instability;
LGG	trans	rs2048656	0.600	rs1976671	chr8:9679634	A/G	cg06636001	chr8:8085503	FLJ10661	0.45	8.12	0.35	4.33e-15	Schizophrenia;
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.25	0.32	1.75e-12	Prudent dietary pattern;
LGG	cis	rs11608355	1.000	rs7132057	chr12:109880279	A/C	cg19025524	chr12:109796872	NA	-0.49	-9.16	-0.39	1.68e-18	Neuroticism;
LGG	cis	rs2011503	1.000	rs78176666	chr19:19636702	T/C	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg05623727	chr3:50126028	RBM5	-0.44	-9.49	-0.4	1.2e-19	Body mass index;
LGG	cis	rs9596863	0.847	rs9316667	chr13:54399759	C/T	ch.13.53330881F	chr13:54432880	NA	0.5	6.71	0.3	5.56e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.19	-0.32	2.54e-12	Lung cancer;
LGG	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg11812906	chr14:75593930	NEK9	-0.53	-9.86	-0.42	6.08e-21	Height;
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg14092988	chr3:52407081	DNAH1	0.31	8.2	0.36	2.45e-15	Bipolar disorder;
LGG	cis	rs2836974	0.583	rs9981884	chr21:40585633	G/A	cg17971929	chr21:40555470	PSMG1	0.64	11.11	0.46	1.37e-25	Cognitive function;
LGG	cis	rs4538187	0.804	rs36123537	chr2:64217490	G/A	cg19915305	chr2:64069682	UGP2	-0.66	-14.9	-0.57	2.8e-41	Systolic blood pressure;
LGG	cis	rs60871478	1.000	rs9195	chr7:825786	C/T	cg05535760	chr7:792225	HEATR2	-0.79	-12.63	-0.51	1.2e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs2117029	0.555	rs9788140	chr12:49520521	G/C	cg24176009	chr12:49580217	TUBA1A	0.62	11.94	0.49	8.02e-29	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg13647721	chr17:30228624	UTP6	0.61	7.91	0.35	1.85e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg07061783	chr6:25882402	NA	0.44	7.63	0.33	1.37e-13	Blood metabolite levels;
LGG	cis	rs981844	0.740	rs10009844	chr4:154681576	C/T	cg14289246	chr4:154710475	SFRP2	-0.58	-10.2	-0.43	3.7e-22	Response to statins (LDL cholesterol change);
LGG	cis	rs6456042	0.893	rs9348088	chr6:166572668	C/A	cg11088901	chr6:166572345	T	-0.36	-7.57	-0.33	2.09e-13	Asthma;
LGG	cis	rs2777491	0.522	rs7169278	chr15:41696932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.84	-0.38	2.09e-17	Ulcerative colitis;
LGG	cis	rs2404602	0.647	rs118129828	chr15:77015200	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.6	-0.56	5.8e-40	Blood metabolite levels;
LGG	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg06481639	chr22:41940642	POLR3H	-0.54	-8.05	-0.35	6.94e-15	Vitiligo;
LGG	cis	rs11583043	1.000	rs6660290	chr1:101483512	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.44	-7.8	-0.34	4.03e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg02002194	chr4:3960332	NA	0.42	7.98	0.35	1.13e-14	Mood instability;
LGG	cis	rs370915	0.963	rs59452206	chr4:187816484	G/T	cg19519643	chr4:187840862	NA	-0.43	-7.94	-0.35	1.56e-14	Gout;
LGG	trans	rs11992162	0.636	rs4841646	chr8:11798707	C/G	cg08975724	chr8:8085496	FLJ10661	0.38	6.99	0.31	9.62e-12	Monocyte count;
LGG	cis	rs9362426	1.000	rs414013	chr6:88085866	T/G	cg06087457	chr6:88040249	C6orf162;GJB7	0.53	10.08	0.42	1.01e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs4820539	0.966	rs5751587	chr22:23470090	G/A	cg21100191	chr22:23484243	RTDR1	1.0	22.97	0.73	1.8e-78	Bone mineral density;
LGG	trans	rs7937682	0.575	rs34888817	chr11:111756455	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs4423214	0.879	rs10898144	chr11:71151540	A/T	cg10847948	chr11:71163743	NADSYN1	0.64	11.71	0.48	6.59e-28	Vitamin D levels;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg06558623	chr16:89946397	TCF25	1.08	11.65	0.48	1.11e-27	Skin colour saturation;
LGG	cis	rs67385638	1.000	rs2855121	chr11:5277291	C/T	cg12559170	chr11:5275217	HBG2	0.57	13.2	0.52	5.31e-34	Hemoglobin levels;
LGG	cis	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg15596359	chr8:11213517	TDH	-0.4	-8.24	-0.36	1.81e-15	Retinal vascular caliber;
LGG	cis	rs7149242	0.662	rs4905998	chr14:101181781	A/G	cg18089426	chr14:101175970	NA	-0.41	-9.28	-0.4	6.36e-19	Platelet count;
LGG	cis	rs7241530	0.536	rs34738964	chr18:75891259	A/G	cg14642773	chr18:75888474	NA	0.46	9.06	0.39	3.73e-18	Educational attainment (years of education);
LGG	cis	rs7659604	0.643	rs6839375	chr4:122663610	G/C	cg19748678	chr4:122722346	EXOSC9	0.44	7.6	0.33	1.66e-13	Type 2 diabetes;
LGG	cis	rs11711311	1.000	rs2242108	chr3:113433903	T/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.68	-0.34	9.53e-14	IgG glycosylation;
LGG	cis	rs9768139	0.708	rs896782	chr7:158114115	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs12476592	0.516	rs11883730	chr2:63592230	A/C	cg17519650	chr2:63277830	OTX1	0.52	7.95	0.35	1.47e-14	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.03	-0.35	8.35e-15	HDL cholesterol;
LGG	cis	rs506338	0.517	rs471618	chr11:64465403	T/C	cg19395706	chr11:64412079	NRXN2	0.41	8.04	0.35	7.72e-15	Body mass index;Urate levels;
LGG	cis	rs2282032	0.550	rs58363992	chr14:90766361	T/C	cg04374321	chr14:90722782	PSMC1	0.49	8.06	0.35	6.39e-15	Longevity;
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg27476859	chr7:2772710	GNA12	0.43	7.21	0.32	2.36e-12	Height;
LGG	cis	rs700651	0.821	rs771005	chr2:198675948	C/T	cg00792783	chr2:198669748	PLCL1	0.69	11.21	0.46	5.89e-26	Intracranial aneurysm;
LGG	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.17	-0.49	9.64e-30	Hemoglobin concentration;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg11584989	chr19:19387371	SF4	-0.42	-7.55	-0.33	2.42e-13	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	1.000	rs4382	chr22:38570842	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs9399137	0.507	rs6940258	chr6:135366132	C/T	cg24558204	chr6:135376177	HBS1L	0.6	10.6	0.44	1.15e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs7833790	0.724	rs6473310	chr8:82707981	A/G	cg06027949	chr8:82754900	SNX16	-0.55	-8.62	-0.37	1.09e-16	Diastolic blood pressure;
LGG	cis	rs9443645	0.901	rs1984195	chr6:79657391	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.63	-0.37	9.65e-17	Intelligence (multi-trait analysis);
LGG	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg26384229	chr12:38710491	ALG10B	0.94	21.2	0.7	3.12e-70	Bladder cancer;
LGG	cis	rs7301016	0.846	rs7302094	chr12:62967430	C/T	cg11441379	chr12:63026424	NA	0.63	8.92	0.38	1.12e-17	IgG glycosylation;
LGG	cis	rs240764	0.659	rs240784	chr6:100970472	C/T	cg21058520	chr6:100914733	NA	0.38	6.71	0.3	5.58e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs700651	0.786	rs58224025	chr2:198821988	G/A	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Intracranial aneurysm;
LGG	cis	rs35740288	0.787	rs2008916	chr15:86221190	C/T	cg07943548	chr15:86304357	KLHL25	-0.34	-6.8	-0.3	3.28e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg16927871	chr3:25469991	RARB	0.41	6.69	0.3	6.28e-11	Menarche (age at onset);
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg18621852	chr3:10150065	C3orf24	0.4	6.65	0.3	8.41e-11	Alzheimer's disease;
LGG	cis	rs2342371	0.599	rs7618690	chr3:196146039	T/C	cg15048948	chr3:196158458	UBXN7	0.62	10.66	0.44	7.22e-24	Fat distribution (HIV);
LGG	trans	rs3808502	0.526	rs7823101	chr8:11422492	C/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.32	-0.36	9.83e-16	Neuroticism;
LGG	cis	rs7107174	1.000	rs1318241	chr11:77930792	C/T	cg02023728	chr11:77925099	USP35	0.45	7.85	0.34	3.01e-14	Testicular germ cell tumor;
LGG	cis	rs72945132	0.660	rs67433166	chr11:70121604	T/A	cg14191688	chr11:70257035	CTTN	0.52	7.59	0.33	1.73e-13	Coronary artery disease;
LGG	cis	rs1816752	0.905	rs8002215	chr13:24990367	A/G	cg02811702	chr13:24901961	NA	0.39	7.38	0.32	7.58e-13	Obesity-related traits;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg26354017	chr1:205819088	PM20D1	0.87	20.89	0.7	9.68e-69	Menarche (age at onset);
LGG	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg02227867	chr8:22457446	C8orf58	-0.44	-8.26	-0.36	1.52e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg11764359	chr7:65958608	NA	-0.72	-12.89	-0.51	1.09e-32	Aortic root size;
LGG	cis	rs6784615	0.744	rs6445486	chr3:52506491	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.65	7.58	0.33	1.95e-13	Waist-hip ratio;
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg22168489	chr12:122356033	WDR66	0.44	10.66	0.44	6.91e-24	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs2185352	chr6:150035776	T/G	cg16507663	chr6:150244633	RAET1G	0.47	8.95	0.38	8.97e-18	Lung cancer;
LGG	cis	rs74781061	0.585	rs4887146	chr15:74732066	T/G	cg02384859	chr15:74862662	ARID3B	-0.41	-6.65	-0.3	8.13e-11	Endometriosis;
LGG	cis	rs7249142	0.549	rs741706	chr19:19281672	C/T	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.56	-0.44	1.69e-23	IgG glycosylation;
LGG	cis	rs972578	1.000	rs2016623	chr22:43370549	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.75e-11	Mean platelet volume;
LGG	trans	rs12339094	1.000	rs12339094	chr9:90410222	A/C	cg24436365	chr6:63940138	NA	0.42	6.68	0.3	6.97e-11	Smoking quantity;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg15352829	chr14:105391018	PLD4	-0.48	-11.28	-0.46	3.21e-26	Rheumatoid arthritis;
LGG	trans	rs9858542	0.953	rs6446264	chr3:49417243	C/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.54	-0.44	1.95e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs79976124	0.879	rs12214948	chr6:66633603	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.27	0.5	3.75e-30	Type 2 diabetes;
LGG	cis	rs8053891	0.615	rs2287997	chr16:72140553	G/A	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.41	-7.33	-0.32	1.06e-12	Coronary artery disease;
LGG	trans	rs34421088	0.678	rs35726503	chr8:11591916	A/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.83	-0.34	3.25e-14	Neuroticism;
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.8	-0.48	2.84e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	1.000	rs35624992	chr11:47615798	G/C	cg20307385	chr11:47447363	PSMC3	-0.49	-8.8	-0.38	2.78e-17	Subjective well-being;
LGG	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.86	-0.3	2.26e-11	Arsenic metabolism;
LGG	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs11711311	0.955	rs10934241	chr3:113394705	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.41	-7.14	-0.31	3.67e-12	IgG glycosylation;
LGG	cis	rs7853377	0.723	rs13296528	chr9:86522550	C/T	cg12437157	chr9:86433764	GKAP1	0.38	6.66	0.3	7.56e-11	Height;
LGG	trans	rs6076960	0.684	rs6054055	chr20:6257517	C/G	cg24759859	chr6:86352639	SYNCRIP	0.43	7.15	0.32	3.51e-12	Smooth-surface caries;
LGG	cis	rs4853012	0.838	rs4452177	chr2:74345206	A/G	cg05890377	chr2:74357713	NA	0.49	9.85	0.42	6.42e-21	Gestational age at birth (maternal effect);
LGG	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs1008375	0.835	rs9760627	chr4:17651508	C/T	cg04450456	chr4:17643702	FAM184B	0.34	7.44	0.33	4.94e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13095912	0.752	rs7613002	chr3:185353235	T/C	cg11274856	chr3:185301563	NA	0.49	7.88	0.34	2.39e-14	Systolic blood pressure;
LGG	cis	rs4820539	0.966	rs2283803	chr22:23454881	G/A	cg21100191	chr22:23484243	RTDR1	0.94	21.45	0.71	2.14e-71	Bone mineral density;
LGG	cis	rs7241530	0.610	rs7230650	chr18:75892679	A/G	cg14642773	chr18:75888474	NA	0.47	8.98	0.39	6.65e-18	Educational attainment (years of education);
LGG	cis	rs3749237	0.595	rs2878298	chr3:49406080	T/C	cg07636037	chr3:49044803	WDR6	0.6	10.45	0.44	4.48e-23	Resting heart rate;
LGG	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.6	-7.13	-0.31	3.91e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7824557	0.778	rs6601572	chr8:11093337	C/G	cg16141378	chr3:129829833	LOC729375	0.37	8.01	0.35	9.58e-15	Retinal vascular caliber;
LGG	cis	rs9486715	1.000	rs9398148	chr6:97063555	A/G	cg18709589	chr6:96969512	KIAA0776	-0.48	-9.38	-0.4	3.02e-19	Headache;
LGG	cis	rs2836974	0.965	rs6517538	chr21:40656242	C/T	cg11644478	chr21:40555479	PSMG1	0.91	17.84	0.64	1.39e-54	Cognitive function;
LGG	cis	rs4737010	0.570	rs7823138	chr8:41644861	C/T	cg08923054	chr8:41654455	ANK1	-0.77	-13.48	-0.53	3.47e-35	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs453301	0.624	rs2979265	chr8:8858717	G/C	cg27411982	chr8:10470053	RP1L1	0.46	7.93	0.35	1.65e-14	Joint mobility (Beighton score);
LGG	cis	rs787274	1.000	rs1539338	chr9:115586187	A/G	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg03161606	chr19:29218774	NA	0.71	11.05	0.46	2.43e-25	Methadone dose in opioid dependence;
LGG	cis	rs10193935	0.901	rs6724626	chr2:42689757	C/G	cg27598129	chr2:42591480	NA	0.66	9.56	0.41	6.77e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9329289	0.888	rs11251273	chr10:2540300	G/C	cg15501526	chr10:2543763	NA	0.68	14.45	0.56	2.6e-39	Age-related hearing impairment;
LGG	cis	rs8114671	0.967	rs1415773	chr20:33765585	G/A	cg24642439	chr20:33292090	TP53INP2	0.45	7.14	0.31	3.65e-12	Height;
LGG	cis	rs853679	0.517	rs9393893	chr6:28109262	T/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.43e-11	Depression;
LGG	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.77	-0.61	1.16e-49	Height;
LGG	trans	rs1478897	0.804	rs9329246	chr8:11392880	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.86	0.3	2.27e-11	Systemic lupus erythematosus;
LGG	cis	rs943466	1.000	rs73412140	chr6:33757014	G/T	cg07519485	chr6:33762594	MLN	0.55	11.22	0.46	5.18e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs28595532	0.920	rs114057512	chr4:119750179	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs4925325	0.955	rs1776262	chr20:60516023	G/T	cg03235661	chr20:60525775	NA	0.31	7.29	0.32	1.31e-12	Obesity-related traits;
LGG	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg19980929	chr12:42632907	YAF2	0.39	8.82	0.38	2.43e-17	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg00405596	chr8:11794950	NA	0.65	11.55	0.47	2.77e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs113835537	0.529	rs11227501	chr11:66274072	T/C	cg24851651	chr11:66362959	CCS	0.45	7.74	0.34	6.14e-14	Airway imaging phenotypes;
LGG	cis	rs7402982	0.934	rs8028620	chr15:99202875	C/T	cg03437748	chr15:99193247	IGF1R	0.92	20.43	0.69	1.36e-66	Birth weight;
LGG	cis	rs7666738	0.830	rs13328005	chr4:99055480	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.98	0.35	1.16e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg06521331	chr12:34319734	NA	-0.43	-7.32	-0.32	1.09e-12	Heart rate;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg05225373	chr14:55657967	DLGAP5	0.48	7.82	0.34	3.5e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs4862750	0.872	rs4862748	chr4:187877388	C/T	cg22105103	chr4:187893119	NA	-0.46	-8.21	-0.36	2.22e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs17376456	0.825	rs10476590	chr5:93244884	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg03970086	chr16:88974840	CBFA2T3	0.42	8.32	0.36	9.74e-16	Social autistic-like traits;
LGG	cis	rs2421770	0.532	rs7106813	chr11:35372432	C/T	cg10331829	chr11:35343789	SLC1A2	-0.35	-7.69	-0.34	9.01e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs6502050	0.835	rs4789738	chr17:80123053	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs56390833	1	rs56390833	chr15:78877381	C/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.48	-0.33	3.66e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6578185	0.810	rs11777061	chr8:142448187	G/A	cg07762003	chr8:142452454	FLJ43860	-0.65	-13.41	-0.53	6.92e-35	Endometriosis;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg00689492	chr4:1303491	MAEA	0.51	8.56	0.37	1.7e-16	Obesity-related traits;
LGG	cis	rs11608355	0.515	rs12579916	chr12:109924528	T/G	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs10865541	0.967	rs6755448	chr2:3397359	T/C	cg13173536	chr2:3403300	TTC15	-0.36	-7.59	-0.33	1.78e-13	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg04025307	chr7:1156635	C7orf50	0.66	8.49	0.37	2.85e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.18e-27	Height;
LGG	cis	rs7618501	0.633	rs7628058	chr3:50039474	C/T	cg24308560	chr3:49941425	MST1R	0.22	6.69	0.3	6.3e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9329221	0.711	rs55864141	chr8:9807022	T/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.87	-0.3	2.08e-11	Neuroticism;
LGG	trans	rs800082	0.698	rs800074	chr3:144347638	A/G	cg24215973	chr2:240111563	HDAC4	-0.72	-13.28	-0.53	2.41e-34	Smoking behavior;
LGG	cis	rs774359	0.797	rs10812604	chr9:27496661	A/C	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.37	-0.36	6.73e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs8177253	0.965	rs7638018	chr3:133495461	C/T	cg01448562	chr3:133502909	NA	0.74	13.63	0.54	8.34e-36	Iron status biomarkers;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.59	0.37	1.33e-16	Prudent dietary pattern;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.5	-0.33	3.39e-13	Life satisfaction;
LGG	cis	rs1595825	0.945	rs6756641	chr2:198849672	T/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.78	-0.3	3.7e-11	Ulcerative colitis;
LGG	cis	rs514406	0.505	rs269286	chr1:53169018	C/T	cg24675658	chr1:53192096	ZYG11B	0.6	13.57	0.53	1.51e-35	Monocyte count;
LGG	cis	rs2133450	0.508	rs9825942	chr3:7350426	C/G	cg19930620	chr3:7340148	GRM7	-0.47	-10.35	-0.43	1.03e-22	Early response to risperidone in schizophrenia;
LGG	cis	rs9522267	0.643	rs9522280	chr13:112221334	G/C	cg10483660	chr13:112241077	NA	-0.37	-7.84	-0.34	3.21e-14	Hepatitis;
LGG	cis	rs7927592	0.956	rs10896343	chr11:68317860	G/C	cg16797656	chr11:68205561	LRP5	0.39	6.87	0.3	2.14e-11	Total body bone mineral density;
LGG	cis	rs372883	0.648	rs1003772	chr21:30736145	A/T	cg08807101	chr21:30365312	RNF160	0.6	9.87	0.42	5.39e-21	Pancreatic cancer;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs12496230	0.855	rs1036971	chr3:66850677	T/A	cg17646820	chr3:66848679	NA	0.52	8.1	0.35	5.06e-15	Type 2 diabetes;
LGG	cis	rs240764	0.658	rs9322182	chr6:101223295	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.15	-0.35	3.46e-15	Neuroticism;
LGG	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg11279151	chr3:101281821	RG9MTD1	-0.47	-8.17	-0.36	2.92e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10046574	0.519	rs10265128	chr7:135211446	A/G	cg27474649	chr7:135195673	CNOT4	0.73	9.12	0.39	2.28e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs13191362	1.000	rs13202339	chr6:163081812	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.69	0.41	2.37e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg01879757	chr17:41196368	BRCA1	0.39	7.96	0.35	1.37e-14	Menopause (age at onset);
LGG	cis	rs975722	0.516	rs994997	chr7:117052950	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	8.5	0.37	2.66e-16	Coronary artery disease;
LGG	cis	rs11748327	0.959	rs1911907	chr5:4064360	C/G	cg01025095	chr5:4101132	NA	-0.57	-9.23	-0.39	9.96e-19	Myocardial infarction;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg19223190	chr17:80058835	NA	-0.44	-8.51	-0.37	2.39e-16	Life satisfaction;
LGG	cis	rs2334880	0.678	rs12922830	chr16:71447270	C/T	cg06353428	chr16:71660113	MARVELD3	-0.7	-10.04	-0.42	1.42e-21	Malaria;
LGG	trans	rs6076960	0.652	rs3852946	chr20:6255311	C/T	cg24759859	chr6:86352639	SYNCRIP	0.42	7.15	0.32	3.31e-12	Smooth-surface caries;
LGG	cis	rs6963495	0.818	rs9769403	chr7:105163091	G/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs17030434	0.728	rs2124641	chr4:154645810	T/C	cg14289246	chr4:154710475	SFRP2	0.62	9.46	0.4	1.51e-19	Electrocardiographic conduction measures;
LGG	cis	rs75920871	0.528	rs7109649	chr11:116943544	C/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.52	-0.33	2.92e-13	Subjective well-being;
LGG	trans	rs453301	0.624	rs330056	chr8:9089695	A/T	cg02002194	chr4:3960332	NA	0.47	9.18	0.39	1.5e-18	Joint mobility (Beighton score);
LGG	cis	rs7829975	0.714	rs4841040	chr8:8654527	T/C	cg06636001	chr8:8085503	FLJ10661	0.53	10.24	0.43	2.53e-22	Mood instability;
LGG	cis	rs4665809	0.531	rs3892649	chr2:26457267	T/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs1957429	0.614	rs73279834	chr14:65352544	G/A	cg23373153	chr14:65346875	NA	-1.08	-12.07	-0.49	2.26e-29	Pediatric areal bone mineral density (radius);
LGG	cis	rs55883249	1.000	rs17453752	chr2:9766171	C/T	cg23886495	chr2:9695866	ADAM17	-0.63	-9.17	-0.39	1.57e-18	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6489785	0.737	rs566704	chr12:121231790	G/A	cg02419362	chr12:121203948	SPPL3	0.43	6.74	0.3	4.82e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3857536	0.740	rs7766407	chr6:66885658	C/A	cg07460842	chr6:66804631	NA	-0.48	-8.41	-0.36	5.29e-16	Blood trace element (Cu levels);
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg06634786	chr22:41940651	POLR3H	0.78	12.92	0.51	8.24e-33	Vitiligo;
LGG	cis	rs718515	0.527	rs17686457	chr18:43870742	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.37	-7.54	-0.33	2.47e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11920090	0.932	rs56791644	chr3:170708830	A/G	cg09710316	chr3:170744871	SLC2A2	0.6	8.44	0.37	4.12e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs193541	0.632	rs30023	chr5:122285299	T/G	cg19412675	chr5:122181750	SNX24	0.55	8.88	0.38	1.45e-17	Glucose homeostasis traits;
LGG	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg26116260	chr4:7069785	GRPEL1	-1.06	-16.01	-0.6	3.13e-46	Monocyte percentage of white cells;
LGG	cis	rs6772849	0.930	rs12487604	chr3:128337075	T/A	cg08795948	chr3:128337044	NA	0.67	11.27	0.46	3.36e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg24130564	chr14:104152367	KLC1	-0.38	-6.86	-0.3	2.19e-11	Reticulocyte count;
LGG	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.01	-0.35	9.61e-15	Initial pursuit acceleration;
LGG	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg12463550	chr7:65579703	CRCP	0.74	7.95	0.35	1.44e-14	Diabetic kidney disease;
LGG	cis	rs929354	0.772	rs10230895	chr7:157007038	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.63	0.59	1.5e-44	Body mass index;
LGG	cis	rs7301826	0.651	rs10773825	chr12:131298913	G/A	cg11011512	chr12:131303247	STX2	0.41	8.93	0.38	1.04e-17	Plasma plasminogen activator levels;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	10.6	0.44	1.15e-23	Obesity-related traits;
LGG	cis	rs7904368	0.754	rs7091240	chr10:16855683	G/A	cg22980697	chr10:16874865	CUBN	0.61	9.95	0.42	2.92e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs11700980	0.551	rs2832014	chr21:30110966	T/A	cg24692254	chr21:30365293	RNF160	-0.48	-6.67	-0.3	7.13e-11	QRS complex (12-leadsum);
LGG	cis	rs977987	0.671	rs9922008	chr16:75335406	T/C	cg07303275	chr16:75499416	TMEM170A	0.39	6.79	0.3	3.5e-11	Dupuytren's disease;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg20887711	chr4:1340912	KIAA1530	-0.53	-9.7	-0.41	2.32e-20	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21930443	chr17:28443747	CCDC55;MIR423	0.45	7.55	0.33	2.4e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06636372	chr16:89349979	ANKRD11	0.38	7.3	0.32	1.23e-12	Pancreatic cancer;
LGG	cis	rs2370759	1.000	rs2769241	chr10:32556229	T/C	cg01819863	chr10:32635814	EPC1	-1.02	-14.1	-0.55	7.77e-38	Sexual dysfunction (female);
LGG	trans	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg02002194	chr4:3960332	NA	-0.49	-9.44	-0.4	1.86e-19	Mood instability;
LGG	cis	rs2439831	1.000	rs28628574	chr15:43802038	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.9	9.9	0.42	4.51e-21	Lung cancer in ever smokers;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg05665937	chr4:1216051	CTBP1	-0.41	-7.22	-0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs17818399	0.653	rs34050156	chr2:46777646	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.51	8.03	0.35	8.19e-15	Height;
LGG	cis	rs7107174	1.000	rs9651768	chr11:77996020	C/T	cg27205649	chr11:78285834	NARS2	-0.43	-7.1	-0.31	4.81e-12	Testicular germ cell tumor;
LGG	cis	rs12549902	0.966	rs4737000	chr8:41509727	A/C	cg25883020	chr8:41504993	NKX6-3	0.32	7.13	0.31	4e-12	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs9303401	0.614	rs17175663	chr17:57108437	G/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.31	0.55	1.03e-38	Cognitive test performance;
LGG	cis	rs67311347	0.955	rs11717036	chr3:40379578	G/T	cg13683864	chr3:40499215	RPL14	1.01	22.05	0.72	3.39e-74	Renal cell carcinoma;
LGG	cis	rs2836974	0.932	rs73221193	chr21:40554693	C/T	cg11644478	chr21:40555479	PSMG1	0.93	17.52	0.63	4.15e-53	Cognitive function;
LGG	cis	rs4478037	1.000	rs75576169	chr3:33167801	G/A	cg19404215	chr3:33155277	CRTAP	1.01	11.88	0.48	1.36e-28	Major depressive disorder;
LGG	cis	rs8060686	0.516	rs7194894	chr16:68145062	C/T	cg27539214	chr16:67997921	SLC12A4	-0.44	-7.05	-0.31	6.37e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs41342147	0.660	rs10933553	chr2:242286747	A/G	cg10173475	chr2:242152697	ANO7	-0.51	-7.96	-0.35	1.34e-14	Vitiligo;
LGG	cis	rs881375	0.501	rs10739591	chr9:123885728	C/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.74	0.3	4.76e-11	Rheumatoid arthritis;
LGG	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11890956	chr21:40555474	PSMG1	-0.96	-19.52	-0.67	2.35e-62	Cognitive function;
LGG	cis	rs597539	0.689	rs596874	chr11:68630874	C/T	cg21862992	chr11:68658383	NA	-0.52	-8.94	-0.38	9.12e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2288073	0.619	rs6713263	chr2:24375463	A/G	cg06627628	chr2:24431161	ITSN2	-0.41	-6.84	-0.3	2.48e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4538187	1.000	rs6715992	chr2:64085344	C/T	cg02541582	chr2:64069798	UGP2	0.61	14.46	0.56	2.21e-39	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20703290	chr7:44645941	OGDH	0.4	6.79	0.3	3.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg17554472	chr22:41940697	POLR3H	-0.47	-7.02	-0.31	8.08e-12	Vitiligo;
LGG	cis	rs826838	0.967	rs11168985	chr12:39045983	A/C	cg26384229	chr12:38710491	ALG10B	-0.99	-23.8	-0.74	2.31e-82	Heart rate;
LGG	cis	rs875971	0.862	rs801203	chr7:66023012	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs651907	0.557	rs11914318	chr3:101453858	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.2	-0.32	2.42e-12	Colorectal cancer;
LGG	trans	rs12310956	0.532	rs10844712	chr12:33961022	G/A	cg26384229	chr12:38710491	ALG10B	0.75	14.87	0.57	3.77e-41	Morning vs. evening chronotype;
LGG	cis	rs5769765	0.862	rs9616381	chr22:50312382	G/A	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	trans	rs1941687	0.797	rs6507069	chr18:31393188	C/G	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.1e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg03806693	chr22:41940476	POLR3H	-0.94	-16.75	-0.61	1.38e-49	Vitiligo;
LGG	trans	rs11098499	0.863	rs3775847	chr4:120447642	A/C	cg25214090	chr10:38739885	LOC399744	0.67	11.73	0.48	5.2e-28	Corneal astigmatism;
LGG	cis	rs877282	0.842	rs35872126	chr10:764545	G/A	cg17470449	chr10:769945	NA	0.56	6.83	0.3	2.65e-11	Uric acid levels;
LGG	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg25173405	chr17:45401733	C17orf57	-0.54	-9.23	-0.39	9.34e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4788570	0.609	rs72795869	chr16:71485515	C/T	cg06353428	chr16:71660113	MARVELD3	-1.0	-13.57	-0.53	1.43e-35	Intelligence (multi-trait analysis);
LGG	cis	rs8017423	0.967	rs11621431	chr14:90709221	C/T	cg04374321	chr14:90722782	PSMC1	0.89	18.93	0.66	1.26e-59	Mortality in heart failure;
LGG	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg16414030	chr3:133502952	NA	-0.59	-10.28	-0.43	1.84e-22	Iron status biomarkers;
LGG	trans	rs1941687	0.563	rs9953034	chr18:31335294	A/G	cg27147174	chr7:100797783	AP1S1	-0.65	-12.34	-0.5	1.97e-30	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs17270561	0.636	rs4360128	chr6:25734558	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.04	-0.31	6.91e-12	Iron status biomarkers;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.15e-16	Prudent dietary pattern;
LGG	cis	rs7011049	0.778	rs6994265	chr8:53866234	G/A	cg26025543	chr8:53854495	NA	0.6	8.42	0.36	4.82e-16	Systolic blood pressure;
LGG	cis	rs975722	0.516	rs4727851	chr7:117048082	C/T	cg10524701	chr7:117356490	CTTNBP2	0.4	8.45	0.37	3.73e-16	Coronary artery disease;
LGG	trans	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.23	0.36	1.95e-15	Neuroticism;
LGG	cis	rs4595586	0.546	rs11609849	chr12:39258090	C/G	cg13010199	chr12:38710504	ALG10B	0.6	10.92	0.45	7.12e-25	Morning vs. evening chronotype;
LGG	cis	rs7747724	0.528	rs9295482	chr6:20761234	A/C	cg13405222	chr6:20811065	CDKAL1	-0.38	-6.83	-0.3	2.63e-11	Bladder cancer;
LGG	cis	rs2836950	0.565	rs2836943	chr21:40592611	C/T	cg11890956	chr21:40555474	PSMG1	-0.73	-12.88	-0.51	1.14e-32	Menarche (age at onset);
LGG	cis	rs6502050	0.835	rs7219138	chr17:80079896	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg08645402	chr16:4508243	NA	0.46	8.68	0.37	6.94e-17	Schizophrenia;
LGG	cis	rs7173389	0.530	rs11636535	chr15:73681648	T/C	cg01796676	chr15:73680284	NA	0.5	9.56	0.41	7.1e-20	Resting heart rate;
LGG	cis	rs977987	0.835	rs3851734	chr16:75371920	T/C	cg03315344	chr16:75512273	CHST6	0.51	10.03	0.42	1.44e-21	Dupuytren's disease;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.74e-18	Life satisfaction;
LGG	trans	rs75804782	0.521	rs72993065	chr2:239409001	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.51	0.37	2.48e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs5769765	1.000	rs764813	chr22:50286172	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.51	0.33	2.99e-13	Schizophrenia;
LGG	cis	rs62103177	0.525	rs4799116	chr18:77736735	A/G	cg20368463	chr18:77673604	PQLC1	-0.56	-7.79	-0.34	4.35e-14	Opioid sensitivity;
LGG	cis	rs2880765	0.743	rs4551990	chr15:86015287	A/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.22	-0.32	2.19e-12	Coronary artery disease;
LGG	cis	rs7904368	0.806	rs3858182	chr10:16855094	C/T	cg23933602	chr10:16859644	RSU1	0.64	9.42	0.4	2.18e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	7.46	0.33	4.42e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.67	-0.41	2.94e-20	Life satisfaction;
LGG	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11098499	0.909	rs1546502	chr4:120235898	A/G	cg24375607	chr4:120327624	NA	0.66	10.7	0.45	5.18e-24	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs4354168	chr6:150017778	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.77	-0.45	2.83e-24	Lung cancer;
LGG	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg18681998	chr4:17616180	MED28	0.81	18.1	0.64	9.22e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4727027	0.870	rs1105261	chr7:148794442	T/G	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.79	0.3	3.47e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg16339924	chr4:17578868	LAP3	0.63	10.92	0.45	7.52e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6951245	0.938	rs112425403	chr7:1071531	A/G	cg12692727	chr7:1102344	C7orf50	0.48	6.82	0.3	2.9100000000000002e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs701145	0.585	rs7612886	chr3:153821176	T/A	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg23758822	chr17:41437982	NA	0.9	15.99	0.6	3.77e-46	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg05863683	chr7:1912471	MAD1L1	0.49	9.58	0.41	6.16e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs9796	0.870	rs2412572	chr15:41264426	G/C	cg18705301	chr15:41695430	NDUFAF1	0.48	8.37	0.36	6.86e-16	Menopause (age at onset);
LGG	cis	rs3733585	0.699	rs4621431	chr4:9947590	C/T	cg11266682	chr4:10021025	SLC2A9	-0.45	-8.46	-0.37	3.43e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs1814175	0.647	rs10839394	chr11:49844747	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.29	-0.5	2.99e-30	Height;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg03351412	chr1:154909251	PMVK	0.59	10.05	0.42	1.25e-21	Prostate cancer;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.96	0.52	5.38e-33	Prudent dietary pattern;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.14	0.7	5.94e-70	Platelet count;
LGG	cis	rs9650657	0.572	rs4841465	chr8:10819854	C/T	cg21775007	chr8:11205619	TDH	-0.53	-8.44	-0.37	4.21e-16	Neuroticism;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg04287289	chr16:89883240	FANCA	0.84	7.95	0.35	1.39e-14	Skin colour saturation;
LGG	cis	rs4330281	0.669	rs4908964	chr3:17758859	C/T	cg20981856	chr3:17787350	NA	-0.39	-7.3	-0.32	1.3e-12	Schizophrenia;
LGG	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.43	7.48	0.33	3.8e-13	Menarche (age at onset);
LGG	cis	rs3790455	1.000	rs3790454	chr1:156451349	T/G	cg14087168	chr1:156450669	MEF2D	0.47	7.72	0.34	7.33e-14	Migraine;
LGG	cis	rs7296418	0.663	rs11057276	chr12:123820397	C/T	cg05973401	chr12:123451056	ABCB9	-0.43	-7.31	-0.32	1.15e-12	Platelet count;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg13939156	chr17:80058883	NA	-0.46	-8.98	-0.39	6.9e-18	Life satisfaction;
LGG	cis	rs881375	0.692	rs2072438	chr9:123651301	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.66	13.04	0.52	2.47e-33	Rheumatoid arthritis;
LGG	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.44	0.44	4.76e-23	Morning vs. evening chronotype;
LGG	cis	rs62400317	0.787	rs10456547	chr6:45219526	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.23	-0.43	2.89e-22	Total body bone mineral density;
LGG	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg05753993	chr18:77199432	NFATC1	0.37	6.79	0.3	3.54e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.43	-0.33	5.39e-13	Morning vs. evening chronotype;
LGG	trans	rs11782517	0.961	rs4276692	chr8:10115695	G/A	cg02002194	chr4:3960332	NA	-0.45	-7.18	-0.32	2.84e-12	Nose size;
LGG	cis	rs2455601	0.507	rs2568044	chr11:9002477	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.5	9.2	0.39	1.2e-18	Schizophrenia;
LGG	cis	rs1318772	1.000	rs414475	chr5:112808617	A/T	cg12552261	chr5:112820674	MCC	-0.71	-7.93	-0.35	1.69e-14	F-cell distribution;
LGG	cis	rs72781680	0.898	rs72781639	chr2:24204148	C/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.61e-20	Lymphocyte counts;
LGG	cis	rs16912285	0.688	rs59246618	chr11:24315201	G/T	ch.11.24196551F	chr11:24239977	NA	0.89	13.49	0.53	3.27e-35	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs4948496	1.000	rs12357548	chr10:63803472	A/G	cg07520810	chr10:63809149	ARID5B	0.35	6.73	0.3	4.94e-11	Systemic lupus erythematosus;
LGG	cis	rs79149102	0.579	rs8033125	chr15:75374970	G/C	cg17294928	chr15:75287854	SCAMP5	-0.7	-7.99	-0.35	1.08e-14	Lung cancer;
LGG	cis	rs910316	0.935	rs3742771	chr14:75599647	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	10.44	0.44	4.62e-23	Height;
LGG	cis	rs2494938	1.000	rs1771304	chr6:40532287	G/C	cg14084896	chr6:40530702	LRFN2	-0.3	-7.06	-0.31	6.15e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9527	1.000	rs9527	chr10:104623578	C/T	cg04362960	chr10:104952993	NT5C2	0.57	9.41	0.4	2.32e-19	Arsenic metabolism;
LGG	cis	rs2267708	0.506	rs1842616	chr7:124582172	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9460578	0.634	rs9465895	chr6:20804563	T/C	cg13405222	chr6:20811065	CDKAL1	0.65	11.7	0.48	6.75e-28	Breast cancer;
LGG	cis	rs6694270	0.529	rs35417699	chr1:19105105	C/T	cg19637330	chr1:19110922	NA	-0.41	-6.67	-0.3	7.21e-11	Drug-induced liver injury (nitrofurantoin);
LGG	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg04455712	chr21:45112962	RRP1B	0.52	9.96	0.42	2.66e-21	Mean corpuscular volume;
LGG	trans	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.23	-0.32	2.02e-12	Calcium levels;
LGG	trans	rs853679	1.000	rs2799077	chr6:28234597	C/T	cg01620082	chr3:125678407	NA	-0.61	-7.53	-0.33	2.61e-13	Depression;
LGG	cis	rs4132509	1.000	rs9287269	chr1:243954551	G/A	cg25706552	chr1:244017396	NA	0.54	8.76	0.38	3.6e-17	RR interval (heart rate);
LGG	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg17545662	chr6:170176663	C6orf70	0.69	8.68	0.37	6.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.13	0.31	3.98e-12	Lung cancer;
LGG	cis	rs644799	1.000	rs505220	chr11:95563228	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs28719689	0.504	rs17669535	chr8:1244224	C/G	cg22761795	chr8:1265118	NA	0.83	8.02	0.35	8.55e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.715	rs7586608	chr2:99558017	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.92	-0.51	8.06e-33	Chronic sinus infection;
LGG	cis	rs3126085	0.935	rs11204941	chr1:152203343	A/G	cg26876637	chr1:152193138	HRNR	0.56	9.19	0.39	1.3e-18	Atopic dermatitis;
LGG	cis	rs8112449	0.822	rs7253185	chr19:10549212	A/G	cg21868191	chr19:10515988	NA	-0.48	-8.03	-0.35	8.15e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg27398817	chr8:82754497	SNX16	0.78	11.26	0.46	3.74e-26	Diastolic blood pressure;
LGG	cis	rs12519773	0.526	rs4242241	chr5:92518370	C/T	cg18783429	chr5:92414398	NA	0.32	7.73	0.34	6.79e-14	Migraine;
LGG	cis	rs986417	1.000	rs3931460	chr14:60939101	A/C	cg27398547	chr14:60952738	C14orf39	0.73	7.25	0.32	1.74e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10911363	0.549	rs2794619	chr1:183459670	G/A	cg09173681	chr1:183549694	NCF2	0.36	8.3	0.36	1.15e-15	Systemic lupus erythematosus;
LGG	cis	rs963731	0.649	rs7577088	chr2:39233500	G/A	cg04010122	chr2:39346883	SOS1	-0.77	-6.65	-0.3	8.37e-11	Corticobasal degeneration;
LGG	cis	rs1018836	0.923	rs13259842	chr8:91550819	A/G	cg16814680	chr8:91681699	NA	-0.8	-15.17	-0.58	1.69e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.830	rs1527517	chr4:98931907	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26074851	chr5:133512410	SKP1	0.41	6.71	0.3	5.68e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7829975	0.714	rs60315134	chr8:8670599	A/G	cg21775007	chr8:11205619	TDH	0.45	7.46	0.33	4.19e-13	Mood instability;
LGG	cis	rs11628318	0.614	rs3783383	chr14:103177420	G/C	cg01864069	chr14:103024347	NA	0.45	7.7	0.34	8.18e-14	Platelet count;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	13.41	0.53	7.07e-35	Obesity-related traits;
LGG	cis	rs11096990	0.793	rs9997050	chr4:39302665	A/G	cg24403649	chr4:39172243	NA	-0.43	-6.87	-0.3	2.06e-11	Cognitive function;
LGG	cis	rs12447804	0.822	rs9926547	chr16:58081794	C/T	cg03859792	chr16:58121049	NA	0.47	7.29	0.32	1.33e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs7149242	0.697	rs12882815	chr14:101183142	C/G	cg18089426	chr14:101175970	NA	-0.41	-9.15	-0.39	1.76e-18	Platelet count;
LGG	cis	rs3768617	0.510	rs1413388	chr1:183096694	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7226408	0.625	rs2847592	chr18:34758343	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.42	-8.97	-0.38	7.29e-18	Obesity-related traits;
LGG	cis	rs2404602	0.735	rs4886798	chr15:76673226	A/G	cg23625390	chr15:77176239	SCAPER	0.64	12.84	0.51	1.72e-32	Blood metabolite levels;
LGG	cis	rs11676348	0.772	rs11687200	chr2:218944615	A/G	cg04731861	chr2:219085781	ARPC2	0.29	6.89	0.31	1.79e-11	Ulcerative colitis;
LGG	cis	rs12579753	0.719	rs10862377	chr12:82270172	C/T	cg07988820	chr12:82153109	PPFIA2	-0.55	-8.03	-0.35	8e-15	Resting heart rate;
LGG	cis	rs1793639	0.902	rs7937152	chr11:131936494	A/G	cg13908476	chr11:131942942	NTM	-0.4	-8.32	-0.36	1.01e-15	Myopia;
LGG	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg08975724	chr8:8085496	FLJ10661	0.4	7.73	0.34	6.78e-14	Mood instability;
LGG	cis	rs1519814	1.000	rs4871041	chr8:121136584	C/T	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs4851254	0.550	rs13402289	chr2:100659389	C/T	cg17356467	chr2:100759845	AFF3	0.43	7.21	0.32	2.26e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.905	rs4433149	chr8:10249268	A/T	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.61	-0.47	1.62e-27	Neuroticism;
LGG	cis	rs9660992	0.547	rs12143121	chr1:205199142	A/G	cg21545522	chr1:205238299	TMCC2	0.41	7.82	0.34	3.62e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7929679	0.571	rs10768100	chr11:34798935	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.89	0.3	1.84e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs236352	0.576	rs2116447	chr6:36837364	T/C	cg03410223	chr6:36853544	C6orf89	0.43	8.26	0.36	1.58e-15	Heart rate;
LGG	cis	rs208520	1.000	rs72880045	chr6:66965232	A/C	cg07460842	chr6:66804631	NA	0.9	14.82	0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs9420907	0.579	rs2756116	chr10:105671804	A/G	cg11005552	chr10:105648138	OBFC1	0.64	6.81	0.3	3.13e-11	Telomere length;
LGG	cis	rs17376456	0.825	rs6898842	chr5:93213221	T/C	cg25358565	chr5:93447407	FAM172A	1.27	15.59	0.59	2.31e-44	Diabetic retinopathy;
LGG	cis	rs4746818	0.901	rs10740317	chr10:70937566	G/A	cg11621586	chr10:70884670	VPS26A	1.14	16.23	0.6	3.37e-47	Left atrial antero-posterior diameter;
LGG	cis	rs559928	0.569	rs7103915	chr11:63944370	A/G	cg05555928	chr11:63887634	MACROD1	0.74	9.75	0.41	1.47e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs7824557	0.806	rs7007394	chr8:11094566	G/A	cg02002194	chr4:3960332	NA	0.47	8.38	0.36	6.29e-16	Retinal vascular caliber;
LGG	cis	rs497273	0.512	rs1177585	chr12:121325321	C/T	cg02419362	chr12:121203948	SPPL3	-0.48	-8.36	-0.36	7.34e-16	Systemic lupus erythematosus;
LGG	cis	rs1059312	0.772	rs11609637	chr12:129300202	T/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.65	-0.69	1.18e-67	Systemic lupus erythematosus;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01840575	chr2:38977957	SFRS7	0.4	6.88	0.3	2.01e-11	Bipolar disorder;
LGG	cis	rs34599045	0.522	rs12758478	chr1:152999973	T/G	cg07796016	chr1:152779584	LCE1C	-0.88	-7.95	-0.35	1.4e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6076065	0.707	rs1419007	chr20:23336895	T/C	cg12633918	chr20:23549525	CST9L	-0.34	-6.9	-0.31	1.69e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg02187348	chr16:89574699	SPG7	0.58	9.73	0.41	1.69e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs4639966	0.836	rs7110526	chr11:118633533	T/C	cg19182353	chr11:118479428	PHLDB1	-0.53	-8.67	-0.37	7.18e-17	Systemic lupus erythematosus;
LGG	trans	rs6787172	0.622	rs9880806	chr3:158116453	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg27432699	chr2:27873401	GPN1	-0.49	-8.29	-0.36	1.2e-15	Total body bone mineral density;
LGG	trans	rs9393777	0.778	rs13219354	chr6:27185664	T/C	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.81	-0.41	9.31e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7100689	0.577	rs2342813	chr10:82046302	T/G	cg01528321	chr10:82214614	TSPAN14	0.82	14.36	0.56	5.94e-39	Post bronchodilator FEV1;
LGG	cis	rs6087990	0.735	rs2424915	chr20:31378448	C/T	cg13636640	chr20:31349939	DNMT3B	0.79	16.14	0.6	8.33e-47	Ulcerative colitis;
LGG	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg00031303	chr3:195681400	NA	-0.45	-6.85	-0.3	2.4e-11	Mean corpuscular volume;
LGG	cis	rs975722	0.543	rs10252350	chr7:116998882	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.39	-8.51	-0.37	2.37e-16	Coronary artery disease;
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.11	-0.35	4.53e-15	Personality dimensions;
LGG	cis	rs7666738	0.830	rs9992639	chr4:98940400	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	6.12e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1577917	0.958	rs34765423	chr6:86484448	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.83	-14.73	-0.56	1.5e-40	Response to antipsychotic treatment;
LGG	cis	rs62400317	0.859	rs55964727	chr6:45259079	A/C	cg20913747	chr6:44695427	NA	-0.61	-10.26	-0.43	2.15e-22	Total body bone mineral density;
LGG	cis	rs2735413	0.750	rs60659587	chr16:78071554	G/T	cg04733911	chr16:78082701	NA	0.61	9.87	0.42	5.79e-21	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2735413	0.632	rs4436790	chr16:78097252	G/A	cg04733911	chr16:78082701	NA	0.7	14.92	0.57	2.17e-41	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg14926445	chr8:58193284	C8orf71	-0.87	-13.12	-0.52	1.19e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs12210905	1.000	rs115268625	chr6:26948229	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.19	-0.36	2.5e-15	Hip circumference adjusted for BMI;
LGG	cis	rs7568458	0.811	rs1446668	chr2:85764960	G/T	cg23752985	chr2:85803571	VAMP8	0.39	7.56	0.33	2.24e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs877282	0.945	rs10904556	chr10:789429	A/G	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs2075371	1.000	rs2544211	chr7:133973230	A/G	cg20476274	chr7:133979776	SLC35B4	0.76	15.19	0.58	1.41e-42	Mean platelet volume;
LGG	cis	rs7937682	0.889	rs7926485	chr11:111536670	G/A	cg22437258	chr11:111473054	SIK2	0.56	9.76	0.41	1.39e-20	Primary sclerosing cholangitis;
LGG	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg03254818	chr6:169586852	NA	0.6	8.65	0.37	8.85e-17	Pulse pressure;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg05861140	chr6:150128134	PCMT1	-0.42	-9.67	-0.41	2.91e-20	Lung cancer;
LGG	cis	rs240764	0.853	rs2398132	chr6:100981200	A/C	cg21058520	chr6:100914733	NA	0.43	7.56	0.33	2.24e-13	Neuroticism;
LGG	cis	rs6089584	0.925	rs35683654	chr20:60625401	G/T	cg06470251	chr20:60548479	NA	-0.51	-8.16	-0.35	3.12e-15	Body mass index;
LGG	cis	rs3096299	0.933	rs3096297	chr16:89453155	T/G	cg02187348	chr16:89574699	SPG7	0.45	7.29	0.32	1.39e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.81	12.73	0.51	4.92e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11074306	0.561	rs9806200	chr15:28073654	G/A	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs9682041	0.597	rs62295834	chr3:170075701	G/A	cg11886554	chr3:170076028	SKIL	0.54	7.06	0.31	6.13e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs6964587	0.967	rs7788092	chr7:91646198	C/T	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs4789693	0.546	rs7220204	chr17:80376130	T/A	cg19579500	chr17:80346614	NA	0.51	8.93	0.38	1.02e-17	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs12282928	0.743	rs10769324	chr11:48213515	A/C	cg20307385	chr11:47447363	PSMC3	-0.42	-6.92	-0.31	1.52e-11	Migraine - clinic-based;
LGG	cis	rs700651	0.685	rs976180	chr2:198880443	C/T	cg00792783	chr2:198669748	PLCL1	-0.65	-10.26	-0.43	2.19e-22	Intracranial aneurysm;
LGG	cis	rs751728	1.000	rs943477	chr6:33750931	T/C	cg25922239	chr6:33757077	LEMD2	0.7	12.27	0.5	3.81e-30	Crohn's disease;
LGG	cis	rs2073300	0.609	rs6132605	chr20:23354839	A/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs701145	0.556	rs355779	chr3:153977253	T/C	cg17054900	chr3:154042577	DHX36	0.48	7.33	0.32	1.01e-12	Coronary artery disease;
LGG	cis	rs2235573	0.527	rs139887	chr22:38371396	G/C	cg19171272	chr22:38449367	NA	-0.49	-8.86	-0.38	1.68e-17	Glioblastoma;Glioma;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg23202291	chr11:1979235	NA	0.37	7.16	0.32	3.13e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs62238980	0.614	rs79667666	chr22:32396346	T/G	cg02631450	chr22:32366979	NA	0.99	9.55	0.41	7.42e-20	Childhood ear infection;
LGG	trans	rs34421088	0.678	rs35928010	chr8:11591876	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-7.27	-0.32	1.49e-12	Neuroticism;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18633432	chr3:135915556	MSL2	0.43	6.94	0.31	1.37e-11	Cognitive performance;
LGG	cis	rs10464366	0.544	rs1525799	chr7:39153131	C/G	cg15212455	chr7:39170539	POU6F2	-0.49	-11.67	-0.48	8.79e-28	IgG glycosylation;
LGG	cis	rs774359	0.789	rs17779457	chr9:27488092	G/T	cg14173147	chr9:27528300	MOBKL2B	-0.48	-9.39	-0.4	2.75e-19	Amyotrophic lateral sclerosis;
LGG	trans	rs6089829	0.962	rs6062777	chr20:61663748	G/A	cg23505145	chr19:12996616	KLF1	0.4	7.14	0.31	3.56e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7618501	0.633	rs9861216	chr3:50059339	A/G	cg24110177	chr3:50126178	RBM5	0.57	10.46	0.44	3.79e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2239547	0.657	rs7620706	chr3:52891756	A/T	cg11645453	chr3:52864694	ITIH4	0.73	11.28	0.46	3.16e-26	Schizophrenia;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12893668	0.667	rs71417869	chr14:104077434	A/G	cg23335576	chr14:104009727	NA	0.49	8.52	0.37	2.28e-16	Reticulocyte count;
LGG	cis	rs4650994	1.000	rs17276513	chr1:178520604	A/T	cg19399532	chr1:178512495	C1orf220	-0.39	-7.53	-0.33	2.72e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7166081	1.000	rs12915085	chr15:67522138	C/G	cg05925327	chr15:68127851	NA	-0.31	-6.68	-0.3	6.72e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1461503	0.838	rs7107012	chr11:122829813	G/A	cg27398637	chr11:122830231	C11orf63	-0.74	-15.35	-0.58	2.74e-43	Menarche (age at onset);
LGG	cis	rs944722	0.839	rs8073631	chr17:26104547	C/T	cg07704981	chr17:26127537	NOS2	-0.57	-10.03	-0.42	1.49e-21	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs11148252	0.669	rs61958050	chr13:52994427	A/C	cg00761968	chr13:53314142	LECT1	-0.4	-8.06	-0.35	6.54e-15	Lewy body disease;
LGG	trans	rs9467711	0.606	rs72836482	chr6:26359241	A/T	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7914558	1.000	rs943038	chr10:104826261	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.69	0.44	5.43e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2011503	0.739	rs4808973	chr19:19725456	A/G	cg11584989	chr19:19387371	SF4	-0.61	-9.56	-0.41	6.91e-20	Bipolar disorder;
LGG	cis	rs10791097	0.694	rs2236717	chr11:130739887	G/T	cg09137382	chr11:130731461	NA	0.35	6.81	0.3	3.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4478037	0.643	rs9875798	chr3:33120448	G/C	cg19404215	chr3:33155277	CRTAP	0.82	9.55	0.41	7.4e-20	Major depressive disorder;
LGG	cis	rs765787	0.530	rs4442750	chr15:45535328	G/T	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Lung cancer in ever smokers;
LGG	cis	rs947211	1.000	rs1775151	chr1:205745684	C/T	cg07157834	chr1:205819609	PM20D1	0.41	6.94	0.31	1.31e-11	Parkinson's disease;
LGG	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg08564027	chr20:61660810	NA	1.02	25.58	0.77	1.28e-90	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs826838	1.000	rs11168218	chr12:38884466	A/G	cg26384229	chr12:38710491	ALG10B	1.06	28.18	0.79	1.71e-102	Heart rate;
LGG	cis	rs62238980	0.614	rs10483162	chr22:32394890	G/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.7	12.51	0.5	3.97e-31	Obesity-related traits;
LGG	cis	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg21775007	chr8:11205619	TDH	-0.78	-13.55	-0.53	1.88e-35	Retinal vascular caliber;
LGG	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg23173402	chr1:227635558	NA	0.49	8.39	0.36	5.92e-16	Major depressive disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08793459	chr17:57784647	PTRH2;TMEM49	0.45	7.39	0.32	6.77e-13	Cognitive performance;
LGG	cis	rs8028313	0.630	rs16951105	chr15:67965694	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.39	-7.48	-0.33	3.77e-13	Obesity;
LGG	cis	rs10791097	0.694	rs876641	chr11:130752040	A/C	cg09137382	chr11:130731461	NA	0.36	6.84	0.3	2.46e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4665809	1.000	rs750451	chr2:26324241	G/A	cg22920501	chr2:26401640	FAM59B	-0.39	-7.72	-0.34	7.04e-14	Gut microbiome composition (summer);
LGG	cis	rs11608355	0.597	rs7300290	chr12:109832545	T/G	cg19025524	chr12:109796872	NA	-0.58	-12.89	-0.51	1.11e-32	Neuroticism;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs801193	0.967	rs3800823	chr7:66147110	C/A	cg11764359	chr7:65958608	NA	-0.62	-10.36	-0.43	8.93e-23	Aortic root size;
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg04025307	chr7:1156635	C7orf50	0.64	8.31	0.36	1.09e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7394190	0.748	rs11000766	chr10:75512952	C/T	cg07699608	chr10:75541558	CHCHD1	0.54	7.05	0.31	6.43e-12	Incident atrial fibrillation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23821755	chr1:173684675	KLHL20	0.46	6.98	0.31	1.01e-11	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.526	rs7748404	chr6:8472500	A/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.01	0.39	5.24e-18	Motion sickness;
LGG	cis	rs875971	0.862	rs6460307	chr7:66060871	A/G	cg18252515	chr7:66147081	NA	-0.42	-7.2	-0.32	2.44e-12	Aortic root size;
LGG	cis	rs12476592	0.602	rs4671516	chr2:63790555	G/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg04568710	chr12:38710424	ALG10B	-0.34	-7.42	-0.33	5.54e-13	Bladder cancer;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg27418500	chr2:123758682	NA	0.32	7.31	0.32	1.2e-12	Pancreatic cancer;
LGG	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.76	-0.3	4.18e-11	Total body bone mineral density;
LGG	cis	rs13395090	0.606	rs13405419	chr2:3720664	T/C	cg15327641	chr2:3715039	ALLC	0.34	7.32	0.32	1.13e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs7577696	0.785	rs6723154	chr2:32365161	C/T	cg02381751	chr2:32503542	YIPF4	-0.41	-6.65	-0.3	8.22e-11	Inflammatory biomarkers;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10224655	chr1:6053295	NPHP4	-0.34	-6.77	-0.3	4.02e-11	Pancreatic cancer;
LGG	cis	rs17376456	0.877	rs10044139	chr5:93407803	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.25	0.39	8.5e-19	Diabetic retinopathy;
LGG	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.44	7.5	0.33	3.37e-13	Colorectal cancer;
LGG	cis	rs7084402	0.934	rs1649051	chr10:60321997	A/G	cg09696939	chr10:60272079	BICC1	-0.43	-8.23	-0.36	1.93e-15	Refractive error;
LGG	cis	rs9814567	0.806	rs2888670	chr3:134326684	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.09	-0.46	1.73e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs11098499	0.865	rs11722183	chr4:120280597	A/C	cg25214090	chr10:38739885	LOC399744	0.67	11.97	0.49	5.72e-29	Corneal astigmatism;
LGG	cis	rs6988985	0.728	rs7003782	chr8:143974828	C/T	cg10324643	chr8:143916377	GML	0.41	8.06	0.35	6.49e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7927592	0.956	rs2155730	chr11:68329474	T/C	cg01657329	chr11:68192670	LRP5	-0.48	-8.38	-0.36	6.52e-16	Total body bone mineral density;
LGG	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.94	0.49	7.95e-29	Rheumatoid arthritis;
LGG	cis	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg19847130	chr8:10466454	RP1L1	-0.32	-6.96	-0.31	1.2e-11	Neuroticism;
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg05091796	chr16:4465799	CORO7	0.61	9.97	0.42	2.37e-21	Schizophrenia;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg22907277	chr7:1156413	C7orf50	0.67	8.68	0.37	6.74e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7659604	0.518	rs17452156	chr4:122733623	T/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.27e-27	Type 2 diabetes;
LGG	cis	rs7474896	0.559	rs1024202	chr10:38278977	A/C	cg00409905	chr10:38381863	ZNF37A	0.45	6.66	0.3	7.6e-11	Obesity (extreme);
LGG	cis	rs473651	0.935	rs35080527	chr2:239351387	T/C	cg18131467	chr2:239335373	ASB1	1.02	23.5	0.74	5.69e-81	Multiple system atrophy;
LGG	trans	rs9929218	1.000	rs12446407	chr16:68804068	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.83	-0.51	1.93e-32	Colorectal cancer;
LGG	cis	rs9906944	0.707	rs9916472	chr17:47109998	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.79	-0.3	3.34e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs72634258	0.842	rs7545677	chr1:8165619	C/T	cg00042356	chr1:8021962	PARK7	0.56	8.19	0.36	2.52e-15	Inflammatory bowel disease;
LGG	cis	rs4700695	1.000	rs12518359	chr5:65397909	T/C	cg21114390	chr5:65439923	SFRS12	-0.56	-7.24	-0.32	1.89e-12	Facial morphology (factor 19);
LGG	cis	rs4132509	1.000	rs12116882	chr1:243959106	G/A	cg21452805	chr1:244014465	NA	0.67	7.99	0.35	1.07e-14	RR interval (heart rate);
LGG	cis	rs4319547	0.698	rs4039670	chr12:122822655	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-16.82	-0.62	7.03e-50	Body mass index;
LGG	cis	rs2739330	0.685	rs4822453	chr22:24254862	G/T	cg09033563	chr22:24373618	LOC391322	-0.48	-7.91	-0.34	1.95e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg17951613	chr5:131705445	SLC22A5	0.64	7.25	0.32	1.75e-12	Rheumatoid arthritis;
LGG	cis	rs2836974	0.604	rs2854727	chr21:40713787	A/G	cg11644478	chr21:40555479	PSMG1	0.65	10.84	0.45	1.5e-24	Cognitive function;
LGG	cis	rs3824867	0.920	rs7107853	chr11:47453518	T/C	cg20307385	chr11:47447363	PSMC3	-0.46	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin;
LGG	cis	rs11992162	0.613	rs6601634	chr8:11806456	T/C	cg00262122	chr8:11665843	FDFT1	-0.43	-6.92	-0.31	1.54e-11	Monocyte count;
LGG	cis	rs6933660	0.646	rs9383899	chr6:151781022	G/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.58	-9.75	-0.41	1.48e-20	Menarche (age at onset);
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg22398616	chr13:53314203	LECT1	-0.55	-12.06	-0.49	2.62e-29	Lewy body disease;
LGG	trans	rs9325144	0.600	rs10785615	chr12:38733627	G/C	cg23762105	chr12:34175262	ALG10	-0.33	-6.71	-0.3	5.76e-11	Morning vs. evening chronotype;
LGG	cis	rs2693698	0.590	rs3850422	chr14:99671788	C/T	cg07440398	chr14:99712966	BCL11B	0.57	12.13	0.49	1.35e-29	Schizophrenia;
LGG	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg13010199	chr12:38710504	ALG10B	0.72	14.79	0.57	7.95e-41	Bladder cancer;
LGG	cis	rs912057	0.965	rs1294415	chr6:6740633	G/A	cg06612196	chr6:6737390	NA	0.46	9.1	0.39	2.67e-18	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs4969178	0.622	rs11657987	chr17:76387363	G/T	cg20026190	chr17:76395443	PGS1	0.44	7.49	0.33	3.57e-13	HDL cholesterol levels;
LGG	cis	rs11997175	0.550	rs10105616	chr8:33786830	G/A	ch.8.33884649F	chr8:33765107	NA	0.39	7.47	0.33	4.15e-13	Body mass index;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs68170813	0.559	rs12534676	chr7:106943640	G/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.55	-0.44	1.88e-23	Coronary artery disease;
LGG	cis	rs1788820	0.917	rs1788785	chr18:21142340	T/C	cg14672496	chr18:21087552	C18orf8	0.38	6.96	0.31	1.14e-11	Body mass index;
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.72e-18	Aortic root size;
LGG	cis	rs8067545	0.611	rs2526466	chr17:20165251	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.52	0.33	2.92e-13	Schizophrenia;
LGG	cis	rs4604732	0.588	rs4925552	chr1:247631749	C/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.92	0.38	1.05e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs12135191	0.900	rs7552553	chr1:236471682	G/A	cg21399712	chr1:236511386	NA	-0.41	-7.82	-0.34	3.67e-14	Urate levels (BMI interaction);
LGG	trans	rs62103177	0.535	rs4799109	chr18:77675188	A/T	cg14227996	chr4:17616232	MED28	0.72	8.46	0.37	3.65e-16	Opioid sensitivity;
LGG	cis	rs2130392	0.962	rs35613786	chr4:185625657	A/G	cg04058563	chr4:185651563	MLF1IP	-0.45	-9.66	-0.41	3.03e-20	Kawasaki disease;
LGG	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg08885076	chr2:99613938	TSGA10	-0.56	-10.27	-0.43	2.04e-22	Chronic sinus infection;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg17227014	chr4:6642450	MRFAP1	0.41	7.0	0.31	9.11e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs972578	0.765	rs5759007	chr22:43274283	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.95e-11	Mean platelet volume;
LGG	trans	rs11875185	0.510	rs35614123	chr18:55634701	G/A	cg15513957	chr14:69354734	ACTN1	-0.94	-8.85	-0.38	1.85e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs72781680	0.716	rs78332127	chr2:24150163	C/G	cg08917208	chr2:24149416	ATAD2B	0.66	8.67	0.37	7.33e-17	Lymphocyte counts;
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg08677398	chr8:58056175	NA	0.59	9.16	0.39	1.64e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg12395012	chr8:11607386	GATA4	0.39	7.08	0.31	5.22e-12	Neuroticism;
LGG	cis	rs2933343	0.729	rs1680781	chr3:128612830	C/A	cg25356066	chr3:128598488	ACAD9	0.48	7.22	0.32	2.17e-12	IgG glycosylation;
LGG	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg19223190	chr17:80058835	NA	-0.45	-8.84	-0.38	1.94e-17	Life satisfaction;
LGG	cis	rs10504229	1.000	rs17217033	chr8:58180061	G/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg00405596	chr8:11794950	NA	-0.42	-6.66	-0.3	7.98e-11	Myopia (pathological);
LGG	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg01620082	chr3:125678407	NA	-0.66	-7.39	-0.32	6.69e-13	Depression;
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.44	0.33	4.96e-13	Lung cancer;
LGG	cis	rs138880	0.542	rs9616371	chr22:50306338	G/A	cg02269571	chr22:50332266	NA	-0.79	-9.71	-0.41	1.99e-20	Schizophrenia;
LGG	cis	rs1915146	0.546	rs1715862	chr10:126856255	C/T	cg23000734	chr10:126850823	CTBP2	-0.25	-7.26	-0.32	1.67e-12	Menarche (age at onset);
LGG	cis	rs7918232	0.882	rs788237	chr10:27457932	C/T	cg14240646	chr10:27532245	ACBD5	0.74	10.22	0.43	2.96e-22	Breast cancer;
LGG	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs9611565	0.559	rs8139993	chr22:41995335	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.27	-0.46	3.5e-26	Vitiligo;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg23129478	chr18:44337922	ST8SIA5	0.37	6.94	0.31	1.29e-11	Personality dimensions;
LGG	cis	rs8014204	0.804	rs35769520	chr14:75255115	G/A	cg06637938	chr14:75390232	RPS6KL1	0.76	15.17	0.58	1.71e-42	Caffeine consumption;
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg08280861	chr8:58055591	NA	0.64	7.87	0.34	2.58e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs16944613	0.541	rs4288973	chr15:91093676	G/A	cg26821196	chr15:91095069	CRTC3	0.57	8.6	0.37	1.2e-16	Colorectal cancer;
LGG	cis	rs9354308	0.764	rs9345705	chr6:66586504	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs2084898	0.891	rs504976	chr11:120000233	C/A	cg07435449	chr11:120005650	TRIM29	0.69	8.35	0.36	7.73e-16	Stroke (pediatric);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27467005	chr19:17622279	PGLS	0.51	8.36	0.36	7.46e-16	Cognitive performance;
LGG	cis	rs2762353	0.603	rs10946798	chr6:25781853	T/G	cg18357526	chr6:26021779	HIST1H4A	-0.48	-7.88	-0.34	2.39e-14	Blood metabolite levels;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.55	10.04	0.42	1.38e-21	Longevity;
LGG	cis	rs864537	0.676	rs2988279	chr1:167419839	G/A	cg09179987	chr1:167433047	CD247	0.41	8.88	0.38	1.47e-17	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs8014204	0.604	rs11159109	chr14:75389074	G/A	cg06637938	chr14:75390232	RPS6KL1	1.08	26.5	0.78	7.65e-95	Caffeine consumption;
LGG	cis	rs10850519	0.751	rs7980016	chr12:115949328	C/T	cg18639984	chr12:115943877	NA	-0.41	-8.93	-0.38	9.73e-18	Diastolic blood pressure;
LGG	cis	rs9916302	0.904	rs4511574	chr17:37532916	A/G	cg00129232	chr17:37814104	STARD3	-0.56	-9.84	-0.42	7.04e-21	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23058863	chr14:24610866	FAM158A	0.46	6.92	0.31	1.53e-11	Gut microbiome composition (summer);
LGG	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.2	-0.32	2.4e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7572263	0.724	rs11883992	chr2:209047468	A/T	cg00164906	chr2:209055251	C2orf80	-0.69	-9.34	-0.4	4.14e-19	Glioma;Non-glioblastoma glioma;
LGG	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg09845145	chr15:78292470	TBC1D2B	0.61	9.42	0.4	2.07e-19	Coronary artery disease or large artery stroke;
LGG	cis	rs13191362	0.935	rs13219926	chr6:163004213	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.57e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs908922	0.887	rs4596895	chr1:152528075	T/G	cg20991723	chr1:152506922	NA	-0.57	-9.51	-0.4	1.02e-19	Hair morphology;
LGG	trans	rs7939886	0.920	rs76934983	chr11:55993334	A/C	cg03929089	chr4:120376271	NA	0.74	6.69	0.3	6.44e-11	Myopia (pathological);
LGG	cis	rs7582180	0.613	rs12988464	chr2:100946285	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.54	-0.47	2.99e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.24	0.46	4.39e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4478858	0.735	rs2889730	chr1:31827159	C/T	cg19084893	chr1:31688959	NA	0.31	6.69	0.3	6.63e-11	Alcohol dependence;
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18876405	chr7:65276391	NA	0.55	9.87	0.42	5.41e-21	Aortic root size;
LGG	cis	rs1552244	1.000	rs35220123	chr3:10083169	C/T	cg08888203	chr3:10149979	C3orf24	0.57	9.79	0.41	1.11e-20	Alzheimer's disease;
LGG	cis	rs2342371	0.848	rs7433483	chr3:196217038	C/T	cg15048948	chr3:196158458	UBXN7	-0.42	-7.11	-0.31	4.48e-12	Fat distribution (HIV);
LGG	cis	rs941408	1.000	rs1736176	chr19:2790394	G/A	cg06609049	chr19:2785107	THOP1	0.63	9.81	0.41	9.12e-21	Total cholesterol levels;
LGG	cis	rs2836974	0.831	rs2836921	chr21:40516070	C/T	cg17971929	chr21:40555470	PSMG1	0.87	15.81	0.59	2.57e-45	Cognitive function;
LGG	cis	rs2011503	1.000	rs34667451	chr19:19617017	C/T	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs11225247	0.881	rs12274405	chr11:102259295	C/T	cg06323957	chr11:102217781	BIRC2	0.82	7.21	0.32	2.36e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.1	-0.31	4.8e-12	Iron status biomarkers;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-7.99	-0.35	1.06e-14	IgG glycosylation;
LGG	cis	rs10751667	0.666	rs7394992	chr11:980690	G/C	cg22143635	chr11:980567	AP2A2	0.44	8.12	0.35	4.22e-15	Alzheimer's disease (late onset);
LGG	cis	rs4268898	0.679	rs2543666	chr2:24446042	C/T	cg06627628	chr2:24431161	ITSN2	0.72	11.81	0.48	2.57e-28	Asthma;
LGG	cis	rs17208368	0.628	rs2129366	chr16:55098616	A/G	cg09947736	chr16:55091198	NA	0.68	13.06	0.52	2.1e-33	Hypospadias;
LGG	cis	rs6952808	0.792	rs13224989	chr7:1953766	C/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.96	-0.54	3.24e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27511599	chr7:32358540	NA	0.64	7.12	0.31	4.18e-12	Body mass index;
LGG	cis	rs17270561	0.609	rs6924794	chr6:25735874	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs7998202	0.667	rs388382	chr13:113353999	G/T	cg17218041	chr13:113365319	ATP11A	-0.44	-7.41	-0.33	6.04e-13	Glycated hemoglobin levels;
LGG	cis	rs2180341	0.960	rs3756996	chr6:127664258	G/C	cg24812749	chr6:127587940	RNF146	0.97	16.03	0.6	2.45e-46	Breast cancer;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg05863683	chr7:1912471	MAD1L1	0.43	8.04	0.35	7.5e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs11088226	0.692	rs7510418	chr21:33890258	G/A	cg09050820	chr6:167586206	TCP10L2	0.48	7.45	0.33	4.65e-13	Gastritis;
LGG	cis	rs11771526	0.686	rs62457463	chr7:32289856	C/T	cg27532318	chr7:32358331	NA	0.73	7.45	0.33	4.56e-13	Body mass index;
LGG	trans	rs1814175	0.559	rs1818892	chr11:49863084	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.7	-0.68	3.47e-63	Height;
LGG	cis	rs17376456	0.825	rs6865441	chr5:93284746	G/A	cg25358565	chr5:93447407	FAM172A	1.28	15.76	0.59	4.27e-45	Diabetic retinopathy;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg01059449	chr18:44338099	ST8SIA5	0.37	7.94	0.35	1.55e-14	Personality dimensions;
LGG	cis	rs4132509	0.895	rs12045787	chr1:244011843	T/A	cg21452805	chr1:244014465	NA	0.68	7.88	0.34	2.29e-14	RR interval (heart rate);
LGG	cis	rs10883723	0.810	rs2296588	chr10:104248087	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.89	0.57	2.93e-41	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.73e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs1799949	1.000	rs4340367	chr17:41307772	G/A	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	trans	rs6787172	0.622	rs4679828	chr3:158132588	A/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.44	-0.33	4.91e-13	Subjective well-being;
LGG	cis	rs12188164	1.000	rs34453673	chr5:434722	G/C	cg00976097	chr5:421733	AHRR	-0.42	-7.06	-0.31	6.1e-12	Cystic fibrosis severity;
LGG	cis	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs12681287	0.517	rs7462883	chr8:87526790	G/A	cg27223183	chr8:87520930	FAM82B	-0.49	-7.41	-0.33	6.18e-13	Caudate activity during reward;
LGG	cis	rs9308731	1.000	rs13396983	chr2:111900598	A/G	cg26001287	chr2:111877753	BCL2L11	-0.39	-7.85	-0.34	2.82e-14	Chronic lymphocytic leukemia;
LGG	trans	rs9329221	0.741	rs58689676	chr8:9806492	T/C	cg21775007	chr8:11205619	TDH	-0.51	-7.87	-0.34	2.61e-14	Neuroticism;
LGG	cis	rs7527798	0.592	rs960087	chr1:207826858	C/G	cg09232269	chr1:207846808	CR1L	-0.37	-6.98	-0.31	1.03e-11	Erythrocyte sedimentation rate;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.76	-0.48	4.07e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs1838472	0.607	rs9844005	chr3:123979763	G/A	cg05766129	chr3:123988013	KALRN	0.4	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs9948	1.000	rs9973492	chr2:97498481	T/A	cg01990225	chr2:97406019	LMAN2L	-0.62	-6.99	-0.31	9.39e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4481887	0.927	rs4453080	chr1:248474671	T/C	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26894438	chr17:15902633	ZSWIM7;TTC19	0.58	6.85	0.3	2.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs516946	1.000	rs35273426	chr8:41524688	C/T	cg01678292	chr8:41522873	ANK1	0.35	8.2	0.36	2.47e-15	Type 2 diabetes;
LGG	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg01557791	chr16:72042693	DHODH	-0.4	-6.67	-0.3	7.09e-11	Coronary artery disease;
LGG	cis	rs4805272	0.512	rs8105613	chr19:29339151	C/T	cg12756686	chr19:29218302	NA	0.62	8.24	0.36	1.83e-15	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.639	rs17331850	chr8:58113538	G/T	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs4292985	chr1:248473692	T/A	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs6964587	1.000	rs36120033	chr7:91679298	G/A	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.75e-16	Breast cancer;
LGG	cis	rs17767392	0.957	rs7140354	chr14:71759616	C/A	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	trans	rs6582630	0.555	rs4601853	chr12:38435569	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	8.15e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg09264619	chr17:80180166	NA	0.35	7.03	0.31	7.42e-12	Life satisfaction;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs17401966	0.838	rs10864449	chr1:10296922	A/T	cg15208524	chr1:10270712	KIF1B	0.45	7.87	0.34	2.54e-14	Hepatocellular carcinoma;
LGG	cis	rs35306767	0.903	rs11253504	chr10:956046	A/G	cg25019033	chr10:957182	NA	-0.63	-12.06	-0.49	2.65e-29	Eosinophil percentage of granulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26788993	chr3:159706828	IL12A	0.45	7.68	0.34	9.36e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs1639906	0.895	rs35038526	chr7:2213106	A/G	cg20308403	chr7:2120281	MAD1L1	-0.36	-7.48	-0.33	3.73e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9534288	0.742	rs1022953	chr13:46649126	G/T	cg15192986	chr13:46630673	CPB2	-0.69	-14.56	-0.56	8e-40	Blood protein levels;
LGG	cis	rs2708377	0.858	rs73051630	chr12:11147188	G/A	cg10857884	chr12:11139710	TAS2R50;PRR4;PRH1	0.46	6.93	0.31	1.39e-11	Bitter taste perception;
LGG	cis	rs9326248	0.559	rs12808524	chr11:116890993	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.72	0.45	4.38e-24	Blood protein levels;
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg19673125	chr6:150240577	RAET1G	0.37	9.09	0.39	3e-18	Testicular germ cell tumor;
LGG	cis	rs1949733	1.000	rs868105	chr4:8501030	G/T	cg13073564	chr4:8508604	NA	0.6	12.05	0.49	2.88e-29	Response to antineoplastic agents;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs1519814	0.696	rs2139439	chr8:121037091	A/G	cg22335954	chr8:121166405	COL14A1	-0.51	-9.06	-0.39	3.81e-18	Breast cancer;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.45	-0.5	6.93e-31	Lymphocyte counts;
LGG	cis	rs916888	0.821	rs199506	chr17:44859031	A/G	cg17911788	chr17:44343683	NA	-0.58	-8.92	-0.38	1.1e-17	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs73787773	0.629	rs6594564	chr5:111467814	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	0.53	7.01	0.31	8.48e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs2070488	1.000	rs1002676	chr3:38444932	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.4	-0.63	1.48e-52	Electrocardiographic conduction measures;
LGG	trans	rs116095464	0.510	rs55750776	chr5:230467	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.4e-15	Breast cancer;
LGG	trans	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs876084	0.505	rs4431629	chr8:121108668	C/T	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs8078723	0.668	rs3859191	chr17:38128714	G/A	cg17467752	chr17:38218738	THRA	0.59	10.69	0.44	5.64e-24	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs240764	0.817	rs239247	chr6:101088350	T/C	cg09795085	chr6:101329169	ASCC3	0.46	7.69	0.34	9.15e-14	Neuroticism;
LGG	cis	rs2658782	0.756	rs3019205	chr11:93109553	A/G	cg15737290	chr11:93063684	CCDC67	0.51	7.75	0.34	5.79e-14	Pulmonary function decline;
LGG	cis	rs765787	0.530	rs4775844	chr15:45542048	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg06634786	chr22:41940651	POLR3H	-0.61	-9.41	-0.4	2.38e-19	Vitiligo;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg02018176	chr4:1364513	KIAA1530	0.41	9.4	0.4	2.49e-19	Obesity-related traits;
LGG	cis	rs2153535	0.542	rs9378553	chr6:8472632	T/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03264133	chr6:25882463	NA	-0.64	-11.65	-0.48	1.14e-27	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.737	rs175510	chr14:75524839	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.53	-9.65	-0.41	3.36e-20	Height;
LGG	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.76	0.3	4.13e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7084402	0.967	rs1649048	chr10:60324282	C/T	cg09696939	chr10:60272079	BICC1	-0.36	-6.92	-0.31	1.54e-11	Refractive error;
LGG	cis	rs972578	0.692	rs4822217	chr22:43278162	T/C	cg01576275	chr22:43409880	NA	-0.23	-7.07	-0.31	5.82e-12	Mean platelet volume;
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg07677032	chr17:61819896	STRADA	-0.58	-10.14	-0.43	5.84e-22	Prudent dietary pattern;
LGG	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.92	0.38	1.06e-17	Neuroticism;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9914544	0.564	rs9907723	chr17:18758853	T/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.7	-0.34	8.46e-14	Educational attainment (years of education);
LGG	cis	rs9644630	0.696	rs35736969	chr8:19319620	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.41	8.21	0.36	2.15e-15	Oropharynx cancer;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg14789911	chr21:47582049	C21orf56	-0.41	-7.04	-0.31	6.93e-12	Testicular germ cell tumor;
LGG	cis	rs7833790	0.724	rs6473309	chr8:82707880	A/G	cg06027949	chr8:82754900	SNX16	-0.55	-8.65	-0.37	8.35e-17	Diastolic blood pressure;
LGG	cis	rs7236492	0.872	rs78538334	chr18:77223322	G/A	cg15532942	chr18:77220712	NFATC1	0.46	7.43	0.33	5.46e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9926296	0.656	rs11861084	chr16:89875710	G/T	cg26513180	chr16:89883248	FANCA	-0.65	-12.41	-0.5	9.9e-31	Vitiligo;
LGG	cis	rs3096299	0.809	rs2911264	chr16:89499272	A/C	cg06640241	chr16:89574553	SPG7	0.73	12.48	0.5	5.15e-31	Multiple myeloma (IgH translocation);
LGG	cis	rs8017423	0.647	rs12587362	chr14:90821227	G/T	cg04374321	chr14:90722782	PSMC1	-0.64	-12.72	-0.51	5.33e-32	Mortality in heart failure;
LGG	cis	rs7084402	1.000	rs1863665	chr10:60266640	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-17.57	-0.63	2.41e-53	Refractive error;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23700044	chr10:98945809	SLIT1	0.54	8.69	0.37	6.36e-17	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs2504143	chr10:38383706	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9309473	0.950	rs7567585	chr2:73751966	G/A	cg20560298	chr2:73613845	ALMS1	-0.48	-7.97	-0.35	1.25e-14	Metabolite levels;
LGG	cis	rs11764590	0.715	rs56289396	chr7:2091415	G/A	cg23422044	chr7:1970798	MAD1L1	-0.6	-9.23	-0.39	9.59e-19	Neuroticism;
LGG	cis	rs2120019	1.000	rs12901243	chr15:75374233	C/T	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.77	-0.68	1.57e-63	Blood trace element (Zn levels);
LGG	cis	rs17818399	0.510	rs1451153	chr2:46799852	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.42	7.11	0.31	4.46e-12	Height;
LGG	cis	rs1153858	1.000	rs4775911	chr15:45649787	G/T	cg10760299	chr15:45669010	GATM	-0.4	-8.05	-0.35	7.3e-15	Homoarginine levels;
LGG	cis	rs4919087	1.000	rs3740512	chr10:99078745	C/T	cg25902810	chr10:99078978	FRAT1	0.52	9.68	0.41	2.68e-20	Monocyte count;
LGG	cis	rs10256972	0.869	rs4720158	chr7:1040325	A/G	cg04025307	chr7:1156635	C7orf50	0.45	7.91	0.34	1.94e-14	Longevity;Endometriosis;
LGG	trans	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	2.11e-13	Menarche (age at onset);
LGG	cis	rs189798	0.592	rs10111263	chr8:8969433	C/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.7	-0.41	2.27e-20	Myopia (pathological);
LGG	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-10.8	-0.45	2.2e-24	Hemoglobin concentration;
LGG	cis	rs7223966	1.000	rs7222060	chr17:61868279	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.93e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs208520	0.779	rs208451	chr6:66906155	G/A	cg07460842	chr6:66804631	NA	-0.93	-15.1	-0.57	3.38e-42	Exhaled nitric oxide output;
LGG	cis	rs1799949	0.965	rs799916	chr17:41243190	G/T	cg24607181	chr17:41446203	NA	0.28	6.64	0.3	8.62e-11	Menopause (age at onset);
LGG	cis	rs68170813	0.652	rs17482494	chr7:107168487	T/C	cg02696742	chr7:106810147	HBP1	-0.66	-8.34	-0.36	8.83e-16	Coronary artery disease;
LGG	cis	rs4788570	0.566	rs8051439	chr16:71495793	A/T	cg06353428	chr16:71660113	MARVELD3	-0.86	-11.95	-0.49	6.97e-29	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.773	rs199445	chr17:44817408	C/T	cg07870213	chr5:140052090	DND1	0.93	17.62	0.63	1.45e-53	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7582180	0.591	rs2241810	chr2:101011877	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-15.97	-0.6	4.56e-46	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.776	rs4820346	chr22:39125074	C/G	cg06022373	chr22:39101656	GTPBP1	-0.79	-14.93	-0.57	1.96e-41	Menopause (age at onset);
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7727544	0.606	rs2631360	chr5:131707429	A/G	cg24060327	chr5:131705240	SLC22A5	-0.41	-6.96	-0.31	1.17e-11	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg23758822	chr17:41437982	NA	-0.72	-12.34	-0.5	1.94e-30	Menopause (age at onset);
LGG	cis	rs9814567	0.806	rs6799543	chr3:134216139	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.88	-0.51	1.14e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3806843	0.966	rs12659129	chr5:140147248	T/C	cg19875535	chr5:140030758	IK	0.52	10.78	0.45	2.51e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs826838	0.678	rs11182781	chr12:38610178	C/T	cg04568710	chr12:38710424	ALG10B	0.34	6.85	0.3	2.42e-11	Heart rate;
LGG	cis	rs13082711	0.554	rs13087873	chr3:27392326	C/T	cg02860705	chr3:27208620	NA	0.9	16.08	0.6	1.59e-46	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.92	-0.31	1.48e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2050392	0.965	rs2265370	chr10:30690581	C/T	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.62	-0.44	1.01e-23	Inflammatory bowel disease;
LGG	cis	rs963731	0.579	rs297120	chr2:39308646	G/A	cg04010122	chr2:39346883	SOS1	-0.73	-7.56	-0.33	2.25e-13	Corticobasal degeneration;
LGG	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.22	0.32	2.18e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.4	-0.33	6.66e-13	Neuroticism;
LGG	cis	rs769267	0.929	rs2905421	chr19:19457908	G/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.65	0.33	1.21e-13	Tonsillectomy;
LGG	cis	rs12497850	1.000	rs1352420	chr3:48757291	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.4	7.05	0.31	6.65e-12	Parkinson's disease;
LGG	cis	rs7223966	0.921	rs11655493	chr17:61733052	C/T	cg05941027	chr17:61774174	LIMD2	0.38	9.56	0.41	7.03e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs17209837	0.607	rs1558376	chr7:87079103	T/A	cg25823085	chr7:87105416	ABCB4	0.3	7.35	0.32	8.96e-13	Gallbladder cancer;
LGG	cis	rs7208859	0.623	rs8068645	chr17:29104342	T/A	cg19761014	chr17:28927070	LRRC37B2	0.61	7.29	0.32	1.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs453301	0.624	rs330058	chr8:9089809	G/A	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.82	-0.38	2.43e-17	Joint mobility (Beighton score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03284175	chr1:146643471	PRKAB2	-0.47	-6.83	-0.3	2.64e-11	Systemic lupus erythematosus;
LGG	trans	rs7819412	0.806	rs2409689	chr8:10932868	A/G	cg06636001	chr8:8085503	FLJ10661	-0.58	-10.81	-0.45	2.02e-24	Triglycerides;
LGG	trans	rs11039798	0.920	rs7478904	chr11:48630323	C/T	cg03929089	chr4:120376271	NA	0.77	8.0	0.35	1.02e-14	Axial length;
LGG	cis	rs36051895	0.589	rs6476950	chr9:5218416	A/T	cg02405213	chr9:5042618	JAK2	-0.78	-14.22	-0.55	2.45e-38	Pediatric autoimmune diseases;
LGG	trans	rs35110281	0.715	rs2838353	chr21:45119228	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	9.06	0.39	3.8e-18	Mean corpuscular volume;
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg07234876	chr8:600039	NA	1.39	13.15	0.52	9.1e-34	IgG glycosylation;
LGG	cis	rs10791323	0.517	rs1120246	chr11:133745212	G/A	cg15485101	chr11:133734466	NA	0.44	7.65	0.33	1.17e-13	Childhood ear infection;
LGG	cis	rs17854409	0.803	rs1048100	chr20:61472073	C/A	cg05147244	chr20:61493195	TCFL5	0.79	7.55	0.33	2.41e-13	Obesity-related traits;
LGG	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg16060761	chr17:80687452	NA	-0.43	-7.54	-0.33	2.51e-13	Glycated hemoglobin levels;
LGG	cis	rs225245	0.817	rs225269	chr17:33967931	G/T	cg05299278	chr17:33885742	SLFN14	0.42	8.03	0.35	8.16e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4740619	0.740	rs7043770	chr9:15785919	A/G	cg14451791	chr9:16040625	NA	0.34	8.69	0.37	6.09e-17	Body mass index;
LGG	cis	rs9467711	0.659	rs36033628	chr6:26456074	T/G	cg12826209	chr6:26865740	GUSBL1	0.78	7.41	0.33	6.14e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09805943	chr6:69345293	BAI3	0.44	7.38	0.32	7.44e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg21911579	chr5:131705225	SLC22A5	0.7	7.77	0.34	5.18e-14	Rheumatoid arthritis;
LGG	cis	rs10463316	0.962	rs61647401	chr5:150743076	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.05	-0.42	1.25e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs7529073	0.815	rs1431983	chr1:214148772	A/C	cg24083324	chr1:214162604	PROX1	0.49	8.95	0.38	8.67e-18	Schizophrenia;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg07701084	chr6:150067640	NUP43	0.65	12.22	0.49	5.84e-30	Lung cancer;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg05036130	chr6:150231994	NA	0.33	6.67	0.3	7.24e-11	Testicular germ cell tumor;
LGG	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.16	-0.49	9.84e-30	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.24	-0.36	1.77e-15	Retinal vascular caliber;
LGG	cis	rs10462794	0.802	rs1562826	chr5:4510772	C/T	cg18482690	chr5:4511582	NA	0.41	7.24	0.32	1.84e-12	DNA methylation (variation);
LGG	cis	rs60871478	0.636	rs73045423	chr7:893952	G/A	cg13798912	chr7:905769	UNC84A	-0.58	-7.2	-0.32	2.45e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg21017887	chr14:105400489	NA	0.43	8.63	0.37	1.02e-16	Rheumatoid arthritis;
LGG	cis	rs524281	1.000	rs547087	chr11:65846264	A/G	cg16950941	chr11:66035639	RAB1B	0.49	7.71	0.34	7.98e-14	Electroencephalogram traits;
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg04891921	chr3:134514173	EPHB1	-0.5	-7.04	-0.31	6.9e-12	Lung cancer in ever smokers;
LGG	cis	rs6445975	0.578	rs6772652	chr3:58406693	A/G	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	trans	rs61931739	0.571	rs4001689	chr12:34243271	C/T	cg26384229	chr12:38710491	ALG10B	0.77	15.44	0.58	1.06e-43	Morning vs. evening chronotype;
LGG	cis	rs7216064	0.734	rs11653507	chr17:65892064	A/T	cg12091567	chr17:66097778	LOC651250	-0.47	-7.5	-0.33	3.37e-13	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs5742933	0.711	rs12693551	chr2:190529231	T/C	cg04003228	chr2:190539410	ANKAR	-0.52	-7.53	-0.33	2.65e-13	Ferritin levels;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06475006	chr16:89985975	MC1R	-0.6	-7.12	-0.31	4.2e-12	Skin colour saturation;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.52	0.37	2.23e-16	Personality dimensions;
LGG	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg13047869	chr3:10149882	C3orf24	0.53	8.75	0.38	3.93e-17	Alzheimer's disease;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.77	0.41	1.3e-20	Schizophrenia;
LGG	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03517284	chr6:25882590	NA	0.54	10.28	0.43	1.75e-22	Blood metabolite levels;
LGG	cis	rs7086627	0.506	rs10749575	chr10:82136921	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	11.95	0.49	7.32e-29	Post bronchodilator FEV1;
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.45	0.33	4.68e-13	Alzheimer's disease;
LGG	cis	rs6938	0.534	rs11854704	chr15:75221015	C/T	cg14664628	chr15:75095509	CSK	-0.54	-10.37	-0.43	8.27e-23	Breast cancer;
LGG	cis	rs1003719	0.523	rs1063949	chr21:38574675	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-14.82	-0.57	5.76e-41	Eye color traits;
LGG	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg11941060	chr3:133502564	NA	-0.53	-9.22	-0.39	1.07e-18	Iron status biomarkers;
LGG	cis	rs10256972	0.567	rs2949185	chr7:1209013	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.34	-0.53	1.37e-34	Longevity;Endometriosis;
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg26150922	chr2:100937072	LONRF2	-0.58	-10.98	-0.45	4.33e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.65	-0.3	8.31e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs6752107	0.967	rs3792111	chr2:234179690	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.9	0.34	2.05e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3020736	0.500	rs28791586	chr22:42500483	A/G	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2290402	0.572	rs3736087	chr4:876318	C/T	cg00846425	chr4:957561	DGKQ	-0.43	-6.79	-0.3	3.55e-11	Type 2 diabetes;
LGG	cis	rs3749237	1.000	rs11920900	chr3:49823024	G/C	cg07636037	chr3:49044803	WDR6	0.46	7.04	0.31	7.11e-12	Resting heart rate;
LGG	cis	rs7633857	0.512	rs7611005	chr3:160698549	A/T	cg03342759	chr3:160939853	NMD3	-0.58	-9.77	-0.41	1.22e-20	Educational attainment (years of education);
LGG	cis	rs4780401	0.609	rs4781141	chr16:11808769	A/C	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.91	-0.51	8.9e-33	Rheumatoid arthritis;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg18404041	chr3:52824283	ITIH1	0.52	10.35	0.43	1.01e-22	Bipolar disorder;
LGG	cis	rs1691799	0.899	rs1168307	chr12:66739539	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.82	-0.59	2.29e-45	White blood cell count (basophil);
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs4803468	0.967	rs3213860	chr19:41920211	T/C	cg14132834	chr19:41945861	ATP5SL	-0.49	-9.43	-0.4	2e-19	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13826264	chr9:125240147	OR1J1	0.37	6.88	0.3	1.97e-11	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.867	rs2255440	chr15:43830467	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	9.56	0.41	7.09e-20	Lung cancer in ever smokers;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg23587005	chr12:9600941	DDX12	-0.44	-6.82	-0.3	2.88e-11	Coronary artery disease;
LGG	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.29	-0.6	1.8e-47	Calcium levels;
LGG	cis	rs868036	0.645	rs4776987	chr15:68123915	A/T	cg02273617	chr15:68117586	LBXCOR1	0.34	7.53	0.33	2.59e-13	Restless legs syndrome;
LGG	cis	rs798554	0.686	rs7777484	chr7:2814271	A/G	cg19524238	chr7:2802976	GNA12	0.31	7.7	0.34	8.51e-14	Height;
LGG	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg16584290	chr5:462447	EXOC3	0.45	9.06	0.39	3.74e-18	Cystic fibrosis severity;
LGG	cis	rs1881396	0.947	rs10173720	chr2:27855397	A/T	cg27432699	chr2:27873401	GPN1	-0.53	-8.43	-0.36	4.28e-16	Nonalcoholic fatty liver disease;
LGG	trans	rs11039798	0.557	rs4436575	chr11:48398894	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.94	-0.42	3.09e-21	Axial length;
LGG	cis	rs4975616	0.804	rs381949	chr5:1322468	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.63	-11.16	-0.46	8.63e-26	Lung cancer;
LGG	cis	rs11122272	0.735	rs2808586	chr1:231515559	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs2797369	0.766	rs61596767	chr6:101596167	G/C	cg27451362	chr6:101846650	GRIK2	0.82	10.83	0.45	1.63e-24	Renal function-related traits (eGRFcrea);
LGG	cis	rs870825	0.616	rs6817521	chr4:185649827	A/G	cg04058563	chr4:185651563	MLF1IP	-0.92	-18.82	-0.66	4.4e-59	Blood protein levels;
LGG	cis	rs6445975	0.666	rs9817356	chr3:58335573	C/T	cg24175188	chr3:58374923	PXK	0.54	8.73	0.38	4.51e-17	Systemic lupus erythematosus;
LGG	cis	rs17376456	0.877	rs12374463	chr5:93483569	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.33	0.43	1.19e-22	Diabetic retinopathy;
LGG	cis	rs9948	0.655	rs62156221	chr2:97410850	A/G	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.81	-0.34	3.79e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg10587741	chr22:38071170	LGALS1	0.6	13.81	0.54	1.43e-36	Fat distribution (HIV);
LGG	cis	rs3858526	0.628	rs1840177	chr11:5944627	T/G	cg02574844	chr11:5959923	NA	0.59	10.14	0.43	5.69e-22	DNA methylation (variation);
LGG	cis	rs798554	1.000	rs798559	chr7:2758341	T/C	cg18446336	chr7:2847575	GNA12	-0.31	-7.24	-0.32	1.84e-12	Height;
LGG	cis	rs1163251	0.902	rs487081	chr1:120217389	G/A	cg19096424	chr1:120255104	PHGDH	0.63	11.0	0.46	3.55e-25	Blood metabolite levels;
LGG	cis	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs911263	0.603	rs11627646	chr14:68809564	A/T	cg18825221	chr14:68749962	RAD51L1	-0.36	-7.82	-0.34	3.55e-14	Primary biliary cholangitis;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg06656553	chr16:89960601	TCF25	-0.61	-6.83	-0.3	2.72e-11	Skin colour saturation;
LGG	cis	rs9916302	0.561	rs12453198	chr17:37741879	T/C	cg07936489	chr17:37558343	FBXL20	-0.77	-10.88	-0.45	1.02e-24	Glomerular filtration rate (creatinine);
LGG	cis	rs5758659	0.569	rs133294	chr22:42382805	C/T	cg15128208	chr22:42549153	NA	-0.4	-7.77	-0.34	5.15e-14	Cognitive function;
LGG	trans	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg26384229	chr12:38710491	ALG10B	0.85	18.51	0.65	1.17e-57	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs2035494	chr17:29130393	T/G	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg14416269	chr4:6271139	WFS1	0.5	9.18	0.39	1.44e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs116095464	1.000	rs10475185	chr5:306981	C/T	cg22857025	chr5:266934	NA	-1.38	-12.92	-0.51	8.07e-33	Breast cancer;
LGG	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg22467129	chr15:76604101	ETFA	-0.46	-7.78	-0.34	4.76e-14	Blood metabolite levels;
LGG	cis	rs2028299	0.839	rs3844575	chr15:90443747	A/G	cg23731826	chr15:90371692	NA	0.35	7.89	0.34	2.18e-14	Type 2 diabetes;
LGG	trans	rs61931739	0.534	rs11053072	chr12:34202399	A/C	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.96e-46	Morning vs. evening chronotype;
LGG	cis	rs981844	0.890	rs55917677	chr4:154701051	C/T	cg14289246	chr4:154710475	SFRP2	0.74	12.01	0.49	4.14e-29	Response to statins (LDL cholesterol change);
LGG	cis	rs12493885	0.654	rs61793488	chr3:153730551	T/C	cg12800244	chr3:153838788	SGEF	-0.8	-8.96	-0.38	8.18e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12824058	0.844	rs7956408	chr12:130807547	A/T	cg24229701	chr12:130821962	PIWIL1	-0.41	-7.2	-0.32	2.53e-12	Menopause (age at onset);
LGG	cis	rs10779751	1.000	rs718206	chr1:11294474	T/A	cg08854313	chr1:11322531	MTOR	0.74	16.1	0.6	1.2e-46	Body mass index;
LGG	cis	rs7527798	0.592	rs12119104	chr1:207861207	A/G	cg09232269	chr1:207846808	CR1L	-0.38	-7.19	-0.32	2.69e-12	Erythrocyte sedimentation rate;
LGG	cis	rs4926611	0.698	rs4307514	chr1:54060248	T/C	cg23596471	chr1:54105337	GLIS1	-0.41	-8.32	-0.36	9.88e-16	Hand grip strength;
LGG	cis	rs7582720	1.000	rs72936873	chr2:203791333	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs875971	1.000	rs6963646	chr7:65685767	T/C	cg23594656	chr7:65796392	TPST1	0.39	8.5	0.37	2.58e-16	Aortic root size;
LGG	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs3808502	0.526	rs11783065	chr8:11417257	A/G	cg19847130	chr8:10466454	RP1L1	0.31	6.9	0.31	1.74e-11	Neuroticism;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg11245990	chr11:68621969	NA	0.41	8.71	0.38	5.26e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02319142	chr5:149339858	SLC26A2	0.4	6.81	0.3	3.09e-11	Cognitive performance;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg08742575	chr21:47604166	C21orf56	-0.55	-9.83	-0.42	7.96e-21	Testicular germ cell tumor;
LGG	cis	rs13191362	1.000	rs67025553	chr6:163011552	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.1	0.35	4.78e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10905065	0.862	rs9423948	chr10:5742491	G/A	cg11519256	chr10:5708881	ASB13	0.43	7.55	0.33	2.37e-13	Menopause (age at onset);
LGG	cis	rs2762353	0.845	rs1937130	chr6:25787554	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.21	-0.39	1.12e-18	Blood metabolite levels;
LGG	cis	rs10991814	0.920	rs78704969	chr9:94118523	C/T	cg14446406	chr9:93919335	NA	-0.74	-8.29	-0.36	1.21e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs1153858	1.000	rs16942568	chr15:45677390	T/C	cg10760299	chr15:45669010	GATM	0.41	8.04	0.35	7.46e-15	Homoarginine levels;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs6601327	0.550	rs4422774	chr8:9522011	A/G	cg16141378	chr3:129829833	LOC729375	0.39	8.45	0.37	3.9e-16	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13177180	0.602	rs256939	chr5:114868238	G/A	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.32	-6.84	-0.3	2.54e-11	Conotruncal heart defects (inherited effects);
LGG	cis	rs930421	0.544	rs4953653	chr2:42989159	C/T	cg14631114	chr2:43023945	NA	0.43	9.21	0.39	1.16e-18	Attention deficit hyperactivity disorder;
LGG	cis	rs79349575	0.870	rs12941262	chr17:46967037	T/A	cg22482690	chr17:47019901	SNF8	0.34	6.71	0.3	5.74e-11	Type 2 diabetes;
LGG	cis	rs561341	1.000	rs483301	chr17:30293398	G/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.63	0.59	1.59e-44	Obesity-related traits;
LGG	cis	rs7937612	1.000	rs894839	chr11:120337705	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.7	-0.51	6.61e-32	Intraocular pressure;
LGG	cis	rs13132184	0.507	rs12645411	chr4:38044516	T/C	cg24826020	chr4:38070998	TBC1D1	0.5	8.5	0.37	2.54e-16	Verbal declarative memory;
LGG	trans	rs970548	0.643	rs7080474	chr10:45931899	C/T	cg14222797	chr10:16859974	RSU1	-0.55	-6.79	-0.3	3.36e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs644799	0.582	rs473157	chr11:95596874	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	12.76	0.51	3.65e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2694528	0.844	rs4541610	chr5:60065941	A/C	cg11474532	chr5:59995715	DEPDC1B	-0.74	-7.85	-0.34	2.88e-14	Parkinson's disease;
LGG	cis	rs2439831	0.867	rs2447208	chr15:43933895	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.58	0.41	5.93e-20	Lung cancer in ever smokers;
LGG	cis	rs12541335	0.639	rs6993855	chr8:22163797	A/G	cg09517075	chr8:22133004	PIWIL2	0.42	9.16	0.39	1.64e-18	Hypertriglyceridemia;
LGG	cis	rs9358372	0.609	rs10806924	chr6:20790509	A/G	cg13405222	chr6:20811065	CDKAL1	0.62	13.05	0.52	2.26e-33	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1109114	0.844	rs6871290	chr5:148642281	C/T	cg06539116	chr5:148597365	ABLIM3	-0.48	-11.52	-0.47	3.63e-27	Body mass index;
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.46	-0.4	1.56e-19	Personality dimensions;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg22842064	chr3:170588183	RPL22L1	0.43	7.3	0.32	1.22e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs1519814	0.696	rs2326430	chr8:121036898	G/A	cg22335954	chr8:121166405	COL14A1	-0.5	-8.99	-0.39	6.23e-18	Breast cancer;
LGG	cis	rs4629180	0.586	rs1159902	chr2:102133641	G/A	cg16435561	chr2:102091048	RFX8	0.47	8.8	0.38	2.76e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg17764715	chr19:33622953	WDR88	-0.56	-7.74	-0.34	6.34e-14	Bone properties (heel);
LGG	cis	rs1355223	0.902	rs12802120	chr11:34747650	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.01	-0.31	8.47e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2032447	0.670	rs198815	chr6:26127271	A/G	cg12310025	chr6:25882481	NA	0.49	9.09	0.39	2.94e-18	Intelligence (multi-trait analysis);
LGG	cis	rs17711722	0.583	rs10085415	chr7:65093568	T/A	cg11764359	chr7:65958608	NA	-0.54	-8.8	-0.38	2.64e-17	Calcium levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20620272	chr3:167968129	C3orf50	-0.4	-6.91	-0.31	1.64e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6061231	0.631	rs2427317	chr20:60975725	C/T	cg23531748	chr20:60969906	CABLES2	0.45	8.26	0.36	1.58e-15	Colorectal cancer;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg15242686	chr22:24348715	GSTTP1	0.4	7.44	0.33	4.83e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7613875	0.620	rs7624030	chr3:50071279	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.78	-0.3	3.73e-11	Body mass index;
LGG	cis	rs67133203	0.606	rs11169731	chr12:51561573	G/A	cg14688905	chr12:51403056	SLC11A2	0.63	9.52	0.4	9.41e-20	Urinary tract infection frequency;
LGG	cis	rs2645694	0.533	rs2645680	chr4:77820956	T/C	cg10057126	chr4:77819792	ANKRD56	0.37	6.96	0.31	1.16e-11	Emphysema distribution in smoking;
LGG	cis	rs4642101	0.597	rs9865624	chr3:12822786	T/A	cg24848339	chr3:12840334	CAND2	0.42	9.91	0.42	4.17e-21	QRS complex (12-leadsum);
LGG	cis	rs912057	0.671	rs1294428	chr6:6744623	A/G	cg06612196	chr6:6737390	NA	0.5	10.77	0.45	2.8e-24	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs34977459	1	rs34977459	chr22:21932653	GA/G	cg11654148	chr22:21984483	YDJC	-0.38	-7.48	-0.33	3.71e-13	Mean corpuscular hemoglobin;
LGG	cis	rs3126085	0.935	rs12409762	chr1:152175398	G/A	cg26876637	chr1:152193138	HRNR	-0.54	-8.66	-0.37	7.65e-17	Atopic dermatitis;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg10505658	chr17:80084571	CCDC57	-0.42	-8.48	-0.37	3.01e-16	Life satisfaction;
LGG	cis	rs1552244	0.882	rs17050699	chr3:10037167	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.35	0.4	3.79e-19	Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	6.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.616	rs6495307	chr15:78890321	C/T	cg22563815	chr15:78856949	CHRNA5	0.26	6.67	0.3	7.36e-11	Sudden cardiac arrest;
LGG	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg12773197	chr13:112238673	NA	-0.36	-7.3	-0.32	1.24e-12	Hepatitis;
LGG	cis	rs11209002	0.567	rs2755269	chr1:67541065	T/C	cg02640540	chr1:67518911	SLC35D1	0.39	6.65	0.3	8.13e-11	Crohn's disease;
LGG	cis	rs6466055	0.639	rs3823752	chr7:104624626	C/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.06	-0.31	6.08e-12	Schizophrenia;
LGG	cis	rs5769765	0.908	rs138864	chr22:50204712	G/A	cg02269571	chr22:50332266	NA	-0.57	-8.92	-0.38	1.08e-17	Schizophrenia;
LGG	cis	rs12477438	0.765	rs2309520	chr2:99570477	C/G	cg08885076	chr2:99613938	TSGA10	0.5	10.56	0.44	1.65e-23	Chronic sinus infection;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg00945932	chr8:28559273	EXTL3	0.47	7.19	0.32	2.56e-12	Hip circumference;
LGG	cis	rs6500395	1.000	rs4785536	chr16:48712980	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.34	-0.32	9.71e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg03806693	chr22:41940476	POLR3H	0.89	14.83	0.57	5.72e-41	Vitiligo;
LGG	cis	rs9341808	0.718	rs9352806	chr6:80980057	G/T	cg08355045	chr6:80787529	NA	0.39	7.58	0.33	1.94e-13	Sitting height ratio;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg16507663	chr6:150244633	RAET1G	0.42	7.81	0.34	3.79e-14	Lung cancer;
LGG	trans	rs1814175	0.645	rs1963215	chr11:49931486	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs3733585	0.604	rs73215003	chr4:10126317	C/G	cg25986240	chr4:9926439	SLC2A9	0.34	6.81	0.3	2.99e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4077515	0.967	rs10781500	chr9:139269338	A/G	cg21253087	chr9:139290292	SNAPC4	-0.33	-6.68	-0.3	6.89e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs68170813	0.559	rs75723759	chr7:106962407	A/G	cg02696742	chr7:106810147	HBP1	-0.73	-10.37	-0.43	8.86e-23	Coronary artery disease;
LGG	cis	rs3845702	0.736	rs72958863	chr2:180808144	C/T	cg01881094	chr2:180872142	CWC22	1.29	16.57	0.61	9.33e-49	Schizophrenia;
LGG	cis	rs713587	0.520	rs493090	chr2:25303772	G/A	cg04586622	chr2:25135609	ADCY3	-0.31	-7.72	-0.34	7.42e-14	Body mass index in non-asthmatics;
LGG	cis	rs4918072	0.667	rs1342212	chr10:105708813	A/C	cg11005552	chr10:105648138	OBFC1	0.45	8.03	0.35	8.36e-15	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs10850519	0.751	rs11067634	chr12:115949656	G/A	cg18639984	chr12:115943877	NA	-0.4	-8.58	-0.37	1.43e-16	Diastolic blood pressure;
LGG	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs2005108	1	rs2005108	chr11:102770353	C/T	cg14995062	chr11:102826570	MMP13	0.53	6.92	0.31	1.51e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs57221529	0.655	rs11948381	chr5:568413	A/T	cg01221209	chr5:554886	NA	-0.51	-8.18	-0.36	2.75e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs760805	1.000	rs10903115	chr1:25261696	A/G	cg03961551	chr1:25251730	RUNX3	0.45	11.98	0.49	5.51e-29	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6089829	0.962	rs6122344	chr20:61661738	C/T	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs9329221	0.623	rs7825778	chr8:10261010	C/T	cg02002194	chr4:3960332	NA	0.4	7.0	0.31	9.02e-12	Neuroticism;
LGG	trans	rs2980439	0.525	rs1850511	chr8:8170329	T/A	cg16141378	chr3:129829833	LOC729375	-0.41	-9.96	-0.42	2.61e-21	Neuroticism;
LGG	cis	rs883565	0.611	rs4676588	chr3:38940741	C/T	cg01426195	chr3:39028469	NA	0.51	9.4	0.4	2.49e-19	Handedness;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.51	0.4	1.02e-19	Obesity-related traits;
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg05793240	chr7:2802953	GNA12	0.33	7.92	0.35	1.77e-14	Height;
LGG	cis	rs758324	0.947	rs4705838	chr5:131150593	G/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.51e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1163251	0.837	rs611365	chr1:120242571	C/T	cg19096424	chr1:120255104	PHGDH	0.66	11.96	0.49	6.33e-29	Blood metabolite levels;
LGG	cis	rs9393692	0.557	rs9379845	chr6:26291601	C/T	cg13736514	chr6:26305472	NA	-0.49	-9.42	-0.4	2.21e-19	Educational attainment;
LGG	trans	rs12579753	0.917	rs10778833	chr12:82197983	G/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg15147215	chr3:52552868	STAB1	-0.38	-7.31	-0.32	1.2e-12	Electroencephalogram traits;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg16507663	chr6:150244633	RAET1G	0.42	7.92	0.35	1.73e-14	Lung cancer;
LGG	cis	rs4889855	0.545	rs61171555	chr17:78465975	T/G	cg16591659	chr17:78472290	NA	-0.4	-9.05	-0.39	4.06e-18	Fractional excretion of uric acid;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg07005078	chr4:17578674	LAP3	0.38	6.91	0.31	1.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs4650994	1.000	rs10913570	chr1:178523126	A/C	cg05059571	chr16:84539110	KIAA1609	-0.43	-7.97	-0.35	1.22e-14	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-7.11	-0.31	4.34e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg11494091	chr17:61959527	GH2	0.52	8.35	0.36	7.98e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6977660	0.507	rs72591449	chr7:19775443	T/C	cg05791153	chr7:19748676	TWISTNB	0.94	12.32	0.5	2.32e-30	Thyroid stimulating hormone;
LGG	cis	rs10934753	0.609	rs2077523	chr3:125905389	A/C	cg06827562	chr3:125932279	NA	0.51	12.21	0.49	6.58e-30	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs9926296	0.568	rs417323	chr16:89746277	T/G	cg04287289	chr16:89883240	FANCA	-0.44	-7.58	-0.33	1.95e-13	Vitiligo;
LGG	cis	rs11758351	0.660	rs55848726	chr6:26224434	T/C	cg01420254	chr6:26195488	NA	0.83	10.71	0.45	4.74e-24	Gout;Renal underexcretion gout;
LGG	trans	rs9944715	0.911	rs718513	chr18:43856267	C/G	cg01718231	chr17:29326311	RNF135	-0.42	-6.7	-0.3	6.25e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs950776	0.720	rs11637890	chr15:78935419	C/G	cg03762349	chr15:79060523	ADAMTS7	-0.32	-7.15	-0.32	3.47e-12	Sudden cardiac arrest;
LGG	cis	rs9815354	1.000	rs56158380	chr3:41885588	G/A	cg03022575	chr3:42003672	ULK4	0.72	9.07	0.39	3.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9768139	0.708	rs921616	chr7:158117960	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	20.21	0.68	1.36e-65	Calcium levels;
LGG	cis	rs894344	0.776	rs16905189	chr8:135598132	C/G	cg17885191	chr8:135476712	NA	0.41	7.07	0.31	5.85e-12	Systolic blood pressure;
LGG	cis	rs12780845	0.540	rs6602178	chr10:17180169	A/C	cg01003015	chr10:17271136	VIM	-0.43	-7.44	-0.33	4.88e-13	Homocysteine levels;
LGG	cis	rs4969178	0.930	rs12452576	chr17:76386037	A/C	cg20026190	chr17:76395443	PGS1	0.57	9.98	0.42	2.17e-21	HDL cholesterol levels;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg27411982	chr8:10470053	RP1L1	0.38	6.66	0.3	7.79e-11	Systolic blood pressure;
LGG	cis	rs60180747	0.909	rs28684409	chr15:66794706	T/C	cg07575407	chr15:66541975	MEGF11	0.39	7.29	0.32	1.33e-12	Testicular germ cell tumor;
LGG	cis	rs4478037	1.000	rs58995409	chr3:33161404	T/C	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs6909430	0.901	rs2029242	chr6:98587906	A/G	cg12860156	chr6:98744658	NA	-0.45	-7.59	-0.33	1.82e-13	Quantitative traits;
LGG	trans	rs1499614	0.831	rs3800822	chr7:66147149	A/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.5	-0.4	1.15e-19	Gout;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg01532694	chr8:8243576	NA	0.41	6.79	0.3	3.43e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg11941060	chr3:133502564	NA	-0.49	-8.35	-0.36	8.17e-16	Iron status biomarkers;
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.4	-0.36	5.49e-16	Aortic root size;
LGG	cis	rs1816752	0.870	rs3825449	chr13:25014441	A/C	cg02811702	chr13:24901961	NA	0.4	7.56	0.33	2.23e-13	Obesity-related traits;
LGG	cis	rs11758351	0.929	rs6906367	chr6:26187125	C/T	cg01420254	chr6:26195488	NA	0.63	9.24	0.39	8.84e-19	Gout;Renal underexcretion gout;
LGG	cis	rs11628318	0.805	rs749543	chr14:103057250	C/A	cg23461800	chr14:103021989	NA	-0.46	-8.4	-0.36	5.35e-16	Platelet count;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg00364696	chr7:1142433	C7orf50	-0.39	-7.63	-0.33	1.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.16	-0.43	4.98e-22	Lung cancer;
LGG	cis	rs9326248	0.539	rs10892065	chr11:116897024	T/C	cg20608306	chr11:116969690	SIK3	0.42	13.29	0.53	2.2e-34	Blood protein levels;
LGG	cis	rs2050392	0.767	rs10763787	chr10:30700753	G/A	cg25182066	chr10:30743637	MAP3K8	0.61	12.44	0.5	7.61e-31	Inflammatory bowel disease;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.58	9.81	0.41	9.51e-21	Lymphocyte counts;
LGG	cis	rs1003719	0.715	rs8130643	chr21:38551715	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.29	-0.58	5.1e-43	Eye color traits;
LGG	trans	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg10756647	chr7:56101905	PSPH	-0.8	-9.18	-0.39	1.43e-18	Diabetic kidney disease;
LGG	cis	rs4731207	0.698	rs17147496	chr7:124449868	G/A	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs6062302	0.545	rs2297430	chr20:62229244	T/C	cg16989086	chr20:62203971	PRIC285	0.47	6.92	0.31	1.47e-11	Glioblastoma;
LGG	cis	rs10197940	0.901	rs2290367	chr2:152266731	T/A	cg06191203	chr2:152266755	RIF1	-0.54	-10.15	-0.43	5.3e-22	Lung cancer;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg07414643	chr4:187882934	NA	0.55	11.4	0.47	1.1e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs875971	0.862	rs11773628	chr7:65982631	G/T	cg18252515	chr7:66147081	NA	0.41	6.88	0.3	1.99e-11	Aortic root size;
LGG	cis	rs1816752	0.666	rs7994022	chr13:25017230	A/G	cg22771759	chr13:24902376	NA	0.41	7.04	0.31	6.92e-12	Obesity-related traits;
LGG	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg20476274	chr7:133979776	SLC35B4	0.71	13.88	0.54	7.11e-37	Mean platelet volume;
LGG	cis	rs9916302	0.904	rs7501488	chr17:37576417	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.71	-0.59	7.19e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9388451	0.839	rs3966775	chr6:126067655	C/A	cg10911889	chr6:126070802	HEY2	0.44	7.59	0.33	1.73e-13	Brugada syndrome;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg19674350	chr21:43229429	PRDM15	0.38	6.78	0.3	3.66e-11	Body fat percentage;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.53	9.38	0.4	2.99e-19	Longevity;
LGG	cis	rs155076	1.000	rs566364	chr13:21837583	T/C	cg25811766	chr13:21894605	NA	-0.57	-7.48	-0.33	3.78e-13	White matter hyperintensity burden;
LGG	trans	rs2727020	0.688	rs11040338	chr11:49360601	A/G	cg11707556	chr5:10655725	ANKRD33B	0.5	9.72	0.41	1.86e-20	Coronary artery disease;
LGG	cis	rs11625487	0.957	rs10145540	chr14:77957354	C/T	cg20045696	chr14:77926864	AHSA1	-0.63	-8.33	-0.36	9.31e-16	Neutrophil percentage of white cells;Sum neutrophil eosinophil counts;Neutrophil count;
LGG	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg04226714	chr8:49833948	SNAI2	-0.44	-7.57	-0.33	2.01e-13	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11096990	0.634	rs7659894	chr4:39284435	G/A	cg24403649	chr4:39172243	NA	-0.39	-7.05	-0.31	6.72e-12	Cognitive function;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg20887711	chr4:1340912	KIAA1530	0.58	11.55	0.47	2.81e-27	Longevity;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs734999	1.000	rs2016366	chr1:2513678	A/T	cg15627072	chr1:2432621	PLCH2	0.42	10.29	0.43	1.66e-22	Ulcerative colitis;
LGG	cis	rs1062177	1.000	rs12653926	chr5:151250248	C/A	cg00977110	chr5:151150581	G3BP1	0.51	7.98	0.35	1.17e-14	Preschool internalizing problems;
LGG	cis	rs1218582	0.745	rs1580943	chr1:154865125	G/A	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.25	-0.32	1.74e-12	Prostate cancer;
LGG	cis	rs798766	1.000	rs4865467	chr4:1745500	G/T	cg00006948	chr4:1768889	NA	0.5	6.87	0.3	2.09e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg21775007	chr8:11205619	TDH	0.6	10.07	0.42	1.08e-21	Retinal vascular caliber;
LGG	cis	rs10089	1.000	rs3792866	chr5:127479900	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.87	0.48	1.54e-28	Ileal carcinoids;
LGG	trans	rs9784649	0.882	rs2201296	chr5:24967119	G/A	cg11038491	chr20:34638489	LOC647979	-0.54	-7.24	-0.32	1.87e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs751728	0.626	rs4711348	chr6:33736295	G/A	cg13560919	chr6:33536144	NA	-0.41	-7.24	-0.32	1.91e-12	Crohn's disease;
LGG	cis	rs72945132	0.882	rs60917762	chr11:70211384	C/T	cg14191688	chr11:70257035	CTTN	0.57	8.21	0.36	2.26e-15	Coronary artery disease;
LGG	cis	rs9911578	1.000	rs9898916	chr17:57048660	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.12	-0.43	7.11e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2644899	0.859	rs2545755	chr19:41293162	T/G	cg24958765	chr19:41283667	RAB4B	-0.52	-7.24	-0.32	1.89e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs858239	0.601	rs11984129	chr7:23152677	A/G	cg23682824	chr7:23144976	KLHL7	0.42	7.02	0.31	7.86e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs721917	0.525	rs2258874	chr10:81679156	C/T	cg25562619	chr10:81652821	NA	-0.35	-7.92	-0.35	1.83e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.44	0.4	1.85e-19	Bone mineral density;
LGG	cis	rs8014204	0.839	rs6574197	chr14:75331487	A/G	cg03030879	chr14:75389066	RPS6KL1	0.37	6.68	0.3	6.81e-11	Caffeine consumption;
LGG	cis	rs2760061	0.659	rs708107	chr1:228189495	C/T	cg02753203	chr1:228287806	NA	0.72	13.85	0.54	1.01e-36	Diastolic blood pressure;
LGG	cis	rs3806843	0.966	rs2563260	chr5:140137867	C/A	cg19875535	chr5:140030758	IK	-0.53	-11.03	-0.46	2.82e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11190604	0.747	rs11190516	chr10:102173525	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.06	0.31	6.08e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3020736	0.500	rs6002604	chr22:42493081	A/T	cg04733989	chr22:42467013	NAGA	-0.57	-10.26	-0.43	2.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3771570	0.901	rs10190033	chr2:242412358	A/C	cg21155796	chr2:242212141	HDLBP	0.59	8.11	0.35	4.7e-15	Prostate cancer;
LGG	cis	rs6879260	1.000	rs7725605	chr5:179732678	T/G	cg02891314	chr5:179741120	GFPT2	-0.63	-11.76	-0.48	3.94e-28	Height;
LGG	cis	rs7646881	0.812	rs113166116	chr3:158460256	C/T	cg19483011	chr3:158453295	NA	-0.59	-8.11	-0.35	4.46e-15	Tetralogy of Fallot;
LGG	cis	rs6496044	0.568	rs7166642	chr15:86061271	A/G	cg13263323	chr15:86062960	AKAP13	-0.37	-8.23	-0.36	1.86e-15	Interstitial lung disease;
LGG	cis	rs9325144	0.647	rs7957185	chr12:38909710	G/A	cg04568710	chr12:38710424	ALG10B	-0.4	-8.18	-0.36	2.86e-15	Morning vs. evening chronotype;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg02002194	chr4:3960332	NA	0.45	8.46	0.37	3.65e-16	Neuroticism;
LGG	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg03806693	chr22:41940476	POLR3H	-0.82	-14.38	-0.56	5.19e-39	Vitiligo;
LGG	cis	rs2273669	0.915	rs6651002	chr6:109318516	G/C	cg05315195	chr6:109294784	ARMC2	-0.48	-6.76	-0.3	4.21e-11	Prostate cancer;
LGG	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.59	7.76	0.34	5.29e-14	HIV-1 control;
LGG	cis	rs2916247	0.954	rs28475789	chr8:93128465	C/T	cg10183463	chr8:93005414	RUNX1T1	0.39	8.12	0.35	4.21e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10911232	0.507	rs4596846	chr1:182976034	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs7945718	0.839	rs2033908	chr11:12838286	G/T	cg25843174	chr11:12811716	TEAD1	0.37	7.45	0.33	4.73e-13	Educational attainment (years of education);
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.4e-12	Lung cancer;
LGG	cis	rs7296418	0.961	rs1790106	chr12:123591596	G/T	cg00376283	chr12:123451042	ABCB9	0.66	12.36	0.5	1.64e-30	Platelet count;
LGG	cis	rs11225247	0.764	rs78166284	chr11:102252087	A/G	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg21782813	chr7:2030301	MAD1L1	0.57	14.24	0.55	2.11e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs42648	0.869	rs1134956	chr7:89938680	C/T	cg25739043	chr7:89950458	NA	-0.44	-9.31	-0.4	4.97e-19	Homocysteine levels;
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.43	8.4	0.36	5.34e-16	Personality dimensions;
LGG	cis	rs798554	0.548	rs1639064	chr7:2896544	G/A	cg19717773	chr7:2847554	GNA12	-0.33	-7.62	-0.33	1.49e-13	Height;
LGG	cis	rs7618501	0.633	rs35065728	chr3:50009176	T/C	cg24110177	chr3:50126178	RBM5	-0.56	-10.38	-0.43	7.71e-23	Intelligence (multi-trait analysis);
LGG	cis	rs12580194	1.000	rs12580194	chr12:55696558	A/G	cg19537932	chr12:55886519	OR6C68	0.39	6.98	0.31	1e-11	Cancer;
LGG	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg01864069	chr14:103024347	NA	0.66	9.35	0.4	3.68e-19	Platelet count;
LGG	cis	rs7617773	0.539	rs1471217	chr3:48384895	A/C	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs6692729	0.966	rs1150897	chr1:227047249	A/G	cg08708961	chr1:227070630	PSEN2	-0.3	-7.49	-0.33	3.51e-13	Electrodermal activity;
LGG	cis	rs10929925	0.966	rs12105832	chr2:6157829	G/A	cg00493617	chr2:6141445	NA	0.32	7.17	0.32	2.97e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs1847202	0.927	rs13081361	chr3:72947895	T/C	cg25664220	chr3:72788482	NA	-0.25	-7.66	-0.34	1.06e-13	Motion sickness;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13433994	chr3:23958502	NKIRAS1;RPL15	0.47	6.85	0.3	2.38e-11	Hip circumference;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg01925397	chr22:45636477	C22orf9	-0.41	-6.81	-0.3	3.09e-11	Brain structure;
LGG	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Calcium levels;
LGG	cis	rs3008870	0.755	rs2755242	chr1:67479598	T/C	cg08660285	chr1:67390436	MIER1;WDR78	0.73	15.7	0.59	7.76e-45	Lymphocyte percentage of white cells;
LGG	cis	rs9443645	0.810	rs9448607	chr6:79715620	G/A	cg18132916	chr6:79620363	NA	-0.26	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	1.000	rs10457159	chr6:96993139	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.87	-0.45	1.17e-24	Migraine;Coronary artery disease;
LGG	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg02466173	chr16:30829666	NA	-0.47	-8.58	-0.37	1.45e-16	Dementia with Lewy bodies;
LGG	cis	rs6750047	0.587	rs2163454	chr2:38279170	A/C	cg07380506	chr2:38303506	CYP1B1	0.44	7.26	0.32	1.69e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs8067545	0.611	rs2526476	chr17:20134289	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.06	-0.42	1.13e-21	Schizophrenia;
LGG	cis	rs875971	0.830	rs6976714	chr7:65891461	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.95	0.31	1.23e-11	Aortic root size;
LGG	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg03609598	chr5:56110824	MAP3K1	-0.51	-7.66	-0.34	1.12e-13	Initial pursuit acceleration;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg14159672	chr1:205819179	PM20D1	0.77	16.48	0.61	2.4e-48	Menarche (age at onset);
LGG	cis	rs899997	0.862	rs11072787	chr15:78972977	T/C	cg17734273	chr15:78292508	TBC1D2B	0.3	6.84	0.3	2.53e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs228769	0.635	rs228754	chr17:42116056	C/A	cg09913183	chr17:42254507	C17orf65;ASB16	-0.52	-7.86	-0.34	2.77e-14	Bone mineral density (hip);Bone mineral density (spine);
LGG	trans	rs853679	0.599	rs149990	chr6:27998258	G/A	cg01620082	chr3:125678407	NA	-0.65	-7.2	-0.32	2.39e-12	Depression;
LGG	cis	rs6831352	0.918	rs2213035	chr4:100064233	G/A	cg12011299	chr4:100065546	ADH4	-0.43	-8.46	-0.37	3.46e-16	Alcohol dependence;
LGG	cis	rs4595586	0.545	rs2388179	chr12:39364036	T/A	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs9858542	0.953	rs11706370	chr3:49441091	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	4.91e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3768617	0.510	rs2296292	chr1:183086757	A/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs883565	0.718	rs1112438	chr3:39152345	G/A	cg01426195	chr3:39028469	NA	-0.54	-10.14	-0.43	5.85e-22	Handedness;
LGG	cis	rs2439831	0.717	rs28495368	chr15:43895642	G/A	cg15269541	chr15:43626905	ADAL	-0.43	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs4319547	0.956	rs7316149	chr12:123063912	G/A	cg23029597	chr12:123009494	RSRC2	-0.97	-18.8	-0.66	5.08e-59	Body mass index;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg21548813	chr6:291882	DUSP22	-0.75	-13.3	-0.53	1.98e-34	Menopause (age at onset);
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg17202724	chr17:61916730	SMARCD2	0.51	11.4	0.47	1.02e-26	Prudent dietary pattern;
LGG	cis	rs2721195	0.967	rs748195	chr8:145682514	T/C	cg15320075	chr8:145703422	NA	0.74	14.76	0.57	1.07e-40	Age at first birth;
LGG	cis	rs2013441	1.000	rs2703815	chr17:20118499	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.67	-0.3	7.11e-11	Obesity-related traits;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg16885296	chr6:26284938	NA	0.39	8.63	0.37	9.86e-17	Educational attainment;
LGG	trans	rs9409565	0.559	rs9409762	chr9:97215040	A/C	cg05679027	chr9:99775184	HIATL2	-0.44	-6.7	-0.3	6.02e-11	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs28386778	0.897	rs2597634	chr17:61878144	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs990171	1.000	rs917997	chr2:103070568	T/C	cg05295703	chr2:102895712	NA	-0.51	-8.92	-0.38	1.1e-17	Lymphocyte counts;
LGG	trans	rs7812879	0.636	rs2618456	chr8:11370733	G/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-7.1	-0.31	4.87e-12	Systemic lupus erythematosus;
LGG	cis	rs6951245	1.000	rs76833820	chr7:1070278	A/T	cg22907277	chr7:1156413	C7orf50	0.69	8.8	0.38	2.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs365132	1.000	rs2292255	chr5:176334195	C/T	cg16309518	chr5:176445507	NA	-0.55	-12.16	-0.49	1e-29	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg02972257	chr16:68554789	NA	-0.51	-7.36	-0.32	8.29e-13	Ulcerative colitis;
LGG	trans	rs225245	0.817	rs225302	chr17:33922396	C/T	cg19694781	chr19:47549865	TMEM160	-0.42	-7.09	-0.31	5.14e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9910055	0.659	rs6503488	chr17:42246158	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	10.87	0.45	1.17e-24	Total body bone mineral density;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg22535103	chr8:58192502	C8orf71	-0.98	-14.9	-0.57	2.64e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs60871478	0.730	rs13222476	chr7:826630	T/C	cg05535760	chr7:792225	HEATR2	0.96	14.52	0.56	1.18e-39	Cerebrospinal P-tau181p levels;
LGG	cis	rs2204008	0.712	rs12371182	chr12:38321143	A/C	cg13010199	chr12:38710504	ALG10B	0.71	14.26	0.55	1.71e-38	Bladder cancer;
LGG	cis	rs4819052	0.632	rs4819050	chr21:46692943	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.41	6.7	0.3	5.95e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17641971	0.619	rs7013425	chr8:49953085	G/A	cg00325661	chr8:49890786	NA	0.54	10.07	0.42	1.08e-21	Blood metabolite levels;
LGG	cis	rs10489167	1.000	rs489213	chr1:41166483	T/C	cg11417323	chr1:41160271	NFYC	-0.45	-7.06	-0.31	6.14e-12	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs62064224	0.720	rs8078837	chr17:30763537	A/G	cg18200150	chr17:30822561	MYO1D	0.8	18.86	0.66	2.68e-59	Schizophrenia;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.64	-11.12	-0.46	1.27e-25	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17274400	chr12:8234945	NECAP1	0.57	9.4	0.4	2.57e-19	Gut microbiome composition (summer);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg17386466	chr2:87035620	CD8A	0.45	6.93	0.31	1.44e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9399137	0.507	rs56164974	chr6:135288716	C/T	cg22676075	chr6:135203613	NA	0.45	7.69	0.34	8.67e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.96	-0.31	1.14e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10267417	0.603	rs6948539	chr7:19879812	C/T	cg07541023	chr7:19748670	TWISTNB	0.53	6.99	0.31	9.57e-12	Night sleep phenotypes;
LGG	cis	rs6495122	0.699	rs1378940	chr15:75083494	C/A	cg20040747	chr15:74715105	SEMA7A	0.39	8.51	0.37	2.46e-16	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1355223	1.000	rs35365094	chr11:34767790	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.39	-0.32	6.83e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs9467711	0.606	rs9393706	chr6:26361500	G/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs929596	0.574	rs75444879	chr2:234587848	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-10.09	-0.42	9.29e-22	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs1570884	0.767	rs3751384	chr13:50123622	G/C	cg11801959	chr13:50123613	RCBTB1	-0.39	-7.0	-0.31	8.96e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs6426551	1.000	rs7517174	chr1:226540327	A/C	cg27539482	chr13:111589090	NA	-0.49	-7.38	-0.32	7.16e-13	Coronary artery disease;
LGG	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg09137382	chr11:130731461	NA	0.35	6.77	0.3	3.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs6561151	0.681	rs17462017	chr13:44472235	C/T	cg12856521	chr11:46389249	DGKZ	0.98	14.42	0.56	3.5e-39	Crohn's disease;
LGG	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg25482853	chr8:67687455	SGK3	1.02	13.2	0.52	5.57e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.51	-0.33	3.15e-13	IgG glycosylation;
LGG	trans	rs11577318	1.000	rs11577318	chr1:26601570	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.43	-0.5	8.52e-31	Granulocyte percentage of myeloid white cells;
LGG	cis	rs10752881	0.809	rs3768613	chr1:183106296	G/C	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.39	8.38e-19	Colorectal cancer;
LGG	cis	rs2239547	0.603	rs9870898	chr3:53092375	A/G	cg11645453	chr3:52864694	ITIH4	0.65	9.92	0.42	3.72e-21	Schizophrenia;
LGG	cis	rs9926296	0.562	rs4785725	chr16:89893243	A/G	cg26513180	chr16:89883248	FANCA	0.65	12.11	0.49	1.69e-29	Vitiligo;
LGG	cis	rs1949733	0.877	rs940133	chr4:8473614	T/C	cg13073564	chr4:8508604	NA	-0.59	-11.35	-0.47	1.59e-26	Response to antineoplastic agents;
LGG	cis	rs10504229	0.775	rs17805074	chr8:58161048	C/T	cg21724239	chr8:58056113	NA	-0.6	-9.37	-0.4	3.32e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs17209837	0.607	rs11561963	chr7:87116550	T/A	cg00919237	chr7:87102261	ABCB4	-0.78	-15.11	-0.57	3.07e-42	Gallbladder cancer;
LGG	cis	rs4555082	0.834	rs2735825	chr14:105710900	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-16.05	-0.6	2.15e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7617773	0.817	rs9830016	chr3:48282494	A/G	cg11946769	chr3:48343235	NME6	0.6	9.91	0.42	3.88e-21	Coronary artery disease;
LGG	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg26384229	chr12:38710491	ALG10B	-0.65	-12.69	-0.51	6.97e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2404602	0.716	rs56351018	chr15:76824591	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs9818758	0.505	rs11716159	chr3:49631585	G/A	cg00383909	chr3:49044727	WDR6	1.12	13.3	0.53	2.02e-34	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg10122326	chr6:28072925	NA	0.87	7.55	0.33	2.34e-13	Parkinson's disease;
LGG	cis	rs7937682	0.632	rs11608193	chr11:111732215	T/C	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	cis	rs11758351	0.660	rs11753655	chr6:26220109	C/T	cg23601095	chr6:26197514	HIST1H3D	0.72	9.09	0.39	2.81e-18	Gout;Renal underexcretion gout;
LGG	cis	rs28595532	0.920	rs114093638	chr4:119729819	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg06634786	chr22:41940651	POLR3H	0.78	12.82	0.51	2.17e-32	Vitiligo;
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.8	-0.3	3.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12949688	1.000	rs7211686	chr17:55816300	T/C	cg12229367	chr17:55822335	NA	0.43	8.07	0.35	6.02e-15	Schizophrenia;
LGG	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.47	-0.37	3.17e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.78	14.21	0.55	2.7e-38	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs8077059	1.000	rs8067868	chr17:55824949	C/T	cg12582317	chr17:55822272	NA	-0.41	-7.47	-0.33	3.96e-13	Sex hormone-binding globulin levels;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.535	rs11717638	chr3:101505468	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.67	-0.34	9.93e-14	Colorectal cancer;
LGG	cis	rs2764208	0.526	rs2744948	chr6:34634953	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.45	-7.72	-0.34	7.19e-14	Systemic lupus erythematosus;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.67	0.41	2.85e-20	Schizophrenia;
LGG	cis	rs9303401	0.921	rs34102441	chr17:56877414	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.58	0.44	1.46e-23	Cognitive test performance;
LGG	cis	rs240764	0.578	rs723743	chr6:101237504	T/C	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	trans	rs11719291	0.915	rs1048940	chr3:48725707	C/T	cg21659725	chr3:3221576	CRBN	-0.72	-6.94	-0.31	1.33e-11	Cognitive function;
LGG	cis	rs2635047	0.967	rs2668779	chr18:44742066	C/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	8.92	0.38	1.08e-17	Educational attainment;
LGG	trans	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg07393940	chr7:158741817	NA	0.6	10.82	0.45	1.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2050392	0.590	rs2065723	chr10:30720462	A/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.32	-0.5	2.26e-30	Inflammatory bowel disease;
LGG	cis	rs7617773	0.707	rs13061269	chr3:48373343	C/T	cg11946769	chr3:48343235	NME6	0.71	11.83	0.48	2.23e-28	Coronary artery disease;
LGG	cis	rs977987	0.872	rs4887825	chr16:75472422	C/A	cg03315344	chr16:75512273	CHST6	0.5	10.0	0.42	1.89e-21	Dupuytren's disease;
LGG	cis	rs9300255	0.679	rs10772998	chr12:123721177	T/G	cg00376283	chr12:123451042	ABCB9	0.65	10.33	0.43	1.17e-22	Neutrophil percentage of white cells;
LGG	cis	rs7084402	0.967	rs2114564	chr10:60314729	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.15	-0.32	3.34e-12	Refractive error;
LGG	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg09307838	chr4:120376055	NA	0.8	13.36	0.53	1.15e-34	Corneal astigmatism;
LGG	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg12636538	chr11:118901039	SLC37A4	-0.66	-14.19	-0.55	3.33e-38	Coronary artery disease;
LGG	cis	rs2133450	0.526	rs17047058	chr3:7343176	T/C	cg19930620	chr3:7340148	GRM7	-0.42	-9.46	-0.4	1.58e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg06654118	chr4:1303317	MAEA	0.47	7.72	0.34	7.29e-14	Obesity-related traits;
LGG	cis	rs7208859	0.573	rs11654035	chr17:29136426	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.26	0.32	1.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6982240	0.514	rs72681579	chr8:142263074	G/A	cg20799268	chr8:142275649	NA	-0.25	-7.07	-0.31	5.82e-12	Tonsillectomy;
LGG	cis	rs929596	0.583	rs77070100	chr2:234587847	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.61	-10.4	-0.44	6.61e-23	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg25894440	chr7:65020034	NA	-0.63	-6.68	-0.3	6.68e-11	Diabetic kidney disease;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg17178900	chr1:205818956	PM20D1	0.55	12.17	0.49	9.21e-30	Menarche (age at onset);
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.49	-8.71	-0.38	5.45e-17	Obesity-related traits;
LGG	trans	rs2797160	0.651	rs9491503	chr6:126031682	G/A	cg05039488	chr6:79577232	IRAK1BP1	0.47	8.34	0.36	8.48e-16	Endometrial cancer;
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg01341218	chr17:43662625	NA	0.8	14.12	0.55	6.83e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4988958	0.525	rs3771159	chr2:103004958	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma (childhood onset);
LGG	cis	rs240764	0.746	rs240141	chr6:101084946	G/A	cg09795085	chr6:101329169	ASCC3	0.47	7.65	0.34	1.16e-13	Neuroticism;
LGG	cis	rs7818345	0.967	rs4549789	chr8:19284015	C/A	cg11303988	chr8:19266685	CSGALNACT1	0.39	6.75	0.3	4.36e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6665290	0.904	rs1045285	chr1:227179054	G/A	cg05696931	chr1:227175867	NA	-0.41	-7.96	-0.35	1.32e-14	Myeloid white cell count;
LGG	trans	rs7404843	0.778	rs72774864	chr16:15512322	A/G	cg02716450	chr16:28638775	NA	0.71	7.14	0.31	3.61e-12	Testicular germ cell tumor;
LGG	cis	rs533581	0.816	rs533406	chr16:88974860	A/G	cg08484992	chr16:88977278	CBFA2T3	0.3	7.13	0.31	3.81e-12	Social autistic-like traits;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg20366258	chr2:113404078	SLC20A1	-0.41	-6.89	-0.3	1.86e-11	Iris color (L* coordinate);
LGG	cis	rs10979	0.679	rs35914889	chr6:143886392	A/T	cg25407410	chr6:143891975	LOC285740	-0.62	-10.07	-0.42	1.11e-21	Hypospadias;
LGG	cis	rs9314323	0.767	rs7012604	chr8:26204089	G/A	cg11498726	chr8:26250323	BNIP3L	-0.52	-10.77	-0.45	2.78e-24	Red cell distribution width;
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.49	0.61	2.21e-48	Obesity-related traits;
LGG	cis	rs1107366	1.000	rs9873704	chr3:125901902	G/C	cg11252792	chr3:125932053	NA	0.55	11.35	0.47	1.66e-26	Metabolite levels;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.23	-0.32	1.98e-12	Menopause (age at onset);
LGG	cis	rs951366	0.789	rs1772148	chr1:205704580	A/T	cg07167872	chr1:205819463	PM20D1	0.57	11.55	0.47	2.69e-27	Menarche (age at onset);
LGG	cis	rs4704846	0.950	rs977257	chr5:156544437	T/C	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	cis	rs2842992	0.789	rs9355748	chr6:160194882	G/A	cg27624424	chr6:160112604	SOD2	0.66	9.54	0.41	8.1e-20	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9815354	0.812	rs59873855	chr3:41929538	T/C	cg03022575	chr3:42003672	ULK4	0.79	9.2	0.39	1.27e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg08677398	chr8:58056175	NA	0.57	12.57	0.5	2.31e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.754	rs2036860	chr4:120248934	A/G	cg24375607	chr4:120327624	NA	0.6	10.12	0.43	6.95e-22	Corneal astigmatism;
LGG	cis	rs9814567	1.000	rs13322305	chr3:134310791	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.12	-0.52	1.15e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4742903	1.000	rs10820603	chr9:106877939	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.28	0.36	1.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00981415	chr19:40502931	ZNF546	0.42	6.79	0.3	3.49e-11	Cognitive performance;
LGG	trans	rs2270927	0.510	rs2937750	chr5:75571511	C/T	cg13563193	chr19:33072644	PDCD5	0.76	9.34	0.4	3.96e-19	Mean corpuscular volume;
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg13047869	chr3:10149882	C3orf24	0.54	9.02	0.39	4.94e-18	Alzheimer's disease;
LGG	cis	rs3008870	1.000	rs12044278	chr1:67460977	T/C	cg08660285	chr1:67390436	MIER1;WDR78	-1.01	-23.97	-0.74	3.55e-83	Lymphocyte percentage of white cells;
LGG	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg02931644	chr1:25747376	RHCE	0.44	9.64	0.41	3.56e-20	Erythrocyte sedimentation rate;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.81	-0.38	2.5e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4664308	1.000	rs4665147	chr2:160917062	A/G	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.18	-0.65	3.95e-56	Idiopathic membranous nephropathy;
LGG	cis	rs11190604	0.767	rs7916904	chr10:102186778	C/G	cg07080220	chr10:102295463	HIF1AN	0.55	9.89	0.42	4.79e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12477438	0.520	rs13022329	chr2:99731189	A/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg23533926	chr12:111358616	MYL2	-0.44	-7.27	-0.32	1.53e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs752010	0.574	rs12130138	chr1:42117792	A/C	cg16096631	chr1:42092165	HIVEP3	0.47	10.96	0.45	5.06e-25	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7215564	0.908	rs4536520	chr17:78660239	C/T	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs6867032	0.527	rs4246752	chr5:1975575	T/A	cg26168224	chr5:2018326	NA	-0.96	-14.39	-0.56	4.36e-39	Gut microbiome composition (winter);
LGG	cis	rs1348850	0.872	rs12991272	chr2:178457339	T/C	cg22681709	chr2:178499509	PDE11A	-0.43	-7.64	-0.33	1.26e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs739401	0.595	rs402806	chr11:3066432	A/G	cg05729581	chr11:3078854	CARS	-0.57	-9.99	-0.42	2.11e-21	Longevity;
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg00495681	chr13:53174319	NA	0.74	15.07	0.57	4.96e-42	Lewy body disease;
LGG	cis	rs3087591	0.922	rs2341348	chr17:29534867	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.18	0.55	3.66e-38	Hip circumference;
LGG	cis	rs41271951	0.512	rs12090246	chr1:151107496	G/A	cg11822372	chr1:151115635	SEMA6C	-0.67	-6.99	-0.31	9.43e-12	Blood protein levels;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2361718	0.521	rs2361724	chr17:78099114	G/A	cg27427491	chr17:78079615	GAA	-0.31	-6.76	-0.3	4.23e-11	Yeast infection;
LGG	cis	rs9487094	0.670	rs7755941	chr6:109815351	T/C	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	cis	rs727505	1.000	rs10265763	chr7:124451514	G/A	cg23710748	chr7:124431027	NA	-0.53	-10.13	-0.43	6.58e-22	Lewy body disease;
LGG	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.74e-14	Homoarginine levels;
LGG	cis	rs2018055	0.826	rs6936540	chr6:117785047	A/G	cg14611402	chr6:117803162	DCBLD1	0.29	7.93	0.35	1.64e-14	Diastolic blood pressure;
LGG	cis	rs13401620	0.555	rs3820768	chr2:120978368	T/G	cg15425061	chr2:121036351	RALB	0.39	6.78	0.3	3.78e-11	Breast size;
LGG	trans	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg23505145	chr19:12996616	KLF1	0.38	6.66	0.3	7.78e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs951366	0.531	rs12047038	chr1:205718468	A/G	cg24503407	chr1:205819492	PM20D1	-0.4	-7.18	-0.32	2.76e-12	Menarche (age at onset);
LGG	cis	rs6582630	0.516	rs12814528	chr12:38296111	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.02	-0.49	3.83e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11690935	0.959	rs11904009	chr2:172627343	T/G	cg21435375	chr2:172878103	MAP1D	-0.31	-6.93	-0.31	1.45e-11	Schizophrenia;
LGG	cis	rs2075371	1.000	rs1862047	chr7:133978078	G/C	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs9513627	0.915	rs80270035	chr13:100121784	C/T	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs4566357	0.539	rs10933164	chr2:227860671	A/G	cg11843606	chr2:227700838	RHBDD1	-0.71	-12.49	-0.5	4.8e-31	Coronary artery disease;
LGG	cis	rs17767392	0.958	rs34480562	chr14:71979724	G/C	cg02058870	chr14:72053146	SIPA1L1	0.46	9.23	0.39	9.51e-19	Mitral valve prolapse;
LGG	cis	rs7552404	0.924	rs3818855	chr1:76198785	C/T	cg22875332	chr1:76189707	ACADM	0.62	10.98	0.45	4.32e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs8078723	1.000	rs8078723	chr17:38166879	A/G	cg17467752	chr17:38218738	THRA	0.73	13.95	0.54	3.5e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs17209837	1.000	rs45447097	chr7:87086144	G/A	cg00919237	chr7:87102261	ABCB4	-0.73	-12.64	-0.51	1.16e-31	Gallbladder cancer;
LGG	cis	rs10267417	0.556	rs879662	chr7:19970584	C/T	cg05791153	chr7:19748676	TWISTNB	0.52	6.93	0.31	1.43e-11	Night sleep phenotypes;
LGG	cis	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg16405210	chr4:1374714	KIAA1530	-0.41	-6.73	-0.3	5.07e-11	Obesity-related traits;
LGG	cis	rs6665290	0.935	rs6659424	chr1:227197875	A/G	cg05696931	chr1:227175867	NA	-0.4	-7.94	-0.35	1.53e-14	Myeloid white cell count;
LGG	cis	rs2013441	0.931	rs4925089	chr17:20064784	A/T	cg13482628	chr17:19912719	NA	0.5	9.34	0.4	4.19e-19	Obesity-related traits;
LGG	cis	rs9916302	0.706	rs11657153	chr17:37699729	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.69	-0.37	6.5e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs12130219	1.000	rs12733173	chr1:152173972	C/T	cg25272121	chr1:152190972	HRNR	0.39	6.81	0.3	2.99e-11	Inflammatory skin disease;
LGG	cis	rs62238980	0.614	rs117715811	chr22:32367895	C/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs11252926	0.617	rs11253319	chr10:722732	C/T	cg08603382	chr10:743973	NA	-0.7	-13.08	-0.52	1.69e-33	Psychosis in Alzheimer's disease;
LGG	cis	rs6878727	0.850	rs12658088	chr5:123719448	T/C	cg01806427	chr5:123737813	NA	0.31	6.72	0.3	5.43e-11	Breast cancer;
LGG	cis	rs4665809	0.590	rs1368902	chr2:26440576	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs1806153	0.611	rs1806158	chr11:31838788	C/G	cg11990419	chr11:31841155	NA	0.33	7.75	0.34	6.01e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs7737355	0.812	rs644964	chr5:131056809	T/C	cg06307176	chr5:131281290	NA	0.52	8.55	0.37	1.8e-16	Life satisfaction;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg16405210	chr4:1374714	KIAA1530	-0.67	-12.26	-0.5	4.06e-30	Longevity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00920043	chr1:11333412	UBIAD1	0.52	8.1	0.35	4.8e-15	Gut microbiome composition (summer);
LGG	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg24209194	chr3:40518798	ZNF619	-0.44	-7.04	-0.31	7.18e-12	Renal cell carcinoma;
LGG	cis	rs67133203	0.851	rs11169667	chr12:51403088	G/A	cg14688905	chr12:51403056	SLC11A2	0.78	12.03	0.49	3.27e-29	Urinary tract infection frequency;
LGG	cis	rs7336332	0.598	rs76249173	chr13:28010445	A/G	cg01674679	chr13:27998804	GTF3A	-0.63	-8.13	-0.35	3.93e-15	Weight;
LGG	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg03342759	chr3:160939853	NMD3	-0.6	-10.97	-0.45	4.88e-25	Morning vs. evening chronotype;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg07315766	chr11:94474627	NA	0.5	6.89	0.3	1.8e-11	Apolipoprotein A-IV levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg15432938	chr10:99078812	FRAT1	0.38	6.74	0.3	4.62e-11	Body mass index;
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg23758822	chr17:41437982	NA	0.87	15.44	0.58	1.06e-43	Menopause (age at onset);
LGG	cis	rs919433	0.963	rs6738836	chr2:198182432	A/G	cg00792783	chr2:198669748	PLCL1	-0.45	-7.02	-0.31	8.17e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	trans	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg10756647	chr7:56101905	PSPH	0.82	10.17	0.43	4.7e-22	Diabetic kidney disease;
LGG	cis	rs9467711	0.606	rs2072806	chr6:26385093	C/G	cg12826209	chr6:26865740	GUSBL1	0.78	8.21	0.36	2.17e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2299587	0.664	rs17593192	chr8:17889195	C/T	cg18067069	chr8:17937731	ASAH1	-0.33	-7.74	-0.34	6.43e-14	Economic and political preferences;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg11766577	chr21:47581405	C21orf56	-0.52	-9.0	-0.39	5.89e-18	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.805	rs4882575	chr12:37940573	G/A	cg06521331	chr12:34319734	NA	0.49	8.85	0.38	1.89e-17	Bladder cancer;
LGG	cis	rs72848980	0.512	rs12359556	chr10:105390677	C/T	cg00126946	chr10:105363258	SH3PXD2A	0.79	12.95	0.52	5.84e-33	White matter hyperintensity burden;
LGG	cis	rs11123170	0.529	rs1015753	chr2:113968803	T/G	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.14	0.31	3.72e-12	Renal function-related traits (BUN);
LGG	cis	rs7666738	0.830	rs11944855	chr4:99068258	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg09699651	chr6:150184138	LRP11	0.45	6.8	0.3	3.17e-11	Lung cancer;
LGG	cis	rs7773004	0.875	rs6456713	chr6:26325843	A/G	cg13736514	chr6:26305472	NA	-0.41	-8.36	-0.36	7.45e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs2228479	0.867	rs12930056	chr16:89946649	C/A	cg19635926	chr16:89946313	TCF25	0.81	9.1	0.39	2.67e-18	Skin colour saturation;
LGG	cis	rs1008375	0.966	rs7666888	chr4:17695722	C/T	cg16339924	chr4:17578868	LAP3	0.49	8.18	0.36	2.73e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2033711	0.870	rs4801270	chr19:58932762	C/A	cg03735888	chr19:58951602	ZNF132	0.42	8.32	0.36	1e-15	Uric acid clearance;
LGG	cis	rs9486719	0.948	rs6920913	chr6:96874297	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	10.67	0.44	6.58e-24	Migraine;Coronary artery disease;
LGG	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg22467129	chr15:76604101	ETFA	-0.43	-7.23	-0.32	1.96e-12	Blood metabolite levels;
LGG	cis	rs9926296	0.533	rs10852623	chr16:89865242	T/C	cg07440826	chr16:89882328	FANCA	-0.26	-6.99	-0.31	9.67e-12	Vitiligo;
LGG	trans	rs9987353	0.793	rs9329182	chr8:9111189	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.7	-0.3	6.06e-11	Recombination measurement;
LGG	cis	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg21775007	chr8:11205619	TDH	-0.47	-7.66	-0.34	1.1e-13	Triglycerides;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs4262150	0.726	rs4398624	chr5:152018343	C/T	cg12297329	chr5:152029980	NA	0.83	17.47	0.63	7.15e-53	Bipolar disorder and schizophrenia;
LGG	cis	rs4975709	0.589	rs1466606	chr5:1865055	C/T	cg12288994	chr5:1860383	NA	0.77	15.33	0.58	3.31e-43	Cardiovascular disease risk factors;
LGG	cis	rs7208859	0.562	rs8078897	chr17:29106257	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs704	0.585	rs2227735	chr17:26693258	C/T	cg10342447	chr17:26645325	TMEM97	-0.52	-9.86	-0.42	5.81e-21	Osteoprotegerin levels;
LGG	cis	rs780096	0.526	rs12476704	chr2:27613031	C/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.31	-0.32	1.15e-12	Total body bone mineral density;
LGG	cis	rs12142240	0.698	rs17361812	chr1:46814008	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.8	-0.3	3.3e-11	Menopause (age at onset);
LGG	cis	rs10819861	0.645	rs4743527	chr9:98851075	C/G	cg14508093	chr9:98862825	NA	0.3	7.16	0.32	3.1e-12	Electrocardiographic traits;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.36e-20	Prudent dietary pattern;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.63	-10.71	-0.45	4.44e-24	Renal function-related traits (BUN);
LGG	cis	rs2836974	0.831	rs34294410	chr21:40555160	C/G	cg17971929	chr21:40555470	PSMG1	0.89	17.64	0.63	1.17e-53	Cognitive function;
LGG	cis	rs10752881	1.000	rs6697739	chr1:182983333	A/C	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs9287719	0.967	rs4668691	chr2:10740494	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs763014	0.931	rs2071982	chr16:630405	T/G	cg09263875	chr16:632152	PIGQ	0.64	12.67	0.51	8.29e-32	Height;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg05335186	chr13:53173507	NA	-0.59	-13.25	-0.52	3.44e-34	Lewy body disease;
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.52	-0.4	9.46e-20	Body mass index;
LGG	cis	rs4689592	0.503	rs56099074	chr4:7071259	A/G	cg26116260	chr4:7069785	GRPEL1	-1.03	-15.63	-0.59	1.56e-44	Monocyte percentage of white cells;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg05861140	chr6:150128134	PCMT1	-0.31	-7.19	-0.32	2.67e-12	Testicular germ cell tumor;
LGG	cis	rs1620921	0.967	rs1247557	chr6:161189670	A/G	cg01280913	chr6:161186852	NA	-0.34	-6.95	-0.31	1.27e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2153535	0.580	rs6941670	chr6:8446346	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.53	0.5	3.24e-31	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00389713	chr6:43138877	SRF	0.5	8.44	0.37	4.17e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs9916302	0.861	rs644173	chr17:37430519	T/C	cg00129232	chr17:37814104	STARD3	-0.62	-11.55	-0.47	2.83e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs12681288	0.550	rs73176529	chr8:962283	G/C	cg08648136	chr8:956695	NA	0.44	9.39	0.4	2.76e-19	Schizophrenia;
LGG	cis	rs10504229	1.000	rs60231757	chr8:58169937	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg00092383	chr7:157075207	NA	-0.39	-6.78	-0.3	3.57e-11	Body mass index;
LGG	cis	rs2204008	0.749	rs10880692	chr12:38592918	C/G	cg26384229	chr12:38710491	ALG10B	-0.99	-23.37	-0.74	2.22e-80	Bladder cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26279152	chr13:20356101	PSPC1	0.38	6.71	0.3	5.85e-11	Obesity-related traits;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02492759	chr16:1401824	C16orf42;GNPTG	-0.43	-7.18	-0.32	2.73e-12	Brain structure;
LGG	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg00021532	chr16:4324280	TFAP4	0.49	12.94	0.52	6.57e-33	Prostate-specific antigen levels;
LGG	cis	rs2084898	0.891	rs477361	chr11:120000873	T/G	cg07435449	chr11:120005650	TRIM29	0.68	8.34	0.36	8.65e-16	Stroke (pediatric);
LGG	cis	rs11644362	1.000	rs11644362	chr16:12994097	T/C	cg08528231	chr16:12997261	SHISA9	-0.34	-6.78	-0.3	3.61e-11	Positive affect;Subjective well-being;
LGG	cis	rs944802	0.684	rs10811665	chr9:22146604	T/C	cg00491127	chr9:22154101	NA	-0.43	-6.66	-0.3	7.76e-11	White blood cell count;
LGG	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.19	0.62	1.47e-51	Chronic sinus infection;
LGG	cis	rs2832191	0.633	rs2832166	chr21:30462395	G/C	cg24692254	chr21:30365293	RNF160	1.02	27.14	0.78	8.71e-98	Dental caries;
LGG	cis	rs9397585	0.857	rs2349432	chr6:153380993	A/T	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs4665809	1.000	rs1030730	chr2:26284143	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-13.9	-0.54	5.94e-37	Gut microbiome composition (summer);
LGG	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg18252515	chr7:66147081	NA	-1.41	-20.6	-0.69	2.18e-67	Gout;
LGG	cis	rs17453880	0.963	rs11956179	chr5:151947064	T/G	cg12297329	chr5:152029980	NA	-0.82	-18.99	-0.66	7.16e-60	Subjective well-being;
LGG	cis	rs1348850	0.567	rs3821006	chr2:178537694	G/A	cg27490568	chr2:178487706	NA	0.49	9.58	0.41	6.01e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4561483	0.583	rs1019814	chr16:11940764	T/C	cg08843971	chr16:11963173	GSPT1	0.54	12.74	0.51	4.61e-32	Testicular germ cell tumor;
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00389713	chr6:43138877	SRF	0.49	7.92	0.35	1.77e-14	Cognitive performance;
LGG	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg01864069	chr14:103024347	NA	-0.65	-9.26	-0.4	7.64e-19	Platelet count;
LGG	cis	rs61931739	0.620	rs1905241	chr12:33709729	G/A	cg06521331	chr12:34319734	NA	0.39	6.73	0.3	4.9e-11	Morning vs. evening chronotype;
LGG	cis	rs8072100	0.744	rs34537623	chr17:45530203	A/G	cg08085267	chr17:45401833	C17orf57	-0.53	-10.45	-0.44	4.19e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs28655083	0.636	rs7194836	chr16:77066830	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-7.07	-0.31	5.64e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3768617	0.510	rs3768615	chr1:183103604	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.05	0.39	4.04e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1552244	1.000	rs7615764	chr3:10082592	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.05	0.31	6.48e-12	Alzheimer's disease;
LGG	cis	rs72781680	1.000	rs72781680	chr2:24238928	C/T	cg08917208	chr2:24149416	ATAD2B	0.9	9.62	0.41	4.16e-20	Lymphocyte counts;
LGG	cis	rs7927592	0.956	rs12277225	chr11:68340967	T/C	cg16797656	chr11:68205561	LRP5	0.39	6.87	0.3	2.02e-11	Total body bone mineral density;
LGG	cis	rs35110281	0.774	rs162344	chr21:44954522	G/A	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.51	-0.37	2.43e-16	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27182555	chr4:83821584	THAP9	0.44	7.08	0.31	5.52e-12	Cognitive performance;
LGG	cis	rs2404602	0.583	rs11072580	chr15:76540231	G/A	cg23625390	chr15:77176239	SCAPER	0.39	7.41	0.33	6.22e-13	Blood metabolite levels;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg06074448	chr4:187884817	NA	-0.59	-12.91	-0.51	8.86e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12474201	0.928	rs13025984	chr2:46938789	T/C	cg06386533	chr2:46925753	SOCS5	0.8	14.85	0.57	4.5e-41	Height;
LGG	cis	rs11583043	0.874	rs6577219	chr1:101415707	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	9.1	0.39	2.62e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs589448	0.902	rs528974	chr12:69765918	A/T	cg22834771	chr12:69754056	YEATS4	-0.5	-8.71	-0.38	5.27e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6582630	0.599	rs1589392	chr12:38418535	G/C	cg26384229	chr12:38710491	ALG10B	-0.65	-12.84	-0.51	1.67e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2304069	1.000	rs7737689	chr5:149396159	C/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.53	7.16	0.32	3.29e-12	HIV-1 control;
LGG	cis	rs2816316	0.830	rs9427559	chr1:192525984	A/C	cg02586212	chr1:192544902	RGS1	0.42	8.57	0.37	1.53e-16	Celiac disease;
LGG	cis	rs7647973	0.626	rs7649428	chr3:49868876	A/T	cg13072238	chr3:49761600	GMPPB	0.52	7.08	0.31	5.44e-12	Menarche (age at onset);
LGG	cis	rs798554	0.616	rs1636251	chr7:2884720	T/C	cg19717773	chr7:2847554	GNA12	-0.34	-7.78	-0.34	4.91e-14	Height;
LGG	cis	rs67311347	1.000	rs7617989	chr3:40512463	A/G	cg13683864	chr3:40499215	RPL14	1.03	23.01	0.73	1.11e-78	Renal cell carcinoma;
LGG	cis	rs2227564	0.620	rs10740418	chr10:75519322	T/C	cg00564723	chr10:75632066	CAMK2G	-0.46	-9.8	-0.41	1.03e-20	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6598955	0.543	rs79778574	chr1:26538482	A/G	cg04990556	chr1:26633338	UBXN11	0.72	10.74	0.45	3.41e-24	Obesity-related traits;
LGG	cis	rs7474896	0.522	rs117157955	chr10:37984164	G/T	cg00409905	chr10:38381863	ZNF37A	-0.48	-7.54	-0.33	2.49e-13	Obesity (extreme);
LGG	cis	rs7512552	0.773	rs3737240	chr1:150483355	C/T	cg15654264	chr1:150340011	RPRD2	0.45	9.01	0.39	5.3e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs61931739	0.534	rs1490109	chr12:34064077	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.93	-0.48	8.44e-29	Morning vs. evening chronotype;
LGG	cis	rs7085104	0.727	rs12773892	chr10:104631177	G/T	cg04362960	chr10:104952993	NT5C2	1.0	14.43	0.56	3.06e-39	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.03	-0.31	7.61e-12	Bipolar disorder;
LGG	cis	rs4731207	0.689	rs2054585	chr7:124552447	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.35	-0.32	8.9e-13	Joint mobility (Beighton score);
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.63	-11.61	-0.47	1.54e-27	Electroencephalogram traits;
LGG	cis	rs11608355	0.545	rs36094325	chr12:109911542	A/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs7959452	0.640	rs11177599	chr12:69721970	G/A	cg14784868	chr12:69753453	YEATS4	0.72	13.77	0.54	2.12e-36	Blood protein levels;
LGG	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg12373951	chr3:133503437	NA	0.4	7.06	0.31	5.96e-12	Iron status biomarkers;
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg03188948	chr7:1209495	NA	0.63	8.33	0.36	9.48e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg09699651	chr6:150184138	LRP11	0.53	9.55	0.41	7.77e-20	Lung cancer;
LGG	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg19847130	chr8:10466454	RP1L1	0.31	6.75	0.3	4.42e-11	Neuroticism;
LGG	cis	rs10266483	0.739	rs12665990	chr7:63865000	G/A	cg24201672	chr7:64023550	ZNF680	0.46	7.01	0.31	8.27e-12	Response to statin therapy;
LGG	cis	rs2764208	0.535	rs3800456	chr6:34664207	T/G	cg07306190	chr6:34760872	UHRF1BP1	0.45	7.78	0.34	4.85e-14	Systemic lupus erythematosus;
LGG	cis	rs6142618	0.562	rs6061203	chr20:30752970	A/G	cg00028034	chr20:30779307	TSPYL3	0.37	8.13	0.35	4e-15	Inflammatory bowel disease;
LGG	cis	rs6594713	0.837	rs13187823	chr5:112722164	C/G	cg12552261	chr5:112820674	MCC	0.51	6.73	0.3	5.04e-11	Brain cytoarchitecture;
LGG	cis	rs3857536	0.813	rs9354405	chr6:66948575	G/T	cg07460842	chr6:66804631	NA	-0.46	-7.79	-0.34	4.34e-14	Blood trace element (Cu levels);
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg09699651	chr6:150184138	LRP11	0.5	8.17	0.36	2.92e-15	Lung cancer;
LGG	cis	rs9527	0.662	rs10883783	chr10:104591152	T/A	cg04362960	chr10:104952993	NT5C2	0.52	9.45	0.4	1.76e-19	Arsenic metabolism;
LGG	trans	rs4714291	0.802	rs2984430	chr6:39983741	A/G	cg02267698	chr19:7991119	CTXN1	-0.59	-9.49	-0.4	1.2e-19	Strep throat;
LGG	cis	rs1153858	0.943	rs67045941	chr15:45677011	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs8064029	0.892	rs62036118	chr16:4901885	G/C	cg04440724	chr16:4920505	UBN1	-0.62	-7.52	-0.33	2.84e-13	Cancer;
LGG	cis	rs12497850	0.931	rs6414613	chr3:49035885	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	11.25	0.46	4.16e-26	Parkinson's disease;
LGG	cis	rs6960043	0.738	rs2358159	chr7:15054908	T/C	cg19272540	chr7:15055459	NA	0.34	7.84	0.34	3.23e-14	Type 2 diabetes;
LGG	cis	rs2599510	0.811	rs62136345	chr2:32807223	G/T	cg02381751	chr2:32503542	YIPF4	0.49	8.03	0.35	8.42e-15	Interleukin-18 levels;
LGG	cis	rs62238980	0.614	rs7289853	chr22:32427773	C/G	cg02631450	chr22:32366979	NA	0.97	9.29	0.4	6.21e-19	Childhood ear infection;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg11062466	chr8:58055876	NA	0.58	13.16	0.52	7.73e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.526	rs7607073	chr2:178375065	C/A	cg22681709	chr2:178499509	PDE11A	-0.52	-7.62	-0.33	1.48e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11577318	0.853	rs11247913	chr1:26648551	G/C	cg04990556	chr1:26633338	UBXN11	-0.51	-7.8	-0.34	4.2e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.75	15.01	0.57	8.96e-42	Obesity-related traits;
LGG	cis	rs12893668	0.638	rs11851616	chr14:104065600	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-10.05	-0.42	1.22e-21	Reticulocyte count;
LGG	cis	rs4566357	0.615	rs2894626	chr2:227916039	T/C	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.97e-18	Coronary artery disease;
LGG	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.27	-0.36	1.47e-15	Retinal vascular caliber;
LGG	cis	rs6089584	0.566	rs55881457	chr20:60608424	G/A	cg06108461	chr20:60628389	TAF4	-0.73	-12.93	-0.51	7.46e-33	Body mass index;
LGG	cis	rs10493773	0.775	rs12756013	chr1:86153532	C/T	cg17807903	chr1:86174739	ZNHIT6	-0.64	-12.87	-0.51	1.26e-32	Urate levels in overweight individuals;
LGG	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg15269541	chr15:43626905	ADAL	-0.46	-8.34	-0.36	8.77e-16	Lung cancer in ever smokers;
LGG	cis	rs7523273	0.606	rs1970530	chr1:207924066	G/A	cg22525895	chr1:207977042	MIR29B2	0.6	11.98	0.49	5.56e-29	Schizophrenia;
LGG	cis	rs10540	1.000	rs61876341	chr11:495892	C/G	cg03576123	chr11:487126	PTDSS2	-1.24	-16.56	-0.61	1.03e-48	Body mass index;
LGG	cis	rs9393813	0.868	rs4711154	chr6:27446359	A/T	cg18711553	chr6:27366782	ZNF391	-0.51	-9.57	-0.41	6.63e-20	Bipolar disorder;
LGG	cis	rs6032067	0.527	rs62206433	chr20:43750118	T/C	cg10761708	chr20:43804764	PI3	0.64	9.63	0.41	3.94e-20	Blood protein levels;
LGG	cis	rs7215564	0.730	rs2316066	chr17:78659785	A/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs870825	0.929	rs55635512	chr4:185589982	G/T	cg04058563	chr4:185651563	MLF1IP	1.03	18.88	0.66	2.31e-59	Blood protein levels;
LGG	cis	rs17767392	0.915	rs1990241	chr14:71774052	T/G	cg02058870	chr14:72053146	SIPA1L1	0.47	9.26	0.4	7.94e-19	Mitral valve prolapse;
LGG	cis	rs6500395	0.588	rs8046716	chr16:48560941	A/G	cg04672837	chr16:48644449	N4BP1	-0.47	-8.24	-0.36	1.81e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14971810	chr2:20251361	LAPTM4A	0.44	7.04	0.31	6.91e-12	Gut microbiome composition (summer);
LGG	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	cis	rs7044106	0.762	rs7024046	chr9:123419178	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.48	0.61	2.28e-48	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.555	rs10880613	chr12:38509553	C/T	cg13010199	chr12:38710504	ALG10B	0.73	14.91	0.57	2.55e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8180040	0.932	rs12490058	chr3:47529063	T/C	cg16586182	chr3:47516702	SCAP	-0.77	-15.37	-0.58	2.33e-43	Colorectal cancer;
LGG	cis	rs899997	0.814	rs28661610	chr15:78985317	G/A	cg09845145	chr15:78292470	TBC1D2B	-0.59	-9.71	-0.41	2.03e-20	Coronary artery disease or large artery stroke;
LGG	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	13.9	0.54	6.01e-37	Cognitive test performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00075589	chr2:219524515	ZNF142;BCS1L	0.41	6.86	0.3	2.23e-11	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.17	0.32	3.07e-12	Obesity-related traits;
LGG	cis	rs2289583	0.597	rs12148708	chr15:75384397	G/A	cg14664628	chr15:75095509	CSK	0.51	9.04	0.39	4.21e-18	Systemic lupus erythematosus;
LGG	cis	rs12497850	0.931	rs7621015	chr3:49016056	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.97	0.45	4.86e-25	Parkinson's disease;
LGG	cis	rs6582630	0.679	rs7301806	chr12:38596667	G/A	cg13010199	chr12:38710504	ALG10B	0.56	11.27	0.46	3.49e-26	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3796352	1.000	rs11717619	chr3:53003179	A/C	cg12962167	chr3:53033115	SFMBT1	0.68	7.36	0.32	8.38e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2013441	1.000	rs11871945	chr17:20206883	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs10805357	chr4:17652352	G/A	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4481887	1.000	rs10888362	chr1:248483975	A/G	cg13385794	chr1:248469461	NA	-0.48	-8.09	-0.35	5.35e-15	Common traits (Other);
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg15665833	chr6:26285013	NA	0.38	7.49	0.33	3.52e-13	Educational attainment;
LGG	cis	rs4481887	0.830	rs4474289	chr1:248474972	T/A	cg00666640	chr1:248458726	OR2T12	0.54	8.66	0.37	8.16e-17	Common traits (Other);
LGG	cis	rs6912958	0.559	rs376633	chr6:88042785	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.69	13.09	0.52	1.53e-33	Monocyte percentage of white cells;
LGG	cis	rs4919087	0.561	rs10082521	chr10:99070526	A/T	cg25902810	chr10:99078978	FRAT1	-0.41	-6.78	-0.3	3.75e-11	Monocyte count;
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg08677398	chr8:58056175	NA	0.56	8.7	0.37	5.8e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2692947	0.644	rs1168968	chr2:96825363	C/T	cg22654517	chr2:96458247	NA	0.36	7.14	0.32	3.55e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Bladder cancer;
LGG	cis	rs11252926	0.673	rs7096559	chr10:499188	C/T	cg16386425	chr10:429943	DIP2C	-0.42	-8.44	-0.37	4.17e-16	Psychosis in Alzheimer's disease;
LGG	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg06219351	chr7:158114137	PTPRN2	-0.8	-16.07	-0.6	1.68e-46	Calcium levels;
LGG	cis	rs847649	0.692	rs7800548	chr7:102481842	C/T	cg18108683	chr7:102477205	FBXL13	0.71	15.79	0.59	2.91e-45	Morning vs. evening chronotype;
LGG	cis	rs7666738	0.791	rs13149968	chr4:99070262	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs75920871	0.925	rs61905716	chr11:116919067	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.52e-12	Subjective well-being;
LGG	cis	rs55986470	0.763	rs6739251	chr2:239419603	A/G	cg18131467	chr2:239335373	ASB1	-0.57	-7.11	-0.31	4.44e-12	Chronotype;
LGG	cis	rs7582720	1.000	rs72934729	chr2:203737770	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg19171272	chr22:38449367	NA	-0.62	-12.28	-0.5	3.3e-30	Glioblastoma;Glioma;
LGG	cis	rs28595532	0.920	rs115576008	chr4:119736967	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs9527	0.590	rs1046411	chr10:104837816	G/A	cg05308233	chr10:104796373	CNNM2	-0.33	-7.27	-0.32	1.54e-12	Arsenic metabolism;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg19635926	chr16:89946313	TCF25	0.71	8.45	0.37	3.69e-16	Skin colour saturation;
LGG	cis	rs2735413	0.958	rs7192416	chr16:78063143	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.1	-0.64	9.41e-56	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs8028313	0.731	rs11857017	chr15:67972908	A/G	cg22044901	chr15:68126292	NA	-0.4	-7.08	-0.31	5.36e-12	Obesity;
LGG	cis	rs1790761	0.806	rs35787427	chr11:67255877	C/T	cg00290607	chr11:67383545	NA	-0.51	-8.83	-0.38	2.13e-17	Mean corpuscular volume;
LGG	trans	rs11722228	0.522	rs73212880	chr4:10115692	T/A	cg26043149	chr18:55253948	FECH	0.94	16.21	0.6	4.08e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs4481887	0.741	rs6587458	chr1:248532290	T/A	cg01631408	chr1:248437212	OR2T33	-0.38	-6.91	-0.31	1.57e-11	Common traits (Other);
LGG	cis	rs9311474	0.597	rs13303	chr3:52558008	T/C	cg15147215	chr3:52552868	STAB1	-0.45	-9.03	-0.39	4.56e-18	Electroencephalogram traits;
LGG	trans	rs7395662	0.571	rs4882020	chr11:48615658	C/T	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	2.01e-11	HDL cholesterol;
LGG	cis	rs6688613	0.694	rs12062326	chr1:166820186	G/A	ch.1.3259774R	chr1:166827647	TADA1	0.54	8.36	0.36	7.6e-16	Refractive astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20916175	chr6:27832956	HIST1H2AL	0.44	6.68	0.3	7e-11	Gut microbiome composition (summer);
LGG	cis	rs654950	0.934	rs662999	chr1:42001160	A/C	cg16096631	chr1:42092165	HIVEP3	0.4	8.03	0.35	7.99e-15	Airway imaging phenotypes;
LGG	cis	rs3806843	1.000	rs11167600	chr5:140174865	G/C	cg19875535	chr5:140030758	IK	0.51	10.4	0.44	6.34e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg01448562	chr3:133502909	NA	-0.73	-13.4	-0.53	7.49e-35	Iron status biomarkers;
LGG	cis	rs806215	0.547	rs9791922	chr7:127559133	T/C	cg25922125	chr7:127225783	GCC1	-0.48	-6.99	-0.31	9.67e-12	Type 2 diabetes;
LGG	cis	rs651907	0.535	rs36060163	chr3:101360963	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.77	0.34	5.28e-14	Colorectal cancer;
LGG	trans	rs7939886	0.920	rs7933691	chr11:56046900	G/A	cg03929089	chr4:120376271	NA	0.72	6.66	0.3	7.95e-11	Myopia (pathological);
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-9.96	-0.42	2.72e-21	Lung cancer;
LGG	cis	rs12580194	0.630	rs60586348	chr12:55745151	A/T	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs3204270	0.673	rs62077190	chr17:79676109	C/A	cg18367735	chr17:79674897	NA	0.58	7.29	0.32	1.34e-12	Dental caries;
LGG	cis	rs12618769	0.652	rs11896729	chr2:99225645	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs10771431	0.713	rs17794353	chr12:9361783	C/T	cg00504896	chr12:9437009	LOC642846	0.5	9.89	0.42	4.57e-21	Breast size;
LGG	cis	rs1799949	0.965	rs11650132	chr17:41326087	T/G	cg12708336	chr17:41446283	NA	-0.32	-7.3	-0.32	1.26e-12	Menopause (age at onset);
LGG	cis	rs3806933	0.500	rs10491423	chr5:110453977	C/A	cg04022379	chr5:110408740	TSLP	0.47	7.92	0.35	1.8e-14	Eosinophilic esophagitis;
LGG	cis	rs4730250	0.707	rs6960148	chr7:106786142	A/G	cg02696742	chr7:106810147	HBP1	0.78	10.89	0.45	9.83e-25	Osteoarthritis;
LGG	cis	rs7666738	0.830	rs10050008	chr4:99025313	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2404602	0.684	rs2454451	chr15:76861461	G/T	cg15268244	chr15:77196840	NA	-0.47	-10.09	-0.42	8.96e-22	Blood metabolite levels;
LGG	cis	rs9325144	0.957	rs1995419	chr12:38950726	C/G	cg26384229	chr12:38710491	ALG10B	0.49	7.09	0.31	5.07e-12	Morning vs. evening chronotype;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07370352	chr1:15269183	KIAA1026	0.34	6.67	0.3	7.23e-11	Menarche (age at onset);
LGG	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg13114125	chr14:105738426	BRF1	-0.83	-15.68	-0.59	9.25e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg13902645	chr11:5959945	NA	-0.47	-7.83	-0.34	3.28e-14	DNA methylation (variation);
LGG	cis	rs7726839	0.540	rs55929359	chr5:595956	C/G	cg09021430	chr5:549028	NA	-0.69	-9.86	-0.42	6.16e-21	Obesity-related traits;
LGG	trans	rs1493916	0.837	rs9949631	chr18:31410567	G/A	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs9914988	0.943	rs67327562	chr17:27108828	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg00990874	chr7:1149470	C7orf50	-0.66	-9.69	-0.41	2.48e-20	Bronchopulmonary dysplasia;
LGG	cis	rs62244186	0.659	rs1806579	chr3:44509281	T/C	cg02073558	chr3:44770973	ZNF501	0.65	11.77	0.48	3.73e-28	Depressive symptoms;
LGG	cis	rs9916302	0.904	rs11078910	chr17:37671269	G/T	cg07936489	chr17:37558343	FBXL20	-0.84	-15.75	-0.59	4.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs11971779	0.638	rs77668044	chr7:139111085	T/A	cg07862535	chr7:139043722	LUC7L2	0.65	9.52	0.4	9.67e-20	Diisocyanate-induced asthma;
LGG	cis	rs10979	1.000	rs12215667	chr6:143893213	T/C	cg25407410	chr6:143891975	LOC285740	-0.71	-12.24	-0.49	4.7e-30	Hypospadias;
LGG	cis	rs6430585	0.528	rs309162	chr2:136690783	T/A	cg07169764	chr2:136633963	MCM6	1.26	25.44	0.76	6.02e-90	Corneal structure;
LGG	trans	rs6600671	0.719	rs9728991	chr1:121264079	G/A	cg00646200	chr1:148855367	NA	0.4	7.1	0.31	4.6e-12	Hip geometry;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs7613875	0.600	rs7061	chr3:50114515	C/T	cg05623727	chr3:50126028	RBM5	-0.44	-9.69	-0.41	2.51e-20	Body mass index;
LGG	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg08975724	chr8:8085496	FLJ10661	0.46	8.33	0.36	9.15e-16	Triglycerides;
LGG	trans	rs1997103	1.000	rs6949222	chr7:55411264	C/T	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg21475434	chr5:93447410	FAM172A	0.7	7.14	0.31	3.72e-12	Diabetic retinopathy;
LGG	cis	rs990171	0.770	rs7562254	chr2:102924947	A/C	cg05295703	chr2:102895712	NA	-0.66	-11.99	-0.49	5.11e-29	Lymphocyte counts;
LGG	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg26384229	chr12:38710491	ALG10B	0.92	20.96	0.7	4.23e-69	Bladder cancer;
LGG	cis	rs28386778	0.897	rs3785572	chr17:61829989	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	2.05e-12	Prudent dietary pattern;
LGG	cis	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg15038512	chr6:170123185	PHF10	0.56	6.95	0.31	1.24e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1814175	0.519	rs3913237	chr11:49551828	G/A	cg11707556	chr5:10655725	ANKRD33B	0.66	11.32	0.47	2.15e-26	Height;
LGG	cis	rs11676348	0.818	rs6436033	chr2:218983763	A/G	cg00012203	chr2:219082015	ARPC2	-0.57	-10.16	-0.43	5.03e-22	Ulcerative colitis;
LGG	trans	rs2204008	0.683	rs11522927	chr12:38137537	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.86	-0.38	1.71e-17	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23359706	chr19:11491839	EPOR	0.48	7.52	0.33	2.93e-13	Gut microbiome composition (summer);
LGG	cis	rs782590	0.902	rs3762513	chr2:55762957	C/T	cg18811423	chr2:55921094	PNPT1	0.87	20.28	0.69	6.31e-66	Metabolic syndrome;
LGG	trans	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.82	0.3	2.94e-11	Neuroticism;
LGG	cis	rs9296092	0.560	rs7765393	chr6:33525598	A/T	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1691799	0.899	rs1168302	chr12:66737518	C/T	cg16791601	chr12:66731901	HELB	-0.67	-15.89	-0.59	1.12e-45	White blood cell count (basophil);
LGG	cis	rs6445975	0.666	rs6767291	chr3:58408910	C/T	cg24175188	chr3:58374923	PXK	-0.56	-9.13	-0.39	2.11e-18	Systemic lupus erythematosus;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg16405210	chr4:1374714	KIAA1530	-0.65	-11.92	-0.48	9e-29	Longevity;
LGG	trans	rs9467711	0.790	rs41266839	chr6:26409890	G/C	cg08344181	chr3:125677491	NA	-0.83	-8.02	-0.35	8.74e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs877282	0.583	rs11595057	chr10:819203	A/C	cg01169559	chr10:831247	NA	0.46	8.12	0.35	4.25e-15	Uric acid levels;
LGG	cis	rs8135665	0.600	rs8139025	chr22:38450881	G/C	cg13116946	chr22:38479732	SLC16A8	0.53	8.69	0.37	6.32e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	trans	rs8002861	0.870	rs1348671	chr13:44449505	C/T	cg12856521	chr11:46389249	DGKZ	0.39	6.67	0.3	7.28e-11	Leprosy;
LGG	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.81	9.12	0.39	2.35e-18	Diabetic retinopathy;
LGG	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg15017067	chr4:17643749	FAM184B	0.32	7.45	0.33	4.52e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.500	rs6488222	chr12:34526289	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs28386778	0.797	rs4968664	chr17:61851366	C/G	cg26338869	chr17:61819248	STRADA	0.58	9.85	0.42	6.84e-21	Prudent dietary pattern;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.13	0.31	3.99e-12	Lung cancer;
LGG	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.24	-0.32	1.87e-12	Restless legs syndrome;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	trans	rs17807624	0.780	rs11250152	chr8:11454200	A/C	cg02002194	chr4:3960332	NA	0.41	7.41	0.33	6.24e-13	Systemic lupus erythematosus;
LGG	cis	rs12143943	0.866	rs3789052	chr1:204494283	A/G	cg20240347	chr1:204465584	NA	0.35	7.54	0.33	2.51e-13	Cognitive performance;
LGG	cis	rs4595586	0.505	rs11611321	chr12:39390803	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs2227564	0.678	rs2242256	chr10:75597546	C/G	cg00564723	chr10:75632066	CAMK2G	0.52	10.91	0.45	8.22e-25	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4819052	0.788	rs2236449	chr21:46702506	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.52	8.09	0.35	5.35e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.04e-42	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.47	0.5	5.56e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12971120	0.891	rs4891557	chr18:72170299	C/T	cg25817165	chr18:72167213	CNDP2	-0.67	-13.9	-0.54	5.69e-37	Refractive error;
LGG	cis	rs4561483	0.583	rs11075027	chr16:11948895	T/C	cg08843971	chr16:11963173	GSPT1	0.56	13.59	0.53	1.18e-35	Testicular germ cell tumor;
LGG	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg16400903	chr5:693638	TPPP	0.45	6.76	0.3	4.13e-11	Obesity-related traits;
LGG	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg04657146	chr19:12876947	HOOK2	0.45	7.32	0.32	1.08e-12	Red blood cell traits;
LGG	cis	rs3106136	0.967	rs7435106	chr4:95169772	T/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-8.11	-0.35	4.65e-15	Capecitabine sensitivity;
LGG	cis	rs1799949	0.860	rs8176279	chr17:41210396	A/C	cg16270222	chr17:41446396	NA	-0.29	-7.04	-0.31	7.01e-12	Menopause (age at onset);
LGG	cis	rs397969	0.596	rs62066350	chr17:19900042	T/C	cg13482628	chr17:19912719	NA	0.52	8.51	0.37	2.4e-16	Platelet count;
LGG	cis	rs2117029	0.555	rs7978448	chr12:49506940	G/C	cg24176009	chr12:49580217	TUBA1A	0.57	10.69	0.44	5.63e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2455826	0.874	rs2455853	chr3:15690025	C/T	cg16303742	chr3:15540471	COLQ	-0.38	-6.82	-0.3	2.78e-11	Inflammatory skin disease;
LGG	cis	rs2334880	0.678	rs12918320	chr16:71463602	A/G	cg06353428	chr16:71660113	MARVELD3	-0.82	-11.84	-0.48	2.01e-28	Malaria;
LGG	cis	rs6732160	0.564	rs60796597	chr2:73382914	C/T	cg01422370	chr2:73384389	NA	0.57	9.79	0.41	1.05e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.65	-10.11	-0.43	7.69e-22	Chronic sinus infection;
LGG	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg26384229	chr12:38710491	ALG10B	0.85	18.51	0.65	1.18e-57	Morning vs. evening chronotype;
LGG	cis	rs1355223	0.934	rs5010670	chr11:34766649	A/C	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.17	-0.32	3.03e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs523522	0.892	rs4767916	chr12:121024032	T/C	cg27279351	chr12:120934652	DYNLL1	0.81	12.97	0.52	5.11e-33	High light scatter reticulocyte count;
LGG	cis	rs208520	0.837	rs208488	chr6:66926902	C/T	cg07460842	chr6:66804631	NA	-0.94	-16.26	-0.6	2.31e-47	Exhaled nitric oxide output;
LGG	cis	rs921968	0.541	rs12617603	chr2:219369288	A/G	cg10223061	chr2:219282414	VIL1	0.3	6.78	0.3	3.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.2	-0.7	3.37e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs16854884	1.000	rs1961542	chr3:143765503	G/A	cg06585982	chr3:143692056	C3orf58	0.55	8.61	0.37	1.14e-16	Economic and political preferences (feminism/equality);
LGG	cis	rs28595532	0.841	rs114965278	chr4:119743694	T/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs72827839	0.793	rs72823513	chr17:46048920	A/G	cg23391107	chr17:45924227	SP6	0.49	6.71	0.3	5.62e-11	Ease of getting up in the morning;
LGG	cis	rs17767392	0.958	rs12879243	chr14:71905815	C/G	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	2.8e-18	Mitral valve prolapse;
LGG	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg18477163	chr1:228402036	OBSCN	0.25	6.67	0.3	7.17e-11	Diastolic blood pressure;
LGG	cis	rs75229567	0.618	rs1882194	chr12:70215086	C/G	cg10114359	chr12:70132523	RAB3IP	-1.1	-9.73	-0.41	1.79e-20	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs854037	0.698	rs10038574	chr5:57053745	C/T	cg08523694	chr5:57076192	NA	0.5	7.13	0.31	3.9e-12	Birth weight;
LGG	cis	rs4660214	0.666	rs7553009	chr1:39713113	C/T	cg18385671	chr1:39797026	MACF1	-0.46	-9.52	-0.4	9.83e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4950322	0.543	rs4950319	chr1:146787963	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs6546550	0.901	rs11902198	chr2:70144596	C/A	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs11148252	0.553	rs7999849	chr13:53249414	A/G	cg00495681	chr13:53174319	NA	0.81	17.33	0.63	3.18e-52	Lewy body disease;
LGG	cis	rs564799	0.842	rs480913	chr3:159729580	T/G	cg04855961	chr3:159719849	NA	-0.27	-7.48	-0.33	3.66e-13	Systemic lupus erythematosus;
LGG	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg13647721	chr17:30228624	UTP6	0.65	8.66	0.37	7.69e-17	Hip circumference adjusted for BMI;
LGG	cis	rs35425515	0.764	rs4919070	chr10:98864269	G/A	cg09122387	chr10:98855762	SLIT1	0.75	9.78	0.41	1.18e-20	Bipolar disorder;
LGG	cis	rs798766	1.000	rs798762	chr4:1731150	T/C	cg00006948	chr4:1768889	NA	-0.5	-6.94	-0.31	1.33e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs4262150	0.883	rs55880278	chr5:152167864	G/A	cg12297329	chr5:152029980	NA	-0.7	-12.8	-0.51	2.57e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs137603	0.933	rs137591	chr22:39685450	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	-0.47	-7.78	-0.34	4.83e-14	Primary biliary cholangitis;
LGG	cis	rs7980687	0.627	rs1727325	chr12:123698332	G/C	cg05973401	chr12:123451056	ABCB9	0.5	7.57	0.33	2.03e-13	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7493	1.000	rs12155103	chr7:95037131	G/A	cg08461772	chr7:95026248	PON3	0.38	8.25	0.36	1.64e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs8060686	0.641	rs1074143	chr16:68127278	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.75	-0.3	4.48e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs377457	0.623	rs1053328	chr16:85711860	A/G	cg08768472	chr16:85689701	KIAA0182	-0.5	-9.66	-0.41	3.13e-20	Type 2 diabetes;
LGG	trans	rs6598955	0.671	rs3924325	chr1:26616320	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.46	-0.5	5.95e-31	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19696333	chr10:124768261	IKZF5;ACADSB	0.44	7.21	0.32	2.36e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2777491	0.915	rs28583065	chr15:41608470	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.6	-0.67	9.46e-63	Ulcerative colitis;
LGG	cis	rs75920871	0.588	rs3181	chr11:116907043	C/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.91	-0.45	7.82e-25	Subjective well-being;
LGG	trans	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-18.11	-0.64	8.17e-56	Morning vs. evening chronotype;
LGG	cis	rs704795	0.775	rs4665975	chr2:27626017	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.74	-0.3	4.84e-11	Menopause (age at onset);
LGG	cis	rs10876993	0.890	rs12302350	chr12:58062589	T/G	cg18357645	chr12:58087776	OS9	0.67	11.93	0.48	8.75e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs8078723	0.714	rs3785550	chr17:38149727	C/T	cg17467752	chr17:38218738	THRA	-0.62	-11.2	-0.46	6.1e-26	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg02018176	chr4:1364513	KIAA1530	0.37	8.38	0.36	6.32e-16	Obesity-related traits;
LGG	cis	rs67460515	0.892	rs7648279	chr3:160979646	G/A	cg03342759	chr3:160939853	NMD3	-0.75	-13.49	-0.53	3.33e-35	Parkinson's disease;
LGG	cis	rs7481584	0.581	rs515481	chr11:3047184	A/G	cg08508325	chr11:3079039	CARS	0.43	8.46	0.37	3.6e-16	Calcium levels;
LGG	cis	rs1595825	0.786	rs116046984	chr2:198884413	G/A	cg00982548	chr2:198649783	BOLL	-0.5	-6.83	-0.3	2.63e-11	Ulcerative colitis;
LGG	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.88e-21	Aortic root size;
LGG	trans	rs561341	1.000	rs72823785	chr17:30273784	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.57	-0.41	6.29e-20	Hip circumference adjusted for BMI;
LGG	cis	rs701145	0.585	rs1527799	chr3:153811226	A/G	cg17054900	chr3:154042577	DHX36	0.8	9.42	0.4	2.19e-19	Coronary artery disease;
LGG	trans	rs853679	0.699	rs9468318	chr6:28209531	T/A	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.92	-0.35	1.8e-14	Depression;
LGG	cis	rs2463822	0.614	rs117699706	chr11:62161659	T/C	cg06239285	chr11:62104954	ASRGL1	-1.15	-15.07	-0.57	4.83e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs7824557	0.545	rs2572450	chr8:11229638	C/T	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.7	-0.37	6.07e-17	Retinal vascular caliber;
LGG	cis	rs9859260	1.000	rs2300778	chr3:195790737	A/G	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.84	-0.3	2.59e-11	Mean corpuscular volume;
LGG	cis	rs4975709	0.610	rs4975704	chr5:1859807	C/A	cg04156016	chr5:1868137	NA	0.32	7.08	0.31	5.39e-12	Cardiovascular disease risk factors;
LGG	trans	rs6076960	0.681	rs4487157	chr20:6249581	G/A	cg21095983	chr6:86352623	SYNCRIP	0.59	10.59	0.44	1.33e-23	Smooth-surface caries;
LGG	cis	rs4262150	0.667	rs4404733	chr5:152251897	T/G	cg12297329	chr5:152029980	NA	0.58	11.27	0.46	3.3e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs8032158	1.000	rs72734373	chr15:56262183	T/G	cg02198044	chr15:56286336	NEDD4	-0.73	-12.76	-0.51	3.72e-32	Keloid;
LGG	cis	rs13191362	0.688	rs73035006	chr6:162997083	G/T	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09820084	chr6:18387507	RNF144B	0.46	7.4	0.33	6.61e-13	Gut microbiome composition (summer);
LGG	cis	rs17209837	0.607	rs2071645	chr7:87105276	G/C	cg00919237	chr7:87102261	ABCB4	-0.8	-16.04	-0.6	2.26e-46	Gallbladder cancer;
LGG	cis	rs16976116	0.901	rs8030981	chr15:55499442	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.22	0.32	2.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1953600	0.729	rs2819872	chr10:81906269	A/G	cg04850286	chr10:81895943	PLAC9	0.37	8.44	0.37	4.08e-16	Sarcoidosis;
LGG	cis	rs798554	0.757	rs1183085	chr7:2875570	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.6	0.37	1.21e-16	Height;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg08280861	chr8:58055591	NA	0.6	7.75	0.34	5.83e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2197308	0.765	rs11182900	chr12:37934009	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg04911050	chr16:677664	RAB40C	0.33	6.73	0.3	5.09e-11	Height;
LGG	cis	rs2880765	0.527	rs1483578	chr15:86075417	A/G	cg10818794	chr15:86012489	AKAP13	-0.41	-8.23	-0.36	1.92e-15	Coronary artery disease;
LGG	cis	rs7587476	0.784	rs13032278	chr2:215698034	G/A	cg04004882	chr2:215674386	BARD1	0.57	8.23	0.36	1.88e-15	Neuroblastoma;
LGG	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg03929089	chr4:120376271	NA	0.44	7.24	0.32	1.89e-12	HDL cholesterol;
LGG	cis	rs3733585	0.648	rs28513781	chr4:9959334	G/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-8.99	-0.39	6.43e-18	Vitiligo;
LGG	cis	rs6815814	0.731	rs10776483	chr4:38775040	A/G	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs4919694	1.000	rs112809537	chr10:104670346	C/T	cg04362960	chr10:104952993	NT5C2	1.06	14.78	0.57	9.05e-41	Arsenic metabolism;
LGG	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06481639	chr22:41940642	POLR3H	-0.45	-6.95	-0.31	1.24e-11	Vitiligo;
LGG	cis	rs13191362	1.000	rs34228197	chr6:163008232	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs910187	0.678	rs8115769	chr20:45813704	A/C	cg27589058	chr20:45804311	EYA2	-0.34	-8.89	-0.38	1.38e-17	Migraine;
LGG	cis	rs7649275	0.882	rs2612030	chr3:53773437	T/C	cg21503701	chr3:53781065	CACNA1D	-0.5	-7.41	-0.33	6.08e-13	Trans fatty acid levels;
LGG	cis	rs6933660	0.760	rs6904364	chr6:151754273	T/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.53	-0.37	2.17e-16	Menarche (age at onset);
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg02018176	chr4:1364513	KIAA1530	0.42	9.46	0.4	1.61e-19	Obesity-related traits;
LGG	cis	rs2718058	0.606	rs1349393	chr7:37869525	C/T	cg15028436	chr7:37888078	TXNDC3	0.54	8.47	0.37	3.29e-16	Alzheimer's disease (late onset);
LGG	cis	rs11122272	0.668	rs2749712	chr1:231537751	T/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.54e-12	Hemoglobin concentration;
LGG	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg02002194	chr4:3960332	NA	-0.39	-7.14	-0.31	3.66e-12	Retinal vascular caliber;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.7	-0.45	4.88e-24	Lung cancer;
LGG	cis	rs7444	0.941	rs140499	chr22:21927231	C/T	cg22858872	chr22:21984481	YDJC	-0.36	-6.72	-0.3	5.51e-11	Systemic lupus erythematosus;
LGG	cis	rs11603023	0.967	rs494560	chr11:118521549	C/T	cg03804240	chr11:118481350	PHLDB1	-0.39	-7.62	-0.33	1.48e-13	Cholesterol, total;
LGG	cis	rs2456568	0.802	rs8181578	chr11:93637442	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.86	-0.3	2.24e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs11105298	0.891	rs3741898	chr12:89933763	G/C	cg00757033	chr12:89920650	WDR51B	0.63	9.1	0.39	2.6e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4771450	0.925	rs4619258	chr13:103981059	T/C	cg02987523	chr13:103978230	NA	-0.33	-7.08	-0.31	5.26e-12	Uric acid levels;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg08888203	chr3:10149979	C3orf24	0.57	8.1	0.35	5.05e-15	Alzheimer's disease;
LGG	cis	rs8064024	0.649	rs11076849	chr16:4888304	G/T	cg04440724	chr16:4920505	UBN1	-0.56	-12.41	-0.5	1.02e-30	Cancer;
LGG	cis	rs57502260	0.704	rs41478448	chr11:68181621	A/G	cg01657329	chr11:68192670	LRP5	-0.6	-8.34	-0.36	8.73e-16	Total body bone mineral density (age 45-60);
LGG	cis	rs12971120	1.000	rs2278161	chr18:72176083	T/C	cg26446133	chr18:72167187	CNDP2	-0.7	-14.8	-0.57	7.54e-41	Refractive error;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.94	-0.54	4.12e-37	Bipolar disorder and schizophrenia;
LGG	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.08	-0.35	5.6e-15	Neuroticism;
LGG	cis	rs2985684	0.894	rs10147029	chr14:50020232	G/T	cg04989706	chr14:50066350	PPIL5	0.6	9.71	0.41	2.15e-20	Carotid intima media thickness;
LGG	cis	rs727563	0.594	rs5758408	chr22:42077737	A/C	cg17376030	chr22:41985996	PMM1	-0.66	-10.74	-0.45	3.43e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.78	15.75	0.59	4.7e-45	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs34164616	chr4:99015251	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg11062466	chr8:58055876	NA	0.48	7.9	0.34	2.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4148087	1.000	rs1117640	chr21:43625274	T/G	cg08841829	chr21:43638893	ABCG1	-0.59	-7.95	-0.35	1.47e-14	Eating disorder in bipolar disorder;
LGG	cis	rs6121246	0.909	rs6088962	chr20:30268184	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.01	-0.31	8.42e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6831352	0.918	rs17218239	chr4:100057020	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs61990749	0.544	rs12435761	chr14:78246077	C/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.2	0.32	2.46e-12	Fibroblast growth factor basic levels;
LGG	cis	rs12200560	0.505	rs4839849	chr6:97076673	T/C	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs2204008	0.555	rs7310307	chr12:38107497	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.7	0.54	4.12e-36	Bladder cancer;
LGG	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg08508325	chr11:3079039	CARS	-0.62	-13.26	-0.52	3e-34	Longevity;
LGG	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.21e-22	Dupuytren's disease;
LGG	cis	rs17102423	0.826	rs10873181	chr14:65604459	A/C	cg11161011	chr14:65562177	MAX	-0.68	-12.97	-0.52	4.82e-33	Obesity-related traits;
LGG	cis	rs12410462	0.551	rs12095502	chr1:227856522	G/A	cg04117972	chr1:227635322	NA	0.43	7.92	0.35	1.73e-14	Major depressive disorder;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg07414643	chr4:187882934	NA	0.57	11.78	0.48	3.35e-28	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg04503457	chr17:41445688	NA	-0.39	-8.99	-0.39	6.32e-18	Menopause (age at onset);
LGG	trans	rs7615952	0.673	rs35001498	chr3:125628644	A/G	cg07211511	chr3:129823064	LOC729375	-1.31	-16.33	-0.6	1.17e-47	Blood pressure (smoking interaction);
LGG	cis	rs10911232	0.507	rs10797816	chr1:182998486	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.41	8.26	0.36	1.53e-15	Hypertriglyceridemia;
LGG	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs2730245	0.527	rs842693	chr7:158660491	C/T	cg24397884	chr7:158709396	WDR60	1.08	15.97	0.6	4.76e-46	Height;
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg15147215	chr3:52552868	STAB1	0.35	6.72	0.3	5.49e-11	Bipolar disorder;
LGG	cis	rs2559856	1.000	rs2695282	chr12:102089502	A/G	cg12924262	chr12:102091054	CHPT1	-0.66	-13.26	-0.52	3.05e-34	Blood protein levels;
LGG	cis	rs17039065	0.920	rs11097994	chr4:109468911	C/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg00684032	chr4:1343700	KIAA1530	0.53	10.65	0.44	7.77e-24	Obesity-related traits;
LGG	trans	rs7395662	0.963	rs12365014	chr11:48629434	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.47	-0.33	4.12e-13	HDL cholesterol;
LGG	cis	rs9644630	0.930	rs4921655	chr8:19366608	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.63	-18.24	-0.65	2.13e-56	Oropharynx cancer;
LGG	cis	rs13191362	1.000	rs35126854	chr6:163012443	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.86	10.12	0.43	6.78e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2204008	0.744	rs11519905	chr12:38222959	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.96	-0.38	7.99e-18	Bladder cancer;
LGG	cis	rs2842992	0.724	rs15982	chr6:160199687	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.76	14.58	0.56	6.67e-40	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg16141378	chr3:129829833	LOC729375	0.45	11.02	0.46	3.18e-25	Mood instability;
LGG	trans	rs7819412	0.783	rs28722721	chr8:10948968	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.16	0.35	3.13e-15	Triglycerides;
LGG	cis	rs834603	0.687	rs17544073	chr7:47451572	C/T	cg23694490	chr7:47445681	TNS3	0.46	13.3	0.53	2.09e-34	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs12368653	0.591	rs1038914	chr12:58011066	G/A	cg12615879	chr12:58013172	SLC26A10	-0.37	-8.64	-0.37	9.02e-17	Multiple sclerosis;
LGG	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg00290607	chr11:67383545	NA	-0.5	-8.99	-0.39	6.5e-18	Mean corpuscular volume;
LGG	cis	rs6426558	0.515	rs7543579	chr1:227377699	A/T	cg10327440	chr1:227177885	CDC42BPA	-0.62	-10.32	-0.43	1.25e-22	Neutrophil percentage of white cells;
LGG	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.99	0.52	3.89e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7301016	0.846	rs12367878	chr12:63027483	C/T	cg01804193	chr12:63026212	NA	0.56	7.21	0.32	2.32e-12	IgG glycosylation;
LGG	cis	rs10504229	0.554	rs2047265	chr8:58153112	T/C	cg08280861	chr8:58055591	NA	0.58	9.88	0.42	5.34e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs10911251	0.508	rs2296297	chr1:183105324	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.79	0.38	3e-17	Colorectal cancer;
LGG	cis	rs713587	1.000	rs713587	chr2:25158281	C/T	cg04586622	chr2:25135609	ADCY3	0.45	12.11	0.49	1.67e-29	Body mass index in non-asthmatics;
LGG	cis	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg07460842	chr6:66804631	NA	0.57	9.51	0.4	1.05e-19	Metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24395307	chr7:39990042	CDK13	0.43	6.94	0.31	1.34e-11	Cognitive performance;
LGG	cis	rs17292804	0.527	rs12887734	chr14:104046834	G/T	cg26031613	chr14:104095156	KLC1	-0.61	-9.67	-0.41	2.76e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg06637938	chr14:75390232	RPS6KL1	0.75	15.0	0.57	9.78e-42	Caffeine consumption;
LGG	cis	rs11764590	0.724	rs1533829	chr7:2082841	A/G	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.91	-0.38	1.22e-17	Neuroticism;
LGG	cis	rs3889237	0.965	rs9915504	chr17:64790434	A/G	cg09655520	chr17:64786064	PRKCA	-0.39	-8.15	-0.35	3.32e-15	Height;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-10.43	-0.44	5.22e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.31e-19	Lung cancer;
LGG	cis	rs9911578	0.681	rs8070135	chr17:56459063	G/A	cg05425664	chr17:57184151	TRIM37	0.58	8.73	0.38	4.5e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6735179	0.550	rs2382559	chr2:1757522	T/C	cg20570797	chr2:1712800	PXDN	-0.45	-8.17	-0.35	2.98e-15	Response to antipsychotic treatment;
LGG	cis	rs3733585	0.699	rs4515163	chr4:9959603	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9443645	0.527	rs9361477	chr6:79710806	C/T	cg18132916	chr6:79620363	NA	-0.27	-6.98	-0.31	1.02e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg16141378	chr3:129829833	LOC729375	0.38	8.3	0.36	1.15e-15	Retinal vascular caliber;
LGG	trans	rs637571	0.654	rs1058068	chr11:65667796	G/A	cg17712092	chr4:129076599	LARP1B	0.91	19.46	0.67	4.61e-62	Eosinophil percentage of white cells;
LGG	cis	rs7264396	0.790	rs6060582	chr20:34313297	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.49	-7.31	-0.32	1.17e-12	Total cholesterol levels;
LGG	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.73	-11.15	-0.46	1.02e-25	Homoarginine levels;
LGG	cis	rs3747547	0.818	rs11790550	chr9:37935319	C/T	cg13774184	chr9:37916125	SHB	-0.72	-8.4	-0.36	5.4e-16	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs270601	0.770	rs1007602	chr5:131602166	T/C	cg07395648	chr5:131743802	NA	-0.36	-7.37	-0.32	7.76e-13	Acylcarnitine levels;
LGG	cis	rs875971	1.000	rs3735148	chr7:65971009	T/G	cg18876405	chr7:65276391	NA	0.55	9.96	0.42	2.58e-21	Aortic root size;
LGG	cis	rs17376456	0.877	rs10035340	chr5:93490465	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.42	0.4	2.21e-19	Diabetic retinopathy;
LGG	trans	rs7829975	0.539	rs4841012	chr8:8551710	C/A	cg16141378	chr3:129829833	LOC729375	0.39	8.64	0.37	9e-17	Mood instability;
LGG	cis	rs2073499	1.000	rs2233474	chr3:50388607	C/A	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.72	9.64	0.41	3.65e-20	Schizophrenia;
LGG	cis	rs12282928	0.836	rs1503177	chr11:48269178	A/G	cg26585981	chr11:48327164	OR4S1	-0.44	-7.15	-0.32	3.34e-12	Migraine - clinic-based;
LGG	cis	rs516946	0.898	rs9694034	chr8:41523358	A/G	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.42	-0.36	4.93e-16	Type 2 diabetes;
LGG	cis	rs368123	1.000	rs505111	chr6:160701424	C/T	cg07349212	chr6:160770346	SLC22A3	0.33	6.9	0.31	1.74e-11	Waist circumference;
LGG	cis	rs4690686	0.836	rs10003662	chr4:177258951	C/G	cg17059388	chr4:177262070	NA	0.73	15.66	0.59	1.16e-44	Essential tremor;
LGG	cis	rs7589342	0.801	rs2889605	chr2:106525073	T/C	cg16077055	chr2:106428750	NCK2	0.26	6.76	0.3	4.08e-11	Addiction;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg08677398	chr8:58056175	NA	0.5	7.94	0.35	1.57e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.847	rs62439808	chr6:149950826	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	9.86e-36	Lung cancer;
LGG	trans	rs7819412	0.740	rs7844536	chr8:11034028	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.86	-0.42	6.17e-21	Triglycerides;
LGG	cis	rs10206020	0.842	rs7609325	chr2:1574718	G/A	cg12573674	chr2:1569213	NA	-0.61	-9.85	-0.42	6.67e-21	IgG glycosylation;
LGG	cis	rs12153243	0.686	rs6580292	chr5:142942241	C/G	cg13907255	chr5:142895549	NA	-0.46	-8.06	-0.35	6.65e-15	Migraine;
LGG	cis	rs2658782	0.547	rs3020065	chr11:93059899	A/G	cg15737290	chr11:93063684	CCDC67	0.66	11.02	0.46	2.99e-25	Pulmonary function decline;
LGG	cis	rs951366	0.705	rs6673687	chr1:205670369	A/T	cg24503407	chr1:205819492	PM20D1	-0.49	-9.69	-0.41	2.49e-20	Menarche (age at onset);
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg02951883	chr7:2050386	MAD1L1	-0.59	-10.55	-0.44	1.89e-23	Bipolar disorder and schizophrenia;
LGG	trans	rs1997103	1.000	rs9642578	chr7:55400320	A/G	cg20935933	chr6:143382018	AIG1	0.57	8.85	0.38	1.92e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs9467160	0.765	rs793712	chr6:24446882	T/C	cg20631270	chr6:24437470	GPLD1	-0.52	-7.85	-0.34	2.82e-14	Liver enzyme levels;
LGG	trans	rs7395662	1.000	rs11039779	chr11:48517895	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.21	-0.32	2.34e-12	HDL cholesterol;
LGG	cis	rs477895	0.653	rs11601577	chr11:63928574	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	11.12	0.46	1.33e-25	Mean platelet volume;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg21911579	chr5:131705225	SLC22A5	0.7	7.77	0.34	5.18e-14	Rheumatoid arthritis;
LGG	cis	rs11122272	0.701	rs2790887	chr1:231523724	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs910316	1.000	rs4903289	chr14:75623988	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.96	-0.45	5.03e-25	Height;
LGG	cis	rs9381040	0.655	rs2268193	chr6:41024625	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.12	-0.31	4.17e-12	Alzheimer's disease (late onset);
LGG	cis	rs8016982	0.589	rs4640110	chr14:81692191	A/G	cg01989461	chr14:81687754	GTF2A1	-0.59	-9.75	-0.41	1.46e-20	Schizophrenia;
LGG	cis	rs12477438	0.834	rs1563108	chr2:99701153	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.6	-10.27	-0.43	1.93e-22	Chronic sinus infection;
LGG	cis	rs12282928	1.000	rs10769345	chr11:48335164	C/G	cg26585981	chr11:48327164	OR4S1	0.45	7.17	0.32	3.01e-12	Migraine - clinic-based;
LGG	cis	rs6462411	0.877	rs10241703	chr7:3919481	A/G	cg18022346	chr7:3920534	SDK1	0.37	7.22	0.32	2.16e-12	Quantitative traits;
LGG	cis	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg00071950	chr4:10020882	SLC2A9	-0.35	-6.76	-0.3	4.2e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10170846	1.000	rs10170846	chr2:223517705	C/G	cg25565276	chr2:223520875	FARSB	-0.76	-13.05	-0.52	2.3e-33	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg05368731	chr17:41323189	NBR1	0.96	18.78	0.66	6.21e-59	Menopause (age at onset);
LGG	cis	rs4737010	0.570	rs6474364	chr8:41646997	T/G	cg17182837	chr8:41585554	ANK1	-0.53	-7.86	-0.34	2.64e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs6598955	0.724	rs3924934	chr1:26644079	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.38	7.58	0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.42	-0.33	5.74e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs889398	0.802	rs2937121	chr16:69870409	T/G	cg00738113	chr16:70207722	CLEC18C	0.24	6.69	0.3	6.43e-11	Body mass index;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg14789911	chr21:47582049	C21orf56	0.52	9.42	0.4	2.19e-19	Testicular germ cell tumor;
LGG	cis	rs6938	0.618	rs11633472	chr15:75184084	T/G	cg17294928	chr15:75287854	SCAMP5	0.66	12.33	0.5	2.19e-30	Breast cancer;
LGG	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg24623649	chr8:11872141	NA	0.3	7.11	0.31	4.41e-12	Retinal vascular caliber;
LGG	cis	rs6582630	0.502	rs11181475	chr12:38348922	G/A	cg26384229	chr12:38710491	ALG10B	0.91	20.37	0.69	2.4e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	1.000	rs4949879	chr1:76237143	G/A	cg03433033	chr1:76189801	ACADM	0.76	12.31	0.5	2.65e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs28647808	0.881	rs7042326	chr9:136266636	T/C	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.7	0.56	1.99e-40	Platelet count;
LGG	cis	rs867371	0.502	rs8025964	chr15:82521770	G/A	cg00614314	chr15:82944287	LOC80154	0.46	7.53	0.33	2.6e-13	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7572263	0.724	rs6710543	chr2:209050447	G/A	cg00164906	chr2:209055251	C2orf80	0.71	9.57	0.41	6.52e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs28829049	0.597	rs2296107	chr1:19476649	C/G	cg13387374	chr1:19411106	UBR4	0.37	6.68	0.3	7e-11	QRS duration in Tripanosoma cruzi seropositivity;
LGG	cis	rs2229238	0.911	rs7556449	chr1:154505886	C/T	cg10237817	chr1:154519846	TDRD10	-0.34	-6.87	-0.3	2.11e-11	Coronary heart disease;
LGG	trans	rs1814175	0.817	rs7947526	chr11:49983654	T/C	cg03929089	chr4:120376271	NA	-1.04	-24.38	-0.75	4.78e-85	Height;
LGG	cis	rs6495122	0.501	rs12148488	chr15:75382542	G/T	cg09165964	chr15:75287851	SCAMP5	-0.54	-9.98	-0.42	2.3e-21	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs941408	0.515	rs1640265	chr19:2784405	C/T	cg22153745	chr1:153894579	GATAD2B	-0.59	-8.64	-0.37	9.05e-17	Total cholesterol levels;
LGG	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg09307838	chr4:120376055	NA	0.8	13.44	0.53	5.47e-35	Corneal astigmatism;
LGG	cis	rs2131877	0.701	rs57357728	chr3:194832106	G/A	cg07250128	chr3:194833983	C3orf21	0.39	6.82	0.3	2.93e-11	Non-small cell lung cancer;
LGG	cis	rs17253792	0.822	rs75288952	chr14:56034010	C/T	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.93	-11.12	-0.46	1.3e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7084402	0.967	rs1649066	chr10:60305916	G/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.49	-0.33	3.61e-13	Refractive error;
LGG	cis	rs713587	0.626	rs62140636	chr2:25233811	T/C	cg04586622	chr2:25135609	ADCY3	-0.37	-9.62	-0.41	4.22e-20	Body mass index in non-asthmatics;
LGG	cis	rs1451375	0.652	rs1470747	chr7:50627009	C/T	cg14593290	chr7:50529359	DDC	0.5	8.75	0.38	3.86e-17	Malaria;
LGG	cis	rs769267	0.930	rs10414830	chr19:19562332	C/T	cg03709012	chr19:19516395	GATAD2A	0.84	17.01	0.62	8.88e-51	Tonsillectomy;
LGG	cis	rs116095464	0.558	rs10056628	chr5:279512	G/A	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25026957	chr14:74416582	FAM161B;COQ6	0.58	9.0	0.39	5.85e-18	Gut microbiome composition (summer);
LGG	cis	rs9788682	0.747	rs2568488	chr15:78736593	T/A	cg06917634	chr15:78832804	PSMA4	0.53	8.06	0.35	6.39e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs28735056	0.935	rs11662267	chr18:77641902	C/G	cg20368463	chr18:77673604	PQLC1	-0.48	-8.06	-0.35	6.79e-15	Schizophrenia;
LGG	cis	rs6754311	0.509	rs10188066	chr2:136539513	G/A	cg07169764	chr2:136633963	MCM6	-0.86	-15.52	-0.59	4.63e-44	Mosquito bite size;
LGG	cis	rs17376456	0.542	rs1982439	chr5:93160560	C/G	cg19507638	chr5:93509721	C5orf36	0.41	6.81	0.3	2.98e-11	Diabetic retinopathy;
LGG	cis	rs3785574	0.962	rs56295011	chr17:61850359	A/G	cg06873352	chr17:61820015	STRADA	0.47	7.37	0.32	7.74e-13	Height;
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg05863683	chr7:1912471	MAD1L1	0.48	9.41	0.4	2.27e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.834	rs10838993	chr11:5979221	T/C	cg02574844	chr11:5959923	NA	-0.56	-8.77	-0.38	3.51e-17	DNA methylation (variation);
LGG	cis	rs3733585	0.534	rs7375642	chr4:9955236	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7107174	1.000	rs11237471	chr11:78082604	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.57	-0.33	2.04e-13	Testicular germ cell tumor;
LGG	cis	rs5758511	0.514	rs5758622	chr22:42563933	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.42	0.33	5.78e-13	Birth weight;
LGG	cis	rs1348850	0.914	rs12612857	chr2:178467144	A/G	cg22681709	chr2:178499509	PDE11A	-0.44	-7.76	-0.34	5.3e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs61931739	0.500	rs7979482	chr12:34542877	C/A	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06905471	chr2:29092871	TRMT61B	0.46	6.86	0.3	2.29e-11	Gut microbiome composition (summer);
LGG	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg27398817	chr8:82754497	SNX16	-0.66	-10.38	-0.43	7.81e-23	Diastolic blood pressure;
LGG	cis	rs17030434	0.784	rs8180349	chr4:154657038	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.7	-0.41	2.29e-20	Electrocardiographic conduction measures;
LGG	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg17376030	chr22:41985996	PMM1	0.68	10.77	0.45	2.66e-24	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs116095464	0.558	rs28558836	chr5:285748	C/G	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs10911232	0.507	rs10797822	chr1:183017769	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	trans	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs1728785	1.000	rs1645936	chr16:68563743	A/G	cg02972257	chr16:68554789	NA	-0.5	-7.63	-0.33	1.39e-13	Ulcerative colitis;
LGG	cis	rs7618501	1.000	rs7372725	chr3:49790544	C/A	cg24110177	chr3:50126178	RBM5	0.4	6.89	0.3	1.82e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.86	0.38	1.77e-17	Common traits (Other);
LGG	cis	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg01145232	chr6:150245071	RAET1G	0.48	8.7	0.37	5.72e-17	Lung cancer;
LGG	cis	rs2479106	0.892	rs549779	chr9:126613028	A/G	cg16191174	chr9:126692580	DENND1A	-0.45	-6.85	-0.3	2.33e-11	Polycystic ovary syndrome;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.79e-12	Blood metabolite levels;
LGG	cis	rs146972365	1	rs146972365	chr16:90022693	T/C	cg07984980	chr16:89898383	SPIRE2	1.14	9.73	0.41	1.75e-20	Brown vs. non-brown hair color;Red vs non-red hair color;Light vs. dark hair color;
LGG	cis	rs13108904	0.539	rs13140926	chr4:1340939	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.62	10.5	0.44	2.77e-23	Obesity-related traits;
LGG	cis	rs9322193	0.566	rs12528243	chr6:150219627	G/A	cg01145232	chr6:150245071	RAET1G	0.48	8.72	0.38	5.15e-17	Lung cancer;
LGG	cis	rs4561483	0.831	rs2075158	chr16:11945231	T/C	cg08843971	chr16:11963173	GSPT1	0.61	14.31	0.55	9.88e-39	Testicular germ cell tumor;
LGG	cis	rs6088580	0.634	rs6120650	chr20:33039973	G/A	cg08999081	chr20:33150536	PIGU	0.41	10.17	0.43	4.57e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg25486957	chr4:152246857	NA	-0.38	-6.67	-0.3	7.39e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7586879	0.675	rs7600421	chr2:25075876	T/G	cg04586622	chr2:25135609	ADCY3	0.35	8.1	0.35	4.86e-15	Body mass index;
LGG	cis	rs4689388	0.926	rs11732178	chr4:6292643	G/C	cg25554036	chr4:6271136	WFS1	0.61	11.68	0.48	8.18e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs17331151	0.573	rs76029595	chr3:52868523	C/T	cg04865290	chr3:52927548	TMEM110	-0.42	-7.11	-0.31	4.46e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.73	13.43	0.53	5.57e-35	Obesity-related traits;
LGG	trans	rs4332037	0.539	rs11764590	chr7:2032803	C/T	cg22232500	chr2:134024266	NCKAP5	0.53	7.33	0.32	1.05e-12	Bipolar disorder;
LGG	cis	rs1153858	1.000	rs4627277	chr15:45652768	C/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.82	0.3	2.78e-11	Homoarginine levels;
LGG	cis	rs7811142	0.830	rs6965458	chr7:99973402	G/A	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.55	-0.41	7.75e-20	Platelet count;
LGG	cis	rs910316	0.934	rs7141705	chr14:75655352	G/C	cg08847533	chr14:75593920	NEK9	-0.59	-11.1	-0.46	1.47e-25	Height;
LGG	trans	rs853679	0.599	rs202906	chr6:28011652	C/T	cg06606381	chr12:133084897	FBRSL1	0.85	9.16	0.39	1.74e-18	Depression;
LGG	cis	rs614226	0.872	rs12307148	chr12:120903179	T/C	cg21053147	chr12:120880522	NA	0.52	7.87	0.34	2.56e-14	Type 1 diabetes nephropathy;
LGG	cis	rs8180040	0.966	rs13064843	chr3:47415467	C/T	cg16586182	chr3:47516702	SCAP	-0.78	-15.94	-0.6	6.2e-46	Colorectal cancer;
LGG	cis	rs1371614	0.632	rs10196501	chr2:27147272	C/T	cg12045002	chr2:27069975	DPYSL5	0.32	6.92	0.31	1.53e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs17376456	1.000	rs9968691	chr5:93509756	C/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.18	0.39	1.38e-18	Diabetic retinopathy;
LGG	cis	rs12824058	0.798	rs4759652	chr12:130808771	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.02	0.52	3.1e-33	Menopause (age at onset);
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg10295955	chr4:187884368	NA	-1.15	-31.62	-0.83	9.56e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2235649	0.798	rs9932983	chr16:1848184	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-7.07	-0.31	5.67e-12	Blood metabolite levels;
LGG	cis	rs2066819	1.000	rs77032009	chr12:56679971	A/G	cg26714650	chr12:56694279	CS	-1.58	-16.53	-0.61	1.36e-48	Psoriasis vulgaris;
LGG	cis	rs9303280	0.837	rs907092	chr17:37922259	A/G	cg19468946	chr17:37922297	IKZF3	0.48	8.71	0.38	5.36e-17	Self-reported allergy;
LGG	cis	rs3768617	0.510	rs10797842	chr1:183081867	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.74	0.38	4.26e-17	Fuchs's corneal dystrophy;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.76	-0.45	2.87e-24	Lung cancer;
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.7e-13	Aortic root size;
LGG	cis	rs6450176	0.638	rs11746856	chr5:53291295	A/C	ch.5.1024479R	chr5:53302184	ARL15	-1.06	-16.22	-0.6	3.61e-47	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs981844	1.000	rs2251900	chr4:154654145	C/T	cg14289246	chr4:154710475	SFRP2	0.68	11.27	0.46	3.46e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs6489882	0.867	rs7958379	chr12:113363284	A/G	cg25319449	chr12:113376135	OAS3	-0.4	-7.41	-0.33	5.93e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7010267	0.570	rs7004459	chr8:120040263	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.32	8.08	0.35	5.57e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs62380364	0.626	rs11749912	chr5:88065628	A/G	cg22951263	chr5:87985283	NA	-0.55	-10.05	-0.42	1.23e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6748734	1.000	rs4675863	chr2:241830763	A/T	cg07537917	chr2:241836409	C2orf54	-0.42	-8.19	-0.36	2.52e-15	Urinary metabolites;
LGG	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.18	-0.36	2.81e-15	HDL cholesterol;
LGG	trans	rs61931739	0.635	rs1825746	chr12:33939984	C/T	cg13010199	chr12:38710504	ALG10B	0.44	8.3	0.36	1.15e-15	Morning vs. evening chronotype;
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg05793240	chr7:2802953	GNA12	0.34	7.7	0.34	8.54e-14	Height;
LGG	trans	rs9354308	0.753	rs10944854	chr6:66604806	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.42	6.99	0.31	9.47e-12	Metabolite levels;
LGG	cis	rs2470578	0.646	rs2733504	chr3:17271759	A/G	cg20981856	chr3:17787350	NA	0.35	6.7	0.3	5.99e-11	Schizophrenia;
LGG	cis	rs6456156	0.586	rs2345753	chr6:167484344	T/A	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	cis	rs9302635	0.640	rs9933009	chr16:72190650	G/A	cg23815491	chr16:72088622	HP	0.44	8.57	0.37	1.6e-16	Blood protein levels;
LGG	cis	rs1018836	0.828	rs7816023	chr8:91567398	T/C	cg16814680	chr8:91681699	NA	-0.73	-13.15	-0.52	8.95e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7599312	0.532	rs7564590	chr2:213387900	C/T	cg16329650	chr2:213403929	ERBB4	0.49	8.08	0.35	5.57e-15	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	1.000	rs67188507	chr8:58187492	A/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6694672	0.867	rs4915307	chr1:197048608	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.43e-40	Retinal vascular caliber;
LGG	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg06494592	chr3:125709126	NA	-0.54	-6.8	-0.3	3.26e-11	Blood pressure (smoking interaction);
LGG	cis	rs2762353	0.595	rs10498728	chr6:25751320	A/T	cg17711541	chr6:26124704	HIST1H2AC;HIST1H2BC	-0.41	-6.65	-0.3	8.03e-11	Blood metabolite levels;
LGG	cis	rs1420338	1.000	rs1420338	chr7:34143256	G/A	cg01275685	chr7:34179230	BMPER	-0.46	-8.27	-0.36	1.4e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.4	0.36	5.64e-16	Tonsillectomy;
LGG	cis	rs9527	0.615	rs9733635	chr10:104711940	G/A	cg04362960	chr10:104952993	NT5C2	0.56	10.33	0.43	1.22e-22	Arsenic metabolism;
LGG	cis	rs7084402	0.967	rs1649019	chr10:60288111	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg22307297	chr20:60903441	LAMA5	-0.44	-8.55	-0.37	1.79e-16	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9487094	0.670	rs10782163	chr6:109854243	C/A	cg01125227	chr6:109776195	MICAL1	0.44	7.8	0.34	4.25e-14	Height;
LGG	cis	rs10028773	0.546	rs13117947	chr4:120257060	A/G	cg09307838	chr4:120376055	NA	0.46	7.68	0.34	9.58e-14	Educational attainment;
LGG	cis	rs1372520	0.745	rs2736994	chr4:90784528	A/G	cg15133208	chr4:90757351	SNCA	-0.34	-6.67	-0.3	7.36e-11	Neuroticism;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg16339924	chr4:17578868	LAP3	0.52	8.7	0.37	5.75e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26386846	chr3:118753714	IGSF11	0.49	7.52	0.33	2.87e-13	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22792272	chr6:43597128	MAD2L1BP;GTPBP2	0.46	7.39	0.32	6.7e-13	Cognitive performance;
LGG	cis	rs992157	0.798	rs1017698	chr2:219170525	A/G	cg00012203	chr2:219082015	ARPC2	-0.64	-11.61	-0.47	1.54e-27	Colorectal cancer;
LGG	cis	rs1908814	0.516	rs7825529	chr8:11794444	C/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs798554	0.610	rs2248390	chr7:2855594	T/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.26	-0.36	1.5e-15	Height;
LGG	cis	rs11628318	0.614	rs10140498	chr14:103154191	A/G	cg01864069	chr14:103024347	NA	0.65	9.45	0.4	1.63e-19	Platelet count;
LGG	cis	rs7551222	0.752	rs12130686	chr1:204554057	G/C	cg20240347	chr1:204465584	NA	-0.48	-9.63	-0.41	4.1e-20	Schizophrenia;
LGG	trans	rs2204008	0.614	rs4578492	chr12:38036350	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.88e-18	Bladder cancer;
LGG	cis	rs3741151	0.881	rs79623427	chr11:73094896	C/T	cg17517138	chr11:73019481	ARHGEF17	0.98	9.39	0.4	2.73e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7712401	0.623	rs30043	chr5:122272293	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	2.9e-12	Mean platelet volume;
LGG	cis	rs9611565	0.694	rs2142505	chr22:41820541	A/G	cg06481639	chr22:41940642	POLR3H	0.58	8.46	0.37	3.54e-16	Vitiligo;
LGG	cis	rs72945132	0.882	rs3900797	chr11:70186614	C/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.19	0.36	2.62e-15	Coronary artery disease;
LGG	cis	rs34599045	1.000	rs34593101	chr1:152881350	C/T	cg07796016	chr1:152779584	LCE1C	-0.82	-8.47	-0.37	3.26e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11148252	0.512	rs9526950	chr13:53174463	C/A	cg05335186	chr13:53173507	NA	0.89	23.82	0.74	1.89e-82	Lewy body disease;
LGG	cis	rs877426	0.681	rs7317994	chr13:114817068	C/T	cg00571178	chr13:114841904	RASA3	-0.56	-10.15	-0.43	5.45e-22	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs6541297	1.000	rs6665367	chr1:230279169	G/A	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs6594713	0.602	rs33992630	chr5:112903169	G/A	cg12552261	chr5:112820674	MCC	0.6	8.12	0.35	4.29e-15	Brain cytoarchitecture;
LGG	cis	rs12681288	0.894	rs66739903	chr8:1010492	C/A	cg04851639	chr8:1020857	NA	-0.47	-9.72	-0.41	1.94e-20	Schizophrenia;
LGG	cis	rs6977660	0.660	rs28663574	chr7:19816905	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.57	0.37	1.5e-16	Thyroid stimulating hormone;
LGG	cis	rs11122272	0.732	rs2808605	chr1:231540187	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.65e-26	Hemoglobin concentration;
LGG	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg24759859	chr6:86352639	SYNCRIP	0.43	7.13	0.31	3.87e-12	Smooth-surface caries;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.69e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.43	-0.33	5.28e-13	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15051960	chr3:55521376	WNT5A	0.43	7.04	0.31	6.78e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7223966	0.655	rs6504165	chr17:61630076	T/C	cg11494091	chr17:61959527	GH2	0.47	7.15	0.32	3.49e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3750450	0.718	rs4978778	chr9:111937890	G/C	cg14171727	chr9:111936775	EPB41L4B	-0.4	-8.01	-0.35	9.11e-15	Low vWF levels;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.84	0.42	7.43e-21	Prudent dietary pattern;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.53	0.37	2.13e-16	Lung cancer;
LGG	cis	rs9640161	0.871	rs56156367	chr7:150047201	A/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-14.53	-0.56	1.14e-39	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9322193	0.683	rs113281309	chr6:150108425	T/G	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.45e-11	Lung cancer;
LGG	trans	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08862035	chr2:2617432	NA	0.42	6.9	0.31	1.75e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs11781690	chr8:58132931	C/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs10193935	0.901	rs92303	chr2:42656337	A/G	cg27598129	chr2:42591480	NA	0.65	9.84	0.42	7.33e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10754283	0.967	rs10737707	chr1:90119304	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.22	-0.32	2.19e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4481887	0.854	rs4534423	chr1:248474993	G/C	cg01631408	chr1:248437212	OR2T33	-0.5	-8.92	-0.38	1.07e-17	Common traits (Other);
LGG	cis	rs8067545	0.720	rs11204420	chr17:19889020	A/C	cg13482628	chr17:19912719	NA	0.55	10.08	0.42	9.79e-22	Schizophrenia;
LGG	cis	rs10493773	0.928	rs12741600	chr1:86191172	A/C	cg17807903	chr1:86174739	ZNHIT6	-0.64	-11.77	-0.48	3.79e-28	Urate levels in overweight individuals;
LGG	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.62	-0.33	1.42e-13	Colorectal cancer;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg19168338	chr16:4465731	CORO7	-0.79	-15.01	-0.57	8.77e-42	Schizophrenia;
LGG	cis	rs7208859	0.673	rs73277967	chr17:29184166	T/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs892961	0.899	rs8071024	chr17:75414067	T/C	cg05865280	chr17:75406074	SEPT9	0.43	10.19	0.43	3.85e-22	Airflow obstruction;
LGG	cis	rs12579753	0.871	rs1922540	chr12:82197496	A/G	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.34	-0.47	1.87e-26	Resting heart rate;
LGG	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26850624	chr5:429559	AHRR	-0.31	-6.94	-0.31	1.36e-11	Cystic fibrosis severity;
LGG	cis	rs3858526	0.606	rs10838883	chr11:5952147	G/A	cg25319279	chr11:5960081	NA	0.59	9.95	0.42	2.79e-21	DNA methylation (variation);
LGG	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg16339924	chr4:17578868	LAP3	0.61	10.71	0.45	4.41e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs600550	0.588	rs11230251	chr11:60088755	G/A	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.77	-0.34	4.94e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs12681288	0.676	rs1562925	chr8:1010894	A/G	cg15309053	chr8:964076	NA	0.43	8.29	0.36	1.22e-15	Schizophrenia;
LGG	cis	rs11249608	0.548	rs2132672	chr5:178457742	A/C	cg21905437	chr5:178450457	ZNF879	0.46	6.68	0.3	6.7e-11	Pubertal anthropometrics;
LGG	trans	rs12310956	0.510	rs10743832	chr12:33884146	A/C	cg26384229	chr12:38710491	ALG10B	0.64	12.32	0.5	2.27e-30	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs67478160	0.643	rs6575997	chr14:104228546	C/T	cg26031613	chr14:104095156	KLC1	0.45	7.39	0.32	7e-13	Schizophrenia;
LGG	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.01	17.39	0.63	1.64e-52	Chronic sinus infection;
LGG	cis	rs28595532	0.920	rs115006522	chr4:119732499	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs853679	0.882	rs9366717	chr6:28191057	C/T	cg08344181	chr3:125677491	NA	-0.66	-7.79	-0.34	4.59e-14	Depression;
LGG	trans	rs877282	0.898	rs11253346	chr10:765313	A/G	cg22713356	chr15:30763199	NA	0.52	7.6	0.33	1.71e-13	Uric acid levels;
LGG	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg04173714	chr15:86211321	AKAP13	0.46	8.52	0.37	2.21e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7928758	0.887	rs117735303	chr11:134271893	C/T	cg22777979	chr11:134283252	B3GAT1	1.04	13.67	0.54	5.64e-36	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4076764	1.000	rs4469696	chr1:163424565	C/T	cg24596788	chr1:163392923	NA	-0.68	-12.74	-0.51	4.36e-32	Motion sickness;
LGG	cis	rs12477438	0.501	rs1451246	chr2:100064283	C/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.89	-0.3	1.88e-11	Chronic sinus infection;
LGG	cis	rs561341	0.700	rs886223	chr17:30229877	G/T	cg00745463	chr17:30367425	LRRC37B	-0.45	-7.1	-0.31	4.62e-12	Hip circumference adjusted for BMI;
LGG	cis	rs17376456	0.569	rs10076965	chr5:93094972	G/A	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs59104589	0.617	rs3755400	chr2:242379795	A/C	cg10021735	chr2:242295487	FARP2	-0.48	-6.74	-0.3	4.63e-11	Fibrinogen levels;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.36	-0.36	7.42e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10895140	0.626	rs4384359	chr11:101510879	T/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs11785400	0.793	rs4301430	chr8:143737416	A/G	cg24634471	chr8:143751801	JRK	0.5	7.66	0.34	1.1e-13	Schizophrenia;
LGG	cis	rs6547741	1.000	rs6749052	chr2:27772879	A/T	cg27432699	chr2:27873401	GPN1	0.7	14.12	0.55	6.41e-38	Oral cavity cancer;
LGG	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg20578329	chr17:80767326	TBCD	-0.77	-10.98	-0.45	4.24e-25	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9470366	0.816	rs4331968	chr6:36623243	A/T	cg08179530	chr6:36648295	CDKN1A	0.63	9.29	0.4	5.87e-19	QRS duration;
LGG	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg24450063	chr1:156163899	SLC25A44	1.21	30.5	0.82	8.23e-113	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs62441284	chr6:150072678	C/A	cg12070911	chr6:150209640	RAET1E	0.3	7.33	0.32	1.04e-12	Lung cancer;
LGG	trans	rs9951602	0.512	rs12607612	chr18:76651799	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04854107	chr15:38544003	SPRED1	0.4	6.68	0.3	6.96e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2204008	0.837	rs8189467	chr12:38241956	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.3	0.53	2.02e-34	Bladder cancer;
LGG	cis	rs17767392	0.813	rs12891975	chr14:71789862	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.75	-0.38	4.06e-17	Mitral valve prolapse;
LGG	cis	rs28595532	0.841	rs112953035	chr4:119752450	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.74	0.34	6.52e-14	Cannabis dependence symptom count;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04024692	chr11:16760046	C11orf58	-0.5	-7.33	-0.32	1.01e-12	Systemic lupus erythematosus;
LGG	cis	rs8133932	0.906	rs75900404	chr21:47105155	G/A	cg11214348	chr21:47283868	PCBP3	-0.43	-7.22	-0.32	2.12e-12	Schizophrenia;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg23978390	chr7:1156363	C7orf50	0.54	9.16	0.39	1.62e-18	Longevity;Endometriosis;
LGG	cis	rs10267417	0.603	rs10273376	chr7:19911647	T/A	cg05791153	chr7:19748676	TWISTNB	0.57	7.54	0.33	2.54e-13	Night sleep phenotypes;
LGG	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.83	-0.48	2.13e-28	Mean platelet volume;
LGG	cis	rs427394	0.735	rs416689	chr5:6740855	C/T	cg15145174	chr5:6755386	POLS	-0.4	-7.69	-0.34	8.98e-14	Menopause (age at onset);
LGG	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6580649	0.941	rs7963934	chr12:48477086	C/G	cg24011408	chr12:48396354	COL2A1	-0.54	-6.69	-0.3	6.39e-11	Lung cancer;
LGG	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg03929089	chr4:120376271	NA	-0.53	-8.97	-0.38	7.18e-18	HDL cholesterol;
LGG	cis	rs9814567	1.000	rs7427492	chr3:134261654	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.08	-0.52	1.75e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs79839061	0.518	rs3755961	chr4:895059	A/G	cg07828340	chr4:882639	GAK	0.93	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.81	0.34	3.88e-14	Schizophrenia;
LGG	cis	rs9815354	1.000	rs10212536	chr3:41827026	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.29	0.36	1.2e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7192750	0.586	rs9806882	chr16:71925511	G/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.5	0.44	2.74e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs7819412	0.668	rs2409721	chr8:11038244	A/T	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.35	-0.43	9.78e-23	Triglycerides;
LGG	cis	rs10743315	0.557	rs16915323	chr12:19437529	A/G	cg02471346	chr12:19282374	PLEKHA5	0.79	7.7	0.34	8.41e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7829975	0.774	rs57312668	chr8:8680477	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.87	0.34	2.5e-14	Mood instability;
LGG	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	28.06	0.79	6.13e-102	Height;
LGG	cis	rs9636252	0.887	rs13026939	chr2:9264924	C/G	cg20341998	chr2:9276514	NA	-0.37	-6.99	-0.31	9.81e-12	IgG glycosylation;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs6866344	0.697	rs61247551	chr5:178133503	G/A	cg03877680	chr5:178157825	ZNF354A	0.77	12.3	0.5	2.81e-30	Neutrophil percentage of white cells;
LGG	cis	rs4660214	0.666	rs663449	chr1:39843958	G/A	cg18385671	chr1:39797026	MACF1	0.47	9.99	0.42	2.14e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs79911532	0.515	rs76180651	chr7:75704350	T/G	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	trans	rs7819412	0.505	rs17782554	chr8:11022106	C/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.05	-0.35	6.84e-15	Triglycerides;
LGG	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs6089829	0.925	rs6122086	chr20:61664528	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.11	0.31	4.52e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs963731	0.649	rs10439459	chr2:39236983	G/T	cg04010122	chr2:39346883	SOS1	-0.79	-7.08	-0.31	5.48e-12	Corticobasal degeneration;
LGG	cis	rs7147624	0.882	rs7141367	chr14:65938641	C/T	cg03016385	chr14:66212404	NA	-0.78	-10.13	-0.43	6.36e-22	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs9467711	0.606	rs9379873	chr6:26402717	T/C	cg06606381	chr12:133084897	FBRSL1	-0.86	-8.61	-0.37	1.13e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.01	-0.31	8.75e-12	Personality dimensions;
LGG	cis	rs526231	0.543	rs246913	chr5:102560370	G/C	cg23492399	chr5:102201601	PAM	-0.6	-8.57	-0.37	1.59e-16	Primary biliary cholangitis;
LGG	cis	rs11690935	0.959	rs3770451	chr2:172668715	T/G	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.61	-0.78	2.37e-95	Schizophrenia;
LGG	cis	rs11585357	0.895	rs34324150	chr1:17632464	C/G	cg08277548	chr1:17600880	PADI3	-0.74	-8.35	-0.36	8.22e-16	Hair shape;
LGG	cis	rs7647973	1.000	rs13088309	chr3:49368317	A/G	cg07636037	chr3:49044803	WDR6	0.76	13.32	0.53	1.68e-34	Menarche (age at onset);
LGG	cis	rs4493873	0.731	rs34250051	chr8:92047462	G/A	cg16814680	chr8:91681699	NA	0.49	8.07	0.35	6.04e-15	Migraine - clinic-based;
LGG	cis	rs4819052	0.807	rs4819047	chr21:46665139	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.01	0.52	3.45e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg06521331	chr12:34319734	NA	-0.46	-8.03	-0.35	8.08e-15	Heart rate;
LGG	cis	rs4953318	0.577	rs67087783	chr2:46363544	C/T	cg12428440	chr2:46370979	PRKCE	0.49	9.02	0.39	5.17e-18	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	trans	rs8073060	0.586	rs226087	chr17:34017652	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7618915	0.547	rs35211965	chr3:52685305	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.75	0.41	1.48e-20	Bipolar disorder;
LGG	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg19761014	chr17:28927070	LRRC37B2	0.67	7.82	0.34	3.62e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg02725872	chr8:58115012	NA	-0.75	-10.46	-0.44	3.89e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.963	rs62160261	chr2:128152661	G/T	cg10021288	chr2:128175891	PROC	-0.67	-13.82	-0.54	1.3e-36	Protein C levels;
LGG	cis	rs2227564	0.700	rs2688613	chr10:75653045	C/T	cg00564723	chr10:75632066	CAMK2G	-0.43	-8.86	-0.38	1.78e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7927592	0.513	rs531163	chr11:68194496	A/G	cg01657329	chr11:68192670	LRP5	-0.59	-10.69	-0.44	5.63e-24	Total body bone mineral density;
LGG	cis	rs7172689	0.955	rs8039027	chr15:81556272	A/G	cg11808699	chr15:81528661	IL16	0.5	10.77	0.45	2.85e-24	Inattentive symptoms;
LGG	cis	rs5753037	0.543	rs131267	chr22:30147861	A/G	cg01021169	chr22:30184971	ASCC2	-0.37	-7.3	-0.32	1.24e-12	Type 1 diabetes;
LGG	cis	rs13102973	0.682	rs7441468	chr4:135886736	C/T	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs778371	1.000	rs709937	chr2:233744021	A/G	cg25237894	chr2:233734115	C2orf82	0.45	7.63	0.33	1.37e-13	Schizophrenia;
LGG	cis	rs939317	0.635	rs843371	chr3:183994536	A/G	cg09405238	chr3:183994500	ECE2	0.55	10.41	0.44	5.91e-23	Menarche (age at onset);
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg13206674	chr6:150067644	NUP43	0.61	13.66	0.54	6.48e-36	Lung cancer;
LGG	cis	rs4595586	0.545	rs58154430	chr12:39386649	C/T	cg26384229	chr12:38710491	ALG10B	0.65	11.78	0.48	3.36e-28	Morning vs. evening chronotype;
LGG	cis	rs4319547	0.956	rs10744275	chr12:123048618	A/G	cg23029597	chr12:123009494	RSRC2	-0.96	-18.41	-0.65	3.55e-57	Body mass index;
LGG	cis	rs701145	0.938	rs355768	chr3:154045001	A/G	cg17054900	chr3:154042577	DHX36	0.97	12.17	0.49	9.72e-30	Coronary artery disease;
LGG	cis	rs3126085	0.877	rs12116736	chr1:152167062	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.83	0.38	2.19e-17	Atopic dermatitis;
LGG	cis	rs8114671	0.562	rs6088640	chr20:33472509	C/T	cg07148914	chr20:33460835	GGT7	0.53	8.9	0.38	1.24e-17	Height;
LGG	trans	rs7824557	0.628	rs58283816	chr8:11192551	G/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.18	0.32	2.73e-12	Retinal vascular caliber;
LGG	cis	rs5769765	0.862	rs138857	chr22:50199589	C/T	cg02269571	chr22:50332266	NA	-0.58	-8.98	-0.39	6.88e-18	Schizophrenia;
LGG	cis	rs72772090	0.539	rs72773932	chr5:96118148	T/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.97	-0.38	7.26e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8072100	0.748	rs9908016	chr17:45551361	G/A	cg25173405	chr17:45401733	C17orf57	-0.53	-9.42	-0.4	2.08e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs72615157	0.634	rs74774557	chr7:99810425	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.62	8.41	0.36	4.99e-16	Lung function (FEV1/FVC);
LGG	cis	rs3785574	0.650	rs2320125	chr17:62008318	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.52	-8.33	-0.36	9.52e-16	Height;
LGG	cis	rs9815354	0.904	rs73081347	chr3:41903582	T/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs1814175	0.791	rs9787917	chr11:49937281	C/T	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	cis	rs939658	0.805	rs2177056	chr15:79441489	T/C	cg17916960	chr15:79447300	NA	-0.66	-12.8	-0.51	2.6e-32	Refractive error;
LGG	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg03030879	chr14:75389066	RPS6KL1	-0.38	-6.91	-0.31	1.63e-11	Caffeine consumption;
LGG	cis	rs4689388	0.609	rs4688988	chr4:6287456	C/T	cg00701064	chr4:6280414	WFS1	0.58	10.6	0.44	1.22e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg06968155	chr5:131705112	SLC22A5	0.71	8.21	0.36	2.21e-15	Rheumatoid arthritis;
LGG	cis	rs1401999	0.898	rs6443928	chr3:183729487	C/T	cg20387954	chr3:183756860	HTR3D	0.69	14.03	0.55	1.66e-37	Anterior chamber depth;
LGG	cis	rs35110281	0.744	rs162396	chr21:44947807	T/C	cg04455712	chr21:45112962	RRP1B	0.54	10.3	0.43	1.54e-22	Mean corpuscular volume;
LGG	trans	rs453301	0.571	rs330057	chr8:9089793	C/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.7	-0.41	2.16e-20	Joint mobility (Beighton score);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg11050988	chr7:1952600	MAD1L1	-0.44	-10.92	-0.45	7.5e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	1.000	rs7766645	chr6:86622238	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs75804782	0.641	rs1030786	chr2:239361150	A/G	cg18131467	chr2:239335373	ASB1	-0.67	-6.76	-0.3	4.26e-11	Morning vs. evening chronotype;Chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg20555477	chr9:86594889	HNRNPK;RMI1	0.42	6.87	0.3	2.11e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs68170813	0.523	rs11766131	chr7:107071138	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	cis	rs9807989	0.507	rs4851579	chr2:103028984	G/A	cg03938978	chr2:103052716	IL18RAP	0.4	9.27	0.4	7.2e-19	Asthma;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.08	-0.7	1.2e-69	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7618501	0.519	rs3774749	chr3:50207227	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.84	-0.34	3.21e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2296342	0.522	rs1536036	chr6:33632014	A/G	cg14003231	chr6:33640908	ITPR3	0.28	6.66	0.3	7.87e-11	Schizophrenia;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg07274523	chr3:49395745	GPX1	0.57	9.42	0.4	2.15e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs561341	1.000	rs497479	chr17:30328605	C/T	cg27661571	chr11:113659931	NA	-0.69	-9.54	-0.41	8.49e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9611519	0.732	rs1883826	chr22:41703428	G/A	cg03806693	chr22:41940476	POLR3H	-0.76	-12.76	-0.51	3.8e-32	Neuroticism;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.23	0.32	1.96e-12	Menopause (age at onset);
LGG	cis	rs1577917	0.917	rs1579886	chr6:86557191	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.01e-30	Response to antipsychotic treatment;
LGG	cis	rs854765	0.547	rs2955385	chr17:17939247	C/T	cg04398451	chr17:18023971	MYO15A	-0.74	-15.59	-0.59	2.41e-44	Total body bone mineral density;
LGG	cis	rs11239187	0.586	rs11239156	chr10:45078096	A/G	cg03916630	chr10:45065415	NA	0.35	8.51	0.37	2.51e-16	Body mass index;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg07511668	chr11:68622177	NA	0.46	8.76	0.38	3.73e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7633857	0.512	rs2376477	chr3:160700699	G/T	cg04691961	chr3:161091175	C3orf57	-0.39	-8.01	-0.35	9.4e-15	Educational attainment (years of education);
LGG	cis	rs3816183	0.716	rs6720606	chr2:43079838	C/T	cg14631114	chr2:43023945	NA	0.44	7.71	0.34	7.8e-14	Hypospadias;
LGG	cis	rs7681440	0.669	rs6814481	chr4:90805660	C/T	cg26578617	chr4:90757533	SNCA	-0.35	-6.87	-0.3	2.03e-11	Dementia with Lewy bodies;
LGG	cis	rs798554	0.797	rs798491	chr7:2800521	A/G	cg18446336	chr7:2847575	GNA12	-0.29	-6.93	-0.31	1.38e-11	Height;
LGG	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg18196295	chr10:418757	DIP2C	0.56	10.98	0.45	4.55e-25	Psychosis in Alzheimer's disease;
LGG	cis	rs4689388	0.853	rs6817447	chr4:6286847	G/T	cg00701064	chr4:6280414	WFS1	0.75	16.97	0.62	1.43e-50	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs597583	0.715	rs11216437	chr11:117394685	A/G	cg27161313	chr11:117392002	DSCAML1	0.62	9.8	0.41	1.02e-20	Putamen volume;
LGG	cis	rs9322193	0.887	rs9505824	chr6:149954799	A/G	cg09699651	chr6:150184138	LRP11	0.51	9.1	0.39	2.69e-18	Lung cancer;
LGG	cis	rs6714710	0.603	rs58546246	chr2:98521823	C/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.07e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg04450456	chr4:17643702	FAM184B	0.32	7.13	0.31	3.86e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7208859	0.673	rs11656462	chr17:29160700	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.11	-0.31	4.44e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12310956	0.532	rs10844707	chr12:33936089	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.19	-0.46	6.99e-26	Morning vs. evening chronotype;
LGG	cis	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs11875185	0.510	rs17692779	chr18:55596274	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4959677	0.718	rs1680853	chr6:2500701	A/G	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.49e-15	Orthostatic hypotension;
LGG	cis	rs2188554	0.561	rs11974545	chr7:117296630	G/T	cg10524701	chr7:117356490	CTTNBP2	0.44	7.56	0.33	2.25e-13	Esophageal adenocarcinoma;
LGG	cis	rs10504229	0.679	rs16921688	chr8:58054659	T/C	cg05313129	chr8:58192883	C8orf71	-0.67	-8.72	-0.38	5.19e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	1.000	rs10189336	chr2:1558015	G/A	cg26248373	chr2:1572462	NA	-0.71	-9.06	-0.39	3.61e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs908922	0.676	rs1337338	chr1:152511885	G/A	cg03606772	chr1:152487856	CRCT1	0.3	7.03	0.31	7.64e-12	Hair morphology;
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg22105103	chr4:187893119	NA	0.54	10.32	0.43	1.31e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10743315	0.643	rs17505214	chr12:19307139	A/G	cg02471346	chr12:19282374	PLEKHA5	0.87	8.59	0.37	1.36e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs11758351	0.660	rs75156165	chr6:26235699	C/A	cg01420254	chr6:26195488	NA	0.82	10.68	0.44	5.91e-24	Gout;Renal underexcretion gout;
LGG	cis	rs35771425	0.600	rs12723208	chr1:211510894	A/G	cg10512769	chr1:211675356	NA	-0.62	-8.23	-0.36	1.9e-15	Educational attainment (years of education);
LGG	cis	rs1023500	0.551	rs2854837	chr22:42458481	G/A	cg15557168	chr22:42548783	NA	-0.41	-8.68	-0.37	6.87e-17	Schizophrenia;
LGG	cis	rs9771228	0.931	rs215629	chr7:32360464	G/C	cg27532318	chr7:32358331	NA	-0.44	-6.86	-0.3	2.16e-11	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs8017423	0.647	rs12883844	chr14:90820519	T/C	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs2204008	0.774	rs11615665	chr12:38328162	T/A	cg26384229	chr12:38710491	ALG10B	0.94	21.08	0.7	1.2e-69	Bladder cancer;
LGG	cis	rs11098499	0.754	rs11098502	chr4:120252063	T/A	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Depression;
LGG	cis	rs61931739	0.517	rs34760282	chr12:34153711	G/T	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.03e-26	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17170111	chr1:173837794	SNORD74;ZBTB37;GAS5	0.44	6.77	0.3	4e-11	Gut microbiome composition (summer);
LGG	cis	rs798554	0.704	rs798531	chr7:2770067	G/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.39	-0.36	6.14e-16	Height;
LGG	cis	rs870825	0.616	rs6844146	chr4:185636396	G/A	cg04058563	chr4:185651563	MLF1IP	1.05	22.92	0.73	2.89e-78	Blood protein levels;
LGG	trans	rs12517041	1.000	rs28472703	chr5:23281381	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.02	-0.46	3.17e-25	Calcium levels;
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	0.714	rs473535	chr17:30312365	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.72	-0.3	5.38e-11	Hip circumference adjusted for BMI;
LGG	trans	rs11039798	0.920	rs61448762	chr11:48923756	G/A	cg03929089	chr4:120376271	NA	0.73	7.83	0.34	3.33e-14	Axial length;
LGG	cis	rs17401966	0.522	rs912962	chr1:10348712	G/T	cg19773385	chr1:10388646	KIF1B	0.33	6.88	0.3	2e-11	Hepatocellular carcinoma;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs941873	0.868	rs7898	chr10:81114959	C/T	cg09469691	chr10:81107165	PPIF	0.59	10.36	0.43	8.91e-23	Height;
LGG	cis	rs7267979	1.000	rs6050565	chr20:25347563	A/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1950500	0.565	rs3181248	chr14:24808168	G/A	cg16194253	chr14:24768981	DHRS1;C14orf21	0.47	8.39	0.36	5.93e-16	Height;
LGG	cis	rs875971	0.862	rs12698521	chr7:65939489	T/C	cg11764359	chr7:65958608	NA	0.81	15.11	0.57	3.13e-42	Aortic root size;
LGG	cis	rs7084783	0.505	rs67220558	chr10:105403967	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.4	7.56	0.33	2.22e-13	Fear of pain;
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.46	0.37	3.42e-16	Alzheimer's disease;
LGG	cis	rs7587476	0.861	rs3768716	chr2:215635794	T/C	cg04004882	chr2:215674386	BARD1	0.51	6.71	0.3	5.73e-11	Neuroblastoma;
LGG	cis	rs79349575	0.716	rs46522	chr17:46988597	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.12	0.35	4.34e-15	Type 2 diabetes;
LGG	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg16147221	chr4:10020634	SLC2A9	0.36	6.7	0.3	6e-11	Bone mineral density;
LGG	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg15557168	chr22:42548783	NA	-0.41	-8.23	-0.36	1.97e-15	Schizophrenia;
LGG	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	6.86	0.3	2.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg21226059	chr5:178986404	RUFY1	0.47	7.62	0.33	1.48e-13	Lung cancer;
LGG	cis	rs116095464	1.000	rs6555159	chr5:311562	G/A	cg22857025	chr5:266934	NA	-1.31	-13.53	-0.53	2.29e-35	Breast cancer;
LGG	cis	rs6951245	0.554	rs79367977	chr7:1152657	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.67	-0.44	6.36e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.647	rs116505114	chr15:77074794	T/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.67	-0.56	2.72e-40	Blood metabolite levels;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.03	0.39	4.49e-18	Obesity-related traits;
LGG	cis	rs6450176	0.633	rs10054623	chr5:53343821	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.7	-11.54	-0.47	3.06e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs262150	0.659	rs2657340	chr7:158796968	C/T	cg04111992	chr7:158790115	NA	0.37	7.39	0.32	6.89e-13	Facial morphology (factor 20);
LGG	cis	rs12220238	0.841	rs10824163	chr10:76136589	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.71	0.38	5.29e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	6.79	0.3	3.36e-11	Neuroticism;
LGG	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.01	0.31	8.46e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6088590	0.707	rs67159833	chr20:33488079	T/C	cg24642439	chr20:33292090	TP53INP2	0.75	12.42	0.5	9.46e-31	Coronary artery disease;
LGG	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.59	-0.37	1.33e-16	Platelet distribution width;
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg00800038	chr16:89945340	TCF25	-0.73	-8.33	-0.36	9.06e-16	Skin colour saturation;
LGG	cis	rs7617773	0.817	rs9818937	chr3:48325281	G/A	cg11946769	chr3:48343235	NME6	0.63	10.56	0.44	1.65e-23	Coronary artery disease;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23394480	chr14:105487615	CDCA4	-0.4	-6.78	-0.3	3.66e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7760949	0.889	rs9475807	chr6:13934597	T/C	cg27413430	chr6:13925136	RNF182	0.48	7.23	0.32	1.95e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10465746	0.747	rs10493741	chr1:84388118	G/C	cg10977910	chr1:84465055	TTLL7	0.58	10.89	0.45	9.64e-25	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg02725872	chr8:58115012	NA	-0.85	-11.64	-0.48	1.19e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg16405210	chr4:1374714	KIAA1530	0.52	8.69	0.37	6.25e-17	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg19894588	chr14:64061835	NA	-0.59	-9.35	-0.4	3.78e-19	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.1e-12	Lung cancer;
LGG	trans	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg18335740	chr13:41363409	SLC25A15	0.6	11.75	0.48	4.33e-28	Lewy body disease;
LGG	trans	rs11098499	0.874	rs13123591	chr4:120105990	T/G	cg25214090	chr10:38739885	LOC399744	0.61	10.71	0.45	4.77e-24	Corneal astigmatism;
LGG	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2624839	0.704	rs2526384	chr3:50181136	C/T	cg24110177	chr3:50126178	RBM5	-0.59	-9.03	-0.39	4.81e-18	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.871	rs7206971	chr17:45425115	A/G	cg08085267	chr17:45401833	C17orf57	0.65	13.34	0.53	1.34e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3849046	0.846	rs10117	chr5:137892170	G/A	cg10920316	chr5:137946599	NA	0.45	7.38	0.32	7.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg26384229	chr12:38710491	ALG10B	0.85	19.18	0.67	8.77e-61	Bladder cancer;
LGG	cis	rs12618769	0.597	rs72820002	chr2:99075259	T/A	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.45e-16	Bipolar disorder;
LGG	cis	rs17376456	0.877	rs56373208	chr5:93491276	C/A	cg21475434	chr5:93447410	FAM172A	0.72	7.31	0.32	1.2e-12	Diabetic retinopathy;
LGG	cis	rs7044106	0.791	rs10985009	chr9:123493039	C/T	cg09833538	chr9:123605306	PSMD5;LOC253039	-0.43	-7.12	-0.31	4.23e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9916302	0.904	rs2338800	chr17:37498149	C/G	cg00129232	chr17:37814104	STARD3	0.59	11.03	0.46	2.76e-25	Glomerular filtration rate (creatinine);
LGG	cis	rs3784262	1.000	rs12903474	chr15:58276747	A/C	cg12031962	chr15:58353849	ALDH1A2	0.38	8.12	0.35	4.28e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg17691542	chr6:26056736	HIST1H1C	0.55	9.84	0.42	7.24e-21	Height;
LGG	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg12193833	chr17:30244370	NA	-0.3	-7.02	-0.31	8.1e-12	Hip circumference adjusted for BMI;
LGG	trans	rs34816374	1	rs34816374	chr6:26949672	A/G	cg01620082	chr3:125678407	NA	-0.91	-9.05	-0.39	3.86e-18	Lung cancer in ever smokers;
LGG	trans	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9811920	0.609	rs6765027	chr3:99687730	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.52	-8.95	-0.38	8.84e-18	Axial length;
LGG	cis	rs17331151	0.573	rs28552648	chr3:52865593	G/A	cg04865290	chr3:52927548	TMEM110	-0.4	-6.98	-0.31	1.05e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg07440826	chr16:89882328	FANCA	-0.26	-7.01	-0.31	8.34e-12	Vitiligo;
LGG	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg11839771	chr15:80205821	ST20	-0.38	-7.99	-0.35	1.09e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg08888203	chr3:10149979	C3orf24	0.54	9.18	0.39	1.43e-18	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.22	0.32	2.11e-12	Alzheimer's disease;
LGG	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.81	0.41	9.25e-21	Height;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.28	-0.43	1.87e-22	Platelet count;
LGG	cis	rs2721195	0.549	rs2958492	chr8:145919126	C/T	cg15320075	chr8:145703422	NA	0.41	7.05	0.31	6.39e-12	Age at first birth;
LGG	cis	rs2075466	0.514	rs79392591	chr16:4899247	C/G	cg04440724	chr16:4920505	UBN1	-0.6	-8.81	-0.38	2.59e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2242116	0.793	rs9855938	chr3:46957298	G/A	cg02527881	chr3:46936655	PTH1R	-0.34	-8.36	-0.36	7.19e-16	Birth weight;
LGG	cis	rs56161922	0.915	rs12562739	chr1:207856658	T/A	cg09557387	chr1:207818395	CR1L	0.94	9.47	0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs11190604	1.000	rs2489053	chr10:102353341	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	10.67	0.44	6.38e-24	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs738321	0.756	rs12167576	chr22:38512562	G/A	cg25457927	chr22:38595422	NA	-0.36	-8.32	-0.36	9.86e-16	Breast cancer;
LGG	cis	rs6952808	0.510	rs13227554	chr7:2048220	G/C	cg11050988	chr7:1952600	MAD1L1	0.33	8.05	0.35	7.18e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.692	rs3816266	chr15:76993835	T/G	cg05677249	chr15:77158041	SCAPER	-0.31	-6.67	-0.3	7.47e-11	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg24607181	chr17:41446203	NA	-0.3	-7.09	-0.31	5.15e-12	Menopause (age at onset);
LGG	cis	rs17253792	0.822	rs76555508	chr14:56071868	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.64	-0.51	1.19e-31	Putamen volume;
LGG	cis	rs755249	0.567	rs61782157	chr1:39762889	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1008375	1.000	rs1860596	chr4:17660082	C/T	cg02297831	chr4:17616191	MED28	0.49	9.33	0.4	4.31e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9596863	0.898	rs9316660	chr13:54353562	T/C	ch.13.53330881F	chr13:54432880	NA	0.53	7.21	0.32	2.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs8176296	chr17:41203591	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.17	-0.32	3e-12	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs12944458	chr17:41180772	C/T	cg05368731	chr17:41323189	NBR1	0.93	17.67	0.63	8.6e-54	Menopause (age at onset);
LGG	cis	rs653465	0.708	rs2370925	chr3:27144161	A/G	cg02860705	chr3:27208620	NA	-0.4	-7.68	-0.34	9.77e-14	Breast cancer (early onset);
LGG	cis	rs7572733	0.840	rs700649	chr2:198622752	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.95	0.35	1.43e-14	Dermatomyositis;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	10.63	0.44	9.29e-24	Lung function (FEV1/FVC);
LGG	cis	rs2072732	0.821	rs12039548	chr1:2947909	C/T	cg22517653	chr1:2918612	NA	0.49	6.69	0.3	6.59e-11	Plateletcrit;
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs7829975	0.564	rs2921057	chr8:8318667	C/T	cg06636001	chr8:8085503	FLJ10661	0.58	11.42	0.47	9.07e-27	Mood instability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25381637	chr19:7938989	NA	0.46	7.17	0.32	2.92e-12	Gut microbiome composition (summer);
LGG	cis	rs7169223	0.653	rs3971703	chr15:79092481	G/C	cg03762349	chr15:79060523	ADAMTS7	-0.36	-7.18	-0.32	2.88e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs2842992	0.662	rs2273825	chr6:160211424	A/C	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7106204	0.514	rs12789549	chr11:24254726	C/G	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3768617	0.510	rs7529465	chr1:183096880	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7296418	0.619	rs7139321	chr12:123719528	T/G	cg00376283	chr12:123451042	ABCB9	0.63	11.72	0.48	5.77e-28	Platelet count;
LGG	trans	rs7762018	0.891	rs12529402	chr6:170147675	A/T	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07001481	chr17:5389669	DERL2;MIS12	-0.49	-7.1	-0.31	4.78e-12	Systemic lupus erythematosus;
LGG	cis	rs4919087	0.962	rs10748694	chr10:99056190	A/T	cg25902810	chr10:99078978	FRAT1	0.52	9.61	0.41	4.69e-20	Monocyte count;
LGG	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.39	-0.5	1.18e-30	Chronic sinus infection;
LGG	cis	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Morning vs. evening chronotype;
LGG	cis	rs9649213	0.614	rs3801258	chr7:97988428	G/A	cg09267113	chr7:98030324	BAIAP2L1	-0.49	-8.42	-0.36	4.67e-16	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6558530	0.692	rs7818406	chr8:1701250	C/T	cg08198773	chr8:1697536	NA	0.45	7.89	0.34	2.12e-14	Systolic blood pressure;
LGG	cis	rs896854	0.818	rs13262110	chr8:95926890	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.24	-0.36	1.82e-15	Type 2 diabetes;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.46	0.56	2.15e-39	Tonsillectomy;
LGG	cis	rs9457247	1.000	rs415842	chr6:167406681	G/A	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs5758659	0.652	rs133347	chr22:42423645	A/T	cg15128208	chr22:42549153	NA	-0.41	-8.02	-0.35	8.63e-15	Cognitive function;
LGG	trans	rs1005277	0.579	rs2474563	chr10:38375938	T/C	cg25373794	chr1:162760220	HSD17B7	-0.45	-7.13	-0.31	3.97e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4737010	0.501	rs2111805	chr8:41643457	G/C	cg08923054	chr8:41654455	ANK1	0.82	13.75	0.54	2.49e-36	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6546537	1.000	rs4852867	chr2:69831449	G/A	cg10773587	chr2:69614142	GFPT1	-0.42	-7.11	-0.31	4.38e-12	Serum thyroid-stimulating hormone levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26969786	chr8:50891848	SNTG1	0.34	7.57	0.33	1.98e-13	Menarche (age at onset);
LGG	cis	rs344364	0.511	rs1657132	chr16:1949924	C/T	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.09	-0.31	5.09e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4918072	0.834	rs12413727	chr10:105711063	G/C	cg11005552	chr10:105648138	OBFC1	0.42	7.32	0.32	1.11e-12	Coronary artery disease;
LGG	trans	rs2235573	0.625	rs139900	chr22:38405417	C/T	cg19894588	chr14:64061835	NA	0.54	8.87	0.38	1.58e-17	Glioblastoma;Glioma;
LGG	cis	rs2153535	0.580	rs7741456	chr6:8452424	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs3816183	0.626	rs7578653	chr2:42896205	G/C	cg14631114	chr2:43023945	NA	0.36	6.94	0.31	1.3e-11	Hypospadias;
LGG	cis	rs6831352	0.879	rs7434491	chr4:100069847	G/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.56	-0.37	1.74e-16	Alcohol dependence;
LGG	cis	rs3785574	0.650	rs2070776	chr17:62007498	A/G	cg11494091	chr17:61959527	GH2	-0.68	-11.99	-0.49	5.07e-29	Height;
LGG	cis	rs2018055	1.000	rs13206490	chr6:117822021	G/A	cg14611402	chr6:117803162	DCBLD1	0.28	7.74	0.34	6.5e-14	Diastolic blood pressure;
LGG	cis	rs1129187	0.755	rs28868299	chr6:42921221	T/G	cg05552183	chr6:42928497	GNMT	0.44	12.86	0.51	1.45e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6752107	0.967	rs55835501	chr2:234157733	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.68	12.6	0.51	1.61e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6912958	0.781	rs9450755	chr6:88303702	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.63	-0.37	9.62e-17	Monocyte percentage of white cells;
LGG	cis	rs9435341	0.965	rs9435441	chr1:107603330	C/G	cg09367891	chr1:107599246	PRMT6	-0.55	-10.08	-0.42	9.39e-22	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs12950390	0.853	rs11655112	chr17:45856563	T/C	cg03474202	chr17:45855739	NA	-0.27	-8.0	-0.35	1.02e-14	IgG glycosylation;
LGG	cis	rs7074356	0.569	rs1832683	chr10:82032331	C/T	cg27171509	chr10:82033454	MAT1A	-0.42	-8.47	-0.37	3.33e-16	Borderline personality disorder;
LGG	cis	rs2865126	0.818	rs7407105	chr18:10758023	G/A	cg21165219	chr18:10698044	FAM38B	-0.45	-7.27	-0.32	1.51e-12	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs561341	1.000	rs4795669	chr17:30244701	C/T	cg27661571	chr11:113659931	NA	-0.65	-9.08	-0.39	3.26e-18	Hip circumference adjusted for BMI;
LGG	cis	rs2839186	0.814	rs2839167	chr21:47661587	A/G	cg11766577	chr21:47581405	C21orf56	-0.58	-10.77	-0.45	2.65e-24	Testicular germ cell tumor;
LGG	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg04568710	chr12:38710424	ALG10B	0.34	6.89	0.3	1.82e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg03315344	chr16:75512273	CHST6	0.5	10.13	0.43	6.52e-22	Dupuytren's disease;
LGG	trans	rs7395662	0.553	rs11040122	chr11:48901038	A/G	cg03929089	chr4:120376271	NA	0.43	7.08	0.31	5.22e-12	HDL cholesterol;
LGG	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.44	7.18	0.32	2.84e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg19539972	chr4:7069911	GRPEL1	0.68	10.12	0.43	7.01e-22	Monocyte percentage of white cells;
LGG	cis	rs1552244	1.000	rs6442147	chr3:10078247	A/G	cg08888203	chr3:10149979	C3orf24	0.54	9.18	0.39	1.42e-18	Alzheimer's disease;
LGG	cis	rs1577917	0.883	rs2660575	chr6:86684995	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.55	-9.78	-0.41	1.13e-20	Response to antipsychotic treatment;
LGG	trans	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg00953403	chr17:74099816	EXOC7	-0.45	-6.85	-0.3	2.33e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs12447804	0.578	rs6499934	chr16:58109313	C/T	cg03859792	chr16:58121049	NA	0.64	10.5	0.44	2.84e-23	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg00689492	chr4:1303491	MAEA	0.43	7.46	0.33	4.33e-13	Obesity-related traits;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg18837051	chr15:64125388	HERC1	-0.41	-6.91	-0.31	1.66e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4818225	0.563	rs1964926	chr21:42653121	A/G	cg21268422	chr21:42620091	BACE2	0.48	8.4	0.36	5.43e-16	Educational attainment;
LGG	cis	rs8062405	1.000	rs62036622	chr16:28837203	T/G	cg07382826	chr16:28625726	SULT1A1	0.38	7.79	0.34	4.37e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8028182	0.636	rs62027181	chr15:75839952	A/G	cg20655648	chr15:75932815	IMP3	0.44	7.27	0.32	1.53e-12	Sudden cardiac arrest;
LGG	cis	rs7086627	0.515	rs1870147	chr10:82212541	A/T	cg01528321	chr10:82214614	TSPAN14	0.66	11.79	0.48	3.04e-28	Post bronchodilator FEV1;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.67	0.61	3.35e-49	Platelet count;
LGG	cis	rs4820834	0.542	rs2240420	chr22:30731066	C/T	cg00101453	chr22:30685584	GATSL3	0.49	6.64	0.3	8.62e-11	Coronary artery calcification;
LGG	cis	rs933688	1.000	rs10041402	chr5:90738948	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.17	0.68	2.17e-65	Smoking behavior;
LGG	cis	rs3796352	1.000	rs11718834	chr3:52963668	A/C	cg12962167	chr3:53033115	SFMBT1	0.69	7.56	0.33	2.12e-13	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.92e-17	Lung cancer;
LGG	cis	rs12579753	0.879	rs11115009	chr12:82165409	G/T	cg07988820	chr12:82153109	PPFIA2	0.8	12.5	0.5	4.19e-31	Resting heart rate;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7296418	0.961	rs11608811	chr12:123529056	A/G	cg05973401	chr12:123451056	ABCB9	0.47	7.97	0.35	1.26e-14	Platelet count;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg01423820	chr14:77228690	VASH1	0.42	6.82	0.3	2.87e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs59197085	0.515	rs17165191	chr7:128451004	T/C	cg00734629	chr7:128471146	FLNC	0.31	6.67	0.3	7.21e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg00684032	chr4:1343700	KIAA1530	0.67	13.89	0.54	6.47e-37	Obesity-related traits;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1.05e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs4144743	0.938	rs35439279	chr17:45321694	C/T	cg18085866	chr17:45331354	ITGB3	-0.78	-9.92	-0.42	3.55e-21	Body mass index;
LGG	cis	rs6028335	0.674	rs66647661	chr20:37671577	C/T	cg16355469	chr20:37678765	NA	0.59	7.95	0.35	1.39e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg10207240	chr12:122356781	WDR66	-0.28	-8.45	-0.37	3.85e-16	Mean corpuscular volume;
LGG	cis	rs769267	1.000	rs2074089	chr19:19449603	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.41	-0.36	5.1e-16	Tonsillectomy;
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs1014246	0.778	rs12256473	chr10:118478448	G/A	cg14919929	chr10:118506882	NA	0.66	12.72	0.51	5.1e-32	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2180341	0.883	rs9388568	chr6:127690694	C/A	cg27446573	chr6:127587934	RNF146	1.14	22.27	0.72	3.09e-75	Breast cancer;
LGG	cis	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg19399532	chr1:178512495	C1orf220	-0.54	-10.81	-0.45	2.01e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2204008	0.837	rs55962152	chr12:38234281	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.46	-8.36	-0.36	7.18e-16	Renal function-related traits (BUN);
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs992157	0.804	rs6758540	chr2:219138625	A/G	cg04731861	chr2:219085781	ARPC2	0.46	11.16	0.46	8.96e-26	Colorectal cancer;
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs2739330	0.857	rs9608229	chr22:24399364	C/G	cg25703541	chr22:24373054	LOC391322	-1.01	-20.89	-0.7	8.99e-69	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg24846343	chr22:24311635	DDTL	-0.44	-7.22	-0.32	2.19e-12	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs17767392	0.781	rs2108057	chr14:72022750	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.42	-8.98	-0.39	6.79e-18	Mitral valve prolapse;
LGG	cis	rs7481584	0.962	rs12805426	chr11:3020580	C/T	cg25174290	chr11:3078921	CARS	-0.48	-8.32	-0.36	1.02e-15	Calcium levels;
LGG	cis	rs12421382	0.659	rs1371332	chr11:109381687	A/T	cg04861929	chr11:109293070	C11orf87	0.55	9.81	0.41	8.9e-21	Schizophrenia;
LGG	cis	rs11168187	0.891	rs4505143	chr12:48124148	G/A	cg12761788	chr12:48120090	P11	0.45	7.46	0.33	4.31e-13	Vertical cup-disc ratio;
LGG	cis	rs3925075	1.000	rs9673405	chr16:31347599	A/C	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg11764359	chr7:65958608	NA	-0.62	-10.76	-0.45	3.09e-24	Aortic root size;
LGG	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg18188782	chr20:61659543	NA	0.4	6.68	0.3	6.93e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7122257	0.507	rs10840585	chr11:11163672	C/T	cg16931664	chr11:11169707	NA	-0.26	-7.33	-0.32	1.01e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs796364	0.806	rs112305133	chr2:201010380	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.86	-0.34	2.67e-14	Schizophrenia;
LGG	cis	rs735860	0.763	rs1429146	chr6:53130285	C/T	cg10236188	chr6:53219634	NA	-0.39	-7.59	-0.33	1.73e-13	Glaucoma;
LGG	cis	rs9911578	0.902	rs12948746	chr17:57071892	A/G	cg05425664	chr17:57184151	TRIM37	-0.7	-11.39	-0.47	1.18e-26	Intelligence (multi-trait analysis);
LGG	cis	rs11608355	0.515	rs11610558	chr12:109925865	C/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs17221829	0.733	rs10765222	chr11:89372109	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.39	-0.32	6.96e-13	Bone mineral density;
LGG	cis	rs9305556	0.825	rs4405831	chr21:36029171	G/C	cg24523685	chr21:36062813	CLIC6	-0.36	-6.87	-0.3	2.07e-11	Psoriasis;
LGG	trans	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg13565492	chr6:43139072	SRF	-0.68	-8.18	-0.36	2.78e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1372356	0.816	rs10873389	chr14:88532403	G/A	cg18078958	chr14:88630771	NA	0.31	7.55	0.33	2.42e-13	Food antigen IgG levels;
LGG	cis	rs17321999	0.951	rs73925103	chr2:30474515	A/C	cg05247661	chr2:30472410	LBH	0.62	9.97	0.42	2.37e-21	Systemic lupus erythematosus;
LGG	cis	rs4481887	0.861	rs4295906	chr1:248429861	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-10.27	-0.43	1.92e-22	Common traits (Other);
LGG	cis	rs17641971	0.684	rs1511367	chr8:49949412	T/C	cg00325661	chr8:49890786	NA	0.55	10.26	0.43	2.2e-22	Blood metabolite levels;
LGG	cis	rs7072216	0.763	rs10748730	chr10:100171440	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.13	-0.31	3.82e-12	Metabolite levels;
LGG	cis	rs2014572	0.967	rs10413037	chr19:57771883	A/G	cg24459738	chr19:57751996	ZNF805	-0.35	-6.69	-0.3	6.46e-11	Hyperactive-impulsive symptoms;
LGG	cis	rs12477438	0.765	rs7591992	chr2:99668954	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs10888329	0.665	rs9662722	chr1:248385891	T/G	cg01631408	chr1:248437212	OR2T33	-0.44	-7.36	-0.32	8.48e-13	Autism spectrum disorder;
LGG	cis	rs4262150	0.693	rs11746770	chr5:152313004	C/T	cg12297329	chr5:152029980	NA	0.58	11.3	0.46	2.64e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4728302	0.608	rs6950383	chr7:133727497	C/T	cg10665199	chr7:133106180	EXOC4	-0.4	-6.91	-0.31	1.58e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg15212455	chr7:39170539	POU6F2	0.47	10.76	0.45	3e-24	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11502736	chr1:179923845	CEP350	0.38	6.87	0.3	2.11e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg18479299	chr3:125709523	NA	-0.57	-7.25	-0.32	1.81e-12	Blood pressure (smoking interaction);
LGG	cis	rs769267	0.965	rs2023882	chr19:19405405	T/C	cg01262667	chr19:19385393	TM6SF2	0.47	11.85	0.48	1.79e-28	Tonsillectomy;
LGG	cis	rs1580019	0.961	rs766660	chr7:32499077	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.8	14.98	0.57	1.15e-41	Cognitive ability;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg09177884	chr7:1199841	ZFAND2A	-0.66	-11.57	-0.47	2.29e-27	Longevity;Endometriosis;
LGG	cis	rs7017914	0.967	rs7825446	chr8:71664174	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	trans	rs79976124	0.800	rs12194767	chr6:66639599	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.71	11.85	0.48	1.76e-28	Type 2 diabetes;
LGG	cis	rs10504229	0.815	rs16921955	chr8:58164553	C/T	cg22535103	chr8:58192502	C8orf71	-1.0	-15.41	-0.58	1.49e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs4704187	0.687	rs4324655	chr5:74373360	C/T	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05596135	chr16:72128010	TXNL4B;DHX38	0.43	7.32	0.32	1.08e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9902453	0.904	rs9900974	chr17:28364456	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.65	-0.54	6.75e-36	Coffee consumption (cups per day);
LGG	cis	rs1552244	1.000	rs9834980	chr3:10065528	G/A	cg00166722	chr3:10149974	C3orf24	0.54	9.12	0.39	2.24e-18	Alzheimer's disease;
LGG	cis	rs769267	0.931	rs2965193	chr19:19454828	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	-0.61	-10.32	-0.43	1.3e-22	Tonsillectomy;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg18272543	chr7:27779524	TAX1BP1	-0.46	-6.7	-0.3	5.98e-11	Systemic lupus erythematosus;
LGG	cis	rs3816788	0.792	rs10097055	chr8:21872328	A/G	cg17168535	chr8:21777572	XPO7	0.78	14.87	0.57	3.62e-41	Lung cancer in ever smokers;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.0	-0.6	3.51e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg15596359	chr8:11213517	TDH	-0.4	-8.24	-0.36	1.73e-15	Retinal vascular caliber;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg07308232	chr7:1071921	C7orf50	-0.69	-13.74	-0.54	2.86e-36	Longevity;Endometriosis;
LGG	cis	rs2404602	0.684	rs965818	chr15:76866785	T/C	cg15268244	chr15:77196840	NA	0.47	9.89	0.42	4.65e-21	Blood metabolite levels;
LGG	trans	rs116095464	1.000	rs10054850	chr5:335827	C/G	cg00938859	chr5:1591904	SDHAP3	0.81	7.06	0.31	6.23e-12	Breast cancer;
LGG	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg22834771	chr12:69754056	YEATS4	-0.43	-7.53	-0.33	2.77e-13	Blood protein levels;
LGG	cis	rs57221529	0.709	rs72706612	chr5:561198	C/T	cg07777115	chr5:623756	CEP72	-0.57	-7.17	-0.32	3.04e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs4262150	0.810	rs17566118	chr5:152088546	C/T	cg12297329	chr5:152029980	NA	-0.75	-14.0	-0.55	2.22e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs8072100	0.935	rs4793978	chr17:45698175	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs509477	1.000	rs11660848	chr18:32574010	T/C	cg23791764	chr18:32556832	MAPRE2	-0.52	-8.81	-0.38	2.45e-17	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs10871290	0.801	rs3851726	chr16:74471644	G/C	cg01733217	chr16:74700730	RFWD3	-0.72	-13.99	-0.55	2.49e-37	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16917406	chr15:85114159	UBE2QP1	0.53	8.12	0.35	4.33e-15	Gut microbiome composition (summer);
LGG	cis	rs8072100	0.967	rs4338849	chr17:45512483	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.68	-0.37	6.89e-17	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11098499	0.866	rs13105020	chr4:120285688	G/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	cis	rs3785574	1.000	rs7223257	chr17:61787684	T/C	cg06873352	chr17:61820015	STRADA	0.47	7.36	0.32	8.71e-13	Height;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg04273556	chr9:35096672	PIGO	0.47	6.68	0.3	6.91e-11	Breast cancer;
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg02243437	chr10:61469599	SLC16A9	-0.49	-6.96	-0.31	1.17e-11	Leprosy;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs826838	1.000	rs10880785	chr12:38655405	T/G	cg06521331	chr12:34319734	NA	-0.46	-8.06	-0.35	6.64e-15	Heart rate;
LGG	cis	rs4319547	0.656	rs10846664	chr12:122823777	C/T	cg05707623	chr12:122985044	ZCCHC8	0.68	10.5	0.44	2.76e-23	Body mass index;
LGG	cis	rs7975161	0.671	rs4475991	chr12:104596756	A/G	cg25273343	chr12:104657179	TXNRD1	0.59	9.73	0.41	1.81e-20	Toenail selenium levels;
LGG	cis	rs59104589	0.521	rs62190404	chr2:242401422	C/T	cg13788902	chr2:242434635	STK25	0.4	6.9	0.31	1.72e-11	Fibrinogen levels;
LGG	cis	rs8114671	0.527	rs2253484	chr20:33405263	A/T	cg07148914	chr20:33460835	GGT7	-0.53	-8.79	-0.38	3.04e-17	Height;
LGG	cis	rs7208859	0.623	rs383436	chr17:28959179	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.26	-0.36	1.54e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9916302	0.706	rs4332770	chr17:37704712	T/C	cg00129232	chr17:37814104	STARD3	-0.58	-8.69	-0.37	6.5e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg12463550	chr7:65579703	CRCP	0.75	7.94	0.35	1.53e-14	Diabetic kidney disease;
LGG	cis	rs483069	1.000	rs483069	chr1:34424491	A/C	cg24941457	chr1:34420873	CSMD2	-0.46	-10.57	-0.44	1.59e-23	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs2247341	0.965	rs1530588	chr4:1742779	G/A	cg08629884	chr4:1719983	TMEM129	-0.56	-10.85	-0.45	1.42e-24	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11229555	0.645	rs12274866	chr11:58177129	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs738322	0.775	rs4375	chr22:38539041	T/C	cg03162506	chr22:38580953	NA	0.33	8.36	0.36	7.18e-16	Cutaneous nevi;
LGG	cis	rs1008375	0.931	rs979823	chr4:17700176	G/A	cg18681998	chr4:17616180	MED28	0.73	15.01	0.57	8.94e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8180040	0.932	rs11711265	chr3:47558448	T/C	cg16586182	chr3:47516702	SCAP	-0.76	-14.58	-0.56	6.89e-40	Colorectal cancer;
LGG	cis	rs7647973	1.000	rs6774724	chr3:49381911	G/T	cg07636037	chr3:49044803	WDR6	0.78	13.38	0.53	9.76e-35	Menarche (age at onset);
LGG	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg00898013	chr13:113819073	PROZ	-0.48	-9.57	-0.41	6.68e-20	Platelet distribution width;
LGG	cis	rs908922	0.542	rs4845785	chr1:152510143	C/T	cg09873164	chr1:152488093	CRCT1	0.63	15.32	0.58	3.73e-43	Hair morphology;
LGG	cis	rs6754311	0.731	rs12615624	chr2:136721603	A/G	cg07169764	chr2:136633963	MCM6	0.81	13.85	0.54	9.42e-37	Mosquito bite size;
LGG	cis	rs7107174	1.000	rs2511168	chr11:77965081	T/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.77	-0.34	4.98e-14	Testicular germ cell tumor;
LGG	cis	rs4595586	0.545	rs1349257	chr12:39397139	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.49e-13	Morning vs. evening chronotype;
LGG	cis	rs10823500	0.674	rs7089860	chr10:71992848	C/G	cg02100629	chr10:71892760	AIFM2	-0.29	-6.68	-0.3	6.78e-11	Blood protein levels;
LGG	trans	rs7395662	0.963	rs11039937	chr11:48712582	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs9329289	0.851	rs61835719	chr10:2543390	A/G	cg15501526	chr10:2543763	NA	0.71	14.87	0.57	3.73e-41	Age-related hearing impairment;
LGG	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg11266682	chr4:10021025	SLC2A9	0.54	10.71	0.45	4.52e-24	Bone mineral density;
LGG	cis	rs68170813	0.599	rs11769901	chr7:106958505	G/A	cg02696742	chr7:106810147	HBP1	-0.76	-10.79	-0.45	2.3e-24	Coronary artery disease;
LGG	cis	rs11239187	0.586	rs899889	chr10:45072819	G/A	cg03916630	chr10:45065415	NA	0.35	8.63	0.37	1e-16	Body mass index;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg05665937	chr4:1216051	CTBP1	0.48	8.74	0.38	4.34e-17	Obesity-related traits;
LGG	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg26384229	chr12:38710491	ALG10B	-0.75	-14.61	-0.56	4.95e-40	Morning vs. evening chronotype;
LGG	cis	rs17253792	0.915	rs76952651	chr14:56188994	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-9.99	-0.42	2e-21	Putamen volume;
LGG	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	7.88	0.34	2.36e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg06719900	chr11:109292894	C11orf87	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs2404602	0.967	rs7174096	chr15:77072400	A/G	cg22467129	chr15:76604101	ETFA	-0.45	-7.68	-0.34	9.78e-14	Blood metabolite levels;
LGG	cis	rs735396	1.000	rs1169311	chr12:121440731	C/T	cg02403541	chr12:121454288	C12orf43	0.53	8.66	0.37	7.64e-17	N-glycan levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18225895	chr6:52149972	MCM3	0.39	6.93	0.31	1.43e-11	Gut microbiome composition (summer);
LGG	cis	rs4689388	0.853	rs11729672	chr4:6293838	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.68	0.48	8.5e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs36093844	0.752	rs79516304	chr11:85547235	G/A	cg16165120	chr11:85566439	CCDC83	-0.46	-7.41	-0.33	6.21e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs77669868	0.866	rs3782023	chr11:114035516	G/C	cg01914181	chr11:114070210	ZBTB16	0.6	7.25	0.32	1.71e-12	Monocyte percentage of white cells;
LGG	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg17330251	chr7:94953956	PON1	-0.43	-8.54	-0.37	2.02e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs11786074	chr8:58133532	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.626	rs10225241	chr7:91524940	A/G	cg17063962	chr7:91808500	NA	-0.44	-7.98	-0.35	1.14e-14	Breast cancer;
LGG	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg07080220	chr10:102295463	HIF1AN	0.73	12.13	0.49	1.35e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1401999	0.966	rs2139560	chr3:183653869	A/G	cg05044414	chr3:183734942	ABCC5	0.77	17.16	0.62	1.9e-51	Anterior chamber depth;
LGG	cis	rs1555322	1.000	rs6058219	chr20:33859244	G/C	cg17927777	chr20:33865990	NA	0.72	7.69	0.34	8.78e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg02187348	chr16:89574699	SPG7	0.6	9.86	0.42	6.26e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs9947295	0.649	rs9675502	chr18:11777138	C/G	cg14735704	chr18:11749182	GNAL	0.48	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg00531865	chr16:30841666	NA	-0.51	-10.48	-0.44	3.4e-23	Dementia with Lewy bodies;
LGG	cis	rs9325144	0.555	rs4882279	chr12:38688918	C/A	cg13010199	chr12:38710504	ALG10B	0.6	12.05	0.49	2.84e-29	Morning vs. evening chronotype;
LGG	cis	rs2544527	0.819	rs2544523	chr2:15920323	T/C	cg26669897	chr2:15909070	NA	0.34	8.15	0.35	3.44e-15	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs1218582	0.774	rs4845680	chr1:154863195	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.56	0.37	1.7e-16	Prostate cancer;
LGG	trans	rs2727020	0.658	rs7120136	chr11:49384358	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.06	-0.46	2.26e-25	Coronary artery disease;
LGG	cis	rs8177179	0.967	rs6439434	chr3:133450371	T/G	cg24879335	chr3:133465180	TF	0.44	7.34	0.32	9.93e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg01403660	chr11:68851641	TPCN2	0.51	7.19	0.32	2.58e-12	Blond vs. brown hair color;
LGG	cis	rs78456975	0.600	rs72776256	chr2:1529595	C/A	cg26248373	chr2:1572462	NA	-0.69	-8.36	-0.36	7.51e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9393692	0.537	rs9358926	chr6:26323132	C/G	cg13736514	chr6:26305472	NA	-0.48	-9.19	-0.39	1.28e-18	Educational attainment;
LGG	cis	rs12580194	0.593	rs61957938	chr12:55747266	C/G	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.11e-21	Cancer;
LGG	cis	rs8114671	0.527	rs6060068	chr20:33415820	T/A	cg07148914	chr20:33460835	GGT7	0.56	9.27	0.4	7.03e-19	Height;
LGG	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg22916017	chr11:64110731	CCDC88B	-0.47	-6.67	-0.3	7.17e-11	Mean platelet volume;
LGG	cis	rs9467773	0.933	rs2024970	chr6:26497520	T/A	cg09904177	chr6:26538194	HMGN4	0.69	14.0	0.55	2.24e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2576037	0.526	rs10853545	chr18:44475220	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.66	-12.05	-0.49	2.83e-29	Personality dimensions;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg05368731	chr17:41323189	NBR1	0.87	17.03	0.62	7.84e-51	Menopause (age at onset);
LGG	cis	rs1065852	0.526	rs2097561	chr22:42389431	T/C	cg15128208	chr22:42549153	NA	0.41	7.03	0.31	7.51e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11489389	chr3:63849240	ATXN7;THOC7	0.6	6.83	0.3	2.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4242434	0.889	rs11783129	chr8:22453426	G/A	cg19455335	chr8:22457658	C8orf58	-0.44	-8.99	-0.39	6.46e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7084402	1.000	rs12257983	chr10:60266555	A/C	cg09696939	chr10:60272079	BICC1	0.38	7.48	0.33	3.72e-13	Refractive error;
LGG	cis	rs7587476	0.601	rs17489231	chr2:215673739	T/G	cg04004882	chr2:215674386	BARD1	-0.56	-8.81	-0.38	2.54e-17	Neuroblastoma;
LGG	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.66	-0.34	1.13e-13	Morning vs. evening chronotype;
LGG	cis	rs7945718	0.621	rs10831887	chr11:12665436	A/C	cg25843174	chr11:12811716	TEAD1	0.32	6.87	0.3	2.06e-11	Educational attainment (years of education);
LGG	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg14582100	chr15:45693742	SPATA5L1	-0.41	-6.85	-0.3	2.34e-11	Homoarginine levels;
LGG	cis	rs1003719	0.715	rs2835675	chr21:38582815	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.74	-14.05	-0.55	1.29e-37	Eye color traits;
LGG	cis	rs12586317	0.576	rs6571702	chr14:35650558	C/A	cg05294307	chr14:35346193	BAZ1A	-0.37	-6.95	-0.31	1.21e-11	Psoriasis;
LGG	trans	rs7939886	0.841	rs1905053	chr11:56011848	C/T	cg15704280	chr7:45808275	SEPT13	0.82	7.61	0.33	1.51e-13	Myopia (pathological);
LGG	cis	rs3780378	0.870	rs7034878	chr9:5058991	G/T	cg02405213	chr9:5042618	JAK2	0.48	8.54	0.37	1.91e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7017914	0.967	rs1471114	chr8:71675547	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	trans	rs11039798	0.764	rs11040030	chr11:48800985	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.96	0.38	8.01e-18	Axial length;
LGG	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.44	8.95	0.38	8.85e-18	Colorectal cancer;
LGG	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg06713675	chr4:122721982	EXOSC9	-0.69	-11.63	-0.48	1.29e-27	Type 2 diabetes;
LGG	cis	rs9640161	0.658	rs57888387	chr7:150004244	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.77	-15.11	-0.57	3.13e-42	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.88e-25	Corneal astigmatism;
LGG	cis	rs7412746	0.646	rs10399947	chr1:150861960	G/A	cg15448220	chr1:150897856	SETDB1	0.38	7.12	0.31	4.21e-12	Melanoma;
LGG	cis	rs7824557	0.843	rs2572418	chr8:11113089	G/A	cg15596359	chr8:11213517	TDH	0.33	6.69	0.3	6.6e-11	Retinal vascular caliber;
LGG	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.76	0.3	4.23e-11	Electroencephalogram traits;
LGG	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs4363385	0.818	rs2070963	chr1:153004004	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	cis	rs308971	0.563	rs2600269	chr3:12033960	C/T	cg15873301	chr3:12045459	SYN2	0.52	6.81	0.3	3.04e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs12431410	0.892	rs12894153	chr14:60156693	T/G	cg07950296	chr14:60194823	RTN1	0.37	7.0	0.31	9.02e-12	Schizophrenia;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg18404041	chr3:52824283	ITIH1	-0.51	-10.01	-0.42	1.69e-21	Bipolar disorder;
LGG	cis	rs2013441	1.000	rs2703778	chr17:20138900	T/C	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16009558	chr6:101846707	GRIK2	0.44	6.93	0.31	1.43e-11	Gut microbiome composition (summer);
LGG	cis	rs1707322	1.000	rs4660318	chr1:46334876	A/G	cg03146154	chr1:46216737	IPP	0.54	10.46	0.44	4.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.04	-0.31	7.04e-12	HDL cholesterol;
LGG	cis	rs2439831	0.867	rs6493085	chr15:43654182	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs524281	0.861	rs7120326	chr11:65849256	C/T	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.54e-11	Electroencephalogram traits;
LGG	cis	rs9325144	0.555	rs7977200	chr12:38713745	C/T	cg26384229	chr12:38710491	ALG10B	0.76	15.58	0.59	2.69e-44	Morning vs. evening chronotype;
LGG	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg25866889	chr13:114914595	NA	-0.35	-7.05	-0.31	6.42e-12	Schizophrenia;
LGG	cis	rs3785574	0.962	rs2727329	chr17:61924566	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.59	9.64	0.41	3.52e-20	Height;
LGG	cis	rs2933343	0.700	rs1680778	chr3:128614185	A/C	cg11901034	chr3:128598214	ACAD9	-0.46	-7.06	-0.31	6.28e-12	IgG glycosylation;
LGG	cis	rs722599	0.748	rs17093914	chr14:75363641	A/G	cg06637938	chr14:75390232	RPS6KL1	0.58	9.71	0.41	2.09e-20	IgG glycosylation;
LGG	cis	rs13132184	0.507	rs17607518	chr4:38092697	A/G	cg24826020	chr4:38070998	TBC1D1	0.49	8.17	0.35	3.04e-15	Verbal declarative memory;
LGG	cis	rs9611519	0.929	rs73174657	chr22:41434158	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-7.9	-0.34	2.02e-14	Neuroticism;
LGG	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg24623649	chr8:11872141	NA	0.33	7.84	0.34	3.11e-14	Monocyte count;
LGG	cis	rs2742417	0.603	rs2673062	chr3:45763635	A/G	cg04837898	chr3:45731254	SACM1L	-0.46	-9.24	-0.39	8.74e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6542838	0.609	rs13028500	chr2:99528296	G/A	cg08885076	chr2:99613938	TSGA10	-0.32	-6.71	-0.3	5.75e-11	Fear of minor pain;
LGG	trans	rs1814175	0.935	rs11040463	chr11:49685574	C/T	cg15704280	chr7:45808275	SEPT13	-1.05	-24.01	-0.74	2.49e-83	Height;
LGG	cis	rs78456975	1.000	rs13397299	chr2:1564222	A/C	cg01028140	chr2:1542097	TPO	-0.53	-8.4	-0.36	5.5e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg14893161	chr1:205819251	PM20D1	0.61	11.61	0.47	1.57e-27	Menarche (age at onset);
LGG	cis	rs7762018	1.000	rs73242910	chr6:170114670	A/G	cg17545662	chr6:170176663	C6orf70	0.68	8.73	0.38	4.72e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6735179	0.603	rs10164788	chr2:1753379	G/A	cg08534653	chr2:1747700	PXDN	0.49	7.39	0.32	6.9e-13	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.520	rs6542870	chr2:99796638	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs2404602	0.967	rs2083762	chr15:76907376	T/C	cg15268244	chr15:77196840	NA	-0.34	-7.51	-0.33	3.12e-13	Blood metabolite levels;
LGG	cis	rs1552244	1.000	rs7648104	chr3:10073311	C/A	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs2171564	0.967	rs9874987	chr3:112435997	G/C	cg06685282	chr3:112453648	NA	-0.4	-7.11	-0.31	4.53e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7216064	0.700	rs4791295	chr17:65997317	G/A	cg12091567	chr17:66097778	LOC651250	-0.67	-9.89	-0.42	4.87e-21	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9487051	0.872	rs9386790	chr6:109608460	G/T	cg21918786	chr6:109611834	NA	0.48	8.85	0.38	1.9e-17	Reticulocyte fraction of red cells;
LGG	cis	rs4356975	0.563	rs4356974	chr4:69972414	A/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.83e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs9815354	0.716	rs73828280	chr3:41833907	A/T	cg03022575	chr3:42003672	ULK4	0.71	8.68	0.37	6.83e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs826838	1.000	rs1719848	chr12:39085586	A/G	cg13010199	chr12:38710504	ALG10B	-0.63	-13.41	-0.53	7.18e-35	Heart rate;
LGG	cis	rs1801251	1.000	rs2675974	chr2:233727071	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.25	0.4	8.14e-19	Coronary artery disease;
LGG	cis	rs8020289	1.000	rs4903494	chr14:77291376	T/G	cg23436960	chr14:77239540	VASH1	-0.25	-6.86	-0.3	2.28e-11	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs6964587	0.843	rs56075286	chr7:91731518	G/A	cg17063962	chr7:91808500	NA	0.49	8.69	0.37	6.43e-17	Breast cancer;
LGG	cis	rs12701220	0.817	rs7798459	chr7:1087965	C/T	cg26769984	chr7:1090371	C7orf50	0.55	10.0	0.42	1.83e-21	Bronchopulmonary dysplasia;
LGG	cis	rs2415984	0.622	rs73245837	chr14:46947914	A/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.21	-0.43	3.27e-22	Number of children ever born;
LGG	cis	rs6540556	0.723	rs1415542	chr1:209902110	T/C	cg23920097	chr1:209922102	NA	-0.42	-7.04	-0.31	6.79e-12	Red blood cell count;
LGG	cis	rs929354	0.742	rs7784442	chr7:156934475	G/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs1790761	0.505	rs2370141	chr11:67348529	A/G	cg00864171	chr11:67383662	NA	-0.42	-6.74	-0.3	4.6e-11	Mean corpuscular volume;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg16311803	chr12:88178298	NA	-0.41	-7.34	-0.32	9.54e-13	Iris color (L* coordinate);
LGG	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg15704280	chr7:45808275	SEPT13	0.79	9.17	0.39	1.55e-18	Axial length;
LGG	cis	rs11252926	0.603	rs11252670	chr10:529152	A/G	cg18196295	chr10:418757	DIP2C	-0.55	-10.79	-0.45	2.31e-24	Psychosis in Alzheimer's disease;
LGG	cis	rs1682825	1.000	rs2217767	chr3:10768889	C/T	cg23512531	chr3:10780469	NA	-0.58	-8.12	-0.35	4.17e-15	Economic and political preferences (feminism/equality);
LGG	cis	rs9322193	0.962	rs9322218	chr6:150103319	A/G	cg12070911	chr6:150209640	RAET1E	0.28	6.95	0.31	1.25e-11	Lung cancer;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg07959490	chr17:80112427	CCDC57	0.45	9.0	0.39	5.84e-18	Life satisfaction;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.73	13.42	0.53	6.52e-35	Obesity-related traits;
LGG	cis	rs7582180	0.934	rs2309824	chr2:100901661	A/G	cg14675211	chr2:100938903	LONRF2	-0.49	-7.51	-0.33	3.1400000000000003e-13	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs115076001	chr4:119764346	T/G	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs35110281	0.837	rs7279968	chr21:45077398	C/G	cg04455712	chr21:45112962	RRP1B	0.52	10.08	0.42	9.47e-22	Mean corpuscular volume;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg18279126	chr7:2041391	MAD1L1	0.32	6.69	0.3	6.48e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	0.761	rs2659888	chr7:66230171	T/G	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.25e-25	Aortic root size;
LGG	trans	rs4427176	0.507	rs7465249	chr8:9578393	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.76	0.3	4.18e-11	Mosquito bite size;
LGG	cis	rs35306767	0.903	rs12769002	chr10:927666	C/G	cg20503657	chr10:835505	NA	-0.95	-12.73	-0.51	4.79e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs977987	0.843	rs28655617	chr16:75489642	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.7	0.3	6.05e-11	Dupuytren's disease;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25632114	chr8:95732714	DPY19L4	0.4	6.94	0.31	1.29e-11	Bipolar disorder;
LGG	trans	rs9329221	0.527	rs4841352	chr8:10327590	A/C	cg16141378	chr3:129829833	LOC729375	-0.33	-6.98	-0.31	1.01e-11	Neuroticism;
LGG	trans	rs9302065	0.681	rs59108692	chr13:95962424	C/A	cg19955956	chr7:72299837	SBDSP;TYW1B	0.44	7.98	0.35	1.17e-14	Blood metabolite levels;
LGG	cis	rs2836950	0.501	rs11702505	chr21:40700614	G/T	cg11890956	chr21:40555474	PSMG1	-0.71	-12.07	-0.49	2.29e-29	Menarche (age at onset);
LGG	cis	rs7209395	0.879	rs17690038	chr17:64195854	A/G	cg19474267	chr17:64306194	PRKCA	0.68	10.15	0.43	5.27e-22	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs713587	0.719	rs4665736	chr2:25187599	C/T	cg04586622	chr2:25135609	ADCY3	-0.39	-10.0	-0.42	1.91e-21	Body mass index in non-asthmatics;
LGG	cis	rs644799	0.625	rs1255177	chr11:95471495	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.6	11.59	0.47	1.93e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs12476592	0.602	rs2592388	chr2:63896096	A/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	cis	rs2228479	0.764	rs7191836	chr16:89961597	T/C	cg27400746	chr16:89904261	SPIRE2	-0.84	-13.65	-0.54	6.65e-36	Skin colour saturation;
LGG	cis	rs6500395	0.962	rs55782524	chr16:48557493	A/G	cg16662043	chr16:48846231	NA	0.35	6.84	0.3	2.45e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2559856	1.000	rs10745921	chr12:102087193	A/G	cg12924262	chr12:102091054	CHPT1	0.66	13.11	0.52	1.32e-33	Blood protein levels;
LGG	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg00495681	chr13:53174319	NA	0.8	16.5	0.61	1.99e-48	Lewy body disease;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg05861140	chr6:150128134	PCMT1	-0.42	-9.24	-0.39	8.88e-19	Lung cancer;
LGG	cis	rs2658782	1.000	rs2658779	chr11:93163137	G/T	cg15737290	chr11:93063684	CCDC67	-0.58	-8.67	-0.37	7.54e-17	Pulmonary function decline;
LGG	cis	rs7843479	0.601	rs6557712	chr8:21826421	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.12	0.6	1.02e-46	Mean corpuscular volume;
LGG	cis	rs8141529	0.732	rs2269577	chr22:29196757	G/C	cg02153584	chr22:29168773	CCDC117	0.69	11.65	0.48	1.08e-27	Lymphocyte counts;
LGG	cis	rs71403859	0.685	rs12444890	chr16:71636026	G/A	cg08717414	chr16:71523259	ZNF19	-1.13	-14.47	-0.56	2.02e-39	Post bronchodilator FEV1;
LGG	cis	rs3820928	0.605	rs7560867	chr2:227780945	C/A	cg11843606	chr2:227700838	RHBDD1	-0.57	-10.71	-0.45	4.42e-24	Pulmonary function;
LGG	cis	rs1729951	0.575	rs747842	chr3:136703121	A/C	cg21827317	chr3:136751795	NA	0.52	9.71	0.41	2.03e-20	Neuroticism;
LGG	cis	rs36051895	0.623	rs76960049	chr9:5064548	G/A	cg02405213	chr9:5042618	JAK2	-0.81	-15.79	-0.59	2.88e-45	Pediatric autoimmune diseases;
LGG	cis	rs3741404	0.791	rs2282491	chr11:63918373	T/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.97	19.12	0.66	1.65e-60	Platelet count;
LGG	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg16325326	chr1:53192061	ZYG11B	0.63	13.45	0.53	4.82e-35	Monocyte count;
LGG	trans	rs6582630	0.599	rs8175936	chr12:38426315	C/G	cg06521331	chr12:34319734	NA	0.44	8.0	0.35	1.03e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4474465	0.790	rs10751295	chr11:78266047	T/A	cg27205649	chr11:78285834	NARS2	0.5	8.54	0.37	1.92e-16	Alzheimer's disease (survival time);
LGG	cis	rs240764	0.853	rs2001102	chr6:100978351	C/T	cg21058520	chr6:100914733	NA	0.42	7.2	0.32	2.52e-12	Neuroticism;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.73e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs477692	1.000	rs530466	chr10:131427717	A/G	cg05714579	chr10:131428358	MGMT	0.58	12.1	0.49	1.85e-29	Response to temozolomide;
LGG	cis	rs138249	0.934	rs138234	chr22:50560372	C/T	cg07310406	chr22:50524374	MLC1	0.41	8.09	0.35	5.18e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs11096990	0.634	rs6531703	chr4:39283406	G/T	cg24403649	chr4:39172243	NA	-0.41	-7.31	-0.32	1.2e-12	Cognitive function;
LGG	trans	rs4843747	0.671	rs28451517	chr16:88109127	A/C	cg00711542	chr16:29343894	RUNDC2C	0.41	6.93	0.31	1.44e-11	Menopause (age at onset);
LGG	cis	rs4808199	0.948	rs7259434	chr19:19428805	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.33	0.32	1.01e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs2228479	0.850	rs17233448	chr16:89816424	G/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs2832270	0.525	rs73192156	chr21:30457526	C/G	cg24692254	chr21:30365293	RNF160	-0.61	-7.22	-0.32	2.12e-12	Response to mTOR inhibitor (everolimus);
LGG	cis	rs1707322	0.964	rs785516	chr1:46564758	T/G	cg03146154	chr1:46216737	IPP	-0.53	-9.59	-0.41	5.58e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs921968	0.643	rs532475	chr2:219434208	C/T	cg01130898	chr2:219473002	PLCD4	-0.39	-6.67	-0.3	7.17e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9964724	0.559	rs8096815	chr18:35161285	A/G	cg27332583	chr18:35150602	NA	0.61	12.17	0.49	9.57e-30	Educational attainment (years of education);
LGG	cis	rs1408799	0.720	rs13302551	chr9:12750812	C/T	cg05274944	chr9:12693694	TYRP1	0.35	8.35	0.36	8.2e-16	Eye color;Blue vs. green eyes;
LGG	trans	rs947612	0.541	rs6453615	chr6:73717179	G/A	cg13494037	chr12:24737079	C12orf67	0.35	7.18	0.32	2.86e-12	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs17253792	0.822	rs10148122	chr14:56146694	G/T	cg01858014	chr14:56050164	KTN1	-0.93	-12.77	-0.51	3.33e-32	Putamen volume;
LGG	trans	rs7618501	1.000	rs34614773	chr3:49753003	T/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03821916	chr17:58755215	BCAS3	-0.43	-6.81	-0.3	2.96e-11	Pancreatic cancer;
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg12395012	chr8:11607386	GATA4	-0.38	-6.84	-0.3	2.44e-11	Neuroticism;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg00689492	chr4:1303491	MAEA	0.52	8.63	0.37	9.83e-17	Obesity-related traits;
LGG	trans	rs7613875	0.580	rs11709503	chr3:49991167	G/T	cg21659725	chr3:3221576	CRBN	0.54	9.43	0.4	2.04e-19	Body mass index;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg08508337	chr8:144660607	NAPRT1	0.91	7.07	0.31	5.74e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg14926445	chr8:58193284	C8orf71	-0.53	-7.47	-0.33	4.01e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.958	rs12879243	chr14:71905815	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.88	-0.38	1.48e-17	Mitral valve prolapse;
LGG	cis	rs1034435	0.547	rs5767174	chr22:48898857	A/G	cg05992904	chr22:48892994	FAM19A5	-0.69	-11.91	-0.48	1e-28	Late-onset Alzheimer's disease;
LGG	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	cis	rs2797369	0.766	rs2629978	chr6:101684574	A/G	cg27451362	chr6:101846650	GRIK2	0.76	10.6	0.44	1.17e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs8031584	0.560	rs1056118	chr15:31203786	G/A	cg08109568	chr15:31115862	NA	0.46	8.22	0.36	2.1e-15	Huntington's disease progression;
LGG	cis	rs28595532	0.623	rs34531766	chr4:119230339	T/C	cg21605333	chr4:119757512	SEC24D	0.87	9.34	0.4	3.97e-19	Cannabis dependence symptom count;
LGG	trans	rs3942852	0.910	rs11603850	chr11:48140900	G/A	cg15704280	chr7:45808275	SEPT13	-0.66	-8.29	-0.36	1.21e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7726839	0.540	rs3749615	chr5:601485	C/T	cg01221209	chr5:554886	NA	-0.46	-6.89	-0.3	1.83e-11	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg00684032	chr4:1343700	KIAA1530	0.45	8.73	0.38	4.66e-17	Obesity-related traits;
LGG	cis	rs2952156	0.920	rs2941506	chr17:37833035	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.96	-0.35	1.34e-14	Asthma;
LGG	cis	rs950776	0.518	rs12914694	chr15:78814444	G/A	cg16751781	chr15:78858589	CHRNA5	0.47	9.19	0.39	1.36e-18	Sudden cardiac arrest;
LGG	cis	rs7584262	1.000	rs7584262	chr2:42250549	C/T	cg27428208	chr2:42229179	NA	0.55	9.74	0.41	1.59e-20	Bone mineral density;
LGG	cis	rs7103648	0.669	rs12577383	chr11:47774238	C/T	cg20307385	chr11:47447363	PSMC3	0.81	16.48	0.61	2.27e-48	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs644799	0.544	rs687559	chr11:95598629	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.6	-10.32	-0.43	1.28e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs8002861	0.619	rs9567289	chr13:44437104	C/T	cg17145862	chr1:211918768	LPGAT1	0.8	17.37	0.63	2.18e-52	Leprosy;
LGG	cis	rs9611565	0.649	rs79009	chr22:41860864	C/A	cg06481639	chr22:41940642	POLR3H	0.6	8.73	0.38	4.77e-17	Vitiligo;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.53	0.37	2.06e-16	Personality dimensions;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs5769765	0.773	rs138834	chr22:50180497	A/C	cg02269571	chr22:50332266	NA	-0.67	-10.06	-0.42	1.12e-21	Schizophrenia;
LGG	trans	rs9409565	0.586	rs7041103	chr9:97067654	A/G	cg05679027	chr9:99775184	HIATL2	0.47	7.36	0.32	8.27e-13	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs9357271	1.000	rs9357270	chr6:38358321	A/G	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	cis	rs4664308	0.935	rs4520993	chr2:160937673	G/A	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.04	-0.64	1.75e-55	Idiopathic membranous nephropathy;
LGG	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg15147215	chr3:52552868	STAB1	-0.44	-8.88	-0.38	1.46e-17	Electroencephalogram traits;
LGG	cis	rs7000551	0.751	rs2469770	chr8:22379856	G/A	cg12081754	chr8:22256438	SLC39A14	0.67	12.56	0.5	2.34e-31	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9325144	0.560	rs11183150	chr12:38674698	A/G	cg26384229	chr12:38710491	ALG10B	-0.8	-16.53	-0.61	1.34e-48	Morning vs. evening chronotype;
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg14137381	chr5:502291	SLC9A3	-0.33	-6.95	-0.31	1.29e-11	Cystic fibrosis severity;
LGG	cis	rs7236492	0.688	rs35455644	chr18:77184282	A/G	cg05753993	chr18:77199432	NFATC1	0.4	7.34	0.32	9.4e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7011049	1.000	rs72648410	chr8:53859225	G/A	cg26025543	chr8:53854495	NA	0.75	9.68	0.41	2.58e-20	Systolic blood pressure;
LGG	cis	rs55823223	0.648	rs936394	chr17:73852008	C/A	cg06969265	chr17:73775802	H3F3B	0.5	6.88	0.3	1.89e-11	Psoriasis;
LGG	cis	rs6752107	1.000	rs13009506	chr2:234175706	A/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	-0.69	-13.09	-0.52	1.57e-33	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg14791747	chr16:20752902	THUMPD1	0.56	10.31	0.43	1.43e-22	Cognitive test performance;
LGG	cis	rs3785574	0.962	rs58131426	chr17:61854375	T/C	cg06873352	chr17:61820015	STRADA	0.47	7.35	0.32	8.81e-13	Height;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg23985595	chr17:80112537	CCDC57	0.47	9.46	0.4	1.53e-19	Life satisfaction;
LGG	cis	rs5753037	0.547	rs140134	chr22:30163332	G/A	cg01021169	chr22:30184971	ASCC2	-0.42	-8.54	-0.37	1.96e-16	Type 1 diabetes;
LGG	cis	rs10256972	0.786	rs3735686	chr7:1062527	G/A	cg04025307	chr7:1156635	C7orf50	0.58	10.82	0.45	1.76e-24	Longevity;Endometriosis;
LGG	cis	rs1008375	1.000	rs10939748	chr4:17691230	T/C	cg18681998	chr4:17616180	MED28	0.73	14.67	0.56	2.74e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs253959	0.545	rs7734133	chr5:115432115	G/A	cg22012333	chr11:118888997	RPS25;TRAPPC4	0.42	6.75	0.3	4.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs722599	0.683	rs7142898	chr14:75254310	A/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.81	0.38	2.5e-17	IgG glycosylation;
LGG	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg00717180	chr2:96193071	NA	-0.44	-7.87	-0.34	2.53e-14	HDL cholesterol;
LGG	cis	rs753778	0.570	rs4961335	chr8:142209142	A/G	cg18755752	chr8:142205143	DENND3	-0.46	-9.34	-0.4	4.03e-19	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7726839	0.574	rs72705017	chr5:623733	G/A	cg09021430	chr5:549028	NA	-0.68	-9.61	-0.41	4.72e-20	Obesity-related traits;
LGG	cis	rs972578	0.715	rs5758985	chr22:43248000	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.79	-0.3	3.38e-11	Mean platelet volume;
LGG	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	10.32	0.43	1.26e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2836974	0.644	rs7281853	chr21:40693490	A/G	cg17971929	chr21:40555470	PSMG1	-0.67	-11.76	-0.48	4.11e-28	Cognitive function;
LGG	cis	rs6582630	0.555	rs2090785	chr12:38424342	G/A	cg13010199	chr12:38710504	ALG10B	0.7	14.52	0.56	1.19e-39	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11098499	0.954	rs10006525	chr4:120408931	T/G	cg09307838	chr4:120376055	NA	0.81	13.65	0.54	6.83e-36	Corneal astigmatism;
LGG	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.78	-0.57	9.34e-41	Schizophrenia;
LGG	cis	rs701145	0.586	rs181443	chr3:153959028	G/T	cg16511985	chr3:153974050	SGEF	0.5	8.49	0.37	2.9e-16	Coronary artery disease;
LGG	cis	rs870825	0.616	rs1401362	chr4:185643775	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg02002194	chr4:3960332	NA	0.43	8.05	0.35	7.27e-15	Neuroticism;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg08925882	chr11:67350491	GSTP1	-0.34	-6.68	-0.3	6.74e-11	Mean corpuscular volume;
LGG	cis	rs2576037	0.501	rs7227700	chr18:44537102	T/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	11.08	0.46	1.8e-25	Personality dimensions;
LGG	cis	rs11711311	1.000	rs2712348	chr3:113460614	C/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.24	0.52	3.64e-34	IgG glycosylation;
LGG	cis	rs7851660	0.874	rs13299924	chr9:100627562	C/T	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs7945705	0.782	rs2742545	chr11:8884308	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.52	-11.59	-0.47	1.88e-27	Hemoglobin concentration;
LGG	cis	rs2243480	1.000	rs56016656	chr7:65383481	C/T	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.43e-59	Diabetic kidney disease;
LGG	cis	rs9398803	0.687	rs7740134	chr6:127009669	T/A	cg19875578	chr6:126661172	C6orf173	-0.52	-9.66	-0.41	3.15e-20	Male-pattern baldness;
LGG	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.35	0.43	9.9e-23	Motion sickness;
LGG	cis	rs638893	0.636	rs548167	chr11:118648396	A/G	cg13782932	chr11:118662891	DDX6	0.37	6.8	0.3	3.25e-11	Vitiligo;
LGG	cis	rs941873	0.772	rs1316312	chr10:81110417	G/C	cg09469691	chr10:81107165	PPIF	0.56	9.59	0.41	5.49e-20	Height;
LGG	cis	rs6076065	0.594	rs6048755	chr20:23337233	A/G	cg11657817	chr20:23433608	CST11	0.4	8.12	0.35	4.28e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	8.2	0.36	2.36e-15	Longevity;
LGG	cis	rs10979	0.603	rs9321920	chr6:143883588	C/G	cg25407410	chr6:143891975	LOC285740	-0.63	-10.12	-0.43	6.74e-22	Hypospadias;
LGG	cis	rs227833	0.586	rs660953	chr6:44645943	C/T	cg18551225	chr6:44695536	NA	-0.43	-6.99	-0.31	9.43e-12	Monobrow;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg14338887	chr6:42928500	GNMT	0.27	8.68	0.37	6.62e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1784581	0.802	rs9365355	chr6:162414604	A/G	cg17173639	chr6:162384350	PARK2	0.76	17.85	0.64	1.35e-54	Itch intensity from mosquito bite;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19954613	chr22:22020219	PPIL2	-0.47	-6.84	-0.3	2.54e-11	Systemic lupus erythematosus;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs875971	0.965	rs7794930	chr7:65778546	A/C	cg11764359	chr7:65958608	NA	-0.79	-14.55	-0.56	9.53e-40	Aortic root size;
LGG	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg06623630	chr22:50017776	C22orf34	-0.37	-7.88	-0.34	2.42e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1682825	0.615	rs239961	chr3:10777950	A/G	cg23512531	chr3:10780469	NA	0.57	9.19	0.39	1.38e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs8016982	0.610	rs2371570	chr14:81709686	C/T	cg01989461	chr14:81687754	GTF2A1	0.81	19.49	0.67	3.26e-62	Schizophrenia;
LGG	cis	rs654950	0.875	rs881719	chr1:41991427	C/T	cg16096631	chr1:42092165	HIVEP3	-0.36	-7.88	-0.34	2.41e-14	Airway imaging phenotypes;
LGG	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg18404041	chr3:52824283	ITIH1	0.4	7.38	0.32	7.4e-13	Electroencephalogram traits;
LGG	cis	rs853679	0.517	rs9393898	chr6:28130376	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg07882059	chr11:68924751	NA	0.42	7.54	0.33	2.54e-13	Blond vs. brown hair color;
LGG	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	11.47	0.47	5.53e-27	Lung cancer in ever smokers;
LGG	trans	rs11039798	0.688	rs12277029	chr11:48852833	G/T	cg15704280	chr7:45808275	SEPT13	0.78	9.05	0.39	3.84e-18	Axial length;
LGG	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg08949735	chr16:89699720	DPEP1	-0.48	-9.96	-0.42	2.66e-21	Vitiligo;
LGG	cis	rs2470578	0.792	rs2596675	chr3:17316259	C/G	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.45e-11	Schizophrenia;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg11301795	chr4:187892539	NA	-0.94	-24.79	-0.76	5.78e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4330281	0.669	rs11929111	chr3:17777546	A/G	cg20981856	chr3:17787350	NA	-0.41	-7.67	-0.34	1e-13	Schizophrenia;
LGG	cis	rs6693567	0.565	rs834238	chr1:150366469	G/T	cg15654264	chr1:150340011	RPRD2	0.33	6.76	0.3	4.18e-11	Migraine;
LGG	cis	rs4969178	0.965	rs12450528	chr17:76395753	G/A	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.22e-45	HDL cholesterol levels;
LGG	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	14.92	0.57	2.29e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg10056627	chr6:42928773	GNMT	0.26	7.21	0.32	2.23e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9393777	0.582	rs6936561	chr6:26640895	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	12.12	0.49	1.53e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10540	0.558	rs12806062	chr11:501429	G/A	cg03576123	chr11:487126	PTDSS2	-1.29	-16.47	-0.61	2.54e-48	Body mass index;
LGG	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg03733263	chr8:22462867	KIAA1967	1.1	29.38	0.81	7.05e-108	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs8031584	0.736	rs11635775	chr15:31160640	A/G	cg14829155	chr15:31115871	NA	-0.68	-11.44	-0.47	7.53e-27	Huntington's disease progression;
LGG	cis	rs7236492	0.748	rs11663658	chr18:77197555	T/C	cg15644404	chr18:77186268	NFATC1	-0.81	-10.11	-0.43	7.74e-22	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs6787172	0.622	rs11709804	chr3:158089733	G/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs4774899	0.869	rs2169465	chr15:57422552	T/G	cg08128148	chr15:57256372	TCF12	0.29	7.16	0.32	3.16e-12	Urinary tract infection frequency;
LGG	cis	rs236352	0.538	rs1150784	chr6:36863884	C/A	cg03410223	chr6:36853544	C6orf89	0.4	7.63	0.33	1.38e-13	Heart rate;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg23166955	chr16:30077191	ALDOA	-0.42	-6.68	-0.3	6.79e-11	Body fat mass;
LGG	cis	rs1799949	1.000	rs9646417	chr17:41424253	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.53	-0.37	2.07e-16	Menopause (age at onset);
LGG	cis	rs2456568	0.802	rs11020585	chr11:93638493	A/C	cg26875233	chr11:93583750	C11orf90	0.35	6.78	0.3	3.66e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.55	-0.41	7.37e-20	Platelet count;
LGG	cis	rs8064024	0.620	rs9923349	chr16:4905124	A/G	cg08329684	chr16:4932620	PPL	0.52	11.46	0.47	6.11e-27	Cancer;
LGG	cis	rs9915657	0.660	rs12602039	chr17:70089384	A/G	cg09344028	chr17:70110421	NA	0.56	11.81	0.48	2.47e-28	Thyroid hormone levels;
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.41	-0.33	6.18e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2073499	0.872	rs2282751	chr3:50291785	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	-0.69	-8.44	-0.37	4.19e-16	Schizophrenia;
LGG	cis	rs853679	0.517	rs9380057	chr6:28104634	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg06951627	chr6:26196580	NA	0.53	8.09	0.35	5.41e-15	Gout;Renal underexcretion gout;
LGG	cis	rs657075	0.697	rs34362950	chr5:131766503	G/A	cg20453264	chr5:131705742	SLC22A5	0.57	7.23	0.32	1.99e-12	Rheumatoid arthritis;
LGG	cis	rs988958	0.600	rs7587291	chr2:42247668	T/A	cg27428208	chr2:42229179	NA	0.55	8.96	0.38	8.07e-18	Hypospadias;
LGG	cis	rs3735485	0.738	rs10266586	chr7:45098325	A/G	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9290065	0.519	rs10513560	chr3:160710798	C/T	cg03342759	chr3:160939853	NMD3	-0.53	-8.84	-0.38	1.96e-17	Kawasaki disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13022174	chr18:23671059	SS18	0.42	6.8	0.3	3.2e-11	Cognitive performance;
LGG	cis	rs2235649	0.789	rs4567715	chr16:1849363	G/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg21238619	chr17:78079768	GAA	-0.32	-6.86	-0.3	2.18e-11	Yeast infection;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.78	-0.3	3.56e-11	Neuroticism;
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg16141378	chr3:129829833	LOC729375	0.43	10.09	0.42	8.85e-22	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08802167	chr14:74959978	NPC2;ISCA2	0.41	6.73	0.3	4.98e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs12950390	0.853	rs12451815	chr17:45855956	A/G	cg03474202	chr17:45855739	NA	-0.25	-7.45	-0.33	4.59e-13	IgG glycosylation;
LGG	cis	rs9875589	0.509	rs2733555	chr3:14099649	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.49	10.3	0.43	1.6e-22	Ovarian reserve;
LGG	cis	rs4819052	0.851	rs2838836	chr21:46665875	G/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.19	0.52	5.95e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.87	-0.3	2.12e-11	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg07606381	chr6:8435919	SLC35B3	-0.67	-12.31	-0.5	2.48e-30	Motion sickness;
LGG	trans	rs8002861	0.967	rs9533689	chr13:44480413	A/C	cg17145862	chr1:211918768	LPGAT1	0.95	24.16	0.75	5.08e-84	Leprosy;
LGG	cis	rs7107174	1.000	rs10793302	chr11:78040961	C/T	cg27205649	chr11:78285834	NARS2	-0.46	-7.62	-0.33	1.44e-13	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs8081541	chr17:61812483	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.06	0.31	6.07e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs701145	0.938	rs355749	chr3:153972500	T/C	cg17054900	chr3:154042577	DHX36	1.01	12.1	0.49	1.7e-29	Coronary artery disease;
LGG	cis	rs2303745	0.589	rs11882562	chr19:17395055	C/G	cg10664184	chr19:17420304	DDA1	-0.54	-8.35	-0.36	8.24e-16	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.580	rs7748455	chr6:8453625	C/T	cg21535247	chr6:8435926	SLC35B3	0.58	9.97	0.42	2.44e-21	Motion sickness;
LGG	cis	rs12472274	0.941	rs12616232	chr2:239080093	C/T	cg17459225	chr2:239074497	NA	0.81	13.96	0.54	3.28e-37	Phospholipid levels (plasma);
LGG	cis	rs7106204	0.688	rs7131103	chr11:24219299	A/G	ch.11.24196551F	chr11:24239977	NA	0.91	11.1	0.46	1.54e-25	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3741151	1.000	rs74776668	chr11:73065909	G/A	cg17517138	chr11:73019481	ARHGEF17	1.05	10.66	0.44	7.15e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs7481584	0.624	rs693687	chr11:3052494	A/G	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg06623918	chr6:96969491	KIAA0776	-0.77	-10.94	-0.45	6.03e-25	Migraine;Coronary artery disease;
LGG	cis	rs6089584	0.528	rs881994	chr20:60623931	G/A	cg13770153	chr20:60521292	NA	-0.49	-8.07	-0.35	6.06e-15	Body mass index;
LGG	cis	rs2115630	0.645	rs3825878	chr15:85174755	C/T	cg12501888	chr15:85177176	SCAND2	-0.56	-9.1	-0.39	2.79e-18	P wave terminal force;
LGG	cis	rs868036	0.681	rs1026737	chr15:68107072	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.41	-0.33	6e-13	Restless legs syndrome;
LGG	cis	rs4731207	0.564	rs7794565	chr7:124648968	A/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs8177253	0.666	rs8177197	chr3:133469530	G/A	cg01448562	chr3:133502909	NA	-0.62	-10.09	-0.42	9.23e-22	Iron status biomarkers;
LGG	cis	rs6784615	0.744	rs887514	chr3:52522659	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.64	-7.28	-0.32	1.42e-12	Waist-hip ratio;
LGG	cis	rs916888	0.773	rs538628	chr17:44787313	G/C	cg15921436	chr17:44337874	NA	0.57	12.24	0.49	4.95e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6061231	1.000	rs11908473	chr20:60957770	C/G	cg24112000	chr20:60950667	NA	-0.36	-7.78	-0.34	4.73e-14	Colorectal cancer;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg20887711	chr4:1340912	KIAA1530	-0.61	-11.3	-0.47	2.48e-26	Obesity-related traits;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-16.82	-0.62	6.6e-50	Bipolar disorder and schizophrenia;
LGG	cis	rs2456568	0.802	rs10765639	chr11:93636194	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs911555	0.692	rs7140647	chr14:103893465	A/G	cg24130564	chr14:104152367	KLC1	0.39	7.29	0.32	1.34e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.626	rs11153213	chr6:110015093	A/G	cg01125227	chr6:109776195	MICAL1	0.44	7.66	0.34	1.07e-13	Height;
LGG	cis	rs67133203	0.606	rs11169729	chr12:51558955	T/C	cg14688905	chr12:51403056	SLC11A2	0.64	9.66	0.41	3.01e-20	Urinary tract infection frequency;
LGG	cis	rs3793683	0.571	rs12781152	chr10:134590257	G/C	cg06453172	chr10:134556979	INPP5A	-0.48	-7.43	-0.33	5.14e-13	Migraine;
LGG	cis	rs2307022	0.671	rs3785117	chr16:68372794	G/A	cg07273125	chr16:68295692	NA	0.45	10.17	0.43	4.69e-22	Body mass index;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg04567435	chr16:85687652	KIAA0182	0.41	7.18	0.32	2.81e-12	Electrocardiographic conduction measures;
LGG	cis	rs61776719	0.738	rs7555461	chr1:38444749	T/C	cg18451016	chr1:38461880	NA	-0.58	-13.17	-0.52	7.32e-34	Coronary artery disease;
LGG	cis	rs9403521	0.553	rs76351911	chr6:143970149	G/C	cg18240653	chr6:144019428	PHACTR2	-0.58	-9.13	-0.39	2.13e-18	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs12810822	chr12:39391807	T/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs2635047	0.934	rs11663321	chr18:44622704	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	7.61	0.33	1.58e-13	Educational attainment;
LGG	cis	rs875971	0.825	rs28480509	chr7:66099224	A/G	cg23594656	chr7:65796392	TPST1	0.42	8.91	0.38	1.2e-17	Aortic root size;
LGG	cis	rs2243480	0.901	rs2900904	chr7:65204264	C/G	cg12463550	chr7:65579703	CRCP	0.73	8.04	0.35	7.48e-15	Diabetic kidney disease;
LGG	cis	rs4975616	0.839	rs2447853	chr5:1333077	A/G	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.21	-0.65	2.82e-56	Lung cancer;
LGG	cis	rs9811920	0.809	rs923472	chr3:99758029	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.48	-8.44	-0.37	3.95e-16	Axial length;
LGG	cis	rs56011263	0.687	rs4690292	chr4:703712	A/G	cg17689763	chr4:710664	PCGF3	-0.8	-16.65	-0.61	3.83e-49	White blood cell count;
LGG	cis	rs2074193	0.627	rs78261515	chr12:47775000	T/C	cg02516419	chr12:47771422	NA	0.71	10.68	0.44	5.88e-24	Migraine with aura;
LGG	cis	rs539514	0.612	rs9573648	chr13:76309279	A/G	cg04757411	chr13:76259545	LMO7	-0.27	-7.1	-0.31	4.74e-12	Type 1 diabetes;
LGG	cis	rs1030268	0.640	rs12707092	chr7:133188145	C/G	cg10665199	chr7:133106180	EXOC4	0.48	6.98	0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.569	rs75466737	chr8:58055034	A/G	cg08677398	chr8:58056175	NA	0.55	8.36	0.36	7.58e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-7.81	-0.34	3.75e-14	IgG glycosylation;
LGG	cis	rs9828933	0.752	rs13433909	chr3:63948609	C/G	cg17941049	chr3:63904683	ATXN7	0.7	8.41	0.36	4.94e-16	Type 2 diabetes;
LGG	cis	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg21775007	chr8:11205619	TDH	-0.56	-9.27	-0.4	6.81e-19	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10542027	chr5:78532229	JMY	0.45	6.76	0.3	4.13e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg19147804	chr7:1989927	MAD1L1	-0.63	-12.63	-0.51	1.25e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	cis	rs9596863	0.898	rs7993276	chr13:54323868	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.2	0.32	2.48e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs12586317	0.620	rs8020370	chr14:35581432	G/A	cg05294307	chr14:35346193	BAZ1A	-0.52	-7.48	-0.33	3.74e-13	Psoriasis;
LGG	cis	rs2197308	0.765	rs12824529	chr12:37931656	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs2688608	0.620	rs7080350	chr10:75577843	A/G	cg19442545	chr10:75533431	FUT11	0.45	7.47	0.33	3.99e-13	Inflammatory bowel disease;
LGG	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg25706552	chr1:244017396	NA	0.55	6.8	0.3	3.3e-11	RR interval (heart rate);
LGG	cis	rs2836974	0.897	rs2776308	chr21:40715175	A/G	cg17971929	chr21:40555470	PSMG1	0.79	14.16	0.55	4.47e-38	Cognitive function;
LGG	cis	rs9584850	0.915	rs7983438	chr13:99103317	T/C	cg20487152	chr13:99095054	FARP1	0.37	6.73	0.3	4.99e-11	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01555122	chr2:55276516	RTN4	-0.47	-6.76	-0.3	4.28e-11	Systemic lupus erythematosus;
LGG	cis	rs10876993	0.890	rs1689597	chr12:58051886	G/A	cg18357645	chr12:58087776	OS9	0.68	12.33	0.5	2.05e-30	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs11671005	0.651	rs11878203	chr19:58920050	G/A	cg13877915	chr19:58951672	ZNF132	0.58	8.38	0.36	6.17e-16	Mean platelet volume;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02717630	chr16:46865118	C16orf87	0.59	6.65	0.3	8.52e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg14416726	chr6:151773293	C6orf211;RMND1	0.72	13.75	0.54	2.58e-36	Menarche (age at onset);
LGG	cis	rs12579753	0.917	rs7313521	chr12:82205656	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg10818794	chr15:86012489	AKAP13	0.37	7.68	0.34	9.79e-14	Interstitial lung disease;
LGG	cis	rs6547631	0.622	rs10180391	chr2:85926345	C/T	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.59e-22	Blood protein levels;
LGG	cis	rs10504229	0.871	rs60342323	chr8:58154899	T/C	cg05313129	chr8:58192883	C8orf71	-0.79	-11.9	-0.48	1.15e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.539	rs1969355	chr12:123742061	G/A	cg00376283	chr12:123451042	ABCB9	0.66	11.49	0.47	4.76e-27	Neutrophil percentage of white cells;
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg19635926	chr16:89946313	TCF25	0.76	7.33	0.32	1.01e-12	Skin colour saturation;
LGG	cis	rs9397585	0.667	rs9479509	chr6:153427265	G/A	cg17707550	chr6:153380415	RGS17	0.47	9.85	0.42	6.65e-21	Body mass index;
LGG	cis	rs6665290	0.870	rs17600725	chr1:227204231	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.26	-39.19	-0.88	3.86e-149	Myeloid white cell count;
LGG	cis	rs6495367	1.000	rs28412916	chr15:79378167	A/C	cg17916960	chr15:79447300	NA	0.51	9.04	0.39	4.42e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9811920	0.599	rs1688758	chr3:99539890	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.62	-0.37	1.08e-16	Axial length;
LGG	cis	rs4819052	0.851	rs2877020	chr21:46658742	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4443100	0.670	rs9608071	chr22:23408118	G/T	cg14186256	chr22:23484241	RTDR1	0.54	8.68	0.37	6.8e-17	Serum parathyroid hormone levels;
LGG	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs9926296	0.609	rs4785714	chr16:89798404	G/T	cg23057051	chr16:89984268	MC1R	0.37	7.18	0.32	2.81e-12	Vitiligo;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg20887711	chr4:1340912	KIAA1530	-0.6	-11.32	-0.47	2.11e-26	Obesity-related traits;
LGG	cis	rs7107174	0.892	rs11601195	chr11:78073501	A/G	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg00149659	chr3:10157352	C3orf10	0.55	8.17	0.35	2.97e-15	Alzheimer's disease;
LGG	cis	rs950169	0.840	rs4842854	chr15:84942339	T/G	cg24253500	chr15:84953950	NA	0.58	10.43	0.44	4.94e-23	Schizophrenia;
LGG	cis	rs6933660	0.646	rs3816778	chr6:151773353	G/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.85	-16.41	-0.61	4.68e-48	Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07161162	chr16:86556439	NA	0.44	7.9	0.34	2.01e-14	Menarche (age at onset);
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.55	11.01	0.46	3.25e-25	Personality dimensions;
LGG	cis	rs7937682	0.924	rs10891284	chr11:111527737	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.15	-26.36	-0.77	3.43e-94	Primary sclerosing cholangitis;
LGG	cis	rs11098499	0.629	rs28369518	chr4:120271630	T/C	cg24375607	chr4:120327624	NA	0.52	8.77	0.38	3.54e-17	Corneal astigmatism;
LGG	cis	rs55871839	0.708	rs13261666	chr8:59814666	G/T	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.75e-34	Pneumonia;
LGG	cis	rs1056053	0.514	rs3127331	chr6:166572744	C/T	cg11088901	chr6:166572345	T	-0.51	-9.71	-0.41	2.15e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs1577917	1.000	rs34581302	chr6:86705948	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.12	-0.52	1.12e-33	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.552	rs11072613	chr15:76961526	A/C	cg23625390	chr15:77176239	SCAPER	-0.7	-12.77	-0.51	3.19e-32	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25617285	chr1:211431773	RCOR3	0.43	6.81	0.3	2.99e-11	Gut microbiome composition (summer);
LGG	cis	rs477895	1.000	rs7938380	chr11:64034866	G/A	cg22916017	chr11:64110731	CCDC88B	-0.49	-6.68	-0.3	7.05e-11	Mean platelet volume;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg12070911	chr6:150209640	RAET1E	0.3	7.43	0.33	5.32e-13	Lung cancer;
LGG	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg25358565	chr5:93447407	FAM172A	-0.66	-9.51	-0.4	1.08e-19	Diabetic retinopathy;
LGG	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg14829155	chr15:31115871	NA	-0.57	-10.02	-0.42	1.64e-21	Huntington's disease progression;
LGG	cis	rs1577917	0.560	rs12193777	chr6:86246709	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.59	11.11	0.46	1.43e-25	Response to antipsychotic treatment;
LGG	cis	rs9906944	0.545	rs12939375	chr17:47089717	C/G	cg22947322	chr17:47091978	IGF2BP1	-0.4	-7.38	-0.32	7.22e-13	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs4927850	0.529	rs6800500	chr3:195833507	T/C	cg12923728	chr3:195709715	SDHAP1	-0.53	-8.77	-0.38	3.56e-17	Pancreatic cancer;
LGG	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg03959625	chr15:84868606	LOC388152	0.56	8.7	0.37	5.79e-17	Schizophrenia;
LGG	cis	rs6800768	0.658	rs10865794	chr3:24101270	T/C	cg10674438	chr3:24145617	LOC152024	-0.32	-6.68	-0.3	6.74e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17270561	0.609	rs1165208	chr6:25803904	G/A	cg12310025	chr6:25882481	NA	-0.45	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	trans	rs916888	0.773	rs199439	chr17:44793503	A/G	cg01341218	chr17:43662625	NA	0.96	16.87	0.62	4.24e-50	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12421382	0.683	rs10789735	chr11:109431361	A/T	cg27471124	chr11:109292789	C11orf87	0.48	8.64	0.37	9.26e-17	Schizophrenia;
LGG	cis	rs62238980	0.614	rs117439638	chr22:32438225	T/C	cg02631450	chr22:32366979	NA	0.97	9.29	0.4	6.21e-19	Childhood ear infection;
LGG	cis	rs4481887	0.927	rs4244173	chr1:248466899	G/C	cg13385794	chr1:248469461	NA	0.48	8.0	0.35	1.03e-14	Common traits (Other);
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg18357526	chr6:26021779	HIST1H4A	0.76	14.1	0.55	7.93e-38	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.904	rs7990581	chr13:53019433	A/G	cg16301924	chr13:53314226	LECT1	-0.55	-11.97	-0.49	5.66e-29	Lewy body disease;
LGG	trans	rs9657904	1.000	rs9631436	chr3:105590120	G/A	cg14088669	chr1:158435396	OR10K1	-0.39	-6.77	-0.3	4.02e-11	Multiple sclerosis;
LGG	cis	rs10865541	0.934	rs4627605	chr2:3411923	G/A	cg13173536	chr2:3403300	TTC15	-0.34	-7.09	-0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs4727027	0.933	rs7788925	chr7:148831621	A/G	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.55e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg04450456	chr4:17643702	FAM184B	0.3	6.7	0.3	6.14e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg00745463	chr17:30367425	LRRC37B	0.51	6.92	0.31	1.56e-11	Hip circumference adjusted for BMI;
LGG	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.37	0.4	3.23e-19	Diabetic retinopathy;
LGG	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg27432699	chr2:27873401	GPN1	-0.42	-6.98	-0.31	9.97e-12	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs9467711	0.591	rs60512607	chr6:26054171	T/A	cg21479132	chr6:26055353	NA	0.77	7.8	0.34	4.18e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10751667	0.643	rs12278229	chr11:946985	A/G	cg22143635	chr11:980567	AP2A2	0.42	7.78	0.34	4.75e-14	Alzheimer's disease (late onset);
LGG	trans	rs12517041	1.000	rs2081952	chr5:23295605	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg15596359	chr8:11213517	TDH	-0.34	-6.96	-0.31	1.18e-11	Retinal vascular caliber;
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg08222618	chr4:941054	TMEM175	0.82	20.39	0.69	2.06e-66	Sjögren's syndrome;
LGG	cis	rs8062405	0.789	rs240704	chr16:28529949	T/C	cg16576597	chr16:28551801	NUPR1	0.36	8.43	0.36	4.48e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs977987	0.843	rs11149824	chr16:75431830	C/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	cis	rs9357271	0.955	rs58807047	chr6:38339961	T/A	cg07362130	chr6:38359646	BTBD9	-0.45	-9.4	-0.4	2.45e-19	Restless legs syndrome;
LGG	cis	rs4481887	0.962	rs4244177	chr1:248468279	C/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.39	-0.36	5.91e-16	Dementia with Lewy bodies;
LGG	cis	rs3741404	0.620	rs882147	chr11:63976689	T/A	cg18225595	chr11:63971243	STIP1	0.53	10.59	0.44	1.29e-23	Platelet count;
LGG	cis	rs11190604	1.000	rs2495752	chr10:102326115	T/C	cg07570687	chr10:102243282	WNT8B	0.42	6.79	0.3	3.45e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2346177	0.777	rs7587138	chr2:46657089	A/G	cg26688816	chr2:46740690	ATP6V1E2	0.5	9.18	0.39	1.45e-18	HDL cholesterol;
LGG	cis	rs2439831	0.867	rs45585139	chr15:43700427	G/A	cg15269541	chr15:43626905	ADAL	-0.45	-7.03	-0.31	7.62e-12	Lung cancer in ever smokers;
LGG	cis	rs738322	1.000	rs738320	chr22:38568715	G/T	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.68	-0.3	6.97e-11	Cutaneous nevi;
LGG	trans	rs453301	0.686	rs28665409	chr8:8869277	G/A	cg02002194	chr4:3960332	NA	0.39	7.29	0.32	1.39e-12	Joint mobility (Beighton score);
LGG	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-0.87	-14.02	-0.55	1.81e-37	Gut microbiome composition (summer);
LGG	cis	rs7301826	0.651	rs4514465	chr12:131313669	T/A	cg11011512	chr12:131303247	STX2	0.41	8.88	0.38	1.53e-17	Plasma plasminogen activator levels;
LGG	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg26617929	chr16:1858877	NA	0.55	7.66	0.34	1.12e-13	Insulin-like growth factors;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06558623	chr16:89946397	TCF25	1.05	13.82	0.54	1.35e-36	Skin colour saturation;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg10802521	chr3:52805072	NEK4	-0.41	-7.08	-0.31	5.26e-12	Bipolar disorder;
LGG	trans	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg24247370	chr13:99142703	STK24	-0.37	-6.87	-0.3	2.11e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7552404	0.731	rs1770885	chr1:76402212	C/T	cg22875332	chr1:76189707	ACADM	-0.58	-8.92	-0.38	1.07e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg05552183	chr6:42928497	GNMT	-0.33	-7.96	-0.35	1.36e-14	Blood protein levels;
LGG	trans	rs1728785	1.000	rs1170442	chr16:68574064	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.54	0.44	1.92e-23	Ulcerative colitis;
LGG	trans	rs61931739	0.649	rs708144	chr12:33731158	T/C	cg26384229	chr12:38710491	ALG10B	0.48	8.6	0.37	1.25e-16	Morning vs. evening chronotype;
LGG	cis	rs6835098	1.000	rs4561909	chr4:174086937	A/T	cg08422745	chr4:174089978	GALNT7	-0.85	-14.61	-0.56	5.14e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs12210905	1.000	rs72843640	chr6:27202093	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.61	-7.34	-0.32	9.73e-13	Hip circumference adjusted for BMI;
LGG	cis	rs1983891	0.955	rs4714487	chr6:41547312	T/C	cg20194872	chr6:41519635	FOXP4	0.6	10.3	0.43	1.49e-22	Prostate cancer;
LGG	cis	rs4740619	0.868	rs10738417	chr9:15870665	T/C	cg14451791	chr9:16040625	NA	-0.39	-9.82	-0.42	8.1899999999999992e-21	Body mass index;
LGG	cis	rs3808502	0.549	rs7831039	chr8:11427637	A/T	cg19847130	chr8:10466454	RP1L1	0.31	6.68	0.3	6.85e-11	Neuroticism;
LGG	cis	rs4731207	0.619	rs4461840	chr7:124581065	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs919433	0.680	rs7568250	chr2:198409611	G/A	cg00792783	chr2:198669748	PLCL1	0.51	7.98	0.35	1.16e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg07659893	chr17:61819838	STRADA	0.47	7.92	0.35	1.75e-14	Prudent dietary pattern;
LGG	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.05	-0.31	6.35e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg19784903	chr17:45786737	TBKBP1	-0.38	-8.1	-0.35	5.08e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4930103	0.602	rs170101	chr11:2008936	C/T	cg23202291	chr11:1979235	NA	0.45	8.88	0.38	1.5e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7659604	1.000	rs73844281	chr4:122664688	A/G	cg20573242	chr4:122745356	CCNA2	0.42	7.79	0.34	4.34e-14	Type 2 diabetes;
LGG	trans	rs9467711	0.651	rs35378061	chr6:26059157	C/A	cg06606381	chr12:133084897	FBRSL1	-0.77	-7.27	-0.32	1.49e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.02	-17.3	-0.63	4.37e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02215898	chr6:24721656	NA	-0.48	-6.9	-0.31	1.7e-11	Systemic lupus erythematosus;
LGG	trans	rs11098499	1.000	rs7659194	chr4:120207147	T/G	cg25214090	chr10:38739885	LOC399744	0.65	11.76	0.48	4.23e-28	Corneal astigmatism;
LGG	cis	rs6088580	0.634	rs1205338	chr20:32925625	C/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.44	-0.37	4.14e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs11792861	0.781	rs17729408	chr9:111740860	A/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	-0.62	-9.71	-0.41	2.01e-20	Menarche (age at onset);
LGG	cis	rs3812565	0.506	rs4259518	chr9:139322503	T/C	cg14019695	chr9:139328340	INPP5E	0.44	8.03	0.35	7.95e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs6750047	0.546	rs10192788	chr2:38272672	C/T	cg07380506	chr2:38303506	CYP1B1	0.44	7.21	0.32	2.3e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs4950322	0.518	rs4950304	chr1:146588267	C/T	cg22381352	chr1:146742008	CHD1L	-0.41	-7.08	-0.31	5.56e-12	Protein quantitative trait loci;
LGG	cis	rs5744897	0.655	rs35131280	chr12:133275974	A/G	cg16945633	chr12:133170342	NA	0.63	6.81	0.3	3.13e-11	Urate levels in overweight individuals;
LGG	cis	rs7666738	0.791	rs13125277	chr4:99009922	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg12927641	chr6:109611667	NA	-0.38	-7.2	-0.32	2.43e-12	Reticulocyte fraction of red cells;
LGG	cis	rs10823500	0.777	rs10509321	chr10:71985733	A/G	cg02100629	chr10:71892760	AIFM2	0.29	6.82	0.3	2.86e-11	Blood protein levels;
LGG	cis	rs427394	0.659	rs274675	chr5:6755319	C/T	cg15145174	chr5:6755386	POLS	-0.41	-7.5	-0.33	3.23e-13	Menopause (age at onset);
LGG	cis	rs943466	0.826	rs3828783	chr6:33767727	C/T	cg07519485	chr6:33762594	MLN	0.5	8.94	0.38	9.59e-18	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.03e-40	Retinal vascular caliber;
LGG	cis	rs9522267	0.502	rs9515450	chr13:112234262	T/C	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.55e-12	Hepatitis;
LGG	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg14191688	chr11:70257035	CTTN	0.6	8.56	0.37	1.66e-16	Coronary artery disease;
LGG	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs853679	0.517	rs4713141	chr6:28101678	G/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg27398817	chr8:82754497	SNX16	-0.69	-10.76	-0.45	3.04e-24	Diastolic blood pressure;
LGG	cis	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg21775007	chr8:11205619	TDH	-0.44	-7.14	-0.31	3.74e-12	Systolic blood pressure;
LGG	cis	rs11671005	0.570	rs73062110	chr19:58936642	G/T	cg13877915	chr19:58951672	ZNF132	0.61	8.53	0.37	2.13e-16	Mean platelet volume;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg23978390	chr7:1156363	C7orf50	0.5	8.66	0.37	8.21e-17	Longevity;Endometriosis;
LGG	cis	rs4075765	0.881	rs17243091	chr11:26184060	G/A	cg19182008	chr11:26298241	NA	0.79	7.68	0.34	9.72e-14	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.41	0.33	6.1e-13	Lung cancer;
LGG	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg00071950	chr4:10020882	SLC2A9	0.42	8.72	0.38	4.91e-17	Bone mineral density;
LGG	cis	rs6028335	0.867	rs66488640	chr20:37710390	A/G	cg16355469	chr20:37678765	NA	0.54	6.72	0.3	5.38e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs2013441	0.760	rs8080827	chr17:20173936	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.26	-0.4	7.37e-19	Obesity-related traits;
LGG	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.39	-0.36	6.13e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	1.000	rs11763835	chr7:1094513	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6942756	0.876	rs822040	chr7:129065922	C/G	cg02491457	chr7:128862824	NA	0.65	11.73	0.48	5.53e-28	White matter hyperintensity burden;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg15286784	chr20:47895175	C20orf199;SNORD12C;ZNFX1	0.41	7.09	0.31	5.04e-12	Bipolar disorder;
LGG	trans	rs9467711	0.606	rs9393712	chr6:26371000	G/C	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs561341	1.000	rs55736640	chr17:30333848	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.71	-0.3	5.87e-11	Hip circumference adjusted for BMI;
LGG	cis	rs12048904	0.619	rs3737581	chr1:101341083	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	16.47	0.61	2.6e-48	Multiple sclerosis;
LGG	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg18876405	chr7:65276391	NA	-0.49	-8.73	-0.38	4.69e-17	Aortic root size;
LGG	cis	rs9640161	0.750	rs11764936	chr7:150025915	G/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.8	-16.96	-0.62	1.52e-50	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6723108	0.603	rs56271357	chr2:135720715	C/T	cg07169764	chr2:136633963	MCM6	0.43	6.66	0.3	7.85e-11	Type 2 diabetes;
LGG	cis	rs2576037	0.583	rs9960463	chr18:44522808	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.49	0.37	2.81e-16	Personality dimensions;
LGG	cis	rs7833790	1.000	rs1463259	chr8:82737745	A/G	cg17211192	chr8:82754475	SNX16	-0.79	-12.38	-0.5	1.26e-30	Diastolic blood pressure;
LGG	trans	rs11722228	1.000	rs11722228	chr4:9915741	C/T	cg26043149	chr18:55253948	FECH	0.6	9.77	0.41	1.22e-20	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs12541335	0.639	rs13257108	chr8:22165043	T/C	cg26039829	chr8:22132926	PIWIL2	0.54	12.46	0.5	6.1e-31	Hypertriglyceridemia;
LGG	cis	rs3862030	0.500	rs11191327	chr10:104303883	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.31	0.58	4.37e-43	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs637571	0.522	rs3016868	chr11:65764383	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.77	0.34	4.97e-14	Eosinophil percentage of white cells;
LGG	cis	rs10266483	0.739	rs12538943	chr7:63856368	G/A	cg24201672	chr7:64023550	ZNF680	0.46	7.0	0.31	9.16e-12	Response to statin therapy;
LGG	cis	rs1408799	0.704	rs1326792	chr9:12761360	T/C	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	5.28e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs1552244	0.935	rs4441636	chr3:10083876	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.16	0.46	9.09e-26	Alzheimer's disease;
LGG	trans	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg13565492	chr6:43139072	SRF	-0.71	-8.6	-0.37	1.2e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4642101	0.590	rs6799544	chr3:12812979	T/C	cg05775895	chr3:12838266	CAND2	0.55	9.1	0.39	2.8e-18	QRS complex (12-leadsum);
LGG	cis	rs8064299	0.655	rs12797	chr17:72766993	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.51	9.02	0.39	5.2e-18	Monocyte count;
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg02475777	chr4:1388615	CRIPAK	0.59	10.58	0.44	1.43e-23	Longevity;
LGG	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg27478167	chr7:817139	HEATR2	-0.44	-6.99	-0.31	9.38e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs3858526	0.635	rs2045046	chr11:5875867	A/C	cg05234568	chr11:5960015	NA	-0.63	-10.01	-0.42	1.78e-21	DNA methylation (variation);
LGG	cis	rs2075371	0.829	rs10954442	chr7:134007587	A/G	cg20476274	chr7:133979776	SLC35B4	-0.68	-12.73	-0.51	4.7e-32	Mean platelet volume;
LGG	cis	rs2836974	0.897	rs1571709	chr21:40553980	T/C	cg11644478	chr21:40555479	PSMG1	0.93	17.71	0.64	6.02e-54	Cognitive function;
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.39e-12	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22841336	chr12:57040011	ATP5B;SNORD59A	0.54	8.17	0.35	2.86e-15	Gut microbiome composition (summer);
LGG	cis	rs17666538	0.591	rs1669716	chr8:593707	C/T	cg07685180	chr8:600429	NA	0.87	8.94	0.38	9.26e-18	IgG glycosylation;
LGG	cis	rs113835537	0.529	rs12099041	chr11:66232773	C/T	cg24851651	chr11:66362959	CCS	0.43	7.59	0.33	1.75e-13	Airway imaging phenotypes;
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.24	-0.46	4.42e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg16507663	chr6:150244633	RAET1G	0.41	7.85	0.34	2.95e-14	Lung cancer;
LGG	cis	rs300703	0.604	rs373375	chr2:203350	C/A	cg24565620	chr2:194026	NA	-0.67	-10.63	-0.44	8.93e-24	Blood protein levels;
LGG	trans	rs853679	1.000	rs1419183	chr6:28242794	A/C	cg08344181	chr3:125677491	NA	-0.56	-7.28	-0.32	1.45e-12	Depression;
LGG	cis	rs2613964	0.504	rs4682466	chr3:112849688	C/G	cg16248390	chr3:112854924	NA	-0.51	-10.69	-0.44	5.72e-24	Pediatric bone mineral density (spine);Pediatric bone mineral content (spine);
LGG	cis	rs12188164	0.965	rs11744539	chr5:451425	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.45	7.68	0.34	9.32e-14	Cystic fibrosis severity;
LGG	cis	rs7267979	1.000	rs2500436	chr20:25406366	G/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.24	-0.43	2.55e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg00761968	chr13:53314142	LECT1	0.36	7.67	0.34	1.05e-13	Lewy body disease;
LGG	cis	rs4555082	0.874	rs2816606	chr14:105716034	C/T	cg27165867	chr14:105738592	BRF1	-0.45	-7.35	-0.32	9.04e-13	Mean platelet volume;Platelet distribution width;
LGG	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg16141378	chr3:129829833	LOC729375	0.32	6.9	0.31	1.75e-11	Neuroticism;
LGG	cis	rs5769765	0.819	rs9616379	chr22:50312035	C/T	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg24690094	chr11:67383802	NA	0.51	9.19	0.39	1.35e-18	Mean corpuscular volume;
LGG	cis	rs4555082	0.874	rs2816621	chr14:105732762	A/T	cg13114125	chr14:105738426	BRF1	-0.86	-16.05	-0.6	2.14e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7552404	0.690	rs7549863	chr1:76327923	T/C	cg22875332	chr1:76189707	ACADM	-0.53	-8.2	-0.36	2.38e-15	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18018828	chr7:79081791	MAGI2	0.44	7.42	0.33	5.7e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.38	0.32	7.25e-13	Total cholesterol levels;
LGG	cis	rs1451375	0.698	rs7797131	chr7:50647934	A/G	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs7177699	0.525	rs7402376	chr15:79113570	A/G	cg00540400	chr15:79124168	NA	-0.54	-11.31	-0.47	2.4e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7312933	0.865	rs1920687	chr12:42398275	T/C	cg01943504	chr12:42538901	GXYLT1	-0.4	-6.73	-0.3	5.05e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs8114671	0.647	rs1415771	chr20:33734493	G/A	cg24642439	chr20:33292090	TP53INP2	0.53	8.7	0.37	5.8e-17	Height;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg19006130	chr11:118478252	PHLDB1	0.4	7.12	0.31	4.12e-12	Cholesterol, total;
LGG	cis	rs2797369	0.600	rs17061230	chr6:101365314	A/G	cg27451362	chr6:101846650	GRIK2	0.77	10.53	0.44	2.11e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs35110281	0.712	rs8133523	chr21:45062403	A/G	cg04455712	chr21:45112962	RRP1B	0.51	9.69	0.41	2.52e-20	Mean corpuscular volume;
LGG	cis	rs72945132	0.882	rs6592554	chr11:70226040	G/A	cg14191688	chr11:70257035	CTTN	0.56	8.2	0.36	2.44e-15	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21705394	chr11:30344510	C11orf46	0.49	7.37	0.32	8.1e-13	Gut microbiome composition (summer);
LGG	cis	rs12956009	0.583	rs12965907	chr18:44888455	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.4e-12	Educational attainment (years of education);
LGG	cis	rs4319547	0.774	rs10773394	chr12:123124778	C/A	cg23029597	chr12:123009494	RSRC2	-0.81	-15.19	-0.58	1.4e-42	Body mass index;
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs17767392	0.881	rs35589413	chr14:71991676	T/A	cg02058870	chr14:72053146	SIPA1L1	0.4	8.37	0.36	6.69e-16	Mitral valve prolapse;
LGG	cis	rs4006360	0.546	rs1846043	chr17:39265300	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.39	-8.17	-0.36	2.94e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs80282103	0.618	rs74117849	chr10:1165425	A/G	cg08668510	chr10:1095578	IDI1	0.8	7.71	0.34	7.7e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs1153858	1.000	rs8032904	chr15:45651309	C/T	cg14582100	chr15:45693742	SPATA5L1	0.4	6.82	0.3	2.93e-11	Homoarginine levels;
LGG	cis	rs11628318	0.853	rs28444760	chr14:103041148	A/G	cg23461800	chr14:103021989	NA	-0.59	-10.92	-0.45	7.46e-25	Platelet count;
LGG	cis	rs72700829	0.531	rs955955	chr1:151011543	G/A	cg11822372	chr1:151115635	SEMA6C	-0.68	-7.09	-0.31	4.96e-12	Schizophrenia;
LGG	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg20848291	chr7:100343083	ZAN	0.44	7.12	0.31	4.27e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs7149337	0.752	rs8021773	chr14:51691528	C/T	cg23942311	chr14:51606299	NA	0.37	8.41	0.36	5.2e-16	Cancer;
LGG	cis	rs7010267	0.583	rs1485303	chr8:119976256	G/A	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.72	0.3	5.48e-11	Total body bone mineral density (age 45-60);
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg09699651	chr6:150184138	LRP11	0.55	9.67	0.41	2.91e-20	Lung cancer;
LGG	cis	rs283228	0.617	rs636796	chr6:101748957	G/T	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg26839252	chr6:160211577	TCP1;MRPL18	0.43	6.89	0.31	1.82e-11	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs2665103	0.715	rs7403041	chr15:82580182	A/C	cg16105309	chr15:79090380	ADAMTS7	-0.35	-6.8	-0.3	3.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7249142	0.562	rs10417796	chr19:19287072	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.25	-0.36	1.62e-15	IgG glycosylation;
LGG	cis	rs1153858	1.000	rs12593230	chr15:45646968	A/T	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.92	0.35	1.79e-14	Homoarginine levels;
LGG	cis	rs1869026	1.000	rs2311600	chr2:121340676	A/G	cg22272644	chr2:121334640	NA	-0.3	-7.15	-0.32	3.51e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.5	-8.28	-0.36	1.3e-15	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg24829409	chr8:58192753	C8orf71	0.74	10.5	0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs112591243	0.685	rs117443865	chr21:47959731	C/G	cg10657630	chr21:48055338	PRMT2	0.88	7.72	0.34	7.49e-14	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs72945132	0.882	rs7935969	chr11:70194175	G/A	cg14088196	chr11:70211408	PPFIA1	0.94	13.16	0.52	7.85e-34	Coronary artery disease;
LGG	cis	rs7226408	0.857	rs55752284	chr18:34447175	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs10046574	0.561	rs56014861	chr7:135203027	A/T	cg27474649	chr7:135195673	CNOT4	0.74	8.97	0.38	7.15e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.59	0.51	1.76e-31	Prudent dietary pattern;
LGG	cis	rs10924309	0.889	rs10802247	chr1:245858508	G/A	cg00036263	chr1:245852353	KIF26B	-0.46	-6.78	-0.3	3.56e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs9486719	0.947	rs9386648	chr6:97035656	T/C	cg18709589	chr6:96969512	KIAA0776	-0.44	-6.66	-0.3	8e-11	Migraine;Coronary artery disease;
LGG	cis	rs1046896	0.552	rs12602280	chr17:80805421	G/C	cg22027946	chr17:80790580	TBCD;ZNF750	0.39	6.76	0.3	4.28e-11	Glycated hemoglobin levels;
LGG	cis	rs12681287	0.640	rs7816629	chr8:87350788	A/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.51	-0.33	3.05e-13	Caudate activity during reward;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg09303159	chr6:26284866	NA	0.35	7.88	0.34	2.31e-14	Educational attainment;
LGG	cis	rs367943	0.644	rs348942	chr5:112824039	T/C	cg12552261	chr5:112820674	MCC	-0.75	-13.84	-0.54	1.11e-36	Type 2 diabetes;
LGG	cis	rs7582180	0.903	rs13032368	chr2:100896112	C/T	cg05692746	chr2:100937584	LONRF2	-0.59	-9.67	-0.41	2.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4684776	1.000	rs34843621	chr3:11450873	A/G	cg24705426	chr3:11550659	ATG7	-0.42	-7.64	-0.33	1.27e-13	Small vessel stroke;
LGG	cis	rs920590	0.758	rs35280191	chr8:19665214	A/C	cg03894339	chr8:19674705	INTS10	0.65	10.58	0.44	1.38e-23	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs3758785	0.512	rs79440247	chr11:94093320	A/G	cg14656441	chr1:39500070	NDUFS5	-0.3	-6.7	-0.3	6.07e-11	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);
LGG	trans	rs7615952	0.512	rs34085484	chr3:125544186	T/C	cg07211511	chr3:129823064	LOC729375	-1.05	-15.12	-0.57	2.95e-42	Blood pressure (smoking interaction);
LGG	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg07747251	chr5:1868357	NA	0.4	7.08	0.31	5.35e-12	Cardiovascular disease risk factors;
LGG	cis	rs2412459	1.000	rs2412459	chr15:40295959	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.82	-9.39	-0.4	2.84e-19	Response to haloperidol in psychosis;
LGG	cis	rs4950322	0.542	rs17159924	chr1:146671044	A/G	cg22381352	chr1:146742008	CHD1L	-0.46	-7.66	-0.34	1.12e-13	Protein quantitative trait loci;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19937698	chr13:60970319	TDRD3	0.52	8.06	0.35	6.76e-15	Gut microbiome composition (summer);
LGG	cis	rs7084783	0.507	rs61870170	chr10:105403300	A/G	cg00126946	chr10:105363258	SH3PXD2A	0.38	7.15	0.32	3.51e-12	Fear of pain;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.818	rs3795381	chr1:153004848	T/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	cis	rs2204008	0.527	rs1315367	chr12:38177487	G/T	cg13010199	chr12:38710504	ALG10B	-0.55	-10.64	-0.44	8.41e-24	Bladder cancer;
LGG	cis	rs524281	0.861	rs10896091	chr11:65950825	T/C	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.32	0.53	1.65e-34	Obesity-related traits;
LGG	cis	rs7089973	0.604	rs2420066	chr10:116583897	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg01145232	chr6:150245071	RAET1G	0.51	9.72	0.41	1.91e-20	Lung cancer;
LGG	cis	rs9952991	0.941	rs7237497	chr18:12777325	T/C	cg23544223	chr18:12777786	NA	0.61	9.24	0.39	9.26e-19	Inflammatory skin disease;
LGG	cis	rs1577917	1.000	rs12190598	chr6:86686074	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.56	-9.28	-0.4	6.8e-19	Response to antipsychotic treatment;
LGG	cis	rs9527	0.615	rs3897401	chr10:104696379	T/C	cg05308233	chr10:104796373	CNNM2	-0.31	-6.72	-0.3	5.47e-11	Arsenic metabolism;
LGG	cis	rs10911363	0.592	rs2702182	chr1:183516440	C/T	cg23894439	chr1:183413866	NA	0.47	8.77	0.38	3.51e-17	Systemic lupus erythematosus;
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg13047869	chr3:10149882	C3orf24	0.57	9.63	0.41	4.01e-20	Alzheimer's disease;
LGG	trans	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg06521331	chr12:34319734	NA	0.5	9.04	0.39	4.38e-18	Bladder cancer;
LGG	trans	rs1829883	0.804	rs2511924	chr5:98721643	C/T	cg08333243	chr5:99726346	NA	0.35	6.92	0.31	1.55e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2273669	0.667	rs11153150	chr6:109316652	C/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	cis	rs739401	0.572	rs12276060	chr11:3015572	A/T	cg05729581	chr11:3078854	CARS	-0.53	-9.03	-0.39	4.6e-18	Longevity;
LGG	cis	rs7737355	0.812	rs10063264	chr5:130898197	C/G	cg06307176	chr5:131281290	NA	0.52	8.66	0.37	8.2e-17	Life satisfaction;
LGG	trans	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg20325293	chr4:54244256	FIP1L1	-0.8	-7.83	-0.34	3.28e-14	IgG glycosylation;
LGG	cis	rs4631830	0.965	rs4306255	chr10:51542444	A/G	cg16070123	chr10:51489643	NA	-0.37	-6.89	-0.3	1.84e-11	Prostate-specific antigen levels;
LGG	cis	rs3740909	1.000	rs7120521	chr11:125882173	C/T	cg24940576	chr11:125904314	CDON	-0.48	-7.45	-0.33	4.61e-13	Blood protein levels;
LGG	cis	rs798554	0.757	rs1182171	chr7:2878510	A/G	cg19524238	chr7:2802976	GNA12	0.37	8.44	0.37	4.12e-16	Height;
LGG	trans	rs67340775	0.748	rs13212651	chr6:27806985	A/G	cg08344181	chr3:125677491	NA	-0.86	-8.4	-0.36	5.33e-16	Lung cancer in ever smokers;
LGG	cis	rs6912958	0.559	rs395358	chr6:88057924	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	12.82	0.51	2.14e-32	Monocyte percentage of white cells;
LGG	cis	rs26232	0.551	rs26431	chr5:102365794	G/C	cg23492399	chr5:102201601	PAM	0.51	7.64	0.33	1.27e-13	Rheumatoid arthritis;
LGG	cis	rs853679	0.517	rs4713137	chr6:28083521	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.53	-0.41	8.54e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4144743	1.000	rs67080286	chr17:45322248	T/G	cg18085866	chr17:45331354	ITGB3	-0.78	-9.92	-0.42	3.55e-21	Body mass index;
LGG	cis	rs7408868	1.000	rs4809030	chr19:15273381	A/G	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs6681460	0.584	rs7528182	chr1:67067369	C/T	cg20812318	chr1:67072952	SGIP1	-0.32	-7.63	-0.33	1.38e-13	Presence of antiphospholipid antibodies;
LGG	cis	rs1577917	1.000	rs955196	chr6:86729951	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.56	9.18	0.39	1.39e-18	Response to antipsychotic treatment;
LGG	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg09696939	chr10:60272079	BICC1	-0.4	-7.76	-0.34	5.51e-14	Refractive error;
LGG	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg00376283	chr12:123451042	ABCB9	0.62	9.35	0.4	3.81e-19	Neutrophil percentage of white cells;
LGG	cis	rs7937682	0.602	rs4936804	chr11:111743851	A/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs2288073	0.965	rs72789923	chr2:24394504	A/C	cg26838691	chr2:24397539	C2orf84	-0.51	-7.15	-0.32	3.37e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs236373	0.522	rs236352	chr6:36817113	A/G	cg07544796	chr6:36817048	NA	0.24	7.19	0.32	2.55e-12	Heart rate;
LGG	cis	rs6456042	0.893	rs3127422	chr6:166539070	G/A	cg11088901	chr6:166572345	T	-0.36	-7.54	-0.33	2.56e-13	Asthma;
LGG	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg20573242	chr4:122745356	CCNA2	0.53	9.83	0.42	7.59e-21	Type 2 diabetes;
LGG	cis	rs6696846	0.749	rs7515178	chr1:205084120	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.26	0.32	1.7e-12	Red blood cell count;
LGG	cis	rs9357271	0.737	rs9349081	chr6:38399009	C/A	cg07362130	chr6:38359646	BTBD9	-0.4	-8.11	-0.35	4.42e-15	Restless legs syndrome;
LGG	cis	rs8062405	1.000	rs80275162	chr16:28863517	T/A	cg16576597	chr16:28551801	NUPR1	0.3	6.82	0.3	2.94e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4561483	0.583	rs33636	chr16:11990323	C/G	cg08843971	chr16:11963173	GSPT1	-0.59	-14.79	-0.57	8.26e-41	Testicular germ cell tumor;
LGG	cis	rs11785400	0.731	rs4736363	chr8:143742112	C/A	cg10596483	chr8:143751796	JRK	0.52	8.12	0.35	4.14e-15	Schizophrenia;
LGG	cis	rs1568889	1.000	rs12803716	chr11:28055111	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.28	-0.32	1.49e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.65	-13.94	-0.54	3.8e-37	Multiple sclerosis;
LGG	cis	rs4819052	0.851	rs1056099	chr21:46678892	G/A	cg06618935	chr21:46677482	NA	-0.43	-8.33	-0.36	9.48e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg06719900	chr11:109292894	C11orf87	0.45	8.37	0.36	7.11e-16	Schizophrenia;
LGG	cis	rs35740288	0.787	rs11635418	chr15:86244178	C/G	cg04173714	chr15:86211321	AKAP13	0.46	7.83	0.34	3.25e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	1.000	rs4793236	chr17:41436440	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.39	-0.4	2.78e-19	Menopause (age at onset);
LGG	cis	rs72634258	0.842	rs4325151	chr1:8168917	T/A	cg00042356	chr1:8021962	PARK7	-0.54	-7.7	-0.34	8.17e-14	Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg19223190	chr17:80058835	NA	0.44	8.51	0.37	2.42e-16	Life satisfaction;
LGG	cis	rs11098499	0.708	rs1546506	chr4:120241240	T/C	cg24375607	chr4:120327624	NA	0.59	9.87	0.42	5.35e-21	Corneal astigmatism;
LGG	cis	rs9636252	0.887	rs10194786	chr2:9267131	G/T	cg20341998	chr2:9276514	NA	-0.38	-7.08	-0.31	5.24e-12	IgG glycosylation;
LGG	cis	rs9473924	0.542	rs13195969	chr6:50814627	C/A	cg14470998	chr6:50812995	TFAP2B	0.69	8.31	0.36	1.06e-15	Body mass index;
LGG	trans	rs5744897	0.708	rs4883582	chr12:133242733	C/A	cg04991071	chr3:71615924	FOXP1	0.6	7.04	0.31	6.92e-12	Urate levels in overweight individuals;
LGG	cis	rs10274279	0.660	rs4716759	chr7:157374986	T/C	cg09270525	chr7:157391030	PTPRN2	0.81	13.39	0.53	8.96e-35	Myopia (pathological);
LGG	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg02733842	chr7:1102375	C7orf50	-0.56	-8.33	-0.36	9.49e-16	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	0.679	rs17800895	chr8:58050085	A/G	cg23782820	chr8:58130467	NA	0.48	6.82	0.3	2.77e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	0.931	rs4608864	chr4:135883488	G/A	cg14419869	chr4:135874104	NA	0.56	10.68	0.44	5.89e-24	Subjective well-being;
LGG	cis	rs1650123	0.932	rs703625	chr12:104035825	A/T	cg23227824	chr12:103980017	STAB2	-0.33	-7.51	-0.33	3.1e-13	IgG glycosylation;
LGG	cis	rs7143963	0.636	rs2103929	chr14:103322471	C/T	cg23020514	chr14:103360112	TRAF3	0.4	8.41	0.36	5.13e-16	Body mass index;
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg00800038	chr16:89945340	TCF25	-0.58	-7.92	-0.35	1.75e-14	Skin colour saturation;
LGG	trans	rs7746199	0.673	rs72847313	chr6:27730082	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25264265	chr3:185080997	MAP3K13	0.55	8.33	0.36	9.08e-16	Gut microbiome composition (summer);
LGG	cis	rs3733585	0.783	rs13148371	chr4:10032561	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.79e-16	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17767392	0.670	rs2159145	chr14:71726351	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.36	-8.28	-0.36	1.36e-15	Mitral valve prolapse;
LGG	cis	rs6540556	0.954	rs7536882	chr1:209936673	C/G	cg23920097	chr1:209922102	NA	-0.46	-8.07	-0.35	6.1e-15	Red blood cell count;
LGG	trans	rs2727020	0.514	rs4980444	chr11:49550764	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-10.91	-0.45	8.05e-25	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs6505207	chr17:29076571	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6088580	0.634	rs6059868	chr20:33079460	A/G	cg06115741	chr20:33292138	TP53INP2	0.51	8.37	0.36	6.63e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs11785400	0.701	rs9721143	chr8:143727511	A/T	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	cis	rs1348850	0.567	rs3770012	chr2:178538023	A/G	cg22681709	chr2:178499509	PDE11A	0.48	8.8	0.38	2.64e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg19143629	chr17:61920732	SMARCD2	0.41	7.15	0.32	3.35e-12	Prudent dietary pattern;
LGG	cis	rs6933660	0.760	rs1825368	chr6:151775259	C/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.47	8.26	0.36	1.51e-15	Menarche (age at onset);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.73	13.97	0.54	2.98e-37	Obesity-related traits;
LGG	cis	rs870825	0.698	rs28412823	chr4:185638829	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.63	0.72	6.95e-77	Blood protein levels;
LGG	cis	rs9768139	0.935	rs62480865	chr7:158122307	A/C	cg25566285	chr7:158114605	PTPRN2	-0.95	-23.57	-0.74	2.63e-81	Calcium levels;
LGG	cis	rs4919694	0.808	rs77521106	chr10:104980726	G/T	cg04362960	chr10:104952993	NT5C2	1.02	12.36	0.5	1.53e-30	Arsenic metabolism;
LGG	cis	rs9560113	1.000	rs9560110	chr13:112181233	C/T	cg14154082	chr13:112174009	NA	0.42	9.19	0.39	1.3e-18	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13126279	chr21:47581558	C21orf56	-0.47	-8.13	-0.35	3.93e-15	Testicular germ cell tumor;
LGG	cis	rs3762637	1.000	rs7609972	chr3:122199426	T/G	cg24169773	chr3:122142474	KPNA1	-0.63	-10.92	-0.45	7.15e-25	LDL cholesterol levels;
LGG	cis	rs10858096	0.608	rs4970843	chr1:109887191	A/G	cg17185401	chr1:110052093	AMIGO1	0.44	8.78	0.38	3.08e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6546550	0.935	rs1531025	chr2:70055505	G/T	cg02498382	chr2:70120550	SNRNP27	-0.36	-7.01	-0.31	8.33e-12	Prevalent atrial fibrillation;
LGG	cis	rs9303401	0.625	rs66508449	chr17:56691034	T/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.9	14.66	0.56	2.92e-40	Cognitive test performance;
LGG	cis	rs2073300	1.000	rs6106655	chr20:23441982	C/G	cg12062639	chr20:23401060	NAPB	0.82	6.73	0.3	5.02e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1008375	0.866	rs2109518	chr4:17572162	G/A	cg18681998	chr4:17616180	MED28	0.85	18.25	0.65	1.81e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4650994	0.507	rs12141152	chr1:178514165	C/T	cg19399532	chr1:178512495	C1orf220	0.55	11.0	0.46	3.55e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg00666640	chr1:248458726	OR2T12	0.5	8.43	0.36	4.48e-16	Common traits (Other);
LGG	cis	rs12701220	0.522	rs868833	chr7:1054973	C/G	cg22444338	chr7:1054449	C7orf50	0.44	9.23	0.39	9.72e-19	Bronchopulmonary dysplasia;
LGG	cis	rs911555	0.706	rs10129426	chr14:104018455	C/T	cg23335576	chr14:104009727	NA	0.49	9.04	0.39	4.46e-18	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg04471375	chr16:58752165	GOT2	-0.56	-7.07	-0.31	5.86e-12	Intelligence (multi-trait analysis);
LGG	cis	rs864537	0.618	rs2988277	chr1:167431352	A/G	cg09179987	chr1:167433047	CD247	-0.44	-9.94	-0.42	3.16e-21	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg08975724	chr8:8085496	FLJ10661	0.61	12.9	0.51	9.67e-33	Mood instability;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26009773	chr6:101329304	ASCC3	-0.42	-7.08	-0.31	5.53e-12	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs295140	1.000	rs13026151	chr2:201164570	T/A	cg25099087	chr2:201172481	SPATS2L	0.27	6.74	0.3	4.66e-11	QT interval;
LGG	cis	rs13108904	0.875	rs10024013	chr4:1280792	C/T	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.17	-0.39	1.55e-18	Obesity-related traits;
LGG	cis	rs17401966	0.838	rs34565762	chr1:10300119	T/C	cg15208524	chr1:10270712	KIF1B	0.45	7.78	0.34	4.73e-14	Hepatocellular carcinoma;
LGG	cis	rs68170813	0.617	rs2283041	chr7:107190415	A/G	cg02696742	chr7:106810147	HBP1	-0.63	-7.98	-0.35	1.15e-14	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04172748	chr2:120124292	DBI;C2orf76	0.55	8.13	0.35	3.83e-15	Gut microbiome composition (summer);
LGG	cis	rs3749237	0.576	rs4241406	chr3:49600426	C/T	cg06212747	chr3:49208901	KLHDC8B	0.43	6.91	0.31	1.63e-11	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00076854	chr13:29233041	POMP	0.49	7.34	0.32	9.48e-13	Gut microbiome composition (summer);
LGG	cis	rs9308731	0.966	rs3827536	chr2:111920741	G/T	cg19992207	chr2:111874495	ACOXL	-0.4	-7.33	-0.32	1.05e-12	Chronic lymphocytic leukemia;
LGG	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.81	0.3	2.98e-11	Bone mineral density;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg19847130	chr8:10466454	RP1L1	0.33	6.89	0.3	1.87e-11	Neuroticism;
LGG	cis	rs3936840	0.752	rs2181343	chr14:102993303	A/C	cg18135206	chr14:102964638	TECPR2	-0.46	-8.14	-0.35	3.75e-15	Plateletcrit;
LGG	cis	rs7945718	0.839	rs10831911	chr11:12834858	C/T	cg25843174	chr11:12811716	TEAD1	0.37	7.54	0.33	2.51e-13	Educational attainment (years of education);
LGG	cis	rs1153858	1.000	rs3759899	chr15:45655903	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.2e-25	Homoarginine levels;
LGG	cis	rs910316	0.967	rs175432	chr14:75615246	C/G	cg08847533	chr14:75593920	NEK9	-0.6	-11.44	-0.47	7.46e-27	Height;
LGG	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg00290607	chr11:67383545	NA	-0.52	-9.26	-0.4	7.43e-19	Mean corpuscular volume;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.31	0.47	2.3e-26	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs7795242	chr7:65390094	T/C	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs2120243	0.874	rs2316709	chr3:157150247	C/T	cg24825693	chr3:157122686	VEPH1	-0.36	-7.67	-0.34	1.02e-13	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs3784262	0.631	rs4646584	chr15:58305402	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.76	-0.3	4.09e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10754283	0.967	rs1934044	chr1:90107501	C/T	cg06121193	chr1:90282411	NA	0.37	7.03	0.31	7.5e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs12765878	0.967	rs11598018	chr10:105661315	C/A	cg11005552	chr10:105648138	OBFC1	1.04	27.3	0.79	1.66e-98	Coronary artery disease;
LGG	cis	rs240764	0.817	rs239219	chr6:101116146	C/T	cg09795085	chr6:101329169	ASCC3	0.46	7.77	0.34	5.01e-14	Neuroticism;
LGG	cis	rs60180747	0.909	rs17200912	chr15:66730307	C/T	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.58	9.79	0.41	1.06e-20	Testicular germ cell tumor;
LGG	cis	rs3785574	0.582	rs62072238	chr17:61948841	A/T	cg06873352	chr17:61820015	STRADA	0.48	7.6	0.33	1.67e-13	Height;
LGG	cis	rs9611565	0.694	rs202617	chr22:41822793	C/T	cg17554472	chr22:41940697	POLR3H	0.46	6.73	0.3	4.88e-11	Vitiligo;
LGG	cis	rs2346177	0.874	rs11125075	chr2:46656344	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-9.03	-0.39	4.57e-18	HDL cholesterol;
LGG	cis	rs7091068	0.518	rs9633674	chr10:95455431	C/T	cg20715218	chr10:95462985	C10orf4	0.65	11.48	0.47	5.22e-27	Urinary tract infection frequency;
LGG	cis	rs35160687	0.871	rs2278105	chr2:86466516	A/G	cg10973622	chr2:86423274	IMMT	0.39	6.72	0.3	5.4e-11	Night sleep phenotypes;
LGG	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg00129232	chr17:37814104	STARD3	0.61	11.51	0.47	4.01e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs8002861	0.870	rs4942251	chr13:44440048	G/T	cg12856521	chr11:46389249	DGKZ	0.39	6.73	0.3	5.07e-11	Leprosy;
LGG	cis	rs17401966	0.931	rs2236678	chr1:10471789	A/T	cg15208524	chr1:10270712	KIF1B	0.41	6.69	0.3	6.47e-11	Hepatocellular carcinoma;
LGG	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	cg15522984	chr1:182991683	LAMC1	0.44	8.88	0.38	1.51e-17	Colorectal cancer;
LGG	cis	rs8114671	0.562	rs6088635	chr20:33466501	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.03	0.31	7.56e-12	Height;
LGG	cis	rs7584330	0.737	rs60187585	chr2:238365159	C/T	cg16989719	chr2:238392110	NA	-0.32	-6.95	-0.31	1.25e-11	Prostate cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04966789	chr14:35591779	PPP2R3C;KIAA0391	0.4	6.85	0.3	2.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2228479	0.850	rs117675822	chr16:89919081	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.68	-0.34	9.44e-14	Skin colour saturation;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg19147804	chr7:1989927	MAD1L1	-0.48	-9.41	-0.4	2.25e-19	Schizophrenia;
LGG	cis	rs17666538	0.535	rs4338080	chr8:615598	A/G	cg23958373	chr8:599963	NA	1.18	11.77	0.48	3.81e-28	IgG glycosylation;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg23594656	chr7:65796392	TPST1	0.4	8.75	0.38	3.89e-17	Aortic root size;
LGG	cis	rs1015291	0.708	rs2638401	chr12:20006985	C/T	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs12681287	0.547	rs6985066	chr8:87526439	A/C	cg27223183	chr8:87520930	FAM82B	-0.48	-7.32	-0.32	1.13e-12	Caudate activity during reward;
LGG	cis	rs4740619	0.689	rs1410446	chr9:15927795	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.38	-0.43	7.88e-23	Body mass index;
LGG	cis	rs6499255	1.000	rs4497676	chr16:69814950	G/A	cg00738113	chr16:70207722	CLEC18C	-0.3	-6.79	-0.3	3.38e-11	IgE levels;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4975616	0.836	rs421629	chr5:1320136	G/A	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.33	-0.65	7.68e-57	Lung cancer;
LGG	trans	rs963265	0.845	rs3780603	chr9:73021495	A/G	cg12611527	chr2:157257110	NA	0.34	6.81	0.3	2.95e-11	Migraine with aura;
LGG	cis	rs6834538	1.000	rs6823117	chr4:113447354	T/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.53	8.63	0.37	9.8e-17	Free thyroxine concentration;
LGG	cis	rs757081	0.669	rs542274	chr11:17207433	C/T	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.59	-0.33	1.84e-13	Systolic blood pressure;
LGG	cis	rs13108904	0.934	rs13125842	chr4:1280947	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs10267417	0.603	rs10263119	chr7:19872844	C/G	cg05791153	chr7:19748676	TWISTNB	0.64	8.28	0.36	1.35e-15	Night sleep phenotypes;
LGG	cis	rs9467160	0.871	rs9467168	chr6:24449036	A/G	cg20631270	chr6:24437470	GPLD1	0.51	7.64	0.33	1.26e-13	Liver enzyme levels;
LGG	trans	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg23762105	chr12:34175262	ALG10	-0.34	-7.0	-0.31	9.06e-12	Morning vs. evening chronotype;
LGG	trans	rs453301	0.624	rs330049	chr8:9087299	C/T	cg08975724	chr8:8085496	FLJ10661	0.43	8.42	0.36	4.87e-16	Joint mobility (Beighton score);
LGG	cis	rs7954584	0.531	rs6486781	chr12:122318985	A/C	cg13699009	chr12:122356056	WDR66	0.55	15.15	0.58	2.19e-42	Mean corpuscular volume;
LGG	cis	rs10050311	0.698	rs78818211	chr4:87636388	C/T	cg11209507	chr4:87813803	C4orf36	0.51	6.72	0.3	5.41e-11	Insulin-related traits;
LGG	cis	rs908922	0.676	rs11205033	chr1:152527966	C/A	cg03606772	chr1:152487856	CRCT1	0.31	7.25	0.32	1.72e-12	Hair morphology;
LGG	cis	rs701145	0.640	rs1657621	chr3:153929795	T/C	cg12800244	chr3:153838788	SGEF	0.84	8.37	0.36	7.08e-16	Coronary artery disease;
LGG	cis	rs2933343	0.700	rs1683777	chr3:128624880	T/G	cg11901034	chr3:128598214	ACAD9	-0.44	-6.65	-0.3	8.31e-11	IgG glycosylation;
LGG	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg01864069	chr14:103024347	NA	0.67	9.68	0.41	2.71e-20	Platelet count;
LGG	cis	rs4788570	0.578	rs7204992	chr16:71658444	G/A	cg06353428	chr16:71660113	MARVELD3	1.28	21.71	0.71	1.36e-72	Intelligence (multi-trait analysis);
LGG	cis	rs17666538	0.585	rs6559063	chr8:623051	C/T	cg07234876	chr8:600039	NA	1.21	11.68	0.48	8.6e-28	IgG glycosylation;
LGG	cis	rs4423214	1.000	rs2276362	chr11:71174452	A/G	cg05163923	chr11:71159392	DHCR7	0.72	14.24	0.55	1.97e-38	Vitamin D levels;
LGG	cis	rs1865760	0.613	rs9358894	chr6:25923315	C/T	cg12310025	chr6:25882481	NA	-0.52	-9.75	-0.41	1.52e-20	Height;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg04772025	chr11:68637568	NA	0.75	13.09	0.52	1.53e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7945705	0.818	rs10769948	chr11:8761782	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-7.9	-0.34	1.98e-14	Hemoglobin concentration;
LGG	cis	rs12956009	0.583	rs12960952	chr18:44857476	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.15	0.32	3.49e-12	Educational attainment (years of education);
LGG	trans	rs6561151	0.681	rs17065161	chr13:44443723	A/T	cg17145862	chr1:211918768	LPGAT1	0.66	10.35	0.43	1.03e-22	Crohn's disease;
LGG	cis	rs13191362	1.000	rs35911566	chr6:162994154	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.77	8.21	0.36	2.18e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.863	rs11649912	chr17:61797515	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.4	0.84	2.1e-125	Prudent dietary pattern;
LGG	cis	rs3091242	0.933	rs11802413	chr1:25760920	A/G	cg27572855	chr1:25598939	RHD	-0.48	-10.65	-0.44	7.87e-24	Erythrocyte sedimentation rate;
LGG	cis	rs2294693	0.947	rs736793	chr6:40997919	A/T	cg14769373	chr6:40998127	UNC5CL	-0.44	-7.65	-0.33	1.2e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs757110	0.740	rs10832776	chr11:17385224	C/A	cg04705435	chr11:17411270	KCNJ11	0.43	8.34	0.36	8.33e-16	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs3762637	1.000	rs7644540	chr3:122210052	C/T	cg24169773	chr3:122142474	KPNA1	-0.6	-10.2	-0.43	3.53e-22	LDL cholesterol levels;
LGG	cis	rs1577917	0.958	rs2084294	chr6:86565943	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.27	-0.5	3.69e-30	Response to antipsychotic treatment;
LGG	cis	rs2404602	0.655	rs3829489	chr15:77223256	A/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.75	-0.3	4.32e-11	Blood metabolite levels;
LGG	cis	rs9303401	0.538	rs3785493	chr17:56472119	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	-0.8	-12.18	-0.49	8.36e-30	Cognitive test performance;
LGG	cis	rs41271473	0.750	rs72751931	chr1:228887129	G/T	cg00850481	chr1:228891306	NA	-0.59	-10.65	-0.44	7.83e-24	Chronic lymphocytic leukemia;
LGG	cis	rs1372520	0.935	rs1442152	chr4:90775649	C/A	cg15133208	chr4:90757351	SNCA	-0.4	-8.21	-0.36	2.26e-15	Neuroticism;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4561483	0.583	rs11647580	chr16:11957609	G/C	cg08843971	chr16:11963173	GSPT1	0.57	13.84	0.54	1.03e-36	Testicular germ cell tumor;
LGG	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg21427119	chr20:30132790	HM13	-0.42	-7.19	-0.32	2.69e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4262150	0.627	rs9968702	chr5:152358404	C/G	cg12297329	chr5:152029980	NA	-0.54	-8.24	-0.36	1.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs11122272	0.735	rs2808604	chr1:231538916	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.47e-12	Hemoglobin concentration;
LGG	cis	rs3849046	0.817	rs68128065	chr5:137926467	T/C	cg10920316	chr5:137946599	NA	-0.47	-7.61	-0.33	1.52e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4417704	0.551	rs4675841	chr2:241876580	A/G	cg05025159	chr2:241905733	NA	0.46	9.45	0.4	1.7e-19	Joint mobility (Beighton score);
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs10769945	0.679	rs217213	chr11:1979118	C/G	cg15394860	chr11:2017084	H19	-0.42	-8.68	-0.37	6.76e-17	DNA methylation (variation);
LGG	cis	rs6933660	0.720	rs6914656	chr6:151753421	C/G	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.9	-0.51	9.68e-33	Menarche (age at onset);
LGG	cis	rs9527	0.590	rs3781281	chr10:104852648	A/G	cg05308233	chr10:104796373	CNNM2	0.32	7.09	0.31	4.88e-12	Arsenic metabolism;
LGG	cis	rs12586317	0.547	rs10145723	chr14:35460954	G/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.63	0.54	8.66e-36	Psoriasis;
LGG	cis	rs2976388	0.566	rs13250661	chr8:143804134	C/T	cg06565975	chr8:143823917	SLURP1	-0.51	-12.81	-0.51	2.3e-32	Urinary tract infection frequency;
LGG	cis	rs3093024	1.000	rs3093023	chr6:167534290	A/G	cg07741184	chr6:167504864	NA	-0.37	-7.94	-0.35	1.5e-14	Rheumatoid arthritis;
LGG	cis	rs35160687	0.644	rs4610056	chr2:86553250	T/C	cg10973622	chr2:86423274	IMMT	-0.4	-7.0	-0.31	8.89e-12	Night sleep phenotypes;
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	9.94	0.42	3.02e-21	Longevity;
LGG	cis	rs2153535	0.580	rs7341206	chr6:8470489	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs9814567	0.896	rs58491661	chr3:134355189	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.68	0.51	8.03e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs910316	1.000	rs7303	chr14:75520065	T/C	cg08847533	chr14:75593920	NEK9	0.62	11.85	0.48	1.83e-28	Height;
LGG	cis	rs1552244	0.882	rs3732966	chr3:10015740	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs9300255	0.602	rs1790098	chr12:123655481	A/C	cg05973401	chr12:123451056	ABCB9	0.51	7.38	0.32	7.45e-13	Neutrophil percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21348357	chr2:171574592	NA	0.38	8.1	0.35	5.09e-15	Gut microbiome composition (summer);
LGG	cis	rs758324	0.947	rs380182	chr5:131319036	A/G	cg06307176	chr5:131281290	NA	-0.57	-9.12	-0.39	2.37e-18	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2985684	0.948	rs12897941	chr14:50016701	G/C	cg02151108	chr14:50098012	C14orf104	-0.42	-9.01	-0.39	5.54e-18	Carotid intima media thickness;
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.65	-0.33	1.2e-13	Tonsillectomy;
LGG	cis	rs16976116	0.951	rs11857087	chr15:55487181	T/A	cg11288833	chr15:55489084	RSL24D1	0.55	7.54	0.33	2.58e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg25319279	chr11:5960081	NA	-0.52	-9.27	-0.4	7.27e-19	DNA methylation (variation);
LGG	cis	rs13108904	0.935	rs13148614	chr4:1248357	G/C	cg05665937	chr4:1216051	CTBP1	0.48	8.79	0.38	2.86e-17	Obesity-related traits;
LGG	cis	rs9916302	0.571	rs28799952	chr17:37533056	C/T	cg07936489	chr17:37558343	FBXL20	1.0	15.52	0.59	4.73e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs8177253	0.930	rs12595	chr3:133496553	T/C	cg12373951	chr3:133503437	NA	0.39	6.95	0.31	1.27e-11	Iron status biomarkers;
LGG	cis	rs992157	0.798	rs7587220	chr2:219160864	C/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.61	-10.14	-0.43	5.86e-22	Colorectal cancer;
LGG	cis	rs12477438	0.798	rs13414153	chr2:99624748	G/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs67311347	1.000	rs11716675	chr3:40485280	G/T	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00735591	chr19:10828665	DNM2;MIR638	0.46	6.97	0.31	1.11e-11	Gut microbiome composition (summer);
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.65	-0.3	8.15e-11	Total body bone mineral density;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.74	13.57	0.53	1.44e-35	Lymphocyte counts;
LGG	cis	rs9858542	0.953	rs3811699	chr3:49396360	T/C	cg03060546	chr3:49711283	APEH	-0.61	-10.14	-0.43	6.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs950776	0.593	rs481134	chr15:78877563	C/T	cg06917634	chr15:78832804	PSMA4	0.72	14.16	0.55	4.71e-38	Sudden cardiac arrest;
LGG	cis	rs6502050	0.835	rs4789676	chr17:80123078	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg00800038	chr16:89945340	TCF25	-0.66	-7.6	-0.33	1.66e-13	Skin colour saturation;
LGG	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg03929089	chr4:120376271	NA	-1.02	-22.5	-0.72	2.6e-76	Height;
LGG	cis	rs7086627	0.515	rs11202959	chr10:82209672	A/G	cg03293884	chr10:82215075	TSPAN14	-0.44	-8.8	-0.38	2.67e-17	Post bronchodilator FEV1;
LGG	cis	rs873946	0.590	rs12259699	chr10:134549692	A/G	cg27286337	chr10:134555280	INPP5A	0.87	14.1	0.55	8e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3087591	0.960	rs2905872	chr17:29525027	C/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.37	0.56	5.69e-39	Hip circumference;
LGG	cis	rs4665809	0.590	rs35727620	chr2:26458364	G/A	cg22920501	chr2:26401640	FAM59B	0.44	9.02	0.39	4.93e-18	Gut microbiome composition (summer);
LGG	cis	rs7084402	0.967	rs1649091	chr10:60289440	T/A	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs6456156	0.586	rs6456154	chr6:167472256	C/T	cg07741184	chr6:167504864	NA	0.4	9.18	0.39	1.46e-18	Primary biliary cholangitis;
LGG	cis	rs7660883	0.860	rs10023050	chr4:88064431	A/G	cg21988461	chr4:88008667	AFF1	-0.34	-9.72	-0.41	1.86e-20	HDL cholesterol levels;
LGG	cis	rs4478037	0.749	rs9681623	chr3:33131375	G/T	cg19404215	chr3:33155277	CRTAP	0.74	9.47	0.4	1.4e-19	Major depressive disorder;
LGG	cis	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs701145	0.585	rs1713798	chr3:153807407	G/A	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	cis	rs10937275	0.826	rs62294593	chr3:186642111	T/G	cg26193484	chr3:186648175	ST6GAL1	0.89	9.2	0.39	1.23e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.58	9.79	0.41	1.05e-20	Obesity-related traits;
LGG	cis	rs9948	0.655	rs57582887	chr2:97406354	A/C	cg01990225	chr2:97406019	LMAN2L	-0.75	-7.45	-0.33	4.62e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs6088590	0.930	rs6087618	chr20:33288407	C/T	cg08999081	chr20:33150536	PIGU	0.33	8.06	0.35	6.4e-15	Coronary artery disease;
LGG	cis	rs1806153	0.673	rs7942007	chr11:31835418	A/G	cg11990419	chr11:31841155	NA	0.36	8.21	0.36	2.28e-15	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs2304069	0.819	rs10875553	chr5:149374932	T/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.57	7.65	0.34	1.14e-13	HIV-1 control;
LGG	cis	rs75804782	0.641	rs3769123	chr2:239349328	C/G	cg18131467	chr2:239335373	ASB1	-0.66	-6.66	-0.3	7.58e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9790314	0.846	rs6441371	chr3:161008727	C/A	cg04691961	chr3:161091175	C3orf57	-0.61	-14.18	-0.55	3.66e-38	Morning vs. evening chronotype;
LGG	cis	rs4148883	0.675	rs11724783	chr4:100099688	C/A	cg12011299	chr4:100065546	ADH4	0.4	8.51	0.37	2.4e-16	Alcohol dependence;
LGG	cis	rs727505	0.866	rs66852389	chr7:124724348	T/A	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	cis	rs9393777	0.623	rs9358948	chr6:26483806	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	11.72	0.48	5.92e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg10057126	chr4:77819792	ANKRD56	0.37	6.97	0.31	1.07e-11	Emphysema distribution in smoking;
LGG	cis	rs9674544	0.757	rs9896443	chr17:47125982	A/G	cg22947322	chr17:47091978	IGF2BP1	-0.43	-7.76	-0.34	5.36e-14	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	trans	rs7829975	0.617	rs4841071	chr8:8791144	G/T	cg16141378	chr3:129829833	LOC729375	-0.34	-7.65	-0.33	1.19e-13	Mood instability;
LGG	cis	rs1348850	0.918	rs12463893	chr2:178448559	G/T	cg27490568	chr2:178487706	NA	0.44	8.67	0.37	7.37e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.779	rs6815934	chr4:120267310	T/C	cg09307838	chr4:120376055	NA	0.68	11.74	0.48	4.89e-28	Corneal astigmatism;
LGG	cis	rs7084402	0.935	rs7474570	chr10:60343085	C/G	cg07615347	chr10:60278583	BICC1	0.62	17.65	0.63	1.13e-53	Refractive error;
LGG	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg12751644	chr20:60527061	NA	-0.29	-6.83	-0.3	2.74e-11	Body mass index;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg08645402	chr16:4508243	NA	0.54	10.38	0.43	7.87e-23	Schizophrenia;
LGG	trans	rs9650657	0.771	rs4840516	chr8:10667335	C/G	cg06636001	chr8:8085503	FLJ10661	0.4	7.31	0.32	1.2e-12	Neuroticism;
LGG	cis	rs977987	0.528	rs9926933	chr16:75501567	A/G	cg07303275	chr16:75499416	TMEM170A	-0.57	-8.6	-0.37	1.29e-16	Dupuytren's disease;
LGG	cis	rs9487094	0.778	rs61318425	chr6:109748506	T/C	cg01125227	chr6:109776195	MICAL1	0.53	8.85	0.38	1.82e-17	Height;
LGG	cis	rs17445774	1.000	rs1509833	chr2:200865225	G/A	cg23649088	chr2:200775458	C2orf69	0.59	10.01	0.42	1.75e-21	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs703842	1.000	rs10877014	chr12:58167661	A/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.49	7.88	0.34	2.43e-14	Multiple sclerosis;
LGG	cis	rs3816183	0.641	rs4952946	chr2:43106093	C/G	cg14631114	chr2:43023945	NA	0.43	7.8	0.34	4.19e-14	Hypospadias;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg03264133	chr6:25882463	NA	-0.42	-7.44	-0.33	5.09e-13	Height;
LGG	cis	rs4363385	0.747	rs7529110	chr1:152966247	A/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.26	-0.4	7.4e-19	Inflammatory skin disease;
LGG	cis	rs34172651	0.917	rs8049667	chr16:24773524	G/A	cg02428538	chr16:24856791	SLC5A11	-0.48	-8.18	-0.36	2.84e-15	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.903	rs11253488	chr10:922482	G/C	cg20503657	chr10:835505	NA	0.73	10.01	0.42	1.8e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6087771	0.682	rs2038397	chr20:30217759	A/G	cg21427119	chr20:30132790	HM13	-0.46	-7.67	-0.34	1e-13	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2115630	0.967	rs11073702	chr15:85310071	G/A	cg12501888	chr15:85177176	SCAND2	-0.41	-6.93	-0.31	1.39e-11	P wave terminal force;
LGG	cis	rs16837677	1.000	rs12402266	chr1:156771781	G/A	cg14991358	chr1:156767203	PRCC	0.77	7.96	0.35	1.38e-14	Sjögren's syndrome;
LGG	cis	rs367943	0.712	rs13359330	chr5:112708529	T/C	cg12552261	chr5:112820674	MCC	0.58	10.55	0.44	1.81e-23	Type 2 diabetes;
LGG	cis	rs17270561	0.609	rs1317817	chr6:25765377	G/A	cg03264133	chr6:25882463	NA	-0.49	-7.87	-0.34	2.54e-14	Iron status biomarkers;
LGG	cis	rs12477438	0.501	rs13008171	chr2:99743419	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg23978390	chr7:1156363	C7orf50	0.51	8.79	0.38	2.84e-17	Longevity;Endometriosis;
LGG	cis	rs11148252	0.875	rs9568728	chr13:52946593	C/T	cg02158880	chr13:53174818	NA	0.4	7.78	0.34	4.88e-14	Lewy body disease;
LGG	cis	rs35264875	1.000	rs6591370	chr11:68843003	G/A	cg03469862	chr11:68924853	NA	0.46	7.14	0.31	3.74e-12	Blond vs. brown hair color;
LGG	cis	rs10504229	0.683	rs72650839	chr8:58130029	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs5762813	0.566	rs5762818	chr22:29211435	C/T	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs17666538	0.585	rs4448252	chr8:615597	A/G	cg13264159	chr8:625131	ERICH1	-1.03	-11.92	-0.48	9.55e-29	IgG glycosylation;
LGG	cis	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg13010199	chr12:38710504	ALG10B	0.72	14.69	0.56	2.3e-40	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11630290	0.628	rs72752941	chr15:64181604	G/C	cg12036633	chr15:63758958	NA	-0.57	-6.68	-0.3	6.69e-11	Iris characteristics;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18099408	chr3:52552593	STAB1	-0.32	-6.69	-0.3	6.46e-11	Bipolar disorder;
LGG	cis	rs11148252	0.538	rs3368	chr13:52707240	C/G	cg22398616	chr13:53314203	LECT1	-0.49	-10.04	-0.42	1.4e-21	Lewy body disease;
LGG	cis	rs9517320	0.534	rs9554478	chr13:99187792	G/A	cg07423050	chr13:99094983	FARP1	-0.56	-10.96	-0.45	5.32e-25	Longevity;
LGG	cis	rs637571	0.780	rs677029	chr11:65683531	A/G	cg02427764	chr11:65769310	BANF1;EIF1AD	0.42	7.01	0.31	8.24e-12	Eosinophil percentage of white cells;
LGG	trans	rs9944715	1.000	rs9952654	chr18:43849568	T/G	cg01718231	chr17:29326311	RNF135	-0.42	-6.73	-0.3	4.95e-11	Red cell distribution width;Mean corpuscular volume;
LGG	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-9.02	-0.39	5.19e-18	Morning vs. evening chronotype;
LGG	cis	rs5753037	0.653	rs140131	chr22:30151716	A/G	cg01021169	chr22:30184971	ASCC2	-0.34	-6.73	-0.3	5.14e-11	Type 1 diabetes;
LGG	cis	rs1832871	0.599	rs1754413	chr6:158764741	C/T	cg07215822	chr6:158701037	NA	0.48	9.49	0.4	1.25e-19	Height;
LGG	cis	rs1152591	0.505	rs968257	chr14:64680285	T/C	cg21174375	chr14:64681225	SYNE2	0.4	7.4	0.33	6.52e-13	Atrial fibrillation;
LGG	cis	rs6500602	0.727	rs4238849	chr16:4538114	G/A	cg01673284	chr16:4527211	HMOX2	0.32	6.78	0.3	3.76e-11	Schizophrenia;
LGG	cis	rs2531992	0.686	rs933392	chr16:4032716	T/G	cg05927578	chr16:4029543	ADCY9	0.74	10.45	0.44	4.38e-23	Waist circumference;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs1003719	0.788	rs2835605	chr21:38490734	T/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.33	0.63	3.07e-52	Eye color traits;
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg17178900	chr1:205818956	PM20D1	0.36	7.08	0.31	5.26e-12	Menarche (age at onset);
LGG	cis	rs12477438	0.798	rs9308816	chr2:99637230	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs6163	0.588	rs12763284	chr10:104508202	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.4	7.3	0.32	1.27e-12	Waist circumference;Hip circumference;
LGG	cis	rs7928758	0.943	rs79449985	chr11:134265121	C/T	cg25213107	chr11:134282864	B3GAT1	1.15	13.92	0.54	4.77e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs56104184	0.779	rs17206686	chr19:49356317	A/G	cg19024700	chr19:49340765	PLEKHA4;HSD17B14	0.51	6.64	0.3	8.54e-11	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7264396	0.733	rs6060515	chr20:34211779	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.44	-0.33	4.9e-13	Total cholesterol levels;
LGG	cis	rs801193	0.773	rs801207	chr7:66020590	T/C	cg11764359	chr7:65958608	NA	-0.55	-9.41	-0.4	2.28e-19	Aortic root size;
LGG	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg05729581	chr11:3078854	CARS	-0.55	-9.64	-0.41	3.73e-20	Longevity;
LGG	cis	rs7927771	0.524	rs4752860	chr11:47705015	C/A	cg20307385	chr11:47447363	PSMC3	-0.56	-10.99	-0.45	3.98e-25	Subjective well-being;
LGG	cis	rs8060686	0.545	rs75229939	chr16:68164949	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2153535	0.580	rs9392224	chr6:8472614	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9467711	0.651	rs35778245	chr6:25944803	G/A	cg21479132	chr6:26055353	NA	0.8	7.29	0.32	1.32e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1799949	1.000	rs3092994	chr17:41215825	C/T	cg23758822	chr17:41437982	NA	0.85	15.01	0.57	8.99e-42	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13776499	chr2:12858298	TRIB2	0.44	7.08	0.31	5.5e-12	Cognitive performance;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg07414643	chr4:187882934	NA	0.56	11.53	0.47	3.32e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs826838	0.935	rs1843639	chr12:39178919	C/A	cg13010199	chr12:38710504	ALG10B	0.71	14.99	0.57	1.09e-41	Heart rate;
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.15e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7512552	0.803	rs11582423	chr1:150493925	C/G	cg15654264	chr1:150340011	RPRD2	0.44	8.98	0.39	6.86e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9322193	0.607	rs12210822	chr6:150226492	C/T	cg16507663	chr6:150244633	RAET1G	0.44	7.16	0.32	3.22e-12	Lung cancer;
LGG	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.43	0.36	4.39e-16	Mood instability;
LGG	cis	rs11239187	0.530	rs78995732	chr10:45062182	C/T	cg03916630	chr10:45065415	NA	0.37	8.97	0.38	7.24e-18	Body mass index;
LGG	cis	rs10504229	0.683	rs59679713	chr8:58134370	G/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2712184	0.756	rs2712163	chr2:217660346	G/A	cg05032264	chr2:217675019	NA	-0.44	-9.62	-0.41	4.22e-20	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	trans	rs6582630	0.537	rs1949610	chr12:38387838	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.41e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg24642439	chr20:33292090	TP53INP2	0.47	7.54	0.33	2.53e-13	Height;
LGG	cis	rs17826219	0.706	rs2322197	chr17:29105805	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.23	-0.36	1.86e-15	Body mass index;
LGG	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs4237845	0.537	rs11172367	chr12:58272486	T/G	cg00677455	chr12:58241039	CTDSP2	0.41	7.64	0.33	1.29e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.08e-20	Common traits (Other);
LGG	cis	rs6951245	0.832	rs10266519	chr7:1142977	C/T	cg22907277	chr7:1156413	C7orf50	0.8	10.9	0.45	8.77e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs757978	1.000	rs73116394	chr2:242367915	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.57	-0.37	1.61e-16	Chronic lymphocytic leukemia;
LGG	cis	rs7762018	1.000	rs73242927	chr6:170129573	T/A	cg19338460	chr6:170058176	WDR27	-0.62	-8.39	-0.36	5.99e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs853679	0.546	rs175597	chr6:27810626	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.44	-0.44	4.54e-23	Depression;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.88	0.34	2.33e-14	Lung cancer;
LGG	cis	rs9487094	0.666	rs2277113	chr6:109775436	T/C	cg01125227	chr6:109776195	MICAL1	0.4	6.87	0.3	2.14e-11	Height;
LGG	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg01206211	chr2:36825736	FEZ2	0.49	9.74	0.41	1.6e-20	Height;
LGG	cis	rs7598759	0.712	rs997400	chr2:232332847	C/T	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.49e-14	Noise-induced hearing loss;
LGG	cis	rs9768139	0.658	rs896778	chr7:158113270	A/G	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.75	-0.34	6.01e-14	Calcium levels;
LGG	trans	rs3942852	0.955	rs7117386	chr11:48125371	G/A	cg03929089	chr4:120376271	NA	-0.64	-8.03	-0.35	8.42e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs1707322	0.721	rs10890341	chr1:46147240	C/A	cg03146154	chr1:46216737	IPP	0.55	10.65	0.44	7.82e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12541335	0.639	rs3923433	chr8:22169798	A/T	cg09517075	chr8:22133004	PIWIL2	0.43	9.48	0.4	1.31e-19	Hypertriglyceridemia;
LGG	cis	rs8180040	0.620	rs749511	chr3:47035735	A/C	cg27129171	chr3:47204927	SETD2	-0.8	-14.46	-0.56	2.16e-39	Colorectal cancer;
LGG	cis	rs9467773	0.511	rs11755443	chr6:26891603	T/C	cg09904177	chr6:26538194	HMGN4	0.45	8.21	0.36	2.24e-15	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.791	rs11040472	chr11:49703116	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.99	-0.78	4.49e-97	Height;
LGG	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg10596483	chr8:143751796	JRK	-0.57	-9.45	-0.4	1.68e-19	Schizophrenia;
LGG	trans	rs61931739	0.534	rs7302688	chr12:34235064	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.81	-0.3	2.95e-11	Iron status biomarkers;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08643953	chr3:132379052	UBA5;ACAD11	-0.4	-6.72	-0.3	5.5e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.3	-0.36	1.17e-15	Retinal vascular caliber;
LGG	cis	rs7937682	0.855	rs527078	chr11:111479713	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.45	-0.74	9.66e-81	Primary sclerosing cholangitis;
LGG	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg03806693	chr22:41940476	POLR3H	1.08	19.39	0.67	9.63e-62	Vitiligo;
LGG	cis	rs6502050	0.835	rs8067875	chr17:80092778	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	4.96e-19	Life satisfaction;
LGG	cis	rs9814567	1.000	rs6763088	chr3:134254989	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2404602	0.692	rs12911902	chr15:77053575	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.17	-0.32	3.04e-12	Blood metabolite levels;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.81	-0.3	3.12e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7666738	0.830	rs28594127	chr4:99001121	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.99e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6964587	0.610	rs10953056	chr7:91466700	C/T	cg17063962	chr7:91808500	NA	0.4	7.18	0.32	2.83e-12	Breast cancer;
LGG	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg20608306	chr11:116969690	SIK3	0.33	8.61	0.37	1.19e-16	Blood protein levels;
LGG	cis	rs9291683	0.530	rs13115193	chr4:9982191	C/T	cg00071950	chr4:10020882	SLC2A9	0.38	7.79	0.34	4.5e-14	Bone mineral density;
LGG	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg00938859	chr5:1591904	SDHAP3	0.89	13.14	0.52	9.22e-34	Breast cancer;
LGG	cis	rs11679564	0.714	rs4389320	chr2:37172531	T/C	cg14987922	chr2:37194071	STRN	0.51	8.27	0.36	1.44e-15	Immature fraction of reticulocytes;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs698833	0.588	rs12615427	chr2:44724790	T/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.42	6.75	0.3	4.36e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs2071403	0.622	rs4076290	chr2:1378969	C/T	cg06500727	chr2:1417164	TPO	-0.42	-7.35	-0.32	8.85e-13	Thyroid peroxidase antibody positivity;
LGG	cis	rs6500395	1.000	rs34844432	chr16:48682418	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.9	0.38	1.27e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6088590	0.561	rs6059932	chr20:33175466	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.71	0.41	2.11e-20	Coronary artery disease;
LGG	cis	rs7737355	0.947	rs58895212	chr5:130797057	C/A	cg06307176	chr5:131281290	NA	-0.56	-9.29	-0.4	6.27e-19	Life satisfaction;
LGG	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg27316798	chr5:14870666	ANKH	-0.53	-10.85	-0.45	1.41e-24	Blood metabolite levels;
LGG	cis	rs10267417	0.535	rs6960731	chr7:19869379	C/G	cg05791153	chr7:19748676	TWISTNB	-0.58	-7.58	-0.33	1.87e-13	Night sleep phenotypes;
LGG	trans	rs7826238	0.524	rs2921055	chr8:8319342	C/A	cg12395012	chr8:11607386	GATA4	-0.37	-6.77	-0.3	3.88e-11	Systolic blood pressure;
LGG	cis	rs67311347	1.000	rs4974017	chr3:40473519	C/T	cg13683864	chr3:40499215	RPL14	-1.01	-21.27	-0.7	1.56e-70	Renal cell carcinoma;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22322834	chr12:50135138	TMBIM6	-0.47	-6.85	-0.3	2.31e-11	Systemic lupus erythematosus;
LGG	cis	rs208520	0.661	rs207099	chr6:66796373	A/C	cg07460842	chr6:66804631	NA	-0.97	-18.22	-0.65	2.62e-56	Exhaled nitric oxide output;
LGG	trans	rs11250098	0.642	rs4841460	chr8:10789493	C/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.63	-0.33	1.36e-13	Morning vs. evening chronotype;
LGG	cis	rs7582720	1.000	rs72936870	chr2:203789679	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1107366	0.722	rs9851577	chr3:125908310	C/T	cg11252792	chr3:125932053	NA	0.61	12.15	0.49	1.1e-29	Metabolite levels;
LGG	cis	rs807669	0.802	rs762528	chr22:19166680	A/G	cg02655711	chr22:19163373	SLC25A1	0.79	16.21	0.6	3.88e-47	Metabolite levels;
LGG	cis	rs4332037	0.713	rs56093134	chr7:1973970	C/T	cg23422044	chr7:1970798	MAD1L1	-0.68	-11.15	-0.46	9.63e-26	Bipolar disorder;
LGG	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.47	0.5	5.61e-31	Hip circumference adjusted for BMI;
LGG	cis	rs4363385	0.647	rs4845513	chr1:152998066	T/C	cg13444842	chr1:152974279	SPRR3	-0.48	-9.68	-0.41	2.55e-20	Inflammatory skin disease;
LGG	cis	rs2486288	0.656	rs9921035	chr15:45546660	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.65	-0.44	8.02e-24	Glomerular filtration rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04854568	chr7:87849748	SRI	0.47	6.95	0.31	1.21e-11	Gut microbiome composition (summer);
LGG	cis	rs12210905	0.920	rs9366690	chr6:27291079	T/C	cg15325629	chr6:28072465	NA	0.84	6.73	0.3	4.88e-11	Hip circumference adjusted for BMI;
LGG	trans	rs9650657	0.737	rs2116095	chr8:10635297	T/C	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	9.22e-14	Neuroticism;
LGG	cis	rs11608355	0.521	rs6606706	chr12:109830173	C/T	cg19025524	chr12:109796872	NA	-0.58	-12.94	-0.52	6.38e-33	Neuroticism;
LGG	cis	rs11122272	0.735	rs2749699	chr1:231520279	A/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9463078	0.774	rs9357480	chr6:45219512	G/A	cg25276700	chr6:44698697	NA	-0.38	-7.89	-0.34	2.15e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2032447	0.933	rs4401650	chr6:26035208	G/A	cg18357526	chr6:26021779	HIST1H4A	0.88	17.03	0.62	7.75e-51	Intelligence (multi-trait analysis);
LGG	cis	rs4936891	0.599	rs2076941	chr11:123893286	A/G	cg22125253	chr11:123886957	OR10G4	0.51	8.77	0.38	3.55e-17	Male fertility;
LGG	cis	rs9487051	0.676	rs6568560	chr6:109592851	G/A	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.16e-14	Reticulocyte fraction of red cells;
LGG	cis	rs6502050	0.835	rs34620191	chr17:80149532	G/A	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg22676075	chr6:135203613	NA	0.4	6.96	0.31	1.16e-11	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs10504229	0.953	rs66676208	chr8:58173866	C/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs57221529	0.766	rs72703070	chr5:590458	T/C	cg25482853	chr8:67687455	SGK3	1.0	12.85	0.51	1.52e-32	Lung disease severity in cystic fibrosis;
LGG	cis	rs6752107	1.000	rs2289474	chr2:234181848	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.37	0.53	1.03e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.4	-0.33	6.53e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9875589	1.000	rs9875589	chr3:13961157	A/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.39	-7.68	-0.34	9.77e-14	Ovarian reserve;
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.93	0.31	1.43e-11	Personality dimensions;
LGG	cis	rs2415984	0.622	rs11846013	chr14:46932291	A/C	cg14871534	chr14:47121158	RPL10L	0.59	10.29	0.43	1.74e-22	Number of children ever born;
LGG	cis	rs7927592	0.913	rs7107622	chr11:68374183	T/C	cg20283391	chr11:68216788	NA	-0.49	-8.05	-0.35	7.04e-15	Total body bone mineral density;
LGG	cis	rs4356932	1.000	rs17288671	chr4:76932001	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.68	-0.3	6.92e-11	Blood protein levels;
LGG	cis	rs7264396	0.676	rs6058380	chr20:34552900	T/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.84	-0.3	2.57e-11	Total cholesterol levels;
LGG	cis	rs62238980	0.614	rs77162015	chr22:32485616	G/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs10174077	0.874	rs10186656	chr2:152475938	T/G	cg19508488	chr2:152266495	RIF1	0.52	9.14	0.39	1.95e-18	Squamous cell lung carcinoma;
LGG	trans	rs9354308	0.764	rs4538687	chr6:66585568	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs79976124	0.876	rs17511913	chr6:66644361	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.37	0.5	1.38e-30	Type 2 diabetes;
LGG	cis	rs2011503	0.825	rs4808932	chr19:19358819	C/T	cg01262667	chr19:19385393	TM6SF2	0.36	7.14	0.31	3.63e-12	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs2474568	chr10:38383147	A/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.52	-0.47	3.43e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs9916302	0.851	rs677888	chr17:37461018	T/G	cg00129232	chr17:37814104	STARD3	0.56	9.92	0.42	3.76e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs477895	0.878	rs7478730	chr11:64018827	C/T	cg04317338	chr11:64019027	PLCB3	0.66	7.88	0.34	2.35e-14	Mean platelet volume;
LGG	cis	rs834603	0.575	rs940861	chr7:47469429	A/T	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs17253792	0.822	rs28754619	chr14:56088394	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	trans	rs66573146	0.831	rs56081162	chr4:6989718	C/T	cg07817883	chr1:32538562	TMEM39B	1.26	11.84	0.48	1.87e-28	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1153858	1.000	rs7164602	chr15:45671325	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.39	0.72	9.14e-76	Homoarginine levels;
LGG	cis	rs17345786	0.511	rs1138818	chr3:101399583	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.08	0.35	5.66e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9929218	0.817	rs8055912	chr16:68802068	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.83	-0.51	1.93e-32	Colorectal cancer;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg14926445	chr8:58193284	C8orf71	-0.95	-12.84	-0.51	1.79e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs1401999	1.000	rs2313217	chr3:183635997	A/G	cg01324343	chr3:183735012	ABCC5	0.85	18.28	0.65	1.39e-56	Anterior chamber depth;
LGG	cis	rs9322193	0.923	rs6913486	chr6:150026196	C/T	cg09699651	chr6:150184138	LRP11	-0.52	-8.97	-0.38	7.46e-18	Lung cancer;
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg05692746	chr2:100937584	LONRF2	-0.62	-11.24	-0.46	4.28e-26	Intelligence (multi-trait analysis);
LGG	trans	rs225245	0.782	rs321601	chr17:33892087	A/C	cg19694781	chr19:47549865	TMEM160	0.4	6.77	0.3	3.9e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4417704	0.526	rs4130554	chr2:241881642	G/A	cg26818257	chr2:241905806	NA	0.48	10.06	0.42	1.11e-21	Joint mobility (Beighton score);
LGG	cis	rs11190604	1.000	rs11190599	chr10:102295420	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.42	0.33	5.83e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4853012	0.838	rs60964317	chr2:74343423	A/T	cg19729930	chr2:74357872	NA	0.51	11.01	0.46	3.27e-25	Gestational age at birth (maternal effect);
LGG	cis	rs3857067	1.000	rs2219755	chr4:95015684	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	trans	rs1908814	0.516	rs13275143	chr8:11796990	T/A	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.19e-18	Neuroticism;
LGG	cis	rs1153858	0.943	rs4774580	chr15:45652086	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs9398803	0.651	rs4339479	chr6:126936953	G/A	cg19875578	chr6:126661172	C6orf173	0.51	9.54	0.41	7.89e-20	Male-pattern baldness;
LGG	cis	rs2717559	0.542	rs34147336	chr8:143884869	A/G	cg07661805	chr8:143867942	LY6D	-0.3	-8.11	-0.35	4.55e-15	Urinary tract infection frequency;
LGG	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.14	0.39	1.93e-18	Aortic root size;
LGG	cis	rs597539	0.616	rs10896386	chr11:68722694	C/T	cg21963583	chr11:68658836	MRPL21	0.57	9.96	0.42	2.59e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13217239	0.646	rs4583981	chr6:26992023	G/T	cg12292205	chr6:26970375	C6orf41	0.55	10.83	0.45	1.69e-24	Schizophrenia;
LGG	cis	rs295140	0.507	rs13019821	chr2:201106815	C/G	cg17644776	chr2:200775616	C2orf69	-0.49	-8.03	-0.35	8.38e-15	QT interval;
LGG	cis	rs7572733	0.840	rs12622674	chr2:198551812	G/A	cg00792783	chr2:198669748	PLCL1	-0.44	-7.51	-0.33	3e-13	Dermatomyositis;
LGG	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.04	-0.35	7.62e-15	Restless legs syndrome;
LGG	cis	rs7647973	0.696	rs7100	chr3:49053219	A/G	cg07636037	chr3:49044803	WDR6	0.9	16.61	0.61	6.22e-49	Menarche (age at onset);
LGG	cis	rs6088590	0.610	rs6120663	chr20:33081906	A/C	cg08999081	chr20:33150536	PIGU	-0.33	-7.99	-0.35	1.1e-14	Coronary artery disease;
LGG	cis	rs988958	0.565	rs6752667	chr2:42235445	G/A	cg27252766	chr2:42229092	NA	0.52	7.38	0.32	7.38e-13	Hypospadias;
LGG	cis	rs4891159	0.548	rs12454625	chr18:74128751	A/G	cg24786174	chr18:74118243	ZNF516	0.68	17.4	0.63	1.53e-52	Longevity;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg02725872	chr8:58115012	NA	-0.88	-11.94	-0.49	7.93e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs981844	0.775	rs17371468	chr4:154759826	G/C	cg14289246	chr4:154710475	SFRP2	0.68	11.09	0.46	1.62e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg14829360	chr17:73884958	NA	-0.7	-8.17	-0.35	3.04e-15	Psoriasis;
LGG	trans	rs2727020	0.576	rs12293522	chr11:49558425	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.37	-0.47	1.33e-26	Coronary artery disease;
LGG	trans	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg16141378	chr3:129829833	LOC729375	-0.37	-8.42	-0.36	4.66e-16	Neuroticism;
LGG	cis	rs4319547	0.619	rs10744208	chr12:122931559	C/A	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.23	-0.43	2.85e-22	Body mass index;
LGG	cis	rs55883249	1.000	rs76964971	chr2:9763904	C/A	cg23886495	chr2:9695866	ADAM17	0.66	9.49	0.4	1.19e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs7395662	0.624	rs11040162	chr11:48959991	C/T	cg15704280	chr7:45808275	SEPT13	0.48	7.89	0.34	2.2e-14	HDL cholesterol;
LGG	trans	rs2270927	0.510	rs246813	chr5:75599605	G/T	cg13563193	chr19:33072644	PDCD5	0.85	10.21	0.43	3.36e-22	Mean corpuscular volume;
LGG	cis	rs722599	0.683	rs17102847	chr14:75324780	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.56	-9.2	-0.39	1.26e-18	IgG glycosylation;
LGG	cis	rs72772090	0.539	rs11742261	chr5:96167608	C/T	cg00188032	chr5:96141721	ERAP1	0.55	7.2	0.32	2.45e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7582720	0.943	rs72934551	chr2:203984117	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.3	0.4	5.46e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg00814883	chr7:100076585	TSC22D4	-0.72	-10.3	-0.43	1.49e-22	Platelet count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14123153	chr12:6602654	NCAPD2;MRPL51	0.44	7.35	0.32	8.83e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs208515	0.525	rs10944868	chr6:66687508	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	17.17	0.62	1.79e-51	Exhaled nitric oxide levels;
LGG	cis	rs6704644	0.651	rs11675254	chr2:234364047	C/T	cg27060346	chr2:234359958	DGKD	-0.59	-7.3	-0.32	1.27e-12	Bilirubin levels;
LGG	cis	rs9487051	0.768	rs445796	chr6:109520145	T/C	cg21918786	chr6:109611834	NA	-0.38	-6.8	-0.3	3.2e-11	Reticulocyte fraction of red cells;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg02353165	chr6:42928485	GNMT	0.5	15.49	0.58	6.31e-44	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg15105011	chr4:940614	TMEM175	0.4	7.57	0.33	2.06e-13	Sjögren's syndrome;
LGG	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg18850127	chr7:39170497	POU6F2	0.55	12.34	0.5	1.93e-30	IgG glycosylation;
LGG	cis	rs2282300	0.739	rs35883696	chr11:30246407	A/C	cg25418670	chr11:30344373	C11orf46	-0.57	-7.95	-0.35	1.47e-14	Morning vs. evening chronotype;
LGG	cis	rs7512552	0.839	rs2647373	chr1:150320570	G/C	cg15654264	chr1:150340011	RPRD2	0.46	9.42	0.4	2.14e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7618501	0.601	rs2624825	chr3:50154989	G/A	cg24110177	chr3:50126178	RBM5	0.58	10.68	0.44	6.12e-24	Intelligence (multi-trait analysis);
LGG	cis	rs2334880	0.587	rs8058188	chr16:71675136	G/A	cg06353428	chr16:71660113	MARVELD3	0.72	12.15	0.49	1.12e-29	Malaria;
LGG	cis	rs3096299	0.809	rs3096325	chr16:89421678	A/G	cg06640241	chr16:89574553	SPG7	0.62	10.2	0.43	3.6e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs7582180	0.627	rs4407265	chr2:101005846	C/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.29	-0.6	1.72e-47	Intelligence (multi-trait analysis);
LGG	cis	rs6089829	0.851	rs6122346	chr20:61661822	C/G	cg18188782	chr20:61659543	NA	0.39	6.73	0.3	5.06e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg22632663	chr12:56615932	RNF41	-0.43	-6.81	-0.3	3.07e-11	Body fat percentage;
LGG	cis	rs4888262	0.526	rs6564142	chr16:74590047	T/C	cg01733217	chr16:74700730	RFWD3	0.82	16.38	0.61	6.42e-48	Testicular germ cell tumor;
LGG	cis	rs7582180	0.903	rs2309819	chr2:100899665	C/T	cg08297393	chr2:100937505	LONRF2	-0.52	-9.16	-0.39	1.66e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg07701084	chr6:150067640	NUP43	0.66	12.45	0.5	6.87e-31	Lung cancer;
LGG	trans	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg25214090	chr10:38739885	LOC399744	0.62	11.22	0.46	5.07e-26	Corneal astigmatism;
LGG	cis	rs12220238	1.000	rs10824102	chr10:75948915	C/A	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.11	0.46	1.44e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs208520	0.837	rs208509	chr6:66941706	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-15.22	-0.58	1.07e-42	Exhaled nitric oxide output;
LGG	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg22920501	chr2:26401640	FAM59B	0.45	9.35	0.4	3.76e-19	Gut microbiome composition (summer);
LGG	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.45	-0.33	4.76e-13	Testicular germ cell tumor;
LGG	cis	rs6088590	0.965	rs6087639	chr20:33443866	G/A	cg24642439	chr20:33292090	TP53INP2	0.83	14.65	0.56	3.34e-40	Coronary artery disease;
LGG	cis	rs988958	0.526	rs12712827	chr2:42244794	T/G	cg27252766	chr2:42229092	NA	0.47	6.75	0.3	4.4e-11	Hypospadias;
LGG	cis	rs3768617	0.510	rs6666259	chr1:183102855	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.51	0.4	1.04e-19	Fuchs's corneal dystrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25452632	chr12:56754141	STAT2	0.47	7.85	0.34	2.82e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg01620082	chr3:125678407	NA	-0.76	-7.62	-0.33	1.43e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs35306767	0.903	rs12240651	chr10:943656	A/G	cg26597838	chr10:835615	NA	0.75	10.32	0.43	1.31e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs2730245	0.510	rs2788471	chr7:158649786	G/T	cg24397884	chr7:158709396	WDR60	0.88	17.83	0.64	1.66e-54	Height;
LGG	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs35110281	0.659	rs11702544	chr21:45091861	C/T	cg04455712	chr21:45112962	RRP1B	0.53	10.09	0.42	8.68e-22	Mean corpuscular volume;
LGG	cis	rs9460578	0.537	rs9465904	chr6:20821662	A/G	cg13405222	chr6:20811065	CDKAL1	0.77	17.39	0.63	1.78e-52	Breast cancer;
LGG	cis	rs9311474	0.597	rs6778735	chr3:52565100	T/C	cg14092988	chr3:52407081	DNAH1	0.25	6.81	0.3	3.12e-11	Electroencephalogram traits;
LGG	cis	rs2692947	0.711	rs56791141	chr2:96587496	C/T	cg22654517	chr2:96458247	NA	0.38	8.14	0.35	3.76e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs11711311	0.955	rs12630791	chr3:113387717	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.41	7.09	0.31	5.08e-12	IgG glycosylation;
LGG	cis	rs4718428	0.705	rs2901311	chr7:66415069	T/C	cg12165864	chr7:66369176	NA	-0.58	-9.15	-0.39	1.88e-18	Corneal structure;
LGG	cis	rs2635047	0.656	rs1355594	chr18:44763994	T/G	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.85	-0.3	2.37e-11	Educational attainment;
LGG	trans	rs12517041	0.786	rs62342672	chr5:23246748	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.55	-7.75	-0.34	6.03e-14	Calcium levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17618194	chr7:100861352	ZNHIT1;PLOD3	0.41	6.87	0.3	2.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8114671	0.562	rs4911450	chr20:33512406	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.02	0.31	8.09e-12	Height;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-8.6	-0.37	1.28e-16	Menopause (age at onset);
LGG	trans	rs9914544	0.545	rs9912568	chr17:18792719	G/A	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs12210905	0.925	rs72838263	chr6:27008894	G/A	cg23155468	chr6:27110703	HIST1H2BK	-0.59	-7.68	-0.34	9.23e-14	Hip circumference adjusted for BMI;
LGG	cis	rs35110281	0.720	rs162375	chr21:44927015	C/T	cg01579765	chr21:45077557	HSF2BP	0.38	8.52	0.37	2.19e-16	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs4642101	1.000	rs7650482	chr3:12841804	A/G	cg05775895	chr3:12838266	CAND2	0.58	9.36	0.4	3.51e-19	QRS complex (12-leadsum);
LGG	cis	rs6860806	0.507	rs2631369	chr5:131705266	G/C	cg07395648	chr5:131743802	NA	0.48	9.88	0.42	5.3e-21	Breast cancer;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg08677398	chr8:58056175	NA	0.52	7.9	0.34	2.04e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg26578617	chr4:90757533	SNCA	-0.43	-8.69	-0.37	6.32e-17	Dementia with Lewy bodies;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23431730	chr12:53887070	MAP3K12	0.42	7.0	0.31	9.02e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs806215	0.950	rs3757793	chr7:127225780	G/A	cg25922125	chr7:127225783	GCC1	-0.79	-10.67	-0.44	6.53e-24	Type 2 diabetes;
LGG	cis	rs6831352	0.918	rs13143133	chr4:100054970	A/G	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg12458913	chr13:53173898	NA	-0.75	-15.61	-0.59	1.94e-44	Lewy body disease;
LGG	cis	rs6087990	0.806	rs4911254	chr20:31357579	C/A	cg13636640	chr20:31349939	DNMT3B	0.98	21.46	0.71	2.02e-71	Ulcerative colitis;
LGG	cis	rs6582630	0.615	rs10880642	chr12:38554152	A/G	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.19e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.3	-7.62	-0.33	1.43e-13	Total body bone mineral density;
LGG	cis	rs10752881	0.652	rs10911262	chr1:183114956	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.21	0.39	1.12e-18	Colorectal cancer;
LGG	cis	rs9611565	0.649	rs202645	chr22:41798520	A/G	cg06850241	chr22:41845214	NA	0.44	6.93	0.31	1.44e-11	Vitiligo;
LGG	cis	rs1153858	0.943	rs7402632	chr15:45701913	A/T	cg05280133	chr15:45670068	GATM;LOC145663	0.45	8.17	0.36	2.87e-15	Homoarginine levels;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg08677398	chr8:58056175	NA	-0.44	-6.9	-0.31	1.74e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05100916	chr7:112090586	IFRD1	0.47	7.05	0.31	6.62e-12	Gut microbiome composition (summer);
LGG	cis	rs3820928	1.000	rs1835158	chr2:227763993	C/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.36	-0.32	8.54e-13	Pulmonary function;
LGG	cis	rs651907	0.712	rs796410	chr3:101610189	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.47	8.87	0.38	1.54e-17	Colorectal cancer;
LGG	cis	rs1670533	0.818	rs585735	chr4:1080391	G/C	cg27284194	chr4:1044797	NA	0.54	9.79	0.41	1.04e-20	Recombination rate (females);
LGG	cis	rs876084	0.505	rs10108373	chr8:121126109	T/C	cg06265175	chr8:121136014	COL14A1	0.46	9.29	0.4	5.97e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs1032833	0.732	rs17363603	chr2:180088505	A/T	cg23654767	chr2:101192981	PDCL3	0.67	8.16	0.35	3.2e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	trans	rs4877691	1.000	rs11139535	chr9:84919492	A/G	cg06422693	chr4:48833587	OCIAD1	-0.43	-6.74	-0.3	4.65e-11	Airway imaging phenotypes;
LGG	cis	rs7814319	0.648	rs10955070	chr8:97312486	G/C	cg20787634	chr8:97240163	UQCRB	-0.63	-13.77	-0.54	2.18e-36	Lung function (FVC);
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03390569	chr2:54013802	LOC100302652;ASB3;ERLEC1	-0.5	-7.47	-0.33	3.89e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.607	rs3798763	chr6:150211100	T/C	cg13206674	chr6:150067644	NUP43	0.44	7.71	0.34	7.93e-14	Lung cancer;
LGG	cis	rs4785763	0.735	rs7189230	chr16:90056958	G/A	cg08547343	chr16:90038815	CENPBD1;AFG3L1	0.88	14.47	0.56	1.97e-39	Melanoma;
LGG	cis	rs2735413	0.564	rs11863846	chr16:78119557	C/G	cg04733911	chr16:78082701	NA	0.57	8.04	0.35	7.78e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs6061231	0.701	rs6061505	chr20:60960211	G/A	cg24112000	chr20:60950667	NA	-0.38	-8.89	-0.38	1.37e-17	Colorectal cancer;
LGG	cis	rs28374715	0.532	rs11070328	chr15:41651569	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.12e-133	Ulcerative colitis;
LGG	cis	rs735539	0.521	rs1348370	chr13:21404658	A/C	cg04906043	chr13:21280425	IL17D	-0.46	-7.32	-0.32	1.07e-12	Dental caries;
LGG	cis	rs977987	0.806	rs7199132	chr16:75450039	C/T	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs7582180	0.564	rs2309795	chr2:100954290	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	0.967	rs28792710	chr17:28450015	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.84	0.51	1.77e-32	Coffee consumption (cups per day);
LGG	cis	rs9322193	0.923	rs9505826	chr6:149955048	A/G	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs9644630	0.864	rs4339658	chr8:19347059	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.5	-11.75	-0.48	4.65e-28	Oropharynx cancer;
LGG	cis	rs2243480	0.808	rs11769505	chr7:65243255	A/T	cg13147721	chr7:65941812	NA	0.78	9.31	0.4	5.28e-19	Diabetic kidney disease;
LGG	cis	rs7481584	0.624	rs440130	chr11:3051476	A/G	cg25174290	chr11:3078921	CARS	-0.51	-9.27	-0.4	6.82e-19	Calcium levels;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	0.27	7.43	0.33	5.42e-13	IgG glycosylation;
LGG	cis	rs3096299	0.967	rs28644774	chr16:89472181	G/C	cg02187348	chr16:89574699	SPG7	0.45	7.28	0.32	1.4e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs2224391	0.628	rs2753244	chr6:5257610	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.34	-0.32	9.56e-13	Height;
LGG	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.75e-22	Motion sickness;
LGG	cis	rs6502050	0.805	rs11077970	chr17:80085916	C/T	cg07959490	chr17:80112427	CCDC57	0.47	9.25	0.4	8.05e-19	Life satisfaction;
LGG	trans	rs4942242	0.763	rs7327129	chr13:44233014	T/C	cg19169023	chr15:41853346	TYRO3	-0.46	-9.24	-0.39	9.07e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6456156	0.586	rs7746628	chr6:167483235	A/G	cg07741184	chr6:167504864	NA	0.41	9.38	0.4	3e-19	Primary biliary cholangitis;
LGG	cis	rs10504229	0.817	rs114173899	chr8:58170640	G/T	cg21724239	chr8:58056113	NA	0.45	6.93	0.31	1.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3008870	0.792	rs72673729	chr1:67441673	T/TG	cg02640540	chr1:67518911	SLC35D1	-0.4	-7.09	-0.31	5.18e-12	Lymphocyte percentage of white cells;
LGG	trans	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg05059571	chr16:84539110	KIAA1609	-0.57	-10.85	-0.45	1.42e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs7727544	0.548	rs4705938	chr5:131694077	A/G	cg24060327	chr5:131705240	SLC22A5	-0.42	-7.11	-0.31	4.53e-12	Blood metabolite levels;
LGG	cis	rs7824557	0.679	rs10110008	chr8:11133736	G/T	cg15596359	chr8:11213517	TDH	0.34	6.85	0.3	2.31e-11	Retinal vascular caliber;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg14073117	chr9:4792649	RCL1	-0.47	-7.23	-0.32	2.03e-12	Coronary artery disease;
LGG	cis	rs4132509	0.744	rs10927065	chr1:243914611	G/T	cg21452805	chr1:244014465	NA	0.94	10.63	0.44	9.42e-24	RR interval (heart rate);
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs897984	0.683	rs729482	chr16:31016970	T/C	cg02466173	chr16:30829666	NA	-0.43	-7.25	-0.32	1.8e-12	Dementia with Lewy bodies;
LGG	cis	rs3741151	0.686	rs17851510	chr11:73106294	A/C	cg17517138	chr11:73019481	ARHGEF17	0.83	8.71	0.38	5.38e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9472414	0.680	rs9463017	chr6:44710304	A/C	cg20913747	chr6:44695427	NA	-0.46	-7.01	-0.31	8.44e-12	Height;
LGG	trans	rs7762018	0.607	rs77004024	chr6:170063437	G/A	cg06875740	chr19:51307921	C19orf48	-0.65	-6.78	-0.3	3.72e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.97	0.49	5.85e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg00334542	chr7:100209784	MOSPD3	-0.61	-8.48	-0.37	3.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9443189	0.527	rs775059	chr6:76370130	G/T	cg01950844	chr6:76311363	SENP6	0.76	10.07	0.42	1.07e-21	Prostate cancer;
LGG	trans	rs58106596	0.950	rs11695646	chr2:232584807	C/T	cg01370599	chr3:116745421	NA	-0.54	-8.27	-0.36	1.41e-15	White blood cell count;Lymphocyte counts;
LGG	cis	rs1953600	0.837	rs2819946	chr10:81951635	G/A	cg04850286	chr10:81895943	PLAC9	0.44	9.68	0.41	2.56e-20	Sarcoidosis;
LGG	cis	rs7811142	1.000	rs73161759	chr7:100009994	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.1	16.94	0.62	1.98e-50	Platelet count;
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg11764359	chr7:65958608	NA	0.7	12.71	0.51	5.92e-32	Aortic root size;
LGG	cis	rs3862030	0.503	rs6584505	chr10:104254412	C/A	cg05096777	chr10:104283225	SUFU	0.32	6.88	0.3	1.92e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg18553732	chr11:67844184	CHKA	0.31	6.77	0.3	3.96e-11	Electrocardiographic conduction measures;
LGG	cis	rs340849	0.678	rs6696711	chr1:214104671	A/G	cg05052969	chr1:214156842	NA	0.37	6.78	0.3	3.6e-11	Alzheimer's disease;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg18279126	chr7:2041391	MAD1L1	-0.32	-6.66	-0.3	7.79e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11096990	0.964	rs9998591	chr4:39242111	C/A	cg24403649	chr4:39172243	NA	0.43	6.95	0.31	1.27e-11	Cognitive function;
LGG	cis	rs6840360	1.000	rs2303866	chr4:152640387	C/T	cg22705602	chr4:152727874	NA	-0.27	-6.73	-0.3	5.18e-11	Intelligence (multi-trait analysis);
LGG	trans	rs73191547	0.965	rs12548428	chr8:10030698	C/T	cg16141378	chr3:129829833	LOC729375	0.32	6.97	0.31	1.08e-11	Schizophrenia;
LGG	cis	rs2718058	0.513	rs7798434	chr7:37804722	C/T	cg15028436	chr7:37888078	TXNDC3	-0.41	-6.82	-0.3	2.9100000000000002e-11	Alzheimer's disease (late onset);
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg14338887	chr6:42928500	GNMT	0.29	9.42	0.4	2.12e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs116095464	0.558	rs7708515	chr5:234989	C/G	cg00938859	chr5:1591904	SDHAP3	0.83	12.88	0.51	1.12e-32	Breast cancer;
LGG	cis	rs10489202	1.000	rs17557135	chr1:167985888	A/G	cg24449463	chr1:168025552	DCAF6	-0.6	-9.93	-0.42	3.31e-21	Schizophrenia;
LGG	cis	rs10504229	0.683	rs66730544	chr8:58127280	A/T	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg12395012	chr8:11607386	GATA4	0.4	7.36	0.32	8.23e-13	Retinal vascular caliber;
LGG	cis	rs4319547	0.656	rs4997380	chr12:122838956	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.68	-10.29	-0.43	1.71e-22	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13852218	chr11:84431850	DLG2	0.45	7.55	0.33	2.38e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs36093844	0.752	rs34106192	chr11:85556099	T/C	cg16165120	chr11:85566439	CCDC83	-0.48	-7.88	-0.34	2.29e-14	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs12893668	0.703	rs2274267	chr14:104029449	G/A	cg26031613	chr14:104095156	KLC1	-0.59	-9.29	-0.4	5.92e-19	Reticulocyte count;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs3736594	0.513	rs60854669	chr2:27786929	T/C	cg27432699	chr2:27873401	GPN1	0.56	8.45	0.37	3.69e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs9322193	0.923	rs12195866	chr6:150014470	A/G	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.59e-12	Lung cancer;
LGG	cis	rs317689	0.819	rs317683	chr12:69713630	T/G	cg14784868	chr12:69753453	YEATS4	0.44	6.87	0.3	2.13e-11	Response to diuretic therapy;
LGG	cis	rs2012796	0.785	rs61986597	chr14:81853107	T/C	cg02996355	chr14:81879375	NA	0.58	9.5	0.4	1.13e-19	Night sleep phenotypes;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	17.48	0.63	6.81e-53	Tonsillectomy;
LGG	cis	rs3849570	0.696	rs13092157	chr3:81875332	T/A	cg07356753	chr3:81810745	GBE1	-0.48	-7.82	-0.34	3.7e-14	Waist circumference;Body mass index;
LGG	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg16586182	chr3:47516702	SCAP	-0.77	-14.98	-0.57	1.17e-41	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16650896	chr7:64838774	ZNF92	0.43	6.92	0.31	1.54e-11	Gut microbiome composition (summer);
LGG	trans	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	9.73	0.41	1.7e-20	Metabolite levels;
LGG	cis	rs6977660	0.714	rs6959039	chr7:19818182	T/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.5	0.37	2.63e-16	Thyroid stimulating hormone;
LGG	cis	rs910316	0.737	rs175071	chr14:75498177	A/G	cg11812906	chr14:75593930	NEK9	-0.46	-8.64	-0.37	9.16e-17	Height;
LGG	cis	rs9300255	0.830	rs28413626	chr12:123861452	G/A	cg00376283	chr12:123451042	ABCB9	-0.59	-9.11	-0.39	2.52e-18	Neutrophil percentage of white cells;
LGG	cis	rs734999	0.588	rs11585048	chr1:2534087	C/T	cg18854424	chr1:2615690	NA	0.35	7.17	0.32	2.91e-12	Ulcerative colitis;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg09359103	chr1:154839909	KCNN3	-0.52	-10.47	-0.44	3.48e-23	Prostate cancer;
LGG	cis	rs7811142	0.830	rs76798830	chr7:99952828	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.65	0.56	3.39e-40	Platelet count;
LGG	trans	rs12517041	0.938	rs12522251	chr5:23251734	G/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.6	-8.52	-0.37	2.22e-16	Calcium levels;
LGG	cis	rs11098499	0.908	rs28559989	chr4:120386627	C/T	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.24e-25	Corneal astigmatism;
LGG	trans	rs61931739	0.500	rs10844863	chr12:34532284	C/T	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs834603	0.575	rs834606	chr7:47450632	A/G	cg09696706	chr7:47479511	TNS3	0.35	7.88	0.34	2.34e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1059312	0.966	rs2291349	chr12:129284248	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.77	-16.85	-0.62	4.83e-50	Systemic lupus erythematosus;
LGG	trans	rs1814175	0.645	rs11040699	chr11:50023798	C/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.65	-0.33	1.18e-13	Neuroticism;
LGG	cis	rs1881797	1.000	rs12081895	chr1:247686666	C/G	cg05639522	chr1:247681581	NA	0.61	10.32	0.43	1.35e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs12677663	1.000	rs7018067	chr8:74013420	T/A	cg19518093	chr8:74006994	C8orf84	-0.5	-9.93	-0.42	3.35e-21	Crohn's disease;
LGG	cis	rs6089829	0.926	rs6011552	chr20:61667894	T/C	cg08045932	chr20:61659980	NA	0.58	12.36	0.5	1.55e-30	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1163251	0.837	rs658442	chr1:120244858	T/G	cg19096424	chr1:120255104	PHGDH	0.66	11.96	0.49	6.33e-29	Blood metabolite levels;
LGG	cis	rs2652834	0.861	rs4774472	chr15:63353760	C/A	cg05507819	chr15:63340323	TPM1	0.62	8.38	0.36	6.18e-16	HDL cholesterol;
LGG	cis	rs3850699	0.886	rs12773833	chr10:104418350	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.42	-6.99	-0.31	9.82e-12	Prostate cancer;
LGG	cis	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.764	rs1938120	chr6:66568919	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.92	-0.31	1.5e-11	Metabolite levels;
LGG	cis	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg21775007	chr8:11205619	TDH	0.62	10.18	0.43	4.21e-22	Retinal vascular caliber;
LGG	cis	rs7017914	1.000	rs7017914	chr8:71591203	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg03709012	chr19:19516395	GATAD2A	0.79	14.98	0.57	1.23e-41	Tonsillectomy;
LGG	trans	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg09048205	chr5:1608656	LOC728613	-0.52	-8.49	-0.37	2.91e-16	Breast cancer;
LGG	trans	rs116095464	0.558	rs10475136	chr5:232796	A/G	cg00938859	chr5:1591904	SDHAP3	0.91	13.39	0.53	8.39e-35	Breast cancer;
LGG	cis	rs6840360	0.550	rs4696269	chr4:152481704	T/A	cg25486957	chr4:152246857	NA	-0.51	-8.42	-0.36	4.71e-16	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs2389802	chr4:120325732	C/A	cg09307838	chr4:120376055	NA	0.81	13.57	0.53	1.44e-35	Corneal astigmatism;
LGG	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg07777115	chr5:623756	CEP72	-0.61	-7.69	-0.34	9.17e-14	Obesity-related traits;
LGG	cis	rs1847505	0.527	rs75961255	chr13:61471645	G/A	cg25164009	chr13:61490935	NA	0.61	9.97	0.42	2.53e-21	Polychlorinated biphenyl levels;
LGG	cis	rs74781061	0.929	rs11072494	chr15:74889163	C/T	cg02384859	chr15:74862662	ARID3B	-0.35	-7.26	-0.32	1.66e-12	Endometriosis;
LGG	cis	rs240764	0.817	rs239211	chr6:101144965	A/C	cg09795085	chr6:101329169	ASCC3	0.45	7.63	0.33	1.32e-13	Neuroticism;
LGG	cis	rs897984	0.806	rs9319588	chr16:30930983	C/T	cg00531865	chr16:30841666	NA	0.56	12.01	0.49	4e-29	Dementia with Lewy bodies;
LGG	trans	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg24247370	chr13:99142703	STK24	-0.43	-7.78	-0.34	4.83e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.517	rs9668303	chr12:34366701	C/T	cg26384229	chr12:38710491	ALG10B	0.95	20.59	0.69	2.34e-67	Morning vs. evening chronotype;
LGG	cis	rs787274	1.000	rs1418409	chr9:115573707	T/C	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg27432699	chr2:27873401	GPN1	-0.5	-8.53	-0.37	2.12e-16	Total body bone mineral density;
LGG	cis	rs9399135	0.660	rs4472368	chr6:135274232	A/G	cg22676075	chr6:135203613	NA	0.41	7.15	0.32	3.44e-12	Red blood cell count;
LGG	cis	rs632111	0.519	rs281380	chr19:49214470	A/G	cg13540341	chr19:49222985	MAMSTR	0.5	12.45	0.5	6.8e-31	Serum lipase activity;
LGG	cis	rs11098499	0.866	rs6857892	chr4:120282696	G/T	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01495344	chr13:39260543	FREM2	-0.47	-7.09	-0.31	5.05e-12	Systemic lupus erythematosus;
LGG	cis	rs6504108	0.624	rs8072282	chr17:46276858	A/G	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.64e-15	Body mass index;
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg19223190	chr17:80058835	NA	-0.45	-8.73	-0.38	4.65e-17	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs6502050	0.805	rs4789721	chr17:80157453	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs2236267	0.693	rs6574993	chr14:88606993	G/A	cg18078958	chr14:88630771	NA	-0.33	-7.7	-0.34	8.12e-14	Food antigen IgG levels;
LGG	cis	rs6725041	0.547	rs1505353	chr2:213203057	C/A	cg16329650	chr2:213403929	ERBB4	-0.38	-6.71	-0.3	5.85e-11	QT interval (ambient particulate matter interaction);
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1034435	0.755	rs5768681	chr22:48894501	C/T	cg05992904	chr22:48892994	FAM19A5	-0.81	-16.7	-0.61	2.37e-49	Late-onset Alzheimer's disease;
LGG	trans	rs9657904	1.000	rs9869648	chr3:105596568	T/C	cg14088669	chr1:158435396	OR10K1	0.38	6.67	0.3	7.44e-11	Multiple sclerosis;
LGG	cis	rs875971	0.964	rs778721	chr7:65845397	C/G	cg12463550	chr7:65579703	CRCP	0.52	8.69	0.37	6.31e-17	Aortic root size;
LGG	cis	rs7582180	0.591	rs1030902	chr2:101007178	T/G	cg21926883	chr2:100939477	LONRF2	-0.68	-16.03	-0.6	2.67e-46	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.673	rs12949860	chr17:29223032	A/G	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg06494592	chr3:125709126	NA	-0.52	-6.7	-0.3	5.91e-11	Blood pressure (smoking interaction);
LGG	cis	rs56161922	0.915	rs12563415	chr1:207856666	G/T	cg09557387	chr1:207818395	CR1L	0.94	9.47	0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs7538876	0.935	rs1408420	chr1:17754815	A/G	cg10329579	chr1:17754830	RCC2	0.59	11.13	0.46	1.16e-25	Basal cell carcinoma;
LGG	cis	rs11229555	0.645	rs35279927	chr11:58212129	G/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9916302	0.851	rs7220650	chr17:37487168	A/G	cg00129232	chr17:37814104	STARD3	0.6	11.46	0.47	5.95e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9322193	0.923	rs9377230	chr6:149934743	T/C	cg13206674	chr6:150067644	NUP43	0.66	15.21	0.58	1.11e-42	Lung cancer;
LGG	cis	rs7107174	1.000	rs2511190	chr11:77988310	T/C	cg27205649	chr11:78285834	NARS2	-0.48	-7.69	-0.34	9.17e-14	Testicular germ cell tumor;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.6	10.24	0.43	2.52e-22	Obesity-related traits;
LGG	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg16141378	chr3:129829833	LOC729375	0.36	7.83	0.34	3.26e-14	Retinal vascular caliber;
LGG	cis	rs34599045	0.803	rs34198967	chr1:152869541	T/C	cg07796016	chr1:152779584	LCE1C	-0.91	-9.13	-0.39	2.19e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg21427119	chr20:30132790	HM13	-0.42	-6.97	-0.31	1.09e-11	Mean corpuscular hemoglobin;
LGG	cis	rs7474896	0.583	rs1208770	chr10:38044683	C/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-7.91	-0.35	1.85e-14	Obesity (extreme);
LGG	cis	rs12580194	0.593	rs13377995	chr12:55757380	C/G	cg19537932	chr12:55886519	OR6C68	-0.55	-10.12	-0.43	7e-22	Cancer;
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs1723269	chr7:65472786	C/G	cg18252515	chr7:66147081	NA	-1.36	-18.96	-0.66	9.44e-60	Diabetic kidney disease;
LGG	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg08250081	chr4:10125330	NA	0.36	6.93	0.31	1.41e-11	Bone mineral density;
LGG	cis	rs2594989	0.943	rs2454500	chr3:11500103	C/T	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.71e-13	Circulating chemerin levels;
LGG	cis	rs4665809	1.000	rs4665823	chr2:26312723	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.44e-33	Gut microbiome composition (summer);
LGG	cis	rs735860	0.763	rs1346603	chr6:53149262	C/T	cg10236188	chr6:53219634	NA	0.38	7.51	0.33	2.99e-13	Glaucoma;
LGG	cis	rs17767392	0.595	rs6574007	chr14:71652763	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.04	-0.31	7.16e-12	Mitral valve prolapse;
LGG	cis	rs6740322	0.748	rs6732337	chr2:43462822	C/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	0.7	11.03	0.46	2.87e-25	Coronary artery disease;
LGG	cis	rs834603	0.575	rs834606	chr7:47450632	A/G	cg23694490	chr7:47445681	TNS3	-0.43	-12.76	-0.51	3.66e-32	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09109450	chr2:21022565	C2orf43	-0.44	-6.66	-0.3	7.98e-11	Pancreatic cancer;
LGG	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-9.45	-0.4	1.74e-19	Uric acid clearance;
LGG	cis	rs4356932	0.905	rs6532086	chr4:76937278	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.41	-6.91	-0.31	1.58e-11	Blood protein levels;
LGG	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg22676075	chr6:135203613	NA	0.37	6.83	0.3	2.66e-11	Red blood cell count;
LGG	cis	rs7119038	0.509	rs10892259	chr11:118583002	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.77	0.3	3.85e-11	Sjögren's syndrome;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.42	0.36	4.65e-16	Prudent dietary pattern;
LGG	trans	rs7395662	0.526	rs4882001	chr11:48546675	A/G	cg03929089	chr4:120376271	NA	-0.53	-9.06	-0.39	3.73e-18	HDL cholesterol;
LGG	cis	rs1707322	1.000	rs4660895	chr1:46329739	C/T	cg03146154	chr1:46216737	IPP	0.54	10.46	0.44	4.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs870825	0.616	rs72703531	chr4:185611092	C/T	cg04058563	chr4:185651563	MLF1IP	1.08	22.22	0.72	5.4e-75	Blood protein levels;
LGG	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg25358565	chr5:93447407	FAM172A	1.28	15.93	0.6	6.94e-46	Diabetic retinopathy;
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg06074448	chr4:187884817	NA	-0.59	-13.24	-0.52	3.52e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2836974	0.965	rs2836965	chr21:40633631	C/G	cg11644478	chr21:40555479	PSMG1	-0.91	-17.77	-0.64	3.04e-54	Cognitive function;
LGG	cis	rs12618769	0.597	rs3754883	chr2:99129451	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.47	0.37	3.33e-16	Bipolar disorder;
LGG	trans	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.1	-0.31	4.8e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs1493916	0.655	rs4534926	chr18:31349072	G/C	cg04226714	chr8:49833948	SNAI2	-0.51	-9.16	-0.39	1.67e-18	Life satisfaction;
LGG	cis	rs950169	0.580	rs17532346	chr15:85171495	A/C	cg03959625	chr15:84868606	LOC388152	0.48	7.17	0.32	2.92e-12	Schizophrenia;
LGG	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg12473912	chr3:136751656	NA	0.44	7.74	0.34	6.34e-14	Neuroticism;
LGG	cis	rs208515	0.525	rs4145045	chr6:66678949	T/C	cg07460842	chr6:66804631	NA	0.93	17.02	0.62	8.63e-51	Exhaled nitric oxide levels;
LGG	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg13010199	chr12:38710504	ALG10B	0.45	8.42	0.36	4.89e-16	Morning vs. evening chronotype;
LGG	cis	rs2274273	0.804	rs28428911	chr14:55843596	G/T	cg04306507	chr14:55594613	LGALS3	0.62	17.15	0.62	2.06e-51	Protein biomarker;
LGG	trans	rs1941687	0.797	rs8098328	chr18:31401732	A/G	cg27147174	chr7:100797783	AP1S1	0.47	7.33	0.32	1.02e-12	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg13010199	chr12:38710504	ALG10B	-0.44	-8.06	-0.35	6.34e-15	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.702	rs62056090	chr16:89930087	T/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.61	-0.37	1.19e-16	Skin colour saturation;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.36e-12	Lung cancer;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg11245990	chr11:68621969	NA	0.4	8.42	0.36	4.88e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs35306767	0.633	rs17221491	chr10:1065191	A/G	cg26597838	chr10:835615	NA	0.51	6.66	0.3	7.81e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs2153535	0.580	rs9328478	chr6:8519183	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.16	0.43	4.91e-22	Motion sickness;
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.1	-0.31	4.86e-12	Bipolar disorder;
LGG	cis	rs8064024	0.599	rs2456779	chr16:4925817	G/C	cg08329684	chr16:4932620	PPL	0.49	10.36	0.43	9.61e-23	Cancer;
LGG	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.55e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg14673194	chr17:80132900	CCDC57	0.47	8.53	0.37	2.14e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6920372	0.692	rs11153216	chr6:110070022	G/A	cg16315928	chr6:109776240	MICAL1	0.43	7.46	0.33	4.41e-13	Height;
LGG	cis	rs1003719	0.788	rs2835579	chr21:38457965	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg22907277	chr7:1156413	C7orf50	0.64	11.28	0.46	3.04e-26	Longevity;Endometriosis;
LGG	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26850624	chr5:429559	AHRR	-0.32	-6.7	-0.3	5.92e-11	Cystic fibrosis severity;
LGG	trans	rs7824557	0.767	rs4559208	chr8:11153925	C/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.25	0.43	2.35e-22	Retinal vascular caliber;
LGG	cis	rs7615952	0.576	rs1127717	chr3:125826059	T/C	cg04553112	chr3:125709451	NA	-0.53	-6.76	-0.3	4.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs17270561	0.636	rs77343532	chr6:25828828	G/A	cg16482183	chr6:26056742	HIST1H1C	0.58	9.2	0.39	1.23e-18	Iron status biomarkers;
LGG	trans	rs2727020	0.554	rs2866490	chr11:49425463	A/G	cg03929089	chr4:120376271	NA	-0.84	-12.91	-0.51	9.01e-33	Coronary artery disease;
LGG	cis	rs504918	0.588	rs73188199	chr3:124031871	G/A	cg05766129	chr3:123988013	KALRN	-0.57	-10.04	-0.42	1.42e-21	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg24368899	chr1:23191470	EPHB2	0.34	7.31	0.32	1.18e-12	Menarche (age at onset);
LGG	cis	rs3735485	0.800	rs1294966	chr7:45073799	G/T	cg03440944	chr7:45023329	C7orf40	-0.46	-7.43	-0.33	5.13e-13	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg07142201	chr11:109293216	C11orf87	0.51	9.36	0.4	3.33e-19	Schizophrenia;
LGG	cis	rs7267979	1.000	rs7343481	chr20:25300113	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg07677032	chr17:61819896	STRADA	0.67	12.48	0.5	5.37e-31	Prudent dietary pattern;
LGG	trans	rs826838	1.000	rs11183196	chr12:38685915	G/T	cg06521331	chr12:34319734	NA	-0.44	-7.65	-0.33	1.21e-13	Heart rate;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04761648	chr13:26829199	CDK8	0.41	6.68	0.3	6.85e-11	Cognitive performance;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.49	-0.37	2.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs919433	0.619	rs699318	chr2:198281743	T/C	cg00792783	chr2:198669748	PLCL1	0.51	7.97	0.35	1.24e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	8.58	0.37	1.42e-16	Bone mineral density;
LGG	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg03315344	chr16:75512273	CHST6	-0.57	-11.04	-0.46	2.67e-25	Dupuytren's disease;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg01341218	chr17:43662625	NA	0.67	12.09	0.49	2e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs597539	0.652	rs686390	chr11:68656077	T/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.77	0.59	3.78e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2011503	0.714	rs7250233	chr19:19630948	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg05313129	chr8:58192883	C8orf71	-0.82	-12.35	-0.5	1.73e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	0.967	rs826856	chr12:39115434	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.23	-0.7	2.33e-70	Heart rate;
LGG	cis	rs55871839	0.708	rs4738731	chr8:59809840	C/G	cg07426533	chr8:59803705	TOX	-0.57	-13.09	-0.52	1.62e-33	Pneumonia;
LGG	cis	rs3020736	0.500	rs8138678	chr22:42516229	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.22	-0.43	3.12e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1218582	0.774	rs11264284	chr1:154875793	C/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.23	-0.32	2e-12	Prostate cancer;
LGG	cis	rs6963495	0.719	rs73190174	chr7:105161216	T/G	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs7264396	0.790	rs2425160	chr20:34425968	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.54	7.81	0.34	3.8e-14	Total cholesterol levels;
LGG	cis	rs12824058	0.831	rs11060825	chr12:130807905	A/G	cg26677194	chr12:130822605	PIWIL1	0.56	9.89	0.42	4.63e-21	Menopause (age at onset);
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.59	-0.33	1.83e-13	Personality dimensions;
LGG	cis	rs9467773	0.967	rs1056347	chr6:26527524	G/C	cg11502198	chr6:26597334	ABT1	0.54	9.41	0.4	2.33e-19	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.659	rs4382480	chr8:8721473	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.8	-0.38	2.84e-17	Mood instability;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg07125947	chr14:91526463	RPS6KA5	-0.4	-6.67	-0.3	7.34e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg24829409	chr8:58192753	C8orf71	-0.76	-10.71	-0.45	4.55e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs6834538	0.597	rs10022515	chr4:113537710	G/A	cg05166686	chr4:113558556	LARP7;C4orf21	0.51	8.44	0.37	4.12e-16	Free thyroxine concentration;
LGG	cis	rs7216064	1.000	rs4318247	chr17:65882172	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs5751150	1	rs5751150	chr22:42153292	T/G	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Cannabis dependence symptom count;
LGG	cis	rs8063160	1.000	rs8063160	chr16:90054709	T/C	cg07984980	chr16:89898383	SPIRE2	0.72	6.99	0.31	9.95e-12	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LGG	trans	rs7173947	0.646	rs11634297	chr15:95267564	A/T	cg11220663	chr2:70994863	ADD2	-0.42	-7.18	-0.32	2.76e-12	Hematological and biochemical traits;
LGG	cis	rs9467711	0.591	rs72834617	chr6:25999175	G/A	cg21479132	chr6:26055353	NA	0.83	8.06	0.35	6.36e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9457247	1.000	rs389956	chr6:167407254	T/G	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg00800038	chr16:89945340	TCF25	-0.69	-8.1	-0.35	5.04e-15	Skin colour saturation;
LGG	cis	rs9863	0.861	rs7132655	chr12:124438973	G/C	cg13487667	chr12:124434373	CCDC92	-0.36	-7.29	-0.32	1.38e-12	White blood cell count;
LGG	cis	rs7617773	0.743	rs6804986	chr3:48363595	A/G	cg11946769	chr3:48343235	NME6	0.65	10.77	0.45	2.63e-24	Coronary artery disease;
LGG	cis	rs2549003	1.000	rs9282761	chr5:131822224	T/C	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.69e-22	Asthma (sex interaction);
LGG	cis	rs4689388	0.647	rs9997824	chr4:6283253	T/C	cg14416269	chr4:6271139	WFS1	0.44	7.38	0.32	7.63e-13	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg04362960	chr10:104952993	NT5C2	0.57	10.63	0.44	9.14e-24	Arsenic metabolism;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.84	0.42	7.34e-21	Prudent dietary pattern;
LGG	cis	rs2544527	1.000	rs2544527	chr2:15926168	A/G	cg26669897	chr2:15909070	NA	0.3	7.01	0.31	8.63e-12	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg24189917	chr7:1970923	MAD1L1	-0.61	-9.16	-0.39	1.7e-18	Bipolar disorder;
LGG	cis	rs6500395	1.000	rs2080508	chr16:48690665	G/C	cg16662043	chr16:48846231	NA	-0.36	-6.94	-0.31	1.33e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6871536	1.000	rs6872131	chr5:131973382	A/G	cg04303330	chr5:131992430	IL13	0.28	6.79	0.3	3.45e-11	Asthma (childhood onset);
LGG	cis	rs9326248	0.954	rs10790177	chr11:117048417	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	9.54	0.41	7.95e-20	Blood protein levels;
LGG	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs6964587	0.610	rs6942852	chr7:91437883	A/C	cg17063962	chr7:91808500	NA	0.4	7.36	0.32	8.69e-13	Breast cancer;
LGG	cis	rs8180040	0.603	rs9854790	chr3:47101306	T/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.35	-0.53	1.28e-34	Colorectal cancer;
LGG	cis	rs2576037	0.526	rs658756	chr18:44431832	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.3	-0.36	1.15e-15	Personality dimensions;
LGG	cis	rs7715806	0.500	rs17563974	chr5:75004175	G/A	cg19683494	chr5:74908142	NA	0.53	6.91	0.31	1.61e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7208859	0.673	rs73265612	chr17:29225983	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62400317	0.762	rs12202704	chr6:44819614	G/T	cg20913747	chr6:44695427	NA	-0.67	-11.31	-0.47	2.32e-26	Total body bone mineral density;
LGG	cis	rs12701220	0.655	rs10241018	chr7:1144774	G/C	cg26769984	chr7:1090371	C7orf50	0.42	7.52	0.33	2.83e-13	Bronchopulmonary dysplasia;
LGG	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg02398342	chr17:80708632	TBCD;FN3K	-0.46	-7.0	-0.31	9.23e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg27411982	chr8:10470053	RP1L1	-0.41	-6.9	-0.31	1.75e-11	Neuroticism;
LGG	cis	rs11628318	1.000	rs12892184	chr14:103040300	C/A	cg01864069	chr14:103024347	NA	-0.62	-10.05	-0.42	1.27e-21	Platelet count;
LGG	cis	rs12912251	0.948	rs34141940	chr15:38989657	G/A	cg01338139	chr15:38987640	C15orf53	-0.55	-8.83	-0.38	2.16e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg15017067	chr4:17643749	FAM184B	0.31	6.97	0.31	1.07e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg02811702	chr13:24901961	NA	0.39	7.21	0.32	2.24e-12	Obesity-related traits;
LGG	cis	rs7044106	0.762	rs1867254	chr9:123429078	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	11.94	0.49	7.72e-29	Hip circumference adjusted for BMI;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.07	-0.35	6.21e-15	IgG glycosylation;
LGG	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	-0.47	-8.39	-0.36	6.07e-16	Menarche (age at onset);
LGG	cis	rs7937612	0.931	rs12417581	chr11:120216906	T/A	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.76	-0.51	3.53e-32	Intraocular pressure;
LGG	cis	rs7481584	0.624	rs1077335	chr11:3030524	A/G	cg08508325	chr11:3079039	CARS	0.41	7.84	0.34	3.17e-14	Calcium levels;
LGG	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg06611532	chr13:114900021	NA	0.29	7.35	0.32	9.24e-13	Schizophrenia;
LGG	cis	rs7737355	0.947	rs6879005	chr5:130615445	C/T	cg06307176	chr5:131281290	NA	0.51	8.63	0.37	1.03e-16	Life satisfaction;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg00106254	chr7:1943704	MAD1L1	-0.38	-6.72	-0.3	5.38e-11	Schizophrenia;
LGG	trans	rs7939886	0.688	rs11227290	chr11:55896577	A/G	cg03929089	chr4:120376271	NA	0.79	8.15	0.35	3.38e-15	Myopia (pathological);
LGG	cis	rs597539	0.552	rs10792006	chr11:68722306	T/C	cg21963583	chr11:68658836	MRPL21	-0.4	-7.4	-0.33	6.4e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12893668	0.603	rs61637848	chr14:104096031	C/T	cg23335576	chr14:104009727	NA	0.43	7.23	0.32	1.98e-12	Reticulocyte count;
LGG	cis	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg24623649	chr8:11872141	NA	-0.29	-6.87	-0.3	2.1e-11	Triglycerides;
LGG	cis	rs17030434	0.813	rs11732480	chr4:154665733	C/A	cg14289246	chr4:154710475	SFRP2	-0.72	-11.3	-0.46	2.65e-26	Electrocardiographic conduction measures;
LGG	cis	rs9303280	0.743	rs12946510	chr17:37912377	C/T	cg19468946	chr17:37922297	IKZF3	-0.46	-8.38	-0.36	6.17e-16	Self-reported allergy;
LGG	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg23601095	chr6:26197514	HIST1H3D	0.73	9.39	0.4	2.67e-19	Gout;Renal underexcretion gout;
LGG	cis	rs4780401	0.933	rs4780396	chr16:11816671	G/A	cg01061890	chr16:11836724	TXNDC11	-0.41	-7.0	-0.31	8.82e-12	Rheumatoid arthritis;
LGG	cis	rs7107174	0.688	rs869202	chr11:78127914	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.57	-0.33	2.07e-13	Testicular germ cell tumor;
LGG	cis	rs4262150	0.883	rs4437425	chr5:152238341	G/A	cg12297329	chr5:152029980	NA	-0.65	-12.33	-0.5	2.12e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs734999	0.545	rs12730932	chr1:2559589	T/G	cg15627072	chr1:2432621	PLCH2	-0.36	-8.15	-0.35	3.37e-15	Ulcerative colitis;
LGG	cis	rs11158026	0.757	rs8013521	chr14:55413725	G/C	cg04306507	chr14:55594613	LGALS3	0.3	6.69	0.3	6.58e-11	Parkinson's disease;
LGG	trans	rs2727020	0.636	rs11040368	chr11:49453602	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.46	-0.71	1.9e-71	Coronary artery disease;
LGG	cis	rs12477438	0.520	rs2516827	chr2:99772565	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	33.32	0.84	4.9e-125	Chronic sinus infection;
LGG	cis	rs11587400	0.679	rs6537834	chr1:115108870	T/C	cg12756093	chr1:115239321	AMPD1	0.38	6.68	0.3	7.02e-11	Autism;
LGG	cis	rs6088580	0.634	rs6088484	chr20:32985961	T/C	cg08999081	chr20:33150536	PIGU	-0.41	-10.24	-0.43	2.54e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs174601	0.833	rs174541	chr11:61565908	T/C	cg19610905	chr11:61596333	FADS2	-0.77	-14.19	-0.55	3.18e-38	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs9522267	0.535	rs9515452	chr13:112234553	A/G	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs10504229	0.593	rs76922080	chr8:57985837	C/G	cg08677398	chr8:58056175	NA	0.48	7.05	0.31	6.44e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9811920	0.809	rs793437	chr3:99559854	C/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.74	-0.38	4.42e-17	Axial length;
LGG	cis	rs4474465	0.920	rs10899529	chr11:78207848	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.84	-0.3	2.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9902453	1.000	rs4239227	chr17:28389103	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs62244186	0.748	rs2888410	chr3:44655476	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.4	6.79	0.3	3.48e-11	Depressive symptoms;
LGG	cis	rs3806843	0.868	rs2531349	chr5:140120953	G/A	cg19875535	chr5:140030758	IK	-0.54	-11.07	-0.46	1.98e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.53	8.98	0.39	6.61e-18	Cognitive test performance;
LGG	cis	rs4804815	0.784	rs2098701	chr19:7840140	G/A	cg09310891	chr19:7854403	CLEC4GP1	0.52	8.13	0.35	3.94e-15	Neutrophil count;
LGG	cis	rs12681287	0.640	rs61106663	chr8:87477081	G/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10098010	chr6:138483709	KIAA1244	0.44	7.75	0.34	5.77e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg20887711	chr4:1340912	KIAA1530	0.52	9.6	0.41	5.22e-20	Obesity-related traits;
LGG	cis	rs877282	1.000	rs11253361	chr10:770387	T/C	cg17470449	chr10:769945	NA	0.62	7.69	0.34	8.69e-14	Uric acid levels;
LGG	cis	rs9534288	0.830	rs3783202	chr13:46631869	G/A	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs9354308	0.764	rs9351537	chr6:66605161	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs7618915	0.524	rs12488461	chr3:52698417	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.15	0.35	3.32e-15	Bipolar disorder;
LGG	cis	rs694739	0.726	rs516124	chr11:64128423	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.79	15.41	0.58	1.5e-43	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg14228332	chr4:119757509	SEC24D	0.98	9.78	0.41	1.21e-20	Cannabis dependence symptom count;
LGG	cis	rs975722	0.638	rs213968	chr7:117229993	C/T	cg10524701	chr7:117356490	CTTNBP2	0.47	10.44	0.44	4.61e-23	Coronary artery disease;
LGG	cis	rs8067545	0.611	rs8078716	chr17:20044291	G/A	cg09818912	chr17:20140352	CYTSB	-0.32	-7.64	-0.33	1.26e-13	Schizophrenia;
LGG	trans	rs7944735	0.508	rs11819955	chr11:47539208	A/G	cg15704280	chr7:45808275	SEPT13	0.6	6.68	0.3	6.99e-11	Intraocular pressure;
LGG	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg18876405	chr7:65276391	NA	0.66	12.52	0.5	3.48e-31	Aortic root size;
LGG	cis	rs7084402	1.000	rs1427204	chr10:60267640	A/C	cg07615347	chr10:60278583	BICC1	-0.63	-17.74	-0.64	4.16e-54	Refractive error;
LGG	cis	rs12701220	0.894	rs12539012	chr7:1052133	G/A	cg00990874	chr7:1149470	C7orf50	-0.71	-11.14	-0.46	1.02e-25	Bronchopulmonary dysplasia;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg23985595	chr17:80112537	CCDC57	0.47	9.34	0.4	3.91e-19	Life satisfaction;
LGG	cis	rs875971	0.789	rs28815324	chr7:65565776	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.26	-0.43	2.07e-22	Aortic root size;
LGG	cis	rs8067545	0.611	rs2703807	chr17:20109189	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.08	-0.42	9.86e-22	Schizophrenia;
LGG	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg21862992	chr11:68658383	NA	0.5	8.35	0.36	7.85e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8067545	0.611	rs12942568	chr17:20117893	G/T	cg13482628	chr17:19912719	NA	-0.53	-10.14	-0.43	6.1e-22	Schizophrenia;
LGG	cis	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg06521331	chr12:34319734	NA	-0.38	-6.68	-0.3	6.89e-11	Morning vs. evening chronotype;
LGG	cis	rs709400	1.000	rs56660916	chr14:104126137	G/T	cg24130564	chr14:104152367	KLC1	-0.44	-8.54	-0.37	2.02e-16	Body mass index;
LGG	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg09998033	chr7:158218633	PTPRN2	-0.4	-7.16	-0.32	3.23e-12	Obesity-related traits;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.14	0.31	3.72e-12	Renal function-related traits (BUN);
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.26e-15	Life satisfaction;
LGG	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg14088196	chr11:70211408	PPFIA1	0.96	12.98	0.52	4.71e-33	Coronary artery disease;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg09033563	chr22:24373618	LOC391322	0.61	10.35	0.43	9.69e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7639513	0.767	rs13060705	chr3:12710016	C/A	cg23032965	chr3:12705835	RAF1	0.85	16.72	0.61	2.04e-49	Itch intensity from mosquito bite;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.22	0.32	2.19e-12	Schizophrenia;
LGG	cis	rs9896933	0.561	rs2264375	chr17:80692709	T/A	cg15664640	chr17:80829946	TBCD	-0.64	-8.99	-0.39	6.53e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs72945132	0.882	rs6592552	chr11:70223831	A/T	cg13802316	chr11:70253460	CTTN	-0.56	-7.31	-0.32	1.21e-12	Coronary artery disease;
LGG	cis	rs864537	0.676	rs3108155	chr1:167422057	C/G	cg09179987	chr1:167433047	CD247	0.43	9.47	0.4	1.49e-19	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs10504229	0.679	rs16921687	chr8:58053514	T/C	cg08677398	chr8:58056175	NA	0.47	7.26	0.32	1.64e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs66573146	0.656	rs56094305	chr4:6956086	C/T	cg00086871	chr4:6988644	TBC1D14	0.84	8.33	0.36	9.23e-16	Granulocyte percentage of myeloid white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02809263	chr1:70671218	LRRC40;SFRS11	0.45	7.32	0.32	1.13e-12	Gut microbiome composition (summer);
LGG	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.59	-0.44	1.35e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.867	rs12930606	chr16:89946682	A/G	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs6795744	0.519	rs59562904	chr3:13918234	C/G	cg19554555	chr3:13937349	NA	0.52	6.93	0.31	1.42e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg20368463	chr18:77673604	PQLC1	-0.66	-13.6	-0.53	1.16e-35	Schizophrenia;
LGG	cis	rs1008375	0.932	rs6449321	chr4:17644472	A/G	cg02297831	chr4:17616191	MED28	0.51	9.3	0.4	5.6e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg10621924	chr7:39171070	POU6F2	0.44	8.55	0.37	1.77e-16	IgG glycosylation;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	20.34	0.69	3.57e-66	Platelet count;
LGG	cis	rs7264396	0.790	rs2425125	chr20:34330954	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	0.43	7.66	0.34	1.1e-13	Total cholesterol levels;
LGG	cis	rs1595825	0.838	rs57437055	chr2:198782617	A/C	cg00982548	chr2:198649783	BOLL	-0.52	-7.11	-0.31	4.53e-12	Ulcerative colitis;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs977987	0.872	rs10781976	chr16:75314838	G/T	cg03315344	chr16:75512273	CHST6	0.51	10.36	0.43	9.34e-23	Dupuytren's disease;
LGG	trans	rs2727020	0.704	rs4144700	chr11:49370834	C/A	cg03929089	chr4:120376271	NA	-0.9	-18.23	-0.65	2.28e-56	Coronary artery disease;
LGG	cis	rs4740619	0.774	rs7868779	chr9:15709795	A/G	cg14451791	chr9:16040625	NA	-0.37	-9.26	-0.4	7.94e-19	Body mass index;
LGG	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg21775007	chr8:11205619	TDH	-0.77	-13.31	-0.53	1.87e-34	Retinal vascular caliber;
LGG	cis	rs787274	1.000	rs786961	chr9:115471346	T/C	cg13803584	chr9:115635662	SNX30	0.54	6.77	0.3	3.88e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9399135	0.935	rs6908681	chr6:135337733	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.46	0.4	1.62e-19	Red blood cell count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08190044	chr1:154298335	ATP8B2	0.5	7.45	0.33	4.48e-13	Gut microbiome composition (summer);
LGG	trans	rs9409565	0.826	rs4612412	chr9:97208627	C/G	cg05679027	chr9:99775184	HIATL2	-0.49	-8.15	-0.35	3.39e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs17445240	1.000	rs80212323	chr2:3703959	C/T	cg17046650	chr2:3699563	NA	0.99	11.22	0.46	5.33e-26	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs12540874	0.931	rs9791817	chr7:50661187	C/G	cg00647317	chr7:50633725	DDC	0.41	10.32	0.43	1.28e-22	Systemic sclerosis;
LGG	trans	rs7819412	0.511	rs7464263	chr8:11434176	A/T	cg13009111	chr11:71350975	NA	-0.32	-6.95	-0.31	1.28e-11	Triglycerides;
LGG	cis	rs12135062	0.901	rs2651928	chr1:3101722	C/T	cg21609526	chr1:3105151	PRDM16	-0.64	-11.38	-0.47	1.24e-26	Migraine;
LGG	cis	rs6430585	0.702	rs3213890	chr2:136552188	G/A	cg07169764	chr2:136633963	MCM6	1.28	24.29	0.75	1.19e-84	Corneal structure;
LGG	cis	rs12477438	0.501	rs769105	chr2:100077966	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.43	-6.75	-0.3	4.44e-11	Chronic sinus infection;
LGG	cis	rs514406	0.698	rs567880	chr1:53348564	T/G	cg25767906	chr1:53392781	SCP2	-0.4	-8.1	-0.35	4.96e-15	Monocyte count;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.77	-0.38	3.35e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs528418	0.592	rs4538734	chr6:145670357	C/T	cg03642472	chr6:145670687	NA	0.55	7.13	0.31	3.8e-12	Methadone dose in opioid dependence;
LGG	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.16e-17	Aortic root size;
LGG	cis	rs2072732	0.861	rs67919793	chr1:2954230	T/C	cg08733933	chr1:2954429	NA	-0.4	-8.48	-0.37	2.99e-16	Plateletcrit;
LGG	cis	rs77372450	0.636	rs11949232	chr5:157011001	A/T	cg25387487	chr5:157003181	ADAM19	-0.58	-7.23	-0.32	2.05e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.24	-0.32	1.85e-12	Menopause (age at onset);
LGG	cis	rs8014204	0.836	rs11159099	chr14:75235397	A/G	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.25	-0.32	1.79e-12	Caffeine consumption;
LGG	cis	rs6988636	1.000	rs59601467	chr8:124193488	C/T	cg23067535	chr8:124195133	FAM83A	-0.57	-6.94	-0.31	1.35e-11	Urinary uromodulin levels;
LGG	cis	rs763121	0.706	rs3827356	chr22:39064806	G/T	cg06022373	chr22:39101656	GTPBP1	-0.82	-16.32	-0.6	1.24e-47	Menopause (age at onset);
LGG	trans	rs9951602	0.512	rs9952372	chr18:76656295	A/G	cg02800362	chr5:177631904	HNRNPAB	0.78	13.65	0.54	6.52e-36	Obesity-related traits;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg08888203	chr3:10149979	C3orf24	0.44	7.93	0.35	1.68e-14	Alzheimer's disease;
LGG	cis	rs6456156	0.586	rs9457261	chr6:167467679	A/G	cg07741184	chr6:167504864	NA	0.39	8.99	0.39	6.14e-18	Primary biliary cholangitis;
LGG	cis	rs8180040	0.768	rs11915074	chr3:47309757	A/T	cg16586182	chr3:47516702	SCAP	0.75	13.5	0.53	3.02e-35	Colorectal cancer;
LGG	cis	rs7524258	0.901	rs11120884	chr1:7305361	C/A	cg07173049	chr1:7289937	CAMTA1	0.71	16.69	0.61	2.56e-49	Tourette's syndrome or obsessive-compulsive disorder;
LGG	trans	rs17807624	0.964	rs13249843	chr8:11459018	G/T	cg06636001	chr8:8085503	FLJ10661	0.49	8.31	0.36	1.04e-15	Systemic lupus erythematosus;
LGG	cis	rs62034325	0.697	rs710410	chr16:28603342	A/G	cg16576597	chr16:28551801	NUPR1	0.44	9.95	0.42	2.79e-21	Body mass index;
LGG	trans	rs1945213	0.694	rs10895985	chr11:55831595	T/C	cg15704280	chr7:45808275	SEPT13	0.88	12.46	0.5	6.14e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg13699009	chr12:122356056	WDR66	-0.43	-10.3	-0.43	1.56e-22	Mean corpuscular volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.1.2890615F	chr1:150313655	PRPF3	0.41	6.82	0.3	2.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs68170813	0.641	rs74524528	chr7:107090979	G/A	cg02696742	chr7:106810147	HBP1	-0.73	-9.86	-0.42	5.98e-21	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs78000724	chr22:32479736	G/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9859260	1.000	rs11718657	chr3:195797553	C/A	cg12923728	chr3:195709715	SDHAP1	-0.39	-6.92	-0.31	1.53e-11	Mean corpuscular volume;
LGG	cis	rs2115630	0.645	rs4842978	chr15:85197253	T/C	cg24253500	chr15:84953950	NA	-0.42	-7.67	-0.34	1.03e-13	P wave terminal force;
LGG	cis	rs597539	0.518	rs35093305	chr11:68730729	A/G	cg21963583	chr11:68658836	MRPL21	0.58	10.08	0.42	9.72e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs273218	0.568	rs1644814	chr5:53365452	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.41	6.92	0.31	1.55e-11	Migraine;
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg19635926	chr16:89946313	TCF25	0.72	7.09	0.31	5.12e-12	Skin colour saturation;
LGG	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs796364	0.865	rs769948	chr2:200728475	C/A	cg17644776	chr2:200775616	C2orf69	0.59	7.38	0.32	7.4e-13	Schizophrenia;
LGG	cis	rs5758511	0.541	rs6002494	chr22:42199860	C/G	cg15128208	chr22:42549153	NA	-0.42	-7.28	-0.32	1.48e-12	Birth weight;
LGG	cis	rs1799949	0.587	rs1824890	chr17:41421904	T/C	cg01879757	chr17:41196368	BRCA1	-0.44	-7.76	-0.34	5.64e-14	Menopause (age at onset);
LGG	cis	rs7000551	0.715	rs2443502	chr8:22340499	G/A	cg12081754	chr8:22256438	SLC39A14	0.7	13.48	0.53	3.77e-35	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs765787	0.530	rs28756676	chr15:45540360	G/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs6835098	0.923	rs7671278	chr4:174095769	A/G	cg08422745	chr4:174089978	GALNT7	-0.84	-14.7	-0.56	2.11e-40	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs72925845	0.577	rs618329	chr17:76429550	T/C	cg03830375	chr17:76426088	DNAH17	0.53	7.52	0.33	2.89e-13	Triglycerides;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg05335186	chr13:53173507	NA	0.44	9.03	0.39	4.68e-18	Lewy body disease;
LGG	cis	rs4481887	0.962	rs10788768	chr1:248456027	G/A	cg13385794	chr1:248469461	NA	0.49	8.25	0.36	1.6e-15	Common traits (Other);
LGG	trans	rs853679	0.546	rs34676049	chr6:28453618	T/G	cg08344181	chr3:125677491	NA	-0.93	-9.09	-0.39	2.97e-18	Depression;
LGG	cis	rs12310956	0.532	rs11052935	chr12:33970946	C/T	cg06521331	chr12:34319734	NA	-0.61	-11.21	-0.46	5.54e-26	Morning vs. evening chronotype;
LGG	cis	rs9815354	0.812	rs73073352	chr3:41842184	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg12310025	chr6:25882481	NA	-0.44	-7.28	-0.32	1.48e-12	Iron status biomarkers;
LGG	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg00012203	chr2:219082015	ARPC2	-0.48	-8.4	-0.36	5.37e-16	Ulcerative colitis;
LGG	cis	rs2073300	0.609	rs6137920	chr20:23363436	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs7395662	0.591	rs10838972	chr11:48611400	A/G	cg00717180	chr2:96193071	NA	-0.46	-8.39	-0.36	5.96e-16	HDL cholesterol;
LGG	trans	rs9650657	0.538	rs6984496	chr8:10796093	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.95	-0.35	1.41e-14	Neuroticism;
LGG	cis	rs2739330	0.761	rs5760176	chr22:24402321	A/G	cg15242686	chr22:24348715	GSTTP1	-0.56	-10.67	-0.44	6.43e-24	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11168187	0.891	rs3764015	chr12:48121301	G/A	cg12761788	chr12:48120090	P11	0.5	8.76	0.38	3.74e-17	Vertical cup-disc ratio;
LGG	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg08994789	chr17:28903642	LRRC37B2	0.72	9.26	0.4	7.53e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs3780486	0.846	rs10813950	chr9:33127640	A/G	cg04842962	chr6:43655489	MRPS18A	-1.13	-24.05	-0.75	1.65e-83	IgG glycosylation;
LGG	cis	rs4742903	0.967	rs7871759	chr9:106865438	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.61e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08265265	chr19:2740053	SLC39A3	0.46	7.21	0.32	2.23e-12	Gut microbiome composition (summer);
LGG	cis	rs11583043	0.708	rs11590358	chr1:101560214	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.53	8.31	0.36	1.1e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg05163923	chr11:71159392	DHCR7	0.73	14.42	0.56	3.53e-39	Vitamin D levels;
LGG	cis	rs7552404	1.000	rs7548962	chr1:76139266	G/A	cg03433033	chr1:76189801	ACADM	0.81	14.3	0.55	1.09e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg03929089	chr4:120376271	NA	0.86	17.23	0.63	8.79e-52	Coronary artery disease;
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg14675211	chr2:100938903	LONRF2	0.69	12.41	0.5	1.03e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7917772	0.512	rs11594073	chr10:104308193	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.63	-0.48	1.27e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7847628	0.666	rs2031974	chr9:123527521	T/C	cg09833538	chr9:123605306	PSMD5;LOC253039	0.5	7.19	0.32	2.65e-12	Birth weight;
LGG	cis	rs6714710	0.603	rs13008968	chr2:98435982	C/T	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs8056893	0.632	rs2863980	chr16:68301985	A/C	cg07273125	chr16:68295692	NA	0.41	8.58	0.37	1.45e-16	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs11112613	0.713	rs4015312	chr12:105948757	A/G	cg03607813	chr12:105948248	NA	0.6	10.13	0.43	6.3e-22	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs868036	0.718	rs28463100	chr15:68078769	T/C	cg05925327	chr15:68127851	NA	-0.37	-7.64	-0.33	1.27e-13	Restless legs syndrome;
LGG	cis	rs8060686	0.641	rs55725810	chr16:68189636	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs875971	0.825	rs7384021	chr7:66077904	A/G	cg18252515	chr7:66147081	NA	0.44	7.35	0.32	9.03e-13	Aortic root size;
LGG	cis	rs990171	0.874	rs6419573	chr2:103027103	T/C	cg05295703	chr2:102895712	NA	-0.54	-9.38	-0.4	2.97e-19	Lymphocyte counts;
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg00166722	chr3:10149974	C3orf24	0.5	7.93	0.35	1.65e-14	Alzheimer's disease;
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.72	0.38	5.09e-17	Neuroticism;
LGG	cis	rs2290402	1.000	rs2290402	chr4:941518	C/T	cg00846425	chr4:957561	DGKQ	-0.44	-6.68	-0.3	6.67e-11	Type 2 diabetes;
LGG	cis	rs8031584	0.651	rs28664821	chr15:31172323	G/A	cg14298792	chr15:30685198	CHRFAM7A	0.5	7.66	0.34	1.11e-13	Huntington's disease progression;
LGG	cis	rs9443645	0.527	rs1413969	chr6:79790982	A/G	cg18132916	chr6:79620363	NA	-0.26	-6.72	-0.3	5.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13191362	1.000	rs34773528	chr6:163088796	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.93	0.42	3.48e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6967414	0.786	rs7782227	chr7:6748594	T/C	cg00387323	chr7:6746715	ZNF12	0.64	6.97	0.31	1.13e-11	Hematocrit;Hemoglobin concentration;
LGG	trans	rs8002861	0.967	rs2166301	chr13:44473955	A/T	cg12856521	chr11:46389249	DGKZ	0.44	7.64	0.33	1.28e-13	Leprosy;
LGG	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg09021430	chr5:549028	NA	0.69	9.72	0.41	1.91e-20	Obesity-related traits;
LGG	cis	rs1465370	0.682	rs62471720	chr7:130016359	C/G	cg25718383	chr7:130020096	CPA1	0.32	8.26	0.36	1.5e-15	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg16270222	chr17:41446396	NA	-0.3	-7.24	-0.32	1.88e-12	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs3857067	0.934	rs1509941	chr4:95018784	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.44	-0.33	4.91e-13	QT interval;
LGG	cis	rs10752881	1.000	rs10797811	chr1:182984432	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.892	rs9379806	chr6:25940958	G/A	cg12310025	chr6:25882481	NA	-0.42	-7.45	-0.33	4.74e-13	Height;
LGG	cis	rs4742903	1.000	rs4742905	chr9:106856972	G/C	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs7833790	0.926	rs72686467	chr8:82758929	T/G	cg17211192	chr8:82754475	SNX16	0.78	12.07	0.49	2.27e-29	Diastolic blood pressure;
LGG	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs6787172	0.592	rs10936129	chr3:158056231	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.39	-0.32	6.99e-13	Subjective well-being;
LGG	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg16414030	chr3:133502952	NA	-0.48	-7.85	-0.34	2.83e-14	Iron status biomarkers;
LGG	cis	rs2842992	0.709	rs1853257	chr6:160212710	C/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	13.87	0.54	7.75e-37	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15068522	chr6:57086371	RAB23	0.4	6.66	0.3	7.89e-11	Cognitive performance;
LGG	trans	rs6601327	0.665	rs4841218	chr8:9653902	T/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.9	-0.31	1.71e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9381040	0.599	rs2057001	chr6:41022947	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.87	-0.3	2.11e-11	Alzheimer's disease (late onset);
LGG	cis	rs368123	0.961	rs581031	chr6:160718770	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	trans	rs9467711	0.606	rs9379875	chr6:26444732	C/T	cg06606381	chr12:133084897	FBRSL1	-0.87	-8.87	-0.38	1.58e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7904368	0.951	rs7905776	chr10:16853609	C/T	cg23933602	chr10:16859644	RSU1	0.66	10.05	0.42	1.28e-21	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.965	rs10831425	chr11:95500628	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.79	0.34	4.42e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg24687543	chr11:63912206	MACROD1	0.59	8.14	0.35	3.72e-15	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg04000281	chr11:63949212	NA	-0.37	-7.37	-0.32	7.93e-13	Platelet count;
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg26353844	chr1:95133907	NA	0.58	6.93	0.31	1.46e-11	Airflow obstruction;
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg06850241	chr22:41845214	NA	-0.45	-6.91	-0.31	1.59e-11	Vitiligo;
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.4e-16	Aortic root size;
LGG	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs60843830	1.000	rs17714252	chr2:285471	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.1	0.35	4.92e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11214589	0.747	rs10891537	chr11:113211370	A/C	cg14159747	chr11:113255604	NA	0.28	7.48	0.33	3.75e-13	Neuroticism;
LGG	cis	rs5769765	0.837	rs8142737	chr22:50291889	T/C	cg02269571	chr22:50332266	NA	-0.63	-10.18	-0.43	4.24e-22	Schizophrenia;
LGG	cis	rs4363385	0.747	rs9659623	chr1:152965158	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-9.11	-0.39	2.57e-18	Inflammatory skin disease;
LGG	trans	rs3198697	0.617	rs11075253	chr16:15148646	C/A	cg04492929	chr16:2155436	PKD1	-0.54	-9.72	-0.41	1.98e-20	Triglycerides;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01245787	chr4:71859630	DCK	0.46	7.7	0.34	8.13e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs11630290	0.592	rs1912048	chr15:64155974	G/A	cg12036633	chr15:63758958	NA	0.49	7.05	0.31	6.66e-12	Iris characteristics;
LGG	cis	rs12153243	0.714	rs17401682	chr5:142896049	A/G	cg13907255	chr5:142895549	NA	-0.51	-9.09	-0.39	3.01e-18	Migraine;
LGG	cis	rs6547631	0.594	rs7585576	chr2:85937785	G/A	cg19805943	chr2:85933069	NA	0.33	6.77	0.3	3.92e-11	Blood protein levels;
LGG	trans	rs8002861	0.846	rs12428112	chr13:44475821	C/A	cg12856521	chr11:46389249	DGKZ	-0.45	-7.8	-0.34	4.28e-14	Leprosy;
LGG	cis	rs9814567	1.000	rs9869981	chr3:134248801	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.38	-0.53	9.34e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs644799	0.540	rs10831419	chr11:95478037	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.57	8.99	0.39	6.18e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.13	-0.39	2.08e-18	Height;
LGG	cis	rs10193935	1.000	rs62144748	chr2:42419468	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.5	-0.4	1.17e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9815354	0.761	rs73083329	chr3:41927151	C/T	cg03022575	chr3:42003672	ULK4	0.82	9.52	0.4	9.89e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10911232	0.507	rs35782443	chr1:183051502	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Hypertriglyceridemia;
LGG	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg06766960	chr11:133703094	NA	-0.55	-11.08	-0.46	1.86e-25	Childhood ear infection;
LGG	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg02705964	chr17:66097276	LOC651250	-0.48	-8.36	-0.36	7.55e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs796364	0.806	rs74706215	chr2:200941367	T/C	cg17644776	chr2:200775616	C2orf69	-0.59	-6.77	-0.3	3.88e-11	Schizophrenia;
LGG	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg03264133	chr6:25882463	NA	-0.49	-7.9	-0.34	2.05e-14	Iron status biomarkers;
LGG	cis	rs1451375	0.755	rs6969081	chr7:50624505	A/T	cg00647317	chr7:50633725	DDC	-0.36	-8.18	-0.36	2.72e-15	Malaria;
LGG	trans	rs7615952	0.641	rs4490307	chr3:125712676	T/G	cg07211511	chr3:129823064	LOC729375	-0.71	-9.95	-0.42	2.77e-21	Blood pressure (smoking interaction);
LGG	cis	rs736408	0.812	rs6778329	chr3:52824610	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.5	8.31	0.36	1.04e-15	Bipolar disorder;
LGG	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.36	0.81	9.16e-108	Chronic sinus infection;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.02e-13	Prudent dietary pattern;
LGG	cis	rs77633900	0.772	rs2956873	chr15:76695305	G/A	cg21673338	chr15:77095150	SCAPER	-0.63	-8.4	-0.36	5.39e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg13206674	chr6:150067644	NUP43	0.42	8.82	0.38	2.39e-17	Testicular germ cell tumor;
LGG	cis	rs9547996	0.879	rs2007577	chr13:38191143	T/C	cg17979426	chr13:38220150	TRPC4	-0.36	-6.86	-0.3	2.21e-11	Diastolic blood pressure;
LGG	cis	rs4664304	1.000	rs6735923	chr2:160769588	A/G	cg03641300	chr2:160917029	PLA2R1	-0.44	-7.75	-0.34	5.68e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg00290607	chr11:67383545	NA	-0.49	-8.78	-0.38	3.16e-17	Mean corpuscular volume;
LGG	trans	rs116095464	0.558	rs10080225	chr5:232175	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.25	-0.36	1.64e-15	Breast cancer;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg06654118	chr4:1303317	MAEA	0.48	8.3	0.36	1.16e-15	Obesity-related traits;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg05052898	chr14:88789655	KCNK10	0.46	6.85	0.3	2.36e-11	Hip circumference;
LGG	trans	rs9567307	1	rs9567307	chr13:44471877	A/G	cg17145862	chr1:211918768	LPGAT1	0.71	12.66	0.51	9.08e-32	Leprosy;
LGG	cis	rs2073300	0.609	rs6132606	chr20:23367453	G/A	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6964587	1.000	rs12533199	chr7:91757393	C/T	cg17063962	chr7:91808500	NA	0.51	9.2	0.39	1.25e-18	Breast cancer;
LGG	trans	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.48	-0.56	1.91e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs4819052	0.645	rs2838817	chr21:46631698	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.57	8.69	0.37	6.47e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21963583	chr11:68658836	MRPL21	0.58	10.04	0.42	1.4e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.934	rs13149952	chr4:1308437	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.69	12.47	0.5	5.87e-31	Obesity-related traits;
LGG	cis	rs1816752	0.905	rs1348110	chr13:24980675	C/T	cg22771759	chr13:24902376	NA	0.43	7.09	0.31	5e-12	Obesity-related traits;
LGG	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-8.42	-0.36	4.64e-16	Asthma;
LGG	cis	rs7582720	1.000	rs80087860	chr2:203673072	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.63	0.41	3.88e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs6582630	0.576	rs4882372	chr12:38356609	C/A	cg04568710	chr12:38710424	ALG10B	-0.4	-8.78	-0.38	3.24e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs789852	0.681	rs789857	chr3:194330250	C/T	cg18000598	chr3:194342907	TMEM44	-0.77	-7.89	-0.34	2.23e-14	QT interval;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg11153328	chr22:36877737	TXN2	-0.46	-7.21	-0.32	2.35e-12	Pancreatic cancer;
LGG	cis	rs910316	0.763	rs175490	chr14:75545685	A/G	cg06637938	chr14:75390232	RPS6KL1	0.52	9.54	0.41	8.24e-20	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25184507	chr17:7760147	CYB5D1;LSMD1	0.44	7.44	0.33	4.81e-13	Gut microbiome composition (summer);
LGG	cis	rs1008375	1.000	rs10939742	chr4:17659936	G/T	cg16339924	chr4:17578868	LAP3	0.59	10.36	0.43	9.09e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13191362	0.935	rs34035978	chr6:163165336	G/C	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.37	0.36	7.07e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.77	0.34	5.28e-14	Bipolar disorder;
LGG	cis	rs11722228	0.539	rs62287552	chr4:10153197	C/T	cg25986240	chr4:9926439	SLC2A9	-0.56	-10.57	-0.44	1.56e-23	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24295300	chr19:4043300	NA	-0.38	-6.92	-0.31	1.55e-11	Cognitive performance;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.13e-66	Alzheimer's disease;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg13395646	chr4:1353034	KIAA1530	0.48	8.13	0.35	4.09e-15	Obesity-related traits;
LGG	cis	rs7937682	0.889	rs490199	chr11:111487890	A/G	cg08305652	chr11:111469057	NA	-0.45	-9.01	-0.39	5.39e-18	Primary sclerosing cholangitis;
LGG	trans	rs9858542	0.953	rs1873625	chr3:49666964	C/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.93	-0.42	3.49e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7975161	0.630	rs7978101	chr12:104630510	A/G	cg25273343	chr12:104657179	TXNRD1	-0.75	-8.34	-0.36	8.53e-16	Toenail selenium levels;
LGG	cis	rs1401999	0.659	rs7622660	chr3:183753337	C/T	cg20387954	chr3:183756860	HTR3D	0.87	18.19	0.65	3.59e-56	Anterior chamber depth;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.45	0.61	3.1e-48	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13236679	chr6:37467396	C6orf129	0.5	7.59	0.33	1.75e-13	Gut microbiome composition (summer);
LGG	trans	rs877282	0.853	rs12763400	chr10:763617	C/T	cg22713356	chr15:30763199	NA	0.52	7.66	0.34	1.12e-13	Uric acid levels;
LGG	cis	rs4262150	0.705	rs72804801	chr5:152331031	C/A	cg12297329	chr5:152029980	NA	-0.69	-11.49	-0.47	4.8e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11676855	1.000	rs729866	chr2:235899359	G/A	cg14917874	chr2:235941519	SH3BP4	0.52	9.29	0.4	5.98e-19	Dialysis-related mortality;
LGG	cis	rs11098499	1.000	rs10029750	chr4:120172543	A/G	cg24375607	chr4:120327624	NA	0.61	10.16	0.43	4.94e-22	Corneal astigmatism;
LGG	trans	rs7395662	1.000	rs7129386	chr11:48616694	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	cis	rs72960926	0.744	rs2351778	chr6:74866814	T/G	cg03266952	chr6:74778945	NA	-0.62	-6.71	-0.3	5.75e-11	Metabolite levels (MHPG);
LGG	cis	rs75920871	0.748	rs12225230	chr11:116728630	G/C	cg20608306	chr11:116969690	SIK3	-0.32	-7.59	-0.33	1.78e-13	Subjective well-being;
LGG	cis	rs2439831	0.850	rs12441984	chr15:44126285	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.98	10.65	0.44	8.04e-24	Lung cancer in ever smokers;
LGG	cis	rs6424115	1.000	rs7515969	chr1:24158398	G/A	cg15997130	chr1:24165203	NA	-0.5	-13.48	-0.53	3.77e-35	Immature fraction of reticulocytes;
LGG	cis	rs4700695	0.614	rs437399	chr5:65208533	A/G	cg21114390	chr5:65439923	SFRS12	0.6	7.02	0.31	7.86e-12	Facial morphology (factor 19);
LGG	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg13395646	chr4:1353034	KIAA1530	-0.44	-7.74	-0.34	6.49e-14	Longevity;
LGG	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.61	8.06	0.35	6.39e-15	HIV-1 control;
LGG	cis	rs6088580	0.634	rs6059880	chr20:33088669	G/A	cg08999081	chr20:33150536	PIGU	0.4	10.09	0.42	9.36e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2131877	0.913	rs1874101	chr3:194849057	C/T	cg07250128	chr3:194833983	C3orf21	-0.39	-7.18	-0.32	2.81e-12	Non-small cell lung cancer;
LGG	cis	rs2836950	0.501	rs11088470	chr21:40689162	A/G	cg11890956	chr21:40555474	PSMG1	-0.72	-12.37	-0.5	1.47e-30	Menarche (age at onset);
LGG	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21659725	chr3:3221576	CRBN	-0.61	-9.7	-0.41	2.3e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3768617	0.510	rs1886499	chr1:183095024	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7954584	0.616	rs10743185	chr12:122356435	G/A	cg13699009	chr12:122356056	WDR66	0.55	15.21	0.58	1.15e-42	Mean corpuscular volume;
LGG	cis	rs11586313	0.507	rs2339385	chr1:152859594	C/G	cg13444842	chr1:152974279	SPRR3	-0.39	-7.4	-0.33	6.29e-13	Vitamin D levels;
LGG	cis	rs67460515	0.892	rs11711695	chr3:161057593	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-12.97	-0.52	4.83e-33	Parkinson's disease;
LGG	cis	rs1650123	0.645	rs703614	chr12:104017614	A/C	cg23227824	chr12:103980017	STAB2	-0.36	-8.38	-0.36	6.38e-16	IgG glycosylation;
LGG	cis	rs3820928	0.967	rs2396435	chr2:227778397	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.48	-0.33	3.8e-13	Pulmonary function;
LGG	cis	rs6500395	1.000	rs9933976	chr16:48590145	A/G	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs35264875	0.898	rs55648928	chr11:68861591	G/T	cg01403660	chr11:68851641	TPCN2	0.5	7.01	0.31	8.6e-12	Blond vs. brown hair color;
LGG	cis	rs735539	0.645	rs9550662	chr13:21141552	C/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.33	-0.36	9.48e-16	Dental caries;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg05692746	chr2:100937584	LONRF2	-0.66	-12.23	-0.49	5.57e-30	Intelligence (multi-trait analysis);
LGG	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg20608306	chr11:116969690	SIK3	0.34	9.01	0.39	5.25e-18	Blood protein levels;
LGG	cis	rs6784615	0.590	rs4687619	chr3:52518786	T/C	cg16850945	chr3:52488229	TNNC1;NISCH	-0.66	-7.49	-0.33	3.44e-13	Waist-hip ratio;
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.09	-0.31	4.97e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4700695	0.764	rs251593	chr5:65313889	G/A	cg21114390	chr5:65439923	SFRS12	0.59	7.35	0.32	8.86e-13	Facial morphology (factor 19);
LGG	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg06808227	chr14:105710500	BRF1	-0.64	-10.79	-0.45	2.33e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg03709012	chr19:19516395	GATAD2A	0.9	10.76	0.45	3.02e-24	Nonalcoholic fatty liver disease;
LGG	cis	rs2688608	0.592	rs10762560	chr10:75495405	T/G	cg19442545	chr10:75533431	FUT11	-0.43	-7.02	-0.31	7.8e-12	Inflammatory bowel disease;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.12	0.55	6.56e-38	Obesity-related traits;
LGG	cis	rs4853012	0.793	rs6707619	chr2:74344656	G/A	cg05890377	chr2:74357713	NA	0.49	9.89	0.42	4.69e-21	Gestational age at birth (maternal effect);
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.31	0.43	1.36e-22	Prudent dietary pattern;
LGG	cis	rs6088580	0.634	rs4911421	chr20:32998948	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9443645	0.588	rs1415310	chr6:79822314	C/T	cg18132916	chr6:79620363	NA	-0.26	-6.81	-0.3	3.13e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg06636001	chr8:8085503	FLJ10661	0.48	8.68	0.37	6.93e-17	Retinal vascular caliber;
LGG	cis	rs6952808	0.636	rs6964522	chr7:1953523	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-12.14	-0.49	1.28e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs3540	0.576	rs10152871	chr15:91047469	G/A	cg22089800	chr15:90895588	ZNF774	-0.67	-12.4	-0.5	1.11e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs4740619	0.544	rs7032634	chr9:15826898	T/C	cg14451791	chr9:16040625	NA	0.32	7.95	0.35	1.47e-14	Body mass index;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.79	-0.48	3.02e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs951366	0.966	rs11240565	chr1:205722958	C/T	cg07157834	chr1:205819609	PM20D1	-0.45	-8.73	-0.38	4.83e-17	Menarche (age at onset);
LGG	cis	rs657075	0.697	rs2304081	chr5:131667548	A/G	cg05556477	chr5:131705319	SLC22A5	-0.82	-9.99	-0.42	2.05e-21	Rheumatoid arthritis;
LGG	cis	rs4363385	0.693	rs440598	chr1:153044733	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs4730779	0.935	rs3926643	chr7:117027432	G/A	cg10524701	chr7:117356490	CTTNBP2	0.41	8.96	0.38	7.89e-18	Waist circumference;
LGG	trans	rs7395662	0.963	rs8189076	chr11:48732975	C/T	cg15704280	chr7:45808275	SEPT13	0.49	8.12	0.35	4.26e-15	HDL cholesterol;
LGG	cis	rs3749237	0.615	rs11130202	chr3:49566715	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.84	-0.3	2.52e-11	Resting heart rate;
LGG	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg05082376	chr22:42548792	NA	-0.36	-7.43	-0.33	5.32e-13	Schizophrenia;
LGG	cis	rs2274273	0.682	rs1201378	chr14:55493408	A/G	cg04306507	chr14:55594613	LGALS3	-0.44	-11.07	-0.46	1.98e-25	Protein biomarker;
LGG	cis	rs9467773	0.595	rs2451736	chr6:26620544	G/A	cg09904177	chr6:26538194	HMGN4	0.67	13.93	0.54	4.36e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg21017887	chr14:105400489	NA	0.43	8.67	0.37	7.22e-17	Rheumatoid arthritis;
LGG	cis	rs2012796	0.956	rs7147254	chr14:81820503	G/A	cg02996355	chr14:81879375	NA	0.52	8.24	0.36	1.74e-15	Night sleep phenotypes;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.5e-33	Obesity-related traits;
LGG	cis	rs9467711	0.591	rs67296946	chr6:26048559	T/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.72	7.58	0.33	1.85e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9463078	0.774	rs9296457	chr6:45264687	A/G	cg25276700	chr6:44698697	NA	-0.4	-8.53	-0.37	2.08e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.87	-0.42	5.78e-21	Menarche (age at onset);
LGG	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.73e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs3942852	0.774	rs10838811	chr11:48186795	A/G	cg15704280	chr7:45808275	SEPT13	-0.69	-10.06	-0.42	1.18e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9467773	0.587	rs10946813	chr6:26345141	A/G	cg09904177	chr6:26538194	HMGN4	0.47	8.58	0.37	1.49e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7765175	0.598	rs2801437	chr6:113653579	G/A	cg26552650	chr6:113682475	NA	0.33	7.39	0.32	6.87e-13	Coronary artery calcification;
LGG	cis	rs34172651	0.517	rs200526	chr16:24760511	C/T	cg06028605	chr16:24865363	SLC5A11	-0.47	-7.78	-0.34	4.82e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1957429	0.901	rs17102320	chr14:65384693	T/C	cg23373153	chr14:65346875	NA	-1.0	-12.91	-0.51	8.85e-33	Pediatric areal bone mineral density (radius);
LGG	cis	rs4689592	0.554	rs3951346	chr4:7073321	C/T	cg25660036	chr4:7070649	GRPEL1	-0.46	-7.01	-0.31	8.28e-12	Monocyte percentage of white cells;
LGG	cis	rs6724607	1.000	rs10165399	chr2:191441595	A/G	cg10560079	chr2:191398806	TMEM194B	0.36	8.07	0.35	6.16e-15	Pulse pressure;
LGG	cis	rs6500602	0.727	rs11076836	chr16:4569331	G/A	cg05091796	chr16:4465799	CORO7	-0.6	-9.82	-0.42	8.07e-21	Schizophrenia;
LGG	cis	rs7582180	0.764	rs12615466	chr2:100924065	C/A	cg14675211	chr2:100938903	LONRF2	0.66	11.42	0.47	8.54e-27	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	1.000	rs2295408	chr22:50261051	A/G	cg02269571	chr22:50332266	NA	0.64	10.1	0.42	8.58e-22	Schizophrenia;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg06214220	chr9:36400252	RNF38	0.41	6.77	0.3	3.8e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs9398803	0.687	rs1262552	chr6:127078752	C/T	cg19875578	chr6:126661172	C6orf173	-0.49	-9.03	-0.39	4.54e-18	Male-pattern baldness;
LGG	trans	rs9354308	0.738	rs1938101	chr6:66600032	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs4622507	0.618	rs12920962	chr16:55058388	C/T	cg09947736	chr16:55091198	NA	0.77	11.03	0.46	2.89e-25	Social communication problems;
LGG	cis	rs11148252	0.634	rs1571189	chr13:52731004	A/T	cg12458913	chr13:53173898	NA	0.48	8.44	0.37	4.12e-16	Lewy body disease;
LGG	cis	rs875971	0.545	rs73150604	chr7:65945532	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.64	0.44	8.09e-24	Aortic root size;
LGG	cis	rs7017914	0.967	rs1902614	chr8:71656167	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.44e-11	Bone mineral density;
LGG	trans	rs7939886	0.920	rs11231821	chr11:55777052	C/G	cg15704280	chr7:45808275	SEPT13	0.88	9.16	0.39	1.63e-18	Myopia (pathological);
LGG	trans	rs7762018	1.000	rs4716380	chr6:170090399	A/G	cg06875740	chr19:51307921	C19orf48	-0.67	-8.4	-0.36	5.58e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.56	0.5	2.34e-31	Prudent dietary pattern;
LGG	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	trans	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Bladder cancer;
LGG	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.54	-0.47	3.1e-27	Coronary artery disease;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6577655	0.517	rs6998749	chr8:135584316	A/G	cg17885191	chr8:135476712	NA	-0.58	-8.73	-0.38	4.7e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs1978968	0.763	rs5992136	chr22:18453103	G/C	cg03078520	chr22:18463400	MICAL3	-0.66	-13.77	-0.54	2.14e-36	Presence of antiphospholipid antibodies;
LGG	trans	rs6981523	0.553	rs11783045	chr8:11056175	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.08	-0.31	5.22e-12	Neuroticism;
LGG	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg12893428	chr3:195717962	SDHAP1	0.51	10.64	0.44	8.64e-24	Pancreatic cancer;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg19318889	chr4:1322082	MAEA	-0.41	-7.22	-0.32	2.16e-12	Obesity-related traits;
LGG	cis	rs2952156	0.684	rs881844	chr17:37810218	C/G	cg00129232	chr17:37814104	STARD3	-0.79	-17.56	-0.63	2.69e-53	Asthma;
LGG	cis	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg11266682	chr4:10021025	SLC2A9	-0.4	-7.28	-0.32	1.46e-12	Bone mineral density;
LGG	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg12654349	chr5:56205094	C5orf35	-0.58	-9.98	-0.42	2.26e-21	Initial pursuit acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08429850	chr19:2236503	PLEKHJ1;SF3A2	0.45	6.67	0.3	7.43e-11	Gut microbiome composition (summer);
LGG	cis	rs1847202	0.859	rs7634316	chr3:72941452	C/G	cg25664220	chr3:72788482	NA	0.25	7.28	0.32	1.45e-12	Motion sickness;
LGG	cis	rs4073582	0.894	rs801733	chr11:65934549	A/C	cg16950941	chr11:66035639	RAB1B	0.41	6.96	0.31	1.16e-11	Gout;
LGG	cis	rs10504229	0.683	rs56208052	chr8:58130207	A/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.684	rs272849	chr5:131690241	A/G	cg07395648	chr5:131743802	NA	-0.55	-12.91	-0.51	8.58e-33	Blood metabolite levels;
LGG	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg04234412	chr22:24373322	LOC391322	0.7	10.86	0.45	1.27e-24	S-phenylmercapturic acid levels in smokers;
LGG	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Colorectal cancer;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.04	0.39	4.31e-18	Schizophrenia;
LGG	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs6964587	0.869	rs7812219	chr7:91545727	C/T	cg17063962	chr7:91808500	NA	-0.44	-7.63	-0.33	1.34e-13	Breast cancer;
LGG	cis	rs62238980	0.614	rs118073663	chr22:32397610	A/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6988985	0.728	rs7003319	chr8:143954747	T/C	cg10324643	chr8:143916377	GML	0.38	7.74	0.34	6.45e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg12826209	chr6:26865740	GUSBL1	0.82	11.66	0.48	1.03e-27	Intelligence (multi-trait analysis);
LGG	cis	rs6735179	0.641	rs10164792	chr2:1753375	G/A	cg20570797	chr2:1712800	PXDN	-0.45	-7.87	-0.34	2.48e-14	Response to antipsychotic treatment;
LGG	cis	rs4665809	0.878	rs4143538	chr2:26290178	A/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.85	-13.57	-0.53	1.51e-35	Gut microbiome composition (summer);
LGG	cis	rs6728642	0.901	rs7584641	chr2:97607655	A/T	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.92	-0.31	1.52e-11	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs12496230	0.953	rs1036970	chr3:66850707	A/G	cg17646820	chr3:66848679	NA	0.55	8.29	0.36	1.22e-15	Type 2 diabetes;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg24829409	chr8:58192753	C8orf71	-0.71	-9.54	-0.41	8.29e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs477895	0.838	rs12794145	chr11:64006484	C/T	cg04317338	chr11:64019027	PLCB3	0.65	7.93	0.35	1.7e-14	Mean platelet volume;
LGG	cis	rs7107174	0.901	rs2450137	chr11:77925233	C/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.44	-0.33	4.86e-13	Testicular germ cell tumor;
LGG	cis	rs6489882	0.867	rs6489877	chr12:113368079	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.63	-0.33	1.33e-13	Chronic lymphocytic leukemia;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.71	0.54	3.71e-36	Obesity-related traits;
LGG	cis	rs614226	0.935	rs2235222	chr12:120892193	G/C	cg01236616	chr12:121019343	POP5	-1.24	-22.67	-0.73	4.15e-77	Type 1 diabetes nephropathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23959187	chr17:46102881	NA	0.51	8.06	0.35	6.42e-15	Gut microbiome composition (summer);
LGG	cis	rs739401	0.611	rs2301140	chr11:3022629	C/T	cg25174290	chr11:3078921	CARS	0.73	14.67	0.56	2.67e-40	Longevity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19906694	chr5:60629770	ZSWIM6	0.63	7.06	0.31	6.06e-12	Intelligence (multi-trait analysis);
LGG	cis	rs8141529	0.529	rs2236141	chr22:29137870	C/T	cg02153584	chr22:29168773	CCDC117	0.6	6.71	0.3	5.8e-11	Lymphocyte counts;
LGG	cis	rs7301826	0.966	rs10734980	chr12:131294626	T/C	cg11011512	chr12:131303247	STX2	0.35	7.57	0.33	2.04e-13	Plasma plasminogen activator levels;
LGG	cis	rs7044106	0.762	rs1411158	chr9:123464804	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.25	0.32	1.73e-12	Hip circumference adjusted for BMI;
LGG	cis	rs68170813	0.559	rs7804979	chr7:106999453	C/G	cg02696742	chr7:106810147	HBP1	-0.68	-9.79	-0.41	1.08e-20	Coronary artery disease;
LGG	cis	rs2249625	0.545	rs2496505	chr6:72891063	C/G	cg27608224	chr6:72922399	RIMS1	0.32	7.16	0.32	3.16e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs6032067	0.527	rs35828065	chr20:43732374	T/C	cg10761708	chr20:43804764	PI3	0.56	8.65	0.37	8.22e-17	Blood protein levels;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg07791516	chr6:150247246	NA	0.34	7.36	0.32	8.33e-13	Testicular germ cell tumor;
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs1552244	0.882	rs36006511	chr3:10054191	C/T	cg00149659	chr3:10157352	C3orf10	0.79	9.92	0.42	3.83e-21	Alzheimer's disease;
LGG	cis	rs2762353	0.904	rs13197601	chr6:25785935	G/A	cg03517284	chr6:25882590	NA	0.52	9.62	0.41	4.3e-20	Blood metabolite levels;
LGG	cis	rs4713675	0.565	rs4713665	chr6:33674419	T/G	cg14003231	chr6:33640908	ITPR3	0.29	6.74	0.3	4.79e-11	Plateletcrit;
LGG	cis	rs9467773	1.000	rs9467779	chr6:26536687	A/T	cg09904177	chr6:26538194	HMGN4	-0.78	-17.66	-0.63	9.38e-54	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.581	rs2723608	chr11:133710149	A/G	cg00579200	chr11:133705235	NA	-0.61	-11.73	-0.48	5.37e-28	Childhood ear infection;
LGG	cis	rs7208859	0.673	rs216435	chr17:28922737	G/T	cg13385521	chr17:29058706	SUZ12P	0.82	9.66	0.41	3.01e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2985684	0.894	rs4900927	chr14:50018741	G/T	cg04989706	chr14:50066350	PPIL5	-0.6	-9.79	-0.41	1.04e-20	Carotid intima media thickness;
LGG	cis	rs4481887	0.676	rs946761	chr1:248521032	T/C	cg01631408	chr1:248437212	OR2T33	-0.38	-7.15	-0.32	3.3e-12	Common traits (Other);
LGG	cis	rs6500637	0.659	rs10500326	chr16:4918326	G/T	cg04440724	chr16:4920505	UBN1	-0.58	-10.46	-0.44	3.83e-23	Cancer;
LGG	cis	rs4959677	0.755	rs10793837	chr6:2474161	A/G	cg20147862	chr6:2634573	C6orf195	-0.34	-7.07	-0.31	5.68e-12	Orthostatic hypotension;
LGG	cis	rs2762353	0.808	rs1165183	chr6:25836380	A/G	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.43	0.33	5.23e-13	Homoarginine levels;
LGG	cis	rs2404602	0.692	rs4886503	chr15:77108874	C/T	cg05677249	chr15:77158041	SCAPER	0.31	6.78	0.3	3.67e-11	Blood metabolite levels;
LGG	cis	rs7188861	0.861	rs2032933	chr16:11445040	G/A	cg01510278	chr16:11456238	NA	-0.32	-7.67	-0.34	1.03e-13	HDL cholesterol;
LGG	cis	rs6787391	0.933	rs6774180	chr3:4742779	C/T	cg11584376	chr3:4789075	ITPR1	-0.33	-6.87	-0.3	2.05e-11	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06248182	chr17:27181818	ERAL1	0.45	7.5	0.33	3.22e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg13565492	chr6:43139072	SRF	-0.72	-8.74	-0.38	4.28e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1580019	0.587	rs7806113	chr7:32553084	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.79	0.79	1.03e-100	Cognitive ability;
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	1.96e-17	Alzheimer's disease;
LGG	cis	rs60843830	1.000	rs3791220	chr2:227066	C/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.51	0.37	2.48e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3741404	0.574	rs638227	chr11:63871549	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	0.39	7.92	0.35	1.82e-14	Platelet count;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.17	-0.39	1.6e-18	Testicular germ cell tumor;
LGG	trans	rs2243480	1.000	rs35825738	chr7:65318027	A/G	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs17445240	1.000	rs80212323	chr2:3703959	C/T	cg14882966	chr2:3699353	NA	0.89	9.09	0.39	2.9e-18	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs798554	0.679	rs7784066	chr7:2819727	T/A	cg27476859	chr7:2772710	GNA12	0.39	6.86	0.3	2.27e-11	Height;
LGG	cis	rs10504229	0.679	rs11783965	chr8:58130510	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.75e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7507204	0.723	rs62125964	chr19:3414742	C/A	cg08382705	chr11:45687319	CHST1	-0.51	-6.75	-0.3	4.5e-11	Height;
LGG	cis	rs6542838	0.554	rs4311103	chr2:99538362	G/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.46	-7.31	-0.32	1.16e-12	Fear of minor pain;
LGG	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg11247378	chr22:39784982	NA	-0.32	-9.01	-0.39	5.42e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7216064	1.000	rs62084213	chr17:65842016	A/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.75	-0.38	3.9e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07262328	chr11:35160709	CD44	0.42	6.95	0.31	1.25e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6988985	0.703	rs6988323	chr8:143946483	A/G	cg10324643	chr8:143916377	GML	0.4	7.99	0.35	1.06e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs61931739	0.500	rs11053271	chr12:34545407	C/A	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg24977338	chr2:113188963	RGPD8;RGPD5	0.59	8.98	0.39	6.89e-18	Yeast infection;
LGG	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg03929089	chr4:120376271	NA	0.84	13.18	0.52	6.49e-34	Coronary artery disease;
LGG	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg02187348	chr16:89574699	SPG7	0.44	7.12	0.31	4.12e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs12893668	0.703	rs34896432	chr14:104027995	C/T	cg23335576	chr14:104009727	NA	0.51	8.87	0.38	1.57e-17	Reticulocyte count;
LGG	cis	rs7917772	0.502	rs2296583	chr10:104244322	T/G	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.79e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4950322	0.580	rs1813002	chr1:146584161	C/G	cg22381352	chr1:146742008	CHD1L	-0.41	-7.08	-0.31	5.56e-12	Protein quantitative trait loci;
LGG	trans	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg06521331	chr12:34319734	NA	0.42	7.21	0.32	2.35e-12	Morning vs. evening chronotype;
LGG	cis	rs6582630	0.502	rs4559747	chr12:38436235	G/A	cg26384229	chr12:38710491	ALG10B	0.92	21.15	0.7	5.75e-70	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9547996	0.808	rs9547976	chr13:38185728	A/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.83	-0.3	2.65e-11	Diastolic blood pressure;
LGG	cis	rs2652834	0.851	rs1976433	chr15:63426912	T/G	cg05507819	chr15:63340323	TPM1	0.5	7.12	0.31	4.27e-12	HDL cholesterol;
LGG	cis	rs11190604	1.000	rs17746014	chr10:102315354	T/C	cg07080220	chr10:102295463	HIF1AN	0.72	11.93	0.48	8.31e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9291683	0.595	rs35250962	chr4:10048271	C/T	cg11266682	chr4:10021025	SLC2A9	0.55	11.12	0.46	1.24e-25	Bone mineral density;
LGG	cis	rs7973719	0.865	rs12228393	chr12:7368182	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	0.3	7.92	0.35	1.72e-14	IgG glycosylation;
LGG	cis	rs12701220	0.895	rs3808348	chr7:1028448	C/T	cg26769984	chr7:1090371	C7orf50	0.56	9.44	0.4	1.82e-19	Bronchopulmonary dysplasia;
LGG	cis	rs9527	0.545	rs12247514	chr10:104958066	C/A	cg04362960	chr10:104952993	NT5C2	0.58	10.91	0.45	7.78e-25	Arsenic metabolism;
LGG	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg18479299	chr3:125709523	NA	-0.59	-7.53	-0.33	2.74e-13	Blood pressure (smoking interaction);
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg19223190	chr17:80058835	NA	0.42	8.04	0.35	7.43e-15	Life satisfaction;
LGG	cis	rs504918	0.676	rs4371456	chr3:124050068	A/T	cg05766129	chr3:123988013	KALRN	-0.46	-8.23	-0.36	1.89e-15	Schizophrenia;
LGG	cis	rs9787249	0.957	rs7518431	chr1:40214944	C/T	cg02773041	chr1:40204384	PPIE	-0.53	-10.01	-0.42	1.79e-21	Blood protein levels;
LGG	cis	rs11096990	0.593	rs7662880	chr4:39285224	C/T	cg24403649	chr4:39172243	NA	-0.39	-6.92	-0.31	1.55e-11	Cognitive function;
LGG	cis	rs1801251	1.000	rs2675971	chr2:233726154	A/G	cg08000102	chr2:233561755	GIGYF2	-0.58	-9.34	-0.4	4.22e-19	Coronary artery disease;
LGG	cis	rs2115536	0.730	rs4238512	chr15:80183898	A/C	cg11839771	chr15:80205821	ST20	0.37	8.09	0.35	5.3e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs17826219	0.500	rs9891256	chr17:29072692	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Body mass index;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.03	-0.31	7.56e-12	Lung cancer;
LGG	cis	rs7762018	1.000	rs7762018	chr6:170113244	G/T	cg15038512	chr6:170123185	PHF10	0.5	6.66	0.3	7.94e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7939886	0.920	rs12223014	chr11:55878290	G/A	cg02254774	chr11:50257496	LOC441601	0.58	6.78	0.3	3.68e-11	Myopia (pathological);
LGG	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg07027305	chr7:2059796	MAD1L1	-0.35	-8.84	-0.38	2.09e-17	Neuroticism;
LGG	cis	rs7113850	0.541	rs7928230	chr11:24220604	A/G	ch.11.24196551F	chr11:24239977	NA	0.9	10.17	0.43	4.49e-22	Bone fracture in osteoporosis;
LGG	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg04617936	chr2:214353	NA	-0.39	-7.18	-0.32	2.8e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11583043	0.708	rs10493942	chr1:101545482	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.41	6.88	0.3	2.01e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs3824867	0.920	rs9919526	chr11:47451623	C/T	cg20307385	chr11:47447363	PSMC3	-0.46	-7.26	-0.32	1.62e-12	Mean corpuscular hemoglobin;
LGG	cis	rs644799	1.000	rs514170	chr11:95556696	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs1945213	0.694	rs11227113	chr11:55828024	C/T	cg11707556	chr5:10655725	ANKRD33B	0.48	7.03	0.31	7.67e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs537930	0.560	rs31205	chr5:134352377	C/T	cg24576358	chr5:134350122	NA	0.41	9.09	0.39	2.93e-18	Height;
LGG	cis	rs2688608	0.592	rs11000758	chr10:75493610	A/T	cg00564723	chr10:75632066	CAMK2G	-0.32	-7.22	-0.32	2.09e-12	Inflammatory bowel disease;
LGG	cis	rs34172651	0.517	rs1465423	chr16:24772680	C/G	cg00339695	chr16:24857497	SLC5A11	-0.39	-6.77	-0.3	4.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2594989	1.000	rs2594989	chr3:11316143	C/T	cg01796438	chr3:11312864	ATG7	-0.6	-8.3	-0.36	1.13e-15	Circulating chemerin levels;
LGG	cis	rs9902453	0.765	rs12601647	chr17:28164953	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.97	0.54	3.01e-37	Coffee consumption (cups per day);
LGG	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg04568710	chr12:38710424	ALG10B	0.33	6.67	0.3	7.23e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs881375	0.678	rs10118357	chr9:123680068	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.56	10.68	0.44	5.9e-24	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs6879260	1.000	rs7730585	chr5:179733440	T/C	cg23248424	chr5:179741104	GFPT2	-0.6	-10.9	-0.45	8.59e-25	Height;
LGG	cis	rs977987	0.966	rs62060551	chr16:75502312	A/C	cg03315344	chr16:75512273	CHST6	0.58	11.5	0.47	4.2e-27	Dupuytren's disease;
LGG	cis	rs7527798	0.592	rs7539772	chr1:207833301	G/A	cg09232269	chr1:207846808	CR1L	-0.37	-6.98	-0.31	1.05e-11	Erythrocyte sedimentation rate;
LGG	cis	rs875971	1.000	rs10215948	chr7:65747786	G/A	cg23594656	chr7:65796392	TPST1	0.38	8.45	0.37	3.69e-16	Aortic root size;
LGG	cis	rs1620921	0.625	rs12215233	chr6:161263453	A/T	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg06215416	chr1:2383473	NA	-0.5	-11.47	-0.47	5.62e-27	Non-obstructive azoospermia;
LGG	trans	rs2562456	0.876	rs10424079	chr19:21589179	G/A	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.24e-13	Pain;
LGG	cis	rs4253772	0.591	rs11703245	chr22:46684890	A/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.78e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg02503808	chr4:7069936	GRPEL1	-0.96	-8.16	-0.35	3.09e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs67133203	0.851	rs67260912	chr12:51487364	T/C	cg14688905	chr12:51403056	SLC11A2	0.67	10.19	0.43	3.94e-22	Urinary tract infection frequency;
LGG	cis	rs72960926	1.000	rs16879383	chr6:75097185	A/G	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs7917772	0.636	rs7911747	chr10:104528890	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.96	-0.35	1.32e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs8073060	0.544	rs17550716	chr17:33893208	A/G	cg19694781	chr19:47549865	TMEM160	1.11	16.82	0.62	6.83e-50	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs138249	1.000	rs138250	chr22:50570361	A/G	cg07310406	chr22:50524374	MLC1	0.45	9.08	0.39	3.11e-18	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs854765	0.964	rs854762	chr17:18009102	G/A	cg04398451	chr17:18023971	MYO15A	0.66	13.81	0.54	1.37e-36	Total body bone mineral density;
LGG	cis	rs992157	1.000	rs736731	chr2:219120588	A/G	cg00012203	chr2:219082015	ARPC2	0.79	14.92	0.57	2.19e-41	Colorectal cancer;
LGG	cis	rs472402	0.540	rs2288445	chr5:6620092	C/T	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.36	-0.32	8.67e-13	Response to amphetamines;
LGG	cis	rs10911232	0.507	rs4422969	chr1:183020762	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.91	0.42	4.06e-21	Hypertriglyceridemia;
LGG	cis	rs10464366	0.571	rs4723825	chr7:39157627	G/C	cg15212455	chr7:39170539	POU6F2	0.51	12.04	0.49	3.18e-29	IgG glycosylation;
LGG	cis	rs4148883	0.504	rs4147544	chr4:100134514	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-7.05	-0.31	6.48e-12	Alcohol dependence;
LGG	cis	rs28386778	0.700	rs11079515	chr17:62005645	C/G	cg07659893	chr17:61819838	STRADA	-0.41	-6.65	-0.3	8.37e-11	Prudent dietary pattern;
LGG	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.81	0.79	8.51e-101	Cognitive ability;
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg07243736	chr16:783730	NARFL	0.41	7.14	0.31	3.73e-12	Height;
LGG	trans	rs6951245	1.000	rs113146460	chr7:1105164	C/G	cg13565492	chr6:43139072	SRF	-0.75	-9.02	-0.39	5.16e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9902453	0.817	rs3115089	chr17:28031881	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.93	0.54	4.35e-37	Coffee consumption (cups per day);
LGG	cis	rs13102973	0.965	rs13129208	chr4:135858263	A/G	cg14419869	chr4:135874104	NA	0.57	10.92	0.45	7.22e-25	Subjective well-being;
LGG	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg19554555	chr3:13937349	NA	-0.54	-9.7	-0.41	2.33e-20	Ovarian reserve;
LGG	cis	rs1476670	0.710	rs4660763	chr1:44503576	T/C	cg09470012	chr1:44509516	NA	0.41	8.09	0.35	5.45e-15	Eotaxin levels;
LGG	cis	rs8062405	1.000	rs7205323	chr16:28865892	C/T	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6920965	0.583	rs9388456	chr6:126147197	C/T	cg05901451	chr6:126070800	HEY2	-0.45	-7.74	-0.34	6.36e-14	High light scatter reticulocyte count;
LGG	cis	rs774359	0.744	rs895022	chr9:27484371	G/C	cg21249376	chr9:27528432	MOBKL2B	0.46	8.38	0.36	6.21e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg06636001	chr8:8085503	FLJ10661	0.49	9.08	0.39	3.25e-18	Monocyte count;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg24846343	chr22:24311635	DDTL	-0.55	-10.43	-0.44	5.21e-23	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10744422	1.000	rs7138398	chr12:123341833	G/C	cg25930673	chr12:123319894	HIP1R	-0.75	-9.39	-0.4	2.8e-19	Schizophrenia;
LGG	trans	rs453301	0.624	rs6987558	chr8:8862521	C/G	cg27411982	chr8:10470053	RP1L1	0.46	8.03	0.35	8.3e-15	Joint mobility (Beighton score);
LGG	cis	rs9814567	0.752	rs4955468	chr3:134340850	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-10.96	-0.45	5.11e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.87	-20.73	-0.69	5.16e-68	Systemic lupus erythematosus;
LGG	cis	rs968451	0.507	rs137618	chr22:39705104	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.55	-9.16	-0.39	1.62e-18	Primary biliary cholangitis;
LGG	cis	rs9311474	0.508	rs2878628	chr3:52584715	C/T	cg15147215	chr3:52552868	STAB1	0.35	6.82	0.3	2.79e-11	Electroencephalogram traits;
LGG	cis	rs9326248	0.559	rs482371	chr11:116752163	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.59	0.44	1.34e-23	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15264811	chr7:64734330	NA	0.48	7.25	0.32	1.78e-12	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg07142201	chr11:109293216	C11orf87	0.67	11.71	0.48	6.47e-28	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.23e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs6594713	0.732	rs7718616	chr5:112727603	C/T	cg12552261	chr5:112820674	MCC	0.54	7.58	0.33	1.93e-13	Brain cytoarchitecture;
LGG	cis	rs35740288	0.929	rs1978391	chr15:86311695	A/G	cg04173714	chr15:86211321	AKAP13	-0.42	-7.29	-0.32	1.36e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13191362	1.000	rs36042757	chr6:163004744	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.23	0.43	2.73e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1577917	0.917	rs1414201	chr6:86500316	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.25	-0.49	4.62e-30	Response to antipsychotic treatment;
LGG	cis	rs826838	1.000	rs1684395	chr12:39083161	T/G	cg13010199	chr12:38710504	ALG10B	-0.62	-13.31	-0.53	1.87e-34	Heart rate;
LGG	cis	rs10865541	0.935	rs4353680	chr2:3393188	T/C	cg11642891	chr2:3452563	TTC15	-0.4	-7.56	-0.33	2.18e-13	Obesity-related traits;
LGG	cis	rs7172689	0.908	rs11630050	chr15:81566295	A/C	cg11808699	chr15:81528661	IL16	-0.43	-8.54	-0.37	2e-16	Inattentive symptoms;
LGG	cis	rs11764590	0.694	rs7797112	chr7:2085165	T/C	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.89	-0.38	1.35e-17	Neuroticism;
LGG	cis	rs12220238	0.822	rs11000979	chr10:76067865	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.94	0.38	9.54e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg26597838	chr10:835615	NA	0.95	12.69	0.51	6.94e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs9682041	0.932	rs9841852	chr3:170067049	C/G	cg11886554	chr3:170076028	SKIL	0.83	10.48	0.44	3.2e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	cis	rs2016266	0.964	rs1110720	chr12:53682326	G/A	cg04065151	chr12:53682969	ESPL1	-0.57	-9.74	-0.41	1.63e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4689388	0.824	rs6446482	chr4:6295693	C/G	cg14416269	chr4:6271139	WFS1	0.52	9.39	0.4	2.75e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs10242455	0.571	rs56167514	chr7:99161347	A/G	cg09045935	chr12:6379348	NA	0.89	7.88	0.34	2.3e-14	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs8065210	chr17:80090960	G/A	cg13939156	chr17:80058883	NA	-0.46	-8.97	-0.38	7.18e-18	Life satisfaction;
LGG	cis	rs71403859	0.730	rs12446333	chr16:71752157	T/C	cg08717414	chr16:71523259	ZNF19	-1.05	-12.98	-0.52	4.48e-33	Post bronchodilator FEV1;
LGG	trans	rs61931739	0.620	rs61927756	chr12:33709931	A/G	cg26384229	chr12:38710491	ALG10B	-0.47	-8.43	-0.36	4.48e-16	Morning vs. evening chronotype;
LGG	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg09904177	chr6:26538194	HMGN4	0.77	17.17	0.62	1.66e-51	Intelligence (multi-trait analysis);
LGG	cis	rs1878931	0.554	rs3207360	chr16:3498115	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.79	14.66	0.56	2.98e-40	Body mass index (adult);
LGG	cis	rs6163	0.588	rs11191392	chr10:104526951	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.4	-7.22	-0.32	2.14e-12	Waist circumference;Hip circumference;
LGG	cis	rs2075371	1.000	rs432487	chr7:133990114	T/G	cg11752832	chr7:134001865	SLC35B4	0.6	10.99	0.45	4.18e-25	Mean platelet volume;
LGG	cis	rs2130392	0.926	rs7677893	chr4:185625523	T/C	cg21366198	chr4:185655624	MLF1IP	-0.44	-7.76	-0.34	5.35e-14	Kawasaki disease;
LGG	cis	rs8072100	0.817	rs11869940	chr17:45578435	T/A	cg25173405	chr17:45401733	C17orf57	0.47	8.1	0.35	4.98e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1580019	0.587	rs6951955	chr7:32548761	A/T	cg06627557	chr7:32535165	LSM5;AVL9	1.1	27.79	0.79	9.91e-101	Cognitive ability;
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-16.92	-0.62	2.43e-50	Skin colour saturation;
LGG	cis	rs9303401	0.614	rs62084387	chr17:57148027	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.87	13.64	0.54	7.61e-36	Cognitive test performance;
LGG	cis	rs7666738	0.830	rs13138051	chr4:99050367	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg16141378	chr3:129829833	LOC729375	0.37	8.56	0.37	1.64e-16	Systolic blood pressure;
LGG	cis	rs10540	1.000	rs61876340	chr11:495699	A/C	cg03352830	chr11:487213	PTDSS2	0.87	11.33	0.47	1.9e-26	Body mass index;
LGG	cis	rs8060686	0.641	rs113502835	chr16:68238965	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.84	-0.3	2.55e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg05044414	chr3:183734942	ABCC5	0.77	17.05	0.62	6.3e-51	Anterior chamber depth;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg09033563	chr22:24373618	LOC391322	-0.52	-8.92	-0.38	1.11e-17	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.935	rs11040438	chr11:49622521	G/A	cg03929089	chr4:120376271	NA	-1.02	-22.51	-0.72	2.45e-76	Height;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg26338869	chr17:61819248	STRADA	-0.57	-9.48	-0.4	1.37e-19	Prudent dietary pattern;
LGG	cis	rs4740619	0.619	rs1887667	chr9:16033109	T/G	cg14451791	chr9:16040625	NA	-0.44	-11.63	-0.48	1.33e-27	Body mass index;
LGG	cis	rs61931739	1.000	rs12427279	chr12:34025898	T/G	cg06521331	chr12:34319734	NA	0.4	6.78	0.3	3.65e-11	Morning vs. evening chronotype;
LGG	cis	rs4243830	0.850	rs13513	chr1:6585804	C/T	cg05709478	chr1:6581295	PLEKHG5	-0.46	-6.72	-0.3	5.31e-11	Body mass index;
LGG	trans	rs9409565	0.826	rs2769813	chr9:97151194	C/T	cg05679027	chr9:99775184	HIATL2	0.49	8.16	0.35	3.13e-15	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs6920965	0.507	rs9385388	chr6:126215296	C/T	cg05901451	chr6:126070800	HEY2	-0.44	-7.55	-0.33	2.28e-13	High light scatter reticulocyte count;
LGG	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg17376030	chr22:41985996	PMM1	0.47	7.89	0.34	2.27e-14	Vitiligo;
LGG	cis	rs12738007	0.967	rs7522989	chr1:29552958	C/A	cg11747820	chr1:29584023	PTPRU	-0.33	-7.54	-0.33	2.58e-13	Schizophrenia;
LGG	cis	rs11098499	0.955	rs1551	chr4:120158500	T/G	cg24375607	chr4:120327624	NA	0.62	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	cis	rs875971	0.862	rs4149461	chr7:65744732	T/C	cg11764359	chr7:65958608	NA	-0.73	-13.02	-0.52	3.13e-33	Aortic root size;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25495613	chr7:134895782	WDR91	0.41	6.69	0.3	6.45e-11	Cognitive performance;
LGG	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg26384229	chr12:38710491	ALG10B	0.74	14.75	0.57	1.17e-40	Morning vs. evening chronotype;
LGG	cis	rs7301016	0.895	rs11174514	chr12:62895074	G/C	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	trans	rs9467711	0.659	rs3823158	chr6:26463271	T/A	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.47	-0.44	3.57e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs735539	0.555	rs2818987	chr13:21304911	C/T	cg04906043	chr13:21280425	IL17D	-0.5	-7.92	-0.35	1.82e-14	Dental caries;
LGG	cis	rs1467026	0.584	rs9865381	chr3:12801685	C/T	cg24848339	chr3:12840334	CAND2	0.38	8.29	0.36	1.24e-15	P wave duration;
LGG	cis	rs503341	0.756	rs12286800	chr11:63593846	G/C	cg04935121	chr11:63775413	MACROD1	0.29	6.98	0.31	1.04e-11	Pulse pressure;
LGG	cis	rs4319547	0.656	rs7135419	chr12:122911861	T/A	cg05707623	chr12:122985044	ZCCHC8	-0.66	-9.7	-0.41	2.16e-20	Body mass index;
LGG	cis	rs1218582	0.772	rs4240874	chr1:154885779	C/T	cg16318349	chr1:154917307	PBXIP1	-0.27	-7.45	-0.33	4.52e-13	Prostate cancer;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	trans	rs2548003	1.000	rs2548003	chr5:28747323	G/C	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs4820539	1.000	rs885965	chr22:23461425	A/G	cg21100191	chr22:23484243	RTDR1	0.96	20.86	0.7	1.23e-68	Bone mineral density;
LGG	cis	rs10892173	0.566	rs12364667	chr11:117675286	A/C	cg21640587	chr11:117668038	DSCAML1	0.89	14.54	0.56	1.02e-39	Myopia;
LGG	cis	rs58688157	0.924	rs35865896	chr11:584591	A/G	cg16486109	chr11:613632	IRF7	0.41	7.19	0.32	2.55e-12	Systemic lupus erythematosus;
LGG	cis	rs4631830	0.657	rs2611502	chr10:51500301	A/G	cg16070123	chr10:51489643	NA	-0.43	-7.79	-0.34	4.35e-14	Prostate-specific antigen levels;
LGG	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg13047869	chr3:10149882	C3orf24	0.51	8.08	0.35	5.57e-15	Alzheimer's disease;
LGG	cis	rs1552244	0.608	rs6764807	chr3:9998803	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.59	-10.61	-0.44	1.05e-23	Alzheimer's disease;
LGG	cis	rs7618915	0.547	rs12496476	chr3:52708737	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.35	-0.43	9.73e-23	Bipolar disorder;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg17178900	chr1:205818956	PM20D1	-0.58	-12.77	-0.51	3.4e-32	Menarche (age at onset);
LGG	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg11984989	chr7:158649758	WDR60	-0.97	-20.24	-0.69	1.07e-65	Height;
LGG	cis	rs12464559	0.649	rs3922996	chr2:152609668	A/G	cg01189475	chr2:152685088	ARL5A	0.75	6.71	0.3	5.77e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs798554	0.757	rs1713919	chr7:2864706	C/A	cg04166393	chr7:2884313	GNA12	0.45	8.39	0.36	6.12e-16	Height;
LGG	cis	rs8114671	0.967	rs6060285	chr20:33770487	G/T	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs7582180	0.606	rs12618908	chr2:100947026	A/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7236492	0.748	rs11664153	chr18:77195813	G/A	cg15532942	chr18:77220712	NFATC1	0.47	7.67	0.34	1.03e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs643506	0.874	rs618421	chr11:111648809	T/C	cg09085632	chr11:111637200	PPP2R1B	0.44	7.01	0.31	8.22e-12	Breast cancer;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg24829409	chr8:58192753	C8orf71	-0.65	-8.38	-0.36	6.5e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs114410095	chr4:119731110	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	trans	rs75804782	0.625	rs56411186	chr2:239466753	A/C	cg01134436	chr17:81009848	B3GNTL1	0.75	7.92	0.35	1.73e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.54	-0.74	3.67e-81	Primary sclerosing cholangitis;
LGG	cis	rs2213920	0.569	rs4979524	chr9:118177617	C/G	cg13918206	chr9:118159781	DEC1	0.52	7.75	0.34	5.93e-14	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25427524	chr10:38739819	LOC399744	-0.66	-12.32	-0.5	2.35e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14893161	chr1:205819251	PM20D1	0.5	7.97	0.35	1.25e-14	Parkinson's disease;
LGG	cis	rs6952808	0.717	rs12534679	chr7:1926745	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.88	-0.54	6.96e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs7017697	0.507	rs3816246	chr8:19682545	A/G	cg03894339	chr8:19674705	INTS10	-0.6	-8.64	-0.37	9.39e-17	Breast cancer;
LGG	cis	rs6604026	0.883	rs7514280	chr1:93320869	C/T	cg22128645	chr1:93425802	FAM69A	-0.38	-7.27	-0.32	1.56e-12	Multiple sclerosis;
LGG	cis	rs986417	0.792	rs4901990	chr14:61015474	C/T	cg27398547	chr14:60952738	C14orf39	-0.76	-7.3	-0.32	1.24e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs12580194	0.556	rs7955088	chr12:55732963	G/T	cg19537932	chr12:55886519	OR6C68	-0.52	-9.41	-0.4	2.3e-19	Cancer;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg08707078	chr7:23720292	C7orf46	0.43	9.79	0.41	1.11e-20	Schizophrenia;
LGG	trans	rs116095464	0.558	rs10052012	chr5:231908	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.25	-0.36	1.64e-15	Breast cancer;
LGG	cis	rs737008	0.959	rs11865598	chr16:11403432	T/C	cg00044050	chr16:11439710	C16orf75	0.53	7.8	0.34	4.01e-14	Obesity-related traits;
LGG	cis	rs7444	0.825	rs2256609	chr22:21925017	A/G	cg05046821	chr22:21984468	YDJC	-0.4	-7.14	-0.31	3.7e-12	Systemic lupus erythematosus;
LGG	cis	rs7319311	0.748	rs9515198	chr13:111029065	C/T	cg06243866	chr13:111019493	COL4A2	0.49	7.91	0.34	1.93e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	0.655	rs7184597	chr16:28921809	T/C	cg07382826	chr16:28625726	SULT1A1	-0.35	-6.79	-0.3	3.38e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2073300	0.609	rs12625164	chr20:23354269	T/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17030434	1.000	rs12646124	chr4:154718084	G/T	cg14289246	chr4:154710475	SFRP2	-0.72	-11.03	-0.46	2.85e-25	Electrocardiographic conduction measures;
LGG	cis	rs769267	1.000	rs2301669	chr19:19453560	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.41	-0.36	5.1e-16	Tonsillectomy;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.62e-12	Lung cancer;
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.25	-0.43	2.44e-22	IgG glycosylation;
LGG	cis	rs6735179	0.609	rs13405140	chr2:1759020	C/T	cg20570797	chr2:1712800	PXDN	-0.46	-8.28	-0.36	1.29e-15	Response to antipsychotic treatment;
LGG	cis	rs9303401	0.614	rs3087762	chr17:56568680	C/T	cg25039879	chr17:56429692	SUPT4H1	0.64	9.0	0.39	5.91e-18	Cognitive test performance;
LGG	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.35	0.36	8.12e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3768617	0.510	rs10797852	chr1:183101302	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.29	0.4	5.84e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7829975	0.624	rs7823056	chr8:8382705	A/G	cg08975724	chr8:8085496	FLJ10661	0.44	8.58	0.37	1.5e-16	Mood instability;
LGG	cis	rs638893	1.000	rs638893	chr11:118698537	G/A	cg22253036	chr11:118662786	DDX6	0.43	7.31	0.32	1.19e-12	Vitiligo;
LGG	cis	rs9875589	0.509	rs6768383	chr3:14076952	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.28	0.46	3.17e-26	Ovarian reserve;
LGG	cis	rs10492096	0.945	rs2041386	chr12:6562538	C/T	cg13857086	chr12:6580257	VAMP1	0.64	9.08	0.39	3.03e-18	Hip geometry;
LGG	cis	rs9486719	1.000	rs2472880	chr6:96860130	G/A	cg06623918	chr6:96969491	KIAA0776	0.76	10.64	0.44	8.5e-24	Migraine;Coronary artery disease;
LGG	cis	rs6500395	1.000	rs6500402	chr16:48687354	C/T	cg04672837	chr16:48644449	N4BP1	0.54	8.92	0.38	1.06e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs11123761	chr2:99705903	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.41	0.63	1.38e-52	Chronic sinus infection;
LGG	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg13798912	chr7:905769	UNC84A	-0.57	-7.1	-0.31	4.75e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	1.000	rs113379801	chr8:58173686	C/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg10792982	chr14:105748885	BRF1	0.67	14.13	0.55	6.2e-38	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7107174	1.000	rs2510036	chr11:77966788	G/T	cg02023728	chr11:77925099	USP35	0.44	7.54	0.33	2.53e-13	Testicular germ cell tumor;
LGG	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg00071950	chr4:10020882	SLC2A9	-0.36	-7.55	-0.33	2.36e-13	Bone mineral density;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.53	0.37	2.02e-16	Skin colour saturation;
LGG	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg04731861	chr2:219085781	ARPC2	-0.51	-13.07	-0.52	1.85e-33	Colorectal cancer;
LGG	cis	rs12464483	0.524	rs4952172	chr2:30888286	A/G	cg07150166	chr2:30669952	LCLAT1	-0.58	-8.13	-0.35	4e-15	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs3096299	0.685	rs4785571	chr16:89565169	A/G	cg08392591	chr16:89556376	ANKRD11	0.53	8.32	0.36	9.87e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs4730250	0.708	rs74983157	chr7:106823951	A/G	cg02696742	chr7:106810147	HBP1	-0.77	-11.12	-0.46	1.31e-25	Osteoarthritis;
LGG	cis	rs9400467	0.506	rs12214933	chr6:111558006	A/G	cg15721981	chr6:111408429	SLC16A10	0.57	6.7	0.3	6.2e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7681440	0.904	rs1372521	chr4:90765223	G/A	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs61931739	0.500	rs7306053	chr12:34510848	T/G	cg06521331	chr12:34319734	NA	-0.55	-9.96	-0.42	2.63e-21	Morning vs. evening chronotype;
LGG	cis	rs9303280	0.806	rs10852935	chr17:38031674	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.17	-0.32	3.04e-12	Self-reported allergy;
LGG	cis	rs9513627	0.920	rs6491510	chr13:100171447	C/T	cg15490075	chr13:100150979	NA	0.63	6.74	0.3	4.69e-11	Obesity-related traits;
LGG	cis	rs4595586	0.525	rs11612680	chr12:39344443	A/G	cg13010199	chr12:38710504	ALG10B	0.48	8.61	0.37	1.14e-16	Morning vs. evening chronotype;
LGG	cis	rs2708240	0.577	rs1177007	chr7:147546371	G/A	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.3	-0.32	1.26e-12	QT interval (drug interaction);
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg04267008	chr7:1944627	MAD1L1	-0.65	-11.49	-0.47	4.89e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	0.935	rs4948524	chr10:60351224	C/A	cg07615347	chr10:60278583	BICC1	0.62	17.16	0.62	1.95e-51	Refractive error;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7166081	0.950	rs28645602	chr15:67531323	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.8	-0.3	3.15e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.28	-0.43	1.85e-22	Intelligence (multi-trait analysis);
LGG	cis	rs3784262	1.000	rs3204689	chr15:58246802	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.38	-8.35	-0.36	7.69e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs1005224	0.963	rs11626062	chr14:76136329	T/C	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.42	-6.96	-0.31	1.15e-11	Large artery stroke;
LGG	cis	rs12545109	0.775	rs10093388	chr8:57318799	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.82	-0.3	2.78e-11	Obesity-related traits;
LGG	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg25358565	chr5:93447407	FAM172A	1.25	14.05	0.55	1.39e-37	Diabetic retinopathy;
LGG	cis	rs7811142	1.000	rs28490152	chr7:100020982	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs2439831	1.000	rs7173487	chr15:43750239	A/G	cg15269541	chr15:43626905	ADAL	-0.42	-6.96	-0.31	1.19e-11	Lung cancer in ever smokers;
LGG	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-9.01	-0.39	5.39e-18	Chronic sinus infection;
LGG	cis	rs9467160	1.000	rs9467161	chr6:24441963	C/T	cg20631270	chr6:24437470	GPLD1	0.53	7.69	0.34	8.89e-14	Liver enzyme levels;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.35	6.81	0.3	2.99e-11	Schizophrenia;
LGG	trans	rs9354308	0.764	rs9351538	chr6:66607743	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.65	-0.3	8.26e-11	Metabolite levels;
LGG	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg11502198	chr6:26597334	ABT1	0.55	9.49	0.4	1.23e-19	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.46	-7.35	-0.32	8.91e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg03115019	chr17:80708279	FN3K	-0.39	-7.44	-0.33	4.92e-13	Glycated hemoglobin levels;
LGG	cis	rs11203032	0.831	rs11203027	chr10:90956290	T/A	cg16672925	chr10:90967113	CH25H	0.8	11.38	0.47	1.23e-26	Heart failure;
LGG	cis	rs559928	0.549	rs57831436	chr11:64007297	C/T	cg05555928	chr11:63887634	MACROD1	-0.66	-8.76	-0.38	3.82e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9309473	0.632	rs6546825	chr2:73592253	G/C	cg20560298	chr2:73613845	ALMS1	-0.49	-8.82	-0.38	2.26e-17	Metabolite levels;
LGG	cis	rs10504229	0.679	rs72649109	chr8:58031274	A/T	cg20607798	chr8:58055168	NA	0.69	7.8	0.34	4.28e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg08742575	chr21:47604166	C21orf56	0.49	8.48	0.37	3.15e-16	Testicular germ cell tumor;
LGG	cis	rs2072732	0.861	rs56088946	chr1:2961370	T/C	cg08733933	chr1:2954429	NA	-0.46	-8.7	-0.37	5.88e-17	Plateletcrit;
LGG	cis	rs7084402	0.967	rs7897298	chr10:60274606	T/C	cg09696939	chr10:60272079	BICC1	0.36	7.02	0.31	7.71e-12	Refractive error;
LGG	cis	rs4132509	0.793	rs7538011	chr1:243703344	A/G	cg21452805	chr1:244014465	NA	0.86	8.08	0.35	5.83e-15	RR interval (heart rate);
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	9.94	0.42	3.07e-21	Longevity;
LGG	cis	rs10504229	1.000	rs67546820	chr8:58168567	G/A	cg11062466	chr8:58055876	NA	0.5	8.55	0.37	1.81e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.645	rs847627	chr11:49927177	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs490234	0.676	rs13299008	chr9:128213966	T/G	cg14078157	chr9:128172775	NA	-0.53	-10.07	-0.42	1.05e-21	Mean arterial pressure;
LGG	cis	rs12580194	0.593	rs61957924	chr12:55744100	T/C	cg19537932	chr12:55886519	OR6C68	-0.52	-9.41	-0.4	2.27e-19	Cancer;
LGG	cis	rs3096299	0.719	rs12934708	chr16:89523790	C/T	cg06640241	chr16:89574553	SPG7	0.87	16.26	0.6	2.37e-47	Multiple myeloma (IgH translocation);
LGG	cis	rs62400317	0.859	rs12201555	chr6:45294400	T/A	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.6e-22	Total body bone mineral density;
LGG	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg14949292	chr17:78079608	GAA	-0.26	-6.72	-0.3	5.32e-11	Yeast infection;
LGG	cis	rs1451375	0.572	rs12666409	chr7:50634976	A/T	cg14593290	chr7:50529359	DDC	-0.48	-8.33	-0.36	9.38e-16	Malaria;
LGG	cis	rs16937	0.686	rs3851285	chr1:205155753	C/T	cg00889227	chr1:205173544	DSTYK	-0.31	-7.73	-0.34	6.75e-14	Schizophrenia;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg07343612	chr16:622815	PIGQ	-0.76	-15.37	-0.58	2.32e-43	Height;
LGG	cis	rs17401966	0.898	rs12117635	chr1:10317445	C/T	cg19773385	chr1:10388646	KIF1B	-0.49	-10.82	-0.45	1.78e-24	Hepatocellular carcinoma;
LGG	cis	rs10752881	0.933	rs2027086	chr1:183057933	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.38e-17	Colorectal cancer;
LGG	cis	rs6500602	0.727	rs10451135	chr16:4580214	T/C	cg19168338	chr16:4465731	CORO7	-0.73	-13.43	-0.53	5.61e-35	Schizophrenia;
LGG	cis	rs2735413	0.564	rs80225322	chr16:78095753	C/A	cg04733911	chr16:78082701	NA	0.63	8.96	0.38	7.77e-18	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs7666738	0.791	rs4699324	chr4:98967496	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12210905	1.000	rs9348752	chr6:27075483	T/C	cg23155468	chr6:27110703	HIST1H2BK	-0.5	-6.8	-0.3	3.23e-11	Hip circumference adjusted for BMI;
LGG	cis	rs79349575	0.783	rs12602933	chr17:47029280	G/C	cg22482690	chr17:47019901	SNF8	0.35	6.88	0.3	1.89e-11	Type 2 diabetes;
LGG	cis	rs2274273	0.600	rs10131730	chr14:55840092	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.34	0.5	1.89e-30	Protein biomarker;
LGG	cis	rs883565	0.502	rs9839582	chr3:38943120	G/A	cg01426195	chr3:39028469	NA	0.59	12.54	0.5	3.05e-31	Handedness;
LGG	cis	rs12701220	0.655	rs7784403	chr7:1153077	G/A	cg02733842	chr7:1102375	C7orf50	-0.43	-7.23	-0.32	2.08e-12	Bronchopulmonary dysplasia;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.34	0.53	1.41e-34	Obesity-related traits;
LGG	cis	rs6951245	0.554	rs10270249	chr7:1151886	G/T	cg24642844	chr7:1081250	C7orf50	-0.45	-8.44	-0.37	4.21e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7493	0.853	rs17166879	chr7:95053415	A/G	cg17330251	chr7:94953956	PON1	-0.43	-8.33	-0.36	9.41e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs1957429	0.808	rs6573580	chr14:65331766	C/G	cg23373153	chr14:65346875	NA	1.05	13.48	0.53	3.76e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.08	0.31	5.36e-12	Prudent dietary pattern;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg00800038	chr16:89945340	TCF25	-0.61	-8.5	-0.37	2.67e-16	Skin colour saturation;
LGG	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg16060761	chr17:80687452	NA	-0.45	-7.86	-0.34	2.66e-14	Glycated hemoglobin levels;
LGG	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg05163923	chr11:71159392	DHCR7	-0.58	-8.46	-0.37	3.52e-16	Vitamin D levels;
LGG	cis	rs2273669	0.667	rs12196024	chr6:109302258	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	2.97e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10267417	0.603	rs12540185	chr7:19881578	G/T	cg05791153	chr7:19748676	TWISTNB	0.64	8.16	0.35	3.09e-15	Night sleep phenotypes;
LGG	cis	rs11148252	0.538	rs2274202	chr13:52722798	C/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.05	-0.39	3.97e-18	Lewy body disease;
LGG	trans	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg10756647	chr7:56101905	PSPH	0.82	10.17	0.43	4.7e-22	Diabetic kidney disease;
LGG	cis	rs1728785	0.901	rs7194664	chr16:68643313	T/C	cg02972257	chr16:68554789	NA	-0.53	-7.81	-0.34	3.85e-14	Ulcerative colitis;
LGG	trans	rs17685	0.725	rs6947068	chr7:75662056	T/C	cg19862616	chr7:65841803	NCRNA00174	-1.05	-25.01	-0.76	5.55e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6121246	0.909	rs6058460	chr20:30363071	G/A	cg13852791	chr20:30311386	BCL2L1	0.78	12.7	0.51	6.19e-32	Mean corpuscular hemoglobin;
LGG	cis	rs78456975	1.000	rs10205916	chr2:1558451	A/T	cg26248373	chr2:1572462	NA	0.68	8.67	0.37	7.07e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs870825	0.616	rs4623061	chr4:185643161	A/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs4417704	0.551	rs6753109	chr2:241877597	C/T	cg05025159	chr2:241905733	NA	-0.48	-9.77	-0.41	1.25e-20	Joint mobility (Beighton score);
LGG	cis	rs6951245	0.638	rs74976697	chr7:1160505	C/T	cg04025307	chr7:1156635	C7orf50	0.76	10.98	0.45	4.42e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6840360	0.615	rs7669465	chr4:152609289	C/T	cg22705602	chr4:152727874	NA	-0.38	-9.53	-0.4	9.18e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10799590	1.000	rs2786558	chr1:224838004	G/T	cg01808320	chr1:224927238	CNIH3	-0.4	-7.13	-0.31	3.78e-12	Opioid dependence;
LGG	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.08	0.35	5.74e-15	Colorectal cancer;
LGG	trans	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg21775007	chr8:11205619	TDH	0.44	7.17	0.32	2.93e-12	Joint mobility (Beighton score);
LGG	cis	rs6076065	0.775	rs6083114	chr20:23379528	G/T	cg11657817	chr20:23433608	CST11	0.4	8.2	0.36	2.39e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs769267	0.930	rs4808203	chr19:19568659	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.89	0.34	2.19e-14	Tonsillectomy;
LGG	cis	rs2013441	0.932	rs3850785	chr17:20185248	A/G	cg09818912	chr17:20140352	CYTSB	0.29	6.65	0.3	8.47e-11	Obesity-related traits;
LGG	cis	rs9910055	0.762	rs184478	chr17:42209751	C/G	cg19774624	chr17:42201019	HDAC5	0.83	16.48	0.61	2.28e-48	Total body bone mineral density;
LGG	trans	rs7829975	0.774	rs1039915	chr8:8679614	T/C	cg21775007	chr8:11205619	TDH	0.44	7.18	0.32	2.75e-12	Mood instability;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs3204270	0.543	rs34034499	chr17:79638568	G/C	cg18367735	chr17:79674897	NA	0.52	7.38	0.32	7.54e-13	Dental caries;
LGG	cis	rs2046867	0.862	rs11922180	chr3:72836119	A/G	cg25664220	chr3:72788482	NA	0.34	9.25	0.4	8.06e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs877282	0.898	rs11253352	chr10:766598	C/A	cg22713356	chr15:30763199	NA	0.52	7.83	0.34	3.29e-14	Uric acid levels;
LGG	cis	rs3858526	0.628	rs4237762	chr11:5956626	A/C	cg05234568	chr11:5960015	NA	-0.69	-13.15	-0.52	9.12e-34	DNA methylation (variation);
LGG	cis	rs3733418	0.860	rs869867	chr4:165930747	C/G	cg10852876	chr4:165953100	TRIM60	-0.5	-6.82	-0.3	2.92e-11	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1649084	chr10:60292117	T/A	cg07615347	chr10:60278583	BICC1	0.63	18.4	0.65	3.62e-57	Refractive error;
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg16482183	chr6:26056742	HIST1H1C	0.54	9.52	0.4	9.66e-20	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09060823	chr12:56862504	SPRYD4	0.48	7.67	0.34	1.05e-13	Gut microbiome composition (summer);
LGG	cis	rs657075	0.639	rs3792885	chr5:131652248	T/A	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.1e-21	Rheumatoid arthritis;
LGG	cis	rs798554	0.679	rs2533877	chr7:2882421	G/A	cg19717773	chr7:2847554	GNA12	-0.31	-6.67	-0.3	7.25e-11	Height;
LGG	cis	rs834603	0.575	rs1534137	chr7:47482719	T/C	cg23694490	chr7:47445681	TNS3	-0.41	-11.89	-0.48	1.24e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24675879	chr17:28444056	MIR423;CCDC55	0.48	8.38	0.36	6.52e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs7811142	1.000	rs7811142	chr7:100065443	A/T	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs10504130	0.569	rs35509250	chr8:52687553	G/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.72	-0.3	5.34e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs283228	0.617	rs577503	chr6:101751860	G/A	cg27451362	chr6:101846650	GRIK2	0.86	13.52	0.53	2.35e-35	Coenzyme Q10 levels;
LGG	cis	rs4969178	0.965	rs56658017	chr17:76396164	G/A	cg02836325	chr17:76403955	PGS1	-0.72	-14.45	-0.56	2.45e-39	HDL cholesterol levels;
LGG	cis	rs2576037	0.526	rs2571026	chr18:44561795	C/T	cg19077165	chr18:44547161	KATNAL2	0.59	11.0	0.46	3.83e-25	Personality dimensions;
LGG	cis	rs9863	0.931	rs2178663	chr12:124433905	C/T	cg13487667	chr12:124434373	CCDC92	-0.38	-7.45	-0.33	4.65e-13	White blood cell count;
LGG	cis	rs6459804	0.967	rs4289696	chr7:157508399	C/T	cg15733309	chr7:157513707	PTPRN2	0.62	14.87	0.57	3.68e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg18681998	chr4:17616180	MED28	0.87	19.15	0.66	1.22e-60	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11187427	chr7:73082056	VPS37D	0.44	6.92	0.31	1.55e-11	Gut microbiome composition (summer);
LGG	cis	rs9910055	0.762	rs6503489	chr17:42246289	G/A	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	8.91	0.38	1.19e-17	Total body bone mineral density;
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.59	0.33	1.81e-13	Morning vs. evening chronotype;
LGG	cis	rs3733585	0.673	rs4467563	chr4:9953460	A/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7923452	0.938	rs753173	chr10:30778738	T/C	cg25182066	chr10:30743637	MAP3K8	0.45	6.73	0.3	4.88e-11	Itch intensity from mosquito bite;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26379672	chr3:4534954	ITPR1	0.46	6.68	0.3	6.86e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1949733	0.523	rs16842557	chr4:8543985	C/T	cg13073564	chr4:8508604	NA	0.42	7.23	0.32	2.07e-12	Response to antineoplastic agents;
LGG	cis	rs1008375	1.000	rs9291659	chr4:17662360	A/C	cg18681998	chr4:17616180	MED28	0.83	18.49	0.65	1.39e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05051957	chr8:141522459	CHRAC1	0.48	7.22	0.32	2.14e-12	Gut microbiome composition (summer);
LGG	cis	rs9810089	0.527	rs838199	chr3:135950090	T/C	cg12473912	chr3:136751656	NA	0.47	8.32	0.36	1e-15	Gestational age at birth (child effect);
LGG	cis	rs10089	0.909	rs7732599	chr5:127370421	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.73	11.47	0.47	5.79e-27	Ileal carcinoids;
LGG	cis	rs35306767	0.855	rs11253465	chr10:897208	A/C	cg26597838	chr10:835615	NA	0.74	10.06	0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19954613	chr22:22020219	PPIL2	0.39	6.92	0.31	1.54e-11	Obesity-related traits;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg09507928	chr5:140027484	IK;NDUFA2	0.41	6.98	0.31	1.01e-11	Lung adenocarcinoma;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.79e-21	Aortic root size;
LGG	cis	rs35740288	0.770	rs36044792	chr15:86146551	A/G	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs3806933	0.522	rs34962120	chr5:110446091	G/A	cg04022379	chr5:110408740	TSLP	0.48	8.0	0.35	1.02e-14	Eosinophilic esophagitis;
LGG	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg11279151	chr3:101281821	RG9MTD1	-0.4	-6.93	-0.31	1.39e-11	Colorectal cancer;
LGG	cis	rs2635047	0.783	rs9952447	chr18:44784700	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.62	0.33	1.41e-13	Educational attainment;
LGG	cis	rs16854884	0.770	rs920158	chr3:143799289	A/T	cg06585982	chr3:143692056	C3orf58	0.57	9.52	0.4	9.85e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs7208859	0.623	rs9911173	chr17:29154750	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	9.6	0.41	4.97e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4563143	0.675	rs56322221	chr19:29270349	A/T	cg03161606	chr19:29218774	NA	0.69	10.56	0.44	1.73e-23	Methadone dose in opioid dependence;
LGG	cis	rs736801	0.836	rs2522052	chr5:131798487	C/T	cg21138405	chr5:131827807	IRF1	0.28	6.73	0.3	5.12e-11	Breast cancer;Mosquito bite size;
LGG	cis	rs28595532	0.920	rs116091383	chr4:119635518	A/G	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs796364	0.568	rs11890894	chr2:201072055	C/T	cg17644776	chr2:200775616	C2orf69	0.58	8.68	0.37	6.84e-17	Schizophrenia;
LGG	cis	rs2204008	0.744	rs12099650	chr12:38317140	C/G	cg13010199	chr12:38710504	ALG10B	0.68	13.7	0.54	4.4e-36	Bladder cancer;
LGG	cis	rs67311347	1.000	rs7631893	chr3:40440869	C/T	cg24209194	chr3:40518798	ZNF619	0.42	6.9	0.31	1.73e-11	Renal cell carcinoma;
LGG	trans	rs853679	0.607	rs67998226	chr6:28238059	T/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	trans	rs12517041	0.935	rs71611217	chr5:23270864	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-9.02	-0.39	5.04e-18	Calcium levels;
LGG	cis	rs6748734	0.948	rs9973366	chr2:241838151	T/C	cg26818257	chr2:241905806	NA	0.38	7.41	0.33	5.85e-13	Urinary metabolites;
LGG	cis	rs9309473	1.000	rs7583255	chr2:73797996	T/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs80282103	0.618	rs2279256	chr10:1132852	G/A	cg08668510	chr10:1095578	IDI1	0.8	7.67	0.34	1.05e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs1577917	0.958	rs34230196	chr6:86526022	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs12477438	0.765	rs2309454	chr2:99595418	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg15268244	chr15:77196840	NA	-0.32	-7.04	-0.31	6.82e-12	Blood metabolite levels;
LGG	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg13607699	chr17:42295918	UBTF	0.9	18.79	0.66	5.65e-59	Total body bone mineral density;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.22e-12	Lung cancer;
LGG	cis	rs972578	0.715	rs12166809	chr22:43287290	C/T	cg01576275	chr22:43409880	NA	-0.22	-6.78	-0.3	3.6e-11	Mean platelet volume;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg04139300	chr20:40247070	CHD6	0.43	6.7	0.3	6.22e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2072732	0.861	rs12042403	chr1:2950872	T/C	cg08733933	chr1:2954429	NA	-0.39	-8.69	-0.37	6.32e-17	Plateletcrit;
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.31	7.03e-12	Bipolar disorder;
LGG	cis	rs765787	0.530	rs4238377	chr15:45541981	A/G	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs12220238	1.000	rs11000890	chr10:75904073	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.83	11.5	0.47	4.23e-27	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.65	0.33	1.18e-13	Lung cancer;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.67	-0.37	7.14e-17	Lung cancer;
LGG	cis	rs9916302	0.800	rs8081220	chr17:37473157	A/C	cg00129232	chr17:37814104	STARD3	0.62	11.57	0.47	2.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2816316	1.000	rs1323297	chr1:192537400	T/C	cg10861751	chr1:192544716	RGS1	0.34	6.91	0.31	1.62e-11	Celiac disease;
LGG	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg14227996	chr4:17616232	MED28	-0.52	-7.13	-0.31	3.76e-12	Opioid sensitivity;
LGG	cis	rs4356203	0.870	rs214919	chr11:17238704	C/T	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.29	-0.32	1.39e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg24247370	chr13:99142703	STK24	-0.43	-7.8	-0.34	4.2e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs2980439	0.557	rs2921056	chr8:8319182	T/C	cg02002194	chr4:3960332	NA	-0.46	-8.94	-0.38	9.24e-18	Neuroticism;
LGG	cis	rs10876993	0.893	rs4760168	chr12:58087737	T/G	cg18357645	chr12:58087776	OS9	0.72	13.05	0.52	2.39e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs6546324	0.625	rs2861645	chr2:67800338	T/A	cg18237512	chr2:67827392	NA	-0.38	-6.75	-0.3	4.47e-11	Endometriosis;
LGG	cis	rs9291683	0.595	rs11722930	chr4:10035454	G/A	cg11266682	chr4:10021025	SLC2A9	0.55	11.17	0.46	7.85e-26	Bone mineral density;
LGG	cis	rs975722	0.646	rs43029	chr7:117105755	T/C	cg10524701	chr7:117356490	CTTNBP2	0.44	9.88	0.42	5.16e-21	Coronary artery disease;
LGG	cis	rs4665809	0.556	rs10221814	chr2:26442759	C/T	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs9463078	0.899	rs9395069	chr6:45128521	A/G	cg25276700	chr6:44698697	NA	-0.38	-7.84	-0.34	3.2e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs10504229	0.724	rs58715581	chr8:58134568	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10865541	0.837	rs4482520	chr2:3447827	T/G	cg11642891	chr2:3452563	TTC15	-0.4	-7.66	-0.34	1.11e-13	Obesity-related traits;
LGG	cis	rs9393692	0.905	rs7761298	chr6:26278436	C/T	cg09303159	chr6:26284866	NA	0.31	6.95	0.31	1.23e-11	Educational attainment;
LGG	cis	rs271738	0.640	rs271760	chr1:234680657	C/T	cg05133706	chr1:234667230	NA	-0.32	-7.38	-0.32	7.62e-13	Bipolar disorder;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.3	0.55	1.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs853679	0.542	rs34131763	chr6:28075000	A/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs7084402	0.967	rs1649023	chr10:60285820	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.45	-0.33	4.51e-13	Refractive error;
LGG	cis	rs1659258	0.568	rs1271103	chr2:88596890	T/C	cg00685853	chr2:88648947	NA	-0.44	-6.68	-0.3	6.72e-11	Visceral fat;
LGG	cis	rs6546324	0.625	rs2902007	chr2:67795462	A/T	cg18237512	chr2:67827392	NA	-0.41	-7.39	-0.32	6.72e-13	Endometriosis;
LGG	cis	rs8114671	0.562	rs4911163	chr20:33470694	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.15	0.32	3.3e-12	Height;
LGG	cis	rs6500395	1.000	rs28577888	chr16:48673281	T/G	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs10224872	chr7:65759773	T/A	cg18252515	chr7:66147081	NA	0.42	7.1	0.31	4.59e-12	Aortic root size;
LGG	cis	rs9878978	0.754	rs6787193	chr3:2436134	T/G	cg21928760	chr3:2462534	CNTN4	0.39	7.8	0.34	4.21e-14	Blood pressure (smoking interaction);
LGG	cis	rs11683229	1.000	rs11683229	chr2:63596836	A/G	cg19915305	chr2:64069682	UGP2	-0.56	-8.11	-0.35	4.59e-15	Protein quantitative trait loci;
LGG	cis	rs12477438	0.798	rs10167015	chr2:99570707	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg26354017	chr1:205819088	PM20D1	0.87	20.73	0.69	4.98e-68	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.82e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12472274	0.646	rs2305171	chr2:239097140	G/A	cg17459225	chr2:239074497	NA	0.75	10.79	0.45	2.26e-24	Phospholipid levels (plasma);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24075738	chr3:50605156	C3orf18	0.48	7.32	0.32	1.14e-12	Gut microbiome composition (summer);
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg12288994	chr5:1860383	NA	0.77	15.3	0.58	4.86e-43	Cardiovascular disease risk factors;
LGG	cis	rs4671458	0.626	rs2278718	chr2:63815801	A/C	cg17519650	chr2:63277830	OTX1	-0.53	-7.33	-0.32	1.01e-12	Subjective well-being;
LGG	cis	rs7208859	0.623	rs426434	chr17:28925353	C/T	cg13385521	chr17:29058706	SUZ12P	0.9	10.35	0.43	1.03e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs41271473	0.687	rs12078883	chr1:228875567	C/T	cg00850481	chr1:228891306	NA	-0.57	-11.43	-0.47	8.07e-27	Chronic lymphocytic leukemia;
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg27471124	chr11:109292789	C11orf87	-0.56	-10.78	-0.45	2.56e-24	Schizophrenia;
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg24101359	chr6:42928495	GNMT	0.53	15.19	0.58	1.37e-42	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs17270561	0.636	rs6456698	chr6:25741664	A/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	cis	rs1506636	0.924	rs2402668	chr7:123296605	T/A	cg03229431	chr7:123269106	ASB15	-0.74	-18.23	-0.65	2.27e-56	Plateletcrit;Platelet count;
LGG	cis	rs9611565	0.512	rs4822052	chr22:42193741	G/A	cg03806693	chr22:41940476	POLR3H	-0.97	-16.1	-0.6	1.24e-46	Vitiligo;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-12.64	-0.51	1.13e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1941023	0.503	rs10792269	chr11:60117126	C/T	cg08716584	chr11:60157161	MS4A7	-0.42	-8.39	-0.36	6.13e-16	Congenital heart disease (maternal effect);
LGG	cis	rs8133932	0.906	rs1059010	chr21:47124833	C/T	cg11214348	chr21:47283868	PCBP3	-0.43	-7.19	-0.32	2.64e-12	Schizophrenia;
LGG	cis	rs17767392	1.000	rs34748537	chr14:71831683	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.98e-19	Mitral valve prolapse;
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg17554472	chr22:41940697	POLR3H	-0.5	-7.1	-0.31	4.72e-12	Vitiligo;
LGG	cis	rs10504229	1.000	rs73607874	chr8:58173433	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2693698	0.649	rs1257437	chr14:99675579	G/A	cg07440398	chr14:99712966	BCL11B	0.57	11.88	0.48	1.3e-28	Schizophrenia;
LGG	trans	rs2204008	0.720	rs11180923	chr12:38255172	A/T	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06470251	chr20:60548479	NA	0.41	7.09	0.31	5.05e-12	Body mass index;
LGG	cis	rs72949976	1.000	rs72949976	chr2:214034104	C/T	cg08319019	chr2:214017104	IKZF2	-0.61	-10.07	-0.42	1.06e-21	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg04709771	chr16:646395	RAB40C	0.37	6.84	0.3	2.57e-11	Height;
LGG	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.46	-6.66	-0.3	7.69e-11	Schizophrenia;
LGG	cis	rs36051895	0.664	rs10117565	chr9:5094461	G/A	cg02405213	chr9:5042618	JAK2	-0.79	-14.53	-0.56	1.16e-39	Pediatric autoimmune diseases;
LGG	cis	rs6977660	0.943	rs9639334	chr7:19838810	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.66	0.37	7.78e-17	Thyroid stimulating hormone;
LGG	cis	rs8005677	1.000	rs4982706	chr14:23381697	C/T	cg01529538	chr14:23388837	RBM23	0.37	6.76	0.3	4.13e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs11112613	0.713	rs12580741	chr12:105941328	A/G	cg03607813	chr12:105948248	NA	-0.53	-8.88	-0.38	1.54e-17	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-7.11	-0.31	4.29e-12	Lung cancer;
LGG	trans	rs1814175	0.715	rs7479622	chr11:49673340	T/G	cg15704280	chr7:45808275	SEPT13	-1.05	-23.83	-0.74	1.72e-82	Height;
LGG	cis	rs933688	1.000	rs7720132	chr5:90745105	T/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs1707322	0.721	rs28501477	chr1:46199084	A/G	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs888405	0.588	rs222336	chr3:64232104	A/C	cg25818214	chr3:64211155	PRICKLE2	-0.4	-6.78	-0.3	3.78e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.43	9.19	0.39	1.33e-18	Schizophrenia;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.06	-0.31	6.12e-12	Bipolar disorder;
LGG	cis	rs17534004	0.920	rs71436421	chr13:31473081	G/A	cg00367615	chr13:31480979	C13orf33	0.35	7.02	0.31	7.87e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg27411982	chr8:10470053	RP1L1	0.42	7.52	0.33	2.84e-13	Mood instability;
LGG	cis	rs701145	0.585	rs1542254	chr3:153864296	C/T	cg17054900	chr3:154042577	DHX36	0.75	9.07	0.39	3.31e-18	Coronary artery disease;
LGG	cis	rs6430585	0.527	rs59413285	chr2:136444185	G/T	cg07169764	chr2:136633963	MCM6	1.0	16.85	0.62	4.88e-50	Corneal structure;
LGG	cis	rs6942756	0.876	rs822038	chr7:129065477	A/G	cg02491457	chr7:128862824	NA	-0.66	-11.9	-0.48	1.13e-28	White matter hyperintensity burden;
LGG	cis	rs9398803	0.865	rs1572569	chr6:126771687	G/A	cg19875578	chr6:126661172	C6orf173	0.56	10.15	0.43	5.6e-22	Male-pattern baldness;
LGG	trans	rs7395662	0.853	rs35255233	chr11:48442870	T/A	cg03929089	chr4:120376271	NA	-0.42	-6.81	-0.3	3.01e-11	HDL cholesterol;
LGG	cis	rs7011049	1.000	rs72648403	chr8:53854848	T/C	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.01e-21	Systolic blood pressure;
LGG	cis	rs3733585	0.624	rs7376154	chr4:9952587	C/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3106136	0.837	rs2289186	chr4:95255637	T/G	cg11021082	chr4:95130006	SMARCAD1	0.39	6.69	0.3	6.32e-11	Capecitabine sensitivity;
LGG	cis	rs7582180	0.614	rs4850931	chr2:101005145	C/T	cg26150922	chr2:100937072	LONRF2	-0.58	-11.39	-0.47	1.17e-26	Intelligence (multi-trait analysis);
LGG	cis	rs9291683	0.595	rs13145442	chr4:10037261	C/A	cg08250081	chr4:10125330	NA	0.41	8.14	0.35	3.81e-15	Bone mineral density;
LGG	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14154082	chr13:112174009	NA	0.43	9.29	0.4	6.19e-19	Menarche (age at onset);
LGG	cis	rs1185460	0.565	rs1182922	chr11:118932859	G/A	cg24687335	chr11:118901407	SLC37A4	-0.59	-10.47	-0.44	3.54e-23	Coronary artery disease;
LGG	cis	rs9611565	0.512	rs132767	chr22:42009520	C/T	cg06634786	chr22:41940651	POLR3H	-0.74	-11.64	-0.48	1.25e-27	Vitiligo;
LGG	cis	rs1062177	1.000	rs2915882	chr5:151145436	T/C	cg00977110	chr5:151150581	G3BP1	0.49	7.85	0.34	2.93e-14	Preschool internalizing problems;
LGG	trans	rs11098499	0.954	rs6847248	chr4:120225955	A/G	cg25214090	chr10:38739885	LOC399744	0.71	12.08	0.49	2.16e-29	Corneal astigmatism;
LGG	cis	rs2299587	0.841	rs17514812	chr8:17880869	T/A	cg18067069	chr8:17937731	ASAH1	-0.29	-6.75	-0.3	4.41e-11	Economic and political preferences;
LGG	cis	rs853679	0.517	rs4713144	chr6:28106790	C/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	trans	rs61931739	0.500	rs11053167	chr12:34387092	A/C	cg26384229	chr12:38710491	ALG10B	0.96	21.15	0.7	5.74e-70	Morning vs. evening chronotype;
LGG	cis	rs3858526	0.527	rs10839168	chr11:6002798	A/G	cg13902645	chr11:5959945	NA	0.47	8.31	0.36	1.05e-15	DNA methylation (variation);
LGG	cis	rs7191439	0.674	rs4782429	chr16:88792097	A/G	cg27087555	chr16:88793112	FAM38A	-1.4	-21.02	-0.7	2.18e-69	Plateletcrit;
LGG	cis	rs1862618	0.802	rs832547	chr5:56183941	C/G	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs947474	0.838	rs10796045	chr10:6402741	G/T	cg19837174	chr10:6389707	NA	0.62	8.7	0.37	5.67e-17	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs10791097	0.694	rs7106995	chr11:130758152	G/T	cg12179176	chr11:130786555	SNX19	0.84	17.15	0.62	2.19e-51	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06746154	chr8:145137177	GPAA1	-0.45	-6.92	-0.31	1.48e-11	Pancreatic cancer;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg03647317	chr4:187891568	NA	-0.4	-8.91	-0.38	1.14e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10751667	0.666	rs6597958	chr11:978087	C/T	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs61931739	0.534	rs7133262	chr12:34279444	G/A	cg06521331	chr12:34319734	NA	-0.65	-11.99	-0.49	5e-29	Morning vs. evening chronotype;
LGG	cis	rs2749592	0.550	rs4934881	chr10:37914346	A/C	cg25427524	chr10:38739819	LOC399744	0.47	8.98	0.39	6.9e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25294185	chr11:65487814	RNASEH2C	-0.47	-7.61	-0.33	1.56e-13	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.663	rs9348704	chr6:26000393	A/C	cg03264133	chr6:25882463	NA	-0.4	-7.18	-0.32	2.81e-12	Height;
LGG	cis	rs7582180	0.676	rs6542940	chr2:100982144	A/T	cg21926883	chr2:100939477	LONRF2	-0.68	-15.96	-0.6	5.41e-46	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs56350499	chr8:58178139	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11229555	0.645	rs12269745	chr11:58176875	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1475911	1.000	rs55645900	chr21:43515728	G/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.49	-8.59	-0.37	1.32e-16	IgG glycosylation;
LGG	cis	rs722599	0.715	rs61978928	chr14:75321714	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.55	-9.04	-0.39	4.4e-18	IgG glycosylation;
LGG	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg16512390	chr1:228756714	NA	0.48	6.69	0.3	6.45e-11	Chronic lymphocytic leukemia;
LGG	cis	rs3780486	0.505	rs7868663	chr9:33141229	A/G	cg13443165	chr9:33130375	B4GALT1	-0.6	-11.96	-0.49	6.54e-29	IgG glycosylation;
LGG	cis	rs9309711	0.544	rs9752130	chr2:3488502	A/G	cg15506890	chr2:3487001	NA	-0.55	-10.54	-0.44	2.03e-23	Neurofibrillary tangles;
LGG	cis	rs868036	1.000	rs4776376	chr15:68093435	G/A	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs9815354	1.000	rs9840532	chr3:41885697	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.45	8.16	0.35	3.29e-15	Intelligence (multi-trait analysis);
LGG	trans	rs561341	1.000	rs113676348	chr17:30244327	A/G	cg20587970	chr11:113659929	NA	-1.22	-20.99	-0.7	3.23e-69	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.682	rs1173417	chr6:86403941	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.47	8.25	0.36	1.65e-15	Response to antipsychotic treatment;
LGG	cis	rs7799006	0.898	rs34418140	chr7:2278183	C/T	cg02951883	chr7:2050386	MAD1L1	-0.45	-7.63	-0.33	1.32e-13	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10174077	0.687	rs4664491	chr2:152479986	C/T	cg19508488	chr2:152266495	RIF1	0.47	7.47	0.33	3.97e-13	Squamous cell lung carcinoma;
LGG	cis	rs2033711	0.840	rs3764533	chr19:58929194	A/G	cg12042659	chr19:58951599	ZNF132	0.36	7.31	0.32	1.2e-12	Uric acid clearance;
LGG	cis	rs694739	0.796	rs479777	chr11:64107477	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.7	12.57	0.5	2.12e-31	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2197308	0.626	rs6581156	chr12:37858731	C/A	cg26384229	chr12:38710491	ALG10B	-0.84	-18.57	-0.65	6.05e-58	Morning vs. evening chronotype;
LGG	cis	rs11190604	1.000	rs4919466	chr10:102241213	T/C	cg07570687	chr10:102243282	WNT8B	0.44	7.75	0.34	5.86e-14	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1814175	0.645	rs4625470	chr11:49983769	T/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs6815814	0.861	rs7658651	chr4:38786002	A/C	cg06935464	chr4:38784597	TLR10	0.53	8.7	0.37	5.83e-17	Breast cancer;
LGG	cis	rs12950390	0.853	rs67441169	chr17:45854462	T/G	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.37e-16	IgG glycosylation;
LGG	cis	rs77633900	0.772	rs283796	chr15:76774105	G/A	cg21673338	chr15:77095150	SCAPER	-0.64	-8.41	-0.36	5.05e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11074306	0.561	rs28472868	chr15:28068083	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.36	0.32	8.33e-13	Uveal melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24243429	chr4:148653539	ARHGAP10	0.49	7.56	0.33	2.15e-13	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs11079056	chr17:41300799	C/A	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.84e-13	Menopause (age at onset);
LGG	cis	rs2952156	0.876	rs2313171	chr17:37833842	T/C	cg07936489	chr17:37558343	FBXL20	-0.51	-8.59	-0.37	1.38e-16	Asthma;
LGG	cis	rs35160687	0.644	rs4832264	chr2:86486834	A/G	cg10973622	chr2:86423274	IMMT	-0.41	-7.23	-0.32	2.04e-12	Night sleep phenotypes;
LGG	cis	rs763121	0.925	rs5750654	chr22:39051428	T/C	cg06022373	chr22:39101656	GTPBP1	0.85	17.28	0.63	5.46e-52	Menopause (age at onset);
LGG	trans	rs67340775	0.541	rs200965	chr6:27866384	G/A	cg06606381	chr12:133084897	FBRSL1	-0.72	-8.48	-0.37	3.12e-16	Lung cancer in ever smokers;
LGG	cis	rs3762637	1.000	rs72960431	chr3:122228661	T/C	cg24169773	chr3:122142474	KPNA1	-0.63	-10.93	-0.45	6.52e-25	LDL cholesterol levels;
LGG	trans	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg10756647	chr7:56101905	PSPH	0.76	8.72	0.38	5.04e-17	Diabetic kidney disease;
LGG	cis	rs7717393	0.786	rs6860183	chr5:155788183	C/T	cg12904904	chr5:155754151	SGCD	0.67	7.71	0.34	7.59e-14	Egg allergy;
LGG	cis	rs6088580	0.660	rs6059893	chr20:33105897	T/G	cg24642439	chr20:33292090	TP53INP2	0.58	9.63	0.41	4.09e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs787274	0.619	rs58643876	chr9:115627285	C/A	cg13803584	chr9:115635662	SNX30	-0.67	-9.77	-0.41	1.24e-20	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs9689716	chr6:149976798	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.72	-0.45	4.23e-24	Lung cancer;
LGG	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg23583168	chr7:148888333	NA	-0.7	-11.47	-0.47	5.53e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs561341	0.843	rs879944	chr17:30242803	A/G	cg20587970	chr11:113659929	NA	-1.07	-18.09	-0.64	1.04e-55	Hip circumference adjusted for BMI;
LGG	cis	rs193541	0.632	rs246276	chr5:122239957	G/A	cg19412675	chr5:122181750	SNX24	0.54	8.68	0.37	6.76e-17	Glucose homeostasis traits;
LGG	cis	rs2842992	0.672	rs4708845	chr6:160219601	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.99	0.49	4.76e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3735485	0.800	rs6969223	chr7:45055214	C/T	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9322193	0.962	rs11155685	chr6:150102785	A/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs12545109	1.000	rs12545109	chr8:57313906	A/C	cg19413350	chr8:57351067	NA	-0.41	-6.71	-0.3	5.81e-11	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs79065504	chr22:32486442	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.9e-19	Childhood ear infection;
LGG	cis	rs6723226	0.572	rs176411	chr2:32643528	A/G	cg02381751	chr2:32503542	YIPF4	0.56	9.62	0.41	4.46e-20	Intelligence (multi-trait analysis);
LGG	cis	rs17092148	0.887	rs2295443	chr20:33173827	T/C	cg12302830	chr20:33297742	TP53INP2	-0.43	-6.91	-0.31	1.63e-11	Neuroticism;
LGG	cis	rs7444	0.825	rs2298428	chr22:21982892	C/T	cg15846791	chr22:21984385	YDJC	-0.47	-6.8	-0.3	3.25e-11	Systemic lupus erythematosus;
LGG	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg12042659	chr19:58951599	ZNF132	0.37	7.53	0.33	2.63e-13	Uric acid clearance;
LGG	cis	rs7000551	0.556	rs6998780	chr8:22254639	C/T	cg12081754	chr8:22256438	SLC39A14	1.16	27.54	0.79	1.45e-99	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9815354	1.000	rs1716999	chr3:41930041	C/G	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg14541582	chr5:601475	NA	0.69	10.98	0.45	4.26e-25	Obesity-related traits;
LGG	cis	rs66887589	0.720	rs11724758	chr4:120239878	G/A	cg09307838	chr4:120376055	NA	0.49	8.3	0.36	1.14e-15	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	8.05e-29	Prudent dietary pattern;
LGG	cis	rs735396	0.770	rs2259820	chr12:121435342	C/T	cg02403541	chr12:121454288	C12orf43	0.65	10.44	0.44	4.61e-23	N-glycan levels;
LGG	cis	rs3806843	0.801	rs801171	chr5:140115303	G/A	cg19875535	chr5:140030758	IK	-0.55	-11.05	-0.46	2.28e-25	Depressive symptoms (multi-trait analysis);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12835684	chr12:53645647	MFSD5	0.43	7.18	0.32	2.82e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9517320	0.515	rs72646416	chr13:99232916	C/G	cg03701759	chr13:99174930	STK24	-0.36	-7.0	-0.31	8.85e-12	Longevity;
LGG	cis	rs533581	0.866	rs865102	chr16:88969969	A/G	cg16701003	chr16:89028210	CBFA2T3	0.46	7.52	0.33	2.78e-13	Social autistic-like traits;
LGG	cis	rs7827545	1.000	rs1372662	chr8:135567046	C/G	cg17885191	chr8:135476712	NA	0.43	6.9	0.31	1.68e-11	Hypertension (SNP x SNP interaction);
LGG	trans	rs35110281	0.715	rs8129601	chr21:45119104	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.51	9.0	0.39	6e-18	Mean corpuscular volume;
LGG	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg03517284	chr6:25882590	NA	-0.41	-6.97	-0.31	1.1e-11	Iron status biomarkers;
LGG	cis	rs9322193	0.923	rs9285524	chr6:150015258	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.23	-0.32	2.05e-12	Lung cancer;
LGG	cis	rs11148252	0.510	rs35895576	chr13:52584900	A/C	cg12458913	chr13:53173898	NA	0.51	8.84	0.38	2.05e-17	Lewy body disease;
LGG	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg17971929	chr21:40555470	PSMG1	0.71	13.42	0.53	6.33e-35	Cognitive function;
LGG	cis	rs7811142	1.000	rs11771419	chr7:99988403	A/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.34	0.4	4.1e-19	Platelet count;
LGG	cis	rs9583531	0.600	rs9521909	chr13:111362170	A/G	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	trans	rs916888	0.610	rs199438	chr17:44791643	G/A	cg06925179	chr17:43578568	NA	0.31	7.97	0.35	1.29e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs853679	0.546	rs200981	chr6:27833174	A/G	cg08344181	chr3:125677491	NA	-0.67	-7.97	-0.35	1.21e-14	Depression;
LGG	cis	rs35771425	1.000	rs55961005	chr1:211567891	C/T	cg10512769	chr1:211675356	NA	-0.75	-11.94	-0.49	7.67e-29	Educational attainment (years of education);
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg10344404	chr17:35969756	SYNRG	-0.41	-6.96	-0.31	1.19e-11	Platelet count;
LGG	trans	rs1814175	0.566	rs1811673	chr11:49602134	A/G	cg03929089	chr4:120376271	NA	-0.88	-13.92	-0.54	4.63e-37	Height;
LGG	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg26688816	chr2:46740690	ATP6V1E2	-0.56	-9.68	-0.41	2.58e-20	Height;
LGG	cis	rs35110281	0.607	rs11701518	chr21:44987079	C/T	cg01579765	chr21:45077557	HSF2BP	-0.35	-7.9	-0.34	1.99e-14	Mean corpuscular volume;
LGG	cis	rs12477438	0.798	rs13412764	chr2:99583733	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.43	-0.63	1.11e-52	Chronic sinus infection;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.58	0.33	1.92e-13	Schizophrenia;
LGG	cis	rs9902453	0.933	rs7225462	chr17:28321226	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.94	0.54	3.88e-37	Coffee consumption (cups per day);
LGG	cis	rs2412208	0.796	rs4500344	chr1:7090814	G/T	cg20434152	chr1:7120926	CAMTA1	-0.43	-7.62	-0.33	1.43e-13	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg15485101	chr11:133734466	NA	-0.46	-7.68	-0.34	9.26e-14	Childhood ear infection;
LGG	cis	rs10752881	1.000	rs4233192	chr1:182970837	A/C	cg07245641	chr1:182991651	LAMC1	-0.42	-9.79	-0.41	1.1e-20	Colorectal cancer;
LGG	cis	rs9287719	0.935	rs728283	chr2:10750090	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs116095464	0.850	rs6896163	chr5:303686	A/G	cg00938859	chr5:1591904	SDHAP3	0.85	8.85	0.38	1.9e-17	Breast cancer;
LGG	cis	rs11574514	1.000	rs8054034	chr16:67773652	C/A	cg09738193	chr16:67926317	PSKH1	-0.74	-6.85	-0.3	2.33e-11	Crohn's disease;
LGG	cis	rs41271473	0.526	rs12136157	chr1:228703236	T/C	cg16512390	chr1:228756714	NA	0.62	8.17	0.35	2.96e-15	Chronic lymphocytic leukemia;
LGG	cis	rs8038465	0.516	rs8037836	chr15:73859855	G/A	cg15420318	chr15:73925796	NPTN	0.56	10.02	0.42	1.63e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2011503	0.941	rs56135441	chr19:19371370	A/T	cg11584989	chr19:19387371	SF4	0.75	12.54	0.5	2.96e-31	Bipolar disorder;
LGG	cis	rs7582180	0.903	rs7609376	chr2:100905828	A/G	cg26150922	chr2:100937072	LONRF2	-0.52	-9.13	-0.39	2.19e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs10872647	chr6:150079823	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-8.87	-0.38	1.65e-17	Lung cancer;
LGG	cis	rs116095464	0.558	rs10057492	chr5:239503	T/C	cg22857025	chr5:266934	NA	-1.51	-26.73	-0.78	6.81e-96	Breast cancer;
LGG	cis	rs11018904	0.906	rs12793836	chr11:89953493	C/T	cg16176437	chr11:89678848	NA	0.41	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	trans	rs1945213	0.694	rs12222077	chr11:55848116	T/A	cg11707556	chr5:10655725	ANKRD33B	0.48	7.11	0.31	4.51e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9916302	0.904	rs8070695	chr17:37478062	C/T	cg07936489	chr17:37558343	FBXL20	0.86	16.08	0.6	1.51e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs9467711	0.651	rs72834677	chr6:26106604	C/A	cg01620082	chr3:125678407	NA	-0.64	-6.72	-0.3	5.45e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9329221	0.698	rs12547997	chr8:10260837	A/G	cg12940923	chr8:10282607	MSRA	0.29	6.99	0.31	9.8e-12	Neuroticism;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg05484376	chr2:27715224	FNDC4	0.46	10.06	0.42	1.19e-21	Total body bone mineral density;
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg02002194	chr4:3960332	NA	0.42	7.81	0.34	3.9e-14	Triglycerides;
LGG	cis	rs611744	0.870	rs2212703	chr8:109198401	G/C	cg21045802	chr8:109455806	TTC35	0.4	7.15	0.32	3.5e-12	Dupuytren's disease;
LGG	cis	rs9377188	0.593	rs6915298	chr6:149370158	C/T	cg21368479	chr6:149415018	NA	0.26	6.72	0.3	5.19e-11	Cancer;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg20887711	chr4:1340912	KIAA1530	0.39	6.74	0.3	4.8e-11	Obesity-related traits;
LGG	trans	rs6601327	0.641	rs11780399	chr8:9589167	C/T	cg02002194	chr4:3960332	NA	0.38	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Gut microbiome composition (summer);
LGG	cis	rs12681288	0.782	rs2123055	chr8:1029500	T/G	cg04851639	chr8:1020857	NA	-0.41	-8.05	-0.35	6.81e-15	Schizophrenia;
LGG	cis	rs7166081	1.000	rs12916403	chr15:67591665	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.6	-0.53	1.17e-35	Alzheimer's disease;
LGG	cis	rs17767392	0.958	rs36072220	chr14:71980744	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.89	-0.38	1.41e-17	Mitral valve prolapse;
LGG	cis	rs67311347	0.955	rs12487955	chr3:40412853	T/C	cg13683864	chr3:40499215	RPL14	-1.0	-20.53	-0.69	4.67e-67	Renal cell carcinoma;
LGG	trans	rs2243480	1.000	rs2707844	chr7:66059509	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.52	0.4	9.67e-20	Diabetic kidney disease;
LGG	cis	rs950776	0.518	rs4887063	chr15:78839715	C/T	cg06917634	chr15:78832804	PSMA4	-0.76	-14.77	-0.57	9.95e-41	Sudden cardiac arrest;
LGG	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.39e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4330281	0.608	rs11128840	chr3:17704787	C/G	cg20981856	chr3:17787350	NA	-0.38	-7.09	-0.31	5.21e-12	Schizophrenia;
LGG	cis	rs4268898	0.722	rs2288072	chr2:24390517	G/A	cg06627628	chr2:24431161	ITSN2	0.47	7.6	0.33	1.63e-13	Asthma;
LGG	cis	rs2836974	1.000	rs2836974	chr21:40663181	A/G	cg06238570	chr21:40685208	BRWD1	-0.44	-6.88	-0.3	1.92e-11	Cognitive function;
LGG	cis	rs2836974	0.644	rs9978775	chr21:40694526	A/G	cg17971929	chr21:40555470	PSMG1	-0.66	-12.01	-0.49	4.08e-29	Cognitive function;
LGG	cis	rs2594989	0.943	rs2454509	chr3:11489653	C/T	cg01796438	chr3:11312864	ATG7	0.55	7.52	0.33	2.93e-13	Circulating chemerin levels;
LGG	cis	rs2228479	0.702	rs17233441	chr16:89817998	C/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg11890956	chr21:40555474	PSMG1	-0.75	-12.91	-0.51	8.95e-33	Menarche (age at onset);
LGG	cis	rs854765	0.547	rs4584886	chr17:17896205	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.77	15.29	0.58	5.09e-43	Total body bone mineral density;
LGG	cis	rs1869026	1.000	rs2311600	chr2:121340676	A/G	cg03661458	chr2:121334411	NA	-0.31	-7.17	-0.32	3.07e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6088590	1.000	rs2236270	chr20:33523155	G/T	cg08999081	chr20:33150536	PIGU	0.3	6.87	0.3	2.07e-11	Coronary artery disease;
LGG	cis	rs9467160	0.581	rs760903	chr6:24474658	A/G	cg20631270	chr6:24437470	GPLD1	0.44	6.99	0.31	9.54e-12	Liver enzyme levels;
LGG	cis	rs8020289	0.581	rs8003145	chr14:77271421	A/G	cg23436960	chr14:77239540	VASH1	-0.36	-10.79	-0.45	2.36e-24	Venlafaxine response in generalised anxiety disorder (remitters vs non-remitters after 12 weeks);
LGG	cis	rs701145	0.537	rs357479	chr3:153891489	A/G	cg17054900	chr3:154042577	DHX36	0.86	10.1	0.42	8.46e-22	Coronary artery disease;
LGG	cis	rs6977660	0.660	rs7357202	chr7:19817911	T/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs7119	0.717	rs12912386	chr15:77817640	T/C	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs3820068	0.705	rs57440988	chr1:15879034	T/C	cg05660106	chr1:15850417	CASP9	1.13	23.73	0.74	4.79e-82	Systolic blood pressure;
LGG	cis	rs9400467	0.506	rs12200610	chr6:111663567	C/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg13565492	chr6:43139072	SRF	-0.68	-10.9	-0.45	8.62e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs10193935	0.901	rs222488	chr2:42648570	T/G	cg27598129	chr2:42591480	NA	-0.65	-9.6	-0.41	5.13e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1497828	0.956	rs2646822	chr1:217535860	A/G	cg04411442	chr1:217543379	NA	-0.47	-7.88	-0.34	2.31e-14	Dialysis-related mortality;
LGG	cis	rs3784262	0.669	rs2414527	chr15:58256672	A/G	cg12031962	chr15:58353849	ALDH1A2	0.34	7.25	0.32	1.71e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9457247	0.663	rs9459835	chr6:167417551	G/T	cg07741184	chr6:167504864	NA	0.39	8.71	0.38	5.43e-17	Crohn's disease;
LGG	cis	rs9858542	0.953	rs9811982	chr3:49624377	A/C	cg07274523	chr3:49395745	GPX1	0.57	9.48	0.4	1.28e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg21775007	chr8:11205619	TDH	-0.57	-9.41	-0.4	2.34e-19	Neuroticism;
LGG	cis	rs3749237	0.595	rs885592	chr3:49497883	T/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.1	0.31	4.74e-12	Resting heart rate;
LGG	cis	rs6500395	1.000	rs12597569	chr16:48693342	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13421350	0.579	rs57878744	chr2:173303047	G/A	cg15021238	chr2:173305865	ITGA6	-0.82	-9.11	-0.39	2.44e-18	Diabetic kidney disease;
LGG	cis	rs7582180	0.701	rs4622752	chr2:100892018	A/G	cg14675211	chr2:100938903	LONRF2	-0.55	-9.16	-0.39	1.66e-18	Intelligence (multi-trait analysis);
LGG	cis	rs968451	0.789	rs11089939	chr22:39680957	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	13.79	0.54	1.68e-36	Primary biliary cholangitis;
LGG	cis	rs344364	0.511	rs1742463	chr16:1946110	A/G	cg14074117	chr16:1909714	C16orf73	-0.54	-8.02	-0.35	8.53e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg19399532	chr1:178512495	C1orf220	-0.5	-10.07	-0.42	1.06e-21	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg13271783	chr10:134563150	INPP5A	-0.53	-7.86	-0.34	2.67e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs2836950	0.520	rs11911087	chr21:40665192	G/A	cg17971929	chr21:40555470	PSMG1	-0.54	-9.28	-0.4	6.5e-19	Menarche (age at onset);
LGG	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg13385521	chr17:29058706	SUZ12P	0.81	9.59	0.41	5.45e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.99	-15.08	-0.57	4.37e-42	Platelet count;
LGG	cis	rs12681288	0.550	rs4272405	chr8:959014	C/G	cg15309053	chr8:964076	NA	0.41	8.9	0.38	1.25e-17	Schizophrenia;
LGG	trans	rs1991651	0.578	rs11778453	chr8:10489836	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.53	-0.37	2.17e-16	Granulocyte count;Neutrophil count;Myeloid white cell count;Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;
LGG	cis	rs10256972	0.616	rs4585652	chr7:1145396	A/G	cg23978390	chr7:1156363	C7orf50	0.57	9.81	0.41	9.46e-21	Longevity;Endometriosis;
LGG	cis	rs1790761	0.520	rs12800028	chr11:67403285	A/G	cg00864171	chr11:67383662	NA	-0.49	-7.19	-0.32	2.56e-12	Mean corpuscular volume;
LGG	cis	rs727505	1.000	rs7777947	chr7:124436063	T/G	cg23710748	chr7:124431027	NA	-0.5	-9.52	-0.4	9.88e-20	Lewy body disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg26278813	chr3:141867862	NA	0.4	6.8	0.3	3.29e-11	Body mass index;
LGG	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg08048268	chr3:133502702	NA	-0.59	-10.98	-0.45	4.41e-25	Iron status biomarkers;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg08645402	chr16:4508243	NA	0.5	9.61	0.41	4.63e-20	Schizophrenia;
LGG	cis	rs4356203	0.543	rs214093	chr11:17294788	C/G	cg15432903	chr11:17409602	KCNJ11	-0.37	-6.65	-0.3	8.07e-11	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs62400317	0.614	rs12210292	chr6:44925293	A/G	cg18551225	chr6:44695536	NA	-0.63	-9.39	-0.4	2.66e-19	Total body bone mineral density;
LGG	cis	rs1023500	0.596	rs5758562	chr22:42448238	C/G	cg04733989	chr22:42467013	NAGA	0.6	10.21	0.43	3.38e-22	Schizophrenia;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg24101359	chr6:42928495	GNMT	-0.56	-16.6	-0.61	6.51e-49	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25495613	chr7:134895782	WDR91	0.37	6.76	0.3	4.16e-11	Obesity-related traits;
LGG	cis	rs11239187	0.606	rs11239166	chr10:45093119	C/G	cg03916630	chr10:45065415	NA	0.35	8.38	0.36	6.3e-16	Body mass index;
LGG	cis	rs4819052	0.851	rs8127834	chr21:46696109	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.77	13.77	0.54	2.05e-36	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2066819	1.000	rs2695788	chr12:56697110	G/A	cg26714650	chr12:56694279	CS	1.49	18.34	0.65	7.36e-57	Psoriasis vulgaris;
LGG	trans	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg06636001	chr8:8085503	FLJ10661	0.49	8.63	0.37	9.96e-17	Neuroticism;
LGG	cis	rs62400317	0.731	rs12198982	chr6:45077914	C/A	cg18551225	chr6:44695536	NA	-0.58	-8.51	-0.37	2.45e-16	Total body bone mineral density;
LGG	cis	rs1372356	0.788	rs12884100	chr14:88529291	A/C	cg18078958	chr14:88630771	NA	0.31	7.49	0.33	3.6e-13	Food antigen IgG levels;
LGG	cis	rs1062177	0.950	rs59580263	chr5:151269577	T/A	cg00977110	chr5:151150581	G3BP1	0.5	7.87	0.34	2.58e-14	Preschool internalizing problems;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09081385	chr12:120972070	RNF10	0.41	7.07	0.31	5.83e-12	Menarche (age at onset);
LGG	trans	rs6601327	0.602	rs11249956	chr8:9658194	G/C	cg16141378	chr3:129829833	LOC729375	0.35	7.74	0.34	6.1e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg11984989	chr7:158649758	WDR60	1.05	23.38	0.74	2.06e-80	Height;
LGG	cis	rs4689592	0.513	rs2358718	chr4:7068743	A/C	cg25660036	chr4:7070649	GRPEL1	0.45	6.94	0.31	1.36e-11	Monocyte percentage of white cells;
LGG	cis	rs1862618	0.671	rs832531	chr5:56228401	A/G	cg12654349	chr5:56205094	C5orf35	-0.58	-10.05	-0.42	1.24e-21	Initial pursuit acceleration;
LGG	cis	rs7681440	0.804	rs1442140	chr4:90816023	A/G	cg20003494	chr4:90757398	SNCA	-0.41	-8.1	-0.35	4.86e-15	Dementia with Lewy bodies;
LGG	cis	rs2916247	1.000	rs7832917	chr8:93036318	A/G	cg10183463	chr8:93005414	RUNX1T1	0.4	8.38	0.36	6.32e-16	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs7701114	chr5:93096028	T/C	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs9296092	0.500	rs35150558	chr6:33519612	T/A	cg13560919	chr6:33536144	NA	-1.04	-21.64	-0.71	2.91e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs35110281	0.755	rs4819270	chr21:45020919	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.74	0.48	4.82e-28	Mean corpuscular volume;
LGG	cis	rs7098414	0.511	rs10466236	chr10:82149717	C/T	cg01528321	chr10:82214614	TSPAN14	-0.65	-11.78	-0.48	3.52e-28	Post bronchodilator FEV1;
LGG	cis	rs6714710	0.603	rs2044459	chr2:98447004	T/C	cg26665480	chr2:98280029	ACTR1B	0.61	9.96	0.42	2.72e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs1055129	0.516	rs7218498	chr17:73931847	C/G	cg14829360	chr17:73884958	NA	-0.53	-10.29	-0.43	1.71e-22	White matter hyperintensity burden;
LGG	cis	rs7819412	0.525	rs10086521	chr8:10783769	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-6.91	-0.31	1.58e-11	Triglycerides;
LGG	cis	rs1107366	0.722	rs35331719	chr3:125907392	C/A	cg17230874	chr3:125932073	NA	0.59	11.76	0.48	3.97e-28	Metabolite levels;
LGG	cis	rs367615	0.506	rs2963013	chr5:108775811	C/T	cg17395555	chr5:108820864	NA	-0.78	-14.19	-0.55	3.45e-38	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs34421088	0.560	rs2618434	chr8:11398865	A/G	cg19847130	chr8:10466454	RP1L1	0.31	7.09	0.31	4.95e-12	Neuroticism;
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.77	0.45	2.69e-24	Longevity;
LGG	cis	rs4731207	0.596	rs10274820	chr7:124629664	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6708331	1.000	rs7597199	chr2:70341575	A/G	cg01613454	chr2:70366299	NA	0.52	9.14	0.39	1.94e-18	Obesity-related traits;
LGG	cis	rs8014204	1.000	rs8014374	chr14:75322914	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.83	-17.11	-0.62	3.19e-51	Caffeine consumption;
LGG	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg27411982	chr8:10470053	RP1L1	0.42	7.29	0.32	1.38e-12	Mood instability;
LGG	cis	rs9660992	0.967	rs1172135	chr1:205247160	G/C	cg21545522	chr1:205238299	TMCC2	0.39	7.25	0.32	1.72e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3008870	0.755	rs2815349	chr1:67472280	G/A	cg02640540	chr1:67518911	SLC35D1	0.37	7.44	0.33	5e-13	Lymphocyte percentage of white cells;
LGG	cis	rs7659604	0.539	rs72680779	chr4:122797263	C/T	cg20573242	chr4:122745356	CCNA2	0.53	9.59	0.41	5.31e-20	Type 2 diabetes;
LGG	cis	rs12949688	0.967	rs12950062	chr17:55825534	G/A	cg12582317	chr17:55822272	NA	0.68	19.45	0.67	4.84e-62	Schizophrenia;
LGG	cis	rs9916302	0.706	rs6503521	chr17:37715551	A/C	cg07936489	chr17:37558343	FBXL20	1.03	15.53	0.59	4.3e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs55823223	0.702	rs3785437	chr17:73906222	G/T	cg02397686	chr17:73851076	WBP2	0.61	7.63	0.33	1.34e-13	Psoriasis;
LGG	cis	rs6580649	0.943	rs3803183	chr12:48398080	T/A	cg24011408	chr12:48396354	COL2A1	0.66	8.29	0.36	1.23e-15	Lung cancer;
LGG	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg25358565	chr5:93447407	FAM172A	1.38	16.91	0.62	2.6e-50	Diabetic retinopathy;
LGG	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg24803719	chr17:45855879	NA	-0.3	-8.46	-0.37	3.57e-16	IgG glycosylation;
LGG	cis	rs9814567	0.896	rs6794258	chr3:134344505	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.68	-12.3	-0.5	2.7e-30	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2976388	0.525	rs2016749	chr8:143836118	G/A	cg06565975	chr8:143823917	SLURP1	-0.34	-8.42	-0.36	4.62e-16	Urinary tract infection frequency;
LGG	cis	rs963731	0.649	rs4670903	chr2:39220975	G/A	cg04010122	chr2:39346883	SOS1	-0.76	-6.86	-0.3	2.22e-11	Corticobasal degeneration;
LGG	cis	rs888194	0.651	rs6606734	chr12:110013639	T/G	cg19025524	chr12:109796872	NA	-0.34	-6.89	-0.3	1.85e-11	Neuroticism;
LGG	cis	rs7582720	1.000	rs72934751	chr2:203747522	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05252892	chr5:154320678	MRPL22	0.38	6.85	0.3	2.35e-11	Bipolar disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02043083	chr6:150070997	PCMT1	0.41	6.77	0.3	3.95e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4356203	0.870	rs7925692	chr11:17271122	A/G	cg15432903	chr11:17409602	KCNJ11	0.39	7.47	0.33	3.97e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg13512537	chr8:22265999	SLC39A14	-0.38	-6.74	-0.3	4.74e-11	Verbal declarative memory;
LGG	cis	rs12496230	0.953	rs12494775	chr3:66874105	A/G	cg04995300	chr3:66848608	NA	-0.55	-8.14	-0.35	3.75e-15	Type 2 diabetes;
LGG	cis	rs2032447	0.832	rs6922788	chr6:26052291	C/T	cg18357526	chr6:26021779	HIST1H4A	0.83	16.03	0.6	2.46e-46	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.629	rs9806826	chr16:1894912	C/T	cg00490583	chr16:1843685	IGFALS	-0.43	-9.62	-0.41	4.39e-20	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4660214	0.666	rs6704246	chr1:39809284	C/T	cg18385671	chr1:39797026	MACF1	-0.47	-9.79	-0.41	1.08e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs992157	1.000	rs2292553	chr2:219146803	G/A	cg04731861	chr2:219085781	ARPC2	-0.42	-10.03	-0.42	1.5e-21	Colorectal cancer;
LGG	cis	rs4732038	1.000	rs706202	chr7:134250704	C/T	cg06906464	chr7:134288099	NA	0.5	12.49	0.5	4.54e-31	Longevity;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg10295955	chr4:187884368	NA	-1.14	-29.66	-0.81	4.11e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9910055	0.683	rs7220138	chr17:42254011	C/G	cg16434002	chr17:42200994	HDAC5	-0.52	-9.78	-0.41	1.19e-20	Total body bone mineral density;
LGG	cis	rs1420338	0.967	rs9655014	chr7:34148632	T/C	cg01275685	chr7:34179230	BMPER	-0.47	-8.3	-0.36	1.17e-15	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs11779988	0.538	rs12541567	chr8:17920077	T/A	cg18067069	chr8:17937731	ASAH1	-0.37	-8.92	-0.38	1.07e-17	Breast cancer;
LGG	cis	rs10493773	1.000	rs2274738	chr1:86119898	A/G	cg17807903	chr1:86174739	ZNHIT6	-0.53	-8.71	-0.38	5.31e-17	Urate levels in overweight individuals;
LGG	trans	rs208520	1.000	rs12194996	chr6:66973366	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.33	0.55	8.16e-39	Exhaled nitric oxide output;
LGG	cis	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-11.17	-0.46	8.16e-26	Mood instability;
LGG	cis	rs4862750	0.872	rs6811837	chr4:187898162	G/A	cg27532560	chr4:187881888	NA	-0.59	-12.93	-0.51	7.46e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7945718	0.535	rs7114698	chr11:12707876	C/T	cg25843174	chr11:12811716	TEAD1	0.34	7.34	0.32	9.55e-13	Educational attainment (years of education);
LGG	cis	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.06	-19.81	-0.68	1.02e-63	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9650657	0.769	rs1968400	chr8:10615431	G/C	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.89	-0.3	1.84e-11	Neuroticism;
LGG	cis	rs56161922	1.000	rs17045979	chr1:207842704	T/C	cg09557387	chr1:207818395	CR1L	0.99	9.66	0.41	3.18e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24442254	chr7:72299888	SBDSP;TYW1B	0.43	7.09	0.31	5.06e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs62244186	0.545	rs7640654	chr3:44763037	A/C	cg15225532	chr3:44803084	KIF15;KIAA1143	0.44	7.85	0.34	3.02e-14	Depressive symptoms;
LGG	cis	rs12580194	0.593	rs7487419	chr12:55769801	C/G	cg19537932	chr12:55886519	OR6C68	-0.56	-10.21	-0.43	3.35e-22	Cancer;
LGG	cis	rs7246865	0.954	rs55957788	chr19:17207851	G/A	cg19418318	chr19:17219073	MYO9B	0.35	9.62	0.41	4.18e-20	Reticulocyte fraction of red cells;
LGG	cis	rs963731	0.579	rs997344	chr2:39281730	G/C	cg04010122	chr2:39346883	SOS1	-0.79	-7.61	-0.33	1.55e-13	Corticobasal degeneration;
LGG	trans	rs6601327	0.641	rs10102170	chr8:9611470	C/T	cg12395012	chr8:11607386	GATA4	-0.38	-6.89	-0.3	1.8e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs367943	0.901	rs348951	chr5:112822017	G/C	cg12552261	chr5:112820674	MCC	-0.75	-14.17	-0.55	3.99e-38	Type 2 diabetes;
LGG	cis	rs75059851	0.756	rs73036087	chr11:133842361	G/A	cg20042908	chr11:133852938	NA	-0.76	-14.2	-0.55	3.1e-38	Schizophrenia;
LGG	cis	rs9487051	0.837	rs6568561	chr6:109592909	A/G	cg21918786	chr6:109611834	NA	-0.42	-7.77	-0.34	4.96e-14	Reticulocyte fraction of red cells;
LGG	cis	rs651907	0.535	rs34161138	chr3:101510388	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.76	-0.34	5.55e-14	Colorectal cancer;
LGG	cis	rs9443645	0.901	rs13191068	chr6:79714867	T/C	cg18132916	chr6:79620363	NA	-0.3	-8.28	-0.36	1.31e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.09e-25	Corneal astigmatism;
LGG	cis	rs1965732	0.504	rs10170315	chr2:3715832	G/A	cg15327641	chr2:3715039	ALLC	0.33	7.04	0.31	7.07e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs3741404	1.000	rs11603042	chr11:64003843	G/T	cg05016508	chr11:63871570	FLRT1;MACROD1	0.43	8.08	0.35	5.69e-15	Platelet count;
LGG	cis	rs9470366	0.816	rs1321310	chr6:36623124	C/T	cg08179530	chr6:36648295	CDKN1A	-0.64	-9.6	-0.41	5e-20	QRS duration;
LGG	trans	rs1941687	0.583	rs8091977	chr18:31359414	T/C	cg04226714	chr8:49833948	SNAI2	-0.48	-8.57	-0.37	1.52e-16	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs8044868	0.530	rs7189115	chr16:72098952	C/T	cg23815491	chr16:72088622	HP	0.39	8.28	0.36	1.33e-15	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6546550	0.935	rs1056482	chr2:70108256	A/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.96	-0.35	1.31e-14	Prevalent atrial fibrillation;
LGG	cis	rs6772849	1.000	rs60228913	chr3:128311331	G/A	cg08795948	chr3:128337044	NA	0.53	8.66	0.37	8.1e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs1577917	0.874	rs11756621	chr6:86740063	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.83	-0.42	7.98e-21	Response to antipsychotic treatment;
LGG	cis	rs11112613	0.775	rs61200462	chr12:105969271	G/A	cg03607813	chr12:105948248	NA	0.57	9.74	0.41	1.56e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16405210	chr4:1374714	KIAA1530	-0.65	-12.1	-0.49	1.78e-29	Longevity;
LGG	cis	rs8114671	0.967	rs4911476	chr20:33780768	A/C	cg24642439	chr20:33292090	TP53INP2	-0.47	-7.49	-0.33	3.47e-13	Height;
LGG	cis	rs4704187	0.617	rs12656177	chr5:74354422	G/A	cg03227963	chr5:74354835	NA	0.34	7.53	0.33	2.62e-13	Response to amphetamines;
LGG	cis	rs2839186	0.771	rs2280959	chr21:47641996	C/G	cg13126279	chr21:47581558	C21orf56	-0.53	-9.48	-0.4	1.37e-19	Testicular germ cell tumor;
LGG	cis	rs4927850	0.958	rs1975582	chr3:195751439	G/T	cg01181863	chr3:195395398	SDHAP2	-0.62	-9.98	-0.42	2.29e-21	Pancreatic cancer;
LGG	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg24209194	chr3:40518798	ZNF619	0.43	6.66	0.3	7.97e-11	Renal cell carcinoma;
LGG	trans	rs561341	1.000	rs546519	chr17:30297682	T/G	cg20587970	chr11:113659929	NA	-1.3	-24.25	-0.75	1.8e-84	Hip circumference adjusted for BMI;
LGG	cis	rs6088580	0.634	rs6141471	chr20:33006730	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.31	-0.36	1.04e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.35	6.73	0.3	4.9e-11	Schizophrenia;
LGG	cis	rs459571	0.585	rs378569	chr9:136902415	T/C	cg13789015	chr9:136890014	NCRNA00094	0.38	7.02	0.31	8.17e-12	Platelet distribution width;
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg02725872	chr8:58115012	NA	-1.06	-14.8	-0.57	7.59e-41	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.56	-0.33	2.2e-13	Menopause (age at onset);
LGG	cis	rs9910055	0.659	rs186603	chr17:42207884	C/T	cg13607699	chr17:42295918	UBTF	-0.54	-9.17	-0.39	1.54e-18	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs1800344	chr16:89816367	T/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg15556689	chr8:8085844	FLJ10661	0.45	7.99	0.35	1.11e-14	Mood instability;
LGG	cis	rs929354	0.806	rs28446734	chr7:156996775	T/C	cg05182265	chr7:156933206	UBE3C	-0.37	-7.45	-0.33	4.63e-13	Body mass index;
LGG	cis	rs774359	0.789	rs2783009	chr9:27514584	T/C	cg21249376	chr9:27528432	MOBKL2B	0.45	8.66	0.37	7.67e-17	Amyotrophic lateral sclerosis;
LGG	trans	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg10756647	chr7:56101905	PSPH	0.84	9.86	0.42	6.24e-21	Diabetic kidney disease;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg05165339	chr4:1420672	NA	-0.35	-8.63	-0.37	9.62e-17	Longevity;
LGG	cis	rs344364	0.552	rs388928	chr16:1909657	G/C	cg00490583	chr16:1843685	IGFALS	0.44	9.75	0.41	1.46e-20	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9503598	0.644	rs9503593	chr6:3430787	T/C	cg00476032	chr6:3446245	SLC22A23	0.43	8.43	0.36	4.38e-16	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs778371	0.676	rs13024330	chr2:233715487	A/G	cg08000102	chr2:233561755	GIGYF2	0.65	10.7	0.45	5.16e-24	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg15971980	chr6:150254442	NA	0.43	8.12	0.35	4.27e-15	Lung cancer;
LGG	cis	rs9460578	0.640	rs9465923	chr6:20882175	A/G	cg13405222	chr6:20811065	CDKAL1	-0.63	-11.34	-0.47	1.88e-26	Breast cancer;
LGG	cis	rs7249142	0.549	rs72997174	chr19:19294389	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.58	-0.44	1.38e-23	IgG glycosylation;
LGG	cis	rs3096299	0.967	rs753852	chr16:89446419	G/A	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.32	-0.32	1.08e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs74417235	0.684	rs13186731	chr5:154056002	C/T	cg08754654	chr5:154026448	NA	0.53	10.86	0.45	1.22e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs7937682	0.883	rs529529	chr11:111461128	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs1953600	0.870	rs2573370	chr10:81951366	C/T	cg04850286	chr10:81895943	PLAC9	0.44	9.79	0.41	1.09e-20	Sarcoidosis;
LGG	cis	rs2658782	0.901	rs2605611	chr11:93229319	T/G	cg15737290	chr11:93063684	CCDC67	0.51	7.37	0.32	8.1e-13	Pulmonary function decline;
LGG	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg05791153	chr7:19748676	TWISTNB	0.6	9.01	0.39	5.46e-18	Thyroid stimulating hormone;
LGG	cis	rs10256972	0.591	rs10229680	chr7:1158565	C/T	cg11360546	chr7:1094263	C7orf50	-0.4	-7.25	-0.32	1.75e-12	Longevity;Endometriosis;
LGG	cis	rs10883723	1.000	rs10883723	chr10:104225832	T/C	cg05096777	chr10:104283225	SUFU	0.31	6.69	0.3	6.59e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7296418	0.961	rs10848428	chr12:123572495	C/T	cg05973401	chr12:123451056	ABCB9	0.46	7.75	0.34	5.73e-14	Platelet count;
LGG	cis	rs7444	0.941	rs878825	chr22:21982249	A/G	cg05046821	chr22:21984468	YDJC	-0.37	-7.06	-0.31	6.14e-12	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.33	0.32	1.07e-12	Height;
LGG	cis	rs4819052	0.851	rs4819038	chr21:46659393	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2587949	0.615	rs2587915	chr3:4190178	G/C	cg16519197	chr3:4211558	NA	-0.33	-6.91	-0.31	1.61e-11	Periodontitis (DPAL);
LGG	cis	rs4689388	0.926	rs12508672	chr4:6287965	G/A	cg25554036	chr4:6271136	WFS1	0.61	11.48	0.47	5.25e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.53	0.5	3.17e-31	Motion sickness;
LGG	trans	rs9818758	0.607	rs61729488	chr3:49067904	T/C	cg21659725	chr3:3221576	CRBN	-0.68	-6.79	-0.3	3.56e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4731207	0.565	rs10954053	chr7:124586815	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg16270222	chr17:41446396	NA	-0.31	-7.38	-0.32	7.21e-13	Menopause (age at onset);
LGG	cis	rs11711311	0.824	rs9833810	chr3:113363762	C/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-6.93	-0.31	1.37e-11	IgG glycosylation;
LGG	cis	rs4731207	0.646	rs7783781	chr7:124454413	T/G	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	trans	rs7395662	0.713	rs11512404	chr11:48936171	T/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.78	-0.34	4.77e-14	HDL cholesterol;
LGG	cis	rs9463078	0.845	rs1329713	chr6:45004028	A/C	cg25276700	chr6:44698697	NA	-0.4	-8.42	-0.36	4.59e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg02018176	chr4:1364513	KIAA1530	0.38	8.53	0.37	2.16e-16	Obesity-related traits;
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.53	-0.33	2.7e-13	Skin colour saturation;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg00908189	chr16:619842	PIGQ	0.85	15.62	0.59	1.72e-44	Height;
LGG	cis	rs1005277	0.540	rs1987431	chr10:37988887	T/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-13.25	-0.52	3.26e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs3733585	0.648	rs7376155	chr4:9952588	C/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7937682	0.924	rs499750	chr11:111513645	T/G	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.76	-0.78	4.73e-96	Primary sclerosing cholangitis;
LGG	cis	rs677665	0.537	rs6688233	chr1:9335745	A/G	cg25755851	chr1:9335794	NA	-0.29	-8.46	-0.37	3.5e-16	Eosinophil percentage of white cells;
LGG	cis	rs2905347	0.726	rs2905320	chr7:22704243	C/A	cg23521230	chr7:22704884	NA	0.4	7.36	0.32	8.38e-13	Major depression and alcohol dependence;
LGG	cis	rs42648	0.869	rs1015403	chr7:89913702	A/G	cg25739043	chr7:89950458	NA	-0.43	-9.2	-0.39	1.28e-18	Homocysteine levels;
LGG	cis	rs1801251	1.000	rs12474040	chr2:233615345	T/G	cg08000102	chr2:233561755	GIGYF2	0.55	9.02	0.39	4.91e-18	Coronary artery disease;
LGG	cis	rs9859260	0.710	rs419068	chr3:195782176	C/T	cg02975922	chr3:195473998	MUC4	0.46	7.33	0.32	1e-12	Mean corpuscular volume;
LGG	cis	rs67478160	0.584	rs2295148	chr14:104195610	T/C	cg26031613	chr14:104095156	KLC1	-0.48	-7.76	-0.34	5.6e-14	Schizophrenia;
LGG	cis	rs1728785	1.000	rs1170433	chr16:68606081	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs7904368	0.901	rs7923189	chr10:16850214	C/T	cg14835575	chr10:16859367	RSU1	0.75	13.87	0.54	7.7e-37	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg21782813	chr7:2030301	MAD1L1	0.39	9.08	0.39	3.04e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg07362569	chr17:61921086	SMARCD2	0.51	9.92	0.42	3.7e-21	Prudent dietary pattern;
LGG	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg23750338	chr8:142222470	SLC45A4	0.34	6.67	0.3	7.19e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.54e-13	IgG glycosylation;
LGG	cis	rs9462027	0.583	rs9469862	chr6:34729848	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs11096990	0.855	rs11737290	chr4:39193938	T/C	cg24403649	chr4:39172243	NA	-0.46	-7.71	-0.34	7.96e-14	Cognitive function;
LGG	cis	rs11628318	0.515	rs1190334	chr14:103112591	T/C	cg12046867	chr14:103022105	NA	0.4	7.65	0.33	1.2e-13	Platelet count;
LGG	cis	rs11800820	0.557	rs10924755	chr1:246666347	T/A	cg16700716	chr1:246684329	NA	0.43	7.68	0.34	9.46e-14	Obesity-related traits;
LGG	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg25706281	chr1:46860511	FAAH	-0.28	-6.71	-0.3	5.55e-11	Menopause (age at onset);
LGG	cis	rs6594713	0.921	rs10051115	chr5:112719597	T/C	cg12552261	chr5:112820674	MCC	0.51	7.3	0.32	1.22e-12	Brain cytoarchitecture;
LGG	cis	rs4936891	1.000	rs4936891	chr11:123920645	C/G	cg22125253	chr11:123886957	OR10G4	0.53	10.07	0.42	1.04e-21	Male fertility;
LGG	cis	rs6489882	0.867	rs2384073	chr12:113367595	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.62	-0.33	1.43e-13	Chronic lymphocytic leukemia;
LGG	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	6.88	0.3	1.9e-11	Resting heart rate;
LGG	cis	rs1018836	0.851	rs7014073	chr8:91618548	T/C	cg16814680	chr8:91681699	NA	-0.84	-16.11	-0.6	1.06e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs34638952	0.577	rs923638	chr17:27453301	T/A	cg13672501	chr17:27410685	MYO18A	-0.39	-7.16	-0.32	3.16e-12	Sitting height ratio;
LGG	trans	rs1005277	0.579	rs1985707	chr10:38434098	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.06	-0.31	6.28e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg18876405	chr7:65276391	NA	0.45	7.94	0.35	1.54e-14	Calcium levels;
LGG	cis	rs2839186	0.560	rs9975345	chr21:47843004	T/C	cg12379764	chr21:47803548	PCNT	0.65	11.55	0.47	2.68e-27	Testicular germ cell tumor;
LGG	cis	rs6582630	0.503	rs4882293	chr12:38388200	G/C	cg26384229	chr12:38710491	ALG10B	-0.64	-12.65	-0.51	1.03e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg05165339	chr4:1420672	NA	0.3	7.95	0.35	1.42e-14	Obesity-related traits;
LGG	cis	rs3091242	0.933	rs932372	chr1:25755014	G/A	cg27572855	chr1:25598939	RHD	0.49	11.0	0.46	3.56e-25	Erythrocyte sedimentation rate;
LGG	cis	rs3770081	0.536	rs7562837	chr2:86306251	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.91	-10.4	-0.44	6.41e-23	Facial emotion recognition (sad faces);
LGG	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Bone mineral density;
LGG	cis	rs10504229	1.000	rs68112919	chr8:58188247	G/A	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs477692	0.655	rs7906680	chr10:131442671	C/G	cg05714579	chr10:131428358	MGMT	-0.7	-15.55	-0.59	3.56e-44	Response to temozolomide;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg27432699	chr2:27873401	GPN1	-0.48	-8.2	-0.36	2.32e-15	Total body bone mineral density;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04912466	chr11:63742028	COX8A	0.39	6.83	0.3	2.74e-11	Obesity-related traits;
LGG	cis	rs7444	0.941	rs181366	chr22:21933780	C/T	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.57e-11	Systemic lupus erythematosus;
LGG	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs7264396	0.790	rs6121018	chr20:34249060	C/A	cg17201900	chr20:34330562	RBM39	0.5	6.78	0.3	3.67e-11	Total cholesterol levels;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12379764	chr21:47803548	PCNT	-0.47	-7.91	-0.35	1.89e-14	Testicular germ cell tumor;
LGG	cis	rs1018836	0.631	rs61276517	chr8:91474406	A/G	cg16814680	chr8:91681699	NA	-0.61	-10.06	-0.42	1.18e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg16507663	chr6:150244633	RAET1G	0.52	10.86	0.45	1.23e-24	Testicular germ cell tumor;
LGG	cis	rs1499614	0.901	rs3936	chr7:66126489	C/T	cg13147721	chr7:65941812	NA	-0.81	-9.92	-0.42	3.69e-21	Gout;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg13009111	chr11:71350975	NA	-0.31	-6.85	-0.3	2.32e-11	Triglycerides;
LGG	cis	rs12701220	0.625	rs12701499	chr7:1061804	G/A	cg04025307	chr7:1156635	C7orf50	0.43	6.76	0.3	4.2e-11	Bronchopulmonary dysplasia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17058777	chr11:71814579	LRTOMT;C11orf59	0.4	6.86	0.3	2.19e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7226408	0.857	rs17567920	chr18:34625813	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg13802316	chr11:70253460	CTTN	-0.56	-7.37	-0.32	8.04e-13	Coronary artery disease;
LGG	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg08000102	chr2:233561755	GIGYF2	-0.57	-9.31	-0.4	5.04e-19	Coronary artery disease;
LGG	cis	rs1371867	0.875	rs1371868	chr8:101330267	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.88	-0.38	1.53e-17	Atrioventricular conduction;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg05368731	chr17:41323189	NBR1	0.94	18.68	0.66	1.98e-58	Menopause (age at onset);
LGG	cis	rs8141529	0.509	rs5762864	chr22:29253364	T/C	cg15103426	chr22:29168792	CCDC117	0.66	9.7	0.41	2.23e-20	Lymphocyte counts;
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg00364696	chr7:1142433	C7orf50	-0.39	-7.45	-0.33	4.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18500714	chr14:100706288	YY1	0.43	7.71	0.34	7.7e-14	Obesity-related traits;
LGG	cis	rs7129556	0.690	rs687037	chr11:77596104	C/A	cg12586386	chr11:77299805	AQP11	0.44	6.98	0.31	1.03e-11	Weight loss (gastric bypass surgery);
LGG	cis	rs7923609	0.756	rs10822183	chr10:65337141	T/C	cg02276361	chr10:65351566	REEP3	-0.31	-6.92	-0.31	1.49e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1799949	0.896	rs35908185	chr17:41255111	A/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.78	-0.38	3.22e-17	Menopause (age at onset);
LGG	cis	rs68170813	0.559	rs74906766	chr7:106885236	T/A	cg02696742	chr7:106810147	HBP1	-0.75	-10.86	-0.45	1.23e-24	Coronary artery disease;
LGG	cis	rs6061231	0.544	rs2427314	chr20:60973666	C/T	cg22601191	chr20:60968625	CABLES2	0.45	8.39	0.36	6.11e-16	Colorectal cancer;
LGG	trans	rs12310956	0.532	rs1352210	chr12:33983187	A/G	cg13010199	chr12:38710504	ALG10B	0.51	9.79	0.41	1.09e-20	Morning vs. evening chronotype;
LGG	cis	rs1065656	0.581	rs1065663	chr16:1839023	G/A	cg26897989	chr16:1907736	C16orf73	0.73	11.5	0.47	4.44e-27	Insulin-like growth factors;
LGG	trans	rs9393777	0.720	rs13217285	chr6:26999845	C/T	cg01620082	chr3:125678407	NA	-0.67	-7.4	-0.33	6.47e-13	Intelligence (multi-trait analysis);
LGG	cis	rs42648	0.837	rs10262472	chr7:89900383	T/C	cg25739043	chr7:89950458	NA	-0.44	-9.55	-0.41	7.31e-20	Homocysteine levels;
LGG	cis	rs4363385	0.693	rs7556517	chr1:152925755	G/T	cg13444842	chr1:152974279	SPRR3	0.4	7.55	0.33	2.33e-13	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15655138	chr6:37139981	PIM1	0.5	7.46	0.33	4.19e-13	Gut microbiome composition (summer);
LGG	cis	rs3733585	0.578	rs4466042	chr4:9955367	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4561483	0.645	rs2192645	chr16:11928019	C/T	cg08843971	chr16:11963173	GSPT1	-0.55	-13.4	-0.53	8.1e-35	Testicular germ cell tumor;
LGG	cis	rs490234	0.812	rs10121109	chr9:128455206	C/A	cg14078157	chr9:128172775	NA	-0.48	-8.38	-0.36	6.25e-16	Mean arterial pressure;
LGG	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg00071950	chr4:10020882	SLC2A9	0.43	8.96	0.38	8.06e-18	Bone mineral density;
LGG	trans	rs2736345	0.516	rs9657551	chr8:11398183	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.11	0.31	4.38e-12	Sjögren's syndrome;Systemic lupus erythematosus;
LGG	cis	rs6089584	0.586	rs4925216	chr20:60599923	G/A	cg13770153	chr20:60521292	NA	-0.43	-7.2	-0.32	2.45e-12	Body mass index;
LGG	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg23231163	chr10:75533350	FUT11	-0.43	-7.19	-0.32	2.6e-12	Inflammatory bowel disease;
LGG	cis	rs2227564	0.729	rs2227551	chr10:75669190	G/T	cg00564723	chr10:75632066	CAMK2G	-0.4	-8.3	-0.36	1.18e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg10523679	chr1:76189770	ACADM	0.71	10.7	0.45	4.94e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1401999	1.000	rs9858774	chr3:183652736	G/A	cg01324343	chr3:183735012	ABCC5	0.87	18.59	0.65	5.22e-58	Anterior chamber depth;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg14494313	chr8:18248453	NAT2	-0.62	-7.49	-0.33	3.44e-13	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.515	rs11052934	chr12:33970381	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.23	0.55	2.15e-38	Morning vs. evening chronotype;
LGG	cis	rs943466	1.000	rs943461	chr6:33769409	C/G	cg07519485	chr6:33762594	MLN	0.56	11.16	0.46	8.73e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs1107366	0.505	rs12489314	chr3:125976864	A/G	cg06827562	chr3:125932279	NA	0.49	11.38	0.47	1.25e-26	Metabolite levels;
LGG	cis	rs7216064	0.906	rs8074644	chr17:65878217	G/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.77	-0.38	3.47e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.31e-19	Lung cancer;
LGG	cis	rs8067545	0.641	rs850623	chr17:19837130	C/T	cg04132472	chr17:19861366	AKAP10	0.26	7.17	0.32	3e-12	Schizophrenia;
LGG	cis	rs6496044	0.568	rs1982742	chr15:86068750	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-6.73	-0.3	5.13e-11	Interstitial lung disease;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	cis	rs6735179	0.565	rs73182754	chr2:1747733	A/C	cg10160682	chr2:1713001	PXDN	-0.55	-9.56	-0.41	7.02e-20	Response to antipsychotic treatment;
LGG	cis	rs7572644	0.640	rs4665392	chr2:28029649	A/G	cg27432699	chr2:27873401	GPN1	0.48	7.02	0.31	7.76e-12	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs6061231	0.793	rs2427320	chr20:60976723	A/G	cg06026331	chr20:60912101	LAMA5	0.57	9.8	0.41	9.66e-21	Colorectal cancer;
LGG	cis	rs1465370	0.533	rs10239342	chr7:130009312	T/G	cg25718383	chr7:130020096	CPA1	0.3	7.49	0.33	3.58e-13	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs75920871	0.748	rs7946399	chr11:116962753	G/C	cg20608306	chr11:116969690	SIK3	-0.34	-8.02	-0.35	8.83e-15	Subjective well-being;
LGG	trans	rs9329221	0.655	rs656319	chr8:9814411	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.41	-0.33	6.21e-13	Neuroticism;
LGG	cis	rs1552244	1.000	rs17032268	chr3:10067972	C/T	cg08888203	chr3:10149979	C3orf24	0.56	9.32	0.4	4.68e-19	Alzheimer's disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02037503	chr14:23540729	ACIN1	0.48	8.46	0.37	3.6e-16	Menarche (age at onset);
LGG	cis	rs28655083	0.913	rs7190129	chr16:77071456	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-7.93	-0.35	1.63e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg11062466	chr8:58055876	NA	0.48	8.26	0.36	1.49e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7149337	0.717	rs4309324	chr14:51606336	A/T	cg23942311	chr14:51606299	NA	-0.41	-9.09	-0.39	2.99e-18	Cancer;
LGG	cis	rs7444	0.941	rs5754352	chr22:21964951	C/T	cg05046821	chr22:21984468	YDJC	-0.38	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	trans	rs1945213	0.694	rs34828123	chr11:55837868	T/A	cg03929089	chr4:120376271	NA	0.8	11.04	0.46	2.62e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4631830	0.733	rs4512771	chr10:51540906	C/A	cg16070123	chr10:51489643	NA	-0.39	-7.15	-0.32	3.42e-12	Prostate-specific antigen levels;
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg03517284	chr6:25882590	NA	0.38	6.86	0.3	2.17e-11	Height;
LGG	cis	rs17209837	1.000	rs45526438	chr7:87089927	G/A	cg00919237	chr7:87102261	ABCB4	-0.69	-11.18	-0.46	7.65e-26	Gallbladder cancer;
LGG	cis	rs7385804	0.796	rs10277087	chr7:100307538	C/G	cg20848291	chr7:100343083	ZAN	0.44	7.09	0.31	5.14e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs10463316	0.925	rs6877344	chr5:150742650	C/T	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.11	-0.43	7.87e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs17767392	0.958	rs2877729	chr14:71887868	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	9.09	0.39	2.86e-18	Mitral valve prolapse;
LGG	cis	rs4917300	0.606	rs7825460	chr8:143114671	T/C	cg06573787	chr8:143070187	NA	0.6	9.96	0.42	2.67e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs9322193	0.923	rs11155671	chr6:149972132	G/A	cg11878867	chr6:150167359	LRP11	-0.52	-10.78	-0.45	2.43e-24	Lung cancer;
LGG	cis	rs1385374	0.858	rs12321643	chr12:129302867	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.61	6.8	0.3	3.26e-11	Systemic lupus erythematosus;
LGG	cis	rs6546537	0.562	rs1985342	chr2:69758927	C/T	cg10773587	chr2:69614142	GFPT1	-0.52	-9.36	-0.4	3.44e-19	Serum thyroid-stimulating hormone levels;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2470578	0.766	rs2733497	chr3:17280282	C/T	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs7122539	0.646	rs627330	chr11:66602099	C/T	cg01599099	chr11:66649832	PC	0.37	7.31	0.32	1.18e-12	HIV-1 susceptibility;
LGG	cis	rs2050392	0.928	rs2250077	chr10:30702929	A/G	cg25182066	chr10:30743637	MAP3K8	-0.52	-10.79	-0.45	2.23e-24	Inflammatory bowel disease;
LGG	cis	rs597539	0.652	rs559032	chr11:68710847	G/T	cg18350739	chr11:68623251	NA	-0.85	-21.64	-0.71	2.95e-72	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7937682	0.824	rs11213962	chr11:111506027	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27597069	chr6:37321822	RNF8	0.46	7.38	0.32	7.51e-13	Cognitive performance;
LGG	cis	rs6088590	1.000	rs11698977	chr20:33449691	C/T	cg24642439	chr20:33292090	TP53INP2	0.83	14.5	0.56	1.55e-39	Coronary artery disease;
LGG	trans	rs853679	0.556	rs34706883	chr6:27805255	A/C	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg22398616	chr13:53314203	LECT1	-0.57	-12.26	-0.5	4.08e-30	Lewy body disease;
LGG	cis	rs4718428	0.705	rs10267335	chr7:66403220	G/T	cg18252515	chr7:66147081	NA	-0.75	-11.9	-0.48	1.15e-28	Corneal structure;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11245990	chr11:68621969	NA	0.4	8.62	0.37	1.11e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7301016	1.000	rs11174504	chr12:62877036	A/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs6752107	0.846	rs7559194	chr2:234206799	G/A	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	12.01	0.49	4.04e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs753955	0.593	rs7982516	chr13:24410278	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.42	7.52	0.33	2.92e-13	Lung cancer;
LGG	cis	rs2153904	0.793	rs1772145	chr1:205695695	C/T	cg23034840	chr1:205782522	SLC41A1	0.69	9.2	0.39	1.28e-18	Prostate-specific antigen levels;
LGG	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg02931644	chr1:25747376	RHCE	0.42	9.4	0.4	2.49e-19	Erythrocyte sedimentation rate;
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg27400746	chr16:89904261	SPIRE2	-1.07	-16.0	-0.6	3.4e-46	Skin colour saturation;
LGG	cis	rs11122272	0.705	rs2491411	chr1:231533448	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs4689388	0.926	rs3821940	chr4:6286711	C/A	cg25554036	chr4:6271136	WFS1	0.62	11.93	0.48	8.35e-29	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00424166	chr6:150045504	NUP43	-0.34	-7.17	-0.32	3.06e-12	Lung cancer;
LGG	cis	rs2228479	0.850	rs12597296	chr16:89822331	C/T	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs1790761	0.967	rs1638556	chr11:67213518	A/G	cg14500267	chr11:67383377	NA	-0.39	-7.08	-0.31	5.37e-12	Mean corpuscular volume;
LGG	cis	rs496300	0.903	rs634978	chr21:44782732	A/C	cg10251070	chr21:44781958	NA	-0.25	-6.73	-0.3	4.95e-11	Metabolic syndrome;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg11301795	chr4:187892539	NA	-0.95	-24.88	-0.76	2.34e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7173743	1.000	rs4420501	chr15:79138478	A/T	cg00540400	chr15:79124168	NA	-0.43	-8.77	-0.38	3.54e-17	Coronary artery disease;
LGG	cis	rs367943	0.712	rs26968	chr5:112742429	A/G	cg12552261	chr5:112820674	MCC	0.58	10.48	0.44	3.44e-23	Type 2 diabetes;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg13047869	chr3:10149882	C3orf24	0.55	9.19	0.39	1.38e-18	Alzheimer's disease;
LGG	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg25237894	chr2:233734115	C2orf82	-0.73	-15.41	-0.58	1.45e-43	Coronary artery disease;
LGG	cis	rs9902453	0.904	rs9897794	chr17:28296327	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.04	0.55	1.5e-37	Coffee consumption (cups per day);
LGG	cis	rs599083	0.530	rs576118	chr11:68177708	C/T	cg01657329	chr11:68192670	LRP5	0.63	10.51	0.44	2.58e-23	Bone mineral density (spine);
LGG	cis	rs763121	0.853	rs11704021	chr22:39074716	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs4950322	0.580	rs72706441	chr1:146594183	C/T	cg22381352	chr1:146742008	CHD1L	-0.46	-7.67	-0.34	1.03e-13	Protein quantitative trait loci;
LGG	trans	rs5756813	0.754	rs8136757	chr22:38185971	A/G	cg19894588	chr14:64061835	NA	-0.63	-9.98	-0.42	2.18e-21	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6564851	0.545	rs4889285	chr16:81252258	C/T	cg00163702	chr16:81254719	PKD1L2	0.37	8.62	0.37	1.03e-16	Carotenoid and tocopherol levels;
LGG	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg10326726	chr10:51549505	MSMB	-0.62	-12.58	-0.5	2.09e-31	Prostate-specific antigen levels;
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg11814155	chr7:99998594	ZCWPW1	0.58	8.53	0.37	2.03e-16	Platelet count;
LGG	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg20302533	chr7:39170763	POU6F2	-0.5	-11.57	-0.47	2.21e-27	IgG glycosylation;
LGG	cis	rs2108225	0.934	rs2301988	chr7:107443833	A/G	cg18560240	chr7:107437656	SLC26A3	0.53	9.52	0.4	9.54e-20	Ulcerative colitis;
LGG	trans	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg21775007	chr8:11205619	TDH	0.46	7.54	0.33	2.57e-13	Systolic blood pressure;
LGG	cis	rs9926296	0.632	rs7184315	chr16:89799373	C/G	cg23057051	chr16:89984268	MC1R	0.36	7.01	0.31	8.23e-12	Vitiligo;
LGG	cis	rs7615952	0.599	rs7652883	chr3:125707977	T/G	cg05084668	chr3:125655381	ALG1L	-0.57	-7.72	-0.34	7.02e-14	Blood pressure (smoking interaction);
LGG	cis	rs1059312	0.771	rs7974764	chr12:129296588	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.35	8.7	0.37	5.99e-17	Systemic lupus erythematosus;
LGG	cis	rs2635047	0.638	rs9956809	chr18:44655843	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.12	0.31	4.22e-12	Educational attainment;
LGG	trans	rs208520	0.690	rs12213561	chr6:66705646	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.56	0.63	2.86e-53	Exhaled nitric oxide output;
LGG	cis	rs9547996	0.879	rs9547958	chr13:38140879	A/T	cg17979426	chr13:38220150	TRPC4	0.39	7.53	0.33	2.7e-13	Diastolic blood pressure;
LGG	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg01043669	chr3:72786069	NA	0.43	7.09	0.31	5.02e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs9467711	0.606	rs9393710	chr6:26367833	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs738322	0.511	rs2267371	chr22:38577119	T/G	cg03162506	chr22:38580953	NA	0.36	8.88	0.38	1.44e-17	Cutaneous nevi;
LGG	cis	rs57590327	0.555	rs3821551	chr3:81710179	A/T	cg07356753	chr3:81810745	GBE1	-0.49	-7.64	-0.33	1.23e-13	Extraversion;
LGG	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.89	-0.42	4.86e-21	Retinal vascular caliber;
LGG	cis	rs11096990	0.855	rs2043102	chr4:39152912	T/C	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	trans	rs7395662	0.711	rs11512405	chr11:48936357	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.63	-0.33	1.31e-13	HDL cholesterol;
LGG	trans	rs56804039	1.000	rs7017341	chr8:8381664	C/A	cg02002194	chr4:3960332	NA	0.44	6.99	0.31	9.54e-12	Cervical cancer;
LGG	trans	rs6951245	0.507	rs11763865	chr7:1194274	G/A	cg13565492	chr6:43139072	SRF	-0.53	-7.53	-0.33	2.75e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs116095464	0.614	rs56299325	chr5:220594	C/T	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs2404602	0.735	rs11629888	chr15:76719880	A/T	cg15268244	chr15:77196840	NA	0.43	8.82	0.38	2.27e-17	Blood metabolite levels;
LGG	cis	rs5769707	0.521	rs6009807	chr22:50058922	A/G	cg06623630	chr22:50017776	C22orf34	-0.45	-8.91	-0.38	1.21e-17	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg01879757	chr17:41196368	BRCA1	-0.46	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs2952156	0.883	rs12150603	chr17:37834715	G/A	cg07936489	chr17:37558343	FBXL20	-0.52	-8.8	-0.38	2.65e-17	Asthma;
LGG	cis	rs17376456	0.877	rs7734897	chr5:93305402	G/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs2735413	0.914	rs2262658	chr16:78060267	A/G	cg04733911	chr16:78082701	NA	-0.73	-16.28	-0.6	1.93e-47	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3741404	0.665	rs594461	chr11:63872543	A/G	cg05016508	chr11:63871570	FLRT1;MACROD1	0.4	8.01	0.35	9.54e-15	Platelet count;
LGG	trans	rs4927850	0.709	rs6765762	chr3:195652851	G/A	cg16724585	chr3:197361211	NA	-0.47	-7.66	-0.34	1.13e-13	Pancreatic cancer;
LGG	cis	rs6066825	0.590	rs729663	chr20:47304306	C/T	cg18078177	chr20:47281410	PREX1	-0.48	-8.06	-0.35	6.76e-15	Colorectal cancer;
LGG	cis	rs975739	1.000	rs1766342	chr13:78384296	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.77	0.3	3.81e-11	Hair color;
LGG	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg07636037	chr3:49044803	WDR6	-0.76	-13.57	-0.53	1.48e-35	Menarche (age at onset);
LGG	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg19507638	chr5:93509721	C5orf36	-0.72	-9.96	-0.42	2.64e-21	Diabetic retinopathy;
LGG	cis	rs7264396	0.790	rs6058294	chr20:34259396	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.97	0.31	1.08e-11	Total cholesterol levels;
LGG	cis	rs2228479	0.681	rs10153055	chr16:89965842	C/T	cg06558623	chr16:89946397	TCF25	0.84	10.49	0.44	2.97e-23	Skin colour saturation;
LGG	cis	rs1153858	1.000	rs1153849	chr15:45695695	G/A	cg26924012	chr15:45694286	SPATA5L1	1.03	20.75	0.69	4.2e-68	Homoarginine levels;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs67517081	1	rs67517081	chr16:30987380	GT/G	cg02466173	chr16:30829666	NA	0.42	7.36	0.32	8.42e-13	Mean corpuscular hemoglobin;
LGG	cis	rs6868223	0.585	rs10058829	chr5:33643190	T/C	cg10594543	chr5:33649717	ADAMTS12	0.66	15.67	0.59	9.99e-45	Mortality in heart failure;
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.43	-9.2	-0.39	1.18e-18	Schizophrenia;
LGG	cis	rs6502050	0.871	rs62079998	chr17:80077245	A/C	cg19223190	chr17:80058835	NA	-0.46	-9.07	-0.39	3.32e-18	Life satisfaction;
LGG	cis	rs2718058	0.606	rs2598077	chr7:37870427	G/C	cg24998770	chr7:37888106	TXNDC3	0.46	7.4	0.33	6.68e-13	Alzheimer's disease (late onset);
LGG	cis	rs1552244	0.832	rs73024575	chr3:10198200	C/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.14	18.26	0.65	1.66e-56	Alzheimer's disease;
LGG	cis	rs6840360	0.593	rs10022023	chr4:152560731	A/G	cg22705602	chr4:152727874	NA	-0.32	-7.67	-0.34	9.95e-14	Intelligence (multi-trait analysis);
LGG	cis	rs921968	0.541	rs532425	chr2:219434194	A/G	cg10223061	chr2:219282414	VIL1	-0.3	-6.72	-0.3	5.51e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4851254	0.961	rs13028981	chr2:100795783	C/T	cg17356467	chr2:100759845	AFF3	0.4	7.05	0.31	6.57e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9341835	0.584	rs1741801	chr6:64145375	T/C	cg00787780	chr6:64151745	NA	0.44	8.12	0.35	4.41e-15	Schizophrenia;
LGG	cis	rs2228479	0.867	rs11646448	chr16:89966357	A/T	cg06558623	chr16:89946397	TCF25	1.16	14.89	0.57	2.84e-41	Skin colour saturation;
LGG	cis	rs11098499	0.722	rs1814814	chr4:120258124	C/G	cg09307838	chr4:120376055	NA	0.69	12.05	0.49	2.74e-29	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg14926445	chr8:58193284	C8orf71	-0.87	-13.06	-0.52	2.08e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7106204	0.534	rs78879754	chr11:24279312	G/A	ch.11.24196551F	chr11:24239977	NA	0.85	8.65	0.37	8.52e-17	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs362296	0.698	rs3135171	chr4:3261127	A/G	cg06533319	chr4:3265114	C4orf44	0.51	10.0	0.42	1.86e-21	Parental longevity (mother's age at death);
LGG	cis	rs4006360	0.542	rs9900575	chr17:39307675	C/T	cg16985667	chr17:39306289	KRTAP4-5	0.66	14.89	0.57	3.09e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg18404041	chr3:52824283	ITIH1	-0.52	-10.0	-0.42	1.84e-21	Bipolar disorder;
LGG	cis	rs514024	0.656	rs537881	chr9:130485618	C/T	cg13643465	chr9:130375613	STXBP1	0.57	10.57	0.44	1.53e-23	Eating disorders (purging via substances);
LGG	cis	rs8017423	0.935	rs7144070	chr14:90753047	T/C	cg04374321	chr14:90722782	PSMC1	0.84	17.69	0.64	7.14e-54	Mortality in heart failure;
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg09303159	chr6:26284866	NA	0.33	7.57	0.33	2e-13	Educational attainment;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg16359550	chr11:109292809	C11orf87	0.52	9.92	0.42	3.59e-21	Schizophrenia;
LGG	cis	rs4566357	0.964	rs4296416	chr2:227921926	C/T	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs4917300	0.572	rs6583568	chr8:143115563	T/C	cg26003909	chr8:143102224	NA	-0.35	-6.81	-0.3	3.01e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg21926883	chr2:100939477	LONRF2	-0.67	-15.74	-0.59	5.03e-45	Intelligence (multi-trait analysis);
LGG	cis	rs7940866	0.874	rs10791113	chr11:130873165	A/G	cg12179176	chr11:130786555	SNX19	0.72	13.03	0.52	2.83e-33	Schizophrenia;
LGG	cis	rs11158198	0.643	rs980468	chr14:58586031	C/T	cg15908186	chr14:58618357	C14orf37	0.55	9.75	0.41	1.54e-20	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	trans	rs3942852	0.806	rs11039515	chr11:48119474	A/G	cg15704280	chr7:45808275	SEPT13	0.64	9.04	0.39	4.32e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.63e-22	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14694896	chr8:104427370	SLC25A32;DCAF13	0.41	6.79	0.3	3.46e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.73	15.21	0.58	1.11e-42	Obesity-related traits;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.76	-0.34	5.53e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.761	rs1871621	chr10:1049596	C/T	cg25019033	chr10:957182	NA	-0.56	-10.28	-0.43	1.88e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs7818345	0.595	rs12155539	chr8:19316086	G/A	cg11303988	chr8:19266685	CSGALNACT1	0.4	6.75	0.3	4.32e-11	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs6763768	0.606	rs7648309	chr3:53291982	C/T	cg16894138	chr3:53270350	TKT	0.38	7.03	0.31	7.33e-12	Bacterial meningitis;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.11	-0.43	7.32e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs61733801	chr8:58192513	A/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.34	-0.32	9.99e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7659604	1.000	rs10005932	chr4:122664782	T/C	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.88	-0.3	2.01e-11	Type 2 diabetes;
LGG	trans	rs1814175	0.645	rs10839382	chr11:49823172	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.39	-0.61	6e-48	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10332296	chr1:42928798	NA	0.51	7.68	0.34	9.71e-14	Gut microbiome composition (summer);
LGG	cis	rs2486288	0.587	rs12899942	chr15:45547280	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.9	-0.42	4.31e-21	Glomerular filtration rate;
LGG	cis	rs6502050	0.835	rs8077772	chr17:80117220	A/G	cg13939156	chr17:80058883	NA	0.45	8.7	0.37	5.71e-17	Life satisfaction;
LGG	cis	rs13065560	0.560	rs11716777	chr3:38957755	G/T	cg01426195	chr3:39028469	NA	0.41	8.05	0.35	6.91e-15	Interleukin-18 levels;
LGG	cis	rs8028182	0.549	rs7402844	chr15:75637396	C/G	cg20655648	chr15:75932815	IMP3	-0.47	-7.63	-0.33	1.33e-13	Sudden cardiac arrest;
LGG	cis	rs9303401	0.614	rs2333409	chr17:57139134	G/A	cg25039879	chr17:56429692	SUPT4H1	0.6	8.48	0.37	2.98e-16	Cognitive test performance;
LGG	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg10818794	chr15:86012489	AKAP13	-0.31	-6.65	-0.3	8.38e-11	Interstitial lung disease;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.51	-0.47	3.82e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg02631450	chr22:32366979	NA	1.02	9.82	0.42	8.63e-21	Childhood ear infection;
LGG	trans	rs9467711	0.606	rs13190739	chr6:26587373	G/T	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11785693	0.862	rs62491189	chr8:4991309	T/C	cg26367366	chr8:4980734	NA	1.02	16.01	0.6	2.99e-46	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs977987	0.843	rs62062568	chr16:75445324	T/C	cg03315344	chr16:75512273	CHST6	0.52	10.43	0.44	5.06e-23	Dupuytren's disease;
LGG	cis	rs7173743	0.756	rs7169511	chr15:79128665	T/C	cg00540400	chr15:79124168	NA	0.42	8.61	0.37	1.15e-16	Coronary artery disease;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.51	-0.47	3.82e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs2304069	0.913	rs3812009	chr5:149380159	G/C	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.9	13.99	0.55	2.4e-37	HIV-1 control;
LGG	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07570687	chr10:102243282	WNT8B	0.41	6.68	0.3	6.86e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4919087	0.748	rs701814	chr10:98975719	C/T	cg25902810	chr10:99078978	FRAT1	-0.42	-7.27	-0.32	1.59e-12	Monocyte count;
LGG	cis	rs1552244	0.882	rs13088350	chr3:10044626	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.57	0.37	1.52e-16	Alzheimer's disease;
LGG	cis	rs61332075	0.540	rs55986470	chr2:239363773	A/G	cg18131467	chr2:239335373	ASB1	-0.66	-7.68	-0.34	9.72e-14	Lung function (FEV1/FVC);
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.84	-0.34	3.1e-14	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.17	-0.58	1.82e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs12681288	0.792	rs12678495	chr8:1000858	C/G	cg04851639	chr8:1020857	NA	-0.43	-9.23	-0.39	9.49e-19	Schizophrenia;
LGG	cis	rs6500395	0.962	rs1564979	chr16:48647017	C/A	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs758324	0.947	rs13170693	chr5:131187826	T/C	cg06307176	chr5:131281290	NA	0.58	9.52	0.4	9.56e-20	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs990171	1.000	rs4851575	chr2:103025203	G/A	cg05295703	chr2:102895712	NA	-0.56	-9.97	-0.42	2.49e-21	Lymphocyte counts;
LGG	cis	rs2204008	0.688	rs12824232	chr12:38175901	G/A	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs9814567	0.806	rs12637301	chr3:134317966	G/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs709400	0.663	rs62007719	chr14:103943130	G/T	cg26031613	chr14:104095156	KLC1	0.8	13.87	0.54	7.6e-37	Body mass index;
LGG	cis	rs8012	0.517	rs17706531	chr19:13015530	A/G	cg11738485	chr19:12877000	HOOK2	-0.45	-7.06	-0.31	6.04e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs12534701	1.000	rs12534701	chr7:154680910	A/C	cg24255201	chr7:154684926	DPP6	-0.56	-10.41	-0.44	6.31e-23	Colorectal cancer (diet interaction);
LGG	cis	rs2228479	0.764	rs7184960	chr16:89961661	C/T	cg19635926	chr16:89946313	TCF25	0.69	8.29	0.36	1.2e-15	Skin colour saturation;
LGG	cis	rs2286885	1.000	rs10819169	chr9:129249625	C/T	cg14319473	chr9:129242481	FAM125B	0.45	8.27	0.36	1.42e-15	Intraocular pressure;
LGG	cis	rs2739330	0.828	rs5760102	chr22:24248761	T/C	cg23131131	chr22:24373011	LOC391322	-0.49	-8.04	-0.35	7.46e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg09699651	chr6:150184138	LRP11	0.57	11.18	0.46	7.18e-26	Testicular germ cell tumor;
LGG	cis	rs11628318	0.660	rs4906242	chr14:103085063	G/A	cg12046867	chr14:103022105	NA	-0.75	-12.39	-0.5	1.21e-30	Platelet count;
LGG	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.15e-15	Monocyte count;
LGG	cis	rs7226408	0.857	rs17652483	chr18:34482270	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.15	-0.32	3.31e-12	Obesity-related traits;
LGG	cis	rs422249	0.512	rs174561	chr11:61582708	T/C	cg19610905	chr11:61596333	FADS2	-0.77	-12.95	-0.52	5.82e-33	Trans fatty acid levels;
LGG	cis	rs769267	0.929	rs2905424	chr19:19473445	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.68	-0.54	5.33e-36	Tonsillectomy;
LGG	trans	rs2548003	0.806	rs2250921	chr5:28766482	C/T	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.7e-11	Hip geometry;
LGG	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.01	0.39	5.55e-18	Motion sickness;
LGG	cis	rs9611565	0.546	rs739134	chr22:42089623	T/C	cg17376030	chr22:41985996	PMM1	-0.6	-9.5	-0.4	1.12e-19	Vitiligo;
LGG	cis	rs7166081	0.950	rs12915601	chr15:67631271	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.27	-0.32	1.51e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs6942756	1.000	rs10954226	chr7:128953095	T/G	cg02491457	chr7:128862824	NA	-0.75	-13.62	-0.53	9.27e-36	White matter hyperintensity burden;
LGG	cis	rs9768139	0.658	rs73746486	chr7:158113191	A/G	cg02855558	chr7:158107723	PTPRN2	-0.41	-7.41	-0.33	6.21e-13	Calcium levels;
LGG	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.36	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg05335186	chr13:53173507	NA	0.52	10.82	0.45	1.8e-24	Lewy body disease;
LGG	cis	rs3741151	0.773	rs73542952	chr11:73108556	A/G	cg17517138	chr11:73019481	ARHGEF17	0.88	8.72	0.38	5.14e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1014246	0.698	rs10787726	chr10:118495978	A/G	cg14919929	chr10:118506882	NA	0.67	12.86	0.51	1.4e-32	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs950169	0.881	rs150965	chr15:85080527	T/G	cg24253500	chr15:84953950	NA	0.58	10.51	0.44	2.6e-23	Schizophrenia;
LGG	cis	rs7618915	0.547	rs2118540	chr3:52629386	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.04	-0.31	7.04e-12	Bipolar disorder;
LGG	cis	rs2247341	0.965	rs2854920	chr4:1715349	C/T	cg08629884	chr4:1719983	TMEM129	-0.57	-11.1	-0.46	1.46e-25	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs2710642	0.779	rs360807	chr2:62926859	C/T	cg17519650	chr2:63277830	OTX1	-0.47	-7.59	-0.33	1.76e-13	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs867371	1.000	rs881308	chr15:82475797	A/G	cg00614314	chr15:82944287	LOC80154	0.59	9.58	0.41	5.98e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4481887	0.927	rs12731721	chr1:248474210	G/A	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg15556689	chr8:8085844	FLJ10661	-0.39	-7.06	-0.31	6.19e-12	Joint mobility (Beighton score);
LGG	cis	rs35883536	0.609	rs2647327	chr1:101041766	C/T	cg06223162	chr1:101003688	GPR88	0.42	10.38	0.43	7.97e-23	Monocyte count;
LGG	cis	rs6502050	0.761	rs13949	chr17:80059596	T/C	cg07959490	chr17:80112427	CCDC57	0.38	7.38	0.32	7.31e-13	Life satisfaction;
LGG	cis	rs79976124	0.879	rs12213669	chr6:66627704	G/A	cg07460842	chr6:66804631	NA	0.74	12.73	0.51	5.04e-32	Type 2 diabetes;
LGG	cis	rs4808199	0.895	rs10403731	chr19:19469296	G/A	cg03709012	chr19:19516395	GATAD2A	0.97	15.39	0.58	1.82e-43	Nonalcoholic fatty liver disease;
LGG	trans	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg22232500	chr2:134024266	NCKAP5	0.52	7.28	0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs9326248	0.581	rs7121898	chr11:116796846	A/T	cg20608306	chr11:116969690	SIK3	0.42	13.37	0.53	1.1e-34	Blood protein levels;
LGG	cis	rs3785574	0.962	rs2584628	chr17:61894578	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	1.14	27.31	0.79	1.57e-98	Height;
LGG	cis	rs11229555	0.598	rs12289876	chr11:58185250	C/T	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7312933	0.670	rs2406568	chr12:42552297	G/C	cg19980929	chr12:42632907	YAF2	0.37	8.23	0.36	1.98e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1799949	1.000	rs1799966	chr17:41223094	T/C	cg18379455	chr17:41446167	NA	-0.31	-7.27	-0.32	1.54e-12	Menopause (age at onset);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg14036868	chr2:38604442	ATL2	-0.42	-6.71	-0.3	5.65e-11	Body fat percentage;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg17290332	chr10:14880008	CDNF;HSPA14	0.41	7.24	0.32	1.91e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs9522267	0.535	rs11069900	chr13:112233285	G/A	cg14952266	chr13:112191215	NA	0.52	10.94	0.45	6.12e-25	Hepatitis;
LGG	cis	rs11758351	0.660	rs11755943	chr6:26211368	A/G	cg23601095	chr6:26197514	HIST1H3D	0.7	8.88	0.38	1.48e-17	Gout;Renal underexcretion gout;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg02462569	chr6:150064036	NUP43	-0.44	-8.83	-0.38	2.25e-17	Lung cancer;
LGG	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.8	13.03	0.52	2.83e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10875746	0.669	rs9634261	chr12:48686871	A/G	cg24011408	chr12:48396354	COL2A1	-0.57	-7.53	-0.33	2.68e-13	Longevity (90 years and older);
LGG	cis	rs713587	0.967	rs6752378	chr2:25150116	C/A	cg04586622	chr2:25135609	ADCY3	0.45	12.13	0.49	1.3e-29	Body mass index in non-asthmatics;
LGG	cis	rs9581857	1.000	rs9581857	chr13:28027714	A/C	cg01674679	chr13:27998804	GTF3A	-0.65	-7.65	-0.33	1.21e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs13108904	0.967	rs13149715	chr4:1278255	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.72	13.35	0.53	1.24e-34	Obesity-related traits;
LGG	cis	rs1124376	0.935	rs67660889	chr3:20170538	G/C	cg05072819	chr3:20081367	KAT2B	0.59	7.85	0.34	2.88e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs412000	0.598	rs8263	chr17:56423114	C/T	cg05425664	chr17:57184151	TRIM37	-0.42	-6.66	-0.3	7.63e-11	Primary tooth development (time to first tooth eruption);
LGG	cis	rs889398	0.774	rs6499263	chr16:69890149	T/C	cg00738113	chr16:70207722	CLEC18C	-0.25	-6.93	-0.31	1.4e-11	Body mass index;
LGG	cis	rs6860806	0.507	rs272854	chr5:131688017	C/T	cg07395648	chr5:131743802	NA	-0.49	-10.06	-0.42	1.11e-21	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12666227	chr12:76742354	BBS10	0.39	6.66	0.3	7.76e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs3808502	0.503	rs34190028	chr8:11417150	G/T	cg11608241	chr8:8085544	FLJ10661	-0.32	-7.5	-0.33	3.19e-13	Neuroticism;
LGG	cis	rs3204270	0.639	rs11871678	chr17:79654285	G/A	cg18367735	chr17:79674897	NA	0.58	7.41	0.33	6.24e-13	Dental caries;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg22211233	chr3:182817584	MCCC1	0.44	6.83	0.3	2.61e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs864537	0.646	rs1773542	chr1:167432949	T/C	cg09179987	chr1:167433047	CD247	0.45	10.42	0.44	5.49e-23	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs4555082	0.834	rs2816652	chr14:105712493	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-15.99	-0.6	3.75e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs3735485	0.663	rs11769415	chr7:45149919	C/G	cg03440944	chr7:45023329	C7orf40	-0.49	-8.16	-0.35	3.16e-15	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg16578609	chr1:2399051	NA	-0.4	-8.35	-0.36	8e-16	Non-obstructive azoospermia;
LGG	cis	rs17253792	0.822	rs76557162	chr14:56064701	A/G	cg01858014	chr14:56050164	KTN1	-0.91	-12.68	-0.51	7.69e-32	Putamen volume;
LGG	cis	rs9309473	0.528	rs11126395	chr2:73564964	A/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.69	-0.34	9.22e-14	Metabolite levels;
LGG	cis	rs490234	0.812	rs13286111	chr9:128429951	A/T	cg14078157	chr9:128172775	NA	-0.47	-8.29	-0.36	1.25e-15	Mean arterial pressure;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.34	-0.32	9.46e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs7089973	0.604	rs8181444	chr10:116588981	C/T	cg03647239	chr10:116582469	FAM160B1	0.42	7.26	0.32	1.69e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7084402	0.967	rs1649025	chr10:60281584	C/G	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.22e-13	Refractive error;
LGG	cis	rs9467773	0.620	rs2504565	chr6:26656890	G/A	cg11502198	chr6:26597334	ABT1	0.7	12.74	0.51	4.36e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2486288	0.656	rs2271438	chr15:45557468	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.1	-0.43	8.07e-22	Glomerular filtration rate;
LGG	cis	rs72945132	0.882	rs17425511	chr11:70183737	C/G	cg14191688	chr11:70257035	CTTN	0.6	8.56	0.37	1.7e-16	Coronary artery disease;
LGG	trans	rs1945213	0.694	rs17149976	chr11:55839746	T/C	cg11707556	chr5:10655725	ANKRD33B	0.49	7.23	0.32	2.05e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs1045714	0.895	rs17833498	chr7:2647007	A/G	cg14042143	chr7:2646782	IQCE	-0.8	-12.45	-0.5	6.83e-31	Urate levels in lean individuals;
LGG	cis	rs2297440	0.506	rs2236504	chr20:62224762	C/T	cg16989086	chr20:62203971	PRIC285	0.49	7.13	0.31	3.97e-12	Glioma;Non-glioblastoma glioma;Glioblastoma;
LGG	cis	rs10791097	0.694	rs10894275	chr11:130756251	C/T	cg09137382	chr11:130731461	NA	0.35	6.79	0.3	3.49e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9905704	0.647	rs12944274	chr17:57041293	C/G	cg12560992	chr17:57184187	TRIM37	-0.51	-8.04	-0.35	7.41e-15	Testicular germ cell tumor;
LGG	cis	rs13108043	0.605	rs35653846	chr4:87922823	A/G	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	trans	rs9929218	0.559	rs12923775	chr16:68756450	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.91	19.85	0.68	6.8e-64	Colorectal cancer;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg11878867	chr6:150167359	LRP11	-0.56	-12.0	-0.49	4.37e-29	Lung cancer;
LGG	cis	rs7241530	0.536	rs34231010	chr18:75891275	T/C	cg14642773	chr18:75888474	NA	0.46	8.99	0.39	6.57e-18	Educational attainment (years of education);
LGG	cis	rs651907	0.557	rs13069443	chr3:101373305	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.64	-0.33	1.24e-13	Colorectal cancer;
LGG	cis	rs6879260	0.963	rs1035412	chr5:179729328	C/T	cg02891314	chr5:179741120	GFPT2	-0.63	-11.57	-0.47	2.3e-27	Height;
LGG	cis	rs7914558	1.000	rs4917380	chr10:104775335	C/G	cg04362960	chr10:104952993	NT5C2	0.53	10.18	0.43	4.2e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs4865875	0.892	rs4457032	chr5:54098171	G/T	cg22421804	chr5:54100067	NA	0.51	7.41	0.33	6.17e-13	Sense of smell;
LGG	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg16230307	chr14:35515116	FAM177A1	0.93	13.72	0.54	3.57e-36	Psoriasis;
LGG	cis	rs9875589	0.509	rs2733548	chr3:14094478	C/T	cg19554555	chr3:13937349	NA	-0.57	-10.24	-0.43	2.48e-22	Ovarian reserve;
LGG	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg00405596	chr8:11794950	NA	-0.61	-10.82	-0.45	1.79e-24	Myopia (pathological);
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg14004847	chr7:1930337	MAD1L1	-0.46	-7.89	-0.34	2.14e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg18200150	chr17:30822561	MYO1D	0.51	9.85	0.42	6.83e-21	Schizophrenia;
LGG	cis	rs9611565	0.643	rs202634	chr22:41809623	A/G	cg06634786	chr22:41940651	POLR3H	0.75	12.24	0.49	4.79e-30	Vitiligo;
LGG	cis	rs10256972	0.681	rs12702016	chr7:1129392	C/T	cg04025307	chr7:1156635	C7orf50	0.87	18.79	0.66	6.14e-59	Longevity;Endometriosis;
LGG	cis	rs6746896	0.683	rs6576984	chr2:97454705	C/T	cg01990225	chr2:97406019	LMAN2L	-0.4	-6.65	-0.3	8.45e-11	Bipolar disorder;
LGG	cis	rs7666738	1.000	rs13144055	chr4:99026849	A/G	cg05340658	chr4:99064831	C4orf37	0.42	6.73	0.3	4.94e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs57502260	0.573	rs11228294	chr11:68388567	C/T	cg16797656	chr11:68205561	LRP5	0.45	7.23	0.32	1.97e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs10937275	0.624	rs10513810	chr3:186667885	A/G	cg13419791	chr3:186648285	ST6GAL1	0.72	7.78	0.34	4.86e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04696559	chr5:36152378	SKP2;LMBRD2	0.45	7.61	0.33	1.58e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.826	rs17209769	chr6:45321205	C/A	cg20913747	chr6:44695427	NA	-0.6	-10.13	-0.43	6.5600000000000005e-22	Total body bone mineral density;
LGG	cis	rs9467711	0.790	rs67777156	chr6:26633711	T/A	cg12826209	chr6:26865740	GUSBL1	0.76	6.7	0.3	6.03e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17683430	0.557	rs4821012	chr22:32387985	A/G	cg02631450	chr22:32366979	NA	1.01	9.71	0.41	2.06e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs28386778	0.865	rs2727276	chr17:61929709	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs7617773	0.817	rs4131361	chr3:48328812	T/C	cg11946769	chr3:48343235	NME6	0.63	10.61	0.44	1.07e-23	Coronary artery disease;
LGG	cis	rs651907	1.000	rs651907	chr3:101600724	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.41	6.96	0.31	1.19e-11	Colorectal cancer;
LGG	cis	rs7824557	0.606	rs2736270	chr8:11192593	G/A	cg21775007	chr8:11205619	TDH	0.81	14.74	0.57	1.34e-40	Retinal vascular caliber;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg26174226	chr8:58114915	NA	-0.6	-8.64	-0.37	9.46e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs273218	1.000	rs273218	chr5:53380555	T/C	ch.5.1024479R	chr5:53302184	ARL15	0.66	9.11	0.39	2.54e-18	Migraine;
LGG	cis	rs2153535	0.580	rs7341381	chr6:8470537	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.23e-18	Motion sickness;
LGG	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg00666640	chr1:248458726	OR2T12	0.5	8.63	0.37	9.57e-17	Common traits (Other);
LGG	cis	rs10504229	0.683	rs11774645	chr8:58132921	G/C	cg22535103	chr8:58192502	C8orf71	-0.94	-12.49	-0.5	4.67e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs509477	1.000	rs7245165	chr18:32567007	C/A	cg23791764	chr18:32556832	MAPRE2	0.51	8.61	0.37	1.18e-16	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.65	0.37	8.5e-17	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs4819046	chr21:46664955	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.08	0.39	3.09e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7095944	0.582	rs2303611	chr10:126517989	G/A	cg08799069	chr10:126477246	METTL10	-0.46	-10.69	-0.44	5.69e-24	Asthma;
LGG	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.47	-0.5	5.88e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs7582180	0.629	rs11123827	chr2:100951248	C/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.36e-30	Intelligence (multi-trait analysis);
LGG	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg00711542	chr16:29343894	RUNDC2C	0.39	6.7	0.3	5.94e-11	Menopause (age at onset);
LGG	cis	rs4302748	0.862	rs57651006	chr7:36184211	T/C	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	trans	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs9858542	0.953	rs7623659	chr3:49414791	C/T	cg03060546	chr3:49711283	APEH	-0.62	-10.31	-0.43	1.41e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs834811	0.505	rs7789711	chr7:135938979	C/T	cg01726295	chr7:135938950	NA	-0.42	-8.72	-0.38	4.96e-17	Post-traumatic stress disorder;
LGG	cis	rs12410462	0.681	rs75876430	chr1:227661157	A/G	cg23173402	chr1:227635558	NA	0.69	10.56	0.44	1.69e-23	Major depressive disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12046375	chr1:150459886	TARS2	0.42	6.96	0.31	1.13e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07939768	chr17:27621433	NUFIP2	0.48	7.86	0.34	2.67e-14	Cognitive performance;
LGG	cis	rs6459804	1.000	rs73163880	chr7:157508755	C/T	cg15733309	chr7:157513707	PTPRN2	0.62	14.74	0.57	1.4e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs68170813	0.559	rs76646886	chr7:107034328	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.22	-0.43	3.14e-22	Coronary artery disease;
LGG	cis	rs514406	0.861	rs10888755	chr1:53240829	A/G	cg16325326	chr1:53192061	ZYG11B	-0.75	-17.8	-0.64	2.28e-54	Monocyte count;
LGG	cis	rs2562456	0.917	rs2562468	chr19:21714850	G/A	cg00806126	chr19:22604979	ZNF98	0.64	9.53	0.4	9.2e-20	Pain;
LGG	cis	rs1691799	0.899	rs1177555	chr12:66727568	A/G	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs45544231	0.569	rs9933556	chr16:52548302	C/T	cg09051775	chr16:52580266	TOX3	-0.4	-6.75	-0.3	4.32e-11	Restless legs syndrome;
LGG	cis	rs4631830	0.720	rs7090326	chr10:51503375	A/T	cg16070123	chr10:51489643	NA	-0.41	-7.47	-0.33	3.93e-13	Prostate-specific antigen levels;
LGG	cis	rs2562456	0.876	rs7252585	chr19:21657943	C/T	cg00806126	chr19:22604979	ZNF98	0.61	9.1	0.39	2.69e-18	Pain;
LGG	cis	rs897984	0.609	rs11862744	chr16:31057800	G/A	cg02466173	chr16:30829666	NA	-0.42	-7.67	-0.34	1.03e-13	Dementia with Lewy bodies;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.84	-0.3	2.46e-11	Aortic root size;
LGG	cis	rs4690686	0.500	rs11725547	chr4:177268444	T/C	cg17059388	chr4:177262070	NA	1.03	24.32	0.75	8.55e-85	Essential tremor;
LGG	cis	rs13260300	0.614	rs4735715	chr8:75514554	G/A	cg22993706	chr8:75542856	NA	0.41	7.95	0.35	1.49e-14	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg18681998	chr4:17616180	MED28	-0.81	-17.74	-0.64	4.23e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11771526	0.901	rs62457494	chr7:32312299	T/G	cg13207630	chr7:32358064	NA	0.68	7.36	0.32	8.29e-13	Body mass index;
LGG	cis	rs950169	0.881	rs34117475	chr15:85108443	T/C	cg03959625	chr15:84868606	LOC388152	0.58	9.23	0.39	9.85e-19	Schizophrenia;
LGG	cis	rs9815354	0.680	rs73830596	chr3:42028223	G/A	cg03022575	chr3:42003672	ULK4	0.71	7.79	0.34	4.5e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2072499	1.000	rs2072499	chr1:156169610	A/G	cg25208724	chr1:156163844	SLC25A44	1.23	30.51	0.82	7.01e-113	Testicular germ cell tumor;
LGG	cis	rs1878931	0.501	rs17136359	chr16:3420814	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.8	-13.77	-0.54	2.15e-36	Body mass index (adult);
LGG	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg08085267	chr17:45401833	C17orf57	0.62	12.65	0.51	9.93e-32	Multiple sclerosis or amyotrophic lateral sclerosis;
LGG	cis	rs986417	0.818	rs10151839	chr14:60980688	T/G	cg27398547	chr14:60952738	C14orf39	0.71	6.84	0.3	2.59e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs8002861	0.935	rs7320988	chr13:44413523	C/T	cg17145862	chr1:211918768	LPGAT1	0.98	25.41	0.76	7.62e-90	Leprosy;
LGG	cis	rs6500602	0.627	rs3848372	chr16:4587875	C/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.06	0.31	6e-12	Schizophrenia;
LGG	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.83	0.3	2.61e-11	Bipolar disorder;
LGG	cis	rs75059851	0.756	rs73036086	chr11:133841782	C/T	cg17703048	chr11:133852993	NA	-0.87	-15.95	-0.6	6.02e-46	Schizophrenia;
LGG	cis	rs9837602	0.507	rs793452	chr3:99529523	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.14	0.35	3.6e-15	Breast cancer;
LGG	cis	rs17221829	0.703	rs7944552	chr11:89377208	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs2251666	0.765	rs17771656	chr16:4928257	C/T	cg08329684	chr16:4932620	PPL	0.47	8.09	0.35	5.35e-15	Cancer;
LGG	cis	rs1862618	0.853	rs252919	chr5:56124111	T/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.51	-0.44	2.57e-23	Initial pursuit acceleration;
LGG	cis	rs67478160	0.643	rs11628332	chr14:104241141	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.69	-0.34	9.06e-14	Schizophrenia;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg11062466	chr8:58055876	NA	0.61	9.79	0.41	1.05e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs17401966	0.898	rs11582123	chr1:10303942	A/T	cg15208524	chr1:10270712	KIF1B	0.44	7.71	0.34	7.71e-14	Hepatocellular carcinoma;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg00689492	chr4:1303491	MAEA	0.51	8.93	0.38	9.8e-18	Obesity-related traits;
LGG	cis	rs6977660	0.714	rs12386623	chr7:19791875	A/G	cg05791153	chr7:19748676	TWISTNB	-0.76	-10.44	-0.44	4.87e-23	Thyroid stimulating hormone;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg05665937	chr4:1216051	CTBP1	-0.41	-7.3	-0.32	1.23e-12	Obesity-related traits;
LGG	cis	rs11583043	0.667	rs4617425	chr1:101543205	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	7.96	0.35	1.35e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs773506	1.000	rs773506	chr9:93975471	C/T	cg14446406	chr9:93919335	NA	0.45	8.24	0.36	1.8e-15	Type 2 diabetes nephropathy;
LGG	trans	rs11039798	0.764	rs10838882	chr11:48393035	T/A	cg15704280	chr7:45808275	SEPT13	0.76	8.94	0.38	9.52e-18	Axial length;
LGG	cis	rs11122272	0.735	rs2808584	chr1:231512925	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs17209837	0.607	rs4148816	chr7:87087731	G/A	cg25823085	chr7:87105416	ABCB4	0.3	7.4	0.33	6.45e-13	Gallbladder cancer;
LGG	cis	rs3087591	0.959	rs2051505	chr17:29699859	C/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.64	-0.56	3.74e-40	Hip circumference;
LGG	cis	rs2760061	0.626	rs591582	chr1:228117360	C/A	cg18477163	chr1:228402036	OBSCN	-0.26	-7.23	-0.32	2.05e-12	Diastolic blood pressure;
LGG	cis	rs7493	0.755	rs2375001	chr7:94964640	A/T	cg08461772	chr7:95026248	PON3	0.38	8.21	0.36	2.2e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs8177253	0.606	rs6787177	chr3:133450720	C/T	cg08048268	chr3:133502702	NA	-0.45	-7.75	-0.34	6.04e-14	Iron status biomarkers;
LGG	cis	rs7833790	0.750	rs10108955	chr8:82690644	C/T	cg27398817	chr8:82754497	SNX16	-0.71	-10.16	-0.43	4.88e-22	Diastolic blood pressure;
LGG	cis	rs11112613	0.713	rs73184082	chr12:105951748	T/C	cg03607813	chr12:105948248	NA	0.58	10.68	0.44	6.23e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs9790314	0.936	rs466399	chr3:161091194	G/T	cg04691961	chr3:161091175	C3orf57	-0.7	-17.27	-0.63	6.01e-52	Morning vs. evening chronotype;
LGG	cis	rs6692729	0.931	rs2855562	chr1:227081850	G/A	cg08708961	chr1:227070630	PSEN2	0.29	7.29	0.32	1.39e-12	Electrodermal activity;
LGG	cis	rs9314323	0.592	rs12165	chr8:26269412	C/T	cg11498726	chr8:26250323	BNIP3L	-0.46	-10.17	-0.43	4.7e-22	Red cell distribution width;
LGG	cis	rs2270875	1.000	rs76695849	chr8:132926989	A/G	cg24184792	chr8:132919238	EFR3A	-0.44	-6.77	-0.3	3.82e-11	Response to cholinesterase inhibitors in Alzheimer's disease;
LGG	cis	rs611744	0.538	rs2298605	chr8:109272006	T/C	cg21045802	chr8:109455806	TTC35	0.56	10.67	0.44	6.51e-24	Dupuytren's disease;
LGG	cis	rs9479482	0.967	rs61730071	chr6:150342232	G/A	cg03788504	chr6:150331562	NA	-0.6	-13.55	-0.53	1.88e-35	Alopecia areata;
LGG	cis	rs9886651	0.935	rs13248719	chr8:128802751	T/C	cg24514600	chr8:128805414	PVT1	-0.56	-12.88	-0.51	1.17e-32	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs12477438	0.798	rs6704766	chr2:99642818	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	trans	rs9944715	1.000	rs6507693	chr18:43829137	G/A	cg01718231	chr17:29326311	RNF135	-0.42	-6.66	-0.3	7.85e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs2224391	0.656	rs17140096	chr6:5287255	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.49	-6.89	-0.31	1.8e-11	Height;
LGG	cis	rs11148252	0.875	rs9526913	chr13:52975837	T/C	cg16301924	chr13:53314226	LECT1	-0.46	-9.38	-0.4	2.93e-19	Lewy body disease;
LGG	cis	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.47	-0.33	4.1e-13	Monocyte count;
LGG	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg12463550	chr7:65579703	CRCP	-0.51	-8.6	-0.37	1.21e-16	Aortic root size;
LGG	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg08085267	chr17:45401833	C17orf57	-0.53	-10.43	-0.44	5.19e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs782590	0.805	rs782578	chr2:55915904	A/C	cg18811423	chr2:55921094	PNPT1	0.94	22.87	0.73	4.85e-78	Metabolic syndrome;
LGG	cis	rs4604732	0.578	rs79203328	chr1:247626581	C/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.33	-0.32	1.05e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10911232	0.507	rs10797820	chr1:183011366	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	cis	rs1256531	0.661	rs10083328	chr14:66227792	T/G	cg15999311	chr14:65749247	NA	0.82	7.01	0.31	8.7e-12	Conduct disorder (symptom count);
LGG	cis	rs6461049	0.765	rs4719432	chr7:2140330	A/G	cg04267008	chr7:1944627	MAD1L1	-0.48	-8.13	-0.35	3.91e-15	Schizophrenia;
LGG	cis	rs4819052	0.851	rs875621	chr21:46682295	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.38	0.53	9.74e-35	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg21535247	chr6:8435926	SLC35B3	-0.5	-8.17	-0.35	3.03e-15	Motion sickness;
LGG	trans	rs9467711	0.606	rs2076030	chr6:26426856	G/A	cg01620082	chr3:125678407	NA	-0.67	-7.12	-0.31	4.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3733585	0.699	rs6844787	chr4:9959233	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg25237894	chr2:233734115	C2orf82	-0.72	-15.29	-0.58	5.3800000000000004e-43	Coronary artery disease;
LGG	cis	rs1451375	0.572	rs68011952	chr7:50638128	C/T	cg14593290	chr7:50529359	DDC	0.48	8.56	0.37	1.67e-16	Malaria;
LGG	cis	rs559928	0.502	rs4963223	chr11:64193418	A/G	cg26318627	chr11:63887540	MACROD1	-0.38	-6.86	-0.3	2.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg08470875	chr2:26401718	FAM59B	-0.43	-8.28	-0.36	1.31e-15	Gut microbiome composition (summer);
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.52	-0.67	2.31e-62	Rheumatoid arthritis;
LGG	cis	rs4919087	0.683	rs7074896	chr10:99071282	T/C	cg25902810	chr10:99078978	FRAT1	-0.41	-6.96	-0.31	1.14e-11	Monocyte count;
LGG	trans	rs6787172	0.728	rs6774461	chr3:158092801	G/T	cg23275840	chr4:47708675	CORIN	-0.4	-8.51	-0.37	2.41e-16	Subjective well-being;
LGG	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg11803278	chr7:157951799	PTPRN2	0.49	9.79	0.41	1.08e-20	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19894588	chr14:64061835	NA	-0.56	-9.16	-0.39	1.63e-18	Glioblastoma;Glioma;
LGG	cis	rs5771242	0.518	rs6010216	chr22:50679471	C/T	cg16473166	chr22:50639996	SELO	0.75	11.87	0.48	1.51e-28	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs4771450	0.925	rs7338381	chr13:103978417	A/G	cg02987523	chr13:103978230	NA	0.32	6.88	0.3	1.95e-11	Uric acid levels;
LGG	trans	rs941408	1.000	rs1640274	chr19:2807375	G/A	cg19676328	chr12:49525230	TUBA1B	-0.64	-10.01	-0.42	1.81e-21	Total cholesterol levels;
LGG	cis	rs10504229	0.683	rs2318148	chr8:58114955	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg05677249	chr15:77158041	SCAPER	-0.31	-6.7	-0.3	6.08e-11	Blood metabolite levels;
LGG	cis	rs975722	0.613	rs43034	chr7:117108449	T/C	cg10524701	chr7:117356490	CTTNBP2	0.45	10.07	0.42	1.06e-21	Coronary artery disease;
LGG	trans	rs9693857	0.520	rs4557706	chr8:9357369	G/C	cg21775007	chr8:11205619	TDH	0.45	6.69	0.3	6.54e-11	Systolic blood pressure;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2120243	0.572	rs6803628	chr3:157125584	G/A	cg24825693	chr3:157122686	VEPH1	-0.59	-13.61	-0.53	1.04e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00340584	chr1:149512963	NA	-0.25	-6.91	-0.31	1.65e-11	Hip geometry;
LGG	cis	rs1801251	1.000	rs7592717	chr2:233577038	G/A	cg08000102	chr2:233561755	GIGYF2	0.59	9.65	0.41	3.43e-20	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg19980929	chr12:42632907	YAF2	0.37	8.14	0.35	3.7e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6460942	0.915	rs62448594	chr7:12442229	C/G	cg06484146	chr7:12443880	VWDE	-0.42	-7.29	-0.32	1.31e-12	Coronary artery disease;
LGG	cis	rs9443645	0.901	rs9361460	chr6:79589467	C/G	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.52e-17	Intelligence (multi-trait analysis);
LGG	cis	rs854765	0.647	rs854770	chr17:18019048	A/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.71	13.65	0.54	6.52e-36	Total body bone mineral density;
LGG	cis	rs3771570	0.901	rs73008106	chr2:242422446	C/T	cg21155796	chr2:242212141	HDLBP	0.7	9.37	0.4	3.19e-19	Prostate cancer;
LGG	trans	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg04842962	chr6:43655489	MRPS18A	1.11	24.19	0.75	3.35e-84	IgG glycosylation;
LGG	cis	rs10791097	0.694	rs4937581	chr11:130740335	T/C	cg09137382	chr11:130731461	NA	0.35	6.81	0.3	3.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs736408	0.522	rs11130310	chr3:52674667	C/T	cg18099408	chr3:52552593	STAB1	-0.35	-7.13	-0.31	3.79e-12	Bipolar disorder;
LGG	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg09427745	chr16:71932006	KIAA0174	-0.5	-7.32	-0.32	1.12e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs11169552	0.510	rs10876063	chr12:50972085	C/T	cg12884762	chr12:50931848	DIP2B	-0.4	-7.62	-0.33	1.47e-13	Colorectal cancer;
LGG	cis	rs653465	0.739	rs67573383	chr3:27138586	C/A	cg02860705	chr3:27208620	NA	-0.38	-7.41	-0.33	6.14e-13	Breast cancer (early onset);
LGG	cis	rs28735056	0.563	rs55642704	chr18:77688124	C/T	cg20368463	chr18:77673604	PQLC1	-0.59	-11.4	-0.47	1.01e-26	Schizophrenia;
LGG	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg01200585	chr1:228362443	C1orf69	0.48	8.44	0.36	4.24e-16	Diastolic blood pressure;
LGG	cis	rs12615966	0.932	rs58391435	chr2:105368520	A/G	cg16465502	chr2:105461796	NA	0.88	10.18	0.43	4.32e-22	Pancreatic cancer;
LGG	cis	rs35771425	1.000	rs35771425	chr1:211609768	T/C	cg10512769	chr1:211675356	NA	-0.74	-11.97	-0.49	5.93e-29	Educational attainment (years of education);
LGG	cis	rs947211	0.898	rs10900524	chr1:205748309	G/A	cg26354017	chr1:205819088	PM20D1	0.47	7.83	0.34	3.35e-14	Parkinson's disease;
LGG	cis	rs4538187	0.950	rs11691987	chr2:64147999	T/C	cg14150252	chr2:64069583	UGP2	-0.51	-10.16	-0.43	4.95e-22	Systolic blood pressure;
LGG	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg01579765	chr21:45077557	HSF2BP	-0.33	-7.22	-0.32	2.15e-12	Mean corpuscular volume;
LGG	trans	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.23	0.36	1.95e-15	Retinal vascular caliber;
LGG	trans	rs853679	0.607	rs67040724	chr6:27905509	T/C	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	cis	rs116095464	0.558	rs10065239	chr5:275288	C/T	cg22496380	chr5:211416	CCDC127	-1.34	-18.85	-0.66	3.08e-59	Breast cancer;
LGG	cis	rs4356932	1.000	rs4859414	chr4:76949997	G/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg05665937	chr4:1216051	CTBP1	0.54	10.03	0.42	1.51e-21	Obesity-related traits;
LGG	cis	rs7166081	0.738	rs2286664	chr15:67701495	A/G	cg18567174	chr15:68126065	LBXCOR1	-0.38	-7.74	-0.34	6.39e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10870270	1.000	rs10159746	chr10:133742677	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.64	-12.82	-0.51	1.97e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.52	-0.33	2.89e-13	Triglycerides;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs949856	chr8:58144496	G/A	cg02725872	chr8:58115012	NA	-1.04	-15.17	-0.58	1.71e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	0.841	rs9896263	chr17:80902741	A/G	cg15664640	chr17:80829946	TBCD	0.74	14.07	0.55	1.09e-37	Breast cancer;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.53	-0.37	2.17e-16	Personality dimensions;
LGG	cis	rs3741404	0.594	rs11231704	chr11:63898182	C/T	cg18225595	chr11:63971243	STIP1	-0.45	-8.63	-0.37	9.65e-17	Platelet count;
LGG	cis	rs329674	0.516	rs1682861	chr11:133759812	C/A	cg06766960	chr11:133703094	NA	-0.62	-6.9	-0.31	1.73e-11	Bipolar disorder;
LGG	cis	rs4969178	0.965	rs16971107	chr17:76394042	C/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.54	-0.56	1e-39	HDL cholesterol levels;
LGG	cis	rs11239187	0.523	rs749001	chr10:45077063	C/T	cg03916630	chr10:45065415	NA	0.41	7.47	0.33	4.07e-13	Body mass index;
LGG	trans	rs9467603	1.000	rs9467613	chr6:25812641	T/C	cg01620082	chr3:125678407	NA	-0.69	-6.77	-0.3	3.81e-11	Intelligence (multi-trait analysis);
LGG	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.95	-0.35	1.4e-14	Neuroticism;
LGG	cis	rs1957429	0.808	rs2357866	chr14:65336517	C/T	cg23373153	chr14:65346875	NA	1.05	13.0	0.52	3.81e-33	Pediatric areal bone mineral density (radius);
LGG	trans	rs853679	0.545	rs35949109	chr6:28025926	T/C	cg06606381	chr12:133084897	FBRSL1	-0.87	-9.16	-0.39	1.7e-18	Depression;
LGG	cis	rs4538187	0.671	rs56904032	chr2:64236488	C/T	cg14150252	chr2:64069583	UGP2	-0.49	-8.91	-0.38	1.16e-17	Systolic blood pressure;
LGG	cis	rs6840360	0.571	rs7685697	chr4:152558849	A/G	cg25486957	chr4:152246857	NA	-0.48	-8.06	-0.35	6.79e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-7.01	-0.31	8.34e-12	Bipolar disorder;
LGG	cis	rs3806843	0.518	rs173471	chr5:140335226	A/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11690935	1.000	rs35549875	chr2:172532392	A/G	cg13550731	chr2:172543902	DYNC1I2	1.05	26.2	0.77	1.87e-93	Schizophrenia;
LGG	cis	rs7937612	0.965	rs4381380	chr11:120273316	A/G	cg24566217	chr11:120254723	ARHGEF12	0.47	11.11	0.46	1.35e-25	Intraocular pressure;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg01879757	chr17:41196368	BRCA1	-0.4	-8.19	-0.36	2.61e-15	Menopause (age at onset);
LGG	cis	rs6815464	1	rs6815464	chr4:1309901	C/G	cg07110949	chr4:1309878	MAEA	-0.93	-7.88	-0.34	2.28e-14	Type 2 diabetes;
LGG	cis	rs6500602	0.727	rs2058811	chr16:4575162	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	7.09	0.31	4.99e-12	Schizophrenia;
LGG	cis	rs2404602	0.536	rs17364330	chr15:76765385	A/T	cg26408565	chr15:76604113	ETFA	-0.39	-6.79	-0.3	3.54e-11	Blood metabolite levels;
LGG	cis	rs929596	0.785	rs11695484	chr2:234654449	A/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.73	-12.94	-0.52	6.65e-33	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs62238980	0.614	rs4821002	chr22:32362687	C/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs17445240	0.515	rs6760466	chr2:3707136	T/C	cg13452994	chr2:3699195	NA	0.48	6.81	0.3	3.09e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs4774899	0.932	rs12908278	chr15:57583780	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.22	-0.32	2.12e-12	Urinary tract infection frequency;
LGG	cis	rs7674212	0.540	rs2720469	chr4:104086484	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-7.2	-0.32	2.49e-12	Type 2 diabetes;
LGG	cis	rs7618915	0.679	rs6802320	chr3:52241835	T/C	cg14092988	chr3:52407081	DNAH1	0.39	10.36	0.43	8.91e-23	Bipolar disorder;
LGG	trans	rs61931739	0.890	rs814663	chr12:34106338	C/T	cg26384229	chr12:38710491	ALG10B	0.64	12.49	0.5	4.73e-31	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.930	rs3765640	chr17:41276247	A/G	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs2840044	0.517	rs2124247	chr17:33885468	G/A	cg05299278	chr17:33885742	SLFN14	0.45	8.96	0.38	7.78e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs2180341	0.960	rs7766942	chr6:127691323	G/T	cg27446573	chr6:127587934	RNF146	1.14	22.27	0.72	3.09e-75	Breast cancer;
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	0.712	rs9838621	chr3:134332319	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4853012	0.775	rs12465641	chr2:74337715	A/G	cg19729930	chr2:74357872	NA	-0.51	-10.28	-0.43	1.83e-22	Gestational age at birth (maternal effect);
LGG	cis	rs3741404	0.620	rs11231722	chr11:63967770	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.78	14.59	0.56	6.16e-40	Platelet count;
LGG	cis	rs4774899	0.934	rs11631541	chr15:57361676	C/G	cg08128148	chr15:57256372	TCF12	0.29	6.84	0.3	2.51e-11	Urinary tract infection frequency;
LGG	trans	rs1997103	1.000	rs6958022	chr7:55397389	G/A	cg20935933	chr6:143382018	AIG1	0.59	9.12	0.39	2.29e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1153858	0.945	rs16943246	chr15:45720597	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.62	0.33	1.45e-13	Homoarginine levels;
LGG	trans	rs9329221	0.686	rs60755617	chr8:10243327	T/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.4	0.33	6.57e-13	Neuroticism;
LGG	cis	rs9463078	0.605	rs4711799	chr6:44765780	A/T	cg25276700	chr6:44698697	NA	0.38	7.94	0.35	1.52e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs79057730	0.599	rs6944167	chr7:826274	G/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.68	7.71	0.34	7.81e-14	Initial pursuit acceleration;
LGG	trans	rs7826238	0.653	rs2979202	chr8:8344127	T/C	cg21775007	chr8:11205619	TDH	0.41	6.66	0.3	8.02e-11	Systolic blood pressure;
LGG	cis	rs17604090	1.000	rs17661938	chr7:29693378	C/T	cg19413766	chr7:29689036	LOC646762	-0.59	-7.23	-0.32	2e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs262150	0.592	rs56062559	chr7:158769109	T/C	cg13444538	chr7:158905317	VIPR2	-0.47	-7.0	-0.31	8.88e-12	Facial morphology (factor 20);
LGG	cis	rs9916302	0.904	rs55660616	chr17:37684990	C/A	cg07936489	chr17:37558343	FBXL20	-0.84	-15.73	-0.59	5.82e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs6952808	0.601	rs3800882	chr7:2120758	G/A	cg04267008	chr7:1944627	MAD1L1	-0.6	-10.12	-0.43	6.72e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs2859741	0.587	rs580029	chr1:37471609	C/A	cg09363841	chr1:37513479	NA	-0.53	-11.5	-0.47	4.38e-27	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs2028299	1.000	rs7111	chr15:90373873	T/C	cg23731826	chr15:90371692	NA	0.37	8.68	0.37	6.65e-17	Type 2 diabetes;
LGG	cis	rs42648	0.720	rs9655741	chr7:89933874	C/G	cg25739043	chr7:89950458	NA	-0.36	-7.39	-0.32	6.73e-13	Homocysteine levels;
LGG	cis	rs6977660	0.619	rs10231972	chr7:19789354	C/G	cg05791153	chr7:19748676	TWISTNB	0.62	9.17	0.39	1.51e-18	Thyroid stimulating hormone;
LGG	cis	rs8064024	0.650	rs8056889	chr16:4903243	C/T	cg04440724	chr16:4920505	UBN1	-0.56	-12.4	-0.5	1.08e-30	Cancer;
LGG	cis	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.02	-0.31	7.99e-12	Systolic blood pressure;
LGG	cis	rs2797160	1.000	rs1739377	chr6:126012236	T/C	cg05901451	chr6:126070800	HEY2	0.44	7.43	0.33	5.34e-13	Endometrial cancer;
LGG	cis	rs2197308	0.740	rs11182251	chr12:37919611	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.21	-0.32	2.35e-12	Morning vs. evening chronotype;
LGG	cis	rs9796	0.840	rs1009913	chr15:41331050	C/T	cg18705301	chr15:41695430	NDUFAF1	0.48	8.2	0.36	2.34e-15	Menopause (age at onset);
LGG	cis	rs7294478	0.839	rs6487849	chr12:7263699	A/G	cg01074767	chr12:7262137	C1RL;LOC283314	-0.55	-14.73	-0.56	1.43e-40	Neuritic plaque;
LGG	cis	rs1355223	0.902	rs10501134	chr11:34749137	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.07	-0.31	5.8e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs870825	0.616	rs2130394	chr4:185642577	C/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg06654118	chr4:1303317	MAEA	0.46	7.99	0.35	1.04e-14	Obesity-related traits;
LGG	trans	rs1493916	0.870	rs8083723	chr18:31384398	C/T	cg04226714	chr8:49833948	SNAI2	-0.46	-8.44	-0.37	4.06e-16	Life satisfaction;
LGG	cis	rs11158198	0.539	rs11626581	chr14:58604534	C/G	cg15908186	chr14:58618357	C14orf37	0.57	10.06	0.42	1.18e-21	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg13395646	chr4:1353034	KIAA1530	-0.61	-10.45	-0.44	4.33e-23	Obesity-related traits;
LGG	cis	rs12477438	1.000	rs6542873	chr2:99824965	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.69	-10.43	-0.44	4.94e-23	Chronic sinus infection;
LGG	cis	rs1461503	0.548	rs7114175	chr11:122813983	A/T	cg27398637	chr11:122830231	C11orf63	-0.67	-13.21	-0.52	4.98e-34	Menarche (age at onset);
LGG	trans	rs116095464	0.558	rs10036253	chr5:238519	A/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs4925386	0.840	rs6142738	chr20:60919960	C/T	cg24112000	chr20:60950667	NA	0.38	7.53	0.33	2.72e-13	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs6032067	0.929	rs6032044	chr20:43819416	C/A	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.3	-7.31	-0.32	1.2e-12	Restless legs syndrome;
LGG	cis	rs11252926	0.574	rs4881254	chr10:453567	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-9.68	-0.41	2.62e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs4692589	0.772	rs34642369	chr4:170973469	G/A	cg19918862	chr4:170955249	NA	0.39	7.48	0.33	3.69e-13	Anxiety disorder;
LGG	cis	rs9388451	0.903	rs9388446	chr6:126064920	T/A	cg18424134	chr6:126068038	NA	0.22	7.03	0.31	7.56e-12	Brugada syndrome;
LGG	cis	rs17125944	0.615	rs7151474	chr14:53313680	C/T	cg00686598	chr14:53173677	PSMC6	-0.75	-7.78	-0.34	4.77e-14	Alzheimer's disease (late onset);
LGG	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg04287289	chr16:89883240	FANCA	0.8	16.57	0.61	9.15e-49	Vitiligo;
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4478858	0.684	rs2062951	chr1:31762981	T/C	cg19084893	chr1:31688959	NA	0.31	6.69	0.3	6.65e-11	Alcohol dependence;
LGG	cis	rs9972944	0.756	rs9907996	chr17:63754889	C/T	cg07283582	chr17:63770753	CCDC46	-0.4	-7.73	-0.34	6.58e-14	Total body bone mineral density;
LGG	cis	rs7106204	0.668	rs7119362	chr11:24218132	G/T	ch.11.24196551F	chr11:24239977	NA	1.04	16.5	0.61	1.98e-48	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg15596359	chr8:11213517	TDH	0.42	8.65	0.37	8.21e-17	Neuroticism;
LGG	trans	rs10838798	0.504	rs10838852	chr11:48286256	C/T	cg15704280	chr7:45808275	SEPT13	-0.55	-9.22	-0.39	1.08e-18	Height;
LGG	cis	rs9517320	1.000	rs9517322	chr13:99126338	C/G	cg07423050	chr13:99094983	FARP1	0.4	8.13	0.35	3.94e-15	Longevity;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg19901468	chr14:105411992	AHNAK2	-0.52	-7.36	-0.32	8.18e-13	IgG glycosylation;
LGG	cis	rs637571	0.510	rs10750772	chr11:65577427	C/T	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.6	-0.33	1.66e-13	Eosinophil percentage of white cells;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg24575275	chr7:1094737	C7orf50	-0.39	-7.44	-0.33	4.79e-13	Longevity;Endometriosis;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-9.79	-0.41	1.12e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs17504614	0.608	rs17570033	chr2:51079664	G/T	cg08066024	chr2:51057548	NRXN1	0.52	6.82	0.3	2.93e-11	Educational attainment (years of education);
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.45	-0.33	4.67e-13	IgG glycosylation;
LGG	cis	rs6840360	0.533	rs4696297	chr4:152725838	T/G	cg22705602	chr4:152727874	NA	0.37	9.12	0.39	2.39e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.825	rs11761818	chr7:1935273	C/T	cg22963979	chr7:1858916	MAD1L1	-0.44	-8.51	-0.37	2.49e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00331096	chr20:22564947	FOXA2	0.41	6.79	0.3	3.42e-11	Gut microbiome composition (summer);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19696333	chr10:124768261	IKZF5;ACADSB	0.45	7.08	0.31	5.38e-12	Cognitive performance;
LGG	cis	rs9325144	0.872	rs11183390	chr12:38729942	G/T	cg13010199	chr12:38710504	ALG10B	-0.38	-6.77	-0.3	3.92e-11	Morning vs. evening chronotype;
LGG	cis	rs1153858	0.723	rs11855527	chr15:45606685	G/A	cg10760299	chr15:45669010	GATM	-0.38	-7.12	-0.31	4.17e-12	Homoarginine levels;
LGG	cis	rs17270561	0.609	rs9358887	chr6:25759406	G/T	cg16482183	chr6:26056742	HIST1H1C	0.57	9.28	0.4	6.29e-19	Iron status biomarkers;
LGG	cis	rs514406	0.708	rs546334	chr1:53326210	T/C	cg27535305	chr1:53392650	SCP2	-0.3	-6.9	-0.31	1.72e-11	Monocyte count;
LGG	cis	rs9814567	0.762	rs13071852	chr3:134223217	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.01	0.46	3.46e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs950776	0.642	rs922691	chr15:78963994	A/G	cg03762349	chr15:79060523	ADAMTS7	0.35	7.66	0.34	1.09e-13	Sudden cardiac arrest;
LGG	cis	rs9463078	0.764	rs9357464	chr6:44952441	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.61	-0.37	1.19e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs6681460	0.565	rs1536112	chr1:67107225	C/T	cg13052034	chr1:66999238	SGIP1	-0.36	-7.34	-0.32	9.51e-13	Presence of antiphospholipid antibodies;
LGG	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.23	-0.36	1.87e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg24955955	chr5:415729	AHRR	0.81	10.82	0.45	1.75e-24	Fat distribution (HIV);
LGG	cis	rs2228479	0.850	rs76075456	chr16:89834270	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg20530580	chr17:40610845	ATP6V0A1	0.46	7.05	0.31	6.58e-12	Hip circumference;
LGG	trans	rs9354308	0.764	rs9445607	chr6:66570492	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg02993943	chr7:39605861	C7orf36	-0.4	-6.79	-0.3	3.5e-11	Leprosy;
LGG	cis	rs787274	0.867	rs1711744	chr9:115453484	A/T	cg13803584	chr9:115635662	SNX30	-0.49	-7.08	-0.31	5.35e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg11941060	chr3:133502564	NA	-0.49	-8.32	-0.36	1.03e-15	Iron status biomarkers;
LGG	trans	rs61931739	0.817	rs188588	chr12:34215277	G/A	cg13010199	chr12:38710504	ALG10B	0.46	8.82	0.38	2.29e-17	Morning vs. evening chronotype;
LGG	cis	rs8031584	0.541	rs2959037	chr15:31218164	T/C	cg08109568	chr15:31115862	NA	0.47	8.4	0.36	5.51e-16	Huntington's disease progression;
LGG	cis	rs6831352	0.879	rs29001229	chr4:100046823	A/G	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	9.43e-17	Alcohol dependence;
LGG	cis	rs11155671	0.530	rs7768626	chr6:150207962	G/T	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs11252926	0.599	rs11252213	chr10:454694	C/T	cg16386425	chr10:429943	DIP2C	-0.46	-9.6	-0.41	4.95e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs9354308	0.764	rs9354322	chr6:66586195	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs17824933	0.943	rs11230566	chr11:60780007	G/A	cg16817237	chr11:60793675	NA	0.35	6.66	0.3	7.77e-11	Multiple sclerosis;
LGG	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg16434002	chr17:42200994	HDAC5	0.43	7.77	0.34	5.04e-14	Total body bone mineral density;
LGG	trans	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg16141378	chr3:129829833	LOC729375	0.41	9.47	0.4	1.42e-19	Neuroticism;
LGG	cis	rs7267979	0.706	rs6138542	chr20:25207773	C/A	cg06421707	chr20:25228305	PYGB	0.47	10.09	0.42	8.74e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11098499	0.865	rs11098513	chr4:120316075	A/G	cg09307838	chr4:120376055	NA	0.8	13.4	0.53	7.61e-35	Corneal astigmatism;
LGG	cis	rs61931739	0.649	rs2263218	chr12:33729679	C/G	cg06521331	chr12:34319734	NA	-0.39	-6.86	-0.3	2.22e-11	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.536	rs12368354	chr12:38042798	G/A	cg04568710	chr12:38710424	ALG10B	0.34	6.71	0.3	5.67e-11	Bladder cancer;
LGG	cis	rs7717393	1.000	rs1857770	chr5:155769455	T/G	cg12904904	chr5:155754151	SGCD	0.91	8.64	0.37	9.25e-17	Egg allergy;
LGG	cis	rs10504229	0.906	rs114627636	chr8:58173732	C/T	cg22535103	chr8:58192502	C8orf71	-1.0	-13.66	-0.54	6.43e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.608	rs3800923	chr7:2184673	A/G	cg04267008	chr7:1944627	MAD1L1	-0.46	-7.74	-0.34	6.09e-14	Schizophrenia;
LGG	cis	rs10479542	0.892	rs7723230	chr5:178980474	T/C	cg00080972	chr5:178986291	RUFY1	0.52	8.94	0.38	9.32e-18	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16136434	chr1:52870037	ORC1L;PRPF38A	0.41	6.77	0.3	3.83e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2692947	0.537	rs11164050	chr2:96352451	T/C	cg06850509	chr2:96314847	NA	-0.36	-6.73	-0.3	5.12e-11	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs5756813	0.635	rs6000899	chr22:38203796	C/T	cg24232236	chr22:38142998	TRIOBP	0.35	6.74	0.3	4.66e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs9398803	0.723	rs853975	chr6:127070234	C/T	cg19875578	chr6:126661172	C6orf173	-0.49	-8.93	-0.38	1e-17	Male-pattern baldness;
LGG	cis	rs2011503	0.941	rs17751061	chr19:19413092	C/T	cg11584989	chr19:19387371	SF4	0.61	9.23	0.39	9.46e-19	Bipolar disorder;
LGG	cis	rs8017423	0.935	rs11159959	chr14:90733656	C/T	cg04374321	chr14:90722782	PSMC1	-0.89	-17.49	-0.63	5.97e-53	Mortality in heart failure;
LGG	cis	rs17666538	0.535	rs896522	chr8:616991	A/G	cg07234876	chr8:600039	NA	1.17	11.6	0.47	1.78e-27	IgG glycosylation;
LGG	cis	rs240764	0.645	rs239208	chr6:101139285	G/A	cg09795085	chr6:101329169	ASCC3	0.45	7.81	0.34	3.89e-14	Neuroticism;
LGG	cis	rs67133203	0.632	rs853235	chr12:51375969	C/T	cg14688905	chr12:51403056	SLC11A2	-0.56	-9.57	-0.41	6.23e-20	Urinary tract infection frequency;
LGG	cis	rs2070488	0.965	rs4679060	chr3:38536261	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-18.23	-0.65	2.37e-56	Electrocardiographic conduction measures;
LGG	cis	rs944722	1.000	rs944722	chr17:26092037	C/T	cg07704981	chr17:26127537	NOS2	-0.49	-8.54	-0.37	1.89e-16	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg08017756	chr2:100939284	LONRF2	0.29	6.85	0.3	2.32e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9937943	0.615	rs8061793	chr16:74507109	C/G	cg01733217	chr16:74700730	RFWD3	0.53	7.66	0.34	1.12e-13	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.639	rs112926738	chr8:58054939	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.01	-0.35	9.38e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs3099143	1.000	rs7174048	chr15:77165416	T/C	cg21673338	chr15:77095150	SCAPER	0.66	10.46	0.44	4.08e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs2180341	0.961	rs7775493	chr6:127615000	C/A	cg24812749	chr6:127587940	RNF146	0.96	15.74	0.59	4.98e-45	Breast cancer;
LGG	cis	rs9902453	1.000	rs12600993	chr17:28291222	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.52	0.53	2.33e-35	Coffee consumption (cups per day);
LGG	cis	rs2730245	0.528	rs1188954	chr7:158691417	G/A	cg24397884	chr7:158709396	WDR60	0.89	18.51	0.65	1.21e-57	Height;
LGG	cis	rs561341	0.739	rs4795663	chr17:30214542	T/C	cg13647721	chr17:30228624	UTP6	-0.78	-12.38	-0.5	1.3e-30	Hip circumference adjusted for BMI;
LGG	trans	rs2727020	0.521	rs7131163	chr11:49574774	C/T	cg03929089	chr4:120376271	NA	-0.85	-13.29	-0.53	2.24e-34	Coronary artery disease;
LGG	cis	rs4975709	0.610	rs4975705	chr5:1860359	T/C	cg15595755	chr5:1867978	NA	0.51	10.39	0.43	7.12e-23	Cardiovascular disease risk factors;
LGG	cis	rs17023223	0.537	rs10923756	chr1:119674648	A/T	cg05756136	chr1:119680316	WARS2	-0.45	-8.9	-0.38	1.26e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg22232500	chr2:134024266	NCKAP5	0.7	9.83	0.42	7.46e-21	Bipolar disorder;
LGG	cis	rs10991814	1.000	rs10991814	chr9:93949075	T/C	cg14446406	chr9:93919335	NA	-0.64	-7.48	-0.33	3.75e-13	Neutrophil percentage of granulocytes;
LGG	cis	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.65	-0.3	8.54e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs17376456	0.825	rs34967135	chr5:93221785	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.64	0.41	3.75e-20	Diabetic retinopathy;
LGG	cis	rs7973719	0.868	rs2053887	chr12:7346530	G/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.29	-7.47	-0.33	3.99e-13	IgG glycosylation;
LGG	cis	rs2693698	0.533	rs28482287	chr14:99683755	G/A	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.71e-28	Schizophrenia;
LGG	cis	rs7618915	0.501	rs34157897	chr3:52716937	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.89e-12	Bipolar disorder;
LGG	cis	rs11785400	0.793	rs6996760	chr8:143722386	G/A	cg24634471	chr8:143751801	JRK	0.48	7.4	0.33	6.49e-13	Schizophrenia;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg27532560	chr4:187881888	NA	-0.59	-12.93	-0.52	7.23e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2749592	0.550	rs9733309	chr10:37882405	G/A	cg25427524	chr10:38739819	LOC399744	0.47	9.0	0.39	6.02e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs875971	0.862	rs778697	chr7:65870426	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs2224391	0.628	rs2773317	chr6:5254509	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.51	-0.33	3e-13	Height;
LGG	cis	rs977987	0.806	rs35263058	chr16:75391937	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs1009647	1.000	rs1890256	chr14:55881276	C/T	cg04306507	chr14:55594613	LGALS3	0.39	7.93	0.35	1.65e-14	Testicular germ cell tumor;
LGG	cis	rs4665809	0.627	rs1465720	chr2:26412638	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.13	-0.7	6.63e-70	Gut microbiome composition (summer);
LGG	cis	rs757978	0.810	rs2055569	chr2:242401439	C/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.62	-6.92	-0.31	1.5e-11	Chronic lymphocytic leukemia;
LGG	trans	rs9858542	0.953	rs9827021	chr3:49514764	C/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.16	-0.43	4.81e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs1814175	0.817	rs4881623	chr11:49804991	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.16	-0.78	7.4e-98	Height;
LGG	trans	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg02002194	chr4:3960332	NA	-0.38	-6.86	-0.3	2.19e-11	Neuroticism;
LGG	cis	rs17767392	0.958	rs10135680	chr14:72030809	G/A	cg13720639	chr14:72061746	SIPA1L1	0.38	8.17	0.36	2.92e-15	Mitral valve prolapse;
LGG	cis	rs1865760	1.000	rs6938233	chr6:25914077	C/T	cg03517284	chr6:25882590	NA	-0.39	-6.9	-0.31	1.69e-11	Height;
LGG	cis	rs2832191	0.791	rs2065270	chr21:30485420	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-24.22	-0.75	2.63e-84	Dental caries;
LGG	trans	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg16141378	chr3:129829833	LOC729375	0.38	8.7	0.37	6.04e-17	Joint mobility (Beighton score);
LGG	cis	rs74781061	0.929	rs8029099	chr15:74766770	A/C	cg02384859	chr15:74862662	ARID3B	-0.34	-6.96	-0.31	1.13e-11	Endometriosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03646474	chr1:174992368	MRPS14	-0.52	-7.59	-0.33	1.74e-13	Systemic lupus erythematosus;
LGG	cis	rs7937890	0.904	rs67623158	chr11:14295196	T/C	cg02251663	chr11:14281053	SPON1	0.34	8.29	0.36	1.26e-15	Mitochondrial DNA levels;
LGG	cis	rs950169	0.840	rs62029595	chr15:84955301	C/T	cg03959625	chr15:84868606	LOC388152	0.55	8.63	0.37	9.91e-17	Schizophrenia;
LGG	cis	rs883115	0.846	rs6665204	chr1:224814765	T/C	cg01808320	chr1:224927238	CNIH3	-0.42	-7.62	-0.33	1.41e-13	Cancer;
LGG	cis	rs9326248	0.559	rs10892052	chr11:116834313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.62	10.63	0.44	9.47e-24	Blood protein levels;
LGG	cis	rs7582180	0.629	rs13010911	chr2:100953390	G/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	3.12e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2933343	0.729	rs6790091	chr3:128608751	G/C	cg25356066	chr3:128598488	ACAD9	0.48	7.28	0.32	1.46e-12	IgG glycosylation;
LGG	cis	rs875971	0.830	rs587360	chr7:65522698	C/A	cg11764359	chr7:65958608	NA	0.69	12.13	0.49	1.33e-29	Aortic root size;
LGG	cis	rs2439831	0.850	rs28684672	chr15:44107662	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.31	0.43	1.47e-22	Lung cancer in ever smokers;
LGG	cis	rs73227498	0.590	rs2114990	chr5:111494103	A/C	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.51	-7.06	-0.31	6.03e-12	Thyroid cancer;
LGG	cis	rs6964587	0.967	rs28594877	chr7:91644070	C/T	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs7538876	0.903	rs1324368	chr1:17752000	A/G	cg10329579	chr1:17754830	RCC2	-0.53	-9.95	-0.42	3e-21	Basal cell carcinoma;
LGG	cis	rs738321	0.701	rs4821754	chr22:38581503	A/G	cg03162506	chr22:38580953	NA	-0.36	-8.61	-0.37	1.19e-16	Breast cancer;
LGG	cis	rs10791323	0.598	rs10750550	chr11:133736083	A/G	cg00579200	chr11:133705235	NA	-0.54	-10.48	-0.44	3.4e-23	Childhood ear infection;
LGG	cis	rs875971	0.964	rs12668936	chr7:65914404	C/T	cg11764359	chr7:65958608	NA	0.81	15.18	0.58	1.62e-42	Aortic root size;
LGG	cis	rs17376456	0.877	rs34595581	chr5:93369422	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.23e-22	Diabetic retinopathy;
LGG	cis	rs8063160	0.935	rs113891247	chr16:90047757	T/A	cg07984980	chr16:89898383	SPIRE2	0.96	8.43	0.36	4.46e-16	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LGG	cis	rs7568458	0.870	rs1562323	chr2:85809711	T/C	cg17127132	chr2:85788382	GGCX	0.46	8.03	0.35	8.03e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4727027	0.933	rs62505074	chr7:148834780	C/T	cg23583168	chr7:148888333	NA	-0.87	-17.01	-0.62	9.55e-51	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs17376456	0.597	rs7728825	chr5:93384594	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.56	-7.96	-0.35	1.36e-14	Diabetic retinopathy;
LGG	cis	rs1577917	1.000	rs12212733	chr6:86726013	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.46	-0.53	4.24e-35	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg19223190	chr17:80058835	NA	0.47	8.67	0.37	7.5e-17	Life satisfaction;
LGG	cis	rs607541	0.764	rs2470114	chr15:45930722	G/A	cg26924012	chr15:45694286	SPATA5L1	0.57	7.79	0.34	4.3e-14	Obesity-related traits;
LGG	cis	rs6502050	0.777	rs7406162	chr17:80086386	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg00035636	chr13:21900591	NA	0.35	7.14	0.31	3.63e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12497850	0.931	rs4974079	chr3:48906469	T/G	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs17666538	1.000	rs57255985	chr8:574131	C/T	cg26554054	chr8:600488	NA	-1.06	-9.46	-0.4	1.58e-19	IgG glycosylation;
LGG	cis	rs10895140	0.756	rs4754778	chr11:101436073	G/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.68	-0.3	6.96e-11	Menarche (age at onset);
LGG	cis	rs12893668	0.703	rs34026011	chr14:104050883	G/A	cg23335576	chr14:104009727	NA	0.47	8.22	0.36	2.01e-15	Reticulocyte count;
LGG	trans	rs7819412	0.521	rs10110684	chr8:11039159	G/C	cg16141378	chr3:129829833	LOC729375	0.31	6.67	0.3	7.52e-11	Triglycerides;
LGG	cis	rs62238980	0.614	rs74658500	chr22:32410101	C/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg04911050	chr16:677664	RAB40C	0.34	6.75	0.3	4.46e-11	Height;
LGG	cis	rs11722228	0.594	rs10939663	chr4:10032516	T/G	cg25986240	chr4:9926439	SLC2A9	-0.64	-13.06	-0.52	2.16e-33	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg12395012	chr8:11607386	GATA4	-0.38	-7.07	-0.31	5.87e-12	Mood instability;
LGG	cis	rs1801251	1.000	rs12990821	chr2:233617585	C/G	cg25237894	chr2:233734115	C2orf82	0.66	12.78	0.51	2.95e-32	Coronary artery disease;
LGG	cis	rs8180040	1.000	rs295461	chr3:47368010	T/C	cg16586182	chr3:47516702	SCAP	-0.77	-15.17	-0.58	1.73e-42	Colorectal cancer;
LGG	cis	rs7776701	1.000	rs7776701	chr7:47442633	T/C	cg23694490	chr7:47445681	TNS3	0.42	11.6	0.47	1.67e-27	Basal cell carcinoma;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg13206674	chr6:150067644	NUP43	0.62	14.12	0.55	6.67e-38	Lung cancer;
LGG	cis	rs854765	0.505	rs4506969	chr17:17899839	A/G	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.42	-0.61	4.57e-48	Total body bone mineral density;
LGG	cis	rs2916247	1.000	rs2976505	chr8:92994972	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.76	-0.38	3.84e-17	Intelligence (multi-trait analysis);
LGG	cis	rs3780378	0.934	rs10815146	chr9:5015901	T/A	cg02405213	chr9:5042618	JAK2	-0.52	-9.33	-0.4	4.32e-19	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg13206674	chr6:150067644	NUP43	0.43	7.5	0.33	3.32e-13	Lung cancer;
LGG	cis	rs4732038	0.510	rs28645396	chr7:134270576	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs9389248	0.690	rs728030	chr6:135246294	G/T	cg24558204	chr6:135376177	HBS1L	-0.54	-9.16	-0.39	1.64e-18	High light scatter reticulocyte percentage of red cells;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11048311	chr10:12084973	UPF2	0.39	6.77	0.3	3.82e-11	Hip circumference;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23006223	chr4:57843834	C4orf14;POLR2B	0.41	6.72	0.3	5.23e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11645898	0.630	rs72791135	chr16:72259718	G/C	cg14768367	chr16:72042858	DHODH	-0.69	-8.99	-0.39	6.16e-18	Blood protein levels;
LGG	cis	rs4664308	0.806	rs4665162	chr2:161060184	A/G	cg03641300	chr2:160917029	PLA2R1	-0.79	-15.92	-0.59	8.03e-46	Idiopathic membranous nephropathy;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg16141378	chr3:129829833	LOC729375	-0.45	-11.2	-0.46	6.3e-26	Mood instability;
LGG	trans	rs6561151	0.681	rs7989702	chr13:44439150	T/C	cg12856521	chr11:46389249	DGKZ	0.89	14.64	0.56	3.74e-40	Crohn's disease;
LGG	trans	rs11650494	0.908	rs73340399	chr17:47372743	G/C	cg11430096	chr6:110968061	CDK19	0.64	6.75	0.3	4.36e-11	Prostate cancer;
LGG	cis	rs7727544	0.636	rs2631365	chr5:131705949	T/C	cg07395648	chr5:131743802	NA	0.55	13.18	0.52	6.39e-34	Blood metabolite levels;
LGG	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg08305652	chr11:111469057	NA	-0.45	-9.27	-0.4	6.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs17824933	0.848	rs11230564	chr11:60776465	A/G	cg16817237	chr11:60793675	NA	0.35	6.68	0.3	7.07e-11	Multiple sclerosis;
LGG	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg18654377	chr3:49208889	KLHDC8B	0.44	6.69	0.3	6.4e-11	Resting heart rate;
LGG	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg05082376	chr22:42548792	NA	-0.39	-8.33	-0.36	9.38e-16	Schizophrenia;
LGG	cis	rs1799949	1.000	rs11659028	chr17:41195025	T/A	cg18379455	chr17:41446167	NA	-0.33	-7.5	-0.33	3.19e-13	Menopause (age at onset);
LGG	cis	rs12765878	1.000	rs11191847	chr10:105650626	G/C	cg11005552	chr10:105648138	OBFC1	1.03	27.18	0.78	6.22e-98	Coronary artery disease;
LGG	cis	rs2404602	0.669	rs8036703	chr15:76951040	A/G	cg15268244	chr15:77196840	NA	-0.31	-6.69	-0.3	6.29e-11	Blood metabolite levels;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs34754328	chr5:131688074	G/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs9291683	0.588	rs6857693	chr4:10018435	G/A	cg08250081	chr4:10125330	NA	0.4	7.95	0.35	1.45e-14	Bone mineral density;
LGG	cis	rs12530134	0.519	rs3920484	chr6:170746081	A/G	cg16453901	chr6:170730693	NA	-0.86	-8.91	-0.38	1.2e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7572644	0.509	rs13001060	chr2:28025061	T/C	cg27432699	chr2:27873401	GPN1	0.47	6.88	0.3	1.95e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs9398803	0.931	rs9375435	chr6:126661858	C/T	cg19875578	chr6:126661172	C6orf173	0.56	10.06	0.42	1.13e-21	Male-pattern baldness;
LGG	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg27523141	chr10:43048294	ZNF37B	0.39	7.57	0.33	2.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs55901549	chr4:119770172	T/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs6426558	0.537	rs2102634	chr1:227324308	T/C	cg10327440	chr1:227177885	CDC42BPA	-0.63	-10.47	-0.44	3.71e-23	Neutrophil percentage of white cells;
LGG	cis	rs16837677	1.000	rs16837677	chr1:156774111	C/T	cg14991358	chr1:156767203	PRCC	0.76	7.66	0.34	1.11e-13	Sjögren's syndrome;
LGG	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.43e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs3736594	0.959	rs10201247	chr2:27974971	A/G	cg27432699	chr2:27873401	GPN1	-0.57	-9.17	-0.39	1.58e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs9457247	0.582	rs9459855	chr6:167466150	G/T	cg07741184	chr6:167504864	NA	0.44	9.95	0.42	2.99e-21	Crohn's disease;
LGG	cis	rs7582180	0.625	rs12612755	chr2:100906061	T/C	cg05692746	chr2:100937584	LONRF2	-0.56	-9.73	-0.41	1.74e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7216064	0.953	rs12450907	chr17:65870644	T/G	cg12091567	chr17:66097778	LOC651250	-0.6	-8.79	-0.38	2.85e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs7301016	0.947	rs10877864	chr12:62893199	T/C	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs7712401	0.601	rs154496	chr5:122221731	A/G	cg19412675	chr5:122181750	SNX24	0.42	6.97	0.31	1.13e-11	Mean platelet volume;
LGG	cis	rs11190604	1.000	rs4919464	chr10:102221195	A/G	cg07080220	chr10:102295463	HIF1AN	0.63	10.79	0.45	2.3e-24	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1707322	1.000	rs1768800	chr1:46549188	A/G	cg03146154	chr1:46216737	IPP	-0.53	-9.66	-0.41	3.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs73198271	0.740	rs10109886	chr8:8680558	G/A	cg16141378	chr3:129829833	LOC729375	0.35	6.89	0.3	1.83e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4319547	0.915	rs3803005	chr12:123110654	T/C	cg23029597	chr12:123009494	RSRC2	-0.92	-18.32	-0.65	8.63e-57	Body mass index;
LGG	cis	rs2235649	0.623	rs8048162	chr16:1848918	C/T	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.91	-0.31	1.65e-11	Blood metabolite levels;
LGG	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	cis	rs2832191	0.716	rs2249028	chr21:30365322	G/A	cg24692254	chr21:30365293	RNF160	1.04	29.64	0.81	4.98e-109	Dental caries;
LGG	cis	rs34845616	0.514	rs4937835	chr11:133691060	G/C	cg06067394	chr11:133789110	IGSF9B	0.39	6.78	0.3	3.65e-11	Hand grip strength;
LGG	trans	rs7615952	0.599	rs16834938	chr3:125706046	C/T	cg07211511	chr3:129823064	LOC729375	-0.65	-9.0	-0.39	5.67e-18	Blood pressure (smoking interaction);
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg06112835	chr11:68658793	MRPL21	-0.6	-9.99	-0.42	2.03e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs769267	0.930	rs7256149	chr19:19566255	T/C	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs3008870	1.000	rs1925408	chr1:67365034	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.98	23.25	0.73	8.37e-80	Lymphocyte percentage of white cells;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs12431410	0.550	rs9323354	chr14:60184735	C/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.28	-0.32	1.42e-12	Schizophrenia;
LGG	cis	rs10754283	0.967	rs1934045	chr1:90107799	A/C	cg06121193	chr1:90282411	NA	0.4	7.76	0.34	5.48e-14	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00349776	chr1:165414189	RXRG	-0.39	-6.75	-0.3	4.57e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs35123781	0.654	rs356484	chr5:139084438	T/A	cg21230503	chr5:139085173	NA	0.38	8.45	0.37	3.74e-16	Schizophrenia;
LGG	cis	rs4722166	0.630	rs13311155	chr7:22789789	A/C	cg05265849	chr7:22767390	IL6	0.42	7.95	0.35	1.39e-14	Lung cancer;
LGG	cis	rs6840360	0.642	rs7682770	chr4:152390413	A/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9859260	0.744	rs419059	chr3:195782184	C/T	cg23484912	chr5:273055	PDCD6	-0.4	-7.93	-0.35	1.66e-14	Mean corpuscular volume;
LGG	trans	rs9329221	0.935	rs3750311	chr8:10283602	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.88	-0.42	5.35e-21	Neuroticism;
LGG	cis	rs13082711	0.595	rs1445114	chr3:27345489	C/A	cg02860705	chr3:27208620	NA	0.93	17.18	0.62	1.56e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg20273122	chr11:68671309	IGHMBP2;MRPL21	0.43	6.72	0.3	5.2e-11	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7395662	0.929	rs11039903	chr11:48679705	G/T	cg00717180	chr2:96193071	NA	-0.42	-7.4	-0.33	6.67e-13	HDL cholesterol;
LGG	trans	rs9467711	0.790	rs35400317	chr6:26593275	C/T	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.68	-0.48	8.76e-28	Autism spectrum disorder or schizophrenia;
LGG	cis	rs16957091	0.909	rs3742988	chr15:43016475	A/G	cg07484255	chr15:43025164	CDAN1	-0.48	-6.67	-0.3	7.27e-11	MGMT methylation in smokers;
LGG	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1.03e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs929354	0.772	rs6459741	chr7:157014553	G/T	cg00092383	chr7:157075207	NA	-0.39	-6.78	-0.3	3.58e-11	Body mass index;
LGG	cis	rs4409675	0.576	rs6565	chr1:28213157	T/C	cg23691781	chr1:28212827	C1orf38	0.42	11.3	0.46	2.58e-26	Corneal astigmatism;
LGG	cis	rs2204008	0.748	rs11514352	chr12:38246954	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.45	0.71	2.11e-71	Bladder cancer;
LGG	cis	rs17039065	1.000	rs72889361	chr4:109381063	T/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.02	0.31	8.15e-12	Gut microbiome composition (summer);
LGG	cis	rs1065852	0.861	rs5758627	chr22:42572547	C/T	cg15128208	chr22:42549153	NA	0.76	11.55	0.47	2.77e-27	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs2115536	0.692	rs6495450	chr15:80162499	C/A	cg00225070	chr15:80189496	MTHFS	0.4	7.6	0.33	1.61e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7084402	0.935	rs10826202	chr10:60359091	C/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.23	-0.32	1.95e-12	Refractive error;
LGG	cis	rs9322193	0.884	rs10872648	chr6:150079835	A/G	cg13206674	chr6:150067644	NUP43	0.64	13.23	0.52	3.91e-34	Lung cancer;
LGG	cis	rs2836950	0.520	rs8133928	chr21:40689963	G/A	cg11644478	chr21:40555479	PSMG1	-0.59	-9.87	-0.42	5.78e-21	Menarche (age at onset);
LGG	cis	rs7255436	0.965	rs11666003	chr19:8452102	G/A	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.74	-0.3	4.67e-11	HDL cholesterol;
LGG	cis	rs9399137	0.507	rs13197750	chr6:135312380	G/A	cg24558204	chr6:135376177	HBS1L	0.62	10.75	0.45	3.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg00405596	chr8:11794950	NA	0.64	11.41	0.47	9.3e-27	Neuroticism;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.04	0.46	2.61e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg11062466	chr8:58055876	NA	0.53	8.09	0.35	5.32e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.39	0.47	1.2e-26	Bipolar disorder;
LGG	cis	rs227833	0.537	rs2817117	chr6:44646741	G/A	cg18551225	chr6:44695536	NA	0.42	6.8	0.3	3.17e-11	Monobrow;
LGG	cis	rs9547996	0.796	rs9547968	chr13:38166068	C/G	cg17979426	chr13:38220150	TRPC4	-0.36	-6.89	-0.3	1.85e-11	Diastolic blood pressure;
LGG	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg20387954	chr3:183756860	HTR3D	0.66	13.57	0.53	1.44e-35	Anterior chamber depth;
LGG	cis	rs35110281	0.782	rs1584917	chr21:45042365	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.93	-0.38	9.8e-18	Mean corpuscular volume;
LGG	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg27205649	chr11:78285834	NARS2	-0.48	-7.69	-0.34	9.17e-14	Testicular germ cell tumor;
LGG	cis	rs6951245	1.000	rs74347384	chr7:1072440	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3942852	0.568	rs6485807	chr11:48102867	G/A	cg15704280	chr7:45808275	SEPT13	-0.7	-10.97	-0.45	4.75e-25	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs12517041	1.000	rs1366454	chr5:23319172	G/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.1e-25	Calcium levels;
LGG	cis	rs2046867	0.862	rs62252360	chr3:72838551	C/T	cg01043669	chr3:72786069	NA	0.42	7.06	0.31	6.24e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg03474202	chr17:45855739	NA	-0.21	-6.76	-0.3	4.08e-11	IgG glycosylation;
LGG	cis	rs9583531	0.600	rs1441043	chr13:111367650	A/G	cg15841412	chr13:111365552	ING1	0.47	7.26	0.32	1.68e-12	Coronary artery disease;
LGG	cis	rs12477438	0.520	rs6711073	chr2:100020742	G/A	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs4862750	0.794	rs7672272	chr4:187896774	T/G	cg03452623	chr4:187889614	NA	-1.04	-29.38	-0.81	7e-108	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10739663	0.520	rs1566362	chr9:128163132	C/T	cg14078157	chr9:128172775	NA	0.59	11.12	0.46	1.27e-25	Resting heart rate;
LGG	cis	rs36051895	0.623	rs12351715	chr9:5262349	A/G	cg02405213	chr9:5042618	JAK2	-0.76	-13.07	-0.52	1.89e-33	Pediatric autoimmune diseases;
LGG	cis	rs1218582	0.774	rs4845681	chr1:154868055	G/T	cg24250549	chr1:154909240	PMVK	0.72	14.19	0.55	3.27e-38	Prostate cancer;
LGG	cis	rs2486288	0.656	rs11632419	chr15:45557456	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.6	-10.1	-0.43	8.07e-22	Glomerular filtration rate;
LGG	cis	rs10504229	0.953	rs116564484	chr8:58172818	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs8002861	0.692	rs9533646	chr13:44410669	T/C	cg12856521	chr11:46389249	DGKZ	-0.51	-9.19	-0.39	1.28e-18	Leprosy;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.71e-19	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs56302600	chr4:119770162	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs17780086	0.527	rs72827712	chr17:30538600	A/G	cg20587970	chr11:113659929	NA	-1.36	-17.03	-0.62	7.21e-51	Height;
LGG	trans	rs9354308	0.781	rs9363455	chr6:66547322	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.28	-0.36	1.29e-15	Metabolite levels;
LGG	cis	rs1008375	1.000	rs2058337	chr4:17678649	C/T	cg18681998	chr4:17616180	MED28	0.82	18.12	0.64	7.46e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1035144	0.506	rs7150858	chr14:81280425	T/C	cg06600135	chr14:81408086	NA	-0.51	-9.85	-0.42	6.47e-21	Male sexual orientation;
LGG	cis	rs2576037	0.583	rs578451	chr18:44404525	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.46	0.65	1.94e-57	Personality dimensions;
LGG	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.86	0.38	1.77e-17	Common traits (Other);
LGG	cis	rs74781061	0.860	rs8037211	chr15:74747402	A/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs9400467	0.506	rs56381513	chr6:111429685	C/G	cg15721981	chr6:111408429	SLC16A10	0.58	7.08	0.31	5.55e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs7552404	0.920	rs1612097	chr1:76218875	C/T	cg22875332	chr1:76189707	ACADM	0.58	10.26	0.43	2.18e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2645694	0.911	rs2703147	chr4:77831307	C/T	cg06046430	chr4:77819534	ANKRD56	0.49	9.6	0.41	5e-20	Emphysema distribution in smoking;
LGG	cis	rs2117029	0.638	rs7296288	chr12:49479968	A/C	cg24176009	chr12:49580217	TUBA1A	0.45	8.47	0.37	3.23e-16	Intelligence (multi-trait analysis);
LGG	cis	rs614226	0.935	rs3887875	chr12:120895749	A/G	cg01236616	chr12:121019343	POP5	-1.22	-22.35	-0.72	1.34e-75	Type 1 diabetes nephropathy;
LGG	cis	rs7326068	0.510	rs4432108	chr13:21342151	G/A	cg04906043	chr13:21280425	IL17D	-0.46	-7.38	-0.32	7.51e-13	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs55883249	1.000	rs60319753	chr2:9767944	A/G	cg23886495	chr2:9695866	ADAM17	0.63	8.74	0.38	4.32e-17	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6933660	0.800	rs6930557	chr6:151755806	G/A	cg14416726	chr6:151773293	C6orf211;RMND1	-0.69	-12.86	-0.51	1.42e-32	Menarche (age at onset);
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg10360139	chr7:1886902	MAD1L1	-0.39	-6.7	-0.3	6.07e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg26578617	chr4:90757533	SNCA	-0.47	-9.52	-0.4	9.72e-20	Dementia with Lewy bodies;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg27532560	chr4:187881888	NA	0.58	12.26	0.5	3.91e-30	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg21775007	chr8:11205619	TDH	0.51	8.27	0.36	1.47e-15	Retinal vascular caliber;
LGG	cis	rs9300255	0.602	rs1716168	chr12:123651966	C/G	cg05973401	chr12:123451056	ABCB9	-0.49	-7.37	-0.32	7.86e-13	Neutrophil percentage of white cells;
LGG	cis	rs2011503	0.882	rs56144632	chr19:19368310	G/A	cg01262667	chr19:19385393	TM6SF2	0.35	6.78	0.3	3.61e-11	Bipolar disorder;
LGG	cis	rs1806153	0.611	rs4440995	chr11:31838128	G/A	cg11990419	chr11:31841155	NA	0.33	7.65	0.33	1.21e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs1124376	0.935	rs28716666	chr3:20148409	C/T	cg05072819	chr3:20081367	KAT2B	0.63	8.42	0.36	4.65e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs2204008	0.668	rs1619009	chr12:38120485	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.98	-0.35	1.13e-14	Bladder cancer;
LGG	cis	rs9300255	0.602	rs1716167	chr12:123651162	C/T	cg05973401	chr12:123451056	ABCB9	-0.5	-7.49	-0.33	3.46e-13	Neutrophil percentage of white cells;
LGG	trans	rs853679	0.607	rs34788973	chr6:27879200	C/A	cg01620082	chr3:125678407	NA	-1.01	-10.12	-0.43	6.8e-22	Depression;
LGG	cis	rs7914558	1.000	rs6584540	chr10:104927634	A/G	cg04362960	chr10:104952993	NT5C2	0.55	10.6	0.44	1.18e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg08847335	chr10:891726	LARP4B	-0.49	-8.92	-0.38	1.05e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg16077055	chr2:106428750	NCK2	-0.32	-8.35	-0.36	7.71e-16	Addiction;
LGG	cis	rs2115536	0.640	rs934134	chr15:80168218	T/C	cg00225070	chr15:80189496	MTHFS	0.4	7.55	0.33	2.28e-13	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01341218	chr17:43662625	NA	0.95	16.73	0.61	1.83e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2228479	0.702	rs11076621	chr16:89837927	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs10131894	0.611	rs175001	chr14:75436452	A/C	cg08847533	chr14:75593920	NEK9	0.46	8.43	0.36	4.47e-16	Coronary artery disease;
LGG	cis	rs10256972	0.524	rs6945202	chr7:1116558	T/C	cg03188948	chr7:1209495	NA	0.41	7.14	0.31	3.61e-12	Longevity;Endometriosis;
LGG	cis	rs11191205	0.686	rs10883669	chr10:103401616	C/T	cg15320455	chr10:103880129	LDB1	-0.46	-6.74	-0.3	4.85e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2494938	1.000	rs10947897	chr6:40530800	A/C	cg14084896	chr6:40530702	LRFN2	-0.3	-7.03	-0.31	7.25e-12	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs9650657	0.740	rs6980805	chr8:10679842	G/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.52	-0.33	2.92e-13	Neuroticism;
LGG	trans	rs36715	1.000	rs36705	chr5:127554486	A/G	cg16011800	chr17:1958478	HIC1	-0.48	-7.18	-0.32	2.83e-12	Breast cancer;
LGG	cis	rs796364	0.806	rs11684895	chr2:201009026	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs2559856	1.000	rs2251187	chr12:102081889	G/A	cg12924262	chr12:102091054	CHPT1	0.64	12.68	0.51	7.64e-32	Blood protein levels;
LGG	cis	rs11155671	0.530	rs7758020	chr6:150208111	T/C	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs9505982	chr6:149939601	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.39	0.36	5.93e-16	Lung cancer;
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.03e-16	Skin colour saturation;
LGG	cis	rs7264396	0.747	rs6058291	chr20:34247769	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.63	-0.33	1.33e-13	Total cholesterol levels;
LGG	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg03929089	chr4:120376271	NA	-0.93	-19.22	-0.67	5.61e-61	Height;
LGG	cis	rs7666738	0.791	rs12233867	chr4:98950233	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.74e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17666538	0.591	rs2878547	chr8:603416	G/A	cg26554054	chr8:600488	NA	0.88	9.68	0.41	2.55e-20	IgG glycosylation;
LGG	cis	rs1395	0.744	rs11686131	chr2:27508710	C/T	cg22903471	chr2:27725779	GCKR	-0.42	-7.04	-0.31	6.76e-12	Blood metabolite levels;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg20453264	chr5:131705742	SLC22A5	0.66	8.36	0.36	7.42e-16	Rheumatoid arthritis;
LGG	cis	rs62238980	0.522	rs76599991	chr22:32495779	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11105298	1.000	rs11105298	chr12:89876143	C/T	cg08166232	chr12:89918718	WDR51B;GALNT4	0.66	9.33	0.4	4.27e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs9322193	0.607	rs4870078	chr6:150201812	A/G	cg09699651	chr6:150184138	LRP11	-0.44	-6.71	-0.3	5.68e-11	Lung cancer;
LGG	cis	rs6834538	1.000	rs6533627	chr4:113479135	A/G	cg05166686	chr4:113558556	LARP7;C4orf21	-0.47	-7.34	-0.32	9.84e-13	Free thyroxine concentration;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22956598	chr17:13973019	COX10	0.4	6.72	0.3	5.3e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs61990749	0.597	rs4632066	chr14:78247282	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.56	-7.21	-0.32	2.31e-12	Fibroblast growth factor basic levels;
LGG	cis	rs9659323	0.689	rs7545737	chr1:119533823	C/T	cg05756136	chr1:119680316	WARS2	0.33	7.13	0.31	3.93e-12	Body mass index;
LGG	cis	rs35264875	0.796	rs72928657	chr11:68852336	T/C	cg01403660	chr11:68851641	TPCN2	0.52	7.27	0.32	1.55e-12	Blond vs. brown hair color;
LGG	cis	rs9911578	1.000	rs10401050	chr17:56953786	A/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg19507638	chr5:93509721	C5orf36	-0.7	-9.71	-0.41	1.99e-20	Diabetic retinopathy;
LGG	cis	rs12410462	0.681	rs76191945	chr1:227673919	A/G	cg21459583	chr1:227974177	NA	0.6	8.64	0.37	8.99e-17	Major depressive disorder;
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg00013410	chr17:60142592	MED13	0.47	7.47	0.33	3.9e-13	Mitral valve prolapse;
LGG	cis	rs3806843	0.547	rs246065	chr5:140323638	A/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.25e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs992157	0.700	rs10165153	chr2:219159629	T/C	cg00012203	chr2:219082015	ARPC2	0.65	11.5	0.47	4.45e-27	Colorectal cancer;
LGG	cis	rs897984	0.806	rs4889571	chr16:30949047	A/G	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg13877915	chr19:58951672	ZNF132	1.01	26.43	0.78	1.65e-94	Uric acid clearance;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg24829409	chr8:58192753	C8orf71	-0.84	-13.48	-0.53	3.68e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs10158431	chr1:248481253	A/G	cg00666640	chr1:248458726	OR2T12	0.6	9.69	0.41	2.37e-20	Common traits (Other);
LGG	cis	rs6860806	0.507	rs272878	chr5:131671769	C/T	cg07395648	chr5:131743802	NA	0.48	9.88	0.42	5.03e-21	Breast cancer;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg19524238	chr7:2802976	GNA12	0.31	7.42	0.33	5.61e-13	Height;
LGG	cis	rs2688608	0.901	rs2664280	chr10:75617344	A/T	cg10168709	chr10:75599394	CAMK2G	0.35	6.82	0.3	2.85e-11	Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.85e-12	Life satisfaction;
LGG	cis	rs2797369	0.825	rs3860239	chr6:101625038	T/C	cg27451362	chr6:101846650	GRIK2	-0.82	-10.9	-0.45	8.76e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs6032067	0.641	rs34602589	chr20:43768734	T/A	cg10761708	chr20:43804764	PI3	0.72	10.61	0.44	1.07e-23	Blood protein levels;
LGG	cis	rs4555082	0.874	rs10151638	chr14:105761592	T/C	cg13114125	chr14:105738426	BRF1	-0.85	-16.92	-0.62	2.4e-50	Mean platelet volume;Platelet distribution width;
LGG	cis	rs889398	0.594	rs1466863	chr16:69904138	A/T	cg00738113	chr16:70207722	CLEC18C	0.26	7.46	0.33	4.19e-13	Body mass index;
LGG	cis	rs1577917	0.958	rs12660846	chr6:86573809	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.21	-0.49	6.3e-30	Response to antipsychotic treatment;
LGG	cis	rs35110281	0.633	rs4819292	chr21:45125223	A/G	cg01579765	chr21:45077557	HSF2BP	-0.36	-7.91	-0.35	1.85e-14	Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs28645862	chr5:93233128	G/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs3087591	1.000	rs2952989	chr17:29516113	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.46	0.56	2.2e-39	Hip circumference;
LGG	cis	rs763014	0.966	rs4984904	chr16:680809	C/G	cg09263875	chr16:632152	PIGQ	0.67	13.59	0.53	1.27e-35	Height;
LGG	cis	rs514406	0.861	rs11206011	chr1:53235910	T/C	cg08859206	chr1:53392774	SCP2	0.34	6.88	0.3	1.89e-11	Monocyte count;
LGG	cis	rs910316	0.904	rs7156089	chr14:75645527	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.44	-0.44	4.79e-23	Height;
LGG	cis	rs6429082	0.715	rs9793740	chr1:235595590	T/C	cg26050004	chr1:235667680	B3GALNT2	-0.55	-8.94	-0.38	9.58e-18	Adiposity;
LGG	cis	rs7582180	0.764	rs12712075	chr2:100924129	T/C	cg08017756	chr2:100939284	LONRF2	-0.3	-7.12	-0.31	4.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs17083377	chr5:93164870	C/G	cg25358565	chr5:93447407	FAM172A	0.8	11.18	0.46	7.62e-26	Diabetic retinopathy;
LGG	cis	rs9487051	0.872	rs7773331	chr6:109609208	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.9	-0.38	1.24e-17	Reticulocyte fraction of red cells;
LGG	cis	rs4409675	0.913	rs4072744	chr1:28271039	A/T	cg00605270	chr1:28261552	SMPDL3B	-0.33	-7.17	-0.32	2.97e-12	Corneal astigmatism;
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.49	-0.4	1.18e-19	Life satisfaction;
LGG	cis	rs6714710	0.603	rs34373359	chr2:98442202	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.94	0.42	3.04e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.562	rs7786844	chr7:99934008	T/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.99	15.13	0.58	2.49e-42	Platelet count;
LGG	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg22467129	chr15:76604101	ETFA	0.46	7.68	0.34	9.33e-14	Blood metabolite levels;
LGG	cis	rs963731	0.579	rs4670904	chr2:39228883	G/C	cg04010122	chr2:39346883	SOS1	-0.69	-7.07	-0.31	5.57e-12	Corticobasal degeneration;
LGG	cis	rs910316	0.839	rs35977276	chr14:75637359	A/C	cg11812906	chr14:75593930	NEK9	-0.52	-9.34	-0.4	4.21e-19	Height;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.69	12.58	0.5	2.04e-31	Obesity-related traits;
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg06108461	chr20:60628389	TAF4	-0.67	-9.65	-0.41	3.42e-20	Obesity-related traits;
LGG	cis	rs7289126	1.000	rs5756986	chr22:38640841	A/G	cg25457927	chr22:38595422	NA	-0.32	-7.7	-0.34	8.58e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs4750440	0.702	rs11258774	chr10:14029701	G/A	cg27542038	chr10:14027202	FRMD4A	-0.69	-13.93	-0.54	4.2e-37	Adiponectin levels;
LGG	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg22980697	chr10:16874865	CUBN	0.43	8.07	0.35	6.28e-15	Platelet distribution width;
LGG	trans	rs1728785	1.000	rs1645935	chr16:68563791	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18252515	chr7:66147081	NA	-0.4	-6.79	-0.3	3.54e-11	Aortic root size;
LGG	cis	rs910187	0.678	rs6124964	chr20:45812536	T/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.47	-0.4	1.43e-19	Migraine;
LGG	cis	rs8141529	0.509	rs6005927	chr22:29255884	A/G	cg02153584	chr22:29168773	CCDC117	0.64	9.71	0.41	2.02e-20	Lymphocyte counts;
LGG	cis	rs116095464	1.000	rs7721278	chr5:310530	G/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.62	-0.44	1.01e-23	Breast cancer;
LGG	cis	rs2978263	0.628	rs6988150	chr8:30326612	C/T	cg05780722	chr8:30327988	RBPMS	0.34	6.97	0.31	1.1e-11	Cognitive performance;
LGG	cis	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg24623649	chr8:11872141	NA	-0.31	-7.36	-0.32	8.74e-13	Neuroticism;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg12070911	chr6:150209640	RAET1E	0.26	6.74	0.3	4.65e-11	Testicular germ cell tumor;
LGG	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs6815814	0.861	rs12233670	chr4:38787216	C/T	cg06935464	chr4:38784597	TLR10	0.55	9.07	0.39	3.32e-18	Breast cancer;
LGG	cis	rs2228479	0.850	rs3785279	chr16:89824562	G/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs2274273	0.653	rs1209087	chr14:55493220	C/T	cg04306507	chr14:55594613	LGALS3	-0.43	-10.71	-0.45	4.78e-24	Protein biomarker;
LGG	trans	rs36715	1.000	rs36693	chr5:127548700	T/C	cg16011800	chr17:1958478	HIC1	-0.46	-6.73	-0.3	5.01e-11	Breast cancer;
LGG	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs9814567	0.806	rs9824185	chr3:134324024	G/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1707322	1.000	rs3922886	chr1:46473902	A/T	cg03146154	chr1:46216737	IPP	0.56	10.33	0.43	1.19e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2832191	0.791	rs2832179	chr21:30480366	C/T	cg08807101	chr21:30365312	RNF160	-0.85	-17.21	-0.62	1.08e-51	Dental caries;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg05863683	chr7:1912471	MAD1L1	0.48	9.44	0.4	1.91e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs6088580	0.634	rs6058052	chr20:33047084	A/G	cg08999081	chr20:33150536	PIGU	0.39	9.73	0.41	1.73e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs992157	1.000	rs992157	chr2:219154781	A/G	cg04731861	chr2:219085781	ARPC2	0.4	9.7	0.41	2.2e-20	Colorectal cancer;
LGG	cis	rs798766	1.000	rs798766	chr4:1734239	C/T	cg00006948	chr4:1768889	NA	0.49	6.87	0.3	2.09e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs921968	0.607	rs529474	chr2:219463283	C/T	cg01130898	chr2:219473002	PLCD4	-0.41	-7.07	-0.31	5.81e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10206020	0.921	rs4072986	chr2:1547734	C/G	cg26248373	chr2:1572462	NA	-0.88	-14.14	-0.55	5.42e-38	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.46	0.33	4.28e-13	Menopause (age at onset);
LGG	cis	rs12479064	0.694	rs1823569	chr2:100113764	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.66	-10.23	-0.43	2.84e-22	Chronic sinus infection;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg11584989	chr19:19387371	SF4	-0.42	-7.67	-0.34	1.02e-13	Tonsillectomy;
LGG	trans	rs3960554	0.674	rs113848658	chr7:75791858	G/A	cg19862616	chr7:65841803	NCRNA00174	0.86	12.23	0.49	5.19e-30	Eotaxin levels;
LGG	cis	rs8056064	0.793	rs71402034	chr16:82782957	C/T	cg08271366	chr16:82816457	CDH13	-0.4	-6.96	-0.31	1.19e-11	Multiple myeloma (IgH translocation);Gut microbiome composition (winter);
LGG	cis	rs758324	0.773	rs13183449	chr5:131116082	C/A	cg06307176	chr5:131281290	NA	0.54	8.93	0.38	1.01e-17	Alzheimer's disease in APOE e4- carriers;
LGG	trans	rs2270927	0.510	rs6876070	chr5:75579237	T/A	cg13563193	chr19:33072644	PDCD5	0.87	10.31	0.43	1.39e-22	Mean corpuscular volume;
LGG	cis	rs9354308	0.727	rs9342517	chr6:66603293	T/C	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.86e-11	Metabolite levels;
LGG	cis	rs2153535	0.580	rs6597327	chr6:8482157	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs9611565	0.694	rs5758324	chr22:41787950	G/T	cg06481639	chr22:41940642	POLR3H	-0.51	-7.67	-0.34	1.01e-13	Vitiligo;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.36	7.74	0.34	6.5e-14	Schizophrenia;
LGG	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	trans	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg18335740	chr13:41363409	SLC25A15	0.81	18.92	0.66	1.46e-59	Lewy body disease;
LGG	cis	rs7762018	1.000	rs4509126	chr6:170068058	A/G	cg17545662	chr6:170176663	C6orf70	0.7	8.77	0.38	3.42e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1552244	0.554	rs3846169	chr3:9997054	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.73	-13.14	-0.52	9.64e-34	Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15208284	chr3:107242730	BBX	0.48	7.77	0.34	5.23e-14	Cognitive performance;
LGG	cis	rs11123170	0.543	rs4849178	chr2:113982608	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.64	0.37	9.36e-17	Renal function-related traits (BUN);
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg03351412	chr1:154909251	PMVK	0.65	12.6	0.51	1.64e-31	Prostate cancer;
LGG	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg25986240	chr4:9926439	SLC2A9	0.39	7.92	0.35	1.78e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg17376030	chr22:41985996	PMM1	0.56	8.81	0.38	2.54e-17	Vitiligo;
LGG	cis	rs9329221	0.538	rs2272598	chr8:10100769	T/C	cg19847130	chr8:10466454	RP1L1	0.31	6.69	0.3	6.63e-11	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06824583	chr1:154297643	ATP8B2;AQP10	0.41	6.77	0.3	3.95e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg23649088	chr2:200775458	C2orf69	0.59	8.67	0.37	7.46e-17	Schizophrenia;
LGG	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg00204512	chr16:28754710	NA	0.25	6.91	0.31	1.64e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7674212	0.539	rs6815783	chr4:104122146	A/C	cg16532752	chr4:104119610	CENPE	-0.41	-7.14	-0.31	3.65e-12	Type 2 diabetes;
LGG	cis	rs7945705	0.747	rs2568045	chr11:9004060	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.41	-8.52	-0.37	2.32e-16	Hemoglobin concentration;
LGG	cis	rs12210905	1.000	rs12203728	chr6:27051750	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	cis	rs2243480	1.000	rs13247184	chr7:65358928	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs1005277	0.579	rs2023351	chr10:38378814	A/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs1799949	0.501	rs9675035	chr17:41415016	A/T	cg25072359	chr17:41440525	NA	0.52	10.14	0.43	5.8e-22	Menopause (age at onset);
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg15147215	chr3:52552868	STAB1	-0.37	-7.04	-0.31	6.97e-12	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17663235	chr19:18263861	PIK3R2	0.48	7.38	0.32	7.41e-13	Gut microbiome composition (summer);
LGG	cis	rs9547996	0.879	rs61957470	chr13:38133049	G/A	cg13634560	chr13:38173852	POSTN	-0.35	-7.08	-0.31	5.25e-12	Diastolic blood pressure;
LGG	cis	rs283228	0.550	rs2787576	chr6:101821986	A/C	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	7.07	0.31	5.75e-12	Longevity;
LGG	cis	rs2243480	1.000	rs13235972	chr7:65883605	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.09	-0.42	8.77e-22	Diabetic kidney disease;
LGG	cis	rs2243480	1.000	rs709607	chr7:65449541	C/G	cg12463550	chr7:65579703	CRCP	-0.66	-7.19	-0.32	2.54e-12	Diabetic kidney disease;
LGG	cis	rs1218582	0.772	rs10908448	chr1:154882544	A/G	cg09359103	chr1:154839909	KCNN3	0.51	10.38	0.43	8.04e-23	Prostate cancer;
LGG	trans	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg06521331	chr12:34319734	NA	-0.5	-8.67	-0.37	7.58e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs73001065	0.892	rs58542926	chr19:19379549	C/T	cg03709012	chr19:19516395	GATAD2A	0.97	8.17	0.35	3.02e-15	LDL cholesterol;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg11050988	chr7:1952600	MAD1L1	-0.39	-9.46	-0.4	1.5700000000000001e-19	Testicular germ cell tumor;
LGG	cis	rs2133450	0.526	rs62234956	chr3:7344222	A/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.39	-0.4	2.68e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs3733585	0.673	rs4495037	chr4:9954050	C/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.84	-0.34	3.21e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs854037	0.698	rs34687405	chr5:57069120	G/A	cg08523694	chr5:57076192	NA	0.5	7.09	0.31	4.95e-12	Birth weight;
LGG	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs17384381	0.700	rs11161616	chr1:85907625	A/G	cg16011679	chr1:85725395	C1orf52	-0.5	-8.83	-0.38	2.22e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg23894439	chr1:183413866	NA	0.47	8.66	0.37	7.69e-17	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg05863683	chr7:1912471	MAD1L1	0.43	8.23	0.36	1.96e-15	Schizophrenia;
LGG	cis	rs7503807	0.515	rs12943155	chr17:78667125	A/G	cg06872548	chr17:78716983	RPTOR	0.37	6.89	0.3	1.84e-11	Obesity;
LGG	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08722104	chr11:47448306	PSMC3	0.52	8.06	0.35	6.44e-15	Gut microbiome composition (summer);
LGG	cis	rs4671458	0.762	rs1109027	chr2:63815206	A/G	cg17519650	chr2:63277830	OTX1	-0.54	-7.15	-0.32	3.43e-12	Subjective well-being;
LGG	trans	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.75	-0.41	1.47e-20	Systolic blood pressure;
LGG	cis	rs12824058	0.831	rs12831363	chr12:130814013	C/T	cg24229701	chr12:130821962	PIWIL1	-0.45	-7.83	-0.34	3.39e-14	Menopause (age at onset);
LGG	cis	rs2816316	1.000	rs1547624	chr1:192543837	A/T	cg02586212	chr1:192544902	RGS1	0.46	9.4	0.4	2.48e-19	Celiac disease;
LGG	cis	rs9768139	0.708	rs896781	chr7:158114114	T/C	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.73	-0.34	6.58e-14	Calcium levels;
LGG	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg18252515	chr7:66147081	NA	-1.46	-20.16	-0.68	2.36e-65	Diabetic kidney disease;
LGG	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	cg07245641	chr1:182991651	LAMC1	0.42	9.32	0.4	4.74e-19	Fuchs's corneal dystrophy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14369405	chr18:32556760	MAPRE2	0.46	8.12	0.35	4.27e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs11155671	0.530	rs7768665	chr6:150208024	G/A	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs2070677	0.935	rs12261048	chr10:135407923	A/G	cg20169779	chr10:135381914	SYCE1	-1.02	-13.24	-0.52	3.6e-34	Gout;
LGG	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.15	0.58	2.11e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6831352	0.918	rs17217949	chr4:100054312	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs2576037	0.763	rs2060418	chr18:44576535	A/C	cg19077165	chr18:44547161	KATNAL2	0.54	9.67	0.41	2.94e-20	Personality dimensions;
LGG	cis	rs4538187	0.806	rs34777730	chr2:64250804	T/C	cg02541582	chr2:64069798	UGP2	-0.58	-13.61	-0.53	9.64e-36	Systolic blood pressure;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	10.72	0.45	4.13e-24	Longevity;
LGG	cis	rs8114671	0.836	rs6142284	chr20:33641367	G/A	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs13102973	0.720	rs7668824	chr4:135884707	A/T	cg14419869	chr4:135874104	NA	0.47	8.0	0.35	1.01e-14	Subjective well-being;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.2	-0.43	3.45e-22	Total body bone mineral density;
LGG	trans	rs12517041	0.786	rs7715927	chr5:23247790	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.54	-8.11	-0.35	4.67e-15	Calcium levels;
LGG	cis	rs11645898	0.935	rs4788605	chr16:72154682	G/T	cg14768367	chr16:72042858	DHODH	-0.82	-11.34	-0.47	1.77e-26	Blood protein levels;
LGG	cis	rs1010254	0.543	rs113559777	chr5:151816645	T/C	cg12297329	chr5:152029980	NA	-0.5	-7.35	-0.32	8.86e-13	Optic nerve measurement (cup area);
LGG	cis	rs6977660	1.000	rs35784097	chr7:19818848	A/G	cg05791153	chr7:19748676	TWISTNB	0.59	8.79	0.38	2.88e-17	Thyroid stimulating hormone;
LGG	cis	rs9291683	0.530	rs35908990	chr4:9976105	G/A	cg00071950	chr4:10020882	SLC2A9	0.38	7.75	0.34	5.69e-14	Bone mineral density;
LGG	cis	rs708547	0.836	rs1718882	chr4:57859533	C/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.8	13.97	0.54	3.03e-37	Response to bleomycin (chromatid breaks);
LGG	cis	rs9303280	0.901	rs883770	chr17:38063381	C/T	cg19468946	chr17:37922297	IKZF3	-0.37	-6.67	-0.3	7.51e-11	Self-reported allergy;
LGG	cis	rs4959677	0.804	rs7751264	chr6:2477490	G/A	cg20147862	chr6:2634573	C6orf195	-0.4	-8.73	-0.38	4.49e-17	Orthostatic hypotension;
LGG	cis	rs9649465	1.000	rs7805759	chr7:123318696	C/A	cg03229431	chr7:123269106	ASB15	-0.4	-8.82	-0.38	2.28e-17	Migraine;
LGG	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.38	-6.91	-0.31	1.64e-11	Colorectal cancer;
LGG	cis	rs929596	0.654	rs28899170	chr2:234604230	C/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.59	-9.75	-0.41	1.48e-20	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs4332037	0.851	rs10268609	chr7:1962163	A/C	cg12591125	chr7:1885375	MAD1L1	0.45	6.78	0.3	3.68e-11	Bipolar disorder;
LGG	cis	rs1371867	0.846	rs1660351	chr8:101275034	C/T	cg06636551	chr8:101224915	SPAG1	-0.48	-8.98	-0.39	6.76e-18	Atrioventricular conduction;
LGG	cis	rs9549367	0.789	rs3794422	chr13:113893729	G/A	cg18105134	chr13:113819100	PROZ	-0.7	-14.27	-0.55	1.49e-38	Platelet distribution width;
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.17	-0.43	4.74e-22	Total body bone mineral density;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg13628971	chr7:2884303	GNA12	0.49	9.84	0.42	7.37e-21	Height;
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.31	-0.32	1.19e-12	Neuroticism;
LGG	cis	rs2153535	0.504	rs9328472	chr6:8470848	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs3818285	0.556	rs3758409	chr10:111669239	A/C	cg00817464	chr10:111662876	XPNPEP1	-0.54	-9.02	-0.39	5.1e-18	Superior crus of antihelix expression;
LGG	cis	rs10752881	1.000	rs4593781	chr1:182984983	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.18	-0.46	7.18e-26	Personality dimensions;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg00761968	chr13:53314142	LECT1	0.35	7.54	0.33	2.48e-13	Lewy body disease;
LGG	trans	rs61332075	0.500	rs55917008	chr2:239380244	C/A	cg01134436	chr17:81009848	B3GNTL1	0.83	8.74	0.38	4.45e-17	Lung function (FEV1/FVC);
LGG	cis	rs4787491	0.729	rs11544328	chr16:30037128	A/C	cg06326092	chr16:30034487	C16orf92	0.42	8.48	0.37	3.05e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2404602	0.647	rs10851892	chr15:77176491	T/C	cg23625390	chr15:77176239	SCAPER	-0.74	-14.79	-0.57	8.3e-41	Blood metabolite levels;
LGG	cis	rs6740322	0.895	rs28456986	chr2:43553321	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.47	-0.4	1.49e-19	Coronary artery disease;
LGG	cis	rs7250872	0.578	rs8102879	chr19:1832317	G/A	cg18850929	chr19:1828978	REXO1	0.47	7.7	0.34	8.56e-14	Bipolar disorder;
LGG	cis	rs17286411	0.750	rs2288030	chr16:71914107	G/A	cg03805757	chr16:71968109	PKD1L3	0.34	7.08	0.31	5.46e-12	Blood protein levels;
LGG	cis	rs9341808	0.718	rs2322636	chr6:80897436	C/T	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs1862618	0.853	rs252909	chr5:56121131	T/C	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	cis	rs736408	0.609	rs13087772	chr3:52782274	T/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.4e-12	Bipolar disorder;
LGG	cis	rs2594989	0.887	rs2454498	chr3:11500953	A/G	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.71e-13	Circulating chemerin levels;
LGG	trans	rs6601327	0.607	rs13276086	chr8:9578982	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.69	-0.34	8.98e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1408799	0.704	rs1326789	chr9:12759838	G/A	cg05274944	chr9:12693694	TYRP1	0.36	8.36	0.36	7.39e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs1790761	0.658	rs684928	chr11:67329742	G/A	cg14500267	chr11:67383377	NA	0.46	8.6	0.37	1.23e-16	Mean corpuscular volume;
LGG	cis	rs875971	0.508	rs10258739	chr7:66062935	A/T	cg11764359	chr7:65958608	NA	-0.55	-9.39	-0.4	2.65e-19	Aortic root size;
LGG	cis	rs7166081	1.000	rs35688953	chr15:67640129	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.71	-0.3	5.77e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4774899	0.966	rs12911256	chr15:57557867	T/A	cg08128148	chr15:57256372	TCF12	-0.32	-7.28	-0.32	1.47e-12	Urinary tract infection frequency;
LGG	cis	rs539514	0.627	rs508596	chr13:76300942	C/A	cg04757411	chr13:76259545	LMO7	-0.27	-6.96	-0.31	1.16e-11	Type 1 diabetes;
LGG	cis	rs514406	0.505	rs448788	chr1:53161620	A/G	cg24675658	chr1:53192096	ZYG11B	0.58	12.4	0.5	1.08e-30	Monocyte count;
LGG	cis	rs62238980	0.614	rs75584049	chr22:32468790	C/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs698813	0.572	rs13424464	chr2:44482263	A/C	cg00619915	chr2:44497795	NA	-0.6	-8.77	-0.38	3.36e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs6088580	0.584	rs2378203	chr20:32993846	A/T	cg08999081	chr20:33150536	PIGU	-0.41	-10.21	-0.43	3.32e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9768139	0.683	rs7779781	chr7:158115071	T/C	cg06219351	chr7:158114137	PTPRN2	-0.81	-16.2	-0.6	4.33e-47	Calcium levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06037631	chr2:74942369	NA	0.51	8.68	0.37	6.63e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs3096299	0.967	rs2965932	chr16:89477051	C/T	cg02187348	chr16:89574699	SPG7	-0.45	-7.32	-0.32	1.07e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs826838	1.000	rs7975243	chr12:38849220	C/T	cg13010199	chr12:38710504	ALG10B	0.76	16.2	0.6	4.58e-47	Heart rate;
LGG	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg15269541	chr15:43626905	ADAL	-0.45	-8.07	-0.35	6.21e-15	Lung cancer in ever smokers;
LGG	cis	rs8180040	0.705	rs73069104	chr3:47280733	T/C	cg16586182	chr3:47516702	SCAP	0.74	13.14	0.52	1.01e-33	Colorectal cancer;
LGG	cis	rs7927592	0.913	rs12294029	chr11:68257059	A/C	cg20283391	chr11:68216788	NA	-0.5	-8.12	-0.35	4.38e-15	Total body bone mineral density;
LGG	cis	rs57221529	0.766	rs4081846	chr5:574019	G/A	cg01221209	chr5:554886	NA	-0.48	-7.23	-0.32	1.97e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs2180341	0.711	rs4371861	chr6:127568447	G/T	cg27446573	chr6:127587934	RNF146	0.73	13.5	0.53	2.94e-35	Breast cancer;
LGG	cis	rs2832077	0.824	rs4816333	chr21:30201777	C/G	cg08807101	chr21:30365312	RNF160	-0.6	-8.09	-0.35	5.32e-15	Cognitive test performance;
LGG	cis	rs6496932	0.802	rs4843047	chr15:85859776	G/A	cg19183879	chr15:85880815	NA	0.42	6.69	0.3	6.3e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs2652834	1.000	rs4344684	chr15:63397318	C/T	cg05507819	chr15:63340323	TPM1	0.58	7.85	0.34	3.02e-14	HDL cholesterol;
LGG	cis	rs7980799	0.682	rs7138529	chr12:33634855	T/C	cg06521331	chr12:34319734	NA	0.41	6.89	0.31	1.79e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs834603	0.611	rs2470993	chr7:47440225	A/G	cg23694490	chr7:47445681	TNS3	-0.47	-13.48	-0.53	3.73e-35	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7937612	1.000	rs2305010	chr11:120330149	C/G	cg24566217	chr11:120254723	ARHGEF12	0.53	12.74	0.51	4.47e-32	Intraocular pressure;
LGG	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg14829360	chr17:73884958	NA	-0.84	-15.37	-0.58	2.19e-43	Psoriasis;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.79	0.34	4.49e-14	Schizophrenia;
LGG	cis	rs11155671	0.530	rs9383914	chr6:150207234	T/G	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	cis	rs897984	0.683	rs72799316	chr16:30827205	A/G	cg00531865	chr16:30841666	NA	-0.69	-16.55	-0.61	1.18e-48	Dementia with Lewy bodies;
LGG	cis	rs10901296	0.660	rs2696141	chr9:133754099	G/T	cg13397898	chr9:133768931	QRFP	0.4	6.91	0.31	1.6e-11	Bilirubin levels;
LGG	cis	rs7584330	0.868	rs67071074	chr2:238395429	T/C	cg16989719	chr2:238392110	NA	-0.39	-8.15	-0.35	3.43e-15	Prostate cancer;
LGG	cis	rs977987	0.732	rs999675	chr16:75306402	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.59	0.41	5.34e-20	Dupuytren's disease;
LGG	trans	rs61931739	0.500	rs11053277	chr12:34553835	T/A	cg13010199	chr12:38710504	ALG10B	0.62	12.47	0.5	5.68e-31	Morning vs. evening chronotype;
LGG	trans	rs637571	0.522	rs7105628	chr11:65763067	C/T	cg17712092	chr4:129076599	LARP1B	0.75	14.48	0.56	1.77e-39	Eosinophil percentage of white cells;
LGG	cis	rs12291225	0.679	rs11605531	chr11:14291594	A/G	cg02886208	chr11:14281011	SPON1	-0.36	-6.85	-0.3	2.4e-11	Sense of smell;
LGG	cis	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg16876255	chr19:9731953	ZNF561	0.76	7.26	0.32	1.68e-12	Pursuit maintenance gain;
LGG	cis	rs5769765	0.865	rs9616369	chr22:50304591	A/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.58	-0.47	2.02e-27	Schizophrenia;
LGG	cis	rs11711311	0.712	rs6795099	chr3:113338782	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.56	11.26	0.46	3.83e-26	IgG glycosylation;
LGG	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.15	0.58	2.14e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg18876405	chr7:65276391	NA	0.56	10.02	0.42	1.55e-21	Aortic root size;
LGG	trans	rs9951602	0.512	rs9949512	chr18:76641845	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs6424115	1.000	rs7514394	chr1:24100223	A/G	cg15997130	chr1:24165203	NA	-0.46	-12.62	-0.51	1.37e-31	Immature fraction of reticulocytes;
LGG	cis	rs7818345	1.000	rs4409408	chr8:19311538	T/G	cg11303988	chr8:19266685	CSGALNACT1	0.41	7.06	0.31	6.32e-12	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg26354017	chr1:205819088	PM20D1	-0.52	-6.77	-0.3	3.81e-11	Prostate-specific antigen levels;
LGG	cis	rs2070433	0.539	rs1008548	chr21:47959692	G/A	cg02959939	chr21:47813025	PCNT	-0.33	-7.23	-0.32	2.03e-12	Lymphocyte counts;
LGG	cis	rs6121246	0.738	rs2376996	chr20:30316667	T/A	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg08645402	chr16:4508243	NA	0.42	6.93	0.31	1.43e-11	Schizophrenia;
LGG	cis	rs4363385	0.791	rs489323	chr1:153006047	G/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs2282300	0.739	rs1631451	chr11:30349133	G/C	cg25418670	chr11:30344373	C11orf46	-0.57	-7.91	-0.35	1.92e-14	Morning vs. evening chronotype;
LGG	cis	rs9419702	0.538	rs9419628	chr10:133539299	A/C	cg04492858	chr10:133558786	NA	0.39	7.57	0.33	2e-13	Survival in rectal cancer;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.75e-13	Prudent dietary pattern;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg00800038	chr16:89945340	TCF25	-0.7	-9.16	-0.39	1.62e-18	Interleukin-17 levels;
LGG	cis	rs2404602	0.692	rs2117369	chr15:76748861	A/T	cg23625390	chr15:77176239	SCAPER	0.49	9.65	0.41	3.33e-20	Blood metabolite levels;
LGG	cis	rs10911363	0.573	rs2702181	chr1:183516985	T/A	cg09173681	chr1:183549694	NCF2	0.38	8.7	0.37	5.92e-17	Systemic lupus erythematosus;
LGG	cis	rs2594989	0.831	rs66488222	chr3:11576289	C/T	cg01796438	chr3:11312864	ATG7	0.53	7.23	0.32	2.02e-12	Circulating chemerin levels;
LGG	cis	rs7555523	0.887	rs4269750	chr1:165711510	C/T	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs11628318	0.614	rs10782496	chr14:103079725	C/G	cg12046867	chr14:103022105	NA	-0.44	-8.79	-0.38	3.03e-17	Platelet count;
LGG	cis	rs2991971	0.967	rs11211130	chr1:45986852	G/C	cg24296786	chr1:45957014	TESK2	0.41	7.35	0.32	9.32e-13	High light scatter reticulocyte count;
LGG	cis	rs1729951	0.575	rs35289288	chr3:136680568	C/T	cg12473912	chr3:136751656	NA	0.43	7.62	0.33	1.42e-13	Neuroticism;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg14675211	chr2:100938903	LONRF2	0.61	10.83	0.45	1.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg07777115	chr5:623756	CEP72	-0.56	-7.12	-0.31	4.26e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7226408	0.600	rs8088359	chr18:34582497	C/G	cg15022739	chr18:34823045	BRUNOL4	0.43	9.29	0.4	6.03e-19	Obesity-related traits;
LGG	cis	rs727505	1.000	rs1541418	chr7:124448672	A/G	cg23710748	chr7:124431027	NA	-0.54	-10.37	-0.43	8.65e-23	Lewy body disease;
LGG	trans	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-7.55	-0.33	2.28e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.863	rs1480939	chr4:120456927	T/C	cg24375607	chr4:120327624	NA	0.65	10.59	0.44	1.32e-23	Corneal astigmatism;
LGG	cis	rs6597981	0.604	rs7945912	chr11:750849	A/T	cg01741372	chr11:783889	NA	0.62	10.81	0.45	1.85e-24	Breast cancer;
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.8	-0.3	3.21e-11	Bipolar disorder;
LGG	cis	rs10791097	0.694	rs4436551	chr11:130755739	A/G	cg12179176	chr11:130786555	SNX19	-0.84	-17.53	-0.63	3.88e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg17376030	chr22:41985996	PMM1	-0.5	-8.11	-0.35	4.72e-15	Vitiligo;
LGG	cis	rs72781680	0.706	rs72796108	chr2:23904990	C/A	cg08917208	chr2:24149416	ATAD2B	0.85	8.86	0.38	1.69e-17	Lymphocyte counts;
LGG	cis	rs7274811	0.779	rs13039908	chr20:32052070	G/A	cg21523528	chr20:32077966	CBFA2T2	0.4	6.72	0.3	5.33e-11	Height;
LGG	cis	rs2839186	0.814	rs12482209	chr21:47664275	C/G	cg12016809	chr21:47604291	C21orf56	-0.59	-10.67	-0.44	6.33e-24	Testicular germ cell tumor;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.81	-0.3	3.04e-11	Lung cancer;
LGG	cis	rs9916302	0.851	rs6503518	chr17:37660469	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs7824557	0.585	rs2572385	chr8:11208903	G/A	cg02002194	chr4:3960332	NA	-0.39	-7.0	-0.31	8.97e-12	Retinal vascular caliber;
LGG	cis	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg06521331	chr12:34319734	NA	-0.64	-12.57	-0.5	2.2e-31	Morning vs. evening chronotype;
LGG	cis	rs2842992	0.768	rs2273824	chr6:160211445	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.79	15.03	0.57	6.88e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs17209837	0.607	rs1473154	chr7:87082042	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-15.69	-0.59	8.61e-45	Gallbladder cancer;
LGG	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.73	0.34	6.59e-14	Glycated hemoglobin levels;
LGG	cis	rs12286929	0.669	rs11606837	chr11:115042837	C/T	cg04055981	chr11:115044050	NA	0.37	6.88	0.3	1.99e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs9487094	0.813	rs13195517	chr6:109736253	C/T	cg01125227	chr6:109776195	MICAL1	0.53	8.88	0.38	1.51e-17	Height;
LGG	cis	rs3793683	0.825	rs3793674	chr10:134555773	C/T	cg27286337	chr10:134555280	INPP5A	-1.07	-23.74	-0.74	4.48e-82	Migraine;
LGG	cis	rs742614	0.533	rs6087526	chr20:32398295	A/C	cg06304546	chr20:32448765	NA	-0.69	-13.91	-0.54	5.4e-37	Stearic acid (18:0) levels;
LGG	cis	rs2204008	0.837	rs11181857	chr12:38413255	C/G	cg04568710	chr12:38710424	ALG10B	0.34	6.94	0.31	1.33e-11	Bladder cancer;
LGG	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg01063088	chr1:162760584	HSD17B7	-0.42	-6.68	-0.3	7.08e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9790314	0.602	rs4679926	chr3:160677240	A/T	cg04691961	chr3:161091175	C3orf57	0.44	9.26	0.4	7.93e-19	Morning vs. evening chronotype;
LGG	trans	rs7762018	0.769	rs4716339	chr6:170063210	C/T	cg06875740	chr19:51307921	C19orf48	-0.67	-8.05	-0.35	7.16e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs1814175	0.645	rs6486022	chr11:49776137	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.01	-0.6	2.98e-46	Height;
LGG	cis	rs1552244	0.832	rs115415687	chr3:10195704	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-12.32	-0.5	2.26e-30	Alzheimer's disease;
LGG	cis	rs7851660	0.809	rs10984230	chr9:100660284	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.86	-0.51	1.35e-32	Strep throat;
LGG	cis	rs11690935	0.959	rs12185567	chr2:172560729	A/C	cg13550731	chr2:172543902	DYNC1I2	1.07	27.45	0.79	3.4e-99	Schizophrenia;
LGG	trans	rs6787172	0.592	rs11714104	chr3:158093469	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs1801251	0.778	rs2250654	chr2:233752376	A/T	cg08000102	chr2:233561755	GIGYF2	-0.44	-7.14	-0.32	3.58e-12	Coronary artery disease;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg12070911	chr6:150209640	RAET1E	0.31	7.67	0.34	1.06e-13	Lung cancer;
LGG	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg26513180	chr16:89883248	FANCA	-0.59	-10.65	-0.44	7.59e-24	Vitiligo;
LGG	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg07777115	chr5:623756	CEP72	-0.58	-7.11	-0.31	4.51e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7647973	0.626	rs1996664	chr3:49878395	A/G	cg13072238	chr3:49761600	GMPPB	0.52	7.04	0.31	6.81e-12	Menarche (age at onset);
LGG	cis	rs6502050	1.000	rs6502050	chr17:80058236	C/G	cg11859384	chr17:80120422	CCDC57	0.43	7.44	0.33	5.04e-13	Life satisfaction;
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.27	-7.19	-0.32	2.59e-12	Total body bone mineral density;
LGG	trans	rs2164273	0.523	rs1435279	chr8:11158387	C/A	cg16141378	chr3:129829833	LOC729375	-0.31	-6.66	-0.3	7.72e-11	Extraversion;
LGG	cis	rs593982	1.000	rs72922786	chr11:65562852	G/C	cg08755490	chr11:65554678	OVOL1	-0.69	-9.76	-0.41	1.38e-20	Atopic dermatitis;
LGG	cis	rs6066825	0.605	rs761273	chr20:47315488	A/G	cg18078177	chr20:47281410	PREX1	0.48	8.08	0.35	5.82e-15	Colorectal cancer;
LGG	cis	rs11877825	0.762	rs9676152	chr18:10571440	C/T	cg07277756	chr18:10589357	NA	0.58	10.36	0.43	9.13e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs2770102	0.597	rs6918975	chr6:21817965	C/G	cg17050756	chr6:21771976	FLJ22536	0.35	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs11758351	0.500	rs75551401	chr6:26185387	T/C	cg11342453	chr6:26196699	NA	0.82	7.0	0.31	9.13e-12	Gout;Renal underexcretion gout;
LGG	trans	rs747782	0.527	rs7129364	chr11:48150576	G/A	cg15704280	chr7:45808275	SEPT13	0.7	7.27	0.32	1.55e-12	Intraocular pressure;
LGG	cis	rs4959677	0.755	rs6899721	chr6:2470570	C/T	cg20147862	chr6:2634573	C6orf195	0.35	7.27	0.32	1.56e-12	Orthostatic hypotension;
LGG	cis	rs2758596	0.850	rs2241110	chr1:156172487	A/G	cg25208724	chr1:156163844	SLC25A44	0.82	7.37	0.32	8.13e-13	Paclitaxel disposition in epithelial ovarian cancer;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg01380533	chr16:68262681	ESRP2	-0.4	-6.93	-0.31	1.45e-11	Apolipoprotein A-IV levels;
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg07685180	chr8:600429	NA	-1.04	-9.19	-0.39	1.31e-18	IgG glycosylation;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg07677032	chr17:61819896	STRADA	0.67	12.46	0.5	6.05e-31	Prudent dietary pattern;
LGG	cis	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg07636037	chr3:49044803	WDR6	0.45	6.91	0.31	1.64e-11	Resting heart rate;
LGG	cis	rs13108904	0.967	rs12642396	chr4:1293055	C/A	cg04863758	chr4:1303710	MAEA	0.44	7.65	0.34	1.15e-13	Obesity-related traits;
LGG	cis	rs5762813	0.561	rs34298044	chr22:29164855	G/C	cg15103426	chr22:29168792	CCDC117	0.65	6.72	0.3	5.26e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs873946	0.586	rs57431984	chr10:134567697	C/T	cg27297192	chr10:134578999	INPP5A	0.33	7.14	0.31	3.63e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3087591	0.960	rs2269855	chr17:29482878	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	14.61	0.56	5.01e-40	Hip circumference;
LGG	cis	rs9341808	0.527	rs2505946	chr6:80810683	A/G	cg08355045	chr6:80787529	NA	0.48	10.05	0.42	1.26e-21	Sitting height ratio;
LGG	cis	rs9322193	0.962	rs2151912	chr6:150152908	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.8	0.3	3.26e-11	Lung cancer;
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs2952156	0.920	rs2517953	chr17:37841211	G/C	cg07936489	chr17:37558343	FBXL20	-0.5	-8.42	-0.36	4.64e-16	Asthma;
LGG	cis	rs6834538	1.000	rs1486864	chr4:113465766	G/T	cg05166686	chr4:113558556	LARP7;C4orf21	0.52	8.34	0.36	8.69e-16	Free thyroxine concentration;
LGG	cis	rs2576037	0.544	rs629097	chr18:44378097	T/C	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.33	-0.32	1e-12	Personality dimensions;
LGG	cis	rs6459788	0.692	rs10807645	chr7:157258979	T/C	cg05333889	chr7:157238977	NA	0.59	11.64	0.48	1.17e-27	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs1728785	1.000	rs1170429	chr16:68604126	A/G	cg02972257	chr16:68554789	NA	-0.56	-8.43	-0.36	4.57e-16	Ulcerative colitis;
LGG	cis	rs1670533	1.000	rs7679432	chr4:1050521	G/A	cg27284194	chr4:1044797	NA	0.54	9.82	0.42	8.6e-21	Recombination rate (females);
LGG	cis	rs10504229	0.861	rs116964504	chr8:58185354	A/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9868809	0.881	rs7631574	chr3:48663046	A/G	cg00383909	chr3:49044727	WDR6	-0.79	-9.25	-0.39	8.26e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs763014	0.931	rs710925	chr16:633354	G/A	cg09263875	chr16:632152	PIGQ	0.65	12.72	0.51	5.27e-32	Height;
LGG	cis	rs11098499	0.863	rs36040693	chr4:120477616	A/G	cg09307838	chr4:120376055	NA	0.81	13.64	0.54	7.2e-36	Corneal astigmatism;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg11711121	chr8:97247942	UQCRB	0.36	6.7	0.3	5.96e-11	Bilirubin levels;
LGG	cis	rs10984970	0.702	rs10985063	chr9:123625936	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.79	-6.88	-0.3	1.99e-11	Lung cancer;
LGG	cis	rs7568458	0.846	rs7605975	chr2:85772548	C/T	cg17127132	chr2:85788382	GGCX	0.48	8.45	0.37	3.91e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1869026	1.000	rs9308615	chr2:121338985	T/C	cg03661458	chr2:121334411	NA	-0.31	-7.26	-0.32	1.65e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg01238044	chr22:24384105	GSTT1	-0.46	-7.7	-0.34	8.35e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs950169	0.922	rs11638445	chr15:85137694	C/A	cg24253500	chr15:84953950	NA	0.58	10.4	0.44	6.61e-23	Schizophrenia;
LGG	cis	rs9814567	0.896	rs4435682	chr3:134344182	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.7	12.67	0.51	8.21e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1355223	0.583	rs2915238	chr11:34884405	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.93	0.57	2.08e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4732038	0.565	rs7796491	chr7:134286215	C/G	cg06906464	chr7:134288099	NA	-0.73	-20.48	-0.69	7.38e-67	Longevity;
LGG	cis	rs9355814	0.565	rs1406889	chr6:161074440	C/A	cg04181478	chr6:161122748	PLG	-0.41	-6.71	-0.3	5.6e-11	Lipoprotein (a) levels;
LGG	cis	rs35110281	0.607	rs8131020	chr21:44981063	C/A	cg01579765	chr21:45077557	HSF2BP	-0.35	-7.87	-0.34	2.51e-14	Mean corpuscular volume;
LGG	cis	rs8114671	0.527	rs2295352	chr20:33320055	C/G	cg24642439	chr20:33292090	TP53INP2	-0.45	-7.32	-0.32	1.14e-12	Height;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	13.3	0.53	2.05e-34	Prudent dietary pattern;
LGG	trans	rs2980439	0.556	rs2921059	chr8:8317887	G/T	cg00405596	chr8:11794950	NA	0.41	6.87	0.3	2.02e-11	Neuroticism;
LGG	cis	rs1408799	0.679	rs1326790	chr9:12761168	T/A	cg05274944	chr9:12693694	TYRP1	0.36	8.41	0.36	5.28e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs240764	0.658	rs10457077	chr6:101196767	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.28	-0.36	1.29e-15	Neuroticism;
LGG	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg21053147	chr12:120880522	NA	0.56	8.33	0.36	9.13e-16	Type 1 diabetes nephropathy;
LGG	cis	rs57590327	0.555	rs11127740	chr3:81743062	A/C	cg07356753	chr3:81810745	GBE1	-0.51	-8.27	-0.36	1.39e-15	Extraversion;
LGG	cis	rs1552244	1.000	rs28684871	chr3:10072635	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.21	0.68	1.44e-65	Alzheimer's disease;
LGG	cis	rs11758351	0.660	rs11759904	chr6:26231443	T/C	cg23601095	chr6:26197514	HIST1H3D	0.68	8.71	0.38	5.61e-17	Gout;Renal underexcretion gout;
LGG	cis	rs240764	0.621	rs4840154	chr6:101225723	A/C	cg09795085	chr6:101329169	ASCC3	-0.48	-8.23	-0.36	1.96e-15	Neuroticism;
LGG	cis	rs881375	0.678	rs10985102	chr9:123707497	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	10.11	0.43	7.3e-22	Rheumatoid arthritis;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-15.92	-0.59	7.83e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs7106204	0.541	rs75552854	chr11:24231824	G/A	ch.11.24196551F	chr11:24239977	NA	0.89	10.14	0.43	5.8e-22	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs67311347	0.955	rs11711994	chr3:40391086	T/C	cg13683864	chr3:40499215	RPL14	-1.13	-25.06	-0.76	3.22e-88	Renal cell carcinoma;
LGG	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.6	-0.44	1.17e-23	Chronic sinus infection;
LGG	trans	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-7.67	-0.34	9.89e-14	Triglycerides;
LGG	cis	rs1153858	1.000	rs2056493	chr15:45648272	A/G	cg21132104	chr15:45694354	SPATA5L1	0.72	11.05	0.46	2.28e-25	Homoarginine levels;
LGG	cis	rs6500395	0.928	rs7199206	chr16:48702538	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.97	-0.38	7.23e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4642101	0.669	rs1467026	chr3:12830775	G/A	cg24848339	chr3:12840334	CAND2	0.43	9.8	0.41	1.02e-20	QRS complex (12-leadsum);
LGG	trans	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.15	-0.35	3.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4262150	0.846	rs72799160	chr5:152129523	C/T	cg12297329	chr5:152029980	NA	-0.7	-12.92	-0.51	7.93e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs6735179	0.565	rs733376	chr2:1751958	C/A	cg20570797	chr2:1712800	PXDN	-0.46	-7.99	-0.35	1.08e-14	Response to antipsychotic treatment;
LGG	cis	rs4595586	0.545	rs12812762	chr12:39371141	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.64	0.44	8.19e-24	Morning vs. evening chronotype;
LGG	cis	rs9926296	0.744	rs164746	chr16:89709019	C/T	cg04287289	chr16:89883240	FANCA	-0.44	-7.62	-0.33	1.43e-13	Vitiligo;
LGG	cis	rs7659604	0.540	rs10024878	chr4:122665451	C/G	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.65	-0.34	1.15e-13	Type 2 diabetes;
LGG	cis	rs2635047	1.000	rs2277717	chr18:44702718	C/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	7.07	0.31	5.67e-12	Educational attainment;
LGG	cis	rs13108904	0.535	rs1250101	chr4:1236111	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.59	-10.32	-0.43	1.35e-22	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12307764	chr15:40861449	RPUSD2	0.4	6.66	0.3	7.78e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7681440	0.641	rs6841352	chr4:90781655	A/C	cg26578617	chr4:90757533	SNCA	0.39	7.64	0.33	1.24e-13	Dementia with Lewy bodies;
LGG	cis	rs16976116	0.901	rs1061824	chr15:55495963	T/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.61	-0.47	1.54e-27	Developmental language disorder (linguistic errors);
LGG	trans	rs2204008	0.747	rs11514040	chr12:38201040	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs2011503	1.000	rs7252453	chr19:19654117	G/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.21	0.32	2.28e-12	Bipolar disorder;
LGG	cis	rs11105298	0.786	rs10858867	chr12:89851166	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6500602	0.535	rs758044	chr16:4431202	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-7.82	-0.34	3.64e-14	Schizophrenia;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs11098499	0.731	rs6846966	chr4:120293208	A/G	cg09307838	chr4:120376055	NA	0.73	12.14	0.49	1.27e-29	Corneal astigmatism;
LGG	cis	rs4975709	0.589	rs1684967	chr5:1863055	G/C	cg04080417	chr5:1859792	NA	-0.53	-8.82	-0.38	2.29e-17	Cardiovascular disease risk factors;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19723775	chr5:179050963	HNRNPH1	-0.46	-7.82	-0.34	3.7e-14	Lung cancer;
LGG	cis	rs7829975	0.714	rs6994038	chr8:8660538	C/A	cg06636001	chr8:8085503	FLJ10661	0.53	10.12	0.43	7.2e-22	Mood instability;
LGG	cis	rs10927875	0.832	rs4661342	chr1:16160773	C/G	cg21385522	chr1:16154831	NA	-1.03	-18.15	-0.64	5.17e-56	Dilated cardiomyopathy;
LGG	cis	rs9831754	0.906	rs2102601	chr3:78410536	G/A	cg06138941	chr3:78371609	NA	-0.86	-17.47	-0.63	6.93e-53	Calcium levels;
LGG	cis	rs62400317	0.821	rs62400269	chr6:45200634	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.15	-0.43	5.63e-22	Total body bone mineral density;
LGG	cis	rs2635047	0.512	rs9962436	chr18:44599109	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.58	10.0	0.42	1.98e-21	Educational attainment;
LGG	trans	rs7615952	0.688	rs9754526	chr3:125542866	C/A	cg07211511	chr3:129823064	LOC729375	-1.05	-15.02	-0.57	8.13e-42	Blood pressure (smoking interaction);
LGG	cis	rs8067545	0.750	rs7223305	chr17:19990986	A/G	cg13482628	chr17:19912719	NA	0.61	12.13	0.49	1.38e-29	Schizophrenia;
LGG	cis	rs365132	0.934	rs6861925	chr5:176324729	C/G	cg16309518	chr5:176445507	NA	-0.53	-11.79	-0.48	2.98e-28	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7590368	1.000	rs55968911	chr2:10961840	C/T	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	cis	rs752092	1.000	rs752092	chr15:101781934	C/T	cg19997662	chr15:101784653	CHSY1	0.85	18.98	0.66	7.28e-60	Corneal structure;
LGG	cis	rs412000	0.553	rs2680702	chr17:56431549	A/G	cg12560992	chr17:57184187	TRIM37	0.49	7.54	0.33	2.53e-13	Primary tooth development (time to first tooth eruption);
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg26338869	chr17:61819248	STRADA	0.59	9.93	0.42	3.34e-21	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.47	8.43	0.36	4.29e-16	Obesity-related traits;
LGG	cis	rs17818399	0.926	rs13032670	chr2:46830794	C/T	cg02822958	chr2:46747628	ATP6V1E2	0.44	6.92	0.31	1.5e-11	Height;
LGG	cis	rs4262150	0.739	rs17455800	chr5:152065789	T/A	cg12297329	chr5:152029980	NA	-0.79	-14.89	-0.57	3.06e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs992157	0.735	rs10932765	chr2:219099484	T/C	cg04731861	chr2:219085781	ARPC2	-0.49	-12.57	-0.5	2.29e-31	Colorectal cancer;
LGG	cis	rs2594989	0.943	rs7646500	chr3:11478000	A/G	cg01796438	chr3:11312864	ATG7	-0.53	-7.28	-0.32	1.48e-12	Circulating chemerin levels;
LGG	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg10760299	chr15:45669010	GATM	-0.4	-7.93	-0.35	1.65e-14	Homoarginine levels;
LGG	cis	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg07274523	chr3:49395745	GPX1	0.55	9.06	0.39	3.59e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6665290	0.935	rs1929862	chr1:227199718	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.28	-43.36	-0.9	3.85e-165	Myeloid white cell count;
LGG	cis	rs7582180	0.629	rs11693471	chr2:100948062	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.26	-0.6	2.31e-47	Intelligence (multi-trait analysis);
LGG	trans	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg20587970	chr11:113659929	NA	-1.09	-16.79	-0.62	9.76e-50	Hip circumference adjusted for BMI;
LGG	trans	rs11098499	0.863	rs13149407	chr4:120437825	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.81	0.48	2.52e-28	Corneal astigmatism;
LGG	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg26441486	chr22:50317300	CRELD2	0.41	7.33	0.32	1.03e-12	Schizophrenia;
LGG	cis	rs62064224	0.714	rs4794915	chr17:30634363	A/G	cg25809561	chr17:30822961	MYO1D	-0.35	-8.2	-0.36	2.46e-15	Schizophrenia;
LGG	trans	rs17685	0.515	rs111240556	chr7:75600863	T/C	cg19862616	chr7:65841803	NCRNA00174	0.55	9.36	0.4	3.36e-19	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs1823874	0.581	rs9920347	chr15:100339331	C/T	cg16400843	chr15:100339927	C15orf51	-0.42	-6.91	-0.31	1.63e-11	IgG glycosylation;
LGG	cis	rs4666002	0.789	rs4616435	chr2:27933642	C/T	cg27432699	chr2:27873401	GPN1	0.56	7.76	0.34	5.29e-14	Phospholipid levels (plasma);
LGG	cis	rs9916302	0.706	rs9944459	chr17:37484185	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.97e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs35160687	0.623	rs1863060	chr2:86511456	G/A	cg10973622	chr2:86423274	IMMT	-0.41	-7.18	-0.32	2.77e-12	Night sleep phenotypes;
LGG	cis	rs6762	0.719	rs4895	chr11:840477	A/G	cg08498830	chr11:832797	CD151	-0.44	-7.18	-0.32	2.85e-12	Mean platelet volume;
LGG	cis	rs55665837	0.540	rs12788030	chr11:14764684	C/T	cg19336497	chr11:14380999	RRAS2	-0.39	-7.41	-0.33	6.12e-13	Vitamin D levels;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg04025307	chr7:1156635	C7orf50	0.58	8.18	0.36	2.84e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9397585	0.637	rs9479498	chr6:153398279	A/G	cg17707550	chr6:153380415	RGS17	-0.45	-9.9	-0.42	4.38e-21	Body mass index;
LGG	cis	rs6933660	0.666	rs9371516	chr6:151739642	G/A	cg17179660	chr6:151773299	C6orf211;RMND1	-0.46	-7.96	-0.35	1.3e-14	Menarche (age at onset);
LGG	cis	rs1620921	0.711	rs2489951	chr6:161259799	T/A	cg01280913	chr6:161186852	NA	-0.36	-7.26	-0.32	1.68e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10463554	0.889	rs246911	chr5:102563203	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.65	-0.33	1.21e-13	Parkinson's disease;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg24503407	chr1:205819492	PM20D1	0.83	20.16	0.68	2.41e-65	Menarche (age at onset);
LGG	cis	rs12643440	0.538	rs2041440	chr4:17136032	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.64	-0.37	9.41e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs7582720	1.000	rs6725887	chr2:203745885	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	-0.8	-9.68	-0.41	2.63e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.73	-0.38	4.67e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg04287289	chr16:89883240	FANCA	0.73	8.07	0.35	5.93e-15	Skin colour saturation;
LGG	cis	rs4750440	0.706	rs11258770	chr10:14018910	G/T	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.85	-0.51	1.5e-32	Adiponectin levels;
LGG	cis	rs4750440	0.706	rs4750443	chr10:14019865	A/T	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.82	-0.51	2.02e-32	Adiponectin levels;
LGG	cis	rs7010267	0.503	rs13264172	chr8:120012861	T/A	cg17171407	chr8:119960777	TNFRSF11B	0.3	7.54	0.33	2.54e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs1451375	0.583	rs3779078	chr7:50610918	C/T	cg14593290	chr7:50529359	DDC	0.66	11.89	0.48	1.19e-28	Malaria;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg08677398	chr8:58056175	NA	0.47	7.52	0.33	2.92e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs3780486	0.846	rs913214	chr9:33135085	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	24.43	0.75	2.65e-85	IgG glycosylation;
LGG	cis	rs6800768	0.633	rs57144868	chr3:24144965	G/C	cg10674438	chr3:24145617	LOC152024	-0.53	-9.5	-0.4	1.12e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12310956	0.532	rs11052952	chr12:33988048	G/A	cg26384229	chr12:38710491	ALG10B	0.81	15.99	0.6	3.93e-46	Morning vs. evening chronotype;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg12419862	chr22:24373484	LOC391322	-0.91	-19.38	-0.67	1.11e-61	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs240764	0.619	rs9373571	chr6:101133834	A/T	cg09795085	chr6:101329169	ASCC3	0.41	6.82	0.3	2.88e-11	Neuroticism;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg00684032	chr4:1343700	KIAA1530	0.42	8.3	0.36	1.18e-15	Longevity;
LGG	cis	rs17711722	0.528	rs73138179	chr7:65294482	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.69	16.31	0.6	1.46e-47	Calcium levels;
LGG	cis	rs1865760	0.713	rs1130000	chr6:25985396	A/G	cg17691542	chr6:26056736	HIST1H1C	0.55	9.83	0.42	7.63e-21	Height;
LGG	cis	rs7615952	0.641	rs66520539	chr3:125780374	G/A	cg02772935	chr3:125709198	NA	-0.52	-6.65	-0.3	8.28e-11	Blood pressure (smoking interaction);
LGG	cis	rs10779751	0.655	rs1884429	chr1:11112836	T/C	cg08854313	chr1:11322531	MTOR	0.74	14.67	0.56	2.75e-40	Body mass index;
LGG	cis	rs6952808	0.792	rs2056480	chr7:1954301	A/G	cg20295408	chr7:1910781	MAD1L1	0.44	7.92	0.35	1.74e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2046867	0.908	rs62251601	chr3:72786768	C/G	cg26655873	chr3:72818019	SHQ1	0.34	6.72	0.3	5.46e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs908922	0.651	rs548252	chr1:152489742	A/G	cg03606772	chr1:152487856	CRCT1	-0.31	-7.32	-0.32	1.12e-12	Hair morphology;
LGG	cis	rs9972944	0.729	rs1541610	chr17:63773836	C/T	cg07283582	chr17:63770753	CCDC46	0.4	7.7	0.34	8.47e-14	Total body bone mineral density;
LGG	cis	rs514406	0.861	rs1412706	chr1:53237721	G/A	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.97	-0.66	8.25e-60	Monocyte count;
LGG	cis	rs6088580	0.634	rs6058070	chr20:33103521	G/C	cg08999081	chr20:33150536	PIGU	0.39	9.72	0.41	1.91e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg17644776	chr2:200775616	C2orf69	-0.6	-7.53	-0.33	2.76e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs59843034	chr8:58195756	T/G	cg11062466	chr8:58055876	NA	0.48	7.98	0.35	1.14e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.42	6.88	0.3	1.92e-11	Longevity;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.02	-0.35	8.48e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs13217239	0.646	rs10456351	chr6:26986792	C/T	cg12292205	chr6:26970375	C6orf41	0.55	10.85	0.45	1.34e-24	Schizophrenia;
LGG	cis	rs11098499	0.909	rs28668716	chr4:120309875	T/C	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs6430585	0.591	rs12476135	chr2:136486340	T/C	cg07169764	chr2:136633963	MCM6	1.11	18.4	0.65	3.94e-57	Corneal structure;
LGG	cis	rs910316	0.763	rs175450	chr14:75590340	G/A	cg11812906	chr14:75593930	NEK9	-0.47	-8.64	-0.37	9.34e-17	Height;
LGG	cis	rs11148252	0.846	rs4886077	chr13:52998697	G/T	cg00761968	chr13:53314142	LECT1	-0.37	-7.98	-0.35	1.18e-14	Lewy body disease;
LGG	cis	rs1580019	0.534	rs13237495	chr7:32560687	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.07	27.19	0.78	5.2e-98	Cognitive ability;
LGG	cis	rs756199	0.848	rs10911493	chr1:183989971	T/C	cg01436608	chr1:184005534	GLT25D2	0.57	8.69	0.37	6.19e-17	Height;
LGG	cis	rs1385374	0.858	rs12305142	chr12:129277490	C/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.6	6.66	0.3	7.69e-11	Systemic lupus erythematosus;
LGG	cis	rs12478296	1.000	rs55758933	chr2:243040289	T/C	cg06360820	chr2:242988706	NA	-0.9	-11.56	-0.47	2.53e-27	Obesity-related traits;
LGG	cis	rs11967485	0.609	rs62434276	chr6:157224825	T/C	cg23222435	chr6:157204239	ARID1B	-0.87	-7.27	-0.32	1.51e-12	Calcium levels;
LGG	trans	rs9467711	0.790	rs34158769	chr6:26336572	G/A	cg08344181	chr3:125677491	NA	-0.63	-6.76	-0.3	4.1e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs300703	0.542	rs415660	chr2:189972	C/T	cg21211680	chr2:198530	NA	1.18	19.79	0.68	1.32e-63	Blood protein levels;
LGG	cis	rs9399135	0.967	rs11757577	chr6:135391465	G/A	cg24558204	chr6:135376177	HBS1L	0.51	9.17	0.39	1.54e-18	Red blood cell count;
LGG	cis	rs9682041	0.627	rs4955722	chr3:170102959	G/T	cg11886554	chr3:170076028	SKIL	0.65	8.43	0.36	4.56e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg11494091	chr17:61959527	GH2	0.52	7.92	0.35	1.83e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs780096	0.506	rs56076827	chr2:27676287	A/T	cg22903471	chr2:27725779	GCKR	-0.59	-13.6	-0.53	1.07e-35	Total body bone mineral density;
LGG	cis	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.71	-0.3	5.64e-11	Bone mineral density;
LGG	cis	rs9296092	0.538	rs9461880	chr6:33518714	C/T	cg13560919	chr6:33536144	NA	-1.03	-20.95	-0.7	4.75e-69	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17384381	0.859	rs12724823	chr1:85906385	G/T	cg16011679	chr1:85725395	C1orf52	0.57	9.61	0.41	4.5e-20	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2070997	0.818	rs11244149	chr9:133684177	C/G	cg13397898	chr9:133768931	QRFP	0.33	6.7	0.3	6.05e-11	Response to amphetamines;
LGG	cis	rs1008375	0.933	rs4698637	chr4:17632843	A/T	cg18681998	chr4:17616180	MED28	0.84	18.28	0.65	1.41e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs910316	0.934	rs8016330	chr14:75657507	G/T	cg08847533	chr14:75593920	NEK9	-0.58	-11.01	-0.46	3.44e-25	Height;
LGG	cis	rs12497850	0.931	rs1134591	chr3:48972892	C/T	cg06212747	chr3:49208901	KLHDC8B	0.57	9.49	0.4	1.25e-19	Parkinson's disease;
LGG	cis	rs9486715	0.867	rs9384602	chr6:96919561	G/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.78	0.59	3.44e-45	Headache;
LGG	trans	rs4948275	0.773	rs2606077	chr10:63288379	C/T	cg10215766	chr19:19612808	GATAD2A	-0.5	-6.86	-0.3	2.26e-11	Night sleep phenotypes;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.39	7.04	0.31	6.83e-12	Schizophrenia;
LGG	cis	rs4969178	0.965	rs8075131	chr17:76394595	T/G	cg02836325	chr17:76403955	PGS1	-0.72	-14.62	-0.56	4.73e-40	HDL cholesterol levels;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg00684032	chr4:1343700	KIAA1530	-0.48	-9.2	-0.39	1.24e-18	Obesity-related traits;
LGG	cis	rs634534	0.562	rs661335	chr11:65754061	G/A	cg02427764	chr11:65769310	BANF1;EIF1AD	0.54	9.05	0.39	3.87e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs314370	0.951	rs3757868	chr7:100482720	G/A	cg10426581	chr7:100472382	SRRT	0.51	7.04	0.31	6.92e-12	Resting heart rate;
LGG	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg11366901	chr6:160182831	ACAT2	1.02	15.87	0.59	1.35e-45	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4974559	0.947	rs10000797	chr4:1345647	G/A	cg02980000	chr4:1222292	CTBP1	0.65	7.88	0.34	2.31e-14	Systolic blood pressure;
LGG	cis	rs4730250	0.708	rs4730242	chr7:107057373	G/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.22	-0.43	3.14e-22	Osteoarthritis;
LGG	cis	rs4718428	0.705	rs13220977	chr7:66337648	A/T	cg18252515	chr7:66147081	NA	0.74	11.75	0.48	4.54e-28	Corneal structure;
LGG	cis	rs701145	0.938	rs701131	chr3:154086138	C/G	cg17054900	chr3:154042577	DHX36	0.99	12.32	0.5	2.26e-30	Coronary artery disease;
LGG	cis	rs4818225	0.793	rs960231	chr21:42622657	C/G	cg21268422	chr21:42620091	BACE2	0.48	8.66	0.37	8.18e-17	Educational attainment;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg14926445	chr8:58193284	C8orf71	-0.87	-13.1	-0.52	1.44e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6489785	0.735	rs12825746	chr12:121268033	A/C	cg02419362	chr12:121203948	SPPL3	0.54	9.38	0.4	3.02e-19	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs16976116	0.803	rs28530662	chr15:55498836	A/G	cg11288833	chr15:55489084	RSL24D1	0.53	7.22	0.32	2.08e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10489202	1.000	rs1060041	chr1:167973976	C/T	cg24449463	chr1:168025552	DCAF6	-0.61	-10.02	-0.42	1.56e-21	Schizophrenia;
LGG	cis	rs1816752	0.905	rs7317850	chr13:24994037	C/G	cg02811702	chr13:24901961	NA	0.4	7.43	0.33	5.45e-13	Obesity-related traits;
LGG	cis	rs6089829	0.962	rs6011544	chr20:61658782	T/C	cg08564027	chr20:61660810	NA	1.02	24.91	0.76	1.59e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs258892	0.895	rs34670	chr5:72162863	T/C	cg21869765	chr5:72125136	TNPO1	0.42	6.76	0.3	4.15e-11	Small cell lung carcinoma;
LGG	cis	rs1256061	0.603	rs928554	chr14:64694195	C/T	cg23250157	chr14:64679961	SYNE2	0.4	7.36	0.32	8.64e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs3540	0.960	rs7167704	chr15:90956801	G/T	cg22089800	chr15:90895588	ZNF774	0.48	7.5	0.33	3.37e-13	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg24637308	chr11:6592297	DNHD1	-0.42	-6.91	-0.31	1.56e-11	Coronary artery calcification;
LGG	cis	rs6541297	1.000	rs4846909	chr1:230285372	G/A	cg05784532	chr1:230284198	GALNT2	0.52	9.29	0.4	6.2e-19	Coronary artery disease;
LGG	trans	rs208520	0.690	rs74707865	chr6:66717352	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.71	0.64	5.77e-54	Exhaled nitric oxide output;
LGG	trans	rs9858542	1.000	rs9822268	chr3:49719729	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.43	-0.33	5.25e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6502050	0.835	rs6502068	chr17:80112223	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg05234568	chr11:5960015	NA	-0.74	-12.42	-0.5	9.48e-31	DNA methylation (variation);
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs56283067	0.887	rs12198016	chr6:44771708	C/T	cg18551225	chr6:44695536	NA	-0.7	-11.46	-0.47	5.99e-27	Total body bone mineral density;
LGG	cis	rs2439831	0.867	rs76542740	chr15:43891512	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-6.87	-0.3	2.06e-11	Lung cancer in ever smokers;
LGG	cis	rs4242434	0.927	rs10099846	chr8:22534178	C/T	cg03733263	chr8:22462867	KIAA1967	-1.06	-26.73	-0.78	6.46e-96	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs735539	0.521	rs9552278	chr13:21352318	C/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.11	-0.35	4.47e-15	Dental caries;
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg08621203	chr6:150244597	RAET1G	0.54	10.01	0.42	1.77e-21	Testicular germ cell tumor;
LGG	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs4481887	0.821	rs7515408	chr1:248425738	C/T	cg00666640	chr1:248458726	OR2T12	0.6	9.31	0.4	4.97e-19	Common traits (Other);
LGG	cis	rs10426930	0.607	rs56251289	chr19:5042732	C/A	cg15621731	chr19:5074616	KDM4B	-0.32	-7.83	-0.34	3.42e-14	Monocyte percentage of white cells;
LGG	cis	rs11190604	1.000	rs2495737	chr10:102338344	T/C	cg11040518	chr10:102331378	NA	-0.36	-6.7	-0.3	6.22e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg14952266	chr13:112191215	NA	-0.53	-11.07	-0.46	1.92e-25	Hepatitis;
LGG	cis	rs6089584	0.566	rs6061972	chr20:60610245	C/T	cg13770153	chr20:60521292	NA	-0.46	-7.72	-0.34	7.44e-14	Body mass index;
LGG	cis	rs1790761	0.505	rs7103713	chr11:67338242	G/A	cg09038676	chr11:67351608	GSTP1	0.36	7.06	0.31	6.23e-12	Mean corpuscular volume;
LGG	cis	rs13294100	0.929	rs7030014	chr9:17581661	C/T	cg11213383	chr9:17579734	SH3GL2	-0.64	-12.01	-0.49	4.09e-29	Parkinson's disease;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg03575189	chr17:44344142	NA	0.49	7.28	0.32	1.48e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6733011	0.508	rs925887	chr2:99514671	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	0.44	7.08	0.31	5.4e-12	Bipolar disorder;
LGG	cis	rs7618501	1.000	rs7634902	chr3:49762662	G/T	cg24110177	chr3:50126178	RBM5	0.4	6.82	0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4650994	0.967	rs6681043	chr1:178525957	A/G	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs72781680	0.898	rs17462558	chr2:24020812	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs7786808	0.653	rs4909213	chr7:158202404	G/A	cg12438819	chr7:158236134	PTPRN2	0.33	8.39	0.36	6.02e-16	Obesity-related traits;
LGG	cis	rs908922	0.676	rs1538082	chr1:152517304	A/G	cg09873164	chr1:152488093	CRCT1	0.65	16.04	0.6	2.32e-46	Hair morphology;
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs10895140	0.625	rs7119885	chr11:101507116	A/G	cg23650423	chr11:101454676	TRPC6	-0.43	-7.07	-0.31	5.83e-12	Menarche (age at onset);
LGG	cis	rs1008375	0.902	rs12503164	chr4:17656107	C/T	cg02297831	chr4:17616191	MED28	0.49	9.27	0.4	7.22e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg24133106	chr7:129690864	ZC3HC1	-0.43	-7.01	-0.31	8.71e-12	Body fat percentage;
LGG	cis	rs2033908	0.620	rs10765993	chr11:12849185	C/G	cg25843174	chr11:12811716	TEAD1	-0.35	-7.19	-0.32	2.54e-12	Sitting height ratio;
LGG	cis	rs9790314	0.723	rs1026572	chr3:160887654	A/G	cg04691961	chr3:161091175	C3orf57	-0.51	-11.25	-0.46	3.85e-26	Morning vs. evening chronotype;
LGG	cis	rs7551222	0.752	rs10793766	chr1:204549496	C/T	cg18851795	chr1:204543875	NA	-0.36	-6.9	-0.31	1.73e-11	Schizophrenia;
LGG	cis	rs17767392	1.000	rs34746156	chr14:71752360	A/T	cg02058870	chr14:72053146	SIPA1L1	0.45	9.05	0.39	4.07e-18	Mitral valve prolapse;
LGG	cis	rs826838	0.935	rs1601579	chr12:39178606	G/C	cg26384229	chr12:38710491	ALG10B	0.99	24.81	0.76	4.56e-87	Heart rate;
LGG	cis	rs4481887	0.830	rs9662041	chr1:248484701	A/T	cg00666640	chr1:248458726	OR2T12	0.57	9.19	0.39	1.32e-18	Common traits (Other);
LGG	cis	rs3741798	1.000	rs17375328	chr12:12485292	T/C	cg08615371	chr12:12503544	MANSC1	0.59	6.67	0.3	7.43e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2712184	0.683	rs2541406	chr2:217635847	C/G	cg05032264	chr2:217675019	NA	-0.4	-8.7	-0.37	6.04e-17	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs12580194	0.593	rs59136392	chr12:55748204	C/T	cg19537932	chr12:55886519	OR6C68	-0.52	-9.31	-0.4	4.99e-19	Cancer;
LGG	cis	rs9944715	1.000	rs3744858	chr18:43845269	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.73	-0.3	4.98e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs2115630	0.645	rs2292463	chr15:85175750	A/G	cg12501888	chr15:85177176	SCAND2	-0.54	-8.93	-0.38	1.01e-17	P wave terminal force;
LGG	cis	rs300703	0.935	rs300755	chr2:228505	C/T	cg21211680	chr2:198530	NA	1.28	15.9	0.59	9.36e-46	Blood protein levels;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.48	-0.58	7.18e-44	Height;
LGG	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg13540341	chr19:49222985	MAMSTR	-0.29	-6.72	-0.3	5.51e-11	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LGG	cis	rs8005677	1.000	rs1956880	chr14:23394007	A/G	cg25600027	chr14:23388339	RBM23	-0.47	-7.68	-0.34	9.33e-14	Cognitive ability (multi-trait analysis);
LGG	cis	rs644799	0.542	rs10831417	chr11:95467262	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	-0.73	-13.58	-0.53	1.39e-35	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs698833	0.962	rs698829	chr2:44730846	G/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.5	7.42	0.33	5.73e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs11583043	0.575	rs7528842	chr1:101583663	G/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.48	-8.08	-0.35	5.86e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	trans	rs459571	0.959	rs2520099	chr9:136918139	T/C	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.67	-11.37	-0.47	1.37e-26	Platelet distribution width;
LGG	cis	rs9467773	0.506	rs9393709	chr6:26365147	C/T	cg09904177	chr6:26538194	HMGN4	-0.42	-7.41	-0.33	6.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.587	rs7934075	chr11:67295949	T/C	cg14500267	chr11:67383377	NA	-0.41	-7.74	-0.34	6.29e-14	Mean corpuscular volume;
LGG	cis	rs72827839	0.846	rs72825517	chr17:46171824	G/T	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.28e-19	Blood metabolite levels;
LGG	cis	rs6558530	0.932	rs6558531	chr8:1707566	A/G	cg19131313	chr8:1704013	NA	-0.3	-6.76	-0.3	4.28e-11	Systolic blood pressure;
LGG	cis	rs9425766	0.640	rs16846439	chr1:173824038	T/G	cg06124660	chr1:173389066	NA	-0.44	-7.81	-0.34	3.77e-14	Life satisfaction;
LGG	cis	rs2404602	0.692	rs34287706	chr15:76942402	A/C	cg05677249	chr15:77158041	SCAPER	-0.33	-7.02	-0.31	8.16e-12	Blood metabolite levels;
LGG	cis	rs2204008	0.597	rs4002591	chr12:38133841	A/G	cg13010199	chr12:38710504	ALG10B	0.67	13.3	0.53	1.99e-34	Bladder cancer;
LGG	cis	rs6754311	0.731	rs4954490	chr2:136608231	G/A	cg07169764	chr2:136633963	MCM6	-0.76	-12.92	-0.51	8.33e-33	Mosquito bite size;
LGG	cis	rs9326248	0.581	rs11216267	chr11:116952392	C/T	cg20608306	chr11:116969690	SIK3	0.42	13.35	0.53	1.25e-34	Blood protein levels;
LGG	cis	rs4363385	0.693	rs310102	chr1:153042423	T/C	cg13444842	chr1:152974279	SPRR3	-0.4	-8.08	-0.35	5.74e-15	Inflammatory skin disease;
LGG	cis	rs8177253	1.000	rs1525892	chr3:133484712	C/T	cg11941060	chr3:133502564	NA	-0.47	-8.04	-0.35	7.31e-15	Iron status biomarkers;
LGG	cis	rs477692	0.569	rs7087541	chr10:131309979	A/C	cg05714579	chr10:131428358	MGMT	0.5	9.65	0.41	3.25e-20	Response to temozolomide;
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.04e-42	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs16942	chr17:41244000	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.63e-12	Menopause (age at onset);
LGG	cis	rs2153535	0.580	rs2327051	chr6:8441150	A/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-10.23	-0.43	2.74e-22	Motion sickness;
LGG	cis	rs28595532	0.920	rs56117870	chr4:119766583	T/C	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs1023500	0.551	rs61665536	chr22:42512613	A/G	cg15557168	chr22:42548783	NA	0.4	8.65	0.37	8.43e-17	Schizophrenia;
LGG	cis	rs6752107	0.935	rs11688431	chr2:234147175	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.21	0.32	2.29e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs3099143	1.000	rs7172639	chr15:77165288	G/A	cg21673338	chr15:77095150	SCAPER	0.66	10.46	0.44	4.08e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs6942756	1.000	rs11979476	chr7:128993756	G/T	cg02491457	chr7:128862824	NA	0.71	12.95	0.52	6.02e-33	White matter hyperintensity burden;
LGG	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg17644776	chr2:200775616	C2orf69	-0.68	-9.18	-0.39	1.38e-18	Schizophrenia;
LGG	cis	rs9859260	0.744	rs406271	chr3:195776976	T/C	cg02975922	chr3:195473998	MUC4	0.46	7.36	0.32	8.22e-13	Mean corpuscular volume;
LGG	cis	rs17376456	0.825	rs7715562	chr5:93222034	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.95	-10.65	-0.44	7.48e-24	Diabetic retinopathy;
LGG	cis	rs3806843	0.735	rs2530235	chr5:140072647	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-6.98	-0.31	1.03e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1801251	0.778	rs778338	chr2:233740227	A/G	cg25237894	chr2:233734115	C2orf82	-0.72	-15.1	-0.57	3.44e-42	Coronary artery disease;
LGG	cis	rs34172651	0.917	rs2343606	chr16:24793741	C/T	cg02428538	chr16:24856791	SLC5A11	-0.48	-8.1	-0.35	4.89e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10461617	0.541	rs7715822	chr5:56043600	G/T	cg12654349	chr5:56205094	C5orf35	-0.65	-8.49	-0.37	2.89e-16	Type 2 diabetes;
LGG	cis	rs4417704	0.551	rs6437221	chr2:241896418	C/T	cg26818257	chr2:241905806	NA	-0.5	-10.96	-0.45	5.44e-25	Joint mobility (Beighton score);
LGG	cis	rs6076065	0.723	rs6083110	chr20:23373674	C/T	cg12633918	chr20:23549525	CST9L	-0.35	-6.68	-0.3	6.88e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4262150	0.726	rs4958568	chr5:152016093	G/A	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg00198680	chr16:28758506	NA	0.29	7.16	0.32	3.2e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2072732	0.861	rs56176404	chr1:2940998	A/G	cg22517653	chr1:2918612	NA	-0.49	-6.67	-0.3	7.23e-11	Plateletcrit;
LGG	cis	rs6089584	0.816	rs6061411	chr20:60634716	C/A	cg06470251	chr20:60548479	NA	0.45	7.36	0.32	8.47e-13	Body mass index;
LGG	cis	rs3733585	0.699	rs6449157	chr4:9960442	G/A	cg08250081	chr4:10125330	NA	-0.37	-7.17	-0.32	3.07e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	-0.6	-10.25	-0.43	2.34e-22	Tonsillectomy;
LGG	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.35	-0.32	8.85e-13	Inflammatory bowel disease;
LGG	cis	rs4073582	0.595	rs708472	chr11:65930990	A/G	cg16950941	chr11:66035639	RAB1B	0.55	10.22	0.43	2.96e-22	Gout;
LGG	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg23306229	chr2:178417860	TTC30B	0.73	8.52	0.37	2.22e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg05793240	chr7:2802953	GNA12	0.31	7.78	0.34	4.64e-14	Height;
LGG	cis	rs1707322	0.638	rs1416706	chr1:46602844	G/A	cg03146154	chr1:46216737	IPP	-0.47	-8.22	-0.36	2.1e-15	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs208520	0.661	rs6937856	chr6:66867468	A/G	cg07460842	chr6:66804631	NA	-0.97	-18.01	-0.64	2.48e-55	Exhaled nitric oxide output;
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs2290159	0.948	rs5746255	chr3:12624321	A/G	cg23032965	chr3:12705835	RAF1	0.54	8.15	0.35	3.4e-15	Cholesterol, total;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.01	0.31	8.46e-12	Lung cancer;
LGG	cis	rs28595532	1.000	rs114039398	chr4:119631627	T/C	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs4740619	0.935	rs2055772	chr9:15602101	C/T	cg14451791	chr9:16040625	NA	-0.37	-9.48	-0.4	1.37e-19	Body mass index;
LGG	cis	rs12786942	0.569	rs12273188	chr11:101313615	A/C	cg03942599	chr11:101341554	TRPC6	0.48	7.31	0.32	1.21e-12	Facial depth;
LGG	trans	rs3780486	1.000	rs10813957	chr9:33153527	G/T	cg04842962	chr6:43655489	MRPS18A	1.04	16.9	0.62	2.92e-50	IgG glycosylation;
LGG	cis	rs4774830	0.744	rs76851035	chr15:56165642	G/A	cg05129572	chr15:56138634	NEDD4	0.9	8.0	0.35	1.01e-14	Delta-5 desaturase activity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22389871	chr6:82463023	FAM46A	0.63	7.71	0.34	7.5e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7923609	0.934	rs10822153	chr10:65056813	C/A	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.79	-0.3	3.43e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.12	19.19	0.67	8.26e-61	Smoking behavior;
LGG	cis	rs643506	0.874	rs618031	chr11:111648863	A/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.95	0.31	1.25e-11	Breast cancer;
LGG	cis	rs2346177	0.554	rs34854267	chr2:46708542	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.63	-11.99	-0.49	4.72e-29	HDL cholesterol;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg11764359	chr7:65958608	NA	-0.72	-12.89	-0.51	1.09e-32	Aortic root size;
LGG	trans	rs1005277	0.505	rs10827835	chr10:38150709	G/A	cg17830980	chr10:43048298	ZNF37B	0.45	10.01	0.42	1.8e-21	Extrinsic epigenetic age acceleration;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22031392	chr19:55962948	NA	0.6	6.98	0.31	1.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.679	rs2838860	chr21:46684904	A/G	cg06618935	chr21:46677482	NA	-0.35	-6.95	-0.31	1.27e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12579753	1.000	rs10862374	chr12:82250809	G/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.12	-0.46	1.3e-25	Resting heart rate;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.29	-0.43	1.74e-22	Obesity-related traits;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.67	-12.63	-0.51	1.28e-31	Obesity-related traits;
LGG	cis	rs7851660	0.809	rs7032086	chr9:100656402	T/G	cg13688889	chr9:100608707	NA	-0.64	-12.82	-0.51	1.99e-32	Strep throat;
LGG	cis	rs780096	0.506	rs2950834	chr2:27627366	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.67	-0.3	7.25e-11	Total body bone mineral density;
LGG	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg00198680	chr16:28758506	NA	0.29	6.92	0.31	1.54e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.6	0.37	1.25e-16	Bipolar disorder;
LGG	cis	rs4716602	0.596	rs4490714	chr7:156162510	C/A	cg16983916	chr7:156159713	NA	-0.5	-9.58	-0.41	6.02e-20	Anti-saccade response;
LGG	cis	rs2742417	1.000	rs1534876	chr3:45741257	G/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.48	-0.33	3.85e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7166081	1.000	rs10152973	chr15:67647218	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.78	-0.3	3.78e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg11081185	chr11:208423	RIC8A;BET1L	-0.41	-6.69	-0.3	6.45e-11	Leprosy;
LGG	cis	rs79349575	0.783	rs962272	chr17:46978283	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs638893	0.636	rs1784295	chr11:118660932	A/G	cg13782932	chr11:118662891	DDX6	0.36	6.7	0.3	5.92e-11	Vitiligo;
LGG	cis	rs8135665	0.600	rs6519096	chr22:38451389	C/T	cg13116946	chr22:38479732	SLC16A8	0.54	8.86	0.38	1.7e-17	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg13206674	chr6:150067644	NUP43	0.68	16.03	0.6	2.43e-46	Lung cancer;
LGG	cis	rs1209950	0.866	rs1734587	chr21:40180884	A/G	cg01359822	chr21:40176597	ETS2	0.36	8.1	0.35	4.92e-15	Non-small cell lung cancer (survival);
LGG	cis	rs9394438	0.628	rs4714080	chr6:37544618	A/G	cg00985040	chr6:37553208	NA	0.37	8.49	0.37	2.93e-16	IgG glycosylation;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.52	10.05	0.42	1.29e-21	Glycated hemoglobin levels;
LGG	trans	rs58106596	0.800	rs11675826	chr2:232565507	T/C	cg01370599	chr3:116745421	NA	0.66	10.0	0.42	1.96e-21	White blood cell count;Lymphocyte counts;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg05665937	chr4:1216051	CTBP1	0.48	8.32	0.36	9.89e-16	Obesity-related traits;
LGG	cis	rs9783347	1.000	rs2061164	chr11:18329006	T/C	cg15585147	chr11:18324498	HPS5	0.44	9.26	0.4	7.88e-19	Pancreatic cancer;
LGG	cis	rs13401104	0.716	rs10929176	chr2:237129131	G/A	cg15742758	chr2:237126235	ASB18	0.47	7.82	0.34	3.66e-14	Educational attainment;
LGG	cis	rs9768139	0.733	rs34173461	chr7:158122175	C/G	cg02855558	chr7:158107723	PTPRN2	-0.38	-6.84	-0.3	2.44e-11	Calcium levels;
LGG	cis	rs2444240	0.935	rs4936509	chr11:120041444	C/T	cg16005559	chr11:120040616	NA	0.32	7.08	0.31	5.45e-12	Corneal curvature;
LGG	cis	rs9513627	0.920	rs2390280	chr13:100208802	A/G	cg25919922	chr13:100150906	NA	0.69	7.12	0.31	4.1e-12	Obesity-related traits;
LGG	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.93	0.52	7.23e-33	Intelligence (multi-trait analysis);
LGG	trans	rs10506458	0.915	rs12424908	chr12:63402364	G/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-22.07	-0.72	2.79e-74	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4363385	0.747	rs1415960	chr1:152973571	G/T	cg13444842	chr1:152974279	SPRR3	-0.44	-9.17	-0.39	1.55e-18	Inflammatory skin disease;
LGG	cis	rs7615952	0.673	rs9841194	chr3:125635739	C/T	cg05084668	chr3:125655381	ALG1L	-1.17	-13.6	-0.53	1.07e-35	Blood pressure (smoking interaction);
LGG	cis	rs7575873	1	rs7575873	chr2:23962647	A/G	cg08917208	chr2:24149416	ATAD2B	0.9	9.47	0.4	1.43e-19	Birth weight;
LGG	cis	rs7582180	0.652	rs4443016	chr2:100876628	C/G	cg21926883	chr2:100939477	LONRF2	-0.58	-12.34	-0.5	1.86e-30	Intelligence (multi-trait analysis);
LGG	cis	rs4721295	0.573	rs3779000	chr7:2181628	G/A	cg02951883	chr7:2050386	MAD1L1	-0.67	-13.41	-0.53	6.83e-35	Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg13736514	chr6:26305472	NA	-0.45	-8.9	-0.38	1.22e-17	Educational attainment;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg20607798	chr8:58055168	NA	0.57	6.87	0.3	2.09e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs7167389	chr15:45535683	A/G	cg24006582	chr15:45444508	DUOX1	-0.68	-12.76	-0.51	3.61e-32	Uric acid levels;
LGG	cis	rs5758659	0.652	rs133327	chr22:42407689	T/C	cg15557168	chr22:42548783	NA	-0.34	-7.63	-0.33	1.3e-13	Cognitive function;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg26338869	chr17:61819248	STRADA	0.58	9.62	0.41	4.46e-20	Prudent dietary pattern;
LGG	cis	rs7110373	1	rs7110373	chr11:122813224	C/T	cg27398637	chr11:122830231	C11orf63	-0.67	-13.31	-0.53	1.88e-34	Age at voice drop;
LGG	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.2	-0.36	2.45e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg07243736	chr16:783730	NARFL	0.41	7.11	0.31	4.3e-12	Height;
LGG	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs1862618	0.529	rs978406	chr5:56259808	A/T	cg12654349	chr5:56205094	C5orf35	0.8	11.77	0.48	3.62e-28	Initial pursuit acceleration;
LGG	cis	rs10262624	1.000	rs11767124	chr7:23919080	G/A	cg09690326	chr7:23720549	C7orf46	-0.33	-6.75	-0.3	4.51e-11	Schizophrenia;
LGG	trans	rs11039798	0.777	rs2202454	chr11:49011009	T/C	cg03929089	chr4:120376271	NA	0.75	8.69	0.37	6.19e-17	Axial length;
LGG	cis	rs7639513	0.767	rs2348201	chr3:12711696	A/G	cg23032965	chr3:12705835	RAF1	0.85	16.75	0.61	1.48e-49	Itch intensity from mosquito bite;
LGG	cis	rs4665809	0.938	rs6742226	chr2:26342537	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.04	-0.52	2.54e-33	Gut microbiome composition (summer);
LGG	trans	rs1728785	1.000	rs1170443	chr16:68573295	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.54	0.44	1.97e-23	Ulcerative colitis;
LGG	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07570687	chr10:102243282	WNT8B	0.4	6.81	0.3	2.95e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4713118	0.586	rs6905516	chr6:28086478	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.75	14.22	0.55	2.4e-38	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7582720	0.806	rs72926770	chr2:203798585	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs936229	0.749	rs8042694	chr15:75225415	G/A	cg10253484	chr15:75165896	SCAMP2	-0.69	-10.78	-0.45	2.62e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs8064024	0.557	rs2251666	chr16:4923091	C/T	cg04440724	chr16:4920505	UBN1	-0.54	-10.91	-0.45	7.97e-25	Cancer;
LGG	cis	rs3206736	0.514	rs1649236	chr7:35004134	C/T	cg13400248	chr7:35225412	NA	0.54	9.43	0.4	2.05e-19	Diastolic blood pressure;
LGG	trans	rs11039798	0.588	rs11039818	chr11:48562120	C/T	cg15704280	chr7:45808275	SEPT13	0.72	10.03	0.42	1.52e-21	Axial length;
LGG	cis	rs11945232	0.624	rs10035024	chr4:88367469	C/T	cg23841344	chr4:88312519	HSD17B11	-0.44	-6.67	-0.3	7.27e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7965445	0.667	rs4907420	chr12:131972434	T/C	cg16675054	chr5:171616574	STK10	0.35	6.69	0.3	6.41e-11	Mortality in heart failure;
LGG	cis	rs17641971	1.000	rs73579339	chr8:49888184	G/A	cg00325661	chr8:49890786	NA	-0.44	-7.08	-0.31	5.56e-12	Blood metabolite levels;
LGG	cis	rs7100689	0.622	rs4536152	chr10:82119242	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.33	0.58	3.54e-43	Post bronchodilator FEV1;
LGG	cis	rs13403149	0.656	rs13401708	chr2:2845963	C/T	cg02105481	chr2:2853515	NA	0.33	7.26	0.32	1.68e-12	Smoking initiation;
LGG	cis	rs832540	1.000	rs192249	chr5:56197514	C/G	cg12654349	chr5:56205094	C5orf35	-0.42	-7.43	-0.33	5.13e-13	Coronary artery disease;
LGG	cis	rs4771450	0.962	rs6491738	chr13:103971436	A/G	cg02987523	chr13:103978230	NA	-0.32	-7.12	-0.31	4.14e-12	Uric acid levels;
LGG	cis	rs6977660	0.607	rs13239423	chr7:19816571	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	3.82e-23	Thyroid stimulating hormone;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23097277	chr12:27676539	PPFIBP1	0.37	6.68	0.3	7.05e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs72945132	0.882	rs7940090	chr11:70227824	C/G	cg13802316	chr11:70253460	CTTN	-0.57	-7.38	-0.32	7.5e-13	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg22857025	chr5:266934	NA	-1.47	-24.87	-0.76	2.44e-87	Breast cancer;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg00149659	chr3:10157352	C3orf10	-0.83	-10.87	-0.45	1.12e-24	Alzheimer's disease;
LGG	cis	rs10504229	0.593	rs78459635	chr8:58004995	G/T	cg02725872	chr8:58115012	NA	-0.93	-11.99	-0.49	5.14e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs12762955	0.687	rs4880470	chr10:1077480	G/A	cg25019033	chr10:957182	NA	0.35	7.35	0.32	9.34e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs6598955	0.724	rs7526545	chr1:26569990	C/A	cg04990556	chr1:26633338	UBXN11	-0.69	-13.95	-0.54	3.45e-37	Obesity-related traits;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg26245302	chr6:163148501	PACRG;PARK2	-0.39	-6.72	-0.3	5.31e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs11931598	0.783	rs28661210	chr4:7050956	C/A	cg26116260	chr4:7069785	GRPEL1	0.54	9.54	0.41	8.01e-20	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs6831352	0.918	rs35662508	chr4:100050974	C/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs7084402	0.967	rs1649081	chr10:60292444	G/A	cg07615347	chr10:60278583	BICC1	0.63	18.28	0.65	1.34e-56	Refractive error;
LGG	cis	rs9947295	0.649	rs73399842	chr18:11776092	A/T	cg14735704	chr18:11749182	GNAL	0.48	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	cis	rs921968	0.643	rs545779	chr2:219336108	A/G	cg02985541	chr2:219472218	PLCD4	0.29	6.9	0.31	1.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2718798	1	rs2718798	chr3:133492088	A/C	cg01448562	chr3:133502909	NA	-0.44	-7.83	-0.34	3.32e-14	Ankle injury;
LGG	cis	rs6815814	0.731	rs4504266	chr4:38773754	G/A	cg06935464	chr4:38784597	TLR10	0.44	6.77	0.3	3.89e-11	Breast cancer;
LGG	cis	rs7301016	1.000	rs11614022	chr12:62891329	A/G	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs9290065	0.686	rs1839021	chr3:160623669	T/G	cg04691961	chr3:161091175	C3orf57	0.41	8.71	0.38	5.58e-17	Kawasaki disease;
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg11494091	chr17:61959527	GH2	0.5	8.07	0.35	5.99e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10464366	0.912	rs2030960	chr7:39106010	G/A	cg21665744	chr7:39171113	POU6F2	0.38	7.31	0.32	1.16e-12	IgG glycosylation;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.08	0.52	1.79e-33	Prudent dietary pattern;
LGG	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg03128945	chr5:622914	CEP72	-0.42	-7.0	-0.31	9.33e-12	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs422164	chr7:65586605	C/G	cg10756647	chr7:56101905	PSPH	0.8	9.3	0.4	5.62e-19	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16369786	chr1:63153804	DOCK7	0.48	7.34	0.32	9.81e-13	Gut microbiome composition (summer);
LGG	cis	rs17376456	0.569	rs6556839	chr5:93206292	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-8.42	-0.36	4.66e-16	Diabetic retinopathy;
LGG	trans	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.18	-0.36	2.76e-15	Intelligence (multi-trait analysis);
LGG	cis	rs3808502	0.516	rs6983727	chr8:11415812	A/G	cg27411982	chr8:10470053	RP1L1	0.39	6.68	0.3	6.67e-11	Neuroticism;
LGG	cis	rs2415984	0.622	rs7156444	chr14:46933296	C/G	cg14871534	chr14:47121158	RPL10L	-0.58	-10.14	-0.43	6.14e-22	Number of children ever born;
LGG	cis	rs4819388	0.793	rs4818887	chr21:45644950	C/T	cg01992765	chr21:45622493	NA	0.45	8.68	0.37	6.58e-17	Celiac disease;
LGG	cis	rs9479482	0.648	rs912558	chr6:150385730	G/T	cg03788504	chr6:150331562	NA	0.46	9.77	0.41	1.26e-20	Alopecia areata;
LGG	cis	rs941873	0.805	rs8837	chr10:81114813	C/G	cg09469691	chr10:81107165	PPIF	0.56	9.55	0.41	7.67e-20	Height;
LGG	cis	rs10189230	0.967	rs12990760	chr2:222354725	G/T	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.85e-32	Urate levels in lean individuals;
LGG	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg13010199	chr12:38710504	ALG10B	-0.64	-12.91	-0.51	8.73e-33	Morning vs. evening chronotype;
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg20110707	chr11:118481992	PHLDB1	0.5	10.48	0.44	3.33e-23	Cholesterol, total;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.93	-0.38	9.76e-18	Lung cancer;
LGG	cis	rs6754311	0.597	rs2082729	chr2:136550109	C/T	cg07169764	chr2:136633963	MCM6	-0.79	-13.88	-0.54	7.17e-37	Mosquito bite size;
LGG	cis	rs988958	0.562	rs13397376	chr2:42221417	A/G	cg27428208	chr2:42229179	NA	0.49	7.61	0.33	1.56e-13	Hypospadias;
LGG	cis	rs4727027	0.870	rs1568945	chr7:148874112	T/G	cg23583168	chr7:148888333	NA	-0.85	-16.42	-0.61	4.43e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11059919	1	rs11059919	chr12:129289190	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.89	-0.64	8.84e-55	Systemic lupus erythematosus;
LGG	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg13010199	chr12:38710504	ALG10B	-0.54	-9.94	-0.42	3.26e-21	Morning vs. evening chronotype;
LGG	cis	rs12410462	0.901	rs79626242	chr1:227650385	A/G	cg21459583	chr1:227974177	NA	0.45	6.95	0.31	1.25e-11	Major depressive disorder;
LGG	cis	rs7666738	0.753	rs11097594	chr4:98944486	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7937890	0.532	rs2575832	chr11:14488810	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs2228479	0.702	rs17233176	chr16:89832751	G/C	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.51	10.93	0.45	6.81e-25	Calcium levels;
LGG	cis	rs1799949	0.930	rs8176194	chr17:41231221	A/C	cg25072359	chr17:41440525	NA	0.53	9.89	0.42	4.73e-21	Menopause (age at onset);
LGG	cis	rs9443189	0.570	rs9341532	chr6:76403674	A/G	cg01950844	chr6:76311363	SENP6	0.76	10.07	0.42	1.07e-21	Prostate cancer;
LGG	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg05692746	chr2:100937584	LONRF2	-0.58	-9.39	-0.4	2.68e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	1.000	rs4949674	chr1:76213715	C/A	cg22875332	chr1:76189707	ACADM	0.62	10.47	0.44	3.55e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4595586	0.545	rs11615638	chr12:39364766	A/C	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2236918	1.000	rs2526699	chr1:242022130	T/C	cg17736920	chr1:242011382	EXO1	0.49	8.91	0.38	1.18e-17	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.739	rs6534130	chr4:120131339	A/T	cg25214090	chr10:38739885	LOC399744	-0.57	-10.12	-0.43	6.8e-22	Corneal astigmatism;
LGG	cis	rs10267417	0.535	rs10242331	chr7:19923552	T/C	cg05791153	chr7:19748676	TWISTNB	0.53	6.69	0.3	6.44e-11	Night sleep phenotypes;
LGG	cis	rs2227564	0.794	rs2633320	chr10:75693306	A/G	cg00564723	chr10:75632066	CAMK2G	-0.41	-8.38	-0.36	6.36e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs35306767	0.903	rs12254002	chr10:929133	A/G	cg25019033	chr10:957182	NA	0.56	10.32	0.43	1.33e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs11622475	1.000	rs56060232	chr14:104386165	G/C	cg12183467	chr14:104352244	NA	-0.45	-7.76	-0.34	5.32e-14	Bipolar disorder;
LGG	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg03352830	chr11:487213	PTDSS2	0.89	11.29	0.46	2.86e-26	Body mass index;
LGG	cis	rs921968	0.612	rs2384950	chr2:219499719	T/C	cg01130898	chr2:219473002	PLCD4	-0.41	-7.15	-0.32	3.38e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.7	0.34	8.1e-14	Lung cancer;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg16507663	chr6:150244633	RAET1G	0.44	7.15	0.32	3.41e-12	Lung cancer;
LGG	cis	rs8005745	0.522	rs3783752	chr14:62185692	A/G	cg01748970	chr14:62088363	NA	-0.9	-9.97	-0.42	2.41e-21	Select biomarker traits;
LGG	cis	rs4242434	0.819	rs751680	chr8:22475627	G/A	cg00599393	chr8:22457479	C8orf58	-0.44	-8.03	-0.35	8.38e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg24642844	chr7:1081250	C7orf50	-0.64	-10.43	-0.44	5.27e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.82	0.84	6.66e-123	Prudent dietary pattern;
LGG	cis	rs868036	0.672	rs7175517	chr15:68077630	A/G	cg05925327	chr15:68127851	NA	-0.37	-7.64	-0.33	1.27e-13	Restless legs syndrome;
LGG	cis	rs7811142	0.830	rs6975660	chr7:99975266	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	19.75	0.68	1.97e-63	Platelet count;
LGG	cis	rs6438424	0.502	rs6792076	chr3:117724113	A/G	cg07910724	chr3:117604411	NA	0.32	8.45	0.37	3.92e-16	Menarche (age at onset);
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.4	-0.58	1.74e-43	Prudent dietary pattern;
LGG	cis	rs1816752	1.000	rs7326932	chr13:25004493	A/T	cg02811702	chr13:24901961	NA	0.43	8.04	0.35	7.49e-15	Obesity-related traits;
LGG	cis	rs8180040	0.726	rs7610636	chr3:47064436	A/C	cg22292345	chr3:47051533	LOC100129354	-0.3	-7.04	-0.31	6.91e-12	Colorectal cancer;
LGG	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg24247370	chr13:99142703	STK24	-0.4	-7.15	-0.32	3.36e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs71007656	1	rs71007656	chr10:37970845	CGGCTG/C	cg17830980	chr10:43048298	ZNF37B	-0.42	-9.53	-0.4	8.97e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs7000551	0.725	rs2449349	chr8:22383284	A/G	cg12081754	chr8:22256438	SLC39A14	0.65	12.05	0.49	2.89e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2274273	0.774	rs17128440	chr14:55861912	C/T	cg04306507	chr14:55594613	LGALS3	0.62	17.4	0.63	1.46e-52	Protein biomarker;
LGG	cis	rs752010	0.967	rs2038978	chr1:42094719	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	12.09	0.49	1.89e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9527	0.571	rs4917985	chr10:104624072	C/T	cg04362960	chr10:104952993	NT5C2	0.51	9.41	0.4	2.39e-19	Arsenic metabolism;
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.87e-34	Prudent dietary pattern;
LGG	cis	rs11971779	0.648	rs6946113	chr7:139106126	A/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	trans	rs7829975	0.536	rs2980439	chr8:8094870	G/A	cg19847130	chr8:10466454	RP1L1	-0.32	-7.1	-0.31	4.59e-12	Mood instability;
LGG	cis	rs9815354	1.000	rs1016669	chr3:41894440	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9341835	0.772	rs6919709	chr6:64139856	C/T	cg00787780	chr6:64151745	NA	0.41	7.54	0.33	2.54e-13	Schizophrenia;
LGG	cis	rs12476592	0.571	rs262475	chr2:63869045	A/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.92	-0.31	1.56e-11	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg08621203	chr6:150244597	RAET1G	0.48	8.25	0.36	1.66e-15	Lung cancer;
LGG	cis	rs13118159	0.801	rs7664474	chr4:1329116	T/A	cg05165339	chr4:1420672	NA	-0.29	-7.8	-0.34	4.12e-14	Longevity;
LGG	trans	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg02002194	chr4:3960332	NA	0.36	6.82	0.3	2.81e-11	Neuroticism;
LGG	trans	rs1994135	0.692	rs7958788	chr12:33692179	T/C	cg26384229	chr12:38710491	ALG10B	0.71	13.03	0.52	2.71e-33	Resting heart rate;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.66	-0.34	1.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs758324	0.773	rs2404776	chr5:131168937	C/T	cg06307176	chr5:131281290	NA	0.54	8.92	0.38	1.08e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs5758343	1	rs5758343	chr22:41816652	A/T	cg06850241	chr22:41845214	NA	0.45	7.08	0.31	5.43e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs765787	0.530	rs12440238	chr15:45512905	T/C	cg24006582	chr15:45444508	DUOX1	0.66	12.09	0.49	1.95e-29	Uric acid levels;
LGG	cis	rs3784262	0.669	rs4646602	chr15:58294757	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.31	-6.72	-0.3	5.28e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03745386	chr12:29534188	ERGIC2	0.44	7.45	0.33	4.61e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg13395646	chr4:1353034	KIAA1530	-0.47	-8.03	-0.35	8.31e-15	Obesity-related traits;
LGG	cis	rs2028299	0.879	rs7163629	chr15:90416740	T/C	cg23731826	chr15:90371692	NA	0.35	7.99	0.35	1.07e-14	Type 2 diabetes;
LGG	cis	rs7843479	0.526	rs3816788	chr8:21832494	A/C	cg17168535	chr8:21777572	XPO7	0.81	15.02	0.57	7.6e-42	Mean corpuscular volume;
LGG	cis	rs9357271	0.955	rs9349077	chr6:38365596	G/A	cg07362130	chr6:38359646	BTBD9	-0.45	-9.56	-0.41	7.09e-20	Restless legs syndrome;
LGG	cis	rs8180040	0.805	rs17410853	chr3:47363971	G/T	cg27129171	chr3:47204927	SETD2	-0.76	-13.72	-0.54	3.51e-36	Colorectal cancer;
LGG	cis	rs9326248	0.906	rs171052	chr11:117081763	C/G	cg11861562	chr11:117069780	TAGLN	-0.26	-7.1	-0.31	4.64e-12	Blood protein levels;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg16145915	chr7:1198662	ZFAND2A	-0.52	-8.84	-0.38	2.01e-17	Longevity;Endometriosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15062310	chr7:100450120	SLC12A9	0.43	6.97	0.31	1.11e-11	Cognitive performance;
LGG	cis	rs62400317	0.826	rs12203466	chr6:45330263	T/A	cg20913747	chr6:44695427	NA	-0.59	-9.88	-0.42	5.27e-21	Total body bone mineral density;
LGG	cis	rs73787773	0.668	rs17134152	chr5:111479955	G/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.57	-7.53	-0.33	2.64e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs36051895	0.632	rs12001334	chr9:5152604	C/A	cg02405213	chr9:5042618	JAK2	-0.77	-14.51	-0.56	1.43e-39	Pediatric autoimmune diseases;
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg05555928	chr11:63887634	MACROD1	-0.75	-10.94	-0.45	6.34e-25	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9522267	0.708	rs914032	chr13:112241019	G/A	cg14952266	chr13:112191215	NA	-0.38	-7.31	-0.32	1.16e-12	Hepatitis;
LGG	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg08400814	chr5:56204995	C5orf35	0.39	6.89	0.3	1.84e-11	Initial pursuit acceleration;
LGG	cis	rs7959452	0.640	rs4761154	chr12:69705362	A/G	cg20891283	chr12:69753455	YEATS4	-0.76	-14.83	-0.57	5.71e-41	Blood protein levels;
LGG	cis	rs4950322	0.570	rs6703892	chr1:146759306	T/C	cg22381352	chr1:146742008	CHD1L	-0.52	-8.45	-0.37	3.73e-16	Protein quantitative trait loci;
LGG	cis	rs7786808	0.712	rs2335167	chr7:158213948	A/C	cg09998033	chr7:158218633	PTPRN2	-0.52	-9.66	-0.41	3.12e-20	Obesity-related traits;
LGG	cis	rs7927592	0.956	rs10896334	chr11:68281494	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.18	-0.36	2.67e-15	Total body bone mineral density;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg05793240	chr7:2802953	GNA12	0.32	7.66	0.34	1.08e-13	Height;
LGG	cis	rs765787	0.530	rs7165889	chr15:45531640	T/C	cg24006582	chr15:45444508	DUOX1	-0.67	-12.79	-0.51	2.86e-32	Uric acid levels;
LGG	cis	rs2559856	1.000	rs2695288	chr12:102088112	T/C	cg15068132	chr12:102092402	CHPT1	-0.36	-6.66	-0.3	7.95e-11	Blood protein levels;
LGG	cis	rs568617	1.000	rs687672	chr11:65649984	T/C	cg26695010	chr11:65641043	EFEMP2	0.47	6.67	0.3	7.4e-11	Crohn's disease;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.39	0.32	6.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9300255	0.537	rs1727334	chr12:123714236	A/G	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	1e-13	Neutrophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	cis	rs8062405	1.000	rs8062405	chr16:28837906	C/T	cg00204512	chr16:28754710	NA	-0.27	-7.6	-0.33	1.69e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3126085	0.867	rs11204948	chr1:152218473	A/G	cg26876637	chr1:152193138	HRNR	0.51	7.91	0.35	1.89e-14	Atopic dermatitis;
LGG	cis	rs523522	0.962	rs687873	chr12:121019634	G/A	cg27279351	chr12:120934652	DYNLL1	0.81	13.07	0.52	1.93e-33	High light scatter reticulocyte count;
LGG	cis	rs9487094	0.670	rs2024852	chr6:109819789	G/C	cg01125227	chr6:109776195	MICAL1	0.44	7.67	0.34	1.05e-13	Height;
LGG	cis	rs4363385	0.747	rs1577965	chr1:152968294	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.3	-0.4	5.5e-19	Inflammatory skin disease;
LGG	cis	rs12474201	0.862	rs7562173	chr2:46976217	C/G	cg06386533	chr2:46925753	SOCS5	-0.79	-14.79	-0.57	8.05e-41	Height;
LGG	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg12458913	chr13:53173898	NA	0.86	19.47	0.67	3.84e-62	Lewy body disease;
LGG	cis	rs1594829	0.553	rs1564577	chr8:26164723	G/A	cg11498726	chr8:26250323	BNIP3L	-0.38	-8.53	-0.37	2.08e-16	Height;
LGG	cis	rs9443645	0.527	rs10943600	chr6:79611505	G/A	cg18132916	chr6:79620363	NA	-0.27	-7.24	-0.32	1.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg00761968	chr13:53314142	LECT1	-0.44	-9.76	-0.41	1.37e-20	Lewy body disease;
LGG	cis	rs801193	0.569	rs4717315	chr7:66178325	C/T	cg18252515	chr7:66147081	NA	-0.44	-7.53	-0.33	2.72e-13	Aortic root size;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg16389209	chr10:63809121	ARID5B	-0.39	-7.78	-0.34	4.62e-14	Systemic lupus erythematosus;
LGG	cis	rs12579753	0.879	rs12829053	chr12:82161926	T/A	cg07988820	chr12:82153109	PPFIA2	-0.81	-12.51	-0.5	3.78e-31	Resting heart rate;
LGG	cis	rs4969178	0.622	rs4129767	chr17:76403984	G/A	cg02836325	chr17:76403955	PGS1	-0.79	-17.31	-0.63	4.13e-52	HDL cholesterol levels;
LGG	cis	rs4363385	0.510	rs6693927	chr1:153044009	G/A	cg13444842	chr1:152974279	SPRR3	-0.47	-9.33	-0.4	4.43e-19	Inflammatory skin disease;
LGG	cis	rs60871478	0.636	rs4719520	chr7:875216	C/G	cg22643751	chr7:855365	UNC84A	-0.42	-7.29	-0.32	1.38e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs807669	0.505	rs8142503	chr22:19166717	G/T	cg02655711	chr22:19163373	SLC25A1	0.52	9.41	0.4	2.24e-19	Metabolite levels;
LGG	trans	rs6787172	0.622	rs12636560	chr3:158171454	C/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.5	-0.33	3.4e-13	Subjective well-being;
LGG	cis	rs9463078	0.774	rs6935398	chr6:45262427	G/A	cg25276700	chr6:44698697	NA	-0.41	-8.6	-0.37	1.23e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs367943	0.666	rs1850412	chr5:112696768	A/G	cg12552261	chr5:112820674	MCC	0.57	10.12	0.43	7.28e-22	Type 2 diabetes;
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg14092988	chr3:52407081	DNAH1	-0.31	-8.05	-0.35	7.02e-15	Bipolar disorder;
LGG	trans	rs656319	0.513	rs1484641	chr8:9986524	A/C	cg06636001	chr8:8085503	FLJ10661	0.45	7.86	0.34	2.67e-14	Myopia (pathological);
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.28	-8.23	-0.36	1.86e-15	IgG glycosylation;
LGG	cis	rs4919044	0.756	rs7073161	chr10:94826465	C/G	cg05127821	chr10:94822908	CYP26C1	0.34	6.68	0.3	7e-11	Coronary artery disease;
LGG	cis	rs988958	0.526	rs7604662	chr2:42243943	A/G	cg27428208	chr2:42229179	NA	0.48	7.57	0.33	2.07e-13	Hypospadias;
LGG	cis	rs6960043	0.818	rs10807778	chr7:15054190	C/G	cg19272540	chr7:15055459	NA	0.37	8.34	0.36	8.61e-16	Type 2 diabetes;
LGG	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg01579765	chr21:45077557	HSF2BP	0.35	7.82	0.34	3.53e-14	Mean corpuscular volume;
LGG	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg07936489	chr17:37558343	FBXL20	0.85	15.91	0.59	8.45e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs61931739	0.500	rs34080094	chr12:34547952	G/A	cg06521331	chr12:34319734	NA	-0.56	-9.59	-0.41	5.32e-20	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg04568710	chr12:38710424	ALG10B	0.35	7.29	0.32	1.34e-12	Bladder cancer;
LGG	cis	rs11098499	0.866	rs9995136	chr4:120286845	A/G	cg24375607	chr4:120327624	NA	0.58	9.6	0.41	5.25e-20	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs16921808	chr8:58106049	C/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs9371215	chr6:150194298	C/T	cg11878867	chr6:150167359	LRP11	-0.38	-7.78	-0.34	4.62e-14	Testicular germ cell tumor;
LGG	cis	rs12188164	0.515	rs11745246	chr5:410943	A/G	cg00976097	chr5:421733	AHRR	-0.44	-7.12	-0.31	4.06e-12	Cystic fibrosis severity;
LGG	cis	rs2244613	0.507	rs7205803	chr16:55794849	C/T	cg02649063	chr16:55794731	CES4	0.47	7.2	0.32	2.44e-12	Response to dabigatran etexilate treatment;
LGG	cis	rs7589342	0.831	rs6714861	chr2:106518893	C/T	cg16077055	chr2:106428750	NCK2	-0.26	-6.84	-0.3	2.56e-11	Addiction;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	1.02e-16	Prudent dietary pattern;
LGG	cis	rs9902453	0.934	rs7213902	chr17:28322935	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.4	0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs2285947	1.000	rs6970597	chr7:21583519	C/A	cg04471919	chr7:21584483	DNAH11	0.5	13.92	0.54	4.8e-37	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg10523679	chr1:76189770	ACADM	0.82	14.96	0.57	1.42e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg04568710	chr12:38710424	ALG10B	0.34	7.16	0.32	3.28e-12	Bladder cancer;
LGG	cis	rs4788570	0.697	rs4788443	chr16:71805160	G/A	cg06353428	chr16:71660113	MARVELD3	1.25	19.69	0.68	3.94e-63	Intelligence (multi-trait analysis);
LGG	cis	rs185694	1.000	rs846498	chr13:30900541	A/G	cg07600127	chr13:30881527	KATNAL1	-0.5	-6.67	-0.3	7.26e-11	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg00745463	chr17:30367425	LRRC37B	-0.73	-10.21	-0.43	3.18e-22	Hip circumference adjusted for BMI;
LGG	cis	rs7508	0.668	rs13280	chr8:17921230	G/A	cg18067069	chr8:17937731	ASAH1	-0.37	-8.52	-0.37	2.29e-16	Atrial fibrillation;
LGG	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.04	0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs754466	0.606	rs10824581	chr10:79599501	A/G	cg17075019	chr10:79541650	NA	-0.96	-20.26	-0.69	7.97e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6938	0.534	rs12904897	chr15:75217686	A/G	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.3	-0.32	1.24e-12	Breast cancer;
LGG	cis	rs875971	0.540	rs4717275	chr7:65265180	C/T	cg18876405	chr7:65276391	NA	-0.68	-13.04	-0.52	2.41e-33	Aortic root size;
LGG	cis	rs2708977	0.899	rs12992413	chr2:97277489	A/G	cg01950434	chr2:97203154	ARID5A	0.56	8.97	0.38	7.33e-18	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.48	0.33	3.69e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2273669	0.915	rs7738483	chr6:109341834	C/T	cg05315195	chr6:109294784	ARMC2	-0.49	-7.22	-0.32	2.18e-12	Prostate cancer;
LGG	cis	rs4774899	0.966	rs12917247	chr15:57363575	G/C	cg08128148	chr15:57256372	TCF12	-0.33	-7.84	-0.34	3.21e-14	Urinary tract infection frequency;
LGG	cis	rs2084898	0.891	rs501021	chr11:120000872	T/C	cg07435449	chr11:120005650	TRIM29	0.69	8.54	0.37	2.02e-16	Stroke (pediatric);
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.52	-8.27	-0.36	1.48e-15	Longevity;
LGG	cis	rs10870270	1.000	rs7098014	chr10:133775029	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.6	-0.53	1.08e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg18187862	chr3:45730750	SACM1L	0.68	11.46	0.47	6.2e-27	Primary sclerosing cholangitis;
LGG	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg13802316	chr11:70253460	CTTN	-0.59	-7.49	-0.33	3.49e-13	Coronary artery disease;
LGG	cis	rs10924309	0.737	rs6700721	chr1:245854173	C/T	cg00036263	chr1:245852353	KIF26B	-0.44	-6.9	-0.31	1.74e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs2880765	0.743	rs6416598	chr15:86011848	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.31	-0.32	1.16e-12	Coronary artery disease;
LGG	cis	rs10752881	0.935	rs12082051	chr1:183051614	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Colorectal cancer;
LGG	cis	rs9398803	0.763	rs576049	chr6:126730543	T/G	cg19875578	chr6:126661172	C6orf173	0.57	10.4	0.44	6.56e-23	Male-pattern baldness;
LGG	cis	rs11098499	0.863	rs7664986	chr4:120429952	A/C	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.21e-25	Corneal astigmatism;
LGG	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.31	0.6	1.35e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3780486	0.846	rs10971438	chr9:33180308	A/G	cg13443165	chr9:33130375	B4GALT1	-0.62	-10.23	-0.43	2.67e-22	IgG glycosylation;
LGG	cis	rs6429082	0.818	rs704722	chr1:235669988	G/A	cg26050004	chr1:235667680	B3GALNT2	0.62	10.26	0.43	2.16e-22	Adiposity;
LGG	cis	rs477895	0.653	rs72918475	chr11:63878644	G/C	cg04317338	chr11:64019027	PLCB3	0.64	7.77	0.34	5.14e-14	Mean platelet volume;
LGG	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg23625390	chr15:77176239	SCAPER	0.67	13.06	0.52	2.05e-33	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg04503457	chr17:41445688	NA	-0.37	-8.8	-0.38	2.81e-17	Menopause (age at onset);
LGG	cis	rs7659604	0.521	rs4240263	chr4:122683623	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.34	0.32	9.5e-13	Type 2 diabetes;
LGG	cis	rs959260	0.623	rs4542691	chr17:73326965	T/C	cg14668889	chr17:73230827	NUP85	-0.51	-8.68	-0.37	6.89e-17	Systemic lupus erythematosus;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.57	-0.53	1.46e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9733	0.566	rs11204675	chr1:150570985	A/C	cg13175981	chr1:150552382	MCL1	0.59	10.18	0.43	4.32e-22	Tonsillectomy;
LGG	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg03538708	chr1:25844672	NA	-0.37	-7.11	-0.31	4.55e-12	Erythrocyte sedimentation rate;
LGG	cis	rs7223966	0.921	rs67018565	chr17:61928055	C/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.28	0.32	1.45e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.9	-17.64	-0.63	1.24e-53	Response to antipsychotic treatment;
LGG	cis	rs9527	0.615	rs11191489	chr10:104740568	C/A	cg05308233	chr10:104796373	CNNM2	-0.31	-6.79	-0.3	3.51e-11	Arsenic metabolism;
LGG	cis	rs11764590	0.724	rs55789728	chr7:2107649	A/G	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.42	-0.36	4.78e-16	Neuroticism;
LGG	cis	rs68170813	0.559	rs17349904	chr7:106897237	A/C	cg02696742	chr7:106810147	HBP1	-0.72	-10.26	-0.43	2.09e-22	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs4821016	chr22:32402598	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs6993813	0.843	rs1485310	chr8:120051656	A/T	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.75	0.3	4.38e-11	Bone mineral density (hip);
LGG	cis	rs36071027	0.554	rs34366240	chr5:158425013	C/A	cg23468002	chr5:158532401	NA	0.44	7.43	0.33	5.33e-13	Carotid intima media thickness;
LGG	cis	rs56283067	0.847	rs62435998	chr6:44695206	C/T	cg20913747	chr6:44695427	NA	-0.68	-12.03	-0.49	3.52e-29	Total body bone mineral density;
LGG	cis	rs9467711	0.538	rs35934643	chr6:26355094	G/A	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs765787	0.530	rs3759893	chr15:45542950	G/T	cg24006582	chr15:45444508	DUOX1	-0.67	-12.77	-0.51	3.18e-32	Uric acid levels;
LGG	cis	rs10769945	0.538	rs739906	chr11:1980568	T/C	cg23202291	chr11:1979235	NA	-0.42	-8.3	-0.36	1.11e-15	DNA methylation (variation);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00914033	chr10:81664698	NA	0.41	7.03	0.31	7.4e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1865760	0.534	rs2032444	chr6:26046744	T/G	cg18357526	chr6:26021779	HIST1H4A	0.46	6.69	0.3	6.46e-11	Height;
LGG	cis	rs11599315	0.507	rs12220555	chr10:1341858	C/T	cg01270228	chr10:1369114	ADARB2	0.52	9.48	0.4	1.28e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2916247	1.000	rs2028652	chr8:92990029	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.28	-0.36	1.29e-15	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg15704280	chr7:45808275	SEPT13	-0.85	-16.88	-0.62	3.73e-50	Height;
LGG	cis	rs17270561	0.609	rs7770037	chr6:25760591	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	cis	rs35306767	0.903	rs7067865	chr10:908387	C/T	cg20503657	chr10:835505	NA	0.75	10.23	0.43	2.85e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08125972	chr19:36705377	ZNF565;ZNF146	0.42	6.84	0.3	2.44e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs73191547	1.000	rs73191547	chr8:10033425	A/T	cg06636001	chr8:8085503	FLJ10661	0.44	7.63	0.33	1.32e-13	Schizophrenia;
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs62400317	0.859	rs11967630	chr6:45128524	G/C	cg20913747	chr6:44695427	NA	-0.62	-10.37	-0.43	8.65e-23	Total body bone mineral density;
LGG	cis	rs2228479	0.867	rs2270459	chr16:89979851	A/C	cg26513180	chr16:89883248	FANCA	-0.78	-8.57	-0.37	1.55e-16	Skin colour saturation;
LGG	cis	rs1843834	1.000	rs1565072	chr2:225545245	C/T	cg22455342	chr2:225449267	CUL3	-0.59	-10.08	-0.42	9.98e-22	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.49	0.37	2.92e-16	Prudent dietary pattern;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg06028808	chr11:68637592	NA	0.73	12.34	0.5	1.95e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs765787	0.530	rs4775822	chr15:45527127	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	8.03e-13	Uric acid levels;
LGG	cis	rs6500602	0.592	rs7206782	chr16:4515145	A/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	9.91	0.42	3.86e-21	Schizophrenia;
LGG	cis	rs1008375	0.966	rs2872957	chr4:17651757	C/A	cg02297831	chr4:17616191	MED28	0.5	9.53	0.4	9.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs783540	1.000	rs11631963	chr15:83318202	T/C	cg16105309	chr15:79090380	ADAMTS7	-0.41	-7.23	-0.32	2.01e-12	Schizophrenia;
LGG	trans	rs3808502	0.549	rs1382563	chr8:11426790	C/G	cg06636001	chr8:8085503	FLJ10661	0.58	10.86	0.45	1.24e-24	Neuroticism;
LGG	cis	rs9389248	0.737	rs56358308	chr6:135306980	A/T	cg24558204	chr6:135376177	HBS1L	0.62	10.67	0.44	6.74e-24	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9399135	0.967	rs6925424	chr6:135313948	T/A	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.97e-20	Red blood cell count;
LGG	cis	rs1843834	0.505	rs4674911	chr2:225345254	A/G	cg12698349	chr2:225449008	CUL3	0.69	11.6	0.47	1.79e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs4555082	1.000	rs7149013	chr14:105759840	T/C	cg13114125	chr14:105738426	BRF1	-0.85	-16.66	-0.61	3.61e-49	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7191700	0.578	rs243327	chr16:11353304	C/T	cg00044050	chr16:11439710	C16orf75	-0.57	-9.69	-0.41	2.34e-20	Multiple sclerosis;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7481584	0.624	rs412842	chr11:3047448	A/G	cg08508325	chr11:3079039	CARS	0.43	8.34	0.36	8.56e-16	Calcium levels;
LGG	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs12282928	1.000	rs12282928	chr11:48332028	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.24	0.32	1.91e-12	Migraine - clinic-based;
LGG	cis	rs17253792	0.822	rs17253744	chr14:56161950	C/G	cg01858014	chr14:56050164	KTN1	-0.9	-11.24	-0.46	4.49e-26	Putamen volume;
LGG	cis	rs7084402	0.967	rs1626532	chr10:60294685	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg24375607	chr4:120327624	NA	0.68	11.22	0.46	5.27e-26	Corneal astigmatism;
LGG	trans	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg18335740	chr13:41363409	SLC25A15	-0.6	-11.73	-0.48	5.16e-28	Lewy body disease;
LGG	cis	rs4319547	1.000	rs6489071	chr12:123025576	C/G	cg05707623	chr12:122985044	ZCCHC8	-0.63	-9.54	-0.41	8.12e-20	Body mass index;
LGG	cis	rs11874712	1.000	rs1800636	chr18:43670420	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs9420907	0.579	rs11597399	chr10:105649752	C/T	cg11005552	chr10:105648138	OBFC1	-0.68	-6.66	-0.3	7.99e-11	Telomere length;
LGG	cis	rs1697139	0.935	rs1625369	chr5:66513022	C/T	cg11553311	chr5:66541588	NA	0.42	9.36	0.4	3.4e-19	Breast cancer;
LGG	cis	rs910316	0.763	rs175047	chr14:75479039	C/G	cg08847533	chr14:75593920	NEK9	-0.55	-10.1	-0.42	8.46e-22	Height;
LGG	cis	rs6952808	0.789	rs35729895	chr7:1885069	C/T	cg10360139	chr7:1886902	MAD1L1	-0.43	-7.76	-0.34	5.66e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs57590327	0.555	rs6767749	chr3:81725513	G/A	cg07356753	chr3:81810745	GBE1	-0.52	-8.31	-0.36	1.04e-15	Extraversion;
LGG	trans	rs7824557	0.564	rs2572395	chr8:11235360	A/C	cg02002194	chr4:3960332	NA	0.44	7.95	0.35	1.46e-14	Retinal vascular caliber;
LGG	cis	rs5769765	1.000	rs2092982	chr22:50282204	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	0.77	11.38	0.47	1.26e-26	Schizophrenia;
LGG	cis	rs9814567	1.000	rs2177601	chr3:134245434	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg21998325	chr6:47277820	TNFRSF21	-0.48	-7.43	-0.33	5.36e-13	Alzheimer's disease (survival time);
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg19774624	chr17:42201019	HDAC5	-0.93	-19.92	-0.68	3.07e-64	Total body bone mineral density;
LGG	cis	rs7444	0.941	rs4821130	chr22:21980894	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-6.67	-0.3	7.45e-11	Systemic lupus erythematosus;
LGG	trans	rs9388451	0.626	rs1935983	chr6:126068914	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.62	-11.57	-0.47	2.36e-27	Brugada syndrome;
LGG	cis	rs6963495	0.818	rs118134111	chr7:105161229	A/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg22705602	chr4:152727874	NA	-0.31	-7.33	-0.32	1.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg24803719	chr17:45855879	NA	-0.29	-8.18	-0.36	2.68e-15	IgG glycosylation;
LGG	cis	rs72781680	1.000	rs72781653	chr2:24215633	T/C	cg08917208	chr2:24149416	ATAD2B	0.78	8.83	0.38	2.24e-17	Lymphocyte counts;
LGG	cis	rs7762018	1.000	rs74900588	chr6:170102180	A/C	cg19338460	chr6:170058176	WDR27	-0.6	-8.16	-0.35	3.29e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg07677032	chr17:61819896	STRADA	0.67	12.62	0.51	1.43e-31	Prudent dietary pattern;
LGG	cis	rs12618769	0.652	rs3769701	chr2:99195111	A/C	cg18455616	chr2:99124870	INPP4A	0.27	7.6	0.33	1.63e-13	Bipolar disorder;
LGG	cis	rs2075371	0.933	rs1421482	chr7:133964383	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.76	0.45	3e-24	Mean platelet volume;
LGG	cis	rs8072100	0.651	rs1912484	chr17:45443664	C/G	cg08085267	chr17:45401833	C17orf57	-0.54	-9.91	-0.42	3.92e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs3749237	0.557	rs7631908	chr3:49425707	T/G	cg07636037	chr3:49044803	WDR6	0.6	10.46	0.44	3.81e-23	Resting heart rate;
LGG	cis	rs7582180	0.585	rs12999151	chr2:100939333	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-10.62	-0.44	9.68e-24	Intelligence (multi-trait analysis);
LGG	cis	rs67311347	1.000	rs7642552	chr3:40424816	T/C	cg13683864	chr3:40499215	RPL14	-1.1	-24.26	-0.75	1.69e-84	Renal cell carcinoma;
LGG	cis	rs916888	0.821	rs199512	chr17:44857352	T/C	cg20120463	chr17:44301886	NA	0.45	7.02	0.31	7.92e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1046896	1.000	rs9909940	chr17:80689036	C/T	cg02711726	chr17:80685570	FN3KRP	-0.65	-13.36	-0.53	1.18e-34	Glycated hemoglobin levels;
LGG	cis	rs2084898	1.000	rs56391092	chr11:120010550	C/T	cg07435449	chr11:120005650	TRIM29	-0.68	-7.74	-0.34	6.2e-14	Stroke (pediatric);
LGG	cis	rs75920871	0.528	rs983567	chr11:116783600	T/C	cg20608306	chr11:116969690	SIK3	-0.4	-10.37	-0.43	8.27e-23	Subjective well-being;
LGG	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg18196295	chr10:418757	DIP2C	-0.55	-10.2	-0.43	3.5e-22	Psychosis in Alzheimer's disease;
LGG	cis	rs6502050	0.605	rs35158616	chr17:80094480	A/G	cg11859384	chr17:80120422	CCDC57	-0.46	-7.87	-0.34	2.62e-14	Life satisfaction;
LGG	cis	rs4936894	0.500	rs10893164	chr11:124076981	C/T	cg27160556	chr11:124181099	OR8D1	0.45	10.29	0.43	1.68e-22	Aging (time to death);
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg24250549	chr1:154909240	PMVK	0.65	11.74	0.48	4.72e-28	Prostate cancer;
LGG	cis	rs734999	0.545	rs4474198	chr1:2553758	C/T	cg15627072	chr1:2432621	PLCH2	0.32	7.5	0.33	3.27e-13	Ulcerative colitis;
LGG	cis	rs6502050	0.835	rs34199331	chr17:80134487	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.33	-0.36	9.01e-16	Life satisfaction;
LGG	trans	rs7824557	0.751	rs2099456	chr8:11127001	A/C	cg16141378	chr3:129829833	LOC729375	-0.39	-8.91	-0.38	1.14e-17	Retinal vascular caliber;
LGG	trans	rs6956675	1.000	rs6956675	chr7:62577770	A/G	cg01314568	chr7:57830625	NA	-0.49	-7.9	-0.34	2.06e-14	Obesity-related traits;
LGG	cis	rs1005277	0.522	rs1208767	chr10:38042295	G/T	cg25427524	chr10:38739819	LOC399744	-0.67	-13.56	-0.53	1.72e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs7107174	0.901	rs4945275	chr11:78119822	G/A	cg02023728	chr11:77925099	USP35	0.44	7.93	0.35	1.66e-14	Testicular germ cell tumor;
LGG	cis	rs798554	0.642	rs2533871	chr7:2883006	C/G	cg04166393	chr7:2884313	GNA12	0.47	9.02	0.39	4.84e-18	Height;
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.92e-14	Bipolar disorder;
LGG	cis	rs657075	0.697	rs3805666	chr5:131646475	G/A	cg14196790	chr5:131705035	SLC22A5	0.62	7.85	0.34	2.87e-14	Rheumatoid arthritis;
LGG	cis	rs28655083	0.956	rs7184167	chr16:77069451	T/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.51	-8.1	-0.35	4.96e-15	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs300703	0.872	rs300752	chr2:209292	A/G	cg24565620	chr2:194026	NA	-0.72	-9.87	-0.42	5.59e-21	Blood protein levels;
LGG	cis	rs1799949	0.931	rs34474989	chr17:41445410	A/T	cg01879757	chr17:41196368	BRCA1	-0.41	-8.34	-0.36	8.44e-16	Menopause (age at onset);
LGG	cis	rs4888262	0.526	rs13330282	chr16:74572373	C/T	cg01733217	chr16:74700730	RFWD3	0.82	16.35	0.6	9.59e-48	Testicular germ cell tumor;
LGG	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg01221209	chr5:554886	NA	-0.51	-7.58	-0.33	1.95e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs11711311	0.955	rs10934247	chr3:113534941	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.96	0.52	5.54e-33	IgG glycosylation;
LGG	cis	rs77972916	0.517	rs17406126	chr2:43546632	A/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-7.12	-0.31	4.26e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9815354	1.000	rs6790732	chr3:41864872	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.63e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9443645	0.901	rs1572584	chr6:79690290	A/G	cg18132916	chr6:79620363	NA	0.32	8.78	0.38	3.19e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.647	rs3747600	chr16:4586222	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.33	6.95	0.31	1.24e-11	Schizophrenia;
LGG	cis	rs1018836	0.923	rs34126139	chr8:91572045	T/G	cg16814680	chr8:91681699	NA	-0.82	-15.09	-0.57	3.73e-42	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.659	rs73178626	chr22:41928371	T/G	cg03806693	chr22:41940476	POLR3H	-1.14	-20.86	-0.7	1.26e-68	Vitiligo;
LGG	cis	rs11214589	1.000	rs11214589	chr11:113245048	C/T	cg14159747	chr11:113255604	NA	0.28	7.66	0.34	1.1e-13	Neuroticism;
LGG	cis	rs4671458	0.846	rs12472865	chr2:63771769	C/T	cg17519650	chr2:63277830	OTX1	-0.56	-7.25	-0.32	1.82e-12	Subjective well-being;
LGG	trans	rs7395662	1.000	rs12421159	chr11:48624841	C/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.39e-15	HDL cholesterol;
LGG	cis	rs9849248	0.627	rs9826925	chr3:88206392	G/T	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	trans	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.89	-0.45	1e-24	Neuroticism;
LGG	cis	rs12447804	0.504	rs12447035	chr16:58101942	C/A	cg03859792	chr16:58121049	NA	0.55	8.36	0.36	7.37e-16	Pulmonary function;Pulmonary function (smoking interaction);
LGG	trans	rs3780486	1.000	rs10813951	chr9:33128021	C/T	cg04842962	chr6:43655489	MRPS18A	-1.0	-16.96	-0.62	1.59e-50	IgG glycosylation;
LGG	cis	rs7044106	0.791	rs747819	chr9:123488441	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.71	12.89	0.51	1.07e-32	Hip circumference adjusted for BMI;
LGG	cis	rs77956314	0.515	rs9804817	chr12:117440220	G/A	cg02017074	chr12:117425053	FBXW8	-0.55	-7.62	-0.33	1.41e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg06719900	chr11:109292894	C11orf87	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg16434002	chr17:42200994	HDAC5	-0.52	-9.09	-0.39	2.8e-18	Total body bone mineral density;
LGG	cis	rs6952808	0.531	rs3778991	chr7:2172455	G/A	cg19147804	chr7:1989927	MAD1L1	-0.51	-10.08	-0.42	9.9e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs12476592	0.602	rs7608470	chr2:63691478	T/C	cg17519650	chr2:63277830	OTX1	-0.46	-7.11	-0.31	4.35e-12	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13383153	chr19:36980459	ZNF566	0.4	6.67	0.3	7.31e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7727544	0.582	rs116749111	chr5:131462918	G/T	cg07395648	chr5:131743802	NA	-0.4	-8.6	-0.37	1.21e-16	Blood metabolite levels;
LGG	cis	rs9611565	0.918	rs73176685	chr22:41781094	C/G	cg03806693	chr22:41940476	POLR3H	-0.9	-15.82	-0.59	2.2e-45	Vitiligo;
LGG	cis	rs7843479	0.601	rs2306645	chr8:21845428	C/T	cg17168535	chr8:21777572	XPO7	-0.79	-15.27	-0.58	6.07e-43	Mean corpuscular volume;
LGG	cis	rs2070997	0.756	rs3824400	chr9:133734075	A/G	cg03924115	chr9:133768966	QRFP	-0.4	-6.68	-0.3	6.78e-11	Response to amphetamines;
LGG	cis	rs651907	0.640	rs771573	chr3:101620896	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	8.62	0.37	1.07e-16	Colorectal cancer;
LGG	cis	rs6840360	0.901	rs1561915	chr4:152479724	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.0	0.31	9.01e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg07701084	chr6:150067640	NUP43	0.69	13.29	0.53	2.25e-34	Lung cancer;
LGG	trans	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg09048205	chr5:1608656	LOC728613	-0.51	-8.29	-0.36	1.22e-15	Breast cancer;
LGG	cis	rs7666738	0.830	rs11725095	chr4:99009711	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2228479	0.867	rs11645970	chr16:89958118	G/A	cg00800038	chr16:89945340	TCF25	-0.72	-9.46	-0.4	1.58e-19	Skin colour saturation;
LGG	cis	rs7481584	0.581	rs105686	chr11:3062467	G/A	cg25174290	chr11:3078921	CARS	-0.53	-9.79	-0.41	1.06e-20	Calcium levels;
LGG	cis	rs2072732	0.861	rs6692292	chr1:2959610	C/T	cg08733933	chr1:2954429	NA	0.4	7.87	0.34	2.55e-14	Plateletcrit;
LGG	cis	rs9467160	0.532	rs2744565	chr6:24458461	G/T	cg20631270	chr6:24437470	GPLD1	-0.45	-7.45	-0.33	4.65e-13	Liver enzyme levels;
LGG	cis	rs758324	0.947	rs1500114	chr5:131138120	C/A	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1865760	0.688	rs1436310	chr6:25969958	G/C	cg12310025	chr6:25882481	NA	-0.41	-7.31	-0.32	1.2e-12	Height;
LGG	cis	rs9916302	0.560	rs907094	chr17:37790371	G/A	cg07936489	chr17:37558343	FBXL20	-0.75	-11.6	-0.47	1.69e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs6933660	0.683	rs6916340	chr6:151779064	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.63	11.22	0.46	5.07e-26	Menarche (age at onset);
LGG	cis	rs6668534	1.000	rs6668534	chr1:161671995	C/T	cg01550473	chr1:161493932	HSPA6	0.52	7.25	0.32	1.73e-12	Blood protein levels;
LGG	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg14829155	chr15:31115871	NA	0.53	8.11	0.35	4.53e-15	Huntington's disease progression;
LGG	cis	rs7681440	0.728	rs1812923	chr4:90739539	C/A	cg26578617	chr4:90757533	SNCA	-0.35	-6.9	-0.31	1.69e-11	Dementia with Lewy bodies;
LGG	cis	rs796364	1.000	rs4410273	chr2:200818258	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	11.11	0.46	1.36e-25	Schizophrenia;
LGG	cis	rs8054556	0.647	rs11863174	chr16:30019375	A/C	cg06326092	chr16:30034487	C16orf92	0.35	7.06	0.31	6.32e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs77633900	0.614	rs2468123	chr15:76931345	T/C	cg21673338	chr15:77095150	SCAPER	-0.65	-10.1	-0.43	7.96e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs2267681	0.583	rs10253277	chr7:139525978	A/G	cg14116596	chr7:139528673	TBXAS1	0.32	7.15	0.32	3.33e-12	Cervical cancer;
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.74	0.66	1.01e-58	Menopause (age at onset);
LGG	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg00204512	chr16:28754710	NA	-0.26	-6.75	-0.3	4.49e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg21948465	chr5:131705150	SLC22A5	0.65	7.17	0.32	2.94e-12	Rheumatoid arthritis;
LGG	cis	rs9300255	0.568	rs1047158	chr12:123644056	C/A	cg05973401	chr12:123451056	ABCB9	0.5	7.66	0.34	1.08e-13	Neutrophil percentage of white cells;
LGG	cis	rs11098499	0.570	rs6832740	chr4:120546136	T/C	cg24375607	chr4:120327624	NA	0.6	10.26	0.43	2.18e-22	Corneal astigmatism;
LGG	cis	rs2978098	1	rs2978098	chr8:101676675	A/C	cg06874326	chr8:101662790	SNX31	-0.37	-7.3	-0.32	1.29e-12	Diastolic blood pressure;
LGG	cis	rs910316	0.763	rs1548807	chr14:75479582	T/G	cg06637938	chr14:75390232	RPS6KL1	0.51	9.08	0.39	3.14e-18	Height;
LGG	cis	rs60695258	0.550	rs2007132	chr4:87972585	G/T	cg11209507	chr4:87813803	C4orf36	0.46	7.89	0.34	2.27e-14	Hematocrit;
LGG	cis	rs2228479	0.850	rs11645916	chr16:89835234	G/A	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	cis	rs7666738	0.830	rs9996098	chr4:98867740	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs116047800	chr4:119773569	G/T	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs12410462	0.681	rs114950580	chr1:227673334	G/C	cg04117972	chr1:227635322	NA	0.86	12.55	0.5	2.58e-31	Major depressive disorder;
LGG	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg06532163	chr17:45867833	NA	0.56	9.26	0.4	7.4e-19	IgG glycosylation;
LGG	trans	rs3857536	0.740	rs7751095	chr6:66891318	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs72945132	0.882	rs67529561	chr11:70162055	G/T	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs1497828	0.956	rs2810774	chr1:217540771	A/G	cg04411442	chr1:217543379	NA	-0.49	-8.23	-0.36	1.87e-15	Dialysis-related mortality;
LGG	cis	rs6952808	0.858	rs4721134	chr7:1912057	G/A	cg11050988	chr7:1952600	MAD1L1	-0.37	-8.56	-0.37	1.67e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs1555322	0.530	rs8122819	chr20:33881586	C/T	cg03689076	chr20:33865952	NA	0.57	7.85	0.34	2.85e-14	Attention deficit hyperactivity disorder;
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.06	-0.49	2.52e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.583	rs6601585	chr8:11233659	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.25	-0.36	1.62e-15	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs57590327	0.503	rs2049415	chr3:81901887	A/T	cg07356753	chr3:81810745	GBE1	-0.46	-7.35	-0.32	8.91e-13	Extraversion;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs994014	0.572	rs1377059	chr4:82272961	A/G	cg07938847	chr4:82126349	PRKG2	-0.28	-6.69	-0.3	6.53e-11	Height;
LGG	cis	rs6089584	0.888	rs6061405	chr20:60617033	A/G	cg06470251	chr20:60548479	NA	0.5	8.37	0.36	7.05e-16	Body mass index;
LGG	cis	rs2688608	0.620	rs7076525	chr10:75512797	C/T	cg23231163	chr10:75533350	FUT11	-0.44	-7.44	-0.33	4.81e-13	Inflammatory bowel disease;
LGG	cis	rs9291683	0.609	rs12507050	chr4:10007305	G/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.46	-0.37	3.52e-16	Bone mineral density;
LGG	cis	rs28735056	0.592	rs12455965	chr18:77688830	G/C	cg20368463	chr18:77673604	PQLC1	-0.62	-11.97	-0.49	5.88e-29	Schizophrenia;
LGG	cis	rs7824557	0.614	rs2293860	chr8:11219386	G/T	cg21775007	chr8:11205619	TDH	0.78	13.66	0.54	6.38e-36	Retinal vascular caliber;
LGG	cis	rs17818399	0.684	rs62134759	chr2:46791849	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.5	7.53	0.33	2.75e-13	Height;
LGG	cis	rs7811142	0.943	rs67483801	chr7:100031758	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs9768139	0.935	rs116290351	chr7:158119712	T/A	cg06219351	chr7:158114137	PTPRN2	0.69	13.63	0.54	8.44e-36	Calcium levels;
LGG	cis	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.48	-0.5	5.34e-31	Bladder cancer;
LGG	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg00490583	chr16:1843685	IGFALS	0.52	9.01	0.39	5.4e-18	Insulin-like growth factors;
LGG	cis	rs9902453	0.845	rs72823935	chr17:28008595	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.92	0.54	4.87e-37	Coffee consumption (cups per day);
LGG	cis	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg21775007	chr8:11205619	TDH	-0.53	-8.37	-0.36	7.12e-16	Neuroticism;
LGG	trans	rs7939886	0.920	rs74699881	chr11:55913852	A/T	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs11690935	0.632	rs62183783	chr2:172865775	A/G	cg13550731	chr2:172543902	DYNC1I2	0.66	12.64	0.51	1.15e-31	Schizophrenia;
LGG	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11764359	chr7:65958608	NA	0.56	9.43	0.4	1.91e-19	Aortic root size;
LGG	cis	rs7923837	0.687	rs11187139	chr10:94466427	T/C	cg25093409	chr10:94429542	NA	0.53	10.5	0.44	2.9e-23	Body mass index;Multiple sclerosis;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.66	-0.34	1.11e-13	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22580087	chr19:12273955	ZNF136	0.48	7.28	0.32	1.49e-12	Gut microbiome composition (summer);
LGG	cis	rs4077515	0.901	rs3812573	chr9:139276680	C/T	cg21253087	chr9:139290292	SNAPC4	0.35	7.07	0.31	5.75e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17376456	0.809	rs13177800	chr5:93307350	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.27	0.4	6.96e-19	Diabetic retinopathy;
LGG	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg00334542	chr7:100209784	MOSPD3	-0.53	-7.32	-0.32	1.13e-12	Other erythrocyte phenotypes;
LGG	cis	rs75920871	0.925	rs17120241	chr11:116915020	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.52e-12	Subjective well-being;
LGG	cis	rs7249142	0.527	rs12975096	chr19:19279409	G/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.12	-0.46	1.29e-25	IgG glycosylation;
LGG	cis	rs1799949	1.000	rs11653460	chr17:41331306	C/T	cg05368731	chr17:41323189	NBR1	0.96	19.1	0.66	2.23e-60	Menopause (age at onset);
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg22105103	chr4:187893119	NA	-0.57	-10.6	-0.44	1.24e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13065560	0.594	rs7633981	chr3:38889901	A/C	cg01426195	chr3:39028469	NA	-0.46	-9.53	-0.41	8.78e-20	Interleukin-18 levels;
LGG	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg13385521	chr17:29058706	SUZ12P	0.9	10.18	0.43	4.36e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	0.793	rs4457308	chr8:143733922	G/A	cg24634471	chr8:143751801	JRK	0.5	7.68	0.34	9.55e-14	Schizophrenia;
LGG	cis	rs7312933	0.703	rs10880268	chr12:42599122	C/T	cg19980929	chr12:42632907	YAF2	0.38	8.56	0.37	1.72e-16	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6138458	1.000	rs227651	chr20:24929834	A/G	cg26195577	chr20:24973756	C20orf3	1.24	25.95	0.77	2.62e-92	Blood protein levels;
LGG	cis	rs13108904	0.870	rs1960426	chr4:1274365	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.74	0.64	4.4e-54	Obesity-related traits;
LGG	trans	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg02002194	chr4:3960332	NA	0.4	7.14	0.31	3.58e-12	Joint mobility (Beighton score);
LGG	cis	rs7267979	1.000	rs2387881	chr20:25378172	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.82e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4974559	0.790	rs28712208	chr4:1316695	A/T	cg02980000	chr4:1222292	CTBP1	0.66	8.96	0.38	7.9e-18	Systolic blood pressure;
LGG	cis	rs17227506	0.535	rs13275339	chr8:13411455	T/G	cg03566418	chr8:13424080	C8orf48	0.56	8.53	0.37	2.11e-16	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6500395	0.962	rs13331902	chr16:48644989	A/G	cg16662043	chr16:48846231	NA	0.39	7.62	0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs73787773	0.867	rs58079319	chr5:111472395	G/A	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.58	-7.44	-0.33	4.83e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg06634786	chr22:41940651	POLR3H	0.72	11.98	0.49	5.46e-29	Vitiligo;
LGG	cis	rs10936602	0.520	rs28525288	chr3:169554872	A/G	cg08193579	chr3:169529701	LRRC34	0.39	7.77	0.34	5.25e-14	Renal cell carcinoma;
LGG	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11785400	1.000	rs3802232	chr8:143746701	A/G	cg24634471	chr8:143751801	JRK	0.53	8.46	0.37	3.55e-16	Schizophrenia;
LGG	trans	rs7923837	0.687	rs10882102	chr10:94466495	G/C	cg27639046	chr2:171608303	NA	-0.35	-6.79	-0.3	3.39e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs457717	0.730	rs465988	chr5:75943918	G/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.16e-11	Hearing impairment;
LGG	cis	rs490234	0.783	rs28729336	chr9:128405488	T/G	cg14078157	chr9:128172775	NA	-0.49	-9.08	-0.39	3.14e-18	Mean arterial pressure;
LGG	cis	rs6121246	0.609	rs6060983	chr20:30420924	T/C	cg13852791	chr20:30311386	BCL2L1	0.93	17.78	0.64	2.69e-54	Mean corpuscular hemoglobin;
LGG	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg25801113	chr15:45476975	SHF	0.87	19.15	0.66	1.2e-60	Uric acid levels;
LGG	trans	rs9914544	0.545	rs12942794	chr17:18767217	A/C	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.53	-0.33	2.7e-13	Educational attainment (years of education);
LGG	cis	rs2032447	0.901	rs2213284	chr6:26031868	G/A	cg03517284	chr6:25882590	NA	-0.64	-12.09	-0.49	1.95e-29	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg17202724	chr17:61916730	SMARCD2	-0.63	-15.64	-0.59	1.44e-44	Prudent dietary pattern;
LGG	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg26655873	chr3:72818019	SHQ1	0.36	7.06	0.31	5.99e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1497406	0.744	rs6677710	chr1:16507618	A/G	cg20430773	chr1:16534157	ARHGEF19	0.3	8.89	0.38	1.35e-17	Gamma gluatamyl transferase levels;Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs988958	0.565	rs10166263	chr2:42235265	C/T	cg19376973	chr2:42229025	NA	0.62	9.12	0.39	2.31e-18	Hypospadias;
LGG	cis	rs9325144	0.555	rs4882359	chr12:38726679	T/C	cg26384229	chr12:38710491	ALG10B	0.75	14.97	0.57	1.35e-41	Morning vs. evening chronotype;
LGG	cis	rs10752881	0.935	rs10911235	chr1:183053746	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs1519814	1.000	rs10087151	chr8:121172261	C/T	cg22335954	chr8:121166405	COL14A1	-0.56	-11.59	-0.47	1.89e-27	Breast cancer;
LGG	cis	rs2153535	0.580	rs6597332	chr6:8504748	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs737008	0.922	rs2070923	chr16:11369855	G/T	cg00044050	chr16:11439710	C16orf75	0.45	6.75	0.3	4.49e-11	Obesity-related traits;
LGG	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg16325326	chr1:53192061	ZYG11B	-0.62	-12.61	-0.51	1.58e-31	Monocyte count;
LGG	cis	rs10214930	0.697	rs12700819	chr7:27599890	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.67	0.3	7.23e-11	Hypospadias;
LGG	cis	rs17102423	0.594	rs2781374	chr14:65568563	C/T	cg16583315	chr14:65563665	MAX	-0.43	-8.56	-0.37	1.67e-16	Obesity-related traits;
LGG	cis	rs9399135	0.935	rs4445070	chr6:135309212	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.47	0.4	1.42e-19	Red blood cell count;
LGG	cis	rs7824557	0.505	rs2572440	chr8:11249010	G/T	cg21775007	chr8:11205619	TDH	0.75	12.64	0.51	1.19e-31	Retinal vascular caliber;
LGG	cis	rs2290159	0.800	rs56363132	chr3:12680403	T/C	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg02524346	chr8:600233	NA	1.14	11.39	0.47	1.12e-26	IgG glycosylation;
LGG	cis	rs798554	0.731	rs2283779	chr7:2815140	G/A	cg18446336	chr7:2847575	GNA12	-0.31	-8.36	-0.36	7.22e-16	Height;
LGG	cis	rs739401	0.611	rs450817	chr11:3056712	A/G	cg25174290	chr11:3078921	CARS	0.74	15.78	0.59	3.22e-45	Longevity;
LGG	cis	rs1401999	1.000	rs939337	chr3:183701147	G/C	cg05044414	chr3:183734942	ABCC5	0.78	17.09	0.62	4.17e-51	Anterior chamber depth;
LGG	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.98	0.49	5.59e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11583043	0.918	rs6675403	chr1:101418569	T/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	8.71	0.38	5.36e-17	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7928758	0.943	rs878987	chr11:134266372	A/G	cg25213107	chr11:134282864	B3GAT1	1.1	13.85	0.54	9.51e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6138458	1.000	rs1977540	chr20:24900290	G/T	cg26195577	chr20:24973756	C20orf3	-1.22	-25.52	-0.76	2.39e-90	Blood protein levels;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.723	rs11766575	chr7:2005747	T/C	cg04565464	chr8:145669602	NFKBIL2	0.39	6.66	0.3	7.64e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9790314	0.875	rs163327	chr3:161062724	A/G	cg04691961	chr3:161091175	C3orf57	-0.57	-13.44	-0.53	5.24e-35	Morning vs. evening chronotype;
LGG	cis	rs1021993	0.545	rs77070927	chr1:209530305	C/T	cg24446417	chr1:209558027	NA	-0.71	-10.3	-0.43	1.57e-22	Gut microbiome composition (winter);
LGG	cis	rs721399	0.539	rs10103029	chr8:18267338	A/G	cg18736775	chr8:18248649	NAT2	-0.76	-11.7	-0.48	7.03e-28	Blood metabolite levels;
LGG	cis	rs4950322	0.570	rs66580541	chr1:146780541	T/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20551965	chr2:70520865	SNRPG	0.46	6.66	0.3	7.64e-11	Gut microbiome composition (summer);
LGG	cis	rs4819388	0.751	rs2838531	chr21:45638586	C/T	cg01992765	chr21:45622493	NA	0.48	9.06	0.39	3.6e-18	Celiac disease;
LGG	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	cg15522984	chr1:182991683	LAMC1	0.44	8.76	0.38	3.79e-17	Colorectal cancer;
LGG	cis	rs17767392	0.670	rs72726701	chr14:71728329	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.36	-8.28	-0.36	1.32e-15	Mitral valve prolapse;
LGG	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg26897989	chr16:1907736	C16orf73	0.5	9.41	0.4	2.33e-19	Insulin-like growth factors;
LGG	trans	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg02002194	chr4:3960332	NA	0.38	7.13	0.31	3.95e-12	Joint mobility (Beighton score);
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-7.81	-0.34	3.98e-14	IgG glycosylation;
LGG	cis	rs798554	0.796	rs2533884	chr7:2836848	T/G	cg14668632	chr7:2872130	GNA12	-0.35	-7.15	-0.32	3.48e-12	Height;
LGG	cis	rs754466	0.651	rs11813532	chr10:79637991	T/C	cg17075019	chr10:79541650	NA	-0.95	-20.33	-0.69	3.88e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg04568710	chr12:38710424	ALG10B	0.33	6.75	0.3	4.34e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9300255	0.596	rs10773002	chr12:123746961	A/T	cg05973401	chr12:123451056	ABCB9	-0.51	-8.16	-0.35	3.1e-15	Neutrophil percentage of white cells;
LGG	cis	rs1865760	0.566	rs9379821	chr6:26054268	A/C	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs12701220	0.604	rs34904312	chr7:1135883	G/A	cg26769984	chr7:1090371	C7orf50	0.43	7.62	0.33	1.43e-13	Bronchopulmonary dysplasia;
LGG	cis	rs9300255	0.507	rs1727302	chr12:123632930	G/A	cg05973401	chr12:123451056	ABCB9	0.5	8.13	0.35	4.09e-15	Neutrophil percentage of white cells;
LGG	cis	rs73591976	0.539	rs12446198	chr16:68125972	G/A	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.74	-0.3	4.77e-11	HDL cholesterol;
LGG	cis	rs708547	0.533	rs3806746	chr4:57773330	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.45	-7.43	-0.33	5.45e-13	Response to bleomycin (chromatid breaks);
LGG	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg08508325	chr11:3079039	CARS	-0.61	-13.35	-0.53	1.29e-34	Longevity;
LGG	cis	rs2228479	0.541	rs13335395	chr16:89952843	T/A	cg27400746	chr16:89904261	SPIRE2	-0.79	-12.8	-0.51	2.56e-32	Skin colour saturation;
LGG	cis	rs2013441	1.000	rs2703791	chr17:20163529	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs644799	0.526	rs542509	chr11:95641602	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.64	12.26	0.49	4.1e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs13066757	chr3:10045030	C/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.07	17.7	0.64	6.66e-54	Alzheimer's disease;
LGG	cis	rs7717393	0.786	rs72798934	chr5:155795332	A/C	cg04435420	chr5:155754009	SGCD	0.71	9.15	0.39	1.83e-18	Egg allergy;
LGG	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg08807101	chr21:30365312	RNF160	-0.6	-8.09	-0.35	5.32e-15	Cognitive test performance;
LGG	trans	rs2243480	0.901	rs2949697	chr7:65464236	A/G	cg10756647	chr7:56101905	PSPH	0.82	9.73	0.41	1.7e-20	Diabetic kidney disease;
LGG	cis	rs7582180	0.590	rs11123828	chr2:100960918	T/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.46	-0.47	6.26e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1927790	0.727	rs1010345	chr13:96968023	A/G	cg02571835	chr13:96230311	CLDN10	-0.35	-7.12	-0.31	4.11e-12	Body mass index;
LGG	cis	rs7647973	1.000	rs8897	chr3:49460407	A/G	cg06212747	chr3:49208901	KLHDC8B	0.5	7.88	0.34	2.42e-14	Menarche (age at onset);
LGG	cis	rs370915	0.542	rs7687552	chr4:187837862	G/C	cg19519643	chr4:187840862	NA	-0.64	-13.18	-0.52	6.62e-34	Gout;
LGG	trans	rs1032833	0.732	rs17363393	chr2:180006052	C/T	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg02733842	chr7:1102375	C7orf50	0.73	10.87	0.45	1.14e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs698833	0.819	rs2340810	chr2:44536546	C/T	cg00619915	chr2:44497795	NA	0.46	6.99	0.31	9.6e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg16524936	chr4:1340807	KIAA1530	-0.46	-7.21	-0.32	2.28e-12	Obesity-related traits;
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.38	-0.36	6.62e-16	Aortic root size;
LGG	cis	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg00405596	chr8:11794950	NA	0.45	7.5	0.33	3.21e-13	Monocyte count;
LGG	cis	rs9322193	0.962	rs4869730	chr6:150129323	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.8	0.3	3.3e-11	Lung cancer;
LGG	cis	rs7428	0.527	rs4832164	chr2:85546932	A/C	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.89	-0.54	6.44e-37	Ear protrusion;
LGG	cis	rs910316	0.967	rs11159121	chr14:75666029	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.11	-0.39	2.51e-18	Height;
LGG	cis	rs9457247	1.000	rs400837	chr6:167411008	T/C	cg07741184	chr6:167504864	NA	0.33	7.34	0.32	9.94e-13	Crohn's disease;
LGG	cis	rs7133214	0.771	rs10842977	chr12:27925443	A/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.9	-0.31	1.72e-11	Gut microbiota (functional units);
LGG	cis	rs2204008	0.654	rs1290325	chr12:38152910	C/T	cg04568710	chr12:38710424	ALG10B	-0.38	-8.16	-0.35	3.22e-15	Bladder cancer;
LGG	cis	rs644799	0.965	rs3016295	chr11:95554311	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9479482	0.967	rs13209192	chr6:150350099	A/G	cg06889755	chr6:150326021	RAET1K	-0.35	-7.09	-0.31	5.11e-12	Alopecia areata;
LGG	cis	rs921968	0.643	rs711191	chr2:219386084	T/A	cg02985541	chr2:219472218	PLCD4	0.29	6.84	0.3	2.54e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01843367	chr3:155589075	GMPS	0.42	7.14	0.31	3.74e-12	Menarche (age at onset);
LGG	trans	rs11098499	0.663	rs28369503	chr4:120238925	G/A	cg25214090	chr10:38739885	LOC399744	0.6	10.97	0.45	4.62e-25	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs1060915	chr17:41234470	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.33	0.32	1.05e-12	Menopause (age at onset);
LGG	cis	rs1865760	0.534	rs1541988	chr6:25950804	C/A	cg16482183	chr6:26056742	HIST1H1C	0.42	7.27	0.32	1.58e-12	Height;
LGG	cis	rs12477438	0.501	rs7349217	chr2:99815146	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	31.94	0.83	3.86e-119	Chronic sinus infection;
LGG	cis	rs3762637	0.823	rs9849013	chr3:122250605	A/G	cg24169773	chr3:122142474	KPNA1	-0.63	-10.75	-0.45	3.25e-24	LDL cholesterol levels;
LGG	cis	rs34845616	0.520	rs1793680	chr11:133798762	C/T	cg06067394	chr11:133789110	IGSF9B	0.36	7.48	0.33	3.67e-13	Hand grip strength;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8063160	0.799	rs1805007	chr16:89986117	A/G	cg07984980	chr16:89898383	SPIRE2	-0.96	-8.91	-0.38	1.18e-17	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LGG	cis	rs10504229	0.815	rs75577263	chr8:58188434	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	0.967	rs10246036	chr7:91558523	G/A	cg17063962	chr7:91808500	NA	-0.49	-8.68	-0.37	6.57e-17	Breast cancer;
LGG	cis	rs13108904	0.901	rs7695691	chr4:1304632	A/G	cg05165339	chr4:1420672	NA	-0.26	-6.86	-0.3	2.22e-11	Obesity-related traits;
LGG	cis	rs2236918	0.710	rs1776130	chr1:242023362	A/G	cg17736920	chr1:242011382	EXO1	0.4	7.21	0.32	2.35e-12	Menopause (age at onset);
LGG	cis	rs2797160	1.000	rs2211418	chr6:125995503	G/A	cg05901451	chr6:126070800	HEY2	-0.47	-7.83	-0.34	3.47e-14	Endometrial cancer;
LGG	trans	rs3857536	0.813	rs1029399	chr6:66952476	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.84	-0.34	3.16e-14	Blood trace element (Cu levels);
LGG	cis	rs10504229	0.516	rs7821160	chr8:57986281	C/T	cg22535103	chr8:58192502	C8orf71	0.45	7.15	0.32	3.33e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.535	rs10005542	chr4:120268302	T/C	cg09307838	chr4:120376055	NA	0.67	11.56	0.47	2.39e-27	Corneal astigmatism;
LGG	cis	rs7949030	0.635	rs1801144	chr11:62381808	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.63	15.1	0.57	3.57e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	1.01e-25	Homoarginine levels;
LGG	cis	rs11966931	0.857	rs4391294	chr6:108090454	G/A	cg04749840	chr6:108095067	SCML4	-0.44	-7.46	-0.33	4.21e-13	Neutrophil percentage of white cells;
LGG	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg04398451	chr17:18023971	MYO15A	-0.74	-15.57	-0.59	2.98e-44	Total body bone mineral density;
LGG	cis	rs9902453	0.817	rs59420007	chr17:28196114	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.71e-36	Coffee consumption (cups per day);
LGG	cis	rs6961069	0.722	rs4626520	chr7:80260023	G/A	cg04458919	chr7:80252533	CD36	0.28	6.74	0.3	4.61e-11	Platelet count;
LGG	cis	rs3749237	0.595	rs1050088	chr3:49570882	C/T	cg07636037	chr3:49044803	WDR6	-0.6	-10.23	-0.43	2.85e-22	Resting heart rate;
LGG	cis	rs11252926	0.801	rs11252332	chr10:467318	A/T	cg18196295	chr10:418757	DIP2C	0.56	10.2	0.43	3.66e-22	Psychosis in Alzheimer's disease;
LGG	trans	rs7618501	0.633	rs3774733	chr3:50037123	C/G	cg21659725	chr3:3221576	CRBN	0.65	12.13	0.49	1.31e-29	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg12463550	chr7:65579703	CRCP	-0.49	-8.22	-0.36	2.11e-15	Aortic root size;
LGG	cis	rs72781680	1.000	rs55982282	chr2:24188128	G/A	cg08917208	chr2:24149416	ATAD2B	0.92	10.13	0.43	6.19e-22	Lymphocyte counts;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09825418	chr1:231377181	GNPAT;C1orf131	0.47	7.54	0.33	2.49e-13	Cognitive performance;
LGG	cis	rs4664308	0.691	rs1877196	chr2:160915150	G/T	cg03641300	chr2:160917029	PLA2R1	-0.8	-16.7	-0.61	2.4e-49	Idiopathic membranous nephropathy;
LGG	cis	rs3617	0.573	rs9810807	chr3:52924227	C/T	cg11645453	chr3:52864694	ITIH4	-0.46	-7.63	-0.33	1.34e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11785693	0.862	rs17435605	chr8:4987302	A/G	cg26367366	chr8:4980734	NA	0.95	15.37	0.58	2.38e-43	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs12464559	0.649	rs4450595	chr2:152622603	T/C	cg01189475	chr2:152685088	ARL5A	0.74	6.73	0.3	4.97e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs950776	0.518	rs952215	chr15:78819153	C/T	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.32	-0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs12476592	0.571	rs2028883	chr2:63804531	G/A	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs6088580	0.713	rs1884669	chr20:33171287	G/A	cg06115741	chr20:33292138	TP53INP2	0.52	8.67	0.37	7.51e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs12493885	0.818	rs61791545	chr3:153768888	G/A	cg17054900	chr3:154042577	DHX36	-0.75	-9.02	-0.39	5.08e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg26085966	chr14:64319812	SYNE2	0.58	6.75	0.3	4.37e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.524	rs13216484	chr6:26762087	C/T	cg06606381	chr12:133084897	FBRSL1	-1.0	-9.37	-0.4	3.28e-19	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27415969	chr3:186500848	EIF4A2	0.47	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs7207005	chr17:61860355	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs9560113	1.000	rs61967684	chr13:112178026	G/C	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg14979609	chr8:8086686	FLJ10661	-0.3	-6.99	-0.31	9.68e-12	Red cell distribution width;
LGG	cis	rs4443100	0.670	rs13056137	chr22:23407261	C/A	cg14186256	chr22:23484241	RTDR1	0.53	8.46	0.37	3.64e-16	Serum parathyroid hormone levels;
LGG	cis	rs4481887	1.000	rs4593862	chr1:248480176	G/T	cg13385794	chr1:248469461	NA	0.49	8.17	0.35	3.06e-15	Common traits (Other);
LGG	trans	rs9467711	0.659	rs3734542	chr6:26468326	G/A	cg01620082	chr3:125678407	NA	-0.75	-7.57	-0.33	2.05e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs951366	0.789	rs823130	chr1:205714372	C/T	cg24503407	chr1:205819492	PM20D1	0.82	19.68	0.67	4.4e-63	Menarche (age at onset);
LGG	cis	rs7027203	1.000	rs34624092	chr9:96523092	G/A	cg14598338	chr9:96623480	NA	0.48	8.22	0.36	2.12e-15	DNA methylation (variation);
LGG	cis	rs12210905	0.688	rs12205044	chr6:27478990	A/G	cg10122326	chr6:28072925	NA	0.93	7.1	0.31	4.69e-12	Hip circumference adjusted for BMI;
LGG	cis	rs4689592	0.503	rs4689064	chr4:7055603	A/G	cg26116260	chr4:7069785	GRPEL1	-1.05	-15.97	-0.6	4.56e-46	Monocyte percentage of white cells;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg02985366	chr16:32360428	NA	-0.46	-7.11	-0.31	4.44e-12	Menopause (age at onset);
LGG	cis	rs745570	1.000	rs745571	chr17:77781387	T/C	cg25456068	chr17:77800718	NA	-0.56	-12.23	-0.49	5.22e-30	Breast cancer;
LGG	cis	rs7666738	0.830	rs28810677	chr4:99043193	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg20368463	chr18:77673604	PQLC1	0.5	7.66	0.34	1.06e-13	Opioid sensitivity;
LGG	cis	rs910316	0.763	rs175016	chr14:75459633	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.26	-0.4	7.78e-19	Height;
LGG	trans	rs7824557	0.544	rs1865521	chr8:11231249	T/C	cg02002194	chr4:3960332	NA	-0.44	-8.03	-0.35	8.42e-15	Retinal vascular caliber;
LGG	cis	rs2204008	0.560	rs4129033	chr12:38301897	A/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.13	-0.39	2.1e-18	Bladder cancer;
LGG	cis	rs8060686	0.641	rs79375669	chr16:68099262	A/T	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2243480	1.000	rs160646	chr7:65556280	C/T	cg18252515	chr7:66147081	NA	-1.37	-20.13	-0.68	3.29e-65	Diabetic kidney disease;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg26513180	chr16:89883248	FANCA	0.85	8.08	0.35	5.54e-15	Skin colour saturation;
LGG	cis	rs988958	0.675	rs1866669	chr2:42221789	C/T	cg19376973	chr2:42229025	NA	0.62	9.7	0.41	2.19e-20	Hypospadias;
LGG	cis	rs9814567	0.727	rs7641798	chr3:134345719	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.94	-0.45	6.08e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs911119	1.000	rs6114208	chr20:23621734	C/G	cg16589663	chr20:23618590	CST3	0.47	6.69	0.3	6.29e-11	Chronic kidney disease;
LGG	cis	rs972578	1.000	rs5759075	chr22:43389090	G/C	cg01576275	chr22:43409880	NA	-0.23	-6.77	-0.3	3.86e-11	Mean platelet volume;
LGG	cis	rs12148488	0.966	rs1867149	chr15:75339993	C/T	cg14664628	chr15:75095509	CSK	0.47	8.92	0.38	1.1e-17	Caffeine consumption;
LGG	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	8.15	0.35	3.37e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6445975	0.617	rs6762478	chr3:58403811	A/G	cg24175188	chr3:58374923	PXK	-0.57	-9.32	-0.4	4.62e-19	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg14004847	chr7:1930337	MAD1L1	-0.45	-7.72	-0.34	7.13e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.58	-9.32	-0.4	4.84e-19	Blood metabolite levels;
LGG	cis	rs2587949	0.638	rs2248840	chr3:4230956	C/T	cg16519197	chr3:4211558	NA	-0.32	-6.75	-0.3	4.46e-11	Periodontitis (DPAL);
LGG	cis	rs834603	0.569	rs834602	chr7:47446215	A/C	cg23694490	chr7:47445681	TNS3	0.45	10.94	0.45	6.41e-25	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2797369	0.713	rs2813640	chr6:101572634	G/A	cg27451362	chr6:101846650	GRIK2	0.83	11.01	0.46	3.34e-25	Renal function-related traits (eGRFcrea);
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.11	0.49	1.58e-29	Prudent dietary pattern;
LGG	cis	rs6121246	0.559	rs6060933	chr20:30351903	C/T	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs74781061	0.860	rs4544202	chr15:74760995	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.0	-0.31	9.17e-12	Endometriosis;
LGG	cis	rs2797369	0.570	rs2149461	chr6:101588023	C/G	cg27451362	chr6:101846650	GRIK2	0.53	7.77	0.34	4.94e-14	Renal function-related traits (eGRFcrea);
LGG	trans	rs6956675	0.673	rs10234147	chr7:62556935	A/G	cg01314568	chr7:57830625	NA	-0.54	-7.77	-0.34	5.09e-14	Obesity-related traits;
LGG	trans	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg11693508	chr17:37793320	STARD3	0.63	9.4	0.4	2.54e-19	Bipolar disorder;
LGG	trans	rs10506458	0.915	rs79133015	chr12:63396838	G/A	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9644630	0.696	rs13261824	chr8:19313912	C/G	cg01280390	chr8:19363452	CSGALNACT1	0.49	12.63	0.51	1.2e-31	Oropharynx cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23166955	chr16:30077191	ALDOA	0.42	6.93	0.31	1.4e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7766436	0.541	rs34278238	chr6:22482395	G/C	cg13666174	chr6:22585274	NA	-0.4	-7.95	-0.35	1.45e-14	Coronary artery disease;
LGG	cis	rs7267979	1.000	rs6083828	chr20:25369918	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.61e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg06470251	chr20:60548479	NA	0.41	7.03	0.31	7.52e-12	Body mass index;
LGG	cis	rs9910055	0.762	rs1135215	chr17:42253519	T/C	cg13607699	chr17:42295918	UBTF	0.64	10.95	0.45	5.69e-25	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs58371676	chr8:58189382	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.747	rs2905981	chr17:42238625	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	0.5	9.05	0.39	3.92e-18	Total body bone mineral density;
LGG	cis	rs2273669	0.667	rs12214567	chr6:109317330	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-8.5	-0.37	2.6e-16	Prostate cancer;
LGG	trans	rs208520	0.661	rs704519	chr6:66801136	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.61	-0.65	4.05e-58	Exhaled nitric oxide output;
LGG	cis	rs953492	0.672	rs10926964	chr1:243359347	G/A	cg02356786	chr1:243265016	LOC731275	-0.38	-6.74	-0.3	4.75e-11	Diastolic blood pressure;
LGG	cis	rs1372520	0.684	rs1837891	chr4:90736131	C/G	cg15133208	chr4:90757351	SNCA	0.4	8.2	0.36	2.32e-15	Neuroticism;
LGG	cis	rs9926296	0.744	rs164747	chr16:89708680	T/G	cg08949735	chr16:89699720	DPEP1	-0.48	-9.98	-0.42	2.23e-21	Vitiligo;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.31	-0.63	4.08e-52	Skin colour saturation;
LGG	cis	rs12618769	0.652	rs7588254	chr2:99217785	G/T	cg18455616	chr2:99124870	INPP4A	0.27	7.73	0.34	6.8e-14	Bipolar disorder;
LGG	cis	rs11671005	0.735	rs3826684	chr19:58918705	T/C	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.77	-0.3	3.88e-11	Mean platelet volume;
LGG	cis	rs1185460	0.967	rs11217133	chr11:118928249	G/A	cg23280166	chr11:118938394	VPS11	0.57	10.03	0.42	1.49e-21	Coronary artery disease;
LGG	cis	rs308971	0.656	rs307558	chr3:12095130	G/A	cg15873301	chr3:12045459	SYN2	0.54	7.82	0.34	3.51e-14	Fasting blood insulin (BMI interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26912984	chr6:111408745	SLC16A10	0.46	7.17	0.32	2.91e-12	Gut microbiome composition (summer);
LGG	cis	rs3849570	1.000	rs11711331	chr3:81819040	A/G	cg07356753	chr3:81810745	GBE1	0.47	7.73	0.34	6.88e-14	Waist circumference;Body mass index;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02735204	chr10:71871463	H2AFY2	0.33	7.31	0.32	1.17e-12	Menarche (age at onset);
LGG	trans	rs73198271	0.729	rs66564323	chr8:8604996	G/A	cg16141378	chr3:129829833	LOC729375	0.38	6.72	0.3	5.48e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs8038465	0.592	rs1542580	chr15:73935834	C/G	cg15420318	chr15:73925796	NPTN	0.5	8.56	0.37	1.7e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg26396452	chr14:65542826	MAX	0.49	10.23	0.43	2.75e-22	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.2	-0.43	3.65e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	0.832	rs66597916	chr3:10195407	T/C	cg13047869	chr3:10149882	C3orf24	0.49	7.69	0.34	9.19e-14	Alzheimer's disease;
LGG	cis	rs4132509	0.744	rs10927068	chr1:243923452	C/T	cg21452805	chr1:244014465	NA	0.94	10.42	0.44	5.52e-23	RR interval (heart rate);
LGG	cis	rs8077889	0.871	rs9893111	chr17:41915767	G/A	cg26893861	chr17:41843967	DUSP3	0.88	14.04	0.55	1.51e-37	Triglycerides;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.92e-21	Lung cancer;
LGG	cis	rs9467773	0.565	rs6925047	chr6:26521435	C/G	cg09904177	chr6:26538194	HMGN4	0.59	11.7	0.48	6.86e-28	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.16e-31	Prudent dietary pattern;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07791516	chr6:150247246	NA	0.31	6.79	0.3	3.55e-11	Testicular germ cell tumor;
LGG	cis	rs6665290	0.835	rs7549465	chr1:227214399	A/C	cg10327440	chr1:227177885	CDC42BPA	-1.25	-38.75	-0.87	2.11e-147	Myeloid white cell count;
LGG	cis	rs7582180	0.764	rs11693424	chr2:100925439	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-15.54	-0.59	3.83e-44	Intelligence (multi-trait analysis);
LGG	cis	rs3820068	0.608	rs9660255	chr1:16031891	T/G	cg05660106	chr1:15850417	CASP9	0.76	14.24	0.55	1.98e-38	Systolic blood pressure;
LGG	cis	rs11122272	0.701	rs7414807	chr1:231476874	G/A	cg10503236	chr1:231470652	EXOC8	-0.36	-6.99	-0.31	9.63e-12	Hemoglobin concentration;
LGG	cis	rs9393692	0.905	rs7747133	chr6:26293470	C/T	cg16885296	chr6:26284938	NA	0.39	8.45	0.37	3.86e-16	Educational attainment;
LGG	cis	rs4917300	0.686	rs7824432	chr8:143104367	T/G	cg06573787	chr8:143070187	NA	0.59	9.91	0.42	3.88e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs9596863	0.898	rs9568901	chr13:54321748	A/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.19	0.32	2.55e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs10504229	1.000	rs57261109	chr8:58172152	C/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs694739	1.000	rs694739	chr11:64097233	A/G	cg02228329	chr11:64053129	BAD;GPR137	0.81	16.11	0.6	1.07e-46	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg00292662	chr22:38071168	LGALS1	0.89	24.24	0.75	2.1e-84	Fat distribution (HIV);
LGG	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg22920501	chr2:26401640	FAM59B	0.46	9.18	0.39	1.44e-18	Gut microbiome composition (summer);
LGG	cis	rs7662987	0.540	rs2851278	chr4:100021253	G/C	cg13256891	chr4:100009986	ADH5	0.56	9.57	0.41	6.31e-20	Smoking initiation;
LGG	cis	rs16854884	1.000	rs34730687	chr3:143813193	A/G	cg06585982	chr3:143692056	C3orf58	0.52	7.69	0.34	8.71e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs4731207	0.698	rs10233306	chr7:124498417	G/C	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.892	rs11776549	chr8:22493124	C/T	cg19455335	chr8:22457658	C8orf58	-0.39	-7.34	-0.32	9.77e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs6933660	0.646	rs6915598	chr6:151778664	T/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.71	-11.03	-0.46	2.86e-25	Menarche (age at onset);
LGG	cis	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg06521331	chr12:34319734	NA	-0.55	-9.45	-0.4	1.75e-19	Morning vs. evening chronotype;
LGG	cis	rs6564851	0.545	rs12149068	chr16:81252903	T/G	cg00163702	chr16:81254719	PKD1L2	0.36	8.4	0.36	5.42e-16	Carotenoid and tocopherol levels;
LGG	trans	rs6787172	0.622	rs12107104	chr3:158126327	G/T	cg23275840	chr4:47708675	CORIN	0.36	7.53	0.33	2.73e-13	Subjective well-being;
LGG	cis	rs7412746	0.634	rs12409208	chr1:150860055	A/G	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.57e-13	Melanoma;
LGG	trans	rs12579753	0.879	rs7958566	chr12:82131478	A/T	cg07923666	chr12:49932857	KCNH3	-0.5	-7.86	-0.34	2.74e-14	Resting heart rate;
LGG	cis	rs9534288	0.659	rs9534314	chr13:46654844	A/G	cg15192986	chr13:46630673	CPB2	-0.69	-14.29	-0.55	1.19e-38	Blood protein levels;
LGG	cis	rs6540556	0.723	rs3765240	chr1:209918151	G/A	cg23920097	chr1:209922102	NA	-0.49	-8.68	-0.37	6.78e-17	Red blood cell count;
LGG	cis	rs7202877	0.706	rs247423	chr16:75456631	C/A	cg03315344	chr16:75512273	CHST6	-0.53	-7.14	-0.31	3.73e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs77372450	0.636	rs10052322	chr5:157014420	C/A	cg25387487	chr5:157003181	ADAM19	-0.54	-6.68	-0.3	6.85e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs988958	0.567	rs11884781	chr2:42221093	C/T	cg19376973	chr2:42229025	NA	-0.61	-9.69	-0.41	2.36e-20	Hypospadias;
LGG	cis	rs9910055	0.821	rs4473241	chr17:42281282	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	0.62	10.89	0.45	9.67e-25	Total body bone mineral density;
LGG	cis	rs9322193	0.607	rs4869755	chr6:150207483	G/A	cg09699651	chr6:150184138	LRP11	0.46	6.92	0.31	1.54e-11	Lung cancer;
LGG	cis	rs1799949	0.965	rs4793230	chr17:41427403	A/C	cg25072359	chr17:41440525	NA	0.51	10.1	0.42	8.29e-22	Menopause (age at onset);
LGG	cis	rs1784581	0.588	rs7752870	chr6:162422510	T/C	cg17173639	chr6:162384350	PARK2	0.64	13.5	0.53	2.92e-35	Itch intensity from mosquito bite;
LGG	cis	rs2470578	0.792	rs2733520	chr3:17246392	C/T	cg20981856	chr3:17787350	NA	0.36	7.0	0.31	9.1e-12	Schizophrenia;
LGG	cis	rs698813	0.674	rs11678787	chr2:44496315	C/T	cg00619915	chr2:44497795	NA	-0.61	-8.65	-0.37	8.56e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2692947	0.770	rs12471925	chr2:96555522	C/A	cg22654517	chr2:96458247	NA	0.38	7.57	0.33	2.08e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10540	1.000	rs61876323	chr11:462855	G/A	cg19913688	chr11:428466	ANO9	-0.69	-8.65	-0.37	8.74e-17	Body mass index;
LGG	trans	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg27523141	chr10:43048294	ZNF37B	0.43	8.68	0.37	6.6e-17	Extrinsic epigenetic age acceleration;
LGG	cis	rs6032067	0.852	rs17424613	chr20:43806441	C/T	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs6993813	0.814	rs4577982	chr8:120029337	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.83	0.3	2.62e-11	Bone mineral density (hip);
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.07e-17	Prudent dietary pattern;
LGG	cis	rs9291683	0.632	rs10939669	chr4:10045827	A/G	cg08250081	chr4:10125330	NA	0.41	8.08	0.35	5.63e-15	Bone mineral density;
LGG	cis	rs1129187	0.755	rs9471985	chr6:42941324	T/C	cg05552183	chr6:42928497	GNMT	0.43	13.04	0.52	2.46e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7011049	1.000	rs6988927	chr8:53837496	T/C	cg26025543	chr8:53854495	NA	0.75	9.94	0.42	3.08e-21	Systolic blood pressure;
LGG	cis	rs3820068	0.553	rs7545782	chr1:15955227	G/C	cg05660106	chr1:15850417	CASP9	0.85	17.25	0.63	7.5e-52	Systolic blood pressure;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00879163	chr7:66386079	C7orf42	-0.42	-8.06	-0.35	6.33e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs11875185	0.510	rs76507172	chr18:55619569	C/A	cg15513957	chr14:69354734	ACTN1	-0.89	-9.04	-0.39	4.15e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg07157834	chr1:205819609	PM20D1	0.42	7.18	0.32	2.74e-12	Prostate-specific antigen levels;
LGG	cis	rs4665809	0.877	rs35224700	chr2:26298037	T/C	cg26119090	chr2:26468346	HADHA;HADHB	0.88	13.34	0.53	1.37e-34	Gut microbiome composition (summer);
LGG	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.15	0.32	3.4e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs59918340	0.764	rs2304282	chr8:142229543	A/G	cg23750338	chr8:142222470	SLC45A4	0.59	12.06	0.49	2.59e-29	Immature fraction of reticulocytes;
LGG	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg09696939	chr10:60272079	BICC1	-0.35	-6.93	-0.31	1.39e-11	Refractive error;
LGG	cis	rs6817170	0.577	rs7688335	chr4:154386317	C/T	cg24020152	chr4:154419554	KIAA0922	0.35	7.6	0.33	1.67e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg14993813	chr1:46806288	NSUN4	0.54	9.07	0.39	3.29e-18	Menopause (age at onset);
LGG	cis	rs6908034	0.607	rs12525152	chr6:19809424	A/T	cg02682789	chr6:19804855	NA	0.9	8.44	0.37	4.02e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs644799	0.687	rs11021318	chr11:95522996	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.8	0.64	2.2e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg24319613	chr5:133340577	VDAC1	-0.46	-6.66	-0.3	7.75e-11	Beard thickness;
LGG	cis	rs4481887	0.927	rs6666903	chr1:248465582	T/A	cg01631408	chr1:248437212	OR2T33	-0.5	-9.08	-0.39	3.06e-18	Common traits (Other);
LGG	cis	rs7737355	0.853	rs26005	chr5:130988029	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	2.98e-19	Life satisfaction;
LGG	cis	rs6750047	0.771	rs2855658	chr2:38296890	T/C	cg07380506	chr2:38303506	CYP1B1	0.45	7.93	0.35	1.72e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg21963583	chr11:68658836	MRPL21	0.61	10.54	0.44	1.91e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7582720	1.000	rs72932793	chr2:203701004	T/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2587949	0.550	rs1825509	chr3:4207147	C/T	cg16519197	chr3:4211558	NA	-0.32	-6.68	-0.3	6.84e-11	Periodontitis (DPAL);
LGG	cis	rs6912958	0.712	rs2246113	chr6:88410050	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.26	-0.36	1.52e-15	Monocyte percentage of white cells;
LGG	trans	rs7395662	0.667	rs2865612	chr11:48780222	A/C	cg03929089	chr4:120376271	NA	0.44	7.11	0.31	4.35e-12	HDL cholesterol;
LGG	cis	rs7618501	0.633	rs7621026	chr3:49975334	A/G	cg24110177	chr3:50126178	RBM5	-0.57	-10.44	-0.44	4.54e-23	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.761	rs12770910	chr10:1050318	A/G	cg20503657	chr10:835505	NA	0.54	7.08	0.31	5.29e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs72615157	0.612	rs7786505	chr7:99817585	G/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.65	-9.45	-0.4	1.69e-19	Lung function (FEV1/FVC);
LGG	cis	rs10504229	0.593	rs75047131	chr8:58001320	A/G	cg05313129	chr8:58192883	C8orf71	-0.59	-7.4	-0.33	6.56e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs10949662	1.000	rs10949662	chr7:157534105	A/G	cg15733309	chr7:157513707	PTPRN2	-0.63	-14.33	-0.55	8.13e-39	Intelligence (multi-trait analysis);
LGG	cis	rs2721195	0.549	rs2620666	chr8:145703413	T/C	cg26752003	chr8:145688521	CYHR1	-0.56	-11.97	-0.49	5.68e-29	Age at first birth;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg11062466	chr8:58055876	NA	-0.53	-8.59	-0.37	1.38e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7107174	1.000	rs2510043	chr11:77977481	C/G	cg27205649	chr11:78285834	NARS2	-0.44	-7.28	-0.32	1.41e-12	Testicular germ cell tumor;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg22398616	chr13:53314203	LECT1	-0.48	-9.85	-0.42	6.44e-21	Lewy body disease;
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs60871478	0.898	rs4725241	chr7:796883	C/T	cg22643751	chr7:855365	UNC84A	0.36	6.93	0.31	1.38e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg18404041	chr3:52824283	ITIH1	-0.41	-7.9	-0.34	2e-14	Bipolar disorder;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg14004847	chr7:1930337	MAD1L1	-0.56	-9.6	-0.41	4.95e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs3750965	0.920	rs4930644	chr11:68819097	C/T	cg23121140	chr11:68816938	TPCN2	0.38	7.39	0.32	7.11e-13	Hair color;
LGG	cis	rs9916302	0.851	rs11657899	chr17:37626963	G/A	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs9926296	0.548	rs12447465	chr16:89829895	C/T	cg26513180	chr16:89883248	FANCA	0.94	20.91	0.7	7.14e-69	Vitiligo;
LGG	cis	rs7737355	0.812	rs32106	chr5:131038940	A/G	cg06307176	chr5:131281290	NA	0.52	8.64	0.37	8.88e-17	Life satisfaction;
LGG	cis	rs4930103	0.904	rs4929984	chr11:2024683	A/C	cg18511798	chr11:2018149	H19;MIR675	0.71	14.18	0.55	3.78e-38	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7582720	1.000	rs72934767	chr2:203766563	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11148252	0.716	rs1887360	chr13:52779166	A/G	cg00495681	chr13:53174319	NA	0.44	7.13	0.31	3.85e-12	Lewy body disease;
LGG	cis	rs6579956	0.517	rs6579952	chr5:152024757	C/T	cg12297329	chr5:152029980	NA	0.52	9.53	0.41	8.79e-20	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs3785574	1.000	rs2955245	chr17:61979845	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-1.07	-21.26	-0.7	1.79e-70	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19236745	chr11:33182890	CSTF3	0.46	7.78	0.34	4.82e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs933688	0.502	rs4916858	chr5:90601290	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.48	-7.09	-0.31	5.13e-12	Smoking behavior;
LGG	cis	rs1129187	0.791	rs1129186	chr6:42932202	C/T	cg14338887	chr6:42928500	GNMT	0.27	8.76	0.38	3.85e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.06	-0.31	6.14e-12	Schizophrenia;
LGG	cis	rs283228	1.000	rs2629983	chr6:101800051	T/C	cg27451362	chr6:101846650	GRIK2	0.54	8.97	0.38	7.33e-18	Coenzyme Q10 levels;
LGG	cis	rs2228479	0.718	rs62054253	chr16:89896932	T/C	cg06558623	chr16:89946397	TCF25	1.16	12.7	0.51	6.62e-32	Skin colour saturation;
LGG	cis	rs2732480	0.517	rs2634676	chr12:48738236	A/G	cg24011408	chr12:48396354	COL2A1	0.49	7.73	0.34	6.82e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6951245	0.678	rs28600085	chr7:1169636	C/T	cg02733842	chr7:1102375	C7orf50	0.61	9.58	0.41	6.14e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2734839	0.896	rs11608109	chr11:113303448	G/C	cg14159747	chr11:113255604	NA	0.27	7.18	0.32	2.75e-12	Information processing speed;
LGG	cis	rs9796	0.727	rs61203391	chr15:41352912	C/G	cg18705301	chr15:41695430	NDUFAF1	-0.57	-9.31	-0.4	5.35e-19	Menopause (age at onset);
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs6692729	0.966	rs7547071	chr1:227014390	A/G	cg08708961	chr1:227070630	PSEN2	0.28	7.24	0.32	1.89e-12	Electrodermal activity;
LGG	cis	rs920590	0.643	rs2083640	chr8:19660212	T/C	cg03894339	chr8:19674705	INTS10	0.5	8.54	0.37	2.01e-16	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs9467711	0.606	rs9379859	chr6:26369549	C/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4363385	0.720	rs1134220	chr1:152976306	T/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.2	-0.39	1.27e-18	Inflammatory skin disease;
LGG	cis	rs3733585	0.781	rs13103690	chr4:9972778	T/G	cg25986240	chr4:9926439	SLC2A9	0.45	9.45	0.4	1.68e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9906944	0.707	rs729003	chr17:47117775	C/T	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs72945132	0.714	rs117232799	chr11:70157182	G/A	cg14088196	chr11:70211408	PPFIA1	0.96	13.09	0.52	1.51e-33	Coronary artery disease;
LGG	cis	rs7762018	0.769	rs74838157	chr6:170077323	G/A	cg17545662	chr6:170176663	C6orf70	0.66	7.4	0.33	6.41e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9329221	0.905	rs28712068	chr8:10251145	G/C	cg06636001	chr8:8085503	FLJ10661	-0.61	-11.62	-0.48	1.49e-27	Neuroticism;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.61	10.32	0.43	1.3e-22	Obesity-related traits;
LGG	cis	rs11771526	0.901	rs62457468	chr7:32301341	C/T	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg23625390	chr15:77176239	SCAPER	-0.73	-14.68	-0.56	2.36e-40	Blood metabolite levels;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.74	15.4	0.58	1.69e-43	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11368578	chr7:150754936	CDK5	0.47	7.87	0.34	2.46e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg24110177	chr3:50126178	RBM5	0.55	10.15	0.43	5.29e-22	Intelligence (multi-trait analysis);
LGG	trans	rs2243480	1.000	rs73142122	chr7:65311298	C/A	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs11167764	0.895	rs9324865	chr5:141488792	T/C	cg08523384	chr5:141488047	NDFIP1	-0.36	-6.88	-0.3	1.92e-11	Crohn's disease;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs7523273	0.526	rs2724375	chr1:207997973	C/A	cg22525895	chr1:207977042	MIR29B2	-0.6	-11.59	-0.47	1.92e-27	Schizophrenia;
LGG	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg15103426	chr22:29168792	CCDC117	0.73	11.9	0.48	1.08e-28	Lymphocyte counts;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.45	-0.4	1.75e-19	Personality dimensions;
LGG	cis	rs4006360	0.541	rs6503606	chr17:39309901	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.65	-14.7	-0.56	2.06e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg22974920	chr21:40686053	BRWD1	-0.42	-6.68	-0.3	7.04e-11	Cognitive function;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg07576142	chr13:93879769	GPC6	0.45	6.85	0.3	2.4e-11	Emphysema imaging phenotypes;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11072373	chr4:100485070	RG9MTD2;MTTP	0.4	6.86	0.3	2.21e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1534166	0.647	rs9853615	chr3:133519981	C/T	cg08048268	chr3:133502702	NA	-0.37	-6.72	-0.3	5.36e-11	Alcohol consumption (transferrin glycosylation);
LGG	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg24375607	chr4:120327624	NA	0.61	10.15	0.43	5.3e-22	Corneal astigmatism;
LGG	cis	rs798554	0.757	rs960273	chr7:2857876	T/C	cg18446336	chr7:2847575	GNA12	-0.28	-6.72	-0.3	5.21e-11	Height;
LGG	cis	rs1003719	0.788	rs7276917	chr21:38451334	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.54	0.63	3.59e-53	Eye color traits;
LGG	cis	rs4423214	1.000	rs7935125	chr11:71184190	C/A	cg05163923	chr11:71159392	DHCR7	0.71	13.83	0.54	1.18e-36	Vitamin D levels;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.62	0.41	4.32e-20	Prudent dietary pattern;
LGG	cis	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg24189917	chr7:1970923	MAD1L1	-0.46	-6.96	-0.31	1.18e-11	Bipolar disorder;
LGG	cis	rs3858526	0.834	rs7125255	chr11:5980384	T/A	cg13902645	chr11:5959945	NA	-0.66	-10.3	-0.43	1.49e-22	DNA methylation (variation);
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg04025307	chr7:1156635	C7orf50	0.67	8.55	0.37	1.78e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs561341	0.505	rs41291021	chr17:30410689	C/A	cg00745463	chr17:30367425	LRRC37B	-0.73	-8.37	-0.36	6.88e-16	Hip circumference adjusted for BMI;
LGG	cis	rs6500395	0.925	rs9933148	chr16:48672099	C/T	cg04672837	chr16:48644449	N4BP1	0.53	8.77	0.38	3.33e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs644799	0.710	rs666398	chr11:95551136	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.62	0.59	1.74e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14650559	chr14:77843620	C14orf174;TMED8	0.4	6.68	0.3	7.03e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1927790	0.759	rs7982697	chr13:96988839	A/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.85	-0.3	2.32e-11	Body mass index;
LGG	trans	rs11098499	0.754	rs4443261	chr4:120249301	T/C	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs6688613	0.649	rs2294195	chr1:166838281	T/C	ch.1.3259774R	chr1:166827647	TADA1	0.56	8.2	0.36	2.36e-15	Refractive astigmatism;
LGG	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs9951602	0.512	rs4798995	chr18:76654344	T/G	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00007032	chr13:30002629	MTUS2	0.55	8.68	0.37	6.74e-17	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs10911239	chr1:183062450	T/C	cg07928641	chr1:182991847	LAMC1	0.47	9.4	0.4	2.55e-19	Fuchs's corneal dystrophy;
LGG	cis	rs1153858	1.000	rs7169818	chr15:45640191	G/A	cg21132104	chr15:45694354	SPATA5L1	0.7	10.49	0.44	3.08e-23	Homoarginine levels;
LGG	cis	rs4820539	0.966	rs2157709	chr22:23457420	T/C	cg14186256	chr22:23484241	RTDR1	0.98	24.69	0.75	1.66e-86	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19990402	chr19:37019372	ZNF260	0.46	6.97	0.31	1.11e-11	Gut microbiome composition (summer);
LGG	cis	rs11123610	0.520	rs35482526	chr2:3720707	C/G	cg26344334	chr2:3718215	ALLC	-0.48	-8.16	-0.35	3.17e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs736408	0.562	rs12497998	chr3:52793602	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.41	0.4	2.42e-19	Bipolar disorder;
LGG	cis	rs7552167	0.925	rs3932664	chr1:24511663	G/T	cg01960748	chr1:24522592	NA	-0.5	-7.98	-0.35	1.15e-14	Psoriasis vulgaris;
LGG	cis	rs477692	0.699	rs509017	chr10:131367174	T/G	cg05714579	chr10:131428358	MGMT	0.47	9.11	0.39	2.53e-18	Response to temozolomide;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.55	9.67	0.41	2.79e-20	Longevity;
LGG	cis	rs9393692	0.676	rs1543681	chr6:26187783	G/T	cg16885296	chr6:26284938	NA	0.36	7.7	0.34	8.2e-14	Educational attainment;
LGG	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg11890956	chr21:40555474	PSMG1	1.14	26.36	0.77	3.2e-94	Cognitive function;
LGG	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg10587741	chr22:38071170	LGALS1	0.65	12.63	0.51	1.23e-31	Fat distribution (HIV);
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.41	-8.34	-0.36	8.64e-16	Schizophrenia;
LGG	cis	rs7681440	0.626	rs1372510	chr4:90817259	G/A	cg26578617	chr4:90757533	SNCA	-0.35	-6.89	-0.31	1.78e-11	Dementia with Lewy bodies;
LGG	cis	rs694739	0.894	rs887314	chr11:64053157	T/G	cg22916017	chr11:64110731	CCDC88B	0.5	10.07	0.42	1.08e-21	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs3824867	0.879	rs10742806	chr11:47456226	T/A	cg20307385	chr11:47447363	PSMC3	0.47	7.59	0.33	1.78e-13	Mean corpuscular hemoglobin;
LGG	cis	rs2439831	0.681	rs1095386	chr15:43609509	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	13.73	0.54	3.14e-36	Lung cancer in ever smokers;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.02	-0.46	3.07e-25	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg21775007	chr8:11205619	TDH	-0.57	-9.18	-0.39	1.47e-18	Retinal vascular caliber;
LGG	cis	rs17504614	0.591	rs72838712	chr2:51063289	C/G	cg23851515	chr2:51057218	NRXN1	0.48	7.82	0.34	3.71e-14	Educational attainment (years of education);
LGG	cis	rs283228	0.798	rs283220	chr6:101759549	C/A	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.38e-23	Coenzyme Q10 levels;
LGG	cis	rs7618915	0.571	rs11130307	chr3:52607682	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.66	0.37	7.7e-17	Bipolar disorder;
LGG	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg15556689	chr8:8085844	FLJ10661	0.48	8.19	0.36	2.55e-15	Neuroticism;
LGG	cis	rs7829975	0.684	rs474892	chr8:8596731	G/T	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.21	-0.36	2.19e-15	Mood instability;
LGG	cis	rs4727027	0.901	rs6943937	chr7:148869915	A/G	cg23583168	chr7:148888333	NA	-0.84	-16.18	-0.6	5.56e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7944584	0.511	rs10838725	chr11:47557871	T/C	cg20307385	chr11:47447363	PSMC3	0.87	18.64	0.65	2.84e-58	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1707322	0.721	rs10890343	chr1:46157922	C/T	cg03146154	chr1:46216737	IPP	0.55	10.75	0.45	3.23e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs752010	0.811	rs10749836	chr1:42086860	G/C	cg06885757	chr1:42089581	HIVEP3	0.52	11.36	0.47	1.55e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs9788333	0.788	rs35007728	chr13:21893221	G/C	cg00035636	chr13:21900591	NA	0.34	6.85	0.3	2.3e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs3942852	0.568	rs10769313	chr11:48097466	A/G	cg03929089	chr4:120376271	NA	-0.69	-10.81	-0.45	1.93e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs3858526	0.959	rs4758219	chr11:5951846	G/C	cg02574844	chr11:5959923	NA	-0.59	-9.07	-0.39	3.29e-18	DNA methylation (variation);
LGG	cis	rs2777491	0.707	rs1622914	chr15:41789212	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.87	-16.78	-0.62	1.01e-49	Ulcerative colitis;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.09	-0.31	5.07e-12	Menopause (age at onset);
LGG	cis	rs1010254	0.510	rs2348422	chr5:151759909	G/A	cg12297329	chr5:152029980	NA	-0.51	-7.25	-0.32	1.8e-12	Optic nerve measurement (cup area);
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.02	-0.31	8.18e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.550	rs4974617	chr4:1373658	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.55	0.41	7.5e-20	Longevity;
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg01262667	chr19:19385393	TM6SF2	0.44	11.3	0.46	2.54e-26	Tonsillectomy;
LGG	cis	rs7412746	0.658	rs11204739	chr1:150865760	A/G	cg15448220	chr1:150897856	SETDB1	0.4	7.28	0.32	1.4e-12	Melanoma;
LGG	cis	rs1915919	0.794	rs12488378	chr3:20022495	C/G	cg12877253	chr3:19992400	RAB5A	-0.32	-6.86	-0.3	2.16e-11	Post-traumatic stress disorder;
LGG	trans	rs853679	0.546	rs34295134	chr6:27828151	T/A	cg01620082	chr3:125678407	NA	-0.81	-9.0	-0.39	5.78e-18	Depression;
LGG	cis	rs7660883	0.860	rs236984	chr4:88008614	G/A	cg21988461	chr4:88008667	AFF1	-0.35	-9.9	-0.42	4.3e-21	HDL cholesterol levels;
LGG	cis	rs1129187	0.748	rs6458312	chr6:42904274	G/T	cg24101359	chr6:42928495	GNMT	0.44	11.6	0.47	1.74e-27	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs11640734	0.619	rs2293586	chr16:89962394	A/G	cg04013166	chr16:89971882	TCF25	0.52	6.98	0.31	1.01e-11	Interleukin-17 levels;
LGG	cis	rs9486719	1.000	rs11152968	chr6:96908653	A/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.61	0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs7647973	1.000	rs7613491	chr3:49508976	T/C	cg07636037	chr3:49044803	WDR6	-0.79	-13.88	-0.54	6.91e-37	Menarche (age at onset);
LGG	cis	rs6912958	0.712	rs7772561	chr6:88331299	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.71	-0.38	5.58e-17	Monocyte percentage of white cells;
LGG	cis	rs6121246	0.657	rs74392247	chr20:30241737	C/T	cg21427119	chr20:30132790	HM13	-0.48	-7.48	-0.33	3.89e-13	Mean corpuscular hemoglobin;
LGG	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.57	-0.44	1.48e-23	Chronic sinus infection;
LGG	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg06212747	chr3:49208901	KLHDC8B	0.43	7.0	0.31	8.76e-12	Resting heart rate;
LGG	cis	rs36051895	0.626	rs3780368	chr9:5093188	G/C	cg02405213	chr9:5042618	JAK2	-0.81	-15.11	-0.57	3.12e-42	Pediatric autoimmune diseases;
LGG	cis	rs3087591	0.853	rs2953003	chr17:29502731	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.51	0.56	1.36e-39	Hip circumference;
LGG	cis	rs2000999	0.573	rs34682685	chr16:72096227	G/A	cg04254540	chr16:71951199	KIAA0174	-0.63	-6.96	-0.31	1.17e-11	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs262150	0.659	rs2527236	chr7:158796644	C/T	cg09640425	chr7:158790006	NA	-0.4	-7.4	-0.33	6.56e-13	Facial morphology (factor 20);
LGG	cis	rs77633900	0.614	rs1443110	chr15:76928322	C/T	cg21673338	chr15:77095150	SCAPER	0.63	9.92	0.42	3.66e-21	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11605275	0.792	rs2568131	chr11:20046407	G/T	cg14835545	chr11:20032148	NAV2	0.62	8.67	0.37	7.19e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.683	rs16921843	chr8:58113338	T/C	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.514	rs10946805	chr6:26077891	C/T	cg17042849	chr6:26104293	HIST1H4C	-0.54	-6.96	-0.31	1.14e-11	Iron status biomarkers;
LGG	cis	rs10463554	0.892	rs13340345	chr5:102339222	T/A	cg23492399	chr5:102201601	PAM	-0.51	-7.62	-0.33	1.49e-13	Parkinson's disease;
LGG	cis	rs2204008	0.527	rs8189480	chr12:38345648	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.19	-0.43	4.04e-22	Bladder cancer;
LGG	trans	rs1814175	0.527	rs7110797	chr11:49644096	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.66	-11.39	-0.47	1.19e-26	Height;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.45	0.33	4.65e-13	Obesity-related traits;
LGG	cis	rs6429082	0.782	rs704705	chr1:235612320	C/T	cg26050004	chr1:235667680	B3GALNT2	-0.59	-9.63	-0.41	4.11e-20	Adiposity;
LGG	cis	rs9796	0.870	rs2925342	chr15:41305733	A/G	cg18705301	chr15:41695430	NDUFAF1	0.49	8.39	0.36	5.86e-16	Menopause (age at onset);
LGG	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg00012203	chr2:219082015	ARPC2	0.86	17.52	0.63	4.26e-53	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs62400317	0.859	rs12205523	chr6:45296618	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.51	-0.44	2.64e-23	Total body bone mineral density;
LGG	cis	rs2075671	0.857	rs11772849	chr7:100308412	G/A	cg00334542	chr7:100209784	MOSPD3	-0.53	-7.35	-0.32	9.19e-13	Other erythrocyte phenotypes;
LGG	cis	rs1153858	1.000	rs2453541	chr15:45645378	G/A	cg10760299	chr15:45669010	GATM	0.4	7.84	0.34	3.03e-14	Homoarginine levels;
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg19223190	chr17:80058835	NA	0.43	8.28	0.36	1.36e-15	Life satisfaction;
LGG	cis	rs2011503	0.943	rs79370636	chr19:19614289	G/A	cg11584989	chr19:19387371	SF4	0.73	12.0	0.49	4.32e-29	Bipolar disorder;
LGG	cis	rs9557207	1.000	rs9557189	chr13:99919880	A/G	cg24509225	chr13:100037070	UBAC2	0.68	12.22	0.49	5.9e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs12188164	0.931	rs115554641	chr5:443236	C/G	cg26076054	chr5:421317	AHRR	-0.46	-7.59	-0.33	1.82e-13	Cystic fibrosis severity;
LGG	cis	rs2243480	1.000	rs1723267	chr7:65473314	G/A	cg18252515	chr7:66147081	NA	-1.35	-19.0	-0.66	6.12e-60	Diabetic kidney disease;
LGG	cis	rs9596863	0.847	rs4537884	chr13:54327936	A/G	ch.13.53330881F	chr13:54432880	NA	0.54	7.3	0.32	1.26e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.12	12.36	0.5	1.55e-30	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7223966	1.000	rs78172786	chr17:61847114	A/C	cg18032289	chr17:61959525	GH2	-0.42	-7.13	-0.31	3.83e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7762018	1.000	rs17860606	chr6:170099561	G/A	cg06875740	chr19:51307921	C19orf48	-0.68	-8.57	-0.37	1.55e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7582180	0.629	rs4851294	chr2:100941109	C/T	cg08017756	chr2:100939284	LONRF2	-0.3	-7.1	-0.31	4.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs13409996	chr2:99575497	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.38	-0.63	1.88e-52	Chronic sinus infection;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.97	-0.35	1.27e-14	Prudent dietary pattern;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg08888203	chr3:10149979	C3orf24	0.52	8.85	0.38	1.87e-17	Alzheimer's disease;
LGG	cis	rs1005277	0.579	rs1780145	chr10:38537070	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.51e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg04149295	chr10:70884716	VPS26A	0.48	7.15	0.32	3.38e-12	Left atrial antero-posterior diameter;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13775091	chr7:158066145	PTPRN2	0.4	7.15	0.32	3.3e-12	Menarche (age at onset);
LGG	cis	rs2273669	0.667	rs4527738	chr6:109309150	T/C	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.12	-0.31	4.25e-12	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13616963	chr3:57583610	ARF4	0.41	6.82	0.3	2.77e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.62	0.44	9.9e-24	Personality dimensions;
LGG	cis	rs897984	0.762	rs12931046	chr16:30987144	G/A	cg02466173	chr16:30829666	NA	0.46	8.24	0.36	1.79e-15	Dementia with Lewy bodies;
LGG	cis	rs597539	0.652	rs564849	chr11:68621440	C/T	cg06028808	chr11:68637592	NA	0.71	11.82	0.48	2.43e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10991814	1.000	rs76226649	chr9:93964150	G/A	cg14446406	chr9:93919335	NA	-0.75	-8.29	-0.36	1.25e-15	Neutrophil percentage of granulocytes;
LGG	cis	rs9322193	0.923	rs4870529	chr6:150037572	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.11	0.6	1.11e-46	Lung cancer;
LGG	cis	rs7208859	0.623	rs9899692	chr17:29156939	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.05	-0.31	6.41e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11875185	0.588	rs74380043	chr18:55641589	C/T	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg17330251	chr7:94953956	PON1	0.6	14.55	0.56	8.83e-40	Paraoxonase activity;
LGG	trans	rs3942852	0.712	rs10742828	chr11:48104555	A/G	cg03929089	chr4:120376271	NA	-0.63	-8.82	-0.38	2.38e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6724607	1.000	rs6434402	chr2:191469322	C/T	cg11845111	chr2:191398756	TMEM194B	-0.35	-8.0	-0.35	1e-14	Pulse pressure;
LGG	cis	rs7572733	0.773	rs11690844	chr2:198515536	G/A	cg00792783	chr2:198669748	PLCL1	0.4	6.64	0.3	8.6e-11	Dermatomyositis;
LGG	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14019695	chr9:139328340	INPP5E	0.38	6.94	0.31	1.35e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08527566	chr12:95611432	FGD6;VEZT	0.47	7.48	0.33	3.7e-13	Cognitive performance;
LGG	cis	rs11155671	0.530	rs2342767	chr6:150209717	C/G	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs7572644	0.699	rs7577342	chr2:28205581	A/G	cg27432699	chr2:27873401	GPN1	0.44	6.73	0.3	5.13e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs3741404	0.791	rs11603192	chr11:63927695	A/G	cg18225595	chr11:63971243	STIP1	0.63	12.44	0.5	7.8e-31	Platelet count;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs7737355	0.898	rs2161414	chr5:131063073	C/T	cg06307176	chr5:131281290	NA	0.56	9.27	0.4	6.99e-19	Life satisfaction;
LGG	cis	rs7432375	0.641	rs1971397	chr3:136527300	C/G	cg21827317	chr3:136751795	NA	0.53	9.51	0.4	1.08e-19	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs4268898	0.697	rs6714652	chr2:24383059	C/T	cg06627628	chr2:24431161	ITSN2	0.47	7.6	0.33	1.66e-13	Asthma;
LGG	cis	rs6988985	0.678	rs4072020	chr8:143997415	T/C	cg10324643	chr8:143916377	GML	0.45	9.45	0.4	1.69e-19	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs7589342	0.628	rs10496403	chr2:106419622	T/G	cg16077055	chr2:106428750	NCK2	0.31	7.41	0.33	5.98e-13	Addiction;
LGG	cis	rs4731207	0.698	rs10227821	chr7:124449587	A/G	cg05630886	chr7:124431682	NA	0.33	7.71	0.34	7.56e-14	Cutaneous malignant melanoma;
LGG	cis	rs1865760	0.865	rs9467650	chr6:25958235	A/G	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.66e-13	Height;
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.86	-0.38	1.73e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6489785	0.710	rs3213566	chr12:121222578	T/C	cg02419362	chr12:121203948	SPPL3	0.58	9.95	0.42	2.99e-21	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs240764	0.687	rs7754085	chr6:101220806	T/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.53e-15	Neuroticism;
LGG	cis	rs7727544	0.617	rs3843503	chr5:131466629	T/A	cg07395648	chr5:131743802	NA	-0.44	-9.34	-0.4	3.96e-19	Blood metabolite levels;
LGG	trans	rs9650657	0.899	rs9650656	chr8:10607254	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.94	0.31	1.32e-11	Neuroticism;
LGG	trans	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.835	rs4789666	chr17:80162276	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.54	-0.33	2.49e-13	Life satisfaction;
LGG	cis	rs67311347	1.000	rs56303661	chr3:40520778	C/G	cg24209194	chr3:40518798	ZNF619	0.43	6.65	0.3	8.09e-11	Renal cell carcinoma;
LGG	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs6433857	0.657	rs2368177	chr2:181501242	T/C	cg23363182	chr2:181467187	NA	-0.36	-7.13	-0.31	3.94e-12	Body mass index;
LGG	cis	rs10463316	0.780	rs6894899	chr5:150775913	C/T	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.06	-0.42	1.13e-21	Metabolite levels (Pyroglutamine);
LGG	cis	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg27411982	chr8:10470053	RP1L1	0.41	6.93	0.31	1.4e-11	Neuroticism;
LGG	cis	rs2933343	0.649	rs789219	chr3:128592520	G/A	cg11901034	chr3:128598214	ACAD9	-0.45	-6.8	-0.3	3.21e-11	IgG glycosylation;
LGG	cis	rs11096990	0.577	rs6830736	chr4:39283087	A/G	cg24403649	chr4:39172243	NA	-0.4	-7.0	-0.31	8.83e-12	Cognitive function;
LGG	cis	rs2692947	0.832	rs62153679	chr2:96558400	C/T	cg22654517	chr2:96458247	NA	0.38	8.03	0.35	8.01e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs739401	0.611	rs572373	chr11:3055361	T/C	cg05729581	chr11:3078854	CARS	-0.54	-9.52	-0.4	9.68e-20	Longevity;
LGG	cis	rs8064024	0.680	rs1827983	chr16:4898517	G/C	cg04440724	chr16:4920505	UBN1	-0.56	-12.43	-0.5	8.51e-31	Cancer;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg01570551	chr7:23719851	C7orf46	-0.36	-7.83	-0.34	3.33e-14	Schizophrenia;
LGG	cis	rs17039065	1.000	rs11736209	chr4:109394658	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.81	0.3	3.12e-11	Gut microbiome composition (summer);
LGG	cis	rs883565	0.792	rs1274958	chr3:39184959	C/T	cg01426195	chr3:39028469	NA	0.61	10.67	0.44	6.71e-24	Handedness;
LGG	cis	rs727505	0.865	rs17325193	chr7:124648385	A/G	cg23710748	chr7:124431027	NA	-0.51	-9.49	-0.4	1.23e-19	Lewy body disease;
LGG	cis	rs6840360	0.571	rs4696100	chr4:152514242	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17826219	0.706	rs8075107	chr17:29106649	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs6429082	0.818	rs291386	chr1:235647050	C/T	cg26050004	chr1:235667680	B3GALNT2	0.61	10.15	0.43	5.46e-22	Adiposity;
LGG	cis	rs9462027	0.506	rs6934662	chr6:34759884	G/C	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.44	-0.47	7.35e-27	Systemic lupus erythematosus;
LGG	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg21095983	chr6:86352623	SYNCRIP	0.61	11.42	0.47	8.97e-27	Smooth-surface caries;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg26174226	chr8:58114915	NA	-0.54	-8.05	-0.35	7.22e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6541297	0.653	rs4846917	chr1:230299222	T/C	cg05784532	chr1:230284198	GALNT2	0.37	6.75	0.3	4.52e-11	Coronary artery disease;
LGG	cis	rs10256972	0.568	rs1133043	chr7:1133305	C/G	cg07308232	chr7:1071921	C7orf50	-0.56	-10.21	-0.43	3.26e-22	Longevity;Endometriosis;
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.81	0.45	1.91e-24	Longevity;
LGG	cis	rs6088590	1.000	rs6088595	chr20:33358499	T/A	cg06115741	chr20:33292138	TP53INP2	0.56	8.9	0.38	1.3e-17	Coronary artery disease;
LGG	cis	rs7226408	0.532	rs7235932	chr18:34565391	A/C	cg15022739	chr18:34823045	BRUNOL4	0.39	8.48	0.37	3.01e-16	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.07e-20	Lung cancer;
LGG	cis	rs2243480	1.000	rs34577383	chr7:65385726	C/T	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs4319547	0.614	rs10846764	chr12:122874297	T/C	cg23029597	chr12:123009494	RSRC2	0.94	17.29	0.63	4.71e-52	Body mass index;
LGG	cis	rs6956675	0.830	rs4585626	chr7:62671592	C/G	cg08930214	chr7:62859557	LOC100287834	-0.49	-8.16	-0.35	3.18e-15	Obesity-related traits;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg26354017	chr1:205819088	PM20D1	-0.73	-16.83	-0.62	6.09e-50	Monocyte percentage of white cells;
LGG	trans	rs9467603	0.920	rs34493019	chr6:25714959	A/G	cg06606381	chr12:133084897	FBRSL1	-0.97	-7.76	-0.34	5.3e-14	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.695	rs10124627	chr9:5025746	T/G	cg02405213	chr9:5042618	JAK2	-0.83	-15.8	-0.59	2.78e-45	Pediatric autoimmune diseases;
LGG	cis	rs12950390	0.853	rs56387656	chr17:45860189	C/G	cg24803719	chr17:45855879	NA	-0.3	-8.5	-0.37	2.55e-16	IgG glycosylation;
LGG	cis	rs12701220	0.803	rs12701432	chr7:1052453	C/T	cg00990874	chr7:1149470	C7orf50	-0.68	-10.93	-0.45	6.86e-25	Bronchopulmonary dysplasia;
LGG	cis	rs4555082	0.874	rs2816626	chr14:105735425	G/A	cg13114125	chr14:105738426	BRF1	-0.86	-16.24	-0.6	3.03e-47	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.21	-0.36	2.27e-15	HDL cholesterol;
LGG	cis	rs796364	1.000	rs11895190	chr2:200838613	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-11.04	-0.46	2.6e-25	Schizophrenia;
LGG	cis	rs883565	0.655	rs6599275	chr3:39050758	C/A	cg01426195	chr3:39028469	NA	-0.73	-17.16	-0.62	1.84e-51	Handedness;
LGG	cis	rs10504130	0.502	rs16916968	chr8:52844411	A/G	cg13492337	chr8:52722140	PXDNL	-0.51	-8.01	-0.35	9.54e-15	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs4746818	1.000	rs10998614	chr10:70923347	G/T	cg11621586	chr10:70884670	VPS26A	1.19	21.99	0.71	6.58e-74	Left atrial antero-posterior diameter;
LGG	cis	rs2188554	0.533	rs213980	chr7:117252874	G/A	cg10524701	chr7:117356490	CTTNBP2	0.45	7.87	0.34	2.51e-14	Esophageal adenocarcinoma;
LGG	trans	rs9650657	0.585	rs4841401	chr8:10489592	C/G	cg02002194	chr4:3960332	NA	0.44	8.26	0.36	1.58e-15	Neuroticism;
LGG	cis	rs7618915	0.547	rs62253733	chr3:52653414	A/G	cg18404041	chr3:52824283	ITIH1	-0.54	-10.27	-0.43	2.03e-22	Bipolar disorder;
LGG	cis	rs1577917	0.771	rs12205013	chr6:86333029	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.05	-0.49	2.77e-29	Response to antipsychotic treatment;
LGG	cis	rs4727027	0.704	rs7787753	chr7:148901779	A/T	cg23583168	chr7:148888333	NA	-0.94	-19.33	-0.67	1.81e-61	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10779751	0.726	rs1205593	chr1:11252716	T/C	cg08854313	chr1:11322531	MTOR	0.71	14.21	0.55	2.62e-38	Body mass index;
LGG	cis	rs2836974	0.584	rs6517535	chr21:40653352	G/C	cg11644478	chr21:40555479	PSMG1	-0.75	-13.89	-0.54	6.71e-37	Cognitive function;
LGG	cis	rs7727544	0.735	rs272867	chr5:131681057	G/A	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.85	-0.38	1.91e-17	Blood metabolite levels;
LGG	cis	rs62400317	0.859	rs10948217	chr6:45187618	A/C	cg18551225	chr6:44695536	NA	-0.64	-9.96	-0.42	2.74e-21	Total body bone mineral density;
LGG	trans	rs7829975	0.539	rs71537846	chr8:8542120	T/C	cg02002194	chr4:3960332	NA	0.41	7.41	0.33	6.07e-13	Mood instability;
LGG	cis	rs273218	0.590	rs156828	chr5:53364230	C/T	ch.5.1024479R	chr5:53302184	ARL15	0.46	7.72	0.34	7.39e-14	Migraine;
LGG	cis	rs992157	0.560	rs7605980	chr2:219100869	C/G	cg00012203	chr2:219082015	ARPC2	0.75	14.16	0.55	4.63e-38	Colorectal cancer;
LGG	cis	rs7572644	0.639	rs17006242	chr2:28001051	A/C	cg27432699	chr2:27873401	GPN1	-0.51	-7.67	-0.34	1.01e-13	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg21605333	chr4:119757512	SEC24D	1.28	12.4	0.5	1.12e-30	Cannabis dependence symptom count;
LGG	trans	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.51	-0.4	1.08e-19	Brugada syndrome;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04861640	chr6:28234605	ZNF187	-0.5	-7.42	-0.33	5.71e-13	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.683	rs12370288	chr12:38127740	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.03	0.7	1.98e-69	Bladder cancer;
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg27286069	chr11:118481882	PHLDB1	0.55	10.53	0.44	2.11e-23	Cholesterol, total;
LGG	trans	rs208520	0.802	rs208496	chr6:66930786	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.92	-15.55	-0.59	3.73e-44	Exhaled nitric oxide output;
LGG	cis	rs1129187	0.967	rs3805951	chr6:42937176	C/A	cg02353165	chr6:42928485	GNMT	0.52	16.02	0.6	2.93e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs478607	1.000	rs478607	chr11:64478063	A/G	cg19395706	chr11:64412079	NRXN2	0.37	6.67	0.3	7.14e-11	Urate levels;
LGG	cis	rs4862750	0.914	rs6553026	chr4:187875648	C/T	cg07414643	chr4:187882934	NA	0.56	11.43	0.47	8.12e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7666738	0.830	rs11097598	chr4:98946057	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.55e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg07362569	chr17:61921086	SMARCD2	0.51	9.81	0.41	8.91e-21	Prudent dietary pattern;
LGG	cis	rs11098499	0.954	rs17005535	chr4:120411562	C/T	cg24375607	chr4:120327624	NA	0.67	11.04	0.46	2.56e-25	Corneal astigmatism;
LGG	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg12395012	chr8:11607386	GATA4	-0.41	-7.8	-0.34	4.24e-14	Mood instability;
LGG	cis	rs7737355	0.947	rs31257	chr5:130828715	C/G	cg06307176	chr5:131281290	NA	0.53	8.98	0.39	7.04e-18	Life satisfaction;
LGG	trans	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg19894588	chr14:64061835	NA	0.54	9.04	0.39	4.29e-18	Glioblastoma;Glioma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05591758	chr2:74685531	WBP1	0.46	7.31	0.32	1.2e-12	Cognitive performance;
LGG	cis	rs7100689	0.784	rs10887838	chr10:82161380	G/A	cg01528321	chr10:82214614	TSPAN14	1.02	19.43	0.67	5.98e-62	Post bronchodilator FEV1;
LGG	cis	rs988958	0.958	rs13419707	chr2:42280927	C/T	cg19376973	chr2:42229025	NA	0.49	8.04	0.35	7.59e-15	Hypospadias;
LGG	cis	rs6951245	1.000	rs79683221	chr7:1096139	A/G	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.8	-16.4	-0.61	5.36e-48	Longevity;Endometriosis;
LGG	cis	rs357618	1.000	rs165351	chr5:150854881	C/T	cg03212797	chr5:150827313	SLC36A1	-0.43	-7.06	-0.31	6.16e-12	Basophil percentage of white cells;
LGG	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg10224037	chr5:178157518	ZNF354A	0.54	7.62	0.33	1.46e-13	Neutrophil percentage of white cells;
LGG	cis	rs972578	0.715	rs1807592	chr22:43226912	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.71	-0.3	5.74e-11	Mean platelet volume;
LGG	trans	rs9818758	0.607	rs9311439	chr3:49310408	A/G	cg21659725	chr3:3221576	CRBN	-0.66	-7.03	-0.31	7.25e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2114646	0.731	rs10174428	chr2:170645486	A/G	cg17598339	chr2:170624727	NA	0.35	6.68	0.3	6.71e-11	Obesity-related traits;
LGG	cis	rs35306767	0.715	rs11253550	chr10:1028288	C/G	cg26597838	chr10:835615	NA	0.56	7.26	0.32	1.59e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs6582630	0.555	rs34145279	chr12:38405588	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.07	-0.39	3.47e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg24232236	chr22:38142998	TRIOBP	-0.36	-7.13	-0.31	3.99e-12	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs12517041	1.000	rs6879916	chr5:23312603	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.76	-11.16	-0.46	8.78e-26	Calcium levels;
LGG	cis	rs4819052	0.851	rs9977178	chr21:46664531	G/T	cg06618935	chr21:46677482	NA	-0.49	-9.74	-0.41	1.63e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1493916	0.905	rs10460051	chr18:31413679	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-13.33	-0.53	1.56e-34	Life satisfaction;
LGG	cis	rs7223966	1.000	rs72848797	chr17:61934664	G/A	cg11494091	chr17:61959527	GH2	0.51	8.19	0.36	2.58e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2046867	0.908	rs6771413	chr3:72790308	G/A	cg25664220	chr3:72788482	NA	-0.32	-9.09	-0.39	3.02e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs780096	0.526	rs2010087	chr2:27637235	C/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.89	-0.3	1.82e-11	Total body bone mineral density;
LGG	cis	rs368123	1.000	rs791583	chr6:160701935	C/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.11	-0.31	4.4e-12	Waist circumference;
LGG	cis	rs708547	0.735	rs1277280	chr4:57866872	T/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.75	12.32	0.5	2.22e-30	Response to bleomycin (chromatid breaks);
LGG	cis	rs2120019	1.000	rs12185102	chr15:75352201	G/A	cg09165964	chr15:75287851	SCAMP5	-1.02	-19.84	-0.68	7.65e-64	Blood trace element (Zn levels);
LGG	cis	rs17376456	0.866	rs13356088	chr5:93423479	C/T	cg25358565	chr5:93447407	FAM172A	1.34	14.4	0.56	4.05e-39	Diabetic retinopathy;
LGG	cis	rs1577917	1.000	rs35419329	chr6:86702291	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.3	-0.53	2.07e-34	Response to antipsychotic treatment;
LGG	trans	rs7777677	0.963	rs4726550	chr7:142370764	C/T	cg18540325	chr9:33795118	PRSS3	-0.42	-7.2	-0.32	2.38e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg07148914	chr20:33460835	GGT7	-0.48	-7.88	-0.34	2.28e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs9926296	0.744	rs352939	chr16:89710378	G/A	cg03605463	chr16:89740564	NA	0.6	10.68	0.44	6.09e-24	Vitiligo;
LGG	trans	rs853679	0.505	rs200992	chr6:27814677	A/G	cg08344181	chr3:125677491	NA	-0.68	-7.73	-0.34	6.57e-14	Depression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05155781	chr11:73472223	RAB6A	0.43	6.71	0.3	5.55e-11	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs62064224	0.614	rs9900089	chr17:30772577	C/T	cg25809561	chr17:30822961	MYO1D	0.4	9.4	0.4	2.58e-19	Schizophrenia;
LGG	cis	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg09307838	chr4:120376055	NA	0.72	12.18	0.49	8.7e-30	Corneal astigmatism;
LGG	cis	rs5756813	0.688	rs8140207	chr22:38130459	G/T	cg19171272	chr22:38449367	NA	0.41	7.03	0.31	7.39e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs12477438	0.822	rs6727170	chr2:99588042	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.67	-10.65	-0.44	7.82e-24	Chronic sinus infection;
LGG	cis	rs11608355	0.618	rs12227736	chr12:109796637	G/A	cg19025524	chr12:109796872	NA	-0.6	-12.78	-0.51	2.9e-32	Neuroticism;
LGG	cis	rs427394	0.659	rs274695	chr5:6732252	G/C	cg15145174	chr5:6755386	POLS	-0.44	-8.07	-0.35	6.01e-15	Menopause (age at onset);
LGG	cis	rs7226408	0.652	rs2586785	chr18:34755673	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.01	-0.39	5.27e-18	Obesity-related traits;
LGG	cis	rs12579753	0.789	rs1343933	chr12:82123301	A/C	cg07988820	chr12:82153109	PPFIA2	-0.79	-12.13	-0.49	1.32e-29	Resting heart rate;
LGG	cis	rs2224391	0.518	rs116670419	chr6:5261263	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.52	-6.75	-0.3	4.36e-11	Height;
LGG	cis	rs898097	0.625	rs898095	chr17:80890638	T/C	cg02711726	chr17:80685570	FN3KRP	-0.42	-8.38	-0.36	6.21e-16	Breast cancer;
LGG	cis	rs2735413	0.563	rs17776016	chr16:78047817	A/G	cg04733911	chr16:78082701	NA	-0.56	-7.45	-0.33	4.77e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs9858542	0.953	rs11922013	chr3:49458355	G/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.2	-0.43	3.44e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12643440	0.538	rs66857912	chr4:17146347	T/C	cg22650099	chr4:17144496	NA	-0.51	-8.76	-0.38	3.65e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs988958	0.958	rs11891490	chr2:42285915	A/G	cg27428208	chr2:42229179	NA	-0.4	-7.06	-0.31	5.95e-12	Hypospadias;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg00424166	chr6:150045504	NUP43	-0.36	-7.13	-0.31	4e-12	Lung cancer;
LGG	cis	rs12310956	0.510	rs1386936	chr12:33875369	G/A	cg06521331	chr12:34319734	NA	-0.38	-6.72	-0.3	5.4e-11	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.24	-0.43	2.53e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs7924176	0.564	rs12572820	chr10:75877145	C/G	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-7.05	-0.31	6.73e-12	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04239009	chr3:141944519	GK5	0.44	6.77	0.3	3.82e-11	Gut microbiome composition (summer);
LGG	trans	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.35	-0.36	7.86e-16	Morning vs. evening chronotype;
LGG	cis	rs801193	1.000	rs2707845	chr7:66198798	C/T	cg18252515	chr7:66147081	NA	-0.4	-6.79	-0.3	3.54e-11	Aortic root size;
LGG	cis	rs1552244	0.810	rs4019706	chr3:10112862	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.24	0.69	1.06e-65	Alzheimer's disease;
LGG	cis	rs2242116	0.796	rs2290546	chr3:46965197	C/G	cg27129171	chr3:47204927	SETD2	0.72	12.49	0.5	4.62e-31	Birth weight;
LGG	trans	rs5756813	0.754	rs8137848	chr22:38185994	T/G	cg19894588	chr14:64061835	NA	-0.63	-9.98	-0.42	2.18e-21	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs2688608	0.839	rs2675662	chr10:75599127	A/G	cg00564723	chr10:75632066	CAMK2G	0.33	7.33	0.32	1.01e-12	Inflammatory bowel disease;
LGG	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg08603382	chr10:743973	NA	0.38	7.01	0.31	8.55e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs9905704	0.647	rs2286299	chr17:57043367	T/G	cg05425664	chr17:57184151	TRIM37	-0.44	-7.01	-0.31	8.22e-12	Testicular germ cell tumor;
LGG	cis	rs10504229	0.861	rs114700910	chr8:58170642	C/T	cg21724239	chr8:58056113	NA	0.45	6.93	0.31	1.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-12.2	-0.49	7.02e-30	Chronic sinus infection;
LGG	trans	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg23484912	chr5:273055	PDCD6	0.47	9.46	0.4	1.6e-19	Pancreatic cancer;
LGG	cis	rs539514	0.664	rs560069	chr13:76309344	A/G	cg04757411	chr13:76259545	LMO7	0.29	7.63	0.33	1.34e-13	Type 1 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16701467	chr17:7475727	EIF4A1	0.42	6.89	0.3	1.8e-11	Cognitive performance;
LGG	cis	rs4262150	0.842	rs55992747	chr5:152253548	C/T	cg12297329	chr5:152029980	NA	-0.65	-12.09	-0.49	1.96e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs11605924	1.000	rs11605924	chr11:45873091	A/C	ch.11.939596F	chr11:45881766	CRY2	-0.47	-7.98	-0.35	1.14e-14	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs4732038	0.510	rs10085674	chr7:134269597	G/T	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs7851660	0.967	rs13288000	chr9:100608980	A/G	cg13688889	chr9:100608707	NA	-0.69	-14.8	-0.57	7.5e-41	Strep throat;
LGG	cis	rs4356203	0.525	rs111416579	chr11:17249008	T/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.57	-0.33	2.03e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs9560113	0.960	rs950891	chr13:112173992	G/A	cg14952266	chr13:112191215	NA	0.42	7.81	0.34	3.75e-14	Menarche (age at onset);
LGG	trans	rs9929218	0.954	rs12596834	chr16:68823199	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	trans	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg08975724	chr8:8085496	FLJ10661	-0.51	-9.71	-0.41	2.14e-20	Neuroticism;
LGG	cis	rs4774899	0.832	rs8033118	chr15:57492693	A/G	cg08128148	chr15:57256372	TCF12	0.29	6.83	0.3	2.68e-11	Urinary tract infection frequency;
LGG	cis	rs6594713	0.879	rs13189910	chr5:112740153	G/A	cg12552261	chr5:112820674	MCC	0.5	7.23	0.32	2.06e-12	Brain cytoarchitecture;
LGG	cis	rs6908034	0.660	rs74795718	chr6:19782299	G/A	cg02682789	chr6:19804855	NA	0.88	7.75	0.34	5.77e-14	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs4474465	0.688	rs7942527	chr11:78280322	A/G	cg27205649	chr11:78285834	NARS2	0.61	11.43	0.47	8.16e-27	Alzheimer's disease (survival time);
LGG	cis	rs7937612	0.561	rs503473	chr11:120355230	A/G	cg24566217	chr11:120254723	ARHGEF12	0.35	8.01	0.35	9.11e-15	Intraocular pressure;
LGG	cis	rs10911232	0.507	rs10911234	chr1:183053001	A/C	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg13010199	chr12:38710504	ALG10B	0.46	8.8	0.38	2.63e-17	Morning vs. evening chronotype;
LGG	cis	rs9646954	0.542	rs4149505	chr2:101033697	G/A	cg21926883	chr2:100939477	LONRF2	-0.68	-15.99	-0.6	3.77e-46	Intelligence (multi-trait analysis);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg26446827	chr20:18268978	ZNF133	-0.4	-6.66	-0.3	7.94e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg09699651	chr6:150184138	LRP11	0.51	8.99	0.39	6.47e-18	Lung cancer;
LGG	trans	rs2235573	0.662	rs2076370	chr22:38463968	A/G	cg19894588	chr14:64061835	NA	0.43	6.86	0.3	2.17e-11	Glioblastoma;Glioma;
LGG	cis	rs12477438	0.798	rs9679602	chr2:99577827	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.71	12.3	0.5	2.77e-30	Chronic sinus infection;
LGG	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg09085632	chr11:111637200	PPP2R1B	1.17	25.61	0.77	9.01e-91	Primary sclerosing cholangitis;
LGG	cis	rs9527	0.614	rs2153774	chr10:104881035	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs9815354	1.000	rs7624372	chr3:41881107	T/A	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs16910800	0.731	rs16910754	chr11:23192015	A/G	cg20040320	chr11:23191996	NA	0.58	6.68	0.3	6.7e-11	Cancer;
LGG	cis	rs1008375	0.966	rs7658240	chr4:17588950	A/G	cg02297831	chr4:17616191	MED28	-0.45	-8.11	-0.35	4.63e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9357271	1.000	rs4714155	chr6:38360900	C/T	cg07362130	chr6:38359646	BTBD9	-0.47	-10.59	-0.44	1.35e-23	Restless legs syndrome;
LGG	cis	rs17221829	0.965	rs12276507	chr11:89457053	T/C	cg02982614	chr11:89391479	FOLH1B	-0.34	-7.58	-0.33	1.93e-13	Anxiety in major depressive disorder;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.84	-0.59	1.74e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.967	rs6142323	chr20:33788983	A/G	cg24642439	chr20:33292090	TP53INP2	-0.46	-7.35	-0.32	8.87e-13	Height;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg21948465	chr5:131705150	SLC22A5	0.66	7.43	0.33	5.3e-13	Rheumatoid arthritis;
LGG	cis	rs9303401	0.659	rs11495824	chr17:56918882	C/A	cg25039879	chr17:56429692	SUPT4H1	0.64	9.05	0.39	3.83e-18	Cognitive test performance;
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.28	-0.36	1.29e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9420907	1.000	rs9420907	chr10:105676465	A/C	cg11005552	chr10:105648138	OBFC1	-0.67	-8.93	-0.38	9.83e-18	Telomere length;
LGG	cis	rs2276314	0.793	rs77590522	chr18:33629410	C/G	cg19628046	chr18:33552617	C18orf21	0.53	7.61	0.33	1.51e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs7481584	0.626	rs2071103	chr11:3040087	C/T	cg25174290	chr11:3078921	CARS	-0.51	-9.22	-0.39	1.01e-18	Calcium levels;
LGG	cis	rs13108904	0.840	rs13149790	chr4:1262239	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.26	0.49	4.18e-30	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24807106	chr8:109095918	RSPO2	0.52	7.98	0.35	1.17e-14	Gut microbiome composition (summer);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06339248	chr11:57435803	ZDHHC5	-0.47	-6.77	-0.3	4.01e-11	Systemic lupus erythematosus;
LGG	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg01620082	chr3:125678407	NA	-1.04	-9.8	-0.41	9.71e-21	Depression;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg22907277	chr7:1156413	C7orf50	0.5	8.73	0.38	4.64e-17	Longevity;Endometriosis;
LGG	cis	rs4665809	0.590	rs13006973	chr2:26454707	C/T	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs6999131	chr8:58127052	C/A	cg26174226	chr8:58114915	NA	-0.63	-8.6	-0.37	1.26e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs9809061	chr3:10085130	C/G	cg00166722	chr3:10149974	C3orf24	0.52	8.84	0.38	2.02e-17	Alzheimer's disease;
LGG	cis	rs4750440	0.706	rs61837399	chr10:14016047	G/A	cg27542038	chr10:14027202	FRMD4A	-0.66	-12.67	-0.51	8.19e-32	Adiponectin levels;
LGG	cis	rs1799949	0.930	rs4445938	chr17:41337900	A/C	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs2204008	0.837	rs11612397	chr12:38357455	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Bladder cancer;
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg03806693	chr22:41940476	POLR3H	-1.16	-21.63	-0.71	3.14e-72	Vitiligo;
LGG	cis	rs4268898	0.662	rs2891380	chr2:24525830	G/A	cg06627628	chr2:24431161	ITSN2	-0.77	-12.57	-0.5	2.15e-31	Asthma;
LGG	cis	rs9322193	0.543	rs9371533	chr6:150210681	G/A	cg09699651	chr6:150184138	LRP11	0.56	10.58	0.44	1.41e-23	Lung cancer;
LGG	cis	rs1799949	1.000	rs8176318	chr17:41197274	G/T	cg01879757	chr17:41196368	BRCA1	-0.44	-8.84	-0.38	2.01e-17	Menopause (age at onset);
LGG	cis	rs7552404	0.883	rs2185436	chr1:76203783	A/G	cg03433033	chr1:76189801	ACADM	0.81	14.74	0.57	1.35e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10078	0.571	rs890977	chr5:476910	T/C	cg07599136	chr5:415885	AHRR	0.84	11.34	0.47	1.84e-26	Fat distribution (HIV);
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg10950524	chr7:2139216	MAD1L1	0.33	7.03	0.31	7.23e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs9398803	0.713	rs6921183	chr6:126869029	A/T	cg19875578	chr6:126661172	C6orf173	0.52	9.58	0.41	5.79e-20	Male-pattern baldness;
LGG	cis	rs9309473	0.898	rs11126403	chr2:73796923	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.73	-0.34	6.71e-14	Metabolite levels;
LGG	cis	rs6089584	1.000	rs6089585	chr20:60564395	G/A	cg06470251	chr20:60548479	NA	0.52	9.2	0.39	1.26e-18	Body mass index;
LGG	cis	rs1506636	1.000	rs7779099	chr7:123295964	C/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.23	-0.65	2.27e-56	Plateletcrit;Platelet count;
LGG	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg16482183	chr6:26056742	HIST1H1C	0.58	9.32	0.4	4.72e-19	Iron status biomarkers;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg17202724	chr17:61916730	SMARCD2	0.54	12.34	0.5	1.85e-30	Prudent dietary pattern;
LGG	cis	rs34599045	0.522	rs12756264	chr1:152914389	G/A	cg07796016	chr1:152779584	LCE1C	-0.86	-8.03	-0.35	7.85e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.65	0.41	3.28e-20	Mean corpuscular volume;
LGG	trans	rs11098499	0.909	rs79026312	chr4:120440677	C/A	cg25214090	chr10:38739885	LOC399744	0.66	11.53	0.47	3.3699999999999996e-27	Corneal astigmatism;
LGG	cis	rs9815354	1.000	rs73077367	chr3:41851959	G/A	cg03022575	chr3:42003672	ULK4	0.65	8.37	0.36	7e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7849585	1.000	rs7864754	chr9:139126120	C/T	cg14094347	chr9:139131620	QSOX2	-0.5	-10.4	-0.44	6.78e-23	Height;
LGG	cis	rs1816752	0.776	rs9511268	chr13:25018320	A/G	cg02811702	chr13:24901961	NA	0.39	7.37	0.32	7.83e-13	Obesity-related traits;
LGG	cis	rs1577917	0.837	rs806529	chr6:86467121	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.29	-0.5	2.98e-30	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.835	rs35070385	chr17:80128447	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.71e-20	Life satisfaction;
LGG	cis	rs7208859	0.573	rs8078656	chr17:29080971	A/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1322639	0.531	rs11751421	chr6:169574993	T/C	cg04662567	chr6:169592167	NA	0.67	13.25	0.52	3.4e-34	Pulse pressure;
LGG	trans	rs11992162	1.000	rs11994417	chr8:11833262	G/A	cg16141378	chr3:129829833	LOC729375	-0.34	-7.7	-0.34	8.3e-14	Monocyte count;
LGG	cis	rs2404602	0.647	rs907594	chr15:77197745	C/A	cg15268244	chr15:77196840	NA	0.47	9.86	0.42	6.13e-21	Blood metabolite levels;
LGG	cis	rs9611565	0.802	rs2234058	chr22:41777883	G/A	cg06850241	chr22:41845214	NA	-0.42	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs11122272	0.735	rs2486743	chr1:231506928	C/G	cg10503236	chr1:231470652	EXOC8	-0.38	-7.4	-0.33	6.3e-13	Hemoglobin concentration;
LGG	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg14829155	chr15:31115871	NA	-0.55	-8.83	-0.38	2.15e-17	Huntington's disease progression;
LGG	cis	rs826838	0.967	rs826855	chr12:39114888	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.29	-0.55	1.23e-38	Heart rate;
LGG	cis	rs745821	1.000	rs745821	chr18:48142854	T/G	cg18923635	chr18:48083994	NA	0.43	7.4	0.33	6.54e-13	Diastolic blood pressure;
LGG	cis	rs6951245	1.000	rs11764748	chr7:1094508	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.54	0.56	1e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10464366	1.000	rs10464366	chr7:39121500	A/T	cg18850127	chr7:39170497	POU6F2	-0.54	-12.37	-0.5	1.51e-30	IgG glycosylation;
LGG	cis	rs7529073	0.740	rs340883	chr1:214145706	A/G	cg00795024	chr1:214157026	NA	0.27	7.48	0.33	3.78e-13	Schizophrenia;
LGG	cis	rs12464483	0.524	rs1348898	chr2:30888026	C/A	cg03795903	chr2:30669940	LCLAT1	0.54	7.44	0.33	4.86e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	9.19	0.39	1.32e-18	Diabetic retinopathy;
LGG	cis	rs7106204	0.534	rs75297923	chr11:24253530	A/G	ch.11.24196551F	chr11:24239977	NA	0.84	9.49	0.4	1.22e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs6547631	0.622	rs34943381	chr2:85923997	A/G	cg24620635	chr2:85921963	GNLY	0.5	10.07	0.42	1.1e-21	Blood protein levels;
LGG	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.48e-13	HDL cholesterol;
LGG	cis	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg07460842	chr6:66804631	NA	0.94	17.1	0.62	3.63e-51	Exhaled nitric oxide levels;
LGG	cis	rs7851660	1.000	rs7851660	chr9:100610759	C/A	cg13688889	chr9:100608707	NA	-0.69	-14.46	-0.56	2.18e-39	Strep throat;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7945718	0.875	rs7924501	chr11:12813870	A/G	cg25843174	chr11:12811716	TEAD1	0.41	8.33	0.36	9.02e-16	Educational attainment (years of education);
LGG	cis	rs7602441	0.521	rs12052706	chr2:14765777	A/G	cg06545361	chr2:14773388	FAM84A	0.79	7.3	0.32	1.22e-12	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.48	8.98	0.39	6.85e-18	Longevity;
LGG	cis	rs1153858	1.000	rs7171577	chr15:45627979	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	10.52	0.44	2.46e-23	Homoarginine levels;
LGG	cis	rs9906944	0.545	rs2088140	chr17:47094599	T/C	cg11673840	chr17:47092156	IGF2BP1	-0.39	-6.84	-0.3	2.57e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs7395662	0.929	rs7108559	chr11:48619151	G/T	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	cis	rs72827839	0.841	rs16952265	chr17:46184883	G/A	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg13147721	chr7:65941812	NA	-0.66	-8.71	-0.38	5.42e-17	Diabetic kidney disease;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.8	15.99	0.6	3.72e-46	Obesity-related traits;
LGG	cis	rs72772090	0.634	rs72773906	chr5:96092274	C/G	cg00188032	chr5:96141721	ERAP1	0.53	7.24	0.32	1.86e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs60843830	1.000	rs79716074	chr2:277003	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.79	14.58	0.56	6.71e-40	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg18188782	chr20:61659543	NA	0.4	6.71	0.3	5.64e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6942756	1.000	rs56026912	chr7:128913937	A/G	cg02491457	chr7:128862824	NA	-0.76	-13.96	-0.54	3.27e-37	White matter hyperintensity burden;
LGG	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg00745463	chr17:30367425	LRRC37B	0.53	7.09	0.31	5.13e-12	Hip circumference adjusted for BMI;
LGG	cis	rs10540	1.000	rs67912009	chr11:495057	G/T	cg19913688	chr11:428466	ANO9	-0.66	-8.52	-0.37	2.23e-16	Body mass index;
LGG	trans	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs12220238	1.000	rs12358614	chr10:75906173	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.81	11.1	0.46	1.58e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs8141529	0.956	rs132539	chr22:29304253	C/T	cg02153584	chr22:29168773	CCDC117	0.59	8.89	0.38	1.34e-17	Lymphocyte counts;
LGG	cis	rs10489202	1.000	rs275157	chr1:168064178	T/C	cg24449463	chr1:168025552	DCAF6	-0.62	-10.11	-0.43	7.57e-22	Schizophrenia;
LGG	cis	rs1577917	1.000	rs955197	chr6:86729675	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.2	-0.52	5.65e-34	Response to antipsychotic treatment;
LGG	cis	rs74781061	0.932	rs11857328	chr15:74802891	T/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.96	-0.31	1.19e-11	Endometriosis;
LGG	cis	rs9513627	1.000	rs2390279	chr13:100208705	A/G	cg25919922	chr13:100150906	NA	-0.68	-7.04	-0.31	6.89e-12	Obesity-related traits;
LGG	cis	rs9611519	0.780	rs9611542	chr22:41677317	C/T	cg03806693	chr22:41940476	POLR3H	-0.69	-11.15	-0.46	1e-25	Neuroticism;
LGG	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg26897989	chr16:1907736	C16orf73	0.77	12.3	0.5	2.66e-30	Insulin-like growth factors;
LGG	cis	rs6866344	0.568	rs4626352	chr5:178096777	G/A	cg03877680	chr5:178157825	ZNF354A	0.57	8.35	0.36	7.73e-16	Neutrophil percentage of white cells;
LGG	cis	rs7937682	0.855	rs7109592	chr11:111533105	C/A	cg08305652	chr11:111469057	NA	-0.43	-8.48	-0.37	3.05e-16	Primary sclerosing cholangitis;
LGG	cis	rs3617	0.573	rs2336668	chr3:52919096	G/T	cg11645453	chr3:52864694	ITIH4	-0.45	-7.58	-0.33	1.95e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg03098644	chr7:100410630	EPHB4	0.46	6.85	0.3	2.44e-11	Other erythrocyte phenotypes;
LGG	cis	rs4730250	0.707	rs257377	chr7:106801088	G/T	cg02696742	chr7:106810147	HBP1	-0.83	-11.6	-0.47	1.66e-27	Osteoarthritis;
LGG	cis	rs4006360	0.601	rs7214364	chr17:39236678	G/A	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.56	-0.47	2.49e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs8060686	0.641	rs75450962	chr16:68210868	C/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs883565	0.569	rs1274968	chr3:39170090	A/G	cg01426195	chr3:39028469	NA	-0.65	-14.08	-0.55	1.02e-37	Handedness;
LGG	cis	rs9905704	0.647	rs8077332	chr17:57105223	A/G	cg12560992	chr17:57184187	TRIM37	0.53	8.68	0.37	6.94e-17	Testicular germ cell tumor;
LGG	cis	rs561341	0.882	rs504887	chr17:30322881	T/A	cg12193833	chr17:30244370	NA	-0.29	-7.33	-0.32	1.01e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11622475	1.000	rs10149651	chr14:104394440	A/G	cg12183467	chr14:104352244	NA	0.44	7.56	0.33	2.26e-13	Bipolar disorder;
LGG	cis	rs6754311	0.773	rs2322818	chr2:136775898	T/C	cg07169764	chr2:136633963	MCM6	0.71	11.65	0.48	1.11e-27	Mosquito bite size;
LGG	cis	rs2576037	0.583	rs1970668	chr18:44523220	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.71	-0.38	5.32e-17	Personality dimensions;
LGG	cis	rs4566357	1.000	rs4536647	chr2:227921977	A/G	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11890956	chr21:40555474	PSMG1	1.12	23.54	0.74	3.7e-81	Cognitive function;
LGG	trans	rs6825911	0.597	rs10008438	chr4:111363899	A/T	cg10580549	chr19:53101634	ZNF137	0.55	6.95	0.31	1.28e-11	Blood pressure;
LGG	cis	rs17253792	0.822	rs77408754	chr14:56082047	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.07	-0.49	2.32e-29	Putamen volume;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg24829409	chr8:58192753	C8orf71	-0.83	-12.76	-0.51	3.67e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs17209837	0.607	rs7789645	chr7:87122603	G/C	cg00919237	chr7:87102261	ABCB4	-0.78	-14.66	-0.56	2.95e-40	Gallbladder cancer;
LGG	cis	rs6141769	0.542	rs28548407	chr20:31301495	T/C	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.83	-0.3	2.71e-11	Subjective well-being;
LGG	cis	rs12580194	0.556	rs11171433	chr12:55757797	A/T	cg19537932	chr12:55886519	OR6C68	-0.57	-10.46	-0.44	3.93e-23	Cancer;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1670533	1.000	rs11724371	chr4:1052125	T/C	cg27284194	chr4:1044797	NA	0.54	9.07	0.39	3.28e-18	Recombination rate (females);
LGG	cis	rs7666738	0.791	rs7678564	chr4:99057341	A/G	cg05340658	chr4:99064831	C4orf37	0.51	8.46	0.37	3.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs225245	0.817	rs225273	chr17:33970935	A/T	cg05299278	chr17:33885742	SLFN14	0.43	8.21	0.36	2.24e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs832540	0.931	rs331499	chr5:56210923	C/T	cg12654349	chr5:56205094	C5orf35	-0.38	-6.88	-0.3	2.01e-11	Coronary artery disease;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg20887711	chr4:1340912	KIAA1530	0.91	19.96	0.68	2.09e-64	Longevity;
LGG	cis	rs2133450	0.679	rs7610696	chr3:7368565	T/C	cg19930620	chr3:7340148	GRM7	-0.37	-8.12	-0.35	4.37e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg12458913	chr13:53173898	NA	0.55	9.9	0.42	4.2e-21	Lewy body disease;
LGG	trans	rs61931739	0.517	rs1817760	chr12:34106060	A/G	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.714	rs2390157	chr7:19786177	G/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.18	0.36	2.71e-15	Thyroid stimulating hormone;
LGG	cis	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg13647721	chr17:30228624	UTP6	-0.77	-10.19	-0.43	4e-22	Hip circumference adjusted for BMI;
LGG	cis	rs10754283	0.967	rs4658307	chr1:90117586	G/T	cg21401794	chr1:90099060	LRRC8C	0.57	11.88	0.48	1.33e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs477895	0.838	rs35090903	chr11:64000598	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.84	10.92	0.45	7.69e-25	Mean platelet volume;
LGG	cis	rs3091242	0.933	rs11249250	chr1:25767609	G/A	cg09222892	chr1:25734099	RHCE	0.46	9.47	0.4	1.43e-19	Erythrocyte sedimentation rate;
LGG	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.6	0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs12479064	0.724	rs737094	chr2:100089078	G/A	cg08885076	chr2:99613938	TSGA10	-0.44	-7.91	-0.34	1.96e-14	Chronic sinus infection;
LGG	cis	rs2251381	0.741	rs2735966	chr21:30538174	G/A	cg24692254	chr21:30365293	RNF160	0.83	17.16	0.62	1.96e-51	Selective IgA deficiency;
LGG	cis	rs6714710	0.603	rs11692010	chr2:98397301	C/T	cg26665480	chr2:98280029	ACTR1B	0.57	9.28	0.4	6.41e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs4737010	0.511	rs7006871	chr8:41670952	A/G	cg08923054	chr8:41654455	ANK1	0.77	13.19	0.52	6.13e-34	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs4819052	0.679	rs2838859	chr21:46684517	C/T	cg06618935	chr21:46677482	NA	-0.35	-6.79	-0.3	3.55e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17125944	0.686	rs7155860	chr14:53335229	G/C	cg00686598	chr14:53173677	PSMC6	-0.64	-6.86	-0.3	2.17e-11	Alzheimer's disease (late onset);
LGG	trans	rs56011263	0.687	rs4690186	chr4:703607	G/A	cg12575136	chr18:32820987	ZNF397	0.47	8.7	0.37	5.88e-17	White blood cell count;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg13628971	chr7:2884303	GNA12	-0.48	-9.48	-0.4	1.29e-19	Height;
LGG	cis	rs9783347	1.000	rs4150641	chr11:18370739	C/A	cg15585147	chr11:18324498	HPS5	0.43	9.14	0.39	1.91e-18	Pancreatic cancer;
LGG	trans	rs3780486	0.846	rs3824458	chr9:33144809	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	23.96	0.74	4.01e-83	IgG glycosylation;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.92	-0.42	3.71e-21	IgG glycosylation;
LGG	cis	rs10193935	1.000	rs10193935	chr2:42419829	C/T	cg27598129	chr2:42591480	NA	-0.62	-9.29	-0.4	6.05e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9303401	0.614	rs28651036	chr17:57080471	G/A	cg25039879	chr17:56429692	SUPT4H1	0.55	7.89	0.34	2.18e-14	Cognitive test performance;
LGG	cis	rs12477438	0.520	rs13031919	chr2:99848932	A/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	14.85	0.57	4.52e-41	Chronic sinus infection;
LGG	cis	rs7737355	0.812	rs798413	chr5:130696586	C/T	cg06307176	chr5:131281290	NA	0.49	8.14	0.35	3.7e-15	Life satisfaction;
LGG	cis	rs11148252	0.634	rs4941727	chr13:52721067	A/G	cg00495681	chr13:53174319	NA	-0.47	-7.89	-0.34	2.14e-14	Lewy body disease;
LGG	cis	rs7945705	0.902	rs10743095	chr11:8936984	T/C	cg21881798	chr11:8931708	C11orf17;ST5	0.54	12.13	0.49	1.32e-29	Hemoglobin concentration;
LGG	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	trans	rs877282	0.842	rs7092986	chr10:756373	G/A	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs2645694	0.626	rs2703140	chr4:77830057	C/G	cg06046430	chr4:77819534	ANKRD56	0.54	11.05	0.46	2.37e-25	Emphysema distribution in smoking;
LGG	cis	rs6500602	0.647	rs4785967	chr16:4523208	G/A	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.33	6.81	0.3	3.14e-11	Schizophrenia;
LGG	cis	rs11874712	1.000	rs13381709	chr18:43670988	C/T	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs8056893	0.550	rs8044823	chr16:68347753	G/A	cg07273125	chr16:68295692	NA	0.46	10.42	0.44	5.64e-23	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4631830	0.869	rs11006207	chr10:51538176	T/C	cg10326726	chr10:51549505	MSMB	-0.67	-13.78	-0.54	1.88e-36	Prostate-specific antigen levels;
LGG	cis	rs2033908	0.620	rs1992335	chr11:12851717	A/C	cg25843174	chr11:12811716	TEAD1	-0.34	-7.26	-0.32	1.62e-12	Sitting height ratio;
LGG	cis	rs7945718	0.934	rs3993110	chr11:12794530	A/C	cg25843174	chr11:12811716	TEAD1	0.4	8.41	0.36	5.27e-16	Educational attainment (years of education);
LGG	cis	rs28386778	0.897	rs7222189	chr17:61836372	T/C	cg26338869	chr17:61819248	STRADA	0.58	9.87	0.42	5.78e-21	Prudent dietary pattern;
LGG	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg21699342	chr2:239360505	ASB1	0.4	7.66	0.34	1.12e-13	Multiple system atrophy;
LGG	cis	rs4774899	0.932	rs4774918	chr15:57582264	T/C	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs2273669	0.667	rs78550764	chr6:109312239	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.39	-0.36	5.81e-16	Prostate cancer;
LGG	cis	rs6964587	0.692	rs10236483	chr7:91797296	A/C	cg17063962	chr7:91808500	NA	0.55	10.55	0.44	1.78e-23	Breast cancer;
LGG	cis	rs877282	1.000	rs10904552	chr10:774326	A/G	cg17470449	chr10:769945	NA	0.63	8.12	0.35	4.25e-15	Uric acid levels;
LGG	cis	rs6502050	0.835	rs11077981	chr17:80147243	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs10845606	1.000	rs10845610	chr12:12839107	G/A	cg09462578	chr12:12878428	APOLD1	-0.52	-7.26	-0.32	1.6e-12	Systemic lupus erythematosus;
LGG	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg12623918	chr2:306882	NA	0.51	9.56	0.41	6.79e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs9693857	1.000	rs9693857	chr8:9267117	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.8	-0.3	3.18e-11	Systolic blood pressure;
LGG	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg04851639	chr8:1020857	NA	-0.45	-9.57	-0.41	6.69e-20	Schizophrenia;
LGG	cis	rs11719291	0.833	rs11715835	chr3:48770732	C/T	cg00383909	chr3:49044727	WDR6	1.07	12.46	0.5	6.28e-31	Cognitive function;
LGG	cis	rs1552244	1.000	rs66797209	chr3:10078526	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-13.38	-0.53	9.59e-35	Alzheimer's disease;
LGG	cis	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	-0.55	-8.05	-0.35	6.88e-15	Lung cancer in ever smokers;
LGG	cis	rs55788414	0.932	rs28583467	chr16:81186428	G/C	cg06400318	chr16:81190750	PKD1L2	-0.9	-10.78	-0.45	2.5300000000000002e-24	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs835154	0.900	rs835153	chr5:14877474	A/G	cg18064842	chr5:14874549	NA	-0.38	-8.36	-0.36	7.18e-16	Blood metabolite levels;
LGG	cis	rs7301016	1.000	rs10877859	chr12:62873873	G/A	cg11441379	chr12:63026424	NA	0.66	8.65	0.37	8.55e-17	IgG glycosylation;
LGG	cis	rs2832077	0.943	rs2832099	chr21:30173460	A/G	cg03476357	chr21:30257390	N6AMT1	-0.57	-8.83	-0.38	2.11e-17	Cognitive test performance;
LGG	cis	rs9329221	0.506	rs17689674	chr8:9981854	C/A	cg19847130	chr8:10466454	RP1L1	-0.33	-7.03	-0.31	7.62e-12	Neuroticism;
LGG	cis	rs2718058	0.560	rs2709109	chr7:37832852	G/A	cg24998770	chr7:37888106	TXNDC3	0.44	7.04	0.31	7.11e-12	Alzheimer's disease (late onset);
LGG	cis	rs6502050	0.835	rs7501527	chr17:80099355	A/C	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.69e-14	Life satisfaction;
LGG	cis	rs6752107	0.901	rs2289477	chr2:234160345	T/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.36	0.53	1.1e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10870270	0.956	rs10870281	chr10:133762642	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.64	-0.54	7.85e-36	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs6088580	0.524	rs7274854	chr20:33228672	A/C	cg07148914	chr20:33460835	GGT7	0.49	8.04	0.35	7.3e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs11074306	0.561	rs4778183	chr15:28061676	C/T	cg26402630	chr15:28053930	OCA2	0.35	7.11	0.31	4.3e-12	Uveal melanoma;
LGG	cis	rs9660992	0.573	rs1172159	chr1:205207512	T/C	cg00857998	chr1:205179979	DSTYK	0.5	7.89	0.34	2.14e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs793571	0.536	rs7183336	chr15:58966236	C/T	cg05156742	chr15:59063176	FAM63B	0.55	8.12	0.35	4.12e-15	Schizophrenia;
LGG	cis	rs1499614	0.803	rs1796229	chr7:66119661	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.42	0.36	4.79e-16	Gout;
LGG	cis	rs62344088	0.590	rs6872820	chr5:178900	G/A	cg22857025	chr5:266934	NA	-1.11	-8.94	-0.38	9.67e-18	Asthma (childhood onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04130657	chr1:161102858	DEDD	0.49	7.37	0.32	7.82e-13	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg14675211	chr2:100938903	LONRF2	0.68	12.42	0.5	9.37e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17376030	chr22:41985996	PMM1	0.55	8.74	0.38	4.4e-17	Vitiligo;
LGG	cis	rs4948102	0.597	rs12669623	chr7:56139179	G/C	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.3	0.32	1.28e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs4819388	0.724	rs4818888	chr21:45645307	C/T	cg01992765	chr21:45622493	NA	-0.45	-8.68	-0.37	7e-17	Celiac disease;
LGG	cis	rs8044868	0.548	rs3909541	chr16:72201119	C/T	cg23815491	chr16:72088622	HP	-0.35	-7.48	-0.33	3.79e-13	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs61884328	0.850	rs79232684	chr11:47171714	G/A	cg03339077	chr11:47165057	C11orf49	0.72	6.69	0.3	6.43e-11	Total body bone mineral density (age over 60);
LGG	cis	rs4332037	0.539	rs55988458	chr7:2059761	G/A	cg12432903	chr7:1882776	MAD1L1	0.44	6.7	0.3	6.19e-11	Bipolar disorder;
LGG	cis	rs4671458	1.000	rs72813412	chr2:63365500	C/T	cg17519650	chr2:63277830	OTX1	-0.62	-7.83	-0.34	3.31e-14	Subjective well-being;
LGG	trans	rs11875185	0.510	rs75958989	chr18:55618202	G/A	cg15513957	chr14:69354734	ACTN1	-0.93	-9.2	-0.39	1.2e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs736801	0.964	rs17622656	chr5:131820997	A/G	cg21138405	chr5:131827807	IRF1	0.3	7.09	0.31	5.12e-12	Breast cancer;Mosquito bite size;
LGG	trans	rs1814175	0.586	rs10769603	chr11:49688837	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.74	-15.6	-0.59	2.08e-44	Height;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.53	-0.37	2.06e-16	Lung cancer;
LGG	cis	rs9486719	1.000	rs11152951	chr6:96894135	C/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs4742903	0.935	rs10739885	chr9:106912892	G/A	cg14250997	chr9:106856677	SMC2	0.4	8.33	0.36	9.09e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs17826219	0.500	rs2874724	chr17:29072433	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Body mass index;
LGG	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs6940638	0.956	rs12190473	chr6:27024687	C/T	cg09904177	chr6:26538194	HMGN4	-0.51	-7.21	-0.32	2.29e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10028187	0.616	rs1369145	chr4:154408279	C/T	cg24020152	chr4:154419554	KIAA0922	0.41	9.43	0.4	1.94e-19	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs62238980	0.614	rs4821037	chr22:32484201	C/T	cg00543991	chr22:32367038	NA	-0.77	-8.44	-0.37	4.18e-16	Childhood ear infection;
LGG	cis	rs13108904	0.967	rs11730939	chr4:1285560	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.58	11.48	0.47	4.91e-27	Obesity-related traits;
LGG	cis	rs9291683	0.588	rs13121211	chr4:9999539	A/G	cg08250081	chr4:10125330	NA	0.38	7.4	0.33	6.61e-13	Bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07663468	chr19:44506883	ZNF230	-0.52	-7.74	-0.34	6.18e-14	Systemic lupus erythematosus;
LGG	cis	rs75920871	0.764	rs61903394	chr11:116931898	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.0	-0.31	9.19e-12	Subjective well-being;
LGG	cis	rs2243480	0.831	rs57294491	chr7:65684901	T/A	cg13147721	chr7:65941812	NA	0.84	10.14	0.43	6.15e-22	Diabetic kidney disease;
LGG	trans	rs1941687	0.735	rs8085989	chr18:31415929	G/A	cg27147174	chr7:100797783	AP1S1	-0.52	-8.74	-0.38	4.47e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10875746	0.669	rs10875767	chr12:48599257	A/C	cg24011408	chr12:48396354	COL2A1	-0.56	-7.37	-0.32	7.78e-13	Longevity (90 years and older);
LGG	cis	rs1040	1.000	rs1040	chr6:169616347	T/C	cg04662567	chr6:169592167	NA	-0.4	-7.34	-0.32	9.88e-13	Joint mobility (Beighton score);
LGG	cis	rs10851411	0.697	rs12439377	chr15:42861362	C/T	cg21293051	chr15:42870591	STARD9	0.5	7.19	0.32	2.67e-12	Glucose homeostasis traits;
LGG	cis	rs12156238	1.000	rs12156238	chr8:11285135	C/G	cg16103604	chr8:11284912	C8orf12;FAM167A	-0.43	-6.83	-0.3	2.74e-11	Cisplatin-induced ototoxicity;
LGG	cis	rs7208859	0.623	rs8075163	chr17:29106310	A/G	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs56235845	0.694	rs6876677	chr5:176755342	T/C	cg17509989	chr5:176798049	RGS14	0.66	11.01	0.46	3.24e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs227808	0.812	rs55643629	chr6:44644224	G/C	cg18551225	chr6:44695536	NA	0.49	7.16	0.32	3.2e-12	Male-pattern baldness;
LGG	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs79149102	0.579	rs3812943	chr15:75312715	C/G	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.55	-0.37	1.85e-16	Lung cancer;
LGG	cis	rs6831352	0.918	rs29001202	chr4:100053782	T/A	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	trans	rs3903072	0.528	rs12800497	chr11:65579762	C/T	cg17712092	chr4:129076599	LARP1B	0.54	9.02	0.39	4.91e-18	Breast cancer;
LGG	cis	rs9788333	0.695	rs12871086	chr13:21890224	A/T	cg19500098	chr13:21900506	NA	0.47	10.02	0.42	1.57e-21	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12643440	0.718	rs515956	chr4:17142835	C/T	cg22650099	chr4:17144496	NA	0.39	7.25	0.32	1.74e-12	Metabolite levels (Pyroglutamine);
LGG	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg01420254	chr6:26195488	NA	-0.89	-11.73	-0.48	5.41e-28	Gout;Renal underexcretion gout;
LGG	cis	rs10752881	0.967	rs4652758	chr1:182975100	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs7737355	0.947	rs10054733	chr5:130989426	C/T	cg06307176	chr5:131281290	NA	0.57	9.39	0.4	2.76e-19	Life satisfaction;
LGG	cis	rs7954584	0.583	rs6486782	chr12:122359172	T/C	cg13699009	chr12:122356056	WDR66	0.55	15.17	0.58	1.71e-42	Mean corpuscular volume;
LGG	cis	rs7647973	0.848	rs4955426	chr3:49143438	C/A	cg06212747	chr3:49208901	KLHDC8B	0.54	7.71	0.34	7.71e-14	Menarche (age at onset);
LGG	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-17.08	-0.62	4.63e-51	Chronic sinus infection;
LGG	cis	rs11098499	0.820	rs28535956	chr4:120536858	C/T	cg24375607	chr4:120327624	NA	-0.65	-10.87	-0.45	1.16e-24	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11628318	0.614	rs7149667	chr14:103129441	G/A	cg12046867	chr14:103022105	NA	0.74	12.52	0.5	3.62e-31	Platelet count;
LGG	cis	rs61931739	0.500	rs11053268	chr12:34545121	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.85e-21	Morning vs. evening chronotype;
LGG	trans	rs10805346	0.505	rs35995899	chr4:10112862	T/C	cg26043149	chr18:55253948	FECH	0.4	6.71	0.3	5.61e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	cis	rs6540556	0.608	rs3817821	chr1:209918503	A/T	cg23920097	chr1:209922102	NA	-0.44	-8.14	-0.35	3.82e-15	Red blood cell count;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg05335186	chr13:53173507	NA	0.79	20.73	0.69	4.94e-68	Lewy body disease;
LGG	cis	rs9303280	0.901	rs9303277	chr17:37976469	C/T	cg00129232	chr17:37814104	STARD3	-0.46	-8.7	-0.37	6.06e-17	Self-reported allergy;
LGG	trans	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg14791747	chr16:20752902	THUMPD1	0.5	7.43	0.33	5.17e-13	Cognitive test performance;
LGG	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg00784671	chr22:46762841	CELSR1	-0.64	-7.38	-0.32	7.55e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6912958	0.781	rs2284908	chr6:88194500	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.54	-0.37	1.98e-16	Monocyte percentage of white cells;
LGG	cis	rs6952808	0.630	rs4719443	chr7:2161099	A/G	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.75	-0.45	3.31e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.565	rs2022392	chr1:183104863	T/A	cg07928641	chr1:182991847	LAMC1	0.45	8.92	0.38	1.07e-17	Fuchs's corneal dystrophy;
LGG	cis	rs1799949	0.602	rs8176257	chr17:41216205	G/T	cg05368731	chr17:41323189	NBR1	0.88	13.95	0.54	3.64e-37	Menopause (age at onset);
LGG	cis	rs9660180	1.000	rs3737628	chr1:1722932	C/T	cg02915803	chr1:1606292	LOC728661;CDK11B	0.38	7.21	0.32	2.32e-12	Body mass index;
LGG	cis	rs1153858	1.000	rs2066090	chr15:45650018	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.91	-0.48	1.01e-28	Alzheimer's disease;
LGG	cis	rs6693567	0.565	rs11205370	chr1:150397567	A/G	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs1008375	0.966	rs3775927	chr4:17599894	G/T	cg10189774	chr4:17578691	LAP3	0.4	7.06	0.31	6.13e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.53	8.91	0.38	1.2e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.818	rs3775099	chr4:1232510	C/G	cg06654118	chr4:1303317	MAEA	0.42	6.89	0.31	1.8e-11	Obesity-related traits;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.52	0.33	2.8e-13	Lung cancer;
LGG	trans	rs853679	0.607	rs13204012	chr6:28201531	G/A	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.41	-0.5	1.02e-30	Depression;
LGG	cis	rs77633900	0.614	rs2585730	chr15:76989344	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-10.5	-0.44	2.8e-23	Non-glioblastoma glioma;Glioma;
LGG	cis	rs7937682	0.663	rs35581942	chr11:111756286	C/T	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.543	rs4719436	chr7:2141239	G/A	cg02951883	chr7:2050386	MAD1L1	-0.71	-14.3	-0.55	1.1e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs832540	0.931	rs1445996	chr5:56235548	C/T	cg12654349	chr5:56205094	C5orf35	0.39	6.99	0.31	9.86e-12	Coronary artery disease;
LGG	cis	rs6430585	0.527	rs2304366	chr2:136467119	C/T	cg07169764	chr2:136633963	MCM6	1.0	16.72	0.61	1.95e-49	Corneal structure;
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00049323	chr5:472564	LOC25845	-0.4	-8.83	-0.38	2.1e-17	Cystic fibrosis severity;
LGG	cis	rs6762477	0.748	rs11711407	chr3:50225029	A/G	cg14019146	chr3:50243930	SLC38A3	0.35	7.6	0.33	1.6e-13	Menarche (age at onset);
LGG	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22857025	chr5:266934	NA	-1.55	-25.44	-0.76	5.97e-90	Breast cancer;
LGG	cis	rs6964587	0.934	rs35968894	chr7:91762145	A/G	cg17063962	chr7:91808500	NA	0.51	8.75	0.38	3.99e-17	Breast cancer;
LGG	trans	rs9467711	0.606	rs9358935	chr6:26369587	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1620921	0.505	rs2115870	chr6:161207992	A/G	cg01280913	chr6:161186852	NA	-0.51	-10.75	-0.45	3.35e-24	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs3790455	0.560	rs1171558	chr1:156452093	G/A	cg14087168	chr1:156450669	MEF2D	-0.65	-9.42	-0.4	2.13e-19	Migraine;
LGG	cis	rs62400317	0.859	rs10456546	chr6:45217424	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.3	-0.43	1.48e-22	Total body bone mineral density;
LGG	cis	rs6088580	0.524	rs6088567	chr20:33263872	A/T	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs6582630	0.519	rs2387812	chr12:38381480	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.87	-0.38	1.63e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7747724	0.715	rs2819993	chr6:20753887	G/A	cg13405222	chr6:20811065	CDKAL1	0.47	9.37	0.4	3.09e-19	Bladder cancer;
LGG	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg16724585	chr3:197361211	NA	-0.49	-8.66	-0.37	7.75e-17	Pancreatic cancer;
LGG	cis	rs28595532	0.720	rs72670225	chr4:119302167	C/T	cg21605333	chr4:119757512	SEC24D	0.9	8.55	0.37	1.84e-16	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg06636001	chr8:8085503	FLJ10661	-0.57	-11.01	-0.46	3.29e-25	Neuroticism;
LGG	cis	rs6714710	0.580	rs1838797	chr2:98454572	G/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs2180341	0.640	rs11154395	chr6:127629138	T/C	cg27446573	chr6:127587934	RNF146	0.73	13.36	0.53	1.18e-34	Breast cancer;
LGG	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	cg07245641	chr1:182991651	LAMC1	0.41	9.33	0.4	4.27e-19	Colorectal cancer;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19410845	chr2:84686791	SUCLG1	0.43	7.54	0.33	2.47e-13	Parental extreme longevity (95 years and older);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg10482924	chr11:62539163	TAF6L	-0.36	-6.81	-0.3	3.06e-11	Iris color (L* coordinate);
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg18402987	chr7:1209562	NA	0.67	9.17	0.39	1.5e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6542838	0.588	rs4851174	chr2:99530113	A/C	cg08885076	chr2:99613938	TSGA10	-0.33	-6.79	-0.3	3.51e-11	Fear of minor pain;
LGG	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	14.06	0.55	1.24e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2916247	1.000	rs35749070	chr8:93053007	C/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.36	-0.36	7.34e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7572733	1.000	rs2139049	chr2:198887660	G/A	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs2243480	1.000	rs4548056	chr7:65298873	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.22	-0.39	1.03e-18	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10794915	chr17:33569985	SLFN5	0.45	7.62	0.33	1.41e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7301016	0.894	rs11174487	chr12:62849999	T/C	cg11441379	chr12:63026424	NA	0.66	8.72	0.38	5.16e-17	IgG glycosylation;
LGG	cis	rs7129556	0.815	rs72947625	chr11:77399602	G/T	cg12586386	chr11:77299805	AQP11	0.46	7.36	0.32	8.19e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4664308	0.618	rs62175488	chr2:160892758	T/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.65	-0.48	1.07e-27	Idiopathic membranous nephropathy;
LGG	cis	rs2730245	0.593	rs842699	chr7:158663404	T/A	cg01943577	chr7:158741284	NA	-0.45	-7.92	-0.35	1.77e-14	Height;
LGG	cis	rs3796352	1.000	rs33999310	chr3:52883332	G/A	cg12962167	chr3:53033115	SFMBT1	0.69	7.3	0.32	1.25e-12	Immune reponse to smallpox (secreted IL-2);
LGG	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.88	-0.34	2.32e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	cis	rs7617773	0.746	rs11713476	chr3:48375434	C/T	cg11946769	chr3:48343235	NME6	0.62	10.58	0.44	1.39e-23	Coronary artery disease;
LGG	cis	rs12950390	0.893	rs4239165	chr17:45847272	A/T	cg06532163	chr17:45867833	NA	0.54	9.21	0.39	1.17e-18	IgG glycosylation;
LGG	cis	rs9815354	0.857	rs794894	chr3:42032483	C/T	cg03022575	chr3:42003672	ULK4	-0.61	-7.52	-0.33	2.84e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs8081454	chr17:61842646	A/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs801193	1.000	rs3857688	chr7:66127806	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.86	-0.45	1.28e-24	Aortic root size;
LGG	cis	rs6076065	0.748	rs6048750	chr20:23334192	T/G	cg11657817	chr20:23433608	CST11	0.4	8.12	0.35	4.33e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs62238980	0.614	rs734091	chr22:32461891	A/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs6032067	0.636	rs7272597	chr20:43908869	T/C	cg10761708	chr20:43804764	PI3	0.58	8.96	0.38	7.96e-18	Blood protein levels;
LGG	cis	rs2236918	0.965	rs2488472	chr1:242019919	T/C	cg17736920	chr1:242011382	EXO1	0.52	9.43	0.4	2.06e-19	Menopause (age at onset);
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg03264133	chr6:25882463	NA	-0.43	-7.61	-0.33	1.52e-13	Height;
LGG	cis	rs10911232	0.507	rs4575047	chr1:182976028	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Hypertriglyceridemia;
LGG	cis	rs7681440	0.835	rs7656954	chr4:90784670	G/A	cg14346243	chr4:90757452	SNCA	-0.39	-7.76	-0.34	5.58e-14	Dementia with Lewy bodies;
LGG	cis	rs56283067	0.816	rs9472367	chr6:44774597	C/T	cg20913747	chr6:44695427	NA	-0.64	-9.66	-0.41	3.1e-20	Total body bone mineral density;
LGG	cis	rs7927771	0.524	rs10742817	chr11:47689343	A/G	cg20307385	chr11:47447363	PSMC3	-0.58	-11.58	-0.47	2.16e-27	Subjective well-being;
LGG	cis	rs2243480	1.000	rs313820	chr7:65574466	A/C	cg13147721	chr7:65941812	NA	-0.83	-10.31	-0.43	1.38e-22	Diabetic kidney disease;
LGG	cis	rs3087591	0.960	rs2905793	chr17:29470072	C/T	cg24425628	chr17:29625626	OMG;NF1	0.69	14.26	0.55	1.61e-38	Hip circumference;
LGG	cis	rs4930103	0.874	rs80047492	chr11:2025032	A/T	cg06197492	chr11:2016605	H19	0.45	8.79	0.38	3.05e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg11890956	chr21:40555474	PSMG1	1.16	27.29	0.79	1.91e-98	Cognitive function;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg18110333	chr6:292329	DUSP22	-0.7	-12.01	-0.49	4.08e-29	Menopause (age at onset);
LGG	cis	rs7107174	1.000	rs2511171	chr11:77930935	G/A	cg02023728	chr11:77925099	USP35	0.44	7.71	0.34	7.74e-14	Testicular germ cell tumor;
LGG	cis	rs3784262	0.669	rs4646564	chr15:58351797	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.85	-0.3	2.32e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs9487051	0.676	rs7773213	chr6:109601885	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.17e-14	Reticulocyte fraction of red cells;
LGG	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg08949735	chr16:89699720	DPEP1	-0.37	-7.22	-0.32	2.18e-12	Hemoglobin concentration;
LGG	cis	rs1505368	0.505	rs12694279	chr2:213253406	C/A	cg16329650	chr2:213403929	ERBB4	0.44	7.81	0.34	3.77e-14	Symmetrical dimethylarginine levels;
LGG	cis	rs9650657	0.538	rs11250093	chr8:10798828	C/T	cg27411982	chr8:10470053	RP1L1	0.43	7.27	0.32	1.59e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26719024	chr10:105156444	PDCD11;USMG5	0.55	8.39	0.36	5.8e-16	Gut microbiome composition (summer);
LGG	cis	rs13217239	0.646	rs12201393	chr6:26975690	C/A	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.31e-11	Schizophrenia;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg26174226	chr8:58114915	NA	-0.59	-8.55	-0.37	1.87e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg04034577	chr2:241836375	C2orf54	-0.51	-10.31	-0.43	1.46e-22	Urinary metabolites;
LGG	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs365132	0.875	rs353477	chr5:176418927	C/T	cg16309518	chr5:176445507	NA	-0.51	-11.25	-0.46	4.05e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs6500395	1.000	rs2354578	chr16:48593298	T/C	cg16662043	chr16:48846231	NA	0.36	7.07	0.31	5.9e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7712401	0.562	rs2927639	chr5:122279666	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs137603	0.603	rs137581	chr22:39677838	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.72	-14.05	-0.55	1.29e-37	Primary biliary cholangitis;
LGG	cis	rs10751667	0.643	rs7396046	chr11:937176	T/C	cg22143635	chr11:980567	AP2A2	0.43	7.89	0.34	2.26e-14	Alzheimer's disease (late onset);
LGG	cis	rs765787	0.530	rs11636404	chr15:45535861	C/G	cg25801113	chr15:45476975	SHF	0.88	20.25	0.69	9.31e-66	Uric acid levels;
LGG	cis	rs4950322	0.570	rs72692953	chr1:146793135	A/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs1865760	0.566	rs9348706	chr6:26065481	G/C	cg03264133	chr6:25882463	NA	-0.38	-6.73	-0.3	5.11e-11	Height;
LGG	cis	rs1348850	0.958	rs4893965	chr2:178463852	G/T	cg22681709	chr2:178499509	PDE11A	-0.43	-7.91	-0.34	1.92e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4631830	0.900	rs4630241	chr10:51532751	G/A	cg16070123	chr10:51489643	NA	-0.4	-7.18	-0.32	2.81e-12	Prostate-specific antigen levels;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.11	0.35	4.74e-15	Bipolar disorder;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs4774899	0.932	rs1545728	chr15:57551912	G/A	cg08128148	chr15:57256372	TCF12	-0.31	-7.16	-0.32	3.27e-12	Urinary tract infection frequency;
LGG	cis	rs6988985	0.560	rs5301	chr8:143955273	T/C	cg10324643	chr8:143916377	GML	0.44	9.15	0.39	1.88e-18	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs10197940	0.662	rs10175134	chr2:152299355	G/A	cg06191203	chr2:152266755	RIF1	-0.46	-8.12	-0.35	4.16e-15	Lung cancer;
LGG	cis	rs17453880	0.890	rs12522538	chr5:152002303	A/G	cg10931792	chr5:152022470	NA	0.38	8.18	0.36	2.69e-15	Subjective well-being;
LGG	cis	rs13102973	0.932	rs13112852	chr4:135838470	C/T	cg14419869	chr4:135874104	NA	0.56	10.58	0.44	1.38e-23	Subjective well-being;
LGG	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg03264133	chr6:25882463	NA	-0.48	-7.73	-0.34	6.64e-14	Iron status biomarkers;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.63	0.37	9.77e-17	Obesity-related traits;
LGG	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg27523141	chr10:43048294	ZNF37B	-0.41	-8.24	-0.36	1.78e-15	Extrinsic epigenetic age acceleration;
LGG	cis	rs9443645	0.527	rs3902856	chr6:79699837	C/T	cg18132916	chr6:79620363	NA	-0.27	-6.96	-0.31	1.13e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs6592772	chr11:78015563	A/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.52	-0.33	2.8e-13	Testicular germ cell tumor;
LGG	cis	rs7580658	0.963	rs10803585	chr2:128130108	G/A	cg10021288	chr2:128175891	PROC	-0.65	-13.43	-0.53	5.94e-35	Protein C levels;
LGG	cis	rs7937682	0.737	rs663763	chr11:111422217	C/T	cg09085632	chr11:111637200	PPP2R1B	-0.91	-18.15	-0.64	5.21e-56	Primary sclerosing cholangitis;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg04008888	chr11:68622739	NA	-0.55	-12.03	-0.49	3.54e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.660	rs13224319	chr7:66007363	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.46	9.64	0.41	3.52e-20	Aortic root size;
LGG	cis	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg06374794	chr16:88002281	BANP	0.45	8.49	0.37	2.82e-16	Menopause (age at onset);
LGG	cis	rs600231	0.665	rs1621277	chr11:65221954	A/G	cg17120908	chr11:65337727	SSSCA1	0.48	8.54	0.37	2.02e-16	Bone mineral density;
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.47	0.4	1.49e-19	Bipolar disorder;
LGG	cis	rs13191362	0.938	rs35211042	chr6:162998703	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.7	7.91	0.35	1.92e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10934753	0.632	rs2001273	chr3:125926110	C/T	cg01346077	chr3:125931526	NA	0.54	13.31	0.53	1.83e-34	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs79057730	1.000	rs79057730	chr7:784943	C/G	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.73	7.81	0.34	3.91e-14	Initial pursuit acceleration;
LGG	cis	rs847577	0.609	rs7791463	chr7:97819047	G/A	cg13397024	chr7:97797637	LMTK2	-0.35	-6.67	-0.3	7.15e-11	Breast cancer;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.77	-14.21	-0.55	2.61e-38	Longevity;Endometriosis;
LGG	cis	rs2282802	0.635	rs397463	chr5:139584275	C/G	cg26211634	chr5:139558579	C5orf32	-0.34	-7.43	-0.33	5.18e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.660	rs665413	chr17:37455678	T/A	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.57e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs12155623	0.932	rs34236473	chr8:49828725	A/T	cg00325661	chr8:49890786	NA	0.43	7.05	0.31	6.65e-12	Sudden cardiac arrest;
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.66	0.3	7.99e-11	Lung cancer;
LGG	cis	rs6743226	0.580	rs11884197	chr2:242242786	C/T	cg10021735	chr2:242295487	FARP2	0.4	7.01	0.31	8.61e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs9894429	0.966	rs6565601	chr17:79580173	C/T	cg10661904	chr17:79619235	PDE6G	-0.42	-8.53	-0.37	2.03e-16	Eye color traits;
LGG	cis	rs6430585	0.591	rs12477421	chr2:136433740	A/G	cg07169764	chr2:136633963	MCM6	1.09	18.37	0.65	4.92e-57	Corneal structure;
LGG	cis	rs73001065	0.636	rs56241616	chr19:19506092	C/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.91	0.45	8.34e-25	LDL cholesterol;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.883	rs566647	chr11:111466607	A/G	cg19812747	chr11:111475976	SIK2	0.49	10.29	0.43	1.74e-22	Primary sclerosing cholangitis;
LGG	cis	rs2456568	0.802	rs10831139	chr11:93640537	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.74	-0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs2228479	0.850	rs62052660	chr16:89847420	T/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.81	-0.34	3.77e-14	Skin colour saturation;
LGG	cis	rs9300255	0.722	rs10773008	chr12:123800820	A/G	cg05973401	chr12:123451056	ABCB9	0.45	6.68	0.3	6.95e-11	Neutrophil percentage of white cells;
LGG	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.25	-0.46	4.15e-26	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg01221209	chr5:554886	NA	-0.49	-7.77	-0.34	5.22e-14	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg21724239	chr8:58056113	NA	0.61	9.03	0.39	4.56e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4604732	0.536	rs12058821	chr1:247649651	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	10.62	0.44	9.67e-24	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.43	-0.53	6.03e-35	Diastolic blood pressure;
LGG	cis	rs13082711	0.554	rs6804440	chr3:27398150	C/T	cg02860705	chr3:27208620	NA	0.93	16.9	0.62	2.87e-50	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg05592184	chr3:40498513	RPL14	-0.42	-6.65	-0.3	8.08e-11	Body fat percentage;
LGG	cis	rs240764	0.817	rs239226	chr6:101107969	G/C	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.94	-0.42	3.17e-21	Lymphocyte counts;
LGG	trans	rs1005277	0.540	rs2474598	chr10:38430296	C/T	cg17830980	chr10:43048298	ZNF37B	0.62	14.35	0.55	6.5e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs11229555	0.645	rs12785578	chr11:58206432	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs854037	1.000	rs854037	chr5:57091783	A/G	cg08523694	chr5:57076192	NA	0.5	7.89	0.34	2.26e-14	Birth weight;
LGG	cis	rs34929064	0.836	rs2961301	chr7:22709029	C/T	cg18045685	chr7:22629474	NA	-0.54	-9.89	-0.42	4.58e-21	Major depression and alcohol dependence;
LGG	cis	rs11758351	1.000	rs2143347	chr6:26198494	C/T	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs4742903	0.904	rs7048676	chr9:106998349	G/A	cg14250997	chr9:106856677	SMC2	0.37	7.77	0.34	5.28e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs28386778	0.799	rs2584612	chr17:61932204	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs12282928	1.000	rs4752923	chr11:48288155	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.31	-0.32	1.21e-12	Migraine - clinic-based;
LGG	cis	rs11096990	0.634	rs6852967	chr4:39283146	G/T	cg24403649	chr4:39172243	NA	-0.41	-7.24	-0.32	1.85e-12	Cognitive function;
LGG	cis	rs9911578	0.933	rs74370218	chr17:57095212	C/T	cg05425664	chr17:57184151	TRIM37	0.71	11.67	0.48	8.79e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1451375	0.617	rs2060763	chr7:50542359	G/A	cg20336341	chr7:50628841	DDC	-0.42	-7.22	-0.32	2.11e-12	Malaria;
LGG	cis	rs7552404	1.000	rs4559448	chr1:76203456	A/G	cg03433033	chr1:76189801	ACADM	0.8	13.76	0.54	2.27e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs16854884	0.657	rs16854816	chr3:143734147	A/G	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs9811920	0.732	rs7613864	chr3:99602470	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	8.92	0.38	1.1e-17	Axial length;
LGG	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg14416269	chr4:6271139	WFS1	0.45	7.32	0.32	1.12e-12	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1862618	0.671	rs252897	chr5:56223000	G/A	cg08400814	chr5:56204995	C5orf35	-0.44	-7.79	-0.34	4.39e-14	Initial pursuit acceleration;
LGG	cis	rs12701220	0.847	rs10272002	chr7:1047615	A/G	cg02733842	chr7:1102375	C7orf50	-0.47	-7.33	-0.32	1.05e-12	Bronchopulmonary dysplasia;
LGG	cis	rs7385804	0.761	rs568733	chr7:100311662	G/T	cg20848291	chr7:100343083	ZAN	0.44	7.13	0.31	3.93e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	trans	rs11764590	0.694	rs2056477	chr7:2079744	G/C	cg11693508	chr17:37793320	STARD3	0.46	7.11	0.31	4.32e-12	Neuroticism;
LGG	cis	rs9355814	0.539	rs9355297	chr6:161023165	C/G	cg04181478	chr6:161122748	PLG	0.43	7.08	0.31	5.39e-12	Lipoprotein (a) levels;
LGG	cis	rs6565180	0.632	rs8050812	chr16:30385837	C/T	cg17640201	chr16:30407289	ZNF48	-0.75	-13.13	-0.52	1.07e-33	Tonsillectomy;
LGG	cis	rs9341835	0.542	rs4710430	chr6:64165344	C/A	cg00787780	chr6:64151745	NA	0.41	7.25	0.32	1.71e-12	Schizophrenia;
LGG	cis	rs8177253	0.633	rs10935073	chr3:133439184	T/C	cg08048268	chr3:133502702	NA	-0.5	-8.36	-0.36	7.27e-16	Iron status biomarkers;
LGG	cis	rs12681287	0.511	rs4129535	chr8:87524094	G/T	cg27223183	chr8:87520930	FAM82B	-0.49	-7.38	-0.32	7.15e-13	Caudate activity during reward;
LGG	cis	rs7551222	0.749	rs10900600	chr1:204559707	G/T	cg20240347	chr1:204465584	NA	-0.47	-8.97	-0.38	7.22e-18	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.38	6.67	0.3	7.16e-11	Obesity-related traits;
LGG	cis	rs10791323	0.572	rs10894755	chr11:133739685	C/T	cg06766960	chr11:133703094	NA	0.53	10.49	0.44	2.99e-23	Childhood ear infection;
LGG	cis	rs1978968	0.913	rs34272636	chr22:18433603	A/C	cg03078520	chr22:18463400	MICAL3	-0.61	-11.2	-0.46	6.45e-26	Presence of antiphospholipid antibodies;
LGG	cis	rs10504229	0.683	rs10504223	chr8:58140944	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9462846	0.691	rs9462853	chr6:42910666	T/C	cg13397359	chr6:42928475	GNMT	0.43	9.46	0.4	1.6e-19	Blood protein levels;
LGG	cis	rs17208368	0.628	rs11645360	chr16:55074488	G/A	cg09947736	chr16:55091198	NA	0.64	10.78	0.45	2.43e-24	Hypospadias;
LGG	cis	rs7309	0.935	rs1921309	chr2:162048975	T/A	cg16506815	chr2:162101123	NA	0.27	6.8	0.3	3.23e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg12419862	chr22:24373484	LOC391322	0.87	17.53	0.63	3.98e-53	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4750440	0.637	rs2447010	chr10:14032115	T/C	cg27542038	chr10:14027202	FRMD4A	-0.53	-10.06	-0.42	1.19e-21	Adiponectin levels;
LGG	cis	rs7399018	1.000	rs7399018	chr12:51610365	C/T	cg25754956	chr12:51612065	POU6F1	-0.55	-8.49	-0.37	2.86e-16	Cisplatin-induced ototoxicity;
LGG	cis	rs2404602	0.716	rs12902174	chr15:76863540	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	1.94e-18	Blood metabolite levels;
LGG	cis	rs12476592	0.571	rs262518	chr2:63891335	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs7177699	0.567	rs67745769	chr15:79124832	G/A	cg00540400	chr15:79124168	NA	-0.53	-11.14	-0.46	1.05e-25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs546131	0.642	rs561477	chr11:34852152	G/A	cg06937548	chr11:34938143	PDHX;APIP	0.44	7.13	0.31	3.97e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs66486766	1	rs66486766	chr15:84806060	G/A	cg03959625	chr15:84868606	LOC388152	0.54	8.23	0.36	1.97e-15	Bipolar disorder lithium response (categorical) or schizophrenia;
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	trans	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg08344181	chr3:125677491	NA	-0.61	-7.08	-0.31	5.25e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2587949	0.571	rs2629253	chr3:4247018	T/C	cg16519197	chr3:4211558	NA	0.37	7.3	0.32	1.27e-12	Periodontitis (DPAL);
LGG	cis	rs4936891	0.543	rs7102719	chr11:123877757	G/A	cg22125253	chr11:123886957	OR10G4	-0.49	-8.19	-0.36	2.55e-15	Male fertility;
LGG	cis	rs225245	0.817	rs1476553	chr17:33994566	C/T	cg05299278	chr17:33885742	SLFN14	0.42	8.1	0.35	5.04e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs858239	0.600	rs13438188	chr7:23144197	C/T	cg23682824	chr7:23144976	KLHL7	-0.44	-7.73	-0.34	6.93e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1620921	0.711	rs1652466	chr6:161249569	T/G	cg01280913	chr6:161186852	NA	-0.34	-7.03	-0.31	7.56e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10089	0.904	rs3087889	chr5:127524944	T/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.6	0.47	1.73e-27	Ileal carcinoids;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg04160749	chr8:58172571	NA	-0.51	-8.11	-0.35	4.57e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.03	-25.36	-0.76	1.28e-89	Prudent dietary pattern;
LGG	cis	rs8177253	0.632	rs6782523	chr3:133438917	C/T	cg01448562	chr3:133502909	NA	-0.55	-8.93	-0.38	9.83e-18	Iron status biomarkers;
LGG	cis	rs116095464	1.000	rs7723693	chr5:306032	G/A	cg22857025	chr5:266934	NA	-1.32	-13.02	-0.52	2.93e-33	Breast cancer;
LGG	trans	rs9987353	0.830	rs2126267	chr8:9107951	C/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-6.93	-0.31	1.38e-11	Recombination measurement;
LGG	cis	rs1552244	0.935	rs7652190	chr3:10105150	G/A	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg06634786	chr22:41940651	POLR3H	0.78	12.41	0.5	9.51e-31	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg08989290	chr16:615782	NHLRC4	0.33	6.81	0.3	3.02e-11	Height;
LGG	cis	rs4838594	0.549	rs11101333	chr10:49668179	A/G	cg17291251	chr10:49678358	ARHGAP22	0.54	11.22	0.46	5.08e-26	Daytime sleep phenotypes;
LGG	cis	rs2274273	0.840	rs10467798	chr14:55724927	C/T	cg04306507	chr14:55594613	LGALS3	0.63	17.39	0.63	1.67e-52	Protein biomarker;
LGG	cis	rs854765	0.647	rs7211714	chr17:17986955	A/G	cg05444541	chr17:17804740	TOM1L2	-0.58	-12.63	-0.51	1.22e-31	Total body bone mineral density;
LGG	cis	rs10791097	0.765	rs10894269	chr11:130722789	C/T	cg12179176	chr11:130786555	SNX19	0.78	14.72	0.56	1.64e-40	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs17685	0.593	rs56265719	chr7:75796269	C/T	cg19862616	chr7:65841803	NCRNA00174	1.06	24.17	0.75	4.6e-84	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg27427491	chr17:78079615	GAA	-0.31	-6.71	-0.3	5.59e-11	Yeast infection;
LGG	cis	rs2201728	0.967	rs2866151	chr4:100198512	A/T	cg07219303	chr4:100140905	ADH6	-0.39	-7.82	-0.34	3.63e-14	Cardiac Troponin-T levels;
LGG	cis	rs1801251	0.896	rs2197563	chr2:233687080	G/A	cg25237894	chr2:233734115	C2orf82	-0.58	-11.21	-0.46	5.9e-26	Coronary artery disease;
LGG	cis	rs7618501	0.602	rs10049087	chr3:50123417	A/G	cg05623727	chr3:50126028	RBM5	-0.37	-8.12	-0.35	4.36e-15	Intelligence (multi-trait analysis);
LGG	cis	rs735860	0.737	rs2115564	chr6:53173482	C/A	cg10236188	chr6:53219634	NA	-0.41	-7.93	-0.35	1.65e-14	Glaucoma;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14928532	chr9:133454630	LOC100272217;FUBP3	0.4	7.29	0.32	1.35e-12	Obesity-related traits;
LGG	cis	rs6918586	0.615	rs198841	chr6:26111671	G/T	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.71	-0.41	2.11e-20	Schizophrenia;
LGG	cis	rs7507204	0.530	rs4807469	chr19:3443382	G/C	cg08380311	chr19:3435252	NFIC	1.05	25.11	0.76	1.96e-88	Height;
LGG	cis	rs7084783	0.967	rs1994837	chr10:105332302	T/C	cg00126946	chr10:105363258	SH3PXD2A	0.38	6.65	0.3	8.12e-11	Fear of pain;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.25	-0.49	4.36e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs1109114	1.000	rs1109114	chr5:148615946	C/T	cg06539116	chr5:148597365	ABLIM3	-0.57	-13.38	-0.53	9.55e-35	Body mass index;
LGG	cis	rs2444240	0.505	rs566935	chr11:120055477	C/G	cg04390734	chr11:120039366	NA	-0.26	-6.94	-0.31	1.34e-11	Corneal curvature;
LGG	cis	rs798554	0.797	rs798488	chr7:2802522	T/C	cg18446336	chr7:2847575	GNA12	-0.28	-6.66	-0.3	7.82e-11	Height;
LGG	cis	rs1562975	0.567	rs7655031	chr4:109407640	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.39	6.76	0.3	4.15e-11	Height;
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg19539972	chr4:7069911	GRPEL1	0.79	11.22	0.46	5.37e-26	Monocyte percentage of white cells;
LGG	cis	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg03060546	chr3:49711283	APEH	-0.63	-10.34	-0.43	1.08e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7192750	0.586	rs4788447	chr16:71874860	C/T	cg06353428	chr16:71660113	MARVELD3	0.67	10.61	0.44	1.14e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03082763	chr19:12662438	ZNF564	0.43	7.33	0.32	1.07e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4481887	0.604	rs10888330	chr1:248410506	A/T	cg01631408	chr1:248437212	OR2T33	-0.43	-7.24	-0.32	1.9e-12	Common traits (Other);
LGG	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg20607798	chr8:58055168	NA	-0.69	-7.75	-0.34	6.03e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04389262	chr14:89882592	FOXN3	0.48	6.92	0.31	1.55e-11	Gut microbiome composition (summer);
LGG	cis	rs4948102	0.595	rs10255049	chr7:56121304	G/A	cg17215666	chr7:56131930	SUMF2	0.5	8.44	0.37	4.05e-16	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs6489785	0.737	rs2454729	chr12:121354956	C/T	cg02419362	chr12:121203948	SPPL3	0.46	7.15	0.32	3.43e-12	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9325144	0.555	rs6582576	chr12:38701230	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.76	-0.34	5.51e-14	Morning vs. evening chronotype;
LGG	trans	rs7980799	0.717	rs12296290	chr12:33503554	G/T	cg26384229	chr12:38710491	ALG10B	-0.39	-6.65	-0.3	8.23e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs7954584	0.604	rs34159444	chr12:122416667	A/G	cg22168489	chr12:122356033	WDR66	0.41	9.48	0.4	1.29e-19	Mean corpuscular volume;
LGG	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg06470251	chr20:60548479	NA	0.4	6.89	0.3	1.82e-11	Body mass index;
LGG	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611519	0.929	rs13055800	chr22:41440424	G/A	cg06634786	chr22:41940651	POLR3H	-0.43	-6.76	-0.3	4.2e-11	Neuroticism;
LGG	cis	rs4423214	0.879	rs1790330	chr11:71147825	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.21	-0.46	5.6e-26	Vitamin D levels;
LGG	cis	rs12497850	0.931	rs7627404	chr3:48819668	A/C	cg07636037	chr3:49044803	WDR6	1.09	27.59	0.79	7.91e-100	Parkinson's disease;
LGG	cis	rs17384381	0.953	rs1498374	chr1:85787334	C/T	cg16011679	chr1:85725395	C1orf52	0.64	10.49	0.44	3.12e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10888329	0.707	rs4916106	chr1:248353537	G/A	cg00666640	chr1:248458726	OR2T12	0.46	6.87	0.3	2.12e-11	Autism spectrum disorder;
LGG	cis	rs7599312	0.534	rs10180824	chr2:213407975	G/A	cg16329650	chr2:213403929	ERBB4	0.78	16.75	0.61	1.45e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg02951883	chr7:2050386	MAD1L1	0.46	6.67	0.3	7.19e-11	Bipolar disorder;
LGG	cis	rs950776	0.518	rs12900783	chr15:78815523	G/A	cg17108064	chr15:78857060	CHRNA5	0.45	9.62	0.41	4.45e-20	Sudden cardiac arrest;
LGG	cis	rs6764363	0.527	rs12497412	chr3:278334	T/C	cg02057681	chr3:285234	CHL1	-0.42	-7.59	-0.33	1.82e-13	Sudden cardiac arrest;
LGG	cis	rs644799	0.965	rs2508713	chr11:95547927	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.95	0.54	3.53e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4959677	0.725	rs1772975	chr6:2503471	G/A	cg20147862	chr6:2634573	C6orf195	-0.38	-8.42	-0.36	4.69e-16	Orthostatic hypotension;
LGG	cis	rs7584330	0.868	rs6760842	chr2:238398165	C/T	cg16989719	chr2:238392110	NA	0.34	7.17	0.32	3.05e-12	Prostate cancer;
LGG	cis	rs526231	0.511	rs28062	chr5:102540201	A/G	cg23492399	chr5:102201601	PAM	-0.56	-8.15	-0.35	3.33e-15	Primary biliary cholangitis;
LGG	trans	rs7746199	0.736	rs10484399	chr6:27534528	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9875589	0.957	rs4407395	chr3:13951673	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.47	-9.33	-0.4	4.47e-19	Ovarian reserve;
LGG	cis	rs208520	0.706	rs851601	chr6:66893853	G/A	cg07460842	chr6:66804631	NA	-0.95	-17.34	-0.63	2.94e-52	Exhaled nitric oxide output;
LGG	cis	rs2228479	0.850	rs12598276	chr16:89829196	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.74	-0.38	4.36e-17	Skin colour saturation;
LGG	cis	rs2278491	0.528	rs4145242	chr8:117728296	C/T	cg23513447	chr8:117778558	UTP23	-0.5	-6.67	-0.3	7.3e-11	Body mass index;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.29e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6502050	0.871	rs7226049	chr17:80071049	A/G	cg10505658	chr17:80084571	CCDC57	0.41	8.5	0.37	2.66e-16	Life satisfaction;
LGG	cis	rs981844	1.000	rs2405431	chr4:154656396	A/G	cg14289246	chr4:154710475	SFRP2	0.68	11.14	0.46	1.1e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs10904908	1.000	rs7920002	chr10:17259766	T/A	cg01003015	chr10:17271136	VIM	-0.54	-8.86	-0.38	1.68e-17	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs9914988	0.945	rs9279	chr17:27187636	G/T	cg20469991	chr17:27169893	C17orf63	0.55	6.92	0.31	1.48e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg15556689	chr8:8085844	FLJ10661	0.44	7.75	0.34	5.76e-14	Neuroticism;
LGG	cis	rs1401999	1.000	rs6443924	chr3:183679532	A/G	cg20387954	chr3:183756860	HTR3D	0.66	13.57	0.53	1.44e-35	Anterior chamber depth;
LGG	cis	rs4774899	0.752	rs2470082	chr15:57337093	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-7.08	-0.31	5.26e-12	Urinary tract infection frequency;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.99	-0.35	1.07e-14	Life satisfaction;
LGG	cis	rs7599312	0.963	rs10184221	chr2:213409014	G/A	cg16329650	chr2:213403929	ERBB4	0.61	10.03	0.42	1.51e-21	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.896	rs8176098	chr17:41268206	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.7e-13	Menopause (age at onset);
LGG	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg06917634	chr15:78832804	PSMA4	0.69	12.71	0.51	6.03e-32	Sudden cardiac arrest;
LGG	cis	rs56399783	0.901	rs73049327	chr7:2795544	T/G	cg19731401	chr7:2775893	GNA12	0.37	7.48	0.33	3.73e-13	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg01729401	chr1:1750560	GNB1	-0.33	-6.71	-0.3	5.85e-11	Apolipoprotein A-IV levels;
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1348850	0.574	rs12988366	chr2:178417945	A/C	cg22681709	chr2:178499509	PDE11A	0.52	7.51	0.33	3.07e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg01420254	chr6:26195488	NA	0.9	12.06	0.49	2.59e-29	Gout;Renal underexcretion gout;
LGG	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg06789500	chr7:2109450	MAD1L1	-0.3	-6.89	-0.3	1.89e-11	Bipolar disorder;
LGG	cis	rs17401966	0.838	rs35759975	chr1:10474430	A/T	cg19773385	chr1:10388646	KIF1B	-0.43	-8.47	-0.37	3.36e-16	Hepatocellular carcinoma;
LGG	cis	rs10883723	0.810	rs3740406	chr10:104272789	C/T	cg05096777	chr10:104283225	SUFU	0.33	7.31	0.32	1.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9549367	0.713	rs553316	chr13:113838015	A/G	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs6547631	0.622	rs4240200	chr2:85925529	A/G	cg19805943	chr2:85933069	NA	0.32	6.82	0.3	2.93e-11	Blood protein levels;
LGG	cis	rs6121246	0.529	rs6060144	chr20:30178624	A/G	cg13852791	chr20:30311386	BCL2L1	0.65	8.55	0.37	1.78e-16	Mean corpuscular hemoglobin;
LGG	cis	rs2635047	1.000	rs2684841	chr18:44724262	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.01	0.39	5.53e-18	Educational attainment;
LGG	cis	rs657075	0.697	rs34590412	chr5:131710027	C/T	cg20453264	chr5:131705742	SLC22A5	0.63	7.99	0.35	1.06e-14	Rheumatoid arthritis;
LGG	cis	rs875971	0.862	rs2420174	chr7:65645361	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.45e-16	Aortic root size;
LGG	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg03264133	chr6:25882463	NA	-0.38	-6.76	-0.3	4.14e-11	Height;
LGG	cis	rs8062405	1.000	rs4451951	chr16:28836205	T/C	cg00198680	chr16:28758506	NA	0.3	7.27	0.32	1.53e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs10504229	0.683	rs79262965	chr8:58129826	G/T	cg14926445	chr8:58193284	C8orf71	-0.84	-10.55	-0.44	1.76e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.756	rs28628143	chr18:44799028	C/T	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.68	-0.3	7.05e-11	Educational attainment;
LGG	cis	rs11203032	0.831	rs3923282	chr10:90946752	C/T	cg16672925	chr10:90967113	CH25H	0.76	11.29	0.46	2.93e-26	Heart failure;
LGG	trans	rs62103177	0.810	rs62103178	chr18:77624555	C/G	cg14227996	chr4:17616232	MED28	0.73	9.02	0.39	4.99e-18	Opioid sensitivity;
LGG	cis	rs932287	0.651	rs1111010	chr11:9049935	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.44	9.1	0.39	2.73e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12368653	0.525	rs1564374	chr12:58010163	C/T	cg00700412	chr12:58011837	NA	0.49	10.45	0.44	4.35e-23	Multiple sclerosis;
LGG	cis	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg00262122	chr8:11665843	FDFT1	-0.42	-6.69	-0.3	6.32e-11	Monocyte count;
LGG	cis	rs35110281	0.659	rs73367822	chr21:45024252	C/T	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.83	-0.42	7.86e-21	Mean corpuscular volume;
LGG	cis	rs17453880	0.853	rs10476785	chr5:151973924	A/G	cg10931792	chr5:152022470	NA	0.38	8.31	0.36	1.08e-15	Subjective well-being;
LGG	cis	rs59918340	1.000	rs59918340	chr8:142232256	A/G	cg03653399	chr8:142233436	SLC45A4	0.35	7.18	0.32	2.71e-12	Immature fraction of reticulocytes;
LGG	cis	rs6714710	0.603	rs7583868	chr2:98588372	C/A	cg26665480	chr2:98280029	ACTR1B	0.59	9.49	0.4	1.18e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs12477438	0.520	rs1453563	chr2:99720267	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs4665809	0.590	rs4665315	chr2:26416036	T/G	cg08470875	chr2:26401718	FAM59B	-0.42	-8.28	-0.36	1.32e-15	Gut microbiome composition (summer);
LGG	cis	rs7546668	1.000	rs10803390	chr1:15865418	G/A	cg21858823	chr1:15850916	CASP9	0.38	6.98	0.31	1.02e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.572	rs67439440	chr3:10169503	C/T	cg00149659	chr3:10157352	C3orf10	1.19	14.13	0.55	6.27e-38	Alzheimer's disease;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg19664712	chr6:20534695	CDKAL1	0.45	6.79	0.3	3.5e-11	Apolipoprotein A-IV levels;
LGG	cis	rs4595586	0.525	rs17464772	chr12:39247777	G/A	cg13010199	chr12:38710504	ALG10B	0.59	10.78	0.45	2.49e-24	Morning vs. evening chronotype;
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs10078	0.559	rs2037077	chr5:447226	A/G	cg26072250	chr5:443457	EXOC3;C5orf55	0.51	7.24	0.32	1.93e-12	Fat distribution (HIV);
LGG	trans	rs7944735	0.517	rs74763661	chr11:48233772	T/C	cg03929089	chr4:120376271	NA	0.68	7.47	0.33	3.93e-13	Intraocular pressure;
LGG	cis	rs2455799	0.533	rs2470550	chr3:15743721	C/T	cg16303742	chr3:15540471	COLQ	-0.37	-7.29	-0.32	1.33e-12	Mean platelet volume;
LGG	cis	rs4819052	0.851	rs2838857	chr21:46681000	A/G	cg06618935	chr21:46677482	NA	-0.44	-8.69	-0.37	6.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg00339695	chr16:24857497	SLC5A11	0.42	7.3	0.32	1.3e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11252926	0.931	rs12358336	chr10:566981	A/T	cg08603382	chr10:743973	NA	-0.62	-11.64	-0.48	1.22e-27	Psychosis in Alzheimer's disease;
LGG	cis	rs9815354	1.000	rs1628874	chr3:41955714	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.26	-0.36	1.58e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs72700829	0.593	rs4418603	chr1:150989274	A/G	cg11822372	chr1:151115635	SEMA6C	-0.65	-6.85	-0.3	2.4e-11	Schizophrenia;
LGG	cis	rs9322193	0.962	rs3805753	chr6:150116798	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.86	0.3	2.22e-11	Lung cancer;
LGG	cis	rs12291225	0.679	rs11238	chr11:14288128	A/C	cg19336497	chr11:14380999	RRAS2	0.56	11.49	0.47	4.76e-27	Sense of smell;
LGG	cis	rs13102973	0.720	rs13129730	chr4:135888329	G/A	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs4319547	0.695	rs4758648	chr12:122900460	A/G	cg23029597	chr12:123009494	RSRC2	-0.88	-16.66	-0.61	3.46e-49	Body mass index;
LGG	cis	rs2242116	0.796	rs4587	chr3:46963502	T/C	cg16586182	chr3:47516702	SCAP	-0.58	-9.77	-0.41	1.31e-20	Birth weight;
LGG	cis	rs763121	0.853	rs7289855	chr22:39042221	G/T	cg06022373	chr22:39101656	GTPBP1	0.86	17.2	0.62	1.2e-51	Menopause (age at onset);
LGG	cis	rs9527	0.590	rs763914	chr10:104841587	T/C	cg05308233	chr10:104796373	CNNM2	-0.33	-7.3	-0.32	1.28e-12	Arsenic metabolism;
LGG	cis	rs7129220	0.588	rs7931957	chr11:10094304	G/A	cg01453529	chr11:10209919	SBF2	-0.42	-6.85	-0.3	2.38e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7647973	0.667	rs9869256	chr3:49624095	T/G	cg07636037	chr3:49044803	WDR6	0.56	7.2	0.32	2.41e-12	Menarche (age at onset);
LGG	cis	rs6952808	0.531	rs3779003	chr7:2184902	C/T	cg11050988	chr7:1952600	MAD1L1	-0.28	-6.71	-0.3	5.7e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16697775	chr6:43543259	POLH;XPO5	0.51	8.62	0.37	1.03e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg22916017	chr11:64110731	CCDC88B	-0.45	-6.66	-0.3	7.66e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.56	-10.39	-0.43	7.43e-23	Obesity-related traits;
LGG	cis	rs1829883	1.000	rs1403661	chr5:98777056	T/A	cg08333243	chr5:99726346	NA	-0.39	-7.67	-0.34	1.01e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4319547	0.737	rs4758646	chr12:122946507	G/A	cg05707623	chr12:122985044	ZCCHC8	-0.56	-8.41	-0.36	5.01e-16	Body mass index;
LGG	cis	rs314370	0.951	rs13226502	chr7:100506381	C/T	cg10426581	chr7:100472382	SRRT	0.5	6.93	0.31	1.44e-11	Resting heart rate;
LGG	cis	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.2	-0.32	2.43e-12	Myopia;Myopia (pathological);
LGG	cis	rs6558530	0.692	rs6558525	chr8:1702523	A/G	cg08198773	chr8:1697536	NA	0.44	7.82	0.34	3.62e-14	Systolic blood pressure;
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg13939156	chr17:80058883	NA	-0.49	-9.2	-0.39	1.26e-18	Life satisfaction;
LGG	cis	rs4242434	0.672	rs2404654	chr8:22484949	T/C	cg00599393	chr8:22457479	C8orf58	-0.44	-8.08	-0.35	5.81e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9902453	0.874	rs62070271	chr17:28268358	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.22	0.55	2.4e-38	Coffee consumption (cups per day);
LGG	cis	rs644799	0.622	rs1255167	chr11:95500213	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.67	11.86	0.48	1.66e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs35110281	0.805	rs4818855	chr21:45038951	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-9.0	-0.39	5.87e-18	Mean corpuscular volume;
LGG	cis	rs7582720	1.000	rs114123510	chr2:203831212	T/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9815354	1.000	rs11928580	chr3:41885722	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs131777	0.577	rs131748	chr22:51024837	A/G	cg25309564	chr22:51001381	C22orf41	-0.42	-7.18	-0.32	2.86e-12	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs796364	0.951	rs12613687	chr2:200999256	C/T	cg23649088	chr2:200775458	C2orf69	-0.6	-7.93	-0.35	1.66e-14	Schizophrenia;
LGG	cis	rs6748734	0.548	rs12618707	chr2:241874559	T/C	cg26818257	chr2:241905806	NA	-0.5	-11.3	-0.46	2.6e-26	Urinary metabolites;
LGG	cis	rs7107174	1.000	rs2510037	chr11:77966099	A/G	cg02023728	chr11:77925099	USP35	0.45	8.03	0.35	8.3e-15	Testicular germ cell tumor;
LGG	cis	rs2730245	0.527	rs2788470	chr7:158649801	G/T	cg18245976	chr7:158708271	WDR60	-0.55	-7.1	-0.31	4.69e-12	Height;
LGG	cis	rs2467099	0.786	rs1135889	chr17:73926121	C/A	cg23806715	chr17:73775811	H3F3B	0.49	7.27	0.32	1.5e-12	Systolic blood pressure;
LGG	cis	rs2842992	0.830	rs2758352	chr6:160122921	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.71	11.88	0.48	1.31e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg22920501	chr2:26401640	FAM59B	-0.39	-7.74	-0.34	6.13e-14	Gut microbiome composition (summer);
LGG	cis	rs7572733	0.534	rs1607375	chr2:198800387	C/T	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	trans	rs10506458	0.688	rs73127095	chr12:63418283	T/G	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.12	-18.16	-0.64	5.06e-56	Hemostatic factors and hematological phenotypes;
LGG	cis	rs35110281	0.807	rs4818850	chr21:45028071	T/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.15	-0.39	1.79e-18	Mean corpuscular volume;
LGG	cis	rs12130219	0.500	rs1552991	chr1:152165878	C/T	cg09127314	chr1:152161683	NA	0.43	7.12	0.31	4.17e-12	Inflammatory skin disease;
LGG	cis	rs7179456	0.593	rs514049	chr15:59042363	A/C	cg05156742	chr15:59063176	FAM63B	-0.65	-12.01	-0.49	3.95e-29	Asperger disorder;
LGG	cis	rs3796352	1.000	rs71299622	chr3:52917038	G/A	cg12962167	chr3:53033115	SFMBT1	0.77	7.68	0.34	9.43e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs1190596	0.650	rs1190600	chr14:102591458	A/C	cg23904247	chr14:102554826	HSP90AA1	-0.25	-6.75	-0.3	4.46e-11	Behavioural disinhibition (generation interaction);
LGG	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg26384229	chr12:38710491	ALG10B	-0.6	-10.8	-0.45	2.15e-24	Morning vs. evening chronotype;
LGG	cis	rs7737355	1.000	rs7719126	chr5:130613749	T/C	cg06307176	chr5:131281290	NA	0.52	8.65	0.37	8.35e-17	Life satisfaction;
LGG	cis	rs7208859	0.623	rs56095789	chr17:29060170	A/G	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10940138	0.830	rs10447112	chr5:67219761	G/A	ch.5.1281357F	chr5:67228439	NA	0.76	13.39	0.53	8.27e-35	Menarche (age at onset);
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08280861	chr8:58055591	NA	0.64	7.85	0.34	2.97e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg01181863	chr3:195395398	SDHAP2	0.61	9.8	0.41	9.62e-21	Pancreatic cancer;
LGG	cis	rs9291683	1.000	rs9291683	chr4:10324160	C/T	cg25986240	chr4:9926439	SLC2A9	-0.33	-6.8	-0.3	3.31e-11	Bone mineral density;
LGG	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg06212747	chr3:49208901	KLHDC8B	0.74	13.19	0.52	6e-34	Menarche (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09742170	chr7:25021208	OSBPL3	0.47	7.79	0.34	4.46e-14	Cognitive performance;
LGG	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	trans	rs2832077	0.689	rs2832055	chr21:30132382	C/G	cg14791747	chr16:20752902	THUMPD1	-0.49	-8.21	-0.36	2.15e-15	Cognitive test performance;
LGG	cis	rs7444	0.825	rs2266963	chr22:21947467	C/G	cg22858872	chr22:21984481	YDJC	-0.37	-6.81	-0.3	3.08e-11	Systemic lupus erythematosus;
LGG	cis	rs12701220	0.568	rs7777700	chr7:1003096	C/G	cg26769984	chr7:1090371	C7orf50	0.45	7.54	0.33	2.56e-13	Bronchopulmonary dysplasia;
LGG	cis	rs875971	1.000	rs4718343	chr7:65874288	T/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs801193	0.569	rs2659892	chr7:66200305	A/G	cg18876405	chr7:65276391	NA	0.49	8.8	0.38	2.83e-17	Aortic root size;
LGG	cis	rs6933660	0.800	rs963193	chr6:151789355	G/T	cg17179660	chr6:151773299	C6orf211;RMND1	0.5	8.61	0.37	1.15e-16	Menarche (age at onset);
LGG	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg03254818	chr6:169586852	NA	0.52	7.96	0.35	1.38e-14	Pulse pressure;
LGG	trans	rs6089829	1.000	rs6089828	chr20:61668998	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.14	0.31	3.6e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs614226	1.000	rs563920	chr12:121017439	A/G	cg21053147	chr12:120880522	NA	-0.55	-8.25	-0.36	1.68e-15	Type 1 diabetes nephropathy;
LGG	cis	rs28588043	1.000	rs16863928	chr1:170960103	T/G	cg03458344	chr1:170964477	C1orf129	-0.5	-7.29	-0.32	1.37e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg04863758	chr4:1303710	MAEA	0.41	7.09	0.31	5.08e-12	Obesity-related traits;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.72	-0.38	5.13e-17	Lung cancer;
LGG	cis	rs2777491	0.668	rs2026946	chr15:41789704	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.87	-16.59	-0.61	7.6e-49	Ulcerative colitis;
LGG	cis	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg11050988	chr7:1952600	MAD1L1	-0.38	-9.25	-0.39	8.45e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7481584	0.926	rs10833024	chr11:3010390	C/T	cg08468577	chr11:2973342	NAP1L4	-0.37	-7.75	-0.34	6.05e-14	Calcium levels;
LGG	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg00405596	chr8:11794950	NA	0.66	11.71	0.48	6.54e-28	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg02269571	chr22:50332266	NA	-0.71	-10.9	-0.45	8.73e-25	Schizophrenia;
LGG	cis	rs9354308	0.738	rs9453473	chr6:66599132	C/T	cg07460842	chr6:66804631	NA	-0.4	-6.86	-0.3	2.26e-11	Metabolite levels;
LGG	cis	rs4423214	1.000	rs7944926	chr11:71165625	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.1	-0.52	1.45e-33	Vitamin D levels;
LGG	cis	rs1109114	0.966	rs2400829	chr5:148611528	G/A	cg06539116	chr5:148597365	ABLIM3	-0.59	-15.4	-0.58	1.64e-43	Body mass index;
LGG	cis	rs7666738	0.791	rs10033994	chr4:98969582	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7827545	1.000	rs6578238	chr8:135569490	A/C	cg17885191	chr8:135476712	NA	0.42	6.69	0.3	6.63e-11	Hypertension (SNP x SNP interaction);
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs9611565	0.559	rs6002408	chr22:41967870	C/T	cg06481639	chr22:41940642	POLR3H	-0.49	-7.03	-0.31	7.36e-12	Vitiligo;
LGG	cis	rs7618915	0.547	rs11130315	chr3:52697163	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.79	0.38	3.05e-17	Bipolar disorder;
LGG	cis	rs920590	0.758	rs62496731	chr8:19659543	C/G	cg01411142	chr8:19674711	INTS10	0.46	7.29	0.32	1.33e-12	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6951245	0.554	rs2070118	chr7:1132505	G/A	cg24642844	chr7:1081250	C7orf50	-0.48	-8.89	-0.38	1.4e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11190604	1.000	rs3750720	chr10:102248884	C/T	cg07080220	chr10:102295463	HIF1AN	0.66	11.3	0.46	2.58e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9534288	0.913	rs9534299	chr13:46625586	A/T	cg15192986	chr13:46630673	CPB2	-0.73	-16.03	-0.6	2.65e-46	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23193116	chr12:96184799	NTN4	0.44	6.69	0.3	6.57e-11	Gut microbiome composition (summer);
LGG	cis	rs9858542	0.953	rs35169793	chr3:49423274	A/G	cg00383909	chr3:49044727	WDR6	0.45	7.39	0.32	6.72e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg27490568	chr2:178487706	NA	0.82	12.61	0.51	1.53e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs7927771	1.000	rs10838748	chr11:47716381	T/G	cg20307385	chr11:47447363	PSMC3	-0.48	-8.52	-0.37	2.31e-16	Subjective well-being;
LGG	cis	rs9815354	1.000	rs6768542	chr3:41865474	G/A	cg03022575	chr3:42003672	ULK4	0.68	8.7	0.37	5.97e-17	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12421382	0.778	rs11213128	chr11:109489575	G/A	cg16359550	chr11:109292809	C11orf87	0.48	8.92	0.38	1.11e-17	Schizophrenia;
LGG	cis	rs1865760	0.865	rs9467647	chr6:25957642	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs17604090	0.529	rs2392128	chr7:29711139	A/G	cg12658982	chr7:29603541	PRR15	0.4	8.44	0.37	4.09e-16	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs6743226	0.934	rs4234100	chr2:242265273	A/G	cg10021735	chr2:242295487	FARP2	-0.53	-9.59	-0.41	5.63e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs523522	0.962	rs11065149	chr12:120956963	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.91	0.51	8.86e-33	High light scatter reticulocyte count;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.74	0.38	4.38e-17	Prudent dietary pattern;
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.27	-0.4	6.84e-19	Aortic root size;
LGG	cis	rs4481887	0.962	rs4369256	chr1:248492274	G/A	cg13385794	chr1:248469461	NA	0.48	8.12	0.35	4.39e-15	Common traits (Other);
LGG	cis	rs1465370	0.644	rs1558919	chr7:130029508	A/T	cg04743876	chr7:130013617	NA	0.35	7.79	0.34	4.48e-14	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.43	-0.33	5.24e-13	Iron status biomarkers;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1107366	1.000	rs1107366	chr3:125904165	A/G	cg17230874	chr3:125932073	NA	0.54	11.22	0.46	5.44e-26	Metabolite levels;
LGG	trans	rs10435719	0.610	rs80269926	chr8:11790527	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.4	0.33	6.53e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1577917	0.876	rs11752223	chr6:86573394	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.7	-12.21	-0.49	6.3e-30	Response to antipsychotic treatment;
LGG	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg13010199	chr12:38710504	ALG10B	0.67	13.62	0.53	9.23e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2075371	0.796	rs1978504	chr7:134006933	C/T	cg11752832	chr7:134001865	SLC35B4	-0.63	-11.68	-0.48	8.59e-28	Mean platelet volume;
LGG	cis	rs2373794	0.845	rs6746919	chr2:40370483	G/A	cg17740179	chr2:40377776	SLC8A1	-0.88	-18.62	-0.65	3.44e-58	Asthma;
LGG	cis	rs2273669	0.667	rs12154092	chr6:109313303	C/T	cg05315195	chr6:109294784	ARMC2	-0.65	-8.39	-0.36	5.81e-16	Prostate cancer;
LGG	cis	rs7552404	1.000	rs7534754	chr1:76185308	G/A	cg22875332	chr1:76189707	ACADM	0.61	10.37	0.43	8.8e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.42	-0.4	2.2e-19	Mean corpuscular volume;
LGG	cis	rs35123781	1.000	rs673632	chr5:139057237	G/T	cg21230503	chr5:139085173	NA	0.31	7.39	0.32	7.09e-13	Schizophrenia;
LGG	cis	rs17689437	0.647	rs1182967	chr16:68574378	C/T	cg02972257	chr16:68554789	NA	-0.43	-7.17	-0.32	3.01e-12	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.8	11.13	0.46	1.14e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4293296	0.830	rs7156971	chr14:54854783	T/C	cg11186706	chr14:54815745	NA	0.42	6.71	0.3	5.58e-11	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs4555082	0.756	rs76863138	chr14:105736379	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-15.86	-0.59	1.45e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1801251	0.574	rs2250660	chr2:233752551	G/C	cg08000102	chr2:233561755	GIGYF2	-0.4	-6.66	-0.3	8.01e-11	Coronary artery disease;
LGG	cis	rs7959452	0.535	rs2305641	chr12:69646914	C/T	cg14784868	chr12:69753453	YEATS4	0.65	12.31	0.5	2.52e-30	Blood protein levels;
LGG	cis	rs17767294	1.000	rs17767294	chr6:28054198	A/G	cg15325629	chr6:28072465	NA	1.02	8.9	0.38	1.26e-17	Parkinson's disease;
LGG	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg04055107	chr11:65626734	MUS81;CFL1	0.74	9.29	0.4	6.02e-19	Crohn's disease;
LGG	cis	rs4363385	0.693	rs6668311	chr1:152964586	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.9	-0.38	1.23e-17	Inflammatory skin disease;
LGG	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg06637938	chr14:75390232	RPS6KL1	0.57	10.49	0.44	3.19e-23	Height;
LGG	cis	rs7928758	0.830	rs11223780	chr11:134261150	C/T	cg25213107	chr11:134282864	B3GAT1	-0.96	-12.63	-0.51	1.23e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs28595532	0.920	rs116799007	chr4:119763562	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs801193	1.000	rs62466794	chr7:66191579	G/A	cg18252515	chr7:66147081	NA	-0.4	-6.73	-0.3	5.17e-11	Aortic root size;
LGG	cis	rs244731	1.000	rs244730	chr5:176539212	A/G	cg17509989	chr5:176798049	RGS14	-0.55	-7.89	-0.34	2.27e-14	Urate levels in lean individuals;
LGG	cis	rs1865760	0.555	rs2051541	chr6:25945211	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.16	-0.39	1.65e-18	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23092635	chr2:107199136	NA	0.44	7.36	0.32	8.36e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1577917	0.958	rs12198971	chr6:86525445	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs1712517	0.566	rs7076274	chr10:105046007	G/A	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.48e-15	Migraine;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg21139845	chr12:7053993	C12orf57	0.41	7.47	0.33	3.95e-13	Obesity-related traits;
LGG	cis	rs35264875	1.000	rs72919415	chr11:68827082	G/A	cg23845249	chr11:68861649	NA	0.44	7.9	0.34	2.1e-14	Blond vs. brown hair color;
LGG	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.25	-0.49	4.24e-30	Colorectal cancer;
LGG	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.69	-12.36	-0.5	1.54e-30	Colorectal cancer;
LGG	cis	rs12421382	0.778	rs12804063	chr11:109495509	C/T	cg07142201	chr11:109293216	C11orf87	-0.61	-10.92	-0.45	7.23e-25	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21092834	chr11:107462721	LOC643923;ELMOD1	0.42	7.04	0.31	7.07e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1107366	0.722	rs9851577	chr3:125908310	C/T	cg01346077	chr3:125931526	NA	0.41	9.95	0.42	2.84e-21	Metabolite levels;
LGG	cis	rs10991814	1.000	rs78826784	chr9:93944200	G/A	cg14446406	chr9:93919335	NA	-0.79	-8.57	-0.37	1.56e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.25	0.46	3.96e-26	Bipolar disorder;
LGG	cis	rs4737010	0.501	rs10099197	chr8:41654458	C/T	cg17182837	chr8:41585554	ANK1	-0.55	-7.87	-0.34	2.47e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs8067287	0.634	rs7225344	chr17:16840498	C/T	cg26910001	chr17:16838321	NA	0.41	8.4	0.36	5.48e-16	Diabetic kidney disease;
LGG	trans	rs3960554	0.673	rs112680895	chr7:75623520	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.26	0.5	4.17e-30	Eotaxin levels;
LGG	cis	rs13424612	0.965	rs4149544	chr2:240943162	C/T	cg01812947	chr2:240904978	NDUFA10	0.43	7.31	0.32	1.18e-12	Odorant perception (isobutyraldehyde);
LGG	trans	rs804280	0.662	rs11784764	chr8:11610874	C/T	cg02002194	chr4:3960332	NA	0.49	7.72	0.34	7.01e-14	Myopia (pathological);
LGG	cis	rs834603	0.518	rs834605	chr7:47450456	T/C	cg09696706	chr7:47479511	TNS3	0.35	7.68	0.34	9.26e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs972578	0.765	rs7511534	chr22:43372372	C/T	cg01576275	chr22:43409880	NA	0.25	7.57	0.33	2.11e-13	Mean platelet volume;
LGG	cis	rs4938330	0.512	rs4938327	chr11:116906728	T/C	cg20608306	chr11:116969690	SIK3	-0.41	-10.91	-0.45	7.82e-25	Blood protein levels;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.82	15.99	0.6	3.68e-46	Lymphocyte counts;
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg00424166	chr6:150045504	NUP43	-0.36	-7.2	-0.32	2.38e-12	Lung cancer;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.81	-0.41	9.1e-21	Lung cancer;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05662582	chr11:93517353	MED17	-0.38	-7.03	-0.31	7.57e-12	Brain structure;
LGG	cis	rs2708977	0.730	rs674920	chr2:97070156	C/G	cg01950434	chr2:97203154	ARID5A	-0.5	-7.61	-0.33	1.54e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs734999	0.505	rs10797438	chr1:2540262	C/T	cg20673091	chr1:2541236	MMEL1	0.78	19.1	0.66	2.06e-60	Ulcerative colitis;
LGG	cis	rs4268898	0.760	rs11676939	chr2:24479057	C/T	cg06627628	chr2:24431161	ITSN2	0.43	7.28	0.32	1.41e-12	Asthma;
LGG	cis	rs681343	1.000	rs516316	chr19:49206145	C/G	cg07051648	chr19:49177693	NTN5;SEC1	-0.45	-8.15	-0.35	3.43e-15	Lung adenocarcinoma;Primary sclerosing cholangitis;Childhood ear infection;
LGG	cis	rs209489	1.000	rs209526	chr6:53215899	A/C	cg15607103	chr6:53167650	ELOVL5	-0.55	-7.71	-0.34	7.99e-14	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg18681998	chr4:17616180	MED28	0.85	18.8	0.66	5.39e-59	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11096990	0.634	rs746678	chr4:39280655	A/G	cg24403649	chr4:39172243	NA	-0.4	-7.14	-0.31	3.68e-12	Cognitive function;
LGG	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg25208724	chr1:156163844	SLC25A44	1.07	22.24	0.72	4.28e-75	Testicular germ cell tumor;
LGG	cis	rs72615157	0.634	rs7789890	chr7:99800559	G/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.65	9.04	0.39	4.45e-18	Lung function (FEV1/FVC);
LGG	trans	rs7819412	0.522	rs13266785	chr8:10989521	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.48	-0.33	3.88e-13	Triglycerides;
LGG	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg06028605	chr16:24865363	SLC5A11	0.47	7.69	0.34	9.01e-14	Intelligence (multi-trait analysis);
LGG	cis	rs72949976	0.584	rs13001511	chr2:214025262	G/A	cg08319019	chr2:214017104	IKZF2	0.67	12.66	0.51	9.2e-32	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg09033563	chr22:24373618	LOC391322	-0.53	-9.18	-0.39	1.42e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12200782	0.932	rs12202419	chr6:26465384	G/T	cg23155468	chr6:27110703	HIST1H2BK	0.61	7.77	0.34	5.05e-14	Small cell lung carcinoma;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg20608306	chr11:116969690	SIK3	-0.34	-8.85	-0.38	1.81e-17	Blood protein levels;
LGG	cis	rs7084402	0.967	rs1649045	chr10:60327047	T/C	cg07615347	chr10:60278583	BICC1	0.62	17.62	0.63	1.57e-53	Refractive error;
LGG	cis	rs7954584	0.567	rs11043246	chr12:122368944	G/A	cg01765077	chr12:122356316	WDR66	0.29	7.67	0.34	1.01e-13	Mean corpuscular volume;
LGG	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.66e-11	Schizophrenia;
LGG	cis	rs67311347	0.911	rs6773917	chr3:40469254	G/T	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	cis	rs2117029	0.553	rs731350	chr12:49524587	G/C	cg24176009	chr12:49580217	TUBA1A	0.65	12.87	0.51	1.33e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7911264	0.739	rs4933734	chr10:94414567	A/T	cg25093409	chr10:94429542	NA	0.5	9.62	0.41	4.21e-20	Inflammatory bowel disease;
LGG	cis	rs4731207	0.505	rs7791488	chr7:124578268	A/G	cg05630886	chr7:124431682	NA	-0.3	-7.0	-0.31	8.91e-12	Cutaneous malignant melanoma;
LGG	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg03806693	chr22:41940476	POLR3H	-1.0	-18.35	-0.65	6.37e-57	Vitiligo;
LGG	cis	rs6764363	0.567	rs12494574	chr3:280701	T/C	cg02057681	chr3:285234	CHL1	-0.42	-7.49	-0.33	3.53e-13	Sudden cardiac arrest;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs9640161	0.750	rs11769348	chr7:150026753	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	0.8	17.27	0.63	6.18e-52	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs9393692	0.840	rs9358915	chr6:26277268	G/A	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.8e-11	Educational attainment;
LGG	cis	rs17767392	1.000	rs61991203	chr14:71767841	C/G	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.19	-0.39	1.37e-18	Mitral valve prolapse;
LGG	trans	rs2898290	0.578	rs34163377	chr8:11450213	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.15	0.35	3.32e-15	Systolic blood pressure;
LGG	cis	rs6684428	0.536	rs11583130	chr1:56400111	A/G	cg11651538	chr1:56320950	NA	-0.46	-8.76	-0.38	3.6e-17	Airflow obstruction;
LGG	trans	rs6787172	0.702	rs827171	chr3:157958667	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.83	0.38	2.1e-17	Subjective well-being;
LGG	cis	rs11155671	0.546	rs1999633	chr6:150187712	C/T	cg11878867	chr6:150167359	LRP11	-0.43	-7.76	-0.34	5.35e-14	Testicular germ cell tumor;
LGG	cis	rs2074193	0.531	rs215382	chr12:47757485	C/T	cg02516419	chr12:47771422	NA	-0.69	-10.3	-0.43	1.59e-22	Migraine with aura;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06419771	chr15:42264912	EHD4	0.5	7.63	0.33	1.32e-13	Gut microbiome composition (summer);
LGG	cis	rs6121246	0.909	rs6119720	chr20:30347568	T/G	cg21427119	chr20:30132790	HM13	-0.42	-7.16	-0.32	3.25e-12	Mean corpuscular hemoglobin;
LGG	cis	rs6088580	0.634	rs6059824	chr20:33014543	T/C	cg06115741	chr20:33292138	TP53INP2	0.49	8.17	0.36	2.87e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7552404	1.000	rs1498315	chr1:76159225	G/A	cg03433033	chr1:76189801	ACADM	0.8	13.96	0.54	3.38e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	7.51e-24	Lung cancer;
LGG	cis	rs35110281	0.782	rs7282933	chr21:45046988	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.96	-0.38	8.23e-18	Mean corpuscular volume;
LGG	cis	rs2836950	0.565	rs4816617	chr21:40540690	T/C	cg17971929	chr21:40555470	PSMG1	-0.53	-8.99	-0.39	6.43e-18	Menarche (age at onset);
LGG	cis	rs300703	0.542	rs300696	chr2:183330	G/A	cg24565620	chr2:194026	NA	0.68	10.52	0.44	2.46e-23	Blood protein levels;
LGG	cis	rs1953600	1.000	rs2789679	chr10:81907884	A/T	cg04850286	chr10:81895943	PLAC9	-0.46	-10.36	-0.43	9.36e-23	Sarcoidosis;
LGG	cis	rs7666738	0.830	rs9992391	chr4:98916052	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.75	0.34	5.68e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3768617	0.811	rs12738377	chr1:183031256	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.71	0.3	5.68e-11	Fuchs's corneal dystrophy;
LGG	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg00071950	chr4:10020882	SLC2A9	0.39	7.91	0.35	1.87e-14	Bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19759923	chr12:105630205	APPL2	-0.4	-6.94	-0.31	1.37e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7193541	0.684	rs4888262	chr16:74670458	C/T	cg01733217	chr16:74700730	RFWD3	1.1	34.35	0.85	1.97e-129	Multiple myeloma;
LGG	cis	rs10028187	0.515	rs7692557	chr4:154416481	A/C	cg24020152	chr4:154419554	KIAA0922	0.57	13.95	0.54	3.58e-37	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	2.82e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg14092988	chr3:52407081	DNAH1	0.31	8.1	0.35	5e-15	Bipolar disorder;
LGG	cis	rs2439831	0.681	rs3742971	chr15:43622916	A/G	cg15269541	chr15:43626905	ADAL	0.45	7.96	0.35	1.3e-14	Lung cancer in ever smokers;
LGG	cis	rs929354	1.000	rs1182413	chr7:157058557	G/A	cg17757837	chr7:157058334	UBE3C	-0.93	-21.32	-0.7	9.27e-71	Body mass index;
LGG	trans	rs2243480	1.000	rs781142	chr7:65438778	C/T	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs9309473	1.000	rs7576245	chr2:73829678	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.78	-0.34	4.7e-14	Metabolite levels;
LGG	trans	rs7824557	0.628	rs11777746	chr8:11204755	T/C	cg06636001	chr8:8085503	FLJ10661	0.46	8.35	0.36	8.18e-16	Retinal vascular caliber;
LGG	trans	rs11875185	0.510	rs79037737	chr18:55600585	C/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs78487399	0.808	rs6731980	chr2:43703183	T/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.72	-0.3	5.46e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg07541023	chr7:19748670	TWISTNB	-0.5	-8.16	-0.35	3.23e-15	Thyroid stimulating hormone;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25636833	chr22:41864805	PHF5A;ACO2	0.46	7.71	0.34	7.67e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs35110281	0.774	rs2838321	chr21:44995488	A/T	cg04455712	chr21:45112962	RRP1B	0.52	10.04	0.42	1.32e-21	Mean corpuscular volume;
LGG	trans	rs35110281	0.506	rs13051661	chr21:45111518	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.31	0.4	5e-19	Mean corpuscular volume;
LGG	cis	rs8072100	0.935	rs12150231	chr17:45717091	G/A	cg08085267	chr17:45401833	C17orf57	0.62	12.94	0.52	6.4e-33	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs875971	1.000	rs6945843	chr7:65734783	G/A	cg18876405	chr7:65276391	NA	-0.56	-9.88	-0.42	4.97e-21	Aortic root size;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg19357499	chr8:144660631	NAPRT1	0.92	7.05	0.31	6.37e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg16141378	chr3:129829833	LOC729375	0.38	8.36	0.36	7.34e-16	Retinal vascular caliber;
LGG	cis	rs62238980	0.614	rs55695217	chr22:32463135	C/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs12618769	0.597	rs12622341	chr2:99074680	A/T	cg18455616	chr2:99124870	INPP4A	0.29	8.52	0.37	2.28e-16	Bipolar disorder;
LGG	cis	rs4819052	0.851	rs2838837	chr21:46665988	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.21	0.52	4.85e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03314080	chr2:178129903	NFE2L2	0.42	7.28	0.32	1.44e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs2288073	0.562	rs112892911	chr2:24590800	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-12.54	-0.5	3.06e-31	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs638893	0.636	rs6421569	chr11:118655775	A/C	cg13782932	chr11:118662891	DDX6	0.37	6.83	0.3	2.64e-11	Vitiligo;
LGG	cis	rs9303401	0.527	rs7224468	chr17:56749943	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	13.84	0.54	1.11e-36	Cognitive test performance;
LGG	cis	rs6565180	1.000	rs6565180	chr16:30361341	G/T	cg17640201	chr16:30407289	ZNF48	-0.87	-17.46	-0.63	8.2e-53	Tonsillectomy;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg26174226	chr8:58114915	NA	-0.51	-7.26	-0.32	1.63e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9487094	0.644	rs910730	chr6:109768295	G/A	cg16315928	chr6:109776240	MICAL1	0.4	6.83	0.3	2.71e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13686143	chr2:201828163	ORC2L	0.43	6.96	0.31	1.17e-11	Gut microbiome composition (summer);
LGG	trans	rs7939886	0.920	rs60087290	chr11:55983527	C/G	cg03929089	chr4:120376271	NA	0.74	6.78	0.3	3.59e-11	Myopia (pathological);
LGG	cis	rs4696584	0.816	rs55810732	chr4:155410667	G/A	cg13738195	chr4:155413469	DCHS2	-0.38	-7.67	-0.34	1.03e-13	Folding of antihelix;
LGG	cis	rs6502050	0.835	rs9911379	chr17:80114529	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.53e-20	Life satisfaction;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	5.08e-20	Skin colour saturation;
LGG	cis	rs6089584	0.830	rs6089309	chr20:60585687	T/C	cg12751644	chr20:60527061	NA	-0.29	-6.77	-0.3	3.89e-11	Body mass index;
LGG	trans	rs9354308	0.714	rs9294667	chr6:66598740	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	trans	rs6011368	0.678	rs6062359	chr20:62900380	G/T	cg13869341	chr1:15865	WASH5P	-0.54	-9.91	-0.42	4.16e-21	Clozapine-induced cytotoxicity;
LGG	cis	rs2404602	0.716	rs12438077	chr15:76863601	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	cis	rs11971779	0.680	rs6946393	chr7:139106169	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg18681998	chr4:17616180	MED28	0.88	20.18	0.68	1.93e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg08999081	chr20:33150536	PIGU	-0.41	-10.26	-0.43	2.24e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs950776	0.518	rs11630349	chr15:78824608	C/T	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs11628318	0.853	rs6575925	chr14:103034507	C/T	cg01864069	chr14:103024347	NA	-0.73	-11.83	-0.48	2.07e-28	Platelet count;
LGG	cis	rs1318772	1.000	rs11746828	chr5:112718008	C/A	cg12552261	chr5:112820674	MCC	0.67	7.78	0.34	4.63e-14	F-cell distribution;
LGG	cis	rs2228479	0.717	rs2270460	chr16:89972416	C/A	cg06475006	chr16:89985975	MC1R	-0.55	-6.74	-0.3	4.86e-11	Skin colour saturation;
LGG	cis	rs2836950	0.545	rs2836922	chr21:40516308	C/T	cg11890956	chr21:40555474	PSMG1	-0.71	-12.24	-0.49	5.07e-30	Menarche (age at onset);
LGG	cis	rs1568889	0.938	rs12795971	chr11:28355104	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.75	13.78	0.54	1.85e-36	Bipolar disorder;
LGG	cis	rs597583	1.000	rs521609	chr11:117407301	C/T	cg27161313	chr11:117392002	DSCAML1	-0.46	-7.61	-0.33	1.6e-13	Putamen volume;
LGG	cis	rs6952808	0.501	rs3778999	chr7:2180885	G/A	cg20308403	chr7:2120281	MAD1L1	0.32	6.96	0.31	1.15e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg08999081	chr20:33150536	PIGU	-0.4	-10.12	-0.43	7.13e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg04080417	chr5:1859792	NA	-0.51	-8.27	-0.36	1.42e-15	Cardiovascular disease risk factors;
LGG	cis	rs4423214	0.921	rs11603330	chr11:71153459	C/A	cg05163923	chr11:71159392	DHCR7	0.69	13.37	0.53	1.02e-34	Vitamin D levels;
LGG	cis	rs73086581	1.000	rs17214621	chr20:3925924	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.46	0.47	6.39e-27	Response to antidepressants in depression;
LGG	cis	rs10479542	0.583	rs4131080	chr5:179044292	G/A	cg09060608	chr5:178986726	RUFY1	0.47	7.56	0.33	2.12e-13	Lung cancer;
LGG	trans	rs3942852	0.568	rs1039484	chr11:48097948	A/G	cg03929089	chr4:120376271	NA	-0.7	-10.85	-0.45	1.33e-24	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs672059	0.934	rs6703054	chr1:183155778	A/C	cg07928641	chr1:182991847	LAMC1	0.34	6.93	0.31	1.45e-11	Hypertriglyceridemia;
LGG	trans	rs7939886	0.920	rs1482009	chr11:55884690	T/G	cg03929089	chr4:120376271	NA	0.79	8.14	0.35	3.74e-15	Myopia (pathological);
LGG	cis	rs1079204	1.000	rs11888211	chr2:219146988	G/A	cg05728596	chr2:219128475	GPBAR1	1.11	10.52	0.44	2.45e-23	Smooth-surface caries;
LGG	cis	rs13006863	0.527	rs7340453	chr2:74428015	C/T	cg09063936	chr2:74408977	NA	0.3	6.9	0.31	1.66e-11	Post-traumatic stress disorder (asjusted for relatedness);Immune reponse to smallpox (secreted TNF-alpha);
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.1	0.31	4.7e-12	Lung cancer;
LGG	cis	rs806215	0.526	rs2402871	chr7:127439519	G/A	cg25922125	chr7:127225783	GCC1	-0.48	-7.06	-0.31	5.98e-12	Type 2 diabetes;
LGG	cis	rs2933343	0.729	rs789228	chr3:128601050	A/G	cg11901034	chr3:128598214	ACAD9	-0.45	-6.69	-0.3	6.57e-11	IgG glycosylation;
LGG	cis	rs875971	1.000	rs2420591	chr7:65912381	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs798554	0.704	rs709282	chr7:2769921	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-8.39	-0.36	6.14e-16	Height;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg16507663	chr6:150244633	RAET1G	0.47	8.86	0.38	1.74e-17	Lung cancer;
LGG	cis	rs1790761	0.868	rs872375	chr11:67205978	G/A	cg24690094	chr11:67383802	NA	-0.39	-6.68	-0.3	6.77e-11	Mean corpuscular volume;
LGG	cis	rs9513627	0.831	rs9582301	chr13:100125814	C/T	cg15490075	chr13:100150979	NA	-0.67	-6.95	-0.31	1.27e-11	Obesity-related traits;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg09177884	chr7:1199841	ZFAND2A	-0.71	-13.16	-0.52	8.08e-34	Longevity;Endometriosis;
LGG	cis	rs10791097	0.609	rs3751039	chr11:130773076	A/G	cg12179176	chr11:130786555	SNX19	-0.94	-21.93	-0.71	1.29e-73	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6088580	0.634	rs6059878	chr20:33087166	A/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.66e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9443189	0.570	rs276684	chr6:76427065	A/G	cg01950844	chr6:76311363	SENP6	-0.72	-8.67	-0.37	7.4e-17	Prostate cancer;
LGG	cis	rs11190604	1.000	rs10509744	chr10:102271579	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.95	0.49	6.97e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs72634258	0.836	rs7545687	chr1:7997183	G/A	cg00042356	chr1:8021962	PARK7	0.69	8.28	0.36	1.3e-15	Inflammatory bowel disease;
LGG	cis	rs3768617	0.510	rs10752904	chr1:183101038	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7615952	0.641	rs12491577	chr3:125731131	C/T	cg15145296	chr3:125709740	NA	-0.62	-8.02	-0.35	8.78e-15	Blood pressure (smoking interaction);
LGG	cis	rs7208859	0.573	rs55661352	chr17:29045628	A/G	cg19761014	chr17:28927070	LRRC37B2	0.64	7.57	0.33	2.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10911232	0.507	rs3934579	chr1:183027432	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	trans	rs9467711	0.606	rs9393705	chr6:26361011	G/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs4363385	0.693	rs662506	chr1:153048386	A/C	cg13444842	chr1:152974279	SPRR3	0.38	7.77	0.34	5.01e-14	Inflammatory skin disease;
LGG	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.43	8.91	0.38	1.22e-17	Aortic root size;
LGG	cis	rs1867631	1.000	rs1867631	chr1:67046126	C/A	cg13052034	chr1:66999238	SGIP1	0.44	8.7	0.37	5.89e-17	Menopause (age at onset);
LGG	cis	rs4253772	0.550	rs6007830	chr22:46711323	C/T	cg24881330	chr22:46731750	TRMU	0.71	7.21	0.32	2.27e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4925386	1.000	rs4925386	chr20:60921044	C/T	cg06026331	chr20:60912101	LAMA5	0.46	8.78	0.38	3.22e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11227306	0.934	rs7102454	chr11:65594820	C/T	cg26695010	chr11:65641043	EFEMP2	0.48	7.54	0.33	2.47e-13	DNA methylation (variation);
LGG	trans	rs7762018	0.660	rs41265385	chr6:170068086	C/T	cg06875740	chr19:51307921	C19orf48	-0.72	-8.51	-0.37	2.39e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.77	16.35	0.61	8.8e-48	Obesity-related traits;
LGG	cis	rs4363385	0.818	rs2339492	chr1:152985552	G/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.46e-17	Inflammatory skin disease;
LGG	cis	rs62064224	0.589	rs4132610	chr17:30801441	C/T	cg18200150	chr17:30822561	MYO1D	0.5	9.56	0.41	6.81e-20	Schizophrenia;
LGG	cis	rs972578	0.818	rs5759012	chr22:43286876	A/G	cg01576275	chr22:43409880	NA	-0.23	-7.14	-0.31	3.75e-12	Mean platelet volume;
LGG	cis	rs951366	0.553	rs11240554	chr1:205671644	C/T	cg14893161	chr1:205819251	PM20D1	-0.5	-8.9	-0.38	1.31e-17	Menarche (age at onset);
LGG	cis	rs9640161	0.659	rs7806429	chr7:150013393	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.7	-14.76	-0.57	1.13e-40	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07092213	chr7:1199455	ZFAND2A	-0.61	-10.74	-0.45	3.44e-24	Longevity;Endometriosis;
LGG	cis	rs473651	0.935	rs578510	chr2:239343140	C/T	cg18131467	chr2:239335373	ASB1	1.02	23.4	0.74	1.75e-80	Multiple system atrophy;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg04234412	chr22:24373322	LOC391322	0.78	16.08	0.6	1.58e-46	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg08344181	chr3:125677491	NA	-0.84	-8.54	-0.37	1.96e-16	Depression;
LGG	cis	rs7949030	0.688	rs11231155	chr11:62365619	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.63	15.88	0.59	1.2e-45	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9790314	0.967	rs7623206	chr3:160971518	G/A	cg04691961	chr3:161091175	C3orf57	-0.64	-15.16	-0.58	1.85e-42	Morning vs. evening chronotype;
LGG	cis	rs1163251	0.837	rs517533	chr1:120229170	T/G	cg19096424	chr1:120255104	PHGDH	0.64	11.59	0.47	1.89e-27	Blood metabolite levels;
LGG	cis	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg14673194	chr17:80132900	CCDC57	-0.43	-7.51	-0.33	3.16e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs883115	0.810	rs1932991	chr1:224783293	T/C	cg01808320	chr1:224927238	CNIH3	-0.41	-7.47	-0.33	4.1e-13	Cancer;
LGG	cis	rs644799	0.526	rs693172	chr11:95636618	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	11.07	0.46	1.96e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6997458	0.785	rs10907474	chr8:86362381	C/T	cg02393479	chr8:86352350	CA3	-0.32	-6.92	-0.31	1.52e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs6028335	0.867	rs66951531	chr20:37707364	C/T	cg16355469	chr20:37678765	NA	0.54	6.76	0.3	4.14e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs6121246	0.529	rs6088814	chr20:30218172	C/T	cg18721089	chr20:30220636	NA	-0.51	-7.59	-0.33	1.76e-13	Mean corpuscular hemoglobin;
LGG	cis	rs559928	0.606	rs61083753	chr11:63892665	C/T	cg18225595	chr11:63971243	STIP1	0.59	8.54	0.37	1.95e-16	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4481887	0.512	rs1538702	chr1:248519665	A/G	cg00666640	chr1:248458726	OR2T12	0.57	7.98	0.35	1.15e-14	Common traits (Other);
LGG	cis	rs174601	0.861	rs174584	chr11:61610750	G/A	cg19610905	chr11:61596333	FADS2	-0.74	-13.41	-0.53	7.32e-35	Blood metabolite levels;Red blood cell fatty acid levels;Liver enzyme levels (alkaline phosphatase);Gondoic acid (20:1n-9) levels;Trans fatty acid levels;
LGG	cis	rs6963495	0.818	rs55825845	chr7:105166713	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.83	0.34	3.3e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg18252515	chr7:66147081	NA	1.33	18.45	0.65	2.19e-57	Diabetic kidney disease;
LGG	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.43	-0.33	5.42e-13	Joint mobility (Beighton score);
LGG	trans	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	9.09	0.39	2.93e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6089584	0.888	rs2146853	chr20:60617908	A/T	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs9460578	0.673	rs6918643	chr6:20897656	C/T	cg13405222	chr6:20811065	CDKAL1	0.67	11.26	0.46	3.52e-26	Breast cancer;
LGG	cis	rs72781680	1.000	rs12617839	chr2:24166277	A/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs60871478	1.000	rs34260834	chr7:822958	A/G	cg04727924	chr7:799746	HEATR2	-0.47	-7.54	-0.33	2.57e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs9815354	0.812	rs73828505	chr3:42042714	C/T	cg03022575	chr3:42003672	ULK4	0.66	7.89	0.34	2.15e-14	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs62103177	0.714	rs7227962	chr18:77603283	T/G	cg05926928	chr17:57297772	GDPD1	0.96	15.47	0.58	7.85e-44	Opioid sensitivity;
LGG	cis	rs2576037	0.526	rs998819	chr18:44564181	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.99	-0.45	3.98e-25	Personality dimensions;
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.38	0.36	6.39e-16	Platelet count;
LGG	cis	rs910187	0.521	rs11699424	chr20:45798548	A/T	cg27589058	chr20:45804311	EYA2	-0.36	-9.39	-0.4	2.73e-19	Migraine;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg27189623	chr16:705930	WDR90	0.41	7.95	0.35	1.47e-14	Height;
LGG	cis	rs9358372	1.000	rs6901110	chr6:20831272	C/T	cg13405222	chr6:20811065	CDKAL1	-0.69	-15.19	-0.58	1.35e-42	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs8012	0.517	rs8113575	chr19:13030280	G/A	cg04657146	chr19:12876947	HOOK2	0.44	7.22	0.32	2.12e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs6565180	1.000	rs8049108	chr16:30376486	A/G	cg17640201	chr16:30407289	ZNF48	-0.86	-17.5	-0.63	5.33e-53	Tonsillectomy;
LGG	cis	rs806215	0.826	rs712699	chr7:127250597	G/A	cg25922125	chr7:127225783	GCC1	0.75	10.28	0.43	1.88e-22	Type 2 diabetes;
LGG	cis	rs4356932	0.967	rs7436646	chr4:76955229	T/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	trans	rs17685	0.712	rs28506984	chr7:75763484	A/G	cg19862616	chr7:65841803	NCRNA00174	1.07	25.71	0.77	3.26e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2274273	0.840	rs3742569	chr14:55818706	T/C	cg04306507	chr14:55594613	LGALS3	0.61	17.03	0.62	7.5e-51	Protein biomarker;
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	trans	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg11693508	chr17:37793320	STARD3	0.72	10.4	0.44	6.74e-23	Bipolar disorder;
LGG	cis	rs9300255	0.596	rs10732573	chr12:123743883	G/C	cg00376283	chr12:123451042	ABCB9	0.69	11.96	0.49	6.32e-29	Neutrophil percentage of white cells;
LGG	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.04	16.2	0.6	4.59e-47	Smoking behavior;
LGG	cis	rs12887734	0.566	rs3742366	chr14:104198351	T/C	cg26031613	chr14:104095156	KLC1	-0.59	-9.28	-0.4	6.35e-19	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.853	rs7133716	chr12:34041847	G/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs12282928	0.918	rs1018136	chr11:48241821	G/A	cg26585981	chr11:48327164	OR4S1	-0.44	-7.05	-0.31	6.43e-12	Migraine - clinic-based;
LGG	cis	rs1949733	0.675	rs2010758	chr4:8475623	G/A	cg13073564	chr4:8508604	NA	-0.52	-10.73	-0.45	3.74e-24	Response to antineoplastic agents;
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25427524	chr10:38739819	LOC399744	-0.67	-12.48	-0.5	5.23e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs4700695	0.841	rs251608	chr5:65247893	C/T	cg21114390	chr5:65439923	SFRS12	0.59	7.53	0.33	2.65e-13	Facial morphology (factor 19);
LGG	cis	rs4746818	1.000	rs7893492	chr10:70960448	C/T	cg11621586	chr10:70884670	VPS26A	-1.04	-15.62	-0.59	1.81e-44	Left atrial antero-posterior diameter;
LGG	cis	rs35146811	0.735	rs1637001	chr7:99808151	G/A	cg13334819	chr7:99746414	C7orf59	0.47	7.31	0.32	1.2e-12	Coronary artery disease;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.43	7.28	0.32	1.4e-12	Longevity;
LGG	cis	rs17428076	0.793	rs7584258	chr2:172659836	A/G	cg21435375	chr2:172878103	MAP1D	0.4	8.67	0.37	7.56e-17	Myopia;
LGG	cis	rs4774830	0.590	rs79693462	chr15:56202398	C/T	cg05129572	chr15:56138634	NEDD4	0.84	7.71	0.34	7.87e-14	Delta-5 desaturase activity;
LGG	cis	rs7827545	0.545	rs6988000	chr8:135559534	C/T	cg17885191	chr8:135476712	NA	0.59	8.57	0.37	1.59e-16	Hypertension (SNP x SNP interaction);
LGG	cis	rs12586317	0.525	rs10144430	chr14:35433682	T/A	cg05294307	chr14:35346193	BAZ1A	-0.6	-10.21	-0.43	3.17e-22	Psoriasis;
LGG	cis	rs875971	0.964	rs778708	chr7:65856319	T/C	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg09264619	chr17:80180166	NA	0.35	6.91	0.31	1.64e-11	Life satisfaction;
LGG	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	trans	rs6582630	0.502	rs10880092	chr12:38262965	A/T	cg06521331	chr12:34319734	NA	-0.52	-8.85	-0.38	1.81e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4911259	0.552	rs13038017	chr20:31467551	T/C	cg13636640	chr20:31349939	DNMT3B	-0.65	-11.92	-0.48	9.47e-29	Inflammatory bowel disease;
LGG	cis	rs79839061	0.610	rs12651368	chr4:856787	G/A	cg07828340	chr4:882639	GAK	0.87	9.27	0.4	7.28e-19	Intelligence (multi-trait analysis);
LGG	cis	rs17784882	0.521	rs11713693	chr3:47074906	T/C	cg27129171	chr3:47204927	SETD2	-0.78	-13.98	-0.54	2.76e-37	QT interval;
LGG	cis	rs975722	0.582	rs177068	chr7:117102020	G/A	cg10524701	chr7:117356490	CTTNBP2	0.44	9.75	0.41	1.49e-20	Coronary artery disease;
LGG	cis	rs9473924	0.505	rs4111288	chr6:50908094	G/A	cg14470998	chr6:50812995	TFAP2B	0.67	8.12	0.35	4.24e-15	Body mass index;
LGG	cis	rs11864453	0.679	rs2303285	chr16:72124495	A/C	cg01557791	chr16:72042693	DHODH	-0.45	-8.21	-0.36	2.2e-15	Fibrinogen levels;
LGG	cis	rs4481887	0.741	rs1361413	chr1:248529521	C/G	cg15454534	chr1:248569605	OR2T1	-0.37	-6.73	-0.3	5.18e-11	Common traits (Other);
LGG	cis	rs12477438	0.520	rs6739579	chr2:99731552	C/T	cg08885076	chr2:99613938	TSGA10	0.42	9.03	0.39	4.59e-18	Chronic sinus infection;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg04267008	chr7:1944627	MAD1L1	-0.65	-11.54	-0.47	3e-27	Bipolar disorder and schizophrenia;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg11699826	chr1:26438425	PDIK1L	0.4	6.9	0.31	1.71e-11	Bipolar disorder;
LGG	trans	rs8073060	0.586	rs4796101	chr17:33998593	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs701145	0.585	rs62276839	chr3:153780407	C/T	cg17054900	chr3:154042577	DHX36	-0.73	-8.86	-0.38	1.66e-17	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs9765929	chr6:150090816	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg22907277	chr7:1156413	C7orf50	0.6	11.08	0.46	1.83e-25	Longevity;Endometriosis;
LGG	trans	rs629535	0.814	rs651985	chr8:70054966	G/A	cg21567404	chr3:27674614	NA	0.4	6.74	0.3	4.72e-11	Dupuytren's disease;
LGG	cis	rs801193	1.000	rs62466793	chr7:66191517	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.44	9.04	0.39	4.35e-18	Aortic root size;
LGG	cis	rs8060686	0.641	rs28548264	chr16:68211321	A/G	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.23	-0.32	1.97e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4919087	0.683	rs1687372	chr10:98978185	A/T	cg25902810	chr10:99078978	FRAT1	-0.45	-7.69	-0.34	8.99e-14	Monocyte count;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25072359	chr17:41440525	NA	0.51	9.7	0.41	2.25e-20	Menopause (age at onset);
LGG	cis	rs3096299	0.563	rs4600467	chr16:89562516	C/T	cg08392591	chr16:89556376	ANKRD11	0.6	9.5	0.4	1.18e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs17345786	0.798	rs9817043	chr3:101281852	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.4	7.18	0.32	2.74e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.83	0.51	1.88e-32	Prudent dietary pattern;
LGG	cis	rs1799949	1.000	rs8176133	chr17:41257458	A/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.31	0.32	1.15e-12	Menopause (age at onset);
LGG	cis	rs2075371	0.932	rs1862048	chr7:133978167	C/G	cg20476274	chr7:133979776	SLC35B4	-0.64	-11.73	-0.48	5.46e-28	Mean platelet volume;
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg22903657	chr4:1355424	KIAA1530	-0.33	-7.26	-0.32	1.63e-12	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01287514	chr5:166406845	NA	0.39	6.81	0.3	2.98e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17376456	0.825	rs67328989	chr5:93243133	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.56e-19	Diabetic retinopathy;
LGG	cis	rs13191362	0.935	rs13212137	chr6:163010261	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4771450	0.962	rs4772544	chr13:103973222	T/G	cg02987523	chr13:103978230	NA	-0.33	-6.9	-0.31	1.76e-11	Uric acid levels;
LGG	cis	rs28386778	0.863	rs2584637	chr17:61942952	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.06	0.55	1.18e-37	Prudent dietary pattern;
LGG	cis	rs10895140	0.756	rs2508727	chr11:101486960	C/T	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.01e-11	Menarche (age at onset);
LGG	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.72	-9.19	-0.39	1.36e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg10760299	chr15:45669010	GATM	0.41	8.01	0.35	9.14e-15	Homoarginine levels;
LGG	cis	rs13191362	0.507	rs2849540	chr6:163094522	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.63	-8.75	-0.38	3.87e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs61931739	0.963	rs1817759	chr12:34101521	G/A	cg06521331	chr12:34319734	NA	0.41	6.9	0.31	1.73e-11	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.527	rs9328733	chr4:1388583	A/G	cg20887711	chr4:1340912	KIAA1530	0.93	19.65	0.67	5.64e-63	Longevity;
LGG	cis	rs2032447	0.839	rs199750	chr6:26016462	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.92	-17.85	-0.64	1.34e-54	Intelligence (multi-trait analysis);
LGG	cis	rs11758351	1.000	rs78012445	chr6:26195080	G/C	cg01420254	chr6:26195488	NA	0.92	12.41	0.5	1.03e-30	Gout;Renal underexcretion gout;
LGG	cis	rs875971	0.862	rs778736	chr7:65813848	C/T	cg23594656	chr7:65796392	TPST1	-0.42	-9.33	-0.4	4.56e-19	Aortic root size;
LGG	cis	rs10540	1.000	rs79808876	chr11:465763	C/A	cg03352830	chr11:487213	PTDSS2	0.87	11.14	0.46	1.08e-25	Body mass index;
LGG	cis	rs9479482	0.967	rs763574	chr6:150349415	G/C	cg07549998	chr6:150325970	RAET1K	-0.37	-7.05	-0.31	6.52e-12	Alopecia areata;
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.54	0.67	1.86e-62	Platelet count;
LGG	trans	rs116095464	0.558	rs11959126	chr5:283880	T/G	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs10197940	0.662	rs4467261	chr2:152281391	G/C	cg06191203	chr2:152266755	RIF1	-0.42	-7.47	-0.33	4.01e-13	Lung cancer;
LGG	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.5e-19	Colorectal cancer;
LGG	cis	rs11098499	0.954	rs17006190	chr4:120418838	C/G	cg09307838	chr4:120376055	NA	0.81	13.59	0.53	1.26e-35	Corneal astigmatism;
LGG	cis	rs3126085	0.935	rs55942250	chr1:152251914	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-7.98	-0.35	1.17e-14	Atopic dermatitis;
LGG	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.41	-8.05	-0.35	7.29e-15	DNA methylation (variation);
LGG	cis	rs4838594	0.590	rs1867579	chr10:49671394	A/G	cg17291251	chr10:49678358	ARHGAP22	-0.52	-10.72	-0.45	4.32e-24	Daytime sleep phenotypes;
LGG	cis	rs990171	0.913	rs1558627	chr2:102984684	G/A	cg05295703	chr2:102895712	NA	-0.56	-9.84	-0.42	7.4e-21	Lymphocyte counts;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	5.04e-12	Prudent dietary pattern;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02994863	chr1:64059297	PGM1	0.41	6.96	0.31	1.19e-11	Bipolar disorder;
LGG	cis	rs36051895	0.626	rs12349785	chr9:5076613	G/C	cg02405213	chr9:5042618	JAK2	-0.83	-15.66	-0.59	1.12e-44	Pediatric autoimmune diseases;
LGG	cis	rs8177253	0.965	rs8177245	chr3:133479230	A/G	cg01448562	chr3:133502909	NA	-0.73	-13.55	-0.53	1.8e-35	Iron status biomarkers;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-10.45	-0.44	4.17e-23	Prudent dietary pattern;
LGG	cis	rs637571	0.522	rs649000	chr11:65742933	T/C	cg26695010	chr11:65641043	EFEMP2	-0.48	-8.08	-0.35	5.74e-15	Eosinophil percentage of white cells;
LGG	cis	rs9486719	0.947	rs2499801	chr6:96854594	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	10.65	0.44	7.95e-24	Migraine;Coronary artery disease;
LGG	cis	rs17221829	0.899	rs10830367	chr11:89459400	T/C	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.7	-0.34	8.32e-14	Anxiety in major depressive disorder;
LGG	cis	rs6582630	0.555	rs10880602	chr12:38505660	T/C	cg13010199	chr12:38710504	ALG10B	0.68	14.19	0.55	3.2e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2274273	0.870	rs10142547	chr14:55763963	T/C	cg04306507	chr14:55594613	LGALS3	0.64	18.06	0.64	1.37e-55	Protein biomarker;
LGG	cis	rs72781680	0.752	rs55806536	chr2:23912697	A/G	cg08917208	chr2:24149416	ATAD2B	0.83	8.86	0.38	1.71e-17	Lymphocyte counts;
LGG	cis	rs11098499	0.657	rs4463052	chr4:120313258	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs4727027	0.651	rs12704068	chr7:148856153	T/C	cg23583168	chr7:148888333	NA	-0.71	-11.48	-0.47	5.2e-27	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg00495681	chr13:53174319	NA	0.56	10.01	0.42	1.72e-21	Lewy body disease;
LGG	cis	rs9487051	0.768	rs399561	chr6:109524979	G/A	cg21918786	chr6:109611834	NA	-0.39	-7.11	-0.31	4.49e-12	Reticulocyte fraction of red cells;
LGG	trans	rs853679	1.000	rs1778511	chr6:28229411	G/A	cg08344181	chr3:125677491	NA	0.56	7.28	0.32	1.45e-12	Depression;
LGG	trans	rs637571	0.676	rs1151523	chr11:65665200	C/T	cg17712092	chr4:129076599	LARP1B	-0.86	-18.25	-0.65	1.77e-56	Eosinophil percentage of white cells;
LGG	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg01529538	chr14:23388837	RBM23	0.37	6.76	0.3	4.13e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs5771225	0.544	rs909688	chr22:50689030	A/G	cg08875078	chr22:50639485	SELO	0.46	6.9	0.31	1.77e-11	Late-onset Alzheimer's disease;
LGG	cis	rs4740619	0.740	rs7860869	chr9:15735618	A/T	cg14451791	chr9:16040625	NA	0.34	8.78	0.38	3.21e-17	Body mass index;
LGG	trans	rs208520	0.690	rs207081	chr6:66773742	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.81	-0.64	2e-54	Exhaled nitric oxide output;
LGG	cis	rs1348850	0.914	rs7573763	chr2:178249808	C/T	cg27490568	chr2:178487706	NA	0.51	10.23	0.43	2.83e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs858239	0.601	rs73272053	chr7:23155525	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.31	0.32	1.17e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4363385	0.776	rs2879490	chr1:152947163	A/G	cg07796016	chr1:152779584	LCE1C	-0.41	-6.68	-0.3	6.68e-11	Inflammatory skin disease;
LGG	cis	rs668210	0.793	rs506873	chr11:65767215	A/C	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.69	-9.43	-0.4	1.96e-19	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg08824895	chr13:115047677	UPF3A	0.39	6.68	0.3	6.87e-11	Schizophrenia;
LGG	trans	rs877282	0.945	rs11253396	chr10:789754	C/T	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs4975616	0.836	rs13178866	chr5:1323212	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.46	-0.65	2.06e-57	Lung cancer;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs897984	0.683	rs13337900	chr16:30822409	G/A	cg00531865	chr16:30841666	NA	-0.68	-16.1	-0.6	1.24e-46	Dementia with Lewy bodies;
LGG	cis	rs7726839	0.540	rs72705030	chr5:645562	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.53e-15	Obesity-related traits;
LGG	cis	rs2243480	0.614	rs34032527	chr7:65565141	C/G	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.52	0.83	1.28e-121	Prudent dietary pattern;
LGG	trans	rs783540	0.967	rs783526	chr15:83285795	C/A	cg16105309	chr15:79090380	ADAMTS7	0.42	7.48	0.33	3.81e-13	Schizophrenia;
LGG	trans	rs11098499	0.954	rs4309825	chr4:120314881	C/T	cg25214090	chr10:38739885	LOC399744	-0.7	-12.4	-0.5	1.07e-30	Corneal astigmatism;
LGG	cis	rs2635047	0.967	rs12960444	chr18:44607314	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.62	11.01	0.46	3.46e-25	Educational attainment;
LGG	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.53e-24	Cutaneous nevi;
LGG	cis	rs9325144	0.532	rs12812406	chr12:38719802	G/A	cg04568710	chr12:38710424	ALG10B	-0.41	-8.68	-0.37	6.62e-17	Morning vs. evening chronotype;
LGG	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg05623727	chr3:50126028	RBM5	-0.38	-8.44	-0.37	4.15e-16	Intelligence (multi-trait analysis);
LGG	cis	rs2244613	0.882	rs7200877	chr16:55794882	A/T	cg04521981	chr16:55850985	CES1	0.43	7.12	0.31	4.26e-12	Response to dabigatran etexilate treatment;
LGG	cis	rs9467773	0.550	rs4712987	chr6:26399615	A/C	cg09904177	chr6:26538194	HMGN4	-0.42	-7.48	-0.33	3.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.958	rs36093218	chr14:71872073	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.89e-18	Mitral valve prolapse;
LGG	cis	rs61931739	0.963	rs59195137	chr12:34091838	G/A	cg06521331	chr12:34319734	NA	0.4	6.79	0.3	3.53e-11	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.932	rs4698626	chr4:17605821	G/C	cg16339924	chr4:17578868	LAP3	0.65	11.18	0.46	7.3e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs73198271	0.740	rs10103163	chr8:8650675	T/C	cg01851573	chr8:8652454	MFHAS1	0.37	6.82	0.3	2.78e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6076065	0.748	rs4142246	chr20:23388975	A/G	cg11657817	chr20:23433608	CST11	0.4	8.21	0.36	2.19e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs561341	0.883	rs1034626	chr17:30219500	C/G	cg00745463	chr17:30367425	LRRC37B	0.54	7.46	0.33	4.26e-13	Hip circumference adjusted for BMI;
LGG	trans	rs9354308	0.764	rs9283823	chr6:66596378	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs1046896	1.000	rs1046875	chr17:80685426	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.4	-6.9	-0.31	1.73e-11	Glycated hemoglobin levels;
LGG	cis	rs7833790	0.929	rs10958048	chr8:82792914	C/T	cg27398817	chr8:82754497	SNX16	0.78	11.21	0.46	5.59e-26	Diastolic blood pressure;
LGG	cis	rs713587	0.571	rs475868	chr2:25318059	A/G	cg04586622	chr2:25135609	ADCY3	-0.27	-6.87	-0.3	2.14e-11	Body mass index in non-asthmatics;
LGG	cis	rs17345786	0.953	rs78645744	chr3:101327789	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.07	0.39	3.36e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12449964	0.515	rs7225141	chr17:17570827	A/G	cg01246520	chr17:17644344	RAI1	0.33	7.33	0.32	1.06e-12	Coronary artery disease or ischemic stroke;
LGG	cis	rs701145	0.585	rs2596629	chr3:153931142	A/C	cg12800244	chr3:153838788	SGEF	0.84	8.33	0.36	9.55e-16	Coronary artery disease;
LGG	cis	rs11971779	0.680	rs10085902	chr7:139109105	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg06634786	chr22:41940651	POLR3H	0.81	13.18	0.52	6.69e-34	Vitiligo;
LGG	cis	rs6500395	0.832	rs8052733	chr16:48691978	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg06886374	chr16:1844152	IGFALS	0.46	8.15	0.35	3.49e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6089829	0.855	rs6090203	chr20:61663632	G/A	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.68e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg15309053	chr8:964076	NA	0.37	7.58	0.33	1.88e-13	Schizophrenia;
LGG	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg23057051	chr16:89984268	MC1R	-0.38	-7.13	-0.31	3.98e-12	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08464053	chr3:181429704	SOX2OT;SOX2	0.43	6.87	0.3	2.02e-11	Gut microbiome composition (summer);
LGG	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.03	-0.31	7.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs1965732	0.958	rs6755529	chr2:3711972	C/T	cg20493526	chr2:3714936	ALLC	-0.37	-7.85	-0.34	2.94e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.82	-0.38	2.34e-17	Morning vs. evening chronotype;
LGG	trans	rs1728785	1.000	rs8058145	chr16:68584090	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg17911788	chr17:44343683	NA	-0.47	-7.98	-0.35	1.13e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg08645402	chr16:4508243	NA	-0.52	-9.89	-0.42	4.73e-21	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05533119	chr20:23343103	NA	0.53	8.22	0.36	2.06e-15	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.56	0.59	3.19e-44	Lung cancer;
LGG	cis	rs7089973	0.628	rs11196953	chr10:116607707	A/G	cg03647239	chr10:116582469	FAM160B1	0.42	7.44	0.33	4.82e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1005277	0.579	rs2505198	chr10:38393183	A/C	cg14646974	chr10:38645378	HSD17B7P2	-0.43	-6.91	-0.31	1.57e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs3820068	0.524	rs34094056	chr1:15824154	G/T	cg05660106	chr1:15850417	CASP9	1.09	26.17	0.77	2.51e-93	Systolic blood pressure;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg05025164	chr4:1340916	KIAA1530	0.88	17.05	0.62	5.94e-51	Longevity;
LGG	cis	rs12681288	0.676	rs34282191	chr8:991290	G/A	cg15309053	chr8:964076	NA	0.38	7.62	0.33	1.44e-13	Schizophrenia;
LGG	trans	rs11739663	0.574	rs67276442	chr5:583918	T/C	cg25482853	chr8:67687455	SGK3	0.48	7.45	0.33	4.76e-13	Ulcerative colitis;
LGG	cis	rs7582180	0.932	rs6542923	chr2:100892516	C/T	cg26150922	chr2:100937072	LONRF2	-0.49	-8.08	-0.35	5.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7703051	0.513	rs59014134	chr5:74589385	C/T	cg19683494	chr5:74908142	NA	0.52	7.46	0.33	4.24e-13	LDL cholesterol;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;
LGG	cis	rs12477438	0.501	rs6542868	chr2:99782848	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.18	0.7	4.2e-70	Chronic sinus infection;
LGG	trans	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg02002194	chr4:3960332	NA	-0.42	-7.51	-0.33	3.12e-13	Red cell distribution width;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15613982	chr20:18488017	SEC23B	0.42	7.04	0.31	7.02e-12	Menarche (age at onset);
LGG	cis	rs57221529	0.825	rs72703051	chr5:582997	G/A	cg09021430	chr5:549028	NA	-0.71	-9.51	-0.4	1.01e-19	Lung disease severity in cystic fibrosis;
LGG	cis	rs28595532	0.920	rs116366070	chr4:119764180	A/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg04503457	chr17:41445688	NA	-0.38	-9.02	-0.39	4.87e-18	Menopause (age at onset);
LGG	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.575	rs78075335	chr8:57997243	A/C	cg05313129	chr8:58192883	C8orf71	-0.46	-6.97	-0.31	1.11e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6692729	0.901	rs1295638	chr1:227069267	A/G	cg08708961	chr1:227070630	PSEN2	0.31	7.98	0.35	1.17e-14	Electrodermal activity;
LGG	cis	rs2735413	0.564	rs73574780	chr16:78088104	C/T	cg04733911	chr16:78082701	NA	0.63	9.31	0.4	5.18e-19	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs875971	0.545	rs221986	chr7:65570310	T/C	cg11764359	chr7:65958608	NA	-0.61	-8.98	-0.39	6.63e-18	Aortic root size;
LGG	cis	rs6988985	0.791	rs11779229	chr8:143998207	G/A	cg10324643	chr8:143916377	GML	-0.38	-7.53	-0.33	2.62e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs6456156	0.586	rs13210649	chr6:167473193	T/G	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.54e-18	Primary biliary cholangitis;
LGG	trans	rs10838798	0.504	rs11039530	chr11:48145746	C/T	cg15704280	chr7:45808275	SEPT13	-0.46	-7.34	-0.32	9.65e-13	Height;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.59	11.67	0.48	9.42e-28	Obesity-related traits;
LGG	cis	rs10464366	0.614	rs62442213	chr7:39146933	C/T	cg18850127	chr7:39170497	POU6F2	0.64	16.41	0.61	4.74e-48	IgG glycosylation;
LGG	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	-0.34	-8.42	-0.36	4.73e-16	Systemic lupus erythematosus;
LGG	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg19717773	chr7:2847554	GNA12	-0.39	-8.89	-0.38	1.33e-17	Height;
LGG	trans	rs7181230	0.961	rs7183977	chr15:40377092	C/T	cg22705835	chr10:65332833	REEP3	0.57	9.82	0.42	8.46e-21	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs72945132	0.882	rs72949076	chr11:70217695	T/C	cg14088196	chr11:70211408	PPFIA1	0.96	13.28	0.53	2.43e-34	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10065162	chr1:27018897	NA	0.46	6.79	0.3	3.37e-11	Gut microbiome composition (summer);
LGG	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg16851482	chr4:6955953	TBC1D14	0.27	6.89	0.3	1.84e-11	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg18351406	chr4:77819688	ANKRD56	0.46	7.84	0.34	3.18e-14	Emphysema distribution in smoking;
LGG	cis	rs4917300	0.571	rs4917276	chr8:143095436	G/T	cg06573787	chr8:143070187	NA	-0.56	-9.34	-0.4	3.93e-19	Amyotrophic lateral sclerosis;
LGG	cis	rs2299587	0.582	rs10087660	chr8:17908973	T/C	cg18067069	chr8:17937731	ASAH1	-0.33	-8.0	-0.35	1.03e-14	Economic and political preferences;
LGG	cis	rs975739	0.868	rs9544661	chr13:78552347	G/A	cg07847733	chr13:78271382	SLAIN1	0.38	6.81	0.3	3.01e-11	Hair color;
LGG	cis	rs981844	0.712	rs4571310	chr4:154746832	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs6942756	0.876	rs822039	chr7:129065774	A/G	cg02491457	chr7:128862824	NA	-0.66	-11.88	-0.48	1.4e-28	White matter hyperintensity burden;
LGG	cis	rs7659604	0.967	rs10008348	chr4:122666987	A/C	cg20573242	chr4:122745356	CCNA2	0.44	7.85	0.34	2.82e-14	Type 2 diabetes;
LGG	cis	rs11148252	0.740	rs9596643	chr13:52912380	G/A	cg22398616	chr13:53314203	LECT1	0.41	8.33	0.36	9.36e-16	Lewy body disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18451256	chr2:128284158	IWS1	0.48	7.96	0.35	1.31e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg00656411	chr7:140773422	NA	-0.42	-6.95	-0.31	1.25e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs737693	1.000	rs72981675	chr11:102721251	C/T	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	5.14e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs526231	0.543	rs34832	chr5:102444595	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.38	-0.36	6.2e-16	Primary biliary cholangitis;
LGG	cis	rs7552404	0.727	rs12093623	chr1:76256232	T/G	cg10523679	chr1:76189770	ACADM	0.77	12.3	0.5	2.77e-30	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1580019	0.885	rs1610141	chr7:32498435	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	16.01	0.6	2.99e-46	Cognitive ability;
LGG	cis	rs2236267	0.601	rs2767532	chr14:88580709	A/G	cg18078958	chr14:88630771	NA	-0.3	-7.0	-0.31	9.14e-12	Food antigen IgG levels;
LGG	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg16096631	chr1:42092165	HIVEP3	0.74	22.0	0.71	5.63e-74	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6735179	0.529	rs1364648	chr2:1754932	A/G	cg08534653	chr2:1747700	PXDN	-0.46	-6.94	-0.31	1.31e-11	Response to antipsychotic treatment;
LGG	cis	rs769267	0.930	rs7254748	chr19:19397479	A/C	cg11584989	chr19:19387371	SF4	0.43	7.83	0.34	3.3e-14	Tonsillectomy;
LGG	cis	rs5744897	0.708	rs5744929	chr12:133221239	G/T	cg17341477	chr12:133246679	POLE	0.58	6.72	0.3	5.49e-11	Urate levels in overweight individuals;
LGG	trans	rs629535	0.814	rs62513378	chr8:70095788	G/C	cg21567404	chr3:27674614	NA	-0.4	-6.71	-0.3	5.71e-11	Dupuytren's disease;
LGG	cis	rs7726839	0.540	rs72703092	chr5:599269	G/A	cg16400903	chr5:693638	TPPP	0.45	6.89	0.3	1.86e-11	Obesity-related traits;
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg01765077	chr12:122356316	WDR66	0.26	7.08	0.31	5.47e-12	Mean corpuscular volume;
LGG	cis	rs796364	0.715	rs1106399	chr2:201003837	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.64	-7.88	-0.34	2.42e-14	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24419099	chr11:47270565	NR1H3;ACP2	0.57	8.99	0.39	6.52e-18	Gut microbiome composition (summer);
LGG	cis	rs4805272	0.626	rs6509072	chr19:29331703	C/G	cg14983838	chr19:29218262	NA	0.59	8.68	0.37	6.59e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs17001868	0.568	rs9607702	chr22:40739177	A/G	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs6089829	0.926	rs7273917	chr20:61665975	G/A	cg08564027	chr20:61660810	NA	1.02	24.89	0.76	1.97e-87	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs11628318	0.515	rs2093259	chr14:103145646	T/A	cg12046867	chr14:103022105	NA	0.42	7.87	0.34	2.54e-14	Platelet count;
LGG	cis	rs701145	0.585	rs436852	chr3:153913403	G/A	cg12800244	chr3:153838788	SGEF	0.83	8.5	0.37	2.71e-16	Coronary artery disease;
LGG	cis	rs12367572	1.000	rs10880704	chr12:45318430	C/T	cg03114573	chr12:45410052	DBX2	-0.54	-9.31	-0.4	5.36e-19	Gut microbiome composition (summer);
LGG	cis	rs1056053	0.539	rs3099270	chr6:166571525	T/C	cg11088901	chr6:166572345	T	-0.51	-9.79	-0.41	1.11e-20	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg07701084	chr6:150067640	NUP43	0.68	12.71	0.51	5.87e-32	Lung cancer;
LGG	cis	rs28595532	0.841	rs114966236	chr4:119733437	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs2236293	0.532	rs7044405	chr9:35870001	A/G	cg12876594	chr9:35791798	NPR2	-0.38	-7.07	-0.31	5.58e-12	Blood protein levels;
LGG	cis	rs10173297	0.686	rs13389263	chr2:3711989	A/G	cg16123090	chr2:3699210	NA	0.56	7.44	0.33	4.98e-13	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs17221829	0.733	rs10830304	chr11:89366754	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs999943	0.846	rs9348923	chr6:33617924	C/T	cg14003231	chr6:33640908	ITPR3	0.61	14.36	0.56	6.23e-39	Obesity (extreme);
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg17178900	chr1:205818956	PM20D1	0.35	7.23	0.32	2.07e-12	Menarche (age at onset);
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs870825	0.929	rs10015218	chr4:185589789	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	18.78	0.66	6.76e-59	Blood protein levels;
LGG	cis	rs2224391	0.628	rs2753230	chr6:5248538	C/G	cg09085698	chr6:5261316	LYRM4;FARS2	0.57	7.78	0.34	4.84e-14	Height;
LGG	cis	rs7904368	0.806	rs7099178	chr10:16862578	C/G	cg14835575	chr10:16859367	RSU1	0.78	14.31	0.55	9.72e-39	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs12042938	0.935	rs1094657	chr1:231773407	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	10.92	0.45	7.4e-25	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs4689388	0.750	rs10001190	chr4:6284633	C/T	cg00701064	chr4:6280414	WFS1	-0.7	-14.88	-0.57	3.24e-41	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7618501	0.602	rs2071206	chr3:50160109	G/A	cg05623727	chr3:50126028	RBM5	-0.34	-7.31	-0.32	1.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4561483	0.583	rs17236573	chr16:11994655	G/C	cg08843971	chr16:11963173	GSPT1	0.59	14.63	0.56	4.25e-40	Testicular germ cell tumor;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg27049318	chr5:68514098	MRPS36	0.42	6.83	0.3	2.62e-11	Cognitive performance;
LGG	cis	rs561341	0.663	rs72821936	chr17:30224068	C/G	cg13647721	chr17:30228624	UTP6	0.78	12.34	0.5	1.98e-30	Hip circumference adjusted for BMI;
LGG	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg09904177	chr6:26538194	HMGN4	0.64	9.71	0.41	2.13e-20	Small cell lung carcinoma;
LGG	cis	rs8017423	0.967	rs11628881	chr14:90713833	C/T	cg04374321	chr14:90722782	PSMC1	0.86	18.25	0.65	1.83e-56	Mortality in heart failure;
LGG	cis	rs988958	0.565	rs6752667	chr2:42235445	G/A	cg27428208	chr2:42229179	NA	0.49	7.6	0.33	1.62e-13	Hypospadias;
LGG	cis	rs17401966	0.838	rs1556917	chr1:10400990	G/T	cg15208524	chr1:10270712	KIF1B	0.41	6.7	0.3	6.11e-11	Hepatocellular carcinoma;
LGG	cis	rs28386778	0.897	rs11654841	chr17:61838259	C/T	cg19143629	chr17:61920732	SMARCD2	0.42	7.22	0.32	2.19e-12	Prudent dietary pattern;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.66	12.31	0.5	2.54e-30	Obesity-related traits;
LGG	trans	rs6582630	0.593	rs7134006	chr12:38596245	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.74	-0.38	4.47e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6466055	0.777	rs10277120	chr7:104834417	A/T	cg04380332	chr7:105027541	SRPK2	0.35	6.83	0.3	2.75e-11	Schizophrenia;
LGG	cis	rs7927592	0.913	rs12284933	chr11:68319489	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs11920090	0.932	rs16855578	chr3:170684592	A/G	cg09710316	chr3:170744871	SLC2A2	0.58	8.33	0.36	9.28e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7918232	0.941	rs4749228	chr10:27433618	C/T	cg14240646	chr10:27532245	ACBD5	0.73	10.25	0.43	2.3e-22	Breast cancer;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg10295955	chr4:187884368	NA	-1.12	-26.55	-0.78	4.72e-95	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1580019	0.713	rs2122632	chr7:32524686	A/G	cg07520158	chr7:32535189	LSM5;AVL9	-0.53	-8.6	-0.37	1.28e-16	Cognitive ability;
LGG	cis	rs8056893	0.569	rs9935025	chr16:68307447	C/T	cg07273125	chr16:68295692	NA	-0.49	-11.04	-0.46	2.6e-25	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs6141769	0.518	rs2377665	chr20:31309054	T/C	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.73	-0.3	5.12e-11	Subjective well-being;
LGG	trans	rs11088226	0.681	rs1015047	chr21:33949423	A/G	cg09050820	chr6:167586206	TCP10L2	0.91	13.72	0.54	3.56e-36	Gastritis;
LGG	cis	rs6582630	0.519	rs4002438	chr12:38484880	C/T	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4689388	0.890	rs9993624	chr4:6286528	C/T	cg25554036	chr4:6271136	WFS1	0.63	12.24	0.49	4.68e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs1185460	0.565	rs584115	chr11:118938880	A/G	cg24687335	chr11:118901407	SLC37A4	-0.57	-10.11	-0.43	7.85e-22	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs11582514	chr1:182992161	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Hypertriglyceridemia;
LGG	cis	rs950776	0.752	rs62010328	chr15:78894971	C/T	cg17108064	chr15:78857060	CHRNA5	0.43	8.72	0.38	5.15e-17	Sudden cardiac arrest;
LGG	cis	rs9467773	0.620	rs4368798	chr6:26593471	A/G	cg11502198	chr6:26597334	ABT1	0.7	12.72	0.51	5.1e-32	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.967	rs4819222	chr21:47707778	G/A	cg05896524	chr21:47604654	C21orf56	0.54	9.26	0.4	7.85e-19	Testicular germ cell tumor;
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs881375	0.967	rs876445	chr9:123677102	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	11.96	0.49	6.25e-29	Rheumatoid arthritis;
LGG	cis	rs10895140	0.624	rs2513193	chr11:101476074	T/G	cg04553838	chr11:101454733	TRPC6	-0.4	-6.66	-0.3	7.76e-11	Menarche (age at onset);
LGG	cis	rs2070488	1.000	rs13074160	chr3:38455650	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.37	0.63	1.99e-52	Electrocardiographic conduction measures;
LGG	trans	rs2562456	0.793	rs11667103	chr19:21486641	G/C	cg00806126	chr19:22604979	ZNF98	-0.56	-7.33	-0.32	1.04e-12	Pain;
LGG	cis	rs7945705	0.846	rs2742540	chr11:8899528	A/G	cg00186954	chr11:8933980	ST5;C11orf17	0.4	8.37	0.36	6.68e-16	Hemoglobin concentration;
LGG	cis	rs3008870	0.958	rs12143044	chr1:67460054	A/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.82	-0.3	2.94e-11	Lymphocyte percentage of white cells;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg21017887	chr14:105400489	NA	0.42	8.26	0.36	1.58e-15	Rheumatoid arthritis;
LGG	cis	rs9322193	0.923	rs10747275	chr6:149943918	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.43	0.58	1.24e-43	Lung cancer;
LGG	cis	rs8032158	0.963	rs12102020	chr15:56125578	G/A	cg02198044	chr15:56286336	NEDD4	-0.69	-11.82	-0.48	2.44e-28	Keloid;
LGG	cis	rs2439831	1.000	rs1814538	chr15:43759774	C/T	cg15269541	chr15:43626905	ADAL	0.43	7.4	0.33	6.45e-13	Lung cancer in ever smokers;
LGG	cis	rs17221829	0.764	rs7945447	chr11:89386070	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.22	-0.39	1.05e-18	Anxiety in major depressive disorder;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg27400746	chr16:89904261	SPIRE2	-1.04	-15.98	-0.6	4.12e-46	Skin colour saturation;
LGG	cis	rs7106204	0.514	rs1596280	chr11:24250853	T/C	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4262150	0.810	rs113759615	chr5:151953062	G/A	cg12297329	chr5:152029980	NA	-0.81	-15.87	-0.59	1.37e-45	Bipolar disorder and schizophrenia;
LGG	cis	rs3806843	0.966	rs2563265	chr5:140137005	C/T	cg19875535	chr5:140030758	IK	-0.53	-10.95	-0.45	5.68e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2599510	0.755	rs67257914	chr2:32804018	G/A	cg02381751	chr2:32503542	YIPF4	0.52	8.27	0.36	1.38e-15	Interleukin-18 levels;
LGG	cis	rs9810089	0.843	rs518972	chr3:136039268	C/A	cg12473912	chr3:136751656	NA	0.41	6.87	0.3	2.08e-11	Gestational age at birth (child effect);
LGG	cis	rs806321	0.534	rs1269278	chr13:50892313	T/C	cg10393508	chr13:50950265	NA	-0.34	-8.58	-0.37	1.44e-16	Multiple sclerosis;
LGG	cis	rs7208859	0.623	rs12103508	chr17:29086781	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2742417	0.624	rs2673030	chr3:45757900	T/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.58e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg23782820	chr8:58130467	NA	0.53	7.45	0.33	4.48e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg16507663	chr6:150244633	RAET1G	0.41	7.72	0.34	7e-14	Lung cancer;
LGG	cis	rs875971	0.798	rs6460304	chr7:65964728	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.94	0.31	1.31e-11	Aortic root size;
LGG	cis	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.29	-0.53	2.37e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62103177	0.810	rs62103195	chr18:77629693	T/C	cg03511173	chr18:77590860	NA	0.6	7.33	0.32	1.06e-12	Opioid sensitivity;
LGG	cis	rs7216064	1.000	rs8074078	chr17:65838743	A/C	cg12091567	chr17:66097778	LOC651250	-0.6	-8.84	-0.38	1.94e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs807669	0.903	rs1780642	chr22:19170604	T/C	cg02655711	chr22:19163373	SLC25A1	0.79	16.13	0.6	9.15e-47	Metabolite levels;
LGG	cis	rs875971	0.545	rs7787063	chr7:65628999	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.38	0.43	7.57e-23	Aortic root size;
LGG	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg15128208	chr22:42549153	NA	0.74	11.44	0.47	7.16e-27	Birth weight;
LGG	cis	rs9682041	0.673	rs1511175	chr3:170076006	C/G	cg11886554	chr3:170076028	SKIL	1.1	11.82	0.48	2.38e-28	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs7660883	0.897	rs342467	chr4:88052219	T/C	cg21988461	chr4:88008667	AFF1	0.35	10.0	0.42	1.89e-21	HDL cholesterol levels;
LGG	cis	rs4906332	1.000	rs35366629	chr14:103903054	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.86	-0.34	2.79e-14	Coronary artery disease;
LGG	cis	rs2224391	0.628	rs9392666	chr6:5249888	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.57	-7.6	-0.33	1.7e-13	Height;
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg06968155	chr5:131705112	SLC22A5	0.74	8.58	0.37	1.49e-16	Rheumatoid arthritis;
LGG	trans	rs9929218	0.551	rs6499193	chr16:68727069	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.04	25.72	0.77	3.06e-91	Colorectal cancer;
LGG	cis	rs2201728	0.677	rs13121287	chr4:100190755	T/G	cg07219303	chr4:100140905	ADH6	-0.37	-6.95	-0.31	1.27e-11	Cardiac Troponin-T levels;
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.93	0.35	1.66e-14	Lung cancer;
LGG	cis	rs9596863	1.000	rs1379833	chr13:54443167	C/T	ch.13.53330881F	chr13:54432880	NA	0.5	6.78	0.3	3.57e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9790314	0.690	rs6441354	chr3:160826404	A/G	cg03342759	chr3:160939853	NMD3	-0.61	-11.12	-0.46	1.24e-25	Morning vs. evening chronotype;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01773306	chr2:85555458	TGOLN2	-0.46	-6.67	-0.3	7.51e-11	Systemic lupus erythematosus;
LGG	cis	rs67311347	1.000	rs11914297	chr3:40410070	T/C	cg13683864	chr3:40499215	RPL14	-1.0	-20.45	-0.69	1.01e-66	Renal cell carcinoma;
LGG	cis	rs17039065	1.000	rs72889372	chr4:109387298	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.8	0.3	3.16e-11	Gut microbiome composition (summer);
LGG	cis	rs11587400	0.634	rs7553926	chr1:115202215	A/G	cg12756093	chr1:115239321	AMPD1	-0.39	-6.75	-0.3	4.45e-11	Autism;
LGG	cis	rs7715811	1.000	rs9688222	chr5:13760906	C/A	cg07548982	chr5:13769939	DNAH5	-0.47	-9.86	-0.42	6.06e-21	Subclinical atherosclerosis traits (other);
LGG	cis	rs9660992	0.573	rs1172158	chr1:205208948	G/A	cg00857998	chr1:205179979	DSTYK	0.51	7.97	0.35	1.22e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs8017423	0.904	rs4603489	chr14:90760607	A/G	cg04374321	chr14:90722782	PSMC1	-0.85	-17.33	-0.63	3.3e-52	Mortality in heart failure;
LGG	cis	rs35146811	0.844	rs10281368	chr7:99655897	A/G	cg22906224	chr7:99728672	NA	0.56	9.14	0.39	2.03e-18	Coronary artery disease;
LGG	cis	rs12586317	0.924	rs4981276	chr14:35696818	A/G	cg05294307	chr14:35346193	BAZ1A	-0.46	-7.2	-0.32	2.38e-12	Psoriasis;
LGG	cis	rs1008375	1.000	rs62295634	chr4:17685346	C/A	cg16339924	chr4:17578868	LAP3	0.59	10.14	0.43	6.17e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2635047	0.638	rs2635051	chr18:44645029	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.42	0.36	4.78e-16	Educational attainment;
LGG	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.22	-0.36	2.11e-15	Retinal vascular caliber;
LGG	cis	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg08250081	chr4:10125330	NA	-0.34	-6.66	-0.3	7.79e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	cis	rs11122272	0.735	rs2808602	chr1:231537303	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.1	-0.46	1.54e-25	Hemoglobin concentration;
LGG	cis	rs870825	0.616	rs6810600	chr4:185616814	T/C	cg04058563	chr4:185651563	MLF1IP	1.05	22.69	0.73	3.48e-77	Blood protein levels;
LGG	cis	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg12826209	chr6:26865740	GUSBL1	0.74	7.94	0.35	1.51e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs753778	0.629	rs2278447	chr8:142206905	G/C	cg18755752	chr8:142205143	DENND3	-0.48	-9.81	-0.41	8.89e-21	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs11190604	1.000	rs2489035	chr10:102319395	C/T	cg11040518	chr10:102331378	NA	-0.39	-6.96	-0.31	1.14e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18039855	chr11:57434952	ZDHHC5	0.42	7.19	0.32	2.54e-12	Body mass index;
LGG	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.78	-0.69	2.97e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs6909430	0.901	rs2087181	chr6:98590686	G/T	cg12860156	chr6:98744658	NA	-0.46	-7.52	-0.33	2.88e-13	Quantitative traits;
LGG	cis	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg24375607	chr4:120327624	NA	0.66	10.71	0.45	4.62e-24	Corneal astigmatism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08811588	chr7:100473311	SRRT	0.41	6.88	0.3	2.01e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2549003	0.966	rs839	chr5:131819126	C/T	cg00578828	chr5:131826934	IRF1	0.41	7.43	0.33	5.3e-13	Asthma (sex interaction);
LGG	cis	rs1355223	0.902	rs1258464	chr11:34731496	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.41	-7.06	-0.31	6.08e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg15556689	chr8:8085844	FLJ10661	0.5	9.28	0.4	6.33e-19	Mood instability;
LGG	cis	rs2836950	0.501	rs2836983	chr21:40689336	G/A	cg11890956	chr21:40555474	PSMG1	-0.72	-12.37	-0.5	1.47e-30	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg00933542	chr6:150070202	PCMT1	0.39	7.02	0.31	8.15e-12	Lung cancer;
LGG	cis	rs5769765	0.908	rs4058453	chr22:50250297	T/C	cg02269571	chr22:50332266	NA	0.65	8.47	0.37	3.4e-16	Schizophrenia;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg05868516	chr6:26286170	HIST1H4H	0.42	6.94	0.31	1.35e-11	Educational attainment;
LGG	cis	rs1008375	0.932	rs11934968	chr4:17667766	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.73	0.45	3.88e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4950322	0.563	rs61838944	chr1:146581857	C/T	cg22381352	chr1:146742008	CHD1L	-0.43	-7.29	-0.32	1.32e-12	Protein quantitative trait loci;
LGG	cis	rs2688608	0.592	rs12253482	chr10:75496130	G/A	cg19442545	chr10:75533431	FUT11	-0.46	-7.52	-0.33	2.92e-13	Inflammatory bowel disease;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.85	-0.34	2.82e-14	Menarche (age at onset);
LGG	cis	rs4356932	1.000	rs11097222	chr4:76987451	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.77	-0.3	4.02e-11	Blood protein levels;
LGG	cis	rs4961252	0.505	rs6990155	chr8:142098977	C/T	cg07964753	chr8:142112622	NA	0.44	6.65	0.3	8.21e-11	Isovolumetric relaxation time;Response to interferon beta therapy;
LGG	cis	rs6540556	0.954	rs654984	chr1:209937382	C/T	cg23920097	chr1:209922102	NA	0.42	7.53	0.33	2.65e-13	Red blood cell count;
LGG	trans	rs7824557	0.614	rs2293858	chr8:11213881	G/C	cg02002194	chr4:3960332	NA	-0.39	-6.98	-0.31	1.05e-11	Retinal vascular caliber;
LGG	cis	rs11191270	0.784	rs11191264	chr10:104096732	A/T	cg15320455	chr10:103880129	LDB1	0.5	6.88	0.3	1.96e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7927592	0.956	rs11228277	chr11:68308324	G/A	cg16797656	chr11:68205561	LRP5	0.41	7.26	0.32	1.61e-12	Total body bone mineral density;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.43	8.8	0.38	2.72e-17	Schizophrenia;
LGG	cis	rs57677839	1	rs57677839	chr11:17028189	G/A	cg15378786	chr11:17036137	PLEKHA7	0.69	13.59	0.53	1.19e-35	Coronary artery disease;
LGG	cis	rs933688	1.000	rs2059207	chr5:90731931	C/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	18.88	0.66	2.14e-59	Smoking behavior;
LGG	cis	rs9837602	0.529	rs793494	chr3:99508768	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.3	-0.36	1.15e-15	Breast cancer;
LGG	cis	rs1595825	0.891	rs73054819	chr2:198625744	G/T	cg00982548	chr2:198649783	BOLL	-0.52	-7.06	-0.31	6.01e-12	Ulcerative colitis;
LGG	cis	rs13217239	0.621	rs12527231	chr6:27001288	G/A	cg12292205	chr6:26970375	C6orf41	0.55	10.82	0.45	1.7e-24	Schizophrenia;
LGG	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg04990556	chr1:26633338	UBXN11	-0.49	-7.62	-0.33	1.4e-13	Monocyte percentage of white cells;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.94	-0.35	1.53e-14	Personality dimensions;
LGG	cis	rs17376456	0.569	rs10050364	chr5:93064127	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.63	8.3	0.36	1.17e-15	Diabetic retinopathy;
LGG	cis	rs870825	0.698	rs72703549	chr4:185623963	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs1153858	1.000	rs12909158	chr15:45621174	A/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.35	0.43	1.04e-22	Homoarginine levels;
LGG	cis	rs7945705	0.935	rs1883098	chr11:8890594	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.37	-7.82	-0.34	3.63e-14	Hemoglobin concentration;
LGG	cis	rs62064224	0.589	rs6505295	chr17:30687522	G/C	cg25809561	chr17:30822961	MYO1D	0.37	8.77	0.38	3.41e-17	Schizophrenia;
LGG	cis	rs7226408	0.857	rs72887051	chr18:34486993	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs2842992	0.872	rs9456440	chr6:160074463	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.7	11.3	0.47	2.46e-26	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs34859456	chr8:58117722	A/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6763768	0.578	rs13090627	chr3:53406425	C/T	cg16894138	chr3:53270350	TKT	0.42	8.08	0.35	5.75e-15	Bacterial meningitis;
LGG	cis	rs7617773	0.563	rs62263035	chr3:48391569	C/T	cg11946769	chr3:48343235	NME6	0.51	8.6	0.37	1.26e-16	Coronary artery disease;
LGG	cis	rs67478160	0.619	rs2368560	chr14:104273311	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.46	-0.33	4.29e-13	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02920897	chr13:50699344	DLEU2	0.46	6.77	0.3	3.98e-11	Gut microbiome composition (summer);
LGG	cis	rs372883	0.648	rs15092	chr21:30718201	G/A	cg08807101	chr21:30365312	RNF160	-0.6	-9.89	-0.42	4.58e-21	Pancreatic cancer;
LGG	cis	rs539514	0.718	rs502171	chr13:76320114	T/C	cg04757411	chr13:76259545	LMO7	-0.27	-6.83	-0.3	2.71e-11	Type 1 diabetes;
LGG	cis	rs62238980	0.614	rs743763	chr22:32458861	C/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9358372	0.597	rs10946414	chr6:20873388	T/C	cg13405222	chr6:20811065	CDKAL1	0.62	13.45	0.53	4.96e-35	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs644799	0.623	rs17207890	chr11:95490754	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.45	7.36	0.32	8.21e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7762018	0.514	rs60671539	chr6:170165981	A/G	cg13891659	chr6:170190454	C6orf122;C6orf208	0.56	8.54	0.37	2.01e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg15556689	chr8:8085844	FLJ10661	0.44	7.88	0.34	2.32e-14	Mood instability;
LGG	cis	rs146009840	1	rs146009840	chr15:78906177	A/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.44	-0.33	4.9e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs1894633	0.519	rs17368942	chr1:172307678	T/C	cg01573306	chr1:172330400	DNM3	-0.42	-7.37	-0.32	7.99e-13	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7666738	0.830	rs1967980	chr4:98966426	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg13939156	chr17:80058883	NA	-0.45	-8.75	-0.38	4.13e-17	Life satisfaction;
LGG	cis	rs6088580	0.634	rs2378133	chr20:32919505	C/G	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.31	-0.36	1.07e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12092561	chr1:11538840	PTCHD2	0.4	6.76	0.3	4.27e-11	Gut microbiome composition (summer);
LGG	cis	rs7904368	0.568	rs7075036	chr10:16864810	C/T	cg22980697	chr10:16874865	CUBN	0.44	7.6	0.33	1.64e-13	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs7267979	1.000	rs7267979	chr20:25298087	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.31	0.43	1.46e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.99	-14.74	-0.57	1.32e-40	Chronic sinus infection;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg00933542	chr6:150070202	PCMT1	0.4	7.34	0.32	9.6e-13	Lung cancer;
LGG	cis	rs28386778	0.897	rs2665844	chr17:61874455	A/G	cg03528353	chr17:61819722	STRADA	0.44	7.56	0.33	2.13e-13	Prudent dietary pattern;
LGG	cis	rs4742903	0.935	rs6479225	chr9:106940330	T/C	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg11584989	chr19:19387371	SF4	0.45	8.01	0.35	9.67e-15	Tonsillectomy;
LGG	cis	rs2404602	0.716	rs67888330	chr15:76752483	A/G	cg23625390	chr15:77176239	SCAPER	0.49	9.65	0.41	3.31e-20	Blood metabolite levels;
LGG	cis	rs367943	1.000	rs348956	chr5:112821464	C/T	cg12552261	chr5:112820674	MCC	0.75	14.29	0.55	1.21e-38	Type 2 diabetes;
LGG	cis	rs4481887	0.927	rs12744455	chr1:248479960	A/G	cg00666640	chr1:248458726	OR2T12	0.55	8.86	0.38	1.77e-17	Common traits (Other);
LGG	trans	rs208520	0.837	rs208486	chr6:66926255	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.21	-0.58	1.12e-42	Exhaled nitric oxide output;
LGG	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs7635838	0.722	rs2594982	chr3:11379958	C/T	cg00170343	chr3:11313890	ATG7	0.49	8.58	0.37	1.45e-16	HDL cholesterol;
LGG	cis	rs72949976	0.646	rs4673731	chr2:214028544	C/T	cg08319019	chr2:214017104	IKZF2	0.64	11.94	0.49	7.74e-29	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs773506	0.655	rs4744037	chr9:93932488	C/G	cg14446406	chr9:93919335	NA	0.6	10.61	0.44	1.09e-23	Type 2 diabetes nephropathy;
LGG	cis	rs7829975	0.593	rs2921061	chr8:8317615	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.62	0.37	1.08e-16	Mood instability;
LGG	cis	rs7226408	0.600	rs11873298	chr18:34635047	A/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.2	-0.39	1.21e-18	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs9393655	chr6:25711338	A/G	cg03517284	chr6:25882590	NA	-0.42	-6.95	-0.31	1.25e-11	Iron status biomarkers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09712606	chr19:50169182	IRF3;BCL2L12	0.49	7.36	0.32	8.64e-13	Gut microbiome composition (summer);
LGG	cis	rs734999	0.549	rs2764840	chr1:2529437	C/T	cg20673091	chr1:2541236	MMEL1	-0.77	-18.79	-0.66	6.1e-59	Ulcerative colitis;
LGG	cis	rs7582180	0.663	rs2309794	chr2:100954270	G/A	cg05692746	chr2:100937584	LONRF2	-0.63	-11.77	-0.48	3.76e-28	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg21724239	chr8:58056113	NA	0.44	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9914988	0.832	rs12946132	chr17:27157362	T/C	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs6977660	1.000	rs12666159	chr7:19804199	T/C	cg07541023	chr7:19748670	TWISTNB	0.47	7.33	0.32	1.07e-12	Thyroid stimulating hormone;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs7113850	0.541	rs4360696	chr11:24217119	C/G	ch.11.24196551F	chr11:24239977	NA	0.92	10.94	0.45	6.41e-25	Bone fracture in osteoporosis;
LGG	cis	rs28386778	0.830	rs2584625	chr17:61903445	G/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.23	0.32	1.98e-12	Prudent dietary pattern;
LGG	cis	rs806215	0.526	rs11768841	chr7:127551403	T/C	cg25922125	chr7:127225783	GCC1	-0.47	-6.84	-0.3	2.46e-11	Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21466042	chr6:17707449	NUP153	0.47	7.1	0.31	4.59e-12	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.597	rs79626430	chr3:42023786	A/G	cg03022575	chr3:42003672	ULK4	0.75	8.2	0.36	2.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10080237	0.564	rs2490230	chr6:80812464	G/A	cg08355045	chr6:80787529	NA	0.4	7.95	0.35	1.48e-14	Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.62	-10.66	-0.44	7.14e-24	Lymphocyte counts;
LGG	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg18709589	chr6:96969512	KIAA0776	0.46	7.06	0.31	6.04e-12	Migraine;Coronary artery disease;
LGG	cis	rs597539	0.652	rs579136	chr11:68637476	C/G	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.03e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs56161922	0.818	rs55638397	chr1:207856040	G/A	cg09557387	chr1:207818395	CR1L	0.94	9.47	0.4	1.46e-19	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs1552244	0.935	rs11926481	chr3:10142102	G/T	cg16606324	chr3:10149918	C3orf24	0.52	6.9	0.31	1.75e-11	Alzheimer's disease;
LGG	cis	rs7474896	0.583	rs7071147	chr10:38003376	T/C	cg00409905	chr10:38381863	ZNF37A	-0.54	-8.43	-0.36	4.38e-16	Obesity (extreme);
LGG	cis	rs6500637	0.570	rs1049205	chr16:4942099	C/T	cg04440724	chr16:4920505	UBN1	0.55	11.69	0.48	7.47e-28	Cancer;
LGG	cis	rs7829975	0.502	rs7820738	chr8:8702607	C/G	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.16	-0.35	3.1e-15	Mood instability;
LGG	cis	rs8114671	0.836	rs734308	chr20:33572096	A/G	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.34	-0.36	8.52e-16	Height;
LGG	cis	rs7582180	0.629	rs13004216	chr2:100945402	G/A	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs11250464	0.833	rs11250467	chr10:1409662	A/G	cg09624528	chr10:1369823	ADARB2	-0.41	-6.93	-0.31	1.45e-11	Radiation response;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27174387	chr12:109535940	UNG	0.45	6.65	0.3	8.3e-11	Gut microbiome composition (summer);
LGG	cis	rs3768617	0.510	rs3765521	chr1:183077615	C/T	cg07245641	chr1:182991651	LAMC1	0.4	9.11	0.39	2.46e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.51	0.58	5.47e-44	Platelet count;
LGG	cis	rs283228	0.798	rs283227	chr6:101755248	T/A	cg27451362	chr6:101846650	GRIK2	0.63	10.42	0.44	5.38e-23	Coenzyme Q10 levels;
LGG	cis	rs2274273	0.840	rs17674463	chr14:55824863	A/T	cg04306507	chr14:55594613	LGALS3	0.61	16.97	0.62	1.45e-50	Protein biomarker;
LGG	cis	rs9814567	0.964	rs9847788	chr3:134186496	A/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.7	-12.58	-0.5	2.05e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs9467711	1.000	rs34569761	chr6:26334306	A/G	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.29	-0.32	1.36e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.63	0.37	1e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.52	8.01	0.35	9.43e-15	Renal function-related traits (BUN);
LGG	cis	rs2204008	0.837	rs2892296	chr12:37969785	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.73	-0.64	4.68e-54	Bladder cancer;
LGG	cis	rs11096990	0.819	rs2711992	chr4:39150271	A/G	cg24403649	chr4:39172243	NA	-0.49	-8.1	-0.35	4.82e-15	Cognitive function;
LGG	cis	rs2013441	1.000	rs11871945	chr17:20206883	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs2204008	0.643	rs1315347	chr12:38162494	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.82	-0.34	3.48e-14	Bladder cancer;
LGG	cis	rs7824557	0.564	rs2736300	chr8:11235579	T/G	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.24e-17	Retinal vascular caliber;
LGG	cis	rs986417	0.901	rs1950316	chr14:61018305	T/C	cg27398547	chr14:60952738	C14orf39	0.71	6.72	0.3	5.46e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7095944	0.585	rs7080838	chr10:126419841	A/G	cg08799069	chr10:126477246	METTL10	0.45	10.09	0.42	8.79e-22	Asthma;
LGG	cis	rs11155671	0.530	rs9371223	chr6:150214806	T/C	cg01145232	chr6:150245071	RAET1G	0.33	6.92	0.31	1.48e-11	Testicular germ cell tumor;
LGG	cis	rs796364	1.000	rs4263095	chr2:200830137	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.85	-11.11	-0.46	1.36e-25	Schizophrenia;
LGG	cis	rs11716531	0.512	rs7612312	chr3:27230230	C/A	cg02860705	chr3:27208620	NA	0.62	12.54	0.5	3.01e-31	Diastolic blood pressure;
LGG	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg06606381	chr12:133084897	FBRSL1	-0.66	-7.96	-0.35	1.29e-14	Depression;
LGG	cis	rs9296092	0.560	rs7765263	chr6:33525559	A/G	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs994014	0.629	rs12332030	chr4:82314432	G/A	cg07938847	chr4:82126349	PRKG2	-0.28	-6.67	-0.3	7.2e-11	Height;
LGG	cis	rs2243480	1.000	rs6460261	chr7:65215580	T/C	cg13147721	chr7:65941812	NA	0.79	9.72	0.41	1.92e-20	Diabetic kidney disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15884202	chr7:158649092	WDR60	-0.48	-7.01	-0.31	8.52e-12	Systemic lupus erythematosus;
LGG	cis	rs8180040	0.800	rs7632501	chr3:47268306	T/C	cg16586182	chr3:47516702	SCAP	0.75	13.55	0.53	1.87e-35	Colorectal cancer;
LGG	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg04117972	chr1:227635322	NA	0.84	12.02	0.49	3.59e-29	Major depressive disorder;
LGG	trans	rs12599106	0.754	rs11640596	chr16:34347277	T/C	cg03395511	chr6:291903	DUSP22	-0.44	-7.5	-0.33	3.28e-13	Menopause (age at onset);
LGG	trans	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg06521331	chr12:34319734	NA	0.42	7.67	0.34	1.05e-13	Bladder cancer;
LGG	trans	rs7395662	0.654	rs12289625	chr11:48817242	A/G	cg00717180	chr2:96193071	NA	0.42	7.5	0.33	3.29e-13	HDL cholesterol;
LGG	trans	rs916888	0.773	rs199443	chr17:44819565	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.94	-15.1	-0.57	3.54e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs79349575	0.811	rs1057897	chr17:47005509	T/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.28	0.36	1.37e-15	Type 2 diabetes;
LGG	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg26384229	chr12:38710491	ALG10B	0.92	19.61	0.67	9.26e-63	Bladder cancer;
LGG	cis	rs2243480	1.000	rs4718309	chr7:65627764	G/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.43	-0.36	4.33e-16	Diabetic kidney disease;
LGG	cis	rs7107174	1.000	rs10501426	chr11:78057122	C/T	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	8.01e-13	Testicular germ cell tumor;
LGG	cis	rs9399137	0.561	rs11753985	chr6:135280438	C/T	cg24558204	chr6:135376177	HBS1L	0.61	10.45	0.44	4.18e-23	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs57221529	0.766	rs72704799	chr5:551457	C/G	cg07777115	chr5:623756	CEP72	-0.59	-6.98	-0.31	1.05e-11	Lung disease severity in cystic fibrosis;
LGG	trans	rs9467711	0.651	rs68194335	chr6:25866243	A/T	cg01620082	chr3:125678407	NA	-0.74	-6.86	-0.3	2.15e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2153535	0.563	rs1737586	chr6:8535897	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.11	0.39	2.41e-18	Motion sickness;
LGG	cis	rs10463316	0.862	rs11747047	chr5:150777953	C/T	cg03212797	chr5:150827313	SLC36A1	-0.6	-10.77	-0.45	2.86e-24	Metabolite levels (Pyroglutamine);
LGG	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12379764	chr21:47803548	PCNT	0.56	8.69	0.37	6.44e-17	Testicular germ cell tumor;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14295842	chr14:50234897	KLHDC2	0.53	7.81	0.34	3.82e-14	Hip circumference;
LGG	cis	rs897984	0.542	rs8061047	chr16:31068960	T/C	cg00531865	chr16:30841666	NA	-0.46	-9.2	-0.39	1.19e-18	Dementia with Lewy bodies;
LGG	cis	rs12541335	0.579	rs59283125	chr8:22212311	G/A	cg26039829	chr8:22132926	PIWIL2	0.53	12.02	0.49	3.59e-29	Hypertriglyceridemia;
LGG	cis	rs727505	0.954	rs1568883	chr7:124710761	G/A	cg23710748	chr7:124431027	NA	-0.48	-8.74	-0.38	4.43e-17	Lewy body disease;
LGG	cis	rs12476592	0.571	rs1446565	chr2:63731575	T/C	cg17519650	chr2:63277830	OTX1	-0.45	-6.89	-0.31	1.81e-11	Childhood ear infection;
LGG	cis	rs11971779	0.648	rs7799165	chr7:139084957	G/T	cg07862535	chr7:139043722	LUC7L2	0.42	7.02	0.31	7.99e-12	Diisocyanate-induced asthma;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg14338887	chr6:42928500	GNMT	0.28	9.27	0.4	6.94e-19	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs35146811	0.844	rs12705071	chr7:99682026	T/C	cg22906224	chr7:99728672	NA	0.56	8.7	0.37	6.05e-17	Coronary artery disease;
LGG	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	cis	rs62025270	1.000	rs62025270	chr15:86300198	G/A	cg25843651	chr15:86329602	KLHL25	0.63	10.17	0.43	4.74e-22	Idiopathic pulmonary fibrosis;
LGG	cis	rs6908034	0.607	rs114146042	chr6:19807229	G/A	cg02682789	chr6:19804855	NA	0.91	8.62	0.37	1.09e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2832270	0.562	rs73193803	chr21:30529326	G/A	cg24692254	chr21:30365293	RNF160	-0.7	-7.44	-0.33	5.04e-13	Response to mTOR inhibitor (everolimus);
LGG	cis	rs4727027	0.866	rs1358062	chr7:148783743	T/C	cg12479418	chr7:148823350	ZNF425;ZNF398	0.45	6.78	0.3	3.7e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs950169	0.544	rs12913702	chr15:85153184	G/A	cg24253500	chr15:84953950	NA	0.5	8.76	0.38	3.72e-17	Schizophrenia;
LGG	cis	rs67133203	0.606	rs1056897	chr12:51566541	G/A	cg14688905	chr12:51403056	SLC11A2	0.65	9.82	0.42	8.39e-21	Urinary tract infection frequency;
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg25072359	chr17:41440525	NA	0.54	10.18	0.43	4.2e-22	Menopause (age at onset);
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg19077165	chr18:44547161	KATNAL2	0.54	9.75	0.41	1.51e-20	Personality dimensions;
LGG	trans	rs634534	0.591	rs688862	chr11:65733393	A/G	cg17712092	chr4:129076599	LARP1B	0.7	13.32	0.53	1.72e-34	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6901004	0.685	rs354550	chr6:111546484	G/A	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.64	-0.33	1.29e-13	Blood metabolite levels;
LGG	cis	rs2235573	0.551	rs139895	chr22:38397034	A/G	cg19171272	chr22:38449367	NA	0.5	9.01	0.39	5.49e-18	Glioblastoma;Glioma;
LGG	cis	rs9660992	0.710	rs1668867	chr1:205240251	C/T	cg00857998	chr1:205179979	DSTYK	0.47	7.09	0.31	4.93e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6694672	1.000	rs1170882	chr1:196949323	C/G	cg13682187	chr1:196946512	CFHR5	-0.49	-6.7	-0.3	6.21e-11	Asthma;
LGG	cis	rs947211	0.948	rs12565968	chr1:205755046	A/G	cg26354017	chr1:205819088	PM20D1	-0.49	-8.02	-0.35	8.54e-15	Parkinson's disease;
LGG	cis	rs4819052	0.851	rs35871601	chr21:46675214	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.89	0.38	1.39e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs738321	0.794	rs5756940	chr22:38558842	C/T	cg25457927	chr22:38595422	NA	-0.43	-10.28	-0.43	1.75e-22	Breast cancer;
LGG	cis	rs4731207	0.596	rs12539580	chr7:124619404	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2067615	0.599	rs10778508	chr12:107159405	A/G	cg15890332	chr12:107067104	RFX4	-0.4	-11.9	-0.48	1.15e-28	Heart rate;
LGG	cis	rs826838	0.967	rs826870	chr12:39120250	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.51	-0.71	1.12e-71	Heart rate;
LGG	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs2652834	0.851	rs6494391	chr15:63406785	T/C	cg05507819	chr15:63340323	TPM1	0.51	7.25	0.32	1.76e-12	HDL cholesterol;
LGG	trans	rs853679	0.769	rs7752608	chr6:28301195	A/G	cg01620082	chr3:125678407	NA	-0.87	-9.59	-0.41	5.4e-20	Depression;
LGG	cis	rs1005277	0.579	rs2021649	chr10:38392122	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.53	-0.33	2.71e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.71	0.64	5.54e-54	Smoking behavior;
LGG	cis	rs9486719	0.947	rs11757102	chr6:96885073	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs7923609	1.000	rs4400684	chr10:65012687	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.75	-0.3	4.51e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4671458	0.626	rs4567921	chr2:63847114	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.22	-0.32	2.18e-12	Subjective well-being;
LGG	trans	rs7395662	0.784	rs79037165	chr11:48865464	G/T	cg15704280	chr7:45808275	SEPT13	0.5	8.19	0.36	2.57e-15	HDL cholesterol;
LGG	cis	rs9354308	0.764	rs9363474	chr6:66587868	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06320982	chr16:58718767	SLC38A7	0.45	7.57	0.33	2.1e-13	Gut microbiome composition (summer);
LGG	cis	rs10499694	0.933	rs12538938	chr7:50592313	A/G	cg04490037	chr7:50633773	DDC	0.32	7.12	0.31	4.14e-12	Body mass index;
LGG	cis	rs8049040	0.547	rs891131	chr16:71432417	G/A	cg06353428	chr16:71660113	MARVELD3	-0.46	-7.09	-0.31	4.95e-12	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25123308	chr2:113300087	POLR1B	0.45	7.26	0.32	1.63e-12	Cognitive performance;
LGG	cis	rs3206736	0.548	rs2021177	chr7:35020188	T/C	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.78e-19	Diastolic blood pressure;
LGG	cis	rs68170813	0.559	rs11769527	chr7:106912948	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.47	-0.44	3.5e-23	Coronary artery disease;
LGG	cis	rs9902453	0.740	rs2729446	chr17:28102499	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg08677398	chr8:58056175	NA	0.44	7.4	0.33	6.39e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.73	0.45	3.92e-24	Arsenic metabolism;
LGG	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg27165867	chr14:105738592	BRF1	-0.44	-7.4	-0.33	6.64e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6952808	1.000	rs59248873	chr7:1888185	A/G	cg02951883	chr7:2050386	MAD1L1	-0.62	-11.62	-0.48	1.48e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs11240074	0.516	rs2353996	chr1:146926498	G/T	cg25205988	chr1:146714368	CHD1L	-0.65	-6.68	-0.3	7.08e-11	Type 2 diabetes;
LGG	cis	rs703842	0.865	rs10877011	chr12:58124992	T/G	cg04478727	chr12:58166393	METTL1;FAM119B	0.53	8.03	0.35	8.2e-15	Multiple sclerosis;
LGG	cis	rs12200560	0.505	rs211183	chr6:97074723	G/T	cg06623918	chr6:96969491	KIAA0776	-0.42	-7.06	-0.31	6.15e-12	Coronary heart disease;
LGG	cis	rs9325144	0.647	rs12424190	chr12:39111206	A/T	cg26384229	chr12:38710491	ALG10B	-0.7	-13.17	-0.52	7.05e-34	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.966	rs10939735	chr4:17578891	A/G	cg02297831	chr4:17616191	MED28	0.44	8.05	0.35	7.03e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7944735	0.517	rs11039520	chr11:48130794	A/G	cg03929089	chr4:120376271	NA	0.65	6.71	0.3	5.76e-11	Intraocular pressure;
LGG	trans	rs561341	0.941	rs2470236	chr17:30304940	G/C	cg20587970	chr11:113659929	NA	-1.28	-23.62	-0.74	1.61e-81	Hip circumference adjusted for BMI;
LGG	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg02002194	chr4:3960332	NA	-0.4	-7.36	-0.32	8.4e-13	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07725658	chr4:71705655	GRSF1	0.42	6.65	0.3	8.25e-11	Gut microbiome composition (summer);
LGG	cis	rs12188164	0.525	rs1114665	chr5:452247	C/T	cg00049323	chr5:472564	LOC25845	0.39	8.52	0.37	2.35e-16	Cystic fibrosis severity;
LGG	cis	rs11622475	1.000	rs2368984	chr14:104372055	A/C	cg20488157	chr14:104394430	TDRD9	0.52	8.39	0.36	6.1e-16	Bipolar disorder;
LGG	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg13939156	chr17:80058883	NA	0.4	7.28	0.32	1.47e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9658691	0.607	rs3758483	chr10:90748736	C/T	cg03111039	chr10:90751583	FAS;ACTA2	0.93	9.99	0.42	1.98e-21	Mosquito bite size;
LGG	cis	rs12210905	0.925	rs12192502	chr6:26995720	A/C	cg23155468	chr6:27110703	HIST1H2BK	0.56	7.36	0.32	8.51e-13	Hip circumference adjusted for BMI;
LGG	cis	rs35079168	0.701	rs3132296	chr9:137302631	C/T	cg00753924	chr9:137298813	RXRA	-0.47	-8.59	-0.37	1.34e-16	Intelligence;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.43	7.78	0.34	4.82e-14	Schizophrenia;
LGG	cis	rs1371867	0.875	rs1788168	chr8:101324960	G/T	cg06636551	chr8:101224915	SPAG1	-0.46	-8.59	-0.37	1.36e-16	Atrioventricular conduction;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg24075738	chr3:50605156	C3orf18	0.52	7.69	0.34	9.07e-14	Hip circumference;
LGG	trans	rs7939886	0.841	rs10501349	chr11:56021284	G/A	cg15704280	chr7:45808275	SEPT13	0.82	7.63	0.33	1.34e-13	Myopia (pathological);
LGG	cis	rs4604732	0.631	rs11490198	chr1:247625703	A/G	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs738322	0.555	rs5750547	chr22:38546700	A/G	cg25457927	chr22:38595422	NA	0.36	8.42	0.36	4.77e-16	Cutaneous nevi;
LGG	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg11965913	chr1:205819406	PM20D1	0.44	7.01	0.31	8.65e-12	Parkinson's disease;
LGG	cis	rs5769765	0.955	rs8135963	chr22:50301476	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.71	0.34	7.52e-14	Schizophrenia;
LGG	cis	rs8031584	0.918	rs61997139	chr15:31273602	C/G	cg14829155	chr15:31115871	NA	-0.56	-9.74	-0.41	1.57e-20	Huntington's disease progression;
LGG	cis	rs6500395	0.926	rs9936446	chr16:48645807	G/C	cg16662043	chr16:48846231	NA	0.39	7.62	0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs72781680	1.000	rs72796389	chr2:24171761	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs858239	0.600	rs59073109	chr7:23133226	C/A	cg23682824	chr7:23144976	KLHL7	0.42	7.26	0.32	1.7e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11605924	0.901	rs7112505	chr11:45840939	A/T	ch.11.939596F	chr11:45881766	CRY2	-0.48	-8.19	-0.36	2.58e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09774198	chr13:33160713	PDS5B	0.43	7.25	0.32	1.76e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg08250081	chr4:10125330	NA	-0.38	-7.31	-0.32	1.15e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4665809	0.590	rs62128455	chr2:26466530	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs9912468	0.528	rs9897002	chr17:64286494	A/G	cg19474267	chr17:64306194	PRKCA	-0.78	-16.64	-0.61	4.7e-49	QRS duration;QRS complex (12-leadsum);QRS complex (Sokolow-Lyon);
LGG	cis	rs67133203	0.606	rs11169736	chr12:51566657	G/T	cg14688905	chr12:51403056	SLC11A2	0.62	9.35	0.4	3.73e-19	Urinary tract infection frequency;
LGG	cis	rs12325245	0.536	rs35908812	chr16:58587426	T/C	cg19824325	chr16:58548873	SETD6	1.21	11.07	0.46	1.93e-25	Schizophrenia;
LGG	cis	rs12586317	0.576	rs6571696	chr14:35630175	A/G	cg16230307	chr14:35515116	FAM177A1	0.42	7.57	0.33	2.06e-13	Psoriasis;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg12070911	chr6:150209640	RAET1E	0.28	6.92	0.31	1.47e-11	Lung cancer;
LGG	cis	rs4454254	0.966	rs4631439	chr8:141059650	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.31	-7.75	-0.34	6.07e-14	Pulse pressure;
LGG	cis	rs936229	0.705	rs936227	chr15:75131959	A/G	cg14664628	chr15:75095509	CSK	-0.63	-12.95	-0.52	6.18e-33	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs11190604	0.945	rs7091356	chr10:102292268	G/C	cg07570687	chr10:102243282	WNT8B	0.43	7.33	0.32	1.05e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4740619	0.525	rs7024440	chr9:15828359	G/C	cg14451791	chr9:16040625	NA	0.32	7.78	0.34	4.67e-14	Body mass index;
LGG	cis	rs2153535	0.601	rs2327059	chr6:8447071	A/G	cg21535247	chr6:8435926	SLC35B3	0.58	10.03	0.42	1.48e-21	Motion sickness;
LGG	trans	rs61931739	0.686	rs708145	chr12:33731580	G/A	cg26384229	chr12:38710491	ALG10B	0.48	8.63	0.37	9.6e-17	Morning vs. evening chronotype;
LGG	cis	rs13314892	0.764	rs56155813	chr3:69879509	A/G	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.41e-14	QRS complex (12-leadsum);
LGG	cis	rs9322193	0.886	rs9767555	chr6:149968158	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-6.86	-0.3	2.16e-11	Lung cancer;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.44	0.44	4.68e-23	Prudent dietary pattern;
LGG	cis	rs62400317	0.859	rs4443508	chr6:45235952	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs8031584	0.958	rs7168641	chr15:31235452	G/A	cg08109568	chr15:31115862	NA	-0.54	-9.45	-0.4	1.72e-19	Huntington's disease progression;
LGG	cis	rs2721811	0.570	rs2721803	chr7:24781532	C/T	cg19706795	chr7:24797839	DFNA5	-0.26	-6.93	-0.31	1.39e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs10463316	0.894	rs4099170	chr5:150766583	G/A	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs7737355	0.812	rs32107	chr5:131039633	C/A	cg06307176	chr5:131281290	NA	0.52	8.64	0.37	8.88e-17	Life satisfaction;
LGG	cis	rs889398	0.741	rs3790075	chr16:69907811	A/G	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.8	-0.3	3.26e-11	Body mass index;
LGG	cis	rs929354	0.742	rs6459734	chr7:156935454	A/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.38	-0.32	7.61e-13	Body mass index;
LGG	cis	rs9303401	0.659	rs35082010	chr17:56936867	A/G	cg25039879	chr17:56429692	SUPT4H1	0.63	8.84	0.38	2.09e-17	Cognitive test performance;
LGG	cis	rs5769765	1.000	rs8138941	chr22:50290678	G/A	cg02269571	chr22:50332266	NA	-0.63	-10.19	-0.43	4.05e-22	Schizophrenia;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg12070911	chr6:150209640	RAET1E	0.28	6.79	0.3	3.52e-11	Lung cancer;
LGG	trans	rs6956675	1.000	rs4718791	chr7:62577991	G/C	cg01314568	chr7:57830625	NA	-0.51	-8.07	-0.35	6.27e-15	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg15736062	chr7:158136485	PTPRN2	-0.39	-7.43	-0.33	5.38e-13	Calcium levels;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.82	0.3	2.94e-11	Prudent dietary pattern;
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg26617929	chr16:1858877	NA	-0.59	-8.5	-0.37	2.69e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.6	0.72	9.27e-77	Homoarginine levels;
LGG	trans	rs6582630	0.519	rs11181294	chr12:38312787	C/T	cg06521331	chr12:34319734	NA	-0.5	-8.73	-0.38	4.78e-17	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs57221529	0.766	rs56216231	chr5:581193	G/A	cg25482853	chr8:67687455	SGK3	1.03	13.3	0.53	2.14e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs6547631	0.844	rs1436968	chr2:85903470	C/G	cg24620635	chr2:85921963	GNLY	0.37	6.99	0.31	9.84e-12	Blood protein levels;
LGG	trans	rs4714291	0.963	rs847777	chr6:40055754	C/T	cg02267698	chr19:7991119	CTXN1	0.6	9.45	0.4	1.64e-19	Strep throat;
LGG	cis	rs4975616	0.804	rs456366	chr5:1337070	T/C	cg06550200	chr5:1325588	CLPTM1L	-0.62	-11.0	-0.46	3.8e-25	Lung cancer;
LGG	cis	rs7523050	0.643	rs12736534	chr1:109399934	T/C	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs16854884	0.586	rs11914731	chr3:143725594	A/G	cg06585982	chr3:143692056	C3orf58	0.68	12.32	0.5	2.39e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs6502050	0.835	rs55679819	chr17:80105450	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.59	-0.41	5.64e-20	Life satisfaction;
LGG	cis	rs7829975	0.533	rs1039917	chr8:8718850	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.76	0.3	4.22e-11	Mood instability;
LGG	cis	rs7226408	0.857	rs8099124	chr18:34593676	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs4665809	0.878	rs4665826	chr2:26367503	A/T	cg22920501	chr2:26401640	FAM59B	0.42	8.32	0.36	9.89e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14546261	chr12:7052696	C12orf57	0.47	7.15	0.32	3.32e-12	Gut microbiome composition (summer);
LGG	cis	rs11229555	0.645	rs12294062	chr11:58175603	G/T	cg15696309	chr11:58395628	NA	-0.94	-15.24	-0.58	8.18e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg23505145	chr19:12996616	KLF1	0.41	7.35	0.32	9.13e-13	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7746199	0.736	rs13192965	chr6:27671825	G/A	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9393777	0.513	rs67540232	chr6:27140866	T/A	cg12292205	chr6:26970375	C6orf41	-0.65	-8.64	-0.37	9.03e-17	Intelligence (multi-trait analysis);
LGG	cis	rs7572644	0.699	rs4390729	chr2:28162861	T/C	cg27432699	chr2:27873401	GPN1	-0.44	-6.66	-0.3	7.92e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs9611565	0.559	rs5758428	chr22:42106216	G/A	cg06634786	chr22:41940651	POLR3H	0.76	12.11	0.49	1.57e-29	Vitiligo;
LGG	cis	rs4925325	0.915	rs2427246	chr20:60517047	T/C	cg18761221	chr20:60518478	NA	0.6	9.8	0.41	9.63e-21	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs1742467	chr16:1950187	G/T	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10851411	0.518	rs17767264	chr15:42886656	C/T	cg21293051	chr15:42870591	STARD9	0.52	7.5	0.33	3.29e-13	Glucose homeostasis traits;
LGG	cis	rs1799949	1.000	rs8176289	chr17:41206056	T/C	cg25172604	chr17:41446521	NA	-0.3	-6.97	-0.31	1.1e-11	Menopause (age at onset);
LGG	cis	rs7945705	0.967	rs10840147	chr11:8920704	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.5	10.58	0.44	1.39e-23	Hemoglobin concentration;
LGG	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg26384229	chr12:38710491	ALG10B	0.87	19.8	0.68	1.1e-63	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7853377	0.771	rs796007	chr9:86577541	G/A	cg12437157	chr9:86433764	GKAP1	0.4	6.96	0.31	1.15e-11	Height;
LGG	cis	rs1707322	1.000	rs1707337	chr1:46508769	A/G	cg03146154	chr1:46216737	IPP	-0.53	-10.17	-0.43	4.6e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7762018	1.000	rs4716375	chr6:170071218	A/C	cg11441553	chr12:57614120	NXPH4	-0.6	-7.42	-0.33	5.54e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11630290	0.592	rs12594446	chr15:64156674	G/T	cg12036633	chr15:63758958	NA	0.49	7.07	0.31	5.58e-12	Iris characteristics;
LGG	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg01620082	chr3:125678407	NA	-0.78	-7.92	-0.35	1.84e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs4843747	0.636	rs11864872	chr16:88105966	A/G	cg00711542	chr16:29343894	RUNDC2C	0.39	6.71	0.3	5.8200000000000003e-11	Menopause (age at onset);
LGG	cis	rs453301	0.624	rs2979256	chr8:8871710	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.42	0.33	5.67e-13	Joint mobility (Beighton score);
LGG	cis	rs9398803	0.865	rs1578060	chr6:126712247	G/C	cg19875578	chr6:126661172	C6orf173	0.57	10.37	0.43	8.47e-23	Male-pattern baldness;
LGG	cis	rs13064447	0.817	rs73022939	chr3:12762264	G/A	cg23032965	chr3:12705835	RAF1	-0.5	-7.53	-0.33	2.62e-13	Major depression and alcohol dependence;
LGG	cis	rs2033711	0.870	rs1465789	chr19:58946056	C/T	cg13877915	chr19:58951672	ZNF132	1.04	24.37	0.75	5.17e-85	Uric acid clearance;
LGG	cis	rs1862618	0.713	rs832550	chr5:56182589	C/T	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs881375	0.502	rs4837811	chr9:123901594	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.41	6.73	0.3	5.08e-11	Rheumatoid arthritis;
LGG	cis	rs1008375	0.900	rs4698625	chr4:17599500	G/T	cg16339924	chr4:17578868	LAP3	0.69	11.91	0.48	9.91e-29	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs741702	0.758	rs2967893	chr19:13033062	T/G	cg23899408	chr19:12877188	HOOK2	0.5	7.95	0.35	1.42e-14	Red blood cell traits;
LGG	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.83	0.57	5.37e-41	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2645694	0.603	rs2703123	chr4:77821154	C/T	cg18351406	chr4:77819688	ANKRD56	0.47	8.04	0.35	7.31e-15	Emphysema distribution in smoking;
LGG	cis	rs909674	0.731	rs6001594	chr22:39837472	C/T	cg11247378	chr22:39784982	NA	-0.31	-8.46	-0.37	3.54e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs35110281	0.748	rs4997353	chr21:45002329	A/C	cg04455712	chr21:45112962	RRP1B	0.52	10.03	0.42	1.53e-21	Mean corpuscular volume;
LGG	cis	rs875971	0.825	rs4587224	chr7:65736182	G/A	cg12463550	chr7:65579703	CRCP	-0.52	-8.6	-0.37	1.26e-16	Aortic root size;
LGG	cis	rs17401966	1.000	rs12141416	chr1:10327867	A/G	cg15208524	chr1:10270712	KIF1B	0.45	8.01	0.35	9.68e-15	Hepatocellular carcinoma;
LGG	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg03162506	chr22:38580953	NA	0.28	6.97	0.31	1.06e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg01528321	chr10:82214614	TSPAN14	1.07	21.29	0.7	1.27e-70	Post bronchodilator FEV1;
LGG	cis	rs9733	0.818	rs4970924	chr1:150633079	A/G	cg13175981	chr1:150552382	MCL1	0.54	9.15	0.39	1.83e-18	Tonsillectomy;
LGG	cis	rs3780486	0.846	rs7865745	chr9:33140976	A/G	cg13443165	chr9:33130375	B4GALT1	0.75	15.01	0.57	9.2e-42	IgG glycosylation;
LGG	cis	rs919433	0.713	rs1455653	chr2:198478320	G/A	cg00792783	chr2:198669748	PLCL1	0.51	8.0	0.35	1.03e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7192750	0.519	rs2008675	chr16:71995980	A/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.66	0.44	6.89e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs10752881	0.809	rs3738829	chr1:183113862	C/T	cg07245641	chr1:182991651	LAMC1	0.41	9.33	0.4	4.27e-19	Colorectal cancer;
LGG	trans	rs1459104	1.000	rs12793778	chr11:55085722	T/C	cg15704280	chr7:45808275	SEPT13	0.72	7.07	0.31	5.77e-12	Body mass index;
LGG	cis	rs228769	1.000	rs12937692	chr17:42256430	G/A	cg19774624	chr17:42201019	HDAC5	-0.78	-13.17	-0.52	7.06e-34	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs1670533	1.000	rs6836350	chr4:1069973	C/T	cg27284194	chr4:1044797	NA	0.54	9.87	0.42	5.68e-21	Recombination rate (females);
LGG	cis	rs12681288	0.676	rs935819	chr8:1021814	T/C	cg04851639	chr8:1020857	NA	-0.45	-9.33	-0.4	4.31e-19	Schizophrenia;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg14926445	chr8:58193284	C8orf71	-0.82	-10.43	-0.44	5.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.73	-13.23	-0.52	3.99e-34	Lung cancer;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg01673284	chr16:4527211	HMOX2	0.33	6.85	0.3	2.34e-11	Schizophrenia;
LGG	cis	rs34524635	1	rs34524635	chr10:65261176	CT/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.71	-0.3	5.62e-11	Vascular endothelial growth factor levels;
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.28	0.4	6.3e-19	Bipolar disorder;
LGG	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg00376283	chr12:123451042	ABCB9	0.63	9.67	0.41	2.94e-20	Neutrophil percentage of white cells;
LGG	cis	rs427394	0.664	rs274701	chr5:6728707	C/A	cg15145174	chr5:6755386	POLS	-0.38	-7.21	-0.32	2.32e-12	Menopause (age at onset);
LGG	cis	rs7044106	0.762	rs7357638	chr9:123389204	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.66	11.81	0.48	2.61e-28	Hip circumference adjusted for BMI;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg13628971	chr7:2884303	GNA12	0.5	9.8	0.41	9.53e-21	Height;
LGG	cis	rs734999	0.566	rs6424092	chr1:2532899	C/A	cg15627072	chr1:2432621	PLCH2	-0.37	-8.28	-0.36	1.3e-15	Ulcerative colitis;
LGG	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg07245641	chr1:182991651	LAMC1	-0.42	-9.72	-0.41	1.88e-20	Colorectal cancer;
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg11878867	chr6:150167359	LRP11	-0.51	-9.94	-0.42	3.1e-21	Lung cancer;
LGG	trans	rs2055729	0.885	rs13268133	chr8:9731470	C/T	cg12395012	chr8:11607386	GATA4	-0.39	-6.88	-0.3	2e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg03452623	chr4:187889614	NA	1.04	30.28	0.82	7.46e-112	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1153858	1.000	rs4774579	chr15:45651803	G/A	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg05931087	chr1:193028490	TROVE2;UCHL5	-0.39	-6.98	-0.31	1.03e-11	Brain structure;
LGG	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg21972741	chr5:435613	AHRR	0.42	7.52	0.33	2.94e-13	Cystic fibrosis severity;
LGG	cis	rs4808199	0.948	rs11085261	chr19:19462606	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.24	0.32	1.93e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs9291683	0.588	rs13113730	chr4:10017628	C/T	cg08250081	chr4:10125330	NA	0.4	7.91	0.35	1.85e-14	Bone mineral density;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.39	6.85	0.3	2.3e-11	Obesity-related traits;
LGG	cis	rs12824058	0.831	rs4759450	chr12:130812732	G/A	cg24838063	chr12:130822603	PIWIL1	0.7	13.19	0.52	5.97e-34	Menopause (age at onset);
LGG	cis	rs3845702	0.935	rs3845695	chr2:180796989	A/G	cg01881094	chr2:180872142	CWC22	-0.89	-14.25	-0.55	1.83e-38	Schizophrenia;
LGG	cis	rs2479724	1.000	rs1536703	chr6:41852755	C/T	cg17623882	chr6:41773611	USP49	-0.45	-7.77	-0.34	5.26e-14	Menarche (age at onset);
LGG	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg10911889	chr6:126070802	HEY2	0.42	7.19	0.32	2.56e-12	Brugada syndrome;
LGG	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-9.93	-0.42	3.41e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4819052	0.851	rs13049337	chr21:46663460	T/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2303745	0.589	rs1465576	chr19:17398487	G/A	cg10664184	chr19:17420304	DDA1	0.56	8.56	0.37	1.66e-16	Systemic lupus erythematosus;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21028463	chr17:74733682	MIR636;SFRS2;MFSD11	0.51	8.4	0.36	5.67e-16	Cognitive performance;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg16507663	chr6:150244633	RAET1G	0.46	8.77	0.38	3.56e-17	Lung cancer;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	0.3	7.84	0.34	3.2e-14	IgG glycosylation;
LGG	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg26384229	chr12:38710491	ALG10B	0.92	20.59	0.69	2.48e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1978968	0.788	rs12169946	chr22:18468105	A/G	cg03078520	chr22:18463400	MICAL3	-0.63	-13.15	-0.52	8.77e-34	Presence of antiphospholipid antibodies;
LGG	cis	rs2073499	1.000	rs739431	chr3:50255305	A/G	cg05260129	chr3:50388622	TUSC4;CYB561D2	0.62	6.94	0.31	1.34e-11	Schizophrenia;
LGG	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg02023345	chr10:63212226	TMEM26	0.39	7.24	0.32	1.83e-12	Night sleep phenotypes;
LGG	cis	rs2067615	0.599	rs3759310	chr12:107166122	C/G	cg15890332	chr12:107067104	RFX4	0.4	11.8	0.48	2.8e-28	Heart rate;
LGG	cis	rs6772849	1.000	rs2712378	chr3:128308794	T/C	cg08795948	chr3:128337044	NA	0.53	8.74	0.38	4.31e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs7267979	1.000	rs6076336	chr20:25319212	C/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs16957091	0.821	rs2412741	chr15:43014044	A/G	cg07484255	chr15:43025164	CDAN1	-0.48	-6.81	-0.3	3.02e-11	MGMT methylation in smokers;
LGG	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg15556689	chr8:8085844	FLJ10661	0.48	8.69	0.37	6.07e-17	Retinal vascular caliber;
LGG	cis	rs2652834	0.904	rs34786874	chr15:63397504	A/G	cg05507819	chr15:63340323	TPM1	0.58	7.83	0.34	3.45e-14	HDL cholesterol;
LGG	cis	rs1519814	0.956	rs4871036	chr8:121101758	T/C	cg22335954	chr8:121166405	COL14A1	-0.54	-10.87	-0.45	1.18e-24	Breast cancer;
LGG	cis	rs9951602	0.703	rs2959407	chr18:76682915	A/G	cg00806245	chr18:76673096	NA	-0.68	-9.22	-0.39	1.03e-18	Obesity-related traits;
LGG	cis	rs739401	0.572	rs739399	chr11:3016452	A/G	cg05729581	chr11:3078854	CARS	-0.52	-8.87	-0.38	1.61e-17	Longevity;
LGG	trans	rs61931739	0.534	rs1817761	chr12:34105719	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	trans	rs6787172	0.677	rs827164	chr3:158020836	A/T	cg23275840	chr4:47708675	CORIN	0.4	8.72	0.38	4.83e-17	Subjective well-being;
LGG	trans	rs6601327	0.571	rs7838571	chr8:9647796	A/G	cg06636001	chr8:8085503	FLJ10661	0.39	7.11	0.31	4.44e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11627756	0.957	rs11846451	chr14:103131723	T/C	cg01864069	chr14:103024347	NA	0.42	6.77	0.3	3.82e-11	Mean platelet volume;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.38e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16405210	chr4:1374714	KIAA1530	-0.62	-11.14	-0.46	1.1e-25	Longevity;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.6.143706070F	chr6:143664377	NA	-0.46	-6.71	-0.3	5.69e-11	Systemic lupus erythematosus;
LGG	cis	rs9611565	0.559	rs132771	chr22:42025350	A/G	cg17376030	chr22:41985996	PMM1	-0.67	-10.86	-0.45	1.31e-24	Vitiligo;
LGG	cis	rs4696584	0.755	rs17031728	chr4:155412581	C/G	cg04517429	chr4:155413618	DCHS2	-0.33	-7.46	-0.33	4.21e-13	Folding of antihelix;
LGG	cis	rs7623687	0.579	rs73082331	chr3:48994943	G/A	cg19401529	chr3:49056140	DALRD3	0.75	8.42	0.36	4.73e-16	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs3736594	0.879	rs77154381	chr2:27982119	A/G	cg27432699	chr2:27873401	GPN1	0.55	9.06	0.39	3.59e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg05623727	chr3:50126028	RBM5	-0.45	-9.77	-0.41	1.28e-20	Body mass index;
LGG	cis	rs10464366	0.957	rs2392618	chr7:39108392	G/A	cg18850127	chr7:39170497	POU6F2	0.55	12.34	0.5	1.93e-30	IgG glycosylation;
LGG	cis	rs1555895	0.576	rs12413228	chr10:849230	G/T	cg10556349	chr10:835070	NA	-0.27	-6.83	-0.3	2.6e-11	Survival in rectal cancer;
LGG	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.46	-6.93	-0.31	1.43e-11	Parkinson's disease;
LGG	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg19507638	chr5:93509721	C5orf36	-0.73	-10.08	-0.42	9.4e-22	Diabetic retinopathy;
LGG	trans	rs7762018	0.941	rs4716387	chr6:170136777	G/C	cg11441553	chr12:57614120	NXPH4	-0.57	-7.04	-0.31	6.92e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7617480	0.648	rs10865953	chr3:48759562	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.0	0.35	9.86e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9388451	0.869	rs7764016	chr6:126070789	T/G	cg10911889	chr6:126070802	HEY2	0.44	7.58	0.33	1.86e-13	Brugada syndrome;
LGG	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg07519485	chr6:33762594	MLN	-0.3	-6.68	-0.3	6.7e-11	Crohn's disease;
LGG	trans	rs12517041	1.000	rs6894688	chr5:23312285	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.79	-11.8	-0.48	2.79e-28	Calcium levels;
LGG	cis	rs4631830	0.869	rs4131357	chr10:51537292	C/A	cg10326726	chr10:51549505	MSMB	-0.67	-13.78	-0.54	1.88e-36	Prostate-specific antigen levels;
LGG	cis	rs60871478	0.947	rs62432239	chr7:794576	C/T	cg22643751	chr7:855365	UNC84A	0.36	6.92	0.31	1.53e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs10109025	0.670	rs7825690	chr8:10858257	G/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.89	-0.3	1.8e-11	Joint mobility (Beighton score);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04122790	chr1:229762148	URB2;TAF5L	0.44	7.71	0.34	8.03e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs12681288	0.823	rs2701906	chr8:1003316	T/C	cg08648136	chr8:956695	NA	0.36	7.56	0.33	2.13e-13	Schizophrenia;
LGG	cis	rs4481887	0.639	rs10749644	chr1:248414587	A/C	cg13385794	chr1:248469461	NA	0.43	7.28	0.32	1.41e-12	Common traits (Other);
LGG	cis	rs7616330	0.887	rs2100142	chr3:71112560	A/G	cg23830205	chr3:71127516	FOXP1	0.48	7.25	0.32	1.75e-12	QT interval;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02520519	chr3:4345006	SETMAR	0.46	7.39	0.32	7.09e-13	Cognitive performance;
LGG	cis	rs1801251	1.000	rs1947105	chr2:233721455	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.14	0.39	2.01e-18	Coronary artery disease;
LGG	cis	rs35146811	0.700	rs866500	chr7:99840461	A/G	cg22906224	chr7:99728672	NA	-0.54	-8.07	-0.35	6.14e-15	Coronary artery disease;
LGG	trans	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg23762105	chr12:34175262	ALG10	-0.35	-7.1	-0.31	4.83e-12	Morning vs. evening chronotype;
LGG	cis	rs780096	0.967	rs1313566	chr2:27748904	G/A	cg22903471	chr2:27725779	GCKR	-0.34	-7.02	-0.31	8.1e-12	Total body bone mineral density;
LGG	cis	rs2839186	0.588	rs7280110	chr21:47619039	G/A	cg13126279	chr21:47581558	C21orf56	0.45	7.41	0.33	6.18e-13	Testicular germ cell tumor;
LGG	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg15440763	chr7:158190612	PTPRN2	0.43	8.84	0.38	2.06e-17	Obesity-related traits;
LGG	cis	rs8179	0.553	rs42235	chr7:92248076	C/T	cg15732164	chr7:92237376	CDK6	-0.53	-11.03	-0.46	2.94e-25	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg04455712	chr21:45112962	RRP1B	-0.52	-9.93	-0.42	3.48e-21	Mean corpuscular volume;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.89	-0.3	1.85e-11	Obesity-related traits;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg22907277	chr7:1156413	C7orf50	0.7	13.15	0.52	9.11e-34	Longevity;Endometriosis;
LGG	cis	rs12188164	0.965	rs11742144	chr5:422178	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.42	0.33	5.68e-13	Cystic fibrosis severity;
LGG	cis	rs11112613	0.775	rs7299470	chr12:105961773	G/A	cg03607813	chr12:105948248	NA	0.58	10.46	0.44	3.85e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs11711311	1.000	rs9830975	chr3:113486019	A/G	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.54	-0.33	2.45e-13	IgG glycosylation;
LGG	cis	rs858239	0.602	rs6953996	chr7:23175946	A/G	cg23682824	chr7:23144976	KLHL7	0.43	7.23	0.32	1.99e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs561341	0.769	rs8074383	chr17:30178793	C/T	cg00745463	chr17:30367425	LRRC37B	0.57	6.95	0.31	1.26e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs300703	0.515	rs364431	chr2:191399	C/A	cg24565620	chr2:194026	NA	-0.64	-10.2	-0.43	3.53e-22	Blood protein levels;
LGG	trans	rs561341	0.882	rs111484028	chr17:30287701	G/A	cg27661571	chr11:113659931	NA	-0.67	-9.58	-0.41	5.98e-20	Hip circumference adjusted for BMI;
LGG	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.7	9.28	0.4	6.41e-19	Diabetic retinopathy;
LGG	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg04034577	chr2:241836375	C2orf54	-0.52	-11.33	-0.47	1.95e-26	Urinary metabolites;
LGG	cis	rs2153535	0.580	rs7341383	chr6:8470634	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs9291683	0.692	rs1558489	chr4:10325489	T/A	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.71e-11	Bone mineral density;
LGG	trans	rs7829975	0.846	rs6601724	chr8:8544872	C/T	cg02002194	chr4:3960332	NA	0.46	8.74	0.38	4.45e-17	Mood instability;
LGG	trans	rs7395662	1.000	rs11039820	chr11:48562252	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.15	-0.35	3.44e-15	HDL cholesterol;
LGG	cis	rs4919087	0.961	rs11189120	chr10:99069493	G/T	cg25902810	chr10:99078978	FRAT1	0.52	9.8	0.41	1.01e-20	Monocyte count;
LGG	trans	rs7246760	0.867	rs2287843	chr19:9769913	G/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs796364	1.000	rs281788	chr2:200783705	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs1008375	0.900	rs6812675	chr4:17597549	A/G	cg07005078	chr4:17578674	LAP3	0.38	6.77	0.3	4.01e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs992157	0.798	rs4674284	chr2:219161241	C/T	cg04731861	chr2:219085781	ARPC2	0.45	11.04	0.46	2.55e-25	Colorectal cancer;
LGG	cis	rs2074585	0.647	rs2601172	chr15:90915666	A/G	cg22089800	chr15:90895588	ZNF774	0.76	14.12	0.55	6.4e-38	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2241941	0.802	rs72927524	chr11:20629584	C/T	cg18855426	chr11:20631935	SLC6A5	-0.44	-7.17	-0.32	2.99e-12	Obesity-related traits;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg11878867	chr6:150167359	LRP11	-0.51	-10.25	-0.43	2.37e-22	Lung cancer;
LGG	cis	rs875971	0.577	rs35072105	chr7:65609817	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.48	-9.81	-0.41	9.4e-21	Aortic root size;
LGG	trans	rs561341	0.941	rs2428336	chr17:30290577	T/C	cg27661571	chr11:113659931	NA	-0.68	-9.58	-0.41	5.81e-20	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg08677398	chr8:58056175	NA	0.5	7.95	0.35	1.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2880765	0.566	rs55899824	chr15:86004091	C/T	cg19183879	chr15:85880815	NA	-0.49	-9.29	-0.4	6e-19	Coronary artery disease;
LGG	cis	rs2737618	0.674	rs2260033	chr1:200086074	G/A	cg21825944	chr1:200113062	NR5A2	-0.6	-11.85	-0.48	1.82e-28	Uric acid levels;
LGG	cis	rs12701220	0.739	rs2293523	chr7:1098518	G/A	cg26769984	chr7:1090371	C7orf50	0.46	7.27	0.32	1.55e-12	Bronchopulmonary dysplasia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26921846	chr21:30671131	BACH1	-0.39	-6.69	-0.3	6.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg22563815	chr15:78856949	CHRNA5	0.3	7.41	0.33	6.24e-13	Sudden cardiac arrest;
LGG	cis	rs1023500	0.552	rs133368	chr22:42463689	T/C	cg04733989	chr22:42467013	NAGA	0.57	10.23	0.43	2.81e-22	Schizophrenia;
LGG	cis	rs9916302	0.904	rs801426	chr17:37441109	C/T	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.23e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs35740288	0.770	rs35447727	chr15:86174399	C/T	cg04173714	chr15:86211321	AKAP13	0.46	8.44	0.37	4.15e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17253792	0.822	rs77555779	chr14:56078430	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs240764	0.658	rs7746947	chr6:101188708	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs7107174	0.681	rs10899499	chr11:78124797	A/G	cg27205649	chr11:78285834	NARS2	0.44	7.3	0.32	1.26e-12	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg19143629	chr17:61920732	SMARCD2	-0.42	-7.31	-0.32	1.22e-12	Prudent dietary pattern;
LGG	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.08	0.42	1.01e-21	Motion sickness;
LGG	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg15704280	chr7:45808275	SEPT13	-0.61	-10.97	-0.45	4.58e-25	Coronary artery disease;
LGG	cis	rs2479724	0.811	rs8393	chr6:41757836	C/A	cg17623882	chr6:41773611	USP49	0.5	8.6	0.37	1.25e-16	Menarche (age at onset);
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg16680214	chr1:154839983	KCNN3	-0.46	-9.06	-0.39	3.56e-18	Prostate cancer;
LGG	trans	rs1814175	0.615	rs11040654	chr11:49939485	T/G	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs7617773	0.780	rs11130164	chr3:48369034	G/A	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs9926296	0.593	rs6500456	chr16:89888341	T/C	cg23057051	chr16:89984268	MC1R	-0.38	-7.4	-0.33	6.58e-13	Vitiligo;
LGG	cis	rs701145	0.556	rs355756	chr3:154021063	G/A	cg16511985	chr3:153974050	SGEF	0.49	8.32	0.36	1.02e-15	Coronary artery disease;
LGG	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg03030879	chr14:75389066	RPS6KL1	0.37	6.68	0.3	6.81e-11	Caffeine consumption;
LGG	cis	rs72772090	0.539	rs17481759	chr5:96114695	A/G	cg00188032	chr5:96141721	ERAP1	0.53	7.03	0.31	7.59e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg26384229	chr12:38710491	ALG10B	0.6	10.81	0.45	1.86e-24	Morning vs. evening chronotype;
LGG	cis	rs7917772	0.503	rs7904955	chr10:104367092	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.19	0.55	3.38e-38	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg07061783	chr6:25882402	NA	0.4	7.05	0.31	6.47e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17209837	1.000	rs17149647	chr7:87086931	T/C	cg00919237	chr7:87102261	ABCB4	-0.71	-11.81	-0.48	2.48e-28	Gallbladder cancer;
LGG	cis	rs1109114	0.816	rs2918264	chr5:148615446	T/C	cg06539116	chr5:148597365	ABLIM3	-0.61	-15.94	-0.6	6.6e-46	Body mass index;
LGG	cis	rs1580019	0.961	rs11768506	chr7:32494788	A/C	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	trans	rs61931739	0.929	rs10844748	chr12:34092930	G/T	cg26384229	chr12:38710491	ALG10B	-0.62	-12.22	-0.49	5.86e-30	Morning vs. evening chronotype;
LGG	cis	rs2562456	0.833	rs2968076	chr19:21637101	C/T	cg00806126	chr19:22604979	ZNF98	0.56	7.97	0.35	1.28e-14	Pain;
LGG	cis	rs9443645	0.687	rs6915558	chr6:79769056	A/T	cg18132916	chr6:79620363	NA	-0.31	-8.42	-0.36	4.84e-16	Intelligence (multi-trait analysis);
LGG	cis	rs3741151	1.000	rs75114310	chr11:73042047	C/T	cg17517138	chr11:73019481	ARHGEF17	1.07	10.77	0.45	2.76e-24	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2227564	0.729	rs2675675	chr10:75649048	G/A	cg00564723	chr10:75632066	CAMK2G	-0.45	-9.03	-0.39	4.64e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg03806693	chr22:41940476	POLR3H	-1.09	-19.99	-0.68	1.52e-64	Vitiligo;
LGG	cis	rs11603023	0.967	rs644273	chr11:118511352	C/T	cg27286069	chr11:118481882	PHLDB1	-0.55	-10.14	-0.43	6.16e-22	Cholesterol, total;
LGG	cis	rs12681287	0.605	rs6471296	chr8:87374654	A/G	cg27223183	chr8:87520930	FAM82B	0.43	6.81	0.3	3.08e-11	Caudate activity during reward;
LGG	cis	rs3126085	0.877	rs10888472	chr1:152206896	C/G	cg26876637	chr1:152193138	HRNR	-0.52	-7.92	-0.35	1.8e-14	Atopic dermatitis;
LGG	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-15.92	-0.59	7.82e-46	Response to antipsychotic treatment;
LGG	cis	rs1983891	0.954	rs1886816	chr6:41544494	A/G	cg20194872	chr6:41519635	FOXP4	0.59	10.27	0.43	1.95e-22	Prostate cancer;
LGG	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg18200150	chr17:30822561	MYO1D	0.79	18.75	0.66	9.16e-59	Schizophrenia;
LGG	cis	rs7927592	0.830	rs10896339	chr11:68302846	G/C	cg16797656	chr11:68205561	LRP5	0.41	7.36	0.32	8.61e-13	Total body bone mineral density;
LGG	cis	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs17376456	0.569	rs2045021	chr5:93224222	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.67	-8.89	-0.38	1.4e-17	Diabetic retinopathy;
LGG	trans	rs3942852	0.622	rs6485806	chr11:48102806	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.95	0.38	8.65e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2594989	0.720	rs2442795	chr3:11551200	T/G	cg01796438	chr3:11312864	ATG7	-0.55	-7.15	-0.32	3.51e-12	Circulating chemerin levels;
LGG	cis	rs16976116	0.901	rs28708989	chr15:55498934	C/T	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg08645402	chr16:4508243	NA	0.5	9.26	0.4	7.67e-19	Schizophrenia;
LGG	cis	rs9611565	0.592	rs5996038	chr22:41965300	T/C	cg03806693	chr22:41940476	POLR3H	-1.0	-17.3	-0.63	4.23e-52	Vitiligo;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.71	-12.95	-0.52	5.78e-33	Obesity-related traits;
LGG	cis	rs7747724	0.702	rs7751154	chr6:20766282	A/C	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.39	-0.4	2.77e-19	Bladder cancer;
LGG	trans	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.4	0.36	5.57e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs4332037	0.851	rs28728306	chr7:1961814	C/A	cg11693508	chr17:37793320	STARD3	0.74	10.74	0.45	3.46e-24	Bipolar disorder;
LGG	cis	rs881375	1.000	rs4323544	chr9:123647377	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	9.03	0.39	4.63e-18	Rheumatoid arthritis;
LGG	cis	rs9915657	0.870	rs4140902	chr17:70133750	A/G	cg09344028	chr17:70110421	NA	0.47	10.38	0.43	7.67e-23	Thyroid hormone levels;
LGG	cis	rs4430311	0.655	rs12744253	chr1:243967674	G/A	cg25706552	chr1:244017396	NA	-0.65	-16.22	-0.6	3.65e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10791097	0.694	rs12361892	chr11:130744490	T/G	cg12179176	chr11:130786555	SNX19	0.85	17.73	0.64	4.49e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg00666640	chr1:248458726	OR2T12	0.58	9.28	0.4	6.41e-19	Common traits (Other);
LGG	cis	rs11758351	0.500	rs4593350	chr6:26184800	T/C	cg23601095	chr6:26197514	HIST1H3D	0.89	6.75	0.3	4.55e-11	Gout;Renal underexcretion gout;
LGG	cis	rs10504229	0.834	rs7015674	chr8:58153166	C/T	cg05313129	chr8:58192883	C8orf71	-0.79	-11.91	-0.48	1.04e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs73086581	1.000	rs2326289	chr20:3952300	T/C	cg02187196	chr20:3869020	PANK2	0.82	11.38	0.47	1.22e-26	Response to antidepressants in depression;
LGG	cis	rs1577917	0.655	rs9450311	chr6:86376586	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.33	0.47	1.91e-26	Response to antipsychotic treatment;
LGG	cis	rs10256972	0.616	rs6957733	chr7:1106327	T/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.43	-0.44	5e-23	Longevity;Endometriosis;
LGG	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	trans	rs9329221	0.525	rs4394398	chr8:10084394	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.39	-0.36	5.78e-16	Neuroticism;
LGG	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.72	-0.3	5.45e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7507204	0.572	rs7246730	chr19:3419781	A/G	cg08382705	chr11:45687319	CHST1	0.55	8.66	0.37	8e-17	Height;
LGG	cis	rs1218582	0.772	rs10796935	chr1:154891363	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.4	8.12	0.35	4.14e-15	Prostate cancer;
LGG	cis	rs17270561	0.636	rs4145218	chr6:25746083	G/A	cg17691542	chr6:26056736	HIST1H1C	0.63	10.31	0.43	1.46e-22	Iron status biomarkers;
LGG	trans	rs75804782	0.572	rs76084375	chr2:239301193	T/C	cg01134436	chr17:81009848	B3GNTL1	0.78	6.75	0.3	4.31e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs953387	1.000	rs4954564	chr2:136895508	A/G	cg05194412	chr2:137003533	NA	-0.32	-6.82	-0.3	2.83e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs422249	0.547	rs174535	chr11:61551356	T/C	cg19610905	chr11:61596333	FADS2	-0.81	-14.69	-0.56	2.33e-40	Trans fatty acid levels;
LGG	cis	rs7208859	0.673	rs9911989	chr17:29237702	A/C	cg19761014	chr17:28927070	LRRC37B2	-0.57	-6.72	-0.3	5.34e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs769267	1.000	rs1009136	chr19:19440428	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.48	-0.37	2.98e-16	Tonsillectomy;
LGG	cis	rs7222240	0.951	rs894686	chr17:43096128	G/A	cg24806326	chr17:43207588	PLCD3	0.47	7.88	0.34	2.38e-14	Craniofacial microsomia;
LGG	cis	rs7615952	0.599	rs2279821	chr3:125734308	G/A	cg02772935	chr3:125709198	NA	-0.53	-6.77	-0.3	3.94e-11	Blood pressure (smoking interaction);
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg03709012	chr19:19516395	GATAD2A	0.84	17.0	0.62	9.8e-51	Tonsillectomy;
LGG	cis	rs12477438	0.501	rs1011633	chr2:100094799	C/T	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	cis	rs2204008	0.745	rs12146863	chr12:38502346	G/A	cg26384229	chr12:38710491	ALG10B	0.94	21.92	0.71	1.37e-73	Bladder cancer;
LGG	cis	rs2455799	0.634	rs11128764	chr3:15902836	G/C	cg16303742	chr3:15540471	COLQ	-0.39	-7.73	-0.34	6.94e-14	Mean platelet volume;
LGG	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg01262667	chr19:19385393	TM6SF2	0.35	7.1	0.31	4.63e-12	Bipolar disorder;
LGG	trans	rs4295623	0.507	rs2256241	chr8:11494657	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.87	-0.3	2.06e-11	Morning vs. evening chronotype;
LGG	cis	rs4144743	0.759	rs34251886	chr17:45320299	G/T	cg18085866	chr17:45331354	ITGB3	-0.74	-7.94	-0.35	1.56e-14	Body mass index;
LGG	cis	rs1318772	0.932	rs13166822	chr5:112873608	C/G	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	cis	rs6496667	0.683	rs1869180	chr15:90895467	T/C	cg22089800	chr15:90895588	ZNF774	0.6	10.45	0.44	4.22e-23	Rheumatoid arthritis;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.73	0.51	4.95e-32	Obesity-related traits;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg11245990	chr11:68621969	NA	0.39	8.35	0.36	8.01e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2916247	0.865	rs7834277	chr8:93110255	A/G	cg10183463	chr8:93005414	RUNX1T1	0.36	7.42	0.33	5.82e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.600	rs10888532	chr1:153063407	C/A	cg13444842	chr1:152974279	SPRR3	-0.35	-6.71	-0.3	5.8200000000000003e-11	Inflammatory skin disease;
LGG	cis	rs258892	0.841	rs266426	chr5:72131255	A/G	cg21869765	chr5:72125136	TNPO1	0.42	6.78	0.3	3.74e-11	Small cell lung carcinoma;
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.591	rs12677543	chr8:8644274	G/C	cg16141378	chr3:129829833	LOC729375	-0.45	-10.91	-0.45	7.86e-25	Mood instability;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.44	0.33	4.93e-13	Schizophrenia;
LGG	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.42	-0.36	4.79e-16	Retinal vascular caliber;
LGG	cis	rs5769707	0.681	rs8137111	chr22:50043750	G/A	cg06623630	chr22:50017776	C22orf34	-0.49	-9.67	-0.41	2.98e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs644799	0.710	rs12272061	chr11:95524067	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.8	0.64	2.2e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	0.44	11.14	0.46	1.07e-25	IgG glycosylation;
LGG	cis	rs74781061	0.929	rs12594447	chr15:74828733	A/C	cg02384859	chr15:74862662	ARID3B	-0.35	-7.2	-0.32	2.52e-12	Endometriosis;
LGG	cis	rs807029	0.577	rs701835	chr10:102762127	A/G	cg04662943	chr10:102668895	NA	0.46	6.83	0.3	2.67e-11	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7208859	0.673	rs73263755	chr17:29198972	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7084402	0.875	rs1593671	chr10:60295969	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs4478858	0.735	rs68008576	chr1:31805905	T/C	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs2280018	0.526	rs2966128	chr16:15153389	G/T	cg27102117	chr16:15229624	NA	0.55	10.05	0.42	1.28e-21	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	cis	rs657075	0.697	rs2073642	chr5:131713774	A/G	cg07538946	chr5:131705188	SLC22A5	-0.58	-6.9	-0.31	1.76e-11	Rheumatoid arthritis;
LGG	cis	rs2404602	1.000	rs2056544	chr15:76826003	G/A	cg15268244	chr15:77196840	NA	-0.33	-7.32	-0.32	1.07e-12	Blood metabolite levels;
LGG	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.74e-12	Aortic root size;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg20607798	chr8:58055168	NA	0.58	6.65	0.3	8.39e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16667845	chr2:131100001	IMP4;CCDC115	0.44	7.0	0.31	9.11e-12	Cognitive performance;
LGG	cis	rs898097	0.841	rs11656358	chr17:80853956	G/A	cg15369054	chr17:80825471	TBCD	0.59	10.97	0.45	4.63e-25	Breast cancer;
LGG	cis	rs16854884	0.739	rs1075113	chr3:143760535	C/T	cg06585982	chr3:143692056	C3orf58	0.55	9.39	0.4	2.8e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs758324	0.738	rs413185	chr5:131315225	A/G	cg06307176	chr5:131281290	NA	0.52	8.49	0.37	2.74e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7666738	0.800	rs13106995	chr4:99028790	A/T	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12220238	0.915	rs2894235	chr10:76082945	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.96	0.38	8.05e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs4481887	0.604	rs4430368	chr1:248411573	A/G	cg01631408	chr1:248437212	OR2T33	-0.52	-8.8	-0.38	2.66e-17	Common traits (Other);
LGG	cis	rs2470578	0.792	rs728022	chr3:17305303	C/G	cg20981856	chr3:17787350	NA	-0.36	-6.81	-0.3	3.1e-11	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17839278	chr11:47664375	MTCH2	0.45	7.01	0.31	8.29e-12	Gut microbiome composition (summer);
LGG	cis	rs2901460	0.509	rs17573253	chr2:62101915	C/T	cg02183531	chr2:62113199	CCT4	0.46	8.21	0.36	2.15e-15	Mean corpuscular volume;
LGG	cis	rs35110281	0.774	rs1378080	chr21:45011315	T/A	cg04455712	chr21:45112962	RRP1B	0.51	9.74	0.41	1.57e-20	Mean corpuscular volume;
LGG	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.95	0.42	2.98e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs13191362	0.935	rs73023493	chr6:162952769	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.91	9.26	0.4	7.67e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg05368731	chr17:41323189	NBR1	0.95	18.37	0.65	5.46e-57	Menopause (age at onset);
LGG	cis	rs10078	0.510	rs2278248	chr5:469570	G/T	cg07599136	chr5:415885	AHRR	0.73	10.35	0.43	9.95e-23	Fat distribution (HIV);
LGG	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg08250081	chr4:10125330	NA	0.44	8.64	0.37	9.09e-17	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg05863683	chr7:1912471	MAD1L1	0.49	9.48	0.4	1.36e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18252515	chr7:66147081	NA	-0.46	-7.99	-0.35	1.08e-14	Aortic root size;
LGG	cis	rs9916302	0.851	rs12947620	chr17:37605364	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.86	-0.59	1.49e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	trans	rs62103177	0.564	rs1715230	chr18:77848002	C/T	cg05926928	chr17:57297772	GDPD1	0.91	11.77	0.48	3.7e-28	Opioid sensitivity;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.47	0.33	3.96e-13	Prudent dietary pattern;
LGG	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg18681998	chr4:17616180	MED28	0.88	20.1	0.68	4.63e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-13.93	-0.54	4.18e-37	Morning vs. evening chronotype;
LGG	cis	rs6546550	0.901	rs6546558	chr2:70145717	C/T	cg02498382	chr2:70120550	SNRNP27	-0.42	-8.0	-0.35	9.9e-15	Prevalent atrial fibrillation;
LGG	cis	rs11583043	1.000	rs2391573	chr1:101489698	T/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.5	8.41	0.36	4.94e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11122272	0.735	rs2486728	chr1:231535883	T/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.55e-12	Hemoglobin concentration;
LGG	cis	rs6977660	0.714	rs6945753	chr7:19814255	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.48	0.44	3.31e-23	Thyroid stimulating hormone;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22468803	chr18:9136381	ANKRD12	0.43	6.98	0.31	1e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7539409	1.000	rs7539409	chr1:84254735	A/G	cg10977910	chr1:84465055	TTLL7	-0.66	-6.88	-0.3	2.01e-11	Alzheimer's disease;
LGG	cis	rs12893668	0.572	rs4906356	chr14:104138701	C/T	cg26031613	chr14:104095156	KLC1	-0.67	-10.74	-0.45	3.67e-24	Reticulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25157604	chr11:57191603	SLC43A3	0.44	7.96	0.35	1.34e-14	Gut microbiome composition (summer);
LGG	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.25	-0.32	1.8e-12	Coronary artery disease;
LGG	cis	rs4689592	0.546	rs907523	chr4:7052777	A/G	cg26116260	chr4:7069785	GRPEL1	1.16	22.31	0.72	2.03e-75	Monocyte percentage of white cells;
LGG	cis	rs459571	0.959	rs416390	chr9:136908549	C/G	cg13789015	chr9:136890014	NCRNA00094	-0.58	-10.84	-0.45	1.43e-24	Platelet distribution width;
LGG	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg19680485	chr15:31195859	MTMR15	-0.45	-7.3	-0.32	1.27e-12	Huntington's disease progression;
LGG	cis	rs2133450	0.712	rs1396404	chr3:7365390	T/C	cg19930620	chr3:7340148	GRM7	-0.38	-8.22	-0.36	2.11e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs1451375	0.607	rs7807335	chr7:50631862	A/C	cg20336341	chr7:50628841	DDC	-0.52	-9.96	-0.42	2.7e-21	Malaria;
LGG	cis	rs2153535	0.580	rs1119690	chr6:8460660	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	9.09	0.39	3.01e-18	Motion sickness;
LGG	cis	rs36051895	0.623	rs7870536	chr9:5245493	C/T	cg02405213	chr9:5042618	JAK2	-0.72	-12.67	-0.51	8.3e-32	Pediatric autoimmune diseases;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.595	rs10106914	chr8:10987651	T/G	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.94e-13	Triglycerides;
LGG	cis	rs1348850	0.567	rs880898	chr2:178532470	C/T	cg22681709	chr2:178499509	PDE11A	-0.46	-8.41	-0.36	5.07e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs1018836	0.884	rs13279263	chr8:91648780	T/C	cg16814680	chr8:91681699	NA	-0.81	-14.9	-0.57	2.75e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs116095464	1.000	rs1567956	chr5:315616	C/A	cg22857025	chr5:266934	NA	-1.3	-13.22	-0.52	4.42e-34	Breast cancer;
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg02018176	chr4:1364513	KIAA1530	0.44	10.19	0.43	3.86e-22	Obesity-related traits;
LGG	cis	rs372883	0.935	rs1153295	chr21:30704080	T/G	cg24692254	chr21:30365293	RNF160	-0.43	-7.63	-0.33	1.32e-13	Pancreatic cancer;
LGG	cis	rs4862750	0.872	rs13110072	chr4:187878524	A/G	cg03647317	chr4:187891568	NA	-0.41	-8.9	-0.38	1.31e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.31	0.6	1.46e-47	Lymphocyte counts;
LGG	cis	rs72772090	0.539	rs111237997	chr5:96114953	C/G	cg00188032	chr5:96141721	ERAP1	0.53	7.05	0.31	6.6e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg23129478	chr18:44337922	ST8SIA5	-0.39	-7.61	-0.33	1.5700000000000001e-13	Personality dimensions;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.71	0.38	5.53e-17	Prudent dietary pattern;
LGG	cis	rs806795	0.605	rs809871	chr6:26256526	C/G	cg09303159	chr6:26284866	NA	-0.32	-6.83	-0.3	2.63e-11	Mosquito bite size;
LGG	cis	rs61931739	0.857	rs999715	chr12:34143253	G/C	cg06521331	chr12:34319734	NA	-0.43	-7.93	-0.35	1.62e-14	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs6558530	0.692	rs12335115	chr8:1699852	C/G	cg08198773	chr8:1697536	NA	0.45	7.92	0.35	1.77e-14	Systolic blood pressure;
LGG	trans	rs7824557	0.564	rs7821459	chr8:11236681	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.72	-0.41	1.93e-20	Retinal vascular caliber;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs74781061	1.000	rs11072488	chr15:74786358	T/C	cg02384859	chr15:74862662	ARID3B	-0.33	-6.96	-0.31	1.19e-11	Endometriosis;
LGG	cis	rs36051895	0.659	rs59668095	chr9:5043688	C/G	cg02405213	chr9:5042618	JAK2	-0.83	-15.58	-0.59	2.61e-44	Pediatric autoimmune diseases;
LGG	cis	rs4253772	0.530	rs9615961	chr22:46754993	T/C	cg00784671	chr22:46762841	CELSR1	-0.64	-7.41	-0.33	6.14e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg03517284	chr6:25882590	NA	-0.66	-12.8	-0.51	2.42e-32	Blood metabolite levels;
LGG	cis	rs11877825	1.000	rs11877825	chr18:10566404	G/T	cg25239095	chr18:10589360	NA	0.49	9.27	0.4	7.3e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs17345786	0.861	rs79181492	chr3:101216021	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.65	-10.93	-0.45	7.08e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs5758511	0.508	rs58099562	chr22:42453772	T/C	cg00645731	chr22:42541494	CYP2D7P1	0.44	6.88	0.3	1.94e-11	Birth weight;
LGG	cis	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.81	-0.64	1.97e-54	Breast cancer;
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg14092988	chr3:52407081	DNAH1	0.3	8.07	0.35	5.99e-15	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.76e-16	Life satisfaction;
LGG	cis	rs4642101	0.512	rs12629892	chr3:12818920	A/G	cg24848339	chr3:12840334	CAND2	0.46	11.12	0.46	1.22e-25	QRS complex (12-leadsum);
LGG	cis	rs8017423	0.935	rs11624295	chr14:90695612	T/G	cg04374321	chr14:90722782	PSMC1	0.87	18.41	0.65	3.37e-57	Mortality in heart failure;
LGG	cis	rs12210905	1.000	rs12201774	chr6:27058312	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.2e-22	Menopause (age at onset);
LGG	cis	rs11585357	0.947	rs2977303	chr1:17611548	A/T	cg08277548	chr1:17600880	PADI3	-0.63	-8.3	-0.36	1.16e-15	Hair shape;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25219047	chr19:3500813	DOHH	0.46	7.01	0.31	8.66e-12	Gut microbiome composition (summer);
LGG	cis	rs2070488	0.965	rs6805386	chr3:38557921	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.83	-17.54	-0.63	3.36e-53	Electrocardiographic conduction measures;
LGG	cis	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg24110177	chr3:50126178	RBM5	-0.65	-11.9	-0.48	1.16e-28	Body mass index;
LGG	cis	rs1552244	1.000	rs3846177	chr3:10068572	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.61	0.69	1.94e-67	Alzheimer's disease;
LGG	cis	rs12431410	0.550	rs7159057	chr14:60209412	A/C	cg07950296	chr14:60194823	RTN1	-0.37	-7.15	-0.32	3.52e-12	Schizophrenia;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg07230380	chr10:102106358	SCD	-0.38	-6.84	-0.3	2.54e-11	Brain structure;
LGG	cis	rs9660992	1.000	rs3851296	chr1:205253839	A/C	cg21545522	chr1:205238299	TMCC2	0.38	7.12	0.31	4.18e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2742417	0.603	rs9826208	chr3:45773991	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7805747	1.000	rs10480299	chr7:151405818	A/G	cg17611936	chr7:151411526	PRKAG2	0.54	8.04	0.35	7.57e-15	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	trans	rs208520	0.690	rs176289	chr6:66766522	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.89	-0.64	8.51e-55	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.897	rs2584627	chr17:61901439	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs4332037	0.522	rs4721098	chr7:1881527	G/C	cg23422044	chr7:1970798	MAD1L1	0.61	10.49	0.44	3.18e-23	Bipolar disorder;
LGG	cis	rs10464366	0.957	rs11765705	chr7:39106942	G/T	cg15212455	chr7:39170539	POU6F2	0.4	8.52	0.37	2.33e-16	IgG glycosylation;
LGG	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg11764359	chr7:65958608	NA	-0.55	-9.39	-0.4	2.65e-19	Aortic root size;
LGG	cis	rs4740619	0.681	rs10738420	chr9:15966656	C/G	cg14451791	chr9:16040625	NA	-0.38	-9.82	-0.42	8.44e-21	Body mass index;
LGG	cis	rs4262150	0.672	rs72806785	chr5:152352104	A/G	cg12297329	chr5:152029980	NA	-0.56	-8.61	-0.37	1.12e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6089584	0.507	rs6061999	chr20:60637429	G/A	cg13770153	chr20:60521292	NA	-0.47	-7.81	-0.34	3.76e-14	Body mass index;
LGG	cis	rs7799006	0.755	rs12534131	chr7:2294123	C/T	cg02951883	chr7:2050386	MAD1L1	-0.41	-7.2	-0.32	2.45e-12	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs3816183	0.626	rs752009	chr2:42803431	C/T	cg14631114	chr2:43023945	NA	0.34	6.74	0.3	4.74e-11	Hypospadias;
LGG	cis	rs7133214	0.771	rs11049141	chr12:27929623	G/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.91	-0.31	1.58e-11	Gut microbiota (functional units);
LGG	trans	rs2204008	0.660	rs2874343	chr12:38239096	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.81	-0.38	2.53e-17	Bladder cancer;
LGG	cis	rs752010	0.905	rs2038977	chr1:42094659	A/G	cg16096631	chr1:42092165	HIVEP3	0.74	20.73	0.69	5.18e-68	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs60180747	1.000	rs14303	chr15:66783261	C/A	cg07575407	chr15:66541975	MEGF11	0.35	6.89	0.3	1.84e-11	Testicular germ cell tumor;
LGG	cis	rs6032067	0.641	rs34638860	chr20:43765839	C/T	cg10761708	chr20:43804764	PI3	0.74	11.11	0.46	1.4e-25	Blood protein levels;
LGG	cis	rs12188164	1.000	rs34847072	chr5:437862	G/C	cg00976097	chr5:421733	AHRR	-0.41	-6.94	-0.31	1.33e-11	Cystic fibrosis severity;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg10505658	chr17:80084571	CCDC57	0.41	8.35	0.36	7.96e-16	Life satisfaction;
LGG	cis	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg07460842	chr6:66804631	NA	0.89	14.76	0.57	1.09e-40	Exhaled nitric oxide output;
LGG	cis	rs2046867	0.818	rs62249874	chr3:72911202	G/C	cg25664220	chr3:72788482	NA	-0.28	-7.77	-0.34	5.11e-14	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs6463523	0.864	rs73047957	chr7:759373	A/T	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.78	13.77	0.54	2.07e-36	Subjective well-being;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02424238	chr17:33905661	PEX12	-0.4	-6.88	-0.3	2.01e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11700980	0.551	rs16983159	chr21:30118326	C/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.7	-0.3	6.09e-11	QRS complex (12-leadsum);
LGG	trans	rs11875185	0.510	rs78118303	chr18:55633002	A/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs933688	0.938	rs6866923	chr5:90669352	A/C	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	19.16	0.66	1.17e-60	Smoking behavior;
LGG	cis	rs1620921	0.625	rs67391812	chr6:161273234	T/C	cg01280913	chr6:161186852	NA	-0.37	-7.48	-0.33	3.82e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs12431410	0.523	rs12587247	chr14:60213375	G/A	cg07950296	chr14:60194823	RTN1	-0.38	-7.24	-0.32	1.94e-12	Schizophrenia;
LGG	cis	rs1799949	1.000	rs8176077	chr17:41276348	T/C	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs7264396	0.790	rs2425083	chr20:34300456	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.85	-0.34	2.88e-14	Total cholesterol levels;
LGG	cis	rs614226	0.935	rs7956998	chr12:120994932	G/A	cg21053147	chr12:120880522	NA	-0.56	-8.31	-0.36	1.08e-15	Type 1 diabetes nephropathy;
LGG	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	6.97	0.31	1.1e-11	Neuroticism;
LGG	cis	rs2836974	0.533	rs4817999	chr21:40554355	C/A	cg11644478	chr21:40555479	PSMG1	-0.76	-13.85	-0.54	9.5e-37	Cognitive function;
LGG	cis	rs4253772	0.530	rs9615349	chr22:46732418	T/G	cg09461388	chr22:46763229	CELSR1	-0.7	-7.07	-0.31	5.66e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4742903	0.935	rs4742907	chr9:106968226	G/A	cg14250997	chr9:106856677	SMC2	0.39	8.09	0.35	5.12e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7614311	0.731	rs3774719	chr3:63950338	C/A	cg22134162	chr3:63841271	THOC7	-0.45	-7.9	-0.34	2e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs4690686	0.769	rs11133146	chr4:177278878	C/T	cg17059388	chr4:177262070	NA	-0.74	-16.36	-0.61	8.18e-48	Essential tremor;
LGG	cis	rs6502050	0.764	rs35416122	chr17:80119006	A/G	cg07959490	chr17:80112427	CCDC57	-0.46	-9.15	-0.39	1.82e-18	Life satisfaction;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05533552	chr11:34074141	CAPRIN1	-0.46	-6.68	-0.3	6.87e-11	Systemic lupus erythematosus;
LGG	cis	rs7493	1.000	rs2299263	chr7:95040411	A/G	cg08461772	chr7:95026248	PON3	-0.37	-8.29	-0.36	1.24e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg27624424	chr6:160112604	SOD2	0.65	9.49	0.4	1.22e-19	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs7041895	0.806	rs2779747	chr9:22171484	A/C	cg24876683	chr5:172386517	RPL26L1;LOC100268168	-0.43	-7.48	-0.33	3.76e-13	Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs453301	0.606	rs6981060	chr8:8908235	C/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.25	-0.36	1.63e-15	Joint mobility (Beighton score);
LGG	cis	rs7980687	0.506	rs1611973	chr12:123622731	C/G	cg00376283	chr12:123451042	ABCB9	0.67	12.24	0.49	4.75e-30	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs1790761	0.967	rs3741168	chr11:67235351	A/G	cg23188684	chr11:67383651	NA	-0.42	-6.91	-0.31	1.6e-11	Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9688938	chr6:150110077	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.94	0.38	9.47e-18	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18673401	chr17:68166021	KCNJ2	0.47	6.81	0.3	3.1e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg06634786	chr22:41940651	POLR3H	-0.68	-11.51	-0.47	3.8e-27	Vitiligo;
LGG	trans	rs6601327	0.603	rs10095171	chr8:9669885	T/C	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.73	-0.3	5.08e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg24189917	chr7:1970923	MAD1L1	-0.46	-6.91	-0.31	1.58e-11	Bipolar disorder;
LGG	cis	rs4332037	0.901	rs11767040	chr7:1945468	C/T	cg12432903	chr7:1882776	MAD1L1	0.56	8.38	0.36	6.54e-16	Bipolar disorder;
LGG	trans	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.21	-0.36	2.29e-15	Breast cancer;
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg19635926	chr16:89946313	TCF25	0.81	9.12	0.39	2.35e-18	Skin colour saturation;
LGG	cis	rs1062177	0.950	rs892005	chr5:151180621	A/G	cg00977110	chr5:151150581	G3BP1	0.5	8.04	0.35	7.42e-15	Preschool internalizing problems;
LGG	cis	rs9467711	0.606	rs12174602	chr6:26372827	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.05	0.35	6.85e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs10937275	0.826	rs62294592	chr3:186635584	C/T	cg13419791	chr3:186648285	ST6GAL1	0.8	8.08	0.35	5.55e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9443645	0.901	rs4706077	chr6:79548845	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.62	-0.37	1.05e-16	Intelligence (multi-trait analysis);
LGG	cis	rs62064224	0.765	rs11650584	chr17:30679330	T/G	cg25809561	chr17:30822961	MYO1D	0.41	9.93	0.42	3.33e-21	Schizophrenia;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg06925179	chr17:43578568	NA	0.31	8.22	0.36	2.09e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg06873352	chr17:61820015	STRADA	0.48	7.45	0.33	4.74e-13	Height;
LGG	cis	rs4481887	0.927	rs4551626	chr1:248489128	G/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.18e-19	Common traits (Other);
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg11494091	chr17:61959527	GH2	-1.12	-33.55	-0.84	4.78e-126	Prudent dietary pattern;
LGG	cis	rs8060686	0.641	rs12599880	chr16:68152035	A/G	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.58	-0.33	1.88e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11676855	0.927	rs4663180	chr2:235921195	A/G	cg06431347	chr2:235935754	SH3BP4	-0.48	-10.97	-0.45	4.81e-25	Dialysis-related mortality;
LGG	cis	rs13191362	1.000	rs66789102	chr6:163104432	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.98	10.14	0.43	5.98e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs877282	0.898	rs11253349	chr10:765897	C/G	cg17470449	chr10:769945	NA	0.57	6.87	0.3	2.05e-11	Uric acid levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08077726	chr17:74734280	SFRS2;MFSD11	0.46	7.23	0.32	2.03e-12	Gut microbiome composition (summer);
LGG	cis	rs597539	0.652	rs646586	chr11:68681653	C/T	cg07511668	chr11:68622177	NA	-0.46	-8.88	-0.38	1.5e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2562456	0.754	rs55771551	chr19:21746380	C/T	cg25042112	chr7:64838748	ZNF92	-0.47	-6.69	-0.3	6.64e-11	Pain;
LGG	trans	rs561341	1.000	rs72823789	chr17:30284084	G/A	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs17209837	0.607	rs2270187	chr7:87080698	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.63	-0.59	1.64e-44	Gallbladder cancer;
LGG	cis	rs61931739	0.500	rs10844846	chr12:34394611	C/G	cg06521331	chr12:34319734	NA	-0.55	-9.99	-0.42	2.05e-21	Morning vs. evening chronotype;
LGG	cis	rs2046867	0.818	rs1502754	chr3:72895345	G/T	cg25664220	chr3:72788482	NA	-0.34	-9.33	-0.4	4.36e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-6.98	-0.31	1.02e-11	Bipolar disorder;
LGG	trans	rs75804782	0.521	rs55657931	chr2:239422072	A/G	cg01134436	chr17:81009848	B3GNTL1	0.74	8.31	0.36	1.07e-15	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs6088580	0.634	rs6059887	chr20:33101102	C/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs1003719	0.788	rs60447195	chr21:38448600	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs11764590	0.694	rs6972969	chr7:2099331	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-9.0	-0.39	5.91e-18	Neuroticism;
LGG	cis	rs10214930	0.671	rs2391452	chr7:27686152	T/C	cg22168087	chr7:27702803	HIBADH	0.45	6.74	0.3	4.79e-11	Hypospadias;
LGG	cis	rs4072980	0.524	rs16824514	chr1:38395947	A/T	cg12658694	chr1:38397304	INPP5B	0.46	9.55	0.41	7.49e-20	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15123824	chr2:85581917	ELMOD3;RETSAT	0.51	8.59	0.37	1.3e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6087771	0.662	rs6058298	chr20:30247916	C/T	cg21427119	chr20:30132790	HM13	-0.39	-6.86	-0.3	2.19e-11	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.49	-7.67	-0.34	1.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9372253	0.967	rs1055301	chr6:110713042	A/G	cg01119278	chr6:110721349	DDO	-0.31	-7.33	-0.32	1.03e-12	Platelet distribution width;
LGG	cis	rs2011503	0.843	rs2860494	chr19:19470426	T/C	cg11584989	chr19:19387371	SF4	-0.74	-12.3	-0.5	2.88e-30	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13616963	chr3:57583610	ARF4	0.42	6.65	0.3	8.22e-11	Cognitive performance;
LGG	cis	rs72781680	1.000	rs72781667	chr2:24225667	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.03	0.39	4.65e-18	Lymphocyte counts;
LGG	cis	rs10206020	0.921	rs72778009	chr2:1573322	G/T	cg26248373	chr2:1572462	NA	-0.9	-15.7	-0.59	7.32e-45	IgG glycosylation;
LGG	cis	rs7223966	1.000	rs8075521	chr17:61804954	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.2	0.32	2.41e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9457247	0.935	rs2757050	chr6:167377165	G/T	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg02463440	chr8:22132932	PIWIL2	0.49	10.94	0.45	6.03e-25	Hypertriglyceridemia;
LGG	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.49	8.28	0.36	1.38e-15	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6860806	0.507	rs274570	chr5:131713226	C/T	cg07395648	chr5:131743802	NA	0.49	10.02	0.42	1.67e-21	Breast cancer;
LGG	cis	rs7084402	0.967	rs2842083	chr10:60329230	A/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.29	-0.32	1.38e-12	Refractive error;
LGG	cis	rs7681440	0.641	rs6841352	chr4:90781655	A/C	cg20003494	chr4:90757398	SNCA	0.36	6.86	0.3	2.22e-11	Dementia with Lewy bodies;
LGG	cis	rs28785552	0.554	rs11084178	chr19:53212361	C/T	cg10871876	chr19:53194124	ZNF83	0.53	10.29	0.43	1.67e-22	Response to paliperidone in schizophrenia (PANSS score);
LGG	cis	rs11250464	0.833	rs2387653	chr10:1407826	A/G	cg08668359	chr10:1443807	ADARB2	-0.65	-12.32	-0.5	2.37e-30	Radiation response;
LGG	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg10760299	chr15:45669010	GATM	0.41	8.05	0.35	7.26e-15	Homoarginine levels;
LGG	cis	rs6542838	0.702	rs6739176	chr2:99536846	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.1	-0.31	4.74e-12	Fear of minor pain;
LGG	trans	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg25214090	chr10:38739885	LOC399744	0.48	7.93	0.35	1.71e-14	Educational attainment;
LGG	cis	rs9611198	0.792	rs2092168	chr22:39947068	T/C	cg03390717	chr22:39966585	CACNA1I	0.32	6.74	0.3	4.66e-11	Schizophrenia;
LGG	cis	rs225245	0.755	rs6505491	chr17:34026335	A/G	cg05299278	chr17:33885742	SLFN14	0.42	8.12	0.35	4.4e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7551222	0.752	rs12138846	chr1:204556478	T/A	cg20240347	chr1:204465584	NA	-0.51	-10.12	-0.43	6.95e-22	Schizophrenia;
LGG	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg09021430	chr5:549028	NA	-0.68	-9.37	-0.4	3.24e-19	Obesity-related traits;
LGG	cis	rs5769707	0.542	rs739242	chr22:50057116	A/G	cg06623630	chr22:50017776	C22orf34	-0.46	-9.19	-0.39	1.36e-18	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.62	-0.33	1.49e-13	Triglycerides;
LGG	cis	rs597539	0.652	rs604524	chr11:68629929	G/A	cg21862992	chr11:68658383	NA	0.51	8.72	0.38	5.02e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11690935	0.549	rs62183819	chr2:172904520	G/T	cg13550731	chr2:172543902	DYNC1I2	0.69	13.61	0.53	9.88e-36	Schizophrenia;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08208917	chr15:42565872	GANC;TMEM87A	-0.4	-6.75	-0.3	4.49e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs79911532	0.515	rs114616297	chr7:75719576	T/G	cg19862616	chr7:65841803	NCRNA00174	0.73	7.65	0.33	1.19e-13	Mononucleosis;
LGG	cis	rs3733585	0.699	rs60045583	chr4:9971950	G/A	cg25986240	chr4:9926439	SLC2A9	0.39	7.84	0.34	3.13e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3733585	0.699	rs11724510	chr4:9958583	C/T	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.61e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72772090	0.539	rs10515249	chr5:96125259	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg19524238	chr7:2802976	GNA12	0.31	7.45	0.33	4.49e-13	Height;
LGG	cis	rs3820068	0.581	rs72645864	chr1:15921153	C/T	cg05660106	chr1:15850417	CASP9	0.87	17.71	0.64	6e-54	Systolic blood pressure;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg04267008	chr7:1944627	MAD1L1	-0.49	-8.21	-0.36	2.3e-15	Schizophrenia;
LGG	cis	rs2862064	0.872	rs1393209	chr5:156477540	G/A	cg12943317	chr5:156479607	HAVCR1	-0.9	-11.1	-0.46	1.53e-25	Platelet count;
LGG	cis	rs10504229	0.595	rs36081958	chr8:58117505	C/G	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.83e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.6	10.28	0.43	1.78e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs943466	0.955	rs1887340	chr6:33730095	C/T	cg07519485	chr6:33762594	MLN	0.53	10.5	0.44	2.88e-23	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs968451	1.000	rs11704615	chr22:39696834	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.82	11.16	0.46	9.03e-26	Primary biliary cholangitis;
LGG	trans	rs6582630	0.519	rs12366667	chr12:38332632	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.31	-0.4	5.19e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4363385	0.510	rs11205187	chr1:153053323	T/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.25	-0.4	8.12e-19	Inflammatory skin disease;
LGG	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11764359	chr7:65958608	NA	0.57	9.57	0.41	6.3e-20	Aortic root size;
LGG	cis	rs9964724	0.865	rs6507210	chr18:35169497	A/T	cg27332583	chr18:35150602	NA	-0.4	-8.57	-0.37	1.56e-16	Educational attainment (years of education);
LGG	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg06885757	chr1:42089581	HIVEP3	-0.63	-13.82	-0.54	1.3e-36	Airway imaging phenotypes;
LGG	cis	rs910316	1.000	rs11623413	chr14:75588824	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.74	-0.45	3.54e-24	Height;
LGG	cis	rs1670533	1.000	rs6812596	chr4:1069866	A/G	cg27284194	chr4:1044797	NA	0.54	9.87	0.42	5.39e-21	Recombination rate (females);
LGG	cis	rs9443645	0.901	rs9341754	chr6:79584973	A/C	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg07936489	chr17:37558343	FBXL20	0.99	15.35	0.58	2.6900000000000002e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs35306767	0.953	rs12357633	chr10:957246	C/T	cg20503657	chr10:835505	NA	0.8	11.27	0.46	3.31e-26	Eosinophil percentage of granulocytes;
LGG	cis	rs3790455	1.000	rs12136856	chr1:156473114	C/G	cg14087168	chr1:156450669	MEF2D	0.47	7.72	0.34	7.08e-14	Migraine;
LGG	cis	rs7614311	0.681	rs2241822	chr3:63965304	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-8.11	-0.35	4.62e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs858239	0.600	rs10241208	chr7:23144914	G/C	cg23682824	chr7:23144976	KLHL7	0.43	7.48	0.33	3.74e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10895140	0.670	rs5003386	chr11:101521067	C/T	cg23650423	chr11:101454676	TRPC6	-0.4	-6.77	-0.3	3.91e-11	Menarche (age at onset);
LGG	cis	rs9796	0.621	rs1659227	chr15:41472398	G/A	cg18705301	chr15:41695430	NDUFAF1	0.59	10.03	0.42	1.43e-21	Menopause (age at onset);
LGG	cis	rs35306767	0.903	rs12250936	chr10:870109	C/T	cg26597838	chr10:835615	NA	0.76	10.46	0.44	4.01e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs2188561	0.697	rs2072064	chr7:107334513	T/A	cg16793755	chr7:107334138	SLC26A4	0.43	7.58	0.33	1.97e-13	Alcohol consumption;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg08888203	chr3:10149979	C3orf24	0.54	9.18	0.39	1.46e-18	Alzheimer's disease;
LGG	cis	rs1552244	1.000	rs9827740	chr3:10120531	T/C	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs755249	0.567	rs4660546	chr1:39679402	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.2	0.32	2.5e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13826447	chr17:46019006	PNPO	0.49	7.19	0.32	2.58e-12	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.522	rs289643	chr10:37941494	T/G	cg00409905	chr10:38381863	ZNF37A	-0.63	-12.94	-0.52	6.6e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.63	10.59	0.44	1.25e-23	Obesity-related traits;
LGG	cis	rs11662586	0.517	rs11663082	chr18:77713494	C/T	cg20368463	chr18:77673604	PQLC1	0.65	13.19	0.52	6.01e-34	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs7808935	0.958	rs10486567	chr7:27976563	G/A	cg22168087	chr7:27702803	HIBADH	0.62	9.42	0.4	2.11e-19	Prostate cancer;
LGG	cis	rs5997397	0.967	rs5762777	chr22:29150044	T/C	cg02153584	chr22:29168773	CCDC117	0.39	6.77	0.3	3.82e-11	Red cell distribution width;
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg27400746	chr16:89904261	SPIRE2	-0.79	-12.77	-0.51	3.18e-32	Skin colour saturation;
LGG	trans	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.93	-0.31	1.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9300255	0.568	rs1790090	chr12:123633424	G/A	cg05973401	chr12:123451056	ABCB9	0.5	7.67	0.34	1.06e-13	Neutrophil percentage of white cells;
LGG	cis	rs9914988	0.832	rs34901720	chr17:27179518	A/G	cg20469991	chr17:27169893	C17orf63	-0.53	-6.72	-0.3	5.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg05335186	chr13:53173507	NA	0.51	10.63	0.44	9.18e-24	Lewy body disease;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg07659893	chr17:61819838	STRADA	0.49	8.26	0.36	1.53e-15	Prudent dietary pattern;
LGG	cis	rs657075	0.697	rs35809179	chr5:131695406	C/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs16866061	0.515	rs114968850	chr2:225352461	C/G	cg12698349	chr2:225449008	CUL3	1.03	26.62	0.78	2.28e-95	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.86	-0.62	4.42e-50	Skin colour saturation;
LGG	cis	rs7119	0.717	rs62009069	chr15:77817877	T/G	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs780094	0.500	rs12995461	chr2:27778167	A/C	cg27432699	chr2:27873401	GPN1	0.45	6.76	0.3	4.06e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs10504130	0.569	rs12676345	chr8:52685809	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7786808	0.741	rs4909222	chr7:158228095	C/T	cg12438819	chr7:158236134	PTPRN2	-0.34	-8.84	-0.38	2e-17	Obesity-related traits;
LGG	cis	rs2361718	0.933	rs8077849	chr17:78104137	C/T	cg27427491	chr17:78079615	GAA	-0.3	-7.7	-0.34	8.42e-14	Yeast infection;
LGG	cis	rs7584330	0.737	rs61212490	chr2:238365230	T/C	cg16989719	chr2:238392110	NA	-0.32	-6.94	-0.31	1.31e-11	Prostate cancer;
LGG	cis	rs868036	1.000	rs1026734	chr15:68100950	T/C	cg05925327	chr15:68127851	NA	-0.37	-8.66	-0.37	7.62e-17	Restless legs syndrome;
LGG	cis	rs7177699	0.557	rs7176187	chr15:79121373	A/G	cg00540400	chr15:79124168	NA	0.54	11.5	0.47	4.14e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7223966	0.655	rs9906882	chr17:61634382	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	8.33	0.36	9.17e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4423214	0.840	rs1619577	chr11:71181485	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.63e-25	Vitamin D levels;
LGG	cis	rs9322193	0.926	rs9689036	chr6:150101699	T/C	cg00933542	chr6:150070202	PCMT1	0.37	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs4664308	0.875	rs2124969	chr2:160989486	T/C	cg03641300	chr2:160917029	PLA2R1	-0.83	-17.04	-0.62	6.75e-51	Idiopathic membranous nephropathy;
LGG	cis	rs9807989	0.507	rs6543133	chr2:103040177	A/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.57	0.41	6.31e-20	Asthma;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg18446336	chr7:2847575	GNA12	-0.26	-6.77	-0.3	3.94e-11	Height;
LGG	cis	rs2204008	0.715	rs3899385	chr12:38169880	C/G	cg26384229	chr12:38710491	ALG10B	0.94	21.35	0.7	6.59e-71	Bladder cancer;
LGG	trans	rs747782	0.583	rs11039666	chr11:48324841	C/G	cg15704280	chr7:45808275	SEPT13	0.7	7.69	0.34	9.09e-14	Intraocular pressure;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	0.31	8.13	0.35	3.91e-15	IgG glycosylation;
LGG	cis	rs10504229	0.953	rs72652908	chr8:58191324	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs898097	1.000	rs898097	chr17:80904310	C/T	cg15369054	chr17:80825471	TBCD	-0.52	-9.7	-0.41	2.24e-20	Breast cancer;
LGG	trans	rs116095464	0.718	rs62331563	chr5:355286	T/C	cg00938859	chr5:1591904	SDHAP3	0.71	6.66	0.3	8e-11	Breast cancer;
LGG	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg11266682	chr4:10021025	SLC2A9	0.41	7.85	0.34	2.94e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7737355	0.947	rs11242078	chr5:130792035	A/C	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.47e-19	Life satisfaction;
LGG	cis	rs1552244	0.515	rs67342818	chr3:10166406	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	15.11	0.57	3.1e-42	Alzheimer's disease;
LGG	cis	rs155076	1.000	rs261404	chr13:21858162	T/G	cg11317459	chr13:21872234	NA	-1.15	-18.78	-0.66	6.22e-59	White matter hyperintensity burden;
LGG	cis	rs7173389	1.000	rs7172796	chr15:73661687	T/G	cg01796676	chr15:73680284	NA	0.51	8.67	0.37	7.39e-17	Resting heart rate;
LGG	cis	rs10193935	1.000	rs4494804	chr2:42395946	A/T	cg27598129	chr2:42591480	NA	-0.61	-9.1	-0.39	2.79e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg17202724	chr17:61916730	SMARCD2	0.42	8.47	0.37	3.23e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs228437	1.000	rs985122	chr6:134931300	A/G	cg24504307	chr6:134963096	NA	0.41	7.6	0.33	1.62e-13	Melanoma;
LGG	cis	rs12477438	0.520	rs2053917	chr2:100070884	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.88	-0.3	1.95e-11	Chronic sinus infection;
LGG	cis	rs9322193	0.884	rs9688699	chr6:150054816	A/G	cg16507663	chr6:150244633	RAET1G	0.47	9.0	0.39	5.72e-18	Lung cancer;
LGG	cis	rs734999	0.566	rs12748729	chr1:2558740	C/T	cg20673091	chr1:2541236	MMEL1	-0.75	-18.21	-0.65	2.77e-56	Ulcerative colitis;
LGG	cis	rs2228479	0.850	rs17227057	chr16:89816333	C/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs7582720	0.887	rs72934589	chr2:204017937	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.78	9.29	0.4	6.08e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.74	-0.34	6.41e-14	Menopause (age at onset);
LGG	cis	rs12681288	0.823	rs2701908	chr8:1003250	T/C	cg08648136	chr8:956695	NA	0.36	7.55	0.33	2.41e-13	Schizophrenia;
LGG	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.46	7.06	0.31	6.23e-12	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12765878	0.603	rs9420904	chr10:105666745	G/A	cg11005552	chr10:105648138	OBFC1	-0.73	-13.0	-0.52	3.62e-33	Coronary artery disease;
LGG	cis	rs7552404	1.000	rs11161515	chr1:76212559	C/T	cg10523679	chr1:76189770	ACADM	0.83	14.49	0.56	1.71e-39	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs2204008	0.837	rs1589395	chr12:38420405	C/T	cg06521331	chr12:34319734	NA	-0.51	-8.96	-0.38	7.84e-18	Bladder cancer;
LGG	trans	rs7824557	0.591	rs2736282	chr8:11225480	C/T	cg02002194	chr4:3960332	NA	-0.37	-6.65	-0.3	8.34e-11	Retinal vascular caliber;
LGG	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.24	0.43	2.48e-22	Dupuytren's disease;
LGG	cis	rs7959452	0.562	rs11177630	chr12:69767963	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-7.52	-0.33	2.83e-13	Blood protein levels;
LGG	cis	rs6964587	0.869	rs4729010	chr7:91486751	G/A	cg17063962	chr7:91808500	NA	-0.4	-6.94	-0.31	1.35e-11	Breast cancer;
LGG	cis	rs2694528	0.920	rs34540810	chr5:60134856	A/T	cg11474532	chr5:59995715	DEPDC1B	0.69	7.34	0.32	9.71e-13	Parkinson's disease;
LGG	cis	rs9487094	0.813	rs61233650	chr6:109686612	C/T	cg16315928	chr6:109776240	MICAL1	0.51	8.44	0.37	3.96e-16	Height;
LGG	cis	rs13191362	0.938	rs35395472	chr6:163008493	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10499694	0.901	rs6975453	chr7:50585211	A/T	cg04490037	chr7:50633773	DDC	0.31	6.86	0.3	2.28e-11	Body mass index;
LGG	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.02e-21	HDL cholesterol levels;
LGG	cis	rs17767392	0.881	rs2190240	chr14:72024889	T/C	cg13720639	chr14:72061746	SIPA1L1	0.37	8.12	0.35	4.38e-15	Mitral valve prolapse;
LGG	cis	rs7226408	0.600	rs1246627	chr18:34469537	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.41	-8.86	-0.38	1.71e-17	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg10756647	chr7:56101905	PSPH	-0.8	-9.27	-0.4	6.91e-19	Diabetic kidney disease;
LGG	cis	rs6951245	1.000	rs1997243	chr7:1083777	A/G	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21659774	chr18:21083441	C18orf8	0.45	6.86	0.3	2.21e-11	Hip circumference;
LGG	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-11.32	-0.47	2.18e-26	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg19774624	chr17:42201019	HDAC5	-0.89	-18.09	-0.64	9.76e-56	Total body bone mineral density;
LGG	cis	rs13421350	0.579	rs80010354	chr2:173303310	G/A	cg15021238	chr2:173305865	ITGA6	-0.8	-9.0	-0.39	6.04e-18	Diabetic kidney disease;
LGG	trans	rs71537559	1	rs71537559	chr6:27309779	G/C	cg06606381	chr12:133084897	FBRSL1	-1.14	-10.44	-0.44	4.78e-23	Squamous cell lung carcinoma;
LGG	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg18252515	chr7:66147081	NA	-1.32	-18.42	-0.65	3.11e-57	Diabetic kidney disease;
LGG	cis	rs6665290	0.904	rs6426559	chr1:227195876	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08120226	chr3:195531633	MUC4	-0.5	-8.02	-0.35	8.43e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs7264396	0.690	rs2425178	chr20:34446395	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.37	-0.32	8.08e-13	Total cholesterol levels;
LGG	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg06102954	chr21:42741788	MX2	-0.38	-7.2	-0.32	2.37e-12	Melanoma;
LGG	cis	rs2439831	0.867	rs8039638	chr15:43634405	C/T	cg15269541	chr15:43626905	ADAL	-0.42	-7.02	-0.31	7.92e-12	Lung cancer in ever smokers;
LGG	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg24130564	chr14:104152367	KLC1	-0.42	-7.83	-0.34	3.36e-14	Body mass index;
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.46	-0.37	3.64e-16	Neuroticism;
LGG	cis	rs7717393	0.881	rs10065774	chr5:155766322	G/A	cg04435420	chr5:155754009	SGCD	0.69	8.71	0.38	5.31e-17	Egg allergy;
LGG	cis	rs721917	0.506	rs1811886	chr10:81649568	G/A	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg21724239	chr8:58056113	NA	-0.61	-9.21	-0.39	1.1e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7727544	0.716	rs7720230	chr5:131592405	T/G	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.33	-0.32	1.07e-12	Blood metabolite levels;
LGG	cis	rs11190604	1.000	rs2295774	chr10:102265847	A/C	cg07570687	chr10:102243282	WNT8B	0.45	7.53	0.33	2.64e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs3096299	0.967	rs11648663	chr16:89466307	C/T	cg08822215	chr16:89438651	ANKRD11	-0.38	-7.43	-0.33	5.36e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs6920965	0.602	rs10872302	chr6:126180631	G/T	cg05901451	chr6:126070800	HEY2	-0.45	-7.74	-0.34	6.11e-14	High light scatter reticulocyte count;
LGG	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg13009111	chr11:71350975	NA	0.35	7.68	0.34	9.66e-14	Neuroticism;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg11473876	chr11:109292803	C11orf87	-0.8	-17.8	-0.64	2.11e-54	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg03217915	chr21:44840965	SIK1	0.36	6.67	0.3	7.11e-11	Menarche (age at onset);
LGG	cis	rs10876993	0.890	rs7976852	chr12:58100551	T/G	cg18357645	chr12:58087776	OS9	0.67	11.76	0.48	4.1e-28	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs17666538	0.585	rs6559064	chr8:623061	G/A	cg13264159	chr8:625131	ERICH1	-1.05	-12.4	-0.5	1.1e-30	IgG glycosylation;
LGG	cis	rs9815354	1.000	rs2625667	chr3:41900951	C/A	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11039798	1.000	rs3902928	chr11:48581458	A/T	cg15704280	chr7:45808275	SEPT13	0.78	9.04	0.39	4.17e-18	Axial length;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26837270	chr19:42746884	GSK3A	0.45	6.94	0.31	1.36e-11	Gut microbiome composition (summer);
LGG	cis	rs514406	0.792	rs481440	chr1:53344976	C/T	cg27535305	chr1:53392650	SCP2	-0.33	-7.92	-0.35	1.73e-14	Monocyte count;
LGG	cis	rs4954585	0.762	rs12986776	chr2:136991517	C/G	cg07169764	chr2:136633963	MCM6	-0.47	-7.54	-0.33	2.48e-13	Colorectal cancer;
LGG	cis	rs875971	1.000	rs1182882	chr7:65562063	C/T	cg18876405	chr7:65276391	NA	-0.57	-9.94	-0.42	3.11e-21	Aortic root size;
LGG	cis	rs35123781	1.000	rs6580200	chr5:139059562	A/G	cg21230503	chr5:139085173	NA	0.3	7.08	0.31	5.4e-12	Schizophrenia;
LGG	cis	rs16912285	0.688	rs1899540	chr11:24339992	A/G	ch.11.24196551F	chr11:24239977	NA	0.93	12.93	0.51	7.44e-33	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21659725	chr3:3221576	CRBN	0.92	20.44	0.69	1.16e-66	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.965	rs2074303	chr19:19381755	C/T	cg01262667	chr19:19385393	TM6SF2	0.47	11.98	0.49	5.32e-29	Tonsillectomy;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11493924	chr5:55008521	SLC38A9	-0.51	-7.67	-0.34	1.02e-13	Systemic lupus erythematosus;
LGG	cis	rs8060686	0.565	rs36046686	chr16:68122269	T/C	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1348850	0.914	rs1374437	chr2:178363423	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.63	-0.37	1.02e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9467711	0.606	rs9379858	chr6:26367689	T/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8072100	0.656	rs2610367	chr17:45569815	A/G	cg08085267	chr17:45401833	C17orf57	-0.51	-9.58	-0.41	5.9e-20	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs8005677	1.000	rs1951119	chr14:23388326	A/C	cg25600027	chr14:23388339	RBM23	-0.45	-7.34	-0.32	1e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.46	9.82	0.42	8.65e-21	Schizophrenia;
LGG	cis	rs17092148	0.945	rs6060042	chr20:33361721	A/G	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.63	-0.33	1.35e-13	Neuroticism;
LGG	cis	rs5760092	0.618	rs4461358	chr22:24260106	T/C	cg00024416	chr22:24240387	NA	0.48	7.82	0.34	3.58e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg18335740	chr13:41363409	SLC25A15	0.84	19.96	0.68	2.13e-64	Lewy body disease;
LGG	cis	rs8060686	0.641	rs8060893	chr16:68191608	A/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.69	-0.3	6.61e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs7766436	0.621	rs2294822	chr6:22596815	C/T	cg13666174	chr6:22585274	NA	0.35	8.37	0.36	6.72e-16	Coronary artery disease;
LGG	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg15485101	chr11:133734466	NA	0.62	10.8	0.45	2.12e-24	Childhood ear infection;
LGG	trans	rs2736340	0.539	rs11250138	chr8:11323312	C/G	cg06636001	chr8:8085503	FLJ10661	-0.41	-6.77	-0.3	3.85e-11	Systemic lupus erythematosus and Systemic sclerosis;Rheumatoid arthritis;Systemic lupus erythematosus;Kawasaki disease;Systemic lupus erythematosus or rheumatoid arthritis;
LGG	cis	rs3747547	0.892	rs74755693	chr9:37951859	A/G	cg13774184	chr9:37916125	SHB	-0.7	-6.85	-0.3	2.38e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg04008888	chr11:68622739	NA	-0.55	-11.8	-0.48	2.92e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2243480	0.901	rs34807232	chr7:65965133	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.22	-0.43	3.1e-22	Diabetic kidney disease;
LGG	cis	rs8062405	0.792	rs12446550	chr16:28543381	G/A	cg00198680	chr16:28758506	NA	0.29	7.2	0.32	2.44e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs796364	0.570	rs35733345	chr2:200647533	T/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.61	-6.67	-0.3	7.35e-11	Schizophrenia;
LGG	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg27446573	chr6:127587934	RNF146	0.96	17.88	0.64	9.59e-55	Breast cancer;
LGG	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg12463550	chr7:65579703	CRCP	0.64	7.89	0.34	2.21e-14	Diabetic kidney disease;
LGG	cis	rs34929064	0.624	rs2905326	chr7:22713957	G/A	cg18045685	chr7:22629474	NA	-0.53	-9.45	-0.4	1.64e-19	Major depression and alcohol dependence;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.34e-16	Blood metabolite levels;
LGG	cis	rs981844	0.807	rs10517577	chr4:154644537	T/C	cg14289246	chr4:154710475	SFRP2	0.66	10.26	0.43	2.16e-22	Response to statins (LDL cholesterol change);
LGG	cis	rs9815354	1.000	rs7648357	chr3:41849670	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.29	0.36	1.24e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12682352	0.602	rs6993494	chr8:8667444	C/T	cg08975724	chr8:8085496	FLJ10661	0.38	7.1	0.31	4.79e-12	Neuroticism;
LGG	cis	rs6933660	0.800	rs13201167	chr6:151773504	T/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	8.03	0.35	8.05e-15	Menarche (age at onset);
LGG	trans	rs7824557	0.872	rs6601577	chr8:11102682	C/G	cg16141378	chr3:129829833	LOC729375	-0.34	-7.59	-0.33	1.8e-13	Retinal vascular caliber;
LGG	cis	rs2013441	1.000	rs17759959	chr17:20024095	A/G	cg13482628	chr17:19912719	NA	0.49	9.13	0.39	2.06e-18	Obesity-related traits;
LGG	cis	rs10256972	0.647	rs10233430	chr7:1051664	T/C	cg07308232	chr7:1071921	C7orf50	-0.48	-8.9	-0.38	1.24e-17	Longevity;Endometriosis;
LGG	cis	rs62400317	0.826	rs10807321	chr6:45330974	T/C	cg18551225	chr6:44695536	NA	-0.61	-9.84	-0.42	7.26e-21	Total body bone mineral density;
LGG	cis	rs826838	0.967	rs73096706	chr12:38860563	G/A	cg26384229	chr12:38710491	ALG10B	1.05	26.71	0.78	8.12e-96	Heart rate;
LGG	cis	rs300774	1.000	rs300778	chr2:111964	C/A	cg04617936	chr2:214353	NA	-0.46	-6.95	-0.31	1.29e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs6831352	0.918	rs13110764	chr4:100062466	C/T	cg13256891	chr4:100009986	ADH5	-0.5	-8.32	-0.36	9.79e-16	Alcohol dependence;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg02725872	chr8:58115012	NA	-0.93	-12.32	-0.5	2.21e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12753569	0.748	rs1013629	chr1:76513759	A/G	cg00791851	chr1:76518896	NA	0.42	9.91	0.42	3.88e-21	Personality dimensions;
LGG	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.99	0.52	3.89e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	trans	rs36715	1.000	rs181850	chr5:127547487	T/C	cg16011800	chr17:1958478	HIC1	-0.47	-6.83	-0.3	2.63e-11	Breast cancer;
LGG	cis	rs13108904	0.967	rs4428235	chr4:1278891	C/T	cg05665937	chr4:1216051	CTBP1	0.59	11.01	0.46	3.43e-25	Obesity-related traits;
LGG	cis	rs7552404	0.731	rs1689275	chr1:76409655	T/C	cg03433033	chr1:76189801	ACADM	-0.64	-9.49	-0.4	1.19e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9368481	0.761	rs4358615	chr6:26998567	A/G	cg18867708	chr6:26865862	GUSBL1	0.44	7.32	0.32	1.14e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg19901956	chr11:77921274	USP35	-0.41	-6.67	-0.3	7.3e-11	Testicular germ cell tumor;
LGG	cis	rs782590	0.818	rs2627782	chr2:55825352	A/G	cg18811423	chr2:55921094	PNPT1	0.82	17.71	0.64	5.73e-54	Metabolic syndrome;
LGG	cis	rs2948294	0.566	rs13274039	chr8:8111659	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.65	0.34	1.16e-13	Red cell distribution width;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18256790	chr17:8532950	MYH10	0.39	6.91	0.31	1.64e-11	Obesity-related traits;
LGG	cis	rs62238980	0.614	rs77886759	chr22:32390956	A/G	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6500602	0.647	rs1641868	chr16:4594503	G/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.44	7.92	0.35	1.76e-14	Schizophrenia;
LGG	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg14088196	chr11:70211408	PPFIA1	0.91	13.0	0.52	3.7e-33	Coronary artery disease;
LGG	cis	rs7904368	0.754	rs7076779	chr10:16852667	C/T	cg14835575	chr10:16859367	RSU1	0.8	15.21	0.58	1.13e-42	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg00343986	chr7:65444356	GUSB	0.48	8.5	0.37	2.71e-16	Aortic root size;
LGG	cis	rs453301	0.686	rs17702602	chr8:8908596	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.84	-0.3	2.44e-11	Joint mobility (Beighton score);
LGG	cis	rs11214589	0.905	rs2186799	chr11:113242533	G/T	cg14373873	chr11:113211441	TTC12	0.44	9.08	0.39	3.03e-18	Neuroticism;
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.46	-7.5	-0.33	3.26e-13	Bipolar disorder;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg12708336	chr17:41446283	NA	-0.29	-6.7	-0.3	6.11e-11	Menopause (age at onset);
LGG	cis	rs6558530	0.666	rs6558518	chr8:1697309	G/T	cg25947184	chr8:1697459	NA	0.47	8.2	0.36	2.41e-15	Systolic blood pressure;
LGG	cis	rs68170813	0.559	rs74584447	chr7:106944755	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.65	-0.44	7.57e-24	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.77	-0.34	5.18e-14	Skin colour saturation;
LGG	cis	rs6582630	0.537	rs6582500	chr12:38534206	G/A	cg26384229	chr12:38710491	ALG10B	0.98	23.13	0.73	3.17e-79	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4819052	0.851	rs28676615	chr21:46676576	G/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.53	8.65	0.37	8.24e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg12386194	chr3:101231763	SENP7	0.43	7.54	0.33	2.54e-13	Colorectal cancer;
LGG	cis	rs2247341	0.965	rs2854917	chr4:1720550	T/C	cg08629884	chr4:1719983	TMEM129	-0.58	-11.24	-0.46	4.39e-26	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1801251	0.964	rs12472839	chr2:233559615	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	8.94	0.38	9.25e-18	Coronary artery disease;
LGG	cis	rs9303401	0.659	rs7224276	chr17:56897827	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs2795502	0.882	rs3123754	chr10:43339011	G/A	cg20628663	chr10:43360327	NA	-0.42	-8.69	-0.37	6.37e-17	Blood protein levels;
LGG	cis	rs3816183	0.585	rs2374435	chr2:42858756	A/C	cg14631114	chr2:43023945	NA	0.34	6.83	0.3	2.61e-11	Hypospadias;
LGG	cis	rs1218582	0.774	rs1007170	chr1:154881461	G/A	cg16680214	chr1:154839983	KCNN3	-0.5	-9.89	-0.42	4.61e-21	Prostate cancer;
LGG	cis	rs2832270	0.562	rs2832250	chr21:30557718	C/G	cg24692254	chr21:30365293	RNF160	0.66	6.78	0.3	3.75e-11	Response to mTOR inhibitor (everolimus);
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg14926445	chr8:58193284	C8orf71	-0.91	-12.66	-0.51	9.74e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs2334880	0.678	rs34400718	chr16:71455852	G/A	cg06353428	chr16:71660113	MARVELD3	-0.75	-10.4	-0.44	6.71e-23	Malaria;
LGG	cis	rs4819852	0.958	rs9606203	chr22:19972118	C/A	cg07821417	chr22:19972146	ARVCF	0.61	12.83	0.51	1.79e-32	Pulse pressure;
LGG	cis	rs17376456	0.778	rs10476604	chr5:93461838	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.59	8.03	0.35	8.23e-15	Diabetic retinopathy;
LGG	cis	rs875971	0.862	rs10261398	chr7:65750164	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.5	-0.37	2.6e-16	Aortic root size;
LGG	cis	rs9674544	0.792	rs8079167	chr17:47108955	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.45	-8.74	-0.38	4.18e-17	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs9790314	0.779	rs1599376	chr3:160900533	C/G	cg03342759	chr3:160939853	NMD3	-0.58	-9.92	-0.42	3.78e-21	Morning vs. evening chronotype;
LGG	cis	rs6088580	0.634	rs6087579	chr20:32985155	A/G	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.4	-0.36	5.39e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs909674	0.515	rs9611170	chr22:39784845	G/C	cg11247378	chr22:39784982	NA	-0.32	-9.32	-0.4	4.75e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs10089	0.953	rs10045113	chr5:127386631	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.7	10.64	0.44	8.38e-24	Ileal carcinoids;
LGG	cis	rs62238980	0.522	rs117304447	chr22:32422267	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs2075371	1.000	rs8134	chr7:133974519	A/G	cg20476274	chr7:133979776	SLC35B4	0.78	15.78	0.59	3.4e-45	Mean platelet volume;
LGG	cis	rs992157	1.000	rs4674280	chr2:219141458	C/G	cg20019365	chr2:219134978	PNKD;AAMP	-0.68	-11.81	-0.48	2.47e-28	Colorectal cancer;
LGG	cis	rs1008375	0.932	rs4698630	chr4:17614692	C/G	cg02297831	chr4:17616191	MED28	0.52	9.36	0.4	3.41e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg02725872	chr8:58115012	NA	-0.91	-11.73	-0.48	5.49e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs17597773	0.527	rs12132819	chr1:220985350	T/C	cg15450098	chr1:221057561	HLX	-0.45	-6.65	-0.3	8.51e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6088580	0.524	rs6088570	chr20:33268295	T/C	cg24642439	chr20:33292090	TP53INP2	-0.45	-7.07	-0.31	5.81e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg09217309	chr6:150244204	RAET1G	0.45	8.28	0.36	1.34e-15	Testicular germ cell tumor;
LGG	cis	rs9398803	0.931	rs1361262	chr6:126701967	T/C	cg19875578	chr6:126661172	C6orf173	0.57	10.31	0.43	1.45e-22	Male-pattern baldness;
LGG	cis	rs651907	0.535	rs12633089	chr3:101528763	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	1.99e-13	Colorectal cancer;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.61	0.37	1.17e-16	Personality dimensions;
LGG	cis	rs897984	0.770	rs12930657	chr16:30931968	C/T	cg02466173	chr16:30829666	NA	0.46	8.3	0.36	1.11e-15	Dementia with Lewy bodies;
LGG	cis	rs10267417	0.603	rs10281833	chr7:19915675	A/C	cg05791153	chr7:19748676	TWISTNB	0.53	6.81	0.3	2.95e-11	Night sleep phenotypes;
LGG	cis	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.61	0.41	4.57e-20	Mood instability;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08030210	chr19:10362462	MRPL4	0.4	6.87	0.3	2.1e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9926296	0.682	rs258328	chr16:89730314	C/T	cg03605463	chr16:89740564	NA	0.61	11.13	0.46	1.15e-25	Vitiligo;
LGG	trans	rs7395662	0.517	rs2021248	chr11:49013054	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-10.95	-0.45	5.7e-25	HDL cholesterol;
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg01988459	chr11:68622903	NA	-0.62	-12.63	-0.51	1.27e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6840360	0.571	rs11940881	chr4:152501050	C/G	cg25486957	chr4:152246857	NA	-0.53	-8.75	-0.38	3.98e-17	Intelligence (multi-trait analysis);
LGG	trans	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg25214090	chr10:38739885	LOC399744	-0.69	-11.99	-0.49	4.8e-29	Corneal astigmatism;
LGG	cis	rs7649275	0.938	rs2169143	chr3:53750681	C/G	cg21503701	chr3:53781065	CACNA1D	-0.49	-7.2	-0.32	2.41e-12	Trans fatty acid levels;
LGG	trans	rs3779273	0.776	rs4727631	chr7:77834209	G/A	cg05596911	chr5:118502651	DMXL1	-0.49	-10.75	-0.45	3.34e-24	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03170834	chr7:99149896	C7orf38	0.46	6.77	0.3	3.97e-11	Gut microbiome composition (summer);
LGG	cis	rs3771570	1.000	rs7557535	chr2:242206555	T/C	cg21155796	chr2:242212141	HDLBP	0.76	9.87	0.42	5.64e-21	Prostate cancer;
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg00405596	chr8:11794950	NA	0.44	7.0	0.31	9.07e-12	Neuroticism;
LGG	cis	rs2072499	0.966	rs6427307	chr1:156190083	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	29.12	0.8	1.09e-106	Testicular germ cell tumor;
LGG	cis	rs4950322	0.570	rs72691095	chr1:146769990	G/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs992157	0.965	rs13427681	chr2:219167563	G/C	cg04731861	chr2:219085781	ARPC2	-0.41	-9.73	-0.41	1.74e-20	Colorectal cancer;
LGG	cis	rs2275620	1.000	rs2275620	chr10:96802598	A/T	cg09036531	chr10:96991505	NA	0.42	7.53	0.33	2.72e-13	Gout;
LGG	cis	rs9397585	0.857	rs1338070	chr6:153365841	G/T	cg17707550	chr6:153380415	RGS17	0.63	14.85	0.57	4.56e-41	Body mass index;
LGG	cis	rs72945132	0.882	rs61260732	chr11:70162145	G/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	trans	rs1814175	0.817	rs11518158	chr11:49985633	G/T	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs875971	1.000	rs12533997	chr7:65965377	A/G	cg18876405	chr7:65276391	NA	0.55	9.86	0.42	5.93e-21	Aortic root size;
LGG	cis	rs11874712	1.000	rs3765636	chr18:43653660	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.95	-0.45	5.7e-25	Migraine - clinic-based;
LGG	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	1.91e-19	Diabetic retinopathy;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.64	0.65	2.85e-58	Menopause (age at onset);
LGG	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	12.19	0.49	7.99e-30	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs9329221	0.710	rs11249995	chr8:10238922	T/C	cg16141378	chr3:129829833	LOC729375	-0.32	-6.84	-0.3	2.58e-11	Neuroticism;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3099143	1.000	rs1398241	chr15:77153386	C/T	cg21673338	chr15:77095150	SCAPER	-0.66	-10.54	-0.44	2.03e-23	Recalcitrant atopic dermatitis;
LGG	cis	rs7635838	0.718	rs2606736	chr3:11400249	C/T	cg00170343	chr3:11313890	ATG7	0.46	7.88	0.34	2.34e-14	HDL cholesterol;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg01145232	chr6:150245071	RAET1G	0.32	6.8	0.3	3.19e-11	Testicular germ cell tumor;
LGG	cis	rs7572733	0.534	rs1589162	chr2:198782692	A/G	cg00792783	chr2:198669748	PLCL1	0.68	10.88	0.45	1.01e-24	Dermatomyositis;
LGG	cis	rs11148252	0.846	rs7333451	chr13:53047709	G/A	cg00495681	chr13:53174319	NA	0.57	10.64	0.44	8.43e-24	Lewy body disease;
LGG	cis	rs1519814	0.654	rs1401810	chr8:121015820	C/T	cg22335954	chr8:121166405	COL14A1	-0.49	-8.67	-0.37	7.6e-17	Breast cancer;
LGG	cis	rs559928	1.000	rs72926050	chr11:64143574	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.53	0.33	2.62e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg08742575	chr21:47604166	C21orf56	0.49	8.48	0.37	3.15e-16	Testicular germ cell tumor;
LGG	cis	rs3796619	0.503	rs13147452	chr4:1078124	G/A	cg27284194	chr4:1044797	NA	0.78	19.35	0.67	1.44e-61	Recombination rate (males);
LGG	cis	rs6429082	0.714	rs184108	chr1:235646160	A/G	cg26050004	chr1:235667680	B3GALNT2	0.61	10.28	0.43	1.86e-22	Adiposity;
LGG	trans	rs12579753	0.917	rs2401003	chr12:82215192	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.87	-0.34	2.56e-14	Resting heart rate;
LGG	cis	rs6952808	0.756	rs13234214	chr7:1878860	C/T	cg13880726	chr7:1868755	MAD1L1	0.5	8.56	0.37	1.73e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6912958	0.558	rs7741825	chr6:88327338	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.44	-7.61	-0.33	1.52e-13	Monocyte percentage of white cells;
LGG	cis	rs2117029	0.782	rs6580699	chr12:49478812	G/T	cg24176009	chr12:49580217	TUBA1A	-0.45	-8.31	-0.36	1.08e-15	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.675	rs1684258	chr11:49340020	G/A	cg11707556	chr5:10655725	ANKRD33B	0.58	9.34	0.4	4.13e-19	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs35198334	chr3:10104553	G/C	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs4936894	0.500	rs10790668	chr11:124179502	G/A	cg27160556	chr11:124181099	OR8D1	-0.46	-10.58	-0.44	1.43e-23	Aging (time to death);
LGG	cis	rs4478858	0.684	rs7515988	chr1:31731061	C/T	cg19084893	chr1:31688959	NA	-0.31	-6.8	-0.3	3.16e-11	Alcohol dependence;
LGG	cis	rs7084402	0.967	rs1896243	chr10:60276291	C/T	cg07615347	chr10:60278583	BICC1	-0.63	-18.18	-0.65	4.01e-56	Refractive error;
LGG	cis	rs459571	1.000	rs459571	chr9:136912626	C/T	cg13789015	chr9:136890014	NCRNA00094	0.58	10.92	0.45	7.23e-25	Platelet distribution width;
LGG	cis	rs1008375	1.000	rs4698634	chr4:17630192	A/C	cg15017067	chr4:17643749	FAM184B	-0.3	-7.06	-0.31	6.2e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.557	rs1680033	chr4:1243404	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.48	-8.67	-0.37	7.34e-17	Obesity-related traits;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1023500	0.573	rs8135801	chr22:42475568	A/G	cg04733989	chr22:42467013	NAGA	-0.57	-10.33	-0.43	1.24e-22	Schizophrenia;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg17951613	chr5:131705445	SLC22A5	0.64	7.35	0.32	8.79e-13	Rheumatoid arthritis;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.44	8.68	0.37	6.83e-17	Schizophrenia;
LGG	cis	rs2976388	1.000	rs2920293	chr8:143765414	C/G	cg06565975	chr8:143823917	SLURP1	-0.41	-10.36	-0.43	9.31e-23	Urinary tract infection frequency;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.93	-20.48	-0.69	7.55e-67	Prudent dietary pattern;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg08621203	chr6:150244597	RAET1G	0.45	7.6	0.33	1.69e-13	Lung cancer;
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9894429	0.752	rs7502883	chr17:79588557	T/C	cg18240062	chr17:79603768	NPLOC4	0.82	15.48	0.58	6.99e-44	Eye color traits;
LGG	trans	rs1032833	0.732	rs116051947	chr2:180095061	T/C	cg23654767	chr2:101192981	PDCL3	0.66	7.77	0.34	5.2e-14	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs1971762	0.545	rs9788134	chr12:54046067	A/T	cg06632207	chr12:54070931	ATP5G2	0.24	7.47	0.33	3.89e-13	Height;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01068136	chr10:115614374	DCLRE1A;NHLRC2	-0.4	-6.81	-0.3	3.07e-11	Menarche (age at onset);
LGG	cis	rs17270561	0.562	rs74293932	chr6:26014811	C/A	cg16482183	chr6:26056742	HIST1H1C	0.96	14.27	0.55	1.57e-38	Iron status biomarkers;
LGG	trans	rs7726839	0.540	rs56325086	chr5:640728	G/A	cg25482853	chr8:67687455	SGK3	0.94	11.81	0.48	2.55e-28	Obesity-related traits;
LGG	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg14191688	chr11:70257035	CTTN	0.55	8.31	0.36	1.07e-15	Coronary artery disease;
LGG	cis	rs7937682	1.000	rs11213980	chr11:111562692	A/T	cg09085632	chr11:111637200	PPP2R1B	1.15	25.09	0.76	2.31e-88	Primary sclerosing cholangitis;
LGG	trans	rs1032833	0.660	rs10497534	chr2:180036775	A/G	cg23654767	chr2:101192981	PDCL3	-0.71	-8.51	-0.37	2.53e-16	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2019137	0.560	rs10206269	chr2:113990393	C/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.17	0.6	6.07e-47	Lymphocyte counts;
LGG	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg09085632	chr11:111637200	PPP2R1B	1.02	19.6	0.67	9.85e-63	Primary sclerosing cholangitis;
LGG	cis	rs1577917	0.771	rs2758847	chr6:86349103	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.88	-17.29	-0.63	4.78e-52	Response to antipsychotic treatment;
LGG	trans	rs11098499	0.954	rs2892848	chr4:120381341	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs1801251	0.963	rs66549961	chr2:233602293	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.14	0.39	1.97e-18	Coronary artery disease;
LGG	cis	rs28386778	0.703	rs2286565	chr17:62010232	G/T	cg07677032	chr17:61819896	STRADA	-0.53	-9.34	-0.4	4.11e-19	Prudent dietary pattern;
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.89	0.42	4.63e-21	Prudent dietary pattern;
LGG	trans	rs7824557	0.650	rs2572406	chr8:11092252	C/G	cg06636001	chr8:8085503	FLJ10661	0.44	7.93	0.35	1.67e-14	Retinal vascular caliber;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg15948088	chr11:109293068	C11orf87	0.44	7.39	0.32	6.8e-13	Schizophrenia;
LGG	cis	rs7195287	0.779	rs2335454	chr16:2828157	G/C	cg05687563	chr16:2837658	PRSS33	0.45	8.59	0.37	1.37e-16	Eosinophil counts;
LGG	cis	rs4713118	0.513	rs149975	chr6:27986340	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.46	-6.68	-0.3	7.06e-11	Parkinson's disease;
LGG	cis	rs9788682	0.747	rs2656072	chr15:78744292	A/G	cg06917634	chr15:78832804	PSMA4	0.53	8.15	0.35	3.31e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1499614	0.803	rs1922723	chr7:66175063	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs55883249	1.000	rs75139639	chr2:9763905	A/T	cg23886495	chr2:9695866	ADAM17	0.66	9.49	0.4	1.19e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg02002194	chr4:3960332	NA	-0.47	-9.35	-0.4	3.86e-19	Systolic blood pressure;
LGG	cis	rs9747201	1.000	rs67588022	chr17:80176071	G/A	cg21453758	chr17:80185943	SLC16A3	0.34	7.22	0.32	2.12e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9880211	0.800	rs17365792	chr3:136497392	C/G	cg21827317	chr3:136751795	NA	-0.47	-6.85	-0.3	2.33e-11	Body mass index;Height;
LGG	cis	rs8141529	0.732	rs6005872	chr22:29172898	T/G	cg02153584	chr22:29168773	CCDC117	0.72	12.24	0.49	5e-30	Lymphocyte counts;
LGG	cis	rs877282	0.838	rs34912955	chr10:772222	T/C	cg17470449	chr10:769945	NA	0.65	8.11	0.35	4.44e-15	Uric acid levels;
LGG	cis	rs698813	0.572	rs6544749	chr2:44478077	G/A	cg00619915	chr2:44497795	NA	-0.6	-8.83	-0.38	2.24e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs950173	1.000	rs6716901	chr2:172673453	C/T	cg13550731	chr2:172543902	DYNC1I2	-0.72	-8.24	-0.36	1.8e-15	Hippocampal volume;
LGG	cis	rs926938	0.505	rs360629	chr1:115414733	A/G	cg12756093	chr1:115239321	AMPD1	0.44	8.28	0.36	1.35e-15	Autism;
LGG	cis	rs875971	0.862	rs801206	chr7:66021966	C/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.31	-0.36	1.07e-15	Aortic root size;
LGG	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg05044414	chr3:183734942	ABCC5	-0.56	-10.92	-0.45	7.1e-25	Anterior chamber depth;
LGG	cis	rs9462027	0.628	rs9348950	chr6:34673678	G/A	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.96	0.45	5.39e-25	Systemic lupus erythematosus;
LGG	trans	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.24	0.39	8.74e-19	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs2839186	0.933	rs4818832	chr21:47708634	C/T	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs4481887	0.927	rs4453081	chr1:248475691	C/G	cg13385794	chr1:248469461	NA	0.48	7.96	0.35	1.36e-14	Common traits (Other);
LGG	cis	rs11190604	1.000	rs2495734	chr10:102338686	G/A	cg07570687	chr10:102243282	WNT8B	0.42	7.18	0.32	2.76e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12493885	0.585	rs7641229	chr3:153634555	T/C	cg12800244	chr3:153838788	SGEF	-0.58	-6.93	-0.31	1.46e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	-0.36	-9.92	-0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs721399	1.000	rs4646250	chr8:18260598	G/A	cg18736775	chr8:18248649	NAT2	0.51	8.99	0.39	6.12e-18	Blood metabolite levels;
LGG	cis	rs3816183	1.000	rs10174617	chr2:43016065	G/A	cg14631114	chr2:43023945	NA	0.51	9.6	0.41	4.87e-20	Hypospadias;
LGG	cis	rs12780845	0.540	rs3824632	chr10:17230999	A/G	cg01003015	chr10:17271136	VIM	0.44	7.55	0.33	2.36e-13	Homocysteine levels;
LGG	cis	rs13191362	1.000	rs34594856	chr6:163051845	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.78	0.3	3.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2050392	0.624	rs2489842	chr10:30721991	T/C	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.42	-0.5	9.2e-31	Inflammatory bowel disease;
LGG	cis	rs7011049	0.818	rs112140190	chr8:53866713	C/T	cg26025543	chr8:53854495	NA	0.58	8.15	0.35	3.41e-15	Systolic blood pressure;
LGG	trans	rs11098499	0.954	rs28429722	chr4:120300093	G/A	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs208520	0.690	rs4618506	chr6:66756889	A/C	cg07460842	chr6:66804631	NA	-0.94	-17.63	-0.63	1.39e-53	Exhaled nitric oxide output;
LGG	trans	rs9858542	0.953	rs9878943	chr3:49434654	G/A	cg21659725	chr3:3221576	CRBN	-0.63	-10.13	-0.43	6.55e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.1	0.43	8e-22	Diabetic retinopathy;
LGG	trans	rs7395662	1.000	rs10742862	chr11:48649316	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.48	-0.33	3.89e-13	HDL cholesterol;
LGG	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg27119904	chr13:114814333	RASA3	0.36	7.62	0.33	1.42e-13	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs1799949	0.931	rs9891977	chr17:41437398	A/G	cg05368731	chr17:41323189	NBR1	0.9	17.1	0.62	3.62e-51	Menopause (age at onset);
LGG	cis	rs6920965	0.507	rs9401853	chr6:126215197	A/T	cg05901451	chr6:126070800	HEY2	-0.45	-7.75	-0.34	5.87e-14	High light scatter reticulocyte count;
LGG	cis	rs2072499	0.931	rs1052053	chr1:156202173	A/G	cg24450063	chr1:156163899	SLC25A44	1.09	24.7	0.75	1.57e-86	Testicular germ cell tumor;
LGG	cis	rs35264875	1.000	rs1542334	chr11:68850773	G/C	cg23845249	chr11:68861649	NA	0.45	8.09	0.35	5.36e-15	Blond vs. brown hair color;
LGG	cis	rs7208859	0.623	rs11651857	chr17:28926362	G/T	cg13385521	chr17:29058706	SUZ12P	0.9	10.23	0.43	2.69e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7618915	0.571	rs17264436	chr3:52610651	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.2e-19	Bipolar disorder;
LGG	cis	rs7444	0.882	rs5754387	chr22:21974703	C/G	cg15846791	chr22:21984385	YDJC	0.44	6.79	0.3	3.42e-11	Systemic lupus erythematosus;
LGG	cis	rs12200782	0.649	rs9467735	chr6:26379814	T/A	cg27193005	chr6:26382695	BTN2A2	-0.5	-7.21	-0.32	2.24e-12	Small cell lung carcinoma;
LGG	cis	rs7944584	0.632	rs11039159	chr11:47294021	G/T	cg20307385	chr11:47447363	PSMC3	0.63	12.13	0.49	1.39e-29	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs6598955	0.671	rs12142535	chr1:26589698	T/A	cg07461501	chr17:79650226	HGS;ARL16	-0.76	-13.04	-0.52	2.54e-33	Obesity-related traits;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs13108904	0.901	rs13124847	chr4:1278206	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.63	0.59	1.59e-44	Obesity-related traits;
LGG	cis	rs1971762	0.545	rs7297461	chr12:54047178	A/T	cg06632207	chr12:54070931	ATP5G2	0.24	7.35	0.32	8.96e-13	Height;
LGG	cis	rs752010	0.746	rs10890146	chr1:42089389	G/A	cg06885757	chr1:42089581	HIVEP3	0.57	13.36	0.53	1.16e-34	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs17253792	0.822	rs77599953	chr14:56058905	C/T	cg01858014	chr14:56050164	KTN1	-0.91	-12.44	-0.5	7.22e-31	Putamen volume;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg13395646	chr4:1353034	KIAA1530	-0.42	-6.94	-0.31	1.33e-11	Obesity-related traits;
LGG	cis	rs1953600	1.000	rs2573346	chr10:81918041	G/A	cg04850286	chr10:81895943	PLAC9	-0.46	-10.14	-0.43	5.68e-22	Sarcoidosis;
LGG	trans	rs2727020	0.704	rs2988340	chr11:49176057	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.66	-13.06	-0.52	2.14e-33	Coronary artery disease;
LGG	trans	rs66887589	0.967	rs2892869	chr4:120521297	T/C	cg25214090	chr10:38739885	LOC399744	-0.36	-6.67	-0.3	7.51e-11	Diastolic blood pressure;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-6.89	-0.31	1.79e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4555082	0.718	rs75139030	chr14:105710853	A/AG	cg27165867	chr14:105738592	BRF1	-0.46	-7.48	-0.33	3.85e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2282300	0.739	rs1222211	chr11:30362239	A/C	cg06241208	chr11:30344200	C11orf46	-0.51	-6.65	-0.3	8.24e-11	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.539	rs4470910	chr7:2071723	C/T	cg23422044	chr7:1970798	MAD1L1	-0.64	-10.95	-0.45	5.58e-25	Bipolar disorder;
LGG	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg20493526	chr2:3714936	ALLC	0.38	7.88	0.34	2.37e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs11190604	1.000	rs1080698	chr10:102295114	G/T	cg07080220	chr10:102295463	HIF1AN	0.7	12.0	0.49	4.4e-29	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs9329221	0.620	rs6601427	chr8:10156025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.68	-0.34	9.73e-14	Neuroticism;
LGG	cis	rs11583043	0.958	rs11583674	chr1:101396560	C/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.39	7.08	0.31	5.53e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs11122272	0.766	rs2739511	chr1:231526490	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.63	-0.48	1.36e-27	Hemoglobin concentration;
LGG	cis	rs3733585	0.673	rs4519796	chr4:9955936	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg02475777	chr4:1388615	CRIPAK	0.42	7.89	0.34	2.15e-14	Longevity;
LGG	cis	rs10088262	0.629	rs7827665	chr8:124804190	G/A	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.6	-0.44	1.23e-23	Pancreatic cancer;
LGG	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg16980736	chr17:78789706	RPTOR	0.67	8.63	0.37	1.02e-16	Myopia (pathological);
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.49	-0.33	3.44e-13	Personality dimensions;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg05665937	chr4:1216051	CTBP1	0.51	9.33	0.4	4.35e-19	Obesity-related traits;
LGG	cis	rs7226408	0.802	rs72887098	chr18:34511073	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs968719	chr17:61908271	C/T	cg17202724	chr17:61916730	SMARCD2	-0.65	-15.21	-0.58	1.16e-42	Prudent dietary pattern;
LGG	cis	rs798554	0.757	rs1182178	chr7:2873763	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.68	0.37	6.62e-17	Height;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.93	-0.31	1.4e-11	Prostate cancer;
LGG	cis	rs9549367	0.789	rs12584008	chr13:113881228	C/T	cg00898013	chr13:113819073	PROZ	-0.44	-8.58	-0.37	1.42e-16	Platelet distribution width;
LGG	trans	rs35110281	0.667	rs4818859	chr21:45117120	G/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	9.83	0.42	7.98e-21	Mean corpuscular volume;
LGG	trans	rs11039798	1.000	rs12223271	chr11:48417420	G/C	cg15704280	chr7:45808275	SEPT13	0.76	8.94	0.38	9.52e-18	Axial length;
LGG	cis	rs2115536	0.967	rs4778734	chr15:80210851	A/G	cg11839771	chr15:80205821	ST20	-0.37	-7.95	-0.35	1.46e-14	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7605378	1.000	rs7605378	chr2:200676926	A/C	cg23649088	chr2:200775458	C2orf69	0.53	8.98	0.38	7.06e-18	Osteoporosis;
LGG	cis	rs6502050	0.835	rs34960918	chr17:80113925	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs765787	0.530	rs11854690	chr15:45516016	C/T	cg25801113	chr15:45476975	SHF	0.88	20.15	0.68	2.83e-65	Uric acid levels;
LGG	cis	rs7503807	0.688	rs901060	chr17:78594990	G/A	cg06872548	chr17:78716983	RPTOR	0.39	8.79	0.38	2.97e-17	Obesity;
LGG	trans	rs62103177	0.759	rs9956512	chr18:77607517	G/A	cg05926928	chr17:57297772	GDPD1	1.41	23.22	0.73	1.17e-79	Opioid sensitivity;
LGG	trans	rs10838798	0.504	rs11039632	chr11:48297280	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-9.07	-0.39	3.41e-18	Height;
LGG	cis	rs754466	0.651	rs10824582	chr10:79603688	T/C	cg17075019	chr10:79541650	NA	-0.96	-20.36	-0.69	2.7500000000000003e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17818399	0.815	rs17768138	chr2:46868217	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.42	6.72	0.3	5.28e-11	Height;
LGG	cis	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg24623649	chr8:11872141	NA	0.3	6.97	0.31	1.13e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg00717180	chr2:96193071	NA	-0.47	-8.9	-0.38	1.26e-17	HDL cholesterol;
LGG	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg16339924	chr4:17578868	LAP3	0.6	10.49	0.44	3.08e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6977660	0.714	rs17141945	chr7:19805056	T/A	cg07541023	chr7:19748670	TWISTNB	0.59	8.3	0.36	1.12e-15	Thyroid stimulating hormone;
LGG	cis	rs4671458	0.948	rs17348207	chr2:63460744	A/G	cg17519650	chr2:63277830	OTX1	-0.64	-8.29	-0.36	1.26e-15	Subjective well-being;
LGG	cis	rs2282802	0.685	rs10077671	chr5:139689505	C/T	cg26211634	chr5:139558579	C5orf32	0.34	7.62	0.33	1.43e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4689592	0.503	rs11937667	chr4:7057037	C/G	cg03847636	chr4:7070632	GRPEL1	0.53	6.73	0.3	5.09e-11	Monocyte percentage of white cells;
LGG	cis	rs11645898	0.683	rs72787038	chr16:72066102	A/C	cg14768367	chr16:72042858	DHODH	-0.71	-9.82	-0.42	8.09e-21	Blood protein levels;
LGG	cis	rs2832191	0.671	rs2832213	chr21:30512914	A/G	cg24692254	chr21:30365293	RNF160	-0.72	-14.1	-0.55	7.87e-38	Dental caries;
LGG	trans	rs2975734	0.709	rs6988826	chr8:10109625	T/C	cg06636001	chr8:8085503	FLJ10661	-0.48	-7.91	-0.35	1.92e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9287719	0.967	rs2110778	chr2:10748970	A/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs2842992	0.830	rs2842974	chr6:160159034	C/T	cg11366901	chr6:160182831	ACAT2	1.04	16.9	0.62	3.06e-50	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.724	rs73603871	chr8:58107612	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg00599393	chr8:22457479	C8orf58	-0.43	-7.99	-0.35	1.06e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3733585	0.699	rs7694997	chr4:9947811	A/G	cg25986240	chr4:9926439	SLC2A9	0.39	8.18	0.36	2.75e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1799949	1.000	rs35070007	chr17:41316747	C/G	cg12708336	chr17:41446283	NA	0.33	7.95	0.35	1.43e-14	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2463822	0.925	rs17157227	chr11:62169772	A/G	cg06239285	chr11:62104954	ASRGL1	1.12	15.16	0.58	1.86e-42	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.68	-9.66	-0.41	3.05e-20	Ulcerative colitis;
LGG	cis	rs9807841	0.670	rs2360942	chr19:10780802	G/A	cg17710535	chr19:10819994	QTRT1	0.44	6.84	0.3	2.57e-11	Inflammatory skin disease;
LGG	cis	rs7582180	0.629	rs12989897	chr2:100940998	A/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7980687	0.662	rs585522	chr12:123550813	A/G	cg00376283	chr12:123451042	ABCB9	0.65	10.45	0.44	4.14e-23	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs12681288	0.550	rs12674921	chr8:957969	A/C	cg04851639	chr8:1020857	NA	-0.33	-6.86	-0.3	2.19e-11	Schizophrenia;
LGG	cis	rs12681288	0.676	rs2701923	chr8:994605	A/G	cg15309053	chr8:964076	NA	0.38	7.64	0.33	1.27e-13	Schizophrenia;
LGG	trans	rs4714291	1.000	rs1546965	chr6:39999149	C/T	cg02267698	chr19:7991119	CTXN1	-0.52	-7.77	-0.34	5.07e-14	Strep throat;
LGG	cis	rs7582180	1.000	rs7582180	chr2:100912463	C/T	cg08297393	chr2:100937505	LONRF2	0.56	9.54	0.41	8.19e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.811	rs11520277	chr12:38359611	G/A	cg06521331	chr12:34319734	NA	-0.5	-8.83	-0.38	2.22e-17	Bladder cancer;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.23e-12	Lung cancer;
LGG	cis	rs2880765	0.527	rs35184622	chr15:86073035	A/G	cg10818794	chr15:86012489	AKAP13	-0.41	-8.23	-0.36	1.92e-15	Coronary artery disease;
LGG	cis	rs12497850	0.805	rs6446198	chr3:49007638	T/A	cg07636037	chr3:49044803	WDR6	1.09	27.84	0.79	6.33e-101	Parkinson's disease;
LGG	cis	rs6952808	0.692	rs59619245	chr7:2068630	C/T	cg04267008	chr7:1944627	MAD1L1	-0.69	-12.18	-0.49	8.55e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.694	rs202656	chr22:41842203	T/A	cg17376030	chr22:41985996	PMM1	-0.55	-8.86	-0.38	1.66e-17	Vitiligo;
LGG	cis	rs6032067	0.714	rs2071651	chr20:43853153	T/G	cg10761708	chr20:43804764	PI3	0.58	8.87	0.38	1.65e-17	Blood protein levels;
LGG	cis	rs2133450	0.967	rs56342345	chr3:7351028	G/A	cg19930620	chr3:7340148	GRM7	-0.38	-8.41	-0.36	4.96e-16	Early response to risperidone in schizophrenia;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.5	7.73	0.34	6.92e-14	Renal function-related traits (BUN);
LGG	cis	rs3008870	1.000	rs2985825	chr1:67412822	T/G	cg08660285	chr1:67390436	MIER1;WDR78	1.03	23.35	0.74	2.84e-80	Lymphocyte percentage of white cells;
LGG	cis	rs61931739	0.649	rs12424056	chr12:33714314	G/A	cg06521331	chr12:34319734	NA	0.39	6.8	0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg04362960	chr10:104952993	NT5C2	-0.57	-10.85	-0.45	1.41e-24	Arsenic metabolism;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg21724239	chr8:58056113	NA	0.5	7.47	0.33	3.98e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9814567	0.762	rs13067564	chr3:134209956	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.69	11.01	0.46	3.46e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4330281	0.647	rs4128509	chr3:17731099	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs9303280	0.806	rs34189114	chr17:38032460	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.17	-0.32	3.04e-12	Self-reported allergy;
LGG	cis	rs9467711	0.651	rs16891334	chr6:26124303	T/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.73	7.44	0.33	5.05e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs882300	0.967	rs12691876	chr2:136963794	A/G	cg07169764	chr2:136633963	MCM6	0.44	7.12	0.31	4.06e-12	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs6504108	0.624	rs1377201	chr17:46312128	T/C	cg02219949	chr17:45927392	SP6	0.43	7.99	0.35	1.06e-14	Body mass index;
LGG	cis	rs950027	0.787	rs1547487	chr15:45723983	A/G	cg26924012	chr15:45694286	SPATA5L1	0.63	11.06	0.46	2.2e-25	Response to fenofibrate (adiponectin levels);
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg07414643	chr4:187882934	NA	-0.55	-11.16	-0.46	9.14e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs769267	0.930	rs10419912	chr19:19597055	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.53	-14.42	-0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs6460942	0.915	rs17541464	chr7:12462675	A/G	cg06484146	chr7:12443880	VWDE	-0.36	-7.0	-0.31	9.09e-12	Coronary artery disease;
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg08888203	chr3:10149979	C3orf24	0.55	9.24	0.39	8.88e-19	Alzheimer's disease;
LGG	cis	rs4302748	0.862	rs57007022	chr7:36187369	C/T	cg24442661	chr7:36192818	EEPD1	0.56	7.34	0.32	9.65e-13	Platelet count;
LGG	trans	rs6089829	0.962	rs7267951	chr20:61665979	A/G	cg08862035	chr2:2617432	NA	0.42	6.89	0.3	1.88e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg09883264	chr5:141489170	NDFIP1	0.44	7.27	0.32	1.52e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6732160	0.934	rs2421390	chr2:73379103	T/C	cg01422370	chr2:73384389	NA	0.53	10.16	0.43	5.21e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6456042	1.000	rs6456040	chr6:166534636	T/C	cg11088901	chr6:166572345	T	-0.36	-7.59	-0.33	1.72e-13	Asthma;
LGG	cis	rs10754283	0.967	rs7523046	chr1:90109499	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.24	0.49	4.9e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3858526	0.959	rs10838795	chr11:5920721	A/G	cg25319279	chr11:5960081	NA	0.53	8.12	0.35	4.18e-15	DNA methylation (variation);
LGG	cis	rs10752881	1.000	rs6701400	chr1:182977197	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs73198271	0.700	rs10090152	chr8:8652104	C/A	cg01851573	chr8:8652454	MFHAS1	0.38	6.9	0.31	1.73e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7666738	0.830	rs4472144	chr4:98956494	G/A	cg05340658	chr4:99064831	C4orf37	0.48	7.85	0.34	2.88e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs1865760	0.929	rs1436307	chr6:25939723	C/T	cg03517284	chr6:25882590	NA	-0.38	-6.78	-0.3	3.62e-11	Height;
LGG	trans	rs453301	0.653	rs7005133	chr8:8901222	T/G	cg02002194	chr4:3960332	NA	-0.47	-8.88	-0.38	1.45e-17	Joint mobility (Beighton score);
LGG	cis	rs8062405	0.755	rs4787456	chr16:28559573	C/T	cg16576597	chr16:28551801	NUPR1	0.43	10.21	0.43	3.38e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.667	rs73014331	chr1:152964533	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-8.91	-0.38	1.17e-17	Inflammatory skin disease;
LGG	cis	rs7824557	0.767	rs28507159	chr8:11166076	C/T	cg15596359	chr8:11213517	TDH	-0.34	-6.87	-0.3	2.14e-11	Retinal vascular caliber;
LGG	cis	rs2857078	0.720	rs9906669	chr17:42305706	A/G	cg19774624	chr17:42201019	HDAC5	-0.56	-9.96	-0.42	2.65e-21	Red cell distribution width;Reticulocyte count;
LGG	cis	rs7662987	0.517	rs1311617	chr4:100012425	T/G	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.79e-20	Smoking initiation;
LGG	cis	rs4732038	0.647	rs2161803	chr7:134261097	C/G	cg06906464	chr7:134288099	NA	-0.64	-17.78	-0.64	2.74e-54	Longevity;
LGG	cis	rs68170813	0.559	rs80017637	chr7:107050660	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.22	-0.43	3.14e-22	Coronary artery disease;
LGG	cis	rs514024	0.729	rs4836575	chr9:130446493	C/T	cg13643465	chr9:130375613	STXBP1	-0.63	-11.93	-0.48	8.43e-29	Eating disorders (purging via substances);
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.7	-13.44	-0.53	5.52e-35	Personality dimensions;
LGG	cis	rs1552244	0.572	rs68013239	chr3:10165711	G/T	cg00149659	chr3:10157352	C3orf10	1.19	13.82	0.54	1.35e-36	Alzheimer's disease;
LGG	trans	rs9650657	0.645	rs56057779	chr8:10516880	G/C	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.61	-0.33	1.55e-13	Neuroticism;
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs7077256	0.564	rs10509188	chr10:65218797	G/A	cg02276361	chr10:65351566	REEP3	-0.34	-6.9	-0.31	1.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs2903154	chr4:99048151	A/G	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.01e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9393692	0.846	rs7771202	chr6:26279907	A/G	cg15665833	chr6:26285013	NA	0.39	7.69	0.34	8.63e-14	Educational attainment;
LGG	cis	rs4862750	0.872	rs6553029	chr4:187876470	G/T	cg10295955	chr4:187884368	NA	1.14	29.21	0.81	4e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4423214	0.840	rs1790328	chr11:71148038	G/A	cg10847948	chr11:71163743	NADSYN1	0.63	11.35	0.47	1.59e-26	Vitamin D levels;
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.82	0.34	3.5e-14	Bipolar disorder;
LGG	cis	rs881375	0.967	rs7875829	chr9:123660398	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs2290402	0.536	rs60492656	chr4:875008	C/T	cg09237302	chr4:906077	GAK	-0.44	-7.46	-0.33	4.17e-13	Type 2 diabetes;
LGG	cis	rs11098499	0.648	rs2002047	chr4:120257228	A/G	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs9788682	0.747	rs4887069	chr15:78909070	A/G	cg06917634	chr15:78832804	PSMA4	-0.55	-8.29	-0.36	1.25e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11166927	0.703	rs2126127	chr8:140788362	G/A	cg16909799	chr8:140841666	TRAPPC9	0.44	8.87	0.38	1.57e-17	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs61931739	0.517	rs12815556	chr12:34319670	G/A	cg06521331	chr12:34319734	NA	-0.66	-12.24	-0.49	4.65e-30	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg17971929	chr21:40555470	PSMG1	0.88	17.79	0.64	2.47e-54	Cognitive function;
LGG	cis	rs4481887	1.000	rs10736378	chr1:248455769	T/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.63	-0.41	4.09e-20	Common traits (Other);
LGG	cis	rs28386778	0.897	rs1062787	chr17:61896004	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs780096	0.546	rs7563162	chr2:27631191	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.02	-0.35	8.85e-15	Total body bone mineral density;
LGG	cis	rs826838	0.967	rs11183514	chr12:38760744	A/T	cg26384229	chr12:38710491	ALG10B	1.07	28.86	0.8	1.49e-105	Heart rate;
LGG	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	trans	rs11098499	1.000	rs1011054	chr4:120202387	A/G	cg25214090	chr10:38739885	LOC399744	-0.66	-11.62	-0.48	1.49e-27	Corneal astigmatism;
LGG	cis	rs12477438	0.765	rs6740054	chr2:99576631	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg11859384	chr17:80120422	CCDC57	-0.46	-7.67	-0.34	1.02e-13	Life satisfaction;
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.5	-0.33	3.19e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6988985	0.728	rs28813538	chr8:143937844	T/G	cg10324643	chr8:143916377	GML	0.39	7.81	0.34	3.84e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs12421382	0.615	rs1386718	chr11:109508311	T/C	cg04861929	chr11:109293070	C11orf87	0.5	8.69	0.37	6.2e-17	Schizophrenia;
LGG	trans	rs11098499	0.789	rs1980024	chr4:120253047	C/T	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.4e-25	Corneal astigmatism;
LGG	cis	rs6594713	0.756	rs10053341	chr5:112784007	G/T	cg12552261	chr5:112820674	MCC	0.62	8.57	0.37	1.56e-16	Brain cytoarchitecture;
LGG	cis	rs1784581	0.588	rs9885762	chr6:162411954	G/A	cg17173639	chr6:162384350	PARK2	0.64	13.52	0.53	2.5e-35	Itch intensity from mosquito bite;
LGG	cis	rs9715521	0.588	rs11731207	chr4:59852246	G/A	cg11281224	chr4:60001000	NA	-0.57	-10.16	-0.43	4.86e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs9467711	0.651	rs13212534	chr6:25983010	G/A	cg06606381	chr12:133084897	FBRSL1	-1.01	-8.18	-0.36	2.72e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7192750	0.586	rs8063324	chr16:71967599	T/G	cg06353428	chr16:71660113	MARVELD3	0.67	10.68	0.44	5.92e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24399406	chr17:33895357	NA	0.42	7.02	0.31	8.01e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg04117972	chr1:227635322	NA	0.67	10.35	0.43	9.72e-23	Major depressive disorder;
LGG	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-14.04	-0.55	1.54e-37	Morning vs. evening chronotype;
LGG	cis	rs41271473	0.687	rs35637401	chr1:228883578	T/C	cg16512390	chr1:228756714	NA	0.42	6.64	0.3	8.61e-11	Chronic lymphocytic leukemia;
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg20821713	chr7:1055600	C7orf50	-0.52	-9.71	-0.41	2.13e-20	Bronchopulmonary dysplasia;
LGG	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg06417478	chr19:12876846	HOOK2	0.41	6.8	0.3	3.18e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs951366	0.617	rs823074	chr1:205774839	T/C	cg24503407	chr1:205819492	PM20D1	0.96	27.11	0.78	1.29e-97	Menarche (age at onset);
LGG	cis	rs6502050	0.635	rs11867440	chr17:80147185	A/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.66	-0.34	1.09e-13	Life satisfaction;
LGG	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.11	0.43	7.4e-22	Motion sickness;
LGG	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg15320455	chr10:103880129	LDB1	-0.64	-8.95	-0.38	8.88e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2075371	1.000	rs2075372	chr7:133984432	C/T	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	cis	rs9660992	0.710	rs1668872	chr1:205236069	G/A	cg21545522	chr1:205238299	TMCC2	0.49	8.98	0.39	6.64e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7089973	0.604	rs58587374	chr10:116597572	A/G	cg08188268	chr10:116634841	FAM160B1	0.33	7.22	0.32	2.18e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs4740619	0.741	rs10756728	chr9:15973288	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.95	-0.42	2.79e-21	Body mass index;
LGG	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.87	0.34	2.47e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9547692	1.000	rs604279	chr13:37471254	G/C	cg01493522	chr13:37497338	NA	-0.48	-8.45	-0.37	3.93e-16	Coronary artery disease;
LGG	cis	rs4555082	0.830	rs3803319	chr14:105752458	G/A	cg13114125	chr14:105738426	BRF1	-0.84	-15.8	-0.59	2.67e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7666738	0.830	rs10007261	chr4:98926155	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7717393	0.881	rs7725923	chr5:155770753	A/C	cg12904904	chr5:155754151	SGCD	0.62	7.26	0.32	1.64e-12	Egg allergy;
LGG	cis	rs4951018	0.853	rs1573104	chr1:205636907	A/C	cg14159672	chr1:205819179	PM20D1	-0.36	-6.91	-0.31	1.57e-11	Prostate-specific antigen levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02594940	chr19:35759230	USF2	0.38	6.72	0.3	5.25e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs57378064	chr8:58169844	C/G	cg22535103	chr8:58192502	C8orf71	-0.95	-15.3	-0.58	4.55e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17663101	chr3:49131524	QRICH1	0.47	7.8	0.34	4.22e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs2354432	0.607	rs58941651	chr1:146784919	T/C	cg25205988	chr1:146714368	CHD1L	-1.43	-14.66	-0.56	3.1e-40	Mitochondrial DNA levels;
LGG	cis	rs7107174	1.000	rs2244508	chr11:77948515	T/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.74	-0.34	6.31e-14	Testicular germ cell tumor;
LGG	trans	rs7726839	0.540	rs72703095	chr5:601789	T/C	cg25482853	chr8:67687455	SGK3	0.94	11.9	0.48	1.15e-28	Obesity-related traits;
LGG	cis	rs2070488	0.761	rs6807940	chr3:38460062	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.7	13.27	0.52	2.69e-34	Electrocardiographic conduction measures;
LGG	cis	rs2131877	0.830	rs1874100	chr3:194849022	G/A	cg07250128	chr3:194833983	C3orf21	0.4	6.67	0.3	7.32e-11	Non-small cell lung cancer;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02018176	chr4:1364513	KIAA1530	0.46	10.94	0.45	5.99e-25	Longevity;
LGG	cis	rs6693567	0.545	rs11205382	chr1:150442466	G/A	cg15654264	chr1:150340011	RPRD2	-0.32	-6.66	-0.3	7.69e-11	Migraine;
LGG	cis	rs2114646	0.731	rs55843487	chr2:170632031	T/C	cg17598339	chr2:170624727	NA	0.36	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	cis	rs910316	0.763	rs735452	chr14:75497984	A/G	cg11812906	chr14:75593930	NEK9	-0.48	-8.57	-0.37	1.54e-16	Height;
LGG	cis	rs9463078	0.774	rs12199720	chr6:45307443	C/T	cg25276700	chr6:44698697	NA	0.4	8.53	0.37	2.05e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs151997	0.509	rs11744954	chr5:50296729	A/G	cg06027927	chr5:50259733	NA	-0.61	-9.02	-0.39	4.92e-18	Callous-unemotional behaviour;
LGG	cis	rs7481584	0.624	rs397919	chr11:3063094	A/C	cg25174290	chr11:3078921	CARS	-0.53	-9.78	-0.41	1.13e-20	Calcium levels;
LGG	cis	rs6976053	0.518	rs314344	chr7:100395003	G/C	cg03098644	chr7:100410630	EPHB4	-0.56	-10.7	-0.45	4.92e-24	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs9611565	0.921	rs761366	chr22:41744022	C/G	cg17376030	chr22:41985996	PMM1	0.47	7.72	0.34	7.15e-14	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04721116	chr6:143999504	PHACTR2	0.44	6.85	0.3	2.33e-11	Gut microbiome composition (summer);
LGG	cis	rs17666538	1.000	rs17666538	chr8:566207	T/C	cg23958373	chr8:599963	NA	-1.22	-10.64	-0.44	8.75e-24	IgG glycosylation;
LGG	cis	rs66569888	0.507	rs11673736	chr2:106886935	T/C	cg23109721	chr2:106886537	NA	-0.35	-6.78	-0.3	3.71e-11	Facial morphology (factor 23);
LGG	cis	rs17270561	0.609	rs1179086	chr6:25791745	A/T	cg16482183	chr6:26056742	HIST1H1C	0.54	8.72	0.38	5.02e-17	Iron status biomarkers;
LGG	cis	rs7208859	0.623	rs3794796	chr17:29130880	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.17	-0.36	2.95e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2204008	0.604	rs11172718	chr12:38069819	T/C	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	cis	rs2033711	0.755	rs4801587	chr19:58936679	C/A	cg00825309	chr19:58991885	ZNF446	-0.46	-9.14	-0.39	1.96e-18	Uric acid clearance;
LGG	cis	rs2117029	0.554	rs12306494	chr12:49530781	A/G	cg24176009	chr12:49580217	TUBA1A	0.66	12.84	0.51	1.73e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg00933542	chr6:150070202	PCMT1	0.39	7.11	0.31	4.51e-12	Lung cancer;
LGG	cis	rs10752881	0.967	rs12404594	chr1:182988027	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.21	0.39	1.12e-18	Colorectal cancer;
LGG	cis	rs7572733	0.935	rs1369512	chr2:198767132	T/A	cg00792783	chr2:198669748	PLCL1	0.47	7.94	0.35	1.49e-14	Dermatomyositis;
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg25172604	chr17:41446521	NA	-0.29	-6.66	-0.3	7.63e-11	Menopause (age at onset);
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg21724239	chr8:58056113	NA	0.58	8.45	0.37	3.95e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg11859384	chr17:80120422	CCDC57	-0.46	-7.97	-0.35	1.25e-14	Life satisfaction;
LGG	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg24848339	chr3:12840334	CAND2	0.39	8.38	0.36	6.55e-16	QRS complex (12-leadsum);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.67	0.34	9.93e-14	Longevity;
LGG	cis	rs709400	0.930	rs2274268	chr14:104029378	C/G	cg26031613	chr14:104095156	KLC1	1.14	26.09	0.77	6.01e-93	Body mass index;
LGG	cis	rs6429082	0.818	rs834198	chr1:235671987	A/G	cg26050004	chr1:235667680	B3GALNT2	0.62	10.26	0.43	2.16e-22	Adiposity;
LGG	cis	rs6502050	0.761	rs62078754	chr17:80058666	C/T	cg23985595	chr17:80112537	CCDC57	0.39	7.78	0.34	4.67e-14	Life satisfaction;
LGG	cis	rs60843830	1.000	rs62114505	chr2:242426	A/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	14.98	0.57	1.15e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg14789911	chr21:47582049	C21orf56	-0.52	-9.28	-0.4	6.7e-19	Testicular germ cell tumor;
LGG	cis	rs11098499	1.000	rs35643470	chr4:120184948	T/C	cg09307838	chr4:120376055	NA	0.7	11.44	0.47	7.54e-27	Corneal astigmatism;
LGG	cis	rs74781061	1.000	rs8040745	chr15:74818132	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.25	-0.32	1.79e-12	Endometriosis;
LGG	cis	rs4731207	0.596	rs7806530	chr7:124659884	C/T	cg05630886	chr7:124431682	NA	0.3	6.85	0.3	2.43e-11	Cutaneous malignant melanoma;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.28	-0.32	1.43e-12	Dementia with Lewy bodies;
LGG	cis	rs9402673	0.558	rs9688342	chr6:135323026	A/T	cg24558204	chr6:135376177	HBS1L	0.53	9.6	0.41	4.95e-20	Reticulocyte count;High light scatter reticulocyte count;
LGG	cis	rs9517320	1.000	rs9584856	chr13:99126551	G/T	cg07423050	chr13:99094983	FARP1	0.4	8.2	0.36	2.44e-15	Longevity;
LGG	cis	rs975722	0.700	rs214160	chr7:117317644	T/C	cg10524701	chr7:117356490	CTTNBP2	0.44	9.1	0.39	2.76e-18	Coronary artery disease;
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg15971980	chr6:150254442	NA	0.46	8.44	0.37	3.96e-16	Lung cancer;
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg12458913	chr13:53173898	NA	-0.56	-10.36	-0.43	9.33e-23	Lewy body disease;
LGG	cis	rs9911578	0.967	rs8082544	chr17:57185807	C/T	cg05425664	chr17:57184151	TRIM37	0.7	11.52	0.47	3.56e-27	Intelligence (multi-trait analysis);
LGG	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs6582630	0.519	rs1851130	chr12:38507819	C/T	cg04568710	chr12:38710424	ALG10B	0.36	7.4	0.33	6.6e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2153535	0.580	rs9505450	chr6:8469902	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.3	-0.58	4.72e-43	Prudent dietary pattern;
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	cis	rs9790314	0.663	rs61105146	chr3:160651949	T/A	cg03342759	chr3:160939853	NMD3	0.44	7.5	0.33	3.19e-13	Morning vs. evening chronotype;
LGG	cis	rs2976388	0.647	rs2585136	chr8:143812141	A/G	cg06565975	chr8:143823917	SLURP1	0.39	9.85	0.42	6.61e-21	Urinary tract infection frequency;
LGG	cis	rs1568889	0.592	rs7110074	chr11:28469325	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.63	9.7	0.41	2.16e-20	Bipolar disorder;
LGG	cis	rs651907	0.967	rs641432	chr3:101587566	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.43	7.49	0.33	3.46e-13	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03705718	chr2:230933322	SLC16A14	0.37	6.71	0.3	5.85e-11	Gut microbiome composition (summer);
LGG	cis	rs9381107	0.932	rs2011335	chr6:9436825	T/A	cg14735645	chr6:9486422	NA	-0.41	-7.14	-0.31	3.71e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs9560113	1.000	rs9560104	chr13:112174389	A/G	cg14952266	chr13:112191215	NA	-0.42	-7.5	-0.33	3.24e-13	Menarche (age at onset);
LGG	cis	rs2718058	0.692	rs2709117	chr7:37787807	A/G	cg15028436	chr7:37888078	TXNDC3	0.6	9.65	0.41	3.47e-20	Alzheimer's disease (late onset);
LGG	trans	rs853679	0.607	rs201002	chr6:27808192	A/G	cg08344181	chr3:125677491	NA	-0.66	-7.84	-0.34	3.06e-14	Depression;
LGG	cis	rs2839186	0.770	rs2280956	chr21:47642323	C/G	cg12016809	chr21:47604291	C21orf56	-0.54	-9.67	-0.41	2.85e-20	Testicular germ cell tumor;
LGG	cis	rs561341	1.000	rs564714	chr17:30318404	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.62	-0.44	9.9899999999999993e-24	Hip circumference adjusted for BMI;
LGG	cis	rs79349575	0.749	rs2270574	chr17:47022270	C/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs1552244	0.554	rs2272118	chr3:10049287	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.61	-10.6	-0.44	1.16e-23	Alzheimer's disease;
LGG	cis	rs12048904	0.964	rs3188491	chr1:101338482	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	9.49	0.4	1.25e-19	Multiple sclerosis;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg19626725	chr5:178986131	RUFY1	0.5	7.9	0.34	1.98e-14	Lung cancer;
LGG	cis	rs9322193	0.884	rs9480009	chr6:150079638	A/G	cg12070911	chr6:150209640	RAET1E	0.31	7.45	0.33	4.6e-13	Lung cancer;
LGG	cis	rs78456975	0.943	rs7602369	chr2:1574754	T/C	cg26248373	chr2:1572462	NA	-0.67	-8.88	-0.38	1.44e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs757081	0.667	rs569780	chr11:17206745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.54	-9.0	-0.39	5.95e-18	Systolic blood pressure;
LGG	cis	rs490234	0.902	rs10739662	chr9:128278687	T/C	cg14078157	chr9:128172775	NA	-0.4	-7.56	-0.33	2.22e-13	Mean arterial pressure;
LGG	cis	rs11155671	0.530	rs9397420	chr6:150206781	C/T	cg12070911	chr6:150209640	RAET1E	-0.27	-7.02	-0.31	8.18e-12	Testicular germ cell tumor;
LGG	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg19500275	chr17:80737654	TBCD	0.5	6.69	0.3	6.5e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg09085632	chr11:111637200	PPP2R1B	1.16	27.0	0.78	3.89e-97	Primary sclerosing cholangitis;
LGG	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.17	-0.32	3e-12	Iron status biomarkers;
LGG	cis	rs7769051	0.522	rs9493449	chr6:133126179	T/A	cg07930552	chr6:133119739	C6orf192	1.13	9.84	0.42	7.36e-21	Type 2 diabetes nephropathy;
LGG	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14298792	chr15:30685198	CHRFAM7A	-0.54	-8.02	-0.35	8.94e-15	Huntington's disease progression;
LGG	cis	rs933688	1.000	rs4382199	chr5:90744228	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	18.3	0.65	1.15e-56	Smoking behavior;
LGG	cis	rs4959677	0.689	rs1772977	chr6:2502900	T/C	cg23817096	chr6:1620687	NA	-0.33	-8.14	-0.35	3.61e-15	Orthostatic hypotension;
LGG	cis	rs12477438	0.520	rs11695751	chr2:99708247	A/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.05	26.89	0.78	1.27e-96	Chronic sinus infection;
LGG	cis	rs1008375	1.000	rs28497813	chr4:17685503	A/G	cg16339924	chr4:17578868	LAP3	0.59	10.15	0.43	5.66e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg12253571	chr8:8283032	NA	-0.31	-6.66	-0.3	7.95e-11	Mood instability;
LGG	cis	rs4782309	0.544	rs8060579	chr16:88751667	G/C	cg27087555	chr16:88793112	FAM38A	-1.25	-12.31	-0.5	2.44e-30	Hair color;
LGG	cis	rs4538187	0.950	rs35336851	chr2:64244541	T/C	cg19915305	chr2:64069682	UGP2	-0.69	-15.39	-0.58	1.83e-43	Systolic blood pressure;
LGG	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg18188782	chr20:61659543	NA	0.42	6.97	0.31	1.09e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3733585	0.673	rs6849729	chr4:9958732	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2276314	0.857	rs28379448	chr18:33604364	C/A	cg05985134	chr18:33552581	C18orf21	0.63	9.75	0.41	1.54e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9790314	0.871	rs466626	chr3:161103629	A/C	cg04691961	chr3:161091175	C3orf57	-0.56	-12.68	-0.51	7.74e-32	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs7755284	chr6:8457479	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs1728785	0.901	rs1183956	chr16:68606726	G/A	cg02972257	chr16:68554789	NA	-0.56	-8.39	-0.36	5.74e-16	Ulcerative colitis;
LGG	cis	rs11676348	1.000	rs11676348	chr2:219010146	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-9.01	-0.39	5.48e-18	Ulcerative colitis;
LGG	cis	rs13177180	0.671	rs10055339	chr5:114973120	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.46	-9.78	-0.41	1.2e-20	Conotruncal heart defects (inherited effects);
LGG	cis	rs6540556	0.906	rs6540554	chr1:209932297	A/T	cg23920097	chr1:209922102	NA	0.44	7.85	0.34	2.91e-14	Red blood cell count;
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg26354017	chr1:205819088	PM20D1	0.87	20.75	0.69	4.06e-68	Menarche (age at onset);
LGG	cis	rs4862750	0.914	rs1863405	chr4:187874528	G/T	cg27532560	chr4:187881888	NA	0.6	13.19	0.52	5.98e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4696584	0.816	rs72729002	chr4:155405405	A/G	cg13738195	chr4:155413469	DCHS2	-0.38	-7.81	-0.34	3.81e-14	Folding of antihelix;
LGG	cis	rs2797160	1.000	rs1777222	chr6:126021030	C/T	cg05901451	chr6:126070800	HEY2	0.44	7.58	0.33	1.91e-13	Endometrial cancer;
LGG	trans	rs853679	0.546	rs34194357	chr6:27818535	A/G	cg08344181	chr3:125677491	NA	-0.86	-8.39	-0.36	5.97e-16	Depression;
LGG	cis	rs11074306	0.522	rs28688261	chr15:28067999	C/T	cg26402630	chr15:28053930	OCA2	0.37	7.35	0.32	9.28e-13	Uveal melanoma;
LGG	cis	rs9300255	0.739	rs1533703	chr12:123742093	T/G	cg00376283	chr12:123451042	ABCB9	0.64	10.26	0.43	2.2e-22	Neutrophil percentage of white cells;
LGG	cis	rs11098499	0.909	rs9759478	chr4:120367998	G/A	cg09307838	chr4:120376055	NA	0.81	13.4	0.53	7.88e-35	Corneal astigmatism;
LGG	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.85	-0.3	2.39e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6878727	0.962	rs10045630	chr5:123736235	C/T	cg01806427	chr5:123737813	NA	0.32	6.69	0.3	6.31e-11	Breast cancer;
LGG	cis	rs9926296	0.533	rs7190823	chr16:89866043	A/G	cg07440826	chr16:89882328	FANCA	-0.26	-6.88	-0.3	1.91e-11	Vitiligo;
LGG	cis	rs908922	0.676	rs493133	chr1:152493875	G/C	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	cis	rs798554	0.660	rs1182175	chr7:2875026	C/T	cg19717773	chr7:2847554	GNA12	0.34	7.86	0.34	2.81e-14	Height;
LGG	cis	rs9858542	0.951	rs1800668	chr3:49395757	G/A	cg03060546	chr3:49711283	APEH	-0.63	-10.34	-0.43	1.14e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.683	rs58883273	chr8:58138275	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs76270388	chr8:58195605	T/A	cg22535103	chr8:58192502	C8orf71	-1.05	-15.94	-0.6	6.75e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	1.000	rs733739	chr21:46666210	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.37	0.43	8.42e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1046896	0.561	rs8076476	chr17:80861017	A/C	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.8	0.34	4.04e-14	Glycated hemoglobin levels;
LGG	cis	rs7833790	0.700	rs7834483	chr8:82704828	A/G	cg17211192	chr8:82754475	SNX16	-0.7	-11.85	-0.48	1.75e-28	Diastolic blood pressure;
LGG	cis	rs4819052	0.851	rs2838855	chr21:46680566	C/G	cg19498844	chr21:46707878	POFUT2;LOC642852	-0.73	-13.05	-0.52	2.22e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6076065	0.630	rs6083127	chr20:23424886	T/C	cg11657817	chr20:23433608	CST11	0.46	9.28	0.4	6.71e-19	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9443645	0.775	rs9359359	chr6:79700980	T/C	cg18132916	chr6:79620363	NA	-0.26	-6.83	-0.3	2.71e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9929218	0.954	rs9923925	chr16:68819444	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.72	-12.28	-0.5	3.25e-30	Colorectal cancer;
LGG	cis	rs6908034	0.607	rs77791009	chr6:19812602	A/G	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7202877	0.706	rs8046184	chr16:75411725	T/C	cg03315344	chr16:75512273	CHST6	0.53	7.2	0.32	2.5e-12	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs2836974	0.739	rs12482181	chr21:40548852	A/G	cg11890956	chr21:40555474	PSMG1	1.21	31.01	0.82	4.36e-115	Cognitive function;
LGG	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.26	0.63	6.59e-52	Chronic sinus infection;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.36	-0.32	8.33e-13	Lung cancer;
LGG	cis	rs1669338	0.588	rs6788122	chr3:3171897	T/C	cg16797762	chr3:3221439	CRBN	-0.89	-11.71	-0.48	6.31e-28	White matter integrity;
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg12070911	chr6:150209640	RAET1E	0.32	7.59	0.33	1.76e-13	Lung cancer;
LGG	cis	rs1552244	0.688	rs7645137	chr3:10020549	A/AT	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.19e-16	Alzheimer's disease;
LGG	cis	rs796364	0.806	rs78527234	chr2:200913453	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs9487051	0.768	rs435611	chr6:109527755	C/T	cg21918786	chr6:109611834	NA	-0.38	-6.84	-0.3	2.58e-11	Reticulocyte fraction of red cells;
LGG	cis	rs7474896	0.559	rs1208560	chr10:38221618	A/T	cg00409905	chr10:38381863	ZNF37A	0.47	7.02	0.31	8e-12	Obesity (extreme);
LGG	cis	rs12410462	0.591	rs16847991	chr1:227791096	A/G	cg04117972	chr1:227635322	NA	0.43	8.01	0.35	9.28e-15	Major depressive disorder;
LGG	cis	rs6964587	1.000	rs12704635	chr7:91737324	T/G	cg17063962	chr7:91808500	NA	0.5	9.09	0.39	2.89e-18	Breast cancer;
LGG	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg18681998	chr4:17616180	MED28	-0.74	-15.19	-0.58	1.38e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7582720	1.000	rs79539678	chr2:203740938	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4423214	0.879	rs1792283	chr11:71135136	T/C	cg05163923	chr11:71159392	DHCR7	-0.63	-10.87	-0.45	1.18e-24	Vitamin D levels;
LGG	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg26656751	chr17:43910226	CRHR1	-0.35	-7.1	-0.31	4.81e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs12618769	0.652	rs1062847	chr2:99226173	T/A	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg12458913	chr13:53173898	NA	0.61	11.7	0.48	6.99e-28	Lewy body disease;
LGG	cis	rs701145	0.640	rs2122365	chr3:153930808	T/G	cg17054900	chr3:154042577	DHX36	0.83	9.26	0.4	7.38e-19	Coronary artery disease;
LGG	cis	rs6809651	0.524	rs6444105	chr3:185811301	C/T	cg00760338	chr3:185826511	ETV5	-0.91	-15.36	-0.58	2.46e-43	Body mass index in physically active individuals;Glomerular filtration rate (creatinine);Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically inactive individuals;
LGG	cis	rs17270561	0.609	rs9358884	chr6:25756592	A/G	cg03517284	chr6:25882590	NA	-0.43	-6.98	-0.31	1.05e-11	Iron status biomarkers;
LGG	cis	rs9660992	0.710	rs4951184	chr1:205240659	A/T	cg21545522	chr1:205238299	TMCC2	0.48	8.95	0.38	8.43e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9547996	0.959	rs7321872	chr13:38246607	A/G	cg17979426	chr13:38220150	TRPC4	-0.4	-7.9	-0.34	2.04e-14	Diastolic blood pressure;
LGG	cis	rs12410462	1.000	rs75360545	chr1:227625419	T/C	cg04117972	chr1:227635322	NA	0.72	11.74	0.48	4.71e-28	Major depressive disorder;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.57	10.41	0.44	6.28e-23	Longevity;
LGG	cis	rs9462027	0.540	rs9469867	chr6:34742449	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.22	-0.46	5.12e-26	Systemic lupus erythematosus;
LGG	cis	rs9992101	0.901	rs10019833	chr4:77357592	T/C	cg17010112	chr4:77227123	STBD1	-0.36	-7.13	-0.31	3.96e-12	Creatinine levels;
LGG	cis	rs11771526	0.686	rs62457501	chr7:32329946	A/G	cg13207630	chr7:32358064	NA	0.69	7.23	0.32	1.98e-12	Body mass index;
LGG	cis	rs7667	0.959	rs1566532	chr1:19727801	C/T	cg15311933	chr1:19638897	PQLC2;AKR7A2	-0.4	-6.82	-0.3	2.8e-11	Crohn's disease and psoriasis;
LGG	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg02227867	chr8:22457446	C8orf58	-0.4	-7.52	-0.33	2.86e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9296092	0.517	rs11751684	chr6:33528739	G/T	cg13560919	chr6:33536144	NA	-1.04	-21.41	-0.71	3.26e-71	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg16141378	chr3:129829833	LOC729375	0.42	10.22	0.43	3.12e-22	Mood instability;
LGG	cis	rs67460515	0.531	rs13060601	chr3:160823159	G/A	cg03342759	chr3:160939853	NMD3	-0.73	-12.32	-0.5	2.35e-30	Parkinson's disease;
LGG	cis	rs6685188	0.920	rs6593964	chr1:205662337	G/T	cg14893161	chr1:205819251	PM20D1	0.56	8.95	0.38	8.84e-18	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg00684032	chr4:1343700	KIAA1530	0.46	8.92	0.38	1.09e-17	Obesity-related traits;
LGG	cis	rs13394619	0.935	rs6746291	chr2:11728381	T/C	cg07314298	chr2:11723111	GREB1	-0.5	-10.53	-0.44	2.12e-23	Endometriosis;
LGG	cis	rs67311347	1.000	rs28536038	chr3:40496382	A/C	cg13683864	chr3:40499215	RPL14	-1.14	-26.54	-0.78	4.94e-95	Renal cell carcinoma;
LGG	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg26818010	chr10:134567672	INPP5A	-0.72	-11.1	-0.46	1.49e-25	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12971120	0.891	rs11151961	chr18:72177340	C/T	cg26446133	chr18:72167187	CNDP2	-0.67	-13.37	-0.53	1.08e-34	Refractive error;
LGG	cis	rs72945132	0.825	rs57871058	chr11:70192344	T/C	cg14088196	chr11:70211408	PPFIA1	0.94	13.23	0.52	3.9e-34	Coronary artery disease;
LGG	cis	rs4144743	1.000	rs7224990	chr17:45326878	C/T	cg18085866	chr17:45331354	ITGB3	-0.81	-9.69	-0.41	2.49e-20	Body mass index;
LGG	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg03806693	chr22:41940476	POLR3H	0.99	16.35	0.6	9.46e-48	Vitiligo;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg10115022	chr1:27527942	NA	0.34	6.85	0.3	2.34e-11	Body fat percentage;
LGG	cis	rs7666738	0.830	rs13106434	chr4:98991651	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9527	0.615	rs11191485	chr10:104729816	G/C	cg04362960	chr10:104952993	NT5C2	0.56	10.32	0.43	1.26e-22	Arsenic metabolism;
LGG	cis	rs9814567	1.000	rs7429866	chr3:134236306	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.93	0.51	7.45e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3096299	0.781	rs2965819	chr16:89501030	G/T	cg06640241	chr16:89574553	SPG7	-0.78	-14.02	-0.55	1.75e-37	Multiple myeloma (IgH translocation);
LGG	cis	rs9467773	1.000	rs1884948	chr6:26567988	G/A	cg11502198	chr6:26597334	ABT1	0.59	10.11	0.43	7.78e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6547741	0.844	rs7586655	chr2:27915659	A/G	cg22903471	chr2:27725779	GCKR	-0.38	-8.44	-0.37	4.07e-16	Oral cavity cancer;
LGG	cis	rs597539	0.615	rs583182	chr11:68678634	C/T	cg21963583	chr11:68658836	MRPL21	0.58	10.15	0.43	5.29e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs75804782	0.630	rs56354063	chr2:239253919	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.37e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs28386778	0.863	rs894414	chr17:61916384	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.07	0.35	6.1e-15	Prudent dietary pattern;
LGG	cis	rs9513627	0.749	rs73556149	chr13:100117012	G/A	cg15490075	chr13:100150979	NA	-0.7	-7.61	-0.33	1.5700000000000001e-13	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs78308415	chr7:1072634	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.03	-0.68	9.87e-65	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg24692254	chr21:30365293	RNF160	-0.87	-20.0	-0.68	1.32e-64	Dental caries;
LGG	cis	rs13095912	0.597	rs112800013	chr3:185313807	A/G	cg11274856	chr3:185301563	NA	0.49	7.93	0.35	1.71e-14	Systolic blood pressure;
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg12826209	chr6:26865740	GUSBL1	0.78	7.46	0.33	4.36e-13	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06343212	chr7:84815881	NA	0.41	7.44	0.33	5.1e-13	Bilirubin levels;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg17691542	chr6:26056736	HIST1H1C	0.56	9.91	0.42	3.85e-21	Height;
LGG	cis	rs7811142	1.000	rs6979335	chr7:100089860	T/C	cg11814155	chr7:99998594	ZCWPW1	0.62	9.62	0.41	4.15e-20	Platelet count;
LGG	cis	rs17453880	0.929	rs4385197	chr5:152047146	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-14.66	-0.56	3.15e-40	Presence of antiphospholipid antibodies;
LGG	cis	rs1577917	0.958	rs6921315	chr6:86471668	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.33	-0.5	2.14e-30	Response to antipsychotic treatment;
LGG	cis	rs2070488	0.804	rs13094715	chr3:38504430	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.75	14.99	0.57	1.07e-41	Electrocardiographic conduction measures;
LGG	cis	rs2985684	0.948	rs6572592	chr14:50080871	G/A	cg02151108	chr14:50098012	C14orf104	-0.46	-9.81	-0.41	9.06e-21	Carotid intima media thickness;
LGG	cis	rs7619833	0.620	rs11129270	chr3:27257943	A/G	cg02860705	chr3:27208620	NA	0.42	8.21	0.36	2.2e-15	Breast cancer;
LGG	cis	rs17453880	0.852	rs6882013	chr5:152049652	T/C	cg12297329	chr5:152029980	NA	-0.9	-23.18	-0.73	1.8e-79	Subjective well-being;
LGG	cis	rs12310956	0.532	rs7955514	chr12:33978737	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.78e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	8.05e-29	Prudent dietary pattern;
LGG	cis	rs2276314	0.857	rs62101376	chr18:33582955	T/C	cg19628046	chr18:33552617	C18orf21	0.51	7.4	0.33	6.26e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs8005677	1.000	rs8006409	chr14:23396511	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.23	-0.32	1.99e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-8.16	-0.35	3.31e-15	Schizophrenia;
LGG	cis	rs2421770	0.532	rs3903688	chr11:35350090	A/T	cg10331829	chr11:35343789	SLC1A2	-0.35	-7.81	-0.34	3.74e-14	Staphylococcus aureus nasal carriage (persistent);
LGG	cis	rs7598759	0.712	rs6727372	chr2:232331906	T/G	cg19187155	chr2:232395269	NMUR1	0.42	7.62	0.33	1.49e-13	Noise-induced hearing loss;
LGG	cis	rs9297145	0.761	rs28545226	chr7:98732472	A/T	cg05967295	chr7:98741636	SMURF1	0.91	14.88	0.57	3.38e-41	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs651907	0.535	rs11711903	chr3:101500748	C/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.22	0.36	2.07e-15	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18045831	chr1:19577885	MRTO4;KIAA0090	0.43	7.11	0.31	4.52e-12	Cognitive performance;
LGG	cis	rs7927771	0.832	rs935914	chr11:47387599	C/T	cg20307385	chr11:47447363	PSMC3	0.58	10.7	0.45	5.08e-24	Subjective well-being;
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg11814155	chr7:99998594	ZCWPW1	0.6	9.23	0.39	1.01e-18	Platelet count;
LGG	cis	rs2985684	1.000	rs17121651	chr14:50097172	T/C	cg02151108	chr14:50098012	C14orf104	-0.47	-10.09	-0.42	8.68e-22	Carotid intima media thickness;
LGG	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.5	8.68	0.37	6.6e-17	Response to antipsychotic treatment;
LGG	cis	rs13401104	0.587	rs6431443	chr2:237150311	T/C	cg15742758	chr2:237126235	ASB18	0.43	7.67	0.34	1e-13	Educational attainment;
LGG	cis	rs447735	0.587	rs258336	chr16:89720831	A/C	cg03605463	chr16:89740564	NA	0.49	8.66	0.37	8.04e-17	Hemoglobin concentration;
LGG	cis	rs11122272	0.766	rs2024879	chr1:231528638	A/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	trans	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.46	-0.37	3.64e-16	Retinal vascular caliber;
LGG	trans	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg06521331	chr12:34319734	NA	0.4	6.71	0.3	5.84e-11	Morning vs. evening chronotype;
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg14092988	chr3:52407081	DNAH1	0.33	8.6	0.37	1.23e-16	Bipolar disorder;
LGG	cis	rs9467711	0.790	rs13195402	chr6:26463575	G/T	cg12826209	chr6:26865740	GUSBL1	0.8	6.89	0.3	1.82e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg26408565	chr15:76604113	ETFA	0.43	7.42	0.33	5.48e-13	Blood metabolite levels;
LGG	cis	rs2658782	0.756	rs2658777	chr11:93148423	C/T	cg15737290	chr11:93063684	CCDC67	0.52	7.86	0.34	2.72e-14	Pulmonary function decline;
LGG	cis	rs754466	0.606	rs3740250	chr10:79580101	C/T	cg17075019	chr10:79541650	NA	-0.98	-21.85	-0.71	2.84e-73	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2594989	1.000	rs346077	chr3:11326102	A/C	cg01796438	chr3:11312864	ATG7	-0.61	-8.51	-0.37	2.37e-16	Circulating chemerin levels;
LGG	trans	rs9650657	0.707	rs11250076	chr8:10647823	A/G	cg16141378	chr3:129829833	LOC729375	0.3	6.82	0.3	2.88e-11	Neuroticism;
LGG	cis	rs975739	0.843	rs1146928	chr13:78366104	A/G	cg07847733	chr13:78271382	SLAIN1	0.38	6.9	0.31	1.72e-11	Hair color;
LGG	cis	rs62064224	0.614	rs6505294	chr17:30687415	C/T	cg25809561	chr17:30822961	MYO1D	0.38	8.97	0.38	7.55e-18	Schizophrenia;
LGG	cis	rs12410462	0.551	rs74997063	chr1:227744537	A/C	cg04117972	chr1:227635322	NA	0.46	8.42	0.36	4.92e-16	Major depressive disorder;
LGG	cis	rs9910055	0.762	rs2526021	chr17:42213347	G/A	cg13607699	chr17:42295918	UBTF	0.64	11.08	0.46	1.89e-25	Total body bone mineral density;
LGG	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	trans	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg02002194	chr4:3960332	NA	0.55	11.07	0.46	1.96e-25	Neuroticism;
LGG	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg19847130	chr8:10466454	RP1L1	0.34	7.39	0.32	6.72e-13	Neuroticism;
LGG	cis	rs7928758	0.848	rs56766695	chr11:134276302	A/G	cg22777979	chr11:134283252	B3GAT1	0.57	8.29	0.36	1.24e-15	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs657075	0.697	rs4646204	chr5:131679995	T/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.72	0.3	5.2e-11	Rheumatoid arthritis;
LGG	cis	rs642743	0.517	rs157077	chr10:106037894	C/T	cg27365978	chr10:106093659	ITPRIP	-0.39	-6.84	-0.3	2.52e-11	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2404602	0.647	rs11072612	chr15:76960984	A/T	cg15268244	chr15:77196840	NA	0.48	10.28	0.43	1.82e-22	Blood metabolite levels;
LGG	cis	rs10895140	0.756	rs2513191	chr11:101489854	T/A	cg23650423	chr11:101454676	TRPC6	-0.44	-7.03	-0.31	7.59e-12	Menarche (age at onset);
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs73198271	0.530	rs11778326	chr8:8651566	T/G	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs7805747	1.000	rs7805747	chr7:151407801	G/A	cg17611936	chr7:151411526	PRKAG2	0.52	7.51	0.33	3.02e-13	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs2760061	0.626	rs1636192	chr1:228124688	A/G	cg01200585	chr1:228362443	C1orf69	-0.43	-7.68	-0.34	9.37e-14	Diastolic blood pressure;
LGG	cis	rs66716358	0.773	rs2054029	chr11:44325700	T/G	cg16977035	chr11:44330474	ALX4	0.38	10.0	0.42	1.83e-21	Monobrow;
LGG	cis	rs739401	0.595	rs6578305	chr11:3001120	C/T	cg05729581	chr11:3078854	CARS	-0.51	-8.69	-0.37	6.15e-17	Longevity;
LGG	trans	rs11098499	0.604	rs34278750	chr4:120571136	G/A	cg25214090	chr10:38739885	LOC399744	0.59	10.2	0.43	3.59e-22	Corneal astigmatism;
LGG	cis	rs6956675	0.915	rs7787116	chr7:62654060	G/A	cg08930214	chr7:62859557	LOC100287834	0.45	7.63	0.33	1.35e-13	Obesity-related traits;
LGG	cis	rs780096	0.526	rs11126999	chr2:27670307	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs4948496	0.754	rs10740059	chr10:63809527	A/G	cg16401465	chr10:63809170	ARID5B	-0.36	-6.96	-0.31	1.16e-11	Systemic lupus erythematosus;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg25450986	chr17:38574356	TOP2A	0.37	6.65	0.3	8.52e-11	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-8.08	-0.35	5.87e-15	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07636362	chr8:79717261	IL7	0.47	7.68	0.34	9.33e-14	Cognitive performance;
LGG	cis	rs796364	0.806	rs11679676	chr2:201040981	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.7	-7.84	-0.34	3.15e-14	Schizophrenia;
LGG	trans	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg21659725	chr3:3221576	CRBN	-0.67	-12.53	-0.5	3.37e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.89e-14	Common traits (Other);
LGG	cis	rs3733585	0.673	rs4292333	chr4:9953871	G/A	cg25986240	chr4:9926439	SLC2A9	0.38	7.85	0.34	2.84e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9902453	0.967	rs8067576	chr17:28444254	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.27	0.52	2.74e-34	Coffee consumption (cups per day);
LGG	cis	rs9660992	0.626	rs61823972	chr1:205201325	A/C	cg00857998	chr1:205179979	DSTYK	0.48	7.62	0.33	1.43e-13	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg19635926	chr16:89946313	TCF25	0.66	7.91	0.34	1.92e-14	Skin colour saturation;
LGG	cis	rs9948	0.655	rs3731940	chr2:97377883	A/G	cg01990225	chr2:97406019	LMAN2L	0.67	6.7	0.3	5.96e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg00713939	chr8:144660590	NAPRT1	0.9	7.28	0.32	1.42e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg08499158	chr17:42289980	UBTF	-0.6	-11.29	-0.46	2.83e-26	Total body bone mineral density;
LGG	cis	rs7584262	0.740	rs13414536	chr2:42245179	T/C	cg19376973	chr2:42229025	NA	0.65	9.58	0.41	6.15e-20	Bone mineral density;
LGG	cis	rs832540	0.931	rs2662040	chr5:56246610	A/G	cg17809284	chr5:56205270	C5orf35	0.35	6.71	0.3	5.81e-11	Coronary artery disease;
LGG	cis	rs10851478	0.558	rs17478785	chr15:49740304	A/C	cg08060515	chr15:49448048	GALK2;COPS2	0.42	7.5	0.33	3.36e-13	Oral cavity cancer;
LGG	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg00495681	chr13:53174319	NA	0.81	17.22	0.62	1.03e-51	Lewy body disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24497897	chr11:65658826	CCDC85B	0.44	7.13	0.31	3.86e-12	Cognitive performance;
LGG	cis	rs11229555	0.645	rs10896814	chr11:58430699	T/C	cg15696309	chr11:58395628	NA	-0.89	-11.87	-0.48	1.46e-28	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg24829409	chr8:58192753	C8orf71	-0.81	-11.44	-0.47	7.21e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg06212747	chr3:49208901	KLHDC8B	0.48	7.35	0.32	8.86e-13	Menarche (age at onset);
LGG	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg12386194	chr3:101231763	SENP7	0.51	8.89	0.38	1.34e-17	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg25482853	chr8:67687455	SGK3	0.85	11.09	0.46	1.67e-25	Obesity-related traits;
LGG	cis	rs240764	0.764	rs13201976	chr6:100933185	T/A	cg21058520	chr6:100914733	NA	0.52	9.16	0.39	1.64e-18	Neuroticism;
LGG	cis	rs10766533	0.663	rs10500844	chr11:19250164	C/A	cg14704941	chr11:19224659	CSRP3	0.4	6.9	0.31	1.77e-11	Mean corpuscular volume;Mean corpuscular hemoglobin;Red blood cell count;
LGG	cis	rs31872	0.521	rs246050	chr5:140326860	T/G	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs6121246	0.529	rs73235789	chr20:30196148	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	trans	rs877282	0.842	rs35872126	chr10:764545	G/A	cg22713356	chr15:30763199	NA	0.52	7.68	0.34	9.24e-14	Uric acid levels;
LGG	cis	rs9393692	0.905	rs6931391	chr6:26279235	G/C	cg13736514	chr6:26305472	NA	-0.46	-9.7	-0.41	2.32e-20	Educational attainment;
LGG	cis	rs7618915	0.501	rs13079063	chr3:52744460	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.22	0.39	1.02e-18	Bipolar disorder;
LGG	trans	rs208520	1.000	rs12193077	chr6:66989548	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.79e-39	Exhaled nitric oxide output;
LGG	cis	rs804280	0.509	rs9886639	chr8:11784529	G/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.78	-0.34	4.83e-14	Myopia (pathological);
LGG	cis	rs6964587	1.000	rs7802668	chr7:91648939	A/G	cg17063962	chr7:91808500	NA	0.47	8.5	0.37	2.53e-16	Breast cancer;
LGG	cis	rs283228	0.502	rs2852506	chr6:101843916	T/A	cg02011392	chr6:101847541	GRIK2	0.52	7.36	0.32	8.34e-13	Coenzyme Q10 levels;
LGG	cis	rs2075371	1.000	rs2544221	chr7:133993014	G/C	cg11752832	chr7:134001865	SLC35B4	0.63	11.52	0.47	3.66e-27	Mean platelet volume;
LGG	cis	rs1799949	0.930	rs66499067	chr17:41248484	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.44	7.1	0.31	4.73e-12	Menopause (age at onset);
LGG	cis	rs17767392	0.958	rs12433040	chr14:72030555	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.82	-0.42	8.45e-21	Mitral valve prolapse;
LGG	cis	rs7000551	0.715	rs2461478	chr8:22378236	A/G	cg12081754	chr8:22256438	SLC39A14	0.66	12.35	0.5	1.72e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.867	rs1002053	chr7:65798545	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.79	-0.41	1.04e-20	Aortic root size;
LGG	cis	rs7618501	0.602	rs34831713	chr3:50118748	T/C	cg24308560	chr3:49941425	MST1R	-0.22	-6.78	-0.3	3.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2985684	0.846	rs4476096	chr14:50019391	A/C	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.4	6.81	0.3	3.13e-11	Carotid intima media thickness;
LGG	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg20887711	chr4:1340912	KIAA1530	0.42	6.76	0.3	4.28e-11	Recombination rate (females);
LGG	cis	rs209489	0.892	rs17543931	chr6:53126837	G/A	cg15607103	chr6:53167650	ELOVL5	0.74	9.13	0.39	2.06e-18	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs12643440	0.538	rs6834807	chr4:17138244	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs9457247	0.663	rs2301436	chr6:167437988	C/T	cg07741184	chr6:167504864	NA	0.38	8.43	0.36	4.35e-16	Crohn's disease;
LGG	cis	rs4696584	1.000	rs4696213	chr4:155396442	G/C	cg04517429	chr4:155413618	DCHS2	0.3	7.04	0.31	6.85e-12	Folding of antihelix;
LGG	cis	rs62238980	0.614	rs118009794	chr22:32470485	G/A	cg02631450	chr22:32366979	NA	0.99	9.37	0.4	3.12e-19	Childhood ear infection;
LGG	cis	rs3091242	0.933	rs35497030	chr1:25783066	A/G	cg03538708	chr1:25844672	NA	0.35	6.69	0.3	6.6e-11	Erythrocyte sedimentation rate;
LGG	trans	rs9467711	0.591	rs13192365	chr6:25993968	T/C	cg06606381	chr12:133084897	FBRSL1	-0.73	-7.16	-0.32	3.15e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs116095464	0.558	rs114607464	chr5:300468	C/T	cg22496380	chr5:211416	CCDC127	-1.19	-15.78	-0.59	3.46e-45	Breast cancer;
LGG	cis	rs7399018	0.739	rs10747608	chr12:51616582	A/G	cg20712883	chr12:51590929	POU6F1	0.44	7.4	0.33	6.46e-13	Cisplatin-induced ototoxicity;
LGG	cis	rs4740619	0.711	rs10756731	chr9:15975600	C/G	cg14451791	chr9:16040625	NA	-0.41	-10.47	-0.44	3.73e-23	Body mass index;
LGG	cis	rs9849248	0.627	rs1006896	chr3:88104411	A/C	cg14530983	chr3:88190749	ZNF654	0.56	7.81	0.34	3.74e-14	Menarche (age at onset);
LGG	cis	rs6500602	0.673	rs4786513	chr16:4576423	T/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.4	6.9	0.31	1.76e-11	Schizophrenia;
LGG	cis	rs1046896	1.000	rs28485881	chr17:80690014	G/A	cg02711726	chr17:80685570	FN3KRP	-0.64	-12.95	-0.52	6.06e-33	Glycated hemoglobin levels;
LGG	cis	rs12500482	0.935	rs2239736	chr4:2438929	T/C	cg08330972	chr4:2403930	ZFYVE28	-0.49	-8.32	-0.36	1.02e-15	Cognitive function;
LGG	cis	rs4888262	0.526	rs7205258	chr16:74642539	C/T	cg01733217	chr16:74700730	RFWD3	0.9	18.32	0.65	8.41e-57	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs4718317	chr7:65648901	A/G	cg18252515	chr7:66147081	NA	1.4	19.46	0.67	4.4e-62	Diabetic kidney disease;
LGG	cis	rs2836974	0.644	rs11088472	chr21:40699376	A/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.2	-0.49	7.36e-30	Cognitive function;
LGG	trans	rs35110281	0.782	rs4818856	chr21:45043495	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.75	0.48	4.39e-28	Mean corpuscular volume;
LGG	cis	rs116095464	0.558	rs10058428	chr5:235608	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs1107366	0.695	rs10934754	chr3:125906237	T/C	cg01346077	chr3:125931526	NA	0.41	9.95	0.42	2.92e-21	Metabolite levels;
LGG	trans	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.51	-0.37	2.35e-16	Retinal vascular caliber;
LGG	cis	rs17208368	0.628	rs35752525	chr16:55095972	C/T	cg11181171	chr16:55090946	NA	0.46	7.61	0.33	1.51e-13	Hypospadias;
LGG	cis	rs17221829	0.525	rs9804670	chr11:89375801	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	trans	rs1728785	0.688	rs698729	chr16:68624205	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.16	0.43	5.12e-22	Ulcerative colitis;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg24575275	chr7:1094737	C7orf50	-0.39	-7.46	-0.33	4.22e-13	Longevity;Endometriosis;
LGG	cis	rs17039065	0.920	rs6836187	chr4:109467230	T/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.17	0.32	3.08e-12	Gut microbiome composition (summer);
LGG	cis	rs765787	0.530	rs11636018	chr15:45539137	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs975722	0.507	rs6960332	chr7:117395888	T/C	cg10524701	chr7:117356490	CTTNBP2	0.35	6.99	0.31	9.46e-12	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs1560865	chr2:26452197	C/A	cg22920501	chr2:26401640	FAM59B	-0.45	-9.35	-0.4	3.76e-19	Gut microbiome composition (summer);
LGG	trans	rs947612	0.541	rs1935511	chr6:73682457	C/T	cg13494037	chr12:24737079	C12orf67	-0.36	-7.43	-0.33	5.45e-13	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.43	-6.92	-0.31	1.51e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7727544	0.716	rs11949055	chr5:131576737	T/C	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.18	-0.32	2.89e-12	Blood metabolite levels;
LGG	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg16145915	chr7:1198662	ZFAND2A	-0.46	-7.9	-0.34	2.09e-14	Longevity;Endometriosis;
LGG	cis	rs72945132	0.579	rs35077099	chr11:70247970	G/A	cg13802316	chr11:70253460	CTTN	-0.72	-9.83	-0.42	7.46e-21	Coronary artery disease;
LGG	cis	rs9911578	1.000	rs368186	chr17:56736659	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.71	0.59	6.92e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	0.763	rs9605478	chr22:18464410	G/A	cg03078520	chr22:18463400	MICAL3	-0.67	-14.17	-0.55	4.08e-38	Presence of antiphospholipid antibodies;
LGG	cis	rs1577917	0.740	rs9450302	chr6:86289673	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.72	13.46	0.53	4.5e-35	Response to antipsychotic treatment;
LGG	trans	rs61931739	0.500	rs3924705	chr12:34557825	A/T	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs8067545	0.750	rs4925081	chr17:19991993	A/G	cg13482628	chr17:19912719	NA	-0.63	-12.62	-0.51	1.43e-31	Schizophrenia;
LGG	cis	rs2629540	0.765	rs12221075	chr10:126534855	G/A	cg08799069	chr10:126477246	METTL10	-0.58	-12.41	-0.5	9.57e-31	Cocaine dependence;
LGG	cis	rs2404602	0.647	rs12440965	chr15:76958591	G/A	cg23625390	chr15:77176239	SCAPER	-0.69	-13.56	-0.53	1.63e-35	Blood metabolite levels;
LGG	cis	rs300774	0.925	rs300715	chr2:137962	A/G	cg04617936	chr2:214353	NA	-0.47	-7.34	-0.32	9.95e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09172817	chr18:9915098	VAPA	0.38	6.71	0.3	5.73e-11	Obesity-related traits;
LGG	cis	rs7264396	0.747	rs2425112	chr20:34319775	A/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.27	0.32	1.54e-12	Total cholesterol levels;
LGG	cis	rs3091242	0.933	rs4649084	chr1:25752617	A/G	cg27572855	chr1:25598939	RHD	0.49	11.26	0.46	3.71e-26	Erythrocyte sedimentation rate;
LGG	cis	rs7089973	0.624	rs17586888	chr10:116598121	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.22	0.32	2.18e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs597539	0.652	rs557625	chr11:68634722	G/A	cg04008888	chr11:68622739	NA	-0.55	-11.73	-0.48	5.5e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg16507663	chr6:150244633	RAET1G	0.46	8.75	0.38	3.85e-17	Lung cancer;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg04166393	chr7:2884313	GNA12	0.46	8.64	0.37	9.12e-17	Height;
LGG	cis	rs58649573	0.509	rs3780683	chr9:126789208	C/T	cg14112217	chr9:126806003	NA	0.4	7.97	0.35	1.26e-14	Post-traumatic stress disorder;
LGG	cis	rs300774	0.800	rs300732	chr2:166725	A/G	cg04617936	chr2:214353	NA	-0.45	-6.87	-0.3	2.14e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs11676348	0.805	rs13007219	chr2:218963859	C/A	cg00012203	chr2:219082015	ARPC2	-0.5	-8.85	-0.38	1.83e-17	Ulcerative colitis;
LGG	trans	rs4714291	0.963	rs4714292	chr6:40003679	A/C	cg02267698	chr19:7991119	CTXN1	0.58	9.01	0.39	5.38e-18	Strep throat;
LGG	cis	rs35306767	0.807	rs1013505	chr10:953273	C/T	cg25019033	chr10:957182	NA	-0.54	-9.38	-0.4	2.92e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg22168489	chr12:122356033	WDR66	0.43	9.99	0.42	2.01e-21	Mean corpuscular volume;
LGG	cis	rs7226408	0.857	rs55992510	chr18:34519130	G/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8025790	0.508	rs28673019	chr15:67809823	T/A	cg25173464	chr15:68126554	NA	-0.34	-7.22	-0.32	2.22e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs2599510	0.811	rs2754520	chr2:32810293	G/A	cg02381751	chr2:32503542	YIPF4	0.49	7.9	0.34	2e-14	Interleukin-18 levels;
LGG	cis	rs68170813	0.559	rs10487271	chr7:106898458	T/C	cg02696742	chr7:106810147	HBP1	-0.73	-10.49	-0.44	3.04e-23	Coronary artery disease;
LGG	cis	rs2180341	1.000	rs9401950	chr6:127655485	C/T	cg24812749	chr6:127587940	RNF146	0.96	16.02	0.6	2.88e-46	Breast cancer;
LGG	cis	rs2153535	0.869	rs11962457	chr6:8375855	A/T	cg07606381	chr6:8435919	SLC35B3	-0.39	-6.85	-0.3	2.37e-11	Motion sickness;
LGG	cis	rs12282928	0.959	rs11500497	chr11:48304461	A/T	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs6912958	0.712	rs6930600	chr6:88349787	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.84	-0.38	2.06e-17	Monocyte percentage of white cells;
LGG	trans	rs2727020	0.553	rs4980447	chr11:49591662	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.64	-10.88	-0.45	1.09e-24	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs7502524	chr17:80107261	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7937682	0.924	rs564601	chr11:111594077	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.18	-27.31	-0.79	1.61e-98	Primary sclerosing cholangitis;
LGG	cis	rs477895	0.653	rs2015226	chr11:63902534	C/T	cg04317338	chr11:64019027	PLCB3	0.66	8.16	0.35	3.15e-15	Mean platelet volume;
LGG	cis	rs8012	0.517	rs2009218	chr19:13034584	A/G	cg23899408	chr19:12877188	HOOK2	0.5	7.95	0.35	1.43e-14	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs778371	0.788	rs778355	chr2:233784749	T/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-8.11	-0.35	4.57e-15	Schizophrenia;
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg00713939	chr8:144660590	NAPRT1	0.86	6.76	0.3	4.07e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs11105298	0.891	rs10858881	chr12:89891474	T/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.37	-0.4	3.23e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs2243480	1.000	rs1979823	chr7:65704613	G/A	cg10756647	chr7:56101905	PSPH	-0.81	-9.52	-0.4	9.98e-20	Diabetic kidney disease;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.46	-0.33	4.42e-13	Bipolar disorder;
LGG	cis	rs7618915	0.570	rs13068293	chr3:52672167	C/A	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs7829975	0.688	rs6995407	chr8:8384647	C/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.96	0.38	7.93e-18	Mood instability;
LGG	cis	rs4660214	0.666	rs7554206	chr1:39929240	A/G	cg18385671	chr1:39797026	MACF1	-0.49	-9.57	-0.41	6.49e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs3808502	0.526	rs7823100	chr8:11422491	C/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.32	-0.36	9.83e-16	Neuroticism;
LGG	cis	rs11608355	0.960	rs11066526	chr12:109854476	G/C	cg19025524	chr12:109796872	NA	-0.49	-9.33	-0.4	4.45e-19	Neuroticism;
LGG	cis	rs7937682	0.663	rs7116280	chr11:111659111	T/C	cg09085632	chr11:111637200	PPP2R1B	1.01	19.56	0.67	1.51e-62	Primary sclerosing cholangitis;
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.6	-0.33	1.62e-13	Menopause (age at onset);
LGG	trans	rs61931739	0.929	rs1490110	chr12:34091605	A/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.42	-0.5	9.13e-31	Morning vs. evening chronotype;
LGG	trans	rs9650657	0.707	rs10097283	chr8:10659406	G/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.34	-0.32	9.87e-13	Neuroticism;
LGG	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.59	-0.37	1.32e-16	Aortic root size;
LGG	cis	rs10504229	0.593	rs77607045	chr8:58010464	T/C	cg11062466	chr8:58055876	NA	0.51	7.79	0.34	4.4e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7659604	0.540	rs7699289	chr4:122671553	G/A	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.73	-0.34	6.73e-14	Type 2 diabetes;
LGG	cis	rs7084402	0.967	rs1658432	chr10:60329069	C/G	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg09127314	chr1:152161683	NA	0.45	7.34	0.32	9.86e-13	Inflammatory skin disease;
LGG	cis	rs62064224	0.765	rs62065463	chr17:30732405	G/T	cg12855166	chr17:30846586	MYO1D	0.39	6.86	0.3	2.24e-11	Schizophrenia;
LGG	cis	rs2236918	0.687	rs1776136	chr1:242026845	G/A	cg17736920	chr1:242011382	EXO1	0.39	7.19	0.32	2.55e-12	Menopause (age at onset);
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.09	-0.31	5.11e-12	Height;
LGG	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg00409905	chr10:38381863	ZNF37A	0.66	13.34	0.53	1.45e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs12439619	0.508	rs8042665	chr15:82481349	A/T	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-7.82	-0.34	3.5e-14	Intelligence (multi-trait analysis);
LGG	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15557168	chr22:42548783	NA	-0.36	-8.06	-0.35	6.4e-15	Cognitive function;
LGG	cis	rs3764563	1.000	rs2283603	chr19:15731128	T/C	cg20725493	chr19:15740067	CYP4F8	-0.66	-8.35	-0.36	7.72e-16	Inflammatory biomarkers;
LGG	cis	rs13191362	0.935	rs73008456	chr6:163013697	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7444	0.941	rs140499	chr22:21927231	C/T	cg05046821	chr22:21984468	YDJC	-0.39	-7.08	-0.31	5.48e-12	Systemic lupus erythematosus;
LGG	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg17294928	chr15:75287854	SCAMP5	0.66	12.23	0.49	5.1e-30	Breast cancer;
LGG	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg16850897	chr7:100343110	ZAN	-0.57	-8.19	-0.36	2.64e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs988958	0.876	rs11902166	chr2:42282829	A/C	cg27252766	chr2:42229092	NA	-0.45	-6.91	-0.31	1.56e-11	Hypospadias;
LGG	trans	rs7939886	0.920	rs10501343	chr11:55759573	G/T	cg15704280	chr7:45808275	SEPT13	0.88	9.21	0.39	1.1e-18	Myopia (pathological);
LGG	cis	rs6951245	0.572	rs73259905	chr7:1023364	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.91	10.17	0.43	4.71e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9296249	0.515	rs9349088	chr6:38466562	C/G	cg07362130	chr6:38359646	BTBD9	-0.34	-7.24	-0.32	1.88e-12	Restless legs syndrome;
LGG	cis	rs2204008	0.811	rs4882300	chr12:38415224	A/T	cg13010199	chr12:38710504	ALG10B	-0.64	-13.65	-0.54	6.92e-36	Bladder cancer;
LGG	cis	rs28386778	0.897	rs8077013	chr17:61850392	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	cis	rs6795744	0.665	rs17303603	chr3:14092316	A/G	cg19554555	chr3:13937349	NA	-0.57	-7.38	-0.32	7.25e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs7084402	0.967	rs1658485	chr10:60288331	A/G	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.49	-0.61	2.14e-48	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1994135	0.692	rs1579909	chr12:33694780	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.66	-0.37	7.81e-17	Resting heart rate;
LGG	cis	rs7954584	0.545	rs12824593	chr12:122374108	G/A	cg21171335	chr12:122356390	WDR66	0.29	8.1	0.35	5.07e-15	Mean corpuscular volume;
LGG	cis	rs7166081	0.704	rs2414952	chr15:67724392	A/T	cg27219399	chr15:67835830	MAP2K5	0.32	7.03	0.31	7.24e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs514406	0.929	rs485631	chr1:53330245	A/G	cg16325326	chr1:53192061	ZYG11B	0.73	16.13	0.6	8.61e-47	Monocyte count;
LGG	cis	rs7818345	0.637	rs4599829	chr8:19358434	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.44	10.76	0.45	2.93e-24	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.4	-0.47	1.01e-26	Extrinsic epigenetic age acceleration;
LGG	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg00031303	chr3:195681400	NA	0.56	9.04	0.39	4.23e-18	Pancreatic cancer;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.29	0.32	1.39e-12	Menopause (age at onset);
LGG	cis	rs1797081	0.646	rs7090256	chr10:16851949	T/G	cg23933602	chr10:16859644	RSU1	0.77	14.91	0.57	2.37e-41	Platelet distribution width;
LGG	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg25173405	chr17:45401733	C17orf57	-0.49	-8.5	-0.37	2.63e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.35	0.58	2.73e-43	Lung cancer;
LGG	cis	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg00689492	chr4:1303491	MAEA	0.47	8.24	0.36	1.74e-15	Obesity-related traits;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg11814155	chr7:99998594	ZCWPW1	0.54	8.09	0.35	5.18e-15	Platelet count;
LGG	cis	rs7824557	0.724	rs2251473	chr8:11177126	C/A	cg12395012	chr8:11607386	GATA4	-0.37	-6.8	-0.3	3.27e-11	Retinal vascular caliber;
LGG	cis	rs9911578	0.813	rs8066773	chr17:56601552	A/G	cg05425664	chr17:57184151	TRIM37	-0.6	-9.21	-0.39	1.15e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4774899	1.000	rs12914625	chr15:57263440	C/T	cg08128148	chr15:57256372	TCF12	-0.34	-8.26	-0.36	1.6e-15	Urinary tract infection frequency;
LGG	cis	rs35160687	0.509	rs35723061	chr2:86549088	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.73	0.3	5.16e-11	Night sleep phenotypes;
LGG	cis	rs6459788	0.693	rs11981578	chr7:157250133	C/T	cg04198125	chr7:157211777	NA	0.41	7.59	0.33	1.76e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs7824557	0.815	rs2736372	chr8:11106041	T/C	cg21775007	chr8:11205619	TDH	-0.58	-9.11	-0.39	2.41e-18	Retinal vascular caliber;
LGG	cis	rs1046896	0.731	rs8067667	chr17:80785875	A/G	cg08200770	chr17:80723486	TBCD	-0.46	-8.32	-0.36	1.01e-15	Glycated hemoglobin levels;
LGG	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg13852791	chr20:30311386	BCL2L1	0.77	12.46	0.5	6.17e-31	Mean corpuscular hemoglobin;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01135200	chr6:147524578	STXBP5	0.41	6.76	0.3	4.05e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02850941	chr16:89767921	SPATA2L	0.46	6.93	0.31	1.45e-11	Gut microbiome composition (summer);
LGG	cis	rs6589964	1.000	rs6589964	chr11:122870683	A/C	cg27398637	chr11:122830231	C11orf63	-0.52	-9.88	-0.42	5.04e-21	Menarche (age at onset);
LGG	cis	rs6674970	1.000	rs6656450	chr1:151089602	A/T	cg04469105	chr1:151031679	CDC42SE1;MLLT11	-0.48	-7.13	-0.31	3.85e-12	Childhood ear infection;
LGG	cis	rs36051895	0.632	rs12684720	chr9:5150800	T/C	cg02405213	chr9:5042618	JAK2	-0.76	-14.39	-0.56	4.58e-39	Pediatric autoimmune diseases;
LGG	cis	rs875971	0.929	rs778712	chr7:65849978	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.39e-17	Aortic root size;
LGG	cis	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg23422044	chr7:1970798	MAD1L1	-0.77	-13.1	-0.52	1.48e-33	Bipolar disorder;
LGG	cis	rs1125355	0.690	rs11691004	chr2:159644175	A/G	cg02251393	chr2:159651559	DAPL1	-0.43	-8.84	-0.38	1.98e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4690686	0.500	rs72623907	chr4:177261965	C/G	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs3735485	0.698	rs62458154	chr7:45117948	C/T	cg03440944	chr7:45023329	C7orf40	-0.57	-9.64	-0.41	3.55e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs823143	0.570	rs1361754	chr1:205801872	C/T	cg11965913	chr1:205819406	PM20D1	-0.69	-14.61	-0.56	5.07e-40	Monocyte percentage of white cells;
LGG	cis	rs3540	1.000	rs3540	chr15:91045408	G/A	cg22089800	chr15:90895588	ZNF774	0.51	8.0	0.35	1.03e-14	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.52e-21	Lymphocyte counts;
LGG	cis	rs7107174	0.892	rs2512519	chr11:77953015	C/T	cg02023728	chr11:77925099	USP35	0.45	7.86	0.34	2.78e-14	Testicular germ cell tumor;
LGG	cis	rs7538876	0.903	rs730153	chr1:17749504	A/G	cg10329579	chr1:17754830	RCC2	0.48	8.95	0.38	8.57e-18	Basal cell carcinoma;
LGG	cis	rs7084402	0.935	rs1658492	chr10:60281267	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.38	0.32	7.4e-13	Refractive error;
LGG	cis	rs11001765	0.530	rs11001750	chr10:78120830	G/A	cg16072382	chr10:78096093	C10orf11	0.5	6.79	0.3	3.55e-11	Chin dimples;
LGG	cis	rs6743376	0.556	rs1800930	chr2:113820530	A/G	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs657075	0.697	rs77975982	chr5:131661993	T/C	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs10744625	1.000	rs10744625	chr12:3868168	C/T	cg22221074	chr12:3862810	EFCAB4B	-0.31	-6.87	-0.3	2.11e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs67311347	1.000	rs10510708	chr3:40404770	A/G	cg13683864	chr3:40499215	RPL14	-0.98	-20.15	-0.68	2.55e-65	Renal cell carcinoma;
LGG	trans	rs9467603	1.000	rs13200921	chr6:25790378	T/C	cg06606381	chr12:133084897	FBRSL1	-0.76	-6.93	-0.31	1.45e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.673	rs6449156	chr4:9956712	G/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.76	0.34	5.63e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12681288	0.676	rs6559208	chr8:1018833	A/G	cg15309053	chr8:964076	NA	0.39	7.79	0.34	4.52e-14	Schizophrenia;
LGG	cis	rs9322193	0.923	rs11155683	chr6:150100477	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.66	-0.3	7.73e-11	Lung cancer;
LGG	cis	rs9308731	0.623	rs2241842	chr2:111879415	A/G	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.91	-0.31	1.59e-11	Chronic lymphocytic leukemia;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg20887711	chr4:1340912	KIAA1530	0.71	14.56	0.56	8.63e-40	Longevity;
LGG	cis	rs79349575	0.783	rs9912829	chr17:46982749	G/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.35	0.36	7.71e-16	Type 2 diabetes;
LGG	cis	rs7552404	0.628	rs5745442	chr1:76342858	T/G	cg10523679	chr1:76189770	ACADM	0.74	11.33	0.47	1.91e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs17604090	0.941	rs114036198	chr7:29676300	C/T	cg19413766	chr7:29689036	LOC646762	-0.57	-6.87	-0.3	2.06e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg00677455	chr12:58241039	CTDSP2	0.4	7.22	0.32	2.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9788333	0.962	rs61951450	chr13:21886354	G/A	cg21970626	chr13:21893289	NA	-0.46	-10.11	-0.43	7.87e-22	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs9549260	0.755	rs2755216	chr13:41156938	G/A	cg21288729	chr13:41239152	FOXO1	0.34	6.81	0.3	2.97e-11	Red blood cell count;
LGG	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.92	-0.38	1.09e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs977987	0.806	rs35937717	chr16:75331567	C/A	cg03315344	chr16:75512273	CHST6	0.49	9.92	0.42	3.65e-21	Dupuytren's disease;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg26318627	chr11:63887540	MACROD1	-0.47	-6.76	-0.3	4.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs12615966	0.932	rs72830462	chr2:105394600	C/T	cg16465502	chr2:105461796	NA	0.89	10.89	0.45	9.49e-25	Pancreatic cancer;
LGG	cis	rs6918586	0.636	rs198817	chr6:26126524	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.71	-0.41	2.01e-20	Schizophrenia;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg03188948	chr7:1209495	NA	0.41	7.1	0.31	4.8e-12	Longevity;Endometriosis;
LGG	cis	rs10256972	0.681	rs6979076	chr7:1116247	C/T	cg16145915	chr7:1198662	ZFAND2A	0.62	10.87	0.45	1.17e-24	Longevity;Endometriosis;
LGG	cis	rs67311347	0.955	rs9821036	chr3:40379007	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.36	-0.69	2.87e-66	Renal cell carcinoma;
LGG	cis	rs1978968	1.000	rs2099942	chr22:18438314	A/C	cg03078520	chr22:18463400	MICAL3	-0.61	-12.41	-0.5	1.03e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04709771	chr16:646395	RAB40C	0.36	6.68	0.3	6.85e-11	Height;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.17	-0.32	2.99e-12	Myopia (pathological);
LGG	cis	rs17286411	0.836	rs1035543	chr16:71983772	C/G	cg03805757	chr16:71968109	PKD1L3	-0.34	-6.65	-0.3	8.37e-11	Blood protein levels;
LGG	cis	rs1691799	0.899	rs1168317	chr12:66746225	C/T	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	trans	rs116095464	1.000	rs56075848	chr5:308352	T/C	cg00938859	chr5:1591904	SDHAP3	0.63	6.86	0.3	2.29e-11	Breast cancer;
LGG	cis	rs7726839	0.574	rs12522955	chr5:639231	C/A	cg16400903	chr5:693638	TPPP	0.46	6.99	0.31	9.34e-12	Obesity-related traits;
LGG	cis	rs6866344	0.697	rs62392831	chr5:178134365	A/G	cg10224037	chr5:178157518	ZNF354A	0.73	11.37	0.47	1.4e-26	Neutrophil percentage of white cells;
LGG	cis	rs72781680	0.898	rs17762609	chr2:24114729	G/T	cg08917208	chr2:24149416	ATAD2B	0.8	9.06	0.39	3.8e-18	Lymphocyte counts;
LGG	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21659725	chr3:3221576	CRBN	0.74	11.71	0.48	6.27e-28	Resting heart rate;
LGG	cis	rs9457247	0.935	rs401260	chr6:167405888	T/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs6951245	1.000	rs2363286	chr7:1091625	A/G	cg24642844	chr7:1081250	C7orf50	-0.84	-14.38	-0.56	4.96e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7772486	0.875	rs10872583	chr6:146396699	G/T	cg23711669	chr6:146136114	FBXO30	-0.38	-6.67	-0.3	7.09e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2228479	0.850	rs11641552	chr16:89838700	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs7289126	0.868	rs2267377	chr22:38629519	T/C	cg25457927	chr22:38595422	NA	-0.31	-7.45	-0.33	4.66e-13	Mammographic density (dense area);Percent mammographic density;
LGG	trans	rs6787172	0.622	rs4309677	chr3:158053803	T/C	cg23275840	chr4:47708675	CORIN	-0.35	-7.25	-0.32	1.71e-12	Subjective well-being;
LGG	cis	rs7717393	1.000	rs72798928	chr5:155790471	G/A	cg01474424	chr5:155754231	SGCD	0.74	7.42	0.33	5.55e-13	Egg allergy;
LGG	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.54	0.79	1.45e-99	Height;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00006032	chr14:66974439	GPHN	0.37	6.87	0.3	2.05e-11	Bipolar disorder;
LGG	cis	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg07460842	chr6:66804631	NA	0.9	14.82	0.57	6.2e-41	Exhaled nitric oxide output;
LGG	cis	rs9513627	0.749	rs73556143	chr13:100116907	G/A	cg15490075	chr13:100150979	NA	-0.7	-7.61	-0.33	1.5700000000000001e-13	Obesity-related traits;
LGG	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.45	-0.4	1.76e-19	Retinal vascular caliber;
LGG	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg02640540	chr1:67518911	SLC35D1	0.37	7.28	0.32	1.41e-12	Lymphocyte percentage of white cells;
LGG	trans	rs783540	1.000	rs1259180	chr15:83244680	T/C	cg16105309	chr15:79090380	ADAMTS7	0.42	7.26	0.32	1.64e-12	Schizophrenia;
LGG	cis	rs6430585	0.583	rs3087343	chr2:136622543	T/G	cg07169764	chr2:136633963	MCM6	1.3	26.85	0.78	1.99e-96	Corneal structure;
LGG	trans	rs2562456	0.833	rs11880624	chr19:21523830	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs735396	0.770	rs2257764	chr12:121446446	T/A	cg02403541	chr12:121454288	C12orf43	-0.64	-10.3	-0.43	1.49e-22	N-glycan levels;
LGG	trans	rs9858542	0.953	rs9858280	chr3:49597737	T/C	cg21659725	chr3:3221576	CRBN	-0.63	-10.04	-0.42	1.42e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs597539	0.617	rs686348	chr11:68636996	A/G	cg21862992	chr11:68658383	NA	0.51	8.64	0.37	9.39e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs11992186	0.597	rs11781841	chr8:8595263	T/A	cg16141378	chr3:129829833	LOC729375	0.38	8.47	0.37	3.16e-16	Neuroticism;
LGG	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-8.86	-0.38	1.75e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7647973	0.580	rs2334958	chr3:49252364	C/T	cg07636037	chr3:49044803	WDR6	0.95	20.4	0.69	1.75e-66	Menarche (age at onset);
LGG	cis	rs2273669	0.667	rs2356575	chr6:109367255	T/C	cg05315195	chr6:109294784	ARMC2	-0.62	-8.37	-0.36	6.92e-16	Prostate cancer;
LGG	cis	rs2373794	0.583	rs7570522	chr2:40386331	A/G	cg17740179	chr2:40377776	SLC8A1	-0.82	-10.24	-0.43	2.65e-22	Asthma;
LGG	cis	rs4853012	0.941	rs2421752	chr2:74341615	A/G	cg19729930	chr2:74357872	NA	0.59	11.96	0.49	6.65e-29	Gestational age at birth (maternal effect);
LGG	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg07777115	chr5:623756	CEP72	-0.63	-8.26	-0.36	1.49e-15	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22037798	chr1:231473786	C1orf124;EXOC8	0.46	7.55	0.33	2.26e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6763768	0.602	rs71301827	chr3:53423343	T/C	cg16894138	chr3:53270350	TKT	0.42	7.81	0.34	3.9e-14	Bacterial meningitis;
LGG	cis	rs7940866	0.903	rs10791112	chr11:130870215	A/C	cg12179176	chr11:130786555	SNX19	-0.72	-13.3	-0.53	2e-34	Schizophrenia;
LGG	cis	rs11785693	0.862	rs10503292	chr8:4992275	A/G	cg26367366	chr8:4980734	NA	1.0	15.83	0.59	2.11e-45	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs7582180	0.903	rs7562372	chr2:100906331	T/C	cg14675211	chr2:100938903	LONRF2	0.47	7.18	0.32	2.79e-12	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.782	rs2051407	chr21:45079245	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.33	0.47	2.02e-26	Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg16606324	chr3:10149918	C3orf24	0.51	6.82	0.3	2.89e-11	Alzheimer's disease;
LGG	cis	rs60871478	0.704	rs62432895	chr7:822050	C/G	cg27478167	chr7:817139	HEATR2	-0.44	-6.97	-0.31	1.11e-11	Cerebrospinal P-tau181p levels;
LGG	trans	rs9467711	0.606	rs9379864	chr6:26372584	G/A	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs757978	0.810	rs1468445	chr2:242395554	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.63	-7.22	-0.32	2.19e-12	Chronic lymphocytic leukemia;
LGG	cis	rs28386778	0.897	rs894406	chr17:61901657	A/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs990171	1.000	rs1035127	chr2:103019919	C/T	cg05295703	chr2:102895712	NA	0.56	9.9	0.42	4.33e-21	Lymphocyte counts;
LGG	trans	rs6598955	0.671	rs12085416	chr1:26627835	T/C	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-12.47	-0.5	5.76e-31	Obesity-related traits;
LGG	cis	rs9644630	0.897	rs28671342	chr8:19352420	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.61	-17.27	-0.63	6.15e-52	Oropharynx cancer;
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs10504229	0.679	rs6474100	chr8:58031161	G/A	cg05313129	chr8:58192883	C8orf71	-0.6	-8.45	-0.37	3.79e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.673	rs75142521	chr17:29240537	G/A	cg13385521	chr17:29058706	SUZ12P	0.76	8.59	0.37	1.37e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs36051895	0.659	rs10283730	chr9:5073289	G/A	cg02405213	chr9:5042618	JAK2	-0.82	-14.94	-0.57	1.84e-41	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.92	-0.31	1.48e-11	Lung cancer;
LGG	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03209809	chr3:126422892	CHCHD6	0.54	8.61	0.37	1.15e-16	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.38	-0.4	3.06e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs10911251	0.508	rs6424890	chr1:183112764	A/G	cg07245641	chr1:182991651	LAMC1	0.4	9.28	0.4	6.56e-19	Colorectal cancer;
LGG	cis	rs3806843	1.000	rs2240692	chr5:140183585	A/G	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	trans	rs3857536	0.813	rs9453639	chr6:66933538	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	cis	rs2594989	0.943	rs2594995	chr3:11369117	A/G	cg01796438	chr3:11312864	ATG7	0.57	7.96	0.35	1.37e-14	Circulating chemerin levels;
LGG	cis	rs7623687	0.786	rs73088161	chr3:49465162	C/T	cg19401529	chr3:49056140	DALRD3	0.71	8.0	0.35	9.83e-15	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs8060686	0.565	rs4359427	chr16:68202747	C/T	cg27539214	chr16:67997921	SLC12A4	-0.44	-6.82	-0.3	2.95e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2307022	0.586	rs1562479	chr16:68387373	C/T	cg07273125	chr16:68295692	NA	0.44	9.91	0.42	4.07e-21	Body mass index;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg15242686	chr22:24348715	GSTTP1	0.37	6.71	0.3	5.65e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs1941687	0.505	rs12605642	chr18:31313965	G/T	cg04226714	chr8:49833948	SNAI2	-0.46	-8.27	-0.36	1.46e-15	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs7182946	1.000	rs3809579	chr15:31394322	C/T	cg18085517	chr15:31394285	TRPM1	-0.3	-6.83	-0.3	2.66e-11	Advanced age-related macular degeneration;
LGG	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	trans	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.35	-0.36	7.76e-16	Neuroticism;
LGG	cis	rs2074977	0.530	rs10401784	chr19:3445721	A/C	cg08380311	chr19:3435252	NFIC	0.59	10.79	0.45	2.34e-24	Height;
LGG	cis	rs4595586	0.545	rs2197940	chr12:39401937	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs7927592	0.913	rs11228293	chr11:68384646	T/C	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs10193935	0.818	rs10221927	chr2:42546680	A/C	cg27598129	chr2:42591480	NA	-0.64	-9.63	-0.41	3.81e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4664308	1.000	rs10929965	chr2:160906931	C/T	cg03641300	chr2:160917029	PLA2R1	0.85	17.79	0.64	2.42e-54	Idiopathic membranous nephropathy;
LGG	cis	rs4731207	0.596	rs7795611	chr7:124578456	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1863824	0.625	rs11202024	chr10:88168024	C/A	cg07322936	chr10:88137208	NA	-0.51	-8.38	-0.36	6.21e-16	Schizophrenia;
LGG	cis	rs877282	0.898	rs12356709	chr10:763365	A/G	cg17470449	chr10:769945	NA	0.55	6.72	0.3	5.4e-11	Uric acid levels;
LGG	cis	rs6951245	0.935	rs79143504	chr7:1110212	A/G	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.18	-0.62	1.47e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg27524515	chr8:38239417	WHSC1L1	0.44	7.47	0.33	4.11e-13	Corneal astigmatism;
LGG	cis	rs6424115	1.000	rs2179395	chr1:24148365	T/C	cg15997130	chr1:24165203	NA	0.49	13.55	0.53	1.83e-35	Immature fraction of reticulocytes;
LGG	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.05	0.35	7.14e-15	Homoarginine levels;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs3770081	1.000	rs2241435	chr2:86360916	C/G	cg01119172	chr2:86362222	SNORD94;PTCD3	0.63	6.81	0.3	3.06e-11	Facial emotion recognition (sad faces);
LGG	cis	rs2742417	0.609	rs11709306	chr3:45773732	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.38	-0.4	3.04e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4481887	1.000	rs9660769	chr1:248484558	C/G	cg01631408	chr1:248437212	OR2T33	0.55	9.92	0.42	3.77e-21	Common traits (Other);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.56	9.2	0.39	1.26e-18	Longevity;
LGG	cis	rs2594989	0.943	rs2595004	chr3:11406721	C/T	cg01796438	chr3:11312864	ATG7	-0.55	-7.15	-0.32	3.34e-12	Circulating chemerin levels;
LGG	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg12458913	chr13:53173898	NA	0.45	7.63	0.33	1.37e-13	Lewy body disease;
LGG	cis	rs1062746	0.834	rs9308347	chr16:87371752	C/T	cg02258303	chr16:87377426	FBXO31	-0.61	-11.87	-0.48	1.53e-28	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	trans	rs6076960	0.684	rs6054059	chr20:6262472	G/T	cg24759859	chr6:86352639	SYNCRIP	0.44	7.4	0.33	6.43e-13	Smooth-surface caries;
LGG	cis	rs6918586	0.636	rs198857	chr6:26102417	G/C	cg18357526	chr6:26021779	HIST1H4A	-0.56	-9.62	-0.41	4.37e-20	Schizophrenia;
LGG	cis	rs870825	0.616	rs36022027	chr4:185639192	C/T	cg04058563	chr4:185651563	MLF1IP	1.04	22.77	0.73	1.54e-77	Blood protein levels;
LGG	cis	rs2153535	0.601	rs7741024	chr6:8530313	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.65	0.51	1.07e-31	Motion sickness;
LGG	cis	rs4776059	1.000	rs12915981	chr15:52901433	C/T	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.21	-0.36	2.19e-15	Schizophrenia;
LGG	cis	rs6062788	0.870	rs8116033	chr20:61699635	T/C	cg04883260	chr20:61718941	NA	0.32	7.16	0.32	3.11e-12	Body mass index;
LGG	cis	rs6586163	0.872	rs7082101	chr10:90741615	C/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.41	-7.13	-0.31	3.79e-12	Chronic lymphocytic leukemia;
LGG	cis	rs6121246	0.567	rs6060263	chr20:30193110	T/C	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs1957429	0.520	rs230718	chr14:65318943	A/G	cg23373153	chr14:65346875	NA	-1.03	-10.91	-0.45	8.42e-25	Pediatric areal bone mineral density (radius);
LGG	cis	rs9368481	0.594	rs7768643	chr6:26891919	C/T	cg18867708	chr6:26865862	GUSBL1	0.46	7.73	0.34	6.69e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	cis	rs6087771	0.926	rs6058431	chr20:30297133	C/T	cg13852791	chr20:30311386	BCL2L1	0.94	18.31	0.65	1.01e-56	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs4253772	0.513	rs12171124	chr22:46710693	A/C	cg00784671	chr22:46762841	CELSR1	-0.57	-7.26	-0.32	1.7e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2288073	0.930	rs7604097	chr2:24401805	G/C	cg26838691	chr2:24397539	C2orf84	-0.49	-6.99	-0.31	9.37e-12	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs3206736	0.548	rs10243141	chr7:35062566	A/G	cg13400248	chr7:35225412	NA	0.55	9.59	0.41	5.63e-20	Diastolic blood pressure;
LGG	cis	rs950776	0.714	rs615470	chr15:78885988	T/C	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.9	-0.34	2.08e-14	Sudden cardiac arrest;
LGG	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.77	-0.48	3.73e-28	Height;
LGG	cis	rs7249142	0.512	rs12981160	chr19:19298099	T/A	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.3	-0.43	1.49e-22	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00966380	chr12:47633443	NA	0.49	8.5	0.37	2.68e-16	Gut microbiome composition (summer);
LGG	cis	rs2408955	0.504	rs11168441	chr12:48576054	G/A	cg24011408	chr12:48396354	COL2A1	0.56	9.07	0.39	3.35e-18	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg08621203	chr6:150244597	RAET1G	0.44	7.63	0.33	1.31e-13	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg08169394	chr17:11143830	SHISA6	0.39	6.77	0.3	3.98e-11	Bipolar disorder;
LGG	cis	rs9309473	0.528	rs6546820	chr2:73553397	G/A	cg20560298	chr2:73613845	ALMS1	-0.43	-7.57	-0.33	2.03e-13	Metabolite levels;
LGG	trans	rs7944735	0.567	rs79837139	chr11:48000780	T/C	cg03929089	chr4:120376271	NA	0.68	6.9	0.31	1.67e-11	Intraocular pressure;
LGG	trans	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg16141378	chr3:129829833	LOC729375	-0.43	-10.27	-0.43	2.05e-22	Mood instability;
LGG	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.57	-0.37	1.58e-16	Neuroticism;
LGG	cis	rs6502050	0.799	rs8082355	chr17:80120316	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs113835537	0.529	rs11227509	chr11:66281194	T/C	cg24851651	chr11:66362959	CCS	0.44	7.58	0.33	1.89e-13	Airway imaging phenotypes;
LGG	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg08305652	chr11:111469057	NA	-0.43	-8.48	-0.37	3.05e-16	Primary sclerosing cholangitis;
LGG	cis	rs7727544	0.735	rs272860	chr5:131684175	C/G	cg07395648	chr5:131743802	NA	-0.55	-13.17	-0.52	7.26e-34	Blood metabolite levels;
LGG	cis	rs61931739	0.517	rs10844815	chr12:34245150	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.47	-0.47	5.41e-27	Morning vs. evening chronotype;
LGG	cis	rs10276381	0.892	rs7786444	chr7:28154384	C/T	cg23620719	chr7:28220237	JAZF1	0.73	9.45	0.4	1.66e-19	Crohn's disease;
LGG	cis	rs736408	0.812	rs1075653	chr3:52825528	T/C	cg14092988	chr3:52407081	DNAH1	0.34	8.91	0.38	1.13e-17	Bipolar disorder;
LGG	cis	rs7264396	0.790	rs6058297	chr20:34271861	G/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.64	-0.33	1.27e-13	Total cholesterol levels;
LGG	cis	rs62400317	0.826	rs17288327	chr6:45349877	A/G	cg18551225	chr6:44695536	NA	-0.61	-10.07	-0.42	1.09e-21	Total body bone mineral density;
LGG	trans	rs17685	0.725	rs2302436	chr7:75676988	A/T	cg19862616	chr7:65841803	NCRNA00174	-1.05	-24.63	-0.75	3.17e-86	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs7613875	0.600	rs1138536	chr3:50153356	C/T	cg14019146	chr3:50243930	SLC38A3	-0.33	-7.22	-0.32	2.17e-12	Body mass index;
LGG	cis	rs908922	0.676	rs12132469	chr1:152491856	G/T	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	cis	rs1008375	0.931	rs6837181	chr4:17701253	A/C	cg16339924	chr4:17578868	LAP3	0.5	8.43	0.36	4.4e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12325245	0.536	rs17821543	chr16:58540875	C/T	cg26666090	chr16:58549219	SETD6	1.15	10.19	0.43	3.94e-22	Schizophrenia;
LGG	cis	rs941873	0.868	rs12780295	chr10:81115438	G/A	cg09469691	chr10:81107165	PPIF	0.59	10.36	0.43	8.91e-23	Height;
LGG	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.5	-0.33	3.2e-13	Joint mobility (Beighton score);
LGG	cis	rs5756391	0.546	rs9607390	chr22:37314533	C/T	cg21209356	chr22:37319042	CSF2RB	0.41	9.32	0.4	4.76e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs988958	0.565	rs34465637	chr2:42229346	G/A	cg19376973	chr2:42229025	NA	0.6	8.65	0.37	8.75e-17	Hypospadias;
LGG	cis	rs2860975	0.542	rs1579029	chr10:96811010	T/C	cg09036531	chr10:96991505	NA	-0.47	-8.15	-0.35	3.37e-15	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs7717393	0.786	rs7722282	chr5:155797834	G/A	cg04435420	chr5:155754009	SGCD	0.75	9.68	0.41	2.72e-20	Egg allergy;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.61	-10.64	-0.44	8.39e-24	Obesity-related traits;
LGG	cis	rs35740288	0.857	rs3803506	chr15:86290940	A/C	cg04173714	chr15:86211321	AKAP13	0.41	6.95	0.31	1.21e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg16583315	chr14:65563665	MAX	-0.37	-7.25	-0.32	1.77e-12	Obesity-related traits;
LGG	cis	rs7558370	0.737	rs77200948	chr2:3710169	C/T	cg14882966	chr2:3699353	NA	0.77	7.11	0.31	4.49e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs61931739	0.500	rs6416261	chr12:34540377	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.91	-0.42	3.9e-21	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.614	rs12418827	chr11:109390649	G/C	cg27471124	chr11:109292789	C11orf87	0.48	9.43	0.4	2.02e-19	Schizophrenia;
LGG	cis	rs9649465	0.561	rs688242	chr7:123420442	C/A	cg03229431	chr7:123269106	ASB15	0.6	13.82	0.54	1.35e-36	Migraine;
LGG	cis	rs7155454	0.935	rs4899159	chr14:65480595	C/T	cg26396452	chr14:65542826	MAX	-0.35	-6.76	-0.3	4.17e-11	Mean corpuscular volume;Red blood cell traits;Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7296418	0.885	rs1790104	chr12:123709409	C/T	cg00376283	chr12:123451042	ABCB9	0.67	12.42	0.5	9.28e-31	Platelet count;
LGG	cis	rs2243480	1.000	rs60683927	chr7:65394768	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs6496044	0.568	rs6496065	chr15:86075372	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-6.69	-0.3	6.63e-11	Interstitial lung disease;
LGG	cis	rs9790314	0.663	rs5004752	chr3:160748380	A/T	cg03342759	chr3:160939853	NMD3	-0.43	-7.24	-0.32	1.93e-12	Morning vs. evening chronotype;
LGG	cis	rs13177180	0.671	rs746566	chr5:114922047	C/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.45	-10.21	-0.43	3.24e-22	Conotruncal heart defects (inherited effects);
LGG	cis	rs17666538	0.535	rs7822126	chr8:643810	A/G	cg13264159	chr8:625131	ERICH1	-0.71	-8.76	-0.38	3.79e-17	IgG glycosylation;
LGG	cis	rs7166081	1.000	rs35688953	chr15:67640129	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.29	-0.32	1.34e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs61931739	0.500	rs7965421	chr12:34523624	G/T	cg06521331	chr12:34319734	NA	-0.56	-9.57	-0.41	6.67e-20	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.48	0.33	3.86e-13	Menopause (age at onset);
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg23782820	chr8:58130467	NA	0.46	7.33	0.32	1.04e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs911392	chr16:1947259	A/G	cg26897989	chr16:1907736	C16orf73	-0.84	-13.92	-0.54	4.66e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10504229	0.871	rs56372514	chr8:58157166	A/G	cg08280861	chr8:58055591	NA	0.51	6.75	0.3	4.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7945718	0.621	rs7931934	chr11:12679245	T/G	cg25843174	chr11:12811716	TEAD1	0.33	6.96	0.31	1.15e-11	Educational attainment (years of education);
LGG	cis	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg03060546	chr3:49711283	APEH	0.58	7.99	0.35	1.11e-14	Menarche (age at onset);
LGG	cis	rs7524258	0.900	rs2412151	chr1:7303216	G/C	cg07173049	chr1:7289937	CAMTA1	0.71	16.72	0.61	2.01e-49	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs2839186	0.681	rs13047198	chr21:47701835	T/C	cg12379764	chr21:47803548	PCNT	-0.49	-8.11	-0.35	4.63e-15	Testicular germ cell tumor;
LGG	cis	rs9616064	0.531	rs867212	chr22:47063330	C/T	cg25730555	chr22:47059586	GRAMD4	-0.39	-6.75	-0.3	4.37e-11	Urate levels in obese individuals;
LGG	cis	rs881375	0.669	rs73541868	chr9:123639264	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.41	0.4	2.38e-19	Rheumatoid arthritis;
LGG	cis	rs4262150	0.617	rs4130911	chr5:152251661	A/G	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs57221529	0.546	rs72707044	chr5:677239	T/C	cg14541582	chr5:601475	NA	-0.71	-10.21	-0.43	3.41e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs8072100	0.967	rs4794058	chr17:45597098	C/T	cg08085267	chr17:45401833	C17orf57	0.59	11.76	0.48	3.9e-28	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6909430	1.000	rs9388294	chr6:98670458	A/G	cg12860156	chr6:98744658	NA	-0.44	-7.39	-0.32	6.75e-13	Quantitative traits;
LGG	cis	rs6840360	0.571	rs10007653	chr4:152524055	A/G	cg25486957	chr4:152246857	NA	-0.42	-6.69	-0.3	6.64e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17023223	0.537	rs7525871	chr1:119621894	T/C	cg05756136	chr1:119680316	WARS2	-0.43	-8.69	-0.37	6.5e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs9987353	0.544	rs2929470	chr8:9062490	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.22	-0.32	2.13e-12	Recombination measurement;
LGG	cis	rs17270561	0.666	rs1141034	chr6:25780332	C/T	cg17691542	chr6:26056736	HIST1H1C	0.67	10.98	0.45	4.49e-25	Iron status biomarkers;
LGG	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-8.02	-0.35	8.58e-15	Aortic root size;
LGG	cis	rs9527	0.615	rs17725614	chr10:104685493	G/C	cg04362960	chr10:104952993	NT5C2	0.55	10.03	0.42	1.51e-21	Arsenic metabolism;
LGG	cis	rs6065	0.618	rs4790719	chr17:4881434	A/G	cg01912298	chr17:4872499	CAMTA2;SPAG7	0.5	7.08	0.31	5.44e-12	Platelet count;
LGG	trans	rs7824557	0.602	rs7833966	chr8:11206220	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.91	-0.31	1.62e-11	Retinal vascular caliber;
LGG	trans	rs11098499	0.863	rs6534141	chr4:120485223	A/T	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.88e-27	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.92e-17	Lung cancer;
LGG	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg02023728	chr11:77925099	USP35	-0.39	-6.88	-0.3	1.91e-11	Alzheimer's disease (survival time);
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	cis	rs1318772	0.577	rs56044911	chr5:112955274	A/G	cg12552261	chr5:112820674	MCC	0.6	6.84	0.3	2.5e-11	F-cell distribution;
LGG	cis	rs1111571	0.576	rs1868158	chr16:68398924	C/T	cg07273125	chr16:68295692	NA	0.38	8.21	0.36	2.17e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs9790314	0.715	rs898681	chr3:160773098	A/G	cg03342759	chr3:160939853	NMD3	-0.5	-8.41	-0.36	5.11e-16	Morning vs. evening chronotype;
LGG	cis	rs1729951	0.575	rs361243	chr3:136697786	C/T	cg21827317	chr3:136751795	NA	0.53	10.01	0.42	1.71e-21	Neuroticism;
LGG	cis	rs2439831	1.000	rs2245790	chr15:43744457	T/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.56	-0.33	2.18e-13	Lung cancer in ever smokers;
LGG	cis	rs7241530	0.689	rs7242994	chr18:75889700	A/G	cg14642773	chr18:75888474	NA	0.46	9.19	0.39	1.38e-18	Educational attainment (years of education);
LGG	cis	rs12893597	0.715	rs71429953	chr14:76819480	C/T	cg20290672	chr14:76816747	NA	-0.51	-7.68	-0.34	9.83e-14	Maximal oxygen uptake response;
LGG	cis	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg21775007	chr8:11205619	TDH	-0.79	-13.63	-0.54	8.36e-36	Retinal vascular caliber;
LGG	cis	rs4789693	0.938	rs12952655	chr17:80421139	C/T	cg04308225	chr17:80449738	NA	-0.63	-9.36	-0.4	3.43e-19	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg04362960	chr10:104952993	NT5C2	0.48	7.99	0.35	1.05e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9549367	0.789	rs2287244	chr13:113887173	C/G	cg18105134	chr13:113819100	PROZ	0.65	13.2	0.52	5.17e-34	Platelet distribution width;
LGG	cis	rs6089584	0.854	rs2380146	chr20:60632233	C/T	cg06470251	chr20:60548479	NA	0.45	7.5	0.33	3.32e-13	Body mass index;
LGG	cis	rs9435341	0.762	rs2878349	chr1:107549245	G/A	cg09367891	chr1:107599246	PRMT6	0.56	9.48	0.4	1.28e-19	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs1949733	0.848	rs2255501	chr4:8475014	G/A	cg13073564	chr4:8508604	NA	0.54	10.45	0.44	4.16e-23	Response to antineoplastic agents;
LGG	cis	rs3206736	0.548	rs10254796	chr7:35070935	A/C	cg13400248	chr7:35225412	NA	0.55	9.51	0.4	1.07e-19	Diastolic blood pressure;
LGG	cis	rs1691799	0.867	rs1183274	chr12:66732057	C/G	cg16791601	chr12:66731901	HELB	-0.65	-15.53	-0.59	4.42e-44	White blood cell count (basophil);
LGG	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4671458	0.626	rs72806055	chr2:63835971	C/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.19	-0.32	2.68e-12	Subjective well-being;
LGG	cis	rs9467773	1.000	rs1056667	chr6:26510564	T/C	cg09904177	chr6:26538194	HMGN4	0.77	17.45	0.63	9.21e-53	Intelligence (multi-trait analysis);
LGG	cis	rs10791097	0.667	rs12363163	chr11:130744509	A/G	cg09137382	chr11:130731461	NA	0.36	6.87	0.3	2.04e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9443189	0.570	rs7770824	chr6:76408189	G/A	cg01950844	chr6:76311363	SENP6	0.76	10.05	0.42	1.24e-21	Prostate cancer;
LGG	cis	rs11711311	1.000	rs3773682	chr3:113520576	T/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	13.13	0.52	1.07e-33	IgG glycosylation;
LGG	trans	rs9657904	1.000	rs1021859	chr3:105593181	T/C	cg14088669	chr1:158435396	OR10K1	0.38	6.67	0.3	7.44e-11	Multiple sclerosis;
LGG	cis	rs4794202	0.629	rs62076106	chr17:45890479	C/T	cg02219949	chr17:45927392	SP6	0.55	6.71	0.3	5.57e-11	Alzheimer's disease (cognitive decline);
LGG	cis	rs11252926	0.966	rs11252923	chr10:566195	G/A	cg16386425	chr10:429943	DIP2C	0.39	7.31	0.32	1.14e-12	Psychosis in Alzheimer's disease;
LGG	cis	rs13108904	0.967	rs62293658	chr4:1276416	T/C	cg05665937	chr4:1216051	CTBP1	-0.51	-9.19	-0.39	1.33e-18	Obesity-related traits;
LGG	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.88	0.34	2.35e-14	Cannabis dependence symptom count;
LGG	cis	rs4321325	0.733	rs78516281	chr2:127944564	G/C	cg11380483	chr2:127933992	NA	0.65	9.16	0.39	1.73e-18	Protein C levels;
LGG	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs9300255	0.679	rs10846507	chr12:123786492	G/T	cg00376283	chr12:123451042	ABCB9	0.56	8.69	0.37	6.45e-17	Neutrophil percentage of white cells;
LGG	cis	rs1046896	0.553	rs72634343	chr17:80827392	T/C	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.73	0.34	6.59e-14	Glycated hemoglobin levels;
LGG	cis	rs3733585	0.699	rs7677710	chr4:9969517	T/G	cg08250081	chr4:10125330	NA	-0.36	-6.89	-0.3	1.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs950169	0.580	rs11633762	chr15:85187152	T/C	cg24253500	chr15:84953950	NA	0.42	7.05	0.31	6.58e-12	Schizophrenia;
LGG	cis	rs7100689	0.646	rs1953972	chr10:82145666	A/G	cg01528321	chr10:82214614	TSPAN14	0.88	15.59	0.59	2.42e-44	Post bronchodilator FEV1;
LGG	cis	rs7618915	0.547	rs13085895	chr3:52678270	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs11191205	0.865	rs11191161	chr10:103726528	C/T	cg00857846	chr10:103824917	HPS6	-0.67	-8.7	-0.37	6.01e-17	Intelligence (multi-trait analysis);
LGG	cis	rs453301	0.592	rs4841084	chr8:8883905	C/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.08	0.42	1e-21	Joint mobility (Beighton score);
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg04863758	chr4:1303710	MAEA	0.45	7.61	0.33	1.5e-13	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	trans	rs208520	1.000	rs12200490	chr6:66976084	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.89	14.34	0.55	7.21e-39	Exhaled nitric oxide output;
LGG	trans	rs637571	0.512	rs660118	chr11:65735174	G/C	cg17712092	chr4:129076599	LARP1B	0.74	13.98	0.54	2.67e-37	Eosinophil percentage of white cells;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12489069	chr17:26898961	PIGS	-0.47	-7.12	-0.31	4.14e-12	Systemic lupus erythematosus;
LGG	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg03929089	chr4:120376271	NA	-0.95	-20.29	-0.69	6.23e-66	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21107223	chr15:75182455	MPI	-0.34	-6.9	-0.31	1.71e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07663468	chr19:44506883	ZNF230	0.44	7.49	0.33	3.58e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.65	0.37	8.74e-17	Diabetic retinopathy;
LGG	cis	rs644799	0.540	rs10831422	chr11:95478968	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.05	0.55	1.28e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs1459104	0.866	rs66989058	chr11:54823043	C/A	cg15704280	chr7:45808275	SEPT13	0.73	7.48	0.33	3.8e-13	Body mass index;
LGG	cis	rs936229	0.626	rs3765066	chr15:75140854	G/A	cg20040747	chr15:74715105	SEMA7A	0.33	7.03	0.31	7.42e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11877270	chr2:65658583	SPRED2	0.51	8.69	0.37	6.22e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs10901296	0.588	rs12003046	chr9:133741626	T/C	cg13397898	chr9:133768931	QRFP	0.35	6.72	0.3	5.24e-11	Bilirubin levels;
LGG	cis	rs2153535	0.542	rs4440510	chr6:8471818	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.49e-22	Motion sickness;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs6430585	0.527	rs12465544	chr2:136451676	C/T	cg07169764	chr2:136633963	MCM6	1.01	16.9	0.62	2.86e-50	Corneal structure;
LGG	cis	rs7236492	0.935	rs60115988	chr18:77226571	G/A	cg15532942	chr18:77220712	NFATC1	0.42	6.89	0.3	1.82e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs735396	0.965	rs2257962	chr12:121445808	T/C	cg14101638	chr12:121416612	HNF1A	0.35	7.39	0.33	6.7e-13	N-glycan levels;
LGG	cis	rs7712401	0.601	rs30022	chr5:122285716	T/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg00701064	chr4:6280414	WFS1	0.59	10.69	0.44	5.49e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9470366	0.637	rs4151702	chr6:36645988	G/C	cg08179530	chr6:36648295	CDKN1A	0.55	7.52	0.33	2.89e-13	QRS duration;
LGG	cis	rs11628318	0.853	rs10151896	chr14:103039936	G/C	cg12046867	chr14:103022105	NA	-0.8	-15.9	-0.59	9.9e-46	Platelet count;
LGG	cis	rs36093924	0.646	rs7285557	chr22:42348790	T/C	cg15128208	chr22:42549153	NA	0.37	6.88	0.3	1.94e-11	Intelligence;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg07132326	chr6:150258058	NA	0.38	8.18	0.36	2.78e-15	Testicular germ cell tumor;
LGG	cis	rs727505	0.954	rs17327014	chr7:124709349	C/T	cg23710748	chr7:124431027	NA	-0.49	-8.86	-0.38	1.72e-17	Lewy body disease;
LGG	cis	rs1915146	0.546	rs9422857	chr10:126861278	C/G	cg23000734	chr10:126850823	CTBP2	0.26	7.57	0.33	2.01e-13	Menarche (age at onset);
LGG	cis	rs11148252	0.967	rs11618716	chr13:53046836	A/G	cg12458913	chr13:53173898	NA	-0.71	-14.71	-0.56	1.87e-40	Lewy body disease;
LGG	cis	rs11864453	0.647	rs8043606	chr16:72135319	T/C	cg23815491	chr16:72088622	HP	0.49	11.12	0.46	1.23e-25	Fibrinogen levels;
LGG	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg01280390	chr8:19363452	CSGALNACT1	-0.48	-12.53	-0.5	3.21e-31	Oropharynx cancer;
LGG	cis	rs651907	0.535	rs34063583	chr3:101509948	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg22072935	chr14:105399595	NA	0.51	10.02	0.42	1.65e-21	Rheumatoid arthritis;
LGG	cis	rs3857067	1.000	rs1509943	chr4:95013366	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.56	-0.33	2.26e-13	QT interval;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.44	6.76	0.3	4.15e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1505368	0.836	rs10201067	chr2:213284411	A/G	cg16329650	chr2:213403929	ERBB4	-0.47	-8.14	-0.35	3.77e-15	Symmetrical dimethylarginine levels;
LGG	cis	rs2576037	0.583	rs593340	chr18:44418346	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.49	-0.37	2.85e-16	Personality dimensions;
LGG	cis	rs3020736	0.500	rs2413672	chr22:42513261	C/T	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9291683	0.575	rs3756223	chr4:10105797	C/T	cg11266682	chr4:10021025	SLC2A9	0.39	7.47	0.33	3.95e-13	Bone mineral density;
LGG	cis	rs2228479	0.867	rs62056110	chr16:89946388	A/C	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.51	-0.33	3.13e-13	Skin colour saturation;
LGG	cis	rs7819412	0.875	rs6981523	chr8:11061792	C/T	cg21775007	chr8:11205619	TDH	-0.5	-8.23	-0.36	1.86e-15	Triglycerides;
LGG	cis	rs4820539	0.902	rs4822359	chr22:23474972	A/G	cg21100191	chr22:23484243	RTDR1	1.0	22.77	0.73	1.5e-77	Bone mineral density;
LGG	cis	rs9952991	0.622	rs8091566	chr18:12826385	G/A	cg23598886	chr18:12777645	NA	0.49	7.13	0.31	3.82e-12	Inflammatory skin disease;
LGG	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.91	0.31	1.57e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs6088580	0.543	rs4911158	chr20:33239512	T/C	cg24642439	chr20:33292090	TP53INP2	-0.44	-6.91	-0.31	1.66e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs17401966	0.540	rs4846216	chr1:10447792	A/T	cg17425144	chr1:10567563	PEX14	0.42	9.33	0.4	4.35e-19	Hepatocellular carcinoma;
LGG	cis	rs11771526	0.901	rs62457503	chr7:32330980	A/C	cg27532318	chr7:32358331	NA	0.75	7.55	0.33	2.32e-13	Body mass index;
LGG	cis	rs2342371	0.720	rs61345811	chr3:196143030	C/T	cg15048948	chr3:196158458	UBXN7	0.62	10.61	0.44	1.08e-23	Fat distribution (HIV);
LGG	cis	rs4819052	0.851	rs10470245	chr21:46658912	A/G	cg06618935	chr21:46677482	NA	-0.5	-9.68	-0.41	2.64e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.62	-0.33	1.48e-13	Lung cancer;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs778371	0.752	rs283487	chr2:233644011	A/G	cg08000102	chr2:233561755	GIGYF2	0.69	11.25	0.46	4.07e-26	Schizophrenia;
LGG	cis	rs12701220	0.895	rs3808348	chr7:1028448	C/T	cg06145435	chr7:1022769	CYP2W1	0.39	6.71	0.3	5.61e-11	Bronchopulmonary dysplasia;
LGG	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg06623630	chr22:50017776	C22orf34	-0.35	-7.33	-0.32	1.03e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs7264396	0.790	rs6060562	chr20:34282053	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.13	-0.31	3.98e-12	Total cholesterol levels;
LGG	cis	rs4936894	0.500	rs12807551	chr11:124129518	A/G	cg27160556	chr11:124181099	OR8D1	-0.44	-10.2	-0.43	3.5e-22	Aging (time to death);
LGG	trans	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg18335740	chr13:41363409	SLC25A15	0.57	10.47	0.44	3.63e-23	Lewy body disease;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg00149659	chr3:10157352	C3orf10	0.88	11.43	0.47	8.33e-27	Alzheimer's disease;
LGG	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg24642439	chr20:33292090	TP53INP2	-0.41	-6.69	-0.3	6.31e-11	Height;
LGG	cis	rs2303319	1.000	rs34731727	chr2:162157280	A/C	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs12450239	0.885	rs12451758	chr17:77446494	A/G	cg07832143	chr17:77435199	HRNBP3	0.43	8.31	0.36	1.07e-15	Body mass index;
LGG	cis	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg22857025	chr5:266934	NA	-1.49	-26.2	-0.77	1.84e-93	Breast cancer;
LGG	cis	rs4950928	0.823	rs4950882	chr1:203164848	A/G	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.9	-0.34	2.12e-14	YKL-40 levels;
LGG	cis	rs453301	0.658	rs3855900	chr8:8901921	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.18	-0.36	2.76e-15	Joint mobility (Beighton score);
LGG	trans	rs11992162	1.000	rs11784499	chr8:11834539	G/T	cg15556689	chr8:8085844	FLJ10661	0.39	6.82	0.3	2.82e-11	Monocyte count;
LGG	cis	rs35883536	1.000	rs11586815	chr1:101089079	C/T	cg06223162	chr1:101003688	GPR88	0.3	6.66	0.3	7.82e-11	Monocyte count;
LGG	cis	rs870825	0.616	rs4437295	chr4:185643336	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs10937275	0.624	rs17774519	chr3:186665247	G/A	cg13419791	chr3:186648285	ST6GAL1	0.78	8.01	0.35	9.67e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs977987	1.000	rs977987	chr16:75506593	G/A	cg03315344	chr16:75512273	CHST6	0.57	11.35	0.47	1.6e-26	Dupuytren's disease;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.91	-17.34	-0.63	2.97e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9549328	0.878	rs9577407	chr13:113639671	G/A	cg08528486	chr13:113648767	MCF2L	-0.32	-6.71	-0.3	5.59e-11	Systolic blood pressure;
LGG	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.75	14.24	0.55	2.05e-38	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2404602	0.647	rs2404604	chr15:76991105	A/G	cg15268244	chr15:77196840	NA	0.49	10.42	0.44	5.44e-23	Blood metabolite levels;
LGG	cis	rs7654585	0.645	rs1123943	chr4:25924426	A/G	cg10409131	chr4:25915609	C4orf52	-0.54	-9.22	-0.39	1.02e-18	Obesity-related traits;
LGG	cis	rs787274	1.000	rs787302	chr9:115543839	G/A	cg13803584	chr9:115635662	SNX30	-0.61	-7.64	-0.33	1.22e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg11890956	chr21:40555474	PSMG1	1.21	30.86	0.82	1.98e-114	Cognitive function;
LGG	cis	rs10197940	0.578	rs6718653	chr2:152346118	C/A	cg19508488	chr2:152266495	RIF1	0.47	8.52	0.37	2.31e-16	Lung cancer;
LGG	cis	rs10883723	0.810	rs1409311	chr10:104282160	G/A	cg05096777	chr10:104283225	SUFU	0.32	6.95	0.31	1.24e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1059312	1.000	rs7135987	chr12:129280117	G/A	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.29	7.16	0.32	3.19e-12	Systemic lupus erythematosus;
LGG	cis	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg08564027	chr20:61660810	NA	-0.9	-20.33	-0.69	3.69e-66	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs6952808	0.929	rs12699483	chr7:1975624	C/G	cg24247370	chr13:99142703	STK24	-0.41	-7.4	-0.33	6.32e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11758351	0.587	rs16891466	chr6:26235737	G/A	cg01420254	chr6:26195488	NA	0.82	10.68	0.44	5.91e-24	Gout;Renal underexcretion gout;
LGG	cis	rs6748734	1.000	rs4311055	chr2:241821017	T/C	cg26818257	chr2:241905806	NA	0.37	7.07	0.31	5.58e-12	Urinary metabolites;
LGG	cis	rs9309473	1.000	rs7607014	chr2:73730174	C/T	cg20560298	chr2:73613845	ALMS1	0.43	7.26	0.32	1.63e-12	Metabolite levels;
LGG	cis	rs975722	0.736	rs213987	chr7:117261293	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.44	-9.13	-0.39	2.09e-18	Coronary artery disease;
LGG	cis	rs9399135	0.967	rs9399129	chr6:135285148	C/A	cg24558204	chr6:135376177	HBS1L	0.52	9.37	0.4	3.11e-19	Red blood cell count;
LGG	cis	rs6942756	1.000	rs7780886	chr7:128879347	G/A	cg02491457	chr7:128862824	NA	-0.77	-14.3	-0.55	1.08e-38	White matter hyperintensity burden;
LGG	cis	rs6088580	0.634	rs6059850	chr20:33044784	C/G	cg24642439	chr20:33292090	TP53INP2	0.57	9.48	0.4	1.28e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs9473924	0.505	rs2817332	chr6:50848522	T/A	cg14470998	chr6:50812995	TFAP2B	-0.69	-8.4	-0.36	5.57e-16	Body mass index;
LGG	cis	rs6088580	0.634	rs6059866	chr20:33075810	A/C	cg24642439	chr20:33292090	TP53INP2	0.58	9.73	0.41	1.7e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9926296	0.744	rs164748	chr16:89708292	C/G	cg04287289	chr16:89883240	FANCA	-0.44	-7.92	-0.35	1.84e-14	Vitiligo;
LGG	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg19442545	chr10:75533431	FUT11	-0.44	-7.22	-0.32	2.18e-12	Inflammatory bowel disease;
LGG	trans	rs1814175	0.935	rs10839317	chr11:49657228	A/C	cg15704280	chr7:45808275	SEPT13	-1.06	-23.97	-0.74	3.67e-83	Height;
LGG	cis	rs137603	0.933	rs137593	chr22:39690021	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	-0.44	-7.45	-0.33	4.66e-13	Primary biliary cholangitis;
LGG	trans	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs1865760	0.865	rs9467641	chr6:25947236	T/C	cg03264133	chr6:25882463	NA	-0.42	-7.48	-0.33	3.69e-13	Height;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.9	-0.34	2.06e-14	Total body bone mineral density;
LGG	cis	rs2739330	0.929	rs5751775	chr22:24266726	T/C	cg25703541	chr22:24373054	LOC391322	-0.89	-18.3	-0.65	1.11e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12643440	0.574	rs62296689	chr4:17139096	G/C	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs9309473	0.898	rs6546852	chr2:73833431	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.72	-0.34	7.3e-14	Metabolite levels;
LGG	cis	rs4481887	1.000	rs4244172	chr1:248466838	A/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.74	-0.41	1.58e-20	Common traits (Other);
LGG	cis	rs7717393	0.786	rs17053449	chr5:155769993	A/G	cg04435420	chr5:155754009	SGCD	-0.74	-9.37	-0.4	3.15e-19	Egg allergy;
LGG	cis	rs11955398	0.692	rs897672	chr5:59996101	C/G	cg02684056	chr5:59996105	DEPDC1B	0.44	7.25	0.32	1.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.872	rs6830828	chr4:187897472	T/G	cg11301795	chr4:187892539	NA	-0.94	-24.92	-0.76	1.46e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs910873	0.505	rs6058099	chr20:33249134	C/T	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.3	-0.32	1.22e-12	Melanoma;
LGG	cis	rs903263	0.965	rs1057738	chr1:84670816	A/C	cg10977910	chr1:84465055	TTLL7	0.41	6.85	0.3	2.34e-11	Breast cancer (male);
LGG	cis	rs9790314	0.715	rs980975	chr3:160771410	G/A	cg04691961	chr3:161091175	C3orf57	-0.46	-9.85	-0.42	6.35e-21	Morning vs. evening chronotype;
LGG	cis	rs6964587	0.626	rs6979235	chr7:91511776	T/C	cg17063962	chr7:91808500	NA	-0.44	-7.94	-0.35	1.56e-14	Breast cancer;
LGG	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.8	-0.34	4.08e-14	Colorectal cancer;
LGG	cis	rs910316	0.726	rs61979167	chr14:75663610	C/T	cg11812906	chr14:75593930	NEK9	-0.47	-8.67	-0.37	7.46e-17	Height;
LGG	cis	rs9911578	0.967	rs2611781	chr17:56703124	C/G	cg12560992	chr17:57184187	TRIM37	0.88	15.46	0.58	8.79e-44	Intelligence (multi-trait analysis);
LGG	cis	rs1555133	0.625	rs6141696	chr20:30969603	T/C	cg00028034	chr20:30779307	TSPYL3	0.32	6.66	0.3	7.63e-11	Monocyte count;
LGG	cis	rs875971	0.545	rs17138149	chr7:65693180	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.52	10.35	0.43	9.73e-23	Aortic root size;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.94	0.49	7.59e-29	Lymphocyte counts;
LGG	cis	rs875971	0.862	rs10240949	chr7:65804417	A/G	cg11764359	chr7:65958608	NA	-0.73	-13.18	-0.52	6.43e-34	Aortic root size;
LGG	cis	rs2361718	0.501	rs11869566	chr17:78143248	T/C	cg09238746	chr17:78121135	EIF4A3	-0.91	-15.63	-0.59	1.57e-44	Yeast infection;
LGG	cis	rs7666738	0.830	rs7662218	chr4:98983126	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2841277	0.708	rs2582533	chr14:105398787	G/C	cg19901468	chr14:105411992	AHNAK2	-0.9	-19.11	-0.66	1.88e-60	Rheumatoid arthritis;
LGG	trans	rs526821	0.595	rs499446	chr11:55355722	A/G	cg15704280	chr7:45808275	SEPT13	-0.42	-6.69	-0.3	6.26e-11	Pediatric bone mineral density (spine);
LGG	cis	rs7829975	0.623	rs10092965	chr8:8373485	A/G	cg06636001	chr8:8085503	FLJ10661	0.55	10.75	0.45	3.25e-24	Mood instability;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg11878867	chr6:150167359	LRP11	-0.49	-9.97	-0.42	2.47e-21	Lung cancer;
LGG	cis	rs2832191	0.935	rs11910475	chr21:30519702	T/C	cg08807101	chr21:30365312	RNF160	-0.77	-14.82	-0.57	6.19e-41	Dental caries;
LGG	cis	rs1595825	0.891	rs59617443	chr2:198653204	C/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	cis	rs9596863	1.000	rs9596859	chr13:54431200	T/A	ch.13.53330881F	chr13:54432880	NA	0.51	6.98	0.31	1.03e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs10875746	0.551	rs2054904	chr12:48724354	C/G	cg24011408	chr12:48396354	COL2A1	-0.56	-7.16	-0.32	3.28e-12	Longevity (90 years and older);
LGG	cis	rs10392	0.706	rs72623596	chr20:37585212	T/C	cg16355469	chr20:37678765	NA	0.55	7.39	0.32	6.74e-13	Alcohol dependence or chronic alcoholic pancreatitis or alcohol-related liver cirrhosis;
LGG	cis	rs9381040	0.610	rs6919961	chr6:41020361	T/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.39	-6.91	-0.31	1.63e-11	Alzheimer's disease (late onset);
LGG	cis	rs11148252	0.514	rs1886539	chr13:52726090	C/T	cg22398616	chr13:53314203	LECT1	-0.41	-7.91	-0.35	1.92e-14	Lewy body disease;
LGG	cis	rs10911232	0.507	rs4652766	chr1:182994336	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.8	0.38	2.76e-17	Hypertriglyceridemia;
LGG	cis	rs7107174	1.000	rs7939646	chr11:78111613	C/T	cg27205649	chr11:78285834	NARS2	0.44	7.34	0.32	9.4e-13	Testicular germ cell tumor;
LGG	cis	rs11190604	1.000	rs2489050	chr10:102350898	T/A	cg11040518	chr10:102331378	NA	-0.37	-6.79	-0.3	3.51e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9399137	0.507	rs7761964	chr6:135314265	T/C	cg22676075	chr6:135203613	NA	0.42	7.3	0.32	1.25e-12	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.66	-0.37	7.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs3935403	chr17:80114145	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs561341	0.941	rs501773	chr17:30314435	T/G	cg13647721	chr17:30228624	UTP6	0.61	7.91	0.35	1.85e-14	Hip circumference adjusted for BMI;
LGG	cis	rs3747547	0.892	rs67076718	chr9:38035758	C/T	cg13774184	chr9:37916125	SHB	-0.68	-6.76	-0.3	4.08e-11	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7937682	0.889	rs497111	chr11:111499512	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs3858526	0.920	rs10742832	chr11:5926020	C/G	cg13902645	chr11:5959945	NA	-0.67	-10.8	-0.45	2.03e-24	DNA methylation (variation);
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg05863683	chr7:1912471	MAD1L1	0.37	7.29	0.32	1.32e-12	Schizophrenia;
LGG	cis	rs7555523	0.887	rs2790053	chr1:165737704	C/G	cg24409356	chr1:165738333	TMCO1	0.76	9.21	0.39	1.17e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg16141378	chr3:129829833	LOC729375	-0.32	-6.9	-0.31	1.77e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg07701084	chr6:150067640	NUP43	0.66	12.47	0.5	5.47e-31	Lung cancer;
LGG	cis	rs2439831	0.867	rs28415933	chr15:43635800	T/C	cg15269541	chr15:43626905	ADAL	-0.42	-7.02	-0.31	7.92e-12	Lung cancer in ever smokers;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg23758822	chr17:41437982	NA	0.83	14.65	0.56	3.34e-40	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs79061246	chr22:32468866	G/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs1505368	0.567	rs972491	chr2:213316573	A/G	cg20637307	chr2:213403960	ERBB4	-0.52	-10.38	-0.43	8.12e-23	Symmetrical dimethylarginine levels;
LGG	cis	rs2075371	0.966	rs722657	chr7:133994956	T/C	cg11752832	chr7:134001865	SLC35B4	0.6	11.0	0.46	3.67e-25	Mean platelet volume;
LGG	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-24.0	-0.74	2.61e-83	Primary sclerosing cholangitis;
LGG	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.5	-0.33	3.19e-13	HDL cholesterol;
LGG	cis	rs6977660	0.652	rs10274428	chr7:19850592	C/T	cg05791153	chr7:19748676	TWISTNB	0.73	10.15	0.43	5.6e-22	Thyroid stimulating hormone;
LGG	cis	rs7618915	0.571	rs6762457	chr3:52609157	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.53	0.4	9.23e-20	Bipolar disorder;
LGG	cis	rs6489785	0.775	rs1168956	chr12:121323229	C/T	cg02419362	chr12:121203948	SPPL3	-0.43	-6.72	-0.3	5.24e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg00343986	chr7:65444356	GUSB	0.49	8.6	0.37	1.23e-16	Calcium levels;
LGG	cis	rs9951602	0.512	rs12455591	chr18:76656028	A/G	cg24134504	chr18:76639479	NA	-0.48	-8.42	-0.36	4.87e-16	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26253258	chr20:60697513	LSM14B	-0.47	-6.98	-0.31	1.05e-11	Gut microbiome composition (summer);
LGG	cis	rs11229555	0.574	rs12272310	chr11:58186462	A/C	cg15696309	chr11:58395628	NA	-0.95	-15.35	-0.58	2.78e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg09699651	chr6:150184138	LRP11	-0.53	-9.42	-0.4	2.09e-19	Lung cancer;
LGG	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.67	-0.34	1e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.35	-0.43	1.03e-22	Lymphocyte counts;
LGG	cis	rs1008375	1.000	rs13119927	chr4:17691640	G/A	cg27347728	chr4:17578864	LAP3	-0.38	-6.75	-0.3	4.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg00405596	chr8:11794950	NA	-0.4	-6.85	-0.3	2.35e-11	Systolic blood pressure;
LGG	cis	rs6868223	0.617	rs4866409	chr5:33643617	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.67	0.59	9.99e-45	Mortality in heart failure;
LGG	cis	rs2075371	0.933	rs1868784	chr7:133945932	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	10.38	0.43	8.02e-23	Mean platelet volume;
LGG	trans	rs7181230	1.000	rs7181230	chr15:40360741	A/G	cg24185116	chr15:52044314	LYSMD2;TMOD2	-0.36	-6.96	-0.31	1.2e-11	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs4242434	0.927	rs2291234	chr8:22464390	T/C	cg03733263	chr8:22462867	KIAA1967	1.12	32.68	0.84	2.63e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs12701220	0.894	rs13224488	chr7:1052353	C/A	cg02733842	chr7:1102375	C7orf50	-0.47	-7.29	-0.32	1.33e-12	Bronchopulmonary dysplasia;
LGG	cis	rs11250464	0.755	rs11250468	chr10:1410060	A/G	cg08668359	chr10:1443807	ADARB2	0.65	12.25	0.49	4.6e-30	Radiation response;
LGG	cis	rs2456568	0.802	rs10831136	chr11:93636860	T/C	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.44	0.53	5.51e-35	Morning vs. evening chronotype;
LGG	cis	rs3740909	1.000	rs77549115	chr11:125885853	G/A	cg24940576	chr11:125904314	CDON	-0.49	-7.58	-0.33	1.86e-13	Blood protein levels;
LGG	cis	rs6831352	0.734	rs1154400	chr4:100010010	C/T	cg12011299	chr4:100065546	ADH4	0.4	8.14	0.35	3.56e-15	Alcohol dependence;
LGG	cis	rs16933812	0.510	rs4880049	chr9:36989333	C/T	cg13738729	chr9:36989127	PAX5	-0.41	-9.12	-0.39	2.3e-18	Obesity-related traits;
LGG	trans	rs12310956	0.510	rs7301767	chr12:33886529	A/T	cg26384229	chr12:38710491	ALG10B	0.63	12.39	0.5	1.2e-30	Morning vs. evening chronotype;
LGG	cis	rs5756813	0.811	rs4396807	chr22:38138379	G/C	cg19171272	chr22:38449367	NA	0.38	6.76	0.3	4.27e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs796364	0.806	rs34582889	chr2:201010527	A/G	cg23649088	chr2:200775458	C2orf69	-0.63	-8.24	-0.36	1.75e-15	Schizophrenia;
LGG	cis	rs7647973	1.000	rs9842132	chr3:49427933	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.69	-0.34	8.96e-14	Menarche (age at onset);
LGG	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.5	0.44	2.81e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2235649	0.833	rs9927047	chr16:1851927	A/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.42	-7.03	-0.31	7.29e-12	Blood metabolite levels;
LGG	cis	rs875971	1.000	rs6460296	chr7:65895139	C/T	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5e-17	Aortic root size;
LGG	cis	rs1355223	0.902	rs836462	chr11:34743263	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs72945132	0.882	rs55905028	chr11:70127750	G/A	cg00319359	chr11:70116639	PPFIA1	0.74	8.21	0.36	2.16e-15	Coronary artery disease;
LGG	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg27511599	chr7:32358540	NA	0.55	6.66	0.3	7.77e-11	Body mass index;
LGG	cis	rs916888	0.821	rs199525	chr17:44847834	T/G	cg15921436	chr17:44337874	NA	0.57	11.87	0.48	1.52e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.835	rs7502676	chr17:80093433	C/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.52	-0.4	9.81e-20	Life satisfaction;
LGG	cis	rs2153535	0.580	rs6910742	chr6:8448328	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs6909430	0.708	rs2505062	chr6:98582695	G/C	cg12860156	chr6:98744658	NA	-0.45	-7.59	-0.33	1.82e-13	Quantitative traits;
LGG	cis	rs17451754	0.626	rs35050470	chr7:117246636	G/A	cg10524701	chr7:117356490	CTTNBP2	0.46	8.03	0.35	8.08e-15	Barrett's esophagus  or Esophageal adenocarcinoma;
LGG	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg16414030	chr3:133502952	NA	-0.6	-10.45	-0.44	4.16e-23	Iron status biomarkers;
LGG	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg05444541	chr17:17804740	TOM1L2	-0.68	-16.44	-0.61	3.76e-48	Total body bone mineral density;
LGG	cis	rs2130392	0.926	rs4610379	chr4:185624388	A/G	cg04058563	chr4:185651563	MLF1IP	0.43	8.79	0.38	3.02e-17	Kawasaki disease;
LGG	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg13114125	chr14:105738426	BRF1	0.82	15.5	0.58	6.02e-44	Mean platelet volume;Platelet distribution width;
LGG	trans	rs6787172	0.702	rs827111	chr3:157980742	T/G	cg23275840	chr4:47708675	CORIN	0.42	8.93	0.38	1.02e-17	Subjective well-being;
LGG	cis	rs703842	0.585	rs10877022	chr12:58223937	A/G	cg02175503	chr12:58329896	NA	0.5	8.11	0.35	4.65e-15	Multiple sclerosis;
LGG	cis	rs13102973	0.899	rs13119071	chr4:135909862	G/T	cg14419869	chr4:135874104	NA	0.45	8.04	0.35	7.42e-15	Subjective well-being;
LGG	cis	rs4731207	0.698	rs10954048	chr7:124533740	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.52	-0.33	2.89e-13	Cutaneous malignant melanoma;
LGG	cis	rs6502050	0.835	rs3935129	chr17:80113381	G/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.86	-0.34	2.65e-14	Life satisfaction;
LGG	trans	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg06521331	chr12:34319734	NA	-0.53	-9.33	-0.4	4.54e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1499614	1.000	rs34250985	chr7:66161062	A/T	cg10756647	chr7:56101905	PSPH	0.74	7.56	0.33	2.19e-13	Gout;
LGG	cis	rs8031584	0.918	rs34331396	chr15:31248736	C/G	cg08704250	chr15:31115839	NA	-0.43	-7.98	-0.35	1.17e-14	Huntington's disease progression;
LGG	cis	rs11225247	0.881	rs7114048	chr11:102253780	C/T	cg06323957	chr11:102217781	BIRC2	0.82	7.17	0.32	2.99e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs7216064	0.655	rs8078543	chr17:66037251	G/T	cg02705964	chr17:66097276	LOC651250	-0.46	-8.09	-0.35	5.26e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs637571	0.522	rs491973	chr11:65727301	A/G	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.1	-0.39	2.75e-18	Eosinophil percentage of white cells;
LGG	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.41e-11	Neuroticism;
LGG	cis	rs9790314	0.638	rs17236725	chr3:160637935	C/T	cg04691961	chr3:161091175	C3orf57	0.41	8.61	0.37	1.11e-16	Morning vs. evening chronotype;
LGG	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg17127132	chr2:85788382	GGCX	0.45	7.9	0.34	2.01e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs13191362	1.000	rs67840803	chr6:163049048	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.88	9.29	0.4	6.09e-19	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg10756647	chr7:56101905	PSPH	0.82	10.17	0.43	4.7e-22	Diabetic kidney disease;
LGG	cis	rs3771570	1.000	rs56156035	chr2:242205955	T/A	cg21155796	chr2:242212141	HDLBP	0.76	9.87	0.42	5.64e-21	Prostate cancer;
LGG	cis	rs4919694	1.000	rs7083328	chr10:104769268	G/A	cg04362960	chr10:104952993	NT5C2	1.06	14.74	0.57	1.33e-40	Arsenic metabolism;
LGG	cis	rs6977660	0.943	rs10249996	chr7:19844935	G/A	cg05791153	chr7:19748676	TWISTNB	0.57	8.47	0.37	3.37e-16	Thyroid stimulating hormone;
LGG	cis	rs4665809	0.590	rs7606351	chr2:26292545	A/C	cg08470875	chr2:26401718	FAM59B	-0.37	-6.85	-0.3	2.33e-11	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs778680	chr7:65840414	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.39e-11	Aortic root size;
LGG	cis	rs4808199	0.948	rs2301671	chr19:19466269	C/T	cg03709012	chr19:19516395	GATAD2A	0.96	15.19	0.58	1.35e-42	Nonalcoholic fatty liver disease;
LGG	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg13114125	chr14:105738426	BRF1	-0.86	-15.95	-0.6	5.93e-46	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg11766577	chr21:47581405	C21orf56	-0.48	-8.15	-0.35	3.33e-15	Testicular germ cell tumor;
LGG	cis	rs9811920	0.732	rs793446	chr3:99578114	A/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.91	-0.38	1.2e-17	Axial length;
LGG	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg19773385	chr1:10388646	KIF1B	-0.51	-10.59	-0.44	1.31e-23	Hepatocellular carcinoma;
LGG	cis	rs3768617	0.510	rs35968946	chr1:183114871	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.12	0.39	2.29e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6933660	0.665	rs6921042	chr6:151732385	T/C	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.84	0.42	7.15e-21	Menarche (age at onset);
LGG	cis	rs57221529	0.766	rs12522303	chr5:555564	A/C	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs1577917	0.740	rs2758845	chr6:86334848	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.19	-0.36	2.61e-15	Response to antipsychotic treatment;
LGG	cis	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg13647721	chr17:30228624	UTP6	0.68	7.2	0.32	2.38e-12	Hip circumference adjusted for BMI;
LGG	cis	rs12901789	1	rs12901789	chr15:67562214	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.69	-0.3	6.44e-11	Total body bone mineral density;
LGG	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg17294928	chr15:75287854	SCAMP5	0.41	6.72	0.3	5.21e-11	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs3820068	0.581	rs72645879	chr1:15928199	A/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	trans	rs7618501	0.902	rs7645061	chr3:49868842	C/T	cg21659725	chr3:3221576	CRBN	0.92	20.34	0.69	3.53e-66	Intelligence (multi-trait analysis);
LGG	trans	rs7246760	1.000	rs67359088	chr19:9863668	C/T	cg02900749	chr2:68251473	NA	-1.07	-11.62	-0.48	1.51e-27	Pursuit maintenance gain;
LGG	cis	rs752010	0.841	rs11210498	chr1:42077958	T/G	cg16096631	chr1:42092165	HIVEP3	0.7	18.44	0.65	2.48e-57	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3748682	0.731	rs3891572	chr1:38298876	C/T	cg12658694	chr1:38397304	INPP5B	0.38	7.08	0.31	5.51e-12	Hypothyroidism;
LGG	cis	rs2153535	0.580	rs718502	chr6:8527400	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs9303401	0.659	rs62083362	chr17:56846464	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs67460515	0.892	rs2054710	chr3:161090616	C/T	cg04691961	chr3:161091175	C3orf57	-0.5	-10.31	-0.43	1.36e-22	Parkinson's disease;
LGG	cis	rs1862618	0.756	rs9292125	chr5:56107200	C/T	cg17809284	chr5:56205270	C5orf35	-0.52	-8.62	-0.37	1.05e-16	Initial pursuit acceleration;
LGG	cis	rs1348850	0.846	rs4893962	chr2:178421106	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.6	-0.37	1.28e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.966	rs4813557	chr20:25292545	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.23	-0.43	2.89e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs79349575	0.749	rs957557	chr17:47003221	G/T	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.51e-11	Type 2 diabetes;
LGG	cis	rs6840360	0.571	rs4696270	chr4:152498289	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.79e-14	Intelligence (multi-trait analysis);
LGG	trans	rs2204008	0.641	rs2387810	chr12:38368875	G/T	cg06521331	chr12:34319734	NA	-0.51	-8.93	-0.38	1.02e-17	Bladder cancer;
LGG	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg17133734	chr15:86042851	AKAP13	-0.28	-6.82	-0.3	2.93e-11	Coronary artery disease;
LGG	cis	rs651907	0.557	rs62284198	chr3:101474699	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.49	0.53	3.24e-35	Colorectal cancer;
LGG	cis	rs6540556	0.723	rs12120361	chr1:209913473	A/C	cg23920097	chr1:209922102	NA	-0.47	-7.79	-0.34	4.58e-14	Red blood cell count;
LGG	cis	rs2180341	0.596	rs12215298	chr6:127676833	C/T	cg27446573	chr6:127587934	RNF146	0.88	16.15	0.6	7.4e-47	Breast cancer;
LGG	cis	rs4819052	0.851	rs2838843	chr21:46669284	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.09	0.52	1.6e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2046867	0.818	rs17010195	chr3:72872852	A/G	cg01043669	chr3:72786069	NA	-0.42	-7.12	-0.31	4.21e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06418184	chr9:34620572	DCTN3	0.46	6.76	0.3	4.29e-11	Gut microbiome composition (summer);
LGG	cis	rs637571	0.528	rs566266	chr11:65573587	A/C	cg04055107	chr11:65626734	MUS81;CFL1	-0.48	-7.64	-0.33	1.26e-13	Eosinophil percentage of white cells;
LGG	cis	rs1005277	0.579	rs2474575	chr10:38387901	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.14	-0.49	1.18e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs77633900	0.772	rs8031672	chr15:76700553	T/C	cg21673338	chr15:77095150	SCAPER	0.57	7.77	0.34	5.01e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11098499	0.789	rs12498994	chr4:120250818	A/C	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	trans	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg10756647	chr7:56101905	PSPH	-0.72	-8.55	-0.37	1.77e-16	Diabetic kidney disease;
LGG	cis	rs2072732	0.861	rs6661908	chr1:2950334	C/T	cg08733933	chr1:2954429	NA	-0.4	-8.43	-0.36	4.4e-16	Plateletcrit;
LGG	cis	rs16854884	0.586	rs7611326	chr3:143736374	C/T	cg06585982	chr3:143692056	C3orf58	0.69	12.45	0.5	6.87e-31	Economic and political preferences (feminism/equality);
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg22535103	chr8:58192502	C8orf71	-0.99	-15.9	-0.59	1.02e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.6e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs4926611	0.736	rs1465035	chr1:54119913	A/G	cg23596471	chr1:54105337	GLIS1	-0.32	-6.67	-0.3	7.26e-11	Hand grip strength;
LGG	cis	rs6495122	0.618	rs4886413	chr15:75262310	G/C	cg14664628	chr15:75095509	CSK	-0.55	-10.45	-0.44	4.22e-23	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs9393777	0.920	rs34150729	chr6:27388754	T/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.27	-0.46	3.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs7647973	0.559	rs9586	chr3:49213637	C/T	cg06212747	chr3:49208901	KLHDC8B	0.62	9.48	0.4	1.28e-19	Menarche (age at onset);
LGG	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	trans	rs7937682	0.847	rs11213948	chr11:111464401	G/A	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs597539	0.552	rs6591361	chr11:68719284	T/C	cg21862992	chr11:68658383	NA	0.45	7.72	0.34	7.22e-14	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03537747	chr2:27886640	SLC4A1AP;SUPT7L	0.41	7.1	0.31	4.68e-12	Bilirubin levels;
LGG	cis	rs6815814	0.950	rs55903115	chr4:38786474	C/A	cg06935464	chr4:38784597	TLR10	0.6	8.41	0.36	5.07e-16	Breast cancer;
LGG	cis	rs9486715	0.867	rs9386500	chr6:96889845	A/C	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs9911578	0.967	rs12944948	chr17:56951474	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs832540	0.931	rs702679	chr5:56221328	A/G	cg12654349	chr5:56205094	C5orf35	-0.43	-7.71	-0.34	7.65e-14	Coronary artery disease;
LGG	cis	rs6502050	0.749	rs7406163	chr17:80086389	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	trans	rs61931739	0.517	rs7486246	chr12:34526419	T/G	cg26384229	chr12:38710491	ALG10B	0.85	18.18	0.65	4.04e-56	Morning vs. evening chronotype;
LGG	cis	rs7659604	1.000	rs28433617	chr4:122664138	C/A	cg20573242	chr4:122745356	CCNA2	0.44	8.2	0.36	2.32e-15	Type 2 diabetes;
LGG	cis	rs6502050	0.799	rs4789667	chr17:80162143	C/T	cg16920238	chr17:80076378	CCDC57	-0.31	-7.0	-0.31	8.84e-12	Life satisfaction;
LGG	cis	rs72945132	0.882	rs72945194	chr11:70138621	A/G	cg14088196	chr11:70211408	PPFIA1	0.96	13.11	0.52	1.35e-33	Coronary artery disease;
LGG	cis	rs2688482	0.557	rs3103952	chr3:195522690	T/C	cg15952060	chr3:195484815	MUC4	0.46	6.67	0.3	7.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs365132	0.875	rs353494	chr5:176431759	C/G	cg16309518	chr5:176445507	NA	-0.51	-11.25	-0.46	4.05e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	trans	rs9657904	0.805	rs1867195	chr3:105548176	G/A	cg14088669	chr1:158435396	OR10K1	0.43	8.09	0.35	5.35e-15	Multiple sclerosis;
LGG	cis	rs2370759	1.000	rs2225152	chr10:32574759	T/C	cg01819863	chr10:32635814	EPC1	1.11	15.33	0.58	3.27e-43	Sexual dysfunction (female);
LGG	trans	rs7507204	0.723	rs12610998	chr19:3413653	T/C	cg08382705	chr11:45687319	CHST1	-0.52	-7.03	-0.31	7.59e-12	Height;
LGG	cis	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg03060546	chr3:49711283	APEH	0.6	7.94	0.35	1.5e-14	Menarche (age at onset);
LGG	cis	rs7681423	0.951	rs13130318	chr4:155538470	T/G	cg20735720	chr4:155535218	FGG	-0.61	-10.99	-0.45	3.9e-25	Fibrinogen;
LGG	cis	rs12477438	0.798	rs2309524	chr2:99659510	A/T	cg08885076	chr2:99613938	TSGA10	-0.6	-12.14	-0.49	1.24e-29	Chronic sinus infection;
LGG	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg03929089	chr4:120376271	NA	0.71	9.79	0.41	1.05e-20	Axial length;
LGG	cis	rs4820294	1.000	rs929039	chr22:38071511	T/C	cg10587741	chr22:38071170	LGALS1	0.82	21.37	0.7	4.98e-71	Fat distribution (HIV);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07990939	chr12:88536410	TMTC3;CEP290	-0.46	-6.69	-0.3	6.63e-11	Systemic lupus erythematosus;
LGG	trans	rs9467711	0.659	rs13220261	chr6:26499185	C/T	cg08344181	chr3:125677491	NA	-0.68	-7.1	-0.31	4.69e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10979	1.000	rs9403505	chr6:143885841	A/G	cg25407410	chr6:143891975	LOC285740	-0.68	-12.04	-0.49	3.15e-29	Hypospadias;
LGG	trans	rs7937682	0.564	rs11600652	chr11:111754368	A/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg00864171	chr11:67383662	NA	-0.44	-7.21	-0.32	2.32e-12	Mean corpuscular volume;
LGG	cis	rs72781680	0.800	rs56398785	chr2:24091515	T/A	cg08917208	chr2:24149416	ATAD2B	0.93	10.18	0.43	4.08e-22	Lymphocyte counts;
LGG	cis	rs7799006	0.527	rs2159045	chr7:2207401	T/C	cg19147804	chr7:1989927	MAD1L1	-0.36	-6.84	-0.3	2.56e-11	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7249142	0.562	rs12980955	chr19:19283646	T/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.01	-0.35	9.69e-15	IgG glycosylation;
LGG	cis	rs7226408	0.576	rs9304168	chr18:34557326	C/G	cg15022739	chr18:34823045	BRUNOL4	0.42	9.1	0.39	2.67e-18	Obesity-related traits;
LGG	cis	rs2120019	0.567	rs8025170	chr15:75170983	A/G	cg09165964	chr15:75287851	SCAMP5	0.83	11.83	0.48	2.12e-28	Blood trace element (Zn levels);
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg18681998	chr4:17616180	MED28	-0.81	-17.7	-0.64	6.69e-54	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12824058	0.831	rs11060826	chr12:130809931	G/C	cg23887609	chr12:130822674	PIWIL1	0.55	9.81	0.41	8.84e-21	Menopause (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02072231	chr2:202508310	ALS2CR4	-0.45	-6.91	-0.31	1.58e-11	Pancreatic cancer;
LGG	cis	rs708547	0.874	rs1713984	chr4:57886493	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.66	9.66	0.41	2.99e-20	Response to bleomycin (chromatid breaks);
LGG	cis	rs2247341	1.000	rs3958122	chr4:1693931	C/T	cg07465881	chr4:1713556	SLBP	-0.46	-7.19	-0.32	2.6e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs7408868	1.000	rs10422818	chr19:15285272	A/G	cg14696996	chr19:15285081	NOTCH3	1.02	12.05	0.49	2.83e-29	Pulse pressure;
LGG	cis	rs17401966	0.838	rs55676616	chr1:10290126	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.57	-0.44	1.59e-23	Hepatocellular carcinoma;
LGG	cis	rs972578	0.818	rs2267463	chr22:43283255	A/C	cg01576275	chr22:43409880	NA	-0.24	-7.21	-0.32	2.33e-12	Mean platelet volume;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg21862992	chr11:68658383	NA	0.5	8.38	0.36	6.43e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.765	rs12612688	chr2:99613091	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.22	-0.43	3.07e-22	Chronic sinus infection;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22539505	chr3:50330110	IFRD2	0.38	6.9	0.31	1.76e-11	Obesity-related traits;
LGG	cis	rs703842	0.616	rs1875125	chr12:58227241	T/G	cg00677455	chr12:58241039	CTDSP2	0.43	7.68	0.34	9.62e-14	Multiple sclerosis;
LGG	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.75	13.22	0.52	4.36e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs888194	0.677	rs7973253	chr12:109878115	A/G	cg19025524	chr12:109796872	NA	-0.47	-9.43	-0.4	1.92e-19	Neuroticism;
LGG	cis	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg21775007	chr8:11205619	TDH	0.63	10.39	0.43	6.96e-23	Retinal vascular caliber;
LGG	cis	rs7582180	0.629	rs6716636	chr2:100940067	C/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs6854703	chr4:98977586	A/T	cg05340658	chr4:99064831	C4orf37	0.48	7.84	0.34	3.02e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg12379764	chr21:47803548	PCNT	-0.45	-7.48	-0.33	3.71e-13	Testicular germ cell tumor;
LGG	cis	rs12410462	0.581	rs77430808	chr1:227540880	C/T	cg23173402	chr1:227635558	NA	0.49	8.44	0.37	4.22e-16	Major depressive disorder;
LGG	cis	rs858239	0.669	rs10950940	chr7:23196816	C/T	cg23682824	chr7:23144976	KLHL7	-0.45	-7.68	-0.34	9.57e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs10504229	0.683	rs6984765	chr8:58127124	T/C	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs6866344	0.697	rs11739893	chr5:178127837	G/A	cg10224037	chr5:178157518	ZNF354A	0.75	11.63	0.48	1.33e-27	Neutrophil percentage of white cells;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11072887	chr6:37322624	RNF8	0.46	7.87	0.34	2.54e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs5758511	0.773	rs11913631	chr22:42347371	G/T	cg15128208	chr22:42549153	NA	0.56	9.07	0.39	3.46e-18	Birth weight;
LGG	trans	rs1814175	0.817	rs7924619	chr11:49620632	G/A	cg03929089	chr4:120376271	NA	-1.03	-23.6	-0.74	1.93e-81	Height;
LGG	cis	rs7010267	0.935	rs6469789	chr8:119960661	C/G	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.43	0.44	5.18e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs11603023	0.874	rs11216934	chr11:118501459	A/G	cg03804240	chr11:118481350	PHLDB1	0.41	8.55	0.37	1.79e-16	Cholesterol, total;
LGG	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg19847130	chr8:10466454	RP1L1	-0.35	-7.38	-0.32	7.3e-13	Neuroticism;
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg21963583	chr11:68658836	MRPL21	0.61	10.41	0.44	6.05e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2229238	0.911	rs57783436	chr1:154511709	A/G	cg10237817	chr1:154519846	TDRD10	0.35	7.01	0.31	8.5e-12	Coronary heart disease;
LGG	cis	rs1046896	0.562	rs9912684	chr17:80873067	C/T	cg02711726	chr17:80685570	FN3KRP	-0.56	-9.78	-0.41	1.16e-20	Glycated hemoglobin levels;
LGG	cis	rs1665650	0.874	rs7909807	chr10:118485453	C/T	cg14919929	chr10:118506882	NA	-0.48	-8.34	-0.36	8.75e-16	Colorectal cancer;
LGG	cis	rs9388451	0.903	rs7758115	chr6:126061502	C/T	cg10911889	chr6:126070802	HEY2	0.42	7.24	0.32	1.83e-12	Brugada syndrome;
LGG	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.41	6.83	0.3	2.68e-11	Longevity;
LGG	cis	rs13118159	0.934	rs4974553	chr4:1356911	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.49	9.43	0.4	1.98e-19	Longevity;
LGG	cis	rs2777491	0.874	rs7161772	chr15:41611066	A/T	cg18705301	chr15:41695430	NDUFAF1	-0.97	-19.6	-0.67	9.46e-63	Ulcerative colitis;
LGG	cis	rs6088580	0.634	rs3746455	chr20:32957216	G/A	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.4e-20	Glomerular filtration rate (creatinine);
LGG	trans	rs6600671	0.693	rs1853731	chr1:121252060	T/A	cg00646200	chr1:148855367	NA	0.4	7.0	0.31	9.3e-12	Hip geometry;
LGG	cis	rs2576037	0.583	rs501882	chr18:44411066	A/T	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.27	-0.32	1.5e-12	Personality dimensions;
LGG	cis	rs7223966	1.000	rs11079509	chr17:61762148	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	7.49	0.33	3.56e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20426860	chr19:19248839	TMEM161A	0.49	7.49	0.33	3.57e-13	Gut microbiome composition (summer);
LGG	trans	rs7395662	0.824	rs12787989	chr11:48970887	G/T	cg03929089	chr4:120376271	NA	-0.43	-6.99	-0.31	9.92e-12	HDL cholesterol;
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg18357526	chr6:26021779	HIST1H4A	0.47	7.73	0.34	6.91e-14	Height;
LGG	cis	rs8056893	0.543	rs3785120	chr16:68374437	C/T	cg07273125	chr16:68295692	NA	0.37	7.83	0.34	3.25e-14	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg05025164	chr4:1340916	KIAA1530	0.56	10.07	0.42	1.08e-21	Obesity-related traits;
LGG	cis	rs4363385	0.667	rs756303	chr1:152908222	C/T	cg13444842	chr1:152974279	SPRR3	-0.39	-7.39	-0.32	6.98e-13	Inflammatory skin disease;
LGG	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.56	-0.41	7.06e-20	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg06873352	chr17:61820015	STRADA	-0.68	-12.36	-0.5	1.57e-30	Prudent dietary pattern;
LGG	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg07978099	chr16:83986941	OSGIN1	0.56	9.16	0.39	1.7e-18	Pursuit maintenance gain;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg13732083	chr21:47605072	C21orf56	0.46	7.74	0.34	6.13e-14	Testicular germ cell tumor;
LGG	cis	rs11622475	1.000	rs1187448	chr14:104406627	C/T	cg20488157	chr14:104394430	TDRD9	0.54	8.77	0.38	3.47e-17	Bipolar disorder;
LGG	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg13312174	chr5:178288687	ZNF354B	-0.35	-6.95	-0.31	1.28e-11	Sleep duration;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg13607699	chr17:42295918	UBTF	0.52	8.95	0.38	8.63e-18	Total body bone mineral density;
LGG	cis	rs11122272	0.735	rs2572263	chr1:231509408	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs2692947	0.696	rs2969490	chr2:96803904	A/G	cg22654517	chr2:96458247	NA	0.38	8.4	0.36	5.62e-16	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs62238980	0.614	rs78443579	chr22:32449283	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs10197940	0.624	rs10497081	chr2:152353395	T/G	cg19508488	chr2:152266495	RIF1	0.59	10.44	0.44	4.86e-23	Lung cancer;
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg22435132	chr17:59312558	BCAS3	-0.31	-6.72	-0.3	5.4e-11	Corneal astigmatism;
LGG	cis	rs6089829	0.925	rs4809270	chr20:61676709	C/A	cg08045932	chr20:61659980	NA	0.6	12.18	0.49	8.18e-30	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12210905	0.920	rs9393802	chr6:27243105	A/G	cg15325629	chr6:28072465	NA	0.7	6.76	0.3	4.22e-11	Hip circumference adjusted for BMI;
LGG	trans	rs28595532	0.545	rs17516512	chr4:119258491	T/C	cg26518628	chr1:97050305	NA	-0.71	-7.54	-0.33	2.57e-13	Cannabis dependence symptom count;
LGG	cis	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg12826209	chr6:26865740	GUSBL1	0.75	8.0	0.35	1.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs13108904	0.967	rs900028	chr4:1279162	A/T	cg00684032	chr4:1343700	KIAA1530	0.51	9.89	0.42	4.55e-21	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.24	-0.32	1.92e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs611744	0.647	rs674391	chr8:109242803	A/T	cg21045802	chr8:109455806	TTC35	0.49	9.26	0.4	7.38e-19	Dupuytren's disease;
LGG	cis	rs4696584	0.761	rs1388080	chr4:155405425	C/G	cg04517429	chr4:155413618	DCHS2	0.32	7.51	0.33	3.16e-13	Folding of antihelix;
LGG	cis	rs4262150	0.507	rs72795350	chr5:151909997	G/A	cg12297329	chr5:152029980	NA	-0.65	-11.75	-0.48	4.6e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg15997130	chr1:24165203	NA	-0.51	-13.78	-0.54	1.85e-36	Immature fraction of reticulocytes;
LGG	cis	rs3770081	1.000	rs17027011	chr2:86406556	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.78	-7.12	-0.31	4.11e-12	Facial emotion recognition (sad faces);
LGG	cis	rs7267979	0.932	rs6037125	chr20:25463382	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.9	0.42	4.27e-21	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg14407698	chr9:34458886	C9orf25;DNAI1	0.41	7.14	0.31	3.71e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs36051895	0.623	rs11506292	chr9:5257048	C/A	cg02405213	chr9:5042618	JAK2	-0.72	-12.1	-0.49	1.84e-29	Pediatric autoimmune diseases;
LGG	cis	rs6446298	0.738	rs1060970	chr3:49708769	T/C	cg03060546	chr3:49711283	APEH	0.65	10.18	0.43	4.41e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2075371	0.830	rs12669960	chr7:133931782	A/G	cg11752832	chr7:134001865	SLC35B4	0.56	9.94	0.42	3.08e-21	Mean platelet volume;
LGG	cis	rs6495122	0.699	rs1378941	chr15:75080150	C/A	cg14664628	chr15:75095509	CSK	-0.78	-16.0	-0.6	3.5e-46	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.43	-0.44	5.05e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg07005078	chr4:17578674	LAP3	0.37	6.88	0.3	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7949566	0.557	rs3781781	chr11:126280545	T/C	cg05055844	chr11:126275997	ST3GAL4	0.38	7.52	0.33	2.9e-13	Platelet distribution width;Mean platelet volume;
LGG	cis	rs9487094	1.000	rs10872032	chr6:109676776	C/T	cg16315928	chr6:109776240	MICAL1	0.47	7.98	0.35	1.17e-14	Height;
LGG	cis	rs7618501	0.574	rs6765484	chr3:50041313	C/T	cg05623727	chr3:50126028	RBM5	-0.33	-7.24	-0.32	1.87e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg13009111	chr11:71350975	NA	-0.33	-7.18	-0.32	2.8e-12	Monocyte count;
LGG	cis	rs6496044	0.547	rs7173125	chr15:86055445	C/G	cg13263323	chr15:86062960	AKAP13	0.35	7.23	0.32	1.95e-12	Interstitial lung disease;
LGG	cis	rs6909430	0.901	rs9490569	chr6:98559975	G/C	cg12860156	chr6:98744658	NA	-0.42	-6.9	-0.31	1.77e-11	Quantitative traits;
LGG	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.15	-31.56	-0.83	1.77e-117	Myeloid white cell count;
LGG	cis	rs3020736	0.500	rs5996110	chr22:42493767	A/G	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1355223	0.573	rs1597961	chr11:34727114	A/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.16	-0.32	3.15e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg06634786	chr22:41940651	POLR3H	-0.44	-6.91	-0.31	1.64e-11	Neuroticism;
LGG	cis	rs10267417	0.535	rs6956976	chr7:19869168	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	6.69	0.3	6.51e-11	Night sleep phenotypes;
LGG	cis	rs7945705	0.791	rs6484484	chr11:8817206	A/G	cg21881798	chr11:8931708	C11orf17;ST5	0.37	7.68	0.34	9.66e-14	Hemoglobin concentration;
LGG	cis	rs6743376	0.556	rs1374286	chr2:113819007	C/G	cg05949173	chr2:113825882	IL1F10	0.48	9.07	0.39	3.42e-18	Inflammatory biomarkers;
LGG	cis	rs9560113	1.000	rs9560105	chr13:112175363	A/T	cg14952266	chr13:112191215	NA	0.42	7.73	0.34	6.9e-14	Menarche (age at onset);
LGG	trans	rs9951602	0.512	rs6506872	chr18:76649695	T/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.6	0.53	1.14e-35	Obesity-related traits;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.17	0.46	8.24e-26	Lymphocyte counts;
LGG	cis	rs17253792	0.822	rs76055105	chr14:56069127	A/G	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs36051895	0.695	rs10815147	chr9:5016145	C/T	cg02405213	chr9:5042618	JAK2	-0.81	-14.82	-0.57	6.12e-41	Pediatric autoimmune diseases;
LGG	cis	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.67	-0.44	6.77e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.67	11.83	0.48	2.05e-28	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.545	rs313828	chr7:65552614	T/C	cg11764359	chr7:65958608	NA	-0.61	-8.98	-0.39	6.95e-18	Aortic root size;
LGG	cis	rs4740619	0.740	rs7861802	chr9:15783128	G/T	cg14451791	chr9:16040625	NA	0.33	8.4	0.36	5.4e-16	Body mass index;
LGG	trans	rs961253	0.501	rs6054183	chr20:6354161	T/C	cg21095983	chr6:86352623	SYNCRIP	0.41	6.77	0.3	4.02e-11	Colorectal cancer;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.49	0.47	4.49e-27	Obesity-related traits;
LGG	cis	rs990171	1.000	rs6705001	chr2:103076210	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.92	-0.38	1.1e-17	Lymphocyte counts;
LGG	cis	rs1799949	1.000	rs2292595	chr17:41290674	G/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.8e-13	Menopause (age at onset);
LGG	cis	rs7819412	0.642	rs11250117	chr8:10972740	C/A	cg21775007	chr8:11205619	TDH	-0.43	-6.82	-0.3	2.84e-11	Triglycerides;
LGG	cis	rs11677416	1.000	rs1040193	chr2:113530099	C/T	cg27083787	chr2:113543245	IL1A	0.53	8.97	0.38	7.43e-18	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.58	-0.41	5.87e-20	Lung cancer;
LGG	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg04617570	chr17:70588444	NA	-0.43	-6.97	-0.31	1.08e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg04974899	chr20:25177027	ENTPD6	0.42	7.27	0.32	1.57e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs28647808	0.881	rs4246171	chr9:136264731	G/A	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs9916302	0.904	rs35335692	chr17:37710006	A/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.76	-0.59	4.1e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.06	0.42	1.13e-21	Obesity-related traits;
LGG	cis	rs11877825	1.000	rs11877825	chr18:10566404	G/T	cg07277756	chr18:10589357	NA	0.56	10.18	0.43	4.17e-22	Gut microbiota (bacterial taxa);
LGG	cis	rs7914558	0.901	rs1926034	chr10:104829102	G/A	cg04362960	chr10:104952993	NT5C2	0.53	9.94	0.42	3.13e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs910316	0.967	rs4899550	chr14:75647666	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.59	-10.79	-0.45	2.32e-24	Height;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg05091796	chr16:4465799	CORO7	-0.79	-12.92	-0.51	8.2e-33	Schizophrenia;
LGG	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06108461	chr20:60628389	TAF4	-0.67	-11.92	-0.48	9.71e-29	Body mass index;
LGG	cis	rs589448	0.900	rs588493	chr12:69751986	G/A	cg20891283	chr12:69753455	YEATS4	1.1	29.0	0.8	3.51e-106	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9951602	1.000	rs9951602	chr18:76657779	C/T	cg00806245	chr18:76673096	NA	-0.59	-7.02	-0.31	7.85e-12	Obesity-related traits;
LGG	trans	rs12517041	0.938	rs16892305	chr5:23267355	G/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.61	-8.91	-0.38	1.15e-17	Calcium levels;
LGG	cis	rs988958	0.526	rs10084239	chr2:42253746	G/T	cg19376973	chr2:42229025	NA	-0.68	-9.8	-0.41	1.03e-20	Hypospadias;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg06642177	chr6:134496341	SGK1	0.44	7.47	0.33	3.92e-13	Bipolar disorder;
LGG	cis	rs4696584	0.877	rs72725354	chr4:155399841	A/G	cg13738195	chr4:155413469	DCHS2	-0.37	-7.28	-0.32	1.44e-12	Folding of antihelix;
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.79	-0.34	4.41e-14	Systolic blood pressure;
LGG	cis	rs1566085	0.704	rs6994100	chr8:142654591	G/A	cg26331504	chr8:142652174	NA	-0.3	-6.93	-0.31	1.46e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7444	0.941	rs12484550	chr22:21941915	C/T	cg05046821	chr22:21984468	YDJC	-0.39	-7.1	-0.31	4.65e-12	Systemic lupus erythematosus;
LGG	cis	rs360798	0.532	rs7573756	chr2:62990637	G/A	cg17519650	chr2:63277830	OTX1	-0.46	-7.44	-0.33	4.91e-13	Coronary artery disease;
LGG	cis	rs360798	0.512	rs2710642	chr2:63149557	G/A	cg17519650	chr2:63277830	OTX1	0.48	7.8	0.34	4.1e-14	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg03517284	chr6:25882590	NA	-0.41	-6.76	-0.3	4.07e-11	Iron status biomarkers;
LGG	cis	rs11608355	0.545	rs55902232	chr12:109902305	G/A	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	cis	rs2243480	1.000	rs1701750	chr7:65467145	T/C	cg13147721	chr7:65941812	NA	-0.79	-9.54	-0.41	7.93e-20	Diabetic kidney disease;
LGG	cis	rs765787	0.530	rs2554453	chr15:45522107	A/G	cg24006582	chr15:45444508	DUOX1	-0.63	-11.41	-0.47	9.88e-27	Uric acid levels;
LGG	cis	rs1401999	0.714	rs1533683	chr3:183635488	C/T	cg20387954	chr3:183756860	HTR3D	0.53	10.59	0.44	1.32e-23	Anterior chamber depth;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.62	-0.37	1.06e-16	Menopause (age at onset);
LGG	cis	rs6694672	0.717	rs1537319	chr1:197052804	T/C	cg13682187	chr1:196946512	CFHR5	0.5	6.94	0.31	1.33e-11	Asthma;
LGG	cis	rs68170813	0.599	rs12532514	chr7:107000952	C/T	cg02696742	chr7:106810147	HBP1	-0.72	-10.09	-0.42	9.27e-22	Coronary artery disease;
LGG	cis	rs5769707	0.521	rs739244	chr22:50060158	A/G	cg20744362	chr22:50050164	C22orf34	0.4	7.22	0.32	2.18e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs62238980	0.614	rs75386630	chr22:32380975	G/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs60180747	1.000	rs77515996	chr15:66708939	C/A	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	11.06	0.46	2.12e-25	Testicular germ cell tumor;
LGG	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg03929089	chr4:120376271	NA	-1.03	-24.46	-0.75	2.05e-85	Height;
LGG	trans	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg23484912	chr5:273055	PDCD6	0.45	9.06	0.39	3.62e-18	Pancreatic cancer;
LGG	cis	rs17428076	0.874	rs17615262	chr2:172683481	A/C	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg07308232	chr7:1071921	C7orf50	-0.66	-13.11	-0.52	1.24e-33	Longevity;Endometriosis;
LGG	cis	rs1045714	0.895	rs1107690	chr7:2640595	G/T	cg14042143	chr7:2646782	IQCE	0.81	12.57	0.5	2.24e-31	Urate levels in lean individuals;
LGG	cis	rs6964587	1.000	rs13231820	chr7:91663529	A/G	cg17063962	chr7:91808500	NA	0.49	8.61	0.37	1.17e-16	Breast cancer;
LGG	cis	rs7523273	0.565	rs11118451	chr1:207887493	A/G	cg22525895	chr1:207977042	MIR29B2	0.45	8.66	0.37	7.91e-17	Schizophrenia;
LGG	cis	rs11748327	0.576	rs17719935	chr5:4090300	A/G	cg01025095	chr5:4101132	NA	-0.63	-10.18	-0.43	4.36e-22	Myocardial infarction;
LGG	cis	rs3748682	0.861	rs28625842	chr1:38310786	G/A	cg12658694	chr1:38397304	INPP5B	0.39	7.17	0.32	3.01e-12	Hypothyroidism;
LGG	cis	rs6807915	0.603	rs7632481	chr3:12293966	A/G	cg15873301	chr3:12045459	SYN2	-0.43	-7.3	-0.32	1.23e-12	Leprosy;
LGG	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg08470875	chr2:26401718	FAM59B	-0.39	-7.21	-0.32	2.28e-12	Gut microbiome composition (summer);
LGG	cis	rs870825	0.655	rs7675046	chr4:185652201	G/A	cg04058563	chr4:185651563	MLF1IP	-1.0	-22.1	-0.72	2.05e-74	Blood protein levels;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.51	-0.4	1.08e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg20503657	chr10:835505	NA	0.62	9.32	0.4	4.78e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg23461800	chr14:103021989	NA	-0.56	-9.78	-0.41	1.17e-20	Platelet count;
LGG	cis	rs10267417	0.535	rs10271196	chr7:19938329	A/C	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs2290159	0.706	rs7643321	chr3:12663233	A/G	cg23032965	chr3:12705835	RAF1	0.67	8.97	0.38	7.12e-18	Cholesterol, total;
LGG	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg05784532	chr1:230284198	GALNT2	0.52	9.19	0.39	1.3e-18	Coronary artery disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19233923	chr11:63753598	OTUB1	-0.43	-7.09	-0.31	5.18e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9906944	0.707	rs3816272	chr17:47120467	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.9	-0.31	1.74e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21217426	chr17:58042342	RNFT1	0.48	7.87	0.34	2.51e-14	Cognitive performance;
LGG	cis	rs4713118	0.527	rs4713151	chr6:28136356	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Parkinson's disease;
LGG	cis	rs709400	1.000	rs2403205	chr14:104143385	C/T	cg26031613	chr14:104095156	KLC1	1.14	27.5	0.79	2.2e-99	Body mass index;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg20607798	chr8:58055168	NA	0.64	7.41	0.33	5.88e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.697	rs34786243	chr5:131704720	T/G	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs916888	0.821	rs199513	chr17:44856932	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.58	-9.02	-0.39	5.19e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2652834	1.000	rs2729782	chr15:63403354	G/C	cg05507819	chr15:63340323	TPM1	0.61	8.43	0.36	4.51e-16	HDL cholesterol;
LGG	cis	rs7241530	0.636	rs7242088	chr18:75903530	A/T	cg14642773	chr18:75888474	NA	0.46	9.17	0.39	1.53e-18	Educational attainment (years of education);
LGG	cis	rs3126085	0.877	rs12065368	chr1:152253497	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.79	0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs2842992	0.714	rs2495278	chr6:160123674	G/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	11.9	0.48	1.11e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10463554	1.000	rs3776862	chr5:102331721	G/A	cg23492399	chr5:102201601	PAM	-0.53	-8.28	-0.36	1.29e-15	Parkinson's disease;
LGG	cis	rs4474465	0.688	rs7927494	chr11:78280578	G/A	cg27205649	chr11:78285834	NARS2	0.59	11.13	0.46	1.12e-25	Alzheimer's disease (survival time);
LGG	cis	rs9815354	0.812	rs73071338	chr3:41824328	G/A	cg03022575	chr3:42003672	ULK4	0.8	9.35	0.4	3.8e-19	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.662	rs13254942	chr8:10257678	C/T	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.25	-0.32	1.72e-12	Neuroticism;
LGG	trans	rs1814175	0.754	rs28593359	chr11:50042357	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.11e-100	Height;
LGG	cis	rs17030434	0.784	rs72617459	chr4:154661686	T/C	cg14289246	chr4:154710475	SFRP2	-0.56	-9.44	-0.4	1.78e-19	Electrocardiographic conduction measures;
LGG	cis	rs7166081	1.000	rs35011221	chr15:67645013	G/C	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.85	-0.3	2.39e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs362272	0.505	rs60208975	chr4:3364530	A/G	cg06533319	chr4:3265114	C4orf44	-0.35	-7.24	-0.32	1.89e-12	Serum sulfate level;
LGG	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs1978968	1.000	rs2099944	chr22:18438578	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.6	-12.18	-0.49	8.12e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs4917300	0.606	rs7825460	chr8:143114671	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.86	-0.3	2.19e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg13628971	chr7:2884303	GNA12	0.5	9.7	0.41	2.2e-20	Height;
LGG	cis	rs950776	0.518	rs3813572	chr15:78832588	T/C	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs5769765	0.542	rs761878	chr22:50249677	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.63	7.34	0.32	9.41e-13	Schizophrenia;
LGG	cis	rs10927875	0.562	rs10803401	chr1:16147377	G/A	cg21385522	chr1:16154831	NA	-1.04	-25.96	-0.77	2.23e-92	Dilated cardiomyopathy;
LGG	cis	rs6089829	0.962	rs1116450	chr20:61658210	T/C	cg08045932	chr20:61659980	NA	0.6	12.93	0.52	7.4e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28374715	0.532	rs28584379	chr15:41670408	C/G	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.03e-133	Ulcerative colitis;
LGG	cis	rs6831256	1.000	rs10007119	chr4:3473066	A/G	cg23495837	chr4:3480318	DOK7	-0.52	-9.81	-0.41	8.85e-21	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs9880211	1.000	rs12695649	chr3:136271916	T/C	cg21827317	chr3:136751795	NA	-0.48	-7.18	-0.32	2.83e-12	Body mass index;Height;
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.931	rs10008337	chr4:17593849	G/C	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1065656	0.553	rs344357	chr16:1836255	C/G	cg00490583	chr16:1843685	IGFALS	-0.43	-7.69	-0.34	9.13e-14	Insulin-like growth factors;
LGG	cis	rs7444	0.941	rs5998619	chr22:21945851	G/A	cg22858872	chr22:21984481	YDJC	-0.36	-6.67	-0.3	7.47e-11	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.694	rs1672436	chr12:38132547	G/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.54	-0.44	1.96e-23	Bladder cancer;
LGG	cis	rs11098499	0.754	rs7672594	chr4:120248543	A/C	cg09307838	chr4:120376055	NA	0.73	12.49	0.5	4.63e-31	Corneal astigmatism;
LGG	cis	rs12421382	0.636	rs1371329	chr11:109382725	G/T	cg16359550	chr11:109292809	C11orf87	-0.4	-7.8	-0.34	4.24e-14	Schizophrenia;
LGG	cis	rs4822044	0.617	rs13054514	chr22:42130383	A/G	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.74e-41	Cannabis dependence symptom count;
LGG	cis	rs476633	0.708	rs9888708	chr15:41446030	G/C	cg18705301	chr15:41695430	NDUFAF1	-0.71	-11.62	-0.48	1.44e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs826838	1.000	rs11168367	chr12:38913397	T/G	cg06521331	chr12:34319734	NA	-0.45	-7.65	-0.33	1.19e-13	Heart rate;
LGG	cis	rs62238980	0.614	rs76592979	chr22:32413239	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7172689	0.908	rs55697022	chr15:81567474	T/G	cg11808699	chr15:81528661	IL16	-0.48	-9.77	-0.41	1.22e-20	Inattentive symptoms;
LGG	cis	rs999943	1.000	rs999943	chr6:33624733	A/G	cg14003231	chr6:33640908	ITPR3	0.55	12.72	0.51	5.3e-32	Obesity (extreme);
LGG	cis	rs11971779	0.616	rs6974907	chr7:139068729	G/C	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs34467563	0.669	rs4475447	chr8:97386573	A/G	cg22138393	chr8:97340270	PTDSS1	0.29	7.01	0.31	8.46e-12	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10189230	0.643	rs2710503	chr2:222374699	C/G	cg14652038	chr2:222343519	EPHA4	-0.38	-7.43	-0.33	5.39e-13	Urate levels in lean individuals;
LGG	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg00129232	chr17:37814104	STARD3	-0.58	-8.66	-0.37	7.91e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs2280018	0.538	rs7404526	chr16:15129162	A/G	cg07549590	chr16:15018862	NA	-0.47	-7.96	-0.35	1.3e-14	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6866344	0.697	rs11742808	chr5:178131658	G/A	cg10224037	chr5:178157518	ZNF354A	0.73	11.33	0.47	1.91e-26	Neutrophil percentage of white cells;
LGG	cis	rs965513	1.000	rs7030280	chr9:100535267	C/T	cg13688889	chr9:100608707	NA	-0.52	-9.55	-0.41	7.32e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs6831352	0.589	rs2602836	chr4:100014805	C/T	cg12011299	chr4:100065546	ADH4	-0.53	-11.78	-0.48	3.25e-28	Alcohol dependence;
LGG	cis	rs2839186	0.565	rs2839183	chr21:47687144	G/A	cg05896524	chr21:47604654	C21orf56	-0.44	-7.05	-0.31	6.7e-12	Testicular germ cell tumor;
LGG	cis	rs875971	0.862	rs2420173	chr7:65645399	A/T	cg11764359	chr7:65958608	NA	-0.74	-13.36	-0.53	1.13e-34	Aortic root size;
LGG	cis	rs9309473	1.000	rs6755241	chr2:73641364	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.76	-0.34	5.45e-14	Metabolite levels;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.3	-0.32	1.29e-12	Menopause (age at onset);
LGG	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg13010199	chr12:38710504	ALG10B	0.65	13.4	0.53	7.47e-35	Bladder cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16910911	chr7:102037347	PRKRIP1	0.49	7.26	0.32	1.67e-12	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.41	0.47	9.94e-27	Obesity-related traits;
LGG	cis	rs2070488	1.000	rs13079757	chr3:38491444	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.19	0.65	3.66e-56	Electrocardiographic conduction measures;
LGG	cis	rs593982	0.920	rs72939198	chr11:65438079	G/A	cg08755490	chr11:65554678	OVOL1	-0.63	-7.26	-0.32	1.6e-12	Atopic dermatitis;
LGG	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg02855558	chr7:158107723	PTPRN2	-0.42	-7.51	-0.33	3.15e-13	Calcium levels;
LGG	cis	rs6500395	1.000	rs11859909	chr16:48668441	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg01472538	chr16:58549086	SETD6	0.98	8.79	0.38	2.84e-17	Schizophrenia;
LGG	cis	rs4417704	0.551	rs56237031	chr2:241875360	C/A	cg05025159	chr2:241905733	NA	-0.49	-10.03	-0.42	1.44e-21	Joint mobility (Beighton score);
LGG	cis	rs10089	1.000	rs4836369	chr5:127486462	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.82	0.48	2.33e-28	Ileal carcinoids;
LGG	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.22	-0.32	2.19e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.799	rs2665836	chr17:61898135	C/A	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg11360546	chr7:1094263	C7orf50	-0.41	-7.42	-0.33	5.81e-13	Longevity;Endometriosis;
LGG	cis	rs10754283	0.967	rs10737708	chr1:90119804	A/G	cg21401794	chr1:90099060	LRRC8C	0.57	11.81	0.48	2.59e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs9325144	0.555	rs11183215	chr12:38693127	G/A	cg23762105	chr12:34175262	ALG10	0.35	7.06	0.31	6.1e-12	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.541	rs6932434	chr6:8467679	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs1814175	0.588	rs1721994	chr11:49914050	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	trans	rs9354308	0.764	rs9354310	chr6:66566718	T/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.99	-0.31	9.41e-12	Metabolite levels;
LGG	cis	rs3020736	0.500	rs4147640	chr22:42485292	T/C	cg15557168	chr22:42548783	NA	0.4	8.55	0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7215564	0.908	rs4243240	chr17:78660342	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs75920871	0.843	rs61905713	chr11:116909429	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.52e-12	Subjective well-being;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.68	0.41	2.67e-20	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs34572725	chr17:41428666	G/A	cg04503457	chr17:41445688	NA	-0.4	-9.46	-0.4	1.56e-19	Menopause (age at onset);
LGG	cis	rs2180341	1.000	rs9388561	chr6:127634921	C/T	cg24812749	chr6:127587940	RNF146	0.97	16.17	0.6	6.09e-47	Breast cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11718235	chr19:56915184	ZNF583	0.47	7.7	0.34	8.42e-14	Cognitive performance;
LGG	cis	rs5769707	0.837	rs5770599	chr22:50019981	C/G	cg20744362	chr22:50050164	C22orf34	0.39	7.6	0.33	1.61e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs11718455	1.000	rs13098215	chr3:44058920	C/T	cg21419209	chr3:44054225	NA	-0.44	-6.96	-0.31	1.2e-11	Coronary artery disease;
LGG	cis	rs774359	0.789	rs3849939	chr9:27525221	G/C	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.04	-0.35	7.45e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs6500602	0.701	rs11643057	chr16:4544505	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.41	7.02	0.31	8.04e-12	Schizophrenia;
LGG	cis	rs11758351	0.660	rs16891455	chr6:26230485	G/A	cg06951627	chr6:26196580	NA	0.45	6.73	0.3	5.03e-11	Gout;Renal underexcretion gout;
LGG	cis	rs3087591	1.000	rs2012988	chr17:29547296	T/C	cg24425628	chr17:29625626	OMG;NF1	0.7	14.3	0.55	1.11e-38	Hip circumference;
LGG	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.36e-11	Aortic root size;
LGG	cis	rs7737355	0.812	rs257391	chr5:130740005	A/C	cg06307176	chr5:131281290	NA	0.49	8.14	0.35	3.58e-15	Life satisfaction;
LGG	cis	rs9611565	0.512	rs139561	chr22:42195410	C/T	cg06634786	chr22:41940651	POLR3H	0.76	12.25	0.49	4.57e-30	Vitiligo;
LGG	cis	rs6424115	0.830	rs12744386	chr1:24168019	C/T	cg24699146	chr1:24152579	HMGCL	-0.26	-7.68	-0.34	9.23e-14	Immature fraction of reticulocytes;
LGG	trans	rs6787172	0.702	rs827131	chr3:158014597	G/C	cg23275840	chr4:47708675	CORIN	0.4	8.59	0.37	1.33e-16	Subjective well-being;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.15e-21	Aortic root size;
LGG	cis	rs2404602	0.716	rs1946650	chr15:76848463	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg10950524	chr7:2139216	MAD1L1	0.32	6.76	0.3	4.28e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2836974	0.897	rs34599551	chr21:40594898	C/A	cg11890956	chr21:40555474	PSMG1	1.19	30.87	0.82	1.83e-114	Cognitive function;
LGG	cis	rs6502050	0.835	rs7209474	chr17:80136418	C/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.7	-0.34	8.33e-14	Life satisfaction;
LGG	cis	rs4740619	0.869	rs10738406	chr9:15712636	G/A	cg14451791	chr9:16040625	NA	-0.39	-9.85	-0.42	6.37e-21	Body mass index;
LGG	trans	rs853679	0.546	rs200990	chr6:27815823	T/G	cg01620082	chr3:125678407	NA	-0.82	-9.46	-0.4	1.62e-19	Depression;
LGG	cis	rs858239	0.539	rs1358442	chr7:23189739	C/T	cg23682824	chr7:23144976	KLHL7	0.42	6.87	0.3	2.15e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11098499	0.909	rs7659501	chr4:120371552	G/T	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs3796352	0.667	rs3755805	chr3:52866299	G/A	cg12962167	chr3:53033115	SFMBT1	0.63	7.09	0.31	4.96e-12	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs657075	0.697	rs4646301	chr5:131711100	G/A	cg05556477	chr5:131705319	SLC22A5	0.8	9.64	0.41	3.66e-20	Rheumatoid arthritis;
LGG	cis	rs1865760	0.566	rs1800702	chr6:26086463	C/G	cg03264133	chr6:25882463	NA	-0.38	-6.75	-0.3	4.56e-11	Height;
LGG	cis	rs752010	0.838	rs11210505	chr1:42104731	G/C	cg06885757	chr1:42089581	HIVEP3	0.51	11.18	0.46	7.25e-26	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.48	-8.9	-0.38	1.24e-17	Lymphocyte counts;
LGG	cis	rs2587949	0.615	rs1994271	chr3:4232276	C/T	cg16519197	chr3:4211558	NA	0.32	6.72	0.3	5.3e-11	Periodontitis (DPAL);
LGG	trans	rs7819412	0.540	rs2409726	chr8:11043138	T/C	cg16141378	chr3:129829833	LOC729375	0.32	6.88	0.3	1.98e-11	Triglycerides;
LGG	cis	rs873946	0.564	rs12263364	chr10:134555548	G/T	cg26818010	chr10:134567672	INPP5A	-0.55	-8.48	-0.37	2.95e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3818285	0.544	rs9787456	chr10:111711822	A/G	cg00817464	chr10:111662876	XPNPEP1	-0.55	-9.65	-0.41	3.28e-20	Superior crus of antihelix expression;
LGG	cis	rs36051895	0.659	rs10974944	chr9:5070831	C/G	cg02405213	chr9:5042618	JAK2	-0.84	-16.04	-0.6	2.25e-46	Pediatric autoimmune diseases;
LGG	cis	rs7945718	0.967	rs11022491	chr11:12777620	A/G	cg25843174	chr11:12811716	TEAD1	-0.38	-7.84	-0.34	3.21e-14	Educational attainment (years of education);
LGG	cis	rs6489882	0.867	rs7304898	chr12:113365667	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.39	-0.32	6.81e-13	Chronic lymphocytic leukemia;
LGG	cis	rs4430311	0.655	rs12141946	chr1:243811634	T/G	cg25706552	chr1:244017396	NA	-0.63	-15.37	-0.58	2.15e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9354308	0.764	rs1604019	chr6:66571977	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.91	-0.31	1.6e-11	Metabolite levels;
LGG	cis	rs1153858	1.000	rs10519022	chr15:45663684	C/T	cg10760299	chr15:45669010	GATM	-0.41	-8.11	-0.35	4.52e-15	Homoarginine levels;
LGG	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.6	0.51	1.63e-31	Motion sickness;
LGG	cis	rs6938	0.618	rs11072514	chr15:75221865	T/A	cg17294928	chr15:75287854	SCAMP5	0.69	12.73	0.51	4.92e-32	Breast cancer;
LGG	cis	rs2730245	0.550	rs2709860	chr7:158651156	A/T	cg24397884	chr7:158709396	WDR60	0.89	19.1	0.66	2.05e-60	Height;
LGG	cis	rs1107366	1.000	rs9874508	chr3:125902417	A/G	cg17230874	chr3:125932073	NA	-0.52	-10.62	-0.44	1.04e-23	Metabolite levels;
LGG	cis	rs6500602	0.535	rs12443618	chr16:4429393	C/G	cg05091796	chr16:4465799	CORO7	-0.91	-14.34	-0.55	7.69e-39	Schizophrenia;
LGG	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg10253484	chr15:75165896	SCAMP2	-0.69	-11.09	-0.46	1.68e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs929354	0.742	rs3808316	chr7:156944787	C/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.47	-0.33	3.98e-13	Body mass index;
LGG	cis	rs2718058	0.519	rs2722233	chr7:37875982	A/T	cg15028436	chr7:37888078	TXNDC3	0.79	14.24	0.55	2.09e-38	Alzheimer's disease (late onset);
LGG	cis	rs8072100	1.000	rs8072100	chr17:45674687	A/T	cg19784903	chr17:45786737	TBKBP1	0.34	7.51	0.33	2.99e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs858239	0.539	rs2178140	chr7:23191625	G/C	cg23682824	chr7:23144976	KLHL7	0.41	6.72	0.3	5.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs11608355	0.515	rs4766605	chr12:109895636	C/A	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs11155671	0.530	rs9371542	chr6:150213085	A/T	cg16507663	chr6:150244633	RAET1G	0.52	10.59	0.44	1.33e-23	Testicular germ cell tumor;
LGG	cis	rs67133203	1.000	rs67133203	chr12:51426657	A/T	cg14688905	chr12:51403056	SLC11A2	0.8	12.28	0.5	3.31e-30	Urinary tract infection frequency;
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg16301924	chr13:53314226	LECT1	-0.46	-9.05	-0.39	3.99e-18	Lewy body disease;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg20309703	chr11:118481025	PHLDB1	0.57	11.32	0.47	2.11e-26	Cholesterol, total;
LGG	cis	rs1568889	0.838	rs7127069	chr11:28325412	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.15	0.66	1.29e-60	Bipolar disorder;
LGG	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.04	0.39	4.32e-18	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04781115	chr1:16010646	PLEKHM2	0.4	7.32	0.32	1.09e-12	Gut microbiome composition (summer);
LGG	cis	rs1862618	0.671	rs2591968	chr5:56233541	A/G	cg17809284	chr5:56205270	C5orf35	-0.55	-10.31	-0.43	1.37e-22	Initial pursuit acceleration;
LGG	cis	rs4742903	0.904	rs2417487	chr9:106887581	A/G	cg14250997	chr9:106856677	SMC2	0.38	7.99	0.35	1.12e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs10504229	0.953	rs67677367	chr8:58175264	T/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg04287289	chr16:89883240	FANCA	0.79	16.15	0.6	7.1500000000000005e-47	Vitiligo;
LGG	cis	rs7100689	0.556	rs10788541	chr10:82016530	T/G	cg01528321	chr10:82214614	TSPAN14	0.79	13.31	0.53	1.93e-34	Post bronchodilator FEV1;
LGG	cis	rs4330281	0.647	rs4568172	chr3:17749661	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg08677398	chr8:58056175	NA	0.57	9.15	0.39	1.8e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.631	rs7843369	chr8:8797786	T/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.7	-0.3	6.19e-11	Joint mobility (Beighton score);
LGG	cis	rs801193	0.569	rs2659907	chr7:66164032	G/A	cg23594656	chr7:65796392	TPST1	-0.37	-8.33	-0.36	9.01e-16	Aortic root size;
LGG	cis	rs61906588	0.595	rs1508108	chr11:116356720	A/G	cg12564567	chr11:116371188	NA	-0.38	-6.95	-0.31	1.22e-11	Post bronchodilator FEV1 in COPD;
LGG	cis	rs62244186	0.520	rs2372828	chr3:44784949	A/G	cg15225532	chr3:44803084	KIF15;KIAA1143	-0.44	-7.82	-0.34	3.5e-14	Depressive symptoms;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.11	0.31	4.37e-12	Prudent dietary pattern;
LGG	cis	rs7267979	1.000	rs2482911	chr20:25395528	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs60871478	0.578	rs62432900	chr7:826794	G/C	cg05535760	chr7:792225	HEATR2	0.97	14.63	0.56	3.95e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs11627756	0.846	rs12887440	chr14:103083899	G/A	cg12046867	chr14:103022105	NA	-0.4	-7.52	-0.33	2.93e-13	Mean platelet volume;
LGG	cis	rs8049040	0.609	rs16972805	chr16:71478249	A/G	cg08717414	chr16:71523259	ZNF19	0.55	8.72	0.38	4.94e-17	Blood protein levels;
LGG	cis	rs12586317	0.547	rs76770287	chr14:35487210	C/A	cg16230307	chr14:35515116	FAM177A1	0.92	13.63	0.54	8.18e-36	Psoriasis;
LGG	cis	rs67311347	1.000	rs11707673	chr3:40450604	C/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.04	-0.77	1e-92	Renal cell carcinoma;
LGG	cis	rs7267979	1.000	rs2482928	chr20:25331530	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.26	-0.43	2.09e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg12386194	chr3:101231763	SENP7	0.46	8.07	0.35	5.97e-15	Colorectal cancer;
LGG	trans	rs61931739	0.857	rs419112	chr12:34130528	A/G	cg26384229	chr12:38710491	ALG10B	0.63	12.5	0.5	4.24e-31	Morning vs. evening chronotype;
LGG	cis	rs798554	0.616	rs1636252	chr7:2884993	A/C	cg13628971	chr7:2884303	GNA12	0.37	7.72	0.34	7.03e-14	Height;
LGG	cis	rs7618915	0.508	rs7628578	chr3:52628321	A/T	cg18099408	chr3:52552593	STAB1	-0.34	-6.88	-0.3	1.97e-11	Bipolar disorder;
LGG	cis	rs2617583	0.967	rs2550947	chr5:1450506	T/C	cg07151155	chr5:1473589	LPCAT1	-0.37	-7.37	-0.32	7.73e-13	Breast cancer;
LGG	trans	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	4.91e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg16507663	chr6:150244633	RAET1G	0.47	8.72	0.38	5.21e-17	Lung cancer;
LGG	cis	rs2250402	0.510	rs2291619	chr15:40329033	C/T	cg10636054	chr15:40330586	SRP14	-1.25	-14.2	-0.55	3.09e-38	Corneal curvature;
LGG	cis	rs7129556	0.954	rs11237220	chr11:77268460	G/A	cg12586386	chr11:77299805	AQP11	0.5	8.19	0.36	2.56e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs6502050	0.769	rs11658272	chr17:80084596	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs12908161	0.960	rs11633450	chr15:85307287	C/T	cg03959625	chr15:84868606	LOC388152	0.45	6.69	0.3	6.63e-11	Schizophrenia;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg11508081	chr17:41442227	NA	0.35	6.91	0.31	1.6e-11	Menopause (age at onset);
LGG	cis	rs250677	0.687	rs41181	chr5:148444257	C/G	cg18129178	chr5:148520854	ABLIM3	0.43	7.08	0.31	5.48e-12	Breast cancer;
LGG	cis	rs1372520	0.684	rs2619356	chr4:90750844	C/T	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg05868516	chr6:26286170	HIST1H4H	0.44	7.71	0.34	7.76e-14	Educational attainment;
LGG	cis	rs2862064	1.000	rs11747316	chr5:156422948	A/G	cg12943317	chr5:156479607	HAVCR1	-0.84	-10.57	-0.44	1.56e-23	Platelet count;
LGG	cis	rs908922	0.582	rs1856121	chr1:152512169	A/T	cg20991723	chr1:152506922	NA	-0.69	-14.07	-0.55	1.05e-37	Hair morphology;
LGG	cis	rs6142618	0.562	rs6061206	chr20:30761972	T/C	cg00028034	chr20:30779307	TSPYL3	0.36	7.88	0.34	2.44e-14	Inflammatory bowel disease;
LGG	cis	rs936229	0.861	rs7180484	chr15:75115416	G/T	cg10253484	chr15:75165896	SCAMP2	0.67	10.06	0.42	1.13e-21	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.45	-0.33	4.71e-13	Life satisfaction;
LGG	cis	rs71403859	1.000	rs71403859	chr16:71640207	C/T	cg08717414	chr16:71523259	ZNF19	-1.15	-14.83	-0.57	5.23e-41	Post bronchodilator FEV1;
LGG	cis	rs1799949	1.000	rs8074136	chr17:41342313	A/C	cg12708336	chr17:41446283	NA	-0.32	-7.43	-0.33	5.43e-13	Menopause (age at onset);
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg00689492	chr4:1303491	MAEA	0.44	7.58	0.33	1.87e-13	Obesity-related traits;
LGG	cis	rs514406	0.929	rs557920	chr1:53338757	C/A	cg24675658	chr1:53192096	ZYG11B	-0.51	-9.67	-0.41	2.88e-20	Monocyte count;
LGG	cis	rs806215	0.951	rs327521	chr7:127249143	G/A	cg25922125	chr7:127225783	GCC1	0.66	9.59	0.41	5.59e-20	Type 2 diabetes;
LGG	cis	rs4730250	0.707	rs10253291	chr7:106786550	C/A	cg02696742	chr7:106810147	HBP1	0.79	11.27	0.46	3.38e-26	Osteoarthritis;
LGG	cis	rs881375	0.933	rs10818485	chr9:123667816	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.06	0.49	2.47e-29	Rheumatoid arthritis;
LGG	cis	rs2797160	0.904	rs1739370	chr6:126011231	C/T	cg05901451	chr6:126070800	HEY2	0.46	7.76	0.34	5.44e-14	Endometrial cancer;
LGG	cis	rs523522	0.962	rs4767914	chr12:120993817	C/T	cg12219531	chr12:120966889	COQ5	0.67	11.18	0.46	7.55e-26	High light scatter reticulocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03637622	chr5:179334771	TBC1D9B	0.48	7.02	0.31	7.76e-12	Gut microbiome composition (summer);
LGG	cis	rs2652834	0.851	rs4468558	chr15:63346681	T/C	cg05507819	chr15:63340323	TPM1	0.6	8.09	0.35	5.45e-15	HDL cholesterol;
LGG	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg19508488	chr2:152266495	RIF1	-0.5	-8.75	-0.38	4e-17	Squamous cell lung carcinoma;
LGG	cis	rs9522267	0.535	rs9522299	chr13:112236013	C/A	cg14952266	chr13:112191215	NA	0.52	10.93	0.45	6.84e-25	Hepatitis;
LGG	cis	rs7582180	0.663	rs4850929	chr2:100990707	A/C	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.43e-24	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	1.000	rs4862750	chr4:187904043	C/T	cg11301795	chr4:187892539	NA	-0.95	-26.34	-0.77	4.08e-94	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg04025307	chr7:1156635	C7orf50	0.8	16.69	0.61	2.62e-49	Longevity;Endometriosis;
LGG	cis	rs2204008	0.744	rs2222344	chr12:38406832	T/G	cg13010199	chr12:38710504	ALG10B	0.68	13.79	0.54	1.74e-36	Bladder cancer;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg21782813	chr7:2030301	MAD1L1	0.43	9.98	0.42	2.34e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg00431813	chr7:1051703	C7orf50	-0.33	-7.05	-0.31	6.7e-12	Longevity;Endometriosis;
LGG	cis	rs6598955	0.671	rs11247896	chr1:26600483	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs7226408	0.600	rs11662022	chr18:34649301	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.18	-0.39	1.4e-18	Obesity-related traits;
LGG	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg03709012	chr19:19516395	GATAD2A	0.96	15.24	0.58	8.91e-43	Nonalcoholic fatty liver disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21452766	chr1:70877088	CTH	0.43	7.06	0.31	6.28e-12	Cognitive performance;
LGG	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.47	-8.38	-0.36	6.6e-16	Blood metabolite levels;
LGG	cis	rs8133932	0.701	rs3788217	chr21:47287321	T/C	cg11214348	chr21:47283868	PCBP3	0.43	7.85	0.34	2.84e-14	Schizophrenia;
LGG	trans	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.69	0.34	9.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6450176	1.000	rs58369491	chr5:53297295	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.46	-0.47	5.9e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs17376456	0.825	rs55724660	chr5:93276636	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg16524936	chr4:1340807	KIAA1530	-0.47	-7.26	-0.32	1.62e-12	Obesity-related traits;
LGG	cis	rs10991814	1.000	rs78806746	chr9:93996269	G/A	cg14446406	chr9:93919335	NA	-0.78	-8.78	-0.38	3.29e-17	Neutrophil percentage of granulocytes;
LGG	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg21926612	chr6:163149169	PACRG;PARK2	1.18	12.48	0.5	5.14e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3e-23	Prudent dietary pattern;
LGG	trans	rs3780486	0.801	rs3780495	chr9:33125942	A/C	cg20290983	chr6:43655470	MRPS18A	1.11	25.38	0.76	1.14e-89	IgG glycosylation;
LGG	cis	rs7998202	0.720	rs914020	chr13:113352848	C/G	cg02820901	chr13:113351484	ATP11A	0.59	7.17	0.32	3.03e-12	Glycated hemoglobin levels;
LGG	cis	rs459571	0.635	rs379471	chr9:136890649	G/A	cg13789015	chr9:136890014	NCRNA00094	0.59	11.03	0.46	2.77e-25	Platelet distribution width;
LGG	cis	rs875971	0.660	rs7807930	chr7:66087165	C/T	cg18876405	chr7:65276391	NA	-0.62	-11.48	-0.47	4.93e-27	Aortic root size;
LGG	cis	rs17711722	1.000	rs17711722	chr7:65271197	C/T	cg18876405	chr7:65276391	NA	-0.68	-13.09	-0.52	1.63e-33	Calcium levels;
LGG	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg17691542	chr6:26056736	HIST1H1C	0.7	11.42	0.47	8.76e-27	Iron status biomarkers;
LGG	cis	rs13082711	0.519	rs13091109	chr3:27229125	G/A	cg02860705	chr3:27208620	NA	0.87	17.49	0.63	5.77e-53	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs34599045	0.522	rs71626744	chr1:152972016	G/A	cg07796016	chr1:152779584	LCE1C	-0.88	-7.39	-0.32	6.72e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs708547	0.647	rs781668	chr4:57825140	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.54	-9.02	-0.39	5.05e-18	Response to bleomycin (chromatid breaks);
LGG	cis	rs34929064	1.000	rs6969856	chr7:22722537	G/A	cg18045685	chr7:22629474	NA	0.55	8.89	0.38	1.42e-17	Major depression and alcohol dependence;
LGG	cis	rs7084402	0.935	rs12248958	chr10:60278255	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.34	0.32	9.6e-13	Refractive error;
LGG	cis	rs7166081	0.950	rs12476	chr15:67493726	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.99	-0.31	9.78e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs826838	1.000	rs1963562	chr12:38662896	C/T	cg06521331	chr12:34319734	NA	-0.46	-8.06	-0.35	6.64e-15	Heart rate;
LGG	cis	rs61826828	1	rs61826828	chr1:174015261	A/G	cg06124660	chr1:173389066	NA	-0.42	-6.86	-0.3	2.25e-11	Schizophrenia;
LGG	cis	rs10463554	0.892	rs62362519	chr5:102301463	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.77	-0.38	3.56e-17	Parkinson's disease;
LGG	cis	rs559928	1.000	rs11601872	chr11:64147627	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.52	0.33	2.93e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs3815700	1.000	rs8113165	chr19:33096316	C/T	cg02997394	chr19:33096574	ANKRD27	0.88	14.84	0.57	4.91e-41	Eosinophilic esophagitis;
LGG	cis	rs57221529	0.766	rs12519469	chr5:581772	A/G	cg09021430	chr5:549028	NA	-0.69	-9.77	-0.41	1.22e-20	Lung disease severity in cystic fibrosis;
LGG	trans	rs9329221	0.935	rs6601450	chr8:10243101	G/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.12	0.39	2.3e-18	Neuroticism;
LGG	cis	rs7020830	0.931	rs7851239	chr9:37138672	A/G	cg14294708	chr9:37120828	ZCCHC7	-1.14	-29.97	-0.81	1.79e-110	Schizophrenia;
LGG	cis	rs9393692	0.875	rs9393690	chr6:26271713	A/T	cg00294572	chr6:26285232	NA	0.41	7.53	0.33	2.72e-13	Educational attainment;
LGG	cis	rs2836950	0.585	rs1029004	chr21:40615343	A/G	cg17971929	chr21:40555470	PSMG1	-0.5	-8.53	-0.37	2.03e-16	Menarche (age at onset);
LGG	cis	rs4819143	0.504	rs6518259	chr21:47317886	C/G	cg11214348	chr21:47283868	PCBP3	0.45	7.94	0.35	1.57e-14	Insulin resistance/response;
LGG	cis	rs35264875	1.000	rs72919428	chr11:68828949	C/T	cg03469862	chr11:68924853	NA	0.44	6.66	0.3	7.64e-11	Blond vs. brown hair color;
LGG	cis	rs910316	1.000	rs10140851	chr14:75512612	G/A	cg08847533	chr14:75593920	NEK9	0.62	11.72	0.48	5.88e-28	Height;
LGG	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg09021430	chr5:549028	NA	-0.86	-20.65	-0.69	1.3e-67	Obesity-related traits;
LGG	cis	rs9398803	0.698	rs1101563	chr6:127049198	T/C	cg19875578	chr6:126661172	C6orf173	-0.49	-9.01	-0.39	5.32e-18	Male-pattern baldness;
LGG	cis	rs9400467	0.537	rs9647629	chr6:111501484	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.11	0.31	4.29e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs12478296	0.792	rs6738361	chr2:243014257	C/T	cg18898632	chr2:242989856	NA	-0.84	-10.42	-0.44	5.66e-23	Obesity-related traits;
LGG	cis	rs12282928	0.959	rs11039631	chr11:48297062	A/G	cg26585981	chr11:48327164	OR4S1	-0.45	-7.2	-0.32	2.51e-12	Migraine - clinic-based;
LGG	cis	rs9768139	0.683	rs28682392	chr7:158116004	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.18	-0.32	2.79e-12	Calcium levels;
LGG	cis	rs7474896	0.537	rs1208591	chr10:38212502	A/T	cg25427524	chr10:38739819	LOC399744	-0.51	-7.24	-0.32	1.93e-12	Obesity (extreme);
LGG	cis	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg13443165	chr9:33130375	B4GALT1	-0.73	-14.3	-0.55	1.13e-38	IgG glycosylation;
LGG	cis	rs193541	0.632	rs10037044	chr5:122123299	A/G	cg19412675	chr5:122181750	SNX24	-0.52	-8.35	-0.36	7.98e-16	Glucose homeostasis traits;
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg07061783	chr6:25882402	NA	-0.39	-6.92	-0.31	1.55e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6433857	0.657	rs2368178	chr2:181501938	T/C	cg23363182	chr2:181467187	NA	-0.35	-7.11	-0.31	4.52e-12	Body mass index;
LGG	trans	rs826838	0.904	rs7973992	chr12:39168233	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.6	-0.33	1.71e-13	Heart rate;
LGG	cis	rs7555523	0.830	rs6660601	chr1:165695855	C/T	cg24409356	chr1:165738333	TMCO1	0.76	9.07	0.39	3.35e-18	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.58	-11.64	-0.48	1.2100000000000001e-27	Obesity-related traits;
LGG	cis	rs4808199	1.000	rs4808199	chr19:19545099	C/T	cg03709012	chr19:19516395	GATAD2A	1.03	16.32	0.6	1.29e-47	Nonalcoholic fatty liver disease;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs755249	0.567	rs61779306	chr1:39922426	G/A	cg18385671	chr1:39797026	MACF1	0.45	7.52	0.33	2.93e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	0.769	rs17804383	chr8:58151830	A/G	cg08280861	chr8:58055591	NA	0.6	7.7	0.34	8.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs950169	0.922	rs4842940	chr15:84831225	C/T	cg03959625	chr15:84868606	LOC388152	-0.55	-8.71	-0.38	5.36e-17	Schizophrenia;
LGG	cis	rs2011503	0.882	rs4808933	chr19:19363812	T/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.83	0.3	2.65e-11	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.22	-0.43	3.15e-22	Initial pursuit acceleration;
LGG	cis	rs80130819	0.515	rs917055	chr12:48385576	A/G	cg24011408	chr12:48396354	COL2A1	0.62	7.31	0.32	1.15e-12	Prostate cancer;
LGG	cis	rs7619833	0.512	rs7653795	chr3:27217080	G/A	cg02860705	chr3:27208620	NA	0.42	8.13	0.35	3.91e-15	Breast cancer;
LGG	cis	rs6502050	0.835	rs8080423	chr17:80102279	A/G	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs11112613	0.713	rs17041546	chr12:105950801	G/T	cg03607813	chr12:105948248	NA	-0.53	-9.83	-0.42	7.65e-21	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs933688	1.000	rs11959525	chr5:90703840	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.08	16.54	0.61	1.33e-48	Smoking behavior;
LGG	trans	rs9951602	0.512	rs77157626	chr18:76644771	C/T	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs61931739	0.612	rs1906136	chr12:33905293	C/T	cg06521331	chr12:34319734	NA	-0.4	-7.02	-0.31	8.12e-12	Morning vs. evening chronotype;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg03804240	chr11:118481350	PHLDB1	0.48	9.75	0.41	1.53e-20	Systemic lupus erythematosus;
LGG	cis	rs7681423	0.951	rs35147053	chr4:155517842	A/G	cg20735720	chr4:155535218	FGG	-0.54	-9.41	-0.4	2.24e-19	Fibrinogen;
LGG	cis	rs9462027	0.630	rs7341267	chr6:34727031	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs4731207	0.724	rs10224946	chr7:124531338	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs910187	0.605	rs6018320	chr20:45804412	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.47	-0.4	1.48e-19	Migraine;
LGG	cis	rs6792151	0.549	rs11914688	chr3:171552423	T/C	cg26441893	chr3:171559851	TMEM212	-0.4	-7.4	-0.33	6.57e-13	Red cell distribution width;
LGG	cis	rs1018836	0.608	rs10111060	chr8:91491152	T/C	cg16814680	chr8:91681699	NA	-0.6	-9.84	-0.42	7.22e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs61008539	0.893	rs4721502	chr7:862186	A/G	cg05535760	chr7:792225	HEATR2	-0.45	-7.67	-0.34	1.04e-13	Perceived unattractiveness to mosquitoes;
LGG	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21659725	chr3:3221576	CRBN	0.75	14.15	0.55	5.02e-38	Intelligence (multi-trait analysis);
LGG	cis	rs4819052	0.851	rs7276828	chr21:46695039	T/G	cg06618935	chr21:46677482	NA	-0.5	-9.67	-0.41	2.82e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs854765	0.547	rs7224047	chr17:17932931	G/A	cg04398451	chr17:18023971	MYO15A	-0.74	-15.53	-0.59	4.38e-44	Total body bone mineral density;
LGG	cis	rs7727544	0.582	rs3805683	chr5:131535125	T/G	cg07395648	chr5:131743802	NA	-0.4	-8.68	-0.37	6.58e-17	Blood metabolite levels;
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs7818345	0.624	rs12682196	chr8:19332963	A/C	cg06699216	chr8:19333253	CSGALNACT1	0.42	9.2	0.39	1.27e-18	Language performance in older adults (adjusted for episodic memory);
LGG	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg16141378	chr3:129829833	LOC729375	-0.36	-7.88	-0.34	2.37e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs875971	1.000	rs4717300	chr7:65947380	T/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	cis	rs72781680	0.898	rs72780188	chr2:24006065	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs657075	0.697	rs3805672	chr5:131658974	G/T	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	cis	rs1005277	0.683	rs7923868	chr10:37989766	T/C	cg00409905	chr10:38381863	ZNF37A	-0.61	-12.13	-0.49	1.4e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs2032447	0.867	rs9295683	chr6:26069495	C/T	cg18357526	chr6:26021779	HIST1H4A	0.76	14.29	0.55	1.26e-38	Intelligence (multi-trait analysis);
LGG	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.81	15.53	0.59	4.32e-44	Hip circumference adjusted for BMI;
LGG	cis	rs9325144	0.600	rs2171405	chr12:38741030	G/T	cg26384229	chr12:38710491	ALG10B	-0.74	-14.26	-0.55	1.68e-38	Morning vs. evening chronotype;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25632114	chr8:95732714	DPY19L4	-0.39	-6.66	-0.3	7.81e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7819412	0.807	rs9657519	chr8:10945439	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.24	-0.36	1.83e-15	Triglycerides;
LGG	cis	rs13031619	1.000	rs6724730	chr2:3697987	G/C	cg01268866	chr2:3683757	COLEC11	-0.37	-6.7	-0.3	6.12e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18640608	chr19:13001970	GCDH	0.53	7.9	0.34	2.07e-14	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs2584635	chr17:61865934	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs9658691	0.646	rs7079111	chr10:90750982	T/G	cg03111039	chr10:90751583	FAS;ACTA2	0.94	10.1	0.42	8.59e-22	Mosquito bite size;
LGG	cis	rs870825	0.616	rs35533356	chr4:185639134	A/G	cg04058563	chr4:185651563	MLF1IP	1.05	22.51	0.72	2.43e-76	Blood protein levels;
LGG	cis	rs9611565	0.694	rs106860	chr22:41840407	C/T	cg06481639	chr22:41940642	POLR3H	-0.6	-8.74	-0.38	4.21e-17	Vitiligo;
LGG	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.38	-0.36	6.5e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.76	16.66	0.61	3.81e-49	Obesity-related traits;
LGG	trans	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg27523141	chr10:43048294	ZNF37B	0.38	7.48	0.33	3.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg13010199	chr12:38710504	ALG10B	0.71	14.86	0.57	4e-41	Heart rate;
LGG	cis	rs424971	1.000	rs424971	chr16:85946450	C/T	cg10334323	chr16:85945517	IRF8	0.33	6.93	0.31	1.41e-11	Monocyte count;
LGG	cis	rs1719271	0.831	rs1719265	chr15:65176608	G/A	cg11671771	chr15:65133392	PLEKHO2	-0.52	-7.25	-0.32	1.78e-12	Platelet count;
LGG	cis	rs8067545	0.532	rs12943904	chr17:20007567	G/C	cg13482628	chr17:19912719	NA	0.51	8.51	0.37	2.36e-16	Schizophrenia;
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg02182114	chr7:139876578	LOC100134229;JHDM1D	-0.38	-6.68	-0.3	6.69e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs10540	1.000	rs61876326	chr11:467368	A/G	cg03352830	chr11:487213	PTDSS2	0.86	11.0	0.46	3.54e-25	Body mass index;
LGG	trans	rs7395662	0.517	rs10454483	chr11:48754997	A/G	cg03929089	chr4:120376271	NA	-0.57	-9.97	-0.42	2.4e-21	HDL cholesterol;
LGG	trans	rs2197308	0.667	rs11181073	chr12:37898543	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.78	-0.41	1.15e-20	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.529	rs170637	chr17:42186868	C/T	cg13607699	chr17:42295918	UBTF	-0.41	-6.64	-0.3	8.6e-11	Total body bone mineral density;
LGG	trans	rs12517041	1.000	rs6866732	chr5:23307656	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.27	-0.46	3.44e-26	Calcium levels;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg00761968	chr13:53314142	LECT1	-0.39	-8.14	-0.35	3.66e-15	Lewy body disease;
LGG	cis	rs2404602	0.735	rs2461871	chr15:76822418	C/G	cg15268244	chr15:77196840	NA	0.41	8.93	0.38	9.89e-18	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02776251	chr12:62654319	USP15	0.44	7.04	0.31	7.2e-12	Cognitive performance;
LGG	cis	rs2836974	0.666	rs4624474	chr21:40686327	T/C	cg17971929	chr21:40555470	PSMG1	-0.67	-12.14	-0.49	1.29e-29	Cognitive function;
LGG	cis	rs9467773	0.526	rs10946817	chr6:26364056	C/T	cg09904177	chr6:26538194	HMGN4	-0.43	-7.58	-0.33	1.93e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	0.686	rs2991977	chr1:46053683	G/A	cg03146154	chr1:46216737	IPP	-0.54	-10.14	-0.43	6.15e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs881375	0.526	rs1930785	chr9:123691237	T/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.39	0.4	2.64e-19	Rheumatoid arthritis;
LGG	cis	rs36051895	0.589	rs16922779	chr9:5200127	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-13.59	-0.53	1.27e-35	Pediatric autoimmune diseases;
LGG	cis	rs4822044	0.561	rs132781	chr22:42046122	T/G	cg06481639	chr22:41940642	POLR3H	0.52	7.23	0.32	2.03e-12	Cannabis dependence symptom count;
LGG	cis	rs7647973	1.000	rs6785045	chr3:49435243	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.69	-0.34	8.96e-14	Menarche (age at onset);
LGG	cis	rs7173743	0.756	rs6495337	chr15:79125689	C/G	cg00540400	chr15:79124168	NA	-0.43	-9.09	-0.39	2.97e-18	Coronary artery disease;
LGG	cis	rs35123781	0.654	rs356443	chr5:139077829	G/C	cg21230503	chr5:139085173	NA	0.37	8.55	0.37	1.85e-16	Schizophrenia;
LGG	cis	rs933688	1.000	rs6867091	chr5:90734333	C/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.88	17.03	0.62	7.67e-51	Smoking behavior;
LGG	cis	rs651907	0.535	rs61396602	chr3:101509046	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.81	-0.34	3.89e-14	Colorectal cancer;
LGG	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg11707556	chr5:10655725	ANKRD33B	0.5	9.74	0.41	1.56e-20	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01016090	chr20:18477958	RBBP9	0.47	6.94	0.31	1.31e-11	Gut microbiome composition (summer);
LGG	trans	rs8073060	0.544	rs225252	chr17:33952401	G/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9487094	0.666	rs736830	chr6:109713299	A/C	cg01125227	chr6:109776195	MICAL1	0.39	6.91	0.31	1.62e-11	Height;
LGG	cis	rs3733585	0.699	rs4339211	chr4:9947658	C/T	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.86	-0.3	2.15e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs12295403	0.723	rs12787397	chr11:18687025	C/T	cg09201001	chr11:18656081	SPTY2D1	0.41	6.75	0.3	4.37e-11	Ovarian reserve;
LGG	cis	rs875971	0.638	rs10249404	chr7:66046724	G/A	cg00343986	chr7:65444356	GUSB	-0.42	-7.18	-0.32	2.85e-12	Aortic root size;
LGG	cis	rs7084402	1.000	rs7074778	chr10:60272248	C/T	cg09696939	chr10:60272079	BICC1	0.38	7.57	0.33	2.1e-13	Refractive error;
LGG	cis	rs7133214	0.771	rs12368838	chr12:27921677	A/G	cg04279139	chr12:27925367	LOC100133893	-0.32	-6.91	-0.31	1.58e-11	Gut microbiota (functional units);
LGG	cis	rs9354308	0.764	rs9342513	chr6:66591068	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs7395662	0.892	rs11040014	chr11:48783057	G/A	cg03929089	chr4:120376271	NA	0.44	7.15	0.32	3.31e-12	HDL cholesterol;
LGG	cis	rs2404602	0.716	rs8025134	chr15:76781729	C/T	cg15268244	chr15:77196840	NA	-0.32	-7.17	-0.32	2.98e-12	Blood metabolite levels;
LGG	cis	rs2153535	0.580	rs2152347	chr6:8474281	A/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs6984449	0.516	rs7830251	chr8:19306522	G/A	cg01280390	chr8:19363452	CSGALNACT1	0.45	10.21	0.43	3.3e-22	Educational attainment;
LGG	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg15454534	chr1:248569605	OR2T1	0.38	6.9	0.31	1.74e-11	Common traits (Other);
LGG	cis	rs4820294	0.669	rs7287358	chr22:38054403	A/G	cg00142150	chr22:38071001	LGALS1	0.68	13.09	0.52	1.54e-33	Fat distribution (HIV);
LGG	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg20991723	chr1:152506922	NA	-0.7	-14.37	-0.56	5.48e-39	Hair morphology;
LGG	cis	rs4687717	0.717	rs13059189	chr3:53288475	G/A	cg16894138	chr3:53270350	TKT	0.41	7.78	0.34	4.76e-14	Blood metabolite levels;Blood metabolite ratios;
LGG	cis	rs11671005	0.735	rs11670871	chr19:58940514	C/T	cg13877915	chr19:58951672	ZNF132	-0.61	-9.1	-0.39	2.7e-18	Mean platelet volume;
LGG	cis	rs9910055	0.529	rs575798	chr17:42181796	A/C	cg19774624	chr17:42201019	HDAC5	0.65	11.42	0.47	9.19e-27	Total body bone mineral density;
LGG	cis	rs7615952	0.576	rs2276726	chr3:125826287	C/G	cg04553112	chr3:125709451	NA	-0.53	-6.86	-0.3	2.17e-11	Blood pressure (smoking interaction);
LGG	cis	rs657075	0.697	rs4646304	chr5:131714778	C/A	cg20453264	chr5:131705742	SLC22A5	0.62	7.97	0.35	1.26e-14	Rheumatoid arthritis;
LGG	cis	rs6424115	0.830	rs3123554	chr1:24196401	C/T	cg24699146	chr1:24152579	HMGCL	-0.26	-7.7	-0.34	8.58e-14	Immature fraction of reticulocytes;
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg00761968	chr13:53314142	LECT1	-0.32	-6.68	-0.3	6.99e-11	Lewy body disease;
LGG	cis	rs72772090	0.539	rs72775810	chr5:96185307	A/T	cg00188032	chr5:96141721	ERAP1	0.56	7.29	0.32	1.33e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7319311	1.000	rs7319311	chr13:111030578	A/G	cg06243866	chr13:111019493	COL4A2	0.51	8.98	0.39	6.79e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg18379455	chr17:41446167	NA	-0.33	-7.26	-0.32	1.62e-12	Menopause (age at onset);
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg07870213	chr5:140052090	DND1	-0.87	-15.84	-0.59	1.79e-45	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs911263	0.603	rs12889949	chr14:68774854	T/G	cg18825221	chr14:68749962	RAD51L1	0.38	8.3	0.36	1.14e-15	Primary biliary cholangitis;
LGG	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg06027949	chr8:82754900	SNX16	-0.48	-7.54	-0.33	2.53e-13	Diastolic blood pressure;
LGG	cis	rs8180040	0.726	rs2305634	chr3:47043538	A/G	cg27129171	chr3:47204927	SETD2	-0.81	-15.2	-0.58	1.33e-42	Colorectal cancer;
LGG	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs4948102	0.924	rs13241866	chr7:56090878	C/G	cg17215666	chr7:56131930	SUMF2	0.42	6.99	0.31	9.37e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg01403660	chr11:68851641	TPCN2	0.5	7.06	0.31	6.31e-12	Blond vs. brown hair color;
LGG	cis	rs738322	0.600	rs6001031	chr22:38556260	G/T	cg25457927	chr22:38595422	NA	0.4	9.91	0.42	4.14e-21	Cutaneous nevi;
LGG	cis	rs7618501	0.633	rs11130228	chr3:50003246	C/T	cg24110177	chr3:50126178	RBM5	-0.57	-10.48	-0.44	3.3e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7786808	0.536	rs4909210	chr7:158194376	T/C	cg15440763	chr7:158190612	PTPRN2	0.46	9.65	0.41	3.28e-20	Obesity-related traits;
LGG	trans	rs7618501	0.521	rs55692411	chr3:49911155	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.43	7.5	0.33	3.24e-13	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11954230	chr10:105677556	OBFC1	0.35	6.71	0.3	5.69e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2842992	0.747	rs4709378	chr6:160227435	G/C	cg11366901	chr6:160182831	ACAT2	1.05	15.27	0.58	6.5e-43	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1552244	0.554	rs13079240	chr3:10047246	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.72	12.42	0.5	8.89e-31	Alzheimer's disease;
LGG	cis	rs10752881	1.000	rs10911190	chr1:182979080	C/T	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs4689388	0.853	rs13103357	chr4:6294544	A/G	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7159888	0.548	rs11627598	chr14:65797766	G/T	cg15999311	chr14:65749247	NA	-0.39	-6.74	-0.3	4.86e-11	IgG glycosylation;N-glycan levels;
LGG	cis	rs4237845	0.514	rs4760339	chr12:58268149	G/T	cg02175503	chr12:58329896	NA	0.55	9.07	0.39	3.32e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4704187	0.663	rs7735057	chr5:74403857	T/A	cg03227963	chr5:74354835	NA	0.31	6.7	0.3	6.12e-11	Response to amphetamines;
LGG	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg13010199	chr12:38710504	ALG10B	0.51	9.91	0.42	3.93e-21	Morning vs. evening chronotype;
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.24	-0.46	4.42e-26	Bipolar disorder;
LGG	cis	rs9560113	0.622	rs4773388	chr13:112195250	A/C	cg14154082	chr13:112174009	NA	0.37	8.08	0.35	5.8e-15	Menarche (age at onset);
LGG	cis	rs4363385	0.818	rs546666	chr1:153015385	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.87	-0.38	1.58e-17	Inflammatory skin disease;
LGG	cis	rs4363385	0.755	rs1933382	chr1:153003295	G/T	cg13444842	chr1:152974279	SPRR3	0.38	7.41	0.33	6.18e-13	Inflammatory skin disease;
LGG	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.44	7.19	0.32	2.57e-12	Hip circumference adjusted for BMI;
LGG	cis	rs899997	1.000	rs12907511	chr15:78998061	C/G	cg22753661	chr15:79092743	ADAMTS7	0.41	6.83	0.3	2.72e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg19147804	chr7:1989927	MAD1L1	-0.57	-11.39	-0.47	1.15e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4780401	0.703	rs8191295	chr16:11766905	A/G	cg01061890	chr16:11836724	TXNDC11	-0.46	-7.54	-0.33	2.55e-13	Rheumatoid arthritis;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg13880726	chr7:1868755	MAD1L1	0.49	8.49	0.37	2.85e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.840	rs4822025	chr22:41776646	C/G	cg17376030	chr22:41985996	PMM1	0.54	8.93	0.38	1e-17	Vitiligo;
LGG	cis	rs6032067	0.929	rs11699850	chr20:43809049	T/C	cg10761708	chr20:43804764	PI3	0.76	11.89	0.48	1.21e-28	Blood protein levels;
LGG	cis	rs944722	0.935	rs2872753	chr17:26095562	A/G	cg07704981	chr17:26127537	NOS2	0.43	7.48	0.33	3.74e-13	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg22907277	chr7:1156413	C7orf50	0.69	8.77	0.38	3.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs453301	0.571	rs2929456	chr8:9083416	G/A	cg15556689	chr8:8085844	FLJ10661	-0.44	-8.14	-0.35	3.6e-15	Joint mobility (Beighton score);
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg26513180	chr16:89883248	FANCA	0.83	8.72	0.38	5.12e-17	Skin colour saturation;
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg12458913	chr13:53173898	NA	0.92	22.08	0.72	2.4e-74	Lewy body disease;
LGG	trans	rs4714291	0.802	rs2983143	chr6:40044850	G/T	cg02267698	chr19:7991119	CTXN1	-0.63	-10.18	-0.43	4.09e-22	Strep throat;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19125715	chr8:67525489	MYBL1	0.49	7.95	0.35	1.42e-14	Cognitive performance;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.71	-0.41	2.08e-20	Lung cancer;
LGG	cis	rs801193	0.967	rs2420827	chr7:66147101	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.6	-0.44	1.17e-23	Aortic root size;
LGG	cis	rs68170813	0.559	rs1002935	chr7:106832361	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-11.09	-0.46	1.7e-25	Coronary artery disease;
LGG	cis	rs12724450	0.793	rs74124686	chr1:150416621	G/C	cg03818307	chr1:150480534	ECM1	0.51	7.17	0.32	2.94e-12	Blood protein levels;
LGG	cis	rs11877825	0.826	rs4121954	chr18:10569713	T/C	cg25239095	chr18:10589360	NA	0.49	9.16	0.39	1.66e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs4689592	0.554	rs3822270	chr4:7069804	C/A	cg25660036	chr4:7070649	GRPEL1	-0.45	-6.86	-0.3	2.19e-11	Monocyte percentage of white cells;
LGG	cis	rs4474465	1.000	rs10899521	chr11:78184560	T/A	cg27205649	chr11:78285834	NARS2	-0.5	-8.67	-0.37	7.1e-17	Alzheimer's disease (survival time);
LGG	cis	rs2289125	0.762	rs10830278	chr11:89216425	T/A	cg03793270	chr11:89224684	NOX4	0.48	7.52	0.33	2.94e-13	Pulse pressure;
LGG	trans	rs7824557	0.602	rs35807737	chr8:11204411	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.9	-0.31	1.71e-11	Retinal vascular caliber;
LGG	cis	rs9487094	0.670	rs3899233	chr6:109976994	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.15	0.35	3.52e-15	Height;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4819052	0.851	rs9754134	chr21:46661751	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12464559	0.522	rs4664498	chr2:152575417	A/G	cg01189475	chr2:152685088	ARL5A	0.7	7.2	0.32	2.42e-12	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9926296	0.715	rs2115401	chr16:89740609	A/G	cg08949735	chr16:89699720	DPEP1	0.45	9.13	0.39	2.19e-18	Vitiligo;
LGG	cis	rs7827545	1.000	rs6578237	chr8:135569358	C/G	cg09855544	chr8:135498122	ZFAT	-0.42	-7.12	-0.31	4.2e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg16339924	chr4:17578868	LAP3	0.64	11.03	0.46	2.85e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs13191362	0.507	rs2803051	chr6:163034979	G/A	cg21926612	chr6:163149169	PACRG;PARK2	-0.6	-8.49	-0.37	2.75e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs34467563	0.670	rs6468501	chr8:97354951	C/T	cg22138393	chr8:97340270	PTDSS1	0.3	7.81	0.34	3.88e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs644799	1.000	rs564675	chr11:95561873	C/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.94	0.54	3.88e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2832077	0.943	rs4816332	chr21:30201706	T/C	cg03476357	chr21:30257390	N6AMT1	-0.51	-7.46	-0.33	4.29e-13	Cognitive test performance;
LGG	cis	rs79976124	0.837	rs10944858	chr6:66646039	G/A	cg07460842	chr6:66804631	NA	0.73	12.52	0.5	3.54e-31	Type 2 diabetes;
LGG	cis	rs826838	0.967	rs11169387	chr12:39145737	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.96	0.57	1.51e-41	Heart rate;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg01171360	chr6:293285	DUSP22	-0.59	-9.79	-0.41	1.06e-20	Menopause (age at onset);
LGG	cis	rs9462027	0.628	rs2814970	chr6:34713500	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.45	-0.47	6.68e-27	Systemic lupus erythematosus;
LGG	cis	rs35160687	0.901	rs35762338	chr2:86513553	G/A	cg10973622	chr2:86423274	IMMT	0.39	6.68	0.3	6.71e-11	Night sleep phenotypes;
LGG	cis	rs2857078	0.654	rs4793083	chr17:42312973	C/T	cg13607699	chr17:42295918	UBTF	-0.88	-17.57	-0.63	2.49e-53	Red cell distribution width;Reticulocyte count;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg01059449	chr18:44338099	ST8SIA5	-0.38	-8.32	-0.36	1.03e-15	Personality dimensions;
LGG	cis	rs2832191	0.716	rs7509628	chr21:30454252	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.92	0.81	2.85e-110	Dental caries;
LGG	trans	rs2980439	0.607	rs2980419	chr8:8114141	A/T	cg16141378	chr3:129829833	LOC729375	-0.54	-13.85	-0.54	9.15e-37	Neuroticism;
LGG	cis	rs12153243	0.686	rs72806733	chr5:142945025	C/T	cg13907255	chr5:142895549	NA	-0.42	-7.26	-0.32	1.61e-12	Migraine;
LGG	cis	rs7726839	0.507	rs72703100	chr5:614291	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.62e-15	Obesity-related traits;
LGG	cis	rs787274	0.543	rs4979177	chr9:115644266	G/A	cg13803584	chr9:115635662	SNX30	-0.64	-9.18	-0.39	1.44e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs10435719	0.744	rs11250175	chr8:11792758	G/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg02571920	chr17:56084885	SFRS1	0.39	6.99	0.31	9.37e-12	Obesity-related traits;
LGG	cis	rs9925964	0.622	rs8046707	chr16:30916233	G/A	cg02466173	chr16:30829666	NA	0.37	6.85	0.3	2.38e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11098499	0.691	rs28396837	chr4:120271541	G/A	cg24375607	chr4:120327624	NA	0.51	8.68	0.37	7.02e-17	Corneal astigmatism;
LGG	cis	rs6582630	0.502	rs11181210	chr12:38298069	G/A	cg26384229	chr12:38710491	ALG10B	0.92	20.46	0.69	9.17e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7572733	0.935	rs1401090	chr2:198808578	C/T	cg00792783	chr2:198669748	PLCL1	0.48	7.93	0.35	1.67e-14	Dermatomyositis;
LGG	cis	rs9790314	0.638	rs13064176	chr3:160644181	A/T	cg04691961	chr3:161091175	C3orf57	-0.44	-9.43	-0.4	1.97e-19	Morning vs. evening chronotype;
LGG	cis	rs67460515	0.563	rs6794882	chr3:160851849	G/A	cg04691961	chr3:161091175	C3orf57	-0.43	-8.35	-0.36	7.9e-16	Parkinson's disease;
LGG	cis	rs1790761	0.505	rs7941648	chr11:67347595	C/T	cg09038676	chr11:67351608	GSTP1	0.36	7.06	0.31	5.97e-12	Mean corpuscular volume;
LGG	cis	rs4819052	1.000	rs2297286	chr21:46707897	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.72	10.97	0.45	4.8e-25	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2762353	0.935	rs1177442	chr6:25809069	A/G	cg03264133	chr6:25882463	NA	-0.54	-10.22	-0.43	3.04e-22	Blood metabolite levels;
LGG	cis	rs4750440	0.735	rs2447014	chr10:14010122	C/T	cg00551146	chr10:14014579	FRMD4A	-0.32	-8.15	-0.35	3.5e-15	Adiponectin levels;
LGG	cis	rs1801251	1.000	rs6747645	chr2:233571033	C/T	cg08000102	chr2:233561755	GIGYF2	-0.54	-8.95	-0.38	8.62e-18	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs1426669	chr4:98945534	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2274273	0.905	rs17128183	chr14:55579513	C/T	cg04306507	chr14:55594613	LGALS3	-0.64	-18.16	-0.64	4.79e-56	Protein biomarker;
LGG	cis	rs6740322	0.948	rs6722694	chr2:43569798	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-9.0	-0.39	5.94e-18	Coronary artery disease;
LGG	trans	rs11231420	1	rs11231420	chr11:55644734	T/C	cg02254774	chr11:50257496	LOC441601	0.42	7.08	0.31	5.54e-12	Pelvic organ prolapse (moderate/severe);
LGG	cis	rs2243480	1.000	rs7792391	chr7:65773429	A/G	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.88e-22	Diabetic kidney disease;
LGG	trans	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.01	-0.35	9.7e-15	Neuroticism;
LGG	cis	rs35740288	0.742	rs2061818	chr15:86136244	G/A	cg04173714	chr15:86211321	AKAP13	0.45	8.55	0.37	1.76e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg21479132	chr6:26055353	NA	0.8	7.29	0.32	1.32e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs7218857	chr17:80161000	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.56	-0.37	1.71e-16	Life satisfaction;
LGG	cis	rs11239187	0.927	rs1480607	chr10:45114277	A/G	cg03916630	chr10:45065415	NA	0.33	7.3	0.32	1.27e-12	Body mass index;
LGG	cis	rs7264396	0.790	rs6060526	chr20:34225302	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	-0.51	-7.32	-0.32	1.14e-12	Total cholesterol levels;
LGG	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg01753270	chr2:239240285	TRAF3IP1	-0.38	-6.88	-0.3	1.92e-11	Multiple system atrophy;
LGG	cis	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.55	-0.37	1.74e-16	Joint mobility (Beighton score);
LGG	cis	rs4742903	0.904	rs10991167	chr9:106974382	C/T	cg14250997	chr9:106856677	SMC2	-0.39	-8.3	-0.36	1.14e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs2832077	0.527	rs9981922	chr21:30212718	A/G	cg14791747	chr16:20752902	THUMPD1	0.56	10.32	0.43	1.32e-22	Cognitive test performance;
LGG	cis	rs4242434	0.927	rs746011	chr8:22457804	C/T	cg00599393	chr8:22457479	C8orf58	-0.48	-8.6	-0.37	1.29e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs123509	0.687	rs6865	chr3:42826041	A/C	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.78	-0.3	3.68e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08316775	chr2:73964643	TPRKB	0.46	7.71	0.34	7.64e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs4740619	0.935	rs10962066	chr9:15555038	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.94	-0.42	3.22e-21	Body mass index;
LGG	trans	rs8073060	1.000	rs8073060	chr17:33875262	T/A	cg19694781	chr19:47549865	TMEM160	0.61	10.09	0.42	9.24e-22	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg21775007	chr8:11205619	TDH	-0.43	-6.83	-0.3	2.66e-11	Mood instability;
LGG	cis	rs11764590	0.671	rs12669370	chr7:2081914	G/A	cg24189917	chr7:1970923	MAD1L1	-0.47	-7.9	-0.34	2.02e-14	Neuroticism;
LGG	cis	rs12928939	0.815	rs10500560	chr16:71681153	G/A	cg08717414	chr16:71523259	ZNF19	-0.48	-7.28	-0.32	1.44e-12	Post bronchodilator FEV1;
LGG	cis	rs739401	0.527	rs418832	chr11:3072236	C/T	cg05729581	chr11:3078854	CARS	-0.56	-9.79	-0.41	1.09e-20	Longevity;
LGG	cis	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg00405596	chr8:11794950	NA	-0.48	-8.5	-0.37	2.66e-16	Systolic blood pressure;
LGG	cis	rs1021993	0.545	rs79950910	chr1:209517898	G/A	cg24446417	chr1:209558027	NA	-0.69	-10.07	-0.42	1.09e-21	Gut microbiome composition (winter);
LGG	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.8	-10.4	-0.44	6.58e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12468557	0.628	rs2371005	chr2:211500887	A/T	cg07063745	chr2:211341572	LANCL1;CPS1	-0.43	-7.49	-0.33	3.55e-13	Body mass index in asthmatics;
LGG	cis	rs826838	1.000	rs11168217	chr12:38884278	T/C	cg26384229	chr12:38710491	ALG10B	1.06	28.18	0.79	1.71e-102	Heart rate;
LGG	cis	rs2762353	0.603	rs4145221	chr6:25763192	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.45	-7.75	-0.34	5.99e-14	Blood metabolite levels;
LGG	trans	rs208520	0.690	rs207740	chr6:66764132	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.84	0.64	1.5e-54	Exhaled nitric oxide output;
LGG	cis	rs26868	0.742	rs26848	chr16:2263516	A/G	cg25665528	chr16:2260870	C16orf79	-0.33	-7.14	-0.31	3.66e-12	Height;
LGG	cis	rs7226408	0.595	rs72887010	chr18:34460257	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs2286771	chr4:17643848	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7301016	0.846	rs17732089	chr12:63023658	A/G	cg11441379	chr12:63026424	NA	-0.68	-9.62	-0.41	4.37e-20	IgG glycosylation;
LGG	cis	rs6496044	0.568	rs2880764	chr15:86056408	A/G	cg13263323	chr15:86062960	AKAP13	-0.37	-8.17	-0.36	2.87e-15	Interstitial lung disease;
LGG	cis	rs2180341	0.814	rs6919082	chr6:127737888	T/G	cg27446573	chr6:127587934	RNF146	0.93	17.31	0.63	3.94e-52	Breast cancer;
LGG	cis	rs4262150	0.883	rs72802889	chr5:152254829	T/C	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs35146811	0.735	rs858505	chr7:99819577	G/A	cg22906224	chr7:99728672	NA	-0.58	-9.32	-0.4	4.87e-19	Coronary artery disease;
LGG	cis	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg03213289	chr20:61660250	NA	0.66	14.33	0.55	8.4e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	cis	rs9611565	0.659	rs169361	chr22:41877989	A/G	cg17376030	chr22:41985996	PMM1	-0.58	-9.14	-0.39	1.91e-18	Vitiligo;
LGG	cis	rs17209837	0.527	rs45479991	chr7:87083339	A/T	cg25823085	chr7:87105416	ABCB4	0.3	7.35	0.32	8.76e-13	Gallbladder cancer;
LGG	cis	rs3733346	0.529	rs6851795	chr4:933660	T/C	cg23939001	chr4:940644	TMEM175	0.68	16.64	0.61	4.32e-49	Sjögren's syndrome;
LGG	cis	rs34734847	0.750	rs708783	chr12:121173932	A/G	cg21892295	chr12:121157589	UNC119B	-0.38	-7.27	-0.32	1.51e-12	Mean corpuscular volume;
LGG	cis	rs6577655	0.517	rs4909293	chr8:135587888	G/A	cg17885191	chr8:135476712	NA	0.59	8.87	0.38	1.62e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs62238980	0.614	rs79390247	chr22:32481517	C/T	cg00543991	chr22:32367038	NA	0.79	8.6	0.37	1.29e-16	Childhood ear infection;
LGG	trans	rs7937682	0.562	rs10891276	chr11:111370415	A/C	cg18187862	chr3:45730750	SACM1L	0.43	7.33	0.32	1.01e-12	Primary sclerosing cholangitis;
LGG	cis	rs6882076	1.000	rs6874202	chr5:156391628	T/C	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.58	-0.47	2.03e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg19147804	chr7:1989927	MAD1L1	-0.63	-12.48	-0.5	5.18e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs7296418	0.663	rs4553407	chr12:123750748	G/C	cg00376283	chr12:123451042	ABCB9	0.63	11.68	0.48	8.12e-28	Platelet count;
LGG	cis	rs9467160	0.581	rs2817207	chr6:24479524	G/A	cg20631270	chr6:24437470	GPLD1	0.42	6.76	0.3	4.27e-11	Liver enzyme levels;
LGG	cis	rs1865760	1.000	rs3799371	chr6:25912816	A/G	cg03517284	chr6:25882590	NA	0.41	7.42	0.33	5.63e-13	Height;
LGG	cis	rs7249142	0.506	rs8101388	chr19:19293938	A/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.56e-13	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs67035623	chr8:58139963	G/T	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs77372450	0.636	rs28712355	chr5:157023508	A/G	cg25387487	chr5:157003181	ADAM19	-0.57	-7.24	-0.32	1.83e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs7546668	1.000	rs7515244	chr1:15873386	A/G	cg21858823	chr1:15850916	CASP9	0.37	6.79	0.3	3.42e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg15665833	chr6:26285013	NA	0.36	6.72	0.3	5.5e-11	Educational attainment;
LGG	trans	rs12439619	0.508	rs11856561	chr15:82453756	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.39	-7.86	-0.34	2.8e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12580194	0.593	rs12099808	chr12:55731178	T/A	cg19537932	chr12:55886519	OR6C68	-0.56	-9.94	-0.42	3.08e-21	Cancer;
LGG	trans	rs4295623	0.585	rs34421088	chr8:11589042	A/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.97	-0.31	1.12e-11	Morning vs. evening chronotype;
LGG	cis	rs17641971	0.662	rs1858312	chr8:49996521	G/A	cg00325661	chr8:49890786	NA	0.57	10.7	0.45	5.1e-24	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.34	-0.5	1.98e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.954	rs12510138	chr4:120423935	C/G	cg01244601	chr4:120671846	NA	-0.35	-6.72	-0.3	5.32e-11	Corneal astigmatism;
LGG	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.86	-0.38	1.67e-17	Bone mineral density;
LGG	cis	rs2290416	0.892	rs3793372	chr8:144664233	A/C	cg19357499	chr8:144660631	NAPRT1	0.87	6.93	0.31	1.4e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs60871478	0.947	rs62432862	chr7:807719	G/C	cg05535760	chr7:792225	HEATR2	0.78	12.52	0.5	3.52e-31	Cerebrospinal P-tau181p levels;
LGG	cis	rs17376456	0.741	rs12374432	chr5:93481348	C/A	cg25358565	chr5:93447407	FAM172A	1.38	17.08	0.62	4.67e-51	Diabetic retinopathy;
LGG	cis	rs9880211	1.000	rs9841529	chr3:136137283	A/C	cg21827317	chr3:136751795	NA	-0.47	-7.05	-0.31	6.67e-12	Body mass index;Height;
LGG	cis	rs12188164	0.965	rs56182240	chr5:423169	C/T	cg26076054	chr5:421317	AHRR	-0.48	-8.01	-0.35	9.52e-15	Cystic fibrosis severity;
LGG	cis	rs6500395	0.963	rs2883642	chr16:48685146	C/T	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2243480	1.000	rs6964530	chr7:65718851	G/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.55	-0.37	1.87e-16	Diabetic kidney disease;
LGG	trans	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg25482853	chr8:67687455	SGK3	0.54	7.9	0.34	2.09e-14	Obesity-related traits;
LGG	cis	rs758324	0.755	rs578637	chr5:131267609	G/A	cg06307176	chr5:131281290	NA	-0.52	-8.51	-0.37	2.37e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg03264133	chr6:25882463	NA	0.7	13.15	0.52	8.48e-34	Blood metabolite levels;
LGG	cis	rs4969178	0.930	rs7208596	chr17:76396528	C/G	cg20026190	chr17:76395443	PGS1	0.58	10.13	0.43	6.36e-22	HDL cholesterol levels;
LGG	trans	rs9467711	0.559	rs12176129	chr6:26514940	C/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.42	-0.36	4.92e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1499614	1.000	rs1267818	chr7:66107024	C/T	cg18252515	chr7:66147081	NA	-1.37	-18.71	-0.66	1.37e-58	Gout;
LGG	cis	rs12701220	0.595	rs12532837	chr7:1122851	T/A	cg02733842	chr7:1102375	C7orf50	-0.53	-8.39	-0.36	5.74e-16	Bronchopulmonary dysplasia;
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4917300	0.572	rs6583568	chr8:143115563	T/C	cg06573787	chr8:143070187	NA	0.6	9.85	0.42	6.33e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs9859260	0.925	rs2300775	chr3:195793339	T/C	cg12923728	chr3:195709715	SDHAP1	-0.4	-6.86	-0.3	2.19e-11	Mean corpuscular volume;
LGG	cis	rs4731207	0.698	rs9886177	chr7:124513450	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.75	-0.34	5.85e-14	Cutaneous malignant melanoma;
LGG	cis	rs2688608	0.592	rs7908825	chr10:75554541	C/G	cg00564723	chr10:75632066	CAMK2G	0.31	7.1	0.31	4.8e-12	Inflammatory bowel disease;
LGG	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.52	-8.08	-0.35	5.8e-15	Menarche (age at onset);
LGG	cis	rs854765	0.547	rs9896837	chr17:17924868	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-15.09	-0.57	3.98e-42	Total body bone mineral density;
LGG	cis	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.65	-0.3	8.3e-11	Joint mobility (Beighton score);
LGG	cis	rs559928	0.606	rs12417635	chr11:63912728	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.47	0.33	4.17e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9636252	0.847	rs4402730	chr2:9268038	T/C	cg20341998	chr2:9276514	NA	0.39	7.44	0.33	5.1e-13	IgG glycosylation;
LGG	cis	rs77972916	0.611	rs10495899	chr2:43602304	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.6	-8.78	-0.38	3.24e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9325144	0.624	rs7979541	chr12:39129679	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-13.65	-0.54	6.78e-36	Morning vs. evening chronotype;
LGG	cis	rs5742933	0.817	rs6942	chr2:190636411	C/G	cg04003228	chr2:190539410	ANKAR	-0.51	-7.41	-0.33	6.06e-13	Ferritin levels;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg13206674	chr6:150067644	NUP43	0.69	15.93	0.59	7.26e-46	Lung cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg14965979	chr2:44588995	PREPL;C2orf34	-0.41	-6.65	-0.3	8.2e-11	Pancreatic cancer;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07685180	chr8:600429	NA	1.13	11.24	0.46	4.55e-26	IgG glycosylation;
LGG	cis	rs9611565	0.568	rs2413656	chr22:42129357	G/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.12	-0.39	2.26e-18	Vitiligo;
LGG	cis	rs9611565	0.512	rs715498	chr22:42148467	G/A	cg06481639	chr22:41940642	POLR3H	0.55	7.72	0.34	7.34e-14	Vitiligo;
LGG	cis	rs5753037	0.809	rs5752964	chr22:30208608	C/T	cg27665648	chr22:30112403	NA	0.29	6.85	0.3	2.34e-11	Type 1 diabetes;
LGG	cis	rs6665290	0.904	rs1045287	chr1:227178962	C/T	cg10327440	chr1:227177885	CDC42BPA	1.29	45.96	0.91	1.19e-174	Myeloid white cell count;
LGG	cis	rs11190604	0.767	rs10883484	chr10:102174803	G/C	cg07570687	chr10:102243282	WNT8B	0.4	7.09	0.31	4.88e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs35110281	0.744	rs8131027	chr21:45104908	G/C	cg04455712	chr21:45112962	RRP1B	0.52	10.0	0.42	1.97e-21	Mean corpuscular volume;
LGG	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg08125733	chr17:73851984	WBP2	0.85	9.65	0.41	3.33e-20	Psoriasis;
LGG	cis	rs11764590	0.694	rs10241537	chr7:2083358	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-9.04	-0.39	4.4e-18	Neuroticism;
LGG	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.67e-18	Primary sclerosing cholangitis;
LGG	trans	rs1814175	0.645	rs1721996	chr11:49915527	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg11062466	chr8:58055876	NA	0.48	7.85	0.34	2.85e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.872	rs11768486	chr7:1101290	C/A	cg24642844	chr7:1081250	C7orf50	-0.85	-14.26	-0.55	1.67e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14242042	chr12:24715250	SOX5	0.43	6.94	0.31	1.36e-11	Cognitive performance;
LGG	cis	rs11718455	1.000	rs28731098	chr3:44019816	A/C	cg21419209	chr3:44054225	NA	-0.42	-6.9	-0.31	1.73e-11	Coronary artery disease;
LGG	cis	rs11676348	0.751	rs6715591	chr2:219019871	T/C	cg04731861	chr2:219085781	ARPC2	0.28	6.83	0.3	2.68e-11	Ulcerative colitis;
LGG	cis	rs11718455	0.883	rs2372579	chr3:44034003	A/T	cg21419209	chr3:44054225	NA	-0.43	-7.02	-0.31	7.94e-12	Coronary artery disease;
LGG	cis	rs4774830	0.744	rs2414455	chr15:56290399	C/A	cg24530489	chr15:56299380	NA	-0.86	-7.72	-0.34	7.11e-14	Delta-5 desaturase activity;
LGG	cis	rs56283067	0.847	rs12208621	chr6:44752003	G/C	cg18551225	chr6:44695536	NA	-0.72	-12.78	-0.51	3.1e-32	Total body bone mineral density;
LGG	cis	rs4595586	0.546	rs11169801	chr12:39241429	G/A	cg26384229	chr12:38710491	ALG10B	0.85	16.44	0.61	3.75e-48	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.642	rs58124215	chr1:152916375	C/T	cg13444842	chr1:152974279	SPRR3	-0.41	-7.94	-0.35	1.55e-14	Inflammatory skin disease;
LGG	cis	rs9926296	0.585	rs8045232	chr16:89857548	A/G	cg07648498	chr16:89883185	FANCA	0.39	6.74	0.3	4.65e-11	Vitiligo;
LGG	cis	rs9902453	0.817	rs62068620	chr17:28167674	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.76	0.54	2.31e-36	Coffee consumption (cups per day);
LGG	cis	rs6840360	0.593	rs1877186	chr4:152692418	C/G	cg22705602	chr4:152727874	NA	-0.4	-10.25	-0.43	2.41e-22	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs7582180	0.585	rs6736311	chr2:100950599	C/G	cg08297393	chr2:100937505	LONRF2	-0.56	-10.65	-0.44	7.64e-24	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg06293395	chr16:1193136	NA	0.35	6.66	0.3	8.01e-11	Pancreatic cancer;
LGG	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.74	-15.61	-0.59	2.03e-44	Height;
LGG	cis	rs7172677	0.508	rs12917120	chr15:75329091	T/C	cg10253484	chr15:75165896	SCAMP2	-0.5	-7.98	-0.35	1.14e-14	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10864302	0.525	rs1894655	chr1:7417290	T/C	cg08923594	chr1:7462176	CAMTA1	0.67	8.29	0.36	1.27e-15	Photic sneeze reflex;
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.12	0.62	2.88e-51	Alzheimer's disease;
LGG	cis	rs2011503	0.941	rs6511027	chr19:19391851	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	6.72	0.3	5.34e-11	Bipolar disorder;
LGG	cis	rs1008375	0.966	rs4235391	chr4:17696409	A/G	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72945132	0.825	rs72947052	chr11:70188575	A/G	cg14191688	chr11:70257035	CTTN	0.61	8.59	0.37	1.35e-16	Coronary artery disease;
LGG	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg17757837	chr7:157058334	UBE3C	0.79	16.13	0.6	8.86e-47	Body mass index;
LGG	cis	rs1865760	0.551	rs9461230	chr6:26019240	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.83	0.42	8.01e-21	Height;
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs9325144	0.560	rs1843911	chr12:38676585	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-7.95	-0.35	1.41e-14	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.841	rs114155681	chr4:119736427	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.27	0.43	1.96e-22	Cannabis dependence symptom count;
LGG	cis	rs240764	0.853	rs1875401	chr6:101023588	G/A	cg21058520	chr6:100914733	NA	0.41	7.2	0.32	2.49e-12	Neuroticism;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg06112835	chr11:68658793	MRPL21	0.64	10.79	0.45	2.34e-24	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs933688	0.532	rs973332	chr5:90555129	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-7.39	-0.32	6.8e-13	Smoking behavior;
LGG	cis	rs644799	0.932	rs480079	chr11:95643777	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	-0.68	-11.72	-0.48	5.83e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8017423	0.967	rs2401875	chr14:90688451	A/G	cg04374321	chr14:90722782	PSMC1	0.88	18.56	0.65	6.93e-58	Mortality in heart failure;
LGG	cis	rs28386778	0.897	rs6504187	chr17:61917099	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.39e-13	Prudent dietary pattern;
LGG	cis	rs704	0.790	rs4795433	chr17:26716821	C/T	cg10342447	chr17:26645325	TMEM97	-0.38	-6.88	-0.3	2.01e-11	Osteoprotegerin levels;
LGG	cis	rs11605924	0.967	rs6485646	chr11:45865764	G/A	ch.11.939596F	chr11:45881766	CRY2	-0.48	-8.12	-0.35	4.34e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs1519814	0.592	rs4870969	chr8:121006548	G/A	cg22335954	chr8:121166405	COL14A1	-0.44	-7.75	-0.34	5.77e-14	Breast cancer;
LGG	cis	rs926938	0.618	rs1286555	chr1:115361896	C/T	cg12756093	chr1:115239321	AMPD1	-0.47	-8.68	-0.37	6.98e-17	Autism;
LGG	cis	rs12447804	1.000	rs12924215	chr16:58071092	C/T	cg03859792	chr16:58121049	NA	0.47	6.97	0.31	1.1e-11	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs7444	0.941	rs140498	chr22:21927064	G/A	cg05046821	chr22:21984468	YDJC	-0.39	-7.08	-0.31	5.48e-12	Systemic lupus erythematosus;
LGG	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg24631222	chr15:78858424	CHRNA5	0.47	6.94	0.31	1.33e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs1218582	0.772	rs1109815	chr1:154909268	A/G	cg06221963	chr1:154839813	KCNN3	-0.5	-10.07	-0.42	1.03e-21	Prostate cancer;
LGG	cis	rs6586163	1.000	rs6586165	chr10:90755056	T/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.4	-6.9	-0.31	1.72e-11	Chronic lymphocytic leukemia;
LGG	cis	rs933688	0.532	rs13165085	chr5:90538448	G/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.59	-7.77	-0.34	5.01e-14	Smoking behavior;
LGG	cis	rs916888	0.773	rs199439	chr17:44793503	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.12	0.43	6.76e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs58785573	0.570	rs4833078	chr4:38646476	C/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.43	7.01	0.31	8.52e-12	Lymphocyte percentage of white cells;
LGG	cis	rs12936587	0.535	rs8065154	chr17:17614947	A/G	cg01246520	chr17:17644344	RAI1	-0.36	-8.29	-0.36	1.27e-15	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs2180341	0.618	rs11154396	chr6:127638911	C/T	cg27446573	chr6:127587934	RNF146	0.73	13.21	0.52	4.84e-34	Breast cancer;
LGG	trans	rs9467711	0.606	rs9348726	chr6:26605206	G/A	cg06606381	chr12:133084897	FBRSL1	-0.9	-9.45	-0.4	1.74e-19	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.920	rs114333298	chr4:119765305	C/A	cg14228332	chr4:119757509	SEC24D	1.01	10.28	0.43	1.89e-22	Cannabis dependence symptom count;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	1.000	rs12447826	chr16:4464617	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.47	0.33	4.09e-13	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.27	-0.4	7.02e-19	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	9.98e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs721917	0.525	rs2819106	chr10:81686080	C/T	cg25562619	chr10:81652821	NA	-0.34	-7.6	-0.33	1.7e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.644	rs2836982	chr21:40689171	C/A	cg11890956	chr21:40555474	PSMG1	-0.96	-19.49	-0.67	3.07e-62	Cognitive function;
LGG	cis	rs35110281	0.659	rs2236667	chr21:45112939	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.92	-0.38	1.12e-17	Mean corpuscular volume;
LGG	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-9.94	-0.42	3.03e-21	Pancreatic cancer;
LGG	cis	rs10769945	0.679	rs2137322	chr11:1917354	A/G	cg06197492	chr11:2016605	H19	-0.41	-8.61	-0.37	1.14e-16	DNA methylation (variation);
LGG	cis	rs651907	0.557	rs2303474	chr3:101371899	G/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.87	0.34	2.57e-14	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05053688	chr1:101702744	S1PR1	0.51	8.37	0.36	6.95e-16	Gut microbiome composition (summer);
LGG	cis	rs3857067	0.806	rs10212784	chr4:95101638	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.9	-0.34	2.09e-14	QT interval;
LGG	cis	rs9487094	0.813	rs12528566	chr6:109738148	A/G	cg16315928	chr6:109776240	MICAL1	0.54	8.96	0.38	8.14e-18	Height;
LGG	cis	rs2976388	0.647	rs2244163	chr8:143784500	T/G	cg06565975	chr8:143823917	SLURP1	0.37	9.53	0.41	8.57e-20	Urinary tract infection frequency;
LGG	cis	rs68170813	0.559	rs6964966	chr7:106933099	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.58	-0.44	1.42e-23	Coronary artery disease;
LGG	cis	rs7917772	0.636	rs2253709	chr10:104542745	T/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.52	8.36	0.36	7.38e-16	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22799212	chr1:161102325	DEDD	0.59	6.69	0.3	6.59e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2011503	1.000	rs7256028	chr19:19628240	C/T	cg11584989	chr19:19387371	SF4	0.68	11.11	0.46	1.41e-25	Bipolar disorder;
LGG	trans	rs1005277	0.577	rs4934906	chr10:38015028	C/T	cg27523141	chr10:43048294	ZNF37B	0.35	7.25	0.32	1.71e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs34421088	0.560	rs1478898	chr8:11395079	G/A	cg16141378	chr3:129829833	LOC729375	0.35	8.34	0.36	8.6e-16	Neuroticism;
LGG	cis	rs477692	0.569	rs10764885	chr10:131310207	G/A	cg05714579	chr10:131428358	MGMT	0.52	10.17	0.43	4.64e-22	Response to temozolomide;
LGG	cis	rs10934753	0.560	rs73859048	chr3:125931603	G/A	cg17230874	chr3:125932073	NA	0.87	18.19	0.65	3.36e-56	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs988958	0.675	rs35657711	chr2:42216386	T/C	cg27252766	chr2:42229092	NA	0.56	8.4	0.36	5.71e-16	Hypospadias;
LGG	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg23306229	chr2:178417860	TTC30B	-0.83	-9.65	-0.41	3.41e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4132509	0.843	rs6671475	chr1:243789342	A/G	cg21452805	chr1:244014465	NA	0.62	7.5	0.33	3.19e-13	RR interval (heart rate);
LGG	cis	rs2153535	0.580	rs9379206	chr6:8458021	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26720767	chr16:3450549	ZNF174;ZNF434	0.47	7.76	0.34	5.5e-14	Cognitive performance;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg03453431	chr7:157225567	NA	-0.59	-10.62	-0.44	9.64e-24	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	trans	rs3942852	0.545	rs10838798	chr11:48091303	T/G	cg15704280	chr7:45808275	SEPT13	-0.7	-11.0	-0.46	3.53e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4242434	0.819	rs55776566	chr8:22469492	T/C	cg02227867	chr8:22457446	C8orf58	-0.42	-8.1	-0.35	5.1e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs911263	0.603	rs7146850	chr14:68787881	A/C	cg18825221	chr14:68749962	RAD51L1	0.36	7.79	0.34	4.45e-14	Primary biliary cholangitis;
LGG	cis	rs314370	1.000	rs314370	chr7:100453208	T/C	cg10426581	chr7:100472382	SRRT	0.53	7.36	0.32	8.37e-13	Resting heart rate;
LGG	cis	rs283228	0.958	rs2629989	chr6:101792157	G/A	cg27451362	chr6:101846650	GRIK2	0.53	8.97	0.38	7.55e-18	Coenzyme Q10 levels;
LGG	cis	rs3096299	0.838	rs3102376	chr16:89402473	A/C	cg06640241	chr16:89574553	SPG7	0.58	9.86	0.42	6.23e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs17655565	1.000	rs76413558	chr12:52694156	A/G	cg02645295	chr12:52705424	NA	-0.6	-8.03	-0.35	8e-15	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs919433	0.617	rs10460394	chr2:198548741	G/A	cg00792783	chr2:198669748	PLCL1	-0.62	-9.95	-0.42	2.92e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs62458065	0.713	rs28421905	chr7:32489501	G/A	cg00845942	chr12:64062724	DPY19L2	-0.53	-6.87	-0.3	2.09e-11	Metabolite levels (HVA/MHPG ratio);
LGG	cis	rs367943	1.000	rs348961	chr5:112819944	A/C	cg27587195	chr5:112824172	MCC	-0.47	-7.06	-0.31	6.01e-12	Type 2 diabetes;
LGG	cis	rs2228479	0.867	rs34604714	chr16:89948985	A/G	cg26513180	chr16:89883248	FANCA	0.83	8.65	0.37	8.77e-17	Skin colour saturation;
LGG	cis	rs112591243	0.685	rs73379602	chr21:48027317	G/A	cg10657630	chr21:48055338	PRMT2	0.79	7.18	0.32	2.71e-12	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.3	-0.43	1.56e-22	Platelet count;
LGG	cis	rs9534288	0.700	rs9316178	chr13:46570449	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg21644426	chr2:191273491	MFSD6	0.62	10.7	0.45	4.92e-24	Pulse pressure;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg07234876	chr8:600039	NA	1.3	12.67	0.51	8.8e-32	IgG glycosylation;
LGG	cis	rs6909430	0.901	rs9401614	chr6:98565236	T/C	cg12860156	chr6:98744658	NA	-0.44	-7.44	-0.33	4.84e-13	Quantitative traits;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17453880	0.929	rs10037655	chr5:152040281	C/T	cg12297329	chr5:152029980	NA	-0.9	-23.72	-0.74	5.66e-82	Subjective well-being;
LGG	cis	rs2797369	0.609	rs673138	chr6:101390162	T/C	cg27451362	chr6:101846650	GRIK2	0.78	10.42	0.44	5.41e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs826838	0.904	rs10880981	chr12:38763911	G/A	cg13010199	chr12:38710504	ALG10B	0.77	16.41	0.61	5.1e-48	Heart rate;
LGG	cis	rs2075371	0.501	rs1646654	chr7:134027547	G/C	cg11752832	chr7:134001865	SLC35B4	0.49	8.7	0.37	5.91e-17	Mean platelet volume;
LGG	cis	rs11203032	0.831	rs61853069	chr10:90935641	C/G	cg16672925	chr10:90967113	CH25H	0.51	7.86	0.34	2.65e-14	Heart failure;
LGG	cis	rs2066819	1.000	rs2066808	chr12:56737973	A/G	cg26714650	chr12:56694279	CS	-1.51	-17.99	-0.64	2.93e-55	Psoriasis vulgaris;
LGG	cis	rs8049040	1.000	rs8049040	chr16:71472704	A/G	cg08717414	chr16:71523259	ZNF19	-0.41	-6.88	-0.3	1.98e-11	Blood protein levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04207976	chr17:79263511	SLC38A10	0.41	6.93	0.31	1.43e-11	Pancreatic cancer;
LGG	cis	rs2718058	0.564	rs10268172	chr7:37795634	G/A	cg24998770	chr7:37888106	TXNDC3	-0.41	-7.0	-0.31	8.91e-12	Alzheimer's disease (late onset);
LGG	cis	rs11214589	0.651	rs11214594	chr11:113259332	G/A	cg14373873	chr11:113211441	TTC12	0.42	8.6	0.37	1.24e-16	Neuroticism;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg01879757	chr17:41196368	BRCA1	-0.46	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs3733585	0.673	rs4467564	chr4:9953472	G/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg06873352	chr17:61820015	STRADA	-0.6	-10.48	-0.44	3.27e-23	Prudent dietary pattern;
LGG	cis	rs36071027	0.615	rs10515785	chr5:158443352	G/T	cg23468002	chr5:158532401	NA	0.41	6.79	0.3	3.56e-11	Carotid intima media thickness;
LGG	cis	rs8060686	0.641	rs36086450	chr16:68046996	A/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.45	-0.33	4.71e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs62056065	chr16:89905115	C/G	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.74	-0.34	6.15e-14	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2665797	chr17:61922485	C/G	cg07659893	chr17:61819838	STRADA	-0.48	-8.08	-0.35	5.48e-15	Prudent dietary pattern;
LGG	cis	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.66	-0.44	7.16e-24	Hip circumference adjusted for BMI;
LGG	cis	rs7851660	0.809	rs10984235	chr9:100660896	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.65	-0.51	1.07e-31	Strep throat;
LGG	cis	rs951366	0.789	rs1775154	chr1:205696615	T/A	cg13453750	chr1:205783389	SLC41A1	-0.41	-7.85	-0.34	2.82e-14	Menarche (age at onset);
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.16	-0.35	3.16e-15	Total body bone mineral density;
LGG	cis	rs7223966	1.000	rs11657306	chr17:61704822	G/A	cg11494091	chr17:61959527	GH2	0.53	8.57	0.37	1.61e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs61931739	0.857	rs1828514	chr12:34139600	A/G	cg26384229	chr12:38710491	ALG10B	0.64	12.62	0.51	1.37e-31	Morning vs. evening chronotype;
LGG	cis	rs826838	0.616	rs7977357	chr12:38626008	C/G	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.41e-20	Heart rate;
LGG	cis	rs62400317	0.826	rs62436781	chr6:45142068	G/A	cg18551225	chr6:44695536	NA	-0.58	-8.54	-0.37	2.01e-16	Total body bone mineral density;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg13549897	chr1:70820344	HHLA3;ANKRD13C	0.39	6.85	0.3	2.43e-11	Body mass index;
LGG	cis	rs4443100	0.670	rs13054331	chr22:23407063	G/A	cg14186256	chr22:23484241	RTDR1	0.53	8.46	0.37	3.64e-16	Serum parathyroid hormone levels;
LGG	cis	rs7598759	0.588	rs6737291	chr2:232329559	T/C	cg19187155	chr2:232395269	NMUR1	0.42	7.62	0.33	1.49e-13	Noise-induced hearing loss;
LGG	cis	rs972578	0.765	rs9607973	chr22:43268502	C/T	cg01576275	chr22:43409880	NA	0.22	6.87	0.3	2.08e-11	Mean platelet volume;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg21724239	chr8:58056113	NA	0.52	7.79	0.34	4.44e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg24006582	chr15:45444508	DUOX1	-0.71	-13.65	-0.54	6.87e-36	Uric acid levels;
LGG	cis	rs2371030	0.802	rs1319591	chr2:211572501	T/C	cg18417063	chr2:211583084	NA	-0.57	-10.6	-0.44	1.15e-23	Non-small cell lung cancer;
LGG	cis	rs2576037	0.583	rs11659693	chr18:44458733	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.82	0.45	1.7e-24	Personality dimensions;
LGG	cis	rs7833790	1.000	rs28696138	chr8:82770794	G/A	cg27398817	chr8:82754497	SNX16	0.76	10.89	0.45	9.79e-25	Diastolic blood pressure;
LGG	cis	rs6502050	0.835	rs4789744	chr17:80101506	A/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg19168338	chr16:4465731	CORO7	-1.18	-27.46	-0.79	3.31e-99	Schizophrenia;
LGG	trans	rs2018683	0.677	rs2057956	chr7:28973460	G/A	cg19402173	chr7:128379420	CALU	-0.53	-9.24	-0.39	8.65e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs6502050	0.799	rs7501461	chr17:80109806	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs1814175	0.817	rs6486044	chr11:49982718	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs8014204	0.806	rs11159105	chr14:75298052	C/T	cg06637938	chr14:75390232	RPS6KL1	0.78	15.64	0.59	1.44e-44	Caffeine consumption;
LGG	cis	rs12949688	0.967	rs1990231	chr17:55821002	G/C	cg12582317	chr17:55822272	NA	0.69	20.11	0.68	4.21e-65	Schizophrenia;
LGG	cis	rs9972944	0.756	rs2318869	chr17:63767736	C/G	cg07283582	chr17:63770753	CCDC46	-0.43	-8.35	-0.36	7.96e-16	Total body bone mineral density;
LGG	cis	rs2290416	0.584	rs3816477	chr8:144685271	T/C	cg01494348	chr8:144660395	NAPRT1	-0.76	-8.48	-0.37	3.01e-16	Attention deficit hyperactivity disorder;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg11798356	chr1:228593833	TRIM11	0.45	6.72	0.3	5.52e-11	Hip circumference;
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg25427524	chr10:38739819	LOC399744	0.64	12.04	0.49	3.04e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg21775007	chr8:11205619	TDH	-0.53	-8.51	-0.37	2.43e-16	Neuroticism;
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg09795085	chr6:101329169	ASCC3	-0.47	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	cis	rs79349575	0.749	rs58838744	chr17:46998902	A/G	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs6489882	0.867	rs6489874	chr12:113367895	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.62	-0.33	1.43e-13	Chronic lymphocytic leukemia;
LGG	cis	rs10089	1.000	rs13357268	chr5:127423051	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.75	11.76	0.48	4.09e-28	Ileal carcinoids;
LGG	cis	rs2013441	1.000	rs2526458	chr17:20092200	C/T	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs10883723	0.810	rs913025	chr10:104276043	C/T	cg05096777	chr10:104283225	SUFU	0.32	6.94	0.31	1.33e-11	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7100689	0.622	rs1340379	chr10:82121455	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs1799949	1.000	rs8176220	chr17:41222462	A/G	cg05368731	chr17:41323189	NBR1	0.94	18.6	0.65	4.5e-58	Menopause (age at onset);
LGG	cis	rs9359856	0.564	rs3818133	chr6:90374456	A/G	cg13799429	chr6:90582589	CASP8AP2	-0.76	-9.82	-0.42	8.61e-21	Bipolar disorder;
LGG	cis	rs9487051	0.735	rs882074	chr6:109611720	C/T	cg21918786	chr6:109611834	NA	-0.48	-8.85	-0.38	1.89e-17	Reticulocyte fraction of red cells;
LGG	cis	rs151234	0.741	rs3194168	chr16:28603012	A/G	cg01378222	chr16:28622494	SULT1A1	-0.73	-10.01	-0.42	1.8e-21	Platelet distribution width;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg23924007	chr4:140099401	NA	0.4	7.05	0.31	6.37e-12	Bilirubin levels;
LGG	cis	rs9311474	0.607	rs34005367	chr3:52558904	A/T	cg18099408	chr3:52552593	STAB1	-0.35	-6.78	-0.3	3.64e-11	Electroencephalogram traits;
LGG	trans	rs7618501	0.521	rs868891	chr3:49949071	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.39	6.73	0.3	5.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs3088215	chr16:28853996	A/C	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.41e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6546550	0.935	rs6546551	chr2:70073703	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.97	-0.35	1.23e-14	Prevalent atrial fibrillation;
LGG	cis	rs8017423	0.935	rs9944124	chr14:90791501	T/C	cg04374321	chr14:90722782	PSMC1	0.84	17.18	0.62	1.58e-51	Mortality in heart failure;
LGG	cis	rs4262150	0.767	rs10037537	chr5:152326018	C/T	cg12297329	chr5:152029980	NA	0.62	11.13	0.46	1.17e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7084402	0.967	rs1649043	chr10:60328209	C/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.33	-0.32	1.02e-12	Refractive error;
LGG	cis	rs899997	0.773	rs11072784	chr15:78966058	T/C	cg09845145	chr15:78292470	TBC1D2B	0.61	9.61	0.41	4.69e-20	Coronary artery disease or large artery stroke;
LGG	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg04851639	chr8:1020857	NA	-0.33	-6.86	-0.3	2.19e-11	Schizophrenia;
LGG	cis	rs7226408	0.600	rs186525	chr18:34597514	G/A	cg15022739	chr18:34823045	BRUNOL4	0.43	9.31	0.4	5.15e-19	Obesity-related traits;
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	2.01e-19	Height;
LGG	cis	rs1144	0.537	rs2470940	chr7:104581974	A/C	cg03782966	chr7:104585482	NA	0.34	7.75	0.34	5.69e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs7681440	0.904	rs3756063	chr4:90757394	G/C	cg14346243	chr4:90757452	SNCA	-0.41	-8.33	-0.36	9.23e-16	Dementia with Lewy bodies;
LGG	cis	rs4665809	0.878	rs35709953	chr2:26334997	G/A	cg26119090	chr2:26468346	HADHA;HADHB	0.88	13.34	0.53	1.3600000000000001e-34	Gut microbiome composition (summer);
LGG	cis	rs929354	0.772	rs1182362	chr7:157019535	A/G	cg05182265	chr7:156933206	UBE3C	0.36	7.43	0.33	5.29e-13	Body mass index;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.33	0.32	1.03e-12	Prudent dietary pattern;
LGG	cis	rs3767633	0.800	rs2341479	chr1:161885352	C/A	cg03391019	chr1:161927947	ATF6	0.51	7.28	0.32	1.4e-12	IgG glycosylation;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24451858	chr11:75379620	MAP6	0.45	7.5	0.33	3.37e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.749	rs7209948	chr17:80086804	T/G	cg19223190	chr17:80058835	NA	-0.44	-8.49	-0.37	2.89e-16	Life satisfaction;
LGG	cis	rs2070997	0.816	rs9695008	chr9:133720877	C/T	cg13397898	chr9:133768931	QRFP	0.38	7.63	0.33	1.33e-13	Response to amphetamines;
LGG	cis	rs4838594	0.563	rs4838597	chr10:49679397	G/A	cg17291251	chr10:49678358	ARHGAP22	0.55	11.63	0.48	1.3e-27	Daytime sleep phenotypes;
LGG	cis	rs7255045	0.789	rs1078264	chr19:12963143	T/C	cg07955356	chr19:12992479	DNASE2	0.43	7.29	0.32	1.31e-12	Mean corpuscular volume;
LGG	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg20673091	chr1:2541236	MMEL1	-0.77	-17.94	-0.64	5.01e-55	Ulcerative colitis;
LGG	cis	rs4629180	0.675	rs6707298	chr2:102089738	A/G	cg16435561	chr2:102091048	RFX8	-0.49	-9.23	-0.39	9.81e-19	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs8067287	0.749	rs62065426	chr17:16831506	G/C	cg26910001	chr17:16838321	NA	-0.49	-8.96	-0.38	7.94e-18	Diabetic kidney disease;
LGG	cis	rs10924309	0.737	rs4378245	chr1:245852727	G/A	cg00036263	chr1:245852353	KIF26B	-0.44	-6.97	-0.31	1.12e-11	Response to serotonin reuptake inhibitors in non-psychotic unipolar depression;
LGG	cis	rs9875589	0.509	rs1586514	chr3:14050157	G/A	cg19554555	chr3:13937349	NA	-0.54	-9.9	-0.42	4.31e-21	Ovarian reserve;
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.59	0.33	1.75e-13	Rheumatoid arthritis;
LGG	cis	rs12477438	0.520	rs2964969	chr2:99782811	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	1.22	32.79	0.84	8.22e-123	Chronic sinus infection;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg20141549	chr3:51534298	VPRBP	0.41	6.8	0.3	3.34e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs9357271	1.000	rs7756267	chr6:38359599	T/C	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	cis	rs4481887	0.617	rs7511986	chr1:248527810	G/A	cg00666640	chr1:248458726	OR2T12	0.5	8.63	0.37	9.57e-17	Common traits (Other);
LGG	cis	rs1799949	0.965	rs33961729	chr17:41287924	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.44	0.33	5.05e-13	Menopause (age at onset);
LGG	cis	rs4321325	0.733	rs78238478	chr2:127936306	G/A	cg11380483	chr2:127933992	NA	0.69	9.2	0.39	1.19e-18	Protein C levels;
LGG	cis	rs62400317	0.859	rs12193030	chr6:45175210	G/A	cg18551225	chr6:44695536	NA	-0.61	-9.99	-0.42	2.12e-21	Total body bone mineral density;
LGG	cis	rs1707322	0.721	rs11211181	chr1:46236800	C/T	cg03146154	chr1:46216737	IPP	0.58	10.83	0.45	1.7e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg10840412	chr1:235813424	GNG4	0.54	7.6	0.33	1.6e-13	Bipolar disorder;
LGG	cis	rs4417704	0.501	rs13015336	chr2:241900706	T/C	cg26818257	chr2:241905806	NA	0.49	10.79	0.45	2.31e-24	Joint mobility (Beighton score);
LGG	cis	rs3806843	0.966	rs3756341	chr5:140171194	C/T	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2718058	0.589	rs10274478	chr7:37792902	T/C	cg24998770	chr7:37888106	TXNDC3	-0.41	-6.97	-0.31	1.07e-11	Alzheimer's disease (late onset);
LGG	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs7681440	0.904	rs2870029	chr4:90772057	G/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs12367572	0.501	rs7964644	chr12:45473723	A/G	cg03114573	chr12:45410052	DBX2	-0.51	-8.54	-0.37	1.9e-16	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs6594713	0.642	rs13169748	chr5:112848999	C/T	cg12552261	chr5:112820674	MCC	0.62	7.72	0.34	7.12e-14	Brain cytoarchitecture;
LGG	cis	rs6997458	0.839	rs1390712	chr8:86307249	C/G	cg02393479	chr8:86352350	CA3	-0.31	-6.72	-0.3	5.27e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs2120019	0.938	rs8036573	chr15:75308690	C/T	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.01	-0.64	2.4e-55	Blood trace element (Zn levels);
LGG	cis	rs9393692	0.905	rs9379838	chr6:26277133	C/T	cg15665833	chr6:26285013	NA	0.36	6.89	0.31	1.81e-11	Educational attainment;
LGG	cis	rs28595532	0.920	rs56291421	chr4:119732294	G/A	cg21605333	chr4:119757512	SEC24D	1.49	14.93	0.57	1.99e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg22535103	chr8:58192502	C8orf71	-0.91	-12.58	-0.5	2.1e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4851266	1.000	rs11693324	chr2:100827753	T/C	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	5.09e-15	Educational attainment;
LGG	cis	rs2071403	0.871	rs55781504	chr2:1406343	T/A	cg06500727	chr2:1417164	TPO	-0.53	-10.08	-0.42	1e-21	Thyroid peroxidase antibody positivity;
LGG	cis	rs9790314	0.632	rs55672403	chr3:160681026	C/A	cg03342759	chr3:160939853	NMD3	0.44	7.34	0.32	9.63e-13	Morning vs. evening chronotype;
LGG	cis	rs10937275	1.000	rs35923019	chr3:186651388	C/T	cg16751732	chr3:186648392	ST6GAL1	0.72	7.31	0.32	1.2e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1577917	0.771	rs9362239	chr6:86429263	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.75	14.0	0.55	2.12e-37	Response to antipsychotic treatment;
LGG	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs854765	0.583	rs11869536	chr17:17826528	T/A	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.26e-29	Total body bone mineral density;
LGG	cis	rs4132509	0.948	rs1458023	chr1:243886673	A/G	cg21452805	chr1:244014465	NA	0.83	9.83	0.42	8.03e-21	RR interval (heart rate);
LGG	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg18129748	chr3:49941408	MST1R	-0.22	-6.97	-0.31	1.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4478858	0.735	rs1566964	chr1:31792794	C/A	cg19084893	chr1:31688959	NA	0.31	6.71	0.3	5.76e-11	Alcohol dependence;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg21055462	chr7:100276975	NA	0.46	9.79	0.41	1.06e-20	Other erythrocyte phenotypes;
LGG	cis	rs7226408	0.857	rs34250790	chr18:34447980	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg06521331	chr12:34319734	NA	-0.49	-8.77	-0.38	3.51e-17	Bladder cancer;
LGG	cis	rs17376456	0.877	rs10057814	chr5:93399092	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.2	0.43	3.5e-22	Diabetic retinopathy;
LGG	cis	rs350251	0.934	rs350248	chr16:12202424	G/C	cg02910054	chr16:12241554	SNX29	0.45	8.31	0.36	1.03e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg04287289	chr16:89883240	FANCA	-0.8	-16.26	-0.6	2.23e-47	Vitiligo;
LGG	cis	rs9902453	0.791	rs3115090	chr17:28035014	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.73	14.78	0.57	9.48e-41	Coffee consumption (cups per day);
LGG	cis	rs62064224	0.554	rs9894877	chr17:30679517	T/A	cg18200150	chr17:30822561	MYO1D	0.48	9.25	0.39	8.28e-19	Schizophrenia;
LGG	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg24130564	chr14:104152367	KLC1	-0.45	-8.66	-0.37	8.03e-17	Body mass index;
LGG	cis	rs12479064	0.604	rs11893359	chr2:99954608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-9.0	-0.39	6.04e-18	Chronic sinus infection;
LGG	cis	rs3087591	0.960	rs12943508	chr17:29599954	C/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.64	0.56	3.73e-40	Hip circumference;
LGG	cis	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg24375607	chr4:120327624	NA	0.67	10.98	0.45	4.21e-25	Corneal astigmatism;
LGG	cis	rs798554	0.757	rs1182187	chr7:2870454	T/G	cg13628971	chr7:2884303	GNA12	0.5	9.84	0.42	6.91e-21	Height;
LGG	cis	rs4330281	0.647	rs4908959	chr3:17736035	G/A	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	trans	rs171408	0.557	rs1493595	chr3:8625604	A/T	cg24185116	chr15:52044314	LYSMD2;TMOD2	0.43	7.26	0.32	1.64e-12	Mitral valve prolapse;
LGG	cis	rs9611565	0.659	rs73178632	chr22:41934573	C/T	cg17554472	chr22:41940697	POLR3H	-0.49	-7.02	-0.31	7.89e-12	Vitiligo;
LGG	cis	rs9788682	1.000	rs9788682	chr15:78802586	A/G	cg06917634	chr15:78832804	PSMA4	0.6	9.01	0.39	5.47e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs3206736	0.604	rs10224131	chr7:35200804	G/A	cg13400248	chr7:35225412	NA	0.38	6.99	0.31	9.55e-12	Diastolic blood pressure;
LGG	cis	rs1008375	0.932	rs4698650	chr4:17692878	G/C	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2282802	0.585	rs2189659	chr5:139697220	C/A	cg26211634	chr5:139558579	C5orf32	-0.34	-7.57	-0.33	2.02e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1941023	0.584	rs2241920	chr11:60164204	A/G	cg08716584	chr11:60157161	MS4A7	0.43	8.73	0.38	4.49e-17	Congenital heart disease (maternal effect);
LGG	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.73e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg21775007	chr8:11205619	TDH	0.43	6.77	0.3	3.86e-11	Myopia (pathological);
LGG	cis	rs1497828	1.000	rs2815225	chr1:217529336	C/T	cg04411442	chr1:217543379	NA	-0.47	-8.01	-0.35	9.09e-15	Dialysis-related mortality;
LGG	cis	rs7552404	0.731	rs10873787	chr1:76367797	G/A	cg22875332	chr1:76189707	ACADM	0.6	8.84	0.38	2.04e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1797081	0.934	rs1797077	chr10:16853252	C/T	cg22980697	chr10:16874865	CUBN	0.38	7.35	0.32	8.95e-13	Platelet distribution width;
LGG	cis	rs740474	0.554	rs251041	chr5:141027888	C/G	cg00076195	chr5:140892677	NA	0.46	7.85	0.34	2.82e-14	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs701145	0.585	rs17817774	chr3:153779868	A/G	cg12800244	chr3:153838788	SGEF	-0.81	-9.74	-0.41	1.63e-20	Coronary artery disease;
LGG	cis	rs7945718	0.934	rs10831909	chr11:12817182	C/G	cg25843174	chr11:12811716	TEAD1	0.42	8.57	0.37	1.59e-16	Educational attainment (years of education);
LGG	cis	rs10540	1.000	rs12419766	chr11:503710	C/T	cg19913688	chr11:428466	ANO9	-0.64	-8.1	-0.35	5.03e-15	Body mass index;
LGG	cis	rs9354308	0.764	rs9354310	chr6:66566718	T/A	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs55883249	0.958	rs17362734	chr2:9730208	A/G	cg23886495	chr2:9695866	ADAM17	0.65	9.37	0.4	3.28e-19	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15826130	chr11:67159072	LOC100130987;RAD9A	0.45	6.78	0.3	3.58e-11	Gut microbiome composition (summer);
LGG	cis	rs1348850	0.914	rs4893944	chr2:178289357	G/T	cg27490568	chr2:178487706	NA	0.46	9.32	0.4	4.81e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2404602	0.716	rs12437627	chr15:76845050	T/C	cg23625390	chr15:77176239	SCAPER	0.49	9.56	0.41	6.83e-20	Blood metabolite levels;
LGG	cis	rs2074585	0.647	rs2589961	chr15:90916840	G/A	cg22089800	chr15:90895588	ZNF774	0.74	13.56	0.53	1.57e-35	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2228479	0.681	rs62052184	chr16:89967217	T/C	cg06558623	chr16:89946397	TCF25	0.91	11.98	0.49	5.59e-29	Skin colour saturation;
LGG	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg18351406	chr4:77819688	ANKRD56	0.47	8.04	0.35	7.31e-15	Emphysema distribution in smoking;
LGG	cis	rs12738007	0.840	rs2819602	chr1:29573723	C/T	cg01115565	chr1:29584222	PTPRU	-0.27	-7.1	-0.31	4.72e-12	Schizophrenia;
LGG	cis	rs1865760	1.000	rs56118523	chr6:25908975	A/G	cg03517284	chr6:25882590	NA	-0.41	-7.4	-0.33	6.57e-13	Height;
LGG	cis	rs2635047	0.615	rs9304343	chr18:44720664	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.38	6.95	0.31	1.23e-11	Educational attainment;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg00114084	chr1:33502651	AK2	-0.34	-7.06	-0.31	6.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.818	rs12029168	chr1:152987993	G/A	cg13444842	chr1:152974279	SPRR3	-0.43	-8.9	-0.38	1.28e-17	Inflammatory skin disease;
LGG	cis	rs6089829	0.962	rs6062780	chr20:61666648	T/C	cg03213289	chr20:61660250	NA	0.65	14.4	0.56	3.98e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs3126085	0.935	rs1496045	chr1:152184704	C/T	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.36e-17	Atopic dermatitis;
LGG	cis	rs9354308	0.764	rs6929147	chr6:66613908	C/A	cg07460842	chr6:66804631	NA	-0.4	-6.74	-0.3	4.71e-11	Metabolite levels;
LGG	cis	rs2346160	0.867	rs412495	chr6:167688940	C/G	cg20683250	chr6:167653907	NA	0.44	7.35	0.32	8.85e-13	Parental extreme longevity (95 years and older);
LGG	cis	rs7226408	0.600	rs2171106	chr18:34635452	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.2	-0.39	1.21e-18	Obesity-related traits;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg08677398	chr8:58056175	NA	0.44	6.93	0.31	1.43e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9486719	0.857	rs6568392	chr6:96861476	G/T	cg06623918	chr6:96969491	KIAA0776	0.74	11.67	0.48	9.01e-28	Migraine;Coronary artery disease;
LGG	cis	rs7223966	0.921	rs34699959	chr17:61960720	T/G	cg05941027	chr17:61774174	LIMD2	0.34	8.43	0.36	4.57e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1005277	0.522	rs7090858	chr10:38003670	A/C	cg27523141	chr10:43048294	ZNF37B	-0.37	-7.65	-0.33	1.16e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2880765	0.835	rs12910373	chr15:86046802	G/C	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs9816226	0.591	rs10513801	chr3:185822353	T/G	cg00760338	chr3:185826511	ETV5	-0.87	-10.52	-0.44	2.42e-23	Obesity;Body mass index;
LGG	cis	rs36051895	0.589	rs10491651	chr9:5200060	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-13.62	-0.53	8.8e-36	Pediatric autoimmune diseases;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12071328	chr11:20690930	NELL1	0.44	7.02	0.31	7.75e-12	Cognitive performance;
LGG	cis	rs796364	1.000	rs11694369	chr2:200741720	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.96	-0.42	2.58e-21	Schizophrenia;
LGG	cis	rs10751667	0.643	rs7479473	chr11:929111	C/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs7107174	1.000	rs2248407	chr11:77937800	G/A	cg02023728	chr11:77925099	USP35	0.45	7.96	0.35	1.32e-14	Testicular germ cell tumor;
LGG	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg04546413	chr19:29218101	NA	0.73	12.5	0.5	4.24e-31	Methadone dose in opioid dependence;
LGG	cis	rs8017423	0.935	rs11621820	chr14:90727154	C/T	cg04374321	chr14:90722782	PSMC1	0.9	19.53	0.67	2.08e-62	Mortality in heart failure;
LGG	cis	rs9322193	0.962	rs9689447	chr6:150110486	T/A	cg13206674	chr6:150067644	NUP43	0.64	14.47	0.56	1.95e-39	Lung cancer;
LGG	cis	rs3733346	0.505	rs11734449	chr4:921733	C/A	cg15105011	chr4:940614	TMEM175	0.39	6.79	0.3	3.54e-11	Sjögren's syndrome;
LGG	cis	rs12980942	0.591	rs4591267	chr19:41765407	A/C	cg25627403	chr19:41769009	HNRNPUL1	0.59	7.57	0.33	2.05e-13	Coronary artery disease;
LGG	cis	rs801193	1.000	rs6958520	chr7:66151453	T/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.54e-24	Aortic root size;
LGG	cis	rs11864453	0.578	rs2072141	chr16:72133211	G/A	cg23815491	chr16:72088622	HP	0.48	10.92	0.45	7.42e-25	Fibrinogen levels;
LGG	cis	rs711245	0.670	rs7560321	chr2:36822318	C/G	cg10546459	chr2:36825355	FEZ2	-0.51	-8.23	-0.36	1.95e-15	Height;
LGG	trans	rs61931739	0.592	rs61927752	chr12:33697205	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.7	-0.37	6e-17	Morning vs. evening chronotype;
LGG	cis	rs9486715	0.867	rs6568428	chr6:96903604	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.62	0.59	1.74e-44	Headache;
LGG	cis	rs7246760	0.748	rs28384439	chr19:9731965	G/A	cg16876255	chr19:9731953	ZNF561	0.9	8.17	0.36	2.92e-15	Pursuit maintenance gain;
LGG	cis	rs6032067	0.704	rs62205505	chr20:43874856	C/T	cg10761708	chr20:43804764	PI3	0.77	11.69	0.48	7.87e-28	Blood protein levels;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg03188948	chr7:1209495	NA	0.67	8.66	0.37	8.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs868036	1.000	rs1026732	chr15:68095085	C/T	cg08079166	chr15:68083412	MAP2K5	0.35	7.87	0.34	2.6e-14	Restless legs syndrome;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg05091796	chr16:4465799	CORO7	-0.84	-14.22	-0.55	2.38e-38	Schizophrenia;
LGG	cis	rs12701220	0.522	rs12334290	chr7:1054517	A/G	cg20821713	chr7:1055600	C7orf50	-0.54	-10.14	-0.43	5.84e-22	Bronchopulmonary dysplasia;
LGG	cis	rs13191362	1.000	rs73016459	chr6:163066323	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	6.94	0.31	1.35e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg00761968	chr13:53314142	LECT1	-0.36	-7.68	-0.34	9.33e-14	Lewy body disease;
LGG	cis	rs2797160	1.000	rs926853	chr6:126021435	A/T	cg05901451	chr6:126070800	HEY2	0.46	7.78	0.34	4.75e-14	Endometrial cancer;
LGG	cis	rs10504229	0.871	rs16921952	chr8:58163317	A/T	cg22535103	chr8:58192502	C8orf71	-0.97	-15.31	-0.58	4.38e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg11905131	chr22:24372483	LOC391322	-0.4	-7.01	-0.31	8.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs295140	0.605	rs296818	chr2:201176944	C/T	cg17644776	chr2:200775616	C2orf69	0.45	7.52	0.33	2.77e-13	QT interval;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.65	8.61	0.37	1.18e-16	Lung function (FEV1/FVC);
LGG	cis	rs28386778	0.897	rs2137144	chr17:61805607	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.39	0.43	7.13e-23	Prudent dietary pattern;
LGG	cis	rs7618501	0.633	rs4688690	chr3:50022292	G/A	cg05623727	chr3:50126028	RBM5	0.32	6.9	0.31	1.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs36051895	0.623	rs11790680	chr9:5248768	C/T	cg02405213	chr9:5042618	JAK2	-0.74	-12.41	-0.5	1.02e-30	Pediatric autoimmune diseases;
LGG	cis	rs3741151	0.773	rs74881062	chr11:73245769	G/A	cg17517138	chr11:73019481	ARHGEF17	0.83	7.88	0.34	2.39e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs35306767	0.761	rs12771539	chr10:1050653	A/G	cg20503657	chr10:835505	NA	0.54	7.08	0.31	5.29e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs17445240	0.901	rs6754703	chr2:3707646	C/A	cg17046650	chr2:3699563	NA	0.92	11.05	0.46	2.32e-25	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6951245	0.572	rs73264028	chr7:1045455	G/A	cg18402987	chr7:1209562	NA	0.62	6.84	0.3	2.46e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs36051895	0.632	rs12352285	chr9:5141476	C/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.8	-0.57	7.61e-41	Pediatric autoimmune diseases;
LGG	trans	rs4689592	0.583	rs12501362	chr4:7083563	C/T	cg07817883	chr1:32538562	TMEM39B	0.51	7.35	0.32	9.24e-13	Monocyte percentage of white cells;
LGG	cis	rs7927771	0.826	rs2293578	chr11:47437403	C/T	cg20307385	chr11:47447363	PSMC3	-0.58	-10.54	-0.44	2.0500000000000001e-23	Subjective well-being;
LGG	cis	rs60843830	1.000	rs114976176	chr2:264621	A/C	cg12623918	chr2:306882	NA	0.49	9.04	0.39	4.38e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg08888203	chr3:10149979	C3orf24	0.52	8.83	0.38	2.14e-17	Alzheimer's disease;
LGG	cis	rs875971	0.928	rs6970357	chr7:65968878	T/C	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs3790455	0.610	rs3790461	chr1:156469364	A/G	cg14087168	chr1:156450669	MEF2D	0.66	9.86	0.42	5.92e-21	Migraine;
LGG	cis	rs17102423	0.651	rs2296316	chr14:65520246	A/G	cg16583315	chr14:65563665	MAX	-0.36	-7.21	-0.32	2.3e-12	Obesity-related traits;
LGG	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg17201900	chr20:34330562	RBM39	0.51	6.67	0.3	7.22e-11	Total cholesterol levels;
LGG	cis	rs10186029	0.582	rs1441166	chr2:214010105	T/C	cg08319019	chr2:214017104	IKZF2	0.44	7.71	0.34	7.98e-14	Systemic sclerosis;
LGG	cis	rs12893668	0.543	rs1799796	chr14:104165927	T/C	cg23335576	chr14:104009727	NA	0.43	7.27	0.32	1.57e-12	Reticulocyte count;
LGG	cis	rs2115630	0.875	rs8039472	chr15:85361644	A/G	cg11189052	chr15:85197271	WDR73	-0.44	-7.07	-0.31	5.93e-12	P wave terminal force;
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg04503457	chr17:41445688	NA	-0.39	-9.13	-0.39	2.09e-18	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs947211	0.948	rs1775143	chr1:205755550	C/T	cg11965913	chr1:205819406	PM20D1	0.46	7.13	0.31	3.78e-12	Parkinson's disease;
LGG	cis	rs657075	0.697	rs71583482	chr5:131697941	T/C	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12997958	chr17:18161617	FLII	0.4	6.87	0.3	2.11e-11	Menarche (age at onset);
LGG	cis	rs4722585	0.533	rs2237335	chr7:26200213	A/G	cg07876897	chr7:26191696	NFE2L3	0.35	7.08	0.31	5.23e-12	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	trans	rs9929218	0.954	rs9928796	chr16:68820718	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.92	-0.48	9.65e-29	Colorectal cancer;
LGG	cis	rs4132509	1.000	rs9782958	chr1:243892972	C/G	cg21452805	chr1:244014465	NA	0.65	8.04	0.35	7.47e-15	RR interval (heart rate);
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg24503407	chr1:205819492	PM20D1	0.57	11.52	0.47	3.72e-27	Menarche (age at onset);
LGG	cis	rs2084898	0.941	rs73004793	chr11:120061255	T/C	cg13907859	chr11:120009124	TRIM29	0.85	11.24	0.46	4.23e-26	Stroke (pediatric);
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.7	12.9	0.51	9.73e-33	Obesity-related traits;
LGG	cis	rs2046867	0.818	rs6789061	chr3:72888690	C/T	cg01043669	chr3:72786069	NA	0.43	6.85	0.3	2.4e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4704187	0.687	rs9293642	chr5:74365026	C/T	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs5756391	0.546	rs9607396	chr22:37315912	C/A	cg21209356	chr22:37319042	CSF2RB	0.41	9.32	0.4	4.64e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1185460	0.546	rs474201	chr11:118958229	G/A	cg12636538	chr11:118901039	SLC37A4	0.56	11.36	0.47	1.5e-26	Coronary artery disease;
LGG	cis	rs17221829	0.502	rs6483018	chr11:89323282	C/A	cg02982614	chr11:89391479	FOLH1B	-0.37	-8.37	-0.36	7e-16	Anxiety in major depressive disorder;
LGG	cis	rs9863	0.861	rs4765305	chr12:124430612	G/A	cg13487667	chr12:124434373	CCDC92	-0.35	-7.05	-0.31	6.71e-12	White blood cell count;
LGG	cis	rs2303319	0.892	rs58627659	chr2:162250910	C/T	cg13806767	chr2:162164127	PSMD14	-0.69	-8.02	-0.35	8.78e-15	Cognitive function;
LGG	trans	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-7.8	-0.34	4.25e-14	Neuroticism;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg11584989	chr19:19387371	SF4	0.41	7.4	0.33	6.57e-13	Tonsillectomy;
LGG	cis	rs981844	0.583	rs2289318	chr4:154633734	G/C	cg14289246	chr4:154710475	SFRP2	0.59	8.68	0.37	6.6e-17	Response to statins (LDL cholesterol change);
LGG	cis	rs943466	0.956	rs11758463	chr6:33762625	A/G	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	1.99e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2273669	0.667	rs9688496	chr6:109364825	G/T	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	cis	rs274567	0.501	rs272855	chr5:131687175	C/T	cg07395648	chr5:131743802	NA	-0.49	-10.06	-0.42	1.2e-21	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs58089675	chr17:29196764	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7619833	0.755	rs491976	chr3:27367221	T/C	cg02860705	chr3:27208620	NA	0.43	8.0	0.35	1.04e-14	Breast cancer;
LGG	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg14664628	chr15:75095509	CSK	-0.56	-10.68	-0.44	5.98e-24	Breast cancer;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.08	0.52	1.71e-33	Obesity-related traits;
LGG	trans	rs7395662	1.000	rs4882117	chr11:48565468	G/T	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.43e-13	HDL cholesterol;
LGG	cis	rs9398803	0.671	rs1155939	chr6:126866133	C/A	cg19875578	chr6:126661172	C6orf173	0.52	9.53	0.4	9.15e-20	Male-pattern baldness;
LGG	cis	rs490234	0.966	rs530628	chr9:128325934	C/G	cg14078157	chr9:128172775	NA	-0.38	-7.16	-0.32	3.21e-12	Mean arterial pressure;
LGG	cis	rs4731207	0.565	rs6466978	chr7:124643786	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs1345301	0.552	rs67880537	chr2:102864106	A/G	cg05295703	chr2:102895712	NA	0.49	9.73	0.41	1.82e-20	Waist circumference;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg19182353	chr11:118479428	PHLDB1	0.67	14.56	0.56	8.59e-40	Systemic lupus erythematosus;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg00495681	chr13:53174319	NA	0.58	10.26	0.43	2.13e-22	Lewy body disease;
LGG	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg21775007	chr8:11205619	TDH	-0.49	-8.0	-0.35	9.78e-15	Neuroticism;
LGG	cis	rs7044106	0.648	rs2031369	chr9:123360294	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.3	0.32	1.25e-12	Hip circumference adjusted for BMI;
LGG	cis	rs7011049	1.000	rs11997538	chr8:53832663	A/C	cg26025543	chr8:53854495	NA	0.74	10.1	0.42	8.47e-22	Systolic blood pressure;
LGG	cis	rs9522267	0.535	rs6492373	chr13:112238627	T/C	cg12773197	chr13:112238673	NA	0.36	7.25	0.32	1.75e-12	Hepatitis;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.87	-0.57	3.74e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs754466	0.651	rs56138814	chr10:79625795	T/C	cg17075019	chr10:79541650	NA	-0.95	-20.43	-0.69	1.25e-66	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs6980850	chr8:58127204	A/G	cg08280861	chr8:58055591	NA	0.55	6.92	0.31	1.54e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs9929218	1.000	rs13333528	chr16:68790502	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.81	-13.87	-0.54	8.13e-37	Colorectal cancer;
LGG	trans	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.84	17.4	0.63	1.48e-52	Obesity-related traits;
LGG	cis	rs4740619	0.776	rs10962121	chr9:15702704	G/T	cg14451791	chr9:16040625	NA	0.33	8.43	0.36	4.5e-16	Body mass index;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg24829409	chr8:58192753	C8orf71	-0.65	-9.18	-0.39	1.44e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4812048	0.503	rs6070690	chr20:57574816	G/C	cg23907860	chr20:57583709	CTSZ	0.49	7.12	0.31	4.26e-12	Mean platelet volume;
LGG	cis	rs7044106	0.791	rs10818473	chr9:123484155	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.44	0.33	4.87e-13	Hip circumference adjusted for BMI;
LGG	trans	rs453301	0.653	rs7853	chr8:8890814	A/G	cg02002194	chr4:3960332	NA	-0.46	-8.64	-0.37	9.08e-17	Joint mobility (Beighton score);
LGG	cis	rs9650657	0.513	rs4314618	chr8:10816772	A/G	cg27411982	chr8:10470053	RP1L1	-0.43	-7.22	-0.32	2.22e-12	Neuroticism;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg11878867	chr6:150167359	LRP11	-0.52	-10.77	-0.45	2.83e-24	Lung cancer;
LGG	cis	rs651907	0.535	rs13084113	chr3:101534039	C/G	cg12386194	chr3:101231763	SENP7	0.45	7.85	0.34	3.02e-14	Colorectal cancer;
LGG	cis	rs4363385	0.679	rs6686285	chr1:152984561	T/G	cg13444842	chr1:152974279	SPRR3	-0.46	-9.46	-0.4	1.54e-19	Inflammatory skin disease;
LGG	cis	rs13191362	1.000	rs34443622	chr6:163208214	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.34	0.32	9.99e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7909791	0.632	rs3752948	chr10:105670762	G/A	cg11005552	chr10:105648138	OBFC1	0.65	9.59	0.41	5.47e-20	White matter hyperintensity burden;
LGG	cis	rs6089584	0.819	rs1467593	chr20:60601432	T/G	cg06470251	chr20:60548479	NA	-0.53	-8.47	-0.37	3.28e-16	Body mass index;
LGG	cis	rs11123610	0.520	rs35752035	chr2:3721353	G/C	cg26344334	chr2:3718215	ALLC	-0.49	-8.34	-0.36	8.28e-16	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10849893	0.595	rs7980819	chr12:121887194	A/G	cg01154721	chr12:121881891	KDM2B	-0.4	-6.95	-0.31	1.25e-11	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs28386778	1.000	rs3020613	chr17:61955983	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.41	6.79	0.3	3.47e-11	Prudent dietary pattern;
LGG	trans	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg16141378	chr3:129829833	LOC729375	0.31	6.86	0.3	2.24e-11	Monocyte count;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg13206674	chr6:150067644	NUP43	0.43	9.31	0.4	5.11e-19	Lung cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05871607	chr1:28241317	RPA2	0.42	7.52	0.33	2.91e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7602441	0.521	rs74742552	chr2:14773375	G/T	cg06545361	chr2:14773388	FAM84A	0.89	7.79	0.34	4.4e-14	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg01879757	chr17:41196368	BRCA1	0.4	8.32	0.36	9.58e-16	Menopause (age at onset);
LGG	cis	rs7020830	0.898	rs12555207	chr9:37315476	C/T	cg14294708	chr9:37120828	ZCCHC7	1.13	31.42	0.83	7.65e-117	Schizophrenia;
LGG	trans	rs3812049	0.784	rs3749748	chr5:127350549	C/T	cg16011800	chr17:1958478	HIC1	0.62	9.53	0.4	9.25e-20	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs2243480	1.000	rs35058610	chr7:65390925	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.18	-0.39	1.49e-18	Diabetic kidney disease;
LGG	cis	rs3858526	0.917	rs10769386	chr11:5973420	C/T	cg05234568	chr11:5960015	NA	0.74	11.92	0.48	9.43e-29	DNA methylation (variation);
LGG	cis	rs796364	0.806	rs79053279	chr2:201057443	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.72	-8.56	-0.37	1.65e-16	Schizophrenia;
LGG	cis	rs10193935	0.901	rs6752455	chr2:42543577	A/C	cg27598129	chr2:42591480	NA	-0.65	-9.75	-0.41	1.48e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2180341	0.889	rs2000909	chr6:127711173	G/A	cg27446573	chr6:127587934	RNF146	0.93	17.78	0.64	2.61e-54	Breast cancer;
LGG	cis	rs266717	0.816	rs710450	chr3:186522633	A/C	cg00373256	chr3:186519153	RFC4	-0.42	-8.55	-0.37	1.75e-16	Adiponectin levels;
LGG	trans	rs561341	0.769	rs9899093	chr17:30191954	C/G	cg27661571	chr11:113659931	NA	-0.58	-7.15	-0.32	3.41e-12	Hip circumference adjusted for BMI;
LGG	cis	rs6500602	0.702	rs2270366	chr16:4558615	A/G	cg00688539	chr16:4524775	NMRAL1;HMOX2	-0.32	-6.88	-0.3	1.96e-11	Schizophrenia;
LGG	cis	rs1322639	0.574	rs9689193	chr6:169588074	A/G	cg04662567	chr6:169592167	NA	-0.88	-11.86	-0.48	1.7e-28	Pulse pressure;
LGG	cis	rs11690935	0.959	rs7572215	chr2:172634228	G/A	cg21435375	chr2:172878103	MAP1D	-0.31	-6.98	-0.31	1e-11	Schizophrenia;
LGG	cis	rs921968	0.541	rs3755041	chr2:219442499	A/T	cg10223061	chr2:219282414	VIL1	0.31	6.85	0.3	2.42e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs116095464	0.558	rs3213838	chr5:223890	G/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	trans	rs1814175	0.817	rs1615305	chr11:49895222	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.3	-0.5	2.67e-30	Height;
LGG	cis	rs11150038	1.000	rs11867104	chr16:78072333	T/C	cg04733911	chr16:78082701	NA	-0.67	-8.83	-0.38	2.2e-17	Colorectal or endometrial cancer;
LGG	cis	rs2249625	0.545	rs55681410	chr6:72877859	G/A	cg27608224	chr6:72922399	RIMS1	-0.33	-7.41	-0.33	5.89e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.41	6.75	0.3	4.38e-11	Prudent dietary pattern;
LGG	trans	rs7906315	0.967	rs3814573	chr10:114898093	C/T	cg26477793	chr10:104262085	ACTR1A	-0.42	-6.85	-0.3	2.34e-11	Breast cancer;
LGG	cis	rs6598955	0.671	rs7417505	chr1:26575523	A/G	cg04990556	chr1:26633338	UBXN11	0.61	8.16	0.35	3.2e-15	Obesity-related traits;
LGG	trans	rs11039798	0.588	rs7116858	chr11:48543920	C/A	cg15704280	chr7:45808275	SEPT13	0.72	9.97	0.42	2.47e-21	Axial length;
LGG	trans	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs151997	0.671	rs27907	chr5:50193797	C/G	cg06027927	chr5:50259733	NA	0.61	10.31	0.43	1.42e-22	Callous-unemotional behaviour;
LGG	cis	rs1005277	0.502	rs2800484	chr10:38542415	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.99	-0.31	9.64e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs6956675	0.915	rs10232119	chr7:62638227	C/T	cg01314568	chr7:57830625	NA	-0.5	-7.92	-0.35	1.76e-14	Obesity-related traits;
LGG	cis	rs12701220	0.655	rs7799656	chr7:1140515	C/T	cg02733842	chr7:1102375	C7orf50	-0.46	-7.59	-0.33	1.74e-13	Bronchopulmonary dysplasia;
LGG	cis	rs12410462	0.551	rs74997063	chr1:227744537	A/C	cg23173402	chr1:227635558	NA	0.38	7.16	0.32	3.16e-12	Major depressive disorder;
LGG	cis	rs12249377	0.519	rs11597471	chr10:92598767	C/G	cg14313238	chr10:92632228	RPP30	0.42	7.21	0.32	2.27e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs11676855	1.000	rs11676855	chr2:235900171	C/T	cg06431347	chr2:235935754	SH3BP4	0.4	8.78	0.38	3.12e-17	Dialysis-related mortality;
LGG	cis	rs4481887	0.861	rs6676061	chr1:248443887	G/C	cg01631408	chr1:248437212	OR2T33	-0.55	-9.88	-0.42	5.26e-21	Common traits (Other);
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg12813108	chr7:99719912	CNPY4	-0.58	-8.64	-0.37	8.92e-17	Lung function (FEV1/FVC);
LGG	cis	rs12477438	0.501	rs3792137	chr2:100061748	C/A	cg23527387	chr2:100056660	REV1	0.42	9.46	0.4	1.52e-19	Chronic sinus infection;
LGG	cis	rs9486719	0.894	rs34826652	chr6:96899085	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs16866061	1.000	rs3768886	chr2:225450161	G/C	cg12698349	chr2:225449008	CUL3	0.92	18.84	0.66	3.27e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs28386778	0.966	rs2854161	chr17:61976093	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.57	-9.91	-0.42	4.13e-21	Prudent dietary pattern;
LGG	cis	rs2415984	0.579	rs11157506	chr14:46976197	T/C	cg14871534	chr14:47121158	RPL10L	-0.56	-9.81	-0.41	9.16e-21	Number of children ever born;
LGG	cis	rs2228479	0.541	rs62052173	chr16:89950739	T/C	cg06558623	chr16:89946397	TCF25	0.92	12.02	0.49	3.71e-29	Skin colour saturation;
LGG	cis	rs727505	0.564	rs56068095	chr7:124831906	A/T	cg23710748	chr7:124431027	NA	-0.44	-8.31	-0.36	1.11e-15	Lewy body disease;
LGG	trans	rs9914544	0.564	rs12451220	chr17:18778421	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs4716602	0.596	rs10253193	chr7:156157801	C/T	cg16983916	chr7:156159713	NA	-0.49	-9.44	-0.4	1.79e-19	Anti-saccade response;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs2576037	0.796	rs2571018	chr18:44585344	T/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.47	-9.42	-0.4	2.2e-19	Personality dimensions;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg24829409	chr8:58192753	C8orf71	-0.9	-13.54	-0.53	2.02e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs11579220	1	rs11579220	chr1:205144363	G/T	cg21545522	chr1:205238299	TMCC2	0.38	7.11	0.31	4.32e-12	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs28595532	0.920	rs114544767	chr4:119728364	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.91	0.57	2.51e-41	Cannabis dependence symptom count;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.639	rs9356989	chr6:25781950	A/G	cg12310025	chr6:25882481	NA	-0.44	-6.93	-0.31	1.38e-11	Iron status biomarkers;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16160182	chr1:2574031	NA	0.4	6.67	0.3	7.41e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs17102423	0.826	rs10873182	chr14:65605408	C/T	cg26396452	chr14:65542826	MAX	0.38	7.35	0.32	8.85e-13	Obesity-related traits;
LGG	trans	rs11148252	0.633	rs9535888	chr13:52733206	C/G	cg18335740	chr13:41363409	SLC25A15	0.57	10.41	0.44	6.25e-23	Lewy body disease;
LGG	trans	rs2243480	1.000	rs2465120	chr7:65620974	C/G	cg10756647	chr7:56101905	PSPH	0.82	9.55	0.41	7.41e-20	Diabetic kidney disease;
LGG	cis	rs8060686	0.545	rs76836953	chr16:68061763	G/C	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.44	-0.33	4.92e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs16866061	1.000	rs10933068	chr2:225418360	G/A	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.93e-11	Menopause (age at onset);
LGG	cis	rs7648466	0.513	rs2201150	chr3:46258902	T/C	cg12441928	chr3:46249985	CCR1	-0.45	-8.71	-0.38	5.6e-17	Eotaxin levels;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	trans	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.17	-0.35	3.06e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15054260	chr8:90769710	RIPK2	0.5	7.35	0.32	9.11e-13	Gut microbiome composition (summer);
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg19901468	chr14:105411992	AHNAK2	-0.88	-18.46	-0.65	1.9e-57	Systemic lupus erythematosus;
LGG	cis	rs11098499	0.562	rs2389879	chr4:120557684	G/A	cg24375607	chr4:120327624	NA	-0.52	-8.96	-0.38	7.79e-18	Corneal astigmatism;
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.87	0.34	2.47e-14	Lung cancer;
LGG	cis	rs2404602	0.716	rs7169394	chr15:76913274	G/A	cg05677249	chr15:77158041	SCAPER	-0.31	-6.7	-0.3	6.04e-11	Blood metabolite levels;
LGG	cis	rs7208859	0.573	rs8064686	chr17:29134839	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg13047869	chr3:10149882	C3orf24	0.55	9.41	0.4	2.3e-19	Alzheimer's disease;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg08280861	chr8:58055591	NA	0.51	6.83	0.3	2.63e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7568458	0.870	rs1009	chr2:85808737	A/G	cg23752985	chr2:85803571	VAMP8	0.43	8.44	0.37	4.01e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7241530	0.610	rs12455089	chr18:75899708	T/G	cg14642773	chr18:75888474	NA	0.47	8.99	0.39	6.21e-18	Educational attainment (years of education);
LGG	cis	rs9291683	0.588	rs35099040	chr4:10018839	T/C	cg00071950	chr4:10020882	SLC2A9	0.44	9.21	0.39	1.14e-18	Bone mineral density;
LGG	cis	rs875971	1.000	rs778696	chr7:65870813	C/G	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs1348850	0.757	rs2166554	chr2:178455824	A/G	cg27490568	chr2:178487706	NA	0.48	9.28	0.4	6.78e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7215564	0.730	rs7212125	chr17:78628863	C/T	cg06153925	chr17:78755379	RPTOR	-0.38	-6.88	-0.3	1.96e-11	Myopia (pathological);
LGG	cis	rs9783347	1.000	rs4150575	chr11:18356466	C/T	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.42	-0.33	5.77e-13	Pancreatic cancer;
LGG	cis	rs4788570	0.566	rs9989376	chr16:71498983	C/T	cg06353428	chr16:71660113	MARVELD3	-0.87	-12.06	-0.49	2.51e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg05425664	chr17:57184151	TRIM37	0.61	9.68	0.41	2.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.927	rs257304	chr5:102416818	C/G	cg23492399	chr5:102201601	PAM	-0.5	-7.47	-0.33	3.9e-13	Parkinson's disease;
LGG	cis	rs11148252	0.904	rs7321964	chr13:53040822	A/G	cg02158880	chr13:53174818	NA	0.51	10.34	0.43	1.14e-22	Lewy body disease;
LGG	cis	rs1568889	1.000	rs7949057	chr11:28255053	A/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	14.86	0.57	4.08e-41	Bipolar disorder;
LGG	trans	rs9467711	0.659	rs35304979	chr6:26356347	C/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs7959452	0.590	rs6581889	chr12:69757429	T/C	cg22834771	chr12:69754056	YEATS4	-0.43	-7.53	-0.33	2.77e-13	Blood protein levels;
LGG	cis	rs12478296	0.892	rs11893879	chr2:243010411	G/A	cg06360820	chr2:242988706	NA	-0.89	-11.58	-0.47	2.1e-27	Obesity-related traits;
LGG	cis	rs7044106	0.762	rs1547268	chr9:123408688	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.31	0.6	1.39e-47	Hip circumference adjusted for BMI;
LGG	trans	rs9354308	0.738	rs9453472	chr6:66599064	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-6.9	-0.31	1.73e-11	Metabolite levels;
LGG	cis	rs7927592	0.871	rs12941	chr11:68382193	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.69	-0.3	6.39e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.86	0.3	2.16e-11	Lung cancer;
LGG	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.65e-15	Obesity-related traits;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.82	-0.34	3.53e-14	Height;
LGG	cis	rs9467773	0.595	rs9366657	chr6:26434914	C/G	cg09904177	chr6:26538194	HMGN4	0.45	7.95	0.35	1.47e-14	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.935	rs4974575	chr4:1252028	A/G	cg20887711	chr4:1340912	KIAA1530	0.58	11.04	0.46	2.53e-25	Obesity-related traits;
LGG	cis	rs2455799	0.613	rs2345736	chr3:15824860	T/G	cg16303742	chr3:15540471	COLQ	-0.4	-8.05	-0.35	7.11e-15	Mean platelet volume;
LGG	cis	rs10492096	0.898	rs12426815	chr12:6580314	A/G	cg13857086	chr12:6580257	VAMP1	0.53	7.85	0.34	3.01e-14	Hip geometry;
LGG	cis	rs7191439	0.728	rs8056374	chr16:88790147	G/T	cg27087555	chr16:88793112	FAM38A	-1.4	-20.2	-0.68	1.55e-65	Plateletcrit;
LGG	cis	rs9951602	0.833	rs9953548	chr18:76640601	C/T	cg24134504	chr18:76639479	NA	-0.63	-8.17	-0.35	3.02e-15	Obesity-related traits;
LGG	cis	rs6964587	0.610	rs6950682	chr7:91464218	G/T	cg17063962	chr7:91808500	NA	0.4	7.2	0.32	2.49e-12	Breast cancer;
LGG	cis	rs12579753	0.956	rs35278765	chr12:82173126	T/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.05	-0.46	2.29e-25	Resting heart rate;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg17202724	chr17:61916730	SMARCD2	0.62	15.29	0.58	5.12e-43	Prudent dietary pattern;
LGG	cis	rs42648	0.819	rs2285399	chr7:89969878	A/G	cg25739043	chr7:89950458	NA	-0.35	-7.17	-0.32	3.08e-12	Homocysteine levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg10952910	chr12:57623761	SHMT2	0.42	6.96	0.31	1.18e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6772849	0.896	rs4557179	chr3:128366726	A/C	cg08795948	chr3:128337044	NA	0.67	11.38	0.47	1.31e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs938295	1.000	rs12091731	chr1:16087824	A/G	cg05660106	chr1:15850417	CASP9	-0.55	-9.08	-0.39	3.15e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs1153858	1.000	rs1719247	chr15:45620985	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.41	7.21	0.32	2.22e-12	Homoarginine levels;
LGG	cis	rs7712401	0.562	rs30046	chr5:122271233	G/C	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs10789491	1.000	rs7547522	chr1:47179918	C/G	cg15501359	chr1:47185051	KIAA0494	0.77	14.5	0.56	1.56e-39	Response to hepatitis C treatment;
LGG	cis	rs4683142	0.518	rs6441938	chr3:46045619	C/G	cg13144783	chr3:46249795	CCR1	-0.43	-6.94	-0.31	1.37e-11	Methadone dose in opioid dependence;
LGG	cis	rs11098499	0.908	rs1002152	chr4:120273387	C/A	cg24375607	chr4:120327624	NA	0.64	10.35	0.43	1.01e-22	Corneal astigmatism;
LGG	trans	rs4650994	1.000	rs12138541	chr1:178518707	G/A	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs6424115	1.000	rs2256179	chr1:24132305	A/G	cg15997130	chr1:24165203	NA	-0.46	-12.7	-0.51	6.39e-32	Immature fraction of reticulocytes;
LGG	cis	rs4780401	0.693	rs8191277	chr16:11764082	A/G	cg01061890	chr16:11836724	TXNDC11	-0.44	-7.23	-0.32	2.02e-12	Rheumatoid arthritis;
LGG	cis	rs7208859	0.623	rs9912440	chr17:29148772	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs16937	0.711	rs10751429	chr1:205107478	C/T	cg00889227	chr1:205173544	DSTYK	-0.29	-7.19	-0.32	2.54e-12	Schizophrenia;
LGG	cis	rs17428076	0.874	rs72885532	chr2:172684033	A/G	cg21435375	chr2:172878103	MAP1D	0.4	8.65	0.37	8.23e-17	Myopia;
LGG	cis	rs9309711	0.623	rs7569694	chr2:3483390	T/G	cg15541040	chr2:3486749	NA	-0.46	-8.46	-0.37	3.6e-16	Neurofibrillary tangles;
LGG	cis	rs6547741	0.844	rs9678851	chr2:27887034	C/A	cg27432699	chr2:27873401	GPN1	-0.76	-15.69	-0.59	8.85e-45	Oral cavity cancer;
LGG	cis	rs8141529	0.732	rs6005881	chr22:29183133	A/G	cg15103426	chr22:29168792	CCDC117	0.74	11.83	0.48	2.18e-28	Lymphocyte counts;
LGG	cis	rs17376456	0.825	rs10214278	chr5:93237679	C/T	cg25358565	chr5:93447407	FAM172A	-1.19	-15.1	-0.57	3.69e-42	Diabetic retinopathy;
LGG	cis	rs873946	0.648	rs12771651	chr10:134554482	C/A	cg27286337	chr10:134555280	INPP5A	0.9	13.38	0.53	9.97e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.28	-0.4	6.43e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs225245	0.791	rs3890901	chr17:34011322	A/C	cg19694781	chr19:47549865	TMEM160	-0.42	-7.21	-0.32	2.33e-12	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2916247	1.000	rs2979856	chr8:92980145	A/T	cg10183463	chr8:93005414	RUNX1T1	0.41	8.29	0.36	1.22e-15	Intelligence (multi-trait analysis);
LGG	cis	rs360798	0.553	rs360804	chr2:62939397	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.91	-0.31	1.58e-11	Coronary artery disease;
LGG	cis	rs12477438	0.520	rs58958283	chr2:100009924	G/A	cg23527387	chr2:100056660	REV1	0.44	9.72	0.41	1.93e-20	Chronic sinus infection;
LGG	trans	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg16141378	chr3:129829833	LOC729375	0.38	8.74	0.38	4.46e-17	Joint mobility (Beighton score);
LGG	cis	rs6933660	0.745	rs6557138	chr6:151732017	C/T	cg17179660	chr6:151773299	C6orf211;RMND1	-0.47	-8.05	-0.35	7.16e-15	Menarche (age at onset);
LGG	cis	rs17376456	0.741	rs10036829	chr5:93309897	G/C	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs7847628	0.587	rs3793638	chr9:123582697	G/T	cg03808351	chr9:123631620	PHF19	0.28	7.0	0.31	8.77e-12	Birth weight;
LGG	cis	rs733592	0.894	rs886589	chr12:48477197	C/T	cg24011408	chr12:48396354	COL2A1	-0.65	-10.92	-0.45	7.28e-25	Plateletcrit;
LGG	cis	rs8062405	0.824	rs28698667	chr16:28533071	C/T	cg00198680	chr16:28758506	NA	0.3	7.45	0.33	4.64e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg17330251	chr7:94953956	PON1	-0.42	-8.25	-0.36	1.63e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4853012	0.838	rs72911122	chr2:74344119	C/G	cg19729930	chr2:74357872	NA	0.53	11.45	0.47	6.56e-27	Gestational age at birth (maternal effect);
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg11878867	chr6:150167359	LRP11	0.47	7.98	0.35	1.13e-14	Lung cancer;
LGG	cis	rs559928	0.502	rs10897504	chr11:64190137	C/G	cg05555928	chr11:63887634	MACROD1	-0.58	-9.69	-0.41	2.34e-20	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.83	-0.48	2.07e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs7474896	0.559	rs1212108	chr10:38094322	A/C	cg00409905	chr10:38381863	ZNF37A	-0.51	-7.48	-0.33	3.8e-13	Obesity (extreme);
LGG	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs7129556	0.859	rs11237215	chr11:77247515	G/A	cg12586386	chr11:77299805	AQP11	0.5	8.5	0.37	2.61e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs12497850	0.931	rs4974085	chr3:48924900	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	11.02	0.46	3.05e-25	Parkinson's disease;
LGG	cis	rs11098499	0.754	rs1980027	chr4:120251577	C/T	cg24375607	chr4:120327624	NA	0.61	10.31	0.43	1.37e-22	Corneal astigmatism;
LGG	cis	rs6831256	0.505	rs11947277	chr4:3473751	C/T	cg17812751	chr4:3478348	DOK7	0.4	7.08	0.31	5.4e-12	LDL cholesterol;Triglyceride levels;Triglycerides;Cholesterol, total;
LGG	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg26384229	chr12:38710491	ALG10B	0.92	20.84	0.7	1.66e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs5769765	0.773	rs7410291	chr22:50300078	A/G	cg02269571	chr22:50332266	NA	-0.63	-10.16	-0.43	5.21e-22	Schizophrenia;
LGG	cis	rs9790314	0.589	rs13097130	chr3:160669279	G/A	cg03342759	chr3:160939853	NMD3	0.45	7.57	0.33	1.98e-13	Morning vs. evening chronotype;
LGG	cis	rs9325144	0.560	rs1825802	chr12:38650341	C/T	cg04568710	chr12:38710424	ALG10B	-0.35	-7.38	-0.32	7.32e-13	Morning vs. evening chronotype;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07243736	chr16:783730	NARFL	0.39	6.76	0.3	4.29e-11	Height;
LGG	cis	rs7296418	0.580	rs78455769	chr12:123856443	G/A	cg00376283	chr12:123451042	ABCB9	0.6	10.88	0.45	1.05e-24	Platelet count;
LGG	cis	rs11252926	0.527	rs10904093	chr10:436848	A/G	cg16386425	chr10:429943	DIP2C	0.47	9.45	0.4	1.7e-19	Psychosis in Alzheimer's disease;
LGG	cis	rs1109114	0.816	rs2963496	chr5:148597378	A/G	cg06539116	chr5:148597365	ABLIM3	-0.62	-16.52	-0.61	1.6e-48	Body mass index;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13732083	chr21:47605072	C21orf56	0.46	7.74	0.34	6.13e-14	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg07701084	chr6:150067640	NUP43	0.66	12.44	0.5	7.43e-31	Lung cancer;
LGG	cis	rs763121	0.853	rs5750662	chr22:39072472	G/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05654049	chr3:23852499	UBE2E1	-0.44	-7.82	-0.34	3.55e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.762	rs12211922	chr6:44847210	A/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs9768139	0.708	rs10234067	chr7:158114542	C/T	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.71	-0.34	7.65e-14	Calcium levels;
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg27476859	chr7:2772710	GNA12	0.39	6.68	0.3	7.02e-11	Height;
LGG	cis	rs10435719	0.902	rs7014580	chr8:11803262	C/G	cg00405596	chr8:11794950	NA	0.66	11.62	0.48	1.49e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs7267979	0.899	rs2179459	chr20:25456141	C/A	cg06421707	chr20:25228305	PYGB	0.47	10.0	0.42	1.85e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2228479	0.850	rs17226512	chr16:89839976	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.53	-0.37	2.16e-16	Skin colour saturation;
LGG	cis	rs1008375	0.931	rs6813374	chr4:17649494	T/C	cg18681998	chr4:17616180	MED28	0.87	20.33	0.69	3.74e-66	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9543976	0.920	rs9543972	chr13:76121675	T/C	cg01531495	chr13:76123901	UCHL3	0.62	7.55	0.33	2.36e-13	Diabetic retinopathy;
LGG	cis	rs7980687	0.657	rs10744151	chr12:123723735	G/C	cg05973401	chr12:123451056	ABCB9	0.5	8.08	0.35	5.69e-15	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs4843747	0.708	rs11866437	chr16:88072279	A/G	cg09044154	chr16:88155775	NA	0.46	7.06	0.31	6.01e-12	Menopause (age at onset);
LGG	cis	rs9894429	0.789	rs7219915	chr17:79591813	C/T	cg10661904	chr17:79619235	PDE6G	-0.4	-8.14	-0.35	3.63e-15	Eye color traits;
LGG	trans	rs7395662	1.000	rs1605364	chr11:48684843	G/T	cg03929089	chr4:120376271	NA	-0.44	-7.18	-0.32	2.85e-12	HDL cholesterol;
LGG	cis	rs9549367	0.789	rs2025247	chr13:113882564	C/G	cg18105134	chr13:113819100	PROZ	-0.7	-14.05	-0.55	1.31e-37	Platelet distribution width;
LGG	cis	rs1153858	1.000	rs2467864	chr15:45641098	C/T	cg21132104	chr15:45694354	SPATA5L1	-0.7	-10.45	-0.44	4.15e-23	Homoarginine levels;
LGG	cis	rs992157	0.560	rs6738394	chr2:219110625	G/A	cg04731861	chr2:219085781	ARPC2	0.51	13.22	0.52	4.52e-34	Colorectal cancer;
LGG	cis	rs7980687	0.628	rs1609520	chr12:123735937	A/G	cg05973401	chr12:123451056	ABCB9	-0.49	-7.76	-0.34	5.48e-14	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs1552244	0.572	rs3894323	chr3:10168967	G/A	cg00166722	chr3:10149974	C3orf24	0.55	7.97	0.35	1.28e-14	Alzheimer's disease;
LGG	cis	rs4919694	1.000	rs12242000	chr10:104702413	A/C	cg04362960	chr10:104952993	NT5C2	1.06	15.11	0.57	3.18e-42	Arsenic metabolism;
LGG	cis	rs4006360	0.553	rs71383383	chr17:39318172	T/A	cg16985667	chr17:39306289	KRTAP4-5	0.61	13.5	0.53	2.97e-35	Bipolar disorder and schizophrenia;
LGG	trans	rs7395662	0.606	rs11512384	chr11:48838187	A/G	cg15704280	chr7:45808275	SEPT13	-0.52	-8.5	-0.37	2.55e-16	HDL cholesterol;
LGG	cis	rs7582180	0.676	rs10048665	chr2:100933085	A/G	cg26150922	chr2:100937072	LONRF2	-0.6	-11.57	-0.47	2.21e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7084402	0.967	rs1658459	chr10:60299246	C/A	cg09696939	chr10:60272079	BICC1	-0.39	-7.66	-0.34	1.06e-13	Refractive error;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg06112835	chr11:68658793	MRPL21	0.59	9.89	0.42	4.61e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9463078	0.764	rs9367211	chr6:44885305	T/C	cg25276700	chr6:44698697	NA	-0.39	-8.46	-0.37	3.65e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg25447359	chr22:30790057	NA	-0.56	-6.8	-0.3	3.24e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8061903	0.710	rs17681592	chr16:9417495	C/T	cg03762483	chr16:10274847	GRIN2A	-0.41	-7.33	-0.32	1.02e-12	HIV-1 viral setpoint;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg05091796	chr16:4465799	CORO7	-0.61	-10.01	-0.42	1.74e-21	Schizophrenia;
LGG	cis	rs1401999	0.565	rs4912515	chr3:183653718	A/G	cg01324343	chr3:183735012	ABCC5	0.57	10.53	0.44	2.12e-23	Anterior chamber depth;
LGG	cis	rs548181	0.668	rs540555	chr11:125486848	T/C	cg03464685	chr11:125439445	EI24	1.33	20.07	0.68	6.39e-65	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7215564	0.818	rs35459747	chr17:78661475	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.65e-16	Myopia (pathological);
LGG	cis	rs9902453	0.817	rs2617881	chr17:28063275	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.41	-0.53	7.38e-35	Coffee consumption (cups per day);
LGG	cis	rs2070677	0.935	rs4350328	chr10:135414948	G/A	cg20169779	chr10:135381914	SYCE1	-0.99	-12.87	-0.51	1.34e-32	Gout;
LGG	cis	rs9397585	0.819	rs12527426	chr6:153392002	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.4	0.56	4.09e-39	Body mass index;
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg14159672	chr1:205819179	PM20D1	0.52	9.66	0.41	3.14e-20	Menarche (age at onset);
LGG	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg10621924	chr7:39171070	POU6F2	0.42	8.43	0.36	4.54e-16	IgG glycosylation;
LGG	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg06713675	chr4:122721982	EXOSC9	0.43	6.93	0.31	1.46e-11	Type 2 diabetes;
LGG	cis	rs2243480	1.000	rs781150	chr7:65480973	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.69	-0.41	2.46e-20	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.82	0.34	3.53e-14	Lung cancer;
LGG	cis	rs4650994	0.623	rs2248666	chr1:178620601	G/T	cg12486710	chr1:178512616	C1orf220	-0.38	-7.51	-0.33	3.01e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4481887	0.741	rs28616194	chr1:248531904	T/A	cg13385794	chr1:248469461	NA	0.45	8.0	0.35	1.02e-14	Common traits (Other);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20295040	chr1:192778396	RGS2	0.47	7.73	0.34	6.8e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs861020	1.000	rs642961	chr1:209989270	A/G	cg05527609	chr1:210001259	C1orf107	0.74	10.12	0.43	6.91e-22	Orofacial clefts;
LGG	cis	rs9291683	0.620	rs4444830	chr4:10124819	A/G	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.86	-0.3	2.2e-11	Bone mineral density;
LGG	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg23815491	chr16:72088622	HP	0.37	7.37	0.32	7.66e-13	Coronary artery disease;
LGG	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg02221750	chr19:17393354	ANKLE1	-0.63	-9.22	-0.39	1.09e-18	Systemic lupus erythematosus;
LGG	cis	rs7681440	0.874	rs1372523	chr4:90775923	G/A	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs2032447	0.898	rs807205	chr6:26075035	C/G	cg18357526	chr6:26021779	HIST1H4A	0.82	15.84	0.59	1.82e-45	Intelligence (multi-trait analysis);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02043159	chr4:134070235	PCDH10	0.58	6.66	0.3	8.01e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs9397585	0.857	rs9397126	chr6:153368561	G/C	cg17707550	chr6:153380415	RGS17	0.62	14.82	0.57	6.15e-41	Body mass index;
LGG	cis	rs2180341	0.814	rs9385424	chr6:127726796	A/G	cg27446573	chr6:127587934	RNF146	0.93	17.54	0.63	3.54e-53	Breast cancer;
LGG	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg14668632	chr7:2872130	GNA12	-0.35	-7.33	-0.32	1.06e-12	Height;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.53	-10.99	-0.45	3.89e-25	Personality dimensions;
LGG	trans	rs6076960	0.650	rs6516126	chr20:6165322	C/A	cg17788362	chr6:86352627	SYNCRIP	0.5	8.58	0.37	1.49e-16	Smooth-surface caries;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg21017887	chr14:105400489	NA	-0.39	-7.65	-0.33	1.19e-13	Rheumatoid arthritis;
LGG	cis	rs7191700	0.674	rs12597893	chr16:11426331	A/G	cg00044050	chr16:11439710	C16orf75	0.63	11.06	0.46	2.12e-25	Multiple sclerosis;
LGG	cis	rs8017423	0.967	rs11621364	chr14:90709115	A/G	cg04374321	chr14:90722782	PSMC1	0.89	18.93	0.66	1.26e-59	Mortality in heart failure;
LGG	cis	rs7928758	0.943	rs878987	chr11:134266372	A/G	cg15243474	chr11:134282918	B3GAT1	1.09	14.63	0.56	4.09e-40	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25704110	chr12:4967040	NA	0.5	7.43	0.33	5.24e-13	Gut microbiome composition (summer);
LGG	cis	rs8062405	0.824	rs153106	chr16:28526897	T/C	cg00204512	chr16:28754710	NA	0.25	7.23	0.32	1.98e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs36051895	0.623	rs3780382	chr9:5232299	G/A	cg02405213	chr9:5042618	JAK2	-0.77	-13.41	-0.53	7.33e-35	Pediatric autoimmune diseases;
LGG	cis	rs7084402	0.967	rs1649030	chr10:60279830	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.12	-0.64	7.26e-56	Refractive error;
LGG	cis	rs8133932	0.701	rs9637207	chr21:47283359	A/G	cg11214348	chr21:47283868	PCBP3	0.43	7.86	0.34	2.73e-14	Schizophrenia;
LGG	trans	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg16724585	chr3:197361211	NA	0.46	8.06	0.35	6.56e-15	Pancreatic cancer;
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg15133208	chr4:90757351	SNCA	-0.38	-8.72	-0.38	4.86e-17	Dementia with Lewy bodies;
LGG	cis	rs11252926	0.831	rs816570	chr10:680475	C/T	cg08603382	chr10:743973	NA	-0.66	-12.59	-0.51	1.82e-31	Psychosis in Alzheimer's disease;
LGG	trans	rs2562456	0.833	rs62107540	chr19:21518495	A/G	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg11878867	chr6:150167359	LRP11	-0.48	-9.85	-0.42	6.62e-21	Lung cancer;
LGG	cis	rs17453880	0.750	rs4262091	chr5:151925416	A/G	cg12297329	chr5:152029980	NA	0.64	13.55	0.53	1.79e-35	Subjective well-being;
LGG	cis	rs758324	0.626	rs676944	chr5:131288468	A/G	cg06307176	chr5:131281290	NA	0.53	8.41	0.36	4.99e-16	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1348850	0.540	rs10172355	chr2:178443225	A/G	cg27490568	chr2:178487706	NA	0.7	12.53	0.5	3.23e-31	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7647973	0.667	rs6446286	chr3:49681704	A/G	cg03060546	chr3:49711283	APEH	0.62	8.67	0.37	7.34e-17	Menarche (age at onset);
LGG	trans	rs9650657	0.771	rs12542888	chr8:10662555	A/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.08	-0.31	5.37e-12	Neuroticism;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs1008375	0.931	rs6449310	chr4:17575530	T/C	cg18681998	chr4:17616180	MED28	0.83	17.96	0.64	4.09e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7226408	0.625	rs2586786	chr18:34750687	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-8.98	-0.39	6.72e-18	Obesity-related traits;
LGG	cis	rs4555082	0.834	rs2816607	chr14:105718385	A/T	cg13114125	chr14:105738426	BRF1	-0.86	-16.22	-0.6	3.73e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs727563	0.635	rs5751149	chr22:42139501	A/G	cg06634786	chr22:41940651	POLR3H	0.76	12.2	0.49	6.91e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6502050	0.769	rs4789741	chr17:80119184	A/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2153535	0.580	rs1414340	chr6:8491139	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg21399703	chr1:247681439	NA	0.63	11.08	0.46	1.81e-25	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg18245976	chr7:158708271	WDR60	-0.57	-10.52	-0.44	2.44e-23	Height;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg05592184	chr3:40498513	RPL14	0.72	6.76	0.3	4.23e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs4718428	0.576	rs12698546	chr7:66266906	G/T	cg18252515	chr7:66147081	NA	-0.73	-11.3	-0.47	2.52e-26	Corneal structure;
LGG	cis	rs13082711	0.871	rs13061912	chr3:27495586	A/G	cg02860705	chr3:27208620	NA	0.69	12.44	0.5	7.18e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg25319279	chr11:5960081	NA	-0.45	-6.8	-0.3	3.14e-11	DNA methylation (variation);
LGG	cis	rs10463316	0.817	rs6897109	chr5:150777738	T/C	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.77	-0.41	1.23e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs2721811	0.535	rs2721805	chr7:24780316	C/T	cg19706795	chr7:24797839	DFNA5	-0.25	-6.72	-0.3	5.35e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4356975	0.563	rs6600891	chr4:69971596	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs35771425	1.000	rs11577134	chr1:211602624	A/G	cg10512769	chr1:211675356	NA	0.7	11.14	0.46	1.03e-25	Educational attainment (years of education);
LGG	trans	rs1005277	0.565	rs2474565	chr10:38380828	A/G	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.38e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs11148252	1.000	rs4886018	chr13:52990717	C/T	cg16301924	chr13:53314226	LECT1	-0.51	-10.83	-0.45	1.59e-24	Lewy body disease;
LGG	cis	rs2046867	0.862	rs6549483	chr3:72805316	T/G	cg26655873	chr3:72818019	SHQ1	0.35	7.24	0.32	1.93e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9767554	chr6:149937996	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.14	0.39	2.02e-18	Lung cancer;
LGG	cis	rs7216064	1.000	rs4791299	chr17:65930937	A/G	cg12091567	chr17:66097778	LOC651250	-0.62	-9.07	-0.39	3.45e-18	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg27400746	chr16:89904261	SPIRE2	-1.17	-17.4	-0.63	1.45e-52	Skin colour saturation;
LGG	trans	rs7980799	0.654	rs10844618	chr12:33625010	A/G	cg26384229	chr12:38710491	ALG10B	-0.64	-11.8	-0.48	2.7e-28	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21365899	chr1:231558446	EGLN1	0.46	6.89	0.3	1.85e-11	Gut microbiome composition (summer);
LGG	trans	rs6787172	0.702	rs827127	chr3:158012009	C/T	cg23275840	chr4:47708675	CORIN	0.4	8.64	0.37	9.35e-17	Subjective well-being;
LGG	trans	rs7829975	0.774	rs11775523	chr8:8679176	A/G	cg02002194	chr4:3960332	NA	-0.42	-7.95	-0.35	1.48e-14	Mood instability;
LGG	cis	rs11711311	0.824	rs35952547	chr3:113352501	G/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.49	0.5	4.52e-31	IgG glycosylation;
LGG	cis	rs1801251	0.752	rs2592126	chr2:233751377	A/G	cg08000102	chr2:233561755	GIGYF2	-0.43	-7.14	-0.31	3.61e-12	Coronary artery disease;
LGG	cis	rs2228479	0.681	rs11641790	chr16:89961957	A/G	cg27400746	chr16:89904261	SPIRE2	0.76	12.21	0.49	6.2e-30	Skin colour saturation;
LGG	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11890956	chr21:40555474	PSMG1	1.16	29.07	0.8	1.73e-106	Cognitive function;
LGG	cis	rs75920871	0.588	rs10892055	chr11:116868371	G/A	cg20608306	chr11:116969690	SIK3	-0.41	-10.96	-0.45	5.06e-25	Subjective well-being;
LGG	cis	rs2644899	0.715	rs2607415	chr19:41262687	C/G	cg24958765	chr19:41283667	RAB4B	-0.49	-7.52	-0.33	2.77e-13	Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7618501	0.933	rs3811695	chr3:49761613	C/T	cg21659725	chr3:3221576	CRBN	-0.92	-20.69	-0.69	8.38e-68	Intelligence (multi-trait analysis);
LGG	cis	rs9910055	0.659	rs7216294	chr17:42251095	T/C	cg13607699	chr17:42295918	UBTF	0.54	9.11	0.39	2.55e-18	Total body bone mineral density;
LGG	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.7	0.34	8.22e-14	Retinal vascular caliber;
LGG	cis	rs3790455	1.000	rs3790459	chr1:156461707	A/T	cg14087168	chr1:156450669	MEF2D	-0.46	-7.57	-0.33	2.06e-13	Migraine;
LGG	cis	rs6752107	1.000	rs6752107	chr2:234161448	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.42	7.72	0.34	7.03e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg05368731	chr17:41323189	NBR1	0.93	17.83	0.64	1.68e-54	Menopause (age at onset);
LGG	cis	rs7954584	0.635	rs7313252	chr12:122347600	G/A	cg13699009	chr12:122356056	WDR66	0.57	15.73	0.59	5.84e-45	Mean corpuscular volume;
LGG	cis	rs4959677	0.901	rs4959678	chr6:2503173	C/A	cg20147862	chr6:2634573	C6orf195	-0.4	-8.65	-0.37	8.6e-17	Orthostatic hypotension;
LGG	trans	rs208520	0.690	rs851459	chr6:66813989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.46	-0.65	2.06e-57	Exhaled nitric oxide output;
LGG	cis	rs10791097	0.694	rs2155751	chr11:130755240	G/A	cg09137382	chr11:130731461	NA	0.35	6.71	0.3	5.76e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7166081	1.000	rs12148121	chr15:67494922	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.06	-0.31	6.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7940866	0.801	rs2113928	chr11:130835975	A/G	cg12179176	chr11:130786555	SNX19	0.72	13.53	0.53	2.29e-35	Schizophrenia;
LGG	cis	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg13010199	chr12:38710504	ALG10B	0.74	15.57	0.59	2.91e-44	Heart rate;
LGG	cis	rs9291683	0.609	rs7678012	chr4:9993772	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	8.52	0.37	2.2e-16	Bone mineral density;
LGG	cis	rs11122272	0.701	rs2486725	chr1:231540288	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.15	-0.46	9.65e-26	Hemoglobin concentration;
LGG	cis	rs7149337	0.805	rs2999355	chr14:51607084	A/G	cg23942311	chr14:51606299	NA	0.32	7.09	0.31	5.16e-12	Cancer;
LGG	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg18655438	chr5:1077845	SLC12A7	0.36	6.73	0.3	4.99e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.47	-0.53	4.02e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.741	rs11264283	chr1:154869552	A/G	cg03351412	chr1:154909251	PMVK	0.67	13.01	0.52	3.38e-33	Prostate cancer;
LGG	trans	rs61931739	0.517	rs7960878	chr12:34055645	C/A	cg13010199	chr12:38710504	ALG10B	0.56	10.44	0.44	4.76e-23	Morning vs. evening chronotype;
LGG	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg27624424	chr6:160112604	SOD2	0.64	9.33	0.4	4.51e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7106204	0.748	rs28656439	chr11:24207653	G/C	ch.11.24196551F	chr11:24239977	NA	0.99	15.61	0.59	1.93e-44	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4631830	0.863	rs10826127	chr10:51530757	G/A	cg10326726	chr10:51549505	MSMB	-0.7	-14.51	-0.56	1.31e-39	Prostate-specific antigen levels;
LGG	cis	rs7208859	0.673	rs1347359	chr17:28914529	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.75	-0.38	3.9e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs9689723	chr6:149977071	C/A	cg00424166	chr6:150045504	NUP43	-0.35	-7.28	-0.32	1.46e-12	Lung cancer;
LGG	cis	rs1218582	0.804	rs4845678	chr1:154853295	A/G	cg09359103	chr1:154839909	KCNN3	-0.5	-10.35	-0.43	1.05e-22	Prostate cancer;
LGG	cis	rs4900538	0.855	rs12587464	chr14:102886561	G/C	cg18135206	chr14:102964638	TECPR2	-0.68	-12.11	-0.49	1.56e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs62238980	0.522	rs78117433	chr22:32421224	G/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2439831	0.850	rs524417	chr15:43772374	C/T	cg15269541	chr15:43626905	ADAL	-0.42	-7.07	-0.31	5.87e-12	Lung cancer in ever smokers;
LGG	cis	rs2204008	0.775	rs8186812	chr12:38305055	C/T	cg26384229	chr12:38710491	ALG10B	0.9	20.08	0.68	5.52e-65	Bladder cancer;
LGG	trans	rs8002861	0.935	rs9525865	chr13:44459647	A/T	cg17145862	chr1:211918768	LPGAT1	0.98	26.2	0.77	1.75e-93	Leprosy;
LGG	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.4	-0.36	5.67e-16	Total body bone mineral density;
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg26116260	chr4:7069785	GRPEL1	1.15	19.9	0.68	4.17e-64	Monocyte percentage of white cells;
LGG	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg06637938	chr14:75390232	RPS6KL1	0.54	9.89	0.42	4.63e-21	Height;
LGG	trans	rs453301	0.658	rs6983877	chr8:8904639	T/C	cg21775007	chr8:11205619	TDH	-0.46	-7.4	-0.33	6.63e-13	Joint mobility (Beighton score);
LGG	cis	rs9611565	0.649	rs202666	chr22:41814719	T/C	cg06634786	chr22:41940651	POLR3H	0.75	12.38	0.5	1.35e-30	Vitiligo;
LGG	cis	rs4555082	0.874	rs2142190	chr14:105719306	G/A	cg06808227	chr14:105710500	BRF1	-0.62	-10.61	-0.44	1.07e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs8067545	0.641	rs4925060	chr17:19863258	C/G	cg13482628	chr17:19912719	NA	0.52	9.57	0.41	6.7e-20	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg15971980	chr6:150254442	NA	0.44	8.46	0.37	3.5e-16	Lung cancer;
LGG	cis	rs4356975	0.563	rs4364327	chr4:69973692	C/T	cg27372994	chr4:70080453	UGT2B11	0.37	6.68	0.3	6.7e-11	Obesity-related traits;
LGG	cis	rs875971	0.838	rs2173570	chr7:65762963	T/A	cg11764359	chr7:65958608	NA	-0.79	-14.76	-0.57	1.1e-40	Aortic root size;
LGG	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10341991	chr3:48229869	CDC25A	-0.43	-6.74	-0.3	4.75e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
LGG	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg05194412	chr2:137003533	NA	-0.31	-6.7	-0.3	6.06e-11	Arthritis (juvenile idiopathic);
LGG	cis	rs2643217	0.953	rs903532	chr15:38997904	C/T	cg10631289	chr15:39006617	NA	-0.43	-7.44	-0.33	4.9e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs7192750	0.586	rs8057124	chr16:71972409	T/C	cg06353428	chr16:71660113	MARVELD3	0.66	10.18	0.43	4.35e-22	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs950169	1.000	rs34751999	chr15:84758419	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	cis	rs6800768	0.633	rs826373	chr3:24163773	C/G	cg10674438	chr3:24145617	LOC152024	-0.52	-9.4	-0.4	2.43e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs34311866	0.808	rs11248060	chr4:964359	C/T	cg07828340	chr4:882639	GAK	0.81	9.0	0.39	5.65e-18	Parkinson's disease;
LGG	cis	rs4481887	0.741	rs11485458	chr1:248569050	A/G	cg13385794	chr1:248469461	NA	0.43	7.38	0.32	7.24e-13	Common traits (Other);
LGG	trans	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.55	0.33	2.37e-13	Retinal vascular caliber;
LGG	cis	rs6121246	0.909	rs6060929	chr20:30345914	C/T	cg13852791	chr20:30311386	BCL2L1	0.78	12.69	0.51	6.98e-32	Mean corpuscular hemoglobin;
LGG	trans	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg02002194	chr4:3960332	NA	0.4	7.4	0.33	6.58e-13	Joint mobility (Beighton score);
LGG	cis	rs4780401	0.933	rs4780395	chr16:11809940	A/G	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.05	-0.31	6.5e-12	Rheumatoid arthritis;
LGG	cis	rs6952808	0.723	rs4721295	chr7:2036669	G/T	cg19147804	chr7:1989927	MAD1L1	0.54	10.98	0.45	4.27e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg02127607	chr17:61920694	SMARCD2	0.47	8.46	0.37	3.54e-16	Prudent dietary pattern;
LGG	cis	rs3806843	0.676	rs2245640	chr5:140029958	A/G	cg19875535	chr5:140030758	IK	-0.59	-12.23	-0.49	5.46e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs951366	0.789	rs864783	chr1:205711974	T/C	cg07167872	chr1:205819463	PM20D1	0.57	11.55	0.47	2.69e-27	Menarche (age at onset);
LGG	cis	rs10088262	0.629	rs1367829	chr8:124797135	A/G	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.82	-0.34	3.6e-14	Pancreatic cancer;
LGG	cis	rs9291683	0.597	rs11723016	chr4:10126189	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.93	-0.35	1.65e-14	Bone mineral density;
LGG	cis	rs1003719	0.737	rs2835587	chr21:38461795	A/T	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs367943	0.608	rs2972662	chr5:112990330	C/T	cg12552261	chr5:112820674	MCC	-0.5	-8.85	-0.38	1.84e-17	Type 2 diabetes;
LGG	cis	rs9467711	0.790	rs1979	chr6:26377591	G/T	cg12826209	chr6:26865740	GUSBL1	0.76	7.98	0.35	1.15e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7633770	0.710	rs11710586	chr3:46693457	A/G	cg11219411	chr3:46661640	NA	-0.55	-12.45	-0.5	6.69e-31	Coronary artery disease;
LGG	cis	rs60871478	0.735	rs4721501	chr7:862166	G/T	cg13798912	chr7:905769	UNC84A	-0.59	-7.35	-0.32	8.9e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs2836974	0.568	rs442972	chr21:40534757	C/T	cg06238570	chr21:40685208	BRWD1	-0.53	-8.78	-0.38	3.1e-17	Cognitive function;
LGG	cis	rs6728642	0.708	rs56807297	chr2:97861340	A/C	cg26665480	chr2:98280029	ACTR1B	-0.77	-8.35	-0.36	7.96e-16	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs9291683	0.632	rs7679916	chr4:10042160	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	cis	rs7953508	0.711	rs10492321	chr12:93980088	T/A	cg18151635	chr12:93972918	NA	-0.48	-8.54	-0.37	1.91e-16	Pubertal anthropometrics;
LGG	cis	rs4936891	0.520	rs61908589	chr11:123869583	C/T	cg22125253	chr11:123886957	OR10G4	-0.47	-7.9	-0.34	2.08e-14	Male fertility;
LGG	cis	rs4604732	0.631	rs12091081	chr1:247623064	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.65	9.76	0.41	1.39e-20	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9964724	0.559	rs9955296	chr18:35156537	G/T	cg27332583	chr18:35150602	NA	-0.63	-12.93	-0.52	6.95e-33	Educational attainment (years of education);
LGG	cis	rs2404602	0.672	rs35374222	chr15:77071394	G/T	cg15268244	chr15:77196840	NA	0.49	10.45	0.44	4.42e-23	Blood metabolite levels;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.85	0.3	2.3e-11	Longevity;
LGG	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg23845249	chr11:68861649	NA	0.45	8.2	0.36	2.42e-15	Blond vs. brown hair color;
LGG	cis	rs57221529	0.709	rs72707023	chr5:667620	G/A	cg07777115	chr5:623756	CEP72	-0.56	-6.66	-0.3	7.57e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.67	-0.3	7.33e-11	Lung cancer;
LGG	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11764359	chr7:65958608	NA	0.57	9.59	0.41	5.56e-20	Aortic root size;
LGG	cis	rs657075	0.697	rs3805673	chr5:131659103	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.26e-15	Rheumatoid arthritis;
LGG	cis	rs2120019	1.000	rs7175720	chr15:75348962	C/G	cg09165964	chr15:75287851	SCAMP5	1.01	19.61	0.67	9.15e-63	Blood trace element (Zn levels);
LGG	trans	rs7824557	0.585	rs2572382	chr8:11211302	T/G	cg08975724	chr8:8085496	FLJ10661	0.39	7.21	0.32	2.35e-12	Retinal vascular caliber;
LGG	cis	rs11148252	0.538	rs9535887	chr13:52730761	G/A	cg00495681	chr13:53174319	NA	0.58	10.41	0.44	5.94e-23	Lewy body disease;
LGG	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg08999081	chr20:33150536	PIGU	0.31	7.38	0.32	7.17e-13	Coronary artery disease;
LGG	cis	rs3815700	0.925	rs414496	chr19:33106761	A/G	cg02997394	chr19:33096574	ANKRD27	0.55	8.69	0.37	6.13e-17	Eosinophilic esophagitis;
LGG	cis	rs4563143	0.675	rs55884228	chr19:29243897	G/T	cg03161606	chr19:29218774	NA	0.69	10.64	0.44	8.63e-24	Methadone dose in opioid dependence;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg22535103	chr8:58192502	C8orf71	-1.01	-15.82	-0.59	2.18e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs7618501	0.633	rs2526751	chr3:50064867	T/C	cg05623727	chr3:50126028	RBM5	-0.32	-6.98	-0.31	1.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg07167872	chr1:205819463	PM20D1	0.38	7.02	0.31	7.88e-12	Menarche (age at onset);
LGG	cis	rs78366141	0.649	rs17014620	chr4:89737376	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.98	8.31	0.36	1.03e-15	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs4713118	0.547	rs2116981	chr6:28067951	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs4771122	0.728	rs7992289	chr13:28036430	G/A	cg01674679	chr13:27998804	GTF3A	0.52	7.0	0.31	9.29e-12	Body mass index;
LGG	cis	rs36051895	0.530	rs6476951	chr9:5221614	A/G	cg02405213	chr9:5042618	JAK2	-0.72	-13.42	-0.53	6.55e-35	Pediatric autoimmune diseases;
LGG	cis	rs526231	0.615	rs26818	chr5:102529719	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.31	-0.36	1.1e-15	Primary biliary cholangitis;
LGG	cis	rs738322	0.967	rs133018	chr22:38572761	G/A	cg25457927	chr22:38595422	NA	-0.42	-10.74	-0.45	3.63e-24	Cutaneous nevi;
LGG	cis	rs4774899	0.934	rs12912810	chr15:57488378	G/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.75	-0.3	4.44e-11	Urinary tract infection frequency;
LGG	cis	rs12497850	0.931	rs3774628	chr3:48801840	C/T	cg06212747	chr3:49208901	KLHDC8B	0.66	11.39	0.47	1.13e-26	Parkinson's disease;
LGG	cis	rs1797081	0.542	rs2603796	chr10:16871456	C/T	cg23933602	chr10:16859644	RSU1	0.79	16.42	0.61	4.28e-48	Platelet distribution width;
LGG	cis	rs17270561	0.636	rs9379782	chr6:25715023	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.15	-0.32	3.35e-12	Iron status biomarkers;
LGG	cis	rs711245	0.573	rs3770796	chr2:36799515	T/C	cg15105969	chr2:36825350	FEZ2	0.51	7.91	0.35	1.85e-14	Height;
LGG	cis	rs3761847	0.622	rs4837807	chr9:123792005	G/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	10.03	0.42	1.48e-21	Rheumatoid arthritis;
LGG	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg08773314	chr2:239334832	ASB1	0.42	8.07	0.35	6.05e-15	Multiple system atrophy;
LGG	trans	rs6582630	0.599	rs7967598	chr12:38540760	C/T	cg06521331	chr12:34319734	NA	0.42	7.58	0.33	1.94e-13	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg07107441	chr3:10157155	C3orf10	-0.4	-7.46	-0.33	4.26e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582720	0.943	rs72936839	chr2:203773237	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.73	0.41	1.82e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2084898	1.000	rs12420591	chr11:120061195	A/G	cg07435449	chr11:120005650	TRIM29	-0.58	-6.83	-0.3	2.62e-11	Stroke (pediatric);
LGG	cis	rs7223966	0.515	rs2727315	chr17:61961458	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	6.97	0.31	1.1e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.45	0.37	3.9e-16	Mood instability;
LGG	cis	rs1318772	1.000	rs11750254	chr5:112718137	T/C	cg12552261	chr5:112820674	MCC	0.67	7.82	0.34	3.6e-14	F-cell distribution;
LGG	cis	rs6542838	0.582	rs6542845	chr2:99537600	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.52	-0.33	2.83e-13	Fear of minor pain;
LGG	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg16850897	chr7:100343110	ZAN	-0.69	-10.11	-0.43	7.54e-22	Other erythrocyte phenotypes;
LGG	cis	rs3824867	0.920	rs4282946	chr11:47456202	G/A	cg20307385	chr11:47447363	PSMC3	0.47	7.59	0.33	1.78e-13	Mean corpuscular hemoglobin;
LGG	cis	rs72781680	0.898	rs56303870	chr2:24086944	G/A	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.34e-18	Lymphocyte counts;
LGG	cis	rs2576037	0.583	rs2164104	chr18:44567743	G/C	cg19077165	chr18:44547161	KATNAL2	0.69	13.24	0.52	3.84e-34	Personality dimensions;
LGG	cis	rs8072100	0.688	rs8079142	chr17:45442049	G/A	cg25173405	chr17:45401733	C17orf57	-0.57	-9.46	-0.4	1.54e-19	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs11148252	0.595	rs4884522	chr13:53053768	C/A	cg05335186	chr13:53173507	NA	0.75	18.05	0.64	1.55e-55	Lewy body disease;
LGG	cis	rs2288073	0.896	rs13404513	chr2:24410780	G/A	cg06627628	chr2:24431161	ITSN2	-0.67	-10.78	-0.45	2.46e-24	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6951245	1.000	rs11763793	chr7:1094342	A/G	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6582630	0.502	rs11610978	chr12:38356957	C/G	cg13010199	chr12:38710504	ALG10B	0.65	13.38	0.53	9.19e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg11473876	chr11:109292803	C11orf87	0.48	9.54	0.41	8.22e-20	Schizophrenia;
LGG	cis	rs3806843	0.766	rs801399	chr5:140034844	C/T	cg19875535	chr5:140030758	IK	-0.53	-10.84	-0.45	1.49e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4660214	0.615	rs597708	chr1:39820963	G/C	cg18385671	chr1:39797026	MACF1	0.46	9.65	0.41	3.32e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs116095464	0.558	rs10057674	chr5:266813	C/T	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs4481887	0.962	rs6663952	chr1:248465682	A/G	cg00666640	chr1:248458726	OR2T12	0.61	9.93	0.42	3.52e-21	Common traits (Other);
LGG	trans	rs11875185	0.510	rs77721848	chr18:55621452	C/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.71	-0.38	5.52e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9486719	0.843	rs2472875	chr6:96844691	G/A	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg05234568	chr11:5960015	NA	0.57	10.16	0.43	5.18e-22	DNA methylation (variation);
LGG	cis	rs6430585	0.591	rs309170	chr2:136672775	C/T	cg07169764	chr2:136633963	MCM6	1.15	20.62	0.69	1.65e-67	Corneal structure;
LGG	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg17201900	chr20:34330562	RBM39	0.51	6.93	0.31	1.37e-11	Total cholesterol levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07003055	chr20:3776921	CDC25B	0.44	6.97	0.31	1.13e-11	Cognitive performance;
LGG	cis	rs274567	0.711	rs404771	chr5:131635092	A/T	cg07395648	chr5:131743802	NA	-0.48	-9.67	-0.41	2.76e-20	Blood metabolite levels;
LGG	cis	rs920590	0.560	rs7823457	chr8:19671334	G/A	cg03894339	chr8:19674705	INTS10	-0.52	-8.82	-0.38	2.33e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.41	-0.33	5.89e-13	Triglycerides;
LGG	cis	rs11105298	0.891	rs11105309	chr12:89909850	T/C	cg00757033	chr12:89920650	WDR51B	0.65	9.63	0.41	4.11e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs10752881	1.000	rs4454510	chr1:182982303	A/G	cg07245641	chr1:182991651	LAMC1	-0.41	-9.53	-0.4	9.08e-20	Colorectal cancer;
LGG	cis	rs7192750	0.586	rs3794692	chr16:71961339	T/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.62	0.44	1.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs7647973	0.626	rs11130217	chr3:49737323	A/G	cg03060546	chr3:49711283	APEH	0.6	8.45	0.37	3.75e-16	Menarche (age at onset);
LGG	cis	rs62238980	0.614	rs80100377	chr22:32368167	G/A	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs7385804	0.796	rs221799	chr7:100288545	G/A	cg20848291	chr7:100343083	ZAN	0.45	7.14	0.31	3.65e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg02071572	chr4:1403502	NA	-0.39	-6.66	-0.3	7.65e-11	Longevity;
LGG	cis	rs7824557	0.767	rs7003241	chr8:11169075	A/G	cg21775007	chr8:11205619	TDH	0.62	10.2	0.43	3.44e-22	Retinal vascular caliber;
LGG	cis	rs1348850	0.914	rs12616443	chr2:178315751	A/G	cg27490568	chr2:178487706	NA	0.47	9.45	0.4	1.68e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7264396	0.790	rs6060542	chr20:34249061	C/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.51	7.5	0.33	3.25e-13	Total cholesterol levels;
LGG	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	cis	rs2067615	0.929	rs752046	chr12:107111560	A/G	cg15890332	chr12:107067104	RFX4	0.3	8.46	0.37	3.43e-16	Heart rate;
LGG	cis	rs2243480	1.000	rs437889	chr7:65509234	G/A	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	cis	rs7945705	0.935	rs2568062	chr11:8887945	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.17	-0.49	9.64e-30	Hemoglobin concentration;
LGG	cis	rs981844	0.961	rs56288418	chr4:154668228	C/A	cg14289246	chr4:154710475	SFRP2	0.69	11.51	0.47	4.02e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs9322193	0.923	rs4869750	chr6:150177132	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.11	-0.46	1.36e-25	Lung cancer;
LGG	cis	rs17767392	0.748	rs7159252	chr14:71704016	A/G	cg02058870	chr14:72053146	SIPA1L1	0.35	7.02	0.31	7.96e-12	Mitral valve prolapse;
LGG	cis	rs9948	0.500	rs62152903	chr2:97570377	T/C	cg26665480	chr2:98280029	ACTR1B	-0.68	-8.28	-0.36	1.38e-15	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg04025307	chr7:1156635	C7orf50	0.83	16.96	0.62	1.64e-50	Longevity;Endometriosis;
LGG	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg10560079	chr2:191398806	TMEM194B	0.36	7.92	0.35	1.82e-14	Pulse pressure;
LGG	cis	rs6754311	0.731	rs3769005	chr2:136603366	C/G	cg07169764	chr2:136633963	MCM6	-0.76	-12.98	-0.52	4.59e-33	Mosquito bite size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27481720	chr19:797202	PTBP1	0.5	7.63	0.33	1.32e-13	Gut microbiome composition (summer);
LGG	cis	rs17401966	0.838	rs7553935	chr1:10375179	G/A	cg15208524	chr1:10270712	KIF1B	0.41	7.12	0.31	4.01e-12	Hepatocellular carcinoma;
LGG	cis	rs2576037	0.796	rs2576043	chr18:44573476	C/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.44	7.44	0.33	4.94e-13	Personality dimensions;
LGG	cis	rs6089584	0.861	rs2180302	chr20:60576369	A/G	cg06470251	chr20:60548479	NA	0.49	8.43	0.36	4.34e-16	Body mass index;
LGG	trans	rs9467603	1.000	rs9467607	chr6:25809477	G/A	cg06606381	chr12:133084897	FBRSL1	-0.73	-6.82	-0.3	2.84e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg06718696	chr17:78121285	EIF4A3	0.42	6.99	0.31	9.39e-12	Yeast infection;
LGG	cis	rs8180040	0.967	rs4858890	chr3:47405456	A/G	cg27129171	chr3:47204927	SETD2	-0.81	-15.32	-0.58	3.62e-43	Colorectal cancer;
LGG	cis	rs1008375	1.000	rs11727312	chr4:17669185	C/T	cg16339924	chr4:17578868	LAP3	0.59	10.45	0.44	4.44e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg05835009	chr4:710272	PCGF3	0.48	8.25	0.36	1.66e-15	White blood cell count;
LGG	cis	rs3741404	0.895	rs2429455	chr11:63995302	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	18.41	0.65	3.4e-57	Platelet count;
LGG	cis	rs4132509	0.793	rs10803152	chr1:243846167	C/A	cg21452805	chr1:244014465	NA	0.92	9.97	0.42	2.49e-21	RR interval (heart rate);
LGG	cis	rs6762	0.748	rs1130719	chr11:838760	T/A	cg10580341	chr11:889148	CHID1	-0.38	-6.88	-0.3	1.91e-11	Mean platelet volume;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs2274273	0.624	rs8015211	chr14:55841447	A/G	cg04306507	chr14:55594613	LGALS3	0.52	12.08	0.49	2.16e-29	Protein biomarker;
LGG	cis	rs75804782	0.641	rs57080728	chr2:239350487	T/C	cg18131467	chr2:239335373	ASB1	-0.66	-6.66	-0.3	8.01e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7223966	0.729	rs7921	chr17:62006259	G/A	cg18032289	chr17:61959525	GH2	-0.43	-7.11	-0.31	4.53e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs34421088	0.560	rs2467520	chr8:11398953	T/C	cg02002194	chr4:3960332	NA	0.54	10.67	0.44	6.35e-24	Neuroticism;
LGG	cis	rs988958	0.565	rs12995780	chr2:42218610	C/T	cg27428208	chr2:42229179	NA	0.52	8.07	0.35	6.05e-15	Hypospadias;
LGG	cis	rs7267979	0.966	rs416745	chr20:25438868	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.26	0.43	2.23e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2708977	0.666	rs17685664	chr2:97315570	C/T	cg01950434	chr2:97203154	ARID5A	0.5	7.6	0.33	1.68e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9549367	0.789	rs6577031	chr13:113878182	T/C	cg18105134	chr13:113819100	PROZ	0.64	13.17	0.52	7.05e-34	Platelet distribution width;
LGG	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg05692746	chr2:100937584	LONRF2	-0.58	-9.37	-0.4	3.22e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg21545522	chr1:205238299	TMCC2	0.37	7.26	0.32	1.7e-12	Red blood cell count;
LGG	cis	rs457717	0.730	rs2431364	chr5:75945477	T/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	cis	rs920590	0.717	rs62496675	chr8:19635733	A/T	cg01411142	chr8:19674711	INTS10	0.43	6.84	0.3	2.48e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs738321	0.690	rs11570750	chr22:38513138	G/A	cg03162506	chr22:38580953	NA	0.36	8.6	0.37	1.27e-16	Breast cancer;
LGG	cis	rs11148252	0.532	rs9536262	chr13:53303074	A/C	cg02158880	chr13:53174818	NA	-0.73	-16.3	-0.6	1.57e-47	Lewy body disease;
LGG	trans	rs2243480	0.764	rs2460423	chr7:65601216	A/T	cg10756647	chr7:56101905	PSPH	0.79	9.23	0.39	1e-18	Diabetic kidney disease;
LGG	cis	rs9926296	0.512	rs11076626	chr16:89865103	T/A	cg27121462	chr16:89883253	FANCA	0.62	11.59	0.47	1.97e-27	Vitiligo;
LGG	cis	rs7927592	0.913	rs67605986	chr11:68300955	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs17767392	0.628	rs72726702	chr14:71733320	A/T	cg02058870	chr14:72053146	SIPA1L1	0.36	7.66	0.34	1.08e-13	Mitral valve prolapse;
LGG	cis	rs6496044	0.568	rs4842888	chr15:86063133	C/T	cg13263323	chr15:86062960	AKAP13	0.37	8.22	0.36	2.06e-15	Interstitial lung disease;
LGG	cis	rs8180040	0.726	rs13094672	chr3:47149439	C/T	cg27129171	chr3:47204927	SETD2	0.83	15.44	0.58	1.06e-43	Colorectal cancer;
LGG	cis	rs4665809	1.000	rs4665809	chr2:26251361	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.8	12.94	0.52	6.87e-33	Gut microbiome composition (summer);
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.34	0.32	9.68e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4481887	0.927	rs4244184	chr1:248486895	G/T	cg00666640	chr1:248458726	OR2T12	0.57	9.17	0.39	1.58e-18	Common traits (Other);
LGG	cis	rs6963495	0.651	rs3892298	chr7:105152187	A/G	cg19920283	chr7:105172520	RINT1	0.6	7.91	0.34	1.95e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs2727020	0.521	rs2088526	chr11:49531968	G/A	cg11707556	chr5:10655725	ANKRD33B	0.66	11.31	0.47	2.37e-26	Coronary artery disease;
LGG	cis	rs35146811	0.771	rs6465762	chr7:99620554	G/A	cg13334819	chr7:99746414	C7orf59	-0.46	-7.08	-0.31	5.33e-12	Coronary artery disease;
LGG	cis	rs2072499	1.000	rs2241107	chr1:156182710	C/T	cg24450063	chr1:156163899	SLC25A44	-1.15	-26.84	-0.78	2.16e-96	Testicular germ cell tumor;
LGG	cis	rs1862618	0.853	rs43184	chr5:56141777	G/C	cg12654349	chr5:56205094	C5orf35	-0.66	-10.31	-0.43	1.45e-22	Initial pursuit acceleration;
LGG	cis	rs9487094	0.961	rs9480957	chr6:109751601	C/T	cg16315928	chr6:109776240	MICAL1	0.52	8.55	0.37	1.74e-16	Height;
LGG	cis	rs4822044	0.680	rs8138780	chr22:42097462	A/T	cg06634786	chr22:41940651	POLR3H	0.77	12.23	0.49	5.27e-30	Cannabis dependence symptom count;
LGG	cis	rs75229567	0.618	rs11177853	chr12:70184924	A/G	cg10114359	chr12:70132523	RAB3IP	1.39	11.1	0.46	1.49e-25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs17666538	0.710	rs11987001	chr8:630755	T/C	cg23958373	chr8:599963	NA	1.26	11.68	0.48	8.12e-28	IgG glycosylation;
LGG	cis	rs9858542	0.953	rs6779524	chr3:49450449	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.38	0.32	7.47e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs12144044	0.869	rs3806441	chr1:113249524	G/C	cg19507217	chr1:113251308	RHOC	-0.58	-10.51	-0.44	2.58e-23	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg08280861	chr8:58055591	NA	0.5	6.71	0.3	5.79e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg09021430	chr5:549028	NA	-0.78	-12.54	-0.5	3.01e-31	Obesity-related traits;
LGG	cis	rs6909430	0.731	rs12526299	chr6:98621599	C/T	cg12860156	chr6:98744658	NA	-0.38	-6.78	-0.3	3.59e-11	Quantitative traits;
LGG	cis	rs9916302	0.808	rs12948906	chr17:37644854	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.85	-0.59	1.65e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs8005745	0.614	rs7143164	chr14:62166755	G/C	cg01748970	chr14:62088363	NA	0.79	9.61	0.41	4.68e-20	Select biomarker traits;
LGG	cis	rs959260	0.588	rs2385263	chr17:73321117	T/C	cg14668889	chr17:73230827	NUP85	-0.51	-8.62	-0.37	1.08e-16	Systemic lupus erythematosus;
LGG	cis	rs11622475	1.000	rs34964872	chr14:104448435	T/A	cg20488157	chr14:104394430	TDRD9	0.56	9.11	0.39	2.48e-18	Bipolar disorder;
LGG	cis	rs12230513	0.732	rs61956327	chr12:55828708	C/T	cg19537932	chr12:55886519	OR6C68	-0.61	-11.06	-0.46	2.19e-25	Contrast sensitivity;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.68	-12.58	-0.5	2.02e-31	Obesity-related traits;
LGG	cis	rs9640161	0.750	rs3735167	chr7:150039555	C/T	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.76	-15.58	-0.59	2.69e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs6060987	1	rs6060987	chr20:30427077	T/A	cg04935436	chr20:30431758	NA	0.39	6.74	0.3	4.61e-11	Mean corpuscular volume;
LGG	cis	rs3733346	0.521	rs3775113	chr4:901323	C/T	cg15105011	chr4:940614	TMEM175	0.41	7.38	0.32	7.52e-13	Sjögren's syndrome;
LGG	cis	rs9325144	0.560	rs10506127	chr12:39126686	C/G	cg13010199	chr12:38710504	ALG10B	-0.51	-10.15	-0.43	5.5e-22	Morning vs. evening chronotype;
LGG	cis	rs992157	1.000	rs3731859	chr2:219124222	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.66	11.34	0.47	1.88e-26	Colorectal cancer;
LGG	cis	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg15556689	chr8:8085844	FLJ10661	0.38	6.68	0.3	6.98e-11	Neuroticism;
LGG	cis	rs4253772	0.550	rs6007819	chr22:46704916	C/G	cg09461388	chr22:46763229	CELSR1	-0.59	-6.66	-0.3	7.9e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs76419734	0.510	rs7659526	chr4:106621643	T/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.72	10.66	0.44	7.33e-24	Post bronchodilator FEV1;
LGG	cis	rs7312933	1.000	rs12372597	chr12:42412850	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.54	0.33	2.52e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg06636001	chr8:8085503	FLJ10661	0.57	10.3	0.43	1.57e-22	Red cell distribution width;
LGG	cis	rs1801251	1.000	rs9653383	chr2:233670380	A/C	cg08000102	chr2:233561755	GIGYF2	-0.6	-9.72	-0.41	1.9e-20	Coronary artery disease;
LGG	cis	rs875971	0.895	rs10447522	chr7:65796074	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs1046896	0.538	rs3803771	chr17:80687758	G/A	cg16060761	chr17:80687452	NA	0.54	9.88	0.42	4.95e-21	Glycated hemoglobin levels;
LGG	cis	rs60871478	0.898	rs4720929	chr7:808009	T/C	cg05535760	chr7:792225	HEATR2	0.79	12.67	0.51	8.73e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs7599312	0.586	rs7565257	chr2:213388276	G/A	cg20637307	chr2:213403960	ERBB4	0.51	8.74	0.38	4.2e-17	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.14	0.6	8.41e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2836974	0.897	rs2836923	chr21:40524236	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.76	0.3	4.11e-11	Cognitive function;
LGG	cis	rs62238980	0.521	rs117792024	chr22:32379444	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs7119	0.717	rs12911963	chr15:77807175	G/C	cg10437265	chr15:77819839	NA	0.25	6.84	0.3	2.52e-11	Type 2 diabetes;
LGG	cis	rs5750830	0.649	rs5750814	chr22:39797987	T/C	cg11247378	chr22:39784982	NA	-0.32	-9.24	-0.39	9.12e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.659	rs12484694	chr22:41919330	A/G	cg06634786	chr22:41940651	POLR3H	-0.78	-12.76	-0.51	3.67e-32	Vitiligo;
LGG	cis	rs2201728	0.714	rs1497377	chr4:100161888	A/G	cg07219303	chr4:100140905	ADH6	-0.38	-6.96	-0.31	1.18e-11	Cardiac Troponin-T levels;
LGG	trans	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg06437703	chr8:37914619	EIF4EBP1	-0.75	-14.01	-0.55	2.04e-37	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9325144	0.647	rs12822023	chr12:39097964	T/C	cg13010199	chr12:38710504	ALG10B	-0.54	-10.1	-0.42	8.54e-22	Morning vs. evening chronotype;
LGG	trans	rs7786808	0.782	rs7787923	chr7:158227312	A/G	cg02030672	chr11:45687055	CHST1	0.43	7.61	0.33	1.5700000000000001e-13	Obesity-related traits;
LGG	trans	rs1459104	0.929	rs2017467	chr11:55234605	G/A	cg15704280	chr7:45808275	SEPT13	0.7	6.67	0.3	7.28e-11	Body mass index;
LGG	cis	rs13421350	0.579	rs2293648	chr2:173352157	A/T	cg15021238	chr2:173305865	ITGA6	-0.79	-8.48	-0.37	3.07e-16	Diabetic kidney disease;
LGG	trans	rs9951602	0.512	rs7232551	chr18:76650702	G/A	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs11098499	0.743	rs10003567	chr4:120241674	C/T	cg09307838	chr4:120376055	NA	0.72	12.42	0.5	9.37e-31	Corneal astigmatism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg14407698	chr9:34458886	C9orf25;DNAI1	0.36	6.66	0.3	7.95e-11	Obesity-related traits;
LGG	cis	rs4689388	0.889	rs10026334	chr4:6294607	G/A	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs832540	0.898	rs252890	chr5:56226410	T/C	cg12654349	chr5:56205094	C5orf35	-0.42	-7.51	-0.33	3.08e-13	Coronary artery disease;
LGG	cis	rs1552244	1.000	rs56270432	chr3:10087517	G/C	cg00149659	chr3:10157352	C3orf10	0.83	10.6	0.44	1.17e-23	Alzheimer's disease;
LGG	cis	rs561341	1.000	rs72825712	chr17:30316119	A/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	trans	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.25	0.49	4.32e-30	Corneal astigmatism;
LGG	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg08847335	chr10:891726	LARP4B	-0.5	-8.98	-0.39	6.73e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.962	rs1112730	chr6:150087519	G/A	cg09699651	chr6:150184138	LRP11	0.49	8.7	0.37	6.01e-17	Lung cancer;
LGG	cis	rs9487094	0.670	rs729888	chr6:109957323	A/G	cg01125227	chr6:109776195	MICAL1	-0.47	-8.09	-0.35	5.34e-15	Height;
LGG	cis	rs9849248	0.574	rs7624215	chr3:88264569	T/C	cg14530983	chr3:88190749	ZNF654	-0.5	-7.14	-0.31	3.68e-12	Menarche (age at onset);
LGG	cis	rs28595532	0.841	rs56046449	chr4:119769302	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7615952	0.512	rs11929125	chr3:125359443	G/A	cg21696256	chr3:125484277	NA	-0.44	-7.46	-0.33	4.39e-13	Blood pressure (smoking interaction);
LGG	cis	rs17453880	0.929	rs12518097	chr5:152030041	T/C	cg10931792	chr5:152022470	NA	0.41	8.94	0.38	9.26e-18	Subjective well-being;
LGG	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg23825213	chr18:77623475	KCNG2	-0.4	-7.15	-0.32	3.33e-12	Schizophrenia;
LGG	trans	rs11875185	0.915	rs17064158	chr18:55624434	C/T	cg15513957	chr14:69354734	ACTN1	0.66	7.42	0.33	5.5e-13	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7247513	0.964	rs12979795	chr19:12717847	C/T	cg01871581	chr19:12707946	ZNF490	0.44	9.18	0.39	1.39e-18	Bipolar disorder;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg05863683	chr7:1912471	MAD1L1	0.47	9.18	0.39	1.47e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs7312933	0.703	rs10880259	chr12:42558003	T/C	cg19980929	chr12:42632907	YAF2	0.37	8.23	0.36	1.87e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs3820928	0.874	rs55748731	chr2:227818629	C/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.81	-0.34	3.82e-14	Pulmonary function;
LGG	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.95	-0.31	1.25e-11	Blood metabolite levels;
LGG	cis	rs9354308	0.764	rs6923333	chr6:66613796	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	cis	rs2839186	0.739	rs2280958	chr21:47642016	C/T	cg12379764	chr21:47803548	PCNT	-0.43	-7.37	-0.32	7.87e-13	Testicular germ cell tumor;
LGG	cis	rs7412746	0.658	rs6658066	chr1:150918937	T/G	cg15448220	chr1:150897856	SETDB1	0.42	7.66	0.34	1.08e-13	Melanoma;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg03188948	chr7:1209495	NA	0.45	7.44	0.33	5.08e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs3857536	0.776	rs6941904	chr6:66931042	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.32	-0.47	2.13e-26	Coronary artery disease;
LGG	cis	rs2197308	0.765	rs12370231	chr12:37917881	T/C	cg26384229	chr12:38710491	ALG10B	0.98	21.53	0.71	8.94e-72	Morning vs. evening chronotype;
LGG	cis	rs709400	0.930	rs57447494	chr14:104034569	G/A	cg26031613	chr14:104095156	KLC1	1.15	26.54	0.78	4.87e-95	Body mass index;
LGG	cis	rs7717393	1.000	rs72798937	chr5:155796766	T/C	cg12904904	chr5:155754151	SGCD	0.8	7.63	0.33	1.36e-13	Egg allergy;
LGG	cis	rs9303280	0.719	rs56750287	chr17:38062944	A/C	cg19468946	chr17:37922297	IKZF3	-0.44	-7.86	-0.34	2.63e-14	Self-reported allergy;
LGG	cis	rs2298450	0.550	rs9974155	chr21:37654390	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.88	-0.38	1.43e-17	Schizophrenia;
LGG	cis	rs7188861	0.813	rs7189989	chr16:11442710	G/A	cg01510278	chr16:11456238	NA	-0.32	-7.69	-0.34	8.69e-14	HDL cholesterol;
LGG	cis	rs9322193	0.961	rs9027	chr6:149916057	T/A	cg13206674	chr6:150067644	NUP43	0.67	15.14	0.58	2.37e-42	Lung cancer;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.35	-0.32	8.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2011503	0.943	rs8102502	chr19:19652746	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.21	0.32	2.36e-12	Bipolar disorder;
LGG	cis	rs7647973	1.000	rs6446275	chr3:49466871	A/G	cg07636037	chr3:49044803	WDR6	-0.78	-13.85	-0.54	1e-36	Menarche (age at onset);
LGG	cis	rs9863	0.828	rs4765562	chr12:124472571	T/C	cg13487667	chr12:124434373	CCDC92	-0.34	-6.85	-0.3	2.35e-11	White blood cell count;
LGG	cis	rs4595586	0.545	rs1607042	chr12:39368028	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs6696846	0.740	rs11240369	chr1:205115099	G/A	cg21545522	chr1:205238299	TMCC2	0.37	7.05	0.31	6.62e-12	Red blood cell count;
LGG	cis	rs7737355	0.947	rs31584	chr5:130993124	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	2.92e-19	Life satisfaction;
LGG	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.09	0.52	1.52e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6976053	0.781	rs4729617	chr7:100473729	C/T	cg03098644	chr7:100410630	EPHB4	-0.43	-7.59	-0.33	1.75e-13	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs2153535	0.580	rs6597330	chr6:8492076	T/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.05	0.39	4.05e-18	Motion sickness;
LGG	cis	rs7618501	0.572	rs4688756	chr3:50040194	T/A	cg05623727	chr3:50126028	RBM5	0.33	7.22	0.32	2.17e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4363385	0.667	rs756303	chr1:152908222	C/T	cg07796016	chr1:152779584	LCE1C	-0.45	-7.19	-0.32	2.54e-12	Inflammatory skin disease;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.13e-19	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9968911	chr6:149978555	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.49	-0.4	1.23e-19	Lung cancer;
LGG	cis	rs10220309	0.591	rs1388385	chr14:80617599	G/A	cg08183125	chr14:80678293	DIO2	-0.44	-6.72	-0.3	5.44e-11	Lung function (FEV1);
LGG	cis	rs727505	0.866	rs3214004	chr7:124720929	T/C	cg23710748	chr7:124431027	NA	-0.49	-9.22	-0.39	1.07e-18	Lewy body disease;
LGG	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.51	-0.33	3e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg08603382	chr10:743973	NA	-0.52	-9.54	-0.41	8.03e-20	Psychosis in Alzheimer's disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08125972	chr19:36705377	ZNF565;ZNF146	0.5	8.09	0.35	5.2e-15	Cognitive performance;
LGG	cis	rs13191362	1.000	rs13212608	chr6:163032128	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.72	7.7	0.34	8.3e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg19223190	chr17:80058835	NA	0.44	8.35	0.36	7.8e-16	Life satisfaction;
LGG	cis	rs2204008	0.775	rs12099736	chr12:38344111	C/G	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.52e-11	Bladder cancer;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	9.83	0.42	7.86e-21	Tonsillectomy;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17607973	chr7:100027408	MEPCE;ZCWPW1	-0.51	-7.4	-0.33	6.68e-13	Systemic lupus erythematosus;
LGG	cis	rs6540556	0.634	rs11485195	chr1:209891738	T/C	cg23920097	chr1:209922102	NA	-0.42	-7.01	-0.31	8.51e-12	Red blood cell count;
LGG	cis	rs2839186	0.770	rs2330353	chr21:47669648	T/A	cg13012494	chr21:47604986	C21orf56	0.56	9.77	0.41	1.22e-20	Testicular germ cell tumor;
LGG	cis	rs344364	0.511	rs1657134	chr16:1953127	A/G	cg14074117	chr16:1909714	C16orf73	-0.51	-7.6	-0.33	1.61e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6502050	0.769	rs9898292	chr17:80100345	A/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs9951602	0.512	rs1599633	chr18:76643526	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs7998202	0.567	rs7982570	chr13:113370892	T/C	cg17218041	chr13:113365319	ATP11A	-0.41	-6.72	-0.3	5.26e-11	Glycated hemoglobin levels;
LGG	cis	rs1009647	1.000	rs35502084	chr14:55876263	C/T	cg04306507	chr14:55594613	LGALS3	0.42	8.28	0.36	1.33e-15	Testicular germ cell tumor;
LGG	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg23594656	chr7:65796392	TPST1	-0.37	-8.34	-0.36	8.38e-16	Aortic root size;
LGG	cis	rs9479482	1.000	rs5006620	chr6:150336665	C/T	cg16395133	chr6:150326394	RAET1K	0.27	6.74	0.3	4.86e-11	Alopecia areata;
LGG	cis	rs6582630	0.519	rs4405392	chr12:38293661	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.65	0.54	7.05e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12188164	0.543	rs7728027	chr5:459943	T/C	cg00473462	chr5:472545	LOC25845	0.35	6.69	0.3	6.37e-11	Cystic fibrosis severity;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.22e-31	Prudent dietary pattern;
LGG	cis	rs9788333	0.792	rs34479949	chr13:21895574	G/A	cg04632378	chr13:21900426	NA	0.44	9.61	0.41	4.75e-20	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.01	13.67	0.54	5.76e-36	Lung cancer in ever smokers;
LGG	cis	rs34891900	0.507	rs12167771	chr22:18124332	G/A	cg19898043	chr22:18121309	BCL2L13	0.57	9.26	0.4	7.42e-19	Sum neutrophil eosinophil counts;
LGG	cis	rs9547996	0.836	rs61957483	chr13:38147504	T/C	cg17979426	chr13:38220150	TRPC4	-0.36	-6.88	-0.3	1.9e-11	Diastolic blood pressure;
LGG	cis	rs2072732	0.861	rs12041583	chr1:2950886	A/G	cg22517653	chr1:2918612	NA	-0.44	-6.98	-0.31	1.03e-11	Plateletcrit;
LGG	cis	rs734999	0.545	rs4648356	chr1:2709164	C/A	cg20673091	chr1:2541236	MMEL1	0.76	17.06	0.62	5.53e-51	Ulcerative colitis;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	cis	rs710865	0.527	rs2275403	chr1:19557713	C/G	cg13387374	chr1:19411106	UBR4	-0.58	-12.3	-0.5	2.86e-30	Brain structure;
LGG	cis	rs2290405	0.527	rs4690332	chr4:910520	C/T	cg24922022	chr4:827675	NA	-0.34	-7.38	-0.32	7.64e-13	Systemic sclerosis;
LGG	cis	rs1008375	1.000	rs2315560	chr4:17677305	C/G	cg16339924	chr4:17578868	LAP3	0.58	10.21	0.43	3.36e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1153858	0.943	rs12439575	chr15:45684816	T/G	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.93	0.35	1.61e-14	Homoarginine levels;
LGG	cis	rs561341	1.000	rs757009	chr17:30243937	A/G	cg12193833	chr17:30244370	NA	-0.27	-7.2	-0.32	2.49e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.4	-0.33	6.61e-13	Lung cancer;
LGG	cis	rs148803332	1	rs148803332	chr17:65958250	CAAAAGAAA/C	cg12091567	chr17:66097778	LOC651250	0.59	8.51	0.37	2.36e-16	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;
LGG	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	6.99	0.31	9.88e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.0	0.49	4.4e-29	Prudent dietary pattern;
LGG	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg11890956	chr21:40555474	PSMG1	-0.97	-20.36	-0.69	2.85e-66	Cognitive function;
LGG	cis	rs2033711	0.840	rs10423138	chr19:58928302	T/C	cg00825309	chr19:58991885	ZNF446	-0.46	-9.35	-0.4	3.64e-19	Uric acid clearance;
LGG	cis	rs4780401	0.609	rs4781143	chr16:11809721	T/G	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.91	-0.51	8.9e-33	Rheumatoid arthritis;
LGG	cis	rs11225247	0.881	rs12291114	chr11:102261549	G/A	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	trans	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg02002194	chr4:3960332	NA	0.42	7.7	0.34	8.28e-14	Neuroticism;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg21724239	chr8:58056113	NA	0.46	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1580019	0.885	rs4580942	chr7:32496435	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.79	14.76	0.57	1.11e-40	Cognitive ability;
LGG	cis	rs28588043	1.000	rs9427213	chr1:170965681	T/C	cg03458344	chr1:170964477	C1orf129	-0.52	-7.61	-0.33	1.55e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg15147215	chr3:52552868	STAB1	-0.38	-7.43	-0.33	5.17e-13	Hemoglobin concentration;
LGG	cis	rs9308731	0.623	rs11674517	chr2:111903832	C/T	cg26001287	chr2:111877753	BCL2L11	-0.35	-7.04	-0.31	7.18e-12	Chronic lymphocytic leukemia;
LGG	cis	rs9972944	0.756	rs8077164	chr17:63764645	C/T	cg07283582	chr17:63770753	CCDC46	-0.41	-8.04	-0.35	7.78e-15	Total body bone mineral density;
LGG	cis	rs3096299	0.719	rs2353581	chr16:89518908	T/C	cg06640241	chr16:89574553	SPG7	0.86	16.07	0.6	1.68e-46	Multiple myeloma (IgH translocation);
LGG	trans	rs75804782	0.630	rs113725999	chr2:239287651	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	7.08	0.31	5.4e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs8072100	0.688	rs12602134	chr17:45582136	C/G	cg08085267	chr17:45401833	C17orf57	0.63	13.17	0.52	7.49e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17376456	0.542	rs10061069	chr5:93071630	G/C	cg25358565	chr5:93447407	FAM172A	0.67	9.34	0.4	4.14e-19	Diabetic retinopathy;
LGG	cis	rs16854884	0.770	rs1445417	chr3:143808972	A/T	cg06585982	chr3:143692056	C3orf58	0.56	9.25	0.39	8.53e-19	Economic and political preferences (feminism/equality);
LGG	cis	rs72960926	1.000	rs72956936	chr6:75092837	G/A	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs972578	0.765	rs7074	chr22:43265827	G/T	cg01576275	chr22:43409880	NA	-0.23	-6.98	-0.31	1.01e-11	Mean platelet volume;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg03464378	chr2:75427699	TACR1	0.36	6.65	0.3	8.41e-11	Obesity-related traits;
LGG	cis	rs72615157	0.613	rs56089143	chr7:99819844	G/A	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.61	8.6	0.37	1.22e-16	Lung function (FEV1/FVC);
LGG	trans	rs2048656	0.578	rs2090061	chr8:9680978	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.47	0.33	3.96e-13	Schizophrenia;
LGG	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.74	-8.71	-0.38	5.62e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg16414030	chr3:133502952	NA	-0.6	-10.34	-0.43	1.07e-22	Iron status biomarkers;
LGG	cis	rs1806153	0.611	rs1540318	chr11:31837949	C/T	cg11990419	chr11:31841155	NA	0.34	7.97	0.35	1.22e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs28498503	0.867	rs1841765	chr18:76644636	A/T	cg00806245	chr18:76673096	NA	-0.56	-6.69	-0.3	6.34e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs2836974	0.865	rs7282624	chr21:40667040	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	3.9e-11	Cognitive function;
LGG	cis	rs736408	0.736	rs4687550	chr3:52823430	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.48	7.74	0.34	6.5e-14	Bipolar disorder;
LGG	trans	rs1941687	0.669	rs56171873	chr18:31400635	G/C	cg27147174	chr7:100797783	AP1S1	-0.52	-9.02	-0.39	4.87e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2019137	0.560	rs7421852	chr2:113990261	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.83	16.22	0.6	3.56e-47	Lymphocyte counts;
LGG	trans	rs7615952	0.866	rs11922276	chr3:125631326	G/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.27	-0.7	1.56e-70	Blood pressure (smoking interaction);
LGG	cis	rs28386778	0.668	rs2286564	chr17:62009991	A/G	cg06873352	chr17:61820015	STRADA	-0.57	-9.91	-0.42	3.85e-21	Prudent dietary pattern;
LGG	cis	rs79146658	0.850	rs17362588	chr2:179721046	G/A	cg17765952	chr2:179737173	CCDC141	0.65	7.44	0.33	4.93e-13	Diastolic blood pressure;
LGG	trans	rs61931739	0.534	rs11052986	chr12:34052578	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.94	0.42	3.08e-21	Morning vs. evening chronotype;
LGG	cis	rs9326248	0.911	rs474339	chr11:117059552	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.61	9.33	0.4	4.48e-19	Blood protein levels;
LGG	cis	rs11628318	0.614	rs62007936	chr14:103198740	G/A	cg01864069	chr14:103024347	NA	0.69	9.34	0.4	4.19e-19	Platelet count;
LGG	cis	rs4819052	0.851	rs4819043	chr21:46660078	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.75	0.38	3.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9657904	1.000	rs10511246	chr3:105582312	G/T	cg14088669	chr1:158435396	OR10K1	-0.39	-6.8	-0.3	3.22e-11	Multiple sclerosis;
LGG	cis	rs6964587	1.000	rs2282968	chr7:91580287	A/C	cg17063962	chr7:91808500	NA	-0.5	-8.71	-0.38	5.24e-17	Breast cancer;
LGG	cis	rs2013441	1.000	rs2058971	chr17:20219508	T/A	cg13482628	chr17:19912719	NA	-0.5	-9.33	-0.4	4.24e-19	Obesity-related traits;
LGG	cis	rs972578	0.765	rs4822210	chr22:43264770	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.98	-0.31	1.01e-11	Mean platelet volume;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg00684032	chr4:1343700	KIAA1530	0.38	7.42	0.33	5.81e-13	Longevity;
LGG	cis	rs12282928	0.788	rs7127946	chr11:48250675	C/T	cg20307385	chr11:47447363	PSMC3	-0.45	-7.39	-0.32	6.87e-13	Migraine - clinic-based;
LGG	cis	rs1008375	1.000	rs6849704	chr4:17652031	G/C	cg16339924	chr4:17578868	LAP3	0.6	10.44	0.44	4.69e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1270639	0.673	rs1263566	chr7:157455933	T/C	cg09833475	chr7:157463804	PTPRN2	-0.48	-7.27	-0.32	1.54e-12	Colorectal cancer;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg22535103	chr8:58192502	C8orf71	-0.99	-15.2	-0.58	1.3e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs12200560	0.505	rs211166	chr6:97068598	T/C	cg06623918	chr6:96969491	KIAA0776	0.47	7.9	0.34	2.05e-14	Coronary heart disease;
LGG	cis	rs10865541	0.902	rs7593978	chr2:3415544	C/T	cg13173536	chr2:3403300	TTC15	-0.32	-6.7	-0.3	5.92e-11	Obesity-related traits;
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.0	-0.35	9.79e-15	Total body bone mineral density;
LGG	cis	rs8053891	0.507	rs34150651	chr16:72028112	G/A	cg01557791	chr16:72042693	DHODH	-0.4	-6.72	-0.3	5.32e-11	Coronary artery disease;
LGG	cis	rs6121246	0.529	rs6060296	chr20:30198480	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.52	-0.33	2.81e-13	Mean corpuscular hemoglobin;
LGG	cis	rs10465746	0.687	rs6576954	chr1:84323701	C/T	cg10977910	chr1:84465055	TTLL7	-0.41	-7.11	-0.31	4.48e-12	Obesity-related traits;
LGG	cis	rs804292	0.800	rs8191589	chr8:11634194	T/A	cg26752888	chr8:11627280	NEIL2	1.08	16.82	0.62	6.89e-50	Alcohol dependence;Nicotine use;
LGG	cis	rs7084402	0.967	rs1658423	chr10:60331627	T/G	cg07615347	chr10:60278583	BICC1	0.62	17.48	0.63	6.56e-53	Refractive error;
LGG	trans	rs7980799	0.935	rs9888363	chr12:33529288	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-8.57	-0.37	1.56e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs644799	0.635	rs10831428	chr11:95508404	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.65	0.63	1.1e-53	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg07869994	chr3:174095190	NA	0.4	6.98	0.31	1.02e-11	Menarche (age at onset);
LGG	cis	rs9354308	1.000	rs9342503	chr6:66565436	A/G	cg07460842	chr6:66804631	NA	-0.53	-9.16	-0.39	1.64e-18	Metabolite levels;
LGG	cis	rs17270561	0.609	rs1165211	chr6:25800922	T/C	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs1465370	0.720	rs5011387	chr7:130017149	C/T	cg04743876	chr7:130013617	NA	0.37	8.64	0.37	9.05e-17	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	1e-15	Response to antipsychotic treatment;
LGG	cis	rs7851660	0.967	rs907577	chr9:100615117	C/T	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs17604090	0.938	rs10276157	chr7:29665016	A/G	cg19413766	chr7:29689036	LOC646762	-0.56	-6.75	-0.3	4.33e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs4566357	0.787	rs12475134	chr2:227880511	C/T	cg11843606	chr2:227700838	RHBDD1	-0.48	-8.25	-0.36	1.63e-15	Coronary artery disease;
LGG	cis	rs2204008	0.774	rs11514062	chr12:38332297	A/C	cg04568710	chr12:38710424	ALG10B	0.36	7.63	0.33	1.32e-13	Bladder cancer;
LGG	trans	rs8002861	0.901	rs9525867	chr13:44463557	G/A	cg17145862	chr1:211918768	LPGAT1	0.98	25.48	0.76	3.74e-90	Leprosy;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07704495	chr21:43916519	RSPH1	0.43	7.16	0.32	3.24e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.566	rs6912330	chr6:150229947	A/C	cg01145232	chr6:150245071	RAET1G	-0.5	-9.21	-0.39	1.11e-18	Lung cancer;
LGG	cis	rs7084402	0.967	rs1658451	chr10:60311527	A/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.25e-12	Refractive error;
LGG	cis	rs1008375	0.898	rs9998130	chr4:17593905	A/G	cg16339924	chr4:17578868	LAP3	0.64	10.99	0.45	3.98e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2124969	0.522	rs6432608	chr2:161034991	C/T	cg03641300	chr2:160917029	PLA2R1	-0.63	-11.93	-0.48	8.46e-29	Waist circumference adjusted for body mass index;
LGG	cis	rs9880211	0.800	rs35422852	chr3:136505915	A/T	cg21827317	chr3:136751795	NA	-0.48	-7.05	-0.31	6.74e-12	Body mass index;Height;
LGG	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg16339924	chr4:17578868	LAP3	0.58	10.21	0.43	3.36e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9811920	0.809	rs35422475	chr3:99711545	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.79	-0.38	2.86e-17	Axial length;
LGG	cis	rs2274273	0.840	rs7144737	chr14:55822946	C/T	cg04306507	chr14:55594613	LGALS3	0.61	16.59	0.61	7.69e-49	Protein biomarker;
LGG	cis	rs9951602	1.000	rs9949784	chr18:76649994	A/G	cg24134504	chr18:76639479	NA	-0.62	-8.02	-0.35	8.81e-15	Obesity-related traits;
LGG	cis	rs2762353	1.000	rs2762353	chr6:25794431	A/G	cg03264133	chr6:25882463	NA	-0.52	-9.84	-0.42	7.07e-21	Blood metabolite levels;
LGG	cis	rs4917300	0.566	rs1388798	chr8:143100592	T/A	cg06573787	chr8:143070187	NA	0.6	10.05	0.42	1.26e-21	Amyotrophic lateral sclerosis;
LGG	trans	rs7819412	0.521	rs9329238	chr8:11033737	C/T	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.09	-0.35	5.28e-15	Triglycerides;
LGG	cis	rs9300255	0.602	rs1626899	chr12:123708063	A/G	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs9486719	1.000	rs4077932	chr6:96905144	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.61	-0.44	1.1e-23	Migraine;Coronary artery disease;
LGG	cis	rs9783347	0.961	rs4150616	chr11:18365114	A/T	cg15585147	chr11:18324498	HPS5	0.41	8.8	0.38	2.72e-17	Pancreatic cancer;
LGG	cis	rs2204008	0.782	rs11514339	chr12:38236670	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.78	0.54	1.94e-36	Bladder cancer;
LGG	cis	rs4918072	0.876	rs4918069	chr10:105654391	T/G	cg11005552	chr10:105648138	OBFC1	0.73	12.31	0.5	2.56e-30	Coronary artery disease;
LGG	cis	rs6743226	0.748	rs12620606	chr2:242154015	A/G	cg10021735	chr2:242295487	FARP2	0.43	7.69	0.34	8.89e-14	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs11992162	1.000	rs12334769	chr8:11833161	A/T	cg13009111	chr11:71350975	NA	0.39	8.9	0.38	1.31e-17	Monocyte count;
LGG	cis	rs9479482	0.686	rs9397137	chr6:150382002	G/A	cg03788504	chr6:150331562	NA	-0.51	-10.52	-0.44	2.38e-23	Alopecia areata;
LGG	cis	rs11098499	0.691	rs2136911	chr4:120265859	G/A	cg09307838	chr4:120376055	NA	0.68	11.74	0.48	4.89e-28	Corneal astigmatism;
LGG	cis	rs6547741	0.752	rs7562863	chr2:27892694	T/A	cg27432699	chr2:27873401	GPN1	-0.74	-15.28	-0.58	5.65e-43	Oral cavity cancer;
LGG	cis	rs4481887	0.927	rs4307598	chr1:248474544	T/C	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs2204008	0.599	rs2320526	chr12:38220405	T/A	cg26384229	chr12:38710491	ALG10B	0.88	19.98	0.68	1.71e-64	Bladder cancer;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg11859384	chr17:80120422	CCDC57	-0.43	-7.49	-0.33	3.44e-13	Life satisfaction;
LGG	cis	rs3806843	0.966	rs6579965	chr5:140168811	T/G	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2797160	0.935	rs1739372	chr6:126011325	G/A	cg05901451	chr6:126070800	HEY2	0.45	7.62	0.33	1.47e-13	Endometrial cancer;
LGG	cis	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg06521331	chr12:34319734	NA	-0.47	-7.94	-0.35	1.58e-14	Resting heart rate;
LGG	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg06360820	chr2:242988706	NA	-1.05	-12.68	-0.51	8.05e-32	Obesity-related traits;
LGG	cis	rs11250464	0.833	rs11250466	chr10:1409378	C/T	cg09624528	chr10:1369823	ADARB2	-0.4	-6.89	-0.31	1.79e-11	Radiation response;
LGG	cis	rs4740619	0.649	rs10962256	chr9:16019790	T/C	cg14451791	chr9:16040625	NA	-0.41	-10.49	-0.44	3.04e-23	Body mass index;
LGG	cis	rs7617773	0.817	rs936427	chr3:48301074	A/G	cg11946769	chr3:48343235	NME6	-0.67	-10.95	-0.45	5.84e-25	Coronary artery disease;
LGG	cis	rs801193	0.967	rs1110414	chr7:66205582	A/G	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.16e-25	Aortic root size;
LGG	cis	rs9322193	0.923	rs9688517	chr6:150061791	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.52	0.33	2.96e-13	Lung cancer;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.94	0.42	3.02e-21	Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10205287	chr4:100815590	MAPKSP1	0.43	7.17	0.32	2.98e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs10779751	1.000	rs11121703	chr1:11293792	G/T	cg08854313	chr1:11322531	MTOR	-0.74	-16.77	-0.61	1.1e-49	Body mass index;
LGG	cis	rs1865760	0.964	rs9379802	chr6:25933898	T/A	cg12310025	chr6:25882481	NA	-0.42	-7.5	-0.33	3.29e-13	Height;
LGG	cis	rs1790761	0.692	rs1269981	chr11:67334959	G/A	cg23188684	chr11:67383651	NA	0.52	8.79	0.38	3.02e-17	Mean corpuscular volume;
LGG	cis	rs7432375	0.610	rs60574021	chr3:136520281	C/G	cg21827317	chr3:136751795	NA	0.44	7.91	0.34	1.96e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg11062466	chr8:58055876	NA	0.49	8.35	0.36	8.18e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg24247370	chr13:99142703	STK24	-0.37	-6.91	-0.31	1.64e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs11255291	0.668	rs719748	chr10:7731885	A/G	cg13340899	chr10:7670827	ITIH5	0.4	7.04	0.31	7.11e-12	Ovarian reserve;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg14926445	chr8:58193284	C8orf71	-0.68	-8.34	-0.36	8.81e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4650994	0.816	rs2761470	chr1:178596033	G/C	cg12486710	chr1:178512616	C1orf220	-0.4	-8.06	-0.35	6.59e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs826838	0.935	rs1160162	chr12:38959795	G/A	cg26384229	chr12:38710491	ALG10B	1.05	28.12	0.79	3.22e-102	Heart rate;
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg05025164	chr4:1340916	KIAA1530	0.54	9.87	0.42	5.56e-21	Longevity;
LGG	cis	rs1577917	1.000	rs12215037	chr6:86727631	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.63	-10.59	-0.44	1.25e-23	Response to antipsychotic treatment;
LGG	cis	rs7267979	0.966	rs2227892	chr20:25264814	T/C	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs453301	0.624	rs4841083	chr8:8870428	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.87	-0.34	2.56e-14	Joint mobility (Beighton score);
LGG	cis	rs3768617	0.528	rs10737241	chr1:183098208	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.23e-18	Fuchs's corneal dystrophy;
LGG	cis	rs7587476	0.822	rs13018304	chr2:215682218	T/G	cg04530015	chr2:215796436	ABCA12	-0.46	-7.84	-0.34	3.14e-14	Neuroblastoma;
LGG	cis	rs1799949	0.965	rs9646418	chr17:41425901	A/G	cg18379455	chr17:41446167	NA	-0.33	-8.03	-0.35	8.26e-15	Menopause (age at onset);
LGG	trans	rs11250098	0.503	rs7821826	chr8:10769439	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-7.96	-0.35	1.36e-14	Morning vs. evening chronotype;
LGG	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg26617929	chr16:1858877	NA	0.6	8.45	0.37	3.84e-16	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs17666538	0.585	rs10090260	chr8:608034	T/C	cg02524346	chr8:600233	NA	1.18	11.78	0.48	3.52e-28	IgG glycosylation;
LGG	cis	rs896854	0.624	rs9297949	chr8:95969445	A/C	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.92	-0.38	1.1e-17	Type 2 diabetes;
LGG	trans	rs561341	0.739	rs9906455	chr17:30215669	G/A	cg27661571	chr11:113659931	NA	0.47	6.78	0.3	3.56e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.555	rs10880520	chr12:38464111	C/T	cg26384229	chr12:38710491	ALG10B	0.94	22.01	0.71	5.53e-74	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07657236	chr3:19190202	KCNH8	0.41	6.93	0.31	1.4e-11	Cognitive performance;
LGG	cis	rs6502050	0.835	rs12945993	chr17:80129485	T/C	cg13939156	chr17:80058883	NA	-0.46	-8.91	-0.38	1.22e-17	Life satisfaction;
LGG	cis	rs7567389	0.504	rs1568278	chr2:128190195	G/A	cg10021288	chr2:128175891	PROC	0.38	6.9	0.31	1.71e-11	Self-rated health;
LGG	cis	rs12493885	0.697	rs11710478	chr3:153777037	A/C	cg17054900	chr3:154042577	DHX36	-0.75	-8.89	-0.38	1.35e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg04861929	chr11:109293070	C11orf87	0.55	10.09	0.42	9.03e-22	Schizophrenia;
LGG	cis	rs11645898	0.935	rs35370634	chr16:72184566	C/T	cg14768367	chr16:72042858	DHODH	-0.82	-11.06	-0.46	2.14e-25	Blood protein levels;
LGG	cis	rs1577917	0.655	rs2842605	chr6:86335150	A/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.24	-0.46	4.33e-26	Response to antipsychotic treatment;
LGG	cis	rs9443645	0.901	rs9448588	chr6:79590061	T/G	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.52e-17	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07677032	chr17:61819896	STRADA	0.66	12.06	0.49	2.53e-29	Prudent dietary pattern;
LGG	cis	rs4843185	0.646	rs35953313	chr16:85710476	T/A	cg26571870	chr16:85723150	GINS2	-0.41	-7.51	-0.33	3.09e-13	Platelet distribution width;
LGG	trans	rs9929218	0.953	rs11075696	chr16:68731365	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.87	-15.87	-0.59	1.36e-45	Colorectal cancer;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.45	8.54	0.37	1.94e-16	Personality dimensions;
LGG	cis	rs7011049	0.841	rs6473777	chr8:53875544	G/C	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	trans	rs9929218	0.954	rs34530130	chr16:68827620	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.87	-0.48	1.46e-28	Colorectal cancer;
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg09359103	chr1:154839909	KCNN3	0.46	9.2	0.39	1.26e-18	Prostate cancer;
LGG	trans	rs8002861	0.905	rs12875052	chr13:44449368	G/C	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.61	-0.71	4.07e-72	Leprosy;
LGG	trans	rs61931739	0.534	rs11052959	chr12:33997095	T/C	cg26384229	chr12:38710491	ALG10B	0.8	15.99	0.6	3.94e-46	Morning vs. evening chronotype;
LGG	cis	rs9783347	0.714	rs11024614	chr11:18326758	C/T	cg15585147	chr11:18324498	HPS5	0.34	7.68	0.34	9.68e-14	Pancreatic cancer;
LGG	cis	rs4481887	0.741	rs28444488	chr1:248531776	C/A	cg15454534	chr1:248569605	OR2T1	0.38	6.96	0.31	1.19e-11	Common traits (Other);
LGG	cis	rs17641971	0.684	rs11785391	chr8:49930203	G/T	cg00325661	chr8:49890786	NA	0.54	9.89	0.42	4.91e-21	Blood metabolite levels;
LGG	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs875971	0.862	rs6944374	chr7:65686929	C/G	cg23594656	chr7:65796392	TPST1	0.4	8.81	0.38	2.6e-17	Aortic root size;
LGG	cis	rs17433780	0.504	rs6428494	chr1:89472196	C/T	cg09516651	chr1:89888402	LOC400759	0.55	12.6	0.51	1.59e-31	Carotid intima media thickness;
LGG	cis	rs2016266	0.929	rs7486393	chr12:53652885	C/T	cg13445358	chr12:53661749	ESPL1	-0.36	-6.82	-0.3	2.9e-11	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs4332037	0.539	rs62444881	chr7:2052318	C/T	cg06789500	chr7:2109450	MAD1L1	-0.29	-6.88	-0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs9902485	chr17:80093701	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.81e-20	Life satisfaction;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg00106254	chr7:1943704	MAD1L1	-0.47	-8.01	-0.35	9.49e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.683	rs55637580	chr8:58135419	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg23985595	chr17:80112537	CCDC57	0.47	9.51	0.4	1.01e-19	Life satisfaction;
LGG	cis	rs8031584	1.000	rs1474380	chr15:31269235	T/C	cg08109568	chr15:31115862	NA	-0.53	-9.34	-0.4	4.23e-19	Huntington's disease progression;
LGG	cis	rs6952808	1.000	rs6957894	chr7:1887362	G/A	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.89	-0.34	2.26e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.61	12.37	0.5	1.47e-30	Obesity-related traits;
LGG	cis	rs75920871	0.800	rs59700451	chr11:116982928	G/A	cg20608306	chr11:116969690	SIK3	-0.32	-6.64	-0.3	8.57e-11	Subjective well-being;
LGG	cis	rs796364	0.589	rs6743217	chr2:201134914	G/A	cg23649088	chr2:200775458	C2orf69	-0.55	-7.86	-0.34	2.81e-14	Schizophrenia;
LGG	cis	rs6963495	0.745	rs73190179	chr7:105162812	C/A	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs708547	0.647	rs2293175	chr4:57861358	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.6	10.27	0.43	2e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs2739330	0.760	rs1007888	chr22:24241101	C/T	cg18538332	chr22:24372958	LOC391322	-0.48	-8.0	-0.35	1.04e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2404602	0.692	rs59088060	chr15:76859974	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22645161	chr19:36391033	NFKBID	0.4	6.85	0.3	2.41e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.723	rs4721264	chr7:2012997	G/A	cg02951883	chr7:2050386	MAD1L1	-0.78	-16.2	-0.6	4.33e-47	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	1.000	rs6978048	chr7:1886872	T/G	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.78	-0.3	3.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.651	rs4974599	chr4:1314430	A/C	cg20887711	chr4:1340912	KIAA1530	0.7	14.67	0.56	2.84e-40	Longevity;
LGG	trans	rs9657904	0.950	rs2089091	chr3:105568602	G/A	cg14088669	chr1:158435396	OR10K1	-0.41	-6.95	-0.31	1.28e-11	Multiple sclerosis;
LGG	trans	rs8002861	0.713	rs7339417	chr13:44413496	A/T	cg12856521	chr11:46389249	DGKZ	0.52	9.25	0.39	8.59e-19	Leprosy;
LGG	cis	rs7927771	0.524	rs10742824	chr11:47864842	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12390003	chr1:160068671	IGSF8	-0.44	-6.79	-0.3	3.49e-11	Pancreatic cancer;
LGG	cis	rs7819412	0.512	rs1435282	chr8:11251705	G/A	cg21775007	chr8:11205619	TDH	-0.64	-10.23	-0.43	2.73e-22	Triglycerides;
LGG	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg07148914	chr20:33460835	GGT7	-0.5	-8.27	-0.36	1.45e-15	Height;
LGG	cis	rs17453880	0.929	rs6860209	chr5:152049547	A/G	cg12297329	chr5:152029980	NA	-0.9	-23.2	-0.73	1.5e-79	Subjective well-being;
LGG	cis	rs3733585	0.699	rs7663079	chr4:9966771	T/C	cg08250081	chr4:10125330	NA	-0.35	-6.71	-0.3	5.8e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs7395662	0.963	rs2089209	chr11:48987120	C/T	cg03929089	chr4:120376271	NA	-0.43	-7.0	-0.31	9.25e-12	HDL cholesterol;
LGG	cis	rs11758351	0.500	rs17533076	chr6:26183816	G/A	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.82e-12	Gout;Renal underexcretion gout;
LGG	cis	rs2072732	0.861	rs72629494	chr1:2951349	T/C	cg22517653	chr1:2918612	NA	-0.44	-6.99	-0.31	9.87e-12	Plateletcrit;
LGG	cis	rs2802728	0.881	rs4658561	chr1:243539911	A/G	cg05593162	chr1:243577377	SDCCAG8	0.53	7.04	0.31	6.79e-12	Toenail selenium levels;
LGG	cis	rs9790314	0.936	rs7629987	chr3:161002023	A/C	cg03342759	chr3:160939853	NMD3	-0.66	-11.77	-0.48	3.6e-28	Morning vs. evening chronotype;
LGG	cis	rs72615157	0.664	rs6953580	chr7:99825275	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.66	-9.49	-0.4	1.26e-19	Lung function (FEV1/FVC);
LGG	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg13073564	chr4:8508604	NA	0.6	11.76	0.48	4e-28	Response to antineoplastic agents;
LGG	cis	rs4474465	0.850	rs7112872	chr11:78227396	C/A	cg02023728	chr11:77925099	USP35	-0.39	-6.79	-0.3	3.45e-11	Alzheimer's disease (survival time);
LGG	cis	rs3096299	0.967	rs2911255	chr16:89487137	C/T	cg02187348	chr16:89574699	SPG7	0.46	7.41	0.33	6.13e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs4822044	0.560	rs7284839	chr22:42010902	C/T	cg17376030	chr22:41985996	PMM1	-0.67	-10.85	-0.45	1.37e-24	Cannabis dependence symptom count;
LGG	cis	rs4474465	0.915	rs12273367	chr11:78173835	A/T	cg02023728	chr11:77925099	USP35	0.38	6.74	0.3	4.72e-11	Alzheimer's disease (survival time);
LGG	trans	rs853679	0.607	rs13217984	chr6:28139710	A/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg02725872	chr8:58115012	NA	-1.04	-15.02	-0.57	7.64e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.580	rs1410766	chr6:8525360	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.33e-31	Motion sickness;
LGG	cis	rs7296418	0.630	rs7974099	chr12:123771475	A/G	cg05973401	chr12:123451056	ABCB9	0.44	7.45	0.33	4.62e-13	Platelet count;
LGG	cis	rs10818894	1.000	rs10818894	chr9:126695770	A/G	cg16191174	chr9:126692580	DENND1A	-0.6	-8.37	-0.36	7.05e-16	Adverse response to chemotherapy in breast cancer (alopecia) (cyclophosphamide+doxorubicin+/-5FU);
LGG	cis	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg24110177	chr3:50126178	RBM5	0.4	6.87	0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.573	rs8070182	chr17:29135594	A/C	cg13385521	chr17:29058706	SUZ12P	0.91	10.58	0.44	1.46e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs58688157	0.592	rs12803048	chr11:584243	C/T	cg03909863	chr11:638404	DRD4	-0.41	-6.69	-0.3	6.46e-11	Systemic lupus erythematosus;
LGG	cis	rs4466137	0.794	rs975595	chr5:83010095	G/A	cg16102102	chr5:83017553	HAPLN1	-0.59	-11.23	-0.46	4.99e-26	Prostate cancer;
LGG	cis	rs10256972	0.516	rs12702081	chr7:1141528	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.64	-11.31	-0.47	2.31e-26	Longevity;Endometriosis;
LGG	cis	rs7582720	1.000	rs6723704	chr2:203738664	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg09426994	chr11:118478258	PHLDB1	0.41	7.16	0.32	3.26e-12	Cholesterol, total;
LGG	cis	rs35883536	0.740	rs4604711	chr1:101089492	A/C	cg06223162	chr1:101003688	GPR88	0.29	6.86	0.3	2.28e-11	Monocyte count;
LGG	cis	rs6032067	1.000	rs6032060	chr20:43852454	A/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs1451375	0.729	rs6593017	chr7:50644812	G/A	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg00080972	chr5:178986291	RUFY1	0.5	8.79	0.38	3e-17	Lung cancer;
LGG	cis	rs28386778	0.765	rs2070680	chr17:61986988	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-24.97	-0.76	8.2e-88	Prudent dietary pattern;
LGG	cis	rs57221529	0.766	rs4527146	chr5:555236	A/G	cg01221209	chr5:554886	NA	-0.48	-7.19	-0.32	2.65e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1183201	0.505	rs1165201	chr6:25874823	A/C	cg03517284	chr6:25882590	NA	-0.82	-16.85	-0.62	5.11e-50	Uric acid levels;
LGG	cis	rs362296	0.698	rs3129319	chr4:3265381	A/G	cg06533319	chr4:3265114	C4orf44	0.53	10.99	0.45	4.13e-25	Parental longevity (mother's age at death);
LGG	cis	rs9486719	0.857	rs4346856	chr6:96880270	C/T	cg18709589	chr6:96969512	KIAA0776	0.45	7.52	0.33	2.83e-13	Migraine;Coronary artery disease;
LGG	trans	rs2624839	0.630	rs2624841	chr3:50198415	C/T	cg21659725	chr3:3221576	CRBN	0.55	8.37	0.36	6.77e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7208859	0.524	rs60114476	chr17:29097667	A/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.54	-0.44	1.96e-23	Triglycerides;
LGG	cis	rs7044106	0.791	rs10739572	chr9:123489815	C/T	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	8.02	0.35	8.73e-15	Hip circumference adjusted for BMI;
LGG	trans	rs7824557	0.701	rs2060465	chr8:11162609	T/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.03	0.42	1.52e-21	Retinal vascular caliber;
LGG	cis	rs12478296	0.901	rs67951957	chr2:243004901	A/G	cg06360820	chr2:242988706	NA	-0.99	-13.0	-0.52	3.58e-33	Obesity-related traits;
LGG	cis	rs11690935	0.959	rs10204622	chr2:172588982	C/T	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.73	-0.78	7.11e-96	Schizophrenia;
LGG	cis	rs936229	0.861	rs12441505	chr15:75107311	A/C	cg10253484	chr15:75165896	SCAMP2	-0.68	-10.5	-0.44	2.85e-23	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7659604	0.540	rs10001092	chr4:122677177	C/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg00290607	chr11:67383545	NA	0.73	14.48	0.56	1.76e-39	Mean corpuscular volume;
LGG	cis	rs11098499	0.554	rs2175381	chr4:120265967	T/C	cg09307838	chr4:120376055	NA	0.68	11.8	0.48	2.73e-28	Corneal astigmatism;
LGG	cis	rs11608355	0.521	rs6606709	chr12:109846714	A/C	cg19025524	chr12:109796872	NA	-0.57	-12.17	-0.49	9.52e-30	Neuroticism;
LGG	cis	rs7937682	0.924	rs10891288	chr11:111552053	G/T	cg22437258	chr11:111473054	SIK2	-0.53	-9.14	-0.39	1.95e-18	Primary sclerosing cholangitis;
LGG	cis	rs28588043	0.938	rs72710577	chr1:170993313	G/A	cg03458344	chr1:170964477	C1orf129	-0.53	-7.21	-0.32	2.28e-12	Number of children (6+ vs. 0 or 1);
LGG	trans	rs1493916	0.777	rs1941685	chr18:31304318	G/T	cg04226714	chr8:49833948	SNAI2	-0.47	-8.46	-0.37	3.54e-16	Life satisfaction;
LGG	cis	rs35079168	0.809	rs11103483	chr9:137287874	G/A	cg00753924	chr9:137298813	RXRA	-0.38	-7.18	-0.32	2.77e-12	Intelligence;
LGG	cis	rs2832191	0.545	rs2251381	chr21:30530692	T/G	cg24692254	chr21:30365293	RNF160	0.66	12.69	0.51	7.25e-32	Dental caries;
LGG	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg02023728	chr11:77925099	USP35	0.44	7.59	0.33	1.74e-13	Testicular germ cell tumor;
LGG	cis	rs6504108	0.581	rs55982346	chr17:46275874	C/T	cg02219949	chr17:45927392	SP6	0.44	8.21	0.36	2.24e-15	Body mass index;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.88	-0.42	5.3e-21	Lung cancer;
LGG	cis	rs28595532	0.920	rs56364904	chr4:119742504	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs6489882	0.867	rs916972	chr12:113366049	G/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.41	-0.33	5.98e-13	Chronic lymphocytic leukemia;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg16405210	chr4:1374714	KIAA1530	-0.42	-6.88	-0.3	1.95e-11	Obesity-related traits;
LGG	cis	rs2502399	0.931	rs774576	chr6:113509882	A/T	cg20413948	chr6:113544930	NA	0.3	6.94	0.31	1.35e-11	Plasma clusterin levels;
LGG	cis	rs6815814	0.898	rs73236616	chr4:38789675	G/A	cg06935464	chr4:38784597	TLR10	0.61	8.26	0.36	1.56e-15	Breast cancer;
LGG	trans	rs853679	0.546	rs200950	chr6:27835772	A/G	cg01620082	chr3:125678407	NA	-0.82	-8.97	-0.38	7.37e-18	Depression;
LGG	cis	rs12410462	0.591	rs72632830	chr1:227728897	G/T	cg04117972	chr1:227635322	NA	0.46	8.42	0.36	4.66e-16	Major depressive disorder;
LGG	cis	rs9400467	0.506	rs12200758	chr6:111710844	A/G	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.73	0.3	5.14e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs62025270	0.806	rs62025266	chr15:86298448	C/A	cg25843651	chr15:86329602	KLHL25	0.65	10.57	0.44	1.48e-23	Idiopathic pulmonary fibrosis;
LGG	cis	rs4242434	0.672	rs6993302	chr8:22527457	T/C	cg19455335	chr8:22457658	C8orf58	0.36	7.2	0.32	2.38e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs644799	1.000	rs534497	chr11:95562868	C/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10876993	0.890	rs2619441	chr12:58083015	C/A	cg18357645	chr12:58087776	OS9	0.72	13.11	0.52	1.27e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs8060686	0.668	rs12448991	chr16:68218894	T/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.14e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs13191362	1.000	rs68045643	chr6:163029709	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.43	7.04	0.31	6.86e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4555082	0.834	rs2735816	chr14:105721603	C/G	cg10792982	chr14:105748885	BRF1	-0.65	-13.26	-0.52	3.09e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1185460	1.000	rs4614	chr11:118952371	A/G	cg23280166	chr11:118938394	VPS11	0.51	8.81	0.38	2.45e-17	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20786246	chr2:72377174	NA	0.37	7.07	0.31	5.7e-12	Obesity-related traits;
LGG	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg08975724	chr8:8085496	FLJ10661	0.42	7.84	0.34	3.02e-14	Myopia (pathological);
LGG	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg00717180	chr2:96193071	NA	-0.41	-7.13	-0.31	3.94e-12	HDL cholesterol;
LGG	cis	rs9322193	0.962	rs3763162	chr6:150140810	A/G	cg00424166	chr6:150045504	NUP43	0.32	6.69	0.3	6.46e-11	Lung cancer;
LGG	cis	rs868036	0.681	rs4776375	chr15:68085555	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.31	-0.36	1.06e-15	Restless legs syndrome;
LGG	cis	rs7100689	0.622	rs2994389	chr10:82062257	C/G	cg01528321	chr10:82214614	TSPAN14	0.81	14.5	0.56	1.55e-39	Post bronchodilator FEV1;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg05941027	chr17:61774174	LIMD2	0.33	8.26	0.36	1.59e-15	Height;
LGG	trans	rs2235573	0.551	rs84770	chr22:38390128	T/G	cg19894588	chr14:64061835	NA	0.6	9.96	0.42	2.7e-21	Glioblastoma;Glioma;
LGG	cis	rs6502050	0.835	rs4789677	chr17:80119842	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1348850	0.768	rs57681892	chr2:178357645	G/C	cg27490568	chr2:178487706	NA	0.5	9.96	0.42	2.58e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1420338	0.933	rs1362460	chr7:34147964	C/T	cg01275685	chr7:34179230	BMPER	-0.51	-9.47	-0.4	1.4e-19	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.53	-0.33	2.59e-13	HDL cholesterol;
LGG	cis	rs4843185	0.731	rs10514608	chr16:85713173	C/G	cg26571870	chr16:85723150	GINS2	-0.41	-7.58	-0.33	1.93e-13	Platelet distribution width;
LGG	cis	rs9393692	0.902	rs6456711	chr6:26302572	A/C	cg05868516	chr6:26286170	HIST1H4H	0.42	6.94	0.31	1.35e-11	Educational attainment;
LGG	trans	rs916888	0.821	rs199513	chr17:44856932	A/G	cg01341218	chr17:43662625	NA	-0.83	-14.2	-0.55	3.02e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7249142	0.597	rs7250650	chr19:19285989	A/T	cg23543615	chr19:19281185	LOC729991-MEF2B;MEF2B	-0.3	-7.76	-0.34	5.61e-14	IgG glycosylation;
LGG	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg26384229	chr12:38710491	ALG10B	0.97	22.13	0.72	1.45e-74	Bladder cancer;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg08621203	chr6:150244597	RAET1G	0.52	9.5	0.4	1.12e-19	Testicular germ cell tumor;
LGG	cis	rs17001868	0.881	rs12484358	chr22:40774660	G/A	cg07138101	chr22:40742427	ADSL	0.63	6.94	0.31	1.36e-11	Mammographic density (dense area);
LGG	cis	rs6076065	0.630	rs2424558	chr20:23429344	A/G	cg12633918	chr20:23549525	CST9L	-0.33	-6.73	-0.3	5.14e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs7843479	0.601	rs12056476	chr8:21854188	T/A	cg17168535	chr8:21777572	XPO7	0.8	15.69	0.59	8.38e-45	Mean corpuscular volume;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.46	-9.27	-0.4	7.1e-19	Personality dimensions;
LGG	cis	rs10504073	0.647	rs59064792	chr8:50018337	A/C	cg00325661	chr8:49890786	NA	0.7	13.75	0.54	2.65e-36	Blood metabolite ratios;
LGG	cis	rs1790761	0.967	rs13859	chr11:67202156	C/T	cg00290607	chr11:67383545	NA	-0.49	-8.78	-0.38	3.16e-17	Mean corpuscular volume;
LGG	cis	rs4819052	0.851	rs2838845	chr21:46670812	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.92	0.38	1.06e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.681	rs11779172	chr8:58045538	A/G	cg14926445	chr8:58193284	C8orf71	-0.72	-9.24	-0.39	8.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2544527	0.819	rs2693018	chr2:15921554	A/G	cg26669897	chr2:15909070	NA	0.33	7.76	0.34	5.59e-14	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs13108904	0.935	rs2293633	chr4:1291640	T/C	cg02018176	chr4:1364513	KIAA1530	0.46	10.53	0.44	2.25e-23	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2486746	chr1:231497324	C/T	cg10503236	chr1:231470652	EXOC8	-0.38	-7.41	-0.33	6e-13	Hemoglobin concentration;
LGG	cis	rs4629180	0.586	rs1509494	chr2:102134862	G/T	cg16435561	chr2:102091048	RFX8	0.48	8.85	0.38	1.86e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs1865760	0.566	rs7772312	chr6:26049616	G/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.89	0.42	4.61e-21	Height;
LGG	trans	rs7618501	0.633	rs2526748	chr3:50080439	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.44	-7.94	-0.35	1.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.926	rs1378764	chr2:46839681	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-10.48	-0.44	3.22e-23	Height;
LGG	cis	rs7113850	0.551	rs4365050	chr11:24245730	G/A	ch.11.24196551F	chr11:24239977	NA	0.91	10.37	0.43	8.76e-23	Bone fracture in osteoporosis;
LGG	cis	rs9547996	0.879	rs17258466	chr13:38194065	A/G	cg13634560	chr13:38173852	POSTN	-0.35	-6.9	-0.31	1.74e-11	Diastolic blood pressure;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg07511668	chr11:68622177	NA	0.47	9.0	0.39	5.98e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2652822	0.710	rs56208666	chr15:63451858	T/G	cg02713581	chr15:63449717	RPS27L	0.48	8.14	0.35	3.65e-15	Metabolic traits;
LGG	cis	rs7937682	0.814	rs1619652	chr11:111469757	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.55e-21	Primary sclerosing cholangitis;
LGG	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg07882059	chr11:68924751	NA	0.41	7.39	0.32	6.87e-13	Blond vs. brown hair color;
LGG	cis	rs2307022	0.530	rs13336173	chr16:68345691	C/T	cg07273125	chr16:68295692	NA	0.46	10.42	0.44	5.64e-23	Body mass index;
LGG	cis	rs7107174	0.901	rs11237487	chr11:78126754	G/C	cg02023728	chr11:77925099	USP35	0.45	7.81	0.34	3.77e-14	Testicular germ cell tumor;
LGG	cis	rs7737355	0.812	rs798406	chr5:130689163	T/C	cg06307176	chr5:131281290	NA	-0.49	-8.17	-0.35	3.06e-15	Life satisfaction;
LGG	cis	rs2204008	0.635	rs1283298	chr12:38147630	G/A	cg13010199	chr12:38710504	ALG10B	-0.56	-10.85	-0.45	1.39e-24	Bladder cancer;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.52	8.24	0.36	1.74e-15	Renal function-related traits (BUN);
LGG	cis	rs13118159	0.573	rs7664763	chr4:1352305	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.59	9.94	0.42	3.01e-21	Longevity;
LGG	trans	rs656319	0.607	rs35437983	chr8:10005053	C/T	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.75	-0.38	3.93e-17	Myopia (pathological);
LGG	cis	rs9649465	1.000	rs1506635	chr7:123317184	C/T	cg03229431	chr7:123269106	ASB15	-0.4	-8.82	-0.38	2.28e-17	Migraine;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.7	-0.41	2.16e-20	Menopause (age at onset);
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	5.9e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs8062405	0.895	rs56186137	chr16:28825953	A/G	cg00204512	chr16:28754710	NA	0.27	7.7	0.34	8.44e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1728785	1.000	rs1094282	chr16:68577260	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs10915437	0.531	rs4233259	chr1:4197842	G/A	cg27165836	chr1:4193882	NA	0.45	8.73	0.38	4.63e-17	Migraine - clinic-based;
LGG	cis	rs6977660	0.507	rs72591450	chr7:19775480	A/G	cg05791153	chr7:19748676	TWISTNB	0.94	12.33	0.5	2.19e-30	Thyroid stimulating hormone;
LGG	cis	rs4740619	0.935	rs4740624	chr9:15753411	C/T	cg14451791	chr9:16040625	NA	0.4	10.08	0.42	9.4e-22	Body mass index;
LGG	cis	rs2131877	0.913	rs3897755	chr3:194847325	A/G	cg07250128	chr3:194833983	C3orf21	0.4	7.43	0.33	5.22e-13	Non-small cell lung cancer;
LGG	cis	rs3768617	0.528	rs4652778	chr1:183097420	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.18	0.39	1.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs3747547	0.892	rs72726029	chr9:38032868	C/T	cg13774184	chr9:37916125	SHB	-0.72	-7.18	-0.32	2.75e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07080220	chr10:102295463	HIF1AN	0.67	11.05	0.46	2.33e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs453301	0.624	rs330060	chr8:9090902	A/G	cg16141378	chr3:129829833	LOC729375	0.41	9.82	0.42	8.51e-21	Joint mobility (Beighton score);
LGG	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.88	-0.3	1.9e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9354308	0.764	rs9345709	chr6:66587678	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs1005277	0.522	rs11011343	chr10:38002698	A/G	cg17830980	chr10:43048298	ZNF37B	-0.44	-9.82	-0.42	8.51e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs9788682	0.668	rs2036529	chr15:78726272	A/T	cg06917634	chr15:78832804	PSMA4	0.52	7.81	0.34	3.8e-14	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs3087591	0.919	rs2952983	chr17:29470288	G/C	cg24425628	chr17:29625626	OMG;NF1	0.69	13.73	0.54	3.23e-36	Hip circumference;
LGG	cis	rs9300255	0.602	rs2695478	chr12:123689521	C/T	cg05973401	chr12:123451056	ABCB9	0.47	6.85	0.3	2.36e-11	Neutrophil percentage of white cells;
LGG	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg02631450	chr22:32366979	NA	0.94	9.1	0.39	2.78e-18	Childhood ear infection;
LGG	cis	rs611744	0.647	rs589347	chr8:109253929	T/A	cg21045802	chr8:109455806	TTC35	0.5	9.47	0.4	1.47e-19	Dupuytren's disease;
LGG	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg21466736	chr12:48725269	NA	-0.36	-7.07	-0.31	5.76e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	cis	rs9308731	0.842	rs56173510	chr2:111928436	G/T	cg26001287	chr2:111877753	BCL2L11	-0.37	-7.48	-0.33	3.65e-13	Chronic lymphocytic leukemia;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04936382	chr20:36662003	RPRD1B;KIAA0406	0.4	6.71	0.3	5.68e-11	Body mass index;
LGG	cis	rs6500395	1.000	rs12919520	chr16:48705760	G/C	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs5742933	0.857	rs1233272	chr2:190679694	A/G	cg04003228	chr2:190539410	ANKAR	0.46	6.83	0.3	2.7e-11	Ferritin levels;
LGG	cis	rs875971	0.545	rs4718335	chr7:65804606	C/T	cg11764359	chr7:65958608	NA	0.63	9.45	0.4	1.68e-19	Aortic root size;
LGG	cis	rs2916247	0.773	rs1471763	chr8:93100864	A/T	cg10183463	chr8:93005414	RUNX1T1	0.38	7.82	0.34	3.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1059312	0.808	rs2170989	chr12:129291317	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.87	20.65	0.69	1.25e-67	Systemic lupus erythematosus;
LGG	trans	rs7395662	0.617	rs1976509	chr11:48964603	C/T	cg00717180	chr2:96193071	NA	0.42	7.55	0.33	2.29e-13	HDL cholesterol;
LGG	cis	rs2131877	0.830	rs952586	chr3:194842322	G/A	cg07250128	chr3:194833983	C3orf21	0.41	6.97	0.31	1.08e-11	Non-small cell lung cancer;
LGG	cis	rs12421382	0.659	rs12417251	chr11:109386273	G/T	cg15948088	chr11:109293068	C11orf87	0.51	8.87	0.38	1.65e-17	Schizophrenia;
LGG	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.61	-0.33	1.56e-13	Myopia (pathological);
LGG	cis	rs28595532	0.920	rs115675321	chr4:119742153	A/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs611744	0.647	rs633901	chr8:109242981	G/T	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs921968	0.612	rs832810	chr2:219322430	T/C	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs151997	0.720	rs152096	chr5:50213850	A/G	cg06027927	chr5:50259733	NA	0.6	10.15	0.43	5.63e-22	Callous-unemotional behaviour;
LGG	cis	rs42648	0.755	rs1557650	chr7:89971556	A/C	cg25739043	chr7:89950458	NA	-0.35	-7.17	-0.32	3.08e-12	Homocysteine levels;
LGG	cis	rs62238980	0.614	rs75526838	chr22:32451830	A/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg18252515	chr7:66147081	NA	-1.31	-19.1	-0.66	2.09e-60	Diabetic kidney disease;
LGG	cis	rs6546550	0.901	rs1979214	chr2:70137498	G/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.04	-0.35	7.71e-15	Prevalent atrial fibrillation;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg07701084	chr6:150067640	NUP43	0.64	12.06	0.49	2.53e-29	Lung cancer;
LGG	cis	rs2587949	0.615	rs1319844	chr3:4229928	T/C	cg16519197	chr3:4211558	NA	-0.32	-6.74	-0.3	4.74e-11	Periodontitis (DPAL);
LGG	cis	rs17270561	0.609	rs4711101	chr6:25741970	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	trans	rs1032833	0.643	rs11900884	chr2:180027503	G/A	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg16507663	chr6:150244633	RAET1G	0.45	8.43	0.36	4.35e-16	Lung cancer;
LGG	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg00319359	chr11:70116639	PPFIA1	0.73	7.81	0.34	3.89e-14	Coronary artery disease;
LGG	cis	rs6088590	0.523	rs6058084	chr20:33183804	C/T	cg08999081	chr20:33150536	PIGU	0.45	11.44	0.47	7.23e-27	Coronary artery disease;
LGG	cis	rs7937682	0.855	rs571462	chr11:111487106	C/G	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg13206674	chr6:150067644	NUP43	0.68	15.96	0.6	5.39e-46	Lung cancer;
LGG	cis	rs1152591	0.524	rs1255990	chr14:64661523	A/G	cg23250157	chr14:64679961	SYNE2	-0.38	-6.89	-0.3	1.86e-11	Atrial fibrillation;
LGG	cis	rs12216125	0.801	rs56107510	chr6:25987436	C/A	cg17691542	chr6:26056736	HIST1H1C	0.72	12.29	0.5	3.09e-30	Iron status biomarkers;
LGG	cis	rs4740619	0.507	rs9407712	chr9:16005285	G/A	cg14451791	chr9:16040625	NA	0.29	7.15	0.32	3.49e-12	Body mass index;
LGG	cis	rs12497850	0.931	rs9311434	chr3:48884147	T/C	cg07636037	chr3:49044803	WDR6	1.06	25.58	0.77	1.28e-90	Parkinson's disease;
LGG	cis	rs7044106	0.791	rs4837792	chr9:123483559	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.88	17.41	0.63	1.42e-52	Hip circumference adjusted for BMI;
LGG	cis	rs4906332	0.782	rs2236281	chr14:104000518	G/T	cg23335576	chr14:104009727	NA	0.5	7.88	0.34	2.28e-14	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs2298862	chr17:41176688	T/C	cg18379455	chr17:41446167	NA	-0.33	-7.52	-0.33	2.94e-13	Menopause (age at onset);
LGG	cis	rs2213920	0.679	rs7860135	chr9:118242257	G/A	cg13918206	chr9:118159781	DEC1	0.59	7.85	0.34	2.93e-14	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.34	-0.53	1.41e-34	Aortic root size;
LGG	cis	rs1949733	0.523	rs55977448	chr4:8542918	G/T	cg11789530	chr4:8429930	ACOX3	-0.68	-10.95	-0.45	5.66e-25	Response to antineoplastic agents;
LGG	trans	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg11887960	chr12:57824829	NA	0.6	7.29	0.32	1.39e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg24375607	chr4:120327624	NA	0.69	11.15	0.46	1e-25	Corneal astigmatism;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg02475777	chr4:1388615	CRIPAK	0.38	6.98	0.31	1.03e-11	Longevity;
LGG	trans	rs61931739	0.892	rs61931711	chr12:34045374	C/T	cg13010199	chr12:38710504	ALG10B	-0.45	-8.18	-0.36	2.84e-15	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.62	-0.37	1.04e-16	Lung cancer;
LGG	cis	rs4774899	0.966	rs4369592	chr15:57559122	G/A	cg08128148	chr15:57256372	TCF12	-0.32	-7.28	-0.32	1.47e-12	Urinary tract infection frequency;
LGG	cis	rs6815464	1	rs6815464	chr4:1309901	C/G	cg17750186	chr4:1291076	MAEA	0.83	6.99	0.31	9.7e-12	Type 2 diabetes;
LGG	cis	rs6500395	1.000	rs3848322	chr16:48620964	C/A	cg04672837	chr16:48644449	N4BP1	0.57	9.43	0.4	1.95e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4730250	0.554	rs76257331	chr7:106916279	G/A	cg02696742	chr7:106810147	HBP1	-0.66	-8.75	-0.38	3.92e-17	Osteoarthritis;
LGG	cis	rs4808199	0.895	rs4808196	chr19:19476520	G/A	cg03709012	chr19:19516395	GATAD2A	1.08	17.52	0.63	4.18e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs9467773	0.620	rs1027203	chr6:26639332	G/C	cg09904177	chr6:26538194	HMGN4	0.62	12.15	0.49	1.11e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	1.000	rs1707317	chr1:46510642	C/T	cg03146154	chr1:46216737	IPP	-0.53	-10.12	-0.43	7.21e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs9487051	0.676	rs7775206	chr6:109597222	A/G	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.38e-14	Reticulocyte fraction of red cells;
LGG	cis	rs514024	0.729	rs3824523	chr9:130426944	T/G	cg13643465	chr9:130375613	STXBP1	0.63	11.86	0.48	1.67e-28	Eating disorders (purging via substances);
LGG	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg26597838	chr10:835615	NA	0.96	12.66	0.51	9.02e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs116095464	0.558	rs6962	chr5:256509	G/A	cg22857025	chr5:266934	NA	-1.52	-24.2	-0.75	3.08e-84	Breast cancer;
LGG	cis	rs4740619	0.967	rs7036674	chr9:15653882	C/T	cg14451791	chr9:16040625	NA	-0.42	-10.97	-0.45	4.71e-25	Body mass index;
LGG	cis	rs4650994	0.524	rs2811299	chr1:178586377	A/G	cg12486710	chr1:178512616	C1orf220	-0.5	-10.28	-0.43	1.77e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs875971	0.520	rs12666485	chr7:65625122	T/C	cg11764359	chr7:65958608	NA	0.63	9.74	0.41	1.64e-20	Aortic root size;
LGG	cis	rs7618501	0.573	rs7634917	chr3:50049299	T/G	cg05623727	chr3:50126028	RBM5	-0.33	-7.13	-0.31	3.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1465370	0.750	rs3807136	chr7:130019481	C/T	cg25718383	chr7:130020096	CPA1	0.33	8.48	0.37	2.95e-16	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	trans	rs1422110	0.515	rs1155791	chr5:85417582	A/C	cg01787110	chr1:109008453	NBPF6	0.8	13.52	0.53	2.41e-35	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg12855166	chr17:30846586	MYO1D	0.39	6.94	0.31	1.33e-11	Schizophrenia;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg08280861	chr8:58055591	NA	0.6	7.76	0.34	5.54e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs765787	0.530	rs1648287	chr15:45516956	T/C	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.97	-0.31	1.08e-11	Uric acid levels;
LGG	cis	rs4819052	1.000	rs4819052	chr21:46699777	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.86	14.03	0.55	1.67e-37	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9309473	0.607	rs7567017	chr2:73596270	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-8.64	-0.37	9.3e-17	Metabolite levels;
LGG	cis	rs262150	0.630	rs2730274	chr7:158796062	C/A	cg19418458	chr7:158789849	NA	-0.53	-10.94	-0.45	6.02e-25	Facial morphology (factor 20);
LGG	cis	rs3770081	1.000	rs2303340	chr2:86333193	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.87	-7.42	-0.33	5.55e-13	Facial emotion recognition (sad faces);
LGG	cis	rs2836974	0.623	rs7280326	chr21:40700408	A/G	cg06238570	chr21:40685208	BRWD1	-0.51	-8.38	-0.36	6.5e-16	Cognitive function;
LGG	cis	rs9297145	0.761	rs62473015	chr7:98763301	G/A	cg05967295	chr7:98741636	SMURF1	0.93	15.57	0.59	2.95e-44	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs12819124	0.502	rs10875718	chr12:48411102	G/T	cg24011408	chr12:48396354	COL2A1	0.61	10.4	0.44	6.83e-23	Glycated hemoglobin levels;
LGG	cis	rs7618915	0.547	rs34017441	chr3:52742413	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.44	4.75e-23	Bipolar disorder;
LGG	cis	rs9557207	1.000	rs9557191	chr13:99937416	C/T	cg24509225	chr13:100037070	UBAC2	0.68	12.18	0.49	8.7e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs972578	0.791	rs738385	chr22:43319320	T/C	cg01576275	chr22:43409880	NA	-0.22	-6.72	-0.3	5.38e-11	Mean platelet volume;
LGG	cis	rs7020830	0.931	rs9775431	chr9:37130433	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	31.06	0.82	2.83e-115	Schizophrenia;
LGG	cis	rs6952808	0.689	rs58227534	chr7:2046328	A/G	cg18279126	chr7:2041391	MAD1L1	0.32	6.79	0.3	3.42e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs1729951	0.575	rs10935214	chr3:136693485	G/A	cg12473912	chr3:136751656	NA	0.44	7.7	0.34	8.39e-14	Neuroticism;
LGG	cis	rs950169	0.887	rs71395453	chr15:85113490	G/C	cg03959625	chr15:84868606	LOC388152	0.57	9.03	0.39	4.55e-18	Schizophrenia;
LGG	cis	rs798502	0.541	rs2644307	chr7:2832973	G/A	cg19717773	chr7:2847554	GNA12	-0.34	-7.69	-0.34	9.04e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Inflammatory bowel disease;Waist circumference adjusted for BMI in non-smokers;Ulcerative colitis;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg11764359	chr7:65958608	NA	0.81	15.14	0.58	2.33e-42	Aortic root size;
LGG	trans	rs2574985	0.813	rs3011773	chr10:52276085	C/T	cg18558237	chr10:81444220	LOC650623	-0.45	-6.93	-0.31	1.4e-11	Subjective well-being;
LGG	trans	rs17685	0.753	rs11982200	chr7:75714883	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.91	0.77	3.84e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg05165339	chr4:1420672	NA	-0.36	-9.02	-0.39	4.86e-18	Longevity;
LGG	cis	rs875971	0.545	rs12671152	chr7:65776127	G/T	cg11764359	chr7:65958608	NA	0.64	9.35	0.4	3.77e-19	Aortic root size;
LGG	cis	rs61931739	0.517	rs11053067	chr12:34191391	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.4	-0.47	1.08e-26	Morning vs. evening chronotype;
LGG	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg14675211	chr2:100938903	LONRF2	0.58	9.19	0.39	1.33e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4938330	0.723	rs7931398	chr11:116879676	T/C	cg20608306	chr11:116969690	SIK3	-0.35	-9.42	-0.4	2.14e-19	Blood protein levels;
LGG	cis	rs597539	0.652	rs592697	chr11:68650064	G/A	cg21862992	chr11:68658383	NA	0.5	8.4	0.36	5.53e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs657075	0.697	rs35497612	chr5:131673106	C/T	cg20453264	chr5:131705742	SLC22A5	0.66	8.3	0.36	1.16e-15	Rheumatoid arthritis;
LGG	cis	rs7106204	0.609	rs11828535	chr11:24295565	G/C	ch.11.24196551F	chr11:24239977	NA	0.89	9.67	0.41	2.96e-20	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08753297	chr6:56716612	DST	0.5	8.13	0.35	3.94e-15	Cognitive performance;
LGG	cis	rs3733585	0.699	rs2018643	chr4:9947121	C/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.05	-0.35	6.85e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7617480	0.549	rs9879978	chr3:48846600	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.3	0.36	1.14e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9549367	0.789	rs2316442	chr13:113877487	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.56	-0.37	1.74e-16	Platelet distribution width;
LGG	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg08297393	chr2:100937505	LONRF2	-0.45	-7.46	-0.33	4.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg07701084	chr6:150067640	NUP43	0.65	12.28	0.5	3.49e-30	Lung cancer;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg21782813	chr7:2030301	MAD1L1	0.47	11.19	0.46	6.75e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg08355456	chr11:67383691	NA	0.5	8.55	0.37	1.85e-16	Mean corpuscular volume;
LGG	trans	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg07211511	chr3:129823064	LOC729375	-1.32	-16.93	-0.62	2.06e-50	Blood pressure (smoking interaction);
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg14196790	chr5:131705035	SLC22A5	0.61	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs72945132	0.882	rs7943840	chr11:70228615	C/A	cg13802316	chr11:70253460	CTTN	-0.57	-7.38	-0.32	7.5e-13	Coronary artery disease;
LGG	cis	rs72781680	0.821	rs12623521	chr2:24181670	C/T	cg08917208	chr2:24149416	ATAD2B	0.65	8.65	0.37	8.75e-17	Lymphocyte counts;
LGG	cis	rs883565	0.654	rs6779880	chr3:39022926	G/T	cg01426195	chr3:39028469	NA	0.73	15.69	0.59	8.58e-45	Handedness;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg22907277	chr7:1156413	C7orf50	0.43	7.58	0.33	1.95e-13	Longevity;Endometriosis;
LGG	cis	rs4319547	0.586	rs7956480	chr12:122817507	A/G	cg23029597	chr12:123009494	RSRC2	-0.89	-16.33	-0.6	1.17e-47	Body mass index;
LGG	cis	rs12347191	0.500	rs925486	chr9:100619733	C/T	cg13688889	chr9:100608707	NA	-0.82	-16.07	-0.6	1.65e-46	Orofacial clefts;
LGG	cis	rs7179456	0.513	rs593742	chr15:59045774	A/G	cg05156742	chr15:59063176	FAM63B	0.59	9.77	0.41	1.24e-20	Asperger disorder;
LGG	cis	rs12477438	0.765	rs62156363	chr2:99693324	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.51	9.03	0.39	4.53e-18	Longevity;
LGG	cis	rs3741404	0.609	rs666497	chr11:63869821	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	15.31	0.58	4.19e-43	Platelet count;
LGG	cis	rs12216125	0.554	rs6942196	chr6:26072804	A/G	cg12310025	chr6:25882481	NA	-0.37	-6.7	-0.3	6.01e-11	Iron status biomarkers;
LGG	cis	rs6912958	0.781	rs2273129	chr6:88182439	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.47	-0.37	3.18e-16	Monocyte percentage of white cells;
LGG	cis	rs11874712	0.527	rs7359798	chr18:43648999	A/C	cg26436583	chr18:43649176	PSTPIP2	0.66	16.17	0.6	5.83e-47	Migraine - clinic-based;
LGG	cis	rs1577917	0.916	rs12203358	chr6:86603224	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.75	-13.37	-0.53	1.04e-34	Response to antipsychotic treatment;
LGG	cis	rs7633770	0.622	rs34063921	chr3:46689922	A/G	cg11219411	chr3:46661640	NA	-0.5	-10.87	-0.45	1.16e-24	Coronary artery disease;
LGG	cis	rs1129187	0.755	rs9471976	chr6:42920549	G/T	cg10056627	chr6:42928773	GNMT	0.26	7.16	0.32	3.11e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs9650657	0.617	rs7814795	chr8:10519285	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.15	-0.35	3.39e-15	Neuroticism;
LGG	cis	rs7833790	0.963	rs72686466	chr8:82758928	G/T	cg23324259	chr8:82754387	SNX16	0.45	7.19	0.32	2.55e-12	Diastolic blood pressure;
LGG	cis	rs10791323	0.569	rs5019134	chr11:133713082	G/C	cg06766960	chr11:133703094	NA	-0.58	-11.39	-0.47	1.13e-26	Childhood ear infection;
LGG	cis	rs1322639	0.614	rs6908401	chr6:169564716	A/C	cg04662567	chr6:169592167	NA	0.77	11.39	0.47	1.15e-26	Pulse pressure;
LGG	cis	rs9467773	0.587	rs12214031	chr6:26376628	T/C	cg09904177	chr6:26538194	HMGN4	-0.46	-8.19	-0.36	2.6e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.02	13.68	0.54	5.35e-36	Platelet count;
LGG	cis	rs78366141	0.649	rs7674009	chr4:89683324	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	-0.72	-7.18	-0.32	2.72e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.54	10.09	0.42	9.26e-22	Rheumatoid arthritis;
LGG	cis	rs12220238	0.722	rs6480743	chr10:76398765	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.5	6.72	0.3	5.22e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs2574985	0.739	rs2983361	chr10:52315880	G/T	cg18558237	chr10:81444220	LOC650623	0.44	6.76	0.3	4.05e-11	Subjective well-being;
LGG	cis	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.32	-0.32	1.1e-12	Mood instability;
LGG	cis	rs3540	0.597	rs1978150	chr15:91037041	A/G	cg22089800	chr15:90895588	ZNF774	-0.7	-12.96	-0.52	5.37e-33	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs950169	0.920	rs11637666	chr15:84703874	A/G	cg03959625	chr15:84868606	LOC388152	0.52	7.53	0.33	2.63e-13	Schizophrenia;
LGG	cis	rs10823500	0.748	rs12355080	chr10:71963608	G/A	cg02100629	chr10:71892760	AIFM2	-0.29	-6.85	-0.3	2.3e-11	Blood protein levels;
LGG	trans	rs561341	1.000	rs72821971	chr17:30269343	T/G	cg27661571	chr11:113659931	NA	-0.7	-9.54	-0.41	8.15e-20	Hip circumference adjusted for BMI;
LGG	cis	rs9911578	0.967	rs4598970	chr17:57076893	T/A	cg12560992	chr17:57184187	TRIM37	-0.91	-15.95	-0.6	6.09e-46	Intelligence (multi-trait analysis);
LGG	cis	rs8180040	0.800	rs11921117	chr3:47294000	T/C	cg27129171	chr3:47204927	SETD2	-0.8	-14.31	-0.55	9.84e-39	Colorectal cancer;
LGG	cis	rs2742417	1.000	rs2673056	chr3:45737802	C/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.41e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg00761968	chr13:53314142	LECT1	-0.37	-7.84	-0.34	3.14e-14	Lewy body disease;
LGG	cis	rs950776	0.518	rs2869544	chr15:78839400	G/A	cg16751781	chr15:78858589	CHRNA5	-0.47	-9.38	-0.4	3.04e-19	Sudden cardiac arrest;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs12643440	0.538	rs56235875	chr4:17138883	T/C	cg22650099	chr4:17144496	NA	-0.5	-8.58	-0.37	1.43e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs2836974	0.568	rs452377	chr21:40537183	T/C	cg17971929	chr21:40555470	PSMG1	0.71	13.42	0.53	6.33e-35	Cognitive function;
LGG	cis	rs3820068	0.734	rs6674806	chr1:15902656	A/G	cg05660106	chr1:15850417	CASP9	1.13	23.46	0.74	9.24e-81	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.45	-0.4	1.66e-19	Menopause (age at onset);
LGG	trans	rs11976180	0.953	rs2951355	chr7:143760562	A/C	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.68	-0.34	9.44e-14	Skin colour saturation;
LGG	cis	rs9296095	0.656	rs547391	chr6:33563913	T/A	cg14003231	chr6:33640908	ITPR3	0.34	7.13	0.31	3.81e-12	Platelet count;
LGG	cis	rs4295623	0.816	rs35558975	chr8:11584476	C/G	cg21775007	chr8:11205619	TDH	-0.44	-6.78	-0.3	3.63e-11	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.835	rs11654584	chr17:80079435	A/T	cg07959490	chr17:80112427	CCDC57	-0.46	-8.91	-0.38	1.16e-17	Life satisfaction;
LGG	cis	rs2839186	0.900	rs2839196	chr21:47708037	G/A	cg13012494	chr21:47604986	C21orf56	0.5	8.75	0.38	4.14e-17	Testicular germ cell tumor;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg04863758	chr4:1303710	MAEA	0.46	7.85	0.34	2.95e-14	Obesity-related traits;
LGG	cis	rs72945132	0.941	rs66803755	chr11:70117473	G/A	cg00319359	chr11:70116639	PPFIA1	0.69	7.55	0.33	2.27e-13	Coronary artery disease;
LGG	cis	rs2832191	0.740	rs2012645	chr21:30445961	G/A	cg08807101	chr21:30365312	RNF160	0.92	19.49	0.67	3.36e-62	Dental caries;
LGG	cis	rs9790314	0.846	rs9815222	chr3:160994897	C/T	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg21548813	chr6:291882	DUSP22	-0.73	-12.84	-0.51	1.7e-32	Menopause (age at onset);
LGG	cis	rs7444	0.825	rs73166630	chr22:21945978	G/A	cg05046821	chr22:21984468	YDJC	-0.39	-7.09	-0.31	5e-12	Systemic lupus erythematosus;
LGG	cis	rs6087990	0.735	rs1855350	chr20:31387525	C/T	cg13636640	chr20:31349939	DNMT3B	0.83	17.21	0.62	1.11e-51	Ulcerative colitis;
LGG	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg20608306	chr11:116969690	SIK3	0.35	9.27	0.4	7.33e-19	Blood protein levels;
LGG	cis	rs10504229	0.815	rs72650877	chr8:58164510	T/C	cg14926445	chr8:58193284	C8orf71	-0.87	-11.37	-0.47	1.42e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs12200782	0.649	rs9467746	chr6:26387405	A/G	cg27193005	chr6:26382695	BTN2A2	-0.52	-7.46	-0.33	4.34e-13	Small cell lung carcinoma;
LGG	cis	rs2302729	1.000	rs7974589	chr12:2785089	G/A	cg19945202	chr12:2788847	CACNA1C	-0.83	-12.28	-0.5	3.34e-30	Sleep quality;
LGG	cis	rs10504229	0.683	rs7463453	chr8:58112053	A/G	cg02725872	chr8:58115012	NA	-1.05	-15.38	-0.58	2.03e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs12579753	1.000	rs7966755	chr12:82221604	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	cis	rs988958	0.567	rs34117938	chr2:42258394	A/C	cg19376973	chr2:42229025	NA	0.67	10.59	0.44	1.26e-23	Hypospadias;
LGG	cis	rs2204008	0.546	rs11519978	chr12:37998170	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.24	0.72	4.35e-75	Bladder cancer;
LGG	cis	rs4006360	0.629	rs72625995	chr17:39253835	C/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-10.93	-0.45	6.52e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6088590	1.000	rs11696546	chr20:33452999	C/G	cg06115741	chr20:33292138	TP53INP2	0.57	9.04	0.39	4.15e-18	Coronary artery disease;
LGG	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg06699216	chr8:19333253	CSGALNACT1	0.4	8.86	0.38	1.76e-17	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs2153535	0.542	rs9505465	chr6:8510846	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.0	0.39	6.01e-18	Motion sickness;
LGG	trans	rs941408	1.000	rs1736184	chr19:2810248	G/A	cg19676328	chr12:49525230	TUBA1B	-0.63	-9.97	-0.42	2.45e-21	Total cholesterol levels;
LGG	cis	rs35740288	0.822	rs17637142	chr15:86240503	T/C	cg04173714	chr15:86211321	AKAP13	0.46	8.01	0.35	9.38e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs738322	0.511	rs2267370	chr22:38576826	G/A	cg03162506	chr22:38580953	NA	0.36	8.99	0.39	6.53e-18	Cutaneous nevi;
LGG	cis	rs13102973	0.899	rs4541577	chr4:135901087	G/T	cg14419869	chr4:135874104	NA	0.45	8.22	0.36	2.12e-15	Subjective well-being;
LGG	cis	rs6088580	0.634	rs6088512	chr20:33095891	G/A	cg24642439	chr20:33292090	TP53INP2	0.56	9.4	0.4	2.6e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg03264133	chr6:25882463	NA	-0.47	-7.08	-0.31	5.51e-12	Height;
LGG	cis	rs17767392	0.958	rs6574016	chr14:72040525	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.81	-0.41	9.44e-21	Mitral valve prolapse;
LGG	trans	rs61931739	0.890	rs11053018	chr12:34105962	T/G	cg26384229	chr12:38710491	ALG10B	-0.64	-12.46	-0.5	6.25e-31	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.553	rs4236381	chr7:1165723	A/C	cg22907277	chr7:1156413	C7orf50	0.7	12.94	0.52	6.47e-33	Longevity;Endometriosis;
LGG	cis	rs1799949	0.965	rs7212284	chr17:41205941	A/G	cg01879757	chr17:41196368	BRCA1	-0.42	-8.62	-0.37	1.08e-16	Menopause (age at onset);
LGG	cis	rs11711311	0.955	rs34458493	chr3:113396473	C/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.5	0.53	2.93e-35	IgG glycosylation;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00349776	chr1:165414189	RXRG	0.4	7.1	0.31	4.68e-12	Bipolar disorder;
LGG	cis	rs7727544	0.557	rs715285	chr5:131485383	A/G	cg07395648	chr5:131743802	NA	-0.4	-8.79	-0.38	2.86e-17	Blood metabolite levels;
LGG	cis	rs7937890	0.532	rs2575833	chr11:14492505	A/C	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs7312933	0.533	rs17551006	chr12:42848738	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.11	0.35	4.72e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs61931739	0.635	rs1352208	chr12:33932543	T/C	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs67366981	1.000	rs17105594	chr14:77713146	C/T	cg22824376	chr14:77648248	TMEM63C	0.69	7.36	0.32	8.35e-13	Obsessive-compulsive symptoms;
LGG	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg06470251	chr20:60548479	NA	0.48	8.31	0.36	1.05e-15	Body mass index;
LGG	cis	rs4460629	0.742	rs11581730	chr1:155082158	A/T	cg13808842	chr1:155066096	NA	-0.29	-7.05	-0.31	6.43e-12	Serum magnesium levels;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg09699651	chr6:150184138	LRP11	0.51	9.13	0.39	2.06e-18	Lung cancer;
LGG	cis	rs8070128	0.597	rs4635395	chr17:17882087	G/A	cg05444541	chr17:17804740	TOM1L2	-0.73	-14.99	-0.57	1.11e-41	Total body bone mineral density;
LGG	cis	rs2287838	0.716	rs7254559	chr19:10003119	C/G	cg00846166	chr19:10022875	OLFM2	0.32	7.36	0.32	8.65e-13	Sleep duration;
LGG	cis	rs12477438	0.765	rs12468807	chr2:99691994	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.59	-0.51	1.75e-31	Chronic sinus infection;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg25703541	chr22:24373054	LOC391322	-0.87	-17.13	-0.62	2.69e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg02475777	chr4:1388615	CRIPAK	0.41	7.55	0.33	2.31e-13	Longevity;
LGG	cis	rs4660214	0.724	rs10788933	chr1:39695155	A/G	cg18385671	chr1:39797026	MACF1	-0.46	-9.44	-0.4	1.79e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs3135071	1.000	rs3135071	chr4:2406321	C/T	cg27239842	chr4:2403781	ZFYVE28	0.96	9.63	0.41	3.91e-20	Influenza A (H1N1) severity;
LGG	cis	rs2067615	0.579	rs10778509	chr12:107162918	G/A	cg15890332	chr12:107067104	RFX4	0.41	12.09	0.49	1.99e-29	Heart rate;
LGG	cis	rs9309473	0.632	rs6706179	chr2:73578577	C/T	cg20560298	chr2:73613845	ALMS1	-0.49	-8.85	-0.38	1.87e-17	Metabolite levels;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg10935494	chr17:80760059	TBCD	-0.37	-6.99	-0.31	9.83e-12	Glycated hemoglobin levels;
LGG	cis	rs4938330	0.600	rs2239010	chr11:117089006	G/C	cg01368799	chr11:117014884	PAFAH1B2	-0.59	-7.63	-0.33	1.39e-13	Blood protein levels;
LGG	cis	rs8062405	0.690	rs6498089	chr16:28629300	C/T	cg16576597	chr16:28551801	NUPR1	-0.36	-7.99	-0.35	1.06e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3770081	1.000	rs60479377	chr2:86283948	A/C	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.98	-8.66	-0.37	7.63e-17	Facial emotion recognition (sad faces);
LGG	cis	rs6752107	1.000	rs2241880	chr2:234183368	A/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.87	0.34	2.61e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7826238	0.564	rs2921053	chr8:8319963	G/C	cg14979609	chr8:8086686	FLJ10661	-0.28	-7.12	-0.31	4.27e-12	Systolic blood pressure;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg07459266	chr17:78234739	RNF213	0.48	6.95	0.31	1.27e-11	Hip circumference;
LGG	trans	rs826838	0.967	rs34496261	chr12:39023829	G/A	cg06521331	chr12:34319734	NA	-0.45	-7.65	-0.33	1.2e-13	Heart rate;
LGG	cis	rs17209837	1.000	rs17209662	chr7:87121968	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-11.57	-0.47	2.19e-27	Gallbladder cancer;
LGG	cis	rs62400317	0.859	rs11964690	chr6:45258068	A/G	cg20913747	chr6:44695427	NA	-0.61	-10.09	-0.42	8.64e-22	Total body bone mineral density;
LGG	cis	rs2820315	1.000	rs2820316	chr1:201811761	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.9	0.31	1.75e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs9818758	0.607	rs34566463	chr3:49245077	T/C	cg00383909	chr3:49044727	WDR6	0.97	12.35	0.5	1.78e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs2730245	0.505	rs1188956	chr7:158690576	G/A	cg24397884	chr7:158709396	WDR60	0.92	20.23	0.69	1.08e-65	Height;
LGG	trans	rs9329221	0.662	rs4240645	chr8:10254463	C/G	cg02002194	chr4:3960332	NA	0.39	6.69	0.3	6.56e-11	Neuroticism;
LGG	cis	rs3820068	0.603	rs1980607	chr1:15975237	A/G	cg05660106	chr1:15850417	CASP9	0.84	17.82	0.64	1.83e-54	Systolic blood pressure;
LGG	cis	rs2836974	0.897	rs11911112	chr21:40528346	A/C	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs4704187	0.687	rs4703657	chr5:74461850	T/G	cg03227963	chr5:74354835	NA	0.32	6.85	0.3	2.4e-11	Response to amphetamines;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg01879757	chr17:41196368	BRCA1	0.43	8.69	0.37	6.24e-17	Menopause (age at onset);
LGG	cis	rs953387	0.910	rs13415439	chr2:136930232	C/A	cg07169764	chr2:136633963	MCM6	0.54	8.84	0.38	2.02e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.29	0.32	1.33e-12	Lung cancer;
LGG	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg26384229	chr12:38710491	ALG10B	-0.73	-13.98	-0.54	2.61e-37	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg24250549	chr1:154909240	PMVK	0.66	11.58	0.47	2.14e-27	Prostate cancer;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	cis	rs13082711	0.911	rs34981505	chr3:27437322	A/T	cg02860705	chr3:27208620	NA	0.7	12.88	0.51	1.21e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	-0.47	-7.36	-0.32	8.65e-13	Height;
LGG	trans	rs4332037	1.000	rs4332037	chr7:1950809	C/T	cg22232500	chr2:134024266	NCKAP5	0.62	8.69	0.37	6.41e-17	Bipolar disorder;
LGG	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.15e-17	Axial length;
LGG	cis	rs300703	0.592	rs300800	chr2:105493	T/C	cg24565620	chr2:194026	NA	0.69	10.06	0.42	1.19e-21	Blood protein levels;
LGG	cis	rs72615157	0.561	rs113401658	chr7:99858505	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.8	11.16	0.46	8.91e-26	Lung function (FEV1/FVC);
LGG	cis	rs68170813	0.559	rs76145119	chr7:107052368	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.18	-0.43	4.3e-22	Coronary artery disease;
LGG	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg19077165	chr18:44547161	KATNAL2	-0.48	-8.34	-0.36	8.42e-16	Educational attainment;
LGG	cis	rs35160687	0.901	rs10520415	chr2:86498738	C/T	cg10973622	chr2:86423274	IMMT	-0.39	-6.74	-0.3	4.71e-11	Night sleep phenotypes;
LGG	cis	rs6460942	1.000	rs62448563	chr7:12400040	G/A	cg06484146	chr7:12443880	VWDE	-0.4	-6.66	-0.3	7.86e-11	Coronary artery disease;
LGG	cis	rs10214930	0.624	rs4719902	chr7:27588342	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.78	0.3	3.68e-11	Hypospadias;
LGG	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg04374321	chr14:90722782	PSMC1	0.5	8.22	0.36	2.03e-15	Longevity;
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.88e-11	Aortic root size;
LGG	cis	rs4148087	0.932	rs2839476	chr21:43609680	A/T	cg08841829	chr21:43638893	ABCG1	-0.54	-7.24	-0.32	1.85e-12	Eating disorder in bipolar disorder;
LGG	cis	rs1552244	0.751	rs12715665	chr3:10021601	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.23	0.63	9.32e-52	Alzheimer's disease;
LGG	cis	rs73086581	1.000	rs6052209	chr20:3961747	G/A	cg02187196	chr20:3869020	PANK2	0.82	11.54	0.47	3e-27	Response to antidepressants in depression;
LGG	cis	rs13191362	0.507	rs2023037	chr6:163120385	C/T	cg21926612	chr6:163149169	PACRG;PARK2	0.63	8.72	0.38	5.19e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6840360	1.000	rs10023298	chr4:152666768	A/C	cg22705602	chr4:152727874	NA	-0.26	-6.71	-0.3	5.59e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10937275	0.826	rs34695488	chr3:186644463	A/G	cg13419791	chr3:186648285	ST6GAL1	0.79	8.02	0.35	9e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7572733	0.935	rs10204166	chr2:198835264	C/G	cg00792783	chr2:198669748	PLCL1	0.49	8.28	0.36	1.34e-15	Dermatomyositis;
LGG	cis	rs6912958	0.559	rs242270	chr6:88062190	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.69	-13.15	-0.52	8.39e-34	Monocyte percentage of white cells;
LGG	cis	rs6743226	0.901	rs7592138	chr2:242218915	G/A	cg10021735	chr2:242295487	FARP2	0.49	8.95	0.38	8.42e-18	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs9902453	0.868	rs11080118	chr17:28475379	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.65	-12.24	-0.49	4.76e-30	Coffee consumption (cups per day);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14154182	chr19:10362775	MRPL4	0.5	7.25	0.32	1.8e-12	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.79	-0.41	1.05e-20	Primary sclerosing cholangitis;
LGG	cis	rs9947295	0.649	rs73401824	chr18:11783354	T/C	cg14735704	chr18:11749182	GNAL	0.47	7.29	0.32	1.35e-12	QT interval (drug interaction);
LGG	cis	rs612683	0.824	rs17454919	chr1:100830370	A/G	cg06223162	chr1:101003688	GPR88	0.4	9.58	0.41	5.78e-20	Breast cancer;
LGG	cis	rs12153243	1.000	rs57450351	chr5:142906561	T/C	cg13907255	chr5:142895549	NA	-0.4	-7.58	-0.33	1.9e-13	Migraine;
LGG	cis	rs9322193	0.923	rs57938011	chr6:149964105	T/A	cg09699651	chr6:150184138	LRP11	0.5	8.65	0.37	8.57e-17	Lung cancer;
LGG	cis	rs6988985	0.728	rs4478551	chr8:143945787	G/T	cg10324643	chr8:143916377	GML	0.38	7.65	0.34	1.14e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs35771425	0.619	rs7538812	chr1:211442186	A/G	cg10512769	chr1:211675356	NA	-0.39	-6.91	-0.31	1.59e-11	Educational attainment (years of education);
LGG	cis	rs4262150	0.764	rs4478308	chr5:151936869	A/G	cg12297329	chr5:152029980	NA	-0.72	-13.79	-0.54	1.79e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs9527	0.590	rs12414232	chr10:104914491	A/T	cg04362960	chr10:104952993	NT5C2	0.56	10.45	0.44	4.28e-23	Arsenic metabolism;
LGG	cis	rs6840360	0.642	rs2724578	chr4:152367304	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.91	-13.11	-0.52	1.3e-33	Schizophrenia;
LGG	cis	rs4698433	0.962	rs4698431	chr4:15961555	G/A	cg15380744	chr4:15964812	FGFBP2	-0.23	-6.65	-0.3	8.12e-11	QT interval;
LGG	cis	rs806215	1.000	rs806219	chr7:127240094	A/C	cg25922125	chr7:127225783	GCC1	0.74	10.22	0.43	3.14e-22	Type 2 diabetes;
LGG	cis	rs4665809	1.000	rs4665820	chr2:26309150	T/C	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	trans	rs9325144	0.602	rs11169100	chr12:39077861	G/T	cg06521331	chr12:34319734	NA	0.4	6.67	0.3	7.38e-11	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.843	rs1525798	chr7:39112580	A/C	cg10621924	chr7:39171070	POU6F2	0.41	8.32	0.36	1.03e-15	IgG glycosylation;
LGG	cis	rs1358748	0.522	rs6701962	chr1:67564857	A/T	cg02640540	chr1:67518911	SLC35D1	0.53	6.98	0.31	1e-11	Tuberculosis;
LGG	cis	rs6558530	1.000	rs6558530	chr8:1706207	A/G	cg19131313	chr8:1704013	NA	-0.3	-6.79	-0.3	3.4e-11	Systolic blood pressure;
LGG	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	trans	rs116095464	0.558	rs9654452	chr5:299561	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.19	-0.36	2.59e-15	Breast cancer;
LGG	cis	rs73001065	0.818	rs12610191	chr19:19721976	C/T	cg03709012	chr19:19516395	GATAD2A	0.79	7.2	0.32	2.37e-12	LDL cholesterol;
LGG	cis	rs4478037	0.558	rs80167648	chr3:33069317	A/G	cg19404215	chr3:33155277	CRTAP	0.74	6.73	0.3	5.18e-11	Major depressive disorder;
LGG	cis	rs2032447	0.831	rs9467664	chr6:26021813	A/T	cg03517284	chr6:25882590	NA	-0.64	-12.04	-0.49	3.16e-29	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs8055138	chr16:28891465	C/T	cg00204512	chr16:28754710	NA	0.26	7.3	0.32	1.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.593	rs4738567	chr8:57997033	A/C	cg05313129	chr8:58192883	C8orf71	-0.57	-7.58	-0.33	1.93e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	1.000	rs67150649	chr5:93292377	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.56	-0.41	6.76e-20	Diabetic retinopathy;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.43	-10.97	-0.45	4.58e-25	IgG glycosylation;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg18713687	chr3:195489789	MUC4	0.6	8.4	0.36	5.57e-16	Lung disease severity in cystic fibrosis;
LGG	cis	rs7927592	0.763	rs7120876	chr11:68261398	C/G	cg16797656	chr11:68205561	LRP5	0.52	10.12	0.43	6.93e-22	Total body bone mineral density;
LGG	cis	rs9581857	0.579	rs2780341	chr13:27996401	C/T	cg01674679	chr13:27998804	GTF3A	0.74	8.61	0.37	1.13e-16	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg17050807	chr22:42548356	NA	-0.39	-7.3	-0.32	1.28e-12	Schizophrenia;
LGG	trans	rs7395662	0.963	rs11040016	chr11:48783497	A/G	cg00717180	chr2:96193071	NA	0.42	7.43	0.33	5.45e-13	HDL cholesterol;
LGG	cis	rs16854884	0.837	rs989665	chr3:143792854	C/T	cg06585982	chr3:143692056	C3orf58	0.58	9.57	0.41	6.5e-20	Economic and political preferences (feminism/equality);
LGG	cis	rs9807841	0.568	rs1560707	chr19:10750738	A/C	cg09936142	chr19:10668400	KRI1	-0.41	-6.83	-0.3	2.64e-11	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01420088	chr10:101491661	CUTC;COX15	0.58	8.81	0.38	2.51e-17	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg03517284	chr6:25882590	NA	0.5	9.52	0.4	9.46e-20	Blood metabolite levels;
LGG	cis	rs7726839	0.574	rs12517345	chr5:628294	G/A	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.6e-15	Obesity-related traits;
LGG	trans	rs1994135	0.549	rs2218650	chr12:33734783	A/G	cg26384229	chr12:38710491	ALG10B	0.65	11.93	0.48	8.47e-29	Resting heart rate;
LGG	cis	rs2404602	0.647	rs12914196	chr15:76941361	C/T	cg15268244	chr15:77196840	NA	0.48	10.22	0.43	2.97e-22	Blood metabolite levels;
LGG	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg26119090	chr2:26468346	HADHA;HADHB	0.97	14.94	0.57	1.83e-41	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05370988	chr3:186500739	EIF4A2	0.48	8.08	0.35	5.6e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs1506636	1.000	rs1911145	chr7:123363658	A/G	cg03229431	chr7:123269106	ASB15	-0.74	-18.49	-0.65	1.39e-57	Plateletcrit;Platelet count;
LGG	cis	rs28386778	0.901	rs2854194	chr17:61952110	T/G	cg11494091	chr17:61959527	GH2	1.04	26.28	0.77	8.03e-94	Prudent dietary pattern;
LGG	trans	rs116095464	0.558	rs6882584	chr5:223411	A/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs847577	0.722	rs6951277	chr7:97711783	A/G	cg13397024	chr7:97797637	LMTK2	-0.35	-6.65	-0.3	8.25e-11	Breast cancer;
LGG	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-7.39	-0.32	6.8e-13	Smoking behavior;
LGG	cis	rs2587949	0.615	rs795293	chr3:4185953	C/T	cg16519197	chr3:4211558	NA	-0.33	-6.76	-0.3	4.15e-11	Periodontitis (DPAL);
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg10603824	chr17:48943588	NA	-0.4	-6.7	-0.3	6.17e-11	Platelet count;
LGG	cis	rs2559856	0.904	rs2695283	chr12:102089391	G/C	cg15068132	chr12:102092402	CHPT1	-0.37	-6.78	-0.3	3.57e-11	Blood protein levels;
LGG	cis	rs362296	0.530	rs3129316	chr4:3287906	A/G	cg06533319	chr4:3265114	C4orf44	-0.42	-8.78	-0.38	3.28e-17	Parental longevity (mother's age at death);
LGG	cis	rs6429082	0.818	rs291344	chr1:235663860	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.61	-10.13	-0.43	6.37e-22	Adiposity;
LGG	cis	rs7811142	1.000	rs11769700	chr7:100090049	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	20.67	0.69	1.01e-67	Platelet count;
LGG	cis	rs1580019	0.568	rs2122633	chr7:32523870	G/T	cg07520158	chr7:32535189	LSM5;AVL9	0.53	8.58	0.37	1.47e-16	Cognitive ability;
LGG	cis	rs1003719	0.688	rs2835662	chr21:38568967	T/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	trans	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg13010199	chr12:38710504	ALG10B	0.44	8.57	0.37	1.55e-16	Morning vs. evening chronotype;
LGG	trans	rs3779273	0.649	rs10256412	chr7:77836723	A/C	cg05596911	chr5:118502651	DMXL1	0.47	10.0	0.42	1.96e-21	Body mass index;
LGG	cis	rs908922	0.887	rs1538084	chr1:152496012	A/C	cg20991723	chr1:152506922	NA	-0.57	-9.58	-0.41	5.95e-20	Hair morphology;
LGG	cis	rs4430311	0.691	rs1531244	chr1:243939970	A/G	cg25706552	chr1:244017396	NA	-0.65	-15.82	-0.59	2.12e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs28386778	0.700	rs12449555	chr17:62003982	T/A	cg11494091	chr17:61959527	GH2	-1.05	-27.08	-0.78	1.72e-97	Prudent dietary pattern;
LGG	cis	rs1218582	0.600	rs72702224	chr1:154911689	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.49	9.38	0.4	2.86e-19	Prostate cancer;
LGG	cis	rs8028313	0.630	rs7169086	chr15:67934454	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.15	-0.35	3.48e-15	Obesity;
LGG	trans	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg13565492	chr6:43139072	SRF	-0.9	-15.52	-0.58	4.76e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2456568	0.548	rs7117597	chr11:93655091	A/G	cg17595323	chr11:93583763	C11orf90	-0.44	-7.91	-0.34	1.96e-14	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs283228	0.617	rs2629982	chr6:101799654	C/T	cg27451362	chr6:101846650	GRIK2	0.85	13.14	0.52	9.84e-34	Coenzyme Q10 levels;
LGG	cis	rs780096	0.526	rs780112	chr2:27665361	C/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.68	-0.51	7.67e-32	Total body bone mineral density;
LGG	cis	rs240764	0.817	rs6905221	chr6:101151537	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.48	-0.33	3.72e-13	Neuroticism;
LGG	cis	rs12143943	0.835	rs4951383	chr1:204452278	A/G	cg20240347	chr1:204465584	NA	-0.34	-7.22	-0.32	2.09e-12	Cognitive performance;
LGG	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg18357526	chr6:26021779	HIST1H4A	0.47	7.74	0.34	6.16e-14	Height;
LGG	cis	rs977987	0.806	rs1544810	chr16:75411163	A/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.05e-11	Dupuytren's disease;
LGG	trans	rs116095464	0.558	rs6866632	chr5:264429	C/G	cg09048205	chr5:1608656	LOC728613	-0.48	-8.23	-0.36	1.89e-15	Breast cancer;
LGG	cis	rs713587	1.000	rs2384054	chr2:25156773	T/C	cg04586622	chr2:25135609	ADCY3	0.45	11.93	0.48	8.79e-29	Body mass index in non-asthmatics;
LGG	cis	rs4144027	0.904	rs10438243	chr14:104345822	A/G	cg20488157	chr14:104394430	TDRD9	0.4	6.83	0.3	2.63e-11	Blood metabolite levels;
LGG	cis	rs17345786	0.511	rs12639028	chr3:101346033	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.09	0.52	1.63e-33	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg11494091	chr17:61959527	GH2	0.5	7.55	0.33	2.32e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg26513180	chr16:89883248	FANCA	-1.01	-9.83	-0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs12142240	0.583	rs5013330	chr1:46815154	G/A	cg25706281	chr1:46860511	FAAH	-0.28	-6.84	-0.3	2.58e-11	Menopause (age at onset);
LGG	cis	rs5758511	0.514	rs5758629	chr22:42574555	C/T	cg00645731	chr22:42541494	CYP2D7P1	0.48	7.71	0.34	7.5e-14	Birth weight;
LGG	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg09307838	chr4:120376055	NA	0.78	12.93	0.51	7.41e-33	Corneal astigmatism;
LGG	cis	rs283228	0.959	rs2852498	chr6:101831261	A/G	cg27451362	chr6:101846650	GRIK2	-0.52	-8.81	-0.38	2.44e-17	Coenzyme Q10 levels;
LGG	trans	rs11148252	0.669	rs4884320	chr13:53006914	T/C	cg18335740	chr13:41363409	SLC25A15	0.54	9.8	0.41	1.02e-20	Lewy body disease;
LGG	cis	rs2594989	0.943	rs346070	chr3:11303874	T/C	cg01796438	chr3:11312864	ATG7	-0.62	-8.41	-0.36	5.23e-16	Circulating chemerin levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02510299	chr8:121457568	MTBP;MRPL13	0.42	6.85	0.3	2.4e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg02002194	chr4:3960332	NA	-0.42	-7.68	-0.34	9.4e-14	Retinal vascular caliber;
LGG	cis	rs2075371	1.000	rs2075373	chr7:133984683	A/C	cg20476274	chr7:133979776	SLC35B4	0.77	15.45	0.58	1e-43	Mean platelet volume;
LGG	cis	rs4917300	0.606	rs4506255	chr8:143111037	A/C	cg06573787	chr8:143070187	NA	0.6	10.13	0.43	6.5600000000000005e-22	Amyotrophic lateral sclerosis;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg05064044	chr6:292385	DUSP22	0.65	11.14	0.46	1.08e-25	Menopause (age at onset);
LGG	cis	rs2273669	0.667	rs12215736	chr6:109330367	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	cis	rs826838	1.000	rs7953227	chr12:38946193	G/A	cg26384229	chr12:38710491	ALG10B	1.05	27.69	0.79	2.97e-100	Heart rate;
LGG	cis	rs2404602	0.692	rs35138393	chr15:76977617	G/A	cg22467129	chr15:76604101	ETFA	-0.41	-6.92	-0.31	1.53e-11	Blood metabolite levels;
LGG	cis	rs1055129	0.537	rs2467100	chr17:73949038	C/G	cg14829360	chr17:73884958	NA	-0.53	-10.15	-0.43	5.33e-22	White matter hyperintensity burden;
LGG	cis	rs6088590	0.710	rs6059992	chr20:33282275	T/C	cg07148914	chr20:33460835	GGT7	0.43	7.07	0.31	5.89e-12	Coronary artery disease;
LGG	cis	rs6748734	0.581	rs4675847	chr2:241865156	A/G	cg05025159	chr2:241905733	NA	0.52	10.05	0.42	1.2e-21	Urinary metabolites;
LGG	cis	rs11166927	1.000	rs10435690	chr8:140802093	C/T	cg16909799	chr8:140841666	TRAPPC9	0.54	11.44	0.47	7.34e-27	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs6807915	0.624	rs7610451	chr3:12293739	G/A	cg15873301	chr3:12045459	SYN2	0.43	7.33	0.32	1e-12	Leprosy;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.954	rs13151285	chr4:120314741	C/A	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs2985684	0.894	rs4900928	chr14:50020817	A/G	cg04989706	chr14:50066350	PPIL5	-0.59	-9.64	-0.41	3.75e-20	Carotid intima media thickness;
LGG	cis	rs12188164	0.502	rs55929184	chr5:405576	G/A	cg00976097	chr5:421733	AHRR	-0.46	-7.32	-0.32	1.14e-12	Cystic fibrosis severity;
LGG	cis	rs758324	0.947	rs7734536	chr5:131162124	C/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2952156	0.684	rs931992	chr17:37821435	G/T	cg07936489	chr17:37558343	FBXL20	-0.55	-9.29	-0.4	6.02e-19	Asthma;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg19318889	chr4:1322082	MAEA	0.47	8.09	0.35	5.33e-15	Longevity;
LGG	cis	rs35110281	0.682	rs162379	chr21:44925334	A/G	cg04455712	chr21:45112962	RRP1B	-0.48	-9.03	-0.39	4.83e-18	Mean corpuscular volume;
LGG	cis	rs2798269	0.966	rs2798271	chr13:22136765	C/T	cg18095732	chr13:22033692	ZDHHC20	-0.4	-6.89	-0.3	1.87e-11	PR segment;
LGG	cis	rs9611565	0.659	rs12483998	chr22:41935362	A/G	cg17376030	chr22:41985996	PMM1	0.59	9.36	0.4	3.35e-19	Vitiligo;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg20110707	chr11:118481992	PHLDB1	0.58	12.04	0.49	3.19e-29	Systemic lupus erythematosus;
LGG	trans	rs6076960	0.684	rs6038408	chr20:6268983	A/C	cg21095983	chr6:86352623	SYNCRIP	0.6	11.19	0.46	6.7e-26	Smooth-surface caries;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11342046	chr2:242641489	ING5	0.53	8.32	0.36	9.78e-16	Gut microbiome composition (summer);
LGG	cis	rs12681287	0.640	rs28561640	chr8:87425638	G/A	cg27223183	chr8:87520930	FAM82B	0.5	7.69	0.34	8.64e-14	Caudate activity during reward;
LGG	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg26384229	chr12:38710491	ALG10B	0.79	15.51	0.58	5.33e-44	Bladder cancer;
LGG	trans	rs11650494	0.710	rs16948071	chr17:47468706	T/G	cg11430096	chr6:110968061	CDK19	0.68	6.7	0.3	5.94e-11	Prostate cancer;
LGG	cis	rs721399	1.000	rs1495748	chr8:18263112	A/G	cg18736775	chr8:18248649	NAT2	0.5	8.83	0.38	2.1e-17	Blood metabolite levels;
LGG	trans	rs853679	0.546	rs493161	chr6:27850714	A/T	cg01620082	chr3:125678407	NA	-0.8	-8.68	-0.37	6.75e-17	Depression;
LGG	cis	rs7826238	0.535	rs2979179	chr8:8320029	C/T	cg14979609	chr8:8086686	FLJ10661	-0.27	-6.81	-0.3	3.08e-11	Systolic blood pressure;
LGG	cis	rs1125355	0.656	rs17809948	chr2:159633415	A/G	cg02251393	chr2:159651559	DAPL1	-0.43	-8.87	-0.38	1.54e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7811142	0.887	rs35111986	chr7:100000274	C/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.21	20.66	0.69	1.14e-67	Platelet count;
LGG	cis	rs2404602	1.000	rs12594212	chr15:76802014	T/A	cg23625390	chr15:77176239	SCAPER	0.5	10.01	0.42	1.82e-21	Blood metabolite levels;
LGG	cis	rs2463822	0.687	rs118012228	chr11:62155914	G/A	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.35	-0.58	2.77e-43	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs3820068	0.608	rs12760450	chr1:16037282	G/A	cg05660106	chr1:15850417	CASP9	0.76	14.03	0.55	1.63e-37	Systolic blood pressure;
LGG	cis	rs4903064	0.578	rs6574101	chr14:73328836	C/T	cg00792184	chr14:73355148	DPF3	0.3	6.73	0.3	5.11e-11	Renal cell carcinoma;
LGG	trans	rs3857536	0.707	rs9345793	chr6:66929807	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.49	-0.33	3.64e-13	Blood trace element (Cu levels);
LGG	cis	rs6142618	0.562	rs6058541	chr20:30758648	C/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.11	0.35	4.74e-15	Inflammatory bowel disease;
LGG	cis	rs10504229	0.953	rs6990806	chr8:58183113	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.647	rs1684600	chr16:4594671	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.41	-7.51	-0.33	3.01e-13	Schizophrenia;
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg01966878	chr4:90757139	SNCA	-0.34	-7.04	-0.31	6.82e-12	Dementia with Lewy bodies;
LGG	cis	rs4077515	0.504	rs7628	chr9:139318071	A/G	cg14169450	chr9:139327907	INPP5E	0.38	7.11	0.31	4.45e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6860806	0.507	rs273901	chr5:131694360	G/T	cg07395648	chr5:131743802	NA	-0.48	-9.89	-0.42	4.88e-21	Breast cancer;
LGG	trans	rs7246760	0.867	rs55846005	chr19:9796709	T/A	cg02900749	chr2:68251473	NA	-1.01	-10.58	-0.44	1.41e-23	Pursuit maintenance gain;
LGG	cis	rs975722	0.659	rs11976705	chr7:117094384	T/C	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.23	-0.39	9.4e-19	Coronary artery disease;
LGG	cis	rs9896933	0.830	rs12450046	chr17:80790388	G/A	cg19500275	chr17:80737654	TBCD	0.52	7.3	0.32	1.25e-12	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs11225247	1.000	rs12293834	chr11:102295477	T/C	cg06323957	chr11:102217781	BIRC2	0.8	6.91	0.31	1.59e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs2270450	0.650	rs11962772	chr6:46709601	A/G	cg10156739	chr6:46714674	LOC100287718	-0.48	-10.67	-0.44	6.62e-24	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.04	0.52	2.51e-33	Obesity-related traits;
LGG	cis	rs4434138	0.568	rs6414569	chr3:52708075	A/T	cg14092988	chr3:52407081	DNAH1	0.3	7.82	0.34	3.51e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg23422044	chr7:1970798	MAD1L1	-0.65	-11.08	-0.46	1.76e-25	Bipolar disorder;
LGG	cis	rs9964724	1.000	rs1557343	chr18:35159172	A/T	cg27332583	chr18:35150602	NA	-0.48	-9.83	-0.42	7.91e-21	Educational attainment (years of education);
LGG	cis	rs13191362	1.000	rs73008453	chr6:163013384	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.46	7.8	0.34	4.12e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs28595532	0.720	rs72670226	chr4:119304136	A/G	cg21605333	chr4:119757512	SEC24D	0.89	8.46	0.37	3.63e-16	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.48	0.33	3.86e-13	Prudent dietary pattern;
LGG	trans	rs2204008	0.837	rs11172728	chr12:38070042	C/A	cg06521331	chr12:34319734	NA	-0.54	-9.73	-0.41	1.78e-20	Bladder cancer;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg17202724	chr17:61916730	SMARCD2	-0.6	-14.38	-0.56	4.8e-39	Prudent dietary pattern;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg04369109	chr6:150039330	LATS1	-0.43	-7.09	-0.31	5.21e-12	Lung cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg23166955	chr16:30077191	ALDOA	0.37	6.67	0.3	7.3e-11	Obesity-related traits;
LGG	cis	rs17030434	0.654	rs1530105	chr4:154646994	C/T	cg14289246	chr4:154710475	SFRP2	0.62	10.28	0.43	1.85e-22	Electrocardiographic conduction measures;
LGG	cis	rs3767633	0.528	rs6671373	chr1:161890796	C/G	cg03391019	chr1:161927947	ATF6	0.63	12.7	0.51	6.39e-32	IgG glycosylation;
LGG	cis	rs3785574	0.927	rs2854183	chr17:61968002	C/T	cg11494091	chr17:61959527	GH2	0.63	10.69	0.45	5.33e-24	Height;
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg27373749	chr11:63775612	MACROD1	0.5	12.04	0.49	3.13e-29	Pulse pressure;
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg18404041	chr3:52824283	ITIH1	-0.53	-10.01	-0.42	1.69e-21	Bipolar disorder;
LGG	cis	rs7552404	0.960	rs61797339	chr1:76189946	G/T	cg10523679	chr1:76189770	ACADM	0.82	14.99	0.57	1.07e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2361718	0.500	rs4889970	chr17:78096086	C/T	cg27427491	chr17:78079615	GAA	0.3	6.67	0.3	7.12e-11	Yeast infection;
LGG	cis	rs17321999	0.904	rs72787716	chr2:30472355	C/T	cg05247661	chr2:30472410	LBH	0.61	9.55	0.41	7.87e-20	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs313831	chr7:65551226	C/T	cg13147721	chr7:65941812	NA	-0.8	-9.73	-0.41	1.73e-20	Diabetic kidney disease;
LGG	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03517284	chr6:25882590	NA	0.7	13.54	0.53	1.94e-35	Blood metabolite levels;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.98	-0.35	1.13e-14	Longevity;
LGG	cis	rs67133203	0.768	rs12810455	chr12:51536043	A/G	cg14688905	chr12:51403056	SLC11A2	0.71	10.69	0.44	5.47e-24	Urinary tract infection frequency;
LGG	cis	rs4443100	0.670	rs9612225	chr22:23406619	G/A	cg14186256	chr22:23484241	RTDR1	0.53	8.42	0.36	4.82e-16	Serum parathyroid hormone levels;
LGG	cis	rs17824933	1.000	rs12797044	chr11:60768018	T/A	cg16817237	chr11:60793675	NA	0.36	6.77	0.3	3.84e-11	Multiple sclerosis;
LGG	cis	rs11098499	0.954	rs10017371	chr4:120293776	A/G	cg09307838	chr4:120376055	NA	0.79	12.92	0.51	7.76e-33	Corneal astigmatism;
LGG	cis	rs834603	0.575	rs865031	chr7:47448640	A/C	cg23694490	chr7:47445681	TNS3	-0.44	-12.81	-0.51	2.29e-32	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs2840044	0.554	rs225267	chr17:33964228	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs4927850	0.752	rs7618864	chr3:195749561	G/A	cg12893428	chr3:195717962	SDHAP1	0.48	10.07	0.42	1.08e-21	Pancreatic cancer;
LGG	cis	rs910316	0.737	rs175084	chr14:75519175	C/T	cg08847533	chr14:75593920	NEK9	-0.54	-10.2	-0.43	3.48e-22	Height;
LGG	cis	rs4664308	0.935	rs6739867	chr2:160942818	G/A	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.87	-0.64	1.02e-54	Idiopathic membranous nephropathy;
LGG	cis	rs11628318	0.763	rs11623312	chr14:103022060	G/T	cg01864069	chr14:103024347	NA	-0.71	-11.08	-0.46	1.8e-25	Platelet count;
LGG	cis	rs4356932	0.935	rs10031452	chr4:76924933	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.68	-0.3	7.07e-11	Blood protein levels;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01341218	chr17:43662625	NA	0.95	16.68	0.61	3.09e-49	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9462027	0.628	rs2395604	chr6:34787976	A/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.26	-0.46	3.83e-26	Systemic lupus erythematosus;
LGG	cis	rs155076	1.000	rs58519241	chr13:21845006	C/A	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.16e-56	White matter hyperintensity burden;
LGG	cis	rs67478160	0.634	rs2368558	chr14:104230518	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.42	-0.33	5.51e-13	Schizophrenia;
LGG	cis	rs6938	0.514	rs35556055	chr15:75253414	G/A	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.18	-0.32	2.82e-12	Breast cancer;
LGG	trans	rs7395662	0.713	rs2865668	chr11:48745046	T/C	cg00717180	chr2:96193071	NA	-0.4	-7.23	-0.32	2.03e-12	HDL cholesterol;
LGG	cis	rs7584330	0.697	rs60278044	chr2:238357118	A/G	cg16989719	chr2:238392110	NA	-0.33	-6.71	-0.3	5.87e-11	Prostate cancer;
LGG	cis	rs9354308	0.764	rs7764095	chr6:66569923	A/T	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	cis	rs10937275	0.826	rs34695488	chr3:186644463	A/G	cg24050613	chr3:186648279	ST6GAL1	0.86	8.87	0.38	1.56e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4751006	0.543	rs880761	chr10:128783906	C/T	cg05702161	chr10:128779687	DOCK1	-0.97	-10.59	-0.44	1.32e-23	Colonoscopy-negative controls vs population controls;
LGG	trans	rs3206736	0.548	rs329240	chr7:35058440	A/G	cg14337134	chr7:102920323	DPY19L2P2	-0.41	-7.27	-0.32	1.51e-12	Diastolic blood pressure;
LGG	cis	rs4974559	0.790	rs7654152	chr4:1325042	G/A	cg02980000	chr4:1222292	CTBP1	0.81	9.16	0.39	1.73e-18	Systolic blood pressure;
LGG	cis	rs2302729	0.860	rs6489375	chr12:2777768	A/G	cg19945202	chr12:2788847	CACNA1C	-0.78	-11.83	-0.48	2.19e-28	Sleep quality;
LGG	cis	rs11190604	0.767	rs10736150	chr10:102195341	G/A	cg07570687	chr10:102243282	WNT8B	-0.42	-7.49	-0.33	3.6e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13160562	0.527	rs27581	chr5:96107774	C/T	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.04	0.31	6.85e-12	Alcohol dependence;
LGG	cis	rs1801251	1.000	rs4517962	chr2:233578337	T/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.21	0.39	1.16e-18	Coronary artery disease;
LGG	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg27489772	chr12:121021490	NA	-0.6	-7.86	-0.34	2.76e-14	Type 1 diabetes nephropathy;
LGG	cis	rs4819052	0.800	rs4819045	chr21:46660138	C/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs734999	0.550	rs2985855	chr1:2531372	A/C	cg18854424	chr1:2615690	NA	-0.35	-7.18	-0.32	2.79e-12	Ulcerative colitis;
LGG	cis	rs7666738	0.606	rs6839946	chr4:99076132	A/C	cg05340658	chr4:99064831	C4orf37	0.43	6.9	0.31	1.71e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17767392	0.958	rs117821900	chr14:71985670	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.98	-0.39	7.01e-18	Mitral valve prolapse;
LGG	cis	rs4808199	0.947	rs1465695	chr19:19588546	A/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.4	7.79	0.34	4.51e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg02475777	chr4:1388615	CRIPAK	0.43	7.98	0.35	1.14e-14	Longevity;
LGG	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg05425664	chr17:57184151	TRIM37	-0.61	-9.68	-0.41	2.73e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7646881	0.812	rs7624408	chr3:158460058	G/A	cg19483011	chr3:158453295	NA	-0.62	-8.34	-0.36	8.53e-16	Tetralogy of Fallot;
LGG	cis	rs17376456	0.877	rs9314093	chr5:93333347	G/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.46	-0.4	1.56e-19	Diabetic retinopathy;
LGG	cis	rs2762353	0.779	rs3799352	chr6:25822620	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	10.58	0.44	1.37e-23	Blood metabolite levels;
LGG	cis	rs8028182	0.636	rs10152155	chr15:75701554	A/T	cg20655648	chr15:75932815	IMP3	0.46	7.6	0.33	1.61e-13	Sudden cardiac arrest;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg11301795	chr4:187892539	NA	-0.94	-25.43	-0.76	6.07e-90	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7582180	0.700	rs4640404	chr2:100980523	C/T	cg05692746	chr2:100937584	LONRF2	0.64	11.62	0.48	1.43e-27	Intelligence (multi-trait analysis);
LGG	cis	rs2479724	0.901	rs10947987	chr6:41754370	C/T	cg17623882	chr6:41773611	USP49	0.45	7.56	0.33	2.17e-13	Menarche (age at onset);
LGG	cis	rs3812831	0.695	rs3118895	chr13:114931742	G/A	cg08824895	chr13:115047677	UPF3A	0.4	6.87	0.3	2.06e-11	Schizophrenia;
LGG	cis	rs8014204	0.748	rs12889277	chr14:75229376	A/T	cg06637938	chr14:75390232	RPS6KL1	0.74	14.41	0.56	3.87e-39	Caffeine consumption;
LGG	trans	rs1814175	0.587	rs847628	chr11:49927064	A/T	cg03929089	chr4:120376271	NA	-0.94	-19.61	-0.67	9.26e-63	Height;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs9467773	0.935	rs1884947	chr6:26553273	G/T	cg09904177	chr6:26538194	HMGN4	0.7	14.38	0.56	5.06e-39	Intelligence (multi-trait analysis);
LGG	trans	rs9929218	0.551	rs3785134	chr16:68728938	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.05	25.62	0.77	8.83e-91	Colorectal cancer;
LGG	trans	rs4714291	0.928	rs1923461	chr6:39984670	A/T	cg02267698	chr19:7991119	CTXN1	0.59	9.23	0.39	1.01e-18	Strep throat;
LGG	cis	rs8062405	0.754	rs151179	chr16:28487056	A/G	cg00198680	chr16:28758506	NA	0.32	7.68	0.34	9.44e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1799949	1.000	rs8176242	chr17:41217874	C/T	cg25072359	chr17:41440525	NA	0.53	10.09	0.42	8.73e-22	Menopause (age at onset);
LGG	cis	rs7681440	0.904	rs6817001	chr4:90766019	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg06046430	chr4:77819534	ANKRD56	0.56	11.36	0.47	1.49e-26	Emphysema distribution in smoking;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg16041611	chr6:43139680	SRF	-0.45	-6.88	-0.3	1.96e-11	Coronary artery disease;
LGG	cis	rs76533333	1.000	rs76533333	chr13:113352916	A/G	cg02820901	chr13:113351484	ATP11A	-0.67	-6.8	-0.3	3.23e-11	Red cell distribution width;
LGG	cis	rs34467563	0.872	rs55651812	chr8:97357614	C/T	cg22138393	chr8:97340270	PTDSS1	0.3	6.68	0.3	6.76e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2845885	0.793	rs3751120	chr11:63884453	C/T	cg24431193	chr11:63883947	FLRT1;MACROD1	0.68	8.18	0.36	2.73e-15	Body mass index;
LGG	cis	rs1862618	0.641	rs170733	chr5:56249251	A/G	cg17809284	chr5:56205270	C5orf35	0.53	9.78	0.41	1.12e-20	Initial pursuit acceleration;
LGG	cis	rs875971	1.000	rs1565531	chr7:65663113	T/A	cg23594656	chr7:65796392	TPST1	0.38	8.36	0.36	7.41e-16	Aortic root size;
LGG	cis	rs6500395	1.000	rs9925406	chr16:48671436	C/A	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7777484	0.517	rs2644306	chr7:2831602	A/G	cg19717773	chr7:2847554	GNA12	-0.43	-9.99	-0.42	2e-21	Height;
LGG	cis	rs7106204	0.514	rs2099890	chr11:24255948	C/T	ch.11.24196551F	chr11:24239977	NA	0.97	14.73	0.56	1.5e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg09044154	chr16:88155775	NA	-0.48	-7.36	-0.32	8.63e-13	Menopause (age at onset);
LGG	cis	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg27411982	chr8:10470053	RP1L1	0.43	6.89	0.3	1.86e-11	Neuroticism;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg14236043	chr10:45567048	NA	0.44	6.94	0.31	1.34e-11	Alzheimer's disease (survival time);
LGG	cis	rs6942756	0.531	rs4731569	chr7:128930828	C/T	cg02491457	chr7:128862824	NA	0.48	9.15	0.39	1.85e-18	White matter hyperintensity burden;
LGG	cis	rs12210905	0.688	rs115030474	chr6:27512220	C/T	cg10122326	chr6:28072925	NA	0.98	7.62	0.33	1.44e-13	Hip circumference adjusted for BMI;
LGG	cis	rs11203032	1.000	rs17117126	chr10:90964026	A/G	cg16672925	chr10:90967113	CH25H	0.84	11.81	0.48	2.57e-28	Heart failure;
LGG	cis	rs2075371	1.000	rs2598286	chr7:133976029	G/A	cg11752832	chr7:134001865	SLC35B4	0.62	11.28	0.46	3.11e-26	Mean platelet volume;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.34	0.32	9.49e-13	Lung cancer;
LGG	cis	rs988958	0.526	rs12712828	chr2:42244795	T/G	cg27428208	chr2:42229179	NA	0.48	7.53	0.33	2.7e-13	Hypospadias;
LGG	cis	rs35306767	0.807	rs34527494	chr10:935192	T/C	cg25019033	chr10:957182	NA	-0.55	-9.11	-0.39	2.42e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs4006360	0.600	rs1828327	chr17:39249464	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.13	-0.46	1.2e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9581857	0.547	rs76971629	chr13:28051031	C/T	cg01674679	chr13:27998804	GTF3A	-0.63	-7.33	-0.32	1.02e-12	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg11878867	chr6:150167359	LRP11	-0.53	-10.95	-0.45	5.92e-25	Lung cancer;
LGG	cis	rs2842992	0.692	rs9347342	chr6:160193129	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.88	17.19	0.62	1.35e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10463554	0.963	rs34826	chr5:102441748	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.74	-0.34	6.26e-14	Parkinson's disease;
LGG	trans	rs3808502	0.574	rs4841559	chr8:11416885	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.3	-0.4	5.59e-19	Neuroticism;
LGG	cis	rs9815354	0.669	rs113059632	chr3:41932858	G/A	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.47e-22	Motion sickness;
LGG	cis	rs6558530	0.626	rs6558524	chr8:1702512	T/G	cg08198773	chr8:1697536	NA	0.44	7.82	0.34	3.62e-14	Systolic blood pressure;
LGG	cis	rs17039065	0.920	rs7668197	chr4:109469541	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.12	0.31	4.02e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.799	rs34795957	chr17:80118013	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg16482183	chr6:26056742	HIST1H1C	0.53	8.23	0.36	1.85e-15	Iron status biomarkers;
LGG	cis	rs55788414	0.932	rs8048115	chr16:81182554	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.17	-0.43	4.46e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs8072100	0.582	rs3826536	chr17:45501967	T/A	cg08085267	chr17:45401833	C17orf57	-0.49	-9.0	-0.39	5.65e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg09264619	chr17:80180166	NA	0.35	6.96	0.31	1.19e-11	Life satisfaction;
LGG	trans	rs12682352	0.650	rs13265731	chr8:8673320	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg24642439	chr20:33292090	TP53INP2	-0.51	-8.75	-0.38	4.1e-17	Coronary artery disease;
LGG	cis	rs713587	0.967	rs6749422	chr2:25150011	C/G	cg04586622	chr2:25135609	ADCY3	0.45	12.21	0.49	6.44e-30	Body mass index in non-asthmatics;
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg08297393	chr2:100937505	LONRF2	0.55	10.48	0.44	3.29e-23	Intelligence (multi-trait analysis);
LGG	cis	rs2797369	0.546	rs1765075	chr6:101481014	C/T	cg27451362	chr6:101846650	GRIK2	0.85	11.36	0.47	1.53e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs8133932	0.636	rs2014421	chr21:47278308	A/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.13	-0.31	3.96e-12	Schizophrenia;
LGG	cis	rs11190604	1.000	rs11190604	chr10:102302457	A/G	cg11040518	chr10:102331378	NA	-0.37	-6.9	-0.31	1.73e-11	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs970548	0.688	rs2082110	chr10:45931070	A/G	cg20477318	chr10:51623047	TIMM23	0.6	7.3	0.32	1.28e-12	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs1707322	0.721	rs11211166	chr1:46157942	G/A	cg03146154	chr1:46216737	IPP	0.56	10.91	0.45	7.93e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6866344	0.570	rs59259518	chr5:178142628	C/T	cg10224037	chr5:178157518	ZNF354A	0.79	13.05	0.52	2.24e-33	Neutrophil percentage of white cells;
LGG	cis	rs17209837	1.000	rs45590633	chr7:87090480	C/T	cg00919237	chr7:87102261	ABCB4	-0.71	-11.29	-0.46	2.85e-26	Gallbladder cancer;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.5	-0.4	1.12e-19	Life satisfaction;
LGG	cis	rs919433	0.713	rs13411968	chr2:198467141	C/T	cg00792783	chr2:198669748	PLCL1	0.51	7.99	0.35	1.1e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9543976	1.000	rs9543976	chr13:76136648	G/A	cg01531495	chr13:76123901	UCHL3	0.61	7.68	0.34	9.41e-14	Diabetic retinopathy;
LGG	cis	rs539514	0.690	rs2328953	chr13:76317459	T/G	cg04757411	chr13:76259545	LMO7	-0.26	-6.87	-0.3	2.03e-11	Type 1 diabetes;
LGG	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg20040747	chr15:74715105	SEMA7A	0.43	9.67	0.41	2.86e-20	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1008375	1.000	rs1121089	chr4:17676476	C/A	cg16339924	chr4:17578868	LAP3	0.58	10.21	0.43	3.36e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2224391	0.822	rs36055504	chr6:5262230	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.95	-0.35	1.47e-14	Height;
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg02475777	chr4:1388615	CRIPAK	0.38	6.81	0.3	3.09e-11	Longevity;
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.38	0.4	3.07e-19	Alzheimer's disease;
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10937275	0.623	rs35166820	chr3:186646140	C/T	cg13419791	chr3:186648285	ST6GAL1	0.79	8.02	0.35	8.56e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7851660	0.874	rs10120412	chr9:100628238	T/C	cg13688889	chr9:100608707	NA	-0.58	-11.55	-0.47	2.77e-27	Strep throat;
LGG	cis	rs4936894	0.500	rs12272169	chr11:124088753	G/T	cg27160556	chr11:124181099	OR8D1	-0.45	-10.41	-0.44	6.05e-23	Aging (time to death);
LGG	cis	rs3771570	0.901	rs62190415	chr2:242426692	A/G	cg21155796	chr2:242212141	HDLBP	0.67	8.89	0.38	1.34e-17	Prostate cancer;
LGG	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg13114125	chr14:105738426	BRF1	-0.84	-16.0	-0.6	3.47e-46	Mean platelet volume;Platelet distribution width;
LGG	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.27	-0.36	1.4e-15	Neuroticism;
LGG	cis	rs9513627	0.920	rs6491510	chr13:100171447	C/T	cg25919922	chr13:100150906	NA	0.74	7.81	0.34	3.83e-14	Obesity-related traits;
LGG	cis	rs950169	0.922	rs67804993	chr15:85104030	T/G	cg03959625	chr15:84868606	LOC388152	0.58	9.36	0.4	3.51e-19	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06657807	chr3:49711660	APEH	0.46	6.93	0.31	1.39e-11	Gut microbiome composition (summer);
LGG	cis	rs9547692	1.000	rs9531991	chr13:37470945	A/G	cg02985381	chr13:37494744	SMAD9	0.73	12.82	0.51	2.1e-32	Coronary artery disease;
LGG	cis	rs6831352	0.918	rs2602896	chr4:100046207	C/T	cg13256891	chr4:100009986	ADH5	-0.58	-10.06	-0.42	1.14e-21	Alcohol dependence;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg19168338	chr16:4465731	CORO7	-0.89	-17.31	-0.63	3.88e-52	Schizophrenia;
LGG	cis	rs888194	0.934	rs3742015	chr12:110017125	T/C	cg19025524	chr12:109796872	NA	-0.37	-7.44	-0.33	4.81e-13	Neuroticism;
LGG	cis	rs1008375	1.000	rs2159583	chr4:17658838	T/C	cg04450456	chr4:17643702	FAM184B	0.34	7.61	0.33	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg06521331	chr12:34319734	NA	-0.5	-8.6	-0.37	1.27e-16	Bladder cancer;
LGG	cis	rs4865169	0.783	rs7668814	chr4:57825190	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.48	8.13	0.35	3.98e-15	Breast cancer;
LGG	cis	rs1005277	0.522	rs289650	chr10:37975505	G/T	cg00409905	chr10:38381863	ZNF37A	-0.63	-13.17	-0.52	7.49e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg26150922	chr2:100937072	LONRF2	-0.61	-11.99	-0.49	4.81e-29	Intelligence (multi-trait analysis);
LGG	cis	rs7681440	0.904	rs1822217	chr4:90765052	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs72945132	0.882	rs72947078	chr11:70197542	G/T	cg13802316	chr11:70253460	CTTN	-0.6	-7.5	-0.33	3.32e-13	Coronary artery disease;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.49	7.71	0.34	7.94e-14	Tonsillectomy;
LGG	cis	rs977987	0.843	rs12443834	chr16:75438469	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.76	0.3	4.13e-11	Dupuytren's disease;
LGG	cis	rs9522267	0.535	rs9522301	chr13:112236726	A/T	cg10483660	chr13:112241077	NA	-0.34	-7.44	-0.33	5.05e-13	Hepatitis;
LGG	cis	rs67460515	0.892	rs13059340	chr3:161062631	T/C	cg03342759	chr3:160939853	NMD3	-0.73	-12.94	-0.52	6.62e-33	Parkinson's disease;
LGG	trans	rs9650657	0.836	rs4841438	chr8:10606756	A/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.79	-0.3	3.45e-11	Neuroticism;
LGG	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg02269571	chr22:50332266	NA	-0.71	-10.9	-0.45	8.73e-25	Schizophrenia;
LGG	cis	rs3008870	0.755	rs4486425	chr1:67460791	T/C	cg02640540	chr1:67518911	SLC35D1	-0.39	-7.73	-0.34	6.91e-14	Lymphocyte percentage of white cells;
LGG	cis	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg04455712	chr21:45112962	RRP1B	0.48	8.82	0.38	2.28e-17	Mean corpuscular volume;
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.84	-0.3	2.49e-11	Neuroticism;
LGG	trans	rs783540	0.967	rs4779044	chr15:83339353	A/C	cg16105309	chr15:79090380	ADAMTS7	-0.4	-7.06	-0.31	6.03e-12	Schizophrenia;
LGG	cis	rs6951245	0.935	rs113365567	chr7:1108785	T/C	cg02733842	chr7:1102375	C7orf50	0.74	11.09	0.46	1.64e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.716	rs7164060	chr15:76707694	T/C	cg15268244	chr15:77196840	NA	-0.32	-7.2	-0.32	2.45e-12	Blood metabolite levels;
LGG	cis	rs2842992	0.789	rs4709376	chr6:160226337	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.83	13.67	0.54	5.78e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs35146811	0.735	rs858512	chr7:99824453	A/G	cg22906224	chr7:99728672	NA	-0.57	-9.34	-0.4	4.06e-19	Coronary artery disease;
LGG	cis	rs10791323	0.604	rs2723607	chr11:133711018	C/G	cg15485101	chr11:133734466	NA	0.6	10.55	0.44	1.83e-23	Childhood ear infection;
LGG	cis	rs9611565	0.694	rs5751107	chr22:41857812	A/G	cg06481639	chr22:41940642	POLR3H	0.59	8.65	0.37	8.46e-17	Vitiligo;
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg23188684	chr11:67383651	NA	-0.51	-8.13	-0.35	4.04e-15	Mean corpuscular volume;
LGG	cis	rs7584262	0.737	rs7591932	chr2:42243550	T/G	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Bone mineral density;
LGG	cis	rs17102423	0.594	rs10151162	chr14:65566695	T/C	cg11161011	chr14:65562177	MAX	-0.66	-12.59	-0.5	1.91e-31	Obesity-related traits;
LGG	cis	rs988958	0.567	rs7594766	chr2:42228804	C/T	cg27252766	chr2:42229092	NA	0.54	8.4	0.36	5.54e-16	Hypospadias;
LGG	cis	rs72634258	0.945	rs12745223	chr1:8094978	C/T	cg00042356	chr1:8021962	PARK7	0.83	10.9	0.45	9.11e-25	Inflammatory bowel disease;
LGG	cis	rs10464366	0.843	rs4723819	chr7:39111241	C/T	cg21665744	chr7:39171113	POU6F2	0.34	6.7	0.3	6.23e-11	IgG glycosylation;
LGG	cis	rs7928758	0.887	rs7945585	chr11:134272451	G/A	cg15243474	chr11:134282918	B3GAT1	1.15	15.73	0.59	5.84e-45	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs506338	0.517	rs530252	chr11:64443465	T/C	cg19395706	chr11:64412079	NRXN2	0.41	8.02	0.35	8.77e-15	Body mass index;Urate levels;
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg26174226	chr8:58114915	NA	-0.44	-6.89	-0.3	1.88e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg13902645	chr11:5959945	NA	0.65	10.17	0.43	4.7e-22	DNA methylation (variation);
LGG	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg23815491	chr16:72088622	HP	0.42	7.34	0.32	9.65e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7666738	0.830	rs13145011	chr4:98993410	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg22907277	chr7:1156413	C7orf50	0.44	7.7	0.34	8.29e-14	Longevity;Endometriosis;
LGG	cis	rs6723226	0.882	rs13035097	chr2:32836362	A/G	cg02381751	chr2:32503542	YIPF4	-0.68	-11.0	-0.46	3.59e-25	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.635	rs6488185	chr12:33933127	G/C	cg13010199	chr12:38710504	ALG10B	0.45	8.44	0.37	4.02e-16	Morning vs. evening chronotype;
LGG	cis	rs9308731	0.644	rs1837368	chr2:111874508	T/C	cg19992207	chr2:111874495	ACOXL	-0.36	-6.72	-0.3	5.4e-11	Chronic lymphocytic leukemia;
LGG	cis	rs9322193	0.923	rs55849538	chr6:149956466	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.49	0.33	3.52e-13	Lung cancer;
LGG	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.1	0.43	8e-22	Diabetic retinopathy;
LGG	cis	rs11758351	0.500	rs79697629	chr6:26196512	A/G	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.53e-12	Gout;Renal underexcretion gout;
LGG	cis	rs6547741	0.935	rs4260197	chr2:27794150	C/G	cg27432699	chr2:27873401	GPN1	-0.68	-14.05	-0.55	1.3e-37	Oral cavity cancer;
LGG	trans	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg06521331	chr12:34319734	NA	-0.48	-8.44	-0.37	4e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9513627	1.000	rs73556178	chr13:100121947	T/C	cg25919922	chr13:100150906	NA	-0.7	-7.18	-0.32	2.87e-12	Obesity-related traits;
LGG	cis	rs11645898	0.748	rs72787056	chr16:72099694	C/T	cg14768367	chr16:72042858	DHODH	-0.93	-12.35	-0.5	1.71e-30	Blood protein levels;
LGG	cis	rs9926296	0.572	rs8047581	chr16:89884502	C/T	cg26513180	chr16:89883248	FANCA	0.66	12.46	0.5	6.09e-31	Vitiligo;
LGG	cis	rs9308433	0.529	rs9430131	chr1:214481121	C/A	cg06198575	chr1:214491504	SMYD2	0.51	7.73	0.34	6.9e-14	IgG glycosylation;
LGG	cis	rs798554	0.759	rs1182189	chr7:2869522	G/A	cg05793240	chr7:2802953	GNA12	0.33	7.38	0.32	7.3e-13	Height;
LGG	cis	rs9309473	0.948	rs2421550	chr2:73658686	A/G	cg20560298	chr2:73613845	ALMS1	-0.46	-7.64	-0.33	1.24e-13	Metabolite levels;
LGG	cis	rs500492	0.542	rs2573148	chr16:1073372	C/T	cg08273874	chr16:1060765	NA	-0.59	-8.64	-0.37	8.95e-17	Polycystic ovary syndrome;
LGG	cis	rs350251	0.833	rs350226	chr16:12240798	C/G	cg02910054	chr16:12241554	SNX29	-0.48	-9.02	-0.39	5.18e-18	Intelligence (multi-trait analysis);
LGG	cis	rs2836974	0.897	rs14194	chr21:40549466	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.62	0.63	1.43e-53	Cognitive function;
LGG	cis	rs1799949	1.000	rs8176234	chr17:41219780	T/C	cg23758822	chr17:41437982	NA	0.86	15.22	0.58	1.01e-42	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs4968599	chr17:61835992	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs561341	1.000	rs15654	chr17:30326360	A/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs2470578	0.792	rs2596636	chr3:17283809	T/A	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg08888203	chr3:10149979	C3orf24	0.56	8.01	0.35	9.23e-15	Alzheimer's disease;
LGG	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg11279151	chr3:101281821	RG9MTD1	-0.66	-11.23	-0.46	4.84e-26	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14082963	chr4:89444434	PIGY	0.45	7.21	0.32	2.36e-12	Cognitive performance;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.36	0.43	9.48e-23	Prudent dietary pattern;
LGG	cis	rs2839186	0.709	rs2839176	chr21:47678173	A/G	cg13012494	chr21:47604986	C21orf56	0.6	10.41	0.44	6.2e-23	Testicular germ cell tumor;
LGG	cis	rs2070433	1.000	rs2839306	chr21:47954219	G/T	cg12379764	chr21:47803548	PCNT	-0.54	-7.69	-0.34	9.12e-14	Lymphocyte counts;
LGG	cis	rs79057730	0.599	rs112891948	chr7:816059	C/T	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.76	8.38	0.36	6.52e-16	Initial pursuit acceleration;
LGG	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.59	-0.33	1.75e-13	IgG glycosylation;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.52	0.33	2.94e-13	Tonsillectomy;
LGG	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.09	0.39	2.89e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1691799	0.899	rs1168314	chr12:66746937	A/G	cg16791601	chr12:66731901	HELB	-0.66	-15.57	-0.59	2.9e-44	White blood cell count (basophil);
LGG	cis	rs2916247	1.000	rs4735044	chr8:93057478	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.41	-0.36	5.29e-16	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	9.56	0.41	7.19e-20	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs4888262	0.545	rs7193959	chr16:74664969	T/A	cg01733217	chr16:74700730	RFWD3	0.91	18.85	0.66	3.16e-59	Testicular germ cell tumor;
LGG	cis	rs9547996	0.879	rs9547964	chr13:38151202	A/C	cg17979426	chr13:38220150	TRPC4	-0.36	-6.85	-0.3	2.29e-11	Diastolic blood pressure;
LGG	cis	rs6121246	0.909	rs3203770	chr20:30382315	A/G	cg21427119	chr20:30132790	HM13	-0.42	-7.17	-0.32	2.99e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4660214	0.666	rs11205739	chr1:39656401	G/A	cg18385671	chr1:39797026	MACF1	-0.45	-9.33	-0.4	4.56e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs17384381	0.634	rs11801146	chr1:85915374	C/T	cg16011679	chr1:85725395	C1orf52	0.56	9.43	0.4	1.95e-19	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9815354	1.000	rs1716642	chr3:41965865	A/C	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg04080417	chr5:1859792	NA	-0.5	-8.06	-0.35	6.59e-15	Cardiovascular disease risk factors;
LGG	cis	rs7660883	0.964	rs11097127	chr4:87990334	G/T	cg21988461	chr4:88008667	AFF1	-0.31	-8.43	-0.36	4.32e-16	HDL cholesterol levels;
LGG	cis	rs7072216	0.763	rs3814140	chr10:100170762	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.16	-0.32	3.11e-12	Metabolite levels;
LGG	cis	rs7666738	0.830	rs1813972	chr4:98886828	C/A	cg05340658	chr4:99064831	C4orf37	0.47	7.79	0.34	4.39e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2645694	0.626	rs2703116	chr4:77824289	C/T	cg10057126	chr4:77819792	ANKRD56	-0.34	-6.65	-0.3	8.23e-11	Emphysema distribution in smoking;
LGG	cis	rs9815354	0.812	rs73073361	chr3:41842926	C/G	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs8141529	0.600	rs739196	chr22:29311271	G/A	cg15103426	chr22:29168792	CCDC117	0.62	7.08	0.31	5.45e-12	Lymphocyte counts;
LGG	cis	rs113084984	0.718	rs7609384	chr2:11683631	A/G	cg07314298	chr2:11723111	GREB1	0.35	6.69	0.3	6.51e-11	Breast cancer;
LGG	cis	rs1008375	1.000	rs28552744	chr4:17620165	A/G	cg16339924	chr4:17578868	LAP3	0.61	10.52	0.44	2.46e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7742824	1.000	rs66629131	chr6:44101468	C/G	cg04074908	chr6:44101190	TMEM63B	0.69	13.24	0.52	3.8e-34	Major depressive disorder;
LGG	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg24006582	chr15:45444508	DUOX1	0.66	12.09	0.49	1.95e-29	Uric acid levels;
LGG	cis	rs634534	0.591	rs688862	chr11:65733393	A/G	cg26695010	chr11:65641043	EFEMP2	-0.56	-9.9	-0.42	4.38e-21	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs8060686	0.545	rs74629553	chr16:68176415	C/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.46	-0.33	4.34e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11644362	0.966	rs35678048	chr16:12989235	A/G	cg06890432	chr16:12997467	SHISA9	-0.33	-7.14	-0.31	3.67e-12	Positive affect;Subjective well-being;
LGG	cis	rs2130392	1.000	rs2130392	chr4:185639169	A/G	cg04058563	chr4:185651563	MLF1IP	0.45	9.42	0.4	2.19e-19	Kawasaki disease;
LGG	cis	rs10870270	1.000	rs10870292	chr10:133770782	G/C	cg08754478	chr10:133766260	PPP2R2D	-0.69	-12.57	-0.5	2.15e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9341808	0.935	rs2298307	chr6:80816296	A/G	cg08355045	chr6:80787529	NA	0.37	7.33	0.32	1.03e-12	Sitting height ratio;
LGG	cis	rs9810089	0.843	rs1279086	chr3:136038574	G/A	cg21827317	chr3:136751795	NA	0.47	8.23	0.36	1.94e-15	Gestational age at birth (child effect);
LGG	cis	rs7618915	0.571	rs2251219	chr3:52584787	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.55	-9.27	-0.4	7.07e-19	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19273467	chr1:32110819	PEF1	0.53	8.11	0.35	4.65e-15	Gut microbiome composition (summer);
LGG	cis	rs951366	0.528	rs1172198	chr1:205662718	C/T	cg26354017	chr1:205819088	PM20D1	0.76	17.41	0.63	1.43e-52	Menarche (age at onset);
LGG	cis	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg13010199	chr12:38710504	ALG10B	-0.51	-10.02	-0.42	1.56e-21	Bladder cancer;
LGG	cis	rs2635047	0.638	rs2668762	chr18:44667871	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	6.96	0.31	1.14e-11	Educational attainment;
LGG	cis	rs7954584	0.710	rs10840641	chr12:122465831	G/T	cg13699009	chr12:122356056	WDR66	0.44	11.13	0.46	1.18e-25	Mean corpuscular volume;
LGG	cis	rs12210905	0.688	rs75968505	chr6:27476996	T/C	cg10122326	chr6:28072925	NA	0.93	7.1	0.31	4.69e-12	Hip circumference adjusted for BMI;
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg05165339	chr4:1420672	NA	-0.35	-8.93	-0.38	1.04e-17	Longevity;
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.6	8.96	0.38	7.97e-18	Renal function-related traits (BUN);
LGG	cis	rs7617773	0.780	rs9846818	chr3:48375685	C/T	cg11946769	chr3:48343235	NME6	0.6	10.2	0.43	3.6e-22	Coronary artery disease;
LGG	cis	rs774359	0.797	rs7041409	chr9:27487221	T/C	cg21249376	chr9:27528432	MOBKL2B	-0.4	-7.95	-0.35	1.39e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs17384381	1.000	rs17384381	chr1:85897570	C/G	cg16011679	chr1:85725395	C1orf52	0.51	8.24	0.36	1.77e-15	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg23397955	chr15:89148733	NA	-0.4	-6.7	-0.3	6.03e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg13142700	chr3:11034501	SLC6A1	0.47	6.8	0.3	3.2e-11	Hip circumference;
LGG	cis	rs9393692	0.620	rs9358918	chr6:26286744	C/T	cg00631329	chr6:26305371	NA	-0.43	-7.39	-0.32	6.82e-13	Educational attainment;
LGG	cis	rs2117029	0.553	rs11168903	chr12:49568666	C/G	cg24176009	chr12:49580217	TUBA1A	0.61	11.6	0.47	1.77e-27	Intelligence (multi-trait analysis);
LGG	cis	rs10979	0.557	rs9376768	chr6:143909492	C/T	cg25407410	chr6:143891975	LOC285740	-0.55	-8.21	-0.36	2.27e-15	Hypospadias;
LGG	cis	rs2404602	0.716	rs66754747	chr15:76828568	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.46e-11	Blood metabolite levels;
LGG	cis	rs11148252	0.755	rs116860555	chr13:52936937	C/T	cg22398616	chr13:53314203	LECT1	0.46	9.58	0.41	6.03e-20	Lewy body disease;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.26	0.32	1.62e-12	Menopause (age at onset);
LGG	cis	rs17209837	1.000	rs45502492	chr7:87089898	C/T	cg00919237	chr7:87102261	ABCB4	-0.69	-11.18	-0.46	7.65e-26	Gallbladder cancer;
LGG	cis	rs2470578	0.755	rs283918	chr3:17328219	C/G	cg20981856	chr3:17787350	NA	0.36	6.84	0.3	2.51e-11	Schizophrenia;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.5	-0.33	3.33e-13	Testicular germ cell tumor;
LGG	cis	rs7223966	1.000	rs9908044	chr17:61747032	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.71	0.34	7.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg13550731	chr2:172543902	DYNC1I2	-1.05	-26.61	-0.78	2.37e-95	Schizophrenia;
LGG	cis	rs6977660	0.660	rs61670426	chr7:19790460	A/G	cg05791153	chr7:19748676	TWISTNB	0.77	10.2	0.43	3.57e-22	Thyroid stimulating hormone;
LGG	trans	rs11098499	0.615	rs28551750	chr4:120264901	C/T	cg25214090	chr10:38739885	LOC399744	0.56	10.36	0.43	9.02e-23	Corneal astigmatism;
LGG	cis	rs17321999	0.516	rs17322090	chr2:30494172	G/T	cg05247661	chr2:30472410	LBH	0.64	8.03	0.35	7.92e-15	Systemic lupus erythematosus;
LGG	trans	rs11039798	0.698	rs6485805	chr11:48101723	C/T	cg15704280	chr7:45808275	SEPT13	0.72	7.47	0.33	4.15e-13	Axial length;
LGG	cis	rs12586317	0.547	rs3759548	chr14:35450333	C/T	cg05294307	chr14:35346193	BAZ1A	-0.58	-8.24	-0.36	1.76e-15	Psoriasis;
LGG	cis	rs2645694	0.533	rs2645674	chr4:77818202	T/C	cg18351406	chr4:77819688	ANKRD56	0.47	8.16	0.35	3.29e-15	Emphysema distribution in smoking;
LGG	cis	rs9611565	0.592	rs9611612	chr22:41961189	T/C	cg06481639	chr22:41940642	POLR3H	-0.5	-7.19	-0.32	2.65e-12	Vitiligo;
LGG	cis	rs10883723	0.810	rs6584508	chr10:104258567	A/G	cg05096777	chr10:104283225	SUFU	0.33	7.13	0.31	3.83e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.36	-8.49	-0.37	2.85e-16	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs3780486	0.846	rs7036812	chr9:33143822	T/C	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.4	-0.56	4.31e-39	IgG glycosylation;
LGG	cis	rs13082711	0.911	rs2003886	chr3:27527732	G/T	cg02860705	chr3:27208620	NA	0.72	12.71	0.51	5.96e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs116095464	0.558	rs7730700	chr5:264713	G/A	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.811	rs7011229	chr8:8543324	T/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.64	-0.41	3.57e-20	Mood instability;
LGG	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg25811766	chr13:21894605	NA	0.66	8.51	0.37	2.42e-16	White matter hyperintensity burden;
LGG	cis	rs977987	0.843	rs11649638	chr16:75488285	G/A	cg07303275	chr16:75499416	TMEM170A	0.38	6.73	0.3	4.89e-11	Dupuytren's disease;
LGG	cis	rs9611565	0.649	rs4822050	chr22:42177453	C/G	cg17376030	chr22:41985996	PMM1	0.53	8.42	0.36	4.6e-16	Vitiligo;
LGG	cis	rs17166499	0.803	rs17166479	chr7:12915193	T/C	cg12945054	chr7:12841881	NA	-0.71	-7.73	-0.34	6.95e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs864537	0.676	rs2056626	chr1:167420425	T/G	cg09179987	chr1:167433047	CD247	0.42	9.19	0.39	1.38e-18	Celiac disease or Rheumatoid arthritis;Celiac disease;
LGG	cis	rs9487051	0.735	rs351754	chr6:109537553	A/G	cg21918786	chr6:109611834	NA	0.43	7.96	0.35	1.37e-14	Reticulocyte fraction of red cells;
LGG	cis	rs9487094	0.626	rs11153213	chr6:110015093	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.01	0.35	9.2e-15	Height;
LGG	cis	rs2404602	1.000	rs2120107	chr15:76869789	A/G	cg23625390	chr15:77176239	SCAPER	0.5	9.95	0.42	2.96e-21	Blood metabolite levels;
LGG	cis	rs3747547	0.818	rs3827519	chr9:37948724	T/C	cg13774184	chr9:37916125	SHB	-0.72	-8.17	-0.35	2.97e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs9291683	0.609	rs36084205	chr4:10028678	A/C	cg26043149	chr18:55253948	FECH	0.4	6.66	0.3	7.66e-11	Bone mineral density;
LGG	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg27478167	chr7:817139	HEATR2	-0.44	-7.1	-0.31	4.84e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg24829409	chr8:58192753	C8orf71	-0.71	-9.36	-0.4	3.4e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs13102973	0.931	rs4561977	chr4:135848936	T/C	cg14419869	chr4:135874104	NA	0.57	10.71	0.45	4.63e-24	Subjective well-being;
LGG	trans	rs11098499	0.863	rs11098532	chr4:120490726	C/A	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.46e-27	Corneal astigmatism;
LGG	cis	rs782590	0.967	rs17798852	chr2:55805172	A/C	cg18811423	chr2:55921094	PNPT1	0.88	20.22	0.68	1.31e-65	Metabolic syndrome;
LGG	cis	rs4330281	0.647	rs11128848	chr3:17744210	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs2635047	1.000	rs2635049	chr18:44687303	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.37	-7.04	-0.31	7.08e-12	Educational attainment;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg10250534	chr4:24586033	DHX15	0.4	6.71	0.3	5.86e-11	Bipolar disorder;
LGG	cis	rs599083	0.530	rs2472415	chr11:68185616	T/C	cg16797656	chr11:68205561	LRP5	-0.46	-7.59	-0.33	1.74e-13	Bone mineral density (spine);
LGG	cis	rs7219021	1.000	rs57185954	chr17:46844961	T/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.78	-0.3	3.68e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs67478160	0.619	rs11623546	chr14:104269098	A/G	cg26031613	chr14:104095156	KLC1	-0.45	-7.46	-0.33	4.45e-13	Schizophrenia;
LGG	cis	rs17376456	0.825	rs12153021	chr5:93073913	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.52	0.4	9.84e-20	Diabetic retinopathy;
LGG	cis	rs4671458	0.626	rs10496102	chr2:63731239	T/C	cg17519650	chr2:63277830	OTX1	-0.54	-7.24	-0.32	1.87e-12	Subjective well-being;
LGG	cis	rs12497850	0.931	rs12493289	chr3:48905161	G/A	cg07636037	chr3:49044803	WDR6	1.1	27.79	0.79	9.88e-101	Parkinson's disease;
LGG	cis	rs7811142	0.830	rs10085549	chr7:99983135	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.76	0.68	1.75e-63	Platelet count;
LGG	cis	rs2227564	1	rs2227564	chr10:75673101	C/T	cg00564723	chr10:75632066	CAMK2G	0.41	8.21	0.36	2.25e-15	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6558530	0.932	rs4370560	chr8:1708194	G/A	cg08198773	chr8:1697536	NA	0.35	6.86	0.3	2.28e-11	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.89	-0.42	4.54e-21	Lung cancer;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.7	14.15	0.55	4.94e-38	Obesity-related traits;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07243736	chr16:783730	NARFL	0.41	7.11	0.31	4.3e-12	Height;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg21782813	chr7:2030301	MAD1L1	0.49	11.66	0.48	9.95e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs916888	0.773	rs1378358	chr17:44787312	C/T	cg17911788	chr17:44343683	NA	0.61	9.26	0.4	7.59e-19	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg07817883	chr1:32538562	TMEM39B	1.27	12.13	0.49	1.37e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1218582	0.772	rs906593	chr1:154885255	G/A	cg24250549	chr1:154909240	PMVK	0.76	15.55	0.59	3.61e-44	Prostate cancer;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg07343612	chr16:622815	PIGQ	-0.76	-15.48	-0.58	7.18e-44	Height;
LGG	cis	rs1322639	0.571	rs13204417	chr6:169575355	G/A	cg03254818	chr6:169586852	NA	-0.45	-9.26	-0.4	7.44e-19	Pulse pressure;
LGG	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.68	-9.28	-0.4	6.64e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs526231	0.575	rs66730942	chr5:102306779	G/C	cg23492399	chr5:102201601	PAM	-0.62	-9.34	-0.4	4.14e-19	Primary biliary cholangitis;
LGG	cis	rs12410462	0.636	rs1495849	chr1:227736363	G/A	cg23173402	chr1:227635558	NA	0.37	7.11	0.31	4.33e-12	Major depressive disorder;
LGG	cis	rs7208859	0.673	rs9895815	chr17:29138033	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11875185	0.510	rs11877916	chr18:55627568	G/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.85	-0.38	1.91e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6573604	1.000	rs10144975	chr14:65773982	C/T	cg15999311	chr14:65749247	NA	0.46	6.69	0.3	6.26e-11	N-glycan levels;
LGG	cis	rs1799949	1.000	rs12942277	chr17:41187974	G/C	cg12708336	chr17:41446283	NA	-0.31	-6.92	-0.31	1.47e-11	Menopause (age at onset);
LGG	cis	rs898097	0.812	rs56405605	chr17:80843663	T/C	cg15369054	chr17:80825471	TBCD	0.58	10.6	0.44	1.19e-23	Breast cancer;
LGG	cis	rs10858096	0.608	rs4970843	chr1:109887191	A/G	cg19896612	chr1:110052200	AMIGO1	0.37	7.35	0.32	8.85e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	1.000	rs255857	chr5:112743066	G/T	cg12552261	chr5:112820674	MCC	0.7	7.99	0.35	1.11e-14	F-cell distribution;
LGG	cis	rs7444	0.941	rs2266961	chr22:21928597	C/G	cg22858872	chr22:21984481	YDJC	-0.37	-6.73	-0.3	5.14e-11	Systemic lupus erythematosus;
LGG	cis	rs644799	0.648	rs1255176	chr11:95471465	A/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	8.14	0.35	3.66e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02994645	chr8:30891371	WRN;PURG	0.45	7.46	0.33	4.33e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs17102423	0.594	rs1270074	chr14:65564856	T/C	cg11161011	chr14:65562177	MAX	-0.63	-12.24	-0.49	4.7e-30	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs1413654	chr6:150105092	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs4319547	0.774	rs7959238	chr12:123131498	A/T	cg05707623	chr12:122985044	ZCCHC8	-0.59	-9.16	-0.39	1.74e-18	Body mass index;
LGG	trans	rs5756813	0.727	rs4821703	chr22:38136676	C/T	cg19894588	chr14:64061835	NA	-0.57	-8.98	-0.39	6.61e-18	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01426831	chr19:12098817	NA	0.47	7.27	0.32	1.53e-12	Gut microbiome composition (summer);
LGG	cis	rs9300255	0.602	rs1616181	chr12:123619856	T/A	cg00376283	chr12:123451042	ABCB9	0.65	10.58	0.44	1.41e-23	Neutrophil percentage of white cells;
LGG	cis	rs10832963	1.000	rs4757676	chr11:18640477	C/T	cg20219074	chr11:18656078	SPTY2D1	0.84	15.97	0.6	4.59e-46	Breast cancer;
LGG	cis	rs1008375	1.000	rs1121091	chr4:17676386	A/C	cg18681998	chr4:17616180	MED28	0.81	18.1	0.64	9.22e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6463523	0.933	rs4724821	chr7:762544	C/T	cg14391382	chr7:866102	UNC84A	0.53	9.61	0.41	4.65e-20	Subjective well-being;
LGG	cis	rs11122272	0.615	rs1465740	chr1:231495255	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.61	-0.44	1.12e-23	Hemoglobin concentration;
LGG	cis	rs9487051	0.768	rs461487	chr6:109525504	A/G	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5e-12	Reticulocyte fraction of red cells;
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.934	rs2257464	chr20:25265872	C/T	cg06421707	chr20:25228305	PYGB	0.47	10.13	0.43	6.35e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12474201	0.928	rs13429704	chr2:46960329	G/T	cg06386533	chr2:46925753	SOCS5	0.8	15.0	0.57	9.91e-42	Height;
LGG	cis	rs41271473	1.000	rs72751929	chr1:228884358	A/G	cg10167378	chr1:228756711	NA	0.55	7.74	0.34	6.33e-14	Chronic lymphocytic leukemia;
LGG	cis	rs1971762	0.545	rs11170632	chr12:54047935	C/T	cg06632207	chr12:54070931	ATP5G2	-0.24	-7.46	-0.33	4.25e-13	Height;
LGG	cis	rs4901847	0.967	rs12433260	chr14:58552893	T/C	cg15908186	chr14:58618357	C14orf37	0.56	9.95	0.42	2.8e-21	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs61931739	0.500	rs11053199	chr12:34450534	C/T	cg06521331	chr12:34319734	NA	0.53	9.52	0.4	9.36e-20	Morning vs. evening chronotype;
LGG	cis	rs477692	1.000	rs506274	chr10:131409392	T/A	cg05714579	chr10:131428358	MGMT	0.56	11.78	0.48	3.41e-28	Response to temozolomide;
LGG	cis	rs11264213	0.892	rs67906703	chr1:36178590	C/T	cg27506609	chr1:36549197	TEKT2	0.7	7.88	0.34	2.3e-14	Schizophrenia;
LGG	trans	rs3858145	0.588	rs61854833	chr10:70037327	C/G	cg04882175	chr6:131122610	NA	-0.56	-7.98	-0.35	1.19e-14	Optic nerve measurement (disc area);Optic cup area;Optic nerve measurement (cup area);
LGG	trans	rs2204008	0.550	rs11495600	chr12:38126654	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs9291683	0.527	rs11727087	chr4:10096020	A/G	cg00071950	chr4:10020882	SLC2A9	0.37	7.66	0.34	1.09e-13	Bone mineral density;
LGG	cis	rs769267	0.566	rs7249692	chr19:19670688	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.44	-6.72	-0.3	5.49e-11	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01162436	chr10:15902292	FAM188A	0.48	8.05	0.35	7.3e-15	Cognitive performance;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg19006130	chr11:118478252	PHLDB1	-0.4	-6.78	-0.3	3.64e-11	Cholesterol, total;
LGG	cis	rs2067615	0.579	rs12424114	chr12:107144328	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.01	0.49	3.97e-29	Heart rate;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg14227996	chr4:17616232	MED28	0.72	8.74	0.38	4.19e-17	Opioid sensitivity;
LGG	cis	rs4900069	0.764	rs2401977	chr14:91591916	A/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.45	-7.59	-0.33	1.75e-13	Resting heart rate;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg23958373	chr8:599963	NA	1.15	11.54	0.47	2.91e-27	IgG glycosylation;
LGG	cis	rs4555082	0.874	rs28625632	chr14:105748849	G/T	cg10792982	chr14:105748885	BRF1	0.66	13.1	0.52	1.39e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs11722228	0.522	rs73212817	chr4:10064011	T/C	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.01	-0.42	1.73e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2842992	0.915	rs2842958	chr6:160108425	A/G	cg27624424	chr6:160112604	SOD2	0.69	10.23	0.43	2.85e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs923375	0.632	rs227802	chr17:3342315	G/A	cg16505927	chr17:3375209	SPATA22	0.5	7.27	0.32	1.58e-12	Myopia (pathological);
LGG	cis	rs9807989	0.507	rs1592458	chr2:103031749	A/T	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma;
LGG	cis	rs11252926	0.550	rs10795122	chr10:466830	C/T	cg16386425	chr10:429943	DIP2C	-0.48	-9.58	-0.41	5.84e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg16070123	chr10:51489643	NA	-0.41	-7.44	-0.33	4.8e-13	Prostate-specific antigen levels;
LGG	cis	rs7928758	0.887	rs34702205	chr11:134270721	G/A	cg22777979	chr11:134283252	B3GAT1	0.96	12.5	0.5	4.18e-31	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg07511668	chr11:68622177	NA	0.51	9.79	0.41	1.1e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17209837	1.000	rs45554032	chr7:87078547	G/T	cg00919237	chr7:87102261	ABCB4	-0.67	-10.93	-0.45	6.79e-25	Gallbladder cancer;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs228437	0.913	rs4896078	chr6:134910571	A/T	cg24504307	chr6:134963096	NA	0.37	7.01	0.31	8.26e-12	Melanoma;
LGG	cis	rs2274273	0.686	rs17253695	chr14:55574610	A/T	cg04306507	chr14:55594613	LGALS3	-0.51	-11.86	-0.48	1.68e-28	Protein biomarker;
LGG	cis	rs28386778	0.897	rs8066754	chr17:61816590	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg05861140	chr6:150128134	PCMT1	-0.3	-6.86	-0.3	2.17e-11	Testicular germ cell tumor;
LGG	cis	rs10504229	0.683	rs903702	chr8:58128557	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.02	-0.52	3.12e-33	Gut microbiome composition (summer);
LGG	cis	rs2013441	0.932	rs2526479	chr17:20130221	T/G	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6.11e-11	Obesity-related traits;
LGG	cis	rs2067615	0.579	rs4964489	chr12:107171808	A/G	cg15890332	chr12:107067104	RFX4	0.4	11.82	0.48	2.42e-28	Heart rate;
LGG	cis	rs9964724	0.758	rs11663050	chr18:35201153	G/T	cg27332583	chr18:35150602	NA	0.38	8.35	0.36	7.89e-16	Educational attainment (years of education);
LGG	cis	rs2721811	0.593	rs2521768	chr7:24784403	C/T	cg06301139	chr7:24798175	DFNA5	-0.48	-9.1	-0.39	2.79e-18	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12476592	0.602	rs2292793	chr2:63661280	A/G	cg17519650	chr2:63277830	OTX1	-0.49	-7.39	-0.32	6.89e-13	Childhood ear infection;
LGG	cis	rs17376456	0.825	rs72786702	chr5:93254656	A/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.69	-0.41	2.36e-20	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg16507663	chr6:150244633	RAET1G	0.48	8.98	0.39	6.78e-18	Lung cancer;
LGG	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.98	0.54	2.68e-37	Colorectal cancer;
LGG	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg06636001	chr8:8085503	FLJ10661	0.69	14.49	0.56	1.61e-39	Neuroticism;
LGG	trans	rs747782	0.640	rs11039603	chr11:48256786	G/A	cg15704280	chr7:45808275	SEPT13	0.71	7.7	0.34	8.17e-14	Intraocular pressure;
LGG	cis	rs1799949	1.000	rs11653231	chr17:41331460	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	trans	rs853679	1.000	rs6901575	chr6:28250984	G/A	cg06606381	chr12:133084897	FBRSL1	-0.71	-8.28	-0.36	1.38e-15	Depression;
LGG	cis	rs3733418	0.860	rs72697987	chr4:165953917	G/A	cg10852876	chr4:165953100	TRIM60	-0.5	-6.91	-0.31	1.57e-11	Obesity-related traits;
LGG	cis	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg06521331	chr12:34319734	NA	-0.63	-11.48	-0.47	5.29e-27	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.793	rs12990917	chr2:178487259	T/G	cg27490568	chr2:178487706	NA	0.55	10.8	0.45	2.04e-24	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.94	0.38	9.58e-18	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs28655083	0.956	rs35848061	chr16:77101327	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.67	-0.34	1.06e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12220238	0.722	rs11001096	chr10:76413103	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.54	7.0	0.31	9.11e-12	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs13191362	0.935	rs34347104	chr6:163055716	C/T	cg06582575	chr6:163149167	PACRG;PARK2	0.86	8.81	0.38	2.62e-17	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs847577	0.715	rs12665986	chr7:97719676	A/G	cg13397024	chr7:97797637	LMTK2	0.41	7.31	0.32	1.18e-12	Breast cancer;
LGG	cis	rs17270561	0.609	rs4712961	chr6:25727334	C/T	cg16482183	chr6:26056742	HIST1H1C	0.52	8.17	0.35	2.97e-15	Iron status biomarkers;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.78	0.41	1.16e-20	Tonsillectomy;
LGG	cis	rs7781557	1.000	rs2041094	chr7:102495434	C/T	cg18108683	chr7:102477205	FBXL13	-0.55	-8.74	-0.38	4.4e-17	Colorectal adenoma (advanced);
LGG	trans	rs1493916	0.837	rs11876492	chr18:31413804	T/C	cg04226714	chr8:49833948	SNAI2	-0.44	-7.94	-0.35	1.5e-14	Life satisfaction;
LGG	cis	rs4631830	0.863	rs2611489	chr10:51524889	C/T	cg10326726	chr10:51549505	MSMB	-0.72	-15.03	-0.57	7.21e-42	Prostate-specific antigen levels;
LGG	cis	rs11901793	0.505	rs34446892	chr2:237495452	C/T	cg25295825	chr2:237489920	CXCR7	0.85	10.49	0.44	3.07e-23	Total mean fractional anisotropy measurement in first episode schizophrenia;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg05313129	chr8:58192883	C8orf71	-0.6	-8.42	-0.36	4.58e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.832	rs6836076	chr4:187899660	A/C	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2404602	0.684	rs11854850	chr15:76844571	C/T	cg15268244	chr15:77196840	NA	0.47	9.94	0.42	3.11e-21	Blood metabolite levels;
LGG	cis	rs4460629	0.710	rs11264318	chr1:155083717	A/T	cg13808842	chr1:155066096	NA	-0.29	-7.02	-0.31	7.84e-12	Serum magnesium levels;
LGG	cis	rs9462027	0.606	rs9394248	chr6:34739875	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.68	-0.44	5.95e-24	Systemic lupus erythematosus;
LGG	cis	rs11645898	0.810	rs11646364	chr16:72108687	A/T	cg14768367	chr16:72042858	DHODH	-0.86	-11.45	-0.47	6.97e-27	Blood protein levels;
LGG	cis	rs2735413	0.709	rs9938043	chr16:78091426	A/G	cg04733911	chr16:78082701	NA	-0.74	-15.94	-0.6	6.52e-46	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs17824933	0.887	rs12790976	chr11:60767420	T/G	cg16817237	chr11:60793675	NA	0.36	6.8	0.3	3.15e-11	Multiple sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10173240	chr14:90849342	NA	0.45	6.97	0.31	1.09e-11	Gut microbiome composition (summer);
LGG	cis	rs6466055	0.720	rs62484712	chr7:105005741	G/A	cg04380332	chr7:105027541	SRPK2	-0.38	-7.04	-0.31	7.07e-12	Schizophrenia;
LGG	cis	rs941873	0.868	rs1483733	chr10:81130036	A/G	cg09469691	chr10:81107165	PPIF	0.58	10.25	0.43	2.32e-22	Height;
LGG	trans	rs11875185	0.510	rs79697165	chr18:55646436	A/G	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10940138	0.501	rs2101598	chr5:67248995	C/T	ch.5.1281357F	chr5:67228439	NA	-0.45	-8.04	-0.35	7.46e-15	Menarche (age at onset);
LGG	cis	rs1908814	0.516	rs4840597	chr8:11796068	A/C	cg24623649	chr8:11872141	NA	0.3	6.87	0.3	2.04e-11	Neuroticism;
LGG	cis	rs10078	0.571	rs890973	chr5:471494	T/C	cg05169099	chr5:481640	SLC9A3	0.46	6.85	0.3	2.42e-11	Fat distribution (HIV);
LGG	cis	rs6500395	1.000	rs1224	chr16:48572817	G/A	cg04672837	chr16:48644449	N4BP1	0.57	9.4	0.4	2.5e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7773004	0.905	rs994379	chr6:26305407	C/G	cg13736514	chr6:26305472	NA	0.41	8.21	0.36	2.27e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg06521331	chr12:34319734	NA	-0.62	-11.08	-0.46	1.82e-25	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg25172604	chr17:41446521	NA	-0.31	-7.15	-0.32	3.47e-12	Menopause (age at onset);
LGG	cis	rs9815354	0.767	rs73079325	chr3:41864565	G/A	cg03022575	chr3:42003672	ULK4	0.67	8.59	0.37	1.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7582180	0.577	rs6542942	chr2:100985378	G/T	cg08297393	chr2:100937505	LONRF2	-0.54	-10.28	-0.43	1.79e-22	Intelligence (multi-trait analysis);
LGG	cis	rs774359	0.797	rs1537712	chr9:27508489	C/T	cg14173147	chr9:27528300	MOBKL2B	0.42	8.63	0.37	9.9e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs9611565	0.921	rs5751081	chr22:41742788	A/T	cg06634786	chr22:41940651	POLR3H	-0.62	-10.53	-0.44	2.15e-23	Vitiligo;
LGG	cis	rs62238980	0.614	rs78781151	chr22:32375462	C/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	cis	rs6461049	0.638	rs3778994	chr7:2175855	G/T	cg21782813	chr7:2030301	MAD1L1	0.38	8.88	0.38	1.45e-17	Schizophrenia;
LGG	cis	rs7226408	0.857	rs56049218	chr18:34429685	C/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs62400317	0.859	rs17209678	chr6:45163601	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.31	-0.43	1.46e-22	Total body bone mineral density;
LGG	cis	rs7792596	0.861	rs7788014	chr7:94012278	C/T	cg20814616	chr7:94014465	NA	0.33	6.9	0.31	1.73e-11	Intelligence;
LGG	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg00334542	chr7:100209784	MOSPD3	-0.56	-7.68	-0.34	9.38e-14	Other erythrocyte phenotypes;
LGG	cis	rs12410462	0.551	rs2819503	chr1:227712488	A/G	cg04117972	chr1:227635322	NA	0.46	8.35	0.36	7.99e-16	Major depressive disorder;
LGG	cis	rs7572733	0.935	rs938929	chr2:198780860	A/G	cg00792783	chr2:198669748	PLCL1	-0.48	-8.14	-0.35	3.61e-15	Dermatomyositis;
LGG	cis	rs4718428	0.705	rs4718422	chr7:66359269	A/G	cg12165864	chr7:66369176	NA	-0.58	-9.37	-0.4	3.29e-19	Corneal structure;
LGG	cis	rs1451375	0.617	rs880029	chr7:50569927	G/C	cg20336341	chr7:50628841	DDC	-0.44	-7.64	-0.33	1.22e-13	Malaria;
LGG	cis	rs6676180	0.514	rs868675	chr1:119773596	A/G	cg05756136	chr1:119680316	WARS2	-0.44	-10.34	-0.43	1.12e-22	Monobrow;
LGG	cis	rs7727544	0.684	rs272869	chr5:131677997	A/G	cg24060327	chr5:131705240	SLC22A5	-0.51	-8.74	-0.38	4.3e-17	Blood metabolite levels;
LGG	cis	rs854765	0.964	rs854813	chr17:18003845	C/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.56	-10.73	-0.45	3.83e-24	Total body bone mineral density;
LGG	cis	rs9303401	0.615	rs35288118	chr17:56600748	A/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.89	14.49	0.56	1.59e-39	Cognitive test performance;
LGG	cis	rs4481887	0.927	rs10127803	chr1:248476196	A/T	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs3796619	0.503	rs1466216	chr4:1071907	C/T	cg27284194	chr4:1044797	NA	-0.78	-19.39	-0.67	9.58e-62	Recombination rate (males);
LGG	cis	rs1862618	0.620	rs189695	chr5:56225769	T/C	cg12654349	chr5:56205094	C5orf35	-0.58	-10.01	-0.42	1.78e-21	Initial pursuit acceleration;
LGG	cis	rs4356203	0.870	rs11024204	chr11:17249805	T/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.37	-0.32	7.68e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7647973	1.000	rs6783003	chr3:49524778	G/C	cg06212747	chr3:49208901	KLHDC8B	-0.54	-8.38	-0.36	6.61e-16	Menarche (age at onset);
LGG	trans	rs6828577	0.560	rs2631147	chr4:119455854	C/T	cg26518628	chr1:97050305	NA	0.53	8.46	0.37	3.47e-16	Perioperative myocardial infarction in coronary artery bypass surgery;
LGG	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg27171569	chr16:83987465	OSGIN1	0.66	11.74	0.48	4.72e-28	Pursuit maintenance gain;
LGG	cis	rs6582630	0.537	rs2204006	chr12:38407098	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.72e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6066825	0.627	rs6012497	chr20:47228591	C/T	cg18078177	chr20:47281410	PREX1	0.47	7.81	0.34	3.75e-14	Colorectal cancer;
LGG	trans	rs9858542	0.953	rs9837027	chr3:49597013	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.09	-0.35	5.26e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg24375607	chr4:120327624	NA	0.67	11.02	0.46	3.09e-25	Corneal astigmatism;
LGG	trans	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.38	-0.32	7.36e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs28386778	0.897	rs3744293	chr17:61841788	T/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.58	0.37	1.4e-16	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs77009951	chr17:29080650	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg16434002	chr17:42200994	HDAC5	0.53	9.87	0.42	5.48e-21	Total body bone mineral density;
LGG	cis	rs883565	0.740	rs2293312	chr3:39111140	C/A	cg01426195	chr3:39028469	NA	-0.7	-15.93	-0.6	6.94e-46	Handedness;
LGG	cis	rs10484885	0.680	rs72921943	chr6:90581542	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.91	-16.15	-0.6	7.22e-47	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs8180040	0.764	rs6794193	chr3:47114904	T/C	cg16586182	chr3:47516702	SCAP	-0.79	-15.24	-0.58	8.86e-43	Colorectal cancer;
LGG	cis	rs4820539	1.000	rs756631	chr22:23463183	A/G	cg14186256	chr22:23484241	RTDR1	1.0	25.58	0.77	1.25e-90	Bone mineral density;
LGG	cis	rs11112613	0.713	rs12296355	chr12:105953321	C/A	cg03607813	chr12:105948248	NA	0.58	10.55	0.44	1.78e-23	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs3816183	0.958	rs2278581	chr2:43020914	A/G	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.1e-18	Hypospadias;
LGG	cis	rs8114671	0.773	rs3746438	chr20:33584289	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-7.24	-0.32	1.9e-12	Height;
LGG	cis	rs6456156	0.792	rs10946213	chr6:167516095	A/G	cg07741184	chr6:167504864	NA	-0.36	-8.08	-0.35	5.87e-15	Primary biliary cholangitis;
LGG	cis	rs60180747	0.544	rs9920422	chr15:66575550	T/A	cg07575407	chr15:66541975	MEGF11	0.62	13.48	0.53	3.64e-35	Testicular germ cell tumor;
LGG	cis	rs6952808	0.893	rs35487994	chr7:1920171	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.5	-0.37	2.72e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.512	rs2050033	chr22:42159229	G/T	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Vitiligo;
LGG	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg12395012	chr8:11607386	GATA4	0.37	6.69	0.3	6.27e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs71281886	1	rs71281886	chr3:48352568	C/CA	cg11946769	chr3:48343235	NME6	0.65	10.39	0.43	6.99e-23	Breast cancer;
LGG	cis	rs9910055	0.659	rs721769	chr17:42261588	T/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	11.11	0.46	1.45e-25	Total body bone mineral density;
LGG	cis	rs8114671	0.539	rs2064453	chr20:33460810	T/C	cg07148914	chr20:33460835	GGT7	0.58	9.44	0.4	1.85e-19	Height;
LGG	cis	rs6951245	1.000	rs74369356	chr7:1071711	T/C	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg06713675	chr4:122721982	EXOSC9	-0.43	-6.89	-0.3	1.82e-11	Type 2 diabetes;
LGG	cis	rs477895	1.000	rs12785488	chr11:64107521	G/A	cg22916017	chr11:64110731	CCDC88B	-0.54	-7.19	-0.32	2.58e-12	Mean platelet volume;
LGG	cis	rs17453880	0.890	rs6869035	chr5:152028258	C/T	cg12297329	chr5:152029980	NA	-0.9	-23.43	-0.74	1.25e-80	Subjective well-being;
LGG	cis	rs9560113	0.960	rs1163862	chr13:112174319	C/T	cg14952266	chr13:112191215	NA	-0.41	-7.64	-0.33	1.3e-13	Menarche (age at onset);
LGG	cis	rs868036	0.718	rs28675295	chr15:68116400	C/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.17	-0.36	2.87e-15	Restless legs syndrome;
LGG	cis	rs9926296	0.535	rs36022917	chr16:89893238	A/G	cg26513180	chr16:89883248	FANCA	0.65	12.11	0.49	1.69e-29	Vitiligo;
LGG	cis	rs13108904	0.935	rs11247984	chr4:1292811	G/A	cg13395646	chr4:1353034	KIAA1530	-0.52	-8.97	-0.38	7.2e-18	Obesity-related traits;
LGG	cis	rs8114671	0.562	rs2424999	chr20:33386430	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	6.89	0.3	1.84e-11	Height;
LGG	cis	rs10911232	0.507	rs10911199	chr1:182998036	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	trans	rs7824557	0.564	rs2572389	chr8:11236392	T/C	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	trans	rs9329221	0.538	rs17750324	chr8:10100912	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.93	-0.31	1.4e-11	Neuroticism;
LGG	cis	rs7762018	0.556	rs78233989	chr6:170102041	C/G	cg19338460	chr6:170058176	WDR27	-0.82	-9.3	-0.4	5.79e-19	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.5	7.73	0.34	6.67e-14	Tonsillectomy;
LGG	cis	rs4665809	0.941	rs7602922	chr2:26265782	C/T	cg22920501	chr2:26401640	FAM59B	-0.41	-8.01	-0.35	9.5e-15	Gut microbiome composition (summer);
LGG	trans	rs11722228	0.508	rs2241472	chr4:10085902	C/G	cg26043149	chr18:55253948	FECH	0.95	16.65	0.61	3.85e-49	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg06636001	chr8:8085503	FLJ10661	0.54	10.22	0.43	2.93e-22	Morning vs. evening chronotype;
LGG	cis	rs9547996	0.885	rs9547991	chr13:38217415	A/G	cg17979426	chr13:38220150	TRPC4	-0.41	-8.08	-0.35	5.78e-15	Diastolic blood pressure;
LGG	cis	rs2439831	1.000	rs2245908	chr15:43731454	C/G	cg15269541	chr15:43626905	ADAL	-0.4	-6.85	-0.3	2.35e-11	Lung cancer in ever smokers;
LGG	cis	rs4731207	0.698	rs13228116	chr7:124480506	A/G	cg05630886	chr7:124431682	NA	0.34	7.99	0.35	1.11e-14	Cutaneous malignant melanoma;
LGG	cis	rs9325144	0.624	rs10506126	chr12:39123244	G/A	cg26384229	chr12:38710491	ALG10B	-0.71	-13.65	-0.54	6.78e-36	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.635	rs7635002	chr3:49989155	T/G	cg21659725	chr3:3221576	CRBN	0.66	12.26	0.5	4.2000000000000004e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs7503111	chr17:80101587	A/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs7737355	0.947	rs10073137	chr5:131091089	A/G	cg06307176	chr5:131281290	NA	0.57	9.38	0.4	3.01e-19	Life satisfaction;
LGG	cis	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg09307838	chr4:120376055	NA	-0.67	-11.76	-0.48	4.21e-28	Corneal astigmatism;
LGG	cis	rs7927771	0.524	rs11039402	chr11:47826090	A/C	cg20307385	chr11:47447363	PSMC3	0.57	11.11	0.46	1.4e-25	Subjective well-being;
LGG	cis	rs7267979	1.000	rs7018	chr20:25278261	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.18	0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs657075	0.697	rs71583480	chr5:131696251	C/G	cg06968155	chr5:131705112	SLC22A5	0.76	8.8	0.38	2.83e-17	Rheumatoid arthritis;
LGG	cis	rs7267979	1.000	rs1077889	chr20:25267893	A/G	cg06421707	chr20:25228305	PYGB	0.48	10.25	0.43	2.28e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2188554	0.583	rs2213958	chr7:117241394	A/T	cg10524701	chr7:117356490	CTTNBP2	0.44	7.82	0.34	3.57e-14	Esophageal adenocarcinoma;
LGG	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg07648498	chr16:89883185	FANCA	0.4	6.9	0.31	1.7e-11	Vitiligo;
LGG	cis	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg01579765	chr21:45077557	HSF2BP	-0.41	-9.54	-0.41	8.18e-20	Mean corpuscular volume;
LGG	cis	rs9910055	0.529	rs228767	chr17:42188311	C/G	cg13607699	chr17:42295918	UBTF	-0.42	-6.73	-0.3	5.01e-11	Total body bone mineral density;
LGG	cis	rs7555523	0.887	rs4656461	chr1:165687205	G/A	cg24409356	chr1:165738333	TMCO1	0.71	8.72	0.38	5.17e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.31	0.43	1.37e-22	Diabetic retinopathy;
LGG	cis	rs10504229	0.639	rs56825757	chr8:58106469	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs11783444	chr8:58131267	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.64	0.67	6.31e-63	Platelet count;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	trans	rs1997103	1.000	rs6953509	chr7:55412179	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.54	0.37	1.94e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4423214	0.535	rs1540129	chr11:71129523	C/G	cg05163923	chr11:71159392	DHCR7	0.51	8.94	0.38	9.21e-18	Vitamin D levels;
LGG	cis	rs2842992	1.000	rs2758322	chr6:160075188	G/T	cg11366901	chr6:160182831	ACAT2	0.93	14.0	0.55	2.23e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7582180	0.629	rs11694642	chr2:100957813	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.48	-0.44	3.46e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs67831559	chr15:45649307	G/T	cg10760299	chr15:45669010	GATM	0.41	8.1	0.35	4.78e-15	Homoarginine levels;
LGG	trans	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg25214090	chr10:38739885	LOC399744	0.72	12.65	0.51	1e-31	Corneal astigmatism;
LGG	cis	rs36051895	0.659	rs62541556	chr9:5049092	G/T	cg02405213	chr9:5042618	JAK2	-0.82	-15.04	-0.57	6.27e-42	Pediatric autoimmune diseases;
LGG	cis	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	8.77e-26	Morning vs. evening chronotype;
LGG	cis	rs4718428	0.705	rs13227468	chr7:66433563	T/C	cg13147721	chr7:65941812	NA	-0.47	-7.13	-0.31	4e-12	Corneal structure;
LGG	cis	rs35740288	0.597	rs12900830	chr15:86326154	T/C	cg04173714	chr15:86211321	AKAP13	0.45	7.39	0.32	6.95e-13	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9467711	0.606	rs9393708	chr6:26362643	C/T	cg12826209	chr6:26865740	GUSBL1	-0.77	-8.12	-0.35	4.18e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.963	rs9356991	chr6:25901758	C/A	cg12310025	chr6:25882481	NA	-0.43	-7.68	-0.34	9.83e-14	Height;
LGG	cis	rs651907	0.557	rs13077925	chr3:101488181	T/A	cg12386194	chr3:101231763	SENP7	0.42	7.46	0.33	4.44e-13	Colorectal cancer;
LGG	cis	rs8072100	0.790	rs1962307	chr17:45707871	A/G	cg19784903	chr17:45786737	TBKBP1	-0.33	-6.94	-0.31	1.36e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4466137	0.903	rs3734092	chr5:83016743	C/T	cg16102102	chr5:83017553	HAPLN1	-0.59	-10.74	-0.45	3.49e-24	Prostate cancer;
LGG	cis	rs13082711	0.863	rs13062327	chr3:27495573	G/A	cg02860705	chr3:27208620	NA	0.69	12.44	0.5	7.18e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2439831	0.867	rs2927072	chr15:43922398	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.66	0.41	3.06e-20	Lung cancer in ever smokers;
LGG	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg10621924	chr7:39171070	POU6F2	0.45	9.12	0.39	2.29e-18	IgG glycosylation;
LGG	cis	rs12079745	0.793	rs60011235	chr1:169254727	T/C	cg09363564	chr1:169337483	NME7;BLZF1	-0.99	-7.24	-0.32	1.85e-12	QT interval;
LGG	cis	rs751728	1.000	rs2296747	chr6:33744882	C/G	cg25922239	chr6:33757077	LEMD2	0.69	12.33	0.5	2.14e-30	Crohn's disease;
LGG	cis	rs12681288	0.523	rs73176528	chr8:961962	G/A	cg04851639	chr8:1020857	NA	-0.34	-7.15	-0.32	3.41e-12	Schizophrenia;
LGG	cis	rs8017423	0.967	rs12896540	chr14:90729392	T/C	cg04374321	chr14:90722782	PSMC1	-0.92	-19.16	-0.67	1.08e-60	Mortality in heart failure;
LGG	cis	rs1670533	1.000	rs7685541	chr4:1058501	G/A	cg27284194	chr4:1044797	NA	0.55	9.85	0.42	6.51e-21	Recombination rate (females);
LGG	cis	rs7599312	0.534	rs7355673	chr2:213404389	T/C	cg20637307	chr2:213403960	ERBB4	0.75	16.9	0.62	3.06e-50	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6735179	0.641	rs2382558	chr2:1752229	A/G	cg08534653	chr2:1747700	PXDN	0.49	7.39	0.32	6.72e-13	Response to antipsychotic treatment;
LGG	cis	rs3857067	0.806	rs12513267	chr4:95109545	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.91	-0.35	1.88e-14	QT interval;
LGG	cis	rs7726839	0.540	rs4957080	chr5:644552	A/C	cg07777115	chr5:623756	CEP72	0.63	8.2	0.36	2.35e-15	Obesity-related traits;
LGG	cis	rs11605275	0.581	rs11606785	chr11:20030430	A/C	cg14835545	chr11:20032148	NAV2	-0.89	-9.78	-0.41	1.17e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1670533	1.000	rs11247972	chr4:1060550	A/G	cg27284194	chr4:1044797	NA	0.55	9.97	0.42	2.4e-21	Recombination rate (females);
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg02127607	chr17:61920694	SMARCD2	0.48	8.66	0.37	7.63e-17	Prudent dietary pattern;
LGG	cis	rs7618501	0.602	rs2624853	chr3:50128893	A/G	cg05623727	chr3:50126028	RBM5	-0.38	-8.44	-0.37	4.15e-16	Intelligence (multi-trait analysis);
LGG	trans	rs12579753	0.871	rs10862362	chr12:82199383	T/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.89	-0.34	2.15e-14	Resting heart rate;
LGG	cis	rs10504229	0.683	rs55645894	chr8:58116145	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs4538187	0.671	rs72893103	chr2:64235312	C/T	cg14150252	chr2:64069583	UGP2	-0.5	-9.1	-0.39	2.61e-18	Systolic blood pressure;
LGG	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg08344181	chr3:125677491	NA	-0.61	-7.33	-0.32	1.03e-12	Depression;
LGG	trans	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.49	-0.56	1.72e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs7226408	0.857	rs72885260	chr18:34431004	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg20308403	chr7:2120281	MAD1L1	0.33	7.06	0.31	6.12e-12	Schizophrenia;
LGG	cis	rs4481887	0.800	rs28590733	chr1:248514978	T/C	cg13385794	chr1:248469461	NA	0.45	7.93	0.35	1.68e-14	Common traits (Other);
LGG	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg27411982	chr8:10470053	RP1L1	-0.42	-6.84	-0.3	2.51e-11	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg04025307	chr7:1156635	C7orf50	0.65	8.24	0.36	1.85e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7633770	0.931	rs12637421	chr3:46695074	T/C	cg11219411	chr3:46661640	NA	0.54	12.11	0.49	1.66e-29	Coronary artery disease;
LGG	cis	rs10435719	0.902	rs7459545	chr8:11804389	G/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.48	-0.33	3.88e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs8062405	0.679	rs72793818	chr16:28893137	G/A	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.35e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg20607798	chr8:58055168	NA	0.57	8.74	0.38	4.21e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs62054599	chr16:89808850	C/G	cg27400746	chr16:89904261	SPIRE2	-1.15	-17.08	-0.62	4.24e-51	Skin colour saturation;
LGG	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.23	-0.49	5.29e-30	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs9771228	0.536	rs10233473	chr7:32265007	C/T	cg27532318	chr7:32358331	NA	0.51	7.42	0.33	5.47e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.68	0.37	6.56e-17	Obesity-related traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12788078	chr18:43546845	KIAA1632	0.41	6.68	0.3	6.96e-11	Menarche (age at onset);
LGG	trans	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg02002194	chr4:3960332	NA	-0.5	-9.23	-0.39	9.55e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10876993	0.893	rs3825078	chr12:58089413	A/T	cg18357645	chr12:58087776	OS9	0.72	12.87	0.51	1.33e-32	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs11098499	0.754	rs12506487	chr4:120271361	T/G	cg25214090	chr10:38739885	LOC399744	0.56	10.25	0.43	2.27e-22	Corneal astigmatism;
LGG	cis	rs7552404	0.924	rs2153126	chr1:76199345	C/G	cg22875332	chr1:76189707	ACADM	0.62	10.87	0.45	1.12e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg03213289	chr20:61660250	NA	0.65	14.15	0.55	4.95e-38	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs17270561	0.609	rs9356985	chr6:25728098	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	trans	rs11098499	0.865	rs1112817	chr4:120297800	T/C	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs208520	0.690	rs12209753	chr6:66703951	A/G	cg07460842	chr6:66804631	NA	0.96	17.81	0.64	2.08e-54	Exhaled nitric oxide output;
LGG	cis	rs1799949	0.965	rs8176140	chr17:41251646	T/A	cg01879757	chr17:41196368	BRCA1	-0.44	-8.92	-0.38	1.13e-17	Menopause (age at onset);
LGG	cis	rs2731664	0.792	rs385981	chr5:176886539	C/T	cg23176889	chr5:176863531	GRK6	-0.65	-13.02	-0.52	2.94e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9674544	0.757	rs3744085	chr17:47131901	A/G	cg18128536	chr17:47092178	IGF2BP1	-0.49	-9.26	-0.4	7.57e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.21	0.32	2.35e-12	Prudent dietary pattern;
LGG	cis	rs2302729	0.545	rs1894979	chr12:2766999	G/A	cg19945202	chr12:2788847	CACNA1C	-0.73	-12.5	-0.5	4.12e-31	Sleep quality;
LGG	cis	rs2404602	0.646	rs3764245	chr15:77223176	G/C	cg15268244	chr15:77196840	NA	-0.46	-9.76	-0.41	1.4e-20	Blood metabolite levels;
LGG	cis	rs6573604	0.892	rs10142617	chr14:65773671	G/T	cg15999311	chr14:65749247	NA	0.46	6.69	0.3	6.26e-11	N-glycan levels;
LGG	trans	rs9858213	1	rs9858213	chr3:49731861	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.48	-0.33	3.85e-13	Educational attainment;
LGG	cis	rs1062177	0.826	rs2915879	chr5:151147442	A/G	cg00977110	chr5:151150581	G3BP1	0.47	7.51	0.33	3.08e-13	Preschool internalizing problems;
LGG	cis	rs7811142	0.830	rs28495773	chr7:99943583	A/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	19.24	0.67	4.67e-61	Platelet count;
LGG	cis	rs9420907	0.579	rs35007589	chr10:105655228	C/T	cg11005552	chr10:105648138	OBFC1	-0.68	-6.66	-0.3	7.97e-11	Telomere length;
LGG	cis	rs7785730	0.652	rs34774784	chr7:28087712	G/A	cg17702455	chr7:28058989	JAZF1	-0.42	-7.62	-0.33	1.49e-13	Free thyroxine concentration;
LGG	cis	rs67311347	1.000	rs7612015	chr3:40399974	A/C	cg13683864	chr3:40499215	RPL14	-0.99	-20.19	-0.68	1.84e-65	Renal cell carcinoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14580567	chr4:145567271	HHIP	-0.39	-6.76	-0.3	4.25e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9910055	0.615	rs189049	chr17:42197213	A/C	cg13607699	chr17:42295918	UBTF	-0.52	-8.69	-0.37	6.07e-17	Total body bone mineral density;
LGG	cis	rs524281	0.861	rs918299	chr11:65927607	C/T	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs11105298	0.891	rs10777163	chr12:89830720	T/C	cg00757033	chr12:89920650	WDR51B	0.59	8.59	0.37	1.32e-16	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12618769	0.625	rs3769726	chr2:99105827	G/C	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.37	-8.63	-0.37	9.79e-17	Schizophrenia;
LGG	cis	rs12477438	1.000	rs12053372	chr2:99810055	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.06	-16.78	-0.61	1.02e-49	Chronic sinus infection;
LGG	cis	rs1355223	0.583	rs2941058	chr11:34880245	C/G	cg24088639	chr11:34937564	PDHX;APIP	-0.39	-6.83	-0.3	2.64e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg00666640	chr1:248458726	OR2T12	0.59	9.69	0.41	2.44e-20	Common traits (Other);
LGG	trans	rs11098499	0.863	rs13140391	chr4:120503437	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.62	0.48	1.44e-27	Corneal astigmatism;
LGG	trans	rs2562456	0.833	rs61035285	chr19:21512277	G/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	cis	rs4727027	0.727	rs3801980	chr7:148878620	T/A	cg23583168	chr7:148888333	NA	-0.7	-11.26	-0.46	3.61e-26	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs988958	0.565	rs6753173	chr2:42235975	C/T	cg27428208	chr2:42229179	NA	0.48	7.66	0.34	1.09e-13	Hypospadias;
LGG	cis	rs59197085	0.636	rs2307036	chr7:128454537	C/A	cg00734629	chr7:128471146	FLNC	0.34	7.05	0.31	6.43e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs736408	0.509	rs1108842	chr3:52720080	A/C	cg15147215	chr3:52552868	STAB1	-0.39	-7.7	-0.34	8.32e-14	Bipolar disorder;
LGG	cis	rs4253772	0.530	rs6008616	chr22:46707954	A/G	cg09461388	chr22:46763229	CELSR1	-0.59	-6.66	-0.3	7.81e-11	LDL cholesterol;Cholesterol, total;
LGG	cis	rs62238980	0.522	rs117656576	chr22:32515901	G/A	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg13683864	chr3:40499215	RPL14	1.08	24.2	0.75	3.34e-84	Renal cell carcinoma;
LGG	cis	rs7208859	0.623	rs216423	chr17:28942109	G/C	cg08994789	chr17:28903642	LRRC37B2	-0.72	-9.17	-0.39	1.54e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3733585	0.648	rs13125029	chr4:9982029	A/G	cg11266682	chr4:10021025	SLC2A9	0.43	8.08	0.35	5.86e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.15	-0.39	1.81e-18	Dementia with Lewy bodies;
LGG	cis	rs74781061	0.929	rs8027066	chr15:74828023	C/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.08	-0.31	5.42e-12	Endometriosis;
LGG	cis	rs4006360	0.646	rs917635	chr17:39302683	A/G	cg16985667	chr17:39306289	KRTAP4-5	0.52	11.29	0.46	2.9e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9333075	0.507	rs1341099	chr10:15751823	A/G	cg14364212	chr10:15760690	ITGA8	-0.44	-9.52	-0.4	9.73e-20	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	ch.11.1222938R	chr11:62653851	SLC3A2	0.41	6.72	0.3	5.35e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs73198271	0.740	rs964771	chr8:8650939	A/G	cg01851573	chr8:8652454	MFHAS1	-0.37	-6.8	-0.3	3.32e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1728785	1.000	rs698719	chr16:68560125	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.25	-0.36	1.6e-15	Ulcerative colitis;
LGG	cis	rs10911232	0.507	rs10911196	chr1:182995233	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.71e-21	Hypertriglyceridemia;
LGG	cis	rs6450176	0.564	rs31227	chr5:53326467	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.32	-0.47	2.14e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs7737355	0.947	rs6864173	chr5:130871822	T/C	cg06307176	chr5:131281290	NA	0.55	9.26	0.4	7.9e-19	Life satisfaction;
LGG	cis	rs2075371	1.000	rs1868783	chr7:133975087	A/G	cg11752832	chr7:134001865	SLC35B4	0.61	11.24	0.46	4.25e-26	Mean platelet volume;
LGG	cis	rs4555082	0.874	rs4677	chr14:105717279	T/C	cg06808227	chr14:105710500	BRF1	-0.65	-11.71	-0.48	6.19e-28	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7084402	0.967	rs1658490	chr10:60281616	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-18.09	-0.64	1.01e-55	Refractive error;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.95	-0.31	1.22e-11	Menopause (age at onset);
LGG	cis	rs2635047	0.783	rs9948677	chr18:44790343	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.59	0.33	1.75e-13	Educational attainment;
LGG	cis	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg21479132	chr6:26055353	NA	0.71	6.89	0.3	1.85e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs897984	0.572	rs4889526	chr16:31030344	C/A	cg02466173	chr16:30829666	NA	-0.44	-7.85	-0.34	2.93e-14	Dementia with Lewy bodies;
LGG	cis	rs68170813	0.559	rs78404515	chr7:106909126	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.52	-0.44	2.38e-23	Coronary artery disease;
LGG	cis	rs35306767	0.855	rs34251037	chr10:867884	C/T	cg26597838	chr10:835615	NA	0.95	13.07	0.52	1.94e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.46	0.63	7.91e-53	Chronic sinus infection;
LGG	cis	rs1552244	0.554	rs13081079	chr3:10056348	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.31	-0.43	1.43e-22	Alzheimer's disease;
LGG	cis	rs763121	0.853	rs5757213	chr22:39053888	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.82	0.64	1.76e-54	Menopause (age at onset);
LGG	cis	rs875971	0.862	rs9791713	chr7:66105198	C/A	cg23594656	chr7:65796392	TPST1	0.42	8.91	0.38	1.2e-17	Aortic root size;
LGG	cis	rs9393692	0.905	rs34916901	chr6:26286149	G/T	cg13736514	chr6:26305472	NA	-0.46	-9.87	-0.42	5.67e-21	Educational attainment;
LGG	cis	rs3820928	0.874	rs7563644	chr2:227846932	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.14e-14	Pulmonary function;
LGG	cis	rs611744	0.870	rs640068	chr8:109158002	A/G	cg21045802	chr8:109455806	TTC35	0.39	6.76	0.3	4.04e-11	Dupuytren's disease;
LGG	cis	rs727505	1.000	rs10271646	chr7:124549573	T/C	cg23710748	chr7:124431027	NA	-0.47	-8.94	-0.38	9.36e-18	Lewy body disease;
LGG	cis	rs3733585	0.637	rs6850684	chr4:9964380	G/T	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs897984	0.511	rs7196726	chr16:31092075	G/A	cg00531865	chr16:30841666	NA	-0.48	-10.06	-0.42	1.14e-21	Dementia with Lewy bodies;
LGG	cis	rs11064837	0.504	rs7310536	chr12:120054073	C/G	cg25937854	chr12:120150414	CIT	-0.57	-9.97	-0.42	2.38e-21	Schizophrenia;
LGG	cis	rs11758351	0.866	rs55815656	chr6:26207303	G/A	cg11342453	chr6:26196699	NA	0.48	6.69	0.3	6.42e-11	Gout;Renal underexcretion gout;
LGG	trans	rs8073060	0.544	rs225249	chr17:33942540	T/C	cg19694781	chr19:47549865	TMEM160	-1.16	-18.3	-0.65	1.09e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	trans	rs61931739	0.517	rs7313663	chr12:34417058	T/C	cg13010199	chr12:38710504	ALG10B	0.65	12.99	0.52	4.15e-33	Morning vs. evening chronotype;
LGG	cis	rs42648	0.693	rs3747800	chr7:89899488	G/T	cg25739043	chr7:89950458	NA	-0.34	-7.18	-0.32	2.74e-12	Homocysteine levels;
LGG	cis	rs4787491	0.588	rs12924622	chr16:30084052	A/T	cg06326092	chr16:30034487	C16orf92	0.43	8.52	0.37	2.21e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg02297831	chr4:17616191	MED28	0.5	9.34	0.4	4.1e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2299587	0.582	rs10112108	chr8:17910777	G/T	cg18067069	chr8:17937731	ASAH1	-0.33	-8.03	-0.35	8.07e-15	Economic and political preferences;
LGG	cis	rs1401999	0.628	rs7639048	chr3:183746044	A/G	cg01324343	chr3:183735012	ABCC5	0.76	14.41	0.56	3.68e-39	Anterior chamber depth;
LGG	cis	rs61931739	0.517	rs2101396	chr12:34048927	T/A	cg06521331	chr12:34319734	NA	-0.63	-11.97	-0.49	6.09e-29	Morning vs. evening chronotype;
LGG	cis	rs3768617	0.510	rs10752902	chr1:183090265	T/A	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8180040	0.764	rs4082155	chr3:47125385	G/A	cg16586182	chr3:47516702	SCAP	-0.78	-15.17	-0.58	1.7e-42	Colorectal cancer;
LGG	cis	rs4969178	0.930	rs11077363	chr17:76397309	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.84	0.59	1.89e-45	HDL cholesterol levels;
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.66	0.3	7.92e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7107174	1.000	rs2511186	chr11:77984306	C/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.65e-13	Testicular germ cell tumor;
LGG	cis	rs10504229	1.000	rs6989060	chr8:58178989	T/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs17683430	0.702	rs117983733	chr22:32387606	C/T	cg02631450	chr22:32366979	NA	1.01	9.71	0.41	2.06e-20	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs11677416	1.000	rs4848300	chr2:113527906	T/C	cg27083787	chr2:113543245	IL1A	0.53	8.8	0.38	2.79e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	trans	rs7824557	0.606	rs2736273	chr8:11199938	C/A	cg16141378	chr3:129829833	LOC729375	-0.35	-8.01	-0.35	9.15e-15	Retinal vascular caliber;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.62e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6787172	0.702	rs1730058	chr3:157976047	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs4474465	1.000	rs11237495	chr11:78155090	A/G	cg02023728	chr11:77925099	USP35	0.4	6.95	0.31	1.28e-11	Alzheimer's disease (survival time);
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg18137308	chr11:63775436	MACROD1	0.46	11.29	0.46	2.89e-26	Pulse pressure;
LGG	cis	rs9393813	0.791	rs35690855	chr6:27341471	A/C	cg18711553	chr6:27366782	ZNF391	-0.53	-9.77	-0.41	1.25e-20	Bipolar disorder;
LGG	cis	rs9467773	1.000	rs9467796	chr6:26568411	A/G	cg09904177	chr6:26538194	HMGN4	0.77	17.02	0.62	8.32e-51	Intelligence (multi-trait analysis);
LGG	trans	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.53	9.32	0.4	4.76e-19	Mean corpuscular volume;
LGG	cis	rs8062405	1.000	rs62036621	chr16:28833299	C/A	cg00198680	chr16:28758506	NA	0.29	7.14	0.31	3.62e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs79911532	0.515	rs79131789	chr7:75756463	C/A	cg15148918	chr7:75625777	STYXL1	-0.7	-7.96	-0.35	1.34e-14	Mononucleosis;
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg14926445	chr8:58193284	C8orf71	-0.72	-8.53	-0.37	2.17e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs283228	0.535	rs2852513	chr6:101846616	C/G	cg27451362	chr6:101846650	GRIK2	1.06	16.34	0.6	1.07e-47	Coenzyme Q10 levels;
LGG	cis	rs6541297	0.941	rs2144299	chr1:230280366	A/G	cg20703242	chr1:230279135	GALNT2	0.4	7.52	0.33	2.87e-13	Coronary artery disease;
LGG	cis	rs826838	0.967	rs1684411	chr12:39128494	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.24	-0.7	2.2e-70	Heart rate;
LGG	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg24565620	chr2:194026	NA	-0.72	-9.02	-0.39	4.84e-18	Blood protein levels;
LGG	trans	rs9858542	1.000	rs11718165	chr3:49696797	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.37	-0.32	8.15e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1552244	0.882	rs17050660	chr3:10001772	A/G	cg13047869	chr3:10149882	C3orf24	-0.47	-7.93	-0.35	1.62e-14	Alzheimer's disease;
LGG	cis	rs62238980	0.614	rs17682819	chr22:32424794	T/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs4948102	0.642	rs766333	chr7:56126704	T/A	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.28	0.32	1.48e-12	Plasma homocysteine levels (post-methionine load test);
LGG	trans	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg02002194	chr4:3960332	NA	0.41	7.2	0.32	2.46e-12	Morning vs. evening chronotype;
LGG	cis	rs9796	0.870	rs3900905	chr15:41260801	G/A	cg18705301	chr15:41695430	NDUFAF1	0.47	8.22	0.36	2.04e-15	Menopause (age at onset);
LGG	trans	rs35110281	0.744	rs162373	chr21:44927107	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.55	-9.55	-0.41	7.4e-20	Mean corpuscular volume;
LGG	cis	rs17067123	0.614	rs7340789	chr4:180052417	C/T	cg26610307	chr4:180072759	NA	-0.51	-7.12	-0.31	4.09e-12	Response to hepatitis C treatment;
LGG	cis	rs943466	1.000	rs6921487	chr6:33749293	G/A	cg07519485	chr6:33762594	MLN	0.54	11.2	0.46	6.03e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs2477686	0.526	rs1998760	chr1:2397136	C/T	cg00157179	chr1:2383687	NA	-0.79	-14.54	-0.56	1.05e-39	Non-obstructive azoospermia;
LGG	cis	rs155076	0.938	rs9509633	chr13:21844482	G/C	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.23e-56	White matter hyperintensity burden;
LGG	cis	rs643506	0.874	rs634983	chr11:111747427	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.79	0.3	3.43e-11	Breast cancer;
LGG	cis	rs12410462	0.551	rs10916178	chr1:227817593	T/G	cg04117972	chr1:227635322	NA	0.43	7.92	0.35	1.72e-14	Major depressive disorder;
LGG	cis	rs1420338	1.000	rs918038	chr7:34153768	A/G	cg01275685	chr7:34179230	BMPER	-0.47	-8.37	-0.36	7.1e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	trans	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg02002194	chr4:3960332	NA	-0.48	-9.14	-0.39	1.93e-18	Parkinson's disease;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.06	0.31	6.3e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1005277	0.522	rs200943	chr10:38148730	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.43	-7.09	-0.31	4.95e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6964587	1.000	rs28735847	chr7:91592755	T/C	cg17063962	chr7:91808500	NA	0.48	8.6	0.37	1.23e-16	Breast cancer;
LGG	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg03342759	chr3:160939853	NMD3	-0.54	-9.13	-0.39	2.07e-18	Kawasaki disease;
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.89	-0.51	1.11e-32	Vitiligo;
LGG	cis	rs908922	0.676	rs568661	chr1:152519787	C/A	cg20991723	chr1:152506922	NA	-0.71	-14.38	-0.56	4.83e-39	Hair morphology;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19971804	chr2:39102883	MORN2;DHX57	0.43	7.17	0.32	3.08e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg00024416	chr22:24240387	NA	-0.36	-6.7	-0.3	6.25e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs908922	0.676	rs12059256	chr1:152515431	G/A	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs2404602	0.692	rs35999717	chr15:77193367	G/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs6952808	0.609	rs10227517	chr7:1950292	A/T	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.2	-0.36	2.33e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs12451471	0.620	rs11150846	chr17:78098520	C/T	cg24585782	chr17:78113791	EIF4A3	-0.51	-8.53	-0.37	2.17e-16	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs1665650	0.957	rs1614273	chr10:118486785	C/T	cg14919929	chr10:118506882	NA	0.48	8.41	0.36	5.05e-16	Colorectal cancer;
LGG	cis	rs6840360	0.967	rs4383600	chr4:152694383	T/C	cg22705602	chr4:152727874	NA	-0.28	-7.06	-0.31	6.13e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10870270	1.000	rs10430617	chr10:133748889	T/C	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.98	-0.52	4.58e-33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs732505	0.618	rs1337057	chr19:5676950	G/A	cg26242866	chr19:5711310	LONP1	0.73	7.92	0.35	1.73e-14	vWF and FVIII levels;
LGG	cis	rs2836974	0.966	rs7283516	chr21:40690537	A/G	cg17971929	chr21:40555470	PSMG1	0.84	15.91	0.59	8.94e-46	Cognitive function;
LGG	cis	rs123509	0.913	rs339685	chr3:42782952	C/G	cg10144569	chr3:42726640	KBTBD5	0.51	7.52	0.33	2.96e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9311474	0.508	rs6805156	chr3:52609362	T/C	cg15147215	chr3:52552868	STAB1	-0.37	-7.0	-0.31	8.86e-12	Electroencephalogram traits;
LGG	cis	rs11023332	0.800	rs12271890	chr11:14934686	A/G	cg18937875	chr11:14930189	NA	-0.55	-9.34	-0.4	4.05e-19	Adiponectin levels;Vitamin D levels;
LGG	cis	rs4740619	0.661	rs10810488	chr9:15943931	G/A	cg14451791	chr9:16040625	NA	-0.4	-9.84	-0.42	6.98e-21	Body mass index;
LGG	cis	rs2576037	0.899	rs2571034	chr18:44578565	A/G	cg19077165	chr18:44547161	KATNAL2	0.51	9.0	0.39	5.89e-18	Personality dimensions;
LGG	cis	rs7615952	0.558	rs17334039	chr3:125540308	A/G	cg05084668	chr3:125655381	ALG1L	-0.65	-8.24	-0.36	1.82e-15	Blood pressure (smoking interaction);
LGG	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	cis	rs9311474	0.508	rs7625743	chr3:52606366	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.41	0.47	9.29e-27	Electroencephalogram traits;
LGG	cis	rs17401966	0.931	rs4240911	chr1:10307453	A/G	cg15208524	chr1:10270712	KIF1B	0.43	7.6	0.33	1.66e-13	Hepatocellular carcinoma;
LGG	cis	rs875971	0.545	rs73142233	chr7:65686280	T/A	cg11764359	chr7:65958608	NA	0.62	9.23	0.39	9.54e-19	Aortic root size;
LGG	cis	rs1129187	0.719	rs3805953	chr6:42936900	C/T	cg05552183	chr6:42928497	GNMT	0.44	12.97	0.52	4.76e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs61931739	0.556	rs7954221	chr12:33825077	C/T	cg13010199	chr12:38710504	ALG10B	0.36	6.84	0.3	2.44e-11	Morning vs. evening chronotype;
LGG	cis	rs9287719	0.674	rs759399	chr2:10796883	T/C	cg02196655	chr2:10830764	NOL10	0.5	8.72	0.38	4.86e-17	Prostate cancer;
LGG	cis	rs2762353	0.808	rs1165151	chr6:25821616	T/G	cg03517284	chr6:25882590	NA	-0.54	-10.34	-0.43	1.1e-22	Blood metabolite levels;
LGG	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg00012203	chr2:219082015	ARPC2	0.69	12.73	0.51	5.08e-32	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs3540	0.554	rs12900987	chr15:91071776	T/C	cg22089800	chr15:90895588	ZNF774	-0.67	-12.15	-0.49	1.08e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs9818758	0.607	rs12715434	chr3:49295025	G/C	cg21659725	chr3:3221576	CRBN	-0.66	-7.09	-0.31	4.92e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	trans	rs11976180	0.569	rs12703565	chr7:143754401	C/T	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.72	-11.61	-0.47	1.65e-27	Obesity-related traits;
LGG	cis	rs9910055	0.718	rs7212854	chr17:42254417	A/G	cg08499158	chr17:42289980	UBTF	-0.58	-11.0	-0.46	3.66e-25	Total body bone mineral density;
LGG	cis	rs3825199	0.515	rs2072593	chr12:93970026	T/C	cg18151635	chr12:93972918	NA	-0.56	-10.31	-0.43	1.4e-22	Height;
LGG	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg26666090	chr16:58549219	SETD6	1.15	10.18	0.43	4.2e-22	Schizophrenia;
LGG	cis	rs721399	0.752	rs1495743	chr8:18273300	C/G	cg18736775	chr8:18248649	NAT2	0.5	8.39	0.36	6.1e-16	Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs13048789	chr21:46660714	A/G	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.12	0.52	1.13e-33	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12621278	0.826	rs13414928	chr2:173304302	A/G	cg15021238	chr2:173305865	ITGA6	-0.78	-9.39	-0.4	2.69e-19	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs10876993	0.890	rs2640630	chr12:58067267	T/C	cg18357645	chr12:58087776	OS9	0.69	12.53	0.5	3.13e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.36	0.32	8.32e-13	Body mass index;
LGG	cis	rs10752881	1.000	rs12133714	chr1:182988252	A/G	cg15522984	chr1:182991683	LAMC1	0.48	10.0	0.42	1.93e-21	Colorectal cancer;
LGG	cis	rs8060686	0.641	rs75796305	chr16:68208791	A/G	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs17767392	0.670	rs4902928	chr14:71732652	G/C	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.02	-0.35	8.83e-15	Mitral valve prolapse;
LGG	cis	rs9393813	1.000	rs1011665	chr6:27332298	T/C	cg18711553	chr6:27366782	ZNF391	0.52	9.53	0.4	9.13e-20	Bipolar disorder;
LGG	cis	rs12701220	0.948	rs10275712	chr7:1082918	G/A	cg20821713	chr7:1055600	C7orf50	-0.57	-8.73	-0.38	4.79e-17	Bronchopulmonary dysplasia;
LGG	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	cg07928641	chr1:182991847	LAMC1	0.45	8.79	0.38	2.92e-17	Fuchs's corneal dystrophy;
LGG	cis	rs7208859	0.623	rs216434	chr17:28922335	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.4	-0.47	1.06e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6764363	0.587	rs7612619	chr3:283076	T/A	cg02057681	chr3:285234	CHL1	-0.45	-8.17	-0.35	2.97e-15	Sudden cardiac arrest;
LGG	cis	rs2072732	0.861	rs12044848	chr1:2960790	C/T	cg08733933	chr1:2954429	NA	-0.44	-8.78	-0.38	3.25e-17	Plateletcrit;
LGG	cis	rs2012796	0.956	rs6574646	chr14:81819809	A/G	cg02996355	chr14:81879375	NA	0.51	8.16	0.35	3.18e-15	Night sleep phenotypes;
LGG	cis	rs701145	0.585	rs6440935	chr3:153816976	A/T	cg17054900	chr3:154042577	DHX36	0.79	9.39	0.4	2.66e-19	Coronary artery disease;
LGG	cis	rs847649	0.842	rs4729860	chr7:102625567	C/T	cg18108683	chr7:102477205	FBXL13	0.61	12.99	0.52	4.16e-33	Morning vs. evening chronotype;
LGG	cis	rs240764	0.578	rs9322216	chr6:101251720	A/C	cg09795085	chr6:101329169	ASCC3	-0.42	-7.0	-0.31	9.13e-12	Neuroticism;
LGG	cis	rs1153858	1.000	rs1153858	chr15:45652703	A/G	cg05280133	chr15:45670068	GATM;LOC145663	-0.41	-7.46	-0.33	4.22e-13	Homoarginine levels;
LGG	cis	rs6121246	0.542	rs6059761	chr20:30110522	G/C	cg18721089	chr20:30220636	NA	-0.51	-7.45	-0.33	4.56e-13	Mean corpuscular hemoglobin;
LGG	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg00343986	chr7:65444356	GUSB	-0.39	-6.72	-0.3	5.3e-11	Aortic root size;
LGG	cis	rs8079658	1.000	rs58176400	chr17:63816098	T/G	cg18091269	chr17:63822838	CCDC46	-0.4	-6.76	-0.3	4.16e-11	Post bronchodilator FEV1;
LGG	cis	rs8114671	0.562	rs4911164	chr20:33479488	G/C	cg07148914	chr20:33460835	GGT7	0.58	9.68	0.41	2.63e-20	Height;
LGG	cis	rs9611565	1.000	rs9611565	chr22:41767486	T/C	cg03806693	chr22:41940476	POLR3H	-0.87	-14.68	-0.56	2.54e-40	Vitiligo;
LGG	trans	rs3857536	0.505	rs208459	chr6:66911055	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.65	-10.83	-0.45	1.65e-24	Blood trace element (Cu levels);
LGG	cis	rs7781557	0.640	rs17135916	chr7:102552997	A/C	cg18108683	chr7:102477205	FBXL13	-0.55	-8.24	-0.36	1.82e-15	Colorectal adenoma (advanced);
LGG	cis	rs2204008	0.744	rs66474616	chr12:38461564	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.84	0.73	6.75e-78	Bladder cancer;
LGG	trans	rs2727020	0.930	rs1164688	chr11:49290604	C/G	cg03929089	chr4:120376271	NA	0.8	14.23	0.55	2.14e-38	Coronary artery disease;
LGG	cis	rs8180040	0.676	rs7633698	chr3:47013452	A/T	cg16586182	chr3:47516702	SCAP	-0.76	-14.19	-0.55	3.39e-38	Colorectal cancer;
LGG	cis	rs769267	0.930	rs1054930	chr19:19648346	G/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.59	9.89	0.42	4.76e-21	Tonsillectomy;
LGG	cis	rs72634258	0.945	rs34466510	chr1:8147412	T/C	cg00042356	chr1:8021962	PARK7	0.81	9.58	0.41	5.93e-20	Inflammatory bowel disease;
LGG	trans	rs4819388	0.915	rs7278940	chr21:45648992	C/T	cg17383793	chr5:52405638	MOCS2	-0.45	-7.07	-0.31	5.85e-12	Celiac disease;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	cis	rs12421382	0.558	rs12422001	chr11:109391880	A/G	cg07142201	chr11:109293216	C11orf87	0.53	9.39	0.4	2.68e-19	Schizophrenia;
LGG	cis	rs7219021	0.926	rs7217983	chr17:46853345	A/G	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.74	-0.3	4.61e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg00198680	chr16:28758506	NA	0.3	7.38	0.32	7.51e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.44	-0.37	4.02e-16	Joint mobility (Beighton score);
LGG	cis	rs2470578	0.792	rs723813	chr3:17240402	C/G	cg20981856	chr3:17787350	NA	0.36	6.83	0.3	2.67e-11	Schizophrenia;
LGG	cis	rs12477438	1.000	rs57846982	chr2:99921574	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-15.06	-0.57	5.11e-42	Chronic sinus infection;
LGG	cis	rs2153535	0.542	rs915354	chr6:8440357	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.09	0.42	8.97e-22	Motion sickness;
LGG	cis	rs317689	0.608	rs650198	chr12:69674595	C/T	cg20891283	chr12:69753455	YEATS4	0.45	6.95	0.31	1.22e-11	Response to diuretic therapy;
LGG	trans	rs7937682	0.602	rs11214036	chr11:111773169	C/T	cg18187862	chr3:45730750	SACM1L	0.58	9.51	0.4	1.06e-19	Primary sclerosing cholangitis;
LGG	cis	rs17030434	0.784	rs11099896	chr4:154664697	T/G	cg14289246	chr4:154710475	SFRP2	-0.56	-9.51	-0.4	1.03e-19	Electrocardiographic conduction measures;
LGG	cis	rs2486288	0.656	rs11631021	chr15:45556829	A/G	cg15395560	chr15:45543142	SLC28A2	0.43	7.24	0.32	1.87e-12	Glomerular filtration rate;
LGG	cis	rs798554	0.797	rs35957220	chr7:2812632	C/G	cg04166393	chr7:2884313	GNA12	0.44	8.21	0.36	2.18e-15	Height;
LGG	cis	rs6460942	1.000	rs17274870	chr7:12406221	G/T	cg06484146	chr7:12443880	VWDE	-0.4	-6.89	-0.3	1.85e-11	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7572733	0.935	rs10207433	chr2:198805930	G/T	cg00792783	chr2:198669748	PLCL1	0.48	8.16	0.35	3.1e-15	Dermatomyositis;
LGG	cis	rs2635047	0.875	rs2251948	chr18:44681356	A/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.21	0.39	1.13e-18	Educational attainment;
LGG	cis	rs4148883	0.675	rs28762430	chr4:100119257	C/A	cg12011299	chr4:100065546	ADH4	0.38	8.17	0.36	2.87e-15	Alcohol dependence;
LGG	cis	rs147144681	1	rs147144681	chr15:78900908	C/T	cg18825076	chr15:78729989	IREB2	-0.45	-7.32	-0.32	1.1e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs28735056	0.933	rs72980085	chr18:77631679	A/C	cg20368463	chr18:77673604	PQLC1	-0.49	-8.79	-0.38	2.9e-17	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03506502	chr4:174443567	NA	0.47	8.23	0.36	1.91e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg18457773	chr20:30865370	KIF3B	0.46	6.86	0.3	2.17e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2294693	0.947	rs9349176	chr6:40989525	C/T	cg14769373	chr6:40998127	UNC5CL	-0.43	-7.58	-0.33	1.91e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs10504229	0.683	rs16921807	chr8:58105967	C/T	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs10876993	0.928	rs2640629	chr12:58065448	C/T	cg18357645	chr12:58087776	OS9	0.7	12.72	0.51	5.36e-32	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs6502050	0.805	rs11651863	chr17:80084539	T/C	cg11859384	chr17:80120422	CCDC57	0.46	8.15	0.35	3.49e-15	Life satisfaction;
LGG	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg01017244	chr2:74357527	NA	0.46	8.24	0.36	1.81e-15	Gestational age at birth (maternal effect);
LGG	cis	rs6732160	0.588	rs62151795	chr2:73376840	G/A	cg01422370	chr2:73384389	NA	0.57	10.02	0.42	1.65e-21	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02071572	chr4:1403502	NA	0.4	6.65	0.3	8.31e-11	Longevity;
LGG	cis	rs74781061	1.000	rs61192812	chr15:74888495	A/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.19	-0.32	2.69e-12	Endometriosis;
LGG	trans	rs826838	0.834	rs2387842	chr12:38736442	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.48	-0.33	3.64e-13	Heart rate;
LGG	cis	rs7580658	0.613	rs6754999	chr2:128195387	G/A	cg10021288	chr2:128175891	PROC	-0.66	-13.51	-0.53	2.68e-35	Protein C levels;
LGG	cis	rs9329289	0.926	rs10903784	chr10:2541943	G/T	cg05625103	chr10:2543513	NA	-0.41	-7.81	-0.34	3.78e-14	Age-related hearing impairment;
LGG	cis	rs8016982	0.674	rs3815953	chr14:81685482	G/A	cg01989461	chr14:81687754	GTF2A1	0.79	19.67	0.67	4.46e-63	Schizophrenia;
LGG	cis	rs35740288	0.721	rs17637276	chr15:86243520	T/C	cg07943548	chr15:86304357	KLHL25	-0.35	-6.8	-0.3	3.19e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs10266483	0.921	rs651934	chr7:63744350	C/T	cg24201672	chr7:64023550	ZNF680	-0.44	-6.97	-0.31	1.13e-11	Response to statin therapy;
LGG	cis	rs9486715	0.867	rs9373907	chr6:96981189	G/A	cg06623918	chr6:96969491	KIAA0776	0.77	15.27	0.58	6.51e-43	Headache;
LGG	cis	rs2071403	0.799	rs11211643	chr2:1402588	A/G	cg06500727	chr2:1417164	TPO	-0.49	-9.14	-0.39	2.04e-18	Thyroid peroxidase antibody positivity;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg26600954	chr7:23719792	C7orf46	-0.32	-6.78	-0.3	3.71e-11	Schizophrenia;
LGG	cis	rs9625935	0.518	rs713718	chr22:30314092	A/C	cg01021169	chr22:30184971	ASCC2	0.34	6.69	0.3	6.52e-11	Tonsillectomy;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg00960700	chr17:80709150	TBCD	0.47	8.99	0.39	6.3e-18	Glycated hemoglobin levels;
LGG	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9368481	0.594	rs2636425	chr6:26799460	A/G	cg18867708	chr6:26865862	GUSBL1	0.45	7.33	0.32	1.01e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs881375	0.715	rs7858209	chr9:123645760	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.88	0.42	4.96e-21	Rheumatoid arthritis;
LGG	cis	rs701145	0.585	rs1713811	chr3:153874566	G/A	cg17054900	chr3:154042577	DHX36	0.78	9.35	0.4	3.63e-19	Coronary artery disease;
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg22535103	chr8:58192502	C8orf71	-1.05	-15.99	-0.6	4.04e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs7746199	0.736	rs13193480	chr6:27702561	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs10506458	0.834	rs58821476	chr12:63389425	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-20.75	-0.69	4.13e-68	Hemostatic factors and hematological phenotypes;
LGG	cis	rs11785400	0.793	rs9297970	chr8:143723386	C/T	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	cis	rs780096	0.565	rs11681351	chr2:27743423	G/A	cg22903471	chr2:27725779	GCKR	-0.58	-13.38	-0.53	9.92e-35	Total body bone mineral density;
LGG	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.8	0.3	3.3e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6088590	1.000	rs6120747	chr20:33449769	T/C	cg08999081	chr20:33150536	PIGU	0.3	6.76	0.3	4.17e-11	Coronary artery disease;
LGG	cis	rs61906588	0.595	rs491428	chr11:116353002	G/T	cg12564567	chr11:116371188	NA	-0.38	-6.99	-0.31	9.87e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs10256972	0.539	rs2949174	chr7:1213923	T/C	cg07308232	chr7:1071921	C7orf50	-0.52	-9.31	-0.4	5.33e-19	Longevity;Endometriosis;
LGG	trans	rs561341	1.000	rs8077092	chr17:30281992	T/C	cg27661571	chr11:113659931	NA	-0.68	-9.65	-0.41	3.25e-20	Hip circumference adjusted for BMI;
LGG	cis	rs473651	0.904	rs501333	chr2:239336045	G/A	cg21699342	chr2:239360505	ASB1	0.4	7.72	0.34	7.01e-14	Multiple system atrophy;
LGG	cis	rs7084402	0.935	rs10740732	chr10:60352888	G/A	cg07615347	chr10:60278583	BICC1	0.61	16.56	0.61	1.07e-48	Refractive error;
LGG	trans	rs561341	1.000	rs2470243	chr17:30290955	C/T	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs3857536	0.741	rs9363556	chr6:66934399	T/C	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.22e-14	Blood trace element (Cu levels);
LGG	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg19847130	chr8:10466454	RP1L1	-0.36	-7.46	-0.33	4.23e-13	Neuroticism;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg24250549	chr1:154909240	PMVK	-0.73	-14.92	-0.57	2.29e-41	Prostate cancer;
LGG	cis	rs17023223	0.537	rs56708249	chr1:119593205	C/G	cg05756136	chr1:119680316	WARS2	-0.41	-8.49	-0.37	2.74e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	trans	rs75804782	0.566	rs56314406	chr2:239280377	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.72	0.3	5.37e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs36051895	0.632	rs62541958	chr9:5175621	T/C	cg02405213	chr9:5042618	JAK2	-0.74	-13.48	-0.53	3.49e-35	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.683	rs7000349	chr8:58114569	C/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10463554	0.784	rs187424	chr5:102587583	T/C	cg23492399	chr5:102201601	PAM	-0.53	-7.81	-0.34	3.89e-14	Parkinson's disease;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg02725872	chr8:58115012	NA	-0.86	-11.73	-0.48	5.27e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs2985684	0.894	rs2354439	chr14:50019417	G/C	cg02151108	chr14:50098012	C14orf104	-0.43	-9.14	-0.39	1.91e-18	Carotid intima media thickness;
LGG	cis	rs6462411	1.000	rs6972806	chr7:3912411	C/T	cg18022346	chr7:3920534	SDK1	-0.35	-6.84	-0.3	2.53e-11	Quantitative traits;
LGG	trans	rs1814175	0.645	rs28445479	chr11:50047999	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.85	0.3	2.33e-11	Dupuytren's disease;
LGG	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg12463550	chr7:65579703	CRCP	0.51	8.6	0.37	1.25e-16	Aortic root size;
LGG	cis	rs7681440	0.967	rs6532191	chr4:90745930	C/T	cg06848047	chr4:90757629	SNCA	-0.38	-7.41	-0.33	6.18e-13	Dementia with Lewy bodies;
LGG	cis	rs10256972	0.721	rs10435145	chr7:1065988	C/T	cg11360546	chr7:1094263	C7orf50	-0.4	-7.26	-0.32	1.67e-12	Longevity;Endometriosis;
LGG	cis	rs1577917	1.000	rs7756203	chr6:86627707	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.13	-0.52	1.08e-33	Response to antipsychotic treatment;
LGG	cis	rs3809863	0.602	rs6504833	chr17:45396087	A/G	cg25173405	chr17:45401733	C17orf57	-0.73	-13.01	-0.52	3.32e-33	Glaucoma (primary open-angle);
LGG	cis	rs9325144	0.560	rs61929893	chr12:38653366	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.07	-0.39	3.43e-18	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02315113	chr1:173684045	KLHL20	0.45	6.96	0.31	1.19e-11	Gut microbiome composition (summer);
LGG	trans	rs7830939	0.586	rs9918809	chr8:9320959	A/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-6.72	-0.3	5.37e-11	Neuroticism;
LGG	cis	rs12143943	0.966	rs2369246	chr1:204567762	C/T	cg20240347	chr1:204465584	NA	-0.32	-6.85	-0.3	2.29e-11	Cognitive performance;
LGG	cis	rs17039065	0.920	rs7695026	chr4:109436476	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.72	0.34	7.24e-14	Gut microbiome composition (summer);
LGG	cis	rs1010254	0.510	rs72806368	chr5:151692742	A/G	cg12297329	chr5:152029980	NA	-0.51	-7.28	-0.32	1.42e-12	Optic nerve measurement (cup area);
LGG	cis	rs35306767	0.855	rs11253468	chr10:903261	G/A	cg20503657	chr10:835505	NA	0.75	10.18	0.43	4.11e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg05368731	chr17:41323189	NBR1	0.98	19.06	0.66	3.1e-60	Menopause (age at onset);
LGG	cis	rs10504130	0.660	rs6473666	chr8:52838295	A/G	cg22653915	chr8:52722023	PXDNL	-0.54	-9.49	-0.4	1.24e-19	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs7762018	1.000	rs1127489	chr6:170107702	C/T	cg06875740	chr19:51307921	C19orf48	-0.66	-8.26	-0.36	1.57e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4948102	0.731	rs6593292	chr7:56043037	G/C	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2762353	0.935	rs2328895	chr6:25802083	C/T	cg12310025	chr6:25882481	NA	-0.52	-10.03	-0.42	1.49e-21	Blood metabolite levels;
LGG	cis	rs6964587	1.000	rs6944591	chr7:91642714	T/C	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs6089829	0.962	rs4809456	chr20:61660849	C/A	cg08564027	chr20:61660810	NA	1.02	25.08	0.76	2.73e-88	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs801193	0.569	rs2707824	chr7:66189243	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.18	0.36	2.83e-15	Aortic root size;
LGG	cis	rs6964587	0.967	rs41371748	chr7:91708219	A/G	cg17063962	chr7:91808500	NA	0.48	8.29	0.36	1.23e-15	Breast cancer;
LGG	cis	rs3858526	0.916	rs11039551	chr11:5930773	C/T	cg13902645	chr11:5959945	NA	-0.7	-11.08	-0.46	1.87e-25	DNA methylation (variation);
LGG	cis	rs1994135	0.565	rs11052767	chr12:33731194	A/G	cg06521331	chr12:34319734	NA	-0.48	-8.12	-0.35	4.2e-15	Resting heart rate;
LGG	trans	rs11148252	0.538	rs2408609	chr13:52714043	C/T	cg18335740	chr13:41363409	SLC25A15	0.57	10.47	0.44	3.63e-23	Lewy body disease;
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg11608241	chr8:8085544	FLJ10661	-0.31	-6.91	-0.31	1.57e-11	Neuroticism;
LGG	cis	rs2304069	0.954	rs6579767	chr5:149406271	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.71	0.54	3.93e-36	HIV-1 control;
LGG	cis	rs2013441	1.000	rs2165897	chr17:20209721	T/C	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs13102973	0.863	rs11099307	chr4:135908104	T/C	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.83e-15	Subjective well-being;
LGG	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.73	-13.74	-0.54	2.83e-36	Colorectal cancer;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.47	7.6	0.33	1.66e-13	Tonsillectomy;
LGG	cis	rs9322193	0.886	rs12525871	chr6:150097018	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.88	-0.42	5.12e-21	Lung cancer;
LGG	cis	rs801193	1.000	rs7789184	chr7:66210195	A/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.38e-19	Aortic root size;
LGG	trans	rs13128441	0.554	rs13142045	chr4:5186883	C/T	cg26099876	chr8:141644609	EIF2C2	-0.5	-6.77	-0.3	3.89e-11	Celiac disease;
LGG	cis	rs11018904	0.906	rs17227345	chr11:89954685	A/T	cg27158573	chr11:89632121	NA	0.42	7.46	0.33	4.2e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.528	rs12942561	chr17:80116639	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.52	-0.33	2.96e-13	Life satisfaction;
LGG	cis	rs7582180	1.000	rs4851285	chr2:100907598	A/G	cg14675211	chr2:100938903	LONRF2	0.47	7.09	0.31	4.92e-12	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs13059470	chr3:101424800	A/G	cg11279151	chr3:101281821	RG9MTD1	0.41	7.25	0.32	1.74e-12	Colorectal cancer;
LGG	cis	rs9611565	1.000	rs5758314	chr22:41762523	T/G	cg03806693	chr22:41940476	POLR3H	-0.8	-13.79	-0.54	1.66e-36	Vitiligo;
LGG	cis	rs36093844	0.752	rs74404559	chr11:85565669	G/A	cg16165120	chr11:85566439	CCDC83	-0.46	-7.35	-0.32	9.18e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs8062405	1.000	rs62036626	chr16:28844284	A/G	cg07382826	chr16:28625726	SULT1A1	0.35	7.31	0.32	1.18e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs8067545	0.611	rs77449863	chr17:20191860	C/G	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.54e-22	Schizophrenia;
LGG	cis	rs17376456	0.569	rs10057664	chr5:93182274	C/T	cg19507638	chr5:93509721	C5orf36	0.41	6.81	0.3	3.13e-11	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.24e-15	Life satisfaction;
LGG	cis	rs734999	0.545	rs12749591	chr1:2563250	G/T	cg15627072	chr1:2432621	PLCH2	-0.33	-7.6	-0.33	1.64e-13	Ulcerative colitis;
LGG	cis	rs35306767	0.903	rs11813210	chr10:919796	G/A	cg25019033	chr10:957182	NA	-0.55	-9.91	-0.42	3.93e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg18252515	chr7:66147081	NA	-1.37	-19.21	-0.67	6.82e-61	Diabetic kidney disease;
LGG	trans	rs11992162	0.569	rs11786149	chr8:11800818	G/A	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.27	-0.32	1.57e-12	Monocyte count;
LGG	cis	rs6840360	0.550	rs62327267	chr4:152518753	G/T	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2276314	0.857	rs62101394	chr18:33592299	C/T	cg19628046	chr18:33552617	C18orf21	0.51	7.5	0.33	3.28e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs45430	1.000	rs364525	chr21:42745578	A/G	cg22778903	chr21:42741698	MX2	-0.43	-8.67	-0.37	7.42e-17	Melanoma;
LGG	cis	rs6456156	0.586	rs12529876	chr6:167461501	G/A	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs763121	0.813	rs2179143	chr22:39037984	A/G	cg06022373	chr22:39101656	GTPBP1	0.83	16.85	0.62	5.04e-50	Menopause (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg07979357	chr19:14142353	IL27RA	-0.45	-6.87	-0.3	2.14e-11	Systemic lupus erythematosus;
LGG	cis	rs372883	0.600	rs2832298	chr21:30743863	C/G	cg24692254	chr21:30365293	RNF160	0.65	11.82	0.48	2.34e-28	Pancreatic cancer;
LGG	cis	rs8062405	0.755	rs17640009	chr16:28595700	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.3	0.43	1.49e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg19357499	chr8:144660631	NAPRT1	0.89	6.91	0.31	1.6e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs897080	0.552	rs1067383	chr2:44645911	C/T	cg00619915	chr2:44497795	NA	-0.5	-7.02	-0.31	7.86e-12	Height;
LGG	trans	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg02002194	chr4:3960332	NA	0.52	10.48	0.44	3.2e-23	Neuroticism;
LGG	cis	rs2204008	0.580	rs11520047	chr12:38051778	T/A	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs6951245	0.938	rs117729148	chr7:1108531	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.86	0.3	2.2e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7582180	0.627	rs6749018	chr2:101001859	G/T	cg08017756	chr2:100939284	LONRF2	-0.29	-6.96	-0.31	1.21e-11	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.38	6.66	0.3	8e-11	Obesity-related traits;
LGG	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg02023728	chr11:77925099	USP35	0.4	7.11	0.31	4.49e-12	Alzheimer's disease (survival time);
LGG	cis	rs7824557	0.510	rs2736297	chr8:11234885	C/G	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs300703	0.576	rs3791216	chr2:237142	C/A	cg21211680	chr2:198530	NA	1.28	15.95	0.6	6.01e-46	Blood protein levels;
LGG	cis	rs13102973	0.640	rs6829739	chr4:135835789	G/A	cg14419869	chr4:135874104	NA	0.51	9.56	0.41	6.76e-20	Subjective well-being;
LGG	cis	rs2224391	0.628	rs2753234	chr6:5251050	G/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.35	-0.32	8.91e-13	Height;
LGG	cis	rs1707322	0.964	rs785499	chr1:46592420	G/A	cg03146154	chr1:46216737	IPP	-0.54	-9.41	-0.4	2.29e-19	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs67311347	1.000	rs17078941	chr3:40450888	A/G	cg13683864	chr3:40499215	RPL14	1.15	26.15	0.77	3.24e-93	Renal cell carcinoma;
LGG	cis	rs11190604	1.000	rs4919470	chr10:102298920	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.57	0.47	2.26e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.61	10.33	0.43	1.21e-22	Tonsillectomy;
LGG	cis	rs911555	0.723	rs7149767	chr14:103863545	G/A	cg24130564	chr14:104152367	KLC1	0.37	6.9	0.31	1.72e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs2342769	chr6:150216507	T/C	cg01145232	chr6:150245071	RAET1G	0.33	6.97	0.31	1.11e-11	Testicular germ cell tumor;
LGG	cis	rs76070545	0.551	rs28566705	chr8:104209017	G/A	cg03923813	chr8:104230441	BAALC	-1.18	-13.02	-0.52	3.08e-33	Alzheimer disease and age of onset;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg09525994	chr12:48512905	PFKM	-0.45	-7.28	-0.32	1.41e-12	Systemic lupus erythematosus;
LGG	cis	rs2282802	0.685	rs62385161	chr5:139635747	T/C	cg26211634	chr5:139558579	C5orf32	0.34	7.52	0.33	2.79e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2072499	0.898	rs2758609	chr1:156202868	G/A	cg24450063	chr1:156163899	SLC25A44	1.01	20.78	0.69	3.1e-68	Testicular germ cell tumor;
LGG	cis	rs8141529	0.764	rs5762824	chr22:29222930	C/T	cg02153584	chr22:29168773	CCDC117	0.7	11.8	0.48	2.8e-28	Lymphocyte counts;
LGG	cis	rs2204008	0.806	rs35534445	chr12:38279093	C/T	cg26384229	chr12:38710491	ALG10B	0.95	21.41	0.71	3.39e-71	Bladder cancer;
LGG	cis	rs6547631	0.622	rs1437743	chr2:85924989	A/G	cg19805943	chr2:85933069	NA	-0.33	-6.86	-0.3	2.24e-11	Blood protein levels;
LGG	cis	rs2239547	0.522	rs9846976	chr3:53007995	T/C	cg11645453	chr3:52864694	ITIH4	0.67	10.61	0.44	1.06e-23	Schizophrenia;
LGG	cis	rs657075	0.697	rs3761659	chr5:131657784	G/C	cg05556477	chr5:131705319	SLC22A5	0.82	9.99	0.42	1.98e-21	Rheumatoid arthritis;
LGG	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg13770153	chr20:60521292	NA	-0.46	-7.71	-0.34	8.01e-14	Body mass index;
LGG	cis	rs17453880	0.929	rs59126622	chr5:151999934	G/T	cg12297329	chr5:152029980	NA	-0.86	-22.17	-0.72	9.33e-75	Subjective well-being;
LGG	cis	rs6679073	1.000	rs6679073	chr1:205756484	A/C	cg07157834	chr1:205819609	PM20D1	0.42	7.13	0.31	3.97e-12	Prostate-specific antigen levels;
LGG	cis	rs4481887	0.893	rs6681339	chr1:248482761	C/G	cg13385794	chr1:248469461	NA	0.49	8.42	0.36	4.85e-16	Common traits (Other);
LGG	cis	rs6693295	0.536	rs6656404	chr1:246255288	A/T	cg11798871	chr1:246315928	SMYD3	-0.57	-7.57	-0.33	2.01e-13	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs6952808	0.529	rs73038442	chr7:2139457	C/T	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs959260	0.588	rs8079197	chr17:73316679	G/C	cg14668889	chr17:73230827	NUP85	-0.52	-8.64	-0.37	8.96e-17	Systemic lupus erythematosus;
LGG	cis	rs17345786	0.906	rs56171035	chr3:101111108	G/C	cg12386194	chr3:101231763	SENP7	0.75	13.14	0.52	9.84e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs114547492	chr4:119773078	G/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg07777115	chr5:623756	CEP72	-0.63	-8.19	-0.36	2.62e-15	Obesity-related traits;
LGG	cis	rs7605378	0.528	rs281767	chr2:200823281	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.48	7.81	0.34	3.82e-14	Osteoporosis;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg12463550	chr7:65579703	CRCP	0.49	8.04	0.35	7.81e-15	Aortic root size;
LGG	cis	rs4774899	0.966	rs17819700	chr15:57279185	G/T	cg08128148	chr15:57256372	TCF12	-0.34	-8.12	-0.35	4.25e-15	Urinary tract infection frequency;
LGG	cis	rs4704187	0.687	rs6862754	chr5:74427193	T/C	cg03227963	chr5:74354835	NA	0.31	6.71	0.3	5.75e-11	Response to amphetamines;
LGG	cis	rs9467773	1.000	rs2208331	chr6:26507319	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.4	0.4	2.52e-19	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs17745543	chr22:32475456	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11230563	1.000	rs11230563	chr11:60776209	C/T	cg27098804	chr11:60776124	CD6	0.58	10.15	0.43	5.54e-22	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs637571	0.565	rs570387	chr11:65637076	T/C	cg26695010	chr11:65641043	EFEMP2	0.61	10.91	0.45	7.84e-25	Eosinophil percentage of white cells;
LGG	cis	rs2739330	0.760	rs5751760	chr22:24243573	G/A	cg25703541	chr22:24373054	LOC391322	-0.91	-17.82	-0.64	1.82e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12421382	0.811	rs11602639	chr11:109472829	C/T	cg07142201	chr11:109293216	C11orf87	0.63	11.03	0.46	2.83e-25	Schizophrenia;
LGG	cis	rs62238980	0.614	rs76037448	chr22:32413653	A/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	trans	rs7937682	0.855	rs539693	chr11:111477387	A/G	cg18187862	chr3:45730750	SACM1L	0.57	9.26	0.4	7.81e-19	Primary sclerosing cholangitis;
LGG	cis	rs9447004	0.557	rs2173854	chr6:74426775	T/A	cg03006477	chr6:74432658	CD109	0.29	7.28	0.32	1.44e-12	Blood protein levels;Calcium levels;
LGG	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg20302533	chr7:39170763	POU6F2	0.53	13.06	0.52	2.01e-33	IgG glycosylation;
LGG	cis	rs9487051	0.676	rs6929438	chr6:109595506	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.98	-0.35	1.12e-14	Reticulocyte fraction of red cells;
LGG	cis	rs11098499	0.874	rs6832670	chr4:120118792	A/G	cg24375607	chr4:120327624	NA	0.59	9.58	0.41	6.07e-20	Corneal astigmatism;
LGG	cis	rs1949733	0.958	rs3103069	chr4:8509451	T/G	cg11789530	chr4:8429930	ACOX3	-0.87	-17.02	-0.62	8.29e-51	Response to antineoplastic agents;
LGG	cis	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs6752107	0.967	rs56227616	chr2:234157741	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.67	12.47	0.5	5.77e-31	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1032833	0.732	rs79496068	chr2:180032423	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2645694	0.626	rs2703151	chr4:77834095	A/G	cg06046430	chr4:77819534	ANKRD56	0.52	10.61	0.44	1.07e-23	Emphysema distribution in smoking;
LGG	cis	rs559928	0.642	rs2286615	chr11:64039175	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.6	7.44	0.33	5.04e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2760061	0.599	rs644794	chr1:228148670	T/C	cg18477163	chr1:228402036	OBSCN	-0.27	-7.22	-0.32	2.2e-12	Diastolic blood pressure;
LGG	cis	rs988958	0.526	rs720043	chr2:42239044	T/C	cg27428208	chr2:42229179	NA	0.47	7.45	0.33	4.73e-13	Hypospadias;
LGG	cis	rs7572733	0.555	rs2164071	chr2:198915467	T/C	cg00792783	chr2:198669748	PLCL1	0.62	9.75	0.41	1.43e-20	Dermatomyositis;
LGG	cis	rs141518190	1	rs141518190	chr15:78900647	A/G	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.61	-0.33	1.51e-13	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg03342759	chr3:160939853	NMD3	-0.65	-11.89	-0.48	1.21e-28	Morning vs. evening chronotype;
LGG	cis	rs9911578	0.934	rs8081967	chr17:57072701	T/C	cg05425664	chr17:57184151	TRIM37	-0.7	-11.38	-0.47	1.27e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6938	0.575	rs12902515	chr15:75160998	G/C	cg17294928	chr15:75287854	SCAMP5	0.57	10.24	0.43	2.48e-22	Breast cancer;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg05863683	chr7:1912471	MAD1L1	0.43	8.4	0.36	5.31e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs11098499	0.909	rs1809406	chr4:120377122	G/A	cg25214090	chr10:38739885	LOC399744	0.68	12.17	0.49	9.5e-30	Corneal astigmatism;
LGG	cis	rs7681440	0.874	rs1372524	chr4:90776045	A/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	cis	rs62238980	0.614	rs116859544	chr22:32433155	A/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07697850	chr16:29973177	TMEM219	0.41	6.85	0.3	2.35e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.26	-0.32	1.63e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs55788414	0.505	rs7190949	chr16:81189583	C/T	cg06400318	chr16:81190750	PKD1L2	0.7	10.61	0.44	1.11e-23	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7208859	0.573	rs28779471	chr17:29084369	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7765175	0.638	rs9387132	chr6:113659696	C/T	cg26552650	chr6:113682475	NA	0.33	7.4	0.33	6.47e-13	Coronary artery calcification;
LGG	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg27205649	chr11:78285834	NARS2	0.49	8.54	0.37	1.91e-16	Alzheimer's disease (survival time);
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.62	0.37	1.09e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs66887589	0.777	rs2017058	chr4:120257739	T/C	cg25214090	chr10:38739885	LOC399744	0.4	7.47	0.33	4.16e-13	Diastolic blood pressure;
LGG	trans	rs4843747	0.671	rs72818577	chr16:88111181	G/A	cg26811252	chr16:29126840	RRN3P2	0.68	10.9	0.45	8.77e-25	Menopause (age at onset);
LGG	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg16482183	chr6:26056742	HIST1H1C	0.5	7.96	0.35	1.29e-14	Iron status biomarkers;
LGG	cis	rs4144743	1.000	rs35704663	chr17:45327321	T/G	cg18085866	chr17:45331354	ITGB3	-0.81	-9.69	-0.41	2.49e-20	Body mass index;
LGG	cis	rs3768617	0.510	rs2027075	chr1:183073266	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.58	0.41	5.88e-20	Fuchs's corneal dystrophy;
LGG	cis	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.54	2.54e-37	Bladder cancer;
LGG	cis	rs9788721	0.836	rs55983731	chr15:78735269	C/T	cg18825076	chr15:78729989	IREB2	-0.57	-9.43	-0.4	1.99e-19	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	trans	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	9.01	0.39	5.31e-18	Resting heart rate;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.731	rs9995026	chr4:120490499	T/A	cg09307838	chr4:120376055	NA	0.8	13.44	0.53	5.47e-35	Corneal astigmatism;
LGG	trans	rs1814175	0.669	rs17472879	chr11:49499520	G/T	cg15704280	chr7:45808275	SEPT13	-0.78	-14.57	-0.56	7.16e-40	Height;
LGG	cis	rs2562456	0.876	rs62110202	chr19:21754601	C/T	cg00806126	chr19:22604979	ZNF98	-0.65	-9.61	-0.41	4.49e-20	Pain;
LGG	cis	rs782590	0.774	rs2627773	chr2:55900459	A/G	cg18811423	chr2:55921094	PNPT1	0.92	22.21	0.72	6.47e-75	Metabolic syndrome;
LGG	trans	rs9291683	0.588	rs12647117	chr4:10022059	T/C	cg26043149	chr18:55253948	FECH	0.4	6.75	0.3	4.45e-11	Bone mineral density;
LGG	cis	rs4538187	1.000	rs6546030	chr2:64071651	G/A	cg02541582	chr2:64069798	UGP2	0.6	13.97	0.54	2.86e-37	Systolic blood pressure;
LGG	cis	rs887829	0.694	rs869283	chr2:234626287	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.28	-0.36	1.33e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs561341	1.000	rs8069199	chr17:30281845	A/G	cg13647721	chr17:30228624	UTP6	0.6	7.72	0.34	7.01e-14	Hip circumference adjusted for BMI;
LGG	cis	rs977987	0.835	rs3851733	chr16:75370263	G/C	cg03315344	chr16:75512273	CHST6	0.52	10.5	0.44	2.78e-23	Dupuytren's disease;
LGG	cis	rs7659604	0.521	rs4833235	chr4:122695136	C/A	cg20573242	chr4:122745356	CCNA2	-0.46	-7.84	-0.34	3.12e-14	Type 2 diabetes;
LGG	cis	rs4969178	0.600	rs4969184	chr17:76393413	G/A	cg05887092	chr17:76393375	PGS1	0.8	19.09	0.66	2.27e-60	HDL cholesterol levels;
LGG	cis	rs9916302	0.706	rs2338799	chr17:37513941	G/A	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.92e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs8072100	0.713	rs11079776	chr17:45546893	C/T	cg08085267	chr17:45401833	C17orf57	-0.49	-9.13	-0.39	2.11e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs17270561	0.609	rs9393665	chr6:25744284	G/A	cg03264133	chr6:25882463	NA	-0.48	-7.76	-0.34	5.44e-14	Iron status biomarkers;
LGG	cis	rs2963155	0.518	rs72801029	chr5:142625806	T/C	cg17617527	chr5:142782415	NR3C1	0.96	12.0	0.49	4.55e-29	Breast cancer;
LGG	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg12654349	chr5:56205094	C5orf35	-0.42	-7.45	-0.33	4.5e-13	Coronary artery disease;
LGG	trans	rs7939886	0.920	rs17150095	chr11:55902900	A/G	cg15704280	chr7:45808275	SEPT13	0.82	8.58	0.37	1.49e-16	Myopia (pathological);
LGG	cis	rs7241530	0.662	rs8088204	chr18:75901055	C/T	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	7.3e-19	Educational attainment (years of education);
LGG	cis	rs7444	0.941	rs5998619	chr22:21945851	G/A	cg15846791	chr22:21984385	YDJC	-0.45	-6.87	-0.3	2.1e-11	Systemic lupus erythematosus;
LGG	cis	rs72945132	0.660	rs7121703	chr11:70140296	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs5769765	0.778	rs8137331	chr22:50313358	G/C	cg02269571	chr22:50332266	NA	-0.68	-10.89	-0.45	9.32e-25	Schizophrenia;
LGG	cis	rs7829975	0.560	rs4841013	chr8:8552013	A/G	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.07	-0.35	6.24e-15	Mood instability;
LGG	cis	rs4073582	1.000	rs4073582	chr11:66050712	G/A	cg16950941	chr11:66035639	RAB1B	0.41	6.78	0.3	3.76e-11	Gout;
LGG	cis	rs3733585	0.699	rs7658170	chr4:9966593	C/T	cg08250081	chr4:10125330	NA	0.36	6.93	0.31	1.45e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs11001765	0.530	rs79125688	chr10:78129771	C/A	cg16072382	chr10:78096093	C10orf11	0.5	6.79	0.3	3.55e-11	Chin dimples;
LGG	cis	rs539514	0.587	rs689418	chr13:76322977	G/A	cg04757411	chr13:76259545	LMO7	-0.31	-7.72	-0.34	7.11e-14	Type 1 diabetes;
LGG	cis	rs28595532	0.920	rs116548907	chr4:119735285	G/A	cg11846333	chr4:119757529	SEC24D	0.85	7.87	0.34	2.5e-14	Cannabis dependence symptom count;
LGG	cis	rs9534288	0.699	rs7139571	chr13:46662584	G/A	cg15192986	chr13:46630673	CPB2	-0.69	-13.98	-0.54	2.58e-37	Blood protein levels;
LGG	cis	rs2249694	0.878	rs2480256	chr10:135352514	A/G	cg20169779	chr10:135381914	SYCE1	0.5	7.59	0.33	1.75e-13	Obesity-related traits;
LGG	cis	rs5758659	0.652	rs4822084	chr22:42435868	A/G	cg15557168	chr22:42548783	NA	0.31	6.76	0.3	4.1e-11	Cognitive function;
LGG	cis	rs12643440	0.538	rs56290948	chr4:17138950	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.58	-0.37	1.43e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs559928	0.947	rs56339474	chr11:64142478	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.6	7.58	0.33	1.91e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs61931739	0.613	rs61927728	chr12:33667690	T/C	cg26384229	chr12:38710491	ALG10B	-0.5	-8.65	-0.37	8.45e-17	Morning vs. evening chronotype;
LGG	cis	rs6967414	0.786	rs3757482	chr7:6748927	A/G	cg00387323	chr7:6746715	ZNF12	0.64	6.97	0.31	1.13e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs6430585	0.759	rs4954623	chr2:136535876	G/A	cg07169764	chr2:136633963	MCM6	-1.26	-23.6	-0.74	1.95e-81	Corneal structure;
LGG	cis	rs3099143	1.000	rs3099143	chr15:77104856	A/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.32	-0.43	1.27e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs910187	0.624	rs6018311	chr20:45792634	A/G	cg27589058	chr20:45804311	EYA2	-0.31	-7.85	-0.34	2.97e-14	Migraine;
LGG	cis	rs6456156	0.967	rs150108	chr6:167513153	C/T	cg07741184	chr6:167504864	NA	0.32	7.22	0.32	2.08e-12	Primary biliary cholangitis;
LGG	cis	rs17384381	0.953	rs2284797	chr1:85792383	C/T	cg16011679	chr1:85725395	C1orf52	0.62	10.48	0.44	3.24e-23	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4639966	0.836	rs7110526	chr11:118633533	T/C	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.45	-0.33	4.71e-13	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg15556689	chr8:8085844	FLJ10661	-0.51	-8.77	-0.38	3.37e-17	Retinal vascular caliber;
LGG	cis	rs4330281	0.608	rs4243836	chr3:17706261	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs1555895	0.656	rs1536338	chr10:838378	C/T	cg10556349	chr10:835070	NA	0.36	9.47	0.4	1.39e-19	Survival in rectal cancer;
LGG	cis	rs700651	0.789	rs10190226	chr2:198901564	A/G	cg00792783	chr2:198669748	PLCL1	-0.59	-9.18	-0.39	1.42e-18	Intracranial aneurysm;
LGG	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg00938859	chr5:1591904	SDHAP3	0.9	13.33	0.53	1.61e-34	Breast cancer;
LGG	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg15103426	chr22:29168792	CCDC117	-0.73	-11.63	-0.48	1.37e-27	Lymphocyte counts;
LGG	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	cg15522984	chr1:182991683	LAMC1	0.45	8.86	0.38	1.79e-17	Colorectal cancer;
LGG	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg22875332	chr1:76189707	ACADM	0.57	8.4	0.36	5.61e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6763768	0.606	rs6795127	chr3:53376669	C/T	cg16894138	chr3:53270350	TKT	0.42	8.07	0.35	6.03e-15	Bacterial meningitis;
LGG	cis	rs4363385	0.747	rs1577962	chr1:152962013	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.82	-0.38	2.35e-17	Inflammatory skin disease;
LGG	cis	rs10492096	0.947	rs61918022	chr12:6614521	C/T	cg13857086	chr12:6580257	VAMP1	0.5	7.2	0.32	2.38e-12	Hip geometry;
LGG	cis	rs116095464	0.558	rs62344300	chr5:246336	A/G	cg22496380	chr5:211416	CCDC127	-1.24	-17.76	-0.64	3.32e-54	Breast cancer;
LGG	cis	rs763014	0.932	rs2269559	chr16:682297	T/C	cg00908189	chr16:619842	PIGQ	0.87	16.32	0.6	1.32e-47	Height;
LGG	cis	rs11711311	0.826	rs13077644	chr3:113467777	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.64	12.85	0.51	1.52e-32	IgG glycosylation;
LGG	cis	rs35160687	0.814	rs7563887	chr2:86516121	C/T	cg10973622	chr2:86423274	IMMT	0.46	8.23	0.36	1.95e-15	Night sleep phenotypes;
LGG	cis	rs933688	0.583	rs10036206	chr5:90609178	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.58	7.78	0.34	4.73e-14	Smoking behavior;
LGG	cis	rs1461503	0.966	rs10790546	chr11:122838426	C/A	cg27398637	chr11:122830231	C11orf63	-0.71	-13.91	-0.54	5.09e-37	Menarche (age at onset);
LGG	cis	rs3816183	0.797	rs4953666	chr2:43030687	T/C	cg14631114	chr2:43023945	NA	0.52	9.47	0.4	1.38e-19	Hypospadias;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg09033563	chr22:24373618	LOC391322	-0.61	-10.11	-0.43	7.79e-22	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11239187	0.530	rs10793546	chr10:45063108	G/T	cg03916630	chr10:45065415	NA	0.37	8.98	0.39	6.66e-18	Body mass index;
LGG	cis	rs4927850	0.881	rs7630489	chr3:195753401	T/C	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.66	-0.41	3.06e-20	Pancreatic cancer;
LGG	cis	rs1008375	0.931	rs7435102	chr4:17571480	C/G	cg16339924	chr4:17578868	LAP3	0.64	10.97	0.45	4.82e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6694672	0.850	rs3891964	chr1:197066074	C/T	cg13682187	chr1:196946512	CFHR5	-0.51	-7.15	-0.32	3.41e-12	Asthma;
LGG	cis	rs17321999	1.000	rs6548005	chr2:30480196	C/G	cg05247661	chr2:30472410	LBH	0.56	9.06	0.39	3.78e-18	Systemic lupus erythematosus;
LGG	cis	rs6032067	0.561	rs2743317	chr20:43936931	C/T	cg10761708	chr20:43804764	PI3	0.57	8.75	0.38	3.98e-17	Blood protein levels;
LGG	cis	rs9926296	0.572	rs2376878	chr16:89885161	G/A	cg04287289	chr16:89883240	FANCA	0.54	10.29	0.43	1.61e-22	Vitiligo;
LGG	trans	rs11098499	0.954	rs71629403	chr4:120372567	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.94e-30	Corneal astigmatism;
LGG	cis	rs6121246	0.821	rs6119718	chr20:30331074	A/G	cg04935436	chr20:30431758	NA	0.41	7.27	0.32	1.59e-12	Mean corpuscular hemoglobin;
LGG	cis	rs4474465	1.000	rs12280198	chr11:78161361	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-8.14	-0.35	3.59e-15	Alzheimer's disease (survival time);
LGG	cis	rs10927875	0.662	rs848309	chr1:16308447	T/C	cg21385522	chr1:16154831	NA	0.52	9.1	0.39	2.75e-18	Dilated cardiomyopathy;
LGG	trans	rs2840044	0.963	rs225247	chr17:33944590	T/A	cg19694781	chr19:47549865	TMEM160	-0.56	-9.19	-0.39	1.35e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg15971980	chr6:150254442	NA	0.44	8.96	0.38	8.11e-18	Testicular germ cell tumor;
LGG	cis	rs4780401	0.539	rs62040604	chr16:11803641	G/A	cg01061890	chr16:11836724	TXNDC11	-0.69	-12.81	-0.51	2.23e-32	Rheumatoid arthritis;
LGG	cis	rs8067545	0.586	rs3850779	chr17:20171872	C/T	cg09818912	chr17:20140352	CYTSB	0.32	7.51	0.33	3.01e-13	Schizophrenia;
LGG	cis	rs11098499	0.605	rs6833140	chr4:120266822	G/A	cg24375607	chr4:120327624	NA	0.54	9.22	0.39	1.08e-18	Corneal astigmatism;
LGG	cis	rs10929925	0.931	rs7599893	chr2:6157186	T/C	cg00493617	chr2:6141445	NA	0.32	7.03	0.31	7.29e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs6089584	0.854	rs6061407	chr20:60622048	A/C	cg13770153	chr20:60521292	NA	-0.54	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs2153535	0.505	rs9405395	chr6:8468622	T/A	cg21535247	chr6:8435926	SLC35B3	0.56	9.62	0.41	4.43e-20	Motion sickness;
LGG	cis	rs8078723	1.000	rs4795415	chr17:38157995	C/T	cg17467752	chr17:38218738	THRA	0.74	13.9	0.54	6.07e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs6952808	0.609	rs6950151	chr7:1953521	T/C	cg02951883	chr7:2050386	MAD1L1	-0.61	-11.8	-0.48	2.82e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9443645	0.869	rs10943585	chr6:79502409	G/C	cg18132916	chr6:79620363	NA	-0.31	-8.47	-0.37	3.25e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9818758	0.607	rs5030795	chr3:49141116	C/T	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.87e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs3784262	0.679	rs4238326	chr15:58336000	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	7.99	0.35	1.07e-14	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs741702	0.928	rs2965214	chr19:13029188	G/A	cg23899408	chr19:12877188	HOOK2	0.48	7.66	0.34	1.13e-13	Red blood cell traits;
LGG	cis	rs12282928	1.000	rs7946076	chr11:48308318	A/G	cg26585981	chr11:48327164	OR4S1	0.45	7.25	0.32	1.75e-12	Migraine - clinic-based;
LGG	cis	rs367615	0.512	rs414724	chr5:108670421	A/G	cg17395555	chr5:108820864	NA	0.75	12.18	0.49	8.41e-30	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs365060	0.630	rs260705	chr2:109571440	A/G	cg00665405	chr12:50899548	DIP2B	-0.44	-6.86	-0.3	2.26e-11	Beard thickness;
LGG	cis	rs2721811	0.701	rs2721810	chr7:24748565	T/C	cg06301139	chr7:24798175	DFNA5	-0.39	-7.08	-0.31	5.49e-12	Depressive symptoms (multi-trait analysis);
LGG	trans	rs61931739	0.500	rs11053208	chr12:34460029	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.2	0.32	2.51e-12	Morning vs. evening chronotype;
LGG	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg08400814	chr5:56204995	C5orf35	-0.46	-7.37	-0.32	7.83e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-13.19	-0.52	6.16e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15586420	chr15:90294517	MESP1	0.4	6.75	0.3	4.39e-11	Cognitive performance;
LGG	cis	rs910316	0.503	rs4903273	chr14:75441795	G/A	cg11812906	chr14:75593930	NEK9	-0.41	-7.37	-0.32	8.16e-13	Height;
LGG	cis	rs13108904	0.870	rs13110563	chr4:1255772	G/C	cg02018176	chr4:1364513	KIAA1530	0.38	8.59	0.37	1.36e-16	Obesity-related traits;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16405210	chr4:1374714	KIAA1530	-0.55	-10.02	-0.42	1.57e-21	Longevity;
LGG	cis	rs3816183	1.000	rs920392	chr2:43019364	G/C	cg27299406	chr2:43020013	HAAO	-0.27	-6.68	-0.3	7.03e-11	Hypospadias;
LGG	cis	rs7666738	0.830	rs13138438	chr4:99050545	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg23248615	chr10:2005709	NA	0.39	7.72	0.34	7.03e-14	Menarche (age at onset);
LGG	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg09904177	chr6:26538194	HMGN4	0.68	14.02	0.55	1.8e-37	Intelligence (multi-trait analysis);
LGG	cis	rs2236267	0.726	rs2093317	chr14:88609578	T/C	cg02175263	chr14:88627849	NA	0.33	7.44	0.33	5.09e-13	Food antigen IgG levels;
LGG	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg16141378	chr3:129829833	LOC729375	0.39	8.55	0.37	1.85e-16	Retinal vascular caliber;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	6.81	0.3	3.06e-11	Schizophrenia;
LGG	cis	rs62238980	0.614	rs734092	chr22:32462167	C/G	cg02631450	chr22:32366979	NA	0.98	9.31	0.4	5.25e-19	Childhood ear infection;
LGG	cis	rs951366	0.539	rs1935025	chr1:205692084	C/A	cg11965913	chr1:205819406	PM20D1	-0.41	-6.89	-0.31	1.78e-11	Menarche (age at onset);
LGG	cis	rs8141529	0.748	rs5997412	chr22:29276747	G/A	cg02153584	chr22:29168773	CCDC117	0.61	9.99	0.42	2.07e-21	Lymphocyte counts;
LGG	cis	rs2013441	1.000	rs4588033	chr17:20029901	C/G	cg13482628	chr17:19912719	NA	-0.51	-9.19	-0.39	1.35e-18	Obesity-related traits;
LGG	cis	rs3785574	0.962	rs2247435	chr17:61892862	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06074314	chr2:70475575	TIA1	0.59	9.18	0.39	1.43e-18	Gut microbiome composition (summer);
LGG	cis	rs4788815	0.712	rs4788563	chr16:71879868	A/C	cg06353428	chr16:71660113	MARVELD3	0.67	10.59	0.44	1.27e-23	Metabolite levels;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	1.000	rs11039868	chr11:48622146	T/C	cg03929089	chr4:120376271	NA	-0.45	-7.29	-0.32	1.35e-12	HDL cholesterol;
LGG	cis	rs16910800	0.731	rs1871953	chr11:23192677	G/A	cg20040320	chr11:23191996	NA	-0.6	-6.94	-0.31	1.3e-11	Cancer;
LGG	cis	rs939658	0.935	rs4778651	chr15:79447810	G/A	cg17916960	chr15:79447300	NA	-0.64	-12.25	-0.49	4.23e-30	Refractive error;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23803311	chr5:147763284	FBXO38	0.47	7.72	0.34	7.02e-14	Cognitive performance;
LGG	cis	rs10464366	1.000	rs10951593	chr7:39121390	C/T	cg18850127	chr7:39170497	POU6F2	0.53	12.32	0.5	2.28e-30	IgG glycosylation;
LGG	cis	rs1847202	0.762	rs62249896	chr3:72949857	C/G	cg25664220	chr3:72788482	NA	-0.25	-7.28	-0.32	1.47e-12	Motion sickness;
LGG	cis	rs2251188	0.565	rs2243544	chr7:6690270	C/T	cg25573915	chr7:6704194	NA	-0.3	-6.7	-0.3	6.1e-11	Neutrophil count;Sum basophil neutrophil counts;
LGG	cis	rs7937682	0.924	rs501089	chr11:111502479	G/T	cg19812747	chr11:111475976	SIK2	0.47	9.47	0.4	1.43e-19	Primary sclerosing cholangitis;
LGG	cis	rs7264396	0.790	rs2295355	chr20:34252654	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.42	-7.6	-0.33	1.63e-13	Total cholesterol levels;
LGG	cis	rs17401966	1.000	rs17411502	chr1:10431158	T/C	cg15208524	chr1:10270712	KIF1B	0.46	7.59	0.33	1.77e-13	Hepatocellular carcinoma;
LGG	cis	rs1994135	0.617	rs12821909	chr12:33723466	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.44	-0.37	4.22e-16	Resting heart rate;
LGG	cis	rs7811142	1.000	rs74460138	chr7:100027339	C/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs4330281	0.647	rs4582042	chr3:17421879	C/T	cg20981856	chr3:17787350	NA	0.36	6.77	0.3	3.81e-11	Schizophrenia;
LGG	cis	rs17711722	0.565	rs4717276	chr7:65294741	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.61	13.76	0.54	2.4e-36	Calcium levels;
LGG	trans	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg16141378	chr3:129829833	LOC729375	-0.35	-8.32	-0.36	9.87e-16	Neuroticism;
LGG	cis	rs6748734	1.000	rs4293565	chr2:241834770	A/G	cg07537917	chr2:241836409	C2orf54	-0.4	-7.9	-0.34	2.1e-14	Urinary metabolites;
LGG	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.17	0.52	7.46e-34	Colorectal cancer;
LGG	cis	rs897984	0.537	rs8045637	chr16:30818662	C/T	cg00531865	chr16:30841666	NA	-0.69	-16.71	-0.61	2.1e-49	Dementia with Lewy bodies;
LGG	cis	rs116095464	0.558	rs55776650	chr5:273826	G/A	cg22857025	chr5:266934	NA	-1.51	-26.78	-0.78	3.97e-96	Breast cancer;
LGG	cis	rs3219090	0.861	rs1341335	chr1:226605081	C/T	cg17127702	chr1:226594323	PARP1	0.38	12.33	0.5	2.01e-30	Melanoma;
LGG	trans	rs9325144	0.671	rs35817541	chr12:38975001	T/C	cg06521331	chr12:34319734	NA	0.42	7.07	0.31	5.86e-12	Morning vs. evening chronotype;
LGG	cis	rs13260300	0.526	rs13249663	chr8:75537351	C/T	cg22993706	chr8:75542856	NA	0.46	9.73	0.41	1.76e-20	Breast cancer-free interval (treatment with aromatase inhibitor);
LGG	cis	rs7762018	1.000	rs41265383	chr6:170068025	T/C	cg17545662	chr6:170176663	C6orf70	0.7	8.94	0.38	9.05e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7666738	0.716	rs13108535	chr4:99046324	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg02002194	chr4:3960332	NA	-0.38	-6.65	-0.3	8.36e-11	Retinal vascular caliber;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23924007	chr4:140099401	NA	0.54	8.81	0.38	2.52e-17	Cognitive performance;
LGG	cis	rs72925845	0.577	rs7212019	chr17:76428553	G/A	cg03830375	chr17:76426088	DNAH17	0.53	7.49	0.33	3.58e-13	Triglycerides;
LGG	cis	rs2985684	1.000	rs2985697	chr14:50092902	A/G	cg04989706	chr14:50066350	PPIL5	-0.51	-7.94	-0.35	1.51e-14	Carotid intima media thickness;
LGG	cis	rs9457247	1.000	rs402749	chr6:167386104	C/T	cg07741184	chr6:167504864	NA	0.32	7.01	0.31	8.57e-12	Crohn's disease;
LGG	cis	rs17270561	0.666	rs12209856	chr6:25793673	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.5	-0.33	3.33e-13	Iron status biomarkers;
LGG	cis	rs2976388	0.578	rs3758081	chr8:143824373	A/G	cg06565975	chr8:143823917	SLURP1	-0.57	-13.81	-0.54	1.44e-36	Urinary tract infection frequency;
LGG	cis	rs61931739	0.500	rs7309931	chr12:34483471	A/C	cg06521331	chr12:34319734	NA	-0.54	-9.82	-0.42	8.58e-21	Morning vs. evening chronotype;
LGG	cis	rs1143633	0.579	rs4849132	chr2:113673471	G/A	cg06771106	chr2:113671356	IL1F7	0.38	7.39	0.32	7.11e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1401999	0.546	rs4148593	chr3:183649870	A/G	cg05044414	chr3:183734942	ABCC5	0.58	11.64	0.48	1.18e-27	Anterior chamber depth;
LGG	cis	rs6977660	0.714	rs7357319	chr7:19817525	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-12.54	-0.5	3.02e-31	Total body bone mineral density;
LGG	cis	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg04568710	chr12:38710424	ALG10B	0.34	7.08	0.31	5.51e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7296418	0.961	rs4148863	chr12:123569375	A/G	cg00376283	chr12:123451042	ABCB9	0.67	12.42	0.5	9.24e-31	Platelet count;
LGG	cis	rs2404602	0.669	rs12438540	chr15:76943213	C/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.18	-0.32	2.8e-12	Blood metabolite levels;
LGG	cis	rs8133932	0.520	rs380120	chr21:47364511	C/A	cg11214348	chr21:47283868	PCBP3	-0.4	-7.15	-0.32	3.48e-12	Schizophrenia;
LGG	cis	rs1790761	0.667	rs4147581	chr11:67351585	C/G	cg00290607	chr11:67383545	NA	0.66	13.2	0.52	5.22e-34	Mean corpuscular volume;
LGG	cis	rs6121246	0.567	rs6120815	chr20:30184866	T/C	cg18721089	chr20:30220636	NA	-0.51	-7.72	-0.34	7.3e-14	Mean corpuscular hemoglobin;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11779988	0.511	rs6586684	chr8:17925331	A/G	cg18067069	chr8:17937731	ASAH1	0.38	9.05	0.39	3.98e-18	Breast cancer;
LGG	cis	rs4474465	0.850	rs10899539	chr11:78243743	T/C	cg02023728	chr11:77925099	USP35	-0.39	-6.9	-0.31	1.69e-11	Alzheimer's disease (survival time);
LGG	cis	rs9972944	0.756	rs6416949	chr17:63767219	A/T	cg07283582	chr17:63770753	CCDC46	-0.42	-8.22	-0.36	2.12e-15	Total body bone mineral density;
LGG	cis	rs6121246	0.909	rs6060633	chr20:30263317	G/T	cg04935436	chr20:30431758	NA	0.41	7.2	0.32	2.51e-12	Mean corpuscular hemoglobin;
LGG	cis	rs1008375	1.000	rs10939743	chr4:17662731	G/A	cg15017067	chr4:17643749	FAM184B	0.29	6.71	0.3	5.84e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7819412	0.502	rs10095003	chr8:11042449	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.12	-0.31	4.02e-12	Triglycerides;
LGG	cis	rs12325245	0.536	rs3169293	chr16:58552959	A/G	cg02549819	chr16:58548995	SETD6	1.45	13.97	0.54	2.81e-37	Schizophrenia;
LGG	cis	rs4363385	0.679	rs6686286	chr1:152984562	T/C	cg13444842	chr1:152974279	SPRR3	-0.45	-9.23	-0.39	9.96e-19	Inflammatory skin disease;
LGG	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg01221209	chr5:554886	NA	-0.51	-7.5	-0.33	3.2e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg08885076	chr2:99613938	TSGA10	-0.44	-8.14	-0.35	3.66e-15	Chronic sinus infection;
LGG	cis	rs1129187	0.755	rs7760250	chr6:42929839	G/A	cg24101359	chr6:42928495	GNMT	0.53	15.1	0.57	3.38e-42	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7208859	0.573	rs60724269	chr17:29113273	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg21724239	chr8:58056113	NA	-0.51	-7.62	-0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.556	rs355787	chr3:153994502	T/C	cg16511985	chr3:153974050	SGEF	0.5	8.43	0.36	4.56e-16	Coronary artery disease;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg07701084	chr6:150067640	NUP43	0.7	13.61	0.53	1.06e-35	Lung cancer;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg05896524	chr21:47604654	C21orf56	0.58	9.88	0.42	5.22e-21	Testicular germ cell tumor;
LGG	cis	rs10927875	0.632	rs6699394	chr1:16145143	C/A	cg07117364	chr1:16154769	NA	-0.5	-9.5	-0.4	1.13e-19	Dilated cardiomyopathy;
LGG	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg19824325	chr16:58548873	SETD6	1.22	11.08	0.46	1.84e-25	Schizophrenia;
LGG	cis	rs7084402	0.967	rs7099881	chr10:60316211	A/G	cg07615347	chr10:60278583	BICC1	-0.61	-16.68	-0.61	3.06e-49	Refractive error;
LGG	cis	rs7208859	0.725	rs9897673	chr17:29243366	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.51	-0.33	3.04e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2018055	0.871	rs13192067	chr6:117808000	G/A	cg14611402	chr6:117803162	DCBLD1	0.3	8.42	0.36	4.89e-16	Diastolic blood pressure;
LGG	cis	rs6951245	0.572	rs75083636	chr7:1050800	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.89	9.98	0.42	2.17e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7769051	0.522	rs7762248	chr6:133105303	A/C	cg07930552	chr6:133119739	C6orf192	1.09	9.41	0.4	2.29e-19	Type 2 diabetes nephropathy;
LGG	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg22437258	chr11:111473054	SIK2	-0.57	-9.57	-0.41	6.3e-20	Primary sclerosing cholangitis;
LGG	trans	rs73198271	0.960	rs17154702	chr8:8609880	C/T	cg16141378	chr3:129829833	LOC729375	0.37	6.82	0.3	2.89e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs17270561	0.609	rs9348695	chr6:25763010	A/T	cg03264133	chr6:25882463	NA	-0.47	-7.69	-0.34	8.67e-14	Iron status biomarkers;
LGG	cis	rs7089973	0.872	rs7072364	chr10:116620840	G/A	cg08188268	chr10:116634841	FAM160B1	0.34	7.41	0.33	6.03e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs10870270	0.957	rs10870307	chr10:133780610	T/C	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.53	-0.5	3.17e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11771526	0.579	rs117934886	chr7:32380547	G/T	cg13207630	chr7:32358064	NA	0.78	6.91	0.31	1.63e-11	Body mass index;
LGG	cis	rs12421382	0.887	rs1439513	chr11:109394795	C/T	cg11473876	chr11:109292803	C11orf87	0.56	10.44	0.44	4.79e-23	Schizophrenia;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg13880726	chr7:1868755	MAD1L1	0.38	6.64	0.3	8.61e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6951245	1.000	rs76804143	chr7:1082021	C/T	cg02733842	chr7:1102375	C7orf50	0.69	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1538970	0.962	rs3219489	chr1:45797505	C/G	cg05343316	chr1:45956843	TESK2	0.71	11.38	0.47	1.22e-26	Platelet count;
LGG	cis	rs853679	0.517	rs9393897	chr6:28127710	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.7	-0.34	8.23e-14	Depression;
LGG	trans	rs7395662	1.000	rs7948486	chr11:48912140	C/G	cg03929089	chr4:120376271	NA	0.44	7.1	0.31	4.88e-12	HDL cholesterol;
LGG	trans	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg25482853	chr8:67687455	SGK3	0.45	6.98	0.31	1.04e-11	Obesity-related traits;
LGG	cis	rs769267	0.965	rs2905425	chr19:19475717	G/C	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.27	-0.32	1.59e-12	Tonsillectomy;
LGG	cis	rs3820068	0.581	rs72645890	chr1:15930602	A/G	cg05660106	chr1:15850417	CASP9	0.85	17.37	0.63	2.12e-52	Systolic blood pressure;
LGG	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg02002194	chr4:3960332	NA	0.44	8.21	0.36	2.23e-15	Monocyte count;
LGG	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg25019033	chr10:957182	NA	-0.51	-9.35	-0.4	3.74e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg15556689	chr8:8085844	FLJ10661	-0.47	-8.11	-0.35	4.51e-15	Retinal vascular caliber;
LGG	cis	rs477895	0.653	rs11606544	chr11:63896901	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.43	0.47	8.32e-27	Mean platelet volume;
LGG	trans	rs970548	0.738	rs61854113	chr10:46004815	C/T	cg20477318	chr10:51623047	TIMM23	0.64	7.51	0.33	3.02e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs12681288	0.644	rs2123058	chr8:1000304	A/G	cg15309053	chr8:964076	NA	0.38	7.53	0.33	2.7e-13	Schizophrenia;
LGG	cis	rs35264875	1.000	rs72928652	chr11:68851547	G/A	cg23845249	chr11:68861649	NA	0.45	8.09	0.35	5.36e-15	Blond vs. brown hair color;
LGG	cis	rs870825	1.000	rs9995633	chr4:185584441	C/T	cg04058563	chr4:185651563	MLF1IP	0.97	18.16	0.64	4.79e-56	Blood protein levels;
LGG	cis	rs921968	0.643	rs13431399	chr2:219469498	G/C	cg01130898	chr2:219473002	PLCD4	0.44	7.69	0.34	9.04e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1799949	1.000	rs34942571	chr17:41273379	G/C	cg25072359	chr17:41440525	NA	0.53	9.95	0.42	2.99e-21	Menopause (age at onset);
LGG	cis	rs17102423	0.654	rs8008095	chr14:65525794	A/G	cg26396452	chr14:65542826	MAX	0.48	10.21	0.43	3.23e-22	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg09823679	chr13:53425813	NA	0.45	7.45	0.33	4.61e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.83	-0.34	3.38e-14	Menopause (age at onset);
LGG	cis	rs10911251	0.528	rs10911264	chr1:183115040	G/A	cg07928641	chr1:182991847	LAMC1	0.46	8.87	0.38	1.6e-17	Colorectal cancer;
LGG	cis	rs710865	0.519	rs3748759	chr1:19487656	C/T	cg13387374	chr1:19411106	UBR4	-0.5	-10.79	-0.45	2.27e-24	Brain structure;
LGG	trans	rs13256369	0.511	rs7012395	chr8:8538009	T/C	cg16141378	chr3:129829833	LOC729375	0.34	7.43	0.33	5.16e-13	Obesity-related traits;
LGG	cis	rs11168618	0.904	rs12366459	chr12:48930900	C/T	cg24011408	chr12:48396354	COL2A1	0.44	7.24	0.32	1.88e-12	Adiponectin levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14457918	chr22:50608509	PANX2	0.59	9.57	0.41	6.56e-20	Gut microbiome composition (summer);
LGG	cis	rs4906332	1.000	rs13987	chr14:103969909	A/G	cg26031613	chr14:104095156	KLC1	-0.51	-7.67	-0.34	1.02e-13	Coronary artery disease;
LGG	cis	rs6547631	1.000	rs6547631	chr2:85909026	A/G	cg24620635	chr2:85921963	GNLY	-0.38	-7.24	-0.32	1.94e-12	Blood protein levels;
LGG	cis	rs10464366	0.517	rs13231075	chr7:39174806	G/T	cg21665744	chr7:39171113	POU6F2	0.43	8.88	0.38	1.45e-17	IgG glycosylation;
LGG	cis	rs2228479	0.867	rs57940434	chr16:89975496	G/A	cg03036210	chr16:89904091	SPIRE2	-0.58	-8.08	-0.35	5.71e-15	Skin colour saturation;
LGG	cis	rs9397585	0.857	rs9371277	chr6:153377217	T/C	cg17707550	chr6:153380415	RGS17	0.62	14.45	0.56	2.48e-39	Body mass index;
LGG	trans	rs7824557	0.534	rs10092549	chr8:11089079	C/G	cg02002194	chr4:3960332	NA	0.41	7.28	0.32	1.45e-12	Retinal vascular caliber;
LGG	cis	rs367615	0.704	rs4286723	chr5:108835959	G/A	cg17395555	chr5:108820864	NA	0.87	15.95	0.6	6.09e-46	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs8073060	0.544	rs7211724	chr17:33993414	C/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.21	-0.65	2.86e-56	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs12135191	0.967	rs12354024	chr1:236465614	G/C	cg21399712	chr1:236511386	NA	-0.39	-7.43	-0.33	5.18e-13	Urate levels (BMI interaction);
LGG	cis	rs7727544	0.788	rs270613	chr5:131640583	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.5	-0.37	2.57e-16	Blood metabolite levels;
LGG	cis	rs6598955	0.671	rs11247893	chr1:26597086	A/C	cg04990556	chr1:26633338	UBXN11	-0.58	-7.87	-0.34	2.54e-14	Obesity-related traits;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.31	0.43	1.42e-22	Prudent dietary pattern;
LGG	cis	rs798554	0.797	rs1182174	chr7:2875420	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.7	-0.3	6.08e-11	Height;
LGG	cis	rs910316	0.763	rs175057	chr14:75489632	C/T	cg08847533	chr14:75593920	NEK9	-0.56	-9.95	-0.42	2.78e-21	Height;
LGG	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg06873352	chr17:61820015	STRADA	0.75	13.76	0.54	2.42e-36	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs73142162	chr7:65374296	A/T	cg18252515	chr7:66147081	NA	-1.36	-18.88	-0.66	2.2e-59	Diabetic kidney disease;
LGG	cis	rs1003719	0.788	rs4817844	chr21:38447064	A/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.85	-17.57	-0.63	2.42e-53	Eye color traits;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03754076	chr1:232766254	NA	0.43	7.3	0.32	1.25e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs55823223	0.590	rs11870142	chr17:73859002	A/G	cg10935138	chr17:73851978	WBP2	0.51	7.32	0.32	1.1e-12	Psoriasis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10661591	chr3:100428033	TFG	0.45	6.77	0.3	3.92e-11	Gut microbiome composition (summer);
LGG	cis	rs1497828	0.956	rs2646814	chr1:217523440	A/G	cg04411442	chr1:217543379	NA	-0.47	-8.03	-0.35	8.41e-15	Dialysis-related mortality;
LGG	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs1008375	1.000	rs3733579	chr4:17694943	A/G	cg18681998	chr4:17616180	MED28	0.72	14.88	0.57	3.45e-41	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7666738	0.830	rs4699574	chr4:98725544	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6831352	0.918	rs1126672	chr4:100047812	G/A	cg13256891	chr4:100009986	ADH5	-0.56	-9.78	-0.41	1.14e-20	Alcohol dependence;
LGG	cis	rs2354432	0.607	rs59606861	chr1:146761478	G/A	cg25205988	chr1:146714368	CHD1L	-1.39	-13.86	-0.54	8.49e-37	Mitochondrial DNA levels;
LGG	cis	rs4740619	0.692	rs2096121	chr9:15765429	G/C	cg14451791	chr9:16040625	NA	0.34	8.91	0.38	1.17e-17	Body mass index;
LGG	cis	rs4742903	0.875	rs2122581	chr9:107008811	G/A	cg14250997	chr9:106856677	SMC2	0.36	7.21	0.32	2.23e-12	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg17330251	chr7:94953956	PON1	-0.63	-16.69	-0.61	2.68e-49	Paraoxonase activity;
LGG	cis	rs3733585	0.781	rs13103879	chr4:9972879	T/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.83	-0.3	2.73e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg23633679	chr1:173793655	CENPL;DARS2	0.41	6.91	0.31	1.65e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs769267	0.895	rs2916073	chr19:19528324	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.04	0.55	1.51e-37	Tonsillectomy;
LGG	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg13232821	chr7:50628718	DDC	0.36	7.13	0.31	3.91e-12	Malaria;
LGG	cis	rs4740619	0.846	rs2105315	chr9:15766694	C/T	cg14451791	chr9:16040625	NA	-0.42	-11.02	-0.46	3.05e-25	Body mass index;
LGG	cis	rs7267979	1.000	rs2482937	chr20:25340786	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.17	-0.43	4.7e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12493885	0.628	rs61790905	chr3:153653032	A/G	cg12800244	chr3:153838788	SGEF	-0.65	-7.62	-0.33	1.46e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6500602	0.701	rs4785971	chr16:4577090	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.5	0.33	3.22e-13	Schizophrenia;
LGG	cis	rs778371	0.874	rs1083522	chr2:233745521	C/T	cg08000102	chr2:233561755	GIGYF2	-0.64	-10.24	-0.43	2.49e-22	Schizophrenia;
LGG	cis	rs8114671	0.839	rs6142290	chr20:33654672	A/C	cg07148914	chr20:33460835	GGT7	-0.49	-8.19	-0.36	2.49e-15	Height;
LGG	cis	rs227833	0.515	rs527082	chr6:44640206	C/T	cg18551225	chr6:44695536	NA	0.42	6.8	0.3	3.27e-11	Monobrow;
LGG	cis	rs7089973	0.872	rs10490908	chr10:116616162	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.68	0.34	9.66e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs12210905	0.688	rs12374607	chr6:27343620	A/G	cg15325629	chr6:28072465	NA	0.91	6.78	0.3	3.76e-11	Hip circumference adjusted for BMI;
LGG	cis	rs17106184	1.000	rs2095864	chr1:51299597	A/G	cg07174182	chr1:51127561	FAF1	-0.56	-8.48	-0.37	2.97e-16	Type 2 diabetes;
LGG	cis	rs757110	0.705	rs10832778	chr11:17394073	C/G	cg15432903	chr11:17409602	KCNJ11	0.81	16.56	0.61	1.07e-48	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.28	0.43	1.81e-22	Prudent dietary pattern;
LGG	cis	rs4363385	0.747	rs1415961	chr1:152973464	G/A	cg13444842	chr1:152974279	SPRR3	-0.45	-9.35	-0.4	3.81e-19	Inflammatory skin disease;
LGG	cis	rs1555895	0.611	rs3763722	chr10:859270	C/T	cg09361094	chr10:834503	NA	-0.29	-7.54	-0.33	2.48e-13	Survival in rectal cancer;
LGG	trans	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg06521331	chr12:34319734	NA	0.51	9.39	0.4	2.81e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12906542	0.516	rs894301	chr15:78297525	G/A	cg24885403	chr15:78208251	LOC645752	0.36	6.67	0.3	7.48e-11	Breast cancer;
LGG	cis	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25427524	chr10:38739819	LOC399744	-0.64	-11.88	-0.48	1.36e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs68170813	0.617	rs10464499	chr7:107137571	C/T	cg02696742	chr7:106810147	HBP1	-0.68	-8.67	-0.37	7.27e-17	Coronary artery disease;
LGG	cis	rs4764124	0.646	rs10744078	chr12:14978535	T/G	cg19759883	chr12:14956454	WBP11;C12orf60	-0.57	-10.87	-0.45	1.17e-24	Pubertal anthropometrics;
LGG	cis	rs8053891	0.507	rs66553600	chr16:72028198	G/C	cg23815491	chr16:72088622	HP	0.38	7.53	0.33	2.63e-13	Coronary artery disease;
LGG	cis	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg24110177	chr3:50126178	RBM5	0.59	10.86	0.45	1.22e-24	Intelligence (multi-trait analysis);
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.53	-8.5	-0.37	2.65e-16	Renal function-related traits (BUN);
LGG	cis	rs6952808	0.595	rs3800916	chr7:2166072	C/T	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.13e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.825	rs34922657	chr7:1938655	C/T	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.67	-0.37	7.1e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6964587	0.869	rs55811257	chr7:91484799	T/A	cg17063962	chr7:91808500	NA	-0.4	-6.99	-0.31	9.73e-12	Breast cancer;
LGG	cis	rs1256061	0.603	rs1256038	chr14:64740739	T/C	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.79e-14	Iron status biomarkers;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg19635926	chr16:89946313	TCF25	0.73	7.2	0.32	2.49e-12	Skin colour saturation;
LGG	cis	rs62400317	0.859	rs62400289	chr6:45203783	T/C	cg20913747	chr6:44695427	NA	-0.63	-10.18	-0.43	4.3e-22	Total body bone mineral density;
LGG	cis	rs11676348	0.818	rs7425447	chr2:218980183	T/C	cg00012203	chr2:219082015	ARPC2	-0.55	-9.78	-0.41	1.13e-20	Ulcerative colitis;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg04503457	chr17:41445688	NA	-0.38	-8.84	-0.38	2.01e-17	Menopause (age at onset);
LGG	cis	rs870825	0.616	rs2310110	chr4:185647902	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs8072100	0.701	rs8078309	chr17:45774072	T/C	cg25173405	chr17:45401733	C17orf57	-0.55	-9.15	-0.39	1.79e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7267979	0.966	rs2257461	chr20:25265554	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9303401	0.659	rs17222523	chr17:56620501	A/G	cg25039879	chr17:56429692	SUPT4H1	0.65	9.13	0.39	2.14e-18	Cognitive test performance;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.4	-0.33	6.66e-13	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07204255	chr16:4377893	NA	0.46	6.85	0.3	2.41e-11	Gut microbiome composition (summer);
LGG	cis	rs3736485	0.609	rs11631725	chr15:51969474	A/G	cg13474965	chr15:52030001	LYSMD2	0.4	6.69	0.3	6.38e-11	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg25072359	chr17:41440525	NA	0.51	9.93	0.42	3.36e-21	Menopause (age at onset);
LGG	cis	rs9747201	1.000	rs56283054	chr17:80135326	C/T	cg09264619	chr17:80180166	NA	0.51	10.11	0.43	7.88e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.48	-0.33	3.82e-13	Life satisfaction;
LGG	trans	rs7647973	0.626	rs9870858	chr3:49769071	C/T	cg21659725	chr3:3221576	CRBN	-0.56	-7.57	-0.33	2.11e-13	Menarche (age at onset);
LGG	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs10046574	0.561	rs6966294	chr7:135196479	G/A	cg27474649	chr7:135195673	CNOT4	0.73	8.8	0.38	2.82e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2153535	0.601	rs9505472	chr6:8538765	T/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.17	0.43	4.56e-22	Motion sickness;
LGG	cis	rs8017423	0.967	rs8015510	chr14:90729984	C/T	cg04374321	chr14:90722782	PSMC1	0.9	19.49	0.67	3.31e-62	Mortality in heart failure;
LGG	cis	rs11651000	0.857	rs16947078	chr17:45825500	A/G	cg06532163	chr17:45867833	NA	0.54	8.24	0.36	1.79e-15	IgG glycosylation;
LGG	cis	rs950776	0.714	rs3743074	chr15:78909480	G/A	cg16751781	chr15:78858589	CHRNA5	-0.4	-7.55	-0.33	2.35e-13	Sudden cardiac arrest;
LGG	cis	rs2730245	0.527	rs62476464	chr7:158698063	C/T	cg24397884	chr7:158709396	WDR60	1.11	17.02	0.62	8.44e-51	Height;
LGG	cis	rs7737355	0.699	rs7711311	chr5:130781339	G/A	cg06307176	chr5:131281290	NA	-0.5	-8.47	-0.37	3.24e-16	Life satisfaction;
LGG	cis	rs6952808	1.000	rs4719319	chr7:1888094	G/A	cg05863683	chr7:1912471	MAD1L1	0.41	7.69	0.34	8.81e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7712401	0.601	rs30027	chr5:122283390	T/C	cg19412675	chr5:122181750	SNX24	0.41	6.93	0.31	1.45e-11	Mean platelet volume;
LGG	cis	rs875971	0.862	rs778705	chr7:65861115	G/A	cg11764359	chr7:65958608	NA	0.73	13.1	0.52	1.39e-33	Aortic root size;
LGG	cis	rs4595586	0.545	rs1607041	chr12:39368206	C/T	cg26384229	chr12:38710491	ALG10B	0.65	11.74	0.48	4.89e-28	Morning vs. evening chronotype;
LGG	cis	rs597539	0.652	rs654071	chr11:68653432	A/C	cg04772025	chr11:68637568	NA	0.75	13.24	0.52	3.68e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg03036210	chr16:89904091	SPIRE2	-0.58	-8.08	-0.35	5.71e-15	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.2	0.55	2.95e-38	Obesity-related traits;
LGG	trans	rs804280	0.509	rs13276433	chr8:11783036	A/G	cg13009111	chr11:71350975	NA	0.36	7.95	0.35	1.46e-14	Myopia (pathological);
LGG	cis	rs7527798	0.592	rs12144801	chr1:207857773	A/G	cg09232269	chr1:207846808	CR1L	-0.38	-7.27	-0.32	1.58e-12	Erythrocyte sedimentation rate;
LGG	cis	rs11190604	1.000	rs11190587	chr10:102266638	C/T	cg07570687	chr10:102243282	WNT8B	0.45	7.53	0.33	2.64e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs807029	0.533	rs735137	chr10:102735835	C/G	cg04662943	chr10:102668895	NA	0.47	6.99	0.31	9.85e-12	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg00689492	chr4:1303491	MAEA	0.45	7.79	0.34	4.41e-14	Obesity-related traits;
LGG	cis	rs796364	0.951	rs11675980	chr2:201051150	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-7.41	-0.33	5.89e-13	Schizophrenia;
LGG	cis	rs4689592	0.503	rs66885632	chr4:7053738	T/C	cg03847636	chr4:7070632	GRPEL1	0.53	6.66	0.3	7.9e-11	Monocyte percentage of white cells;
LGG	cis	rs8062405	0.723	rs113208333	chr16:28606160	G/T	cg16576597	chr16:28551801	NUPR1	0.44	10.36	0.43	9.34e-23	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19524238	chr7:2802976	GNA12	0.38	8.85	0.38	1.89e-17	Height;
LGG	cis	rs4665809	0.759	rs62128394	chr2:26364026	T/G	cg22920501	chr2:26401640	FAM59B	0.45	8.31	0.36	1.04e-15	Gut microbiome composition (summer);
LGG	trans	rs7819412	0.745	rs4841498	chr8:10985432	C/T	cg16141378	chr3:129829833	LOC729375	0.38	8.74	0.38	4.29e-17	Triglycerides;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg08677398	chr8:58056175	NA	0.57	8.73	0.38	4.8e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg16606324	chr3:10149918	C3orf24	0.55	7.25	0.32	1.74e-12	Alzheimer's disease;
LGG	cis	rs2635047	0.811	rs12958943	chr18:44786818	T/C	cg19077165	chr18:44547161	KATNAL2	-0.41	-6.92	-0.31	1.56e-11	Educational attainment;
LGG	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg13010199	chr12:38710504	ALG10B	0.5	9.7	0.41	2.16e-20	Morning vs. evening chronotype;
LGG	cis	rs10504130	0.502	rs877248	chr8:52851634	G/A	cg22653915	chr8:52722023	PXDNL	-0.5	-8.72	-0.38	4.96e-17	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs17270561	0.609	rs1937131	chr6:25744831	A/T	cg12310025	chr6:25882481	NA	0.45	7.37	0.32	7.69e-13	Iron status biomarkers;
LGG	cis	rs10504229	0.817	rs60646469	chr8:58195348	T/C	cg05313129	chr8:58192883	C8orf71	-0.83	-12.35	-0.5	1.81e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs787274	1.000	rs787303	chr9:115491795	C/T	cg13803584	chr9:115635662	SNX30	0.56	7.0	0.31	9.15e-12	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4819052	0.851	rs10470258	chr21:46658989	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2204008	0.744	rs11181635	chr12:38378420	C/T	cg26384229	chr12:38710491	ALG10B	0.98	22.47	0.72	3.56e-76	Bladder cancer;
LGG	cis	rs847851	0.710	rs111868030	chr6:34651306	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.0	-0.42	1.96e-21	Colonoscopy-negative controls vs population controls;
LGG	cis	rs832540	0.902	rs194059	chr5:56197416	G/A	cg12654349	chr5:56205094	C5orf35	-0.4	-7.11	-0.31	4.39e-12	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs1270639	0.818	rs1079358	chr7:157462544	A/C	cg13357408	chr7:157437802	PTPRN2	0.53	6.93	0.31	1.46e-11	Colorectal cancer;
LGG	cis	rs7762018	0.607	rs75438963	chr6:170047695	G/A	cg19338460	chr6:170058176	WDR27	-0.87	-9.11	-0.39	2.49e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4808199	0.948	rs1859287	chr19:19422187	T/C	cg03709012	chr19:19516395	GATAD2A	0.94	14.95	0.57	1.56e-41	Nonalcoholic fatty liver disease;
LGG	cis	rs9557207	0.851	rs34723794	chr13:99799524	T/C	cg24509225	chr13:100037070	UBAC2	0.67	11.91	0.48	9.86e-29	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs3768617	0.510	rs12095664	chr1:183101686	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs60871478	1.000	rs60871478	chr7:827325	A/G	cg27478167	chr7:817139	HEATR2	-0.47	-7.27	-0.32	1.53e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs9517320	0.534	rs3825430	chr13:99129653	C/T	cg07423050	chr13:99094983	FARP1	-0.56	-10.8	-0.45	2.06e-24	Longevity;
LGG	cis	rs11098499	0.644	rs6855918	chr4:120546299	C/T	cg09307838	chr4:120376055	NA	0.72	12.48	0.5	5.17e-31	Corneal astigmatism;
LGG	trans	rs7181230	0.885	rs4497657	chr15:40359433	A/T	cg22705835	chr10:65332833	REEP3	-0.62	-10.21	-0.43	3.36e-22	Dehydroepiandrosterone sulphate levels;
LGG	cis	rs1707322	0.721	rs4415615	chr1:46132109	C/T	cg03146154	chr1:46216737	IPP	0.55	10.71	0.45	4.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs35771425	0.564	rs10159455	chr1:211407118	C/T	cg10512769	chr1:211675356	NA	-0.64	-8.45	-0.37	3.87e-16	Educational attainment (years of education);
LGG	cis	rs2228479	0.702	rs62052710	chr16:89854893	C/T	cg06558623	chr16:89946397	TCF25	1.1	11.81	0.48	2.56e-28	Skin colour saturation;
LGG	trans	rs61931739	0.517	rs10844830	chr12:34308133	C/T	cg26384229	chr12:38710491	ALG10B	0.71	14.5	0.56	1.51e-39	Morning vs. evening chronotype;
LGG	cis	rs4253772	0.591	rs9615938	chr22:46689468	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.95e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs17376456	0.504	rs7702649	chr5:93065149	C/A	cg19507638	chr5:93509721	C5orf36	-0.43	-7.03	-0.31	7.54e-12	Diabetic retinopathy;
LGG	cis	rs6694672	0.850	rs1953064	chr1:197064826	A/G	cg13682187	chr1:196946512	CFHR5	0.51	7.15	0.32	3.41e-12	Asthma;
LGG	trans	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.77	0.64	2.95e-54	Exhaled nitric oxide output;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg11494091	chr17:61959527	GH2	1.03	26.42	0.78	1.71e-94	Prudent dietary pattern;
LGG	trans	rs2243480	1.000	rs316313	chr7:65593548	G/A	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	trans	rs61931739	0.749	rs7315233	chr12:34271975	G/T	cg13010199	chr12:38710504	ALG10B	0.47	8.87	0.38	1.61e-17	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.9	0.31	1.67e-11	Lung cancer;
LGG	cis	rs7089973	0.872	rs35622181	chr10:116631976	C/T	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs10489167	1.000	rs12060189	chr1:41160281	C/T	cg11417323	chr1:41160271	NFYC	0.44	7.07	0.31	5.79e-12	Depressive and manic episodes in bipolar disorder;
LGG	cis	rs12497850	0.797	rs61583136	chr3:49189195	C/T	cg18654377	chr3:49208889	KLHDC8B	-0.48	-7.21	-0.32	2.29e-12	Parkinson's disease;
LGG	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg01181863	chr3:195395398	SDHAP2	0.48	7.38	0.32	7.3e-13	Mean corpuscular volume;
LGG	cis	rs2242116	1.000	rs1138518	chr3:46944274	T/C	cg02527881	chr3:46936655	PTH1R	-0.38	-9.28	-0.4	6.76e-19	Birth weight;
LGG	cis	rs3733585	0.775	rs13124007	chr4:10043931	G/C	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs796364	0.951	rs72932280	chr2:200996851	G/C	cg23649088	chr2:200775458	C2orf69	-0.61	-8.22	-0.36	2.03e-15	Schizophrenia;
LGG	cis	rs61989804	0.623	rs7161058	chr14:65737606	G/A	cg15999311	chr14:65749247	NA	0.77	7.72	0.34	7.08e-14	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	cis	rs2629540	0.824	rs1552345	chr10:126477406	A/G	cg08799069	chr10:126477246	METTL10	-0.69	-14.59	-0.56	5.84e-40	Cocaine dependence;
LGG	cis	rs504918	0.556	rs73188191	chr3:124016463	T/C	cg05766129	chr3:123988013	KALRN	-0.57	-10.22	-0.43	2.91e-22	Schizophrenia;
LGG	cis	rs9463078	0.764	rs6904015	chr6:44785502	G/A	cg25276700	chr6:44698697	NA	-0.4	-8.51	-0.37	2.5e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs651907	0.557	rs56291106	chr3:101377474	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.66	-0.34	1.09e-13	Colorectal cancer;
LGG	trans	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg15556689	chr8:8085844	FLJ10661	0.42	7.11	0.31	4.47e-12	Retinal vascular caliber;
LGG	cis	rs9549367	0.789	rs6577035	chr13:113879997	G/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.51	-0.37	2.45e-16	Platelet distribution width;
LGG	cis	rs8072100	0.840	rs9895746	chr17:45479099	C/A	cg08085267	chr17:45401833	C17orf57	-0.53	-10.43	-0.44	5.26e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7829975	0.577	rs7816329	chr8:8543843	G/A	cg02002194	chr4:3960332	NA	0.4	7.2	0.32	2.47e-12	Mood instability;
LGG	cis	rs12476592	0.571	rs2604617	chr2:63898663	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	cis	rs3768617	0.510	rs20557	chr1:183093875	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs4330281	0.669	rs11128839	chr3:17703391	C/T	cg20981856	chr3:17787350	NA	-0.4	-7.61	-0.33	1.59e-13	Schizophrenia;
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.08	-0.52	1.77e-33	Aortic root size;
LGG	cis	rs12410462	1.000	rs6672162	chr1:227632335	G/A	cg04117972	chr1:227635322	NA	0.75	12.11	0.49	1.7e-29	Major depressive disorder;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	cis	rs3785574	0.962	rs2584630	chr17:61887561	T/A	cg11494091	chr17:61959527	GH2	0.6	10.0	0.42	1.95e-21	Height;
LGG	cis	rs6061231	1.000	rs11696991	chr20:60959694	G/T	cg24112000	chr20:60950667	NA	-0.42	-9.91	-0.42	4.02e-21	Colorectal cancer;
LGG	cis	rs3857067	0.773	rs10023115	chr4:95095502	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.98	-0.35	1.2e-14	QT interval;
LGG	cis	rs1267303	0.642	rs7542296	chr1:46998009	A/G	cg25110126	chr1:46999211	NA	0.58	9.22	0.39	1.06e-18	Monobrow;
LGG	cis	rs916888	0.821	rs199504	chr17:44861003	C/T	cg01570182	chr17:44337453	NA	-0.66	-10.83	-0.45	1.64e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7618501	0.602	rs2526743	chr3:50115245	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-8.28	-0.36	1.29e-15	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.612	rs2004961	chr12:33994599	A/G	cg26384229	chr12:38710491	ALG10B	0.6	11.28	0.46	3.08e-26	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg05368731	chr17:41323189	NBR1	0.95	18.98	0.66	7.81e-60	Menopause (age at onset);
LGG	cis	rs2201728	0.967	rs12512084	chr4:100173159	A/G	cg07219303	chr4:100140905	ADH6	-0.42	-8.4	-0.36	5.55e-16	Cardiac Troponin-T levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11522767	chr6:157342961	ARID1B	0.49	7.71	0.34	7.76e-14	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.867	rs75110337	chr16:89962635	C/A	cg00800038	chr16:89945340	TCF25	-0.71	-9.35	-0.4	3.72e-19	Skin colour saturation;
LGG	cis	rs28374715	0.532	rs28535540	chr15:41659277	G/A	cg18705301	chr15:41695430	NDUFAF1	-1.35	-35.26	-0.85	3.12e-133	Ulcerative colitis;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg05867925	chr6:26033854	HIST1H2AB	0.39	6.82	0.3	2.79e-11	Bilirubin levels;
LGG	cis	rs17818399	0.547	rs4952831	chr2:46761181	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.56	8.5	0.37	2.63e-16	Height;
LGG	cis	rs12541335	0.639	rs11779277	chr8:22200683	C/T	cg18135555	chr8:22132992	PIWIL2	0.4	10.61	0.44	1.1e-23	Hypertriglyceridemia;
LGG	cis	rs2229238	0.911	rs41269915	chr1:154521584	T/A	cg10237817	chr1:154519846	TDRD10	0.35	7.06	0.31	5.96e-12	Coronary heart disease;
LGG	cis	rs11992162	0.551	rs35010200	chr8:11785655	G/A	cg12395012	chr8:11607386	GATA4	0.41	7.38	0.32	7.32e-13	Monocyte count;
LGG	cis	rs10883723	0.810	rs10786671	chr10:104271303	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1e-42	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1401999	0.898	rs9876143	chr3:183731362	C/G	cg01324343	chr3:183735012	ABCC5	0.87	18.07	0.64	1.2e-55	Anterior chamber depth;
LGG	cis	rs526231	0.578	rs3776870	chr5:102295070	G/A	cg23492399	chr5:102201601	PAM	-0.6	-9.23	-0.39	9.95e-19	Primary biliary cholangitis;
LGG	cis	rs4740619	0.836	rs10810462	chr9:15889634	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.96	-0.42	2.6e-21	Body mass index;
LGG	trans	rs10802346	0.545	rs10802347	chr1:246374268	G/A	cg13514129	chr1:39547527	MACF1	0.68	12.62	0.51	1.33e-31	Fractional exhaled nitric oxide (childhood);
LGG	trans	rs7824557	0.547	rs2409749	chr8:11078949	G/A	cg16141378	chr3:129829833	LOC729375	0.4	8.98	0.39	6.92e-18	Retinal vascular caliber;
LGG	cis	rs8067545	0.611	rs2703776	chr17:20137709	C/A	cg13482628	chr17:19912719	NA	-0.53	-10.12	-0.43	6.84e-22	Schizophrenia;
LGG	cis	rs7937682	0.737	rs518294	chr11:111424716	A/T	cg22437258	chr11:111473054	SIK2	0.4	7.0	0.31	8.94e-12	Primary sclerosing cholangitis;
LGG	cis	rs713587	0.525	rs11675457	chr2:25079770	C/T	cg04586622	chr2:25135609	ADCY3	0.4	10.81	0.45	1.97e-24	Body mass index in non-asthmatics;
LGG	trans	rs1814175	0.546	rs1614397	chr11:49913384	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.12	-0.49	1.5e-29	Height;
LGG	cis	rs752010	0.630	rs11210507	chr1:42105488	T/C	cg16096631	chr1:42092165	HIVEP3	0.54	12.88	0.51	1.22e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs738322	0.935	rs133014	chr22:38571087	T/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.37e-11	Cutaneous nevi;
LGG	cis	rs7786808	0.608	rs9692003	chr7:158204696	G/A	cg15440763	chr7:158190612	PTPRN2	-0.44	-9.25	-0.39	8.48e-19	Obesity-related traits;
LGG	cis	rs9358372	0.574	rs4710950	chr6:20803099	A/T	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.26	-0.4	7.91e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10895140	0.756	rs2186578	chr11:101506434	A/C	cg23650423	chr11:101454676	TRPC6	-0.43	-7.04	-0.31	6.88e-12	Menarche (age at onset);
LGG	cis	rs2439831	0.867	rs2412780	chr15:43655794	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	11.31	0.47	2.43e-26	Lung cancer in ever smokers;
LGG	cis	rs4665809	0.590	rs9309474	chr2:26448830	T/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.16	-0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs12701220	0.817	rs59471534	chr7:1085224	G/A	cg00990874	chr7:1149470	C7orf50	-0.69	-11.41	-0.47	1e-26	Bronchopulmonary dysplasia;
LGG	trans	rs6601327	0.635	rs10099122	chr8:9568003	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.15	0.32	3.44e-12	Multiple myeloma (hyperdiploidy);
LGG	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg08975724	chr8:8085496	FLJ10661	-0.36	-6.67	-0.3	7.45e-11	Triglycerides;
LGG	trans	rs12579753	0.917	rs10862375	chr12:82254809	C/G	cg07923666	chr12:49932857	KCNH3	0.44	6.88	0.3	1.95e-11	Resting heart rate;
LGG	cis	rs2072499	0.695	rs112223391	chr1:156156094	G/A	cg25208724	chr1:156163844	SLC25A44	1.14	20.0	0.68	1.39e-64	Testicular germ cell tumor;
LGG	cis	rs12949688	1.000	rs886926	chr17:55817413	A/G	cg12582317	chr17:55822272	NA	-0.64	-17.14	-0.62	2.26e-51	Schizophrenia;
LGG	cis	rs36071027	0.615	rs56176059	chr5:158414823	T/C	cg18496440	chr5:158532302	NA	0.41	6.81	0.3	3.04e-11	Carotid intima media thickness;
LGG	cis	rs2762353	0.808	rs1165179	chr6:25826514	C/T	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg18402987	chr7:1209562	NA	0.5	8.31	0.36	1.08e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13383153	chr19:36980459	ZNF566	-0.47	-6.96	-0.31	1.14e-11	Systemic lupus erythematosus;
LGG	trans	rs9650657	0.711	rs35091929	chr8:10693492	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.45	-0.33	4.72e-13	Neuroticism;
LGG	cis	rs4780401	0.632	rs7192366	chr16:11835209	C/G	cg01061890	chr16:11836724	TXNDC11	-0.7	-12.97	-0.52	4.81e-33	Rheumatoid arthritis;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16680214	chr1:154839983	KCNN3	-0.46	-9.05	-0.39	4.04e-18	Prostate cancer;
LGG	cis	rs6582630	0.623	rs12299293	chr12:38436288	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.3	-0.4	5.61e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs72781680	0.898	rs72796396	chr2:24178154	G/A	cg08917208	chr2:24149416	ATAD2B	0.81	9.54	0.41	8.07e-20	Lymphocyte counts;
LGG	cis	rs2131877	0.956	rs10933698	chr3:194868369	T/C	cg07250128	chr3:194833983	C3orf21	0.41	7.59	0.33	1.83e-13	Non-small cell lung cancer;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs12210905	0.925	rs9467965	chr6:26992539	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.55	-7.54	-0.33	2.43e-13	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.04	-0.39	4.2e-18	Obesity-related traits;
LGG	cis	rs7000551	0.751	rs2443494	chr8:22372262	C/G	cg12081754	chr8:22256438	SLC39A14	0.65	12.27	0.5	3.51e-30	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs17376456	0.877	rs66696214	chr5:93424533	G/A	cg21475434	chr5:93447410	FAM172A	0.7	7.08	0.31	5.27e-12	Diabetic retinopathy;
LGG	cis	rs6815814	0.948	rs73236649	chr4:38873332	C/T	cg06935464	chr4:38784597	TLR10	0.55	7.4	0.33	6.6e-13	Breast cancer;
LGG	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.91	-0.42	3.9e-21	Response to antipsychotic treatment;
LGG	cis	rs6951245	0.507	rs10227709	chr7:1180515	T/G	cg23978390	chr7:1156363	C7orf50	0.53	7.92	0.35	1.74e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7927592	0.645	rs7936582	chr11:68292930	T/C	cg01657329	chr11:68192670	LRP5	-0.38	-6.74	-0.3	4.81e-11	Total body bone mineral density;
LGG	cis	rs7928758	0.887	rs76369658	chr11:134268110	C/T	cg22777979	chr11:134283252	B3GAT1	1.0	12.68	0.51	8.14e-32	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs3780486	0.846	rs7864705	chr9:33140352	A/C	cg13443165	chr9:33130375	B4GALT1	-0.74	-14.72	-0.56	1.61e-40	IgG glycosylation;
LGG	cis	rs3743104	0.966	rs33963919	chr15:33023670	C/T	cg07179000	chr15:33023586	GREM1	-0.5	-9.73	-0.41	1.75e-20	Hypospadias;
LGG	cis	rs6743226	0.603	rs11675957	chr2:242208792	A/G	cg10021735	chr2:242295487	FARP2	-0.4	-7.11	-0.31	4.35e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs2243480	1.000	rs316331	chr7:65604622	A/G	cg10756647	chr7:56101905	PSPH	-0.81	-9.47	-0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs477895	0.568	rs12418035	chr11:63871558	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.81	10.45	0.44	4.44e-23	Mean platelet volume;
LGG	cis	rs7572263	0.528	rs6722000	chr2:209075957	C/T	cg00164906	chr2:209055251	C2orf80	-0.49	-7.69	-0.34	8.94e-14	Glioma;Non-glioblastoma glioma;
LGG	cis	rs867371	1.000	rs8041868	chr15:82472326	C/T	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	3.2e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7954584	0.531	rs11043271	chr12:122394921	A/C	cg01765077	chr12:122356316	WDR66	0.29	7.73	0.34	6.78e-14	Mean corpuscular volume;
LGG	cis	rs1552244	0.554	rs3846167	chr3:9996426	T/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.99	0.52	3.94e-33	Alzheimer's disease;
LGG	cis	rs9303280	0.776	rs9910826	chr17:38035648	A/G	cg19468946	chr17:37922297	IKZF3	-0.43	-7.73	-0.34	6.88e-14	Self-reported allergy;
LGG	cis	rs2797369	0.609	rs72942892	chr6:101403847	T/C	cg27451362	chr6:101846650	GRIK2	0.76	10.31	0.43	1.41e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs8014204	0.967	rs2359240	chr14:75328247	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.84	-16.96	-0.62	1.52e-50	Caffeine consumption;
LGG	cis	rs367943	0.712	rs26959	chr5:112736615	A/G	cg12552261	chr5:112820674	MCC	0.57	10.2	0.43	3.73e-22	Type 2 diabetes;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg02951883	chr7:2050386	MAD1L1	-0.77	-15.98	-0.6	4.2e-46	Bipolar disorder and schizophrenia;
LGG	cis	rs11148252	0.595	rs9526974	chr13:53251040	C/G	cg05335186	chr13:53173507	NA	0.73	17.83	0.64	1.67e-54	Lewy body disease;
LGG	cis	rs714515	0.868	rs10752944	chr1:172363524	C/T	cg01573306	chr1:172330400	DNM3	0.34	7.34	0.32	9.78e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs11785400	1.000	rs6988393	chr8:143740596	A/G	cg24634471	chr8:143751801	JRK	0.53	8.56	0.37	1.62e-16	Schizophrenia;
LGG	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg12438819	chr7:158236134	PTPRN2	0.33	8.82	0.38	2.33e-17	Obesity-related traits;
LGG	cis	rs902774	0.530	rs12819597	chr12:53353956	T/C	cg05393297	chr12:53359155	NA	-0.57	-7.04	-0.31	7.18e-12	Prostate cancer;
LGG	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg05793240	chr7:2802953	GNA12	0.33	8.0	0.35	1.03e-14	Height;
LGG	trans	rs3206736	0.548	rs1637673	chr7:34997850	A/G	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.91e-12	Diastolic blood pressure;
LGG	cis	rs7582180	0.669	rs4455176	chr2:100876629	T/A	cg14675211	chr2:100938903	LONRF2	0.49	8.02	0.35	8.88e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.923	rs9371199	chr6:150138662	A/T	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.34e-11	Lung cancer;
LGG	cis	rs68170813	0.559	rs7794598	chr7:106826381	C/T	cg02696742	chr7:106810147	HBP1	-0.74	-11.0	-0.46	3.77e-25	Coronary artery disease;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg17178900	chr1:205818956	PM20D1	0.4	7.36	0.32	8.72e-13	Prostate-specific antigen levels;
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg11878867	chr6:150167359	LRP11	-0.36	-7.57	-0.33	2.05e-13	Lung cancer;
LGG	cis	rs4718428	0.672	rs13241598	chr7:66300652	A/G	cg12165864	chr7:66369176	NA	-0.57	-9.22	-0.39	1.03e-18	Corneal structure;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.550	rs28522910	chr4:1374774	C/T	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.12	-0.6	9.86e-47	Longevity;
LGG	cis	rs4665809	0.590	rs7260	chr2:26413917	C/T	cg08470875	chr2:26401718	FAM59B	-0.4	-7.94	-0.35	1.53e-14	Gut microbiome composition (summer);
LGG	cis	rs10248839	0.518	rs1317741	chr7:29711149	T/C	cg12525768	chr7:29689996	LOC646762	0.55	7.84	0.34	3.07e-14	Facial emotion recognition (angry faces);
LGG	cis	rs7226408	0.857	rs59634585	chr18:34437032	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs12701220	0.590	rs1881124	chr7:1096766	A/C	cg20821713	chr7:1055600	C7orf50	-0.46	-6.66	-0.3	7.86e-11	Bronchopulmonary dysplasia;
LGG	trans	rs7647973	0.710	rs34890793	chr3:49619493	C/T	cg21659725	chr3:3221576	CRBN	-0.6	-7.74	-0.34	6.51e-14	Menarche (age at onset);
LGG	cis	rs758324	0.812	rs4705840	chr5:131206624	C/T	cg06307176	chr5:131281290	NA	0.53	8.78	0.38	3.16e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs2576037	0.526	rs538221	chr18:44375111	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.42	-8.52	-0.37	2.3e-16	Personality dimensions;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg11062466	chr8:58055876	NA	0.44	7.35	0.32	9.08e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.934	rs4974608	chr4:1356780	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.41	0.4	2.31e-19	Longevity;
LGG	cis	rs8031584	0.918	rs11639169	chr15:31255438	C/T	cg14829155	chr15:31115871	NA	-0.57	-9.74	-0.41	1.61e-20	Huntington's disease progression;
LGG	cis	rs17270561	0.609	rs9366629	chr6:25741216	G/A	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg07659893	chr17:61819838	STRADA	-0.48	-8.15	-0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg08470875	chr2:26401718	FAM59B	-0.37	-6.79	-0.3	3.36e-11	Gut microbiome composition (summer);
LGG	cis	rs9400467	0.537	rs12213673	chr6:111544839	C/T	cg15721981	chr6:111408429	SLC16A10	0.59	7.08	0.31	5.26e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs2439831	0.850	rs2277531	chr15:44069069	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.84	9.14	0.39	1.9e-18	Lung cancer in ever smokers;
LGG	cis	rs2836974	0.666	rs12626405	chr21:40663121	G/T	cg11890956	chr21:40555474	PSMG1	-0.97	-20.48	-0.69	7.85e-67	Cognitive function;
LGG	cis	rs6121246	0.909	rs6058463	chr20:30385192	C/T	cg21427119	chr20:30132790	HM13	-0.42	-7.17	-0.32	2.99e-12	Mean corpuscular hemoglobin;
LGG	cis	rs853679	0.517	rs9468298	chr6:28122345	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs7107174	1.000	rs10899474	chr11:78043636	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.54	-0.33	2.49e-13	Testicular germ cell tumor;
LGG	trans	rs7726839	0.561	rs72703044	chr5:579737	G/A	cg25482853	chr8:67687455	SGK3	0.84	11.06	0.46	2.19e-25	Obesity-related traits;
LGG	cis	rs17376456	0.935	rs10036891	chr5:93171738	T/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.34	0.4	4.06e-19	Diabetic retinopathy;
LGG	cis	rs9381040	0.655	rs7775972	chr6:41038116	A/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.36	-6.89	-0.3	1.88e-11	Alzheimer's disease (late onset);
LGG	cis	rs2836950	0.565	rs3171465	chr21:40552307	A/G	cg17971929	chr21:40555470	PSMG1	-0.54	-9.09	-0.39	3e-18	Menarche (age at onset);
LGG	cis	rs8017423	0.904	rs11621127	chr14:90802050	G/A	cg04374321	chr14:90722782	PSMC1	-0.87	-17.54	-0.63	3.32e-53	Mortality in heart failure;
LGG	cis	rs11608355	0.545	rs2302705	chr12:109898716	C/T	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	trans	rs6921919	0.562	rs13198809	chr6:28323702	G/A	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.22	-0.49	5.79e-30	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs7459925	chr8:58111771	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.35	-0.58	2.65e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.712	rs9665784	chr11:50030617	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.97	-0.49	5.69e-29	Height;
LGG	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg01620082	chr3:125678407	NA	-0.79	-7.96	-0.35	1.3e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1055129	0.681	rs7221792	chr17:73834690	T/G	cg14829360	chr17:73884958	NA	-0.43	-7.76	-0.34	5.6e-14	White matter hyperintensity burden;
LGG	cis	rs79349575	0.745	rs170319	chr17:46991531	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.5e-11	Type 2 diabetes;
LGG	cis	rs7949030	0.626	rs1061093	chr11:62334908	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.32	0.65	9.24e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2274273	0.615	rs17672058	chr14:55673394	C/T	cg04306507	chr14:55594613	LGALS3	0.51	11.87	0.48	1.51e-28	Protein biomarker;
LGG	cis	rs9948	0.541	rs6734326	chr2:97569735	G/A	cg26665480	chr2:98280029	ACTR1B	-0.65	-6.68	-0.3	6.75e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.04	-0.31	6.96e-12	Lung cancer;
LGG	trans	rs7824557	0.569	rs2409718	chr8:11012977	C/T	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.4	-0.4	2.49e-19	Retinal vascular caliber;
LGG	cis	rs283228	0.798	rs636135	chr6:101758352	A/C	cg27451362	chr6:101846650	GRIK2	0.64	10.55	0.44	1.89e-23	Coenzyme Q10 levels;
LGG	cis	rs9463078	0.625	rs7742360	chr6:44998692	C/G	cg25276700	chr6:44698697	NA	-0.33	-6.85	-0.3	2.31e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs28595532	0.920	rs115446044	chr4:119754635	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs7011049	0.778	rs72648429	chr8:53872390	C/T	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09976724	chr15:41186526	VPS18	0.47	7.63	0.33	1.38e-13	Cognitive performance;
LGG	cis	rs11690935	0.843	rs9784123	chr2:172785005	T/A	cg21435375	chr2:172878103	MAP1D	-0.35	-7.69	-0.34	8.82e-14	Schizophrenia;
LGG	cis	rs11169552	0.510	rs10506295	chr12:51085471	A/G	cg12884762	chr12:50931848	DIP2B	-0.41	-7.86	-0.34	2.65e-14	Colorectal cancer;
LGG	cis	rs7647973	0.925	rs6446257	chr3:49253492	A/G	cg07636037	chr3:49044803	WDR6	-0.76	-13.15	-0.52	8.89e-34	Menarche (age at onset);
LGG	cis	rs11608355	0.545	rs12818120	chr12:109901916	C/T	cg05360138	chr12:110035743	NA	0.84	12.08	0.49	2.13e-29	Neuroticism;
LGG	cis	rs6489882	0.867	rs4766673	chr12:113365161	C/T	cg25319449	chr12:113376135	OAS3	0.4	7.42	0.33	5.66e-13	Chronic lymphocytic leukemia;
LGG	cis	rs2832191	0.791	rs2832198	chr21:30498240	C/T	cg08807101	chr21:30365312	RNF160	0.82	16.83	0.62	6.41e-50	Dental caries;
LGG	cis	rs8077889	0.957	rs17742929	chr17:41891437	C/T	cg26893861	chr17:41843967	DUSP3	0.9	14.55	0.56	9.28e-40	Triglycerides;
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8031584	1.000	rs8031584	chr15:31287343	A/T	cg19680485	chr15:31195859	MTMR15	-0.43	-6.65	-0.3	8.53e-11	Huntington's disease progression;
LGG	cis	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg07777115	chr5:623756	CEP72	-0.63	-8.0	-0.35	9.92e-15	Obesity-related traits;
LGG	cis	rs7937682	0.632	rs11214009	chr11:111683142	T/C	cg22437258	chr11:111473054	SIK2	-0.42	-6.91	-0.31	1.59e-11	Primary sclerosing cholangitis;
LGG	cis	rs13108904	0.905	rs1732108	chr4:1276550	C/T	cg04863758	chr4:1303710	MAEA	-0.4	-6.79	-0.3	3.48e-11	Obesity-related traits;
LGG	cis	rs769267	0.965	rs2315025	chr19:19426609	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.52	0.33	2.84e-13	Tonsillectomy;
LGG	cis	rs1408224	0.657	rs1570620	chr13:47201874	C/T	cg24453118	chr13:47229927	LRCH1	-0.3	-7.05	-0.31	6.53e-12	QRS complex (12-leadsum);
LGG	cis	rs9815354	1.000	rs2371627	chr3:41839219	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.19	0.36	2.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.649	rs126092	chr22:42178441	A/G	cg03806693	chr22:41940476	POLR3H	0.9	14.96	0.57	1.49e-41	Vitiligo;
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs17818399	0.547	rs13020299	chr2:46758717	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.53	8.14	0.35	3.66e-15	Height;
LGG	cis	rs7615952	0.599	rs2333408	chr3:125732098	G/A	cg15145296	chr3:125709740	NA	-0.6	-7.71	-0.34	7.65e-14	Blood pressure (smoking interaction);
LGG	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg06092702	chr1:163392909	NA	-0.48	-8.56	-0.37	1.68e-16	Motion sickness;
LGG	trans	rs9329221	0.537	rs6983332	chr8:9977918	A/G	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.92	-0.35	1.78e-14	Neuroticism;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg04772025	chr11:68637568	NA	0.75	13.2	0.52	5.47e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	0.897	rs6504177	chr17:61812655	C/T	cg26338869	chr17:61819248	STRADA	0.57	9.63	0.41	3.81e-20	Prudent dietary pattern;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg13628971	chr7:2884303	GNA12	0.36	7.43	0.33	5.4e-13	Height;
LGG	cis	rs4684776	0.800	rs62248260	chr3:11613528	C/T	cg24705426	chr3:11550659	ATG7	-0.43	-7.42	-0.33	5.82e-13	Small vessel stroke;
LGG	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg12654349	chr5:56205094	C5orf35	0.58	9.92	0.42	3.81e-21	Initial pursuit acceleration;
LGG	cis	rs10875595	0.836	rs4912747	chr5:140676027	T/A	cg24830062	chr5:140700576	TAF7	-0.55	-7.0	-0.31	8.94e-12	Pulmonary function decline;
LGG	cis	rs2658782	1.000	rs2658781	chr11:93166368	C/T	cg15737290	chr11:93063684	CCDC67	-0.58	-8.56	-0.37	1.73e-16	Pulmonary function decline;
LGG	cis	rs1784581	0.588	rs7453474	chr6:162421736	C/T	cg17173639	chr6:162384350	PARK2	0.64	13.5	0.53	2.92e-35	Itch intensity from mosquito bite;
LGG	cis	rs765787	0.530	rs11070444	chr15:45513121	T/C	cg25801113	chr15:45476975	SHF	-0.88	-19.15	-0.66	1.2e-60	Uric acid levels;
LGG	cis	rs2071426	1.000	rs2071426	chr10:96828323	T/C	cg09036531	chr10:96991505	NA	-0.44	-7.35	-0.32	8.84e-13	Blood metabolite levels;
LGG	cis	rs7119038	0.509	rs11216956	chr11:118575326	G/A	cg19182353	chr11:118479428	PHLDB1	0.4	7.16	0.32	3.09e-12	Sjögren's syndrome;
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.91	-11.26	-0.46	3.84e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2224391	0.628	rs1609808	chr6:5246333	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.54	-7.06	-0.31	6.33e-12	Height;
LGG	cis	rs858239	0.669	rs1990365	chr7:23115966	T/C	cg23682824	chr7:23144976	KLHL7	0.47	8.05	0.35	6.83e-15	Cerebrospinal fluid biomarker levels;
LGG	cis	rs6951245	0.572	rs11559183	chr7:1037025	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.98	-12.79	-0.51	2.8e-32	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg13009111	chr11:71350975	NA	-0.4	-9.17	-0.39	1.5e-18	Neuroticism;
LGG	cis	rs6061231	0.624	rs8668	chr20:60964064	C/T	cg22601191	chr20:60968625	CABLES2	-0.47	-9.02	-0.39	5.06e-18	Colorectal cancer;
LGG	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg14979609	chr8:8086686	FLJ10661	-0.34	-8.75	-0.38	4.15e-17	Systolic blood pressure;
LGG	cis	rs2354432	0.943	rs6660219	chr1:146691404	A/T	cg25205988	chr1:146714368	CHD1L	1.32	17.03	0.62	7.34e-51	Mitochondrial DNA levels;
LGG	cis	rs17253792	0.545	rs12894613	chr14:56016221	T/C	cg01858014	chr14:56050164	KTN1	-0.75	-9.29	-0.4	6.07e-19	Putamen volume;
LGG	cis	rs2213920	0.569	rs6478170	chr9:118246331	G/A	cg13918206	chr9:118159781	DEC1	0.59	7.74	0.34	6.4e-14	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs6502050	0.835	rs4789675	chr17:80123144	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs300774	0.925	rs6735974	chr2:179581	A/G	cg21211680	chr2:198530	NA	-0.55	-7.18	-0.32	2.84e-12	Suicide attempts in bipolar disorder;
LGG	trans	rs11039798	1.000	rs7479655	chr11:48576714	G/T	cg15704280	chr7:45808275	SEPT13	0.77	8.91	0.38	1.17e-17	Axial length;
LGG	cis	rs8180040	0.764	rs4682852	chr3:47177772	C/T	cg16586182	chr3:47516702	SCAP	-0.78	-15.08	-0.57	4.56e-42	Colorectal cancer;
LGG	cis	rs614226	0.938	rs7972244	chr12:120994872	A/G	cg01236616	chr12:121019343	POP5	1.27	22.78	0.73	1.36e-77	Type 1 diabetes nephropathy;
LGG	trans	rs11875185	0.588	rs112131452	chr18:55640298	T/C	cg15513957	chr14:69354734	ACTN1	-0.94	-9.32	-0.4	4.72e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs4740619	0.619	rs10810517	chr9:16026664	C/T	cg14451791	chr9:16040625	NA	-0.43	-11.35	-0.47	1.66e-26	Body mass index;
LGG	cis	rs7617480	0.610	rs10865954	chr3:49211989	T/C	cg06212747	chr3:49208901	KLHDC8B	0.79	14.09	0.55	8.89e-38	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9807989	0.507	rs1420097	chr2:103009354	C/G	cg03938978	chr2:103052716	IL18RAP	-0.38	-8.89	-0.38	1.34e-17	Asthma;
LGG	cis	rs4704187	0.687	rs1422699	chr5:74442410	G/A	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17309711	chr11:45826527	SLC35C1	0.5	7.85	0.34	2.94e-14	Gut microbiome composition (summer);
LGG	cis	rs4704187	0.687	rs4621540	chr5:74371203	T/G	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs12042938	0.579	rs6692440	chr1:231760047	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.63	-10.86	-0.45	1.22e-24	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs1670533	0.932	rs13140341	chr4:1054235	T/C	cg27284194	chr4:1044797	NA	0.55	9.8	0.41	9.7e-21	Recombination rate (females);
LGG	cis	rs972578	1.000	rs4822244	chr22:43389028	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.77	-0.3	3.86e-11	Mean platelet volume;
LGG	cis	rs10504229	0.683	rs16921829	chr8:58110950	A/G	cg08677398	chr8:58056175	NA	0.51	7.99	0.35	1.05e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.749	rs62226489	chr21:47710519	T/C	cg11766577	chr21:47581405	C21orf56	-0.47	-8.07	-0.35	6.24e-15	Testicular germ cell tumor;
LGG	cis	rs73416724	1.000	rs112870457	chr6:43280714	T/G	cg26312998	chr6:43337775	ZNF318	0.6	8.06	0.35	6.47e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.609	rs6944877	chr7:1952582	T/G	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.24	-0.36	1.8e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs17655565	1.000	rs73309373	chr12:52701409	C/T	cg02645295	chr12:52705424	NA	-0.66	-9.14	-0.39	2.03e-18	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs2243480	1.000	rs316326	chr7:65609453	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs9487094	0.600	rs1885690	chr6:109672998	C/A	cg16315928	chr6:109776240	MICAL1	0.38	6.68	0.3	7.05e-11	Height;
LGG	cis	rs7166081	1.000	rs34296414	chr15:67514409	C/T	cg05925327	chr15:68127851	NA	-0.32	-6.76	-0.3	4.25e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg25856450	chr11:111750277	C11orf1;FDXACB1	-0.46	-6.81	-0.3	3.02e-11	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.547	rs13064064	chr3:52657002	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.0	-0.31	9.31e-12	Bipolar disorder;
LGG	trans	rs6598955	0.671	rs11247905	chr1:26627907	G/C	cg07461501	chr17:79650226	HGS;ARL16	-0.7	-12.47	-0.5	5.76e-31	Obesity-related traits;
LGG	cis	rs2439831	0.681	rs1549525	chr15:43627855	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.64	-0.33	1.24e-13	Lung cancer in ever smokers;
LGG	cis	rs7824557	0.527	rs2572446	chr8:11239565	C/T	cg12395012	chr8:11607386	GATA4	0.4	7.11	0.31	4.47e-12	Retinal vascular caliber;
LGG	cis	rs2204008	0.807	rs11182461	chr12:38539288	T/C	cg13010199	chr12:38710504	ALG10B	0.72	14.69	0.56	2.3e-40	Bladder cancer;
LGG	cis	rs2249694	0.586	rs9418987	chr10:135324409	A/G	cg20169779	chr10:135381914	SYCE1	0.59	8.61	0.37	1.12e-16	Obesity-related traits;
LGG	cis	rs2117029	1.000	rs3782357	chr12:49427652	C/T	cg24176009	chr12:49580217	TUBA1A	0.42	7.54	0.33	2.52e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs17461634	chr15:76764107	G/A	cg23625390	chr15:77176239	SCAPER	0.49	9.68	0.41	2.56e-20	Blood metabolite levels;
LGG	cis	rs2836950	0.545	rs4818001	chr21:40575088	T/C	cg11644478	chr21:40555479	PSMG1	-0.62	-10.34	-0.43	1.06e-22	Menarche (age at onset);
LGG	cis	rs4295623	0.553	rs34962960	chr8:11594597	G/A	cg21775007	chr8:11205619	TDH	-0.46	-7.5	-0.33	3.28e-13	Morning vs. evening chronotype;
LGG	trans	rs2270927	0.510	rs67771044	chr5:75577819	A/G	cg13563193	chr19:33072644	PDCD5	0.84	9.91	0.42	4.03e-21	Mean corpuscular volume;
LGG	cis	rs9311474	0.508	rs1570	chr3:52586682	T/A	cg18404041	chr3:52824283	ITIH1	-0.51	-9.82	-0.42	8.63e-21	Electroencephalogram traits;
LGG	cis	rs9902453	0.967	rs17825877	chr17:28515188	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.53	0.53	2.23e-35	Coffee consumption (cups per day);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg19049616	chr17:58042270	RNFT1	0.44	7.14	0.31	3.59e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs11628318	0.614	rs3825565	chr14:103060465	G/A	cg23461800	chr14:103021989	NA	-0.52	-8.39	-0.36	5.9e-16	Platelet count;
LGG	cis	rs17428076	0.874	rs62182372	chr2:172684487	C/T	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs7618915	0.547	rs11130317	chr3:52731483	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.06	-0.31	5.96e-12	Bipolar disorder;
LGG	cis	rs4665809	1.000	rs10048648	chr2:26320315	T/C	cg22920501	chr2:26401640	FAM59B	-0.37	-7.57	-0.33	1.97e-13	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs4515155	chr4:17696477	G/T	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg26174226	chr8:58114915	NA	-0.44	-6.89	-0.3	1.88e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.41	-0.53	7.33e-35	Response to antipsychotic treatment;
LGG	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg11871910	chr12:69753446	YEATS4	-1.05	-28.78	-0.8	3.58e-105	Cerebrospinal fluid biomarker levels;
LGG	trans	rs1814175	0.645	rs7115592	chr11:50013243	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs514406	0.644	rs1855127	chr1:53199594	A/G	cg24675658	chr1:53192096	ZYG11B	0.62	13.36	0.53	1.15e-34	Monocyte count;
LGG	cis	rs11792861	0.926	rs77567374	chr9:111835034	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.56e-19	Menarche (age at onset);
LGG	trans	rs57221529	0.766	rs12519763	chr5:559145	C/T	cg25482853	chr8:67687455	SGK3	1.03	13.23	0.52	4.2e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs12282928	0.959	rs1503168	chr11:48272696	A/G	cg26585981	chr11:48327164	OR4S1	-0.42	-6.89	-0.3	1.87e-11	Migraine - clinic-based;
LGG	cis	rs736408	0.609	rs13082208	chr3:52781539	T/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.57	0.41	6.34e-20	Bipolar disorder;
LGG	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg25600027	chr14:23388339	RBM23	-0.45	-7.34	-0.32	1e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs10540	1.000	rs61876332	chr11:487101	C/T	cg19913688	chr11:428466	ANO9	-0.71	-8.93	-0.38	1.04e-17	Body mass index;
LGG	cis	rs1065656	0.581	rs1065666	chr16:1839134	T/C	cg00490583	chr16:1843685	IGFALS	0.49	8.48	0.37	3.13e-16	Insulin-like growth factors;
LGG	cis	rs5758659	0.652	rs129857	chr22:42399686	C/T	cg15128208	chr22:42549153	NA	0.37	7.49	0.33	3.5e-13	Cognitive function;
LGG	cis	rs11650494	0.908	rs9891264	chr17:47407342	T/A	cg08112188	chr17:47440006	ZNF652	1.2	14.56	0.56	8.66e-40	Prostate cancer;
LGG	cis	rs35160687	0.644	rs17738058	chr2:86513203	G/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.81	0.3	2.96e-11	Night sleep phenotypes;
LGG	cis	rs11785400	1.000	rs4736368	chr8:143748528	G/C	cg24634471	chr8:143751801	JRK	0.52	8.31	0.36	1.04e-15	Schizophrenia;
LGG	cis	rs7312933	0.703	rs7957471	chr12:42545591	G/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.95	0.31	1.23e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6964587	0.967	rs12535601	chr7:91718346	A/G	cg17063962	chr7:91808500	NA	0.47	8.34	0.36	8.39e-16	Breast cancer;
LGG	cis	rs933688	1.000	rs10045280	chr5:90717675	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	19.11	0.66	1.93e-60	Smoking behavior;
LGG	trans	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.69	-0.34	8.65e-14	Joint mobility (Beighton score);
LGG	cis	rs992157	0.835	rs4674282	chr2:219144230	A/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.4	-0.44	6.48e-23	Colorectal cancer;
LGG	cis	rs79149102	0.579	rs6495146	chr15:75367630	A/T	cg17294928	chr15:75287854	SCAMP5	-0.68	-7.74	-0.34	6.31e-14	Lung cancer;
LGG	cis	rs16976116	0.901	rs9920219	chr15:55503964	T/C	cg11288833	chr15:55489084	RSL24D1	0.57	7.68	0.34	9.55e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs769267	0.930	rs892022	chr19:19613381	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.01	0.55	2.08e-37	Tonsillectomy;
LGG	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg02993010	chr8:124780839	FAM91A1	-0.69	-10.75	-0.45	3.37e-24	Pancreatic cancer;
LGG	cis	rs798554	0.757	rs1182176	chr7:2874601	A/G	cg05793240	chr7:2802953	GNA12	0.35	8.11	0.35	4.42e-15	Height;
LGG	trans	rs9650657	0.504	rs10109167	chr8:11033525	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.97	-0.42	2.5e-21	Neuroticism;
LGG	cis	rs13424612	0.965	rs4149541	chr2:240957734	G/A	cg01812947	chr2:240904978	NDUFA10	0.41	6.92	0.31	1.53e-11	Odorant perception (isobutyraldehyde);
LGG	cis	rs10504229	0.775	rs17216236	chr8:58159352	G/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg08250081	chr4:10125330	NA	-0.36	-6.94	-0.31	1.32e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7219021	0.705	rs12939844	chr17:47025559	T/A	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.95	-0.31	1.27e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs7647973	1.000	rs7647973	chr3:49510931	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.54	-8.29	-0.36	1.22e-15	Menarche (age at onset);
LGG	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg22920501	chr2:26401640	FAM59B	-0.39	-7.68	-0.34	9.44e-14	Gut microbiome composition (summer);
LGG	cis	rs17102423	0.755	rs942627	chr14:65550025	A/G	cg11161011	chr14:65562177	MAX	-0.78	-15.87	-0.59	1.37e-45	Obesity-related traits;
LGG	cis	rs2544527	0.586	rs2544532	chr2:15904993	C/T	cg26669897	chr2:15909070	NA	-0.36	-8.97	-0.38	7.43e-18	Pulmonary function (smoking interaction);Pulmonary function;
LGG	cis	rs988958	0.526	rs12712821	chr2:42238864	C/T	cg27252766	chr2:42229092	NA	0.51	7.01	0.31	8.53e-12	Hypospadias;
LGG	cis	rs3087591	1.000	rs2525578	chr17:29711411	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.68	-13.9	-0.54	5.76e-37	Hip circumference;
LGG	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	trans	rs9467711	0.790	rs55706012	chr6:26266311	A/C	cg01620082	chr3:125678407	NA	-0.85	-7.74	-0.34	6.42e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2839186	0.656	rs4819226	chr21:47712412	A/G	cg12379764	chr21:47803548	PCNT	-0.5	-8.23	-0.36	1.93e-15	Testicular germ cell tumor;
LGG	cis	rs2643217	0.903	rs1472293	chr15:38989919	C/G	cg10631289	chr15:39006617	NA	-0.43	-7.3	-0.32	1.24e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7618501	1.000	rs6446295	chr3:49809063	G/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.88	-0.3	2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1346302	chr10:60267137	G/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.8	-0.64	2.33e-54	Refractive error;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22958951	chr11:119252637	USP2	0.4	6.82	0.3	2.78e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9527	0.590	rs3861984	chr10:104916980	T/C	cg04362960	chr10:104952993	NT5C2	0.55	10.27	0.43	1.97e-22	Arsenic metabolism;
LGG	cis	rs6840360	0.642	rs2709833	chr4:152377622	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.17	0.32	2.94e-12	Intelligence (multi-trait analysis);
LGG	cis	rs55823223	0.646	rs55868394	chr17:73851113	C/A	cg06969265	chr17:73775802	H3F3B	0.9	10.32	0.43	1.28e-22	Psoriasis;
LGG	cis	rs1065852	0.526	rs4822079	chr22:42394612	G/C	cg15128208	chr22:42549153	NA	0.41	7.1	0.31	4.74e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs36071027	0.615	rs13189454	chr5:158410515	C/T	cg04248271	chr5:158524404	EBF1	0.41	7.24	0.32	1.87e-12	Carotid intima media thickness;
LGG	cis	rs7727544	0.904	rs7736102	chr5:131604257	G/A	cg07395648	chr5:131743802	NA	-0.52	-11.9	-0.48	1.08e-28	Blood metabolite levels;
LGG	cis	rs2404602	0.692	rs35170561	chr15:77130695	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.11e-11	Blood metabolite levels;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.01	-0.46	3.4e-25	Intelligence (multi-trait analysis);
LGG	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.49	8.08	0.35	5.75e-15	Colorectal cancer;
LGG	cis	rs7851660	0.809	rs10512255	chr9:100652582	C/T	cg13688889	chr9:100608707	NA	-0.64	-12.55	-0.5	2.56e-31	Strep throat;
LGG	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg15704280	chr7:45808275	SEPT13	0.87	14.71	0.56	1.78e-40	Coronary artery disease;
LGG	cis	rs477692	0.629	rs945231	chr10:131294827	A/G	cg05714579	chr10:131428358	MGMT	0.46	8.78	0.38	3.3e-17	Response to temozolomide;
LGG	cis	rs12701220	0.503	rs12702047	chr7:1132720	G/A	cg02733842	chr7:1102375	C7orf50	-0.5	-7.33	-0.32	1.03e-12	Bronchopulmonary dysplasia;
LGG	trans	rs747782	0.582	rs11039571	chr11:48207259	G/A	cg03929089	chr4:120376271	NA	0.69	7.56	0.33	2.24e-13	Intraocular pressure;
LGG	cis	rs5756813	0.870	rs5756812	chr22:38173113	C/T	cg10587741	chr22:38071170	LGALS1	-0.36	-6.99	-0.31	9.76e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs1218582	0.772	rs10796934	chr1:154849479	C/G	cg06221963	chr1:154839813	KCNN3	-0.53	-11.05	-0.46	2.47e-25	Prostate cancer;
LGG	cis	rs3091242	0.933	rs1534954	chr1:25761924	A/T	cg09222892	chr1:25734099	RHCE	0.45	9.44	0.4	1.86e-19	Erythrocyte sedimentation rate;
LGG	cis	rs2739330	0.760	rs1002286	chr22:24257337	A/G	cg15242686	chr22:24348715	GSTTP1	-0.44	-8.1	-0.35	4.75e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6541297	0.887	rs6541295	chr1:230281698	A/G	cg20703242	chr1:230279135	GALNT2	0.41	7.23	0.32	2.06e-12	Coronary artery disease;
LGG	cis	rs9858542	0.953	rs11713474	chr3:49611457	A/G	cg07274523	chr3:49395745	GPX1	0.57	9.48	0.4	1.28e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9611565	0.546	rs739132	chr22:42123099	A/T	cg06481639	chr22:41940642	POLR3H	0.54	7.61	0.33	1.55e-13	Vitiligo;
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg11878867	chr6:150167359	LRP11	-0.45	-8.03	-0.35	8.39e-15	Lung cancer;
LGG	cis	rs6723226	0.803	rs387780	chr2:32502495	T/C	cg02381751	chr2:32503542	YIPF4	0.76	12.5	0.5	4.44e-31	Intelligence (multi-trait analysis);
LGG	cis	rs12200782	0.505	rs7765920	chr6:26514771	C/T	cg11502198	chr6:26597334	ABT1	0.89	12.9	0.51	9.97e-33	Small cell lung carcinoma;
LGG	cis	rs4481887	0.893	rs10788774	chr1:248471712	T/C	cg01631408	chr1:248437212	OR2T33	-0.54	-9.81	-0.41	8.87e-21	Common traits (Other);
LGG	cis	rs35264875	0.898	rs56140802	chr11:68861631	G/A	cg07882059	chr11:68924751	NA	0.41	7.39	0.32	6.87e-13	Blond vs. brown hair color;
LGG	cis	rs2836950	0.520	rs59916147	chr21:40634702	T/G	cg17971929	chr21:40555470	PSMG1	-0.55	-9.46	-0.4	1.58e-19	Menarche (age at onset);
LGG	cis	rs4642101	0.883	rs11718898	chr3:12848822	T/C	cg05775895	chr3:12838266	CAND2	0.53	8.6	0.37	1.25e-16	QRS complex (12-leadsum);
LGG	cis	rs4689642	1.000	rs11725639	chr4:7216550	A/G	cg21353189	chr4:7228343	SORCS2	0.3	7.52	0.33	2.91e-13	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	10.25	0.43	2.29e-22	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23213688	chr1:231473791	C1orf124;EXOC8	0.5	8.22	0.36	2.1e-15	Cognitive performance;
LGG	cis	rs17376456	0.877	rs13153245	chr5:93374891	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.28	0.43	1.9e-22	Diabetic retinopathy;
LGG	cis	rs2836974	0.666	rs35182074	chr21:40685284	A/C	cg22974920	chr21:40686053	BRWD1	-0.42	-6.8	-0.3	3.32e-11	Cognitive function;
LGG	cis	rs35123781	0.533	rs7728485	chr5:139077144	A/G	cg10513866	chr5:139070639	NA	0.42	8.21	0.36	2.15e-15	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg11494091	chr17:61959527	GH2	1.0	24.71	0.75	1.39e-86	Prudent dietary pattern;
LGG	cis	rs9815354	1.000	rs1716657	chr3:41918456	C/T	cg03022575	chr3:42003672	ULK4	-0.64	-8.26	-0.36	1.5e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3540	0.513	rs2589963	chr15:90922675	A/G	cg22089800	chr15:90895588	ZNF774	0.74	13.56	0.53	1.57e-35	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.42	-8.06	-0.35	6.74e-15	Schizophrenia;
LGG	cis	rs6748734	0.948	rs9973334	chr2:241838142	A/G	cg07537917	chr2:241836409	C2orf54	-0.41	-8.22	-0.36	2.07e-15	Urinary metabolites;
LGG	cis	rs2075371	0.966	rs2544214	chr7:133985736	G/A	cg20476274	chr7:133979776	SLC35B4	0.78	15.72	0.59	6.54e-45	Mean platelet volume;
LGG	cis	rs11711311	1.000	rs2242109	chr3:113434100	G/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.2	0.55	3.15e-38	IgG glycosylation;
LGG	cis	rs4924935	0.683	rs34413375	chr17:18802028	C/A	cg26378065	chr17:18585709	ZNF286B	-0.52	-7.07	-0.31	5.72e-12	Pancreatic cancer;
LGG	cis	rs561341	1.000	rs72825740	chr17:30338356	A/G	cg13647721	chr17:30228624	UTP6	0.62	7.56	0.33	2.18e-13	Hip circumference adjusted for BMI;
LGG	cis	rs7523273	0.565	rs2761420	chr1:207889368	G/T	cg22525895	chr1:207977042	MIR29B2	-0.46	-8.69	-0.37	6.13e-17	Schizophrenia;
LGG	cis	rs6582630	0.560	rs4882325	chr12:38510037	C/T	cg26384229	chr12:38710491	ALG10B	-0.69	-13.99	-0.55	2.35e-37	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg22963979	chr7:1858916	MAD1L1	-0.39	-7.58	-0.33	1.89e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4900069	0.872	rs12883886	chr14:91602024	A/G	cg12167284	chr14:91592793	SNORA11B;C14orf159	-0.39	-6.67	-0.3	7.15e-11	Resting heart rate;
LGG	cis	rs7737355	0.947	rs10067982	chr5:130835940	C/G	cg06307176	chr5:131281290	NA	0.56	9.25	0.39	8.2e-19	Life satisfaction;
LGG	cis	rs10504229	0.683	rs7816733	chr8:58129855	G/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs657075	0.640	rs13167994	chr5:131706823	T/A	cg20453264	chr5:131705742	SLC22A5	0.65	8.18	0.36	2.68e-15	Rheumatoid arthritis;
LGG	cis	rs6489882	0.836	rs6489878	chr12:113368125	A/G	cg25319449	chr12:113376135	OAS3	-0.41	-7.63	-0.33	1.33e-13	Chronic lymphocytic leukemia;
LGG	cis	rs7945718	0.967	rs10765990	chr11:12769444	G/A	cg25843174	chr11:12811716	TEAD1	0.41	8.35	0.36	8.14e-16	Educational attainment (years of education);
LGG	cis	rs769267	1.000	rs12985655	chr19:19442434	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.86	-0.54	8.44e-37	Tonsillectomy;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07786668	chr16:73092391	ZFHX3	0.47	7.4	0.33	6.42e-13	Cognitive performance;
LGG	cis	rs11764590	0.671	rs3800872	chr7:2110272	C/G	cg23422044	chr7:1970798	MAD1L1	-0.52	-9.05	-0.39	3.86e-18	Neuroticism;
LGG	cis	rs8028182	0.636	rs7175852	chr15:75694535	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.52	0.33	2.81e-13	Sudden cardiac arrest;
LGG	cis	rs17270561	0.609	rs9393659	chr6:25731358	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.14	0.43	5.74e-22	Iron status biomarkers;
LGG	cis	rs6502050	0.787	rs8080682	chr17:80058901	G/A	cg11859384	chr17:80120422	CCDC57	0.39	6.76	0.3	4.23e-11	Life satisfaction;
LGG	cis	rs9863	0.828	rs11057412	chr12:124489142	G/C	cg13487667	chr12:124434373	CCDC92	-0.34	-6.88	-0.3	1.89e-11	White blood cell count;
LGG	cis	rs3099143	0.901	rs76101229	chr15:77134975	C/T	cg21673338	chr15:77095150	SCAPER	-0.67	-9.95	-0.42	2.98e-21	Recalcitrant atopic dermatitis;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06873352	chr17:61820015	STRADA	0.74	13.9	0.54	6.13e-37	Prudent dietary pattern;
LGG	cis	rs35306767	0.953	rs12259338	chr10:969377	C/T	cg25019033	chr10:957182	NA	-0.59	-12.59	-0.5	1.91e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs12318506	0.793	rs11180432	chr12:75661314	C/T	cg04728562	chr12:75699417	CAPS2	-1.1	-9.51	-0.4	1.04e-19	Coronary artery calcification;
LGG	cis	rs116095464	0.558	rs10060089	chr5:205565	G/A	cg22496380	chr5:211416	CCDC127	-1.34	-18.64	-0.65	3e-58	Breast cancer;
LGG	cis	rs5758511	0.508	rs2413667	chr22:42472237	A/C	cg15128208	chr22:42549153	NA	0.76	11.29	0.46	2.73e-26	Birth weight;
LGG	trans	rs1945213	0.659	rs2086558	chr11:55844453	T/G	cg15704280	chr7:45808275	SEPT13	0.89	12.6	0.51	1.73e-31	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25367318	chr6:138725211	HEBP2	0.43	6.65	0.3	8.36e-11	Gut microbiome composition (summer);
LGG	cis	rs4774830	0.661	rs12443357	chr15:56305980	C/T	cg05129572	chr15:56138634	NEDD4	0.72	6.91	0.31	1.63e-11	Delta-5 desaturase activity;
LGG	cis	rs4423214	0.879	rs1792282	chr11:71135166	G/A	cg10847948	chr11:71163743	NADSYN1	0.65	11.59	0.47	1.98e-27	Vitamin D levels;
LGG	cis	rs12493885	0.725	rs73158447	chr3:153729792	A/G	cg17054900	chr3:154042577	DHX36	-0.72	-8.75	-0.38	3.92e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4740619	0.647	rs10738415	chr9:15824475	T/A	cg14451791	chr9:16040625	NA	-0.37	-9.48	-0.4	1.29e-19	Body mass index;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	0.3	8.11	0.35	4.44e-15	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs2854221	chr17:61941445	G/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.11	-0.57	3.04e-42	Prudent dietary pattern;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg05313129	chr8:58192883	C8orf71	-0.76	-10.57	-0.44	1.55e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9815354	0.812	rs73071208	chr3:41978738	A/T	cg03022575	chr3:42003672	ULK4	0.81	9.43	0.4	2e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9611565	0.659	rs9611603	chr22:41912750	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-6.84	-0.3	2.45e-11	Vitiligo;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07440826	chr16:89882328	FANCA	-0.26	-6.89	-0.3	1.82e-11	Vitiligo;
LGG	cis	rs9393692	0.645	rs766407	chr6:26319534	T/C	cg13736514	chr6:26305472	NA	-0.49	-9.88	-0.42	5.12e-21	Educational attainment;
LGG	cis	rs7044106	0.537	rs10818474	chr9:123489964	C/T	cg13959647	chr9:123605229	PSMD5;LOC253039	0.46	7.11	0.31	4.53e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	trans	rs9747201	0.962	rs35051180	chr17:80135046	G/A	cg07393940	chr7:158741817	NA	-0.57	-10.5	-0.44	2.74e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2836974	0.965	rs8134733	chr21:40683459	C/T	cg06238570	chr21:40685208	BRWD1	0.45	6.92	0.31	1.51e-11	Cognitive function;
LGG	cis	rs9388451	0.839	rs3757217	chr6:126069636	G/C	cg18424134	chr6:126068038	NA	0.21	6.82	0.3	2.85e-11	Brugada syndrome;
LGG	trans	rs7819412	0.522	rs10101329	chr8:10990672	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.6	-0.33	1.71e-13	Triglycerides;
LGG	cis	rs939658	0.805	rs11638004	chr15:79425765	A/C	cg17916960	chr15:79447300	NA	-0.67	-13.31	-0.53	1.93e-34	Refractive error;
LGG	cis	rs11250098	0.541	rs6997839	chr8:10766028	T/C	cg27411982	chr8:10470053	RP1L1	-0.43	-7.15	-0.32	3.41e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.83	0.3	2.67e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11252926	0.507	rs4881199	chr10:428090	C/G	cg18196295	chr10:418757	DIP2C	0.66	13.48	0.53	3.47e-35	Psychosis in Alzheimer's disease;
LGG	cis	rs10464366	0.544	rs953874	chr7:39147916	G/A	cg15212455	chr7:39170539	POU6F2	0.5	11.72	0.48	5.66e-28	IgG glycosylation;
LGG	cis	rs2735413	0.564	rs8059851	chr16:78118332	A/G	cg04733911	chr16:78082701	NA	0.57	8.06	0.35	6.57e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs73110464	0.609	rs4919752	chr12:53359229	G/C	cg05393297	chr12:53359155	NA	-0.64	-14.84	-0.57	5.15e-41	Cancer (pleiotropy);
LGG	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg02527881	chr3:46936655	PTH1R	0.32	7.6	0.33	1.7e-13	Birth weight;
LGG	trans	rs9467711	0.584	rs34244947	chr6:26761745	T/C	cg08344181	chr3:125677491	NA	-0.74	-7.69	-0.34	9.11e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs7502078	chr17:80131879	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.32	-0.36	9.71e-16	Life satisfaction;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.45	9.64	0.41	3.6e-20	Schizophrenia;
LGG	trans	rs458649	0.947	rs457961	chr5:4277869	A/G	cg06848247	chr2:6635800	NA	0.41	6.72	0.3	5.45e-11	Endometriosis;
LGG	cis	rs76693355	0.512	rs10892569	chr11:120270249	A/G	cg15690696	chr11:120217718	ARHGEF12	-0.43	-6.7	-0.3	5.98e-11	Intraocular pressure;
LGG	cis	rs7296418	0.754	rs1619283	chr12:123717362	A/G	cg05973401	chr12:123451056	ABCB9	0.48	7.97	0.35	1.26e-14	Platelet count;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.44	7.26	0.32	1.61e-12	Tonsillectomy;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.3	0.4	5.7e-19	Height;
LGG	trans	rs1032833	0.732	rs79640162	chr2:180005464	T/C	cg23654767	chr2:101192981	PDCL3	0.68	8.2	0.36	2.47e-15	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg23045935	chr7:21583304	DNAH11	0.42	9.27	0.4	6.86e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs300774	0.748	rs413523	chr2:131203	C/G	cg04617936	chr2:214353	NA	-0.52	-7.85	-0.34	2.88e-14	Suicide attempts in bipolar disorder;
LGG	trans	rs6598955	0.671	rs10902732	chr1:26606174	A/C	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs7084402	0.565	rs11006187	chr10:60333383	A/G	cg07615347	chr10:60278583	BICC1	-0.51	-12.59	-0.5	1.84e-31	Refractive error;
LGG	cis	rs12681287	0.570	rs10956830	chr8:87430483	T/A	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs7937840	0.581	rs4963286	chr11:61887232	C/A	cg01969543	chr11:61895209	INCENP	-0.48	-9.69	-0.41	2.48e-20	Breast cancer;
LGG	cis	rs2439831	0.867	rs8041132	chr15:43635136	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	trans	rs72991	0.793	rs4936619	chr11:121228469	T/C	cg27192990	chr6:129479024	LAMA2	-0.43	-7.19	-0.32	2.66e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs11098499	0.954	rs13133522	chr4:120324424	A/T	cg09307838	chr4:120376055	NA	0.81	13.52	0.53	2.53e-35	Corneal astigmatism;
LGG	cis	rs741702	0.928	rs2974749	chr19:13038791	A/G	cg04657146	chr19:12876947	HOOK2	0.45	7.33	0.32	1.04e-12	Red blood cell traits;
LGG	trans	rs7613875	0.537	rs6446195	chr3:50070853	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.76	-0.3	4.06e-11	Body mass index;
LGG	cis	rs1908814	0.516	rs4841641	chr8:11798227	G/A	cg12395012	chr8:11607386	GATA4	-0.42	-7.67	-0.34	1.03e-13	Neuroticism;
LGG	cis	rs5769765	0.778	rs4574208	chr22:50256738	C/T	cg26441486	chr22:50317300	CRELD2	-0.4	-7.4	-0.33	6.48e-13	Schizophrenia;
LGG	cis	rs6121246	0.529	rs6060171	chr20:30183269	C/T	cg13852791	chr20:30311386	BCL2L1	0.63	8.48	0.37	3.06e-16	Mean corpuscular hemoglobin;
LGG	cis	rs1322639	0.614	rs9455889	chr6:169566087	A/T	cg04662567	chr6:169592167	NA	-0.78	-11.28	-0.46	2.96e-26	Pulse pressure;
LGG	cis	rs7666738	0.800	rs10008654	chr4:98820498	C/A	cg05340658	chr4:99064831	C4orf37	0.48	7.82	0.34	3.57e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7172689	1.000	rs60317813	chr15:81533000	T/G	cg11808699	chr15:81528661	IL16	-0.49	-9.97	-0.42	2.52e-21	Inattentive symptoms;
LGG	cis	rs2153535	0.580	rs1932282	chr6:8477330	G/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs1552244	0.816	rs17050701	chr3:10041554	A/G	cg08888203	chr3:10149979	C3orf24	0.51	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.71	-8.46	-0.37	3.45e-16	Schizophrenia;
LGG	cis	rs2386661	0.826	rs10795723	chr10:5675983	C/T	cg26603656	chr10:5671107	NA	0.39	7.73	0.34	6.63e-14	Breast cancer;
LGG	cis	rs2404602	0.692	rs67570291	chr15:77020502	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.82	-0.3	2.9100000000000002e-11	Blood metabolite levels;
LGG	cis	rs9611565	0.729	rs73176686	chr22:41782119	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-12.8	-0.51	2.44e-32	Vitiligo;
LGG	cis	rs7216064	1.000	rs62084208	chr17:65827443	C/T	cg12091567	chr17:66097778	LOC651250	-0.6	-8.53	-0.37	2.09e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs3091242	0.933	rs12402120	chr1:25751632	C/T	cg03538708	chr1:25844672	NA	-0.34	-6.68	-0.3	6.86e-11	Erythrocyte sedimentation rate;
LGG	cis	rs6724607	1.000	rs28452331	chr2:191471847	C/T	cg21644426	chr2:191273491	MFSD6	-0.59	-10.23	-0.43	2.81e-22	Pulse pressure;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.03	-0.35	8.22e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.765	rs28604950	chr22:41785812	A/G	cg06634786	chr22:41940651	POLR3H	-0.74	-12.5	-0.5	4.2e-31	Vitiligo;
LGG	cis	rs2386661	0.547	rs11259582	chr10:5646767	C/T	cg12223502	chr10:5658492	NA	-0.37	-7.1	-0.31	4.69e-12	Breast cancer;
LGG	cis	rs7168592	1.000	rs67175901	chr15:101748227	C/T	cg24254196	chr15:101719523	CHSY1	-0.62	-6.79	-0.3	3.45e-11	Neutrophil count;Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil percentage of white cells;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.03	0.31	7.4e-12	Lung cancer;
LGG	cis	rs9467711	0.606	rs4634439	chr6:26598004	C/T	cg12826209	chr6:26865740	GUSBL1	-0.75	-8.11	-0.35	4.46e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7.07e-23	Bipolar disorder;
LGG	cis	rs7954584	0.523	rs11043280	chr12:122426643	T/C	cg01765077	chr12:122356316	WDR66	0.28	7.42	0.33	5.49e-13	Mean corpuscular volume;
LGG	cis	rs11123170	0.543	rs2863242	chr2:113989236	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.63	0.33	1.37e-13	Renal function-related traits (BUN);
LGG	trans	rs62103177	0.733	rs62103193	chr18:77629217	C/T	cg05926928	chr17:57297772	GDPD1	1.36	21.6	0.71	4.56e-72	Opioid sensitivity;
LGG	cis	rs12931792	0.712	rs4787495	chr16:30165725	C/T	cg17640201	chr16:30407289	ZNF48	-0.49	-8.46	-0.37	3.52e-16	Tonsillectomy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04191342	chr3:62859289	CADPS	0.53	8.03	0.35	7.85e-15	Gut microbiome composition (summer);
LGG	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg14912033	chr15:79043428	NA	0.37	8.35	0.36	8.19e-16	Coronary artery disease or large artery stroke;
LGG	trans	rs11650494	0.710	rs77653195	chr17:47468868	A/T	cg11430096	chr6:110968061	CDK19	0.68	6.7	0.3	5.94e-11	Prostate cancer;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07362569	chr17:61921086	SMARCD2	-0.48	-8.85	-0.38	1.84e-17	Prudent dietary pattern;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg02951883	chr7:2050386	MAD1L1	0.73	14.86	0.57	4.12e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.85	-0.3	2.3e-11	Total body bone mineral density;
LGG	cis	rs4930561	0.714	rs7950451	chr11:67962406	C/A	cg16338278	chr11:67432957	ALDH3B2	0.42	7.84	0.34	3.13e-14	Breast cancer in childhood cancer survivors;IgG glycosylation;
LGG	cis	rs6879260	0.928	rs11739624	chr5:179727290	T/C	cg23248424	chr5:179741104	GFPT2	-0.59	-10.13	-0.43	6.31e-22	Height;
LGG	cis	rs9921192	0.967	rs251737	chr16:4318305	C/T	cg13035052	chr16:4323854	TFAP4	0.45	7.78	0.34	4.7e-14	Prostate-specific antigen levels;
LGG	cis	rs929354	0.772	rs6957939	chr7:156978485	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.09e-13	Body mass index;
LGG	trans	rs61931739	0.500	rs34418276	chr12:34535976	C/T	cg26384229	chr12:38710491	ALG10B	0.96	20.52	0.69	4.83e-67	Morning vs. evening chronotype;
LGG	cis	rs7929679	0.571	rs2136508	chr11:34796846	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.89	0.3	1.84e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs9894429	1.000	rs7223613	chr17:79574803	C/T	cg18240062	chr17:79603768	NPLOC4	-0.75	-13.86	-0.54	8.31e-37	Eye color traits;
LGG	cis	rs8062405	0.965	rs56040780	chr16:28861881	C/T	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1018697	1.000	rs11191397	chr10:104558274	C/A	cg04362960	chr10:104952993	NT5C2	0.49	9.1	0.39	2.68e-18	Colorectal adenoma (advanced);
LGG	cis	rs477895	0.838	rs11605738	chr11:64013406	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.94	0.35	1.56e-14	Mean platelet volume;
LGG	trans	rs7762018	0.891	rs7740218	chr6:170141552	G/A	cg11441553	chr12:57614120	NXPH4	-0.57	-7.31	-0.32	1.15e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4740619	0.967	rs10756689	chr9:15660904	C/T	cg14451791	chr9:16040625	NA	-0.38	-9.92	-0.42	3.73e-21	Body mass index;
LGG	cis	rs6800768	0.658	rs6550848	chr3:24145084	C/T	cg10674438	chr3:24145617	LOC152024	0.34	6.98	0.31	1.02e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12367572	0.601	rs1495036	chr12:45410643	T/C	cg03114573	chr12:45410052	DBX2	-0.68	-12.42	-0.5	8.88e-31	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.897	rs2315554	chr4:17660407	T/C	cg02297831	chr4:17616191	MED28	0.5	8.8	0.38	2.73e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg02428538	chr16:24856791	SLC5A11	-0.67	-10.21	-0.43	3.24e-22	Intelligence (multi-trait analysis);
LGG	cis	rs4478037	0.822	rs59834381	chr3:33116313	G/A	cg19404215	chr3:33155277	CRTAP	0.81	9.51	0.4	1.01e-19	Major depressive disorder;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.68	-0.34	9.74e-14	Lung cancer;
LGG	trans	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.04e-12	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs2562456	0.837	rs62110205	chr19:21760071	A/G	cg25042112	chr7:64838748	ZNF92	-0.48	-6.84	-0.3	2.59e-11	Pain;
LGG	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.26	0.75	1.7e-84	Chronic sinus infection;
LGG	cis	rs36071027	0.593	rs11745589	chr5:158428274	A/T	cg00594129	chr5:158524270	EBF1	0.45	8.1	0.35	4.88e-15	Carotid intima media thickness;
LGG	cis	rs72615157	0.595	rs112241539	chr7:99847237	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.79	10.98	0.45	4.48e-25	Lung function (FEV1/FVC);
LGG	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg07005078	chr4:17578674	LAP3	0.38	6.75	0.3	4.43e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs75920871	0.528	rs11216241	chr11:116899249	A/C	cg20608306	chr11:116969690	SIK3	-0.38	-10.38	-0.43	7.79e-23	Subjective well-being;
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22618164	chr12:122356400	WDR66	0.38	11.13	0.46	1.16e-25	Mean corpuscular volume;
LGG	cis	rs6450176	0.564	rs255759	chr5:53328549	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.68	-11.23	-0.46	5e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.41	0.53	7.18e-35	Height;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-10.96	-0.45	5.25e-25	Personality dimensions;
LGG	cis	rs7617773	0.501	rs12185901	chr3:48382919	G/T	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs2836974	0.644	rs2836981	chr21:40688365	C/T	cg06238570	chr21:40685208	BRWD1	-0.51	-8.35	-0.36	7.75e-16	Cognitive function;
LGG	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg20026190	chr17:76395443	PGS1	0.57	10.07	0.42	1.02e-21	HDL cholesterol levels;
LGG	cis	rs6951245	0.745	rs79788515	chr7:1101079	C/T	cg02733842	chr7:1102375	C7orf50	0.75	11.15	0.46	1.01e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1862618	0.853	rs6450408	chr5:56098146	T/C	cg08400814	chr5:56204995	C5orf35	-0.47	-7.5	-0.33	3.35e-13	Initial pursuit acceleration;
LGG	cis	rs10911251	0.528	rs4652779	chr1:183104552	G/A	cg07928641	chr1:182991847	LAMC1	0.44	8.78	0.38	3.18e-17	Colorectal cancer;
LGG	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg03342759	chr3:160939853	NMD3	-0.73	-12.2	-0.49	7.12e-30	Parkinson's disease;
LGG	cis	rs12200782	0.530	rs9379892	chr6:26582414	G/A	cg18867708	chr6:26865862	GUSBL1	0.48	6.69	0.3	6.51e-11	Small cell lung carcinoma;
LGG	cis	rs9322193	0.632	rs3828700	chr6:150112169	C/G	cg02462569	chr6:150064036	NUP43	-0.36	-7.6	-0.33	1.61e-13	Lung cancer;
LGG	cis	rs10479542	0.892	rs7736163	chr5:178980316	G/C	cg26516362	chr5:178986906	RUFY1	0.43	7.94	0.35	1.53e-14	Lung cancer;
LGG	cis	rs3784262	0.904	rs3784260	chr15:58253269	T/G	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.17	-0.35	2.95e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6088580	0.609	rs945674	chr20:32964247	G/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.27	-0.36	1.42e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7208859	0.673	rs11658435	chr17:29228561	A/G	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7191439	0.858	rs4238685	chr16:88775220	T/C	cg27087555	chr16:88793112	FAM38A	-1.43	-18.54	-0.65	8.31e-58	Plateletcrit;
LGG	cis	rs763014	0.932	rs35067229	chr16:649638	T/C	cg04911050	chr16:677664	RAB40C	0.33	6.65	0.3	8.31e-11	Height;
LGG	cis	rs1497828	0.956	rs2810782	chr1:217544443	C/G	cg04411442	chr1:217543379	NA	0.47	7.96	0.35	1.31e-14	Dialysis-related mortality;
LGG	cis	rs2247341	1.000	rs13124276	chr4:1700368	C/T	cg05026014	chr4:1749153	NA	-0.3	-8.0	-0.35	9.96e-15	Hip circumference adjusted for BMI;Height;
LGG	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.43e-12	Self-reported allergy;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg00149659	chr3:10157352	C3orf10	0.87	11.23	0.46	4.6e-26	Alzheimer's disease;
LGG	cis	rs9487094	0.614	rs11968978	chr6:110096896	A/G	cg16315928	chr6:109776240	MICAL1	0.48	7.61	0.33	1.54e-13	Height;
LGG	cis	rs734999	0.545	rs10797441	chr1:2551660	T/G	cg15627072	chr1:2432621	PLCH2	0.36	7.99	0.35	1.07e-14	Ulcerative colitis;
LGG	cis	rs6951245	1.000	rs113858334	chr7:1073476	A/G	cg03188948	chr7:1209495	NA	0.65	8.47	0.37	3.26e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11864453	0.826	rs2240243	chr16:72137561	A/G	cg23815491	chr16:72088622	HP	-0.49	-10.79	-0.45	2.23e-24	Fibrinogen levels;
LGG	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg05973401	chr12:123451056	ABCB9	-0.44	-7.41	-0.33	6.06e-13	Neutrophil percentage of white cells;
LGG	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11644478	chr21:40555479	PSMG1	-0.75	-13.76	-0.54	2.26e-36	Cognitive function;
LGG	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg04450456	chr4:17643702	FAM184B	0.33	7.34	0.32	9.55e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11098499	0.863	rs3775843	chr4:120427844	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.71e-27	Corneal astigmatism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12909921	chr17:37558512	FBXL20	0.45	6.99	0.31	9.89e-12	Gut microbiome composition (summer);
LGG	cis	rs490234	0.702	rs10120000	chr9:128288428	C/T	cg14078157	chr9:128172775	NA	-0.56	-10.51	-0.44	2.59e-23	Mean arterial pressure;
LGG	cis	rs6547741	1.000	rs11127071	chr2:27838058	C/A	cg27432699	chr2:27873401	GPN1	0.7	14.26	0.55	1.64e-38	Oral cavity cancer;
LGG	cis	rs6450176	0.909	rs12659966	chr5:53292892	C/G	ch.5.1024479R	chr5:53302184	ARL15	0.68	11.17	0.46	7.93e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs9487094	0.567	rs13196280	chr6:110085366	G/T	cg16315928	chr6:109776240	MICAL1	0.49	7.91	0.35	1.89e-14	Height;
LGG	cis	rs7647973	0.626	rs12715437	chr3:49751856	T/C	cg03060546	chr3:49711283	APEH	0.6	8.45	0.37	3.75e-16	Menarche (age at onset);
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.55	9.16	0.39	1.7e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17209837	0.646	rs11532733	chr7:87117982	A/G	cg00919237	chr7:87102261	ABCB4	-0.78	-15.04	-0.57	6.4e-42	Gallbladder cancer;
LGG	cis	rs2718058	0.836	rs4723711	chr7:37844263	T/A	cg24998770	chr7:37888106	TXNDC3	-0.45	-8.46	-0.37	3.64e-16	Alzheimer's disease (late onset);
LGG	cis	rs11055008	0.868	rs10845602	chr12:12825237	A/G	cg09462578	chr12:12878428	APOLD1	-0.47	-7.68	-0.34	9.37e-14	Pulse pressure;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.43	0.4	1.93e-19	Longevity;
LGG	cis	rs1129187	0.755	rs9462855	chr6:42925936	G/C	cg05552183	chr6:42928497	GNMT	0.44	13.19	0.52	5.79e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6032067	0.683	rs34508373	chr20:43788087	T/C	cg10761708	chr20:43804764	PI3	0.59	9.06	0.39	3.81e-18	Blood protein levels;
LGG	cis	rs7089973	0.604	rs7923693	chr10:116619566	A/G	cg08188268	chr10:116634841	FAM160B1	0.31	6.86	0.3	2.28e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg15383120	chr6:291909	DUSP22	-0.56	-9.21	-0.39	1.16e-18	Menopause (age at onset);
LGG	cis	rs883565	0.528	rs6599271	chr3:38970730	A/G	cg01426195	chr3:39028469	NA	0.59	12.39	0.5	1.23e-30	Handedness;
LGG	cis	rs67311347	1.000	rs7633809	chr3:40517737	A/G	cg13683864	chr3:40499215	RPL14	1.16	29.45	0.81	3.57e-108	Renal cell carcinoma;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg07503684	chr12:54121449	CALCOCO1	0.41	6.91	0.31	1.62e-11	Bipolar disorder;
LGG	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.6	0.47	1.74e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2124969	0.527	rs72982044	chr2:161049395	G/A	cg03641300	chr2:160917029	PLA2R1	-0.62	-9.19	-0.39	1.29e-18	Waist circumference adjusted for body mass index;
LGG	trans	rs9650657	0.812	rs4240669	chr8:10629987	C/T	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.01	-0.31	8.26e-12	Neuroticism;
LGG	cis	rs10799590	1.000	rs6667034	chr1:224823056	C/T	cg01808320	chr1:224927238	CNIH3	-0.37	-6.7	-0.3	6.01e-11	Opioid dependence;
LGG	trans	rs4688759	0.719	rs73079018	chr3:49875327	T/C	cg21659725	chr3:3221576	CRBN	-0.67	-6.74	-0.3	4.78e-11	Blood protein levels;
LGG	cis	rs881375	1.000	rs10760118	chr9:123641616	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.62	11.5	0.47	4.1e-27	Rheumatoid arthritis;
LGG	cis	rs2839186	0.934	rs17176520	chr21:47682081	T/C	cg12016809	chr21:47604291	C21orf56	0.5	8.44	0.37	4.2e-16	Testicular germ cell tumor;
LGG	cis	rs3749237	0.964	rs11714957	chr3:49776178	C/T	cg02487422	chr3:49467188	NICN1	0.43	6.99	0.31	9.71e-12	Resting heart rate;
LGG	cis	rs8031584	0.672	rs17815726	chr15:31313252	C/G	cg08109568	chr15:31115862	NA	0.48	7.47	0.33	4.12e-13	Huntington's disease progression;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.25	-0.32	1.78e-12	Menopause (age at onset);
LGG	cis	rs3096299	0.900	rs744327	chr16:89439270	C/T	cg06640241	chr16:89574553	SPG7	0.7	12.08	0.49	2.21e-29	Multiple myeloma (IgH translocation);
LGG	cis	rs7833790	0.963	rs7836040	chr8:82698328	G/A	cg23324259	chr8:82754387	SNX16	-0.45	-7.33	-0.32	1.03e-12	Diastolic blood pressure;
LGG	cis	rs11583043	0.708	rs874905	chr1:101539702	G/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	8.07	0.35	6.32e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs644799	1.000	rs586498	chr11:95537828	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs881375	0.967	rs7864019	chr9:123692868	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.83	0.48	2.17e-28	Rheumatoid arthritis;
LGG	cis	rs735860	0.712	rs3736732	chr6:53160383	G/T	cg10236188	chr6:53219634	NA	-0.41	-7.98	-0.35	1.18e-14	Glaucoma;
LGG	trans	rs7937682	0.587	rs571594	chr11:111359334	A/G	cg18187862	chr3:45730750	SACM1L	-0.43	-7.4	-0.33	6.45e-13	Primary sclerosing cholangitis;
LGG	cis	rs7100689	0.580	rs7083519	chr10:82207524	C/G	cg00277334	chr10:82204260	NA	-0.45	-9.62	-0.41	4.13e-20	Post bronchodilator FEV1;
LGG	cis	rs11690935	0.959	rs10194102	chr2:172626143	G/C	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.76	-0.78	5.01e-96	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12529055	chr3:137906050	ARMC8	0.47	6.85	0.3	2.43e-11	Gut microbiome composition (summer);
LGG	cis	rs977987	0.645	rs34904236	chr16:75498253	G/T	cg07303275	chr16:75499416	TMEM170A	0.41	7.35	0.32	8.93e-13	Dupuytren's disease;
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.7	-12.71	-0.51	5.65e-32	Longevity;Endometriosis;
LGG	cis	rs4417704	0.578	rs4675842	chr2:241876480	C/G	cg05025159	chr2:241905733	NA	-0.48	-9.69	-0.41	2.51e-20	Joint mobility (Beighton score);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12924588	chr2:68694517	APLF;FBXO48	0.43	6.96	0.31	1.21e-11	Cognitive performance;
LGG	cis	rs7945705	0.714	rs2653570	chr11:8987823	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.54	-11.67	-0.48	8.89e-28	Hemoglobin concentration;
LGG	cis	rs2797369	0.713	rs4240592	chr6:101550593	G/A	cg27451362	chr6:101846650	GRIK2	-0.85	-11.52	-0.47	3.65e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs727505	1.000	rs6952721	chr7:124480075	T/C	cg23710748	chr7:124431027	NA	-0.48	-9.19	-0.39	1.38e-18	Lewy body disease;
LGG	cis	rs17270561	0.609	rs9379788	chr6:25742759	A/C	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.12	-0.49	1.54e-29	Depression;
LGG	trans	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg06521331	chr12:34319734	NA	0.46	8.06	0.35	6.64e-15	Bladder cancer;
LGG	cis	rs7726839	0.540	rs11738281	chr5:662547	T/C	cg14541582	chr5:601475	NA	-0.71	-10.82	-0.45	1.82e-24	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20560182	chr5:140700478	TAF7	0.45	7.12	0.31	4.11e-12	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14022322	chr14:104206702	PPP1R13B	0.41	7.09	0.31	5.14e-12	Gut microbiome composition (summer);
LGG	cis	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg00405596	chr8:11794950	NA	-0.41	-6.78	-0.3	3.63e-11	Triglycerides;
LGG	cis	rs1957429	0.808	rs8009510	chr14:65351338	T/G	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs11622475	1.000	rs2368984	chr14:104372055	A/C	cg12183467	chr14:104352244	NA	-0.45	-7.76	-0.34	5.45e-14	Bipolar disorder;
LGG	cis	rs4650994	0.816	rs1074896	chr1:178591190	A/G	cg19399532	chr1:178512495	C1orf220	-0.36	-6.92	-0.31	1.5e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4604732	0.527	rs12031949	chr1:247624463	G/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.77e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	trans	rs8002861	0.870	rs2121030	chr13:44444574	C/T	cg12856521	chr11:46389249	DGKZ	-0.4	-6.77	-0.3	3.99e-11	Leprosy;
LGG	cis	rs2073499	0.935	rs2526396	chr3:50188309	C/T	cg03645007	chr3:50255295	SLC38A3	0.61	6.84	0.3	2.46e-11	Schizophrenia;
LGG	cis	rs4788570	0.667	rs9302630	chr16:71789529	A/C	cg06353428	chr16:71660113	MARVELD3	1.26	20.24	0.69	1.04e-65	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg14926445	chr8:58193284	C8orf71	-0.85	-10.4	-0.44	6.65e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9644630	0.965	rs10105097	chr8:19364883	A/C	cg01280390	chr8:19363452	CSGALNACT1	-0.62	-17.89	-0.64	8.57e-55	Oropharynx cancer;
LGG	trans	rs2008242	0.593	rs985222	chr4:5229884	A/G	cg26099876	chr8:141644609	EIF2C2	-0.53	-10.26	-0.43	2.18e-22	Electrocardiographic conduction measures;
LGG	cis	rs703842	0.616	rs870392	chr12:58219173	C/A	cg00677455	chr12:58241039	CTDSP2	0.44	7.85	0.34	2.89e-14	Multiple sclerosis;
LGG	trans	rs9650657	0.740	rs10481451	chr8:10649328	A/G	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.1	-0.31	4.79e-12	Neuroticism;
LGG	cis	rs9894429	0.646	rs7405937	chr17:79597811	G/A	cg10661904	chr17:79619235	PDE6G	-0.49	-10.04	-0.42	1.36e-21	Eye color traits;
LGG	cis	rs7927592	0.956	rs10896337	chr11:68284236	T/C	cg16797656	chr11:68205561	LRP5	0.39	6.88	0.3	2e-11	Total body bone mineral density;
LGG	cis	rs7617773	0.780	rs77044321	chr3:48349314	C/T	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs6840360	0.642	rs2724551	chr4:152355383	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3857536	0.776	rs7765531	chr6:66932886	G/A	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.41e-14	Blood trace element (Cu levels);
LGG	cis	rs34233420	1	rs34233420	chr17:38004929	GATTT/G	cg00129232	chr17:37814104	STARD3	-0.44	-8.09	-0.35	5.14e-15	Lymphocyte counts;
LGG	cis	rs7566780	0.549	rs6746795	chr2:16682166	A/G	cg09580478	chr2:16689509	NA	0.45	6.75	0.3	4.44e-11	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs9463078	0.683	rs227848	chr6:44698499	G/A	cg25276700	chr6:44698697	NA	0.43	8.86	0.38	1.77e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.67	0.34	1.03e-13	Lung cancer;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4595586	0.525	rs12812749	chr12:39363254	C/T	cg26384229	chr12:38710491	ALG10B	0.59	10.51	0.44	2.55e-23	Morning vs. evening chronotype;
LGG	cis	rs11711311	0.911	rs34337798	chr3:113396704	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.3	-0.32	1.25e-12	IgG glycosylation;
LGG	cis	rs9486719	0.947	rs11153071	chr6:97039741	G/A	cg06623918	chr6:96969491	KIAA0776	-0.76	-10.71	-0.45	4.5e-24	Migraine;Coronary artery disease;
LGG	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg02002194	chr4:3960332	NA	-0.52	-9.69	-0.41	2.43e-20	Retinal vascular caliber;
LGG	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg15269541	chr15:43626905	ADAL	-0.43	-7.15	-0.32	3.43e-12	Lung cancer in ever smokers;
LGG	cis	rs701145	0.585	rs1542254	chr3:153864296	C/T	cg12800244	chr3:153838788	SGEF	0.77	8.47	0.37	3.18e-16	Coronary artery disease;
LGG	cis	rs1008375	1.000	rs12507142	chr4:17656103	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.27	0.32	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg02182803	chr16:29823685	PRRT2	0.46	6.81	0.3	3.12e-11	Hip circumference;
LGG	cis	rs6750047	0.585	rs62136319	chr2:38272950	G/A	cg07380506	chr2:38303506	CYP1B1	0.44	7.21	0.32	2.3e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs9790314	0.695	rs7637086	chr3:160836822	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-10.97	-0.45	4.88e-25	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.54	-0.44	2.04e-23	Platelet count;
LGG	cis	rs35306767	0.903	rs12769431	chr10:922633	T/C	cg08847335	chr10:891726	LARP4B	-0.5	-9.02	-0.39	5.1e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12550012	chr3:106959716	LOC344595;LOC100302640	0.48	7.68	0.34	9.54e-14	Gut microbiome composition (summer);
LGG	trans	rs3808502	0.527	rs4410870	chr8:11156120	C/G	cg02002194	chr4:3960332	NA	0.45	8.26	0.36	1.56e-15	Neuroticism;
LGG	cis	rs4242434	0.672	rs10113779	chr8:22485934	G/C	cg02227867	chr8:22457446	C8orf58	-0.4	-7.62	-0.33	1.48e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2032447	0.639	rs198810	chr6:26128618	A/G	cg03264133	chr6:25882463	NA	0.51	9.28	0.4	6.45e-19	Intelligence (multi-trait analysis);
LGG	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg24231037	chr15:68117551	LBXCOR1	-0.38	-8.35	-0.36	7.87e-16	Restless legs syndrome;
LGG	cis	rs7267979	1.000	rs2258769	chr20:25276680	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10046574	0.519	rs34274894	chr7:135214725	G/C	cg27474649	chr7:135195673	CNOT4	0.71	9.01	0.39	5.5e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01754028	chr2:159825833	TANC1	0.41	6.65	0.3	8.42e-11	Cognitive performance;
LGG	cis	rs763121	0.853	rs2267393	chr22:39101619	G/C	cg06022373	chr22:39101656	GTPBP1	0.91	18.9	0.66	1.89e-59	Menopause (age at onset);
LGG	cis	rs9880211	0.821	rs9832813	chr3:136065565	A/G	cg21827317	chr3:136751795	NA	-0.56	-9.48	-0.4	1.31e-19	Body mass index;Height;
LGG	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.8	-14.24	-0.55	1.95e-38	Response to antipsychotic treatment;
LGG	cis	rs963731	0.579	rs10166631	chr2:39220510	C/G	cg04010122	chr2:39346883	SOS1	-0.67	-6.94	-0.31	1.31e-11	Corticobasal degeneration;
LGG	cis	rs9790314	1.000	rs3849524	chr3:161015589	C/T	cg03342759	chr3:160939853	NMD3	-0.65	-11.57	-0.47	2.31e-27	Morning vs. evening chronotype;
LGG	cis	rs4713118	0.587	rs61471148	chr6:28037032	T/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	9.15e-14	Parkinson's disease;
LGG	cis	rs17102423	0.723	rs55658675	chr14:65554638	C/T	cg26396452	chr14:65542826	MAX	0.42	8.41	0.36	5.14e-16	Obesity-related traits;
LGG	trans	rs11039798	0.920	rs116109043	chr11:48976940	C/T	cg03929089	chr4:120376271	NA	0.73	8.43	0.36	4.47e-16	Axial length;
LGG	cis	rs4132509	0.947	rs320339	chr1:243870910	G/T	cg25706552	chr1:244017396	NA	0.53	8.53	0.37	2.14e-16	RR interval (heart rate);
LGG	cis	rs60180747	0.544	rs1020927	chr15:66551258	G/C	cg07575407	chr15:66541975	MEGF11	0.64	13.6	0.53	1.1e-35	Testicular germ cell tumor;
LGG	cis	rs981844	1.000	rs2606342	chr4:154659980	C/A	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs2153535	0.580	rs6927589	chr6:8456632	A/G	cg21535247	chr6:8435926	SLC35B3	-0.58	-9.92	-0.42	3.7e-21	Motion sickness;
LGG	cis	rs8064299	0.967	rs880827	chr17:72767435	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	-0.65	-12.6	-0.51	1.59e-31	Monocyte count;
LGG	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-9.97	-0.42	2.42e-21	Response to antipsychotic treatment;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06936108	chr17:7894917	NA	-0.57	-7.11	-0.31	4.48e-12	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.45	0.37	3.71e-16	Retinal vascular caliber;
LGG	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg06212747	chr3:49208901	KLHDC8B	0.45	6.85	0.3	2.37e-11	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs714031	0.934	rs9607667	chr22:40077488	C/T	cg21377881	chr22:40064566	CACNA1I	-0.63	-14.88	-0.57	3.28e-41	Schizophrenia;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.5	-0.4	1.11e-19	Obesity-related traits;
LGG	cis	rs73110464	0.609	rs11170348	chr12:53355588	A/G	cg16329197	chr12:53359506	NA	-0.66	-11.53	-0.47	3.33e-27	Cancer (pleiotropy);
LGG	cis	rs12210905	1.000	rs9368493	chr6:27228300	T/G	cg15325629	chr6:28072465	NA	0.71	6.67	0.3	7.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs6977660	1.000	rs6959889	chr7:19822024	A/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.88	0.38	1.44e-17	Thyroid stimulating hormone;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg12531328	chr13:31192104	USPL1	0.44	6.71	0.3	5.8e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs751728	0.648	rs6922275	chr6:33749739	G/A	cg25922239	chr6:33757077	LEMD2	0.42	7.39	0.33	6.7e-13	Crohn's disease;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg23978390	chr7:1156363	C7orf50	0.51	8.49	0.37	2.79e-16	Longevity;Endometriosis;
LGG	trans	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.36	0.43	9.51e-23	Ulcerative colitis;
LGG	cis	rs1620921	0.657	rs7383738	chr6:161276047	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.27	-0.32	1.52e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs4819052	0.851	rs2838826	chr21:46655785	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.24	0.36	1.75e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs977987	0.778	rs11862719	chr16:75431708	T/A	cg03315344	chr16:75512273	CHST6	0.5	10.05	0.42	1.29e-21	Dupuytren's disease;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.22	-0.32	2.21e-12	Menopause (age at onset);
LGG	cis	rs1519814	0.659	rs6469891	chr8:121037417	A/C	cg22335954	chr8:121166405	COL14A1	-0.48	-8.69	-0.37	6.41e-17	Breast cancer;
LGG	cis	rs2304069	0.954	rs216125	chr5:149428395	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.89	13.53	0.53	2.14e-35	HIV-1 control;
LGG	cis	rs11155671	0.530	rs9322228	chr6:150209309	C/G	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs4909189	0.957	rs35750670	chr7:158137569	C/T	cg15736062	chr7:158136485	PTPRN2	-0.51	-9.02	-0.39	4.83e-18	Response to amphetamines;
LGG	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs2836974	0.899	rs35774464	chr21:40580169	G/A	cg11890956	chr21:40555474	PSMG1	1.17	27.66	0.79	3.87e-100	Cognitive function;
LGG	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg01221209	chr5:554886	NA	-0.48	-7.99	-0.35	1.08e-14	Obesity-related traits;
LGG	cis	rs8141529	0.748	rs132533	chr22:29299571	A/G	cg02153584	chr22:29168773	CCDC117	-0.59	-9.39	-0.4	2.72e-19	Lymphocyte counts;
LGG	cis	rs2404602	0.716	rs12441550	chr15:76863682	A/T	cg15268244	chr15:77196840	NA	-0.31	-6.75	-0.3	4.48e-11	Blood metabolite levels;
LGG	cis	rs8180040	0.726	rs4078466	chr3:47126543	C/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.33	-0.58	3.29e-43	Colorectal cancer;
LGG	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg13607699	chr17:42295918	UBTF	-0.44	-6.98	-0.31	1.05e-11	Total body bone mineral density;
LGG	cis	rs11764590	0.724	rs55669426	chr7:2090129	G/C	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.53	-0.37	2.11e-16	Neuroticism;
LGG	cis	rs4927850	1.000	rs10881564	chr3:195750326	C/T	cg12923728	chr3:195709715	SDHAP1	-0.78	-14.6	-0.56	5.37e-40	Pancreatic cancer;
LGG	trans	rs11098499	0.863	rs10009626	chr4:120470005	T/C	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.96e-27	Corneal astigmatism;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg10947003	chr16:67218230	KIAA0895L	0.38	6.68	0.3	6.74e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1421811	0.532	rs72740626	chr5:32692220	G/C	cg16267343	chr5:32710456	NPR3	0.59	8.02	0.35	9.03e-15	Blood pressure;
LGG	cis	rs6942756	0.747	rs692432	chr7:129113287	G/A	cg02491457	chr7:128862824	NA	-0.66	-11.56	-0.47	2.51e-27	White matter hyperintensity burden;
LGG	cis	rs7215564	0.908	rs2340770	chr17:78754770	T/C	cg16980736	chr17:78789706	RPTOR	0.58	7.65	0.33	1.18e-13	Myopia (pathological);
LGG	cis	rs6032067	0.929	rs17333555	chr20:43809761	C/T	cg10761708	chr20:43804764	PI3	0.76	11.9	0.48	1.11e-28	Blood protein levels;
LGG	cis	rs7666738	0.830	rs35433756	chr4:99070555	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-8.11	-0.35	4.58e-15	Prudent dietary pattern;
LGG	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg04207632	chr4:6986609	TBC1D14	-0.41	-7.8	-0.34	4.21e-14	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs1707322	1.000	rs1768818	chr1:46514286	G/C	cg03146154	chr1:46216737	IPP	-0.53	-10.09	-0.42	8.88e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2576037	0.796	rs2576041	chr18:44580919	C/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.42	-8.04	-0.35	7.52e-15	Personality dimensions;
LGG	cis	rs62400317	0.731	rs72867436	chr6:44975488	T/G	cg20913747	chr6:44695427	NA	-0.66	-11.24	-0.46	4.56e-26	Total body bone mineral density;
LGG	trans	rs7944735	0.568	rs59631865	chr11:47501619	T/G	cg15704280	chr7:45808275	SEPT13	0.61	6.79	0.3	3.4e-11	Intraocular pressure;
LGG	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.05e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs7166081	1.000	rs35688953	chr15:67640129	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.86	-0.3	2.24e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17345786	0.511	rs13061565	chr3:101392270	T/C	cg12386194	chr3:101231763	SENP7	0.45	8.01	0.35	9.16e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12476592	0.602	rs262482	chr2:63877042	C/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.88	-0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs2285947	1.000	rs2285947	chr7:21584088	A/G	cg23045935	chr7:21583304	DNAH11	-0.42	-9.3	-0.4	5.61e-19	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2985684	0.901	rs57119148	chr14:50097226	T/C	cg04989706	chr14:50066350	PPIL5	-0.54	-8.43	-0.36	4.31e-16	Carotid intima media thickness;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.94	-0.38	9.07e-18	Lung cancer;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.22	0.55	2.43e-38	Obesity-related traits;
LGG	cis	rs77633900	0.772	rs157775	chr15:76755641	A/G	cg21673338	chr15:77095150	SCAPER	-0.64	-8.41	-0.36	5.04e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs887829	0.570	rs45615240	chr2:234599296	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs75920871	0.588	rs721783	chr11:116907449	C/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.91	-0.45	7.82e-25	Subjective well-being;
LGG	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg18200150	chr17:30822561	MYO1D	0.79	18.46	0.65	1.95e-57	Schizophrenia;
LGG	cis	rs3858526	0.584	rs10769271	chr11:5860572	T/C	cg25319279	chr11:5960081	NA	-0.45	-7.27	-0.32	1.5e-12	DNA methylation (variation);
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg26338869	chr17:61819248	STRADA	0.58	9.75	0.41	1.48e-20	Prudent dietary pattern;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg15971980	chr6:150254442	NA	0.44	7.91	0.35	1.9e-14	Lung cancer;
LGG	cis	rs4740619	0.836	rs7019430	chr9:15704337	A/G	cg14451791	chr9:16040625	NA	-0.36	-9.02	-0.39	5.12e-18	Body mass index;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg02951883	chr7:2050386	MAD1L1	-0.68	-13.56	-0.53	1.59e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs2235642	0.533	rs9922661	chr16:1605163	C/A	cg03034668	chr16:1723424	CRAMP1L	-0.43	-6.9	-0.31	1.69e-11	Coronary artery disease;
LGG	cis	rs1799949	1.000	rs16941	chr17:41244435	T/C	cg23758822	chr17:41437982	NA	0.9	15.82	0.59	2.25e-45	Menopause (age at onset);
LGG	cis	rs11239187	0.530	rs12242558	chr10:45066526	A/G	cg03916630	chr10:45065415	NA	0.36	8.86	0.38	1.76e-17	Body mass index;
LGG	cis	rs2013441	1.000	rs2703817	chr17:20119677	A/C	cg13482628	chr17:19912719	NA	-0.51	-9.41	-0.4	2.31e-19	Obesity-related traits;
LGG	cis	rs9361491	0.543	rs1507153	chr6:79484386	C/A	cg18132916	chr6:79620363	NA	-0.27	-7.04	-0.31	6.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9457247	0.765	rs10484531	chr6:167454434	G/A	cg07741184	chr6:167504864	NA	0.42	9.38	0.4	2.97e-19	Crohn's disease;
LGG	cis	rs11792861	0.641	rs10979586	chr9:111647764	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.58	9.64	0.41	3.64e-20	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs56255635	chr8:58178264	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9443189	0.615	rs602873	chr6:76323818	T/A	cg01950844	chr6:76311363	SENP6	0.77	10.13	0.43	6.29e-22	Prostate cancer;
LGG	cis	rs2734839	1.000	rs2734839	chr11:113286490	C/T	cg14159747	chr11:113255604	NA	0.28	7.45	0.33	4.49e-13	Information processing speed;
LGG	cis	rs4132509	0.696	rs10927062	chr1:243889364	A/G	cg25706552	chr1:244017396	NA	0.54	8.62	0.37	1.07e-16	RR interval (heart rate);
LGG	cis	rs698833	0.542	rs13418572	chr2:44705614	T/C	cg18685995	chr2:44588913	PREPL;C2orf34	0.43	7.01	0.31	8.47e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs2797369	0.656	rs68114029	chr6:101590792	C/T	cg27451362	chr6:101846650	GRIK2	0.83	11.42	0.47	8.69e-27	Renal function-related traits (eGRFcrea);
LGG	cis	rs798554	1.000	rs798560	chr7:2758309	A/G	cg04166393	chr7:2884313	GNA12	0.48	8.78	0.38	3.1e-17	Height;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.07	16.52	0.61	1.61e-48	Platelet count;
LGG	cis	rs2243480	1.000	rs419603	chr7:65597341	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg08753297	chr6:56716612	DST	0.41	6.82	0.3	2.92e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs7824557	0.564	rs2736304	chr8:11236964	C/T	cg16141378	chr3:129829833	LOC729375	0.36	7.81	0.34	3.98e-14	Retinal vascular caliber;
LGG	trans	rs7395662	0.963	rs2135681	chr11:48728388	T/C	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs9309473	0.583	rs6718864	chr2:73574591	A/G	cg20560298	chr2:73613845	ALMS1	-0.45	-8.05	-0.35	7.01e-15	Metabolite levels;
LGG	cis	rs929354	0.713	rs6946660	chr7:156948648	T/C	cg17757837	chr7:157058334	UBE3C	0.76	15.36	0.58	2.43e-43	Body mass index;
LGG	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.7	14.79	0.57	7.8e-41	Menarche (age at onset);
LGG	cis	rs4330281	0.669	rs9310524	chr3:17640706	C/T	cg20981856	chr3:17787350	NA	0.4	7.37	0.32	8.08e-13	Schizophrenia;
LGG	cis	rs3733585	0.781	rs4292328	chr4:9970962	C/T	cg25986240	chr4:9926439	SLC2A9	0.48	10.39	0.43	6.95e-23	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs737693	1.000	rs114176245	chr11:102719534	C/T	cg19620758	chr11:102826565	MMP13	0.59	7.11	0.31	4.5e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9815354	0.953	rs1717003	chr3:41937000	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg06453172	chr10:134556979	INPP5A	-0.55	-8.18	-0.36	2.7e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4819052	0.851	rs2236443	chr21:46678174	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.3	0.36	1.16e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9287719	0.967	rs12622765	chr2:10728331	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.61	-0.41	4.65e-20	Lung cancer;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs975722	0.541	rs6966836	chr7:117002998	T/C	cg10524701	chr7:117356490	CTTNBP2	0.39	8.33	0.36	9.02e-16	Coronary artery disease;
LGG	cis	rs847577	0.575	rs41278842	chr7:97815999	A/G	cg13397024	chr7:97797637	LMTK2	0.43	7.53	0.33	2.59e-13	Breast cancer;
LGG	cis	rs9849248	0.574	rs6419869	chr3:88263487	T/G	cg14530983	chr3:88190749	ZNF654	-0.56	-7.73	-0.34	6.92e-14	Menarche (age at onset);
LGG	cis	rs17270561	0.609	rs4711094	chr6:25706174	T/A	cg03264133	chr6:25882463	NA	-0.46	-7.41	-0.33	6.19e-13	Iron status biomarkers;
LGG	cis	rs7166081	1.000	rs12900758	chr15:67523043	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.8	-0.3	3.15e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs875971	1.000	rs7789554	chr7:65946038	A/G	cg12463550	chr7:65579703	CRCP	0.51	8.58	0.37	1.45e-16	Aortic root size;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	7.26e-15	Obesity-related traits;
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.31	-0.43	1.4e-22	Bipolar disorder;
LGG	trans	rs931812	0.691	rs884488	chr8:101898523	C/G	cg20993868	chr7:22813445	NA	0.55	10.66	0.44	7.4e-24	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2275620	1.000	rs7910936	chr10:96804451	C/T	cg09036531	chr10:96991505	NA	-0.41	-7.27	-0.32	1.56e-12	Gout;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08677398	chr8:58056175	NA	0.48	8.01	0.35	9.41e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg03606772	chr1:152487856	CRCT1	0.31	7.3	0.32	1.23e-12	Hair morphology;
LGG	trans	rs2243480	1.000	rs781157	chr7:65478311	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.87	0.42	5.72e-21	Diabetic kidney disease;
LGG	cis	rs6960043	0.738	rs12538043	chr7:15058998	C/G	cg19272540	chr7:15055459	NA	0.36	7.89	0.34	2.26e-14	Type 2 diabetes;
LGG	cis	rs12410462	0.591	rs2644162	chr1:227703397	C/T	cg04117972	chr1:227635322	NA	0.46	8.4	0.36	5.32e-16	Major depressive disorder;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg07308232	chr7:1071921	C7orf50	-0.55	-10.14	-0.43	5.79e-22	Longevity;Endometriosis;
LGG	cis	rs4926611	1.000	rs6657679	chr1:54110425	G/A	cg23596471	chr1:54105337	GLIS1	0.41	8.56	0.37	1.72e-16	Hand grip strength;
LGG	cis	rs61931739	0.534	rs1608911	chr12:34010249	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.12	-0.46	1.28e-25	Morning vs. evening chronotype;
LGG	cis	rs6582630	0.679	rs10785514	chr12:38573689	T/C	cg26384229	chr12:38710491	ALG10B	0.72	14.54	0.56	9.96e-40	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg16141378	chr3:129829833	LOC729375	0.44	9.96	0.42	2.66e-21	Neuroticism;
LGG	cis	rs9902453	0.817	rs55758314	chr17:28173978	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs950169	0.723	rs17589320	chr15:84919996	C/A	cg03959625	chr15:84868606	LOC388152	0.56	8.84	0.38	1.96e-17	Schizophrenia;
LGG	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-6.86	-0.3	2.28e-11	Neuroticism;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01154537	chr10:95462167	C10orf4	-0.46	-6.75	-0.3	4.47e-11	Systemic lupus erythematosus;
LGG	cis	rs2797369	0.600	rs705601	chr6:101314005	G/A	cg27451362	chr6:101846650	GRIK2	0.67	9.22	0.39	1.09e-18	Renal function-related traits (eGRFcrea);
LGG	trans	rs12579753	0.917	rs12316644	chr12:82205497	C/T	cg07923666	chr12:49932857	KCNH3	0.52	7.89	0.34	2.15e-14	Resting heart rate;
LGG	cis	rs1994135	0.669	rs10844629	chr12:33697096	T/A	cg06521331	chr12:34319734	NA	-0.5	-8.58	-0.37	1.49e-16	Resting heart rate;
LGG	trans	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg06606381	chr12:133084897	FBRSL1	-0.78	-8.42	-0.36	4.92e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6866344	0.570	rs6896799	chr5:178147014	G/C	cg03877680	chr5:178157825	ZNF354A	0.82	13.89	0.54	6.17e-37	Neutrophil percentage of white cells;
LGG	trans	rs3206736	0.520	rs328934	chr7:35043726	C/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.24	0.32	1.93e-12	Diastolic blood pressure;
LGG	cis	rs4664308	0.694	rs4665140	chr2:160890710	T/A	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.64	-0.48	1.2e-27	Idiopathic membranous nephropathy;
LGG	cis	rs7223966	1.000	rs9909992	chr17:61731931	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	11.07	0.46	1.96e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1665650	0.957	rs1867988	chr10:118485935	C/T	cg14919929	chr10:118506882	NA	-0.46	-7.93	-0.35	1.66e-14	Colorectal cancer;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.4	-0.36	5.56e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.861	rs5010991	chr4:98972179	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21575558	chr1:222763513	TAF1A	0.49	8.13	0.35	3.89e-15	Cognitive performance;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs7107174	1.000	rs9651769	chr11:77996166	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.34	-0.32	9.96e-13	Testicular germ cell tumor;
LGG	cis	rs7843479	0.898	rs13282562	chr8:21869727	G/A	cg17168535	chr8:21777572	XPO7	0.57	9.18	0.39	1.4e-18	Mean corpuscular volume;
LGG	cis	rs9467711	0.591	rs35902160	chr6:26128538	C/G	cg21479132	chr6:26055353	NA	0.75	7.28	0.32	1.42e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7143963	0.943	rs10133111	chr14:103377321	A/G	cg23020514	chr14:103360112	TRAF3	-0.49	-9.45	-0.4	1.64e-19	Body mass index;
LGG	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.46	8.35	0.36	8.1e-16	Intelligence (multi-trait analysis);
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg27189623	chr16:705930	WDR90	0.42	8.14	0.35	3.67e-15	Height;
LGG	trans	rs12545912	0.908	rs6994557	chr8:9578230	G/T	cg16141378	chr3:129829833	LOC729375	0.34	6.67	0.3	7.15e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg09995631	chr15:28393738	HERC2	-0.34	-6.81	-0.3	3.09e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs1799949	1.000	rs33918839	chr17:41329172	T/C	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.57e-12	Menopause (age at onset);
LGG	cis	rs6582630	0.555	rs11503799	chr12:38294578	G/A	cg26384229	chr12:38710491	ALG10B	-0.63	-12.03	-0.49	3.34e-29	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2439831	1.000	rs2467426	chr15:43989518	A/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.85	9.57	0.41	6.65e-20	Lung cancer in ever smokers;
LGG	cis	rs61931739	0.629	rs1842886	chr12:33704257	A/T	cg06521331	chr12:34319734	NA	0.4	6.95	0.31	1.24e-11	Morning vs. evening chronotype;
LGG	cis	rs8008758	1.000	rs12435364	chr14:101690209	G/A	cg26224664	chr14:101693935	NA	-0.55	-9.6	-0.41	5.14e-20	Body mass index (alcohol intake interaction);
LGG	trans	rs804280	0.542	rs36100659	chr8:11791653	A/T	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Myopia (pathological);
LGG	cis	rs61931739	0.500	rs10844829	chr12:34304916	G/T	cg06521331	chr12:34319734	NA	-0.65	-11.98	-0.49	5.21e-29	Morning vs. evening chronotype;
LGG	cis	rs11758351	1.000	rs80095925	chr6:26184942	C/T	cg06951627	chr6:26196580	NA	0.52	7.51	0.33	3.1400000000000003e-13	Gout;Renal underexcretion gout;
LGG	cis	rs10540	0.730	rs61876338	chr11:493730	A/G	cg03576123	chr11:487126	PTDSS2	-1.25	-16.81	-0.62	7.53e-50	Body mass index;
LGG	cis	rs1408799	0.579	rs970947	chr9:12738813	A/G	cg05274944	chr9:12693694	TYRP1	-0.31	-6.82	-0.3	2.86e-11	Eye color;Blue vs. green eyes;
LGG	cis	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.6	-0.37	1.26e-16	Mood instability;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07279963	chr3:61546526	PTPRG	0.43	6.87	0.3	2.1e-11	Cognitive performance;
LGG	cis	rs7819412	0.659	rs4073948	chr8:10772644	A/T	cg27411982	chr8:10470053	RP1L1	-0.46	-7.5	-0.33	3.22e-13	Triglycerides;
LGG	cis	rs8058578	1.000	rs2289442	chr16:30739919	A/G	cg02466173	chr16:30829666	NA	-0.57	-10.23	-0.43	2.84e-22	Multiple myeloma;
LGG	cis	rs2688608	0.592	rs10824032	chr10:75528130	G/A	cg00564723	chr10:75632066	CAMK2G	-0.31	-7.0	-0.31	8.89e-12	Inflammatory bowel disease;
LGG	trans	rs9329221	0.537	rs1484640	chr8:9983243	G/T	cg21775007	chr8:11205619	TDH	0.42	6.74	0.3	4.65e-11	Neuroticism;
LGG	cis	rs12579753	0.956	rs34747993	chr12:82217777	C/T	cg07988820	chr12:82153109	PPFIA2	-0.79	-11.45	-0.47	6.54e-27	Resting heart rate;
LGG	cis	rs9467711	0.591	rs13208859	chr6:25894609	G/A	cg21479132	chr6:26055353	NA	0.83	7.44	0.33	4.97e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1129187	0.935	rs9986447	chr6:42942779	C/T	cg05552183	chr6:42928497	GNMT	-0.47	-14.72	-0.56	1.71e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4722166	0.508	rs1474347	chr7:22768124	A/C	cg05265849	chr7:22767390	IL6	-0.41	-7.94	-0.35	1.57e-14	Lung cancer;
LGG	cis	rs4650994	1.000	rs4511075	chr1:178518636	G/A	cg12486710	chr1:178512616	C1orf220	0.42	8.48	0.37	3.1e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2273669	0.915	rs11970599	chr6:109314350	C/T	cg05315195	chr6:109294784	ARMC2	0.5	7.5	0.33	3.33e-13	Prostate cancer;
LGG	cis	rs35146811	0.700	rs4729579	chr7:99780282	C/G	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs7618915	0.547	rs2590846	chr3:52692359	C/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.17	-0.32	3.04e-12	Bipolar disorder;
LGG	cis	rs2228479	0.681	rs3212346	chr16:89982358	G/A	cg27400746	chr16:89904261	SPIRE2	-0.87	-14.62	-0.56	4.56e-40	Skin colour saturation;
LGG	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg02023728	chr11:77925099	USP35	0.4	7.14	0.31	3.73e-12	Alzheimer's disease (survival time);
LGG	cis	rs9487094	0.670	rs12194157	chr6:109961344	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.79	0.34	4.48e-14	Height;
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg20295408	chr7:1910781	MAD1L1	-0.43	-7.57	-0.33	2.07e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs963731	0.649	rs297150	chr2:39326164	C/T	cg04010122	chr2:39346883	SOS1	-0.89	-8.02	-0.35	8.6e-15	Corticobasal degeneration;
LGG	cis	rs9341835	0.593	rs9449297	chr6:64164249	T/C	cg00787780	chr6:64151745	NA	0.41	7.15	0.32	3.31e-12	Schizophrenia;
LGG	cis	rs11168187	0.891	rs757284	chr12:48128119	C/G	cg12761788	chr12:48120090	P11	-0.44	-7.44	-0.33	4.85e-13	Vertical cup-disc ratio;
LGG	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg02269571	chr22:50332266	NA	-0.64	-10.37	-0.43	8.16e-23	Schizophrenia;
LGG	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	Neuroticism;
LGG	cis	rs7727544	0.716	rs4705928	chr5:131578637	A/G	cg24060327	chr5:131705240	SLC22A5	0.43	7.02	0.31	8.11e-12	Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs1006779	chr21:46670752	A/G	cg06618935	chr21:46677482	NA	-0.42	-8.17	-0.35	3e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9303401	0.538	rs8078280	chr17:56473132	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	0.8	12.35	0.5	1.71e-30	Cognitive test performance;
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.93	-0.31	1.42e-11	Aortic root size;
LGG	cis	rs7572263	0.724	rs67989853	chr2:209055164	T/C	cg00164906	chr2:209055251	C2orf80	0.75	9.72	0.41	1.84e-20	Glioma;Non-glioblastoma glioma;
LGG	cis	rs9557207	1.000	rs12232061	chr13:99974992	G/T	cg24509225	chr13:100037070	UBAC2	0.71	12.4	0.5	1.12e-30	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs1797081	0.840	rs10904820	chr10:16848473	A/G	cg14835575	chr10:16859367	RSU1	0.36	7.26	0.32	1.67e-12	Platelet distribution width;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg07701084	chr6:150067640	NUP43	0.71	13.85	0.54	9.65e-37	Lung cancer;
LGG	cis	rs7945718	0.935	rs4757059	chr11:12812356	G/A	cg25843174	chr11:12811716	TEAD1	-0.39	-8.18	-0.36	2.81e-15	Educational attainment (years of education);
LGG	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-12.31	-0.5	2.48e-30	Hemoglobin concentration;
LGG	cis	rs7143963	0.666	rs66970053	chr14:103307655	G/C	cg23020514	chr14:103360112	TRAF3	0.43	9.01	0.39	5.26e-18	Body mass index;
LGG	cis	rs72901758	0.768	rs11657271	chr17:76249682	A/T	cg26068271	chr17:76253126	NA	0.5	10.61	0.44	1.13e-23	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4356203	0.792	rs677540	chr11:17213759	A/C	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.3	-0.32	1.24e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs1552244	0.816	rs13076197	chr3:10019773	T/C	cg00166722	chr3:10149974	C3orf24	0.5	8.34	0.36	8.39e-16	Alzheimer's disease;
LGG	cis	rs62238980	0.614	rs74928243	chr22:32439681	C/T	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs7945705	0.818	rs1988708	chr11:8882893	C/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.89	-0.34	2.17e-14	Hemoglobin concentration;
LGG	cis	rs2839186	0.771	rs13046451	chr21:47641373	T/A	cg13732083	chr21:47605072	C21orf56	-0.5	-8.58	-0.37	1.44e-16	Testicular germ cell tumor;
LGG	cis	rs8028313	0.731	rs7172055	chr15:67938334	G/C	cg16208657	chr15:68119293	LBXCOR1	-0.36	-7.08	-0.31	5.33e-12	Obesity;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg16680214	chr1:154839983	KCNN3	-0.44	-8.45	-0.37	3.92e-16	Prostate cancer;
LGG	cis	rs4974559	0.947	rs10018627	chr4:1356358	G/A	cg02980000	chr4:1222292	CTBP1	0.65	7.91	0.34	1.96e-14	Systolic blood pressure;
LGG	cis	rs798554	0.660	rs2644296	chr7:2859061	A/T	cg19717773	chr7:2847554	GNA12	-0.39	-9.19	-0.39	1.36e-18	Height;
LGG	cis	rs2180341	0.781	rs7742161	chr6:127571676	T/C	cg27446573	chr6:127587934	RNF146	0.9	16.73	0.61	1.66e-49	Breast cancer;
LGG	cis	rs2114646	0.731	rs58947617	chr2:170636137	A/G	cg17598339	chr2:170624727	NA	0.35	6.65	0.3	8.44e-11	Obesity-related traits;
LGG	cis	rs5758511	0.573	rs2267439	chr22:42237769	C/T	cg15128208	chr22:42549153	NA	-0.43	-7.33	-0.32	1.07e-12	Birth weight;
LGG	cis	rs6502050	0.697	rs8078634	chr17:80126208	C/T	cg19223190	chr17:80058835	NA	0.44	8.55	0.37	1.81e-16	Life satisfaction;
LGG	cis	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.23	-0.32	2.04e-12	Mood instability;
LGG	cis	rs12477438	0.501	rs2632284	chr2:99775865	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	38.56	0.87	1.13e-146	Chronic sinus infection;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg03188948	chr7:1209495	NA	0.61	7.91	0.35	1.85e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10254118	0.730	rs6961517	chr7:133130940	G/T	cg10665199	chr7:133106180	EXOC4	0.58	9.63	0.41	4.03e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7833790	0.963	rs10958046	chr8:82729210	A/G	cg27398817	chr8:82754497	SNX16	-0.8	-11.64	-0.48	1.2100000000000001e-27	Diastolic blood pressure;
LGG	cis	rs6089829	0.926	rs73921625	chr20:61660891	C/T	cg08564027	chr20:61660810	NA	-0.88	-15.58	-0.59	2.51e-44	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs317689	0.876	rs547332	chr12:69743639	C/G	cg11871910	chr12:69753446	YEATS4	0.77	13.18	0.52	6.44e-34	Response to diuretic therapy;
LGG	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg03060546	chr3:49711283	APEH	-0.63	-10.5	-0.44	2.89e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs459571	0.959	rs2520100	chr9:136918137	A/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.69	-11.97	-0.49	5.73e-29	Platelet distribution width;
LGG	cis	rs769267	0.896	rs10410664	chr19:19556651	G/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs11098499	0.738	rs34965784	chr4:120361586	G/C	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs11771526	0.901	rs62457467	chr7:32301101	T/A	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	cis	rs7223966	1.000	rs8073373	chr17:61703320	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.81	-0.38	2.51e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12410462	0.591	rs903693	chr1:227732787	A/G	cg04117972	chr1:227635322	NA	0.46	8.62	0.37	1.04e-16	Major depressive disorder;
LGG	cis	rs757278	0.552	rs1594189	chr7:117311713	T/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.53	0.33	2.72e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7659604	1.000	rs6814995	chr4:122664963	A/T	cg19748678	chr4:122722346	EXOSC9	-0.52	-10.0	-0.42	1.98e-21	Type 2 diabetes;
LGG	cis	rs8177253	0.634	rs6798547	chr3:133448499	G/A	cg01448562	chr3:133502909	NA	-0.52	-8.7	-0.37	5.9e-17	Iron status biomarkers;
LGG	cis	rs9649465	0.967	rs12539091	chr7:123291314	C/T	cg03229431	chr7:123269106	ASB15	-0.41	-8.85	-0.38	1.87e-17	Migraine;
LGG	cis	rs9443645	0.838	rs9350800	chr6:79729489	A/C	cg18132916	chr6:79620363	NA	-0.3	-8.42	-0.36	4.84e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9534288	0.797	rs2094246	chr13:46602163	C/T	cg15192986	chr13:46630673	CPB2	-0.61	-13.31	-0.53	1.78e-34	Blood protein levels;
LGG	cis	rs3770081	1.000	rs2303339	chr2:86346180	A/G	cg23655155	chr2:86332777	POLR1A;PTCD3	0.88	7.5	0.33	3.36e-13	Facial emotion recognition (sad faces);
LGG	cis	rs79057730	1.000	rs79057730	chr7:784943	C/G	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.76	8.15	0.35	3.51e-15	Initial pursuit acceleration;
LGG	cis	rs2282032	0.527	rs55664487	chr14:90765880	C/T	cg14092571	chr14:90743983	NA	0.43	7.59	0.33	1.72e-13	Longevity;
LGG	cis	rs11471957	1	rs11471957	chr20:57598332	C/CAA	cg23907860	chr20:57583709	CTSZ	0.47	7.07	0.31	5.79e-12	Platelet count;Mean platelet volume;
LGG	cis	rs12681288	0.550	rs4637864	chr8:959761	C/T	cg08648136	chr8:956695	NA	0.45	9.75	0.41	1.44e-20	Schizophrenia;
LGG	cis	rs13118159	0.573	rs7657357	chr4:1372939	C/T	cg02475777	chr4:1388615	CRIPAK	0.6	11.34	0.47	1.85e-26	Longevity;
LGG	cis	rs13108904	0.539	rs13141169	chr4:1340353	C/T	cg16524936	chr4:1340807	KIAA1530	-0.48	-7.35	-0.32	9.22e-13	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs112847840	chr3:10101652	C/T	cg00166722	chr3:10149974	C3orf24	0.55	9.17	0.39	1.6e-18	Alzheimer's disease;
LGG	trans	rs11098499	0.754	rs10212775	chr4:120239244	G/C	cg25214090	chr10:38739885	LOC399744	0.61	11.04	0.46	2.51e-25	Corneal astigmatism;
LGG	trans	rs7746199	0.736	rs34038546	chr6:27607660	C/A	cg01620082	chr3:125678407	NA	-1.04	-10.09	-0.42	9.09e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg00409905	chr10:38381863	ZNF37A	0.56	10.6	0.44	1.24e-23	Extrinsic epigenetic age acceleration;
LGG	trans	rs453301	0.658	rs9329175	chr8:8866661	C/T	cg16141378	chr3:129829833	LOC729375	0.32	7.48	0.33	3.7e-13	Joint mobility (Beighton score);
LGG	cis	rs2117029	0.586	rs10783308	chr12:49531458	T/C	cg24176009	chr12:49580217	TUBA1A	0.66	12.71	0.51	5.67e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7927771	0.524	rs2290851	chr11:47753370	C/T	cg20307385	chr11:47447363	PSMC3	-0.56	-10.92	-0.45	7.23e-25	Subjective well-being;
LGG	cis	rs6714710	0.603	rs11684749	chr2:98420142	G/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.51	0.4	1.06e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01620308	chr20:4666848	PRNP	0.46	6.86	0.3	2.23e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06634786	chr22:41940651	POLR3H	-0.81	-13.12	-0.52	1.22e-33	Vitiligo;
LGG	cis	rs12458462	0.812	rs36073957	chr18:77488441	C/T	cg11879182	chr18:77439856	CTDP1	0.79	14.67	0.56	2.64e-40	Monocyte count;
LGG	cis	rs422249	0.504	rs174538	chr11:61560081	G/A	cg19610905	chr11:61596333	FADS2	-0.77	-13.68	-0.54	5.22e-36	Trans fatty acid levels;
LGG	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg04568710	chr12:38710424	ALG10B	-0.4	-8.14	-0.35	3.82e-15	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.627	rs9938228	chr16:4530597	T/C	cg19168338	chr16:4465731	CORO7	-0.89	-17.0	-0.62	9.88e-51	Schizophrenia;
LGG	cis	rs6665290	0.935	rs17528667	chr1:227201770	C/T	cg05696931	chr1:227175867	NA	-0.4	-7.86	-0.34	2.73e-14	Myeloid white cell count;
LGG	cis	rs899997	0.953	rs11633519	chr15:78999552	A/G	cg09448879	chr15:79043637	NA	-0.52	-12.33	-0.5	2.17e-30	Coronary artery disease or large artery stroke;
LGG	cis	rs6704644	0.932	rs11676524	chr2:234460968	A/T	cg27060346	chr2:234359958	DGKD	0.62	7.9	0.34	2.01e-14	Bilirubin levels;
LGG	cis	rs9463078	0.845	rs1023090	chr6:45012381	T/C	cg25276700	chr6:44698697	NA	-0.38	-8.1	-0.35	4.8e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1620921	0.533	rs9365218	chr6:161269903	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.33	-0.32	1.02e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg12463550	chr7:65579703	CRCP	0.73	8.04	0.35	7.48e-15	Diabetic kidney disease;
LGG	trans	rs6787172	0.622	rs67385174	chr3:158111325	C/G	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs4948102	0.551	rs4275190	chr7:56104388	C/T	cg12555334	chr7:56120290	CCT6A;PSPH	0.41	7.28	0.32	1.45e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg11161011	chr14:65562177	MAX	-0.73	-14.26	-0.55	1.62e-38	Obesity-related traits;
LGG	cis	rs2888674	0.527	rs12673413	chr7:150512379	C/G	cg03964111	chr7:150498493	TMEM176B;TMEM176A	0.3	7.6	0.33	1.71e-13	Forced expiratory volume in 1 second (occupational environmental exposures interaction);
LGG	cis	rs4731207	0.698	rs10085888	chr7:124486391	T/C	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	trans	rs9467711	0.675	rs58825580	chr6:26365679	T/G	cg06606381	chr12:133084897	FBRSL1	-0.77	-8.13	-0.35	3.99e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7192750	0.535	rs152826	chr16:72126180	A/G	cg14768367	chr16:72042858	DHODH	0.78	8.04	0.35	7.41e-15	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs35146811	0.731	rs2257213	chr7:99810113	T/C	cg22906224	chr7:99728672	NA	-0.57	-9.36	-0.4	3.49e-19	Coronary artery disease;
LGG	cis	rs4363385	0.818	rs946096	chr1:153006529	T/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26595520	chr7:127671033	LRRC4;SND1	0.43	7.35	0.32	9.33e-13	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg00830817	chr11:109293614	C11orf87	0.41	6.92	0.31	1.49e-11	Schizophrenia;
LGG	cis	rs12476592	0.602	rs166385	chr2:63888023	T/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.6	0.33	1.7e-13	Lung cancer;
LGG	cis	rs3820928	1.000	rs10193404	chr2:227777757	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.35	-0.32	9.22e-13	Pulmonary function;
LGG	cis	rs6450176	1.000	rs12521454	chr5:53297304	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.46	-0.47	5.9e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs2880765	0.743	rs6497194	chr15:86014116	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-7.27	-0.32	1.54e-12	Coronary artery disease;
LGG	trans	rs61931739	0.517	rs11513519	chr12:34075077	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.75	0.45	3.25e-24	Morning vs. evening chronotype;
LGG	cis	rs2239547	0.562	rs6794389	chr3:53096394	A/G	cg11645453	chr3:52864694	ITIH4	0.65	10.1	0.42	8.36e-22	Schizophrenia;
LGG	cis	rs10779751	0.770	rs7553827	chr1:11222393	C/T	cg08854313	chr1:11322531	MTOR	0.73	14.99	0.57	1.09e-41	Body mass index;
LGG	cis	rs7923609	0.936	rs4405189	chr10:65013935	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.8	-0.3	3.26e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2108225	0.967	rs6466189	chr7:107448516	C/T	cg18560240	chr7:107437656	SLC26A3	-0.53	-9.39	-0.4	2.63e-19	Ulcerative colitis;
LGG	cis	rs9463078	0.845	rs6458419	chr6:45085038	T/C	cg25276700	chr6:44698697	NA	-0.39	-8.18	-0.36	2.81e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	trans	rs3749237	1.000	rs2307021	chr3:49765483	C/G	cg21659725	chr3:3221576	CRBN	0.74	11.63	0.48	1.3e-27	Resting heart rate;
LGG	cis	rs9300255	0.602	rs1616131	chr12:123619838	G/A	cg00376283	chr12:123451042	ABCB9	0.65	10.58	0.44	1.41e-23	Neutrophil percentage of white cells;
LGG	cis	rs6088590	1.000	rs6058111	chr20:33310999	T/C	cg06115741	chr20:33292138	TP53INP2	0.61	10.05	0.42	1.3e-21	Coronary artery disease;
LGG	cis	rs9462027	0.628	rs2814942	chr6:34644261	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.83	-0.45	1.67e-24	Systemic lupus erythematosus;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg27219399	chr15:67835830	MAP2K5	0.32	6.98	0.31	1.04e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.67	-10.69	-0.44	5.7e-24	HIV-1 control;
LGG	cis	rs11157436	0.602	rs11157437	chr14:22636954	C/T	cg00994629	chr14:22694547	NA	0.33	7.14	0.31	3.68e-12	Neurocognitive impairment in HIV-1 infection (continuous);
LGG	cis	rs7481584	0.962	rs2071110	chr11:2991219	C/G	cg25174290	chr11:3078921	CARS	-0.46	-8.09	-0.35	5.26e-15	Calcium levels;
LGG	cis	rs9611565	0.559	rs13056262	chr22:42081921	A/G	cg03806693	chr22:41940476	POLR3H	1.03	17.57	0.63	2.42e-53	Vitiligo;
LGG	trans	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg26043149	chr18:55253948	FECH	-0.48	-8.25	-0.36	1.67e-15	Bone mineral density;
LGG	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.85	-0.38	1.8e-17	Response to antipsychotic treatment;
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.47	-0.37	3.31e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1797081	0.901	rs703059	chr10:16876402	G/A	cg14835575	chr10:16859367	RSU1	0.37	7.23	0.32	1.96e-12	Platelet distribution width;
LGG	cis	rs10267417	0.603	rs10277701	chr7:19886762	G/C	cg07541023	chr7:19748670	TWISTNB	0.5	6.76	0.3	4.19e-11	Night sleep phenotypes;
LGG	trans	rs11992162	0.551	rs13268217	chr8:11782609	T/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.92	-0.31	1.47e-11	Monocyte count;
LGG	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg21972741	chr5:435613	AHRR	0.48	7.42	0.33	5.78e-13	Cystic fibrosis severity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03229959	chr8:38089560	DDHD2	0.44	6.9	0.31	1.71e-11	Gut microbiome composition (summer);
LGG	cis	rs782590	0.729	rs706548	chr2:55850106	C/G	cg18811423	chr2:55921094	PNPT1	0.84	17.43	0.63	1.12e-52	Metabolic syndrome;
LGG	cis	rs112591243	0.570	rs117906758	chr21:48037968	T/C	cg10657630	chr21:48055338	PRMT2	0.86	7.46	0.33	4.18e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs7208859	0.524	rs77498725	chr17:29063986	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2404602	0.716	rs12441247	chr15:76812316	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.93	-0.31	1.44e-11	Blood metabolite levels;
LGG	cis	rs8177179	0.967	rs4994582	chr3:133437566	G/C	cg24879335	chr3:133465180	TF	0.43	7.08	0.31	5.54e-12	Iron status biomarkers (transferrin levels);
LGG	trans	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.58	0.65	5.76e-58	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg24829409	chr8:58192753	C8orf71	-0.67	-9.72	-0.41	1.93e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg16070123	chr10:51489643	NA	0.42	7.79	0.34	4.37e-14	Prostate-specific antigen levels;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg21165519	chr14:105310921	NA	0.39	6.68	0.3	7.09e-11	IgG glycosylation;
LGG	cis	rs4242434	0.927	rs11781149	chr8:22473158	C/T	cg00599393	chr8:22457479	C8orf58	-0.45	-8.12	-0.35	4.24e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2040771	0.804	rs2073754	chr22:19221406	G/T	cg02655711	chr22:19163373	SLC25A1	-0.46	-8.43	-0.36	4.52e-16	Metabolite levels (small molecules and protein measures);
LGG	cis	rs17376456	0.825	rs28610997	chr5:93248374	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.33	0.4	4.24e-19	Diabetic retinopathy;
LGG	trans	rs1459104	0.866	rs34179570	chr11:54823141	C/T	cg15704280	chr7:45808275	SEPT13	0.73	7.48	0.33	3.8e-13	Body mass index;
LGG	cis	rs17767392	0.957	rs35692397	chr14:71756683	A/C	cg02058870	chr14:72053146	SIPA1L1	0.47	9.51	0.4	1.05e-19	Mitral valve prolapse;
LGG	cis	rs9322193	0.923	rs9404048	chr6:149937324	C/T	cg12070911	chr6:150209640	RAET1E	0.29	7.02	0.31	7.71e-12	Lung cancer;
LGG	cis	rs4700695	0.841	rs251304	chr5:65249700	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.25	0.32	1.81e-12	Facial morphology (factor 19);
LGG	cis	rs2046867	0.908	rs62251634	chr3:72788705	A/C	cg25664220	chr3:72788482	NA	-0.32	-8.94	-0.38	9.04e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504073	0.647	rs10808745	chr8:49989037	G/A	cg00325661	chr8:49890786	NA	0.75	14.62	0.56	4.51e-40	Blood metabolite ratios;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.07	0.55	1.07e-37	Obesity-related traits;
LGG	cis	rs7552404	0.655	rs1146646	chr1:76265500	G/A	cg05598546	chr1:76251766	SNORD45C;RABGGTB	0.39	7.44	0.33	4.94e-13	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.636	rs77753517	chr8:58115897	C/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1658457	chr10:60302716	T/C	cg09696939	chr10:60272079	BICC1	-0.38	-7.4	-0.33	6.48e-13	Refractive error;
LGG	cis	rs1865760	1.000	rs2071299	chr6:25914801	G/A	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.94	19.16	0.67	1.06e-60	Smoking behavior;
LGG	cis	rs4356203	0.905	rs1989405	chr11:17184819	C/T	cg15432903	chr11:17409602	KCNJ11	0.39	7.28	0.32	1.47e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs9354308	0.738	rs1499706	chr6:66593415	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.84	-0.3	2.51e-11	Metabolite levels;
LGG	cis	rs9303401	0.659	rs62083525	chr17:56658088	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.9	0.57	2.72e-41	Cognitive test performance;
LGG	cis	rs9303401	0.659	rs35928756	chr17:56702652	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs774359	0.711	rs10967965	chr9:27497988	A/T	cg21249376	chr9:27528432	MOBKL2B	0.51	9.07	0.39	3.38e-18	Amyotrophic lateral sclerosis;
LGG	cis	rs1799949	0.894	rs71367985	chr17:41374463	G/A	cg23758822	chr17:41437982	NA	0.85	15.39	0.58	1.87e-43	Menopause (age at onset);
LGG	cis	rs10779751	1.000	rs11121704	chr1:11293959	A/G	cg08854313	chr1:11322531	MTOR	-0.77	-15.92	-0.59	8.1e-46	Body mass index;
LGG	cis	rs4731207	0.596	rs10231355	chr7:124581218	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9596863	1.000	rs7328595	chr13:54424070	G/A	ch.13.53330881F	chr13:54432880	NA	-0.48	-6.81	-0.3	3.11e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs537930	0.734	rs31211	chr5:134363145	G/A	cg24576358	chr5:134350122	NA	0.36	6.87	0.3	2.07e-11	Height;
LGG	cis	rs988958	0.917	rs13401037	chr2:42282632	A/T	cg27252766	chr2:42229092	NA	0.45	7.33	0.32	1.03e-12	Hypospadias;
LGG	cis	rs317689	0.613	rs315112	chr12:69785926	T/A	cg19645103	chr12:69753606	YEATS4	-0.48	-7.14	-0.31	3.71e-12	Response to diuretic therapy;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg17852997	chr13:21100460	CRYL1	0.4	6.78	0.3	3.7e-11	Body mass index;
LGG	trans	rs8073060	0.586	rs4796104	chr17:34046832	T/C	cg19694781	chr19:47549865	TMEM160	1.16	17.64	0.63	1.17e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs7762018	1.000	rs7747645	chr6:170070291	G/C	cg15038512	chr6:170123185	PHF10	0.52	6.86	0.3	2.21e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12282928	0.699	rs7940877	chr11:48225680	A/G	cg20307385	chr11:47447363	PSMC3	-0.43	-7.0	-0.31	8.93e-12	Migraine - clinic-based;
LGG	cis	rs6860806	0.507	rs272883	chr5:131668698	A/G	cg07395648	chr5:131743802	NA	-0.48	-9.87	-0.42	5.39e-21	Breast cancer;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg11878867	chr6:150167359	LRP11	-0.53	-11.14	-0.46	1.04e-25	Lung cancer;
LGG	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.28	0.32	1.43e-12	Hip circumference adjusted for BMI;
LGG	cis	rs3816183	0.916	rs920394	chr2:43022496	T/G	cg14631114	chr2:43023945	NA	0.49	9.08	0.39	3.1e-18	Hypospadias;
LGG	cis	rs4073582	0.595	rs2508657	chr11:66043898	G/A	cg14036092	chr11:66035641	RAB1B	0.46	7.97	0.35	1.23e-14	Gout;
LGG	cis	rs13191362	1.000	rs13191362	chr6:163033350	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.83	9.05	0.39	3.85e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7635838	0.819	rs6776159	chr3:11519324	A/G	cg00170343	chr3:11313890	ATG7	0.41	6.83	0.3	2.62e-11	HDL cholesterol;
LGG	trans	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg13565492	chr6:43139072	SRF	-0.77	-10.39	-0.43	7.34e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg00149659	chr3:10157352	C3orf10	0.76	9.75	0.41	1.48e-20	Alzheimer's disease;
LGG	cis	rs6089584	0.850	rs881993	chr20:60623862	A/G	cg13770153	chr20:60521292	NA	-0.56	-8.76	-0.38	3.77e-17	Body mass index;
LGG	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.15	0.7	5.84e-70	Gut microbiome composition (summer);
LGG	trans	rs4650994	0.524	rs2761465	chr1:178579404	G/T	cg05059571	chr16:84539110	KIAA1609	0.54	10.14	0.43	6.15e-22	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs240764	0.817	rs12214151	chr6:101159516	G/T	cg09795085	chr6:101329169	ASCC3	-0.45	-7.62	-0.33	1.49e-13	Neuroticism;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22694749	chr19:814917	LPPR3	0.36	7.09	0.31	5.1e-12	Menarche (age at onset);
LGG	trans	rs10802346	0.514	rs4443861	chr1:246372574	G/T	cg13514129	chr1:39547527	MACF1	0.7	12.65	0.51	9.95e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs9875589	0.957	rs35485647	chr3:13937937	G/C	cg19554555	chr3:13937349	NA	0.72	13.61	0.53	9.64e-36	Ovarian reserve;
LGG	cis	rs7824557	0.527	rs2409756	chr8:11242025	A/C	cg15596359	chr8:11213517	TDH	0.41	8.09	0.35	5.24e-15	Retinal vascular caliber;
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-7.96	-0.35	1.33e-14	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs66573146	0.831	rs67665838	chr4:7064870	G/A	cg07817883	chr1:32538562	TMEM39B	0.85	7.64	0.33	1.24e-13	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg06481639	chr22:41940642	POLR3H	-0.52	-7.77	-0.34	4.97e-14	Vitiligo;
LGG	cis	rs7044106	0.734	rs1981020	chr9:123388464	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.14	0.49	1.28e-29	Hip circumference adjusted for BMI;
LGG	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg03929089	chr4:120376271	NA	-1.04	-24.43	-0.75	2.68e-85	Height;
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.45	-0.37	3.86e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17376456	0.825	rs28412976	chr5:93248377	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.35	0.43	1e-22	Diabetic retinopathy;
LGG	cis	rs7208859	0.673	rs11650305	chr17:29229361	A/C	cg13385521	chr17:29058706	SUZ12P	0.75	8.56	0.37	1.71e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6763768	0.606	rs9942027	chr3:53392663	C/T	cg16894138	chr3:53270350	TKT	0.42	8.08	0.35	5.75e-15	Bacterial meningitis;
LGG	cis	rs9399135	0.967	rs4142299	chr6:135377186	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.36	0.4	3.54e-19	Red blood cell count;
LGG	cis	rs1372520	0.627	rs2737025	chr4:90719192	A/G	cg15133208	chr4:90757351	SNCA	-0.4	-8.23	-0.36	1.91e-15	Neuroticism;
LGG	trans	rs7726839	0.561	rs4957048	chr5:583442	G/A	cg25482853	chr8:67687455	SGK3	0.85	11.15	0.46	9.37e-26	Obesity-related traits;
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.36	-7.11	-0.31	4.46e-12	Aortic root size;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg12288994	chr5:1860383	NA	0.79	16.03	0.6	2.66e-46	Cardiovascular disease risk factors;
LGG	cis	rs1707322	0.785	rs10890348	chr1:46242423	G/T	cg03146154	chr1:46216737	IPP	0.59	10.57	0.44	1.48e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs870825	0.655	rs67798981	chr4:185619567	A/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs1355223	0.768	rs11032806	chr11:34692305	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.43	-7.17	-0.32	2.97e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg03103770	chr19:1753464	ONECUT3	0.49	7.1	0.31	4.86e-12	Hip circumference;
LGG	cis	rs867371	1.000	rs8037224	chr15:82464530	G/A	cg00614314	chr15:82944287	LOC80154	0.59	9.83	0.42	7.52e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs4746818	1.000	rs7901617	chr10:70904063	C/T	cg04149295	chr10:70884716	VPS26A	0.48	7.19	0.32	2.58e-12	Left atrial antero-posterior diameter;
LGG	cis	rs9341808	0.727	rs4706834	chr6:81012605	G/T	cg08355045	chr6:80787529	NA	0.39	7.53	0.33	2.61e-13	Sitting height ratio;
LGG	cis	rs9557207	0.507	rs12877831	chr13:99988752	C/T	cg24509225	chr13:100037070	UBAC2	0.44	8.3	0.36	1.13e-15	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs7267979	0.966	rs2261794	chr20:25263062	T/G	cg06421707	chr20:25228305	PYGB	0.47	10.19	0.43	3.79e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9527	0.640	rs6584541	chr10:104929124	A/G	cg05308233	chr10:104796373	CNNM2	-0.32	-6.98	-0.31	1.02e-11	Arsenic metabolism;
LGG	cis	rs12497850	1.000	rs4858831	chr3:48735558	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.69	0.3	6.33e-11	Parkinson's disease;
LGG	cis	rs2243480	1.000	rs59794892	chr7:65415873	G/A	cg18252515	chr7:66147081	NA	-1.31	-19.1	-0.66	2.09e-60	Diabetic kidney disease;
LGG	cis	rs12210905	0.687	rs12191649	chr6:27421208	A/T	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg00071950	chr4:10020882	SLC2A9	0.41	8.47	0.37	3.33e-16	Bone mineral density;
LGG	cis	rs1153858	1.000	rs56850226	chr15:45633118	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.04	0.35	7.76e-15	Homoarginine levels;
LGG	cis	rs600231	0.542	rs10896008	chr11:65245904	C/G	cg17120908	chr11:65337727	SSSCA1	-0.59	-8.63	-0.37	9.59e-17	Bone mineral density;
LGG	cis	rs9534288	0.797	rs994351	chr13:46588194	A/G	cg15192986	chr13:46630673	CPB2	-0.6	-13.28	-0.53	2.43e-34	Blood protein levels;
LGG	cis	rs9611519	0.894	rs13053242	chr22:41459486	G/A	cg03806693	chr22:41940476	POLR3H	-0.54	-8.12	-0.35	4.17e-15	Neuroticism;
LGG	cis	rs1799949	1.000	rs8070085	chr17:41341984	C/T	cg25072359	chr17:41440525	NA	-0.4	-7.67	-0.34	1.02e-13	Menopause (age at onset);
LGG	cis	rs12950390	0.853	rs17773010	chr17:45858297	C/T	cg03474202	chr17:45855739	NA	-0.27	-8.0	-0.35	1.02e-14	IgG glycosylation;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg11494091	chr17:61959527	GH2	0.51	8.15	0.35	3.5e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1499614	0.901	rs2178742	chr7:66197799	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	cis	rs853679	0.517	rs4713148	chr6:28115921	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs10883723	0.773	rs1326193	chr10:104271674	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.45e-39	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs28595532	0.920	rs114051506	chr4:119772893	A/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs9467711	1.000	rs9467704	chr6:26319486	A/G	cg06606381	chr12:133084897	FBRSL1	0.63	6.91	0.31	1.62e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6445975	0.666	rs6445974	chr3:58366837	A/G	cg24175188	chr3:58374923	PXK	-0.54	-8.83	-0.38	2.11e-17	Systemic lupus erythematosus;
LGG	cis	rs12701220	0.894	rs12701348	chr7:1039457	C/T	cg00990874	chr7:1149470	C7orf50	-0.67	-10.52	-0.44	2.43e-23	Bronchopulmonary dysplasia;
LGG	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg01221209	chr5:554886	NA	-0.51	-8.21	-0.36	2.17e-15	Obesity-related traits;
LGG	cis	rs12410462	0.591	rs903693	chr1:227732787	A/G	cg21459583	chr1:227974177	NA	0.36	6.85	0.3	2.31e-11	Major depressive disorder;
LGG	cis	rs1816752	0.870	rs8000215	chr13:25009786	A/G	cg22771759	chr13:24902376	NA	0.42	7.17	0.32	3.03e-12	Obesity-related traits;
LGG	cis	rs910316	0.967	rs10142770	chr14:75525449	G/A	cg11812906	chr14:75593930	NEK9	0.55	10.35	0.43	1.02e-22	Height;
LGG	trans	rs4332037	0.575	rs55952733	chr7:2070680	G/A	cg10840412	chr1:235813424	GNG4	0.51	6.87	0.3	2.04e-11	Bipolar disorder;
LGG	cis	rs28595532	0.841	rs116521340	chr4:119757415	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.722	rs202635	chr22:41809637	C/T	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs7089973	0.604	rs11196942	chr10:116596872	G/A	cg03647239	chr10:116582469	FAM160B1	0.41	7.11	0.31	4.38e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs7819412	0.522	rs11776603	chr8:11020313	G/T	cg21775007	chr8:11205619	TDH	-0.54	-8.28	-0.36	1.38e-15	Triglycerides;
LGG	cis	rs10744422	1.000	rs7309225	chr12:123288439	A/G	cg25930673	chr12:123319894	HIP1R	-0.67	-7.93	-0.35	1.65e-14	Schizophrenia;
LGG	cis	rs1568889	0.838	rs7125749	chr11:28154692	A/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.24	0.67	4.89e-61	Bipolar disorder;
LGG	cis	rs6901004	0.803	rs168522	chr6:111506628	A/G	cg15721981	chr6:111408429	SLC16A10	-0.4	-7.23	-0.32	2.08e-12	Blood metabolite levels;
LGG	trans	rs3942852	0.774	rs10838812	chr11:48186924	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-10.18	-0.43	4.27e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9303401	0.527	rs2116450	chr17:56745561	C/T	cg25039879	chr17:56429692	SUPT4H1	0.59	7.72	0.34	7.4e-14	Cognitive test performance;
LGG	cis	rs2346177	0.542	rs6718875	chr2:46687982	G/T	cg02822958	chr2:46747628	ATP6V1E2	0.52	8.98	0.39	6.6e-18	HDL cholesterol;
LGG	cis	rs13191362	0.507	rs2846519	chr6:163045463	G/A	cg06582575	chr6:163149167	PACRG;PARK2	-0.49	-6.67	-0.3	7.27e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2204008	0.640	rs2320744	chr12:38162389	A/G	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	cis	rs1018836	0.923	rs6986088	chr8:91538474	A/C	cg16814680	chr8:91681699	NA	-0.78	-14.27	-0.55	1.57e-38	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs611744	0.560	rs58605513	chr8:109279122	A/C	cg21045802	chr8:109455806	TTC35	0.53	9.94	0.42	3.21e-21	Dupuytren's disease;
LGG	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg14664628	chr15:75095509	CSK	-1.14	-26.9	-0.78	1.15e-96	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2832077	1.000	rs2832077	chr21:30141021	G/A	cg24692254	chr21:30365293	RNF160	-0.56	-8.37	-0.36	6.88e-16	Cognitive test performance;
LGG	trans	rs453301	0.571	rs330054	chr8:9088291	G/A	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.76	-0.34	5.35e-14	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg11878867	chr6:150167359	LRP11	-0.53	-11.08	-0.46	1.76e-25	Lung cancer;
LGG	trans	rs9467711	0.606	rs28360517	chr6:26602453	A/G	cg08344181	chr3:125677491	NA	-0.58	-6.66	-0.3	7.83e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg09699651	chr6:150184138	LRP11	0.51	9.04	0.39	4.24e-18	Lung cancer;
LGG	trans	rs9393777	0.920	rs35120058	chr6:27358166	A/G	cg08344181	chr3:125677491	NA	-0.8	-8.06	-0.35	6.67e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10197940	0.578	rs6718372	chr2:152345871	C/G	cg19508488	chr2:152266495	RIF1	0.47	8.52	0.37	2.31e-16	Lung cancer;
LGG	cis	rs7635838	0.617	rs2594971	chr3:11313910	G/A	cg00170343	chr3:11313890	ATG7	0.55	9.47	0.4	1.4e-19	HDL cholesterol;
LGG	cis	rs1862618	0.802	rs33327	chr5:56142693	T/G	cg12654349	chr5:56205094	C5orf35	-0.66	-10.34	-0.43	1.13e-22	Initial pursuit acceleration;
LGG	cis	rs1595825	0.838	rs73056856	chr2:198801209	C/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.96	-0.31	1.19e-11	Ulcerative colitis;
LGG	cis	rs4356203	0.870	rs7937176	chr11:17279745	C/T	cg15432903	chr11:17409602	KCNJ11	-0.4	-7.54	-0.33	2.54e-13	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	trans	rs1814175	0.646	rs1722010	chr11:49897958	A/G	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	trans	rs7762018	0.655	rs2184195	chr6:170148397	C/T	cg06875740	chr19:51307921	C19orf48	-0.65	-8.21	-0.36	2.26e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7444	0.941	rs2070512	chr22:21949411	A/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs9486719	0.947	rs12213375	chr6:96902134	A/G	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.69	-0.3	6.56e-11	Migraine;Coronary artery disease;
LGG	cis	rs9322193	0.923	rs1984111	chr6:150152856	G/A	cg04369109	chr6:150039330	LATS1	-0.4	-6.79	-0.3	3.41e-11	Lung cancer;
LGG	cis	rs76419734	0.510	rs4699198	chr4:106645771	G/A	cg24545054	chr4:106630052	GSTCD;INTS12	0.73	10.91	0.45	8.29e-25	Post bronchodilator FEV1;
LGG	cis	rs9611565	0.659	rs56319767	chr22:41933837	G/A	cg06634786	chr22:41940651	POLR3H	-0.8	-12.9	-0.51	9.69e-33	Vitiligo;
LGG	cis	rs9814567	1.000	rs4974483	chr3:134219001	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.46e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs68170813	0.559	rs75313693	chr7:106863170	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.79	-0.45	2.22e-24	Coronary artery disease;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg02462569	chr6:150064036	NUP43	-0.36	-7.62	-0.33	1.48e-13	Lung cancer;
LGG	trans	rs7395662	0.504	rs11039701	chr11:48389838	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.77	-0.34	5.2e-14	HDL cholesterol;
LGG	cis	rs34172651	0.517	rs36113933	chr16:24838862	A/G	cg02428538	chr16:24856791	SLC5A11	-0.66	-10.13	-0.43	6.38e-22	Intelligence (multi-trait analysis);
LGG	trans	rs6787172	0.540	rs28522438	chr3:158170996	C/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.56	-0.33	2.22e-13	Subjective well-being;
LGG	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg13512537	chr8:22265999	SLC39A14	-0.37	-6.73	-0.3	4.97e-11	Verbal declarative memory;
LGG	cis	rs933688	1.000	rs2839728	chr5:90727412	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.06	16.86	0.62	4.53e-50	Smoking behavior;
LGG	cis	rs6502050	0.835	rs8065037	chr17:80158966	T/G	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg13206674	chr6:150067644	NUP43	-0.43	-7.51	-0.33	3.06e-13	Lung cancer;
LGG	cis	rs1348850	0.567	rs3770011	chr2:178537890	C/T	cg22681709	chr2:178499509	PDE11A	-0.48	-8.75	-0.38	3.99e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs79149102	0.579	rs12593542	chr15:75282147	C/G	cg17294928	chr15:75287854	SCAMP5	-0.72	-8.31	-0.36	1.05e-15	Lung cancer;
LGG	cis	rs7666738	0.753	rs4699604	chr4:99056353	T/C	cg05340658	chr4:99064831	C4orf37	0.48	7.98	0.35	1.2e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs28595532	0.920	rs115994240	chr4:119744622	C/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.835	rs10163482	chr17:80110394	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs870825	0.616	rs2141257	chr4:185609463	C/T	cg04058563	chr4:185651563	MLF1IP	-1.05	-21.25	-0.7	1.98e-70	Blood protein levels;
LGG	cis	rs7412746	0.658	rs72704652	chr1:150819470	A/G	cg15448220	chr1:150897856	SETDB1	0.39	7.14	0.31	3.6e-12	Melanoma;
LGG	cis	rs7918232	0.941	rs788210	chr10:27476948	T/C	cg14442939	chr10:27389572	ANKRD26	-0.76	-11.32	-0.47	2.16e-26	Breast cancer;
LGG	cis	rs953387	0.824	rs6716987	chr2:136963494	G/T	cg07169764	chr2:136633963	MCM6	0.51	8.48	0.37	3e-16	Arthritis (juvenile idiopathic);
LGG	cis	rs6604026	0.922	rs12746956	chr1:93312142	A/G	cg22128645	chr1:93425802	FAM69A	-0.41	-7.55	-0.33	2.39e-13	Multiple sclerosis;
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg13047869	chr3:10149882	C3orf24	0.6	8.6	0.37	1.24e-16	Alzheimer's disease;
LGG	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg22491629	chr6:157744540	C6orf35	-0.97	-13.51	-0.53	2.71e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg08885076	chr2:99613938	TSGA10	-0.59	-10.62	-0.44	1.02e-23	Chronic sinus infection;
LGG	cis	rs7010267	0.740	rs7464496	chr8:119954842	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.33	8.24	0.36	1.85e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs7911264	1.000	rs7911264	chr10:94436851	C/T	cg25093409	chr10:94429542	NA	-0.57	-12.0	-0.49	4.36e-29	Inflammatory bowel disease;
LGG	trans	rs7824557	0.564	rs12547100	chr8:11242632	G/A	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.6	-0.37	1.25e-16	Retinal vascular caliber;
LGG	cis	rs3857536	0.842	rs2188590	chr6:66939534	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs7828089	0.582	rs3817445	chr8:22266054	G/T	cg13512537	chr8:22265999	SLC39A14	-0.49	-8.8	-0.38	2.79e-17	Verbal declarative memory;
LGG	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg20503657	chr10:835505	NA	0.56	7.26	0.32	1.69e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs8062405	1.000	rs2008514	chr16:28825605	A/G	cg00204512	chr16:28754710	NA	-0.27	-7.69	-0.34	8.66e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2880765	0.835	rs4360874	chr15:86040820	A/T	cg10818794	chr15:86012489	AKAP13	-0.38	-8.08	-0.35	5.66e-15	Coronary artery disease;
LGG	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg01448562	chr3:133502909	NA	0.76	13.73	0.54	3.17e-36	Iron status biomarkers;
LGG	cis	rs752010	0.875	rs11210502	chr1:42093712	A/C	cg16096631	chr1:42092165	HIVEP3	0.75	19.64	0.67	6.81e-63	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg21775007	chr8:11205619	TDH	-0.75	-13.09	-0.52	1.58e-33	Retinal vascular caliber;
LGG	cis	rs3091242	0.933	rs34933589	chr1:25788198	T/C	cg02931644	chr1:25747376	RHCE	-0.41	-8.78	-0.38	3.18e-17	Erythrocyte sedimentation rate;
LGG	cis	rs28595532	0.920	rs116428408	chr4:119758514	G/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs225245	0.610	rs321608	chr17:33880636	A/G	cg19694781	chr19:47549865	TMEM160	-0.48	-8.35	-0.36	7.88e-16	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4077515	0.967	rs4266763	chr9:139289825	C/T	cg21253087	chr9:139290292	SNAPC4	-0.35	-7.11	-0.31	4.43e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1218582	0.688	rs2135219	chr1:154857217	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.22	-0.32	2.21e-12	Prostate cancer;
LGG	cis	rs67311347	0.544	rs13098483	chr3:40342743	G/C	cg13683864	chr3:40499215	RPL14	-0.81	-16.03	-0.6	2.65e-46	Renal cell carcinoma;
LGG	cis	rs2901656	0.677	rs2269615	chr1:172415451	C/T	cg03748243	chr1:172413542	C1orf105;PIGC	0.3	6.99	0.31	9.9e-12	Red cell distribution width;Platelet distribution width;
LGG	cis	rs9527	0.569	rs78193706	chr10:104780564	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.97	-0.31	1.13e-11	Arsenic metabolism;
LGG	cis	rs7546668	1.000	rs4646100	chr1:15820041	C/T	cg21858823	chr1:15850916	CASP9	0.38	7.14	0.32	3.56e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs3087591	1.000	rs2057769	chr17:29691368	C/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.63	-0.56	4.23e-40	Hip circumference;
LGG	trans	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.91	-0.31	1.58e-11	Heart rate;
LGG	cis	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg22857025	chr5:266934	NA	-1.5	-26.58	-0.78	3.13e-95	Breast cancer;
LGG	cis	rs9902453	0.933	rs9908901	chr17:28469713	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.84	0.51	1.79e-32	Coffee consumption (cups per day);
LGG	cis	rs2645694	0.626	rs2645684	chr4:77819892	A/C	cg03477792	chr4:77819574	ANKRD56	0.54	9.46	0.4	1.53e-19	Emphysema distribution in smoking;
LGG	cis	rs614226	1.000	rs541126	chr12:120972396	C/T	cg21053147	chr12:120880522	NA	0.56	8.2	0.36	2.31e-15	Type 1 diabetes nephropathy;
LGG	cis	rs4144743	1.000	rs4541130	chr17:45321037	G/A	cg18085866	chr17:45331354	ITGB3	-0.78	-9.86	-0.42	5.97e-21	Body mass index;
LGG	trans	rs2204008	0.582	rs11179135	chr12:38204689	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.36	-0.36	7.47e-16	Bladder cancer;
LGG	cis	rs798554	0.567	rs1182194	chr7:2868824	C/G	cg27476859	chr7:2772710	GNA12	0.54	10.45	0.44	4.39e-23	Height;
LGG	cis	rs4430311	0.723	rs12136847	chr1:243747358	A/G	cg25706552	chr1:244017396	NA	-0.64	-15.53	-0.59	4.44e-44	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg24623649	chr8:11872141	NA	0.3	6.96	0.31	1.18e-11	Neuroticism;
LGG	cis	rs2439831	0.681	rs1549523	chr15:43624189	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.89	0.54	6.34e-37	Lung cancer in ever smokers;
LGG	cis	rs240764	0.782	rs239222	chr6:101112817	T/A	cg09795085	chr6:101329169	ASCC3	0.46	7.72	0.34	7.14e-14	Neuroticism;
LGG	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04530015	chr2:215796436	ABCA12	0.46	8.43	0.36	4.28e-16	Neuroblastoma;
LGG	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg11789530	chr4:8429930	ACOX3	-0.67	-10.89	-0.45	9.63e-25	Response to antineoplastic agents;
LGG	cis	rs9443645	0.869	rs7756858	chr6:79619968	A/G	cg18132916	chr6:79620363	NA	-0.32	-8.98	-0.39	6.94e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7186908	0.711	rs9923344	chr16:72190653	T/C	cg01557791	chr16:72042693	DHODH	-0.57	-8.98	-0.39	6.8e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs2070488	0.965	rs1058945	chr3:38532511	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.85	-18.22	-0.65	2.57e-56	Electrocardiographic conduction measures;
LGG	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg10792982	chr14:105748885	BRF1	0.56	11.06	0.46	2.09e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2880765	0.525	rs35899940	chr15:86053697	A/G	cg10818794	chr15:86012489	AKAP13	-0.47	-10.06	-0.42	1.18e-21	Coronary artery disease;
LGG	cis	rs1595825	1.000	rs74935794	chr2:198871195	T/G	cg00982548	chr2:198649783	BOLL	-0.51	-7.07	-0.31	5.56e-12	Ulcerative colitis;
LGG	cis	rs657075	0.643	rs4646298	chr5:131705219	C/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs1010254	0.559	rs991637	chr5:151748808	C/A	cg12297329	chr5:152029980	NA	-0.46	-6.74	-0.3	4.86e-11	Optic nerve measurement (cup area);
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.54e-12	Prudent dietary pattern;
LGG	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg17757837	chr7:157058334	UBE3C	-0.78	-15.99	-0.6	3.83e-46	Body mass index;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg21775007	chr8:11205619	TDH	-0.49	-7.64	-0.33	1.23e-13	Neuroticism;
LGG	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.24	0.39	8.9e-19	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs383402	chr7:65586653	A/C	cg12463550	chr7:65579703	CRCP	-0.71	-7.91	-0.34	1.94e-14	Diabetic kidney disease;
LGG	cis	rs9443645	0.901	rs2050663	chr6:79753394	T/C	cg18132916	chr6:79620363	NA	-0.3	-8.25	-0.36	1.63e-15	Intelligence (multi-trait analysis);
LGG	cis	rs6539288	0.677	rs2216221	chr12:107327231	A/T	cg26297688	chr12:107349093	C12orf23	-0.38	-7.05	-0.31	6.63e-12	Total body bone mineral density;
LGG	cis	rs9682041	0.627	rs10936625	chr3:170094908	G/T	cg11886554	chr3:170076028	SKIL	-0.56	-7.31	-0.32	1.16e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2197308	0.765	rs11182434	chr12:37923968	C/A	cg13010199	chr12:38710504	ALG10B	0.71	14.18	0.55	3.56e-38	Morning vs. evening chronotype;
LGG	cis	rs3806843	0.735	rs801189	chr5:140063091	A/G	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs11874712	0.545	rs3745002	chr18:43652345	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.45	-9.11	-0.39	2.41e-18	Migraine - clinic-based;
LGG	cis	rs6502050	0.835	rs35038106	chr17:80180346	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-7.94	-0.35	1.6e-14	Life satisfaction;
LGG	cis	rs12477438	0.765	rs13390672	chr2:99589829	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs981844	0.816	rs62325148	chr4:154727993	A/G	cg14289246	chr4:154710475	SFRP2	0.71	11.66	0.48	1.05e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs7811142	0.830	rs7792525	chr7:99972122	A/G	cg11814155	chr7:99998594	ZCWPW1	0.59	8.82	0.38	2.3e-17	Platelet count;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg07167872	chr1:205819463	PM20D1	0.58	11.56	0.47	2.52e-27	Menarche (age at onset);
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg25427524	chr10:38739819	LOC399744	-0.71	-14.95	-0.57	1.58e-41	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs7432375	0.641	rs1971397	chr3:136527300	C/G	cg12473912	chr3:136751656	NA	0.43	7.21	0.32	2.34e-12	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.89	-0.38	1.33e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9611565	0.512	rs139566	chr22:42199277	A/G	cg17376030	chr22:41985996	PMM1	0.67	10.87	0.45	1.12e-24	Vitiligo;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg09264619	chr17:80180166	NA	-0.38	-7.58	-0.33	1.96e-13	Life satisfaction;
LGG	cis	rs7551222	0.789	rs4951408	chr1:204558984	C/G	cg20240347	chr1:204465584	NA	-0.48	-9.37	-0.4	3.25e-19	Schizophrenia;
LGG	cis	rs10214930	0.671	rs6963585	chr7:27583823	A/G	cg22168087	chr7:27702803	HIBADH	0.46	6.76	0.3	4.27e-11	Hypospadias;
LGG	cis	rs6424115	0.964	rs2473375	chr1:24136545	C/T	cg24699146	chr1:24152579	HMGCL	0.25	7.31	0.32	1.18e-12	Immature fraction of reticulocytes;
LGG	cis	rs7582180	0.967	rs7595580	chr2:100896964	A/G	cg21926883	chr2:100939477	LONRF2	-0.54	-10.38	-0.43	7.58e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9467711	0.606	rs9379851	chr6:26354780	A/C	cg12826209	chr6:26865740	GUSBL1	0.75	7.95	0.35	1.45e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs368123	0.961	rs415934	chr6:160717292	G/A	cg04181478	chr6:161122748	PLG	-0.37	-6.65	-0.3	8.11e-11	Waist circumference;
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg06221963	chr1:154839813	KCNN3	-0.53	-11.06	-0.46	2.12e-25	Prostate cancer;
LGG	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs3733346	0.553	rs2290403	chr4:942006	G/A	cg23939001	chr4:940644	TMEM175	0.74	19.1	0.66	2.2e-60	Sjögren's syndrome;
LGG	cis	rs13102973	0.720	rs4473702	chr4:135851159	C/G	cg14419869	chr4:135874104	NA	0.5	8.48	0.37	3e-16	Subjective well-being;
LGG	cis	rs2153535	0.580	rs1360054	chr6:8520377	C/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.81e-22	Motion sickness;
LGG	cis	rs7607369	0.580	rs7594289	chr2:219652286	A/G	cg01130898	chr2:219473002	PLCD4	0.41	6.86	0.3	2.17e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs2836974	0.931	rs13625	chr21:40669083	G/T	cg11890956	chr21:40555474	PSMG1	1.16	29.07	0.8	1.73e-106	Cognitive function;
LGG	cis	rs2878628	0.596	rs57039206	chr3:52758570	T/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	7.77e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	1.000	rs6953693	chr7:1886388	C/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.4	-0.33	6.48e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.727	rs12443748	chr16:4541831	C/T	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.6	0.33	1.68e-13	Schizophrenia;
LGG	cis	rs11190604	1.000	rs1800662	chr10:102289078	C/A	cg07570687	chr10:102243282	WNT8B	0.43	7.32	0.32	1.07e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs12479064	0.724	rs2309618	chr2:99974473	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.86	-0.38	1.71e-17	Chronic sinus infection;
LGG	cis	rs6908034	0.607	rs76245225	chr6:19813188	T/G	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg06139259	chr16:4526053	HMOX2;NMRAL1	-0.33	-6.79	-0.3	3.37e-11	Schizophrenia;
LGG	cis	rs77972916	0.561	rs10167415	chr2:43552460	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.55	-6.84	-0.3	2.46e-11	Granulocyte percentage of myeloid white cells;
LGG	cis	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg06521331	chr12:34319734	NA	-0.43	-7.73	-0.34	6.74e-14	Morning vs. evening chronotype;
LGG	cis	rs2404618	0.504	rs2906567	chr8:1494118	C/T	cg13402656	chr8:1511478	DLGAP2	-0.8	-15.33	-0.58	3.27e-43	Lung cancer;
LGG	cis	rs5769707	0.616	rs6009786	chr22:50015145	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.54	-0.41	8.29e-20	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02343318	chr19:37329498	ZNF790	-0.44	-7.34	-0.32	9.79e-13	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs951366	0.617	rs9438393	chr1:205782718	A/G	cg14159672	chr1:205819179	PM20D1	0.9	21.31	0.7	1.05e-70	Menarche (age at onset);
LGG	cis	rs12220238	1.000	rs10824088	chr10:75921490	G/C	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.9	0.45	9.21e-25	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs801193	0.591	rs9986881	chr7:66173040	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.59	13.4	0.53	7.58e-35	Aortic root size;
LGG	cis	rs8058578	1.000	rs6565197	chr16:30706477	T/C	cg02466173	chr16:30829666	NA	-0.52	-9.26	-0.4	7.8e-19	Multiple myeloma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12626377	chr20:34330591	RBM39	0.52	7.79	0.34	4.56e-14	Gut microbiome composition (summer);
LGG	cis	rs7614311	0.731	rs73130534	chr3:63859813	A/G	cg22134162	chr3:63841271	THOC7	-0.45	-8.01	-0.35	9.05e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg00012203	chr2:219082015	ARPC2	0.81	15.64	0.59	1.49e-44	Colorectal cancer;
LGG	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg15145296	chr3:125709740	NA	-0.62	-7.94	-0.35	1.55e-14	Blood pressure (smoking interaction);
LGG	trans	rs3780486	0.874	rs10813955	chr9:33141791	C/T	cg20290983	chr6:43655470	MRPS18A	1.1	24.86	0.76	2.71e-87	IgG glycosylation;
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg07648498	chr16:89883185	FANCA	0.41	6.94	0.31	1.31e-11	Vitiligo;
LGG	cis	rs738322	0.967	rs4380	chr22:38569529	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-7.0	-0.31	9.33e-12	Cutaneous nevi;
LGG	cis	rs9560113	1.000	rs9555807	chr13:112179965	C/T	cg14952266	chr13:112191215	NA	-0.43	-7.74	-0.34	6.45e-14	Menarche (age at onset);
LGG	cis	rs8177253	1.000	rs8177272	chr3:133482870	C/T	cg01448562	chr3:133502909	NA	-0.73	-13.57	-0.53	1.53e-35	Iron status biomarkers;
LGG	cis	rs113835537	0.529	rs11227514	chr11:66286627	G/A	cg24851651	chr11:66362959	CCS	0.44	7.73	0.34	6.79e-14	Airway imaging phenotypes;
LGG	cis	rs72772090	0.539	rs72773922	chr5:96116660	A/G	cg00188032	chr5:96141721	ERAP1	0.55	7.21	0.32	2.24e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.38	0.56	4.78e-39	Platelet count;
LGG	cis	rs10504229	1.000	rs56344560	chr8:58180626	C/G	cg21724239	chr8:58056113	NA	0.42	6.65	0.3	8.03e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs897984	0.609	rs57576577	chr16:31036367	G/A	cg02466173	chr16:30829666	NA	-0.43	-7.58	-0.33	1.97e-13	Dementia with Lewy bodies;
LGG	trans	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07923666	chr12:49932857	KCNH3	-0.52	-7.91	-0.35	1.9e-14	Resting heart rate;
LGG	cis	rs2842992	0.872	rs2758328	chr6:160090731	T/A	cg27624424	chr6:160112604	SOD2	0.71	10.44	0.44	4.83e-23	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10504229	0.683	rs67492041	chr8:58140077	G/A	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6504108	0.624	rs4794525	chr17:46298358	C/T	cg02219949	chr17:45927392	SP6	0.43	7.99	0.35	1.06e-14	Body mass index;
LGG	cis	rs1790761	0.967	rs1638556	chr11:67213518	A/G	cg00290607	chr11:67383545	NA	-0.46	-8.22	-0.36	2.02e-15	Mean corpuscular volume;
LGG	cis	rs7551222	0.721	rs4252717	chr1:204512100	T/C	cg20240347	chr1:204465584	NA	-0.56	-11.3	-0.46	2.67e-26	Schizophrenia;
LGG	trans	rs7829975	0.711	rs1039916	chr8:8685854	A/G	cg02002194	chr4:3960332	NA	-0.43	-8.25	-0.36	1.72e-15	Mood instability;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg17227014	chr4:6642450	MRFAP1	0.39	7.01	0.31	8.54e-12	Obesity-related traits;
LGG	cis	rs35146811	0.844	rs4424195	chr7:99642745	A/G	cg22906224	chr7:99728672	NA	0.54	8.88	0.38	1.44e-17	Coronary artery disease;
LGG	cis	rs2479724	0.792	rs7739064	chr6:41834037	C/A	cg17623882	chr6:41773611	USP49	-0.52	-9.33	-0.4	4.33e-19	Menarche (age at onset);
LGG	cis	rs12458462	0.665	rs2035085	chr18:77485280	C/T	cg11879182	chr18:77439856	CTDP1	0.79	14.55	0.56	9.3e-40	Monocyte count;
LGG	cis	rs854037	0.698	rs7722058	chr5:57073666	T/C	cg08523694	chr5:57076192	NA	0.51	7.1	0.31	4.88e-12	Birth weight;
LGG	cis	rs300703	0.719	rs389621	chr2:206636	C/T	cg24565620	chr2:194026	NA	0.73	11.12	0.46	1.23e-25	Blood protein levels;
LGG	cis	rs2576037	0.583	rs8086286	chr18:44467515	A/G	cg26155939	chr18:44337853	ST8SIA5	0.37	6.81	0.3	3.1e-11	Personality dimensions;
LGG	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.83	-0.38	2.2e-17	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.923	rs9479094	chr6:150046219	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-10.05	-0.42	1.2e-21	Lung cancer;
LGG	cis	rs7843479	0.601	rs10866827	chr8:21801141	G/A	cg17168535	chr8:21777572	XPO7	0.82	16.38	0.61	6.59e-48	Mean corpuscular volume;
LGG	cis	rs9325144	0.647	rs10875953	chr12:39050536	G/C	cg13010199	chr12:38710504	ALG10B	-0.54	-9.99	-0.42	2.02e-21	Morning vs. evening chronotype;
LGG	cis	rs700651	0.789	rs1978889	chr2:198889366	G/A	cg00792783	chr2:198669748	PLCL1	0.64	10.35	0.43	9.95e-23	Intracranial aneurysm;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg23630158	chr17:74722648	C17orf95;JMJD6	-0.38	-6.78	-0.3	3.77e-11	Brain structure;
LGG	cis	rs236352	0.521	rs6457963	chr6:36883540	A/G	cg03410223	chr6:36853544	C6orf89	0.41	7.59	0.33	1.72e-13	Heart rate;
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs10504229	1.000	rs59275611	chr8:58195191	G/A	cg08677398	chr8:58056175	NA	0.46	7.37	0.32	7.85e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4332037	0.624	rs11766944	chr7:1888051	G/A	cg12432903	chr7:1882776	MAD1L1	0.55	8.82	0.38	2.26e-17	Bipolar disorder;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg16141378	chr3:129829833	LOC729375	0.37	8.07	0.35	6.15e-15	Myopia (pathological);
LGG	cis	rs2842992	0.789	rs2277072	chr6:160182845	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	12.13	0.49	1.33e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg24375607	chr4:120327624	NA	0.63	10.46	0.44	3.83e-23	Corneal astigmatism;
LGG	cis	rs2816316	0.573	rs35197737	chr1:192531645	G/T	cg02586212	chr1:192544902	RGS1	-0.5	-7.39	-0.32	7.12e-13	Celiac disease;
LGG	cis	rs1799949	1.000	rs2037076	chr17:41305883	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs11098499	0.691	rs12502524	chr4:120271414	G/A	cg09307838	chr4:120376055	NA	0.66	11.32	0.47	2.19e-26	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs9322204	chr6:149957183	A/C	cg08621203	chr6:150244597	RAET1G	0.45	7.82	0.34	3.69e-14	Lung cancer;
LGG	cis	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg16400903	chr5:693638	TPPP	0.44	6.78	0.3	3.72e-11	Obesity-related traits;
LGG	cis	rs2243480	1.000	rs35735127	chr7:65300423	G/T	cg12463550	chr7:65579703	CRCP	0.74	8.23	0.36	1.98e-15	Diabetic kidney disease;
LGG	cis	rs564799	0.966	rs4679867	chr3:159723903	A/T	cg04855961	chr3:159719849	NA	0.29	7.62	0.33	1.45e-13	Systemic lupus erythematosus;
LGG	cis	rs17023223	0.537	rs17023174	chr1:119593301	T/C	cg05756136	chr1:119680316	WARS2	-0.41	-8.6	-0.37	1.21e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs7444	0.882	rs5998644	chr22:21953288	T/C	cg22858872	chr22:21984481	YDJC	-0.35	-6.8	-0.3	3.27e-11	Systemic lupus erythematosus;
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg19774624	chr17:42201019	HDAC5	-0.96	-20.83	-0.7	1.78e-68	Total body bone mineral density;
LGG	cis	rs11168618	0.904	rs7135125	chr12:48926268	A/T	cg24011408	chr12:48396354	COL2A1	0.45	7.25	0.32	1.72e-12	Adiponectin levels;
LGG	cis	rs12367572	1.000	rs12822444	chr12:45276677	G/A	cg03114573	chr12:45410052	DBX2	-0.52	-8.87	-0.38	1.55e-17	Gut microbiome composition (summer);
LGG	cis	rs6076065	0.748	rs2180139	chr20:23405281	G/A	cg11657817	chr20:23433608	CST11	0.41	8.3	0.36	1.16e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs2549003	1.000	rs2706384	chr5:131826880	G/T	cg00578828	chr5:131826934	IRF1	-0.38	-6.71	-0.3	5.86e-11	Asthma (sex interaction);
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg00424166	chr6:150045504	NUP43	-0.36	-7.49	-0.33	3.43e-13	Lung cancer;
LGG	cis	rs17253792	0.545	rs12893610	chr14:56016347	C/T	cg01858014	chr14:56050164	KTN1	-0.76	-9.49	-0.4	1.27e-19	Putamen volume;
LGG	cis	rs11711311	0.712	rs3773684	chr3:113334488	A/T	cg15478005	chr3:113465772	ATP6V1A;NAA50	-0.6	-12.17	-0.49	9.41e-30	IgG glycosylation;
LGG	cis	rs9486719	1.000	rs2971603	chr6:97035418	C/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-7.48	-0.33	3.87e-13	Migraine;Coronary artery disease;
LGG	cis	rs2282978	0.557	rs42045	chr7:92250354	C/T	cg15732164	chr7:92237376	CDK6	-0.34	-7.06	-0.31	6.09e-12	Height;
LGG	cis	rs6952808	0.929	rs12532128	chr7:1925454	T/C	cg19147804	chr7:1989927	MAD1L1	-0.61	-12.4	-0.5	1.08e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.05	0.7	1.61e-69	Alzheimer's disease;
LGG	cis	rs2976388	0.609	rs2717550	chr8:143787808	T/A	cg06565975	chr8:143823917	SLURP1	0.35	9.09	0.39	2.97e-18	Urinary tract infection frequency;
LGG	trans	rs1005277	0.579	rs1780121	chr10:38529437	C/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.41	-0.33	6.11e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4478037	0.558	rs7614585	chr3:33078170	A/G	cg19404215	chr3:33155277	CRTAP	-0.68	-6.79	-0.3	3.52e-11	Major depressive disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15046935	chr19:45595006	NA	0.49	8.03	0.35	8.2e-15	Cognitive performance;
LGG	cis	rs875971	0.862	rs778724	chr7:65829291	T/C	cg18252515	chr7:66147081	NA	-0.41	-6.98	-0.31	1.04e-11	Aortic root size;
LGG	cis	rs10540	1.000	rs35231079	chr11:515224	G/A	cg03576123	chr11:487126	PTDSS2	-1.21	-14.81	-0.57	6.4e-41	Body mass index;
LGG	cis	rs2180341	0.694	rs2875972	chr6:127585522	T/C	cg27446573	chr6:127587934	RNF146	0.95	17.72	0.64	5.35e-54	Breast cancer;
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-15.96	-0.6	5.38e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	1.000	rs9487051	chr6:109617079	A/G	cg21918786	chr6:109611834	NA	-0.44	-8.31	-0.36	1.1e-15	Reticulocyte fraction of red cells;
LGG	cis	rs6502050	0.835	rs34287733	chr17:80078236	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.3	0.32	1.26e-12	Life satisfaction;
LGG	cis	rs908922	0.676	rs486283	chr1:152525957	A/G	cg03606772	chr1:152487856	CRCT1	0.29	6.86	0.3	2.15e-11	Hair morphology;
LGG	cis	rs6424115	1.000	rs6424115	chr1:24153231	A/G	cg24699146	chr1:24152579	HMGCL	-0.26	-7.6	-0.33	1.67e-13	Immature fraction of reticulocytes;
LGG	cis	rs2243480	0.908	rs55876148	chr7:65379800	G/A	cg12463550	chr7:65579703	CRCP	0.74	8.0	0.35	1.01e-14	Diabetic kidney disease;
LGG	cis	rs17826219	0.585	rs8064302	chr17:28724938	G/A	cg01831904	chr17:28903510	LRRC37B2	0.66	8.21	0.36	2.26e-15	Body mass index;
LGG	cis	rs3806843	0.735	rs2530241	chr5:140054485	C/T	cg19875535	chr5:140030758	IK	-0.56	-11.5	-0.47	4.37e-27	Depressive symptoms (multi-trait analysis);
LGG	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg07636037	chr3:49044803	WDR6	0.44	6.74	0.3	4.8e-11	Resting heart rate;
LGG	cis	rs62238980	0.521	rs78578916	chr22:32456881	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs7928758	1.000	rs7108503	chr11:134280766	A/G	cg15243474	chr11:134282918	B3GAT1	1.03	14.19	0.55	3.45e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs4787491	0.704	rs12445768	chr16:30089911	T/C	cg06326092	chr16:30034487	C16orf92	0.43	8.5	0.37	2.65e-16	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.572	rs12107622	chr3:10171898	T/A	cg00149659	chr3:10157352	C3orf10	1.21	14.37	0.56	5.56e-39	Alzheimer's disease;
LGG	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg11634705	chr7:873449	UNC84A	0.43	7.39	0.32	6.78e-13	Subjective well-being;
LGG	cis	rs9916302	0.706	rs4795358	chr17:37573065	A/C	cg00129232	chr17:37814104	STARD3	-0.56	-8.42	-0.36	4.6e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9522267	0.535	rs9522302	chr13:112236874	C/T	cg14952266	chr13:112191215	NA	0.51	10.89	0.45	9.71e-25	Hepatitis;
LGG	cis	rs6554196	0.686	rs13106834	chr4:55501728	C/T	cg18836493	chr4:55524333	KIT	0.41	7.62	0.33	1.48e-13	Monocyte count;
LGG	cis	rs548181	0.611	rs1293672	chr11:125461034	A/G	cg03464685	chr11:125439445	EI24	1.39	20.07	0.68	6.2e-65	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs8053891	0.855	rs8053861	chr16:71997675	C/G	cg09427745	chr16:71932006	KIAA0174	-0.36	-6.66	-0.3	7.62e-11	Coronary artery disease;
LGG	cis	rs1552244	0.872	rs6803517	chr3:10065426	C/T	cg13047869	chr3:10149882	C3orf24	0.54	9.08	0.39	3.22e-18	Alzheimer's disease;
LGG	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg17809284	chr5:56205270	C5orf35	0.54	10.01	0.42	1.72e-21	Initial pursuit acceleration;
LGG	cis	rs4639966	0.684	rs487177	chr11:118657297	C/G	cg19182353	chr11:118479428	PHLDB1	-0.52	-8.5	-0.37	2.54e-16	Systemic lupus erythematosus;
LGG	cis	rs67366981	0.778	rs3952319	chr14:77684379	A/T	cg22824376	chr14:77648248	TMEM63C	0.87	11.42	0.47	8.68e-27	Obsessive-compulsive symptoms;
LGG	cis	rs7077256	0.542	rs12773235	chr10:65014675	G/A	cg02276361	chr10:65351566	REEP3	-0.33	-6.81	-0.3	3.11e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7959452	0.718	rs10878963	chr12:69717166	T/G	cg11871910	chr12:69753446	YEATS4	0.55	10.47	0.44	3.78e-23	Blood protein levels;
LGG	cis	rs11098499	0.866	rs12513310	chr4:120288039	T/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg08621203	chr6:150244597	RAET1G	0.42	7.21	0.32	2.3e-12	Lung cancer;
LGG	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs9972944	0.692	rs6504346	chr17:63757175	C/A	cg07283582	chr17:63770753	CCDC46	-0.41	-7.85	-0.34	2.82e-14	Total body bone mineral density;
LGG	trans	rs9354308	0.764	rs6929147	chr6:66613908	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.39	-6.66	-0.3	7.97e-11	Metabolite levels;
LGG	cis	rs9400467	0.537	rs17606481	chr6:111542388	A/G	cg15721981	chr6:111408429	SLC16A10	0.59	7.08	0.31	5.26e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4555082	0.834	rs2816631	chr14:105739477	G/A	cg27165867	chr14:105738592	BRF1	-0.46	-7.34	-0.32	9.58e-13	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg00142150	chr22:38071001	LGALS1	0.67	10.55	0.44	1.91e-23	Fat distribution (HIV);
LGG	cis	rs4819052	0.851	rs2877018	chr21:46658306	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs2161208	0.585	rs2909871	chr5:85332606	C/T	cg01787110	chr1:109008453	NBPF6	0.45	6.76	0.3	4.1e-11	Daytime sleep phenotypes;
LGG	cis	rs1728785	0.786	rs1728770	chr16:68564124	G/C	cg02972257	chr16:68554789	NA	-0.56	-8.33	-0.36	9.25e-16	Ulcerative colitis;
LGG	cis	rs2235649	0.833	rs9926962	chr16:1851826	A/G	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.4	-6.71	-0.3	5.8200000000000003e-11	Blood metabolite levels;
LGG	cis	rs113835537	0.529	rs57634456	chr11:66250838	A/C	cg24851651	chr11:66362959	CCS	0.44	7.71	0.34	7.87e-14	Airway imaging phenotypes;
LGG	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.92	0.38	1.12e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg26384229	chr12:38710491	ALG10B	-0.59	-10.56	-0.44	1.71e-23	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs28403500	chr4:90769729	T/G	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	cis	rs78456975	0.739	rs11891867	chr2:1517894	C/T	cg01028140	chr2:1542097	TPO	-0.51	-8.08	-0.35	5.53e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7937682	0.921	rs4616071	chr11:111440865	C/G	cg08305652	chr11:111469057	NA	0.43	8.31	0.36	1.04e-15	Primary sclerosing cholangitis;
LGG	trans	rs12439619	0.846	rs28470877	chr15:82538138	T/C	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.65	-0.3	8.29e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.518	rs55896564	chr8:11447093	G/A	cg06636001	chr8:8085503	FLJ10661	-0.62	-11.96	-0.49	6.26e-29	Retinal vascular caliber;
LGG	cis	rs2880765	0.835	rs900573	chr15:86037993	G/T	cg10818794	chr15:86012489	AKAP13	0.38	8.04	0.35	7.53e-15	Coronary artery disease;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg11050988	chr7:1952600	MAD1L1	0.35	8.52	0.37	2.19e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	cis	rs798554	0.959	rs798556	chr7:2759002	C/A	cg13628971	chr7:2884303	GNA12	0.5	9.65	0.41	3.35e-20	Height;
LGG	trans	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg08975724	chr8:8085496	FLJ10661	0.45	8.73	0.38	4.83e-17	Retinal vascular caliber;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg03188948	chr7:1209495	NA	0.48	7.75	0.34	5.84e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7647973	0.626	rs9829155	chr3:49817450	T/C	cg03060546	chr3:49711283	APEH	-0.6	-8.45	-0.37	3.75e-16	Menarche (age at onset);
LGG	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.46	-0.37	3.65e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs765787	0.530	rs10467979	chr15:45521270	G/A	cg25801113	chr15:45476975	SHF	0.87	19.95	0.68	2.28e-64	Uric acid levels;
LGG	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg22961513	chr11:14280813	SPON1	-0.3	-6.71	-0.3	5.73e-11	Sense of smell;
LGG	cis	rs981844	0.683	rs1037655	chr4:154750408	A/G	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs7949030	0.596	rs71490394	chr11:62370155	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.2	0.6	4.19e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs4718428	0.705	rs12536410	chr7:66254290	G/A	cg10756647	chr7:56101905	PSPH	0.46	6.93	0.31	1.44e-11	Corneal structure;
LGG	cis	rs713587	0.571	rs563590	chr2:25331172	A/G	cg04586622	chr2:25135609	ADCY3	-0.27	-6.79	-0.3	3.41e-11	Body mass index in non-asthmatics;
LGG	trans	rs11039798	0.764	rs11039929	chr11:48703289	A/G	cg15704280	chr7:45808275	SEPT13	0.78	9.03	0.39	4.69e-18	Axial length;
LGG	cis	rs9462027	0.583	rs2744974	chr6:34579431	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.52	-10.4	-0.44	6.84e-23	Systemic lupus erythematosus;
LGG	trans	rs61931739	0.534	rs11052991	chr12:34059018	G/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.08	-0.42	9.89e-22	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.923	rs9800686	chr6:149955600	A/C	cg15971980	chr6:150254442	NA	0.44	8.09	0.35	5.45e-15	Lung cancer;
LGG	trans	rs7824557	0.592	rs920044	chr8:11224313	C/T	cg08975724	chr8:8085496	FLJ10661	0.37	6.74	0.3	4.66e-11	Retinal vascular caliber;
LGG	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg13263323	chr15:86062960	AKAP13	-0.35	-7.28	-0.32	1.42e-12	Coronary artery disease;
LGG	trans	rs7937682	0.883	rs1789358	chr11:111474116	G/A	cg18187862	chr3:45730750	SACM1L	0.57	9.25	0.39	8.54e-19	Primary sclerosing cholangitis;
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.17	-0.32	2.89e-12	Bipolar disorder;
LGG	cis	rs6430585	0.527	rs62168833	chr2:136449254	G/A	cg07169764	chr2:136633963	MCM6	1.01	16.9	0.62	2.86e-50	Corneal structure;
LGG	cis	rs3733585	0.638	rs6449155	chr4:9956547	T/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.8	-0.34	4.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg09263875	chr16:632152	PIGQ	0.65	12.72	0.51	5.27e-32	Height;
LGG	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg20503657	chr10:835505	NA	0.73	10.17	0.43	4.71e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg12960782	chr5:59996455	DEPDC1B	0.43	6.99	0.31	9.92e-12	Cognitive performance;
LGG	cis	rs9354308	0.933	rs2802063	chr6:66564148	T/C	cg07460842	chr6:66804631	NA	0.57	9.47	0.4	1.47e-19	Metabolite levels;
LGG	trans	rs7939886	0.844	rs7118562	chr11:56050180	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.49	0.33	3.61e-13	Myopia (pathological);
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg19635926	chr16:89946313	TCF25	0.76	7.33	0.32	1.01e-12	Skin colour saturation;
LGG	cis	rs916888	0.687	rs199456	chr17:44797919	C/T	cg01570182	chr17:44337453	NA	0.74	12.5	0.5	4.38e-31	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2470578	0.792	rs283922	chr3:17325841	T/C	cg20981856	chr3:17787350	NA	0.35	6.73	0.3	5.19e-11	Schizophrenia;
LGG	cis	rs72945132	0.882	rs17160777	chr11:70163723	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	trans	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.51	0.37	2.42e-16	Retinal vascular caliber;
LGG	cis	rs4880487	0.505	rs4880778	chr10:1205810	C/G	cg03183215	chr10:1252341	ADARB2	-0.37	-6.84	-0.3	2.53e-11	Migraine;
LGG	cis	rs7572733	0.935	rs11675025	chr2:198838315	G/A	cg00792783	chr2:198669748	PLCL1	0.5	8.31	0.36	1.04e-15	Dermatomyositis;
LGG	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg03060546	chr3:49711283	APEH	0.74	13.38	0.53	9.6e-35	Resting heart rate;
LGG	cis	rs6748734	0.581	rs10207380	chr2:241860911	A/G	cg05025159	chr2:241905733	NA	0.52	10.05	0.42	1.31e-21	Urinary metabolites;
LGG	cis	rs877426	0.645	rs2297103	chr13:114775816	G/T	cg25338242	chr13:114786047	RASA3	0.44	6.85	0.3	2.35e-11	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs35110281	0.782	rs9981291	chr21:45031458	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.65	11.76	0.48	4.07e-28	Mean corpuscular volume;
LGG	cis	rs637571	0.522	rs679581	chr11:65746653	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.71	0.34	7.69e-14	Eosinophil percentage of white cells;
LGG	cis	rs992157	1.000	rs2168704	chr2:219142492	G/A	cg00012203	chr2:219082015	ARPC2	0.77	14.6	0.56	5.63e-40	Colorectal cancer;
LGG	cis	rs2013441	0.866	rs10438824	chr17:20058510	C/T	cg13482628	chr17:19912719	NA	0.4	6.92	0.31	1.53e-11	Obesity-related traits;
LGG	cis	rs295137	0.836	rs1217429	chr2:201094151	G/T	cg17644776	chr2:200775616	C2orf69	0.51	8.65	0.37	8.78e-17	Asthma (bronchodilator response);
LGG	cis	rs7811142	1.000	rs7783550	chr7:99987805	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	-0.99	-15.34	-0.58	3.11e-43	Platelet count;
LGG	cis	rs5758659	1.000	rs5758677	chr22:42643039	A/C	cg15557168	chr22:42548783	NA	-0.4	-8.95	-0.38	8.78e-18	Cognitive function;
LGG	cis	rs2404602	0.647	rs11072619	chr15:77043242	A/C	cg15268244	chr15:77196840	NA	0.48	10.21	0.43	3.4e-22	Blood metabolite levels;
LGG	cis	rs941764	0.830	rs6575189	chr14:91840267	C/T	cg10511902	chr14:91842949	CCDC88C	0.69	15.06	0.57	5.13e-42	Breast cancer;
LGG	cis	rs473651	0.837	rs563458	chr2:239345613	T/A	cg21699342	chr2:239360505	ASB1	0.39	7.44	0.33	4.99e-13	Multiple system atrophy;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25427524	chr10:38739819	LOC399744	-0.68	-12.89	-0.51	1.1e-32	Extrinsic epigenetic age acceleration;
LGG	cis	rs6456156	0.586	rs13208636	chr6:167461965	T/G	cg07741184	chr6:167504864	NA	0.39	8.97	0.38	7.43e-18	Primary biliary cholangitis;
LGG	cis	rs2777491	0.874	rs28716108	chr15:41655523	G/C	cg18705301	chr15:41695430	NDUFAF1	-1.03	-20.58	-0.69	2.6900000000000002e-67	Ulcerative colitis;
LGG	cis	rs1620921	0.625	rs10945699	chr6:161266748	G/C	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1552244	1.000	rs68067759	chr3:10150535	T/C	cg13047869	chr3:10149882	C3orf24	0.54	9.09	0.39	2.93e-18	Alzheimer's disease;
LGG	cis	rs9393813	0.901	rs12529756	chr6:27471448	C/T	cg18711553	chr6:27366782	ZNF391	-0.5	-9.55	-0.41	7.41e-20	Bipolar disorder;
LGG	cis	rs9443645	0.505	rs9359364	chr6:79795992	G/A	cg18132916	chr6:79620363	NA	-0.26	-6.9	-0.31	1.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9849248	0.574	rs55932154	chr3:88173756	A/G	cg14530983	chr3:88190749	ZNF654	0.58	7.91	0.35	1.88e-14	Menarche (age at onset);
LGG	cis	rs981844	0.775	rs62323977	chr4:154746141	G/A	cg14289246	chr4:154710475	SFRP2	0.67	11.01	0.46	3.39e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs1707322	0.721	rs12043945	chr1:46106922	T/A	cg03146154	chr1:46216737	IPP	0.58	11.14	0.46	1.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs774359	0.797	rs2814708	chr9:27513716	G/C	cg21249376	chr9:27528432	MOBKL2B	0.43	8.84	0.38	2.04e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs60871478	0.636	rs7792072	chr7:886239	C/T	cg05535760	chr7:792225	HEATR2	-0.81	-11.45	-0.47	6.42e-27	Cerebrospinal P-tau181p levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16281248	chr11:64014554	PPP1R14B	0.42	7.05	0.31	6.46e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs1799949	1.000	rs8176103	chr17:41267050	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.42	0.33	5.74e-13	Menopause (age at onset);
LGG	cis	rs698813	0.674	rs4952707	chr2:44500683	G/C	cg00619915	chr2:44497795	NA	-0.61	-8.63	-0.37	1e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs155076	1.000	rs195570	chr13:21867580	T/G	cg06138931	chr13:21896616	NA	-0.48	-7.82	-0.34	3.66e-14	White matter hyperintensity burden;
LGG	trans	rs7395662	0.504	rs1814158	chr11:48437937	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.38	-0.32	7.56e-13	HDL cholesterol;
LGG	cis	rs6912958	0.781	rs9450723	chr6:88226641	C/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.47	8.37	0.36	7.12e-16	Monocyte percentage of white cells;
LGG	cis	rs1018697	1.000	rs4919677	chr10:104554304	G/A	cg04362960	chr10:104952993	NT5C2	0.49	9.09	0.39	2.88e-18	Colorectal adenoma (advanced);
LGG	cis	rs2742417	1.000	rs2742436	chr3:45741397	T/C	cg04837898	chr3:45731254	SACM1L	-0.37	-7.23	-0.32	2e-12	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4862750	0.872	rs6825289	chr4:187879109	T/G	cg11301795	chr4:187892539	NA	-0.94	-24.71	-0.75	1.34e-86	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9557704	0.551	rs9557678	chr13:102148670	A/G	cg13538571	chr13:102108074	ITGBL1	-0.43	-6.66	-0.3	7.61e-11	Waist-to-hip circumference ratio (dietary energy interaction);
LGG	cis	rs10911251	0.546	rs2027084	chr1:183110801	G/A	cg07245641	chr1:182991651	LAMC1	0.39	8.99	0.39	6.39e-18	Colorectal cancer;
LGG	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg00631329	chr6:26305371	NA	-0.43	-7.43	-0.33	5.16e-13	Educational attainment;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg00389713	chr6:43138877	SRF	-0.41	-6.72	-0.3	5.29e-11	Leprosy;
LGG	cis	rs6952808	0.692	rs11765549	chr7:2027311	G/T	cg11050988	chr7:1952600	MAD1L1	-0.34	-7.88	-0.34	2.4e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs9784649	1.000	rs55924805	chr5:24999756	C/T	cg08600765	chr20:34638493	LOC647979	-0.63	-7.99	-0.35	1.06e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6141769	0.542	rs2064934	chr20:31314757	C/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs2739330	0.796	rs5760106	chr22:24250645	A/C	cg18538332	chr22:24372958	LOC391322	0.43	7.11	0.31	4.53e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7914558	1.000	rs10786740	chr10:104935593	G/C	cg04362960	chr10:104952993	NT5C2	0.55	10.6	0.44	1.15e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7659604	0.539	rs11098648	chr4:122759872	C/T	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.41	-0.47	9.55e-27	Type 2 diabetes;
LGG	cis	rs7824557	0.628	rs3779891	chr8:11183505	G/A	cg15596359	chr8:11213517	TDH	-0.4	-8.13	-0.35	3.84e-15	Retinal vascular caliber;
LGG	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg16339924	chr4:17578868	LAP3	-0.61	-10.3	-0.43	1.49e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.44	-0.44	4.82e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg01673284	chr16:4527211	HMOX2	0.33	6.97	0.31	1.1e-11	Schizophrenia;
LGG	cis	rs3824867	0.920	rs7108143	chr11:47453722	T/G	cg20307385	chr11:47447363	PSMC3	-0.45	-7.06	-0.31	6.3e-12	Mean corpuscular hemoglobin;
LGG	cis	rs8028182	0.537	rs4371118	chr15:75898890	C/A	cg16427107	chr15:75912924	SNUPN	-0.51	-10.07	-0.42	1.09e-21	Sudden cardiac arrest;
LGG	cis	rs4740619	0.810	rs12004358	chr9:15704527	A/C	cg14451791	chr9:16040625	NA	0.32	8.26	0.36	1.57e-15	Body mass index;
LGG	cis	rs2760061	0.626	rs2527615	chr1:228119283	A/G	cg02753203	chr1:228287806	NA	-0.63	-11.65	-0.48	1.15e-27	Diastolic blood pressure;
LGG	cis	rs67311347	0.544	rs2887965	chr3:40334154	A/G	cg13683864	chr3:40499215	RPL14	0.82	16.5	0.61	1.91e-48	Renal cell carcinoma;
LGG	cis	rs62238980	0.614	rs76473853	chr22:32365685	G/C	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01174096	chr2:196521556	SLC39A10	0.42	6.97	0.31	1.11e-11	Cognitive performance;
LGG	cis	rs2836974	0.568	rs371625	chr21:40535271	A/G	cg06238570	chr21:40685208	BRWD1	-0.53	-8.71	-0.38	5.62e-17	Cognitive function;
LGG	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg05294307	chr14:35346193	BAZ1A	-0.39	-7.35	-0.32	8.8e-13	Psoriasis;
LGG	cis	rs7582180	0.764	rs12622318	chr2:100927375	T/C	cg08297393	chr2:100937505	LONRF2	-0.53	-9.6	-0.41	5.22e-20	Intelligence (multi-trait analysis);
LGG	cis	rs2243480	1.000	rs1715235	chr7:65488394	T/C	cg13147721	chr7:65941812	NA	-0.8	-9.66	-0.41	3.11e-20	Diabetic kidney disease;
LGG	trans	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs11920090	0.932	rs10513689	chr3:170727658	C/T	cg09710316	chr3:170744871	SLC2A2	0.6	8.51	0.37	2.38e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7618915	0.571	rs12487445	chr3:52618319	A/C	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.37	4.01e-16	Bipolar disorder;
LGG	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg20821713	chr7:1055600	C7orf50	-0.47	-7.47	-0.33	4.13e-13	Bronchopulmonary dysplasia;
LGG	trans	rs7395662	1.000	rs11039777	chr11:48517049	T/G	cg03929089	chr4:120376271	NA	-0.45	-7.21	-0.32	2.34e-12	HDL cholesterol;
LGG	cis	rs6502050	0.835	rs28640920	chr17:80105151	A/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.69	-0.37	6.36e-17	Life satisfaction;
LGG	cis	rs4750440	0.706	rs1599413	chr10:14019197	C/A	cg00551146	chr10:14014579	FRMD4A	0.29	6.96	0.31	1.17e-11	Adiponectin levels;
LGG	cis	rs7223966	0.621	rs28571160	chr17:61638723	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.56	8.63	0.37	1.01e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.11	0.31	4.45e-12	Lung cancer;
LGG	trans	rs1941687	0.563	rs2032189	chr18:31332200	T/A	cg04226714	chr8:49833948	SNAI2	-0.47	-8.65	-0.37	8.38e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.774	rs72650880	chr8:58164727	C/T	cg11062466	chr8:58055876	NA	0.63	10.24	0.43	2.62e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11203032	0.908	rs4282908	chr10:90943967	C/T	cg16672925	chr10:90967113	CH25H	0.51	8.09	0.35	5.14e-15	Heart failure;
LGG	trans	rs1728785	1.000	rs1728789	chr16:68595776	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.34	0.43	1.07e-22	Ulcerative colitis;
LGG	cis	rs6003958	1	rs6003958	chr22:24264089	T/G	cg24846343	chr22:24311635	DDTL	-0.48	-7.36	-0.32	8.26e-13	S-phenylmercapturic acid levels in smokers;
LGG	cis	rs1577917	0.771	rs4383777	chr6:86435960	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.76	14.42	0.56	3.31e-39	Response to antipsychotic treatment;
LGG	cis	rs6787391	0.933	rs9867580	chr3:4747247	A/C	cg11584376	chr3:4789075	ITPR1	-0.34	-7.01	-0.31	8.52e-12	Breast cancer;
LGG	cis	rs7408868	0.908	rs10416865	chr19:15277601	T/C	cg14696996	chr19:15285081	NOTCH3	1.07	13.15	0.52	8.82e-34	Pulse pressure;
LGG	trans	rs637571	0.557	rs1204649	chr11:65702776	A/C	cg17712092	chr4:129076599	LARP1B	0.76	14.44	0.56	2.86e-39	Eosinophil percentage of white cells;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg06719900	chr11:109292894	C11orf87	0.44	8.43	0.36	4.27e-16	Schizophrenia;
LGG	cis	rs6831352	0.879	rs56295995	chr4:100060899	C/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	trans	rs1814175	0.645	rs1851850	chr11:50012168	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.52	-0.71	1.05e-71	Height;
LGG	cis	rs4319547	0.915	rs7966094	chr12:123115771	A/G	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.55	-0.41	7.84e-20	Body mass index;
LGG	cis	rs1519814	1.000	rs4271006	chr8:121146640	T/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.44	-0.47	7.32e-27	Breast cancer;
LGG	cis	rs2239547	0.657	rs13072536	chr3:52861211	A/T	cg11645453	chr3:52864694	ITIH4	0.72	11.24	0.46	4.56e-26	Schizophrenia;
LGG	cis	rs769267	0.931	rs15622	chr19:19468734	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.39	-0.32	6.73e-13	Tonsillectomy;
LGG	cis	rs1775715	0.707	rs2808073	chr10:32179275	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.72	0.3	5.47e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs7917772	0.636	rs2863718	chr10:104519631	G/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.94	-0.35	1.56e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1568889	1.000	rs16917689	chr11:28064466	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs5769765	0.819	rs9616377	chr22:50310880	T/C	cg26441486	chr22:50317300	CRELD2	0.42	7.34	0.32	9.95e-13	Schizophrenia;
LGG	cis	rs10504229	0.728	rs17804822	chr8:58156276	T/C	cg08677398	chr8:58056175	NA	0.57	9.15	0.39	1.89e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs8049040	0.609	rs4258624	chr16:71467951	C/T	cg08717414	chr16:71523259	ZNF19	0.53	8.42	0.36	4.88e-16	Blood protein levels;
LGG	cis	rs4430311	0.563	rs10927056	chr1:243822570	T/C	cg25706552	chr1:244017396	NA	-0.6	-13.18	-0.52	6.35e-34	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs7819412	0.558	rs4841483	chr8:10908354	G/A	cg02002194	chr4:3960332	NA	-0.39	-6.67	-0.3	7.41e-11	Triglycerides;
LGG	cis	rs79149102	0.579	rs28394281	chr15:75326754	C/G	cg17294928	chr15:75287854	SCAMP5	-0.79	-8.63	-0.37	9.65e-17	Lung cancer;
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg27476859	chr7:2772710	GNA12	0.41	6.98	0.31	1.02e-11	Height;
LGG	cis	rs6665290	0.904	rs1045252	chr1:227181555	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.28	-45.99	-0.91	9.7e-175	Myeloid white cell count;
LGG	cis	rs9527	0.590	rs12246739	chr10:104787019	A/C	cg04362960	chr10:104952993	NT5C2	-0.55	-10.22	-0.43	2.91e-22	Arsenic metabolism;
LGG	trans	rs853679	0.760	rs9393910	chr6:28208192	C/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.92	-0.35	1.8e-14	Depression;
LGG	cis	rs7659604	0.502	rs13104233	chr4:122672473	T/C	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.38e-12	Type 2 diabetes;
LGG	cis	rs858239	0.539	rs10254544	chr7:23220235	T/C	cg23682824	chr7:23144976	KLHL7	0.41	6.75	0.3	4.58e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07099627	chr19:11466020	LPPR2	0.48	7.48	0.33	3.69e-13	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.824	rs510866	chr11:111484113	A/C	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg04166393	chr7:2884313	GNA12	0.46	9.2	0.39	1.27e-18	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22024508	chr19:16771032	TMEM38A;C19orf42	0.38	6.69	0.3	6.63e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7659604	0.689	rs4283687	chr4:122663460	A/G	cg19748678	chr4:122722346	EXOSC9	0.46	8.16	0.35	3.27e-15	Type 2 diabetes;
LGG	cis	rs12368653	0.607	rs7966795	chr12:58031413	C/A	cg12615879	chr12:58013172	SLC26A10	0.38	8.68	0.37	6.6e-17	Multiple sclerosis;
LGG	cis	rs2070488	0.804	rs13085153	chr3:38461279	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.75	0.57	1.19e-40	Electrocardiographic conduction measures;
LGG	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg17971929	chr21:40555470	PSMG1	0.79	14.25	0.55	1.9e-38	Cognitive function;
LGG	cis	rs13082711	0.834	rs2172297	chr3:27428423	C/T	cg02860705	chr3:27208620	NA	0.71	12.62	0.51	1.31e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs473651	0.935	rs10170056	chr2:239339291	G/C	cg18131467	chr2:239335373	ASB1	0.89	15.87	0.59	1.29e-45	Multiple system atrophy;
LGG	cis	rs2334880	0.610	rs8051767	chr16:71731720	C/T	cg06353428	chr16:71660113	MARVELD3	1.26	20.96	0.7	4.18e-69	Malaria;
LGG	cis	rs6121246	0.909	rs2376992	chr20:30263418	T/C	cg21427119	chr20:30132790	HM13	-0.41	-7.07	-0.31	5.91e-12	Mean corpuscular hemoglobin;
LGG	cis	rs2730245	1.000	rs2527199	chr7:158737113	G/A	cg23730037	chr7:158596552	ESYT2	0.39	6.77	0.3	3.92e-11	Height;
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.89	-0.3	1.84e-11	Total body bone mineral density;
LGG	cis	rs975739	0.612	rs1970037	chr13:78580939	A/C	cg07847733	chr13:78271382	SLAIN1	0.44	7.62	0.33	1.43e-13	Hair color;
LGG	cis	rs17776563	0.887	rs8024132	chr15:89132681	G/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.4	-0.44	6.52e-23	Thyroid hormone levels;
LGG	trans	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg10840412	chr1:235813424	GNG4	0.53	7.28	0.32	1.41e-12	Bipolar disorder;
LGG	cis	rs6502050	0.835	rs8071737	chr17:80117537	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.45e-20	Life satisfaction;
LGG	cis	rs2836974	0.897	rs12481860	chr21:40537836	T/A	cg11644478	chr21:40555479	PSMG1	0.93	17.85	0.64	1.32e-54	Cognitive function;
LGG	cis	rs4363385	0.510	rs6587724	chr1:153034501	T/A	cg13444842	chr1:152974279	SPRR3	-0.46	-9.31	-0.4	5.07e-19	Inflammatory skin disease;
LGG	cis	rs1862618	0.853	rs832568	chr5:56153776	G/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.3	-0.32	1.29e-12	Initial pursuit acceleration;
LGG	cis	rs10256972	0.621	rs2280725	chr7:1087426	G/T	cg18402987	chr7:1209562	NA	0.38	7.01	0.31	8.48e-12	Longevity;Endometriosis;
LGG	cis	rs35110281	0.641	rs4818858	chr21:45083097	C/T	cg01579765	chr21:45077557	HSF2BP	0.39	8.62	0.37	1.1e-16	Mean corpuscular volume;
LGG	cis	rs17826219	0.636	rs4055314	chr17:29079769	T/C	cg13385521	chr17:29058706	SUZ12P	0.93	10.86	0.45	1.21e-24	Body mass index;
LGG	cis	rs4363385	0.747	rs1413848	chr1:152970210	C/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.26	-0.4	7.57e-19	Inflammatory skin disease;
LGG	cis	rs4363385	0.747	rs4845330	chr1:152981505	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs12824058	0.549	rs4759453	chr12:130824565	C/G	cg24838063	chr12:130822603	PIWIL1	0.73	13.67	0.54	5.65e-36	Menopause (age at onset);
LGG	cis	rs7613875	0.600	rs2247510	chr3:50126215	A/C	cg24110177	chr3:50126178	RBM5	-0.65	-12.06	-0.49	2.56e-29	Body mass index;
LGG	cis	rs9916302	0.706	rs9909304	chr17:37500508	G/T	cg00129232	chr17:37814104	STARD3	0.57	8.55	0.37	1.84e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7833790	0.660	rs10091077	chr8:82705464	A/G	cg06027949	chr8:82754900	SNX16	-0.52	-8.17	-0.35	3.02e-15	Diastolic blood pressure;
LGG	cis	rs1552244	0.554	rs28667821	chr3:10050767	A/G	cg00149659	chr3:10157352	C3orf10	0.6	8.61	0.37	1.16e-16	Alzheimer's disease;
LGG	cis	rs6089584	0.606	rs2296082	chr20:60573983	A/G	cg06470251	chr20:60548479	NA	0.44	7.71	0.34	7.82e-14	Body mass index;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg04703951	chr17:43578652	NA	0.39	7.92	0.35	1.8e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs453301	0.631	rs11780774	chr8:8799111	C/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.11	-0.31	4.47e-12	Joint mobility (Beighton score);
LGG	cis	rs4731207	0.671	rs4731221	chr7:124481403	T/A	cg05630886	chr7:124431682	NA	0.34	7.99	0.35	1.11e-14	Cutaneous malignant melanoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10663503	chr17:8126298	C17orf44	0.53	8.15	0.35	3.38e-15	Gut microbiome composition (summer);
LGG	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.29e-16	Common traits (Other);
LGG	cis	rs11605275	1.000	rs78091560	chr11:20032279	G/A	cg14835545	chr11:20032148	NAV2	-0.96	-11.38	-0.47	1.26e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs300774	1.000	rs300799	chr2:105514	G/A	cg04617936	chr2:214353	NA	-0.48	-7.21	-0.32	2.23e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs875971	0.862	rs6460302	chr7:65960257	C/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.6	-0.37	1.26e-16	Aortic root size;
LGG	cis	rs896854	0.812	rs4582532	chr8:95969257	G/A	cg13393036	chr8:95962371	TP53INP1	-0.25	-6.85	-0.3	2.31e-11	Type 2 diabetes;
LGG	cis	rs7000551	0.606	rs13256933	chr8:22267199	T/G	cg13512537	chr8:22265999	SLC39A14	-0.46	-7.38	-0.32	7.48e-13	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6502050	0.723	rs11650635	chr17:80083816	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7020830	0.931	rs1388978	chr9:37144062	G/T	cg14294708	chr9:37120828	ZCCHC7	1.15	31.49	0.83	3.58e-117	Schizophrenia;
LGG	cis	rs6956675	0.915	rs1609795	chr7:62650531	T/C	cg08930214	chr7:62859557	LOC100287834	0.45	7.62	0.33	1.4e-13	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs316327	chr7:65609201	G/T	cg10756647	chr7:56101905	PSPH	-0.77	-9.14	-0.39	2.04e-18	Diabetic kidney disease;
LGG	cis	rs17428076	0.794	rs62183763	chr2:172829681	C/A	cg21435375	chr2:172878103	MAP1D	0.41	7.62	0.33	1.4e-13	Myopia;
LGG	cis	rs11122272	0.735	rs2491405	chr1:231513431	C/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg03806693	chr22:41940476	POLR3H	-0.99	-17.45	-0.63	9.44e-53	Vitiligo;
LGG	cis	rs875971	0.830	rs427973	chr7:65526648	C/A	cg23594656	chr7:65796392	TPST1	-0.34	-7.37	-0.32	8.16e-13	Aortic root size;
LGG	cis	rs2011503	1.000	rs45556231	chr19:19654189	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs12586317	0.547	rs114371385	chr14:35503724	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.72	-0.34	7.2e-14	Psoriasis;
LGG	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg16590910	chr6:42928470	GNMT	0.29	6.89	0.3	1.89e-11	Blood protein levels;
LGG	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg04490037	chr7:50633773	DDC	0.35	7.49	0.33	3.59e-13	Systemic sclerosis;
LGG	trans	rs61931739	0.513	rs1608906	chr12:33894986	T/C	cg26384229	chr12:38710491	ALG10B	0.65	12.49	0.5	4.5e-31	Morning vs. evening chronotype;
LGG	cis	rs7255045	0.742	rs10407116	chr19:12962272	G/A	cg07955356	chr19:12992479	DNASE2	0.43	7.29	0.32	1.31e-12	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18247177	chr17:7745472	KDM6B	0.46	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs926392	0.666	rs912179	chr20:37710775	G/A	cg16355469	chr20:37678765	NA	0.54	8.56	0.37	1.73e-16	Dialysis-related mortality;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg15999104	chr3:93780377	NSUN3;DHFRL1	0.38	6.89	0.3	1.78e-11	Pancreatic cancer;
LGG	trans	rs2204008	0.542	rs34770471	chr12:38009613	C/T	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs12540874	0.794	rs1470750	chr7:50576648	C/G	cg00647317	chr7:50633725	DDC	0.45	10.85	0.45	1.31e-24	Systemic sclerosis;
LGG	cis	rs1801251	1.000	rs71421663	chr2:233619131	A/G	cg25237894	chr2:233734115	C2orf82	0.66	12.78	0.51	2.95e-32	Coronary artery disease;
LGG	trans	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg02002194	chr4:3960332	NA	-0.41	-7.33	-0.32	1.02e-12	Retinal vascular caliber;
LGG	cis	rs4720575	1.000	rs917108	chr7:47088047	A/G	cg00036614	chr7:47093842	NA	-0.49	-9.89	-0.42	4.7e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs1949733	0.656	rs2688243	chr4:8436286	A/G	cg11789530	chr4:8429930	ACOX3	0.74	14.34	0.55	7.72e-39	Response to antineoplastic agents;
LGG	cis	rs1552244	0.572	rs2054478	chr3:10172211	C/T	cg00149659	chr3:10157352	C3orf10	1.21	14.37	0.56	5.56e-39	Alzheimer's disease;
LGG	cis	rs1799949	1.000	rs4793189	chr17:41190715	G/A	cg25172604	chr17:41446521	NA	-0.31	-6.92	-0.31	1.51e-11	Menopause (age at onset);
LGG	cis	rs7829975	0.540	rs2976909	chr8:8346690	C/T	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.74	-0.34	6.47e-14	Mood instability;
LGG	cis	rs10910092	1	rs10910092	chr1:2501516	A/G	cg20673091	chr1:2541236	MMEL1	0.56	12.38	0.5	1.27e-30	Ulcerative colitis;
LGG	cis	rs2576037	0.583	rs530205	chr18:44385150	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.83	-0.42	7.64e-21	Personality dimensions;
LGG	cis	rs2070433	0.500	rs9306156	chr21:47960493	T/C	cg12379764	chr21:47803548	PCNT	0.65	11.17	0.46	8.35e-26	Lymphocyte counts;
LGG	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs4474465	1.000	rs7131199	chr11:78192148	T/G	cg02023728	chr11:77925099	USP35	0.4	6.9	0.31	1.69e-11	Alzheimer's disease (survival time);
LGG	cis	rs28595532	1.000	rs115706377	chr4:119628481	G/A	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs6456156	0.586	rs6909180	chr6:167460537	A/G	cg07741184	chr6:167504864	NA	0.4	9.03	0.39	4.5e-18	Primary biliary cholangitis;
LGG	trans	rs9467711	0.591	rs9461222	chr6:25905111	G/A	cg06606381	chr12:133084897	FBRSL1	-0.69	-6.71	-0.3	5.57e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs61201557	chr8:58138370	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4727027	0.704	rs13229244	chr7:148898219	A/C	cg23583168	chr7:148888333	NA	0.95	19.68	0.67	4.43e-63	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16448126	chr12:123921461	RILPL2	-0.46	-6.76	-0.3	4.25e-11	Systemic lupus erythematosus;
LGG	cis	rs10206020	0.885	rs6746052	chr2:1576811	T/C	cg01028140	chr2:1542097	TPO	-0.43	-8.16	-0.35	3.24e-15	IgG glycosylation;
LGG	cis	rs4919087	0.561	rs61861820	chr10:98998974	G/A	cg25902810	chr10:99078978	FRAT1	-0.43	-7.01	-0.31	8.27e-12	Monocyte count;
LGG	cis	rs912057	0.526	rs1294400	chr6:6733421	A/G	cg06612196	chr6:6737390	NA	-0.5	-11.32	-0.47	2.17e-26	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs4930103	0.711	rs217710	chr11:2007244	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.45	-8.13	-0.35	4.01e-15	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs9467711	0.659	rs34605993	chr6:26454363	C/T	cg01620082	chr3:125678407	NA	-0.76	-7.62	-0.33	1.43e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7666738	0.830	rs9998582	chr4:98938949	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs709400	1.000	rs861539	chr14:104165753	G/A	cg24130564	chr14:104152367	KLC1	-0.44	-8.35	-0.36	8.22e-16	Body mass index;
LGG	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg00579200	chr11:133705235	NA	-0.59	-11.28	-0.46	3.07e-26	Childhood ear infection;
LGG	cis	rs17122278	1.000	rs10892245	chr11:118472354	C/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	trans	rs11875185	0.510	rs79850949	chr18:55598308	G/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs10791323	0.604	rs2723598	chr11:133711652	G/A	cg06766960	chr11:133703094	NA	-0.57	-11.15	-0.46	1.02e-25	Childhood ear infection;
LGG	cis	rs6089829	0.962	rs4586690	chr20:61658595	G/T	cg08045932	chr20:61659980	NA	0.6	12.93	0.52	7.24e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4077515	0.935	rs3812565	chr9:139272502	T/C	cg14019695	chr9:139328340	INPP5E	0.38	6.79	0.3	3.53e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2576037	0.623	rs2571000	chr18:44580347	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.52	-10.3	-0.43	1.51e-22	Personality dimensions;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg12379764	chr21:47803548	PCNT	-0.46	-7.93	-0.35	1.62e-14	Testicular germ cell tumor;
LGG	cis	rs6502050	0.635	rs9889327	chr17:80087839	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs4862750	0.624	rs34414639	chr4:187873417	C/A	cg06074448	chr4:187884817	NA	-0.6	-12.84	-0.51	1.66e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs765787	0.530	rs2433227	chr15:45517119	A/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.3e-13	Uric acid levels;
LGG	trans	rs7395662	0.681	rs2865641	chr11:48941099	A/C	cg15704280	chr7:45808275	SEPT13	-0.52	-8.72	-0.38	5.06e-17	HDL cholesterol;
LGG	cis	rs9359856	0.564	rs11961752	chr6:90481896	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.78	-10.14	-0.43	5.91e-22	Bipolar disorder;
LGG	cis	rs72945132	0.882	rs12274436	chr11:70132204	T/C	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.13	-0.31	3.99e-12	Triglycerides;
LGG	cis	rs96067	0.643	rs274133	chr1:36581792	G/A	cg27506609	chr1:36549197	TEKT2	-0.52	-6.78	-0.3	3.63e-11	Corneal structure;
LGG	cis	rs10883723	0.810	rs2296582	chr10:104244139	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.44	0.56	2.8e-39	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7107174	0.901	rs1055248	chr11:77925573	T/C	cg27205649	chr11:78285834	NARS2	-0.45	-7.44	-0.33	5.09e-13	Testicular germ cell tumor;
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg21782813	chr7:2030301	MAD1L1	0.41	9.46	0.4	1.52e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs751728	0.664	rs2395402	chr6:33753673	G/A	cg25922239	chr6:33757077	LEMD2	0.42	7.32	0.32	1.12e-12	Crohn's disease;
LGG	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg02187348	chr16:89574699	SPG7	0.63	10.61	0.44	1.1e-23	Multiple myeloma (IgH translocation);
LGG	cis	rs490234	0.691	rs3104551	chr9:128164279	G/A	cg14078157	chr9:128172775	NA	-0.47	-9.05	-0.39	4.13e-18	Mean arterial pressure;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg02018176	chr4:1364513	KIAA1530	0.47	11.01	0.46	3.5e-25	Obesity-related traits;
LGG	cis	rs7572733	0.806	rs10169453	chr2:198835212	T/C	cg00792783	chr2:198669748	PLCL1	0.49	8.28	0.36	1.34e-15	Dermatomyositis;
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg13009111	chr11:71350975	NA	-0.32	-7.08	-0.31	5.54e-12	Systolic blood pressure;
LGG	trans	rs2204008	0.549	rs12312109	chr12:38228251	G/T	cg06521331	chr12:34319734	NA	0.44	7.98	0.35	1.15e-14	Bladder cancer;
LGG	cis	rs7267979	1.000	rs6050566	chr20:25351071	G/A	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.21e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6028335	0.674	rs16987779	chr20:37671455	C/T	cg16355469	chr20:37678765	NA	0.59	7.95	0.35	1.39e-14	Alcohol and nicotine co-dependence;
LGG	trans	rs7404843	0.777	rs6498552	chr16:15539901	T/G	cg02716450	chr16:28638775	NA	-0.69	-7.25	-0.32	1.76e-12	Testicular germ cell tumor;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg19673125	chr6:150240577	RAET1G	0.36	8.97	0.38	7.33e-18	Testicular germ cell tumor;
LGG	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.49	-0.33	3.4e-13	Neuroticism;
LGG	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2836974	0.897	rs13049280	chr21:40594656	C/G	cg11644478	chr21:40555479	PSMG1	0.9	16.88	0.62	3.72e-50	Cognitive function;
LGG	cis	rs6500602	0.727	rs6500607	chr16:4503631	C/T	cg05091796	chr16:4465799	CORO7	-0.64	-10.57	-0.44	1.58e-23	Schizophrenia;
LGG	trans	rs11875185	0.510	rs113199651	chr18:55646761	C/T	cg15513957	chr14:69354734	ACTN1	-1.01	-9.74	-0.41	1.65e-20	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs2204008	0.837	rs4312131	chr12:38181087	G/T	cg06521331	chr12:34319734	NA	-0.52	-8.96	-0.38	8.22e-18	Bladder cancer;
LGG	cis	rs1506636	0.962	rs1506640	chr7:123349627	T/G	cg03229431	chr7:123269106	ASB15	-0.75	-18.65	-0.65	2.61e-58	Plateletcrit;Platelet count;
LGG	cis	rs11966931	0.817	rs2883361	chr6:108090328	G/A	cg04749840	chr6:108095067	SCML4	-0.44	-7.38	-0.32	7.17e-13	Neutrophil percentage of white cells;
LGG	cis	rs2282300	0.739	rs34855782	chr11:30225470	G/A	cg25418670	chr11:30344373	C11orf46	-0.56	-7.89	-0.34	2.25e-14	Morning vs. evening chronotype;
LGG	cis	rs6735179	0.958	rs7577768	chr2:1772552	T/C	cg10160682	chr2:1713001	PXDN	-0.47	-7.6	-0.33	1.69e-13	Response to antipsychotic treatment;
LGG	cis	rs8077889	1.000	rs17674998	chr17:41879544	A/G	cg26893861	chr17:41843967	DUSP3	0.91	15.64	0.59	1.36e-44	Triglycerides;
LGG	cis	rs2251666	0.514	rs2271135	chr16:4929392	A/G	cg04440724	chr16:4920505	UBN1	-0.58	-8.23	-0.36	1.89e-15	Cancer;
LGG	cis	rs861020	1.000	rs861020	chr1:209977111	A/G	cg05527609	chr1:210001259	C1orf107	0.71	9.7	0.41	2.24e-20	Orofacial clefts;
LGG	cis	rs7319311	0.589	rs9588150	chr13:111025042	T/C	cg06243866	chr13:111019493	COL4A2	0.46	6.78	0.3	3.59e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18765753	chr7:1198926	ZFAND2A	-0.38	-6.69	-0.3	6.53e-11	Longevity;Endometriosis;
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg07959490	chr17:80112427	CCDC57	0.46	9.08	0.39	3.17e-18	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05476231	chr6:26055835	NA	0.49	7.44	0.33	4.99e-13	Gut microbiome composition (summer);
LGG	cis	rs9487051	0.836	rs9487036	chr6:109607449	C/T	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs11098499	0.739	rs951570	chr4:120150467	T/C	cg09307838	chr4:120376055	NA	-0.6	-9.64	-0.41	3.56e-20	Corneal astigmatism;
LGG	cis	rs13053817	1.000	rs13053758	chr22:29855489	C/T	cg20285224	chr22:29838184	RFPL1S;RFPL1	-0.44	-6.73	-0.3	5.16e-11	Carotid atherosclerosis in HIV infection;
LGG	cis	rs7552404	0.727	rs5745433	chr1:76333163	T/G	cg03433033	chr1:76189801	ACADM	0.62	9.43	0.4	2.05e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg19628046	chr18:33552617	C18orf21	0.54	7.87	0.34	2.51e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs9322193	0.923	rs9383812	chr6:150033491	C/T	cg08621203	chr6:150244597	RAET1G	0.46	8.03	0.35	8.4e-15	Lung cancer;
LGG	cis	rs875971	0.862	rs7783779	chr7:65796626	A/G	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs9467773	0.967	rs6924865	chr6:26521353	A/G	cg11502198	chr6:26597334	ABT1	0.55	9.58	0.41	5.87e-20	Intelligence (multi-trait analysis);
LGG	cis	rs72960926	0.744	rs11753898	chr6:74861057	C/T	cg03266952	chr6:74778945	NA	-0.62	-6.71	-0.3	5.75e-11	Metabolite levels (MHPG);
LGG	cis	rs2880765	0.546	rs36098649	chr15:86056807	C/T	cg10818794	chr15:86012489	AKAP13	-0.39	-7.97	-0.35	1.26e-14	Coronary artery disease;
LGG	cis	rs9291683	0.679	rs2278122	chr4:10096241	T/A	cg11266682	chr4:10021025	SLC2A9	-0.46	-9.0	-0.39	5.73e-18	Bone mineral density;
LGG	cis	rs72772090	0.539	rs72773989	chr5:96163613	C/T	cg00188032	chr5:96141721	ERAP1	0.55	7.24	0.32	1.83e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs11088226	0.681	rs1134747	chr21:33939011	T/A	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs7077256	0.500	rs72835361	chr10:65098465	A/G	cg02276361	chr10:65351566	REEP3	-0.33	-6.85	-0.3	2.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs561341	0.941	rs2428338	chr17:30299629	T/C	cg00745463	chr17:30367425	LRRC37B	-0.69	-10.13	-0.43	6.21e-22	Hip circumference adjusted for BMI;
LGG	cis	rs4474465	0.833	rs6592792	chr11:78271614	A/C	cg27205649	chr11:78285834	NARS2	0.5	8.07	0.35	6.04e-15	Alzheimer's disease (survival time);
LGG	cis	rs1552244	0.572	rs73117481	chr3:10160132	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.85	-0.48	1.74e-28	Alzheimer's disease;
LGG	cis	rs10781543	0.839	rs10870071	chr9:139382184	T/C	cg14019695	chr9:139328340	INPP5E	0.4	7.11	0.31	4.42e-12	Monocyte percentage of white cells;
LGG	cis	rs7949030	0.653	rs2849030	chr11:62366986	G/A	cg11742103	chr11:62369870	EML3;MTA2	-0.62	-15.43	-0.58	1.19e-43	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs490234	0.841	rs548793	chr9:128301931	C/T	cg14078157	chr9:128172775	NA	0.44	8.25	0.36	1.69e-15	Mean arterial pressure;
LGG	cis	rs1552244	1.000	rs17032283	chr3:10081545	C/G	cg13047869	chr3:10149882	C3orf24	0.53	8.94	0.38	9.39e-18	Alzheimer's disease;
LGG	cis	rs6541297	0.941	rs6690424	chr1:230278892	C/T	cg05784532	chr1:230284198	GALNT2	0.51	8.98	0.39	6.85e-18	Coronary artery disease;
LGG	cis	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg25986240	chr4:9926439	SLC2A9	0.35	7.03	0.31	7.27e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs35306767	0.903	rs61833260	chr10:975148	T/G	cg26597838	chr10:835615	NA	0.77	11.02	0.46	3.01e-25	Eosinophil percentage of granulocytes;
LGG	cis	rs6844506	0.898	rs4862359	chr4:185234037	T/G	cg12654155	chr4:185238627	NA	-0.41	-7.12	-0.31	4.02e-12	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs8180040	0.764	rs13061071	chr3:47138708	G/A	cg27129171	chr3:47204927	SETD2	0.83	15.54	0.59	3.85e-44	Colorectal cancer;
LGG	cis	rs9733	0.621	rs932054	chr1:150539867	C/G	cg13175981	chr1:150552382	MCL1	0.54	9.23	0.39	9.65e-19	Tonsillectomy;
LGG	cis	rs7843479	0.965	rs11135763	chr8:21813962	A/G	cg17168535	chr8:21777572	XPO7	0.61	10.03	0.42	1.47e-21	Mean corpuscular volume;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg10877147	chr1:9648619	TMEM201	0.55	6.66	0.3	7.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs58438731	chr8:58134790	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.43	-7.46	-0.33	4.41e-13	Alzheimer's disease (late onset);
LGG	cis	rs3816183	0.641	rs4594497	chr2:43106277	A/G	cg14631114	chr2:43023945	NA	0.43	7.81	0.34	3.78e-14	Hypospadias;
LGG	cis	rs17376456	0.825	rs28705226	chr5:93233135	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.69	-0.41	2.36e-20	Diabetic retinopathy;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg14403583	chr14:105418241	AHNAK2	-0.76	-15.48	-0.58	7.58e-44	Rheumatoid arthritis;
LGG	cis	rs4555082	0.830	rs2816648	chr14:105708289	C/T	cg13114125	chr14:105738426	BRF1	-0.85	-16.29	-0.6	1.64e-47	Mean platelet volume;Platelet distribution width;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13775832	chr3:184080450	CLCN2;POLR2H	0.57	8.67	0.37	7.56e-17	Gut microbiome composition (summer);
LGG	cis	rs138249	0.898	rs138232	chr22:50559838	C/G	cg07310406	chr22:50524374	MLC1	0.41	8.1	0.35	4.99e-15	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs3729931	0.507	rs79945102	chr3:12711975	A/C	cg23032965	chr3:12705835	RAF1	0.84	15.34	0.58	3.21e-43	Cardiac hypertrophy;
LGG	cis	rs11603023	0.967	rs4245184	chr11:118510562	G/A	cg03804240	chr11:118481350	PHLDB1	-0.4	-7.84	-0.34	3.17e-14	Cholesterol, total;
LGG	cis	rs9911578	0.839	rs7208505	chr17:57187729	C/T	cg12560992	chr17:57184187	TRIM37	0.85	15.09	0.57	4.11e-42	Intelligence (multi-trait analysis);
LGG	trans	rs2749592	0.550	rs12255038	chr10:37869332	T/C	cg17830980	chr10:43048298	ZNF37B	0.39	8.78	0.38	3.25e-17	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	8.13e-13	Schizophrenia;
LGG	trans	rs3857536	0.611	rs6927407	chr6:66870010	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.5	-8.74	-0.38	4.17e-17	Blood trace element (Cu levels);
LGG	cis	rs5769707	0.935	rs5770594	chr22:50018497	G/A	cg20744362	chr22:50050164	C22orf34	0.39	7.59	0.33	1.79e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs13118159	0.714	rs6843025	chr4:1334418	C/G	cg20887711	chr4:1340912	KIAA1530	0.7	14.58	0.56	7.05e-40	Longevity;
LGG	cis	rs736408	0.545	rs6445529	chr3:52662722	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.46	0.47	6.14e-27	Bipolar disorder;
LGG	cis	rs11583043	0.708	rs6577227	chr1:101562132	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.69	0.3	6.57e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7503807	0.515	rs34388940	chr17:78663350	G/T	cg22878693	chr17:78755604	RPTOR	-0.54	-8.85	-0.38	1.91e-17	Obesity;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg11062466	chr8:58055876	NA	0.43	7.6	0.33	1.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg11764359	chr7:65958608	NA	0.7	12.68	0.51	7.6e-32	Aortic root size;
LGG	cis	rs473651	0.503	rs515342	chr2:239367296	A/G	cg00800569	chr2:239229395	TRAF3IP1	-0.47	-6.77	-0.3	4.02e-11	Multiple system atrophy;
LGG	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg05802129	chr4:122689817	NA	-0.41	-6.94	-0.31	1.29e-11	Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11673391	chr1:10459052	PGD	0.51	8.31	0.36	1.08e-15	Cognitive performance;
LGG	cis	rs873946	0.586	rs3793684	chr10:134568645	G/A	cg06453172	chr10:134556979	INPP5A	-0.55	-8.14	-0.35	3.62e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6956675	0.881	rs1829737	chr7:62576000	G/A	cg08930214	chr7:62859557	LOC100287834	0.43	7.04	0.31	6.86e-12	Obesity-related traits;
LGG	cis	rs7666738	0.830	rs28417577	chr4:99053007	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9814567	0.929	rs9838834	chr3:134207077	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-13.34	-0.53	1.44e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs910316	1.000	rs7145159	chr14:75583268	A/G	cg08847533	chr14:75593920	NEK9	0.62	12.01	0.49	3.92e-29	Height;
LGG	cis	rs13392177	0.684	rs11682371	chr2:219079513	G/A	cg04731861	chr2:219085781	ARPC2	0.49	12.63	0.51	1.2e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.52	8.98	0.39	6.6e-18	HDL cholesterol;
LGG	trans	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg24247370	chr13:99142703	STK24	0.43	7.67	0.34	1.04e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12710567	chr17:79876120	SIRT7	0.48	7.62	0.33	1.44e-13	Gut microbiome composition (summer);
LGG	cis	rs4820539	0.902	rs737846	chr22:23460669	A/G	cg21100191	chr22:23484243	RTDR1	1.0	22.93	0.73	2.65e-78	Bone mineral density;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg09033563	chr22:24373618	LOC391322	-0.51	-8.56	-0.37	1.66e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11098499	0.697	rs35280960	chr4:120257059	G/A	cg24375607	chr4:120327624	NA	0.61	10.29	0.43	1.74e-22	Corneal astigmatism;
LGG	cis	rs12425451	0.552	rs7310603	chr12:3139418	G/A	cg05389053	chr12:3131226	TEAD4	0.71	12.71	0.51	5.92e-32	Narcolepsy with cataplexy;
LGG	cis	rs4665809	1.000	rs10170359	chr2:26272219	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-13.38	-0.53	9.29e-35	Gut microbiome composition (summer);
LGG	cis	rs2762353	0.595	rs12207270	chr6:25751721	A/G	cg18357526	chr6:26021779	HIST1H4A	0.54	8.91	0.38	1.19e-17	Blood metabolite levels;
LGG	trans	rs7824557	0.872	rs1347410	chr8:11111242	G/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.04	-0.35	7.63e-15	Retinal vascular caliber;
LGG	cis	rs1729951	0.575	rs361245	chr3:136695706	A/G	cg12473912	chr3:136751656	NA	0.43	7.63	0.33	1.34e-13	Neuroticism;
LGG	cis	rs2303319	0.901	rs62194249	chr2:162122961	G/T	cg13806767	chr2:162164127	PSMD14	-0.65	-7.58	-0.33	1.92e-13	Cognitive function;
LGG	cis	rs6504108	0.624	rs8069064	chr17:46280663	G/A	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.64e-15	Body mass index;
LGG	cis	rs2067615	0.542	rs7133161	chr12:107139540	A/G	cg15890332	chr12:107067104	RFX4	0.41	12.17	0.49	9.33e-30	Heart rate;
LGG	cis	rs1348850	0.574	rs13431105	chr2:178434674	A/G	cg27490568	chr2:178487706	NA	0.83	14.06	0.55	1.16e-37	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6743226	0.934	rs6705421	chr2:242212672	A/G	cg10021735	chr2:242295487	FARP2	0.52	9.53	0.41	8.65e-20	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs7618915	0.547	rs3774365	chr3:52642487	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.19	-0.32	2.53e-12	Bipolar disorder;
LGG	cis	rs7582720	1.000	rs72926769	chr2:203798318	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11190604	0.943	rs113791644	chr10:102324330	T/G	cg07080220	chr10:102295463	HIF1AN	0.73	12.03	0.49	3.42e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6693567	0.507	rs863862	chr1:150352361	T/A	cg15654264	chr1:150340011	RPRD2	0.33	6.78	0.3	3.61e-11	Migraine;
LGG	cis	rs4597304	1	rs4597304	chr16:85055741	G/C	cg16671652	chr16:85009995	ZDHHC7	0.45	6.77	0.3	3.95e-11	Dysphagia;
LGG	trans	rs6601450	0.579	rs11775625	chr8:10272439	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.79	-0.34	4.42e-14	Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6831352	0.959	rs6848050	chr4:100053733	T/C	cg12011299	chr4:100065546	ADH4	0.45	9.34	0.4	3.99e-19	Alcohol dependence;
LGG	cis	rs8133932	0.701	rs9653791	chr21:47303328	G/A	cg13695288	chr21:47294981	PCBP3	-0.36	-7.19	-0.32	2.59e-12	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg16507663	chr6:150244633	RAET1G	0.51	10.58	0.44	1.46e-23	Testicular germ cell tumor;
LGG	cis	rs882632	0.668	rs17744052	chr2:29289411	C/T	cg23429306	chr2:29287725	C2orf71	-0.39	-8.14	-0.35	3.73e-15	Major depressive disorder;
LGG	cis	rs9393692	0.905	rs9357004	chr6:26303319	A/G	cg09303159	chr6:26284866	NA	0.34	7.67	0.34	1e-13	Educational attainment;
LGG	cis	rs4774899	0.869	rs213149	chr15:57248360	G/A	cg08128148	chr15:57256372	TCF12	0.3	7.21	0.32	2.32e-12	Urinary tract infection frequency;
LGG	cis	rs13191362	1.000	rs71567659	chr6:163001736	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.74	8.16	0.35	3.14e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4262150	0.667	rs11740655	chr5:152258232	A/G	cg12297329	chr5:152029980	NA	0.6	11.68	0.48	8.41e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2070488	0.861	rs1858740	chr3:38438372	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.82	16.82	0.62	6.97e-50	Electrocardiographic conduction measures;
LGG	cis	rs8114671	0.562	rs6120763	chr20:33506400	C/G	cg07148914	chr20:33460835	GGT7	0.54	9.06	0.39	3.68e-18	Height;
LGG	trans	rs11722228	0.508	rs3756227	chr4:10087995	C/A	cg26043149	chr18:55253948	FECH	0.91	16.0	0.6	3.57e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.45	-0.33	4.48e-13	IgG glycosylation;
LGG	cis	rs2439831	0.681	rs484029	chr15:43619560	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	1.04	13.88	0.54	6.93e-37	Lung cancer in ever smokers;
LGG	cis	rs9859260	0.710	rs41298097	chr3:195779155	C/T	cg02975922	chr3:195473998	MUC4	0.45	7.16	0.32	3.11e-12	Mean corpuscular volume;
LGG	cis	rs7937682	0.883	rs542831	chr11:111471392	T/A	cg08305652	chr11:111469057	NA	-0.46	-9.24	-0.39	8.89e-19	Primary sclerosing cholangitis;
LGG	cis	rs11169552	0.510	rs10876060	chr12:50965630	C/T	cg12884762	chr12:50931848	DIP2B	-0.41	-7.7	-0.34	8.42e-14	Colorectal cancer;
LGG	cis	rs2795502	1.000	rs3121323	chr10:43377166	A/G	cg20628663	chr10:43360327	NA	-0.42	-8.6	-0.37	1.23e-16	Blood protein levels;
LGG	cis	rs1153858	1.000	rs11070457	chr15:45686943	A/C	cg26924012	chr15:45694286	SPATA5L1	1.04	22.29	0.72	2.71e-75	Homoarginine levels;
LGG	cis	rs782590	0.967	rs11125581	chr2:55796527	C/G	cg18811423	chr2:55921094	PNPT1	0.88	20.56	0.69	3.16e-67	Metabolic syndrome;
LGG	cis	rs6831352	0.918	rs2851253	chr4:100043505	G/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.72	-0.41	1.94e-20	Alcohol dependence;
LGG	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg15490075	chr13:100150979	NA	-0.7	-7.61	-0.33	1.5700000000000001e-13	Obesity-related traits;
LGG	cis	rs4917300	0.606	rs13261328	chr8:143096137	T/C	cg26003909	chr8:143102224	NA	-0.33	-6.66	-0.3	7.83e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs2243480	1.000	rs427044	chr7:65508545	G/A	cg13147721	chr7:65941812	NA	-0.82	-9.83	-0.42	7.49e-21	Diabetic kidney disease;
LGG	cis	rs35771425	1.000	rs35699165	chr1:211594287	G/C	cg10512769	chr1:211675356	NA	-0.74	-11.94	-0.49	7.58e-29	Educational attainment (years of education);
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-7.02	-0.31	7.86e-12	IgG glycosylation;
LGG	cis	rs8067545	0.750	rs4924804	chr17:19991839	C/T	cg13482628	chr17:19912719	NA	0.61	12.1	0.49	1.73e-29	Schizophrenia;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg04455180	chr1:227506639	CDC42BPA	0.37	6.75	0.3	4.46e-11	Obesity-related traits;
LGG	cis	rs4423214	0.921	rs12807827	chr11:71203790	A/C	cg10847948	chr11:71163743	NADSYN1	-0.66	-12.88	-0.51	1.22e-32	Vitamin D levels;
LGG	cis	rs4631830	0.720	rs11004422	chr10:51498336	A/G	cg16070123	chr10:51489643	NA	0.41	7.42	0.33	5.59e-13	Prostate-specific antigen levels;
LGG	trans	rs9354308	0.802	rs2814102	chr6:66523230	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.57	9.2	0.39	1.23e-18	Metabolite levels;
LGG	cis	rs3785574	0.650	rs8077653	chr17:62008965	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.88	-16.67	-0.61	3.22e-49	Height;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg19223190	chr17:80058835	NA	-0.44	-8.52	-0.37	2.3e-16	Life satisfaction;
LGG	cis	rs1790761	0.802	rs2276118	chr11:67288594	A/G	cg24690094	chr11:67383802	NA	-0.39	-6.82	-0.3	2.87e-11	Mean corpuscular volume;
LGG	cis	rs6693295	0.536	rs55912974	chr1:246225155	C/T	cg11798871	chr1:246315928	SMYD3	-0.62	-8.37	-0.36	6.77e-16	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs9322193	0.923	rs35961297	chr6:149989065	T/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.79	-0.41	1.07e-20	Lung cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26451873	chr13:26829095	CDK8	0.38	6.84	0.3	2.52e-11	Obesity-related traits;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg16854524	chr4:83931902	LIN54	-0.42	-7.16	-0.32	3.22e-12	Leprosy;
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg04450456	chr4:17643702	FAM184B	0.31	6.83	0.3	2.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs757978	1.000	rs11681497	chr2:242344333	A/G	cg03294028	chr2:242255774	SEPT2;HDLBP	-0.79	-8.56	-0.37	1.73e-16	Chronic lymphocytic leukemia;
LGG	cis	rs1497828	0.956	rs2815233	chr1:217539236	T/C	cg04411442	chr1:217543379	NA	-0.48	-8.15	-0.35	3.48e-15	Dialysis-related mortality;
LGG	cis	rs7937682	0.924	rs495460	chr11:111504777	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg14893161	chr1:205819251	PM20D1	-0.87	-20.44	-0.69	1.16e-66	Menarche (age at onset);
LGG	cis	rs10256972	0.721	rs2030959	chr7:1075906	T/C	cg07308232	chr7:1071921	C7orf50	-0.72	-14.54	-0.56	9.94e-40	Longevity;Endometriosis;
LGG	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.29	0.36	1.2e-15	Colorectal cancer;
LGG	cis	rs950776	0.616	rs56276142	chr15:78889795	T/C	cg16751781	chr15:78858589	CHRNA5	0.44	8.79	0.38	3.01e-17	Sudden cardiac arrest;
LGG	cis	rs7727544	0.678	rs7735891	chr5:131597005	C/T	cg07395648	chr5:131743802	NA	-0.43	-9.19	-0.39	1.32e-18	Blood metabolite levels;
LGG	cis	rs4974559	0.739	rs28412861	chr4:1320092	A/G	cg02980000	chr4:1222292	CTBP1	0.79	9.1	0.39	2.65e-18	Systolic blood pressure;
LGG	cis	rs3785574	0.962	rs8066463	chr17:61818390	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.55	0.79	1.3e-99	Height;
LGG	cis	rs11722228	0.549	rs3796818	chr4:10097976	C/T	cg08250081	chr4:10125330	NA	0.68	12.35	0.5	1.76e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9378357	0.702	rs4386860	chr6:3280621	C/G	cg08754725	chr6:3293098	SLC22A23	0.57	6.85	0.3	2.36e-11	Obesity-related traits;
LGG	cis	rs60180747	0.818	rs2414902	chr15:66636518	C/T	cg07575407	chr15:66541975	MEGF11	0.39	7.64	0.33	1.24e-13	Testicular germ cell tumor;
LGG	cis	rs2404602	0.735	rs1607015	chr15:76702429	C/T	cg15268244	chr15:77196840	NA	0.44	9.67	0.41	2.82e-20	Blood metabolite levels;
LGG	cis	rs1005277	0.505	rs7917943	chr10:38195811	T/A	cg25427524	chr10:38739819	LOC399744	0.7	14.25	0.55	1.91e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.527	rs34835800	chr17:56764990	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	13.92	0.54	5.03e-37	Cognitive test performance;
LGG	cis	rs7044106	0.718	rs10616	chr9:123363533	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.23	0.32	2.02e-12	Hip circumference adjusted for BMI;
LGG	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.18	-0.43	4.21e-22	Neuroticism;
LGG	cis	rs910316	1.000	rs7156105	chr14:75541954	C/A	cg08847533	chr14:75593920	NEK9	0.62	12.11	0.49	1.69e-29	Height;
LGG	cis	rs2243480	1.000	rs1404147	chr7:65264524	C/T	cg12463550	chr7:65579703	CRCP	0.68	8.23	0.36	1.92e-15	Diabetic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18570997	chr7:129710291	KLHDC10	0.49	7.26	0.32	1.67e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg11878867	chr6:150167359	LRP11	-0.49	-9.93	-0.42	3.53e-21	Lung cancer;
LGG	cis	rs2377058	1.000	rs2377058	chr16:89734831	A/G	cg03605463	chr16:89740564	NA	-0.43	-6.69	-0.3	6.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9902453	0.780	rs10445384	chr17:28182685	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.46	0.53	4.58e-35	Coffee consumption (cups per day);
LGG	cis	rs2562456	0.917	rs10420016	chr19:21688602	C/G	cg00806126	chr19:22604979	ZNF98	0.63	9.4	0.4	2.48e-19	Pain;
LGG	cis	rs2415984	0.562	rs12882684	chr14:46931802	C/T	cg14871534	chr14:47121158	RPL10L	0.45	7.55	0.33	2.38e-13	Number of children ever born;
LGG	cis	rs7666738	0.830	rs6848404	chr4:98946750	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2046867	0.818	rs34582798	chr3:72882778	A/C	cg01043669	chr3:72786069	NA	0.42	6.79	0.3	3.49e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3806843	0.900	rs2531341	chr5:140130894	C/T	cg19875535	chr5:140030758	IK	-0.53	-11.01	-0.46	3.22e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg23102388	chr7:1867652	MAD1L1	-0.35	-6.78	-0.3	3.68e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs35306767	0.714	rs67205460	chr10:1090366	C/T	cg20503657	chr10:835505	NA	0.53	6.94	0.31	1.34e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs1580019	0.587	rs7804457	chr7:32557981	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.0	0.42	1.94e-21	Cognitive ability;
LGG	cis	rs6582630	0.615	rs12821226	chr12:38546406	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.02e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg05868516	chr6:26286170	HIST1H4H	0.44	7.47	0.33	3.92e-13	Educational attainment;
LGG	cis	rs561341	0.843	rs2028067	chr17:30239698	T/C	cg13647721	chr17:30228624	UTP6	0.69	9.88	0.42	5.24e-21	Hip circumference adjusted for BMI;
LGG	cis	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg06374794	chr16:88002281	BANP	0.44	8.27	0.36	1.47e-15	Menopause (age at onset);
LGG	cis	rs2290402	0.536	rs17165130	chr4:875339	A/C	cg09237302	chr4:906077	GAK	0.43	7.34	0.32	9.87e-13	Type 2 diabetes;
LGG	cis	rs920590	0.837	rs4398935	chr8:19649487	T/C	cg01411142	chr8:19674711	INTS10	0.42	6.87	0.3	2.06e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	0.635	rs72649130	chr8:58053810	G/T	cg21724239	chr8:58056113	NA	0.59	8.58	0.37	1.47e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs114486414	chr8:58185103	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.571	rs17275598	chr4:152568478	C/A	cg25486957	chr4:152246857	NA	-0.53	-8.54	-0.37	2.01e-16	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs7101429	chr11:77992967	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.59	-0.33	1.83e-13	Testicular germ cell tumor;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.56	-9.72	-0.41	1.86e-20	Longevity;Endometriosis;
LGG	cis	rs6743226	0.603	rs12619677	chr2:242213195	A/G	cg10021735	chr2:242295487	FARP2	0.41	7.14	0.31	3.64e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs1568889	1.000	rs34667360	chr11:28055650	T/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	13.93	0.54	4.38e-37	Bipolar disorder;
LGG	cis	rs4689388	0.853	rs1079216	chr4:6282473	T/C	cg25554036	chr4:6271136	WFS1	0.61	11.1	0.46	1.54e-25	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs657075	0.697	rs3788987	chr5:131706289	G/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.52	0.33	2.84e-13	Rheumatoid arthritis;
LGG	cis	rs2298450	0.722	rs62232372	chr21:37631951	C/T	cg02919814	chr21:37666008	DOPEY2	-0.44	-8.04	-0.35	7.67e-15	Schizophrenia;
LGG	cis	rs3858526	0.514	rs1530973	chr11:5861449	C/T	cg02574844	chr11:5959923	NA	-0.56	-9.44	-0.4	1.87e-19	DNA methylation (variation);
LGG	cis	rs7914558	1.000	rs11191577	chr10:104902165	A/G	cg04362960	chr10:104952993	NT5C2	0.54	10.41	0.44	6.01e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg05313129	chr8:58192883	C8orf71	-0.59	-8.38	-0.36	6.17e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs8017423	0.647	rs11626821	chr14:90824945	A/G	cg04374321	chr14:90722782	PSMC1	-0.63	-12.46	-0.5	6.48e-31	Mortality in heart failure;
LGG	cis	rs1535500	0.756	rs3807042	chr6:39290834	G/T	cg06347083	chr6:39282316	KCNK17	-0.39	-10.55	-0.44	1.78e-23	Type 2 diabetes;
LGG	cis	rs9322193	0.962	rs9322223	chr6:150122645	G/A	cg12070911	chr6:150209640	RAET1E	0.28	6.95	0.31	1.25e-11	Lung cancer;
LGG	cis	rs12421382	0.659	rs1439518	chr11:109382921	T/G	cg15948088	chr11:109293068	C11orf87	0.51	9.05	0.39	3.97e-18	Schizophrenia;
LGG	cis	rs9810089	0.786	rs10935183	chr3:136149139	C/T	cg21827317	chr3:136751795	NA	0.47	8.45	0.37	3.88e-16	Gestational age at birth (child effect);
LGG	cis	rs1670533	1.000	rs4690213	chr4:1054868	C/T	cg27284194	chr4:1044797	NA	0.55	9.81	0.41	8.99e-21	Recombination rate (females);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22187843	chr7:2395126	EIF3B	0.44	6.95	0.31	1.24e-11	Gut microbiome composition (summer);
LGG	cis	rs11166927	1.000	rs13256625	chr8:140805003	G/T	cg16909799	chr8:140841666	TRAPPC9	0.59	12.5	0.5	4.17e-31	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs6669919	0.653	rs7522450	chr1:211683424	C/A	cg10512769	chr1:211675356	NA	-0.69	-14.43	-0.56	3.17e-39	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs11775568	chr8:58133762	G/A	cg08280861	chr8:58055591	NA	0.63	7.79	0.34	4.59e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4689388	0.824	rs4580722	chr4:6306144	C/A	cg25554036	chr4:6271136	WFS1	0.57	10.48	0.44	3.25e-23	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs12210905	1.000	rs7759955	chr6:26709424	G/A	cg11502198	chr6:26597334	ABT1	-0.9	-7.98	-0.35	1.14e-14	Hip circumference adjusted for BMI;
LGG	cis	rs7267979	0.753	rs400357	chr20:25479058	A/G	cg06421707	chr20:25228305	PYGB	0.43	8.97	0.38	7.46e-18	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9858542	0.953	rs9862080	chr3:49674458	A/G	cg03060546	chr3:49711283	APEH	-0.66	-11.15	-0.46	9.93e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1129187	0.934	rs9471974	chr6:42918984	T/A	cg24101359	chr6:42928495	GNMT	0.57	16.61	0.61	6.08e-49	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1318772	0.932	rs2914151	chr5:112895819	A/C	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	trans	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg18187862	chr3:45730750	SACM1L	0.56	9.28	0.4	6.36e-19	Primary sclerosing cholangitis;
LGG	cis	rs7565124	1.000	rs7570953	chr2:20255015	T/C	cg24657347	chr2:20261756	NA	-0.72	-13.79	-0.54	1.79e-36	Major depressive disorder;
LGG	cis	rs367943	0.698	rs4336355	chr5:113000368	C/T	cg12552261	chr5:112820674	MCC	0.55	9.86	0.42	5.94e-21	Type 2 diabetes;
LGG	cis	rs5771225	0.563	rs738334	chr22:50688235	T/C	cg16473166	chr22:50639996	SELO	0.64	9.9	0.42	4.23e-21	Late-onset Alzheimer's disease;
LGG	cis	rs2354432	0.556	rs4424557	chr1:146871119	A/G	cg25205988	chr1:146714368	CHD1L	1.19	11.64	0.48	1.25e-27	Mitochondrial DNA levels;
LGG	cis	rs7769051	1.000	rs7769051	chr6:133146796	G/T	cg22852734	chr6:133119734	C6orf192	1.11	14.08	0.55	9.5e-38	Type 2 diabetes nephropathy;
LGG	cis	rs1348850	0.872	rs4893825	chr2:178298687	A/G	cg27490568	chr2:178487706	NA	0.52	10.2	0.43	3.73e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6540556	0.723	rs6540551	chr1:209925295	C/T	cg23920097	chr1:209922102	NA	-0.5	-8.93	-0.38	1.04e-17	Red blood cell count;
LGG	cis	rs2718058	0.613	rs2709115	chr7:37790325	C/T	cg24998770	chr7:37888106	TXNDC3	-0.4	-7.65	-0.33	1.19e-13	Alzheimer's disease (late onset);
LGG	cis	rs7937682	0.889	rs479667	chr11:111484034	C/T	cg22437258	chr11:111473054	SIK2	0.56	9.8	0.41	9.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs1620921	0.625	rs9458047	chr6:161262336	A/C	cg01280913	chr6:161186852	NA	-0.36	-7.43	-0.33	5.46e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.953	rs66509078	chr8:58174734	G/C	cg21724239	chr8:58056113	NA	0.42	6.66	0.3	7.74e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs3857536	0.813	rs7769683	chr6:66946256	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs9291683	0.588	rs3733586	chr4:9997534	C/T	cg11266682	chr4:10021025	SLC2A9	0.54	10.94	0.45	6.34e-25	Bone mineral density;
LGG	cis	rs4595586	0.545	rs9668716	chr12:39378833	G/T	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.13	0.43	6.65e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg08975724	chr8:8085496	FLJ10661	0.41	7.53	0.33	2.63e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9291683	0.632	rs13101785	chr4:10042915	T/A	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.98e-14	Neuroticism;
LGG	cis	rs9916302	0.861	rs8081033	chr17:37506650	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.63e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9815354	1.000	rs9865780	chr3:41895802	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg15556689	chr8:8085844	FLJ10661	0.45	7.56	0.33	2.14e-13	Neuroticism;
LGG	cis	rs9858542	0.953	rs9821311	chr3:49543656	C/T	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.49e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2013441	0.866	rs8070401	chr17:20214492	C/T	cg13482628	chr17:19912719	NA	-0.4	-6.93	-0.31	1.42e-11	Obesity-related traits;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg03709012	chr19:19516395	GATAD2A	0.84	16.98	0.62	1.22e-50	Tonsillectomy;
LGG	cis	rs6500602	0.564	rs3747584	chr16:4516092	A/G	cg06916706	chr16:4465613	CORO7	-0.92	-16.58	-0.61	8.35e-49	Schizophrenia;
LGG	cis	rs8017423	0.967	rs59980414	chr14:90687738	G/C	cg04374321	chr14:90722782	PSMC1	0.88	18.71	0.66	1.43e-58	Mortality in heart failure;
LGG	cis	rs11628318	0.614	rs10132160	chr14:103058023	A/G	cg12046867	chr14:103022105	NA	-0.76	-13.08	-0.52	1.68e-33	Platelet count;
LGG	cis	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg07777115	chr5:623756	CEP72	-0.62	-7.72	-0.34	7.46e-14	Obesity-related traits;
LGG	cis	rs6089584	0.528	rs4925335	chr20:60627034	G/A	cg06470251	chr20:60548479	NA	0.4	6.94	0.31	1.35e-11	Body mass index;
LGG	cis	rs6748734	0.857	rs4675857	chr2:241842326	T/C	cg26818257	chr2:241905806	NA	0.37	6.99	0.31	9.92e-12	Urinary metabolites;
LGG	cis	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg00383909	chr3:49044727	WDR6	0.44	7.09	0.31	4.92e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs910316	0.935	rs11159119	chr14:75636967	C/T	cg11812906	chr14:75593930	NEK9	-0.52	-9.54	-0.41	7.89e-20	Height;
LGG	cis	rs1862618	0.853	rs2548665	chr5:56131805	T/A	cg08400814	chr5:56204995	C5orf35	-0.45	-7.36	-0.32	8.22e-13	Initial pursuit acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00854637	chr16:67840857	TSNAXIP1;RANBP10	0.48	7.0	0.31	8.93e-12	Gut microbiome composition (summer);
LGG	trans	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Myopia (pathological);
LGG	cis	rs78487399	0.808	rs6746610	chr2:43677253	T/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.7	-0.3	6.23e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	trans	rs6582630	0.563	rs923281	chr12:38590241	G/A	cg06521331	chr12:34319734	NA	0.43	7.76	0.34	5.5e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs868036	0.718	rs28399056	chr15:68116010	C/A	cg05925327	chr15:68127851	NA	-0.4	-8.3	-0.36	1.11e-15	Restless legs syndrome;
LGG	trans	rs35110281	0.592	rs6417729	chr21:44967202	A/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.72	13.49	0.53	3.26e-35	Mean corpuscular volume;
LGG	cis	rs1008375	0.966	rs28441502	chr4:17598384	G/A	cg02297831	chr4:17616191	MED28	0.48	8.86	0.38	1.79e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08527566	chr12:95611432	FGD6;VEZT	0.39	6.99	0.31	9.87e-12	Obesity-related traits;
LGG	cis	rs73198271	0.531	rs56100346	chr8:8652844	C/T	cg01851573	chr8:8652454	MFHAS1	0.52	8.54	0.37	1.95e-16	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	trans	rs9329221	0.870	rs11777976	chr8:10255402	A/G	cg02002194	chr4:3960332	NA	0.44	7.95	0.35	1.45e-14	Neuroticism;
LGG	cis	rs7107174	0.892	rs2510033	chr11:77941771	T/G	cg02023728	chr11:77925099	USP35	0.43	7.3	0.32	1.3e-12	Testicular germ cell tumor;
LGG	cis	rs701145	0.556	rs355763	chr3:154012881	C/T	cg12800244	chr3:153838788	SGEF	0.58	8.24	0.36	1.81e-15	Coronary artery disease;
LGG	cis	rs17270561	0.723	rs12213243	chr6:25890108	C/T	cg17691542	chr6:26056736	HIST1H1C	0.89	14.04	0.55	1.43e-37	Iron status biomarkers;
LGG	cis	rs6831352	0.879	rs2602879	chr4:100040652	G/A	cg13256891	chr4:100009986	ADH5	0.56	9.58	0.41	5.88e-20	Alcohol dependence;
LGG	cis	rs1806153	0.611	rs1806180	chr11:31840265	G/A	cg11990419	chr11:31841155	NA	0.34	7.97	0.35	1.22e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg11366901	chr6:160182831	ACAT2	1.05	15.97	0.6	4.76e-46	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs344364	0.511	rs12599337	chr16:1946751	A/G	cg00046913	chr16:1877150	HAGH;FAHD1	0.56	7.12	0.31	4.1e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6076065	0.748	rs6048781	chr20:23380027	T/C	cg11657817	chr20:23433608	CST11	0.4	8.17	0.35	3.04e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg14952266	chr13:112191215	NA	0.39	7.65	0.34	1.14e-13	Hepatitis;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.4	-10.25	-0.43	2.44e-22	IgG glycosylation;
LGG	trans	rs637571	0.584	rs594689	chr11:65635559	G/A	cg17712092	chr4:129076599	LARP1B	-0.77	-15.02	-0.57	8.16e-42	Eosinophil percentage of white cells;
LGG	cis	rs798554	0.549	rs1623138	chr7:2899410	A/G	cg19717773	chr7:2847554	GNA12	-0.33	-7.65	-0.33	1.21e-13	Height;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.66	0.34	1.1e-13	Longevity;
LGG	cis	rs1862618	0.525	rs832403	chr5:56265992	G/T	cg08400814	chr5:56204995	C5orf35	0.56	8.07	0.35	6.14e-15	Initial pursuit acceleration;
LGG	cis	rs1153858	1.000	rs60476496	chr15:45713801	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.32	0.72	1.9e-75	Homoarginine levels;
LGG	cis	rs9341808	0.754	rs9361591	chr6:80953255	C/A	cg08355045	chr6:80787529	NA	0.41	7.83	0.34	3.29e-14	Sitting height ratio;
LGG	cis	rs9322193	0.884	rs2095375	chr6:150128173	C/A	cg00933542	chr6:150070202	PCMT1	0.38	6.85	0.3	2.4e-11	Lung cancer;
LGG	cis	rs7192380	1.000	rs11640319	chr16:69633515	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.62	-0.33	1.45e-13	Sjögren's syndrome;
LGG	cis	rs2153535	0.607	rs9502722	chr6:8541483	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.01	0.39	5.49e-18	Motion sickness;
LGG	cis	rs9291683	0.609	rs12500810	chr4:10031068	G/A	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.55	-0.37	1.76e-16	Bone mineral density;
LGG	cis	rs2302777	0.507	rs9889711	chr17:38108292	A/T	cg17467752	chr17:38218738	THRA	0.45	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs1994135	0.692	rs1816958	chr12:33695066	A/T	cg13010199	chr12:38710504	ALG10B	0.47	8.43	0.36	4.46e-16	Resting heart rate;
LGG	cis	rs4076764	0.522	rs4265409	chr1:163414559	C/T	cg24596788	chr1:163392923	NA	-0.56	-10.24	-0.43	2.54e-22	Motion sickness;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg25893869	chr1:70687106	SFRS11	-0.29	-6.81	-0.3	3.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3126085	0.935	rs12738889	chr1:152257688	G/A	cg26876637	chr1:152193138	HRNR	-0.54	-8.79	-0.38	3.03e-17	Atopic dermatitis;
LGG	cis	rs7568458	0.846	rs6705971	chr2:85761417	G/T	cg02493740	chr2:85810744	VAMP5	0.41	7.39	0.32	6.83e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs898097	0.625	rs2125479	chr17:80890262	A/G	cg15664640	chr17:80829946	TBCD	-0.45	-8.74	-0.38	4.34e-17	Breast cancer;
LGG	cis	rs10504229	0.593	rs10504216	chr8:57981470	G/A	cg22535103	chr8:58192502	C8orf71	-0.79	-9.82	-0.42	8.25e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.545	rs73376394	chr7:65637681	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.44	0.44	4.69e-23	Aortic root size;
LGG	cis	rs9325144	0.647	rs12830095	chr12:38864199	C/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.91	-0.54	5.54e-37	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.764	rs2961760	chr5:151939905	C/T	cg12297329	chr5:152029980	NA	0.7	13.28	0.53	2.5e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs2832077	0.689	rs2832052	chr21:30130073	G/C	cg08807101	chr21:30365312	RNF160	-0.51	-7.87	-0.34	2.57e-14	Cognitive test performance;
LGG	cis	rs1125355	0.690	rs11679019	chr2:159661511	C/T	cg02251393	chr2:159651559	DAPL1	0.39	7.59	0.33	1.8e-13	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs28374715	0.532	rs316606	chr15:41772202	A/C	cg18705301	chr15:41695430	NDUFAF1	-1.34	-32.56	-0.83	8.31e-122	Ulcerative colitis;
LGG	trans	rs7208859	0.623	rs8082537	chr17:29015932	T/C	cg22358067	chr17:16797159	NA	-0.51	-7.08	-0.31	5.47e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7412746	0.658	rs10305704	chr1:150804429	A/C	cg15448220	chr1:150897856	SETDB1	0.38	7.1	0.31	4.75e-12	Melanoma;
LGG	trans	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs9583531	0.600	rs7330080	chr13:111367115	C/T	cg24331049	chr13:111365604	ING1	0.84	15.24	0.58	8.39e-43	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.16	0.32	3.1e-12	Skin colour saturation;
LGG	cis	rs736408	1.000	rs2710331	chr3:52837855	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-9.81	-0.41	9.46e-21	Bipolar disorder;
LGG	cis	rs2576037	0.583	rs2571028	chr18:44561100	C/G	cg23129478	chr18:44337922	ST8SIA5	0.37	7.05	0.31	6.69e-12	Personality dimensions;
LGG	cis	rs9325144	0.560	rs11182979	chr12:38642562	C/A	cg13010199	chr12:38710504	ALG10B	-0.64	-12.87	-0.51	1.26e-32	Morning vs. evening chronotype;
LGG	cis	rs7586879	0.828	rs11685125	chr2:25092104	A/G	cg04586622	chr2:25135609	ADCY3	0.36	8.62	0.37	1.06e-16	Body mass index;
LGG	cis	rs9815354	0.812	rs73830516	chr3:41876056	A/G	cg03022575	chr3:42003672	ULK4	0.82	9.55	0.41	7.81e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1799949	1.000	rs11655505	chr17:41278377	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	trans	rs11039798	1.000	rs10769370	chr11:48515430	A/G	cg03929089	chr4:120376271	NA	0.73	8.46	0.37	3.54e-16	Axial length;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.3e-17	Schizophrenia;
LGG	cis	rs138249	0.867	rs715616	chr22:50558505	G/A	cg18875453	chr22:50517795	MLC1	0.26	6.73	0.3	5.07e-11	Gestational age at birth in labor-initiated deliveries (child effect);
LGG	cis	rs17366136	0.895	rs1122913	chr7:22602932	A/G	cg18045685	chr7:22629474	NA	0.45	8.31	0.36	1.04e-15	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
LGG	cis	rs7572733	0.534	rs700683	chr2:198712332	G/A	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg26150922	chr2:100937072	LONRF2	-0.58	-11.03	-0.46	2.9e-25	Intelligence (multi-trait analysis);
LGG	cis	rs11071200	0.550	rs12903822	chr15:55958417	C/T	cg17396834	chr15:56014697	PRTG	0.33	6.89	0.3	1.85e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs12200560	0.505	rs984520	chr6:97076454	A/G	cg06623918	chr6:96969491	KIAA0776	-0.45	-7.68	-0.34	9.27e-14	Coronary heart disease;
LGG	cis	rs853679	0.517	rs1853097	chr6:28058635	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs459571	0.959	rs461462	chr9:136911272	C/T	cg13789015	chr9:136890014	NCRNA00094	0.55	10.31	0.43	1.37e-22	Platelet distribution width;
LGG	cis	rs7582180	0.629	rs13031508	chr2:100952757	A/G	cg08297393	chr2:100937505	LONRF2	-0.55	-10.34	-0.43	1.14e-22	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs9393714	chr6:26373740	G/T	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs738322	0.934	rs133019	chr22:38573035	A/G	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.98	-0.31	1.02e-11	Cutaneous nevi;
LGG	cis	rs2439831	0.867	rs689616	chr15:43761901	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	cis	rs11098499	0.954	rs10034623	chr4:120397829	G/A	cg09307838	chr4:120376055	NA	0.81	13.84	0.54	1.06e-36	Corneal astigmatism;
LGG	cis	rs1788820	0.871	rs1623003	chr18:21165163	C/T	cg14672496	chr18:21087552	C18orf8	0.37	6.7	0.3	5.99e-11	Body mass index;
LGG	cis	rs13108904	0.934	rs35201724	chr4:1310717	C/G	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	7.17e-15	Obesity-related traits;
LGG	cis	rs798554	0.757	rs1182177	chr7:2874540	C/T	cg13628971	chr7:2884303	GNA12	0.51	10.12	0.43	6.74e-22	Height;
LGG	cis	rs4788570	0.697	rs2173702	chr16:71812671	G/A	cg06353428	chr16:71660113	MARVELD3	1.26	19.81	0.68	1.04e-63	Intelligence (multi-trait analysis);
LGG	cis	rs9972944	0.756	rs7215462	chr17:63770498	T/C	cg07283582	chr17:63770753	CCDC46	-0.43	-8.39	-0.36	5.77e-16	Total body bone mineral density;
LGG	trans	rs7618501	0.538	rs9856572	chr3:50109073	A/T	cg21659725	chr3:3221576	CRBN	-0.65	-12.11	-0.49	1.64e-29	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.890	rs3843724	chr16:48618573	C/G	cg16662043	chr16:48846231	NA	0.37	7.25	0.32	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs66887589	0.592	rs11731571	chr4:120221185	G/A	cg09307838	chr4:120376055	NA	0.48	7.93	0.35	1.66e-14	Diastolic blood pressure;
LGG	cis	rs10504229	1.000	rs66886949	chr8:58187613	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.610	rs199530	chr17:44836653	C/T	cg15921436	chr17:44337874	NA	-0.42	-9.96	-0.42	2.75e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1577917	0.958	rs114467802	chr6:86572350	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.09	-0.49	1.88e-29	Response to antipsychotic treatment;
LGG	cis	rs12447804	1.000	rs2241774	chr16:58072153	C/T	cg03859792	chr16:58121049	NA	0.47	6.95	0.31	1.22e-11	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs9325144	0.513	rs7977596	chr12:38649067	C/A	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs12950390	0.820	rs58391889	chr17:45865959	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.99	-0.35	1.07e-14	IgG glycosylation;
LGG	cis	rs2760061	0.583	rs708113	chr1:228192753	T/A	cg02753203	chr1:228287806	NA	0.9	18.85	0.66	3.24e-59	Diastolic blood pressure;
LGG	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.586	rs11710916	chr3:161130070	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.66	-0.37	8.1e-17	Morning vs. evening chronotype;
LGG	trans	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg02002194	chr4:3960332	NA	0.42	7.15	0.32	3.36e-12	Neuroticism;
LGG	cis	rs736801	0.780	rs11951091	chr5:131786595	G/A	cg07395648	chr5:131743802	NA	-0.53	-11.16	-0.46	8.9e-26	Breast cancer;Mosquito bite size;
LGG	trans	rs656319	0.513	rs17746227	chr8:9981654	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.89	-0.34	2.13e-14	Myopia (pathological);
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg14196790	chr5:131705035	SLC22A5	0.61	7.61	0.33	1.5e-13	Rheumatoid arthritis;
LGG	cis	rs8060686	0.641	rs76419201	chr16:68153553	G/A	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.65	-0.3	8.13e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs9467711	0.560	rs6900665	chr6:26487169	C/T	cg08344181	chr3:125677491	NA	-0.58	-6.88	-0.3	1.98e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs873946	0.618	rs12775767	chr10:134545628	C/T	cg13271783	chr10:134563150	INPP5A	-0.49	-7.22	-0.32	2.11e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6930083	0.510	rs4713994	chr6:36621533	A/G	cg08179530	chr6:36648295	CDKN1A	-0.56	-9.34	-0.4	4.06e-19	Coronary artery disease;
LGG	cis	rs4917300	0.606	rs6583564	chr8:143114363	G/T	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.32e-11	Amyotrophic lateral sclerosis;
LGG	trans	rs12310956	0.532	rs10844720	chr12:33987859	G/T	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.53e-21	Morning vs. evening chronotype;
LGG	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg13683864	chr3:40499215	RPL14	-1.13	-26.01	-0.77	1.31e-92	Renal cell carcinoma;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.09	-0.39	2.89e-18	Obesity-related traits;
LGG	cis	rs763121	0.853	rs5750669	chr22:39080638	T/A	cg06022373	chr22:39101656	GTPBP1	0.9	18.33	0.65	7.54e-57	Menopause (age at onset);
LGG	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11890956	chr21:40555474	PSMG1	1.17	30.07	0.81	6.31e-111	Cognitive function;
LGG	trans	rs7939886	0.623	rs77065109	chr11:55906843	G/A	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	cis	rs1552244	0.882	rs56332224	chr3:10037321	G/A	cg00149659	chr3:10157352	C3orf10	0.76	9.52	0.4	9.66e-20	Alzheimer's disease;
LGG	trans	rs9467711	0.559	rs13208916	chr6:26601940	G/A	cg08344181	chr3:125677491	NA	-0.59	-6.7	-0.3	6e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6743226	0.901	rs4675968	chr2:242222492	T/C	cg10021735	chr2:242295487	FARP2	0.48	8.79	0.38	2.89e-17	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg15556689	chr8:8085844	FLJ10661	0.47	8.61	0.37	1.14e-16	Neuroticism;
LGG	cis	rs8062405	0.755	rs111693583	chr16:28583610	C/T	cg16576597	chr16:28551801	NUPR1	0.43	10.29	0.43	1.61e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9309711	0.666	rs6767	chr2:3483205	C/T	cg15541040	chr2:3486749	NA	-0.46	-8.46	-0.37	3.6e-16	Neurofibrillary tangles;
LGG	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.54	8.91	0.38	1.14e-17	Personality dimensions;
LGG	cis	rs35146811	0.555	rs1981550	chr7:99541952	G/A	cg22906224	chr7:99728672	NA	0.44	6.86	0.3	2.15e-11	Coronary artery disease;
LGG	cis	rs526231	0.543	rs32851	chr5:102468671	A/G	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs11920090	0.800	rs6806926	chr3:170743747	T/A	cg09710316	chr3:170744871	SLC2A2	0.64	8.76	0.38	3.72e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg05941027	chr17:61774174	LIMD2	0.35	8.86	0.38	1.78e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	1.000	rs12199516	chr6:86726221	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-9.95	-0.42	2.78e-21	Response to antipsychotic treatment;
LGG	cis	rs28655083	1.000	rs1843455	chr16:77072343	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.49	-7.7	-0.34	8.35e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1005277	0.579	rs2474569	chr10:38383491	C/G	cg25427524	chr10:38739819	LOC399744	-0.62	-11.45	-0.47	6.78e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs4622507	0.618	rs12925757	chr16:55058628	T/G	cg09947736	chr16:55091198	NA	0.77	11.1	0.46	1.49e-25	Social communication problems;
LGG	cis	rs1008375	1.000	rs6848360	chr4:17634442	G/T	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.32e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6866344	0.598	rs11742176	chr5:178147931	C/T	cg10224037	chr5:178157518	ZNF354A	0.78	12.7	0.51	6.69e-32	Neutrophil percentage of white cells;
LGG	cis	rs12478296	0.901	rs59477854	chr2:243015490	T/C	cg06360820	chr2:242988706	NA	-0.88	-11.61	-0.47	1.54e-27	Obesity-related traits;
LGG	cis	rs9926296	0.585	rs1800337	chr16:89845194	A/G	cg26513180	chr16:89883248	FANCA	0.94	21.76	0.71	8.08e-73	Vitiligo;
LGG	trans	rs9858542	0.953	rs11926781	chr3:49603289	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.49	-7.79	-0.34	4.38e-14	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11782517	0.961	rs4276692	chr8:10115695	G/A	cg16141378	chr3:129829833	LOC729375	-0.37	-7.17	-0.32	2.96e-12	Nose size;
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg24250549	chr1:154909240	PMVK	0.76	15.1	0.57	3.61e-42	Prostate cancer;
LGG	cis	rs7100689	0.646	rs10736356	chr10:82148325	A/G	cg01528321	chr10:82214614	TSPAN14	0.89	15.8	0.59	2.76e-45	Post bronchodilator FEV1;
LGG	cis	rs4862750	0.872	rs7679956	chr4:187900229	C/T	cg10295955	chr4:187884368	NA	-1.14	-32.32	-0.83	8.88e-121	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08677398	chr8:58056175	NA	0.53	7.98	0.35	1.2e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649076	chr10:60294061	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs7618501	0.633	rs55751738	chr3:49972101	A/G	cg05623727	chr3:50126028	RBM5	0.34	7.33	0.32	1.02e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.580	rs1414348	chr6:8471940	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.84e-22	Motion sickness;
LGG	trans	rs7819412	0.749	rs11991118	chr8:10939273	A/C	cg08975724	chr8:8085496	FLJ10661	0.47	8.84	0.38	2.03e-17	Triglycerides;
LGG	cis	rs9906944	0.933	rs35051752	chr17:47089908	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.72	-0.3	5.27e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs7395662	0.784	rs2170661	chr11:48378186	C/T	cg00717180	chr2:96193071	NA	-0.43	-7.75	-0.34	5.94e-14	HDL cholesterol;
LGG	cis	rs9596863	0.898	rs9316658	chr13:54333620	C/T	ch.13.53330881F	chr13:54432880	NA	-0.53	-6.84	-0.3	2.48e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs701145	0.585	rs357494	chr3:153937753	G/A	cg17054900	chr3:154042577	DHX36	0.91	10.03	0.42	1.43e-21	Coronary artery disease;
LGG	cis	rs1865760	1.000	rs2071297	chr6:25924513	C/G	cg03264133	chr6:25882463	NA	0.42	7.35	0.32	9.01e-13	Height;
LGG	cis	rs796364	1.000	rs1509835	chr2:200814809	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.83	10.84	0.45	1.44e-24	Schizophrenia;
LGG	cis	rs600231	0.651	rs2846862	chr11:65219790	A/G	cg17120908	chr11:65337727	SSSCA1	-0.49	-8.85	-0.38	1.92e-17	Bone mineral density;
LGG	trans	rs1997103	1.000	rs12718956	chr7:55407763	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6496044	0.568	rs2344436	chr15:86074906	C/T	cg10818794	chr15:86012489	AKAP13	-0.31	-6.69	-0.3	6.63e-11	Interstitial lung disease;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg01238044	chr22:24384105	GSTT1	0.44	7.37	0.32	7.78e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.33	7.04	0.31	7.2e-12	Schizophrenia;
LGG	cis	rs7639513	0.767	rs7617041	chr3:12709167	A/G	cg23032965	chr3:12705835	RAF1	0.85	16.72	0.61	2.04e-49	Itch intensity from mosquito bite;
LGG	cis	rs6740322	0.857	rs11690012	chr2:43542480	C/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.57	-8.96	-0.38	8.22e-18	Coronary artery disease;
LGG	cis	rs1577917	0.798	rs7772384	chr6:86639680	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.41	-0.53	6.89e-35	Response to antipsychotic treatment;
LGG	trans	rs7937682	0.601	rs2187388	chr11:111387116	C/T	cg18187862	chr3:45730750	SACM1L	-0.44	-7.2	-0.32	2.41e-12	Primary sclerosing cholangitis;
LGG	cis	rs7524258	0.517	rs6577430	chr1:7324468	C/T	cg08033730	chr1:7319125	CAMTA1	0.42	7.18	0.32	2.71e-12	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs12477438	0.765	rs6722164	chr2:99561527	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.28	-0.58	5.42e-43	Chronic sinus infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02054479	chr16:20911997	LYRM1;DCUN1D3	0.44	7.35	0.32	9.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9880211	1.000	rs6775314	chr3:136275948	G/A	cg21827317	chr3:136751795	NA	-0.48	-7.24	-0.32	1.86e-12	Body mass index;Height;
LGG	trans	rs11088226	1.000	rs2833890	chr21:33927886	A/G	cg09050820	chr6:167586206	TCP10L2	-0.67	-9.96	-0.42	2.76e-21	Gastritis;
LGG	trans	rs75804782	0.521	rs66477197	chr2:239403832	C/T	cg01134436	chr17:81009848	B3GNTL1	0.8	8.73	0.38	4.54e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs2243480	1.000	rs402418	chr7:65509469	G/A	cg18252515	chr7:66147081	NA	-1.41	-19.61	-0.67	9.39e-63	Diabetic kidney disease;
LGG	cis	rs10779751	1.000	rs7526649	chr1:11278163	C/T	cg08854313	chr1:11322531	MTOR	0.73	15.97	0.6	4.6e-46	Body mass index;
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.8	-0.38	2.81e-17	Schizophrenia;
LGG	cis	rs875971	0.830	rs7799834	chr7:65880694	A/C	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs9472414	0.680	rs9472335	chr6:44709967	G/A	cg20913747	chr6:44695427	NA	0.46	7.14	0.32	3.53e-12	Height;
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg15971980	chr6:150254442	NA	0.43	8.22	0.36	2.11e-15	Lung cancer;
LGG	trans	rs9929218	0.529	rs2296404	chr16:68729525	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	24.94	0.76	1.23e-87	Colorectal cancer;
LGG	trans	rs1005277	0.579	rs2749612	chr10:38488610	G/A	cg04469686	chr1:162760199	HSD17B7	-0.47	-7.57	-0.33	2.1e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg01988459	chr11:68622903	NA	-0.61	-12.4	-0.5	1.11e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7928758	0.945	rs11223787	chr11:134277978	G/A	cg22777979	chr11:134283252	B3GAT1	0.76	10.6	0.44	1.18e-23	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2795502	0.873	rs3121282	chr10:43423626	T/A	cg27426351	chr10:43362370	NA	0.55	7.8	0.34	4.14e-14	Blood protein levels;
LGG	cis	rs875971	0.862	rs1695820	chr7:65844563	G/A	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs4481887	0.927	rs4282853	chr1:248475127	A/G	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs4704846	1.000	rs3087616	chr5:156513282	C/T	cg12943317	chr5:156479607	HAVCR1	-0.57	-7.28	-0.32	1.44e-12	Blood protein levels;
LGG	cis	rs10504229	0.683	rs10504221	chr8:58140256	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2235649	0.753	rs7200472	chr16:1849669	T/C	cg09540102	chr16:1822124	NME3;MRPS34;EME2	-0.41	-6.94	-0.31	1.29e-11	Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs1999334	chr21:46670457	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.27	0.36	1.42e-15	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7587476	0.784	rs17424051	chr2:215688992	G/C	cg04004882	chr2:215674386	BARD1	0.56	8.16	0.35	3.19e-15	Neuroblastoma;
LGG	cis	rs7100689	0.599	rs946892	chr10:82127551	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs6502050	0.835	rs8079389	chr17:80158656	T/G	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.58e-14	Life satisfaction;
LGG	trans	rs6952808	0.636	rs6461005	chr7:1947687	A/G	cg24247370	chr13:99142703	STK24	-0.38	-6.92	-0.31	1.53e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs13095912	0.752	rs13061708	chr3:185339984	T/C	cg11274856	chr3:185301563	NA	0.49	7.9	0.34	2.03e-14	Systolic blood pressure;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg07497933	chr5:170678705	RANBP17	0.34	7.0	0.31	8.82e-12	Electrocardiographic conduction measures;
LGG	cis	rs5771242	0.518	rs7290465	chr22:50679758	C/T	cg16473166	chr22:50639996	SELO	-0.73	-11.38	-0.47	1.23e-26	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs7582180	0.677	rs11694723	chr2:100878122	C/T	cg05692746	chr2:100937584	LONRF2	-0.53	-8.81	-0.38	2.57e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg20026190	chr17:76395443	PGS1	0.56	9.91	0.42	4.04e-21	HDL cholesterol levels;
LGG	cis	rs12493885	0.725	rs4680113	chr3:153727337	C/T	cg17054900	chr3:154042577	DHX36	-0.62	-7.99	-0.35	1.08e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.28	8.21	0.36	2.19e-15	IgG glycosylation;
LGG	trans	rs9393777	1.000	rs9393777	chr6:26942027	T/C	cg06606381	chr12:133084897	FBRSL1	-0.69	-7.71	-0.34	7.59e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.608	rs9837460	chr3:10049922	G/C	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.55	0.5	2.76e-31	Alzheimer's disease;
LGG	cis	rs2243480	1.000	rs316318	chr7:65612904	A/G	cg18252515	chr7:66147081	NA	-1.43	-20.57	-0.69	3.04e-67	Diabetic kidney disease;
LGG	cis	rs7828089	0.935	rs896378	chr8:22262321	T/C	cg12081754	chr8:22256438	SLC39A14	0.7	13.54	0.53	1.98e-35	Verbal declarative memory;
LGG	cis	rs72772090	0.539	rs67140788	chr5:96116286	A/G	cg00188032	chr5:96141721	ERAP1	0.55	7.25	0.32	1.76e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg04369109	chr6:150039330	LATS1	-0.42	-6.87	-0.3	2.04e-11	Lung cancer;
LGG	cis	rs4851266	1.000	rs2871344	chr2:100839430	A/G	cg21926883	chr2:100939477	LONRF2	-0.44	-8.0	-0.35	1.04e-14	Educational attainment;
LGG	cis	rs7590368	0.924	rs72779464	chr2:10963159	T/C	cg15705551	chr2:10952987	PDIA6	0.61	9.08	0.39	3.09e-18	Educational attainment (years of education);
LGG	cis	rs9911578	1.000	rs11079365	chr17:56945430	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6963495	0.818	rs73192113	chr7:105169603	C/T	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg03474202	chr17:45855739	NA	-0.27	-7.96	-0.35	1.36e-14	IgG glycosylation;
LGG	cis	rs858239	0.862	rs1728292	chr7:23263474	C/G	cg00469287	chr7:23338798	C7orf30	0.39	6.67	0.3	7.43e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2952156	0.920	rs1476278	chr17:37836243	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-16.5	-0.61	1.88e-48	Asthma;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.84	0.66	3.29e-59	Platelet count;
LGG	cis	rs9325144	0.647	rs34963631	chr12:38912260	T/A	cg04568710	chr12:38710424	ALG10B	-0.39	-8.13	-0.35	3.84e-15	Morning vs. evening chronotype;
LGG	cis	rs35264875	0.898	rs72928701	chr11:68861564	C/T	cg23845249	chr11:68861649	NA	0.45	8.2	0.36	2.42e-15	Blond vs. brown hair color;
LGG	cis	rs17376456	0.778	rs10440717	chr5:93424852	C/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.79e-21	Diabetic retinopathy;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05025164	chr4:1340916	KIAA1530	-0.71	-13.39	-0.53	8.27e-35	Obesity-related traits;
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.82	12.46	0.5	5.96e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs765787	0.530	rs12906537	chr15:45520061	T/C	cg24006582	chr15:45444508	DUOX1	0.67	12.11	0.49	1.64e-29	Uric acid levels;
LGG	cis	rs4700695	0.719	rs153390	chr5:65431087	G/C	cg21114390	chr5:65439923	SFRS12	-0.71	-10.46	-0.44	4.02e-23	Facial morphology (factor 19);
LGG	cis	rs4423214	0.592	rs78300366	chr11:71205514	A/G	cg10847948	chr11:71163743	NADSYN1	0.57	8.41	0.36	5.23e-16	Vitamin D levels;
LGG	cis	rs612683	0.602	rs2030048	chr1:101006577	C/T	cg06223162	chr1:101003688	GPR88	-0.45	-11.03	-0.46	2.9e-25	Breast cancer;
LGG	cis	rs17209837	1.000	rs59616301	chr7:87118407	T/C	cg00919237	chr7:87102261	ABCB4	-0.74	-12.0	-0.49	4.53e-29	Gallbladder cancer;
LGG	cis	rs12765878	0.967	rs34887477	chr10:105643436	C/T	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs2046867	0.818	rs62249862	chr3:72867949	G/C	cg25664220	chr3:72788482	NA	-0.33	-8.94	-0.38	9.11e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs13160562	0.527	rs25863	chr5:96105926	G/A	cg17330273	chr5:96107758	CAST;ERAP1	0.32	7.12	0.31	4.02e-12	Alcohol dependence;
LGG	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg02002194	chr4:3960332	NA	-0.39	-6.96	-0.31	1.15e-11	Retinal vascular caliber;
LGG	cis	rs13421350	0.579	rs10930559	chr2:173352824	C/T	cg15021238	chr2:173305865	ITGA6	-0.79	-8.48	-0.37	3.07e-16	Diabetic kidney disease;
LGG	trans	rs1005277	0.579	rs2505241	chr10:38442421	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.48	-0.33	3.69e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs12682352	0.602	rs28399241	chr8:8663215	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.38	0.4	3.07e-19	Neuroticism;
LGG	cis	rs2276314	0.857	rs62101402	chr18:33629435	A/G	cg19628046	chr18:33552617	C18orf21	0.5	7.32	0.32	1.12e-12	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs11098499	0.863	rs11947234	chr4:120474859	A/G	cg24375607	chr4:120327624	NA	0.68	11.11	0.46	1.44e-25	Corneal astigmatism;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26260386	chr4:140477698	SETD7	0.4	7.09	0.31	5.16e-12	Obesity-related traits;
LGG	cis	rs751728	0.687	rs9357164	chr6:33761021	T/C	cg13560919	chr6:33536144	NA	-0.42	-7.85	-0.34	2.9e-14	Crohn's disease;
LGG	trans	rs1005277	0.579	rs2474571	chr10:38384639	T/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.9	-0.31	1.73e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2938670	1	rs2938670	chr15:78740688	T/G	cg18825076	chr15:78729989	IREB2	-0.55	-9.19	-0.39	1.36e-18	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9322193	0.923	rs9322196	chr6:149940781	T/G	cg07701084	chr6:150067640	NUP43	0.71	13.7	0.54	4.2e-36	Lung cancer;
LGG	cis	rs559928	1.000	rs72926046	chr11:64143387	A/G	cg23796481	chr11:64053134	BAD;GPR137	0.53	6.77	0.3	3.87e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4253772	0.591	rs6008546	chr22:46686377	T/G	cg24881330	chr22:46731750	TRMU	0.72	8.05	0.35	7.28e-15	LDL cholesterol;Cholesterol, total;
LGG	cis	rs123509	0.913	rs339682	chr3:42791123	A/G	cg10144569	chr3:42726640	KBTBD5	0.51	7.46	0.33	4.34e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg09238746	chr17:78121135	EIF4A3	-0.6	-10.33	-0.43	1.2e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	trans	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg26043149	chr18:55253948	FECH	-0.48	-8.33	-0.36	9.42e-16	Bone mineral density;
LGG	cis	rs12142240	0.667	rs12062	chr1:46830447	G/T	cg00530320	chr1:46809349	NSUN4	-0.44	-8.38	-0.36	6.58e-16	Menopause (age at onset);
LGG	cis	rs59197085	0.551	rs58518485	chr7:128437731	G/A	cg00734629	chr7:128471146	FLNC	0.33	6.67	0.3	7.09e-11	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs17270561	0.609	rs4712960	chr6:25727265	C/T	cg17691542	chr6:26056736	HIST1H1C	0.63	10.33	0.43	1.21e-22	Iron status biomarkers;
LGG	cis	rs2070997	0.586	rs7851994	chr9:133749848	C/T	cg01000188	chr9:133769184	QRFP	0.3	7.0	0.31	8.95e-12	Response to amphetamines;
LGG	cis	rs7769051	1.000	rs7761365	chr6:133101561	T/A	cg07930552	chr6:133119739	C6orf192	0.85	11.23	0.46	4.61e-26	Type 2 diabetes nephropathy;
LGG	cis	rs2544527	0.557	rs2112101	chr2:15902679	C/T	cg26669897	chr2:15909070	NA	-0.38	-9.5	-0.4	1.15e-19	Pulmonary function (smoking interaction);Pulmonary function;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19016253	chr10:101945959	ERLIN1	0.45	6.92	0.31	1.56e-11	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg20295408	chr7:1910781	MAD1L1	0.39	6.68	0.3	6.92e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg27400746	chr16:89904261	SPIRE2	-1.12	-16.9	-0.62	2.99e-50	Skin colour saturation;
LGG	cis	rs6089584	0.566	rs3787422	chr20:60555346	G/A	cg06470251	chr20:60548479	NA	0.47	8.29	0.36	1.21e-15	Body mass index;
LGG	cis	rs7219021	0.705	rs12939844	chr17:47025559	T/A	cg09029085	chr17:47094198	IGF2BP1	0.27	6.88	0.3	1.97e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs7619833	0.566	rs9848482	chr3:27224050	G/A	cg02860705	chr3:27208620	NA	0.41	7.92	0.35	1.72e-14	Breast cancer;
LGG	cis	rs6815814	0.950	rs5743593	chr4:38802913	A/G	cg06935464	chr4:38784597	TLR10	0.61	8.46	0.37	3.5e-16	Breast cancer;
LGG	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg24611264	chr11:120008944	TRIM29	0.37	9.27	0.4	7.28e-19	Stroke (pediatric);
LGG	cis	rs9902453	0.817	rs2617880	chr17:28106118	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.88	-0.54	6.98e-37	Coffee consumption (cups per day);
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.37	-0.43	8.66e-23	Platelet count;
LGG	cis	rs8072100	0.676	rs7221345	chr17:45405144	G/A	cg08085267	chr17:45401833	C17orf57	-0.73	-14.62	-0.56	4.66e-40	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs5756813	0.530	rs5756822	chr22:38196474	C/T	cg19894588	chr14:64061835	NA	0.78	15.09	0.57	3.83e-42	Optic cup area;Vertical cup-disc ratio;
LGG	trans	rs61931739	0.534	rs1387789	chr12:34056304	C/A	cg26384229	chr12:38710491	ALG10B	0.73	14.72	0.56	1.58e-40	Morning vs. evening chronotype;
LGG	cis	rs11711311	1.000	rs7633832	chr3:113472292	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.59	-0.33	1.75e-13	IgG glycosylation;
LGG	cis	rs155076	0.625	rs4769159	chr13:21881978	A/C	cg06138931	chr13:21896616	NA	0.51	8.49	0.37	2.91e-16	White matter hyperintensity burden;
LGG	cis	rs62400317	0.762	rs6908606	chr6:44998888	A/G	cg18551225	chr6:44695536	NA	-0.67	-11.01	-0.46	3.35e-25	Total body bone mineral density;
LGG	trans	rs656319	0.559	rs17689289	chr8:9977980	C/G	cg08975724	chr8:8085496	FLJ10661	0.37	6.87	0.3	2.04e-11	Myopia (pathological);
LGG	cis	rs4664308	0.618	rs66667042	chr2:160886703	A/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.71	-0.48	6.67e-28	Idiopathic membranous nephropathy;
LGG	cis	rs1707322	1.000	rs11211236	chr1:46443767	C/A	cg03146154	chr1:46216737	IPP	0.52	9.87	0.42	5.65e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg27411982	chr8:10470053	RP1L1	-0.43	-7.64	-0.33	1.3e-13	Neuroticism;
LGG	cis	rs4704846	0.797	rs6898322	chr5:156506352	C/T	cg12943317	chr5:156479607	HAVCR1	-0.6	-7.53	-0.33	2.6e-13	Blood protein levels;
LGG	cis	rs2131877	0.599	rs61218008	chr3:194881130	A/G	cg07250128	chr3:194833983	C3orf21	0.33	6.99	0.31	9.4e-12	Non-small cell lung cancer;
LGG	cis	rs9355814	0.539	rs6926896	chr6:161028908	C/G	cg04181478	chr6:161122748	PLG	0.43	7.11	0.31	4.54e-12	Lipoprotein (a) levels;
LGG	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg22875332	chr1:76189707	ACADM	0.56	8.85	0.38	1.86e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7824557	0.628	rs7841394	chr8:11185671	G/T	cg21775007	chr8:11205619	TDH	0.8	14.28	0.55	1.3e-38	Retinal vascular caliber;
LGG	cis	rs2073300	0.609	rs6137948	chr20:23416845	G/A	cg12062639	chr20:23401060	NAPB	0.92	8.7	0.37	5.96e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6703335	0.632	rs10927025	chr1:243639218	A/G	cg25706552	chr1:244017396	NA	0.35	7.45	0.33	4.68e-13	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;
LGG	cis	rs2739330	0.731	rs5751792	chr22:24401542	G/A	cg25703541	chr22:24373054	LOC391322	-1.06	-23.61	-0.74	1.71e-81	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4919087	0.781	rs7901853	chr10:99082360	T/C	cg25902810	chr10:99078978	FRAT1	0.5	9.04	0.39	4.13e-18	Monocyte count;
LGG	cis	rs3862030	0.720	rs2025713	chr10:104230156	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.51	-9.62	-0.41	4.13e-20	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;
LGG	cis	rs10504229	0.683	rs73603877	chr8:58108428	C/T	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.07e-11	Blood metabolite levels;
LGG	cis	rs6500602	0.727	rs4786509	chr16:4568769	C/G	cg06916706	chr16:4465613	CORO7	0.72	12.38	0.5	1.38e-30	Schizophrenia;
LGG	trans	rs800082	0.507	rs1121562	chr3:144259665	A/G	cg24215973	chr2:240111563	HDAC4	0.37	6.82	0.3	2.78e-11	Smoking behavior;
LGG	cis	rs8016947	0.583	rs12879818	chr14:35830938	G/A	cg03549618	chr14:35838977	NA	0.37	7.6	0.33	1.66e-13	Psoriasis;
LGG	cis	rs7173389	1.000	rs11630367	chr15:73662855	A/G	cg01796676	chr15:73680284	NA	0.5	8.47	0.37	3.25e-16	Resting heart rate;
LGG	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg26528311	chr1:38462546	FHL3	0.32	8.04	0.35	7.32e-15	Coronary artery disease;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg13047869	chr3:10149882	C3orf24	0.6	8.46	0.37	3.42e-16	Alzheimer's disease;
LGG	cis	rs2594989	0.778	rs6764721	chr3:11470639	A/T	cg01796438	chr3:11312864	ATG7	-0.51	-7.07	-0.31	5.83e-12	Circulating chemerin levels;
LGG	cis	rs12579753	0.917	rs7306043	chr12:82191282	G/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.96	-0.45	5.06e-25	Resting heart rate;
LGG	cis	rs975210	0.530	rs8037205	chr15:70367762	G/A	cg01666796	chr15:70364327	TLE3	-0.49	-7.63	-0.33	1.39e-13	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs950776	0.593	rs555018	chr15:78879242	G/A	cg22563815	chr15:78856949	CHRNA5	-0.27	-6.77	-0.3	3.93e-11	Sudden cardiac arrest;
LGG	cis	rs12497850	0.931	rs28642807	chr3:48926816	A/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.64e-25	Parkinson's disease;
LGG	cis	rs35306767	0.761	rs12773961	chr10:1013215	C/G	cg26597838	chr10:835615	NA	0.54	7.07	0.31	5.77e-12	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg09699651	chr6:150184138	LRP11	0.5	8.67	0.37	7.07e-17	Lung cancer;
LGG	cis	rs60180747	0.575	rs17198181	chr15:66577043	T/C	cg07575407	chr15:66541975	MEGF11	0.62	13.16	0.52	8.15e-34	Testicular germ cell tumor;
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs875971	0.543	rs801191	chr7:66032955	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.9	-0.45	8.71e-25	Aortic root size;
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-7.09	-0.31	5e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4481887	0.893	rs7528645	chr1:248427291	T/A	cg13385794	chr1:248469461	NA	0.48	8.11	0.35	4.61e-15	Common traits (Other);
LGG	cis	rs9291683	0.546	rs7442336	chr4:10045783	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs61931739	0.929	rs10844730	chr12:34026721	C/G	cg06521331	chr12:34319734	NA	0.39	6.85	0.3	2.33e-11	Morning vs. evening chronotype;
LGG	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.59	-11.16	-0.46	8.56e-26	Height;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg08621203	chr6:150244597	RAET1G	0.45	7.69	0.34	8.96e-14	Lung cancer;
LGG	cis	rs9325144	0.534	rs4882350	chr12:38686979	A/G	cg13010199	chr12:38710504	ALG10B	0.6	12.03	0.49	3.54e-29	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.747	rs2879488	chr1:152975241	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.18	-0.39	1.4e-18	Inflammatory skin disease;
LGG	cis	rs3020736	0.519	rs5996116	chr22:42517492	G/A	cg04733989	chr22:42467013	NAGA	-0.57	-10.25	-0.43	2.38e-22	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1459104	0.866	rs12787024	chr11:54883667	C/T	cg15704280	chr7:45808275	SEPT13	0.79	7.71	0.34	7.7e-14	Body mass index;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg11878867	chr6:150167359	LRP11	-0.56	-11.63	-0.48	1.3e-27	Lung cancer;
LGG	trans	rs916888	0.821	rs199505	chr17:44859410	A/G	cg01341218	chr17:43662625	NA	-0.87	-14.93	-0.57	2.01e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs2898290	0.622	rs1382567	chr8:11350899	T/C	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.62	-0.41	4.21e-20	Systolic blood pressure;
LGG	trans	rs7937682	0.961	rs11828343	chr11:111491322	A/G	cg18187862	chr3:45730750	SACM1L	-0.61	-9.97	-0.42	2.35e-21	Primary sclerosing cholangitis;
LGG	cis	rs763014	0.932	rs2384975	chr16:651115	G/T	cg08989290	chr16:615782	NHLRC4	0.32	6.66	0.3	7.72e-11	Height;
LGG	cis	rs367943	0.698	rs10046061	chr5:112976533	A/G	cg12552261	chr5:112820674	MCC	0.53	9.35	0.4	3.75e-19	Type 2 diabetes;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs2066819	1.000	rs59295315	chr12:56708576	G/A	cg26714650	chr12:56694279	CS	-1.58	-16.18	-0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs67133203	0.768	rs6580793	chr12:51531111	T/A	cg14688905	chr12:51403056	SLC11A2	0.72	10.85	0.45	1.38e-24	Urinary tract infection frequency;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg11168104	chr5:1857477	NA	-0.4	-6.96	-0.31	1.2e-11	Cardiovascular disease risk factors;
LGG	cis	rs17711722	0.701	rs4467826	chr7:65368708	A/G	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.18e-33	Calcium levels;
LGG	cis	rs67311347	1.000	rs4128740	chr3:40519532	C/A	cg13683864	chr3:40499215	RPL14	-1.13	-25.99	-0.77	1.66e-92	Renal cell carcinoma;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs2084898	0.506	rs488672	chr11:120047745	A/G	cg13907859	chr11:120009124	TRIM29	0.46	8.55	0.37	1.82e-16	Stroke (pediatric);
LGG	cis	rs6502050	0.805	rs7225560	chr17:80160884	C/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.67	-0.41	2.77e-20	Life satisfaction;
LGG	cis	rs28386778	0.897	rs2727326	chr17:61923016	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.17	0.49	9.4e-30	Prudent dietary pattern;
LGG	cis	rs2251260	0.685	rs1088673	chr14:62005648	A/G	cg23386212	chr14:62041363	NA	-0.54	-7.64	-0.33	1.29e-13	Yeast infection;
LGG	cis	rs6088580	0.602	rs6058064	chr20:33086622	A/G	cg24642439	chr20:33292090	TP53INP2	0.55	9.22	0.39	1.02e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs12893668	0.697	rs67899457	chr14:104060066	A/T	cg23335576	chr14:104009727	NA	0.49	8.56	0.37	1.72e-16	Reticulocyte count;
LGG	cis	rs754466	0.651	rs55738779	chr10:79652395	C/T	cg17075019	chr10:79541650	NA	-0.94	-18.65	-0.66	2.52e-58	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10766496	1.000	rs4261259	chr11:18737952	A/C	cg02515468	chr11:18743222	IGSF22	0.47	7.93	0.35	1.6e-14	Diabetic kidney disease;
LGG	cis	rs7267979	0.932	rs6138588	chr20:25487523	C/T	cg06421707	chr20:25228305	PYGB	0.47	9.96	0.42	2.58e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10752881	1.000	rs10737236	chr1:182988608	C/T	cg07928641	chr1:182991847	LAMC1	-0.48	-9.98	-0.42	2.16e-21	Colorectal cancer;
LGG	cis	rs3764563	1.000	rs4239617	chr19:15741537	C/T	cg20725493	chr19:15740067	CYP4F8	-0.65	-8.36	-0.36	7.5e-16	Inflammatory biomarkers;
LGG	cis	rs2274273	0.588	rs17128145	chr14:55536406	G/T	cg04306507	chr14:55594613	LGALS3	-0.38	-8.7	-0.37	5.93e-17	Protein biomarker;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg08888203	chr3:10149979	C3orf24	0.55	9.26	0.4	7.42e-19	Alzheimer's disease;
LGG	trans	rs3808502	0.534	rs1529858	chr8:11145662	G/T	cg16141378	chr3:129829833	LOC729375	-0.32	-6.85	-0.3	2.39e-11	Neuroticism;
LGG	cis	rs4917300	0.606	rs4917277	chr8:143095525	C/G	cg06573787	chr8:143070187	NA	-0.6	-10.08	-0.42	9.73e-22	Amyotrophic lateral sclerosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg06789412	chr3:101405552	RPL24	0.44	7.09	0.31	4.9e-12	Cognitive performance;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg05313129	chr8:58192883	C8orf71	-0.61	-8.55	-0.37	1.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg15017067	chr4:17643749	FAM184B	0.3	6.93	0.31	1.42e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500602	0.527	rs13338333	chr16:4443250	T/C	cg26783146	chr16:4423632	VASN;CORO7	-0.43	-7.84	-0.34	3.11e-14	Schizophrenia;
LGG	cis	rs12701220	0.947	rs1007765	chr7:1032805	G/C	cg00990874	chr7:1149470	C7orf50	-0.7	-10.56	-0.44	1.69e-23	Bronchopulmonary dysplasia;
LGG	cis	rs8058578	0.887	rs28421305	chr16:30838128	G/A	cg05768032	chr16:30646687	NA	0.39	6.65	0.3	8.3e-11	Multiple myeloma;
LGG	cis	rs10949834	0.517	rs810536	chr7:73504233	G/A	cg07137043	chr7:73588983	EIF4H	0.46	7.37	0.32	8.05e-13	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs6429082	0.683	rs868815	chr1:235584543	C/G	cg26050004	chr1:235667680	B3GALNT2	-0.55	-8.98	-0.39	6.93e-18	Adiposity;
LGG	cis	rs2071403	0.933	rs12329058	chr2:1400608	C/G	cg06500727	chr2:1417164	TPO	0.5	9.58	0.41	5.82e-20	Thyroid peroxidase antibody positivity;
LGG	cis	rs6951245	0.786	rs77943789	chr7:1140158	C/T	cg22907277	chr7:1156413	C7orf50	0.79	11.1	0.46	1.59e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs769267	0.965	rs2965198	chr19:19473030	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.43	-0.33	5.45e-13	Tonsillectomy;
LGG	cis	rs17345786	1.000	rs3804775	chr3:101306507	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.65	-11.13	-0.46	1.12e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9868809	0.772	rs9841602	chr3:48713570	A/G	cg00383909	chr3:49044727	WDR6	0.8	10.02	0.42	1.61e-21	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.96	-0.31	1.19e-11	Joint mobility (Beighton score);
LGG	cis	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg09021430	chr5:549028	NA	-0.72	-10.12	-0.43	7.18e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs9457247	0.967	rs387733	chr6:167409771	C/T	cg07741184	chr6:167504864	NA	-0.34	-7.38	-0.32	7.42e-13	Crohn's disease;
LGG	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg00543991	chr22:32367038	NA	0.79	8.54	0.37	1.97e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs17270561	0.525	rs12201678	chr6:25978993	C/T	cg16482183	chr6:26056742	HIST1H1C	0.97	14.37	0.56	5.77e-39	Iron status biomarkers;
LGG	cis	rs9611565	0.694	rs19573	chr22:41865809	C/A	cg06481639	chr22:41940642	POLR3H	0.57	8.59	0.37	1.37e-16	Vitiligo;
LGG	cis	rs59197085	0.748	rs62479619	chr7:128463864	G/A	cg00734629	chr7:128471146	FLNC	0.36	7.22	0.32	2.17e-12	Reading disability or specific language impairment (pleiotropy);Reading disability or specific language impairment adjusted for intelligence quotient (pleiotropy);
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg14074117	chr16:1909714	C16orf73	-0.54	-7.86	-0.34	2.76e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6582630	0.519	rs12578283	chr12:38325349	A/T	cg13010199	chr12:38710504	ALG10B	0.7	14.14	0.55	5.49e-38	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9894429	0.546	rs9906979	chr17:79608765	A/G	cg18240062	chr17:79603768	NPLOC4	0.67	11.62	0.48	1.42e-27	Eye color traits;
LGG	cis	rs7914558	1.000	rs1890184	chr10:104748459	A/C	cg04362960	chr10:104952993	NT5C2	0.54	10.47	0.44	3.73e-23	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs35160687	0.644	rs4832265	chr2:86488265	A/G	cg10973622	chr2:86423274	IMMT	-0.41	-7.23	-0.32	2.04e-12	Night sleep phenotypes;
LGG	trans	rs11992162	0.560	rs7846248	chr8:11794049	T/A	cg16141378	chr3:129829833	LOC729375	-0.34	-7.49	-0.33	3.41e-13	Monocyte count;
LGG	cis	rs2180341	0.618	rs11154398	chr6:127654281	C/A	cg27446573	chr6:127587934	RNF146	0.73	13.28	0.53	2.62e-34	Breast cancer;
LGG	cis	rs12291225	0.679	rs4756786	chr11:14285900	C/A	cg22961513	chr11:14280813	SPON1	-0.29	-6.75	-0.3	4.38e-11	Sense of smell;
LGG	cis	rs1318772	1.000	rs13189851	chr5:112592294	A/G	cg12552261	chr5:112820674	MCC	0.7	8.15	0.35	3.37e-15	F-cell distribution;
LGG	cis	rs9463078	0.683	rs227841	chr6:44690309	A/T	cg25276700	chr6:44698697	NA	0.43	8.94	0.38	9.24e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2274273	1.000	rs10149435	chr14:55627489	C/T	cg04306507	chr14:55594613	LGALS3	0.61	16.94	0.62	2.02e-50	Protein biomarker;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.9	0.59	9.48e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg18187862	chr3:45730750	SACM1L	0.56	9.22	0.39	1.02e-18	Primary sclerosing cholangitis;
LGG	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.58	-0.33	1.94e-13	Initial pursuit acceleration;
LGG	cis	rs240764	0.853	rs12190903	chr6:100983505	C/T	cg21058520	chr6:100914733	NA	0.42	7.45	0.33	4.54e-13	Neuroticism;
LGG	cis	rs1552244	1.000	rs68045038	chr3:10151828	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.72	0.3	5.5e-11	Alzheimer's disease;
LGG	cis	rs3617	0.573	rs9825230	chr3:52901974	G/A	cg11645453	chr3:52864694	ITIH4	0.46	7.76	0.34	5.57e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs735539	0.521	rs9552289	chr13:21427839	C/T	cg04906043	chr13:21280425	IL17D	-0.5	-7.85	-0.34	3e-14	Dental caries;
LGG	cis	rs858239	0.600	rs6978827	chr7:23125544	A/T	cg23682824	chr7:23144976	KLHL7	0.45	7.81	0.34	3.96e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs12048904	0.930	rs11166529	chr1:101333733	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	9.78	0.41	1.15e-20	Multiple sclerosis;
LGG	cis	rs4919694	1.000	rs78893207	chr10:104796138	T/C	cg04362960	chr10:104952993	NT5C2	1.07	15.08	0.57	4.53e-42	Arsenic metabolism;
LGG	cis	rs7937890	0.559	rs2575829	chr11:14485021	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.92	-0.35	1.72e-14	Mitochondrial DNA levels;
LGG	cis	rs9611565	0.681	rs5751094	chr22:41803279	C/T	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs9810089	0.835	rs655836	chr3:136097576	T/C	cg21827317	chr3:136751795	NA	0.43	7.51	0.33	3.01e-13	Gestational age at birth (child effect);
LGG	cis	rs172166	0.694	rs1770131	chr6:28086413	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.49	-7.12	-0.31	4.2e-12	Cardiac Troponin-T levels;
LGG	trans	rs7762018	0.882	rs4716342	chr6:170137959	A/G	cg11441553	chr12:57614120	NXPH4	-0.57	-7.18	-0.32	2.72e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12477438	0.501	rs6753063	chr2:99801469	A/G	cg08885076	chr2:99613938	TSGA10	0.42	9.01	0.39	5.24e-18	Chronic sinus infection;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.58	11.48	0.47	4.91e-27	Obesity-related traits;
LGG	cis	rs7133214	0.656	rs11049133	chr12:27923396	T/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.99	-0.31	9.53e-12	Gut microbiota (functional units);
LGG	cis	rs11711311	0.747	rs7638449	chr3:113343646	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.32	-0.32	1.08e-12	IgG glycosylation;
LGG	cis	rs9290877	0.667	rs9833465	chr3:188454859	C/A	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	cis	rs876084	0.505	rs11985197	chr8:121107553	G/A	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs921968	0.541	rs1863704	chr2:219562675	C/T	cg01130898	chr2:219473002	PLCD4	0.5	8.55	0.37	1.85e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4819052	0.788	rs4819051	chr21:46693128	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.57	9.35	0.4	3.63e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs3858526	0.834	rs10769395	chr11:5979620	G/A	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.69e-22	DNA methylation (variation);
LGG	cis	rs3857536	0.813	rs6903678	chr6:66931208	C/T	cg07460842	chr6:66804631	NA	0.44	7.53	0.33	2.74e-13	Blood trace element (Cu levels);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27010576	chr16:21964792	UQCRC2	0.48	7.11	0.31	4.55e-12	Gut microbiome composition (summer);
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.92	-0.31	1.55e-11	Menopause (age at onset);
LGG	cis	rs4774899	0.934	rs11636348	chr15:57470630	G/T	cg08128148	chr15:57256372	TCF12	-0.3	-7.05	-0.31	6.37e-12	Urinary tract infection frequency;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15642758	chr15:83876612	HDGFRP3	0.45	7.57	0.33	2.09e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs2235642	0.893	rs2076440	chr16:1587322	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.43	10.48	0.44	3.23e-23	Coronary artery disease;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg14196790	chr5:131705035	SLC22A5	0.6	7.51	0.33	3.16e-13	Rheumatoid arthritis;
LGG	cis	rs826838	0.967	rs1719856	chr12:39127201	C/T	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs5769765	0.862	rs138870	chr22:50209737	C/T	cg26441486	chr22:50317300	CRELD2	0.4	7.46	0.33	4.21e-13	Schizophrenia;
LGG	cis	rs4604732	0.578	rs112449432	chr1:247624180	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.61	9.26	0.4	7.72e-19	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs3735485	0.760	rs4720491	chr7:45057251	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg02461776	chr11:598696	PHRF1	0.42	6.96	0.31	1.16e-11	Systemic lupus erythematosus;
LGG	cis	rs3768617	0.727	rs12066735	chr1:183101451	T/G	ch.1.3577855R	chr1:183094577	LAMC1	0.36	6.87	0.3	2.04e-11	Fuchs's corneal dystrophy;
LGG	cis	rs6582630	0.598	rs10880614	chr12:38509766	G/A	cg13010199	chr12:38710504	ALG10B	-0.54	-10.82	-0.45	1.76e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4302748	0.862	rs79729347	chr7:36184584	G/A	cg24442661	chr7:36192818	EEPD1	0.55	7.16	0.32	3.17e-12	Platelet count;
LGG	cis	rs826838	0.933	rs1906263	chr12:38653362	T/C	cg26384229	chr12:38710491	ALG10B	1.05	27.88	0.79	3.87e-101	Heart rate;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1909881	1.000	rs10100528	chr8:96518914	G/C	cg04203453	chr8:96504381	NA	-1.09	-18.54	-0.65	8.79e-58	Obesity-related traits;
LGG	cis	rs3785574	0.962	rs2584633	chr17:61879501	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.58	9.23	0.39	9.37e-19	Height;
LGG	cis	rs7223966	1.000	rs61360320	chr17:61800392	C/T	cg11494091	chr17:61959527	GH2	0.5	8.11	0.35	4.55e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17711722	0.503	rs453835	chr7:65511159	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.67	-15.72	-0.59	6.55e-45	Calcium levels;
LGG	cis	rs1865760	0.613	rs2071300	chr6:25914572	C/T	cg12310025	chr6:25882481	NA	-0.51	-9.78	-0.41	1.17e-20	Height;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.27	-0.32	1.57e-12	Lung cancer;
LGG	cis	rs9325144	0.577	rs12314639	chr12:39119869	T/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.63	-0.33	1.35e-13	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.517	rs75486476	chr8:58056079	G/T	cg20607798	chr8:58055168	NA	0.71	11.24	0.46	4.26e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2576037	0.562	rs612519	chr18:44379490	G/A	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.33	-0.32	1e-12	Personality dimensions;
LGG	cis	rs9583531	0.527	rs12875067	chr13:111365104	A/G	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	cis	rs1865760	1.000	rs6910138	chr6:25904352	C/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.26	0.32	1.63e-12	Height;
LGG	cis	rs2282802	0.685	rs4913079	chr5:139683029	A/G	cg26211634	chr5:139558579	C5orf32	0.34	7.53	0.33	2.65e-13	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.750	rs36077949	chr17:19985782	C/T	cg13482628	chr17:19912719	NA	0.63	12.46	0.5	6.09e-31	Schizophrenia;
LGG	trans	rs116095464	0.558	rs9312977	chr5:221916	G/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.22	-0.36	2.04e-15	Breast cancer;
LGG	cis	rs826838	1.000	rs11183747	chr12:38822595	A/G	cg13010199	chr12:38710504	ALG10B	-0.76	-16.28	-0.6	1.89e-47	Heart rate;
LGG	cis	rs1008375	0.966	rs6813375	chr4:17649499	T/G	cg02297831	chr4:17616191	MED28	0.5	9.53	0.4	9.06e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20205877	chr17:47841033	FAM117A	0.49	7.97	0.35	1.25e-14	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs7007805	chr8:58179327	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg02002194	chr4:3960332	NA	-0.5	-9.45	-0.4	1.67e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9790314	0.687	rs62280331	chr3:160682092	C/A	cg04691961	chr3:161091175	C3orf57	0.43	9.0	0.39	5.83e-18	Morning vs. evening chronotype;
LGG	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.72	-0.48	5.81e-28	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs9906247	chr17:61857314	T/C	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs703842	0.964	rs10431552	chr12:58178148	G/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.97	0.35	1.23e-14	Multiple sclerosis;
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg16270222	chr17:41446396	NA	-0.29	-6.93	-0.31	1.42e-11	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26649251	chr19:44598564	ZNF224	0.48	7.7	0.34	8.15e-14	Cognitive performance;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.21	-0.43	3.17e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg08677398	chr8:58056175	NA	0.5	7.91	0.34	1.97e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg00784671	chr22:46762841	CELSR1	-0.61	-7.09	-0.31	5.07e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7923609	0.935	rs10995477	chr10:65010672	T/C	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.8	-0.3	3.32e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg15971980	chr6:150254442	NA	0.43	8.12	0.35	4.2e-15	Lung cancer;
LGG	cis	rs6500602	0.609	rs7202910	chr16:4518948	T/A	cg19168338	chr16:4465731	CORO7	-0.91	-17.49	-0.63	6.01e-53	Schizophrenia;
LGG	cis	rs9771228	0.560	rs9639646	chr7:32280243	A/G	cg27532318	chr7:32358331	NA	0.53	7.67	0.34	1.02e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs4950928	0.712	rs7518666	chr1:203163590	C/T	cg17014757	chr1:203156097	CHI3L1	-0.38	-7.94	-0.35	1.55e-14	YKL-40 levels;
LGG	cis	rs6089584	1.000	rs6089580	chr20:60558976	G/A	cg06470251	chr20:60548479	NA	0.53	9.26	0.4	7.88e-19	Body mass index;
LGG	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg25554036	chr4:6271136	WFS1	0.62	11.48	0.47	5.23e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg05556477	chr5:131705319	SLC22A5	0.85	9.92	0.42	3.78e-21	Rheumatoid arthritis;
LGG	cis	rs2456568	0.548	rs6483281	chr11:93661840	G/C	cg26875233	chr11:93583750	C11orf90	-0.44	-8.61	-0.37	1.15e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs10895140	0.626	rs1938846	chr11:101521916	C/G	cg23650423	chr11:101454676	TRPC6	-0.4	-6.79	-0.3	3.53e-11	Menarche (age at onset);
LGG	cis	rs11644362	1.000	rs4781349	chr16:12987249	T/C	cg08528231	chr16:12997261	SHISA9	-0.33	-6.73	-0.3	5.08e-11	Positive affect;Subjective well-being;
LGG	cis	rs9486719	1.000	rs4839837	chr6:96908706	G/A	cg18709589	chr6:96969512	KIAA0776	0.45	7.2	0.32	2.39e-12	Migraine;Coronary artery disease;
LGG	cis	rs7107174	0.892	rs4944196	chr11:78008731	G/A	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs4684776	1.000	rs2454511	chr3:11489133	A/G	cg24705426	chr3:11550659	ATG7	0.44	7.84	0.34	3.09e-14	Small vessel stroke;
LGG	cis	rs6466055	0.720	rs6466057	chr7:104952483	A/G	cg04380332	chr7:105027541	SRPK2	0.38	7.16	0.32	3.11e-12	Schizophrenia;
LGG	cis	rs2688419	0.527	rs2171030	chr3:23083720	A/G	cg00327796	chr3:23032191	NA	-0.37	-6.95	-0.31	1.24e-11	Type 2 diabetes;
LGG	cis	rs950169	1.000	rs12916348	chr15:84765527	C/T	cg24253500	chr15:84953950	NA	0.6	10.91	0.45	8.06e-25	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07781040	chr3:8664898	C3orf32	0.44	6.79	0.3	3.51e-11	Gut microbiome composition (summer);
LGG	cis	rs887829	0.570	rs13002774	chr2:234593706	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.08	-0.35	5.58e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs2274273	0.840	rs1045002	chr14:55818517	T/A	cg04306507	chr14:55594613	LGALS3	0.61	16.8	0.62	8.48e-50	Protein biomarker;
LGG	cis	rs9300255	0.602	rs1727306	chr12:123665695	A/G	cg00376283	chr12:123451042	ABCB9	0.64	9.93	0.42	3.35e-21	Neutrophil percentage of white cells;
LGG	cis	rs9486719	0.895	rs3734238	chr6:96996228	A/T	cg18709589	chr6:96969512	KIAA0776	-0.47	-7.15	-0.32	3.41e-12	Migraine;Coronary artery disease;
LGG	cis	rs2839186	0.749	rs62226488	chr21:47710517	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.87	-0.34	2.6e-14	Testicular germ cell tumor;
LGG	cis	rs765787	0.505	rs4439707	chr15:45524216	G/A	cg25801113	chr15:45476975	SHF	-0.88	-18.75	-0.66	9e-59	Uric acid levels;
LGG	cis	rs151234	0.741	rs11074908	chr16:28608356	C/T	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.56	-0.41	6.78e-20	Platelet distribution width;
LGG	cis	rs4481887	1.000	rs4244176	chr1:248468231	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg11764359	chr7:65958608	NA	0.69	12.36	0.5	1.52e-30	Aortic root size;
LGG	cis	rs10435719	0.834	rs11250176	chr8:11792816	A/G	cg12395012	chr8:11607386	GATA4	-0.42	-7.64	-0.33	1.28e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs3857067	0.901	rs965807	chr4:95045567	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.92	-0.35	1.78e-14	QT interval;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.63	-0.48	1.35e-27	Personality dimensions;
LGG	cis	rs17169635	0.879	rs3800737	chr7:134537875	A/G	cg02516134	chr7:134575187	CALD1	0.37	8.14	0.35	3.8e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs10751667	0.666	rs10902249	chr11:958566	C/T	cg22143635	chr11:980567	AP2A2	-0.44	-8.28	-0.36	1.35e-15	Alzheimer's disease (late onset);
LGG	trans	rs208515	0.525	rs12214310	chr6:66666308	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	16.99	0.62	1.16e-50	Exhaled nitric oxide levels;
LGG	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg20573242	chr4:122745356	CCNA2	0.53	9.84	0.42	7.11e-21	Type 2 diabetes;
LGG	cis	rs9486719	0.656	rs4839826	chr6:96853616	A/G	cg06623918	chr6:96969491	KIAA0776	-0.68	-10.51	-0.44	2.68e-23	Migraine;Coronary artery disease;
LGG	cis	rs875971	1.000	rs7789768	chr7:65938980	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16092773	chr10:111767594	ADD3	0.45	7.28	0.32	1.42e-12	Gut microbiome composition (summer);
LGG	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg06027949	chr8:82754900	SNX16	0.54	8.34	0.36	8.36e-16	Diastolic blood pressure;
LGG	cis	rs17376456	0.825	rs10075217	chr5:93176774	C/G	cg25358565	chr5:93447407	FAM172A	1.21	15.23	0.58	9.57e-43	Diabetic retinopathy;
LGG	trans	rs61931739	0.500	rs6488221	chr12:34525671	A/G	cg13010199	chr12:38710504	ALG10B	0.62	12.45	0.5	6.6e-31	Morning vs. evening chronotype;
LGG	cis	rs4690686	0.500	rs35703625	chr4:177263286	G/A	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	trans	rs637571	0.522	rs566590	chr11:65754062	C/T	cg17712092	chr4:129076599	LARP1B	0.74	14.15	0.55	4.83e-38	Eosinophil percentage of white cells;
LGG	cis	rs60871478	1.000	rs62432899	chr7:826542	G/C	cg22643751	chr7:855365	UNC84A	0.39	6.66	0.3	7.98e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg11764359	chr7:65958608	NA	-0.73	-13.05	-0.52	2.3e-33	Aortic root size;
LGG	cis	rs7666738	0.716	rs6814353	chr4:99074202	A/G	cg05340658	chr4:99064831	C4orf37	0.45	7.16	0.32	3.15e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088580	0.634	rs6141465	chr20:32967314	T/C	cg06115741	chr20:33292138	TP53INP2	-0.49	-8.17	-0.36	2.94e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs7084402	0.967	rs1620186	chr10:60314275	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.21	-0.32	2.25e-12	Refractive error;
LGG	cis	rs835154	1.000	rs835154	chr5:14876569	A/G	cg27316798	chr5:14870666	ANKH	0.46	9.38	0.4	2.95e-19	Blood metabolite levels;
LGG	cis	rs2201728	0.677	rs1497379	chr4:100176070	T/C	cg07219303	chr4:100140905	ADH6	-0.37	-6.94	-0.31	1.32e-11	Cardiac Troponin-T levels;
LGG	cis	rs10883723	0.773	rs2296578	chr10:104240974	C/G	cg05096777	chr10:104283225	SUFU	0.32	7.01	0.31	8.26e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9783347	0.600	rs10766467	chr11:18310449	T/C	cg15585147	chr11:18324498	HPS5	0.32	7.2	0.32	2.46e-12	Pancreatic cancer;
LGG	cis	rs2832191	0.791	rs7282843	chr21:30475226	A/G	cg24692254	chr21:30365293	RNF160	0.97	24.98	0.76	7.68e-88	Dental caries;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg26338869	chr17:61819248	STRADA	0.58	9.7	0.41	2.25e-20	Prudent dietary pattern;
LGG	cis	rs6840360	0.571	rs12648420	chr4:152543434	G/C	cg22705602	chr4:152727874	NA	-0.32	-7.78	-0.34	4.85e-14	Intelligence (multi-trait analysis);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21567625	chr5:159436125	TTC1	-0.45	-6.76	-0.3	4.15e-11	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08987413	chr6:166419791	NA	0.5	7.47	0.33	4.13e-13	Gut microbiome composition (summer);
LGG	trans	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg06521331	chr12:34319734	NA	0.43	7.74	0.34	6.5e-14	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11992162	0.597	rs7016320	chr8:11781052	G/C	cg16141378	chr3:129829833	LOC729375	0.31	6.75	0.3	4.4e-11	Monocyte count;
LGG	cis	rs28595532	0.841	rs115852209	chr4:119753465	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg13012494	chr21:47604986	C21orf56	0.49	8.01	0.35	9.27e-15	Testicular germ cell tumor;
LGG	cis	rs7824557	0.564	rs55758514	chr8:11230259	A/T	cg15596359	chr8:11213517	TDH	0.41	8.47	0.37	3.35e-16	Retinal vascular caliber;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.1	0.39	2.67e-18	Lung cancer;
LGG	cis	rs4776059	0.958	rs933860	chr15:52965468	T/C	cg22715398	chr15:52968154	KIAA1370	-0.55	-8.9	-0.38	1.22e-17	Schizophrenia;
LGG	cis	rs11992186	0.597	rs77717027	chr8:8591632	T/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.36	-0.32	8.46e-13	Neuroticism;
LGG	cis	rs7250872	0.606	rs2304616	chr19:1826164	G/T	cg18850929	chr19:1828978	REXO1	0.49	8.06	0.35	6.4e-15	Bipolar disorder;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13797019	chr14:105303134	NA	0.37	6.78	0.3	3.56e-11	Menarche (age at onset);
LGG	cis	rs9902453	0.726	rs3115088	chr17:28031275	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.59	0.56	6.28e-40	Coffee consumption (cups per day);
LGG	cis	rs6500395	0.926	rs1039344	chr16:48577569	A/G	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs36093844	0.752	rs56261432	chr11:85548381	C/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.2	-0.32	2.41e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg02564969	chr6:151773285	C6orf211;RMND1	0.46	8.02	0.35	8.86e-15	Menarche (age at onset);
LGG	cis	rs7666738	0.830	rs7662114	chr4:99019985	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12410462	0.591	rs16847966	chr1:227771014	A/G	cg04117972	chr1:227635322	NA	0.46	8.46	0.37	3.47e-16	Major depressive disorder;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg24503407	chr1:205819492	PM20D1	0.76	17.36	0.63	2.35e-52	Menarche (age at onset);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg11156230	chr4:83351251	HNRPDL;ENOPH1	0.63	7.05	0.31	6.7e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10193935	0.901	rs2286701	chr2:42555636	T/C	cg27598129	chr2:42591480	NA	-0.65	-9.71	-0.41	2e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7143963	0.636	rs1131877	chr14:103342049	T/C	cg23020514	chr14:103360112	TRAF3	0.4	8.33	0.36	9.12e-16	Body mass index;
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg26617929	chr16:1858877	NA	-0.62	-8.69	-0.37	6.34e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg22963979	chr7:1858916	MAD1L1	-0.51	-10.39	-0.43	7.21e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs7572733	0.935	rs12995110	chr2:198789013	T/C	cg00792783	chr2:198669748	PLCL1	-0.49	-8.28	-0.36	1.37e-15	Dermatomyositis;
LGG	cis	rs7493	1.000	rs2299264	chr7:95046708	C/T	cg08461772	chr7:95026248	PON3	0.38	8.33	0.36	9.36e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7614311	0.689	rs73120898	chr3:63828780	G/A	cg22134162	chr3:63841271	THOC7	-0.43	-7.34	-0.32	9.61e-13	Lung function (FVC);Lung function (FEV1);
LGG	trans	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg25482853	chr8:67687455	SGK3	1.02	13.2	0.52	5.57e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs8060686	0.641	rs113790673	chr16:68244347	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.67	-0.34	1e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg15948088	chr11:109293068	C11orf87	0.51	8.9	0.38	1.3e-17	Schizophrenia;
LGG	cis	rs7928758	0.887	rs111711955	chr11:134264529	A/G	cg15243474	chr11:134282918	B3GAT1	1.27	16.31	0.6	1.44e-47	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2228479	0.717	rs2074904	chr16:89811546	A/G	cg26513180	chr16:89883248	FANCA	1.01	9.6	0.41	4.86e-20	Skin colour saturation;
LGG	cis	rs9291683	0.935	rs1860910	chr4:10275470	T/G	cg00071950	chr4:10020882	SLC2A9	0.33	6.83	0.3	2.6e-11	Bone mineral density;
LGG	cis	rs7613875	0.600	rs2624832	chr3:50030858	C/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.85	-0.45	1.34e-24	Body mass index;
LGG	cis	rs2243480	1.000	rs316307	chr7:65570171	C/T	cg18252515	chr7:66147081	NA	-1.4	-20.05	-0.68	7.71e-65	Diabetic kidney disease;
LGG	cis	rs11969893	0.649	rs9485415	chr6:101279459	C/T	cg12253828	chr6:101329408	ASCC3	0.76	7.14	0.31	3.68e-12	Economic and political preferences (immigration/crime);
LGG	cis	rs7267979	0.744	rs6050464	chr20:25209299	C/A	cg08601574	chr20:25228251	PYGB	0.36	7.27	0.32	1.58e-12	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg15490075	chr13:100150979	NA	-0.69	-7.22	-0.32	2.17e-12	Obesity-related traits;
LGG	cis	rs2797160	1.000	rs2747717	chr6:126008435	A/G	cg05901451	chr6:126070800	HEY2	0.44	7.56	0.33	2.21e-13	Endometrial cancer;
LGG	cis	rs881375	0.967	rs2416806	chr9:123690292	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.83	0.48	2.17e-28	Rheumatoid arthritis;
LGG	cis	rs9815354	1.000	rs9863915	chr3:41762002	G/A	cg03022575	chr3:42003672	ULK4	0.59	7.59	0.33	1.76e-13	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7395662	0.709	rs11040113	chr11:48895653	G/A	cg15704280	chr7:45808275	SEPT13	-0.48	-7.91	-0.35	1.97e-14	HDL cholesterol;
LGG	cis	rs17376456	0.569	rs10067754	chr5:93093110	T/A	cg19507638	chr5:93509721	C5orf36	-0.43	-7.04	-0.31	7.02e-12	Diabetic retinopathy;
LGG	cis	rs13118159	0.836	rs12647145	chr4:1338618	C/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.53	10.25	0.43	2.28e-22	Longevity;
LGG	cis	rs3813567	0.759	rs12595350	chr15:78953464	G/A	cg05914723	chr15:78953907	NA	0.5	6.96	0.31	1.2e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs8025790	0.508	rs12905371	chr15:67845930	C/T	cg25173464	chr15:68126554	NA	-0.34	-7.15	-0.32	3.52e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg04267008	chr7:1944627	MAD1L1	-0.62	-10.68	-0.44	6.17e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7615952	0.641	rs7618515	chr3:125790578	C/T	cg18479299	chr3:125709523	NA	-0.58	-7.37	-0.32	7.86e-13	Blood pressure (smoking interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17286253	chr1:185703489	HMCN1	0.45	7.24	0.32	1.85e-12	Gut microbiome composition (summer);
LGG	cis	rs10214930	0.647	rs2098316	chr7:27568637	C/A	cg22168087	chr7:27702803	HIBADH	0.46	7.0	0.31	8.99e-12	Hypospadias;
LGG	cis	rs1153858	0.668	rs63603561	chr15:45593323	T/A	cg10760299	chr15:45669010	GATM	-0.4	-7.5	-0.33	3.3e-13	Homoarginine levels;
LGG	trans	rs61931739	0.620	rs745608	chr12:33711564	A/G	cg26384229	chr12:38710491	ALG10B	0.47	8.42	0.36	4.8e-16	Morning vs. evening chronotype;
LGG	cis	rs9549367	0.713	rs9549682	chr13:113830181	C/T	cg00898013	chr13:113819073	PROZ	-0.51	-10.02	-0.42	1.55e-21	Platelet distribution width;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02339682	chr6:56819432	DST;BEND6	0.57	6.86	0.3	2.26e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.533	rs13274028	chr8:8729193	A/C	cg08975724	chr8:8085496	FLJ10661	0.37	6.67	0.3	7.2e-11	Mood instability;
LGG	trans	rs9944715	0.834	rs9949494	chr18:43811300	T/C	cg01718231	chr17:29326311	RNF135	-0.41	-6.65	-0.3	8.44e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs7582720	1.000	rs72932572	chr2:203859391	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg08621203	chr6:150244597	RAET1G	0.45	7.82	0.34	3.72e-14	Lung cancer;
LGG	cis	rs10492096	0.947	rs11064231	chr12:6604415	T/G	cg13857086	chr12:6580257	VAMP1	0.51	7.33	0.32	1.05e-12	Hip geometry;
LGG	cis	rs2131877	0.871	rs62290354	chr3:194867296	A/G	cg07250128	chr3:194833983	C3orf21	0.41	6.7	0.3	6e-11	Non-small cell lung cancer;
LGG	trans	rs783540	0.656	rs783524	chr15:83284144	A/C	cg16105309	chr15:79090380	ADAMTS7	0.48	8.27	0.36	1.47e-15	Schizophrenia;
LGG	cis	rs988958	0.526	rs36036427	chr2:42252889	G/A	cg27252766	chr2:42229092	NA	0.49	7.14	0.31	3.75e-12	Hypospadias;
LGG	trans	rs6598955	0.671	rs55791848	chr1:26582711	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.88	-0.51	1.21e-32	Obesity-related traits;
LGG	cis	rs6831352	0.918	rs4699712	chr4:100060490	A/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs7172677	0.960	rs8026273	chr15:75413766	T/A	cg14664628	chr15:75095509	CSK	-0.47	-7.21	-0.32	2.28e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1800682	0.528	rs3903454	chr10:90743434	A/T	cg03111039	chr10:90751583	FAS;ACTA2	0.72	14.52	0.56	1.25e-39	Chronic lymphocytic leukemia;
LGG	cis	rs1185460	0.546	rs549893	chr11:118959732	A/G	cg23280166	chr11:118938394	VPS11	-0.42	-7.34	-0.32	9.55e-13	Coronary artery disease;
LGG	cis	rs4700695	0.841	rs251325	chr5:65269618	A/G	cg21114390	chr5:65439923	SFRS12	0.59	7.26	0.32	1.66e-12	Facial morphology (factor 19);
LGG	cis	rs7219021	0.961	rs7215901	chr17:46858083	A/C	cg16584676	chr17:46985605	UBE2Z	-0.43	-6.73	-0.3	4.99e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs10504229	0.954	rs903717	chr8:58167856	A/G	cg02725872	chr8:58115012	NA	-0.74	-11.56	-0.47	2.57e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs16866061	1.000	rs17480230	chr2:225399864	G/A	cg12698349	chr2:225449008	CUL3	0.93	19.26	0.67	3.86e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs10911251	0.546	rs10911267	chr1:183115323	C/T	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.09e-18	Colorectal cancer;
LGG	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg18240062	chr17:79603768	NPLOC4	0.81	15.51	0.58	5.32e-44	Eye color traits;
LGG	cis	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.86	-7.48	-0.33	3.75e-13	Facial emotion recognition (sad faces);
LGG	trans	rs7824557	0.767	rs6991606	chr8:11176159	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.13	0.43	6.29e-22	Retinal vascular caliber;
LGG	cis	rs875971	0.965	rs9969301	chr7:65781655	G/A	cg23594656	chr7:65796392	TPST1	0.39	8.56	0.37	1.64e-16	Aortic root size;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg20295408	chr7:1910781	MAD1L1	-0.46	-8.08	-0.35	5.84e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs17376456	0.877	rs67066109	chr5:93494101	G/C	cg25358565	chr5:93447407	FAM172A	1.35	16.72	0.61	1.96e-49	Diabetic retinopathy;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs4604732	0.578	rs12036417	chr1:247624805	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs10504229	0.906	rs73607869	chr8:58172665	G/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	0.927	rs4390209	chr1:248472613	A/T	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs9322193	0.923	rs62439842	chr6:149996983	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.76	0.54	2.4e-36	Lung cancer;
LGG	cis	rs2019137	0.560	rs10175462	chr2:113988492	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	16.16	0.6	6.62e-47	Lymphocyte counts;
LGG	cis	rs1978968	1.000	rs5992917	chr22:18443699	G/T	cg03078520	chr22:18463400	MICAL3	-0.62	-12.56	-0.5	2.43e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs9457247	1.000	rs239935	chr6:167411788	G/A	cg07741184	chr6:167504864	NA	0.34	7.33	0.32	1.01e-12	Crohn's disease;
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg21948465	chr5:131705150	SLC22A5	0.65	7.31	0.32	1.2e-12	Rheumatoid arthritis;
LGG	cis	rs977987	0.800	rs11149815	chr16:75336173	T/G	cg03315344	chr16:75512273	CHST6	0.48	9.32	0.4	4.79e-19	Dupuytren's disease;
LGG	cis	rs7223966	1.000	rs11871767	chr17:61698723	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.64	10.77	0.45	2.77e-24	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12493885	0.769	rs61791507	chr3:153748886	C/A	cg17054900	chr3:154042577	DHX36	-0.72	-8.92	-0.38	1.13e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs9858542	0.953	rs7633271	chr3:49555963	T/C	cg21659725	chr3:3221576	CRBN	-0.64	-10.5	-0.44	2.92e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9650657	0.836	rs891556	chr8:10623633	G/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.94	-0.35	1.57e-14	Neuroticism;
LGG	cis	rs7444	0.941	rs2266959	chr22:21922904	G/T	cg11654148	chr22:21984483	YDJC	-0.41	-7.8	-0.34	4.25e-14	Systemic lupus erythematosus;
LGG	cis	rs6732160	0.564	rs7605716	chr2:73376250	G/A	cg01422370	chr2:73384389	NA	0.57	9.96	0.42	2.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg16583315	chr14:65563665	MAX	-0.36	-6.81	-0.3	2.95e-11	Obesity-related traits;
LGG	cis	rs2013441	0.866	rs62067558	chr17:20025706	G/T	cg09818912	chr17:20140352	CYTSB	-0.32	-6.99	-0.31	9.34e-12	Obesity-related traits;
LGG	cis	rs7424096	0.613	rs72873859	chr2:37246738	T/G	cg14987922	chr2:37194071	STRN	0.49	7.23	0.32	2e-12	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs7267979	0.932	rs6132848	chr20:25561645	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.23	0.43	2.75e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs877282	0.891	rs11253393	chr10:788824	G/T	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg00745463	chr17:30367425	LRRC37B	-0.8	-11.0	-0.46	3.71e-25	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	0.515	rs67626468	chr3:10161518	C/A	cg16606324	chr3:10149918	C3orf24	0.64	7.17	0.32	3e-12	Alzheimer's disease;
LGG	cis	rs77106637	1.000	rs11600585	chr11:72727840	A/G	cg03713592	chr11:72463424	ARAP1	0.39	7.56	0.33	2.14e-13	Type 2 diabetes;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.37	-0.43	8.27e-23	Bipolar disorder;
LGG	cis	rs7659604	0.605	rs1396080	chr4:122740454	T/G	cg06713675	chr4:122721982	EXOSC9	-0.6	-10.09	-0.42	8.95e-22	Type 2 diabetes;
LGG	cis	rs35306767	0.903	rs12249828	chr10:894838	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.18	-0.39	1.41e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7560272	0.695	rs13022149	chr2:73641515	T/A	cg20560298	chr2:73613845	ALMS1	0.36	6.67	0.3	7.28e-11	Schizophrenia;
LGG	trans	rs7246760	0.867	rs8107594	chr19:9835957	G/C	cg02900749	chr2:68251473	NA	-1.01	-10.79	-0.45	2.29e-24	Pursuit maintenance gain;
LGG	cis	rs9916302	0.706	rs12937013	chr17:37665571	G/A	cg07936489	chr17:37558343	FBXL20	-0.99	-15.34	-0.58	2.95e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.39	-6.96	-0.31	1.15e-11	Total cholesterol levels;
LGG	cis	rs10504073	0.527	rs118032023	chr8:49926296	A/T	cg00325661	chr8:49890786	NA	0.8	16.1	0.6	1.21e-46	Blood metabolite ratios;
LGG	cis	rs875971	0.660	rs3857686	chr7:66036191	C/T	cg11764359	chr7:65958608	NA	-0.63	-10.81	-0.45	1.97e-24	Aortic root size;
LGG	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	trans	rs9657904	0.950	rs1867192	chr3:105568246	T/C	cg14088669	chr1:158435396	OR10K1	-0.4	-6.87	-0.3	2.11e-11	Multiple sclerosis;
LGG	cis	rs17641971	0.645	rs4873099	chr8:50025683	G/T	cg00325661	chr8:49890786	NA	0.55	10.47	0.44	3.7e-23	Blood metabolite levels;
LGG	cis	rs317689	0.581	rs160829	chr12:69769538	G/C	cg19645103	chr12:69753606	YEATS4	-0.49	-7.29	-0.32	1.31e-12	Response to diuretic therapy;
LGG	cis	rs2859741	1.000	rs543121	chr1:37497098	T/C	cg09363841	chr1:37513479	NA	-0.64	-15.81	-0.59	2.36e-45	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	cis	rs6089584	0.566	rs2146852	chr20:60616492	T/G	cg06470251	chr20:60548479	NA	0.41	7.17	0.32	2.98e-12	Body mass index;
LGG	trans	rs561341	1.000	rs757009	chr17:30243937	A/G	cg20587970	chr11:113659929	NA	-1.14	-19.81	-0.68	1.09e-63	Hip circumference adjusted for BMI;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-9.0	-0.39	5.98e-18	Personality dimensions;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	6.12e-20	Life satisfaction;
LGG	cis	rs7635838	0.718	rs2248971	chr3:11403441	T/C	cg00170343	chr3:11313890	ATG7	0.46	7.92	0.35	1.82e-14	HDL cholesterol;
LGG	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7811142	1.000	rs2406253	chr7:100077273	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	19.44	0.67	5.53e-62	Platelet count;
LGG	cis	rs2228479	0.850	rs11644213	chr16:89837367	C/T	cg06558623	chr16:89946397	TCF25	-1.11	-12.36	-0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs11864453	0.647	rs3852781	chr16:72123556	T/A	cg23815491	chr16:72088622	HP	0.51	11.57	0.47	2.27e-27	Fibrinogen levels;
LGG	cis	rs9322193	1.000	rs9767077	chr6:150109615	T/A	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg13902645	chr11:5959945	NA	-0.65	-10.1	-0.42	8.62e-22	DNA methylation (variation);
LGG	cis	rs9457247	0.565	rs12178491	chr6:167512474	C/T	cg07741184	chr6:167504864	NA	0.46	10.46	0.44	4.02e-23	Crohn's disease;
LGG	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg08754478	chr10:133766260	PPP2R2D	-0.68	-12.52	-0.5	3.58e-31	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08625260	chr13:110439234	IRS2	0.48	7.27	0.32	1.58e-12	Gut microbiome composition (summer);
LGG	cis	rs7143963	0.609	rs11846158	chr14:103292959	A/G	cg23020514	chr14:103360112	TRAF3	0.4	8.33	0.36	9.24e-16	Body mass index;
LGG	cis	rs9287719	0.967	rs7587114	chr2:10739963	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs9287719	0.967	rs2024431	chr2:10731327	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs6502050	0.835	rs3935816	chr17:80137173	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.36	-0.4	3.33e-19	Life satisfaction;
LGG	cis	rs2742417	1.000	rs1969626	chr3:45746836	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	trans	rs7726839	0.540	rs11739847	chr5:609661	G/A	cg25482853	chr8:67687455	SGK3	0.94	11.86	0.48	1.7e-28	Obesity-related traits;
LGG	trans	rs11088226	0.846	rs2833884	chr21:33923075	A/G	cg09050820	chr6:167586206	TCP10L2	0.68	10.48	0.44	3.2e-23	Gastritis;
LGG	cis	rs367943	0.712	rs7714734	chr5:112691261	G/A	cg12552261	chr5:112820674	MCC	0.58	10.45	0.44	4.34e-23	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05596664	chr3:171179040	TNIK	0.39	6.74	0.3	4.8e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7107174	0.892	rs3018313	chr11:77989644	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.64	-0.33	1.24e-13	Testicular germ cell tumor;
LGG	trans	rs3198697	0.663	rs12928099	chr16:15150505	C/A	cg04146151	chr16:2155961	PKD1	-0.51	-8.74	-0.38	4.46e-17	Triglycerides;
LGG	cis	rs9911578	0.803	rs8069033	chr17:57131581	T/A	cg12560992	chr17:57184187	TRIM37	-0.93	-16.62	-0.61	5.28e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs6853266	chr4:99047528	G/T	cg05340658	chr4:99064831	C4orf37	0.49	8.31	0.36	1.05e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11170468	0.697	rs1375797	chr12:39435183	A/C	cg26384229	chr12:38710491	ALG10B	-0.43	-6.81	-0.3	3.03e-11	Body mass index;
LGG	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg06212747	chr3:49208901	KLHDC8B	0.72	12.82	0.51	2.04e-32	Menarche (age at onset);
LGG	cis	rs17767392	0.918	rs61991202	chr14:71766675	G/A	cg02058870	chr14:72053146	SIPA1L1	0.44	9.06	0.39	3.64e-18	Mitral valve prolapse;
LGG	cis	rs9926296	0.605	rs6500449	chr16:89856393	T/C	cg27121462	chr16:89883253	FANCA	0.62	11.26	0.46	3.66e-26	Vitiligo;
LGG	cis	rs597583	0.951	rs599411	chr11:117422262	T/G	cg27161313	chr11:117392002	DSCAML1	-0.41	-6.88	-0.3	1.93e-11	Putamen volume;
LGG	cis	rs7493	0.950	rs17166868	chr7:95033416	C/T	cg08461772	chr7:95026248	PON3	0.37	8.01	0.35	9.32e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs5769765	0.955	rs6520066	chr22:50294988	C/T	cg26441486	chr22:50317300	CRELD2	0.41	7.63	0.33	1.35e-13	Schizophrenia;
LGG	trans	rs6561151	0.718	rs11842000	chr13:44413467	T/C	cg17145862	chr1:211918768	LPGAT1	0.64	8.81	0.38	2.59e-17	Crohn's disease;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg00933542	chr6:150070202	PCMT1	0.38	7.08	0.31	5.52e-12	Lung cancer;
LGG	cis	rs1153858	1.000	rs7167900	chr15:45639471	A/G	cg26924012	chr15:45694286	SPATA5L1	1.05	22.74	0.73	2.04e-77	Homoarginine levels;
LGG	cis	rs4295623	0.789	rs12541318	chr8:11594970	G/T	cg21775007	chr8:11205619	TDH	-0.42	-6.73	-0.3	5.1e-11	Morning vs. evening chronotype;
LGG	cis	rs2729354	0.779	rs2454663	chr11:57358083	T/C	cg24343310	chr11:57249947	NA	0.36	6.7	0.3	6.1e-11	Blood protein levels;
LGG	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg13256891	chr4:100009986	ADH5	0.56	9.85	0.42	6.83e-21	Alcohol dependence;
LGG	trans	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg17712092	chr4:129076599	LARP1B	-0.57	-9.57	-0.41	6.45e-20	Breast cancer;
LGG	cis	rs7647973	0.626	rs6809879	chr3:49834571	A/G	cg03060546	chr3:49711283	APEH	-0.61	-8.52	-0.37	2.25e-16	Menarche (age at onset);
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg00800038	chr16:89945340	TCF25	-0.73	-8.33	-0.36	9.06e-16	Skin colour saturation;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg13763550	chr16:4524223	NMRAL1;HMOX2	0.32	6.69	0.3	6.3e-11	Schizophrenia;
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	-0.59	-11.7	-0.48	7.01e-28	Prudent dietary pattern;
LGG	cis	rs637571	0.522	rs556643	chr11:65733289	C/T	cg17985854	chr11:65770987	BANF1;EIF1AD	0.43	7.55	0.33	2.36e-13	Eosinophil percentage of white cells;
LGG	cis	rs2274273	1.000	rs7160110	chr14:55594635	A/G	cg04306507	chr14:55594613	LGALS3	0.6	16.98	0.62	1.24e-50	Protein biomarker;
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg06558623	chr16:89946397	TCF25	1.09	12.0	0.49	4.65e-29	Skin colour saturation;
LGG	cis	rs782590	0.559	rs12617719	chr2:55915826	G/C	cg18811423	chr2:55921094	PNPT1	-0.77	-16.06	-0.6	1.82e-46	Metabolic syndrome;
LGG	cis	rs9341835	0.593	rs9361779	chr6:64159064	C/A	cg00787780	chr6:64151745	NA	0.41	7.22	0.32	2.15e-12	Schizophrenia;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.11e-20	Lung cancer;
LGG	trans	rs6089829	0.962	rs6089825	chr20:61668447	C/T	cg08862035	chr2:2617432	NA	0.41	6.66	0.3	7.79e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.53	0.4	9.09e-20	Lung cancer;
LGG	cis	rs2985684	1.000	rs8014170	chr14:50071694	C/G	cg04989706	chr14:50066350	PPIL5	-0.55	-8.72	-0.38	5.17e-17	Carotid intima media thickness;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.44	0.33	4.89e-13	Prudent dietary pattern;
LGG	cis	rs78456975	0.943	rs13421238	chr2:1576879	G/A	cg01028140	chr2:1542097	TPO	-0.46	-7.25	-0.32	1.72e-12	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10463554	0.927	rs7717343	chr5:102361983	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.71	-0.34	7.88e-14	Parkinson's disease;
LGG	trans	rs12599106	0.584	rs12929704	chr16:34898258	C/A	cg18000306	chr6:288505	NA	0.6	10.66	0.44	6.94e-24	Menopause (age at onset);
LGG	cis	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg15596359	chr8:11213517	TDH	-0.41	-8.33	-0.36	8.92e-16	Retinal vascular caliber;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg04503457	chr17:41445688	NA	-0.4	-9.62	-0.41	4.31e-20	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06766273	chr11:62521983	ZBTB3	0.52	8.34	0.36	8.7e-16	Gut microbiome composition (summer);
LGG	cis	rs9457247	0.967	rs382009	chr6:167403121	G/C	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	cis	rs2732480	0.500	rs11168468	chr12:48612465	C/T	cg21466736	chr12:48725269	NA	-0.36	-7.37	-0.32	8.13e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs868036	0.609	rs2278076	chr15:68099600	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.3	-0.32	1.28e-12	Restless legs syndrome;
LGG	cis	rs4363385	0.553	rs11580383	chr1:152942192	A/G	cg13444842	chr1:152974279	SPRR3	-0.51	-10.37	-0.43	8.85e-23	Inflammatory skin disease;
LGG	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.83	-0.62	6.31e-50	Height;
LGG	cis	rs10504229	0.906	rs7846666	chr8:58172302	T/C	cg02725872	chr8:58115012	NA	-0.76	-11.33	-0.47	1.96e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs2444217	0.868	rs2601792	chr16:4043980	G/A	cg09300795	chr16:4042428	ADCY9	0.6	11.1	0.46	1.51e-25	Body mass index;
LGG	trans	rs7786808	0.741	rs11769149	chr7:158227127	A/G	cg02030672	chr11:45687055	CHST1	-0.48	-8.55	-0.37	1.8e-16	Obesity-related traits;
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg09699651	chr6:150184138	LRP11	0.52	9.08	0.39	3.23e-18	Lung cancer;
LGG	cis	rs10911251	0.528	rs2147584	chr1:183074764	T/C	cg07928641	chr1:182991847	LAMC1	0.46	9.29	0.4	6.11e-19	Colorectal cancer;
LGG	cis	rs8179	0.593	rs17164683	chr7:92286980	C/T	cg15732164	chr7:92237376	CDK6	-0.54	-10.36	-0.43	9.1e-23	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs7527798	0.592	rs12022909	chr1:207859743	T/C	cg09232269	chr1:207846808	CR1L	-0.35	-6.72	-0.3	5.48e-11	Erythrocyte sedimentation rate;
LGG	cis	rs17539620	0.624	rs56791414	chr6:154849605	A/G	cg17771515	chr6:154831774	CNKSR3	0.63	7.41	0.33	6.04e-13	Lipoprotein (a) levels;
LGG	cis	rs28386778	0.700	rs12452767	chr17:62010503	G/A	cg07677032	chr17:61819896	STRADA	-0.56	-9.72	-0.41	1.86e-20	Prudent dietary pattern;
LGG	cis	rs6963495	0.818	rs116845562	chr7:105217038	T/C	cg19920283	chr7:105172520	RINT1	0.65	8.54	0.37	2.01e-16	Bipolar disorder (body mass index interaction);
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4330281	0.647	rs12487916	chr3:17733795	G/C	cg20981856	chr3:17787350	NA	-0.4	-7.43	-0.33	5.31e-13	Schizophrenia;
LGG	cis	rs643506	0.874	rs582465	chr11:111668585	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.96	0.31	1.18e-11	Breast cancer;
LGG	cis	rs7833790	0.700	rs28390260	chr8:82769175	A/T	cg27398817	chr8:82754497	SNX16	0.69	10.6	0.44	1.23e-23	Diastolic blood pressure;
LGG	cis	rs2980436	1	rs2980436	chr8:8092025	A/G	cg08975724	chr8:8085496	FLJ10661	-0.59	-12.05	-0.49	2.93e-29	Schizophrenia;
LGG	cis	rs10504229	0.683	rs16921817	chr8:58107563	A/T	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4006360	0.604	rs3914090	chr17:39230058	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.07	-0.42	1.09e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg09626363	chr16:4524711	NMRAL1;HMOX2	-0.38	-7.16	-0.32	3.16e-12	Schizophrenia;
LGG	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg12183467	chr14:104352244	NA	-0.41	-6.66	-0.3	7.68e-11	Bipolar disorder;
LGG	cis	rs2046867	0.628	rs7356055	chr3:72912878	A/C	cg01043669	chr3:72786069	NA	0.39	7.01	0.31	8.67e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs7011049	0.660	rs112735381	chr8:53867352	T/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs4808199	1.000	rs60003758	chr19:19557353	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12629250	chr15:20149347	NA	0.39	7.1	0.31	4.73e-12	Menarche (age at onset);
LGG	cis	rs2046867	0.661	rs28599586	chr3:72907185	A/G	cg26655873	chr3:72818019	SHQ1	0.32	6.67	0.3	7.23e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.51	0.37	2.4e-16	Obesity-related traits;
LGG	cis	rs2153535	0.584	rs62395677	chr6:8371589	G/A	cg23788917	chr6:8435910	SLC35B3	-0.45	-7.39	-0.32	6.71e-13	Motion sickness;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.7	13.81	0.54	1.39e-36	Obesity-related traits;
LGG	trans	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01341218	chr17:43662625	NA	-0.87	-14.9	-0.57	2.78e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4919044	0.808	rs2486680	chr10:94805529	C/T	cg05127821	chr10:94822908	CYP26C1	-0.45	-8.03	-0.35	8.33e-15	Coronary artery disease;
LGG	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg12386194	chr3:101231763	SENP7	0.47	8.19	0.36	2.62e-15	Colorectal cancer;
LGG	cis	rs4308124	0.708	rs61358692	chr2:111965159	T/C	cg04571233	chr2:111982156	NA	-0.6	-9.79	-0.41	1.05e-20	Vitiligo;
LGG	trans	rs961253	0.522	rs2225115	chr20:6360465	C/T	cg21095983	chr6:86352623	SYNCRIP	0.42	7.02	0.31	8.05e-12	Colorectal cancer;
LGG	cis	rs1046896	0.562	rs2380172	chr17:80887719	C/A	cg08200770	chr17:80723486	TBCD	-0.47	-8.42	-0.36	4.82e-16	Glycated hemoglobin levels;
LGG	cis	rs1594829	0.535	rs17055121	chr8:26170975	C/T	cg11498726	chr8:26250323	BNIP3L	-0.39	-8.57	-0.37	1.57e-16	Height;
LGG	cis	rs1355223	1.000	rs1355223	chr11:34764479	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.26	-0.32	1.62e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9612	0.950	rs346546	chr19:44256910	T/C	cg08581076	chr19:44259116	C19orf61	0.51	8.56	0.37	1.63e-16	Exhaled nitric oxide output;
LGG	cis	rs559928	1.000	rs7105178	chr11:64145109	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.19	-0.32	2.57e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs6901004	0.803	rs405948	chr6:111540372	C/T	cg15721981	chr6:111408429	SLC16A10	-0.4	-7.14	-0.31	3.63e-12	Blood metabolite levels;
LGG	cis	rs3742264	0.615	rs9534255	chr13:46517275	T/C	cg15192986	chr13:46630673	CPB2	-0.35	-6.88	-0.3	2e-11	Blood protein levels;
LGG	cis	rs9322193	0.847	rs12210605	chr6:150138403	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.34e-11	Lung cancer;
LGG	cis	rs4979906	0.920	rs11002239	chr10:79443836	A/C	cg07817648	chr10:79422355	NA	-0.5	-8.01	-0.35	9.63e-15	Mortality in heart failure;
LGG	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg22681709	chr2:178499509	PDE11A	-0.48	-6.8	-0.3	3.28e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg19812747	chr11:111475976	SIK2	-0.49	-10.24	-0.43	2.46e-22	Primary sclerosing cholangitis;
LGG	cis	rs3790455	1.000	rs3790455	chr1:156456301	C/T	cg14087168	chr1:156450669	MEF2D	0.47	7.77	0.34	5.03e-14	Migraine;
LGG	cis	rs12824058	0.831	rs12297939	chr12:130811923	G/C	cg26677194	chr12:130822605	PIWIL1	0.57	10.2	0.43	3.68e-22	Menopause (age at onset);
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg16405210	chr4:1374714	KIAA1530	-0.5	-8.53	-0.37	2.15e-16	Obesity-related traits;
LGG	cis	rs57221529	0.766	rs56278696	chr5:582669	A/G	cg14541582	chr5:601475	NA	-0.71	-11.1	-0.46	1.54e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs2243480	1.000	rs1796220	chr7:66062100	C/T	cg12463550	chr7:65579703	CRCP	0.76	8.3	0.36	1.12e-15	Diabetic kidney disease;
LGG	cis	rs710865	1.000	rs710866	chr1:19568722	G/C	cg13387374	chr1:19411106	UBR4	0.45	8.7	0.37	5.74e-17	Brain structure;
LGG	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs3106136	0.843	rs901615	chr4:95228687	A/C	cg11021082	chr4:95130006	SMARCAD1	-0.43	-7.33	-0.32	1.06e-12	Capecitabine sensitivity;
LGG	cis	rs13108904	0.846	rs3775100	chr4:1225106	T/C	cg20887711	chr4:1340912	KIAA1530	0.46	8.22	0.36	2.05e-15	Obesity-related traits;
LGG	cis	rs79911532	0.515	rs17148983	chr7:75649821	C/G	cg15148918	chr7:75625777	STYXL1	-0.66	-7.67	-0.34	1.06e-13	Mononucleosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07409680	chr12:32260442	BICD1	0.5	8.18	0.36	2.69e-15	Gut microbiome composition (summer);
LGG	cis	rs2153535	0.601	rs7775274	chr6:8530303	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs78456975	1.000	rs13422995	chr2:1553554	C/A	cg01028140	chr2:1542097	TPO	-0.55	-8.5	-0.37	2.68e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs17345786	0.520	rs1476123	chr3:101313413	C/G	cg27318481	chr3:100970896	IMPG2	0.34	7.0	0.31	8.98e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg07511668	chr11:68622177	NA	0.51	9.86	0.42	6.01e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9534288	0.762	rs9534264	chr13:46541673	T/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.17	-0.52	7.26e-34	Blood protein levels;
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg18479299	chr3:125709523	NA	-0.6	-7.72	-0.34	7.34e-14	Blood pressure (smoking interaction);
LGG	cis	rs787274	0.764	rs1891402	chr9:115567184	T/C	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs67385638	1.000	rs67385638	chr11:5290370	C/G	cg12559170	chr11:5275217	HBG2	0.56	12.81	0.51	2.37e-32	Hemoglobin levels;
LGG	cis	rs11167764	1.000	rs7730511	chr5:141480418	T/C	cg08523384	chr5:141488047	NDFIP1	-0.37	-6.94	-0.31	1.37e-11	Crohn's disease;
LGG	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg06873352	chr17:61820015	STRADA	0.47	7.39	0.32	6.94e-13	Height;
LGG	cis	rs7166081	1.000	rs4536412	chr15:67653764	A/C	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.34	-0.32	9.99e-13	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9527	0.615	rs10883810	chr10:104727224	A/C	cg04362960	chr10:104952993	NT5C2	0.56	10.39	0.43	7.42e-23	Arsenic metabolism;
LGG	cis	rs4731207	0.564	rs6466970	chr7:124592755	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs920590	0.510	rs4922101	chr8:19648895	A/G	cg01411142	chr8:19674711	INTS10	0.7	10.52	0.44	2.41e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7568458	1.000	rs7568458	chr2:85788175	T/A	cg02493740	chr2:85810744	VAMP5	-0.39	-6.91	-0.31	1.62e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6912958	0.559	rs173333	chr6:88047754	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	13.03	0.52	2.76e-33	Monocyte percentage of white cells;
LGG	trans	rs11875185	0.510	rs75957996	chr18:55610758	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.34e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.73	-0.64	4.42e-54	Breast cancer;
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg21422208	chr3:53164667	RFT1	-0.42	-6.68	-0.3	7.02e-11	Body fat percentage;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg05368731	chr17:41323189	NBR1	0.84	15.81	0.59	2.38e-45	Menopause (age at onset);
LGG	cis	rs11098499	0.954	rs6820115	chr4:120398182	T/C	cg09307838	chr4:120376055	NA	0.74	12.72	0.51	5.31e-32	Corneal astigmatism;
LGG	cis	rs12477438	0.501	rs2632260	chr2:99771590	G/T	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs3008870	0.959	rs3008852	chr1:67383416	G/A	cg08660285	chr1:67390436	MIER1;WDR78	1.05	23.01	0.73	1.16e-78	Lymphocyte percentage of white cells;
LGG	trans	rs2562456	0.833	rs62107539	chr19:21517712	T/C	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.93e-13	Pain;
LGG	cis	rs861020	0.563	rs12046618	chr1:210043135	C/T	cg23166289	chr1:210001082	C1orf107	0.35	6.77	0.3	4.02e-11	Orofacial clefts;
LGG	trans	rs7819412	0.775	rs4841490	chr8:10936891	T/C	cg02002194	chr4:3960332	NA	0.42	7.8	0.34	4.24e-14	Triglycerides;
LGG	cis	rs1790761	0.933	rs1790752	chr11:67202044	G/A	cg00864171	chr11:67383662	NA	-0.43	-7.14	-0.31	3.65e-12	Mean corpuscular volume;
LGG	cis	rs9926296	0.712	rs447735	chr16:89734349	T/C	cg26513180	chr16:89883248	FANCA	-0.52	-8.84	-0.38	2.03e-17	Vitiligo;
LGG	cis	rs2153535	0.580	rs3938660	chr6:8443335	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	trans	rs453301	0.606	rs7462373	chr8:8899318	G/C	cg21775007	chr8:11205619	TDH	-0.47	-7.59	-0.33	1.8e-13	Joint mobility (Beighton score);
LGG	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg05585630	chr7:157510462	PTPRN2	-0.64	-13.41	-0.53	7.17e-35	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs6987435	chr8:58177334	G/A	cg23782820	chr8:58130467	NA	0.44	6.74	0.3	4.67e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg13010199	chr12:38710504	ALG10B	-0.56	-10.37	-0.43	8.83e-23	Morning vs. evening chronotype;
LGG	cis	rs12421382	0.614	rs11213104	chr11:109391297	G/T	cg15948088	chr11:109293068	C11orf87	0.46	8.16	0.35	3.24e-15	Schizophrenia;
LGG	cis	rs7572733	0.534	rs4550664	chr2:198691405	C/T	cg00792783	chr2:198669748	PLCL1	0.69	11.11	0.46	1.4e-25	Dermatomyositis;
LGG	cis	rs193541	0.617	rs2045628	chr5:122095154	C/T	cg19412675	chr5:122181750	SNX24	0.53	8.51	0.37	2.42e-16	Glucose homeostasis traits;
LGG	cis	rs56161922	1.000	rs74401244	chr1:207844799	T/C	cg09557387	chr1:207818395	CR1L	0.99	9.66	0.41	3.18e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs79387448	0.655	rs11891827	chr2:102951182	A/G	cg20060108	chr2:102954350	IL1RL1	-0.44	-6.92	-0.31	1.47e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7737355	0.738	rs7734666	chr5:130861456	A/G	cg06307176	chr5:131281290	NA	0.51	8.59	0.37	1.33e-16	Life satisfaction;
LGG	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg05333889	chr7:157238977	NA	-0.41	-7.85	-0.34	2.91e-14	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs6582630	0.576	rs2387837	chr12:38403164	G/T	cg26384229	chr12:38710491	ALG10B	-0.64	-12.72	-0.51	5.56e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs71403859	0.730	rs17356316	chr16:71746921	C/T	cg08717414	chr16:71523259	ZNF19	-1.06	-13.08	-0.52	1.8e-33	Post bronchodilator FEV1;
LGG	cis	rs738322	0.967	rs4385	chr22:38573229	T/C	cg17652424	chr22:38574118	PLA2G6	-0.27	-6.94	-0.31	1.33e-11	Cutaneous nevi;
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg03517284	chr6:25882590	NA	-0.39	-7.0	-0.31	8.87e-12	Height;
LGG	cis	rs12477438	0.520	rs11685759	chr2:99766217	T/C	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg08645402	chr16:4508243	NA	0.54	9.94	0.42	3.04e-21	Schizophrenia;
LGG	cis	rs16933812	0.510	rs7854114	chr9:36989004	T/C	cg13738729	chr9:36989127	PAX5	0.41	9.13	0.39	2.14e-18	Obesity-related traits;
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg01570182	chr17:44337453	NA	-0.66	-10.95	-0.45	5.71e-25	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6502050	0.805	rs9898507	chr17:80119628	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs11203032	0.614	rs11203025	chr10:90955474	A/C	cg16672925	chr10:90967113	CH25H	0.79	11.33	0.47	2.03e-26	Heart failure;
LGG	cis	rs2228479	0.702	rs78331410	chr16:89917775	C/T	cg27400746	chr16:89904261	SPIRE2	-1.19	-17.29	-0.63	5.07e-52	Skin colour saturation;
LGG	cis	rs2228479	0.867	rs62052189	chr16:89975555	G/C	cg27400746	chr16:89904261	SPIRE2	-0.99	-16.92	-0.62	2.43e-50	Skin colour saturation;
LGG	cis	rs889312	0.500	rs832585	chr5:56125904	T/C	cg12654349	chr5:56205094	C5orf35	-0.38	-6.9	-0.31	1.72e-11	Breast cancer;Breast cancer (early onset);
LGG	trans	rs7939886	0.920	rs12224086	chr11:55798259	G/T	cg03929089	chr4:120376271	NA	0.84	8.7	0.37	5.63e-17	Myopia (pathological);
LGG	trans	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg13009111	chr11:71350975	NA	0.35	7.58	0.33	1.9e-13	Myopia (pathological);
LGG	cis	rs1552244	1.000	rs57631744	chr3:10118962	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	trans	rs7210837	0.656	rs12942688	chr17:16790626	C/A	cg11294312	chr17:28900046	NA	-0.73	-9.1	-0.39	2.8e-18	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs2033732	0.706	rs7833023	chr8:85053241	A/C	cg05716166	chr8:85095498	RALYL	-0.43	-7.05	-0.31	6.44e-12	Body mass index;
LGG	cis	rs17376456	0.569	rs7729807	chr5:93104089	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.64	8.4	0.36	5.54e-16	Diabetic retinopathy;
LGG	cis	rs6665290	0.669	rs3795446	chr1:227180981	C/T	cg10327440	chr1:227177885	CDC42BPA	1.15	32.18	0.83	3.75e-120	Myeloid white cell count;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg11645453	chr3:52864694	ITIH4	0.39	6.77	0.3	3.94e-11	Electroencephalogram traits;
LGG	cis	rs2549003	0.933	rs3846731	chr5:131814264	T/C	cg00578828	chr5:131826934	IRF1	0.41	7.48	0.33	3.64e-13	Asthma (sex interaction);
LGG	cis	rs2404602	0.583	rs2456076	chr15:76557553	T/G	cg22467129	chr15:76604101	ETFA	0.43	7.1	0.31	4.72e-12	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs9911997	chr17:29124648	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3736594	0.513	rs62138971	chr2:27840754	G/A	cg27432699	chr2:27873401	GPN1	0.56	8.54	0.37	1.88e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs2562456	0.833	rs2359145	chr19:21592593	T/C	cg00806126	chr19:22604979	ZNF98	-0.58	-7.68	-0.34	9.62e-14	Pain;
LGG	trans	rs4332037	0.624	rs11764337	chr7:1892309	A/G	cg10840412	chr1:235813424	GNG4	-0.52	-7.63	-0.33	1.34e-13	Bipolar disorder;
LGG	trans	rs66887589	0.592	rs62320740	chr4:120279486	C/A	cg25214090	chr10:38739885	LOC399744	0.46	8.39	0.36	6.1e-16	Diastolic blood pressure;
LGG	cis	rs7827545	1.000	rs7008121	chr8:135565904	T/C	cg09855544	chr8:135498122	ZFAT	0.46	7.86	0.34	2.74e-14	Hypertension (SNP x SNP interaction);
LGG	cis	rs1005224	0.853	rs6574251	chr14:76136883	C/T	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.4	-6.65	-0.3	8.07e-11	Large artery stroke;
LGG	cis	rs8072100	0.581	rs4267364	chr17:45781264	A/G	cg25173405	chr17:45401733	C17orf57	-0.49	-8.07	-0.35	6.22e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs490234	0.702	rs13284551	chr9:128411969	C/T	cg14078157	chr9:128172775	NA	-0.53	-9.78	-0.41	1.14e-20	Mean arterial pressure;
LGG	cis	rs7552404	1.000	rs441109	chr1:76120430	T/G	cg10523679	chr1:76189770	ACADM	-0.81	-14.08	-0.55	1.03e-37	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7017914	0.967	rs12680166	chr8:71678638	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs7223966	0.960	rs113155878	chr17:61706560	C/A	cg18032289	chr17:61959525	GH2	-0.41	-7.12	-0.31	4.27e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs61931739	0.817	rs10772143	chr12:34230651	T/G	cg26384229	chr12:38710491	ALG10B	0.64	12.27	0.5	3.71e-30	Morning vs. evening chronotype;
LGG	cis	rs2721195	0.967	rs10108150	chr8:145687475	A/G	cg11211951	chr8:145729740	GPT	-0.51	-11.05	-0.46	2.4e-25	Age at first birth;
LGG	trans	rs7618501	1.000	rs11130219	chr3:49752427	C/T	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	cis	rs7394190	0.630	rs113799665	chr10:75575138	C/T	cg07699608	chr10:75541558	CHCHD1	0.58	7.64	0.33	1.24e-13	Incident atrial fibrillation;
LGG	cis	rs953387	1.000	rs2056297	chr2:136899116	G/T	cg07169764	chr2:136633963	MCM6	0.55	9.15	0.39	1.88e-18	Arthritis (juvenile idiopathic);
LGG	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg19748678	chr4:122722346	EXOSC9	-0.57	-9.82	-0.42	8.31e-21	Type 2 diabetes;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg00495681	chr13:53174319	NA	0.67	13.34	0.53	1.45e-34	Lewy body disease;
LGG	cis	rs3741404	0.895	rs1860368	chr11:63994692	T/C	cg18225595	chr11:63971243	STIP1	-0.62	-11.87	-0.48	1.44e-28	Platelet count;
LGG	cis	rs950027	0.787	rs2433616	chr15:45728599	A/G	cg26924012	chr15:45694286	SPATA5L1	0.62	10.97	0.45	4.6e-25	Response to fenofibrate (adiponectin levels);
LGG	cis	rs897984	0.568	rs72799330	chr16:30893555	C/A	cg02466173	chr16:30829666	NA	-0.52	-8.65	-0.37	8.23e-17	Dementia with Lewy bodies;
LGG	cis	rs35883536	0.647	rs10875328	chr1:101169328	C/T	cg06223162	chr1:101003688	GPR88	-0.4	-9.32	-0.4	4.68e-19	Monocyte count;
LGG	cis	rs514024	0.645	rs504434	chr9:130477768	G/A	cg13643465	chr9:130375613	STXBP1	0.53	9.56	0.41	6.81e-20	Eating disorders (purging via substances);
LGG	cis	rs4242434	0.927	rs3735901	chr8:22462374	T/C	cg02227867	chr8:22457446	C8orf58	-0.46	-8.82	-0.38	2.41e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	trans	rs35110281	0.720	rs162372	chr21:44928863	C/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	-0.63	-11.06	-0.46	2.16e-25	Mean corpuscular volume;
LGG	cis	rs3857067	0.806	rs28408270	chr4:95114572	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.13	-0.35	3.83e-15	QT interval;
LGG	cis	rs8072100	1.000	rs4794016	chr17:45725931	T/A	cg25173405	chr17:45401733	C17orf57	0.49	8.55	0.37	1.85e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg23782820	chr8:58130467	NA	0.57	8.39	0.36	5.77e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg00129232	chr17:37814104	STARD3	0.61	11.36	0.47	1.5e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg26513180	chr16:89883248	FANCA	0.88	8.51	0.37	2.5e-16	Skin colour saturation;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg02158880	chr13:53174818	NA	-0.44	-8.29	-0.36	1.28e-15	Lewy body disease;
LGG	cis	rs6840360	0.571	rs4696276	chr4:152532682	G/A	cg25486957	chr4:152246857	NA	-0.49	-8.1	-0.35	4.8e-15	Intelligence (multi-trait analysis);
LGG	cis	rs12618769	0.652	rs72823796	chr2:99227812	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.71	0.34	7.79e-14	Bipolar disorder;
LGG	cis	rs10479542	0.896	rs4701131	chr5:178982446	A/G	cg09060608	chr5:178986726	RUFY1	0.51	9.1	0.39	2.64e-18	Lung cancer;
LGG	trans	rs826838	0.935	rs4583043	chr12:38645147	T/G	cg06521331	chr12:34319734	NA	-0.47	-8.16	-0.35	3.3e-15	Heart rate;
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg10207240	chr12:122356781	WDR66	0.26	7.68	0.34	9.88e-14	Mean corpuscular volume;
LGG	cis	rs9393692	0.905	rs7746807	chr6:26293338	C/A	cg00631329	chr6:26305371	NA	-0.53	-9.87	-0.42	5.74e-21	Educational attainment;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg15113064	chr3:124774855	HEG1	-0.42	-6.78	-0.3	3.72e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs9393692	0.905	rs1124999	chr6:26287043	G/T	cg00631329	chr6:26305371	NA	-0.52	-9.8	-0.41	9.81e-21	Educational attainment;
LGG	cis	rs3858526	0.585	rs10734568	chr11:5970962	C/T	cg02574844	chr11:5959923	NA	-0.42	-7.15	-0.32	3.3e-12	DNA methylation (variation);
LGG	cis	rs13102973	0.965	rs7693757	chr4:135856609	C/T	cg14419869	chr4:135874104	NA	0.56	10.65	0.44	7.94e-24	Subjective well-being;
LGG	cis	rs7208859	0.673	rs73277978	chr17:29191449	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg06848047	chr4:90757629	SNCA	-0.42	-8.0	-0.35	1.03e-14	Dementia with Lewy bodies;
LGG	cis	rs7017914	0.967	rs13264669	chr8:71626772	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	cis	rs1790761	0.967	rs1638565	chr11:67223921	A/C	cg00864171	chr11:67383662	NA	-0.44	-7.21	-0.32	2.32e-12	Mean corpuscular volume;
LGG	cis	rs2180341	0.960	rs9398840	chr6:127669744	G/A	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	cis	rs758324	0.947	rs10478989	chr5:131116055	A/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs1552244	0.752	rs9867091	chr3:10043429	T/C	cg13047869	chr3:10149882	C3orf24	0.47	7.92	0.35	1.74e-14	Alzheimer's disease;
LGG	cis	rs72781680	1.000	rs72781671	chr2:24231123	A/G	cg08917208	chr2:24149416	ATAD2B	0.91	9.72	0.41	1.9e-20	Lymphocyte counts;
LGG	cis	rs921968	0.541	rs7604319	chr2:219538799	A/C	cg01130898	chr2:219473002	PLCD4	0.49	8.42	0.36	4.8e-16	Mean corpuscular hemoglobin concentration;
LGG	cis	rs4718428	0.705	rs28648401	chr7:66367132	T/C	cg12165864	chr7:66369176	NA	-0.58	-9.39	-0.4	2.8e-19	Corneal structure;
LGG	trans	rs11039798	0.844	rs41431447	chr11:48983199	A/G	cg03929089	chr4:120376271	NA	0.75	7.84	0.34	3.15e-14	Axial length;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.56	-9.97	-0.42	2.4e-21	Lymphocyte counts;
LGG	cis	rs4481887	0.676	rs7527991	chr1:248527649	T/A	cg13385794	chr1:248469461	NA	0.44	8.05	0.35	7.28e-15	Common traits (Other);
LGG	cis	rs41271473	0.687	rs4388674	chr1:228878563	A/G	cg00850481	chr1:228891306	NA	-0.56	-11.23	-0.46	4.89e-26	Chronic lymphocytic leukemia;
LGG	cis	rs10463316	0.894	rs4099168	chr5:150766467	A/G	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs708547	0.575	rs6847086	chr4:57791864	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.55	-9.39	-0.4	2.67e-19	Response to bleomycin (chromatid breaks);
LGG	cis	rs1218582	0.628	rs12130132	chr1:154880386	C/T	cg16680214	chr1:154839983	KCNN3	-0.46	-8.6	-0.37	1.29e-16	Prostate cancer;
LGG	cis	rs28735056	0.904	rs11665111	chr18:77622996	T/C	cg20368463	chr18:77673604	PQLC1	0.42	7.48	0.33	3.83e-13	Schizophrenia;
LGG	cis	rs6577655	0.517	rs2241893	chr8:135586659	C/T	cg17885191	chr8:135476712	NA	0.59	8.87	0.38	1.62e-17	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs10791323	0.546	rs55801927	chr11:133713094	A/C	cg15485101	chr11:133734466	NA	0.61	10.7	0.45	4.97e-24	Childhood ear infection;
LGG	cis	rs72781680	0.821	rs72796378	chr2:24167385	G/A	cg08917208	chr2:24149416	ATAD2B	0.65	8.69	0.37	6.24e-17	Lymphocyte counts;
LGG	cis	rs7223966	0.618	rs9906903	chr17:61634508	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.54	8.25	0.36	1.67e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4862750	0.794	rs7692427	chr4:187901727	G/A	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9303401	0.659	rs16943176	chr17:56769887	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.23	0.58	9.61e-43	Cognitive test performance;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg16920238	chr17:80076378	CCDC57	-0.31	-7.16	-0.32	3.25e-12	Life satisfaction;
LGG	cis	rs881375	0.867	rs10818484	chr9:123661194	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs6993813	0.872	rs10955924	chr8:120053343	A/C	cg17171407	chr8:119960777	TNFRSF11B	-0.27	-6.77	-0.3	4.01e-11	Bone mineral density (hip);
LGG	cis	rs7618915	0.501	rs2109634	chr3:52752075	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.23	0.39	9.96e-19	Bipolar disorder;
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.78	0.45	2.45e-24	Personality dimensions;
LGG	cis	rs561341	1.000	rs55978022	chr17:30275937	T/C	cg13647721	chr17:30228624	UTP6	0.63	7.81	0.34	3.77e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg04568710	chr12:38710424	ALG10B	-0.37	-8.1	-0.35	4.75e-15	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1577917	0.652	rs75593931	chr6:86719539	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.6	-10.06	-0.42	1.2e-21	Response to antipsychotic treatment;
LGG	cis	rs1799949	1.000	rs8176233	chr17:41219804	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.16	-0.32	3.18e-12	Menopause (age at onset);
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg16524936	chr4:1340807	KIAA1530	-0.42	-6.75	-0.3	4.5e-11	Longevity;
LGG	cis	rs10876993	0.715	rs2169987	chr12:58012111	G/A	cg18357645	chr12:58087776	OS9	-0.64	-10.69	-0.44	5.66e-24	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs1182196	0.502	rs757786	chr7:2836019	C/T	cg23009067	chr7:2775923	GNA12	0.26	7.25	0.32	1.79e-12	Plateletcrit;
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg22753661	chr15:79092743	ADAMTS7	-0.39	-6.7	-0.3	6.08e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs9858542	1.000	rs6770670	chr3:49686682	T/C	cg07274523	chr3:49395745	GPX1	0.55	9.09	0.39	3.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg16141378	chr3:129829833	LOC729375	-0.35	-7.43	-0.33	5.24e-13	Neuroticism;
LGG	cis	rs853679	0.517	rs1904841	chr6:28108085	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.56	-7.42	-0.33	5.5e-13	Depression;
LGG	trans	rs11039798	0.588	rs6485857	chr11:48556511	C/A	cg15704280	chr7:45808275	SEPT13	0.72	9.97	0.42	2.47e-21	Axial length;
LGG	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg11995313	chr8:8860691	ERI1	0.43	7.13	0.31	3.86e-12	Joint mobility (Beighton score);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg22481344	chr6:144607497	NA	0.62	7.17	0.32	2.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs4481887	0.790	rs10888364	chr1:248488387	T/G	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.06e-19	Common traits (Other);
LGG	cis	rs9911578	0.935	rs2567912	chr17:56731270	T/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.9	-0.42	4.49e-21	Intelligence (multi-trait analysis);
LGG	cis	rs1318772	1.000	rs11738587	chr5:112693781	C/G	cg12552261	chr5:112820674	MCC	0.7	8.43	0.36	4.53e-16	F-cell distribution;
LGG	cis	rs12410462	0.581	rs111356515	chr1:227537236	C/G	cg04117972	chr1:227635322	NA	0.58	9.41	0.4	2.26e-19	Major depressive disorder;
LGG	cis	rs34172651	0.917	rs35283675	chr16:24820393	A/G	cg00339695	chr16:24857497	SLC5A11	0.34	6.75	0.3	4.35e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1348850	0.608	rs2364845	chr2:178226240	T/C	cg22681709	chr2:178499509	PDE11A	-0.38	-7.32	-0.32	1.12e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1015291	0.708	rs2694976	chr12:20007123	A/G	cg25401612	chr12:20009446	NA	-0.33	-7.09	-0.31	5.13e-12	Diastolic blood pressure;
LGG	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26306683	chr17:18585705	ZNF286B	-0.41	-7.03	-0.31	7.47e-12	Pancreatic cancer;
LGG	cis	rs1816854	0.872	rs11182275	chr12:44206289	T/G	cg00106942	chr12:44200524	TWF1	0.41	6.69	0.3	6.64e-11	Inflammatory bowel disease;
LGG	cis	rs6977660	0.714	rs10257947	chr7:19824099	A/C	cg07541023	chr7:19748670	TWISTNB	0.59	8.48	0.37	2.97e-16	Thyroid stimulating hormone;
LGG	cis	rs10504229	1.000	rs73607863	chr8:58170178	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.28	-0.53	2.58e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.12e-43	Prudent dietary pattern;
LGG	trans	rs7615952	0.599	rs60847438	chr3:125746005	T/C	cg07211511	chr3:129823064	LOC729375	-0.65	-9.0	-0.39	5.87e-18	Blood pressure (smoking interaction);
LGG	cis	rs4731207	0.698	rs17147583	chr7:124470125	C/G	cg05630886	chr7:124431682	NA	0.34	7.88	0.34	2.34e-14	Cutaneous malignant melanoma;
LGG	cis	rs11190604	1.000	rs10883508	chr10:102294413	G/A	cg07080220	chr10:102295463	HIF1AN	0.7	11.88	0.48	1.3e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11225247	0.649	rs11607214	chr11:102225224	A/G	cg06323957	chr11:102217781	BIRC2	0.81	7.51	0.33	3.03e-13	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs7659604	0.539	rs3217773	chr4:122739121	A/G	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.44	-0.47	7.45e-27	Type 2 diabetes;
LGG	cis	rs35306767	0.903	rs11253493	chr10:936931	T/C	cg08847335	chr10:891726	LARP4B	-0.49	-8.88	-0.38	1.46e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs7843479	0.601	rs11785043	chr8:21810377	C/T	cg17168535	chr8:21777572	XPO7	0.82	16.27	0.6	2.02e-47	Mean corpuscular volume;
LGG	cis	rs9534288	0.731	rs7981685	chr13:46605495	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-13.31	-0.53	1.88e-34	Blood protein levels;
LGG	cis	rs9650657	0.645	rs4841407	chr8:10516185	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.57	-0.33	2.04e-13	Neuroticism;
LGG	cis	rs12477438	0.520	rs6542866	chr2:99764592	T/C	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs4481887	0.893	rs28579823	chr1:248506881	C/T	cg01631408	chr1:248437212	OR2T33	-0.5	-9.18	-0.39	1.48e-18	Common traits (Other);
LGG	cis	rs7647973	0.807	rs4955416	chr3:49108428	T/C	cg07636037	chr3:49044803	WDR6	0.93	17.82	0.64	1.79e-54	Menarche (age at onset);
LGG	trans	rs783540	0.592	rs2567632	chr15:83284804	A/G	cg16105309	chr15:79090380	ADAMTS7	0.48	8.27	0.36	1.47e-15	Schizophrenia;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.49	8.9	0.38	1.24e-17	Obesity-related traits;
LGG	cis	rs34172651	0.917	rs11640931	chr16:24797919	A/G	cg02428538	chr16:24856791	SLC5A11	-0.44	-7.54	-0.33	2.5e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2997447	0.655	rs55820521	chr1:26374286	C/T	cg19633962	chr1:26362018	EXTL1	-0.64	-8.49	-0.37	2.93e-16	QRS complex (12-leadsum);
LGG	cis	rs6083	0.571	rs17190678	chr15:58847372	C/G	cg05156742	chr15:59063176	FAM63B	-0.45	-8.19	-0.36	2.56e-15	Schizophrenia;
LGG	cis	rs12928939	0.815	rs34731378	chr16:71745748	C/T	cg08717414	chr16:71523259	ZNF19	-0.47	-7.16	-0.32	3.19e-12	Post bronchodilator FEV1;
LGG	cis	rs7618915	0.501	rs10865974	chr3:52718280	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	-0.61	-10.96	-0.45	5.28e-25	Bipolar disorder;
LGG	cis	rs11764590	0.694	rs11773643	chr7:2104063	A/G	cg02825527	chr7:2087843	MAD1L1	-0.38	-7.5	-0.33	3.33e-13	Neuroticism;
LGG	trans	rs8073060	0.505	rs225270	chr17:33968871	A/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs34929064	0.671	rs13240836	chr7:22744442	A/T	cg18045685	chr7:22629474	NA	0.51	7.03	0.31	7.41e-12	Major depression and alcohol dependence;
LGG	cis	rs208520	1.000	rs72882079	chr6:66973878	T/C	cg07460842	chr6:66804631	NA	0.9	14.83	0.57	5.65e-41	Exhaled nitric oxide output;
LGG	cis	rs35264875	1.000	rs35264875	chr11:68846399	A/T	cg23740940	chr11:68924746	NA	0.44	6.96	0.31	1.16e-11	Blond vs. brown hair color;
LGG	cis	rs2075371	1.000	rs2241334	chr7:133979225	C/G	cg11752832	chr7:134001865	SLC35B4	0.61	11.25	0.46	4.18e-26	Mean platelet volume;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.78	0.3	3.73e-11	Lung cancer;
LGG	cis	rs8005677	0.828	rs12437151	chr14:23372913	G/A	cg25600027	chr14:23388339	RBM23	-0.44	-7.4	-0.33	6.52e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg10167378	chr1:228756711	NA	0.7	9.46	0.4	1.5700000000000001e-19	Chronic lymphocytic leukemia;
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg16507663	chr6:150244633	RAET1G	0.46	8.76	0.38	3.73e-17	Lung cancer;
LGG	cis	rs62238980	0.614	rs77661466	chr22:32520016	A/G	cg00543991	chr22:32367038	NA	0.78	8.47	0.37	3.26e-16	Childhood ear infection;
LGG	cis	rs9910055	0.659	rs227578	chr17:42210189	C/A	cg08499158	chr17:42289980	UBTF	0.55	10.37	0.43	8.78e-23	Total body bone mineral density;
LGG	cis	rs10479542	0.806	rs4700836	chr5:178976393	A/G	cg09060608	chr5:178986726	RUFY1	0.47	8.33	0.36	9.28e-16	Lung cancer;
LGG	cis	rs453301	0.562	rs1038248	chr8:9040858	G/T	cg06636001	chr8:8085503	FLJ10661	-0.37	-6.76	-0.3	4.08e-11	Joint mobility (Beighton score);
LGG	cis	rs2836974	0.897	rs8132568	chr21:40527916	C/T	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs2028299	0.920	rs4932265	chr15:90423293	T/C	cg23731826	chr15:90371692	NA	0.35	7.78	0.34	4.84e-14	Type 2 diabetes;
LGG	cis	rs975739	0.872	rs914913	chr13:78364029	T/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.8	0.3	3.26e-11	Hair color;
LGG	cis	rs9394152	0.845	rs9394153	chr6:33471630	A/C	cg13560919	chr6:33536144	NA	0.68	12.45	0.5	6.75e-31	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg20913747	chr6:44695427	NA	-0.65	-10.93	-0.45	6.59e-25	Total body bone mineral density;
LGG	cis	rs7811142	1.000	rs4472444	chr7:100070758	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.93	0.66	1.25e-59	Platelet count;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg11584989	chr19:19387371	SF4	0.47	8.22	0.36	2.1e-15	Tonsillectomy;
LGG	cis	rs7647973	0.710	rs6446284	chr3:49616997	A/G	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	trans	rs11098499	0.863	rs3822191	chr4:120428101	A/T	cg25214090	chr10:38739885	LOC399744	0.65	11.4	0.47	1.02e-26	Corneal astigmatism;
LGG	cis	rs13108904	0.936	rs4974540	chr4:1213463	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.62	10.61	0.44	1.1e-23	Obesity-related traits;
LGG	cis	rs2013441	1.000	rs2703815	chr17:20118499	C/T	cg13482628	chr17:19912719	NA	0.5	9.23	0.39	9.44e-19	Obesity-related traits;
LGG	trans	rs747782	0.582	rs7949865	chr11:48346202	A/C	cg03929089	chr4:120376271	NA	-0.69	-8.25	-0.36	1.62e-15	Intraocular pressure;
LGG	cis	rs6502050	0.871	rs6502055	chr17:80070868	G/T	cg23985595	chr17:80112537	CCDC57	0.47	9.47	0.4	1.49e-19	Life satisfaction;
LGG	cis	rs10911251	0.546	rs20560	chr1:183105534	T/C	cg15522984	chr1:182991683	LAMC1	0.43	8.45	0.37	3.83e-16	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs1043127	chr17:61791210	T/G	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	cis	rs1506636	1.000	rs2429617	chr7:123418027	A/G	cg03229431	chr7:123269106	ASB15	0.73	17.88	0.64	9.97e-55	Plateletcrit;Platelet count;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs11792861	0.816	rs72607157	chr9:111748001	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.98	0.42	2.26e-21	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs7307583	chr12:34521711	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	trans	rs3206736	0.556	rs1649235	chr7:35003882	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.3	0.32	1.28e-12	Diastolic blood pressure;
LGG	cis	rs72615157	0.634	rs74742883	chr7:99785765	T/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.74	10.75	0.45	3.17e-24	Lung function (FEV1/FVC);
LGG	cis	rs67366981	1.000	rs67366981	chr14:77703964	T/C	cg22824376	chr14:77648248	TMEM63C	0.7	7.45	0.33	4.76e-13	Obsessive-compulsive symptoms;
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg13628971	chr7:2884303	GNA12	0.51	10.54	0.44	1.98e-23	Height;
LGG	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs2245008	0.950	rs824400	chr16:83989936	C/G	cg03891598	chr16:83986782	OSGIN1	-0.55	-8.42	-0.36	4.72e-16	Pursuit maintenance gain;
LGG	cis	rs12477438	0.765	rs4851183	chr2:99629149	G/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs1008375	0.932	rs4698629	chr4:17608884	C/G	cg02297831	chr4:17616191	MED28	0.5	8.84	0.38	2.01e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7681440	0.904	rs1442153	chr4:90775719	T/G	cg20003494	chr4:90757398	SNCA	-0.42	-8.38	-0.36	6.58e-16	Dementia with Lewy bodies;
LGG	cis	rs721399	0.512	rs4560828	chr8:18276294	A/T	cg18736775	chr8:18248649	NAT2	-0.71	-10.54	-0.44	1.98e-23	Blood metabolite levels;
LGG	cis	rs4918072	0.667	rs4439443	chr10:105704814	G/T	cg11005552	chr10:105648138	OBFC1	0.47	8.28	0.36	1.37e-15	Coronary artery disease;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.59	10.06	0.42	1.15e-21	Obesity-related traits;
LGG	cis	rs12618769	0.652	rs4851146	chr2:99237439	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.67	0.34	1.01e-13	Bipolar disorder;
LGG	cis	rs1878931	0.501	rs4785934	chr16:3419934	G/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.8	13.8	0.54	1.59e-36	Body mass index (adult);
LGG	cis	rs66573146	0.572	rs73199995	chr4:6955801	G/C	cg26116260	chr4:7069785	GRPEL1	-0.83	-8.53	-0.37	2.12e-16	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7811142	1.000	rs2406255	chr7:100053690	T/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.25	0.69	9.45e-66	Platelet count;
LGG	cis	rs1915146	0.656	rs10794201	chr10:126846531	C/T	cg05090351	chr10:126851162	NA	0.3	6.75	0.3	4.34e-11	Menarche (age at onset);
LGG	cis	rs17376456	0.542	rs2043979	chr5:93120782	T/A	cg25358565	chr5:93447407	FAM172A	-0.67	-9.25	-0.4	8.01e-19	Diabetic retinopathy;
LGG	trans	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg21659725	chr3:3221576	CRBN	-0.62	-9.9	-0.42	4.39e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs250677	0.687	rs250663	chr5:148453117	T/C	cg18129178	chr5:148520854	ABLIM3	-0.45	-7.39	-0.32	6.84e-13	Breast cancer;
LGG	cis	rs4727027	0.754	rs11764892	chr7:148858916	G/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.6	8.84	0.38	2.01e-17	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs6582630	0.555	rs12372536	chr12:38400864	C/G	cg06521331	chr12:34319734	NA	-0.51	-8.89	-0.38	1.39e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10857712	1.000	rs10857712	chr10:135225666	T/C	cg00491522	chr10:135256596	NA	0.46	7.31	0.32	1.2e-12	Systemic lupus erythematosus;
LGG	cis	rs12928939	0.815	rs12448022	chr16:71724369	T/C	cg03805757	chr16:71968109	PKD1L3	-0.49	-9.34	-0.4	4.08e-19	Post bronchodilator FEV1;
LGG	cis	rs2188561	0.697	rs6947099	chr7:107360916	G/C	cg16793755	chr7:107334138	SLC26A4	0.42	7.3	0.32	1.29e-12	Alcohol consumption;
LGG	cis	rs7998202	0.667	rs282577	chr13:113358838	G/A	cg17218041	chr13:113365319	ATP11A	-0.41	-6.88	-0.3	1.96e-11	Glycated hemoglobin levels;
LGG	trans	rs9650657	0.801	rs718741	chr8:10614384	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.1	-0.31	4.87e-12	Neuroticism;
LGG	cis	rs1620921	0.657	rs13203427	chr6:161275892	G/A	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs1865760	1.000	rs9467636	chr6:25919549	A/C	cg12310025	chr6:25882481	NA	-0.43	-7.78	-0.34	4.69e-14	Height;
LGG	cis	rs7572733	0.967	rs10166845	chr2:198896071	A/G	cg00792783	chr2:198669748	PLCL1	0.44	7.44	0.33	5.01e-13	Dermatomyositis;
LGG	cis	rs4243971	0.516	rs4911232	chr20:31029615	G/C	cg00028034	chr20:30779307	TSPYL3	0.32	6.69	0.3	6.49e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7106204	0.534	rs113048476	chr11:24257588	T/C	ch.11.24196551F	chr11:24239977	NA	0.84	8.57	0.37	1.54e-16	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg19233923	chr11:63753598	OTUB1	-0.47	-6.87	-0.3	2.02e-11	Systemic lupus erythematosus;
LGG	cis	rs11105298	0.891	rs4842661	chr12:89930399	A/G	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.31	-0.4	5.11e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs12421382	0.576	rs116158609	chr11:109389358	T/A	cg06719900	chr11:109292894	C11orf87	0.45	8.62	0.37	1.05e-16	Schizophrenia;
LGG	trans	rs9858542	0.953	rs67216675	chr3:49493151	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.56	-0.37	1.69e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs8177253	0.665	rs11921527	chr3:133441167	G/A	cg08048268	chr3:133502702	NA	-0.45	-7.84	-0.34	3.09e-14	Iron status biomarkers;
LGG	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg27490568	chr2:178487706	NA	0.85	15.14	0.58	2.3e-42	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9354308	0.764	rs9345714	chr6:66596523	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs9354308	0.702	rs2351716	chr6:66585927	A/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs853679	0.607	rs13208096	chr6:28225311	C/G	cg06606381	chr12:133084897	FBRSL1	-1.31	-12.52	-0.5	3.58e-31	Depression;
LGG	trans	rs2562456	0.833	rs55790393	chr19:21506184	A/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.43	-0.33	5.29e-13	Pain;
LGG	cis	rs7618915	0.501	rs3733039	chr3:52719088	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.91	0.35	1.87e-14	Bipolar disorder;
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.51	0.4	1.07e-19	Height;
LGG	cis	rs2180341	1.000	rs6569482	chr6:127631371	C/T	cg27446573	chr6:127587934	RNF146	1.13	22.42	0.72	6.49e-76	Breast cancer;
LGG	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg07936489	chr17:37558343	FBXL20	1.0	15.66	0.59	1.21e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs3806843	0.966	rs1030166	chr5:140185473	G/A	cg19875535	chr5:140030758	IK	0.5	10.34	0.43	1.13e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs899997	1.000	rs11629824	chr15:79005524	T/G	cg17734273	chr15:78292508	TBC1D2B	-0.35	-8.46	-0.37	3.47e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg23825213	chr18:77623475	KCNG2	-0.4	-7.17	-0.32	3.04e-12	Schizophrenia;
LGG	cis	rs9527	0.668	rs7092815	chr10:104736345	G/T	cg05308233	chr10:104796373	CNNM2	-0.31	-6.73	-0.3	5.12e-11	Arsenic metabolism;
LGG	cis	rs951366	0.789	rs823095	chr1:205679239	G/A	cg07167872	chr1:205819463	PM20D1	0.57	11.47	0.47	5.62e-27	Menarche (age at onset);
LGG	cis	rs9814567	1.000	rs11708531	chr3:134224902	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.35e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs12476592	0.602	rs6546004	chr2:63639529	T/C	cg17519650	chr2:63277830	OTX1	-0.5	-7.61	-0.33	1.52e-13	Childhood ear infection;
LGG	cis	rs6462411	0.938	rs1962783	chr7:3920544	C/G	cg18022346	chr7:3920534	SDK1	-0.37	-7.17	-0.32	2.89e-12	Quantitative traits;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg20102877	chr2:27665638	KRTCAP3	-0.29	-6.65	-0.3	8.46e-11	Total body bone mineral density;
LGG	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg06886374	chr16:1844152	IGFALS	-0.44	-8.04	-0.35	7.31e-15	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs61931739	0.544	rs6488163	chr12:33599127	C/T	cg26384229	chr12:38710491	ALG10B	-0.45	-7.93	-0.35	1.69e-14	Morning vs. evening chronotype;
LGG	cis	rs972578	0.691	rs56013521	chr22:43360681	T/C	cg01576275	chr22:43409880	NA	-0.24	-7.23	-0.32	2.02e-12	Mean platelet volume;
LGG	cis	rs13108904	0.875	rs1732099	chr4:1282696	T/C	cg16405210	chr4:1374714	KIAA1530	0.51	8.66	0.37	7.91e-17	Obesity-related traits;
LGG	cis	rs6500395	0.963	rs6500405	chr16:48690486	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28530618	0.603	rs11697988	chr20:31248176	C/G	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.73	-0.3	5.14e-11	Birth weight;
LGG	trans	rs6076960	0.684	rs3844461	chr20:6253115	G/A	cg17788362	chr6:86352627	SYNCRIP	0.55	9.66	0.41	3.12e-20	Smooth-surface caries;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.07	0.35	6.1e-15	Prudent dietary pattern;
LGG	cis	rs56283067	0.578	rs12201563	chr6:45359394	T/C	cg18551225	chr6:44695536	NA	-0.59	-8.65	-0.37	8.74e-17	Total body bone mineral density;
LGG	cis	rs17345786	1.000	rs17345786	chr3:101318318	A/C	cg12386194	chr3:101231763	SENP7	-0.69	-11.98	-0.49	5.17e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs740474	0.544	rs2299024	chr5:140880765	G/C	cg00076195	chr5:140892677	NA	0.38	6.96	0.31	1.19e-11	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs6956675	1.000	rs7801458	chr7:62597651	A/G	cg01314568	chr7:57830625	NA	-0.51	-8.16	-0.35	3.19e-15	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs8067064	chr17:61825984	A/C	cg17202724	chr17:61916730	SMARCD2	-0.42	-8.47	-0.37	3.28e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3768617	0.510	rs1413389	chr1:183096668	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6951245	1.000	rs80094748	chr7:1103958	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	13.85	0.54	9.72e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2354432	0.660	rs10751415	chr1:146830785	T/A	cg25205988	chr1:146714368	CHD1L	1.21	12.45	0.5	7.04e-31	Mitochondrial DNA levels;
LGG	cis	rs12950390	0.548	rs7215477	chr17:45858117	A/C	cg03474202	chr17:45855739	NA	-0.22	-6.88	-0.3	1.97e-11	IgG glycosylation;
LGG	cis	rs1008375	1.000	rs7654345	chr4:17691796	A/G	cg16339924	chr4:17578868	LAP3	0.51	8.52	0.37	2.23e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs947211	0.898	rs1775146	chr1:205756168	A/G	cg14159672	chr1:205819179	PM20D1	0.45	7.09	0.31	5.12e-12	Parkinson's disease;
LGG	trans	rs453301	0.522	rs2929309	chr8:9083771	C/A	cg02002194	chr4:3960332	NA	0.44	8.41	0.36	5.28e-16	Joint mobility (Beighton score);
LGG	cis	rs7914558	0.966	rs10786725	chr10:104682357	T/C	cg04362960	chr10:104952993	NT5C2	0.53	10.02	0.42	1.58e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs17818399	0.620	rs6739397	chr2:46858321	G/C	cg26688816	chr2:46740690	ATP6V1E2	-0.44	-7.94	-0.35	1.6e-14	Height;
LGG	cis	rs798554	0.836	rs2260230	chr7:2822986	T/A	cg18446336	chr7:2847575	GNA12	-0.29	-6.92	-0.31	1.56e-11	Height;
LGG	cis	rs2361718	0.933	rs8066452	chr17:78104080	A/G	cg27427491	chr17:78079615	GAA	-0.3	-7.84	-0.34	3.23e-14	Yeast infection;
LGG	cis	rs6752107	0.967	rs12162308	chr2:234172188	C/G	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.43	7.99	0.35	1.05e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs79349575	0.783	rs59270107	chr17:47026185	A/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.32	0.36	9.75e-16	Type 2 diabetes;
LGG	cis	rs9814567	1.000	rs9854299	chr3:134206728	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.26	-0.52	3.18e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7635838	0.687	rs9849485	chr3:11395741	G/A	cg00170343	chr3:11313890	ATG7	0.49	8.56	0.37	1.73e-16	HDL cholesterol;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.01	-0.46	3.25e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	0.958	rs12215232	chr6:86785430	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.58	-9.55	-0.41	7.43e-20	Response to antipsychotic treatment;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg00424166	chr6:150045504	NUP43	-0.36	-7.37	-0.32	7.84e-13	Lung cancer;
LGG	cis	rs3540	0.514	rs2601194	chr15:90937051	T/A	cg22089800	chr15:90895588	ZNF774	0.71	12.99	0.52	4.05e-33	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs526231	0.578	rs6860588	chr5:102280302	A/G	cg23492399	chr5:102201601	PAM	0.6	9.29	0.4	6.14e-19	Primary biliary cholangitis;
LGG	cis	rs546131	0.642	rs523246	chr11:34845011	C/G	cg06937548	chr11:34938143	PDHX;APIP	0.43	7.03	0.31	7.36e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	ch.12.31424680R	chr12:31533413	NA	-0.43	-6.66	-0.3	7.82e-11	Systemic lupus erythematosus;
LGG	cis	rs752010	1.000	rs6656183	chr1:42094025	A/G	cg06885757	chr1:42089581	HIVEP3	0.57	12.96	0.52	5.58e-33	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6951245	1.000	rs79422648	chr7:1080241	T/C	cg18402987	chr7:1209562	NA	0.67	9.33	0.4	4.57e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg11878867	chr6:150167359	LRP11	-0.53	-11.15	-0.46	9.69e-26	Lung cancer;
LGG	cis	rs28386778	0.897	rs9913323	chr17:61851485	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.3	0.5	2.77e-30	Prudent dietary pattern;
LGG	cis	rs7953249	0.656	rs6489786	chr12:121397875	A/G	cg02403541	chr12:121454288	C12orf43	-0.54	-8.93	-0.38	1.04e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	trans	rs8073060	0.702	rs7221322	chr17:33873772	A/G	cg19694781	chr19:47549865	TMEM160	0.55	9.09	0.39	3.02e-18	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9296092	0.538	rs62405943	chr6:33517359	A/G	cg13560919	chr6:33536144	NA	-1.05	-21.67	-0.71	2.07e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs8031584	0.958	rs3512	chr15:31235005	G/C	cg08109568	chr15:31115862	NA	-0.54	-9.52	-0.4	9.67e-20	Huntington's disease progression;
LGG	cis	rs17767392	0.670	rs61991192	chr14:71742923	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.35	-8.05	-0.35	7.19e-15	Mitral valve prolapse;
LGG	cis	rs6138458	0.717	rs2179732	chr20:25000446	A/T	cg26195577	chr20:24973756	C20orf3	0.93	17.27	0.63	5.77e-52	Blood protein levels;
LGG	cis	rs1862618	0.853	rs1423620	chr5:56100996	G/T	cg17809284	chr5:56205270	C5orf35	-0.49	-8.01	-0.35	9.48e-15	Initial pursuit acceleration;
LGG	cis	rs1707322	1.000	rs4489497	chr1:46438698	C/T	cg03146154	chr1:46216737	IPP	0.52	9.86	0.42	6.11e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg18402987	chr7:1209562	NA	0.62	6.91	0.31	1.64e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7786808	0.741	rs11765319	chr7:158226790	A/G	cg02030672	chr11:45687055	CHST1	0.47	8.43	0.36	4.35e-16	Obesity-related traits;
LGG	cis	rs9341835	0.681	rs9352960	chr6:64150426	C/G	cg00787780	chr6:64151745	NA	0.41	7.57	0.33	2.07e-13	Schizophrenia;
LGG	cis	rs4604732	0.578	rs12040725	chr1:247644697	T/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.68	10.61	0.44	1.12e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs7923837	1.000	rs4933736	chr10:94471595	C/T	cg25093409	chr10:94429542	NA	0.39	7.18	0.32	2.71e-12	Body mass index;Multiple sclerosis;
LGG	cis	rs13191362	0.507	rs13207363	chr6:163201285	C/G	cg06582575	chr6:163149167	PACRG;PARK2	-0.52	-7.19	-0.32	2.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2885056	0.699	rs34275421	chr19:10644812	T/A	cg08312369	chr19:10679775	CDKN2D	-0.48	-6.65	-0.3	8.42e-11	Red cell distribution width;
LGG	cis	rs1799949	0.929	rs12937015	chr17:41307473	A/C	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs10435719	0.902	rs7006538	chr8:11804982	A/G	cg21775007	chr8:11205619	TDH	0.43	6.84	0.3	2.46e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs6908034	0.660	rs74457659	chr6:19760725	C/T	cg02682789	chr6:19804855	NA	0.93	7.97	0.35	1.22e-14	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs2635047	0.713	rs8086549	chr18:44756421	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.48	-7.83	-0.34	3.3e-14	Educational attainment;
LGG	cis	rs2290405	1.000	rs2290405	chr4:946974	A/G	cg04824913	chr4:887549	GAK	-0.61	-11.74	-0.48	4.87e-28	Systemic sclerosis;
LGG	trans	rs2243480	1.000	rs34637256	chr7:65360131	G/A	cg10756647	chr7:56101905	PSPH	0.84	10.22	0.43	3.08e-22	Diabetic kidney disease;
LGG	cis	rs2916247	1.000	rs7833370	chr8:93066653	C/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs61077902	chr3:10126153	T/G	cg16606324	chr3:10149918	C3orf24	0.54	7.17	0.32	2.9e-12	Alzheimer's disease;
LGG	cis	rs2304069	0.954	rs10068537	chr5:149403193	G/A	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.86	12.98	0.52	4.5e-33	HIV-1 control;
LGG	cis	rs7659604	0.676	rs6534323	chr4:122695888	G/A	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.3	-0.47	2.52e-26	Type 2 diabetes;
LGG	cis	rs7829975	0.510	rs332037	chr8:8722675	C/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.31	0.4	5.26e-19	Mood instability;
LGG	cis	rs7219021	0.705	rs2270576	chr17:47007963	C/T	cg16584676	chr17:46985605	UBE2Z	-0.42	-6.92	-0.31	1.48e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs9611519	0.566	rs4821981	chr22:41415644	A/C	cg03806693	chr22:41940476	POLR3H	0.47	7.81	0.34	3.94e-14	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01773951	chr1:247094386	AHCTF1	0.46	6.85	0.3	2.39e-11	Gut microbiome composition (summer);
LGG	cis	rs35306767	0.807	rs34982663	chr10:852521	C/G	cg20503657	chr10:835505	NA	0.92	12.31	0.5	2.45e-30	Eosinophil percentage of granulocytes;
LGG	cis	rs9291683	0.530	rs11723970	chr4:9980462	T/C	cg11266682	chr4:10021025	SLC2A9	0.48	9.45	0.4	1.68e-19	Bone mineral density;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs59071610	chr8:58186301	A/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.558	rs2968	chr21:47608580	C/T	cg05896524	chr21:47604654	C21orf56	-0.66	-11.21	-0.46	5.51e-26	Testicular germ cell tumor;
LGG	trans	rs208520	0.526	rs9294682	chr6:66795159	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.14	-31.9	-0.83	6.05e-119	Exhaled nitric oxide output;
LGG	cis	rs9354308	0.764	rs2000386	chr6:66597937	C/G	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs7926971	0.729	rs5016300	chr11:12659464	G/A	cg25843174	chr11:12811716	TEAD1	0.32	6.88	0.3	1.99e-11	Height;
LGG	cis	rs7169223	0.653	rs3743057	chr15:79089007	T/C	cg03762349	chr15:79060523	ADAMTS7	-0.36	-6.96	-0.31	1.15e-11	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg20308403	chr7:2120281	MAD1L1	0.34	7.28	0.32	1.47e-12	Schizophrenia;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg13206674	chr6:150067644	NUP43	0.67	15.7	0.59	8.04e-45	Lung cancer;
LGG	trans	rs7726839	0.540	rs58599998	chr5:596087	A/G	cg25482853	chr8:67687455	SGK3	0.95	12.17	0.49	9.15e-30	Obesity-related traits;
LGG	cis	rs8180040	1.000	rs2159400	chr3:47375890	T/C	cg16586182	chr3:47516702	SCAP	0.78	15.39	0.58	1.85e-43	Colorectal cancer;
LGG	cis	rs35146811	0.771	rs1060544	chr7:99613476	C/T	cg13334819	chr7:99746414	C7orf59	-0.46	-7.08	-0.31	5.33e-12	Coronary artery disease;
LGG	cis	rs17208368	0.628	rs12444201	chr16:55093998	A/G	cg11181171	chr16:55090946	NA	-0.46	-7.71	-0.34	7.7e-14	Hypospadias;
LGG	cis	rs1799949	1.000	rs4793229	chr17:41418334	C/T	cg18379455	chr17:41446167	NA	0.32	7.59	0.33	1.77e-13	Menopause (age at onset);
LGG	cis	rs6089584	0.893	rs6089306	chr20:60574868	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-16.54	-0.61	1.27e-48	Body mass index;
LGG	cis	rs11671005	0.735	rs11666303	chr19:58922502	T/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.78	-0.3	3.76e-11	Mean platelet volume;
LGG	cis	rs12282928	0.885	rs10838874	chr11:48347140	T/C	cg26585981	chr11:48327164	OR4S1	0.46	7.5	0.33	3.19e-13	Migraine - clinic-based;
LGG	cis	rs4740619	0.619	rs11788695	chr9:16032323	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.98	-0.45	4.45e-25	Body mass index;
LGG	cis	rs875971	0.798	rs12698522	chr7:65967341	T/C	cg11764359	chr7:65958608	NA	0.74	13.25	0.52	3.26e-34	Aortic root size;
LGG	cis	rs4684776	0.867	rs2305686	chr3:11350553	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.58	-0.37	1.4e-16	Small vessel stroke;
LGG	cis	rs3020736	0.500	rs6002616	chr22:42504679	A/G	cg04733989	chr22:42467013	NAGA	-0.59	-10.64	-0.44	8.35e-24	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9467773	0.967	rs9358954	chr6:26531178	A/G	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg16301924	chr13:53314226	LECT1	-0.43	-8.14	-0.35	3.77e-15	Lewy body disease;
LGG	cis	rs10504229	1.000	rs72650887	chr8:58177343	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs228437	1.000	rs1535118	chr6:134912447	C/T	cg24504307	chr6:134963096	NA	0.41	7.78	0.34	4.9e-14	Melanoma;
LGG	cis	rs7000551	0.751	rs2469775	chr8:22373238	T/C	cg12081754	chr8:22256438	SLC39A14	0.63	11.81	0.48	2.56e-28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs2665103	0.655	rs1501367	chr15:82522816	A/G	cg00614314	chr15:82944287	LOC80154	0.47	7.82	0.34	3.67e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg06074448	chr4:187884817	NA	0.59	12.6	0.51	1.69e-31	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs853679	1.000	rs68141011	chr6:28217797	G/T	cg08344181	chr3:125677491	NA	-0.57	-7.42	-0.33	5.63e-13	Depression;
LGG	cis	rs7712401	0.601	rs425573	chr5:122326008	G/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	cis	rs994014	0.640	rs7670007	chr4:82191458	C/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.44	-0.33	5.05e-13	Height;
LGG	cis	rs7937682	0.632	rs3944619	chr11:111774743	A/G	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs9916302	0.595	rs4795371	chr17:37636695	T/G	cg07936489	chr17:37558343	FBXL20	-0.84	-15.48	-0.58	7.62e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs17030434	0.784	rs67664355	chr4:154660229	A/G	cg14289246	chr4:154710475	SFRP2	-0.56	-9.55	-0.41	7.33e-20	Electrocardiographic conduction measures;
LGG	trans	rs2727020	0.576	rs1917321	chr11:49377760	A/C	cg15704280	chr7:45808275	SEPT13	-0.71	-12.96	-0.52	5.4e-33	Coronary artery disease;
LGG	cis	rs6977660	1.000	rs12672557	chr7:19804237	G/A	cg07541023	chr7:19748670	TWISTNB	0.45	6.88	0.3	1.95e-11	Thyroid stimulating hormone;
LGG	trans	rs2243480	1.000	rs4718334	chr7:65789454	G/A	cg10756647	chr7:56101905	PSPH	-0.82	-9.77	-0.41	1.28e-20	Diabetic kidney disease;
LGG	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg03517284	chr6:25882590	NA	-0.44	-7.09	-0.31	4.94e-12	Iron status biomarkers;
LGG	cis	rs8060686	0.641	rs1125331	chr16:68228119	T/C	cg27539214	chr16:67997921	SLC12A4	-0.47	-7.31	-0.32	1.2e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.32	0.32	1.08e-12	Menopause (age at onset);
LGG	cis	rs8114671	0.562	rs2064454	chr20:33496169	C/T	cg24642439	chr20:33292090	TP53INP2	0.46	7.11	0.31	4.46e-12	Height;
LGG	cis	rs4820539	1.000	rs916584	chr22:23469433	A/G	cg21100191	chr22:23484243	RTDR1	0.99	22.71	0.73	2.84e-77	Bone mineral density;
LGG	cis	rs72960926	1.000	rs11756290	chr6:75093529	A/G	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs4650994	0.816	rs2209169	chr1:178601492	C/T	cg12486710	chr1:178512616	C1orf220	-0.41	-8.34	-0.36	8.46e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs763014	0.966	rs12935215	chr16:670605	T/C	cg04709771	chr16:646395	RAB40C	0.36	6.67	0.3	7.48e-11	Height;
LGG	cis	rs2734839	0.964	rs2234690	chr11:113291748	T/A	cg14159747	chr11:113255604	NA	0.27	7.25	0.32	1.77e-12	Information processing speed;
LGG	cis	rs2033711	0.870	rs3764534	chr19:58929136	G/A	cg13877915	chr19:58951672	ZNF132	1.0	26.81	0.78	2.99e-96	Uric acid clearance;
LGG	cis	rs9322193	0.923	rs12529698	chr6:149972087	G/A	cg02462569	chr6:150064036	NUP43	-0.41	-8.78	-0.38	3.15e-17	Lung cancer;
LGG	cis	rs1790761	0.900	rs1638564	chr11:67223920	C/G	cg24690094	chr11:67383802	NA	-0.4	-7.01	-0.31	8.38e-12	Mean corpuscular volume;
LGG	cis	rs13177180	0.671	rs10077239	chr5:114960881	T/C	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.43	-9.5	-0.4	1.1e-19	Conotruncal heart defects (inherited effects);
LGG	cis	rs7172677	0.768	rs72730587	chr15:75358053	A/G	cg14664628	chr15:75095509	CSK	0.61	10.19	0.43	4e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9916302	0.904	rs12952384	chr17:37669536	T/C	cg00129232	chr17:37814104	STARD3	-0.61	-11.54	-0.47	3.07e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs4696584	1.000	rs4696213	chr4:155396442	G/C	cg13738195	chr4:155413469	DCHS2	0.37	7.5	0.33	3.18e-13	Folding of antihelix;
LGG	cis	rs1401999	1.000	rs13317532	chr3:183641669	G/C	cg20387954	chr3:183756860	HTR3D	0.66	13.46	0.53	4.58e-35	Anterior chamber depth;
LGG	cis	rs62244186	0.659	rs4431151	chr3:44510906	G/C	cg02073558	chr3:44770973	ZNF501	0.68	12.51	0.5	4.03e-31	Depressive symptoms;
LGG	cis	rs79349575	0.783	rs62075852	chr17:47017176	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.95	0.31	1.26e-11	Type 2 diabetes;
LGG	cis	rs9457247	1.000	rs364283	chr6:167383750	C/T	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs7106204	0.514	rs1443043	chr11:24251991	A/G	ch.11.24196551F	chr11:24239977	NA	0.96	14.64	0.56	3.89e-40	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11239187	0.530	rs10159976	chr10:45059905	A/G	cg03916630	chr10:45065415	NA	0.35	8.63	0.37	9.94e-17	Body mass index;
LGG	cis	rs8064024	0.582	rs2660241	chr16:4940023	T/C	cg04440724	chr16:4920505	UBN1	-0.51	-10.01	-0.42	1.7e-21	Cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16344026	chr5:149109979	PPARGC1B	0.51	8.34	0.36	8.6e-16	Cognitive performance;
LGG	cis	rs7572733	0.534	rs6760891	chr2:198768166	T/G	cg00792783	chr2:198669748	PLCL1	0.69	11.19	0.46	7.05e-26	Dermatomyositis;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg11062466	chr8:58055876	NA	0.61	9.78	0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs4698648	chr4:17692715	C/G	cg18681998	chr4:17616180	MED28	0.73	14.74	0.57	1.35e-40	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17014483	0.749	rs2924934	chr4:89628242	G/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.62	7.06	0.31	5.96e-12	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7010267	0.551	rs6469801	chr8:120025675	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.34	8.77	0.38	3.4e-17	Total body bone mineral density (age 45-60);
LGG	cis	rs1665650	0.957	rs1620936	chr10:118493945	A/G	cg14919929	chr10:118506882	NA	0.49	8.59	0.37	1.36e-16	Colorectal cancer;
LGG	cis	rs6728642	1.000	rs57035274	chr2:97608124	C/A	cg26665480	chr2:98280029	ACTR1B	-0.71	-7.59	-0.33	1.73e-13	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs6142618	0.562	rs6141277	chr20:30831157	G/C	cg00028034	chr20:30779307	TSPYL3	0.37	7.99	0.35	1.04e-14	Inflammatory bowel disease;
LGG	cis	rs9951602	0.512	rs7237214	chr18:76657394	C/G	cg24134504	chr18:76639479	NA	-0.48	-8.4	-0.36	5.44e-16	Obesity-related traits;
LGG	cis	rs67460515	0.892	rs11710489	chr3:161093332	G/A	cg03342759	chr3:160939853	NMD3	-0.72	-12.77	-0.51	3.37e-32	Parkinson's disease;
LGG	trans	rs9388451	0.839	rs3799711	chr6:126075313	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.52	9.51	0.4	1.06e-19	Brugada syndrome;
LGG	cis	rs2576037	0.526	rs9304340	chr18:44526582	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.14	-0.35	3.6e-15	Personality dimensions;
LGG	cis	rs3020736	0.500	rs2413669	chr22:42507748	A/C	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9916302	0.904	rs9892055	chr17:37510402	C/T	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs10752881	0.905	rs12132262	chr1:182989949	T/A	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	cis	rs9527	0.590	rs2281877	chr10:104866062	C/T	cg04362960	chr10:104952993	NT5C2	0.55	10.32	0.43	1.3e-22	Arsenic metabolism;
LGG	cis	rs721917	0.506	rs2254013	chr10:81658448	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs9611565	0.512	rs139573	chr22:42214785	G/A	cg03806693	chr22:41940476	POLR3H	-1.04	-17.54	-0.63	3.45e-53	Vitiligo;
LGG	cis	rs6743376	0.509	rs3180234	chr2:113820655	A/T	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs7618501	0.521	rs952594	chr3:49908023	G/A	cg05623727	chr3:50126028	RBM5	0.41	8.88	0.38	1.45e-17	Intelligence (multi-trait analysis);
LGG	cis	rs270601	0.913	rs273899	chr5:131695178	G/A	cg07395648	chr5:131743802	NA	-0.48	-9.89	-0.42	4.88e-21	Acylcarnitine levels;
LGG	cis	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg11663600	chr3:49941416	MST1R	0.23	6.67	0.3	7.29e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg01043669	chr3:72786069	NA	0.43	7.12	0.31	4.25e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg01570182	chr17:44337453	NA	0.73	12.41	0.5	1e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8072100	0.676	rs9905308	chr17:45409386	T/A	cg25173405	chr17:45401733	C17orf57	-0.64	-10.94	-0.45	5.98e-25	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs12579753	0.872	rs12319937	chr12:82182545	T/G	cg07988820	chr12:82153109	PPFIA2	-0.74	-10.86	-0.45	1.29e-24	Resting heart rate;
LGG	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg04662567	chr6:169592167	NA	0.85	14.29	0.55	1.29e-38	Pulse pressure;
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg08017756	chr2:100939284	LONRF2	-0.29	-6.66	-0.3	8.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4969178	0.832	rs4969185	chr17:76398157	G/C	cg05887092	chr17:76393375	PGS1	0.72	15.71	0.59	6.58e-45	HDL cholesterol levels;
LGG	cis	rs3820928	0.874	rs9288618	chr2:227872617	A/G	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.76	-0.34	5.63e-14	Pulmonary function;
LGG	cis	rs2228479	0.850	rs1108063	chr16:89893983	A/G	cg06558623	chr16:89946397	TCF25	1.19	12.96	0.52	5.41e-33	Skin colour saturation;
LGG	cis	rs10479542	0.721	rs6894113	chr5:178974789	G/C	cg21226059	chr5:178986404	RUFY1	0.47	8.65	0.37	8.39e-17	Lung cancer;
LGG	cis	rs988958	0.637	rs67710195	chr2:42219378	G/C	cg19376973	chr2:42229025	NA	0.64	10.09	0.42	8.83e-22	Hypospadias;
LGG	cis	rs1065656	0.581	rs344353	chr16:1846636	C/G	cg14074117	chr16:1909714	C16orf73	0.48	6.87	0.3	2.05e-11	Insulin-like growth factors;
LGG	trans	rs208520	1.000	rs12191403	chr6:66978137	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.23	0.55	2.23e-38	Exhaled nitric oxide output;
LGG	cis	rs6838801	0.823	rs7691621	chr4:77589959	A/G	cg17476223	chr4:77663285	SHROOM3	0.38	6.77	0.3	4.01e-11	Cleft lip with or without cleft palate;
LGG	trans	rs12517041	0.938	rs10037500	chr5:23270158	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	0.6	8.9	0.38	1.31e-17	Calcium levels;
LGG	cis	rs727505	0.754	rs55723877	chr7:124780899	T/A	cg23710748	chr7:124431027	NA	-0.44	-8.5	-0.37	2.64e-16	Lewy body disease;
LGG	cis	rs6539288	0.677	rs2287163	chr12:107349294	C/T	cg26297688	chr12:107349093	C12orf23	-0.39	-7.4	-0.33	6.65e-13	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs12944597	chr17:41187684	A/C	cg05368731	chr17:41323189	NBR1	0.96	18.12	0.64	7.07e-56	Menopause (age at onset);
LGG	cis	rs7824557	0.628	rs7008205	chr8:11197323	T/G	cg15596359	chr8:11213517	TDH	-0.4	-8.24	-0.36	1.81e-15	Retinal vascular caliber;
LGG	trans	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg27349345	chr7:35225932	NA	-0.52	-7.42	-0.33	5.67e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2718058	0.601	rs2709104	chr7:37762810	A/G	cg15028436	chr7:37888078	TXNDC3	-0.57	-8.94	-0.38	9.18e-18	Alzheimer's disease (late onset);
LGG	cis	rs6032067	0.777	rs13039211	chr20:43784396	C/T	cg10761708	chr20:43804764	PI3	0.75	11.8	0.48	2.8e-28	Blood protein levels;
LGG	cis	rs1816752	1.000	rs7988810	chr13:25019096	T/C	cg22771759	chr13:24902376	NA	0.45	7.61	0.33	1.5700000000000001e-13	Obesity-related traits;
LGG	cis	rs7444	0.941	rs181362	chr22:21932068	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs4948275	0.773	rs2606097	chr10:63278953	T/G	cg03237606	chr10:63212265	TMEM26	-0.37	-6.7	-0.3	6.21e-11	Night sleep phenotypes;
LGG	cis	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg12395012	chr8:11607386	GATA4	0.39	7.06	0.31	6e-12	Neuroticism;
LGG	cis	rs10088262	0.591	rs13270541	chr8:124794849	G/A	cg20713898	chr8:124780851	FAM91A1	-0.5	-7.82	-0.34	3.63e-14	Pancreatic cancer;
LGG	cis	rs12493885	0.697	rs11710478	chr3:153777037	A/C	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2842992	0.724	rs9365097	chr6:160211259	G/A	cg27624424	chr6:160112604	SOD2	0.6	9.31	0.4	4.97e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2228479	0.867	rs17784386	chr16:89947457	A/G	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.66e-14	Skin colour saturation;
LGG	cis	rs1865760	0.516	rs9393684	chr6:26075531	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.34	0.43	1.07e-22	Height;
LGG	cis	rs853679	0.517	rs9380061	chr6:28132803	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16020249	chr1:27930640	AHDC1	0.58	7.01	0.31	8.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs17767392	0.781	rs34388001	chr14:71883500	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.8	-0.38	2.83e-17	Mitral valve prolapse;
LGG	cis	rs6500596	0.506	rs1530088	chr16:4439131	C/T	cg26783146	chr16:4423632	VASN;CORO7	-0.36	-6.84	-0.3	2.49e-11	Schizophrenia;
LGG	cis	rs2011503	0.941	rs998732	chr19:19378671	A/G	cg01262667	chr19:19385393	TM6SF2	0.35	6.76	0.3	4.21e-11	Bipolar disorder;
LGG	cis	rs8067545	0.685	rs4479309	chr17:19971583	C/T	cg09818912	chr17:20140352	CYTSB	-0.29	-6.71	-0.3	5.56e-11	Schizophrenia;
LGG	cis	rs10504229	0.609	rs56289889	chr8:58116276	G/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.54	9.44	0.4	1.86e-19	Longevity;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05025164	chr4:1340916	KIAA1530	0.66	12.37	0.5	1.48e-30	Longevity;
LGG	cis	rs919433	0.519	rs700658	chr2:198655007	A/T	cg00792783	chr2:198669748	PLCL1	0.68	11.01	0.46	3.43e-25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg04025307	chr7:1156635	C7orf50	0.64	8.33	0.36	9.24e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14082963	chr4:89444434	PIGY	-0.46	-6.73	-0.3	5.03e-11	Systemic lupus erythematosus;
LGG	cis	rs8114671	0.562	rs6087653	chr20:33522054	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.07	0.31	5.89e-12	Height;
LGG	cis	rs7465272	1.000	rs7017842	chr8:143685116	G/A	cg10104451	chr8:143696006	ARC	-0.75	-10.85	-0.45	1.42e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg11062466	chr8:58055876	NA	0.46	7.57	0.33	2.1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4601821	0.522	rs754672	chr11:113249136	C/T	cg14159747	chr11:113255604	NA	0.32	8.67	0.37	7.57e-17	Alcoholic chronic pancreatitis;
LGG	trans	rs1814175	0.587	rs7948538	chr11:50021353	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06202984	chr9:98079903	FANCC	0.49	7.23	0.32	2.05e-12	Gut microbiome composition (summer);
LGG	cis	rs12310956	0.532	rs11052933	chr12:33969881	G/A	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs6496044	0.547	rs8039929	chr15:86080962	C/T	cg13263323	chr15:86062960	AKAP13	-0.36	-7.77	-0.34	5.01e-14	Interstitial lung disease;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10921983	chr12:124155712	TCTN2	-0.48	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	cis	rs2762353	0.574	rs34067542	chr6:25728210	T/A	cg03264133	chr6:25882463	NA	0.74	14.2	0.55	3.14e-38	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20930618	chr1:151162157	VPS72	0.49	7.39	0.32	7.1e-13	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg22437258	chr11:111473054	SIK2	-0.42	-7.08	-0.31	5.39e-12	Primary sclerosing cholangitis;
LGG	cis	rs8040855	0.644	rs7495437	chr15:85726290	A/G	cg10818794	chr15:86012489	AKAP13	0.36	7.42	0.33	5.79e-13	Bulimia nervosa;
LGG	cis	rs7223966	1.000	rs6504167	chr17:61693194	G/C	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.55	-0.37	1.84e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10824796	0.638	rs11003117	chr10:54518083	A/T	cg27418851	chr10:54531653	MBL2	0.42	7.53	0.33	2.63e-13	Blood protein levels;
LGG	cis	rs12701220	0.690	rs10243973	chr7:1064983	T/C	cg26769984	chr7:1090371	C7orf50	0.54	9.85	0.42	6.76e-21	Bronchopulmonary dysplasia;
LGG	cis	rs6912958	0.754	rs4587143	chr6:88292291	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.89	-0.38	1.41e-17	Monocyte percentage of white cells;
LGG	cis	rs9487094	0.922	rs10782162	chr6:109806263	A/T	cg16315928	chr6:109776240	MICAL1	-0.53	-8.78	-0.38	3.12e-17	Height;
LGG	cis	rs4740619	0.905	rs7045018	chr9:15773606	C/A	cg14451791	chr9:16040625	NA	-0.39	-10.18	-0.43	4.41e-22	Body mass index;
LGG	cis	rs763014	0.966	rs35642938	chr16:642249	T/C	cg00908189	chr16:619842	PIGQ	0.86	15.99	0.6	3.87e-46	Height;
LGG	cis	rs2153535	0.580	rs1414342	chr6:8462552	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.26	0.43	2.1e-22	Motion sickness;
LGG	cis	rs6795744	0.908	rs13317352	chr3:13917918	A/G	cg19554555	chr3:13937349	NA	0.59	7.31	0.32	1.22e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs9790314	0.747	rs9820825	chr3:160848155	A/G	cg04691961	chr3:161091175	C3orf57	-0.52	-11.45	-0.47	6.57e-27	Morning vs. evening chronotype;
LGG	cis	rs61931739	0.553	rs68124042	chr12:34064431	C/A	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	8.77e-26	Morning vs. evening chronotype;
LGG	cis	rs4731207	0.672	rs10249081	chr7:124468519	T/G	cg05630886	chr7:124431682	NA	0.33	7.82	0.34	3.53e-14	Cutaneous malignant melanoma;
LGG	trans	rs916888	0.610	rs199453	chr17:44800946	C/T	cg10053473	chr17:62856997	LRRC37A3	-0.79	-13.82	-0.54	1.35e-36	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7523273	0.565	rs2796250	chr1:207903654	T/C	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.6	-0.37	1.28e-16	Schizophrenia;
LGG	cis	rs920590	0.684	rs59259846	chr8:19669468	C/G	cg01411142	chr8:19674711	INTS10	0.48	7.37	0.32	7.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg26174226	chr8:58114915	NA	-0.46	-6.73	-0.3	4.98e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7662987	0.517	rs1133485	chr4:100023811	T/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs4742903	0.904	rs7029970	chr9:107006565	G/A	cg14250997	chr9:106856677	SMC2	0.37	7.54	0.33	2.59e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs9329221	0.905	rs13252982	chr8:10255105	C/G	cg19847130	chr8:10466454	RP1L1	0.33	6.89	0.3	1.87e-11	Neuroticism;
LGG	trans	rs2898290	0.622	rs978802	chr8:11343278	A/T	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.61	-0.41	4.66e-20	Systolic blood pressure;
LGG	cis	rs7312933	0.558	rs1051453	chr12:42852217	C/T	cg19980929	chr12:42632907	YAF2	0.34	7.72	0.34	7.33e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	trans	rs208520	0.526	rs4710310	chr6:66802808	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-1.15	-32.61	-0.83	5.12e-122	Exhaled nitric oxide output;
LGG	cis	rs7666738	0.830	rs6819047	chr4:98866902	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg02002194	chr4:3960332	NA	0.42	8.01	0.35	9.45e-15	Morning vs. evening chronotype;
LGG	cis	rs6547741	0.717	rs2178197	chr2:27860551	C/T	cg27432699	chr2:27873401	GPN1	0.72	15.05	0.57	6.05e-42	Oral cavity cancer;
LGG	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg06636001	chr8:8085503	FLJ10661	0.48	8.74	0.38	4.48e-17	Neuroticism;
LGG	cis	rs9926296	0.712	rs459920	chr16:89730827	T/C	cg26513180	chr16:89883248	FANCA	-0.53	-9.28	-0.4	6.47e-19	Vitiligo;
LGG	cis	rs2019137	0.936	rs731834	chr2:113957198	A/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.0500000000000001e-23	Lymphocyte counts;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26790547	chr11:14542185	PSMA1	-0.5	-7.2	-0.32	2.46e-12	Systemic lupus erythematosus;
LGG	cis	rs9291683	0.618	rs13137343	chr4:10043028	C/A	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	cis	rs7208859	0.623	rs73263788	chr17:29216490	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1816752	0.837	rs57052031	chr13:24983868	T/A	cg02811702	chr13:24901961	NA	0.39	7.22	0.32	2.16e-12	Obesity-related traits;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg27400746	chr16:89904261	SPIRE2	-0.86	-14.68	-0.56	2.44e-40	Skin colour saturation;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg06654118	chr4:1303317	MAEA	0.46	7.98	0.35	1.18e-14	Obesity-related traits;
LGG	cis	rs533581	0.866	rs475796	chr16:88970776	C/G	cg16701003	chr16:89028210	CBFA2T3	0.47	7.62	0.33	1.48e-13	Social autistic-like traits;
LGG	cis	rs295140	0.546	rs842830	chr2:201131124	C/T	cg17644776	chr2:200775616	C2orf69	-0.47	-7.76	-0.34	5.65e-14	QT interval;
LGG	cis	rs7216064	0.532	rs3890640	chr17:66053028	C/T	cg02705964	chr17:66097276	LOC651250	-0.47	-8.33	-0.36	9.14e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6032067	0.929	rs17424668	chr20:43809647	C/T	cg10761708	chr20:43804764	PI3	-0.76	-11.93	-0.49	8.22e-29	Blood protein levels;
LGG	cis	rs2180341	1.000	rs9321073	chr6:127609691	C/T	cg24812749	chr6:127587940	RNF146	0.96	16.01	0.6	3.3e-46	Breast cancer;
LGG	cis	rs6740322	0.841	rs10211126	chr2:43551416	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.63	-9.74	-0.41	1.64e-20	Coronary artery disease;
LGG	cis	rs2072732	0.861	rs12040299	chr1:2951041	C/T	cg08733933	chr1:2954429	NA	-0.39	-8.65	-0.37	8.22e-17	Plateletcrit;
LGG	cis	rs657075	0.697	rs3805667	chr5:131646516	A/G	cg05556477	chr5:131705319	SLC22A5	0.83	10.07	0.42	1.04e-21	Rheumatoid arthritis;
LGG	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg13482628	chr17:19912719	NA	0.61	12.15	0.49	1.09e-29	Schizophrenia;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg11764359	chr7:65958608	NA	0.73	13.09	0.52	1.51e-33	Aortic root size;
LGG	cis	rs9322193	0.923	rs4455682	chr6:150021297	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.42	0.33	5.7e-13	Lung cancer;
LGG	cis	rs17767392	0.595	rs60536344	chr14:71654400	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.35	-7.08	-0.31	5.46e-12	Mitral valve prolapse;
LGG	cis	rs2692947	0.832	rs2579550	chr2:96741944	G/A	cg22654517	chr2:96458247	NA	0.37	7.3	0.32	1.29e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs941408	0.928	rs2260414	chr19:2796316	G/A	cg06609049	chr19:2785107	THOP1	0.62	9.62	0.41	4.34e-20	Total cholesterol levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00381974	chr18:44260357	ST8SIA5	0.46	7.81	0.34	3.8e-14	Pancreatic cancer;
LGG	cis	rs12360000	0.864	rs34695673	chr10:1907540	G/T	cg26364871	chr10:1889757	NA	-0.71	-13.66	-0.54	6.48e-36	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs11763147	1	rs11763147	chr7:65326821	C/T	cg00343986	chr7:65444356	GUSB	-0.49	-8.47	-0.37	3.29e-16	Corneal structure;
LGG	cis	rs3747547	0.710	rs11789061	chr9:37950230	A/G	cg13774184	chr9:37916125	SHB	-0.72	-7.99	-0.35	1.11e-14	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs28595532	1.000	rs28600971	chr4:119712728	G/T	cg11846333	chr4:119757529	SEC24D	0.83	7.25	0.32	1.71e-12	Cannabis dependence symptom count;
LGG	cis	rs9457247	1.000	rs404222	chr6:167402150	G/A	cg07741184	chr6:167504864	NA	0.32	7.15	0.32	3.34e-12	Crohn's disease;
LGG	cis	rs11992162	0.613	rs6998690	chr8:11798796	A/T	cg00405596	chr8:11794950	NA	0.61	10.57	0.44	1.55e-23	Monocyte count;
LGG	cis	rs7851726	0.738	rs4744370	chr9:97477793	A/G	cg13402635	chr9:97669802	C9orf3	0.32	7.09	0.31	5.15e-12	Urinary albumin-to-creatinine ratio;
LGG	cis	rs4629180	0.586	rs57563359	chr2:102125309	A/G	cg16435561	chr2:102091048	RFX8	0.48	8.95	0.38	8.86e-18	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs994014	0.640	rs6814232	chr4:82189803	A/G	cg07938847	chr4:82126349	PRKG2	0.3	7.41	0.33	6.22e-13	Height;
LGG	cis	rs4363385	0.510	rs11576797	chr1:153049417	T/C	cg13444842	chr1:152974279	SPRR3	-0.47	-9.22	-0.39	1.07e-18	Inflammatory skin disease;
LGG	cis	rs11148252	0.538	rs2408611	chr13:52709742	C/T	cg22398616	chr13:53314203	LECT1	-0.49	-10.08	-0.42	9.92e-22	Lewy body disease;
LGG	cis	rs3768617	0.510	rs4652776	chr1:183091920	G/A	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs12425451	0.544	rs1990330	chr12:3147462	A/C	cg05389053	chr12:3131226	TEAD4	0.59	10.14	0.43	5.71e-22	Narcolepsy with cataplexy;
LGG	trans	rs9467711	0.659	rs66757203	chr6:26454956	C/T	cg01620082	chr3:125678407	NA	-0.76	-7.63	-0.33	1.39e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7659604	1.000	rs35224452	chr4:122664677	C/T	cg20573242	chr4:122745356	CCNA2	0.43	7.81	0.34	3.87e-14	Type 2 diabetes;
LGG	cis	rs6500395	0.962	rs7199625	chr16:48650217	G/C	cg16662043	chr16:48846231	NA	0.39	7.62	0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs77741769	0.529	rs3213572	chr12:121205078	A/G	cg02419362	chr12:121203948	SPPL3	-0.57	-9.94	-0.42	3.01e-21	Mean corpuscular volume;
LGG	cis	rs1153858	1.000	rs67461176	chr15:45676819	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.08	0.46	1.85e-25	Homoarginine levels;
LGG	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	12.25	0.49	4.39e-30	Rheumatoid arthritis;
LGG	cis	rs7107174	1.000	rs2511178	chr11:77923220	C/T	cg02023728	chr11:77925099	USP35	0.45	7.79	0.34	4.57e-14	Testicular germ cell tumor;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg07511668	chr11:68622177	NA	0.52	10.07	0.42	1.1e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7927592	0.956	rs7113287	chr11:68372186	A/T	cg01657329	chr11:68192670	LRP5	-0.5	-8.67	-0.37	7.26e-17	Total body bone mineral density;
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.76	-0.3	4.05e-11	Menopause (age at onset);
LGG	trans	rs1814175	0.616	rs1794139	chr11:49910855	C/T	cg15704280	chr7:45808275	SEPT13	-0.98	-21.23	-0.7	2.49e-70	Height;
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg10295955	chr4:187884368	NA	-1.14	-31.55	-0.83	1.93e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg04861929	chr11:109293070	C11orf87	0.56	10.17	0.43	4.65e-22	Schizophrenia;
LGG	cis	rs2249625	0.564	rs2496489	chr6:72877338	G/A	cg27608224	chr6:72922399	RIMS1	0.32	7.25	0.32	1.79e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.39e-11	Lung cancer;
LGG	cis	rs2976388	0.556	rs4736300	chr8:143829269	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-13.9	-0.54	6.09e-37	Urinary tract infection frequency;
LGG	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg12011299	chr4:100065546	ADH4	-0.44	-8.75	-0.38	4.07e-17	Alcohol dependence;
LGG	cis	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg03511173	chr18:77590860	NA	0.62	7.82	0.34	3.58e-14	Opioid sensitivity;
LGG	cis	rs12477438	0.520	rs2516829	chr2:99773201	T/G	cg08885076	chr2:99613938	TSGA10	0.43	9.17	0.39	1.55e-18	Chronic sinus infection;
LGG	cis	rs1728785	1.000	rs7205960	chr16:68565604	G/C	cg02972257	chr16:68554789	NA	-0.54	-8.18	-0.36	2.8e-15	Ulcerative colitis;
LGG	cis	rs798554	0.680	rs1713912	chr7:2895784	C/A	cg14668632	chr7:2872130	GNA12	-0.33	-6.98	-0.31	1.01e-11	Height;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05525867	chr15:75661090	MAN2C1	0.44	7.57	0.33	2.09e-13	Bipolar disorder;
LGG	cis	rs10484885	0.824	rs72919982	chr6:90532600	C/G	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.72	-0.45	4.34e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs597539	0.652	rs11603827	chr11:68719221	C/T	cg11245990	chr11:68621969	NA	0.4	8.52	0.37	2.24e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9393777	0.513	rs1104871	chr6:26665235	T/G	cg12826209	chr6:26865740	GUSBL1	0.81	11.96	0.49	6.27e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.745	rs56262555	chr14:55561962	C/T	cg04306507	chr14:55594613	LGALS3	0.46	11.55	0.47	2.83e-27	Protein biomarker;
LGG	cis	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg25427524	chr10:38739819	LOC399744	-0.67	-13.51	-0.53	2.58e-35	Extrinsic epigenetic age acceleration;
LGG	cis	rs9911578	1.000	rs999431	chr17:56854441	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.93	0.59	7.54e-46	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.781	rs2866734	chr11:49886338	A/G	cg15704280	chr7:45808275	SEPT13	-1.08	-27.04	-0.78	2.68e-97	Height;
LGG	cis	rs41563	0.609	rs4727614	chr7:104600854	C/A	cg04380332	chr7:105027541	SRPK2	-0.35	-6.65	-0.3	8.51e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs6964437	chr7:65686444	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.89e-19	Aortic root size;
LGG	cis	rs1965732	0.917	rs9750735	chr2:3708383	A/T	cg15327641	chr2:3715039	ALLC	0.32	6.81	0.3	3.04e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.33	0.5	2.08e-30	Prudent dietary pattern;
LGG	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.64	0.41	3.64e-20	Hypertriglyceridemia;
LGG	cis	rs4474465	1.000	rs7124092	chr11:78155086	T/C	cg27205649	chr11:78285834	NARS2	-0.5	-8.48	-0.37	3.08e-16	Alzheimer's disease (survival time);
LGG	cis	rs1348850	0.574	rs11889488	chr2:178426793	A/G	cg22681709	chr2:178499509	PDE11A	0.49	7.18	0.32	2.84e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg03258749	chr1:151040405	MLLT11	-0.44	-7.95	-0.35	1.43e-14	Childhood ear infection;
LGG	trans	rs2243480	1.000	rs12698509	chr7:65418876	C/T	cg10756647	chr7:56101905	PSPH	0.81	10.07	0.42	1.03e-21	Diabetic kidney disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg10321208	chr1:53662243	CPT2	0.39	7.74	0.34	6.12e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9768139	0.683	rs4909178	chr7:158117752	T/A	cg06219351	chr7:158114137	PTPRN2	-0.74	-14.18	-0.55	3.66e-38	Calcium levels;
LGG	cis	rs875971	0.508	rs10253883	chr7:66061138	T/C	cg23594656	chr7:65796392	TPST1	0.3	6.69	0.3	6.57e-11	Aortic root size;
LGG	cis	rs2985684	0.789	rs7161649	chr14:50064028	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.42	6.92	0.31	1.54e-11	Carotid intima media thickness;
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg26354017	chr1:205819088	PM20D1	-0.42	-8.36	-0.36	7.29e-16	Prostate-specific antigen levels;
LGG	cis	rs10461617	0.617	rs79742142	chr5:56104377	A/G	cg03609598	chr5:56110824	MAP3K1	-0.54	-7.97	-0.35	1.25e-14	Type 2 diabetes;
LGG	cis	rs34734847	0.766	rs3794214	chr12:121168245	C/T	cg21892295	chr12:121157589	UNC119B	0.39	7.19	0.32	2.63e-12	Mean corpuscular volume;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.74	-13.54	-0.53	2.05e-35	Obesity-related traits;
LGG	trans	rs800082	1.000	rs2717391	chr3:144279698	T/C	cg24215973	chr2:240111563	HDAC4	0.48	8.35	0.36	7.91e-16	Smoking behavior;
LGG	cis	rs4474465	0.736	rs10899542	chr11:78246572	T/G	cg27205649	chr11:78285834	NARS2	0.51	8.82	0.38	2.27e-17	Alzheimer's disease (survival time);
LGG	cis	rs7208859	0.623	rs73269974	chr17:29112384	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs7080356	chr10:102266735	A/C	cg07570687	chr10:102243282	WNT8B	0.44	7.44	0.33	4.78e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4722166	0.597	rs2069845	chr7:22770149	G/A	cg05265849	chr7:22767390	IL6	0.41	8.14	0.35	3.61e-15	Lung cancer;
LGG	cis	rs4237845	0.837	rs7954591	chr12:58299037	A/G	cg02175503	chr12:58329896	NA	0.69	12.8	0.51	2.39e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.35	0.32	9.2e-13	Morning vs. evening chronotype;
LGG	trans	rs877282	0.838	rs11253408	chr10:796374	T/C	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg11347840	chr17:38804311	SMARCE1	-0.39	-6.73	-0.3	4.9e-11	Brain structure;
LGG	cis	rs4332037	0.722	rs55934553	chr7:1914059	T/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.54	-0.5	2.93e-31	Bipolar disorder;
LGG	cis	rs9790314	0.586	rs11713185	chr3:161111357	C/G	cg03342759	chr3:160939853	NMD3	-0.65	-11.27	-0.46	3.29e-26	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.19	0.43	3.88e-22	Height;
LGG	cis	rs796364	0.806	rs12619136	chr2:200910347	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-6.91	-0.31	1.57e-11	Lung cancer;
LGG	cis	rs6502050	0.835	rs9904520	chr17:80100117	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs3087591	0.960	rs2285812	chr17:29533871	A/G	cg24425628	chr17:29625626	OMG;NF1	0.69	14.25	0.55	1.86e-38	Hip circumference;
LGG	cis	rs8114671	0.562	rs6088622	chr20:33419977	C/A	cg07148914	chr20:33460835	GGT7	0.56	9.27	0.4	7.03e-19	Height;
LGG	cis	rs732765	1.000	rs3742785	chr14:75373034	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.5	-7.15	-0.32	3.49e-12	Non-small cell lung cancer;
LGG	cis	rs6500602	0.702	rs3761680	chr16:4524060	C/A	cg19168338	chr16:4465731	CORO7	-0.75	-14.02	-0.55	1.83e-37	Schizophrenia;
LGG	cis	rs4330281	0.626	rs13095571	chr3:17532320	T/C	cg20981856	chr3:17787350	NA	0.4	7.52	0.33	2.78e-13	Schizophrenia;
LGG	cis	rs9715521	0.677	rs4490528	chr4:59854572	T/G	cg11281224	chr4:60001000	NA	-0.57	-10.05	-0.42	1.23e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3735485	0.678	rs72599518	chr7:45157289	C/T	cg03440944	chr7:45023329	C7orf40	-0.52	-8.82	-0.38	2.33e-17	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9487094	0.670	rs7755941	chr6:109815351	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs4845570	0.920	rs1521185	chr1:151764049	A/G	cg07092448	chr1:151763213	TDRKH	1.16	23.8	0.74	2.21e-82	Coronary artery disease;
LGG	cis	rs7223966	0.881	rs3020608	chr17:61979993	C/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.57	0.44	1.52e-23	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs368123	1.000	rs370278	chr6:160726284	C/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.78e-12	Waist circumference;
LGG	cis	rs7107174	1.000	rs10793309	chr11:78093799	G/A	cg02023728	chr11:77925099	USP35	0.46	8.12	0.35	4.32e-15	Testicular germ cell tumor;
LGG	cis	rs10262624	0.504	rs4722255	chr7:23746072	G/T	cg26309111	chr7:23720005	C7orf46	-0.39	-8.21	-0.36	2.16e-15	Schizophrenia;
LGG	cis	rs1865760	0.533	rs1408270	chr6:25873184	A/G	cg03517284	chr6:25882590	NA	-0.45	-6.92	-0.31	1.52e-11	Height;
LGG	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg19131313	chr8:1704013	NA	-0.3	-6.77	-0.3	3.91e-11	Systolic blood pressure;
LGG	cis	rs3857747	0.520	rs12701817	chr7:40364841	A/T	cg00420559	chr7:40367873	C7orf10	-0.42	-8.54	-0.37	2.02e-16	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs11864453	0.612	rs12924413	chr16:72129745	T/C	cg23815491	chr16:72088622	HP	0.48	10.92	0.45	7.42e-25	Fibrinogen levels;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg10053473	chr17:62856997	LRRC37A3	0.77	13.36	0.53	1.14e-34	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4478858	0.735	rs10798845	chr1:31822636	A/G	cg19084893	chr1:31688959	NA	-0.32	-6.82	-0.3	2.79e-11	Alcohol dependence;
LGG	cis	rs9297145	0.916	rs4236540	chr7:98769025	A/C	cg05967295	chr7:98741636	SMURF1	0.95	19.12	0.66	1.7e-60	Crohn's disease;Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs9926296	0.581	rs2108838	chr16:89904426	A/G	cg04287289	chr16:89883240	FANCA	0.56	10.44	0.44	4.86e-23	Vitiligo;
LGG	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg09165964	chr15:75287851	SCAMP5	0.66	12.05	0.49	2.88e-29	Caffeine consumption;
LGG	cis	rs36051895	0.623	rs7025005	chr9:5261794	T/C	cg02405213	chr9:5042618	JAK2	-0.72	-12.76	-0.51	3.83e-32	Pediatric autoimmune diseases;
LGG	cis	rs868036	0.718	rs7170185	chr15:68117300	T/A	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.25	-0.32	1.77e-12	Restless legs syndrome;
LGG	cis	rs9487094	0.696	rs12191353	chr6:109941975	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.1	0.35	5.09e-15	Height;
LGG	cis	rs68170813	0.559	rs4730226	chr7:106887274	A/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.56	-0.44	1.75e-23	Coronary artery disease;
LGG	cis	rs7954584	0.567	rs1720037	chr12:122382229	G/T	cg22168489	chr12:122356033	WDR66	-0.4	-9.45	-0.4	1.73e-19	Mean corpuscular volume;
LGG	trans	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg16141378	chr3:129829833	LOC729375	-0.54	-13.95	-0.54	3.76e-37	Neuroticism;
LGG	cis	rs17253792	0.822	rs77182097	chr14:56136695	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	cis	rs769267	1.000	rs2074090	chr19:19449686	G/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.73	-0.48	5.2e-28	Tonsillectomy;
LGG	cis	rs9911578	1.000	rs7216680	chr17:56988243	G/C	cg12560992	chr17:57184187	TRIM37	0.89	15.82	0.59	2.27e-45	Intelligence (multi-trait analysis);
LGG	cis	rs5758511	0.596	rs55644935	chr22:42666069	A/G	cg15128208	chr22:42549153	NA	0.73	11.59	0.47	1.96e-27	Birth weight;
LGG	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.88	0.3	1.92e-11	Glycated hemoglobin levels;
LGG	cis	rs12210905	0.688	rs72845030	chr6:27532643	A/G	cg10122326	chr6:28072925	NA	0.94	7.23	0.32	1.96e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg12419862	chr22:24373484	LOC391322	-0.89	-18.39	-0.65	4.03e-57	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9303401	1.000	rs9303401	chr17:56847945	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.61	10.44	0.44	4.76e-23	Cognitive test performance;
LGG	cis	rs9397585	0.857	rs2185027	chr6:153381622	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg06197492	chr11:2016605	H19	0.45	8.72	0.38	4.99e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs7824557	0.736	rs10107010	chr8:11132712	C/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.5	-0.4	1.13e-19	Retinal vascular caliber;
LGG	cis	rs60871478	1.000	rs4397290	chr7:828493	T/C	cg05535760	chr7:792225	HEATR2	-0.81	-12.68	-0.51	7.54e-32	Cerebrospinal P-tau181p levels;
LGG	cis	rs651907	0.535	rs11714444	chr3:101513682	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs4819052	0.851	rs2838842	chr21:46669217	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.72	-0.41	1.8899999999999998e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs35110281	0.548	rs2838350	chr21:45109972	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.26	0.4	7.42e-19	Mean corpuscular volume;
LGG	cis	rs367943	0.712	rs26964	chr5:112738532	T/C	cg12552261	chr5:112820674	MCC	0.58	10.47	0.44	3.64e-23	Type 2 diabetes;
LGG	trans	rs6426551	0.958	rs6702917	chr1:226547174	C/T	cg27539482	chr13:111589090	NA	-0.49	-7.47	-0.33	4.14e-13	Coronary artery disease;
LGG	trans	rs7819412	0.634	rs4841485	chr8:10909936	T/C	cg15556689	chr8:8085844	FLJ10661	0.46	7.75	0.34	5.84e-14	Triglycerides;
LGG	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22496380	chr5:211416	CCDC127	-1.24	-17.55	-0.63	3.12e-53	Breast cancer;
LGG	cis	rs2117029	0.555	rs10747561	chr12:49500509	C/T	cg24176009	chr12:49580217	TUBA1A	0.55	10.58	0.44	1.46e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7507204	0.906	rs62125968	chr19:3422261	G/A	cg08380311	chr19:3435252	NFIC	0.81	12.21	0.49	6.65e-30	Height;
LGG	cis	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg21775007	chr8:11205619	TDH	0.51	8.42	0.36	4.69e-16	Retinal vascular caliber;
LGG	trans	rs800082	0.531	rs2204603	chr3:144258720	T/A	cg24215973	chr2:240111563	HDAC4	0.37	6.82	0.3	2.78e-11	Smoking behavior;
LGG	cis	rs6456156	0.586	rs1358883	chr6:167467433	C/G	cg07741184	chr6:167504864	NA	-0.38	-8.76	-0.38	3.64e-17	Primary biliary cholangitis;
LGG	cis	rs12421382	0.659	rs35093943	chr11:109379872	C/A	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.75e-21	Schizophrenia;
LGG	cis	rs11992162	0.597	rs7824564	chr8:11780180	A/G	cg00405596	chr8:11794950	NA	-0.63	-11.06	-0.46	2.23e-25	Monocyte count;
LGG	cis	rs7444	0.825	rs2266963	chr22:21947467	C/G	cg15846791	chr22:21984385	YDJC	-0.47	-7.09	-0.31	5.06e-12	Systemic lupus erythematosus;
LGG	cis	rs2235573	0.657	rs5756890	chr22:38445400	C/A	cg19171272	chr22:38449367	NA	-0.55	-10.9	-0.45	9.03e-25	Glioblastoma;Glioma;
LGG	cis	rs3806933	0.522	rs12522383	chr5:110455266	C/T	cg04022379	chr5:110408740	TSLP	0.46	7.8	0.34	4.21e-14	Eosinophilic esophagitis;
LGG	cis	rs483069	0.967	rs487736	chr1:34422313	C/T	cg24941457	chr1:34420873	CSMD2	-0.47	-11.46	-0.47	5.9e-27	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs73001065	0.536	rs10408596	chr19:19512657	A/T	cg03709012	chr19:19516395	GATAD2A	0.95	10.91	0.45	8.34e-25	LDL cholesterol;
LGG	cis	rs12477438	0.765	rs2278895	chr2:99613484	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg26338869	chr17:61819248	STRADA	-0.58	-9.54	-0.41	8.41e-20	Prudent dietary pattern;
LGG	cis	rs3789045	1.000	rs45501495	chr1:204596454	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.4	-8.13	-0.35	3.96e-15	Educational attainment (college completion);
LGG	cis	rs929354	0.772	rs933344	chr7:157011265	A/T	cg05182265	chr7:156933206	UBE3C	-0.36	-7.4	-0.33	6.47e-13	Body mass index;
LGG	trans	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.83	0.48	2.1e-28	Lewy body disease;
LGG	cis	rs10504073	0.669	rs341809	chr8:50042557	C/T	cg00325661	chr8:49890786	NA	0.68	13.29	0.53	2.24e-34	Blood metabolite ratios;
LGG	cis	rs1862618	0.853	rs832578	chr5:56164223	C/T	cg08400814	chr5:56204995	C5orf35	-0.46	-7.56	-0.33	2.22e-13	Initial pursuit acceleration;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs208520	0.690	rs207077	chr6:66769855	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.63	-0.63	1.41e-53	Exhaled nitric oxide output;
LGG	cis	rs9322193	0.923	rs9688452	chr6:149979900	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.17	0.32	2.99e-12	Lung cancer;
LGG	cis	rs7223966	1.000	rs752621	chr17:61901880	G/C	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.93	-0.38	9.75e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17376456	0.877	rs12716457	chr5:93397627	T/C	cg25358565	chr5:93447407	FAM172A	1.34	16.46	0.61	2.82e-48	Diabetic retinopathy;
LGG	trans	rs11098499	0.954	rs67265404	chr4:120359270	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.09	0.49	1.99e-29	Corneal astigmatism;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg11814155	chr7:99998594	ZCWPW1	0.57	8.88	0.38	1.5e-17	Platelet count;
LGG	cis	rs870825	0.616	rs10006828	chr4:185651416	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs7223966	1.000	rs8066719	chr17:61825764	C/T	cg18032289	chr17:61959525	GH2	-0.39	-6.71	-0.3	5.75e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg18402987	chr7:1209562	NA	0.45	7.81	0.34	3.92e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	cis	rs2797369	0.656	rs606032	chr6:101347029	G/A	cg27451362	chr6:101846650	GRIK2	0.77	10.49	0.44	3.01e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs8067545	0.611	rs12603372	chr17:20181566	C/T	cg09818912	chr17:20140352	CYTSB	-0.31	-7.21	-0.32	2.26e-12	Schizophrenia;
LGG	cis	rs10504229	0.871	rs7002070	chr8:58153817	A/G	cg14926445	chr8:58193284	C8orf71	-0.86	-12.02	-0.49	3.66e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs1639906	0.528	rs1637728	chr7:2269552	G/T	cg08027265	chr7:2291960	NA	-0.55	-10.83	-0.45	1.61e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg20887711	chr4:1340912	KIAA1530	-0.75	-15.48	-0.58	7.68e-44	Obesity-related traits;
LGG	cis	rs66573146	0.831	rs1048009	chr4:6988677	G/A	cg00086871	chr4:6988644	TBC1D14	1.12	11.04	0.46	2.68e-25	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13095912	0.785	rs4686682	chr3:185307402	C/T	cg11274856	chr3:185301563	NA	0.49	8.01	0.35	9.71e-15	Systolic blood pressure;
LGG	cis	rs873946	0.586	rs12259688	chr10:134549628	A/G	cg13271783	chr10:134563150	INPP5A	-0.54	-8.11	-0.35	4.74e-15	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs754466	0.914	rs12219971	chr10:79701526	T/C	cg17075019	chr10:79541650	NA	-0.8	-13.42	-0.53	6.41e-35	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504073	0.647	rs62507245	chr8:50006939	A/T	cg00325661	chr8:49890786	NA	0.74	14.34	0.55	7.46e-39	Blood metabolite ratios;
LGG	trans	rs3780486	0.522	rs1328898	chr9:33163271	A/G	cg20290983	chr6:43655470	MRPS18A	0.8	15.37	0.58	2.22e-43	IgG glycosylation;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg06925179	chr17:43578568	NA	0.41	9.7	0.41	2.22e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs7939886	0.920	rs11231885	chr11:55804022	T/A	cg15704280	chr7:45808275	SEPT13	0.87	9.18	0.39	1.4e-18	Myopia (pathological);
LGG	cis	rs13108043	0.639	rs34140562	chr4:87945401	G/T	cg11209507	chr4:87813803	C4orf36	0.54	7.08	0.31	5.54e-12	Red blood cell count;
LGG	cis	rs11225247	1.000	rs117983416	chr11:102315169	G/A	cg06323957	chr11:102217781	BIRC2	0.77	6.72	0.3	5.22e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs7937682	0.960	rs480293	chr11:111469132	A/C	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg07132326	chr6:150258058	NA	0.38	7.94	0.35	1.51e-14	Testicular germ cell tumor;
LGG	cis	rs3858526	0.834	rs7129481	chr11:5991114	G/T	cg25319279	chr11:5960081	NA	-0.55	-8.6	-0.37	1.24e-16	DNA methylation (variation);
LGG	cis	rs4803468	1.000	rs11883104	chr19:41923799	T/C	cg09537434	chr19:41945824	ATP5SL	-0.91	-24.6	-0.75	4.37e-86	Height;
LGG	cis	rs9549367	0.789	rs71446679	chr13:113894821	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.07e-16	Platelet distribution width;
LGG	cis	rs2276314	0.857	rs8087539	chr18:33631537	C/T	cg19628046	chr18:33552617	C18orf21	0.51	7.54	0.33	2.49e-13	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg04503457	chr17:41445688	NA	-0.38	-8.82	-0.38	2.43e-17	Menopause (age at onset);
LGG	cis	rs10791323	0.693	rs10750544	chr11:133718740	A/G	cg00579200	chr11:133705235	NA	-0.58	-11.32	-0.47	2.16e-26	Childhood ear infection;
LGG	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg16434002	chr17:42200994	HDAC5	0.44	8.01	0.35	9.47e-15	Total body bone mineral density;
LGG	cis	rs9322193	0.962	rs9397022	chr6:150133188	C/T	cg09699651	chr6:150184138	LRP11	0.47	8.3	0.36	1.15e-15	Lung cancer;
LGG	cis	rs2645694	0.626	rs2703126	chr4:77819842	T/C	cg18351406	chr4:77819688	ANKRD56	0.47	8.01	0.35	9.55e-15	Emphysema distribution in smoking;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02759489	chr4:55098483	PDGFRA	0.42	7.28	0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs10892173	0.818	rs7947524	chr11:117671091	C/T	cg21640587	chr11:117668038	DSCAML1	0.48	7.98	0.35	1.2e-14	Myopia;
LGG	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19671926	chr4:122722719	EXOSC9	0.54	8.31	0.36	1.04e-15	Type 2 diabetes;
LGG	cis	rs2307022	0.586	rs11075672	chr16:68384039	A/G	cg07273125	chr16:68295692	NA	0.44	9.94	0.42	3.04e-21	Body mass index;
LGG	cis	rs644799	0.648	rs1255178	chr11:95471908	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.47	8.14	0.35	3.65e-15	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9322193	0.886	rs4870055	chr6:150169569	C/T	cg07701084	chr6:150067640	NUP43	0.61	11.48	0.47	4.97e-27	Lung cancer;
LGG	cis	rs2836974	0.563	rs6517522	chr21:40553845	T/C	cg17971929	chr21:40555470	PSMG1	0.69	12.04	0.49	3.13e-29	Cognitive function;
LGG	trans	rs3942852	0.955	rs1503190	chr11:48117873	A/G	cg03929089	chr4:120376271	NA	-0.65	-8.15	-0.35	3.39e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs4555082	0.874	rs2816611	chr14:105722976	G/C	cg10792982	chr14:105748885	BRF1	0.67	13.73	0.54	3.16e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7017914	0.967	rs13256250	chr8:71596193	G/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.93	-0.31	1.39e-11	Bone mineral density;
LGG	cis	rs6089584	1.000	rs6142910	chr20:60562181	C/A	cg06108461	chr20:60628389	TAF4	-0.84	-15.47	-0.58	8.14e-44	Body mass index;
LGG	cis	rs7932354	0.528	rs11039074	chr11:47081732	C/T	cg03339077	chr11:47165057	C11orf49	-0.53	-9.98	-0.42	2.23e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs509477	0.662	rs273343	chr18:32604173	G/C	cg23791764	chr18:32556832	MAPRE2	0.43	7.21	0.32	2.34e-12	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs2067615	0.560	rs1882542	chr12:107070049	A/C	cg15890332	chr12:107067104	RFX4	0.41	11.94	0.49	7.64e-29	Heart rate;
LGG	cis	rs4957048	0.541	rs12519390	chr5:676546	A/G	cg16400903	chr5:693638	TPPP	0.48	6.73	0.3	5.01e-11	Ulcerative colitis;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.03	0.31	7.36e-12	Lung cancer;
LGG	cis	rs6696846	0.765	rs61822619	chr1:205090885	C/G	cg21545522	chr1:205238299	TMCC2	0.37	7.18	0.32	2.79e-12	Red blood cell count;
LGG	cis	rs12477438	0.765	rs7605218	chr2:99593080	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.88	-0.51	1.2e-32	Chronic sinus infection;
LGG	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg01028140	chr2:1542097	TPO	-0.55	-8.55	-0.37	1.82e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs739401	0.572	rs389128	chr11:3083873	G/T	cg08508325	chr11:3079039	CARS	-0.62	-13.56	-0.53	1.6e-35	Longevity;
LGG	cis	rs975722	0.569	rs10245477	chr7:116983083	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	8.23	0.36	1.94e-15	Coronary artery disease;
LGG	trans	rs3942852	0.806	rs10838805	chr11:48118993	A/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.15	-0.39	1.83e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.64	-0.37	9.41e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg20673091	chr1:2541236	MMEL1	0.76	17.62	0.63	1.43e-53	Ulcerative colitis;
LGG	cis	rs981844	1.000	rs17371021	chr4:154664295	A/G	cg14289246	chr4:154710475	SFRP2	-0.7	-11.68	-0.48	8.56e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs6076065	0.748	rs2295239	chr20:23387550	C/T	cg11657817	chr20:23433608	CST11	0.41	8.26	0.36	1.52e-15	Facial morphology (factor 15, philtrum width);
LGG	cis	rs10504229	0.906	rs903718	chr8:58167726	A/G	cg02725872	chr8:58115012	NA	-0.8	-11.86	-0.48	1.67e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.710	rs10831433	chr11:95519787	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	17.76	0.64	3.33e-54	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs3087591	1.000	rs2051507	chr17:29700101	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.64	-0.56	3.74e-40	Hip circumference;
LGG	cis	rs7071206	0.947	rs11002226	chr10:79399656	T/A	cg07817648	chr10:79422355	NA	-0.8	-14.77	-0.57	1.01e-40	Bone mineral density;
LGG	cis	rs2050392	0.630	rs303428	chr10:30739058	C/T	cg25182066	chr10:30743637	MAP3K8	0.54	11.14	0.46	1.12e-25	Inflammatory bowel disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg27550618	chr3:175696286	NA	0.35	7.05	0.31	6.67e-12	Menarche (age at onset);
LGG	cis	rs17453880	0.853	rs10476785	chr5:151973924	A/G	cg12297329	chr5:152029980	NA	-0.87	-22.05	-0.72	3.39e-74	Subjective well-being;
LGG	cis	rs1555322	0.530	rs6060347	chr20:33874151	A/G	cg03689076	chr20:33865952	NA	0.64	8.99	0.39	6.37e-18	Attention deficit hyperactivity disorder;
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg21724239	chr8:58056113	NA	0.51	7.5	0.33	3.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7829975	0.774	rs1703982	chr8:8598388	A/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-9.27	-0.4	7.05e-19	Mood instability;
LGG	cis	rs9300255	0.739	rs10846491	chr12:123753492	C/G	cg00376283	chr12:123451042	ABCB9	0.63	10.05	0.42	1.23e-21	Neutrophil percentage of white cells;
LGG	cis	rs7084402	0.967	rs1649027	chr10:60280911	T/G	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs736408	0.527	rs2577831	chr3:52628056	C/A	cg14092988	chr3:52407081	DNAH1	0.27	7.32	0.32	1.13e-12	Bipolar disorder;
LGG	cis	rs7493	1.000	rs2040993	chr7:95047300	T/A	cg08461772	chr7:95026248	PON3	0.38	8.35	0.36	7.98e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9309473	0.948	rs10173534	chr2:73813432	C/T	cg20560298	chr2:73613845	ALMS1	-0.46	-7.39	-0.32	7.05e-13	Metabolite levels;
LGG	trans	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.67	13.01	0.52	3.38e-33	Intelligence (multi-trait analysis);
LGG	cis	rs72772090	0.539	rs56395748	chr5:96176893	G/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.16	-0.35	3.13e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1153858	0.943	rs1145079	chr15:45681761	T/C	cg10760299	chr15:45669010	GATM	0.4	7.78	0.34	4.67e-14	Homoarginine levels;
LGG	cis	rs1008375	0.932	rs7697329	chr4:17657853	C/A	cg02297831	chr4:17616191	MED28	0.46	8.3	0.36	1.14e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2286885	1.000	rs741025	chr9:129251792	C/T	cg14319473	chr9:129242481	FAM125B	0.45	8.5	0.37	2.58e-16	Intraocular pressure;
LGG	cis	rs7267979	1.000	rs6107046	chr20:25442049	G/A	cg06421707	chr20:25228305	PYGB	0.47	9.98	0.42	2.15e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs853679	0.517	rs9468297	chr6:28118874	G/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.76	-0.34	5.4e-14	Depression;
LGG	cis	rs6076065	0.651	rs6114085	chr20:23419276	T/A	cg12633918	chr20:23549525	CST9L	-0.36	-6.74	-0.3	4.68e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4774899	0.966	rs12908760	chr15:57505217	G/T	cg08128148	chr15:57256372	TCF12	-0.31	-7.21	-0.32	2.35e-12	Urinary tract infection frequency;
LGG	cis	rs1816752	0.811	rs9507337	chr13:24984945	A/T	cg02811702	chr13:24901961	NA	0.4	7.34	0.32	9.63e-13	Obesity-related traits;
LGG	cis	rs4819052	0.634	rs8128636	chr21:46690633	G/T	cg06618935	chr21:46677482	NA	-0.35	-6.86	-0.3	2.21e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs28386778	0.863	rs3826341	chr17:61819222	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.32	0.5	2.34e-30	Prudent dietary pattern;
LGG	trans	rs629535	0.699	rs539956	chr8:70033647	G/A	cg21567404	chr3:27674614	NA	0.4	6.7	0.3	6.04e-11	Dupuytren's disease;
LGG	cis	rs9859260	0.555	rs9877493	chr3:195832147	T/C	cg12923728	chr3:195709715	SDHAP1	-0.53	-8.78	-0.38	3.22e-17	Mean corpuscular volume;
LGG	cis	rs2694528	0.800	rs59292447	chr5:60418014	C/G	cg11474532	chr5:59995715	DEPDC1B	0.68	7.29	0.32	1.35e-12	Parkinson's disease;
LGG	cis	rs765787	0.530	rs1648285	chr15:45517505	C/G	cg25801113	chr15:45476975	SHF	0.87	20.04	0.68	8.71e-65	Uric acid levels;
LGG	cis	rs12477438	0.501	rs7608938	chr2:99782226	C/T	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs4006360	0.579	rs2320223	chr17:39234769	G/T	cg16985667	chr17:39306289	KRTAP4-5	-0.52	-11.32	-0.47	2.12e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs116095464	0.867	rs7726582	chr5:215349	C/G	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg14092988	chr3:52407081	DNAH1	0.32	8.45	0.37	3.86e-16	Bipolar disorder;
LGG	cis	rs4356203	0.870	rs2171615	chr11:17252641	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.29	-0.32	1.39e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs7712401	0.601	rs246315	chr5:122266438	C/T	cg19412675	chr5:122181750	SNX24	0.43	7.17	0.32	3.01e-12	Mean platelet volume;
LGG	cis	rs4363385	0.693	rs10788849	chr1:152902240	C/A	cg07796016	chr1:152779584	LCE1C	-0.46	-7.19	-0.32	2.65e-12	Inflammatory skin disease;
LGG	cis	rs155076	0.666	rs9509640	chr13:21872880	T/C	cg11317459	chr13:21872234	NA	1.41	25.82	0.77	1.05e-91	White matter hyperintensity burden;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06638810	chr6:161695210	AGPAT4	0.49	7.27	0.32	1.52e-12	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs112343653	chr5:257174	G/A	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs9868809	0.881	rs13076269	chr3:48675925	T/C	cg00383909	chr3:49044727	WDR6	0.81	9.34	0.4	4.12e-19	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.59	-11.9	-0.48	1.17e-28	Presence of antiphospholipid antibodies;
LGG	trans	rs1728785	0.901	rs11642189	chr16:68583990	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs2186369	0.681	rs2073389	chr22:24133493	C/T	cg10122452	chr22:24128767	SMARCB1	-0.4	-7.89	-0.34	2.2e-14	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg07460842	chr6:66804631	NA	0.74	12.76	0.51	3.64e-32	Type 2 diabetes;
LGG	cis	rs651907	1.000	rs665211	chr3:101600028	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.39	7.52	0.33	2.9e-13	Colorectal cancer;
LGG	cis	rs9308731	1.000	rs2015454	chr2:111872148	A/G	cg19992207	chr2:111874495	ACOXL	-0.39	-7.02	-0.31	7.99e-12	Chronic lymphocytic leukemia;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs3768617	0.510	rs1413387	chr1:183096774	G/A	cg07245641	chr1:182991651	LAMC1	0.41	9.21	0.39	1.16e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1577917	1.000	rs1337850	chr6:86729103	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.42	-0.53	6.63e-35	Response to antipsychotic treatment;
LGG	cis	rs17826219	0.500	rs2449749	chr17:29078298	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs13108904	0.905	rs11247983	chr4:1281951	C/G	cg05665937	chr4:1216051	CTBP1	0.59	10.97	0.45	4.92e-25	Obesity-related traits;
LGG	cis	rs1372356	0.816	rs10130801	chr14:88528910	T/C	cg18078958	chr14:88630771	NA	0.3	7.31	0.32	1.15e-12	Food antigen IgG levels;
LGG	cis	rs13427251	0.692	rs17765112	chr2:100149336	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.53	-9.22	-0.39	1.08e-18	Chronic sinus infection;
LGG	cis	rs4653767	1.000	rs708774	chr1:226921530	C/G	cg00279406	chr1:226924739	ITPKB	0.27	6.91	0.31	1.63e-11	Parkinson's disease;
LGG	cis	rs2204008	0.777	rs114096617	chr12:38342557	A/C	cg04568710	chr12:38710424	ALG10B	0.33	6.65	0.3	8.52e-11	Bladder cancer;
LGG	cis	rs12286929	0.576	rs2275997	chr11:115100186	A/G	cg04055981	chr11:115044050	NA	0.36	6.72	0.3	5.37e-11	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10876993	0.890	rs10783844	chr12:58098425	A/C	cg18357645	chr12:58087776	OS9	0.71	12.65	0.51	1.01e-31	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs17376456	0.825	rs10056879	chr5:93282218	C/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.37	0.4	3.25e-19	Diabetic retinopathy;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg14307892	chr10:124767941	IKZF5;ACADSB	0.39	6.75	0.3	4.4e-11	Eye color traits;
LGG	cis	rs2046867	0.529	rs62249900	chr3:72951863	T/C	cg25664220	chr3:72788482	NA	-0.26	-7.39	-0.32	6.72e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs992157	0.710	rs12612347	chr2:219057338	C/T	cg00012203	chr2:219082015	ARPC2	-0.82	-16.27	-0.6	2.21e-47	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23147149	chr17:2304328	MNT	0.45	7.07	0.31	5.6e-12	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05021896	chr14:51562526	TRIM9	0.57	9.59	0.41	5.38e-20	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.63	10.56	0.44	1.72e-23	Longevity;
LGG	cis	rs875971	0.756	rs2901210	chr7:66017505	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.18	-0.52	6.29e-34	Aortic root size;
LGG	cis	rs7296418	0.518	rs28825193	chr12:123878262	T/C	cg05973401	chr12:123451056	ABCB9	0.43	6.98	0.31	1.01e-11	Platelet count;
LGG	trans	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg21051086	chr3:73046214	PPP4R2	-0.38	-6.75	-0.3	4.54e-11	Pancreatic cancer;
LGG	cis	rs4650994	0.525	rs4651000	chr1:178532223	A/G	cg19399532	chr1:178512495	C1orf220	0.55	10.93	0.45	6.57e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.18	0.32	2.75e-12	Menopause (age at onset);
LGG	cis	rs9486715	0.793	rs2499777	chr6:97013814	T/C	cg06623918	chr6:96969491	KIAA0776	-0.8	-16.35	-0.6	9.64e-48	Headache;
LGG	cis	rs7737355	1.000	rs6876350	chr5:130604109	G/T	cg06307176	chr5:131281290	NA	0.51	8.47	0.37	3.37e-16	Life satisfaction;
LGG	trans	rs2204008	0.837	rs11180482	chr12:38235950	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.75	-0.38	4.1e-17	Bladder cancer;
LGG	cis	rs68170813	0.559	rs6967745	chr7:106850548	G/T	cg02696742	chr7:106810147	HBP1	-0.74	-10.65	-0.44	7.82e-24	Coronary artery disease;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg15112475	chr7:1198522	ZFAND2A	-0.4	-7.2	-0.32	2.41e-12	Longevity;Endometriosis;
LGG	cis	rs1519814	1.000	rs6469902	chr8:121171911	A/T	cg22335954	chr8:121166405	COL14A1	-0.56	-11.46	-0.47	6.11e-27	Breast cancer;
LGG	trans	rs9467711	0.591	rs6913795	chr6:25848025	T/C	cg01620082	chr3:125678407	NA	-0.7	-6.92	-0.31	1.55e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg17691542	chr6:26056736	HIST1H1C	0.57	10.3	0.43	1.53e-22	Height;
LGG	cis	rs7582180	0.629	rs11684516	chr2:100949883	C/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.33e-11	Intelligence (multi-trait analysis);
LGG	cis	rs912057	0.901	rs744056	chr6:6733540	A/G	cg06612196	chr6:6737390	NA	0.41	8.26	0.36	1.57e-15	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg10141938	chr7:26240087	HNRNPA2B1;CBX3	-0.4	-6.65	-0.3	8.4e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs9467711	0.720	rs35627490	chr6:26462104	C/T	cg01620082	chr3:125678407	NA	-0.76	-7.62	-0.33	1.43e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs62025270	0.688	rs76902341	chr15:86280290	T/C	cg25843651	chr15:86329602	KLHL25	0.58	9.04	0.39	4.27e-18	Idiopathic pulmonary fibrosis;
LGG	cis	rs7617773	0.963	rs12494304	chr3:48178029	C/T	cg11946769	chr3:48343235	NME6	-0.5	-8.05	-0.35	6.88e-15	Coronary artery disease;
LGG	cis	rs17345786	1.000	rs3804778	chr3:101294572	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.64	-11.01	-0.46	3.23e-25	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.830	rs10001702	chr4:99065160	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.36	4.23e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg14593290	chr7:50529359	DDC	0.65	11.81	0.48	2.49e-28	Malaria;
LGG	cis	rs9896933	0.667	rs2253131	chr17:80696547	T/A	cg15664640	chr17:80829946	TBCD	-0.65	-9.2	-0.39	1.25e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	trans	rs7819412	0.668	rs4841507	chr8:11046394	C/G	cg16141378	chr3:129829833	LOC729375	0.3	6.78	0.3	3.63e-11	Triglycerides;
LGG	trans	rs4718428	0.705	rs12698547	chr7:66278258	T/C	cg10756647	chr7:56101905	PSPH	0.46	6.96	0.31	1.16e-11	Corneal structure;
LGG	cis	rs4808199	0.739	rs2240117	chr19:19418916	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.45	7.8	0.34	4.08e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs9790314	0.905	rs6441370	chr3:160993754	C/T	cg03342759	chr3:160939853	NMD3	-0.68	-12.34	-0.5	1.93e-30	Morning vs. evening chronotype;
LGG	cis	rs12912251	1.000	rs7163869	chr15:38988391	G/C	cg01338139	chr15:38987640	C15orf53	-0.55	-8.82	-0.38	2.42e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs9815354	0.812	rs73071222	chr3:41986896	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6121246	0.954	rs73241710	chr20:30424956	G/A	cg21427119	chr20:30132790	HM13	-0.44	-7.46	-0.33	4.2e-13	Mean corpuscular hemoglobin;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg07701084	chr6:150067640	NUP43	0.43	7.99	0.35	1.07e-14	Testicular germ cell tumor;
LGG	trans	rs34119086	1	rs34119086	chr6:28562247	TG/T	cg01620082	chr3:125678407	NA	-1.08	-10.22	-0.43	2.92e-22	Breast cancer;
LGG	cis	rs9302635	0.513	rs3812987	chr16:72158920	C/A	cg01557791	chr16:72042693	DHODH	-0.58	-9.17	-0.39	1.56e-18	Blood protein levels;
LGG	cis	rs9916302	0.904	rs8076494	chr17:37516722	A/G	cg07936489	chr17:37558343	FBXL20	0.84	15.41	0.58	1.57e-43	Glomerular filtration rate (creatinine);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23036426	chr1:10093530	UBE4B	0.42	6.75	0.3	4.51e-11	Gut microbiome composition (summer);
LGG	cis	rs11690935	0.959	rs4667694	chr2:172605399	G/A	cg13550731	chr2:172543902	DYNC1I2	-1.06	-26.36	-0.77	3.35e-94	Schizophrenia;
LGG	trans	rs6951245	0.872	rs112309216	chr7:1100296	A/T	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9814567	1.000	rs9289476	chr3:134237103	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.35	-0.53	1.23e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg05692746	chr2:100937584	LONRF2	-0.58	-10.2	-0.43	3.52e-22	Intelligence (multi-trait analysis);
LGG	cis	rs8072100	0.720	rs4794057	chr17:45786452	C/T	cg25173405	chr17:45401733	C17orf57	-0.5	-8.4	-0.36	5.66e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10504229	0.679	rs72649107	chr8:58030453	C/A	cg02725872	chr8:58115012	NA	-0.85	-12.22	-0.49	6.06e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs155076	0.938	rs261375	chr13:21871882	A/G	cg21970626	chr13:21893289	NA	-0.43	-6.99	-0.31	9.72e-12	White matter hyperintensity burden;
LGG	trans	rs6787172	0.564	rs4289388	chr3:158164288	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.45	-0.33	4.69e-13	Subjective well-being;
LGG	cis	rs4332037	0.950	rs11771828	chr7:1941003	T/C	cg12591125	chr7:1885375	MAD1L1	0.46	6.69	0.3	6.45e-11	Bipolar disorder;
LGG	cis	rs4740619	0.901	rs4741510	chr9:15591372	A/T	cg14451791	chr9:16040625	NA	-0.39	-10.08	-0.42	9.42e-22	Body mass index;
LGG	cis	rs7618501	0.602	rs2245365	chr3:50097319	C/A	cg05623727	chr3:50126028	RBM5	-0.33	-7.08	-0.31	5.55e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1614887	1	rs1614887	chr6:26393021	A/G	cg09904177	chr6:26538194	HMGN4	0.53	9.89	0.42	4.8e-21	Intelligence (multi-trait analysis);Lobe attachment (rater-scored or self-reported);
LGG	cis	rs757081	0.634	rs17472942	chr11:17094702	A/G	cg15432903	chr11:17409602	KCNJ11	-0.53	-8.69	-0.37	6.14e-17	Systolic blood pressure;
LGG	cis	rs2477686	0.526	rs2477690	chr1:2395563	G/A	cg02275930	chr1:2372054	NA	-0.87	-17.4	-0.63	1.48e-52	Non-obstructive azoospermia;
LGG	cis	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg04455712	chr21:45112962	RRP1B	0.49	8.96	0.38	7.91e-18	Mean corpuscular volume;
LGG	cis	rs7794364	0.538	rs10233018	chr7:117523709	A/G	cg21880328	chr7:117514017	CTTNBP2	-0.34	-7.01	-0.31	8.57e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs504918	1.000	rs653269	chr3:124102139	G/T	cg05766129	chr3:123988013	KALRN	0.38	6.98	0.31	1.02e-11	Schizophrenia;
LGG	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg22563815	chr15:78856949	CHRNA5	0.27	6.85	0.3	2.38e-11	Sudden cardiac arrest;
LGG	cis	rs4538187	1.000	rs4671071	chr2:64085638	C/T	cg02541582	chr2:64069798	UGP2	0.61	14.46	0.56	2.21e-39	Systolic blood pressure;
LGG	cis	rs6831352	0.959	rs4699710	chr4:100051819	C/T	cg12011299	chr4:100065546	ADH4	0.45	9.27	0.4	6.97e-19	Alcohol dependence;
LGG	cis	rs2694528	0.858	rs7723754	chr5:60466269	C/T	cg11474532	chr5:59995715	DEPDC1B	0.69	7.5	0.33	3.25e-13	Parkinson's disease;
LGG	cis	rs921968	0.643	rs2278530	chr2:219501133	G/A	cg01130898	chr2:219473002	PLCD4	-0.38	-6.72	-0.3	5.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2153535	0.580	rs6921036	chr6:8455400	G/A	cg21535247	chr6:8435926	SLC35B3	0.6	10.18	0.43	4.37e-22	Motion sickness;
LGG	trans	rs75804782	0.641	rs72987309	chr2:239348025	A/G	cg01134436	chr17:81009848	B3GNTL1	0.82	8.69	0.37	6.49e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.01	-0.31	8.74e-12	Bipolar disorder;
LGG	cis	rs1712517	0.566	rs7917388	chr10:105054963	C/T	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.48e-15	Migraine;
LGG	trans	rs1814175	0.645	rs11040702	chr11:50024827	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.81	-0.71	4.42e-73	Height;
LGG	cis	rs9303401	0.659	rs16943326	chr17:57050365	C/T	cg25039879	chr17:56429692	SUPT4H1	0.63	8.83	0.38	2.16e-17	Cognitive test performance;
LGG	cis	rs2073300	1.000	rs78000067	chr20:23439507	A/G	cg12062639	chr20:23401060	NAPB	0.86	6.96	0.31	1.19e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs787274	1.000	rs2796035	chr9:115515597	C/T	cg13803584	chr9:115635662	SNX30	-0.58	-7.36	-0.32	8.51e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs13118159	0.801	rs10024996	chr4:1328297	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.48	0.33	3.87e-13	Longevity;
LGG	cis	rs727505	0.721	rs67607629	chr7:124765867	C/T	cg23710748	chr7:124431027	NA	-0.41	-8.23	-0.36	1.86e-15	Lewy body disease;
LGG	cis	rs2282802	0.651	rs10060071	chr5:139599097	T/C	cg26211634	chr5:139558579	C5orf32	0.34	7.51	0.33	3.04e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6546550	0.901	rs4852375	chr2:70125988	C/G	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.04e-15	Prevalent atrial fibrillation;
LGG	cis	rs9291683	0.609	rs13149985	chr4:10028390	G/A	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.67e-25	Bone mineral density;
LGG	cis	rs909674	0.541	rs5757655	chr22:39797178	C/G	cg11247378	chr22:39784982	NA	0.32	9.29	0.4	5.92e-19	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.6	-0.53	1.1e-35	Personality dimensions;
LGG	cis	rs9354308	0.764	rs9294672	chr6:66604801	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs4924590	0.550	rs1426889	chr15:42231658	C/T	cg20935245	chr15:42234343	EHD4	-0.42	-7.92	-0.35	1.83e-14	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LGG	cis	rs11966931	0.947	rs72935321	chr6:108122137	G/A	cg04749840	chr6:108095067	SCML4	0.45	7.65	0.33	1.2e-13	Neutrophil percentage of white cells;
LGG	cis	rs950169	0.840	rs62019457	chr15:85102142	T/C	cg03959625	chr15:84868606	LOC388152	0.58	9.36	0.4	3.51e-19	Schizophrenia;
LGG	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.84	-0.51	1.76e-32	Chronic sinus infection;
LGG	cis	rs7937682	1.000	rs9734135	chr11:111536190	G/A	cg19812747	chr11:111475976	SIK2	-0.46	-9.29	-0.4	5.9e-19	Primary sclerosing cholangitis;
LGG	cis	rs11252926	0.604	rs2050970	chr10:515870	C/T	cg08603382	chr10:743973	NA	0.44	8.08	0.35	5.8e-15	Psychosis in Alzheimer's disease;
LGG	cis	rs2797369	0.665	rs2749129	chr6:101454056	A/C	cg27451362	chr6:101846650	GRIK2	0.76	10.36	0.43	8.93e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs72945132	0.882	rs56368190	chr11:70204328	T/G	cg00319359	chr11:70116639	PPFIA1	0.73	7.9	0.34	1.98e-14	Coronary artery disease;
LGG	trans	rs208520	0.690	rs10455194	chr6:66743356	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.75	0.64	3.64e-54	Exhaled nitric oxide output;
LGG	cis	rs8180040	0.726	rs10461018	chr3:46995242	C/T	cg16586182	chr3:47516702	SCAP	0.72	12.87	0.51	1.23e-32	Colorectal cancer;
LGG	cis	rs77106637	1.000	rs3862791	chr11:72501002	C/T	cg03713592	chr11:72463424	ARAP1	0.39	7.3	0.32	1.3e-12	Type 2 diabetes;
LGG	cis	rs734999	0.545	rs12752515	chr1:2564465	T/C	cg15627072	chr1:2432621	PLCH2	-0.35	-7.85	-0.34	3.01e-14	Ulcerative colitis;
LGG	cis	rs2120243	0.539	rs7618737	chr3:157095621	G/A	cg24825693	chr3:157122686	VEPH1	-0.57	-12.94	-0.52	6.44e-33	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4363385	0.818	rs11205167	chr1:152989727	T/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.84	-0.38	1.96e-17	Inflammatory skin disease;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19057882	chr20:37101373	RALGAPB	0.4	6.66	0.3	7.84e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs597539	0.652	rs513359	chr11:68669496	A/T	cg04008888	chr11:68622739	NA	0.54	11.5	0.47	4.32e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9354308	0.738	rs9342514	chr6:66591188	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs9522267	0.535	rs4773392	chr13:112227358	A/G	cg10483660	chr13:112241077	NA	0.37	7.99	0.35	1.11e-14	Hepatitis;
LGG	cis	rs9325144	0.624	rs7312879	chr12:39150752	G/A	cg26384229	chr12:38710491	ALG10B	-0.7	-13.37	-0.53	1.05e-34	Morning vs. evening chronotype;
LGG	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	Myopia (pathological);
LGG	cis	rs9309473	1.000	rs6546839	chr2:73680508	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.5	-0.33	3.22e-13	Metabolite levels;
LGG	cis	rs7582180	0.629	rs11686880	chr2:100956229	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.37	-0.61	7.72e-48	Intelligence (multi-trait analysis);
LGG	cis	rs757110	0.770	rs11024271	chr11:17395540	T/C	cg04705435	chr11:17411270	KCNJ11	0.43	8.48	0.37	3.02e-16	Type 2 diabetes;
LGG	cis	rs490234	0.841	rs521119	chr9:128314394	T/C	cg14078157	chr9:128172775	NA	0.44	8.25	0.36	1.69e-15	Mean arterial pressure;
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg09699651	chr6:150184138	LRP11	0.52	9.2	0.39	1.27e-18	Lung cancer;
LGG	cis	rs7172689	1.000	rs7172689	chr15:81533695	C/T	cg11808699	chr15:81528661	IL16	-0.5	-10.27	-0.43	2.06e-22	Inattentive symptoms;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg05414835	chr15:59225898	SLTM	-0.34	-6.65	-0.3	8.4e-11	Iris color (L* coordinate);
LGG	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg06532163	chr17:45867833	NA	0.55	9.33	0.4	4.58e-19	IgG glycosylation;
LGG	trans	rs3960554	0.610	rs10265696	chr7:75766712	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.43	0.5	7.87e-31	Eotaxin levels;
LGG	cis	rs1957429	0.808	rs4899150	chr14:65344400	A/G	cg23373153	chr14:65346875	NA	1.0	12.37	0.5	1.5e-30	Pediatric areal bone mineral density (radius);
LGG	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg11266682	chr4:10021025	SLC2A9	0.53	10.51	0.44	2.53e-23	Bone mineral density;
LGG	trans	rs80264589	1	rs80264589	chr6:26927602	G/A	cg08344181	chr3:125677491	NA	-0.78	-8.01	-0.35	9.16e-15	Lung cancer;Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.728	rs1011749	chr16:89510869	G/C	cg06640241	chr16:89574553	SPG7	0.85	15.52	0.58	4.87e-44	Multiple myeloma (IgH translocation);
LGG	cis	rs9362426	1.000	rs242271	chr6:88082029	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	9.98	0.42	2.24e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs1348850	0.526	rs4893829	chr2:178399810	A/G	cg23306229	chr2:178417860	TTC30B	-0.72	-8.77	-0.38	3.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4732038	0.510	rs55798822	chr7:134272131	T/C	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs7098414	0.511	rs7907575	chr10:82152675	T/G	cg01528321	chr10:82214614	TSPAN14	0.67	11.99	0.49	4.89e-29	Post bronchodilator FEV1;
LGG	cis	rs9911578	1.000	rs2009948	chr17:56611920	A/C	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9534288	0.956	rs962694	chr13:46619026	T/C	cg15192986	chr13:46630673	CPB2	-0.73	-16.0	-0.6	3.59e-46	Blood protein levels;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg15218456	chr17:25289681	NA	0.36	6.77	0.3	3.84e-11	Parkinson's disease (motor and cognition);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19720917	chr19:36606221	POLR2I;TBCB	0.42	7.44	0.33	5.08e-13	Obesity-related traits;
LGG	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg22484793	chr3:52261325	TLR9	0.3	6.94	0.31	1.3e-11	Bipolar disorder;
LGG	trans	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.74	-0.34	6.17e-14	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10211518	chr19:633735	POLRMT	0.55	8.3	0.36	1.13e-15	Gut microbiome composition (summer);
LGG	cis	rs12477438	0.520	rs7560996	chr2:100025483	G/A	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs12586317	0.576	rs2415265	chr14:35630388	A/G	cg16230307	chr14:35515116	FAM177A1	0.43	7.54	0.33	2.55e-13	Psoriasis;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs951366	0.764	rs823143	chr1:205743425	A/C	cg17178900	chr1:205818956	PM20D1	0.58	12.79	0.51	2.78e-32	Menarche (age at onset);
LGG	trans	rs853679	0.607	rs13211507	chr6:28257377	T/C	cg06606381	chr12:133084897	FBRSL1	-1.28	-12.23	-0.49	5.51e-30	Depression;
LGG	cis	rs73787773	0.644	rs76177172	chr5:111474244	C/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.2	-0.32	2.44e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs8017423	0.967	rs11845329	chr14:90727749	C/T	cg04374321	chr14:90722782	PSMC1	0.9	19.54	0.67	1.87e-62	Mortality in heart failure;
LGG	cis	rs17767392	0.633	rs7160587	chr14:71704684	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.25	-0.32	1.74e-12	Mitral valve prolapse;
LGG	cis	rs2153535	0.580	rs9328484	chr6:8524843	A/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.66	0.51	9.67e-32	Motion sickness;
LGG	cis	rs7954584	0.813	rs12827200	chr12:122451278	G/A	cg10207240	chr12:122356781	WDR66	0.24	7.37	0.32	7.71e-13	Mean corpuscular volume;
LGG	cis	rs3796619	1.000	rs55741287	chr4:1094670	T/C	cg21130718	chr4:1044621	NA	0.38	7.23	0.32	1.96e-12	Recombination rate (males);
LGG	cis	rs9611565	0.729	rs9611570	chr22:41782721	G/T	cg17376030	chr22:41985996	PMM1	0.53	8.65	0.37	8.52e-17	Vitiligo;
LGG	cis	rs12464483	0.524	rs2602772	chr2:30885263	C/A	cg07150166	chr2:30669952	LCLAT1	0.62	8.6	0.37	1.2e-16	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16360987	chr14:96829588	ATG2B	0.62	7.09	0.31	4.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7219021	0.669	rs35584414	chr17:47022727	C/G	cg09029085	chr17:47094198	IGF2BP1	0.27	6.71	0.3	5.77e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs7649275	0.882	rs7373253	chr3:53789594	T/C	cg21503701	chr3:53781065	CACNA1D	-0.47	-7.36	-0.32	8.57e-13	Trans fatty acid levels;
LGG	cis	rs308971	0.656	rs307563	chr3:12055011	G/T	cg15873301	chr3:12045459	SYN2	0.54	7.82	0.34	3.6e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.8	-0.41	9.56e-21	Aortic root size;
LGG	cis	rs9595066	1.000	rs4942282	chr13:44708416	G/A	cg04068111	chr13:44716778	NA	-0.57	-8.11	-0.35	4.64e-15	Schizophrenia;
LGG	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg21798802	chr22:38057573	PDXP	0.39	8.34	0.36	8.31e-16	Fat distribution (HIV);
LGG	cis	rs10504229	1.000	rs9650139	chr8:58190508	G/T	cg11062466	chr8:58055876	NA	0.48	8.26	0.36	1.49e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4689592	0.546	rs10937784	chr4:7060935	G/C	cg26116260	chr4:7069785	GRPEL1	1.14	22.37	0.72	1.08e-75	Monocyte percentage of white cells;
LGG	cis	rs6582630	0.502	rs1589390	chr12:38416139	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.01	-0.39	5.52e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs67478160	0.572	rs8015603	chr14:104293678	C/G	cg26031613	chr14:104095156	KLC1	-0.43	-7.0	-0.31	9.04e-12	Schizophrenia;
LGG	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.32	-0.58	3.76e-43	Chronic sinus infection;
LGG	cis	rs757278	0.543	rs35941557	chr7:117372067	A/G	cg10524701	chr7:117356490	CTTNBP2	0.42	7.4	0.33	6.63e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs10504229	0.689	rs17801390	chr8:58054768	T/C	cg02725872	chr8:58115012	NA	-0.97	-12.73	-0.51	4.94e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs826838	1.000	rs2129627	chr12:38653036	C/T	cg26384229	chr12:38710491	ALG10B	1.05	27.9	0.79	3.32e-101	Heart rate;
LGG	cis	rs9420907	0.748	rs9419958	chr10:105675946	T/C	cg11005552	chr10:105648138	OBFC1	0.68	8.71	0.38	5.59e-17	Telomere length;
LGG	cis	rs12618769	0.597	rs2278206	chr2:99172244	A/G	cg18455616	chr2:99124870	INPP4A	0.27	7.65	0.34	1.17e-13	Bipolar disorder;
LGG	trans	rs9329221	0.521	rs17693945	chr8:10106010	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.2	-0.32	2.4e-12	Neuroticism;
LGG	cis	rs6732160	0.684	rs2043095	chr2:73407442	T/C	cg01422370	chr2:73384389	NA	0.49	9.42	0.4	2.13e-19	Intelligence (multi-trait analysis);
LGG	cis	rs193541	0.632	rs6878609	chr5:122095549	C/G	cg19412675	chr5:122181750	SNX24	0.52	8.37	0.36	7.02e-16	Glucose homeostasis traits;
LGG	cis	rs6768930	0.509	rs7627431	chr3:57723828	T/G	cg01571842	chr3:57934672	NA	0.3	6.7	0.3	5.89e-11	Obesity-related traits;
LGG	cis	rs17209837	0.915	rs7805184	chr7:87118601	G/A	cg00919237	chr7:87102261	ABCB4	-0.74	-12.0	-0.49	4.55e-29	Gallbladder cancer;
LGG	cis	rs897984	0.644	rs73524556	chr16:30823162	G/A	cg02466173	chr16:30829666	NA	-0.6	-12.06	-0.49	2.63e-29	Dementia with Lewy bodies;
LGG	cis	rs6748734	0.817	rs4465762	chr2:241798862	G/A	cg07537917	chr2:241836409	C2orf54	-0.39	-7.87	-0.34	2.58e-14	Urinary metabolites;
LGG	cis	rs3916	0.955	rs2066938	chr12:121160615	A/G	cg21892295	chr12:121157589	UNC119B	-0.42	-7.41	-0.33	6.23e-13	Urinary metabolites (H-NMR features);
LGG	cis	rs7584330	0.910	rs6757376	chr2:238400036	G/C	cg16989719	chr2:238392110	NA	-0.32	-7.03	-0.31	7.26e-12	Prostate cancer;
LGG	cis	rs10927875	0.632	rs904911	chr1:16126932	C/T	cg21385522	chr1:16154831	NA	-1.04	-25.65	-0.77	6.13e-91	Dilated cardiomyopathy;
LGG	cis	rs12765878	0.603	rs2475213	chr10:105664459	A/T	cg11005552	chr10:105648138	OBFC1	0.72	12.93	0.52	7.32e-33	Coronary artery disease;
LGG	cis	rs36071027	0.554	rs34366240	chr5:158425013	C/A	cg04248271	chr5:158524404	EBF1	0.42	7.45	0.33	4.61e-13	Carotid intima media thickness;
LGG	cis	rs8031584	0.958	rs11637469	chr15:31238783	T/C	cg08704250	chr15:31115839	NA	-0.42	-7.83	-0.34	3.42e-14	Huntington's disease progression;
LGG	trans	rs7395662	0.777	rs7114291	chr11:48608251	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.79e-15	HDL cholesterol;
LGG	cis	rs11098499	0.863	rs9884402	chr4:120489982	A/G	cg24375607	chr4:120327624	NA	0.68	11.18	0.46	7.68e-26	Corneal astigmatism;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.58	0.33	1.9e-13	Neutrophil percentage of white cells;
LGG	cis	rs2841277	0.738	rs1036713	chr14:105396693	C/G	cg14403583	chr14:105418241	AHNAK2	0.63	11.77	0.48	3.68e-28	Rheumatoid arthritis;
LGG	trans	rs877282	0.898	rs35743076	chr10:758991	C/T	cg22713356	chr15:30763199	NA	0.49	7.52	0.33	2.89e-13	Uric acid levels;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.41	0.36	4.97e-16	Prudent dietary pattern;
LGG	cis	rs1790761	0.967	rs1790753	chr11:67201008	C/T	cg23188684	chr11:67383651	NA	-0.41	-6.76	-0.3	4.17e-11	Mean corpuscular volume;
LGG	cis	rs6952808	0.608	rs6461049	chr7:2017445	C/T	cg22963979	chr7:1858916	MAD1L1	0.43	8.42	0.36	4.7e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9463078	0.547	rs1418434	chr6:44748365	C/T	cg25276700	chr6:44698697	NA	-0.4	-8.22	-0.36	2.12e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs12190007	1.000	rs12211973	chr6:169727141	T/C	cg16388071	chr6:169726476	NA	-0.35	-6.77	-0.3	3.88e-11	Obesity-related traits;
LGG	cis	rs2088885	0.846	rs4502609	chr3:170976903	A/G	cg18052528	chr3:170975382	TNIK	-0.28	-6.84	-0.3	2.45e-11	Brain imaging in schizophrenia (dorsolateral prefrontal cortex interaction);
LGG	cis	rs10949834	1.000	rs10949835	chr7:73488922	A/G	cg07137043	chr7:73588983	EIF4H	-0.69	-7.7	-0.34	8.16e-14	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs7726839	0.794	rs11739663	chr5:594083	A/G	cg09021430	chr5:549028	NA	-0.69	-12.02	-0.49	3.85e-29	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs609063	chr17:28951513	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6912958	0.781	rs3757368	chr6:88224495	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.47	-8.34	-0.36	8.85e-16	Monocyte percentage of white cells;
LGG	cis	rs5760092	0.618	rs5996631	chr22:24256894	T/C	cg00024416	chr22:24240387	NA	0.47	7.73	0.34	6.7e-14	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs208520	0.874	rs208470	chr6:66916402	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.9	-15.26	-0.58	7.17e-43	Exhaled nitric oxide output;
LGG	cis	rs2072732	0.861	rs12567620	chr1:2956999	T/G	cg08733933	chr1:2954429	NA	-0.43	-8.56	-0.37	1.63e-16	Plateletcrit;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.24	-0.32	1.91e-12	Life satisfaction;
LGG	cis	rs2361718	0.500	rs12451697	chr17:78100690	T/A	cg21238619	chr17:78079768	GAA	-0.49	-9.47	-0.4	1.47e-19	Yeast infection;
LGG	cis	rs875971	0.862	rs11984115	chr7:65773859	C/T	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs2153535	0.563	rs1737585	chr6:8536594	A/G	cg21535247	chr6:8435926	SLC35B3	-0.59	-10.1	-0.42	8.09e-22	Motion sickness;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg16437679	chr6:146056419	EPM2A	0.59	6.66	0.3	7.67e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7584330	0.868	rs58057291	chr2:238395479	T/A	cg16989719	chr2:238392110	NA	-0.38	-7.83	-0.34	3.41e-14	Prostate cancer;
LGG	cis	rs2115630	0.645	rs3825877	chr15:85174631	G/A	cg24253500	chr15:84953950	NA	-0.42	-7.75	-0.34	6.07e-14	P wave terminal force;
LGG	cis	rs17641971	0.645	rs186891	chr8:50038758	T/C	cg00325661	chr8:49890786	NA	0.56	10.51	0.44	2.59e-23	Blood metabolite levels;
LGG	cis	rs1862618	0.853	rs10051747	chr5:56083289	C/A	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.76	-0.34	5.32e-14	Initial pursuit acceleration;
LGG	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg03078520	chr22:18463400	MICAL3	0.61	12.47	0.5	5.44e-31	Presence of antiphospholipid antibodies;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg27144592	chr16:783916	NARFL	0.42	7.06	0.31	6e-12	Height;
LGG	cis	rs9952991	0.566	rs657555	chr18:12847136	C/T	cg23598886	chr18:12777645	NA	0.53	7.44	0.33	4.82e-13	Inflammatory skin disease;
LGG	cis	rs4481887	0.927	rs6678798	chr1:248476617	C/T	cg13385794	chr1:248469461	NA	0.49	8.41	0.36	5.22e-16	Common traits (Other);
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.51	0.37	2.47e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	0.762	rs11745923	chr5:475408	T/G	cg26850624	chr5:429559	AHRR	-0.35	-7.48	-0.33	3.66e-13	Cystic fibrosis severity;
LGG	trans	rs61931739	0.534	rs1352206	chr12:34036668	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.3e-41	Morning vs. evening chronotype;
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg13013644	chr5:502571	SLC9A3	-0.3	-6.76	-0.3	4.06e-11	Cystic fibrosis severity;
LGG	cis	rs7927771	0.524	rs12362318	chr11:47682671	T/C	cg20307385	chr11:47447363	PSMC3	0.56	10.89	0.45	9.65e-25	Subjective well-being;
LGG	cis	rs2693698	0.651	rs11160507	chr14:99683302	T/A	cg07440398	chr14:99712966	BCL11B	0.58	11.85	0.48	1.72e-28	Schizophrenia;
LGG	trans	rs11098499	0.691	rs9995716	chr4:120264996	T/C	cg25214090	chr10:38739885	LOC399744	0.56	10.36	0.43	9.02e-23	Corneal astigmatism;
LGG	trans	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg02002194	chr4:3960332	NA	0.48	9.19	0.39	1.29e-18	Systolic blood pressure;
LGG	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg02631450	chr22:32366979	NA	0.85	9.26	0.4	7.48e-19	Childhood ear infection;
LGG	cis	rs11098499	0.909	rs35165976	chr4:120325630	G/A	cg24375607	chr4:120327624	NA	0.67	11.1	0.46	1.47e-25	Corneal astigmatism;
LGG	cis	rs8010715	0.636	rs3825584	chr14:24587639	C/T	cg06429887	chr14:24600500	FITM1	0.35	7.23	0.32	2.03e-12	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg09699651	chr6:150184138	LRP11	0.5	8.77	0.38	3.4e-17	Lung cancer;
LGG	trans	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.92	-0.35	1.74e-14	Neuroticism;
LGG	cis	rs9467773	0.967	rs1535276	chr6:26520941	T/C	cg09904177	chr6:26538194	HMGN4	0.78	17.94	0.64	4.85e-55	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.825	rs8180562	chr6:28141460	G/A	cg01620082	chr3:125678407	NA	-0.66	-7.34	-0.32	9.78e-13	Depression;
LGG	cis	rs2980439	0.846	rs2980437	chr8:8094763	C/T	cg15556689	chr8:8085844	FLJ10661	-0.57	-10.9	-0.45	8.62e-25	Neuroticism;
LGG	cis	rs3806843	1.000	rs10037757	chr5:140197222	G/T	cg19875535	chr5:140030758	IK	0.49	9.97	0.42	2.54e-21	Depressive symptoms (multi-trait analysis);
LGG	cis	rs796364	0.806	rs10931890	chr2:201102055	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.71	-8.65	-0.37	8.27e-17	Schizophrenia;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg00684032	chr4:1343700	KIAA1530	0.51	10.02	0.42	1.61e-21	Obesity-related traits;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.55	9.44	0.4	1.87e-19	Electroencephalogram traits;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs9303401	0.734	rs8073316	chr17:57211381	A/T	cg10487724	chr17:56770010	TEX14;RAD51C	-0.53	-8.92	-0.38	1.08e-17	Cognitive test performance;
LGG	cis	rs12477438	0.520	rs6708576	chr2:99801308	G/A	cg08885076	chr2:99613938	TSGA10	0.43	9.24	0.39	8.95e-19	Chronic sinus infection;
LGG	cis	rs80282103	0.571	rs56183119	chr10:1068370	C/T	cg08668510	chr10:1095578	IDI1	0.76	7.9	0.34	2.07e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs3816183	0.602	rs4350800	chr2:43113206	A/G	cg14631114	chr2:43023945	NA	-0.38	-6.92	-0.31	1.47e-11	Hypospadias;
LGG	cis	rs4731207	0.662	rs6466950	chr7:124453074	G/C	cg05630886	chr7:124431682	NA	0.33	7.72	0.34	7.28e-14	Cutaneous malignant melanoma;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg04267008	chr7:1944627	MAD1L1	-0.54	-9.16	-0.39	1.7e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs12282928	1.000	rs2870510	chr11:48321334	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.3	0.32	1.24e-12	Migraine - clinic-based;
LGG	cis	rs1799949	0.965	rs8070179	chr17:41202688	G/A	cg12708336	chr17:41446283	NA	-0.33	-8.03	-0.35	7.93e-15	Menopause (age at onset);
LGG	cis	rs66887589	0.775	rs6843229	chr4:120424087	T/C	cg09307838	chr4:120376055	NA	0.5	8.6	0.37	1.25e-16	Diastolic blood pressure;
LGG	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.3	-0.36	1.14e-15	Retinal vascular caliber;
LGG	cis	rs62238980	0.614	rs2413064	chr22:32458536	G/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs10504229	0.683	rs55868006	chr8:58135703	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2798269	0.564	rs1967778	chr13:22164868	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.19	-0.32	2.65e-12	PR segment;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg21548813	chr6:291882	DUSP22	-0.74	-13.23	-0.52	4.14e-34	Menopause (age at onset);
LGG	trans	rs9409565	0.586	rs9409764	chr9:97219391	C/T	cg05679027	chr9:99775184	HIATL2	-0.44	-6.76	-0.3	4.23e-11	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs941873	0.772	rs1892498	chr10:81103862	A/G	cg09469691	chr10:81107165	PPIF	0.57	9.86	0.42	6.02e-21	Height;
LGG	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs7712401	0.601	rs246275	chr5:122231413	C/T	cg19412675	chr5:122181750	SNX24	0.43	7.05	0.31	6.72e-12	Mean platelet volume;
LGG	cis	rs60871478	1.000	rs6460801	chr7:810506	T/C	cg27478167	chr7:817139	HEATR2	-0.44	-7.14	-0.31	3.64e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs36071027	0.577	rs11747844	chr5:158441176	A/T	cg23468002	chr5:158532401	NA	-0.41	-6.77	-0.3	4.01e-11	Carotid intima media thickness;
LGG	cis	rs939658	1.000	rs8031019	chr15:79458512	C/T	cg17916960	chr15:79447300	NA	-0.63	-12.15	-0.49	1.16e-29	Refractive error;
LGG	cis	rs7208859	0.623	rs60890550	chr17:29030861	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.17	-0.36	2.94e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.68	-0.41	2.75e-20	Life satisfaction;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00270311	chr16:30366760	CD2BP2	0.42	6.75	0.3	4.35e-11	Cognitive performance;
LGG	cis	rs11676348	0.818	rs4674256	chr2:218987893	A/T	cg00012203	chr2:219082015	ARPC2	-0.55	-9.78	-0.41	1.18e-20	Ulcerative colitis;
LGG	cis	rs6088590	0.965	rs6058108	chr20:33288655	A/G	cg24642439	chr20:33292090	TP53INP2	0.78	14.28	0.55	1.3e-38	Coronary artery disease;
LGG	cis	rs6831352	0.879	rs35146617	chr4:100066686	C/T	cg13256891	chr4:100009986	ADH5	-0.57	-9.54	-0.41	8.28e-20	Alcohol dependence;
LGG	cis	rs11758351	0.866	rs75091077	chr6:26207546	A/C	cg01420254	chr6:26195488	NA	0.87	11.66	0.48	9.65e-28	Gout;Renal underexcretion gout;
LGG	cis	rs10206020	0.842	rs7590900	chr2:1574902	A/G	cg12573674	chr2:1569213	NA	-0.61	-9.85	-0.42	6.67e-21	IgG glycosylation;
LGG	cis	rs8062405	1.000	rs8061590	chr16:28895130	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.65	0.3	8.16e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1021993	0.597	rs17014323	chr1:209513852	G/A	cg24446417	chr1:209558027	NA	-0.69	-10.01	-0.42	1.75e-21	Gut microbiome composition (winter);
LGG	cis	rs7762018	1.000	rs6941766	chr6:170131653	A/G	cg17545662	chr6:170176663	C6orf70	0.69	8.68	0.37	6.62e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7582180	0.629	rs6731549	chr2:100939937	T/G	cg26150922	chr2:100937072	LONRF2	-0.61	-11.94	-0.49	7.65e-29	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg11494091	chr17:61959527	GH2	1.01	25.12	0.76	1.69e-88	Prudent dietary pattern;
LGG	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg04568710	chr12:38710424	ALG10B	-0.34	-7.22	-0.32	2.09e-12	Morning vs. evening chronotype;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg24642844	chr7:1081250	C7orf50	-0.84	-14.0	-0.55	2.1e-37	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7481584	0.624	rs516443	chr11:3047294	A/G	cg08508325	chr11:3079039	CARS	0.43	8.46	0.37	3.6e-16	Calcium levels;
LGG	cis	rs528418	0.540	rs6570679	chr6:145709131	C/T	cg03642472	chr6:145670687	NA	0.56	7.35	0.32	8.8e-13	Methadone dose in opioid dependence;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg12458913	chr13:53173898	NA	-0.57	-10.63	-0.44	9.19e-24	Lewy body disease;
LGG	trans	rs453301	0.631	rs11779804	chr8:8797952	C/T	cg02002194	chr4:3960332	NA	0.4	7.22	0.32	2.16e-12	Joint mobility (Beighton score);
LGG	cis	rs4689388	0.853	rs6446479	chr4:6291737	G/C	cg14416269	chr4:6271139	WFS1	0.47	8.45	0.37	3.79e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs9325144	0.555	rs7301258	chr12:38706942	C/T	cg13010199	chr12:38710504	ALG10B	0.57	11.07	0.46	1.96e-25	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.664	rs72704802	chr5:554211	C/T	cg07777115	chr5:623756	CEP72	-0.58	-7.21	-0.32	2.29e-12	Lung disease severity in cystic fibrosis;
LGG	trans	rs6951245	0.882	rs11764817	chr7:1064610	T/C	cg13565492	chr6:43139072	SRF	-0.55	-7.34	-0.32	9.61e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9527	0.614	rs11191589	chr10:104930382	T/C	cg05308233	chr10:104796373	CNNM2	-0.32	-6.96	-0.31	1.2e-11	Arsenic metabolism;
LGG	cis	rs9549260	0.755	rs9577091	chr13:41227865	G/A	cg21288729	chr13:41239152	FOXO1	0.33	6.71	0.3	5.84e-11	Red blood cell count;
LGG	cis	rs66887589	0.967	rs1155577	chr4:120449810	C/T	cg09307838	chr4:120376055	NA	-0.45	-7.82	-0.34	3.61e-14	Diastolic blood pressure;
LGG	cis	rs7582180	0.614	rs1530031	chr2:101009326	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.18	-0.43	4.39e-22	Intelligence (multi-trait analysis);
LGG	cis	rs11122272	0.735	rs1416916	chr1:231533027	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.87	-0.3	2.12e-11	Monocyte count;
LGG	cis	rs11920090	0.860	rs7646100	chr3:170692496	C/T	cg09710316	chr3:170744871	SLC2A2	0.6	8.5	0.37	2.54e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4664304	0.900	rs17231993	chr2:160741415	C/T	cg03641300	chr2:160917029	PLA2R1	-0.42	-7.17	-0.32	3.08e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9296092	0.560	rs3846853	chr6:33528194	C/G	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs2153535	0.505	rs1335629	chr6:8491863	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg07341007	chr3:195489909	MUC4	-0.57	-8.22	-0.36	2.03e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs2587949	0.593	rs795307	chr3:4164274	C/T	cg16519197	chr3:4211558	NA	-0.36	-7.27	-0.32	1.55e-12	Periodontitis (DPAL);
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	0.68	11.32	0.47	2.09e-26	Renal function-related traits (BUN);
LGG	trans	rs6598955	0.671	rs12089149	chr1:26638500	C/A	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.19	-0.49	7.83e-30	Obesity-related traits;
LGG	cis	rs1865760	0.566	rs9366634	chr6:26072396	C/G	cg12310025	chr6:25882481	NA	-0.38	-6.74	-0.3	4.73e-11	Height;
LGG	cis	rs12477438	0.520	rs34252185	chr2:99737646	A/G	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs11190604	1.000	rs11816840	chr10:102309220	G/C	cg07570687	chr10:102243282	WNT8B	0.42	7.04	0.31	6.85e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2117029	0.586	rs11168884	chr12:49539892	C/T	cg24176009	chr12:49580217	TUBA1A	0.66	12.83	0.51	1.88e-32	Intelligence (multi-trait analysis);
LGG	cis	rs7552404	0.731	rs2029683	chr1:76341643	T/G	cg10523679	chr1:76189770	ACADM	-0.75	-11.78	-0.48	3.42e-28	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9487094	1.000	rs9480953	chr6:109739144	A/G	cg16315928	chr6:109776240	MICAL1	0.47	7.96	0.35	1.35e-14	Height;
LGG	cis	rs11676348	0.818	rs7426289	chr2:218966315	C/T	cg00012203	chr2:219082015	ARPC2	-0.59	-10.52	-0.44	2.3e-23	Ulcerative colitis;
LGG	cis	rs17767392	0.958	rs56407721	chr14:71963503	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.23	-0.39	9.94e-19	Mitral valve prolapse;
LGG	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs7917772	0.582	rs10786695	chr10:104368756	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.67	0.48	8.94e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6502050	0.835	rs4789731	chr17:80145904	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	trans	rs11098499	0.954	rs6848389	chr4:120402622	A/G	cg25214090	chr10:38739885	LOC399744	0.7	12.37	0.5	1.49e-30	Corneal astigmatism;
LGG	cis	rs6121246	0.567	rs6087701	chr20:30217708	A/C	cg18721089	chr20:30220636	NA	-0.51	-7.59	-0.33	1.76e-13	Mean corpuscular hemoglobin;
LGG	cis	rs10754283	0.967	rs7523518	chr1:90110010	G/A	cg06121193	chr1:90282411	NA	-0.37	-7.24	-0.32	1.83e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs4728302	0.643	rs2346440	chr7:133685512	G/C	cg10665199	chr7:133106180	EXOC4	0.39	6.68	0.3	6.71e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	trans	rs1160351	0.863	rs7159493	chr14:47889952	A/C	cg21442773	chr1:236029828	LYST	-0.4	-6.97	-0.31	1.06e-11	Sexual dysfunction (SSRI/SNRI-related);
LGG	cis	rs10791097	0.694	rs7942621	chr11:130751308	C/G	cg12179176	chr11:130786555	SNX19	0.84	17.62	0.63	1.52e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6951245	0.872	rs76713558	chr7:1095866	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs698813	0.543	rs12468824	chr2:44482448	G/T	cg00619915	chr2:44497795	NA	-0.6	-8.73	-0.38	4.71e-17	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs9322193	0.923	rs56397000	chr6:150060483	C/T	cg16507663	chr6:150244633	RAET1G	0.46	8.74	0.38	4.37e-17	Lung cancer;
LGG	cis	rs57221529	0.654	rs72707041	chr5:677152	G/A	cg14541582	chr5:601475	NA	-0.71	-10.17	-0.43	4.55e-22	Lung disease severity in cystic fibrosis;
LGG	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg04132146	chr6:87862158	NA	-0.37	-6.67	-0.3	7.1e-11	Monocyte percentage of white cells;
LGG	cis	rs1862618	0.853	rs252916	chr5:56121788	G/C	cg17809284	chr5:56205270	C5orf35	-0.53	-8.67	-0.37	7.46e-17	Initial pursuit acceleration;
LGG	cis	rs2071403	0.509	rs56302939	chr2:1409056	C/T	cg06500727	chr2:1417164	TPO	-0.6	-12.14	-0.49	1.23e-29	Thyroid peroxidase antibody positivity;
LGG	cis	rs8177253	1.000	rs8177247	chr3:133479499	T/G	cg12373951	chr3:133503437	NA	0.4	7.06	0.31	5.96e-12	Iron status biomarkers;
LGG	cis	rs6952808	0.723	rs55689856	chr7:2037215	G/A	cg02951883	chr7:2050386	MAD1L1	-0.81	-18.09	-0.64	1.06e-55	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs11053189	chr12:34433455	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.51	0.53	2.75e-35	Morning vs. evening chronotype;
LGG	cis	rs9947295	0.649	rs28696966	chr18:11752736	C/G	cg14735704	chr18:11749182	GNAL	0.55	7.76	0.34	5.62e-14	QT interval (drug interaction);
LGG	cis	rs4919087	1.000	rs7076523	chr10:99089296	T/C	cg25902810	chr10:99078978	FRAT1	-0.5	-9.17	-0.39	1.51e-18	Monocyte count;
LGG	cis	rs67311347	1.000	rs73078163	chr3:40479958	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-26.01	-0.77	1.31e-92	Renal cell carcinoma;
LGG	cis	rs9309473	1.000	rs56154726	chr2:73721767	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.78	-0.34	4.69e-14	Metabolite levels;
LGG	cis	rs597539	0.652	rs686877	chr11:68637169	G/A	cg06028808	chr11:68637592	NA	0.75	13.08	0.52	1.78e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07362569	chr17:61921086	SMARCD2	-0.46	-8.9	-0.38	1.32e-17	Prudent dietary pattern;
LGG	cis	rs4718428	0.705	rs4717331	chr7:66378886	C/T	cg12165864	chr7:66369176	NA	-0.58	-9.35	-0.4	3.61e-19	Corneal structure;
LGG	cis	rs28386778	0.897	rs10221279	chr17:61806138	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.32e-15	Prudent dietary pattern;
LGG	cis	rs10743315	0.557	rs77782809	chr12:19364138	T/C	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.09e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7474896	0.515	rs675628	chr10:38305331	C/G	cg00409905	chr10:38381863	ZNF37A	0.5	7.41	0.33	6.21e-13	Obesity (extreme);
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.82	-0.59	2.34e-45	Tonsillectomy;
LGG	trans	rs11098499	0.697	rs28655325	chr4:120372999	A/G	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.93e-30	Corneal astigmatism;
LGG	cis	rs9463078	0.550	rs7769231	chr6:45284921	A/G	cg25276700	chr6:44698697	NA	-0.33	-6.81	-0.3	2.97e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs988958	0.565	rs56407905	chr2:42236607	G/A	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs7726839	0.540	rs11750321	chr5:599196	C/T	cg01221209	chr5:554886	NA	-0.45	-6.76	-0.3	4.29e-11	Obesity-related traits;
LGG	cis	rs875971	0.545	rs3936065	chr7:65790564	C/T	cg11764359	chr7:65958608	NA	0.63	9.45	0.4	1.68e-19	Aortic root size;
LGG	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.47	0.58	8.36e-44	Coronary artery disease;
LGG	cis	rs77669868	0.929	rs76761091	chr11:114067058	A/G	cg01914181	chr11:114070210	ZBTB16	0.64	8.33	0.36	8.97e-16	Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06390694	chr16:22308564	POLR3E	0.47	6.8	0.3	3.18e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.512	rs6002474	chr22:42168181	A/G	cg03806693	chr22:41940476	POLR3H	1.05	17.66	0.63	9.32e-54	Vitiligo;
LGG	cis	rs4417704	0.551	rs6437221	chr2:241896418	C/T	cg05025159	chr2:241905733	NA	-0.52	-10.78	-0.45	2.58e-24	Joint mobility (Beighton score);
LGG	cis	rs2576037	0.583	rs541634	chr18:44420271	C/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.09	-0.31	4.92e-12	Personality dimensions;
LGG	trans	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg02002194	chr4:3960332	NA	-0.44	-7.88	-0.34	2.28e-14	Red cell distribution width;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg04503457	chr17:41445688	NA	-0.39	-8.83	-0.38	2.12e-17	Menopause (age at onset);
LGG	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg16141378	chr3:129829833	LOC729375	0.39	8.49	0.37	2.91e-16	Retinal vascular caliber;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26258108	chr2:232329189	NCL	0.43	6.87	0.3	2.07e-11	Cognitive performance;
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.2	-0.46	6.04e-26	Neuroticism;
LGG	cis	rs7215564	0.908	rs35151535	chr17:78661695	C/T	cg06153925	chr17:78755379	RPTOR	0.38	6.67	0.3	7.39e-11	Myopia (pathological);
LGG	cis	rs875971	0.571	rs160641	chr7:65577346	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.26	-0.43	2.23e-22	Aortic root size;
LGG	cis	rs4242434	0.689	rs4872006	chr8:22536502	T/C	cg03733263	chr8:22462867	KIAA1967	-0.96	-22.11	-0.72	1.86e-74	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs936229	0.749	rs4886633	chr15:75178207	G/A	cg10253484	chr15:75165896	SCAMP2	-0.67	-10.88	-0.45	1.04e-24	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs6663390	0.831	rs11118880	chr1:208085583	T/A	cg00387621	chr1:208086895	NA	0.65	7.1	0.31	4.71e-12	Facial morphology (factor 18);
LGG	cis	rs875971	0.862	rs4368860	chr7:65608482	C/G	cg18876405	chr7:65276391	NA	-0.55	-9.89	-0.42	4.79e-21	Aortic root size;
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.76	9.09	0.39	2.91e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs7084402	0.902	rs1658484	chr10:60288543	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.47	-0.33	3.9e-13	Refractive error;
LGG	cis	rs977987	0.843	rs12927562	chr16:75482860	G/A	cg03315344	chr16:75512273	CHST6	0.52	10.31	0.43	1.38e-22	Dupuytren's disease;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.29	-0.36	1.27e-15	Life satisfaction;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14237749	chr9:136344651	SLC2A6	0.42	6.95	0.31	1.26e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs854765	0.647	rs7212447	chr17:17987067	G/A	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.65	-0.51	1.01e-31	Total body bone mineral density;
LGG	cis	rs4819052	0.851	rs10470246	chr21:46659017	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.75	0.38	3.89e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs490234	0.966	rs545900	chr9:128341278	C/T	cg14078157	chr9:128172775	NA	0.4	7.4	0.33	6.42e-13	Mean arterial pressure;
LGG	cis	rs6952808	0.691	rs2398709	chr7:2112548	C/T	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.32	-0.32	1.07e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs916888	0.610	rs199536	chr17:44820425	T/C	cg07870213	chr5:140052090	DND1	-0.67	-13.07	-0.52	1.95e-33	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs240764	0.658	rs9485410	chr6:101261007	A/G	cg09795085	chr6:101329169	ASCC3	0.46	7.83	0.34	3.46e-14	Neuroticism;
LGG	trans	rs194045	0.609	rs252344	chr16:29184882	G/A	cg17334114	chr3:133646504	NA	0.51	7.59	0.33	1.8e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs6542838	0.641	rs4850890	chr2:99535426	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.47	-7.52	-0.33	2.83e-13	Fear of minor pain;
LGG	cis	rs1898910	0.848	rs35598010	chr5:124532468	T/C	cg04217498	chr5:124532763	NA	-0.37	-6.87	-0.3	2.14e-11	Glucose homeostasis traits;
LGG	cis	rs7727544	0.625	rs3091338	chr5:131402738	C/T	cg07395648	chr5:131743802	NA	-0.41	-8.51	-0.37	2.44e-16	Blood metabolite levels;
LGG	cis	rs1010254	0.510	rs10515658	chr5:151758452	C/T	cg08593883	chr5:151785301	NMUR2	-0.45	-6.91	-0.31	1.58e-11	Optic nerve measurement (cup area);
LGG	trans	rs1728785	0.901	rs11075687	chr16:68655894	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.7	11.03	0.46	2.85e-25	Ulcerative colitis;
LGG	cis	rs11622475	1.000	rs2273610	chr14:104387642	G/C	cg12183467	chr14:104352244	NA	-0.46	-7.96	-0.35	1.36e-14	Bipolar disorder;
LGG	cis	rs4684776	1.000	rs2454489	chr3:11516535	G/A	cg24705426	chr3:11550659	ATG7	-0.47	-8.68	-0.37	6.7e-17	Small vessel stroke;
LGG	cis	rs735860	0.712	rs9395855	chr6:53176765	G/T	cg10236188	chr6:53219634	NA	-0.4	-7.91	-0.35	1.91e-14	Glaucoma;
LGG	cis	rs4481887	0.927	rs4558008	chr1:248477641	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.51	-0.4	1.09e-19	Common traits (Other);
LGG	trans	rs10802346	0.545	rs10802345	chr1:246372834	C/T	cg13514129	chr1:39547527	MACF1	0.68	12.69	0.51	6.93e-32	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs11771526	0.818	rs17161140	chr7:32324199	T/C	cg13207630	chr7:32358064	NA	0.68	7.21	0.32	2.33e-12	Body mass index;
LGG	cis	rs6502050	0.761	rs11653003	chr17:80058795	G/T	cg13939156	chr17:80058883	NA	0.54	11.04	0.46	2.48e-25	Life satisfaction;
LGG	cis	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg03213289	chr20:61660250	NA	0.66	14.49	0.56	1.67e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1799949	0.965	rs33988650	chr17:41287880	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs6582630	0.559	rs12318620	chr12:38522340	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-11.09	-0.46	1.69e-25	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2243480	0.908	rs4718273	chr7:65216099	G/A	cg10756647	chr7:56101905	PSPH	-0.82	-9.84	-0.42	7.25e-21	Diabetic kidney disease;
LGG	cis	rs10504229	0.636	rs77290284	chr8:58055269	G/T	cg21724239	chr8:58056113	NA	0.63	9.11	0.39	2.41e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs7618501	0.602	rs2013208	chr3:50129399	C/T	cg21659725	chr3:3221576	CRBN	-0.65	-11.92	-0.48	9.69e-29	Intelligence (multi-trait analysis);
LGG	cis	rs9486715	0.867	rs1127175	chr6:96999725	C/T	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.43	-0.36	4.47e-16	Headache;
LGG	cis	rs2243480	1.000	rs1392104	chr7:65759107	G/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.44	-0.37	4.2e-16	Diabetic kidney disease;
LGG	cis	rs9831754	0.865	rs9842838	chr3:78387904	A/C	cg06138941	chr3:78371609	NA	-0.9	-18.57	-0.65	5.83e-58	Calcium levels;
LGG	cis	rs2734839	0.964	rs7131440	chr11:113299910	A/G	cg14159747	chr11:113255604	NA	-0.25	-6.77	-0.3	3.93e-11	Information processing speed;
LGG	cis	rs7811142	1.000	rs11761784	chr7:100039970	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.48	-0.44	3.26e-23	Platelet count;
LGG	cis	rs6540556	0.954	rs10863786	chr1:209937764	A/G	cg23920097	chr1:209922102	NA	-0.42	-7.48	-0.33	3.73e-13	Red blood cell count;
LGG	cis	rs6942756	0.806	rs2566886	chr7:128917866	G/A	cg02491457	chr7:128862824	NA	0.64	12.05	0.49	2.83e-29	White matter hyperintensity burden;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.64	0.48	1.2e-27	Prudent dietary pattern;
LGG	cis	rs6743226	0.626	rs12612578	chr2:242236660	G/A	cg10021735	chr2:242295487	FARP2	0.4	6.92	0.31	1.48e-11	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs10504229	0.953	rs6985942	chr8:58173412	T/C	cg22535103	chr8:58192502	C8orf71	-0.95	-15.42	-0.58	1.36e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs62238980	0.614	rs75348576	chr22:32395467	A/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs208520	0.526	rs7775830	chr6:66755249	A/G	cg07460842	chr6:66804631	NA	1.12	29.76	0.81	1.47e-109	Exhaled nitric oxide output;
LGG	cis	rs7940866	0.903	rs10750457	chr11:130850277	T/C	cg12179176	chr11:130786555	SNX19	0.71	13.16	0.52	8.17e-34	Schizophrenia;
LGG	cis	rs2652834	0.904	rs8032506	chr15:63371644	G/A	cg05507819	chr15:63340323	TPM1	-0.59	-7.95	-0.35	1.45e-14	HDL cholesterol;
LGG	cis	rs10927875	0.830	rs1763610	chr1:16335527	C/G	cg22431228	chr1:16359049	CLCNKA	0.41	6.76	0.3	4.07e-11	Dilated cardiomyopathy;
LGG	cis	rs17742757	0.905	rs6989817	chr8:11330364	A/C	cg26274995	chr8:11302983	FAM167A	0.35	6.71	0.3	5.66e-11	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);
LGG	cis	rs9322193	0.886	rs4870049	chr6:150158194	G/T	cg00933542	chr6:150070202	PCMT1	0.38	6.71	0.3	5.63e-11	Lung cancer;
LGG	cis	rs7975161	0.630	rs4964732	chr12:104652705	A/T	cg25273343	chr12:104657179	TXNRD1	-0.86	-7.71	-0.34	7.57e-14	Toenail selenium levels;
LGG	cis	rs877282	0.898	rs11253341	chr10:765008	G/C	cg17470449	chr10:769945	NA	0.56	6.83	0.3	2.65e-11	Uric acid levels;
LGG	cis	rs10214930	0.697	rs2080245	chr7:27569530	C/G	cg22168087	chr7:27702803	HIBADH	0.45	6.77	0.3	3.84e-11	Hypospadias;
LGG	cis	rs7851660	0.967	rs1867280	chr9:100616066	G/C	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs62238980	0.614	rs79807615	chr22:32415867	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	trans	rs9467711	0.651	rs34555420	chr6:26090270	G/T	cg01620082	chr3:125678407	NA	-0.88	-7.49	-0.33	3.48e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9902453	0.904	rs12948898	chr17:28410324	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.68	-13.34	-0.53	1.34e-34	Coffee consumption (cups per day);
LGG	trans	rs35110281	0.667	rs7282405	chr21:45123611	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.56	9.63	0.41	3.85e-20	Mean corpuscular volume;
LGG	cis	rs7633857	0.532	rs1580254	chr3:160767278	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-10.05	-0.42	1.26e-21	Educational attainment (years of education);
LGG	cis	rs11190604	0.943	rs2495744	chr10:102329409	C/T	cg07570687	chr10:102243282	WNT8B	0.42	6.89	0.3	1.82e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs67460515	0.563	rs34630898	chr3:160827038	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.09	-0.35	5.43e-15	Parkinson's disease;
LGG	cis	rs4889855	0.614	rs9898443	chr17:78469357	C/T	cg16591659	chr17:78472290	NA	0.4	9.06	0.39	3.57e-18	Fractional excretion of uric acid;
LGG	cis	rs9583531	0.600	rs7984468	chr13:111362093	C/A	cg15841412	chr13:111365552	ING1	0.45	7.04	0.31	7.01e-12	Coronary artery disease;
LGG	cis	rs6938	0.514	rs56338926	chr15:75259335	C/A	cg09165964	chr15:75287851	SCAMP5	0.64	12.18	0.49	8.54e-30	Breast cancer;
LGG	cis	rs7584262	0.737	rs7591932	chr2:42243550	T/G	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Bone mineral density;
LGG	trans	rs526821	0.595	rs504661	chr11:55312683	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.37	-6.65	-0.3	8.11e-11	Pediatric bone mineral density (spine);
LGG	trans	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.81	-0.41	8.91e-21	Systolic blood pressure;
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg19143629	chr17:61920732	SMARCD2	0.4	6.79	0.3	3.45e-11	Prudent dietary pattern;
LGG	trans	rs116095464	1.000	rs2015774	chr5:312958	G/T	cg00938859	chr5:1591904	SDHAP3	0.81	8.71	0.38	5.32e-17	Breast cancer;
LGG	cis	rs3749237	0.595	rs3924462	chr3:49524236	T/G	cg06212747	chr3:49208901	KLHDC8B	0.44	7.09	0.31	4.99e-12	Resting heart rate;
LGG	cis	rs6665290	0.901	rs68087483	chr1:227202668	T/C	cg10327440	chr1:227177885	CDC42BPA	-1.27	-42.87	-0.89	2.7e-163	Myeloid white cell count;
LGG	trans	rs1005277	0.579	rs2474599	chr10:38438939	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.42	-0.56	3.32e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs2302729	0.556	rs4765986	chr12:2837538	T/G	cg19945202	chr12:2788847	CACNA1C	0.67	8.34	0.36	8.64e-16	Sleep quality;
LGG	cis	rs2760061	0.598	rs1774755	chr1:228115282	T/G	cg18477163	chr1:228402036	OBSCN	-0.26	-6.98	-0.31	1.03e-11	Diastolic blood pressure;
LGG	cis	rs8067545	0.641	rs203450	chr17:19823070	C/T	cg04132472	chr17:19861366	AKAP10	0.26	7.2	0.32	2.41e-12	Schizophrenia;
LGG	cis	rs7829975	0.846	rs11779061	chr8:8549432	G/A	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.0	-0.35	1.02e-14	Mood instability;
LGG	cis	rs7828089	1.000	rs34542820	chr8:22264079	C/T	cg12081754	chr8:22256438	SLC39A14	0.72	13.77	0.54	2.2e-36	Verbal declarative memory;
LGG	cis	rs4805272	0.512	rs4805279	chr19:29336966	A/G	cg04546413	chr19:29218101	NA	0.64	8.76	0.38	3.64e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9682041	0.696	rs13067560	chr3:170094190	G/A	cg11886554	chr3:170076028	SKIL	0.64	8.36	0.36	7.55e-16	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.55e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	0.729	rs2003549	chr17:62008437	C/T	cg11494091	chr17:61959527	GH2	0.5	7.56	0.33	2.16e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12477438	0.520	rs6741772	chr2:99738961	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.98	23.57	0.74	2.71e-81	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs12936831	chr17:41331816	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.7	0.34	8.6e-14	Menopause (age at onset);
LGG	cis	rs6840360	0.550	rs4696289	chr4:152621237	C/T	cg25486957	chr4:152246857	NA	-0.51	-8.11	-0.35	4.55e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg10896456	chr17:42255109	ASB16;C17orf65	-0.58	-10.73	-0.45	3.87e-24	Total body bone mineral density;
LGG	cis	rs35306767	0.855	rs61830931	chr10:932497	T/C	cg08847335	chr10:891726	LARP4B	-0.55	-9.14	-0.39	2.02e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs9815354	0.680	rs73073242	chr3:42015335	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6063312	1.000	rs6063313	chr20:47343532	G/A	cg18078177	chr20:47281410	PREX1	0.75	8.87	0.38	1.56e-17	Tonometry;
LGG	cis	rs60871478	0.679	rs4076965	chr7:793272	A/G	cg05535760	chr7:792225	HEATR2	0.93	13.62	0.53	9e-36	Cerebrospinal P-tau181p levels;
LGG	cis	rs10911363	0.592	rs2702178	chr1:183452545	G/A	cg23894439	chr1:183413866	NA	0.49	9.19	0.39	1.38e-18	Systemic lupus erythematosus;
LGG	trans	rs10506458	1.000	rs73128794	chr12:63445313	C/T	cg22491629	chr6:157744540	C6orf35	-0.91	-12.54	-0.5	2.8e-31	Hemostatic factors and hematological phenotypes;
LGG	cis	rs2153535	0.580	rs1414345	chr6:8471537	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs727505	1.000	rs10281582	chr7:124423688	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.27	-0.4	7.1e-19	Lewy body disease;
LGG	trans	rs208520	1.000	rs9453671	chr6:66991208	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.87	14.2	0.55	3.13e-38	Exhaled nitric oxide output;
LGG	cis	rs8017423	0.934	rs11159952	chr14:90684874	T/C	cg04374321	chr14:90722782	PSMC1	0.86	18.34	0.65	7.14e-57	Mortality in heart failure;
LGG	trans	rs7939886	0.920	rs61887958	chr11:55938234	A/G	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs4075765	0.764	rs17243204	chr11:26260899	C/T	cg19182008	chr11:26298241	NA	0.99	8.74	0.38	4.34e-17	Cannabis dependence symptom count;
LGG	cis	rs654950	0.934	rs638859	chr1:42001444	A/G	cg16096631	chr1:42092165	HIVEP3	0.35	6.68	0.3	6.76e-11	Airway imaging phenotypes;
LGG	cis	rs7949030	0.964	rs2957122	chr11:62392100	G/C	cg22862634	chr11:62369728	EML3;MTA2	-0.55	-12.2	-0.49	7.25e-30	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12478296	0.901	rs58906257	chr2:243028248	T/C	cg18898632	chr2:242989856	NA	-0.77	-9.66	-0.41	3.17e-20	Obesity-related traits;
LGG	cis	rs10504229	0.906	rs66480865	chr8:58187100	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9858542	0.953	rs1987628	chr3:49399259	G/A	cg21659725	chr3:3221576	CRBN	-0.65	-10.45	-0.44	4.22e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2645694	0.626	rs2703118	chr4:77823672	A/G	cg06046430	chr4:77819534	ANKRD56	0.53	11.07	0.46	1.91e-25	Emphysema distribution in smoking;
LGG	cis	rs2404602	0.716	rs7179142	chr15:76698268	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.01	-0.31	8.55e-12	Blood metabolite levels;
LGG	cis	rs7432375	0.609	rs835637	chr3:136673157	A/T	cg21827317	chr3:136751795	NA	0.43	7.68	0.34	9.35e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs35110281	0.693	rs11089093	chr21:45121161	C/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.14	-0.39	1.92e-18	Mean corpuscular volume;
LGG	cis	rs2643217	0.953	rs2643219	chr15:38999354	G/C	cg10631289	chr15:39006617	NA	-0.43	-7.34	-0.32	9.81e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs12579753	1.000	rs2400979	chr12:82197353	T/C	cg07988820	chr12:82153109	PPFIA2	-0.78	-11.45	-0.47	6.51e-27	Resting heart rate;
LGG	cis	rs13392177	0.684	rs6720105	chr2:219080718	G/A	cg04731861	chr2:219085781	ARPC2	0.49	12.63	0.51	1.2e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs2204008	0.748	rs8186658	chr12:38301461	A/C	cg13010199	chr12:38710504	ALG10B	0.64	13.48	0.53	3.61e-35	Bladder cancer;
LGG	cis	rs490234	0.966	rs569408	chr9:128304824	G/A	cg14078157	chr9:128172775	NA	0.39	7.29	0.32	1.35e-12	Mean arterial pressure;
LGG	trans	rs6810798	0.520	rs57997710	chr4:148329382	G/T	cg13149281	chr14:23389818	RBM23;PRMT5	-0.49	-7.1	-0.31	4.7e-12	Coronary artery disease;
LGG	cis	rs12362504	0.532	rs7930281	chr11:9927980	C/G	cg07197493	chr11:9884649	SBF2	0.35	6.66	0.3	7.84e-11	Survival in pancreatic cancer;
LGG	trans	rs4714291	0.862	rs2984445	chr6:40069935	C/T	cg02267698	chr19:7991119	CTXN1	-0.61	-9.98	-0.42	2.18e-21	Strep throat;
LGG	cis	rs4363385	0.510	rs4390126	chr1:153055177	G/A	cg13444842	chr1:152974279	SPRR3	-0.46	-9.08	-0.39	3.24e-18	Inflammatory skin disease;
LGG	cis	rs713587	0.520	rs1530016	chr2:25305756	C/T	cg04586622	chr2:25135609	ADCY3	-0.31	-7.83	-0.34	3.44e-14	Body mass index in non-asthmatics;
LGG	trans	rs1728785	0.901	rs12929568	chr16:68596689	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.33	0.43	1.18e-22	Ulcerative colitis;
LGG	cis	rs4665809	0.590	rs10495756	chr2:26485586	A/G	cg22920501	chr2:26401640	FAM59B	0.44	9.06	0.39	3.62e-18	Gut microbiome composition (summer);
LGG	cis	rs4380275	0.782	rs60367761	chr2:766414	C/T	cg14072418	chr2:740025	NA	-0.36	-7.18	-0.32	2.78e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs67478160	0.619	rs11160759	chr14:104231542	C/T	cg26031613	chr14:104095156	KLC1	-0.46	-7.56	-0.33	2.21e-13	Schizophrenia;
LGG	cis	rs5742933	0.681	rs4525728	chr2:190645050	G/A	cg04003228	chr2:190539410	ANKAR	-0.49	-7.06	-0.31	6.28e-12	Ferritin levels;
LGG	cis	rs9790314	1.000	rs336577	chr3:161066294	C/T	cg04691961	chr3:161091175	C3orf57	-0.65	-15.44	-0.58	1.14e-43	Morning vs. evening chronotype;
LGG	cis	rs12701220	0.817	rs1058727	chr7:1087095	A/G	cg02733842	chr7:1102375	C7orf50	-0.47	-7.68	-0.34	9.54e-14	Bronchopulmonary dysplasia;
LGG	cis	rs10504130	0.569	rs34372756	chr8:52821356	T/C	cg24946253	chr8:52722146	PXDNL	-0.45	-6.65	-0.3	8.41e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7267979	0.903	rs1118963	chr20:25247449	G/A	cg06421707	chr20:25228305	PYGB	0.48	10.52	0.44	2.27e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs953387	1.000	rs6715785	chr2:136910273	C/T	cg07169764	chr2:136633963	MCM6	0.54	8.91	0.38	1.19e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs9329221	0.905	rs17765901	chr8:10249480	G/T	cg19847130	chr8:10466454	RP1L1	0.34	7.29	0.32	1.31e-12	Neuroticism;
LGG	cis	rs12200782	1.000	rs12213722	chr6:26473083	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.63	-8.03	-0.35	8.22e-15	Small cell lung carcinoma;
LGG	trans	rs2898290	0.540	rs35005793	chr8:11450472	G/A	cg15556689	chr8:8085844	FLJ10661	0.49	8.25	0.36	1.62e-15	Systolic blood pressure;
LGG	cis	rs6088590	1.000	rs6087623	chr20:33317662	C/G	cg08999081	chr20:33150536	PIGU	0.32	7.49	0.33	3.58e-13	Coronary artery disease;
LGG	cis	rs1801251	0.964	rs7589201	chr2:233724536	A/G	cg25237894	chr2:233734115	C2orf82	-0.66	-12.47	-0.5	5.57e-31	Coronary artery disease;
LGG	cis	rs7226408	0.802	rs11665058	chr18:34469552	C/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.91	-0.31	1.64e-11	Obesity-related traits;
LGG	trans	rs3206736	0.548	rs73110545	chr7:35063794	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.12	0.31	4.04e-12	Diastolic blood pressure;
LGG	cis	rs2635047	0.542	rs2668772	chr18:44770621	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.45	7.38	0.32	7.51e-13	Educational attainment;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26649251	chr19:44598564	ZNF224	0.52	8.91	0.38	1.2e-17	Gut microbiota (bacterial taxa);
LGG	trans	rs11992162	0.548	rs4841631	chr8:11781668	C/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-7.01	-0.31	8.3e-12	Monocyte count;
LGG	cis	rs10892173	0.667	rs12364606	chr11:117680787	T/C	cg21640587	chr11:117668038	DSCAML1	0.45	7.45	0.33	4.52e-13	Myopia;
LGG	cis	rs72772090	0.539	rs11746534	chr5:96124807	G/A	cg17330273	chr5:96107758	CAST;ERAP1	-0.58	-8.9	-0.38	1.25e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2180341	0.574	rs13192350	chr6:127677762	G/T	cg24812749	chr6:127587940	RNF146	0.64	10.75	0.45	3.26e-24	Breast cancer;
LGG	cis	rs9814567	0.752	rs13064209	chr3:134335993	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	0.63	10.99	0.45	4.14e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7811142	1.000	rs67163493	chr7:100023838	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	trans	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg10756647	chr7:56101905	PSPH	0.91	12.94	0.52	6.67e-33	Diabetic kidney disease;
LGG	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg18252515	chr7:66147081	NA	0.41	6.92	0.31	1.47e-11	Aortic root size;
LGG	cis	rs6762477	0.505	rs17304079	chr3:50085153	A/G	cg24110177	chr3:50126178	RBM5	-0.53	-8.16	-0.35	3.22e-15	Menarche (age at onset);
LGG	trans	rs1814175	0.500	rs1825677	chr11:49233099	T/G	cg00717180	chr2:96193071	NA	-0.52	-9.86	-0.42	5.9e-21	Height;
LGG	cis	rs11800820	0.557	rs12735611	chr1:246660197	G/T	cg16700716	chr1:246684329	NA	0.42	7.29	0.32	1.33e-12	Obesity-related traits;
LGG	cis	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg07460842	chr6:66804631	NA	-0.95	-17.42	-0.63	1.25e-52	Exhaled nitric oxide output;
LGG	cis	rs4423214	1.000	rs4944959	chr11:71168234	C/T	cg05163923	chr11:71159392	DHCR7	-0.7	-13.69	-0.54	4.81e-36	Vitamin D levels;
LGG	cis	rs2067615	0.579	rs10861663	chr12:107183589	G/A	cg15890332	chr12:107067104	RFX4	0.41	12.13	0.49	1.34e-29	Heart rate;
LGG	cis	rs1046896	1.000	rs1046917	chr17:80685655	A/G	cg03160526	chr17:80928410	B3GNTL1	-0.4	-6.77	-0.3	3.86e-11	Glycated hemoglobin levels;
LGG	cis	rs796364	0.950	rs188146	chr2:200750444	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.7	9.1	0.39	2.61e-18	Schizophrenia;
LGG	cis	rs1552244	0.510	rs13075308	chr3:10034925	G/C	cg00149659	chr3:10157352	C3orf10	0.76	9.69	0.41	2.51e-20	Alzheimer's disease;
LGG	cis	rs6089584	0.927	rs3787427	chr20:60579789	T/C	cg12751644	chr20:60527061	NA	-0.3	-7.05	-0.31	6.71e-12	Body mass index;
LGG	cis	rs2274273	0.638	rs58269011	chr14:55684388	A/G	cg04306507	chr14:55594613	LGALS3	0.51	11.83	0.48	2.21e-28	Protein biomarker;
LGG	cis	rs1862618	0.715	rs6866779	chr5:56090000	G/A	cg17809284	chr5:56205270	C5orf35	-0.53	-8.54	-0.37	1.92e-16	Initial pursuit acceleration;
LGG	cis	rs769267	0.895	rs2315279	chr19:19479936	C/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.44	-7.34	-0.32	9.85e-13	Tonsillectomy;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs854765	0.647	rs854763	chr17:18010095	C/G	cg04398451	chr17:18023971	MYO15A	-0.85	-18.98	-0.66	7.52e-60	Total body bone mineral density;
LGG	cis	rs6750047	0.771	rs1056837	chr2:38298150	A/G	cg07380506	chr2:38303506	CYP1B1	0.45	7.9	0.34	2.08e-14	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs7617773	0.780	rs6442111	chr3:48312060	G/C	cg11946769	chr3:48343235	NME6	0.63	10.58	0.44	1.43e-23	Coronary artery disease;
LGG	cis	rs7226408	0.625	rs11081968	chr18:34441664	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.41	-8.8	-0.38	2.78e-17	Obesity-related traits;
LGG	cis	rs7851660	0.654	rs2120264	chr9:100645728	A/G	cg13688889	chr9:100608707	NA	-0.58	-11.49	-0.47	4.68e-27	Strep throat;
LGG	cis	rs72781680	1.000	rs12614452	chr2:24194608	C/T	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs10256972	0.721	rs4720249	chr7:1072563	C/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.36	-0.32	8.46e-13	Longevity;Endometriosis;
LGG	cis	rs12421382	0.615	rs11607972	chr11:109392155	A/G	cg11473876	chr11:109292803	C11orf87	0.48	9.13	0.39	2.07e-18	Schizophrenia;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.82	0.3	2.79e-11	Lung cancer;
LGG	cis	rs1577917	0.771	rs12199873	chr6:86294947	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.68	-12.04	-0.49	3.21e-29	Response to antipsychotic treatment;
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg03036210	chr16:89904091	SPIRE2	-0.57	-7.53	-0.33	2.7e-13	Skin colour saturation;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.04	0.31	6.84e-12	Prudent dietary pattern;
LGG	cis	rs1005277	0.579	rs2474567	chr10:38382492	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-11.87	-0.48	1.42e-28	Extrinsic epigenetic age acceleration;
LGG	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg13877915	chr19:58951672	ZNF132	1.01	26.74	0.78	6.4e-96	Uric acid clearance;
LGG	cis	rs4666002	0.956	rs10179872	chr2:27778572	G/A	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	4.88e-11	Phospholipid levels (plasma);
LGG	cis	rs113084984	0.684	rs4669745	chr2:11681572	A/G	cg07314298	chr2:11723111	GREB1	0.36	6.68	0.3	6.98e-11	Breast cancer;
LGG	cis	rs4925325	1.000	rs4925325	chr20:60514224	G/A	cg18761221	chr20:60518478	NA	-0.54	-8.6	-0.37	1.28e-16	Obesity-related traits;
LGG	cis	rs2477686	0.526	rs12042427	chr1:2398107	C/T	cg06215416	chr1:2383473	NA	-0.5	-11.77	-0.48	3.86e-28	Non-obstructive azoospermia;
LGG	cis	rs12282928	1.000	rs10769343	chr11:48321098	G/A	cg26585981	chr11:48327164	OR4S1	0.45	7.29	0.32	1.31e-12	Migraine - clinic-based;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg06112835	chr11:68658793	MRPL21	0.64	10.38	0.43	7.51e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs769267	1.000	rs8103197	chr19:19443466	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.59	-0.33	1.83e-13	Tonsillectomy;
LGG	cis	rs9388451	0.505	rs6920965	chr6:126179111	G/A	cg05901451	chr6:126070800	HEY2	-0.58	-10.23	-0.43	2.78e-22	Brugada syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02252918	chr12:124458442	ZNF664;CCDC92	0.49	7.62	0.33	1.43e-13	Gut microbiome composition (summer);
LGG	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg25922239	chr6:33757077	LEMD2	0.42	7.26	0.32	1.62e-12	Crohn's disease;
LGG	trans	rs1814175	0.765	rs11493326	chr11:50018063	T/C	cg03929089	chr4:120376271	NA	-1.02	-23.85	-0.74	1.34e-82	Height;
LGG	cis	rs8177253	0.829	rs6794945	chr3:133518463	A/G	cg11941060	chr3:133502564	NA	0.5	8.4	0.36	5.45e-16	Iron status biomarkers;
LGG	cis	rs1045714	0.895	rs2293405	chr7:2644607	G/T	cg14042143	chr7:2646782	IQCE	0.81	12.47	0.5	5.84e-31	Urate levels in lean individuals;
LGG	cis	rs12950390	0.853	rs12450729	chr17:45855363	A/G	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	6.76e-11	IgG glycosylation;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg07959490	chr17:80112427	CCDC57	-0.46	-9.18	-0.39	1.39e-18	Life satisfaction;
LGG	trans	rs7395662	0.816	rs11039764	chr11:48484616	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.54	-0.33	2.48e-13	HDL cholesterol;
LGG	cis	rs9768139	0.935	rs10949715	chr7:158117246	G/T	cg25566285	chr7:158114605	PTPRN2	0.97	25.31	0.76	2.3e-89	Calcium levels;
LGG	cis	rs11239187	0.586	rs994178	chr10:45103415	G/A	cg03916630	chr10:45065415	NA	0.34	8.24	0.36	1.79e-15	Body mass index;
LGG	cis	rs1971762	0.527	rs1247957	chr12:53961493	G/T	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.77	-0.3	4.03e-11	Height;
LGG	cis	rs10089	1.000	rs3805606	chr5:127470813	A/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	-0.76	-11.71	-0.48	6.57e-28	Ileal carcinoids;
LGG	cis	rs4242434	0.672	rs3758042	chr8:22486951	T/C	cg02227867	chr8:22457446	C8orf58	-0.41	-7.94	-0.35	1.51e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7534801	0.603	rs12134861	chr1:244915937	A/T	cg20597013	chr1:244894274	NA	-0.26	-7.03	-0.31	7.31e-12	Longitudinal change in brain amyloid plaque burden;
LGG	cis	rs597539	0.552	rs10896384	chr11:68720011	A/G	cg04772025	chr11:68637568	NA	-0.71	-12.62	-0.51	1.42e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-10.97	-0.45	4.74e-25	Total body bone mineral density;
LGG	cis	rs9916302	0.706	rs582176	chr17:37453999	T/C	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1046896	0.553	rs3744160	chr17:80828303	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.87	0.3	2.11e-11	Glycated hemoglobin levels;
LGG	cis	rs3749237	0.595	rs4855864	chr3:49521974	C/T	cg03060546	chr3:49711283	APEH	0.74	13.22	0.52	4.31e-34	Resting heart rate;
LGG	cis	rs2729354	0.502	rs2848641	chr11:57263068	G/C	cg24343310	chr11:57249947	NA	0.37	7.86	0.34	2.69e-14	Blood protein levels;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.5	-8.35	-0.36	7.92e-16	Renal function-related traits (BUN);
LGG	cis	rs7100689	0.577	rs9285726	chr10:82035150	A/T	cg01528321	chr10:82214614	TSPAN14	0.82	13.91	0.54	5.17e-37	Post bronchodilator FEV1;
LGG	trans	rs6582630	0.537	rs7299661	chr12:38527713	C/T	cg06521331	chr12:34319734	NA	-0.48	-8.46	-0.37	3.67e-16	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs4843747	0.619	rs66508972	chr16:88086385	C/G	cg00711542	chr16:29343894	RUNDC2C	0.43	7.13	0.31	3.91e-12	Menopause (age at onset);
LGG	cis	rs8031584	0.678	rs8035703	chr15:31168472	T/C	cg14829155	chr15:31115871	NA	-0.68	-11.33	-0.47	1.91e-26	Huntington's disease progression;
LGG	cis	rs9303401	0.573	rs35104446	chr17:57180234	A/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.81	12.76	0.51	3.7e-32	Cognitive test performance;
LGG	cis	rs9906944	0.707	rs9899931	chr17:47108282	G/A	cg09029085	chr17:47094198	IGF2BP1	0.31	8.26	0.36	1.57e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg00106254	chr7:1943704	MAD1L1	-0.46	-8.01	-0.35	9.11e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs896854	0.548	rs574183	chr8:95973816	A/G	cg16049864	chr8:95962084	TP53INP1	0.4	8.29	0.36	1.21e-15	Type 2 diabetes;
LGG	cis	rs11877825	0.826	rs8088257	chr18:10579953	T/G	cg07277756	chr18:10589357	NA	0.58	10.49	0.44	3.06e-23	Gut microbiota (bacterial taxa);
LGG	cis	rs6912958	0.781	rs3918467	chr6:88180388	C/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.8	-0.38	2.7e-17	Monocyte percentage of white cells;
LGG	trans	rs57221529	0.766	rs12518859	chr5:587432	C/T	cg11887960	chr12:57824829	NA	0.6	7.34	0.32	9.36e-13	Lung disease severity in cystic fibrosis;
LGG	trans	rs7819412	0.527	rs7821914	chr8:10805015	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.57	-0.33	1.98e-13	Triglycerides;
LGG	cis	rs9972944	0.756	rs9901885	chr17:63769559	T/C	cg07283582	chr17:63770753	CCDC46	-0.44	-8.5	-0.37	2.58e-16	Total body bone mineral density;
LGG	cis	rs10504229	1.000	rs72650885	chr8:58175131	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7959452	0.532	rs2291005	chr12:69764388	A/G	cg11871910	chr12:69753446	YEATS4	0.92	22.2	0.72	6.71e-75	Blood protein levels;
LGG	cis	rs6500602	0.653	rs3747579	chr16:4445327	A/G	cg06916706	chr16:4465613	CORO7	0.68	11.09	0.46	1.72e-25	Schizophrenia;
LGG	cis	rs4700695	0.719	rs27079	chr5:65443966	C/T	cg21114390	chr5:65439923	SFRS12	-0.72	-10.54	-0.44	2.04e-23	Facial morphology (factor 19);
LGG	cis	rs546131	0.642	rs7946980	chr11:34820438	C/T	cg06937548	chr11:34938143	PDHX;APIP	0.46	7.35	0.32	8.76e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs9611565	0.503	rs5996062	chr22:42167464	C/G	cg17376030	chr22:41985996	PMM1	-0.66	-10.63	-0.44	8.84e-24	Vitiligo;
LGG	cis	rs9368481	0.547	rs2093303	chr6:26864406	C/T	cg18867708	chr6:26865862	GUSBL1	0.48	7.96	0.35	1.31e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7226408	0.802	rs117913067	chr18:34454822	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs11771526	0.901	rs10267589	chr7:32280156	T/C	cg13207630	chr7:32358064	NA	0.63	6.94	0.31	1.35e-11	Body mass index;
LGG	cis	rs4595586	0.545	rs61939641	chr12:39378001	T/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs2287838	0.692	rs7254989	chr19:10006618	G/A	cg00846166	chr19:10022875	OLFM2	0.33	7.41	0.33	6.01e-13	Sleep duration;
LGG	cis	rs1165205	0.558	rs531750	chr6:25882642	C/G	cg03264133	chr6:25882463	NA	-1.03	-23.01	-0.73	1.07e-78	Urate levels;
LGG	cis	rs7223966	1.000	rs8081612	chr17:61724695	A/G	cg17202724	chr17:61916730	SMARCD2	0.43	8.63	0.37	1e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2279817	1.000	rs1339800	chr1:18020201	C/G	cg21791023	chr1:18019539	ARHGEF10L	-0.71	-13.23	-0.52	4.22e-34	Neuroticism;
LGG	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg12193833	chr17:30244370	NA	-0.26	-6.95	-0.31	1.26e-11	Hip circumference adjusted for BMI;
LGG	cis	rs1153858	0.945	rs2467854	chr15:45701597	A/G	cg21132104	chr15:45694354	SPATA5L1	0.72	10.58	0.44	1.41e-23	Homoarginine levels;
LGG	cis	rs2153535	0.580	rs6597322	chr6:8449952	T/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs10887265	1	rs10887265	chr10:86015573	G/C	cg00169964	chr10:85974172	PCDH21	0.37	7.54	0.33	2.49e-13	Myopia;
LGG	cis	rs9513627	0.920	rs7320057	chr13:100155586	G/A	cg25919922	chr13:100150906	NA	0.71	7.58	0.33	1.9e-13	Obesity-related traits;
LGG	cis	rs17799476	1.000	rs17799476	chr2:46352326	C/G	cg12428440	chr2:46370979	PRKCE	0.43	6.81	0.3	3.11e-11	Hemoglobin concentration;Hematocrit;
LGG	cis	rs2985684	0.894	rs4581611	chr14:50043520	A/T	cg02151108	chr14:50098012	C14orf104	-0.42	-8.89	-0.38	1.37e-17	Carotid intima media thickness;
LGG	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg03352830	chr11:487213	PTDSS2	0.85	10.67	0.44	6.4e-24	Body mass index;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg09699651	chr6:150184138	LRP11	0.49	8.66	0.37	8.12e-17	Lung cancer;
LGG	cis	rs17604090	1.000	rs17603986	chr7:29690489	C/T	cg19413766	chr7:29689036	LOC646762	-0.57	-6.93	-0.31	1.38e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7166081	1.000	rs2289262	chr15:67501033	C/T	cg05925327	chr15:68127851	NA	-0.33	-6.98	-0.31	1.05e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs28386778	0.897	rs11079510	chr17:61820902	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.64	0.41	3.63e-20	Prudent dietary pattern;
LGG	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg00092383	chr7:157075207	NA	-0.39	-6.72	-0.3	5.47e-11	Body mass index;
LGG	cis	rs2228479	0.850	rs62054640	chr16:89823157	C/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs5769765	1.000	rs5770741	chr22:50270215	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.78	11.51	0.47	4.04e-27	Schizophrenia;
LGG	cis	rs7737355	0.773	rs10793812	chr5:130593363	T/G	cg06307176	chr5:131281290	NA	-0.48	-7.96	-0.35	1.38e-14	Life satisfaction;
LGG	cis	rs368123	0.889	rs221968	chr6:160748940	A/G	cg07349212	chr6:160770346	SLC22A3	-0.35	-7.55	-0.33	2.29e-13	Waist circumference;
LGG	cis	rs9354308	0.738	rs1938117	chr6:66593480	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.8	-0.3	3.24e-11	Metabolite levels;
LGG	cis	rs7811142	0.943	rs28660238	chr7:100023308	C/T	cg00814883	chr7:100076585	TSC22D4	-0.7	-10.41	-0.44	6.07e-23	Platelet count;
LGG	trans	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-7.97	-0.35	1.28e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9325144	0.534	rs1843866	chr12:38703160	G/T	cg26384229	chr12:38710491	ALG10B	0.76	15.48	0.58	7.34e-44	Morning vs. evening chronotype;
LGG	cis	rs9633740	0.773	rs1870148	chr10:82271341	G/A	cg01528321	chr10:82214614	TSPAN14	1.03	15.37	0.58	2.36e-43	Post bronchodilator FEV1;
LGG	cis	rs10791323	0.654	rs2851119	chr11:133706382	T/C	cg06766960	chr11:133703094	NA	-0.48	-9.45	-0.4	1.64e-19	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16513467	chr10:28822500	WAC	0.4	6.67	0.3	7.51e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs875971	0.619	rs10278371	chr7:66051540	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.61	-0.41	4.68e-20	Aortic root size;
LGG	trans	rs66887589	0.660	rs4833613	chr4:120150156	A/C	cg25214090	chr10:38739885	LOC399744	-0.39	-7.02	-0.31	7.7e-12	Diastolic blood pressure;
LGG	cis	rs12249377	0.519	rs66650915	chr10:92592468	T/C	cg14313238	chr10:92632228	RPP30	0.4	7.2	0.32	2.5e-12	White matter microstructure (global fractional anisotropy);
LGG	cis	rs739401	0.611	rs2239900	chr11:3030992	C/T	cg05729581	chr11:3078854	CARS	-0.52	-9.14	-0.39	1.93e-18	Longevity;
LGG	cis	rs72781680	1.000	rs74704838	chr2:24158270	C/A	cg08917208	chr2:24149416	ATAD2B	0.82	9.66	0.41	3.19e-20	Lymphocyte counts;
LGG	cis	rs3815700	1.000	rs7260624	chr19:33096562	A/G	cg02997394	chr19:33096574	ANKRD27	0.91	14.47	0.56	2e-39	Eosinophilic esophagitis;
LGG	cis	rs4689388	0.610	rs4328980	chr4:6281756	A/G	cg25554036	chr4:6271136	WFS1	0.53	9.03	0.39	4.61e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7020830	0.898	rs2790063	chr9:37287405	G/A	cg14294708	chr9:37120828	ZCCHC7	1.15	30.89	0.82	1.47e-114	Schizophrenia;
LGG	cis	rs7666738	0.830	rs4502686	chr4:98765117	T/C	cg05340658	chr4:99064831	C4orf37	0.47	7.77	0.34	5.17e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2980439	0.870	rs2945230	chr8:8109936	A/G	cg08975724	chr8:8085496	FLJ10661	0.53	10.71	0.45	4.62e-24	Neuroticism;
LGG	cis	rs9926296	0.546	rs9935541	chr16:89905925	G/C	cg03605463	chr16:89740564	NA	-0.41	-6.91	-0.31	1.61e-11	Vitiligo;
LGG	cis	rs9322193	0.847	rs12191643	chr6:149950048	C/T	cg05861140	chr6:150128134	PCMT1	-0.43	-9.66	-0.41	3.16e-20	Lung cancer;
LGG	cis	rs368123	0.924	rs417770	chr6:160719167	T/G	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs6831352	0.918	rs13110176	chr4:100062430	C/T	cg13256891	chr4:100009986	ADH5	0.55	9.58	0.41	5.79e-20	Alcohol dependence;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.15	0.43	5.57e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11096990	0.634	rs7666632	chr4:39240188	C/T	cg24403649	chr4:39172243	NA	0.39	6.93	0.31	1.42e-11	Cognitive function;
LGG	cis	rs1577917	1.000	rs6923148	chr6:86767786	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.64	11.01	0.46	3.29e-25	Response to antipsychotic treatment;
LGG	trans	rs3942852	0.568	rs10769314	chr11:48097620	C/T	cg03929089	chr4:120376271	NA	-0.69	-10.81	-0.45	1.93e-24	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg13009111	chr11:71350975	NA	0.36	7.86	0.34	2.63e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg27624424	chr6:160112604	SOD2	0.67	9.94	0.42	3.05e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10876993	0.928	rs1689586	chr12:58079586	A/T	cg18357645	chr12:58087776	OS9	0.7	13.01	0.52	3.28e-33	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs9443645	0.527	rs12527806	chr6:79507667	A/T	cg18132916	chr6:79620363	NA	-0.27	-7.08	-0.31	5.31e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10435719	0.902	rs4840599	chr8:11805380	C/T	cg24623649	chr8:11872141	NA	-0.31	-7.06	-0.31	6.01e-12	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs7829975	0.682	rs7013471	chr8:8687325	A/G	cg02002194	chr4:3960332	NA	0.39	7.12	0.31	4.1e-12	Mood instability;
LGG	cis	rs28595532	0.920	rs116717907	chr4:119762568	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs71403859	0.502	rs12927456	chr16:71505706	A/G	cg08717414	chr16:71523259	ZNF19	-1.36	-18.63	-0.65	3.33e-58	Post bronchodilator FEV1;
LGG	cis	rs6500395	1.000	rs1004909	chr16:48725580	C/G	cg04672837	chr16:48644449	N4BP1	-0.53	-8.82	-0.38	2.26e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg01470637	chr2:183580950	DNAJC10	0.45	6.95	0.31	1.28e-11	Hip circumference;
LGG	cis	rs2204008	0.777	rs2387813	chr12:38382091	A/C	cg26384229	chr12:38710491	ALG10B	0.91	20.72	0.69	5.72e-68	Bladder cancer;
LGG	cis	rs2836974	0.584	rs34436313	chr21:40685246	A/G	cg11644478	chr21:40555479	PSMG1	-0.72	-12.78	-0.51	3.13e-32	Cognitive function;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg16405210	chr4:1374714	KIAA1530	0.67	12.3	0.5	2.82e-30	Obesity-related traits;
LGG	cis	rs3771570	1.000	rs60209440	chr2:242260340	G/C	cg21155796	chr2:242212141	HDLBP	0.73	9.31	0.4	5.02e-19	Prostate cancer;
LGG	cis	rs4731207	0.698	rs962863	chr7:124558339	C/T	cg05630886	chr7:124431682	NA	0.33	7.75	0.34	5.75e-14	Cutaneous malignant melanoma;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg04863758	chr4:1303710	MAEA	0.42	7.22	0.32	2.16e-12	Obesity-related traits;
LGG	cis	rs4819052	1.000	rs13047688	chr21:46669290	G/A	cg06618935	chr21:46677482	NA	-0.53	-9.41	-0.4	2.37e-19	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs12130219	0.500	rs4845743	chr1:152184149	A/G	cg25272121	chr1:152190972	HRNR	-0.41	-8.3	-0.36	1.16e-15	Inflammatory skin disease;
LGG	cis	rs3741404	0.825	rs11604782	chr11:63946650	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	1.04	20.48	0.69	7.37e-67	Platelet count;
LGG	cis	rs5769765	1.000	rs4824106	chr22:50267822	T/C	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs7216064	0.589	rs8072723	chr17:66056970	T/A	cg12091567	chr17:66097778	LOC651250	0.77	12.44	0.5	7.3e-31	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs4481887	0.861	rs7412034	chr1:248434150	G/C	cg00666640	chr1:248458726	OR2T12	0.53	8.62	0.37	1.06e-16	Common traits (Other);
LGG	cis	rs36093844	0.800	rs59179556	chr11:85573897	A/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.17	-0.32	3.07e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs67460515	0.500	rs1562464	chr3:160681614	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-7.97	-0.35	1.27e-14	Parkinson's disease;
LGG	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg19680485	chr15:31195859	MTMR15	-0.44	-6.73	-0.3	5.09e-11	Huntington's disease progression;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.11	-0.43	7.39e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25759457	chr1:172502420	C1orf9	0.45	7.02	0.31	7.88e-12	Gut microbiome composition (summer);
LGG	trans	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-7.1	-0.31	4.79e-12	Blood pressure (smoking interaction);
LGG	cis	rs2916247	1.000	rs28728418	chr8:93061878	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs894344	0.650	rs4909912	chr8:135572297	C/T	cg09855544	chr8:135498122	ZFAT	0.42	7.57	0.33	2.05e-13	Systolic blood pressure;
LGG	cis	rs9992101	0.645	rs62303267	chr4:77306930	C/T	cg17010112	chr4:77227123	STBD1	-0.46	-9.4	-0.4	2.56e-19	Creatinine levels;
LGG	cis	rs9640161	0.742	rs2159236	chr7:150017214	A/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.74	-15.62	-0.59	1.77e-44	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs13191362	0.935	rs35378894	chr6:163123933	T/C	cg06582575	chr6:163149167	PACRG;PARK2	0.99	9.92	0.42	3.66e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9467773	0.596	rs2451750	chr6:26646579	A/T	cg11502198	chr6:26597334	ABT1	0.69	12.65	0.51	1.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs4808199	0.948	rs8108647	chr19:19427623	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	15.41	0.58	1.43e-43	Nonalcoholic fatty liver disease;
LGG	cis	rs9611565	0.592	rs9611613	chr22:41961831	T/C	cg17376030	chr22:41985996	PMM1	0.54	8.68	0.37	7.01e-17	Vitiligo;
LGG	cis	rs9644630	0.804	rs11779939	chr8:19327487	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.35	6.82	0.3	2.77e-11	Oropharynx cancer;
LGG	cis	rs2011503	1.000	rs4808206	chr19:19645645	C/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs9916302	0.904	rs11869109	chr17:37518205	G/T	cg07936489	chr17:37558343	FBXL20	0.85	16.11	0.6	1.14e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7264396	0.616	rs6142476	chr20:34581216	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.56	-0.33	2.11e-13	Total cholesterol levels;
LGG	cis	rs722599	0.683	rs10139016	chr14:75274288	T/C	cg06637938	chr14:75390232	RPS6KL1	0.54	8.85	0.38	1.92e-17	IgG glycosylation;
LGG	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg18252515	chr7:66147081	NA	-0.41	-7.04	-0.31	7.05e-12	Aortic root size;
LGG	cis	rs28374715	0.681	rs28712264	chr15:41588797	T/C	cg18705301	chr15:41695430	NDUFAF1	-1.28	-29.15	-0.8	7.99e-107	Ulcerative colitis;
LGG	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg06636001	chr8:8085503	FLJ10661	0.4	6.99	0.31	9.85e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs116095464	1.000	rs56235400	chr5:312625	G/A	cg22496380	chr5:211416	CCDC127	-1.1	-10.58	-0.44	1.4e-23	Breast cancer;
LGG	cis	rs6502050	0.871	rs6502054	chr17:80066715	G/A	cg11859384	chr17:80120422	CCDC57	0.44	7.73	0.34	6.61e-14	Life satisfaction;
LGG	cis	rs4642101	0.686	rs13085726	chr3:12832672	A/C	cg05775895	chr3:12838266	CAND2	0.8	16.01	0.6	3.21e-46	QRS complex (12-leadsum);
LGG	cis	rs7552404	0.627	rs12127049	chr1:76353248	G/A	cg03433033	chr1:76189801	ACADM	0.63	8.95	0.38	8.56e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	6.93	0.31	1.42e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs3750082	0.582	rs7800883	chr7:32971282	G/A	cg08946731	chr7:32981826	RP9P	0.55	8.76	0.38	3.69e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs28595532	0.841	rs114735834	chr4:119772722	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs2075371	1.000	rs2544213	chr7:133982867	G/C	cg20476274	chr7:133979776	SLC35B4	0.78	15.67	0.59	1.03e-44	Mean platelet volume;
LGG	cis	rs4936891	0.543	rs7102393	chr11:123877696	C/T	cg22125253	chr11:123886957	OR10G4	-0.48	-8.13	-0.35	3.98e-15	Male fertility;
LGG	cis	rs2290402	0.536	rs4690336	chr4:867242	A/G	cg09237302	chr4:906077	GAK	0.43	7.42	0.33	5.77e-13	Type 2 diabetes;
LGG	cis	rs11229555	0.645	rs12272911	chr11:58183839	G/C	cg15696309	chr11:58395628	NA	-0.94	-15.32	-0.58	3.76e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs459193	1.000	rs173964	chr5:55809465	A/G	cg26646659	chr5:55776364	NA	0.3	6.78	0.3	3.65e-11	Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-hip ratio;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs4665809	0.941	rs2289021	chr2:26362515	A/C	cg08470875	chr2:26401718	FAM59B	0.36	6.68	0.3	6.97e-11	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg07541023	chr7:19748670	TWISTNB	0.5	6.73	0.3	5.12e-11	Night sleep phenotypes;
LGG	cis	rs5769765	1.000	rs2295409	chr22:50261060	G/C	cg02269571	chr22:50332266	NA	0.64	10.1	0.42	8.58e-22	Schizophrenia;
LGG	cis	rs2153535	0.580	rs9393016	chr6:8458573	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs13102973	0.864	rs7697346	chr4:135899283	G/A	cg14419869	chr4:135874104	NA	0.46	8.29	0.36	1.23e-15	Subjective well-being;
LGG	cis	rs5769707	0.837	rs5769709	chr22:50021757	C/T	cg06623630	chr22:50017776	C22orf34	-0.38	-7.96	-0.35	1.32e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs72615157	0.645	rs76281814	chr7:99846414	T/C	cg16268157	chr7:99778414	STAG3	-0.47	-7.32	-0.32	1.13e-12	Lung function (FEV1/FVC);
LGG	cis	rs2455601	0.786	rs11042127	chr11:8947586	C/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.77	-13.46	-0.53	4.42e-35	Schizophrenia;
LGG	cis	rs17270561	0.609	rs3922842	chr6:25736564	T/C	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs73086581	1.000	rs56324992	chr20:3978153	C/A	cg02187196	chr20:3869020	PANK2	0.81	11.46	0.47	6.29e-27	Response to antidepressants in depression;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16281248	chr11:64014554	PPP1R14B	0.41	7.4	0.33	6.51e-13	Obesity-related traits;
LGG	cis	rs9487094	0.670	rs1885691	chr6:109703391	C/T	cg01125227	chr6:109776195	MICAL1	0.38	6.69	0.3	6.58e-11	Height;
LGG	cis	rs3824867	0.676	rs7104366	chr11:47462115	G/A	cg20307385	chr11:47447363	PSMC3	0.47	7.55	0.33	2.4e-13	Mean corpuscular hemoglobin;
LGG	cis	rs12949688	0.967	rs8064970	chr17:55824687	T/C	cg12582317	chr17:55822272	NA	0.69	19.86	0.68	5.81e-64	Schizophrenia;
LGG	cis	rs2228479	0.850	rs17227064	chr16:89816314	A/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs9487094	0.813	rs13195517	chr6:109736253	C/T	cg16315928	chr6:109776240	MICAL1	0.54	9.0	0.39	5.85e-18	Height;
LGG	cis	rs2404602	0.692	rs12595586	chr15:77172210	A/G	cg22467129	chr15:76604101	ETFA	-0.42	-7.08	-0.31	5.32e-12	Blood metabolite levels;
LGG	cis	rs9362426	1.000	rs9450662	chr6:88088593	A/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	10.0	0.42	1.91e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.84	-0.34	3.14e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs6665290	0.904	rs3795449	chr1:227181838	T/G	cg05696931	chr1:227175867	NA	-0.4	-7.94	-0.35	1.51e-14	Myeloid white cell count;
LGG	cis	rs17227506	0.730	rs36106719	chr8:13457693	G/C	cg03566418	chr8:13424080	C8orf48	0.63	9.97	0.42	2.45e-21	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs3780486	0.801	rs6476398	chr9:33119241	C/T	cg04842962	chr6:43655489	MRPS18A	1.11	23.77	0.74	3.21e-82	IgG glycosylation;
LGG	cis	rs7674212	0.570	rs2711898	chr4:104063071	C/T	cg16532752	chr4:104119610	CENPE	-0.42	-7.41	-0.33	6.01e-13	Type 2 diabetes;
LGG	cis	rs709400	1.000	rs10135248	chr14:104122310	T/C	cg24130564	chr14:104152367	KLC1	-0.45	-8.54	-0.37	1.92e-16	Body mass index;
LGG	cis	rs916888	0.773	rs199535	chr17:44822662	A/G	cg01570182	chr17:44337453	NA	0.72	12.12	0.49	1.48e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7618915	0.547	rs2164884	chr3:52629633	C/T	cg14092988	chr3:52407081	DNAH1	0.32	8.4	0.36	5.44e-16	Bipolar disorder;
LGG	cis	rs1552244	0.882	rs13100734	chr3:10022878	A/G	cg00149659	chr3:10157352	C3orf10	0.72	9.17	0.39	1.59e-18	Alzheimer's disease;
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.69	-0.34	8.85e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg13607699	chr17:42295918	UBTF	0.54	9.11	0.39	2.55e-18	Total body bone mineral density;
LGG	cis	rs8177253	0.665	rs12639304	chr3:133441594	A/T	cg08048268	chr3:133502702	NA	-0.45	-7.93	-0.35	1.61e-14	Iron status biomarkers;
LGG	trans	rs1814175	0.645	rs1608632	chr11:49967148	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.82	-0.71	4e-73	Height;
LGG	cis	rs875971	0.545	rs7811204	chr7:65852200	G/A	cg11764359	chr7:65958608	NA	0.63	9.55	0.41	7.64e-20	Aortic root size;
LGG	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg16751781	chr15:78858589	CHRNA5	0.42	7.87	0.34	2.54e-14	Sudden cardiac arrest;
LGG	cis	rs7647973	0.580	rs11716334	chr3:49230096	G/A	cg18654377	chr3:49208889	KLHDC8B	-0.54	-8.6	-0.37	1.25e-16	Menarche (age at onset);
LGG	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg26513180	chr16:89883248	FANCA	-0.89	-18.78	-0.66	6.48e-59	Vitiligo;
LGG	cis	rs9381040	0.610	rs4140579	chr6:41041752	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.68	-0.3	6.83e-11	Alzheimer's disease (late onset);
LGG	cis	rs77741769	0.569	rs10774572	chr12:121309561	A/G	cg02419362	chr12:121203948	SPPL3	0.53	9.25	0.39	8.61e-19	Mean corpuscular volume;
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg07959490	chr17:80112427	CCDC57	0.47	9.27	0.4	6.88e-19	Life satisfaction;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	18.52	0.65	1.07e-57	Platelet count;
LGG	cis	rs727505	1.000	rs7791430	chr7:124429953	G/T	cg23710748	chr7:124431027	NA	-0.55	-10.44	-0.44	4.62e-23	Lewy body disease;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.21	0.68	1.44e-65	Alzheimer's disease;
LGG	cis	rs3820928	0.605	rs6718767	chr2:227800776	A/G	cg11843606	chr2:227700838	RHBDD1	-0.58	-10.95	-0.45	5.58e-25	Pulmonary function;
LGG	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg09667589	chr1:151400745	POGZ	0.31	7.19	0.32	2.67e-12	Lung cancer;
LGG	cis	rs7582180	0.663	rs4850930	chr2:100990955	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.16	-0.43	4.85e-22	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.663	rs7630674	chr3:160813597	G/A	cg04691961	chr3:161091175	C3orf57	-0.51	-10.85	-0.45	1.35e-24	Morning vs. evening chronotype;
LGG	cis	rs9583531	0.600	rs6492303	chr13:111356800	G/A	cg15841412	chr13:111365552	ING1	0.43	6.86	0.3	2.27e-11	Coronary artery disease;
LGG	cis	rs1799949	0.965	rs8176087	chr17:41270666	C/A	cg25172604	chr17:41446521	NA	-0.3	-6.68	-0.3	6.79e-11	Menopause (age at onset);
LGG	cis	rs5769765	0.954	rs5770709	chr22:50245196	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.75	11.04	0.46	2.55e-25	Schizophrenia;
LGG	cis	rs801193	0.844	rs732465	chr7:65998450	T/C	cg18876405	chr7:65276391	NA	0.6	11.42	0.47	8.43e-27	Aortic root size;
LGG	cis	rs79349575	0.749	rs12601672	chr17:47006493	T/C	cg22482690	chr17:47019901	SNF8	0.35	6.92	0.31	1.47e-11	Type 2 diabetes;
LGG	cis	rs2721195	1.000	rs750472	chr8:145701453	A/C	cg26752003	chr8:145688521	CYHR1	0.58	12.54	0.5	2.92e-31	Age at first birth;
LGG	cis	rs3857536	0.813	rs7770349	chr6:66946659	G/T	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21582582	chr3:182698605	DCUN1D1	-0.52	-9.63	-0.41	3.85e-20	Intelligence (multi-trait analysis);
LGG	trans	rs2727020	0.702	rs609054	chr11:49219725	C/G	cg15704280	chr7:45808275	SEPT13	0.9	18.55	0.65	7.47e-58	Coronary artery disease;
LGG	cis	rs28386778	0.863	rs7221573	chr17:61859390	G/A	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.2e-14	Prudent dietary pattern;
LGG	cis	rs9326248	0.581	rs10892072	chr11:116960313	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.65	11.13	0.46	1.12e-25	Blood protein levels;
LGG	cis	rs12153243	0.714	rs55848514	chr5:142902056	C/T	cg13907255	chr5:142895549	NA	-0.5	-8.73	-0.38	4.56e-17	Migraine;
LGG	cis	rs9487094	0.922	rs13204102	chr6:109938944	C/A	cg16315928	chr6:109776240	MICAL1	0.54	9.08	0.39	3.21e-18	Height;
LGG	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.61	11.45	0.47	6.63e-27	Rheumatoid arthritis;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.43	7.34	0.32	9.67e-13	Longevity;
LGG	cis	rs1862618	0.641	rs2591954	chr5:56245044	G/C	cg08400814	chr5:56204995	C5orf35	0.4	7.09	0.31	5.13e-12	Initial pursuit acceleration;
LGG	cis	rs6138458	1.000	rs11905625	chr20:24977065	A/C	cg26195577	chr20:24973756	C20orf3	1.24	25.98	0.77	1.77e-92	Blood protein levels;
LGG	cis	rs7659604	0.539	rs7686084	chr4:122764725	A/C	cg19748678	chr4:122722346	EXOSC9	0.67	13.25	0.52	3.42e-34	Type 2 diabetes;
LGG	cis	rs9486719	1.000	rs12208449	chr6:96903253	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	10.06	0.42	1.16e-21	Migraine;Coronary artery disease;
LGG	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs6502050	0.799	rs12940433	chr17:80120826	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs988958	0.675	rs7576689	chr2:42218358	C/T	cg19376973	chr2:42229025	NA	0.62	9.74	0.41	1.63e-20	Hypospadias;
LGG	cis	rs11718455	1.000	rs4682928	chr3:44037192	T/C	cg21419209	chr3:44054225	NA	-0.43	-6.93	-0.31	1.43e-11	Coronary artery disease;
LGG	cis	rs8031584	1.000	rs35239376	chr15:31290538	A/C	cg08109568	chr15:31115862	NA	-0.52	-8.59	-0.37	1.32e-16	Huntington's disease progression;
LGG	cis	rs1005277	0.579	rs2472174	chr10:38375382	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.46	-0.33	4.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6450176	1.000	rs6886510	chr5:53303127	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.69	11.53	0.47	3.36e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs75920871	0.841	rs112151056	chr11:116919368	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-7.03	-0.31	7.52e-12	Subjective well-being;
LGG	cis	rs4481887	0.927	rs7519334	chr1:248472076	C/T	cg13385794	chr1:248469461	NA	0.49	8.46	0.37	3.43e-16	Common traits (Other);
LGG	cis	rs870825	0.616	rs6818447	chr4:185650154	G/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	trans	rs1994135	0.586	rs7308214	chr12:33713834	T/A	cg26384229	chr12:38710491	ALG10B	0.75	13.81	0.54	1.48e-36	Resting heart rate;
LGG	cis	rs1018697	0.966	rs1953930	chr10:104549461	G/A	cg04362960	chr10:104952993	NT5C2	0.48	8.93	0.38	9.86e-18	Colorectal adenoma (advanced);
LGG	cis	rs9290877	0.667	rs62291298	chr3:188460544	A/G	cg17392043	chr3:188495102	LPP	-0.42	-7.31	-0.32	1.22e-12	IgE levels;
LGG	cis	rs12142240	0.698	rs41294478	chr1:46818442	G/A	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs921968	0.541	rs58650092	chr2:219304851	C/A	cg01130898	chr2:219473002	PLCD4	0.42	7.35	0.32	9.13e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9487094	0.644	rs1960325	chr6:109913308	G/A	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.97e-14	Height;
LGG	cis	rs11644362	0.966	rs12933348	chr16:12991081	C/T	cg06890432	chr16:12997467	SHISA9	-0.31	-6.81	-0.3	3.06e-11	Positive affect;Subjective well-being;
LGG	cis	rs9311474	0.508	rs11720159	chr3:52617802	T/G	cg15147215	chr3:52552868	STAB1	-0.37	-7.04	-0.31	6.97e-12	Electroencephalogram traits;
LGG	cis	rs9875589	0.747	rs1488378	chr3:14014725	G/A	cg19554555	chr3:13937349	NA	-0.66	-11.43	-0.47	8.21e-27	Ovarian reserve;
LGG	cis	rs11711311	1.000	rs2603793	chr3:113496418	A/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.84	-0.34	3.1e-14	IgG glycosylation;
LGG	cis	rs6951245	0.529	rs76001997	chr7:1152615	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.66	-0.44	6.87e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3858526	0.959	rs4559671	chr11:5923419	C/T	cg13902645	chr11:5959945	NA	-0.7	-10.99	-0.45	3.99e-25	DNA methylation (variation);
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg12310025	chr6:25882481	NA	-0.51	-9.59	-0.41	5.55e-20	Height;
LGG	cis	rs78487399	0.808	rs6746058	chr2:43687542	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.92	-0.31	1.51e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs4243830	1.000	rs41278016	chr1:6584045	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.8	10.32	0.43	1.35e-22	Body mass index;
LGG	cis	rs6938	0.575	rs12909335	chr15:75214789	T/G	cg09165964	chr15:75287851	SCAMP5	0.64	12.18	0.49	8.21e-30	Breast cancer;
LGG	cis	rs2880765	0.566	rs17553790	chr15:86013665	C/T	cg10818794	chr15:86012489	AKAP13	0.56	12.92	0.51	7.64e-33	Coronary artery disease;
LGG	cis	rs2880765	0.835	rs4843062	chr15:86040137	A/G	cg17133734	chr15:86042851	AKAP13	-0.29	-6.76	-0.3	4.28e-11	Coronary artery disease;
LGG	cis	rs7666738	0.830	rs11721726	chr4:98996314	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.592	rs4822044	chr22:41979668	G/C	cg06481639	chr22:41940642	POLR3H	-0.56	-7.75	-0.34	6.06e-14	Vitiligo;
LGG	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg03264133	chr6:25882463	NA	-0.38	-6.7	-0.3	6.01e-11	Height;
LGG	cis	rs4743820	0.620	rs7848226	chr9:93920117	C/G	cg14446406	chr9:93919335	NA	-0.91	-15.82	-0.59	2.25e-45	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7851660	0.809	rs12006522	chr9:100652711	G/C	cg13688889	chr9:100608707	NA	-0.64	-12.76	-0.51	3.55e-32	Strep throat;
LGG	cis	rs13217239	0.646	rs12523820	chr6:27001502	A/G	cg12292205	chr6:26970375	C6orf41	0.55	10.82	0.45	1.7e-24	Schizophrenia;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs3741798	1.000	rs61922023	chr12:12485555	G/A	cg08615371	chr12:12503544	MANSC1	0.6	6.82	0.3	2.93e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs3771570	1.000	rs1056801	chr2:242292307	T/C	cg21155796	chr2:242212141	HDLBP	0.72	9.26	0.4	7.95e-19	Prostate cancer;
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.84	-0.38	2.08e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg09021430	chr5:549028	NA	-0.82	-12.79	-0.51	2.73e-32	Ulcerative colitis;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg13939156	chr17:80058883	NA	-0.46	-8.87	-0.38	1.66e-17	Life satisfaction;
LGG	cis	rs72945132	0.882	rs72947012	chr11:70149472	G/A	cg13802316	chr11:70253460	CTTN	-0.6	-7.63	-0.33	1.31e-13	Coronary artery disease;
LGG	cis	rs963731	0.649	rs297139	chr2:39318310	A/G	cg04010122	chr2:39346883	SOS1	-0.91	-8.0	-0.35	9.94e-15	Corticobasal degeneration;
LGG	cis	rs4075765	0.881	rs72887658	chr11:26197972	A/T	cg19182008	chr11:26298241	NA	0.78	7.48	0.33	3.89e-13	Cannabis dependence symptom count;
LGG	trans	rs7777677	0.925	rs2156964	chr7:142372587	C/T	cg18540325	chr9:33795118	PRSS3	-0.43	-7.36	-0.32	8.63e-13	Alcoholic chronic pancreatitis;
LGG	cis	rs28595532	0.920	rs116607127	chr4:119731072	T/C	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs2841277	0.676	rs10438246	chr14:105410183	T/C	cg21017887	chr14:105400489	NA	0.44	8.67	0.37	7.6e-17	Rheumatoid arthritis;
LGG	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg05973401	chr12:123451056	ABCB9	0.48	6.93	0.31	1.41e-11	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs7580658	0.929	rs2276583	chr2:128014684	G/A	cg10021288	chr2:128175891	PROC	-0.64	-13.11	-0.52	1.34e-33	Protein C levels;
LGG	cis	rs875971	0.660	rs2013222	chr7:66035936	C/G	cg18876405	chr7:65276391	NA	-0.63	-11.79	-0.48	3.02e-28	Aortic root size;
LGG	cis	rs2228479	0.850	rs11076623	chr16:89844120	G/T	cg06558623	chr16:89946397	TCF25	1.11	12.33	0.5	2.15e-30	Skin colour saturation;
LGG	cis	rs240764	0.853	rs108422	chr6:101039279	G/C	cg09795085	chr6:101329169	ASCC3	0.43	7.2	0.32	2.38e-12	Neuroticism;
LGG	cis	rs988958	0.526	rs12712822	chr2:42238995	C/G	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.11e-19	Hypospadias;
LGG	cis	rs6489882	0.867	rs6489876	chr12:113368055	G/A	cg25319449	chr12:113376135	OAS3	-0.41	-7.63	-0.33	1.33e-13	Chronic lymphocytic leukemia;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg26513180	chr16:89883248	FANCA	0.97	9.03	0.39	4.56e-18	Skin colour saturation;
LGG	cis	rs2455601	0.744	rs2163626	chr11:8983547	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.67	-11.54	-0.47	3.11e-27	Schizophrenia;
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg05861140	chr6:150128134	PCMT1	-0.44	-9.91	-0.42	3.86e-21	Lung cancer;
LGG	trans	rs7824557	0.592	rs2736280	chr8:11223022	C/A	cg15556689	chr8:8085844	FLJ10661	0.41	7.05	0.31	6.75e-12	Retinal vascular caliber;
LGG	cis	rs9858542	1.000	rs4283605	chr3:49678651	A/G	cg07274523	chr3:49395745	GPX1	0.55	9.1	0.39	2.7e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs701145	0.537	rs1713831	chr3:153836299	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs4665809	0.590	rs7579504	chr2:26439995	T/C	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs11158198	0.620	rs1998102	chr14:58598811	T/C	cg15908186	chr14:58618357	C14orf37	0.59	10.44	0.44	4.86e-23	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs9487051	0.872	rs9487034	chr6:109605899	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.98	-0.38	7.11e-18	Reticulocyte fraction of red cells;
LGG	cis	rs11148252	0.508	rs11148260	chr13:53162643	A/C	cg00495681	chr13:53174319	NA	0.73	15.17	0.58	1.78e-42	Lewy body disease;
LGG	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg15212455	chr7:39170539	POU6F2	0.48	11.17	0.46	7.87e-26	IgG glycosylation;
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg00142150	chr22:38071001	LGALS1	0.92	19.76	0.68	1.8e-63	Fat distribution (HIV);
LGG	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.88e-21	Aortic root size;
LGG	cis	rs896854	0.654	rs4735340	chr8:95976251	A/T	cg16049864	chr8:95962084	TP53INP1	-0.4	-8.97	-0.38	7.18e-18	Type 2 diabetes;
LGG	cis	rs12210905	0.688	rs114188783	chr6:27449604	T/C	cg15325629	chr6:28072465	NA	1.04	7.84	0.34	3.09e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2108225	0.872	rs6980029	chr7:107446127	T/C	cg18560240	chr7:107437656	SLC26A3	-0.58	-10.34	-0.43	1.11e-22	Ulcerative colitis;
LGG	cis	rs2742417	0.967	rs2742419	chr3:45731929	G/A	cg04837898	chr3:45731254	SACM1L	-0.37	-7.48	-0.33	3.81e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg19524238	chr7:2802976	GNA12	0.3	7.38	0.32	7.55e-13	Height;
LGG	cis	rs2153535	0.580	rs6597334	chr6:8504779	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.26	0.43	2.11e-22	Motion sickness;
LGG	cis	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg09998033	chr7:158218633	PTPRN2	-0.5	-9.05	-0.39	4.13e-18	Obesity-related traits;
LGG	cis	rs6719977	0.935	rs2289355	chr2:42981990	C/T	cg14631114	chr2:43023945	NA	0.42	8.94	0.38	9.12e-18	Hyperactive-impulsive symptoms;
LGG	cis	rs4595586	1.000	rs4768388	chr12:39223924	G/A	cg26384229	chr12:38710491	ALG10B	-0.41	-7.34	-0.32	9.92e-13	Morning vs. evening chronotype;
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg05552183	chr6:42928497	GNMT	0.47	14.57	0.56	7.82e-40	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6456156	0.586	rs10946208	chr6:167459596	C/T	cg07741184	chr6:167504864	NA	0.4	9.16	0.39	1.67e-18	Primary biliary cholangitis;
LGG	cis	rs6748734	0.817	rs10182575	chr2:241806690	C/T	cg04034577	chr2:241836375	C2orf54	-0.48	-10.11	-0.43	7.47e-22	Urinary metabolites;
LGG	cis	rs9467773	0.572	rs62394558	chr6:26604650	G/A	cg09904177	chr6:26538194	HMGN4	0.62	11.83	0.48	2.22e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9790314	0.934	rs465985	chr3:161098552	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-13.39	-0.53	8.57e-35	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg07092213	chr7:1199455	ZFAND2A	-0.41	-6.77	-0.3	3.81e-11	Longevity;Endometriosis;
LGG	cis	rs9388451	0.839	rs4897155	chr6:126095144	C/A	cg10911889	chr6:126070802	HEY2	0.43	7.37	0.32	7.69e-13	Brugada syndrome;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs651907	0.557	rs7651721	chr3:101393583	C/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.27	0.52	2.77e-34	Colorectal cancer;
LGG	trans	rs2727020	0.556	rs2866365	chr11:49390731	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-13.88	-0.54	7.41e-37	Coronary artery disease;
LGG	cis	rs858239	0.601	rs6971002	chr7:23172304	C/G	cg23682824	chr7:23144976	KLHL7	0.43	7.08	0.31	5.37e-12	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7712401	0.601	rs35157167	chr5:122318201	G/C	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs12478296	0.786	rs72620862	chr2:243044787	T/C	cg06360820	chr2:242988706	NA	-0.89	-11.48	-0.47	5.3e-27	Obesity-related traits;
LGG	cis	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7412746	0.658	rs6669855	chr1:150861229	C/T	cg15448220	chr1:150897856	SETDB1	0.4	7.29	0.32	1.36e-12	Melanoma;
LGG	cis	rs10504229	0.683	rs2318143	chr8:58114660	C/T	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1920116	0.744	rs9833035	chr3:169553498	G/T	cg00832555	chr3:169529716	LRRC34	0.38	6.66	0.3	7.9e-11	Glioma (high-grade);
LGG	cis	rs11677416	1.000	rs1304037	chr2:113532236	C/T	cg27083787	chr2:113543245	IL1A	-0.5	-8.21	-0.36	2.22e-15	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs2299587	0.828	rs13258901	chr8:17857028	T/C	cg18067069	chr8:17937731	ASAH1	-0.3	-6.81	-0.3	3.01e-11	Economic and political preferences;
LGG	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg23649088	chr2:200775458	C2orf69	0.6	8.05	0.35	7.02e-15	Schizophrenia;
LGG	cis	rs9527	0.622	rs12779263	chr10:104886533	G/T	cg04362960	chr10:104952993	NT5C2	0.57	10.68	0.44	6.03e-24	Arsenic metabolism;
LGG	trans	rs6582630	0.555	rs7978749	chr12:38527141	G/T	cg06521331	chr12:34319734	NA	-0.47	-8.26	-0.36	1.54e-15	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11088226	0.645	rs2833917	chr21:33957544	C/T	cg09050820	chr6:167586206	TCP10L2	0.94	13.55	0.53	1.74e-35	Gastritis;
LGG	cis	rs17376456	0.825	rs13361613	chr5:93272176	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.47	0.4	1.41e-19	Diabetic retinopathy;
LGG	cis	rs12200782	1.000	rs3800304	chr6:26598798	G/A	cg11502198	chr6:26597334	ABT1	-0.9	-7.71	-0.34	7.53e-14	Small cell lung carcinoma;
LGG	cis	rs910316	1.000	rs12435391	chr14:75601737	A/G	cg06637938	chr14:75390232	RPS6KL1	0.57	10.32	0.43	1.34e-22	Height;
LGG	cis	rs9818758	0.607	rs34823813	chr3:49749976	G/A	cg00383909	chr3:49044727	WDR6	1.13	13.43	0.53	6.03e-35	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	12.25	0.49	4.28e-30	Obesity-related traits;
LGG	cis	rs1003719	0.713	rs2835594	chr21:38466064	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg06766960	chr11:133703094	NA	-0.57	-11.42	-0.47	8.56e-27	Childhood ear infection;
LGG	trans	rs7395662	0.818	rs34486360	chr11:48782472	G/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.8	-0.34	4.23e-14	HDL cholesterol;
LGG	cis	rs2836974	0.568	rs419469	chr21:40537234	C/T	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.62e-17	Cognitive function;
LGG	cis	rs2290402	0.536	rs12509561	chr4:850701	C/T	cg09237302	chr4:906077	GAK	-0.44	-7.46	-0.33	4.4e-13	Type 2 diabetes;
LGG	cis	rs807669	0.772	rs809901	chr22:19228736	C/T	cg02655711	chr22:19163373	SLC25A1	0.64	12.59	0.5	1.87e-31	Metabolite levels;
LGG	cis	rs4696584	0.696	rs1873367	chr4:155413362	C/T	cg04517429	chr4:155413618	DCHS2	-0.33	-7.28	-0.32	1.41e-12	Folding of antihelix;
LGG	cis	rs7084402	0.934	rs1649089	chr10:60289695	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs10504229	0.728	rs72650861	chr8:58153273	T/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs11603023	0.967	rs654423	chr11:118511757	G/A	cg20309703	chr11:118481025	PHLDB1	-0.56	-10.36	-0.43	9.01e-23	Cholesterol, total;
LGG	cis	rs1577917	0.655	rs7742691	chr6:86278691	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.48	8.3	0.36	1.12e-15	Response to antipsychotic treatment;
LGG	cis	rs16976116	0.901	rs2899582	chr15:55491734	T/C	cg11288833	chr15:55489084	RSL24D1	0.56	7.67	0.34	1.03e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7192380	0.893	rs12924052	chr16:69777246	T/C	cg00738113	chr16:70207722	CLEC18C	0.3	8.63	0.37	9.82e-17	Sjögren's syndrome;
LGG	cis	rs2228479	0.850	rs17226519	chr16:89839854	T/C	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs35160687	0.623	rs2276625	chr2:86481835	A/G	cg10973622	chr2:86423274	IMMT	0.4	7.2	0.32	2.49e-12	Night sleep phenotypes;
LGG	cis	rs6696846	0.715	rs12139373	chr1:205054879	A/C	cg00857998	chr1:205179979	DSTYK	0.59	9.69	0.41	2.41e-20	Red blood cell count;
LGG	cis	rs4740619	0.619	rs1328279	chr9:16030606	A/G	cg14451791	chr9:16040625	NA	-0.42	-11.23	-0.46	5.02e-26	Body mass index;
LGG	cis	rs4774899	0.966	rs12898327	chr15:57363937	G/T	cg08128148	chr15:57256372	TCF12	-0.33	-7.84	-0.34	3.21e-14	Urinary tract infection frequency;
LGG	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg12856521	chr11:46389249	DGKZ	0.51	8.99	0.39	6.16e-18	Leprosy;
LGG	cis	rs9911578	1.000	rs2531734	chr17:56550804	T/C	cg12560992	chr17:57184187	TRIM37	-0.87	-15.29	-0.58	5.17e-43	Intelligence (multi-trait analysis);
LGG	cis	rs7614311	0.636	rs66490742	chr3:63913653	G/A	cg22134162	chr3:63841271	THOC7	-0.44	-7.78	-0.34	4.7e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs17739167	0.532	rs11638953	chr15:42245652	G/A	cg20935245	chr15:42234343	EHD4	0.38	7.38	0.32	7.54e-13	Monocyte count;
LGG	cis	rs2153535	0.601	rs6906170	chr6:8543128	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.58	0.5	1.93e-31	Motion sickness;
LGG	cis	rs1007190	0.881	rs6503406	chr17:42937105	C/T	cg15406952	chr17:42872593	NA	1.09	13.69	0.54	4.5e-36	DNA methylation (variation);
LGG	cis	rs11758351	1.000	rs80313145	chr6:26194965	T/A	cg01420254	chr6:26195488	NA	0.91	11.48	0.47	5.07e-27	Gout;Renal underexcretion gout;
LGG	cis	rs1046896	0.731	rs9906115	chr17:80791469	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.51	0.33	3.07e-13	Glycated hemoglobin levels;
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.66	0.37	7.66e-17	Longevity;
LGG	cis	rs61931739	0.517	rs11052964	chr12:34010996	G/C	cg06521331	chr12:34319734	NA	-0.62	-11.15	-0.46	9.6e-26	Morning vs. evening chronotype;
LGG	cis	rs950169	0.922	rs4586394	chr15:84822385	G/A	cg03959625	chr15:84868606	LOC388152	-0.55	-8.68	-0.37	6.89e-17	Schizophrenia;
LGG	cis	rs2204008	0.687	rs2320523	chr12:38251397	T/C	cg26384229	chr12:38710491	ALG10B	0.88	19.88	0.68	4.87e-64	Bladder cancer;
LGG	cis	rs7236492	0.688	rs9709477	chr18:77202786	C/A	cg15532942	chr18:77220712	NFATC1	0.46	7.4	0.33	6.33e-13	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg20587970	chr11:113659929	NA	0.93	12.92	0.51	8.18e-33	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg23533926	chr12:111358616	MYL2	-0.42	-6.86	-0.3	2.24e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9849248	0.585	rs73132546	chr3:88180661	A/C	cg14530983	chr3:88190749	ZNF654	0.56	7.82	0.34	3.52e-14	Menarche (age at onset);
LGG	cis	rs6951245	0.938	rs11764937	chr7:1092074	C/T	cg24642844	chr7:1081250	C7orf50	-0.83	-14.17	-0.55	4.11e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs736408	0.812	rs1076425	chr3:52825462	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.21	-0.32	2.26e-12	Bipolar disorder;
LGG	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.66	13.04	0.52	2.52e-33	Total body bone mineral density;
LGG	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg19524238	chr7:2802976	GNA12	0.29	7.01	0.31	8.41e-12	Height;
LGG	cis	rs4684776	1.000	rs13085240	chr3:11459645	C/G	cg24705426	chr3:11550659	ATG7	-0.42	-7.74	-0.34	6.21e-14	Small vessel stroke;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg22256960	chr15:77711686	NA	0.41	6.77	0.3	3.83e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28595532	0.920	rs115683389	chr4:119735557	T/G	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs7226408	0.857	rs8099118	chr18:34593699	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.17	-0.32	3.04e-12	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2486741	chr1:231516450	G/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7208859	0.673	rs73263981	chr17:28920502	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.92	-12.01	-0.49	4.07e-29	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.500	rs3800902	chr7:2144378	C/T	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	8.62e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7927592	0.913	rs7109294	chr11:68332093	A/G	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs7385804	0.761	rs1617640	chr7:100317298	C/A	cg16850897	chr7:100343110	ZAN	0.44	7.07	0.31	5.84e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs6952808	0.760	rs34961072	chr7:1948620	G/C	cg20295408	chr7:1910781	MAD1L1	-0.44	-7.54	-0.33	2.52e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs11997175	0.599	rs66474258	chr8:33640225	A/T	ch.8.33884649F	chr8:33765107	NA	0.38	6.96	0.31	1.17e-11	Body mass index;
LGG	cis	rs769267	0.859	rs2916076	chr19:19545990	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.08	0.55	9.52e-38	Tonsillectomy;
LGG	cis	rs806215	0.526	rs17151470	chr7:127517965	A/G	cg25922125	chr7:127225783	GCC1	-0.48	-6.98	-0.31	1.04e-11	Type 2 diabetes;
LGG	trans	rs61931739	0.963	rs3912355	chr12:34079616	A/G	cg26384229	chr12:38710491	ALG10B	0.62	10.95	0.45	5.54e-25	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	trans	rs7829975	0.688	rs7826654	chr8:8379106	C/T	cg21775007	chr8:11205619	TDH	0.41	6.91	0.31	1.63e-11	Mood instability;
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg08677398	chr8:58056175	NA	0.47	7.28	0.32	1.44e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.529	rs228764	chr17:42185469	A/G	cg19774624	chr17:42201019	HDAC5	0.64	11.33	0.47	2.01e-26	Total body bone mineral density;
LGG	cis	rs1580019	0.587	rs9638880	chr7:32552401	A/G	cg07520158	chr7:32535189	LSM5;AVL9	0.59	10.03	0.42	1.44e-21	Cognitive ability;
LGG	cis	rs2346160	0.831	rs1467391	chr6:167690062	A/G	cg20683250	chr6:167653907	NA	-0.42	-6.87	-0.3	2.11e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs12936587	0.538	rs1869771	chr17:17561094	C/A	cg01246520	chr17:17644344	RAI1	0.3	6.85	0.3	2.4e-11	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	cis	rs367943	0.637	rs6891711	chr5:113009026	G/T	cg12552261	chr5:112820674	MCC	-0.5	-8.17	-0.35	3.06e-15	Type 2 diabetes;
LGG	trans	rs6601327	0.603	rs13275545	chr8:9667914	G/C	cg16141378	chr3:129829833	LOC729375	0.33	7.43	0.33	5.4e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs77140172	0.677	rs77860352	chr4:89627774	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.91	8.4	0.36	5.61e-16	Post bronchodilator FEV1;
LGG	cis	rs950169	0.922	rs8037078	chr15:84818871	A/G	cg24253500	chr15:84953950	NA	-0.56	-10.23	-0.43	2.7e-22	Schizophrenia;
LGG	cis	rs4332037	0.539	rs34571717	chr7:2106855	T/C	cg23422044	chr7:1970798	MAD1L1	-0.48	-8.7	-0.37	5.83e-17	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15238008	chr12:9600875	DDX12	0.44	7.11	0.31	4.45e-12	Cognitive performance;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11841349	chr3:9791615	OGG1	0.48	7.99	0.35	1.12e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs3808502	0.509	rs2729940	chr8:11382367	G/A	cg02002194	chr4:3960332	NA	-0.5	-9.45	-0.4	1.68e-19	Neuroticism;
LGG	cis	rs10744422	0.800	rs11059724	chr12:123235978	T/G	cg25930673	chr12:123319894	HIP1R	0.7	8.31	0.36	1.09e-15	Schizophrenia;
LGG	cis	rs7552404	0.883	rs7513363	chr1:76143443	A/G	cg10523679	chr1:76189770	ACADM	0.82	15.75	0.59	4.57e-45	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs751728	0.664	rs12190029	chr6:33749152	T/A	cg13560919	chr6:33536144	NA	-0.42	-7.77	-0.34	5.24e-14	Crohn's disease;
LGG	cis	rs877282	0.583	rs11253425	chr10:815173	G/A	cg01169559	chr10:831247	NA	0.53	9.28	0.4	6.79e-19	Uric acid levels;
LGG	cis	rs1348850	0.914	rs2060929	chr2:178280031	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-8.42	-0.36	4.81e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11190604	1.000	rs35106985	chr10:102307542	T/C	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2072499	0.966	rs11587860	chr1:156156951	G/C	cg25208724	chr1:156163844	SLC25A44	1.24	30.9	0.82	1.37e-114	Testicular germ cell tumor;
LGG	cis	rs17376456	0.825	rs17314825	chr5:93234937	A/G	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	cis	rs2361718	0.631	rs12601637	chr17:78142455	T/C	cg09238746	chr17:78121135	EIF4A3	-0.7	-12.91	-0.51	8.38e-33	Yeast infection;
LGG	cis	rs10908458	0.584	rs10908455	chr1:155067283	C/T	cg13808842	chr1:155066096	NA	0.33	8.44	0.37	4.06e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9914544	1.000	rs8066385	chr17:18761133	C/T	cg26306683	chr17:18585705	ZNF286B	0.49	9.33	0.4	4.51e-19	Educational attainment (years of education);
LGG	cis	rs12724450	0.546	rs11801255	chr1:150424300	G/A	cg03818307	chr1:150480534	ECM1	0.49	6.99	0.31	9.8e-12	Blood protein levels;
LGG	cis	rs12210905	1.000	rs9348756	chr6:27228259	G/A	cg11502198	chr6:26597334	ABT1	-0.88	-6.72	-0.3	5.46e-11	Hip circumference adjusted for BMI;
LGG	cis	rs208520	0.507	rs3903670	chr6:66812183	T/C	cg07460842	chr6:66804631	NA	-1.15	-32.48	-0.83	1.77e-121	Exhaled nitric oxide output;
LGG	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9815354	0.812	rs113144620	chr3:42008312	A/G	cg03022575	chr3:42003672	ULK4	0.79	9.16	0.39	1.72e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11039798	0.844	rs6485820	chr11:48264711	A/G	cg15704280	chr7:45808275	SEPT13	0.74	8.69	0.37	6.53e-17	Axial length;
LGG	cis	rs559928	0.606	rs56207008	chr11:63883215	C/T	cg26318627	chr11:63887540	MACROD1	-0.47	-6.79	-0.3	3.46e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24942186	chr3:55521373	WNT5A	-0.47	-6.69	-0.3	6.64e-11	Systemic lupus erythematosus;
LGG	cis	rs7017914	0.934	rs35214141	chr8:71574564	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg27336068	chr10:1336103	ADARB2	-0.4	-9.16	-0.39	1.71e-18	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs75229567	0.618	rs75389984	chr12:70212879	A/G	cg10114359	chr12:70132523	RAB3IP	1.37	10.96	0.45	5.17e-25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg13880726	chr7:1868755	MAD1L1	0.4	7.09	0.31	5.03e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1577917	0.883	rs2166664	chr6:86596622	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.83	-0.34	3.38e-14	Response to antipsychotic treatment;
LGG	cis	rs4750440	0.706	rs12358733	chr10:14016290	A/G	cg00551146	chr10:14014579	FRMD4A	-0.29	-7.11	-0.31	4.36e-12	Adiponectin levels;
LGG	cis	rs780096	0.526	rs1260341	chr2:27663215	T/A	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs6466055	0.720	rs1204060	chr7:104963064	T/C	cg04380332	chr7:105027541	SRPK2	0.4	7.36	0.32	8.45e-13	Schizophrenia;
LGG	cis	rs9515201	0.627	rs952359	chr13:111026734	G/A	cg06243866	chr13:111019493	COL4A2	-0.71	-13.66	-0.54	6.34e-36	White matter hyperintensity burden;
LGG	cis	rs4262150	0.883	rs12652844	chr5:152315418	T/C	cg12297329	chr5:152029980	NA	-0.62	-11.3	-0.46	2.64e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs72945132	0.638	rs11236127	chr11:70241536	G/C	cg14088196	chr11:70211408	PPFIA1	0.78	10.89	0.45	9.9e-25	Coronary artery disease;
LGG	trans	rs11098499	0.754	rs12711071	chr4:120240934	A/G	cg25214090	chr10:38739885	LOC399744	0.61	10.94	0.45	6.05e-25	Corneal astigmatism;
LGG	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg25110423	chr6:41068646	NFYA;LOC221442	0.38	6.99	0.31	9.74e-12	Alzheimer's disease (late onset);
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.38	-0.43	8.08e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs8076717	chr17:61850301	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.48	7.28	0.32	1.4e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2386661	0.826	rs4749834	chr10:5671808	G/A	cg26603656	chr10:5671107	NA	0.39	7.72	0.34	7.48e-14	Breast cancer;
LGG	cis	rs4642101	0.662	rs57411588	chr3:12820384	C/G	cg24848339	chr3:12840334	CAND2	0.45	10.85	0.45	1.39e-24	QRS complex (12-leadsum);
LGG	cis	rs9902453	1.000	rs9902453	chr17:28349095	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.29	-0.53	2.21e-34	Coffee consumption (cups per day);
LGG	cis	rs12477438	1.000	rs12466388	chr2:99916538	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.7	-10.69	-0.44	5.68e-24	Chronic sinus infection;
LGG	trans	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs1008375	1.000	rs10009541	chr4:17682218	C/T	cg02297831	chr4:17616191	MED28	-0.47	-8.73	-0.38	4.61e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs8180040	0.966	rs6792488	chr3:47503349	C/T	cg16586182	chr3:47516702	SCAP	0.77	15.39	0.58	1.86e-43	Colorectal cancer;
LGG	cis	rs9611565	0.659	rs1810461	chr22:41927820	G/A	cg17376030	chr22:41985996	PMM1	0.59	9.3	0.4	5.81e-19	Vitiligo;
LGG	cis	rs9715521	0.900	rs62301182	chr4:59834267	A/G	cg11281224	chr4:60001000	NA	-0.44	-7.34	-0.32	9.72e-13	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.935	rs6853002	chr4:1295991	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.59	10.42	0.44	5.69e-23	Obesity-related traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01869136	chr14:56755262	PELI2	0.33	6.82	0.3	2.85e-11	Menarche (age at onset);
LGG	cis	rs11098499	0.863	rs59732491	chr4:120489588	G/C	cg24375607	chr4:120327624	NA	0.68	11.2	0.46	6.41e-26	Corneal astigmatism;
LGG	cis	rs657075	0.697	rs13179900	chr5:131647590	A/G	cg06968155	chr5:131705112	SLC22A5	-0.68	-7.8	-0.34	4.25e-14	Rheumatoid arthritis;
LGG	trans	rs5756813	0.700	rs1894525	chr22:38186400	G/A	cg19894588	chr14:64061835	NA	-0.63	-9.83	-0.42	8e-21	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs12476592	0.571	rs7577952	chr2:63787212	C/T	cg17519650	chr2:63277830	OTX1	-0.45	-6.95	-0.31	1.27e-11	Childhood ear infection;
LGG	cis	rs12479064	0.671	rs62155807	chr2:100076579	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.56	-8.79	-0.38	2.96e-17	Chronic sinus infection;
LGG	cis	rs35306767	0.761	rs11253558	chr10:1043983	T/C	cg26597838	chr10:835615	NA	0.55	7.1	0.31	4.87e-12	Eosinophil percentage of granulocytes;
LGG	trans	rs3764147	0.510	rs1888302	chr13:44375330	G/A	cg12856521	chr11:46389249	DGKZ	-0.56	-8.06	-0.35	6.68e-15	Inflammatory bowel disease;Crohn's disease;Leprosy;
LGG	cis	rs11098499	0.738	rs28687057	chr4:120280812	A/G	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg08508325	chr11:3079039	CARS	-0.54	-10.99	-0.45	3.89e-25	Longevity;
LGG	cis	rs758324	0.773	rs4540167	chr5:131163022	G/A	cg06307176	chr5:131281290	NA	0.53	8.73	0.38	4.71e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6540556	0.608	rs2884090	chr1:209884059	C/T	cg23920097	chr1:209922102	NA	-0.39	-6.91	-0.31	1.58e-11	Red blood cell count;
LGG	cis	rs1580019	0.523	rs9791770	chr7:32582252	C/A	cg07520158	chr7:32535189	LSM5;AVL9	0.56	9.41	0.4	2.41e-19	Cognitive ability;
LGG	cis	rs4555082	0.874	rs2816613	chr14:105726367	C/T	cg10792982	chr14:105748885	BRF1	0.68	13.66	0.54	6.48e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs651907	0.557	rs13081846	chr3:101383321	T/C	cg12386194	chr3:101231763	SENP7	0.46	8.12	0.35	4.14e-15	Colorectal cancer;
LGG	cis	rs17376456	0.825	rs66564678	chr5:93165894	C/T	cg19507638	chr5:93509721	C5orf36	-0.65	-9.2	-0.39	1.27e-18	Diabetic retinopathy;
LGG	cis	rs9467773	0.620	rs9461275	chr6:26590801	C/T	cg11502198	chr6:26597334	ABT1	0.7	12.72	0.51	5.1e-32	Intelligence (multi-trait analysis);
LGG	cis	rs9644630	0.897	rs6984644	chr8:19363425	C/T	cg06699216	chr8:19333253	CSGALNACT1	-0.49	-11.44	-0.47	7.6e-27	Oropharynx cancer;
LGG	cis	rs7289126	0.966	rs5995554	chr22:38630272	T/C	cg25457927	chr22:38595422	NA	-0.33	-7.94	-0.35	1.51e-14	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.35	0.36	7.75e-16	Tonsillectomy;
LGG	cis	rs2204008	0.658	rs12371956	chr12:38298010	A/T	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.04e-36	Bladder cancer;
LGG	cis	rs2117029	0.782	rs6580698	chr12:49478658	A/G	cg24176009	chr12:49580217	TUBA1A	0.43	7.72	0.34	7.16e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1408799	0.750	rs977888	chr9:12624357	G/T	cg05274944	chr9:12693694	TYRP1	0.32	7.54	0.33	2.48e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs17253792	0.822	rs17685053	chr14:56125771	T/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.51	-0.5	3.89e-31	Putamen volume;
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg26850624	chr5:429559	AHRR	-0.37	-7.96	-0.35	1.34e-14	Cystic fibrosis severity;
LGG	trans	rs4843747	0.697	rs72818533	chr16:88073841	G/A	cg00711542	chr16:29343894	RUNDC2C	0.43	7.16	0.32	3.13e-12	Menopause (age at onset);
LGG	cis	rs2732480	0.500	rs2450989	chr12:48653408	A/G	cg21466736	chr12:48725269	NA	0.35	7.07	0.31	5.61e-12	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2242116	0.743	rs11719795	chr3:46951935	T/C	cg02527881	chr3:46936655	PTH1R	-0.31	-6.94	-0.31	1.33e-11	Birth weight;
LGG	trans	rs61931739	0.534	rs1486886	chr12:34043619	C/T	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs2760061	0.784	rs1745414	chr1:228212159	T/A	cg02753203	chr1:228287806	NA	0.78	15.12	0.57	3.04e-42	Diastolic blood pressure;
LGG	cis	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg06636001	chr8:8085503	FLJ10661	0.46	8.41	0.36	5.22e-16	Joint mobility (Beighton score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg08316775	chr2:73964643	TPRKB	-0.46	-6.7	-0.3	6.21e-11	Systemic lupus erythematosus;
LGG	cis	rs40363	0.672	rs1617722	chr16:3520806	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.44	6.7	0.3	6.24e-11	Tuberculosis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg21498772	chr8:63161077	NKAIN3	0.4	6.93	0.31	1.41e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2795502	1.000	rs2795502	chr10:43340662	G/A	cg20628663	chr10:43360327	NA	-0.42	-8.7	-0.37	5.94e-17	Blood protein levels;
LGG	cis	rs2396545	0.680	rs35467761	chr11:571568	A/G	cg03576123	chr11:487126	PTDSS2	-0.56	-7.38	-0.32	7.37e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg02071572	chr4:1403502	NA	0.38	7.11	0.31	4.36e-12	Longevity;
LGG	cis	rs7666738	0.830	rs13134216	chr4:98919765	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.27e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9910055	0.639	rs7217858	chr17:42254527	T/G	cg08499158	chr17:42289980	UBTF	-0.54	-10.16	-0.43	5.16e-22	Total body bone mineral density;
LGG	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	11.14	0.46	1.05e-25	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2764980	1.000	rs2764978	chr10:3283385	C/G	cg20244327	chr10:3283946	NA	-0.32	-8.57	-0.37	1.57e-16	Attention deficit hyperactivity disorder and conduct disorder;
LGG	trans	rs7824557	0.603	rs2249804	chr8:11215617	C/G	cg15556689	chr8:8085844	FLJ10661	0.5	8.79	0.38	2.95e-17	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs13119532	chr4:1304505	G/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.46	8.38	0.36	6.4e-16	Obesity-related traits;
LGG	cis	rs11792861	0.962	rs72607162	chr9:111793719	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.56	0.41	6.73e-20	Menarche (age at onset);
LGG	cis	rs4237845	0.537	rs7969844	chr12:58278271	C/T	cg00677455	chr12:58241039	CTDSP2	0.41	7.66	0.34	1.12e-13	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg24623649	chr8:11872141	NA	0.33	7.99	0.35	1.07e-14	Neuroticism;
LGG	cis	rs11122272	0.735	rs2491407	chr1:231518928	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs208520	0.690	rs6932475	chr6:66863155	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.66	-0.63	9.65e-54	Exhaled nitric oxide output;
LGG	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg25358565	chr5:93447407	FAM172A	1.39	17.11	0.62	3.18e-51	Diabetic retinopathy;
LGG	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.28	0.6	1.86e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs62025270	0.632	rs78572940	chr15:86239770	A/C	cg25843651	chr15:86329602	KLHL25	0.57	8.52	0.37	2.23e-16	Idiopathic pulmonary fibrosis;
LGG	cis	rs2013441	0.866	rs2703773	chr17:20131814	T/C	cg13482628	chr17:19912719	NA	-0.41	-6.98	-0.31	1.04e-11	Obesity-related traits;
LGG	cis	rs10864907	0.553	rs7580877	chr2:113718310	C/A	cg06156847	chr2:113672199	IL1F7	-0.35	-6.98	-0.31	1.04e-11	Pulmonary function;
LGG	trans	rs208520	0.690	rs207114	chr6:66791703	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.98	-18.48	-0.65	1.54e-57	Exhaled nitric oxide output;
LGG	cis	rs13126513	0.872	rs1072626	chr4:100407267	A/G	cg05468953	chr4:100565104	NA	0.35	6.65	0.3	8.08e-11	Metabolite levels (MHPG);
LGG	cis	rs3099143	1.000	rs4886831	chr15:77106801	T/C	cg21673338	chr15:77095150	SCAPER	0.65	10.63	0.44	8.89e-24	Recalcitrant atopic dermatitis;
LGG	cis	rs1030877	1.000	rs2576737	chr2:105891510	C/T	cg02079111	chr2:105885981	TGFBRAP1	0.74	14.8	0.57	7.2e-41	Obesity-related traits;
LGG	cis	rs10982213	0.830	rs2274163	chr9:117188714	C/T	cg00969271	chr9:117093052	ORM2	-0.42	-7.89	-0.34	2.19e-14	Interleukin-6 levels;
LGG	cis	rs7582180	0.606	rs11684004	chr2:100954783	C/T	cg05692746	chr2:100937584	LONRF2	-0.66	-12.27	-0.5	3.54e-30	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs10944147	chr6:86550786	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.24	-0.43	2.62e-22	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.595	rs77615399	chr8:58117394	C/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs1055129	0.537	rs1135640	chr17:73949540	C/G	cg08125733	chr17:73851984	WBP2	-0.42	-7.0	-0.31	9.26e-12	White matter hyperintensity burden;
LGG	cis	rs10046574	0.656	rs76799185	chr7:135194266	G/C	cg27474649	chr7:135195673	CNOT4	0.72	8.4	0.36	5.65e-16	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1046896	0.520	rs9895409	chr17:80902719	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.44	7.56	0.33	2.12e-13	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg11878867	chr6:150167359	LRP11	-0.51	-10.68	-0.44	6.21e-24	Lung cancer;
LGG	cis	rs7106204	0.514	rs2068454	chr11:24256166	C/G	ch.11.24196551F	chr11:24239977	NA	-0.9	-13.44	-0.53	5.35e-35	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs7615952	0.800	rs35390120	chr3:125599809	G/A	cg05084668	chr3:125655381	ALG1L	-1.06	-12.31	-0.5	2.45e-30	Blood pressure (smoking interaction);
LGG	cis	rs4808199	0.947	rs10401193	chr19:19591066	A/G	cg03709012	chr19:19516395	GATAD2A	1.08	17.74	0.64	4.41e-54	Nonalcoholic fatty liver disease;
LGG	cis	rs9790314	0.663	rs1599379	chr3:160860665	A/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.39	-0.43	7.06e-23	Morning vs. evening chronotype;
LGG	cis	rs503734	0.620	rs508537	chr3:101011537	C/T	cg27318481	chr3:100970896	IMPG2	-0.36	-7.2	-0.32	2.51e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10911251	0.546	rs1547714	chr1:183114119	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.4	0.4	2.48e-19	Colorectal cancer;
LGG	cis	rs2439831	0.867	rs11856184	chr15:43919162	A/C	cg15269541	chr15:43626905	ADAL	-0.43	-6.83	-0.3	2.65e-11	Lung cancer in ever smokers;
LGG	cis	rs17102423	0.731	rs998247	chr14:65546299	C/T	cg11161011	chr14:65562177	MAX	-0.61	-11.74	-0.48	4.94e-28	Obesity-related traits;
LGG	cis	rs3796352	0.764	rs34872575	chr3:52986277	G/A	cg12962167	chr3:53033115	SFMBT1	0.77	8.07	0.35	6.18e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs55871839	0.559	rs2326268	chr8:59841217	C/T	cg07426533	chr8:59803705	TOX	0.57	11.98	0.49	5.34e-29	Pneumonia;
LGG	cis	rs2386661	0.826	rs1317517	chr10:5672580	T/G	cg26603656	chr10:5671107	NA	0.38	7.69	0.34	8.83e-14	Breast cancer;
LGG	cis	rs12908161	0.960	rs34452033	chr15:85221993	A/G	cg03959625	chr15:84868606	LOC388152	0.48	7.07	0.31	5.67e-12	Schizophrenia;
LGG	cis	rs3808502	0.503	rs2061830	chr8:11397457	C/G	cg27411982	chr8:10470053	RP1L1	0.43	7.62	0.33	1.44e-13	Neuroticism;
LGG	cis	rs2120243	0.845	rs2316710	chr3:157150180	G/T	cg01018701	chr3:157155998	VEPH1;PTX3	0.33	6.93	0.31	1.37e-11	Hepatocellular carcinoma in hepatitis B infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05191792	chr6:2765113	WRNIP1	0.46	7.74	0.34	6.39e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.33	-0.4	4.38e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10911363	0.592	rs2702177	chr1:183450622	G/C	cg09173681	chr1:183549694	NCF2	0.37	8.36	0.36	7.52e-16	Systemic lupus erythematosus;
LGG	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg20916646	chr4:852691	GAK	0.67	11.13	0.46	1.13e-25	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs9318086	0.712	rs12875437	chr13:24453956	A/G	cg25267304	chr13:24462978	PCOTH;MIPEP	0.48	9.35	0.4	3.61e-19	Myopia (pathological);
LGG	cis	rs769267	0.930	rs2099334	chr19:19578450	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg11644478	chr21:40555479	PSMG1	-0.72	-12.77	-0.51	3.23e-32	Cognitive function;
LGG	cis	rs11758351	0.500	rs76607472	chr6:26191557	C/T	cg03181300	chr6:26195995	NA	0.88	6.68	0.3	6.88e-11	Gout;Renal underexcretion gout;
LGG	cis	rs8141529	0.529	rs5762816	chr22:29206209	T/C	cg15103426	chr22:29168792	CCDC117	0.66	6.91	0.31	1.59e-11	Lymphocyte counts;
LGG	cis	rs35160687	0.798	rs11127029	chr2:86554625	C/G	cg10973622	chr2:86423274	IMMT	-0.4	-7.26	-0.32	1.64e-12	Night sleep phenotypes;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg13770153	chr20:60521292	NA	-0.5	-8.16	-0.35	3.2e-15	Body mass index;
LGG	trans	rs6787172	0.622	rs9850856	chr3:158129855	T/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs4077515	0.540	rs4487900	chr9:139303301	A/G	cg21253087	chr9:139290292	SNAPC4	0.34	6.69	0.3	6.35e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9486715	1.000	rs6899647	chr6:97065661	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-14.33	-0.55	8.12e-39	Headache;
LGG	cis	rs9322193	0.923	rs9766886	chr6:149958184	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.0	0.31	8.84e-12	Lung cancer;
LGG	cis	rs9472414	0.680	rs1418435	chr6:44710880	A/C	cg20913747	chr6:44695427	NA	0.47	7.24	0.32	1.93e-12	Height;
LGG	cis	rs7681440	0.904	rs10004413	chr4:90769479	T/C	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs1298908	0.639	rs2994388	chr10:82034262	A/G	cg01528321	chr10:82214614	TSPAN14	-0.45	-7.61	-0.33	1.55e-13	Diabetic kidney disease;
LGG	cis	rs8180040	1.000	rs8180040	chr3:47388947	A/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.77	-0.59	3.73e-45	Colorectal cancer;
LGG	cis	rs4950322	0.518	rs55697094	chr1:146592787	T/C	cg22381352	chr1:146742008	CHD1L	-0.44	-7.4	-0.33	6.34e-13	Protein quantitative trait loci;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg03188948	chr7:1209495	NA	0.63	8.4	0.36	5.51e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg01879757	chr17:41196368	BRCA1	-0.46	-9.17	-0.39	1.5e-18	Menopause (age at onset);
LGG	cis	rs4650994	0.507	rs2811312	chr1:178617603	A/G	cg12486710	chr1:178512616	C1orf220	-0.48	-9.95	-0.42	2.98e-21	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs916888	0.531	rs183211	chr17:44788310	G/A	cg22433210	chr17:43662623	NA	0.63	10.84	0.45	1.52e-24	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2075371	0.932	rs2544215	chr7:133987896	T/C	cg20476274	chr7:133979776	SLC35B4	0.78	15.58	0.59	2.64e-44	Mean platelet volume;
LGG	cis	rs17376456	1.000	rs58734583	chr5:93532155	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.05	0.39	4.08e-18	Diabetic retinopathy;
LGG	cis	rs35740288	0.752	rs11636138	chr15:86287547	T/A	cg07943548	chr15:86304357	KLHL25	-0.35	-6.88	-0.3	1.89e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06481639	chr22:41940642	POLR3H	-0.65	-9.18	-0.39	1.43e-18	Vitiligo;
LGG	cis	rs1109114	0.844	rs2895838	chr5:148628555	C/T	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.36	-0.47	1.51e-26	Body mass index;
LGG	cis	rs3808502	0.563	rs12541800	chr8:11423072	A/G	cg00405596	chr8:11794950	NA	0.43	7.25	0.32	1.73e-12	Neuroticism;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg00586367	chr8:74790437	UBE2W	0.43	6.77	0.3	3.87e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg05313129	chr8:58192883	C8orf71	-0.64	-8.63	-0.37	1.02e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.628	rs7831346	chr8:11193530	C/T	cg02002194	chr4:3960332	NA	-0.39	-6.87	-0.3	2.1e-11	Retinal vascular caliber;
LGG	cis	rs7618501	0.573	rs2624824	chr3:50088266	T/C	cg18129748	chr3:49941408	MST1R	-0.22	-6.85	-0.3	2.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg07791516	chr6:150247246	NA	0.33	7.28	0.32	1.48e-12	Testicular germ cell tumor;
LGG	cis	rs516946	1.000	rs28591316	chr8:41524425	A/G	cg01678292	chr8:41522873	ANK1	0.35	8.21	0.36	2.19e-15	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs8180040	0.726	rs6785790	chr3:47146932	C/T	cg27129171	chr3:47204927	SETD2	0.83	15.98	0.6	4.27e-46	Colorectal cancer;
LGG	trans	rs9354308	0.764	rs9294659	chr6:66579131	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.09	-0.31	5.16e-12	Metabolite levels;
LGG	cis	rs7937682	1.000	rs10502147	chr11:111569931	G/A	cg22437258	chr11:111473054	SIK2	-0.58	-9.68	-0.41	2.62e-20	Primary sclerosing cholangitis;
LGG	cis	rs9790314	0.613	rs4679666	chr3:160629025	C/G	cg03342759	chr3:160939853	NMD3	0.44	7.33	0.32	1.01e-12	Morning vs. evening chronotype;
LGG	cis	rs9325144	0.510	rs6582599	chr12:38715965	T/G	cg04568710	chr12:38710424	ALG10B	0.39	8.27	0.36	1.42e-15	Morning vs. evening chronotype;
LGG	cis	rs2862064	0.685	rs2862066	chr5:156447395	T/G	cg12943317	chr5:156479607	HAVCR1	-0.79	-10.49	-0.44	3.07e-23	Platelet count;
LGG	cis	rs1978968	1.000	rs5992919	chr22:18443855	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2180341	0.961	rs910720	chr6:127619070	T/C	cg24812749	chr6:127587940	RNF146	0.96	15.74	0.59	4.98e-45	Breast cancer;
LGG	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg21053147	chr12:120880522	NA	-0.53	-7.83	-0.34	3.45e-14	Type 1 diabetes nephropathy;
LGG	cis	rs2816316	0.945	rs1359062	chr1:192541472	C/G	cg10861751	chr1:192544716	RGS1	0.33	6.88	0.3	1.93e-11	Celiac disease;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg01017349	chr2:3648229	COLEC11	0.37	6.84	0.3	2.48e-11	Pancreatic cancer;
LGG	cis	rs909674	0.818	rs5757680	chr22:39844793	C/T	cg11247378	chr22:39784982	NA	0.3	8.21	0.36	2.25e-15	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs7805747	0.961	rs10254101	chr7:151415536	C/T	cg17611936	chr7:151411526	PRKAG2	0.48	7.0	0.31	8.83e-12	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.850	rs12597299	chr16:89822364	C/A	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs3858526	0.883	rs10769320	chr11:5932831	G/C	cg02574844	chr11:5959923	NA	-0.54	-8.55	-0.37	1.77e-16	DNA methylation (variation);
LGG	cis	rs8064024	0.680	rs8056320	chr16:4918017	T/C	cg04440724	chr16:4920505	UBN1	-0.57	-12.78	-0.51	2.99e-32	Cancer;
LGG	cis	rs6952808	0.630	rs10239050	chr7:2158390	A/G	cg02951883	chr7:2050386	MAD1L1	-0.73	-15.4	-0.58	1.74e-43	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.565	rs8055825	chr16:89832848	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	0.4	6.82	0.3	2.93e-11	Vitiligo;
LGG	cis	rs637571	0.522	rs503524	chr11:65751764	C/T	cg26695010	chr11:65641043	EFEMP2	-0.52	-8.79	-0.38	2.95e-17	Eosinophil percentage of white cells;
LGG	cis	rs9303401	0.659	rs12150536	chr17:56640834	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.7	0.56	2.01e-40	Cognitive test performance;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg13206674	chr6:150067644	NUP43	0.68	15.37	0.58	2.33e-43	Lung cancer;
LGG	cis	rs35264875	0.851	rs72930631	chr11:68867835	T/C	cg01403660	chr11:68851641	TPCN2	0.43	6.69	0.3	6.4e-11	Blond vs. brown hair color;
LGG	cis	rs1577917	0.687	rs1470531	chr6:86507369	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.68	-11.91	-0.48	1.04e-28	Response to antipsychotic treatment;
LGG	cis	rs6750795	0.746	rs2916579	chr2:232421159	A/G	cg19187155	chr2:232395269	NMUR1	0.6	11.21	0.46	5.61e-26	Height;
LGG	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.38	-0.43	7.79e-23	Subjective well-being;
LGG	cis	rs2730245	0.851	rs2657333	chr7:158728743	G/A	cg18245976	chr7:158708271	WDR60	0.45	7.67	0.34	1.06e-13	Height;
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.74	-0.38	4.39e-17	Personality dimensions;
LGG	cis	rs888194	0.738	rs1045255	chr12:109973979	G/C	cg19025524	chr12:109796872	NA	-0.36	-7.15	-0.32	3.31e-12	Neuroticism;
LGG	trans	rs208520	0.690	rs7764570	chr6:66827600	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.89	-16.61	-0.61	5.86e-49	Exhaled nitric oxide output;
LGG	trans	rs453301	0.624	rs2288673	chr8:8860276	G/T	cg27411982	chr8:10470053	RP1L1	0.46	8.08	0.35	5.79e-15	Joint mobility (Beighton score);
LGG	cis	rs2273669	0.915	rs6904998	chr6:109311560	G/T	cg05315195	chr6:109294784	ARMC2	0.47	6.73	0.3	5.15e-11	Prostate cancer;
LGG	cis	rs7107174	1.000	rs10899470	chr11:78020052	C/T	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs8114671	0.562	rs6088647	chr20:33505997	T/C	cg24642439	chr20:33292090	TP53INP2	0.45	7.02	0.31	8.09e-12	Height;
LGG	cis	rs209489	0.892	rs16883632	chr6:53112991	C/T	cg15607103	chr6:53167650	ELOVL5	-0.57	-7.04	-0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs9291683	0.588	rs4697705	chr4:10108127	G/A	cg26043149	chr18:55253948	FECH	-0.49	-8.27	-0.36	1.46e-15	Bone mineral density;
LGG	cis	rs4740619	0.647	rs2891007	chr9:15826335	T/A	cg14451791	chr9:16040625	NA	-0.36	-9.34	-0.4	3.97e-19	Body mass index;
LGG	trans	rs1814175	0.669	rs12416837	chr11:49669761	G/T	cg15704280	chr7:45808275	SEPT13	-0.84	-16.5	-0.61	2.02e-48	Height;
LGG	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg15017067	chr4:17643749	FAM184B	0.31	7.17	0.32	3.02e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7618915	0.501	rs3774366	chr3:52641255	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.34	0.4	4.17e-19	Bipolar disorder;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg12432903	chr7:1882776	MAD1L1	0.44	6.78	0.3	3.75e-11	Neuroticism;
LGG	cis	rs2645694	0.626	rs2703120	chr4:77822470	G/A	cg03477792	chr4:77819574	ANKRD56	0.52	9.14	0.39	1.97e-18	Emphysema distribution in smoking;
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.17	0.32	2.93e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg13047869	chr3:10149882	C3orf24	0.53	8.67	0.37	7.23e-17	Alzheimer's disease;
LGG	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg04455712	chr21:45112962	RRP1B	-0.55	-10.49	-0.44	2.93e-23	Mean corpuscular volume;
LGG	cis	rs7044106	0.791	rs3904196	chr9:123480369	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.56	0.5	2.4e-31	Hip circumference adjusted for BMI;
LGG	cis	rs13108904	0.901	rs12509700	chr4:1296321	A/G	cg02018176	chr4:1364513	KIAA1530	0.45	10.34	0.43	1.1e-22	Obesity-related traits;
LGG	cis	rs6502050	0.805	rs4789720	chr17:80157490	G/C	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.86e-16	Life satisfaction;
LGG	cis	rs34783982	0.510	rs34275450	chr15:89529489	C/T	cg09489435	chr15:89561491	NA	-0.38	-7.23	-0.32	2.08e-12	Squamous cell lung carcinoma;
LGG	cis	rs17001868	0.568	rs9607699	chr22:40737036	G/A	cg07138101	chr22:40742427	ADSL	0.67	8.66	0.37	8.21e-17	Mammographic density (dense area);
LGG	cis	rs61931739	0.517	rs1586409	chr12:34046614	C/A	cg06521331	chr12:34319734	NA	-0.63	-11.91	-0.48	1.04e-28	Morning vs. evening chronotype;
LGG	cis	rs754466	1.000	rs67059283	chr10:79683235	C/T	cg17075019	chr10:79541650	NA	-0.81	-13.85	-0.54	1e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs1451375	1.000	rs10250513	chr7:50621488	T/G	cg20336341	chr7:50628841	DDC	0.37	7.18	0.32	2.8e-12	Malaria;
LGG	cis	rs6089584	0.507	rs6061989	chr20:60627893	C/T	cg13770153	chr20:60521292	NA	-0.49	-8.12	-0.35	4.36e-15	Body mass index;
LGG	cis	rs7824557	0.628	rs11782706	chr8:11186215	A/C	cg15596359	chr8:11213517	TDH	-0.4	-8.06	-0.35	6.35e-15	Retinal vascular caliber;
LGG	cis	rs11098499	0.954	rs10006706	chr4:120409152	A/G	cg24375607	chr4:120327624	NA	0.67	10.9	0.45	9.02e-25	Corneal astigmatism;
LGG	trans	rs11650494	0.803	rs117801358	chr17:47447950	C/A	cg11430096	chr6:110968061	CDK19	0.68	7.05	0.31	6.7e-12	Prostate cancer;
LGG	cis	rs35110281	0.591	rs86138	chr21:44932398	G/A	cg04455712	chr21:45112962	RRP1B	0.47	8.67	0.37	7.56e-17	Mean corpuscular volume;
LGG	cis	rs35110281	0.626	rs162368	chr21:44934767	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.85	0.38	1.9e-17	Mean corpuscular volume;
LGG	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.04	-0.31	7.07e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs1267303	1.000	rs1267303	chr1:46990457	A/G	cg25110126	chr1:46999211	NA	0.48	7.7	0.34	8.31e-14	Monobrow;
LGG	cis	rs873946	0.564	rs12772704	chr10:134557318	G/A	cg13271783	chr10:134563150	INPP5A	-0.54	-7.87	-0.34	2.56e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10504229	0.683	rs2005392	chr8:58106896	T/C	cg22535103	chr8:58192502	C8orf71	-0.92	-12.6	-0.51	1.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.598	rs1010554	chr3:52542919	T/C	cg14092988	chr3:52407081	DNAH1	-0.26	-6.94	-0.31	1.35e-11	Electroencephalogram traits;
LGG	cis	rs34172651	0.517	rs3803716	chr16:24802325	C/T	cg06028605	chr16:24865363	SLC5A11	0.48	7.85	0.34	2.92e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	0.963	rs6429581	chr1:46319096	G/A	cg03146154	chr1:46216737	IPP	0.54	10.29	0.43	1.65e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6504108	0.624	rs7225550	chr17:46225243	T/C	cg02219949	chr17:45927392	SP6	0.44	8.3	0.36	1.18e-15	Body mass index;
LGG	cis	rs3784262	1.000	rs12915901	chr15:58279432	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.37	-8.11	-0.35	4.56e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs28595532	0.920	rs116205107	chr4:119730910	G/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs2346177	0.844	rs34712412	chr2:46652428	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.44	7.72	0.34	7.31e-14	HDL cholesterol;
LGG	cis	rs9399135	0.967	rs7773126	chr6:135318390	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs3785574	0.962	rs4968660	chr17:61792221	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.83	0.79	6.62e-101	Height;
LGG	cis	rs708547	0.915	rs28605409	chr4:57766261	A/G	cg16868167	chr4:57843880	C4orf14;POLR2B	0.57	8.56	0.37	1.64e-16	Response to bleomycin (chromatid breaks);
LGG	cis	rs9322193	0.887	rs11155662	chr6:149913867	T/G	cg09699651	chr6:150184138	LRP11	0.53	9.05	0.39	3.99e-18	Lung cancer;
LGG	cis	rs7742824	0.917	rs6922473	chr6:44098287	G/A	cg04074908	chr6:44101190	TMEM63B	0.65	13.87	0.54	7.85e-37	Major depressive disorder;
LGG	cis	rs6952808	0.723	rs11765550	chr7:2027324	G/A	cg00106254	chr7:1943704	MAD1L1	-0.5	-8.88	-0.38	1.44e-17	Bipolar disorder and schizophrenia;
LGG	trans	rs747782	0.527	rs75915859	chr11:48232931	C/T	cg15704280	chr7:45808275	SEPT13	0.72	7.82	0.34	3.64e-14	Intraocular pressure;
LGG	cis	rs6089584	0.888	rs6061979	chr20:60617141	C/G	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs4700695	0.764	rs36299	chr5:65348120	G/T	cg21114390	chr5:65439923	SFRS12	0.58	7.04	0.31	7.18e-12	Facial morphology (factor 19);
LGG	cis	rs4481887	1.000	rs4360555	chr1:248468591	G/T	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	1.03e-20	Common traits (Other);
LGG	cis	rs6502050	0.799	rs7502533	chr17:80109778	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs1008375	1.000	rs2109522	chr4:17658645	T/A	cg16339924	chr4:17578868	LAP3	0.59	10.33	0.43	1.18e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2658782	0.789	rs3019206	chr11:93111073	A/G	cg15737290	chr11:93063684	CCDC67	0.51	7.72	0.34	7.19e-14	Pulmonary function decline;
LGG	cis	rs2153535	0.580	rs1119689	chr6:8460754	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.75e-31	Motion sickness;
LGG	cis	rs9905704	0.624	rs34718875	chr17:57072461	G/A	cg12560992	chr17:57184187	TRIM37	0.51	8.32	0.36	9.94e-16	Testicular germ cell tumor;
LGG	cis	rs9467711	0.659	rs34246779	chr6:26549212	G/A	cg12826209	chr6:26865740	GUSBL1	0.79	7.53	0.33	2.76e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3126085	0.935	rs10888470	chr1:152200472	T/C	cg26876637	chr1:152193138	HRNR	0.56	9.04	0.39	4.41e-18	Atopic dermatitis;
LGG	cis	rs11748327	0.959	rs17662489	chr5:4068808	A/G	cg01025095	chr5:4101132	NA	0.58	9.44	0.4	1.9e-19	Myocardial infarction;
LGG	cis	rs673604	1.000	rs7543044	chr1:35674311	A/G	cg12633102	chr1:35676489	NA	-0.51	-9.7	-0.41	2.21e-20	Endometrial cancer;
LGG	trans	rs2760061	0.655	rs686533	chr1:228119604	A/G	cg16006296	chr10:38738647	LOC399744	0.35	6.78	0.3	3.67e-11	Diastolic blood pressure;
LGG	cis	rs7819412	0.745	rs2898260	chr8:10939490	G/T	cg21775007	chr8:11205619	TDH	-0.5	-8.04	-0.35	7.52e-15	Triglycerides;
LGG	cis	rs35110281	0.811	rs7275705	chr21:45056453	G/C	cg04455712	chr21:45112962	RRP1B	0.51	9.6	0.41	5.25e-20	Mean corpuscular volume;
LGG	trans	rs10435719	0.678	rs74724594	chr8:11790576	C/A	cg13009111	chr11:71350975	NA	0.35	7.64	0.33	1.25e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs193541	0.632	rs2407402	chr5:122107105	G/C	cg19412675	chr5:122181750	SNX24	0.53	8.48	0.37	3.1e-16	Glucose homeostasis traits;
LGG	cis	rs12291225	0.639	rs61883858	chr11:14294708	C/T	cg02886208	chr11:14281011	SPON1	-0.36	-6.86	-0.3	2.15e-11	Sense of smell;
LGG	cis	rs2692947	0.666	rs10183151	chr2:96774786	T/G	cg22654517	chr2:96458247	NA	-0.36	-7.48	-0.33	3.79e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs10504229	1.000	rs73607875	chr8:58173522	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10752881	0.875	rs10752894	chr1:183050610	A/G	cg07928641	chr1:182991847	LAMC1	0.48	9.85	0.42	6.81e-21	Colorectal cancer;
LGG	cis	rs7590368	1.000	rs72779469	chr2:10963764	C/G	cg15705551	chr2:10952987	PDIA6	0.61	9.08	0.39	3.09e-18	Educational attainment (years of education);
LGG	cis	rs367943	0.626	rs7718480	chr5:112704486	G/T	cg12552261	chr5:112820674	MCC	0.56	10.1	0.43	7.98e-22	Type 2 diabetes;
LGG	trans	rs10877945	0.522	rs7297754	chr12:63443521	T/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-0.41	-7.74	-0.34	6.43e-14	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15564865	chr6:4021423	PRPF4B	0.46	7.52	0.33	2.78e-13	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.672	rs10110443	chr8:22484296	C/G	cg19455335	chr8:22457658	C8orf58	-0.39	-8.0	-0.35	9.72e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs875971	0.862	rs12698526	chr7:65969105	T/C	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.39e-12	Aortic root size;
LGG	cis	rs9467711	0.591	rs35528636	chr6:25995701	A/C	cg21479132	chr6:26055353	NA	0.82	7.98	0.35	1.17e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9815354	0.812	rs73071304	chr3:41797504	G/C	cg03022575	chr3:42003672	ULK4	0.78	9.0	0.39	6.04e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2153535	0.580	rs1319169	chr6:8464456	G/A	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs8067545	0.586	rs2526478	chr17:20130452	A/G	cg09818912	chr17:20140352	CYTSB	-0.31	-7.34	-0.32	9.41e-13	Schizophrenia;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg08677398	chr8:58056175	NA	0.58	8.85	0.38	1.86e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9583531	0.689	rs9588247	chr13:111375571	G/T	cg24331049	chr13:111365604	ING1	-0.81	-14.25	-0.55	1.85e-38	Coronary artery disease;
LGG	cis	rs7223966	1.000	rs9903897	chr17:61716705	T/A	cg11494091	chr17:61959527	GH2	0.55	9.05	0.39	3.89e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1008375	0.966	rs6839660	chr4:17667987	C/T	cg02297831	chr4:17616191	MED28	0.49	9.22	0.39	1.03e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4820539	1.000	rs885963	chr22:23460939	G/T	cg14186256	chr22:23484241	RTDR1	1.0	25.57	0.77	1.43e-90	Bone mineral density;
LGG	cis	rs916888	0.531	rs183211	chr17:44788310	G/A	cg01570182	chr17:44337453	NA	0.51	9.19	0.39	1.37e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7166081	1.000	rs34699563	chr15:67514217	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.09	-0.31	5.08e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	0.825	rs13182631	chr5:93115701	A/G	cg25358565	chr5:93447407	FAM172A	1.26	15.38	0.58	2.02e-43	Diabetic retinopathy;
LGG	cis	rs17376456	1.000	rs35184505	chr5:93561535	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.04	0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs13118159	0.872	rs3903127	chr4:1348806	A/C	cg16524936	chr4:1340807	KIAA1530	-0.46	-7.68	-0.34	9.67e-14	Longevity;
LGG	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg06212747	chr3:49208901	KLHDC8B	0.43	7.01	0.31	8.62e-12	Resting heart rate;
LGG	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.67	-0.3	7.1e-11	Neuroticism;
LGG	cis	rs12476592	0.602	rs7576316	chr2:63741122	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.85	-0.3	2.43e-11	Childhood ear infection;
LGG	cis	rs9534288	0.797	rs2104516	chr13:46602123	T/C	cg15192986	chr13:46630673	CPB2	-0.61	-13.31	-0.53	1.78e-34	Blood protein levels;
LGG	cis	rs10504229	0.906	rs6990615	chr8:58182956	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs13108904	0.846	rs4974574	chr4:1224811	A/G	cg02018176	chr4:1364513	KIAA1530	0.33	7.04	0.31	6.9e-12	Obesity-related traits;
LGG	cis	rs4980532	1	rs4980532	chr11:63680719	C/T	cg09182533	chr11:63775071	MACROD1	0.26	7.87	0.34	2.6e-14	Pulse pressure;
LGG	cis	rs6735179	0.958	rs10048704	chr2:1777819	G/C	cg10160682	chr2:1713001	PXDN	-0.45	-7.51	-0.33	3.17e-13	Response to antipsychotic treatment;
LGG	cis	rs17401966	0.538	rs7418410	chr1:10236402	A/G	cg17425144	chr1:10567563	PEX14	0.33	6.7	0.3	5.94e-11	Hepatocellular carcinoma;
LGG	cis	rs9325144	0.555	rs61929925	chr12:38698828	C/A	cg04568710	chr12:38710424	ALG10B	-0.42	-8.9	-0.38	1.31e-17	Morning vs. evening chronotype;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg24250549	chr1:154909240	PMVK	0.71	14.07	0.55	1.08e-37	Prostate cancer;
LGG	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs1023500	0.573	rs133377	chr22:42466950	C/T	cg05082376	chr22:42548792	NA	-0.37	-7.71	-0.34	7.67e-14	Schizophrenia;
LGG	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg24642439	chr20:33292090	TP53INP2	0.57	9.66	0.41	3.05e-20	Coronary artery disease;
LGG	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg24375607	chr4:120327624	NA	-0.56	-9.35	-0.4	3.76e-19	Corneal astigmatism;
LGG	trans	rs4295623	0.553	rs11250163	chr8:11596437	G/T	cg15556689	chr8:8085844	FLJ10661	0.45	8.07	0.35	6.01e-15	Morning vs. evening chronotype;
LGG	cis	rs11250098	0.574	rs7015168	chr8:10772210	G/C	cg21775007	chr8:11205619	TDH	-0.48	-7.45	-0.33	4.66e-13	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.23e-36	Bladder cancer;
LGG	cis	rs17776563	0.887	rs72763812	chr15:89135461	G/A	cg05013243	chr15:89149849	MIR1179	-0.5	-10.28	-0.43	1.88e-22	Thyroid hormone levels;
LGG	cis	rs6032067	0.516	rs57047308	chr20:43899974	T/C	cg10761708	chr20:43804764	PI3	0.46	7.35	0.32	8.92e-13	Blood protein levels;
LGG	cis	rs62238980	0.614	rs79781828	chr22:32413050	C/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs2798269	0.668	rs1199938	chr13:22068225	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.49	-8.9	-0.38	1.25e-17	PR segment;
LGG	cis	rs910187	0.571	rs3827049	chr20:45801319	T/A	cg27589058	chr20:45804311	EYA2	-0.38	-10.08	-0.42	9.96e-22	Migraine;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15877295	chr7:138915876	UBN2	0.53	8.58	0.37	1.4e-16	Gut microbiome composition (summer);
LGG	cis	rs10937275	1.000	rs10937275	chr3:186650790	A/G	cg24050613	chr3:186648279	ST6GAL1	-0.85	-8.77	-0.38	3.36e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1816752	0.905	rs4769348	chr13:24975113	G/A	cg22771759	chr13:24902376	NA	0.42	6.84	0.3	2.49e-11	Obesity-related traits;
LGG	cis	rs561341	0.941	rs4795664	chr17:30233467	C/T	cg00745463	chr17:30367425	LRRC37B	-0.55	-7.53	-0.33	2.75e-13	Hip circumference adjusted for BMI;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14871712	chr9:102861491	INVS;ERP44	0.4	6.72	0.3	5.52e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs8058578	1.000	rs6565201	chr16:30747191	C/T	cg00531865	chr16:30841666	NA	-0.55	-11.36	-0.47	1.47e-26	Multiple myeloma;
LGG	cis	rs826838	1.000	rs11609286	chr12:38875511	A/G	cg13010199	chr12:38710504	ALG10B	-0.76	-16.1	-0.6	1.29e-46	Heart rate;
LGG	cis	rs908922	0.573	rs7544564	chr1:152527007	A/C	cg20991723	chr1:152506922	NA	-0.7	-14.42	-0.56	3.2e-39	Hair morphology;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20025072	chr10:126480608	METTL10	0.39	6.73	0.3	5.14e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7726839	0.540	rs74553517	chr5:665671	C/T	cg14541582	chr5:601475	NA	-0.72	-10.98	-0.45	4.23e-25	Obesity-related traits;
LGG	cis	rs1801251	1.000	rs13008942	chr2:233594875	G/A	cg25237894	chr2:233734115	C2orf82	0.66	12.7	0.51	6.62e-32	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs113575110	chr7:1084394	G/A	cg22907277	chr7:1156413	C7orf50	0.69	8.93	0.38	1.03e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19524238	chr7:2802976	GNA12	0.4	9.05	0.39	3.91e-18	Height;
LGG	cis	rs7917772	0.503	rs56219824	chr10:104302337	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.74	14.33	0.55	8.13e-39	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs9926296	0.585	rs4785595	chr16:89835521	C/T	cg07440826	chr16:89882328	FANCA	0.27	7.14	0.31	3.63e-12	Vitiligo;
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02475777	chr4:1388615	CRIPAK	0.59	10.7	0.45	4.99e-24	Longevity;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.24	0.46	4.45e-26	Bipolar disorder;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19410845	chr2:84686791	SUCLG1	0.44	7.2	0.32	2.49e-12	Cognitive performance;
LGG	cis	rs4075765	0.764	rs72872794	chr11:26275280	G/A	cg19182008	chr11:26298241	NA	1.0	8.97	0.38	7.49e-18	Cannabis dependence symptom count;
LGG	cis	rs5769765	0.865	rs10854860	chr22:50320029	G/T	cg02269571	chr22:50332266	NA	-0.65	-9.73	-0.41	1.76e-20	Schizophrenia;
LGG	cis	rs2117029	0.586	rs10783307	chr12:49529605	A/T	cg24176009	chr12:49580217	TUBA1A	0.66	12.83	0.51	1.88e-32	Intelligence (multi-trait analysis);
LGG	cis	rs504918	1.000	rs666144	chr3:124101536	C/T	cg05766129	chr3:123988013	KALRN	0.38	7.02	0.31	8.18e-12	Schizophrenia;
LGG	cis	rs74417235	0.517	rs13179034	chr5:154059487	C/A	cg08754654	chr5:154026448	NA	0.53	10.83	0.45	1.56e-24	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs3820928	0.874	rs4675137	chr2:227883910	G/C	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.66	-0.34	1.06e-13	Pulmonary function;
LGG	cis	rs4925386	1.000	rs6089351	chr20:60916153	G/A	cg24112000	chr20:60950667	NA	0.34	7.79	0.34	4.49e-14	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7666738	0.830	rs10001479	chr4:98918764	A/G	cg05340658	chr4:99064831	C4orf37	-0.45	-7.45	-0.33	4.76e-13	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9329221	0.736	rs2001338	chr8:10251217	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.43	0.33	5.31e-13	Neuroticism;
LGG	cis	rs76419734	0.510	rs2216515	chr4:106750214	C/T	cg24545054	chr4:106630052	GSTCD;INTS12	-0.56	-7.86	-0.34	2.72e-14	Post bronchodilator FEV1;
LGG	cis	rs1023500	0.505	rs134887	chr22:42674239	A/G	cg04733989	chr22:42467013	NAGA	0.51	8.87	0.38	1.6e-17	Schizophrenia;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg15704358	chr7:150210980	GIMAP7	0.34	6.88	0.3	1.95e-11	Menarche (age at onset);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12501923	chr17:73937416	FBF1	-0.47	-6.92	-0.31	1.47e-11	Systemic lupus erythematosus;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg26174226	chr8:58114915	NA	-0.52	-7.24	-0.32	1.85e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.592	rs5758427	chr22:42099688	A/G	cg06634786	chr22:41940651	POLR3H	0.75	11.89	0.48	1.28e-28	Vitiligo;
LGG	cis	rs77216612	0.877	rs7956514	chr12:12879254	T/G	cg04607235	chr12:12878440	APOLD1	-1.01	-20.44	-0.69	1.14e-66	Lymphocyte counts;
LGG	cis	rs11098499	0.604	rs10022185	chr4:120571765	C/G	cg24375607	chr4:120327624	NA	0.64	10.47	0.44	3.78e-23	Corneal astigmatism;
LGG	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg01200585	chr1:228362443	C1orf69	-0.44	-7.76	-0.34	5.46e-14	Diastolic blood pressure;
LGG	cis	rs963731	0.649	rs7568552	chr2:39257667	T/C	cg04010122	chr2:39346883	SOS1	-0.91	-7.56	-0.33	2.19e-13	Corticobasal degeneration;
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg21970626	chr13:21893289	NA	-0.41	-6.86	-0.3	2.22e-11	White matter hyperintensity burden;
LGG	trans	rs6952808	0.858	rs12671113	chr7:1965255	G/A	cg24247370	chr13:99142703	STK24	-0.39	-7.13	-0.31	3.76e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs881375	0.678	rs1014530	chr9:123685092	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.98	0.42	2.16e-21	Rheumatoid arthritis;
LGG	cis	rs9467773	1.000	rs6933176	chr6:26540178	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.34	0.4	3.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg22878388	chr2:105853796	NA	-0.49	-9.04	-0.39	4.33e-18	Type 2 diabetes;
LGG	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg21775007	chr8:11205619	TDH	0.43	6.67	0.3	7.18e-11	Myopia (pathological);
LGG	cis	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11785400	1.000	rs11780221	chr8:143748215	T/A	cg24634471	chr8:143751801	JRK	0.53	8.42	0.36	4.63e-16	Schizophrenia;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.34	-7.32	-0.32	1.14e-12	Schizophrenia;
LGG	cis	rs2635047	1.000	rs2684818	chr18:44712965	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.52	9.08	0.39	3.23e-18	Educational attainment;
LGG	trans	rs7819412	0.635	rs4841501	chr8:11000976	T/C	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.03	-0.31	7.53e-12	Triglycerides;
LGG	cis	rs10870270	0.956	rs7915388	chr10:133734972	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.65	-12.84	-0.51	1.72e-32	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs765787	0.530	rs28526629	chr15:45540462	C/T	cg25801113	chr15:45476975	SHF	0.88	20.25	0.69	9.31e-66	Uric acid levels;
LGG	trans	rs6089829	0.962	rs6011548	chr20:61666063	C/T	cg23505145	chr19:12996616	KLF1	0.41	7.34	0.32	9.54e-13	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg22963979	chr7:1858916	MAD1L1	-0.56	-11.14	-0.46	1.04e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs5742933	0.744	rs13009889	chr2:190628568	G/A	cg04003228	chr2:190539410	ANKAR	-0.52	-7.49	-0.33	3.4e-13	Ferritin levels;
LGG	cis	rs2404602	0.583	rs12907668	chr15:76589767	A/T	cg23625390	chr15:77176239	SCAPER	0.41	7.69	0.34	8.71e-14	Blood metabolite levels;
LGG	cis	rs2898279	0.614	rs7007712	chr8:11290802	C/T	cg26274995	chr8:11302983	FAM167A	-0.46	-8.72	-0.38	4.85e-17	Small cell lung carcinoma;
LGG	cis	rs61990749	0.597	rs1008988	chr14:78260795	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.59	7.19	0.32	2.56e-12	Fibroblast growth factor basic levels;
LGG	trans	rs7824557	0.527	rs11785394	chr8:11238029	C/T	cg02002194	chr4:3960332	NA	0.42	7.47	0.33	3.99e-13	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs12951869	chr17:41187567	T/G	cg12708336	chr17:41446283	NA	-0.31	-7.22	-0.32	2.16e-12	Menopause (age at onset);
LGG	trans	rs9650657	0.707	rs7814757	chr8:10675188	T/C	cg06636001	chr8:8085503	FLJ10661	-0.4	-7.22	-0.32	2.14e-12	Neuroticism;
LGG	cis	rs283228	1.000	rs1933355	chr6:101821928	G/A	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs9534288	0.913	rs9534298	chr13:46625566	C/G	cg15192986	chr13:46630673	CPB2	-0.73	-16.03	-0.6	2.65e-46	Blood protein levels;
LGG	cis	rs876084	0.505	rs12546625	chr8:121155225	C/T	cg06265175	chr8:121136014	COL14A1	0.45	9.04	0.39	4.28e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06470251	chr20:60548479	NA	0.47	8.32	0.36	1.03e-15	Body mass index;
LGG	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg08994789	chr17:28903642	LRRC37B2	-0.58	-7.39	-0.32	7.02e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7084402	0.902	rs1658417	chr10:60333039	T/C	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.51e-12	Refractive error;
LGG	cis	rs17373728	1.000	rs17373728	chr8:76225516	C/T	cg07016329	chr8:76221503	NA	0.51	8.7	0.37	5.99e-17	Diabetic kidney disease;
LGG	cis	rs992157	0.798	rs12053514	chr2:219167965	C/T	cg00012203	chr2:219082015	ARPC2	-0.67	-11.88	-0.48	1.36e-28	Colorectal cancer;
LGG	cis	rs657075	0.697	rs13185655	chr5:131706747	C/G	cg06968155	chr5:131705112	SLC22A5	0.73	8.5	0.37	2.71e-16	Rheumatoid arthritis;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg03528353	chr17:61819722	STRADA	0.43	7.3	0.32	1.3e-12	Prudent dietary pattern;
LGG	cis	rs3749237	0.555	rs7637665	chr3:49552295	T/C	cg06212747	chr3:49208901	KLHDC8B	0.43	7.02	0.31	7.89e-12	Resting heart rate;
LGG	cis	rs1843834	0.539	rs2068244	chr2:225440011	A/G	cg12698349	chr2:225449008	CUL3	-0.69	-11.44	-0.47	7.3e-27	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs1577917	0.958	rs34795473	chr6:86461799	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.13	-0.39	2.21e-18	Response to antipsychotic treatment;
LGG	cis	rs796364	0.950	rs56155997	chr2:200768491	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.03	-0.35	8.39e-15	Schizophrenia;
LGG	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	10.1	0.42	8.5e-22	Height;
LGG	cis	rs9831754	0.704	rs6774325	chr3:78458727	G/A	cg06138941	chr3:78371609	NA	-0.8	-15.67	-0.59	1.09e-44	Calcium levels;
LGG	cis	rs561341	0.714	rs75861674	chr17:30304317	A/G	cg13647721	chr17:30228624	UTP6	0.61	7.85	0.34	2.83e-14	Hip circumference adjusted for BMI;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-10.82	-0.45	1.72e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs6500602	0.702	rs11645519	chr16:4538989	G/A	cg08645402	chr16:4508243	NA	0.51	9.69	0.41	2.44e-20	Schizophrenia;
LGG	cis	rs858239	0.601	rs7805206	chr7:23160210	C/T	cg23682824	chr7:23144976	KLHL7	0.39	6.94	0.31	1.3e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2074585	0.679	rs2601195	chr15:90938232	G/A	cg22089800	chr15:90895588	ZNF774	0.69	12.7	0.51	6.53e-32	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs8177253	0.965	rs3811658	chr3:133476852	C/T	cg16414030	chr3:133502952	NA	-0.59	-10.1	-0.42	8.13e-22	Iron status biomarkers;
LGG	trans	rs1045529	0.524	rs34251783	chr8:8891376	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.67	-0.34	1.03e-13	Myopia;Myopia (pathological);
LGG	cis	rs801193	1.000	rs4717319	chr7:66242593	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	cis	rs780096	0.546	rs4425043	chr2:27733452	G/A	cg05484376	chr2:27715224	FNDC4	0.46	9.99	0.42	2.07e-21	Total body bone mineral density;
LGG	cis	rs4474465	0.790	rs10751293	chr11:78250956	A/T	cg02023728	chr11:77925099	USP35	-0.39	-6.82	-0.3	2.78e-11	Alzheimer's disease (survival time);
LGG	trans	rs116095464	0.558	rs6872854	chr5:209038	G/T	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.69	9.19	0.39	1.32e-18	Diabetic retinopathy;
LGG	cis	rs4950322	0.570	rs72691032	chr1:146732774	G/A	cg22381352	chr1:146742008	CHD1L	-0.52	-8.53	-0.37	2.17e-16	Protein quantitative trait loci;
LGG	cis	rs10504229	0.906	rs7003285	chr8:58173108	A/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2635047	0.710	rs36095873	chr18:44603199	T/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.48	8.33	0.36	9.27e-16	Educational attainment;
LGG	cis	rs12893668	0.703	rs7140568	chr14:104041374	C/T	cg26031613	chr14:104095156	KLC1	-0.6	-9.63	-0.41	3.88e-20	Reticulocyte count;
LGG	cis	rs9858213	1	rs9858213	chr3:49731861	G/T	cg00383909	chr3:49044727	WDR6	0.45	7.31	0.32	1.2e-12	Educational attainment;
LGG	cis	rs752010	0.875	rs11210501	chr1:42091634	T/C	cg16096631	chr1:42092165	HIVEP3	0.76	21.35	0.7	6.48e-71	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs6694672	1.000	rs10922169	chr1:197101105	T/C	cg13682187	chr1:196946512	CFHR5	0.49	6.89	0.3	1.88e-11	Asthma;
LGG	trans	rs2980439	0.783	rs2955587	chr8:8098079	A/G	cg21775007	chr8:11205619	TDH	0.46	7.48	0.33	3.85e-13	Neuroticism;
LGG	cis	rs9815354	1.000	rs2128835	chr3:41862873	A/G	cg03022575	chr3:42003672	ULK4	0.67	8.52	0.37	2.27e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7917772	0.604	rs7908249	chr10:104373300	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.69	0.48	7.82e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs975739	0.610	rs1360373	chr13:78627703	C/T	cg07847733	chr13:78271382	SLAIN1	0.38	6.67	0.3	7.31e-11	Hair color;
LGG	cis	rs2120019	0.567	rs72625793	chr15:75207083	A/G	cg09165964	chr15:75287851	SCAMP5	-0.86	-12.81	-0.51	2.22e-32	Blood trace element (Zn levels);
LGG	cis	rs240764	0.658	rs6570922	chr6:101177262	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-7.95	-0.35	1.44e-14	Neuroticism;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00689492	chr4:1303491	MAEA	0.52	9.01	0.39	5.33e-18	Obesity-related traits;
LGG	cis	rs875971	0.862	rs10282433	chr7:65721439	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.77	-0.41	1.32e-20	Aortic root size;
LGG	cis	rs7149242	0.857	rs12435171	chr14:101155220	G/A	cg18089426	chr14:101175970	NA	-0.37	-7.35	-0.32	8.83e-13	Platelet count;
LGG	cis	rs7613875	0.580	rs3774745	chr3:50204745	C/T	cg05623727	chr3:50126028	RBM5	-0.35	-7.29	-0.32	1.35e-12	Body mass index;
LGG	cis	rs4555082	0.874	rs78923231	chr14:105754033	C/T	cg06808227	chr14:105710500	BRF1	-0.63	-10.53	-0.44	2.14e-23	Mean platelet volume;Platelet distribution width;
LGG	trans	rs9858542	0.953	rs35115732	chr3:49475155	T/C	cg21659725	chr3:3221576	CRBN	-0.65	-10.6	-0.44	1.19e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2018055	0.618	rs12528785	chr6:117791595	C/T	cg14611402	chr6:117803162	DCBLD1	0.28	8.36	0.36	7.48e-16	Diastolic blood pressure;
LGG	cis	rs11690935	0.885	rs6752812	chr2:172851502	C/A	cg13550731	chr2:172543902	DYNC1I2	-0.96	-21.77	-0.71	7.1e-73	Schizophrenia;
LGG	cis	rs651907	0.557	rs13066768	chr3:101486920	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	-0.65	-13.75	-0.54	2.63e-36	Colorectal cancer;
LGG	cis	rs17270561	0.666	rs3923725	chr6:25734920	C/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.02	0.42	1.55e-21	Iron status biomarkers;
LGG	cis	rs9747201	0.962	rs62079995	chr17:80076624	C/T	cg13939156	chr17:80058883	NA	0.45	8.1	0.35	5.07e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10426930	0.607	rs2613762	chr19:5064948	T/G	cg18473234	chr19:5097819	KDM4B	-0.45	-7.78	-0.34	4.85e-14	Monocyte percentage of white cells;
LGG	cis	rs6582630	0.598	rs10880645	chr12:38556172	G/A	cg13010199	chr12:38710504	ALG10B	-0.55	-10.99	-0.45	3.93e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62238980	0.614	rs74321309	chr22:32483022	C/T	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs1107366	0.722	rs750714	chr3:125904688	G/A	cg01346077	chr3:125931526	NA	0.41	9.9	0.42	4.21e-21	Metabolite levels;
LGG	cis	rs17875496	1.000	rs17875496	chr15:81587757	T/A	cg19620333	chr15:81596332	IL16	0.45	8.49	0.37	2.93e-16	Number of common colds;
LGG	cis	rs4555082	0.915	rs79048296	chr14:105754944	G/A	cg10792982	chr14:105748885	BRF1	0.66	13.19	0.52	5.7e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs7582720	1.000	rs72932737	chr2:203654540	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs1941687	0.563	rs7232237	chr18:31324934	C/T	cg04226714	chr8:49833948	SNAI2	0.48	8.72	0.38	5.17e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs60180747	1.000	rs79065844	chr15:66690111	T/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.61	10.95	0.45	5.71e-25	Testicular germ cell tumor;
LGG	cis	rs2075371	0.933	rs2544191	chr7:133954248	A/G	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs8067102	chr17:61848779	C/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.36e-29	Prudent dietary pattern;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg06118578	chr18:67872897	RTTN	0.46	7.78	0.34	4.84e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs657075	0.697	rs4646305	chr5:131718539	G/A	cg07538946	chr5:131705188	SLC22A5	0.64	7.56	0.33	2.21e-13	Rheumatoid arthritis;
LGG	cis	rs6089584	0.927	rs11697597	chr20:60584748	C/T	cg06108461	chr20:60628389	TAF4	-0.88	-16.38	-0.61	6.54e-48	Body mass index;
LGG	cis	rs61990749	0.597	rs176944	chr14:78176211	G/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.34	-0.32	9.85e-13	Fibroblast growth factor basic levels;
LGG	cis	rs7980799	0.653	rs11052722	chr12:33626530	G/A	cg06521331	chr12:34319734	NA	0.39	6.71	0.3	5.8e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs6089829	0.962	rs7273930	chr20:61666017	G/A	cg08862035	chr2:2617432	NA	0.42	6.88	0.3	1.93e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs897984	0.542	rs11864839	chr16:31095251	G/C	cg02466173	chr16:30829666	NA	-0.41	-7.52	-0.33	2.92e-13	Dementia with Lewy bodies;
LGG	cis	rs1018697	0.966	rs11191396	chr10:104552865	A/G	cg04362960	chr10:104952993	NT5C2	0.49	9.09	0.39	2.88e-18	Colorectal adenoma (advanced);
LGG	cis	rs910873	0.505	rs2378249	chr20:33218090	G/A	cg12302830	chr20:33297742	TP53INP2	-0.45	-7.16	-0.32	3.27e-12	Melanoma;
LGG	cis	rs17270561	0.609	rs1892254	chr6:25750530	T/C	cg17691542	chr6:26056736	HIST1H1C	0.62	10.2	0.43	3.67e-22	Iron status biomarkers;
LGG	cis	rs12421382	0.659	rs2165137	chr11:109381995	G/T	cg27471124	chr11:109292789	C11orf87	0.5	9.82	0.42	8.42e-21	Schizophrenia;
LGG	trans	rs6762477	0.715	rs12631337	chr3:50198537	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.95	-0.35	1.47e-14	Menarche (age at onset);
LGG	cis	rs11148252	0.740	rs9526914	chr13:52976300	G/T	cg00495681	chr13:53174319	NA	0.49	8.81	0.38	2.58e-17	Lewy body disease;
LGG	cis	rs12482904	0.578	rs9981624	chr21:43825722	G/C	cg23042151	chr21:43824109	UBASH3A	-0.53	-10.59	-0.44	1.25e-23	Vitiligo;
LGG	cis	rs10504229	0.815	rs72650879	chr8:58164648	A/G	cg02725872	chr8:58115012	NA	-0.95	-12.99	-0.52	4.09e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg11941060	chr3:133502564	NA	0.5	8.58	0.37	1.41e-16	Iron status biomarkers;
LGG	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg14228332	chr4:119757509	SEC24D	0.97	9.77	0.41	1.24e-20	Cannabis dependence symptom count;
LGG	cis	rs1620921	0.625	rs9355841	chr6:161267335	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.27	-0.32	1.53e-12	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs11098499	0.754	rs12510269	chr4:120241646	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.98	0.45	4.36e-25	Corneal astigmatism;
LGG	cis	rs28374715	0.662	rs72737786	chr15:41500361	G/T	cg18705301	chr15:41695430	NDUFAF1	-1.01	-17.88	-0.64	9.3e-55	Ulcerative colitis;
LGG	cis	rs12310956	0.532	rs11494810	chr12:33952881	C/A	cg06521331	chr12:34319734	NA	-0.6	-11.06	-0.46	2.2e-25	Morning vs. evening chronotype;
LGG	cis	rs4253772	0.550	rs6007779	chr22:46678615	A/C	cg24881330	chr22:46731750	TRMU	0.78	9.5	0.4	1.1e-19	LDL cholesterol;Cholesterol, total;
LGG	cis	rs9911578	1.000	rs12453049	chr17:56611372	C/T	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6489882	0.836	rs2384071	chr12:113367343	A/G	cg25319449	chr12:113376135	OAS3	-0.43	-7.72	-0.34	7.23e-14	Chronic lymphocytic leukemia;
LGG	cis	rs12586317	0.513	rs11156871	chr14:35481196	G/A	cg05294307	chr14:35346193	BAZ1A	-0.55	-7.84	-0.34	3.15e-14	Psoriasis;
LGG	cis	rs6502050	0.765	rs6502074	chr17:80121776	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs657075	0.697	rs3805678	chr5:131675207	G/A	cg20453264	chr5:131705742	SLC22A5	0.65	8.24	0.36	1.81e-15	Rheumatoid arthritis;
LGG	cis	rs9611565	0.592	rs80477	chr22:42001183	C/T	cg06634786	chr22:41940651	POLR3H	0.7	11.19	0.46	7e-26	Vitiligo;
LGG	cis	rs73086581	1.000	rs73088421	chr20:3997871	A/G	cg02187196	chr20:3869020	PANK2	0.8	10.93	0.45	6.98e-25	Response to antidepressants in depression;
LGG	cis	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg12395012	chr8:11607386	GATA4	-0.42	-7.47	-0.33	4.06e-13	Monocyte count;
LGG	cis	rs6500602	0.627	rs841231	chr16:4583147	C/T	cg05091796	chr16:4465799	CORO7	0.79	12.83	0.51	1.89e-32	Schizophrenia;
LGG	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg00204512	chr16:28754710	NA	0.26	7.23	0.32	2.07e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs3784262	0.679	rs11071365	chr15:58334126	G/A	cg12031962	chr15:58353849	ALDH1A2	-0.39	-8.05	-0.35	7.22e-15	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.48	-0.44	3.33e-23	Bipolar disorder;
LGG	cis	rs10504229	0.817	rs55949560	chr8:58167603	T/C	cg23782820	chr8:58130467	NA	0.46	7.37	0.32	7.98e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs8063160	0.808	rs45610233	chr16:90048395	C/T	cg07984980	chr16:89898383	SPIRE2	1.12	9.48	0.4	1.35e-19	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LGG	cis	rs701145	0.878	rs442480	chr3:153992952	T/A	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs7945718	0.967	rs7930077	chr11:12778769	C/T	cg25843174	chr11:12811716	TEAD1	0.38	7.97	0.35	1.28e-14	Educational attainment (years of education);
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg21782813	chr7:2030301	MAD1L1	0.41	9.66	0.41	3.15e-20	Schizophrenia;
LGG	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg27398817	chr8:82754497	SNX16	-0.71	-10.21	-0.43	3.35e-22	Diastolic blood pressure;
LGG	cis	rs72772090	0.539	rs10515248	chr5:96112005	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1568889	0.838	rs7943538	chr11:28288955	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.85	18.39	0.65	4.12e-57	Bipolar disorder;
LGG	cis	rs793571	0.543	rs4775087	chr15:58974904	T/C	cg05156742	chr15:59063176	FAM63B	0.59	10.1	0.43	7.97e-22	Schizophrenia;
LGG	cis	rs7582180	0.966	rs4851283	chr2:100894802	C/G	cg05692746	chr2:100937584	LONRF2	-0.48	-7.15	-0.32	3.52e-12	Intelligence (multi-trait analysis);
LGG	trans	rs6598955	0.671	rs11247900	chr1:26612460	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.73	-12.76	-0.51	3.65e-32	Obesity-related traits;
LGG	cis	rs2404602	0.692	rs8043474	chr15:76974723	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.13	0.39	2.11e-18	Blood metabolite levels;
LGG	cis	rs13064447	0.817	rs73022951	chr3:12767557	G/A	cg23032965	chr3:12705835	RAF1	-0.48	-7.43	-0.33	5.26e-13	Major depression and alcohol dependence;
LGG	cis	rs4481887	0.573	rs6689894	chr1:248409579	C/T	cg01631408	chr1:248437212	OR2T33	-0.43	-7.43	-0.33	5.2e-13	Common traits (Other);
LGG	cis	rs6121246	0.909	rs6060979	chr20:30417522	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	11.61	0.47	1.56e-27	Mean corpuscular hemoglobin;
LGG	cis	rs875971	0.516	rs6945322	chr7:65336056	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.5	10.64	0.44	8.64e-24	Aortic root size;
LGG	cis	rs9467773	0.595	rs3846845	chr6:26444915	G/A	cg09904177	chr6:26538194	HMGN4	-0.44	-7.81	-0.34	3.88e-14	Intelligence (multi-trait analysis);
LGG	cis	rs754466	0.580	rs12356063	chr10:79558131	G/C	cg17075019	chr10:79541650	NA	-0.97	-21.6	-0.71	4.31e-72	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs780096	0.565	rs813592	chr2:27721971	T/C	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.74	-0.3	4.75e-11	Total body bone mineral density;
LGG	cis	rs9393813	0.529	rs7761966	chr6:27445703	C/T	cg18711553	chr6:27366782	ZNF391	-0.47	-9.05	-0.39	3.96e-18	Bipolar disorder;
LGG	cis	rs7916697	0.898	rs1900005	chr10:69998055	A/C	cg18338521	chr10:69995036	NA	0.33	7.17	0.32	2.96e-12	Optic disc area;
LGG	cis	rs2836974	0.899	rs68004583	chr21:40659587	T/C	cg11890956	chr21:40555474	PSMG1	1.15	28.55	0.8	3.87e-104	Cognitive function;
LGG	cis	rs9649213	0.533	rs1541409	chr7:98027580	C/T	cg09267113	chr7:98030324	BAIAP2L1	-0.48	-8.14	-0.35	3.69e-15	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7584330	0.697	rs9287620	chr2:238368730	C/T	cg16989719	chr2:238392110	NA	-0.35	-7.08	-0.31	5.34e-12	Prostate cancer;
LGG	cis	rs1577917	0.958	rs12197463	chr6:86445242	T/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.69	-0.37	6.31e-17	Response to antipsychotic treatment;
LGG	cis	rs4650994	0.525	rs2761463	chr1:178557137	T/C	cg19399532	chr1:178512495	C1orf220	-0.54	-10.87	-0.45	1.18e-24	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11650494	0.908	rs73324323	chr17:47420054	G/T	cg08112188	chr17:47440006	ZNF652	1.3	15.35	0.58	2.76e-43	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12442404	chr3:122512787	DIRC2;HSPBAP1	0.51	7.58	0.33	1.89e-13	Gut microbiome composition (summer);
LGG	cis	rs7660883	0.929	rs28432336	chr4:87984331	A/G	cg21988461	chr4:88008667	AFF1	-0.33	-8.8	-0.38	2.65e-17	HDL cholesterol levels;
LGG	cis	rs56116382	0.605	rs12715435	chr3:49338992	G/A	cg03060546	chr3:49711283	APEH	-0.53	-7.07	-0.31	5.81e-12	Intelligence (multi-trait analysis);High light scatter reticulocyte count;
LGG	cis	rs473651	0.692	rs579511	chr2:239334914	C/G	cg21699342	chr2:239360505	ASB1	0.38	7.34	0.32	9.81e-13	Multiple system atrophy;
LGG	cis	rs2730245	0.583	rs2788473	chr7:158649280	T/C	cg18245976	chr7:158708271	WDR60	-0.55	-9.54	-0.41	8.41e-20	Height;
LGG	cis	rs7100689	0.646	rs2095994	chr10:82127956	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs7924176	0.564	rs6480727	chr10:76003073	C/T	cg19889307	chr10:75911429	ADK;AP3M1	-0.41	-6.96	-0.31	1.18e-11	Primary tooth development (time to first tooth eruption);Permanent tooth development;Primary tooth development (number of teeth);
LGG	cis	rs68170813	0.605	rs75659533	chr7:107134987	A/G	cg02696742	chr7:106810147	HBP1	-0.72	-9.6	-0.41	4.86e-20	Coronary artery disease;
LGG	cis	rs7107174	0.688	rs10899501	chr11:78131408	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.12e-13	Testicular germ cell tumor;
LGG	cis	rs447735	0.507	rs11645271	chr16:89729125	G/T	cg03605463	chr16:89740564	NA	-0.5	-8.62	-0.37	1.04e-16	Hemoglobin concentration;
LGG	cis	rs28386778	0.897	rs7210443	chr17:61785374	A/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.04	0.52	2.47e-33	Prudent dietary pattern;
LGG	cis	rs9457247	1.000	rs430293	chr6:167404958	A/G	cg07741184	chr6:167504864	NA	0.32	7.04	0.31	6.77e-12	Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03925809	chr19:6393419	GTF2F1	0.53	7.79	0.34	4.45e-14	Gut microbiome composition (summer);
LGG	cis	rs3741151	0.892	rs76854106	chr11:73027110	G/A	cg17517138	chr11:73019481	ARHGEF17	0.96	9.92	0.42	3.55e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2075371	0.933	rs1833475	chr7:133958263	C/T	cg11752832	chr7:134001865	SLC35B4	0.59	10.61	0.44	1.1e-23	Mean platelet volume;
LGG	cis	rs9649465	1.000	rs1073670	chr7:123345029	A/C	cg03229431	chr7:123269106	ASB15	-0.4	-8.92	-0.38	1.13e-17	Migraine;
LGG	cis	rs2494938	0.901	rs374337	chr6:40523971	C/G	cg14084896	chr6:40530702	LRFN2	-0.3	-6.95	-0.31	1.24e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs11622475	1.000	rs8021692	chr14:104428576	C/G	cg20488157	chr14:104394430	TDRD9	0.62	9.74	0.41	1.59e-20	Bipolar disorder;
LGG	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg22437258	chr11:111473054	SIK2	0.52	8.87	0.38	1.55e-17	Primary sclerosing cholangitis;
LGG	trans	rs11992162	0.551	rs59191504	chr8:11785081	A/G	cg02002194	chr4:3960332	NA	0.44	8.1	0.35	4.84e-15	Monocyte count;
LGG	cis	rs7666738	0.830	rs62318471	chr4:98925848	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg02461776	chr11:598696	PHRF1	0.54	8.49	0.37	2.92e-16	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.602	rs7828711	chr8:11205665	G/C	cg21775007	chr8:11205619	TDH	0.82	14.59	0.56	6.43e-40	Retinal vascular caliber;
LGG	cis	rs2762353	0.808	rs1185569	chr6:25831603	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.38	-0.43	7.56e-23	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.62	-7.36	-0.32	8.21e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3858526	0.883	rs1453429	chr11:5933478	C/T	cg13902645	chr11:5959945	NA	-0.67	-10.81	-0.45	1.86e-24	DNA methylation (variation);
LGG	cis	rs2186369	0.711	rs5760029	chr22:24144280	C/T	cg10122452	chr22:24128767	SMARCB1	-0.4	-7.88	-0.34	2.34e-14	IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;
LGG	cis	rs4862750	0.914	rs11943333	chr4:187872455	A/G	cg11301795	chr4:187892539	NA	-0.86	-20.91	-0.7	7.44e-69	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7011049	0.778	rs7822512	chr8:53874273	A/G	cg26025543	chr8:53854495	NA	0.59	8.35	0.36	7.96e-16	Systolic blood pressure;
LGG	cis	rs6840360	0.571	rs2407069	chr4:152533201	G/A	cg25486957	chr4:152246857	NA	-0.48	-7.97	-0.35	1.28e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.82	-0.34	3.73e-14	Mood instability;
LGG	cis	rs2735413	0.564	rs73580814	chr16:78108899	T/G	cg04733911	chr16:78082701	NA	0.57	7.98	0.35	1.19e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs1595825	0.891	rs73058864	chr2:198889587	C/T	cg00982548	chr2:198649783	BOLL	-0.51	-6.84	-0.3	2.56e-11	Ulcerative colitis;
LGG	cis	rs193541	0.632	rs400207	chr5:122318497	C/T	cg19412675	chr5:122181750	SNX24	-0.52	-8.34	-0.36	8.87e-16	Glucose homeostasis traits;
LGG	cis	rs1153858	1.000	rs9783731	chr15:45642884	C/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.43	-7.86	-0.34	2.7e-14	Homoarginine levels;
LGG	cis	rs798554	0.679	rs1636250	chr7:2884433	T/C	cg04166393	chr7:2884313	GNA12	0.46	9.18	0.39	1.39e-18	Height;
LGG	cis	rs6580649	0.943	rs1859444	chr12:48399403	T/C	cg24011408	chr12:48396354	COL2A1	0.62	7.8	0.34	4.07e-14	Lung cancer;
LGG	cis	rs7084402	0.934	rs1658471	chr10:60291911	A/T	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.71e-13	Refractive error;
LGG	cis	rs4716602	1.000	rs4716602	chr7:156166549	G/A	cg16983916	chr7:156159713	NA	-0.41	-7.47	-0.33	4.06e-13	Anti-saccade response;
LGG	cis	rs67311347	1.000	rs12638199	chr3:40475285	A/G	cg13683864	chr3:40499215	RPL14	-0.98	-20.34	-0.69	3.37e-66	Renal cell carcinoma;
LGG	cis	rs2120019	0.938	rs8040169	chr15:75370958	C/A	cg09165964	chr15:75287851	SCAMP5	-0.98	-19.59	-0.67	1.16e-62	Blood trace element (Zn levels);
LGG	trans	rs11875185	0.510	rs112676031	chr18:55631322	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs283228	0.798	rs485947	chr6:101748814	C/A	cg27451362	chr6:101846650	GRIK2	0.65	10.61	0.44	1.12e-23	Coenzyme Q10 levels;
LGG	cis	rs4132509	0.779	rs4515770	chr1:243686913	A/G	cg25706552	chr1:244017396	NA	0.38	6.69	0.3	6.47e-11	RR interval (heart rate);
LGG	trans	rs7474896	0.507	rs2474555	chr10:38465220	G/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-6.86	-0.3	2.24e-11	Obesity (extreme);
LGG	cis	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg26384229	chr12:38710491	ALG10B	-0.69	-13.55	-0.53	1.83e-35	Bladder cancer;
LGG	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.45	0.4	1.75e-19	Educational attainment;
LGG	cis	rs7208859	0.673	rs11652409	chr17:29182707	T/A	cg13385521	chr17:29058706	SUZ12P	0.76	8.66	0.37	7.96e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6952808	0.594	rs3778965	chr7:2138296	G/A	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.2	-0.36	2.46e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs1368882	0.814	rs1702020	chr1:55105728	C/T	cg01517571	chr1:55089959	ACOT11;FAM151A	0.37	6.76	0.3	4.27e-11	Non-substance related behavioral disinhibition;
LGG	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.93	0.42	3.38e-21	Colorectal cancer;
LGG	cis	rs1008375	1.000	rs10939740	chr4:17617490	T/C	cg04450456	chr4:17643702	FAM184B	0.31	6.72	0.3	5.41e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg18654377	chr3:49208889	KLHDC8B	-0.51	-8.03	-0.35	7.89e-15	Menarche (age at onset);
LGG	cis	rs3806843	0.705	rs2530230	chr5:140088131	G/A	cg19875535	chr5:140030758	IK	-0.56	-11.6	-0.47	1.68e-27	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4622507	0.819	rs4784455	chr16:55054810	T/A	cg09947736	chr16:55091198	NA	0.57	10.16	0.43	4.81e-22	Social communication problems;
LGG	cis	rs7084402	0.967	rs1658480	chr10:60289374	C/G	cg07615347	chr10:60278583	BICC1	0.62	17.78	0.64	2.64e-54	Refractive error;
LGG	cis	rs7619833	0.719	rs552647	chr3:27353716	C/A	cg02860705	chr3:27208620	NA	0.39	7.39	0.32	6.94e-13	Breast cancer;
LGG	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg06115741	chr20:33292138	TP53INP2	0.54	9.16	0.39	1.65e-18	Coronary artery disease;
LGG	cis	rs2836950	0.545	rs2836940	chr21:40588696	T/C	cg17971929	chr21:40555470	PSMG1	-0.52	-8.89	-0.38	1.37e-17	Menarche (age at onset);
LGG	cis	rs2797369	0.713	rs9390724	chr6:101521557	G/C	cg27451362	chr6:101846650	GRIK2	-0.85	-11.16	-0.46	8.81e-26	Renal function-related traits (eGRFcrea);
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg08499158	chr17:42289980	UBTF	0.57	10.99	0.45	4.05e-25	Total body bone mineral density;
LGG	cis	rs2153904	0.793	rs71633563	chr1:205735854	C/T	cg26354017	chr1:205819088	PM20D1	-0.53	-6.87	-0.3	2.14e-11	Prostate-specific antigen levels;
LGG	cis	rs4849845	0.637	rs4077564	chr2:121004241	C/T	cg15425061	chr2:121036351	RALB	0.39	7.11	0.31	4.43e-12	Mean platelet volume;
LGG	cis	rs9611565	0.840	rs9607799	chr22:41777558	A/G	cg03806693	chr22:41940476	POLR3H	-0.95	-16.66	-0.61	3.79e-49	Vitiligo;
LGG	cis	rs981844	0.961	rs17299034	chr4:154671396	A/G	cg14289246	chr4:154710475	SFRP2	0.7	11.71	0.48	6.55e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs9611565	0.592	rs8779	chr22:42070276	T/C	cg06481639	chr22:41940642	POLR3H	0.53	7.54	0.33	2.52e-13	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10446143	chr21:44394730	PKNOX1	0.48	7.66	0.34	1.08e-13	Gut microbiome composition (summer);
LGG	cis	rs701145	0.938	rs701143	chr3:154060047	A/G	cg17054900	chr3:154042577	DHX36	1.0	12.28	0.5	3.29e-30	Coronary artery disease;
LGG	cis	rs11098499	0.863	rs6835635	chr4:120458867	A/G	cg24375607	chr4:120327624	NA	0.65	10.71	0.45	4.47e-24	Corneal astigmatism;
LGG	cis	rs17376456	0.542	rs35672980	chr5:93284877	A/T	cg25358565	chr5:93447407	FAM172A	-0.68	-9.84	-0.42	7.11e-21	Diabetic retinopathy;
LGG	trans	rs66573146	0.572	rs66819208	chr4:6946128	A/G	cg07817883	chr1:32538562	TMEM39B	1.17	12.32	0.5	2.26e-30	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2836974	0.644	rs2836986	chr21:40702136	A/C	cg22974920	chr21:40686053	BRWD1	-0.42	-6.65	-0.3	8.22e-11	Cognitive function;
LGG	cis	rs6502050	0.842	rs8080305	chr17:80074516	A/C	cg07959490	chr17:80112427	CCDC57	0.47	9.3	0.4	5.44e-19	Life satisfaction;
LGG	cis	rs644799	0.710	rs473852	chr11:95568757	C/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.86	18.03	0.64	1.88e-55	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1153858	1.000	rs10519021	chr15:45631795	G/A	cg21132104	chr15:45694354	SPATA5L1	0.71	10.47	0.44	3.5e-23	Homoarginine levels;
LGG	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg16141378	chr3:129829833	LOC729375	-0.48	-12.38	-0.5	1.31e-30	Mood instability;
LGG	cis	rs2731664	0.792	rs466256	chr5:176875956	C/A	cg23176889	chr5:176863531	GRK6	-0.65	-12.77	-0.51	3.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4417704	0.551	rs4675841	chr2:241876580	A/G	cg14055004	chr2:241860995	NA	0.28	7.54	0.33	2.42e-13	Joint mobility (Beighton score);
LGG	cis	rs35740288	0.822	rs11638720	chr15:86229273	C/T	cg07943548	chr15:86304357	KLHL25	-0.35	-6.94	-0.31	1.29e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2898290	0.694	rs2248909	chr8:11392093	A/C	cg12395012	chr8:11607386	GATA4	0.39	7.14	0.31	3.68e-12	Systolic blood pressure;
LGG	cis	rs950169	0.544	rs2036949	chr15:85163605	T/C	cg24253500	chr15:84953950	NA	0.46	7.74	0.34	6.15e-14	Schizophrenia;
LGG	cis	rs988958	0.526	rs10166598	chr2:42242872	A/G	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Hypospadias;
LGG	cis	rs7959452	0.557	rs899224	chr12:69784774	A/G	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01614729	chr20:55107833	C20orf107	0.34	7.01	0.31	8.56e-12	Menarche (age at onset);
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg00933542	chr6:150070202	PCMT1	0.39	7.09	0.31	5.05e-12	Lung cancer;
LGG	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg06197492	chr11:2016605	H19	0.45	8.9	0.38	1.26e-17	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.68	0.37	6.97e-17	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs861283	chr5:56184610	C/T	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.75	-0.34	5.91e-14	Initial pursuit acceleration;
LGG	cis	rs258892	0.895	rs6871969	chr5:72085036	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	trans	rs7824557	0.872	rs2572417	chr8:11111462	A/T	cg02002194	chr4:3960332	NA	0.5	9.38	0.4	2.87e-19	Retinal vascular caliber;
LGG	trans	rs1005277	0.579	rs1780122	chr10:38529509	C/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-6.97	-0.31	1.08e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs4660214	0.639	rs6699928	chr1:39733499	T/G	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9858542	0.953	rs9824092	chr3:49674147	C/G	cg03060546	chr3:49711283	APEH	-0.66	-11.15	-0.46	9.93e-26	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9302635	0.816	rs7202323	chr16:72217113	T/G	cg01557791	chr16:72042693	DHODH	-0.43	-6.77	-0.3	3.82e-11	Blood protein levels;
LGG	cis	rs79349575	0.783	rs15563	chr17:47005193	A/G	cg16584676	chr17:46985605	UBE2Z	0.47	8.02	0.35	8.79e-15	Type 2 diabetes;
LGG	cis	rs5769707	0.681	rs4622843	chr22:50036916	T/G	cg06623630	chr22:50017776	C22orf34	-0.49	-10.02	-0.42	1.57e-21	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs9341808	0.754	rs9341811	chr6:80982701	G/A	cg08355045	chr6:80787529	NA	0.37	7.23	0.32	2.07e-12	Sitting height ratio;
LGG	cis	rs11225247	1.000	rs78270346	chr11:102290831	A/G	cg06323957	chr11:102217781	BIRC2	0.79	6.71	0.3	5.53e-11	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs1847505	0.559	rs2323133	chr13:61568946	G/A	cg25164009	chr13:61490935	NA	-0.6	-11.75	-0.48	4.27e-28	Polychlorinated biphenyl levels;
LGG	cis	rs2153535	0.601	rs1928183	chr6:8530018	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs7617480	0.648	rs4858800	chr3:48755820	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.04	0.35	7.34e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs61884328	0.852	rs57964319	chr11:47146599	C/T	cg03339077	chr11:47165057	C11orf49	0.63	6.65	0.3	8.03e-11	Total body bone mineral density (age over 60);
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg26513180	chr16:89883248	FANCA	0.96	8.38	0.36	6.61e-16	Skin colour saturation;
LGG	cis	rs11734570	0.581	rs79354477	chr4:38597448	C/T	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.32	0.36	1.01e-15	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs3741151	0.892	rs2027760	chr11:73036481	G/A	cg17517138	chr11:73019481	ARHGEF17	0.94	9.91	0.42	4.11e-21	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs2762353	0.595	rs12200838	chr6:25753603	C/T	cg07061783	chr6:25882402	NA	0.45	7.93	0.35	1.63e-14	Blood metabolite levels;
LGG	cis	rs11225247	0.881	rs12279056	chr11:102257584	T/A	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs9397585	0.667	rs7767938	chr6:153367613	T/C	cg17707550	chr6:153380415	RGS17	0.56	11.76	0.48	3.97e-28	Body mass index;
LGG	cis	rs7998202	0.775	rs282580	chr13:113357540	T/C	cg17218041	chr13:113365319	ATP11A	-0.46	-7.52	-0.33	2.85e-13	Glycated hemoglobin levels;
LGG	cis	rs568617	0.716	rs17854357	chr11:65601560	G/C	cg26695010	chr11:65641043	EFEMP2	-0.53	-6.72	-0.3	5.45e-11	Crohn's disease;
LGG	cis	rs9354308	0.738	rs1938116	chr6:66593478	A/G	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.45e-11	Metabolite levels;
LGG	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg12856521	chr11:46389249	DGKZ	0.89	14.77	0.57	1.05e-40	Crohn's disease;
LGG	cis	rs17767392	0.834	rs17767380	chr14:71747031	C/T	cg02058870	chr14:72053146	SIPA1L1	0.44	8.63	0.37	1e-16	Mitral valve prolapse;
LGG	cis	rs2635047	0.638	rs2668761	chr18:44673049	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.49	8.2	0.36	2.4e-15	Educational attainment;
LGG	cis	rs7493	1.000	rs3735586	chr7:95035582	A/T	cg08461772	chr7:95026248	PON3	0.37	8.21	0.36	2.29e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	trans	rs7824557	0.564	rs2736301	chr8:11236413	C/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.47	-0.37	3.25e-16	Retinal vascular caliber;
LGG	cis	rs11734570	0.581	rs75356782	chr4:38600053	T/G	cg18361445	chr4:38666374	KLF3;FLJ13197	0.59	8.33	0.36	9.12e-16	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7805747	0.961	rs17173238	chr7:151406220	A/G	cg17611936	chr7:151411526	PRKAG2	0.53	7.98	0.35	1.16e-14	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;Glomerular filtration rate (creatinine);
LGG	cis	rs35110281	0.776	rs9983763	chr21:44990578	A/G	cg04455712	chr21:45112962	RRP1B	-0.5	-9.23	-0.39	9.84e-19	Mean corpuscular volume;
LGG	cis	rs7208859	0.623	rs7219712	chr17:29080570	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4969178	0.965	rs12450500	chr17:76395750	C/T	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.22e-45	HDL cholesterol levels;
LGG	cis	rs6951245	0.882	rs56048221	chr7:1092533	A/G	cg03188948	chr7:1209495	NA	0.52	7.38	0.32	7.45e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9467711	0.651	rs13220395	chr6:26055368	A/G	cg21479132	chr6:26055353	NA	-0.79	-7.29	-0.32	1.39e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6032067	1.000	rs6032042	chr20:43815949	T/C	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs2013441	0.813	rs4925088	chr17:20049344	A/G	cg09818912	chr17:20140352	CYTSB	-0.3	-7.09	-0.31	4.92e-12	Obesity-related traits;
LGG	cis	rs9291683	0.632	rs11734375	chr4:10046298	A/G	cg11266682	chr4:10021025	SLC2A9	0.55	11.09	0.46	1.61e-25	Bone mineral density;
LGG	cis	rs9914544	0.966	rs9915346	chr17:18787931	G/A	cg26378065	chr17:18585709	ZNF286B	0.51	9.54	0.41	8.22e-20	Educational attainment (years of education);
LGG	cis	rs804280	0.509	rs4841639	chr8:11796093	A/T	cg12395012	chr8:11607386	GATA4	-0.43	-7.77	-0.34	5.18e-14	Myopia (pathological);
LGG	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg16414030	chr3:133502952	NA	-0.52	-8.13	-0.35	4.04e-15	Iron status biomarkers;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.5	-0.61	1.99e-48	Skin colour saturation;
LGG	cis	rs8064024	0.620	rs8048709	chr16:4913761	A/C	cg04440724	chr16:4920505	UBN1	-0.56	-12.65	-0.51	1.06e-31	Cancer;
LGG	cis	rs4262150	0.883	rs72799178	chr5:152157489	A/G	cg12297329	chr5:152029980	NA	-0.7	-12.92	-0.51	8.02e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs2964802	0.505	rs6897847	chr5:10831632	T/C	cg14521931	chr5:10832172	NA	-0.77	-16.99	-0.62	1.15e-50	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs5771225	0.505	rs2341111	chr22:50690322	G/C	cg16473166	chr22:50639996	SELO	0.64	9.8	0.41	9.76e-21	Late-onset Alzheimer's disease;
LGG	cis	rs10861342	1.000	rs703683	chr12:105567135	T/C	cg23923672	chr12:105501055	KIAA1033	0.8	7.25	0.32	1.76e-12	IgG glycosylation;
LGG	cis	rs6502050	0.699	rs9901808	chr17:80107814	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.37	-0.32	8.17e-13	Life satisfaction;
LGG	cis	rs10256972	0.641	rs12702017	chr7:1129413	C/T	cg22907277	chr7:1156413	C7orf50	0.68	12.42	0.5	8.74e-31	Longevity;Endometriosis;
LGG	cis	rs3820928	0.874	rs7576081	chr2:227843634	C/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.89	-0.34	2.14e-14	Pulmonary function;
LGG	cis	rs4665809	0.938	rs4665822	chr2:26312555	C/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.81	-0.34	3.94e-14	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.923	rs9800580	chr6:149953981	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs6696846	0.765	rs11576867	chr1:205064676	C/T	cg21545522	chr1:205238299	TMCC2	0.37	7.15	0.32	3.52e-12	Red blood cell count;
LGG	cis	rs9902453	0.967	rs1042173	chr17:28525011	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.83	0.51	1.9e-32	Coffee consumption (cups per day);
LGG	cis	rs2228479	0.850	rs17226973	chr16:89825248	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs12282928	0.876	rs7942250	chr11:48243481	G/A	cg26585981	chr11:48327164	OR4S1	-0.43	-6.88	-0.3	1.96e-11	Migraine - clinic-based;
LGG	trans	rs7615952	0.512	rs1077621	chr3:125819799	A/G	cg07211511	chr3:129823064	LOC729375	-0.63	-8.54	-0.37	1.92e-16	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg21724239	chr8:58056113	NA	0.62	9.1	0.39	2.64e-18	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25281183	chr12:7013887	LRRC23	0.46	6.96	0.31	1.2e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.659	rs116959331	chr22:41932774	A/G	cg17554472	chr22:41940697	POLR3H	-0.49	-7.08	-0.31	5.51e-12	Vitiligo;
LGG	cis	rs620875	1.000	rs583795	chr11:126848207	G/A	cg06504925	chr11:126872760	NA	-0.54	-7.55	-0.33	2.36e-13	Response to antipsychotic treatment;
LGG	trans	rs7824557	0.569	rs7816601	chr8:11205593	T/C	cg02002194	chr4:3960332	NA	-0.4	-7.06	-0.31	6.08e-12	Retinal vascular caliber;
LGG	cis	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg14979609	chr8:8086686	FLJ10661	-0.29	-7.2	-0.32	2.52e-12	Mood instability;
LGG	cis	rs3750450	1.000	rs3750450	chr9:111945049	A/C	cg14171727	chr9:111936775	EPB41L4B	-0.32	-6.8	-0.3	3.3e-11	Low vWF levels;
LGG	cis	rs755249	0.501	rs2484749	chr1:39758955	A/G	cg18385671	chr1:39797026	MACF1	-0.48	-9.49	-0.4	1.23e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7917772	0.503	rs1409310	chr10:104282265	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.22	0.58	1.07e-42	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg05313129	chr8:58192883	C8orf71	-0.62	-8.42	-0.36	4.93e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs975210	0.556	rs2291986	chr15:70368432	C/T	cg01666796	chr15:70364327	TLE3	0.5	7.94	0.35	1.51e-14	Height;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs3820068	0.581	rs68052904	chr1:15916714	T/C	cg05660106	chr1:15850417	CASP9	0.88	18.19	0.65	3.58e-56	Systolic blood pressure;
LGG	cis	rs2762353	0.603	rs9393670	chr6:25789061	A/G	cg17691542	chr6:26056736	HIST1H1C	-0.43	-7.41	-0.33	5.85e-13	Blood metabolite levels;
LGG	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg26119090	chr2:26468346	HADHA;HADHB	-1.08	-21.21	-0.7	2.83e-70	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03260790	chr12:56211718	ORMDL2;SARNP	0.6	9.08	0.39	3.11e-18	Gut microbiome composition (summer);
LGG	cis	rs58688157	0.549	rs11246192	chr11:572473	T/C	cg16486109	chr11:613632	IRF7	0.42	7.51	0.33	3.03e-13	Systemic lupus erythematosus;
LGG	cis	rs7412746	0.611	rs9661876	chr1:150910911	C/T	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Melanoma;
LGG	cis	rs300774	0.925	rs300719	chr2:136203	C/T	cg04617936	chr2:214353	NA	-0.49	-7.46	-0.33	4.25e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs10504229	1.000	rs66479724	chr8:58188309	T/G	cg11062466	chr8:58055876	NA	0.49	8.34	0.36	8.67e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.550	rs10258339	chr7:158670243	T/C	cg18245976	chr7:158708271	WDR60	-0.58	-10.58	-0.44	1.45e-23	Height;
LGG	cis	rs2276314	0.857	rs16967327	chr18:33587036	C/T	cg05985134	chr18:33552581	C18orf21	0.63	9.9	0.42	4.32e-21	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7824557	0.527	rs2736298	chr8:11235136	C/G	cg21775007	chr8:11205619	TDH	-0.77	-13.44	-0.53	5.06e-35	Retinal vascular caliber;
LGG	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg12479418	chr7:148823350	ZNF425;ZNF398	0.46	6.88	0.3	1.97e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg04665180	chr9:132934972	FREQ	0.39	6.7	0.3	5.91e-11	Lung adenocarcinoma;
LGG	trans	rs1997103	0.954	rs10246216	chr7:55390479	C/T	cg20935933	chr6:143382018	AIG1	0.58	9.07	0.39	3.38e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6912958	0.631	rs9450704	chr6:88182704	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.49	-8.76	-0.38	3.7e-17	Monocyte percentage of white cells;
LGG	cis	rs7529073	0.815	rs1431982	chr1:214149061	T/G	cg00795024	chr1:214157026	NA	0.26	7.34	0.32	9.47e-13	Schizophrenia;
LGG	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs9790314	0.905	rs6774276	chr3:160941318	C/T	cg03342759	chr3:160939853	NMD3	-0.69	-12.37	-0.5	1.45e-30	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs17216711	chr8:58170856	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2290416	0.786	rs60401352	chr8:144673097	G/A	cg01494348	chr8:144660395	NAPRT1	0.9	6.92	0.31	1.54e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs9318086	0.712	rs66683041	chr13:24442090	T/A	cg25267304	chr13:24462978	PCOTH;MIPEP	0.85	16.69	0.61	2.75e-49	Myopia (pathological);
LGG	cis	rs12220238	0.915	rs12217890	chr10:76024496	G/A	cg19889307	chr10:75911429	ADK;AP3M1	0.7	8.91	0.38	1.21e-17	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs3768617	0.510	rs2296288	chr1:183072590	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.06	0.39	3.79e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Hypertriglyceridemia;
LGG	cis	rs78456975	0.550	rs11904276	chr2:1524006	T/C	cg01028140	chr2:1542097	TPO	-0.53	-9.77	-0.41	1.3e-20	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg12310025	chr6:25882481	NA	0.61	11.59	0.47	1.9e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7551222	0.752	rs12741351	chr1:204528256	G/A	cg20240347	chr1:204465584	NA	-0.53	-10.57	-0.44	1.48e-23	Schizophrenia;
LGG	cis	rs1865760	0.786	rs2164487	chr6:25950800	A/C	cg18357526	chr6:26021779	HIST1H4A	0.45	7.42	0.33	5.72e-13	Height;
LGG	cis	rs4595586	0.525	rs4450203	chr12:39381493	T/G	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs2404602	0.735	rs437131	chr15:76781051	C/T	cg23625390	chr15:77176239	SCAPER	0.6	11.36	0.47	1.51e-26	Blood metabolite levels;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg21911579	chr5:131705225	SLC22A5	0.71	7.83	0.34	3.45e-14	Rheumatoid arthritis;
LGG	cis	rs4268898	0.722	rs10445893	chr2:24407128	A/G	cg06627628	chr2:24431161	ITSN2	0.47	7.69	0.34	8.62e-14	Asthma;
LGG	cis	rs9611565	0.729	rs132902	chr22:41797758	A/G	cg06634786	chr22:41940651	POLR3H	-0.73	-12.38	-0.5	1.31e-30	Vitiligo;
LGG	cis	rs10504229	0.728	rs17804335	chr8:58151428	G/T	cg05313129	chr8:58192883	C8orf71	0.75	10.47	0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg18531175	chr5:43483681	C5orf28	0.61	6.96	0.31	1.14e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.579	rs7672718	chr4:98645122	A/G	cg05340658	chr4:99064831	C4orf37	0.44	6.71	0.3	5.74e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7726839	0.578	rs112516582	chr5:584319	G/A	cg16447950	chr5:562315	NA	-0.46	-7.62	-0.33	1.45e-13	Obesity-related traits;
LGG	cis	rs10754283	0.557	rs1215508	chr1:90088697	C/T	cg21401794	chr1:90099060	LRRC8C	0.41	7.93	0.35	1.69e-14	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs35160687	0.623	rs7569654	chr2:86478022	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.38	6.99	0.31	9.68e-12	Night sleep phenotypes;
LGG	cis	rs4948275	0.530	rs10994747	chr10:63149922	A/G	cg03237606	chr10:63212265	TMEM26	0.44	7.86	0.34	2.69e-14	Night sleep phenotypes;
LGG	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.65	0.37	8.27e-17	Hypertriglyceridemia;
LGG	trans	rs9650657	0.711	rs7007318	chr8:10592278	C/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.76	-0.3	4.14e-11	Neuroticism;
LGG	cis	rs6750795	0.765	rs6742387	chr2:232354832	G/T	cg19187155	chr2:232395269	NMUR1	0.53	9.93	0.42	3.45e-21	Height;
LGG	cis	rs10256972	0.567	rs2960850	chr7:1211649	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-7.81	-0.34	3.97e-14	Longevity;Endometriosis;
LGG	trans	rs7395662	1.000	rs10838943	chr11:48557442	T/G	cg00717180	chr2:96193071	NA	-0.43	-7.57	-0.33	2e-13	HDL cholesterol;
LGG	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg12463550	chr7:65579703	CRCP	0.77	8.46	0.37	3.6e-16	Gout;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19603847	chr7:42276981	GLI3	0.44	6.72	0.3	5.34e-11	Gut microbiome composition (summer);
LGG	cis	rs12410462	0.502	rs77615958	chr1:227806083	T/C	cg23173402	chr1:227635558	NA	0.66	9.49	0.4	1.2e-19	Major depressive disorder;
LGG	trans	rs1493916	0.905	rs4799727	chr18:31393095	T/G	cg04226714	chr8:49833948	SNAI2	-0.5	-9.11	-0.39	2.46e-18	Life satisfaction;
LGG	cis	rs7715811	0.913	rs10513154	chr5:13780601	T/C	cg07548982	chr5:13769939	DNAH5	-0.45	-8.99	-0.39	6.12e-18	Subclinical atherosclerosis traits (other);
LGG	cis	rs10504229	0.728	rs72650856	chr8:58152695	C/T	cg20607798	chr8:58055168	NA	0.64	7.52	0.33	2.84e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg19336497	chr11:14380999	RRAS2	-0.59	-12.02	-0.49	3.73e-29	Sense of smell;
LGG	trans	rs9467711	0.790	rs13204572	chr6:26189356	G/C	cg01620082	chr3:125678407	NA	-0.92	-8.19	-0.36	2.52e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs798554	1.000	rs798548	chr7:2760935	A/G	cg04166393	chr7:2884313	GNA12	0.45	8.54	0.37	2e-16	Height;
LGG	cis	rs8062405	1.000	rs8055982	chr16:28881202	A/C	cg00198680	chr16:28758506	NA	0.28	6.94	0.31	1.32e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04578997	chr12:104850759	CHST11	0.47	6.98	0.31	1.04e-11	Gut microbiome composition (summer);
LGG	cis	rs10267417	0.589	rs6960989	chr7:19869349	G/A	cg05791153	chr7:19748676	TWISTNB	0.62	7.99	0.35	1.12e-14	Night sleep phenotypes;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg11062466	chr8:58055876	NA	0.54	8.87	0.38	1.56e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs3206736	0.521	rs329232	chr7:35054951	C/T	cg13400248	chr7:35225412	NA	0.55	9.55	0.41	7.78e-20	Diastolic blood pressure;
LGG	cis	rs1065852	0.526	rs7290907	chr22:42390209	G/A	cg15128208	chr22:42549153	NA	0.41	7.09	0.31	4.97e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs7107174	0.792	rs10751287	chr11:78072476	T/C	cg27205649	chr11:78285834	NARS2	-0.44	-7.37	-0.32	8.01e-13	Testicular germ cell tumor;
LGG	cis	rs10464366	0.544	rs9639812	chr7:39192058	C/T	cg15212455	chr7:39170539	POU6F2	0.49	11.64	0.48	1.2e-27	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs117231141	chr8:58185465	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs10857712	0.754	rs2297033	chr10:135234848	C/T	cg00491522	chr10:135256596	NA	0.52	8.23	0.36	1.85e-15	Systemic lupus erythematosus;
LGG	cis	rs736408	0.660	rs2019065	chr3:52809525	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.49	-8.26	-0.36	1.53e-15	Bipolar disorder;
LGG	cis	rs737693	0.527	rs72983552	chr11:102764093	T/G	cg19620758	chr11:102826565	MMP13	0.56	7.87	0.34	2.61e-14	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7143963	0.943	rs10132977	chr14:103370119	C/T	cg23020514	chr14:103360112	TRAF3	0.47	8.85	0.38	1.84e-17	Body mass index;
LGG	cis	rs1023500	0.505	rs134878	chr22:42663874	A/G	cg15557168	chr22:42548783	NA	-0.46	-9.96	-0.42	2.69e-21	Schizophrenia;
LGG	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03517284	chr6:25882590	NA	0.52	9.6	0.41	5.03e-20	Blood metabolite levels;
LGG	trans	rs6787172	0.702	rs1095641	chr3:157971102	A/G	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs67311347	1.000	rs11720360	chr3:40448397	G/A	cg24209194	chr3:40518798	ZNF619	0.44	6.79	0.3	3.46e-11	Renal cell carcinoma;
LGG	cis	rs9818758	0.607	rs13087930	chr3:48961726	A/G	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs17092148	0.943	rs4911160	chr20:33349940	G/A	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.72	-0.34	7.14e-14	Neuroticism;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg05368731	chr17:41323189	NBR1	0.94	18.6	0.65	4.5e-58	Menopause (age at onset);
LGG	cis	rs7267979	1.000	rs4815405	chr20:25317492	T/C	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg10360403	chr3:46064716	XCR1	0.4	7.03	0.31	7.53e-12	Electrocardiographic conduction measures;
LGG	cis	rs3820928	0.839	rs12151848	chr2:227859326	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.42	-0.33	5.79e-13	Pulmonary function;
LGG	cis	rs7949566	0.557	rs2230279	chr11:126278075	C/T	cg05055844	chr11:126275997	ST3GAL4	0.38	7.74	0.34	6.25e-14	Platelet distribution width;Mean platelet volume;
LGG	trans	rs2204008	0.652	rs11520002	chr12:38022179	G/T	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.88e-18	Bladder cancer;
LGG	cis	rs6495122	0.532	rs2470890	chr15:75047426	C/T	cg14664628	chr15:75095509	CSK	-0.59	-10.97	-0.45	4.75e-25	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7582180	0.629	rs2309798	chr2:100956949	G/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.86	-0.48	1.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7000551	0.527	rs11783730	chr8:22244897	C/T	cg13512537	chr8:22265999	SLC39A14	-0.43	-6.76	-0.3	4.18e-11	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7236492	0.577	rs7236190	chr18:77198217	T/C	cg15644404	chr18:77186268	NFATC1	-0.57	-8.73	-0.38	4.6e-17	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg22907277	chr7:1156413	C7orf50	0.46	7.93	0.35	1.7e-14	Longevity;Endometriosis;
LGG	cis	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg22496380	chr5:211416	CCDC127	-1.3	-10.64	-0.44	8.37e-24	Breast cancer;
LGG	cis	rs7737355	0.812	rs171523	chr5:130844946	A/G	cg06307176	chr5:131281290	NA	0.51	8.48	0.37	3.03e-16	Life satisfaction;
LGG	cis	rs2243480	1.000	rs34970380	chr7:65431493	C/T	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs11098499	0.698	rs4422403	chr4:120258194	C/T	cg24375607	chr4:120327624	NA	0.53	9.12	0.39	2.37e-18	Corneal astigmatism;
LGG	cis	rs4481887	0.893	rs4576683	chr1:248472390	T/C	cg01631408	chr1:248437212	OR2T33	-0.51	-9.39	-0.4	2.81e-19	Common traits (Other);
LGG	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg21775007	chr8:11205619	TDH	-0.52	-8.53	-0.37	2.05e-16	Triglycerides;
LGG	cis	rs1729951	0.575	rs1654904	chr3:136681149	T/C	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	5.86e-21	Neuroticism;
LGG	cis	rs8179	0.648	rs42036	chr7:92241451	C/G	cg15732164	chr7:92237376	CDK6	-0.56	-10.31	-0.43	1.4e-22	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs72772090	0.539	rs17481856	chr5:96116808	G/A	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6582630	0.537	rs11520294	chr12:38402705	C/A	cg04568710	chr12:38710424	ALG10B	0.34	6.91	0.31	1.58e-11	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs889122	0.531	rs7246906	chr19:10017135	A/C	cg00846166	chr19:10022875	OLFM2	0.31	6.71	0.3	5.84e-11	Menarche (age at onset);
LGG	cis	rs2470578	0.792	rs283925	chr3:17325403	C/G	cg20981856	chr3:17787350	NA	0.35	6.75	0.3	4.53e-11	Schizophrenia;
LGG	trans	rs1005277	0.540	rs2145487	chr10:38010077	A/G	cg17830980	chr10:43048298	ZNF37B	-0.45	-10.03	-0.42	1.43e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs4919044	0.688	rs11187221	chr10:94704990	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.28	-0.32	1.4e-12	Coronary artery disease;
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg07332563	chr6:291687	DUSP22	-0.57	-9.41	-0.4	2.25e-19	Menopause (age at onset);
LGG	cis	rs11098499	0.954	rs17046116	chr4:120387259	G/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs769267	0.930	rs3752151	chr19:19616026	T/C	cg01262667	chr19:19385393	TM6SF2	0.44	11.0	0.46	3.73e-25	Tonsillectomy;
LGG	trans	rs9650657	0.589	rs12542037	chr8:10758496	G/A	cg15556689	chr8:8085844	FLJ10661	0.46	7.85	0.34	2.82e-14	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05014952	chr14:35873130	NFKBIA	0.46	7.76	0.34	5.49e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs6681460	0.625	rs12138066	chr1:67103816	C/T	cg20812318	chr1:67072952	SGIP1	-0.31	-7.27	-0.32	1.49e-12	Presence of antiphospholipid antibodies;
LGG	cis	rs3768617	0.565	rs10752897	chr1:183071024	C/T	cg15522984	chr1:182991683	LAMC1	0.44	8.54	0.37	1.93e-16	Fuchs's corneal dystrophy;
LGG	cis	rs12472274	0.941	rs11677230	chr2:239092054	T/C	cg17459225	chr2:239074497	NA	0.79	13.24	0.52	3.84e-34	Phospholipid levels (plasma);
LGG	cis	rs4853012	0.887	rs77148265	chr2:74339519	C/T	cg05890377	chr2:74357713	NA	0.52	9.94	0.42	3.06e-21	Gestational age at birth (maternal effect);
LGG	cis	rs57221529	0.766	rs72703042	chr5:579269	C/T	cg07777115	chr5:623756	CEP72	-0.55	-6.88	-0.3	1.9e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs13088318	0.521	rs7374860	chr3:101223721	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.39	-7.39	-0.32	7.08e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2985684	0.894	rs2281837	chr14:50065359	C/G	cg04989706	chr14:50066350	PPIL5	-0.58	-9.24	-0.39	8.8e-19	Carotid intima media thickness;
LGG	trans	rs2243480	1.000	rs13310597	chr7:65598540	A/G	cg10756647	chr7:56101905	PSPH	0.81	9.47	0.4	1.5e-19	Diabetic kidney disease;
LGG	cis	rs28386778	0.897	rs2854214	chr17:61945449	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.59	-10.22	-0.43	3.1e-22	Prudent dietary pattern;
LGG	cis	rs79349575	0.749	rs8182364	chr17:47018025	A/G	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs870825	0.616	rs28490461	chr4:185651638	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs9303280	0.806	rs36038753	chr17:38035370	G/T	cg00129232	chr17:37814104	STARD3	-0.47	-8.77	-0.38	3.37e-17	Self-reported allergy;
LGG	cis	rs11920090	0.858	rs57005472	chr3:170758329	T/G	cg09710316	chr3:170744871	SLC2A2	0.71	8.52	0.37	2.34e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4642101	0.883	rs6810325	chr3:12840934	T/C	cg05775895	chr3:12838266	CAND2	0.56	9.18	0.39	1.41e-18	QRS complex (12-leadsum);
LGG	cis	rs77633900	0.614	rs2170998	chr15:77007159	C/T	cg21673338	chr15:77095150	SCAPER	0.63	10.14	0.43	5.78e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs11630290	1.000	rs72750981	chr15:63983737	A/T	cg12036633	chr15:63758958	NA	-0.62	-8.66	-0.37	8.18e-17	Iris characteristics;
LGG	cis	rs12130219	1.000	rs1552994	chr1:152171461	A/G	cg25272121	chr1:152190972	HRNR	0.4	6.9	0.31	1.68e-11	Inflammatory skin disease;
LGG	cis	rs3931020	0.688	rs277375	chr1:75204143	A/G	cg00121533	chr1:75199117	CRYZ;TYW3	0.43	6.76	0.3	4.08e-11	Resistin levels;
LGG	cis	rs910316	0.503	rs12894709	chr14:75441734	G/A	cg11812906	chr14:75593930	NEK9	0.43	7.8	0.34	4.29e-14	Height;
LGG	cis	rs35306767	0.903	rs35968821	chr10:910225	A/G	cg26597838	chr10:835615	NA	0.74	10.14	0.43	6e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs17767392	0.836	rs61989383	chr14:71983644	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.94	-0.38	9.03e-18	Mitral valve prolapse;
LGG	cis	rs56283067	0.847	rs62435999	chr6:44695273	T/G	cg18551225	chr6:44695536	NA	-0.72	-12.47	-0.5	5.74e-31	Total body bone mineral density;
LGG	trans	rs11722228	0.549	rs2241488	chr4:10101131	T/C	cg26043149	chr18:55253948	FECH	0.95	16.39	0.61	5.91e-48	Gout;Urate levels;Serum uric acid levels;
LGG	trans	rs10435719	0.899	rs11250177	chr8:11799099	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.93	-0.35	1.68e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11148252	0.716	rs3803262	chr13:53036398	A/G	cg12458913	chr13:53173898	NA	0.63	12.32	0.5	2.37e-30	Lewy body disease;
LGG	cis	rs8114671	0.836	rs1885114	chr20:33577361	A/G	cg24642439	chr20:33292090	TP53INP2	-0.49	-7.94	-0.35	1.51e-14	Height;
LGG	cis	rs1577917	0.958	rs12192546	chr6:86476484	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.65	10.78	0.45	2.45e-24	Response to antipsychotic treatment;
LGG	cis	rs9880211	0.848	rs71336069	chr3:136351866	G/C	cg21827317	chr3:136751795	NA	-0.48	-7.2	-0.32	2.49e-12	Body mass index;Height;
LGG	cis	rs7811142	0.830	rs73401443	chr7:99977582	T/G	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.76	-0.41	1.41e-20	Platelet count;
LGG	trans	rs9467711	0.606	rs9366655	chr6:26377385	C/G	cg08344181	chr3:125677491	NA	-0.62	-7.04	-0.31	6.94e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7465272	0.500	rs7463655	chr8:143731034	G/C	cg24634471	chr8:143751801	JRK	0.49	7.47	0.33	4.01e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs4665809	0.590	rs36064164	chr2:26502768	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.86e-66	Gut microbiome composition (summer);
LGG	cis	rs13421350	0.579	rs10207640	chr2:173307726	C/T	cg15021238	chr2:173305865	ITGA6	0.82	9.58	0.41	5.88e-20	Diabetic kidney disease;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.79	0.38	2.9e-17	Platelet count;
LGG	cis	rs2439831	0.867	rs16957632	chr15:43642897	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	1.03	13.13	0.52	1.03e-33	Lung cancer in ever smokers;
LGG	cis	rs9814567	0.806	rs4955534	chr3:134319723	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs757081	0.613	rs11024151	chr11:17105730	T/G	cg15432903	chr11:17409602	KCNJ11	-0.41	-6.79	-0.3	3.48e-11	Systolic blood pressure;
LGG	cis	rs2071403	0.622	rs11683117	chr2:1382411	C/T	cg06500727	chr2:1417164	TPO	-0.41	-7.19	-0.32	2.61e-12	Thyroid peroxidase antibody positivity;
LGG	trans	rs7937682	0.575	rs7930208	chr11:111741463	T/C	cg18187862	chr3:45730750	SACM1L	-0.59	-9.78	-0.41	1.18e-20	Primary sclerosing cholangitis;
LGG	cis	rs67614146	1	rs67614146	chr6:87821827	AC/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.68	-12.68	-0.51	7.73e-32	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs12472274	0.646	rs35468889	chr2:239090959	G/A	cg17459225	chr2:239074497	NA	0.75	11.09	0.46	1.63e-25	Phospholipid levels (plasma);
LGG	cis	rs7432375	0.610	rs56695781	chr3:136510601	G/T	cg21827317	chr3:136751795	NA	0.45	7.99	0.35	1.07e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3740909	1.000	rs79378329	chr11:125883862	T/C	cg24940576	chr11:125904314	CDON	-0.46	-7.22	-0.32	2.11e-12	Blood protein levels;
LGG	cis	rs4820294	1.000	rs62236665	chr22:38059847	C/A	cg00292662	chr22:38071168	LGALS1	0.89	24.41	0.75	3.45e-85	Fat distribution (HIV);
LGG	cis	rs6964587	1.000	rs12333563	chr7:91667326	G/A	cg17063962	chr7:91808500	NA	0.48	8.48	0.37	3.11e-16	Breast cancer;
LGG	cis	rs597539	0.652	rs513615	chr11:68705504	G/T	cg04008888	chr11:68622739	NA	-0.56	-11.93	-0.48	8.4e-29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs55883249	1.000	rs11676903	chr2:9763201	G/C	cg23886495	chr2:9695866	ADAM17	0.69	10.0	0.42	1.96e-21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs1908814	0.516	rs60176945	chr8:11796674	T/C	cg21775007	chr8:11205619	TDH	0.43	6.79	0.3	3.39e-11	Neuroticism;
LGG	cis	rs7582180	0.903	rs7557977	chr2:100897573	G/A	cg08297393	chr2:100937505	LONRF2	-0.56	-9.73	-0.41	1.81e-20	Intelligence (multi-trait analysis);
LGG	cis	rs11866815	0.857	rs2361988	chr16:398151	T/C	cg12437481	chr16:420112	MRPL28	-0.54	-8.52	-0.37	2.22e-16	Body mass index;
LGG	cis	rs9400467	0.506	rs12195578	chr6:111614786	C/T	cg21044968	chr6:111895086	TRAF3IP2	0.43	6.89	0.31	1.8e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs61931739	0.534	rs2667447	chr12:34133468	C/A	cg13010199	chr12:38710504	ALG10B	0.54	10.54	0.44	2.01e-23	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.747	rs4240868	chr1:152981599	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.09	-0.39	2.84e-18	Inflammatory skin disease;
LGG	cis	rs17039065	0.920	rs12508024	chr4:109413413	A/G	cg16022748	chr4:109541635	LOC285456;RPL34	-0.59	-7.21	-0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs240764	0.658	rs9404053	chr6:101254456	G/A	cg09795085	chr6:101329169	ASCC3	-0.47	-8.01	-0.35	9.29e-15	Neuroticism;
LGG	cis	rs2204008	0.837	rs11183232	chr12:37941053	A/G	cg26384229	chr12:38710491	ALG10B	0.89	20.17	0.68	2.22e-65	Bladder cancer;
LGG	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg26384229	chr12:38710491	ALG10B	0.71	14.49	0.56	1.61e-39	Heart rate;
LGG	cis	rs3760047	0.668	rs2858923	chr16:207375	A/T	cg25425005	chr16:202905	HBZ	-0.62	-10.09	-0.42	9.21e-22	Mean corpuscular hemoglobin concentration;
LGG	trans	rs6787172	0.622	rs9872089	chr3:158077995	C/T	cg23275840	chr4:47708675	CORIN	-0.36	-7.38	-0.32	7.45e-13	Subjective well-being;
LGG	cis	rs2587949	0.571	rs1304143	chr3:4249222	C/T	cg16519197	chr3:4211558	NA	0.36	7.24	0.32	1.92e-12	Periodontitis (DPAL);
LGG	cis	rs2629540	0.889	rs10901808	chr10:126399159	A/C	cg08799069	chr10:126477246	METTL10	0.65	13.2	0.52	5.66e-34	Cocaine dependence;
LGG	cis	rs568617	1.000	rs568617	chr11:65653242	C/T	cg04055107	chr11:65626734	MUS81;CFL1	0.51	7.05	0.31	6.71e-12	Crohn's disease;
LGG	cis	rs963731	0.579	rs12712630	chr2:39284582	A/G	cg04010122	chr2:39346883	SOS1	-0.8	-7.69	-0.34	8.63e-14	Corticobasal degeneration;
LGG	cis	rs950169	0.922	rs11630507	chr15:85095725	A/G	cg03959625	chr15:84868606	LOC388152	0.58	9.41	0.4	2.4e-19	Schizophrenia;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.07	-0.35	6.16e-15	IgG glycosylation;
LGG	cis	rs4295623	0.585	rs13259242	chr8:11593033	T/G	cg13293535	chr8:11597251	GATA4	0.3	7.0	0.31	9.13e-12	Morning vs. evening chronotype;
LGG	trans	rs7613875	0.641	rs6446194	chr3:50067298	T/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.61	-0.41	4.74e-20	Body mass index;
LGG	cis	rs17102423	0.594	rs1256417	chr14:65563678	C/T	cg26396452	chr14:65542826	MAX	0.48	10.09	0.42	8.8e-22	Obesity-related traits;
LGG	cis	rs9291683	0.510	rs4318649	chr4:10016815	T/C	cg08250081	chr4:10125330	NA	0.43	8.37	0.36	6.88e-16	Bone mineral density;
LGG	trans	rs2727020	0.724	rs4109837	chr11:49372051	A/T	cg03929089	chr4:120376271	NA	-0.8	-13.43	-0.53	6.09e-35	Coronary artery disease;
LGG	cis	rs12431410	0.521	rs11848115	chr14:60214991	G/T	cg07950296	chr14:60194823	RTN1	-0.38	-7.3	-0.32	1.24e-12	Schizophrenia;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg24690094	chr11:67383802	NA	0.4	6.72	0.3	5.21e-11	Mean corpuscular volume;
LGG	trans	rs11098499	0.754	rs66900435	chr4:120249425	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.93	0.45	6.66e-25	Corneal astigmatism;
LGG	cis	rs1670533	1.000	rs1670534	chr4:1087265	T/C	cg27284194	chr4:1044797	NA	0.55	9.94	0.42	3.23e-21	Recombination rate (females);
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg25427524	chr10:38739819	LOC399744	-0.69	-13.03	-0.52	2.78e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg05863683	chr7:1912471	MAD1L1	0.41	8.03	0.35	8.15e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6708331	0.941	rs7609359	chr2:70358976	T/C	cg01613454	chr2:70366299	NA	0.53	9.4	0.4	2.57e-19	Obesity-related traits;
LGG	cis	rs12477438	0.798	rs4324365	chr2:99623845	T/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.53	-0.5	3.15e-31	Chronic sinus infection;
LGG	cis	rs4144743	0.877	rs7223766	chr17:45326734	T/G	cg18085866	chr17:45331354	ITGB3	-0.81	-9.69	-0.41	2.49e-20	Body mass index;
LGG	cis	rs2154319	0.673	rs2011982	chr1:41540861	T/C	cg02290550	chr1:41487317	SLFNL1	-0.5	-9.02	-0.39	5.03e-18	Height;
LGG	cis	rs6952808	0.717	rs6967442	chr7:1926090	A/G	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.78	-0.45	2.59e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs7208859	0.673	rs17826219	chr17:29161845	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.76	-9.01	-0.39	5.46e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15130565	chr3:61546275	PTPRG	0.52	7.79	0.34	4.52e-14	Gut microbiome composition (summer);
LGG	cis	rs919433	0.653	rs700651	chr2:198631714	G/A	cg00792783	chr2:198669748	PLCL1	0.65	10.64	0.44	8.19e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg06719900	chr11:109292894	C11orf87	0.45	8.37	0.36	7.11e-16	Schizophrenia;
LGG	cis	rs13191362	0.938	rs13213746	chr6:163167777	T/A	cg21926612	chr6:163149169	PACRG;PARK2	1.0	11.19	0.46	6.79e-26	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs734999	0.588	rs10910098	chr1:2533250	C/A	cg18854424	chr1:2615690	NA	0.35	7.17	0.32	2.97e-12	Ulcerative colitis;
LGG	trans	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg10756647	chr7:56101905	PSPH	0.81	9.43	0.4	1.98e-19	Diabetic kidney disease;
LGG	cis	rs7811142	0.830	rs6945952	chr7:99981775	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.4	0.36	5.61e-16	Platelet count;
LGG	cis	rs9815354	0.812	rs56332587	chr3:42012714	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.2	0.39	1.18e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs9329221	0.736	rs11249999	chr8:10251265	C/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.52	-0.33	2.83e-13	Neuroticism;
LGG	cis	rs4665809	0.816	rs2384359	chr2:26371364	T/C	cg22920501	chr2:26401640	FAM59B	-0.43	-8.45	-0.37	3.68e-16	Gut microbiome composition (summer);
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg04772025	chr11:68637568	NA	0.76	12.87	0.51	1.3e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2486288	0.656	rs11629859	chr15:45547121	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.58	-9.72	-0.41	1.91e-20	Glomerular filtration rate;
LGG	cis	rs9611565	0.694	rs202639	chr22:41856137	T/A	cg17376030	chr22:41985996	PMM1	-0.56	-8.97	-0.38	7.17e-18	Vitiligo;
LGG	cis	rs916888	0.773	rs199457	chr17:44795469	C/T	cg20120463	chr17:44301886	NA	-0.48	-7.41	-0.33	6.15e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11122272	0.735	rs910823	chr1:231498766	G/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.16	-0.46	8.84e-26	Hemoglobin concentration;
LGG	cis	rs836589	0.506	rs6712686	chr2:173562687	C/G	cg06468108	chr2:173539091	NA	-0.46	-6.82	-0.3	2.83e-11	Erectile dysfunction in type 1 diabetes;
LGG	cis	rs1046896	0.519	rs9900369	chr17:80829807	G/A	cg03160526	chr17:80928410	B3GNTL1	0.5	8.05	0.35	7.19e-15	Glycated hemoglobin levels;
LGG	cis	rs7819412	0.875	rs11250121	chr8:11060311	A/C	cg24623649	chr8:11872141	NA	-0.31	-7.3	-0.32	1.24e-12	Triglycerides;
LGG	cis	rs10504229	0.683	rs79284841	chr8:58107611	T/A	cg08677398	chr8:58056175	NA	0.58	8.86	0.38	1.68e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12200560	0.505	rs4839848	chr6:97076577	G/A	cg06623918	chr6:96969491	KIAA0776	0.45	7.61	0.33	1.55e-13	Coronary heart disease;
LGG	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg13010199	chr12:38710504	ALG10B	0.69	13.76	0.54	2.31e-36	Bladder cancer;
LGG	cis	rs12541335	0.692	rs2290274	chr8:22214374	C/T	cg02463440	chr8:22132932	PIWIL2	0.49	10.73	0.45	3.84e-24	Hypertriglyceridemia;
LGG	trans	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	trans	rs1814175	0.817	rs11040700	chr11:50023832	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.93	-0.48	8.43e-29	Height;
LGG	cis	rs7566780	0.602	rs10198308	chr2:16683402	C/T	cg09580478	chr2:16689509	NA	0.49	7.44	0.33	4.96e-13	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	cis	rs9894429	0.716	rs7405578	chr17:79588306	C/A	cg10661904	chr17:79619235	PDE6G	-0.4	-8.08	-0.35	5.72e-15	Eye color traits;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg13903179	chr13:21900392	NA	0.41	7.12	0.31	4.06e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs7084402	0.967	rs1649049	chr10:60324095	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.46	-0.33	4.36e-13	Refractive error;
LGG	cis	rs77106637	0.860	rs1552224	chr11:72433098	A/C	cg03713592	chr11:72463424	ARAP1	0.44	7.82	0.34	3.71e-14	Type 2 diabetes;
LGG	cis	rs1401999	1.000	rs3805108	chr3:183691650	T/C	cg01324343	chr3:183735012	ABCC5	0.85	18.05	0.64	1.59e-55	Anterior chamber depth;
LGG	trans	rs2562456	0.833	rs11672583	chr19:21562165	A/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.75	-0.34	5.85e-14	Pain;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.67	11.83	0.48	2.16e-28	Lymphocyte counts;
LGG	cis	rs8031584	0.541	rs2955797	chr15:31210981	A/G	cg08109568	chr15:31115862	NA	0.46	8.23	0.36	1.89e-15	Huntington's disease progression;
LGG	trans	rs11875185	0.510	rs78191812	chr18:55650508	G/T	cg15513957	chr14:69354734	ACTN1	-1.08	-11.59	-0.47	1.87e-27	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.79	0.34	4.3e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7100689	0.784	rs2153455	chr10:82139732	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	17.43	0.63	1.15e-52	Post bronchodilator FEV1;
LGG	trans	rs11098499	0.863	rs3775848	chr4:120447724	C/T	cg25214090	chr10:38739885	LOC399744	0.67	11.73	0.48	5.2e-28	Corneal astigmatism;
LGG	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg21995147	chr19:1064017	ABCA7	-0.48	-7.52	-0.33	2.82e-13	Alzheimer's disease (late onset);
LGG	cis	rs72781680	0.950	rs56128748	chr2:24126809	T/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.49	0.4	1.23e-19	Lymphocyte counts;
LGG	cis	rs7781557	0.640	rs7779854	chr7:102551582	G/A	cg18108683	chr7:102477205	FBXL13	-0.54	-8.06	-0.35	6.34e-15	Colorectal adenoma (advanced);
LGG	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg13607699	chr17:42295918	UBTF	-0.9	-18.36	-0.65	5.71e-57	Red cell distribution width;Reticulocyte count;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg23835219	chr4:1244017	CTBP1;C4orf42	0.58	10.85	0.45	1.34e-24	Longevity;
LGG	cis	rs2842992	0.789	rs9365093	chr6:160175819	C/G	cg11366901	chr6:160182831	ACAT2	1.06	17.04	0.62	6.97e-51	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs3768617	1.000	rs3820697	chr1:183100226	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.79	0.3	3.35e-11	Fuchs's corneal dystrophy;
LGG	cis	rs7119	0.717	rs12910513	chr15:77817258	C/T	cg10437265	chr15:77819839	NA	0.25	6.99	0.31	9.78e-12	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs9322197	chr6:149943713	C/A	cg02462569	chr6:150064036	NUP43	-0.38	-8.06	-0.35	6.73e-15	Lung cancer;
LGG	trans	rs6089829	0.962	rs1060490	chr20:61665871	A/G	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.33e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg01169559	chr10:831247	NA	0.45	6.98	0.31	1.01e-11	Uric acid levels;
LGG	cis	rs7829975	0.514	rs2945873	chr8:8260445	C/T	cg06636001	chr8:8085503	FLJ10661	0.53	10.08	0.42	1.02e-21	Mood instability;
LGG	cis	rs7267979	0.932	rs449370	chr20:25451180	A/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.34	-0.43	1.12e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4819052	0.851	rs28622522	chr21:46676599	G/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.54	8.89	0.38	1.33e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs701145	0.585	rs6440935	chr3:153816976	A/T	cg12800244	chr3:153838788	SGEF	0.82	8.96	0.38	7.93e-18	Coronary artery disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25452632	chr12:56754141	STAT2	0.46	7.3	0.32	1.24e-12	Cognitive performance;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11554610	chr20:30410856	MYLK2	-0.47	-6.96	-0.31	1.14e-11	Systemic lupus erythematosus;
LGG	cis	rs1372520	0.567	rs2619349	chr4:90746646	G/T	cg15133208	chr4:90757351	SNCA	-0.41	-8.23	-0.36	1.94e-15	Neuroticism;
LGG	cis	rs9788721	0.900	rs72740964	chr15:78868636	G/A	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.58	-0.33	1.92e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2730245	0.527	rs2709858	chr7:158675266	C/G	cg18245976	chr7:158708271	WDR60	-0.58	-7.6	-0.33	1.69e-13	Height;
LGG	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg02023728	chr11:77925099	USP35	-0.38	-6.8	-0.3	3.19e-11	Alzheimer's disease (survival time);
LGG	cis	rs2243480	1.000	rs7804223	chr7:65664559	T/G	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.08	0.6	1.5e-46	Lung cancer;
LGG	cis	rs17826219	0.500	rs57005940	chr17:29066329	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs368123	1.000	rs412128	chr6:160728678	C/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.23	-0.32	1.99e-12	Waist circumference;
LGG	cis	rs258892	0.895	rs13170247	chr5:72069684	A/G	cg21869765	chr5:72125136	TNPO1	-0.42	-6.7	-0.3	5.98e-11	Small cell lung carcinoma;
LGG	cis	rs2832270	0.562	rs73192155	chr21:30455919	A/G	cg24692254	chr21:30365293	RNF160	-0.65	-7.23	-0.32	2.02e-12	Response to mTOR inhibitor (everolimus);
LGG	cis	rs4975709	0.589	rs4975707	chr5:1864028	C/T	cg15595755	chr5:1867978	NA	0.52	10.5	0.44	2.78e-23	Cardiovascular disease risk factors;
LGG	cis	rs7215564	0.908	rs4969411	chr17:78747982	T/C	cg16980736	chr17:78789706	RPTOR	0.59	7.79	0.34	4.46e-14	Myopia (pathological);
LGG	trans	rs9467711	0.591	rs13195279	chr6:25919431	T/A	cg01620082	chr3:125678407	NA	-0.67	-6.69	-0.3	6.37e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9649465	1.000	rs13225220	chr7:123371026	C/A	cg03229431	chr7:123269106	ASB15	-0.41	-8.91	-0.38	1.15e-17	Migraine;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg17178900	chr1:205818956	PM20D1	-0.42	-7.37	-0.32	7.96e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs6500602	0.627	rs709632	chr16:4587811	C/G	cg06916706	chr16:4465613	CORO7	0.87	14.79	0.57	8.1e-41	Schizophrenia;
LGG	cis	rs9354308	0.764	rs9453462	chr6:66583491	A/G	cg07460842	chr6:66804631	NA	0.42	7.11	0.31	4.45e-12	Metabolite levels;
LGG	cis	rs240764	0.658	rs9390679	chr6:101216102	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs9290065	0.519	rs7613316	chr3:160674533	A/G	cg03342759	chr3:160939853	NMD3	-0.51	-8.59	-0.37	1.39e-16	Kawasaki disease;
LGG	cis	rs10754283	0.967	rs6663363	chr1:90116854	A/G	cg06121193	chr1:90282411	NA	-0.38	-7.31	-0.32	1.17e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg15596359	chr8:11213517	TDH	-0.4	-8.18	-0.36	2.71e-15	Retinal vascular caliber;
LGG	cis	rs3106136	0.967	rs282449	chr4:95141228	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.98	-0.35	1.17e-14	Capecitabine sensitivity;
LGG	cis	rs11239187	0.530	rs10047358	chr10:45060874	A/C	cg03916630	chr10:45065415	NA	0.36	8.59	0.37	1.31e-16	Body mass index;
LGG	cis	rs11239187	0.586	rs1999775	chr10:45081343	C/T	cg03916630	chr10:45065415	NA	0.37	8.86	0.38	1.74e-17	Body mass index;
LGG	trans	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg06636001	chr8:8085503	FLJ10661	0.51	9.41	0.4	2.39e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs801193	0.904	rs4718403	chr7:66242729	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.2	0.39	1.19e-18	Aortic root size;
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg08677398	chr8:58056175	NA	0.44	7.42	0.33	5.75e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.686	rs907180	chr8:8702827	A/G	cg02002194	chr4:3960332	NA	-0.39	-7.15	-0.32	3.47e-12	Mood instability;
LGG	trans	rs453301	0.658	rs13271797	chr8:8885954	G/A	cg02002194	chr4:3960332	NA	0.39	7.29	0.32	1.39e-12	Joint mobility (Beighton score);
LGG	cis	rs6831352	0.918	rs2602891	chr4:100043284	C/T	cg13256891	chr4:100009986	ADH5	0.57	9.92	0.42	3.8e-21	Alcohol dependence;
LGG	cis	rs10155981	0.510	rs4719706	chr7:22592796	G/A	cg05062323	chr7:22590069	NA	-0.87	-10.35	-0.43	9.66e-23	Bilirubin levels;
LGG	cis	rs13065560	0.534	rs6789111	chr3:38904222	G/A	cg01426195	chr3:39028469	NA	-0.43	-8.86	-0.38	1.77e-17	Interleukin-18 levels;
LGG	trans	rs9329221	0.905	rs4610752	chr8:10248962	A/G	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.12	-0.35	4.36e-15	Neuroticism;
LGG	cis	rs12477438	0.501	rs12619780	chr2:99707307	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.93	22.44	0.72	5.13e-76	Chronic sinus infection;
LGG	cis	rs7044106	0.762	rs1886337	chr9:123443776	G/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.68	12.16	0.49	1.04e-29	Hip circumference adjusted for BMI;
LGG	cis	rs6951245	0.872	rs75493422	chr7:1072890	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.15e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2247341	0.894	rs2592831	chr4:1711404	T/C	cg07465881	chr4:1713556	SLBP	-0.46	-7.31	-0.32	1.16e-12	Hip circumference adjusted for BMI;Height;
LGG	cis	rs8180040	1.000	rs295449	chr3:47375955	G/A	cg16586182	chr3:47516702	SCAP	-0.77	-15.17	-0.58	1.73e-42	Colorectal cancer;
LGG	cis	rs801193	0.660	rs1016265	chr7:66214567	C/T	cg11764359	chr7:65958608	NA	0.77	14.39	0.56	4.46e-39	Aortic root size;
LGG	cis	rs72766638	0.806	rs56303154	chr9:136936376	C/T	cg13789015	chr9:136890014	NCRNA00094	0.47	6.97	0.31	1.09e-11	Mosquito bite size;
LGG	cis	rs9472414	0.680	rs4714812	chr6:44700714	G/A	cg20913747	chr6:44695427	NA	0.48	7.32	0.32	1.11e-12	Height;
LGG	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg02855558	chr7:158107723	PTPRN2	-0.41	-7.45	-0.33	4.65e-13	Calcium levels;
LGG	trans	rs9329221	0.572	rs4841295	chr8:10105115	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.35	0.36	8.26e-16	Neuroticism;
LGG	cis	rs10504229	0.861	rs67042991	chr8:58191749	G/C	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs250677	0.687	rs42364	chr5:148438858	T/A	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.27	-0.32	1.5e-12	Breast cancer;
LGG	cis	rs9674544	0.646	rs6504594	chr17:47142697	C/A	cg11673840	chr17:47092156	IGF2BP1	-0.41	-7.31	-0.32	1.17e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs7618501	0.633	rs2856234	chr3:50139142	A/G	cg24308560	chr3:49941425	MST1R	-0.22	-6.74	-0.3	4.61e-11	Intelligence (multi-trait analysis);
LGG	cis	rs919433	0.680	rs2564389	chr2:198260098	A/T	cg00792783	chr2:198669748	PLCL1	0.5	7.95	0.35	1.43e-14	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs7666738	0.924	rs13124368	chr4:99039615	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs910316	1.000	rs10873275	chr14:75531460	A/T	cg06637938	chr14:75390232	RPS6KL1	0.59	10.98	0.45	4.51e-25	Height;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg24829409	chr8:58192753	C8orf71	-0.79	-11.26	-0.46	3.7e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs11096990	0.656	rs3733284	chr4:39301334	A/G	cg24403649	chr4:39172243	NA	-0.37	-6.67	-0.3	7.17e-11	Cognitive function;
LGG	cis	rs9322193	0.923	rs10872650	chr6:150082095	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.72	0.34	7.19e-14	Lung cancer;
LGG	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg00938859	chr5:1591904	SDHAP3	0.91	13.36	0.53	1.12e-34	Breast cancer;
LGG	trans	rs947612	0.509	rs1935513	chr6:73678125	G/A	cg13494037	chr12:24737079	C12orf67	0.36	7.56	0.33	2.17e-13	HIV-1 viral setpoint;Body mass index;
LGG	cis	rs4901847	0.716	rs7152617	chr14:58561819	A/T	cg15908186	chr14:58618357	C14orf37	0.41	7.22	0.32	2.21e-12	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7829975	0.688	rs7826660	chr8:8379107	C/A	cg15556689	chr8:8085844	FLJ10661	0.48	8.98	0.39	6.81e-18	Mood instability;
LGG	cis	rs12421382	0.881	rs1808843	chr11:109389471	A/G	cg00830817	chr11:109293614	C11orf87	0.47	7.39	0.32	7e-13	Schizophrenia;
LGG	cis	rs9522267	0.535	rs2039915	chr13:112238794	C/T	cg12773197	chr13:112238673	NA	-0.36	-7.25	-0.32	1.75e-12	Hepatitis;
LGG	cis	rs7223966	0.921	rs3020612	chr17:61960878	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.37	0.47	1.41e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg00689492	chr4:1303491	MAEA	0.5	8.51	0.37	2.47e-16	Obesity-related traits;
LGG	cis	rs7811142	1.000	rs11766752	chr7:100073292	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	20.78	0.69	2.88e-68	Platelet count;
LGG	cis	rs1055129	0.560	rs9891076	chr17:73911715	C/T	cg14829360	chr17:73884958	NA	-0.54	-10.54	-0.44	1.96e-23	White matter hyperintensity burden;
LGG	cis	rs9322193	0.884	rs7450246	chr6:150023653	C/T	cg09699651	chr6:150184138	LRP11	0.52	9.21	0.39	1.12e-18	Lung cancer;
LGG	cis	rs7666738	1.000	rs13124102	chr4:98990696	G/A	cg05340658	chr4:99064831	C4orf37	0.42	6.74	0.3	4.68e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12701220	0.542	rs6957866	chr7:1111674	G/A	cg02733842	chr7:1102375	C7orf50	-0.55	-8.27	-0.36	1.43e-15	Bronchopulmonary dysplasia;
LGG	cis	rs6951245	0.554	rs35126802	chr7:1134842	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.38	0.32	7.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7523273	0.606	rs2796263	chr1:207915978	T/C	cg22525895	chr1:207977042	MIR29B2	0.6	11.85	0.48	1.74e-28	Schizophrenia;
LGG	trans	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg06521331	chr12:34319734	NA	0.43	7.83	0.34	3.39e-14	Bladder cancer;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	-0.63	-11.17	-0.46	8.03e-26	Obesity-related traits;
LGG	cis	rs4356203	0.905	rs17472886	chr11:17086167	G/A	cg15432903	chr11:17409602	KCNJ11	-0.39	-7.33	-0.32	1e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs12477438	0.520	rs6732750	chr2:100003890	T/C	cg23527387	chr2:100056660	REV1	0.44	9.74	0.41	1.66e-20	Chronic sinus infection;
LGG	cis	rs2000999	0.725	rs12924886	chr16:72075593	A/T	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.43	-7.44	-0.33	5.01e-13	Total cholesterol levels;Cholesterol, total;Blood protein levels;LDL cholesterol levels;Haptoglobin levels;LDL cholesterol;
LGG	cis	rs2228479	0.850	rs11639925	chr16:89908250	C/T	cg04287289	chr16:89883240	FANCA	0.84	7.84	0.34	3.02e-14	Skin colour saturation;
LGG	cis	rs7267979	1.000	rs2482940	chr20:25349830	C/T	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9368481	0.761	rs4713062	chr6:26948195	A/G	cg12292205	chr6:26970375	C6orf41	-0.73	-14.37	-0.56	5.4300000000000003e-39	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1046896	0.553	rs2292965	chr17:80900645	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.46	7.91	0.35	1.85e-14	Glycated hemoglobin levels;
LGG	cis	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	trans	rs11039798	0.614	rs116427493	chr11:48776141	C/T	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	cis	rs10256972	0.552	rs6978842	chr7:1204599	A/C	cg18402987	chr7:1209562	NA	0.45	8.67	0.37	7.42e-17	Longevity;Endometriosis;
LGG	cis	rs4838594	0.563	rs3853762	chr10:49678456	G/C	cg17291251	chr10:49678358	ARHGAP22	0.55	11.54	0.47	3.11e-27	Daytime sleep phenotypes;
LGG	cis	rs2180341	0.960	rs1964130	chr6:127677391	C/G	cg24812749	chr6:127587940	RNF146	0.94	15.43	0.58	1.19e-43	Breast cancer;
LGG	cis	rs7223966	1.000	rs55868506	chr17:61851686	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.04	0.46	2.58e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2153535	0.580	rs2184583	chr6:8447808	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg05025164	chr4:1340916	KIAA1530	0.89	17.57	0.63	2.67e-53	Longevity;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs738322	0.532	rs9622746	chr22:38564041	C/G	cg03162506	chr22:38580953	NA	0.4	9.74	0.41	1.6e-20	Cutaneous nevi;
LGG	cis	rs7394190	0.748	rs11000764	chr10:75506864	A/G	cg07699608	chr10:75541558	CHCHD1	0.54	7.12	0.31	4.13e-12	Incident atrial fibrillation;
LGG	cis	rs4356932	1.000	rs4333205	chr4:76984795	A/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.76	-0.3	4.05e-11	Blood protein levels;
LGG	cis	rs1401999	1.000	rs6767013	chr3:183680102	G/A	cg01324343	chr3:183735012	ABCC5	0.85	18.05	0.64	1.64e-55	Anterior chamber depth;
LGG	cis	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg11266682	chr4:10021025	SLC2A9	-0.47	-9.08	-0.39	3.15e-18	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs4332037	0.950	rs7807014	chr7:1939021	T/C	cg11693508	chr17:37793320	STARD3	0.73	10.41	0.44	5.81e-23	Bipolar disorder;
LGG	cis	rs9487051	0.872	rs6924776	chr6:109612276	A/G	cg21918786	chr6:109611834	NA	-0.48	-8.95	-0.38	8.73e-18	Reticulocyte fraction of red cells;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg16270222	chr17:41446396	NA	-0.29	-6.74	-0.3	4.6e-11	Menopause (age at onset);
LGG	cis	rs721399	0.962	rs2410558	chr8:18263484	T/C	cg18736775	chr8:18248649	NAT2	0.5	8.71	0.38	5.39e-17	Blood metabolite levels;
LGG	cis	rs4819052	0.788	rs35323494	chr21:46703739	G/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	10.41	0.44	6.14e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1451375	0.652	rs7803903	chr7:50625945	C/T	cg20336341	chr7:50628841	DDC	0.51	9.51	0.4	1e-19	Malaria;
LGG	trans	rs1728785	0.818	rs12926059	chr16:68569459	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	cis	rs72945132	0.882	rs6592522	chr11:70128271	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	7.68	0.34	9.76e-14	Coronary artery disease;
LGG	trans	rs1814175	0.803	rs11040451	chr11:49650639	C/T	cg03929089	chr4:120376271	NA	-1.02	-22.5	-0.72	2.6e-76	Height;
LGG	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg26441486	chr22:50317300	CRELD2	-0.42	-7.58	-0.33	1.96e-13	Schizophrenia;
LGG	cis	rs75920871	0.623	rs7946729	chr11:116963180	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-8.02	-0.35	8.83e-15	Subjective well-being;
LGG	trans	rs6601327	0.603	rs10095171	chr8:9669885	T/C	cg16141378	chr3:129829833	LOC729375	0.33	7.42	0.33	5.55e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7326068	0.558	rs4770071	chr13:21330883	C/G	cg04906043	chr13:21280425	IL17D	-0.5	-8.07	-0.35	6.27e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	trans	rs11722228	0.522	rs7681250	chr4:10133013	G/T	cg26043149	chr18:55253948	FECH	1.0	18.57	0.65	5.95e-58	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7619833	0.653	rs6787882	chr3:27270459	G/C	cg02860705	chr3:27208620	NA	0.4	7.7	0.34	8.19e-14	Breast cancer;
LGG	cis	rs1387259	0.723	rs2732488	chr12:48771444	G/A	cg24011408	chr12:48396354	COL2A1	0.45	7.02	0.31	7.9e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs2228479	0.850	rs17226428	chr16:89842884	T/A	cg03036210	chr16:89904091	SPIRE2	-0.65	-7.94	-0.35	1.53e-14	Skin colour saturation;
LGG	cis	rs7617773	0.539	rs11706939	chr3:48383992	G/T	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs12621445	1	rs12621445	chr2:24154964	C/T	cg08917208	chr2:24149416	ATAD2B	0.94	10.24	0.43	2.54e-22	Immature fraction of reticulocytes;
LGG	cis	rs9640161	0.789	rs60283368	chr7:150023258	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.79	-0.59	3.14e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs12477438	0.798	rs6761570	chr2:99577276	T/G	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs13191362	0.872	rs13194619	chr6:163203657	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.43	0.33	5.11e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10752881	1.000	rs6658501	chr1:182991417	C/T	cg07928641	chr1:182991847	LAMC1	-0.49	-9.98	-0.42	2.24e-21	Colorectal cancer;
LGG	cis	rs977987	0.806	rs11865004	chr16:75395777	C/T	cg03315344	chr16:75512273	CHST6	0.5	10.21	0.43	3.17e-22	Dupuytren's disease;
LGG	cis	rs738321	0.701	rs2413506	chr22:38593128	T/C	cg25457927	chr22:38595422	NA	-0.4	-9.38	-0.4	2.94e-19	Breast cancer;
LGG	cis	rs17122278	1.000	rs9735421	chr11:118447597	G/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.14e-11	Total cholesterol levels;
LGG	cis	rs1348850	0.831	rs1345139	chr2:178449791	G/T	cg27490568	chr2:178487706	NA	0.47	9.08	0.39	3.11e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs868036	0.681	rs13329582	chr15:68104608	G/C	cg22044901	chr15:68126292	NA	-0.4	-6.78	-0.3	3.71e-11	Restless legs syndrome;
LGG	cis	rs889398	0.741	rs10852461	chr16:69928846	T/C	cg00738113	chr16:70207722	CLEC18C	-0.25	-7.01	-0.31	8.74e-12	Body mass index;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg23188684	chr11:67383651	NA	0.45	7.87	0.34	2.6e-14	Mean corpuscular volume;
LGG	cis	rs2404602	0.692	rs34478400	chr15:76923510	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.49e-11	Blood metabolite levels;
LGG	cis	rs943466	1.000	rs12524768	chr6:33760478	G/A	cg07519485	chr6:33762594	MLN	0.54	11.2	0.46	6.03e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs7312774	0.618	rs4964500	chr12:107320788	T/C	cg16260113	chr12:107380972	MTERFD3	0.91	8.29	0.36	1.25e-15	Severe influenza A (H1N1) infection;
LGG	trans	rs916888	0.821	rs199509	chr17:44858728	G/A	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg02462569	chr6:150064036	NUP43	-0.35	-7.38	-0.32	7.26e-13	Lung cancer;
LGG	cis	rs2228479	0.850	rs11639906	chr16:89798183	T/C	cg26513180	chr16:89883248	FANCA	1.0	9.57	0.41	6.29e-20	Skin colour saturation;
LGG	cis	rs42648	0.935	rs42644	chr7:89974864	G/A	cg25739043	chr7:89950458	NA	-0.42	-8.97	-0.38	7.26e-18	Homocysteine levels;
LGG	cis	rs10504229	0.861	rs116923397	chr8:58185162	T/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.37	-0.5	1.47e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.544	rs555556	chr11:95618425	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.66	11.52	0.47	3.71e-27	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs9322193	0.884	rs12528279	chr6:150072028	A/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.35	-0.32	8.85e-13	Lung cancer;
LGG	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.31	0.5	2.59e-30	Colorectal cancer;
LGG	cis	rs9487094	0.813	rs11753645	chr6:109695054	T/C	cg01125227	chr6:109776195	MICAL1	0.5	8.38	0.36	6.62e-16	Height;
LGG	cis	rs7927592	0.913	rs11228292	chr11:68379772	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02220755	chr2:136288843	R3HDM1;ZRANB3	-0.46	-6.66	-0.3	7.7e-11	Systemic lupus erythematosus;
LGG	trans	rs12310956	0.532	rs11052954	chr12:33993512	C/G	cg13010199	chr12:38710504	ALG10B	0.51	9.63	0.41	3.85e-20	Morning vs. evening chronotype;
LGG	cis	rs2717559	0.542	rs2717590	chr8:143900712	A/G	cg07661805	chr8:143867942	LY6D	-0.3	-8.03	-0.35	8.02e-15	Urinary tract infection frequency;
LGG	cis	rs920590	0.721	rs920587	chr8:19663339	C/A	cg01411142	chr8:19674711	INTS10	0.47	7.34	0.32	9.8e-13	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs847649	0.699	rs10271157	chr7:102527591	A/G	cg18108683	chr7:102477205	FBXL13	-0.64	-14.09	-0.55	8.71e-38	Morning vs. evening chronotype;
LGG	trans	rs3206736	0.548	rs10278195	chr7:35064459	G/T	cg14337134	chr7:102920323	DPY19L2P2	0.42	7.3	0.32	1.26e-12	Diastolic blood pressure;
LGG	cis	rs9356171	0.572	rs13198847	chr6:164326504	T/C	cg25752492	chr6:164341247	NA	-0.46	-9.09	-0.39	2.83e-18	Diisocyanate-induced asthma;
LGG	trans	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg21659725	chr3:3221576	CRBN	0.62	9.88	0.42	5e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs2727020	0.729	rs10839268	chr11:49380328	G/A	cg03929089	chr4:120376271	NA	-0.91	-18.49	-0.65	1.48e-57	Coronary artery disease;
LGG	cis	rs7246657	0.678	rs2927740	chr19:38140966	A/G	cg18154014	chr19:37997991	ZNF793	-0.4	-7.1	-0.31	4.69e-12	Coronary artery calcification;
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.7	12.69	0.51	6.91e-32	Obesity-related traits;
LGG	cis	rs10435719	0.509	rs13248956	chr8:11789768	C/A	cg00405596	chr8:11794950	NA	0.64	11.14	0.46	1.03e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs11920090	0.932	rs11924648	chr3:170717996	A/G	cg09710316	chr3:170744871	SLC2A2	0.56	8.14	0.35	3.73e-15	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs1005277	0.638	rs1005278	chr10:38218748	G/A	cg25427524	chr10:38739819	LOC399744	0.59	11.2	0.46	6.44e-26	Extrinsic epigenetic age acceleration;
LGG	cis	rs9467773	1.000	rs9467787	chr6:26556769	G/T	cg11502198	chr6:26597334	ABT1	0.56	9.77	0.41	1.28e-20	Intelligence (multi-trait analysis);
LGG	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg10326726	chr10:51549505	MSMB	-0.67	-13.64	-0.54	7.37e-36	Prostate-specific antigen levels;
LGG	cis	rs3087591	0.960	rs12945157	chr17:29603631	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.61	0.56	5.19e-40	Hip circumference;
LGG	trans	rs11039798	0.512	rs1588069	chr11:48694871	A/G	cg03929089	chr4:120376271	NA	0.71	9.81	0.41	8.94e-21	Axial length;
LGG	cis	rs17169635	0.765	rs1015350	chr7:134575255	C/T	cg02516134	chr7:134575187	CALD1	0.44	9.41	0.4	2.3e-19	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 1 peripheral neuropathy);
LGG	cis	rs12220238	0.822	rs73286281	chr10:76083337	T/C	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.96	0.38	8.05e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs17504614	0.648	rs17504635	chr2:51080824	A/G	cg23851515	chr2:51057218	NRXN1	-0.67	-8.13	-0.35	3.88e-15	Educational attainment (years of education);
LGG	cis	rs2229238	0.826	rs111742980	chr1:154508764	T/A	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.13e-11	Coronary heart disease;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg23782820	chr8:58130467	NA	0.5	7.67	0.34	1e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7747724	0.715	rs6936300	chr6:20775221	A/G	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.37	-0.4	3.1400000000000002e-19	Bladder cancer;
LGG	cis	rs2153535	0.580	rs9406159	chr6:8464859	C/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs9557207	0.760	rs35407628	chr13:99806693	G/T	cg24509225	chr13:100037070	UBAC2	0.66	11.91	0.48	1.03e-28	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs9527	0.590	rs12785223	chr10:104844011	C/T	cg05308233	chr10:104796373	CNNM2	0.32	7.17	0.32	2.99e-12	Arsenic metabolism;
LGG	cis	rs11155671	0.530	rs1334510	chr6:150201179	A/G	cg09217309	chr6:150244204	RAET1G	0.44	8.19	0.36	2.66e-15	Testicular germ cell tumor;
LGG	cis	rs9894429	1.000	rs4074915	chr17:79579230	G/A	cg10661904	chr17:79619235	PDE6G	0.42	8.53	0.37	2.03e-16	Eye color traits;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg04025307	chr7:1156635	C7orf50	0.91	19.4	0.67	8.24e-62	Longevity;Endometriosis;
LGG	cis	rs2404602	0.740	rs34924128	chr15:76965169	T/G	cg15268244	chr15:77196840	NA	-0.31	-6.84	-0.3	2.44e-11	Blood metabolite levels;
LGG	cis	rs12477438	0.765	rs7340412	chr2:99661148	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.91	-0.51	8.96e-33	Chronic sinus infection;
LGG	cis	rs1129187	0.720	rs9471972	chr6:42915021	G/A	cg24101359	chr6:42928495	GNMT	0.52	14.4	0.56	4.2e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4500972	1	rs4500972	chr2:73767897	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.62	-0.33	1.49e-13	Glomerular filtration rate (creatinine);
LGG	cis	rs2916247	1.000	rs7002565	chr8:93057196	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.41	-0.36	5.29e-16	Intelligence (multi-trait analysis);
LGG	cis	rs1218582	0.804	rs4845398	chr1:154859038	G/C	cg24250549	chr1:154909240	PMVK	0.74	15.14	0.58	2.37e-42	Prostate cancer;
LGG	cis	rs28595532	0.920	rs114080496	chr4:119726372	C/T	cg11846333	chr4:119757529	SEC24D	0.85	7.86	0.34	2.73e-14	Cannabis dependence symptom count;
LGG	cis	rs2073499	0.935	rs28365992	chr3:50340996	T/C	cg03645007	chr3:50255295	SLC38A3	0.61	6.69	0.3	6.45e-11	Schizophrenia;
LGG	trans	rs1814175	0.935	rs7482690	chr11:49648814	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.57	-11.01	-0.46	3.24e-25	Height;
LGG	cis	rs4689592	0.503	rs59640165	chr4:7051661	G/A	cg19539972	chr4:7069911	GRPEL1	-0.76	-9.98	-0.42	2.32e-21	Monocyte percentage of white cells;
LGG	cis	rs12575642	0.660	rs58632573	chr11:63896299	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.43	0.47	8.32e-27	Attention deficit hyperactivity disorder;
LGG	cis	rs72945132	0.882	rs7943547	chr11:70133282	C/A	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs4474465	0.790	rs10793325	chr11:78252575	T/C	cg27205649	chr11:78285834	NARS2	0.51	8.8	0.38	2.72e-17	Alzheimer's disease (survival time);
LGG	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg06374794	chr16:88002281	BANP	0.49	8.89	0.38	1.34e-17	Menopause (age at onset);
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.53	0.33	2.77e-13	Schizophrenia;
LGG	cis	rs1008375	0.966	rs28750296	chr4:17685826	A/T	cg04450456	chr4:17643702	FAM184B	0.31	6.79	0.3	3.52e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3785574	0.962	rs2584632	chr17:61880641	G/A	cg11494091	chr17:61959527	GH2	0.6	10.18	0.43	4.39e-22	Height;
LGG	cis	rs9326248	0.569	rs10047459	chr11:116721826	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.54	6.74	0.3	4.78e-11	Blood protein levels;
LGG	cis	rs10504229	0.679	rs2218271	chr8:58052446	T/A	cg20607798	chr8:58055168	NA	0.63	7.33	0.32	1.05e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs11039798	1.000	rs12280020	chr11:48618844	G/C	cg03929089	chr4:120376271	NA	0.75	8.64	0.37	9.37e-17	Axial length;
LGG	cis	rs763121	0.853	rs5750652	chr22:39048316	A/G	cg06022373	chr22:39101656	GTPBP1	0.89	18.44	0.65	2.56e-57	Menopause (age at onset);
LGG	cis	rs9486719	1.000	rs2472890	chr6:96867646	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs7829975	0.582	rs11783950	chr8:8597831	A/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.07	-0.31	5.73e-12	Mood instability;
LGG	cis	rs6594499	0.872	rs10060003	chr5:110449357	A/G	cg04022379	chr5:110408740	TSLP	0.4	7.38	0.32	7.42e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs3219090	0.924	rs1104893	chr1:226598652	A/G	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.96	-0.35	1.38e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs57221529	0.766	rs1399381	chr5:589853	G/T	cg14541582	chr5:601475	NA	-0.71	-11.15	-0.46	9.91e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs7582720	0.943	rs115827549	chr2:203725678	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs11098499	0.954	rs9685777	chr4:120365965	C/A	cg09307838	chr4:120376055	NA	0.82	13.72	0.54	3.33e-36	Corneal astigmatism;
LGG	cis	rs11690935	0.885	rs6727017	chr2:172766847	T/A	cg21435375	chr2:172878103	MAP1D	-0.34	-7.64	-0.33	1.29e-13	Schizophrenia;
LGG	cis	rs6120849	0.707	rs6120799	chr20:33614955	T/C	cg24642439	chr20:33292090	TP53INP2	0.54	6.65	0.3	8.51e-11	Protein C levels;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg04861929	chr11:109293070	C11orf87	0.52	9.62	0.41	4.34e-20	Schizophrenia;
LGG	cis	rs67311347	1.000	rs12108041	chr3:40487535	C/T	cg24209194	chr3:40518798	ZNF619	0.43	6.67	0.3	7.24e-11	Renal cell carcinoma;
LGG	cis	rs28386778	0.897	rs6504176	chr17:61811920	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs6960043	0.738	rs4721400	chr7:15059906	G/A	cg19272540	chr7:15055459	NA	0.38	8.37	0.36	6.78e-16	Type 2 diabetes;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg08280861	chr8:58055591	NA	0.54	6.91	0.31	1.63e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9398803	0.723	rs861237	chr6:127073798	C/T	cg19875578	chr6:126661172	C6orf173	-0.49	-9.03	-0.39	4.58e-18	Male-pattern baldness;
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg26318627	chr11:63887540	MACROD1	-0.46	-6.7	-0.3	6.24e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2797160	1.000	rs1739376	chr6:126012084	C/G	cg05901451	chr6:126070800	HEY2	0.42	6.98	0.31	1.04e-11	Endometrial cancer;
LGG	cis	rs933688	0.532	rs2367292	chr5:90556785	A/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.53	-6.73	-0.3	5.12e-11	Smoking behavior;
LGG	cis	rs13118159	0.742	rs34947293	chr4:1335034	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.49	8.77	0.38	3.35e-17	Longevity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24738475	chr1:89149492	PKN2	0.43	7.21	0.32	2.26e-12	Gut microbiota (bacterial taxa);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04389422	chr12:24715564	SOX5	0.46	6.97	0.31	1.09e-11	Gut microbiome composition (summer);
LGG	cis	rs9359856	0.564	rs72915933	chr6:90441464	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.51	-0.4	1.05e-19	Bipolar disorder;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.48	0.33	3.89e-13	Menopause (age at onset);
LGG	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg23625390	chr15:77176239	SCAPER	-0.47	-9.1	-0.39	2.61e-18	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs11792861	0.962	rs72607161	chr9:111792640	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.56	0.41	6.73e-20	Menarche (age at onset);
LGG	cis	rs4843747	0.641	rs11117353	chr16:88090895	A/G	cg09044154	chr16:88155775	NA	-0.54	-8.03	-0.35	7.86e-15	Menopause (age at onset);
LGG	cis	rs2303745	0.640	rs10403581	chr19:17384192	A/C	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.15	-0.39	1.77e-18	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg00933542	chr6:150070202	PCMT1	0.39	6.99	0.31	9.58e-12	Lung cancer;
LGG	cis	rs10193935	0.901	rs6544549	chr2:42693056	C/T	cg27598129	chr2:42591480	NA	0.67	9.79	0.41	1.12e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg18402987	chr7:1209562	NA	0.45	8.69	0.37	6.44e-17	Longevity;Endometriosis;
LGG	cis	rs9300255	0.510	rs1790109	chr12:123637752	C/G	cg00376283	chr12:123451042	ABCB9	0.64	10.3	0.43	1.5e-22	Neutrophil percentage of white cells;
LGG	cis	rs9747201	1.000	rs58472289	chr17:80111895	G/T	cg09264619	chr17:80180166	NA	0.51	10.16	0.43	4.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26330133	chr20:35089838	DLGAP4	-0.53	-7.8	-0.34	4.06e-14	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs4235392	chr4:17696422	A/G	cg18681998	chr4:17616180	MED28	0.73	15.1	0.57	3.66e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2188554	0.785	rs6943105	chr7:117156341	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	6.76	0.3	4.05e-11	Esophageal adenocarcinoma;
LGG	cis	rs1577917	1.000	rs1911552	chr6:86638024	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs17767392	0.748	rs55896578	chr14:71712185	G/A	cg02058870	chr14:72053146	SIPA1L1	0.36	7.12	0.31	4.16e-12	Mitral valve prolapse;
LGG	cis	rs35306767	0.903	rs12764024	chr10:922861	A/G	cg25019033	chr10:957182	NA	-0.54	-10.1	-0.42	8.55e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg01840575	chr2:38977957	SFRS7	-0.4	-6.76	-0.3	4.16e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs1728785	1.000	rs11642045	chr16:68583892	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.68	9.72	0.41	1.85e-20	Ulcerative colitis;
LGG	cis	rs7765175	0.598	rs12201269	chr6:113630195	G/C	cg26552650	chr6:113682475	NA	0.33	7.14	0.31	3.66e-12	Coronary artery calcification;
LGG	cis	rs3857536	0.776	rs9342535	chr6:66932963	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.91	-0.34	1.96e-14	Blood trace element (Cu levels);
LGG	cis	rs701145	0.585	rs1713811	chr3:153874566	G/A	cg12800244	chr3:153838788	SGEF	0.78	8.51	0.37	2.5e-16	Coronary artery disease;
LGG	cis	rs10927875	0.632	rs4661666	chr1:16162471	C/A	cg21385522	chr1:16154831	NA	-1.04	-25.81	-0.77	1.11e-91	Dilated cardiomyopathy;
LGG	cis	rs13191362	1.000	rs13192894	chr6:163052444	T/A	cg18825119	chr6:163149453	PACRG;PARK2	0.45	6.78	0.3	3.75e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1421811	0.532	rs17540044	chr5:32692238	C/G	cg16267343	chr5:32710456	NPR3	-0.59	-8.15	-0.35	3.38e-15	Blood pressure;
LGG	cis	rs2797160	1.000	rs6569435	chr6:125998186	T/C	cg05901451	chr6:126070800	HEY2	-0.43	-7.25	-0.32	1.77e-12	Endometrial cancer;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg07233135	chr10:33623121	NRP1	0.36	6.7	0.3	6.15e-11	Obesity-related traits;
LGG	cis	rs4356932	0.935	rs10336	chr4:76922988	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.73	-0.3	4.88e-11	Blood protein levels;
LGG	trans	rs6089829	0.925	rs6122087	chr20:61664553	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.15	0.32	3.48e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7107174	0.688	rs2063724	chr11:78133077	T/C	cg02023728	chr11:77925099	USP35	0.45	7.94	0.35	1.58e-14	Testicular germ cell tumor;
LGG	cis	rs4595586	0.545	rs12828001	chr12:39392208	G/A	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg21775007	chr8:11205619	TDH	-0.47	-7.85	-0.34	2.85e-14	Mood instability;
LGG	cis	rs9788682	0.948	rs34664138	chr15:78831624	T/G	cg06917634	chr15:78832804	PSMA4	-0.64	-9.7	-0.41	2.24e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs9287719	0.967	rs728282	chr2:10750303	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs11074306	0.561	rs924314	chr15:28054346	G/A	cg26402630	chr15:28053930	OCA2	0.36	7.22	0.32	2.21e-12	Uveal melanoma;
LGG	cis	rs9947295	0.649	rs1941225	chr18:11778612	G/A	cg14735704	chr18:11749182	GNAL	0.48	7.32	0.32	1.07e-12	QT interval (drug interaction);
LGG	cis	rs7766436	0.885	rs13198323	chr6:22577065	C/T	cg13666174	chr6:22585274	NA	-0.51	-11.89	-0.48	1.2e-28	Coronary artery disease;
LGG	cis	rs12580194	0.556	rs58780687	chr12:55736498	A/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.07	-0.42	1.03e-21	Cancer;
LGG	cis	rs6754311	0.517	rs1469995	chr2:136542559	G/A	cg07169764	chr2:136633963	MCM6	1.0	19.01	0.66	5.48e-60	Mosquito bite size;
LGG	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg20821713	chr7:1055600	C7orf50	-0.42	-8.07	-0.35	6.15e-15	Longevity;Endometriosis;
LGG	cis	rs2576037	0.796	rs2571031	chr18:44577063	T/C	cg19077165	chr18:44547161	KATNAL2	0.53	9.69	0.41	2.47e-20	Personality dimensions;
LGG	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg15704280	chr7:45808275	SEPT13	0.85	8.87	0.38	1.62e-17	Myopia (pathological);
LGG	cis	rs66731853	0.769	rs657624	chr1:20888348	C/T	cg04087271	chr1:20915334	CDA	-0.42	-7.3	-0.32	1.24e-12	Mean corpuscular volume;
LGG	cis	rs72634258	0.945	rs2294889	chr1:8075934	A/G	cg00042356	chr1:8021962	PARK7	0.83	11.16	0.46	9.25e-26	Inflammatory bowel disease;
LGG	cis	rs11874712	1.000	rs9783886	chr18:43651270	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.5	-10.91	-0.45	8.26e-25	Migraine - clinic-based;
LGG	cis	rs10504229	0.636	rs77691549	chr8:58055126	G/T	cg26174226	chr8:58114915	NA	-0.57	-7.8	-0.34	4.04e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17767392	0.595	rs59985720	chr14:71651342	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.97	-0.31	1.12e-11	Mitral valve prolapse;
LGG	cis	rs742614	0.533	rs6059496	chr20:32446931	T/C	cg06304546	chr20:32448765	NA	-0.71	-13.98	-0.54	2.63e-37	Stearic acid (18:0) levels;
LGG	cis	rs10504229	1.000	rs10504229	chr8:58196495	A/G	cg11062466	chr8:58055876	NA	0.48	7.87	0.34	2.53e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7940866	0.804	rs10894289	chr11:130808685	C/T	cg12179176	chr11:130786555	SNX19	0.77	14.81	0.57	6.81e-41	Schizophrenia;
LGG	cis	rs8060686	0.641	rs73598006	chr16:68074454	C/G	cg27539214	chr16:67997921	SLC12A4	-0.43	-6.89	-0.3	1.88e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7824557	0.547	rs2736287	chr8:11228006	G/A	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.75	-0.3	4.35e-11	Retinal vascular caliber;
LGG	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.8	-0.3	3.21e-11	Migraine;Coronary artery disease;
LGG	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg23335576	chr14:104009727	NA	0.42	7.01	0.31	8.44e-12	Reticulocyte count;
LGG	cis	rs9911578	0.835	rs9889419	chr17:56473259	C/T	cg12560992	chr17:57184187	TRIM37	0.79	13.55	0.53	1.79e-35	Intelligence (multi-trait analysis);
LGG	cis	rs60843830	1.000	rs7595075	chr2:264019	C/A	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.43	0.36	4.53e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs734999	0.545	rs6666788	chr1:2567500	A/G	cg15627072	chr1:2432621	PLCH2	-0.35	-7.97	-0.35	1.23e-14	Ulcerative colitis;
LGG	cis	rs1345301	0.935	rs11691721	chr2:102876679	G/A	cg05295703	chr2:102895712	NA	0.38	7.73	0.34	6.89e-14	Waist circumference;
LGG	trans	rs453301	0.682	rs2929451	chr8:9085295	A/T	cg21775007	chr8:11205619	TDH	0.42	6.96	0.31	1.14e-11	Joint mobility (Beighton score);
LGG	cis	rs929354	0.772	rs3802118	chr7:156986814	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.37	-0.32	7.68e-13	Body mass index;
LGG	cis	rs8014204	0.804	rs2241274	chr14:75251331	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.38	-7.09	-0.31	4.92e-12	Caffeine consumption;
LGG	trans	rs3780486	0.505	rs10758194	chr9:33157419	G/T	cg20290983	chr6:43655470	MRPS18A	0.83	16.16	0.6	6.57e-47	IgG glycosylation;
LGG	cis	rs13108904	0.775	rs2279282	chr4:1216033	G/C	cg20887711	chr4:1340912	KIAA1530	0.46	8.1	0.35	5.1e-15	Obesity-related traits;
LGG	cis	rs16854884	1.000	rs58251824	chr3:143786258	T/C	cg06585982	chr3:143692056	C3orf58	0.53	8.31	0.36	1.08e-15	Economic and political preferences (feminism/equality);
LGG	trans	rs61931739	0.500	rs11519398	chr12:34473553	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.26	0.52	2.92e-34	Morning vs. evening chronotype;
LGG	cis	rs151997	0.925	rs26089	chr5:50172251	A/G	cg06027927	chr5:50259733	NA	-0.67	-10.98	-0.45	4.3e-25	Callous-unemotional behaviour;
LGG	cis	rs1218582	0.741	rs4339857	chr1:154888962	A/G	cg03351412	chr1:154909251	PMVK	0.67	13.01	0.52	3.47e-33	Prostate cancer;
LGG	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg00334542	chr7:100209784	MOSPD3	-0.55	-7.53	-0.33	2.6e-13	Other erythrocyte phenotypes;
LGG	cis	rs9875589	0.957	rs1579551	chr3:13945571	C/G	cg19554555	chr3:13937349	NA	-0.71	-13.72	-0.54	3.37e-36	Ovarian reserve;
LGG	cis	rs6088580	0.634	rs6088475	chr20:32964987	T/C	cg08999081	chr20:33150536	PIGU	-0.39	-9.85	-0.42	6.67e-21	Glomerular filtration rate (creatinine);
LGG	cis	rs4481887	0.927	rs4916121	chr1:248432003	C/T	cg01631408	chr1:248437212	OR2T33	-0.56	-10.16	-0.43	5.12e-22	Common traits (Other);
LGG	cis	rs2880765	0.835	rs7180923	chr15:86050890	A/T	cg10818794	chr15:86012489	AKAP13	-0.37	-7.97	-0.35	1.25e-14	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs75585481	chr8:58192202	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.55	-0.53	1.76e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg06873352	chr17:61820015	STRADA	-0.6	-10.31	-0.43	1.42e-22	Prudent dietary pattern;
LGG	cis	rs686320	0.748	rs481335	chr11:65207469	T/C	cg17392047	chr11:65247138	NA	0.51	6.76	0.3	4.26e-11	Hip circumference adjusted for BMI;
LGG	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.19e-16	Aortic root size;
LGG	cis	rs2249694	0.960	rs8192776	chr10:135348187	T/C	cg20169779	chr10:135381914	SYCE1	0.53	8.02	0.35	8.87e-15	Obesity-related traits;
LGG	cis	rs1978968	1.000	rs13057203	chr22:18446024	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.36	-0.5	1.58e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs1790761	0.505	rs7938563	chr11:67304131	A/G	cg14500267	chr11:67383377	NA	-0.38	-6.67	-0.3	7.45e-11	Mean corpuscular volume;
LGG	cis	rs780096	0.545	rs6716894	chr2:27583273	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.28	-7.11	-0.31	4.37e-12	Total body bone mineral density;
LGG	cis	rs12477438	0.798	rs6705583	chr2:99602625	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.05	-18.68	-0.66	1.83e-58	Chronic sinus infection;
LGG	cis	rs12188164	0.515	rs17562461	chr5:411361	C/T	cg21972741	chr5:435613	AHRR	0.46	7.99	0.35	1.05e-14	Cystic fibrosis severity;
LGG	cis	rs12477438	0.520	rs13798	chr2:99813614	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.15	0.62	2.2e-51	Chronic sinus infection;
LGG	cis	rs926392	0.547	rs8118808	chr20:37674996	C/G	cg16355469	chr20:37678765	NA	0.63	9.94	0.42	3.02e-21	Dialysis-related mortality;
LGG	cis	rs10791323	0.569	rs2282601	chr11:133712594	C/G	cg06766960	chr11:133703094	NA	-0.56	-11.09	-0.46	1.66e-25	Childhood ear infection;
LGG	cis	rs3106136	0.967	rs17310266	chr4:95177051	T/C	cg11021082	chr4:95130006	SMARCAD1	-0.47	-8.21	-0.36	2.25e-15	Capecitabine sensitivity;
LGG	cis	rs12497850	0.805	rs11130176	chr3:48844077	A/G	cg07636037	chr3:49044803	WDR6	1.1	27.96	0.79	1.75e-101	Parkinson's disease;
LGG	cis	rs6977660	0.714	rs7798760	chr7:19803487	T/C	cg05791153	chr7:19748676	TWISTNB	0.75	10.29	0.43	1.6400000000000001e-22	Thyroid stimulating hormone;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.38	7.53	0.33	2.66e-13	Schizophrenia;
LGG	cis	rs9814567	0.537	rs9879993	chr3:134162559	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.52	9.35	0.4	3.62e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs701145	0.938	rs789380	chr3:154081424	G/A	cg17054900	chr3:154042577	DHX36	0.98	12.27	0.5	3.53e-30	Coronary artery disease;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg05552183	chr6:42928497	GNMT	0.44	12.98	0.52	4.32e-33	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs71403859	0.502	rs34766979	chr16:71475511	G/A	cg08717414	chr16:71523259	ZNF19	-1.36	-17.74	-0.64	4.41e-54	Post bronchodilator FEV1;
LGG	cis	rs5769765	0.862	rs9616385	chr22:50313124	C/T	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	7.65e-13	Schizophrenia;
LGG	cis	rs798554	0.567	rs1182192	chr7:2869274	G/A	cg27476859	chr7:2772710	GNA12	0.52	10.13	0.43	6.62e-22	Height;
LGG	cis	rs1023500	0.551	rs133371	chr22:42465574	G/A	cg04733989	chr22:42467013	NAGA	0.57	10.18	0.43	4.26e-22	Schizophrenia;
LGG	cis	rs2013441	0.508	rs4350625	chr17:19980665	C/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg23461800	chr14:103021989	NA	0.52	8.21	0.36	2.29e-15	Platelet count;
LGG	cis	rs10479542	0.784	rs6896940	chr5:178985994	G/C	cg26516362	chr5:178986906	RUFY1	0.46	8.25	0.36	1.71e-15	Lung cancer;
LGG	trans	rs1814175	0.645	rs1721995	chr11:49915488	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.56	-0.67	1.56e-62	Height;
LGG	trans	rs8002861	0.664	rs895266	chr13:44461179	T/C	cg12856521	chr11:46389249	DGKZ	0.55	9.99	0.42	2.11e-21	Leprosy;
LGG	cis	rs10883723	0.810	rs7912901	chr10:104277440	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg11764359	chr7:65958608	NA	-0.69	-11.87	-0.48	1.46e-28	Aortic root size;
LGG	cis	rs2842992	0.830	rs2758312	chr6:160153452	G/A	cg27624424	chr6:160112604	SOD2	0.67	9.93	0.42	3.29e-21	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1790761	0.520	rs7124513	chr11:67395714	C/T	cg00864171	chr11:67383662	NA	-0.51	-8.16	-0.35	3.21e-15	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00396520	chr2:70314546	PCBP1	0.47	7.0	0.31	9.05e-12	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.28	-0.4	6.53e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs262150	0.579	rs4481540	chr7:158785846	A/G	cg19418458	chr7:158789849	NA	0.44	7.03	0.31	7.27e-12	Facial morphology (factor 20);
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg01988459	chr11:68622903	NA	-0.63	-12.81	-0.51	2.23e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17122278	0.577	rs537975	chr11:118362869	T/C	cg20110707	chr11:118481992	PHLDB1	0.46	7.2	0.32	2.44e-12	Total cholesterol levels;
LGG	cis	rs9487094	0.961	rs7773095	chr6:109727077	G/T	cg16315928	chr6:109776240	MICAL1	-0.55	-9.35	-0.4	3.81e-19	Height;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg02353165	chr6:42928485	GNMT	0.48	14.43	0.56	3.04e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs6964587	1.000	rs6956596	chr7:91750107	T/G	cg17063962	chr7:91808500	NA	0.52	9.33	0.4	4.57e-19	Breast cancer;
LGG	cis	rs4959677	0.901	rs9328100	chr6:2480664	G/T	cg20147862	chr6:2634573	C6orf195	-0.41	-9.0	-0.39	5.85e-18	Orthostatic hypotension;
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.83	-0.59	1.91e-45	Skin colour saturation;
LGG	cis	rs4625783	0.583	rs11077974	chr17:80095193	A/G	cg19223190	chr17:80058835	NA	0.44	8.57	0.37	1.51e-16	Blood metabolite levels;
LGG	cis	rs738322	0.553	rs28565947	chr22:38570775	C/G	cg03162506	chr22:38580953	NA	0.41	10.19	0.43	3.89e-22	Cutaneous nevi;
LGG	cis	rs28735056	0.875	rs62103181	chr18:77625652	A/G	cg20368463	chr18:77673604	PQLC1	0.43	7.53	0.33	2.59e-13	Schizophrenia;
LGG	cis	rs2072438	0.503	rs10739590	chr9:123871481	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.43	7.67	0.34	1e-13	Rheumatoid arthritis;
LGG	cis	rs9814567	0.929	rs1863912	chr3:134205227	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-12.99	-0.52	3.91e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7619833	0.719	rs490706	chr3:27330615	G/A	cg02860705	chr3:27208620	NA	0.39	7.5	0.33	3.25e-13	Breast cancer;
LGG	cis	rs4988958	0.565	rs1420100	chr2:103037002	C/A	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs6952808	0.692	rs6950627	chr7:2086672	C/T	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.74	-0.34	6.36e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.82	0.34	3.67e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs597539	0.652	rs636049	chr11:68667198	A/C	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.36	0.61	8.02e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9322193	0.886	rs17672976	chr6:150097343	T/A	cg13206674	chr6:150067644	NUP43	0.64	14.49	0.56	1.62e-39	Lung cancer;
LGG	cis	rs9362426	0.708	rs6907825	chr6:88102822	C/T	cg06087457	chr6:88040249	C6orf162;GJB7	0.41	8.06	0.35	6.48e-15	Depressive episodes in bipolar disorder;
LGG	cis	rs2836974	0.644	rs1882779	chr21:40690938	T/C	cg06238570	chr21:40685208	BRWD1	-0.52	-8.49	-0.37	2.79e-16	Cognitive function;
LGG	cis	rs6582630	0.519	rs11182021	chr12:38443709	A/T	cg13010199	chr12:38710504	ALG10B	-0.64	-13.5	-0.53	2.89e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1065852	0.526	rs12166549	chr22:42410419	T/C	cg15128208	chr22:42549153	NA	0.42	7.14	0.31	3.69e-12	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs10892173	0.566	rs2298649	chr11:117672225	A/G	cg21640587	chr11:117668038	DSCAML1	0.95	15.67	0.59	1.07e-44	Myopia;
LGG	cis	rs9311474	0.508	rs6786043	chr3:52604861	A/G	cg14092988	chr3:52407081	DNAH1	0.3	8.1	0.35	4.88e-15	Electroencephalogram traits;
LGG	cis	rs17227506	0.529	rs13258748	chr8:13470909	A/T	cg03566418	chr8:13424080	C8orf48	-0.56	-8.46	-0.37	3.63e-16	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1152591	0.624	rs1266927	chr14:64651663	C/A	cg21174375	chr14:64681225	SYNE2	0.4	7.54	0.33	2.42e-13	Atrial fibrillation;
LGG	trans	rs17685	0.712	rs10235086	chr7:75833138	G/T	cg19862616	chr7:65841803	NCRNA00174	1.04	23.64	0.74	1.25e-81	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs6496667	0.533	rs2074584	chr15:91009381	C/T	cg22089800	chr15:90895588	ZNF774	0.52	8.45	0.37	3.88e-16	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs17032414	chr3:10158302	C/G	cg13047869	chr3:10149882	C3orf24	0.53	9.08	0.39	3.19e-18	Alzheimer's disease;
LGG	cis	rs9329221	0.537	rs6601414	chr8:9976748	G/A	cg19847130	chr8:10466454	RP1L1	-0.32	-6.83	-0.3	2.6e-11	Neuroticism;
LGG	cis	rs240764	0.817	rs240113	chr6:101058886	G/A	cg09795085	chr6:101329169	ASCC3	0.45	7.59	0.33	1.83e-13	Neuroticism;
LGG	cis	rs10911363	0.549	rs12742245	chr1:183446922	T/A	cg23894439	chr1:183413866	NA	0.5	9.3	0.4	5.64e-19	Systemic lupus erythematosus;
LGG	cis	rs6793245	0.810	rs9843500	chr3:38588095	G/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.51	-8.51	-0.37	2.48e-16	QT interval;
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg22903471	chr2:27725779	GCKR	-0.57	-12.94	-0.52	6.7e-33	Total body bone mineral density;
LGG	cis	rs2050392	0.517	rs160018	chr10:30772703	T/C	cg25182066	chr10:30743637	MAP3K8	-0.63	-12.75	-0.51	3.86e-32	Inflammatory bowel disease;
LGG	cis	rs798554	0.723	rs798518	chr7:2777825	A/G	cg14668632	chr7:2872130	GNA12	-0.36	-7.26	-0.32	1.68e-12	Height;
LGG	cis	rs2274273	0.967	rs8013027	chr14:55610940	C/G	cg04306507	chr14:55594613	LGALS3	0.64	18.05	0.64	1.51e-55	Protein biomarker;
LGG	cis	rs950169	0.959	rs66801143	chr15:84736657	C/T	cg24253500	chr15:84953950	NA	0.59	10.84	0.45	1.45e-24	Schizophrenia;
LGG	cis	rs7927592	0.956	rs7126340	chr11:68257293	C/T	cg16797656	chr11:68205561	LRP5	0.39	6.9	0.31	1.76e-11	Total body bone mineral density;
LGG	cis	rs11190604	1.000	rs2295779	chr10:102296061	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.44	0.33	4.79e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs854037	0.698	rs11738474	chr5:57065232	T/G	cg08523694	chr5:57076192	NA	0.49	6.88	0.3	1.94e-11	Birth weight;
LGG	cis	rs826838	0.654	rs7977738	chr12:38722460	G/A	cg04568710	chr12:38710424	ALG10B	0.4	8.46	0.37	3.52e-16	Heart rate;
LGG	cis	rs17453880	0.929	rs7725525	chr5:152041960	C/G	cg12297329	chr5:152029980	NA	0.92	23.8	0.74	2.33e-82	Subjective well-being;
LGG	cis	rs2841277	0.708	rs28600075	chr14:105408315	T/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.69	-0.34	8.95e-14	Rheumatoid arthritis;
LGG	cis	rs3733585	0.699	rs6844316	chr4:9958977	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2013441	0.508	rs11869931	chr17:19975070	G/T	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs4631830	0.720	rs2611475	chr10:51503178	G/A	cg10326726	chr10:51549505	MSMB	-0.61	-12.24	-0.49	4.69e-30	Prostate-specific antigen levels;
LGG	cis	rs4642101	0.765	rs9872103	chr3:12827452	G/T	cg24848339	chr3:12840334	CAND2	0.41	9.33	0.4	4.57e-19	QRS complex (12-leadsum);
LGG	cis	rs2282300	0.739	rs1717772	chr11:30340133	C/T	cg25418670	chr11:30344373	C11orf46	-0.56	-7.85	-0.34	2.9e-14	Morning vs. evening chronotype;
LGG	cis	rs1065852	0.906	rs5751232	chr22:42564304	C/T	cg15128208	chr22:42549153	NA	0.75	11.4	0.47	1.08e-26	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.19e-19	Fuchs's corneal dystrophy;
LGG	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg18478394	chr8:109455254	TTC35	0.42	8.38	0.36	6.41e-16	Dupuytren's disease;
LGG	cis	rs7044106	0.791	rs12554440	chr9:123485333	T/C	cg13959647	chr9:123605229	PSMD5;LOC253039	0.43	6.86	0.3	2.15e-11	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.829	rs1877317	chr17:61776479	T/C	cg07659893	chr17:61819838	STRADA	0.5	8.29	0.36	1.25e-15	Prudent dietary pattern;
LGG	cis	rs36051895	0.589	rs62543573	chr9:5201675	A/G	cg02405213	chr9:5042618	JAK2	-0.77	-13.56	-0.53	1.69e-35	Pediatric autoimmune diseases;
LGG	cis	rs9611565	0.694	rs5758411	chr22:42079734	G/A	cg06634786	chr22:41940651	POLR3H	0.67	10.82	0.45	1.76e-24	Vitiligo;
LGG	cis	rs80282103	0.618	rs1079389	chr10:1161980	A/G	cg08668510	chr10:1095578	IDI1	0.74	7.29	0.32	1.33e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs7395662	0.547	rs10769442	chr11:48765027	C/T	cg15704280	chr7:45808275	SEPT13	-0.49	-7.99	-0.35	1.06e-14	HDL cholesterol;
LGG	trans	rs9325144	0.556	rs34565156	chr12:39028239	G/A	cg06521331	chr12:34319734	NA	0.4	6.76	0.3	4.29e-11	Morning vs. evening chronotype;
LGG	cis	rs763014	0.932	rs34498660	chr16:666149	A/G	cg08989290	chr16:615782	NHLRC4	0.33	6.68	0.3	6.87e-11	Height;
LGG	cis	rs6815814	0.861	rs4833095	chr4:38799710	T/C	cg06935464	chr4:38784597	TLR10	0.51	8.27	0.36	1.47e-15	Breast cancer;
LGG	cis	rs559928	0.692	rs876064	chr11:64037033	G/A	cg05555928	chr11:63887634	MACROD1	-0.67	-9.24	-0.39	8.85e-19	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs9547996	0.879	rs2007577	chr13:38191143	T/C	cg13634560	chr13:38173852	POSTN	-0.34	-6.79	-0.3	3.56e-11	Diastolic blood pressure;
LGG	cis	rs2404602	0.735	rs2048856	chr15:76800083	C/T	cg15268244	chr15:77196840	NA	0.42	9.04	0.39	4.42e-18	Blood metabolite levels;
LGG	cis	rs6951245	0.935	rs112554101	chr7:1065535	A/G	cg03188948	chr7:1209495	NA	0.51	7.24	0.32	1.94e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7811142	0.666	rs28401739	chr7:99905684	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.6	0.37	1.28e-16	Platelet count;
LGG	cis	rs17208368	0.628	rs35752525	chr16:55095972	C/T	cg09947736	chr16:55091198	NA	0.67	12.55	0.5	2.68e-31	Hypospadias;
LGG	trans	rs11098499	1.000	rs6837898	chr4:120179154	C/T	cg25214090	chr10:38739885	LOC399744	0.64	11.58	0.47	2.06e-27	Corneal astigmatism;
LGG	cis	rs3785574	0.925	rs2727340	chr17:61970224	T/A	cg07677032	chr17:61819896	STRADA	0.42	6.65	0.3	8.32e-11	Height;
LGG	cis	rs10504229	0.683	rs11786843	chr8:58133629	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.47	-0.44	3.67e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2742417	1.000	rs2673051	chr3:45732409	G/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.49	-0.33	3.63e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2832191	0.626	rs2254796	chr21:30341891	A/G	cg24692254	chr21:30365293	RNF160	-1.01	-27.12	-0.78	1.19e-97	Dental caries;
LGG	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg06636001	chr8:8085503	FLJ10661	0.55	10.15	0.43	5.24e-22	Retinal vascular caliber;
LGG	cis	rs4363385	0.818	rs532773	chr1:153011750	T/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs17428076	0.536	rs62182438	chr2:172796774	A/T	cg21435375	chr2:172878103	MAP1D	0.38	8.39	0.36	5.87e-16	Myopia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26374823	chr8:15398053	TUSC3	0.42	7.85	0.34	2.9e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs561341	1.000	rs111454793	chr17:30319267	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7618501	0.966	rs13085679	chr3:49869631	G/A	cg24110177	chr3:50126178	RBM5	-0.41	-7.01	-0.31	8.36e-12	Intelligence (multi-trait analysis);
LGG	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg04398451	chr17:18023971	MYO15A	0.75	16.08	0.6	1.47e-46	Total body bone mineral density;
LGG	trans	rs2243480	1.000	rs3885839	chr7:65290403	G/T	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs10504229	0.683	rs11786523	chr8:58131319	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs6582630	0.538	rs12304844	chr12:38335870	C/T	cg06521331	chr12:34319734	NA	0.45	7.98	0.35	1.15e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2760061	0.626	rs634106	chr1:228121548	C/T	cg18477163	chr1:228402036	OBSCN	-0.27	-7.3	-0.32	1.3e-12	Diastolic blood pressure;
LGG	cis	rs4144743	1.000	rs4144745	chr17:45323349	T/C	cg18085866	chr17:45331354	ITGB3	-0.78	-9.87	-0.42	5.56e-21	Body mass index;
LGG	cis	rs657075	0.697	rs78003854	chr5:131760389	T/C	cg06968155	chr5:131705112	SLC22A5	0.68	7.75	0.34	5.93e-14	Rheumatoid arthritis;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06112835	chr11:68658793	MRPL21	0.62	10.36	0.43	9.35e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg14689365	chr7:158441557	NCAPG2	-0.58	-9.57	-0.41	6.36e-20	Height;
LGG	trans	rs10838798	0.563	rs4752894	chr11:48120936	G/A	cg15704280	chr7:45808275	SEPT13	-0.43	-6.74	-0.3	4.6e-11	Height;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs6714710	0.603	rs13023980	chr2:98502987	T/C	cg26665480	chr2:98280029	ACTR1B	0.59	9.47	0.4	1.4e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs2576037	0.796	rs2571032	chr18:44578250	T/A	cg19077165	chr18:44547161	KATNAL2	0.53	9.69	0.41	2.47e-20	Personality dimensions;
LGG	cis	rs1790761	0.967	rs10274	chr11:67202826	G/A	cg00864171	chr11:67383662	NA	-0.41	-6.74	-0.3	4.84e-11	Mean corpuscular volume;
LGG	cis	rs4742903	1.000	rs4742906	chr9:106857078	A/G	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1152591	0.543	rs1152590	chr14:64681193	C/T	cg21174375	chr14:64681225	SYNE2	0.44	8.26	0.36	1.59e-15	Atrial fibrillation;
LGG	cis	rs6684428	1.000	rs58538058	chr1:56370474	G/A	cg11651538	chr1:56320950	NA	-0.75	-12.82	-0.51	2.04e-32	Airflow obstruction;
LGG	cis	rs9596863	0.898	rs7984502	chr13:54344640	T/C	ch.13.53330881F	chr13:54432880	NA	0.53	7.16	0.32	3.15e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs1816752	0.783	rs7317712	chr13:24985503	C/T	cg22771759	chr13:24902376	NA	0.42	7.0	0.31	8.93e-12	Obesity-related traits;
LGG	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg13902645	chr11:5959945	NA	-0.66	-10.3	-0.43	1.59e-22	DNA methylation (variation);
LGG	cis	rs60843830	0.661	rs7588043	chr2:104979	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.32	0.4	4.75e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6952808	1.000	rs10233560	chr7:1885415	T/C	cg21782813	chr7:2030301	MAD1L1	0.45	10.34	0.43	1.11e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs4843747	0.749	rs8053309	chr16:88044980	G/A	cg26811252	chr16:29126840	RRN3P2	0.64	9.41	0.4	2.36e-19	Menopause (age at onset);
LGG	cis	rs9467773	0.620	rs2494696	chr6:26620894	A/G	cg11502198	chr6:26597334	ABT1	0.7	12.93	0.52	7.18e-33	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	1.000	rs72793812	chr16:28840381	A/G	cg00204512	chr16:28754710	NA	0.26	7.16	0.32	3.24e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6500395	0.962	rs11647046	chr16:48623217	T/C	cg04672837	chr16:48644449	N4BP1	0.53	8.61	0.37	1.13e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg08344181	chr3:125677491	NA	-0.56	-7.28	-0.32	1.45e-12	Depression;
LGG	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg09904177	chr6:26538194	HMGN4	0.38	6.83	0.3	2.69e-11	Schizophrenia;
LGG	cis	rs72945132	0.882	rs11235953	chr11:70184937	C/T	cg14088196	chr11:70211408	PPFIA1	0.93	13.1	0.52	1.39e-33	Coronary artery disease;
LGG	cis	rs11122272	0.735	rs2790891	chr1:231513190	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	cis	rs9815354	1.000	rs11923562	chr3:41760331	G/T	cg03022575	chr3:42003672	ULK4	0.6	7.42	0.33	5.63e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7312933	0.576	rs11181364	chr12:42567800	C/T	cg19980929	chr12:42632907	YAF2	0.36	7.97	0.35	1.23e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7666738	0.830	rs11727235	chr4:98946331	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1348850	0.645	rs11889272	chr2:178432378	C/T	cg27490568	chr2:178487706	NA	0.74	12.94	0.52	6.84e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4262150	0.667	rs4246037	chr5:152249065	C/T	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	trans	rs931812	0.825	rs34153562	chr8:101893441	T/C	cg20993868	chr7:22813445	NA	0.69	12.88	0.51	1.12e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs910316	0.967	rs11624893	chr14:75660124	A/G	cg11812906	chr14:75593930	NEK9	-0.51	-9.44	-0.4	1.76e-19	Height;
LGG	cis	rs7582720	1.000	rs115810193	chr2:203943168	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.77	9.4	0.4	2.58e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs2229238	0.911	rs73023339	chr1:154510852	C/T	cg10237817	chr1:154519846	TDRD10	0.34	6.88	0.3	1.99e-11	Coronary heart disease;
LGG	cis	rs4851266	1.000	rs4851268	chr2:100825864	C/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs68170813	0.559	rs10953531	chr7:106827867	A/G	cg02696742	chr7:106810147	HBP1	0.77	11.16	0.46	9.11e-26	Coronary artery disease;
LGG	cis	rs868036	0.681	rs4776978	chr15:68108305	A/G	cg05925327	chr15:68127851	NA	-0.38	-7.82	-0.34	3.48e-14	Restless legs syndrome;
LGG	cis	rs7582180	0.652	rs11678158	chr2:100932297	T/C	cg21926883	chr2:100939477	LONRF2	-0.7	-16.61	-0.61	6.06e-49	Intelligence (multi-trait analysis);
LGG	cis	rs4330281	0.631	rs6789467	chr3:17802134	G/C	cg20981856	chr3:17787350	NA	-0.39	-7.03	-0.31	7.21e-12	Schizophrenia;
LGG	cis	rs11252926	0.627	rs10751997	chr10:561952	C/T	cg18196295	chr10:418757	DIP2C	0.54	10.18	0.43	4.2e-22	Psychosis in Alzheimer's disease;
LGG	cis	rs11096990	0.634	rs1451818	chr4:39258771	G/A	cg24403649	chr4:39172243	NA	0.38	6.81	0.3	3.07e-11	Cognitive function;
LGG	cis	rs2439831	0.850	rs16963953	chr15:44081719	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	10.62	0.44	1e-23	Lung cancer in ever smokers;
LGG	cis	rs4692589	0.802	rs1480542	chr4:170953614	C/T	cg19918862	chr4:170955249	NA	0.44	8.64	0.37	9.07e-17	Anxiety disorder;
LGG	cis	rs1218582	0.772	rs10908445	chr1:154849590	A/G	cg16680214	chr1:154839983	KCNN3	0.48	9.48	0.4	1.34e-19	Prostate cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11877577	chr6:133135687	RPS12;SNORD101	0.49	8.07	0.35	6.22e-15	Cognitive performance;
LGG	cis	rs9902453	0.704	rs2617874	chr17:28085172	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.85	0.54	9.33e-37	Coffee consumption (cups per day);
LGG	cis	rs657075	0.527	rs13180169	chr5:131705526	G/T	cg07538946	chr5:131705188	SLC22A5	0.67	7.85	0.34	2.89e-14	Rheumatoid arthritis;
LGG	cis	rs1267303	0.798	rs1267302	chr1:46990545	G/C	cg16387850	chr1:46982889	NA	0.32	7.3	0.32	1.29e-12	Monobrow;
LGG	cis	rs9381040	0.655	rs2268188	chr6:41042590	T/G	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.68	-0.3	6.83e-11	Alzheimer's disease (late onset);
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg01059449	chr18:44338099	ST8SIA5	-0.34	-7.39	-0.32	7.14e-13	Personality dimensions;
LGG	cis	rs9399135	0.967	rs4895436	chr6:135295001	G/A	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.57e-19	Red blood cell count;
LGG	cis	rs6696846	0.729	rs72757512	chr1:205079203	G/A	cg00857998	chr1:205179979	DSTYK	0.55	8.95	0.38	8.97e-18	Red blood cell count;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg06916706	chr16:4465613	CORO7	-0.83	-14.65	-0.56	3.19e-40	Schizophrenia;
LGG	trans	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg12856521	chr11:46389249	DGKZ	0.44	7.64	0.33	1.23e-13	Leprosy;
LGG	cis	rs11583043	1.000	rs12567858	chr1:101517688	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.42	7.76	0.34	5.43e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.58	-0.41	6.1e-20	Schizophrenia;
LGG	cis	rs2594989	0.837	rs2922348	chr3:11309784	T/C	cg00170343	chr3:11313890	ATG7	0.53	6.66	0.3	7.91e-11	Circulating chemerin levels;
LGG	cis	rs6840360	0.516	rs6535794	chr4:152302783	G/T	cg17217059	chr4:152329364	FAM160A1	0.2	6.97	0.31	1.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs34929064	1.000	rs6980465	chr7:22724533	C/T	cg18045685	chr7:22629474	NA	0.56	8.94	0.38	9.02e-18	Major depression and alcohol dependence;
LGG	cis	rs796364	0.806	rs1509832	chr2:200874443	G/T	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.58e-12	Schizophrenia;
LGG	cis	rs826838	1.000	rs1684416	chr12:39130301	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs6724607	1.000	rs6724607	chr2:191466532	C/T	cg27211696	chr2:191398769	TMEM194B	0.4	9.24	0.39	8.86e-19	Pulse pressure;
LGG	cis	rs6500602	0.727	rs55939215	chr16:4541390	C/G	cg01673284	chr16:4527211	HMOX2	0.33	6.82	0.3	2.84e-11	Schizophrenia;
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg17691542	chr6:26056736	HIST1H1C	0.59	10.47	0.44	3.63e-23	Height;
LGG	cis	rs13118159	0.550	rs11941200	chr4:1369093	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.77	0.34	5.03e-14	Longevity;
LGG	cis	rs1008375	0.900	rs4698622	chr4:17589557	C/T	cg16339924	chr4:17578868	LAP3	0.67	11.41	0.47	9.75e-27	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs875971	0.660	rs10281080	chr7:66042441	T/C	cg18876405	chr7:65276391	NA	-0.63	-11.92	-0.48	9.18e-29	Aortic root size;
LGG	cis	rs911263	0.961	rs8008961	chr14:68752643	A/G	cg18825221	chr14:68749962	RAD51L1	0.51	10.84	0.45	1.44e-24	Primary biliary cholangitis;
LGG	cis	rs295140	0.507	rs4673814	chr2:201108133	G/A	cg17644776	chr2:200775616	C2orf69	-0.47	-7.73	-0.34	6.64e-14	QT interval;
LGG	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.1	0.42	8.3e-22	Motion sickness;
LGG	cis	rs2228479	0.850	rs11076624	chr16:89855749	T/C	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25187227	chr4:40058080	N4BP2;LOC344967	0.42	6.74	0.3	4.73e-11	Cognitive performance;
LGG	cis	rs17030434	0.953	rs11099905	chr4:154686183	A/G	cg14289246	chr4:154710475	SFRP2	0.67	10.3	0.43	1.59e-22	Electrocardiographic conduction measures;
LGG	cis	rs9677476	0.909	rs7562116	chr2:232108246	A/G	cg23338755	chr2:231921595	PSMD1	0.47	7.03	0.31	7.51e-12	Food antigen IgG levels;
LGG	cis	rs7717393	0.786	rs10044891	chr5:155781866	G/A	cg04435420	chr5:155754009	SGCD	0.71	9.22	0.39	1.03e-18	Egg allergy;
LGG	cis	rs17270561	0.609	rs4712968	chr6:25760344	T/C	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs611744	0.538	rs59930666	chr8:109262296	T/C	cg18478394	chr8:109455254	TTC35	0.47	9.69	0.41	2.35e-20	Dupuytren's disease;
LGG	cis	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg14541582	chr5:601475	NA	-0.71	-11.1	-0.46	1.54e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs11748327	0.919	rs7706161	chr5:4047892	A/G	cg01025095	chr5:4101132	NA	-0.55	-9.07	-0.39	3.41e-18	Myocardial infarction;
LGG	trans	rs7939886	0.764	rs1552142	chr11:56087538	T/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs2836950	0.565	rs7279497	chr21:40531306	A/G	cg11644478	chr21:40555479	PSMG1	0.58	9.61	0.41	4.54e-20	Menarche (age at onset);
LGG	trans	rs2898290	0.617	rs13278965	chr8:11466745	A/T	cg06636001	chr8:8085503	FLJ10661	0.5	9.25	0.39	8.42e-19	Systolic blood pressure;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg16405210	chr4:1374714	KIAA1530	-0.45	-7.67	-0.34	1.04e-13	Obesity-related traits;
LGG	cis	rs763121	1.000	rs138464	chr22:38906432	C/T	cg06022373	chr22:39101656	GTPBP1	-0.81	-16.08	-0.6	1.54e-46	Menopause (age at onset);
LGG	cis	rs6735179	0.648	rs6706107	chr2:1761661	C/A	cg20570797	chr2:1712800	PXDN	-0.45	-8.18	-0.36	2.75e-15	Response to antipsychotic treatment;
LGG	cis	rs7586879	0.828	rs1968482	chr2:25086858	T/C	cg04586622	chr2:25135609	ADCY3	0.35	8.52	0.37	2.3e-16	Body mass index;
LGG	cis	rs28386778	0.700	rs4968672	chr17:62011352	G/A	cg02127607	chr17:61920694	SMARCD2	-0.4	-6.93	-0.31	1.39e-11	Prudent dietary pattern;
LGG	cis	rs1775715	0.707	rs2799019	chr10:32142850	C/T	cg14930904	chr10:32216787	ARHGAP12	0.36	7.07	0.31	5.88e-12	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs13108904	0.934	rs4974596	chr4:1301052	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.07	0.42	1.05e-21	Obesity-related traits;
LGG	cis	rs2587949	0.615	rs2686702	chr3:4190452	C/T	cg16519197	chr3:4211558	NA	-0.33	-6.84	-0.3	2.58e-11	Periodontitis (DPAL);
LGG	cis	rs6840360	0.642	rs2709825	chr4:152365563	C/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7572733	0.967	rs2196171	chr2:198889807	T/G	cg00792783	chr2:198669748	PLCL1	0.45	7.48	0.33	3.84e-13	Dermatomyositis;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg07701084	chr6:150067640	NUP43	0.64	11.9	0.48	1.14e-28	Lung cancer;
LGG	trans	rs2400749	0.685	rs2400744	chr14:100026717	A/C	cg16638793	chr11:134176850	GLB1L3	-0.34	-6.82	-0.3	2.83e-11	Alzheimer's disease (survival time);
LGG	cis	rs6546537	1.000	rs12478540	chr2:69844524	C/T	cg10773587	chr2:69614142	GFPT1	-0.45	-7.6	-0.33	1.68e-13	Serum thyroid-stimulating hormone levels;
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg07701084	chr6:150067640	NUP43	-0.47	-6.98	-0.31	1.02e-11	Lung cancer;
LGG	cis	rs10504229	0.906	rs59336968	chr8:58176857	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17453880	0.929	rs11951715	chr5:151953104	A/G	cg10931792	chr5:152022470	NA	0.38	8.22	0.36	2.07e-15	Subjective well-being;
LGG	cis	rs62400317	0.859	rs10456549	chr6:45225761	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.3	-0.43	1.48e-22	Total body bone mineral density;
LGG	trans	rs61931739	0.782	rs7969373	chr12:34249655	T/G	cg13010199	chr12:38710504	ALG10B	0.46	8.76	0.38	3.7e-17	Morning vs. evening chronotype;
LGG	cis	rs8072100	0.967	rs9894905	chr17:45485982	C/T	cg08085267	chr17:45401833	C17orf57	-0.64	-13.27	-0.52	2.75e-34	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs453301	0.686	rs28482034	chr8:8869664	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.7	-0.34	8.45e-14	Joint mobility (Beighton score);
LGG	cis	rs4853012	0.838	rs4563249	chr2:74354016	G/T	cg05890377	chr2:74357713	NA	0.48	9.74	0.41	1.57e-20	Gestational age at birth (maternal effect);
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg00814883	chr7:100076585	TSC22D4	-0.69	-9.92	-0.42	3.72e-21	Platelet count;
LGG	cis	rs2839186	0.903	rs61182475	chr21:47707050	T/A	cg12379764	chr21:47803548	PCNT	-0.46	-7.73	-0.34	6.87e-14	Testicular germ cell tumor;
LGG	cis	rs4689592	0.513	rs3857177	chr4:7066332	G/A	cg03847636	chr4:7070632	GRPEL1	-0.5	-7.13	-0.31	3.95e-12	Monocyte percentage of white cells;
LGG	cis	rs6951245	1.000	rs111899361	chr7:1112348	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.17	-0.62	1.68e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6743226	0.811	rs12471975	chr2:242154849	C/T	cg10021735	chr2:242295487	FARP2	0.42	7.47	0.33	3.98e-13	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs74054849	0.850	rs10927835	chr1:16034201	A/T	cg05660106	chr1:15850417	CASP9	0.57	6.79	0.3	3.52e-11	Alcoholic chronic pancreatitis;
LGG	cis	rs1451882	0.562	rs12541630	chr8:1072534	C/T	cg07395941	chr8:1078200	NA	0.5	6.88	0.3	1.91e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11722228	0.508	rs73212864	chr4:10104191	G/A	cg26043149	chr18:55253948	FECH	0.95	16.33	0.6	1.16e-47	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1153858	1.000	rs4775909	chr15:45643042	T/C	cg14582100	chr15:45693742	SPATA5L1	0.4	6.71	0.3	5.63e-11	Homoarginine levels;
LGG	cis	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg24189917	chr7:1970923	MAD1L1	-0.61	-8.92	-0.38	1.12e-17	Bipolar disorder;
LGG	cis	rs2153535	0.580	rs4451187	chr6:8473910	C/T	cg07606381	chr6:8435919	SLC35B3	0.69	12.77	0.51	3.18e-32	Motion sickness;
LGG	cis	rs7191439	0.858	rs2290902	chr16:88782676	A/G	cg27087555	chr16:88793112	FAM38A	-1.46	-18.81	-0.66	4.8e-59	Plateletcrit;
LGG	cis	rs7811142	0.943	rs3900792	chr7:100004577	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.18	21.0	0.7	2.85e-69	Platelet count;
LGG	trans	rs61332075	0.518	rs112649209	chr2:239422814	C/G	cg01134436	chr17:81009848	B3GNTL1	0.78	8.6	0.37	1.26e-16	Lung function (FEV1/FVC);
LGG	cis	rs657075	0.697	rs3792880	chr5:131644965	A/C	cg21911579	chr5:131705225	SLC22A5	-0.65	-7.46	-0.33	4.3e-13	Rheumatoid arthritis;
LGG	trans	rs9393777	0.920	rs13195040	chr6:27413924	C/T	cg01620082	chr3:125678407	NA	0.96	9.38	0.4	3.01e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	0.843	rs3849198	chr6:97036539	C/A	cg06623918	chr6:96969491	KIAA0776	-0.77	-11.08	-0.46	1.75e-25	Migraine;Coronary artery disease;
LGG	cis	rs7586879	0.789	rs7560156	chr2:25124794	T/C	cg04586622	chr2:25135609	ADCY3	0.39	9.54	0.41	8.03e-20	Body mass index;
LGG	trans	rs10506458	0.915	rs17687426	chr12:63397900	G/C	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9796	0.621	rs11858678	chr15:41467932	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.08	-0.42	9.49e-22	Menopause (age at onset);
LGG	cis	rs11792861	0.564	rs3816237	chr9:111718348	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.67	11.89	0.48	1.27e-28	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11616271	chr3:49711647	APEH	0.48	7.1	0.31	4.75e-12	Gut microbiome composition (summer);
LGG	cis	rs6909430	0.901	rs1039738	chr6:98747835	A/G	cg12860156	chr6:98744658	NA	-0.45	-7.02	-0.31	8.01e-12	Quantitative traits;
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg25517755	chr10:38738941	LOC399744	-0.38	-7.06	-0.31	6.31e-12	Breast cancer;
LGG	cis	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg24189917	chr7:1970923	MAD1L1	-0.47	-7.9	-0.34	2.03e-14	Bipolar disorder;
LGG	cis	rs12048904	0.512	rs932798	chr1:101249355	G/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	-0.46	-8.76	-0.38	3.68e-17	Multiple sclerosis;
LGG	trans	rs7181230	0.845	rs4923852	chr15:40377865	A/G	cg22705835	chr10:65332833	REEP3	0.46	8.09	0.35	5.46e-15	Dehydroepiandrosterone sulphate levels;
LGG	trans	rs208520	0.754	rs7753158	chr6:66875633	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.88	-0.59	1.2e-45	Exhaled nitric oxide output;
LGG	trans	rs3780486	0.757	rs10121987	chr9:33119818	A/G	cg20290983	chr6:43655470	MRPS18A	1.1	24.51	0.75	1.12e-85	IgG glycosylation;
LGG	cis	rs8060686	0.545	rs12444313	chr16:68254404	A/C	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs4986172	0.690	rs11657325	chr17:43242694	C/T	cg10701640	chr17:43249399	NA	0.43	7.46	0.33	4.29e-13	Height;
LGG	cis	rs1355223	0.867	rs7943755	chr11:34691451	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.46	-0.33	4.26e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs11098499	0.909	rs35111518	chr4:120440682	A/G	cg25214090	chr10:38739885	LOC399744	0.66	11.53	0.47	3.3699999999999996e-27	Corneal astigmatism;
LGG	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.4	0.44	6.67e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7172689	0.908	rs8026245	chr15:81561001	A/G	cg11808699	chr15:81528661	IL16	-0.48	-10.02	-0.42	1.67e-21	Inattentive symptoms;
LGG	cis	rs75229567	0.618	rs77168443	chr12:70208563	G/A	cg10114359	chr12:70132523	RAB3IP	1.38	11.0	0.46	3.6e-25	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs1799949	1.000	rs11657835	chr17:41291953	C/G	cg25072359	chr17:41440525	NA	0.54	10.22	0.43	3e-22	Menopause (age at onset);
LGG	cis	rs12368653	0.789	rs2270777	chr12:58145156	C/T	cg02175503	chr12:58329896	NA	-0.42	-6.97	-0.31	1.12e-11	Multiple sclerosis;
LGG	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg09696939	chr10:60272079	BICC1	0.38	7.4	0.33	6.63e-13	Refractive error;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg09263875	chr16:632152	PIGQ	0.67	13.51	0.53	2.66e-35	Height;
LGG	cis	rs2734839	0.537	rs10891549	chr11:113278447	T/C	cg14159747	chr11:113255604	NA	0.3	8.21	0.36	2.14e-15	Information processing speed;
LGG	cis	rs9560113	0.573	rs7988040	chr13:112226534	C/G	cg10483660	chr13:112241077	NA	0.44	9.03	0.39	4.71e-18	Menarche (age at onset);
LGG	cis	rs2762353	0.526	rs6912391	chr6:25710763	C/G	cg17691542	chr6:26056736	HIST1H1C	-0.4	-7.05	-0.31	6.73e-12	Blood metabolite levels;
LGG	trans	rs1997103	1.000	rs4628219	chr7:55410449	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg22044901	chr15:68126292	NA	-0.44	-7.16	-0.32	3.12e-12	Restless legs syndrome;
LGG	cis	rs17376456	0.877	rs10063045	chr5:93457584	A/T	cg25358565	chr5:93447407	FAM172A	1.38	16.29	0.6	1.64e-47	Diabetic retinopathy;
LGG	cis	rs10504229	0.861	rs6990617	chr8:58182960	G/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2880765	0.710	rs11630457	chr15:86004801	T/C	cg10818794	chr15:86012489	AKAP13	-0.36	-7.52	-0.33	2.87e-13	Coronary artery disease;
LGG	cis	rs2070433	0.559	rs11089057	chr21:47721228	T/A	cg12379764	chr21:47803548	PCNT	0.62	8.6	0.37	1.29e-16	Lymphocyte counts;
LGG	cis	rs763121	0.651	rs738249	chr22:39037979	T/C	cg06022373	chr22:39101656	GTPBP1	0.87	17.52	0.63	4.48e-53	Menopause (age at onset);
LGG	cis	rs4750440	0.523	rs4565801	chr10:14032358	G/A	cg00551146	chr10:14014579	FRMD4A	0.3	7.13	0.31	3.99e-12	Adiponectin levels;
LGG	cis	rs62238980	0.522	rs117129307	chr22:32519810	A/C	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg05863683	chr7:1912471	MAD1L1	0.45	8.88	0.38	1.43e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs6908034	0.556	rs7750703	chr6:19804814	C/G	cg02682789	chr6:19804855	NA	0.84	9.62	0.41	4.41e-20	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs727563	0.593	rs132770	chr22:42017264	A/G	cg06481639	chr22:41940642	POLR3H	0.56	7.92	0.35	1.8e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg00149659	chr3:10157352	C3orf10	-0.86	-11.15	-0.46	9.38e-26	Alzheimer's disease;
LGG	cis	rs9291683	0.609	rs55959894	chr4:10026580	G/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.88	0.3	1.92e-11	Bone mineral density;
LGG	cis	rs4417704	0.578	rs4675842	chr2:241876480	C/G	cg26818257	chr2:241905806	NA	-0.47	-10.28	-0.43	1.8e-22	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs41342147	0.660	rs12476462	chr2:242260662	A/G	cg10173475	chr2:242152697	ANO7	-0.57	-8.65	-0.37	8.46e-17	Vitiligo;
LGG	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg14673194	chr17:80132900	CCDC57	-0.45	-8.12	-0.35	4.23e-15	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7811142	0.720	rs7795656	chr7:99950297	A/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.16	18.46	0.65	2.03e-57	Platelet count;
LGG	cis	rs2204008	0.837	rs12369089	chr12:38060263	G/A	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs2429369	0.528	rs2526376	chr17:56427142	A/C	cg05425664	chr17:57184151	TRIM37	-0.48	-7.58	-0.33	1.93e-13	Cognitive function;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg04025307	chr7:1156635	C7orf50	0.82	14.7	0.56	2.07e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4919044	0.736	rs56087738	chr10:94767057	T/A	cg05127821	chr10:94822908	CYP26C1	-0.51	-7.82	-0.34	3.56e-14	Coronary artery disease;
LGG	cis	rs9875589	0.957	rs1433358	chr3:13943862	A/C	cg19554555	chr3:13937349	NA	0.7	13.28	0.53	2.48e-34	Ovarian reserve;
LGG	cis	rs12220238	0.822	rs2395087	chr10:76082637	T/A	cg19889307	chr10:75911429	ADK;AP3M1	0.71	8.96	0.38	8.05e-18	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7582180	0.652	rs4851307	chr2:100971778	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.39	-0.61	6.35e-48	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.556	rs10948196	chr6:44959384	A/T	cg18551225	chr6:44695536	NA	-0.58	-10.47	-0.44	3.57e-23	Total body bone mineral density;
LGG	cis	rs10220309	0.591	rs1352814	chr14:80608598	T/C	cg08183125	chr14:80678293	DIO2	-0.45	-6.85	-0.3	2.37e-11	Lung function (FEV1);
LGG	cis	rs35110281	0.743	rs230640	chr21:44914815	A/T	cg04455712	chr21:45112962	RRP1B	-0.54	-10.31	-0.43	1.47e-22	Mean corpuscular volume;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.0	-0.42	1.97e-21	Bipolar disorder;
LGG	cis	rs9393692	0.620	rs9379844	chr6:26291527	A/G	cg00631329	chr6:26305371	NA	0.43	7.32	0.32	1.1e-12	Educational attainment;
LGG	cis	rs10927875	0.662	rs698893	chr1:16302982	C/T	cg21385522	chr1:16154831	NA	0.52	9.28	0.4	6.34e-19	Dilated cardiomyopathy;
LGG	cis	rs7717393	0.786	rs6872904	chr5:155777713	C/G	cg12904904	chr5:155754151	SGCD	0.68	7.73	0.34	6.54e-14	Egg allergy;
LGG	cis	rs2072499	1.000	rs2241108	chr1:156181007	C/G	cg25208724	chr1:156163844	SLC25A44	1.22	29.75	0.81	1.64e-109	Testicular germ cell tumor;
LGG	cis	rs11098499	0.954	rs17009122	chr4:120362403	G/A	cg09307838	chr4:120376055	NA	0.82	13.72	0.54	3.33e-36	Corneal astigmatism;
LGG	cis	rs1775715	0.705	rs2778651	chr10:32106575	C/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.77	0.3	3.8e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs9790314	1.000	rs7647327	chr3:161016421	T/C	cg04691961	chr3:161091175	C3orf57	-0.62	-14.55	-0.56	8.82e-40	Morning vs. evening chronotype;
LGG	cis	rs2131877	1.000	rs2131877	chr3:194858374	C/T	cg07250128	chr3:194833983	C3orf21	0.39	7.39	0.32	6.87e-13	Non-small cell lung cancer;
LGG	cis	rs774359	0.744	rs895021	chr9:27484911	G/A	cg22262168	chr9:27528999	MOBKL2B	0.45	6.7	0.3	6.02e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs62238980	0.614	rs1475997	chr22:32465025	G/A	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg09307838	chr4:120376055	NA	0.8	13.28	0.53	2.45e-34	Corneal astigmatism;
LGG	cis	rs3806843	1.000	rs991918	chr5:140194858	C/T	cg19875535	chr5:140030758	IK	0.5	10.13	0.43	6.7e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6977660	0.714	rs10252597	chr7:19791171	G/T	cg05791153	chr7:19748676	TWISTNB	-0.78	-10.46	-0.44	4.01e-23	Thyroid stimulating hormone;
LGG	cis	rs9972944	0.657	rs9904302	chr17:63758238	A/G	cg07283582	chr17:63770753	CCDC46	-0.34	-6.7	-0.3	6.09e-11	Total body bone mineral density;
LGG	cis	rs12210905	0.841	rs28410967	chr6:27265235	T/C	cg15325629	chr6:28072465	NA	0.85	6.73	0.3	5.1e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9487094	0.626	rs3799849	chr6:110036763	C/A	cg01125227	chr6:109776195	MICAL1	0.44	7.65	0.33	1.19e-13	Height;
LGG	cis	rs9534288	0.912	rs4941540	chr13:46604710	C/T	cg15192986	chr13:46630673	CPB2	-0.71	-15.77	-0.59	3.64e-45	Blood protein levels;
LGG	cis	rs7937682	0.575	rs7107213	chr11:111750430	A/G	cg09085632	chr11:111637200	PPP2R1B	1.0	20.22	0.68	1.22e-65	Primary sclerosing cholangitis;
LGG	cis	rs4423214	1.000	rs12278461	chr11:71182185	C/T	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.02	-0.52	3.18e-33	Vitamin D levels;
LGG	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg08048268	chr3:133502702	NA	-0.41	-7.38	-0.32	7.35e-13	Iron status biomarkers;
LGG	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg09696939	chr10:60272079	BICC1	-0.37	-7.33	-0.32	1.01e-12	Refractive error;
LGG	cis	rs9611565	0.729	rs4822027	chr22:41786227	G/A	cg06850241	chr22:41845214	NA	-0.43	-6.89	-0.31	1.79e-11	Vitiligo;
LGG	cis	rs17666538	0.642	rs7821983	chr8:643696	A/G	cg13264159	chr8:625131	ERICH1	-1.04	-11.48	-0.47	4.94e-27	IgG glycosylation;
LGG	cis	rs875971	0.545	rs10950036	chr7:65818228	G/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.22	0.43	2.92e-22	Aortic root size;
LGG	cis	rs62283056	0.512	rs1079215	chr4:6282393	A/G	cg25554036	chr4:6271136	WFS1	0.53	8.95	0.38	8.6e-18	Cisplatin-induced ototoxicity;
LGG	cis	rs6489882	0.836	rs10850100	chr12:113364512	T/C	cg25319449	chr12:113376135	OAS3	-0.41	-7.52	-0.33	2.83e-13	Chronic lymphocytic leukemia;
LGG	cis	rs3733585	0.699	rs62294331	chr4:9959889	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.77e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7503807	0.688	rs11150745	chr17:78757626	A/G	cg18469159	chr17:78755841	RPTOR	-0.51	-9.17	-0.39	1.54e-18	Obesity;
LGG	cis	rs801193	1.000	rs2286684	chr7:66129830	G/T	cg18876405	chr7:65276391	NA	-0.59	-10.86	-0.45	1.28e-24	Aortic root size;
LGG	cis	rs2836950	0.959	rs4818008	chr21:40611442	T/A	cg11890956	chr21:40555474	PSMG1	-0.69	-11.23	-0.46	4.9e-26	Menarche (age at onset);
LGG	trans	rs75804782	0.521	rs56373856	chr2:239437926	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	8.69	0.37	6.49e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs763014	0.931	rs10903017	chr16:627920	T/C	cg04911050	chr16:677664	RAB40C	0.34	6.86	0.3	2.22e-11	Height;
LGG	trans	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg06521331	chr12:34319734	NA	0.44	7.91	0.35	1.93e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs875971	0.862	rs17747530	chr7:65994729	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.4e-11	Aortic root size;
LGG	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg22643751	chr7:855365	UNC84A	-0.44	-7.6	-0.33	1.71e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs911263	0.561	rs7150454	chr14:68765658	C/T	cg18825221	chr14:68749962	RAD51L1	0.4	6.8	0.3	3.31e-11	Primary biliary cholangitis;
LGG	cis	rs10504073	0.647	rs7817571	chr8:50003218	T/C	cg00325661	chr8:49890786	NA	0.7	13.89	0.54	6.36e-37	Blood metabolite ratios;
LGG	cis	rs7091068	0.574	rs10748610	chr10:95462235	C/G	cg20715218	chr10:95462985	C10orf4	0.68	10.49	0.44	3.09e-23	Urinary tract infection frequency;
LGG	cis	rs17227506	0.704	rs66965169	chr8:13454056	C/T	cg03566418	chr8:13424080	C8orf48	0.63	9.97	0.42	2.54e-21	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs870825	0.616	rs7668009	chr4:185641998	A/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs7017914	0.967	rs7819332	chr8:71668265	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs9611565	0.512	rs5758464	chr22:42171300	A/G	cg03806693	chr22:41940476	POLR3H	1.03	15.41	0.58	1.49e-43	Vitiligo;
LGG	cis	rs3733585	0.648	rs67820465	chr4:9975873	A/G	cg11266682	chr4:10021025	SLC2A9	-0.43	-8.08	-0.35	5.57e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs60871478	0.636	rs12532761	chr7:905229	C/T	cg22643751	chr7:855365	UNC84A	-0.43	-7.52	-0.33	2.78e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs2842992	0.789	rs6908680	chr6:160218209	G/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.85	13.93	0.54	4.27e-37	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6879260	1.000	rs729568	chr5:179732350	C/T	cg23248424	chr5:179741104	GFPT2	0.6	11.01	0.46	3.24e-25	Height;
LGG	cis	rs933688	1.000	rs12188467	chr5:90765632	A/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.1	18.18	0.65	4.1e-56	Smoking behavior;
LGG	cis	rs11148252	0.553	rs9536219	chr13:53227301	C/T	cg02158880	chr13:53174818	NA	0.67	15.34	0.58	3.2e-43	Lewy body disease;
LGG	cis	rs10504229	0.953	rs114806125	chr8:58182416	C/T	cg22535103	chr8:58192502	C8orf71	-0.95	-15.42	-0.58	1.36e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs12368653	0.545	rs2277324	chr12:58013175	G/A	cg20892847	chr12:58011875	NA	0.39	8.0	0.35	1.04e-14	Multiple sclerosis;
LGG	cis	rs7742824	1.000	rs7773700	chr6:44097472	T/C	cg04074908	chr6:44101190	TMEM63B	0.69	13.27	0.52	2.71e-34	Major depressive disorder;
LGG	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.27	-0.32	1.55e-12	Lung cancer in ever smokers;
LGG	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg20848291	chr7:100343083	ZAN	0.44	7.12	0.31	4.27e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs4718428	0.705	rs4718424	chr7:66376095	G/A	cg13147721	chr7:65941812	NA	-0.44	-6.76	-0.3	4.04e-11	Corneal structure;
LGG	cis	rs155076	1.000	rs261369	chr13:21868420	C/A	cg06138931	chr13:21896616	NA	-0.47	-7.61	-0.33	1.5e-13	White matter hyperintensity burden;
LGG	cis	rs9815354	0.638	rs73073258	chr3:42017894	G/A	cg03022575	chr3:42003672	ULK4	0.75	8.21	0.36	2.27e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1829883	1.000	rs2461989	chr5:98793999	T/A	cg08333243	chr5:99726346	NA	-0.39	-7.64	-0.33	1.27e-13	Hemostatic factors and hematological phenotypes;
LGG	cis	rs769267	1.000	rs2285627	chr19:19467937	T/C	cg01262667	chr19:19385393	TM6SF2	-0.44	-10.47	-0.44	3.62e-23	Tonsillectomy;
LGG	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg18876405	chr7:65276391	NA	0.56	10.04	0.42	1.42e-21	Aortic root size;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14795047	chr12:38710433	ALG10B	-0.48	-6.94	-0.31	1.29e-11	Systemic lupus erythematosus;
LGG	trans	rs1005277	0.540	rs116205409	chr10:38478970	G/A	cg04469686	chr1:162760199	HSD17B7	-0.48	-7.73	-0.34	6.89e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs9326248	1.000	rs585849	chr11:117069061	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.6	9.17	0.39	1.62e-18	Blood protein levels;
LGG	cis	rs7811142	0.830	rs73401451	chr7:99981895	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.97	-14.66	-0.56	3.04e-40	Platelet count;
LGG	cis	rs1799949	1.000	rs8176297	chr17:41203325	T/A	cg25072359	chr17:41440525	NA	0.52	9.96	0.42	2.64e-21	Menopause (age at onset);
LGG	cis	rs11098499	0.754	rs12509621	chr4:120249660	T/C	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs6597981	0.675	rs4963120	chr11:825777	A/G	cg01741372	chr11:783889	NA	-0.64	-12.31	-0.5	2.45e-30	Breast cancer;
LGG	cis	rs72843166	0.545	rs72839486	chr17:61014661	T/C	cg06641342	chr17:61514920	CYB561	0.46	7.19	0.32	2.54e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg11050988	chr7:1952600	MAD1L1	-0.36	-8.62	-0.37	1.1e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs6582630	0.599	rs12824838	chr12:38373584	G/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.12	-0.52	1.17e-33	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11190604	1.000	rs7079136	chr10:102292709	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.99	0.49	4.72e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7619833	0.685	rs9838558	chr3:27317858	C/G	cg02860705	chr3:27208620	NA	0.39	7.42	0.33	5.6e-13	Breast cancer;
LGG	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg12623918	chr2:306882	NA	0.5	9.53	0.4	9.24e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1799949	0.930	rs2298861	chr17:41176831	G/A	cg23758822	chr17:41437982	NA	0.85	14.59	0.56	6.04e-40	Menopause (age at onset);
LGG	cis	rs13191362	1.000	rs13206253	chr6:163166902	A/G	cg06582575	chr6:163149167	PACRG;PARK2	0.79	8.4	0.36	5.45e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9467773	1.000	rs4713008	chr6:26538268	T/C	cg09904177	chr6:26538194	HMGN4	0.78	18.09	0.64	1.01e-55	Intelligence (multi-trait analysis);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26439238	chr13:45563672	NUFIP1;KIAA1704	0.45	7.14	0.31	3.67e-12	Cognitive performance;
LGG	cis	rs1775715	0.513	rs2808089	chr10:32145112	A/T	cg14930904	chr10:32216787	ARHGAP12	0.36	6.97	0.31	1.12e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs17209837	0.564	rs117373803	chr7:87096783	A/G	cg04996195	chr7:87105398	ABCB4	0.26	6.67	0.3	7.19e-11	Gallbladder cancer;
LGG	cis	rs2243480	0.708	rs781141	chr7:65438553	A/G	cg18252515	chr7:66147081	NA	-1.31	-19.17	-0.67	9.93e-61	Diabetic kidney disease;
LGG	cis	rs736408	0.716	rs2300149	chr3:52822921	C/T	cg18404041	chr3:52824283	ITIH1	-0.59	-11.45	-0.47	6.59e-27	Bipolar disorder;
LGG	cis	rs10936602	0.527	rs1920119	chr3:169540397	T/C	cg00832555	chr3:169529716	LRRC34	0.35	7.26	0.32	1.66e-12	Renal cell carcinoma;
LGG	cis	rs7011049	0.778	rs72648436	chr8:53881267	G/C	cg26025543	chr8:53854495	NA	0.59	8.38	0.36	6.34e-16	Systolic blood pressure;
LGG	cis	rs79976124	0.879	rs77185357	chr6:66629070	G/A	cg07460842	chr6:66804631	NA	0.74	12.73	0.51	5.04e-32	Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg23166955	chr16:30077191	ALDOA	0.47	7.53	0.33	2.68e-13	Cognitive performance;
LGG	trans	rs4650994	0.525	rs4076563	chr1:178516901	C/T	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.52e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs875971	0.862	rs11765791	chr7:65936574	A/G	cg18252515	chr7:66147081	NA	-0.44	-7.38	-0.32	7.35e-13	Aortic root size;
LGG	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg11693508	chr17:37793320	STARD3	0.51	7.25	0.32	1.75e-12	Neuroticism;
LGG	cis	rs10186029	0.623	rs10497996	chr2:213997865	T/C	cg08319019	chr2:214017104	IKZF2	0.42	7.51	0.33	3.03e-13	Systemic sclerosis;
LGG	cis	rs9473924	0.505	rs7746581	chr6:50853479	T/C	cg14470998	chr6:50812995	TFAP2B	0.67	8.18	0.36	2.77e-15	Body mass index;
LGG	cis	rs10173297	0.686	rs6738533	chr2:3711919	G/T	cg17046650	chr2:3699563	NA	0.66	9.25	0.39	8.37e-19	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6546550	0.901	rs6754896	chr2:70138170	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.07	-0.35	6.12e-15	Prevalent atrial fibrillation;
LGG	cis	rs7089973	0.604	rs61596353	chr10:116597763	T/C	cg03647239	chr10:116582469	FAM160B1	0.42	7.45	0.33	4.56e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6933660	0.760	rs3806982	chr6:151774916	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.73	15.45	0.58	1.01e-43	Menarche (age at onset);
LGG	cis	rs11074306	0.561	rs4778191	chr15:28077308	T/C	cg26402630	chr15:28053930	OCA2	0.36	7.16	0.32	3.09e-12	Uveal melanoma;
LGG	trans	rs35851103	0.506	rs4841659	chr8:11828200	C/T	cg06636001	chr8:8085503	FLJ10661	0.55	10.56	0.44	1.75e-23	Neuroticism;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16949933	chr10:32734823	CCDC7	0.41	6.85	0.3	2.38e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11920090	0.858	rs66674286	chr3:170679289	T/C	cg09710316	chr3:170744871	SLC2A2	0.68	8.66	0.37	8.02e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs4535497	0.544	rs4975642	chr5:1107828	G/A	cg00278107	chr5:1061253	SLC12A7	0.43	7.25	0.32	1.81e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs738322	0.555	rs6001029	chr22:38555193	C/A	cg03162506	chr22:38580953	NA	0.39	9.89	0.42	4.57e-21	Cutaneous nevi;
LGG	cis	rs4727027	0.901	rs1534198	chr7:148772323	T/C	cg23583168	chr7:148888333	NA	-0.84	-16.17	-0.6	5.95e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs3087591	0.659	rs2525570	chr17:29681245	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	12.18	0.49	8.63e-30	Hip circumference;
LGG	cis	rs7107174	0.892	rs11237463	chr11:78060464	A/G	cg27205649	chr11:78285834	NARS2	-0.46	-7.49	-0.33	3.44e-13	Testicular germ cell tumor;
LGG	cis	rs1784581	0.894	rs1790001	chr6:162387504	G/T	cg17173639	chr6:162384350	PARK2	-0.88	-22.8	-0.73	1.03e-77	Itch intensity from mosquito bite;
LGG	cis	rs2549003	1.000	rs2070724	chr5:131822072	A/G	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	trans	rs59191668	0.903	rs2899680	chr15:62833859	A/G	cg12181634	chr1:235812280	GNG4	0.37	6.75	0.3	4.37e-11	Immature fraction of reticulocytes;
LGG	cis	rs763014	0.898	rs2017567	chr16:637212	T/C	cg04911050	chr16:677664	RAB40C	0.35	7.01	0.31	8.69e-12	Height;
LGG	cis	rs950169	0.840	rs12905223	chr15:85114268	T/C	cg24253500	chr15:84953950	NA	0.6	10.97	0.45	4.71e-25	Schizophrenia;
LGG	cis	rs921968	0.643	rs526134	chr2:219402371	G/A	cg02985541	chr2:219472218	PLCD4	0.29	6.86	0.3	2.17e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3126085	0.935	rs10888471	chr1:152200849	G/T	cg26876637	chr1:152193138	HRNR	-0.55	-9.1	-0.39	2.78e-18	Atopic dermatitis;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.88	18.54	0.65	8.02e-58	Personality dimensions;
LGG	cis	rs15676	0.947	rs2293968	chr9:131587240	G/A	cg04621255	chr9:131581398	ENDOG	-0.39	-6.96	-0.31	1.15e-11	Blood metabolite levels;
LGG	cis	rs12928939	0.517	rs8050058	chr16:71981374	T/G	cg03805757	chr16:71968109	PKD1L3	-0.66	-13.43	-0.53	5.94e-35	Post bronchodilator FEV1;
LGG	trans	rs1941687	0.831	rs12954615	chr18:31384449	G/T	cg27147174	chr7:100797783	AP1S1	-0.54	-9.27	-0.4	6.9e-19	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs4262150	0.667	rs4958592	chr5:152288222	A/G	cg12297329	chr5:152029980	NA	0.59	11.19	0.46	7.02e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs4262150	0.667	rs4958594	chr5:152298956	C/T	cg12297329	chr5:152029980	NA	0.58	11.34	0.47	1.76e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs740474	0.569	rs4912761	chr5:140881474	G/T	cg00076195	chr5:140892677	NA	0.38	7.03	0.31	7.26e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2084898	0.550	rs550164	chr11:120002727	C/T	cg13907859	chr11:120009124	TRIM29	-0.46	-8.42	-0.36	4.61e-16	Stroke (pediatric);
LGG	cis	rs10256972	0.678	rs6962989	chr7:1017512	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	8.88	0.38	1.52e-17	Longevity;Endometriosis;
LGG	cis	rs10191773	0.522	rs6747639	chr2:112967458	C/T	cg23609528	chr2:113191194	RGPD5;RGPD8	0.56	6.67	0.3	7.51e-11	Yeast infection;
LGG	cis	rs11683229	0.598	rs13023873	chr2:64039567	C/T	cg14150252	chr2:64069583	UGP2	-0.43	-7.5	-0.33	3.21e-13	Protein quantitative trait loci;
LGG	cis	rs7582720	0.945	rs72934601	chr2:204031137	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.37	0.4	3.21e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs4722166	0.695	rs7793125	chr7:22809160	A/G	cg05265849	chr7:22767390	IL6	0.37	7.16	0.32	3.21e-12	Lung cancer;
LGG	cis	rs533581	0.844	rs564669	chr16:88968540	T/C	cg16701003	chr16:89028210	CBFA2T3	0.59	10.15	0.43	5.28e-22	Social autistic-like traits;
LGG	cis	rs10435719	0.702	rs77055881	chr8:11790581	T/C	cg12395012	chr8:11607386	GATA4	-0.43	-7.64	-0.33	1.29e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs13118159	0.550	rs2878607	chr4:1353310	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.13	0.35	4.09e-15	Longevity;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.68	-0.34	9.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs360798	0.512	rs12989754	chr2:63020970	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-7.68	-0.34	9.48e-14	Coronary artery disease;
LGG	cis	rs79839061	0.610	rs12651271	chr4:854071	C/T	cg07828340	chr4:882639	GAK	0.83	8.94	0.38	9.09e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	1.000	rs6037086	chr20:25306338	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.13	-0.43	6.65e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11190604	1.000	rs1417823	chr10:102227886	C/T	cg07570687	chr10:102243282	WNT8B	-0.43	-7.67	-0.34	1.05e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11122272	0.766	rs2486732	chr1:231531476	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.51	-0.47	3.83e-27	Hemoglobin concentration;
LGG	cis	rs916888	0.773	rs199447	chr17:44812188	C/T	cg11489262	chr17:43973426	MAPT;LOC100128977;LOC100130148	0.43	6.77	0.3	3.92e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs933688	0.526	rs9293565	chr5:90609736	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	0.78	8.97	0.38	7.41e-18	Smoking behavior;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg24607181	chr17:41446203	NA	-0.29	-6.76	-0.3	4.3e-11	Menopause (age at onset);
LGG	cis	rs9788721	0.836	rs11858836	chr15:78783277	G/A	cg16751781	chr15:78858589	CHRNA5	-0.41	-7.33	-0.32	1e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7582180	0.629	rs34745556	chr2:100942506	A/G	cg05692746	chr2:100937584	LONRF2	-0.67	-12.48	-0.5	5.02e-31	Intelligence (multi-trait analysis);
LGG	cis	rs9398803	0.661	rs1101557	chr6:127067996	T/C	cg19875578	chr6:126661172	C6orf173	-0.5	-9.19	-0.39	1.37e-18	Male-pattern baldness;
LGG	trans	rs867371	0.717	rs3858954	chr15:82558034	G/C	cg18393722	chr15:85113863	UBE2QP1	-0.4	-6.97	-0.31	1.12e-11	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs6582630	0.519	rs11182457	chr12:38538331	G/A	cg13010199	chr12:38710504	ALG10B	0.72	14.73	0.56	1.45e-40	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11098499	0.863	rs17050695	chr4:120489527	G/T	cg25214090	chr10:38739885	LOC399744	0.64	11.42	0.47	8.43e-27	Corneal astigmatism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg03164238	chr19:54494652	CACNG6	-0.43	-7.14	-0.31	3.65e-12	Pancreatic cancer;
LGG	cis	rs2050392	0.861	rs303448	chr10:30727084	G/T	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.99	-0.45	3.93e-25	Inflammatory bowel disease;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.24	0.65	2.15e-56	Personality dimensions;
LGG	cis	rs801193	0.844	rs7779971	chr7:66161790	T/C	cg00343986	chr7:65444356	GUSB	0.39	6.72	0.3	5.27e-11	Aortic root size;
LGG	cis	rs6977660	0.714	rs9969381	chr7:19827454	C/T	cg05791153	chr7:19748676	TWISTNB	0.76	10.01	0.42	1.81e-21	Thyroid stimulating hormone;
LGG	cis	rs9300255	0.566	rs1716169	chr12:123716930	A/T	cg00376283	chr12:123451042	ABCB9	0.63	9.52	0.4	9.44e-20	Neutrophil percentage of white cells;
LGG	cis	rs11771526	0.901	rs62456038	chr7:32288663	G/A	cg13207630	chr7:32358064	NA	0.69	7.3	0.32	1.3e-12	Body mass index;
LGG	cis	rs1816752	0.713	rs7336357	chr13:25017590	T/C	cg02811702	chr13:24901961	NA	0.4	7.51	0.33	3.07e-13	Obesity-related traits;
LGG	trans	rs4332037	1.000	rs6947019	chr7:1950337	G/A	cg10840412	chr1:235813424	GNG4	0.64	8.54	0.37	1.95e-16	Bipolar disorder;
LGG	cis	rs7129220	0.588	rs34984386	chr11:10095987	A/C	cg01453529	chr11:10209919	SBF2	-0.42	-6.92	-0.31	1.49e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs875971	0.545	rs6460281	chr7:65681115	A/C	cg11764359	chr7:65958608	NA	0.63	9.75	0.41	1.51e-20	Aortic root size;
LGG	cis	rs2204008	0.837	rs7308714	chr12:38274307	T/C	cg26384229	chr12:38710491	ALG10B	0.94	20.91	0.7	7.83e-69	Bladder cancer;
LGG	cis	rs6732160	0.691	rs10197935	chr2:73412362	A/T	cg01422370	chr2:73384389	NA	0.47	9.03	0.39	4.54e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4555082	0.874	rs2816625	chr14:105734565	G/A	cg10792982	chr14:105748885	BRF1	0.67	13.34	0.53	1.33e-34	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1728785	1.000	rs864742	chr16:68575309	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.46e-15	Ulcerative colitis;
LGG	cis	rs7659604	0.502	rs28435300	chr4:122709412	T/C	cg19748678	chr4:122722346	EXOSC9	-0.56	-10.12	-0.43	6.92e-22	Type 2 diabetes;
LGG	cis	rs10782582	0.586	rs1796813	chr1:76400403	G/A	cg03433033	chr1:76189801	ACADM	-0.42	-6.67	-0.3	7.33e-11	Daytime sleep phenotypes;
LGG	trans	rs4942242	0.574	rs9533557	chr13:44197487	C/G	cg19169023	chr15:41853346	TYRO3	0.42	8.14	0.35	3.7e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg21399703	chr1:247681439	NA	0.63	11.2	0.46	6.05e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs798554	0.757	rs1182179	chr7:2873648	A/G	cg19717773	chr7:2847554	GNA12	-0.32	-6.72	-0.3	5.25e-11	Height;
LGG	cis	rs1005277	0.529	rs1780125	chr10:38531376	A/G	cg25517755	chr10:38738941	LOC399744	-0.37	-6.72	-0.3	5.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs6062302	0.522	rs914558	chr20:62216976	A/G	cg16989086	chr20:62203971	PRIC285	0.48	7.05	0.31	6.49e-12	Glioblastoma;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg21724239	chr8:58056113	NA	0.63	9.09	0.39	2.99e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9534288	0.619	rs9526146	chr13:46680854	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-14.17	-0.55	4.26e-38	Blood protein levels;
LGG	cis	rs12701220	0.901	rs12701713	chr7:1090505	G/A	cg26769984	chr7:1090371	C7orf50	0.55	9.88	0.42	5.2e-21	Bronchopulmonary dysplasia;
LGG	trans	rs9393777	0.920	rs13191227	chr6:27390115	G/C	cg06606381	chr12:133084897	FBRSL1	-1.23	-11.27	-0.46	3.4e-26	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs75855890	chr2:27625005	G/T	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.31	-0.32	1.15e-12	Total body bone mineral density;
LGG	cis	rs6752107	0.967	rs11694081	chr2:234148586	A/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.64	11.63	0.48	1.28e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4917300	0.606	rs6583570	chr8:143115783	A/G	cg06573787	chr8:143070187	NA	0.6	9.92	0.42	3.81e-21	Amyotrophic lateral sclerosis;
LGG	trans	rs853679	0.607	rs56075693	chr6:28290328	T/G	cg08344181	chr3:125677491	NA	-0.91	-9.28	-0.4	6.54e-19	Depression;
LGG	trans	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg06636001	chr8:8085503	FLJ10661	0.46	8.18	0.36	2.75e-15	Retinal vascular caliber;
LGG	cis	rs877282	0.853	rs12763400	chr10:763617	C/T	cg17470449	chr10:769945	NA	0.56	6.79	0.3	3.51e-11	Uric acid levels;
LGG	cis	rs4853012	1.000	rs2280643	chr2:74358286	T/C	cg01017244	chr2:74357527	NA	0.46	8.24	0.36	1.81e-15	Gestational age at birth (maternal effect);
LGG	cis	rs612683	0.658	rs12407689	chr1:100999585	C/G	cg06223162	chr1:101003688	GPR88	0.47	11.31	0.47	2.39e-26	Breast cancer;
LGG	cis	rs7614311	0.681	rs73117083	chr3:63948455	G/C	cg22134162	chr3:63841271	THOC7	-0.43	-7.81	-0.34	3.85e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs787274	0.543	rs62576453	chr9:115629921	C/T	cg13803584	chr9:115635662	SNX30	-0.64	-9.9	-0.42	4.41e-21	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16130600	chr7:120590585	ING3	0.43	6.84	0.3	2.51e-11	Cognitive performance;
LGG	cis	rs1568889	0.838	rs4614434	chr11:28302234	C/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.16	0.67	1.07e-60	Bipolar disorder;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14332129	chr19:3035779	TLE2	0.5	7.55	0.33	2.32e-13	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs11654452	chr17:41189383	G/T	cg23758822	chr17:41437982	NA	0.86	14.74	0.57	1.37e-40	Menopause (age at onset);
LGG	trans	rs12682352	0.652	rs3789843	chr8:8724257	C/T	cg02002194	chr4:3960332	NA	-0.39	-7.37	-0.32	8.11e-13	Neuroticism;
LGG	cis	rs7106204	0.609	rs34376029	chr11:24291233	C/T	ch.11.24196551F	chr11:24239977	NA	0.89	9.68	0.41	2.67e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs3767633	0.925	rs4657103	chr1:161740483	G/T	cg09175582	chr1:161736000	ATF6	0.66	8.24	0.36	1.81e-15	IgG glycosylation;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs7927771	0.524	rs7111576	chr11:47787445	G/A	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25262866	chr7:16686311	BZW2;ANKMY2	0.51	7.87	0.34	2.55e-14	Gut microbiome composition (summer);
LGG	cis	rs611744	0.647	rs7015513	chr8:109262570	A/C	cg18478394	chr8:109455254	TTC35	0.41	8.13	0.35	3.97e-15	Dupuytren's disease;
LGG	cis	rs2721195	0.967	rs748193	chr8:145682115	C/T	cg17328964	chr8:145687451	CYHR1	-0.67	-13.26	-0.52	3.1e-34	Age at first birth;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg21114840	chr21:40752097	WRB	-0.43	-6.9	-0.31	1.7e-11	Pancreatic cancer;
LGG	cis	rs240764	0.658	rs11155673	chr6:101243283	A/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.16	-0.35	3.26e-15	Neuroticism;
LGG	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg26441486	chr22:50317300	CRELD2	0.4	6.97	0.31	1.08e-11	Schizophrenia;
LGG	cis	rs2070433	0.615	rs2073379	chr21:47863025	C/T	cg12379764	chr21:47803548	PCNT	0.68	9.49	0.4	1.24e-19	Lymphocyte counts;
LGG	cis	rs7565124	0.909	rs6747473	chr2:20252008	C/G	cg24657347	chr2:20261756	NA	-0.73	-14.37	-0.56	5.59e-39	Major depressive disorder;
LGG	cis	rs12950390	0.853	rs56137679	chr17:45862112	C/G	cg03474202	chr17:45855739	NA	-0.27	-8.0	-0.35	9.89e-15	IgG glycosylation;
LGG	cis	rs7552404	0.924	rs114752222	chr1:76180878	C/T	cg03433033	chr1:76189801	ACADM	0.82	15.3	0.58	4.71e-43	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2404602	0.692	rs8024476	chr15:76983954	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-6.99	-0.31	9.79e-12	Blood metabolite levels;
LGG	cis	rs2439831	1.000	rs689647	chr15:43762196	C/T	cg15269541	chr15:43626905	ADAL	-0.43	-7.38	-0.32	7.6e-13	Lung cancer in ever smokers;
LGG	cis	rs6582630	0.638	rs11182428	chr12:38526387	T/C	cg13010199	chr12:38710504	ALG10B	-0.55	-11.15	-0.46	1.01e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg21775007	chr8:11205619	TDH	-0.77	-13.35	-0.53	1.32e-34	Retinal vascular caliber;
LGG	trans	rs9858542	1.000	rs13085791	chr3:49721798	C/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.46	-7.43	-0.33	5.25e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1799949	1.000	rs12950607	chr17:41299928	G/C	cg01879757	chr17:41196368	BRCA1	-0.43	-8.72	-0.38	5.06e-17	Menopause (age at onset);
LGG	cis	rs2072499	0.833	rs2758605	chr1:156200445	G/C	cg24450063	chr1:156163899	SLC25A44	1.06	21.77	0.71	6.84e-73	Testicular germ cell tumor;
LGG	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7615952	0.512	rs2979336	chr3:125357470	G/A	cg21696256	chr3:125484277	NA	-0.44	-7.32	-0.32	1.07e-12	Blood pressure (smoking interaction);
LGG	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06634786	chr22:41940651	POLR3H	-0.77	-12.23	-0.49	5.26e-30	Vitiligo;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24903225	chr12:108956097	SART3;ISCU	0.41	6.66	0.3	7.67e-11	Cognitive performance;
LGG	trans	rs7618501	1.000	rs9859153	chr3:49807085	G/T	cg21659725	chr3:3221576	CRBN	0.93	20.77	0.69	3.23e-68	Intelligence (multi-trait analysis);
LGG	cis	rs765787	0.530	rs4444275	chr15:45535347	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs2760061	0.603	rs697762	chr1:228192410	G/A	cg01200585	chr1:228362443	C1orf69	0.46	8.04	0.35	7.34e-15	Diastolic blood pressure;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg02733842	chr7:1102375	C7orf50	0.57	8.06	0.35	6.69e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6089584	0.888	rs6061983	chr20:60621202	T/C	cg06470251	chr20:60548479	NA	0.5	8.32	0.36	1.02e-15	Body mass index;
LGG	cis	rs7085104	0.572	rs284857	chr10:104574063	C/T	cg04362960	chr10:104952993	NT5C2	-0.46	-8.34	-0.36	8.57e-16	Immature fraction of reticulocytes;Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg27343216	chr2:44588835	PREPL;C2orf34	0.42	6.9	0.31	1.72e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs988958	0.567	rs2165239	chr2:42254356	C/T	cg27428208	chr2:42229179	NA	0.52	9.12	0.39	2.26e-18	Hypospadias;
LGG	cis	rs4713118	0.586	rs6905522	chr6:28086479	A/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Parkinson's disease;
LGG	cis	rs933688	1.000	rs12654787	chr5:90713259	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg07243736	chr16:783730	NARFL	0.39	6.69	0.3	6.56e-11	Height;
LGG	trans	rs453301	0.686	rs11787026	chr8:8902371	A/T	cg27411982	chr8:10470053	RP1L1	0.47	8.14	0.35	3.67e-15	Joint mobility (Beighton score);
LGG	cis	rs78456975	0.527	rs11884165	chr2:1561052	A/G	cg01028140	chr2:1542097	TPO	-0.46	-8.52	-0.37	2.34e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs950776	0.545	rs34275594	chr15:78981282	A/C	cg03762349	chr15:79060523	ADAMTS7	0.38	8.35	0.36	7.75e-16	Sudden cardiac arrest;
LGG	cis	rs9616064	0.557	rs9616085	chr22:47045556	T/A	cg05621596	chr22:47072043	GRAMD4	-0.34	-6.81	-0.3	3.03e-11	Urate levels in obese individuals;
LGG	cis	rs6748734	1.000	rs3936203	chr2:241834654	C/T	cg07537917	chr2:241836409	C2orf54	0.42	8.24	0.36	1.81e-15	Urinary metabolites;
LGG	cis	rs12496230	1.000	rs34508066	chr3:66837509	G/T	cg04995300	chr3:66848608	NA	0.52	7.66	0.34	1.1e-13	Type 2 diabetes;
LGG	cis	rs9513627	1.000	rs7327068	chr13:100126965	A/G	cg15490075	chr13:100150979	NA	-0.66	-6.97	-0.31	1.13e-11	Obesity-related traits;
LGG	cis	rs1348850	0.645	rs10181259	chr2:178428256	C/A	cg22681709	chr2:178499509	PDE11A	-0.48	-7.79	-0.34	4.31e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1801251	1.000	rs6745879	chr2:233590007	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.37	0.4	3.28e-19	Coronary artery disease;
LGG	cis	rs657075	0.697	rs71583483	chr5:131698019	T/C	cg21948465	chr5:131705150	SLC22A5	0.69	7.64	0.33	1.28e-13	Rheumatoid arthritis;
LGG	cis	rs155076	0.938	rs536209	chr13:21847714	C/T	cg14456004	chr13:21872349	NA	-1.16	-18.29	-0.65	1.26e-56	White matter hyperintensity burden;
LGG	cis	rs6141769	0.542	rs6057628	chr20:31308684	C/T	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.83	-0.3	2.63e-11	Subjective well-being;
LGG	cis	rs709400	1.000	rs861538	chr14:104166733	C/T	cg24130564	chr14:104152367	KLC1	-0.43	-8.17	-0.35	2.98e-15	Body mass index;
LGG	cis	rs9790314	0.628	rs4342141	chr3:160783922	T/C	cg03342759	chr3:160939853	NMD3	-0.6	-10.5	-0.44	2.75e-23	Morning vs. evening chronotype;
LGG	cis	rs36051895	0.632	rs10974993	chr9:5182159	C/T	cg02405213	chr9:5042618	JAK2	-0.76	-14.78	-0.57	9.5e-41	Pediatric autoimmune diseases;
LGG	cis	rs13118159	0.527	rs6599308	chr4:1387780	A/G	cg02071572	chr4:1403502	NA	0.4	6.71	0.3	5.86e-11	Longevity;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg04267008	chr7:1944627	MAD1L1	-0.75	-13.28	-0.53	2.41e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg02951883	chr7:2050386	MAD1L1	-0.74	-14.58	-0.56	7e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs6519955	0.796	rs4072455	chr22:46422938	T/C	cg09285095	chr22:46440394	LOC100271722	-0.42	-7.55	-0.33	2.31e-13	Dupuytren's disease;
LGG	cis	rs7937682	0.793	rs7130440	chr11:111417779	A/G	cg19812747	chr11:111475976	SIK2	0.38	7.51	0.33	3.03e-13	Primary sclerosing cholangitis;
LGG	cis	rs787274	1.000	rs10739373	chr9:115593239	G/A	cg13803584	chr9:115635662	SNX30	-0.6	-7.6	-0.33	1.68e-13	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs35264875	1.000	rs72928636	chr11:68848386	C/T	cg07882059	chr11:68924751	NA	0.41	7.33	0.32	1.02e-12	Blond vs. brown hair color;
LGG	cis	rs4423214	0.879	rs1792281	chr11:71135496	G/A	cg10847948	chr11:71163743	NADSYN1	0.65	11.74	0.48	4.95e-28	Vitamin D levels;
LGG	cis	rs11239187	0.543	rs11239153	chr10:45072521	G/A	cg03916630	chr10:45065415	NA	0.36	8.62	0.37	1.04e-16	Body mass index;
LGG	cis	rs801193	0.839	rs12534943	chr7:66070520	A/G	cg18252515	chr7:66147081	NA	0.41	7.07	0.31	5.78e-12	Aortic root size;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.02	0.46	2.97e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs11976180	1.000	rs2951354	chr7:143761001	G/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs35740288	0.688	rs12904047	chr15:86212866	A/G	cg07943548	chr15:86304357	KLHL25	-0.33	-6.75	-0.3	4.36e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs5750830	0.594	rs1010170	chr22:39778327	C/T	cg04986931	chr22:39850128	NA	-0.36	-7.65	-0.34	1.16e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.663	rs6542944	chr2:100988038	T/C	cg21926883	chr2:100939477	LONRF2	-0.68	-16.14	-0.6	8.21e-47	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.931	rs9840050	chr3:49133310	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.95	0.31	1.24e-11	Parkinson's disease;
LGG	cis	rs1707322	1.000	rs6676982	chr1:46275401	A/T	cg03146154	chr1:46216737	IPP	0.54	10.28	0.43	1.78e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs861020	0.630	rs585627	chr1:210004199	C/G	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs7666738	0.753	rs7698541	chr4:98986351	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7444	0.941	rs73166622	chr22:21938863	G/C	cg11654148	chr22:21984483	YDJC	-0.39	-7.7	-0.34	8.36e-14	Systemic lupus erythematosus;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19524238	chr7:2802976	GNA12	0.31	7.48	0.33	3.66e-13	Height;
LGG	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg03929089	chr4:120376271	NA	0.66	7.26	0.32	1.65e-12	Intraocular pressure;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.92	0.51	8.24e-33	Prudent dietary pattern;
LGG	cis	rs4975616	0.869	rs455433	chr5:1336243	A/G	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.32	-0.47	2.09e-26	Lung cancer;
LGG	cis	rs17767392	0.958	rs10135680	chr14:72030809	G/A	cg02058870	chr14:72053146	SIPA1L1	-0.47	-9.82	-0.42	8.45e-21	Mitral valve prolapse;
LGG	cis	rs2073300	1.000	rs6132628	chr20:23446734	G/A	cg12062639	chr20:23401060	NAPB	0.85	6.79	0.3	3.44e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg18721089	chr20:30220636	NA	-0.53	-7.77	-0.34	5.27e-14	Mean corpuscular hemoglobin;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08092588	chr14:105041452	NA	0.37	7.27	0.32	1.51e-12	Menarche (age at onset);
LGG	trans	rs17685	0.753	rs6976532	chr7:75681094	A/G	cg19862616	chr7:65841803	NCRNA00174	1.04	24.46	0.75	2.03e-85	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9900972	0.918	rs6501258	chr17:76877824	T/A	cg00961940	chr17:76876995	TIMP2	0.46	9.08	0.39	3.16e-18	Obesity-related traits;
LGG	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg00666640	chr1:248458726	OR2T12	0.58	9.15	0.39	1.75e-18	Common traits (Other);
LGG	cis	rs13118159	0.836	rs2276903	chr4:1343405	A/G	cg20887711	chr4:1340912	KIAA1530	0.66	13.27	0.52	2.86e-34	Longevity;
LGG	trans	rs826838	0.904	rs10876086	chr12:39188208	C/A	cg06521331	chr12:34319734	NA	-0.44	-7.7	-0.34	8.32e-14	Heart rate;
LGG	cis	rs2976388	1.000	rs2920282	chr8:143757763	T/C	cg06565975	chr8:143823917	SLURP1	-0.42	-10.57	-0.44	1.58e-23	Urinary tract infection frequency;
LGG	cis	rs4671458	0.656	rs72821632	chr2:63701374	G/A	cg17519650	chr2:63277830	OTX1	-0.51	-6.83	-0.3	2.74e-11	Subjective well-being;
LGG	cis	rs13191362	0.872	rs13196631	chr6:163001588	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.92	10.61	0.44	1.13e-23	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7681440	0.904	rs28734152	chr4:90767359	C/T	cg18258770	chr4:90757814	SNCA	-0.39	-7.31	-0.32	1.16e-12	Dementia with Lewy bodies;
LGG	cis	rs3849046	0.875	rs255999	chr5:137889799	A/G	cg10920316	chr5:137946599	NA	0.45	7.38	0.32	7.35e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24487784	chr11:696252	TMEM80;DEAF1	0.46	7.03	0.31	7.48e-12	Gut microbiome composition (summer);
LGG	cis	rs61931739	0.890	rs1705753	chr12:34144594	C/T	cg06521331	chr12:34319734	NA	-0.43	-7.78	-0.34	4.88e-14	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.89	-0.38	1.38e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs12188164	0.686	rs72711370	chr5:421057	A/C	cg13013644	chr5:502571	SLC9A3	-0.35	-6.8	-0.3	3.24e-11	Cystic fibrosis severity;
LGG	cis	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	7.1	0.31	4.7e-12	Obesity-related traits;
LGG	cis	rs11676348	0.772	rs12471105	chr2:218950209	G/A	cg04731861	chr2:219085781	ARPC2	0.28	6.73	0.3	5.18e-11	Ulcerative colitis;
LGG	trans	rs7824557	0.767	rs2060463	chr8:11161610	T/G	cg15556689	chr8:8085844	FLJ10661	0.47	8.19	0.36	2.55e-15	Retinal vascular caliber;
LGG	cis	rs2013441	1.000	rs2526480	chr17:20130074	A/G	cg13482628	chr17:19912719	NA	0.5	9.04	0.39	4.3e-18	Obesity-related traits;
LGG	cis	rs4689388	0.890	rs4481292	chr4:6298375	C/T	cg25554036	chr4:6271136	WFS1	0.61	11.47	0.47	5.59e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs933688	0.941	rs6452954	chr5:90735692	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.89	17.59	0.63	1.98e-53	Smoking behavior;
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg00424166	chr6:150045504	NUP43	0.34	7.09	0.31	5.03e-12	Lung cancer;
LGG	cis	rs10739663	0.520	rs2819624	chr9:128156519	A/G	cg14078157	chr9:128172775	NA	-0.57	-10.72	-0.45	4.26e-24	Resting heart rate;
LGG	cis	rs1975974	0.590	rs113830378	chr17:21744147	G/C	cg18423549	chr17:21743878	NA	-0.52	-7.75	-0.34	5.82e-14	Psoriasis;
LGG	cis	rs6121246	0.954	rs6060989	chr20:30429763	C/T	cg13852791	chr20:30311386	BCL2L1	0.73	11.61	0.47	1.61e-27	Mean corpuscular hemoglobin;
LGG	cis	rs7582180	0.652	rs11687864	chr2:100946993	T/A	cg21926883	chr2:100939477	LONRF2	-0.69	-15.95	-0.6	5.78e-46	Intelligence (multi-trait analysis);
LGG	cis	rs9460578	0.537	rs10806927	chr6:20828334	T/C	cg13405222	chr6:20811065	CDKAL1	0.76	17.1	0.62	3.43e-51	Breast cancer;
LGG	trans	rs970548	0.779	rs56145077	chr10:45939991	C/T	cg20477318	chr10:51623047	TIMM23	0.62	7.41	0.33	5.99e-13	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs13082711	0.911	rs997680	chr3:27443638	G/A	cg02860705	chr3:27208620	NA	0.72	13.38	0.53	9.7e-35	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs28595532	0.920	rs115240535	chr4:119745395	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs9646954	0.560	rs4149507	chr2:101032745	C/T	cg14675211	chr2:100938903	LONRF2	0.67	12.13	0.49	1.34e-29	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs17270561	0.609	rs12192077	chr6:25732794	G/A	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	trans	rs1997103	1.000	rs6948112	chr7:55411302	G/A	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7937682	0.883	rs568506	chr11:111466429	C/T	cg22437258	chr11:111473054	SIK2	0.54	9.59	0.41	5.64e-20	Primary sclerosing cholangitis;
LGG	cis	rs12478296	1.000	rs60533128	chr2:243028088	A/G	cg18898632	chr2:242989856	NA	-0.87	-9.97	-0.42	2.34e-21	Obesity-related traits;
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg21963583	chr11:68658836	MRPL21	0.59	10.03	0.42	1.54e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9910055	0.659	rs227580	chr17:42223068	C/T	cg08499158	chr17:42289980	UBTF	0.55	10.28	0.43	1.83e-22	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs12506095	chr4:1262233	T/C	cg00684032	chr4:1343700	KIAA1530	0.47	9.1	0.39	2.6e-18	Obesity-related traits;
LGG	cis	rs28830936	1.000	rs11629678	chr15:41932530	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.55	-12.46	-0.5	5.99e-31	Diastolic blood pressure;
LGG	cis	rs28386778	0.897	rs2584640	chr17:61863488	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs2933343	0.729	rs6767104	chr3:128648117	G/T	cg25356066	chr3:128598488	ACAD9	-0.45	-6.84	-0.3	2.5e-11	IgG glycosylation;
LGG	cis	rs35146811	0.961	rs11771139	chr7:99736059	C/T	cg13334819	chr7:99746414	C7orf59	-0.55	-8.18	-0.36	2.7e-15	Coronary artery disease;
LGG	cis	rs589448	0.934	rs554591	chr12:69753847	T/C	cg14784868	chr12:69753453	YEATS4	1.01	24.09	0.75	1.07e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7236492	0.748	rs11663202	chr18:77209180	T/C	cg15644404	chr18:77186268	NFATC1	-0.82	-10.07	-0.42	1.06e-21	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7947523	0.813	rs4999940	chr11:80942337	C/T	cg05751979	chr8:74883978	TCEB1	0.45	6.77	0.3	3.9e-11	Emphysema imaging phenotypes;
LGG	cis	rs1552244	1.000	rs6789156	chr3:10124120	C/T	cg00149659	chr3:10157352	C3orf10	0.82	10.46	0.44	3.83e-23	Alzheimer's disease;
LGG	cis	rs1552244	0.765	rs17050675	chr3:10027686	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.03	16.69	0.61	2.71e-49	Alzheimer's disease;
LGG	cis	rs796364	1.000	rs71424239	chr2:200725473	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.67	-8.03	-0.35	8.39e-15	Schizophrenia;
LGG	trans	rs3780486	0.834	rs75443249	chr9:33149207	A/G	cg20290983	chr6:43655470	MRPS18A	1.03	17.53	0.63	3.9e-53	IgG glycosylation;
LGG	cis	rs11877825	0.826	rs9961960	chr18:10570303	A/G	cg25239095	chr18:10589360	NA	-0.48	-9.21	-0.39	1.14e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs714515	0.934	rs2213732	chr1:172333595	G/A	cg01573306	chr1:172330400	DNM3	0.34	7.46	0.33	4.43e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	8.94	0.38	9.49e-18	Schizophrenia;
LGG	cis	rs7824557	0.527	rs4634600	chr8:11239017	T/A	cg15596359	chr8:11213517	TDH	0.42	8.71	0.38	5.27e-17	Retinal vascular caliber;
LGG	trans	rs9467711	0.591	rs41266779	chr6:26021872	C/T	cg01620082	chr3:125678407	NA	-0.88	-7.46	-0.33	4.45e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1153858	1.000	rs1145091	chr15:45649996	A/G	cg05280133	chr15:45670068	GATM;LOC145663	0.4	7.23	0.32	2.04e-12	Homoarginine levels;
LGG	cis	rs4629710	0.592	rs11759793	chr6:131546384	G/A	cg12606694	chr6:131520996	AKAP7	0.51	8.36	0.36	7.38e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs7503807	0.701	rs1485329	chr17:78643561	A/G	cg18469159	chr17:78755841	RPTOR	-0.4	-7.61	-0.33	1.5700000000000001e-13	Obesity;
LGG	cis	rs36051895	0.695	rs2183137	chr9:5026293	A/G	cg02405213	chr9:5042618	JAK2	-0.82	-14.99	-0.57	1.06e-41	Pediatric autoimmune diseases;
LGG	cis	rs2046867	0.818	rs17010133	chr3:72827987	T/C	cg26655873	chr3:72818019	SHQ1	0.35	6.77	0.3	4.01e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.65	-0.37	8.64e-17	Schizophrenia;
LGG	cis	rs1957429	0.614	rs117722345	chr14:65381464	C/G	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs12447804	0.863	rs35622589	chr16:58097849	C/G	cg03859792	chr16:58121049	NA	0.49	7.39	0.32	7.03e-13	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs11758351	0.500	rs113738935	chr6:26196567	T/A	cg01420254	chr6:26195488	NA	0.97	7.36	0.32	8.35e-13	Gout;Renal underexcretion gout;
LGG	cis	rs8114671	0.836	rs6142280	chr20:33622242	A/C	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.43	-0.36	4.41e-16	Height;
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg06636001	chr8:8085503	FLJ10661	-0.57	-10.62	-0.44	1.04e-23	Triglycerides;
LGG	cis	rs1799949	0.965	rs35521261	chr17:41313612	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs3733585	0.631	rs7699671	chr4:10125874	C/T	cg25986240	chr4:9926439	SLC2A9	0.35	6.92	0.31	1.51e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4909189	0.957	rs71547528	chr7:158135431	T/C	cg06219351	chr7:158114137	PTPRN2	-0.83	-14.31	-0.55	9.67e-39	Response to amphetamines;
LGG	cis	rs7223966	1.000	rs8068603	chr17:61755211	T/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	2e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7503807	0.664	rs35524093	chr17:78574246	A/G	cg18469159	chr17:78755841	RPTOR	-0.41	-7.75	-0.34	5.93e-14	Obesity;
LGG	cis	rs8135665	0.600	rs3948	chr22:38456680	G/A	cg13116946	chr22:38479732	SLC16A8	0.53	8.4	0.36	5.43e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs2652834	1.000	rs34575783	chr15:63397686	G/C	cg05507819	chr15:63340323	TPM1	0.58	7.83	0.34	3.45e-14	HDL cholesterol;
LGG	cis	rs7223966	1.000	rs2874121	chr17:61731024	C/T	cg11494091	chr17:61959527	GH2	0.51	8.17	0.36	2.88e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg02002194	chr4:3960332	NA	0.41	7.29	0.32	1.32e-12	Retinal vascular caliber;
LGG	cis	rs13102973	0.932	rs4130840	chr4:135869598	T/G	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.46	7.54	0.33	2.58e-13	Bipolar disorder;
LGG	cis	rs2180341	0.700	rs4598100	chr6:127565314	G/A	cg24812749	chr6:127587940	RNF146	0.8	12.68	0.51	7.78e-32	Breast cancer;
LGG	cis	rs4075765	0.764	rs17243231	chr11:26277412	C/T	cg19182008	chr11:26298241	NA	1.0	8.96	0.38	7.81e-18	Cannabis dependence symptom count;
LGG	cis	rs8049634	0.869	rs3759975	chr16:84221085	A/C	cg26466773	chr16:84211947	TAF1C	0.45	7.2	0.32	2.39e-12	Small cell lung carcinoma;
LGG	cis	rs123509	0.913	rs123506	chr3:42775976	T/C	cg12982090	chr3:42733453	KBTBD5	0.96	16.13	0.6	9.25e-47	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7208859	0.573	rs11656278	chr17:29075188	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4132509	1.000	rs12403316	chr1:243956903	C/T	cg21452805	chr1:244014465	NA	0.64	7.59	0.33	1.77e-13	RR interval (heart rate);
LGG	trans	rs1459104	0.759	rs7939392	chr11:55257285	C/T	cg03929089	chr4:120376271	NA	0.62	7.49	0.33	3.48e-13	Body mass index;
LGG	cis	rs6502050	0.835	rs8077926	chr17:80117315	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7811142	1.000	rs6953107	chr7:100095664	C/T	cg11814155	chr7:99998594	ZCWPW1	0.63	9.7	0.41	2.28e-20	Platelet count;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs365132	0.875	rs353496	chr5:176429898	T/C	cg16309518	chr5:176445507	NA	-0.51	-11.25	-0.46	4.05e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs875971	0.862	rs778686	chr7:65835910	C/T	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs611744	0.573	rs629996	chr8:109255206	C/T	cg18478394	chr8:109455254	TTC35	0.48	10.04	0.42	1.38e-21	Dupuytren's disease;
LGG	cis	rs1552244	0.882	rs67762674	chr3:10014485	C/T	cg13047869	chr3:10149882	C3orf24	0.48	7.83	0.34	3.45e-14	Alzheimer's disease;
LGG	cis	rs9549367	0.826	rs2287249	chr13:113889355	A/G	cg18105134	chr13:113819100	PROZ	-0.7	-14.18	-0.55	3.73e-38	Platelet distribution width;
LGG	cis	rs9303280	0.936	rs907091	chr17:37921742	A/G	cg00129232	chr17:37814104	STARD3	-0.46	-8.74	-0.38	4.19e-17	Self-reported allergy;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg00933542	chr6:150070202	PCMT1	0.39	7.2	0.32	2.46e-12	Lung cancer;
LGG	cis	rs41271473	0.526	rs12094319	chr1:228717836	G/C	cg16512390	chr1:228756714	NA	0.61	8.02	0.35	8.72e-15	Chronic lymphocytic leukemia;
LGG	cis	rs6708331	0.941	rs6749886	chr2:70290100	T/C	cg01613454	chr2:70366299	NA	0.54	9.31	0.4	5.34e-19	Obesity-related traits;
LGG	cis	rs1881797	0.872	rs12408686	chr1:247691141	C/T	cg05639522	chr1:247681581	NA	0.62	10.45	0.44	4.33e-23	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs1005277	0.579	rs1740745	chr10:38520056	T/C	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	0.49	9.2	0.39	1.24e-18	Longevity;
LGG	cis	rs3796619	0.924	rs4690209	chr4:1077575	G/A	cg27284194	chr4:1044797	NA	0.56	11.71	0.48	6.33e-28	Recombination rate (males);
LGG	cis	rs7829975	0.606	rs891570	chr8:8794454	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.03	-0.35	8.21e-15	Mood instability;
LGG	cis	rs4808199	1.000	rs7258508	chr19:19475469	T/C	cg03709012	chr19:19516395	GATAD2A	1.01	16.53	0.61	1.34e-48	Nonalcoholic fatty liver disease;
LGG	cis	rs2688608	0.592	rs7080579	chr10:75504029	T/A	cg23231163	chr10:75533350	FUT11	-0.4	-6.79	-0.3	3.37e-11	Inflammatory bowel disease;
LGG	cis	rs2273669	0.588	rs111353760	chr6:109306493	T/G	cg05315195	chr6:109294784	ARMC2	-0.65	-8.5	-0.37	2.63e-16	Prostate cancer;
LGG	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg13902645	chr11:5959945	NA	-0.67	-10.81	-0.45	1.93e-24	DNA methylation (variation);
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.76	-0.38	3.67e-17	Lung cancer;
LGG	cis	rs115575488	0.610	rs12741635	chr1:119593821	A/T	cg05756136	chr1:119680316	WARS2	0.42	6.87	0.3	2.07e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.623	rs77544470	chr17:28934550	C/A	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.33	-0.36	9.12e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg18245976	chr7:158708271	WDR60	0.44	7.52	0.33	2.87e-13	Height;
LGG	cis	rs7945705	0.902	rs7479407	chr11:9023421	C/T	cg00186954	chr11:8933980	ST5;C11orf17	0.34	6.88	0.3	1.95e-11	Hemoglobin concentration;
LGG	cis	rs13191362	1.000	rs13190742	chr6:163008758	G/A	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.19	0.43	3.87e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3735485	0.678	rs10229955	chr7:45156167	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.23	-0.39	9.94e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2694528	0.858	rs158700	chr5:60324081	C/T	cg11474532	chr5:59995715	DEPDC1B	-0.68	-7.28	-0.32	1.45e-12	Parkinson's disease;
LGG	cis	rs953387	0.956	rs4954396	chr2:136927557	A/C	cg07169764	chr2:136633963	MCM6	0.54	8.9	0.38	1.23e-17	Arthritis (juvenile idiopathic);
LGG	trans	rs1814175	0.558	rs5025146	chr11:49795724	C/G	cg03929089	chr4:120376271	NA	-0.95	-19.94	-0.68	2.55e-64	Height;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg01059449	chr18:44338099	ST8SIA5	-0.37	-8.11	-0.35	4.42e-15	Personality dimensions;
LGG	cis	rs6964587	1.000	rs2961020	chr7:91573308	G/A	cg17063962	chr7:91808500	NA	-0.5	-8.75	-0.38	4.11e-17	Breast cancer;
LGG	cis	rs4474465	1.000	rs7950756	chr11:78157309	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.44	-0.37	4.04e-16	Alzheimer's disease (survival time);
LGG	cis	rs28588043	0.877	rs16863950	chr1:170994761	G/A	cg03458344	chr1:170964477	C1orf129	-0.53	-7.22	-0.32	2.19e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs12928939	0.517	rs10852507	chr16:71971900	G/A	cg03805757	chr16:71968109	PKD1L3	-0.68	-13.42	-0.53	6.47e-35	Post bronchodilator FEV1;
LGG	cis	rs9875589	0.509	rs6778884	chr3:14044681	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.46	9.49	0.4	1.18e-19	Ovarian reserve;
LGG	cis	rs2247341	0.894	rs61675353	chr4:1720794	T/G	cg05026014	chr4:1749153	NA	-0.34	-9.47	-0.4	1.46e-19	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4660214	0.666	rs1180376	chr1:39884433	A/G	cg18385671	chr1:39797026	MACF1	0.48	9.77	0.41	1.31e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7523273	0.526	rs12132176	chr1:207884287	A/T	cg22525895	chr1:207977042	MIR29B2	0.45	8.61	0.37	1.13e-16	Schizophrenia;
LGG	cis	rs6772849	0.965	rs67790930	chr3:128310036	C/T	cg08795948	chr3:128337044	NA	0.53	8.74	0.38	4.31e-17	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs7072216	0.726	rs4474372	chr10:100164571	C/T	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.11	-0.31	4.45e-12	Metabolite levels;
LGG	cis	rs7208859	0.673	rs216409	chr17:28906269	C/T	cg01831904	chr17:28903510	LRRC37B2	0.94	12.54	0.5	2.86e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs2576037	0.583	rs501062	chr18:44411135	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.46	-0.53	4.2e-35	Personality dimensions;
LGG	cis	rs9875589	0.509	rs6770928	chr3:14077189	G/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.28	0.46	3.17e-26	Ovarian reserve;
LGG	cis	rs6088590	1.000	rs2295353	chr20:33356511	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	9.85	0.42	6.35e-21	Coronary artery disease;
LGG	trans	rs6601327	0.600	rs10103925	chr8:9652211	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-7.09	-0.31	4.99e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs2404602	0.716	rs12907805	chr15:76690606	C/T	cg23625390	chr15:77176239	SCAPER	0.48	9.36	0.4	3.5e-19	Blood metabolite levels;
LGG	cis	rs727563	0.580	rs202626	chr22:41847190	C/A	cg06634786	chr22:41940651	POLR3H	0.73	12.14	0.49	1.18e-29	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4563143	0.675	rs34113156	chr19:29270822	G/A	cg12756686	chr19:29218302	NA	0.71	11.56	0.47	2.4200000000000002e-27	Methadone dose in opioid dependence;
LGG	cis	rs28595532	0.920	rs115103359	chr4:119739608	A/T	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg21735648	chr20:46130382	NCOA3	-0.47	-8.24	-0.36	1.84e-15	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs2204008	0.774	rs11495520	chr12:38060605	T/G	cg13010199	chr12:38710504	ALG10B	0.71	14.11	0.55	7.21e-38	Bladder cancer;
LGG	cis	rs763121	0.785	rs5750646	chr22:39013830	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.29	0.65	1.17e-56	Menopause (age at onset);
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg02110701	chr16:88556838	ZFPM1	0.38	6.9	0.31	1.73e-11	Electrocardiographic conduction measures;
LGG	cis	rs16976116	0.901	rs28489312	chr15:55494048	A/C	cg11288833	chr15:55489084	RSL24D1	0.53	7.29	0.32	1.31e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg18279126	chr7:2041391	MAD1L1	0.32	6.69	0.3	6.39e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs68170813	0.559	rs1121312	chr7:106927820	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.54	-0.44	2e-23	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs1881123	chr7:1084706	C/T	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7208859	0.623	rs56018041	chr17:29059985	G/A	cg13385521	chr17:29058706	SUZ12P	0.93	10.87	0.45	1.11e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12230513	1.000	rs76126658	chr12:55942458	C/A	cg19537932	chr12:55886519	OR6C68	-0.46	-7.27	-0.32	1.49e-12	Contrast sensitivity;
LGG	cis	rs7615952	0.599	rs12486459	chr3:125741465	T/G	cg02772935	chr3:125709198	NA	-0.53	-6.73	-0.3	4.9e-11	Blood pressure (smoking interaction);
LGG	cis	rs6840360	0.615	rs4696268	chr4:152464723	G/A	cg25486957	chr4:152246857	NA	-0.5	-8.35	-0.36	7.71e-16	Intelligence (multi-trait analysis);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26820641	chr20:30326728	TPX2	-0.46	-6.87	-0.3	2.02e-11	Systemic lupus erythematosus;
LGG	trans	rs7824557	0.527	rs2736296	chr8:11234844	G/A	cg02002194	chr4:3960332	NA	0.45	8.08	0.35	5.61e-15	Retinal vascular caliber;
LGG	trans	rs853679	0.546	rs200989	chr6:27816442	A/G	cg06606381	chr12:133084897	FBRSL1	-1.0	-10.49	-0.44	3.15e-23	Depression;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg06968155	chr5:131705112	SLC22A5	0.73	8.46	0.37	3.49e-16	Rheumatoid arthritis;
LGG	cis	rs7312774	0.529	rs12314792	chr12:107333672	T/C	cg16260113	chr12:107380972	MTERFD3	0.91	8.47	0.37	3.18e-16	Severe influenza A (H1N1) infection;
LGG	trans	rs877282	0.797	rs7079164	chr10:756363	A/G	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs3857536	0.740	rs4710574	chr6:66890631	T/G	cg07460842	chr6:66804631	NA	-0.48	-8.3	-0.36	1.19e-15	Blood trace element (Cu levels);
LGG	cis	rs2816316	1.000	rs1323296	chr1:192537508	A/G	cg02586212	chr1:192544902	RGS1	0.45	9.02	0.39	4.85e-18	Celiac disease;
LGG	cis	rs6546550	0.935	rs2305523	chr2:70039677	G/T	cg02498382	chr2:70120550	SNRNP27	0.4	7.47	0.33	4.04e-13	Prevalent atrial fibrillation;
LGG	cis	rs67133203	0.904	rs7305638	chr12:51363790	C/T	cg14688905	chr12:51403056	SLC11A2	0.78	11.99	0.49	5e-29	Urinary tract infection frequency;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09662431	chr10:73975914	ASCC1;C10orf104	0.52	8.03	0.35	8e-15	Gut microbiome composition (summer);
LGG	trans	rs7829975	0.807	rs519019	chr8:8595104	A/T	cg02002194	chr4:3960332	NA	0.47	9.02	0.39	4.93e-18	Mood instability;
LGG	cis	rs875971	0.862	rs908915	chr7:65614651	G/T	cg11764359	chr7:65958608	NA	-0.74	-13.41	-0.53	7.13e-35	Aortic root size;
LGG	cis	rs440932	1.000	rs440932	chr8:9026929	T/C	cg06636001	chr8:8085503	FLJ10661	0.41	6.89	0.3	1.87e-11	High light scatter reticulocyte percentage of red cells;
LGG	cis	rs2597513	0.789	rs2731342	chr3:13562812	C/T	cg24006715	chr3:13568212	NA	0.63	10.46	0.44	3.86e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs10421328	0.784	rs8107058	chr19:19759651	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	7.22	0.32	2.09e-12	Parental longevity (combined parental age at death);
LGG	trans	rs10435719	0.867	rs6999030	chr8:11795308	G/A	cg16141378	chr3:129829833	LOC729375	-0.35	-7.86	-0.34	2.8e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1318772	0.932	rs58479323	chr5:112877691	C/T	cg12552261	chr5:112820674	MCC	0.68	7.65	0.33	1.19e-13	F-cell distribution;
LGG	cis	rs4319547	0.695	rs11058034	chr12:122894936	G/T	cg23029597	chr12:123009494	RSRC2	0.93	15.99	0.6	3.76e-46	Body mass index;
LGG	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg17202724	chr17:61916730	SMARCD2	0.39	7.54	0.33	2.49e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2953174	0.938	rs2953167	chr2:241539366	T/C	cg07929629	chr2:241523174	NA	0.56	6.73	0.3	5.15e-11	Bipolar disorder;
LGG	cis	rs9581857	0.556	rs9579085	chr13:28041039	G/A	cg01674679	chr13:27998804	GTF3A	-0.6	-8.18	-0.36	2.68e-15	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs597539	0.617	rs672853	chr11:68636362	G/A	cg11245990	chr11:68621969	NA	0.43	9.05	0.39	4.01e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9894429	0.646	rs6565609	chr17:79592267	G/A	cg10661904	chr17:79619235	PDE6G	-0.49	-10.04	-0.42	1.36e-21	Eye color traits;
LGG	cis	rs7945718	0.967	rs10831906	chr11:12783042	C/T	cg25843174	chr11:12811716	TEAD1	0.39	8.18	0.36	2.77e-15	Educational attainment (years of education);
LGG	cis	rs910316	1.000	rs12889472	chr14:75543979	A/G	cg08847533	chr14:75593920	NEK9	0.63	12.01	0.49	4.14e-29	Height;
LGG	cis	rs17209837	0.607	rs4148821	chr7:87079602	G/C	cg00919237	chr7:87102261	ABCB4	-0.75	-14.01	-0.55	1.91e-37	Gallbladder cancer;
LGG	cis	rs951366	0.764	rs708724	chr1:205743663	A/C	cg26354017	chr1:205819088	PM20D1	0.87	20.7	0.69	7.15e-68	Menarche (age at onset);
LGG	cis	rs6088580	0.524	rs6088564	chr20:33249444	A/G	cg08999081	chr20:33150536	PIGU	-0.3	-7.04	-0.31	6.85e-12	Glomerular filtration rate (creatinine);
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg15112032	chr13:58204365	PCDH17	0.72	6.71	0.3	5.73e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg08923054	chr8:41654455	ANK1	0.79	13.74	0.54	2.78e-36	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	trans	rs6582630	0.555	rs11181657	chr12:38381858	T/C	cg06521331	chr12:34319734	NA	0.5	8.76	0.38	3.84e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1059312	1.000	rs7136092	chr12:129280164	G/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.8	-18.23	-0.65	2.3e-56	Systemic lupus erythematosus;
LGG	cis	rs597539	0.616	rs513476	chr11:68698996	C/T	cg04772025	chr11:68637568	NA	0.72	12.55	0.5	2.55e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.1	-0.42	8.6e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	1.000	rs7168156	chr15:68102933	T/C	cg08079166	chr15:68083412	MAP2K5	0.35	7.82	0.34	3.51e-14	Restless legs syndrome;
LGG	cis	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg00405596	chr8:11794950	NA	-0.43	-6.72	-0.3	5.24e-11	Retinal vascular caliber;
LGG	cis	rs7666738	0.830	rs6834014	chr4:98951431	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9788682	1.000	rs7164594	chr15:78803057	C/T	cg24631222	chr15:78858424	CHRNA5	0.45	6.95	0.31	1.28e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.34	-0.36	8.82e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs950776	0.518	rs12915428	chr15:78823368	G/A	cg06917634	chr15:78832804	PSMA4	0.83	17.54	0.63	3.41e-53	Sudden cardiac arrest;
LGG	cis	rs6831352	0.918	rs13133647	chr4:100058727	C/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs4740619	0.525	rs4146293	chr9:15811562	T/G	cg14451791	chr9:16040625	NA	0.3	7.61	0.33	1.53e-13	Body mass index;
LGG	cis	rs7072216	0.763	rs10883090	chr10:100167236	G/C	cg26618903	chr10:100175079	PYROXD2	-0.29	-7.2	-0.32	2.5e-12	Metabolite levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02949340	chr10:102820489	KAZALD1	0.46	7.7	0.34	8.47e-14	Gut microbiota (bacterial taxa);
LGG	trans	rs61931739	0.534	rs10844732	chr12:34037104	A/C	cg26384229	chr12:38710491	ALG10B	0.8	15.94	0.6	6.71e-46	Morning vs. evening chronotype;
LGG	cis	rs4803468	1.000	rs4803465	chr19:41918158	A/G	cg14132834	chr19:41945861	ATP5SL	0.48	9.17	0.39	1.61e-18	Height;
LGG	cis	rs2131877	0.830	rs11707112	chr3:194881473	G/T	cg07250128	chr3:194833983	C3orf21	0.43	7.31	0.32	1.17e-12	Non-small cell lung cancer;
LGG	cis	rs10504229	0.683	rs16921831	chr8:58111142	G/A	cg26174226	chr8:58114915	NA	-0.58	-8.39	-0.36	5.98e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9896933	0.832	rs75552659	chr17:80804630	G/A	cg15664640	chr17:80829946	TBCD	-0.65	-9.05	-0.39	3.98e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs283228	1.000	rs283182	chr6:101745729	A/T	cg27451362	chr6:101846650	GRIK2	0.53	8.99	0.39	6.23e-18	Coenzyme Q10 levels;
LGG	cis	rs1046896	0.503	rs2459703	chr17:80690632	C/T	cg10935494	chr17:80760059	TBCD	0.38	7.07	0.31	5.69e-12	Glycated hemoglobin levels;
LGG	cis	rs9329289	0.851	rs9732077	chr10:2539925	A/T	cg05625103	chr10:2543513	NA	0.39	7.4	0.33	6.4e-13	Age-related hearing impairment;
LGG	cis	rs2243480	1.000	rs2707831	chr7:66062511	G/A	cg18252515	chr7:66147081	NA	-1.41	-20.58	-0.69	2.5e-67	Diabetic kidney disease;
LGG	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg15704280	chr7:45808275	SEPT13	0.49	7.97	0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs924043	0.500	rs12528344	chr6:170395680	G/A	cg00389036	chr6:170409598	NA	0.54	6.89	0.31	1.81e-11	Type 1 diabetes;
LGG	cis	rs490234	0.702	rs7864945	chr9:128373469	C/T	cg14078157	chr9:128172775	NA	-0.55	-10.3	-0.43	1.49e-22	Mean arterial pressure;
LGG	cis	rs3889237	1.000	rs3889237	chr17:64779430	A/C	cg09655520	chr17:64786064	PRKCA	0.41	8.53	0.37	2.04e-16	Height;
LGG	cis	rs11148252	0.583	rs9536048	chr13:52958788	T/C	cg00761968	chr13:53314142	LECT1	-0.36	-6.76	-0.3	4.28e-11	Lewy body disease;
LGG	cis	rs7582180	0.764	rs10180423	chr2:100919012	C/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.21	-0.58	1.19e-42	Intelligence (multi-trait analysis);
LGG	cis	rs701145	0.585	rs1470664	chr3:153865193	C/T	cg17054900	chr3:154042577	DHX36	0.76	9.06	0.39	3.8e-18	Coronary artery disease;
LGG	cis	rs6496044	0.568	rs3743321	chr15:86064968	A/G	cg13263323	chr15:86062960	AKAP13	-0.37	-8.24	-0.36	1.73e-15	Interstitial lung disease;
LGG	cis	rs2688608	0.869	rs2250140	chr10:75612881	T/C	cg23231163	chr10:75533350	FUT11	-0.39	-6.76	-0.3	4.05e-11	Inflammatory bowel disease;
LGG	cis	rs7681440	0.874	rs1372522	chr4:90765280	A/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.83	-0.34	3.25e-14	Dementia with Lewy bodies;
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg06925179	chr17:43578568	NA	-0.31	-8.14	-0.35	3.7e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4919087	0.748	rs701810	chr10:98974849	C/T	cg25902810	chr10:99078978	FRAT1	-0.42	-7.38	-0.32	7.32e-13	Monocyte count;
LGG	cis	rs34599045	0.522	rs78073526	chr1:152901982	G/C	cg07796016	chr1:152779584	LCE1C	-0.81	-7.51	-0.33	3.03e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12497850	0.931	rs7431710	chr3:48935583	G/A	cg07636037	chr3:49044803	WDR6	1.06	25.82	0.77	1.01e-91	Parkinson's disease;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg24607181	chr17:41446203	NA	-0.29	-6.76	-0.3	4.17e-11	Menopause (age at onset);
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg14159672	chr1:205819179	PM20D1	0.77	16.44	0.61	3.74e-48	Menarche (age at onset);
LGG	cis	rs9788682	0.748	rs2456020	chr15:78868398	C/T	cg24631222	chr15:78858424	CHRNA5	0.42	6.76	0.3	4.24e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs12579753	1.000	rs7956826	chr12:82173365	A/G	cg07923666	chr12:49932857	KCNH3	-0.5	-7.5	-0.33	3.19e-13	Resting heart rate;
LGG	cis	rs10504229	0.679	rs111843870	chr8:58126798	A/G	cg11062466	chr8:58055876	NA	0.56	9.18	0.39	1.48e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs55883249	1.000	rs62119391	chr2:9712272	A/G	cg23886495	chr2:9695866	ADAM17	0.67	9.55	0.41	7.77e-20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs8038465	0.622	rs56712926	chr15:73886849	G/T	cg15420318	chr15:73925796	NPTN	0.49	8.31	0.36	1.05e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs721917	0.507	rs2819101	chr10:81696742	G/A	cg25562619	chr10:81652821	NA	-0.34	-7.67	-0.34	1.01e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs2033732	0.706	rs1370414	chr8:85076043	G/A	cg05716166	chr8:85095498	RALYL	0.46	7.32	0.32	1.1e-12	Body mass index;
LGG	cis	rs10911251	0.508	rs944970	chr1:183112566	T/C	cg07245641	chr1:182991651	LAMC1	0.4	9.28	0.4	6.56e-19	Colorectal cancer;
LGG	cis	rs977987	0.732	rs999675	chr16:75306402	C/T	cg07303275	chr16:75499416	TMEM170A	0.38	6.73	0.3	4.98e-11	Dupuytren's disease;
LGG	cis	rs11105298	0.891	rs10858869	chr12:89857611	C/T	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04267008	chr7:1944627	MAD1L1	0.56	9.31	0.4	5.36e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.607	rs9383941	chr6:150233236	A/G	cg11878867	chr6:150167359	LRP11	0.46	8.01	0.35	9.49e-15	Lung cancer;
LGG	cis	rs757110	0.770	rs2051772	chr11:17389850	G/A	cg04705435	chr11:17411270	KCNJ11	0.43	8.33	0.36	8.91e-16	Type 2 diabetes;
LGG	cis	rs873946	0.648	rs12766050	chr10:134549108	G/A	cg27286337	chr10:134555280	INPP5A	0.89	13.38	0.53	9.82e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs769267	0.930	rs1047361	chr19:19606634	G/A	cg01262667	chr19:19385393	TM6SF2	0.44	11.38	0.47	1.27e-26	Tonsillectomy;
LGG	cis	rs13082711	0.911	rs6776318	chr3:27523457	T/C	cg02860705	chr3:27208620	NA	0.73	12.81	0.51	2.22e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs6461049	0.765	rs4719431	chr7:2140312	T/C	cg21782813	chr7:2030301	MAD1L1	0.43	10.56	0.44	1.68e-23	Schizophrenia;
LGG	cis	rs11971779	0.838	rs4728468	chr7:139122978	G/A	cg07862535	chr7:139043722	LUC7L2	0.58	9.11	0.39	2.58e-18	Diisocyanate-induced asthma;
LGG	cis	rs9914544	0.652	rs7207570	chr17:18723995	C/T	cg26378065	chr17:18585709	ZNF286B	0.45	8.28	0.36	1.29e-15	Educational attainment (years of education);
LGG	cis	rs10028773	0.515	rs9994651	chr4:120587803	C/T	cg09307838	chr4:120376055	NA	0.67	10.72	0.45	4.2e-24	Educational attainment;
LGG	cis	rs11064837	0.523	rs3930004	chr12:120102426	C/A	cg25937854	chr12:120150414	CIT	-0.68	-11.31	-0.47	2.27e-26	Schizophrenia;
LGG	cis	rs2274273	0.870	rs7153612	chr14:55788762	T/C	cg04306507	chr14:55594613	LGALS3	0.62	17.19	0.62	1.35e-51	Protein biomarker;
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg05091796	chr16:4465799	CORO7	-0.64	-10.56	-0.44	1.75e-23	Schizophrenia;
LGG	cis	rs344364	0.511	rs1742468	chr16:1950243	C/G	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.47	-7.19	-0.32	2.66e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs875971	0.895	rs3857684	chr7:65938158	G/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.75	-0.38	4.01e-17	Aortic root size;
LGG	cis	rs7590720	1.000	rs7590720	chr2:216898658	A/G	cg12620499	chr2:216877984	MREG	-0.75	-13.89	-0.54	6.59e-37	Alcohol dependence;
LGG	cis	rs9925964	0.748	rs11640961	chr16:30979818	C/T	cg02466173	chr16:30829666	NA	0.39	7.34	0.32	9.44e-13	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6912958	0.781	rs6940150	chr6:88287114	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	trans	rs7824557	0.564	rs11782430	chr8:11226071	A/G	cg06636001	chr8:8085503	FLJ10661	-0.51	-9.02	-0.39	4.91e-18	Retinal vascular caliber;
LGG	cis	rs7937682	0.593	rs1944121	chr11:111347223	T/C	cg09085632	chr11:111637200	PPP2R1B	0.62	10.37	0.43	8.25e-23	Primary sclerosing cholangitis;
LGG	cis	rs774359	0.797	rs10738775	chr9:27514318	T/A	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.27	-0.36	1.42e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs9549367	0.826	rs1885688	chr13:113894236	G/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.7	-0.37	5.68e-17	Platelet distribution width;
LGG	cis	rs36093844	0.800	rs76663264	chr11:85578455	C/G	cg16165120	chr11:85566439	CCDC83	-0.44	-7.09	-0.31	5.04e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs68170813	0.559	rs17428071	chr7:106878200	C/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.93	-0.45	6.76e-25	Coronary artery disease;
LGG	trans	rs1432133	0.844	rs12899579	chr15:27224321	C/T	cg00031340	chr16:81130212	GCSH;LOC100329108	0.45	6.8	0.3	3.21e-11	Hepatitis;
LGG	trans	rs11098499	0.908	rs71614449	chr4:120387055	C/T	cg25214090	chr10:38739885	LOC399744	0.69	12.29	0.5	2.99e-30	Corneal astigmatism;
LGG	cis	rs7975161	0.882	rs4964270	chr12:104652398	A/G	cg25273343	chr12:104657179	TXNRD1	-0.79	-10.59	-0.44	1.27e-23	Toenail selenium levels;
LGG	cis	rs11190604	1.000	rs2273694	chr10:102256496	G/T	cg07570687	chr10:102243282	WNT8B	0.41	7.08	0.31	5.24e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07659893	chr17:61819838	STRADA	-0.46	-7.47	-0.33	4.08e-13	Prudent dietary pattern;
LGG	cis	rs6997458	0.742	rs11985733	chr8:86347074	A/G	cg02393479	chr8:86352350	CA3	-0.31	-6.78	-0.3	3.6e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7582180	0.629	rs12620139	chr2:100943446	A/G	cg14675211	chr2:100938903	LONRF2	0.68	12.33	0.5	2.08e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7011049	0.778	rs79555929	chr8:53866655	C/T	cg26025543	chr8:53854495	NA	0.59	8.29	0.36	1.26e-15	Systolic blood pressure;
LGG	cis	rs2762353	0.718	rs1165207	chr6:25865266	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.35	-0.43	9.7e-23	Blood metabolite levels;
LGG	cis	rs8067545	0.641	rs203458	chr17:19816898	A/C	cg13482628	chr17:19912719	NA	0.52	9.55	0.41	7.42e-20	Schizophrenia;
LGG	cis	rs6952808	1.000	rs6952808	chr7:1886535	C/G	cg10360139	chr7:1886902	MAD1L1	-0.42	-7.39	-0.32	6.83e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.830	rs2665841	chr17:61861219	A/T	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs2404602	0.647	rs11072626	chr15:77090826	A/G	cg23625390	chr15:77176239	SCAPER	-0.76	-15.18	-0.58	1.55e-42	Blood metabolite levels;
LGG	trans	rs45509595	0.841	rs9368531	chr6:27781872	G/C	cg06606381	chr12:133084897	FBRSL1	-0.99	-10.63	-0.44	9.15e-24	Breast cancer;
LGG	cis	rs17453880	0.889	rs6871986	chr5:151947459	T/C	cg12297329	chr5:152029980	NA	-0.83	-19.39	-0.67	9.44e-62	Subjective well-being;
LGG	cis	rs9513627	0.833	rs73556146	chr13:100116920	A/G	cg25919922	chr13:100150906	NA	-0.71	-7.58	-0.33	1.85e-13	Obesity-related traits;
LGG	cis	rs2797369	0.883	rs2518330	chr6:101697518	A/G	cg27451362	chr6:101846650	GRIK2	0.8	10.61	0.44	1.12e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg06873352	chr17:61820015	STRADA	0.75	14.07	0.55	1.05e-37	Prudent dietary pattern;
LGG	cis	rs4604732	0.631	rs74154675	chr1:247625836	G/A	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.1	0.39	2.68e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs35110281	0.805	rs2838317	chr21:44991791	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.55	-0.41	7.28e-20	Mean corpuscular volume;
LGG	cis	rs9902453	1.000	rs4465650	chr17:28396721	C/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.65	12.86	0.51	1.35e-32	Coffee consumption (cups per day);
LGG	cis	rs1577917	1.000	rs1857964	chr6:86635994	A/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.59	-9.83	-0.42	7.44e-21	Response to antipsychotic treatment;
LGG	trans	rs61931739	0.613	rs4931773	chr12:33749131	G/A	cg26384229	chr12:38710491	ALG10B	0.46	8.18	0.36	2.69e-15	Morning vs. evening chronotype;
LGG	cis	rs66573146	0.831	rs6851488	chr4:6987412	C/T	cg00086871	chr4:6988644	TBC1D14	1.11	10.35	0.43	9.98e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs17376456	0.825	rs12716453	chr5:93271697	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.94	10.6	0.44	1.15e-23	Diabetic retinopathy;
LGG	cis	rs2739330	0.760	rs5760095	chr22:24247293	A/G	cg01238044	chr22:24384105	GSTT1	-0.45	-7.56	-0.33	2.17e-13	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7552404	0.924	rs7535991	chr1:76162624	C/T	cg22875332	chr1:76189707	ACADM	0.62	11.02	0.46	3.17e-25	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6938	0.534	rs1130741	chr15:75189930	A/G	cg14664628	chr15:75095509	CSK	-0.55	-10.69	-0.44	5.46e-24	Breast cancer;
LGG	cis	rs9325144	0.602	rs10785590	chr12:38694145	C/T	cg26384229	chr12:38710491	ALG10B	0.76	15.34	0.58	3.14e-43	Morning vs. evening chronotype;
LGG	cis	rs2692947	0.770	rs11689832	chr2:96554851	A/C	cg22654517	chr2:96458247	NA	0.38	7.52	0.33	2.86e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs9790314	0.747	rs9990115	chr3:160838412	C/G	cg04691961	chr3:161091175	C3orf57	-0.54	-11.74	-0.48	5.07e-28	Morning vs. evening chronotype;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg08508337	chr8:144660607	NAPRT1	0.91	7.07	0.31	5.74e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs7173743	0.967	rs28694044	chr15:79134718	A/T	cg00540400	chr15:79124168	NA	-0.43	-8.63	-0.37	1.02e-16	Coronary artery disease;
LGG	cis	rs4975709	0.589	rs4975747	chr5:1862836	G/A	cg11168104	chr5:1857477	NA	-0.4	-7.0	-0.31	9.18e-12	Cardiovascular disease risk factors;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27228168	chr16:54320674	IRX3	0.46	6.84	0.3	2.57e-11	Gut microbiome composition (summer);
LGG	cis	rs950027	0.620	rs1153862	chr15:45631868	A/G	cg26924012	chr15:45694286	SPATA5L1	0.68	12.29	0.5	3.08e-30	Response to fenofibrate (adiponectin levels);
LGG	cis	rs9527	0.615	rs7096452	chr10:104736563	G/A	cg04362960	chr10:104952993	NT5C2	0.57	10.57	0.44	1.58e-23	Arsenic metabolism;
LGG	cis	rs1451375	0.698	rs1839740	chr7:50646280	C/T	cg00647317	chr7:50633725	DDC	-0.33	-7.47	-0.33	4.01e-13	Malaria;
LGG	cis	rs920590	0.684	rs57837509	chr8:19670088	A/G	cg03894339	chr8:19674705	INTS10	0.66	10.6	0.44	1.22e-23	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs35110281	0.805	rs8131005	chr21:45041954	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.58	0.41	5.96e-20	Mean corpuscular volume;
LGG	cis	rs4740619	0.766	rs1341736	chr9:15799724	G/T	cg14451791	chr9:16040625	NA	0.33	8.31	0.36	1.08e-15	Body mass index;
LGG	cis	rs4906332	1.000	rs2065017	chr14:103879579	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.97	-0.35	1.27e-14	Coronary artery disease;
LGG	cis	rs11574514	1.000	rs9938862	chr16:67723801	T/C	cg09738193	chr16:67926317	PSKH1	-0.73	-6.67	-0.3	7.34e-11	Crohn's disease;
LGG	cis	rs9879311	0.966	rs4684685	chr3:10411553	C/T	cg11030744	chr3:10328490	GHRL;GHRLOS	0.34	6.74	0.3	4.69e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15459742	chr9:111775564	CTNNAL1	0.48	7.5	0.33	3.36e-13	Gut microbiome composition (summer);
LGG	cis	rs11866815	0.901	rs9938786	chr16:399054	C/T	cg07915516	chr16:377344	AXIN1	-0.27	-6.79	-0.3	3.51e-11	Body mass index;
LGG	cis	rs6121246	0.609	rs2149281	chr20:30417918	G/A	cg13852791	chr20:30311386	BCL2L1	0.94	18.19	0.65	3.71e-56	Mean corpuscular hemoglobin;
LGG	trans	rs3749237	1.000	rs11130214	chr3:49735746	C/G	cg21659725	chr3:3221576	CRBN	-0.74	-11.86	-0.48	1.58e-28	Resting heart rate;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg07701084	chr6:150067640	NUP43	0.61	11.28	0.46	3.1e-26	Lung cancer;
LGG	cis	rs753955	0.592	rs7325382	chr13:24350093	T/C	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-7.34	-0.32	9.73e-13	Lung cancer;
LGG	trans	rs28735056	0.572	rs4799100	chr18:77640207	A/G	cg05926928	chr17:57297772	GDPD1	-0.7	-12.74	-0.51	4.56e-32	Schizophrenia;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.75e-21	Schizophrenia;
LGG	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg15485101	chr11:133734466	NA	0.6	10.58	0.44	1.41e-23	Childhood ear infection;
LGG	trans	rs7395662	1.000	rs6485882	chr11:48592435	C/G	cg03929089	chr4:120376271	NA	0.42	6.79	0.3	3.42e-11	HDL cholesterol;
LGG	cis	rs453301	0.686	rs2409120	chr8:8882571	G/C	cg11995313	chr8:8860691	ERI1	0.44	7.54	0.33	2.5e-13	Joint mobility (Beighton score);
LGG	cis	rs1881797	0.932	rs10925071	chr1:247686521	C/T	cg18198730	chr1:247681584	NA	-0.74	-12.64	-0.51	1.13e-31	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7623687	0.786	rs73077157	chr3:49749705	A/C	cg19401529	chr3:49056140	DALRD3	0.76	7.4	0.33	6.41e-13	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs45430	1.000	rs416981	chr21:42745414	G/A	cg22778903	chr21:42741698	MX2	0.44	8.75	0.38	4.11e-17	Melanoma;
LGG	cis	rs12618769	0.597	rs3754891	chr2:99088018	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.51	0.37	2.41e-16	Bipolar disorder;
LGG	cis	rs11148252	0.538	rs9526842	chr13:52727723	T/G	cg12458913	chr13:53173898	NA	0.56	10.18	0.43	4.22e-22	Lewy body disease;
LGG	cis	rs2839186	0.807	rs2032226	chr21:47680352	G/A	cg13732083	chr21:47605072	C21orf56	0.49	8.14	0.35	3.75e-15	Testicular germ cell tumor;
LGG	cis	rs3736485	0.578	rs2305716	chr15:51981291	C/T	cg13474965	chr15:52030001	LYSMD2	0.42	7.13	0.31	3.82e-12	BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs16854884	0.657	rs6791078	chr3:143736876	A/G	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs380904	0.552	rs10099003	chr8:144645460	C/T	cg13399544	chr8:144649678	C8orf73	-0.28	-6.68	-0.3	6.95e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs12762955	0.561	rs4880744	chr10:1012026	A/G	cg25019033	chr10:957182	NA	0.33	6.85	0.3	2.34e-11	Response to angiotensin II receptor blocker therapy;
LGG	trans	rs6787172	0.622	rs2222326	chr3:158068532	G/A	cg23275840	chr4:47708675	CORIN	-0.36	-7.41	-0.33	6.08e-13	Subjective well-being;
LGG	cis	rs1799949	1.000	rs11656097	chr17:41290613	G/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.62	0.33	1.44e-13	Menopause (age at onset);
LGG	cis	rs11203032	1.000	rs17117088	chr10:90961799	G/A	cg16672925	chr10:90967113	CH25H	0.84	11.62	0.48	1.42e-27	Heart failure;
LGG	cis	rs12291225	0.535	rs10832248	chr11:14413087	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.03	-0.42	1.53e-21	Sense of smell;
LGG	cis	rs7226408	0.901	rs72887101	chr18:34513774	G/T	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs9910055	1.000	rs2071167	chr17:42287519	A/G	cg16434002	chr17:42200994	HDAC5	0.45	7.9	0.34	2e-14	Total body bone mineral density;
LGG	trans	rs61931739	0.749	rs11053093	chr12:34231095	A/G	cg13010199	chr12:38710504	ALG10B	0.44	8.55	0.37	1.81e-16	Morning vs. evening chronotype;
LGG	cis	rs10262624	0.504	rs59865844	chr7:23733040	T/C	cg18857889	chr7:23719661	C7orf46	0.35	7.24	0.32	1.91e-12	Schizophrenia;
LGG	cis	rs17221829	0.627	rs10830315	chr11:89375574	G/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	trans	rs970548	0.730	rs61854093	chr10:45934881	C/A	cg20477318	chr10:51623047	TIMM23	0.63	7.72	0.34	7.1e-14	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs7849585	1.000	rs12338076	chr9:139121740	A/C	cg14094347	chr9:139131620	QSOX2	-0.48	-9.98	-0.42	2.2e-21	Height;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg02127607	chr17:61920694	SMARCD2	0.47	8.61	0.37	1.13e-16	Prudent dietary pattern;
LGG	cis	rs12579753	0.667	rs7485826	chr12:82301554	C/T	cg07988820	chr12:82153109	PPFIA2	-0.51	-7.32	-0.32	1.11e-12	Resting heart rate;
LGG	cis	rs992157	0.835	rs4674283	chr2:219144254	G/A	cg20019365	chr2:219134978	PNKD;AAMP	-0.62	-10.34	-0.43	1.07e-22	Colorectal cancer;
LGG	cis	rs4363385	0.818	rs1334850	chr1:153004519	G/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	cis	rs4555082	0.718	rs2816619	chr14:105732551	G/C	cg06808227	chr14:105710500	BRF1	-0.63	-10.58	-0.44	1.38e-23	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg16405210	chr4:1374714	KIAA1530	-0.4	-6.66	-0.3	7.91e-11	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00838250	chr3:186287958	TBCCD1;DNAJB11	0.44	7.51	0.33	2.98e-13	Cognitive performance;
LGG	trans	rs11098499	0.865	rs4001305	chr4:120359236	G/T	cg25214090	chr10:38739885	LOC399744	0.67	11.7	0.48	6.88e-28	Corneal astigmatism;
LGG	cis	rs1552244	0.882	rs113268531	chr3:10167069	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.17	20.02	0.68	1.09e-64	Alzheimer's disease;
LGG	cis	rs735396	1.000	rs2464195	chr12:121435475	G/A	cg14101638	chr12:121416612	HNF1A	0.35	7.48	0.33	3.65e-13	N-glycan levels;
LGG	cis	rs61931739	0.500	rs7308338	chr12:34553181	A/G	cg06521331	chr12:34319734	NA	-0.54	-9.83	-0.42	7.79e-21	Morning vs. evening chronotype;
LGG	cis	rs10504229	1.000	rs72650892	chr8:58179714	A/G	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.534	rs1705757	chr12:34091637	A/G	cg26384229	chr12:38710491	ALG10B	0.73	14.73	0.56	1.52e-40	Morning vs. evening chronotype;
LGG	cis	rs9611565	0.500	rs2011053	chr22:42121278	G/A	cg03806693	chr22:41940476	POLR3H	0.89	14.84	0.57	4.89e-41	Vitiligo;
LGG	cis	rs240764	0.817	rs239204	chr6:101135580	T/C	cg09795085	chr6:101329169	ASCC3	0.46	7.67	0.34	1.03e-13	Neuroticism;
LGG	cis	rs2692947	0.770	rs2579552	chr2:96737083	A/G	cg22654517	chr2:96458247	NA	0.37	7.3	0.32	1.29e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg11877270	chr2:65658583	SPRED2	-0.43	-7.15	-0.32	3.44e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg07701084	chr6:150067640	NUP43	0.42	7.7	0.34	8.26e-14	Testicular germ cell tumor;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23088430	chr8:144679052	EEF1D;TIGD5	0.48	8.47	0.37	3.18e-16	Bipolar disorder;
LGG	cis	rs4262150	0.883	rs72799157	chr5:152119416	C/A	cg12297329	chr5:152029980	NA	-0.7	-12.9	-0.51	9.38e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs9282681	chr16:89805914	T/C	cg26513180	chr16:89883248	FANCA	1.0	9.64	0.41	3.56e-20	Skin colour saturation;
LGG	cis	rs3812049	0.737	rs790154	chr5:127501235	A/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.63	9.91	0.42	4.16e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs6840360	0.530	rs6839802	chr4:152485834	G/A	cg22705602	chr4:152727874	NA	-0.33	-7.92	-0.35	1.79e-14	Intelligence (multi-trait analysis);
LGG	cis	rs3747547	0.786	rs72726024	chr9:38020824	G/T	cg13774184	chr9:37916125	SHB	-0.69	-7.07	-0.31	5.67e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs11039798	0.588	rs10160381	chr11:48599491	A/G	cg15704280	chr7:45808275	SEPT13	0.73	10.05	0.42	1.26e-21	Axial length;
LGG	cis	rs10911363	0.615	rs9286848	chr1:183426249	C/G	cg23894439	chr1:183413866	NA	-0.48	-8.98	-0.39	6.79e-18	Systemic lupus erythematosus;
LGG	cis	rs938554	0.876	rs10017945	chr4:9937852	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.07	0.31	5.57e-12	Blood metabolite levels;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg03806693	chr22:41940476	POLR3H	-1.13	-20.7	-0.69	7e-68	Vitiligo;
LGG	cis	rs1799949	0.965	rs8067269	chr17:41235799	C/T	cg25172604	chr17:41446521	NA	-0.3	-7.04	-0.31	6.94e-12	Menopause (age at onset);
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs701145	0.640	rs357495	chr3:153939099	A/G	cg17054900	chr3:154042577	DHX36	0.83	9.26	0.4	7.38e-19	Coronary artery disease;
LGG	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg16414030	chr3:133502952	NA	-0.6	-10.45	-0.44	4.16e-23	Iron status biomarkers;
LGG	cis	rs17767392	0.958	rs7156313	chr14:72052310	G/C	cg02058870	chr14:72053146	SIPA1L1	-0.48	-9.73	-0.41	1.72e-20	Mitral valve prolapse;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19839588	chr6:42419466	TRERF1	0.52	8.07	0.35	5.95e-15	Gut microbiome composition (summer);
LGG	cis	rs11971779	0.564	rs6467841	chr7:139066092	T/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs2444240	1.000	rs470606	chr11:120028202	T/G	cg16005559	chr11:120040616	NA	-0.32	-7.13	-0.31	3.91e-12	Corneal curvature;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg19147804	chr7:1989927	MAD1L1	-0.59	-11.95	-0.49	7.13e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.568	rs4420527	chr16:89814188	C/T	cg02609749	chr16:89786786	C16orf7;ZNF276	-0.4	-6.87	-0.3	2.09e-11	Vitiligo;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg14789911	chr21:47582049	C21orf56	-0.4	-6.74	-0.3	4.71e-11	Testicular germ cell tumor;
LGG	cis	rs11864453	0.612	rs11862813	chr16:72132356	C/T	cg23815491	chr16:72088622	HP	0.5	11.27	0.46	3.47e-26	Fibrinogen levels;
LGG	trans	rs9329221	0.698	rs35388602	chr8:10259188	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.07	0.31	5.91e-12	Neuroticism;
LGG	cis	rs745080	0.519	rs10129385	chr14:52959478	C/T	cg23333723	chr14:53022898	GPR137C	0.39	7.96	0.35	1.37e-14	Orofacial clefts;
LGG	cis	rs2576037	0.545	rs9948405	chr18:44494527	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.54	10.9	0.45	8.68e-25	Personality dimensions;
LGG	cis	rs10463316	0.894	rs7712569	chr5:150766089	A/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.21	-0.43	3.2800000000000002e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs4900538	0.855	rs1210074	chr14:102889098	G/A	cg18135206	chr14:102964638	TECPR2	-0.67	-12.0	-0.49	4.56e-29	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2836950	0.502	rs2150411	chr21:40574552	G/T	cg11644478	chr21:40555479	PSMG1	-0.62	-10.34	-0.43	1.06e-22	Menarche (age at onset);
LGG	cis	rs12425451	0.544	rs28623776	chr12:3147631	C/T	cg05389053	chr12:3131226	TEAD4	-0.62	-10.47	-0.44	3.66e-23	Narcolepsy with cataplexy;
LGG	cis	rs62400317	0.826	rs12216308	chr6:45342305	T/G	cg20913747	chr6:44695427	NA	-0.61	-10.23	-0.43	2.89e-22	Total body bone mineral density;
LGG	cis	rs13191362	1.000	rs34697913	chr6:163000187	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.42	-0.33	5.64e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1927790	0.637	rs7337506	chr13:96936978	G/A	cg02571835	chr13:96230311	CLDN10	-0.36	-7.19	-0.32	2.62e-12	Body mass index;
LGG	cis	rs6547741	0.935	rs4665384	chr2:27848397	A/G	cg22903471	chr2:27725779	GCKR	0.38	8.48	0.37	3.08e-16	Oral cavity cancer;
LGG	trans	rs853679	0.550	rs34477097	chr6:28197186	C/T	cg01620082	chr3:125678407	NA	-0.45	-6.67	-0.3	7.12e-11	Depression;
LGG	trans	rs12682352	0.602	rs11783966	chr8:8665147	A/G	cg16141378	chr3:129829833	LOC729375	0.41	9.54	0.41	8.19e-20	Neuroticism;
LGG	trans	rs9467711	0.606	rs9358939	chr6:26416787	C/G	cg01620082	chr3:125678407	NA	-0.66	-7.12	-0.31	4.01e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1125355	0.690	rs17810428	chr2:159661451	G/A	cg02251393	chr2:159651559	DAPL1	0.43	8.7	0.38	5.65e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.9e-21	Lung cancer;
LGG	cis	rs17818399	0.926	rs7590693	chr2:46823992	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.54	-9.31	-0.4	5.28e-19	Height;
LGG	cis	rs75920871	0.528	rs11600552	chr11:116900947	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.4	-0.33	6.2800000000000005e-13	Subjective well-being;
LGG	cis	rs9443189	0.570	rs485906	chr6:76300550	A/C	cg01950844	chr6:76311363	SENP6	0.75	9.8	0.41	1.02e-20	Prostate cancer;
LGG	cis	rs526231	0.543	rs34784	chr5:102457330	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.35	-0.36	8.05e-16	Primary biliary cholangitis;
LGG	cis	rs17270561	0.609	rs1317816	chr6:25765390	T/C	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs2470578	0.792	rs2060624	chr3:17338719	C/T	cg20981856	chr3:17787350	NA	0.36	6.86	0.3	2.15e-11	Schizophrenia;
LGG	cis	rs12477438	0.765	rs1115756	chr2:99659845	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.59	-10.3	-0.43	1.57e-22	Chronic sinus infection;
LGG	cis	rs8062405	0.824	rs4788084	chr16:28539848	C/T	cg09754948	chr16:28834200	ATXN2L	0.42	6.76	0.3	4.29e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00933542	chr6:150070202	PCMT1	0.38	6.96	0.31	1.15e-11	Lung cancer;
LGG	cis	rs10197940	0.624	rs4461258	chr2:152429679	A/G	cg06191203	chr2:152266755	RIF1	0.48	8.27	0.36	1.43e-15	Lung cancer;
LGG	trans	rs12439619	0.693	rs7165536	chr15:82566084	T/A	cg04831495	chr15:85060580	GOLGA6L5	-0.4	-6.86	-0.3	2.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7107174	1.000	rs2510045	chr11:77920563	G/T	cg02023728	chr11:77925099	USP35	0.44	7.62	0.33	1.46e-13	Testicular germ cell tumor;
LGG	cis	rs4363385	0.510	rs11803710	chr1:153053096	C/G	cg13444842	chr1:152974279	SPRR3	-0.47	-9.25	-0.39	8.27e-19	Inflammatory skin disease;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02571920	chr17:56084885	SFRS1	0.49	8.09	0.35	5.38e-15	Cognitive performance;
LGG	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.6	-10.71	-0.45	4.58e-24	Alzheimer's disease;
LGG	cis	rs2880765	0.835	rs12708553	chr15:86046833	C/G	cg13263323	chr15:86062960	AKAP13	0.35	7.25	0.32	1.81e-12	Coronary artery disease;
LGG	cis	rs10504229	0.953	rs115634610	chr8:58190533	G/A	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.72e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.842	rs7211808	chr17:80071244	T/C	cg11859384	chr17:80120422	CCDC57	0.45	7.84	0.34	3.17e-14	Life satisfaction;
LGG	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.02	-0.31	8.02e-12	Systolic blood pressure;
LGG	cis	rs6964587	1.000	rs6953515	chr7:91658620	C/T	cg17063962	chr7:91808500	NA	0.49	8.65	0.37	8.26e-17	Breast cancer;
LGG	cis	rs4262150	0.883	rs113844564	chr5:152317522	G/A	cg12297329	chr5:152029980	NA	-0.61	-10.97	-0.45	4.82e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs11877825	0.826	rs4121955	chr18:10569879	C/A	cg07277756	chr18:10589357	NA	0.59	10.76	0.45	2.87e-24	Gut microbiota (bacterial taxa);
LGG	cis	rs1552244	1.000	rs2272125	chr3:10138069	A/C	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	20.36	0.69	2.77e-66	Alzheimer's disease;
LGG	cis	rs17014483	0.749	rs3017902	chr4:89638082	G/A	cg01026744	chr4:89619053	NAP1L5;HERC3	0.59	6.8	0.3	3.31e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg24642844	chr7:1081250	C7orf50	-0.81	-13.66	-0.54	6.28e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4853012	0.838	rs12619982	chr2:74356022	G/A	cg20891558	chr2:74357851	NA	0.51	9.75	0.41	1.53e-20	Gestational age at birth (maternal effect);
LGG	cis	rs9322193	0.923	rs9322207	chr6:149978321	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.07	0.31	5.66e-12	Lung cancer;
LGG	cis	rs3806843	0.966	rs7710380	chr5:140156264	T/C	cg19875535	chr5:140030758	IK	0.52	10.78	0.45	2.58e-24	Depressive symptoms (multi-trait analysis);
LGG	trans	rs7777677	0.925	rs6969951	chr7:142369586	A/G	cg18540325	chr9:33795118	PRSS3	0.42	7.17	0.32	2.95e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs7773004	0.905	rs6932727	chr6:26327087	C/A	cg13736514	chr6:26305472	NA	-0.41	-8.43	-0.36	4.43e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs10435719	0.773	rs7842810	chr8:11794163	A/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs2243480	1.000	rs56985706	chr7:65394562	C/T	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs1401999	0.674	rs562	chr3:183637845	T/C	cg20387954	chr3:183756860	HTR3D	0.5	9.87	0.42	5.39e-21	Anterior chamber depth;
LGG	cis	rs10256972	0.552	rs7805591	chr7:1210745	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.27	-0.52	2.75e-34	Longevity;Endometriosis;
LGG	cis	rs2576037	0.566	rs2437854	chr18:44557613	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.89	-18.65	-0.66	2.51e-58	Personality dimensions;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg11473876	chr11:109292803	C11orf87	0.48	9.33	0.4	4.45e-19	Schizophrenia;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg07701084	chr6:150067640	NUP43	0.64	12.14	0.49	1.28e-29	Lung cancer;
LGG	cis	rs12188164	0.930	rs72717436	chr5:448291	C/A	cg21972741	chr5:435613	AHRR	0.5	9.09	0.39	2.9e-18	Cystic fibrosis severity;
LGG	cis	rs9355814	0.539	rs35600881	chr6:161026764	G/A	cg04181478	chr6:161122748	PLG	0.43	7.08	0.31	5.39e-12	Lipoprotein (a) levels;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg08677398	chr8:58056175	NA	0.42	6.71	0.3	5.79e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4917300	0.650	rs10094562	chr8:143072936	C/T	cg06573787	chr8:143070187	NA	0.77	16.12	0.6	1.03e-46	Amyotrophic lateral sclerosis;
LGG	cis	rs875971	0.658	rs432667	chr7:65514633	A/G	cg00343986	chr7:65444356	GUSB	0.41	7.05	0.31	6.7e-12	Aortic root size;
LGG	cis	rs11229555	0.609	rs12270515	chr11:58217945	G/A	cg15696309	chr11:58395628	NA	-0.94	-15.27	-0.58	6.36e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28386778	0.897	rs2859619	chr17:61917686	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.81	0.41	8.91e-21	Prudent dietary pattern;
LGG	trans	rs2204008	0.683	rs11519834	chr12:38053575	T/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs526231	0.543	rs34377	chr5:102400556	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg02002194	chr4:3960332	NA	-0.52	-9.69	-0.41	2.37e-20	Retinal vascular caliber;
LGG	cis	rs2180341	1.000	rs6569486	chr6:127708424	A/C	cg27446573	chr6:127587934	RNF146	1.13	22.37	0.72	1.09e-75	Breast cancer;
LGG	cis	rs5769707	0.605	rs2071900	chr22:50052175	A/G	cg20744362	chr22:50050164	C22orf34	0.42	7.4	0.33	6.49e-13	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs78366141	0.649	rs78959409	chr4:89659712	C/T	cg01026744	chr4:89619053	NAP1L5;HERC3	0.92	8.55	0.37	1.87e-16	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs7084402	0.967	rs1649036	chr10:60331878	C/A	cg07615347	chr10:60278583	BICC1	0.62	17.83	0.64	1.67e-54	Refractive error;
LGG	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg04727924	chr7:799746	HEATR2	-0.48	-7.64	-0.33	1.29e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	trans	rs1814175	0.647	rs10769646	chr11:49992204	C/A	cg03929089	chr4:120376271	NA	-0.94	-19.79	-0.68	1.27e-63	Height;
LGG	cis	rs988958	0.565	rs6756395	chr2:42236128	G/C	cg27252766	chr2:42229092	NA	0.52	7.47	0.33	4.16e-13	Hypospadias;
LGG	trans	rs28595532	0.545	rs55699931	chr4:119249835	G/A	cg26518628	chr1:97050305	NA	-0.72	-7.62	-0.33	1.42e-13	Cannabis dependence symptom count;
LGG	cis	rs67133203	0.799	rs7976777	chr12:51501412	C/T	cg14688905	chr12:51403056	SLC11A2	0.68	9.92	0.42	3.64e-21	Urinary tract infection frequency;
LGG	cis	rs61931739	0.620	rs11829476	chr12:33699285	C/T	cg06521331	chr12:34319734	NA	0.4	6.78	0.3	3.78e-11	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg16284684	chr7:1164063	C7orf50	0.36	6.9	0.31	1.69e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6951245	1.000	rs79443843	chr7:1075245	G/A	cg13565492	chr6:43139072	SRF	-0.71	-8.65	-0.37	8.66e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8062405	1.000	rs12446589	chr16:28870962	G/A	cg09754948	chr16:28834200	ATXN2L	0.47	7.34	0.32	9.63e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1348850	0.598	rs1405717	chr2:178500101	G/T	cg22681709	chr2:178499509	PDE11A	-0.53	-9.68	-0.41	2.62e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs427394	1.000	rs427394	chr5:6745875	A/G	cg15145174	chr5:6755386	POLS	-0.37	-7.13	-0.31	3.87e-12	Menopause (age at onset);
LGG	cis	rs4820294	1.000	rs732856	chr22:38060691	C/G	cg00292662	chr22:38071168	LGALS1	-0.9	-24.86	-0.76	2.89e-87	Fat distribution (HIV);
LGG	cis	rs11864453	0.963	rs7185215	chr16:72034864	T/C	cg01557791	chr16:72042693	DHODH	-0.59	-11.12	-0.46	1.31e-25	Fibrinogen levels;
LGG	cis	rs7662987	0.517	rs2602876	chr4:100039535	A/T	cg12011299	chr4:100065546	ADH4	0.4	7.84	0.34	3.07e-14	Smoking initiation;
LGG	cis	rs11785400	0.793	rs4736367	chr8:143742477	G/A	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs2710642	0.927	rs2539980	chr2:63208460	T/C	cg17519650	chr2:63277830	OTX1	0.55	9.11	0.39	2.43e-18	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs13118159	0.550	rs2336081	chr4:1350322	A/G	cg19318889	chr4:1322082	MAEA	-0.47	-8.11	-0.35	4.63e-15	Longevity;
LGG	trans	rs7615952	0.736	rs9866347	chr3:125669925	C/T	cg07211511	chr3:129823064	LOC729375	-1.23	-14.6	-0.56	5.82e-40	Blood pressure (smoking interaction);
LGG	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg19717773	chr7:2847554	GNA12	-0.37	-8.41	-0.36	5.01e-16	Height;
LGG	cis	rs968567	0.559	rs174544	chr11:61567753	C/A	cg19610905	chr11:61596333	FADS2	-0.77	-13.03	-0.52	2.89e-33	Blood metabolite levels;Rheumatoid arthritis;Vitiligo;Glycerophospholipid levels;
LGG	cis	rs9359856	0.564	rs72915903	chr6:90420190	A/C	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.88	-0.42	5.08e-21	Bipolar disorder;
LGG	trans	rs11148252	0.904	rs9568732	chr13:52993412	A/G	cg18335740	chr13:41363409	SLC25A15	-0.66	-13.58	-0.53	1.33e-35	Lewy body disease;
LGG	cis	rs74781061	0.929	rs7173006	chr15:74810133	C/T	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs7524258	0.835	rs2412150	chr1:7303343	A/C	cg07173049	chr1:7289937	CAMTA1	0.79	18.57	0.65	5.97e-58	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs1865760	0.963	rs3846838	chr6:25911775	T/C	cg03264133	chr6:25882463	NA	-0.43	-7.66	-0.34	1.06e-13	Height;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg12395012	chr8:11607386	GATA4	0.42	7.3	0.32	1.27e-12	Neuroticism;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg05025164	chr4:1340916	KIAA1530	0.45	7.79	0.34	4.32e-14	Obesity-related traits;
LGG	cis	rs61931739	0.612	rs1906137	chr12:33939676	T/A	cg06521331	chr12:34319734	NA	-0.39	-6.85	-0.3	2.4e-11	Morning vs. evening chronotype;
LGG	cis	rs796364	0.760	rs2202922	chr2:200882610	C/T	cg23649088	chr2:200775458	C2orf69	0.58	7.03	0.31	7.58e-12	Schizophrenia;
LGG	cis	rs7552404	1.000	rs11161511	chr1:76210477	A/G	cg10523679	chr1:76189770	ACADM	-0.81	-14.97	-0.57	1.31e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg21724239	chr8:58056113	NA	0.42	6.72	0.3	5.51e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.521	rs7114564	chr11:49571231	C/T	cg03929089	chr4:120376271	NA	0.84	13.24	0.52	3.56e-34	Coronary artery disease;
LGG	cis	rs220324	0.954	rs467589	chr21:43582763	C/T	cg15319517	chr21:43638949	ABCG1	0.45	7.27	0.32	1.5e-12	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs7208859	0.623	rs216436	chr17:28922900	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	10.24	0.43	2.48e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2290159	0.800	rs5746191	chr3:12658774	G/A	cg23032965	chr3:12705835	RAF1	0.68	9.78	0.41	1.13e-20	Cholesterol, total;
LGG	cis	rs9486719	0.857	rs2971606	chr6:97043025	C/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.83	-0.34	3.35e-14	Migraine;Coronary artery disease;
LGG	cis	rs7789940	1.000	rs17149161	chr7:75978229	C/A	cg10167463	chr7:75959203	YWHAG	-0.46	-7.83	-0.34	3.29e-14	Multiple sclerosis;
LGG	cis	rs3219090	0.861	rs2695240	chr1:226607336	T/C	cg17127702	chr1:226594323	PARP1	0.4	12.41	0.5	9.69e-31	Melanoma;
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.9	-0.45	9.18e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.830	rs13102652	chr4:99006737	T/G	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs11250098	0.547	rs2409764	chr8:11281273	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.46	0.33	4.24e-13	Morning vs. evening chronotype;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.96	14.28	0.55	1.39e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs773506	0.965	rs2457714	chr9:94076628	C/T	cg14446406	chr9:93919335	NA	-0.46	-8.33	-0.36	9.31e-16	Type 2 diabetes nephropathy;
LGG	cis	rs3764563	0.935	rs17708232	chr19:15686744	A/G	cg20725493	chr19:15740067	CYP4F8	-0.57	-6.72	-0.3	5.46e-11	Inflammatory biomarkers;
LGG	cis	rs6835098	0.924	rs12639929	chr4:174156538	C/T	cg08422745	chr4:174089978	GALNT7	-0.82	-13.94	-0.54	3.92e-37	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs3806843	0.606	rs251377	chr5:140255792	C/A	cg19875535	chr5:140030758	IK	-0.38	-7.47	-0.33	4.08e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2732480	0.557	rs2409004	chr12:48721451	T/C	cg24011408	chr12:48396354	COL2A1	0.48	7.69	0.34	8.97e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs344364	0.576	rs238677	chr16:1883279	T/C	cg06886374	chr16:1844152	IGFALS	0.44	7.91	0.34	1.96e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1348850	0.914	rs10194648	chr2:178337031	G/A	cg22681709	chr2:178499509	PDE11A	-0.46	-8.69	-0.37	6.27e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs600231	0.508	rs34582634	chr11:65220206	G/A	cg17120908	chr11:65337727	SSSCA1	-0.6	-8.65	-0.37	8.47e-17	Bone mineral density;
LGG	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26187876	chr2:191514902	NAB1	-0.46	-6.76	-0.3	4.1e-11	Systemic lupus erythematosus;
LGG	cis	rs977987	0.778	rs4888400	chr16:75425596	G/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.81	0.3	3.05e-11	Dupuytren's disease;
LGG	cis	rs4731207	0.724	rs4383910	chr7:124540841	A/C	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs8028182	1.000	rs8028182	chr15:75718669	G/T	cg20655648	chr15:75932815	IMP3	0.46	6.97	0.31	1.07e-11	Sudden cardiac arrest;
LGG	cis	rs7107174	1.000	rs1893447	chr11:77973182	A/G	cg27205649	chr11:78285834	NARS2	-0.43	-7.05	-0.31	6.43e-12	Testicular germ cell tumor;
LGG	cis	rs10504229	0.728	rs1495867	chr8:58155500	G/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs9388451	0.839	rs10457469	chr6:126083658	G/A	cg05901451	chr6:126070800	HEY2	-0.81	-17.5	-0.63	5.11e-53	Brugada syndrome;
LGG	cis	rs4740619	0.587	rs1328274	chr9:16023669	G/T	cg14451791	chr9:16040625	NA	-0.4	-10.44	-0.44	4.72e-23	Body mass index;
LGG	trans	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg19847130	chr8:10466454	RP1L1	0.3	6.65	0.3	8.06e-11	Joint mobility (Beighton score);
LGG	cis	rs10504229	0.683	rs7822631	chr8:58130916	C/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17039065	1.000	rs16996969	chr4:109382668	A/T	cg16022748	chr4:109541635	LOC285456;RPL34	0.57	6.82	0.3	2.93e-11	Gut microbiome composition (summer);
LGG	cis	rs5756813	0.688	rs56114444	chr22:38123364	C/T	cg24232236	chr22:38142998	TRIOBP	0.37	7.2	0.32	2.38e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs67460515	0.563	rs4494975	chr3:160866768	C/T	cg04691961	chr3:161091175	C3orf57	-0.43	-8.2	-0.36	2.31e-15	Parkinson's disease;
LGG	cis	rs548181	0.736	rs556884	chr11:125550049	G/A	cg03464685	chr11:125439445	EI24	1.4	20.11	0.68	4.15e-65	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs7246760	1.000	rs68176351	chr19:9864222	G/A	cg16876255	chr19:9731953	ZNF561	0.76	7.13	0.31	3.92e-12	Pursuit maintenance gain;
LGG	cis	rs9322193	0.923	rs10782311	chr6:149943728	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.77	-0.38	3.32e-17	Lung cancer;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg08742575	chr21:47604166	C21orf56	0.48	8.36	0.36	7.57e-16	Testicular germ cell tumor;
LGG	cis	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg12826209	chr6:26865740	GUSBL1	0.78	7.42	0.33	5.66e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7444	0.941	rs73166632	chr22:21946173	A/G	cg22858872	chr22:21984481	YDJC	-0.36	-6.71	-0.3	5.57e-11	Systemic lupus erythematosus;
LGG	cis	rs17270561	0.609	rs4712964	chr6:25740822	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	trans	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg13565492	chr6:43139072	SRF	-0.72	-8.89	-0.38	1.41e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs28595532	0.920	rs114659035	chr4:119740028	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	trans	rs1814175	0.650	rs6486000	chr11:49659090	T/A	cg03929089	chr4:120376271	NA	-0.93	-18.15	-0.64	5.14e-56	Height;
LGG	cis	rs4731207	0.596	rs11980178	chr7:124604660	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg15971980	chr6:150254442	NA	0.46	8.44	0.37	4.13e-16	Lung cancer;
LGG	trans	rs2072153	0.715	rs34367165	chr17:47330796	G/A	cg11430096	chr6:110968061	CDK19	0.52	8.61	0.37	1.13e-16	Height;
LGG	cis	rs3126085	0.935	rs12405678	chr1:152195308	C/G	cg26876637	chr1:152193138	HRNR	-0.49	-7.03	-0.31	7.38e-12	Atopic dermatitis;
LGG	cis	rs7927771	0.524	rs2242081	chr11:47500267	T/C	cg20307385	chr11:47447363	PSMC3	0.57	11.29	0.46	2.92e-26	Subjective well-being;
LGG	cis	rs2658782	0.756	rs3019223	chr11:93084182	G/A	cg15737290	chr11:93063684	CCDC67	0.56	8.15	0.35	3.33e-15	Pulmonary function decline;
LGG	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.45e-24	Aortic root size;
LGG	cis	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Myopia (pathological);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg22832407	chr4:169931373	CBR4	-0.43	-6.92	-0.31	1.52e-11	Pancreatic cancer;
LGG	cis	rs11885103	0.692	rs4314025	chr2:568100	C/T	cg21195176	chr2:593345	NA	-0.41	-7.91	-0.35	1.87e-14	Heschl's gyrus morphology;
LGG	cis	rs1790761	0.806	rs7114510	chr11:67224594	C/T	cg00864171	chr11:67383662	NA	0.43	6.85	0.3	2.41e-11	Mean corpuscular volume;
LGG	cis	rs4481887	0.927	rs7555310	chr1:248487638	A/G	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs1401999	1.000	rs1401999	chr3:183678342	C/G	cg01324343	chr3:183735012	ABCC5	0.85	18.03	0.64	1.9e-55	Anterior chamber depth;
LGG	cis	rs742614	0.935	rs6057929	chr20:32477633	A/G	cg06304546	chr20:32448765	NA	-0.48	-8.67	-0.37	7.4e-17	Stearic acid (18:0) levels;
LGG	cis	rs2154319	0.887	rs2144788	chr1:41532444	G/A	cg02290550	chr1:41487317	SLFNL1	-0.49	-8.92	-0.38	1.06e-17	Height;
LGG	cis	rs757081	0.671	rs214072	chr11:17305270	C/T	cg15432903	chr11:17409602	KCNJ11	-0.56	-8.49	-0.37	2.85e-16	Systolic blood pressure;
LGG	cis	rs2073300	0.609	rs6137936	chr20:23385232	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7911264	0.507	rs2901597	chr10:94342663	C/T	cg25093409	chr10:94429542	NA	0.36	6.97	0.31	1.07e-11	Inflammatory bowel disease;
LGG	cis	rs9790314	0.663	rs6804650	chr3:160648953	A/G	cg03342759	chr3:160939853	NMD3	-0.42	-7.11	-0.31	4.36e-12	Morning vs. evening chronotype;
LGG	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg24375607	chr4:120327624	NA	0.43	7.3	0.32	1.28e-12	Diastolic blood pressure;
LGG	cis	rs6502050	0.799	rs6502088	chr17:80169484	C/T	cg19223190	chr17:80058835	NA	0.43	8.22	0.36	2.14e-15	Life satisfaction;
LGG	cis	rs4901847	0.716	rs7157794	chr14:58562040	A/G	cg15908186	chr14:58618357	C14orf37	-0.4	-6.93	-0.31	1.42e-11	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs801193	1.000	rs2003301	chr7:66147656	G/C	cg00343986	chr7:65444356	GUSB	-0.4	-6.82	-0.3	2.93e-11	Aortic root size;
LGG	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg03929089	chr4:120376271	NA	0.74	8.5	0.37	2.6e-16	Axial length;
LGG	cis	rs9513627	1.000	rs2390278	chr13:100159712	G/A	cg25919922	chr13:100150906	NA	0.75	8.04	0.35	7.56e-15	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs4870052	chr6:150161114	G/A	cg13206674	chr6:150067644	NUP43	0.66	14.4	0.56	4.3e-39	Lung cancer;
LGG	cis	rs1371867	0.846	rs1788189	chr8:101249762	G/T	cg06636551	chr8:101224915	SPAG1	0.48	8.88	0.38	1.43e-17	Atrioventricular conduction;
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs9863	0.794	rs7978610	chr12:124468572	C/G	cg13487667	chr12:124434373	CCDC92	0.35	7.23	0.32	2.06e-12	White blood cell count;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg16578609	chr1:2399051	NA	-0.41	-9.01	-0.39	5.6e-18	Non-obstructive azoospermia;
LGG	cis	rs9291683	0.527	rs3822247	chr4:10094671	G/A	cg08250081	chr4:10125330	NA	-0.43	-8.48	-0.37	3.05e-16	Bone mineral density;
LGG	cis	rs36051895	0.658	rs72699574	chr9:5020089	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-14.64	-0.56	3.77e-40	Pediatric autoimmune diseases;
LGG	trans	rs2739330	0.892	rs4822455	chr22:24255296	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.66	-12.19	-0.49	7.71e-30	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7937682	0.924	rs1784782	chr11:111525764	A/C	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs1863824	0.625	rs11202023	chr10:88165453	C/T	cg07322936	chr10:88137208	NA	-0.52	-8.65	-0.37	8.76e-17	Schizophrenia;
LGG	cis	rs11191205	0.644	rs7899178	chr10:103359285	G/A	cg15320455	chr10:103880129	LDB1	0.52	7.48	0.33	3.74e-13	Intelligence (multi-trait analysis);
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg05793240	chr7:2802953	GNA12	0.34	7.79	0.34	4.51e-14	Height;
LGG	cis	rs735539	0.521	rs2762989	chr13:21392521	C/G	cg04906043	chr13:21280425	IL17D	-0.52	-8.08	-0.35	5.64e-15	Dental caries;
LGG	trans	rs853679	0.760	rs2299029	chr6:28198831	G/A	cg06606381	chr12:133084897	FBRSL1	-0.64	-8.22	-0.36	2.01e-15	Depression;
LGG	cis	rs9322193	0.923	rs10747276	chr6:150079875	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.93	0.35	1.68e-14	Lung cancer;
LGG	cis	rs72781680	0.898	rs72782126	chr2:24039901	A/C	cg08917208	chr2:24149416	ATAD2B	0.8	9.08	0.39	3.21e-18	Lymphocyte counts;
LGG	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg15704280	chr7:45808275	SEPT13	0.49	8.17	0.35	3.05e-15	HDL cholesterol;
LGG	cis	rs1008375	0.900	rs6851783	chr4:17578469	A/G	cg10189774	chr4:17578691	LAP3	0.41	7.13	0.31	4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6963495	0.818	rs114865717	chr7:105158526	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs4595586	0.505	rs12827136	chr12:39412790	C/T	cg26384229	chr12:38710491	ALG10B	0.61	11.11	0.46	1.44e-25	Morning vs. evening chronotype;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01171360	chr6:293285	DUSP22	-0.58	-9.62	-0.41	4.45e-20	Menopause (age at onset);
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.64	-0.41	3.59e-20	Systolic blood pressure;
LGG	trans	rs11098499	0.691	rs9996494	chr4:120238880	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.94	0.45	6.04e-25	Corneal astigmatism;
LGG	cis	rs2798269	1.000	rs17622791	chr13:22093824	T/A	cg18095732	chr13:22033692	ZDHHC20	-0.41	-7.02	-0.31	8.14e-12	PR segment;
LGG	cis	rs1862618	0.853	rs832569	chr5:56154584	T/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.03	-0.35	8.35e-15	Initial pursuit acceleration;
LGG	cis	rs4268898	0.608	rs72793980	chr2:24428859	T/C	cg06627628	chr2:24431161	ITSN2	-0.71	-11.93	-0.48	8.9e-29	Asthma;
LGG	cis	rs9788682	0.747	rs7183604	chr15:78899213	T/C	cg24631222	chr15:78858424	CHRNA5	-0.41	-6.65	-0.3	8.26e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs72634258	0.945	rs28624	chr1:8084355	G/T	cg00042356	chr1:8021962	PARK7	-0.55	-7.7	-0.34	8.37e-14	Inflammatory bowel disease;
LGG	cis	rs9354308	0.764	rs9453468	chr6:66592880	G/A	cg07460842	chr6:66804631	NA	-0.41	-6.98	-0.31	1.01e-11	Metabolite levels;
LGG	cis	rs7223966	1.000	rs992416	chr17:61745905	A/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.78	-0.38	3.26e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.04	0.31	7.04e-12	Lung cancer;
LGG	cis	rs735539	0.645	rs6490601	chr13:21245897	G/A	cg04906043	chr13:21280425	IL17D	-0.52	-8.59	-0.37	1.31e-16	Dental caries;
LGG	cis	rs116095464	0.558	rs55664502	chr5:270485	T/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg27532318	chr7:32358331	NA	0.71	7.28	0.32	1.47e-12	Body mass index;
LGG	trans	rs61931739	0.500	rs10844864	chr12:34532468	A/G	cg04568710	chr12:38710424	ALG10B	0.34	7.0	0.31	8.93e-12	Morning vs. evening chronotype;
LGG	cis	rs7737355	0.947	rs244733	chr5:130822778	T/C	cg06307176	chr5:131281290	NA	0.55	9.26	0.4	7.9e-19	Life satisfaction;
LGG	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg23533926	chr12:111358616	MYL2	-0.42	-6.91	-0.31	1.57e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01993413	chr14:21979151	METTL3	0.49	7.96	0.35	1.3e-14	Cognitive performance;
LGG	cis	rs9308731	0.966	rs36018702	chr2:111928373	G/T	cg19992207	chr2:111874495	ACOXL	0.4	7.49	0.33	3.41e-13	Chronic lymphocytic leukemia;
LGG	cis	rs796364	0.951	rs11897245	chr2:201063644	A/G	cg17644776	chr2:200775616	C2orf69	0.6	8.44	0.37	4.02e-16	Schizophrenia;
LGG	cis	rs439731	0.518	rs2260241	chr16:1075147	G/A	cg05970874	chr16:1061053	NA	-0.87	-10.24	-0.43	2.65e-22	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg02023728	chr11:77925099	USP35	0.4	6.87	0.3	2.05e-11	Alzheimer's disease (survival time);
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.7	-0.41	2.17e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.526	rs649076	chr18:44414614	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.8	16.34	0.6	9.89e-48	Personality dimensions;
LGG	cis	rs4363385	0.747	rs6670614	chr1:152964338	A/G	cg13444842	chr1:152974279	SPRR3	-0.44	-9.28	-0.4	6.3e-19	Inflammatory skin disease;
LGG	cis	rs7617773	0.815	rs7624450	chr3:48350375	A/G	cg11946769	chr3:48343235	NME6	0.72	12.08	0.49	2.13e-29	Coronary artery disease;
LGG	cis	rs832540	0.618	rs2548663	chr5:56172778	G/A	cg12654349	chr5:56205094	C5orf35	-0.43	-7.56	-0.33	2.12e-13	Coronary artery disease;
LGG	cis	rs7444	0.941	rs4821116	chr22:21973319	A/G	cg11654148	chr22:21984483	YDJC	0.4	7.79	0.34	4.5e-14	Systemic lupus erythematosus;
LGG	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs12618769	0.652	rs7585747	chr2:99219071	T/C	cg18455616	chr2:99124870	INPP4A	0.27	7.81	0.34	3.78e-14	Bipolar disorder;
LGG	cis	rs736408	0.812	rs746694	chr3:52826620	C/T	cg14092988	chr3:52407081	DNAH1	0.33	8.73	0.38	4.72e-17	Bipolar disorder;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	10.05	0.42	1.24e-21	Obesity-related traits;
LGG	cis	rs8180040	0.966	rs3816779	chr3:47543389	C/T	cg27129171	chr3:47204927	SETD2	0.78	14.85	0.57	4.56e-41	Colorectal cancer;
LGG	cis	rs769267	0.965	rs2315281	chr19:19480099	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	-0.51	-8.37	-0.36	6.68e-16	Tonsillectomy;
LGG	cis	rs798554	0.567	rs2527695	chr7:2858267	T/G	cg05793240	chr7:2802953	GNA12	0.3	7.46	0.33	4.2e-13	Height;
LGG	cis	rs9902453	0.874	rs3936006	chr17:28257660	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.46	0.56	2.35e-39	Coffee consumption (cups per day);
LGG	trans	rs7395662	0.611	rs4882089	chr11:48515612	A/T	cg21153622	chr11:89784906	NA	-0.39	-6.69	-0.3	6.54e-11	HDL cholesterol;
LGG	cis	rs1862618	0.853	rs1833896	chr5:56097669	C/A	cg17809284	chr5:56205270	C5orf35	-0.49	-8.09	-0.35	5.16e-15	Initial pursuit acceleration;
LGG	trans	rs11039798	0.764	rs11040208	chr11:49012509	A/G	cg03929089	chr4:120376271	NA	0.75	7.85	0.34	2.97e-14	Axial length;
LGG	cis	rs9290877	0.667	rs6763591	chr3:188455971	T/C	cg17392043	chr3:188495102	LPP	-0.42	-7.23	-0.32	2.02e-12	IgE levels;
LGG	trans	rs62103177	0.759	rs7227794	chr18:77610925	C/T	cg14227996	chr4:17616232	MED28	0.72	8.8	0.38	2.75e-17	Opioid sensitivity;
LGG	trans	rs4650994	1.000	rs4650993	chr1:178515187	A/G	cg05059571	chr16:84539110	KIAA1609	-0.44	-8.11	-0.35	4.46e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9914544	1.000	rs7223231	chr17:18811846	C/T	cg26378065	chr17:18585709	ZNF286B	0.49	9.07	0.39	3.3e-18	Educational attainment (years of education);
LGG	cis	rs72945132	0.882	rs72945168	chr11:70131471	G/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg16850897	chr7:100343110	ZAN	-0.68	-10.1	-0.42	8.48e-22	Other erythrocyte phenotypes;
LGG	cis	rs283228	1.000	rs2518324	chr6:101810451	T/C	cg27451362	chr6:101846650	GRIK2	0.54	9.07	0.39	3.46e-18	Coenzyme Q10 levels;
LGG	cis	rs1018697	0.966	rs1475643	chr10:104546467	C/T	cg04362960	chr10:104952993	NT5C2	0.51	9.25	0.4	8.11e-19	Colorectal adenoma (advanced);
LGG	cis	rs7917772	0.604	rs11191358	chr10:104399250	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.5	-9.12	-0.39	2.27e-18	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs8031584	1.000	rs35811129	chr15:31241346	G/A	cg08704250	chr15:31115839	NA	-0.43	-7.63	-0.33	1.37e-13	Huntington's disease progression;
LGG	cis	rs7766436	0.848	rs13211568	chr6:22573180	A/T	cg13666174	chr6:22585274	NA	-0.52	-11.67	-0.48	9.18e-28	Coronary artery disease;
LGG	cis	rs796364	0.806	rs79897806	chr2:201073968	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	cis	rs611744	0.647	rs2594358	chr8:109256018	A/G	cg21045802	chr8:109455806	TTC35	0.49	9.11	0.39	2.5e-18	Dupuytren's disease;
LGG	cis	rs9902453	1.000	rs7221743	chr17:28407876	T/G	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.3	-0.53	2.08e-34	Coffee consumption (cups per day);
LGG	cis	rs6088590	1.000	rs2295354	chr20:33356541	T/C	cg24642439	chr20:33292090	TP53INP2	0.83	15.39	0.58	1.8e-43	Coronary artery disease;
LGG	cis	rs10504229	0.815	rs17805008	chr8:58160185	G/T	cg05313129	chr8:58192883	C8orf71	-0.74	-10.43	-0.44	5.01e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs929354	0.772	rs3802120	chr7:156977794	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs758324	0.947	rs924434	chr5:131143369	A/C	cg06307176	chr5:131281290	NA	0.57	9.51	0.4	1.08e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg15736062	chr7:158136485	PTPRN2	0.37	7.27	0.32	1.53e-12	Calcium levels;
LGG	cis	rs7267979	0.933	rs2387887	chr20:25427081	G/T	cg06421707	chr20:25228305	PYGB	0.48	10.37	0.43	8.2000000000000006e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg23802518	chr10:80827482	ZMIZ1;LOC283050	0.41	7.01	0.31	8.37e-12	Bipolar disorder;
LGG	cis	rs6740322	0.793	rs13414908	chr2:43546658	G/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-9.62	-0.41	4.32e-20	Coronary artery disease;
LGG	cis	rs6088590	0.965	rs13040449	chr20:33358901	T/A	cg08999081	chr20:33150536	PIGU	0.31	7.32	0.32	1.1e-12	Coronary artery disease;
LGG	trans	rs6076960	0.711	rs6085426	chr20:6165768	A/G	cg21095983	chr6:86352623	SYNCRIP	0.49	8.92	0.38	1.07e-17	Smooth-surface caries;
LGG	cis	rs7193541	0.859	rs12598791	chr16:74500745	A/C	cg01733217	chr16:74700730	RFWD3	0.83	17.6	0.63	1.84e-53	Multiple myeloma;
LGG	trans	rs7746199	0.736	rs67652222	chr6:27586220	C/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg02825527	chr7:2087843	MAD1L1	-0.41	-7.87	-0.34	2.6e-14	Neuroticism;
LGG	cis	rs28595532	0.920	rs56252481	chr4:119754023	C/T	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	trans	rs931812	0.825	rs35472498	chr8:101894167	G/A	cg20993868	chr7:22813445	NA	0.69	12.8	0.51	2.39e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs5769765	0.955	rs9616394	chr22:50314927	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-14.07	-0.55	1.06e-37	Schizophrenia;
LGG	cis	rs7937682	0.924	rs10891286	chr11:111532691	C/G	cg19812747	chr11:111475976	SIK2	-0.48	-9.82	-0.42	8.37e-21	Primary sclerosing cholangitis;
LGG	trans	rs7819412	0.505	rs17726209	chr8:11022185	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.09	0.31	5.08e-12	Triglycerides;
LGG	cis	rs9910055	0.614	rs12944572	chr17:42245241	T/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.55	0.5	2.59e-31	Total body bone mineral density;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.43	-0.36	4.38e-16	Aortic root size;
LGG	cis	rs7223966	1.000	rs7223672	chr17:61720565	T/C	cg05941027	chr17:61774174	LIMD2	0.38	9.77	0.41	1.25e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4665809	1.000	rs4665305	chr2:26313524	C/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.82	-13.5	-0.53	2.97e-35	Gut microbiome composition (summer);
LGG	cis	rs250677	0.798	rs11168080	chr5:148409821	C/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.01	-0.31	8.45e-12	Breast cancer;
LGG	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07570687	chr10:102243282	WNT8B	0.45	7.81	0.34	3.84e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs151234	0.676	rs231970	chr16:28567004	A/G	cg01378222	chr16:28622494	SULT1A1	-0.71	-9.74	-0.41	1.56e-20	Platelet distribution width;
LGG	cis	rs9322193	0.884	rs62439836	chr6:149990309	A/G	cg15971980	chr6:150254442	NA	0.45	8.52	0.37	2.31e-16	Lung cancer;
LGG	cis	rs6430585	0.583	rs12472293	chr2:136648077	T/C	cg07169764	chr2:136633963	MCM6	1.23	23.8	0.74	2.26e-82	Corneal structure;
LGG	cis	rs9291683	0.588	rs4280729	chr4:10013861	C/T	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.06	-0.35	6.64e-15	Bone mineral density;
LGG	cis	rs7249142	0.549	rs12609573	chr19:19297567	C/T	cg08207377	chr19:19281140	LOC729991-MEF2B;MEF2B	0.36	9.95	0.42	2.93e-21	IgG glycosylation;
LGG	cis	rs832540	1.000	rs832540	chr5:56199202	G/A	cg14703610	chr5:56206110	C5orf35	0.43	7.39	0.32	6.84e-13	Coronary artery disease;
LGG	cis	rs7208859	0.623	rs12006	chr17:29110652	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6444746	0.877	rs2651164	chr3:193507309	A/G	cg22553634	chr3:193489233	NA	-0.68	-7.9	-0.34	1.99e-14	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs6028335	0.610	rs3752291	chr20:37570404	G/T	cg16355469	chr20:37678765	NA	0.55	7.33	0.32	1.06e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs300774	0.764	rs300756	chr2:233416	G/A	cg21211680	chr2:198530	NA	0.57	6.93	0.31	1.45e-11	Suicide attempts in bipolar disorder;
LGG	cis	rs1957429	0.901	rs3813422	chr14:65347404	G/A	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs10504229	0.565	rs7010503	chr8:58147127	G/A	cg14926445	chr8:58193284	C8orf71	-0.69	-9.16	-0.39	1.67e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg03528353	chr17:61819722	STRADA	0.43	7.35	0.32	8.9e-13	Prudent dietary pattern;
LGG	cis	rs2046867	0.908	rs9880763	chr3:72789805	G/C	cg25664220	chr3:72788482	NA	-0.32	-9.24	-0.39	8.98e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4132509	1.000	rs57824597	chr1:243930399	C/T	cg21452805	chr1:244014465	NA	0.67	8.15	0.35	3.32e-15	RR interval (heart rate);
LGG	cis	rs28386778	0.897	rs8079818	chr17:61824667	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs2494938	0.730	rs1771307	chr6:40515132	T/C	cg14084896	chr6:40530702	LRFN2	-0.3	-6.69	-0.3	6.4e-11	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg06873352	chr17:61820015	STRADA	0.74	13.87	0.54	7.63e-37	Prudent dietary pattern;
LGG	cis	rs3096299	0.658	rs34590044	chr16:89543157	A/C	cg05484508	chr16:89589025	SPG7	0.45	7.38	0.32	7.3e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg16141378	chr3:129829833	LOC729375	0.35	8.23	0.36	1.9e-15	Systolic blood pressure;
LGG	cis	rs9674544	0.646	rs8069452	chr17:47140999	A/G	cg11673840	chr17:47092156	IGF2BP1	0.4	7.06	0.31	5.97e-12	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs9952991	0.566	rs7241016	chr18:12880206	A/G	cg23598886	chr18:12777645	NA	-0.53	-7.81	-0.34	3.95e-14	Inflammatory skin disease;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg25072359	chr17:41440525	NA	0.49	9.6	0.41	4.91e-20	Menopause (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg12016039	chr2:54013874	LOC100302652;ASB3;ERLEC1	0.38	6.74	0.3	4.61e-11	Obesity-related traits;
LGG	cis	rs6831352	0.918	rs1042365	chr4:100045500	G/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.55	-0.37	1.8e-16	Alcohol dependence;
LGG	cis	rs8114671	0.967	rs1415774	chr20:33765616	C/T	cg07148914	chr20:33460835	GGT7	-0.43	-6.88	-0.3	2.01e-11	Height;
LGG	cis	rs250677	0.687	rs2963485	chr5:148452043	A/G	cg18129178	chr5:148520854	ABLIM3	0.45	7.51	0.33	3.13e-13	Breast cancer;
LGG	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.65	11.66	0.48	1e-27	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2739330	0.796	rs1006771	chr22:24314006	G/T	cg23131131	chr22:24373011	LOC391322	-0.46	-7.15	-0.32	3.49e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2243480	1.000	rs73142166	chr7:65375832	A/G	cg12463550	chr7:65579703	CRCP	0.74	8.0	0.35	1.01e-14	Diabetic kidney disease;
LGG	cis	rs4665809	1.000	rs7573118	chr2:26308086	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs1109114	0.844	rs1438689	chr5:148631433	A/G	cg06539116	chr5:148597365	ABLIM3	-0.47	-11.33	-0.47	2.04e-26	Body mass index;
LGG	cis	rs6977660	0.507	rs28402966	chr7:19774469	A/C	cg07541023	chr7:19748670	TWISTNB	0.78	10.53	0.44	2.16e-23	Thyroid stimulating hormone;
LGG	cis	rs9911578	0.900	rs7214335	chr17:57158840	G/A	cg12560992	chr17:57184187	TRIM37	0.89	15.92	0.59	8.25e-46	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.616	rs1794131	chr11:49904194	A/G	cg03929089	chr4:120376271	NA	-0.94	-19.63	-0.67	7.28e-63	Height;
LGG	cis	rs10256972	0.616	rs4998392	chr7:1113344	A/C	cg22907277	chr7:1156413	C7orf50	0.49	8.53	0.37	2.05e-16	Longevity;Endometriosis;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs1371867	0.846	rs1660323	chr8:101278724	T/A	cg06636551	chr8:101224915	SPAG1	-0.49	-8.94	-0.38	9.52e-18	Atrioventricular conduction;
LGG	cis	rs365132	0.875	rs2456178	chr5:176413570	C/G	cg16309518	chr5:176445507	NA	-0.55	-12.32	-0.5	2.26e-30	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	trans	rs7819412	0.745	rs6601569	chr8:11073578	C/T	cg06636001	chr8:8085503	FLJ10661	-0.56	-10.51	-0.44	2.69e-23	Triglycerides;
LGG	cis	rs526231	0.578	rs34794	chr5:102423368	T/A	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg07701084	chr6:150067640	NUP43	0.7	13.27	0.53	2.67e-34	Lung cancer;
LGG	cis	rs9322193	0.884	rs9689702	chr6:150061856	G/A	cg13206674	chr6:150067644	NUP43	0.68	15.78	0.59	3.33e-45	Lung cancer;
LGG	cis	rs10484885	0.715	rs2585013	chr6:90553402	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.91	-16.16	-0.6	6.93e-47	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs75920871	0.528	rs11216240	chr11:116899248	A/T	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.4	-0.33	6.2800000000000005e-13	Subjective well-being;
LGG	cis	rs4819388	0.874	rs13052840	chr21:45649848	T/C	cg01992765	chr21:45622493	NA	-0.43	-8.37	-0.36	7.03e-16	Celiac disease;
LGG	cis	rs1707322	0.686	rs1084086	chr1:46041100	A/C	cg03146154	chr1:46216737	IPP	-0.56	-10.0	-0.42	1.84e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs62103177	0.525	rs4799117	chr18:77756604	G/A	cg14227996	chr4:17616232	MED28	-0.52	-6.74	-0.3	4.75e-11	Opioid sensitivity;
LGG	cis	rs2249625	0.545	rs2463746	chr6:72876954	C/G	cg27608224	chr6:72922399	RIMS1	0.32	7.24	0.32	1.88e-12	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs11608355	0.618	rs60819157	chr12:109795766	G/A	cg19025524	chr12:109796872	NA	-0.6	-13.09	-0.52	1.61e-33	Neuroticism;
LGG	cis	rs7824557	0.603	rs7016671	chr8:11182455	A/G	cg21775007	chr8:11205619	TDH	0.81	14.51	0.56	1.34e-39	Retinal vascular caliber;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15144697	chr2:201935974	NDUFB3;FAM126B	0.48	7.08	0.31	5.56e-12	Gut microbiome composition (summer);
LGG	cis	rs870825	0.616	rs7678900	chr4:185635249	A/G	cg04058563	chr4:185651563	MLF1IP	1.02	22.05	0.72	3.5e-74	Blood protein levels;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg02462569	chr6:150064036	NUP43	-0.42	-8.85	-0.38	1.84e-17	Lung cancer;
LGG	cis	rs8180040	0.764	rs11712716	chr3:47193432	T/C	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	cis	rs4959677	0.689	rs1772980	chr6:2499839	C/T	cg23817096	chr6:1620687	NA	-0.33	-8.1	-0.35	4.77e-15	Orthostatic hypotension;
LGG	cis	rs10883723	0.810	rs6584507	chr10:104254623	G/A	cg05096777	chr10:104283225	SUFU	0.33	7.18	0.32	2.85e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg08024992	chr7:2133441	MAD1L1	0.34	6.7	0.3	6.14e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.850	rs17226666	chr16:89835401	G/A	cg06558623	chr16:89946397	TCF25	1.11	12.36	0.5	1.58e-30	Skin colour saturation;
LGG	cis	rs2153535	0.580	rs1832100	chr6:8446956	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7824557	0.521	rs11995206	chr8:11450133	G/A	cg21775007	chr8:11205619	TDH	0.51	8.49	0.37	2.91e-16	Retinal vascular caliber;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg11905131	chr22:24372483	LOC391322	-0.4	-6.9	-0.31	1.76e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs910316	0.935	rs175448	chr14:75591071	G/A	cg08847533	chr14:75593920	NEK9	-0.6	-11.65	-0.48	1.07e-27	Height;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs4253772	0.513	rs11090863	chr22:46705407	C/T	cg09461388	chr22:46763229	CELSR1	-0.71	-7.43	-0.33	5.43e-13	LDL cholesterol;Cholesterol, total;
LGG	trans	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg06636001	chr8:8085503	FLJ10661	0.61	11.81	0.48	2.65e-28	Neuroticism;
LGG	cis	rs8067545	0.616	rs203470	chr17:19858626	C/T	cg13482628	chr17:19912719	NA	0.53	9.77	0.41	1.31e-20	Schizophrenia;
LGG	cis	rs7617773	0.817	rs34728236	chr3:48259108	A/G	cg11946769	chr3:48343235	NME6	0.68	11.21	0.46	5.81e-26	Coronary artery disease;
LGG	cis	rs6500602	0.701	rs6500614	chr16:4573938	A/G	cg05091796	chr16:4465799	CORO7	-0.82	-13.72	-0.54	3.32e-36	Schizophrenia;
LGG	cis	rs9393777	0.513	rs926300	chr6:27059443	A/T	cg12292205	chr6:26970375	C6orf41	-0.62	-8.19	-0.36	2.61e-15	Intelligence (multi-trait analysis);
LGG	cis	rs704795	0.836	rs1647281	chr2:27612938	G/C	cg27432699	chr2:27873401	GPN1	-0.49	-8.34	-0.36	8.35e-16	Menopause (age at onset);
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.41	8.46	0.37	3.48e-16	Schizophrenia;
LGG	cis	rs4819052	0.851	rs4819040	chr21:46659762	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.7	12.44	0.5	7.74e-31	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2470578	0.792	rs1463218	chr3:17301087	G/C	cg20981856	chr3:17787350	NA	0.36	6.85	0.3	2.4e-11	Schizophrenia;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg08355456	chr11:67383691	NA	0.49	8.36	0.36	7.61e-16	Mean corpuscular volume;
LGG	cis	rs875971	1.000	rs709595	chr7:65817333	G/C	cg18876405	chr7:65276391	NA	0.55	9.84	0.42	7.35e-21	Aortic root size;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.98	0.84	1.27e-123	Prudent dietary pattern;
LGG	cis	rs3749237	0.964	rs62260719	chr3:49852419	G/A	cg03060546	chr3:49711283	APEH	0.55	8.49	0.37	2.75e-16	Resting heart rate;
LGG	trans	rs6601327	0.641	rs7461939	chr8:9571621	C/T	cg02002194	chr4:3960332	NA	0.38	6.86	0.3	2.17e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24371536	chr6:79943342	HMGN3	0.51	8.17	0.35	2.89e-15	Gut microbiome composition (summer);
LGG	cis	rs1878931	0.582	rs9937267	chr16:3421073	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	0.72	11.51	0.47	3.86e-27	Body mass index (adult);
LGG	cis	rs1499614	1.000	rs2707832	chr7:66136549	C/T	cg18252515	chr7:66147081	NA	-1.38	-20.56	-0.69	3.1e-67	Gout;
LGG	cis	rs62064224	0.658	rs62065460	chr17:30715007	A/G	cg12561776	chr17:30844705	MYO1D	-0.28	-7.03	-0.31	7.39e-12	Schizophrenia;
LGG	cis	rs3820068	0.655	rs72645823	chr1:15887442	C/T	cg05660106	chr1:15850417	CASP9	1.13	23.72	0.74	5.7e-82	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs17805549	chr8:58179653	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	-0.32	-7.24	-0.32	1.89e-12	Schizophrenia;
LGG	cis	rs877426	0.515	rs57506460	chr13:114767789	G/A	cg00571178	chr13:114841904	RASA3	-0.46	-8.82	-0.38	2.42e-17	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs11096990	0.855	rs2711986	chr4:39153878	G/A	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs75920871	0.843	rs17120111	chr11:116744018	C/T	cg20608306	chr11:116969690	SIK3	-0.32	-6.72	-0.3	5.37e-11	Subjective well-being;
LGG	cis	rs9322193	0.962	rs3805748	chr6:150093678	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.91	0.35	1.87e-14	Lung cancer;
LGG	cis	rs10504229	0.600	rs6987243	chr8:58115406	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11785400	0.701	rs9297967	chr8:143723002	A/C	cg10596483	chr8:143751796	JRK	0.51	7.95	0.35	1.48e-14	Schizophrenia;
LGG	cis	rs10504229	0.593	rs1442127	chr8:57992136	T/C	cg26174226	chr8:58114915	NA	-0.52	-7.32	-0.32	1.13e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs2290937	chr5:93356515	A/T	cg25358565	chr5:93447407	FAM172A	1.22	15.24	0.58	8.14e-43	Diabetic retinopathy;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03773681	chr2:63815918	MDH1;C2orf86	-0.47	-7.93	-0.35	1.62e-14	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs2736337	0.530	rs2003422	chr8:11303137	G/C	cg02002194	chr4:3960332	NA	-0.42	-7.25	-0.32	1.75e-12	Rheumatoid arthritis;
LGG	cis	rs2153535	0.580	rs1932281	chr6:8473765	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs727563	0.608	rs2076200	chr22:41985956	G/T	cg06481639	chr22:41940642	POLR3H	-0.56	-7.78	-0.34	4.75e-14	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.35	0.4	3.86e-19	Rheumatoid arthritis;
LGG	cis	rs2762353	0.808	rs1165180	chr6:25826347	A/T	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs6459788	0.502	rs9692347	chr7:157232659	C/T	cg05333889	chr7:157238977	NA	-0.63	-13.02	-0.52	3.1e-33	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs9783347	0.600	rs2403254	chr11:18325146	A/G	cg03595886	chr11:18357587	GTF2H1	0.47	11.11	0.46	1.39e-25	Pancreatic cancer;
LGG	cis	rs752010	0.695	rs11210508	chr1:42106935	A/G	cg06885757	chr1:42089581	HIVEP3	0.54	12.39	0.5	1.21e-30	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs72945132	0.882	rs7116059	chr11:70159690	G/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	trans	rs6582630	0.555	rs11182217	chr12:38480030	G/A	cg06521331	chr12:34319734	NA	-0.52	-9.0	-0.39	5.83e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1799949	1.000	rs4793231	chr17:41427469	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.24	-0.39	8.73e-19	Menopause (age at onset);
LGG	cis	rs6694672	1.000	rs6003	chr1:197031021	C/T	cg13682187	chr1:196946512	CFHR5	0.52	7.2	0.32	2.49e-12	Asthma;
LGG	cis	rs933688	1.000	rs9293568	chr5:90737845	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs5769707	0.554	rs10854876	chr22:50010570	T/C	cg06623630	chr22:50017776	C22orf34	-0.48	-9.91	-0.42	3.93e-21	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs1814175	0.645	rs28839231	chr11:50044292	G/T	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs10504229	0.639	rs16921812	chr8:58106737	C/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4481887	1.000	rs6666690	chr1:248465323	T/C	cg00666640	chr1:248458726	OR2T12	0.61	9.94	0.42	3.17e-21	Common traits (Other);
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6681460	0.625	rs6679568	chr1:67074177	C/T	cg20812318	chr1:67072952	SGIP1	-0.32	-7.7	-0.34	8.43e-14	Presence of antiphospholipid antibodies;
LGG	cis	rs2839186	0.867	rs13050387	chr21:47701423	C/T	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.45e-16	Testicular germ cell tumor;
LGG	cis	rs7223966	0.961	rs17631783	chr17:61687600	A/G	cg05941027	chr17:61774174	LIMD2	-0.33	-8.1	-0.35	4.76e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4975709	0.589	rs4975744	chr5:1860049	A/G	cg15595755	chr5:1867978	NA	0.51	10.15	0.43	5.65e-22	Cardiovascular disease risk factors;
LGG	cis	rs7769051	0.522	rs3736725	chr6:133095172	A/G	cg22852734	chr6:133119734	C6orf192	1.07	9.39	0.4	2.77e-19	Type 2 diabetes nephropathy;
LGG	cis	rs17604090	0.878	rs4000284	chr7:29726917	G/A	cg19413766	chr7:29689036	LOC646762	-0.6	-7.52	-0.33	2.85e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7215564	0.749	rs7217825	chr17:78733901	C/T	cg06153925	chr17:78755379	RPTOR	-0.4	-7.21	-0.32	2.29e-12	Myopia (pathological);
LGG	cis	rs12148488	0.816	rs4886655	chr15:75385568	C/T	cg17294928	chr15:75287854	SCAMP5	0.59	10.36	0.43	8.93e-23	Caffeine consumption;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg18402987	chr7:1209562	NA	0.68	9.35	0.4	3.63e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.877	rs13170509	chr5:93378564	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.18	0.43	4.4e-22	Diabetic retinopathy;
LGG	cis	rs35110281	0.712	rs162345	chr21:44954155	T/G	cg04455712	chr21:45112962	RRP1B	0.52	9.8	0.41	1.03e-20	Mean corpuscular volume;
LGG	cis	rs916888	0.773	rs199448	chr17:44809001	A/G	cg01570182	chr17:44337453	NA	0.73	12.32	0.5	2.3e-30	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8180040	0.845	rs295441	chr3:47333295	T/A	cg16586182	chr3:47516702	SCAP	-0.76	-15.06	-0.57	5.06e-42	Colorectal cancer;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.05	-0.6	2.13e-46	Developmental language disorder (linguistic errors);
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg10820262	chr4:111866929	NA	0.4	7.34	0.32	9.91e-13	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs9650657	0.812	rs6993841	chr8:10632684	G/A	cg06636001	chr8:8085503	FLJ10661	-0.38	-6.67	-0.3	7.31e-11	Neuroticism;
LGG	trans	rs72991	0.793	rs10892744	chr11:121236701	A/G	cg27192990	chr6:129479024	LAMA2	-0.42	-7.08	-0.31	5.28e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8062405	1.000	rs3888190	chr16:28889486	C/A	cg00204512	chr16:28754710	NA	0.26	7.18	0.32	2.79e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs769267	0.930	rs2301786	chr19:19413947	A/G	cg03709012	chr19:19516395	GATAD2A	0.8	15.26	0.58	6.79e-43	Tonsillectomy;
LGG	cis	rs4959677	0.934	rs1891198	chr6:2501828	A/C	cg20147862	chr6:2634573	C6orf195	-0.4	-8.79	-0.38	3.05e-17	Orthostatic hypotension;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg05313129	chr8:58192883	C8orf71	-0.75	-10.33	-0.43	1.18e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs56283067	0.578	rs12203052	chr6:45398958	C/G	cg18551225	chr6:44695536	NA	-0.54	-7.84	-0.34	3.13e-14	Total body bone mineral density;
LGG	cis	rs2153535	0.601	rs9505473	chr6:8538777	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.41e-31	Motion sickness;
LGG	cis	rs6502050	0.865	rs8073679	chr17:80155343	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.36	-0.36	7.44e-16	Life satisfaction;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg07701084	chr6:150067640	NUP43	0.64	12.14	0.49	1.28e-29	Lung cancer;
LGG	cis	rs4538187	0.671	rs72893103	chr2:64235312	C/T	cg02541582	chr2:64069798	UGP2	-0.61	-12.98	-0.52	4.46e-33	Systolic blood pressure;
LGG	cis	rs17453880	0.929	rs7707955	chr5:152042028	G/T	cg12297329	chr5:152029980	NA	0.9	23.42	0.74	1.4e-80	Subjective well-being;
LGG	cis	rs4665809	0.590	rs1122972	chr2:26418788	A/C	cg08470875	chr2:26401718	FAM59B	-0.42	-8.27	-0.36	1.39e-15	Gut microbiome composition (summer);
LGG	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg17971929	chr21:40555470	PSMG1	-0.55	-9.38	-0.4	3.04e-19	Menarche (age at onset);
LGG	cis	rs7481584	0.962	rs11603638	chr11:2990526	G/A	cg08508325	chr11:3079039	CARS	0.39	7.18	0.32	2.83e-12	Calcium levels;
LGG	trans	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.33	-0.36	9.29e-16	Retinal vascular caliber;
LGG	cis	rs6500395	0.890	rs9936445	chr16:48617754	T/G	cg16662043	chr16:48846231	NA	0.37	7.25	0.32	1.73e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs3785574	0.962	rs62077509	chr17:61848973	A/G	cg06873352	chr17:61820015	STRADA	0.47	7.37	0.32	7.74e-13	Height;
LGG	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg09038676	chr11:67351608	GSTP1	0.36	6.92	0.31	1.5e-11	Mean corpuscular volume;
LGG	cis	rs67478160	0.643	rs2223937	chr14:104286380	A/G	cg26031613	chr14:104095156	KLC1	-0.46	-7.55	-0.33	2.38e-13	Schizophrenia;
LGG	cis	rs7586879	0.616	rs876186	chr2:25125585	C/T	cg04586622	chr2:25135609	ADCY3	0.47	12.9	0.51	1.01e-32	Body mass index;
LGG	cis	rs6912958	0.667	rs7746545	chr6:88090225	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	11.13	0.46	1.16e-25	Monocyte percentage of white cells;
LGG	trans	rs9929218	1.000	rs67359183	chr16:68814204	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.78	-13.19	-0.52	5.96e-34	Colorectal cancer;
LGG	cis	rs7444	0.941	rs12158299	chr22:21979584	C/T	cg05046821	chr22:21984468	YDJC	-0.37	-6.68	-0.3	6.87e-11	Systemic lupus erythematosus;
LGG	cis	rs12144309	0.608	rs1217408	chr1:114396280	T/C	cg13572289	chr1:114447746	DCLRE1B;AP4B1	0.33	6.76	0.3	4.1e-11	Coronary artery disease;
LGG	cis	rs3858526	0.959	rs61876224	chr11:5952859	G/A	cg05234568	chr11:5960015	NA	-0.74	-12.15	-0.49	1.17e-29	DNA methylation (variation);
LGG	cis	rs7666738	0.830	rs34461023	chr4:99023751	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7089973	0.604	rs7914792	chr10:116591391	T/C	cg08188268	chr10:116634841	FAM160B1	0.33	7.21	0.32	2.31e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07458698	chr2:67624494	ETAA1	0.43	7.09	0.31	5.16e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2050392	0.771	rs303446	chr10:30728489	C/T	cg25182066	chr10:30743637	MAP3K8	-0.53	-10.99	-0.45	3.93e-25	Inflammatory bowel disease;
LGG	cis	rs651907	0.535	rs17347156	chr3:101504674	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.61	12.31	0.5	2.43e-30	Colorectal cancer;
LGG	cis	rs5769765	0.954	rs6009900	chr22:50236610	T/C	cg02269571	chr22:50332266	NA	-0.62	-9.8	-0.41	9.8e-21	Schizophrenia;
LGG	cis	rs3096299	0.606	rs2965946	chr16:89516612	T/C	cg06640241	chr16:89574553	SPG7	0.69	10.77	0.45	2.7e-24	Multiple myeloma (IgH translocation);
LGG	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg03733263	chr8:22462867	KIAA1967	1.04	27.02	0.78	3.19e-97	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4742903	0.904	rs10761015	chr9:107007200	C/T	cg14250997	chr9:106856677	SMC2	0.38	7.64	0.33	1.3e-13	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg17809284	chr5:56205270	C5orf35	-0.54	-8.95	-0.38	8.32e-18	Initial pursuit acceleration;
LGG	cis	rs875971	0.862	rs7798630	chr7:65771479	G/C	cg18876405	chr7:65276391	NA	-0.54	-9.68	-0.41	2.74e-20	Aortic root size;
LGG	cis	rs514406	0.823	rs501006	chr1:53368292	T/A	cg24675658	chr1:53192096	ZYG11B	-0.48	-9.55	-0.41	7.47e-20	Monocyte count;
LGG	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.01	-0.35	9.18e-15	Response to antipsychotic treatment;
LGG	cis	rs1882538	0.551	rs6974618	chr7:133084031	C/A	cg10665199	chr7:133106180	EXOC4	0.57	9.71	0.41	2.03e-20	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	0.925	rs12193463	chr6:26961882	T/G	cg23155468	chr6:27110703	HIST1H2BK	-0.57	-7.42	-0.33	5.49e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6121246	0.909	rs4518038	chr20:30419051	A/G	cg13852791	chr20:30311386	BCL2L1	0.81	12.54	0.5	3.03e-31	Mean corpuscular hemoglobin;
LGG	cis	rs1799949	0.931	rs34410138	chr17:41279770	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.27	-0.32	1.51e-12	Menopause (age at onset);
LGG	cis	rs9322193	0.962	rs10452626	chr6:150088617	T/C	cg12070911	chr6:150209640	RAET1E	0.29	6.91	0.31	1.57e-11	Lung cancer;
LGG	cis	rs6489882	0.807	rs1859333	chr12:113370966	T/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.32	-0.32	1.13e-12	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	1.000	rs67039591	chr8:58174553	T/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.935	rs35446205	chr6:162938769	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.71	6.72	0.3	5.29e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11992186	0.570	rs17628941	chr8:8587534	G/C	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.18	-0.32	2.77e-12	Neuroticism;
LGG	cis	rs6450176	0.904	rs4351101	chr5:53300591	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.48	-0.47	5.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs11997175	0.846	rs7388664	chr8:33768773	T/G	ch.8.33884649F	chr8:33765107	NA	0.43	8.08	0.35	5.84e-15	Body mass index;
LGG	cis	rs10504229	0.683	rs56211106	chr8:58113497	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs4243971	0.516	rs17270685	chr20:31011937	A/G	cg00028034	chr20:30779307	TSPYL3	0.32	6.74	0.3	4.84e-11	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg07701084	chr6:150067640	NUP43	0.68	12.88	0.51	1.13e-32	Lung cancer;
LGG	cis	rs4073582	0.595	rs801731	chr11:65938446	G/C	cg14036092	chr11:66035641	RAB1B	0.45	7.85	0.34	2.88e-14	Gout;
LGG	cis	rs9463078	0.764	rs2396370	chr6:44946472	A/G	cg25276700	chr6:44698697	NA	-0.4	-8.51	-0.37	2.39e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg23131131	chr22:24373011	LOC391322	-0.49	-7.99	-0.35	1.05e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs854572	0.600	rs854570	chr7:94952692	C/A	cg20119798	chr7:94954144	PON1	0.39	7.96	0.35	1.37e-14	Paraoxonase activity;
LGG	cis	rs769267	0.864	rs7245983	chr19:19657632	A/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.48	7.38	0.32	7.48e-13	Tonsillectomy;
LGG	cis	rs6500602	0.685	rs62037617	chr16:4435163	G/C	cg05091796	chr16:4465799	CORO7	-0.57	-8.73	-0.38	4.66e-17	Schizophrenia;
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg00800038	chr16:89945340	TCF25	-0.74	-8.7	-0.37	5.94e-17	Skin colour saturation;
LGG	cis	rs4076764	0.522	rs10799914	chr1:163353205	A/G	cg24596788	chr1:163392923	NA	-0.51	-9.48	-0.4	1.28e-19	Motion sickness;
LGG	cis	rs1707322	1.000	rs4298677	chr1:46306619	G/A	cg03146154	chr1:46216737	IPP	0.54	10.21	0.43	3.31e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2228479	0.850	rs2286393	chr16:89809548	C/A	cg27400746	chr16:89904261	SPIRE2	-1.11	-16.48	-0.61	2.48e-48	Skin colour saturation;
LGG	cis	rs9322193	1.000	rs9399693	chr6:149933854	C/T	cg00933542	chr6:150070202	PCMT1	0.4	7.22	0.32	2.15e-12	Lung cancer;
LGG	trans	rs4843747	0.671	rs4075599	chr16:88107423	C/G	cg26811252	chr16:29126840	RRN3P2	0.65	10.29	0.43	1.69e-22	Menopause (age at onset);
LGG	cis	rs7824557	0.564	rs2572392	chr8:11235605	T/G	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.24e-17	Retinal vascular caliber;
LGG	cis	rs13191362	1.000	rs34653853	chr6:163114362	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.48	7.11	0.31	4.3e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11792861	0.926	rs75472294	chr9:111804239	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.46	0.4	1.54e-19	Menarche (age at onset);
LGG	cis	rs6460942	0.915	rs62447638	chr7:12484667	G/A	cg06484146	chr7:12443880	VWDE	-0.39	-6.8	-0.3	3.32e-11	Coronary artery disease;
LGG	trans	rs1908814	0.516	rs58869268	chr8:11797095	G/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.19e-18	Neuroticism;
LGG	cis	rs60871478	0.636	rs12534606	chr7:895928	A/G	cg10204951	chr7:910479	UNC84A	-0.53	-7.1	-0.31	4.87e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs3733585	0.673	rs7672947	chr4:9961368	G/C	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.78	-0.34	4.65e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10791323	0.593	rs10791329	chr11:133716356	T/C	cg00579200	chr11:133705235	NA	-0.61	-11.62	-0.48	1.49e-27	Childhood ear infection;
LGG	cis	rs992157	0.697	rs13384682	chr2:219069137	G/A	cg00012203	chr2:219082015	ARPC2	0.85	17.52	0.63	4.27e-53	Colorectal cancer;
LGG	cis	rs7666738	0.962	rs2865991	chr4:99067369	C/A	cg05340658	chr4:99064831	C4orf37	0.44	7.09	0.31	4.96e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs3749237	0.595	rs7637999	chr3:49535115	C/T	cg07636037	chr3:49044803	WDR6	0.59	10.39	0.43	7.27e-23	Resting heart rate;
LGG	cis	rs4132509	0.793	rs34477525	chr1:243966454	T/A	cg21452805	chr1:244014465	NA	0.65	7.74	0.34	6.08e-14	RR interval (heart rate);
LGG	cis	rs7084402	0.967	rs2393448	chr10:60333260	T/G	cg07615347	chr10:60278583	BICC1	0.63	18.13	0.64	6.8e-56	Refractive error;
LGG	cis	rs13191362	1.000	rs67046187	chr6:163068532	C/A	cg21926612	chr6:163149169	PACRG;PARK2	1.07	11.59	0.47	1.83e-27	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs61931739	0.817	rs10743842	chr12:34306859	C/T	cg13010199	chr12:38710504	ALG10B	0.49	9.34	0.4	4.17e-19	Morning vs. evening chronotype;
LGG	cis	rs9858542	1.000	rs9858542	chr3:49701983	A/G	cg00383909	chr3:49044727	WDR6	-0.44	-7.1	-0.31	4.63e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1059611	0.515	rs28413168	chr8:19674725	G/C	cg01411142	chr8:19674711	INTS10	0.82	10.41	0.44	6e-23	Lipid metabolism phenotypes;
LGG	cis	rs4740619	0.661	rs10810494	chr9:15947462	G/A	cg14451791	chr9:16040625	NA	-0.42	-10.51	-0.44	2.52e-23	Body mass index;
LGG	cis	rs1552244	0.882	rs2030564	chr3:10039044	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	cis	rs1577917	0.545	rs1335443	chr6:86478737	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.48	-8.23	-0.36	1.98e-15	Response to antipsychotic treatment;
LGG	cis	rs2708977	0.933	rs2708976	chr2:97184532	C/G	cg01950434	chr2:97203154	ARID5A	-0.6	-9.63	-0.41	4e-20	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg15208524	chr1:10270712	KIF1B	0.44	7.53	0.33	2.6e-13	Hepatocellular carcinoma;
LGG	cis	rs28595532	0.841	rs114970257	chr4:119756937	G/A	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.9e-21	Cannabis dependence symptom count;
LGG	cis	rs1263173	0.910	rs1263170	chr11:116678413	T/C	cg20608306	chr11:116969690	SIK3	0.29	7.48	0.33	3.67e-13	HDL cholesterol;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.75	-0.51	3.89e-32	Total body bone mineral density;
LGG	cis	rs4820294	1.000	rs62236667	chr22:38061520	C/G	cg08835221	chr22:38071607	LGALS1	0.27	7.55	0.33	2.4e-13	Fat distribution (HIV);
LGG	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	0.83	10.38	0.43	7.5e-23	Mean platelet volume;
LGG	trans	rs853679	0.607	rs34505829	chr6:28133239	A/T	cg01620082	chr3:125678407	NA	-1.06	-10.37	-0.43	8.65e-23	Depression;
LGG	cis	rs2839186	0.619	rs2187118	chr21:47611310	C/T	cg13126279	chr21:47581558	C21orf56	-0.46	-7.55	-0.33	2.29e-13	Testicular germ cell tumor;
LGG	cis	rs6121246	0.559	rs6119650	chr20:30258480	C/A	cg13852791	chr20:30311386	BCL2L1	0.94	18.55	0.65	7.34e-58	Mean corpuscular hemoglobin;
LGG	cis	rs2404602	0.692	rs55729975	chr15:76803226	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.78	-0.3	3.73e-11	Blood metabolite levels;
LGG	cis	rs2235573	0.662	rs738442	chr22:38457329	T/C	cg10587741	chr22:38071170	LGALS1	-0.33	-6.71	-0.3	5.6e-11	Glioblastoma;Glioma;
LGG	cis	rs9633740	1.000	rs10748526	chr10:82273079	T/C	cg01528321	chr10:82214614	TSPAN14	1.01	15.5	0.58	6.11e-44	Post bronchodilator FEV1;
LGG	cis	rs6976053	0.935	rs13226043	chr7:100475838	C/T	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.84e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs7552404	1.000	rs4949874	chr1:76161889	T/C	cg22875332	chr1:76189707	ACADM	0.61	10.37	0.43	8.2000000000000006e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16706631	chr6:26204823	HIST1H4E	0.46	7.34	0.32	9.46e-13	Cognitive performance;
LGG	cis	rs4740619	0.792	rs12377371	chr9:15737363	T/G	cg14451791	chr9:16040625	NA	0.33	8.57	0.37	1.54e-16	Body mass index;
LGG	trans	rs3733585	0.657	rs62286568	chr4:10124889	C/T	cg26043149	chr18:55253948	FECH	-0.44	-7.09	-0.31	5.15e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4974559	0.641	rs28647383	chr4:1312908	G/C	cg02980000	chr4:1222292	CTBP1	0.81	9.23	0.39	9.41e-19	Systolic blood pressure;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.72e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs12615966	0.872	rs55688943	chr2:105374842	T/A	cg16465502	chr2:105461796	NA	0.89	10.54	0.44	1.96e-23	Pancreatic cancer;
LGG	cis	rs3206736	0.549	rs10257774	chr7:35229608	G/T	cg13400248	chr7:35225412	NA	0.45	7.79	0.34	4.45e-14	Diastolic blood pressure;
LGG	cis	rs2439831	0.867	rs3809481	chr15:43662829	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	11.48	0.47	4.9e-27	Lung cancer in ever smokers;
LGG	trans	rs79976124	0.842	rs7760550	chr6:66628788	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.72	12.34	0.5	1.97e-30	Type 2 diabetes;
LGG	cis	rs17092148	0.895	rs4417778	chr20:33350987	T/C	cg12302830	chr20:33297742	TP53INP2	-0.46	-7.8	-0.34	4.2e-14	Neuroticism;
LGG	cis	rs981844	0.922	rs2118863	chr4:154657579	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.17e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs9611565	0.765	rs132914	chr22:41805749	T/C	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs911119	1.000	rs3827143	chr20:23619617	A/G	cg16589663	chr20:23618590	CST3	0.48	6.75	0.3	4.41e-11	Chronic kidney disease;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05665937	chr4:1216051	CTBP1	0.54	9.93	0.42	3.38e-21	Obesity-related traits;
LGG	trans	rs6952808	0.929	rs1801368	chr7:1976457	C/T	cg24247370	chr13:99142703	STK24	-0.41	-7.42	-0.33	5.83e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs13191362	0.935	rs67368176	chr6:162968436	A/T	cg21926612	chr6:163149169	PACRG;PARK2	0.89	9.01	0.39	5.38e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs12143943	0.866	rs10458588	chr1:204505487	T/C	cg20240347	chr1:204465584	NA	-0.35	-7.54	-0.33	2.51e-13	Cognitive performance;
LGG	trans	rs34421088	0.559	rs12386974	chr8:11400628	C/G	cg02002194	chr4:3960332	NA	-0.51	-10.11	-0.43	7.43e-22	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01906197	chr14:23067002	ABHD4	0.51	8.2	0.36	2.35e-15	Gut microbiome composition (summer);
LGG	cis	rs67311347	1.000	rs17078813	chr3:40434162	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-25.92	-0.77	3.49e-92	Renal cell carcinoma;
LGG	cis	rs9527	0.640	rs35195396	chr10:104928770	T/A	cg05308233	chr10:104796373	CNNM2	-0.32	-6.96	-0.31	1.2e-11	Arsenic metabolism;
LGG	cis	rs17209837	0.607	rs7793196	chr7:87122847	A/G	cg25823085	chr7:87105416	ABCB4	0.28	6.81	0.3	3.09e-11	Gallbladder cancer;
LGG	trans	rs2072153	0.738	rs9895945	chr17:47329255	A/G	cg11430096	chr6:110968061	CDK19	0.54	9.43	0.4	2.02e-19	Height;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.84	-0.38	2.08e-17	Lung cancer;
LGG	cis	rs7582180	0.629	rs4851297	chr2:100949571	G/A	cg05692746	chr2:100937584	LONRF2	-0.66	-12.32	-0.5	2.4e-30	Intelligence (multi-trait analysis);
LGG	cis	rs7613875	0.620	rs13079006	chr3:49996924	G/T	cg24110177	chr3:50126178	RBM5	-0.6	-10.96	-0.45	5.15e-25	Body mass index;
LGG	cis	rs116095464	0.558	rs7710005	chr5:233572	A/G	cg22496380	chr5:211416	CCDC127	-1.26	-17.88	-0.64	9.15e-55	Breast cancer;
LGG	cis	rs3733585	0.699	rs28613263	chr4:9964880	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs988958	0.567	rs11884781	chr2:42221093	C/T	cg27252766	chr2:42229092	NA	-0.57	-9.02	-0.39	4.92e-18	Hypospadias;
LGG	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg00717180	chr2:96193071	NA	0.41	7.31	0.32	1.17e-12	HDL cholesterol;
LGG	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg24189917	chr7:1970923	MAD1L1	-0.42	-7.07	-0.31	5.93e-12	Neuroticism;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00884529	chr7:16685823	BZW2;ANKMY2	0.48	7.6	0.33	1.66e-13	Gut microbiome composition (summer);
LGG	cis	rs6665290	0.835	rs7549586	chr1:227214566	A/G	cg10327440	chr1:227177885	CDC42BPA	-1.24	-37.43	-0.87	3.86e-142	Myeloid white cell count;
LGG	cis	rs4242434	0.927	rs34027561	chr8:22465385	T/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.73	-0.38	4.55e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs13118159	0.801	rs1128427	chr4:1330759	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.44	8.13	0.35	4.03e-15	Longevity;
LGG	cis	rs7444	0.825	rs738129	chr22:21971041	C/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.97	-0.35	1.28e-14	Systemic lupus erythematosus;
LGG	cis	rs8067545	0.750	rs4005937	chr17:19959828	A/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.88	-0.3	1.98e-11	Schizophrenia;
LGG	cis	rs72781680	0.898	rs10490752	chr2:24025132	C/T	cg08917208	chr2:24149416	ATAD2B	0.79	8.98	0.39	6.98e-18	Lymphocyte counts;
LGG	cis	rs4716602	0.596	rs4997808	chr7:156158734	C/G	cg16983916	chr7:156159713	NA	-0.49	-9.53	-0.41	8.79e-20	Anti-saccade response;
LGG	cis	rs2153535	0.580	rs9393019	chr6:8462091	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.57e-31	Motion sickness;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19701416	chr10:28592092	NA	0.44	6.99	0.31	9.74e-12	Gut microbiome composition (summer);
LGG	cis	rs7582180	0.614	rs4340543	chr2:101005511	G/A	cg05692746	chr2:100937584	LONRF2	-0.64	-11.75	-0.48	4.48e-28	Intelligence (multi-trait analysis);
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.49	-8.94	-0.38	9.47e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg07005078	chr4:17578674	LAP3	-0.37	-6.94	-0.31	1.35e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17345786	0.861	rs11707689	chr3:101086475	A/G	cg12386194	chr3:101231763	SENP7	0.75	13.18	0.52	6.84e-34	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7618915	0.501	rs1468638	chr3:52748058	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.21	-0.32	2.32e-12	Bipolar disorder;
LGG	cis	rs1008375	0.966	rs11722132	chr4:17697217	T/C	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.962	rs10872656	chr6:150120580	A/C	cg09699651	chr6:150184138	LRP11	0.49	8.55	0.37	1.74e-16	Lung cancer;
LGG	cis	rs56399783	0.901	rs17132741	chr7:2868997	C/T	cg19731401	chr7:2775893	GNA12	-0.35	-7.24	-0.32	1.87e-12	Childhood ear infection;
LGG	cis	rs7044106	0.500	rs56725168	chr9:123492576	T/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.49	8.06	0.35	6.45e-15	Hip circumference adjusted for BMI;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg13047869	chr3:10149882	C3orf24	0.53	8.75	0.38	3.93e-17	Alzheimer's disease;
LGG	cis	rs151349	1.000	rs151344	chr20:57585301	A/G	cg23907860	chr20:57583709	CTSZ	-0.45	-9.24	-0.39	8.79e-19	Platelet distribution width;
LGG	cis	rs2040771	0.745	rs2283646	chr22:19273902	A/G	cg02655711	chr22:19163373	SLC25A1	-0.46	-8.25	-0.36	1.7e-15	Metabolite levels (small molecules and protein measures);
LGG	cis	rs62238980	0.614	rs117209345	chr22:32504935	G/C	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	cis	rs10426930	0.621	rs6510833	chr19:5008399	G/A	cg15621731	chr19:5074616	KDM4B	-0.3	-6.68	-0.3	6.7e-11	Monocyte percentage of white cells;
LGG	cis	rs35160687	0.644	rs10165626	chr2:86536707	C/T	cg10973622	chr2:86423274	IMMT	-0.39	-6.98	-0.31	1.04e-11	Night sleep phenotypes;
LGG	cis	rs4304924	0.500	rs2281856	chr13:79207644	C/T	cg01819759	chr13:79234251	RNF219	-0.46	-6.99	-0.31	9.88e-12	Large artery stroke;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.73	-0.34	6.76e-14	Testicular germ cell tumor;
LGG	cis	rs3733585	0.638	rs13145554	chr4:9979589	C/T	cg25986240	chr4:9926439	SLC2A9	-0.38	-7.96	-0.35	1.32e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs55665837	1.000	rs7945167	chr11:14451820	T/G	cg19336497	chr11:14380999	RRAS2	-0.44	-8.72	-0.38	4.94e-17	Vitamin D levels;
LGG	cis	rs4253772	0.530	rs79354880	chr22:46746419	C/A	cg00784671	chr22:46762841	CELSR1	-0.64	-6.99	-0.31	9.38e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2718058	0.606	rs2718054	chr7:37835854	T/A	cg24998770	chr7:37888106	TXNDC3	0.41	7.01	0.31	8.3e-12	Alzheimer's disease (late onset);
LGG	trans	rs853679	0.546	rs36116761	chr6:27818482	C/G	cg08344181	chr3:125677491	NA	-0.86	-8.39	-0.36	5.97e-16	Depression;
LGG	cis	rs12586317	0.557	rs72664863	chr14:35643588	C/T	cg05294307	chr14:35346193	BAZ1A	-0.37	-6.98	-0.31	9.98e-12	Psoriasis;
LGG	cis	rs2243480	1.000	rs7778911	chr7:65694506	T/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.48	-0.37	2.94e-16	Diabetic kidney disease;
LGG	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg06827562	chr3:125932279	NA	0.66	16.44	0.61	3.55e-48	Metabolite levels;
LGG	cis	rs2276314	1.000	rs1540042	chr18:33555236	C/T	cg05985134	chr18:33552581	C18orf21	0.66	10.35	0.43	1.03e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs2710642	0.927	rs1468748	chr2:63204611	C/T	cg17519650	chr2:63277830	OTX1	0.49	8.11	0.35	4.56e-15	LDL cholesterol levels;LDL cholesterol;
LGG	cis	rs6426558	0.537	rs2492630	chr1:227286931	A/G	cg10327440	chr1:227177885	CDC42BPA	0.61	10.2	0.43	3.61e-22	Neutrophil percentage of white cells;
LGG	cis	rs1552244	0.572	rs57268864	chr3:10164233	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.91	-11.85	-0.48	1.74e-28	Alzheimer's disease;
LGG	cis	rs6951245	0.706	rs1133116	chr7:1195215	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.77	11.08	0.46	1.81e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11098499	0.774	rs73842616	chr4:120290683	G/A	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.23	-0.58	9.88e-43	Prudent dietary pattern;
LGG	cis	rs140364877	1	rs140364877	chr7:1885178	C/T	cg00106254	chr7:1943704	MAD1L1	-0.47	-7.99	-0.35	1.09e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28595532	0.920	rs55869953	chr4:119751893	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs4421206	chr6:150004027	A/C	cg09699651	chr6:150184138	LRP11	0.52	9.29	0.4	6.17e-19	Lung cancer;
LGG	cis	rs6500395	0.963	rs12919278	chr16:48692537	A/G	cg04672837	chr16:48644449	N4BP1	-0.54	-8.96	-0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9660992	0.512	rs12142402	chr1:205128215	A/T	cg00857998	chr1:205179979	DSTYK	0.55	8.86	0.38	1.73e-17	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs35851103	0.507	rs6601649	chr8:11857317	A/G	cg00405596	chr8:11794950	NA	-0.4	-6.67	-0.3	7.48e-11	Neuroticism;
LGG	cis	rs4918072	0.793	rs12784155	chr10:105708310	A/G	cg11005552	chr10:105648138	OBFC1	0.45	7.5	0.33	3.27e-13	Coronary artery disease;
LGG	cis	rs12893668	0.703	rs35026580	chr14:104042753	A/G	cg23335576	chr14:104009727	NA	0.47	8.19	0.36	2.56e-15	Reticulocyte count;
LGG	cis	rs539514	1.000	rs539514	chr13:76326282	A/T	cg04757411	chr13:76259545	LMO7	-0.26	-6.81	-0.3	3.05e-11	Type 1 diabetes;
LGG	trans	rs7980799	0.935	rs7312012	chr12:33517984	A/G	cg26384229	chr12:38710491	ALG10B	-0.49	-8.57	-0.37	1.59e-16	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs10911232	0.507	rs10752888	chr1:182993751	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs651907	0.512	rs771324	chr3:101610365	T/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.46	8.17	0.35	3.01e-15	Colorectal cancer;
LGG	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg11764359	chr7:65958608	NA	-0.62	-10.24	-0.43	2.48e-22	Aortic root size;
LGG	cis	rs9303401	0.659	rs35103007	chr17:56900738	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.17	0.58	1.72e-42	Cognitive test performance;
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg07414643	chr4:187882934	NA	0.53	11.07	0.46	1.94e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg07677032	chr17:61819896	STRADA	0.67	12.52	0.5	3.45e-31	Prudent dietary pattern;
LGG	cis	rs2290159	1.000	rs2290159	chr3:12628920	G/C	cg23032965	chr3:12705835	RAF1	0.56	8.4	0.36	5.46e-16	Cholesterol, total;
LGG	cis	rs12893668	0.543	rs12147645	chr14:104100208	T/A	cg24130564	chr14:104152367	KLC1	-0.39	-6.95	-0.31	1.22e-11	Reticulocyte count;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg26666512	chr16:30934656	NCRNA00095;FBXL19	-0.4	-6.79	-0.3	3.53e-11	Brain structure;
LGG	cis	rs763014	0.865	rs710924	chr16:633353	T/C	cg00908189	chr16:619842	PIGQ	0.85	15.62	0.59	1.72e-44	Height;
LGG	trans	rs9784649	1.000	rs6864025	chr5:24960691	G/C	cg08600765	chr20:34638493	LOC647979	-0.57	-7.43	-0.33	5.23e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs62064224	0.512	rs9912766	chr17:30712780	A/G	cg25809561	chr17:30822961	MYO1D	0.37	8.75	0.38	3.94e-17	Schizophrenia;
LGG	cis	rs2294693	0.945	rs2073015	chr6:41008747	A/G	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.72	-0.3	5.35e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs4474465	0.850	rs10793322	chr11:78242615	T/C	cg27205649	chr11:78285834	NARS2	0.48	8.32	0.36	9.89e-16	Alzheimer's disease (survival time);
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7582180	0.764	rs11683121	chr2:100920705	C/T	cg05692746	chr2:100937584	LONRF2	-0.62	-11.08	-0.46	1.86e-25	Intelligence (multi-trait analysis);
LGG	cis	rs6558530	0.897	rs10481354	chr8:1704030	A/G	cg08198773	chr8:1697536	NA	-0.35	-6.79	-0.3	3.5e-11	Systolic blood pressure;
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.81	0.64	2.09e-54	Alzheimer's disease;
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg03647317	chr4:187891568	NA	-0.41	-8.87	-0.38	1.57e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7618915	0.547	rs34537256	chr3:52657472	A/G	cg10802521	chr3:52805072	NEK4	-0.43	-7.23	-0.32	1.99e-12	Bipolar disorder;
LGG	cis	rs1003719	0.612	rs2835652	chr21:38557408	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.08	-0.57	4.13e-42	Eye color traits;
LGG	cis	rs35160687	0.644	rs11680025	chr2:86545338	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.8	0.3	3.17e-11	Night sleep phenotypes;
LGG	trans	rs6601327	0.518	rs13264850	chr8:9575331	A/T	cg16141378	chr3:129829833	LOC729375	0.36	8.07	0.35	6.06e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs782590	0.783	rs7594279	chr2:55812073	T/G	cg18811423	chr2:55921094	PNPT1	0.88	20.05	0.68	8.16e-65	Metabolic syndrome;
LGG	cis	rs4740619	0.846	rs10121591	chr9:15676255	T/G	cg14451791	chr9:16040625	NA	0.32	8.2	0.36	2.46e-15	Body mass index;
LGG	cis	rs9322193	1.000	rs9377228	chr6:149921998	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.86	0.34	2.78e-14	Lung cancer;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg00684032	chr4:1343700	KIAA1530	0.41	8.21	0.36	2.27e-15	Longevity;
LGG	cis	rs11148252	0.564	rs2296350	chr13:52710044	T/C	cg12458913	chr13:53173898	NA	0.55	9.97	0.42	2.37e-21	Lewy body disease;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg23758822	chr17:41437982	NA	0.86	15.7	0.59	7.84e-45	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.71e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs7756850	chr6:150212596	G/C	cg05036130	chr6:150231994	NA	0.33	6.67	0.3	7.24e-11	Testicular germ cell tumor;
LGG	cis	rs9322193	0.926	rs3805751	chr6:150112329	G/A	cg16507663	chr6:150244633	RAET1G	0.41	7.65	0.34	1.14e-13	Lung cancer;
LGG	cis	rs9611565	0.592	rs12484254	chr22:41962003	T/A	cg06481639	chr22:41940642	POLR3H	-0.49	-7.05	-0.31	6.38e-12	Vitiligo;
LGG	cis	rs60871478	0.588	rs6952577	chr7:872100	C/T	cg05535760	chr7:792225	HEATR2	0.8	11.6	0.47	1.79e-27	Cerebrospinal P-tau181p levels;
LGG	cis	rs3847687	1.000	rs3847688	chr12:131525310	C/T	cg06093039	chr12:131527216	GPR133	0.28	7.04	0.31	7.11e-12	Longevity;
LGG	cis	rs4732038	0.510	rs10246041	chr7:134272478	C/T	cg06906464	chr7:134288099	NA	-0.66	-17.19	-0.62	1.42e-51	Longevity;
LGG	cis	rs6089584	0.927	rs2281734	chr20:60582401	C/A	cg06108461	chr20:60628389	TAF4	-0.89	-16.99	-0.62	1.18e-50	Body mass index;
LGG	cis	rs9916302	0.768	rs62077464	chr17:37656056	C/G	cg07936489	chr17:37558343	FBXL20	-0.85	-15.62	-0.59	1.71e-44	Glomerular filtration rate (creatinine);
LGG	cis	rs13394619	1.000	rs2358040	chr2:11731774	G/T	cg07314298	chr2:11723111	GREB1	0.49	10.19	0.43	3.92e-22	Endometriosis;
LGG	trans	rs9467711	0.651	rs35506517	chr6:26044864	T/C	cg06606381	chr12:133084897	FBRSL1	-1.0	-8.37	-0.36	7.13e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg12379764	chr21:47803548	PCNT	-0.44	-7.25	-0.32	1.75e-12	Testicular germ cell tumor;
LGG	cis	rs651907	0.535	rs13065944	chr3:101473088	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.03	0.52	2.84e-33	Colorectal cancer;
LGG	cis	rs899997	1.000	rs11632672	chr15:79044330	A/G	cg10852096	chr15:79043040	NA	-0.3	-8.62	-0.37	1.03e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs741702	0.892	rs11085824	chr19:13001547	A/G	cg06417478	chr19:12876846	HOOK2	-0.41	-6.79	-0.3	3.47e-11	Red blood cell traits;
LGG	cis	rs67478160	0.609	rs1547604	chr14:104270659	A/T	cg26031613	chr14:104095156	KLC1	-0.44	-7.11	-0.31	4.34e-12	Schizophrenia;
LGG	cis	rs921968	0.643	rs2556385	chr2:219532905	G/A	cg01130898	chr2:219473002	PLCD4	0.42	7.22	0.32	2.14e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs10504229	0.683	rs2291765	chr8:58142874	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-11.95	-0.49	7.04e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	0.701	rs11693044	chr2:100922313	T/C	cg05692746	chr2:100937584	LONRF2	-0.63	-11.21	-0.46	5.71e-26	Intelligence (multi-trait analysis);
LGG	cis	rs6032067	0.925	rs6032061	chr20:43853276	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	trans	rs7824557	0.767	rs2164272	chr8:11162496	A/C	cg15556689	chr8:8085844	FLJ10661	0.45	7.86	0.34	2.66e-14	Retinal vascular caliber;
LGG	trans	rs72766638	1.000	rs72766638	chr9:136931778	C/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.57	-7.7	-0.34	8.48e-14	Mosquito bite size;
LGG	cis	rs7017914	0.934	rs7015035	chr8:71653601	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.79	-0.3	3.44e-11	Bone mineral density;
LGG	cis	rs10504229	0.861	rs57942497	chr8:58171239	G/T	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.966	rs11947836	chr4:17697187	A/G	cg16339924	chr4:17578868	LAP3	-0.52	-8.76	-0.38	3.7e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.64	0.44	8.34e-24	Personality dimensions;
LGG	cis	rs3762637	1.000	rs10049131	chr3:122202102	A/T	cg24169773	chr3:122142474	KPNA1	-0.62	-10.57	-0.44	1.56e-23	LDL cholesterol levels;
LGG	cis	rs7122539	0.646	rs10791889	chr11:66493825	C/T	cg01599099	chr11:66649832	PC	0.47	9.4	0.4	2.53e-19	HIV-1 susceptibility;
LGG	cis	rs7975161	0.671	rs7313063	chr12:104602208	G/A	cg25273343	chr12:104657179	TXNRD1	-0.59	-9.6	-0.41	4.88e-20	Toenail selenium levels;
LGG	cis	rs17767392	0.788	rs7492426	chr14:71699139	T/G	cg02058870	chr14:72053146	SIPA1L1	0.35	6.93	0.31	1.42e-11	Mitral valve prolapse;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.19	0.32	2.69e-12	Prudent dietary pattern;
LGG	trans	rs116095464	0.614	rs10059220	chr5:242813	C/T	cg09048205	chr5:1608656	LOC728613	-0.51	-8.45	-0.37	3.82e-16	Breast cancer;
LGG	cis	rs4293296	0.525	rs75175834	chr14:54825714	T/C	cg11186706	chr14:54815745	NA	0.57	7.89	0.34	2.23e-14	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs3742264	0.656	rs2075427	chr13:46515605	T/C	cg15192986	chr13:46630673	CPB2	0.36	7.03	0.31	7.4e-12	Blood protein levels;
LGG	cis	rs9818758	0.556	rs13086240	chr3:49001409	G/A	cg00383909	chr3:49044727	WDR6	1.05	12.7	0.51	6.51e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs7264396	0.570	rs6060717	chr20:34544647	T/C	cg04508476	chr20:34239394	CPNE1;RBM12	-0.4	-7.1	-0.31	4.71e-12	Total cholesterol levels;
LGG	cis	rs6964587	0.933	rs13230837	chr7:91779017	A/G	cg17063962	chr7:91808500	NA	0.53	9.7	0.41	2.28e-20	Breast cancer;
LGG	cis	rs2762353	0.574	rs9467573	chr6:25704190	C/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-8.99	-0.39	6.21e-18	Blood metabolite levels;
LGG	cis	rs722599	0.748	rs61978948	chr14:75363369	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.6	-9.92	-0.42	3.78e-21	IgG glycosylation;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg06916706	chr16:4465613	CORO7	-0.88	-15.97	-0.6	4.88e-46	Schizophrenia;
LGG	trans	rs9784649	1.000	rs55806673	chr5:24957298	A/G	cg11038491	chr20:34638489	LOC647979	-0.52	-6.89	-0.3	1.86e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs911555	0.755	rs35233301	chr14:103885291	A/G	cg24130564	chr14:104152367	KLC1	0.4	7.37	0.32	8.17e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1419980	0.556	rs11054516	chr12:7724875	C/T	cg10578777	chr12:7781093	NA	-0.59	-7.87	-0.34	2.59e-14	HDL cholesterol levels;
LGG	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg21545522	chr1:205238299	TMCC2	0.37	7.07	0.31	5.62e-12	Red blood cell count;
LGG	cis	rs7773004	0.875	rs9393700	chr6:26309380	G/A	cg13736514	chr6:26305472	NA	-0.41	-8.44	-0.37	4.19e-16	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.23	0.36	1.88e-15	Personality dimensions;
LGG	cis	rs651907	0.557	rs7645391	chr3:101361506	C/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.29	0.53	2.25e-34	Colorectal cancer;
LGG	cis	rs11168351	0.927	rs11168342	chr12:48383797	G/T	cg24011408	chr12:48396354	COL2A1	0.57	9.37	0.4	3.22e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs739401	0.572	rs404629	chr11:3077025	A/G	cg05729581	chr11:3078854	CARS	-0.57	-10.03	-0.42	1.43e-21	Longevity;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg06719900	chr11:109292894	C11orf87	0.44	8.5	0.37	2.56e-16	Schizophrenia;
LGG	cis	rs9467711	0.651	rs2051539	chr6:25947259	G/C	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.0	0.31	8.95e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg25919922	chr13:100150906	NA	-0.7	-7.11	-0.31	4.43e-12	Obesity-related traits;
LGG	cis	rs6500395	1.000	rs1477134	chr16:48706973	G/A	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28588043	0.759	rs114283104	chr1:170989942	G/A	cg03458344	chr1:170964477	C1orf129	-0.54	-7.23	-0.32	2e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs7503807	1.000	rs12936076	chr17:78601195	C/T	cg09596252	chr17:78655493	RPTOR	0.43	7.73	0.34	6.64e-14	Obesity;
LGG	cis	rs4975616	0.686	rs37008	chr5:1351538	C/T	cg06550200	chr5:1325588	CLPTM1L	-0.51	-8.49	-0.37	2.77e-16	Lung cancer;
LGG	trans	rs1997103	0.954	rs6593222	chr7:55372932	A/C	cg20935933	chr6:143382018	AIG1	0.59	8.96	0.38	7.94e-18	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs3785574	0.962	rs4480868	chr17:61788859	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.61	10.4	0.44	6.68e-23	Height;
LGG	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg16147221	chr4:10020634	SLC2A9	0.37	6.69	0.3	6.39e-11	Bone mineral density;
LGG	cis	rs709400	0.593	rs12898029	chr14:103877884	T/C	cg26031613	chr14:104095156	KLC1	-0.8	-14.34	-0.55	7.56e-39	Body mass index;
LGG	cis	rs6461049	0.646	rs3778970	chr7:2143208	C/A	cg20308403	chr7:2120281	MAD1L1	0.35	7.33	0.32	1.01e-12	Schizophrenia;
LGG	cis	rs1552244	0.872	rs6792951	chr3:10119603	C/A	cg08888203	chr3:10149979	C3orf24	0.54	9.23	0.39	9.49e-19	Alzheimer's disease;
LGG	cis	rs9816226	0.618	rs869399	chr3:185826764	C/T	cg00760338	chr3:185826511	ETV5	0.97	18.09	0.64	1.06e-55	Obesity;Body mass index;
LGG	cis	rs3087591	0.960	rs9807077	chr17:29634457	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.47	-0.56	2.05e-39	Hip circumference;
LGG	cis	rs2188554	0.675	rs12536356	chr7:117082485	A/C	cg10524701	chr7:117356490	CTTNBP2	0.4	7.79	0.34	4.49e-14	Esophageal adenocarcinoma;
LGG	cis	rs13118159	0.899	rs3796613	chr4:1353321	A/T	cg00684032	chr4:1343700	KIAA1530	0.43	8.29	0.36	1.23e-15	Longevity;
LGG	trans	rs7829975	0.626	rs907183	chr8:8729761	C/G	cg21775007	chr8:11205619	TDH	-0.42	-7.0	-0.31	9.15e-12	Mood instability;
LGG	cis	rs919433	0.647	rs1979239	chr2:198498316	T/G	cg00792783	chr2:198669748	PLCL1	0.57	9.22	0.39	1.02e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs116095464	0.558	rs9688136	chr5:229348	T/C	cg22496380	chr5:211416	CCDC127	-1.23	-17.51	-0.63	4.99e-53	Breast cancer;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.792	rs12537914	chr7:1948359	C/T	cg21782813	chr7:2030301	MAD1L1	0.47	11.3	0.46	2.61e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg01145232	chr6:150245071	RAET1G	0.47	8.52	0.37	2.23e-16	Lung cancer;
LGG	cis	rs7762018	0.556	rs80250989	chr6:170105553	T/C	cg17545662	chr6:170176663	C6orf70	0.66	6.72	0.3	5.52e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9329221	0.527	rs6989657	chr8:10330873	C/G	cg21775007	chr8:11205619	TDH	0.45	6.91	0.31	1.59e-11	Neuroticism;
LGG	cis	rs10462794	0.853	rs973156	chr5:4505421	T/C	cg18482690	chr5:4511582	NA	-0.43	-7.23	-0.32	2.07e-12	DNA methylation (variation);
LGG	cis	rs909674	0.514	rs7423	chr22:39781429	C/T	cg04986931	chr22:39850128	NA	0.33	7.49	0.33	3.42e-13	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs148734725	1	rs148734725	chr3:49406708	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.4	0.33	6.61e-13	Educational attainment (college completion);
LGG	cis	rs12142240	0.698	rs77185326	chr1:46818417	T/C	cg00530320	chr1:46809349	NSUN4	0.45	8.21	0.36	2.17e-15	Menopause (age at onset);
LGG	cis	rs7582180	0.934	rs2309817	chr2:100897674	T/A	cg26150922	chr2:100937072	LONRF2	-0.57	-10.01	-0.42	1.68e-21	Intelligence (multi-trait analysis);
LGG	cis	rs7444	0.941	rs2266964	chr22:21958304	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs7789940	1.000	rs758944	chr7:75953297	G/T	cg10167463	chr7:75959203	YWHAG	-0.47	-7.89	-0.34	2.2e-14	Multiple sclerosis;
LGG	cis	rs875971	1.000	rs11974219	chr7:65647410	C/T	cg11764359	chr7:65958608	NA	-0.8	-14.88	-0.57	3.28e-41	Aortic root size;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg27471124	chr11:109292789	C11orf87	0.51	9.92	0.42	3.6e-21	Schizophrenia;
LGG	cis	rs5750830	0.649	rs5757663	chr22:39821319	T/C	cg04986931	chr22:39850128	NA	0.34	7.64	0.33	1.24e-13	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.500	rs11053246	chr12:34516620	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.62	-0.41	4.27e-20	Morning vs. evening chronotype;
LGG	cis	rs1865760	0.566	rs9467663	chr6:26021456	C/G	cg17691542	chr6:26056736	HIST1H1C	0.56	10.12	0.43	7.04e-22	Height;
LGG	cis	rs7618915	0.781	rs12489732	chr3:52566820	C/A	cg11645453	chr3:52864694	ITIH4	0.44	6.98	0.31	1.01e-11	Bipolar disorder;
LGG	cis	rs11190604	1.000	rs11190589	chr10:102275471	A/G	cg07570687	chr10:102243282	WNT8B	0.43	7.18	0.32	2.89e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.14	-0.32	3.56e-12	Life satisfaction;
LGG	cis	rs5758265	1	rs5758265	chr22:41617897	G/A	cg03806693	chr22:41940476	POLR3H	-0.51	-8.01	-0.35	9.43e-15	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1190596	0.830	rs4947	chr14:102550803	G/A	cg23904247	chr14:102554826	HSP90AA1	-0.26	-6.9	-0.31	1.67e-11	Behavioural disinhibition (generation interaction);
LGG	cis	rs8032158	0.634	rs12898589	chr15:56127733	A/G	cg02198044	chr15:56286336	NEDD4	0.5	8.54	0.37	1.95e-16	Keloid;
LGG	cis	rs2067615	0.524	rs10861645	chr12:107071130	C/T	cg15890332	chr12:107067104	RFX4	0.44	12.87	0.51	1.24e-32	Heart rate;
LGG	cis	rs9560113	1.000	rs4773384	chr13:112177987	A/G	cg14952266	chr13:112191215	NA	-0.42	-7.59	-0.33	1.8e-13	Menarche (age at onset);
LGG	cis	rs751728	1.000	rs4342423	chr6:33732679	C/T	cg25922239	chr6:33757077	LEMD2	0.67	11.57	0.47	2.18e-27	Crohn's disease;
LGG	cis	rs7819412	0.774	rs34208825	chr8:11014616	T/G	cg27411982	chr8:10470053	RP1L1	-0.44	-7.43	-0.33	5.3e-13	Triglycerides;
LGG	cis	rs769267	0.965	rs4808937	chr19:19398005	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.32	0.36	9.64e-16	Tonsillectomy;
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg02951883	chr7:2050386	MAD1L1	-0.69	-13.8	-0.54	1.5e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs6692729	0.933	rs2855559	chr1:227080459	G/A	cg08708961	chr1:227070630	PSEN2	0.31	7.89	0.34	2.15e-14	Electrodermal activity;
LGG	cis	rs3091242	0.933	rs35148262	chr1:25766623	A/G	cg27572855	chr1:25598939	RHD	0.52	11.71	0.48	6.33e-28	Erythrocyte sedimentation rate;
LGG	cis	rs2760061	0.819	rs708120	chr1:228207651	G/C	cg02753203	chr1:228287806	NA	0.76	14.49	0.56	1.63e-39	Diastolic blood pressure;
LGG	cis	rs561341	0.609	rs7214626	chr17:30190989	G/A	cg13647721	chr17:30228624	UTP6	-0.73	-9.34	-0.4	4.21e-19	Hip circumference adjusted for BMI;
LGG	trans	rs9325144	0.647	rs12831609	chr12:39051576	C/A	cg06521331	chr12:34319734	NA	0.4	6.71	0.3	5.84e-11	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.702	rs16977724	chr15:44151299	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.91	9.56	0.41	6.94e-20	Lung cancer in ever smokers;
LGG	cis	rs5771242	0.518	rs67881086	chr22:50673439	G/A	cg08875078	chr22:50639485	SELO	0.51	7.39	0.32	7.02e-13	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs774359	0.797	rs868856	chr9:27489251	A/G	cg21249376	chr9:27528432	MOBKL2B	-0.4	-8.22	-0.36	2.1e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs8060686	0.641	rs76595854	chr16:68130233	T/C	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.18e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs968451	0.813	rs5757619	chr22:39724558	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.84	12.22	0.49	5.77e-30	Primary biliary cholangitis;
LGG	cis	rs9486719	1.000	rs12214469	chr6:97019471	G/T	cg18709589	chr6:96969512	KIAA0776	-0.45	-6.78	-0.3	3.58e-11	Migraine;Coronary artery disease;
LGG	cis	rs10779751	1.000	rs4845859	chr1:11304873	A/G	cg08854313	chr1:11322531	MTOR	0.75	16.6	0.61	6.45e-49	Body mass index;
LGG	cis	rs61931739	0.534	rs11052960	chr12:33997754	A/T	cg06521331	chr12:34319734	NA	-0.62	-11.16	-0.46	9.04e-26	Morning vs. evening chronotype;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg02475777	chr4:1388615	CRIPAK	0.45	8.46	0.37	3.44e-16	Longevity;
LGG	cis	rs701145	0.585	rs1727949	chr3:153875713	A/G	cg17054900	chr3:154042577	DHX36	0.69	8.85	0.38	1.87e-17	Coronary artery disease;
LGG	cis	rs951366	0.576	rs12046305	chr1:205714478	G/A	cg11965913	chr1:205819406	PM20D1	-0.41	-6.89	-0.3	1.84e-11	Menarche (age at onset);
LGG	trans	rs3857536	0.785	rs2157964	chr6:66938419	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs7483296	0.765	rs11215589	chr11:115403539	C/T	cg02820646	chr11:115398838	NA	-0.5	-8.89	-0.38	1.35e-17	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs796364	0.806	rs11688194	chr2:200916239	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.81	-9.73	-0.41	1.75e-20	Schizophrenia;
LGG	cis	rs7208859	0.673	rs73263785	chr17:29214808	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2727020	0.513	rs10839307	chr11:49609843	A/C	cg03929089	chr4:120376271	NA	-0.97	-21.09	-0.7	1.05e-69	Coronary artery disease;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg16885296	chr6:26284938	NA	0.36	7.63	0.33	1.32e-13	Educational attainment;
LGG	cis	rs28595532	0.920	rs115430947	chr4:119737149	C/A	cg21605333	chr4:119757512	SEC24D	1.49	15.07	0.57	4.79e-42	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg09699651	chr6:150184138	LRP11	0.54	9.74	0.41	1.57e-20	Lung cancer;
LGG	trans	rs12310956	0.532	rs11052922	chr12:33957476	A/G	cg26384229	chr12:38710491	ALG10B	0.71	14.25	0.55	1.86e-38	Morning vs. evening chronotype;
LGG	cis	rs7613875	0.600	rs2856237	chr3:50158774	A/G	cg14019146	chr3:50243930	SLC38A3	0.31	6.73	0.3	5.18e-11	Body mass index;
LGG	cis	rs6546537	0.955	rs2312215	chr2:69839825	T/A	cg10773587	chr2:69614142	GFPT1	-0.48	-8.07	-0.35	6.09e-15	Serum thyroid-stimulating hormone levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06391107	chr19:40502439	ZNF546	0.53	8.4	0.36	5.58e-16	Gut microbiome composition (summer);
LGG	cis	rs6489882	0.867	rs6489868	chr12:113363692	C/G	cg25319449	chr12:113376135	OAS3	0.41	7.6	0.33	1.68e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9381040	0.610	rs2294694	chr6:41046177	G/A	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.66	-0.3	7.75e-11	Alzheimer's disease (late onset);
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.6	0.53	1.08e-35	Prudent dietary pattern;
LGG	cis	rs7659604	1.000	rs28640980	chr4:122664284	T/C	cg19748678	chr4:122722346	EXOSC9	0.53	10.36	0.43	9.43e-23	Type 2 diabetes;
LGG	cis	rs55788414	0.932	rs35424543	chr16:81181983	G/A	cg06400318	chr16:81190750	PKD1L2	-1.04	-11.23	-0.46	4.67e-26	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs11098499	0.604	rs12642411	chr4:120580525	T/C	cg01244601	chr4:120671846	NA	-0.4	-7.52	-0.33	2.9e-13	Corneal astigmatism;
LGG	cis	rs4332037	0.586	rs62442944	chr7:2015047	T/G	cg02743256	chr7:2109353	MAD1L1	-0.36	-7.29	-0.32	1.36e-12	Bipolar disorder;
LGG	cis	rs9560113	0.960	rs61967677	chr13:112174044	A/G	cg10483660	chr13:112241077	NA	0.34	6.77	0.3	3.87e-11	Menarche (age at onset);
LGG	cis	rs6909430	0.803	rs1451342	chr6:98657850	C/T	cg12860156	chr6:98744658	NA	-0.43	-7.29	-0.32	1.38e-12	Quantitative traits;
LGG	cis	rs61931739	0.782	rs3903201	chr12:34248275	G/A	cg06521331	chr12:34319734	NA	-0.41	-7.14	-0.32	3.59e-12	Morning vs. evening chronotype;
LGG	trans	rs8002861	0.810	rs9533664	chr13:44440527	T/C	cg17145862	chr1:211918768	LPGAT1	0.98	25.29	0.76	2.75e-89	Leprosy;
LGG	cis	rs8177253	1.000	rs8177271	chr3:133482230	G/A	cg12373951	chr3:133503437	NA	0.4	7.1	0.31	4.81e-12	Iron status biomarkers;
LGG	cis	rs1799949	1.000	rs12952790	chr17:41299607	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.38e-12	Menopause (age at onset);
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg15971980	chr6:150254442	NA	0.45	8.74	0.38	4.35e-17	Testicular germ cell tumor;
LGG	cis	rs2985684	0.948	rs2883437	chr14:50031666	A/G	cg02151108	chr14:50098012	C14orf104	-0.42	-8.85	-0.38	1.86e-17	Carotid intima media thickness;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	cis	rs17102423	0.755	rs7143495	chr14:65546361	C/T	cg11161011	chr14:65562177	MAX	0.73	14.62	0.56	4.57e-40	Obesity-related traits;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg08200770	chr17:80723486	TBCD	-0.5	-9.4	-0.4	2.61e-19	Glycated hemoglobin levels;
LGG	cis	rs1801251	0.752	rs2675966	chr2:233735543	T/C	cg08000102	chr2:233561755	GIGYF2	-0.42	-6.97	-0.31	1.07e-11	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs10001115	chr4:119781867	A/C	cg14228332	chr4:119757509	SEC24D	0.99	10.14	0.43	6.09e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg12070911	chr6:150209640	RAET1E	0.29	6.98	0.31	9.97e-12	Lung cancer;
LGG	cis	rs2204008	0.745	rs8189516	chr12:38239084	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.01	0.7	2.63e-69	Bladder cancer;
LGG	cis	rs6582630	0.537	rs11611326	chr12:38547958	C/A	cg26384229	chr12:38710491	ALG10B	0.98	23.25	0.73	8.47e-80	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2727020	0.658	rs4980442	chr11:49445016	G/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.44	-0.71	2.47e-71	Coronary artery disease;
LGG	cis	rs787274	0.718	rs4979178	chr9:115644335	G/C	cg13803584	chr9:115635662	SNX30	-0.64	-9.18	-0.39	1.44e-18	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs4731207	0.596	rs6945951	chr7:124667200	T/C	cg05630886	chr7:124431682	NA	-0.31	-7.09	-0.31	5.01e-12	Cutaneous malignant melanoma;
LGG	cis	rs7086627	0.515	rs2125040	chr10:82208422	G/C	cg00277334	chr10:82204260	NA	-0.53	-12.83	-0.51	1.8e-32	Post bronchodilator FEV1;
LGG	cis	rs6665290	0.901	rs3795453	chr1:227205331	A/G	cg05696931	chr1:227175867	NA	-0.38	-7.44	-0.33	5.08e-13	Myeloid white cell count;
LGG	cis	rs4731207	0.596	rs1531715	chr7:124638207	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs7647973	0.593	rs4855885	chr3:49690199	G/A	cg13072238	chr3:49761600	GMPPB	-0.55	-7.22	-0.32	2.12e-12	Menarche (age at onset);
LGG	cis	rs2404602	0.692	rs8037005	chr15:76951109	C/T	cg05677249	chr15:77158041	SCAPER	-0.32	-6.96	-0.31	1.17e-11	Blood metabolite levels;
LGG	cis	rs8114671	0.967	rs2065978	chr20:33767291	C/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.14	0.31	3.65e-12	Height;
LGG	cis	rs8072100	0.807	rs2175290	chr17:45479917	C/A	cg25173405	chr17:45401733	C17orf57	-0.49	-8.49	-0.37	2.74e-16	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9894429	1.000	rs4074916	chr17:79579248	G/A	cg18240062	chr17:79603768	NPLOC4	-0.75	-13.85	-0.54	9.66e-37	Eye color traits;
LGG	cis	rs7017914	0.934	rs13274062	chr8:71737087	G/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.8	-0.3	3.18e-11	Bone mineral density;
LGG	cis	rs8032158	1.000	rs60482539	chr15:56180297	A/C	cg05129572	chr15:56138634	NEDD4	-0.41	-6.67	-0.3	7.51e-11	Keloid;
LGG	cis	rs2018055	0.957	rs13216575	chr6:117811905	G/A	cg14611402	chr6:117803162	DCBLD1	0.29	8.12	0.35	4.12e-15	Diastolic blood pressure;
LGG	cis	rs11098499	0.780	rs7680914	chr4:120563053	A/G	cg24375607	chr4:120327624	NA	0.65	10.76	0.45	2.9e-24	Corneal astigmatism;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.0	-0.6	3.35e-46	Longevity;
LGG	cis	rs11603023	0.874	rs613243	chr11:118514022	C/G	cg19182353	chr11:118479428	PHLDB1	0.56	11.98	0.49	5.55e-29	Cholesterol, total;
LGG	cis	rs868036	0.609	rs28742003	chr15:68127769	C/T	cg05925327	chr15:68127851	NA	-0.44	-9.06	-0.39	3.67e-18	Restless legs syndrome;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg02835499	chr17:46178918	CBX1	0.59	6.66	0.3	7.77e-11	Intelligence (multi-trait analysis);
LGG	cis	rs7777484	0.534	rs2533890	chr7:2828743	C/T	cg27476859	chr7:2772710	GNA12	0.65	13.17	0.52	7.32e-34	Height;
LGG	cis	rs74781061	0.929	rs16969247	chr15:74778882	A/G	cg02384859	chr15:74862662	ARID3B	-0.33	-6.86	-0.3	2.18e-11	Endometriosis;
LGG	cis	rs7811142	1.000	rs68116612	chr7:100006493	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.8	0.38	2.74e-17	Platelet count;
LGG	cis	rs950776	0.714	rs472054	chr15:78887994	A/G	cg22563815	chr15:78856949	CHRNA5	-0.28	-6.79	-0.3	3.5e-11	Sudden cardiac arrest;
LGG	trans	rs9354352	0.784	rs2062327	chr6:66689923	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.67	-12.27	-0.5	3.69e-30	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg05665937	chr4:1216051	CTBP1	0.45	7.69	0.34	8.89e-14	Obesity-related traits;
LGG	cis	rs9326248	1.000	rs664922	chr11:117070895	C/A	cg11861562	chr11:117069780	TAGLN	0.27	7.16	0.32	3.1e-12	Blood protein levels;
LGG	cis	rs769267	0.930	rs1865034	chr19:19605763	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.09e-13	Tonsillectomy;
LGG	cis	rs6460942	0.915	rs7809263	chr7:12450589	C/G	cg06484146	chr7:12443880	VWDE	-0.41	-7.18	-0.32	2.83e-12	Coronary artery disease;
LGG	cis	rs858239	0.600	rs9691762	chr7:23125922	G/C	cg23682824	chr7:23144976	KLHL7	0.45	7.86	0.34	2.76e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs5758659	0.716	rs2143138	chr22:42618340	T/C	cg15128208	chr22:42549153	NA	-0.5	-9.95	-0.42	2.95e-21	Cognitive function;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg07005078	chr4:17578674	LAP3	0.36	6.73	0.3	4.9e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.579	rs2474580	chr10:38398713	G/A	cg25427524	chr10:38739819	LOC399744	-0.62	-11.54	-0.47	3.03e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs875971	0.964	rs2161065	chr7:65932905	A/G	cg18876405	chr7:65276391	NA	0.54	9.69	0.41	2.43e-20	Aortic root size;
LGG	cis	rs537930	0.560	rs40976	chr5:134350017	T/G	cg24576358	chr5:134350122	NA	0.45	10.06	0.42	1.12e-21	Height;
LGG	cis	rs1881797	0.932	rs41305741	chr1:247689543	A/G	cg11166453	chr1:247681781	NA	0.64	10.31	0.43	1.38e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs68170813	0.559	rs7803290	chr7:106907353	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.52	-0.44	2.38e-23	Coronary artery disease;
LGG	cis	rs1109114	0.816	rs2963491	chr5:148595046	T/C	cg06539116	chr5:148597365	ABLIM3	-0.62	-16.53	-0.61	1.44e-48	Body mass index;
LGG	cis	rs6032067	0.852	rs2868240	chr20:43874039	A/G	cg10761708	chr20:43804764	PI3	-0.77	-12.08	-0.49	2.13e-29	Blood protein levels;
LGG	cis	rs11764590	0.694	rs60626033	chr7:2099719	A/G	cg07027305	chr7:2059796	MAD1L1	-0.34	-8.33	-0.36	8.99e-16	Neuroticism;
LGG	cis	rs11074306	0.503	rs7169607	chr15:28062978	C/T	cg26402630	chr15:28053930	OCA2	0.36	7.21	0.32	2.3e-12	Uveal melanoma;
LGG	cis	rs7618915	0.547	rs11714419	chr3:52628816	A/G	cg10802521	chr3:52805072	NEK4	-0.41	-6.85	-0.3	2.32e-11	Bipolar disorder;
LGG	trans	rs656319	0.625	rs4526366	chr8:9890179	C/G	cg12395012	chr8:11607386	GATA4	0.42	7.33	0.32	1.04e-12	Myopia (pathological);
LGG	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	cis	rs4702718	0.616	rs267984	chr5:10714364	T/A	cg14521931	chr5:10832172	NA	-0.44	-8.29	-0.36	1.26e-15	Obesity-related traits;
LGG	cis	rs7084402	0.967	rs1658460	chr10:60299151	T/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.4	-0.33	6.47e-13	Refractive error;
LGG	cis	rs10504229	0.636	rs10958525	chr8:58051528	C/A	cg14926445	chr8:58193284	C8orf71	-0.73	-9.33	-0.4	4.49e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.642	rs1372977	chr4:152452398	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	6.85	0.3	2.32e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2735413	0.514	rs7192129	chr16:78136414	A/G	cg04733911	chr16:78082701	NA	0.58	12.41	0.5	9.93e-31	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs7819412	0.558	rs4841483	chr8:10908354	G/A	cg06636001	chr8:8085503	FLJ10661	0.51	8.84	0.38	2.01e-17	Triglycerides;
LGG	cis	rs2288073	0.965	rs10199334	chr2:24392618	T/C	cg06627628	chr2:24431161	ITSN2	-0.67	-10.62	-0.44	1.02e-23	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs7193541	0.929	rs12933037	chr16:74660174	G/A	cg01733217	chr16:74700730	RFWD3	0.9	20.82	0.7	1.97e-68	Multiple myeloma;
LGG	cis	rs1978968	0.912	rs13057016	chr22:18466779	G/A	cg00227156	chr22:18463646	MICAL3;MIR648	-0.7	-14.15	-0.55	4.95e-38	Presence of antiphospholipid antibodies;
LGG	cis	rs727505	1.000	rs66665074	chr7:124550526	C/T	cg23710748	chr7:124431027	NA	-0.52	-9.77	-0.41	1.22e-20	Lewy body disease;
LGG	cis	rs6489882	0.867	rs1154970	chr12:113370427	A/C	cg25319449	chr12:113376135	OAS3	-0.39	-7.32	-0.32	1.14e-12	Chronic lymphocytic leukemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18556179	chr13:29293454	SLC46A3	0.48	6.91	0.31	1.61e-11	Gut microbiome composition (summer);
LGG	cis	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25427524	chr10:38739819	LOC399744	-0.69	-13.14	-0.52	9.53e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs12310956	0.532	rs1589903	chr12:33943019	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.96	0.6	5.27e-46	Morning vs. evening chronotype;
LGG	trans	rs2548003	0.966	rs2161537	chr5:28725359	T/C	cg12623145	chr2:97778927	ANKRD36	0.48	7.15	0.32	3.48e-12	Hip geometry;
LGG	cis	rs7829975	0.742	rs12547493	chr8:8661534	C/T	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.36	-0.36	7.37e-16	Mood instability;
LGG	cis	rs4481887	0.597	rs4504921	chr1:248582011	T/C	cg00666640	chr1:248458726	OR2T12	0.5	7.04	0.31	6.98e-12	Common traits (Other);
LGG	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg00784671	chr22:46762841	CELSR1	-0.64	-7.41	-0.33	6.14e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2243480	0.803	rs35268390	chr7:65416536	C/G	cg13147721	chr7:65941812	NA	-0.72	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	cis	rs57221529	0.654	rs11740553	chr5:672593	C/T	cg14541582	chr5:601475	NA	-0.7	-10.4	-0.44	6.84e-23	Lung disease severity in cystic fibrosis;
LGG	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg12773197	chr13:112238673	NA	-0.37	-7.5	-0.33	3.24e-13	Hepatitis;
LGG	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg24803719	chr17:45855879	NA	-0.3	-8.59	-0.37	1.34e-16	IgG glycosylation;
LGG	cis	rs11874712	1.000	rs1800637	chr18:43670190	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	trans	rs10506458	1.000	rs12425932	chr12:63410497	C/A	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.36	-21.74	-0.71	9.88e-73	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7149242	1.000	rs11620937	chr14:101151012	C/G	cg18089426	chr14:101175970	NA	0.32	6.77	0.3	3.98e-11	Platelet count;
LGG	cis	rs990171	1.000	rs12712145	chr2:103008710	T/C	cg05295703	chr2:102895712	NA	-0.56	-9.98	-0.42	2.19e-21	Lymphocyte counts;
LGG	cis	rs11122272	0.735	rs2749714	chr1:231538634	G/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.47e-12	Hemoglobin concentration;
LGG	cis	rs453301	0.686	rs7017868	chr8:8873293	G/A	cg06636001	chr8:8085503	FLJ10661	-0.44	-8.05	-0.35	7.28e-15	Joint mobility (Beighton score);
LGG	trans	rs1814175	0.645	rs7103554	chr11:50027612	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.09	-0.6	1.37e-46	Height;
LGG	cis	rs67133203	0.634	rs7977104	chr12:51559511	A/G	cg14688905	chr12:51403056	SLC11A2	0.64	9.65	0.41	3.34e-20	Urinary tract infection frequency;
LGG	cis	rs66573146	0.831	rs68111914	chr4:6986677	C/T	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs28595532	0.920	rs17325129	chr4:119778284	T/C	cg11846333	chr4:119757529	SEC24D	0.84	7.82	0.34	3.64e-14	Cannabis dependence symptom count;
LGG	cis	rs1912483	0.545	rs35161461	chr17:45401757	A/G	cg08085267	chr17:45401833	C17orf57	-0.74	-13.84	-0.54	1.1e-36	Coronary artery disease;
LGG	trans	rs9329221	0.967	rs7005363	chr8:10283748	C/T	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.48	-0.33	3.78e-13	Neuroticism;
LGG	cis	rs10504229	1.000	rs115548028	chr8:58170672	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.27	-0.53	2.65e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.932	rs56306759	chr21:40608106	G/A	cg17971929	chr21:40555470	PSMG1	0.86	16.61	0.61	5.91e-49	Cognitive function;
LGG	cis	rs2066819	1.000	rs11575229	chr12:56750737	C/T	cg26714650	chr12:56694279	CS	-1.58	-15.14	-0.58	2.42e-42	Psoriasis vulgaris;
LGG	cis	rs9393692	0.676	rs806977	chr6:26189615	A/G	cg00631329	chr6:26305371	NA	-0.45	-8.09	-0.35	5.19e-15	Educational attainment;
LGG	cis	rs9291683	0.551	rs2276961	chr4:10022981	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.94	0.31	1.29e-11	Bone mineral density;
LGG	cis	rs17221829	0.965	rs4553368	chr11:89459742	T/C	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.66	-0.34	1.1e-13	Anxiety in major depressive disorder;
LGG	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg25039879	chr17:56429692	SUPT4H1	0.65	9.15	0.39	1.79e-18	Cognitive test performance;
LGG	cis	rs1003719	0.715	rs2835649	chr21:38552230	C/T	cg10648535	chr21:38446584	PIGP;TTC3	0.77	14.87	0.57	3.78e-41	Eye color traits;
LGG	cis	rs7811142	1.000	rs4989959	chr7:100032288	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.93	-0.6	7.12e-46	Platelet count;
LGG	cis	rs4740619	1.000	rs2175082	chr9:15641279	A/G	cg14451791	chr9:16040625	NA	0.36	8.81	0.38	2.54e-17	Body mass index;
LGG	trans	rs2727020	0.521	rs7126835	chr11:49594658	T/C	cg15704280	chr7:45808275	SEPT13	-0.89	-13.94	-0.54	4.1e-37	Coronary artery disease;
LGG	cis	rs1018836	0.923	rs10956749	chr8:91621573	G/A	cg16814680	chr8:91681699	NA	-0.85	-16.06	-0.6	1.94e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs1005277	0.579	rs1614236	chr10:38502996	C/T	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.03	-0.31	7.57e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2228479	0.850	rs17233455	chr16:89816407	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg06606381	chr12:133084897	FBRSL1	-0.86	-9.24	-0.39	9.32e-19	Breast cancer;
LGG	cis	rs3087591	0.683	rs2525567	chr17:29675673	C/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.59	0.51	1.82e-31	Hip circumference;
LGG	cis	rs597539	0.652	rs602364	chr11:68662167	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	15.81	0.59	2.43e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4481887	1.000	rs6697735	chr1:248465315	G/C	cg13385794	chr1:248469461	NA	0.49	8.36	0.36	7.33e-16	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09764697	chr1:109940754	SORT1	0.48	7.23	0.32	1.95e-12	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.916	rs12198730	chr6:86555138	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.33	-0.43	1.22e-22	Response to antipsychotic treatment;
LGG	trans	rs8073060	0.504	rs225271	chr17:33969836	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.9	-0.64	7.78e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6461049	0.638	rs1859993	chr7:2183702	A/G	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.75	-0.34	5.82e-14	Schizophrenia;
LGG	cis	rs7172689	0.908	rs66935966	chr15:81562827	C/T	cg11808699	chr15:81528661	IL16	-0.46	-9.4	-0.4	2.5e-19	Inattentive symptoms;
LGG	cis	rs7937682	0.883	rs12366001	chr11:111433916	A/G	cg19812747	chr11:111475976	SIK2	0.5	10.52	0.44	2.44e-23	Primary sclerosing cholangitis;
LGG	cis	rs472402	0.580	rs6884552	chr5:6661966	C/T	cg08700190	chr5:6636046	SRD5A1	-0.32	-6.71	-0.3	5.59e-11	Response to amphetamines;
LGG	cis	rs7493	1.000	rs12026	chr7:95041016	G/C	cg08461772	chr7:95026248	PON3	0.39	8.41	0.36	5.3e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs875971	0.964	rs778723	chr7:65829497	T/C	cg18876405	chr7:65276391	NA	0.55	9.87	0.42	5.39e-21	Aortic root size;
LGG	cis	rs2916247	1.000	rs36005889	chr8:93058638	A/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.41	-0.36	5e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4930103	0.935	rs2075744	chr11:2018449	A/G	cg23202291	chr11:1979235	NA	0.37	7.16	0.32	3.27e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs561341	0.609	rs9906443	chr17:30185565	C/T	cg13647721	chr17:30228624	UTP6	-0.72	-9.07	-0.39	3.43e-18	Hip circumference adjusted for BMI;
LGG	cis	rs4743820	0.651	rs73494920	chr9:93923153	G/C	cg14446406	chr9:93919335	NA	-0.9	-15.43	-0.58	1.18e-43	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6723226	0.721	rs10172510	chr2:32620888	A/G	cg02381751	chr2:32503542	YIPF4	0.6	10.38	0.43	7.54e-23	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs6534139	chr4:120449456	A/G	cg09307838	chr4:120376055	NA	-0.79	-13.01	-0.52	3.41e-33	Corneal astigmatism;
LGG	cis	rs559928	0.606	rs76653616	chr11:63936139	T/G	cg19465662	chr11:63993652	NUDT22;TRPT1	0.77	9.16	0.39	1.63e-18	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs17453880	0.708	rs7711928	chr5:151928442	G/A	cg12297329	chr5:152029980	NA	-0.64	-13.48	-0.53	3.76e-35	Subjective well-being;
LGG	cis	rs3771570	1.000	rs62193197	chr2:242294301	G/A	cg21155796	chr2:242212141	HDLBP	0.72	9.26	0.4	7.95e-19	Prostate cancer;
LGG	cis	rs1018697	1.000	rs4919678	chr10:104554363	C/G	cg04362960	chr10:104952993	NT5C2	0.49	9.08	0.39	3.11e-18	Colorectal adenoma (advanced);
LGG	trans	rs9393777	0.920	rs35768595	chr6:27141904	C/T	cg01620082	chr3:125678407	NA	-1.02	-9.24	-0.39	8.88e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7918232	0.943	rs4747584	chr10:27373333	G/A	cg14240646	chr10:27532245	ACBD5	-0.76	-11.09	-0.46	1.65e-25	Breast cancer;
LGG	cis	rs12291225	0.877	rs2303974	chr11:14264979	G/T	cg19336497	chr11:14380999	RRAS2	-0.49	-8.84	-0.38	2.02e-17	Sense of smell;
LGG	cis	rs17376456	0.825	rs10053405	chr5:93275403	A/G	cg25358565	chr5:93447407	FAM172A	-1.15	-12.43	-0.5	8.51e-31	Diabetic retinopathy;
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg11141652	chr22:24348549	GSTTP1	0.38	6.66	0.3	7.56e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg16507663	chr6:150244633	RAET1G	0.51	10.53	0.44	2.11e-23	Testicular germ cell tumor;
LGG	cis	rs6815814	0.851	rs10023850	chr4:38763693	G/A	cg06935464	chr4:38784597	TLR10	0.53	7.15	0.32	3.44e-12	Breast cancer;
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.35	-0.32	8.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs8049040	0.967	rs8044168	chr16:71506983	C/T	cg08717414	chr16:71523259	ZNF19	-0.4	-6.66	-0.3	7.7e-11	Blood protein levels;
LGG	cis	rs3785574	0.962	rs7219920	chr17:61811642	C/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.93	0.42	3.46e-21	Height;
LGG	cis	rs17208368	0.723	rs4784469	chr16:55090609	T/A	cg09947736	chr16:55091198	NA	0.78	13.64	0.54	7.53e-36	Hypospadias;
LGG	cis	rs10911232	0.507	rs4266836	chr1:183029070	T/G	cg15522984	chr1:182991683	LAMC1	0.48	9.76	0.41	1.32e-20	Hypertriglyceridemia;
LGG	cis	rs10824796	0.951	rs3925313	chr10:54533873	A/G	cg27418851	chr10:54531653	MBL2	0.43	8.63	0.37	9.71e-17	Blood protein levels;
LGG	cis	rs11098499	0.954	rs34858317	chr4:120387110	A/C	cg09307838	chr4:120376055	NA	0.81	13.55	0.53	1.76e-35	Corneal astigmatism;
LGG	cis	rs8180040	0.966	rs11130137	chr3:47578838	C/T	cg27129171	chr3:47204927	SETD2	0.76	14.3	0.55	1.17e-38	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg00424166	chr6:150045504	NUP43	-0.33	-6.71	-0.3	5.54e-11	Lung cancer;
LGG	cis	rs9503598	0.662	rs2326232	chr6:3451953	A/G	cg00476032	chr6:3446245	SLC22A23	0.55	11.36	0.47	1.55e-26	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	cis	rs6761276	0.505	rs13019891	chr2:113829869	G/T	cg02302587	chr2:113829866	IL1F10	0.41	9.18	0.39	1.45e-18	Protein quantitative trait loci;
LGG	cis	rs72827839	0.846	rs72823599	chr17:46132424	C/G	cg02219949	chr17:45927392	SP6	0.54	8.07	0.35	5.93e-15	Ease of getting up in the morning;
LGG	cis	rs7551222	0.752	rs4252694	chr1:204499056	A/G	cg20240347	chr1:204465584	NA	-0.56	-11.27	-0.46	3.43e-26	Schizophrenia;
LGG	cis	rs2075671	0.903	rs11983334	chr7:100302434	C/T	cg00334542	chr7:100209784	MOSPD3	-0.53	-7.4	-0.33	6.38e-13	Other erythrocyte phenotypes;
LGG	cis	rs141670911	1	rs141670911	chr6:26581258	A/T	cg23155468	chr6:27110703	HIST1H2BK	-0.64	-8.14	-0.35	3.81e-15	Small cell lung carcinoma;
LGG	cis	rs9462027	0.628	rs2296360	chr6:34803558	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs10904887	1.000	rs7900163	chr10:17188637	C/T	cg01003015	chr10:17271136	VIM	-0.44	-7.46	-0.33	4.37e-13	Telomere length;
LGG	trans	rs7618501	1.000	rs9872864	chr3:49792023	A/G	cg21659725	chr3:3221576	CRBN	-0.93	-20.74	-0.69	4.45e-68	Intelligence (multi-trait analysis);
LGG	cis	rs7296418	0.630	rs11057238	chr12:123767971	C/A	cg00376283	chr12:123451042	ABCB9	0.62	11.5	0.47	4.25e-27	Platelet count;
LGG	cis	rs7937682	0.889	rs487985	chr11:111517908	G/A	cg22437258	chr11:111473054	SIK2	0.57	9.92	0.42	3.73e-21	Primary sclerosing cholangitis;
LGG	cis	rs2735413	0.564	rs7201557	chr16:78110059	C/A	cg04733911	chr16:78082701	NA	0.57	7.99	0.35	1.09e-14	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs701145	0.537	rs2695845	chr3:153881836	G/A	cg17054900	chr3:154042577	DHX36	0.82	9.77	0.41	1.28e-20	Coronary artery disease;
LGG	cis	rs597539	0.652	rs569777	chr11:68706848	G/A	cg21963583	chr11:68658836	MRPL21	0.59	10.33	0.43	1.19e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08761248	chr12:56615735	RNF41	-0.37	-7.24	-0.32	1.87e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.962	rs9478848	chr6:150146216	G/T	cg16507663	chr6:150244633	RAET1G	0.42	7.9	0.34	2.04e-14	Lung cancer;
LGG	cis	rs514406	0.548	rs6670871	chr1:53212082	A/C	cg24675658	chr1:53192096	ZYG11B	0.61	12.59	0.51	1.79e-31	Monocyte count;
LGG	cis	rs7085104	0.632	rs7097872	chr10:104606636	C/T	cg04362960	chr10:104952993	NT5C2	0.49	9.2	0.39	1.22e-18	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs9300255	0.679	rs12817892	chr12:123728702	G/A	cg00376283	chr12:123451042	ABCB9	-0.63	-9.48	-0.4	1.29e-19	Neutrophil percentage of white cells;
LGG	cis	rs8112449	1.000	rs12978984	chr19:10520891	A/T	cg21868191	chr19:10515988	NA	-0.48	-8.28	-0.36	1.3e-15	Multiple sclerosis;Gastritis;
LGG	cis	rs4595586	0.545	rs11610886	chr12:39390613	C/G	cg26384229	chr12:38710491	ALG10B	0.6	10.79	0.45	2.34e-24	Morning vs. evening chronotype;
LGG	cis	rs72827839	0.644	rs72833479	chr17:45960449	G/A	cg23391107	chr17:45924227	SP6	0.53	7.98	0.35	1.19e-14	Ease of getting up in the morning;
LGG	cis	rs5769765	0.862	rs7410537	chr22:50317330	G/A	cg02269571	chr22:50332266	NA	-0.66	-9.89	-0.42	4.76e-21	Schizophrenia;
LGG	cis	rs7902587	0.850	rs1265165	chr10:105671527	T/C	cg11005552	chr10:105648138	OBFC1	0.66	7.09	0.31	4.97e-12	Lung cancer;Serous borderline ovarian cancer;Thyroid cancer;Low-grade serous and serous borderline ovarian cancer;
LGG	cis	rs490234	0.783	rs13283793	chr9:128441641	C/T	cg14078157	chr9:128172775	NA	-0.41	-7.49	-0.33	3.45e-13	Mean arterial pressure;
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg23034840	chr1:205782522	SLC41A1	0.49	7.83	0.34	3.28e-14	Menarche (age at onset);
LGG	trans	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12421382	0.593	rs2118973	chr11:109389231	G/A	cg00830817	chr11:109293614	C11orf87	0.41	7.0	0.31	9.08e-12	Schizophrenia;
LGG	cis	rs7587476	1.000	rs2121285	chr2:215656168	C/G	cg04530015	chr2:215796436	ABCA12	0.43	7.1	0.31	4.62e-12	Neuroblastoma;
LGG	cis	rs7493	1.000	rs2068604	chr7:95041542	G/T	cg08461772	chr7:95026248	PON3	0.38	8.33	0.36	9.55e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-9.66	-0.41	3.12e-20	Lung cancer;
LGG	cis	rs607541	1.000	rs675876	chr15:45936856	G/A	cg26924012	chr15:45694286	SPATA5L1	0.51	7.12	0.31	4.11e-12	Obesity-related traits;
LGG	cis	rs1003719	0.708	rs3787788	chr21:38502804	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.14	-0.58	2.33e-42	Eye color traits;
LGG	cis	rs2011503	1.000	rs4808951	chr19:19550306	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.72	0.3	5.34e-11	Bipolar disorder;
LGG	cis	rs7208859	0.673	rs61348930	chr17:29221763	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg08888203	chr3:10149979	C3orf24	0.56	7.98	0.35	1.16e-14	Alzheimer's disease;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg27400746	chr16:89904261	SPIRE2	-0.87	-14.92	-0.57	2.09e-41	Skin colour saturation;
LGG	cis	rs1816854	1.000	rs10880570	chr12:44202465	A/T	cg20956634	chr12:44200518	TWF1	-0.52	-7.54	-0.33	2.48e-13	Inflammatory bowel disease;
LGG	cis	rs4953318	0.694	rs3768747	chr2:46352058	G/T	cg12428440	chr2:46370979	PRKCE	-0.41	-7.96	-0.35	1.35e-14	Red blood cell count;Hematocrit;Red blood cell traits;
LGG	cis	rs1552244	0.554	rs6800204	chr3:9995404	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.73	12.99	0.52	3.94e-33	Alzheimer's disease;
LGG	cis	rs9611565	0.592	rs5751101	chr22:41828111	C/T	cg06850241	chr22:41845214	NA	0.45	7.14	0.32	3.54e-12	Vitiligo;
LGG	cis	rs7937682	0.961	rs1784784	chr11:111483185	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.08	-23.53	-0.74	4.24e-81	Primary sclerosing cholangitis;
LGG	cis	rs17221829	0.645	rs4753227	chr11:89369102	C/T	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.19	-0.39	1.3e-18	Anxiety in major depressive disorder;
LGG	cis	rs5758511	0.514	rs5751222	chr22:42517922	T/A	cg15128208	chr22:42549153	NA	0.79	12.63	0.51	1.2e-31	Birth weight;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.39	7.56	0.33	2.17e-13	Schizophrenia;
LGG	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg15557168	chr22:42548783	NA	0.45	9.86	0.42	5.82e-21	Schizophrenia;
LGG	cis	rs12496230	0.953	rs4856960	chr3:66843301	T/C	cg04995300	chr3:66848608	NA	0.56	8.26	0.36	1.58e-15	Type 2 diabetes;
LGG	cis	rs3816183	0.558	rs7607881	chr2:42784539	C/T	cg14631114	chr2:43023945	NA	0.35	6.68	0.3	6.86e-11	Hypospadias;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg22963979	chr7:1858916	MAD1L1	-0.52	-10.27	-0.43	1.98e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs9398803	0.865	rs9401882	chr6:126755055	A/G	cg19875578	chr6:126661172	C6orf173	0.57	10.48	0.44	3.43e-23	Male-pattern baldness;
LGG	cis	rs67133203	0.904	rs67025973	chr12:51336444	G/A	cg14688905	chr12:51403056	SLC11A2	0.73	10.8	0.45	2.06e-24	Urinary tract infection frequency;
LGG	cis	rs17376456	1.000	rs13163610	chr5:93548877	A/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.06	0.42	1.14e-21	Diabetic retinopathy;
LGG	cis	rs75920871	0.688	rs61905678	chr11:116834785	C/T	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.04e-12	Subjective well-being;
LGG	cis	rs1008375	0.966	rs6833808	chr4:17652526	T/A	cg15017067	chr4:17643749	FAM184B	0.31	7.17	0.32	3.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs28386778	0.897	rs2584624	chr17:61904546	A/G	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs10504229	1.000	rs949848	chr8:58169125	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6733011	0.508	rs6542843	chr2:99533729	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-7.1	-0.31	4.65e-12	Bipolar disorder;
LGG	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg10224037	chr5:178157518	ZNF354A	0.73	11.37	0.47	1.4e-26	Neutrophil percentage of white cells;
LGG	cis	rs3747547	0.892	rs72726021	chr9:38010435	A/G	cg13774184	chr9:37916125	SHB	-0.71	-7.27	-0.32	1.59e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg20744362	chr22:50050164	C22orf34	0.39	6.88	0.3	1.97e-11	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg00684032	chr4:1343700	KIAA1530	0.47	9.03	0.39	4.49e-18	Obesity-related traits;
LGG	cis	rs7267979	0.586	rs1473695	chr20:25186965	A/G	cg06421707	chr20:25228305	PYGB	0.39	7.98	0.35	1.14e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4704187	0.687	rs7709707	chr5:74363575	T/G	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	trans	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg17830980	chr10:43048298	ZNF37B	0.45	9.88	0.42	5.09e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs11250098	0.541	rs6997997	chr8:10766082	T/C	cg21775007	chr8:11205619	TDH	-0.46	-7.31	-0.32	1.21e-12	Morning vs. evening chronotype;
LGG	cis	rs8177253	1.000	rs8177262	chr3:133480652	A/G	cg12373951	chr3:133503437	NA	-0.39	-6.94	-0.31	1.3e-11	Iron status biomarkers;
LGG	cis	rs3806843	1.000	rs10038174	chr5:140210616	G/A	cg19875535	chr5:140030758	IK	0.51	10.44	0.44	4.53e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs55665837	0.961	rs11023226	chr11:14458817	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.68	-0.37	6.59e-17	Vitamin D levels;
LGG	cis	rs600550	0.588	rs7103808	chr11:60078176	A/G	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.92	-0.35	1.78e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs459571	0.876	rs2520095	chr9:136919568	A/G	cg13789015	chr9:136890014	NCRNA00094	0.58	10.98	0.45	4.23e-25	Platelet distribution width;
LGG	cis	rs1927790	0.727	rs1925115	chr13:96958817	G/A	cg02571835	chr13:96230311	CLDN10	-0.34	-6.86	-0.3	2.26e-11	Body mass index;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg12894336	chr3:47823524	SMARCC1	-0.39	-6.65	-0.3	8.05e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs17826219	0.706	rs28469200	chr17:29133572	T/A	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.53	-0.44	2.22e-23	Body mass index;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.42	-0.33	5.8e-13	Menopause (age at onset);
LGG	cis	rs523522	0.923	rs3916065	chr12:120934624	A/C	cg12219531	chr12:120966889	COQ5	0.66	10.95	0.45	5.84e-25	High light scatter reticulocyte count;
LGG	cis	rs2732480	0.500	rs2932093	chr12:48648271	G/T	cg21466736	chr12:48725269	NA	-0.37	-7.45	-0.33	4.55e-13	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs11122272	0.668	rs2790874	chr1:231537988	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.13	-0.46	1.19e-25	Hemoglobin concentration;
LGG	cis	rs61884328	0.713	rs76716952	chr11:46990462	A/T	cg03339077	chr11:47165057	C11orf49	0.62	6.66	0.3	7.83e-11	Total body bone mineral density (age over 60);
LGG	cis	rs11249608	0.548	rs62393074	chr5:178450476	G/C	cg21905437	chr5:178450457	ZNF879	0.47	6.67	0.3	7.52e-11	Pubertal anthropometrics;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg08872617	chr16:4783947	ANKS3;C16orf71	-0.4	-6.77	-0.3	4.02e-11	Brain structure;
LGG	cis	rs929354	0.742	rs62491945	chr7:156955580	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs7129220	0.588	rs7950718	chr11:10086624	C/A	cg01453529	chr11:10209919	SBF2	-0.42	-6.79	-0.3	3.5e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs9467773	0.935	rs9461270	chr6:26544110	A/G	cg09904177	chr6:26538194	HMGN4	0.78	17.77	0.64	3.04e-54	Intelligence (multi-trait analysis);
LGG	trans	rs7824557	0.527	rs2572448	chr8:11239352	G/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.44	-0.37	4.17e-16	Retinal vascular caliber;
LGG	cis	rs151234	0.741	rs151229	chr16:28584937	G/A	cg01378222	chr16:28622494	SULT1A1	-0.72	-9.97	-0.42	2.53e-21	Platelet distribution width;
LGG	cis	rs62025270	0.576	rs62022925	chr15:86236066	A/G	cg25843651	chr15:86329602	KLHL25	0.59	8.87	0.38	1.57e-17	Idiopathic pulmonary fibrosis;
LGG	cis	rs875971	0.862	rs2901152	chr7:65765004	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.64	-0.41	3.67e-20	Aortic root size;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg11865578	chr3:47043996	NBEAL2	0.39	7.2	0.32	2.43e-12	Electrocardiographic conduction measures;
LGG	cis	rs921968	0.541	rs3755042	chr2:219317248	T/C	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2074585	0.560	rs1973537	chr15:91062901	T/C	cg22089800	chr15:90895588	ZNF774	-0.49	-8.0	-0.35	1e-14	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7954584	0.635	rs11043242	chr12:122356293	G/C	cg22618164	chr12:122356400	WDR66	0.4	12.44	0.5	7.28e-31	Mean corpuscular volume;
LGG	cis	rs10435719	0.867	rs35778860	chr8:11791338	C/T	cg12395012	chr8:11607386	GATA4	-0.42	-7.57	-0.33	2.08e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs35110281	0.720	rs162376	chr21:44926759	G/T	cg01579765	chr21:45077557	HSF2BP	0.39	8.69	0.37	6.13e-17	Mean corpuscular volume;
LGG	cis	rs2282300	0.739	rs1616223	chr11:30338783	A/C	cg25418670	chr11:30344373	C11orf46	-0.56	-7.85	-0.34	2.9e-14	Morning vs. evening chronotype;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg04267008	chr7:1944627	MAD1L1	-0.61	-10.36	-0.43	9.09e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs75059851	1.000	rs3802924	chr11:133827733	A/C	cg20042908	chr11:133852938	NA	-0.71	-12.37	-0.5	1.39e-30	Schizophrenia;
LGG	cis	rs4132509	0.793	rs74379351	chr1:243779604	T/C	cg21452805	chr1:244014465	NA	0.89	8.6	0.37	1.24e-16	RR interval (heart rate);
LGG	cis	rs113835537	0.597	rs11227527	chr11:66313026	A/G	cg24851651	chr11:66362959	CCS	0.46	7.9	0.34	2.04e-14	Airway imaging phenotypes;
LGG	cis	rs7959452	0.868	rs10784774	chr12:69737879	C/T	cg11871910	chr12:69753446	YEATS4	-0.74	-15.51	-0.58	5.58e-44	Blood protein levels;
LGG	cis	rs3857536	0.813	rs2188589	chr6:66939570	C/T	cg07460842	chr6:66804631	NA	-0.46	-7.88	-0.34	2.28e-14	Blood trace element (Cu levels);
LGG	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.7	-8.36	-0.36	7.51e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6540556	0.769	rs10157973	chr1:209924425	C/T	cg05527609	chr1:210001259	C1orf107	-0.48	-6.74	-0.3	4.86e-11	Red blood cell count;
LGG	cis	rs11997175	1.000	rs11997175	chr8:33770070	A/G	ch.8.33884649F	chr8:33765107	NA	-0.36	-6.68	-0.3	6.96e-11	Body mass index;
LGG	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg02398342	chr17:80708632	TBCD;FN3K	0.45	7.46	0.33	4.34e-13	Glycated hemoglobin levels;
LGG	cis	rs2549003	1.000	rs10068129	chr5:131821246	A/G	cg21138405	chr5:131827807	IRF1	-0.38	-10.07	-0.42	1.07e-21	Asthma (sex interaction);
LGG	cis	rs2250402	0.510	rs2291621	chr15:40324837	C/T	cg20255370	chr15:40268687	EIF2AK4	-0.8	-8.59	-0.37	1.32e-16	Corneal curvature;
LGG	cis	rs7811142	0.830	rs11765869	chr7:99964789	T/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.03	14.65	0.56	3.39e-40	Platelet count;
LGG	cis	rs4891159	0.790	rs59762437	chr18:74153146	G/A	cg24786174	chr18:74118243	ZNF516	-0.58	-13.48	-0.53	3.72e-35	Longevity;
LGG	cis	rs6502050	0.799	rs6502089	chr17:80169523	G/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.61	-0.41	4.67e-20	Life satisfaction;
LGG	trans	rs8002861	0.664	rs2184882	chr13:44450346	C/T	cg17145862	chr1:211918768	LPGAT1	0.79	16.86	0.62	4.53e-50	Leprosy;
LGG	trans	rs9467711	0.606	rs9393715	chr6:26375645	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.64	-0.37	9.53e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs36093844	0.706	rs76852274	chr11:85543760	T/G	cg16165120	chr11:85566439	CCDC83	-0.45	-7.07	-0.31	5.59e-12	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	trans	rs9329221	0.619	rs591346	chr8:9818065	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.32	-0.32	1.09e-12	Neuroticism;
LGG	cis	rs12153243	0.714	rs72806723	chr5:142930282	G/T	cg13907255	chr5:142895549	NA	-0.46	-8.14	-0.35	3.66e-15	Migraine;
LGG	cis	rs1790761	0.692	rs10896179	chr11:67316928	C/A	cg14500267	chr11:67383377	NA	0.44	8.32	0.36	9.62e-16	Mean corpuscular volume;
LGG	cis	rs933688	0.532	rs2973478	chr5:90553428	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.56	-7.39	-0.32	6.8e-13	Smoking behavior;
LGG	cis	rs344364	0.511	rs337286	chr16:1965719	C/T	cg14074117	chr16:1909714	C16orf73	-0.54	-7.88	-0.34	2.42e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs4948275	0.773	rs2606078	chr10:63289215	A/T	cg03237606	chr10:63212265	TMEM26	-0.39	-7.04	-0.31	6.83e-12	Night sleep phenotypes;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg10295955	chr4:187884368	NA	1.15	29.17	0.8	6.08e-107	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs798554	0.757	rs2533879	chr7:2859847	G/A	cg27476859	chr7:2772710	GNA12	0.39	6.74	0.3	4.71e-11	Height;
LGG	cis	rs796364	0.806	rs10931887	chr2:200968905	G/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.8	-9.43	-0.4	1.94e-19	Schizophrenia;
LGG	cis	rs9287719	0.967	rs4669599	chr2:10758029	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	trans	rs6940638	0.956	rs72838268	chr6:27021173	A/G	cg06606381	chr12:133084897	FBRSL1	-0.58	-7.36	-0.32	8.58e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4639966	0.756	rs61219050	chr11:118648624	C/A	cg20309703	chr11:118481025	PHLDB1	-0.49	-7.34	-0.32	9.81e-13	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.962	rs4869731	chr6:150131208	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.95	0.31	1.21e-11	Lung cancer;
LGG	cis	rs4363385	0.818	rs1750309	chr1:153013630	G/C	cg13444842	chr1:152974279	SPRR3	-0.42	-8.85	-0.38	1.9e-17	Inflammatory skin disease;
LGG	cis	rs7246760	0.867	rs2336090	chr19:9879584	A/G	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.51e-11	Pursuit maintenance gain;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.48	8.04	0.35	7.52e-15	Longevity;
LGG	cis	rs11148252	0.532	rs9536185	chr13:53179801	G/A	cg16301924	chr13:53314226	LECT1	-0.41	-7.74	-0.34	6.24e-14	Lewy body disease;
LGG	cis	rs798554	0.660	rs2527694	chr7:2858240	T/C	cg05793240	chr7:2802953	GNA12	0.32	7.86	0.34	2.65e-14	Height;
LGG	cis	rs6582630	0.577	rs12312748	chr12:38343326	T/C	cg26384229	chr12:38710491	ALG10B	-0.64	-11.97	-0.49	6.07e-29	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs6575793	0.532	rs12433699	chr14:101035546	C/G	cg09399377	chr6:136611038	BCLAF1	0.49	7.54	0.33	2.47e-13	Menarche (age at onset);
LGG	cis	rs9303401	0.659	rs62083410	chr17:56964386	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.98	0.57	1.14e-41	Cognitive test performance;
LGG	cis	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg24110177	chr3:50126178	RBM5	-0.4	-6.96	-0.31	1.2e-11	Intelligence (multi-trait analysis);
LGG	cis	rs546131	0.963	rs539044	chr11:34841542	G/T	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.31	0.32	1.17e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs11771526	0.901	rs34376799	chr7:32316932	T/C	cg27532318	chr7:32358331	NA	0.75	7.7	0.34	8.59e-14	Body mass index;
LGG	trans	rs7618501	0.966	rs7372966	chr3:49788969	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-13.06	-0.52	2.08e-33	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.599	rs4882313	chr12:38454011	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.45	-0.4	1.67e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17125944	0.505	rs10483617	chr14:53202605	A/G	cg13660082	chr14:53194042	PSMC6	0.53	7.51	0.33	3.16e-13	Alzheimer's disease (late onset);
LGG	cis	rs240764	0.604	rs705586	chr6:101268046	C/G	cg09795085	chr6:101329169	ASCC3	0.46	7.95	0.35	1.47e-14	Neuroticism;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.31	-0.36	1.08e-15	Obesity;
LGG	cis	rs3206736	0.548	rs328904	chr7:35021176	T/C	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.19e-19	Diastolic blood pressure;
LGG	cis	rs7584262	0.653	rs10210654	chr2:42264686	G/A	cg19376973	chr2:42229025	NA	0.67	9.41	0.4	2.26e-19	Bone mineral density;
LGG	cis	rs2117029	0.586	rs10875929	chr12:49568388	A/C	cg24176009	chr12:49580217	TUBA1A	0.66	12.79	0.51	2.83e-32	Intelligence (multi-trait analysis);
LGG	cis	rs13421350	0.579	rs56882727	chr2:173401348	A/G	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs704	0.726	rs2073867	chr17:26678960	G/C	cg10342447	chr17:26645325	TMEM97	-0.39	-7.23	-0.32	1.98e-12	Osteoprotegerin levels;
LGG	trans	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg13009111	chr11:71350975	NA	0.35	7.8	0.34	4.27e-14	Neuroticism;
LGG	cis	rs433406	0.708	rs426077	chr11:131372168	C/T	cg27203895	chr11:131369037	NTM	0.79	18.35	0.65	6.51e-57	Male fertility;
LGG	cis	rs2280018	1.000	rs2280018	chr16:15150833	A/C	cg07549590	chr16:15018862	NA	-0.45	-8.1	-0.35	4.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1401999	1.000	rs10937158	chr3:183708439	T/C	cg01324343	chr3:183735012	ABCC5	0.86	18.23	0.65	2.2e-56	Anterior chamber depth;
LGG	cis	rs877282	0.945	rs17293517	chr10:778770	C/T	cg17470449	chr10:769945	NA	0.58	7.24	0.32	1.93e-12	Uric acid levels;
LGG	cis	rs514406	0.893	rs512723	chr1:53343880	C/T	cg16325326	chr1:53192061	ZYG11B	-0.74	-14.58	-0.56	6.88e-40	Monocyte count;
LGG	cis	rs1008375	0.966	rs4698619	chr4:17580955	G/A	cg16339924	chr4:17578868	LAP3	0.63	10.97	0.45	4.84e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1218582	0.772	rs4845690	chr1:154886817	C/T	cg24250549	chr1:154909240	PMVK	-0.76	-15.62	-0.59	1.67e-44	Prostate cancer;
LGG	cis	rs7582720	1.000	rs72932745	chr2:203662888	A/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.79	9.4	0.4	2.57e-19	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7746199	0.668	rs7749305	chr6:27446566	T/C	cg08344181	chr3:125677491	NA	-0.79	-8.25	-0.36	1.68e-15	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9303280	0.901	rs7216389	chr17:38069949	C/T	cg00129232	chr17:37814104	STARD3	0.45	8.39	0.36	6.16e-16	Self-reported allergy;
LGG	cis	rs1010254	0.510	rs72806361	chr5:151685160	C/T	cg12297329	chr5:152029980	NA	-0.52	-7.42	-0.33	5.56e-13	Optic nerve measurement (cup area);
LGG	cis	rs4716602	0.550	rs12672151	chr7:156159053	A/G	cg16983916	chr7:156159713	NA	-0.49	-9.58	-0.41	5.77e-20	Anti-saccade response;
LGG	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	trans	rs116095464	0.558	rs56043030	chr5:220917	A/G	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs4906332	0.966	rs7401563	chr14:103964425	G/A	cg26031613	chr14:104095156	KLC1	-0.51	-7.63	-0.33	1.37e-13	Coronary artery disease;
LGG	cis	rs7928758	0.943	rs11824649	chr11:134279352	T/C	cg22777979	chr11:134283252	B3GAT1	0.84	10.84	0.45	1.52e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9303401	0.659	rs17741087	chr17:56550300	C/T	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.36	0.56	5.99e-39	Cognitive test performance;
LGG	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg22875332	chr1:76189707	ACADM	0.6	10.51	0.44	2.56e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs10189230	0.546	rs6436266	chr2:222357235	T/C	cg14652038	chr2:222343519	EPHA4	0.42	7.9	0.34	2.04e-14	Urate levels in lean individuals;
LGG	cis	rs6582630	0.502	rs4385963	chr12:38295264	G/A	cg26384229	chr12:38710491	ALG10B	0.91	20.3	0.69	5.43e-66	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12155623	0.578	rs13277226	chr8:49883029	G/T	cg22283653	chr8:49824208	NA	-0.42	-7.73	-0.34	6.73e-14	Sudden cardiac arrest;
LGG	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg26119090	chr2:26468346	HADHA;HADHB	0.97	17.65	0.63	1.06e-53	Gut microbiome composition (summer);
LGG	cis	rs62064224	0.614	rs4794923	chr17:30763009	G/A	cg18200150	chr17:30822561	MYO1D	0.49	9.47	0.4	1.41e-19	Schizophrenia;
LGG	cis	rs7107174	0.681	rs4340079	chr11:78007920	C/T	cg02023728	chr11:77925099	USP35	0.43	7.52	0.33	2.81e-13	Testicular germ cell tumor;
LGG	cis	rs5758511	0.680	rs5751243	chr22:42617177	T/C	cg15128208	chr22:42549153	NA	0.73	11.13	0.46	1.17e-25	Birth weight;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26790547	chr11:14542185	PSMA1	0.43	6.85	0.3	2.35e-11	Cognitive performance;
LGG	trans	rs853679	0.824	rs34712084	chr6:28043828	A/G	cg08344181	chr3:125677491	NA	-0.65	-7.73	-0.34	6.73e-14	Depression;
LGG	cis	rs9486719	0.857	rs1157316	chr6:96869710	G/A	cg06623918	chr6:96969491	KIAA0776	0.74	11.63	0.48	1.32e-27	Migraine;Coronary artery disease;
LGG	cis	rs6964587	1.000	rs12540565	chr7:91633213	T/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.15e-16	Breast cancer;
LGG	cis	rs7481584	0.624	rs511990	chr11:3052936	A/G	cg08508325	chr11:3079039	CARS	0.43	8.42	0.36	4.75e-16	Calcium levels;
LGG	cis	rs1577917	0.958	rs36042496	chr6:86524214	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg03452623	chr4:187889614	NA	-1.04	-31.51	-0.83	2.96e-117	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs736408	0.812	rs9324	chr3:52825585	T/C	cg11645453	chr3:52864694	ITIH4	0.42	6.91	0.31	1.63e-11	Bipolar disorder;
LGG	cis	rs295140	0.934	rs74853338	chr2:201171651	C/T	cg25099087	chr2:201172481	SPATS2L	0.28	6.91	0.31	1.59e-11	QT interval;
LGG	cis	rs1355223	0.902	rs1773908	chr11:34743380	A/G	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.16	-0.32	3.17e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg24829409	chr8:58192753	C8orf71	-0.79	-11.17	-0.46	8.08e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs5769707	0.967	rs763127	chr22:50006078	C/T	cg20744362	chr22:50050164	C22orf34	0.38	7.31	0.32	1.2e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs60871478	0.636	rs4721834	chr7:896142	C/T	cg22643751	chr7:855365	UNC84A	-0.44	-7.68	-0.34	9.72e-14	Cerebrospinal P-tau181p levels;
LGG	trans	rs7824557	0.688	rs2572397	chr8:11176403	G/A	cg02002194	chr4:3960332	NA	-0.5	-9.77	-0.41	1.22e-20	Retinal vascular caliber;
LGG	cis	rs2153535	0.580	rs1932275	chr6:8442333	T/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.7e-31	Motion sickness;
LGG	cis	rs9354308	0.764	rs9283825	chr6:66598457	G/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.15e-11	Metabolite levels;
LGG	cis	rs36051895	0.625	rs12340344	chr9:5176281	C/A	cg02405213	chr9:5042618	JAK2	-0.76	-14.78	-0.57	8.68e-41	Pediatric autoimmune diseases;
LGG	cis	rs6580649	0.883	rs1793955	chr12:48393106	G/T	cg24011408	chr12:48396354	COL2A1	0.68	8.2	0.36	2.47e-15	Lung cancer;
LGG	cis	rs1577917	0.740	rs2758842	chr6:86308731	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	9.95e-16	Response to antipsychotic treatment;
LGG	cis	rs2046867	0.661	rs9861834	chr3:72909272	C/T	cg25664220	chr3:72788482	NA	-0.28	-8.33	-0.36	9.31e-16	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs4771450	0.925	rs7327132	chr13:103985980	C/G	cg02987523	chr13:103978230	NA	-0.33	-7.08	-0.31	5.53e-12	Uric acid levels;
LGG	cis	rs12519773	0.526	rs4869191	chr5:92525434	A/T	cg18783429	chr5:92414398	NA	-0.32	-7.61	-0.33	1.6e-13	Migraine;
LGG	cis	rs2455601	0.608	rs10840137	chr11:8890079	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.49	-9.77	-0.41	1.28e-20	Schizophrenia;
LGG	cis	rs651907	0.557	rs17347644	chr3:101547733	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.41	-7.23	-0.32	2.05e-12	Colorectal cancer;
LGG	cis	rs240764	0.658	rs11155637	chr6:101203592	A/G	cg09795085	chr6:101329169	ASCC3	-0.47	-7.92	-0.35	1.82e-14	Neuroticism;
LGG	cis	rs2377585	0.524	rs10505736	chr12:8841834	T/C	cg03761649	chr12:8850719	RIMKLB	0.48	8.04	0.35	7.7e-15	Reticulocyte fraction of red cells;
LGG	cis	rs13108904	0.967	rs11247986	chr4:1294347	G/A	cg05665937	chr4:1216051	CTBP1	0.58	10.86	0.45	1.25e-24	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs2156049	chr18:44455717	G/A	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.41	-0.53	7.4e-35	Personality dimensions;
LGG	cis	rs1862618	0.853	rs252904	chr5:56118733	A/T	cg17809284	chr5:56205270	C5orf35	-0.52	-8.42	-0.36	4.81e-16	Initial pursuit acceleration;
LGG	cis	rs4129767	0.869	rs4969142	chr17:76398304	G/A	cg02836325	chr17:76403955	PGS1	-0.8	-17.35	-0.63	2.45e-52	HDL cholesterol;
LGG	trans	rs2270927	0.510	rs2913265	chr5:75603886	C/A	cg13563193	chr19:33072644	PDCD5	0.86	10.19	0.43	3.92e-22	Mean corpuscular volume;
LGG	trans	rs6598955	0.671	rs17163749	chr1:26568165	A/G	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.62	-0.51	1.38e-31	Obesity-related traits;
LGG	cis	rs12447804	0.556	rs12934822	chr16:58125839	G/A	cg03859792	chr16:58121049	NA	0.57	8.29	0.36	1.23e-15	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg10295110	chr16:4524375	NMRAL1;HMOX2	-0.4	-6.67	-0.3	7.53e-11	Schizophrenia;
LGG	cis	rs7666738	0.800	rs2865988	chr4:99067807	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.46	0.37	3.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs62400317	0.859	rs4479922	chr6:45248371	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs1801251	1.000	rs1044480	chr2:233633736	A/G	cg08000102	chr2:233561755	GIGYF2	0.56	9.14	0.39	1.9e-18	Coronary artery disease;
LGG	cis	rs875971	0.638	rs801205	chr7:66022144	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.65	-0.41	3.5e-20	Aortic root size;
LGG	cis	rs992157	0.710	rs6719789	chr2:219057810	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.54	-9.29	-0.4	5.85e-19	Colorectal cancer;
LGG	cis	rs12681288	0.550	rs4410933	chr8:959581	A/G	cg04851639	chr8:1020857	NA	-0.33	-6.93	-0.31	1.42e-11	Schizophrenia;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg21862992	chr11:68658383	NA	0.51	8.62	0.37	1.07e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17376456	0.569	rs11135397	chr5:93214975	G/T	cg25358565	chr5:93447407	FAM172A	0.82	11.48	0.47	4.99e-27	Diabetic retinopathy;
LGG	cis	rs12950390	0.853	rs12450733	chr17:45855404	A/G	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	6.76e-11	IgG glycosylation;
LGG	cis	rs899997	0.862	rs4887074	chr15:78952110	G/C	cg14912033	chr15:79043428	NA	-0.34	-8.33	-0.36	9.2e-16	Coronary artery disease or large artery stroke;
LGG	cis	rs6894268	0.762	rs4701137	chr5:179026192	C/A	cg22014891	chr5:179071901	C5orf60	-0.35	-6.99	-0.31	9.58e-12	Eating disorders;
LGG	cis	rs6951245	0.706	rs28685743	chr7:1197736	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.75	10.04	0.42	1.4e-21	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg08923669	chr16:420230	MRPL28	-0.46	-7.2	-0.32	2.39e-12	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs12421382	0.659	rs12420684	chr11:109391788	T/C	cg15948088	chr11:109293068	C11orf87	0.5	8.74	0.38	4.2e-17	Schizophrenia;
LGG	cis	rs4805272	0.512	rs7260055	chr19:29341599	G/A	cg04546413	chr19:29218101	NA	0.65	8.87	0.38	1.63e-17	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs9596863	0.861	rs4088520	chr13:54441906	C/T	ch.13.53330881F	chr13:54432880	NA	-0.48	-6.84	-0.3	2.45e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs6502050	0.698	rs67143649	chr17:80117772	C/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs13421350	0.579	rs16860515	chr2:173342416	C/T	cg15021238	chr2:173305865	ITGA6	-0.78	-8.45	-0.37	3.95e-16	Diabetic kidney disease;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg00933542	chr6:150070202	PCMT1	0.38	6.94	0.31	1.34e-11	Lung cancer;
LGG	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.38	0.53	9.85e-35	Colorectal cancer;
LGG	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg10253484	chr15:75165896	SCAMP2	-0.53	-8.22	-0.36	2.08e-15	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9868809	0.772	rs9812977	chr3:48720303	G/A	cg00383909	chr3:49044727	WDR6	0.83	9.04	0.39	4.45e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs11992162	0.967	rs7461062	chr8:11831948	T/C	cg24623649	chr8:11872141	NA	0.3	7.26	0.32	1.66e-12	Monocyte count;
LGG	cis	rs5750830	0.621	rs5750810	chr22:39792943	A/G	cg04986931	chr22:39850128	NA	0.33	7.69	0.34	8.8e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12230513	1.000	rs11171556	chr12:55949852	G/A	cg19537932	chr12:55886519	OR6C68	-0.44	-6.94	-0.31	1.36e-11	Contrast sensitivity;
LGG	cis	rs9926296	0.581	rs6500457	chr16:89898764	C/G	cg23057051	chr16:89984268	MC1R	0.36	7.07	0.31	5.65e-12	Vitiligo;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg02297831	chr4:17616191	MED28	0.5	9.24	0.39	8.72e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17767392	0.846	rs4453405	chr14:71757251	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.77	-0.38	3.51e-17	Mitral valve prolapse;
LGG	cis	rs854765	0.547	rs4368210	chr17:17896090	A/G	cg05444541	chr17:17804740	TOM1L2	0.7	16.87	0.62	4.13e-50	Total body bone mineral density;
LGG	cis	rs1008375	1.000	rs1008375	chr4:17682834	T/C	cg16339924	chr4:17578868	LAP3	0.58	10.1	0.42	8.62e-22	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs873946	0.648	rs12783354	chr10:134557235	T/A	cg27297192	chr10:134578999	INPP5A	0.31	6.73	0.3	4.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs911555	0.755	rs12432803	chr14:103930032	C/T	cg24130564	chr14:104152367	KLC1	0.39	7.31	0.32	1.16e-12	Intelligence (multi-trait analysis);
LGG	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.33	0.7	8.12e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2798269	1.000	rs12430739	chr13:22146413	A/T	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.88	-0.3	1.94e-11	PR segment;
LGG	cis	rs9611565	0.608	rs202652	chr22:41838792	A/G	cg17376030	chr22:41985996	PMM1	-0.48	-7.82	-0.34	3.54e-14	Vitiligo;
LGG	cis	rs12049351	0.665	rs6690907	chr1:229593390	C/G	cg13547644	chr1:229569608	ACTA1	0.34	7.53	0.33	2.64e-13	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs4363385	0.818	rs472076	chr1:153013742	G/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.77e-17	Inflammatory skin disease;
LGG	cis	rs2243480	1.000	rs1964692	chr7:65454183	G/A	cg13147721	chr7:65941812	NA	-0.79	-9.55	-0.41	7.5e-20	Diabetic kidney disease;
LGG	cis	rs7107174	1.000	rs2450122	chr11:77930345	T/C	cg27205649	chr11:78285834	NARS2	-0.43	-7.02	-0.31	8.13e-12	Testicular germ cell tumor;
LGG	trans	rs783540	0.934	rs10400906	chr15:83297138	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.43	-7.72	-0.34	7.42e-14	Schizophrenia;
LGG	trans	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg17830980	chr10:43048298	ZNF37B	-0.36	-7.93	-0.35	1.68e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2228479	0.702	rs62056087	chr16:89920383	C/A	cg06558623	chr16:89946397	TCF25	1.24	13.52	0.53	2.52e-35	Skin colour saturation;
LGG	cis	rs9948	0.786	rs62152783	chr2:97457389	T/A	cg01990225	chr2:97406019	LMAN2L	-0.67	-6.96	-0.31	1.14e-11	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2841277	0.741	rs9672139	chr14:105408182	T/G	cg15352829	chr14:105391018	PLD4	-0.53	-13.4	-0.53	7.46e-35	Rheumatoid arthritis;
LGG	cis	rs1691799	0.899	rs1168292	chr12:66732660	C/T	cg16791601	chr12:66731901	HELB	-0.65	-15.46	-0.58	9.28e-44	White blood cell count (basophil);
LGG	cis	rs6977660	0.714	rs12537283	chr7:19817658	G/T	cg05791153	chr7:19748676	TWISTNB	0.76	10.1	0.42	8.39e-22	Thyroid stimulating hormone;
LGG	cis	rs6502050	0.835	rs4641801	chr17:80154021	G/A	cg07959490	chr17:80112427	CCDC57	-0.46	-9.14	-0.39	1.93e-18	Life satisfaction;
LGG	cis	rs12681366	0.708	rs2470728	chr8:95366370	C/T	cg13257157	chr8:95487014	RAD54B	-0.37	-6.74	-0.3	4.81e-11	Nonsyndromic cleft lip with cleft palate;
LGG	trans	rs7726839	0.540	rs72703083	chr5:595365	C/T	cg27053975	chr1:166958233	MAEL	-0.49	-7.02	-0.31	7.98e-12	Obesity-related traits;
LGG	cis	rs4595586	0.545	rs969469	chr12:39366775	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.39	0.32	7.14e-13	Morning vs. evening chronotype;
LGG	cis	rs6977660	0.660	rs10253753	chr7:19823032	A/G	cg05791153	chr7:19748676	TWISTNB	0.76	10.1	0.43	7.94e-22	Thyroid stimulating hormone;
LGG	cis	rs13118159	0.556	rs4974615	chr4:1373551	A/G	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.61	-10.36	-0.43	9.06e-23	Longevity;
LGG	cis	rs3806843	0.735	rs2530242	chr5:140053351	G/C	cg16577123	chr5:140027231	NDUFA2;IK	-0.44	-6.99	-0.31	9.46e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6500395	0.926	rs11076570	chr16:48597915	G/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6088580	0.634	rs6087587	chr20:33058628	G/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.53	0.4	9.07e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9951602	0.512	rs4799247	chr18:76653449	G/A	cg24134504	chr18:76639479	NA	-0.46	-8.17	-0.35	2.96e-15	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs2854223	chr17:61939014	A/G	cg05941027	chr17:61774174	LIMD2	0.34	8.62	0.37	1.06e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs1829883	0.685	rs7448995	chr5:98709481	C/T	cg08333243	chr5:99726346	NA	0.34	6.76	0.3	4.27e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs7829975	0.560	rs56094035	chr8:8551622	G/A	cg08975724	chr8:8085496	FLJ10661	-0.4	-7.25	-0.32	1.73e-12	Mood instability;
LGG	cis	rs6558530	0.965	rs4372027	chr8:1707958	T/C	cg08198773	chr8:1697536	NA	0.36	6.93	0.31	1.43e-11	Systolic blood pressure;
LGG	cis	rs526231	0.512	rs34797	chr5:102425727	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	trans	rs75804782	0.641	rs60841092	chr2:239349640	G/A	cg01134436	chr17:81009848	B3GNTL1	0.84	8.75	0.38	3.99e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs453301	0.686	rs6748	chr8:8890802	C/T	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.2	-0.32	2.43e-12	Joint mobility (Beighton score);
LGG	cis	rs6964587	0.869	rs10278155	chr7:91532456	T/G	cg17063962	chr7:91808500	NA	-0.41	-7.28	-0.32	1.41e-12	Breast cancer;
LGG	cis	rs7582180	0.614	rs4851309	chr2:100975390	C/T	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	2.96e-23	Intelligence (multi-trait analysis);
LGG	cis	rs7666738	0.830	rs36028444	chr4:98968635	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	9.73e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7927592	0.731	rs7108376	chr11:68347870	A/G	cg16797656	chr11:68205561	LRP5	-0.51	-10.05	-0.42	1.29e-21	Total body bone mineral density;
LGG	cis	rs1387259	0.690	rs1601985	chr12:48761914	A/G	cg24011408	chr12:48396354	COL2A1	0.45	6.97	0.31	1.1e-11	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg26384229	chr12:38710491	ALG10B	-0.67	-13.49	-0.53	3.39e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs13217239	0.646	rs10946897	chr6:26995251	A/C	cg12292205	chr6:26970375	C6orf41	0.55	10.83	0.45	1.69e-24	Schizophrenia;
LGG	cis	rs1008375	1.000	rs6818639	chr4:17633049	A/G	cg02297831	chr4:17616191	MED28	0.5	9.32	0.4	4.68e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2602381	0.599	rs2741049	chr2:234581834	T/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.14	-0.31	3.65e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs9399137	0.507	rs7768278	chr6:135274957	T/C	cg22676075	chr6:135203613	NA	0.45	7.88	0.34	2.34e-14	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs11190604	1.000	rs11190552	chr10:102206607	G/A	cg07080220	chr10:102295463	HIF1AN	0.63	10.91	0.45	8.27e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs367615	0.512	rs246105	chr5:108672946	C/T	cg17395555	chr5:108820864	NA	0.75	12.2	0.49	6.75e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7208859	0.623	rs55638872	chr17:29149552	G/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.38	0.32	7.18e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs10504229	0.683	rs35889486	chr8:58117749	T/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs854765	0.647	rs4365346	chr17:17989373	G/T	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.73	13.92	0.54	4.67e-37	Total body bone mineral density;
LGG	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg16751781	chr15:78858589	CHRNA5	-0.43	-8.24	-0.36	1.77e-15	Sudden cardiac arrest;
LGG	cis	rs5753037	0.543	rs140122	chr22:30138908	C/G	cg01021169	chr22:30184971	ASCC2	-0.37	-7.26	-0.32	1.69e-12	Type 1 diabetes;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.21	-0.32	2.36e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs561341	1.000	rs473356	chr17:30321762	G/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9325144	0.671	rs7485963	chr12:38768254	C/G	cg04568710	chr12:38710424	ALG10B	-0.4	-8.35	-0.36	7.78e-16	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.591	rs10838968	chr11:48595046	A/G	cg03929089	chr4:120376271	NA	-0.54	-9.16	-0.39	1.62e-18	HDL cholesterol;
LGG	trans	rs4332037	0.539	rs11763750	chr7:2080114	G/A	cg10840412	chr1:235813424	GNG4	0.49	6.71	0.3	5.85e-11	Bipolar disorder;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg24594819	chr4:105416480	NA	-0.41	-6.69	-0.3	6.26e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs2916247	1.000	rs1899666	chr8:93006087	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.61	-0.37	1.11e-16	Intelligence (multi-trait analysis);
LGG	cis	rs13217239	0.646	rs6456767	chr6:27070543	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-10.7	-0.45	5.1e-24	Schizophrenia;
LGG	cis	rs67311347	1.000	rs28491638	chr3:40496263	T/C	cg13683864	chr3:40499215	RPL14	-1.14	-26.54	-0.78	4.94e-95	Renal cell carcinoma;
LGG	cis	rs4319547	0.695	rs12314643	chr12:122917423	C/T	cg23029597	chr12:123009494	RSRC2	-0.87	-16.56	-0.61	1.01e-48	Body mass index;
LGG	cis	rs5756813	0.754	rs3788529	chr22:38158709	A/G	cg24232236	chr22:38142998	TRIOBP	0.36	6.99	0.31	9.4e-12	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs9944715	1.000	rs9952972	chr18:43842617	T/A	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.73	-0.3	4.98e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs9443189	0.570	rs661229	chr6:76293793	G/A	cg01950844	chr6:76311363	SENP6	0.75	10.04	0.42	1.32e-21	Prostate cancer;
LGG	cis	rs1218582	0.772	rs11264290	chr1:154912300	C/T	cg24250549	chr1:154909240	PMVK	0.75	15.06	0.57	5.44e-42	Prostate cancer;
LGG	cis	rs1862618	0.802	rs986049	chr5:56110233	G/A	cg12654349	chr5:56205094	C5orf35	-0.68	-10.76	-0.45	3.01e-24	Initial pursuit acceleration;
LGG	trans	rs7746199	0.673	rs35501037	chr6:27739566	T/A	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6594713	0.717	rs2972690	chr5:112945945	T/C	cg12552261	chr5:112820674	MCC	-0.6	-7.68	-0.34	9.69e-14	Brain cytoarchitecture;
LGG	cis	rs9300255	0.602	rs1727317	chr12:123618942	T/C	cg00376283	chr12:123451042	ABCB9	0.59	8.93	0.38	1.02e-17	Neutrophil percentage of white cells;
LGG	cis	rs9486719	0.948	rs11152952	chr6:96894303	A/G	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	cis	rs2832191	0.720	rs7277028	chr21:30494604	T/C	cg24692254	chr21:30365293	RNF160	-0.95	-24.12	-0.75	7.69e-84	Dental caries;
LGG	cis	rs300774	1.000	rs300782	chr2:110345	C/T	cg04617936	chr2:214353	NA	-0.49	-7.25	-0.32	1.8e-12	Suicide attempts in bipolar disorder;
LGG	cis	rs7107174	1.000	rs2510046	chr11:77988817	T/C	cg27205649	chr11:78285834	NARS2	-0.47	-7.56	-0.33	2.18e-13	Testicular germ cell tumor;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.45	-9.04	-0.39	4.24e-18	Schizophrenia;
LGG	cis	rs13082711	0.911	rs6773733	chr3:27502131	C/A	cg02860705	chr3:27208620	NA	0.74	13.2	0.52	5.57e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13108904	0.901	rs66987549	chr4:1272617	C/T	cg20887711	chr4:1340912	KIAA1530	0.59	11.22	0.46	5.46e-26	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs56027489	chr4:119780882	A/G	cg21605333	chr4:119757512	SEC24D	1.48	14.97	0.57	1.32e-41	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.923	rs9767123	chr6:149981459	A/G	cg07701084	chr6:150067640	NUP43	0.71	13.82	0.54	1.26e-36	Lung cancer;
LGG	cis	rs35110281	0.667	rs2155722	chr21:45096206	A/G	cg01579765	chr21:45077557	HSF2BP	0.39	8.78	0.38	3.3e-17	Mean corpuscular volume;
LGG	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg00334542	chr7:100209784	MOSPD3	-0.56	-7.62	-0.33	1.41e-13	Other erythrocyte phenotypes;
LGG	cis	rs42648	0.564	rs11563947	chr7:89808764	C/T	cg04070188	chr7:89809444	NA	0.27	6.66	0.3	7.99e-11	Homocysteine levels;
LGG	cis	rs806215	0.547	rs62481385	chr7:127410711	G/A	cg25922125	chr7:127225783	GCC1	-0.49	-7.13	-0.31	3.86e-12	Type 2 diabetes;
LGG	cis	rs9309711	0.736	rs28619526	chr2:3496804	T/C	cg10845886	chr2:3471009	TTC15	-0.62	-11.3	-0.47	2.53e-26	Neurofibrillary tangles;
LGG	cis	rs6089829	0.962	rs3746749	chr20:61667333	T/C	cg18188782	chr20:61659543	NA	0.4	6.76	0.3	4.15e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9291683	0.588	rs11732054	chr4:9999877	C/T	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.94	-0.38	9.21e-18	Bone mineral density;
LGG	cis	rs3806843	0.676	rs753280	chr5:140024042	C/T	cg16577123	chr5:140027231	NDUFA2;IK	0.45	7.22	0.32	2.1e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1799949	0.965	rs11658499	chr17:41334749	C/T	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	cis	rs4538187	0.950	rs12996866	chr2:64130965	G/A	cg19915305	chr2:64069682	UGP2	-0.67	-15.12	-0.57	2.91e-42	Systolic blood pressure;
LGG	cis	rs4664308	0.505	rs1037694	chr2:161028992	A/G	cg03641300	chr2:160917029	PLA2R1	-0.63	-11.93	-0.48	8.51e-29	Idiopathic membranous nephropathy;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg23782820	chr8:58130467	NA	0.51	7.07	0.31	5.68e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7267979	0.966	rs910996	chr20:25264196	A/G	cg06421707	chr20:25228305	PYGB	0.47	10.2	0.43	3.47e-22	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs7819412	0.501	rs10903340	chr8:11450587	T/G	cg08975724	chr8:8085496	FLJ10661	0.48	9.33	0.4	4.55e-19	Triglycerides;
LGG	cis	rs7208859	0.623	rs216439	chr17:28927884	T/C	cg13385521	chr17:29058706	SUZ12P	0.9	10.23	0.43	2.69e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7927592	0.956	rs55816191	chr11:68262979	G/T	cg20283391	chr11:68216788	NA	-0.5	-8.24	-0.36	1.77e-15	Total body bone mineral density;
LGG	cis	rs875971	0.638	rs10278816	chr7:66036987	T/C	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.49e-24	Aortic root size;
LGG	cis	rs2624839	0.704	rs13064381	chr3:50233317	C/T	cg05623727	chr3:50126028	RBM5	0.36	6.83	0.3	2.76e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg24375607	chr4:120327624	NA	0.67	10.93	0.45	6.6e-25	Corneal astigmatism;
LGG	trans	rs9987353	0.566	rs34389718	chr8:9065525	A/G	cg16141378	chr3:129829833	LOC729375	0.32	6.97	0.31	1.08e-11	Recombination measurement;
LGG	cis	rs3820068	0.603	rs10492986	chr1:15988702	T/C	cg05660106	chr1:15850417	CASP9	0.83	16.57	0.61	8.88e-49	Systolic blood pressure;
LGG	cis	rs8017423	0.935	rs8012299	chr14:90715822	G/T	cg04374321	chr14:90722782	PSMC1	0.86	18.16	0.65	4.62e-56	Mortality in heart failure;
LGG	cis	rs798554	0.959	rs798528	chr7:2772431	A/C	cg19717773	chr7:2847554	GNA12	-0.33	-6.87	-0.3	2.12e-11	Height;
LGG	cis	rs5758511	0.508	rs28715885	chr22:42441091	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.43	6.77	0.3	4.01e-11	Birth weight;
LGG	cis	rs867371	1.000	rs7166570	chr15:82466221	C/T	cg00614314	chr15:82944287	LOC80154	0.59	9.83	0.42	7.52e-21	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs72781680	0.566	rs6713979	chr2:23899876	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	7.01	0.31	8.28e-12	Lymphocyte counts;
LGG	cis	rs34845616	0.514	rs11822562	chr11:133690456	A/C	cg06067394	chr11:133789110	IGSF9B	0.39	6.94	0.31	1.34e-11	Hand grip strength;
LGG	cis	rs644799	0.511	rs1016030	chr11:95472693	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.56	9.04	0.39	4.26e-18	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04554905	chr3:172428857	NCEH1	0.51	8.18	0.36	2.85e-15	Gut microbiome composition (summer);
LGG	cis	rs4851313	0.527	rs10183150	chr2:100939117	A/G	cg14675211	chr2:100938903	LONRF2	0.63	11.28	0.46	3.06e-26	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.929	rs2389272	chr12:34067771	T/C	cg06521331	chr12:34319734	NA	0.42	7.58	0.33	1.92e-13	Morning vs. evening chronotype;
LGG	cis	rs6933660	0.720	rs6936936	chr6:151753395	A/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.54	9.62	0.41	4.16e-20	Menarche (age at onset);
LGG	cis	rs6500395	0.962	rs1386042	chr16:48600332	G/A	cg16662043	chr16:48846231	NA	0.37	7.27	0.32	1.57e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs13118159	0.725	rs71614967	chr4:1341291	A/G	cg02475777	chr4:1388615	CRIPAK	0.42	7.85	0.34	2.92e-14	Longevity;
LGG	cis	rs12898370	0.561	rs8028830	chr15:77508046	A/G	cg17802220	chr15:77601643	NA	-0.46	-7.14	-0.31	3.63e-12	Risky sexual behaviors (alcohol dependence interaction);
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.632	rs60505453	chr3:143643864	C/G	cg06585982	chr3:143692056	C3orf58	0.66	11.63	0.48	1.28e-27	Economic and political preferences (feminism/equality);
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	0.85	17.46	0.63	8.16e-53	Obesity-related traits;
LGG	trans	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg18335740	chr13:41363409	SLC25A15	0.56	10.38	0.43	7.66e-23	Lewy body disease;
LGG	cis	rs6977660	0.607	rs7357321	chr7:19817636	C/T	cg07541023	chr7:19748670	TWISTNB	0.58	8.56	0.37	1.62e-16	Thyroid stimulating hormone;
LGG	cis	rs35771425	0.600	rs35791308	chr1:211520914	G/C	cg10512769	chr1:211675356	NA	-0.61	-8.14	-0.35	3.59e-15	Educational attainment (years of education);
LGG	cis	rs61931739	0.635	rs1852225	chr12:33963004	C/T	cg06521331	chr12:34319734	NA	-0.4	-7.05	-0.31	6.5e-12	Morning vs. evening chronotype;
LGG	cis	rs6088580	0.634	rs6059779	chr20:32950325	C/T	cg08999081	chr20:33150536	PIGU	-0.4	-10.15	-0.43	5.43e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4862750	0.872	rs13101380	chr4:187894744	G/A	cg22105103	chr4:187893119	NA	0.54	10.3	0.43	1.59e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7481584	0.669	rs12421922	chr11:3035070	A/G	cg08468577	chr11:2973342	NAP1L4	-0.32	-6.78	-0.3	3.59e-11	Calcium levels;
LGG	trans	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg06521331	chr12:34319734	NA	-0.42	-7.2	-0.32	2.43e-12	Heart rate;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg12016809	chr21:47604291	C21orf56	0.59	10.5	0.44	2.85e-23	Testicular germ cell tumor;
LGG	cis	rs67311347	1.000	rs9827461	chr3:40489351	T/A	cg24209194	chr3:40518798	ZNF619	0.44	6.82	0.3	2.9100000000000002e-11	Renal cell carcinoma;
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-6.94	-0.31	1.34e-11	Lung cancer;
LGG	cis	rs17767392	0.748	rs7159252	chr14:71704016	A/G	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.25	-0.32	1.74e-12	Mitral valve prolapse;
LGG	cis	rs11122272	0.701	rs2749702	chr1:231523808	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs597539	0.616	rs631001	chr11:68642974	C/T	cg18350739	chr11:68623251	NA	-0.89	-22.86	-0.73	5.37e-78	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.18	-0.52	6.43e-34	Aortic root size;
LGG	cis	rs9560113	0.959	rs9555803	chr13:112179560	G/T	cg10483660	chr13:112241077	NA	0.36	6.99	0.31	9.63e-12	Menarche (age at onset);
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6817170	0.624	rs13105829	chr4:154369706	C/T	cg07229402	chr4:154369277	NA	0.33	6.77	0.3	4e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs4243830	1.000	rs12047931	chr1:6587614	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.83	10.54	0.44	1.99e-23	Body mass index;
LGG	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.87	18.94	0.66	1.15e-59	Chronic sinus infection;
LGG	cis	rs7659604	0.517	rs56311153	chr4:122729685	T/C	cg06713675	chr4:122721982	EXOSC9	-0.68	-11.53	-0.47	3.27e-27	Type 2 diabetes;
LGG	cis	rs1008375	1.000	rs56308330	chr4:17643050	G/A	cg04450456	chr4:17643702	FAM184B	0.33	7.39	0.32	7.04e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6787391	0.933	rs6762558	chr3:4742251	A/G	cg11584376	chr3:4789075	ITPR1	-0.32	-6.67	-0.3	7.29e-11	Breast cancer;
LGG	cis	rs6502050	0.835	rs4789670	chr17:80151805	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.68	-0.34	9.85e-14	Life satisfaction;
LGG	cis	rs11724804	0.532	rs62297079	chr4:879977	G/A	cg08222618	chr4:941054	TMEM175	0.69	13.33	0.53	1.53e-34	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs10979	1.000	rs9376756	chr6:143886125	C/T	cg25407410	chr6:143891975	LOC285740	-0.69	-12.29	-0.5	2.92e-30	Hypospadias;
LGG	cis	rs209489	0.892	rs116344371	chr6:53117872	T/C	cg15607103	chr6:53167650	ELOVL5	0.69	8.13	0.35	4.08e-15	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs12517041	1.000	rs71611219	chr5:23280981	T/C	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.92	-0.45	7.29e-25	Calcium levels;
LGG	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg09029085	chr17:47094198	IGF2BP1	0.32	8.55	0.37	1.86e-16	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs2288073	0.965	rs10192600	chr2:24396680	A/G	cg26838691	chr2:24397539	C2orf84	-0.49	-6.97	-0.31	1.1e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs4862750	0.957	rs6858853	chr4:187903412	A/C	cg22105103	chr4:187893119	NA	-0.53	-10.15	-0.43	5.32e-22	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6951245	0.608	rs10252234	chr7:1114381	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.6	10.45	0.44	4.13e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs644799	0.965	rs11021313	chr11:95506907	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.21	0.7	3.07e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9486719	0.948	rs11152953	chr6:96894305	C/T	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.48	-0.44	3.34e-23	Migraine;Coronary artery disease;
LGG	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg15556689	chr8:8085844	FLJ10661	-0.4	-6.95	-0.31	1.22e-11	Neuroticism;
LGG	cis	rs514406	0.825	rs6588441	chr1:53223494	G/A	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.83e-61	Monocyte count;
LGG	cis	rs10499694	1.000	rs10499694	chr7:50614173	A/G	cg00647317	chr7:50633725	DDC	0.36	8.92	0.38	1.07e-17	Body mass index;
LGG	cis	rs1008375	1.000	rs6846238	chr4:17629939	A/G	cg16339924	chr4:17578868	LAP3	0.61	10.56	0.44	1.65e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12493885	0.585	rs787814	chr3:153621740	T/A	cg12800244	chr3:153838788	SGEF	-0.59	-7.04	-0.31	6.88e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs9329221	0.543	rs2952205	chr8:10139865	A/G	cg15556689	chr8:8085844	FLJ10661	0.44	7.37	0.32	8.01e-13	Neuroticism;
LGG	cis	rs2832077	0.943	rs2832106	chr21:30191767	A/G	cg08807101	chr21:30365312	RNF160	-0.58	-7.92	-0.35	1.84e-14	Cognitive test performance;
LGG	cis	rs826838	0.806	rs826873	chr12:39121305	G/A	cg13010199	chr12:38710504	ALG10B	-0.67	-14.37	-0.56	5.53e-39	Heart rate;
LGG	cis	rs1506636	1.000	rs641491	chr7:123399726	C/A	cg03229431	chr7:123269106	ASB15	0.73	18.17	0.65	4.25e-56	Plateletcrit;Platelet count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13933409	chr20:43150562	SERINC3	0.49	7.13	0.31	3.76e-12	Gut microbiome composition (summer);
LGG	cis	rs9814567	0.964	rs3856729	chr3:134200925	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.72	-0.51	5.6e-32	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs41271473	0.898	rs12028277	chr1:228829657	A/G	cg00850481	chr1:228891306	NA	-0.51	-8.38	-0.36	6.61e-16	Chronic lymphocytic leukemia;
LGG	cis	rs2153535	0.601	rs2327054	chr6:8443130	T/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.51	1.75e-31	Motion sickness;
LGG	trans	rs3780486	0.718	rs73645257	chr9:33132354	C/T	cg04842962	chr6:43655489	MRPS18A	0.86	12.37	0.5	1.41e-30	IgG glycosylation;
LGG	cis	rs933688	1.000	rs61612071	chr5:90741470	G/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	16.82	0.62	6.78e-50	Smoking behavior;
LGG	cis	rs13191362	0.935	rs13193473	chr6:162966852	C/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.37	0.32	8.16e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4363385	0.818	rs3795382	chr1:153004853	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.61	-0.37	1.12e-16	Inflammatory skin disease;
LGG	cis	rs12477438	0.520	rs2309581	chr2:99784292	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.78	-15.06	-0.57	5.4e-42	Chronic sinus infection;
LGG	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg21775007	chr8:11205619	TDH	-0.76	-13.11	-0.52	1.31e-33	Retinal vascular caliber;
LGG	cis	rs7447593	0.666	rs12659266	chr5:176807197	C/T	cg06060754	chr5:176797920	RGS14	0.45	6.92	0.31	1.51e-11	Urinary electrolytes (magnesium/calcium ratio);
LGG	cis	rs11098499	0.644	rs7676296	chr4:120555687	A/G	cg09307838	chr4:120376055	NA	0.72	12.43	0.5	7.88e-31	Corneal astigmatism;
LGG	cis	rs2842992	0.724	rs4709368	chr6:160204127	C/T	cg27624424	chr6:160112604	SOD2	-0.57	-9.14	-0.39	2.05e-18	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6502050	0.805	rs62078303	chr17:80085210	A/G	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs6582630	0.519	rs4436613	chr12:38293653	T/C	cg13010199	chr12:38710504	ALG10B	0.67	13.65	0.54	7.05e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12431410	0.892	rs1957986	chr14:60158165	C/A	cg07950296	chr14:60194823	RTN1	0.38	7.2	0.32	2.44e-12	Schizophrenia;
LGG	cis	rs12421382	0.593	rs1808842	chr11:109389454	C/T	cg16359550	chr11:109292809	C11orf87	0.4	8.02	0.35	8.52e-15	Schizophrenia;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.58	-10.49	-0.44	3.18e-23	Lymphocyte counts;
LGG	cis	rs11191205	0.686	rs10883668	chr10:103398834	G/A	cg15320455	chr10:103880129	LDB1	0.48	6.93	0.31	1.4e-11	Intelligence (multi-trait analysis);
LGG	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg14088196	chr11:70211408	PPFIA1	0.96	13.25	0.52	3.27e-34	Coronary artery disease;
LGG	cis	rs17125944	0.686	rs1952090	chr14:53342992	A/G	cg00686598	chr14:53173677	PSMC6	-0.63	-6.76	-0.3	4.17e-11	Alzheimer's disease (late onset);
LGG	cis	rs10504229	0.728	rs17216187	chr8:58158778	G/T	cg11062466	chr8:58055876	NA	0.61	10.12	0.43	7.17e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	1.000	rs76129108	chr7:1089159	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12477438	0.798	rs896886	chr2:99652713	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.86	15.41	0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs7613875	0.578	rs2624822	chr3:50107219	T/C	cg05623727	chr3:50126028	RBM5	-0.4	-8.75	-0.38	4.13e-17	Body mass index;
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.64	11.19	0.46	6.63e-26	Lymphocyte counts;
LGG	trans	rs7248779	0.512	rs12610522	chr19:2413228	C/T	cg25835954	chr13:50160062	RCBTB1	0.52	7.93	0.35	1.64e-14	Cortisol levels (saliva);
LGG	cis	rs2011503	0.941	rs72999068	chr19:19380685	A/G	cg11584989	chr19:19387371	SF4	0.77	12.84	0.51	1.76e-32	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs1961778	chr8:58168756	G/A	cg11062466	chr8:58055876	NA	0.5	8.55	0.37	1.81e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	trans	rs11098499	0.954	rs2389803	chr4:120393511	A/G	cg25214090	chr10:38739885	LOC399744	-0.71	-12.82	-0.51	1.99e-32	Corneal astigmatism;
LGG	cis	rs7226408	0.857	rs11664002	chr18:34526377	C/G	cg15022739	chr18:34823045	BRUNOL4	-0.41	-6.67	-0.3	7.44e-11	Obesity-related traits;
LGG	cis	rs7617480	0.648	rs9882443	chr3:48749064	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.91	0.34	1.93e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg01585723	chr16:33734837	NA	0.46	8.17	0.35	2.92e-15	Menopause (age at onset);
LGG	cis	rs7208859	0.673	rs11654914	chr17:29229424	C/G	cg01831904	chr17:28903510	LRRC37B2	-0.7	-8.3	-0.36	1.18e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9291683	0.588	rs17247314	chr4:10004743	C/G	cg08250081	chr4:10125330	NA	0.37	7.06	0.31	6.21e-12	Bone mineral density;
LGG	cis	rs9604529	0.532	rs41291213	chr13:114774991	C/T	cg12337884	chr13:114819908	RASA3	-0.47	-6.77	-0.3	4.01e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs853679	0.556	rs45509595	chr6:27840926	T/C	cg01620082	chr3:125678407	NA	-1.03	-9.79	-0.41	1.07e-20	Depression;
LGG	trans	rs34421088	0.702	rs7838131	chr8:11596163	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-8.05	-0.35	7.02e-15	Neuroticism;
LGG	cis	rs300774	1.000	rs300692	chr2:181415	C/T	cg04617936	chr2:214353	NA	-0.54	-7.86	-0.34	2.73e-14	Suicide attempts in bipolar disorder;
LGG	cis	rs2820315	1.000	rs2132363	chr1:201826482	C/T	cg10061532	chr1:201886748	LMOD1	0.33	6.83	0.3	2.76e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs28595532	0.841	rs116329146	chr4:119733438	G/A	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.6	-0.33	1.61e-13	Blood pressure (smoking interaction);
LGG	cis	rs2717559	0.542	rs11774823	chr8:143887568	G/T	cg06565975	chr8:143823917	SLURP1	-0.29	-7.1	-0.31	4.86e-12	Urinary tract infection frequency;
LGG	cis	rs796364	0.806	rs188102	chr2:200903189	T/A	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.77	-9.34	-0.4	3.94e-19	Schizophrenia;
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.2	-0.32	2.43e-12	Menopause (age at onset);
LGG	cis	rs6565180	0.525	rs1132812	chr16:30198151	A/G	cg17640201	chr16:30407289	ZNF48	0.54	9.26	0.4	7.86e-19	Tonsillectomy;
LGG	cis	rs2739330	1.000	rs2739330	chr22:24295286	T/C	cg23131131	chr22:24373011	LOC391322	-0.42	-6.82	-0.3	2.85e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7412746	0.658	rs12410394	chr1:150860186	G/A	cg15448220	chr1:150897856	SETDB1	0.4	7.42	0.33	5.57e-13	Melanoma;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg22535103	chr8:58192502	C8orf71	-0.99	-15.81	-0.59	2.59e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs3857536	0.776	rs4710316	chr6:66935097	T/A	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.16e-14	Blood trace element (Cu levels);
LGG	cis	rs4380275	0.965	rs4375894	chr2:772567	G/C	cg14072418	chr2:740025	NA	-0.41	-7.62	-0.33	1.41e-13	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);
LGG	cis	rs13392177	0.672	rs4674270	chr2:219053141	G/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.51	-8.27	-0.36	1.47e-15	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs11155671	0.530	rs4869764	chr6:150211828	T/C	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21514227	chr19:15288315	NOTCH3	0.47	7.04	0.31	7.1e-12	Gut microbiome composition (summer);
LGG	cis	rs11252926	0.931	rs4881399	chr10:567325	A/G	cg18196295	chr10:418757	DIP2C	0.55	10.22	0.43	2.98e-22	Psychosis in Alzheimer's disease;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg08280861	chr8:58055591	NA	0.56	7.02	0.31	7.94e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4917300	0.606	rs4917225	chr8:143116169	T/C	cg26003909	chr8:143102224	NA	-0.34	-6.8	-0.3	3.29e-11	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.679	rs4738574	chr8:58033771	T/C	cg24829409	chr8:58192753	C8orf71	-0.62	-8.92	-0.38	1.11e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs9460578	0.537	rs9465910	chr6:20824830	C/T	cg13405222	chr6:20811065	CDKAL1	0.76	17.21	0.62	1.18e-51	Breast cancer;
LGG	cis	rs1008375	1.000	rs4698635	chr4:17630242	C/A	cg04450456	chr4:17643702	FAM184B	0.33	7.18	0.32	2.75e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9296092	0.538	rs75501442	chr6:33519493	A/G	cg13560919	chr6:33536144	NA	-1.04	-21.71	-0.71	1.3e-72	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs1927790	0.727	rs12867783	chr13:96974576	A/T	cg02571835	chr13:96230311	CLDN10	-0.34	-6.96	-0.31	1.14e-11	Body mass index;
LGG	trans	rs1814175	0.541	rs12287397	chr11:49819799	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.16	-0.75	4.91e-84	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01094787	chr12:2921657	ITFG2	0.45	6.73	0.3	4.88e-11	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs1890565	chr15:45663299	T/C	cg10760299	chr15:45669010	GATM	0.41	8.11	0.35	4.71e-15	Homoarginine levels;
LGG	cis	rs17666538	0.585	rs336444	chr8:633123	C/G	cg23958373	chr8:599963	NA	-1.1	-11.37	-0.47	1.41e-26	IgG glycosylation;
LGG	cis	rs735396	0.595	rs2258287	chr12:121454313	G/T	cg14101638	chr12:121416612	HNF1A	0.34	7.1	0.31	4.63e-12	N-glycan levels;
LGG	cis	rs1847505	0.594	rs3127043	chr13:61400263	T/C	cg25164009	chr13:61490935	NA	-0.55	-8.52	-0.37	2.32e-16	Polychlorinated biphenyl levels;
LGG	cis	rs9790314	1.000	rs336579	chr3:161086610	G/A	cg04691961	chr3:161091175	C3orf57	-0.66	-15.64	-0.59	1.49e-44	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs12642797	chr4:1245990	G/A	cg04863758	chr4:1303710	MAEA	0.42	7.13	0.31	3.85e-12	Obesity-related traits;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.67	10.68	0.44	5.75e-24	Renal function-related traits (BUN);
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.79	-0.38	2.91e-17	Life satisfaction;
LGG	cis	rs10504229	0.683	rs72649188	chr8:58108829	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.33	-0.43	1.19e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.729	rs114133083	chr12:38182923	G/C	cg04568710	chr12:38710424	ALG10B	-0.37	-7.78	-0.34	4.77e-14	Bladder cancer;
LGG	cis	rs6540556	0.769	rs6665715	chr1:209931353	A/C	cg23920097	chr1:209922102	NA	0.49	8.72	0.38	5.08e-17	Red blood cell count;
LGG	cis	rs11628318	0.614	rs7143048	chr14:103119800	C/T	cg01864069	chr14:103024347	NA	0.66	9.35	0.4	3.68e-19	Platelet count;
LGG	trans	rs7826238	0.601	rs2979206	chr8:8345581	G/C	cg16141378	chr3:129829833	LOC729375	-0.44	-10.53	-0.44	2.12e-23	Systolic blood pressure;
LGG	cis	rs9399135	0.967	rs9376082	chr6:135346389	T/A	cg22676075	chr6:135203613	NA	0.36	6.68	0.3	6.71e-11	Red blood cell count;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg21862992	chr11:68658383	NA	0.5	8.47	0.37	3.36e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.694	rs5758365	chr22:41858657	A/G	cg06850241	chr22:41845214	NA	0.46	7.17	0.32	2.93e-12	Vitiligo;
LGG	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg22467129	chr15:76604101	ETFA	-0.42	-7.13	-0.31	3.98e-12	Blood metabolite levels;
LGG	cis	rs11148252	0.508	rs6561671	chr13:53182314	G/A	cg00495681	chr13:53174319	NA	0.71	14.44	0.56	2.74e-39	Lewy body disease;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg05091796	chr16:4465799	CORO7	0.76	13.27	0.52	2.79e-34	Schizophrenia;
LGG	trans	rs7395662	1.000	rs1809986	chr11:48987539	C/A	cg03929089	chr4:120376271	NA	-0.43	-6.95	-0.31	1.24e-11	HDL cholesterol;
LGG	cis	rs12210905	1.000	rs72843615	chr6:27150569	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.0	-0.35	9.97e-15	Hip circumference adjusted for BMI;
LGG	cis	rs17270561	0.609	rs4145216	chr6:25743559	G/A	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs2964802	0.505	rs13164697	chr5:10831212	C/T	cg14521931	chr5:10832172	NA	-0.75	-16.46	-0.61	2.85e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	trans	rs853679	0.882	rs2743555	chr6:28241081	G/A	cg01620082	chr3:125678407	NA	-0.61	-7.51	-0.33	2.98e-13	Depression;
LGG	cis	rs6759839	0.761	rs7606503	chr2:16624447	G/A	cg09580478	chr2:16689509	NA	0.47	7.38	0.32	7.42e-13	Mean platelet volume;
LGG	cis	rs2832191	0.729	rs2832201	chr21:30499841	A/G	cg08807101	chr21:30365312	RNF160	-0.9	-19.1	-0.66	2.11e-60	Dental caries;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01293313	chr2:122406171	CLASP1	0.43	7.19	0.32	2.61e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17253792	0.822	rs118027213	chr14:56039076	T/C	cg01858014	chr14:56050164	KTN1	-0.88	-10.85	-0.45	1.39e-24	Putamen volume;
LGG	cis	rs12477438	0.765	rs56167745	chr2:99600478	T/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.83	-0.51	1.96e-32	Chronic sinus infection;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg04936382	chr20:36662003	RPRD1B;KIAA0406	-0.48	-6.89	-0.3	1.82e-11	Systemic lupus erythematosus;
LGG	cis	rs1005277	0.540	rs4934907	chr10:38015230	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.42	-6.99	-0.31	9.5e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg23034840	chr1:205782522	SLC41A1	0.54	8.81	0.38	2.59e-17	Menarche (age at onset);
LGG	cis	rs1799949	1.000	rs33994002	chr17:41328818	T/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.46e-17	Menopause (age at onset);
LGG	cis	rs2071403	1.000	rs4927604	chr2:1416435	A/G	cg06500727	chr2:1417164	TPO	-0.52	-9.89	-0.42	4.61e-21	Thyroid peroxidase antibody positivity;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.99	14.46	0.56	2.21e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06848247	chr2:6635800	NA	-0.53	-6.79	-0.3	3.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9547996	0.879	rs11619443	chr13:38169715	C/G	cg13634560	chr13:38173852	POSTN	-0.35	-6.99	-0.31	9.58e-12	Diastolic blood pressure;
LGG	trans	rs7395662	0.553	rs4882155	chr11:48705801	T/C	cg15704280	chr7:45808275	SEPT13	-0.61	-10.91	-0.45	7.92e-25	HDL cholesterol;
LGG	trans	rs11039798	1.000	rs7942042	chr11:48520270	A/G	cg15704280	chr7:45808275	SEPT13	0.77	8.93	0.38	9.88e-18	Axial length;
LGG	cis	rs6500602	0.653	rs4786487	chr16:4440397	C/G	cg08645402	chr16:4508243	NA	-0.41	-7.2	-0.32	2.51e-12	Schizophrenia;
LGG	cis	rs9788333	0.762	rs4441120	chr13:21886863	T/A	cg00035636	chr13:21900591	NA	0.38	8.2	0.36	2.42e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg26688816	chr2:46740690	ATP6V1E2	-0.49	-8.9	-0.38	1.29e-17	HDL cholesterol;
LGG	cis	rs2764208	0.576	rs2814998	chr6:34625211	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.44	-7.58	-0.33	1.91e-13	Systemic lupus erythematosus;
LGG	cis	rs2011503	0.941	rs4808934	chr19:19370917	C/T	cg01262667	chr19:19385393	TM6SF2	0.37	7.35	0.32	8.8e-13	Bipolar disorder;
LGG	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.15	0.46	9.47e-26	Homoarginine levels;
LGG	cis	rs7241530	0.662	rs12970916	chr18:75901198	A/T	cg14642773	chr18:75888474	NA	-0.44	-8.72	-0.38	4.87e-17	Educational attainment (years of education);
LGG	cis	rs7084402	0.967	rs10763551	chr10:60273898	G/A	cg07615347	chr10:60278583	BICC1	-0.62	-17.57	-0.63	2.47e-53	Refractive error;
LGG	cis	rs7617773	0.780	rs13066758	chr3:48343877	G/A	cg11946769	chr3:48343235	NME6	0.72	12.01	0.49	4.14e-29	Coronary artery disease;
LGG	cis	rs10824796	1.000	rs10824796	chr10:54534613	A/G	cg27418851	chr10:54531653	MBL2	0.43	8.72	0.38	5.01e-17	Blood protein levels;
LGG	cis	rs11264213	1.000	rs11264203	chr1:36239234	C/T	cg27506609	chr1:36549197	TEKT2	0.64	7.13	0.31	3.79e-12	Schizophrenia;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg06916706	chr16:4465613	CORO7	-1.16	-24.34	-0.75	7.12e-85	Schizophrenia;
LGG	cis	rs8031584	0.958	rs7176569	chr15:31244495	G/T	cg14829155	chr15:31115871	NA	0.58	10.12	0.43	6.93e-22	Huntington's disease progression;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.528	rs10880238	chr12:42489613	A/G	cg01943504	chr12:42538901	GXYLT1	-0.52	-9.48	-0.4	1.31e-19	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6088590	0.735	rs6088618	chr20:33409350	G/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.44	0.37	4.04e-16	Coronary artery disease;
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg07157834	chr1:205819609	PM20D1	0.42	7.12	0.31	4.27e-12	Parkinson's disease;
LGG	cis	rs7584262	0.740	rs13401161	chr2:42245267	C/T	cg27428208	chr2:42229179	NA	0.47	7.51	0.33	3.06e-13	Bone mineral density;
LGG	cis	rs6502050	0.764	rs28676462	chr17:80105100	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4788570	0.615	rs889568	chr16:71772399	T/C	cg06353428	chr16:71660113	MARVELD3	1.27	20.96	0.7	4.55e-69	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.837	rs7279958	chr21:45016016	C/A	cg04455712	chr21:45112962	RRP1B	0.51	9.83	0.42	8.03e-21	Mean corpuscular volume;
LGG	cis	rs2274273	0.624	rs4580079	chr14:55780366	G/A	cg04306507	chr14:55594613	LGALS3	0.53	12.45	0.5	6.96e-31	Protein biomarker;
LGG	cis	rs1555895	0.576	rs7080989	chr10:851455	C/G	cg09361094	chr10:834503	NA	-0.29	-7.62	-0.33	1.41e-13	Survival in rectal cancer;
LGG	trans	rs853679	0.546	rs200977	chr6:27854301	T/C	cg01620082	chr3:125678407	NA	-0.79	-8.6	-0.37	1.22e-16	Depression;
LGG	cis	rs16854884	0.837	rs7644767	chr3:143803092	C/G	cg06585982	chr3:143692056	C3orf58	0.56	9.15	0.39	1.85e-18	Economic and political preferences (feminism/equality);
LGG	cis	rs7208859	0.673	rs11652370	chr17:29097223	G/A	cg19761014	chr17:28927070	LRRC37B2	0.59	7.44	0.33	4.93e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2455799	0.573	rs2470523	chr3:15768091	G/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.98	-0.35	1.14e-14	Mean platelet volume;
LGG	cis	rs79839061	0.610	rs2279182	chr4:882625	T/G	cg07828340	chr4:882639	GAK	0.93	9.96	0.42	2.68e-21	Intelligence (multi-trait analysis);
LGG	cis	rs806215	1.000	rs712697	chr7:127247132	T/A	cg25922125	chr7:127225783	GCC1	0.75	10.3	0.43	1.48e-22	Type 2 diabetes;
LGG	cis	rs801193	1.000	rs2707854	chr7:66212597	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.45	9.41	0.4	2.31e-19	Aortic root size;
LGG	cis	rs9308433	0.553	rs9308435	chr1:214500166	C/T	cg06198575	chr1:214491504	SMYD2	0.51	7.73	0.34	6.8e-14	IgG glycosylation;
LGG	cis	rs7666738	0.830	rs9999200	chr4:99030690	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7726839	0.574	rs11739866	chr5:636299	C/T	cg25482853	chr8:67687455	SGK3	0.93	11.61	0.47	1.55e-27	Obesity-related traits;
LGG	cis	rs9326248	0.861	rs4938353	chr11:117046197	G/A	cg01368799	chr11:117014884	PAFAH1B2	0.6	7.77	0.34	4.96e-14	Blood protein levels;
LGG	cis	rs1915919	0.794	rs4398451	chr3:20010886	T/C	cg05072819	chr3:20081367	KAT2B	0.45	7.9	0.34	1.99e-14	Post-traumatic stress disorder;
LGG	cis	rs62402013	1	rs62402013	chr6:26915000	A/G	cg12292205	chr6:26970375	C6orf41	0.73	14.17	0.55	3.9e-38	Schizophrenia;
LGG	cis	rs1799949	1.000	rs12936816	chr17:41301709	C/T	cg12708336	chr17:41446283	NA	-0.31	-7.34	-0.32	9.73e-13	Menopause (age at onset);
LGG	cis	rs17641971	0.708	rs2137013	chr8:49981091	C/T	cg00325661	chr8:49890786	NA	0.54	10.12	0.43	6.78e-22	Blood metabolite levels;
LGG	cis	rs11122272	0.735	rs910824	chr1:231498773	C/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.16	-0.46	8.84e-26	Hemoglobin concentration;
LGG	cis	rs9788721	0.967	rs2036527	chr15:78851615	G/A	cg18825076	chr15:78729989	IREB2	-0.48	-7.66	-0.34	1.06e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs9814567	1.000	rs9864439	chr3:134298671	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.4	-0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg26174226	chr8:58114915	NA	-0.57	-7.7	-0.34	8.47e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10791097	0.694	rs2155752	chr11:130755998	C/T	cg09137382	chr11:130731461	NA	0.35	6.77	0.3	3.89e-11	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs2576037	0.526	rs7234570	chr18:44459656	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.33	-0.36	8.91e-16	Personality dimensions;
LGG	cis	rs12773846	0.666	rs35422383	chr10:126267528	C/T	cg04949429	chr10:126290192	LHPP	0.46	6.88	0.3	1.96e-11	Subcutaneous adipose tissue;
LGG	cis	rs10754283	0.967	rs10922685	chr1:90118320	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.02	-0.31	8.14e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9487094	0.813	rs13203252	chr6:109672736	A/G	cg16315928	chr6:109776240	MICAL1	0.52	8.58	0.37	1.5e-16	Height;
LGG	trans	rs3808502	0.605	rs11784572	chr8:11174484	C/G	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.69	-0.3	6.35e-11	Neuroticism;
LGG	cis	rs5758659	0.653	rs133383	chr22:42473603	C/T	cg15128208	chr22:42549153	NA	-0.5	-10.07	-0.42	1.09e-21	Cognitive function;
LGG	cis	rs561341	0.882	rs2521594	chr17:30302087	C/T	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9473924	0.542	rs9473928	chr6:50842003	G/A	cg14470998	chr6:50812995	TFAP2B	0.68	8.21	0.36	2.27e-15	Body mass index;
LGG	cis	rs477895	0.838	rs7111278	chr11:64016284	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.87	0.34	2.61e-14	Mean platelet volume;
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg04703951	chr17:43578652	NA	-0.39	-7.91	-0.35	1.9e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7928758	0.943	rs77897340	chr11:134265173	C/T	cg15243474	chr11:134282918	B3GAT1	1.19	15.37	0.58	2.23e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs7558370	1.000	rs112582847	chr2:3714971	A/G	cg17046650	chr2:3699563	NA	0.78	7.93	0.35	1.63e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1801251	0.963	rs6739638	chr2:233576015	G/A	cg08000102	chr2:233561755	GIGYF2	0.57	9.22	0.39	1.08e-18	Coronary artery disease;
LGG	cis	rs472402	0.540	rs10062086	chr5:6633042	C/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-6.99	-0.31	9.64e-12	Response to amphetamines;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.67	-0.61	3.18e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2860975	1.000	rs11188133	chr10:96772015	G/A	cg09036531	chr10:96991505	NA	-0.5	-9.13	-0.39	2.18e-18	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05743054	chr3:158288903	MLF1	0.53	8.36	0.36	7.41e-16	Gut microbiome composition (summer);
LGG	cis	rs10089	1.000	rs1842006	chr5:127508687	G/A	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.76	11.63	0.48	1.33e-27	Ileal carcinoids;
LGG	cis	rs12701220	0.553	rs13245507	chr7:1163694	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-7.71	-0.34	7.93e-14	Bronchopulmonary dysplasia;
LGG	cis	rs12681287	0.640	rs7460342	chr8:87475137	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg07227728	chr7:131012528	MKLN1	-0.46	-7.27	-0.32	1.49e-12	Pancreatic cancer;
LGG	cis	rs1023500	0.505	rs134886	chr22:42673856	C/T	cg04733989	chr22:42467013	NAGA	-0.51	-8.99	-0.39	6.38e-18	Schizophrenia;
LGG	cis	rs9768139	0.708	rs921615	chr7:158117935	A/G	cg25566285	chr7:158114605	PTPRN2	0.89	20.21	0.68	1.36e-65	Calcium levels;
LGG	trans	rs7819412	0.521	rs4451268	chr8:11034859	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.16	-0.35	3.3e-15	Triglycerides;
LGG	trans	rs11098499	0.874	rs13139045	chr4:120168588	T/C	cg25517755	chr10:38738941	LOC399744	-0.38	-6.68	-0.3	6.86e-11	Corneal astigmatism;
LGG	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.85	9.04	0.39	4.21e-18	Diabetic retinopathy;
LGG	cis	rs7227917	0.536	rs72916027	chr18:45513453	A/G	cg22195133	chr18:45534586	NA	0.77	7.02	0.31	8.02e-12	Lung cancer in ever smokers;
LGG	cis	rs988958	0.526	rs34006080	chr2:42239736	T/C	cg27252766	chr2:42229092	NA	0.47	6.72	0.3	5.28e-11	Hypospadias;
LGG	cis	rs6580649	0.941	rs11612578	chr12:48414798	T/C	cg24011408	chr12:48396354	COL2A1	-0.55	-6.88	-0.3	1.95e-11	Lung cancer;
LGG	cis	rs873946	0.648	rs35417213	chr10:134553749	A/G	cg27286337	chr10:134555280	INPP5A	0.9	13.43	0.53	5.96e-35	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs7296418	0.961	rs10773921	chr12:123541606	C/T	cg00376283	chr12:123451042	ABCB9	0.67	12.48	0.5	5.04e-31	Platelet count;
LGG	cis	rs67311347	0.866	rs2371183	chr3:40334247	C/T	cg13683864	chr3:40499215	RPL14	0.89	18.08	0.64	1.08e-55	Renal cell carcinoma;
LGG	cis	rs875971	1.000	rs6970030	chr7:65968679	T/C	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs2730245	0.527	rs842695	chr7:158662182	G/A	cg24397884	chr7:158709396	WDR60	1.05	15.23	0.58	9.69e-43	Height;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.31	0.4	5.14e-19	Obesity-related traits;
LGG	cis	rs17021463	0.872	rs11097417	chr4:95268071	C/T	cg11021082	chr4:95130006	SMARCAD1	-0.49	-9.11	-0.39	2.49e-18	Testicular germ cell tumor;
LGG	cis	rs1348850	0.872	rs10165785	chr2:178293295	C/T	cg27490568	chr2:178487706	NA	0.5	10.07	0.42	1.06e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg01191920	chr7:158217561	PTPRN2	0.69	14.72	0.56	1.74e-40	Obesity-related traits;
LGG	cis	rs7824557	0.627	rs7838897	chr8:11207326	C/A	cg21775007	chr8:11205619	TDH	0.81	14.32	0.55	9.34e-39	Retinal vascular caliber;
LGG	cis	rs2455799	0.613	rs4684261	chr3:15796505	G/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.03	-0.35	7.91e-15	Mean platelet volume;
LGG	cis	rs2243480	1.000	rs316332	chr7:65604299	A/G	cg18252515	chr7:66147081	NA	-1.43	-20.67	-0.69	1.03e-67	Diabetic kidney disease;
LGG	cis	rs9914544	0.966	rs1737943	chr17:18841590	A/G	cg26306683	chr17:18585705	ZNF286B	-0.45	-8.24	-0.36	1.81e-15	Educational attainment (years of education);
LGG	cis	rs9916302	0.851	rs9909064	chr17:37500434	G/T	cg00129232	chr17:37814104	STARD3	0.61	11.52	0.47	3.49e-27	Glomerular filtration rate (creatinine);
LGG	trans	rs61931739	0.534	rs1912773	chr12:34097401	T/C	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	cis	rs765787	0.530	rs2433229	chr15:45515235	C/A	cg24006582	chr15:45444508	DUOX1	-0.67	-12.66	-0.51	9.45e-32	Uric acid levels;
LGG	cis	rs2012796	0.661	rs59969857	chr14:81841579	A/G	cg02996355	chr14:81879375	NA	0.57	9.5	0.4	1.14e-19	Night sleep phenotypes;
LGG	cis	rs10504229	0.871	rs10504226	chr8:58159283	A/G	cg08280861	chr8:58055591	NA	0.51	6.75	0.3	4.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6495122	0.501	rs6495144	chr15:75343438	T/C	cg14664628	chr15:75095509	CSK	0.48	9.1	0.39	2.71e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs7937682	0.889	rs11213971	chr11:111529829	A/G	cg22437258	chr11:111473054	SIK2	0.56	9.74	0.41	1.68e-20	Primary sclerosing cholangitis;
LGG	cis	rs7582720	1.000	rs4510208	chr2:203734866	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9381107	0.932	rs9349172	chr6:9458941	C/G	cg14735645	chr6:9486422	NA	-0.46	-7.43	-0.33	5.18e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs17826219	0.706	rs8071236	chr17:29100002	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs4728302	0.534	rs6976069	chr7:133152898	T/C	cg10665199	chr7:133106180	EXOC4	0.58	9.9	0.42	4.49e-21	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs4979906	1.000	rs11002241	chr10:79445327	C/T	cg07817648	chr10:79422355	NA	-0.48	-7.68	-0.34	9.74e-14	Mortality in heart failure;
LGG	cis	rs796364	0.806	rs74266489	chr2:201005732	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-6.96	-0.31	1.17e-11	Schizophrenia;
LGG	cis	rs3784262	0.740	rs4646598	chr15:58300328	G/C	cg12031962	chr15:58353849	ALDH1A2	-0.34	-7.21	-0.32	2.35e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6089584	0.566	rs2181589	chr20:60622817	C/T	cg06470251	chr20:60548479	NA	-0.42	-7.26	-0.32	1.69e-12	Body mass index;
LGG	cis	rs34172651	0.917	rs200529	chr16:24758502	T/C	cg02428538	chr16:24856791	SLC5A11	0.43	7.45	0.33	4.53e-13	Intelligence (multi-trait analysis);
LGG	cis	rs3857067	0.776	rs6858265	chr4:95112565	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.43	-8.11	-0.35	4.69e-15	QT interval;
LGG	cis	rs28830936	1.000	rs28754734	chr15:42093152	C/T	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-6.82	-0.3	2.93e-11	Diastolic blood pressure;
LGG	cis	rs2842992	0.789	rs4276525	chr6:160193612	G/A	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.23	0.55	2.22e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs11190604	0.767	rs77838250	chr10:102180090	T/G	cg07080220	chr10:102295463	HIF1AN	0.57	9.96	0.42	2.65e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7944584	0.511	rs10838731	chr11:47607135	C/T	cg20307385	chr11:47447363	PSMC3	0.87	18.65	0.65	2.64e-58	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs67478160	0.643	rs12878868	chr14:104233725	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-7.56	-0.33	2.21e-13	Schizophrenia;
LGG	cis	rs4330281	0.692	rs11719326	chr3:17781780	A/C	cg20981856	chr3:17787350	NA	-0.39	-7.22	-0.32	2.22e-12	Schizophrenia;
LGG	cis	rs4974559	0.501	rs1250129	chr4:1254930	C/T	cg02980000	chr4:1222292	CTBP1	0.62	7.7	0.34	8.41e-14	Systolic blood pressure;
LGG	cis	rs7503807	0.905	rs62068345	chr17:78608040	C/T	cg09596252	chr17:78655493	RPTOR	0.44	7.96	0.35	1.38e-14	Obesity;
LGG	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg01338084	chr22:32026380	PISD	1.49	12.74	0.51	4.61e-32	Age-related hearing impairment;
LGG	cis	rs7481584	0.962	rs2001006	chr11:2974912	A/G	cg08508325	chr11:3079039	CARS	0.41	7.77	0.34	5.11e-14	Calcium levels;
LGG	cis	rs10911232	0.507	rs10911231	chr1:183051745	T/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs61884328	0.733	rs61897852	chr11:47203155	G/A	cg03339077	chr11:47165057	C11orf49	0.62	6.71	0.3	5.77e-11	Total body bone mineral density (age over 60);
LGG	cis	rs2028299	0.919	rs3759831	chr15:90414642	C/G	cg23731826	chr15:90371692	NA	0.36	8.2	0.36	2.35e-15	Type 2 diabetes;
LGG	cis	rs12049351	0.665	rs4925453	chr1:229597627	A/T	cg13547644	chr1:229569608	ACTA1	-0.33	-6.97	-0.31	1.09e-11	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs68170813	0.559	rs12538769	chr7:106984288	C/T	cg02696742	chr7:106810147	HBP1	-0.7	-9.9	-0.42	4.32e-21	Coronary artery disease;
LGG	cis	rs4076764	0.958	rs11590567	chr1:163396438	A/G	cg24596788	chr1:163392923	NA	-0.72	-13.76	-0.54	2.22e-36	Motion sickness;
LGG	cis	rs13108904	0.935	rs3755920	chr4:1243617	T/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.75	14.87	0.57	3.8e-41	Obesity-related traits;
LGG	trans	rs7618501	0.933	rs1128535	chr3:49866392	C/T	cg21659725	chr3:3221576	CRBN	0.92	20.59	0.69	2.48e-67	Intelligence (multi-trait analysis);
LGG	cis	rs9522267	0.535	rs9515451	chr13:112234382	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.27	-0.32	1.53e-12	Hepatitis;
LGG	trans	rs75804782	0.572	rs77008212	chr2:239307113	A/G	cg01134436	chr17:81009848	B3GNTL1	0.77	6.71	0.3	5.71e-11	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.721	rs13051200	chr21:47701693	A/T	cg05896524	chr21:47604654	C21orf56	0.55	9.62	0.41	4.38e-20	Testicular germ cell tumor;
LGG	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg07245641	chr1:182991651	LAMC1	0.42	9.58	0.41	5.88e-20	Fuchs's corneal dystrophy;
LGG	cis	rs11098499	0.863	rs12502389	chr4:120454191	A/G	cg24375607	chr4:120327624	NA	0.66	10.72	0.45	4.12e-24	Corneal astigmatism;
LGG	cis	rs2735413	0.881	rs12920025	chr16:78083005	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.84	-0.66	3.46e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs3857536	0.813	rs1891599	chr6:66941699	A/G	cg07460842	chr6:66804631	NA	-0.46	-7.89	-0.34	2.15e-14	Blood trace element (Cu levels);
LGG	cis	rs9397585	0.824	rs6902703	chr6:153379662	G/A	cg17707550	chr6:153380415	RGS17	0.62	14.38	0.56	4.86e-39	Body mass index;
LGG	trans	rs1814175	0.630	rs1722019	chr11:49904102	G/A	cg00717180	chr2:96193071	NA	-0.42	-7.62	-0.33	1.46e-13	Height;
LGG	cis	rs12477438	0.798	rs7606635	chr2:99644782	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs72945132	0.678	rs7113595	chr11:70236819	T/C	cg13802316	chr11:70253460	CTTN	-0.65	-8.97	-0.38	7.21e-18	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.68	0.37	6.92e-17	Lung cancer;
LGG	cis	rs16912285	0.591	rs12794505	chr11:24364195	A/G	ch.11.24196551F	chr11:24239977	NA	-0.84	-12.1	-0.49	1.73e-29	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	trans	rs208520	0.874	rs208515	chr6:66945749	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.46	-0.58	8.81e-44	Exhaled nitric oxide output;
LGG	cis	rs1729951	0.546	rs835632	chr3:136676525	A/T	cg12473912	chr3:136751656	NA	0.43	7.62	0.33	1.41e-13	Neuroticism;
LGG	cis	rs9837602	0.529	rs1087198	chr3:99524381	C/T	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.5	-8.43	-0.36	4.55e-16	Breast cancer;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.9	0.42	4.19e-21	Prudent dietary pattern;
LGG	cis	rs2762353	0.526	rs9461203	chr6:25710555	C/T	cg17691542	chr6:26056736	HIST1H1C	-0.4	-7.05	-0.31	6.73e-12	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11798976	chr1:36916164	OSCP1	0.39	7.36	0.32	8.27e-13	Gut microbiome composition (summer);
LGG	cis	rs11800820	0.555	rs6661155	chr1:246628943	C/G	cg16700716	chr1:246684329	NA	-0.4	-7.15	-0.32	3.3e-12	Obesity-related traits;
LGG	cis	rs9308731	0.623	rs6708784	chr2:111927379	A/G	cg26001287	chr2:111877753	BCL2L11	-0.34	-6.87	-0.3	2.13e-11	Chronic lymphocytic leukemia;
LGG	cis	rs7582180	0.629	rs11686842	chr2:100956139	C/T	cg21926883	chr2:100939477	LONRF2	-0.69	-16.38	-0.61	7.05e-48	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs12196377	chr6:86566775	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-10.33	-0.43	1.22e-22	Response to antipsychotic treatment;
LGG	cis	rs13257813	0.727	rs691617	chr8:19028789	A/G	cg15587955	chr8:19026658	NA	-0.47	-7.02	-0.31	7.74e-12	Mean platelet volume;
LGG	cis	rs9467711	0.606	rs34550936	chr6:26361985	A/G	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12701220	0.522	rs1881116	chr7:1053958	C/T	cg23978390	chr7:1156363	C7orf50	0.48	7.65	0.34	1.14e-13	Bronchopulmonary dysplasia;
LGG	cis	rs769267	0.930	rs2301784	chr19:19390749	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	trans	rs7824557	0.564	rs34964435	chr8:11230206	G/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.48	-0.4	1.33e-19	Retinal vascular caliber;
LGG	cis	rs13108904	0.875	rs3822017	chr4:1236312	C/T	cg04863758	chr4:1303710	MAEA	0.41	7.23	0.32	1.98e-12	Obesity-related traits;
LGG	cis	rs875971	0.638	rs801216	chr7:66011667	T/C	cg11764359	chr7:65958608	NA	-0.63	-10.84	-0.45	1.51e-24	Aortic root size;
LGG	cis	rs5758659	0.652	rs133326	chr22:42406885	G/A	cg15557168	chr22:42548783	NA	-0.34	-7.69	-0.34	8.62e-14	Cognitive function;
LGG	cis	rs7172689	1.000	rs67689826	chr15:81546373	A/G	cg11808699	chr15:81528661	IL16	-0.51	-10.31	-0.43	1.45e-22	Inattentive symptoms;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-9.43	-0.4	2.02e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2011503	0.882	rs10401714	chr19:19363630	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.83	0.3	2.65e-11	Bipolar disorder;
LGG	cis	rs8031584	1.000	rs11638409	chr15:31288190	A/C	cg14829155	chr15:31115871	NA	-0.55	-8.95	-0.38	8.52e-18	Huntington's disease progression;
LGG	cis	rs5753037	0.585	rs36572	chr22:30200936	T/C	cg01021169	chr22:30184971	ASCC2	-0.41	-8.33	-0.36	9.31e-16	Type 1 diabetes;
LGG	cis	rs62400317	0.859	rs6919998	chr6:45159289	C/T	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg19077165	chr18:44547161	KATNAL2	-0.68	-13.04	-0.52	2.43e-33	Personality dimensions;
LGG	cis	rs9326248	0.581	rs4938331	chr11:116930682	C/A	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.94	0.45	6.22e-25	Blood protein levels;
LGG	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg06636001	chr8:8085503	FLJ10661	0.52	9.12	0.39	2.3e-18	Neuroticism;
LGG	cis	rs4702718	0.549	rs267951	chr5:10743420	C/T	cg14521931	chr5:10832172	NA	-0.45	-8.71	-0.38	5.43e-17	Obesity-related traits;
LGG	cis	rs7824557	0.602	rs11784458	chr8:11204184	G/A	cg15596359	chr8:11213517	TDH	-0.41	-8.34	-0.36	8.67e-16	Retinal vascular caliber;
LGG	trans	rs9467711	0.606	rs34781270	chr6:26593037	A/G	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs17756712	0.697	rs2294669	chr6:625673	C/G	cg14374089	chr6:596013	EXOC2	0.48	7.87	0.34	2.54e-14	Vertical cup-disc ratio;
LGG	cis	rs7223966	1.000	rs15637	chr17:61772050	C/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.66	0.34	1.09e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2836974	0.568	rs428602	chr21:40547004	A/G	cg11644478	chr21:40555479	PSMG1	0.75	13.76	0.54	2.23e-36	Cognitive function;
LGG	cis	rs9467773	1.000	rs9467791	chr6:26562486	A/G	cg09904177	chr6:26538194	HMGN4	-0.77	-16.72	-0.61	1.86e-49	Intelligence (multi-trait analysis);
LGG	cis	rs6429082	0.806	rs2382570	chr1:235570523	G/A	cg26050004	chr1:235667680	B3GALNT2	-0.44	-7.38	-0.32	7.25e-13	Adiposity;
LGG	cis	rs425535	0.757	rs164617	chr4:74796915	A/G	cg01447579	chr4:74847100	PF4	0.54	6.67	0.3	7.37e-11	Blood protein levels;
LGG	trans	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.53	0.44	2.15e-23	Ulcerative colitis;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg01171360	chr6:293285	DUSP22	-0.58	-9.6	-0.41	5.01e-20	Menopause (age at onset);
LGG	cis	rs769267	0.899	rs67720221	chr19:19440864	C/T	cg01262667	chr19:19385393	TM6SF2	-0.46	-11.51	-0.47	3.77e-27	Tonsillectomy;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg05368731	chr17:41323189	NBR1	0.86	16.38	0.61	6.83e-48	Menopause (age at onset);
LGG	cis	rs757978	0.810	rs1468445	chr2:242395554	A/G	cg10173475	chr2:242152697	ANO7	-0.55	-7.27	-0.32	1.5e-12	Chronic lymphocytic leukemia;
LGG	cis	rs778371	0.958	rs778341	chr2:233728801	C/A	cg08000102	chr2:233561755	GIGYF2	-0.62	-9.33	-0.4	4.43e-19	Schizophrenia;
LGG	cis	rs10186029	0.676	rs35922168	chr2:213949018	T/C	cg08319019	chr2:214017104	IKZF2	0.48	8.38	0.36	6.27e-16	Systemic sclerosis;
LGG	cis	rs17376456	0.877	rs28637444	chr5:93495548	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.25	0.43	2.38e-22	Diabetic retinopathy;
LGG	cis	rs13118159	0.509	rs4974554	chr4:1356967	A/C	cg02071572	chr4:1403502	NA	0.41	7.14	0.32	3.58e-12	Longevity;
LGG	cis	rs17401966	0.898	rs12757288	chr1:10323921	T/C	cg15208524	chr1:10270712	KIF1B	0.44	7.99	0.35	1.11e-14	Hepatocellular carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11515196	chr15:44829065	EIF3J	0.42	6.99	0.31	9.65e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2130392	0.962	rs7660116	chr4:185626542	G/A	cg04058563	chr4:185651563	MLF1IP	0.45	9.58	0.41	5.84e-20	Kawasaki disease;
LGG	cis	rs12421382	0.659	rs979603	chr11:109384996	A/G	cg27471124	chr11:109292789	C11orf87	-0.48	-9.54	-0.41	8.06e-20	Schizophrenia;
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	1.07e-29	Prudent dietary pattern;
LGG	cis	rs4925325	0.956	rs1776263	chr20:60515820	A/G	cg03235661	chr20:60525775	NA	-0.32	-7.36	-0.32	8.19e-13	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs17159950	chr10:875287	T/G	cg20503657	chr10:835505	NA	0.76	10.51	0.44	2.55e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs986417	0.748	rs10142401	chr14:61039403	A/G	cg27398547	chr14:60952738	C14orf39	0.63	6.78	0.3	3.57e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs561341	0.883	rs2074102	chr17:30228884	G/A	cg00745463	chr17:30367425	LRRC37B	-0.54	-7.46	-0.33	4.38e-13	Hip circumference adjusted for BMI;
LGG	cis	rs9902453	0.730	rs4583306	chr17:28538715	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.58	-11.13	-0.46	1.12e-25	Coffee consumption (cups per day);
LGG	cis	rs11758351	1.000	rs16891405	chr6:26204506	A/G	cg23601095	chr6:26197514	HIST1H3D	0.73	9.29	0.4	6.2e-19	Gout;Renal underexcretion gout;
LGG	cis	rs79349575	0.783	rs2112617	chr17:46977125	G/A	cg22482690	chr17:47019901	SNF8	0.35	6.72	0.3	5.39e-11	Type 2 diabetes;
LGG	cis	rs4332037	0.950	rs11767515	chr7:1941051	C/T	cg12591125	chr7:1885375	MAD1L1	0.47	6.85	0.3	2.42e-11	Bipolar disorder;
LGG	cis	rs1421811	0.606	rs10057069	chr5:32716589	A/G	cg16267343	chr5:32710456	NPR3	0.6	8.47	0.37	3.19e-16	Blood pressure;
LGG	cis	rs61931739	0.853	rs7137146	chr12:34102394	G/A	cg06521331	chr12:34319734	NA	0.41	7.24	0.32	1.93e-12	Morning vs. evening chronotype;
LGG	trans	rs11875185	0.510	rs113436399	chr18:55620745	A/G	cg15513957	chr14:69354734	ACTN1	-0.92	-9.14	-0.39	2.04e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg26384229	chr12:38710491	ALG10B	-0.8	-16.54	-0.61	1.29e-48	Morning vs. evening chronotype;
LGG	cis	rs62238980	0.614	rs116866390	chr22:32533595	G/A	cg02631450	chr22:32366979	NA	1.03	9.44	0.4	1.9e-19	Childhood ear infection;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg05377417	chr17:59940892	BRIP1	0.4	7.12	0.31	4.03e-12	Menarche (age at onset);
LGG	cis	rs1799949	0.965	rs4793237	chr17:41436595	A/T	cg23758822	chr17:41437982	NA	0.87	15.56	0.59	3.22e-44	Menopause (age at onset);
LGG	cis	rs7527798	0.592	rs11118337	chr1:207852693	G/C	cg09232269	chr1:207846808	CR1L	-0.38	-7.24	-0.32	1.92e-12	Erythrocyte sedimentation rate;
LGG	cis	rs1385374	0.858	rs11059927	chr12:129294333	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.62	6.83	0.3	2.68e-11	Systemic lupus erythematosus;
LGG	cis	rs13190036	1.000	rs13185316	chr5:176640340	T/C	cg06733329	chr5:176740039	MXD3	0.5	6.9	0.31	1.7e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs9747201	1.000	rs8082212	chr17:80175100	G/C	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg23335576	chr14:104009727	NA	0.39	6.67	0.3	7.15e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4478037	0.915	rs78193453	chr3:33141680	G/T	cg19404215	chr3:33155277	CRTAP	1.0	11.2	0.46	6.53e-26	Major depressive disorder;
LGG	cis	rs62238980	0.520	rs77155221	chr22:32514092	G/A	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs908922	0.676	rs2105117	chr1:152484129	G/A	cg09873164	chr1:152488093	CRCT1	0.62	15.2	0.58	1.34e-42	Hair morphology;
LGG	cis	rs9322193	0.772	rs7738696	chr6:150170121	A/G	cg08621203	chr6:150244597	RAET1G	0.48	8.5	0.37	2.7e-16	Lung cancer;
LGG	cis	rs919433	0.679	rs6757669	chr2:198530355	C/T	cg00792783	chr2:198669748	PLCL1	0.55	9.06	0.39	3.71e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9611519	0.780	rs1535048	chr22:41684093	C/T	cg03806693	chr22:41940476	POLR3H	-0.7	-11.37	-0.47	1.41e-26	Neuroticism;
LGG	cis	rs7044106	0.762	rs1530370	chr9:123424552	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.67	0.61	3.29e-49	Hip circumference adjusted for BMI;
LGG	cis	rs16854884	0.586	rs6796460	chr3:143756367	G/A	cg06585982	chr3:143692056	C3orf58	0.68	12.32	0.5	2.39e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs3768617	0.510	rs3765522	chr1:183077618	C/T	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs9487094	0.961	rs12193493	chr6:109692776	T/C	cg01125227	chr6:109776195	MICAL1	0.51	8.82	0.38	2.41e-17	Height;
LGG	cis	rs2120019	0.638	rs12050628	chr15:75333494	G/A	cg17294928	chr15:75287854	SCAMP5	1.0	19.57	0.67	1.4e-62	Blood trace element (Zn levels);
LGG	cis	rs9916302	0.904	rs68178216	chr17:37526241	A/C	cg07936489	chr17:37558343	FBXL20	0.83	15.42	0.58	1.31e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.83	-9.87	-0.42	5.64e-21	Schizophrenia;
LGG	cis	rs7223966	0.621	rs9906747	chr17:61639694	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.54	-8.19	-0.36	2.54e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2635047	0.967	rs12960378	chr18:44614090	A/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.59	10.34	0.43	1.13e-22	Educational attainment;
LGG	cis	rs10254118	0.757	rs13241123	chr7:133135507	A/T	cg10665199	chr7:133106180	EXOC4	0.58	9.39	0.4	2.67e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	0.868	rs6107019	chr20:25233985	C/T	cg06421707	chr20:25228305	PYGB	0.48	10.66	0.44	6.87e-24	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs11792861	0.926	rs7046725	chr9:111882729	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.55	8.58	0.37	1.41e-16	Menarche (age at onset);
LGG	cis	rs11885103	0.791	rs2685235	chr2:591205	A/G	cg21195176	chr2:593345	NA	0.42	7.87	0.34	2.48e-14	Heschl's gyrus morphology;
LGG	cis	rs61931739	0.500	rs11053210	chr12:34461771	A/G	cg06521331	chr12:34319734	NA	0.56	9.74	0.41	1.67e-20	Morning vs. evening chronotype;
LGG	cis	rs7493	1.000	rs1034809	chr7:95051652	G/A	cg08461772	chr7:95026248	PON3	0.37	8.08	0.35	5.87e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7618915	1.000	rs3844291	chr3:52341215	A/C	cg18404041	chr3:52824283	ITIH1	-0.47	-8.19	-0.36	2.61e-15	Bipolar disorder;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.67	0.82	1.35e-113	Prudent dietary pattern;
LGG	cis	rs11583043	0.708	rs1060481	chr1:101546699	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.51	8.0	0.35	1.01e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs8114671	0.935	rs945960	chr20:33762854	A/G	cg07148914	chr20:33460835	GGT7	0.43	6.92	0.31	1.55e-11	Height;
LGG	cis	rs644799	1.000	rs566204	chr11:95580926	G/A	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.25	0.7	2e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs117285117	chr16:89910250	T/G	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	cis	rs5769765	0.908	rs56351880	chr22:50316597	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.88	-12.54	-0.5	3.01e-31	Schizophrenia;
LGG	cis	rs897080	0.515	rs1067346	chr2:44618811	C/A	cg00619915	chr2:44497795	NA	-0.48	-6.77	-0.3	4.01e-11	Height;
LGG	cis	rs2760061	0.583	rs708123	chr1:228220495	A/G	cg02753203	chr1:228287806	NA	0.96	21.33	0.7	8.11e-71	Diastolic blood pressure;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg17554472	chr22:41940697	POLR3H	-0.48	-6.9	-0.31	1.67e-11	Vitiligo;
LGG	cis	rs6747952	0.899	rs1374387	chr2:239085687	A/C	cg17459225	chr2:239074497	NA	0.43	7.84	0.34	3.08e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs651907	0.514	rs34301719	chr3:101417993	C/T	cg12386194	chr3:101231763	SENP7	0.45	7.83	0.34	3.39e-14	Colorectal cancer;
LGG	cis	rs7208859	0.673	rs9899943	chr17:29223925	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs523522	0.962	rs651627	chr12:121009198	C/T	cg12219531	chr12:120966889	COQ5	0.65	10.91	0.45	8.27e-25	High light scatter reticulocyte count;
LGG	cis	rs910316	1.000	rs11159117	chr14:75584867	C/T	cg08847533	chr14:75593920	NEK9	0.63	12.2	0.49	7.04e-30	Height;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.72e-12	Height;
LGG	cis	rs7829975	0.511	rs2948286	chr8:8130160	A/G	cg06636001	chr8:8085503	FLJ10661	0.65	12.95	0.52	5.93e-33	Mood instability;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.14	0.52	9.77e-34	Prudent dietary pattern;
LGG	cis	rs12618769	0.543	rs6753380	chr2:99129040	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.5	0.37	2.57e-16	Bipolar disorder;
LGG	cis	rs2075671	0.903	rs4729602	chr7:100260591	T/C	cg03098644	chr7:100410630	EPHB4	0.47	7.0	0.31	9.26e-12	Other erythrocyte phenotypes;
LGG	cis	rs10937275	0.624	rs10513810	chr3:186667885	A/G	cg24050613	chr3:186648279	ST6GAL1	0.78	8.4	0.36	5.7e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1153858	1.000	rs12591058	chr15:45640172	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.74	0.73	2.04e-77	Homoarginine levels;
LGG	cis	rs2354432	0.556	rs7520661	chr1:146793149	A/G	cg25205988	chr1:146714368	CHD1L	-1.41	-14.48	-0.56	1.84e-39	Mitochondrial DNA levels;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg06221963	chr1:154839813	KCNN3	-0.5	-10.0	-0.42	1.89e-21	Prostate cancer;
LGG	cis	rs10504229	0.683	rs57866073	chr8:58139138	A/G	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2243480	0.706	rs6460257	chr7:65196780	C/T	cg13147721	chr7:65941812	NA	-0.65	-8.73	-0.38	4.76e-17	Diabetic kidney disease;
LGG	cis	rs2439831	0.850	rs28891769	chr15:44072860	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.74	0.45	3.54e-24	Lung cancer in ever smokers;
LGG	trans	rs2243480	1.000	rs1167613	chr7:65487439	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs62439840	chr6:149995775	G/A	cg16507663	chr6:150244633	RAET1G	0.46	8.64	0.37	9.01e-17	Lung cancer;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.79	11.97	0.49	5.76e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.929	rs4721217	chr7:1973579	C/T	cg05863683	chr7:1912471	MAD1L1	0.45	8.59	0.37	1.34e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs6601327	0.550	rs4422774	chr8:9522011	A/G	cg02002194	chr4:3960332	NA	0.39	6.76	0.3	4.29e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1971762	0.527	rs1683151	chr12:53946219	C/G	cg06632207	chr12:54070931	ATP5G2	-0.22	-6.83	-0.3	2.6e-11	Height;
LGG	cis	rs7833790	0.777	rs6473301	chr8:82691340	A/G	cg23324259	chr8:82754387	SNX16	-0.43	-6.86	-0.3	2.27e-11	Diastolic blood pressure;
LGG	cis	rs2836974	0.568	rs8130795	chr21:40549983	T/A	cg06238570	chr21:40685208	BRWD1	0.53	8.73	0.38	4.74e-17	Cognitive function;
LGG	cis	rs2130392	0.962	rs13132498	chr4:185611454	T/C	cg04058563	chr4:185651563	MLF1IP	-0.49	-10.44	-0.44	4.61e-23	Kawasaki disease;
LGG	cis	rs11122272	0.735	rs2749705	chr1:231526696	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.08	-0.46	1.88e-25	Hemoglobin concentration;
LGG	cis	rs17023223	0.581	rs10923750	chr1:119650795	T/G	cg05756136	chr1:119680316	WARS2	-0.43	-8.42	-0.36	4.77e-16	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs2303745	0.589	rs10401700	chr19:17397700	A/C	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.25	-0.39	8.21e-19	Systemic lupus erythematosus;
LGG	cis	rs9911578	1.000	rs12938772	chr17:56776320	T/C	cg05425664	chr17:57184151	TRIM37	-0.64	-10.22	-0.43	3.08e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7503807	0.515	rs869190	chr17:78668593	G/T	cg06872548	chr17:78716983	RPTOR	0.37	6.89	0.3	1.84e-11	Obesity;
LGG	cis	rs7267979	0.565	rs6107060	chr20:25592476	C/G	cg06421707	chr20:25228305	PYGB	0.37	7.54	0.33	2.42e-13	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6539288	0.677	rs1348566	chr12:107325648	C/T	cg15890332	chr12:107067104	RFX4	0.31	8.18	0.36	2.84e-15	Total body bone mineral density;
LGG	cis	rs7811142	0.945	rs6955362	chr7:100056166	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	15.25	0.58	8.01e-43	Platelet count;
LGG	trans	rs1997103	0.954	rs7811098	chr7:55413012	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.36e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs796364	1.000	rs1658807	chr2:200767512	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	cis	rs1904096	0.506	rs12511433	chr4:95162425	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.58	-11.02	-0.46	3.01e-25	Type 2 diabetes;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg01758539	chr8:56981229	RPS20	-0.39	-6.8	-0.3	3.32e-11	Apolipoprotein A-IV levels;
LGG	cis	rs9796	0.624	rs9920619	chr15:41318845	A/G	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.33	-0.43	1.2e-22	Menopause (age at onset);
LGG	cis	rs1909881	0.504	rs16917761	chr8:96498076	C/T	cg04203453	chr8:96504381	NA	-0.75	-11.49	-0.47	4.78e-27	Obesity-related traits;
LGG	cis	rs7937682	0.883	rs659529	chr11:111436896	T/A	cg09085632	chr11:111637200	PPP2R1B	-1.07	-23.1	-0.73	4.19e-79	Primary sclerosing cholangitis;
LGG	trans	rs36715	0.953	rs36706	chr5:127556698	C/A	cg16011800	chr17:1958478	HIC1	-0.48	-7.08	-0.31	5.53e-12	Breast cancer;
LGG	cis	rs1005277	0.579	rs1740749	chr10:38521646	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2587949	0.638	rs2629233	chr3:4195011	T/C	cg16519197	chr3:4211558	NA	-0.34	-7.09	-0.31	4.95e-12	Periodontitis (DPAL);
LGG	cis	rs638893	0.578	rs500254	chr11:118678780	A/G	cg22253036	chr11:118662786	DDX6	-0.5	-7.79	-0.34	4.57e-14	Vitiligo;
LGG	trans	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg10840412	chr1:235813424	GNG4	0.5	6.78	0.3	3.64e-11	Neuroticism;
LGG	trans	rs7824557	0.724	rs2572398	chr8:11178093	A/C	cg02002194	chr4:3960332	NA	-0.5	-9.78	-0.41	1.21e-20	Retinal vascular caliber;
LGG	cis	rs1957429	0.522	rs76721513	chr14:65403891	C/G	cg23373153	chr14:65346875	NA	-1.05	-9.98	-0.42	2.28e-21	Pediatric areal bone mineral density (radius);
LGG	cis	rs17401966	0.931	rs2185252	chr1:10415912	T/C	cg15208524	chr1:10270712	KIF1B	0.43	7.41	0.33	6.01e-13	Hepatocellular carcinoma;
LGG	cis	rs4356975	0.522	rs7693957	chr4:69971796	T/A	cg27372994	chr4:70080453	UGT2B11	0.37	6.66	0.3	7.82e-11	Obesity-related traits;
LGG	cis	rs875971	0.540	rs1723268	chr7:65473080	A/C	cg11987759	chr7:65425863	GUSB	-0.41	-8.01	-0.35	9.6e-15	Aortic root size;
LGG	cis	rs2075371	0.932	rs34664116	chr7:133984878	G/A	cg20476274	chr7:133979776	SLC35B4	0.74	14.13	0.55	5.86e-38	Mean platelet volume;
LGG	trans	rs7939886	0.920	rs57873399	chr11:56059112	T/A	cg15704280	chr7:45808275	SEPT13	0.82	7.62	0.33	1.47e-13	Myopia (pathological);
LGG	cis	rs10479542	0.766	rs7733389	chr5:178974997	C/T	cg21226059	chr5:178986404	RUFY1	0.45	8.31	0.36	1.1e-15	Lung cancer;
LGG	cis	rs2836950	0.545	rs11700449	chr21:40522419	A/T	cg11890956	chr21:40555474	PSMG1	-0.74	-12.74	-0.51	4.27e-32	Menarche (age at onset);
LGG	cis	rs12618769	0.597	rs3769730	chr2:99101453	T/C	cg18455616	chr2:99124870	INPP4A	0.29	8.53	0.37	2.15e-16	Bipolar disorder;
LGG	cis	rs13421350	0.579	rs2293647	chr2:173344680	G/T	cg15021238	chr2:173305865	ITGA6	0.74	8.09	0.35	5.26e-15	Diabetic kidney disease;
LGG	cis	rs12618769	0.520	rs11892744	chr2:99237792	C/T	cg18455616	chr2:99124870	INPP4A	0.26	6.86	0.3	2.16e-11	Bipolar disorder;
LGG	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg22467129	chr15:76604101	ETFA	-0.42	-7.1	-0.31	4.81e-12	Blood metabolite levels;
LGG	trans	rs2548003	0.518	rs967080	chr5:28755831	T/C	cg12623145	chr2:97778927	ANKRD36	0.47	6.67	0.3	7.38e-11	Hip geometry;
LGG	cis	rs892961	0.932	rs66886702	chr17:75412714	G/A	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs13108904	0.539	rs11247997	chr4:1361057	T/C	cg06654118	chr4:1303317	MAEA	0.47	7.79	0.34	4.54e-14	Obesity-related traits;
LGG	cis	rs11096990	0.855	rs2566169	chr4:39152040	G/T	cg24403649	chr4:39172243	NA	-0.48	-7.75	-0.34	5.89e-14	Cognitive function;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26627486	chr7:2595589	C7orf27	0.43	7.12	0.31	4.08e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9611565	0.592	rs4481089	chr22:41980892	T/C	cg06481639	chr22:41940642	POLR3H	-0.49	-7.0	-0.31	8.77e-12	Vitiligo;
LGG	cis	rs524281	1.000	rs472518	chr11:65851902	A/G	cg16950941	chr11:66035639	RAB1B	0.49	7.74	0.34	6.32e-14	Electroencephalogram traits;
LGG	cis	rs4865875	0.901	rs4074332	chr5:54141187	G/T	cg22421804	chr5:54100067	NA	-0.45	-6.65	-0.3	8.22e-11	Sense of smell;
LGG	trans	rs1814175	0.645	rs11040535	chr11:49808669	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.71	-0.68	2.95e-63	Height;
LGG	cis	rs5769765	1.000	rs4597652	chr22:50270570	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs79839061	0.610	rs3775122	chr4:893287	A/G	cg07828340	chr4:882639	GAK	-0.93	-9.96	-0.42	2.65e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12980942	0.810	rs8105901	chr19:41792092	T/A	cg25627403	chr19:41769009	HNRNPUL1	0.6	7.67	0.34	1.05e-13	Coronary artery disease;
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg09033563	chr22:24373618	LOC391322	0.54	8.99	0.39	6.26e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9399135	0.967	rs13199205	chr6:135286505	T/C	cg22676075	chr6:135203613	NA	0.36	6.65	0.3	8.35e-11	Red blood cell count;
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg23939001	chr4:940644	TMEM175	0.73	18.58	0.65	5.7e-58	Sjögren's syndrome;
LGG	cis	rs4819052	0.851	rs9974891	chr21:46680767	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.5	8.34	0.36	8.82e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2075371	1.000	rs1862051	chr7:133981021	G/A	cg11752832	chr7:134001865	SLC35B4	0.59	10.67	0.44	6.44e-24	Mean platelet volume;
LGG	trans	rs9354308	0.868	rs9363457	chr6:66549080	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.28	-0.36	1.29e-15	Metabolite levels;
LGG	trans	rs11098499	0.866	rs3756156	chr4:120524841	G/A	cg25214090	chr10:38739885	LOC399744	0.64	11.32	0.47	2.07e-26	Corneal astigmatism;
LGG	cis	rs9527	0.590	rs4917992	chr10:104786313	G/A	cg05308233	chr10:104796373	CNNM2	-0.32	-7.13	-0.31	3.9e-12	Arsenic metabolism;
LGG	cis	rs875971	1.000	rs6958271	chr7:65979331	A/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.73	-0.38	4.64e-17	Aortic root size;
LGG	cis	rs4774899	0.934	rs12898356	chr15:57497722	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-6.87	-0.3	2.05e-11	Urinary tract infection frequency;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg11062466	chr8:58055876	NA	0.54	8.82	0.38	2.43e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2739330	0.760	rs5751761	chr22:24243736	A/G	cg25703541	chr22:24373054	LOC391322	0.87	16.58	0.61	8.67e-49	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6089829	0.855	rs4809459	chr20:61661345	C/T	cg03213289	chr20:61660250	NA	0.65	14.15	0.55	4.95e-38	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs4555082	0.957	rs2816627	chr14:105736109	A/G	cg13114125	chr14:105738426	BRF1	-0.87	-17.6	-0.63	1.81e-53	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9811920	0.809	rs796976	chr3:99621002	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.5	8.92	0.38	1.1e-17	Axial length;
LGG	cis	rs3805663	1.000	rs474853	chr5:134365091	T/C	cg24576358	chr5:134350122	NA	0.35	7.36	0.32	8.61e-13	Testicular germ cell tumor;
LGG	cis	rs4356932	1.000	rs4550961	chr4:76978693	A/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.66	-0.3	7.69e-11	Blood protein levels;
LGG	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg10189774	chr4:17578691	LAP3	0.38	6.8	0.3	3.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7923609	0.756	rs7077256	chr10:65336185	A/G	cg02276361	chr10:65351566	REEP3	-0.31	-6.89	-0.31	1.8e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7084402	0.967	rs1658434	chr10:60328756	G/C	cg07615347	chr10:60278583	BICC1	0.63	17.77	0.64	2.95e-54	Refractive error;
LGG	cis	rs7572733	0.534	rs1518365	chr2:198809410	T/C	cg00792783	chr2:198669748	PLCL1	0.68	11.1	0.46	1.47e-25	Dermatomyositis;
LGG	cis	rs1018697	0.518	rs284846	chr10:104557290	T/C	cg04362960	chr10:104952993	NT5C2	-0.63	-9.98	-0.42	2.22e-21	Colorectal adenoma (advanced);
LGG	cis	rs7811142	0.779	rs28680963	chr7:99905475	C/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.04	14.38	0.56	5.24e-39	Platelet count;
LGG	cis	rs8078723	1.000	rs4794824	chr17:38179290	G/A	cg17467752	chr17:38218738	THRA	0.73	13.75	0.54	2.58e-36	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs67133203	0.665	rs77706234	chr12:51475604	C/A	cg14688905	chr12:51403056	SLC11A2	0.68	10.41	0.44	6.12e-23	Urinary tract infection frequency;
LGG	cis	rs1008375	0.932	rs13109475	chr4:17677565	C/G	cg18681998	chr4:17616180	MED28	-0.83	-17.53	-0.63	3.81e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs75920871	0.925	rs61903426	chr11:116968268	C/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.83	-0.3	2.66e-11	Subjective well-being;
LGG	cis	rs9875589	0.509	rs1601868	chr3:14065450	T/C	cg19554555	chr3:13937349	NA	-0.56	-10.06	-0.42	1.19e-21	Ovarian reserve;
LGG	cis	rs2404602	0.647	rs35940181	chr15:77180019	G/A	cg15268244	chr15:77196840	NA	0.47	9.98	0.42	2.18e-21	Blood metabolite levels;
LGG	cis	rs8067545	0.750	rs4925080	chr17:19991838	T/A	cg09818912	chr17:20140352	CYTSB	-0.29	-6.82	-0.3	2.84e-11	Schizophrenia;
LGG	cis	rs897984	0.762	rs7206511	chr16:30950352	G/A	cg00531865	chr16:30841666	NA	0.56	11.98	0.49	5.17e-29	Dementia with Lewy bodies;
LGG	cis	rs1552244	0.882	rs35056669	chr3:10014171	C/T	cg08888203	chr3:10149979	C3orf24	0.51	8.59	0.37	1.35e-16	Alzheimer's disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg12275487	chr18:76397672	NA	0.42	7.81	0.34	3.92e-14	Menarche (age at onset);
LGG	cis	rs1003719	0.715	rs9980353	chr21:38558812	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.78	-15.14	-0.58	2.41e-42	Eye color traits;
LGG	cis	rs10214930	0.697	rs2080246	chr7:27569704	G/A	cg22168087	chr7:27702803	HIBADH	0.46	7.0	0.31	8.99e-12	Hypospadias;
LGG	cis	rs2976388	0.556	rs4736321	chr8:143822194	C/T	cg06565975	chr8:143823917	SLURP1	-0.57	-13.92	-0.54	4.98e-37	Urinary tract infection frequency;
LGG	cis	rs9926296	0.568	rs1230	chr16:89804855	A/G	cg27121462	chr16:89883253	FANCA	-0.61	-10.82	-0.45	1.72e-24	Vitiligo;
LGG	cis	rs34172651	0.837	rs1978451	chr16:24818286	C/G	cg00339695	chr16:24857497	SLC5A11	0.34	6.68	0.3	6.75e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.749	rs4142759	chr2:46783890	A/G	cg02822958	chr2:46747628	ATP6V1E2	0.47	7.2	0.32	2.44e-12	Height;
LGG	cis	rs2718058	0.630	rs2722290	chr7:37820403	C/G	cg24998770	chr7:37888106	TXNDC3	0.44	7.17	0.32	3.02e-12	Alzheimer's disease (late onset);
LGG	cis	rs362296	0.661	rs3095077	chr4:3265710	A/G	cg06533319	chr4:3265114	C4orf44	-0.53	-11.06	-0.46	2.2e-25	Parental longevity (mother's age at death);
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.16	0.43	4.92e-22	Prudent dietary pattern;
LGG	cis	rs7937682	0.883	rs1611989	chr11:111456299	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.15	-0.72	1.23e-74	Primary sclerosing cholangitis;
LGG	cis	rs2839186	0.814	rs13052376	chr21:47707403	G/C	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	trans	rs6952808	0.792	rs12531315	chr7:1953650	C/G	cg24247370	chr13:99142703	STK24	-0.39	-7.17	-0.32	3.06e-12	Bipolar disorder and schizophrenia;
LGG	trans	rs7824557	0.564	rs35009431	chr8:11232788	G/A	cg02002194	chr4:3960332	NA	0.45	7.95	0.35	1.46e-14	Retinal vascular caliber;
LGG	cis	rs250677	0.687	rs40149	chr5:148444275	A/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.26	-0.32	1.67e-12	Breast cancer;
LGG	cis	rs7953249	0.502	rs1169294	chr12:121426594	G/A	cg14101638	chr12:121416612	HNF1A	0.43	8.97	0.38	7.68e-18	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs694739	0.654	rs10897488	chr11:64140806	T/C	cg22916017	chr11:64110731	CCDC88B	0.47	9.45	0.4	1.66e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7769051	0.522	rs6928933	chr6:133116073	G/A	cg07930552	chr6:133119739	C6orf192	1.13	9.71	0.41	2.01e-20	Type 2 diabetes nephropathy;
LGG	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2836974	0.568	rs4816620	chr21:40613786	A/G	cg11644478	chr21:40555479	PSMG1	-0.73	-13.25	-0.52	3.39e-34	Cognitive function;
LGG	cis	rs13082711	0.911	rs2887926	chr3:27494475	T/C	cg02860705	chr3:27208620	NA	0.69	12.53	0.5	3.33e-31	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7219021	0.705	rs11869991	chr17:47027763	C/T	cg16584676	chr17:46985605	UBE2Z	-0.43	-7.03	-0.31	7.41e-12	Schizophrenia or bipolar disorder;
LGG	cis	rs11877825	0.826	rs8088257	chr18:10579953	T/G	cg25239095	chr18:10589360	NA	0.48	8.74	0.38	4.33e-17	Gut microbiota (bacterial taxa);
LGG	cis	rs12042938	0.905	rs823160	chr1:231776636	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.6	10.96	0.45	5.43e-25	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs73416724	1.000	rs111408004	chr6:43326139	T/A	cg26312998	chr6:43337775	ZNF318	0.6	8.45	0.37	3.75e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs5769707	0.967	rs2051626	chr22:50008973	G/A	cg06623630	chr22:50017776	C22orf34	-0.34	-7.19	-0.32	2.54e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs8180040	0.903	rs11710013	chr3:47296921	T/C	cg16586182	chr3:47516702	SCAP	-0.78	-15.3	-0.58	4.48e-43	Colorectal cancer;
LGG	cis	rs2071403	0.933	rs1972113	chr2:1407046	T/C	cg06500727	chr2:1417164	TPO	-0.49	-9.31	-0.4	5.16e-19	Thyroid peroxidase antibody positivity;
LGG	cis	rs9393692	0.905	rs9393694	chr6:26279296	T/C	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.47e-20	Educational attainment;
LGG	cis	rs9611565	0.918	rs9611562	chr22:41760172	T/G	cg17376030	chr22:41985996	PMM1	0.51	8.14	0.35	3.79e-15	Vitiligo;
LGG	cis	rs151997	0.962	rs39955	chr5:50187501	C/A	cg06027927	chr5:50259733	NA	0.68	11.01	0.46	3.48e-25	Callous-unemotional behaviour;
LGG	cis	rs112591243	0.685	rs115448966	chr21:47988420	G/A	cg10657630	chr21:48055338	PRMT2	0.85	7.38	0.32	7.57e-13	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg04267008	chr7:1944627	MAD1L1	-0.56	-9.49	-0.4	1.25e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg04568710	chr12:38710424	ALG10B	0.34	7.19	0.32	2.55e-12	Morning vs. evening chronotype;
LGG	cis	rs2777491	0.915	rs28578057	chr15:41621921	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg12402800	chr5:56204917	C5orf35	0.43	6.74	0.3	4.61e-11	Initial pursuit acceleration;
LGG	cis	rs9467711	0.538	rs9467632	chr6:25889706	A/G	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.7	6.75	0.3	4.52e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.27	0.53	2.65e-34	Prudent dietary pattern;
LGG	cis	rs6448317	0.906	rs6448313	chr4:24905088	G/A	cg21108841	chr4:24914750	CCDC149	0.52	7.22	0.32	2.09e-12	Heschl's gyrus morphology;
LGG	cis	rs6065	0.618	rs16954342	chr17:4907103	G/A	cg16045459	chr17:4872488	CAMTA2;SPAG7	-0.6	-7.79	-0.34	4.52e-14	Platelet count;
LGG	cis	rs7904985	1.000	rs7084928	chr10:88122516	C/T	cg07322936	chr10:88137208	NA	-0.47	-7.15	-0.32	3.45e-12	Barrett's esophagus;
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.59	-10.28	-0.43	1.87e-22	Obesity-related traits;
LGG	trans	rs61931739	0.824	rs406753	chr12:34117408	A/G	cg26384229	chr12:38710491	ALG10B	0.63	12.52	0.5	3.68e-31	Morning vs. evening chronotype;
LGG	cis	rs17767392	0.957	rs36057816	chr14:71760546	A/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.46	0.4	1.62e-19	Mitral valve prolapse;
LGG	cis	rs6141769	0.542	rs28542091	chr20:31301402	T/C	cg13636640	chr20:31349939	DNMT3B	-0.46	-6.83	-0.3	2.71e-11	Subjective well-being;
LGG	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg04990556	chr1:26633338	UBXN11	-0.49	-8.18	-0.36	2.84e-15	Granulocyte percentage of myeloid white cells;
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.8	-0.3	3.26e-11	Total body bone mineral density;
LGG	trans	rs1908814	0.516	rs13252853	chr8:11792974	T/C	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	Neuroticism;
LGG	cis	rs6964587	0.967	rs7786031	chr7:91649001	T/G	cg17063962	chr7:91808500	NA	0.47	8.53	0.37	2.1e-16	Breast cancer;
LGG	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg13147721	chr7:65941812	NA	-0.83	-10.08	-0.42	9.88e-22	Diabetic kidney disease;
LGG	cis	rs4665809	1.000	rs4665811	chr2:26260017	A/G	cg22920501	chr2:26401640	FAM59B	-0.39	-7.84	-0.34	3.08e-14	Gut microbiome composition (summer);
LGG	cis	rs9309473	1.000	rs10187416	chr2:73713741	T/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.33	-0.32	1e-12	Metabolite levels;
LGG	cis	rs6938	0.563	rs12917376	chr15:75116167	C/T	cg17294928	chr15:75287854	SCAMP5	0.63	11.53	0.47	3.34e-27	Breast cancer;
LGG	cis	rs2243480	1.000	rs160642	chr7:65558373	C/T	cg18252515	chr7:66147081	NA	-1.37	-20.19	-0.68	1.79e-65	Diabetic kidney disease;
LGG	trans	rs6601327	0.663	rs12543346	chr8:9655823	C/G	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.78e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7129556	0.775	rs11237263	chr11:77378805	A/G	cg12586386	chr11:77299805	AQP11	0.43	7.09	0.31	5.04e-12	Weight loss (gastric bypass surgery);
LGG	trans	rs7819412	0.715	rs2409727	chr8:11043236	C/T	cg02002194	chr4:3960332	NA	0.39	7.16	0.32	3.21e-12	Triglycerides;
LGG	cis	rs9303280	0.773	rs4795397	chr17:38023745	A/G	cg00129232	chr17:37814104	STARD3	-0.47	-8.88	-0.38	1.51e-17	Self-reported allergy;
LGG	cis	rs1799949	1.000	rs3950989	chr17:41237953	G/A	cg25072359	chr17:41440525	NA	0.51	9.76	0.41	1.37e-20	Menopause (age at onset);
LGG	cis	rs11096990	0.593	rs35552004	chr4:39172534	C/T	cg24403649	chr4:39172243	NA	0.4	7.27	0.32	1.52e-12	Cognitive function;
LGG	cis	rs6088580	0.634	rs4911152	chr20:32955024	T/C	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.19	-0.36	2.54e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg00121148	chr3:113603874	GRAMD1C	0.41	7.12	0.31	4.27e-12	Menarche (age at onset);
LGG	cis	rs7044106	0.762	rs12003646	chr9:123470621	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.24	0.32	1.88e-12	Hip circumference adjusted for BMI;
LGG	trans	rs459571	0.959	rs461462	chr9:136911272	C/T	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.65	-11.1	-0.46	1.59e-25	Platelet distribution width;
LGG	cis	rs16837677	1.000	rs9330271	chr1:156747138	C/T	cg14991358	chr1:156767203	PRCC	-0.72	-7.48	-0.33	3.87e-13	Sjögren's syndrome;
LGG	cis	rs13126513	0.708	rs1057613	chr4:100504985	G/A	cg05468953	chr4:100565104	NA	0.39	7.87	0.34	2.45e-14	Metabolite levels (MHPG);
LGG	cis	rs908922	0.676	rs4845782	chr1:152492225	A/G	cg20991723	chr1:152506922	NA	-0.73	-14.94	-0.57	1.85e-41	Hair morphology;
LGG	cis	rs780096	0.546	rs1060525	chr2:27635582	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.9	-0.31	1.72e-11	Total body bone mineral density;
LGG	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg07936489	chr17:37558343	FBXL20	-0.99	-15.15	-0.58	2.19e-42	Glomerular filtration rate (creatinine);
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	-0.59	-11.9	-0.48	1.11e-28	Prudent dietary pattern;
LGG	cis	rs4538187	0.671	rs72893103	chr2:64235312	C/T	cg19915305	chr2:64069682	UGP2	-0.67	-13.57	-0.53	1.52e-35	Systolic blood pressure;
LGG	cis	rs3020736	0.500	rs11090076	chr22:42514190	T/C	cg15557168	chr22:42548783	NA	0.4	8.67	0.37	7.43e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8064299	0.934	rs895692	chr17:72766252	G/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.65	12.5	0.5	4.39e-31	Monocyte count;
LGG	cis	rs9443645	0.901	rs6912683	chr6:79543492	C/A	cg18132916	chr6:79620363	NA	-0.31	-8.52	-0.37	2.19e-16	Intelligence (multi-trait analysis);
LGG	cis	rs58688157	0.639	rs60568231	chr11:575553	A/T	cg02461776	chr11:598696	PHRF1	0.52	8.02	0.35	8.73e-15	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.923	rs1572229	chr6:150064977	T/A	cg02462569	chr6:150064036	NUP43	-0.42	-9.01	-0.39	5.49e-18	Lung cancer;
LGG	cis	rs61989804	0.623	rs7147344	chr14:65735050	C/G	cg15999311	chr14:65749247	NA	0.77	7.73	0.34	6.64e-14	Midgestational circulating levels of PCBs (fetal genetic effect);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16923011	chr12:110337926	TCHP	0.43	6.9	0.31	1.76e-11	Cognitive performance;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17696166	chr17:36981606	CCDC49	0.47	7.45	0.33	4.67e-13	Cognitive performance;
LGG	trans	rs826838	0.967	rs826858	chr12:39116731	A/G	cg06521331	chr12:34319734	NA	0.42	7.56	0.33	2.14e-13	Heart rate;
LGG	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs4648739	0.613	rs13303201	chr1:1903712	G/T	cg27587063	chr1:1912065	KIAA1751	-0.37	-8.45	-0.37	3.69e-16	Severe influenza A (H1N1) infection;
LGG	trans	rs1005277	0.579	rs2474595	chr10:38426782	C/G	cg25373794	chr1:162760220	HSD17B7	0.42	6.85	0.3	2.34e-11	Extrinsic epigenetic age acceleration;
LGG	trans	rs9354308	0.933	rs2814134	chr6:66566658	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.01	0.42	1.71e-21	Metabolite levels;
LGG	cis	rs8017423	1.000	rs1959001	chr14:90667739	G/A	cg04374321	chr14:90722782	PSMC1	0.85	18.0	0.64	2.53e-55	Mortality in heart failure;
LGG	cis	rs3849046	0.790	rs17207604	chr5:137931590	G/A	cg10920316	chr5:137946599	NA	-0.47	-7.39	-0.32	6.84e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg09264619	chr17:80180166	NA	-0.53	-10.27	-0.43	1.94e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4423214	1.000	rs4944946	chr11:71159429	G/A	cg05163923	chr11:71159392	DHCR7	0.71	14.01	0.55	1.89e-37	Vitamin D levels;
LGG	cis	rs4780401	0.933	rs1592572	chr16:11810382	T/C	cg01061890	chr16:11836724	TXNDC11	-0.42	-7.2	-0.32	2.4e-12	Rheumatoid arthritis;
LGG	cis	rs7615952	0.932	rs13086087	chr3:125646281	A/C	cg05084668	chr3:125655381	ALG1L	-0.86	-10.65	-0.44	7.65e-24	Blood pressure (smoking interaction);
LGG	cis	rs8060686	0.641	rs76053508	chr16:68243054	A/T	cg04539111	chr16:67997858	SLC12A4	-0.41	-6.67	-0.3	7.37e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6088580	0.634	rs6087580	chr20:32992592	A/G	cg24642439	chr20:33292090	TP53INP2	-0.56	-9.44	-0.4	1.85e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00262122	chr8:11665843	FDFT1	0.42	6.77	0.3	3.84e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs861020	1.000	rs595918	chr1:209966843	A/G	cg05527609	chr1:210001259	C1orf107	0.7	9.63	0.41	3.82e-20	Orofacial clefts;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg20887711	chr4:1340912	KIAA1530	-0.55	-10.79	-0.45	2.32e-24	Obesity-related traits;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs7395662	0.517	rs10838960	chr11:48584741	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.7	-0.3	6.02e-11	HDL cholesterol;
LGG	cis	rs4566357	0.615	rs10190621	chr2:227914484	A/G	cg11843606	chr2:227700838	RHBDD1	-0.51	-9.21	-0.39	1.18e-18	Coronary artery disease;
LGG	cis	rs2760061	0.598	rs605410	chr1:228116281	A/G	cg02753203	chr1:228287806	NA	-0.64	-11.79	-0.48	3.09e-28	Diastolic blood pressure;
LGG	cis	rs2074193	0.627	rs215370	chr12:47742359	T/C	cg02516419	chr12:47771422	NA	-0.65	-9.23	-0.39	9.86e-19	Migraine with aura;
LGG	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg18165381	chr3:44552316	NA	-0.41	-6.65	-0.3	8.51e-11	Depressive symptoms;
LGG	cis	rs9790314	1.000	rs4597724	chr3:160963110	A/G	cg04691961	chr3:161091175	C3orf57	-0.63	-15.02	-0.57	8.02e-42	Morning vs. evening chronotype;
LGG	cis	rs7681440	0.904	rs28415623	chr4:90767110	C/T	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs3771570	0.901	rs4675969	chr2:242217627	C/T	cg21155796	chr2:242212141	HDLBP	0.63	8.56	0.37	1.66e-16	Prostate cancer;
LGG	cis	rs6868223	0.617	rs4635933	chr5:33648062	G/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.57	0.59	2.8e-44	Mortality in heart failure;
LGG	cis	rs1865760	1.000	rs7770139	chr6:25925823	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.82	-0.34	3.53e-14	Height;
LGG	cis	rs2762353	0.595	rs1892256	chr6:25754271	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-8.99	-0.39	6.53e-18	Blood metabolite levels;
LGG	cis	rs6582630	0.560	rs12315134	chr12:38419857	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.6	-0.44	1.2e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1858740	0.509	rs196375	chr3:38422919	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.69	13.23	0.52	4.22e-34	Schizophrenia;
LGG	cis	rs17125944	0.505	rs77137752	chr14:53230496	G/T	cg13660082	chr14:53194042	PSMC6	-0.55	-7.82	-0.34	3.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs7766436	0.961	rs6900627	chr6:22570245	G/A	cg13666174	chr6:22585274	NA	-0.43	-9.77	-0.41	1.3e-20	Coronary artery disease;
LGG	cis	rs2086824	0.538	rs4785673	chr16:89536545	A/G	cg06640241	chr16:89574553	SPG7	0.83	14.68	0.56	2.48e-40	Multiple myeloma (IgH translocation);
LGG	trans	rs804280	0.543	rs13261205	chr8:11791216	A/G	cg13009111	chr11:71350975	NA	0.35	7.74	0.34	6.35e-14	Myopia (pathological);
LGG	cis	rs10791097	0.694	rs2155750	chr11:130751261	A/C	cg12179176	chr11:130786555	SNX19	0.84	17.66	0.63	1.02e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10267417	0.603	rs116877803	chr7:19925205	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	6.76	0.3	4.1e-11	Night sleep phenotypes;
LGG	cis	rs4363385	0.782	rs2152993	chr1:152991695	C/A	cg13444842	chr1:152974279	SPRR3	-0.42	-8.69	-0.37	6.52e-17	Inflammatory skin disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16189954	chr22:29138267	HSCB;CHEK2	0.53	8.56	0.37	1.62e-16	Gut microbiome composition (summer);
LGG	cis	rs780096	0.546	rs1647284	chr2:27608115	C/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.75	-0.3	4.54e-11	Total body bone mineral density;
LGG	cis	rs6963495	0.818	rs55983796	chr7:105170941	C/T	cg19920283	chr7:105172520	RINT1	0.59	7.8	0.34	4.25e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs28595532	0.925	rs56200441	chr4:119497440	T/G	cg14228332	chr4:119757509	SEC24D	0.95	9.45	0.4	1.63e-19	Cannabis dependence symptom count;
LGG	cis	rs10463554	0.892	rs66505956	chr5:102279557	C/T	cg23492399	chr5:102201601	PAM	-0.53	-8.19	-0.36	2.66e-15	Parkinson's disease;
LGG	cis	rs36207871	1	rs36207871	chr12:56684496	TAGGAA/T	cg26714650	chr12:56694279	CS	1.48	18.03	0.64	1.97e-55	Inflammatory skin disease;
LGG	cis	rs657075	0.697	rs35373795	chr5:131753824	G/T	cg05556477	chr5:131705319	SLC22A5	0.77	9.17	0.39	1.5e-18	Rheumatoid arthritis;
LGG	cis	rs637571	0.522	rs28578718	chr11:65748400	C/A	cg17985854	chr11:65770987	BANF1;EIF1AD	0.45	7.7	0.34	8.31e-14	Eosinophil percentage of white cells;
LGG	cis	rs11792861	0.926	rs12683988	chr9:111867290	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.6	9.41	0.4	2.41e-19	Menarche (age at onset);
LGG	cis	rs9527	0.590	rs2148198	chr10:104915310	A/G	cg05308233	chr10:104796373	CNNM2	0.31	6.71	0.3	5.77e-11	Arsenic metabolism;
LGG	cis	rs919433	0.750	rs788010	chr2:198230949	T/C	cg00792783	chr2:198669748	PLCL1	0.46	7.31	0.32	1.2e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9399135	0.967	rs1854865	chr6:135360300	C/G	cg24558204	chr6:135376177	HBS1L	0.52	9.53	0.4	9.25e-20	Red blood cell count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25261764	chr18:55288998	NARS	0.43	7.12	0.31	4.21e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7712401	0.601	rs193539	chr5:122257617	C/G	cg19412675	chr5:122181750	SNX24	0.43	7.19	0.32	2.68e-12	Mean platelet volume;
LGG	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg04617936	chr2:214353	NA	-0.36	-6.71	-0.3	5.68e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1218582	0.772	rs12069356	chr1:154849771	C/T	cg24250549	chr1:154909240	PMVK	0.74	14.99	0.57	1.11e-41	Prostate cancer;
LGG	cis	rs780096	0.546	rs4665976	chr2:27640325	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.88	-0.3	2.01e-11	Total body bone mineral density;
LGG	cis	rs929354	0.629	rs6950739	chr7:156982450	T/C	cg17757837	chr7:157058334	UBE3C	0.77	15.41	0.58	1.57e-43	Body mass index;
LGG	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg15704280	chr7:45808275	SEPT13	-0.9	-17.9	-0.64	7.98e-55	Height;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.6	-10.13	-0.43	6.26e-22	Obesity-related traits;
LGG	cis	rs11785400	1.000	rs6997771	chr8:143747752	T/G	cg24634471	chr8:143751801	JRK	0.53	8.4	0.36	5.55e-16	Schizophrenia;
LGG	cis	rs6912958	0.559	rs446851	chr6:88043640	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	0.31	6.66	0.3	7.75e-11	Monocyte percentage of white cells;
LGG	cis	rs7267979	1.000	rs6037099	chr20:25356876	T/G	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6028335	0.610	rs67487809	chr20:37688597	C/G	cg16355469	chr20:37678765	NA	0.63	7.11	0.31	4.34e-12	Alcohol and nicotine co-dependence;
LGG	trans	rs11039798	1.000	rs115429994	chr11:48761183	C/G	cg15704280	chr7:45808275	SEPT13	0.77	9.0	0.39	6.06e-18	Axial length;
LGG	trans	rs3733585	0.579	rs4235356	chr4:10123106	G/C	cg26043149	chr18:55253948	FECH	-0.48	-7.76	-0.34	5.49e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4555082	0.794	rs2735829	chr14:105708472	C/T	cg06808227	chr14:105710500	BRF1	-0.62	-10.84	-0.45	1.55e-24	Mean platelet volume;Platelet distribution width;
LGG	cis	rs13108904	0.901	rs6826029	chr4:1307689	A/G	cg06654118	chr4:1303317	MAEA	0.41	7.07	0.31	5.7e-12	Obesity-related traits;
LGG	cis	rs7975161	0.580	rs4246270	chr12:104728530	G/A	cg25273343	chr12:104657179	TXNRD1	-0.77	-7.39	-0.32	6.88e-13	Toenail selenium levels;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg03105603	chr7:39772936	LOC349114	0.65	7.51	0.33	2.98e-13	Intelligence (multi-trait analysis);
LGG	cis	rs7481584	0.624	rs377765	chr11:3046298	C/T	cg08508325	chr11:3079039	CARS	0.43	8.46	0.37	3.6e-16	Calcium levels;
LGG	cis	rs1799949	0.965	rs8176130	chr17:41258043	C/T	cg23758822	chr17:41437982	NA	0.87	15.4	0.58	1.61e-43	Menopause (age at onset);
LGG	cis	rs7267979	0.903	rs2500400	chr20:25354705	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.03	-0.42	1.52e-21	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs459571	0.839	rs10993895	chr9:136887726	C/T	cg13789015	chr9:136890014	NCRNA00094	-0.59	-11.18	-0.46	7.74e-26	Platelet distribution width;
LGG	cis	rs9863	0.861	rs34878139	chr12:124446253	T/C	cg13487667	chr12:124434373	CCDC92	-0.36	-7.19	-0.32	2.63e-12	White blood cell count;
LGG	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg08392591	chr16:89556376	ANKRD11	0.6	9.49	0.4	1.21e-19	Multiple myeloma (IgH translocation);
LGG	cis	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg21775007	chr8:11205619	TDH	0.61	9.88	0.42	5.05e-21	Retinal vascular caliber;
LGG	cis	rs7208859	0.623	rs80355557	chr17:29154421	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.78	-9.34	-0.4	4.14e-19	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4242434	0.889	rs7817772	chr8:22539316	A/G	cg00599393	chr8:22457479	C8orf58	0.42	7.48	0.33	3.75e-13	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4740619	0.792	rs4740614	chr9:15554960	A/G	cg14451791	chr9:16040625	NA	-0.31	-7.98	-0.35	1.12e-14	Body mass index;
LGG	cis	rs35110281	0.626	rs162367	chr21:44934857	A/G	cg04455712	chr21:45112962	RRP1B	0.46	8.59	0.37	1.33e-16	Mean corpuscular volume;
LGG	cis	rs2576037	0.523	rs4890705	chr18:44509758	A/G	cg26155939	chr18:44337853	ST8SIA5	-0.38	-6.92	-0.31	1.48e-11	Personality dimensions;
LGG	cis	rs3780486	0.522	rs10217770	chr9:33146393	C/A	cg13443165	chr9:33130375	B4GALT1	-0.57	-11.05	-0.46	2.47e-25	IgG glycosylation;
LGG	cis	rs7084402	0.934	rs1158212	chr10:60318276	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs6461049	0.734	rs1558465	chr7:2151398	G/C	cg22963979	chr7:1858916	MAD1L1	-0.42	-8.3	-0.36	1.12e-15	Schizophrenia;
LGG	cis	rs727505	1.000	rs7801661	chr7:124483222	C/T	cg23710748	chr7:124431027	NA	0.53	10.18	0.43	4.35e-22	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14590817	chr10:1779730	ADARB2	0.48	7.53	0.33	2.59e-13	Gut microbiome composition (summer);
LGG	cis	rs7618501	1.000	rs4855867	chr3:49745822	C/T	cg24110177	chr3:50126178	RBM5	0.4	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17067123	0.614	rs72712844	chr4:180060895	C/A	cg26610307	chr4:180072759	NA	-0.49	-6.89	-0.3	1.86e-11	Response to hepatitis C treatment;
LGG	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg27286337	chr10:134555280	INPP5A	0.84	12.15	0.49	1.15e-29	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs13191362	0.935	rs34587258	chr6:162945580	T/C	cg21926612	chr6:163149169	PACRG;PARK2	0.86	8.37	0.36	7.05e-16	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs3106136	0.967	rs767657	chr4:95227901	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.84	-0.34	3.13e-14	Capecitabine sensitivity;
LGG	cis	rs1003719	0.586	rs2298685	chr21:38533390	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs780096	0.546	rs12473776	chr2:27636474	A/G	cg21747090	chr2:27597821	SNX17	-0.38	-6.8	-0.3	3.28e-11	Total body bone mineral density;
LGG	trans	rs57221529	0.563	rs4957057	chr5:569230	C/G	cg25482853	chr8:67687455	SGK3	0.86	11.22	0.46	5.25e-26	Lung disease severity in cystic fibrosis;
LGG	cis	rs11074306	0.561	rs4778120	chr15:28065035	T/G	cg26402630	chr15:28053930	OCA2	0.36	7.21	0.32	2.3e-12	Uveal melanoma;
LGG	cis	rs10911251	0.546	rs2027085	chr1:183108611	G/T	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-8.53	-0.37	2.03e-16	Colorectal cancer;
LGG	cis	rs67311347	1.000	rs11706148	chr3:40407243	A/C	cg13683864	chr3:40499215	RPL14	-1.14	-25.19	-0.76	8.16e-89	Renal cell carcinoma;
LGG	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg07636037	chr3:49044803	WDR6	0.61	10.57	0.44	1.51e-23	Resting heart rate;
LGG	cis	rs2997447	0.846	rs3008231	chr1:26402023	A/G	cg23602478	chr1:26503979	CNKSR1	0.31	6.85	0.3	2.43e-11	QRS complex (12-leadsum);
LGG	cis	rs77741769	0.529	rs2893876	chr12:121245158	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.08	0.39	3.04e-18	Mean corpuscular volume;
LGG	cis	rs9814567	0.752	rs7649910	chr3:134241310	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.08	-0.52	1.75e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg12395012	chr8:11607386	GATA4	0.37	6.72	0.3	5.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1865760	1.000	rs6910174	chr6:25904414	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.52	0.4	9.66e-20	Height;
LGG	cis	rs997295	0.504	rs12905397	chr15:68034150	T/C	cg08079166	chr15:68083412	MAP2K5	-0.3	-6.9	-0.31	1.72e-11	Motion sickness;
LGG	cis	rs4642101	0.640	rs3901666	chr3:12824363	G/T	cg05775895	chr3:12838266	CAND2	-0.63	-11.14	-0.46	1.11e-25	QRS complex (12-leadsum);
LGG	cis	rs1865760	0.929	rs2876693	chr6:25954434	C/G	cg16482183	chr6:26056742	HIST1H1C	0.52	9.33	0.4	4.55e-19	Height;
LGG	cis	rs11603023	0.874	rs483598	chr11:118509668	A/G	cg20309703	chr11:118481025	PHLDB1	0.57	11.24	0.46	4.35e-26	Cholesterol, total;
LGG	cis	rs1153858	1.000	rs61365925	chr15:45650311	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs477895	1.000	rs34292685	chr11:64049021	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.63	0.37	1e-16	Mean platelet volume;
LGG	cis	rs9771228	0.560	rs9639648	chr7:32282142	G/A	cg27532318	chr7:32358331	NA	0.53	7.67	0.34	1.02e-13	Cognitive ability;Verbal-numerical reasoning;
LGG	cis	rs9393692	0.875	rs12526215	chr6:26262916	T/C	cg15665833	chr6:26285013	NA	0.39	7.53	0.33	2.61e-13	Educational attainment;
LGG	cis	rs7747724	0.715	rs2819997	chr6:20758347	A/G	cg13405222	chr6:20811065	CDKAL1	-0.48	-9.48	-0.4	1.36e-19	Bladder cancer;
LGG	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg11890956	chr21:40555474	PSMG1	-1.0	-21.47	-0.71	1.74e-71	Cognitive function;
LGG	cis	rs6977660	0.941	rs4721825	chr7:19823427	A/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.64	0.33	1.22e-13	Thyroid stimulating hormone;
LGG	cis	rs12468557	0.669	rs2371006	chr2:211501202	A/G	cg07063745	chr2:211341572	LANCL1;CPS1	-0.43	-7.52	-0.33	2.94e-13	Body mass index in asthmatics;
LGG	cis	rs473651	0.935	rs541013	chr2:239336492	G/A	cg18131467	chr2:239335373	ASB1	1.02	23.75	0.74	3.77e-82	Multiple system atrophy;
LGG	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg14228332	chr4:119757509	SEC24D	-0.98	-10.0	-0.42	1.89e-21	Cannabis dependence symptom count;
LGG	cis	rs4950322	0.947	rs72694723	chr1:146844891	C/T	cg22381352	chr1:146742008	CHD1L	-0.44	-6.98	-0.31	1.04e-11	Protein quantitative trait loci;
LGG	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.25e-18	Neuroticism;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg26203845	chr14:105293866	NA	0.45	7.17	0.32	2.9e-12	IgG glycosylation;
LGG	cis	rs6500602	0.627	rs934929	chr16:4587789	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	-0.43	-7.75	-0.34	5.83e-14	Schizophrenia;
LGG	cis	rs6952808	0.689	rs79950306	chr7:2022063	C/G	cg22963979	chr7:1858916	MAD1L1	-0.46	-9.1	-0.39	2.65e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs11168618	0.904	rs7978948	chr12:48930023	A/G	cg24011408	chr12:48396354	COL2A1	0.44	7.24	0.32	1.88e-12	Adiponectin levels;
LGG	cis	rs4737010	0.959	rs4737009	chr8:41630405	A/G	cg17182837	chr8:41585554	ANK1	-0.47	-7.42	-0.33	5.62e-13	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs6502050	0.842	rs62079996	chr17:80076862	A/G	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs1697139	0.583	rs13186050	chr5:66528139	C/T	cg11553311	chr5:66541588	NA	0.46	10.3	0.43	1.57e-22	Breast cancer;
LGG	cis	rs826838	0.874	rs10880943	chr12:38734317	C/T	cg13010199	chr12:38710504	ALG10B	0.78	16.95	0.62	1.72e-50	Heart rate;
LGG	cis	rs6502050	0.761	rs9908277	chr17:80060829	T/C	cg09264619	chr17:80180166	NA	0.33	6.65	0.3	8.05e-11	Life satisfaction;
LGG	cis	rs11577318	0.853	rs3795684	chr1:26632781	C/T	cg10402321	chr1:26617780	UBXN11	-0.43	-7.79	-0.34	4.54e-14	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9815354	1.000	rs9865127	chr3:41807448	C/T	cg03022575	chr3:42003672	ULK4	0.6	7.66	0.34	1.08e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2084898	1.000	rs7119954	chr11:120046224	T/C	cg13907859	chr11:120009124	TRIM29	0.85	11.72	0.48	5.85e-28	Stroke (pediatric);
LGG	trans	rs826838	0.967	rs11169169	chr12:39093153	A/C	cg06521331	chr12:34319734	NA	-0.43	-7.51	-0.33	3.12e-13	Heart rate;
LGG	cis	rs7444	0.941	rs59391722	chr22:21920817	G/C	cg05046821	chr22:21984468	YDJC	-0.4	-7.14	-0.31	3.7e-12	Systemic lupus erythematosus;
LGG	cis	rs7315438	0.512	rs7958261	chr12:115941121	T/C	cg18639984	chr12:115943877	NA	-0.39	-8.58	-0.37	1.44e-16	Colorectal cancer;
LGG	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg22875332	chr1:76189707	ACADM	-0.5	-7.86	-0.34	2.79e-14	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs5756813	0.661	rs5995500	chr22:38204640	A/G	cg24232236	chr22:38142998	TRIOBP	0.35	6.83	0.3	2.68e-11	Optic cup area;Vertical cup-disc ratio;
LGG	cis	rs765787	0.530	rs4331289	chr15:45515338	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.43	-0.33	5.24e-13	Uric acid levels;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg26260386	chr4:140477698	SETD7	0.44	7.16	0.32	3.25e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs9329221	0.741	rs534523	chr8:9884999	C/G	cg16141378	chr3:129829833	LOC729375	0.38	8.64	0.37	9.23e-17	Neuroticism;
LGG	cis	rs714031	0.934	rs5757768	chr22:40071322	G/A	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.24	-0.55	2.08e-38	Schizophrenia;
LGG	cis	rs7618915	0.501	rs13060048	chr3:52598608	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.64	11.6	0.47	1.75e-27	Bipolar disorder;
LGG	cis	rs9875589	0.509	rs9836573	chr3:14065239	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.54	11.31	0.47	2.37e-26	Ovarian reserve;
LGG	cis	rs2153535	0.580	rs2327064	chr6:8454052	C/T	cg23788917	chr6:8435910	SLC35B3	0.52	8.9	0.38	1.27e-17	Motion sickness;
LGG	cis	rs3087591	0.708	rs2285894	chr17:29654876	T/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.2	0.49	7.27e-30	Hip circumference;
LGG	cis	rs78456975	1.000	rs13414537	chr2:1556330	C/T	cg26248373	chr2:1572462	NA	-0.7	-8.78	-0.38	3.22e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs35110281	0.807	rs28840140	chr21:45039163	T/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.1	-0.39	2.63e-18	Mean corpuscular volume;
LGG	trans	rs9329221	0.513	rs4841296	chr8:10105447	C/G	cg00405596	chr8:11794950	NA	-0.44	-7.02	-0.31	7.96e-12	Neuroticism;
LGG	cis	rs6908034	0.546	rs74514942	chr6:19810520	G/A	cg02682789	chr6:19804855	NA	0.9	8.45	0.37	3.87e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.27	-0.32	1.59e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	0.932	rs10831447	chr11:95663017	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	-0.67	-11.92	-0.48	9.01e-29	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs11039798	0.858	rs7121333	chr11:48332138	C/T	cg03929089	chr4:120376271	NA	0.68	8.07	0.35	6.23e-15	Axial length;
LGG	cis	rs16937	0.711	rs10751430	chr1:205107497	A/G	cg00889227	chr1:205173544	DSTYK	-0.29	-7.27	-0.32	1.57e-12	Schizophrenia;
LGG	cis	rs4731207	0.596	rs1383751	chr7:124579721	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	trans	rs7395662	0.759	rs11529442	chr11:48819986	T/C	cg15704280	chr7:45808275	SEPT13	0.49	8.02	0.35	8.96e-15	HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08692282	chr15:79165379	MORF4L1	0.43	7.05	0.31	6.61e-12	Cognitive performance;
LGG	cis	rs11098499	0.955	rs13129661	chr4:120152909	C/G	cg09307838	chr4:120376055	NA	0.71	11.73	0.48	5.27e-28	Corneal astigmatism;
LGG	cis	rs8114671	0.562	rs6058120	chr20:33402829	A/G	cg07148914	chr20:33460835	GGT7	0.53	8.83	0.38	2.18e-17	Height;
LGG	cis	rs9790314	0.581	rs6772578	chr3:160760851	T/A	cg04691961	chr3:161091175	C3orf57	-0.46	-9.65	-0.41	3.49e-20	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.914	rs6837117	chr4:187872379	C/T	cg22105103	chr4:187893119	NA	0.51	9.21	0.39	1.16e-18	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs61931739	0.576	rs7297346	chr12:33700544	T/C	cg26384229	chr12:38710491	ALG10B	-0.49	-8.6	-0.37	1.21e-16	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00850039	chr19:12476508	ZNF442	0.47	7.15	0.32	3.37e-12	Gut microbiome composition (summer);
LGG	cis	rs9322193	0.886	rs4039600	chr6:149897455	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.13	0.52	1.07e-33	Lung cancer;
LGG	cis	rs9354308	0.764	rs6929496	chr6:66614031	C/A	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg25160593	chr3:44666684	ZNF197	0.46	6.68	0.3	6.92e-11	Hip circumference;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg18500714	chr14:100706288	YY1	0.42	6.88	0.3	2.01e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6089829	0.962	rs6122350	chr20:61664617	A/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs1475911	0.708	rs11701371	chr21:43523972	C/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.58	-9.63	-0.41	3.94e-20	IgG glycosylation;
LGG	cis	rs11098499	0.644	rs28787668	chr4:120554687	G/A	cg24375607	chr4:120327624	NA	0.6	10.25	0.43	2.34e-22	Corneal astigmatism;
LGG	cis	rs16866061	0.890	rs72972401	chr2:225404668	T/C	cg12698349	chr2:225449008	CUL3	0.92	19.17	0.67	9.61e-61	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	trans	rs2204008	0.580	rs1315373	chr12:38179114	T/G	cg06521331	chr12:34319734	NA	0.46	8.12	0.35	4.16e-15	Bladder cancer;
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.44	7.12	0.31	4.1e-12	Prudent dietary pattern;
LGG	cis	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg18252515	chr7:66147081	NA	-1.37	-18.78	-0.66	6.23e-59	Diabetic kidney disease;
LGG	cis	rs7726839	0.794	rs10053310	chr5:595661	C/G	cg09021430	chr5:549028	NA	-0.69	-11.92	-0.48	8.98e-29	Obesity-related traits;
LGG	cis	rs9309473	1.000	rs10207220	chr2:73785046	G/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs1843834	0.539	rs1494109	chr2:225441833	G/A	cg12698349	chr2:225449008	CUL3	0.7	11.84	0.48	2e-28	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs58688157	0.660	rs12797496	chr11:583767	C/T	cg03909863	chr11:638404	DRD4	-0.42	-6.86	-0.3	2.26e-11	Systemic lupus erythematosus;
LGG	trans	rs877282	0.898	rs11253343	chr10:765117	C/T	cg22713356	chr15:30763199	NA	0.52	7.6	0.33	1.71e-13	Uric acid levels;
LGG	cis	rs920590	0.643	rs7012694	chr8:19662732	C/T	cg03894339	chr8:19674705	INTS10	0.5	8.52	0.37	2.18e-16	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9926296	0.533	rs12102297	chr16:89812762	C/A	cg26513180	chr16:89883248	FANCA	0.93	20.06	0.68	6.86e-65	Vitiligo;
LGG	cis	rs427394	0.659	rs274674	chr5:6755460	C/T	cg15145174	chr5:6755386	POLS	-0.44	-8.0	-0.35	1.03e-14	Menopause (age at onset);
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg26645635	chr12:58240817	CTDSP2	-0.45	-7.21	-0.32	2.25e-12	Pancreatic cancer;
LGG	cis	rs5769765	0.825	rs7511620	chr22:50307932	T/C	cg26441486	chr22:50317300	CRELD2	0.41	7.22	0.32	2.14e-12	Schizophrenia;
LGG	cis	rs7394190	0.748	rs2242254	chr10:75585307	G/A	cg07699608	chr10:75541558	CHCHD1	0.54	7.2	0.32	2.4e-12	Incident atrial fibrillation;
LGG	cis	rs1847202	0.859	rs13075769	chr3:72939295	C/T	cg25664220	chr3:72788482	NA	-0.25	-7.4	-0.33	6.64e-13	Motion sickness;
LGG	cis	rs4751006	0.543	rs2890130	chr10:128783848	T/C	cg05702161	chr10:128779687	DOCK1	-1.0	-10.67	-0.44	6.36e-24	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2013441	0.508	rs8075343	chr17:19975487	T/C	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.5e-12	Obesity-related traits;
LGG	trans	rs62103177	0.810	rs62096746	chr18:77619556	T/A	cg14227996	chr4:17616232	MED28	0.75	9.21	0.39	1.1e-18	Opioid sensitivity;
LGG	trans	rs2204008	0.623	rs1315348	chr12:38163044	G/A	cg06521331	chr12:34319734	NA	0.45	8.04	0.35	7.3e-15	Bladder cancer;
LGG	cis	rs3820068	0.637	rs4646080	chr1:15826627	A/T	cg05660106	chr1:15850417	CASP9	1.1	26.33	0.77	4.59e-94	Systolic blood pressure;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg22105103	chr4:187893119	NA	-0.56	-10.8	-0.45	2.17e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs916888	0.773	rs199443	chr17:44819565	C/T	cg17911788	chr17:44343683	NA	0.62	9.53	0.4	9.16e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9910055	0.762	rs7213436	chr17:42252163	A/G	cg16434002	chr17:42200994	HDAC5	0.52	9.51	0.4	1.01e-19	Total body bone mineral density;
LGG	cis	rs6951245	0.507	rs11976805	chr7:1138716	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.6	0.33	1.66e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs7833790	1.000	rs7834808	chr8:82704996	A/G	cg06027949	chr8:82754900	SNX16	-0.49	-6.95	-0.31	1.23e-11	Diastolic blood pressure;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.61	8.34	0.36	8.65e-16	Platelet count;
LGG	cis	rs12893668	0.608	rs12889721	chr14:104034863	C/T	cg26031613	chr14:104095156	KLC1	-0.61	-9.65	-0.41	3.3e-20	Reticulocyte count;
LGG	cis	rs17683430	0.702	rs117117069	chr22:32539693	T/A	cg02631450	chr22:32366979	NA	0.99	9.34	0.4	4.17e-19	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs3219090	0.962	rs1865222	chr1:226601884	A/C	cg17127702	chr1:226594323	PARP1	0.38	12.35	0.5	1.79e-30	Melanoma;
LGG	cis	rs372883	0.638	rs371432	chr21:30710876	G/A	cg08807101	chr21:30365312	RNF160	-0.59	-9.75	-0.41	1.44e-20	Pancreatic cancer;
LGG	cis	rs60871478	1.000	rs4720930	chr7:808073	G/A	cg05535760	chr7:792225	HEATR2	0.8	13.01	0.52	3.4e-33	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg11062466	chr8:58055876	NA	0.6	10.02	0.42	1.63e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs9926296	0.605	rs7205053	chr16:89856763	G/C	cg07648498	chr16:89883185	FANCA	0.39	6.71	0.3	5.8e-11	Vitiligo;
LGG	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.62e-12	Schizophrenia;
LGG	cis	rs10256972	0.521	rs7457418	chr7:1110255	C/T	cg16145915	chr7:1198662	ZFAND2A	-0.56	-10.12	-0.43	7.14e-22	Longevity;Endometriosis;
LGG	cis	rs7444	0.941	rs181366	chr22:21933780	C/T	cg11654148	chr22:21984483	YDJC	-0.39	-7.7	-0.34	8.36e-14	Systemic lupus erythematosus;
LGG	cis	rs651907	0.514	rs55654108	chr3:101425703	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.71	13.22	0.52	4.65e-34	Colorectal cancer;
LGG	cis	rs5758511	0.689	rs11913578	chr22:42347391	A/C	cg15128208	chr22:42549153	NA	0.58	9.31	0.4	4.99e-19	Birth weight;
LGG	cis	rs13108904	0.901	rs12641735	chr4:1304434	G/C	cg16405210	chr4:1374714	KIAA1530	-0.53	-9.16	-0.39	1.65e-18	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2474625	chr1:231519331	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs7617773	0.743	rs11715876	chr3:48377922	G/A	cg11946769	chr3:48343235	NME6	0.69	11.26	0.46	3.54e-26	Coronary artery disease;
LGG	cis	rs909674	0.662	rs2899318	chr22:39837625	A/G	cg11247378	chr22:39784982	NA	-0.31	-8.46	-0.37	3.54e-16	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16139199	chr18:19180362	ESCO1	0.45	6.97	0.31	1.12e-11	Gut microbiome composition (summer);
LGG	cis	rs875971	0.830	rs1167406	chr7:65556936	G/C	cg12463550	chr7:65579703	CRCP	-0.52	-8.48	-0.37	3.01e-16	Aortic root size;
LGG	trans	rs7824557	0.806	rs34171564	chr8:11095346	C/A	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.47	-0.37	3.32e-16	Retinal vascular caliber;
LGG	cis	rs5769765	0.632	rs13056783	chr22:50259152	A/T	cg02269571	chr22:50332266	NA	0.64	10.21	0.43	3.17e-22	Schizophrenia;
LGG	cis	rs2304069	0.695	rs6866298	chr5:149439588	A/G	cg22760475	chr5:149380129	HMGXB3;TIGD6	0.7	10.74	0.45	3.41e-24	HIV-1 control;
LGG	cis	rs9790314	1.000	rs62279921	chr3:161065441	T/C	cg03342759	chr3:160939853	NMD3	-0.64	-11.31	-0.47	2.38e-26	Morning vs. evening chronotype;
LGG	cis	rs6502050	0.799	rs7406257	chr17:80089340	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs6489882	0.867	rs7298184	chr12:113368249	C/A	cg25319449	chr12:113376135	OAS3	-0.41	-7.62	-0.33	1.43e-13	Chronic lymphocytic leukemia;
LGG	cis	rs1943345	0.642	rs642669	chr11:82892454	A/T	cg07047830	chr11:82868014	PCF11	0.56	10.38	0.43	8.1e-23	Obesity-related traits;
LGG	cis	rs17818399	0.926	rs1824050	chr2:46839477	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.61	-10.48	-0.44	3.22e-23	Height;
LGG	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.74	-0.41	1.59e-20	Retinal vascular caliber;
LGG	cis	rs2742417	0.603	rs2742371	chr3:45782763	G/A	cg04837898	chr3:45731254	SACM1L	-0.47	-9.25	-0.4	8.04e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2486288	0.656	rs6493145	chr15:45573862	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.63	-10.91	-0.45	8.33e-25	Glomerular filtration rate;
LGG	cis	rs1865760	0.865	rs6929805	chr6:25950834	T/A	cg18357526	chr6:26021779	HIST1H4A	0.45	7.42	0.33	5.72e-13	Height;
LGG	cis	rs4243830	0.737	rs6692747	chr1:6610049	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	0.85	10.58	0.44	1.47e-23	Body mass index;
LGG	cis	rs709400	0.628	rs2273700	chr14:103923414	A/G	cg26031613	chr14:104095156	KLC1	0.79	13.85	0.54	9.58e-37	Body mass index;
LGG	cis	rs1799949	1.000	rs72829113	chr17:41181835	C/T	cg12708336	chr17:41446283	NA	-0.32	-7.25	-0.32	1.77e-12	Menopause (age at onset);
LGG	cis	rs2274273	1.000	rs2075603	chr14:55609955	C/A	cg04306507	chr14:55594613	LGALS3	0.61	17.0	0.62	1.01e-50	Protein biomarker;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg13097342	chr7:38217509	STARD3NL	0.71	6.67	0.3	7.2e-11	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg21724239	chr8:58056113	NA	0.63	9.24	0.39	8.92e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.511	rs1742395	chr16:1955965	G/A	cg00490583	chr16:1843685	IGFALS	-0.4	-6.97	-0.31	1.06e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs644799	0.544	rs525087	chr11:95632266	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	10.25	0.43	2.42e-22	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9926296	0.605	rs886951	chr16:89836865	A/G	cg07440826	chr16:89882328	FANCA	-0.26	-7.05	-0.31	6.51e-12	Vitiligo;
LGG	cis	rs8180040	0.729	rs11720439	chr3:47347003	T/G	cg27129171	chr3:47204927	SETD2	-0.77	-13.81	-0.54	1.42e-36	Colorectal cancer;
LGG	cis	rs9894429	0.690	rs12949956	chr17:79542813	C/T	cg18240062	chr17:79603768	NPLOC4	-0.82	-15.61	-0.59	1.96e-44	Eye color traits;
LGG	cis	rs4950322	0.570	rs4950402	chr1:146791402	T/G	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.67	-0.34	9.95e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg02269571	chr22:50332266	NA	0.79	9.82	0.42	8.36e-21	Schizophrenia;
LGG	cis	rs12444795	0.805	rs76087945	chr16:4949440	G/A	cg04440724	chr16:4920505	UBN1	-0.57	-8.0	-0.35	1.02e-14	Cancer;
LGG	trans	rs2243480	1.000	rs35283677	chr7:65359233	C/T	cg10756647	chr7:56101905	PSPH	0.84	10.0	0.42	1.92e-21	Diabetic kidney disease;
LGG	cis	rs6815814	0.950	rs5743595	chr4:38802644	A/G	cg06935464	chr4:38784597	TLR10	0.61	8.24	0.36	1.77e-15	Breast cancer;
LGG	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg14664628	chr15:75095509	CSK	-0.78	-15.88	-0.59	1.15e-45	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs3816183	0.756	rs6544605	chr2:43081928	A/G	cg14631114	chr2:43023945	NA	0.47	8.31	0.36	1.11e-15	Hypospadias;
LGG	cis	rs74781061	0.929	rs7177407	chr15:74843785	C/T	cg02384859	chr15:74862662	ARID3B	-0.35	-7.19	-0.32	2.68e-12	Endometriosis;
LGG	cis	rs4665809	1.000	rs10048683	chr2:26320519	C/T	cg22920501	chr2:26401640	FAM59B	-0.37	-7.49	-0.33	3.49e-13	Gut microbiome composition (summer);
LGG	cis	rs17122278	1.000	rs11216916	chr11:118461605	T/C	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.21e-11	Total cholesterol levels;
LGG	cis	rs2905347	0.737	rs2010437	chr7:22631180	C/G	cg18045685	chr7:22629474	NA	0.88	21.7	0.71	1.49e-72	Major depression and alcohol dependence;
LGG	cis	rs258892	0.895	rs34302030	chr5:72059832	T/A	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg14004847	chr7:1930337	MAD1L1	-0.52	-8.66	-0.37	7.74e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs35123781	1.000	rs601336	chr5:139057167	T/C	cg21230503	chr5:139085173	NA	0.31	7.4	0.33	6.53e-13	Schizophrenia;
LGG	trans	rs208520	0.690	rs1304672	chr6:66847973	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.9	15.45	0.58	1.04e-43	Exhaled nitric oxide output;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.69	-0.41	2.47e-20	Triglycerides;
LGG	cis	rs28595532	0.546	rs17516389	chr4:119239267	T/C	cg21605333	chr4:119757512	SEC24D	0.85	9.0	0.39	5.72e-18	Cannabis dependence symptom count;
LGG	trans	rs853679	0.567	rs3799499	chr6:28354250	G/T	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.72	-0.3	5.22e-11	Depression;
LGG	cis	rs11214589	0.905	rs12805699	chr11:113241810	T/A	cg14373873	chr11:113211441	TTC12	0.44	9.01	0.39	5.3e-18	Neuroticism;
LGG	cis	rs10752881	1.000	rs4420053	chr1:182976133	A/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Colorectal cancer;
LGG	cis	rs2075371	0.863	rs1646635	chr7:134006728	T/C	cg11752832	chr7:134001865	SLC35B4	0.64	11.93	0.48	8.5e-29	Mean platelet volume;
LGG	cis	rs2836974	0.666	rs2836975	chr21:40663620	A/G	cg17971929	chr21:40555470	PSMG1	-0.7	-12.99	-0.52	3.99e-33	Cognitive function;
LGG	cis	rs1577917	0.917	rs13213603	chr6:86534758	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.06	-0.49	2.47e-29	Response to antipsychotic treatment;
LGG	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg25338242	chr13:114786047	RASA3	0.41	7.45	0.33	4.72e-13	Schizophrenia;
LGG	cis	rs4665809	0.590	rs35746418	chr2:26455002	C/G	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs12421382	0.507	rs11600810	chr11:109356443	G/A	cg04861929	chr11:109293070	C11orf87	0.85	16.93	0.62	2.07e-50	Schizophrenia;
LGG	trans	rs7726839	0.540	rs72707016	chr5:665148	A/G	cg25482853	chr8:67687455	SGK3	0.97	11.92	0.48	9.56e-29	Obesity-related traits;
LGG	cis	rs7681440	0.904	rs7671549	chr4:90771147	T/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.81	-0.34	3.91e-14	Dementia with Lewy bodies;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg00987630	chr7:2393812	EIF3B	0.4	6.76	0.3	4.18e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.72	16.83	0.62	6.04e-50	Multiple sclerosis;
LGG	cis	rs13108904	0.837	rs4519749	chr4:1280102	A/G	cg05025164	chr4:1340916	KIAA1530	0.48	8.24	0.36	1.85e-15	Obesity-related traits;
LGG	cis	rs13118159	1.000	rs13118159	chr4:1365127	A/G	cg02475777	chr4:1388615	CRIPAK	0.43	7.83	0.34	3.37e-14	Longevity;
LGG	cis	rs2070488	0.775	rs6780349	chr3:38555178	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.72	-14.32	-0.55	9.54e-39	Electrocardiographic conduction measures;
LGG	cis	rs35306767	0.903	rs12244253	chr10:889320	G/T	cg20503657	chr10:835505	NA	0.75	10.4	0.44	6.72e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs8064024	0.590	rs7186142	chr16:4900987	A/G	cg08329684	chr16:4932620	PPL	0.53	11.83	0.48	2.08e-28	Cancer;
LGG	cis	rs35146811	0.700	rs7788301	chr7:99782753	C/G	cg22906224	chr7:99728672	NA	0.57	9.39	0.4	2.65e-19	Coronary artery disease;
LGG	cis	rs4319547	0.585	rs10846792	chr12:122882374	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.43	-0.4	1.96e-19	Body mass index;
LGG	trans	rs11148252	0.875	rs4885953	chr13:52976491	G/A	cg18335740	chr13:41363409	SLC25A15	0.59	11.45	0.47	6.77e-27	Lewy body disease;
LGG	cis	rs1345301	0.905	rs2310243	chr2:102877560	A/G	cg05295703	chr2:102895712	NA	0.38	7.57	0.33	2.05e-13	Waist circumference;
LGG	cis	rs8064024	0.681	rs9925944	chr16:4885229	G/A	cg04440724	chr16:4920505	UBN1	-0.55	-12.08	-0.49	2.11e-29	Cancer;
LGG	cis	rs2274273	0.529	rs7149965	chr14:55508191	G/A	cg04306507	chr14:55594613	LGALS3	0.36	8.35	0.36	7.9e-16	Protein biomarker;
LGG	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg27454842	chr22:32027588	PISD	-0.61	-6.81	-0.3	3e-11	Age-related hearing impairment;
LGG	cis	rs7084402	0.967	rs1649060	chr10:60310480	C/G	cg09696939	chr10:60272079	BICC1	0.37	7.21	0.32	2.32e-12	Refractive error;
LGG	trans	rs6825911	0.537	rs6836908	chr4:111388061	G/C	cg10580549	chr19:53101634	ZNF137	0.53	6.99	0.31	9.75e-12	Blood pressure;
LGG	cis	rs9557207	0.901	rs9554559	chr13:99809471	C/T	cg24509225	chr13:100037070	UBAC2	0.66	11.85	0.48	1.79e-28	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.51	-0.4	1.09e-19	Personality dimensions;
LGG	cis	rs950169	0.650	rs12902052	chr15:85125838	A/T	cg24253500	chr15:84953950	NA	0.58	10.54	0.44	1.96e-23	Schizophrenia;
LGG	cis	rs1008375	1.000	rs11724495	chr4:17621310	G/A	cg15017067	chr4:17643749	FAM184B	0.3	7.07	0.31	5.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs208520	0.661	rs4710566	chr6:66848538	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.77	-0.64	2.89e-54	Exhaled nitric oxide output;
LGG	cis	rs2635047	0.967	rs2576056	chr18:44675462	G/C	cg19077165	chr18:44547161	KATNAL2	-0.51	-8.98	-0.39	6.73e-18	Educational attainment;
LGG	cis	rs1218582	0.804	rs869506	chr1:154859581	A/C	cg24250549	chr1:154909240	PMVK	0.74	15.22	0.58	1.02e-42	Prostate cancer;
LGG	cis	rs12532878	0.652	rs62482223	chr7:100198878	C/A	cg20848291	chr7:100343083	ZAN	-0.51	-7.07	-0.31	5.89e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7923837	0.656	rs2497306	chr10:94485211	A/C	cg25093409	chr10:94429542	NA	-0.41	-7.63	-0.33	1.39e-13	Body mass index;Multiple sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19977494	chr7:128431264	CCDC136	0.48	7.33	0.32	1.07e-12	Gut microbiome composition (summer);
LGG	cis	rs12447804	0.911	rs2241773	chr16:58080910	C/T	cg03859792	chr16:58121049	NA	0.48	7.3	0.32	1.3e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg00409905	chr10:38381863	ZNF37A	-0.53	-9.98	-0.42	2.26e-21	Breast cancer;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg16405210	chr4:1374714	KIAA1530	-0.57	-10.14	-0.43	5.94e-22	Longevity;
LGG	cis	rs5769765	0.955	rs9616204	chr22:50303530	T/C	cg02269571	chr22:50332266	NA	-0.69	-10.71	-0.45	4.59e-24	Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg07362569	chr17:61921086	SMARCD2	0.5	9.69	0.41	2.35e-20	Prudent dietary pattern;
LGG	trans	rs7939886	0.920	rs1905069	chr11:55887135	T/C	cg15704280	chr7:45808275	SEPT13	0.85	8.82	0.38	2.37e-17	Myopia (pathological);
LGG	cis	rs10462794	1.000	rs4296773	chr5:4486970	G/C	cg18482690	chr5:4511582	NA	0.38	6.7	0.3	6.22e-11	DNA methylation (variation);
LGG	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg13939156	chr17:80058883	NA	-0.4	-6.95	-0.31	1.26e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg16507663	chr6:150244633	RAET1G	0.49	8.56	0.37	1.69e-16	Lung cancer;
LGG	cis	rs4819852	0.958	rs1034564	chr22:19984013	A/G	cg07821417	chr22:19972146	ARVCF	-0.62	-13.4	-0.53	8e-35	Pulse pressure;
LGG	cis	rs644799	0.965	rs598876	chr11:95560853	A/G	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.28	0.7	1.43e-70	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2274273	0.868	rs1572611	chr14:55833874	T/A	cg04306507	chr14:55594613	LGALS3	0.59	16.29	0.6	1.8e-47	Protein biomarker;
LGG	trans	rs10506458	0.834	rs12426893	chr12:63388120	G/T	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.38	-21.4	-0.71	3.74e-71	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4731207	0.624	rs1031955	chr7:124710858	G/C	cg05630886	chr7:124431682	NA	-0.32	-7.37	-0.32	7.82e-13	Cutaneous malignant melanoma;
LGG	cis	rs10435719	0.899	rs9329251	chr8:11793606	G/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	trans	rs853679	0.769	rs7752448	chr6:28301099	A/G	cg06606381	chr12:133084897	FBRSL1	-0.76	-8.09	-0.35	5.39e-15	Depression;
LGG	cis	rs12188164	1.000	rs72717412	chr5:429381	C/T	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.47	0.33	4.06e-13	Cystic fibrosis severity;
LGG	trans	rs2739330	0.731	rs2000468	chr22:24241611	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.68	-11.93	-0.48	8.35e-29	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12765878	1.000	rs34300861	chr10:105643332	A/C	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.99	-0.39	6.14e-18	Longevity;Endometriosis;
LGG	cis	rs6500602	0.789	rs2404546	chr16:4479734	C/G	cg05091796	chr16:4465799	CORO7	-0.75	-13.08	-0.52	1.79e-33	Schizophrenia;
LGG	cis	rs11966931	0.948	rs72933169	chr6:108090799	A/G	cg04749840	chr6:108095067	SCML4	0.42	7.25	0.32	1.73e-12	Neutrophil percentage of white cells;
LGG	cis	rs12431410	0.892	rs4243617	chr14:60165070	T/G	cg07950296	chr14:60194823	RTN1	0.38	7.15	0.32	3.43e-12	Schizophrenia;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.48	-9.45	-0.4	1.75e-19	Personality dimensions;
LGG	cis	rs7911264	0.739	rs7914814	chr10:94382950	A/G	cg25093409	chr10:94429542	NA	0.48	9.39	0.4	2.71e-19	Inflammatory bowel disease;
LGG	cis	rs12497850	0.864	rs12493001	chr3:49181885	A/G	cg07636037	chr3:49044803	WDR6	1.07	25.01	0.76	5.7e-88	Parkinson's disease;
LGG	cis	rs2120243	0.592	rs4640513	chr3:157115950	A/G	cg24825693	chr3:157122686	VEPH1	-0.49	-11.41	-0.47	9.57e-27	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.94e-11	Aortic root size;
LGG	cis	rs7582180	0.606	rs4851299	chr2:100954191	C/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	9.09e-48	Intelligence (multi-trait analysis);
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg19847130	chr8:10466454	RP1L1	-0.31	-6.8	-0.3	3.27e-11	Mood instability;
LGG	cis	rs11640734	0.609	rs11647746	chr16:89806343	C/A	cg27400746	chr16:89904261	SPIRE2	-0.99	-15.67	-0.59	9.93e-45	Interleukin-17 levels;
LGG	cis	rs6089829	0.888	rs4809468	chr20:61673566	T/C	cg08045932	chr20:61659980	NA	0.6	12.18	0.49	8.18e-30	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7192380	1.000	rs8061052	chr16:69656532	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.77	-0.34	4.94e-14	Sjögren's syndrome;
LGG	cis	rs774359	0.797	rs10812604	chr9:27496661	A/C	cg21249376	chr9:27528432	MOBKL2B	-0.41	-8.41	-0.36	5.22e-16	Amyotrophic lateral sclerosis;
LGG	trans	rs9325144	0.560	rs11183189	chr12:38683770	T/A	cg23762105	chr12:34175262	ALG10	-0.35	-7.21	-0.32	2.32e-12	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg20302533	chr7:39170763	POU6F2	0.53	13.06	0.52	2.01e-33	IgG glycosylation;
LGG	trans	rs7726839	0.574	rs11134149	chr5:637277	A/G	cg25482853	chr8:67687455	SGK3	0.81	10.47	0.44	3.58e-23	Obesity-related traits;
LGG	cis	rs17030434	1.000	rs75083896	chr4:154719082	A/G	cg14289246	chr4:154710475	SFRP2	-0.72	-11.0	-0.46	3.77e-25	Electrocardiographic conduction measures;
LGG	cis	rs2976388	1.000	rs2976388	chr8:143760256	G/A	cg06565975	chr8:143823917	SLURP1	-0.41	-10.4	-0.44	6.69e-23	Urinary tract infection frequency;
LGG	cis	rs4595586	0.525	rs7977228	chr12:39395060	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs12477438	0.798	rs2045057	chr2:99684929	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs950776	0.684	rs61012457	chr15:78865694	C/G	cg16751781	chr15:78858589	CHRNA5	0.43	8.15	0.35	3.42e-15	Sudden cardiac arrest;
LGG	cis	rs10504229	1.000	rs67705655	chr8:58177688	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs62056103	chr16:89942781	G/A	cg26513180	chr16:89883248	FANCA	0.85	8.19	0.36	2.57e-15	Skin colour saturation;
LGG	cis	rs939658	0.567	rs11631829	chr15:79446529	C/T	cg17916960	chr15:79447300	NA	-0.52	-9.5	-0.4	1.16e-19	Refractive error;
LGG	cis	rs6772849	0.896	rs9816260	chr3:128352083	A/T	cg08795948	chr3:128337044	NA	0.66	11.3	0.47	2.47e-26	Monocyte percentage of white cells;Monocyte count;
LGG	cis	rs2030746	1.000	rs2030746	chr2:121309488	C/T	cg22272644	chr2:121334640	NA	-0.28	-6.69	-0.3	6.48e-11	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	cis	rs9487094	0.922	rs11153181	chr6:109750027	A/T	cg16315928	chr6:109776240	MICAL1	0.55	9.18	0.39	1.4e-18	Height;
LGG	cis	rs9393692	0.967	rs6456712	chr6:26302573	A/C	cg00294572	chr6:26285232	NA	0.44	7.85	0.34	3.02e-14	Educational attainment;
LGG	trans	rs853679	0.882	rs4713140	chr6:28097193	C/T	cg06606381	chr12:133084897	FBRSL1	-0.88	-9.84	-0.42	6.99e-21	Depression;
LGG	cis	rs9512730	0.517	rs1967772	chr13:28036062	G/A	cg04070771	chr13:27998621	GTF3A	0.48	7.45	0.33	4.58e-13	Schizophrenia;
LGG	cis	rs4332037	0.538	rs4721164	chr7:1932629	C/G	cg23422044	chr7:1970798	MAD1L1	-0.64	-11.73	-0.48	5.29e-28	Bipolar disorder;
LGG	cis	rs8133932	0.701	rs2150454	chr21:47288142	T/C	cg11214348	chr21:47283868	PCBP3	0.45	8.08	0.35	5.74e-15	Schizophrenia;
LGG	cis	rs1799949	1.000	rs33945274	chr17:41280073	G/A	cg23758822	chr17:41437982	NA	0.87	15.21	0.58	1.14e-42	Menopause (age at onset);
LGG	cis	rs7223966	1.000	rs7209758	chr17:61913621	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.07	0.46	1.9e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs13191362	0.507	rs13197051	chr6:163201728	A/T	cg06582575	chr6:163149167	PACRG;PARK2	0.52	7.19	0.32	2.54e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg20363699	chr7:23626180	CLK2P	0.29	6.82	0.3	2.84e-11	Schizophrenia;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs4731207	0.698	rs10263573	chr7:124469267	A/T	cg05630886	chr7:124431682	NA	0.33	7.83	0.34	3.47e-14	Cutaneous malignant melanoma;
LGG	cis	rs657075	0.697	rs13180295	chr5:131705588	G/A	cg20453264	chr5:131705742	SLC22A5	0.65	8.27	0.36	1.46e-15	Rheumatoid arthritis;
LGG	cis	rs6669919	0.967	rs894983	chr1:211675279	T/C	cg10512769	chr1:211675356	NA	-0.7	-15.7	-0.59	8.07e-45	Intelligence (multi-trait analysis);
LGG	cis	rs704	0.585	rs1007398	chr17:26665648	A/G	cg10342447	chr17:26645325	TMEM97	-0.52	-9.78	-0.41	1.16e-20	Osteoprotegerin levels;
LGG	cis	rs2030746	0.521	rs6750309	chr2:121332191	A/G	cg22272644	chr2:121334640	NA	-0.37	-9.48	-0.4	1.35e-19	LDL cholesterol;Total cholesterol levels;LDL cholesterol levels;
LGG	trans	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg18335740	chr13:41363409	SLC25A15	0.63	12.43	0.5	7.9e-31	Lewy body disease;
LGG	cis	rs4851254	0.584	rs56935201	chr2:100637788	G/A	cg17356467	chr2:100759845	AFF3	0.48	7.75	0.34	5.99e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6733011	0.502	rs6542847	chr2:99573471	A/G	cg23527387	chr2:100056660	REV1	0.35	7.75	0.34	5.75e-14	Bipolar disorder;
LGG	trans	rs7939886	0.920	rs11227180	chr11:55855611	G/C	cg03929089	chr4:120376271	NA	0.79	8.19	0.36	2.51e-15	Myopia (pathological);
LGG	cis	rs79976124	0.879	rs10944856	chr6:66636960	G/C	cg07460842	chr6:66804631	NA	0.73	12.62	0.51	1.32e-31	Type 2 diabetes;
LGG	trans	rs116095464	0.558	rs2288458	chr5:231260	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.47e-15	Breast cancer;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs564799	0.966	rs629209	chr3:159728713	C/G	cg04855961	chr3:159719849	NA	-0.28	-7.52	-0.33	2.89e-13	Systemic lupus erythematosus;
LGG	cis	rs769267	0.930	rs4808965	chr19:19631655	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.15	0.35	3.31e-15	Tonsillectomy;
LGG	cis	rs62025270	0.848	rs2554	chr15:86302643	T/C	cg25843651	chr15:86329602	KLHL25	0.65	10.51	0.44	2.65e-23	Idiopathic pulmonary fibrosis;
LGG	cis	rs780096	0.526	rs4803	chr2:27667297	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.19	-0.36	2.61e-15	Total body bone mineral density;
LGG	cis	rs537930	0.560	rs657223	chr5:134355800	A/T	cg24576358	chr5:134350122	NA	-0.41	-9.23	-0.39	9.92e-19	Height;
LGG	cis	rs7659604	0.628	rs6838153	chr4:122720999	A/G	cg19748678	chr4:122722346	EXOSC9	0.7	14.15	0.55	4.86e-38	Type 2 diabetes;
LGG	cis	rs798554	0.660	rs2527687	chr7:2838485	G/A	cg05793240	chr7:2802953	GNA12	0.32	7.95	0.35	1.44e-14	Height;
LGG	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg08885076	chr2:99613938	TSGA10	0.45	9.48	0.4	1.33e-19	Chronic sinus infection;
LGG	cis	rs67385638	0.802	rs7119142	chr11:5309078	A/G	cg12559170	chr11:5275217	HBG2	0.49	11.0	0.46	3.66e-25	Hemoglobin levels;
LGG	cis	rs308971	0.572	rs307559	chr3:12094965	G/T	cg02700894	chr3:12045449	SYN2	0.48	6.83	0.3	2.61e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs7236492	0.572	rs112024357	chr18:77175610	T/C	cg05753993	chr18:77199432	NFATC1	0.41	6.78	0.3	3.65e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6951245	1.000	rs77868187	chr7:1093968	A/C	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5753037	0.543	rs131268	chr22:30147938	C/G	cg01021169	chr22:30184971	ASCC2	-0.37	-7.3	-0.32	1.24e-12	Type 1 diabetes;
LGG	cis	rs77741769	0.571	rs4454799	chr12:121317075	A/C	cg02419362	chr12:121203948	SPPL3	-0.53	-9.25	-0.39	8.58e-19	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.67e-12	Prudent dietary pattern;
LGG	cis	rs7091068	0.566	rs7082701	chr10:95501042	G/T	cg20715218	chr10:95462985	C10orf4	0.69	10.05	0.42	1.3e-21	Urinary tract infection frequency;
LGG	cis	rs6598955	0.671	rs6681452	chr1:26621101	G/A	cg04990556	chr1:26633338	UBXN11	0.57	7.92	0.35	1.74e-14	Obesity-related traits;
LGG	cis	rs7546668	1.000	rs10803389	chr1:15861287	C/T	cg21858823	chr1:15850916	CASP9	0.38	7.01	0.31	8.46e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.862	rs1083554	chr7:65852341	T/C	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.07	0.39	3.34e-18	Educational attainment;
LGG	cis	rs10754283	0.934	rs6428563	chr1:90111583	T/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs3770081	1.000	rs12620810	chr2:86391481	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.66	7.14	0.32	3.57e-12	Facial emotion recognition (sad faces);
LGG	cis	rs4959677	0.792	rs10793838	chr6:2474246	T/G	cg20147862	chr6:2634573	C6orf195	-0.34	-7.12	-0.31	4.22e-12	Orthostatic hypotension;
LGG	cis	rs7529073	1.000	rs7529073	chr1:214147889	T/C	cg00795024	chr1:214157026	NA	0.26	7.36	0.32	8.31e-13	Schizophrenia;
LGG	cis	rs4566357	1.000	rs3769637	chr2:227922623	T/C	cg11843606	chr2:227700838	RHBDD1	-0.4	-7.08	-0.31	5.55e-12	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18304674	chr10:114206557	ZDHHC6;VTI1A	0.45	6.67	0.3	7.53e-11	Gut microbiome composition (summer);
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg01262667	chr19:19385393	TM6SF2	0.46	11.5	0.47	4.11e-27	Tonsillectomy;
LGG	cis	rs68170813	0.559	rs12540475	chr7:106886295	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.93	-0.45	6.76e-25	Coronary artery disease;
LGG	cis	rs1670533	1.000	rs6599279	chr4:1058833	G/A	cg27284194	chr4:1044797	NA	0.56	9.98	0.42	2.19e-21	Recombination rate (females);
LGG	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg27279351	chr12:120934652	DYNLL1	0.79	12.55	0.5	2.71e-31	High light scatter reticulocyte count;
LGG	trans	rs7618501	0.735	rs9876508	chr3:49780844	G/A	cg21659725	chr3:3221576	CRBN	-0.92	-20.44	-0.69	1.21e-66	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.882	rs2130813	chr3:10038706	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.82	-12.91	-0.51	8.39e-33	Alzheimer's disease;
LGG	cis	rs1707322	0.964	rs796773	chr1:46564475	C/T	cg03146154	chr1:46216737	IPP	-0.54	-9.67	-0.41	2.77e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg20503657	chr10:835505	NA	0.75	10.44	0.44	4.84e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs8028182	0.636	rs4886716	chr15:75856022	G/C	cg20655648	chr15:75932815	IMP3	0.44	7.26	0.32	1.68e-12	Sudden cardiac arrest;
LGG	cis	rs7582720	1.000	rs72932780	chr2:203695826	G/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.42	6.93	0.31	1.4e-11	Prudent dietary pattern;
LGG	cis	rs2645694	0.626	rs2703119	chr4:77823640	C/T	cg18351406	chr4:77819688	ANKRD56	0.46	8.03	0.35	7.86e-15	Emphysema distribution in smoking;
LGG	cis	rs4595586	0.545	rs4438082	chr12:39363870	C/T	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs798554	0.959	rs798557	chr7:2758982	G/A	cg14668632	chr7:2872130	GNA12	-0.36	-7.24	-0.32	1.92e-12	Height;
LGG	trans	rs7395662	0.819	rs11039913	chr11:48692081	G/A	cg03929089	chr4:120376271	NA	-0.44	-7.09	-0.31	4.89e-12	HDL cholesterol;
LGG	cis	rs9815354	0.812	rs73071352	chr3:41828300	A/G	cg03022575	chr3:42003672	ULK4	0.8	9.42	0.4	2.14e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1920116	0.778	rs59800107	chr3:169556383	T/C	cg08193579	chr3:169529701	LRRC34	0.41	7.03	0.31	7.59e-12	Glioma (high-grade);
LGG	cis	rs6500602	0.702	rs1051308	chr16:4560301	A/G	cg08645402	chr16:4508243	NA	-0.51	-9.65	-0.41	3.44e-20	Schizophrenia;
LGG	cis	rs2842992	0.789	rs3818300	chr6:160201677	G/A	cg11366901	chr6:160182831	ACAT2	1.05	16.24	0.6	2.85e-47	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2797369	0.656	rs635258	chr6:101349583	G/A	cg27451362	chr6:101846650	GRIK2	0.76	10.51	0.44	2.49e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs11764590	0.694	rs10276536	chr7:2086960	C/T	cg12432903	chr7:1882776	MAD1L1	0.39	6.91	0.31	1.62e-11	Neuroticism;
LGG	cis	rs4430311	0.755	rs4658585	chr1:243803922	A/G	cg25706552	chr1:244017396	NA	0.63	15.43	0.58	1.25e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10504229	1.000	rs73607871	chr8:58173007	T/C	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.31	0.32	1.2e-12	Electroencephalogram traits;
LGG	cis	rs28386778	0.863	rs2597633	chr17:61872871	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs7615952	0.576	rs4646748	chr3:125826329	G/A	cg05084668	chr3:125655381	ALG1L	-0.56	-7.53	-0.33	2.73e-13	Blood pressure (smoking interaction);
LGG	cis	rs2404602	0.692	rs12910734	chr15:77149931	A/G	cg23625390	chr15:77176239	SCAPER	0.48	9.45	0.4	1.69e-19	Blood metabolite levels;
LGG	cis	rs780094	0.606	rs6729709	chr2:27583156	G/A	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.71	-0.3	5.63e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	trans	rs7819412	0.618	rs10105377	chr8:10975733	A/G	cg06636001	chr8:8085503	FLJ10661	-0.47	-8.62	-0.37	1.09e-16	Triglycerides;
LGG	cis	rs6541297	0.645	rs4846918	chr1:230300586	A/G	cg05784532	chr1:230284198	GALNT2	-0.45	-7.03	-0.31	7.66e-12	Coronary artery disease;
LGG	cis	rs8062405	0.720	rs9926245	chr16:28555706	T/A	cg07382826	chr16:28625726	SULT1A1	0.39	8.5	0.37	2.67e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg15556689	chr8:8085844	FLJ10661	0.4	6.69	0.3	6.58e-11	Systemic lupus erythematosus;
LGG	cis	rs1775715	0.677	rs2491272	chr10:32186783	A/G	cg14930904	chr10:32216787	ARHGAP12	0.35	6.72	0.3	5.37e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs1401999	0.510	rs17817736	chr3:183720313	A/T	cg01324343	chr3:183735012	ABCC5	-0.56	-10.13	-0.43	6.48e-22	Anterior chamber depth;
LGG	cis	rs9549367	0.789	rs3861720	chr13:113906097	A/G	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg18161036	chr17:58513332	NA	0.42	6.77	0.3	3.87e-11	Menarche (age at onset);
LGG	cis	rs4237845	0.591	rs4760344	chr12:58320783	A/T	cg02175503	chr12:58329896	NA	0.8	15.24	0.58	8.27e-43	Intelligence (multi-trait analysis);
LGG	cis	rs2880765	0.835	rs6496027	chr15:86049988	C/T	cg13263323	chr15:86062960	AKAP13	-0.34	-7.05	-0.31	6.74e-12	Coronary artery disease;
LGG	cis	rs848	0.500	rs7700346	chr5:131983426	G/A	cg04303330	chr5:131992430	IL13	0.29	6.78	0.3	3.64e-11	Alopecia areata;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6500395	0.775	rs1968903	chr16:48664014	C/T	cg04672837	chr16:48644449	N4BP1	0.5	8.46	0.37	3.5e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.679	rs4737454	chr8:58033965	A/T	cg22535103	chr8:58192502	C8orf71	-0.73	-10.01	-0.42	1.73e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs2197308	0.715	rs11181816	chr12:37911626	A/G	cg04568710	chr12:38710424	ALG10B	-0.35	-7.49	-0.33	3.61e-13	Morning vs. evening chronotype;
LGG	cis	rs1801251	1.000	rs283480	chr2:233648742	G/A	cg08000102	chr2:233561755	GIGYF2	0.6	9.75	0.41	1.52e-20	Coronary artery disease;
LGG	cis	rs7953249	0.618	rs2650000	chr12:121388962	G/T	cg02403541	chr12:121454288	C12orf43	0.52	8.77	0.38	3.51e-17	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs2228479	0.717	rs9282682	chr16:89805794	A/G	cg04287289	chr16:89883240	FANCA	0.83	8.97	0.38	7.22e-18	Skin colour saturation;
LGG	cis	rs7552404	1.000	rs12127402	chr1:76205643	C/A	cg22875332	chr1:76189707	ACADM	0.6	10.14	0.43	6.15e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2032447	0.613	rs6456708	chr6:26032847	G/C	cg03517284	chr6:25882590	NA	-0.48	-9.12	-0.39	2.29e-18	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.752	rs62010327	chr15:78892784	G/A	cg17108064	chr15:78857060	CHRNA5	0.44	9.06	0.39	3.58e-18	Sudden cardiac arrest;
LGG	cis	rs17767392	0.813	rs12887261	chr14:71941979	A/T	cg02058870	chr14:72053146	SIPA1L1	0.39	8.13	0.35	3.86e-15	Mitral valve prolapse;
LGG	cis	rs10504229	0.728	rs72650858	chr8:58152832	G/A	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9357271	0.910	rs9349079	chr6:38369032	C/T	cg07362130	chr6:38359646	BTBD9	-0.44	-10.04	-0.42	1.32e-21	Restless legs syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21146272	chr6:42858716	C6orf226	0.51	7.8	0.34	4.17e-14	Gut microbiome composition (summer);
LGG	cis	rs9443645	0.901	rs2174743	chr6:79591805	G/A	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs9788682	1.000	rs12438181	chr15:78812098	G/A	cg06917634	chr15:78832804	PSMA4	-0.65	-9.97	-0.42	2.47e-21	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs72781680	0.665	rs72788298	chr2:24104293	T/C	cg08917208	chr2:24149416	ATAD2B	0.66	8.66	0.37	7.61e-17	Lymphocyte counts;
LGG	cis	rs5742933	0.857	rs12471217	chr2:190572063	G/A	cg04003228	chr2:190539410	ANKAR	-0.5	-7.28	-0.32	1.45e-12	Ferritin levels;
LGG	cis	rs769267	0.965	rs10419245	chr19:19383755	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.46	7.46	0.33	4.35e-13	Tonsillectomy;
LGG	cis	rs4132509	0.744	rs7519673	chr1:243993123	A/G	cg21452805	chr1:244014465	NA	0.99	9.59	0.41	5.42e-20	RR interval (heart rate);
LGG	cis	rs8014204	1.000	rs4553560	chr14:75334199	T/C	cg06637938	chr14:75390232	RPS6KL1	-0.82	-16.67	-0.61	3.28e-49	Caffeine consumption;
LGG	cis	rs79911532	0.515	rs113229120	chr7:75748581	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-7.96	-0.35	1.34e-14	Mononucleosis;
LGG	cis	rs6993813	0.843	rs28437165	chr8:120030474	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.78	0.3	3.68e-11	Bone mineral density (hip);
LGG	cis	rs9322193	0.923	rs9479810	chr6:150072495	C/T	cg12070911	chr6:150209640	RAET1E	0.29	6.95	0.31	1.26e-11	Lung cancer;
LGG	cis	rs4481887	0.927	rs4564179	chr1:248472422	T/C	cg00666640	chr1:248458726	OR2T12	0.56	9.03	0.39	4.59e-18	Common traits (Other);
LGG	cis	rs9828933	1.000	rs1060897	chr3:63997872	C/T	cg17941049	chr3:63904683	ATXN7	-0.66	-8.33	-0.36	9.07e-16	Type 2 diabetes;
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg08645402	chr16:4508243	NA	-0.51	-9.14	-0.39	1.95e-18	Schizophrenia;
LGG	trans	rs6598955	0.670	rs7531518	chr1:26539749	T/C	cg07461501	chr17:79650226	HGS;ARL16	0.36	7.49	0.33	3.47e-13	Obesity-related traits;
LGG	cis	rs8017423	0.935	rs11628906	chr14:90738002	C/T	cg04374321	chr14:90722782	PSMC1	-0.84	-17.54	-0.63	3.63e-53	Mortality in heart failure;
LGG	cis	rs4731207	0.565	rs10954056	chr7:124600534	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs2731664	0.792	rs337374	chr5:176890416	A/G	cg23176889	chr5:176863531	GRK6	0.65	13.12	0.52	1.19e-33	Intelligence (multi-trait analysis);
LGG	cis	rs757278	0.564	rs17550567	chr7:117362167	C/T	cg10524701	chr7:117356490	CTTNBP2	0.45	7.6	0.33	1.65e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs55728055	0.661	rs7293143	chr22:32013365	A/G	cg27454842	chr22:32027588	PISD	0.58	6.69	0.3	6.32e-11	Age-related hearing impairment;
LGG	cis	rs1806153	0.611	rs1806154	chr11:31844104	T/C	cg11990419	chr11:31841155	NA	0.32	7.4	0.33	6.65e-13	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs910316	0.737	rs175055	chr14:75488946	T/G	cg08847533	chr14:75593920	NEK9	-0.54	-10.03	-0.42	1.51e-21	Height;
LGG	trans	rs1814175	0.781	rs28681334	chr11:50051177	C/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.66	-0.79	4.11e-100	Height;
LGG	cis	rs300774	0.925	rs300708	chr2:140449	A/G	cg04617936	chr2:214353	NA	-0.49	-7.59	-0.33	1.81e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs533581	0.873	rs579740	chr16:88973937	A/G	cg08484992	chr16:88977278	CBFA2T3	-0.35	-8.31	-0.36	1.09e-15	Social autistic-like traits;
LGG	trans	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs1005277	0.579	rs2504148	chr10:38400788	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.17	-0.32	2.98e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs17122278	1.000	rs11216906	chr11:118443944	G/A	cg19182353	chr11:118479428	PHLDB1	-0.52	-6.76	-0.3	4.14e-11	Total cholesterol levels;
LGG	cis	rs1552244	0.810	rs7612908	chr3:10089148	A/G	cg00149659	chr3:10157352	C3orf10	0.86	11.02	0.46	3.2e-25	Alzheimer's disease;
LGG	cis	rs9527	0.590	rs2066322	chr10:104909339	T/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.87	-0.3	2.14e-11	Arsenic metabolism;
LGG	cis	rs208520	0.754	rs1100989	chr6:66880532	G/A	cg07460842	chr6:66804631	NA	-0.96	-17.65	-0.63	1.1e-53	Exhaled nitric oxide output;
LGG	cis	rs736408	0.562	rs13071584	chr3:52804487	T/C	cg18099408	chr3:52552593	STAB1	-0.35	-6.98	-0.31	1.02e-11	Bipolar disorder;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg18350739	chr11:68623251	NA	-0.89	-23.03	-0.73	8.53e-79	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.903	rs708723	chr1:205739266	C/T	cg11965913	chr1:205819406	PM20D1	0.59	10.82	0.45	1.72e-24	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03125394	chr5:102091191	NA	0.45	6.65	0.3	8.42e-11	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg20607798	chr8:58055168	NA	0.58	6.69	0.3	6.61e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9682041	0.696	rs6774380	chr3:170091644	T/A	cg11886554	chr3:170076028	SKIL	0.67	8.64	0.37	8.9e-17	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs262150	0.851	rs2657326	chr7:158766262	C/T	cg19418458	chr7:158789849	NA	-0.46	-9.0	-0.39	5.93e-18	Facial morphology (factor 20);
LGG	cis	rs2439831	0.867	rs16957627	chr15:43642657	G/A	cg15269541	chr15:43626905	ADAL	-0.41	-6.81	-0.3	3.08e-11	Lung cancer in ever smokers;
LGG	cis	rs58688157	0.705	rs7112149	chr11:595890	G/A	cg02461776	chr11:598696	PHRF1	0.54	8.68	0.37	6.88e-17	Systemic lupus erythematosus;
LGG	cis	rs8180040	0.966	rs62260711	chr3:47564491	G/C	cg27129171	chr3:47204927	SETD2	-0.78	-14.83	-0.57	5.69e-41	Colorectal cancer;
LGG	cis	rs1552244	1.000	rs722509	chr3:10102377	T/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-13.17	-0.52	7.57e-34	Alzheimer's disease;
LGG	trans	rs11088226	0.681	rs2833897	chr21:33931792	T/C	cg09050820	chr6:167586206	TCP10L2	0.89	12.4	0.5	1.1e-30	Gastritis;
LGG	cis	rs1348850	0.914	rs7604673	chr2:178392346	A/G	cg22681709	chr2:178499509	PDE11A	-0.47	-8.58	-0.37	1.47e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6500602	0.701	rs1362626	chr16:4549226	C/G	cg05091796	chr16:4465799	CORO7	-0.76	-12.42	-0.5	8.72e-31	Schizophrenia;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg22946670	chr1:154909930	PMVK	0.4	6.67	0.3	7.37e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs7312933	0.592	rs1551210	chr12:42865874	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.52	8.23	0.36	1.91e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6952808	0.862	rs4721135	chr7:1912222	A/G	cg21782813	chr7:2030301	MAD1L1	0.42	9.9	0.42	4.23e-21	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.7	-0.34	8.46e-14	Monocyte count;
LGG	cis	rs875971	0.895	rs7782806	chr7:65657897	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.81	0.38	2.6e-17	Aortic root size;
LGG	cis	rs13191362	1.000	rs35092540	chr6:163090778	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.34	0.32	9.67e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.32	-0.5	2.42e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs8180040	0.966	rs11130128	chr3:47486632	T/C	cg16586182	chr3:47516702	SCAP	0.77	15.39	0.58	1.86e-43	Colorectal cancer;
LGG	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg13482628	chr17:19912719	NA	0.54	10.26	0.43	2.16e-22	Schizophrenia;
LGG	cis	rs10504229	0.683	rs1495865	chr8:58141160	T/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg11062466	chr8:58055876	NA	0.48	8.29	0.36	1.23e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.573	rs73277974	chr17:29189869	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4319547	0.656	rs7294559	chr12:122837564	C/A	cg23029597	chr12:123009494	RSRC2	-0.91	-16.71	-0.61	2.21e-49	Body mass index;
LGG	cis	rs4595586	0.545	rs7980848	chr12:39375166	G/C	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs875971	1.000	rs4718357	chr7:65960878	A/G	cg18876405	chr7:65276391	NA	0.55	9.97	0.42	2.54e-21	Aortic root size;
LGG	cis	rs7546668	0.948	rs12736181	chr1:15869284	G/A	cg21858823	chr1:15850916	CASP9	0.36	6.67	0.3	7.38e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs11122272	0.735	rs2244994	chr1:231537127	C/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.19	-0.32	2.69e-12	Hemoglobin concentration;
LGG	cis	rs8056893	0.679	rs9933029	chr16:68303410	C/T	cg07273125	chr16:68295692	NA	-0.37	-7.79	-0.34	4.53e-14	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	1.000	rs2665851	chr17:61957023	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	30.32	0.82	5.04e-112	Prudent dietary pattern;
LGG	cis	rs950169	0.922	rs12915832	chr15:85111457	C/T	cg03959625	chr15:84868606	LOC388152	0.57	9.23	0.39	1.01e-18	Schizophrenia;
LGG	cis	rs116095464	0.850	rs10057272	chr5:340188	T/C	cg22857025	chr5:266934	NA	-1.36	-11.37	-0.47	1.33e-26	Breast cancer;
LGG	cis	rs2033711	0.654	rs734380	chr19:58898963	A/C	cg13877915	chr19:58951672	ZNF132	0.73	14.29	0.55	1.18e-38	Uric acid clearance;
LGG	cis	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg24623649	chr8:11872141	NA	0.3	6.99	0.31	9.56e-12	Neuroticism;
LGG	cis	rs6502050	0.835	rs4789732	chr17:80131382	A/G	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	cis	rs17666538	0.710	rs12716640	chr8:645376	A/C	cg02524346	chr8:600233	NA	1.23	11.89	0.48	1.19e-28	IgG glycosylation;
LGG	cis	rs17376456	0.825	rs12716454	chr5:93272279	A/C	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs734999	1.000	rs734999	chr1:2513216	C/T	cg05697835	chr1:2722811	NA	0.3	7.13	0.31	3.79e-12	Ulcerative colitis;
LGG	cis	rs6964587	1.000	rs58965837	chr7:91585258	T/A	cg17063962	chr7:91808500	NA	0.48	8.54	0.37	1.93e-16	Breast cancer;
LGG	cis	rs68170813	0.559	rs114221457	chr7:107019913	C/G	cg02696742	chr7:106810147	HBP1	-0.72	-9.81	-0.41	8.82e-21	Coronary artery disease;
LGG	cis	rs9291683	0.588	rs35438220	chr4:9999398	C/T	cg00071950	chr4:10020882	SLC2A9	0.41	8.51	0.37	2.52e-16	Bone mineral density;
LGG	cis	rs4959677	0.792	rs6923507	chr6:2474347	T/C	cg20147862	chr6:2634573	C6orf195	-0.34	-7.08	-0.31	5.51e-12	Orthostatic hypotension;
LGG	cis	rs6693567	0.507	rs828784	chr1:150335240	T/A	cg15654264	chr1:150340011	RPRD2	0.32	6.67	0.3	7.19e-11	Migraine;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg22624255	chr19:19779476	ZNF101	-0.42	-6.94	-0.31	1.33e-11	Leprosy;
LGG	cis	rs7949030	0.635	rs1801144	chr11:62381808	G/C	cg13298116	chr11:62369859	EML3;MTA2	0.7	16.7	0.61	2.32e-49	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6735179	0.648	rs10469992	chr2:1760091	A/G	cg20570797	chr2:1712800	PXDN	0.46	8.36	0.36	7.14e-16	Response to antipsychotic treatment;
LGG	cis	rs78905543	0.967	rs4242388	chr8:22932711	T/C	cg13462030	chr8:22926911	TNFRSF10B	0.41	7.73	0.34	6.75e-14	Mean corpuscular volume;
LGG	cis	rs41271951	0.512	rs41266632	chr1:151042980	C/T	cg11822372	chr1:151115635	SEMA6C	-0.67	-7.02	-0.31	7.83e-12	Blood protein levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg24147849	chr3:100053372	NIT2	0.4	7.38	0.32	7.6e-13	Obesity-related traits;
LGG	cis	rs1865760	0.508	rs9379820	chr6:26049924	T/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs171408	0.895	rs15734	chr3:8615489	C/T	cg03557445	chr3:8615444	LOH3CR2A	0.48	8.81	0.38	2.57e-17	Mitral valve prolapse;
LGG	cis	rs4319547	0.656	rs10734918	chr12:122921512	A/C	cg05707623	chr12:122985044	ZCCHC8	-0.65	-9.68	-0.41	2.68e-20	Body mass index;
LGG	cis	rs7444	0.941	rs5749493	chr22:21939687	C/A	cg05046821	chr22:21984468	YDJC	-0.37	-7.02	-0.31	8.11e-12	Systemic lupus erythematosus;
LGG	cis	rs11711311	1.000	rs9288984	chr3:113525956	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.63	12.81	0.51	2.25e-32	IgG glycosylation;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg19318889	chr4:1322082	MAEA	0.47	7.82	0.34	3.65e-14	Longevity;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg11062466	chr8:58055876	NA	0.5	8.44	0.37	3.97e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.775	rs6946768	chr7:99954393	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.16	18.88	0.66	2.18e-59	Platelet count;
LGG	cis	rs2718058	0.630	rs2722228	chr7:37859818	G/A	cg15028436	chr7:37888078	TXNDC3	0.52	8.2	0.36	2.31e-15	Alzheimer's disease (late onset);
LGG	cis	rs13108904	0.870	rs11727987	chr4:1261435	A/G	cg00684032	chr4:1343700	KIAA1530	0.47	9.04	0.39	4.35e-18	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs33926631	chr17:41304463	T/C	cg12708336	chr17:41446283	NA	-0.31	-7.39	-0.33	6.7e-13	Menopause (age at onset);
LGG	cis	rs701145	0.938	rs701147	chr3:154048295	C/T	cg17054900	chr3:154042577	DHX36	1.01	12.41	0.5	9.91e-31	Coronary artery disease;
LGG	cis	rs4006360	0.551	rs2320193	chr17:39243414	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.14	-0.46	1.02e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs7577696	0.597	rs17011801	chr2:32298072	A/T	cg02381751	chr2:32503542	YIPF4	-0.46	-6.75	-0.3	4.5e-11	Inflammatory biomarkers;
LGG	cis	rs7666738	0.830	rs10022331	chr4:98960392	C/A	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.47e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17270561	0.609	rs6924782	chr6:25735816	C/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs992157	1.000	rs6736362	chr2:219115108	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.65	11.15	0.46	1.02e-25	Colorectal cancer;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg08677398	chr8:58056175	NA	0.58	9.27	0.4	7.29e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs62244186	0.608	rs2888390	chr3:44511405	G/A	cg02073558	chr3:44770973	ZNF501	0.68	12.56	0.5	2.52e-31	Depressive symptoms;
LGG	cis	rs9543976	1.000	rs2031236	chr13:76169777	C/T	cg01531495	chr13:76123901	UCHL3	-0.63	-7.4	-0.33	6.37e-13	Diabetic retinopathy;
LGG	cis	rs4481887	0.927	rs11204631	chr1:248479530	A/G	cg00666640	chr1:248458726	OR2T12	0.56	8.88	0.38	1.45e-17	Common traits (Other);
LGG	cis	rs597539	0.652	rs507520	chr11:68666054	C/T	cg11245990	chr11:68621969	NA	0.42	8.76	0.38	3.58e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg22535103	chr8:58192502	C8orf71	-0.58	-8.48	-0.37	3.05e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.792	rs6971752	chr7:65737986	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.7	-0.41	2.29e-20	Aortic root size;
LGG	cis	rs17270561	0.609	rs9358885	chr6:25758024	T/C	cg03264133	chr6:25882463	NA	-0.49	-7.9	-0.34	2.05e-14	Iron status biomarkers;
LGG	cis	rs3785574	0.650	rs2005132	chr17:62008232	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.89	-16.76	-0.61	1.24e-49	Height;
LGG	cis	rs372883	0.600	rs407712	chr21:30722531	G/A	cg24692254	chr21:30365293	RNF160	-0.65	-12.04	-0.49	2.98e-29	Pancreatic cancer;
LGG	cis	rs6541297	0.938	rs1555289	chr1:230292499	C/T	cg20703242	chr1:230279135	GALNT2	-0.39	-7.36	-0.32	8.65e-13	Coronary artery disease;
LGG	cis	rs9487094	0.670	rs2024849	chr6:109818291	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22874627	chr3:31575329	STT3B	0.51	7.94	0.35	1.51e-14	Gut microbiome composition (summer);
LGG	cis	rs4918072	0.797	rs7912308	chr10:105713840	C/T	cg11005552	chr10:105648138	OBFC1	0.42	7.31	0.32	1.17e-12	Coronary artery disease;
LGG	cis	rs6784615	0.744	rs34551211	chr3:52286825	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.67	7.4	0.33	6.56e-13	Waist-hip ratio;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg09217309	chr6:150244204	RAET1G	0.43	8.01	0.35	9.46e-15	Testicular germ cell tumor;
LGG	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg20891558	chr2:74357851	NA	0.51	9.58	0.41	5.94e-20	Gestational age at birth (maternal effect);
LGG	cis	rs3768617	0.510	rs10797849	chr1:183088988	A/G	cg07928641	chr1:182991847	LAMC1	0.45	8.78	0.38	3.06e-17	Fuchs's corneal dystrophy;
LGG	cis	rs11098499	0.866	rs72676074	chr4:120359841	A/C	cg24375607	chr4:120327624	NA	0.67	11.01	0.46	3.23e-25	Corneal astigmatism;
LGG	cis	rs13082711	0.520	rs2724494	chr3:27563920	C/A	cg02860705	chr3:27208620	NA	0.55	9.67	0.41	2.79e-20	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4662750	0.674	rs777437	chr2:128357647	C/T	cg10021288	chr2:128175891	PROC	0.38	7.15	0.32	3.35e-12	Renal cell carcinoma;
LGG	cis	rs9916302	0.660	rs4795367	chr17:37608843	G/C	cg07936489	chr17:37558343	FBXL20	-0.99	-15.36	-0.58	2.56e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs9878978	1.000	rs13084976	chr3:2462852	A/G	cg21928760	chr3:2462534	CNTN4	0.47	10.36	0.43	8.91e-23	Blood pressure (smoking interaction);
LGG	cis	rs6121246	0.529	rs112367115	chr20:30178627	G/A	cg21427119	chr20:30132790	HM13	-0.57	-8.82	-0.38	2.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs514406	0.825	rs6693210	chr1:53223398	A/G	cg16325326	chr1:53192061	ZYG11B	-0.79	-19.22	-0.67	5.79e-61	Monocyte count;
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs7615952	0.576	rs4646763	chr3:125822129	G/A	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.47	7.58	0.33	1.85e-13	Renal function-related traits (BUN);
LGG	cis	rs6500395	1.000	rs9936004	chr16:48566088	A/G	cg04672837	chr16:48644449	N4BP1	0.54	8.79	0.38	2.86e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs6601327	0.571	rs7820675	chr8:9647748	C/G	cg16141378	chr3:129829833	LOC729375	-0.35	-8.05	-0.35	7.12e-15	Multiple myeloma (hyperdiploidy);
LGG	cis	rs7215564	0.908	rs35646299	chr17:78653506	T/G	cg16980736	chr17:78789706	RPTOR	-0.62	-8.34	-0.36	8.85e-16	Myopia (pathological);
LGG	cis	rs42648	0.935	rs42629	chr7:89963324	G/T	cg25739043	chr7:89950458	NA	-0.42	-8.89	-0.38	1.42e-17	Homocysteine levels;
LGG	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.93	0.54	4.37e-37	Bladder cancer;
LGG	trans	rs9987353	0.566	rs6998368	chr8:9070288	G/C	cg16141378	chr3:129829833	LOC729375	0.31	6.82	0.3	2.92e-11	Recombination measurement;
LGG	cis	rs2916247	1.000	rs734113	chr8:93060095	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.41	-0.36	5.21e-16	Intelligence (multi-trait analysis);
LGG	cis	rs12738007	0.870	rs1908088	chr1:29572966	G/C	cg01115565	chr1:29584222	PTPRU	-0.28	-7.65	-0.33	1.18e-13	Schizophrenia;
LGG	trans	rs941408	1.000	rs4807332	chr19:2793289	T/C	cg22153745	chr1:153894579	GATAD2B	-0.64	-10.42	-0.44	5.49e-23	Total cholesterol levels;
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	11.07	0.46	1.9e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9900972	0.918	rs4789942	chr17:76877495	T/C	cg00961940	chr17:76876995	TIMP2	0.46	9.1	0.39	2.64e-18	Obesity-related traits;
LGG	trans	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg25214090	chr10:38739885	LOC399744	0.6	10.71	0.45	4.51e-24	Corneal astigmatism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg04262392	chr16:2136746	TSC2	0.41	6.84	0.3	2.5e-11	Pancreatic cancer;
LGG	trans	rs1969363	0.509	rs8189633	chr12:38065155	C/G	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Morning vs. evening chronotype;
LGG	cis	rs796364	0.951	rs59695400	chr2:201021325	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-7.38	-0.32	7.47e-13	Schizophrenia;
LGG	cis	rs6933660	0.646	rs9397410	chr6:151770503	C/T	cg14416726	chr6:151773293	C6orf211;RMND1	-0.84	-16.18	-0.6	5.27e-47	Menarche (age at onset);
LGG	cis	rs919433	0.617	rs34632716	chr2:198542619	C/T	cg00792783	chr2:198669748	PLCL1	-0.62	-10.06	-0.42	1.15e-21	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg15971980	chr6:150254442	NA	0.45	8.28	0.36	1.29e-15	Lung cancer;
LGG	cis	rs10173297	0.686	rs12621171	chr2:3710463	A/G	cg14882966	chr2:3699353	NA	-0.55	-6.94	-0.31	1.34e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs1018836	0.851	rs7007129	chr8:91629790	T/G	cg16814680	chr8:91681699	NA	-0.84	-16.1	-0.6	1.23e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2016266	0.785	rs10747660	chr12:53649874	C/G	cg04065151	chr12:53682969	ESPL1	-0.61	-10.45	-0.44	4.36e-23	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7166081	0.688	rs4776361	chr15:67762056	G/A	cg18050959	chr15:68126178	NA	-0.38	-7.19	-0.32	2.7e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1865760	0.566	rs2032443	chr6:26046802	A/G	cg18357526	chr6:26021779	HIST1H4A	0.46	7.67	0.34	1.02e-13	Height;
LGG	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg07245641	chr1:182991651	LAMC1	0.41	9.52	0.4	9.7e-20	Hypertriglyceridemia;
LGG	cis	rs1218582	0.772	rs6686873	chr1:154913404	C/G	cg09359103	chr1:154839909	KCNN3	-0.48	-9.49	-0.4	1.25e-19	Prostate cancer;
LGG	cis	rs1728785	1.000	rs12925177	chr16:68569645	A/G	cg02972257	chr16:68554789	NA	0.54	8.27	0.36	1.46e-15	Ulcerative colitis;
LGG	cis	rs1046896	0.512	rs3785513	chr17:80886748	G/A	cg10935494	chr17:80760059	TBCD	-0.41	-7.24	-0.32	1.93e-12	Glycated hemoglobin levels;
LGG	cis	rs727563	0.593	rs5758461	chr22:42162189	G/C	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs988958	0.675	rs12712815	chr2:42224021	A/G	cg19376973	chr2:42229025	NA	0.59	9.41	0.4	2.28e-19	Hypospadias;
LGG	cis	rs651907	0.557	rs13099674	chr3:101489629	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.82	0.34	3.73e-14	Colorectal cancer;
LGG	cis	rs9397585	0.598	rs17083510	chr6:153398700	G/T	cg17707550	chr6:153380415	RGS17	-0.47	-10.37	-0.43	8.52e-23	Body mass index;
LGG	cis	rs7106204	0.609	rs12788920	chr11:24284514	C/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.71	0.41	2e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.69	12.34	0.5	1.97e-30	Colorectal cancer;
LGG	cis	rs9311474	0.508	rs4687629	chr3:52615227	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.3	0.4	5.61e-19	Electroencephalogram traits;
LGG	cis	rs7917772	0.629	rs1475646	chr10:104522564	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.98	-0.35	1.16e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2404602	0.647	rs12904417	chr15:76964152	A/G	cg15268244	chr15:77196840	NA	-0.48	-10.36	-0.43	9.64e-23	Blood metabolite levels;
LGG	cis	rs28595532	0.623	rs17516540	chr4:119278443	A/G	cg21605333	chr4:119757512	SEC24D	0.72	7.74	0.34	6.41e-14	Cannabis dependence symptom count;
LGG	cis	rs6088590	0.735	rs6060003	chr20:33294945	T/C	cg07148914	chr20:33460835	GGT7	0.42	7.06	0.31	6.08e-12	Coronary artery disease;
LGG	cis	rs654950	1.000	rs646228	chr1:41986066	A/C	cg16096631	chr1:42092165	HIVEP3	0.37	7.9	0.34	2.11e-14	Airway imaging phenotypes;
LGG	cis	rs2762353	0.718	rs1747550	chr6:25851533	A/G	cg07061783	chr6:25882402	NA	-0.39	-7.04	-0.31	6.87e-12	Blood metabolite levels;
LGG	cis	rs765787	0.530	rs13329228	chr15:45533017	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.42	-6.99	-0.31	9.47e-12	Uric acid levels;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg24642844	chr7:1081250	C7orf50	-0.63	-10.33	-0.43	1.24e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12908161	1.000	rs62019464	chr15:85294469	T/A	cg03959625	chr15:84868606	LOC388152	0.49	7.24	0.32	1.84e-12	Schizophrenia;
LGG	cis	rs9487051	0.714	rs7755970	chr6:109602359	A/G	cg21918786	chr6:109611834	NA	-0.48	-9.05	-0.39	3.86e-18	Reticulocyte fraction of red cells;
LGG	cis	rs11098499	0.909	rs28793658	chr4:120307214	A/C	cg24375607	chr4:120327624	NA	0.67	10.9	0.45	8.83e-25	Corneal astigmatism;
LGG	cis	rs6500602	1.000	rs7204827	chr16:4467533	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.32	7.05	0.31	6.75e-12	Schizophrenia;
LGG	trans	rs7944735	0.508	rs4752871	chr11:47849432	C/G	cg15704280	chr7:45808275	SEPT13	0.63	6.88	0.3	1.98e-11	Intraocular pressure;
LGG	cis	rs1552244	0.935	rs7618815	chr3:10151045	A/G	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs67311347	1.000	rs1004655	chr3:40490009	G/A	cg24209194	chr3:40518798	ZNF619	0.44	6.85	0.3	2.4e-11	Renal cell carcinoma;
LGG	cis	rs6088580	0.634	rs6059867	chr20:33078103	C/T	cg06115741	chr20:33292138	TP53INP2	0.51	8.42	0.36	4.71e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs875971	0.545	rs6969224	chr7:65834998	T/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.56	10.58	0.44	1.39e-23	Aortic root size;
LGG	cis	rs6502050	0.835	rs6502079	chr17:80124454	T/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs8062405	1.000	rs11861174	chr16:28871989	A/G	cg00204512	chr16:28754710	NA	0.26	7.29	0.32	1.38e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2213920	0.749	rs4978637	chr9:118222448	T/A	cg13918206	chr9:118159781	DEC1	0.61	8.53	0.37	2.14e-16	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs12497850	0.864	rs6779394	chr3:49157771	G/A	cg07636037	chr3:49044803	WDR6	1.1	26.54	0.78	5.13e-95	Parkinson's disease;
LGG	cis	rs9543976	0.800	rs4885318	chr13:76151537	G/A	cg01531495	chr13:76123901	UCHL3	0.61	7.33	0.32	1.04e-12	Diabetic retinopathy;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.99	0.35	1.07e-14	Life satisfaction;
LGG	cis	rs62238980	0.614	rs1967470	chr22:32424480	A/G	cg00543991	chr22:32367038	NA	0.76	8.34	0.36	8.43e-16	Childhood ear infection;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25346576	chr17:28443852	CCDC55;MIR423	-0.4	-6.65	-0.3	8.53e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg26384229	chr12:38710491	ALG10B	0.8	15.84	0.59	1.87e-45	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.953	rs59034808	chr8:58185337	T/C	cg08677398	chr8:58056175	NA	0.4	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.507	rs2929306	chr8:9084909	C/T	cg08975724	chr8:8085496	FLJ10661	-0.43	-8.46	-0.37	3.43e-16	Joint mobility (Beighton score);
LGG	cis	rs9354308	0.764	rs9363473	chr6:66587713	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs7395662	1.000	rs4882017	chr11:48570182	C/T	cg03929089	chr4:120376271	NA	0.45	7.29	0.32	1.36e-12	HDL cholesterol;
LGG	cis	rs9486715	1.000	rs9386670	chr6:97060688	C/A	cg18709589	chr6:96969512	KIAA0776	-0.46	-8.85	-0.38	1.86e-17	Headache;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01809819	chr1:31192165	MATN1	0.44	6.96	0.31	1.13e-11	Gut microbiome composition (summer);
LGG	cis	rs6912958	0.703	rs9362427	chr6:88097634	G/T	cg08069147	chr6:88032118	GJB7;C6orf162	0.62	11.24	0.46	4.28e-26	Monocyte percentage of white cells;
LGG	cis	rs12681288	0.550	rs6989880	chr8:957209	A/G	cg04851639	chr8:1020857	NA	-0.33	-6.86	-0.3	2.22e-11	Schizophrenia;
LGG	cis	rs10489202	1.000	rs1846416	chr1:167905411	G/A	cg24449463	chr1:168025552	DCAF6	-0.6	-9.67	-0.41	2.82e-20	Schizophrenia;
LGG	cis	rs7949030	0.626	rs61296092	chr11:62320838	T/C	cg13298116	chr11:62369859	EML3;MTA2	0.72	18.34	0.65	6.95e-57	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs701145	0.585	rs454837	chr3:153915417	T/C	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs2797369	0.689	rs1753569	chr6:101617146	A/C	cg27451362	chr6:101846650	GRIK2	-0.49	-7.2	-0.32	2.48e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs3785574	0.962	rs2584614	chr17:61929445	C/T	cg06873352	chr17:61820015	STRADA	0.48	7.48	0.33	3.67e-13	Height;
LGG	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg18196295	chr10:418757	DIP2C	0.65	13.19	0.52	5.71e-34	Psychosis in Alzheimer's disease;
LGG	cis	rs4555082	0.957	rs10140586	chr14:105749582	A/G	cg10792982	chr14:105748885	BRF1	0.56	11.16	0.46	8.9e-26	Mean platelet volume;Platelet distribution width;
LGG	cis	rs981844	0.712	rs897610	chr4:154755439	C/A	cg14289246	chr4:154710475	SFRP2	-0.56	-9.63	-0.41	4.07e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs8114671	0.967	rs6058202	chr20:33777983	A/G	cg07148914	chr20:33460835	GGT7	0.42	6.73	0.3	5.14e-11	Height;
LGG	cis	rs1577917	0.629	rs6927475	chr6:86206773	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.6	11.29	0.46	2.94e-26	Response to antipsychotic treatment;
LGG	cis	rs2836974	0.863	rs6517519	chr21:40540245	A/G	cg11890956	chr21:40555474	PSMG1	1.21	30.94	0.82	8.7e-115	Cognitive function;
LGG	cis	rs11214589	0.905	rs10891539	chr11:113236492	G/C	cg14159747	chr11:113255604	NA	0.3	8.27	0.36	1.45e-15	Neuroticism;
LGG	cis	rs6502050	0.835	rs7406220	chr17:80077850	T/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs3820068	0.608	rs7516683	chr1:16020502	A/G	cg05660106	chr1:15850417	CASP9	-0.77	-13.88	-0.54	7.43e-37	Systolic blood pressure;
LGG	cis	rs13118159	0.550	rs13123016	chr4:1340889	T/C	cg02475777	chr4:1388615	CRIPAK	0.6	10.71	0.45	4.62e-24	Longevity;
LGG	cis	rs2221894	0.506	rs78814308	chr8:28847683	T/C	cg07962641	chr8:28805897	HMBOX1	-0.54	-7.88	-0.34	2.4e-14	Obesity-related traits;
LGG	cis	rs9611565	0.729	rs203319	chr22:41914593	C/T	cg17376030	chr22:41985996	PMM1	0.47	7.81	0.34	3.95e-14	Vitiligo;
LGG	cis	rs919433	0.647	rs6741205	chr2:198525997	G/C	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11117896	chr2:220094984	ANKZF1;ATG9A	0.49	7.56	0.33	2.24e-13	Gut microbiome composition (summer);
LGG	cis	rs11214589	0.935	rs2186800	chr11:113242860	G/A	cg14373873	chr11:113211441	TTC12	0.44	8.92	0.38	1.11e-17	Neuroticism;
LGG	cis	rs9914544	0.932	rs11870265	chr17:18820985	A/T	cg26378065	chr17:18585709	ZNF286B	0.49	9.11	0.39	2.52e-18	Educational attainment (years of education);
LGG	trans	rs2797160	0.651	rs1268066	chr6:126035041	C/T	cg05039488	chr6:79577232	IRAK1BP1	0.48	8.4	0.36	5.71e-16	Endometrial cancer;
LGG	cis	rs12477438	0.501	rs6737560	chr2:100095219	C/T	cg23527387	chr2:100056660	REV1	0.42	9.36	0.4	3.42e-19	Chronic sinus infection;
LGG	cis	rs35110281	0.807	rs2838326	chr21:45014315	C/T	cg01579765	chr21:45077557	HSF2BP	-0.38	-8.67	-0.37	7.42e-17	Mean corpuscular volume;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg11473876	chr11:109292803	C11orf87	0.49	9.47	0.4	1.41e-19	Schizophrenia;
LGG	cis	rs2228479	0.850	rs11648689	chr16:89806732	G/A	cg04287289	chr16:89883240	FANCA	0.89	8.67	0.37	7.41e-17	Skin colour saturation;
LGG	cis	rs9462027	0.606	rs2395606	chr6:34778486	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.12	-0.46	1.31e-25	Systemic lupus erythematosus;
LGG	cis	rs921968	0.643	rs2278529	chr2:219502132	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.35	-0.32	8.86e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs28374715	0.662	rs521890	chr15:41473143	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.0	-17.93	-0.64	5.47e-55	Ulcerative colitis;
LGG	cis	rs988958	0.526	rs7604533	chr2:42243861	A/T	cg27252766	chr2:42229092	NA	0.48	6.81	0.3	2.98e-11	Hypospadias;
LGG	cis	rs2832191	0.791	rs2832182	chr21:30481612	G/A	cg08807101	chr21:30365312	RNF160	-0.85	-17.22	-0.62	9.9e-52	Dental caries;
LGG	cis	rs7998202	0.668	rs2774422	chr13:113352392	C/T	cg02820901	chr13:113351484	ATP11A	0.61	7.33	0.32	1.03e-12	Glycated hemoglobin levels;
LGG	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-17.22	-0.62	1.03e-51	Chronic sinus infection;
LGG	cis	rs4689388	0.782	rs4262051	chr4:6281775	G/A	cg14416269	chr4:6271139	WFS1	0.52	9.39	0.4	2.81e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs2243480	1.000	rs410128	chr7:65603173	C/T	cg13147721	chr7:65941812	NA	-0.78	-9.07	-0.39	3.37e-18	Diabetic kidney disease;
LGG	trans	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg25214090	chr10:38739885	LOC399744	0.64	11.57	0.47	2.26e-27	Corneal astigmatism;
LGG	trans	rs3942852	0.868	rs11039514	chr11:48109598	A/G	cg15704280	chr7:45808275	SEPT13	-0.66	-8.26	-0.36	1.57e-15	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7613875	0.641	rs2624845	chr3:50062437	C/A	cg24110177	chr3:50126178	RBM5	0.6	10.98	0.45	4.34e-25	Body mass index;
LGG	trans	rs9329221	0.662	rs34155841	chr8:10247529	T/G	cg16141378	chr3:129829833	LOC729375	-0.31	-6.7	-0.3	6.09e-11	Neuroticism;
LGG	cis	rs7236492	0.935	rs7239086	chr18:77217030	A/C	cg15532942	chr18:77220712	NFATC1	0.45	7.21	0.32	2.37e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9972944	0.756	rs6504343	chr17:63755458	C/T	cg07283582	chr17:63770753	CCDC46	-0.4	-7.82	-0.34	3.7e-14	Total body bone mineral density;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.64	-11.69	-0.48	7.63e-28	Personality dimensions;
LGG	cis	rs4930103	0.967	rs3890907	chr11:2028143	G/A	cg15394860	chr11:2017084	H19	0.58	12.09	0.49	1.95e-29	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs1814175	0.588	rs1794144	chr11:49918233	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.75	-16.71	-0.61	2.1e-49	Height;
LGG	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg19498844	chr21:46707878	POFUT2;LOC642852	0.65	11.45	0.47	6.46e-27	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs8048589	0.948	rs71385189	chr16:12182179	G/T	cg02910054	chr16:12241554	SNX29	0.42	6.68	0.3	7.03e-11	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs12762955	0.561	rs7075141	chr10:1091195	C/T	cg18964960	chr10:1102726	WDR37	-0.46	-7.46	-0.33	4.45e-13	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs28830936	1.000	rs11632424	chr15:42095351	G/A	cg17847044	chr15:42102381	MAPKBP1	-0.58	-13.17	-0.52	7.49e-34	Diastolic blood pressure;
LGG	cis	rs12421382	0.659	rs11600110	chr11:109392438	A/G	cg15948088	chr11:109293068	C11orf87	0.48	8.24	0.36	1.79e-15	Schizophrenia;
LGG	cis	rs77956314	0.515	rs4767490	chr12:117435016	A/G	cg02017074	chr12:117425053	FBXW8	0.56	7.63	0.33	1.33e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg19168338	chr16:4465731	CORO7	0.91	18.77	0.66	7.37e-59	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg07701084	chr6:150067640	NUP43	0.65	12.32	0.5	2.33e-30	Lung cancer;
LGG	trans	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg00405596	chr8:11794950	NA	-0.47	-7.75	-0.34	5.96e-14	Neuroticism;
LGG	cis	rs1957429	0.808	rs6573581	chr14:65331955	G/A	cg23373153	chr14:65346875	NA	1.05	13.49	0.53	3.34e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs926938	0.618	rs516985	chr1:115495011	G/A	cg12756093	chr1:115239321	AMPD1	0.51	9.73	0.41	1.73e-20	Autism;
LGG	cis	rs2072732	0.808	rs56091202	chr1:2936803	A/G	cg22517653	chr1:2918612	NA	-0.52	-7.29	-0.32	1.32e-12	Plateletcrit;
LGG	cis	rs6539288	0.677	rs1348565	chr12:107329104	G/T	cg15890332	chr12:107067104	RFX4	0.31	8.24	0.36	1.8e-15	Total body bone mineral density;
LGG	cis	rs1568889	0.592	rs11828877	chr11:28384030	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.66	9.74	0.41	1.63e-20	Bipolar disorder;
LGG	cis	rs12701220	0.604	rs12702122	chr7:1149494	C/G	cg00990874	chr7:1149470	C7orf50	-0.84	-15.33	-0.58	3.51e-43	Bronchopulmonary dysplasia;
LGG	cis	rs7107174	0.892	rs2510031	chr11:77969956	T/C	cg02023728	chr11:77925099	USP35	0.45	7.98	0.35	1.13e-14	Testicular germ cell tumor;
LGG	cis	rs17376456	0.825	rs17374166	chr5:93238655	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.67	-0.41	2.79e-20	Diabetic retinopathy;
LGG	cis	rs8062405	0.656	rs7189927	chr16:28913787	T/C	cg09754948	chr16:28834200	ATXN2L	-0.45	-6.69	-0.3	6.35e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1475911	1.000	rs2839465	chr21:43511232	C/T	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.44	-8.09	-0.35	5.2e-15	IgG glycosylation;
LGG	cis	rs617791	0.508	rs2276132	chr11:65770545	G/A	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	8.97	0.38	7.61e-18	Breast cancer;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg07511668	chr11:68622177	NA	0.48	9.12	0.39	2.37e-18	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs881375	0.934	rs1468671	chr9:123657502	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.59	10.21	0.43	3.21e-22	Rheumatoid arthritis;
LGG	cis	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg21453758	chr17:80185943	SLC16A3	0.33	6.94	0.31	1.29e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9527	0.521	rs12259163	chr10:104961477	A/G	cg04362960	chr10:104952993	NT5C2	0.58	10.55	0.44	1.84e-23	Arsenic metabolism;
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	10.9	0.45	8.72e-25	Total body bone mineral density;
LGG	cis	rs17401966	0.898	rs11587495	chr1:10448999	T/C	cg15208524	chr1:10270712	KIF1B	0.44	7.49	0.33	3.42e-13	Hepatocellular carcinoma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16513167	chr13:39612418	NHLRC3;C13orf23	0.42	6.99	0.31	9.68e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg16507663	chr6:150244633	RAET1G	0.46	8.15	0.35	3.54e-15	Lung cancer;
LGG	cis	rs698813	0.774	rs2304769	chr2:44569474	G/A	cg00619915	chr2:44497795	NA	-0.5	-6.94	-0.31	1.34e-11	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs847577	0.677	rs951988	chr7:97762474	C/G	cg13397024	chr7:97797637	LMTK2	0.41	7.24	0.32	1.86e-12	Breast cancer;
LGG	cis	rs9896933	0.732	rs590886	chr17:80767350	A/G	cg15664640	chr17:80829946	TBCD	0.65	9.13	0.39	2.08e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7086627	0.515	rs4934189	chr10:82214792	C/T	cg00277334	chr10:82204260	NA	-0.51	-12.02	-0.49	3.6e-29	Post bronchodilator FEV1;
LGG	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg02151108	chr14:50098012	C14orf104	-0.47	-10.15	-0.43	5.25e-22	Carotid intima media thickness;
LGG	trans	rs1814175	0.715	rs1722007	chr11:49897319	T/C	cg15704280	chr7:45808275	SEPT13	-1.08	-26.28	-0.77	7.6e-94	Height;
LGG	cis	rs10752881	1.000	rs4233193	chr1:182970865	C/T	cg07245641	chr1:182991651	LAMC1	0.43	10.0	0.42	1.91e-21	Colorectal cancer;
LGG	cis	rs951366	0.617	rs823080	chr1:205789282	G/A	cg26354017	chr1:205819088	PM20D1	0.99	27.67	0.79	3.49e-100	Menarche (age at onset);
LGG	cis	rs6815814	0.950	rs55830619	chr4:38807364	G/A	cg06935464	chr4:38784597	TLR10	0.6	8.23	0.36	1.97e-15	Breast cancer;
LGG	cis	rs9517313	0.523	rs4772104	chr13:99235677	G/A	cg03701759	chr13:99174930	STK24	-0.36	-6.79	-0.3	3.41e-11	Neuroticism;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.15	-0.32	3.47e-12	Lung cancer;
LGG	cis	rs3768617	0.510	rs2027083	chr1:183088330	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs7582720	1.000	rs72932791	chr2:203700870	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.73	0.41	1.69e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7766436	0.922	rs13217043	chr6:22612831	T/A	cg13666174	chr6:22585274	NA	-0.48	-10.59	-0.44	1.31e-23	Coronary artery disease;
LGG	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg17376030	chr22:41985996	PMM1	0.58	9.15	0.39	1.77e-18	Vitiligo;
LGG	cis	rs2032447	0.702	rs199753	chr6:26001888	G/A	cg18357526	chr6:26021779	HIST1H4A	0.93	17.75	0.64	3.65e-54	Intelligence (multi-trait analysis);
LGG	cis	rs7267979	1.000	rs2259928	chr20:25281834	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.28e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs12325245	0.536	rs34676074	chr16:58549321	G/C	cg01472538	chr16:58549086	SETD6	0.98	8.69	0.37	6.49e-17	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16857181	chr7:32931955	KBTBD2	0.49	7.81	0.34	3.81e-14	Gut microbiome composition (summer);
LGG	cis	rs12724450	0.793	rs35437473	chr1:150297233	C/A	cg03818307	chr1:150480534	ECM1	0.5	6.96	0.31	1.19e-11	Blood protein levels;
LGG	cis	rs4959677	0.725	rs1772975	chr6:2503471	G/A	cg23817096	chr6:1620687	NA	-0.34	-8.19	-0.36	2.55e-15	Orthostatic hypotension;
LGG	cis	rs9916302	0.706	rs4516267	chr17:37471482	G/T	cg00129232	chr17:37814104	STARD3	0.57	8.58	0.37	1.42e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	1.000	rs6793396	chr3:10110927	T/C	cg00166722	chr3:10149974	C3orf24	0.54	8.99	0.39	6.48e-18	Alzheimer's disease;
LGG	cis	rs9944715	0.954	rs7240354	chr18:43809614	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.36	-6.65	-0.3	8.16e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs1867631	1.000	rs6665859	chr1:67077555	A/T	cg13052034	chr1:66999238	SGIP1	0.47	9.04	0.39	4.38e-18	Menopause (age at onset);
LGG	cis	rs2760061	0.583	rs3094911	chr1:228210179	A/G	cg02753203	chr1:228287806	NA	0.93	20.17	0.68	2.28e-65	Diastolic blood pressure;
LGG	cis	rs807669	0.903	rs1771540	chr22:19173933	T/A	cg02655711	chr22:19163373	SLC25A1	0.78	15.98	0.6	4.14e-46	Metabolite levels;
LGG	cis	rs4430311	0.723	rs7548254	chr1:243891570	C/T	cg25706552	chr1:244017396	NA	-0.65	-16.07	-0.6	1.75e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs9398803	0.723	rs2793052	chr6:127064917	T/A	cg19875578	chr6:126661172	C6orf173	-0.49	-8.93	-0.38	9.75e-18	Male-pattern baldness;
LGG	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Fuchs's corneal dystrophy;
LGG	cis	rs4819852	1.000	rs2073743	chr22:19989612	C/G	cg07821417	chr22:19972146	ARVCF	0.55	10.23	0.43	2.8e-22	Pulse pressure;
LGG	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2019137	0.936	rs2305133	chr2:113956821	C/G	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.5	2.13e-30	Lymphocyte counts;
LGG	cis	rs6089584	0.566	rs7274240	chr20:60622004	C/T	cg06108461	chr20:60628389	TAF4	-0.75	-13.58	-0.53	1.36e-35	Body mass index;
LGG	cis	rs4478858	0.684	rs7549245	chr1:31752187	A/G	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.26e-11	Alcohol dependence;
LGG	cis	rs9325144	0.541	rs7303395	chr12:38664124	C/T	cg26384229	chr12:38710491	ALG10B	-0.79	-16.37	-0.61	7.11e-48	Morning vs. evening chronotype;
LGG	cis	rs12548874	0.607	rs12543492	chr8:95891843	C/A	cg16049864	chr8:95962084	TP53INP1	-0.31	-6.87	-0.3	2.03e-11	Hemoglobin concentration;
LGG	cis	rs6951245	1.000	rs74652290	chr7:1090109	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.49	0.37	2.77e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1865760	0.593	rs2097273	chr6:25941310	A/C	cg17691542	chr6:26056736	HIST1H1C	0.5	8.74	0.38	4.27e-17	Height;
LGG	trans	rs6787172	0.622	rs12494098	chr3:158088596	A/G	cg23275840	chr4:47708675	CORIN	-0.36	-7.47	-0.33	4.11e-13	Subjective well-being;
LGG	trans	rs6582630	0.555	rs11180986	chr12:38264486	G/A	cg06521331	chr12:34319734	NA	0.44	7.95	0.35	1.46e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.630	rs1860832	chr7:2161849	G/A	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.42	-0.36	4.64e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg00636124	chr16:27215281	JMJD5	-0.53	-7.99	-0.35	1.1e-14	Systemic lupus erythematosus;
LGG	cis	rs2204008	0.702	rs3849999	chr12:38483498	G/A	cg26384229	chr12:38710491	ALG10B	-0.66	-13.18	-0.52	6.42e-34	Bladder cancer;
LGG	cis	rs9611565	0.694	rs5758389	chr22:41941749	T/C	cg17376030	chr22:41985996	PMM1	0.45	7.3	0.32	1.28e-12	Vitiligo;
LGG	cis	rs2841277	0.646	rs2819419	chr14:105406238	A/C	cg19901468	chr14:105411992	AHNAK2	-0.92	-19.19	-0.67	8.33e-61	Rheumatoid arthritis;
LGG	cis	rs3857067	0.967	rs7668980	chr4:95037320	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.68	-0.34	9.35e-14	QT interval;
LGG	cis	rs67460515	0.852	rs2404341	chr3:161092405	T/C	cg04691961	chr3:161091175	C3orf57	-0.49	-10.09	-0.42	8.84e-22	Parkinson's disease;
LGG	cis	rs6502050	0.731	rs34796376	chr17:80116635	G/T	cg19223190	chr17:80058835	NA	0.43	8.42	0.36	4.85e-16	Life satisfaction;
LGG	cis	rs1595825	1.000	rs1440087	chr2:198871476	G/C	cg00982548	chr2:198649783	BOLL	-0.49	-6.79	-0.3	3.54e-11	Ulcerative colitis;
LGG	cis	rs11098499	0.954	rs4345162	chr4:120312959	G/A	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs6089584	0.888	rs6061982	chr20:60620673	C/T	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs7751419	0.675	rs6458096	chr6:39107698	C/T	cg08089693	chr6:39098871	NA	-0.41	-7.44	-0.33	4.84e-13	Cardiovascular disease in hypertension (calcium channel blocker interaction);
LGG	cis	rs9381040	1.000	rs2093395	chr6:41155026	C/G	cg09580153	chr6:41068724	NFYA;LOC221442	0.44	7.44	0.33	4.88e-13	Alzheimer's disease (late onset);
LGG	cis	rs861020	0.771	rs1962735	chr1:210012102	A/G	cg05527609	chr1:210001259	C1orf107	0.67	10.65	0.44	7.42e-24	Orofacial clefts;
LGG	cis	rs7582720	1.000	rs72936881	chr2:203794262	T/C	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.61	0.41	4.62e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	trans	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.43	-0.36	4.3e-16	Retinal vascular caliber;
LGG	cis	rs2439831	1.000	rs690263	chr15:43704465	C/G	cg27015174	chr15:43622946	ADAL;LCMT2	1.02	12.56	0.5	2.41e-31	Lung cancer in ever smokers;
LGG	cis	rs7326068	0.524	rs9506531	chr13:21232983	C/T	cg04906043	chr13:21280425	IL17D	0.42	7.32	0.32	1.14e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs11676348	0.967	rs4674258	chr2:218990586	C/T	cg00012203	chr2:219082015	ARPC2	-0.5	-8.77	-0.38	3.51e-17	Ulcerative colitis;
LGG	cis	rs7829975	0.559	rs4841025	chr8:8603160	A/G	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.21	-0.36	2.28e-15	Mood instability;
LGG	cis	rs919433	0.617	rs700643	chr2:198601370	A/G	cg00792783	chr2:198669748	PLCL1	0.65	10.62	0.44	9.89e-24	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs3749237	0.595	rs11130199	chr3:49538799	T/C	cg03060546	chr3:49711283	APEH	0.74	13.22	0.52	4.31e-34	Resting heart rate;
LGG	trans	rs7819412	0.744	rs4841503	chr8:11024326	A/C	cg13009111	chr11:71350975	NA	-0.31	-6.72	-0.3	5.22e-11	Triglycerides;
LGG	cis	rs3733585	0.673	rs4447861	chr4:9953940	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.93	0.35	1.69e-14	Colorectal cancer;
LGG	cis	rs6500395	0.775	rs13331298	chr16:48661489	G/A	cg04672837	chr16:48644449	N4BP1	0.48	8.0	0.35	1.04e-14	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs367943	0.966	rs348924	chr5:112817930	T/G	cg12552261	chr5:112820674	MCC	-0.75	-14.34	-0.55	7.65e-39	Type 2 diabetes;
LGG	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.91	-0.42	3.87e-21	Neuroticism;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg16141378	chr3:129829833	LOC729375	0.4	9.39	0.4	2.78e-19	Systolic blood pressure;
LGG	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg07382826	chr16:28625726	SULT1A1	0.43	9.04	0.39	4.23e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6450176	0.564	rs381024	chr5:53326234	G/A	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.28	-0.46	3.05e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs193541	0.632	rs1460040	chr5:122105232	A/G	cg19412675	chr5:122181750	SNX24	0.54	8.74	0.38	4.32e-17	Glucose homeostasis traits;
LGG	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg12463550	chr7:65579703	CRCP	0.77	8.31	0.36	1.08e-15	Diabetic kidney disease;
LGG	cis	rs3858526	0.883	rs4758183	chr11:5925178	C/G	cg13902645	chr11:5959945	NA	-0.67	-10.8	-0.45	2.03e-24	DNA methylation (variation);
LGG	cis	rs1008375	0.966	rs3733581	chr4:17695206	C/G	cg16339924	chr4:17578868	LAP3	-0.53	-8.84	-0.38	2.08e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9393777	0.588	rs6933213	chr6:26493909	T/C	cg12826209	chr6:26865740	GUSBL1	0.84	12.63	0.51	1.24e-31	Intelligence (multi-trait analysis);
LGG	cis	rs10779751	0.690	rs2791646	chr1:11133242	C/T	cg08854313	chr1:11322531	MTOR	0.76	16.88	0.62	3.52e-50	Body mass index;
LGG	cis	rs10504229	0.645	rs6995814	chr8:58114159	C/T	cg23782820	chr8:58130467	NA	0.57	8.46	0.37	3.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.716	rs12592171	chr15:76755133	G/C	cg15268244	chr15:77196840	NA	-0.33	-7.23	-0.32	1.96e-12	Blood metabolite levels;
LGG	cis	rs6714710	0.603	rs17488897	chr2:98365164	G/C	cg26665480	chr2:98280029	ACTR1B	0.63	10.2	0.43	3.52e-22	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10883723	0.810	rs61873733	chr10:104251458	G/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.66	0.56	3.12e-40	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs853679	1.000	rs2799079	chr6:28235176	A/C	cg08344181	chr3:125677491	NA	-0.54	-7.2	-0.32	2.45e-12	Depression;
LGG	cis	rs9911578	0.704	rs72628393	chr17:56585314	A/T	cg05425664	chr17:57184151	TRIM37	0.61	9.44	0.4	1.85e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.55	-0.33	2.35e-13	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg13939156	chr17:80058883	NA	-0.49	-9.07	-0.39	3.41e-18	Life satisfaction;
LGG	cis	rs8017423	0.967	rs7147809	chr14:90715025	A/G	cg04374321	chr14:90722782	PSMC1	0.86	18.23	0.65	2.31e-56	Mortality in heart failure;
LGG	trans	rs7824557	0.564	rs2043508	chr8:11227406	G/A	cg16141378	chr3:129829833	LOC729375	0.39	8.54	0.37	1.94e-16	Retinal vascular caliber;
LGG	cis	rs1799949	0.930	rs34210004	chr17:41370337	A/T	cg23758822	chr17:41437982	NA	0.86	15.61	0.59	1.97e-44	Menopause (age at onset);
LGG	cis	rs765787	0.530	rs4514617	chr15:45535439	A/G	cg26924012	chr15:45694286	SPATA5L1	-0.43	-7.11	-0.31	4.4e-12	Uric acid levels;
LGG	cis	rs8058578	0.945	rs34480360	chr16:30798689	G/A	cg02466173	chr16:30829666	NA	-0.54	-9.65	-0.41	3.35e-20	Multiple myeloma;
LGG	cis	rs35362007	0.530	rs10484053	chr14:96011645	C/T	cg13511115	chr14:96000878	GLRX5;SNHG10;SCARNA13	0.77	9.44	0.4	1.86e-19	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs17021463	0.673	rs1426566	chr4:95292086	T/G	cg11021082	chr4:95130006	SMARCAD1	0.4	6.85	0.3	2.31e-11	Testicular germ cell tumor;
LGG	cis	rs17102423	0.768	rs8005829	chr14:65576165	C/T	cg16583315	chr14:65563665	MAX	0.4	7.96	0.35	1.37e-14	Obesity-related traits;
LGG	cis	rs698833	0.828	rs4952710	chr2:44524575	T/C	cg00619915	chr2:44497795	NA	-0.44	-6.78	-0.3	3.72e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs801193	1.000	rs2420824	chr7:66131116	G/A	cg18252515	chr7:66147081	NA	0.41	7.01	0.31	8.66e-12	Aortic root size;
LGG	trans	rs2898290	0.617	rs13273172	chr8:11461111	A/G	cg02002194	chr4:3960332	NA	0.46	8.68	0.37	6.58e-17	Systolic blood pressure;
LGG	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg12473912	chr3:136751656	NA	0.77	16.07	0.6	1.76e-46	Schizophrenia;
LGG	cis	rs62400317	0.859	rs12205860	chr6:45157323	G/A	cg20913747	chr6:44695427	NA	-0.62	-10.26	-0.43	2.2e-22	Total body bone mineral density;
LGG	trans	rs2832077	0.943	rs2832100	chr21:30175628	A/C	cg14791747	chr16:20752902	THUMPD1	0.52	7.82	0.34	3.67e-14	Cognitive test performance;
LGG	cis	rs1348850	0.526	rs2178017	chr2:178374788	G/T	cg23306229	chr2:178417860	TTC30B	0.71	8.51	0.37	2.5e-16	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1559088	1.000	rs1559088	chr19:33551061	C/T	cg17764715	chr19:33622953	WDR88	0.47	8.09	0.35	5.47e-15	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs883565	0.531	rs813668	chr3:39180867	G/T	cg01426195	chr3:39028469	NA	0.56	10.23	0.43	2.69e-22	Handedness;
LGG	trans	rs853679	0.567	rs7740429	chr6:28399246	G/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.66	-0.3	7.89e-11	Depression;
LGG	trans	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03314080	chr2:178129903	NFE2L2	0.39	6.75	0.3	4.5e-11	Dupuytren's disease;
LGG	cis	rs7712401	0.584	rs30037	chr5:122277990	T/C	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs4363385	0.818	rs378010	chr1:153007987	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.82	-0.38	2.3e-17	Inflammatory skin disease;
LGG	cis	rs9858542	0.953	rs7622302	chr3:49547561	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.77	0.41	1.24e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs5769765	0.913	rs4824111	chr22:50284305	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.85	12.52	0.5	3.5e-31	Schizophrenia;
LGG	cis	rs6582630	0.576	rs11504369	chr12:38274566	C/T	cg13010199	chr12:38710504	ALG10B	-0.52	-10.25	-0.43	2.33e-22	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs8114671	0.562	rs4911449	chr20:33512236	T/G	cg07148914	chr20:33460835	GGT7	0.54	9.06	0.39	3.68e-18	Height;
LGG	cis	rs9914544	0.689	rs1634423	chr17:18844736	C/T	cg26306683	chr17:18585705	ZNF286B	0.52	10.19	0.43	3.77e-22	Educational attainment (years of education);
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	cis	rs10193935	0.901	rs9789740	chr2:42486799	A/G	cg27598129	chr2:42591480	NA	-0.64	-9.68	-0.41	2.66e-20	Colonoscopy-negative controls vs population controls;
LGG	trans	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.78	-0.38	3.29e-17	Joint mobility (Beighton score);
LGG	cis	rs10048158	0.647	rs2215414	chr17:64215895	A/G	cg19474267	chr17:64306194	PRKCA	-0.65	-12.94	-0.52	6.43e-33	&beta2-Glycoprotein I (β2-GPI) plasma levels;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2842992	0.915	rs2758335	chr6:160111011	G/A	cg27624424	chr6:160112604	SOD2	0.69	10.23	0.43	2.85e-22	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2652834	0.851	rs4775628	chr15:63426463	A/C	cg05507819	chr15:63340323	TPM1	0.5	7.06	0.31	6.23e-12	HDL cholesterol;
LGG	cis	rs17270561	0.583	rs7765833	chr6:25712433	C/A	cg03264133	chr6:25882463	NA	-0.46	-7.7	-0.34	8.13e-14	Iron status biomarkers;
LGG	cis	rs5769765	0.908	rs2319464	chr22:50265777	A/G	cg02269571	chr22:50332266	NA	0.65	10.21	0.43	3.21e-22	Schizophrenia;
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg04709771	chr16:646395	RAB40C	0.36	6.67	0.3	7.48e-11	Height;
LGG	cis	rs526231	0.543	rs257310	chr5:102418853	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.42	-0.36	4.77e-16	Primary biliary cholangitis;
LGG	cis	rs8016982	0.698	rs8021385	chr14:81704682	G/A	cg01989461	chr14:81687754	GTF2A1	0.75	17.69	0.64	6.96e-54	Schizophrenia;
LGG	cis	rs1185460	0.546	rs589925	chr11:118955679	C/T	cg12636538	chr11:118901039	SLC37A4	-0.57	-11.41	-0.47	9.4e-27	Coronary artery disease;
LGG	cis	rs116095464	0.558	rs7725227	chr5:233517	G/A	cg22496380	chr5:211416	CCDC127	-1.26	-17.88	-0.64	9.15e-55	Breast cancer;
LGG	cis	rs12477438	0.765	rs6542846	chr2:99563654	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.71	-12.87	-0.51	1.27e-32	Chronic sinus infection;
LGG	cis	rs6582630	0.555	rs12828034	chr12:38274249	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.94	-0.38	9.32e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9890032	0.618	rs1979507	chr17:29138020	A/T	cg13385521	chr17:29058706	SUZ12P	0.47	7.0	0.31	8.86e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.54	-0.33	2.43e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs9747164	chr17:61864787	T/C	cg11494091	chr17:61959527	GH2	0.51	8.01	0.35	9.5e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7246760	1.000	rs17849496	chr19:9922223	G/A	cg16876255	chr19:9731953	ZNF561	0.79	7.22	0.32	2.1e-12	Pursuit maintenance gain;
LGG	trans	rs2204008	0.837	rs12370891	chr12:37984531	A/G	cg06521331	chr12:34319734	NA	-0.53	-9.09	-0.39	2.89e-18	Bladder cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16826947	chr7:44084618	DBNL	0.43	6.97	0.31	1.06e-11	Cognitive performance;
LGG	cis	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg06521331	chr12:34319734	NA	0.4	6.8	0.3	3.28e-11	Morning vs. evening chronotype;
LGG	cis	rs11122272	0.735	rs2808591	chr1:231523421	G/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs4731207	0.596	rs13231916	chr7:124640225	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.93	-0.57	1.99e-41	Morning vs. evening chronotype;
LGG	trans	rs9329221	0.537	rs6601415	chr8:9976805	C/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.27	0.43	1.94e-22	Neuroticism;
LGG	cis	rs7208859	0.673	rs2470251	chr17:29095061	T/C	cg13385521	chr17:29058706	SUZ12P	0.82	9.99	0.42	2.06e-21	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs854765	0.583	rs11078406	chr17:17840823	G/T	cg05444541	chr17:17804740	TOM1L2	-0.79	-21.76	-0.71	8.02e-73	Total body bone mineral density;
LGG	cis	rs7766436	0.848	rs6903685	chr6:22605813	C/T	cg13666174	chr6:22585274	NA	-0.48	-10.76	-0.45	2.88e-24	Coronary artery disease;
LGG	trans	rs8073060	0.586	rs225280	chr17:33976296	C/T	cg19694781	chr19:47549865	TMEM160	-1.16	-17.61	-0.63	1.63e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs2836974	0.931	rs7283569	chr21:40644062	T/G	cg11644478	chr21:40555479	PSMG1	0.92	18.08	0.64	1.08e-55	Cognitive function;
LGG	cis	rs7444	0.941	rs2266959	chr22:21922904	G/T	cg05046821	chr22:21984468	YDJC	-0.4	-7.14	-0.31	3.7e-12	Systemic lupus erythematosus;
LGG	cis	rs4838594	0.577	rs3888299	chr10:49687030	C/T	cg17291251	chr10:49678358	ARHGAP22	0.41	8.04	0.35	7.59e-15	Daytime sleep phenotypes;
LGG	cis	rs1355223	0.816	rs2136506	chr11:34748260	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.42	-7.07	-0.31	5.8e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs1401999	1.000	rs4148571	chr3:183720576	A/C	cg20387954	chr3:183756860	HTR3D	0.67	13.64	0.54	7.49e-36	Anterior chamber depth;
LGG	cis	rs2404602	0.692	rs4383105	chr15:77055510	T/C	cg15268244	chr15:77196840	NA	-0.32	-6.97	-0.31	1.07e-11	Blood metabolite levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04888647	chr3:52739135	SPCS1;GLT8D1	0.45	7.19	0.32	2.68e-12	Cognitive performance;
LGG	trans	rs9393777	0.841	rs13191474	chr6:27413345	C/T	cg08344181	chr3:125677491	NA	-0.8	-8.05	-0.35	7.11e-15	Intelligence (multi-trait analysis);
LGG	cis	rs11098499	0.863	rs2306456	chr4:120472422	C/G	cg09307838	chr4:120376055	NA	0.81	13.64	0.54	7.2e-36	Corneal astigmatism;
LGG	cis	rs7917772	0.619	rs2251772	chr10:104470918	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	9.56	0.41	7.1e-20	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.55	-11.08	-0.46	1.88e-25	Obesity-related traits;
LGG	cis	rs7647973	1.000	rs940045	chr3:49449638	G/A	cg07636037	chr3:49044803	WDR6	0.77	13.74	0.54	2.92e-36	Menarche (age at onset);
LGG	cis	rs477895	0.938	rs28395875	chr11:64024048	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.74	8.67	0.37	7.6e-17	Mean platelet volume;
LGG	cis	rs7129556	0.638	rs11604207	chr11:77367542	C/T	cg12586386	chr11:77299805	AQP11	0.48	7.13	0.31	3.97e-12	Weight loss (gastric bypass surgery);
LGG	cis	rs17253792	0.822	rs113350960	chr14:56087713	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs2274273	0.901	rs12050099	chr14:55764331	G/C	cg04306507	chr14:55594613	LGALS3	0.61	16.8	0.62	8.54e-50	Protein biomarker;
LGG	cis	rs7106204	0.609	rs34102968	chr11:24304149	C/T	ch.11.24196551F	chr11:24239977	NA	0.88	9.65	0.41	3.42e-20	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11098499	0.697	rs4373140	chr4:120307698	A/G	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs2645694	0.626	rs2703122	chr4:77821418	A/C	cg03477792	chr4:77819574	ANKRD56	0.53	9.25	0.39	8.6e-19	Emphysema distribution in smoking;
LGG	cis	rs1005277	0.505	rs719569	chr10:38154415	T/G	cg18963800	chr10:38644991	HSD17B7P2	0.42	7.05	0.31	6.67e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2066819	1.000	rs2371454	chr12:56647243	A/G	cg26714650	chr12:56694279	CS	1.58	16.18	0.6	5.66e-47	Psoriasis vulgaris;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.44	-7.95	-0.35	1.41e-14	Longevity;
LGG	cis	rs6088580	0.634	rs6088478	chr20:32971719	T/C	cg08999081	chr20:33150536	PIGU	-0.4	-10.17	-0.43	4.75e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs2011503	1.000	rs11669730	chr19:19648713	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs11096990	0.855	rs1820939	chr4:39171735	C/T	cg24403649	chr4:39172243	NA	-0.48	-7.59	-0.33	1.83e-13	Cognitive function;
LGG	cis	rs9322193	0.923	rs2184369	chr6:150097817	G/A	cg08621203	chr6:150244597	RAET1G	0.4	6.79	0.3	3.35e-11	Lung cancer;
LGG	cis	rs10779751	1.000	rs4845982	chr1:11271576	T/C	cg08854313	chr1:11322531	MTOR	0.74	16.66	0.61	3.57e-49	Body mass index;
LGG	cis	rs28386778	0.897	rs2727327	chr17:61923422	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.02	-0.57	8.06e-42	Prudent dietary pattern;
LGG	trans	rs9329221	0.618	rs4314693	chr8:10258932	G/T	cg15556689	chr8:8085844	FLJ10661	-0.41	-6.9	-0.31	1.7e-11	Neuroticism;
LGG	cis	rs11628318	0.614	rs1190337	chr14:103106159	A/C	cg23461800	chr14:103021989	NA	-0.52	-8.23	-0.36	1.97e-15	Platelet count;
LGG	cis	rs4950322	0.570	rs7554833	chr1:146761044	A/G	cg22381352	chr1:146742008	CHD1L	0.5	8.2	0.36	2.4e-15	Protein quantitative trait loci;
LGG	cis	rs10861661	0.963	rs11113118	chr12:107199142	G/A	cg15890332	chr12:107067104	RFX4	0.3	7.36	0.32	8.35e-13	Triglyceride levels;
LGG	cis	rs1908814	0.510	rs57655799	chr8:11782417	A/C	cg24623649	chr8:11872141	NA	0.3	6.9	0.31	1.75e-11	Neuroticism;
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.59	-10.68	-0.44	5.83e-24	Total body bone mineral density;
LGG	cis	rs4843747	0.671	rs28671027	chr16:88116323	G/A	cg06374794	chr16:88002281	BANP	0.44	8.2	0.36	2.39e-15	Menopause (age at onset);
LGG	trans	rs561341	1.000	rs510264	chr17:30323414	A/G	cg20587970	chr11:113659929	NA	-1.36	-24.24	-0.75	2.03e-84	Hip circumference adjusted for BMI;
LGG	cis	rs4356975	0.563	rs6600895	chr4:69983412	T/C	cg27372994	chr4:70080453	UGT2B11	0.38	6.89	0.3	1.82e-11	Obesity-related traits;
LGG	cis	rs780096	0.526	rs1647267	chr2:27651054	A/T	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs7674212	0.539	rs6850461	chr4:104120041	C/T	cg16532752	chr4:104119610	CENPE	-0.41	-7.09	-0.31	5.05e-12	Type 2 diabetes;
LGG	cis	rs1461503	0.900	rs1057704	chr11:122830274	T/C	cg27398637	chr11:122830231	C11orf63	-0.73	-15.15	-0.58	2.17e-42	Menarche (age at onset);
LGG	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00262122	chr8:11665843	FDFT1	0.43	6.81	0.3	3.04e-11	Myopia (pathological);
LGG	cis	rs722599	0.847	rs2058919	chr14:75310812	C/G	cg06637938	chr14:75390232	RPS6KL1	-0.62	-11.45	-0.47	6.81e-27	IgG glycosylation;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.84	-0.42	7.27e-21	Aortic root size;
LGG	cis	rs56161922	1.000	rs57587123	chr1:207825415	A/G	cg09557387	chr1:207818395	CR1L	0.99	9.63	0.41	4.06e-20	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs12188164	0.686	rs56279338	chr5:416118	G/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.42	6.88	0.3	1.92e-11	Cystic fibrosis severity;
LGG	cis	rs3749237	1.000	rs11710675	chr3:49751900	C/A	cg03060546	chr3:49711283	APEH	0.55	8.54	0.37	1.99e-16	Resting heart rate;
LGG	trans	rs7726839	0.561	rs72703058	chr5:584519	G/A	cg25482853	chr8:67687455	SGK3	0.85	11.15	0.46	9.37e-26	Obesity-related traits;
LGG	cis	rs2576037	0.899	rs2246877	chr18:44577005	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-9.8	-0.41	9.85e-21	Personality dimensions;
LGG	cis	rs72945132	0.579	rs61341131	chr11:70246956	C/A	cg14191688	chr11:70257035	CTTN	0.58	8.68	0.37	6.57e-17	Coronary artery disease;
LGG	cis	rs7781557	1.000	rs4610658	chr7:102445895	T/C	cg18108683	chr7:102477205	FBXL13	-0.55	-8.7	-0.37	5.83e-17	Colorectal adenoma (advanced);
LGG	cis	rs7927592	0.913	rs6591340	chr11:68297636	A/G	cg01657329	chr11:68192670	LRP5	-0.48	-8.19	-0.36	2.51e-15	Total body bone mineral density;
LGG	cis	rs10504130	0.569	rs34213209	chr8:52685901	G/A	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01671314	chr6:135502610	MYB	0.59	6.95	0.31	1.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs941408	1.000	rs1736180	chr19:2796021	C/T	cg06609049	chr19:2785107	THOP1	0.59	9.3	0.4	5.52e-19	Total cholesterol levels;
LGG	trans	rs1814175	0.817	rs1996982	chr11:49972619	G/T	cg15704280	chr7:45808275	SEPT13	-1.08	-27.27	-0.79	2.28e-98	Height;
LGG	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg03929089	chr4:120376271	NA	0.66	6.8	0.3	3.19e-11	Intraocular pressure;
LGG	trans	rs4689592	0.619	rs2359011	chr4:7066052	T/G	cg07817883	chr1:32538562	TMEM39B	-0.67	-9.6	-0.41	4.94e-20	Monocyte percentage of white cells;
LGG	cis	rs9916302	0.653	rs11654954	chr17:37745979	C/T	cg00129232	chr17:37814104	STARD3	0.65	10.29	0.43	1.71e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg10792982	chr14:105748885	BRF1	0.59	12.15	0.49	1.13e-29	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1577917	0.771	rs2484355	chr6:86394403	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.62	-11.0	-0.46	3.83e-25	Response to antipsychotic treatment;
LGG	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg00490583	chr16:1843685	IGFALS	0.44	9.71	0.41	2.02e-20	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs12517041	1.000	rs10054160	chr5:23297609	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.94	-0.45	6.09e-25	Calcium levels;
LGG	cis	rs6723108	0.603	rs6708336	chr2:135719132	T/A	cg07169764	chr2:136633963	MCM6	0.43	6.65	0.3	8.13e-11	Type 2 diabetes;
LGG	cis	rs9462027	0.628	rs2814961	chr6:34706951	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.92	-0.45	7.12e-25	Systemic lupus erythematosus;
LGG	cis	rs2735413	0.875	rs8053987	chr16:78084834	G/A	cg04733911	chr16:78082701	NA	0.78	18.77	0.66	7.47e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	trans	rs7395662	0.963	rs1588068	chr11:48671745	C/G	cg00717180	chr2:96193071	NA	-0.41	-7.28	-0.32	1.49e-12	HDL cholesterol;
LGG	cis	rs7786877	0.521	rs4729606	chr7:100321790	T/C	cg03098644	chr7:100410630	EPHB4	0.5	7.52	0.33	2.79e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs13108904	0.967	rs13150571	chr4:1278636	C/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	trans	rs4332037	0.802	rs12113633	chr7:1932936	G/A	cg22232500	chr2:134024266	NCKAP5	0.68	9.53	0.4	9.2e-20	Bipolar disorder;
LGG	cis	rs4862750	0.872	rs9998173	chr4:187898778	T/A	cg11301795	chr4:187892539	NA	-0.94	-25.33	-0.76	1.79e-89	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11190604	1.000	rs2489043	chr10:102334327	T/C	cg07570687	chr10:102243282	WNT8B	0.42	7.12	0.31	4.08e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7819412	0.806	rs6980856	chr8:10938260	A/G	cg11608241	chr8:8085544	FLJ10661	0.31	6.91	0.31	1.62e-11	Triglycerides;
LGG	cis	rs2072732	0.821	rs60287244	chr1:2943668	A/G	cg08733933	chr1:2954429	NA	-0.44	-8.73	-0.38	4.7e-17	Plateletcrit;
LGG	trans	rs61931739	0.517	rs7958755	chr12:34294699	T/C	cg26384229	chr12:38710491	ALG10B	0.8	16.15	0.6	7.52e-47	Morning vs. evening chronotype;
LGG	cis	rs12493885	0.725	rs4679728	chr3:153732761	G/C	cg12800244	chr3:153838788	SGEF	-0.8	-8.96	-0.38	8.18e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg17691542	chr6:26056736	HIST1H1C	0.61	10.0	0.42	1.83e-21	Iron status biomarkers;
LGG	trans	rs6582630	0.519	rs1607868	chr12:38385512	G/T	cg06521331	chr12:34319734	NA	-0.5	-8.65	-0.37	8.57e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2798269	0.763	rs4769169	chr13:22171158	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.44	-7.65	-0.33	1.19e-13	PR segment;
LGG	trans	rs7395662	1.000	rs11039857	chr11:48610853	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-7.97	-0.35	1.27e-14	HDL cholesterol;
LGG	cis	rs877282	0.583	rs11253441	chr10:828288	C/T	cg15764593	chr10:829463	NA	0.68	10.34	0.43	1.13e-22	Uric acid levels;
LGG	cis	rs1153858	1.000	rs2668747	chr15:45617216	T/C	cg10760299	chr15:45669010	GATM	0.39	7.51	0.33	3.1e-13	Homoarginine levels;
LGG	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg03433033	chr1:76189801	ACADM	0.64	9.3	0.4	5.5e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg18876405	chr7:65276391	NA	0.55	9.81	0.41	9.29e-21	Aortic root size;
LGG	cis	rs6558530	0.897	rs7838456	chr8:1707591	T/G	cg08198773	chr8:1697536	NA	0.36	6.95	0.31	1.26e-11	Systolic blood pressure;
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg06197492	chr11:2016605	H19	0.49	10.08	0.42	1.02e-21	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7666738	0.830	rs2114425	chr4:99023967	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1814175	0.617	rs6486020	chr11:49769149	T/G	cg11707556	chr5:10655725	ANKRD33B	-0.73	-16.01	-0.6	2.98e-46	Height;
LGG	cis	rs1577917	1.000	rs35761942	chr6:86629504	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.61	-10.19	-0.43	3.82e-22	Response to antipsychotic treatment;
LGG	cis	rs4481887	1.000	rs4481887	chr1:248496863	A/G	cg01631408	chr1:248437212	OR2T33	-0.56	-10.11	-0.43	7.73e-22	Common traits (Other);
LGG	cis	rs898097	0.691	rs7222745	chr17:80907253	C/T	cg15664640	chr17:80829946	TBCD	-0.54	-10.86	-0.45	1.24e-24	Breast cancer;
LGG	cis	rs733592	0.723	rs10875766	chr12:48593580	G/C	cg24011408	chr12:48396354	COL2A1	0.65	10.54	0.44	1.96e-23	Plateletcrit;
LGG	cis	rs6784615	0.590	rs409803	chr3:52443280	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.76	0.34	5.37e-14	Waist-hip ratio;
LGG	cis	rs10504229	0.679	rs72649120	chr8:58040308	C/T	cg26174226	chr8:58114915	NA	-0.51	-7.41	-0.33	5.97e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs11130313	chr3:52676190	A/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs2073300	1.000	rs12625804	chr20:23441981	G/A	cg12062639	chr20:23401060	NAPB	0.86	6.94	0.31	1.31e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2361718	0.500	rs8068856	chr17:78100731	A/G	cg21238619	chr17:78079768	GAA	-0.53	-10.21	-0.43	3.2800000000000002e-22	Yeast infection;
LGG	cis	rs4732038	0.510	rs10085559	chr7:134271725	G/A	cg06906464	chr7:134288099	NA	-0.66	-17.21	-0.62	1.13e-51	Longevity;
LGG	cis	rs2275620	1.000	rs1934985	chr10:96801753	C/T	cg09036531	chr10:96991505	NA	-0.43	-7.65	-0.34	1.14e-13	Gout;
LGG	trans	rs7980799	0.682	rs1351682	chr12:33598775	G/A	cg26384229	chr12:38710491	ALG10B	-0.64	-11.56	-0.47	2.49e-27	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs861020	0.771	rs126280	chr1:210019824	A/G	cg09163369	chr1:210001066	C1orf107	0.38	6.94	0.31	1.3e-11	Orofacial clefts;
LGG	cis	rs7084402	0.565	rs6481407	chr10:60335090	C/T	cg07615347	chr10:60278583	BICC1	-0.49	-11.75	-0.48	4.35e-28	Refractive error;
LGG	cis	rs9783347	0.621	rs10832920	chr11:18341869	A/G	cg15585147	chr11:18324498	HPS5	0.31	6.94	0.31	1.36e-11	Pancreatic cancer;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg02470625	chr7:39453784	POU6F2	-0.41	-6.78	-0.3	3.69e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10910775	chr17:45266517	CDC27	0.31	7.26	0.32	1.6e-12	Menarche (age at onset);
LGG	trans	rs6787172	0.702	rs2682404	chr3:157993937	G/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs9381107	0.932	rs9349224	chr6:9471146	G/T	cg14735645	chr6:9486422	NA	-0.45	-7.49	-0.33	3.61e-13	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs736408	0.609	rs2268025	chr3:52795224	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.55	9.39	0.4	2.67e-19	Bipolar disorder;
LGG	cis	rs17208368	0.689	rs11861573	chr16:55091114	A/T	cg11181171	chr16:55090946	NA	0.45	6.8	0.3	3.25e-11	Hypospadias;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg16511870	chr7:6145057	USP42	-0.4	-6.8	-0.3	3.27e-11	Brain structure;
LGG	trans	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg24247370	chr13:99142703	STK24	-0.39	-7.03	-0.31	7.66e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10256972	0.591	rs6968988	chr7:1169619	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.66	-11.59	-0.47	1.95e-27	Longevity;Endometriosis;
LGG	cis	rs7618915	0.547	rs11130323	chr3:52770277	T/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.45	-0.44	4.34e-23	Bipolar disorder;
LGG	cis	rs68170813	0.559	rs6971675	chr7:106833797	G/A	cg02696742	chr7:106810147	HBP1	-0.77	-11.01	-0.46	3.22e-25	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs7753812	chr6:150011286	C/T	cg00424166	chr6:150045504	NUP43	-0.34	-7.23	-0.32	2.05e-12	Lung cancer;
LGG	cis	rs6502050	0.835	rs7503189	chr17:80099486	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs7615952	0.576	rs2276727	chr3:125826243	C/T	cg18479299	chr3:125709523	NA	-0.55	-6.96	-0.31	1.16e-11	Blood pressure (smoking interaction);
LGG	cis	rs8133932	0.701	rs9653780	chr21:47303774	A/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.23	-0.32	1.96e-12	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9480031	chr6:150080011	A/C	cg09699651	chr6:150184138	LRP11	0.51	8.96	0.38	8.06e-18	Lung cancer;
LGG	cis	rs7829975	0.623	rs7010753	chr8:8373956	A/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.65	0.33	1.2e-13	Mood instability;
LGG	cis	rs9393692	0.645	rs2179152	chr6:26325888	T/C	cg00294572	chr6:26285232	NA	0.39	6.76	0.3	4.08e-11	Educational attainment;
LGG	cis	rs3849570	0.925	rs9841087	chr3:81907949	A/G	cg07356753	chr3:81810745	GBE1	-0.43	-6.82	-0.3	2.86e-11	Waist circumference;Body mass index;
LGG	cis	rs875971	0.862	rs801195	chr7:66026115	A/G	cg23594656	chr7:65796392	TPST1	0.42	9.26	0.4	7.64e-19	Aortic root size;
LGG	cis	rs7843479	0.965	rs2291317	chr8:21827162	C/T	cg17168535	chr8:21777572	XPO7	0.58	9.4	0.4	2.55e-19	Mean corpuscular volume;
LGG	cis	rs7552404	1.000	rs4949875	chr1:76173080	G/A	cg03433033	chr1:76189801	ACADM	0.8	12.85	0.51	1.6e-32	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs806215	0.666	rs12672945	chr7:127510489	A/G	cg25922125	chr7:127225783	GCC1	-0.5	-7.14	-0.31	3.71e-12	Type 2 diabetes;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12682607	chr3:32634705	NA	0.39	6.76	0.3	4.28e-11	Pancreatic cancer;
LGG	cis	rs9300255	0.739	rs1969354	chr12:123741776	T/C	cg05973401	chr12:123451056	ABCB9	0.51	7.67	0.34	9.98e-14	Neutrophil percentage of white cells;
LGG	cis	rs774359	0.744	rs2484319	chr9:27563755	A/C	cg14173147	chr9:27528300	MOBKL2B	0.43	7.87	0.34	2.45e-14	Amyotrophic lateral sclerosis;
LGG	cis	rs2742417	0.609	rs2673066	chr3:45771200	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.71e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg08807101	chr21:30365312	RNF160	-0.59	-8.2	-0.36	2.38e-15	Cognitive test performance;
LGG	cis	rs3820068	0.603	rs7516453	chr1:15972558	C/G	cg05660106	chr1:15850417	CASP9	0.84	16.85	0.62	4.87e-50	Systolic blood pressure;
LGG	cis	rs9660992	0.548	rs1172152	chr1:205220718	T/A	cg21545522	chr1:205238299	TMCC2	0.42	7.98	0.35	1.19e-14	Mean corpuscular volume;Mean platelet volume;
LGG	trans	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg21775007	chr8:11205619	TDH	0.45	7.42	0.33	5.48e-13	Mood instability;
LGG	cis	rs7572733	0.935	rs10931797	chr2:198840793	C/T	cg00792783	chr2:198669748	PLCL1	0.49	8.28	0.36	1.33e-15	Dermatomyositis;
LGG	cis	rs806215	0.950	rs2073561	chr7:127227769	G/C	cg25922125	chr7:127225783	GCC1	-0.79	-10.69	-0.44	5.7e-24	Type 2 diabetes;
LGG	cis	rs1862618	0.853	rs832583	chr5:56178217	A/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.45	-0.44	4.22e-23	Initial pursuit acceleration;
LGG	cis	rs9290065	0.519	rs6808386	chr3:160673263	A/T	cg04691961	chr3:161091175	C3orf57	-0.44	-9.13	-0.39	2.18e-18	Kawasaki disease;
LGG	cis	rs4746818	1.000	rs7071904	chr10:70903005	C/T	cg11621586	chr10:70884670	VPS26A	1.18	21.7	0.71	1.5299999999999999e-72	Left atrial antero-posterior diameter;
LGG	trans	rs116095464	0.510	rs10057501	chr5:239545	T/C	cg09048205	chr5:1608656	LOC728613	-0.5	-8.39	-0.36	5.82e-16	Breast cancer;
LGG	cis	rs2070488	0.804	rs13059256	chr3:38504315	T/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.74	14.72	0.56	1.73e-40	Electrocardiographic conduction measures;
LGG	cis	rs977987	0.585	rs62059845	chr16:75430713	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.81	0.3	2.95e-11	Dupuytren's disease;
LGG	cis	rs7786808	0.776	rs11983316	chr7:158209742	A/G	cg01191920	chr7:158217561	PTPRN2	-0.79	-17.96	-0.64	4.06e-55	Obesity-related traits;
LGG	cis	rs10504229	0.911	rs77203035	chr8:58175458	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	trans	rs12599106	0.771	rs2163975	chr16:34884821	C/G	cg02985366	chr16:32360428	NA	-0.47	-7.39	-0.32	7.14e-13	Menopause (age at onset);
LGG	cis	rs9393692	1.000	rs9393692	chr6:26276650	A/G	cg15665833	chr6:26285013	NA	0.41	7.86	0.34	2.68e-14	Educational attainment;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg20887711	chr4:1340912	KIAA1530	0.47	8.21	0.36	2.25e-15	Obesity-related traits;
LGG	cis	rs739401	0.588	rs10219272	chr11:3020789	G/A	cg08508325	chr11:3079039	CARS	-0.62	-13.47	-0.53	4.05e-35	Longevity;
LGG	cis	rs1790761	0.967	rs12787021	chr11:67204342	A/G	cg14500267	chr11:67383377	NA	-0.41	-7.51	-0.33	3.17e-13	Mean corpuscular volume;
LGG	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg22044901	chr15:68126292	NA	-0.41	-6.94	-0.31	1.34e-11	Restless legs syndrome;
LGG	cis	rs6840360	0.582	rs4696260	chr4:152318924	T/C	cg17217059	chr4:152329364	FAM160A1	0.2	6.96	0.31	1.17e-11	Intelligence (multi-trait analysis);
LGG	cis	rs992157	0.965	rs13419763	chr2:219134950	C/T	cg04731861	chr2:219085781	ARPC2	-0.42	-10.14	-0.43	5.8e-22	Colorectal cancer;
LGG	cis	rs9951602	0.573	rs78623099	chr18:76646228	G/T	cg24134504	chr18:76639479	NA	-0.47	-8.28	-0.36	1.35e-15	Obesity-related traits;
LGG	trans	rs61931739	0.517	rs11053224	chr12:34484919	G/A	cg13010199	chr12:38710504	ALG10B	0.66	13.28	0.53	2.55e-34	Morning vs. evening chronotype;
LGG	cis	rs8114671	0.967	rs6088734	chr20:33745046	A/T	cg24642439	chr20:33292090	TP53INP2	0.45	7.1	0.31	4.62e-12	Height;
LGG	cis	rs151997	0.925	rs28077	chr5:50191946	T/A	cg06027927	chr5:50259733	NA	0.68	11.13	0.46	1.18e-25	Callous-unemotional behaviour;
LGG	cis	rs769267	0.896	rs10405625	chr19:19579046	T/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg11878867	chr6:150167359	LRP11	-0.47	-9.59	-0.41	5.45e-20	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12713142	chr12:57081325	PTGES3	0.51	8.01	0.35	9.29e-15	Gut microbiome composition (summer);
LGG	cis	rs2204008	0.905	rs7294297	chr12:38442573	T/C	cg26384229	chr12:38710491	ALG10B	0.89	19.94	0.68	2.51e-64	Bladder cancer;
LGG	trans	rs9329221	0.678	rs560638	chr8:9882767	A/G	cg16141378	chr3:129829833	LOC729375	0.4	8.99	0.39	6.22e-18	Neuroticism;
LGG	cis	rs798554	0.759	rs798495	chr7:2797267	T/C	cg05793240	chr7:2802953	GNA12	0.34	7.79	0.34	4.35e-14	Height;
LGG	cis	rs2180341	0.781	rs7760652	chr6:127572096	A/G	cg24812749	chr6:127587940	RNF146	0.78	13.07	0.52	1.98e-33	Breast cancer;
LGG	trans	rs6787172	0.677	rs1193537	chr3:157972453	T/C	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs593531	0.571	rs10898981	chr11:74092465	A/C	cg18195628	chr11:73498948	MRPL48	-0.4	-6.65	-0.3	8.33e-11	Neuroticism;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg15971980	chr6:150254442	NA	0.46	9.15	0.39	1.87e-18	Testicular germ cell tumor;
LGG	cis	rs2836950	0.565	rs7276046	chr21:40581293	T/C	cg11644478	chr21:40555479	PSMG1	-0.62	-10.34	-0.43	1.06e-22	Menarche (age at onset);
LGG	cis	rs2576037	0.526	rs2051292	chr18:44484372	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.78	0.45	2.56e-24	Personality dimensions;
LGG	cis	rs7572733	0.534	rs4850815	chr2:198786167	G/T	cg00792783	chr2:198669748	PLCL1	-0.68	-11.05	-0.46	2.39e-25	Dermatomyositis;
LGG	cis	rs6723108	0.626	rs1530559	chr2:135755629	C/T	cg07169764	chr2:136633963	MCM6	-0.44	-6.73	-0.3	5.18e-11	Type 2 diabetes;
LGG	cis	rs589448	0.902	rs315113	chr12:69786543	G/T	cg20891283	chr12:69753455	YEATS4	-1.09	-29.16	-0.8	6.86e-107	Cerebrospinal fluid biomarker levels;
LGG	cis	rs801193	1.000	rs11773829	chr7:66141074	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.87	-0.45	1.2e-24	Aortic root size;
LGG	cis	rs7737355	0.812	rs798407	chr5:130688378	C/G	cg06307176	chr5:131281290	NA	-0.49	-8.13	-0.35	3.87e-15	Life satisfaction;
LGG	trans	rs6089829	1.000	rs6089829	chr20:61669036	C/T	cg23505145	chr19:12996616	KLF1	-0.37	-6.69	-0.3	6.46e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27552081	chr17:25621774	WSB1	0.54	8.12	0.35	4.2e-15	Gut microbiome composition (summer);
LGG	cis	rs1519814	0.659	rs7829279	chr8:121023514	A/G	cg22335954	chr8:121166405	COL14A1	-0.48	-8.63	-0.37	9.68e-17	Breast cancer;
LGG	cis	rs11122272	0.735	rs2474633	chr1:231486989	A/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.32	-0.43	1.25e-22	Hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23434193	chr8:74884752	TCEB1	0.48	7.68	0.34	9.48e-14	Gut microbiome composition (summer);
LGG	trans	rs62103177	0.525	rs10438902	chr18:77745640	A/G	cg05926928	chr17:57297772	GDPD1	-0.86	-11.88	-0.48	1.31e-28	Opioid sensitivity;
LGG	cis	rs4974559	1.000	rs10006789	chr4:1330333	T/C	cg02980000	chr4:1222292	CTBP1	0.7	10.24	0.43	2.51e-22	Systolic blood pressure;
LGG	cis	rs6500602	0.563	rs917305	chr16:4440593	C/T	cg19168338	chr16:4465731	CORO7	-0.99	-18.52	-0.65	9.95e-58	Schizophrenia;
LGG	trans	rs1814175	0.645	rs28634872	chr11:50042175	T/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.95	-0.6	5.56e-46	Height;
LGG	cis	rs62238980	0.614	rs76549479	chr22:32510944	G/A	cg02631450	chr22:32366979	NA	0.98	9.23	0.39	9.36e-19	Childhood ear infection;
LGG	cis	rs3733585	0.673	rs7378340	chr4:9955198	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.1	-0.31	4.68e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6831352	0.959	rs1139490	chr4:100045141	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.61	0.41	4.61e-20	Alcohol dependence;
LGG	cis	rs2976388	0.609	rs1560986	chr8:143789775	T/C	cg06565975	chr8:143823917	SLURP1	0.37	9.53	0.4	8.89e-20	Urinary tract infection frequency;
LGG	cis	rs1691799	0.899	rs1168301	chr12:66736771	C/T	cg16791601	chr12:66731901	HELB	-0.64	-14.98	-0.57	1.23e-41	White blood cell count (basophil);
LGG	cis	rs6502050	0.835	rs8081949	chr17:80117490	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.44	-0.33	5.05e-13	Life satisfaction;
LGG	cis	rs2739330	0.828	rs5760107	chr22:24252597	T/C	cg12419862	chr22:24373484	LOC391322	-0.89	-18.39	-0.65	4.03e-57	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2721195	0.654	rs4610795	chr8:145881333	C/T	cg26752003	chr8:145688521	CYHR1	0.38	7.86	0.34	2.81e-14	Age at first birth;
LGG	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg02227867	chr8:22457446	C8orf58	-0.45	-8.47	-0.37	3.37e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs12682352	0.602	rs1473029	chr8:8668917	A/C	cg02002194	chr4:3960332	NA	-0.38	-6.92	-0.31	1.52e-11	Neuroticism;
LGG	cis	rs1129187	0.967	rs9462857	chr6:42943098	T/C	cg05552183	chr6:42928497	GNMT	0.47	14.44	0.56	2.86e-39	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4820294	1.000	rs7291867	chr22:38062112	C/G	cg10587741	chr22:38071170	LGALS1	0.82	21.63	0.71	3.14e-72	Fat distribution (HIV);
LGG	cis	rs17428076	0.836	rs3770455	chr2:172667895	C/T	cg21435375	chr2:172878103	MAP1D	0.4	8.77	0.38	3.41e-17	Myopia;
LGG	cis	rs847649	0.842	rs11976237	chr7:102641383	A/G	cg18108683	chr7:102477205	FBXL13	0.57	12.08	0.49	2.18e-29	Morning vs. evening chronotype;
LGG	cis	rs951366	0.576	rs11240559	chr1:205709621	T/G	cg14893161	chr1:205819251	PM20D1	-0.44	-7.57	-0.33	2.06e-13	Menarche (age at onset);
LGG	cis	rs344364	0.511	rs337284	chr16:1954799	A/C	cg00490583	chr16:1843685	IGFALS	-0.4	-6.93	-0.31	1.46e-11	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20227976	chr9:35757314	NA	0.47	7.4	0.33	6.41e-13	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.538	rs11040373	chr11:49461791	T/C	cg00717180	chr2:96193071	NA	-0.49	-8.84	-0.38	2e-17	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4916128	chr1:248466706	G/A	cg00666640	chr1:248458726	OR2T12	0.61	9.91	0.42	4.08e-21	Common traits (Other);
LGG	cis	rs35146811	0.844	rs4729576	chr7:99692594	G/A	cg13334819	chr7:99746414	C7orf59	-0.47	-7.16	-0.32	3.26e-12	Coronary artery disease;
LGG	cis	rs9341808	0.718	rs9448899	chr6:80845864	G/A	cg08355045	chr6:80787529	NA	0.41	7.91	0.35	1.84e-14	Sitting height ratio;
LGG	cis	rs9611565	0.649	rs5751108	chr22:41858035	T/C	cg06481639	chr22:41940642	POLR3H	0.59	8.65	0.37	8.46e-17	Vitiligo;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg24829409	chr8:58192753	C8orf71	-0.75	-10.5	-0.44	2.7e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2074193	0.627	rs11183910	chr12:47769021	A/G	cg02516419	chr12:47771422	NA	-0.72	-10.54	-0.44	2.01e-23	Migraine with aura;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	ch.3.96438232F	chr3:94955542	NA	-0.37	-6.74	-0.3	4.72e-11	Pancreatic cancer;
LGG	trans	rs11250097	0.528	rs36043848	chr8:11309533	A/G	cg02002194	chr4:3960332	NA	0.39	7.04	0.31	7.06e-12	Neuroticism;
LGG	cis	rs7227917	0.536	rs72916016	chr18:45511310	T/C	cg22195133	chr18:45534586	NA	0.77	7.0	0.31	9.3e-12	Lung cancer in ever smokers;
LGG	cis	rs7927771	0.524	rs10838763	chr11:47794802	C/T	cg20307385	chr11:47447363	PSMC3	0.57	11.1	0.46	1.56e-25	Subjective well-being;
LGG	cis	rs7904985	0.960	rs34731943	chr10:88125890	C/A	cg07322936	chr10:88137208	NA	-0.51	-7.61	-0.33	1.55e-13	Barrett's esophagus;
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg05861140	chr6:150128134	PCMT1	0.43	9.67	0.41	2.89e-20	Lung cancer;
LGG	cis	rs9362426	0.708	rs7744793	chr6:88102040	G/A	cg06087457	chr6:88040249	C6orf162;GJB7	0.41	7.92	0.35	1.76e-14	Depressive episodes in bipolar disorder;
LGG	trans	rs61931739	0.500	rs3934517	chr12:34451396	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs4819052	1.000	rs3746980	chr21:46711580	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.7	10.64	0.44	8.13e-24	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9479482	1.000	rs9479405	chr6:150338065	G/A	cg03788504	chr6:150331562	NA	-0.59	-13.57	-0.53	1.52e-35	Alopecia areata;
LGG	cis	rs11764590	0.694	rs4721321	chr7:2068470	A/G	cg23422044	chr7:1970798	MAD1L1	-0.49	-8.89	-0.38	1.37e-17	Neuroticism;
LGG	cis	rs11676855	1.000	rs6710499	chr2:235898590	A/G	cg06431347	chr2:235935754	SH3BP4	-0.42	-9.08	-0.39	3.06e-18	Dialysis-related mortality;
LGG	cis	rs7223966	1.000	rs8070650	chr17:61744040	A/G	cg18032289	chr17:61959525	GH2	-0.4	-6.82	-0.3	2.82e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2243480	0.901	rs313808	chr7:65499873	T/G	cg12463550	chr7:65579703	CRCP	0.76	8.13	0.35	4.01e-15	Diabetic kidney disease;
LGG	cis	rs8072100	0.688	rs7221224	chr17:45419061	T/G	cg19784903	chr17:45786737	TBKBP1	0.34	6.87	0.3	2.09e-11	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4700695	0.841	rs706680	chr5:65317338	T/C	cg21114390	chr5:65439923	SFRS12	0.58	7.17	0.32	3.03e-12	Facial morphology (factor 19);
LGG	trans	rs6601327	0.613	rs11785458	chr8:9506810	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.84	0.34	3.19e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg05425664	chr17:57184151	TRIM37	-0.71	-11.43	-0.47	7.92e-27	Intelligence (multi-trait analysis);
LGG	cis	rs1451375	0.617	rs2876829	chr7:50566762	A/G	cg14593290	chr7:50529359	DDC	0.65	11.73	0.48	5.33e-28	Malaria;
LGG	cis	rs12477438	0.501	rs11685756	chr2:99766215	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.21	32.25	0.83	1.76e-120	Chronic sinus infection;
LGG	cis	rs4732038	0.630	rs1465473	chr7:134259962	T/C	cg06906464	chr7:134288099	NA	-0.64	-17.72	-0.64	5.02e-54	Longevity;
LGG	cis	rs9790314	0.690	rs4679930	chr3:160842875	C/G	cg04691961	chr3:161091175	C3orf57	-0.47	-10.36	-0.43	9.49e-23	Morning vs. evening chronotype;
LGG	cis	rs4474465	1.000	rs7950865	chr11:78157401	A/G	cg02023728	chr11:77925099	USP35	0.39	6.85	0.3	2.31e-11	Alzheimer's disease (survival time);
LGG	cis	rs3087591	0.960	rs11080146	chr17:29578724	C/T	cg24425628	chr17:29625626	OMG;NF1	-0.72	-15.02	-0.57	8.28e-42	Hip circumference;
LGG	cis	rs17826219	0.636	rs12946563	chr17:29103166	C/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.16	-0.35	3.13e-15	Body mass index;
LGG	cis	rs7512552	0.809	rs9436112	chr1:150406449	A/C	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs11966931	0.948	rs17528484	chr6:108095573	A/G	cg04749840	chr6:108095067	SCML4	0.43	7.26	0.32	1.68e-12	Neutrophil percentage of white cells;
LGG	cis	rs10911232	0.507	rs28477876	chr1:183019882	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Hypertriglyceridemia;
LGG	trans	rs3749237	1.000	rs11717256	chr3:49868520	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.14	0.39	1.94e-18	Resting heart rate;
LGG	cis	rs4730779	0.571	rs254537	chr7:116971883	T/C	cg10524701	chr7:117356490	CTTNBP2	0.36	7.02	0.31	8.04e-12	Waist circumference;
LGG	cis	rs7635838	0.819	rs2454476	chr3:11545442	G/A	cg00170343	chr3:11313890	ATG7	0.41	6.77	0.3	3.96e-11	HDL cholesterol;
LGG	cis	rs9522267	0.707	rs9522282	chr13:112222410	T/C	cg10483660	chr13:112241077	NA	-0.38	-8.02	-0.35	8.77e-15	Hepatitis;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg08730330	chr17:61904790	PSMC5;FTSJ3	0.43	7.76	0.34	5.48e-14	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs9891962	chr17:80153594	T/C	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs7824557	0.614	rs2060456	chr8:11213363	C/T	cg21775007	chr8:11205619	TDH	0.81	14.31	0.55	9.68e-39	Retinal vascular caliber;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg26597500	chr13:73356092	PIBF1;DIS3	0.39	6.73	0.3	5.1e-11	Lung adenocarcinoma;
LGG	cis	rs8141529	0.732	rs3788409	chr22:29198151	T/G	cg02153584	chr22:29168773	CCDC117	0.69	11.77	0.48	3.86e-28	Lymphocyte counts;
LGG	cis	rs1577917	0.740	rs9353327	chr6:86394066	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-12.1	-0.49	1.84e-29	Response to antipsychotic treatment;
LGG	cis	rs7493	0.950	rs17880101	chr7:95031457	A/T	cg17330251	chr7:94953956	PON1	-0.43	-8.14	-0.35	3.77e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs963731	0.649	rs1377860	chr2:39290425	C/G	cg04010122	chr2:39346883	SOS1	0.76	6.73	0.3	4.94e-11	Corticobasal degeneration;
LGG	trans	rs61931739	0.892	rs73309466	chr12:34093146	A/G	cg26384229	chr12:38710491	ALG10B	-0.58	-10.56	-0.44	1.7e-23	Morning vs. evening chronotype;
LGG	trans	rs57046232	0.552	rs6038445	chr20:6329093	A/G	cg21095983	chr6:86352623	SYNCRIP	0.41	6.89	0.3	1.82e-11	Colorectal cancer;
LGG	cis	rs10799590	1.000	rs12121558	chr1:224832749	T/C	cg01808320	chr1:224927238	CNIH3	-0.38	-6.83	-0.3	2.69e-11	Opioid dependence;
LGG	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg07570687	chr10:102243282	WNT8B	0.42	7.0	0.31	9.27e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7824557	0.806	rs6601573	chr8:11094751	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-8.66	-0.37	7.87e-17	Retinal vascular caliber;
LGG	cis	rs7208859	0.623	rs7220999	chr17:29149298	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.54e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9322193	0.923	rs1934534	chr6:150033032	A/G	cg08621203	chr6:150244597	RAET1G	0.45	7.82	0.34	3.57e-14	Lung cancer;
LGG	cis	rs644799	1.000	rs3748256	chr11:95521953	A/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.91	0.35	1.91e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs8177253	1.000	rs8177253	chr3:133480192	A/G	cg12373951	chr3:133503437	NA	-0.4	-6.99	-0.31	9.47e-12	Iron status biomarkers;
LGG	cis	rs17401966	0.838	rs7553228	chr1:10350438	G/C	cg15208524	chr1:10270712	KIF1B	0.44	7.71	0.34	7.84e-14	Hepatocellular carcinoma;
LGG	cis	rs1799949	0.965	rs7223952	chr17:41194885	T/C	cg01879757	chr17:41196368	BRCA1	-0.42	-8.57	-0.37	1.51e-16	Menopause (age at onset);
LGG	cis	rs854765	0.647	rs854808	chr17:18006634	C/T	cg05444541	chr17:17804740	TOM1L2	-0.59	-12.79	-0.51	2.87e-32	Total body bone mineral density;
LGG	cis	rs9303280	0.742	rs11557466	chr17:38024626	C/T	cg17467752	chr17:38218738	THRA	-0.44	-6.99	-0.31	9.58e-12	Self-reported allergy;
LGG	cis	rs798554	0.610	rs2644297	chr7:2858906	A/C	cg19717773	chr7:2847554	GNA12	-0.38	-8.88	-0.38	1.51e-17	Height;
LGG	cis	rs12643440	0.502	rs56163730	chr4:17143120	A/G	cg22650099	chr4:17144496	NA	-0.5	-8.64	-0.37	9.13e-17	Metabolite levels (Pyroglutamine);
LGG	trans	rs1814175	0.817	rs10128730	chr11:50023369	G/T	cg03929089	chr4:120376271	NA	-1.03	-24.63	-0.75	3.12e-86	Height;
LGG	trans	rs11098499	0.954	rs35091806	chr4:120325529	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.34	0.5	1.92e-30	Corneal astigmatism;
LGG	cis	rs6951245	0.572	rs80133931	chr7:1027286	C/T	cg18402987	chr7:1209562	NA	0.73	7.74	0.34	6.35e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1408224	0.508	rs4942559	chr13:47206814	G/C	cg24453118	chr13:47229927	LRCH1	-0.29	-6.82	-0.3	2.79e-11	QRS complex (12-leadsum);
LGG	cis	rs9527	0.590	rs2148200	chr10:104879847	C/A	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg05368731	chr17:41323189	NBR1	0.94	18.76	0.66	8.18e-59	Menopause (age at onset);
LGG	cis	rs7512552	0.839	rs834231	chr1:150389392	A/T	cg15654264	chr1:150340011	RPRD2	-0.45	-9.23	-0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg04025307	chr7:1156635	C7orf50	0.8	14.43	0.56	3.1e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg10950524	chr7:2139216	MAD1L1	0.35	7.56	0.33	2.14e-13	Schizophrenia;
LGG	cis	rs2576037	0.583	rs646128	chr18:44397691	A/C	cg23302884	chr18:44338147	ST8SIA5	-0.49	-9.84	-0.42	7.19e-21	Personality dimensions;
LGG	cis	rs1707322	0.685	rs6690926	chr1:46134978	T/C	cg03146154	chr1:46216737	IPP	0.56	10.96	0.45	5.12e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04410161	chr6:116892488	RWDD1	0.44	6.95	0.31	1.25e-11	Cognitive performance;
LGG	cis	rs6940638	0.688	rs9295730	chr6:27128806	T/C	cg12826209	chr6:26865740	GUSBL1	0.47	7.73	0.34	6.86e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6445975	0.617	rs9859048	chr3:58420418	T/C	cg24175188	chr3:58374923	PXK	-0.53	-8.76	-0.38	3.6e-17	Systemic lupus erythematosus;
LGG	cis	rs11719291	0.667	rs9877542	chr3:48748545	C/T	cg00383909	chr3:49044727	WDR6	0.92	11.49	0.47	4.54e-27	Cognitive function;
LGG	cis	rs4148087	0.929	rs4148098	chr21:43639553	T/A	cg08841829	chr21:43638893	ABCG1	-0.67	-9.69	-0.41	2.46e-20	Eating disorder in bipolar disorder;
LGG	cis	rs881375	0.967	rs2109895	chr9:123677827	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.2	0.39	1.19e-18	Rheumatoid arthritis;
LGG	cis	rs17539620	0.624	rs111868524	chr6:154839960	G/C	cg17771515	chr6:154831774	CNKSR3	0.62	7.65	0.34	1.17e-13	Lipoprotein (a) levels;
LGG	cis	rs2188554	0.675	rs10227378	chr7:117078966	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	7.79	0.34	4.49e-14	Esophageal adenocarcinoma;
LGG	cis	rs6500395	1.000	rs7191028	chr16:48626023	T/C	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.44e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs78456975	1.000	rs7584264	chr2:1565555	A/G	cg01028140	chr2:1542097	TPO	-0.51	-8.21	-0.36	2.16e-15	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs10936602	0.520	rs12486767	chr3:169550759	A/G	cg08193579	chr3:169529701	LRRC34	-0.38	-7.58	-0.33	1.89e-13	Renal cell carcinoma;
LGG	cis	rs283228	0.535	rs579069	chr6:101839539	A/T	cg27451362	chr6:101846650	GRIK2	1.0	15.44	0.58	1.11e-43	Coenzyme Q10 levels;
LGG	cis	rs13108904	0.604	rs11946375	chr4:1313488	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.6	0.33	1.65e-13	Obesity-related traits;
LGG	cis	rs7223966	1.000	rs16947042	chr17:61766457	T/G	cg11494091	chr17:61959527	GH2	0.54	8.85	0.38	1.92e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6502050	0.799	rs4789673	chr17:80123218	T/C	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.09e-15	Life satisfaction;
LGG	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg07382826	chr16:28625726	SULT1A1	0.39	8.44	0.37	3.99e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4727027	0.901	rs1534197	chr7:148771970	T/C	cg23583168	chr7:148888333	NA	-0.82	-15.66	-0.59	1.21e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs28386778	0.897	rs2665795	chr17:61925272	A/G	cg03528353	chr17:61819722	STRADA	-0.43	-7.42	-0.33	5.63e-13	Prudent dietary pattern;
LGG	cis	rs9326248	0.911	rs11216284	chr11:117003060	C/T	cg01368799	chr11:117014884	PAFAH1B2	0.62	9.29	0.4	5.93e-19	Blood protein levels;
LGG	trans	rs7939886	0.920	rs17149859	chr11:55795356	G/A	cg15704280	chr7:45808275	SEPT13	0.88	9.18	0.39	1.45e-18	Myopia (pathological);
LGG	cis	rs8133932	0.859	rs74681567	chr21:47054985	T/C	cg11214348	chr21:47283868	PCBP3	-0.4	-6.66	-0.3	7.74e-11	Schizophrenia;
LGG	cis	rs8060686	0.641	rs79577483	chr16:68036939	A/G	cg27539214	chr16:67997921	SLC12A4	-0.46	-7.25	-0.32	1.78e-12	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs6977660	0.619	rs4721823	chr7:19785888	G/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.27	0.36	1.39e-15	Thyroid stimulating hormone;
LGG	cis	rs897984	0.806	rs8050588	chr16:30937799	G/A	cg00531865	chr16:30841666	NA	-0.58	-12.42	-0.5	9.31e-31	Dementia with Lewy bodies;
LGG	trans	rs7615952	0.512	rs2979334	chr3:125358824	G/A	cg07211511	chr3:129823064	LOC729375	-0.48	-7.08	-0.31	5.28e-12	Blood pressure (smoking interaction);
LGG	cis	rs79057730	0.599	rs34411410	chr7:811721	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.53	0.33	2.73e-13	Initial pursuit acceleration;
LGG	cis	rs2708977	0.667	rs772156	chr2:97029830	G/A	cg01950434	chr2:97203154	ARID5A	-0.49	-7.56	-0.33	2.17e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6905628	1	rs6905628	chr6:90344869	C/G	cg23505970	chr6:90529759	MDN1	0.48	7.15	0.32	3.36e-12	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26988800	chr17:2415132	METT10D	0.47	6.95	0.31	1.27e-11	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.925	rs6808036	chr3:49236439	T/G	cg07636037	chr3:49044803	WDR6	0.76	13.6	0.53	1.11e-35	Menarche (age at onset);
LGG	cis	rs62064224	0.818	rs11080180	chr17:30682998	G/A	cg12561776	chr17:30844705	MYO1D	-0.27	-6.95	-0.31	1.27e-11	Schizophrenia;
LGG	cis	rs17376456	1.000	rs34854140	chr5:93538169	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	0.84	9.05	0.39	4.08e-18	Diabetic retinopathy;
LGG	cis	rs6912958	0.677	rs111990232	chr6:88022240	A/C	cg08069147	chr6:88032118	GJB7;C6orf162	0.57	9.68	0.41	2.59e-20	Monocyte percentage of white cells;
LGG	cis	rs1348850	0.789	rs2197611	chr2:178369036	G/C	cg27490568	chr2:178487706	NA	0.51	10.08	0.42	1.01e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs929354	0.935	rs1182392	chr7:157036200	C/T	cg17757837	chr7:157058334	UBE3C	-0.89	-20.07	-0.68	6.41e-65	Body mass index;
LGG	cis	rs7829975	0.557	rs7816427	chr8:8545884	T/C	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.83	-0.34	3.39e-14	Mood instability;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg14928991	chr14:61448281	TRMT5;SLC38A6	-0.46	-6.9	-0.31	1.76e-11	Systemic lupus erythematosus;
LGG	cis	rs9354308	0.764	rs9354324	chr6:66587013	C/T	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	trans	rs1908814	0.516	rs4367597	chr8:11793529	C/T	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs7618915	0.501	rs1866268	chr3:52719398	C/A	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.05e-13	Bipolar disorder;
LGG	cis	rs9303401	1.000	rs9904677	chr17:56873025	A/G	cg12560992	chr17:57184187	TRIM37	0.47	7.02	0.31	7.73e-12	Cognitive test performance;
LGG	cis	rs2455799	0.613	rs2470548	chr3:15737689	G/A	cg16303742	chr3:15540471	COLQ	-0.39	-7.62	-0.33	1.42e-13	Mean platelet volume;
LGG	cis	rs68170813	0.559	rs79543528	chr7:106891090	C/T	cg02696742	chr7:106810147	HBP1	-0.75	-10.66	-0.44	6.92e-24	Coronary artery disease;
LGG	cis	rs9549367	0.789	rs9549711	chr13:113900557	C/T	cg00898013	chr13:113819073	PROZ	-0.43	-8.67	-0.37	7.53e-17	Platelet distribution width;
LGG	cis	rs875971	0.862	rs6978028	chr7:65886300	G/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg05091796	chr16:4465799	CORO7	-0.64	-10.61	-0.44	1.1e-23	Schizophrenia;
LGG	trans	rs11098499	0.863	rs3733525	chr4:120447048	A/G	cg25214090	chr10:38739885	LOC399744	0.67	11.73	0.48	5.2e-28	Corneal astigmatism;
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg16060761	chr17:80687452	NA	-0.41	-6.67	-0.3	7.47e-11	Glycated hemoglobin levels;
LGG	cis	rs7613875	0.600	rs2624826	chr3:50155468	T/G	cg24110177	chr3:50126178	RBM5	0.64	11.63	0.48	1.38e-27	Body mass index;
LGG	trans	rs208520	0.690	rs12213575	chr6:66735989	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.68	0.63	7.72e-54	Exhaled nitric oxide output;
LGG	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg12560992	chr17:57184187	TRIM37	0.47	7.02	0.31	7.73e-12	Cognitive test performance;
LGG	cis	rs17102423	0.685	rs7156617	chr14:65541381	G/A	cg26396452	chr14:65542826	MAX	0.44	8.87	0.38	1.54e-17	Obesity-related traits;
LGG	cis	rs7659604	0.539	rs56159666	chr4:122782879	G/A	cg20573242	chr4:122745356	CCNA2	0.53	9.88	0.42	5.06e-21	Type 2 diabetes;
LGG	cis	rs2836950	0.805	rs62223042	chr21:40683740	A/G	cg11890956	chr21:40555474	PSMG1	-0.69	-11.33	-0.47	2.03e-26	Menarche (age at onset);
LGG	cis	rs35740288	0.822	rs17574774	chr15:86233370	C/T	cg04173714	chr15:86211321	AKAP13	-0.46	-7.95	-0.35	1.41e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6504108	0.624	rs1452666	chr17:46307750	T/C	cg02219949	chr17:45927392	SP6	0.43	7.99	0.35	1.06e-14	Body mass index;
LGG	cis	rs7617773	0.780	rs13079728	chr3:48339360	A/G	cg11946769	chr3:48343235	NME6	0.71	12.03	0.49	3.52e-29	Coronary artery disease;
LGG	cis	rs6693295	0.536	rs12118406	chr1:246230312	G/A	cg11798871	chr1:246315928	SMYD3	-0.62	-8.34	-0.36	8.28e-16	Migraine - clinic-based;Migraine with aura;
LGG	cis	rs2652834	0.799	rs2729837	chr15:63430330	C/A	cg05507819	chr15:63340323	TPM1	0.49	7.01	0.31	8.48e-12	HDL cholesterol;
LGG	cis	rs11785400	0.928	rs750529	chr8:143744877	G/C	cg10596483	chr8:143751796	JRK	0.59	9.69	0.41	2.51e-20	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21824902	chr1:27560832	WDTC1	0.45	7.45	0.33	4.65e-13	Cognitive performance;
LGG	cis	rs67311347	1.000	rs6801185	chr3:40505060	C/T	cg13683864	chr3:40499215	RPL14	1.15	28.26	0.8	7.65e-103	Renal cell carcinoma;
LGG	cis	rs9814567	0.752	rs1880378	chr3:134330709	T/C	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7777484	0.500	rs757787	chr7:2836355	G/A	cg23009067	chr7:2775923	GNA12	0.26	7.25	0.32	1.79e-12	Height;
LGG	cis	rs7618915	0.571	rs6778844	chr3:52596398	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	-0.53	-8.7	-0.37	5.7e-17	Bipolar disorder;
LGG	cis	rs9814567	0.702	rs9871226	chr3:134331466	A/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.6	-10.56	-0.44	1.63e-23	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs11764590	0.585	rs11772463	chr7:2078132	A/C	cg23422044	chr7:1970798	MAD1L1	-0.61	-9.33	-0.4	4.37e-19	Neuroticism;
LGG	cis	rs10791323	0.569	rs2282602	chr11:133714522	G/A	cg15485101	chr11:133734466	NA	0.61	10.67	0.44	6.29e-24	Childhood ear infection;
LGG	cis	rs6993813	0.786	rs7017691	chr8:120023414	G/C	cg17171407	chr8:119960777	TNFRSF11B	0.27	6.77	0.3	3.95e-11	Bone mineral density (hip);
LGG	cis	rs9811920	0.965	rs6767441	chr3:99863183	T/C	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.46	8.04	0.35	7.41e-15	Axial length;
LGG	cis	rs1005277	0.579	rs2505240	chr10:38442419	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.43	-0.33	5.29e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs765787	0.530	rs2899381	chr15:45529630	C/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.37	-0.32	7.73e-13	Uric acid levels;
LGG	cis	rs798554	0.683	rs1182155	chr7:2902890	C/G	cg14668632	chr7:2872130	GNA12	-0.32	-6.66	-0.3	7.99e-11	Height;
LGG	trans	rs1814175	0.616	rs1722001	chr11:49894427	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.74	-16.4	-0.61	5.56e-48	Height;
LGG	cis	rs17253792	0.545	rs3742571	chr14:56016704	A/G	cg01858014	chr14:56050164	KTN1	-0.72	-8.76	-0.38	3.71e-17	Putamen volume;
LGG	cis	rs2304069	0.507	rs7728264	chr5:149394954	C/G	cg12661370	chr5:149340060	SLC26A2	0.49	8.3	0.36	1.13e-15	HIV-1 control;
LGG	cis	rs4243830	0.737	rs7552172	chr1:6612269	C/T	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.78	-12.06	-0.49	2.61e-29	Body mass index;
LGG	cis	rs7567389	0.812	rs6710496	chr2:127976374	A/C	cg10021288	chr2:128175891	PROC	-0.37	-6.7	-0.3	5.88e-11	Self-rated health;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg05279229	chr7:1896384	MAD1L1	-0.39	-6.88	-0.3	1.98e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs9910055	0.762	rs4239142	chr17:42205876	A/G	cg13607699	chr17:42295918	UBTF	-0.63	-10.98	-0.45	4.47e-25	Total body bone mineral density;
LGG	cis	rs11630290	0.592	rs1912049	chr15:64155606	G/T	cg12036633	chr15:63758958	NA	0.5	7.33	0.32	1.03e-12	Iris characteristics;
LGG	cis	rs1707322	0.686	rs2152078	chr1:46055600	C/T	cg03146154	chr1:46216737	IPP	-0.55	-10.1	-0.42	8.44e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.19	0.32	2.55e-12	Retinal vascular caliber;
LGG	cis	rs28595532	0.920	rs114796605	chr4:119744472	C/A	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	trans	rs11098499	0.818	rs55825515	chr4:120486402	A/G	cg25517755	chr10:38738941	LOC399744	-0.4	-6.71	-0.3	5.64e-11	Corneal astigmatism;
LGG	cis	rs7617773	0.780	rs11714944	chr3:48366971	C/A	cg11946769	chr3:48343235	NME6	0.71	11.92	0.48	9.17e-29	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs10782316	chr6:150073891	A/C	cg11878867	chr6:150167359	LRP11	-0.52	-10.9	-0.45	8.65e-25	Lung cancer;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.11	-0.57	3.04e-42	Prudent dietary pattern;
LGG	cis	rs1865760	0.865	rs2164485	chr6:25952106	G/A	cg03517284	chr6:25882590	NA	-0.39	-6.99	-0.31	9.66e-12	Height;
LGG	cis	rs11874712	1.000	rs9783888	chr18:43651370	G/T	cg26436583	chr18:43649176	PSTPIP2	-0.55	-11.99	-0.49	4.94e-29	Migraine - clinic-based;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.45	0.58	9.89e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1580019	0.713	rs2167274	chr7:32524844	A/G	cg06627557	chr7:32535165	LSM5;AVL9	0.99	21.24	0.7	2.16e-70	Cognitive ability;
LGG	cis	rs17604090	0.646	rs10258473	chr7:29690439	A/C	cg19413766	chr7:29689036	LOC646762	-0.61	-7.83	-0.34	3.45e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs1865760	1.000	rs6905887	chr6:25912103	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.77	-0.34	5.15e-14	Height;
LGG	cis	rs9290065	0.519	rs956447	chr3:160668917	G/C	cg03342759	chr3:160939853	NMD3	-0.6	-10.23	-0.43	2.78e-22	Kawasaki disease;
LGG	cis	rs300703	0.719	rs423314	chr2:195372	A/G	cg24565620	chr2:194026	NA	-0.7	-10.9	-0.45	8.59e-25	Blood protein levels;
LGG	cis	rs9322193	0.886	rs9485408	chr6:149940024	T/C	cg15971980	chr6:150254442	NA	0.43	8.14	0.35	3.61e-15	Lung cancer;
LGG	cis	rs933688	0.532	rs13164949	chr5:90538489	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.53	-6.89	-0.31	1.8e-11	Smoking behavior;
LGG	cis	rs12478296	0.892	rs60545379	chr2:243034390	A/T	cg06360820	chr2:242988706	NA	-0.9	-11.58	-0.47	2.16e-27	Obesity-related traits;
LGG	cis	rs62380364	0.558	rs34319	chr5:88023349	A/T	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.14e-23	Intelligence (multi-trait analysis);
LGG	cis	rs6831352	0.801	rs2602897	chr4:100046293	A/T	cg13256891	chr4:100009986	ADH5	0.56	9.79	0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs1978968	1.000	rs12158906	chr22:18437382	A/G	cg03078520	chr22:18463400	MICAL3	-0.6	-12.25	-0.49	4.28e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00689492	chr4:1303491	MAEA	0.5	8.67	0.37	7.16e-17	Obesity-related traits;
LGG	cis	rs71403859	0.502	rs75986475	chr16:71464058	C/G	cg08717414	chr16:71523259	ZNF19	-1.21	-13.72	-0.54	3.36e-36	Post bronchodilator FEV1;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11041264	chr20:33872554	EIF6	0.43	7.23	0.32	2.02e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs17125944	0.505	rs75838476	chr14:53242362	G/A	cg13660082	chr14:53194042	PSMC6	-0.54	-7.64	-0.33	1.25e-13	Alzheimer's disease (late onset);
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg23758822	chr17:41437982	NA	0.87	15.48	0.58	7.57e-44	Menopause (age at onset);
LGG	cis	rs2282802	0.635	rs199152	chr5:139539235	C/T	cg26211634	chr5:139558579	C5orf32	-0.32	-7.05	-0.31	6.5e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.77	-0.38	3.36e-17	Personality dimensions;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19447636	chr7:126894250	NA	0.46	6.82	0.3	2.9e-11	Gut microbiome composition (summer);
LGG	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.14	0.43	5.74e-22	Iron status biomarkers;
LGG	cis	rs61612642	0.523	rs59004693	chr6:42157392	G/A	cg01092361	chr6:42185687	MRPS10	0.9	12.03	0.49	3.45e-29	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Eosinophil counts;
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg12463550	chr7:65579703	CRCP	-0.51	-8.4	-0.36	5.64e-16	Aortic root size;
LGG	cis	rs832540	0.669	rs832539	chr5:56199386	A/C	cg08400814	chr5:56204995	C5orf35	-0.38	-6.68	-0.3	7.07e-11	Coronary artery disease;
LGG	cis	rs4808199	0.948	rs757001	chr19:19448808	G/A	cg03709012	chr19:19516395	GATAD2A	0.98	15.63	0.59	1.62e-44	Nonalcoholic fatty liver disease;
LGG	cis	rs7524258	0.900	rs7551574	chr1:7314363	G/T	cg07173049	chr1:7289937	CAMTA1	0.69	16.47	0.61	2.76e-48	Tourette's syndrome or obsessive-compulsive disorder;
LGG	cis	rs3771570	1.000	rs16843590	chr2:242298228	G/A	cg21155796	chr2:242212141	HDLBP	0.72	9.2	0.39	1.27e-18	Prostate cancer;
LGG	cis	rs2615252	1	rs2615252	chr15:57473075	T/C	cg08128148	chr15:57256372	TCF12	-0.3	-7.3	-0.32	1.3e-12	Urinary tract infection frequency;
LGG	cis	rs6502050	0.835	rs9900128	chr17:80087920	A/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs7264396	0.635	rs6058346	chr20:34481043	G/T	cg23207816	chr20:34252616	CPNE1;RBM12	0.48	7.05	0.31	6.73e-12	Total cholesterol levels;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg04011206	chr18:74204120	NA	0.4	6.78	0.3	3.75e-11	Parental extreme longevity (95 years and older);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25328417	chr13:50655384	DLEU1;DLEU2	0.4	6.82	0.3	2.89e-11	Bipolar disorder;
LGG	trans	rs12310956	0.527	rs1608910	chr12:33895414	T/C	cg13010199	chr12:38710504	ALG10B	0.48	9.13	0.39	2.08e-18	Morning vs. evening chronotype;
LGG	cis	rs910316	0.737	rs108621	chr14:75480637	T/C	cg08847533	chr14:75593920	NEK9	-0.54	-9.99	-0.42	2.05e-21	Height;
LGG	cis	rs593982	1.000	rs650619	chr11:65506483	G/A	cg08755490	chr11:65554678	OVOL1	0.76	11.99	0.49	4.82e-29	Atopic dermatitis;
LGG	cis	rs7666738	0.830	rs10012271	chr4:99065154	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	3.96e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.962	rs3763163	chr6:150140906	G/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.63	-0.41	3.86e-20	Lung cancer;
LGG	cis	rs9463078	0.809	rs57020561	chr6:44862734	T/C	cg25276700	chr6:44698697	NA	-0.37	-7.8	-0.34	4.02e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9513627	0.834	rs73556197	chr13:100128479	A/G	cg25919922	chr13:100150906	NA	-0.74	-7.6	-0.33	1.69e-13	Obesity-related traits;
LGG	cis	rs10895140	0.666	rs6590893	chr11:101508645	C/T	cg23650423	chr11:101454676	TRPC6	-0.44	-7.07	-0.31	5.7e-12	Menarche (age at onset);
LGG	cis	rs1620921	1.000	rs1614840	chr6:161197845	A/G	cg01280913	chr6:161186852	NA	-0.33	-6.87	-0.3	2.02e-11	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs9354308	0.868	rs9363456	chr6:66548343	G/A	cg07460842	chr6:66804631	NA	-0.48	-8.21	-0.36	2.18e-15	Metabolite levels;
LGG	cis	rs5769765	0.908	rs4824109	chr22:50271460	T/C	cg26441486	chr22:50317300	CRELD2	-0.41	-7.48	-0.33	3.7e-13	Schizophrenia;
LGG	cis	rs9399135	0.967	rs4896125	chr6:135342569	C/T	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	trans	rs17685	0.753	rs10251863	chr7:75790192	T/C	cg19862616	chr7:65841803	NCRNA00174	1.07	25.14	0.76	1.45e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs965513	1.000	rs7850258	chr9:100549013	C/T	cg13688889	chr9:100608707	NA	0.52	9.69	0.41	2.53e-20	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs4975709	0.569	rs931509	chr5:1858821	A/T	cg14773178	chr5:1868261	NA	0.36	7.85	0.34	2.95e-14	Cardiovascular disease risk factors;
LGG	cis	rs765787	0.530	rs11858988	chr15:45522114	T/C	cg24006582	chr15:45444508	DUOX1	-0.63	-11.41	-0.47	9.88e-27	Uric acid levels;
LGG	cis	rs834603	0.575	rs1612394	chr7:47467609	G/A	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2032447	0.670	rs198848	chr6:26106325	A/G	cg12310025	chr6:25882481	NA	-0.48	-8.94	-0.38	8.98e-18	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.870	rs4974578	chr4:1266072	A/G	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.4	-0.36	5.32e-16	Obesity-related traits;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10378054	chr19:690844	PRSSL1	0.37	6.87	0.3	2.04e-11	Menarche (age at onset);
LGG	cis	rs4332037	0.539	rs56016347	chr7:2060126	C/T	cg07027305	chr7:2059796	MAD1L1	-0.32	-6.87	-0.3	2.05e-11	Bipolar disorder;
LGG	trans	rs72991	0.793	rs891437	chr11:121224776	C/T	cg27192990	chr6:129479024	LAMA2	-0.44	-7.36	-0.32	8.58e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4671458	0.626	rs4671062	chr2:63724044	G/A	cg17519650	chr2:63277830	OTX1	-0.53	-7.13	-0.31	3.84e-12	Subjective well-being;
LGG	cis	rs7975161	0.506	rs7953434	chr12:104622101	T/G	cg25273343	chr12:104657179	TXNRD1	-0.74	-8.5	-0.37	2.66e-16	Toenail selenium levels;
LGG	cis	rs7267979	1.000	rs2258201	chr20:25272490	G/C	cg06421707	chr20:25228305	PYGB	0.48	10.4	0.44	6.54e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs3857536	0.740	rs7756519	chr6:66892275	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg26513180	chr16:89883248	FANCA	0.98	9.02	0.39	4.96e-18	Skin colour saturation;
LGG	cis	rs2762353	0.808	rs1185153	chr6:25834548	A/G	cg18357526	chr6:26021779	HIST1H4A	0.6	10.63	0.44	8.93e-24	Blood metabolite levels;
LGG	cis	rs7590720	0.788	rs4674050	chr2:216907322	G/T	cg12620499	chr2:216877984	MREG	0.79	15.38	0.58	2.08e-43	Alcohol dependence;
LGG	cis	rs9911578	0.765	rs66954617	chr17:56999427	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	trans	rs11039798	0.925	rs7482967	chr11:48613527	T/A	cg15704280	chr7:45808275	SEPT13	0.78	9.04	0.39	4.28e-18	Axial length;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23781003	chr4:120988207	MAD2L1	0.53	8.15	0.35	3.46e-15	Gut microbiome composition (summer);
LGG	cis	rs6500395	0.962	rs55782524	chr16:48557493	A/G	cg04672837	chr16:48644449	N4BP1	0.51	8.31	0.36	1.1e-15	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.58	10.1	0.42	8.35e-22	Prudent dietary pattern;
LGG	cis	rs7618915	0.547	rs34610142	chr3:52708429	G/A	cg10802521	chr3:52805072	NEK4	-0.43	-7.17	-0.32	2.9e-12	Bipolar disorder;
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.5	-8.96	-0.38	8.25e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1568889	1.000	rs35343234	chr11:28034379	C/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.78	14.41	0.56	3.61e-39	Bipolar disorder;
LGG	trans	rs6601327	0.635	rs7844461	chr8:9653055	T/A	cg16141378	chr3:129829833	LOC729375	-0.34	-7.69	-0.34	8.82e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.52	-0.53	2.35e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg00405596	chr8:11794950	NA	0.66	11.67	0.48	9.5e-28	Neuroticism;
LGG	cis	rs1153858	1.000	rs11852800	chr15:45639131	A/G	cg26924012	chr15:45694286	SPATA5L1	-1.06	-22.94	-0.73	2.38e-78	Homoarginine levels;
LGG	cis	rs1878931	0.517	rs17685105	chr16:3413749	C/T	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.91	-18.91	-0.66	1.6e-59	Body mass index (adult);
LGG	trans	rs9467711	0.606	rs9358936	chr6:26370657	A/G	cg01620082	chr3:125678407	NA	-0.64	-6.98	-0.31	1.02e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs61931739	0.500	rs11053261	chr12:34530810	C/T	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs9868809	0.505	rs13434258	chr3:48738491	T/C	cg00383909	chr3:49044727	WDR6	0.92	11.43	0.47	8.27e-27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs72945132	0.882	rs7929271	chr11:70165749	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs10267417	0.603	rs28819981	chr7:19933631	A/G	cg05791153	chr7:19748676	TWISTNB	0.52	6.84	0.3	2.58e-11	Night sleep phenotypes;
LGG	cis	rs11992162	0.529	rs6995037	chr8:11780887	A/G	cg12395012	chr8:11607386	GATA4	0.42	7.66	0.34	1.08e-13	Monocyte count;
LGG	cis	rs4481887	0.830	rs28581861	chr1:248506028	T/G	cg13385794	chr1:248469461	NA	0.46	7.81	0.34	3.89e-14	Common traits (Other);
LGG	cis	rs6061231	0.834	rs2427307	chr20:60966686	G/A	cg22601191	chr20:60968625	CABLES2	0.43	8.0	0.35	1.03e-14	Colorectal cancer;
LGG	cis	rs2439831	0.681	rs7175434	chr15:43628542	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.95	12.32	0.5	2.35e-30	Lung cancer in ever smokers;
LGG	cis	rs17376456	0.877	rs55832164	chr5:93436579	C/T	cg25358565	chr5:93447407	FAM172A	1.39	17.13	0.62	2.67e-51	Diabetic retinopathy;
LGG	trans	rs6787172	0.728	rs28820925	chr3:158111936	T/C	cg23275840	chr4:47708675	CORIN	-0.4	-8.51	-0.37	2.41e-16	Subjective well-being;
LGG	cis	rs10504229	0.593	rs79874994	chr8:57993709	C/A	cg02725872	chr8:58115012	NA	-0.93	-12.13	-0.49	1.31e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg12070911	chr6:150209640	RAET1E	0.29	7.07	0.31	5.82e-12	Lung cancer;
LGG	cis	rs2243480	1.000	rs160648	chr7:65543384	C/A	cg13147721	chr7:65941812	NA	-0.81	-9.7	-0.41	2.23e-20	Diabetic kidney disease;
LGG	cis	rs7635838	0.617	rs346084	chr3:11281159	C/T	cg00170343	chr3:11313890	ATG7	0.55	9.62	0.41	4.14e-20	HDL cholesterol;
LGG	cis	rs10170846	0.861	rs7571732	chr2:223538316	A/C	cg25565276	chr2:223520875	FARSB	-0.61	-10.82	-0.45	1.73e-24	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs9788682	0.706	rs924840	chr15:78731808	A/T	cg06917634	chr15:78832804	PSMA4	-0.53	-8.12	-0.35	4.23e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs17767392	0.958	rs3784066	chr14:72007454	A/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.28	-0.4	6.48e-19	Mitral valve prolapse;
LGG	cis	rs72827839	0.793	rs72823513	chr17:46048920	A/G	cg02219949	chr17:45927392	SP6	0.5	7.65	0.33	1.19e-13	Ease of getting up in the morning;
LGG	cis	rs1707322	0.752	rs4586014	chr1:46150443	A/G	cg03146154	chr1:46216737	IPP	0.55	10.34	0.43	1.11e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10256972	0.630	rs13235747	chr7:1129123	T/C	cg07092213	chr7:1199455	ZFAND2A	-0.57	-9.39	-0.4	2.64e-19	Longevity;Endometriosis;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg09264619	chr17:80180166	NA	-0.38	-7.72	-0.34	7.44e-14	Life satisfaction;
LGG	cis	rs10504229	0.610	rs7011877	chr8:58147181	C/T	cg11062466	chr8:58055876	NA	0.48	8.08	0.35	5.82e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.626	rs11868521	chr17:80100195	T/G	cg19223190	chr17:80058835	NA	-0.47	-9.08	-0.39	3.22e-18	Life satisfaction;
LGG	trans	rs11039798	0.764	rs12277213	chr11:48782176	G/A	cg03929089	chr4:120376271	NA	0.74	8.52	0.37	2.23e-16	Axial length;
LGG	cis	rs2304069	0.779	rs245050	chr5:149346960	C/G	cg12661370	chr5:149340060	SLC26A2	-0.55	-8.26	-0.36	1.53e-15	HIV-1 control;
LGG	cis	rs4631830	0.828	rs10763567	chr10:51538169	C/A	cg10326726	chr10:51549505	MSMB	0.67	13.86	0.54	9.12e-37	Prostate-specific antigen levels;
LGG	cis	rs1670533	0.932	rs935968	chr4:1063187	G/T	cg27284194	chr4:1044797	NA	0.55	9.98	0.42	2.27e-21	Recombination rate (females);
LGG	cis	rs3806843	0.898	rs3756335	chr5:140213510	A/T	cg19875535	chr5:140030758	IK	0.5	10.1	0.42	8.57e-22	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6977660	0.714	rs12666488	chr7:19788403	G/A	cg05791153	chr7:19748676	TWISTNB	0.76	10.17	0.43	4.5e-22	Thyroid stimulating hormone;
LGG	cis	rs11155671	0.530	rs9397398	chr6:150193603	G/A	cg07791516	chr6:150247246	NA	0.31	6.73	0.3	5.03e-11	Testicular germ cell tumor;
LGG	cis	rs769267	0.965	rs13964	chr19:19468710	C/G	cg03709012	chr19:19516395	GATAD2A	-0.83	-16.11	-0.6	1.09e-46	Tonsillectomy;
LGG	trans	rs5760092	0.755	rs4585126	chr22:24270005	T/C	cg06437703	chr8:37914619	EIF4EBP1	0.72	10.84	0.45	1.43e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	trans	rs7746199	0.736	rs13193542	chr6:27702425	G/T	cg01620082	chr3:125678407	NA	-1.05	-10.12	-0.43	7.08e-22	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs6665290	0.904	rs6684821	chr1:227190233	G/A	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs1408799	0.704	rs7039325	chr9:12758156	C/T	cg05274944	chr9:12693694	TYRP1	0.34	8.11	0.35	4.43e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs9783347	0.643	rs4150581	chr11:18357270	C/T	cg03595886	chr11:18357587	GTF2H1	0.5	12.46	0.5	6.37e-31	Pancreatic cancer;
LGG	cis	rs4862750	0.957	rs1030381	chr4:187903568	G/C	cg06074448	chr4:187884817	NA	-0.6	-13.71	-0.54	3.81e-36	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs208520	0.690	rs2208442	chr6:66867004	T/C	cg07460842	chr6:66804631	NA	-0.97	-18.01	-0.64	2.48e-55	Exhaled nitric oxide output;
LGG	cis	rs2760061	0.626	rs635563	chr1:228136834	C/T	cg02753203	chr1:228287806	NA	-0.67	-12.56	-0.5	2.39e-31	Diastolic blood pressure;
LGG	cis	rs4862750	0.830	rs13152425	chr4:187894726	A/T	cg06074448	chr4:187884817	NA	-0.58	-12.81	-0.51	2.19e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11758351	1.000	rs11758351	chr6:26203910	T/G	cg06951627	chr6:26196580	NA	0.52	7.86	0.34	2.74e-14	Gout;Renal underexcretion gout;
LGG	cis	rs644799	1.000	rs474252	chr11:95619292	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.91	19.8	0.68	1.22e-63	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1008375	0.800	rs10008598	chr4:17607323	T/C	cg07005078	chr4:17578674	LAP3	0.38	6.88	0.3	2e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12922317	1.000	rs16958792	chr16:12075684	C/A	cg08843971	chr16:11963173	GSPT1	-0.32	-6.67	-0.3	7.51e-11	Schizophrenia;
LGG	cis	rs875971	0.830	rs809025	chr7:65849819	C/G	cg12463550	chr7:65579703	CRCP	0.51	8.47	0.37	3.33e-16	Aortic root size;
LGG	cis	rs4696584	0.816	rs1490666	chr4:155403285	G/T	cg13738195	chr4:155413469	DCHS2	0.35	7.1	0.31	4.67e-12	Folding of antihelix;
LGG	cis	rs7084402	0.967	rs1649037	chr10:60331135	C/T	cg07615347	chr10:60278583	BICC1	0.63	17.85	0.64	1.31e-54	Refractive error;
LGG	cis	rs4936894	0.500	rs11219535	chr11:124119565	G/A	cg27160556	chr11:124181099	OR8D1	-0.44	-10.27	-0.43	1.91e-22	Aging (time to death);
LGG	cis	rs9291683	0.588	rs12506364	chr4:10023448	C/T	cg16147221	chr4:10020634	SLC2A9	0.37	6.94	0.31	1.29e-11	Bone mineral density;
LGG	cis	rs79911532	0.515	rs79859948	chr7:75679099	A/G	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.47e-14	Mononucleosis;
LGG	cis	rs2439831	1.000	rs2253708	chr15:43797273	G/C	cg15269541	chr15:43626905	ADAL	-0.43	-7.33	-0.32	1.03e-12	Lung cancer in ever smokers;
LGG	cis	rs28595532	0.688	rs116566508	chr4:119619195	G/A	cg21605333	chr4:119757512	SEC24D	1.37	12.95	0.52	5.78e-33	Cannabis dependence symptom count;
LGG	cis	rs9926296	0.744	rs154657	chr16:89708096	A/G	cg03605463	chr16:89740564	NA	-0.59	-10.74	-0.45	3.63e-24	Vitiligo;
LGG	cis	rs763121	0.853	rs2076028	chr22:39150450	G/A	cg06022373	chr22:39101656	GTPBP1	0.84	15.5	0.58	5.68e-44	Menopause (age at onset);
LGG	cis	rs2016266	0.826	rs61928079	chr12:53741468	T/C	cg04065151	chr12:53682969	ESPL1	0.58	9.05	0.39	4.03e-18	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs782590	0.607	rs2061032	chr2:55679490	T/C	cg18811423	chr2:55921094	PNPT1	0.68	12.86	0.51	1.44e-32	Metabolic syndrome;
LGG	trans	rs208520	0.739	rs1935894	chr6:66891434	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-16.98	-0.62	1.31e-50	Exhaled nitric oxide output;
LGG	cis	rs55788414	0.932	rs12102728	chr16:81181436	C/T	cg06400318	chr16:81190750	PKD1L2	-0.75	-9.68	-0.41	2.55e-20	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg07701084	chr6:150067640	NUP43	0.65	12.31	0.5	2.51e-30	Lung cancer;
LGG	cis	rs1577917	0.883	rs6454505	chr6:86592362	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.57	-9.9	-0.42	4.44e-21	Response to antipsychotic treatment;
LGG	cis	rs4690686	0.836	rs10015351	chr4:177258952	A/G	cg17059388	chr4:177262070	NA	0.73	15.66	0.59	1.16e-44	Essential tremor;
LGG	cis	rs4819052	0.851	rs8133045	chr21:46658137	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.06	0.39	3.76e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.92	-0.42	3.79e-21	Lung cancer;
LGG	cis	rs35110281	0.517	rs11089020	chr21:44939991	C/T	cg01579765	chr21:45077557	HSF2BP	-0.34	-7.68	-0.34	9.4e-14	Mean corpuscular volume;
LGG	trans	rs853679	0.546	rs2232426	chr6:28360659	G/C	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	cis	rs9487094	0.670	rs1998811	chr6:109812138	A/G	cg16315928	chr6:109776240	MICAL1	0.44	7.66	0.34	1.11e-13	Height;
LGG	cis	rs9900972	0.721	rs11656224	chr17:76867996	A/G	cg00961940	chr17:76876995	TIMP2	0.46	8.45	0.37	3.73e-16	Obesity-related traits;
LGG	cis	rs7582180	0.903	rs13033057	chr2:100896415	C/T	cg14675211	chr2:100938903	LONRF2	0.48	7.38	0.32	7.21e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4892230	1	rs4892230	chr18:72155572	G/A	cg27029518	chr18:72166324	CNDP2	-0.29	-6.82	-0.3	2.87e-11	Mononucleosis;
LGG	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg26597838	chr10:835615	NA	0.75	10.43	0.44	5.03e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs7666738	0.830	rs10440379	chr4:98902822	G/T	cg05340658	chr4:99064831	C4orf37	0.47	7.76	0.34	5.32e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2204008	0.583	rs12307593	chr12:38317803	A/G	cg04568710	chr12:38710424	ALG10B	0.41	8.87	0.38	1.62e-17	Bladder cancer;
LGG	cis	rs2153535	0.580	rs1119688	chr6:8460850	T/C	cg23788917	chr6:8435910	SLC35B3	0.53	9.03	0.39	4.5e-18	Motion sickness;
LGG	cis	rs1167827	0.710	rs1167836	chr7:75168900	T/A	cg16384552	chr7:74938386	SPDYE8P	-0.53	-9.13	-0.39	2.12e-18	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1814175	0.645	rs1851844	chr11:50021773	T/C	cg03929089	chr4:120376271	NA	-0.94	-19.83	-0.68	8.29e-64	Height;
LGG	cis	rs9604529	1.000	rs9604529	chr13:114622597	A/G	cg13259177	chr13:114761607	RASA3	-0.47	-6.94	-0.31	1.33e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg07636037	chr3:49044803	WDR6	0.55	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs8032158	0.574	rs56093337	chr15:56133199	A/T	cg02198044	chr15:56286336	NEDD4	-0.43	-7.0	-0.31	8.99e-12	Keloid;
LGG	cis	rs11722228	0.508	rs3796826	chr4:10092728	G/A	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.22	-0.43	2.91e-22	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs10464366	0.912	rs6979668	chr7:39104228	G/A	cg15212455	chr7:39170539	POU6F2	0.4	8.55	0.37	1.87e-16	IgG glycosylation;
LGG	cis	rs477692	0.569	rs1762418	chr10:131303353	G/A	cg05714579	chr10:131428358	MGMT	0.51	10.08	0.42	9.9700000000000009e-22	Response to temozolomide;
LGG	cis	rs7582180	0.629	rs13031906	chr2:100939524	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-10.7	-0.45	5.18e-24	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.963	rs61930968	chr11:48581649	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.19	-0.36	2.62e-15	HDL cholesterol;
LGG	cis	rs17711722	0.701	rs55773927	chr7:65337902	T/C	cg18876405	chr7:65276391	NA	0.68	13.02	0.52	3.13e-33	Calcium levels;
LGG	cis	rs9303280	0.806	rs11870965	chr17:38030205	T/A	cg17467752	chr17:38218738	THRA	-0.43	-6.96	-0.31	1.18e-11	Self-reported allergy;
LGG	cis	rs10504073	0.605	rs62507176	chr8:49930321	G/A	cg00325661	chr8:49890786	NA	0.82	16.47	0.61	2.54e-48	Blood metabolite ratios;
LGG	cis	rs9326248	0.954	rs521171	chr11:117064693	C/G	cg11861562	chr11:117069780	TAGLN	0.26	6.95	0.31	1.27e-11	Blood protein levels;
LGG	cis	rs67311347	1.000	rs2276868	chr3:40498845	C/T	cg24209194	chr3:40518798	ZNF619	-0.42	-6.87	-0.3	2.05e-11	Renal cell carcinoma;
LGG	cis	rs10504229	0.724	rs72650827	chr8:58126884	A/T	cg14926445	chr8:58193284	C8orf71	-0.84	-10.9	-0.45	8.98e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1878931	0.580	rs7194596	chr16:3404408	T/A	cg26668626	chr16:3451006	ZNF174;ZNF434	0.9	17.73	0.64	4.48e-54	Body mass index (adult);
LGG	cis	rs3924048	0.574	rs11121925	chr1:12613130	A/C	cg00291366	chr1:12616550	NA	0.37	8.99	0.39	6.31e-18	Optic cup area;
LGG	cis	rs951366	0.844	rs823096	chr1:205679887	G/T	cg26354017	chr1:205819088	PM20D1	0.84	20.08	0.68	5.72e-65	Menarche (age at onset);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg26260386	chr4:140477698	SETD7	0.46	6.88	0.3	1.91e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs9611519	0.929	rs9611466	chr22:41426299	A/T	cg03806693	chr22:41940476	POLR3H	-0.53	-8.0	-0.35	9.92e-15	Neuroticism;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg13129888	chr1:28415099	EYA3	0.39	6.69	0.3	6.31e-11	Bilirubin levels;
LGG	cis	rs17270561	0.609	rs4711095	chr6:25726774	A/C	cg03264133	chr6:25882463	NA	-0.48	-7.8	-0.34	4.16e-14	Iron status biomarkers;
LGG	cis	rs798554	0.757	rs2644312	chr7:2841164	G/A	cg05793240	chr7:2802953	GNA12	0.34	7.92	0.35	1.75e-14	Height;
LGG	cis	rs4356932	0.967	rs4547819	chr4:76977768	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.22e-11	Blood protein levels;
LGG	cis	rs2028299	0.959	rs2165069	chr15:90407119	C/T	cg23731826	chr15:90371692	NA	0.37	8.72	0.38	5.03e-17	Type 2 diabetes;
LGG	cis	rs1322639	0.574	rs9364360	chr6:169580174	G/A	cg03254818	chr6:169586852	NA	0.64	9.41	0.4	2.41e-19	Pulse pressure;
LGG	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.66	-13.51	-0.53	2.61e-35	Presence of antiphospholipid antibodies;
LGG	cis	rs9467773	0.620	rs2451741	chr6:26629404	A/G	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs6582630	0.576	rs3900594	chr12:38272429	C/T	cg04568710	chr12:38710424	ALG10B	-0.41	-8.88	-0.38	1.44e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7727544	0.735	rs270605	chr5:131651811	C/T	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.64	-0.37	9.15e-17	Blood metabolite levels;
LGG	cis	rs12476592	0.543	rs262480	chr2:63873032	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.88	-0.3	1.89e-11	Childhood ear infection;
LGG	cis	rs9875589	0.509	rs1601870	chr3:14024162	T/C	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.53	10.99	0.45	4.04e-25	Ovarian reserve;
LGG	cis	rs4555082	0.645	rs2816605	chr14:105715515	C/T	cg10792982	chr14:105748885	BRF1	0.67	13.51	0.53	2.61e-35	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7618501	0.699	rs9821675	chr3:49902544	A/G	cg21582582	chr3:182698605	DCUN1D1	0.39	6.82	0.3	2.79e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1978968	1.000	rs1110660	chr22:18444693	A/C	cg00227156	chr22:18463646	MICAL3;MIR648	-0.61	-12.33	-0.5	2.16e-30	Presence of antiphospholipid antibodies;
LGG	cis	rs2762353	0.505	rs2096386	chr6:25787817	C/T	cg12310025	chr6:25882481	NA	0.44	8.29	0.36	1.25e-15	Blood metabolite levels;
LGG	cis	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.87	-0.34	2.55e-14	Triglycerides;
LGG	cis	rs367615	0.537	rs1965670	chr5:108649798	A/T	cg17395555	chr5:108820864	NA	-0.75	-12.37	-0.5	1.48e-30	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs4148883	0.615	rs2187483	chr4:100134103	G/T	cg12011299	chr4:100065546	ADH4	-0.34	-7.02	-0.31	8.15e-12	Alcohol dependence;
LGG	cis	rs7927592	0.913	rs7925275	chr11:68290433	T/C	cg20283391	chr11:68216788	NA	-0.51	-8.2	-0.36	2.47e-15	Total body bone mineral density;
LGG	cis	rs1125355	0.622	rs11678112	chr2:159613337	G/A	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1978968	0.763	rs9605473	chr22:18463266	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	0.64	13.69	0.54	4.81e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs2032447	0.507	rs199748	chr6:25909045	C/G	cg12310025	chr6:25882481	NA	-0.89	-17.58	-0.63	2.31e-53	Intelligence (multi-trait analysis);
LGG	cis	rs6427508	1	rs6427508	chr1:160238857	T/C	cg02974968	chr1:160236444	NA	-0.7	-14.03	-0.55	1.61e-37	Breast size;
LGG	cis	rs6867032	0.834	rs4526149	chr5:1990166	G/A	cg26168224	chr5:2018326	NA	-1.08	-18.99	-0.66	7.19e-60	Gut microbiome composition (winter);
LGG	cis	rs2576037	0.526	rs1893427	chr18:44434987	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.35	-6.73	-0.3	4.88e-11	Personality dimensions;
LGG	cis	rs9611565	0.649	rs139559	chr22:42191636	A/G	cg06634786	chr22:41940651	POLR3H	-0.67	-10.86	-0.45	1.2e-24	Vitiligo;
LGG	cis	rs6951245	0.572	rs112072378	chr7:1039400	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.0	-12.65	-0.51	1.04e-31	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4481887	0.732	rs6703399	chr1:248416343	T/C	cg00666640	chr1:248458726	OR2T12	0.59	9.49	0.4	1.2e-19	Common traits (Other);
LGG	cis	rs1881509	0.702	rs7102832	chr11:1435143	T/C	cg07067744	chr11:1421172	BRSK2	0.35	6.81	0.3	2.95e-11	Heroin dependence;
LGG	cis	rs7937682	0.632	rs1045282	chr11:111754574	A/C	cg09085632	chr11:111637200	PPP2R1B	0.98	19.09	0.66	2.41e-60	Primary sclerosing cholangitis;
LGG	cis	rs17286411	0.750	rs4788561	chr16:71878255	G/A	cg03805757	chr16:71968109	PKD1L3	0.33	6.92	0.31	1.5e-11	Blood protein levels;
LGG	trans	rs9329221	0.597	rs17751178	chr8:10116730	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	9.6	0.41	5.25e-20	Neuroticism;
LGG	cis	rs10504130	0.569	rs35603537	chr8:52686459	T/C	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg09699651	chr6:150184138	LRP11	-0.5	-8.73	-0.38	4.52e-17	Lung cancer;
LGG	trans	rs853679	0.607	rs68188794	chr6:28080777	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.92	-0.38	1.07e-17	Depression;
LGG	trans	rs7395662	1.000	rs8189391	chr11:48859789	A/G	cg03929089	chr4:120376271	NA	0.49	7.93	0.35	1.7e-14	HDL cholesterol;
LGG	cis	rs10504229	0.683	rs17194487	chr8:58104912	C/T	cg08219700	chr8:58056026	NA	0.45	6.84	0.3	2.47e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6598955	0.671	rs10902727	chr1:26597781	C/T	cg04990556	chr1:26633338	UBXN11	0.61	8.28	0.36	1.3e-15	Obesity-related traits;
LGG	cis	rs4631830	0.900	rs7075009	chr10:51544143	T/G	cg10326726	chr10:51549505	MSMB	-0.65	-13.19	-0.52	5.79e-34	Prostate-specific antigen levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg02835038	chr21:47743854	PCNT;C21orf58	0.4	6.8	0.3	3.22e-11	Body mass index;
LGG	cis	rs35570576	0.585	rs35796193	chr17:77537418	A/G	cg08506369	chr17:77610316	NA	0.45	6.68	0.3	7.07e-11	Photic sneeze reflex;
LGG	cis	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.86	-15.43	-0.58	1.22e-43	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs867371	1.000	rs13380317	chr15:82506790	A/G	cg00614314	chr15:82944287	LOC80154	-0.58	-9.42	-0.4	2.16e-19	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs7824557	0.564	rs2736294	chr8:11234626	T/C	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs9359856	0.564	rs72915946	chr6:90447924	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.78	-9.86	-0.42	5.97e-21	Bipolar disorder;
LGG	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06481639	chr22:41940642	POLR3H	0.56	7.95	0.35	1.44e-14	Vitiligo;
LGG	cis	rs2070677	0.668	rs7899159	chr10:135431451	C/T	cg20169779	chr10:135381914	SYCE1	-0.81	-9.83	-0.42	7.78e-21	Gout;
LGG	cis	rs1799949	0.965	rs799908	chr17:41278916	A/G	cg24607181	chr17:41446203	NA	-0.3	-7.0	-0.31	9.07e-12	Menopause (age at onset);
LGG	cis	rs6462411	1.000	rs6971953	chr7:3912558	G/C	cg18022346	chr7:3920534	SDK1	-0.36	-6.93	-0.31	1.46e-11	Quantitative traits;
LGG	cis	rs877282	0.945	rs12782447	chr10:771870	C/T	cg17470449	chr10:769945	NA	0.59	7.42	0.33	5.59e-13	Uric acid levels;
LGG	cis	rs1552244	0.882	rs13062917	chr3:10017032	T/A	cg00149659	chr3:10157352	C3orf10	0.74	9.28	0.4	6.49e-19	Alzheimer's disease;
LGG	cis	rs634534	0.622	rs593525	chr11:65727799	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.55	0.33	2.36e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6866344	0.697	rs58549512	chr5:178133204	C/T	cg03877680	chr5:178157825	ZNF354A	0.77	12.3	0.5	2.81e-30	Neutrophil percentage of white cells;
LGG	cis	rs35425515	0.706	rs4917756	chr10:98875408	G/A	cg09122387	chr10:98855762	SLIT1	0.72	8.99	0.39	6.44e-18	Bipolar disorder;
LGG	cis	rs6500602	0.627	rs860891	chr16:4586529	C/T	cg08645402	chr16:4508243	NA	-0.53	-9.43	-0.4	2.04e-19	Schizophrenia;
LGG	cis	rs367615	0.918	rs17161889	chr5:108855251	A/G	cg17395555	chr5:108820864	NA	-0.64	-8.95	-0.38	8.91e-18	Colorectal cancer (SNP x SNP interaction);
LGG	trans	rs6787172	0.633	rs7626909	chr3:157888902	C/G	cg23275840	chr4:47708675	CORIN	0.41	8.8	0.38	2.81e-17	Subjective well-being;
LGG	cis	rs9309473	0.847	rs4547554	chr2:73867862	G/C	cg20560298	chr2:73613845	ALMS1	-0.45	-7.21	-0.32	2.23e-12	Metabolite levels;
LGG	cis	rs7546668	1.000	rs4646093	chr1:15821400	G/T	cg21858823	chr1:15850916	CASP9	0.37	6.91	0.31	1.58e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs881375	0.900	rs1008383	chr9:123683579	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.01	0.49	4.24e-29	Rheumatoid arthritis;
LGG	cis	rs9393692	0.557	rs9366648	chr6:26306282	T/C	cg13736514	chr6:26305472	NA	-0.48	-9.42	-0.4	2.18e-19	Educational attainment;
LGG	cis	rs899997	1.000	rs11633170	chr15:79004642	A/G	cg14912033	chr15:79043428	NA	0.35	7.98	0.35	1.2e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs12148488	0.763	rs2304902	chr15:75340727	G/T	cg14664628	chr15:75095509	CSK	-0.47	-8.44	-0.37	4.09e-16	Caffeine consumption;
LGG	cis	rs875971	0.545	rs4441996	chr7:65588220	T/C	cg11764359	chr7:65958608	NA	-0.64	-9.82	-0.42	8.38e-21	Aortic root size;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.596	rs7004566	chr8:58115602	G/C	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs62103177	0.608	rs59300126	chr18:77694439	C/A	cg05926928	chr17:57297772	GDPD1	1.27	18.78	0.66	6.52e-59	Opioid sensitivity;
LGG	cis	rs5769765	1.000	rs8184990	chr22:50273174	A/G	cg26441486	chr22:50317300	CRELD2	-0.4	-7.41	-0.33	6.07e-13	Schizophrenia;
LGG	cis	rs12497850	0.931	rs11924597	chr3:48937790	T/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.9	0.45	8.66e-25	Parkinson's disease;
LGG	cis	rs1941023	0.584	rs10750937	chr11:60172087	C/T	cg08716584	chr11:60157161	MS4A7	-0.43	-8.58	-0.37	1.46e-16	Congenital heart disease (maternal effect);
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	-0.45	-7.47	-0.33	4.06e-13	Tonsillectomy;
LGG	cis	rs1008375	1.000	rs7673500	chr4:17621383	C/T	cg02297831	chr4:17616191	MED28	0.5	9.5	0.4	1.18e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2019137	0.936	rs3828188	chr2:113954247	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.34	-0.5	1.88e-30	Lymphocyte counts;
LGG	cis	rs882632	0.668	rs34253433	chr2:29294629	C/T	cg23429306	chr2:29287725	C2orf71	0.37	7.52	0.33	2.91e-13	Major depressive disorder;
LGG	cis	rs116095464	0.558	rs7715108	chr5:264661	A/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	trans	rs2204008	0.563	rs2320512	chr12:38266913	G/A	cg06521331	chr12:34319734	NA	0.44	7.76	0.34	5.59e-14	Bladder cancer;
LGG	cis	rs2153535	0.541	rs6923558	chr6:8461467	T/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.62	0.51	1.43e-31	Motion sickness;
LGG	cis	rs4975709	0.569	rs4975743	chr5:1859941	G/T	cg01114163	chr5:1856713	NA	-0.41	-7.15	-0.32	3.31e-12	Cardiovascular disease risk factors;
LGG	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg15017067	chr4:17643749	FAM184B	0.3	7.01	0.31	8.7e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6424115	1.000	rs58035855	chr1:24165248	G/C	cg24699146	chr1:24152579	HMGCL	-0.26	-7.75	-0.34	5.87e-14	Immature fraction of reticulocytes;
LGG	cis	rs7255045	0.582	rs4804209	chr19:12985955	G/C	cg07955356	chr19:12992479	DNASE2	0.44	6.83	0.3	2.64e-11	Mean corpuscular volume;
LGG	cis	rs2287838	0.740	rs12974239	chr19:10004340	C/T	cg07950397	chr19:10022659	OLFM2	0.3	7.01	0.31	8.33e-12	Sleep duration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06620269	chr17:2952258	NA	0.43	6.73	0.3	4.9e-11	Gut microbiome composition (summer);
LGG	cis	rs9815354	0.903	rs9822598	chr3:41954587	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.72e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs7937682	0.889	rs3017767	chr11:111508098	A/G	cg18187862	chr3:45730750	SACM1L	0.64	10.65	0.44	7.83e-24	Primary sclerosing cholangitis;
LGG	cis	rs12410462	0.591	rs66491073	chr1:227782721	A/C	cg23173402	chr1:227635558	NA	0.38	7.19	0.32	2.58e-12	Major depressive disorder;
LGG	cis	rs7959663	1	rs7959663	chr12:109884367	G/C	cg05360138	chr12:110035743	NA	0.59	8.36	0.36	7.47e-16	Bipolar disorder lithium response (categorical) or schizophrenia;
LGG	cis	rs8017423	0.647	rs4900037	chr14:90821478	A/G	cg04374321	chr14:90722782	PSMC1	0.64	12.82	0.51	2.07e-32	Mortality in heart failure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08619797	chr16:57219959	RSPRY1;FAM192A	0.49	7.29	0.32	1.36e-12	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs3935128	chr17:80113414	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs8073060	0.586	rs226084	chr17:34019582	T/A	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs9487051	0.676	rs9400268	chr6:109600550	C/T	cg21918786	chr6:109611834	NA	-0.43	-7.96	-0.35	1.33e-14	Reticulocyte fraction of red cells;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg18963800	chr10:38644991	HSD17B7P2	-0.47	-7.56	-0.33	2.12e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4919044	0.641	rs56112656	chr10:94678966	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.22	-0.32	2.2e-12	Coronary artery disease;
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg26152485	chr19:19281474	LOC729991-MEF2B;MEF2B	-0.31	-8.15	-0.35	3.39e-15	IgG glycosylation;
LGG	cis	rs6817170	0.577	rs11099885	chr4:154385570	T/C	cg24020152	chr4:154419554	KIAA0922	0.32	6.93	0.31	1.46e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs7681440	0.935	rs3756059	chr4:90757272	G/A	cg18258770	chr4:90757814	SNCA	-0.42	-7.61	-0.33	1.5e-13	Dementia with Lewy bodies;
LGG	cis	rs1552244	1.000	rs6764168	chr3:10123805	A/G	cg13047869	chr3:10149882	C3orf24	0.55	9.11	0.39	2.56e-18	Alzheimer's disease;
LGG	cis	rs62244186	0.715	rs11130032	chr3:44704083	G/A	cg02073558	chr3:44770973	ZNF501	0.71	13.74	0.54	2.71e-36	Depressive symptoms;
LGG	cis	rs17376456	0.877	rs9314099	chr5:93447375	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.87	9.43	0.4	2.05e-19	Diabetic retinopathy;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-15.94	-0.6	6.75e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.596	rs10274513	chr7:124650537	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg24829409	chr8:58192753	C8orf71	-0.68	-9.34	-0.4	3.97e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs713587	0.691	rs754536	chr2:25176200	C/T	cg04586622	chr2:25135609	ADCY3	-0.37	-9.45	-0.4	1.66e-19	Body mass index in non-asthmatics;
LGG	cis	rs9910055	0.659	rs2246287	chr17:42232442	C/G	cg10896456	chr17:42255109	ASB16;C17orf65	0.59	10.88	0.45	1.04e-24	Total body bone mineral density;
LGG	cis	rs738322	1.000	rs4379	chr22:38569171	T/C	cg17652424	chr22:38574118	PLA2G6	-0.26	-6.84	-0.3	2.47e-11	Cutaneous nevi;
LGG	cis	rs6938	0.618	rs11857695	chr15:75165751	G/T	cg14664628	chr15:75095509	CSK	-0.56	-10.79	-0.45	2.25e-24	Breast cancer;
LGG	cis	rs67311347	0.876	rs13068097	chr3:40504424	T/A	cg13683864	chr3:40499215	RPL14	1.15	27.55	0.79	1.21e-99	Renal cell carcinoma;
LGG	cis	rs11971779	0.584	rs6962029	chr7:139034719	T/C	cg07862535	chr7:139043722	LUC7L2	0.41	6.84	0.3	2.49e-11	Diisocyanate-induced asthma;
LGG	cis	rs2808510	0.521	rs12131135	chr1:200418613	G/T	cg10889502	chr1:200398670	NA	-0.32	-7.38	-0.32	7.38e-13	Myopia;
LGG	cis	rs209489	0.892	rs60729238	chr6:53113448	G/A	cg15607103	chr6:53167650	ELOVL5	0.57	7.04	0.31	6.98e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs614226	1.000	rs614226	chr12:120974510	C/T	cg27489772	chr12:121021490	NA	-0.6	-7.84	-0.34	3.13e-14	Type 1 diabetes nephropathy;
LGG	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg13271783	chr10:134563150	INPP5A	-0.54	-7.87	-0.34	2.56e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1790761	0.803	rs2302264	chr11:67207426	G/A	cg14500267	chr11:67383377	NA	-0.38	-6.93	-0.31	1.45e-11	Mean corpuscular volume;
LGG	cis	rs7107174	1.000	rs2511155	chr11:77969223	G/A	cg27205649	chr11:78285834	NARS2	-0.45	-7.33	-0.32	1.01e-12	Testicular germ cell tumor;
LGG	cis	rs651907	0.557	rs7629753	chr3:101371922	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-8.33	-0.36	9.33e-16	Colorectal cancer;
LGG	cis	rs3770081	0.826	rs1019591	chr2:86298599	C/T	cg01119172	chr2:86362222	SNORD94;PTCD3	0.69	7.17	0.32	2.9e-12	Facial emotion recognition (sad faces);
LGG	cis	rs1949733	0.701	rs4696828	chr4:8455604	G/A	cg13073564	chr4:8508604	NA	0.53	10.89	0.45	9.67e-25	Response to antineoplastic agents;
LGG	cis	rs1552244	1.000	rs55882090	chr3:10139082	C/T	cg08888203	chr3:10149979	C3orf24	0.53	9.03	0.39	4.71e-18	Alzheimer's disease;
LGG	cis	rs2964802	0.505	rs2083232	chr5:10812811	G/A	cg14521931	chr5:10832172	NA	-0.75	-16.78	-0.62	1.01e-49	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs4268898	1.000	rs2303294	chr2:24432620	A/G	cg06627628	chr2:24431161	ITSN2	0.53	8.94	0.38	9e-18	Asthma;
LGG	cis	rs7614311	0.555	rs3774715	chr3:63919876	T/C	cg22134162	chr3:63841271	THOC7	-0.44	-7.72	-0.34	7.42e-14	Lung function (FVC);Lung function (FEV1);
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg08098457	chr2:63815963	MDH1;C2orf86	-0.4	-6.72	-0.3	5.44e-11	Leprosy;
LGG	cis	rs11148252	0.811	rs9536030	chr13:52938291	G/A	cg02158880	chr13:53174818	NA	-0.4	-7.77	-0.34	4.93e-14	Lewy body disease;
LGG	cis	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg21775007	chr8:11205619	TDH	-0.44	-6.94	-0.31	1.32e-11	Morning vs. evening chronotype;
LGG	cis	rs77633900	0.614	rs2454453	chr15:76913976	T/A	cg21673338	chr15:77095150	SCAPER	-0.65	-10.17	-0.43	4.62e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg07511668	chr11:68622177	NA	0.35	7.11	0.31	4.41e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8017423	0.935	rs3783838	chr14:90733012	A/G	cg04374321	chr14:90722782	PSMC1	-0.85	-17.7	-0.64	6.29e-54	Mortality in heart failure;
LGG	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg17294928	chr15:75287854	SCAMP5	0.65	12.12	0.49	1.44e-29	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	trans	rs634534	0.622	rs552130	chr11:65732800	T/C	cg17712092	chr4:129076599	LARP1B	0.7	13.49	0.53	3.2e-35	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs7264396	0.790	rs761826	chr20:34194243	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.43	6.69	0.3	6.5500000000000006e-11	Total cholesterol levels;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg26174226	chr8:58114915	NA	-0.55	-7.32	-0.32	1.14e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs453301	0.686	rs1045527	chr8:8890041	A/G	cg06636001	chr8:8085503	FLJ10661	-0.45	-8.31	-0.36	1.08e-15	Joint mobility (Beighton score);
LGG	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg15017067	chr4:17643749	FAM184B	0.29	6.71	0.3	5.8200000000000003e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.500	rs10844845	chr12:34381117	C/T	cg13010199	chr12:38710504	ALG10B	0.65	13.07	0.52	1.95e-33	Morning vs. evening chronotype;
LGG	cis	rs2153904	1.000	rs2153904	chr1:205642790	A/C	cg23034840	chr1:205782522	SLC41A1	0.57	7.15	0.32	3.41e-12	Prostate-specific antigen levels;
LGG	cis	rs28386778	0.863	rs2665834	chr17:61904724	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.61	12.34	0.5	1.83e-30	Prudent dietary pattern;
LGG	trans	rs853679	0.760	rs9295768	chr6:28209102	G/A	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.41e-11	Depression;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.37	0.32	8.13e-13	Tonsillectomy;
LGG	cis	rs4969178	0.965	rs8072632	chr17:76397830	T/C	cg02836325	chr17:76403955	PGS1	-0.72	-14.53	-0.56	1.1e-39	HDL cholesterol levels;
LGG	cis	rs10752881	0.967	rs8179361	chr1:182974572	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs9768139	0.733	rs71545585	chr7:158118672	G/A	cg25566285	chr7:158114605	PTPRN2	0.9	20.24	0.69	1.06e-65	Calcium levels;
LGG	cis	rs10504229	0.683	rs61241336	chr8:58106585	A/G	cg08280861	chr8:58055591	NA	0.54	6.84	0.3	2.46e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs34059614	chr17:41303071	C/T	cg23758822	chr17:41437982	NA	0.9	15.88	0.59	1.2e-45	Menopause (age at onset);
LGG	cis	rs9636202	1.000	rs34518929	chr19:18455444	G/A	cg02383626	chr19:18455508	PGPEP1	0.91	17.93	0.64	5.39e-55	Life satisfaction;
LGG	cis	rs9815354	0.830	rs1716983	chr3:41964128	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.24	-0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs736408	0.509	rs3774349	chr3:52722335	A/C	cg18404041	chr3:52824283	ITIH1	-0.4	-7.84	-0.34	3.21e-14	Bipolar disorder;
LGG	trans	rs11250098	0.574	rs4554431	chr8:10771638	T/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.51	-0.33	3.16e-13	Morning vs. evening chronotype;
LGG	cis	rs7084402	0.967	rs1658496	chr10:60279909	G/A	cg09696939	chr10:60272079	BICC1	0.37	7.3	0.32	1.25e-12	Refractive error;
LGG	cis	rs1552244	0.882	rs55808392	chr3:10054681	C/T	cg13047869	chr3:10149882	C3orf24	0.46	7.61	0.33	1.58e-13	Alzheimer's disease;
LGG	cis	rs6061231	1.000	rs13043313	chr20:60958269	A/G	cg06026331	chr20:60912101	LAMA5	0.47	8.36	0.36	7.16e-16	Colorectal cancer;
LGG	cis	rs1371867	0.846	rs1660326	chr8:101290447	G/A	cg06636551	chr8:101224915	SPAG1	-0.48	-8.74	-0.38	4.47e-17	Atrioventricular conduction;
LGG	cis	rs12701220	0.503	rs12702024	chr7:1129820	G/C	cg00990874	chr7:1149470	C7orf50	-0.78	-12.02	-0.49	3.76e-29	Bronchopulmonary dysplasia;
LGG	cis	rs981844	0.712	rs1037649	chr4:154737796	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.77	-0.41	1.3e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs853679	0.517	rs9357061	chr6:28051772	A/G	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.32e-11	Depression;
LGG	trans	rs12599106	0.709	rs1501462	chr16:34964515	A/T	cg03395511	chr6:291903	DUSP22	-0.67	-11.47	-0.47	5.63e-27	Menopause (age at onset);
LGG	cis	rs921968	0.509	rs7571743	chr2:219352572	C/T	cg01130898	chr2:219473002	PLCD4	-0.42	-7.23	-0.32	2.02e-12	Mean corpuscular hemoglobin concentration;
LGG	trans	rs11250097	0.535	rs11250086	chr8:10769783	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.51	-0.33	3.16e-13	Neuroticism;
LGG	cis	rs11252926	0.673	rs816620	chr10:645916	A/G	cg18196295	chr10:418757	DIP2C	-0.5	-9.17	-0.39	1.61e-18	Psychosis in Alzheimer's disease;
LGG	cis	rs8180040	0.654	rs9837343	chr3:47177388	C/T	cg16586182	chr3:47516702	SCAP	-0.72	-12.94	-0.52	6.54e-33	Colorectal cancer;
LGG	cis	rs12949688	1.000	rs7211686	chr17:55816300	T/C	cg12582317	chr17:55822272	NA	0.64	17.35	0.63	2.48e-52	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03103770	chr19:1753464	ONECUT3	0.5	7.54	0.33	2.51e-13	Gut microbiome composition (summer);
LGG	cis	rs7166081	1.000	rs34310656	chr15:67599975	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.17	-0.32	2.97e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7741085	0.872	rs11755164	chr6:44639184	A/G	cg18551225	chr6:44695536	NA	0.41	6.76	0.3	4.24e-11	Total body bone mineral density;
LGG	cis	rs10504229	0.680	rs11777459	chr8:58044241	A/T	cg14926445	chr8:58193284	C8orf71	-0.72	-8.87	-0.38	1.56e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2070677	1.000	rs12263487	chr10:135403585	A/G	cg20169779	chr10:135381914	SYCE1	-0.97	-12.51	-0.5	3.95e-31	Gout;
LGG	trans	rs2898290	0.622	rs7829381	chr8:11344573	A/G	cg02002194	chr4:3960332	NA	0.48	9.19	0.39	1.3e-18	Systolic blood pressure;
LGG	cis	rs5769765	0.657	rs8136116	chr22:50256886	T/A	cg02269571	chr22:50332266	NA	0.66	8.76	0.38	3.6e-17	Schizophrenia;
LGG	cis	rs7084402	0.967	rs1658462	chr10:60298284	A/C	cg07615347	chr10:60278583	BICC1	0.63	18.3	0.65	1.14e-56	Refractive error;
LGG	cis	rs7568458	0.510	rs10206961	chr2:85814984	C/T	cg17127132	chr2:85788382	GGCX	0.41	6.83	0.3	2.68e-11	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs989128	0.600	rs739924	chr17:48631607	T/C	cg20467136	chr17:48638190	CACNA1G	0.46	6.9	0.31	1.75e-11	Type 2 diabetes;
LGG	cis	rs994014	0.640	rs1452364	chr4:82208444	G/T	cg07938847	chr4:82126349	PRKG2	-0.3	-7.25	-0.32	1.76e-12	Height;
LGG	cis	rs72781680	0.752	rs12616649	chr2:23890913	G/A	cg08917208	chr2:24149416	ATAD2B	0.83	8.47	0.37	3.38e-16	Lymphocyte counts;
LGG	cis	rs7954584	0.583	rs10770186	chr12:122361412	A/G	cg21171335	chr12:122356390	WDR66	0.29	8.4	0.36	5.63e-16	Mean corpuscular volume;
LGG	cis	rs13392177	0.637	rs61041183	chr2:219056380	G/A	cg20019365	chr2:219134978	PNKD;AAMP	0.47	7.81	0.34	3.83e-14	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs10504229	0.639	rs67996345	chr8:58117127	A/G	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1595825	0.891	rs60129872	chr2:198653192	A/G	cg00982548	chr2:198649783	BOLL	-0.52	-7.08	-0.31	5.51e-12	Ulcerative colitis;
LGG	cis	rs7937682	0.883	rs472465	chr11:111468962	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs7928758	0.945	rs28378882	chr11:134280503	G/T	cg22777979	chr11:134283252	B3GAT1	0.85	10.84	0.45	1.44e-24	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs13108904	1.000	rs13108904	chr4:1291113	G/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.45	8.08	0.35	5.6e-15	Obesity-related traits;
LGG	cis	rs1943345	0.830	rs571055	chr11:82898829	G/C	cg07047830	chr11:82868014	PCF11	0.43	6.69	0.3	6.3e-11	Obesity-related traits;
LGG	cis	rs9807841	0.500	rs1368459	chr19:10835338	C/G	cg17710535	chr19:10819994	QTRT1	0.55	9.63	0.41	3.82e-20	Inflammatory skin disease;
LGG	cis	rs367943	0.576	rs2972673	chr5:112980671	C/T	cg12552261	chr5:112820674	MCC	-0.51	-8.97	-0.38	7.48e-18	Type 2 diabetes;
LGG	cis	rs10504229	1.000	rs73609747	chr8:58189104	G/C	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.56	-9.57	-0.41	6.65e-20	Renal function-related traits (BUN);
LGG	cis	rs7828089	0.504	rs12676477	chr8:22266425	T/C	cg12081754	chr8:22256438	SLC39A14	0.98	21.16	0.7	5.16e-70	Verbal declarative memory;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.18e-31	Prudent dietary pattern;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05025164	chr4:1340916	KIAA1530	-0.48	-8.29	-0.36	1.25e-15	Obesity-related traits;
LGG	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg23583168	chr7:148888333	NA	0.87	16.95	0.62	1.68e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs7208859	0.673	rs9894876	chr17:29182020	G/A	cg13385521	chr17:29058706	SUZ12P	0.79	8.8	0.38	2.68e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6138458	1.000	rs6106984	chr20:24977006	T/C	cg26195577	chr20:24973756	C20orf3	1.24	25.98	0.77	1.77e-92	Blood protein levels;
LGG	cis	rs34891900	0.507	rs1008378	chr22:18207251	T/C	cg19898043	chr22:18121309	BCL2L13	0.56	8.91	0.38	1.18e-17	Sum neutrophil eosinophil counts;
LGG	cis	rs7773324	1.000	rs7773324	chr6:382559	A/G	cg23785612	chr6:387171	NA	0.38	8.0	0.35	9.85e-15	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs8002861	0.754	rs7330760	chr13:44403088	A/T	cg17145862	chr1:211918768	LPGAT1	-0.71	-14.64	-0.56	3.77e-40	Leprosy;
LGG	cis	rs13108904	0.967	rs11247987	chr4:1294532	G/A	cg05025164	chr4:1340916	KIAA1530	0.49	8.37	0.36	6.69e-16	Obesity-related traits;
LGG	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9611565	0.512	rs4820446	chr22:42215684	C/T	cg06634786	chr22:41940651	POLR3H	-0.79	-12.36	-0.5	1.59e-30	Vitiligo;
LGG	cis	rs4851254	0.660	rs74340261	chr2:100696827	C/T	cg17356467	chr2:100759845	AFF3	0.45	7.33	0.32	1.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7829975	0.577	rs940032	chr8:8546343	C/T	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.93	-0.35	1.63e-14	Mood instability;
LGG	cis	rs12579753	0.917	rs11115029	chr12:82202219	C/G	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.25e-25	Resting heart rate;
LGG	cis	rs35484700	1	rs35484700	chr4:55498781	CG/C	cg18836493	chr4:55524333	KIT	-0.41	-7.71	-0.34	7.95e-14	White blood cell count;
LGG	cis	rs7959452	0.605	rs12819406	chr12:69696400	G/T	cg20891283	chr12:69753455	YEATS4	0.76	14.64	0.56	3.65e-40	Blood protein levels;
LGG	cis	rs6977660	1.000	rs6977660	chr7:19805480	C/T	cg05791153	chr7:19748676	TWISTNB	0.57	8.56	0.37	1.7e-16	Thyroid stimulating hormone;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg16218610	chr6:26124417	HIST1H2AC;HIST1H2BC	0.41	6.82	0.3	2.89e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs225245	0.817	rs225269	chr17:33967931	G/T	cg19694781	chr19:47549865	TMEM160	-0.41	-6.98	-0.31	1.01e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs11155671	0.530	rs7758033	chr6:150208135	T/C	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.97e-12	Testicular germ cell tumor;
LGG	cis	rs1018836	0.527	rs13268721	chr8:91481549	G/A	cg16814680	chr8:91681699	NA	-0.72	-12.32	-0.5	2.34e-30	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg00914033	chr10:81664698	NA	0.39	6.78	0.3	3.62e-11	Bipolar disorder;
LGG	trans	rs4332037	0.539	rs11772627	chr7:2109821	G/C	cg22232500	chr2:134024266	NCKAP5	0.53	7.37	0.32	7.96e-13	Bipolar disorder;
LGG	cis	rs6840360	0.615	rs56319216	chr4:152463716	C/T	cg25486957	chr4:152246857	NA	-0.52	-8.75	-0.38	3.87e-17	Intelligence (multi-trait analysis);
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.12	-0.31	4.03e-12	Bipolar disorder;
LGG	cis	rs9399135	0.967	rs9376075	chr6:135296963	A/G	cg24558204	chr6:135376177	HBS1L	0.52	9.4	0.4	2.57e-19	Red blood cell count;
LGG	cis	rs2287838	0.704	rs12979606	chr19:9999998	A/T	cg00846166	chr19:10022875	OLFM2	0.33	7.54	0.33	2.53e-13	Sleep duration;
LGG	cis	rs9790314	0.715	rs9290065	chr3:160776964	A/G	cg03342759	chr3:160939853	NMD3	0.5	8.47	0.37	3.31e-16	Morning vs. evening chronotype;
LGG	cis	rs5769707	1.000	rs5769707	chr22:50013402	G/T	cg20744362	chr22:50050164	C22orf34	0.4	7.87	0.34	2.57e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs2952156	0.920	rs12940986	chr17:37836581	A/G	cg07936489	chr17:37558343	FBXL20	0.52	8.8	0.38	2.64e-17	Asthma;
LGG	cis	rs9658691	0.607	rs12415680	chr10:90780737	A/T	cg03111039	chr10:90751583	FAS;ACTA2	-0.73	-9.13	-0.39	2.12e-18	Mosquito bite size;
LGG	cis	rs227584	0.663	rs3180912	chr17:42259463	A/G	cg19774624	chr17:42201019	HDAC5	-0.71	-14.18	-0.55	3.77e-38	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs62238980	0.614	rs62240588	chr22:32358473	C/T	cg00543991	chr22:32367038	NA	0.74	9.53	0.41	8.71e-20	Childhood ear infection;
LGG	cis	rs56283067	0.887	rs62437973	chr6:44761978	G/A	cg18551225	chr6:44695536	NA	-0.7	-11.51	-0.47	3.97e-27	Total body bone mineral density;
LGG	cis	rs1018836	0.892	rs4735224	chr8:91567046	C/A	cg16814680	chr8:91681699	NA	-0.72	-12.69	-0.51	7.43e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs1005277	0.579	rs2472173	chr10:38374638	G/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs61931739	0.534	rs73103090	chr12:34098801	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.64	0.44	8.22e-24	Morning vs. evening chronotype;
LGG	trans	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.61	-11.45	-0.47	6.99e-27	Brugada syndrome;
LGG	cis	rs6977660	0.714	rs10244210	chr7:19823972	T/C	cg05791153	chr7:19748676	TWISTNB	0.76	10.11	0.43	7.81e-22	Thyroid stimulating hormone;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg22535103	chr8:58192502	C8orf71	-1.05	-15.94	-0.6	6.75e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.837	rs11169157	chr12:37980047	T/C	cg26384229	chr12:38710491	ALG10B	0.89	20.27	0.69	7.37e-66	Bladder cancer;
LGG	cis	rs2071403	0.509	rs11675434	chr2:1407815	A/G	cg06500727	chr2:1417164	TPO	0.59	11.97	0.49	5.89e-29	Thyroid peroxidase antibody positivity;
LGG	cis	rs35264875	1.000	rs72919409	chr11:68826553	G/C	cg07882059	chr11:68924751	NA	0.38	6.65	0.3	8.27e-11	Blond vs. brown hair color;
LGG	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg00405596	chr8:11794950	NA	-0.41	-6.81	-0.3	3.05e-11	Neuroticism;
LGG	cis	rs1008375	1.000	rs7661631	chr4:17679751	T/C	cg02297831	chr4:17616191	MED28	-0.48	-8.95	-0.38	8.71e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9902453	0.904	rs7212292	chr17:28409264	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.75	-0.54	2.69e-36	Coffee consumption (cups per day);
LGG	cis	rs7572644	0.699	rs10175508	chr2:28213424	C/T	cg27432699	chr2:27873401	GPN1	-0.44	-6.67	-0.3	7.29e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs3845702	0.736	rs2678936	chr2:180872179	G/C	cg01881094	chr2:180872142	CWC22	1.27	16.87	0.62	4.14e-50	Schizophrenia;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg23731668	chr2:149410331	EPC2	0.29	6.66	0.3	7.62e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7503807	0.664	rs9902390	chr17:78574387	G/A	cg06872548	chr17:78716983	RPTOR	0.41	9.19	0.39	1.29e-18	Obesity;
LGG	cis	rs10256972	0.552	rs2960830	chr7:1200641	T/C	cg09177884	chr7:1199841	ZFAND2A	-0.72	-13.45	-0.53	4.75e-35	Longevity;Endometriosis;
LGG	cis	rs6445975	0.666	rs4518147	chr3:58393574	T/G	cg24175188	chr3:58374923	PXK	-0.53	-8.75	-0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.850	rs2239358	chr16:89827330	C/G	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs4561483	0.734	rs33655	chr16:11970381	C/T	cg08843971	chr16:11963173	GSPT1	-0.67	-18.19	-0.65	3.53e-56	Testicular germ cell tumor;
LGG	trans	rs7615952	0.599	rs66532274	chr3:125731845	G/A	cg07211511	chr3:129823064	LOC729375	-0.7	-9.71	-0.41	2.05e-20	Blood pressure (smoking interaction);
LGG	trans	rs6601327	0.767	rs10109026	chr8:9411986	C/T	cg06636001	chr8:8085503	FLJ10661	0.41	7.09	0.31	5e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs929354	0.772	rs6969244	chr7:157004012	A/G	cg00092383	chr7:157075207	NA	-0.38	-6.65	-0.3	8.41e-11	Body mass index;
LGG	trans	rs116095464	0.558	rs7736600	chr5:231337	A/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.47e-15	Breast cancer;
LGG	cis	rs6918586	1.000	rs6918586	chr6:26097384	T/C	cg18357526	chr6:26021779	HIST1H4A	0.51	8.57	0.37	1.5e-16	Schizophrenia;
LGG	cis	rs1707322	0.685	rs56177313	chr1:46225806	A/C	cg03146154	chr1:46216737	IPP	0.58	10.65	0.44	7.99e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg06074448	chr4:187884817	NA	-0.58	-12.68	-0.51	7.93e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11741688	0.557	rs6898923	chr5:178330559	C/T	cg20935368	chr5:178288625	ZNF354B	0.34	6.91	0.31	1.57e-11	Sleep duration;
LGG	cis	rs11098499	0.687	rs71610270	chr4:120287436	A/G	cg09307838	chr4:120376055	NA	0.72	12.1	0.49	1.82e-29	Corneal astigmatism;
LGG	cis	rs28386778	0.805	rs9911714	chr17:61828952	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg27532560	chr4:187881888	NA	-0.6	-12.87	-0.51	1.26e-32	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2739330	0.734	rs2000467	chr22:24241533	C/T	cg24846343	chr22:24311635	DDTL	-0.55	-10.05	-0.42	1.21e-21	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9322193	0.923	rs12211511	chr6:150066342	G/C	cg00933542	chr6:150070202	PCMT1	0.4	7.3	0.32	1.27e-12	Lung cancer;
LGG	trans	rs3960554	0.808	rs59882870	chr7:75638421	G/A	cg19862616	chr7:65841803	NCRNA00174	0.86	12.12	0.49	1.43e-29	Eotaxin levels;
LGG	cis	rs2762353	0.935	rs1892249	chr6:25768992	A/G	cg03517284	chr6:25882590	NA	0.51	9.6	0.41	4.98e-20	Blood metabolite levels;
LGG	cis	rs12477438	0.798	rs2123686	chr2:99690135	G/A	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs4332037	0.552	rs11773627	chr7:2002733	A/G	cg23422044	chr7:1970798	MAD1L1	-0.63	-11.56	-0.47	2.6e-27	Bipolar disorder;
LGG	cis	rs1595825	1.000	rs7579905	chr2:198868109	T/A	cg00982548	chr2:198649783	BOLL	-0.52	-7.19	-0.32	2.55e-12	Ulcerative colitis;
LGG	cis	rs4356932	0.967	rs7659236	chr4:76953611	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.72	-0.3	5.21e-11	Blood protein levels;
LGG	cis	rs9322193	0.962	rs9505974	chr6:150100430	C/T	cg16507663	chr6:150244633	RAET1G	0.42	7.87	0.34	2.47e-14	Lung cancer;
LGG	cis	rs4595586	0.545	rs7958118	chr12:39376685	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs6424115	0.708	rs13551	chr1:24180962	T/C	cg15997130	chr1:24165203	NA	-0.42	-10.32	-0.43	1.26e-22	Immature fraction of reticulocytes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05332869	chr20:39658073	TOP1	0.38	6.69	0.3	6.56e-11	Cognitive performance;
LGG	cis	rs13118159	0.872	rs4974604	chr4:1345798	T/C	cg02475777	chr4:1388615	CRIPAK	0.39	7.18	0.32	2.84e-12	Longevity;
LGG	cis	rs7660883	0.836	rs442177	chr4:88030261	G/T	cg21988461	chr4:88008667	AFF1	0.32	9.14	0.39	1.9e-18	HDL cholesterol levels;
LGG	cis	rs834603	0.965	rs834601	chr7:47445812	T/C	cg23694490	chr7:47445681	TNS3	-0.53	-16.17	-0.6	5.82e-47	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6089829	0.962	rs4809462	chr20:61661560	A/G	cg08045932	chr20:61659980	NA	0.6	13.23	0.52	4.05e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs972578	0.765	rs9611950	chr22:43274722	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.81	-0.3	2.95e-11	Mean platelet volume;
LGG	cis	rs13108904	0.967	rs4405964	chr4:1278814	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs6871536	1.000	rs2106984	chr5:131953066	T/A	cg04303330	chr5:131992430	IL13	0.28	6.88	0.3	1.92e-11	Asthma (childhood onset);
LGG	cis	rs894344	0.650	rs11166599	chr8:135581430	T/C	cg09855544	chr8:135498122	ZFAT	0.42	7.58	0.33	1.92e-13	Systolic blood pressure;
LGG	trans	rs9329221	0.683	rs658385	chr8:9892177	C/T	cg21775007	chr8:11205619	TDH	-0.44	-6.97	-0.31	1.07e-11	Neuroticism;
LGG	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.61	-0.71	3.77e-72	Height;
LGG	cis	rs12586317	0.620	rs7147571	chr14:35530236	T/C	cg05294307	chr14:35346193	BAZ1A	-0.48	-6.81	-0.3	3e-11	Psoriasis;
LGG	cis	rs1670533	1.000	rs676561	chr4:1083112	C/T	cg27284194	chr4:1044797	NA	0.55	9.9	0.42	4.21e-21	Recombination rate (females);
LGG	cis	rs4332037	0.901	rs7791899	chr7:1935988	T/C	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.92	-0.38	1.11e-17	Bipolar disorder;
LGG	cis	rs4253772	0.550	rs12165597	chr22:46705584	A/G	cg24881330	chr22:46731750	TRMU	0.69	6.98	0.31	9.97e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10504229	1.000	rs60651159	chr8:58174074	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg08048268	chr3:133502702	NA	-0.67	-12.91	-0.51	8.62e-33	Iron status biomarkers;
LGG	cis	rs9527	0.615	rs2152915	chr10:104691732	A/T	cg04362960	chr10:104952993	NT5C2	0.56	10.25	0.43	2.4e-22	Arsenic metabolism;
LGG	cis	rs7924005	0.543	rs71479758	chr10:6177894	A/G	cg17191567	chr10:6178319	NA	-0.44	-8.21	-0.36	2.24e-15	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs7623687	1.000	rs7623687	chr3:49448566	A/C	cg19401529	chr3:49056140	DALRD3	0.68	7.88	0.34	2.39e-14	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	cis	rs2243480	1.000	rs316330	chr7:65605372	C/A	cg12463550	chr7:65579703	CRCP	0.79	8.66	0.37	7.69e-17	Diabetic kidney disease;
LGG	trans	rs7829975	0.871	rs7829826	chr8:8578120	T/A	cg02002194	chr4:3960332	NA	0.48	8.93	0.38	9.76e-18	Mood instability;
LGG	cis	rs1519814	0.915	rs6992410	chr8:121113566	T/G	cg22335954	chr8:121166405	COL14A1	-0.56	-11.41	-0.47	9.52e-27	Breast cancer;
LGG	trans	rs116095464	0.619	rs2303741	chr5:218356	T/C	cg00938859	chr5:1591904	SDHAP3	0.9	13.27	0.52	2.7200000000000002e-34	Breast cancer;
LGG	cis	rs1003719	0.788	rs2835578	chr21:38457671	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg16486109	chr11:613632	IRF7	0.41	7.4	0.33	6.48e-13	Systemic lupus erythematosus;
LGG	trans	rs62103177	0.714	rs28691615	chr18:77612254	C/T	cg14227996	chr4:17616232	MED28	0.56	7.83	0.34	3.29e-14	Opioid sensitivity;
LGG	cis	rs60871478	0.945	rs62432254	chr7:804175	C/T	cg22643751	chr7:855365	UNC84A	0.36	6.94	0.31	1.32e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg12591125	chr7:1885375	MAD1L1	0.46	7.12	0.31	4.03e-12	Bipolar disorder;
LGG	cis	rs28386778	0.830	rs2665798	chr17:61921397	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.53	0.33	2.64e-13	Prudent dietary pattern;
LGG	cis	rs17092148	0.945	rs6060034	chr20:33351864	T/C	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs7523273	0.526	rs2745980	chr1:208018367	A/C	cg22525895	chr1:207977042	MIR29B2	0.61	11.9	0.48	1.12e-28	Schizophrenia;
LGG	cis	rs2635047	0.967	rs2684820	chr18:44664304	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.42	0.4	2.1e-19	Educational attainment;
LGG	cis	rs17270561	0.723	rs12192635	chr6:25880907	A/T	cg16482183	chr6:26056742	HIST1H1C	0.73	11.05	0.46	2.44e-25	Iron status biomarkers;
LGG	cis	rs651907	0.557	rs3094297	chr3:101399260	A/G	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	13.58	0.53	1.36e-35	Colorectal cancer;
LGG	cis	rs9611565	0.512	rs5758465	chr22:42175314	T/C	cg17376030	chr22:41985996	PMM1	-0.67	-10.68	-0.44	6.19e-24	Vitiligo;
LGG	cis	rs2228479	0.850	rs17233497	chr16:89815152	G/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-14.89	-0.57	2.97e-41	Skin colour saturation;
LGG	cis	rs9487094	0.670	rs12214639	chr6:109897617	T/C	cg16315928	chr6:109776240	MICAL1	0.46	8.12	0.35	4.21e-15	Height;
LGG	trans	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg02002194	chr4:3960332	NA	-0.46	-8.99	-0.39	6.12e-18	Mood instability;
LGG	trans	rs2235573	0.570	rs5995529	chr22:38415721	A/G	cg19894588	chr14:64061835	NA	-0.49	-8.18	-0.36	2.69e-15	Glioblastoma;Glioma;
LGG	cis	rs13108904	0.901	rs4516656	chr4:1279860	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.21e-35	Obesity-related traits;
LGG	cis	rs6952808	0.609	rs6970034	chr7:1948088	G/A	cg21782813	chr7:2030301	MAD1L1	0.39	8.93	0.38	1.03e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.636	rs6923839	chr6:25745853	G/A	cg03264133	chr6:25882463	NA	-0.49	-7.9	-0.34	2.05e-14	Iron status biomarkers;
LGG	cis	rs7166081	1.000	rs28696998	chr15:67656863	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.34	-7.27	-0.32	1.58e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs35306767	0.903	rs10904577	chr10:922077	A/G	cg25019033	chr10:957182	NA	-0.55	-10.05	-0.42	1.25e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs888194	0.738	rs7956788	chr12:109960962	T/C	cg19025524	chr12:109796872	NA	-0.36	-7.15	-0.32	3.31e-12	Neuroticism;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg23451424	chr7:82073339	CACNA2D1	-0.41	-6.7	-0.3	6.14e-11	Coronary artery disease;
LGG	cis	rs6459804	1.000	rs6459805	chr7:157510294	T/C	cg11757124	chr7:157526947	PTPRN2	-0.51	-9.35	-0.4	3.79e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs4430311	0.723	rs11585986	chr1:243792591	G/C	cg25706552	chr1:244017396	NA	-0.64	-15.77	-0.59	3.8e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs28386778	0.897	rs716880	chr17:61902822	C/G	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.39	-0.58	1.88e-43	Prudent dietary pattern;
LGG	cis	rs7103648	0.569	rs11039266	chr11:47532395	T/G	cg20307385	chr11:47447363	PSMC3	0.84	16.92	0.62	2.41e-50	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs2797160	1.000	rs4897152	chr6:126002400	A/G	cg05901451	chr6:126070800	HEY2	-0.45	-7.47	-0.33	3.98e-13	Endometrial cancer;
LGG	cis	rs9902453	0.808	rs8069669	chr17:28239502	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.87	0.54	7.97e-37	Coffee consumption (cups per day);
LGG	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg19507638	chr5:93509721	C5orf36	-0.79	-10.04	-0.42	1.39e-21	Diabetic retinopathy;
LGG	cis	rs2732480	0.577	rs2732486	chr12:48737834	G/A	cg24011408	chr12:48396354	COL2A1	0.5	7.82	0.34	3.5e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs6912958	0.754	rs4707374	chr6:88255438	T/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.64	-0.37	9.55e-17	Monocyte percentage of white cells;
LGG	cis	rs2013441	1.000	rs4924808	chr17:20026548	C/T	cg13482628	chr17:19912719	NA	-0.48	-8.83	-0.38	2.18e-17	Obesity-related traits;
LGG	cis	rs10904908	0.931	rs7903137	chr10:17259567	C/T	cg01003015	chr10:17271136	VIM	-0.55	-9.23	-0.39	9.73e-19	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs883565	0.792	rs784501	chr3:39183895	A/G	cg01426195	chr3:39028469	NA	0.59	9.94	0.42	3.07e-21	Handedness;
LGG	cis	rs10504229	0.775	rs72650869	chr8:58157923	T/A	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.581	rs72987336	chr2:239365345	T/C	cg01134436	chr17:81009848	B3GNTL1	0.83	8.72	0.38	5.07e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9322193	0.884	rs9688858	chr6:149959047	C/A	cg16507663	chr6:150244633	RAET1G	0.41	7.66	0.34	1.09e-13	Lung cancer;
LGG	cis	rs657075	0.595	rs35719560	chr5:131584395	T/C	cg05556477	chr5:131705319	SLC22A5	0.62	8.16	0.35	3.1e-15	Rheumatoid arthritis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17591343	chr1:93646016	TMED5;CCDC18	0.42	6.73	0.3	5.14e-11	Cognitive performance;
LGG	cis	rs2594989	1.000	rs2606742	chr3:11391717	G/A	cg01796438	chr3:11312864	ATG7	-0.54	-7.5	-0.33	3.2e-13	Circulating chemerin levels;
LGG	cis	rs6500395	0.963	rs2041921	chr16:48714002	T/C	cg16662043	chr16:48846231	NA	-0.37	-7.26	-0.32	1.7e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs559928	0.597	rs11600667	chr11:63976183	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.75	8.8	0.38	2.63e-17	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs9650657	0.769	rs2116093	chr8:10613299	C/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-7.15	-0.32	3.38e-12	Neuroticism;
LGG	cis	rs1348850	0.668	rs4893971	chr2:178495743	T/C	cg22681709	chr2:178499509	PDE11A	-0.46	-7.43	-0.33	5.45e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7084402	1.000	rs4113952	chr10:60268599	A/G	cg07615347	chr10:60278583	BICC1	0.64	18.18	0.65	4.04e-56	Refractive error;
LGG	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg19442545	chr10:75533431	FUT11	-0.44	-7.22	-0.32	2.18e-12	Inflammatory bowel disease;
LGG	cis	rs10791097	0.728	rs10894265	chr11:130714613	T/C	cg12179176	chr11:130786555	SNX19	-0.65	-11.61	-0.47	1.53e-27	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs17376456	0.542	rs2084916	chr5:93194961	A/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.63	-8.42	-0.36	4.66e-16	Diabetic retinopathy;
LGG	cis	rs283228	0.837	rs57353721	chr6:101823606	T/G	cg27451362	chr6:101846650	GRIK2	0.53	8.89	0.38	1.41e-17	Coenzyme Q10 levels;
LGG	cis	rs7267979	0.932	rs1985737	chr20:25591468	T/A	cg06421707	chr20:25228305	PYGB	0.5	10.58	0.44	1.41e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs2727020	0.595	rs10466496	chr11:49501514	C/T	cg15704280	chr7:45808275	SEPT13	-1.01	-22.66	-0.73	4.81e-77	Coronary artery disease;
LGG	cis	rs2013441	1.000	rs2526490	chr17:20097526	A/G	cg13482628	chr17:19912719	NA	-0.51	-9.4	-0.4	2.56e-19	Obesity-related traits;
LGG	trans	rs2749592	0.918	rs1208653	chr10:38253826	C/G	cg17830980	chr10:43048298	ZNF37B	0.34	6.67	0.3	7.25e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs28386778	0.765	rs1974435	chr17:61994096	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	-1.02	-24.63	-0.75	3.3e-86	Prudent dietary pattern;
LGG	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	trans	rs7939886	0.920	rs11227463	chr11:55955447	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.83	0.34	3.4e-14	Myopia (pathological);
LGG	cis	rs8077889	1.000	rs59044152	chr17:41888747	A/G	cg26893861	chr17:41843967	DUSP3	0.93	15.5	0.58	5.77e-44	Triglycerides;
LGG	cis	rs908922	0.676	rs7532535	chr1:152517597	T/A	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg20607798	chr8:58055168	NA	-0.67	-7.79	-0.34	4.3e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs12893668	0.703	rs4906337	chr14:104040414	C/A	cg26031613	chr14:104095156	KLC1	-0.6	-9.63	-0.41	3.88e-20	Reticulocyte count;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.38	-0.32	7.49e-13	Menopause (age at onset);
LGG	cis	rs2658782	0.951	rs2608214	chr11:93148665	C/T	cg15737290	chr11:93063684	CCDC67	0.52	7.84	0.34	3.15e-14	Pulmonary function decline;
LGG	cis	rs7582180	0.845	rs7607676	chr2:100896966	G/A	cg14675211	chr2:100938903	LONRF2	0.48	7.41	0.33	5.86e-13	Intelligence (multi-trait analysis);
LGG	cis	rs17345786	0.906	rs72944107	chr3:101197190	C/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7098414	0.511	rs12262228	chr10:82160425	C/T	cg01528321	chr10:82214614	TSPAN14	0.69	12.55	0.5	2.58e-31	Post bronchodilator FEV1;
LGG	cis	rs1894633	0.547	rs61806090	chr1:172343604	A/G	cg01573306	chr1:172330400	DNM3	-0.41	-7.2	-0.32	2.38e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs17221829	0.733	rs72971005	chr11:89358412	G/A	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.13	-0.39	2.09e-18	Anxiety in major depressive disorder;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.659	rs8074016	chr17:56840587	A/G	cg25039879	chr17:56429692	SUPT4H1	0.63	8.82	0.38	2.28e-17	Cognitive test performance;
LGG	cis	rs4819052	0.851	rs2838856	chr21:46680766	T/G	cg06618935	chr21:46677482	NA	-0.43	-8.33	-0.36	9.09e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1814175	0.754	rs28663627	chr11:50048829	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.85	-0.48	1.77e-28	Height;
LGG	cis	rs10504229	1.000	rs17805326	chr8:58169533	A/C	cg05313129	chr8:58192883	C8orf71	-0.78	-12.18	-0.49	8.88e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs3206736	0.548	rs17793874	chr7:35065558	A/G	cg13400248	chr7:35225412	NA	0.55	9.57	0.41	6.27e-20	Diastolic blood pressure;
LGG	cis	rs698833	0.828	rs3738984	chr2:44531484	A/G	cg00619915	chr2:44497795	NA	0.44	6.82	0.3	2.86e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg16482183	chr6:26056742	HIST1H1C	0.54	9.6	0.41	5.03e-20	Height;
LGG	cis	rs921968	0.541	rs17462853	chr2:219345637	T/G	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs1552244	1.000	rs17032277	chr3:10077023	T/C	cg16606324	chr3:10149918	C3orf24	0.55	7.34	0.32	9.76e-13	Alzheimer's disease;
LGG	cis	rs35110281	0.744	rs162395	chr21:44945759	T/C	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.82	-0.38	2.31e-17	Mean corpuscular volume;
LGG	cis	rs9911578	1.000	rs4372750	chr17:57013803	A/C	cg05425664	chr17:57184151	TRIM37	0.63	10.18	0.43	4.09e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10791323	0.569	rs2187450	chr11:133743792	A/G	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	cis	rs55883249	0.957	rs16867083	chr2:9767441	C/T	cg23886495	chr2:9695866	ADAM17	-0.58	-8.49	-0.37	2.83e-16	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs77633900	0.614	rs2629025	chr15:76943363	G/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.17	-0.43	4.54e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs16986825	0.664	rs5997409	chr22:29222096	T/C	cg02153584	chr22:29168773	CCDC117	0.59	7.41	0.33	6.2e-13	Pancreatic cancer;
LGG	cis	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg18252515	chr7:66147081	NA	1.32	18.88	0.66	2.17e-59	Diabetic kidney disease;
LGG	trans	rs7824557	0.527	rs2572376	chr8:11237756	C/A	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.43	-0.36	4.52e-16	Retinal vascular caliber;
LGG	cis	rs7647973	0.600	rs12631989	chr3:49273996	C/T	cg16497277	chr3:49208875	KLHDC8B	-0.42	-6.77	-0.3	3.98e-11	Menarche (age at onset);
LGG	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.4	7.23	0.32	2.01e-12	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs992157	0.560	rs12987130	chr2:219104990	T/C	cg04731861	chr2:219085781	ARPC2	0.52	13.46	0.53	4.17e-35	Colorectal cancer;
LGG	trans	rs7246760	1.000	rs1592997	chr19:9900983	G/A	cg02900749	chr2:68251473	NA	-1.04	-11.35	-0.47	1.63e-26	Pursuit maintenance gain;
LGG	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg06238570	chr21:40685208	BRWD1	0.44	6.81	0.3	3.1e-11	Cognitive function;
LGG	cis	rs7726839	0.540	rs72703087	chr5:598029	C/T	cg16400903	chr5:693638	TPPP	0.45	6.89	0.3	1.86e-11	Obesity-related traits;
LGG	cis	rs8064299	0.655	rs734232	chr17:72765731	C/T	cg25054828	chr17:72772726	NAT9;TMEM104	0.52	8.99	0.39	6.37e-18	Monocyte count;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg13897145	chr3:113557582	GRAMD1C	0.44	7.25	0.32	1.75e-12	Cognitive performance;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg01341218	chr17:43662625	NA	0.67	12.14	0.49	1.21e-29	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs503734	0.502	rs2660803	chr3:100914035	A/G	cg27318481	chr3:100970896	IMPG2	-0.59	-13.35	-0.53	1.22e-34	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs13086611	1	rs13086611	chr3:49385417	A/T	cg00383909	chr3:49044727	WDR6	0.47	7.7	0.34	8.23e-14	Educational attainment;
LGG	cis	rs4595586	0.545	rs7972590	chr12:39376615	A/G	cg13010199	chr12:38710504	ALG10B	0.41	7.33	0.32	1.05e-12	Morning vs. evening chronotype;
LGG	cis	rs4595586	0.505	rs12827467	chr12:39374014	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg10360139	chr7:1886902	MAD1L1	-0.45	-8.11	-0.35	4.58e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg14369405	chr18:32556760	MAPRE2	0.38	6.96	0.31	1.14e-11	Bilirubin levels;
LGG	trans	rs11976180	1.000	rs1919950	chr7:143767898	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.4	-7.2	-0.32	2.49e-12	Obesity-related traits;
LGG	trans	rs7395662	0.929	rs10838982	chr11:48640168	C/T	cg15704280	chr7:45808275	SEPT13	-0.54	-9.07	-0.39	3.31e-18	HDL cholesterol;
LGG	cis	rs72615157	0.606	rs941288	chr7:99776808	G/A	cg12813108	chr7:99719912	CNPY4	-0.62	-9.85	-0.42	6.55e-21	Lung function (FEV1/FVC);
LGG	cis	rs3096299	0.679	rs3096322	chr16:89441123	A/G	cg06640241	chr16:89574553	SPG7	-0.66	-11.24	-0.46	4.51e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg26408565	chr15:76604113	ETFA	-0.38	-6.68	-0.3	6.76e-11	Blood metabolite levels;
LGG	trans	rs2727020	0.617	rs7102702	chr11:49401125	T/G	cg03929089	chr4:120376271	NA	-0.86	-15.31	-0.58	4.15e-43	Coronary artery disease;
LGG	cis	rs2836950	0.565	rs2836930	chr21:40545656	A/G	cg17971929	chr21:40555470	PSMG1	-0.55	-9.35	-0.4	3.88e-19	Menarche (age at onset);
LGG	cis	rs9858542	0.953	rs6803222	chr3:49665976	T/G	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.61e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17376456	0.690	rs6892055	chr5:93113023	A/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	11.09	0.46	1.67e-25	Diabetic retinopathy;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg08499158	chr17:42289980	UBTF	-0.58	-10.83	-0.45	1.63e-24	Total body bone mineral density;
LGG	cis	rs7789940	1.000	rs11765693	chr7:75985373	A/G	cg10167463	chr7:75959203	YWHAG	-0.46	-7.74	-0.34	6.14e-14	Multiple sclerosis;
LGG	cis	rs7618915	0.501	rs55678971	chr3:52717229	T/A	cg11645453	chr3:52864694	ITIH4	0.4	6.68	0.3	6.72e-11	Bipolar disorder;
LGG	cis	rs28735056	0.563	rs12968139	chr18:77685520	A/G	cg05491587	chr18:77659695	KCNG2	0.4	7.27	0.32	1.56e-12	Schizophrenia;
LGG	cis	rs1348850	0.609	rs1348851	chr2:178418677	C/T	cg22681709	chr2:178499509	PDE11A	0.54	7.54	0.33	2.54e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg25358565	chr5:93447407	FAM172A	-0.86	-11.76	-0.48	4e-28	Diabetic retinopathy;
LGG	cis	rs9650657	0.572	rs11250098	chr8:10818607	A/G	cg19847130	chr8:10466454	RP1L1	0.32	6.89	0.3	1.84e-11	Neuroticism;
LGG	cis	rs11096990	0.855	rs57488936	chr4:39222246	C/T	cg24403649	chr4:39172243	NA	-0.45	-7.54	-0.33	2.43e-13	Cognitive function;
LGG	cis	rs10504229	0.603	rs6471591	chr8:58159949	C/T	cg09858108	chr8:58055024	NA	0.42	6.72	0.3	5.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs10262624	0.967	rs2188845	chr7:23922010	C/A	cg09690326	chr7:23720549	C7orf46	-0.32	-6.69	-0.3	6.59e-11	Schizophrenia;
LGG	trans	rs10435719	0.528	rs13250020	chr8:11789769	A/G	cg02002194	chr4:3960332	NA	-0.5	-9.23	-0.39	9.55e-19	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs897984	0.609	rs72800847	chr16:31022639	G/A	cg02466173	chr16:30829666	NA	-0.45	-7.55	-0.33	2.35e-13	Dementia with Lewy bodies;
LGG	cis	rs11098499	0.863	rs10034450	chr4:120455649	A/G	cg09307838	chr4:120376055	NA	0.8	13.14	0.52	9.94e-34	Corneal astigmatism;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.57	9.8	0.41	9.73e-21	Lymphocyte counts;
LGG	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg08297393	chr2:100937505	LONRF2	-0.56	-9.56	-0.41	7.26e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13421350	0.579	rs1574256	chr2:173313965	G/C	cg15021238	chr2:173305865	ITGA6	-0.79	-9.37	-0.4	3.25e-19	Diabetic kidney disease;
LGG	cis	rs4936894	0.500	rs4936919	chr11:124180082	C/T	cg27160556	chr11:124181099	OR8D1	0.46	10.01	0.42	1.68e-21	Aging (time to death);
LGG	cis	rs9322193	0.567	rs7742692	chr6:150213499	A/G	cg07132326	chr6:150258058	NA	0.37	8.0	0.35	1.01e-14	Lung cancer;
LGG	cis	rs28735056	0.933	rs499472	chr18:77589759	C/T	cg25885449	chr18:77638415	KCNG2	0.35	6.89	0.31	1.8e-11	Schizophrenia;
LGG	cis	rs11603023	0.967	rs7936556	chr11:118501299	G/A	cg09426994	chr11:118478258	PHLDB1	-0.43	-7.5	-0.33	3.37e-13	Cholesterol, total;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg24829409	chr8:58192753	C8orf71	-0.68	-9.3	-0.4	5.38e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg05941027	chr17:61774174	LIMD2	0.37	9.4	0.4	2.62e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg12070911	chr6:150209640	RAET1E	0.31	7.62	0.33	1.42e-13	Lung cancer;
LGG	cis	rs1008375	0.931	rs2098151	chr4:17577490	T/C	cg16339924	chr4:17578868	LAP3	0.63	10.88	0.45	1.06e-24	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs734999	0.588	rs2843404	chr1:2530558	T/C	cg18854424	chr1:2615690	NA	-0.35	-7.13	-0.31	3.96e-12	Ulcerative colitis;
LGG	cis	rs57502260	0.704	rs2306862	chr11:68177510	C/T	cg01657329	chr11:68192670	LRP5	-0.6	-8.3	-0.36	1.17e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs1125355	0.653	rs72937273	chr2:159618716	T/G	cg02251393	chr2:159651559	DAPL1	0.42	8.23	0.36	1.87e-15	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs13082711	0.554	rs1494423	chr3:27375345	A/G	cg02860705	chr3:27208620	NA	-0.74	-12.86	-0.51	1.42e-32	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs951366	0.531	rs12030754	chr1:205678043	G/C	cg24503407	chr1:205819492	PM20D1	-0.41	-7.06	-0.31	6.04e-12	Menarche (age at onset);
LGG	cis	rs16866061	1.000	rs72974267	chr2:225454209	T/C	cg12698349	chr2:225449008	CUL3	0.92	18.84	0.66	3.27e-59	Acute graft versus host disease in bone marrow transplantation (recipient effect);
LGG	cis	rs701145	0.585	rs398512	chr3:153909988	T/C	cg12800244	chr3:153838788	SGEF	0.83	8.38	0.36	6.39e-16	Coronary artery disease;
LGG	cis	rs3820068	0.705	rs11577225	chr1:15864242	T/C	cg05660106	chr1:15850417	CASP9	1.1	25.46	0.76	4.86e-90	Systolic blood pressure;
LGG	cis	rs2290416	0.892	rs62523607	chr8:144667432	G/A	cg15537850	chr8:144661051	NAPRT1	0.96	7.48	0.33	3.88e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs1595825	0.891	rs73056877	chr2:198816724	A/C	cg00982548	chr2:198649783	BOLL	-0.5	-6.79	-0.3	3.47e-11	Ulcerative colitis;
LGG	trans	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.51	-0.4	1.06e-19	Retinal vascular caliber;
LGG	cis	rs698833	0.828	rs6745281	chr2:44534472	A/C	cg00619915	chr2:44497795	NA	-0.45	-6.94	-0.31	1.33e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs7107174	0.892	rs1567891	chr11:78101985	A/G	cg27205649	chr11:78285834	NARS2	-0.47	-7.61	-0.33	1.59e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.83	0.38	2.13e-17	Lung cancer;
LGG	trans	rs11165623	0.740	rs12126692	chr1:96889258	C/G	cg10631902	chr5:14652156	NA	0.59	13.78	0.54	1.89e-36	Hip circumference;Waist circumference;
LGG	cis	rs6554196	0.508	rs999020	chr4:55524304	T/C	cg18836493	chr4:55524333	KIT	-0.43	-7.95	-0.35	1.42e-14	Monocyte count;
LGG	cis	rs17253792	0.545	rs34719936	chr14:56015134	G/A	cg01858014	chr14:56050164	KTN1	-0.75	-9.38	-0.4	3.06e-19	Putamen volume;
LGG	cis	rs8031584	0.723	rs711224	chr15:31127921	G/C	cg08109568	chr15:31115862	NA	0.6	10.19	0.43	3.8e-22	Huntington's disease progression;
LGG	cis	rs951366	0.585	rs72750964	chr1:205675240	C/T	cg11965913	chr1:205819406	PM20D1	0.84	18.57	0.65	5.97e-58	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06549955	chr12:110434341	GIT2	0.49	7.25	0.32	1.75e-12	Gut microbiome composition (summer);
LGG	cis	rs11168618	0.626	rs2731107	chr12:48887159	G/C	cg24011408	chr12:48396354	COL2A1	-0.43	-7.02	-0.31	8.01e-12	Adiponectin levels;
LGG	trans	rs4689592	0.503	rs11945642	chr4:7051065	G/C	cg07817883	chr1:32538562	TMEM39B	0.63	8.23	0.36	1.98e-15	Monocyte percentage of white cells;
LGG	cis	rs3771570	1.000	rs56363214	chr2:242227157	A/G	cg21155796	chr2:242212141	HDLBP	0.74	9.78	0.41	1.21e-20	Prostate cancer;
LGG	cis	rs8177253	1.000	rs6439439	chr3:133481498	G/T	cg11941060	chr3:133502564	NA	-0.49	-8.37	-0.36	7.02e-16	Iron status biomarkers;
LGG	cis	rs9443645	0.901	rs9343844	chr6:79586463	T/A	cg18132916	chr6:79620363	NA	-0.31	-8.55	-0.37	1.79e-16	Intelligence (multi-trait analysis);
LGG	cis	rs60843830	0.633	rs1078763	chr2:113763	A/G	cg12623918	chr2:306882	NA	-0.37	-6.89	-0.3	1.85e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs7264396	0.790	rs6058283	chr20:34216276	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.22	0.32	2.17e-12	Total cholesterol levels;
LGG	cis	rs2046867	0.818	rs7637138	chr3:72910886	A/G	cg26655873	chr3:72818019	SHQ1	0.35	7.07	0.31	5.6e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1355223	0.902	rs4465347	chr11:34727333	C/T	cg11058730	chr11:34937778	PDHX;APIP	-0.4	-6.7	-0.3	6.1e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2439831	0.681	rs2278858	chr15:43632755	G/T	cg15269541	chr15:43626905	ADAL	-0.43	-6.97	-0.31	1.07e-11	Lung cancer in ever smokers;
LGG	cis	rs2153535	0.580	rs915350	chr6:8443486	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.96	0.38	8.1e-18	Motion sickness;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22043361	chr14:64970199	ZBTB1;ZBTB25	0.41	6.94	0.31	1.29e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs12599106	0.680	rs34728702	chr16:34896584	A/G	cg01516881	chr6:292596	DUSP22	-0.69	-11.68	-0.48	8.61e-28	Menopause (age at onset);
LGG	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07343612	chr16:622815	PIGQ	-0.77	-15.76	-0.59	3.97e-45	Height;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07149862	chr1:185286441	IVNS1ABP	0.48	7.35	0.32	9.05e-13	Gut microbiome composition (summer);
LGG	cis	rs584438	0.873	rs598892	chr17:38600092	G/A	cg09358481	chr17:38600305	IGFBP4	-0.46	-8.7	-0.37	5.98e-17	Height;
LGG	cis	rs9368481	0.761	rs6918835	chr6:27017827	T/G	cg18867708	chr6:26865862	GUSBL1	-0.44	-7.13	-0.31	3.8e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10752881	1.000	rs10737235	chr1:182971816	T/C	cg15522984	chr1:182991683	LAMC1	0.49	10.07	0.42	1.04e-21	Colorectal cancer;
LGG	cis	rs6121246	0.559	rs6060952	chr20:30382108	T/G	cg13852791	chr20:30311386	BCL2L1	0.93	17.93	0.64	5.8e-55	Mean corpuscular hemoglobin;
LGG	cis	rs3790455	0.965	rs3818463	chr1:156453441	C/T	cg14087168	chr1:156450669	MEF2D	0.47	7.73	0.34	6.61e-14	Migraine;
LGG	cis	rs798554	0.757	rs2533882	chr7:2846894	G/T	cg13628971	chr7:2884303	GNA12	0.51	10.26	0.43	2.24e-22	Height;
LGG	cis	rs79976124	0.797	rs78317899	chr6:66652896	C/A	cg07460842	chr6:66804631	NA	0.73	12.6	0.51	1.7e-31	Type 2 diabetes;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg19147804	chr7:1989927	MAD1L1	-0.6	-11.85	-0.48	1.8e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs2839186	0.588	rs2839140	chr21:47616080	G/A	cg08742575	chr21:47604166	C21orf56	-0.53	-8.94	-0.38	9.62e-18	Testicular germ cell tumor;
LGG	cis	rs8014204	0.720	rs34752362	chr14:75232306	G/A	cg03030879	chr14:75389066	RPS6KL1	-0.39	-7.1	-0.31	4.63e-12	Caffeine consumption;
LGG	cis	rs7937682	0.961	rs17113227	chr11:111620491	A/G	cg19812747	chr11:111475976	SIK2	-0.44	-8.72	-0.38	5.2e-17	Primary sclerosing cholangitis;
LGG	cis	rs9534288	0.797	rs7990238	chr13:46578379	T/C	cg15192986	chr13:46630673	CPB2	-0.6	-13.2	-0.52	5.41e-34	Blood protein levels;
LGG	cis	rs738321	0.658	rs5756916	chr22:38507047	G/A	cg25457927	chr22:38595422	NA	-0.37	-8.48	-0.37	2.98e-16	Breast cancer;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg02840092	chr6:168748530	NA	0.36	6.77	0.3	3.93e-11	Pancreatic cancer;
LGG	cis	rs2916247	1.000	rs11785362	chr8:93045784	G/A	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.16	-0.35	3.12e-15	Intelligence (multi-trait analysis);
LGG	cis	rs4262150	0.544	rs4391147	chr5:151898364	G/C	cg12297329	chr5:152029980	NA	-0.64	-11.6	-0.47	1.75e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg21782813	chr7:2030301	MAD1L1	0.49	11.72	0.48	5.96e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.741	rs6674078	chr1:248543026	G/A	cg13385794	chr1:248469461	NA	0.45	7.91	0.35	1.86e-14	Common traits (Other);
LGG	cis	rs9290877	0.580	rs1568670	chr3:188467161	T/C	cg17392043	chr3:188495102	LPP	-0.45	-7.97	-0.35	1.28e-14	IgE levels;
LGG	cis	rs240764	0.817	rs12216304	chr6:101174161	A/G	cg09795085	chr6:101329169	ASCC3	-0.46	-7.69	-0.34	9.12e-14	Neuroticism;
LGG	cis	rs9309473	0.607	rs1522926	chr2:73591241	T/C	cg20560298	chr2:73613845	ALMS1	-0.47	-8.51	-0.37	2.35e-16	Metabolite levels;
LGG	trans	rs7246760	0.867	rs57999229	chr19:9817357	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	cis	rs11190604	1.000	rs2295772	chr10:102265183	G/A	cg07080220	chr10:102295463	HIF1AN	0.69	11.85	0.48	1.75e-28	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04969808	chr3:13922158	WNT7A	0.43	6.86	0.3	2.24e-11	Gut microbiome composition (summer);
LGG	trans	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg13565492	chr6:43139072	SRF	-0.72	-8.81	-0.38	2.58e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs35110281	0.807	rs2838328	chr21:45023234	G/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.18	-0.39	1.47e-18	Mean corpuscular volume;
LGG	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.8	-0.3	3.3e-11	Body mass index;
LGG	cis	rs7100689	0.516	rs10788546	chr10:82034854	T/C	cg01528321	chr10:82214614	TSPAN14	0.8	13.6	0.53	1.06e-35	Post bronchodilator FEV1;
LGG	cis	rs2204008	0.521	rs7311188	chr12:38542813	C/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.82	-0.45	1.79e-24	Bladder cancer;
LGG	cis	rs1790761	0.692	rs638140	chr11:67333858	G/C	cg09038676	chr11:67351608	GSTP1	-0.36	-7.24	-0.32	1.87e-12	Mean corpuscular volume;
LGG	cis	rs9398803	0.687	rs9401897	chr6:126940641	A/G	cg19875578	chr6:126661172	C6orf173	0.52	9.68	0.41	2.68e-20	Male-pattern baldness;
LGG	cis	rs72781680	0.768	rs112139157	chr2:24150783	A/C	cg08917208	chr2:24149416	ATAD2B	0.66	8.67	0.37	7.33e-17	Lymphocyte counts;
LGG	cis	rs4750440	0.576	rs2447011	chr10:14032199	C/T	cg27542038	chr10:14027202	FRMD4A	-0.53	-10.14	-0.43	5.73e-22	Adiponectin levels;
LGG	cis	rs11608355	0.545	rs2302708	chr12:109893726	A/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs1129187	0.805	rs1053538	chr6:42903763	C/G	cg24101359	chr6:42928495	GNMT	0.46	12.84	0.51	1.63e-32	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg02002194	chr4:3960332	NA	-0.42	-7.82	-0.34	3.7e-14	Neuroticism;
LGG	cis	rs933688	0.532	rs12514092	chr5:90540522	T/G	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.52	-6.71	-0.3	5.6e-11	Smoking behavior;
LGG	cis	rs11122272	0.735	rs2572252	chr1:231513653	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs9902453	0.817	rs67206808	chr17:28190096	A/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.31	0.53	1.92e-34	Coffee consumption (cups per day);
LGG	cis	rs7765175	0.549	rs3963345	chr6:113655376	G/C	cg26552650	chr6:113682475	NA	0.33	7.3	0.32	1.24e-12	Coronary artery calcification;
LGG	cis	rs2204008	0.744	rs11180504	chr12:38236313	C/T	cg13010199	chr12:38710504	ALG10B	0.67	13.19	0.52	6.23e-34	Bladder cancer;
LGG	cis	rs7565124	0.955	rs11674278	chr2:20266381	C/T	cg24657347	chr2:20261756	NA	-0.76	-14.85	-0.57	4.47e-41	Major depressive disorder;
LGG	cis	rs4846580	0.660	rs1416004	chr1:219906274	G/A	cg08034750	chr1:219919793	NA	0.41	7.29	0.32	1.35e-12	Total body bone mineral density;
LGG	trans	rs61931739	0.500	rs7484658	chr12:34515879	A/G	cg26384229	chr12:38710491	ALG10B	0.85	18.43	0.65	2.76e-57	Morning vs. evening chronotype;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg01171360	chr6:293285	DUSP22	-0.59	-9.82	-0.42	8.61e-21	Menopause (age at onset);
LGG	cis	rs3820068	0.580	rs7512308	chr1:16006604	C/A	cg05660106	chr1:15850417	CASP9	0.74	13.35	0.53	1.32e-34	Systolic blood pressure;
LGG	cis	rs9467773	1.000	rs3736781	chr6:26505362	G/A	cg11502198	chr6:26597334	ABT1	0.54	9.35	0.4	3.64e-19	Intelligence (multi-trait analysis);
LGG	cis	rs7095944	0.614	rs10901817	chr10:126443404	A/T	cg08799069	chr10:126477246	METTL10	-0.48	-10.78	-0.45	2.43e-24	Asthma;
LGG	cis	rs35740288	0.822	rs2306225	chr15:86227952	A/G	cg04173714	chr15:86211321	AKAP13	0.47	8.09	0.35	5.45e-15	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs9611565	0.659	rs4822037	chr22:41945113	G/T	cg06634786	chr22:41940651	POLR3H	-0.83	-13.39	-0.53	8.84e-35	Vitiligo;
LGG	trans	rs35110281	0.811	rs1122873	chr21:45044672	G/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.2	0.49	6.83e-30	Mean corpuscular volume;
LGG	cis	rs2933343	0.621	rs883843	chr3:128567383	C/T	cg25356066	chr3:128598488	ACAD9	-0.45	-6.78	-0.3	3.75e-11	IgG glycosylation;
LGG	cis	rs1408799	0.711	rs10960726	chr9:12627999	G/A	cg05274944	chr9:12693694	TYRP1	0.33	7.7	0.34	8.55e-14	Eye color;Blue vs. green eyes;
LGG	cis	rs7949030	0.626	rs11231141	chr11:62326265	T/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.31	0.6	1.33e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2559856	0.967	rs2695290	chr12:102087844	A/G	cg15068132	chr12:102092402	CHPT1	0.37	6.8	0.3	3.26e-11	Blood protein levels;
LGG	cis	rs4853012	0.838	rs6715351	chr2:74346119	G/A	cg05890377	chr2:74357713	NA	0.48	9.81	0.41	8.91e-21	Gestational age at birth (maternal effect);
LGG	cis	rs2439831	1.000	rs2467740	chr15:43746792	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.54	0.5	2.93e-31	Lung cancer in ever smokers;
LGG	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg01842473	chr11:617407	IRF7;MUPCDH	-0.54	-7.49	-0.33	3.55e-13	Systemic lupus erythematosus;
LGG	cis	rs6598955	1.000	rs10902728	chr1:26598281	T/C	cg04990556	chr1:26633338	UBXN11	0.75	14.2	0.55	2.98e-38	Obesity-related traits;
LGG	cis	rs60871478	0.679	rs6962050	chr7:817201	A/G	cg05535760	chr7:792225	HEATR2	0.96	14.74	0.57	1.29e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs2576037	0.796	rs2571033	chr18:44578552	C/T	cg23302884	chr18:44338147	ST8SIA5	0.36	6.97	0.31	1.12e-11	Personality dimensions;
LGG	trans	rs11992162	0.967	rs10112888	chr8:11830208	G/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.96	0.35	1.34e-14	Monocyte count;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg09699651	chr6:150184138	LRP11	0.5	8.78	0.38	3.23e-17	Lung cancer;
LGG	trans	rs2204008	0.583	rs12820907	chr12:37990931	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs9486715	0.825	rs211158	chr6:97022938	C/G	cg18709589	chr6:96969512	KIAA0776	-0.43	-8.29	-0.36	1.2e-15	Headache;
LGG	cis	rs1348850	0.561	rs57986285	chr2:178468663	C/T	cg22681709	chr2:178499509	PDE11A	-0.47	-6.82	-0.3	2.93e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2130392	0.926	rs10428357	chr4:185636217	T/A	cg04058563	chr4:185651563	MLF1IP	0.47	10.04	0.42	1.31e-21	Kawasaki disease;
LGG	cis	rs10782582	0.609	rs5745347	chr1:76274520	C/T	cg10523679	chr1:76189770	ACADM	0.41	6.66	0.3	8.02e-11	Daytime sleep phenotypes;
LGG	cis	rs1552244	1.000	rs12374115	chr3:10134766	A/G	cg16606324	chr3:10149918	C3orf24	-0.51	-6.68	-0.3	6.83e-11	Alzheimer's disease;
LGG	cis	rs9419702	0.568	rs9419635	chr10:133546164	C/T	cg20568497	chr10:133558893	NA	0.34	7.49	0.33	3.45e-13	Survival in rectal cancer;
LGG	cis	rs7737355	0.738	rs7710364	chr5:130842724	T/C	cg06307176	chr5:131281290	NA	0.5	8.47	0.37	3.4e-16	Life satisfaction;
LGG	cis	rs9902453	1.000	rs9890205	chr17:28382704	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	cis	rs7503807	0.515	rs12601001	chr17:78681084	T/C	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs876084	1.000	rs876084	chr8:121101522	A/G	cg22335954	chr8:121166405	COL14A1	-0.31	-7.04	-0.31	6.99e-12	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4808199	0.948	rs968525	chr19:19459215	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.22	0.32	2.16e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs875971	0.790	rs10257911	chr7:65743770	A/G	cg18252515	chr7:66147081	NA	0.44	7.46	0.33	4.44e-13	Aortic root size;
LGG	cis	rs7503807	0.688	rs901062	chr17:78595674	C/T	cg06872548	chr17:78716983	RPTOR	0.39	8.56	0.37	1.65e-16	Obesity;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14189758	chr20:36156486	BLCAP	-0.42	-7.03	-0.31	7.6e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs1799949	0.930	rs35292991	chr17:41334016	C/A	cg12708336	chr17:41446283	NA	-0.32	-7.52	-0.33	2.93e-13	Menopause (age at onset);
LGG	cis	rs11229555	0.645	rs11229442	chr11:58196790	C/T	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs977987	0.832	rs37597	chr16:75500275	T/G	cg07303275	chr16:75499416	TMEM170A	-0.44	-7.84	-0.34	3.13e-14	Dupuytren's disease;
LGG	cis	rs17376456	0.877	rs34184666	chr5:93444584	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.95	10.29	0.43	1.65e-22	Diabetic retinopathy;
LGG	cis	rs7191439	0.858	rs4390574	chr16:88776297	T/C	cg27087555	chr16:88793112	FAM38A	-1.34	-16.9	-0.62	2.91e-50	Plateletcrit;
LGG	cis	rs8028182	0.636	rs11636031	chr15:75815758	T/C	cg20655648	chr15:75932815	IMP3	0.45	7.53	0.33	2.74e-13	Sudden cardiac arrest;
LGG	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg00071950	chr4:10020882	SLC2A9	0.36	7.37	0.32	7.9e-13	Bone mineral density;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg18379455	chr17:41446167	NA	-0.3	-6.9	-0.31	1.77e-11	Menopause (age at onset);
LGG	cis	rs4731207	0.596	rs1026837	chr7:124673079	C/T	cg05630886	chr7:124431682	NA	-0.31	-7.13	-0.31	3.91e-12	Cutaneous malignant melanoma;
LGG	cis	rs9522267	0.535	rs914037	chr13:112235308	A/G	cg12773197	chr13:112238673	NA	-0.36	-7.3	-0.32	1.28e-12	Hepatitis;
LGG	cis	rs4925386	0.921	rs11204472	chr20:60920887	G/A	cg06026331	chr20:60912101	LAMA5	-0.46	-8.82	-0.38	2.31e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs9325144	0.560	rs11183090	chr12:38662293	G/C	cg13010199	chr12:38710504	ALG10B	-0.61	-12.47	-0.5	5.52e-31	Morning vs. evening chronotype;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14797243	chr11:68671428	IGHMBP2;MRPL21	0.48	7.8	0.34	4.16e-14	Gut microbiome composition (summer);
LGG	cis	rs4774899	1.000	rs12899915	chr15:57302608	A/G	cg08128148	chr15:57256372	TCF12	-0.33	-7.98	-0.35	1.16e-14	Urinary tract infection frequency;
LGG	cis	rs1005277	0.579	rs2474584	chr10:38416389	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.18	-0.32	2.81e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2239547	0.522	rs6771610	chr3:53026104	T/C	cg11645453	chr3:52864694	ITIH4	0.67	10.45	0.44	4.13e-23	Schizophrenia;
LGG	trans	rs7824557	0.564	rs7828263	chr8:11231886	A/G	cg16141378	chr3:129829833	LOC729375	0.36	7.89	0.34	2.25e-14	Retinal vascular caliber;
LGG	trans	rs9354308	0.764	rs1938073	chr6:66583387	C/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.41	6.85	0.3	2.38e-11	Metabolite levels;
LGG	cis	rs16976116	0.901	rs56328329	chr15:55502977	A/T	cg11288833	chr15:55489084	RSL24D1	0.56	7.51	0.33	3.17e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs11098499	0.909	rs10017335	chr4:120381523	C/G	cg09307838	chr4:120376055	NA	-0.81	-13.33	-0.53	1.59e-34	Corneal astigmatism;
LGG	cis	rs6088590	0.561	rs6087600	chr20:33157217	T/C	cg06115741	chr20:33292138	TP53INP2	0.51	8.59	0.37	1.35e-16	Coronary artery disease;
LGG	cis	rs7587476	0.601	rs1129804	chr2:215674323	C/G	cg04004882	chr2:215674386	BARD1	-0.54	-8.42	-0.36	4.71e-16	Neuroblastoma;
LGG	cis	rs7177699	0.557	rs10083697	chr15:79124039	G/A	cg00540400	chr15:79124168	NA	-0.54	-11.43	-0.47	7.77e-27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.43	-0.33	5.24e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2952156	0.883	rs2941505	chr17:37832704	A/G	cg07936489	chr17:37558343	FBXL20	-0.47	-7.96	-0.35	1.34e-14	Asthma;
LGG	cis	rs6951245	0.706	rs28483034	chr7:1170171	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.93	-17.31	-0.63	3.8e-52	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504130	0.569	rs34073804	chr8:52689368	C/T	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs41271473	1.000	rs17352654	chr1:228878193	T/C	cg10167378	chr1:228756711	NA	0.56	8.02	0.35	8.82e-15	Chronic lymphocytic leukemia;
LGG	trans	rs7829975	0.782	rs6990746	chr8:8547811	A/G	cg16141378	chr3:129829833	LOC729375	0.47	11.05	0.46	2.39e-25	Mood instability;
LGG	cis	rs17253792	0.545	rs3742570	chr14:56016434	A/C	cg01858014	chr14:56050164	KTN1	-0.76	-9.43	-0.4	1.99e-19	Putamen volume;
LGG	cis	rs4253772	0.678	rs1053332	chr22:46640179	A/G	cg24881330	chr22:46731750	TRMU	0.58	7.34	0.32	9.37e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg21926612	chr6:163149169	PACRG;PARK2	1.11	12.49	0.5	4.53e-31	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs7395662	1.000	rs11039854	chr11:48607688	G/A	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.79e-15	HDL cholesterol;
LGG	cis	rs11209002	0.522	rs2224502	chr1:67539439	A/G	cg02640540	chr1:67518911	SLC35D1	0.39	6.65	0.3	8.13e-11	Crohn's disease;
LGG	cis	rs36071027	0.615	rs57523915	chr5:158434036	G/T	cg23468002	chr5:158532401	NA	0.42	7.04	0.31	7.11e-12	Carotid intima media thickness;
LGG	cis	rs782590	0.620	rs4322879	chr2:55797033	G/T	cg18811423	chr2:55921094	PNPT1	-0.68	-12.28	-0.5	3.26e-30	Metabolic syndrome;
LGG	trans	rs9951602	0.512	rs12607561	chr18:76644284	G/A	cg02800362	chr5:177631904	HNRNPAB	0.76	13.05	0.52	2.35e-33	Obesity-related traits;
LGG	cis	rs2985684	1.000	rs3007030	chr14:50086563	C/T	cg04989706	chr14:50066350	PPIL5	-0.53	-8.37	-0.36	6.89e-16	Carotid intima media thickness;
LGG	cis	rs11711311	0.712	rs2271498	chr3:113334752	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.57	11.63	0.48	1.3e-27	IgG glycosylation;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg08677398	chr8:58056175	NA	0.45	7.15	0.32	3.33e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4330281	0.669	rs35697509	chr3:17763957	G/T	cg20981856	chr3:17787350	NA	-0.39	-7.3	-0.32	1.3e-12	Schizophrenia;
LGG	trans	rs7395662	1.000	rs4882015	chr11:48565573	A/T	cg00717180	chr2:96193071	NA	-0.43	-7.62	-0.33	1.43e-13	HDL cholesterol;
LGG	cis	rs8032158	0.702	rs2288345	chr15:56122461	T/C	cg02198044	chr15:56286336	NEDD4	-0.53	-9.02	-0.39	5.15e-18	Keloid;
LGG	cis	rs4474465	0.915	rs12288436	chr11:78161430	T/C	cg02023728	chr11:77925099	USP35	0.38	6.72	0.3	5.49e-11	Alzheimer's disease (survival time);
LGG	cis	rs7973719	0.833	rs7962563	chr12:7353514	G/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.31	-7.97	-0.35	1.26e-14	IgG glycosylation;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg18000306	chr6:288505	NA	0.61	10.93	0.45	6.69e-25	Menopause (age at onset);
LGG	cis	rs2239547	0.522	rs2336669	chr3:52994138	C/T	cg11645453	chr3:52864694	ITIH4	-0.68	-10.66	-0.44	7.33e-24	Schizophrenia;
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-8.18	-0.36	2.71e-15	Systolic blood pressure;
LGG	cis	rs3820928	0.874	rs55743026	chr2:227802813	G/A	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.85	-0.34	2.93e-14	Pulmonary function;
LGG	cis	rs1552244	0.572	rs59132826	chr3:10169725	G/A	cg13047869	chr3:10149882	C3orf24	0.58	8.43	0.36	4.31e-16	Alzheimer's disease;
LGG	trans	rs7829975	0.514	rs2976926	chr8:8261624	T/C	cg02002194	chr4:3960332	NA	-0.5	-9.81	-0.41	8.88e-21	Mood instability;
LGG	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.66	12.06	0.49	2.57e-29	Personality dimensions;
LGG	cis	rs77741769	0.571	rs11065324	chr12:121346795	C/G	cg02419362	chr12:121203948	SPPL3	-0.54	-9.27	-0.4	6.94e-19	Mean corpuscular volume;
LGG	cis	rs12282928	0.959	rs7120768	chr11:48264835	T/A	cg26585981	chr11:48327164	OR4S1	0.45	7.21	0.32	2.24e-12	Migraine - clinic-based;
LGG	cis	rs988958	0.600	rs10189068	chr2:42247361	G/A	cg27252766	chr2:42229092	NA	0.52	7.84	0.34	3.07e-14	Hypospadias;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22068764	chr1:170501645	GORAB	0.46	7.84	0.34	3.15e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs8141529	0.732	rs2239815	chr22:29192670	C/T	cg02153584	chr22:29168773	CCDC117	-0.69	-11.57	-0.47	2.27e-27	Lymphocyte counts;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.38	8.85	0.38	1.79e-17	Schizophrenia;
LGG	cis	rs2228479	0.702	rs3819574	chr16:89826630	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs2108225	1.000	rs989960	chr7:107445727	C/T	cg18560240	chr7:107437656	SLC26A3	-0.52	-9.34	-0.4	3.91e-19	Ulcerative colitis;
LGG	cis	rs9291683	0.609	rs13141233	chr4:10028729	T/C	cg08250081	chr4:10125330	NA	0.41	7.96	0.35	1.35e-14	Bone mineral density;
LGG	cis	rs910316	0.664	rs2098252	chr14:75492732	T/C	cg08847533	chr14:75593920	NEK9	0.55	10.35	0.43	9.91e-23	Height;
LGG	cis	rs12497850	0.931	rs7636057	chr3:48992582	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.97	0.45	4.86e-25	Parkinson's disease;
LGG	cis	rs4740619	0.689	rs10810502	chr9:15952197	C/T	cg14451791	chr9:16040625	NA	-0.41	-10.11	-0.43	7.51e-22	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01947862	chr2:86116624	ST3GAL5	0.47	7.37	0.32	7.67e-13	Gut microbiome composition (summer);
LGG	cis	rs8067545	0.611	rs11653869	chr17:20197586	T/G	cg13482628	chr17:19912719	NA	-0.54	-10.15	-0.43	5.42e-22	Schizophrenia;
LGG	trans	rs9329221	0.527	rs7833781	chr8:10333477	A/G	cg06636001	chr8:8085503	FLJ10661	0.54	9.49	0.4	1.2e-19	Neuroticism;
LGG	cis	rs7666738	0.791	rs2903151	chr4:99027218	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.44	0.37	4.16e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11764590	0.694	rs56072378	chr7:2104364	A/G	cg02825527	chr7:2087843	MAD1L1	-0.38	-7.5	-0.33	3.33e-13	Neuroticism;
LGG	cis	rs644799	1.000	rs651445	chr11:95539122	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs769267	0.930	rs1063966	chr19:19616742	G/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.21	0.43	3.31e-22	Tonsillectomy;
LGG	cis	rs7726839	0.526	rs11960159	chr5:568685	C/T	cg09021430	chr5:549028	NA	-0.81	-13.0	-0.52	3.6e-33	Obesity-related traits;
LGG	cis	rs2386661	0.591	rs11255051	chr10:5653450	A/G	cg17085576	chr10:5658249	NA	-0.38	-7.18	-0.32	2.72e-12	Breast cancer;
LGG	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg02227867	chr8:22457446	C8orf58	-0.46	-8.86	-0.38	1.73e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs4819052	0.851	rs2838832	chr21:46664904	A/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.54	-8.92	-0.38	1.05e-17	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2976388	0.609	rs1594999	chr8:143790574	G/A	cg06565975	chr8:143823917	SLURP1	0.35	9.09	0.39	2.97e-18	Urinary tract infection frequency;
LGG	trans	rs1814175	0.904	rs1846289	chr11:49620253	G/A	cg03929089	chr4:120376271	NA	-1.02	-22.5	-0.72	2.84e-76	Height;
LGG	cis	rs2115536	1.000	rs7163338	chr15:80198408	C/G	cg00225070	chr15:80189496	MTHFS	0.37	6.9	0.31	1.69e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs875971	0.660	rs10215132	chr7:66054406	C/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.67	-0.41	2.76e-20	Aortic root size;
LGG	cis	rs9611565	0.802	rs73176692	chr22:41785735	G/A	cg06634786	chr22:41940651	POLR3H	-0.74	-12.46	-0.5	6.18e-31	Vitiligo;
LGG	cis	rs6867032	0.695	rs3902820	chr5:2000330	T/A	cg26168224	chr5:2018326	NA	-1.12	-20.46	-0.69	1.01e-66	Gut microbiome composition (winter);
LGG	cis	rs4731207	0.596	rs1904973	chr7:124669547	G/A	cg05630886	chr7:124431682	NA	-0.31	-7.1	-0.31	4.85e-12	Cutaneous malignant melanoma;
LGG	cis	rs12135191	0.933	rs7528504	chr1:236471577	C/T	cg21399712	chr1:236511386	NA	-0.4	-7.72	-0.34	7.33e-14	Urate levels (BMI interaction);
LGG	cis	rs2227564	0.574	rs3849969	chr10:75525999	C/T	cg00564723	chr10:75632066	CAMK2G	0.45	9.78	0.41	1.18e-20	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs826838	0.967	rs4768330	chr12:39129399	T/C	cg13010199	chr12:38710504	ALG10B	-0.67	-14.27	-0.55	1.48e-38	Heart rate;
LGG	cis	rs1008375	0.932	rs10029173	chr4:17659598	C/T	cg02297831	chr4:17616191	MED28	-0.48	-8.73	-0.38	4.62e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs5769765	0.542	rs5769751	chr22:50242733	T/G	cg02269571	chr22:50332266	NA	0.84	9.41	0.4	2.35e-19	Schizophrenia;
LGG	cis	rs533581	0.866	rs871756	chr16:88969076	G/C	cg16701003	chr16:89028210	CBFA2T3	0.53	8.15	0.35	3.39e-15	Social autistic-like traits;
LGG	cis	rs7923609	0.561	rs6479906	chr10:65315486	C/G	cg02276361	chr10:65351566	REEP3	-0.32	-7.02	-0.31	8.08e-12	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg26116260	chr4:7069785	GRPEL1	-0.78	-7.05	-0.31	6.37e-12	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4474465	1.000	rs2063729	chr11:78185969	C/T	cg02023728	chr11:77925099	USP35	0.39	6.82	0.3	2.79e-11	Alzheimer's disease (survival time);
LGG	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg13770153	chr20:60521292	NA	-0.42	-7.01	-0.31	8.52e-12	Body mass index;
LGG	cis	rs8062405	0.823	rs7202948	chr16:28558289	T/A	cg07382826	chr16:28625726	SULT1A1	0.39	8.44	0.37	3.99e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22830663	chr2:131975750	POTEE	0.35	6.74	0.3	4.87e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs55714371	chr8:58131846	T/G	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs12142240	0.698	rs72677585	chr1:46812374	T/C	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.46e-15	Menopause (age at onset);
LGG	cis	rs1965732	1.000	rs11696000	chr2:3709907	A/G	cg20493526	chr2:3714936	ALLC	0.37	7.8	0.34	4.27e-14	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs75920871	0.920	rs61905687	chr11:116862144	T/C	cg20608306	chr11:116969690	SIK3	-0.33	-7.02	-0.31	8.11e-12	Subjective well-being;
LGG	cis	rs2201728	0.702	rs13142106	chr4:100178151	G/A	cg07219303	chr4:100140905	ADH6	-0.37	-6.93	-0.31	1.4e-11	Cardiac Troponin-T levels;
LGG	cis	rs13108904	0.870	rs2291199	chr4:1244267	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.76	13.34	0.53	1.44e-34	Obesity-related traits;
LGG	cis	rs7172677	0.793	rs8029712	chr15:75418170	T/A	cg14664628	chr15:75095509	CSK	-0.45	-6.89	-0.31	1.77e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7824557	0.602	rs7819395	chr8:11211068	T/C	cg15596359	chr8:11213517	TDH	-0.4	-8.12	-0.35	4.25e-15	Retinal vascular caliber;
LGG	trans	rs4650994	0.544	rs4652301	chr1:178499799	T/C	cg05059571	chr16:84539110	KIAA1609	-0.58	-11.1	-0.46	1.5e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs8062405	0.824	rs62034319	chr16:28532188	T/G	cg09754948	chr16:28834200	ATXN2L	0.42	6.67	0.3	7.33e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs10504229	0.593	rs79615400	chr8:57988740	C/T	cg21724239	chr8:58056113	NA	0.53	7.62	0.33	1.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7819412	0.775	rs4841489	chr8:10936811	A/G	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.71	-0.41	2.12e-20	Triglycerides;
LGG	cis	rs933688	0.938	rs12110065	chr5:90718474	A/G	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.92	18.54	0.65	8.66e-58	Smoking behavior;
LGG	cis	rs10937275	0.826	rs35508867	chr3:186643240	C/T	cg24050613	chr3:186648279	ST6GAL1	0.83	8.66	0.37	8.08e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4664308	0.905	rs7567781	chr2:160999537	A/G	cg03641300	chr2:160917029	PLA2R1	-0.84	-17.1	-0.62	3.5e-51	Idiopathic membranous nephropathy;
LGG	cis	rs2857078	0.745	rs4793085	chr17:42320732	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.39	-6.77	-0.3	3.88e-11	Red cell distribution width;Reticulocyte count;
LGG	cis	rs9858542	0.953	rs6766581	chr3:49539401	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.82	0.42	8.35e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg07701084	chr6:150067640	NUP43	0.65	12.28	0.5	3.2e-30	Lung cancer;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.35	7.63	0.33	1.33e-13	Schizophrenia;
LGG	cis	rs698833	0.828	rs2165421	chr2:44526010	G/A	cg00619915	chr2:44497795	NA	-0.44	-6.84	-0.3	2.54e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs9303280	0.773	rs11078925	chr17:38025208	T/C	cg17467752	chr17:38218738	THRA	-0.44	-7.01	-0.31	8.42e-12	Self-reported allergy;
LGG	cis	rs6582630	0.502	rs3902522	chr12:38271203	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.11	0.31	4.31e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07362569	chr17:61921086	SMARCD2	0.5	9.82	0.42	8.41e-21	Prudent dietary pattern;
LGG	cis	rs9964724	0.865	rs12709690	chr18:35165852	T/C	cg27332583	chr18:35150602	NA	-0.42	-8.99	-0.39	6.16e-18	Educational attainment (years of education);
LGG	cis	rs875971	0.767	rs1695815	chr7:65831344	A/G	cg12463550	chr7:65579703	CRCP	0.52	8.72	0.38	5e-17	Aortic root size;
LGG	cis	rs8072100	0.967	rs4793842	chr17:45671506	G/A	cg19784903	chr17:45786737	TBKBP1	0.37	8.22	0.36	2.01e-15	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg06873352	chr17:61820015	STRADA	0.73	13.76	0.54	2.28e-36	Prudent dietary pattern;
LGG	cis	rs8028313	0.630	rs3784700	chr15:68017752	A/G	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.67	-0.34	1.05e-13	Obesity;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg26174226	chr8:58114915	NA	-0.6	-8.42	-0.36	4.75e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7301826	0.651	rs7971046	chr12:131286807	G/A	cg11011512	chr12:131303247	STX2	0.41	8.89	0.38	1.38e-17	Plasma plasminogen activator levels;
LGG	cis	rs8077889	0.871	rs7212648	chr17:41917962	A/C	cg26893861	chr17:41843967	DUSP3	0.93	15.7	0.59	8.04e-45	Triglycerides;
LGG	trans	rs9354308	0.764	rs1604019	chr6:66571977	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.41	-7.03	-0.31	7.63e-12	Metabolite levels;
LGG	cis	rs283228	1.000	rs283215	chr6:101762241	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.96	0.38	8.08e-18	Coenzyme Q10 levels;
LGG	cis	rs12220238	1.000	rs11000931	chr10:75984800	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.8	-10.6	-0.44	1.21e-23	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs1355223	0.506	rs1828299	chr11:34870418	T/C	cg11058730	chr11:34937778	PDHX;APIP	-0.51	-8.36	-0.36	7.56e-16	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs7937612	1.000	rs9633950	chr11:120248249	T/G	cg24566217	chr11:120254723	ARHGEF12	-0.54	-12.89	-0.51	1.03e-32	Intraocular pressure;
LGG	cis	rs79349575	0.783	rs55771415	chr17:46999937	C/T	cg16584676	chr17:46985605	UBE2Z	0.48	8.29	0.36	1.28e-15	Type 2 diabetes;
LGG	cis	rs10865541	0.902	rs6739163	chr2:3419011	G/A	cg13173536	chr2:3403300	TTC15	-0.33	-6.85	-0.3	2.42e-11	Obesity-related traits;
LGG	cis	rs975722	0.646	rs756665	chr7:117128942	A/C	cg10524701	chr7:117356490	CTTNBP2	0.45	9.92	0.42	3.54e-21	Coronary artery disease;
LGG	cis	rs3820068	0.705	rs4646083	chr1:15825564	G/A	cg05660106	chr1:15850417	CASP9	1.11	26.82	0.78	2.77e-96	Systolic blood pressure;
LGG	cis	rs2737618	0.674	rs2816973	chr1:200084743	C/G	cg21825944	chr1:200113062	NR5A2	0.61	12.0	0.49	4.4e-29	Uric acid levels;
LGG	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg20991723	chr1:152506922	NA	-0.71	-14.64	-0.56	3.67e-40	Hair morphology;
LGG	cis	rs12586317	0.547	rs112138868	chr14:35444385	C/T	cg16230307	chr14:35515116	FAM177A1	0.92	13.43	0.53	5.81e-35	Psoriasis;
LGG	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg18854424	chr1:2615690	NA	-0.37	-7.82	-0.34	3.48e-14	Ulcerative colitis;
LGG	cis	rs7617773	1.000	rs11711766	chr3:48193170	G/C	cg11946769	chr3:48343235	NME6	-0.54	-8.58	-0.37	1.47e-16	Coronary artery disease;
LGG	cis	rs4481887	0.772	rs4916127	chr1:248466615	A/G	cg01631408	chr1:248437212	OR2T33	-0.53	-9.66	-0.41	3.22e-20	Common traits (Other);
LGG	cis	rs7552404	0.924	rs1146588	chr1:76229787	C/G	cg10523679	chr1:76189770	ACADM	0.75	14.1	0.55	8.24e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs7727544	0.684	rs272889	chr5:131665378	A/G	cg24060327	chr5:131705240	SLC22A5	-0.49	-8.38	-0.36	6.37e-16	Blood metabolite levels;
LGG	cis	rs7618915	0.547	rs10865973	chr3:52718154	A/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.12	-0.31	4.09e-12	Bipolar disorder;
LGG	cis	rs41278232	1.000	rs3764735	chr20:62668732	A/G	cg03065311	chr20:62601662	ZNF512B	0.64	9.05	0.39	3.89e-18	Tonsillectomy;
LGG	cis	rs17776563	0.887	rs72761998	chr15:89125207	G/T	cg05013243	chr15:89149849	MIR1179	-0.5	-10.43	-0.44	5.32e-23	Thyroid hormone levels;
LGG	cis	rs6952808	0.531	rs3778998	chr7:2180753	C/A	cg19147804	chr7:1989927	MAD1L1	-0.49	-9.75	-0.41	1.45e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs8017423	0.935	rs11626869	chr14:90788985	A/G	cg04374321	chr14:90722782	PSMC1	-0.88	-17.74	-0.64	4.01e-54	Mortality in heart failure;
LGG	cis	rs457717	0.730	rs430389	chr5:75946260	A/G	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.8	0.3	3.14e-11	Hearing impairment;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14771734	chr5:79703670	ZFYVE16	0.49	7.47	0.33	4.02e-13	Gut microbiome composition (summer);
LGG	trans	rs28595532	0.545	rs13101451	chr4:119253427	A/G	cg26518628	chr1:97050305	NA	-0.71	-7.53	-0.33	2.71e-13	Cannabis dependence symptom count;
LGG	cis	rs5756391	0.546	rs4821565	chr22:37314415	C/T	cg21209356	chr22:37319042	CSF2RB	-0.4	-9.22	-0.39	1.04e-18	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs28595532	0.920	rs114584210	chr4:119773363	G/A	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs9287719	0.967	rs7563816	chr2:10763400	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.45	-0.33	4.67e-13	Prostate cancer;
LGG	trans	rs2832077	0.527	rs2705690	chr21:30239245	T/A	cg14791747	chr16:20752902	THUMPD1	-0.51	-9.09	-0.39	2.87e-18	Cognitive test performance;
LGG	cis	rs7618915	0.571	rs7623199	chr3:52605974	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.51	0.4	1.02e-19	Bipolar disorder;
LGG	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg13770153	chr20:60521292	NA	-0.49	-8.04	-0.35	7.31e-15	Body mass index;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg05863683	chr7:1912471	MAD1L1	0.44	9.04	0.39	4.17e-18	Bipolar disorder and schizophrenia;
LGG	trans	rs4332037	0.624	rs58169303	chr7:1883274	T/C	cg22232500	chr2:134024266	NCKAP5	0.56	8.03	0.35	7.99e-15	Bipolar disorder;
LGG	cis	rs28386778	0.863	rs2727288	chr17:61901197	T/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.46	0.44	3.9699999999999997e-23	Prudent dietary pattern;
LGG	trans	rs11146838	1	rs11146838	chr10:39149977	A/T	cg17830980	chr10:43048298	ZNF37B	-0.48	-10.56	-0.44	1.73e-23	Breast cancer;
LGG	cis	rs3816183	0.547	rs12996087	chr2:42725198	G/A	cg14631114	chr2:43023945	NA	0.43	7.89	0.34	2.25e-14	Hypospadias;
LGG	cis	rs898097	0.841	rs12453162	chr17:80859971	C/T	cg20578329	chr17:80767326	TBCD	-0.46	-7.91	-0.35	1.88e-14	Breast cancer;
LGG	cis	rs7107174	1.000	rs901104	chr11:77930499	C/T	cg27205649	chr11:78285834	NARS2	-0.45	-7.29	-0.32	1.36e-12	Testicular germ cell tumor;
LGG	cis	rs916888	0.821	rs70600	chr17:44860021	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.64	9.97	0.42	2.38e-21	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs933688	0.526	rs7727632	chr5:90609009	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	-0.81	-9.2	-0.39	1.27e-18	Smoking behavior;
LGG	cis	rs7084402	0.967	rs1649080	chr10:60293294	C/T	cg07615347	chr10:60278583	BICC1	0.63	17.84	0.64	1.4e-54	Refractive error;
LGG	cis	rs283228	0.535	rs2518181	chr6:101835744	G/A	cg27451362	chr6:101846650	GRIK2	0.97	14.94	0.57	1.85e-41	Coenzyme Q10 levels;
LGG	cis	rs3806843	1.000	rs2240694	chr5:140183058	G/A	cg19875535	chr5:140030758	IK	0.51	10.42	0.44	5.66e-23	Depressive symptoms (multi-trait analysis);
LGG	cis	rs8072100	0.875	rs62073966	chr17:45600013	T/A	cg19784903	chr17:45786737	TBKBP1	0.33	7.38	0.32	7.43e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1552244	0.882	rs7636817	chr3:10014876	G/T	cg13047869	chr3:10149882	C3orf24	0.45	7.42	0.33	5.68e-13	Alzheimer's disease;
LGG	cis	rs10870270	0.956	rs10430618	chr10:133748996	C/T	cg17892150	chr10:133769511	PPP2R2D	-0.66	-12.98	-0.52	4.58e-33	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs11690935	0.877	rs72890834	chr2:172835802	G/T	cg13550731	chr2:172543902	DYNC1I2	-1.04	-25.15	-0.76	1.21e-88	Schizophrenia;
LGG	cis	rs7914558	0.933	rs1538204	chr10:104733893	T/A	cg04362960	chr10:104952993	NT5C2	0.54	10.3	0.43	1.57e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs240764	0.658	rs9390685	chr6:101224725	A/T	cg09795085	chr6:101329169	ASCC3	0.47	8.21	0.36	2.2e-15	Neuroticism;
LGG	cis	rs4748857	0.782	rs1319250	chr10:23529098	C/T	cg18853376	chr10:23633759	C10orf67	0.36	6.71	0.3	5.83e-11	Systemic lupus erythematosus;
LGG	cis	rs4740619	0.935	rs4741535	chr9:15727144	A/G	cg14451791	chr9:16040625	NA	-0.38	-9.79	-0.41	1.12e-20	Body mass index;
LGG	cis	rs2549003	1.000	rs10214312	chr5:131821866	T/G	cg00578828	chr5:131826934	IRF1	0.41	7.41	0.33	5.98e-13	Asthma (sex interaction);
LGG	cis	rs2013441	0.931	rs12937827	chr17:20033202	G/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.69	-0.3	6.61e-11	Obesity-related traits;
LGG	cis	rs1552244	1.000	rs12152512	chr3:10143770	C/T	cg16606324	chr3:10149918	C3orf24	0.53	6.95	0.31	1.21e-11	Alzheimer's disease;
LGG	cis	rs896854	0.684	rs10098778	chr8:95992020	C/T	cg16049864	chr8:95962084	TP53INP1	-0.38	-8.53	-0.37	2.07e-16	Type 2 diabetes;
LGG	cis	rs2842992	0.789	rs4709370	chr6:160210061	A/G	cg19482086	chr6:160211437	TCP1;MRPL18	0.86	14.13	0.55	5.75e-38	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs10911251	0.546	rs2147578	chr1:183107699	G/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.63	0.37	1.01e-16	Colorectal cancer;
LGG	cis	rs28595532	0.920	rs115690307	chr4:119768289	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs758324	1.000	rs758324	chr5:131109545	G/T	cg06307176	chr5:131281290	NA	0.57	9.47	0.4	1.47e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs17767392	0.958	rs2109276	chr14:71889767	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-8.93	-0.38	9.91e-18	Mitral valve prolapse;
LGG	cis	rs10462794	0.853	rs1562825	chr5:4510983	C/T	cg18482690	chr5:4511582	NA	-0.42	-7.44	-0.33	4.89e-13	DNA methylation (variation);
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg20003494	chr4:90757398	SNCA	-0.41	-8.07	-0.35	6.03e-15	Dementia with Lewy bodies;
LGG	cis	rs7737355	0.898	rs4706024	chr5:130904163	G/A	cg06307176	chr5:131281290	NA	0.54	9.01	0.39	5.52e-18	Life satisfaction;
LGG	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg03959625	chr15:84868606	LOC388152	0.57	8.81	0.38	2.54e-17	Schizophrenia;
LGG	cis	rs12786942	0.569	rs4255512	chr11:101313991	A/T	cg03942599	chr11:101341554	TRPC6	0.49	7.35	0.32	8.98e-13	Facial depth;
LGG	cis	rs611744	0.550	rs1448154	chr8:109281053	T/C	cg18478394	chr8:109455254	TTC35	0.43	8.72	0.38	4.95e-17	Dupuytren's disease;
LGG	cis	rs709400	0.930	rs61996717	chr14:104048571	T/C	cg26031613	chr14:104095156	KLC1	1.18	27.8	0.79	9.65e-101	Body mass index;
LGG	cis	rs10845606	1.000	rs11055013	chr12:12829037	T/C	cg04607235	chr12:12878440	APOLD1	-0.53	-7.72	-0.34	7.05e-14	Systemic lupus erythematosus;
LGG	trans	rs2204008	0.702	rs8175764	chr12:38363690	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.84	-0.38	1.96e-17	Bladder cancer;
LGG	cis	rs8062405	0.895	rs62036658	chr16:28850371	T/G	cg09754948	chr16:28834200	ATXN2L	0.45	7.03	0.31	7.36e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs561341	1.000	rs55962687	chr17:30260369	C/T	cg13647721	chr17:30228624	UTP6	0.61	7.55	0.33	2.3e-13	Hip circumference adjusted for BMI;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs4891159	0.660	rs4891160	chr18:74102135	C/T	cg24786174	chr18:74118243	ZNF516	0.56	13.14	0.52	1e-33	Longevity;
LGG	cis	rs2251666	0.630	rs13334749	chr16:4952194	C/T	cg08329684	chr16:4932620	PPL	0.44	7.37	0.32	8.15e-13	Cancer;
LGG	cis	rs10504229	0.683	rs7464038	chr8:58111908	T/C	cg21724239	chr8:58056113	NA	0.51	7.75	0.34	6.07e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7937682	0.924	rs12791699	chr11:111505880	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.16	-26.6	-0.78	2.71e-95	Primary sclerosing cholangitis;
LGG	cis	rs1801251	0.964	rs10933411	chr2:233706847	A/G	cg08000102	chr2:233561755	GIGYF2	-0.56	-9.04	-0.39	4.35e-18	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs10073039	chr5:93467709	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.43	0.4	1.99e-19	Diabetic retinopathy;
LGG	trans	rs7829975	0.714	rs4840362	chr8:8670082	C/G	cg00405596	chr8:11794950	NA	-0.44	-7.53	-0.33	2.74e-13	Mood instability;
LGG	cis	rs2108225	0.900	rs4518594	chr7:107451060	G/C	cg18560240	chr7:107437656	SLC26A3	-0.54	-9.64	-0.41	3.69e-20	Ulcerative colitis;
LGG	cis	rs9399135	0.967	rs7741626	chr6:135314182	C/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs12477438	0.501	rs11899745	chr2:100064072	A/G	cg23527387	chr2:100056660	REV1	0.43	9.62	0.41	4.32e-20	Chronic sinus infection;
LGG	cis	rs12477438	0.501	rs6751927	chr2:99740175	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.85	18.48	0.65	1.53e-57	Chronic sinus infection;
LGG	cis	rs4332037	0.707	rs56070303	chr7:1891015	C/T	cg24189917	chr7:1970923	MAD1L1	-0.51	-7.86	-0.34	2.67e-14	Bipolar disorder;
LGG	cis	rs7937682	0.883	rs1784776	chr11:111472392	C/T	cg19812747	chr11:111475976	SIK2	-0.51	-10.71	-0.45	4.78e-24	Primary sclerosing cholangitis;
LGG	cis	rs9747201	0.963	rs11077983	chr17:80185188	C/T	cg14673194	chr17:80132900	CCDC57	-0.45	-7.92	-0.35	1.84e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11628318	0.614	rs7155883	chr14:103123404	A/C	cg12046867	chr14:103022105	NA	0.73	12.03	0.49	3.39e-29	Platelet count;
LGG	cis	rs7100689	0.646	rs1890889	chr10:82090827	G/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.72	0.56	1.7e-40	Post bronchodilator FEV1;
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg06642177	chr6:134496341	SGK1	0.45	6.71	0.3	5.66e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs2576037	0.583	rs8096263	chr18:44515216	C/T	cg23129478	chr18:44337922	ST8SIA5	-0.37	-7.15	-0.32	3.44e-12	Personality dimensions;
LGG	cis	rs6500602	0.626	rs7665	chr16:4562512	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.41	8.24	0.36	1.8e-15	Schizophrenia;
LGG	cis	rs367943	0.604	rs28519541	chr5:113006931	C/G	cg12552261	chr5:112820674	MCC	0.51	8.3	0.36	1.12e-15	Type 2 diabetes;
LGG	cis	rs751728	0.931	rs2296746	chr6:33744711	C/T	cg25922239	chr6:33757077	LEMD2	0.69	12.25	0.49	4.48e-30	Crohn's disease;
LGG	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	8.22e-33	High light scatter reticulocyte count;
LGG	cis	rs9611565	0.659	rs9611609	chr22:41945357	C/A	cg06481639	chr22:41940642	POLR3H	-0.62	-8.94	-0.38	9.62e-18	Vitiligo;
LGG	cis	rs975739	0.657	rs7338319	chr13:78598218	G/C	cg07847733	chr13:78271382	SLAIN1	0.43	7.38	0.32	7.62e-13	Hair color;
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg05368731	chr17:41323189	NBR1	0.87	16.95	0.62	1.65e-50	Menopause (age at onset);
LGG	cis	rs1912483	0.505	rs3760372	chr17:45380002	T/C	cg25173405	chr17:45401733	C17orf57	-0.78	-13.26	-0.52	2.99e-34	Coronary artery disease;
LGG	cis	rs1728785	1.000	rs1645981	chr16:68571648	T/C	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs2797160	0.967	rs6910786	chr6:126017141	A/T	cg05901451	chr6:126070800	HEY2	0.44	7.44	0.33	4.9e-13	Endometrial cancer;
LGG	cis	rs4243830	0.850	rs1064835	chr1:6585539	A/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.79	12.51	0.5	3.84e-31	Body mass index;
LGG	cis	rs4650994	0.816	rs2811301	chr1:178594196	T/C	cg19399532	chr1:178512495	C1orf220	-0.37	-6.99	-0.31	9.79e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs344364	0.511	rs1742462	chr16:1946062	A/C	cg26617929	chr16:1858877	NA	-0.62	-8.69	-0.37	6.34e-17	Glomerular filtration rate in chronic kidney disease;
LGG	trans	rs6601327	0.571	rs35874762	chr8:9565392	C/A	cg06636001	chr8:8085503	FLJ10661	-0.41	-7.2	-0.32	2.45e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg13628971	chr7:2884303	GNA12	0.55	11.55	0.47	2.63e-27	Height;
LGG	cis	rs7103648	1.000	rs7103648	chr11:47461783	A/G	cg20307385	chr11:47447363	PSMC3	0.99	24.03	0.74	1.96e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs10426930	0.607	rs858423	chr19:5048374	T/C	cg15621731	chr19:5074616	KDM4B	0.32	7.97	0.35	1.24e-14	Monocyte percentage of white cells;
LGG	cis	rs9467711	0.651	rs13192713	chr6:25943234	C/A	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.74	7.0	0.31	8.95e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.769	rs9904237	chr17:80119664	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7829975	0.617	rs4841072	chr8:8791253	C/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.89	-0.3	1.86e-11	Mood instability;
LGG	cis	rs4689388	0.926	rs4308429	chr4:6294001	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.34	0.4	4.12e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs7289126	1.000	rs8142686	chr22:38634266	C/T	cg03162506	chr22:38580953	NA	0.27	6.71	0.3	5.7e-11	Mammographic density (dense area);Percent mammographic density;
LGG	cis	rs6502050	0.835	rs6502069	chr17:80112599	G/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs28386778	0.897	rs1062790	chr17:61896455	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	trans	rs9291683	0.605	rs73224439	chr4:10331818	C/A	cg26043149	chr18:55253948	FECH	-0.42	-6.76	-0.3	4.24e-11	Bone mineral density;
LGG	cis	rs6951245	1.000	rs11767527	chr7:1097394	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	0.608	rs2075310	chr3:10067651	C/T	cg00149659	chr3:10157352	C3orf10	0.64	9.23	0.39	9.77e-19	Alzheimer's disease;
LGG	cis	rs701145	0.585	rs1713828	chr3:153838553	C/T	cg12800244	chr3:153838788	SGEF	0.82	8.92	0.38	1.08e-17	Coronary artery disease;
LGG	cis	rs12431410	0.550	rs1952036	chr14:60179947	C/G	cg07950296	chr14:60194823	RTN1	-0.4	-7.72	-0.34	7.15e-14	Schizophrenia;
LGG	cis	rs3733585	0.588	rs6449154	chr4:9956404	C/T	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.8	-0.34	4.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9611565	0.500	rs10775759	chr22:42088158	T/C	cg06634786	chr22:41940651	POLR3H	0.71	11.41	0.47	9.33e-27	Vitiligo;
LGG	trans	rs7395662	1.000	rs6485872	chr11:48579710	A/C	cg03929089	chr4:120376271	NA	-0.44	-7.14	-0.31	3.63e-12	HDL cholesterol;
LGG	cis	rs2235573	0.527	rs139866	chr22:38354684	C/T	cg19171272	chr22:38449367	NA	-0.48	-8.68	-0.37	7.01e-17	Glioblastoma;Glioma;
LGG	trans	rs7395662	0.926	rs11039893	chr11:48657754	G/A	cg15704280	chr7:45808275	SEPT13	-0.52	-8.86	-0.38	1.67e-17	HDL cholesterol;
LGG	cis	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg06521331	chr12:34319734	NA	-0.62	-11.26	-0.46	3.63e-26	Morning vs. evening chronotype;
LGG	cis	rs9878978	0.722	rs11708578	chr3:2515894	A/G	cg21928760	chr3:2462534	CNTN4	0.37	7.25	0.32	1.75e-12	Blood pressure (smoking interaction);
LGG	cis	rs1018836	0.770	rs12543806	chr8:91664011	C/T	cg16814680	chr8:91681699	NA	-1.01	-21.15	-0.7	5.73e-70	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs950169	0.887	rs220333	chr15:85091133	C/T	cg24253500	chr15:84953950	NA	0.61	11.5	0.47	4.28e-27	Schizophrenia;
LGG	cis	rs7412746	0.658	rs2275235	chr1:150730279	A/G	cg15448220	chr1:150897856	SETDB1	0.38	6.94	0.31	1.31e-11	Melanoma;
LGG	cis	rs6450176	1.000	rs3776718	chr5:53298714	G/C	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.44	-0.47	7.25e-27	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs6976053	0.935	rs4729620	chr7:100506528	C/A	cg03098644	chr7:100410630	EPHB4	-0.39	-6.93	-0.31	1.44e-11	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs4919044	0.534	rs7918909	chr10:94660689	G/A	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.22	-0.32	2.2e-12	Coronary artery disease;
LGG	cis	rs3733585	0.673	rs4560411	chr4:9953361	A/G	cg08250081	chr4:10125330	NA	-0.37	-7.09	-0.31	5.06e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs1062177	0.826	rs1549920	chr5:151140844	A/T	cg00977110	chr5:151150581	G3BP1	0.46	7.4	0.33	6.63e-13	Preschool internalizing problems;
LGG	cis	rs9287719	0.967	rs6735074	chr2:10734766	G/T	cg02196655	chr2:10830764	NOL10	0.43	7.22	0.32	2.14e-12	Prostate cancer;
LGG	cis	rs2285947	1.000	rs10229224	chr7:21583921	G/A	cg04471919	chr7:21584483	DNAH11	0.5	13.88	0.54	6.95e-37	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	trans	rs61931739	0.517	rs1843738	chr12:34056935	C/T	cg26384229	chr12:38710491	ALG10B	0.79	15.7	0.59	7.53e-45	Morning vs. evening chronotype;
LGG	cis	rs5750830	0.594	rs9611165	chr22:39775250	A/G	cg04986931	chr22:39850128	NA	0.35	7.68	0.34	9.57e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.520	rs4347885	chr2:99804007	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs6912958	0.559	rs6921504	chr6:88058972	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	0.68	12.82	0.51	2.14e-32	Monocyte percentage of white cells;
LGG	cis	rs9611565	0.918	rs12484074	chr22:41752747	G/A	cg06481639	chr22:41940642	POLR3H	-0.53	-7.79	-0.34	4.36e-14	Vitiligo;
LGG	cis	rs10911251	0.546	rs944971	chr1:183112505	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.42	8.67	0.37	7.22e-17	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg07701084	chr6:150067640	NUP43	0.63	11.61	0.47	1.55e-27	Lung cancer;
LGG	cis	rs11190604	0.943	rs9420792	chr10:102258439	C/T	cg07080220	chr10:102295463	HIF1AN	0.68	11.63	0.48	1.27e-27	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7587476	1.000	rs1542173	chr2:215657560	C/T	cg04004882	chr2:215674386	BARD1	-0.54	-7.63	-0.33	1.37e-13	Neuroblastoma;
LGG	trans	rs941408	1.000	rs1640272	chr19:2800192	A/T	cg19676328	chr12:49525230	TUBA1B	-0.63	-10.19	-0.43	3.76e-22	Total cholesterol levels;
LGG	cis	rs9920506	0.518	rs11072774	chr15:78952697	C/T	cg05914723	chr15:78953907	NA	0.51	7.51	0.33	3e-13	Post bronchodilator FEV1;
LGG	trans	rs8005745	0.505	rs710047	chr14:62118819	C/G	cg09126467	chr6:42796794	KIAA0240	0.37	6.8	0.3	3.29e-11	Select biomarker traits;
LGG	cis	rs368123	1.000	rs606329	chr6:160718764	G/T	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	cis	rs2842992	0.830	rs1853259	chr6:160147441	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	-0.72	-12.11	-0.49	1.67e-29	Age-related macular degeneration (geographic atrophy);
LGG	trans	rs1005277	0.602	rs1780141	chr10:38504299	T/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.84	0.34	3.21e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs870825	0.616	rs4256263	chr4:185622959	C/A	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs17373728	0.526	rs7017326	chr8:76146574	C/T	cg07016329	chr8:76221503	NA	0.47	8.68	0.37	6.86e-17	Diabetic kidney disease;
LGG	cis	rs972578	0.645	rs2007395	chr22:43271171	T/C	cg01576275	chr22:43409880	NA	-0.23	-6.93	-0.31	1.45e-11	Mean platelet volume;
LGG	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.26	-0.52	3.09e-34	Extrinsic epigenetic age acceleration;
LGG	trans	rs11098499	0.818	rs10008791	chr4:120431469	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.71e-27	Corneal astigmatism;
LGG	cis	rs2841277	0.708	rs28454709	chr14:105405942	G/A	cg20978937	chr14:105399321	PLD4	0.49	11.19	0.46	6.96e-26	Rheumatoid arthritis;
LGG	cis	rs1045714	0.895	rs4719602	chr7:2647800	G/A	cg14042143	chr7:2646782	IQCE	0.78	11.91	0.48	1.07e-28	Urate levels in lean individuals;
LGG	cis	rs17767392	0.958	rs2332638	chr14:72028915	A/G	cg13720639	chr14:72061746	SIPA1L1	0.38	8.31	0.36	1.06e-15	Mitral valve prolapse;
LGG	cis	rs4820539	0.641	rs5759602	chr22:23489362	C/T	cg14186256	chr22:23484241	RTDR1	-0.91	-20.44	-0.69	1.12e-66	Bone mineral density;
LGG	cis	rs7618915	0.501	rs2079929	chr3:52765646	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.13	0.39	2.11e-18	Bipolar disorder;
LGG	cis	rs1670533	0.872	rs11727136	chr4:1051804	G/A	cg27284194	chr4:1044797	NA	0.5	9.05	0.39	3.86e-18	Recombination rate (females);
LGG	cis	rs28374715	0.578	rs17730888	chr15:41637547	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.32	-32.56	-0.83	8.43e-122	Ulcerative colitis;
LGG	cis	rs611744	0.647	rs11785776	chr8:109264933	C/T	cg21045802	chr8:109455806	TTC35	0.53	9.96	0.42	2.56e-21	Dupuytren's disease;
LGG	cis	rs1451375	1.000	rs1966839	chr7:50627101	T/C	cg20336341	chr7:50628841	DDC	0.38	7.23	0.32	1.96e-12	Malaria;
LGG	cis	rs1799949	1.000	rs12516	chr17:41196408	G/A	cg18379455	chr17:41446167	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs4732038	0.565	rs706200	chr7:134265938	T/G	cg06906464	chr7:134288099	NA	-0.72	-20.81	-0.7	2.28e-68	Longevity;
LGG	cis	rs10504073	0.584	rs4873304	chr8:49922733	G/A	cg00325661	chr8:49890786	NA	0.82	16.47	0.61	2.54e-48	Blood metabolite ratios;
LGG	cis	rs10256972	0.567	rs7782651	chr7:1159895	T/G	cg18765753	chr7:1198926	ZFAND2A	-0.41	-6.96	-0.31	1.19e-11	Longevity;Endometriosis;
LGG	cis	rs1045902	0.583	rs36106493	chr2:73442339	C/T	cg01422370	chr2:73384389	NA	0.41	7.44	0.33	4.88e-13	Intelligence (multi-trait analysis);
LGG	cis	rs1335587	0.586	rs7323294	chr13:102135172	A/T	cg13538571	chr13:102108074	ITGBL1	0.35	6.73	0.3	5.17e-11	Obesity-related traits;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.52	0.37	2.2e-16	Prostate cancer;
LGG	cis	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.92	-0.45	7.3e-25	Resting heart rate;
LGG	cis	rs6502050	0.805	rs7406682	chr17:80084368	C/T	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	cis	rs2658782	0.789	rs2658773	chr11:93126914	A/G	cg15737290	chr11:93063684	CCDC67	0.51	7.73	0.34	6.85e-14	Pulmonary function decline;
LGG	cis	rs62238980	0.614	rs17683704	chr22:32506041	A/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs78487399	0.710	rs7561114	chr2:43701951	G/T	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.61	-6.72	-0.3	5.46e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs55882075	0.583	rs9637934	chr5:179114025	G/C	cg14593053	chr5:179126677	CANX	0.4	6.72	0.3	5.21e-11	Monocyte percentage of white cells;
LGG	cis	rs875971	1.000	rs778699	chr7:65868290	G/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg02018176	chr4:1364513	KIAA1530	-0.42	-9.36	-0.4	3.36e-19	Obesity-related traits;
LGG	trans	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg16141378	chr3:129829833	LOC729375	-0.35	-7.94	-0.35	1.49e-14	Joint mobility (Beighton score);
LGG	trans	rs11098499	0.954	rs12505469	chr4:120249585	C/T	cg25214090	chr10:38739885	LOC399744	0.68	12.0	0.49	4.31e-29	Corneal astigmatism;
LGG	cis	rs975739	1.000	rs1759979	chr13:78386854	T/G	cg07847733	chr13:78271382	SLAIN1	0.37	6.76	0.3	4.27e-11	Hair color;
LGG	cis	rs10463554	0.927	rs11952361	chr5:102287920	A/G	cg23492399	chr5:102201601	PAM	-0.54	-8.23	-0.36	1.9e-15	Parkinson's disease;
LGG	cis	rs12586317	0.576	rs2415264	chr14:35630377	C/G	cg16230307	chr14:35515116	FAM177A1	0.43	7.55	0.33	2.29e-13	Psoriasis;
LGG	cis	rs801193	0.742	rs9969300	chr7:65781646	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.45	-8.84	-0.38	2.06e-17	Aortic root size;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs4819052	0.704	rs2297283	chr21:46683590	G/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.46	7.33	0.32	1.06e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17767392	0.915	rs1990241	chr14:71774052	T/G	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.32e-18	Mitral valve prolapse;
LGG	cis	rs4665809	0.590	rs7604564	chr2:26501953	C/A	cg22920501	chr2:26401640	FAM59B	0.47	9.7	0.41	2.3e-20	Gut microbiome composition (summer);
LGG	cis	rs4820294	0.547	rs62236743	chr22:38096053	T/C	cg26138144	chr22:38071188	LGALS1	0.68	12.67	0.51	8.79e-32	Fat distribution (HIV);
LGG	cis	rs3858526	0.665	rs10839170	chr11:6003512	C/T	cg02574844	chr11:5959923	NA	-0.5	-8.07	-0.35	6.13e-15	DNA methylation (variation);
LGG	cis	rs13217239	0.646	rs2142685	chr6:27054497	C/T	cg12292205	chr6:26970375	C6orf41	-0.55	-10.82	-0.45	1.84e-24	Schizophrenia;
LGG	trans	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg04469686	chr1:162760199	HSD17B7	-0.45	-7.36	-0.32	8.33e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7618915	0.547	rs2878726	chr3:52748271	C/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.51	0.4	1.06e-19	Bipolar disorder;
LGG	cis	rs12478665	1	rs12478665	chr2:210123032	C/T	cg09336323	chr2:210074276	NA	0.43	6.9	0.31	1.72e-11	Hippocampal volume;
LGG	cis	rs537930	0.560	rs676706	chr5:134349885	A/G	cg24576358	chr5:134350122	NA	0.45	10.01	0.42	1.78e-21	Height;
LGG	cis	rs597539	0.615	rs629426	chr11:68671104	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.85	16.11	0.6	1.16e-46	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8179	0.593	rs73232024	chr7:92277315	G/A	cg15732164	chr7:92237376	CDK6	-0.52	-9.81	-0.41	8.92e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs9393692	1.000	rs3999544	chr6:26285867	C/T	cg00294572	chr6:26285232	NA	0.47	8.4	0.36	5.58e-16	Educational attainment;
LGG	cis	rs7428	0.545	rs2366404	chr2:85551779	G/A	cg24342717	chr2:85555507	TGOLN2	-0.73	-13.9	-0.54	6.05e-37	Ear protrusion;
LGG	cis	rs4930103	0.935	rs2839698	chr11:2018853	G/A	cg23202291	chr11:1979235	NA	0.37	7.16	0.32	3.13e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05603623	chr19:8008081	TIMM44	0.38	7.03	0.31	7.29e-12	Obesity-related traits;
LGG	cis	rs8177253	0.761	rs1830084	chr3:133508464	A/T	cg11941060	chr3:133502564	NA	0.53	9.33	0.4	4.39e-19	Iron status biomarkers;
LGG	cis	rs2439831	1.000	rs689781	chr15:43792097	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.96	12.34	0.5	1.9e-30	Lung cancer in ever smokers;
LGG	cis	rs2019137	0.868	rs3748916	chr2:113984033	C/T	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	-0.57	-10.19	-0.43	3.95e-22	Lymphocyte counts;
LGG	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.19	-0.32	2.63e-12	Colorectal cancer;
LGG	cis	rs798766	1.000	rs1665362	chr4:1726367	T/A	cg05874882	chr4:1763078	NA	-0.48	-6.9	-0.31	1.68e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs72772090	0.539	rs11738810	chr5:96119055	T/C	cg00188032	chr5:96141721	ERAP1	0.54	7.22	0.32	2.11e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12497850	0.543	rs6446218	chr3:49075513	A/T	cg07636037	chr3:49044803	WDR6	1.12	28.54	0.8	4.39e-104	Parkinson's disease;
LGG	trans	rs656319	0.607	rs55836143	chr8:10100070	G/T	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.12	-0.39	2.27e-18	Myopia (pathological);
LGG	cis	rs12971120	0.838	rs2241510	chr18:72180739	G/A	cg26446133	chr18:72167187	CNDP2	-0.67	-13.23	-0.52	3.91e-34	Refractive error;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.97	0.42	2.49e-21	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg02733842	chr7:1102375	C7orf50	0.7	10.46	0.44	3.79e-23	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6952808	0.771	rs10950415	chr7:1914477	A/G	cg00106254	chr7:1943704	MAD1L1	-0.4	-6.85	-0.3	2.4e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs16937	0.711	rs10900467	chr1:205160074	G/A	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.5e-13	Schizophrenia;
LGG	cis	rs4595586	0.545	rs12812959	chr12:39371197	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.7	0.45	4.81e-24	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg13012494	chr21:47604986	C21orf56	-0.56	-9.68	-0.41	2.58e-20	Testicular germ cell tumor;
LGG	cis	rs1218582	0.803	rs7531728	chr1:154840516	C/A	cg03351412	chr1:154909251	PMVK	0.66	12.32	0.5	2.21e-30	Prostate cancer;
LGG	cis	rs6500602	0.826	rs11076830	chr16:4460049	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	6.95	0.31	1.25e-11	Schizophrenia;
LGG	trans	rs916888	0.738	rs199515	chr17:44856641	C/G	cg04703951	chr17:43578652	NA	-0.37	-7.61	-0.33	1.53e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg13010199	chr12:38710504	ALG10B	-0.55	-11.04	-0.46	2.6e-25	Heart rate;
LGG	cis	rs9322193	0.923	rs10782310	chr6:149943594	A/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.38	-0.43	7.82e-23	Lung cancer;
LGG	cis	rs1046896	0.739	rs28459016	chr17:80741194	G/A	cg03160526	chr17:80928410	B3GNTL1	0.42	6.82	0.3	2.9100000000000002e-11	Glycated hemoglobin levels;
LGG	cis	rs1005277	0.579	rs2008449	chr10:38414204	A/T	cg14646974	chr10:38645378	HSD17B7P2	0.41	6.64	0.3	8.6e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs28595532	0.920	rs55758547	chr4:119769475	T/C	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs60695258	0.517	rs867196	chr4:87971600	G/C	cg01323104	chr4:87958903	AFF1	0.24	6.78	0.3	3.57e-11	Hematocrit;
LGG	cis	rs8133932	0.861	rs71324446	chr21:47231428	C/T	cg11214348	chr21:47283868	PCBP3	-0.43	-7.11	-0.31	4.45e-12	Schizophrenia;
LGG	cis	rs11148252	0.538	rs2296349	chr13:52710058	T/G	cg00495681	chr13:53174319	NA	0.57	10.24	0.43	2.65e-22	Lewy body disease;
LGG	cis	rs4702718	0.519	rs2918386	chr5:10734647	G/A	cg18867653	chr5:10760375	DAP	0.32	7.74	0.34	6.21e-14	Obesity-related traits;
LGG	cis	rs12464483	0.524	rs2593470	chr2:30887402	G/T	cg12454169	chr2:30669597	LCLAT1	0.53	7.63	0.33	1.35e-13	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs2075466	0.510	rs8060738	chr16:4939116	C/T	cg04440724	chr16:4920505	UBN1	-0.55	-7.72	-0.34	7.27e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.683	rs77548248	chr8:58117542	G/A	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.83e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg26656751	chr17:43910226	CRHR1	-0.43	-7.85	-0.34	3e-14	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.830	rs2854210	chr17:61946338	C/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.64	0.48	1.25e-27	Prudent dietary pattern;
LGG	cis	rs4650994	0.967	rs4650992	chr1:178515135	A/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.17e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10464366	0.519	rs6974609	chr7:39219149	C/T	cg21665744	chr7:39171113	POU6F2	0.42	8.42	0.36	4.73e-16	IgG glycosylation;
LGG	cis	rs4689388	0.853	rs13114527	chr4:6294655	T/G	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs216026	0.689	rs216049	chr12:2766711	C/T	cg19945202	chr12:2788847	CACNA1C	0.64	9.38	0.4	2.99e-19	Fractional exhaled nitric oxide (childhood);
LGG	cis	rs6952808	0.729	rs35797753	chr7:1954914	G/A	cg04267008	chr7:1944627	MAD1L1	-0.73	-13.08	-0.52	1.72e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs62103177	0.810	rs62103189	chr18:77627815	G/A	cg14227996	chr4:17616232	MED28	0.73	8.93	0.38	1.02e-17	Opioid sensitivity;
LGG	cis	rs11252926	0.565	rs4881308	chr10:484983	G/T	cg16386425	chr10:429943	DIP2C	-0.44	-8.84	-0.38	2.02e-17	Psychosis in Alzheimer's disease;
LGG	trans	rs9929218	0.817	rs3114405	chr16:68722377	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.93	-16.47	-0.61	2.5e-48	Colorectal cancer;
LGG	cis	rs28386778	0.897	rs2665831	chr17:61912392	C/T	cg11494091	chr17:61959527	GH2	1.0	24.67	0.75	1.98e-86	Prudent dietary pattern;
LGG	cis	rs295140	1.000	rs3769476	chr2:201181428	T/C	cg25099087	chr2:201172481	SPATS2L	0.28	6.95	0.31	1.27e-11	QT interval;
LGG	cis	rs6740322	0.748	rs1549723	chr2:43460514	C/A	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.7	-10.77	-0.45	2.85e-24	Coronary artery disease;
LGG	cis	rs1506636	1.000	rs2299984	chr7:123356921	G/T	cg03229431	chr7:123269106	ASB15	0.73	18.02	0.64	2.13e-55	Plateletcrit;Platelet count;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg19077165	chr18:44547161	KATNAL2	-0.71	-13.68	-0.54	4.93e-36	Personality dimensions;
LGG	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg10189774	chr4:17578691	LAP3	0.41	7.13	0.31	4e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg15242771	chr6:114292051	HDAC2	0.61	6.84	0.3	2.56e-11	Intelligence (multi-trait analysis);
LGG	trans	rs9329221	0.527	rs34308302	chr8:10332022	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.57	-0.33	2.05e-13	Neuroticism;
LGG	cis	rs7444	0.941	rs5754422	chr22:21980257	A/G	cg15846791	chr22:21984385	YDJC	-0.45	-6.77	-0.3	3.81e-11	Systemic lupus erythematosus;
LGG	cis	rs2073300	0.609	rs74273791	chr20:23418067	A/T	cg12062639	chr20:23401060	NAPB	0.92	8.7	0.37	5.96e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.56	0.37	1.68e-16	Bipolar disorder;
LGG	cis	rs4862750	0.872	rs4862747	chr4:187877236	A/T	cg07414643	chr4:187882934	NA	-0.54	-11.09	-0.46	1.61e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10540	1.000	rs79440439	chr11:478147	A/C	cg03352830	chr11:487213	PTDSS2	0.88	10.71	0.45	4.8e-24	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07522229	chr6:144164505	LTV1	0.48	7.07	0.31	5.73e-12	Gut microbiome composition (summer);
LGG	cis	rs4851254	0.920	rs13011874	chr2:100752497	C/T	cg17356467	chr2:100759845	AFF3	0.41	7.09	0.31	4.9e-12	Intelligence (multi-trait analysis);
LGG	cis	rs62400317	0.826	rs62400290	chr6:45209788	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.07	-0.42	1.02e-21	Total body bone mineral density;
LGG	cis	rs7172689	0.908	rs4468565	chr15:81575699	C/A	cg11808699	chr15:81528661	IL16	-0.48	-9.7	-0.41	2.17e-20	Inattentive symptoms;
LGG	cis	rs28386778	0.897	rs2584610	chr17:61934783	T/C	cg11494091	chr17:61959527	GH2	1.01	25.12	0.76	1.69e-88	Prudent dietary pattern;
LGG	cis	rs8067287	0.640	rs62065424	chr17:16828650	A/G	cg26910001	chr17:16838321	NA	-0.47	-8.76	-0.38	3.79e-17	Diabetic kidney disease;
LGG	cis	rs9393692	1.000	rs2393593	chr6:26285683	T/C	cg00294572	chr6:26285232	NA	0.47	8.4	0.36	5.58e-16	Educational attainment;
LGG	cis	rs225245	0.817	rs225297	chr17:33924587	G/A	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs6951245	0.935	rs11763765	chr7:1060510	C/T	cg02733842	chr7:1102375	C7orf50	0.68	10.17	0.43	4.5e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4742903	0.818	rs1857981	chr9:106992584	T/G	cg14250997	chr9:106856677	SMC2	0.38	7.76	0.34	5.58e-14	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7851660	0.933	rs894673	chr9:100612270	A/T	cg13688889	chr9:100608707	NA	-0.69	-14.68	-0.56	2.44e-40	Strep throat;
LGG	cis	rs5769765	0.818	rs138850	chr22:50193337	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	0.57	8.59	0.37	1.35e-16	Schizophrenia;
LGG	cis	rs4072980	0.545	rs10890285	chr1:38453576	A/C	cg18451016	chr1:38461880	NA	-0.53	-10.32	-0.43	1.32e-22	Coronary artery disease;
LGG	cis	rs780096	0.546	rs2911712	chr2:27626945	A/T	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.82	-0.3	2.82e-11	Total body bone mineral density;
LGG	trans	rs7395662	0.747	rs11040106	chr11:48889126	C/T	cg03929089	chr4:120376271	NA	0.44	7.09	0.31	4.97e-12	HDL cholesterol;
LGG	trans	rs9747201	1.000	rs9747201	chr17:80177852	A/C	cg07393940	chr7:158741817	NA	0.58	10.36	0.43	9.4e-23	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg22681709	chr2:178499509	PDE11A	-0.53	-9.63	-0.41	4.02e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11148252	0.740	rs9596642	chr13:52900879	A/G	cg22398616	chr13:53314203	LECT1	0.41	8.21	0.36	2.29e-15	Lewy body disease;
LGG	trans	rs7980799	0.649	rs1994135	chr12:33682405	T/C	cg26384229	chr12:38710491	ALG10B	0.62	11.39	0.47	1.13e-26	Heart rate;Heart rate variability traits (RMSSD);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03965827	chr15:50979356	TRPM7	0.55	8.72	0.38	5.11e-17	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs6958294	chr7:65794796	C/A	cg23594656	chr7:65796392	TPST1	0.42	9.29	0.4	6.01e-19	Aortic root size;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17027945	chr15:74284732	STOML1	0.46	6.95	0.31	1.25e-11	Gut microbiome composition (summer);
LGG	cis	rs1595825	1.000	rs73058820	chr2:198864358	A/G	cg00982548	chr2:198649783	BOLL	-0.5	-6.87	-0.3	2.02e-11	Ulcerative colitis;
LGG	cis	rs3733585	0.683	rs3796839	chr4:10009917	G/A	cg00071950	chr4:10020882	SLC2A9	0.4	8.12	0.35	4.3e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.92	-0.31	1.47e-11	Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09015484	chr9:96929106	NA	0.54	8.64	0.37	9.13e-17	Gut microbiome composition (summer);
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs9463078	0.932	rs1324538	chr6:45080144	T/A	cg25276700	chr6:44698697	NA	-0.36	-7.39	-0.32	6.92e-13	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1386478	0.853	rs13086657	chr3:113801826	C/T	cg14431476	chr3:113822413	NA	-0.45	-7.13	-0.31	3.81e-12	Crohn's disease and psoriasis;
LGG	cis	rs74781061	0.932	rs7176491	chr15:74807216	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.25	-0.32	1.79e-12	Endometriosis;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg23594656	chr7:65796392	TPST1	-0.42	-9.26	-0.4	7.64e-19	Aortic root size;
LGG	trans	rs1814175	0.645	rs847632	chr11:49926097	C/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.43	-0.71	2.8e-71	Height;
LGG	cis	rs963731	0.579	rs297131	chr2:39300259	C/T	cg04010122	chr2:39346883	SOS1	-0.7	-7.32	-0.32	1.09e-12	Corticobasal degeneration;
LGG	cis	rs13191362	1.000	rs34714518	chr6:163080778	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.97	9.67	0.41	2.83e-20	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs11608355	0.618	rs4486687	chr12:109790741	T/A	cg19025524	chr12:109796872	NA	-0.6	-13.04	-0.52	2.57e-33	Neuroticism;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg00733780	chr10:26505127	GAD2	-0.38	-7.06	-0.31	6.17e-12	Pancreatic cancer;
LGG	cis	rs2274273	0.624	rs10143136	chr14:55743528	G/A	cg04306507	chr14:55594613	LGALS3	0.54	12.54	0.5	3.06e-31	Protein biomarker;
LGG	cis	rs11239187	0.927	rs1480606	chr10:45109692	T/C	cg03916630	chr10:45065415	NA	0.34	7.56	0.33	2.12e-13	Body mass index;
LGG	cis	rs10791323	0.660	rs2156681	chr11:133731644	G/T	cg15485101	chr11:133734466	NA	0.58	10.33	0.43	1.18e-22	Childhood ear infection;
LGG	cis	rs1707322	1.000	rs11211217	chr1:46348229	C/G	cg03146154	chr1:46216737	IPP	0.54	10.44	0.44	4.52e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg21972741	chr5:435613	AHRR	0.5	8.95	0.38	8.72e-18	Cystic fibrosis severity;
LGG	cis	rs11096990	0.634	rs6854358	chr4:39283112	C/G	cg24403649	chr4:39172243	NA	-0.4	-7.08	-0.31	5.37e-12	Cognitive function;
LGG	cis	rs6694672	0.764	rs10801593	chr1:197144383	T/G	cg13682187	chr1:196946512	CFHR5	0.48	6.81	0.3	3.05e-11	Asthma;
LGG	cis	rs4731207	0.623	rs12706629	chr7:124574045	A/G	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9715521	0.775	rs62301195	chr4:59846934	G/T	cg11281224	chr4:60001000	NA	-0.51	-8.48	-0.37	2.94e-16	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs5769707	0.632	rs135876	chr22:50013573	A/G	cg06623630	chr22:50017776	C22orf34	-0.48	-9.64	-0.41	3.58e-20	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs6558530	0.587	rs6986102	chr8:1700640	C/G	cg25947184	chr8:1697459	NA	0.47	8.07	0.35	6.16e-15	Systolic blood pressure;
LGG	cis	rs1124376	1.000	rs61138004	chr3:20145855	C/G	cg05072819	chr3:20081367	KAT2B	0.63	8.29	0.36	1.2e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs1908814	0.516	rs13281077	chr8:11794814	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.6e-18	Neuroticism;
LGG	cis	rs7674212	0.570	rs6813563	chr4:104099110	G/A	cg16532752	chr4:104119610	CENPE	-0.42	-7.17	-0.32	3.05e-12	Type 2 diabetes;
LGG	cis	rs12188164	1.000	rs56104584	chr5:437542	T/C	cg26076054	chr5:421317	AHRR	-0.45	-7.57	-0.33	2.07e-13	Cystic fibrosis severity;
LGG	cis	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg12395012	chr8:11607386	GATA4	0.37	6.89	0.3	1.82e-11	Neuroticism;
LGG	cis	rs12579753	0.913	rs12579018	chr12:82231943	T/C	cg07988820	chr12:82153109	PPFIA2	-0.76	-11.06	-0.46	2.26e-25	Resting heart rate;
LGG	cis	rs7633857	0.512	rs1868109	chr3:160682500	G/A	cg03342759	chr3:160939853	NMD3	-0.58	-9.87	-0.42	5.57e-21	Educational attainment (years of education);
LGG	cis	rs910316	1.000	rs28626045	chr14:75589195	G/C	cg11812906	chr14:75593930	NEK9	0.54	10.18	0.43	4.33e-22	Height;
LGG	cis	rs9322193	0.923	rs7769101	chr6:150169904	C/A	cg00933542	chr6:150070202	PCMT1	0.38	7.06	0.31	6.19e-12	Lung cancer;
LGG	cis	rs12497850	0.931	rs13316620	chr3:49045355	T/C	cg06212747	chr3:49208901	KLHDC8B	0.65	11.08	0.46	1.88e-25	Parkinson's disease;
LGG	cis	rs2836974	0.965	rs2836967	chr21:40639102	T/G	cg06238570	chr21:40685208	BRWD1	0.44	6.86	0.3	2.25e-11	Cognitive function;
LGG	cis	rs2404602	0.611	rs2404734	chr15:76936165	T/C	cg23625390	chr15:77176239	SCAPER	-0.7	-13.61	-0.53	9.93e-36	Blood metabolite levels;
LGG	cis	rs7546668	1.000	rs3795758	chr1:15853551	C/T	cg21858823	chr1:15850916	CASP9	0.37	6.87	0.3	2.08e-11	Glomerular filtration rate (creatinine);
LGG	cis	rs72766638	0.848	rs11789898	chr9:136925663	A/C	cg13789015	chr9:136890014	NCRNA00094	-0.47	-7.28	-0.32	1.43e-12	Mosquito bite size;
LGG	cis	rs1552244	0.572	rs113406084	chr3:10170190	T/C	cg13047869	chr3:10149882	C3orf24	0.58	8.43	0.36	4.31e-16	Alzheimer's disease;
LGG	cis	rs11098499	0.866	rs12374244	chr4:120281972	A/T	cg09307838	chr4:120376055	NA	0.73	12.17	0.49	9.3e-30	Corneal astigmatism;
LGG	cis	rs9326248	0.581	rs6589590	chr11:116936081	A/C	cg20608306	chr11:116969690	SIK3	0.42	13.44	0.53	5.07e-35	Blood protein levels;
LGG	cis	rs61884328	0.852	rs60174717	chr11:47106994	G/A	cg03339077	chr11:47165057	C11orf49	0.63	6.85	0.3	2.32e-11	Total body bone mineral density (age over 60);
LGG	trans	rs2574985	0.813	rs1203382	chr10:52212309	C/T	cg18558237	chr10:81444220	LOC650623	0.43	6.74	0.3	4.67e-11	Subjective well-being;
LGG	trans	rs2727020	0.521	rs10839285	chr11:49496852	T/G	cg11707556	chr5:10655725	ANKRD33B	0.64	11.64	0.48	1.2e-27	Coronary artery disease;
LGG	cis	rs7223966	0.961	rs112709843	chr17:61836936	T/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.98	0.45	4.36e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17666538	0.710	rs1703941	chr8:658447	G/A	cg07234876	chr8:600039	NA	1.16	11.36	0.47	1.49e-26	IgG glycosylation;
LGG	cis	rs597539	0.690	rs552517	chr11:68625286	T/G	cg06112835	chr11:68658793	MRPL21	0.65	10.59	0.44	1.26e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs796364	0.806	rs34510964	chr2:201010676	C/G	cg23649088	chr2:200775458	C2orf69	-0.61	-8.03	-0.35	8.03e-15	Schizophrenia;
LGG	cis	rs6952808	0.601	rs3778978	chr7:2159817	A/G	cg14004847	chr7:1930337	MAD1L1	-0.5	-8.63	-0.37	9.96e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9356171	0.572	rs2281406	chr6:164325848	C/T	cg25752492	chr6:164341247	NA	-0.47	-9.3	-0.4	5.8e-19	Diisocyanate-induced asthma;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18247126	chr11:121163951	SC5DL	0.43	6.9	0.31	1.71e-11	Cognitive performance;
LGG	cis	rs698813	0.604	rs12712916	chr2:44482099	A/C	cg00619915	chr2:44497795	NA	-0.58	-8.56	-0.37	1.63e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	trans	rs9329221	0.741	rs55975067	chr8:9806824	C/G	cg15556689	chr8:8085844	FLJ10661	-0.49	-8.38	-0.36	6.19e-16	Neuroticism;
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg27411982	chr8:10470053	RP1L1	-0.4	-7.09	-0.31	5.07e-12	Mood instability;
LGG	cis	rs1552244	1.000	rs9849434	chr3:10133710	A/G	cg16606324	chr3:10149918	C3orf24	-0.52	-6.89	-0.3	1.87e-11	Alzheimer's disease;
LGG	cis	rs4077515	0.577	rs3812584	chr9:139312719	C/T	cg14019695	chr9:139328340	INPP5E	-0.36	-6.68	-0.3	7.07e-11	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6942756	1.000	rs66970518	chr7:128871006	G/A	cg02491457	chr7:128862824	NA	-0.77	-14.22	-0.55	2.56e-38	White matter hyperintensity burden;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08730330	chr17:61904790	PSMC5;FTSJ3	0.43	7.17	0.32	2.99e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs11158026	0.757	rs2183085	chr14:55472391	A/C	cg04306507	chr14:55594613	LGALS3	0.31	6.96	0.31	1.16e-11	Parkinson's disease;
LGG	cis	rs701145	0.585	rs1727884	chr3:153838368	A/C	cg17054900	chr3:154042577	DHX36	0.79	9.41	0.4	2.38e-19	Coronary artery disease;
LGG	cis	rs3733585	0.699	rs6449159	chr4:9960498	G/A	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9467711	0.606	rs28362606	chr6:26365586	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.2	0.36	2.38e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10911251	0.508	rs2245784	chr1:183107665	G/A	cg07928641	chr1:182991847	LAMC1	0.45	9.1	0.39	2.74e-18	Colorectal cancer;
LGG	cis	rs9463078	0.764	rs1935551	chr6:44786035	T/G	cg25276700	chr6:44698697	NA	-0.41	-8.65	-0.37	8.54e-17	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs270601	0.770	rs10463891	chr5:131597392	C/T	cg07395648	chr5:131743802	NA	0.36	7.25	0.32	1.73e-12	Acylcarnitine levels;
LGG	cis	rs9322193	0.961	rs4870144	chr6:149896676	C/G	cg00933542	chr6:150070202	PCMT1	0.39	7.02	0.31	7.83e-12	Lung cancer;
LGG	cis	rs11190604	0.652	rs76629555	chr10:102191417	T/C	cg07570687	chr10:102243282	WNT8B	0.41	7.49	0.33	3.59e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg05665937	chr4:1216051	CTBP1	0.5	8.69	0.37	6.51e-17	Obesity-related traits;
LGG	cis	rs654950	0.806	rs1815257	chr1:42041479	A/C	cg16096631	chr1:42092165	HIVEP3	-0.42	-9.14	-0.39	1.91e-18	Airway imaging phenotypes;
LGG	cis	rs3741404	0.609	rs669913	chr11:63869879	A/G	cg18225595	chr11:63971243	STIP1	0.48	9.3	0.4	5.57e-19	Platelet count;
LGG	cis	rs10504130	0.569	rs2069119	chr8:52686436	A/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs3219090	0.962	rs1865221	chr1:226601974	G/T	cg17127702	chr1:226594323	PARP1	0.38	12.34	0.5	1.85e-30	Melanoma;
LGG	cis	rs5742933	0.744	rs12693557	chr2:190590937	G/A	cg04003228	chr2:190539410	ANKAR	-0.5	-7.35	-0.32	9.27e-13	Ferritin levels;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg07575478	chr14:73924855	NUMB	-0.38	-6.75	-0.3	4.54e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg03605463	chr16:89740564	NA	-0.41	-6.82	-0.3	2.86e-11	Vitiligo;
LGG	cis	rs9910055	0.659	rs3826412	chr17:42255097	A/G	cg13607699	chr17:42295918	UBTF	0.54	8.93	0.38	9.96e-18	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs12950779	chr17:41306523	C/T	cg16270222	chr17:41446396	NA	-0.29	-6.65	-0.3	8.17e-11	Menopause (age at onset);
LGG	cis	rs2952156	0.920	rs2517955	chr17:37843681	C/T	cg00129232	chr17:37814104	STARD3	-0.75	-15.94	-0.6	6.77e-46	Asthma;
LGG	cis	rs2762353	0.718	rs1165205	chr6:25870542	A/T	cg03264133	chr6:25882463	NA	0.6	11.39	0.47	1.13e-26	Blood metabolite levels;
LGG	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg11871910	chr12:69753446	YEATS4	0.67	12.36	0.5	1.65e-30	Response to diuretic therapy;
LGG	cis	rs657075	0.639	rs2306772	chr5:131675981	C/T	cg21911579	chr5:131705225	SLC22A5	0.7	7.56	0.33	2.22e-13	Rheumatoid arthritis;
LGG	cis	rs7829975	0.577	rs17684466	chr8:8545233	G/A	cg15556689	chr8:8085844	FLJ10661	-0.39	-6.68	-0.3	6.85e-11	Mood instability;
LGG	cis	rs11771526	0.892	rs76035550	chr7:32371359	G/A	cg13207630	chr7:32358064	NA	0.79	8.14	0.35	3.78e-15	Body mass index;
LGG	cis	rs62209	0.752	rs1928720	chr10:11014351	T/A	cg26901096	chr10:10994189	LOC254312	0.6	8.84	0.38	1.96e-17	Alzheimer's disease (late onset);
LGG	trans	rs629535	0.862	rs638412	chr8:70047690	C/T	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	trans	rs7829975	0.623	rs10087493	chr8:8373557	A/G	cg02002194	chr4:3960332	NA	0.47	9.11	0.39	2.41e-18	Mood instability;
LGG	cis	rs875971	0.638	rs3898855	chr7:66036398	G/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.46	-9.65	-0.41	3.51e-20	Aortic root size;
LGG	cis	rs947211	0.950	rs885224	chr1:205753097	A/G	cg26354017	chr1:205819088	PM20D1	0.47	7.86	0.34	2.68e-14	Parkinson's disease;
LGG	cis	rs6444746	1.000	rs596821	chr3:193514313	G/C	cg22553634	chr3:193489233	NA	-0.69	-8.11	-0.35	4.62e-15	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);
LGG	cis	rs17711722	0.522	rs62469933	chr7:65265639	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.6	13.68	0.54	5.33e-36	Calcium levels;
LGG	cis	rs2279817	0.818	rs34036216	chr1:17986046	C/T	cg21791023	chr1:18019539	ARHGEF10L	-0.64	-9.01	-0.39	5.56e-18	Neuroticism;
LGG	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.55e-43	Chronic sinus infection;
LGG	trans	rs7395662	1.000	rs12421879	chr11:48689978	A/T	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs8030485	0.756	rs2102999	chr15:79410710	C/T	cg17916960	chr15:79447300	NA	-0.47	-8.81	-0.38	2.62e-17	Left ventricle wall thickness;
LGG	cis	rs701145	0.585	rs1727958	chr3:153824800	G/A	cg12800244	chr3:153838788	SGEF	0.82	9.0	0.39	5.82e-18	Coronary artery disease;
LGG	cis	rs17376456	1.000	rs56046246	chr5:93531545	T/G	cg25358565	chr5:93447407	FAM172A	1.36	16.52	0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs977987	0.806	rs4993970	chr16:75411619	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.75	0.3	4.32e-11	Dupuytren's disease;
LGG	cis	rs7586879	0.828	rs2384056	chr2:25092649	G/A	cg04586622	chr2:25135609	ADCY3	0.36	8.62	0.37	1.06e-16	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04273556	chr9:35096672	PIGO	0.46	7.5	0.33	3.34e-13	Cognitive performance;
LGG	trans	rs12599106	0.560	rs34151874	chr16:34989694	G/A	cg02985366	chr16:32360428	NA	-0.46	-7.12	-0.31	4.08e-12	Menopause (age at onset);
LGG	trans	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg13565492	chr6:43139072	SRF	-0.9	-15.56	-0.59	3.36e-44	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs941408	1.000	rs2741990	chr19:2796644	C/T	cg06609049	chr19:2785107	THOP1	0.6	9.53	0.41	8.55e-20	Total cholesterol levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17854078	chr15:55489399	RSL24D1	0.48	6.98	0.31	1.04e-11	Gut microbiome composition (summer);
LGG	cis	rs7811142	1.000	rs11559117	chr7:100076614	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs736408	0.609	rs13082960	chr3:52785168	A/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.57	0.41	6.28e-20	Bipolar disorder;
LGG	cis	rs9469913	0.542	rs114543162	chr6:34696793	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.47	-8.38	-0.36	6.37e-16	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9291683	0.679	rs3756225	chr4:10094133	G/C	cg08250081	chr4:10125330	NA	-0.37	-7.22	-0.32	2.16e-12	Bone mineral density;
LGG	cis	rs1865760	1.000	rs2071301	chr6:25914263	G/T	cg03264133	chr6:25882463	NA	-0.43	-7.6	-0.33	1.62e-13	Height;
LGG	cis	rs17401966	1.000	rs2229687	chr1:10473196	C/T	cg15208524	chr1:10270712	KIF1B	0.41	6.69	0.3	6.47e-11	Hepatocellular carcinoma;
LGG	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg18825076	chr15:78729989	IREB2	-0.47	-7.55	-0.33	2.3e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs763014	0.932	rs2384972	chr16:674424	G/A	cg27144592	chr16:783916	NARFL	0.4	6.67	0.3	7.14e-11	Height;
LGG	cis	rs7226408	0.842	rs1609426	chr18:34345587	A/G	cg15022739	chr18:34823045	BRUNOL4	-0.47	-6.81	-0.3	3.07e-11	Obesity-related traits;
LGG	cis	rs9682041	0.825	rs6785326	chr3:170095145	T/C	cg11886554	chr3:170076028	SKIL	1.01	12.08	0.49	2.21e-29	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs13314892	0.806	rs56007401	chr3:69861186	G/A	cg17445875	chr3:69859618	MITF	-0.4	-7.78	-0.34	4.76e-14	QRS complex (12-leadsum);
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg24503407	chr1:205819492	PM20D1	0.46	7.77	0.34	5.07e-14	Prostate-specific antigen levels;
LGG	cis	rs28595532	0.844	rs55845920	chr4:119490085	C/T	cg21605333	chr4:119757512	SEC24D	1.33	12.6	0.51	1.65e-31	Cannabis dependence symptom count;
LGG	cis	rs801193	0.660	rs974239	chr7:66213491	G/A	cg12463550	chr7:65579703	CRCP	0.49	8.31	0.36	1.1e-15	Aortic root size;
LGG	cis	rs9309711	0.621	rs7586472	chr2:3473670	G/A	cg10845886	chr2:3471009	TTC15	-0.5	-9.87	-0.42	5.79e-21	Neurofibrillary tangles;
LGG	cis	rs7666738	0.753	rs17483788	chr4:98985623	G/A	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6089584	0.927	rs6089593	chr20:60572312	G/A	cg06108461	chr20:60628389	TAF4	-0.88	-16.58	-0.61	8.69e-49	Body mass index;
LGG	cis	rs861020	0.771	rs674804	chr1:210014603	C/G	cg23166289	chr1:210001082	C1orf107	0.38	7.31	0.32	1.15e-12	Orofacial clefts;
LGG	cis	rs12479064	0.694	rs1823569	chr2:100113764	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.55	-8.5	-0.37	2.54e-16	Chronic sinus infection;
LGG	cis	rs6459804	0.935	rs72505543	chr7:157508867	G/A	cg01625945	chr7:157512322	PTPRN2	-0.46	-10.49	-0.44	2.96e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs6445975	0.666	rs11130629	chr3:58352599	G/A	cg24175188	chr3:58374923	PXK	-0.55	-8.88	-0.38	1.43e-17	Systemic lupus erythematosus;
LGG	cis	rs11148252	1.000	rs11148252	chr13:53009048	C/T	cg16301924	chr13:53314226	LECT1	-0.51	-10.9	-0.45	8.56e-25	Lewy body disease;
LGG	cis	rs2836950	0.520	rs2836966	chr21:40637521	A/G	cg11890956	chr21:40555474	PSMG1	-0.74	-12.9	-0.51	9.72e-33	Menarche (age at onset);
LGG	cis	rs7949030	0.620	rs2428551	chr11:62329758	T/A	cg22862634	chr11:62369728	EML3;MTA2	0.61	14.01	0.55	1.96e-37	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs7819412	0.594	rs7460507	chr8:10969075	C/T	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.99	-0.35	1.05e-14	Triglycerides;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg13282195	chr8:144660772	NAPRT1	0.98	7.59	0.33	1.83e-13	Attention deficit hyperactivity disorder;
LGG	trans	rs9854771	0.507	rs4686529	chr3:189497616	A/G	cg09921682	chr7:50133131	ZPBP	0.32	6.67	0.3	7.19e-11	Pancreatic cancer;
LGG	cis	rs2760061	0.626	rs2313118	chr1:228118084	T/C	cg18477163	chr1:228402036	OBSCN	-0.26	-7.13	-0.31	3.97e-12	Diastolic blood pressure;
LGG	trans	rs7819412	0.654	rs4840550	chr8:11029029	T/G	cg16141378	chr3:129829833	LOC729375	0.4	9.05	0.39	4.01e-18	Triglycerides;
LGG	cis	rs3741404	0.825	rs11603538	chr11:63986713	C/A	cg18225595	chr11:63971243	STIP1	0.62	12.04	0.49	3.03e-29	Platelet count;
LGG	cis	rs2075671	0.903	rs11979818	chr7:100293639	A/G	cg00334542	chr7:100209784	MOSPD3	0.54	7.47	0.33	4.04e-13	Other erythrocyte phenotypes;
LGG	cis	rs559928	0.948	rs1198984	chr11:64148420	G/A	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.56	-7.23	-0.32	1.99e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs769267	0.930	rs4808957	chr19:19567248	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.42	0.56	3.52e-39	Tonsillectomy;
LGG	trans	rs73191547	0.771	rs11777161	chr8:10043145	A/T	cg06636001	chr8:8085503	FLJ10661	0.43	7.65	0.33	1.2e-13	Schizophrenia;
LGG	cis	rs4743820	0.620	rs10991787	chr9:93917218	A/G	cg14446406	chr9:93919335	NA	-0.9	-15.15	-0.58	2.16e-42	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs8028182	0.636	rs4545784	chr15:75755651	A/G	cg20655648	chr15:75932815	IMP3	0.46	7.86	0.34	2.73e-14	Sudden cardiac arrest;
LGG	trans	rs2727020	0.635	rs7124266	chr11:49280857	T/G	cg03929089	chr4:120376271	NA	0.79	13.82	0.54	1.27e-36	Coronary artery disease;
LGG	cis	rs3733585	0.699	rs4588456	chr4:9963895	A/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7662987	0.517	rs2602858	chr4:100030461	T/C	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg11608241	chr8:8085544	FLJ10661	0.31	7.17	0.32	2.91e-12	Triglycerides;
LGG	trans	rs9818758	0.607	rs11710247	chr3:49249800	G/T	cg21659725	chr3:3221576	CRBN	-0.65	-6.99	-0.31	9.39e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4927850	1.000	rs7630875	chr3:195753766	A/G	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.76	-0.41	1.32e-20	Pancreatic cancer;
LGG	cis	rs3126085	0.935	rs1496050	chr1:152163549	T/C	cg26876637	chr1:152193138	HRNR	0.54	8.74	0.38	4.47e-17	Atopic dermatitis;
LGG	cis	rs6909430	0.901	rs59635538	chr6:98642222	G/A	cg12860156	chr6:98744658	NA	-0.44	-7.16	-0.32	3.14e-12	Quantitative traits;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	0.51	7.5	0.33	3.36e-13	Renal function-related traits (BUN);
LGG	cis	rs10197940	0.662	rs4592848	chr2:152337822	G/A	cg06191203	chr2:152266755	RIF1	-0.46	-8.03	-0.35	8.08e-15	Lung cancer;
LGG	cis	rs9916302	0.706	rs6503500	chr17:37485925	C/T	cg07936489	chr17:37558343	FBXL20	-0.99	-15.44	-0.58	1.11e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs2228479	0.867	rs62052185	chr16:89969254	C/T	cg06558623	chr16:89946397	TCF25	1.16	14.96	0.57	1.45e-41	Skin colour saturation;
LGG	cis	rs9393692	0.905	rs9358919	chr6:26287862	C/T	cg13736514	chr6:26305472	NA	-0.47	-9.75	-0.41	1.45e-20	Educational attainment;
LGG	cis	rs654950	0.505	rs2475839	chr1:42006005	A/G	cg16096631	chr1:42092165	HIVEP3	-0.35	-7.17	-0.32	2.93e-12	Airway imaging phenotypes;
LGG	cis	rs9487094	0.922	rs10499053	chr6:109940498	A/G	cg01125227	chr6:109776195	MICAL1	0.51	8.74	0.38	4.42e-17	Height;
LGG	trans	rs7726839	0.540	rs3749618	chr5:602650	A/G	cg25482853	chr8:67687455	SGK3	0.94	11.94	0.49	7.65e-29	Obesity-related traits;
LGG	cis	rs1682825	0.858	rs58731244	chr3:10756497	G/A	cg23512531	chr3:10780469	NA	0.61	7.84	0.34	3.15e-14	Economic and political preferences (feminism/equality);
LGG	cis	rs736408	0.648	rs3774355	chr3:52817778	G/A	cg14092988	chr3:52407081	DNAH1	0.28	7.28	0.32	1.45e-12	Bipolar disorder;
LGG	trans	rs11039798	0.502	rs961863	chr11:48417021	T/C	cg15704280	chr7:45808275	SEPT13	-0.72	-9.94	-0.42	3.09e-21	Axial length;
LGG	trans	rs6601327	0.550	rs4422774	chr8:9522011	A/G	cg12395012	chr8:11607386	GATA4	0.4	6.97	0.31	1.08e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9303401	0.614	rs35245220	chr17:56510305	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.87	14.1	0.55	7.88e-38	Cognitive test performance;
LGG	cis	rs17376456	0.825	rs17372615	chr5:93124768	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.84	0.45	1.49e-24	Diabetic retinopathy;
LGG	cis	rs3858526	0.959	rs11039723	chr11:5956002	G/C	cg05234568	chr11:5960015	NA	-0.75	-12.25	-0.49	4.58e-30	DNA methylation (variation);
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg05064044	chr6:292385	DUSP22	-0.65	-11.01	-0.46	3.46e-25	Menopause (age at onset);
LGG	cis	rs11098499	0.954	rs6834796	chr4:120414693	A/C	cg09307838	chr4:120376055	NA	0.81	13.6	0.53	1.15e-35	Corneal astigmatism;
LGG	cis	rs11722228	0.893	rs6449144	chr4:9944650	T/G	cg08250081	chr4:10125330	NA	-0.53	-9.84	-0.42	6.98e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9487094	0.961	rs12528822	chr6:109661541	C/G	cg01125227	chr6:109776195	MICAL1	0.51	8.75	0.38	4.08e-17	Height;
LGG	trans	rs11875185	0.510	rs111416457	chr18:55594075	G/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9467773	1.000	rs9467782	chr6:26542773	G/A	cg09904177	chr6:26538194	HMGN4	0.77	17.74	0.64	4.22e-54	Intelligence (multi-trait analysis);
LGG	cis	rs208520	0.661	rs150263	chr6:66777620	T/C	cg07460842	chr6:66804631	NA	-0.96	-17.85	-0.64	1.24e-54	Exhaled nitric oxide output;
LGG	cis	rs2249694	0.878	rs2987792	chr10:135371466	T/C	cg20169779	chr10:135381914	SYCE1	0.5	7.51	0.33	3e-13	Obesity-related traits;
LGG	cis	rs10078	0.559	rs2671891	chr5:456386	A/G	cg08916839	chr5:415575	AHRR	0.99	14.18	0.55	3.73e-38	Fat distribution (HIV);
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg10460130	chr2:242625978	DTYMK	0.44	7.41	0.33	5.92e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs4481887	0.893	rs1339990	chr1:248509495	C/T	cg13385794	chr1:248469461	NA	-0.46	-7.76	-0.34	5.53e-14	Common traits (Other);
LGG	cis	rs6502050	0.871	rs9916649	chr17:80075739	G/A	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs4750440	0.735	rs2447014	chr10:14010122	C/T	cg27542038	chr10:14027202	FRMD4A	0.63	12.06	0.49	2.49e-29	Adiponectin levels;
LGG	cis	rs2708377	0.858	rs55748583	chr12:11139712	T/C	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.78	-0.3	3.75e-11	Bitter taste perception;
LGG	trans	rs3960554	0.674	rs112742093	chr7:75800597	T/C	cg19862616	chr7:65841803	NCRNA00174	0.87	12.31	0.5	2.55e-30	Eotaxin levels;
LGG	cis	rs6466055	0.669	rs10808141	chr7:104715490	T/G	cg04380332	chr7:105027541	SRPK2	-0.39	-7.34	-0.32	9.82e-13	Schizophrenia;
LGG	cis	rs7582720	1.000	rs72932566	chr2:203855342	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.65	0.41	3.24e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9311474	0.508	rs11714565	chr3:52606292	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.31	-0.32	1.15e-12	Electroencephalogram traits;
LGG	cis	rs13108904	0.539	rs13141992	chr4:1340765	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.64	10.72	0.45	4.37e-24	Obesity-related traits;
LGG	cis	rs6956675	0.534	rs7780975	chr7:62652443	G/A	cg08930214	chr7:62859557	LOC100287834	0.38	6.99	0.31	9.5e-12	Obesity-related traits;
LGG	cis	rs1018836	0.923	rs6988733	chr8:91535686	C/T	cg16814680	chr8:91681699	NA	-0.8	-14.56	-0.56	8.63e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7107174	1.000	rs2510032	chr11:77968631	G/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.32	-0.32	1.11e-12	Testicular germ cell tumor;
LGG	cis	rs17376456	0.877	rs10066791	chr5:93350255	G/T	cg19507638	chr5:93509721	C5orf36	-0.7	-9.7	-0.41	2.16e-20	Diabetic retinopathy;
LGG	cis	rs354225	0.546	rs10170646	chr2:54799606	T/C	cg26097391	chr2:54893211	SPTBN1	0.32	7.99	0.35	1.12e-14	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08703324	chr15:43785408	TP53BP1	0.44	6.78	0.3	3.57e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg04025307	chr7:1156635	C7orf50	0.82	14.76	0.57	1.15e-40	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4555082	0.874	rs11625098	chr14:105756891	A/G	cg10792982	chr14:105748885	BRF1	0.67	12.97	0.52	4.78e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg27535305	chr1:53392650	SCP2	0.35	7.78	0.34	4.91e-14	Monocyte count;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg04267008	chr7:1944627	MAD1L1	-0.68	-11.53	-0.47	3.36e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7980687	0.550	rs1727324	chr12:123698603	A/T	cg00376283	chr12:123451042	ABCB9	0.61	9.26	0.4	7.96e-19	Height;Educational attainment;Head circumference (infant);
LGG	cis	rs2587949	0.615	rs1385485	chr3:4231751	C/T	cg16519197	chr3:4211558	NA	-0.32	-6.72	-0.3	5.3e-11	Periodontitis (DPAL);
LGG	cis	rs11711311	1.000	rs62268168	chr3:113489447	A/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.59	-0.33	1.75e-13	IgG glycosylation;
LGG	cis	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg08975724	chr8:8085496	FLJ10661	0.44	8.48	0.37	3.16e-16	Joint mobility (Beighton score);
LGG	cis	rs4481887	1.000	rs10888351	chr1:248451608	G/A	cg13385794	chr1:248469461	NA	0.48	8.04	0.35	7.56e-15	Common traits (Other);
LGG	cis	rs4731207	0.596	rs12535807	chr7:124591433	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.82	-0.3	2.92e-11	Cutaneous malignant melanoma;
LGG	cis	rs12478296	0.681	rs6598999	chr2:242994405	C/A	cg18898632	chr2:242989856	NA	-0.73	-8.99	-0.39	6.53e-18	Obesity-related traits;
LGG	cis	rs924043	0.636	rs28506963	chr6:170395474	T/C	cg00389036	chr6:170409598	NA	0.54	6.89	0.31	1.81e-11	Type 1 diabetes;
LGG	cis	rs7503807	0.515	rs12939413	chr17:78679449	C/T	cg18469159	chr17:78755841	RPTOR	-0.66	-11.48	-0.47	5.35e-27	Obesity;
LGG	cis	rs5769765	1.000	rs4824112	chr22:50284345	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.85	-12.52	-0.5	3.5e-31	Schizophrenia;
LGG	cis	rs4900538	0.963	rs8017980	chr14:102961341	C/G	cg18135206	chr14:102964638	TECPR2	0.84	16.4	0.61	5.33e-48	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs2243480	1.000	rs4149468	chr7:65825690	T/C	cg12463550	chr7:65579703	CRCP	0.78	8.51	0.37	2.43e-16	Diabetic kidney disease;
LGG	cis	rs1550582	1.000	rs4909827	chr8:135517576	C/T	cg17885191	chr8:135476712	NA	0.67	10.5	0.44	2.82e-23	Educational attainment;
LGG	cis	rs7249142	0.549	rs1858846	chr19:19281187	T/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.19	-0.46	7.03e-26	IgG glycosylation;
LGG	cis	rs28595532	0.920	rs116098781	chr4:119771613	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs12476592	0.636	rs262493	chr2:63845066	G/T	cg17519650	chr2:63277830	OTX1	-0.44	-6.78	-0.3	3.68e-11	Childhood ear infection;
LGG	cis	rs9547996	0.879	rs73184517	chr13:38194023	G/A	cg13634560	chr13:38173852	POSTN	-0.35	-6.85	-0.3	2.43e-11	Diastolic blood pressure;
LGG	cis	rs17767392	0.958	rs55883127	chr14:71980236	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.19	-0.39	1.36e-18	Mitral valve prolapse;
LGG	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg12623918	chr2:306882	NA	0.51	9.37	0.4	3.33e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs727563	0.635	rs2899348	chr22:42164516	C/G	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs8177253	1.000	rs8177252	chr3:133480174	C/A	cg08048268	chr3:133502702	NA	-0.6	-11.13	-0.46	1.19e-25	Iron status biomarkers;
LGG	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg16482183	chr6:26056742	HIST1H1C	0.62	9.82	0.42	8.2e-21	Height;
LGG	cis	rs4481887	0.927	rs4534422	chr1:248479482	A/G	cg00666640	chr1:248458726	OR2T12	0.56	8.91	0.38	1.21e-17	Common traits (Other);
LGG	cis	rs2228479	0.681	rs10153196	chr16:89967397	A/C	cg27400746	chr16:89904261	SPIRE2	-0.77	-12.59	-0.51	1.77e-31	Skin colour saturation;
LGG	cis	rs7296418	0.961	rs11613937	chr12:123520071	C/T	cg05973401	chr12:123451056	ABCB9	0.46	7.54	0.33	2.47e-13	Platelet count;
LGG	cis	rs1577917	0.883	rs9450348	chr6:86598036	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.56	-10.0	-0.42	1.87e-21	Response to antipsychotic treatment;
LGG	cis	rs597539	0.690	rs608810	chr11:68624118	G/C	cg04772025	chr11:68637568	NA	0.76	12.87	0.51	1.3e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.545	rs2707851	chr7:66089165	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.57	-10.32	-0.43	1.29e-22	Aortic root size;
LGG	cis	rs11585357	0.947	rs3003441	chr1:17611869	C/T	cg08277548	chr1:17600880	PADI3	0.7	8.37	0.36	6.82e-16	Hair shape;
LGG	cis	rs4253772	0.575	rs74879643	chr22:46660014	T/C	cg09461388	chr22:46763229	CELSR1	-0.69	-7.12	-0.31	4.25e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs4901869	0.902	rs2162491	chr14:59296247	C/T	cg02291164	chr14:59296302	NA	0.26	6.7	0.3	6.05e-11	Panic disorder;
LGG	cis	rs2180341	0.883	rs6904630	chr6:127696869	A/G	cg27446573	chr6:127587934	RNF146	1.14	22.25	0.72	4.01e-75	Breast cancer;
LGG	cis	rs9788721	0.933	rs72738786	chr15:78828086	G/T	cg17108064	chr15:78857060	CHRNA5	-0.38	-7.6	-0.33	1.61e-13	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs11098499	0.738	rs34566984	chr4:120361270	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.25	0.49	4.32e-30	Corneal astigmatism;
LGG	cis	rs2273669	0.667	rs16822	chr6:109307710	G/A	cg05315195	chr6:109294784	ARMC2	-0.65	-8.55	-0.37	1.84e-16	Prostate cancer;
LGG	trans	rs1814175	0.585	rs4881661	chr11:50000117	A/G	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	cis	rs10274279	1.000	rs6459798	chr7:157381735	C/T	cg09270525	chr7:157391030	PTPRN2	0.74	9.61	0.41	4.56e-20	Myopia (pathological);
LGG	trans	rs1814175	0.645	rs28436748	chr11:50046422	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs13118159	0.934	rs7656122	chr4:1373042	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.92	0.35	1.84e-14	Longevity;
LGG	cis	rs7929679	0.602	rs1588354	chr11:34808486	T/A	cg06937548	chr11:34938143	PDHX;APIP	0.4	6.76	0.3	4.26e-11	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs2439831	0.850	rs9944216	chr15:44160773	C/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.88	-9.67	-0.41	2.76e-20	Lung cancer in ever smokers;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg09359103	chr1:154839909	KCNN3	-0.48	-9.63	-0.41	4.11e-20	Prostate cancer;
LGG	cis	rs12477438	0.520	rs13012481	chr2:99754290	C/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.86	18.76	0.66	8.07e-59	Chronic sinus infection;
LGG	cis	rs10876993	0.784	rs1871417	chr12:58018979	C/T	cg18357645	chr12:58087776	OS9	-0.64	-11.07	-0.46	1.98e-25	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs6952808	0.689	rs2008263	chr7:2048335	A/G	cg04267008	chr7:1944627	MAD1L1	-0.63	-11.13	-0.46	1.14e-25	Bipolar disorder and schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09379601	chr19:12992224	DNASE2	0.48	7.76	0.34	5.43e-14	Gut microbiome composition (summer);
LGG	cis	rs2235573	0.625	rs139901	chr22:38406147	T/C	cg10587741	chr22:38071170	LGALS1	-0.33	-6.72	-0.3	5.39e-11	Glioblastoma;Glioma;
LGG	cis	rs8044868	0.530	rs12446480	chr16:72056757	A/G	cg06353428	chr16:71660113	MARVELD3	0.42	7.05	0.31	6.71e-12	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs1318772	0.932	rs11745445	chr5:112947682	G/T	cg12552261	chr5:112820674	MCC	0.67	7.21	0.32	2.35e-12	F-cell distribution;
LGG	cis	rs752010	0.714	rs6600384	chr1:42085141	A/G	cg16096631	chr1:42092165	HIVEP3	-0.73	-20.78	-0.69	3.08e-68	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2635047	0.967	rs3816125	chr18:44601611	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.36	-6.94	-0.31	1.33e-11	Educational attainment;
LGG	cis	rs11096990	0.613	rs1451821	chr4:39180417	G/T	cg24403649	chr4:39172243	NA	-0.4	-7.08	-0.31	5.21e-12	Cognitive function;
LGG	cis	rs758324	0.947	rs615305	chr5:131291856	A/G	cg06307176	chr5:131281290	NA	-0.59	-9.5	-0.4	1.16e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs7089973	0.604	rs2420069	chr10:116605103	A/G	cg08188268	chr10:116634841	FAM160B1	0.34	7.42	0.33	5.52e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	trans	rs7829975	0.564	rs2921060	chr8:8317817	G/T	cg27411982	chr8:10470053	RP1L1	-0.41	-7.18	-0.32	2.86e-12	Mood instability;
LGG	cis	rs6138458	1.000	rs227632	chr20:24913729	G/A	cg26195577	chr20:24973756	C20orf3	1.24	26.06	0.77	7.75e-93	Blood protein levels;
LGG	cis	rs3820068	0.603	rs7531396	chr1:15969870	G/C	cg05660106	chr1:15850417	CASP9	0.84	17.15	0.62	2.17e-51	Systolic blood pressure;
LGG	cis	rs4936894	0.500	rs10893202	chr11:124165987	G/A	cg27160556	chr11:124181099	OR8D1	-0.46	-10.64	-0.44	8.48e-24	Aging (time to death);
LGG	cis	rs1620921	0.653	rs2489967	chr6:161262877	G/T	cg01280913	chr6:161186852	NA	-0.37	-7.48	-0.33	3.81e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs7106204	0.514	rs7107321	chr11:24259879	T/C	ch.11.24196551F	chr11:24239977	NA	0.9	12.18	0.49	8.56e-30	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs11169552	0.510	rs7307419	chr12:51007013	T/C	cg12884762	chr12:50931848	DIP2B	-0.41	-7.73	-0.34	6.86e-14	Colorectal cancer;
LGG	cis	rs6714710	0.663	rs71429376	chr2:98534412	T/C	cg26665480	chr2:98280029	ACTR1B	0.57	9.23	0.39	9.44e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs10484885	0.878	rs55750696	chr6:90552336	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.6	-0.44	1.22e-23	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs4535700	0.543	rs2174459	chr7:55991293	T/C	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	4.01e-11	Macular telangiectasia type 2;
LGG	cis	rs72634258	0.554	rs10462018	chr1:7879627	C/T	cg00042356	chr1:8021962	PARK7	0.59	7.63	0.33	1.33e-13	Inflammatory bowel disease;
LGG	cis	rs7582180	0.629	rs6757754	chr2:100951273	C/T	cg05692746	chr2:100937584	LONRF2	0.65	12.14	0.49	1.25e-29	Intelligence (multi-trait analysis);
LGG	cis	rs875971	1.000	rs7801282	chr7:65613687	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.6	-0.37	1.21e-16	Aortic root size;
LGG	cis	rs9747201	1.000	rs36048409	chr17:80096961	T/A	cg09264619	chr17:80180166	NA	0.52	10.22	0.43	2.93e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2916247	0.954	rs990747	chr8:93173000	C/T	cg10183463	chr8:93005414	RUNX1T1	0.35	7.01	0.31	8.75e-12	Intelligence (multi-trait analysis);
LGG	cis	rs745080	0.890	rs67875014	chr14:52927482	T/C	cg23333723	chr14:53022898	GPR137C	-0.33	-7.12	-0.31	4.03e-12	Orofacial clefts;
LGG	cis	rs9944715	0.906	rs8095729	chr18:43741982	T/C	cg26436583	chr18:43649176	PSTPIP2	0.42	7.98	0.35	1.2e-14	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.39	7.64	0.33	1.28e-13	Schizophrenia;
LGG	cis	rs9611565	0.649	rs6002480	chr22:42176917	A/T	cg06634786	chr22:41940651	POLR3H	-0.68	-11.02	-0.46	3.12e-25	Vitiligo;
LGG	cis	rs116095464	0.681	rs9687745	chr5:229309	C/T	cg22857025	chr5:266934	NA	-1.49	-26.29	-0.77	7.14e-94	Breast cancer;
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg18350739	chr11:68623251	NA	-0.87	-22.17	-0.72	9.23e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12477438	0.798	rs12477754	chr2:99628073	G/A	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs2228479	0.850	rs62056063	chr16:89903680	C/T	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.02e-34	Skin colour saturation;
LGG	cis	rs7089973	0.604	rs55759483	chr10:116573423	T/C	cg03647239	chr10:116582469	FAM160B1	0.41	7.16	0.32	3.09e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6066825	0.644	rs6066823	chr20:47338768	C/G	cg18078177	chr20:47281410	PREX1	0.45	7.63	0.33	1.38e-13	Colorectal cancer;
LGG	cis	rs2075371	0.501	rs1646653	chr7:134024686	A/G	cg20476274	chr7:133979776	SLC35B4	0.53	9.47	0.4	1.44e-19	Mean platelet volume;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg13939156	chr17:80058883	NA	-0.45	-8.75	-0.38	4.09e-17	Life satisfaction;
LGG	cis	rs3925075	1.000	rs3925074	chr16:31347807	G/A	cg02846316	chr16:31340340	ITGAM	0.4	7.99	0.35	1.11e-14	IgA nephropathy;
LGG	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg02466173	chr16:30829666	NA	0.51	8.72	0.38	4.85e-17	Dementia with Lewy bodies;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg16524936	chr4:1340807	KIAA1530	-0.42	-6.78	-0.3	3.67e-11	Longevity;
LGG	cis	rs7824557	0.564	rs13274106	chr8:11233958	A/G	cg21775007	chr8:11205619	TDH	-0.76	-13.16	-0.52	8.01e-34	Retinal vascular caliber;
LGG	cis	rs986417	1.000	rs1254254	chr14:60831146	G/A	cg27398547	chr14:60952738	C14orf39	-0.73	-7.01	-0.31	8.51e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6708331	0.938	rs13389246	chr2:70354231	A/G	cg01613454	chr2:70366299	NA	0.53	9.05	0.39	3.93e-18	Obesity-related traits;
LGG	cis	rs975722	0.646	rs7810506	chr7:117116183	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.26	-0.4	7.8e-19	Coronary artery disease;
LGG	cis	rs1559088	0.576	rs10407255	chr19:33581150	A/G	cg03563238	chr19:33554763	RHPN2	0.44	10.11	0.43	7.46e-22	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3747547	0.818	rs11794350	chr9:37947420	C/G	cg13774184	chr9:37916125	SHB	-0.75	-8.63	-0.37	9.85e-17	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs2836974	0.897	rs35064900	chr21:40555492	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.71	0.64	6.02e-54	Cognitive function;
LGG	trans	rs12599106	0.792	rs76039834	chr16:34598453	G/A	cg01171360	chr6:293285	DUSP22	-0.41	-6.9	-0.31	1.7e-11	Menopause (age at onset);
LGG	trans	rs61931739	0.926	rs13377754	chr12:34051765	T/C	cg13010199	chr12:38710504	ALG10B	-0.45	-8.25	-0.36	1.61e-15	Morning vs. evening chronotype;
LGG	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg00938859	chr5:1591904	SDHAP3	0.88	12.74	0.51	4.46e-32	Breast cancer;
LGG	cis	rs9302065	0.565	rs2993584	chr13:95961678	C/A	cg26751094	chr13:95954534	ABCC4	-0.33	-7.78	-0.34	4.79e-14	Blood metabolite levels;
LGG	cis	rs3010562	1.000	rs3010562	chr6:167765251	A/G	cg22772386	chr6:167763320	NA	-0.52	-10.64	-0.44	8.78e-24	Gut microbiome composition (summer and winter);
LGG	cis	rs3733585	0.699	rs7686538	chr4:9948077	C/T	cg00071950	chr4:10020882	SLC2A9	-0.33	-6.68	-0.3	6.72e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg00745463	chr17:30367425	LRRC37B	0.53	7.08	0.31	5.33e-12	Hip circumference adjusted for BMI;
LGG	trans	rs2243480	0.522	rs73150635	chr7:65972490	C/T	cg10756647	chr7:56101905	PSPH	0.75	7.39	0.32	6.72e-13	Diabetic kidney disease;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg00684032	chr4:1343700	KIAA1530	0.41	7.69	0.34	9.21e-14	Obesity-related traits;
LGG	cis	rs4075765	0.764	rs55996110	chr11:26275560	C/G	cg19182008	chr11:26298241	NA	1.0	8.97	0.38	7.49e-18	Cannabis dependence symptom count;
LGG	trans	rs12579753	0.879	rs7131927	chr12:82166313	T/C	cg07923666	chr12:49932857	KCNH3	-0.5	-7.88	-0.34	2.41e-14	Resting heart rate;
LGG	trans	rs3733585	0.660	rs13122290	chr4:9933832	A/G	cg26043149	chr18:55253948	FECH	-0.41	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2361718	0.500	rs4889818	chr17:78085228	A/G	cg21238619	chr17:78079768	GAA	-0.52	-9.91	-0.42	4.16e-21	Yeast infection;
LGG	cis	rs714031	1.000	rs5750869	chr22:40065332	T/C	cg21377881	chr22:40064566	CACNA1I	-0.61	-14.51	-0.56	1.33e-39	Schizophrenia;
LGG	cis	rs2133450	0.508	rs6443100	chr3:7333382	G/T	cg19930620	chr3:7340148	GRM7	0.41	8.94	0.38	9.3e-18	Early response to risperidone in schizophrenia;
LGG	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg13393036	chr8:95962371	TP53INP1	-0.27	-7.11	-0.31	4.44e-12	Type 2 diabetes;
LGG	cis	rs11700980	0.636	rs17797032	chr21:30265585	G/A	cg24692254	chr21:30365293	RNF160	-0.63	-7.49	-0.33	3.56e-13	QRS complex (12-leadsum);
LGG	cis	rs7847628	0.551	rs10818476	chr9:123572038	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.88	18.87	0.66	2.52e-59	Birth weight;
LGG	cis	rs9611565	0.592	rs6519270	chr22:42078666	A/G	cg17376030	chr22:41985996	PMM1	-0.56	-9.0	-0.39	5.75e-18	Vitiligo;
LGG	cis	rs12477438	0.520	rs4851187	chr2:99745860	G/T	cg08885076	chr2:99613938	TSGA10	-0.41	-8.74	-0.38	4.17e-17	Chronic sinus infection;
LGG	cis	rs1322639	1.000	rs9689079	chr6:169587148	A/G	cg03254818	chr6:169586852	NA	-0.62	-10.9	-0.45	8.66e-25	Pulse pressure;
LGG	cis	rs561341	1.000	rs560132	chr17:30320019	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.57	-0.44	1.52e-23	Hip circumference adjusted for BMI;
LGG	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg08508325	chr11:3079039	CARS	0.38	7.05	0.31	6.43e-12	Calcium levels;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg01458961	chr4:102269425	PPP3CA	0.39	6.68	0.3	6.72e-11	Body mass index;
LGG	cis	rs2976388	0.647	rs2572906	chr8:143798269	G/A	cg06565975	chr8:143823917	SLURP1	0.37	9.4	0.4	2.6e-19	Urinary tract infection frequency;
LGG	cis	rs877282	0.583	rs10904562	chr10:819058	T/C	cg15764593	chr10:829463	NA	-0.67	-9.77	-0.41	1.22e-20	Uric acid levels;
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.37	0.36	7.07e-16	Tonsillectomy;
LGG	cis	rs28386778	0.897	rs7221853	chr17:61859836	A/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs769267	0.965	rs8101938	chr19:19390497	G/A	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs55823223	0.646	rs74410877	chr17:73832384	C/T	cg23806715	chr17:73775811	H3F3B	0.98	10.87	0.45	1.13e-24	Psoriasis;
LGG	trans	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-8.05	-0.35	7.2e-15	Neuroticism;
LGG	cis	rs798766	1.000	rs798744	chr4:1714684	C/A	cg00006948	chr4:1768889	NA	-0.51	-7.01	-0.31	8.54e-12	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs7769051	0.522	rs6911773	chr6:133128848	T/C	cg07930552	chr6:133119739	C6orf192	1.16	10.15	0.43	5.4e-22	Type 2 diabetes nephropathy;
LGG	trans	rs7395662	0.963	rs4882170	chr11:48724214	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs701145	0.585	rs1727944	chr3:153826603	A/C	cg17054900	chr3:154042577	DHX36	-0.76	-9.11	-0.39	2.52e-18	Coronary artery disease;
LGG	cis	rs9486719	0.948	rs2092095	chr6:96870864	T/G	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs2153535	0.580	rs6905242	chr6:8471799	A/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.5	1.86e-31	Motion sickness;
LGG	cis	rs28595532	1.000	rs28595532	chr4:119716950	A/C	cg21605333	chr4:119757512	SEC24D	1.36	13.66	0.54	5.99e-36	Cannabis dependence symptom count;
LGG	cis	rs7326068	0.610	rs2772169	chr13:21314725	T/C	cg04906043	chr13:21280425	IL17D	-0.49	-7.87	-0.34	2.47e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs5769765	0.730	rs62233964	chr22:50317410	C/G	cg26441486	chr22:50317300	CRELD2	0.41	7.1	0.31	4.61e-12	Schizophrenia;
LGG	cis	rs10504229	0.679	rs16921623	chr8:58039473	G/C	cg20607798	chr8:58055168	NA	0.59	7.14	0.31	3.72e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs16921677	chr8:58052431	T/C	cg20607798	chr8:58055168	NA	0.63	7.33	0.32	1.05e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs693839	0.664	rs7996611	chr13:81051090	A/C	cg16840616	chr7:93831	NA	0.39	7.03	0.31	7.54e-12	Body fat percentage;
LGG	trans	rs6089829	0.962	rs6062393	chr20:61663230	G/A	cg08862035	chr2:2617432	NA	0.42	6.95	0.31	1.29e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs875971	0.558	rs4433015	chr7:65639723	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.5	-10.07	-0.42	1.05e-21	Aortic root size;
LGG	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg21427119	chr20:30132790	HM13	-0.55	-8.43	-0.36	4.45e-16	Mean corpuscular hemoglobin;
LGG	cis	rs17221829	0.645	rs9804648	chr11:89375840	A/G	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs2439831	0.850	rs7169322	chr15:44131014	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.5	0.4	1.13e-19	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg09699651	chr6:150184138	LRP11	0.52	9.3	0.4	5.5e-19	Lung cancer;
LGG	cis	rs4072980	0.527	rs11210825	chr1:38446986	G/A	cg04673462	chr1:38461896	NA	0.52	10.67	0.44	6.6e-24	Coronary artery disease;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg12070911	chr6:150209640	RAET1E	0.28	7.14	0.31	3.75e-12	Testicular germ cell tumor;
LGG	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.06	-0.31	6.13e-12	HDL cholesterol;
LGG	cis	rs778371	0.723	rs6704763	chr2:233592487	C/T	cg08000102	chr2:233561755	GIGYF2	0.71	11.98	0.49	5.24e-29	Schizophrenia;
LGG	cis	rs910316	0.935	rs2268620	chr14:75640403	G/A	cg06637938	chr14:75390232	RPS6KL1	-0.57	-10.19	-0.43	3.87e-22	Height;
LGG	cis	rs3749237	0.595	rs11130192	chr3:49467206	C/G	cg03060546	chr3:49711283	APEH	0.74	13.34	0.53	1.3600000000000001e-34	Resting heart rate;
LGG	cis	rs6815814	0.950	rs67206233	chr4:38807853	T/C	cg06935464	chr4:38784597	TLR10	0.6	8.31	0.36	1.08e-15	Breast cancer;
LGG	cis	rs4716602	0.609	rs12386633	chr7:156158232	G/C	cg16983916	chr7:156159713	NA	-0.49	-9.5	-0.4	1.14e-19	Anti-saccade response;
LGG	cis	rs4481887	0.927	rs11204637	chr1:248492581	G/A	cg01631408	chr1:248437212	OR2T33	-0.53	-9.48	-0.4	1.31e-19	Common traits (Other);
LGG	cis	rs9814567	1.000	rs13089966	chr3:134279197	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.96	0.52	5.42e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs2839186	0.647	rs9976233	chr21:47616913	G/A	cg14789911	chr21:47582049	C21orf56	0.45	7.35	0.32	8.98e-13	Testicular germ cell tumor;
LGG	cis	rs7122539	1.000	rs7122539	chr11:66662731	G/A	cg01599099	chr11:66649832	PC	0.38	7.57	0.33	2.02e-13	HIV-1 susceptibility;
LGG	cis	rs1799949	1.000	rs4793190	chr17:41200109	T/C	cg05368731	chr17:41323189	NBR1	0.93	18.29	0.65	1.2e-56	Menopause (age at onset);
LGG	cis	rs7226408	0.600	rs880714	chr18:34576790	A/G	cg15022739	chr18:34823045	BRUNOL4	0.43	9.29	0.4	6.03e-19	Obesity-related traits;
LGG	cis	rs2797685	0.755	rs41402249	chr1:7822723	C/G	cg04725166	chr1:7887271	PER3	0.55	7.22	0.32	2.17e-12	Crohn's disease;
LGG	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs6684428	0.536	rs11804906	chr1:56394231	A/G	cg11651538	chr1:56320950	NA	-0.43	-8.32	-0.36	1.01e-15	Airflow obstruction;
LGG	cis	rs7615952	0.512	rs4646765	chr3:125820707	G/A	cg15145296	chr3:125709740	NA	-0.61	-7.79	-0.34	4.48e-14	Blood pressure (smoking interaction);
LGG	cis	rs3820068	0.603	rs6668726	chr1:15962614	G/A	cg05660106	chr1:15850417	CASP9	0.85	17.21	0.62	1.17e-51	Systolic blood pressure;
LGG	cis	rs7264396	0.580	rs6119655	chr20:34412049	G/A	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.08	-0.31	5.33e-12	Total cholesterol levels;
LGG	cis	rs2439831	0.867	rs12443102	chr15:43932103	G/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.86	9.72	0.41	1.9e-20	Lung cancer in ever smokers;
LGG	cis	rs875971	0.862	rs801204	chr7:66022921	T/C	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.38e-12	Aortic root size;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg23985595	chr17:80112537	CCDC57	0.47	9.41	0.4	2.38e-19	Life satisfaction;
LGG	cis	rs2735413	0.881	rs12919818	chr16:78082862	C/T	cg04733911	chr16:78082701	NA	-0.78	-18.77	-0.66	7.31e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs977987	0.806	rs11643410	chr16:75428306	C/T	cg03315344	chr16:75512273	CHST6	0.5	9.89	0.42	4.56e-21	Dupuytren's disease;
LGG	cis	rs7659604	0.676	rs7691955	chr4:122700462	A/T	cg05802129	chr4:122689817	NA	-0.4	-6.7	-0.3	6.16e-11	Type 2 diabetes;
LGG	trans	rs747782	0.528	rs11039669	chr11:48328818	C/T	cg15704280	chr7:45808275	SEPT13	0.72	8.59	0.37	1.38e-16	Intraocular pressure;
LGG	cis	rs2688608	0.901	rs2664282	chr10:75620757	T/C	cg00564723	chr10:75632066	CAMK2G	-0.29	-6.73	-0.3	5.03e-11	Inflammatory bowel disease;
LGG	cis	rs7264396	0.676	rs6060729	chr20:34557004	G/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	cis	rs7106204	0.534	rs4923167	chr11:24274441	G/T	ch.11.24196551F	chr11:24239977	NA	0.86	9.5	0.4	1.12e-19	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs1961637	0.670	rs895773	chr2:223892804	C/G	cg02552189	chr2:223891284	NA	-0.38	-7.49	-0.33	3.43e-13	Oropharynx cancer;
LGG	cis	rs7927592	0.626	rs11228279	chr11:68309680	C/T	cg16797656	chr11:68205561	LRP5	-0.51	-10.04	-0.42	1.38e-21	Total body bone mineral density;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg11494091	chr17:61959527	GH2	0.99	24.19	0.75	3.53e-84	Prudent dietary pattern;
LGG	cis	rs12451471	0.500	rs8077056	chr17:78076006	C/T	cg06718696	chr17:78121285	EIF4A3	0.86	13.45	0.53	4.99e-35	Plateletcrit;Mean corpuscular hemoglobin concentration;
LGG	cis	rs17756712	0.527	rs1747586	chr6:614375	A/C	cg14374089	chr6:596013	EXOC2	0.58	8.49	0.37	2.78e-16	Vertical cup-disc ratio;
LGG	cis	rs2594989	0.943	rs9877694	chr3:11418873	A/C	cg01796438	chr3:11312864	ATG7	-0.51	-6.77	-0.3	3.84e-11	Circulating chemerin levels;
LGG	cis	rs6976053	0.870	rs6942607	chr7:100482526	C/G	cg03098644	chr7:100410630	EPHB4	-0.4	-7.02	-0.31	7.84e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs11098499	0.913	rs67073020	chr4:120152557	C/T	cg24375607	chr4:120327624	NA	0.61	9.99	0.42	2.14e-21	Corneal astigmatism;
LGG	cis	rs10464366	0.746	rs4723822	chr7:39141613	C/T	cg21665744	chr7:39171113	POU6F2	0.39	7.97	0.35	1.23e-14	IgG glycosylation;
LGG	trans	rs35110281	0.641	rs9978858	chr21:45085552	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.58	9.45	0.4	1.67e-19	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.09	0.84	4.45e-124	Prudent dietary pattern;
LGG	trans	rs561341	0.941	rs17780080	chr17:30343146	G/A	cg27661571	chr11:113659931	NA	-0.73	-9.73	-0.41	1.7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg21535247	chr6:8435926	SLC35B3	0.6	10.2	0.43	3.46e-22	Motion sickness;
LGG	cis	rs9560113	0.724	rs4771755	chr13:112170900	G/A	cg14952266	chr13:112191215	NA	0.42	7.47	0.33	3.9e-13	Menarche (age at onset);
LGG	cis	rs12681287	0.640	rs12679811	chr8:87465370	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.76	-0.34	5.3e-14	Caudate activity during reward;
LGG	cis	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg06521331	chr12:34319734	NA	-0.54	-9.82	-0.42	8.58e-21	Morning vs. evening chronotype;
LGG	trans	rs7939886	0.920	rs11231901	chr11:55811529	A/G	cg03929089	chr4:120376271	NA	0.8	8.38	0.36	6.51e-16	Myopia (pathological);
LGG	cis	rs1552244	0.572	rs7645759	chr3:10157368	C/T	cg00166722	chr3:10149974	C3orf24	0.57	8.19	0.36	2.64e-15	Alzheimer's disease;
LGG	cis	rs472402	0.560	rs2288447	chr5:6626091	C/T	cg08700190	chr5:6636046	SRD5A1	-0.34	-7.19	-0.32	2.57e-12	Response to amphetamines;
LGG	cis	rs9783347	1.000	rs4150655	chr11:18375164	A/T	cg03595886	chr11:18357587	GTF2H1	0.35	7.14	0.31	3.64e-12	Pancreatic cancer;
LGG	cis	rs9611565	0.592	rs57102627	chr22:41987627	T/C	cg06634786	chr22:41940651	POLR3H	-0.7	-11.27	-0.46	3.5e-26	Vitiligo;
LGG	cis	rs977987	0.806	rs4888405	chr16:75428196	A/C	cg03315344	chr16:75512273	CHST6	0.34	7.01	0.31	8.32e-12	Dupuytren's disease;
LGG	cis	rs7264396	0.790	rs6058293	chr20:34248891	T/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.5	7.44	0.33	5.05e-13	Total cholesterol levels;
LGG	cis	rs4843747	0.671	rs9921236	chr16:88117015	G/T	cg09044154	chr16:88155775	NA	-0.46	-7.05	-0.31	6.65e-12	Menopause (age at onset);
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg25173464	chr15:68126554	NA	-0.34	-7.14	-0.32	3.56e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08703553	chr2:111436428	BUB1	0.39	6.86	0.3	2.18e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs62400317	0.859	rs6919813	chr6:45159177	C/T	cg20913747	chr6:44695427	NA	-0.61	-10.09	-0.42	9.2e-22	Total body bone mineral density;
LGG	cis	rs7598759	0.679	rs6740843	chr2:232332139	A/C	cg19187155	chr2:232395269	NMUR1	0.43	7.79	0.34	4.56e-14	Noise-induced hearing loss;
LGG	cis	rs1018836	0.570	rs6471084	chr8:91463666	T/C	cg16814680	chr8:91681699	NA	-0.58	-9.77	-0.41	1.23e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2997447	0.655	rs2275949	chr1:26385150	C/G	cg19633962	chr1:26362018	EXTL1	-0.58	-8.63	-0.37	9.56e-17	QRS complex (12-leadsum);
LGG	trans	rs11098499	0.722	rs10006192	chr4:120263022	T/C	cg25214090	chr10:38739885	LOC399744	0.56	10.36	0.43	9.02e-23	Corneal astigmatism;
LGG	cis	rs4696584	0.696	rs72731014	chr4:155410650	T/C	cg04517429	chr4:155413618	DCHS2	-0.33	-7.5	-0.33	3.2e-13	Folding of antihelix;
LGG	cis	rs9300255	0.508	rs1716176	chr12:123655467	T/G	cg00376283	chr12:123451042	ABCB9	0.62	9.35	0.4	3.81e-19	Neutrophil percentage of white cells;
LGG	cis	rs780096	0.526	rs704791	chr2:27657167	T/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs11626933	1.000	rs11626933	chr14:90754311	A/G	cg04374321	chr14:90722782	PSMC1	0.43	6.7	0.3	6.13e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9399135	0.935	rs9376086	chr6:135371329	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.08e-19	Red blood cell count;
LGG	cis	rs3768617	0.510	rs10797851	chr1:183098001	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs9784649	1.000	rs9784649	chr5:25011524	G/A	cg08600765	chr20:34638493	LOC647979	-0.61	-7.64	-0.33	1.22e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2173063	1.000	rs74029126	chr15:93132100	A/C	cg07052004	chr15:93132129	NA	0.64	7.39	0.32	6.82e-13	Subcutaneous adipose tissue;
LGG	cis	rs477895	1.000	rs7947143	chr11:64090422	G/A	cg22916017	chr11:64110731	CCDC88B	-0.53	-7.12	-0.31	4.2e-12	Mean platelet volume;
LGG	cis	rs4631830	0.900	rs10763588	chr10:51539762	G/T	cg16070123	chr10:51489643	NA	-0.4	-7.25	-0.32	1.76e-12	Prostate-specific antigen levels;
LGG	cis	rs9517320	0.534	rs3858778	chr13:99172249	A/C	cg07423050	chr13:99094983	FARP1	0.57	10.61	0.44	1.13e-23	Longevity;
LGG	cis	rs155076	1.000	rs261431	chr13:21865738	A/G	cg11317459	chr13:21872234	NA	1.15	19.1	0.66	2.06e-60	White matter hyperintensity burden;
LGG	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg18446336	chr7:2847575	GNA12	-0.32	-8.48	-0.37	3.14e-16	Height;
LGG	cis	rs9393692	0.557	rs725575	chr6:26301919	A/T	cg13736514	chr6:26305472	NA	-0.49	-9.62	-0.41	4.33e-20	Educational attainment;
LGG	cis	rs13185787	1	rs13185787	chr5:130627884	A/G	cg06307176	chr5:131281290	NA	0.48	8.06	0.35	6.79e-15	Subjective well-being;
LGG	cis	rs7937682	0.889	rs2850247	chr11:111637202	C/A	cg08305652	chr11:111469057	NA	0.4	8.09	0.35	5.14e-15	Primary sclerosing cholangitis;
LGG	cis	rs9911578	1.000	rs8071280	chr17:57010225	T/C	cg12560992	chr17:57184187	TRIM37	0.89	15.74	0.59	4.98e-45	Intelligence (multi-trait analysis);
LGG	cis	rs3733585	0.805	rs882222	chr4:9981294	G/A	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.45	-0.44	4.28e-23	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs559928	0.606	rs57021319	chr11:63956102	G/A	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.93	0.31	1.41e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs933688	0.532	rs2973477	chr5:90553722	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	-0.53	-6.78	-0.3	3.57e-11	Smoking behavior;
LGG	cis	rs986417	0.711	rs761556	chr14:61061034	T/G	cg27398547	chr14:60952738	C14orf39	0.76	7.05	0.31	6.58e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs36715	1.000	rs181850	chr5:127547487	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.49	7.66	0.34	1.13e-13	Breast cancer;
LGG	cis	rs11148252	0.870	rs11148246	chr13:52797537	C/T	cg05335186	chr13:53173507	NA	0.48	9.98	0.42	2.26e-21	Lewy body disease;
LGG	cis	rs60843830	1.000	rs4497901	chr2:239969	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.8	15.33	0.58	3.35e-43	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs977987	0.931	rs1834013	chr16:75496163	G/T	cg03315344	chr16:75512273	CHST6	0.58	11.55	0.47	2.81e-27	Dupuytren's disease;
LGG	cis	rs6502050	0.805	rs4356529	chr17:80157797	A/G	cg16920238	chr17:80076378	CCDC57	0.31	6.87	0.3	2.13e-11	Life satisfaction;
LGG	trans	rs7980799	0.682	rs4931719	chr12:33602986	G/A	cg13010199	chr12:38710504	ALG10B	-0.44	-7.98	-0.35	1.18e-14	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs769267	0.930	rs6909	chr19:19619542	A/G	cg02546618	chr19:19431379	KIAA0892;SF4	0.45	7.45	0.33	4.57e-13	Tonsillectomy;
LGG	cis	rs72945132	0.556	rs57172967	chr11:70160060	G/A	cg00319359	chr11:70116639	PPFIA1	0.75	8.35	0.36	8.24e-16	Coronary artery disease;
LGG	cis	rs8062405	1.000	rs7198606	chr16:28875122	T/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9921192	1.000	rs2892165	chr16:4324293	A/T	cg13035052	chr16:4323854	TFAP4	0.45	7.94	0.35	1.54e-14	Prostate-specific antigen levels;
LGG	cis	rs2245008	0.762	rs168800	chr16:83980391	T/C	cg08589960	chr16:83986755	OSGIN1	0.51	7.98	0.35	1.2e-14	Pursuit maintenance gain;
LGG	cis	rs11203032	0.831	rs10887927	chr10:90940687	T/C	cg16672925	chr10:90967113	CH25H	0.75	11.18	0.46	7.27e-26	Heart failure;
LGG	cis	rs7226408	0.749	rs11664744	chr18:34435111	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs12458462	0.787	rs56006341	chr18:77439844	G/T	cg11879182	chr18:77439856	CTDP1	0.8	15.22	0.58	1.09e-42	Monocyte count;
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	trans	rs3857536	0.785	rs6455089	chr6:66944733	A/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs524281	0.861	rs6591208	chr11:65949689	A/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.65	-0.3	8.3e-11	Electroencephalogram traits;
LGG	cis	rs7635838	0.785	rs2574698	chr3:11557126	G/A	cg00170343	chr3:11313890	ATG7	0.4	6.69	0.3	6.41e-11	HDL cholesterol;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg00933542	chr6:150070202	PCMT1	-0.39	-7.23	-0.32	2.06e-12	Lung cancer;
LGG	cis	rs2243480	1.000	rs313803	chr7:65514731	G/A	cg12463550	chr7:65579703	CRCP	0.75	7.94	0.35	1.53e-14	Diabetic kidney disease;
LGG	cis	rs6951245	1.000	rs28399710	chr7:1070631	G/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.66	-0.54	6.46e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4689388	0.890	rs11732208	chr4:6292716	G/C	cg14416269	chr4:6271139	WFS1	0.5	9.19	0.39	1.3e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg08677398	chr8:58056175	NA	0.58	8.84	0.38	1.98e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1941687	0.509	rs6507060	chr18:31322278	C/T	cg27147174	chr7:100797783	AP1S1	0.62	11.39	0.47	1.11e-26	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13126279	chr21:47581558	C21orf56	-0.49	-8.53	-0.37	2.08e-16	Testicular germ cell tumor;
LGG	cis	rs7481584	0.603	rs399467	chr11:3072348	G/A	cg08508325	chr11:3079039	CARS	0.42	8.06	0.35	6.74e-15	Calcium levels;
LGG	cis	rs3845702	1.000	rs3845702	chr2:180848488	A/C	cg01881094	chr2:180872142	CWC22	0.9	13.92	0.54	4.63e-37	Schizophrenia;
LGG	cis	rs4774899	0.752	rs2585112	chr15:57358428	C/T	cg08128148	chr15:57256372	TCF12	-0.28	-6.84	-0.3	2.57e-11	Urinary tract infection frequency;
LGG	cis	rs1008375	0.902	rs6844984	chr4:17651304	C/G	cg18681998	chr4:17616180	MED28	0.87	20.11	0.68	3.95e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs2204008	0.806	rs7305409	chr12:38349133	G/A	cg06521331	chr12:34319734	NA	-0.53	-8.99	-0.39	6.29e-18	Bladder cancer;
LGG	cis	rs6964587	0.692	rs4727268	chr7:91840724	T/C	cg17063962	chr7:91808500	NA	0.54	10.41	0.44	5.82e-23	Breast cancer;
LGG	cis	rs3808502	0.549	rs11991139	chr8:11428395	C/T	cg19847130	chr8:10466454	RP1L1	0.31	6.74	0.3	4.62e-11	Neuroticism;
LGG	trans	rs1814175	0.765	rs1721990	chr11:49912154	G/C	cg03929089	chr4:120376271	NA	-1.02	-23.82	-0.74	1.78e-82	Height;
LGG	cis	rs67311347	0.956	rs4974029	chr3:40521318	C/G	cg13683864	chr3:40499215	RPL14	-1.16	-29.31	-0.81	1.43e-107	Renal cell carcinoma;
LGG	cis	rs6951245	0.580	rs78894484	chr7:1138721	T/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.58	-10.9	-0.45	8.87e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1814175	0.817	rs2866863	chr11:49953242	C/T	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs6963495	0.818	rs73190187	chr7:105164401	A/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg06636001	chr8:8085503	FLJ10661	-0.53	-10.25	-0.43	2.31e-22	Morning vs. evening chronotype;
LGG	cis	rs9467711	0.606	rs9358937	chr6:26374274	C/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3923380	0.503	rs10020050	chr4:77467819	A/G	cg07933720	chr4:77468187	SHROOM3	0.35	7.52	0.33	2.8e-13	Craniofacial microsomia;
LGG	cis	rs651907	0.557	rs34181125	chr3:101490278	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.55	0.56	9.43e-40	Colorectal cancer;
LGG	cis	rs12701220	0.744	rs2030958	chr7:1076010	G/T	cg26769984	chr7:1090371	C7orf50	0.56	9.5	0.4	1.11e-19	Bronchopulmonary dysplasia;
LGG	cis	rs4819052	0.851	rs2838831	chr21:46664775	C/T	cg02159808	chr21:46707872	POFUT2;LOC642852	0.56	9.14	0.39	1.95e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs709400	0.663	rs10141388	chr14:103939679	A/G	cg26031613	chr14:104095156	KLC1	0.79	13.69	0.54	4.58e-36	Body mass index;
LGG	cis	rs526231	0.511	rs1011453	chr5:102368027	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.52	-0.37	2.34e-16	Primary biliary cholangitis;
LGG	cis	rs62064224	0.748	rs72813015	chr17:30693331	T/C	cg12561776	chr17:30844705	MYO1D	-0.27	-6.87	-0.3	2.12e-11	Schizophrenia;
LGG	cis	rs910316	1.000	rs10149880	chr14:75633008	A/G	cg08847533	chr14:75593920	NEK9	-0.61	-11.46	-0.47	5.89e-27	Height;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg02018176	chr4:1364513	KIAA1530	0.46	10.26	0.43	2.14e-22	Obesity-related traits;
LGG	cis	rs7223966	0.921	rs2854207	chr17:61947107	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.25	-0.32	1.77e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs950776	0.518	rs11632604	chr15:78821914	T/C	cg16751781	chr15:78858589	CHRNA5	0.47	9.36	0.4	3.43e-19	Sudden cardiac arrest;
LGG	cis	rs61931739	0.635	rs7979207	chr12:33910566	C/T	cg06521331	chr12:34319734	NA	0.4	7.06	0.31	6.24e-12	Morning vs. evening chronotype;
LGG	cis	rs9303401	0.703	rs9911583	chr17:57210721	A/G	cg10487724	chr17:56770010	TEX14;RAD51C	-0.51	-8.64	-0.37	9.34e-17	Cognitive test performance;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	trans	rs2197308	0.765	rs117216293	chr12:37882982	T/C	cg06521331	chr12:34319734	NA	0.5	9.34	0.4	3.94e-19	Morning vs. evening chronotype;
LGG	cis	rs727505	1.000	rs720614	chr7:124452790	T/C	cg23710748	chr7:124431027	NA	-0.54	-10.3	-0.43	1.55e-22	Lewy body disease;
LGG	cis	rs35771425	0.600	rs2280079	chr1:211517202	A/G	cg10512769	chr1:211675356	NA	0.6	8.02	0.35	8.49e-15	Educational attainment (years of education);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10205287	chr4:100815590	MAPKSP1	0.42	6.71	0.3	5.53e-11	Cognitive performance;
LGG	cis	rs72945132	0.882	rs56770826	chr11:70128874	A/G	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs17221829	0.733	rs72971011	chr11:89358858	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.0	-0.39	5.85e-18	Anxiety in major depressive disorder;
LGG	cis	rs4690686	0.510	rs10520348	chr4:177261738	T/A	cg17059388	chr4:177262070	NA	1.02	24.07	0.75	1.34e-83	Essential tremor;
LGG	trans	rs6582630	0.519	rs11514372	chr12:38308613	T/G	cg06521331	chr12:34319734	NA	-0.5	-8.68	-0.37	6.68e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7572644	0.679	rs6745545	chr2:28021845	C/G	cg27432699	chr2:27873401	GPN1	0.47	6.72	0.3	5.42e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs963731	0.649	rs12620071	chr2:39345873	G/A	cg04010122	chr2:39346883	SOS1	0.93	8.14	0.35	3.78e-15	Corticobasal degeneration;
LGG	cis	rs908922	0.676	rs6674451	chr1:152531054	C/T	cg09873164	chr1:152488093	CRCT1	0.61	14.96	0.57	1.48e-41	Hair morphology;
LGG	cis	rs10173297	0.686	rs13389263	chr2:3711989	A/G	cg14882966	chr2:3699353	NA	0.56	7.04	0.31	7.17e-12	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs9522267	0.535	rs914031	chr13:112240176	C/A	cg12773197	chr13:112238673	NA	-0.37	-7.34	-0.32	9.44e-13	Hepatitis;
LGG	cis	rs4242434	0.672	rs4615566	chr8:22520682	T/C	cg03733263	chr8:22462867	KIAA1967	-0.96	-21.67	-0.71	2e-72	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg12070911	chr6:150209640	RAET1E	0.3	7.2	0.32	2.38e-12	Lung cancer;
LGG	cis	rs28735056	0.875	rs62103176	chr18:77623611	G/C	cg03511173	chr18:77590860	NA	0.43	7.28	0.32	1.4e-12	Schizophrenia;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.832	rs79808627	chr7:1092519	C/G	cg22907277	chr7:1156413	C7orf50	0.55	7.37	0.32	8.1e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5750830	0.649	rs5750813	chr22:39795228	G/C	cg11247378	chr22:39784982	NA	-0.31	-9.0	-0.39	5.78e-18	Intelligence (multi-trait analysis);
LGG	cis	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.63	-0.33	1.36e-13	Neuroticism;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg00933542	chr6:150070202	PCMT1	0.37	6.87	0.3	2.03e-11	Lung cancer;
LGG	cis	rs10256972	0.669	rs10229964	chr7:1051776	A/G	cg07308232	chr7:1071921	C7orf50	-0.48	-8.9	-0.38	1.31e-17	Longevity;Endometriosis;
LGG	cis	rs7829975	0.711	rs4481596	chr8:8704330	G/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.23	0.36	1.93e-15	Mood instability;
LGG	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.44e-31	Motion sickness;
LGG	trans	rs9354308	0.868	rs9453438	chr6:66540534	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.48	-8.28	-0.36	1.29e-15	Metabolite levels;
LGG	cis	rs11122272	0.735	rs2808611	chr1:231548480	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.63	11.03	0.46	2.79e-25	Hemoglobin concentration;
LGG	trans	rs1351696	1	rs1351696	chr11:48382471	A/G	cg15704280	chr7:45808275	SEPT13	-0.76	-8.94	-0.38	9.14e-18	D-dimer levels;
LGG	cis	rs9911578	0.935	rs12948039	chr17:57045184	C/T	cg12560992	chr17:57184187	TRIM37	0.83	14.76	0.57	1.11e-40	Intelligence (multi-trait analysis);
LGG	cis	rs2370759	1.000	rs16933177	chr10:32565705	G/A	cg01819863	chr10:32635814	EPC1	1.07	14.95	0.57	1.62e-41	Sexual dysfunction (female);
LGG	cis	rs7927592	0.956	rs60212556	chr11:68305494	C/T	cg01657329	chr11:68192670	LRP5	-0.48	-8.41	-0.36	5.18e-16	Total body bone mineral density;
LGG	cis	rs7811142	0.830	rs11769057	chr7:99964661	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.37	0.56	5.4300000000000003e-39	Platelet count;
LGG	cis	rs9291683	0.526	rs12506122	chr4:10033538	C/A	cg25986240	chr4:9926439	SLC2A9	-0.35	-7.0	-0.31	9e-12	Bone mineral density;
LGG	cis	rs453301	0.658	rs6986044	chr8:8874786	G/C	cg15556689	chr8:8085844	FLJ10661	-0.4	-7.05	-0.31	6.75e-12	Joint mobility (Beighton score);
LGG	trans	rs2439831	0.850	rs12702	chr15:44093927	C/T	cg20419181	chr4:38063874	TBC1D1	-0.49	-6.96	-0.31	1.18e-11	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.923	rs12174035	chr6:150084447	A/T	cg16507663	chr6:150244633	RAET1G	0.42	7.84	0.34	3.09e-14	Lung cancer;
LGG	cis	rs12195424	0.730	rs76618205	chr6:56305131	T/C	cg07152817	chr6:56299822	NA	-0.58	-6.98	-0.31	1e-11	Cerebrospinal fluid clusterin levels;
LGG	cis	rs4704187	0.687	rs1600074	chr5:74436574	C/T	cg03227963	chr5:74354835	NA	0.31	6.67	0.3	7.25e-11	Response to amphetamines;
LGG	trans	rs7819412	0.537	rs2127127	chr8:11434792	C/G	cg11608241	chr8:8085544	FLJ10661	-0.33	-7.54	-0.33	2.5e-13	Triglycerides;
LGG	trans	rs7819412	0.805	rs4333549	chr8:10979561	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.21	-0.46	5.71e-26	Triglycerides;
LGG	cis	rs10904908	0.733	rs55873260	chr10:17332529	C/T	cg01003015	chr10:17271136	VIM	0.48	7.81	0.34	3.8e-14	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg19761014	chr17:28927070	LRRC37B2	0.62	7.26	0.32	1.64e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7587476	0.862	rs13001462	chr2:215678346	G/A	cg04004882	chr2:215674386	BARD1	0.54	7.85	0.34	2.83e-14	Neuroblastoma;
LGG	cis	rs62400317	0.859	rs12206561	chr6:45182809	C/T	cg20913747	chr6:44695427	NA	-0.63	-10.25	-0.43	2.31e-22	Total body bone mineral density;
LGG	cis	rs7227917	0.536	rs56055402	chr18:45511924	G/A	cg22195133	chr18:45534586	NA	0.76	7.0	0.31	8.87e-12	Lung cancer in ever smokers;
LGG	cis	rs7917772	0.560	rs10786697	chr10:104378563	G/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.46	0.47	6.36e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs7444	0.882	rs140492	chr22:21923144	A/C	cg11654148	chr22:21984483	YDJC	-0.4	-8.05	-0.35	6.98e-15	Systemic lupus erythematosus;
LGG	cis	rs13102973	0.720	rs7687463	chr4:135885773	G/T	cg14419869	chr4:135874104	NA	0.47	7.98	0.35	1.17e-14	Subjective well-being;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg01114163	chr5:1856713	NA	-0.39	-6.74	-0.3	4.59e-11	Cardiovascular disease risk factors;
LGG	cis	rs3733585	0.699	rs7676733	chr4:9966956	G/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	4.99e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6121246	0.909	rs6089071	chr20:30378384	C/G	cg13852791	chr20:30311386	BCL2L1	0.77	12.35	0.5	1.75e-30	Mean corpuscular hemoglobin;
LGG	cis	rs8077889	0.700	rs28571770	chr17:41904066	A/T	cg26893861	chr17:41843967	DUSP3	0.9	15.49	0.58	6.74e-44	Triglycerides;
LGG	cis	rs17270561	0.609	rs1165155	chr6:25795577	A/T	cg17691542	chr6:26056736	HIST1H1C	0.61	10.15	0.43	5.64e-22	Iron status biomarkers;
LGG	cis	rs1008375	0.898	rs4698623	chr4:17594702	T/C	cg04450456	chr4:17643702	FAM184B	0.31	6.71	0.3	5.63e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-7.2	-0.32	2.39e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs8005677	1.000	rs4981449	chr14:23388871	C/G	cg25600027	chr14:23388339	RBM23	-0.45	-7.34	-0.32	1e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs10940138	0.501	rs6872249	chr5:67239774	T/C	ch.5.1281357F	chr5:67228439	NA	-0.48	-8.79	-0.38	2.87e-17	Menarche (age at onset);
LGG	cis	rs2050392	1.000	rs2480280	chr10:30696092	A/G	cg25182066	chr10:30743637	MAP3K8	-0.51	-10.44	-0.44	4.56e-23	Inflammatory bowel disease;
LGG	cis	rs79349575	0.783	rs17635252	chr17:47006950	T/C	cg16584676	chr17:46985605	UBE2Z	0.48	8.38	0.36	6.33e-16	Type 2 diabetes;
LGG	trans	rs7618501	0.633	rs9853222	chr3:50022926	T/C	cg21659725	chr3:3221576	CRBN	0.66	12.43	0.5	8.47e-31	Intelligence (multi-trait analysis);
LGG	trans	rs12310956	0.510	rs6488178	chr12:33885251	C/G	cg26384229	chr12:38710491	ALG10B	0.63	12.22	0.49	5.91e-30	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.782	rs117824012	chr12:38215517	T/C	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs10504229	0.683	rs67048677	chr8:58140023	C/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.966	rs807932	chr3:47354241	C/T	cg27129171	chr3:47204927	SETD2	0.78	15.03	0.57	6.87e-42	Colorectal cancer;
LGG	cis	rs2415984	0.562	rs4306423	chr14:46915671	G/A	cg14871534	chr14:47121158	RPL10L	0.44	7.33	0.32	1.03e-12	Number of children ever born;
LGG	cis	rs796364	0.951	rs281793	chr2:200847990	G/A	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs7084402	0.967	rs1649033	chr10:60279634	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.12	-0.64	7.26e-56	Refractive error;
LGG	cis	rs6500395	1.000	rs2883475	chr16:48560315	C/T	cg16662043	chr16:48846231	NA	0.35	6.86	0.3	2.25e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6735179	0.579	rs13396623	chr2:1758481	T/C	cg20570797	chr2:1712800	PXDN	-0.45	-8.17	-0.35	2.98e-15	Response to antipsychotic treatment;
LGG	cis	rs7726839	0.540	rs72705102	chr5:659437	T/C	cg14541582	chr5:601475	NA	-0.7	-10.67	-0.44	6.27e-24	Obesity-related traits;
LGG	trans	rs2562456	0.876	rs11668606	chr19:21737420	T/G	cg25042112	chr7:64838748	ZNF92	-0.46	-6.67	-0.3	7.35e-11	Pain;
LGG	cis	rs9527	0.590	rs10883834	chr10:104881402	T/C	cg05308233	chr10:104796373	CNNM2	-0.3	-6.68	-0.3	6.88e-11	Arsenic metabolism;
LGG	cis	rs2836974	0.568	rs7282604	chr21:40536910	C/T	cg11890956	chr21:40555474	PSMG1	-1.01	-21.0	-0.7	2.71e-69	Cognitive function;
LGG	cis	rs11190604	0.767	rs10883483	chr10:102174244	T/C	cg07570687	chr10:102243282	WNT8B	0.4	7.08	0.31	5.48e-12	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs7395662	1.000	rs12419576	chr11:48581644	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.19	-0.36	2.62e-15	HDL cholesterol;
LGG	cis	rs1018836	0.828	rs9297871	chr8:91572731	G/A	cg16814680	chr8:91681699	NA	-0.72	-13.07	-0.52	1.96e-33	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4819052	0.851	rs2838844	chr21:46670733	A/C	cg06618935	chr21:46677482	NA	-0.5	-9.73	-0.41	1.81e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg20296188	chr17:77397067	HRNBP3	0.4	6.66	0.3	7.97e-11	Body mass index;
LGG	cis	rs6696846	0.703	rs112653854	chr1:205079251	G/T	cg21545522	chr1:205238299	TMCC2	0.36	6.99	0.31	9.4e-12	Red blood cell count;
LGG	trans	rs12579753	0.879	rs1986537	chr12:82156475	G/C	cg07923666	chr12:49932857	KCNH3	-0.51	-7.88	-0.34	2.42e-14	Resting heart rate;
LGG	cis	rs10911232	0.507	rs4369195	chr1:182996291	G/C	cg15522984	chr1:182991683	LAMC1	0.48	9.77	0.41	1.24e-20	Hypertriglyceridemia;
LGG	cis	rs2073300	0.609	rs1936011	chr20:23341912	G/C	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs798554	0.679	rs7807978	chr7:2814635	C/T	cg27476859	chr7:2772710	GNA12	0.52	10.36	0.43	9.48e-23	Height;
LGG	cis	rs28386778	0.897	rs2584615	chr17:61927774	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs2229238	0.911	rs60760897	chr1:154504849	C/T	cg10237817	chr1:154519846	TDRD10	0.34	6.87	0.3	2.11e-11	Coronary heart disease;
LGG	cis	rs7493	1.000	rs2286232	chr7:95039445	C/T	cg08461772	chr7:95026248	PON3	0.37	8.26	0.36	1.52e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7769051	0.711	rs9493436	chr6:133088275	T/C	cg22852734	chr6:133119734	C6orf192	1.19	14.98	0.57	1.14e-41	Type 2 diabetes nephropathy;
LGG	cis	rs9952991	0.941	rs888270	chr18:12774894	G/A	cg23544223	chr18:12777786	NA	-0.65	-9.46	-0.4	1.59e-19	Inflammatory skin disease;
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg00405596	chr8:11794950	NA	0.45	7.67	0.34	1.01e-13	Mood instability;
LGG	trans	rs35110281	0.667	rs9941787	chr21:45116042	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.38	0.43	7.68e-23	Mean corpuscular volume;
LGG	cis	rs2236267	0.726	rs2295740	chr14:88602804	G/C	cg02175263	chr14:88627849	NA	-0.31	-6.81	-0.3	2.97e-11	Food antigen IgG levels;
LGG	trans	rs35110281	0.565	rs7278003	chr21:44966069	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.72	13.57	0.53	1.52e-35	Mean corpuscular volume;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13012494	chr21:47604986	C21orf56	0.5	8.34	0.36	8.49e-16	Testicular germ cell tumor;
LGG	cis	rs9372253	1.000	rs2235989	chr6:110714584	A/T	cg01119278	chr6:110721349	DDO	-0.29	-7.07	-0.31	5.72e-12	Platelet distribution width;
LGG	cis	rs1552244	0.626	rs2886396	chr3:10037670	C/T	cg13047869	chr3:10149882	C3orf24	0.47	7.89	0.34	2.2e-14	Alzheimer's disease;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg05665937	chr4:1216051	CTBP1	-0.51	-9.19	-0.39	1.34e-18	Obesity-related traits;
LGG	cis	rs283228	0.833	rs283207	chr6:101729237	C/T	cg27451362	chr6:101846650	GRIK2	-0.56	-8.88	-0.38	1.52e-17	Coenzyme Q10 levels;
LGG	cis	rs727563	0.520	rs132773	chr22:42031768	T/A	cg03806693	chr22:41940476	POLR3H	1.04	17.7	0.64	6.6e-54	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs763014	1.000	rs2269558	chr16:682250	C/T	cg00908189	chr16:619842	PIGQ	0.88	16.69	0.61	2.61e-49	Height;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg02733842	chr7:1102375	C7orf50	0.41	7.13	0.31	3.93e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3741404	0.825	rs60452247	chr11:63981507	G/A	cg18225595	chr11:63971243	STIP1	0.63	12.33	0.5	2.02e-30	Platelet count;
LGG	cis	rs875971	0.862	rs6945775	chr7:65968974	G/A	cg11764359	chr7:65958608	NA	0.74	13.39	0.53	8.69e-35	Aortic root size;
LGG	cis	rs11148252	0.553	rs2147692	chr13:53287023	C/G	cg05335186	chr13:53173507	NA	0.78	20.07	0.68	6.41e-65	Lewy body disease;
LGG	cis	rs2153535	0.580	rs9406164	chr6:8470048	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs910316	0.737	rs28687415	chr14:75495482	T/C	cg08847533	chr14:75593920	NEK9	0.55	10.32	0.43	1.25e-22	Height;
LGG	trans	rs2243480	0.831	rs7806717	chr7:65393174	A/G	cg10756647	chr7:56101905	PSPH	-0.83	-10.13	-0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs6500602	0.627	rs4786494	chr16:4506232	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.22	0.32	2.11e-12	Schizophrenia;
LGG	cis	rs6088590	1.000	rs2076668	chr20:33437621	G/A	cg08999081	chr20:33150536	PIGU	0.3	6.84	0.3	2.44e-11	Coronary artery disease;
LGG	cis	rs17039065	0.920	rs6810653	chr4:109467096	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.58	7.11	0.31	4.5e-12	Gut microbiome composition (summer);
LGG	cis	rs975722	0.638	rs213963	chr7:117229167	G/A	cg10524701	chr7:117356490	CTTNBP2	0.47	10.44	0.44	4.61e-23	Coronary artery disease;
LGG	cis	rs12360000	0.864	rs11250842	chr10:1904284	A/C	cg26364871	chr10:1889757	NA	-0.73	-14.42	-0.56	3.34e-39	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs6500602	0.647	rs4786514	chr16:4576798	A/C	cg19168338	chr16:4465731	CORO7	-0.88	-16.44	-0.61	3.56e-48	Schizophrenia;
LGG	cis	rs2576037	0.583	rs680018	chr18:44409167	T/A	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.74	-0.41	1.69e-20	Personality dimensions;
LGG	cis	rs10504229	0.683	rs72649192	chr8:58110490	T/C	cg05313129	chr8:58192883	C8orf71	-0.73	-9.79	-0.41	1.11e-20	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11821591	chr8:10697633	PINX1	0.41	7.04	0.31	7.2e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs738322	0.554	rs6001033	chr22:38557513	T/A	cg25457927	chr22:38595422	NA	-0.41	-10.15	-0.43	5.67e-22	Cutaneous nevi;
LGG	cis	rs10504130	0.502	rs10087958	chr8:52866669	A/G	cg24946253	chr8:52722146	PXDNL	-0.48	-7.73	-0.34	6.79e-14	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs2531992	0.800	rs2601782	chr16:4021051	T/C	cg05927578	chr16:4029543	ADCY9	0.67	9.27	0.4	6.82e-19	Waist circumference;
LGG	cis	rs10504229	0.773	rs60466370	chr8:58171248	A/C	cg11062466	chr8:58055876	NA	0.43	7.6	0.33	1.6e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4595586	0.545	rs6580910	chr12:39390052	C/A	cg13010199	chr12:38710504	ALG10B	0.41	7.36	0.32	8.22e-13	Morning vs. evening chronotype;
LGG	cis	rs7811142	0.830	rs7792959	chr7:99972403	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.98	14.78	0.57	8.91e-41	Platelet count;
LGG	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg16662043	chr16:48846231	NA	0.39	7.62	0.33	1.45e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6076065	0.748	rs2253834	chr20:23387816	C/T	cg11657817	chr20:23433608	CST11	-0.41	-8.16	-0.35	3.28e-15	Facial morphology (factor 15, philtrum width);
LGG	trans	rs7944735	0.508	rs4752791	chr11:47736023	C/T	cg15704280	chr7:45808275	SEPT13	-0.62	-6.76	-0.3	4.17e-11	Intraocular pressure;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg04044021	chr22:38577768	PLA2G6	0.38	6.79	0.3	3.54e-11	Menarche (age at onset);
LGG	trans	rs11098499	0.645	rs72676059	chr4:120290828	C/G	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs3008870	0.755	rs2815365	chr1:67499628	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.7	14.61	0.56	4.87e-40	Lymphocyte percentage of white cells;
LGG	cis	rs1799949	0.965	rs9646413	chr17:41426157	A/G	cg01879757	chr17:41196368	BRCA1	-0.41	-8.54	-0.37	1.9e-16	Menopause (age at onset);
LGG	cis	rs17345786	1.000	rs17345528	chr3:101294830	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.56	-8.38	-0.36	6.56e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9549367	0.713	rs3024761	chr13:113824090	C/G	cg00898013	chr13:113819073	PROZ	0.49	9.79	0.41	1.11e-20	Platelet distribution width;
LGG	cis	rs9807841	0.568	rs1560708	chr19:10749236	T/C	cg09936142	chr19:10668400	KRI1	-0.42	-6.9	-0.31	1.73e-11	Inflammatory skin disease;
LGG	cis	rs977987	0.898	rs12918797	chr16:75493810	T/C	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.09e-28	Dupuytren's disease;
LGG	cis	rs4700695	1.000	rs111340	chr5:65420285	C/A	cg21114390	chr5:65439923	SFRS12	-0.56	-6.89	-0.3	1.86e-11	Facial morphology (factor 19);
LGG	cis	rs35306767	0.903	rs11253495	chr10:937064	C/T	cg08847335	chr10:891726	LARP4B	-0.49	-8.88	-0.38	1.47e-17	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg02462569	chr6:150064036	NUP43	-0.38	-7.97	-0.35	1.21e-14	Lung cancer;
LGG	cis	rs4665809	1.000	rs4233709	chr2:26291493	C/T	cg26119090	chr2:26468346	HADHA;HADHB	0.8	12.82	0.51	2e-32	Gut microbiome composition (summer);
LGG	cis	rs2415984	0.562	rs12895104	chr14:46972736	G/A	cg14871534	chr14:47121158	RPL10L	0.45	7.25	0.32	1.78e-12	Number of children ever born;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9308731	0.644	rs60286362	chr2:111877493	G/C	cg26001287	chr2:111877753	BCL2L11	-0.35	-6.99	-0.31	9.77e-12	Chronic lymphocytic leukemia;
LGG	trans	rs9467711	0.651	rs13197334	chr6:26122648	G/C	cg06606381	chr12:133084897	FBRSL1	-0.68	-6.83	-0.3	2.73e-11	Autism spectrum disorder or schizophrenia;
LGG	trans	rs7615952	0.799	rs13315434	chr3:125641394	T/G	cg07211511	chr3:129823064	LOC729375	-1.37	-22.16	-0.72	1.1e-74	Blood pressure (smoking interaction);
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg18350739	chr11:68623251	NA	-0.89	-22.43	-0.72	5.84e-76	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs8062405	0.690	rs7187604	chr16:28565953	A/G	cg16576597	chr16:28551801	NUPR1	0.43	10.21	0.43	3.38e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs28386778	0.799	rs2955234	chr17:61983601	A/C	cg07677032	chr17:61819896	STRADA	-0.61	-11.06	-0.46	2.22e-25	Prudent dietary pattern;
LGG	cis	rs8025790	0.508	rs12441823	chr15:67912977	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.99	-0.35	1.07e-14	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs6763768	0.606	rs2029213	chr3:53378245	C/T	cg16894138	chr3:53270350	TKT	0.41	7.75	0.34	5.83e-14	Bacterial meningitis;
LGG	cis	rs7727544	0.709	rs441969	chr5:131702120	G/A	cg07395648	chr5:131743802	NA	-0.55	-12.91	-0.51	8.44e-33	Blood metabolite levels;
LGG	cis	rs881375	0.900	rs2241003	chr9:123666777	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.6	11.36	0.47	1.52e-26	Rheumatoid arthritis;
LGG	cis	rs694739	0.892	rs647152	chr11:64109118	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.22	0.52	4.64e-34	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs16912285	0.688	rs10834313	chr11:24348447	G/C	ch.11.24196551F	chr11:24239977	NA	0.92	12.69	0.51	7.24e-32	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs2594989	0.831	rs7642605	chr3:11469503	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.48	-0.33	3.65e-13	Circulating chemerin levels;
LGG	cis	rs7666738	0.830	rs3907020	chr4:99038583	T/C	cg05340658	chr4:99064831	C4orf37	0.48	8.0	0.35	1.02e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs9467711	0.591	rs16891235	chr6:26017542	T/C	cg01620082	chr3:125678407	NA	-0.62	-6.65	-0.3	8.31e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.877	rs10514380	chr5:93409370	C/T	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.25	0.43	2.35e-22	Diabetic retinopathy;
LGG	cis	rs9322193	0.923	rs11155670	chr6:149966128	C/G	cg12070911	chr6:150209640	RAET1E	0.31	7.4	0.33	6.58e-13	Lung cancer;
LGG	cis	rs17125944	0.505	rs77433996	chr14:53212263	G/A	cg13660082	chr14:53194042	PSMC6	-0.54	-7.68	-0.34	9.5e-14	Alzheimer's disease (late onset);
LGG	cis	rs2905347	0.560	rs2961291	chr7:22681504	C/T	cg23521230	chr7:22704884	NA	0.38	6.95	0.31	1.26e-11	Major depression and alcohol dependence;
LGG	cis	rs11203032	0.831	rs10887924	chr10:90937247	C/T	cg16672925	chr10:90967113	CH25H	0.5	7.73	0.34	6.87e-14	Heart failure;
LGG	cis	rs61990749	0.597	rs2267758	chr14:78147429	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	-0.58	-7.09	-0.31	5.05e-12	Fibroblast growth factor basic levels;
LGG	cis	rs7904368	0.806	rs12242261	chr10:16872929	T/C	cg14835575	chr10:16859367	RSU1	0.78	14.55	0.56	9.55e-40	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	trans	rs2727020	0.823	rs7102374	chr11:49261795	G/A	cg03929089	chr4:120376271	NA	0.79	13.89	0.54	6.29e-37	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12580847	chr5:39425450	DAB2	0.45	6.68	0.3	6.86e-11	Gut microbiome composition (summer);
LGG	cis	rs2836974	0.897	rs13052882	chr21:40555351	G/C	cg11890956	chr21:40555474	PSMG1	1.21	30.35	0.82	3.78e-112	Cognitive function;
LGG	cis	rs2635047	0.507	rs2668767	chr18:44785302	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.92	0.31	1.5e-11	Educational attainment;
LGG	cis	rs2762353	0.935	rs1165152	chr6:25818766	A/G	cg18357526	chr6:26021779	HIST1H4A	0.56	9.68	0.41	2.73e-20	Blood metabolite levels;
LGG	cis	rs2549003	1.000	rs2549002	chr5:131829578	C/A	cg21138405	chr5:131827807	IRF1	-0.39	-10.35	-0.43	1.04e-22	Asthma (sex interaction);
LGG	cis	rs36051895	0.632	rs111573904	chr9:5169804	A/T	cg02405213	chr9:5042618	JAK2	-0.77	-13.71	-0.54	3.68e-36	Pediatric autoimmune diseases;
LGG	cis	rs3768617	0.510	rs2296290	chr1:183079412	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.57	0.41	6.4e-20	Fuchs's corneal dystrophy;
LGG	trans	rs28735056	0.935	rs552957	chr18:77595748	G/A	cg05926928	chr17:57297772	GDPD1	-0.46	-7.1	-0.31	4.65e-12	Schizophrenia;
LGG	cis	rs2274273	0.662	rs60445539	chr14:55624245	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.11	0.49	1.56e-29	Protein biomarker;
LGG	cis	rs4930103	0.935	rs2075745	chr11:2018336	A/T	cg08461457	chr11:2027003	NA	0.39	7.62	0.33	1.46e-13	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs1348850	0.793	rs6734528	chr2:178493731	G/A	cg22681709	chr2:178499509	PDE11A	-0.53	-9.84	-0.42	7.16e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs711245	1.000	rs711245	chr2:36768875	G/A	cg01206211	chr2:36825736	FEZ2	0.39	7.39	0.32	6.82e-13	Height;
LGG	cis	rs10908907	0.955	rs10908908	chr9:92255332	A/G	cg01515543	chr9:92254510	LOC100129066	0.42	7.64	0.33	1.3e-13	Alcoholism (heaviness of drinking);
LGG	cis	rs9300255	0.506	rs11057251	chr12:123791227	A/G	cg00376283	chr12:123451042	ABCB9	-0.62	-11.43	-0.47	8.31e-27	Neutrophil percentage of white cells;
LGG	cis	rs9910055	0.530	rs2269908	chr17:42294198	G/C	cg19774624	chr17:42201019	HDAC5	-0.57	-10.13	-0.43	6.24e-22	Total body bone mineral density;
LGG	cis	rs7712401	0.601	rs30067	chr5:122293668	A/T	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17218495	chr19:11071743	SMARCA4	0.46	7.58	0.33	1.85e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7927592	0.956	rs10896341	chr11:68313180	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs12928939	0.815	rs1345868	chr16:71669624	G/T	cg03805757	chr16:71968109	PKD1L3	-0.48	-8.85	-0.38	1.83e-17	Post bronchodilator FEV1;
LGG	cis	rs155076	0.711	rs9550724	chr13:21885030	G/T	cg11317459	chr13:21872234	NA	1.39	26.65	0.78	1.6e-95	White matter hyperintensity burden;
LGG	cis	rs854765	0.647	rs2056842	chr17:18009028	C/T	cg05444541	chr17:17804740	TOM1L2	-0.58	-12.6	-0.51	1.69e-31	Total body bone mineral density;
LGG	cis	rs9400467	0.506	rs12199656	chr6:111675143	A/C	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg08645402	chr16:4508243	NA	0.54	9.82	0.42	8.22e-21	Schizophrenia;
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg02018176	chr4:1364513	KIAA1530	0.5	12.3	0.5	2.83e-30	Longevity;
LGG	cis	rs12230513	0.732	rs4318592	chr12:55837124	C/A	cg19537932	chr12:55886519	OR6C68	-0.61	-11.14	-0.46	1.11e-25	Contrast sensitivity;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.23	0.46	4.61e-26	Bipolar disorder;
LGG	cis	rs9611565	0.546	rs5758431	chr22:42109917	A/G	cg06481639	chr22:41940642	POLR3H	0.5	7.07	0.31	5.9e-12	Vitiligo;
LGG	cis	rs7020830	0.867	rs56098516	chr9:37362220	A/G	cg14294708	chr9:37120828	ZCCHC7	1.16	31.9	0.83	5.71e-119	Schizophrenia;
LGG	trans	rs7395662	0.571	rs1605358	chr11:48689318	T/A	cg03929089	chr4:120376271	NA	-0.46	-7.69	-0.34	9.04e-14	HDL cholesterol;
LGG	cis	rs4704846	1.000	rs919744	chr5:156531254	G/C	cg12943317	chr5:156479607	HAVCR1	-0.56	-7.32	-0.32	1.12e-12	Blood protein levels;
LGG	cis	rs4900538	0.821	rs2009575	chr14:102820787	C/T	cg18135206	chr14:102964638	TECPR2	-0.67	-11.47	-0.47	5.56e-27	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs11018904	0.906	rs35129016	chr11:89948689	T/C	cg27158573	chr11:89632121	NA	-0.42	-7.49	-0.33	3.62e-13	Intelligence (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20317180	chr19:56111252	FIZ1;ZNF524	0.38	6.68	0.3	7e-11	Bipolar disorder;
LGG	cis	rs9300255	0.596	rs11057202	chr12:123720775	G/T	cg05973401	chr12:123451056	ABCB9	0.51	8.22	0.36	2.13e-15	Neutrophil percentage of white cells;
LGG	cis	rs939658	0.805	rs1915726	chr15:79420620	C/G	cg17916960	chr15:79447300	NA	-0.67	-13.28	-0.53	2.51e-34	Refractive error;
LGG	cis	rs7191439	0.522	rs745326	chr16:88755245	C/G	cg27087555	chr16:88793112	FAM38A	-1.15	-12.09	-0.49	1.87e-29	Plateletcrit;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.49e-12	Obesity-related traits;
LGG	cis	rs2153535	0.580	rs9328488	chr6:8529411	G/C	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs62209	0.752	rs72772071	chr10:11011821	A/G	cg26901096	chr10:10994189	LOC254312	0.61	9.14	0.39	2.02e-18	Alzheimer's disease (late onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03358216	chr9:74383998	TMEM2	0.45	6.79	0.3	3.35e-11	Gut microbiome composition (summer);
LGG	cis	rs7811142	0.830	rs41280971	chr7:99954457	G/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.17	19.54	0.67	1.86e-62	Platelet count;
LGG	cis	rs9910055	0.529	rs228765	chr17:42186422	C/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.4	-6.87	-0.3	2.12e-11	Total body bone mineral density;
LGG	cis	rs9814567	1.000	rs4535272	chr3:134299916	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.0	0.52	3.78e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7188861	0.813	rs1541700	chr16:11445818	T/C	cg01510278	chr16:11456238	NA	-0.33	-7.76	-0.34	5.61e-14	HDL cholesterol;
LGG	cis	rs35146811	0.883	rs4134903	chr7:99711040	G/A	cg22906224	chr7:99728672	NA	0.58	9.32	0.4	4.65e-19	Coronary artery disease;
LGG	cis	rs8192482	1	rs8192482	chr15:78886198	C/T	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.32	-0.32	1.08e-12	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs11758351	1.000	rs112751982	chr6:26191958	C/T	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs9926296	0.632	rs2011925	chr16:89814064	T/G	cg26513180	chr16:89883248	FANCA	0.59	10.29	0.43	1.66e-22	Vitiligo;
LGG	trans	rs4332037	0.707	rs62435132	chr7:1891315	C/T	cg11693508	chr17:37793320	STARD3	0.63	9.4	0.4	2.54e-19	Bipolar disorder;
LGG	cis	rs11105298	0.891	rs10858865	chr12:89846476	G/A	cg00757033	chr12:89920650	WDR51B	0.64	9.15	0.39	1.76e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg09222892	chr1:25734099	RHCE	0.47	10.15	0.43	5.56e-22	Erythrocyte sedimentation rate;
LGG	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg00579200	chr11:133705235	NA	-0.55	-10.83	-0.45	1.6e-24	Childhood ear infection;
LGG	cis	rs17023223	0.537	rs1325938	chr1:119582642	C/T	cg05756136	chr1:119680316	WARS2	-0.39	-8.05	-0.35	6.93e-15	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs13108904	0.517	rs13134568	chr4:1334289	G/A	cg05025164	chr4:1340916	KIAA1530	0.45	7.49	0.33	3.61e-13	Obesity-related traits;
LGG	cis	rs6784615	0.744	rs13089892	chr3:52413670	C/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.89	0.34	2.2e-14	Waist-hip ratio;
LGG	cis	rs9747201	0.926	rs34153075	chr17:80135728	C/A	cg21453758	chr17:80185943	SLC16A3	-0.34	-7.34	-0.32	9.55e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.57	-9.36	-0.4	3.41e-19	IgG glycosylation;
LGG	cis	rs6752107	1.000	rs3792112	chr2:234176609	C/T	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.71	13.55	0.53	1.85e-35	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7095944	0.614	rs3824765	chr10:126433570	C/G	cg08799069	chr10:126477246	METTL10	-0.48	-10.79	-0.45	2.25e-24	Asthma;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08209724	chr17:30677138	MIR632;ZNF207	0.46	7.5	0.33	3.27e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs59104589	0.521	rs886809	chr2:242397460	A/G	cg13788902	chr2:242434635	STK25	0.41	7.03	0.31	7.3e-12	Fibrinogen levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03670153	chr3:184079754	CLCN2;POLR2H	0.44	6.85	0.3	2.4e-11	Gut microbiome composition (summer);
LGG	trans	rs1032833	0.732	rs6725309	chr2:180021531	A/G	cg23654767	chr2:101192981	PDCL3	0.55	7.15	0.32	3.47e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs8064024	1.000	rs8064024	chr16:4855279	C/T	cg04440724	chr16:4920505	UBN1	0.47	10.39	0.43	6.88e-23	Cancer;
LGG	cis	rs7264396	0.676	rs58372200	chr20:34555445	C/A	cg23207816	chr20:34252616	CPNE1;RBM12	0.46	6.77	0.3	3.82e-11	Total cholesterol levels;
LGG	cis	rs4555082	0.915	rs66527719	chr14:105750523	C/G	cg13114125	chr14:105738426	BRF1	-0.86	-17.09	-0.62	4.16e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs870825	0.616	rs1401360	chr4:185643571	T/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs7223966	1.000	rs11658329	chr17:61763031	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	0.46	7.22	0.32	2.09e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2721811	0.701	rs2721808	chr7:24744309	C/A	cg06301139	chr7:24798175	DFNA5	-0.38	-7.04	-0.31	7.1e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2204008	0.652	rs11513964	chr12:37998214	C/G	cg13010199	chr12:38710504	ALG10B	0.71	14.1	0.55	8.14e-38	Bladder cancer;
LGG	cis	rs2273669	0.667	rs75263286	chr6:109350489	G/C	cg05315195	chr6:109294784	ARMC2	-0.64	-8.47	-0.37	3.22e-16	Prostate cancer;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg08883955	chr16:11945066	RSL1D1	0.39	6.82	0.3	2.88e-11	Bilirubin levels;
LGG	cis	rs35306767	0.953	rs12762973	chr10:960761	C/G	cg08847335	chr10:891726	LARP4B	-0.36	-6.9	-0.31	1.68e-11	Eosinophil percentage of granulocytes;
LGG	cis	rs1451375	1.000	rs2329342	chr7:50624971	A/G	cg20336341	chr7:50628841	DDC	-0.38	-7.23	-0.32	1.96e-12	Malaria;
LGG	cis	rs4748857	0.947	rs10828426	chr10:23602901	C/T	cg18853376	chr10:23633759	C10orf67	0.37	7.1	0.31	4.86e-12	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg26338869	chr17:61819248	STRADA	0.59	9.95	0.42	2.99e-21	Prudent dietary pattern;
LGG	cis	rs8072100	0.701	rs8075566	chr17:45771037	G/A	cg25173405	chr17:45401733	C17orf57	-0.56	-9.19	-0.39	1.38e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6951245	0.744	rs10265758	chr7:1172518	C/T	cg18402987	chr7:1209562	NA	0.72	10.98	0.45	4.54e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9527	0.590	rs7910900	chr10:104829898	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.21	-0.32	2.22e-12	Arsenic metabolism;
LGG	cis	rs175714	0.845	rs175706	chr14:75976200	G/A	cg01624173	chr14:75981868	NA	0.49	11.41	0.47	9.76e-27	Lymphocyte counts;
LGG	cis	rs9880211	0.800	rs13433683	chr3:136518670	C/T	cg21827317	chr3:136751795	NA	0.49	7.05	0.31	6.56e-12	Body mass index;Height;
LGG	cis	rs4926611	0.863	rs2141083	chr1:54082352	C/T	cg23596471	chr1:54105337	GLIS1	-0.44	-8.53	-0.37	2.03e-16	Hand grip strength;
LGG	cis	rs208515	0.518	rs12209790	chr6:66662965	T/C	cg07460842	chr6:66804631	NA	0.94	16.94	0.62	2.02e-50	Exhaled nitric oxide levels;
LGG	cis	rs6459804	0.967	rs10233396	chr7:157512290	C/T	cg01625945	chr7:157512322	PTPRN2	-0.49	-11.5	-0.47	4.46e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs78487399	0.808	rs78191305	chr2:43673978	A/G	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs2735413	0.522	rs2075737	chr16:78056974	T/C	cg04733911	chr16:78082701	NA	0.56	8.0	0.35	9.89e-15	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs774359	0.789	rs700795	chr9:27520508	A/G	cg14173147	chr9:27528300	MOBKL2B	0.46	8.82	0.38	2.37e-17	Amyotrophic lateral sclerosis;
LGG	cis	rs10504229	0.906	rs7006539	chr8:58178799	A/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7927592	0.913	rs10896346	chr11:68352671	C/T	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs644799	0.710	rs11021311	chr11:95505227	G/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.83	15.26	0.58	6.89e-43	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7267979	0.873	rs6083853	chr20:25404541	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.18	-0.43	4.29e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs796364	0.760	rs1569178	chr2:201024512	T/C	cg23649088	chr2:200775458	C2orf69	-0.55	-6.66	-0.3	7.86e-11	Schizophrenia;
LGG	cis	rs8062405	1.000	rs62036624	chr16:28839930	G/T	cg07382826	chr16:28625726	SULT1A1	0.35	7.35	0.32	9.16e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7762018	0.943	rs11546265	chr6:170108363	G/A	cg17545662	chr6:170176663	C6orf70	0.68	8.65	0.37	8.7e-17	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2354432	1.000	rs2354432	chr1:146693229	C/T	cg25205988	chr1:146714368	CHD1L	1.31	17.11	0.62	3.26e-51	Mitochondrial DNA levels;
LGG	cis	rs10875595	0.836	rs56756237	chr5:140678342	T/C	cg24830062	chr5:140700576	TAF7	-0.58	-7.33	-0.32	1.04e-12	Pulmonary function decline;
LGG	cis	rs1018836	0.923	rs7833025	chr8:91568470	G/C	cg16814680	chr8:91681699	NA	-0.8	-14.84	-0.57	5.12e-41	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs12478296	1.000	rs4973685	chr2:243019089	A/C	cg18898632	chr2:242989856	NA	-0.88	-10.59	-0.44	1.3e-23	Obesity-related traits;
LGG	cis	rs6952808	0.575	rs10280993	chr7:1948096	T/C	cg05863683	chr7:1912471	MAD1L1	0.4	7.81	0.34	3.98e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs1032833	0.732	rs3816345	chr2:179974885	A/G	cg23654767	chr2:101192981	PDCL3	-0.56	-7.24	-0.32	1.86e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs10435719	0.902	rs11250179	chr8:11800332	C/T	cg00405596	chr8:11794950	NA	0.65	11.54	0.47	2.9e-27	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs559928	0.597	rs947939	chr11:63885287	C/T	cg05555928	chr11:63887634	MACROD1	-0.79	-10.47	-0.44	3.67e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg20887711	chr4:1340912	KIAA1530	0.52	9.67	0.41	2.9e-20	Obesity-related traits;
LGG	cis	rs4731207	0.596	rs1525618	chr7:124654706	G/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	cis	rs10504130	0.502	rs4321994	chr8:52684240	T/G	cg22653915	chr8:52722023	PXDNL	-0.42	-6.79	-0.3	3.49e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg10205403	chr12:95867231	METAP2	-0.47	-6.89	-0.3	1.77e-11	Systemic lupus erythematosus;
LGG	cis	rs56235845	0.694	rs4976643	chr5:176760227	A/C	cg17509989	chr5:176798049	RGS14	0.66	10.96	0.45	5.28e-25	Hemoglobin concentration;Hematocrit;
LGG	cis	rs6088580	0.608	rs2105109	chr20:32971932	A/G	cg06115741	chr20:33292138	TP53INP2	-0.5	-8.17	-0.36	2.92e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg14768946	chr2:191878941	STAT1	-0.39	-6.69	-0.3	6.64e-11	Brain structure;
LGG	trans	rs7647973	0.593	rs9870755	chr3:49809841	A/G	cg21659725	chr3:3221576	CRBN	-0.58	-7.79	-0.34	4.56e-14	Menarche (age at onset);
LGG	cis	rs9768139	0.708	rs10233815	chr7:158114348	C/T	cg25566285	chr7:158114605	PTPRN2	0.91	20.87	0.7	1.19e-68	Calcium levels;
LGG	cis	rs9322193	0.962	rs17673294	chr6:150134993	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.42e-11	Lung cancer;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg08677398	chr8:58056175	NA	0.57	8.78	0.38	3.25e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.49	7.87	0.34	2.62e-14	Longevity;
LGG	cis	rs9916302	0.851	rs11078904	chr17:37650569	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	6.15e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9462846	0.658	rs9471970	chr6:42913646	G/A	cg02353165	chr6:42928485	GNMT	0.31	7.51	0.33	3.05e-13	Blood protein levels;
LGG	cis	rs2188561	0.697	rs739518	chr7:107384127	G/A	cg16793755	chr7:107334138	SLC26A4	0.4	7.11	0.31	4.5e-12	Alcohol consumption;
LGG	trans	rs1814175	0.645	rs7395438	chr11:49877379	G/T	cg03929089	chr4:120376271	NA	-0.94	-19.62	-0.67	7.91e-63	Height;
LGG	cis	rs2274273	0.870	rs11851169	chr14:55815932	G/A	cg04306507	chr14:55594613	LGALS3	0.61	17.07	0.62	5.16e-51	Protein biomarker;
LGG	cis	rs796364	0.806	rs1605900	chr2:200870197	C/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.85	10.04	0.42	1.4e-21	Schizophrenia;
LGG	cis	rs113084984	0.642	rs13021546	chr2:11681043	G/T	cg07314298	chr2:11723111	GREB1	0.36	6.74	0.3	4.67e-11	Breast cancer;
LGG	cis	rs72634258	0.796	rs4369247	chr1:8168993	C/T	cg00042356	chr1:8021962	PARK7	-0.54	-7.7	-0.34	8.17e-14	Inflammatory bowel disease;
LGG	cis	rs4478858	0.735	rs6681286	chr1:31799384	G/C	cg19084893	chr1:31688959	NA	0.32	6.86	0.3	2.19e-11	Alcohol dependence;
LGG	cis	rs2635047	0.638	rs16954921	chr18:44610526	G/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.36	6.88	0.3	2e-11	Educational attainment;
LGG	cis	rs12135191	0.867	rs10925067	chr1:236475703	G/C	cg21399712	chr1:236511386	NA	-0.41	-7.88	-0.34	2.3e-14	Urate levels (BMI interaction);
LGG	cis	rs9858542	1.000	rs9823546	chr3:49705512	T/A	cg07274523	chr3:49395745	GPX1	0.54	8.91	0.38	1.2e-17	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7666738	0.784	rs4699602	chr4:99034903	T/C	cg05340658	chr4:99064831	C4orf37	0.49	8.13	0.35	4.1e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs881301	0.624	rs328300	chr8:38344499	A/C	cg17120578	chr8:38329836	NA	0.36	7.8	0.34	4.12e-14	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.67e-12	Neuroticism;
LGG	cis	rs7192750	0.586	rs4788585	chr16:71993638	A/G	cg06353428	chr16:71660113	MARVELD3	0.68	10.88	0.45	1.07e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs12453935	0.640	rs12452044	chr17:59919361	C/T	cg14757157	chr17:59911755	BRIP1	0.34	6.76	0.3	4.04e-11	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	cis	rs9863	0.513	rs34102591	chr12:124480801	A/G	cg13487667	chr12:124434373	CCDC92	-0.44	-6.85	-0.3	2.33e-11	White blood cell count;
LGG	cis	rs514024	0.735	rs2039205	chr9:130375643	G/C	cg13643465	chr9:130375613	STXBP1	0.62	11.82	0.48	2.3e-28	Eating disorders (purging via substances);
LGG	cis	rs7853377	0.800	rs696825	chr9:86583076	C/T	cg12437157	chr9:86433764	GKAP1	0.4	6.87	0.3	2.12e-11	Height;
LGG	cis	rs1865760	1.000	rs9348698	chr6:25929689	T/A	cg03264133	chr6:25882463	NA	-0.43	-7.52	-0.33	2.83e-13	Height;
LGG	cis	rs7781557	0.640	rs73714541	chr7:102622664	T/C	cg18108683	chr7:102477205	FBXL13	-0.54	-8.02	-0.35	8.54e-15	Colorectal adenoma (advanced);
LGG	trans	rs116095464	0.558	rs6875291	chr5:264192	T/C	cg00938859	chr5:1591904	SDHAP3	0.92	13.67	0.54	5.83e-36	Breast cancer;
LGG	cis	rs10267417	0.603	rs1557772	chr7:19908535	A/C	cg05791153	chr7:19748676	TWISTNB	0.56	7.44	0.33	4.84e-13	Night sleep phenotypes;
LGG	cis	rs10751667	0.621	rs10794353	chr11:948740	A/G	cg22143635	chr11:980567	AP2A2	0.42	7.78	0.34	4.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs10504229	1.000	rs116995796	chr8:58181960	G/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.597	rs1031423	chr5:93276883	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.54	-7.64	-0.33	1.25e-13	Diabetic retinopathy;
LGG	trans	rs453301	0.598	rs1025395	chr8:8836603	G/C	cg21775007	chr8:11205619	TDH	0.43	7.0	0.31	9.29e-12	Joint mobility (Beighton score);
LGG	cis	rs8177253	0.761	rs1830083	chr3:133508551	G/A	cg01448562	chr3:133502909	NA	-0.8	-15.81	-0.59	2.47e-45	Iron status biomarkers;
LGG	cis	rs12421382	0.614	rs12799395	chr11:109390862	G/T	cg07142201	chr11:109293216	C11orf87	0.5	9.18	0.39	1.48e-18	Schizophrenia;
LGG	cis	rs950027	0.620	rs1145080	chr15:45681338	C/T	cg26924012	chr15:45694286	SPATA5L1	0.67	12.11	0.49	1.63e-29	Response to fenofibrate (adiponectin levels);
LGG	trans	rs9650657	0.535	rs7011756	chr8:11019578	C/G	cg02002194	chr4:3960332	NA	0.43	7.83	0.34	3.28e-14	Neuroticism;
LGG	trans	rs11165623	0.792	rs9437607	chr1:96977788	G/A	cg10631902	chr5:14652156	NA	-0.52	-11.46	-0.47	6.37e-27	Hip circumference;Waist circumference;
LGG	cis	rs2153535	0.563	rs7739249	chr6:8534590	C/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.82	0.38	2.39e-17	Motion sickness;
LGG	cis	rs6694672	0.867	rs7534353	chr1:197096480	T/G	cg13682187	chr1:196946512	CFHR5	0.5	6.95	0.31	1.27e-11	Asthma;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	1.18	21.21	0.7	3.1e-70	Alzheimer's disease;
LGG	cis	rs7998202	0.614	rs282571	chr13:113366234	C/G	cg02820901	chr13:113351484	ATP11A	0.58	6.88	0.3	1.95e-11	Glycated hemoglobin levels;
LGG	cis	rs9486715	0.830	rs4425602	chr6:96893906	G/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs7552404	0.924	rs7550974	chr1:76204185	A/G	cg03433033	chr1:76189801	ACADM	0.81	14.6	0.56	5.41e-40	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2836974	0.932	rs11910151	chr21:40560262	T/C	cg11890956	chr21:40555474	PSMG1	1.19	29.41	0.81	5.12e-108	Cognitive function;
LGG	cis	rs9322193	0.607	rs6557165	chr6:150228019	C/G	cg08621203	chr6:150244597	RAET1G	-0.46	-6.91	-0.31	1.63e-11	Lung cancer;
LGG	cis	rs17376456	0.825	rs55947981	chr5:93278104	G/T	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs2307022	0.671	rs9889191	chr16:68377848	A/G	cg07273125	chr16:68295692	NA	-0.45	-10.11	-0.43	7.76e-22	Body mass index;
LGG	cis	rs2576037	0.899	rs2060417	chr18:44576486	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.4	-7.59	-0.33	1.74e-13	Personality dimensions;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg12375025	chr18:67873125	RTTN	0.41	6.74	0.3	4.87e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14893161	chr1:205819251	PM20D1	0.5	8.21	0.36	2.28e-15	Prostate-specific antigen levels;
LGG	cis	rs2285947	0.933	rs10275354	chr7:21580599	G/A	cg03697024	chr7:21583438	DNAH11	0.36	8.63	0.37	9.57e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs7223966	1.000	rs8080211	chr17:61729882	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.68	11.11	0.46	1.37e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1218582	0.596	rs4845676	chr1:154827861	C/G	cg03351412	chr1:154909251	PMVK	0.48	8.43	0.36	4.42e-16	Prostate cancer;
LGG	trans	rs2548003	1.000	rs2548004	chr5:28746743	A/G	cg12623145	chr2:97778927	ANKRD36	0.45	6.9	0.31	1.73e-11	Hip geometry;
LGG	cis	rs7089973	0.604	rs12218498	chr10:116578489	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.27	0.32	1.55e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs6489882	0.867	rs7972033	chr12:113363283	C/T	cg25319449	chr12:113376135	OAS3	-0.4	-7.41	-0.33	5.93e-13	Chronic lymphocytic leukemia;
LGG	cis	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg13010199	chr12:38710504	ALG10B	0.73	15.08	0.57	4.45e-42	Heart rate;
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.58	-0.59	2.57e-44	Rheumatoid arthritis;
LGG	cis	rs35264875	0.950	rs72928659	chr11:68852358	C/T	cg07882059	chr11:68924751	NA	0.42	7.38	0.32	7.31e-13	Blond vs. brown hair color;
LGG	trans	rs1005277	0.505	rs200936	chr10:38134935	T/C	cg17830980	chr10:43048298	ZNF37B	-0.45	-9.82	-0.42	8.17e-21	Extrinsic epigenetic age acceleration;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	13.13	0.52	1.11e-33	Tonsillectomy;
LGG	cis	rs1799949	0.930	rs3092987	chr17:41222723	T/C	cg05368731	chr17:41323189	NBR1	0.96	18.74	0.66	9.83e-59	Menopause (age at onset);
LGG	cis	rs11971779	0.941	rs28395455	chr7:139035986	A/G	cg07862535	chr7:139043722	LUC7L2	0.59	8.82	0.38	2.41e-17	Diisocyanate-induced asthma;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.6	-10.59	-0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs2839186	0.709	rs2156117	chr21:47669300	C/A	cg12016809	chr21:47604291	C21orf56	0.58	10.3	0.43	1.52e-22	Testicular germ cell tumor;
LGG	cis	rs73198271	0.562	rs55961293	chr8:8675478	T/C	cg01851573	chr8:8652454	MFHAS1	0.5	7.91	0.35	1.85e-14	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs4454254	0.796	rs35758124	chr8:141048964	C/T	cg05910124	chr8:141057427	TRAPPC9	-0.27	-6.68	-0.3	6.9e-11	Pulse pressure;
LGG	cis	rs910316	1.000	rs2300601	chr14:75639571	A/G	cg11812906	chr14:75593930	NEK9	0.5	9.02	0.39	5.05e-18	Height;
LGG	cis	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg13072238	chr3:49761600	GMPPB	-0.54	-7.37	-0.32	8.12e-13	Menarche (age at onset);
LGG	cis	rs4689642	1.000	rs10010462	chr4:7224294	A/C	cg21353189	chr4:7228343	SORCS2	0.32	7.94	0.35	1.53e-14	Attention function in attention deficit hyperactive disorder;
LGG	trans	rs7647973	0.593	rs7652179	chr3:49808618	T/A	cg21659725	chr3:3221576	CRBN	0.56	7.21	0.32	2.25e-12	Menarche (age at onset);
LGG	cis	rs67311347	1.000	rs6762251	chr3:40531136	A/G	cg24209194	chr3:40518798	ZNF619	-0.46	-7.31	-0.32	1.2e-12	Renal cell carcinoma;
LGG	trans	rs7824557	0.510	rs4841524	chr8:11243126	C/G	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.32	-0.36	9.65e-16	Retinal vascular caliber;
LGG	cis	rs11700980	0.591	rs2832025	chr21:30114322	C/G	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	trans	rs7819412	0.715	rs35223712	chr8:11043926	C/T	cg08975724	chr8:8085496	FLJ10661	-0.47	-9.1	-0.39	2.78e-18	Triglycerides;
LGG	cis	rs1153858	0.887	rs28569043	chr15:45730926	A/T	cg10760299	chr15:45669010	GATM	0.36	6.81	0.3	3.08e-11	Homoarginine levels;
LGG	cis	rs9674544	0.740	rs11870560	chr17:47114033	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.5	-9.56	-0.41	6.97e-20	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs8062405	0.789	rs1968751	chr16:28631759	T/C	cg16576597	chr16:28551801	NUPR1	-0.36	-8.0	-0.35	1e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6456156	0.586	rs12198816	chr6:167483546	G/A	cg07741184	chr6:167504864	NA	0.42	9.51	0.4	1.03e-19	Primary biliary cholangitis;
LGG	cis	rs35306767	0.953	rs10904581	chr10:964685	A/T	cg25019033	chr10:957182	NA	-0.59	-12.64	-0.51	1.11e-31	Eosinophil percentage of granulocytes;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.45	-0.33	4.54e-13	Bipolar disorder;
LGG	cis	rs1348850	0.668	rs2365619	chr2:178497366	A/G	cg23306229	chr2:178417860	TTC30B	-0.6	-7.7	-0.34	8.47e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg17168838	chr19:54663528	LENG1	-0.5	-7.25	-0.32	1.8e-12	Systemic lupus erythematosus;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg19143629	chr17:61920732	SMARCD2	0.41	7.16	0.32	3.09e-12	Prudent dietary pattern;
LGG	cis	rs887829	0.570	rs10171367	chr2:234597667	C/G	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.47	-8.11	-0.35	4.7e-15	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs4819052	0.851	rs2838829	chr21:46664040	A/C	cg06618935	chr21:46677482	NA	-0.5	-9.72	-0.41	1.94e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs9393777	0.778	rs13212921	chr6:27205422	C/T	cg08344181	chr3:125677491	NA	-0.65	-7.52	-0.33	2.81e-13	Intelligence (multi-trait analysis);
LGG	cis	rs41271951	0.512	rs12074309	chr1:151087827	T/C	cg11822372	chr1:151115635	SEMA6C	-0.66	-6.94	-0.31	1.32e-11	Blood protein levels;
LGG	trans	rs11039798	0.764	rs4357721	chr11:48354907	G/A	cg15704280	chr7:45808275	SEPT13	-0.74	-8.83	-0.38	2.15e-17	Axial length;
LGG	cis	rs9322193	0.962	rs2342764	chr6:150156204	G/A	cg08621203	chr6:150244597	RAET1G	0.45	7.66	0.34	1.11e-13	Lung cancer;
LGG	cis	rs10089	1.000	rs62373701	chr5:127416294	C/T	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.74	11.29	0.46	2.88e-26	Ileal carcinoids;
LGG	cis	rs7904368	0.754	rs12269366	chr10:16850344	G/A	cg23933602	chr10:16859644	RSU1	0.65	9.44	0.4	1.76e-19	Ratio of the peak velocity of the mitral E-Wave divided by the peak velocity of the mitral A-wave.;
LGG	cis	rs9463078	0.746	rs9395095	chr6:45273877	C/A	cg25276700	chr6:44698697	NA	-0.4	-8.46	-0.37	3.6e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs7937682	0.847	rs583032	chr11:111432757	C/T	cg19812747	chr11:111475976	SIK2	-0.49	-10.33	-0.43	1.17e-22	Primary sclerosing cholangitis;
LGG	cis	rs10876993	0.784	rs7314152	chr12:58017701	T/G	cg18357645	chr12:58087776	OS9	-0.65	-11.05	-0.46	2.28e-25	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07633499	chr22:19467075	UFD1L;CDC45L	0.43	7.07	0.31	5.77e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs2832191	0.716	rs8132085	chr21:30501389	G/T	cg24692254	chr21:30365293	RNF160	-0.98	-24.97	-0.76	8.6e-88	Dental caries;
LGG	cis	rs72781680	0.665	rs2675356	chr2:24074734	C/T	cg08917208	chr2:24149416	ATAD2B	0.63	8.25	0.36	1.69e-15	Lymphocyte counts;
LGG	cis	rs7582180	0.676	rs11691135	chr2:100934038	C/T	cg26150922	chr2:100937072	LONRF2	-0.6	-11.79	-0.48	3.08e-28	Intelligence (multi-trait analysis);
LGG	trans	rs1941687	0.702	rs1493924	chr18:31314721	T/C	cg27147174	chr7:100797783	AP1S1	-0.54	-9.03	-0.39	4.73e-18	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs9462027	0.628	rs2764206	chr6:34712900	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.55	-11.37	-0.47	1.39e-26	Systemic lupus erythematosus;
LGG	cis	rs1865760	0.515	rs2003208	chr6:25940719	G/C	cg17691542	chr6:26056736	HIST1H1C	0.49	8.57	0.37	1.6e-16	Height;
LGG	cis	rs7742824	1.000	rs7742824	chr6:44065311	G/A	cg04074908	chr6:44101190	TMEM63B	0.68	13.15	0.52	8.43e-34	Major depressive disorder;
LGG	cis	rs4819852	0.662	rs2073748	chr22:19968971	G/A	cg06346307	chr22:19949965	COMT	0.29	6.99	0.31	9.94e-12	Pulse pressure;
LGG	cis	rs6728642	0.901	rs10179966	chr2:97845100	C/T	cg26665480	chr2:98280029	ACTR1B	-0.74	-8.65	-0.37	8.48e-17	Bipolar disorder lithium response (continuous) or schizophrenia;
LGG	cis	rs3796352	0.764	rs11714902	chr3:53101544	G/C	cg12962167	chr3:53033115	SFMBT1	0.78	8.16	0.35	3.17e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs2832191	0.632	rs2246777	chr21:30309586	T/C	cg24692254	chr21:30365293	RNF160	-1.02	-28.74	-0.8	5.34e-105	Dental caries;
LGG	cis	rs7819412	0.765	rs7000132	chr8:11030935	T/C	cg27411982	chr8:10470053	RP1L1	-0.44	-7.31	-0.32	1.17e-12	Triglycerides;
LGG	cis	rs4740619	0.846	rs10962106	chr9:15644441	G/A	cg14451791	chr9:16040625	NA	0.35	9.04	0.39	4.22e-18	Body mass index;
LGG	cis	rs2153535	0.521	rs6939827	chr6:8461360	C/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.55	0.5	2.57e-31	Motion sickness;
LGG	cis	rs916888	0.773	rs169201	chr17:44790203	A/G	cg01570182	chr17:44337453	NA	0.72	11.9	0.48	1.09e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs13108904	0.645	rs56115381	chr4:1324994	G/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.63	10.62	0.44	1.03e-23	Obesity-related traits;
LGG	cis	rs9397585	0.857	rs6557255	chr6:153384438	A/T	cg17707550	chr6:153380415	RGS17	0.61	14.18	0.55	3.52e-38	Body mass index;
LGG	cis	rs7552404	0.824	rs1251079	chr1:76189445	C/T	cg10523679	chr1:76189770	ACADM	0.8	16.92	0.62	2.47e-50	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.1	0.43	8.05e-22	Tonsillectomy;
LGG	cis	rs514406	0.505	rs425520	chr1:53179805	C/G	cg24675658	chr1:53192096	ZYG11B	-0.59	-12.84	-0.51	1.71e-32	Monocyte count;
LGG	cis	rs3768617	0.510	rs10797843	chr1:183081995	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs3747547	0.818	rs72724194	chr9:37945506	A/G	cg13774184	chr9:37916125	SHB	-0.74	-8.29	-0.36	1.28e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7223966	1.000	rs7211213	chr17:61769456	A/G	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.57	-0.37	1.55e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs453301	0.631	rs13250781	chr8:8793343	T/G	cg27411982	chr8:10470053	RP1L1	-0.41	-7.01	-0.31	8.53e-12	Joint mobility (Beighton score);
LGG	cis	rs7208859	0.623	rs9914499	chr17:29107588	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs3845702	0.736	rs72960664	chr2:180832672	C/T	cg01881094	chr2:180872142	CWC22	1.26	16.51	0.61	1.72e-48	Schizophrenia;
LGG	cis	rs4665809	1.000	rs6720314	chr2:26334852	G/A	cg22920501	chr2:26401640	FAM59B	-0.4	-7.9	-0.34	2.11e-14	Gut microbiome composition (summer);
LGG	cis	rs10464366	0.544	rs4540324	chr7:39185299	G/C	cg21665744	chr7:39171113	POU6F2	0.43	8.94	0.38	9.18e-18	IgG glycosylation;
LGG	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg03929089	chr4:120376271	NA	-0.65	-9.17	-0.39	1.51e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs41005	0.597	rs34452414	chr2:8101593	C/T	cg03155496	chr2:8117019	LOC339788	-0.53	-9.27	-0.4	6.93e-19	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs523522	0.962	rs4766968	chr12:120947788	G/C	cg12219531	chr12:120966889	COQ5	0.67	11.08	0.46	1.82e-25	High light scatter reticulocyte count;
LGG	cis	rs8114671	0.562	rs7266550	chr20:33495510	C/T	cg24642439	chr20:33292090	TP53INP2	0.43	6.96	0.31	1.18e-11	Height;
LGG	cis	rs1497828	0.913	rs1032599	chr1:217548568	T/A	cg04411442	chr1:217543379	NA	0.48	8.2	0.36	2.34e-15	Dialysis-related mortality;
LGG	cis	rs11190604	1.000	rs12219789	chr10:102213778	A/G	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs11039798	0.557	rs4441015	chr11:49027070	A/G	cg03929089	chr4:120376271	NA	0.74	10.37	0.43	8.17e-23	Axial length;
LGG	cis	rs4665809	0.652	rs11685594	chr2:26402846	A/G	cg22920501	chr2:26401640	FAM59B	-0.42	-8.62	-0.37	1.09e-16	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.83e-11	Menopause (age at onset);
LGG	cis	rs1707322	0.752	rs11211147	chr1:46110094	A/G	cg03146154	chr1:46216737	IPP	0.57	10.83	0.45	1.59e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs10911232	0.507	rs6664995	chr1:183017345	T/C	cg07245641	chr1:182991651	LAMC1	0.41	9.61	0.41	4.6e-20	Hypertriglyceridemia;
LGG	cis	rs11671005	0.735	rs11668814	chr19:58946833	T/C	cg11952622	chr19:58962976	ZNF324B	-0.45	-6.84	-0.3	2.51e-11	Mean platelet volume;
LGG	cis	rs950776	0.593	rs6495306	chr15:78865893	C/T	cg06917634	chr15:78832804	PSMA4	-0.72	-14.2	-0.55	2.95e-38	Sudden cardiac arrest;
LGG	trans	rs7939886	0.920	rs1552151	chr11:55780951	A/G	cg15704280	chr7:45808275	SEPT13	-0.88	-9.27	-0.4	6.88e-19	Myopia (pathological);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06895436	chr8:82434543	NA	-0.59	-6.98	-0.31	1.01e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18854735	chr1:1822972	GNB1	0.55	9.51	0.4	1.07e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs13118159	0.872	rs1882105	chr4:1345956	T/C	cg20887711	chr4:1340912	KIAA1530	0.73	15.48	0.58	7.09e-44	Longevity;
LGG	cis	rs7267979	0.966	rs2151144	chr20:25414924	G/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.14	-0.43	6.11e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs13118159	0.509	rs4974556	chr4:1358141	G/C	cg08948841	chr4:1244042	CTBP1;C4orf42	0.58	9.44	0.4	1.83e-19	Longevity;
LGG	cis	rs4148883	0.675	rs10015824	chr4:100074544	C/G	cg13256891	chr4:100009986	ADH5	0.38	6.69	0.3	6.43e-11	Alcohol dependence;
LGG	cis	rs765787	0.530	rs11636410	chr15:45535913	A/C	cg24006582	chr15:45444508	DUOX1	0.66	12.24	0.49	4.98e-30	Uric acid levels;
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg24829409	chr8:58192753	C8orf71	-0.76	-9.89	-0.42	4.86e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.571	rs12632381	chr3:52607685	G/A	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.66e-12	Bipolar disorder;
LGG	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg13010199	chr12:38710504	ALG10B	-0.46	-8.34	-0.36	8.61e-16	Morning vs. evening chronotype;
LGG	cis	rs6032067	0.852	rs6032046	chr20:43823679	A/G	cg10761708	chr20:43804764	PI3	0.76	11.71	0.48	6.14e-28	Blood protein levels;
LGG	cis	rs7927771	0.524	rs4752798	chr11:47886364	T/C	cg20307385	chr11:47447363	PSMC3	-0.55	-10.72	-0.45	4.17e-24	Subjective well-being;
LGG	cis	rs1865760	0.865	rs1436306	chr6:25948421	A/G	cg16482183	chr6:26056742	HIST1H1C	0.53	9.35	0.4	3.85e-19	Height;
LGG	cis	rs11098499	0.580	rs12509234	chr4:120319434	T/C	cg24375607	chr4:120327624	NA	0.68	11.04	0.46	2.56e-25	Corneal astigmatism;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.66	-0.34	1.08e-13	Testicular germ cell tumor;
LGG	trans	rs9325144	0.534	rs1843887	chr12:38692380	T/C	cg23762105	chr12:34175262	ALG10	-0.34	-7.0	-0.31	9.21e-12	Morning vs. evening chronotype;
LGG	cis	rs1371867	0.846	rs1660328	chr8:101303450	A/G	cg06636551	chr8:101224915	SPAG1	-0.46	-8.52	-0.37	2.23e-16	Atrioventricular conduction;
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	trans	rs916888	0.821	rs199525	chr17:44847834	T/G	cg01341218	chr17:43662625	NA	0.93	15.59	0.59	2.46e-44	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs35110281	0.805	rs2838319	chr21:44991901	A/G	cg04455712	chr21:45112962	RRP1B	0.51	10.0	0.42	1.89e-21	Mean corpuscular volume;
LGG	cis	rs3733585	0.638	rs28715627	chr4:9958140	T/A	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	5.22e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.64	-9.05	-0.39	3.85e-18	Lung function (FEV1/FVC);
LGG	cis	rs6901004	0.835	rs1150079	chr6:111471425	A/T	cg15721981	chr6:111408429	SLC16A10	-0.43	-7.85	-0.34	2.95e-14	Blood metabolite levels;
LGG	trans	rs911186	0.782	rs34569203	chr6:27153984	A/C	cg06606381	chr12:133084897	FBRSL1	-0.61	-7.29	-0.32	1.34e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12464559	0.649	rs4605370	chr2:152628288	C/T	cg01189475	chr2:152685088	ARL5A	-0.74	-6.71	-0.3	5.62e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs3790455	1.000	rs10908504	chr1:156464429	C/A	cg14087168	chr1:156450669	MEF2D	0.47	7.65	0.33	1.19e-13	Migraine;
LGG	cis	rs13102973	0.867	rs4521398	chr4:135906934	T/G	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.83e-15	Subjective well-being;
LGG	cis	rs10504229	0.679	rs78941440	chr8:58052095	A/G	cg20607798	chr8:58055168	NA	0.61	7.06	0.31	6.3e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12476592	0.602	rs262523	chr2:63892684	T/C	cg17519650	chr2:63277830	OTX1	-0.44	-6.76	-0.3	4.17e-11	Childhood ear infection;
LGG	cis	rs6748734	0.779	rs4401206	chr2:241796905	A/G	cg07537917	chr2:241836409	C2orf54	-0.39	-7.78	-0.34	4.71e-14	Urinary metabolites;
LGG	cis	rs763121	0.853	rs138705	chr22:39133803	C/T	cg06022373	chr22:39101656	GTPBP1	0.87	17.29	0.63	4.87e-52	Menopause (age at onset);
LGG	cis	rs67460515	0.596	rs4856700	chr3:160922951	A/C	cg04691961	chr3:161091175	C3orf57	-0.46	-8.93	-0.38	1.04e-17	Parkinson's disease;
LGG	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg12011299	chr4:100065546	ADH4	0.41	8.02	0.35	8.94e-15	Smoking initiation;
LGG	cis	rs2130392	0.926	rs7680323	chr4:185652871	A/T	cg04058563	chr4:185651563	MLF1IP	-0.47	-10.08	-0.42	9.53e-22	Kawasaki disease;
LGG	cis	rs11239187	0.566	rs1904837	chr10:45117466	C/T	cg03916630	chr10:45065415	NA	0.29	6.73	0.3	5.06e-11	Body mass index;
LGG	cis	rs644799	0.526	rs693792	chr11:95622200	C/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.66	12.66	0.51	9.37e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.75	0.38	4.01e-17	Skin colour saturation;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs2802728	0.881	rs72759853	chr1:243547098	C/G	cg05593162	chr1:243577377	SDCCAG8	0.52	7.09	0.31	5.2e-12	Toenail selenium levels;
LGG	cis	rs116095464	0.558	rs56081398	chr5:247318	C/T	cg22857025	chr5:266934	NA	-1.55	-25.65	-0.77	6.11e-91	Breast cancer;
LGG	cis	rs9916302	0.706	rs2302073	chr17:37457342	A/G	cg00129232	chr17:37814104	STARD3	0.57	8.57	0.37	1.59e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs9611565	0.659	rs17367716	chr22:41913844	A/G	cg17554472	chr22:41940697	POLR3H	-0.47	-6.74	-0.3	4.6e-11	Vitiligo;
LGG	trans	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg25482853	chr8:67687455	SGK3	0.95	12.01	0.49	4.27e-29	Obesity-related traits;
LGG	cis	rs8180040	0.620	rs6414435	chr3:47121140	A/G	cg16586182	chr3:47516702	SCAP	-0.73	-13.25	-0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs1799949	0.965	rs2236762	chr17:41226675	A/T	cg18379455	chr17:41446167	NA	-0.31	-7.3	-0.32	1.23e-12	Menopause (age at onset);
LGG	cis	rs1577917	0.958	rs1414199	chr6:86522370	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.02	-0.49	3.83e-29	Response to antipsychotic treatment;
LGG	cis	rs4722166	0.630	rs4722168	chr7:22779002	G/A	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	8.91e-16	Lung cancer;
LGG	cis	rs2576037	0.583	rs2187091	chr18:44520048	T/C	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.66	-0.37	7.79e-17	Personality dimensions;
LGG	cis	rs208520	0.742	rs208454	chr6:66907783	T/C	cg07460842	chr6:66804631	NA	-0.93	-15.1	-0.57	3.38e-42	Exhaled nitric oxide output;
LGG	cis	rs734999	0.588	rs2764848	chr1:2530694	G/A	cg20673091	chr1:2541236	MMEL1	-0.78	-18.09	-0.64	1.05e-55	Ulcerative colitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23753457	chr11:69455870	CCND1	0.45	6.81	0.3	2.95e-11	Gut microbiome composition (summer);
LGG	cis	rs12887734	0.524	rs722637	chr14:104261723	G/T	cg26031613	chr14:104095156	KLC1	0.53	8.54	0.37	2e-16	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs3858526	0.883	rs7481923	chr11:5933342	T/C	cg25319279	chr11:5960081	NA	-0.54	-8.69	-0.37	6.39e-17	DNA methylation (variation);
LGG	cis	rs4774899	1.000	rs1628067	chr15:57258866	C/T	cg08128148	chr15:57256372	TCF12	0.31	7.34	0.32	9.55e-13	Urinary tract infection frequency;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg09699651	chr6:150184138	LRP11	0.49	8.67	0.37	7.16e-17	Lung cancer;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.7	-0.37	5.71e-17	Obesity-related traits;
LGG	cis	rs11148252	0.744	rs77466241	chr13:52862914	C/G	cg12458913	chr13:53173898	NA	0.66	12.85	0.51	1.62e-32	Lewy body disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07000785	chr1:68150823	GADD45A	0.47	7.0	0.31	8.78e-12	Gut microbiome composition (summer);
LGG	cis	rs36051895	0.559	rs7874495	chr9:5209804	A/G	cg02405213	chr9:5042618	JAK2	-0.66	-12.04	-0.49	3.05e-29	Pediatric autoimmune diseases;
LGG	trans	rs17685	0.535	rs41296542	chr7:75600008	A/G	cg19862616	chr7:65841803	NCRNA00174	0.53	9.03	0.39	4.65e-18	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs28386778	0.897	rs4968663	chr17:61835603	A/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.21	0.52	4.91e-34	Prudent dietary pattern;
LGG	cis	rs9325144	0.624	rs10783333	chr12:39118931	A/T	cg26384229	chr12:38710491	ALG10B	0.68	12.93	0.52	7.31e-33	Morning vs. evening chronotype;
LGG	cis	rs67460515	0.563	rs9876142	chr3:160780968	A/G	cg04691961	chr3:161091175	C3orf57	0.39	7.53	0.33	2.61e-13	Parkinson's disease;
LGG	cis	rs58649573	0.530	rs2159792	chr9:126778821	A/G	cg14112217	chr9:126806003	NA	0.39	7.62	0.33	1.47e-13	Post-traumatic stress disorder;
LGG	cis	rs7568458	0.684	rs3731828	chr2:85806266	C/T	cg17127132	chr2:85788382	GGCX	0.53	8.4	0.36	5.39e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2243480	1.000	rs4718333	chr7:65772758	T/C	cg13147721	chr7:65941812	NA	0.83	10.08	0.42	9.88e-22	Diabetic kidney disease;
LGG	cis	rs539514	0.612	rs1830760	chr13:76296625	G/A	cg04757411	chr13:76259545	LMO7	-0.27	-6.86	-0.3	2.28e-11	Type 1 diabetes;
LGG	cis	rs10489202	0.865	rs744168	chr1:168094079	G/T	cg24449463	chr1:168025552	DCAF6	-0.58	-8.17	-0.36	2.94e-15	Schizophrenia;
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg05084668	chr3:125655381	ALG1L	-0.57	-7.67	-0.34	1.01e-13	Blood pressure (smoking interaction);
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.39	-0.32	6.97e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12824058	0.831	rs12314111	chr12:130813663	G/T	cg24229701	chr12:130821962	PIWIL1	0.44	7.71	0.34	7.77e-14	Menopause (age at onset);
LGG	cis	rs12911832	0.727	rs2604454	chr15:59098732	C/A	cg05156742	chr15:59063176	FAM63B	0.61	10.85	0.45	1.41e-24	Schizophrenia;
LGG	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg24545054	chr4:106630052	GSTCD;INTS12	0.71	10.55	0.44	1.85e-23	Post bronchodilator FEV1;
LGG	cis	rs7264396	0.690	rs2425170	chr20:34442672	A/G	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.21	0.32	2.37e-12	Total cholesterol levels;
LGG	cis	rs9611565	0.559	rs132765	chr22:42008068	A/G	cg06481639	chr22:41940642	POLR3H	0.56	7.95	0.35	1.44e-14	Vitiligo;
LGG	cis	rs9951602	0.512	rs1599634	chr18:76643645	T/C	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs651907	0.640	rs771575	chr3:101619359	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.47	7.67	0.34	1.05e-13	Colorectal cancer;
LGG	cis	rs2797369	0.665	rs817226	chr6:101464025	C/G	cg27451362	chr6:101846650	GRIK2	0.77	10.21	0.43	3.18e-22	Renal function-related traits (eGRFcrea);
LGG	trans	rs7824557	0.806	rs10503418	chr8:11118983	C/T	cg15556689	chr8:8085844	FLJ10661	-0.44	-7.76	-0.34	5.56e-14	Retinal vascular caliber;
LGG	cis	rs1008375	0.932	rs11938710	chr4:17670664	G/C	cg18681998	chr4:17616180	MED28	-0.85	-17.92	-0.64	5.94e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs782590	0.537	rs7575170	chr2:55886780	C/T	cg18811423	chr2:55921094	PNPT1	-0.67	-11.13	-0.46	1.17e-25	Metabolic syndrome;
LGG	cis	rs2842992	0.747	rs1547093	chr6:160205991	C/A	cg16489826	chr6:160211363	TCP1;MRPL18	0.74	12.41	0.5	9.7e-31	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1983891	0.955	rs4714479	chr6:41518807	A/G	cg20194872	chr6:41519635	FOXP4	0.6	10.45	0.44	4.15e-23	Prostate cancer;
LGG	cis	rs4862750	0.914	rs9995391	chr4:187873749	A/T	cg03647317	chr4:187891568	NA	0.42	8.76	0.38	3.83e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1577917	0.740	rs7771612	chr6:86264374	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.7	13.07	0.52	1.86e-33	Response to antipsychotic treatment;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.9	19.48	0.67	3.57e-62	Personality dimensions;
LGG	cis	rs61192259	0.896	rs6909898	chr6:38410739	T/C	cg07362130	chr6:38359646	BTBD9	-0.29	-6.73	-0.3	5.18e-11	Restless legs syndrome;
LGG	cis	rs10504229	0.861	rs59873610	chr8:58172290	T/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-8.76	-0.38	3.75e-17	Lung cancer;
LGG	cis	rs6963495	0.719	rs73190172	chr7:105161210	T/C	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg22681709	chr2:178499509	PDE11A	-0.52	-7.77	-0.34	5.17e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.593	rs74760806	chr8:58024785	C/T	cg11062466	chr8:58055876	NA	0.46	7.01	0.31	8.31e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs1493916	1.000	rs11081827	chr18:31390228	C/A	cg04226714	chr8:49833948	SNAI2	-0.49	-8.73	-0.38	4.53e-17	Life satisfaction;
LGG	cis	rs4727027	0.901	rs4727019	chr7:148822266	A/G	cg23583168	chr7:148888333	NA	-0.86	-16.59	-0.61	7.85e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9916302	0.861	rs752314	chr17:37410700	C/T	cg00129232	chr17:37814104	STARD3	-0.62	-11.63	-0.48	1.27e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9397585	0.857	rs7762794	chr6:153380228	A/G	cg17707550	chr6:153380415	RGS17	0.62	14.42	0.56	3.23e-39	Body mass index;
LGG	cis	rs12410462	0.502	rs75429875	chr1:227957200	A/C	cg04117972	chr1:227635322	NA	0.69	10.19	0.43	3.85e-22	Major depressive disorder;
LGG	trans	rs4942242	0.663	rs1472330	chr13:44209628	A/G	cg19169023	chr15:41853346	TYRO3	0.44	8.82	0.38	2.31e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2535633	0.631	rs2465101	chr3:52991307	A/T	cg11645453	chr3:52864694	ITIH4	-0.49	-8.28	-0.36	1.34e-15	Body mass index;
LGG	cis	rs13202913	0.837	rs3734800	chr6:151766552	G/A	cg10883421	chr6:151773342	RMND1;C6orf211	0.61	6.76	0.3	4.07e-11	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs12142240	0.698	rs17413694	chr1:46818416	A/C	cg14993813	chr1:46806288	NSUN4	-0.54	-8.93	-0.38	9.92e-18	Menopause (age at onset);
LGG	cis	rs1507153	0.651	rs9350781	chr6:79481815	A/T	cg18132916	chr6:79620363	NA	-0.27	-6.79	-0.3	3.49e-11	Sjögren's syndrome;
LGG	cis	rs4481887	0.888	rs12042602	chr1:248482053	C/T	cg13385794	chr1:248469461	NA	0.49	8.34	0.36	8.6e-16	Common traits (Other);
LGG	cis	rs7829975	0.567	rs6601273	chr8:8796519	T/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.74	-0.34	6.48e-14	Mood instability;
LGG	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg06115741	chr20:33292138	TP53INP2	0.5	8.25	0.36	1.6e-15	Glomerular filtration rate (creatinine);
LGG	cis	rs4930103	0.619	rs10769945	chr11:1985127	C/T	cg15394860	chr11:2017084	H19	0.55	11.99	0.49	5.11e-29	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs7662987	0.517	rs3018048	chr4:100005538	C/T	cg12011299	chr4:100065546	ADH4	0.41	8.07	0.35	5.89e-15	Smoking initiation;
LGG	cis	rs67311347	1.000	rs7628247	chr3:40512682	G/T	cg24209194	chr3:40518798	ZNF619	-0.44	-7.04	-0.31	7.09e-12	Renal cell carcinoma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08599300	chr7:144533232	TPK1	0.44	6.73	0.3	5.01e-11	Gut microbiome composition (summer);
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs6032067	0.673	rs4522674	chr20:43893276	T/C	cg10761708	chr20:43804764	PI3	0.6	9.2	0.39	1.27e-18	Blood protein levels;
LGG	cis	rs2576037	0.583	rs2576050	chr18:44558912	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.55	-11.01	-0.46	3.47e-25	Personality dimensions;
LGG	cis	rs7945718	0.621	rs10831890	chr11:12671211	A/G	cg25843174	chr11:12811716	TEAD1	0.34	7.26	0.32	1.65e-12	Educational attainment (years of education);
LGG	cis	rs1008375	1.000	rs10805359	chr4:17684886	A/G	cg18681998	chr4:17616180	MED28	0.82	18.08	0.64	1.18e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6539267	0.741	rs7314289	chr12:106686260	A/C	cg00173435	chr12:106696525	TCP11L2	0.65	9.81	0.41	9.31e-21	Tourette syndrome;
LGG	cis	rs1124376	0.810	rs6807771	chr3:20160634	C/A	cg05072819	chr3:20081367	KAT2B	0.6	8.01	0.35	9.25e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7681440	0.904	rs6816736	chr4:90765746	G/A	cg14346243	chr4:90757452	SNCA	-0.38	-7.79	-0.34	4.32e-14	Dementia with Lewy bodies;
LGG	trans	rs9650657	1.000	rs9650657	chr8:10607400	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.68	-0.37	6.61e-17	Neuroticism;
LGG	trans	rs2204008	0.805	rs2874289	chr12:38258420	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.37e-18	Bladder cancer;
LGG	cis	rs9322193	0.962	rs2065664	chr6:150083621	A/G	cg11878867	chr6:150167359	LRP11	-0.5	-10.26	-0.43	2.16e-22	Lung cancer;
LGG	cis	rs2180341	0.960	rs9398839	chr6:127665863	G/A	cg27446573	chr6:127587934	RNF146	1.15	22.7	0.73	3.01e-77	Breast cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20409358	chr4:174255887	HMGB2	0.46	6.73	0.3	4.95e-11	Gut microbiome composition (summer);
LGG	cis	rs9911578	1.000	rs7223955	chr17:56917053	C/A	cg05425664	chr17:57184151	TRIM37	-0.63	-10.04	-0.42	1.4e-21	Intelligence (multi-trait analysis);
LGG	cis	rs34421088	0.560	rs2248315	chr8:11397086	T/A	cg21775007	chr8:11205619	TDH	-0.45	-7.48	-0.33	3.69e-13	Neuroticism;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg13264159	chr8:625131	ERICH1	0.96	9.02	0.39	4.84e-18	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.19	-0.32	2.56e-12	Bipolar disorder;
LGG	cis	rs7959452	0.535	rs10878953	chr12:69674187	A/G	cg14784868	chr12:69753453	YEATS4	0.66	12.43	0.5	7.91e-31	Blood protein levels;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg22535103	chr8:58192502	C8orf71	-0.74	-10.12	-0.43	7.02e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.863	rs3775849	chr4:120450908	G/C	cg09307838	chr4:120376055	NA	0.79	13.09	0.52	1.62e-33	Corneal astigmatism;
LGG	trans	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg21659725	chr3:3221576	CRBN	-0.62	-9.9	-0.42	4.3e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10504229	0.683	rs16921823	chr8:58108612	G/C	cg26174226	chr8:58114915	NA	-0.58	-8.3	-0.36	1.15e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.884	rs880245	chr6:150167398	A/G	cg08621203	chr6:150244597	RAET1G	-0.46	-8.01	-0.35	9.25e-15	Lung cancer;
LGG	cis	rs1707322	1.000	rs10890370	chr1:46389217	C/T	cg03146154	chr1:46216737	IPP	0.55	9.92	0.42	3.54e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs12701220	0.696	rs12112029	chr7:1137889	G/A	cg22630939	chr7:1135958	C7orf50	0.32	6.67	0.3	7.13e-11	Bronchopulmonary dysplasia;
LGG	cis	rs62244186	0.659	rs6441844	chr3:44503579	C/T	cg02073558	chr3:44770973	ZNF501	0.68	12.56	0.5	2.52e-31	Depressive symptoms;
LGG	cis	rs344364	0.602	rs2437745	chr16:1908431	G/C	cg06886374	chr16:1844152	IGFALS	-0.44	-8.02	-0.35	8.46e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9393692	0.557	rs56763414	chr6:26286468	T/C	cg00631329	chr6:26305371	NA	-0.44	-7.22	-0.32	2.19e-12	Educational attainment;
LGG	cis	rs6500395	1.000	rs1420704	chr16:48716902	C/T	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1497828	0.956	rs2132993	chr1:217547640	A/G	cg04411442	chr1:217543379	NA	0.48	8.22	0.36	2.09e-15	Dialysis-related mortality;
LGG	cis	rs17102423	0.929	rs4902363	chr14:65601689	T/G	cg11161011	chr14:65562177	MAX	-0.61	-11.38	-0.47	1.25e-26	Obesity-related traits;
LGG	cis	rs6964587	0.900	rs11984136	chr7:91766953	T/C	cg17063962	chr7:91808500	NA	0.53	9.76	0.41	1.38e-20	Breast cancer;
LGG	cis	rs3790515	1.000	rs3790515	chr1:151786372	A/G	cg07092448	chr1:151763213	TDRKH	0.81	10.18	0.43	4.1e-22	Depressive symptoms (SSRI exposure interaction);
LGG	cis	rs977987	0.800	rs4888378	chr16:75332041	A/G	cg03315344	chr16:75512273	CHST6	0.48	9.73	0.41	1.81e-20	Dupuytren's disease;
LGG	cis	rs7523273	0.565	rs2796251	chr1:207903688	C/G	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.6	-0.37	1.28e-16	Schizophrenia;
LGG	cis	rs858239	0.539	rs6956828	chr7:23187347	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.77	0.3	3.92e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.48e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs614226	1.000	rs1167726	chr12:120967364	A/C	cg01236616	chr12:121019343	POP5	-1.29	-23.47	-0.74	7.98e-81	Type 1 diabetes nephropathy;
LGG	trans	rs45509595	0.822	rs200484	chr6:27775674	A/G	cg01620082	chr3:125678407	NA	-0.83	-9.36	-0.4	3.54e-19	Breast cancer;
LGG	cis	rs1497828	0.956	rs1353666	chr1:217523885	A/G	cg04411442	chr1:217543379	NA	0.49	8.21	0.36	2.15e-15	Dialysis-related mortality;
LGG	cis	rs12971120	0.891	rs3764510	chr18:72166846	A/G	cg26446133	chr18:72167187	CNDP2	-0.7	-14.23	-0.55	2.22e-38	Refractive error;
LGG	cis	rs7666738	0.830	rs6817645	chr4:99016054	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.38	0.36	6.18e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7590368	0.673	rs17365216	chr2:10939241	A/G	cg15705551	chr2:10952987	PDIA6	0.57	7.41	0.33	6e-13	Educational attainment (years of education);
LGG	cis	rs834603	0.710	rs11761475	chr7:47444807	C/T	cg23694490	chr7:47445681	TNS3	0.47	13.3	0.53	2.06e-34	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs6693567	0.545	rs1260391	chr1:150373077	T/C	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg05659262	chr3:195539315	MUC4	-0.56	-8.15	-0.35	3.5e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.64	0.33	1.24e-13	Lung cancer;
LGG	cis	rs524281	1.000	rs565198	chr11:65913508	A/T	cg14541915	chr11:65894463	PACS1	-0.3	-6.84	-0.3	2.44e-11	Electroencephalogram traits;
LGG	cis	rs9291683	0.588	rs13133766	chr4:10019732	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Bone mineral density;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg01145475	chr6:7313460	SSR1	0.59	6.72	0.3	5.23e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6456042	1.000	rs6924688	chr6:166534443	T/G	cg11088901	chr6:166572345	T	-0.35	-7.34	-0.32	9.43e-13	Asthma;
LGG	cis	rs7178909	0.732	rs57163265	chr15:90400650	A/T	cg19708238	chr15:90437601	AP3S2	0.41	6.81	0.3	3.11e-11	Common traits (Other);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19738812	chr7:99102438	ZKSCAN5	0.39	6.65	0.3	8.19e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs2153535	0.580	rs1928184	chr6:8532108	T/A	cg23788917	chr6:8435910	SLC35B3	0.52	9.02	0.39	4.94e-18	Motion sickness;
LGG	cis	rs11155671	0.530	rs9371544	chr6:150217360	A/G	cg15971980	chr6:150254442	NA	0.42	8.24	0.36	1.84e-15	Testicular germ cell tumor;
LGG	trans	rs7618501	1.000	rs695238	chr3:49869158	A/C	cg21582582	chr3:182698605	DCUN1D1	0.51	9.43	0.4	2.05e-19	Intelligence (multi-trait analysis);
LGG	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg26597838	chr10:835615	NA	0.95	13.07	0.52	1.94e-33	Eosinophil percentage of granulocytes;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.08	0.57	4.28e-42	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04578304	chr7:75796096	NA	0.51	7.78	0.34	4.76e-14	Gut microbiome composition (summer);
LGG	cis	rs4242434	0.927	rs11136092	chr8:22466488	T/G	cg00599393	chr8:22457479	C8orf58	-0.47	-8.4	-0.36	5.36e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs7246760	1.000	rs67844335	chr19:9898039	G/A	cg02900749	chr2:68251473	NA	-1.11	-11.84	-0.48	2.02e-28	Pursuit maintenance gain;
LGG	cis	rs988958	0.526	rs7604533	chr2:42243861	A/T	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Hypospadias;
LGG	cis	rs7917772	0.636	rs7088981	chr10:104520423	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.49	-7.99	-0.35	1.1e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18541042	chr7:140227195	DENND2A	0.39	7.06	0.31	6.21e-12	Pancreatic cancer;
LGG	cis	rs4423214	0.592	rs11234027	chr11:71234107	G/A	cg05163923	chr11:71159392	DHCR7	-0.55	-8.07	-0.35	5.93e-15	Vitamin D levels;
LGG	cis	rs11190604	1.000	rs2495753	chr10:102325640	C/T	cg07080220	chr10:102295463	HIF1AN	0.74	12.21	0.49	6.32e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs834603	0.575	rs834608	chr7:47451918	A/T	cg23694490	chr7:47445681	TNS3	0.43	12.37	0.5	1.39e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7580658	0.614	rs7585198	chr2:127962635	C/T	cg10021288	chr2:128175891	PROC	0.4	7.75	0.34	5.88e-14	Protein C levels;
LGG	cis	rs9467773	1.000	rs4871	chr6:26545632	G/A	cg09904177	chr6:26538194	HMGN4	0.78	17.8	0.64	2.15e-54	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs7459958	chr8:58111905	G/T	cg22535103	chr8:58192502	C8orf71	-0.91	-12.56	-0.5	2.33e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.725	rs6449201	chr4:9973894	C/T	cg11266682	chr4:10021025	SLC2A9	-0.42	-7.86	-0.34	2.63e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13095912	0.752	rs62291883	chr3:185313842	T/C	cg11274856	chr3:185301563	NA	0.49	7.93	0.35	1.71e-14	Systolic blood pressure;
LGG	cis	rs6582630	0.638	rs1829584	chr12:38526299	G/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.27	-0.4	6.97e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs4870267	chr6:149992708	C/G	cg12070911	chr6:150209640	RAET1E	0.3	7.43	0.33	5.26e-13	Lung cancer;
LGG	cis	rs2228479	0.702	rs17233253	chr16:89828437	A/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs2213920	0.679	rs6478168	chr9:118225951	A/T	cg13918206	chr9:118159781	DEC1	0.54	7.32	0.32	1.09e-12	Docetaxel-induced peripheral neuropathy in metastatic castrate-resistant prostate cancer;
LGG	cis	rs4689388	0.581	rs11727100	chr4:6281458	A/C	cg25554036	chr4:6271136	WFS1	0.52	8.4	0.36	5.45e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs60871478	1.000	rs4374882	chr7:821798	C/T	cg22643751	chr7:855365	UNC84A	0.35	6.71	0.3	5.78e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg19671926	chr4:122722719	EXOSC9	0.53	8.13	0.35	3.87e-15	Type 2 diabetes;
LGG	cis	rs804280	0.560	rs10503426	chr8:11589383	A/C	cg21775007	chr8:11205619	TDH	0.47	7.49	0.33	3.62e-13	Myopia (pathological);
LGG	cis	rs35425515	0.706	rs78295680	chr10:98869131	T/A	cg09122387	chr10:98855762	SLIT1	0.72	8.97	0.38	7.4e-18	Bipolar disorder;
LGG	cis	rs694739	0.726	rs17857342	chr11:64138905	T/G	cg23796481	chr11:64053134	BAD;GPR137	0.71	13.02	0.52	3.05e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs7264396	0.790	rs4519606	chr20:34324648	T/C	cg17201900	chr20:34330562	RBM39	0.52	7.12	0.31	4.24e-12	Total cholesterol levels;
LGG	cis	rs11997175	0.846	rs6999445	chr8:33732693	G/A	ch.8.33884649F	chr8:33765107	NA	0.43	8.2	0.36	2.36e-15	Body mass index;
LGG	cis	rs7847628	0.587	rs4837796	chr9:123610288	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	-0.59	-10.63	-0.44	9.04e-24	Birth weight;
LGG	cis	rs12643440	0.538	rs12650732	chr4:17141641	A/T	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs11966931	0.948	rs72933160	chr6:108088865	G/T	cg04749840	chr6:108095067	SCML4	0.44	7.49	0.33	3.46e-13	Neutrophil percentage of white cells;
LGG	cis	rs1555322	0.530	rs2425044	chr20:33869735	C/T	cg03689076	chr20:33865952	NA	0.64	8.23	0.36	1.89e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs72781680	0.821	rs17045981	chr2:24109316	A/G	cg08917208	chr2:24149416	ATAD2B	0.71	8.53	0.37	2.16e-16	Lymphocyte counts;
LGG	cis	rs12220238	1.000	rs11000909	chr10:75944828	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.31	0.47	2.43e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	trans	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg15556689	chr8:8085844	FLJ10661	-0.48	-8.35	-0.36	7.78e-16	Retinal vascular caliber;
LGG	cis	rs10504229	0.728	rs17804365	chr8:58151537	C/A	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2439831	0.557	rs13329084	chr15:44151063	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	-0.91	-9.39	-0.4	2.65e-19	Lung cancer in ever smokers;
LGG	cis	rs1799949	1.000	rs4792981	chr17:41308274	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.53	-0.33	2.63e-13	Menopause (age at onset);
LGG	cis	rs477895	0.713	rs1059440	chr11:63991801	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.86	-11.47	-0.47	5.5e-27	Mean platelet volume;
LGG	cis	rs10929925	0.966	rs2693833	chr2:6152133	C/T	cg00493617	chr2:6141445	NA	0.32	7.13	0.31	3.82e-12	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs5769707	0.642	rs135880	chr22:50018654	T/A	cg06623630	chr22:50017776	C22orf34	-0.51	-10.28	-0.43	1.86e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs16973500	0.808	rs72801786	chr16:71955085	C/T	cg09427745	chr16:71932006	KIAA0174	-0.49	-7.25	-0.32	1.76e-12	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs9303401	0.659	rs12600349	chr17:57054245	A/G	cg25039879	chr17:56429692	SUPT4H1	-0.64	-8.95	-0.38	8.64e-18	Cognitive test performance;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.67	0.34	1.04e-13	Schizophrenia;
LGG	cis	rs7572733	0.840	rs13034353	chr2:198565763	A/G	cg00792783	chr2:198669748	PLCL1	-0.44	-7.51	-0.33	3e-13	Dermatomyositis;
LGG	cis	rs2439831	1.000	rs689596	chr15:43761717	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.82	10.19	0.43	3.99e-22	Lung cancer in ever smokers;
LGG	trans	rs61931739	0.500	rs11053211	chr12:34464334	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg19676328	chr12:49525230	TUBA1B	-0.54	-8.0	-0.35	1.01e-14	Total cholesterol levels;
LGG	trans	rs208520	1.000	rs12209225	chr6:66996443	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.24	0.55	2.01e-38	Exhaled nitric oxide output;
LGG	cis	rs1005277	0.579	rs1780146	chr10:38517874	C/A	cg25951256	chr10:38645740	HSD17B7P2	-0.43	-6.72	-0.3	5.26e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.962	rs9688940	chr6:150110113	G/A	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs853679	0.517	rs12332979	chr6:28141548	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.69	-0.34	8.61e-14	Depression;
LGG	cis	rs3736594	0.559	rs1919129	chr2:27818721	C/G	cg27432699	chr2:27873401	GPN1	0.56	8.57	0.37	1.59e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs7824557	0.767	rs7837036	chr8:11175489	A/G	cg16141378	chr3:129829833	LOC729375	-0.39	-8.73	-0.38	4.77e-17	Retinal vascular caliber;
LGG	cis	rs12980942	0.630	rs7257825	chr19:41788344	T/C	cg25627403	chr19:41769009	HNRNPUL1	0.51	6.97	0.31	1.07e-11	Coronary artery disease;
LGG	cis	rs283228	0.550	rs2787577	chr6:101818753	A/G	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs6502050	0.835	rs4247357	chr17:80166989	G/T	cg11859384	chr17:80120422	CCDC57	-0.44	-7.62	-0.33	1.4e-13	Life satisfaction;
LGG	cis	rs4731207	0.698	rs6945104	chr7:124557915	A/G	cg05630886	chr7:124431682	NA	-0.33	-7.89	-0.34	2.26e-14	Cutaneous malignant melanoma;
LGG	trans	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg27523141	chr10:43048294	ZNF37B	0.4	7.8	0.34	4.14e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs12497850	0.864	rs4513485	chr3:49139966	G/A	cg07636037	chr3:49044803	WDR6	1.08	25.58	0.77	1.33e-90	Parkinson's disease;
LGG	cis	rs6840360	0.606	rs2724550	chr4:152358986	C/T	cg17217059	chr4:152329364	FAM160A1	0.2	7.09	0.31	5.03e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1577917	0.637	rs1838957	chr6:86565056	T/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.5	-0.44	2.77e-23	Response to antipsychotic treatment;
LGG	cis	rs67133203	0.904	rs12809563	chr12:51356673	T/C	cg14688905	chr12:51403056	SLC11A2	0.71	10.89	0.45	1e-24	Urinary tract infection frequency;
LGG	cis	rs898097	1.000	rs898098	chr17:80904564	G/A	cg15664640	chr17:80829946	TBCD	0.68	13.14	0.52	1.01e-33	Breast cancer;
LGG	cis	rs7267979	0.844	rs6107017	chr20:25232300	A/G	cg06421707	chr20:25228305	PYGB	0.54	12.2	0.49	7.06e-30	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs514406	0.679	rs499239	chr1:53310594	A/G	cg08859206	chr1:53392774	SCP2	-0.43	-8.6	-0.37	1.21e-16	Monocyte count;
LGG	cis	rs2836974	0.899	rs34978594	chr21:40580003	C/T	cg11644478	chr21:40555479	PSMG1	0.92	17.87	0.64	1.01e-54	Cognitive function;
LGG	cis	rs4478037	1.000	rs61433006	chr3:33162363	T/A	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs4631830	0.869	rs7896437	chr10:51529593	A/C	cg10326726	chr10:51549505	MSMB	-0.68	-14.21	-0.55	2.84e-38	Prostate-specific antigen levels;
LGG	cis	rs3087591	0.708	rs10438801	chr17:29693785	G/A	cg24425628	chr17:29625626	OMG;NF1	0.6	12.55	0.5	2.6e-31	Hip circumference;
LGG	cis	rs35306767	0.716	rs34487581	chr10:897201	G/A	cg25019033	chr10:957182	NA	-0.55	-9.22	-0.39	1.06e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs897984	0.806	rs12928852	chr16:30943988	C/T	cg02466173	chr16:30829666	NA	0.46	8.29	0.36	1.27e-15	Dementia with Lewy bodies;
LGG	cis	rs7582180	0.614	rs1530030	chr2:101009600	G/A	cg08297393	chr2:100937505	LONRF2	-0.55	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs9811771	chr3:10133949	A/G	cg08888203	chr3:10149979	C3orf24	0.54	9.15	0.39	1.76e-18	Alzheimer's disease;
LGG	cis	rs599083	0.573	rs3018713	chr11:68390986	A/G	cg16797656	chr11:68205561	LRP5	0.51	9.76	0.41	1.39e-20	Bone mineral density (spine);
LGG	trans	rs7395662	1.000	rs7121992	chr11:48592582	C/T	cg03929089	chr4:120376271	NA	-0.46	-7.35	-0.32	9.16e-13	HDL cholesterol;
LGG	cis	rs1862618	0.853	rs10461617	chr5:56104308	A/G	cg12654349	chr5:56205094	C5orf35	-0.68	-10.71	-0.45	4.62e-24	Initial pursuit acceleration;
LGG	cis	rs17253792	0.545	rs12879705	chr14:56017684	C/G	cg01858014	chr14:56050164	KTN1	-0.76	-9.44	-0.4	1.79e-19	Putamen volume;
LGG	trans	rs6598955	0.671	rs7550997	chr1:26596080	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.75	-12.59	-0.51	1.75e-31	Obesity-related traits;
LGG	cis	rs4799461	1.000	rs11664242	chr18:35176161	A/G	cg27332583	chr18:35150602	NA	-0.56	-11.23	-0.46	4.83e-26	Neuroticism;
LGG	cis	rs4666002	0.956	rs10169065	chr2:27778560	A/G	cg27432699	chr2:27873401	GPN1	0.45	6.73	0.3	4.88e-11	Phospholipid levels (plasma);
LGG	cis	rs2228479	1.000	rs117406136	chr16:89974605	C/T	cg04287289	chr16:89883240	FANCA	0.78	7.57	0.33	2.03e-13	Skin colour saturation;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	-0.43	-8.81	-0.38	2.52e-17	Schizophrenia;
LGG	cis	rs62238980	0.521	rs733907	chr22:32462564	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs1005277	0.522	rs289648	chr10:37971837	T/C	cg25427524	chr10:38739819	LOC399744	-0.62	-12.42	-0.5	9.29e-31	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.823	rs58222895	chr7:1885064	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-11.76	-0.48	4.07e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs11645898	0.935	rs4788611	chr16:72175256	A/G	cg14768367	chr16:72042858	DHODH	-0.82	-11.03	-0.46	2.81e-25	Blood protein levels;
LGG	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg24101359	chr6:42928495	GNMT	0.39	8.72	0.38	4.85e-17	Blood protein levels;
LGG	cis	rs1784581	0.588	rs9346894	chr6:162430763	T/C	cg17173639	chr6:162384350	PARK2	0.66	13.77	0.54	2.19e-36	Itch intensity from mosquito bite;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg18124201	chr20:46414952	SULF2	0.51	8.49	0.37	2.82e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs11123170	0.529	rs112692022	chr2:113970182	C/T	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.65	0.37	8.34e-17	Renal function-related traits (BUN);
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg11050988	chr7:1952600	MAD1L1	-0.32	-7.63	-0.33	1.37e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2242116	0.734	rs4683294	chr3:46979013	C/G	cg16586182	chr3:47516702	SCAP	0.58	9.74	0.41	1.65e-20	Birth weight;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg00800038	chr16:89945340	TCF25	-0.72	-8.25	-0.36	1.61e-15	Skin colour saturation;
LGG	trans	rs2235573	0.527	rs139865	chr22:38353932	C/G	cg19894588	chr14:64061835	NA	0.63	10.34	0.43	1.09e-22	Glioblastoma;Glioma;
LGG	cis	rs1005277	0.579	rs1780133	chr10:38499509	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.3	-0.32	1.25e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs2404602	0.716	rs17363713	chr15:76746128	G/C	cg15268244	chr15:77196840	NA	-0.33	-7.3	-0.32	1.25e-12	Blood metabolite levels;
LGG	cis	rs12824058	0.799	rs4759656	chr12:130815804	G/A	cg24229701	chr12:130821962	PIWIL1	0.44	7.59	0.33	1.82e-13	Menopause (age at onset);
LGG	cis	rs9329289	0.510	rs2029604	chr10:2554700	T/C	cg15501526	chr10:2543763	NA	0.48	9.07	0.39	3.49e-18	Age-related hearing impairment;
LGG	trans	rs9354308	0.868	rs4392709	chr6:66547178	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.51	-8.7	-0.37	5.63e-17	Metabolite levels;
LGG	cis	rs490234	0.702	rs3814129	chr9:128365953	A/G	cg14078157	chr9:128172775	NA	-0.53	-10.03	-0.42	1.47e-21	Mean arterial pressure;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg21911579	chr5:131705225	SLC22A5	0.7	7.73	0.34	6.79e-14	Rheumatoid arthritis;
LGG	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg03517284	chr6:25882590	NA	-0.42	-6.96	-0.31	1.15e-11	Iron status biomarkers;
LGG	cis	rs7582180	0.676	rs4264577	chr2:100930662	T/C	cg14675211	chr2:100938903	LONRF2	0.66	11.69	0.48	7.7e-28	Intelligence (multi-trait analysis);
LGG	cis	rs2292864	0.764	rs2292867	chr17:45357489	C/T	cg18085866	chr17:45331354	ITGB3	-0.64	-6.65	-0.3	8.11e-11	Left atrial antero-posterior diameter;
LGG	cis	rs2880765	0.835	rs7178991	chr15:86050944	G/C	cg17133734	chr15:86042851	AKAP13	-0.28	-6.81	-0.3	3.05e-11	Coronary artery disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg10335659	chr2:99757356	C2orf15;TSGA10	0.38	6.7	0.3	6.11e-11	Bilirubin levels;
LGG	cis	rs56146971	0.763	rs34854034	chr14:91870677	A/G	cg14409461	chr14:91925021	SMEK1	-0.42	-6.95	-0.31	1.21e-11	Alzheimer disease and age of onset;
LGG	cis	rs981844	0.775	rs10517580	chr4:154744128	T/G	cg14289246	chr4:154710475	SFRP2	0.67	11.01	0.46	3.46e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs6499255	0.638	rs57824734	chr16:69811995	C/T	cg00738113	chr16:70207722	CLEC18C	-0.32	-8.12	-0.35	4.35e-15	IgE levels;
LGG	cis	rs2739330	0.789	rs5760109	chr22:24252938	C/G	cg01238044	chr22:24384105	GSTT1	-0.41	-7.0	-0.31	9.05e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7712401	0.601	rs396941	chr5:122318265	G/T	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs57221529	0.825	rs7443550	chr5:578404	G/T	cg01221209	chr5:554886	NA	-0.47	-6.96	-0.31	1.19e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs1008375	1.000	rs1558378	chr4:17650351	T/C	cg04450456	chr4:17643702	FAM184B	0.34	7.55	0.33	2.28e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01436486	chr19:58963005	ZNF324B	0.47	6.94	0.31	1.3e-11	Gut microbiome composition (summer);
LGG	cis	rs2346177	0.542	rs13024414	chr2:46687062	G/A	cg26688816	chr2:46740690	ATP6V1E2	-0.66	-12.76	-0.51	3.51e-32	HDL cholesterol;
LGG	cis	rs4262150	0.810	rs17565693	chr5:152070764	C/T	cg12297329	chr5:152029980	NA	-0.74	-13.36	-0.53	1.2e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs7527798	0.592	rs11118281	chr1:207832102	C/T	cg09232269	chr1:207846808	CR1L	-0.37	-6.98	-0.31	1.05e-11	Erythrocyte sedimentation rate;
LGG	cis	rs58616815	0.857	rs72824612	chr10:92156953	T/C	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs17826219	0.636	rs2449770	chr17:29101064	G/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Body mass index;
LGG	cis	rs8031584	0.505	rs2959036	chr15:31219742	T/G	cg14829155	chr15:31115871	NA	0.49	8.53	0.37	2.06e-16	Huntington's disease progression;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23202349	chr5:178053533	CLK4	0.45	6.71	0.3	5.55e-11	Gut microbiome composition (summer);
LGG	cis	rs2455799	0.613	rs6802048	chr3:15883933	A/G	cg16303742	chr3:15540471	COLQ	-0.39	-7.72	-0.34	7.07e-14	Mean platelet volume;
LGG	cis	rs4774830	0.744	rs62046391	chr15:56310688	C/T	cg05129572	chr15:56138634	NEDD4	0.71	6.89	0.3	1.88e-11	Delta-5 desaturase activity;
LGG	cis	rs11785693	0.862	rs11778367	chr8:4988398	T/C	cg26367366	chr8:4980734	NA	0.93	14.93	0.57	1.95e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs367943	0.712	rs9326886	chr5:112728458	A/C	cg12552261	chr5:112820674	MCC	0.57	10.36	0.43	9.29e-23	Type 2 diabetes;
LGG	cis	rs4929949	0.901	rs9737312	chr11:8585689	T/G	cg23764900	chr11:8616102	STK33	-0.4	-7.12	-0.31	4.03e-12	Body mass index;
LGG	trans	rs9427116	0.502	rs12125166	chr1:154582129	A/G	cg25858983	chr17:42295711	UBTF	0.36	6.82	0.3	2.93e-11	Blood protein levels;
LGG	cis	rs7552404	1.000	rs7516226	chr1:76234257	G/A	cg10523679	chr1:76189770	ACADM	0.8	13.73	0.54	3.01e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs12478296	0.681	rs55802421	chr2:243033962	C/T	cg18898632	chr2:242989856	NA	-0.81	-10.1	-0.42	8.49e-22	Obesity-related traits;
LGG	cis	rs60843830	1.000	rs56321614	chr2:268191	G/T	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.54	0.37	1.9e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs3816183	1.000	rs7422835	chr2:43016007	A/G	cg14631114	chr2:43023945	NA	0.51	9.52	0.4	9.56e-20	Hypospadias;
LGG	cis	rs11105298	0.891	rs1008764	chr12:89887649	T/C	cg08166232	chr12:89918718	WDR51B;GALNT4	-0.67	-9.3	-0.4	5.79e-19	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs7618915	0.547	rs2268027	chr3:52766606	G/A	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7.17e-23	Bipolar disorder;
LGG	cis	rs4743820	0.590	rs73650935	chr9:93917658	T/C	cg14446406	chr9:93919335	NA	-0.91	-15.46	-0.58	9.04e-44	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs875971	0.545	rs73376401	chr7:65639828	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.3	0.43	1.57e-22	Aortic root size;
LGG	cis	rs6500602	0.592	rs4785966	chr16:4518754	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.41	-8.13	-0.35	4.01e-15	Schizophrenia;
LGG	cis	rs6951245	1.000	rs77083167	chr7:1071823	C/T	cg03188948	chr7:1209495	NA	0.65	8.49	0.37	2.81e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12476592	0.602	rs262519	chr2:63891464	G/A	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg14664628	chr15:75095509	CSK	-0.91	-19.23	-0.67	5.32e-61	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs4132509	0.948	rs320322	chr1:243750755	G/A	cg25706552	chr1:244017396	NA	-0.53	-8.43	-0.36	4.3e-16	RR interval (heart rate);
LGG	cis	rs870825	0.721	rs72703528	chr4:185607311	A/G	cg04058563	chr4:185651563	MLF1IP	1.09	20.35	0.69	3.13e-66	Blood protein levels;
LGG	cis	rs7666738	0.830	rs11722272	chr4:99000839	C/T	cg05340658	chr4:99064831	C4orf37	0.46	7.37	0.32	7.7e-13	Colonoscopy-negative controls vs population controls;
LGG	cis	rs12477438	0.520	rs36071868	chr2:99737120	G/A	cg08885076	chr2:99613938	TSGA10	0.41	8.7	0.37	6.06e-17	Chronic sinus infection;
LGG	cis	rs16957091	0.909	rs3199486	chr15:43012195	T/C	cg07484255	chr15:43025164	CDAN1	-0.48	-6.9	-0.31	1.76e-11	MGMT methylation in smokers;
LGG	cis	rs12928939	0.774	rs7192860	chr16:71643622	G/A	cg03805757	chr16:71968109	PKD1L3	-0.48	-8.88	-0.38	1.45e-17	Post bronchodilator FEV1;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg20453264	chr5:131705742	SLC22A5	0.58	7.47	0.33	3.96e-13	Rheumatoid arthritis;
LGG	cis	rs6754311	0.773	rs309179	chr2:136613780	G/A	cg07169764	chr2:136633963	MCM6	-0.77	-13.08	-0.52	1.77e-33	Mosquito bite size;
LGG	cis	rs10504229	1.000	rs67388517	chr8:58176617	C/A	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg02273617	chr15:68117586	LBXCOR1	-0.33	-7.44	-0.33	4.82e-13	Restless legs syndrome;
LGG	trans	rs61931739	0.500	rs10844734	chr12:34043083	G/A	cg26384229	chr12:38710491	ALG10B	0.74	14.97	0.57	1.32e-41	Morning vs. evening chronotype;
LGG	cis	rs763014	0.898	rs1045277	chr16:633125	T/C	cg00908189	chr16:619842	PIGQ	0.85	15.62	0.59	1.72e-44	Height;
LGG	cis	rs2180341	1.000	rs9398838	chr6:127635285	C/T	cg27446573	chr6:127587934	RNF146	1.14	22.53	0.72	1.89e-76	Breast cancer;
LGG	cis	rs870825	0.616	rs6834156	chr4:185639903	G/C	cg04058563	chr4:185651563	MLF1IP	1.05	23.18	0.73	1.89e-79	Blood protein levels;
LGG	cis	rs365132	0.875	rs4976665	chr5:176352736	C/T	cg16309518	chr5:176445507	NA	-0.51	-11.18	-0.46	7.49e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs757278	0.860	rs10230544	chr7:117395160	C/G	cg10524701	chr7:117356490	CTTNBP2	0.36	7.25	0.32	1.73e-12	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs11622475	1.000	rs1187446	chr14:104409896	C/T	cg12183467	chr14:104352244	NA	-0.43	-7.35	-0.32	9.1e-13	Bipolar disorder;
LGG	cis	rs4918072	0.686	rs9325509	chr10:105703030	C/T	cg11005552	chr10:105648138	OBFC1	0.51	8.77	0.38	3.41e-17	Coronary artery disease;
LGG	cis	rs910316	1.000	rs175512	chr14:75523382	T/C	cg08847533	chr14:75593920	NEK9	-0.62	-12.0	-0.49	4.53e-29	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00653609	chr6:39082964	C6orf64	0.47	7.0	0.31	9.2e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg24375607	chr4:120327624	NA	0.66	10.99	0.46	3.84e-25	Corneal astigmatism;
LGG	cis	rs11105298	0.786	rs3803128	chr12:89860319	C/A	cg00757033	chr12:89920650	WDR51B	0.65	9.53	0.41	8.74e-20	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs651907	0.535	rs11707250	chr3:101509371	A/T	cg23548719	chr3:101395035	LOC100009676;ZBTB11	-0.5	-8.22	-0.36	2.08e-15	Colorectal cancer;
LGG	cis	rs7959452	0.590	rs11177643	chr12:69785712	T/G	cg20891283	chr12:69753455	YEATS4	0.96	22.84	0.73	6.76e-78	Blood protein levels;
LGG	cis	rs736408	0.609	rs62255396	chr3:52782839	C/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.44	-0.44	4.55e-23	Bipolar disorder;
LGG	cis	rs6997458	1.000	rs6997458	chr8:86274030	A/C	cg02393479	chr8:86352350	CA3	-0.32	-6.99	-0.31	9.68e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9527	0.662	rs4919686	chr10:104592249	A/C	cg04362960	chr10:104952993	NT5C2	0.47	8.13	0.35	4.04e-15	Arsenic metabolism;
LGG	cis	rs6997458	0.652	rs7827051	chr8:86337848	A/G	cg02393479	chr8:86352350	CA3	-0.3	-6.76	-0.3	4.1e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs13108904	0.517	rs4974551	chr4:1336410	C/A	cg00689492	chr4:1303491	MAEA	0.51	8.54	0.37	2.02e-16	Obesity-related traits;
LGG	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg02221750	chr19:17393354	ANKLE1	-0.62	-9.17	-0.39	1.58e-18	Systemic lupus erythematosus;
LGG	cis	rs965469	0.652	rs4507156	chr20:3228460	A/G	cg25506879	chr20:3388711	C20orf194	0.45	7.11	0.31	4.29e-12	IFN-related cytopenia;
LGG	cis	rs7551222	0.681	rs4252686	chr1:204496895	A/G	cg20240347	chr1:204465584	NA	-0.57	-11.45	-0.47	6.66e-27	Schizophrenia;
LGG	cis	rs12775980	0.737	rs55765119	chr10:29846944	A/G	cg12329853	chr10:29834266	MIR604;SVIL	-0.65	-6.7	-0.3	6.07e-11	Bone fracture in osteoporosis;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26187219	chr5:52095812	ITGA1;PELO	0.49	8.05	0.35	6.83e-15	Cognitive performance;
LGG	cis	rs889312	0.500	rs702691	chr5:56114526	T/G	cg12654349	chr5:56205094	C5orf35	-0.38	-6.78	-0.3	3.65e-11	Breast cancer;Breast cancer (early onset);
LGG	trans	rs7824557	0.713	rs6601575	chr8:11097804	A/C	cg06636001	chr8:8085503	FLJ10661	0.47	8.65	0.37	8.4e-17	Retinal vascular caliber;
LGG	cis	rs611744	0.647	rs2848620	chr8:109249551	G/T	cg21045802	chr8:109455806	TTC35	0.5	9.42	0.4	2.23e-19	Dupuytren's disease;
LGG	cis	rs12188164	0.543	rs2434694	chr5:462734	C/T	cg00473462	chr5:472545	LOC25845	0.35	6.69	0.3	6.37e-11	Cystic fibrosis severity;
LGG	cis	rs4262150	0.883	rs72799190	chr5:152187123	T/G	cg12297329	chr5:152029980	NA	-0.7	-13.15	-0.52	8.67e-34	Bipolar disorder and schizophrenia;
LGG	cis	rs62400317	0.762	rs62436369	chr6:44867539	C/G	cg20913747	chr6:44695427	NA	-0.66	-11.3	-0.47	2.48e-26	Total body bone mineral density;
LGG	cis	rs4771450	0.962	rs7336446	chr13:103975157	A/C	cg02987523	chr13:103978230	NA	-0.33	-6.92	-0.31	1.51e-11	Uric acid levels;
LGG	cis	rs2249694	1.000	rs2249694	chr10:135352153	A/G	cg20169779	chr10:135381914	SYCE1	0.54	7.94	0.35	1.51e-14	Obesity-related traits;
LGG	cis	rs2479724	0.805	rs11756454	chr6:41798578	T/A	cg17623882	chr6:41773611	USP49	0.45	7.7	0.34	8.1e-14	Menarche (age at onset);
LGG	cis	rs11722228	0.549	rs73212853	chr4:10096230	C/T	cg25986240	chr4:9926439	SLC2A9	-0.54	-10.03	-0.42	1.48e-21	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs1046896	0.739	rs2379358	chr17:80741612	G/A	cg10935494	chr17:80760059	TBCD	-0.38	-6.79	-0.3	3.52e-11	Glycated hemoglobin levels;
LGG	cis	rs11190604	1.000	rs2495736	chr10:102338410	T/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.96	0.49	6.46e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7827545	0.545	rs6998092	chr8:135557449	A/G	cg17885191	chr8:135476712	NA	0.59	8.73	0.38	4.49e-17	Hypertension (SNP x SNP interaction);
LGG	cis	rs1008375	1.000	rs3933453	chr4:17636319	A/C	cg02297831	chr4:17616191	MED28	0.5	9.38	0.4	2.87e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7017914	0.902	rs13269513	chr8:71578079	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.99	-0.31	9.62e-12	Bone mineral density;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg13206674	chr6:150067644	NUP43	0.42	9.13	0.39	2.2e-18	Testicular germ cell tumor;
LGG	trans	rs7613875	0.620	rs7634441	chr3:50071677	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	-0.39	-6.72	-0.3	5.28e-11	Body mass index;
LGG	cis	rs9400467	0.537	rs12214886	chr6:111500081	C/T	cg15721981	chr6:111408429	SLC16A10	0.58	6.87	0.3	2.09e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs644799	0.965	rs565771	chr11:95644179	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.33	0.32	1.01e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs1997103	0.798	rs12154964	chr7:55414041	G/A	cg20935933	chr6:143382018	AIG1	0.53	8.24	0.36	1.73e-15	QRS interval (sulfonylurea treatment interaction);
LGG	trans	rs10435719	0.871	rs7815186	chr8:11792062	C/G	cg08975724	chr8:8085496	FLJ10661	0.4	7.36	0.32	8.2e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs4950322	0.895	rs17356735	chr1:146850049	T/C	cg22381352	chr1:146742008	CHD1L	-0.44	-6.98	-0.31	1.04e-11	Protein quantitative trait loci;
LGG	cis	rs7619833	0.564	rs6551182	chr3:27252491	T/A	cg02860705	chr3:27208620	NA	0.42	8.19	0.36	2.51e-15	Breast cancer;
LGG	cis	rs4595586	0.545	rs11611625	chr12:39387207	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs5769707	0.681	rs2319346	chr22:50029640	A/G	cg20744362	chr22:50050164	C22orf34	0.38	6.65	0.3	8.13e-11	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00146837	chr17:60142491	MED13	0.44	6.69	0.3	6.36e-11	Gut microbiome composition (summer);
LGG	cis	rs9358372	1.000	rs4712552	chr6:20818478	G/A	cg13405222	chr6:20811065	CDKAL1	-0.7	-15.47	-0.58	7.84e-44	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs1950500	0.585	rs8003339	chr14:24817817	T/C	cg16194253	chr14:24768981	DHRS1;C14orf21	0.39	6.72	0.3	5.41e-11	Height;
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg14500267	chr11:67383377	NA	0.44	8.3	0.36	1.18e-15	Mean corpuscular volume;
LGG	cis	rs524281	0.861	rs2177053	chr11:65966145	A/C	cg16950941	chr11:66035639	RAB1B	-0.46	-6.69	-0.3	6.39e-11	Electroencephalogram traits;
LGG	cis	rs875971	0.862	rs6962717	chr7:65883735	G/A	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.93e-20	Aortic root size;
LGG	cis	rs1552244	1.000	rs17032278	chr3:10077955	A/G	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs7916697	1.000	rs7916697	chr10:69991853	A/G	cg18338521	chr10:69995036	NA	0.32	7.3	0.32	1.28e-12	Optic disc area;
LGG	cis	rs1552244	1.000	rs9879080	chr3:10084224	C/T	cg08888203	chr3:10149979	C3orf24	0.54	9.26	0.4	7.58e-19	Alzheimer's disease;
LGG	cis	rs7192750	0.562	rs9888748	chr16:71987851	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.75	0.45	3.29e-24	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs2739330	0.828	rs5760098	chr22:24248314	A/G	cg12419862	chr22:24373484	LOC391322	-0.87	-17.15	-0.62	2.03e-51	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7940866	0.838	rs7949071	chr11:130877478	T/C	cg12179176	chr11:130786555	SNX19	0.71	13.13	0.52	1.08e-33	Schizophrenia;
LGG	cis	rs12967678	1	rs12967678	chr18:12805388	G/A	cg23598886	chr18:12777645	NA	-0.66	-7.91	-0.35	1.88e-14	Selective IgA deficiency;
LGG	cis	rs8028182	0.636	rs12708520	chr15:75830539	C/T	cg20655648	chr15:75932815	IMP3	0.45	7.49	0.33	3.41e-13	Sudden cardiac arrest;
LGG	cis	rs10463554	0.818	rs2241564	chr5:102302251	A/G	cg23492399	chr5:102201601	PAM	-0.57	-8.74	-0.38	4.48e-17	Parkinson's disease;
LGG	cis	rs1008375	0.931	rs10939733	chr4:17570658	T/C	cg16339924	chr4:17578868	LAP3	0.64	10.97	0.45	4.82e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1975974	0.748	rs67473406	chr17:21726745	G/A	cg18423549	chr17:21743878	NA	-0.46	-6.7	-0.3	6.19e-11	Psoriasis;
LGG	cis	rs1865760	0.865	rs9467648	chr6:25957933	T/A	cg16482183	chr6:26056742	HIST1H1C	0.51	9.19	0.39	1.37e-18	Height;
LGG	cis	rs1566085	0.766	rs7006068	chr8:142656636	C/T	cg26331504	chr8:142652174	NA	0.31	7.31	0.32	1.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.817	rs78138632	chr8:58191341	G/T	cg05313129	chr8:58192883	C8orf71	-0.81	-11.04	-0.46	2.65e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9910055	0.639	rs227583	chr17:42231698	C/G	cg16434002	chr17:42200994	HDAC5	-0.55	-10.29	-0.43	1.7e-22	Total body bone mineral density;
LGG	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg17644776	chr2:200775616	C2orf69	-0.61	-6.99	-0.31	9.57e-12	Schizophrenia;
LGG	cis	rs7215564	0.908	rs9900687	chr17:78739721	C/T	cg06153925	chr17:78755379	RPTOR	-0.39	-7.11	-0.31	4.49e-12	Myopia (pathological);
LGG	cis	rs10504229	0.683	rs17194995	chr8:58109220	A/C	cg21724239	chr8:58056113	NA	-0.62	-9.15	-0.39	1.87e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.545	rs7650459	chr3:143658934	C/G	cg06585982	chr3:143692056	C3orf58	0.6	9.94	0.42	3.11e-21	Economic and political preferences (feminism/equality);
LGG	cis	rs10752881	1.000	rs10752883	chr1:182980963	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.93	0.38	9.93e-18	Colorectal cancer;
LGG	cis	rs2758596	1.000	rs2842866	chr1:156159721	G/A	cg24450063	chr1:156163899	SLC25A44	0.91	8.53	0.37	2.11e-16	Paclitaxel disposition in epithelial ovarian cancer;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.42	-0.33	5.52e-13	IgG glycosylation;
LGG	trans	rs853679	0.567	rs16894106	chr6:28400339	G/A	cg06606381	chr12:133084897	FBRSL1	-0.45	-6.66	-0.3	7.89e-11	Depression;
LGG	cis	rs7937682	0.564	rs10891277	chr11:111373103	A/G	cg09085632	chr11:111637200	PPP2R1B	0.65	11.04	0.46	2.58e-25	Primary sclerosing cholangitis;
LGG	cis	rs6952808	0.689	rs12670737	chr7:2046830	C/T	cg02951883	chr7:2050386	MAD1L1	-0.8	-17.74	-0.64	4.27e-54	Bipolar disorder and schizophrenia;
LGG	cis	rs10791097	0.694	rs4457753	chr11:130755575	A/G	cg12179176	chr11:130786555	SNX19	0.84	17.54	0.63	3.41e-53	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs10504130	0.569	rs9650305	chr8:52824673	T/C	cg24946253	chr8:52722146	PXDNL	-0.45	-6.71	-0.3	5.86e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs988958	0.565	rs12712820	chr2:42236370	C/T	cg27252766	chr2:42229092	NA	0.52	7.47	0.33	4.16e-13	Hypospadias;
LGG	trans	rs561341	0.943	rs508566	chr17:30289861	G/C	cg20587970	chr11:113659929	NA	-1.34	-23.77	-0.74	3.02e-82	Hip circumference adjusted for BMI;
LGG	cis	rs951366	0.789	rs823094	chr1:205689807	G/T	cg07167872	chr1:205819463	PM20D1	-0.59	-11.81	-0.48	2.54e-28	Menarche (age at onset);
LGG	cis	rs4481887	0.720	rs4543835	chr1:248468608	A/T	cg01631408	chr1:248437212	OR2T33	-0.53	-9.59	-0.41	5.64e-20	Common traits (Other);
LGG	cis	rs17683430	0.702	rs116989257	chr22:32378613	A/G	cg02631450	chr22:32366979	NA	1.01	8.39	0.36	6.03e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs1577917	0.655	rs9359658	chr6:86305769	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.5	8.55	0.37	1.75e-16	Response to antipsychotic treatment;
LGG	cis	rs3789045	0.560	rs4553256	chr1:204411144	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.59	-10.83	-0.45	1.62e-24	Educational attainment (college completion);
LGG	cis	rs17401966	0.931	rs746881	chr1:10346810	C/T	cg19773385	chr1:10388646	KIF1B	0.47	9.78	0.41	1.17e-20	Hepatocellular carcinoma;
LGG	cis	rs992157	0.798	rs10932772	chr2:219177148	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.59	9.86	0.42	6.03e-21	Colorectal cancer;
LGG	cis	rs4566357	1.000	rs7567796	chr2:227922109	T/A	cg11843606	chr2:227700838	RHBDD1	-0.39	-6.86	-0.3	2.23e-11	Coronary artery disease;
LGG	cis	rs7100689	0.646	rs9420370	chr10:82073248	C/T	cg01528321	chr10:82214614	TSPAN14	0.81	14.53	0.56	1.14e-39	Post bronchodilator FEV1;
LGG	cis	rs1595825	0.891	rs73058876	chr2:198895022	A/G	cg00982548	chr2:198649783	BOLL	-0.51	-6.83	-0.3	2.73e-11	Ulcerative colitis;
LGG	trans	rs6787172	0.702	rs1101158	chr3:157995772	T/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs981844	0.645	rs72731677	chr4:154671475	C/G	cg14289246	chr4:154710475	SFRP2	0.7	11.71	0.48	6.31e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs35160687	0.901	rs12999029	chr2:86502913	G/A	cg10973622	chr2:86423274	IMMT	0.39	6.73	0.3	5.15e-11	Night sleep phenotypes;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	trans	rs3857536	0.674	rs9345798	chr6:66951331	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs283228	0.550	rs2629976	chr6:101812654	G/T	cg27451362	chr6:101846650	GRIK2	0.94	14.31	0.55	1.02e-38	Coenzyme Q10 levels;
LGG	cis	rs875971	0.862	rs35034167	chr7:65580166	C/G	cg18252515	chr7:66147081	NA	0.44	7.31	0.32	1.15e-12	Aortic root size;
LGG	cis	rs9951602	0.512	rs7241419	chr18:76640778	C/G	cg24134504	chr18:76639479	NA	-0.47	-8.25	-0.36	1.71e-15	Obesity-related traits;
LGG	cis	rs637571	0.510	rs12575663	chr11:65574535	G/A	cg26695010	chr11:65641043	EFEMP2	0.51	8.63	0.37	9.55e-17	Eosinophil percentage of white cells;
LGG	cis	rs6500395	1.000	rs9938308	chr16:48607229	A/G	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.46e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2470578	0.792	rs2596637	chr3:17285288	T/G	cg20981856	chr3:17787350	NA	0.35	6.69	0.3	6.56e-11	Schizophrenia;
LGG	trans	rs8002861	0.905	rs80209017	chr13:44473182	T/C	cg17145862	chr1:211918768	LPGAT1	0.96	24.62	0.75	3.43e-86	Leprosy;
LGG	cis	rs4148087	0.518	rs61207594	chr21:43610807	A/C	cg08841829	chr21:43638893	ABCG1	-0.54	-7.24	-0.32	1.85e-12	Eating disorder in bipolar disorder;
LGG	cis	rs15676	0.947	rs7854319	chr9:131567995	G/A	cg04621255	chr9:131581398	ENDOG	0.39	6.95	0.31	1.25e-11	Blood metabolite levels;
LGG	trans	rs9325144	0.560	rs11183046	chr12:38655270	A/T	cg06521331	chr12:34319734	NA	0.42	7.35	0.32	9.24e-13	Morning vs. evening chronotype;
LGG	cis	rs4423214	0.610	rs12793607	chr11:71129316	C/T	cg05163923	chr11:71159392	DHCR7	-0.51	-9.48	-0.4	1.33e-19	Vitamin D levels;
LGG	cis	rs6951245	0.554	rs11761322	chr7:1151657	A/G	cg18402987	chr7:1209562	NA	0.49	8.19	0.36	2.51e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9359856	0.564	rs17292768	chr6:90379311	T/C	cg13799429	chr6:90582589	CASP8AP2	-0.74	-9.61	-0.41	4.54e-20	Bipolar disorder;
LGG	cis	rs2439831	0.850	rs2228368	chr15:44102010	A/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.31	0.43	1.47e-22	Lung cancer in ever smokers;
LGG	cis	rs1059312	0.966	rs12370194	chr12:129277250	A/T	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.57	-0.63	2.52e-53	Systemic lupus erythematosus;
LGG	cis	rs9309473	0.948	rs10183818	chr2:73714556	A/G	cg20560298	chr2:73613845	ALMS1	-0.48	-7.97	-0.35	1.27e-14	Metabolite levels;
LGG	cis	rs7824557	0.628	rs7820301	chr8:11228672	G/A	cg15596359	chr8:11213517	TDH	-0.39	-8.08	-0.35	5.77e-15	Retinal vascular caliber;
LGG	cis	rs17030434	0.953	rs76442373	chr4:154694783	G/A	cg14289246	chr4:154710475	SFRP2	-0.76	-11.69	-0.48	7.44e-28	Electrocardiographic conduction measures;
LGG	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg00898013	chr13:113819073	PROZ	-0.44	-8.56	-0.37	1.72e-16	Platelet distribution width;
LGG	cis	rs2228479	0.702	rs62053701	chr16:89860584	G/A	cg06558623	chr16:89946397	TCF25	1.12	12.16	0.49	1.01e-29	Skin colour saturation;
LGG	cis	rs12497850	0.897	rs7373778	chr3:48836392	C/G	cg06212747	chr3:49208901	KLHDC8B	0.64	10.89	0.45	1e-24	Parkinson's disease;
LGG	cis	rs1552244	1.000	rs76041173	chr3:10078695	G/T	cg13047869	chr3:10149882	C3orf24	0.54	9.09	0.39	2.98e-18	Alzheimer's disease;
LGG	cis	rs7143963	1.000	rs7156191	chr14:103297847	C/G	cg23020514	chr14:103360112	TRAF3	-0.53	-10.19	-0.43	3.8e-22	Body mass index;
LGG	trans	rs61931739	0.500	rs7310576	chr12:34474735	T/C	cg26384229	chr12:38710491	ALG10B	0.85	17.72	0.64	5e-54	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.870	rs4974543	chr4:1251222	A/G	cg04863758	chr4:1303710	MAEA	0.42	7.24	0.32	1.9e-12	Obesity-related traits;
LGG	cis	rs6977660	0.652	rs58559474	chr7:19751569	C/T	cg07541023	chr7:19748670	TWISTNB	0.98	13.97	0.54	3.03e-37	Thyroid stimulating hormone;
LGG	cis	rs12950390	0.853	rs66471233	chr17:45867086	C/T	cg24803719	chr17:45855879	NA	-0.29	-8.18	-0.36	2.68e-15	IgG glycosylation;
LGG	trans	rs453301	0.686	rs6601281	chr8:8911004	A/G	cg16141378	chr3:129829833	LOC729375	0.37	8.39	0.36	5.84e-16	Joint mobility (Beighton score);
LGG	cis	rs514406	0.679	rs61768344	chr1:53229274	G/A	cg25767906	chr1:53392781	SCP2	0.42	8.12	0.35	4.17e-15	Monocyte count;
LGG	cis	rs6882076	0.961	rs58198139	chr5:156399039	C/T	cg12943317	chr5:156479607	HAVCR1	-0.65	-11.62	-0.48	1.48e-27	LDL cholesterol levels;Cholesterol, total;Total cholesterol levels;Triglycerides;LDL cholesterol;
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg16507663	chr6:150244633	RAET1G	0.45	8.52	0.37	2.21e-16	Lung cancer;
LGG	cis	rs11583043	1.000	rs35445887	chr1:101523639	C/T	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	7.93	0.35	1.7e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs3733585	0.631	rs4697707	chr4:10119787	G/T	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.69	-0.3	6.61e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17021463	0.902	rs2016483	chr4:95229039	A/T	cg11021082	chr4:95130006	SMARCAD1	-0.52	-9.77	-0.41	1.24e-20	Testicular germ cell tumor;
LGG	cis	rs12824058	0.831	rs1390849	chr12:130811547	A/G	cg24229701	chr12:130821962	PIWIL1	0.44	7.7	0.34	8.24e-14	Menopause (age at onset);
LGG	trans	rs9393777	0.778	rs67457459	chr6:27198343	T/G	cg06606381	chr12:133084897	FBRSL1	-0.92	-9.81	-0.41	9.31e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9303280	0.806	rs9904624	chr17:38036586	A/G	cg17467752	chr17:38218738	THRA	-0.44	-7.11	-0.31	4.43e-12	Self-reported allergy;
LGG	cis	rs1707322	0.964	rs1768802	chr1:46547868	A/G	cg03146154	chr1:46216737	IPP	-0.53	-9.66	-0.41	3.12e-20	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7236492	0.872	rs74949301	chr18:77229409	C/G	cg15532942	chr18:77220712	NFATC1	0.47	7.39	0.32	6.95e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs782590	0.935	rs2627776	chr2:55873301	T/A	cg18811423	chr2:55921094	PNPT1	0.9	20.83	0.7	1.75e-68	Metabolic syndrome;
LGG	cis	rs2386661	0.826	rs4749922	chr10:5680689	A/G	cg26603656	chr10:5671107	NA	0.38	7.58	0.33	1.91e-13	Breast cancer;
LGG	cis	rs7953249	0.564	rs1183910	chr12:121420807	G/A	cg14101638	chr12:121416612	HNF1A	0.45	9.7	0.41	2.18e-20	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs7829975	0.777	rs560544	chr8:8637429	G/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.5	-0.44	2.86e-23	Mood instability;
LGG	cis	rs208520	0.754	rs851594	chr6:66876695	A/G	cg07460842	chr6:66804631	NA	-0.96	-17.65	-0.63	1.1e-53	Exhaled nitric oxide output;
LGG	cis	rs17270561	0.609	rs9358873	chr6:25731783	C/T	cg03517284	chr6:25882590	NA	-0.43	-6.91	-0.31	1.66e-11	Iron status biomarkers;
LGG	cis	rs208515	0.556	rs1872309	chr6:66660432	A/C	cg07460842	chr6:66804631	NA	0.85	14.72	0.56	1.59e-40	Exhaled nitric oxide levels;
LGG	cis	rs4704846	1.000	rs10067589	chr5:156524999	C/T	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.47	-0.33	3.98e-13	Blood protein levels;
LGG	cis	rs9611565	0.879	rs2235845	chr22:41729294	T/G	cg06634786	chr22:41940651	POLR3H	-0.61	-10.37	-0.43	8.43e-23	Vitiligo;
LGG	cis	rs5769707	0.749	rs3884944	chr22:50062996	T/C	cg06623630	chr22:50017776	C22orf34	-0.36	-7.57	-0.33	1.99e-13	Monocyte count;Monocyte percentage of white cells;
LGG	trans	rs17685	0.753	rs10476	chr7:75696420	C/T	cg19862616	chr7:65841803	NCRNA00174	-1.07	-25.07	-0.76	2.92e-88	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs67311347	0.544	rs4974040	chr3:40331059	G/A	cg13683864	chr3:40499215	RPL14	-0.82	-16.46	-0.61	2.86e-48	Renal cell carcinoma;
LGG	cis	rs3820068	0.581	rs1547031	chr1:15918960	G/A	cg05660106	chr1:15850417	CASP9	0.84	17.3	0.63	4.57e-52	Systolic blood pressure;
LGG	cis	rs10220309	0.501	rs74064456	chr14:80655946	A/T	cg08183125	chr14:80678293	DIO2	-0.48	-7.56	-0.33	2.24e-13	Lung function (FEV1);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg08733960	chr6:52529248	LOC730101	0.43	7.04	0.31	7.19e-12	Cognitive performance;
LGG	cis	rs8114671	0.570	rs3761144	chr20:33544075	C/G	cg24642439	chr20:33292090	TP53INP2	0.46	7.43	0.33	5.12e-13	Height;
LGG	cis	rs10504229	0.516	rs60398072	chr8:58086559	G/A	cg25937216	chr8:58172855	NA	-0.58	-9.24	-0.39	8.85e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.825	rs6951503	chr7:65718936	T/G	cg23594656	chr7:65796392	TPST1	0.41	9.16	0.39	1.64e-18	Aortic root size;
LGG	trans	rs57221529	0.766	rs12522140	chr5:587261	C/A	cg25482853	chr8:67687455	SGK3	1.02	13.2	0.52	5.57e-34	Lung disease severity in cystic fibrosis;
LGG	cis	rs55823223	0.648	rs11867582	chr17:73857306	A/G	cg10935138	chr17:73851978	WBP2	0.63	8.91	0.38	1.2e-17	Psoriasis;
LGG	cis	rs2742417	0.603	rs1962800	chr3:45779943	C/T	cg04837898	chr3:45731254	SACM1L	-0.45	-8.92	-0.38	1.09e-17	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs7223966	1.000	rs16947005	chr17:61702989	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	-0.67	-11.19	-0.46	6.99e-26	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4975709	0.589	rs1466607	chr5:1864856	A/G	cg15595755	chr5:1867978	NA	0.51	10.16	0.43	4.96e-22	Cardiovascular disease risk factors;
LGG	cis	rs7143963	1.000	rs72704712	chr14:103312965	T/G	cg23020514	chr14:103360112	TRAF3	0.54	9.79	0.41	1.09e-20	Body mass index;
LGG	cis	rs4563143	0.675	rs73025085	chr19:29247018	C/A	cg04546413	chr19:29218101	NA	0.75	12.59	0.51	1.78e-31	Methadone dose in opioid dependence;
LGG	cis	rs6831352	0.918	rs29001214	chr4:100051733	A/G	cg13256891	chr4:100009986	ADH5	-0.56	-9.74	-0.41	1.59e-20	Alcohol dependence;
LGG	trans	rs7395662	0.963	rs12418721	chr11:48618451	C/T	cg03929089	chr4:120376271	NA	-0.45	-7.24	-0.32	1.87e-12	HDL cholesterol;
LGG	trans	rs7726839	0.507	rs56282020	chr5:596701	T/C	cg27053975	chr1:166958233	MAEL	-0.49	-7.02	-0.31	7.98e-12	Obesity-related traits;
LGG	cis	rs6882046	0.513	rs651666	chr5:88048767	A/G	cg22951263	chr5:87985283	NA	-0.56	-10.36	-0.43	9.49e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs953387	1.000	rs1401687	chr2:136908062	G/C	cg07169764	chr2:136633963	MCM6	0.54	9.0	0.39	5.91e-18	Arthritis (juvenile idiopathic);
LGG	cis	rs17666538	0.792	rs1669715	chr8:593641	T/C	cg13264159	chr8:625131	ERICH1	-0.95	-9.82	-0.42	8.43e-21	IgG glycosylation;
LGG	cis	rs74781061	0.929	rs8025915	chr15:74870529	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-6.96	-0.31	1.18e-11	Endometriosis;
LGG	cis	rs28386778	0.591	rs2584619	chr17:61913215	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.03	0.31	7.66e-12	Prudent dietary pattern;
LGG	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg03929089	chr4:120376271	NA	-0.98	-21.48	-0.71	1.68e-71	Coronary artery disease;
LGG	cis	rs4731207	0.596	rs6466988	chr7:124678116	G/A	cg05630886	chr7:124431682	NA	-0.32	-7.43	-0.33	5.18e-13	Cutaneous malignant melanoma;
LGG	trans	rs9329221	0.683	rs688491	chr8:9884823	C/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.18	-0.46	7.8e-26	Neuroticism;
LGG	cis	rs9858542	1.000	rs9882740	chr3:49702484	T/C	cg03060546	chr3:49711283	APEH	-0.69	-11.66	-0.48	1.05e-27	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.82	-14.65	-0.56	3.26e-40	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.850	rs1800331	chr16:89858417	C/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	cis	rs1008375	1.000	rs9991307	chr4:17662408	A/G	cg18681998	chr4:17616180	MED28	0.83	18.49	0.65	1.39e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg16141378	chr3:129829833	LOC729375	-0.38	-8.56	-0.37	1.73e-16	Retinal vascular caliber;
LGG	cis	rs6952808	0.689	rs11771625	chr7:2050401	C/T	cg02951883	chr7:2050386	MAD1L1	-0.81	-17.99	-0.64	2.86e-55	Bipolar disorder and schizophrenia;
LGG	cis	rs7727544	0.735	rs274559	chr5:131720070	A/G	cg07395648	chr5:131743802	NA	0.56	13.24	0.52	3.84e-34	Blood metabolite levels;
LGG	cis	rs12477438	0.520	rs6542869	chr2:99783403	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.82	17.38	0.63	1.97e-52	Chronic sinus infection;
LGG	cis	rs11098499	0.739	rs4833612	chr4:120147596	A/C	cg09307838	chr4:120376055	NA	-0.6	-9.65	-0.41	3.34e-20	Corneal astigmatism;
LGG	cis	rs6696846	0.515	rs12136320	chr1:205110946	T/C	cg00889227	chr1:205173544	DSTYK	-0.3	-7.45	-0.33	4.52e-13	Red blood cell count;
LGG	cis	rs2290416	0.892	rs58774517	chr8:144656764	C/T	cg13282195	chr8:144660772	NAPRT1	0.92	7.15	0.32	3.36e-12	Attention deficit hyperactivity disorder;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg08223945	chr7:151829665	NA	0.36	6.95	0.31	1.28e-11	Menarche (age at onset);
LGG	cis	rs2108225	1.000	rs2108225	chr7:107453103	G/A	cg18560240	chr7:107437656	SLC26A3	-0.54	-9.61	-0.41	4.67e-20	Ulcerative colitis;
LGG	trans	rs7829975	0.667	rs1877119	chr8:8707197	C/G	cg21775007	chr8:11205619	TDH	0.43	6.75	0.3	4.52e-11	Mood instability;
LGG	cis	rs11190604	1.000	rs2495742	chr10:102331364	C/T	cg07080220	chr10:102295463	HIF1AN	0.69	11.83	0.48	2.2e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs8012	0.537	rs11085825	chr19:13007458	A/G	cg11738485	chr19:12877000	HOOK2	0.45	7.32	0.32	1.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs6546537	0.955	rs1396798	chr2:69887837	G/T	cg10773587	chr2:69614142	GFPT1	-0.41	-6.88	-0.3	1.97e-11	Serum thyroid-stimulating hormone levels;
LGG	cis	rs10911232	0.507	rs12037585	chr1:183000041	G/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs2708977	0.699	rs631746	chr2:97065499	A/G	cg01950434	chr2:97203154	ARID5A	-0.49	-7.51	-0.33	3.05e-13	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2075371	0.527	rs1862046	chr7:134023524	T/C	cg20476274	chr7:133979776	SLC35B4	0.65	11.46	0.47	6.26e-27	Mean platelet volume;
LGG	cis	rs11190604	1.000	rs10883493	chr10:102208188	A/T	cg07570687	chr10:102243282	WNT8B	0.45	7.79	0.34	4.37e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2274273	0.840	rs943590	chr14:55738596	T/C	cg04306507	chr14:55594613	LGALS3	0.63	17.65	0.63	1.06e-53	Protein biomarker;
LGG	cis	rs992157	0.560	rs6436048	chr2:219109033	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.52	8.46	0.37	3.61e-16	Colorectal cancer;
LGG	cis	rs7954584	0.567	rs11043233	chr12:122330733	C/T	cg22618164	chr12:122356400	WDR66	0.37	11.06	0.46	2.16e-25	Mean corpuscular volume;
LGG	cis	rs28595532	0.920	rs116331303	chr4:119754542	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs7219021	0.892	rs9913867	chr17:46849602	G/T	cg16584676	chr17:46985605	UBE2Z	-0.41	-6.69	-0.3	6.32e-11	Schizophrenia or bipolar disorder;
LGG	cis	rs11098499	0.754	rs10213554	chr4:120260785	A/G	cg24375607	chr4:120327624	NA	-0.59	-10.06	-0.42	1.13e-21	Corneal astigmatism;
LGG	cis	rs17854409	1.000	rs6010770	chr20:61494225	G/T	cg06598544	chr20:61472147	COL9A3	-0.86	-9.89	-0.42	4.88e-21	Obesity-related traits;
LGG	cis	rs868036	0.560	rs12443086	chr15:68080454	C/A	cg08079166	chr15:68083412	MAP2K5	0.28	6.67	0.3	7.24e-11	Restless legs syndrome;
LGG	cis	rs9322193	0.607	rs9322229	chr6:150230085	A/G	cg16507663	chr6:150244633	RAET1G	0.42	6.88	0.3	1.97e-11	Lung cancer;
LGG	cis	rs2732480	0.557	rs2732454	chr12:48719677	T/C	cg21466736	chr12:48725269	NA	-0.39	-7.89	-0.34	2.21e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs35306767	0.623	rs34034003	chr10:1143435	G/A	cg25019033	chr10:957182	NA	-0.49	-8.54	-0.37	1.94e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs8016982	0.651	rs1885601	chr14:81641210	C/T	cg01989461	chr14:81687754	GTF2A1	0.8	19.27	0.67	3.6e-61	Schizophrenia;
LGG	cis	rs1994135	0.617	rs10844642	chr12:33730368	A/C	cg06521331	chr12:34319734	NA	-0.49	-8.31	-0.36	1.04e-15	Resting heart rate;
LGG	cis	rs9322193	0.923	rs9767309	chr6:150037943	A/G	cg00424166	chr6:150045504	NUP43	-0.35	-7.51	-0.33	3.03e-13	Lung cancer;
LGG	cis	rs9937943	0.564	rs74820302	chr16:74698252	A/T	cg01733217	chr16:74700730	RFWD3	0.71	10.54	0.44	2.01e-23	Neutrophil percentage of white cells;
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.61	11.88	0.48	1.4e-28	Lymphocyte counts;
LGG	trans	rs7773004	0.601	rs13210340	chr6:26326314	G/C	cg01620082	chr3:125678407	NA	-0.9	-8.13	-0.35	3.83e-15	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for BMI (adjusted for smoking behaviour);
LGG	trans	rs7944735	0.671	rs1228044	chr11:48011180	A/G	cg15704280	chr7:45808275	SEPT13	0.64	8.81	0.38	2.44e-17	Intraocular pressure;
LGG	cis	rs7222240	0.516	rs60436856	chr17:43122061	A/C	cg24806326	chr17:43207588	PLCD3	0.45	7.49	0.33	3.55e-13	Craniofacial microsomia;
LGG	cis	rs6908034	0.607	rs112599867	chr6:19805532	A/G	cg02682789	chr6:19804855	NA	0.92	8.66	0.37	8.01e-17	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7618915	0.547	rs2336542	chr3:52710636	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.68	0.37	6.95e-17	Bipolar disorder;
LGG	cis	rs73086581	1.000	rs6107391	chr20:3983083	A/G	cg02187196	chr20:3869020	PANK2	0.8	11.2	0.46	6.28e-26	Response to antidepressants in depression;
LGG	cis	rs6142618	0.562	rs6142609	chr20:30692035	A/G	cg00028034	chr20:30779307	TSPYL3	0.36	7.92	0.35	1.75e-14	Inflammatory bowel disease;
LGG	cis	rs11122272	0.735	rs2749716	chr1:231486908	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.59	-10.31	-0.43	1.42e-22	Hemoglobin concentration;
LGG	cis	rs11169552	0.510	rs4238106	chr12:50997591	A/C	cg12884762	chr12:50931848	DIP2B	-0.41	-7.72	-0.34	7.25e-14	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg24098302	chr15:44719665	CTDSPL2	0.45	7.32	0.32	1.13e-12	Cognitive performance;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg16405210	chr4:1374714	KIAA1530	0.8	14.63	0.56	4.05e-40	Longevity;
LGG	cis	rs9906944	0.545	rs11079850	chr17:47092252	G/T	cg18128536	chr17:47092178	IGF2BP1	-0.5	-9.52	-0.4	9.28e-20	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.38	-0.43	8.04e-23	Bipolar disorder;
LGG	cis	rs2439831	1.000	rs2444029	chr15:43737484	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.97	12.35	0.5	1.69e-30	Lung cancer in ever smokers;
LGG	cis	rs4851266	1.000	rs4583487	chr2:100837126	G/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.1	-0.35	4.75e-15	Educational attainment;
LGG	cis	rs2404602	0.622	rs2003344	chr15:76632301	T/C	cg15268244	chr15:77196840	NA	0.42	8.43	0.36	4.29e-16	Blood metabolite levels;
LGG	cis	rs10504229	1.000	rs34616626	chr8:58184650	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2635047	0.638	rs2635054	chr18:44653028	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.49	-8.39	-0.36	5.9e-16	Educational attainment;
LGG	cis	rs17039065	0.920	rs73838432	chr4:109434153	A/C	cg16022748	chr4:109541635	LOC285456;RPL34	0.61	7.35	0.32	9.13e-13	Gut microbiome composition (summer);
LGG	cis	rs7508	0.596	rs7824644	chr8:17920807	A/G	cg18067069	chr8:17937731	ASAH1	-0.35	-7.97	-0.35	1.26e-14	Atrial fibrillation;
LGG	trans	rs984440	0.542	rs7815305	chr8:139083637	T/C	cg03334052	chr1:168888044	NA	0.34	6.79	0.3	3.51e-11	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg25072359	chr17:41440525	NA	0.54	9.9	0.42	4.23e-21	Menopause (age at onset);
LGG	cis	rs13006863	0.509	rs1667605	chr2:74374884	G/A	cg09063936	chr2:74408977	NA	-0.29	-6.82	-0.3	2.8e-11	Post-traumatic stress disorder (asjusted for relatedness);Immune reponse to smallpox (secreted TNF-alpha);
LGG	cis	rs721917	0.506	rs2819102	chr10:81688670	A/G	cg25562619	chr10:81652821	NA	-0.35	-7.81	-0.34	3.75e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs1816854	0.938	rs10880571	chr12:44207279	T/C	cg20956634	chr12:44200518	TWF1	0.45	6.84	0.3	2.53e-11	Inflammatory bowel disease;
LGG	cis	rs834603	0.575	rs865031	chr7:47448640	A/C	cg09696706	chr7:47479511	TNS3	0.34	7.61	0.33	1.56e-13	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs10504229	0.683	rs11786845	chr8:58133642	T/C	cg22535103	chr8:58192502	C8orf71	-0.89	-12.35	-0.5	1.79e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg00689492	chr4:1303491	MAEA	0.46	7.95	0.35	1.47e-14	Obesity-related traits;
LGG	trans	rs853679	0.599	rs149949	chr6:28011516	T/C	cg01620082	chr3:125678407	NA	-0.69	-7.66	-0.34	1.08e-13	Depression;
LGG	cis	rs909674	0.524	rs5757670	chr22:39829736	G/A	cg04986931	chr22:39850128	NA	0.34	7.96	0.35	1.36e-14	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);IgG glycosylation;IgG digalactosylation phenotypes (multivariate analysis);IgG sialylation phenotypes (multivariate analysis);IgG monogalactosylation phenotypes (multivariate analysis);IgG fucosylation phenotypes (multivariate analysis);IgG N-glycosylation phenotypes (multivariate analysis);IgG disialylation phenotypes (multivariate analysis);IgG galactosylation phenotypes (multivariate analysis);Post bronchodilator FEV1;
LGG	cis	rs8025790	0.508	rs4776943	chr15:67836069	T/C	cg27219399	chr15:67835830	MAP2K5	0.33	7.14	0.31	3.69e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs28386778	0.897	rs894408	chr17:61896814	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.43	0.84	1.61e-125	Prudent dietary pattern;
LGG	cis	rs9303280	0.806	rs2872507	chr17:38040763	C/T	cg17467752	chr17:38218738	THRA	-0.45	-7.25	-0.32	1.77e-12	Self-reported allergy;
LGG	trans	rs3749237	1.000	rs2291542	chr3:49751585	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.57	8.97	0.38	7.23e-18	Resting heart rate;
LGG	cis	rs10099921	0.743	rs34421889	chr8:41636251	T/C	cg08923054	chr8:41654455	ANK1	-0.63	-11.06	-0.46	2.22e-25	Neutrophil percentage of white cells;
LGG	cis	rs644799	1.000	rs525404	chr11:95566520	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.8	13.98	0.54	2.55e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6121246	0.909	rs1075698	chr20:30387992	G/C	cg13852791	chr20:30311386	BCL2L1	0.78	12.67	0.51	8.42e-32	Mean corpuscular hemoglobin;
LGG	cis	rs12195424	0.730	rs6917087	chr6:56298479	A/G	cg07152817	chr6:56299822	NA	0.53	7.03	0.31	7.64e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs1799949	0.894	rs8176160	chr17:41241503	T/C	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.94e-18	Menopause (age at onset);
LGG	trans	rs9329221	0.527	rs4452832	chr8:10320554	G/C	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.62	-0.41	4.2e-20	Neuroticism;
LGG	cis	rs7647973	0.710	rs6797299	chr3:49609794	G/T	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	cis	rs17376456	0.877	rs9314100	chr5:93447394	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.4	0.4	2.48e-19	Diabetic retinopathy;
LGG	cis	rs28595532	0.920	rs114037572	chr4:119735609	T/G	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs2285947	1.000	rs2285946	chr7:21583329	T/C	cg03697024	chr7:21583438	DNAH11	0.35	8.72	0.38	5.19e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs2576037	0.583	rs478820	chr18:44397782	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.87	18.38	0.65	4.77e-57	Personality dimensions;
LGG	cis	rs11992162	0.636	rs13265816	chr8:11797485	G/A	cg00405596	chr8:11794950	NA	0.61	10.55	0.44	1.84e-23	Monocyte count;
LGG	cis	rs9300255	0.544	rs2049114	chr12:123657338	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.28	0.32	1.42e-12	Neutrophil percentage of white cells;
LGG	cis	rs139371	0.713	rs139305	chr22:39498677	A/C	cg17972162	chr22:39496387	APOBEC3H	-0.26	-6.75	-0.3	4.51e-11	Multiple myeloma (IgH translocation);Multiple myeloma (hyperdiploidy);
LGG	cis	rs10504229	1.000	rs66870803	chr8:58180022	G/C	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg22963979	chr7:1858916	MAD1L1	-0.43	-8.23	-0.36	1.89e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg25373794	chr1:162760220	HSD17B7	-0.44	-7.02	-0.31	7.75e-12	Extrinsic epigenetic age acceleration;
LGG	trans	rs9650657	0.524	rs2163379	chr8:10732050	G/T	cg06636001	chr8:8085503	FLJ10661	0.46	8.06	0.35	6.47e-15	Neuroticism;
LGG	cis	rs4727027	0.870	rs62507509	chr7:148795522	C/T	cg23583168	chr7:148888333	NA	-0.85	-16.12	-0.6	9.68e-47	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10504229	0.639	rs35527749	chr8:58128077	G/T	cg08219700	chr8:58056026	NA	0.47	7.05	0.31	6.59e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2011503	1.000	rs4808970	chr19:19651140	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs28655083	0.956	rs8060627	chr16:77077065	A/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.53	-8.69	-0.37	6.27e-17	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9868809	0.649	rs3733086	chr3:48699519	C/T	cg00383909	chr3:49044727	WDR6	0.81	9.12	0.39	2.39e-18	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs62238980	0.614	rs75414196	chr22:32415980	C/A	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs1784581	0.588	rs9295179	chr6:162420546	G/A	cg17173639	chr6:162384350	PARK2	0.64	13.47	0.53	3.84e-35	Itch intensity from mosquito bite;
LGG	cis	rs2762353	0.776	rs1165177	chr6:25829659	T/A	cg12310025	chr6:25882481	NA	-0.58	-11.42	-0.47	8.87e-27	Blood metabolite levels;
LGG	cis	rs713587	0.563	rs7605335	chr2:25109317	G/A	cg04586622	chr2:25135609	ADCY3	0.43	11.53	0.47	3.36e-27	Body mass index in non-asthmatics;
LGG	trans	rs4714291	0.832	rs3008839	chr6:40052660	G/A	cg02267698	chr19:7991119	CTXN1	-0.6	-9.8	-0.41	1.02e-20	Strep throat;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg12862611	chr4:147443109	SLC10A7	-0.49	-7.21	-0.32	2.25e-12	Systemic lupus erythematosus;
LGG	cis	rs7814319	0.899	rs1878638	chr8:97258719	C/T	cg20787634	chr8:97240163	UQCRB	-0.75	-17.68	-0.63	7.52e-54	Lung function (FVC);
LGG	cis	rs9308731	0.644	rs3789068	chr2:111909247	A/G	cg19992207	chr2:111874495	ACOXL	-0.36	-6.7	-0.3	6.06e-11	Chronic lymphocytic leukemia;
LGG	cis	rs939658	0.805	rs11631590	chr15:79446199	C/T	cg17916960	chr15:79447300	NA	-0.67	-13.11	-0.52	1.3e-33	Refractive error;
LGG	trans	rs6582630	0.555	rs10785443	chr12:38463792	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.85	-0.38	1.83e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1372520	0.935	rs1372519	chr4:90757309	A/G	cg15133208	chr4:90757351	SNCA	-0.43	-8.61	-0.37	1.13e-16	Neuroticism;
LGG	cis	rs7208859	0.673	rs450585	chr17:28951039	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.71	-9.05	-0.39	4.06e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1881797	1.000	rs7527856	chr1:247688139	C/T	cg05639522	chr1:247681581	NA	0.61	10.18	0.43	4.1e-22	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs11190604	1.000	rs2489045	chr10:102344754	C/T	cg11040518	chr10:102331378	NA	-0.37	-6.81	-0.3	3.02e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2594989	0.836	rs1546231	chr3:11513678	T/G	cg01796438	chr3:11312864	ATG7	-0.55	-7.53	-0.33	2.66e-13	Circulating chemerin levels;
LGG	trans	rs2197308	0.619	rs4002730	chr12:37876400	T/C	cg06521331	chr12:34319734	NA	-0.53	-9.23	-0.39	9.73e-19	Morning vs. evening chronotype;
LGG	cis	rs4988958	0.565	rs10206291	chr2:103038863	T/C	cg03938978	chr2:103052716	IL18RAP	0.41	9.47	0.4	1.44e-19	Asthma (childhood onset);
LGG	cis	rs9513627	0.920	rs7335315	chr13:100121308	G/A	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs6942756	1.000	rs9640854	chr7:128884057	A/T	cg02491457	chr7:128862824	NA	-0.76	-13.65	-0.54	7.01e-36	White matter hyperintensity burden;
LGG	cis	rs2963155	0.518	rs712189	chr5:142631258	C/T	cg17617527	chr5:142782415	NR3C1	0.97	13.26	0.52	3.04e-34	Breast cancer;
LGG	cis	rs62244186	0.748	rs4682987	chr3:44674996	C/T	cg02073558	chr3:44770973	ZNF501	0.71	13.52	0.53	2.38e-35	Depressive symptoms;
LGG	cis	rs10220309	0.501	rs74064450	chr14:80641672	T/C	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.12e-11	Lung function (FEV1);
LGG	trans	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg21775007	chr8:11205619	TDH	-0.48	-7.69	-0.34	8.8e-14	Joint mobility (Beighton score);
LGG	cis	rs826838	0.900	rs9739128	chr12:38948960	A/T	cg26384229	chr12:38710491	ALG10B	1.05	27.17	0.78	6.94e-98	Heart rate;
LGG	cis	rs35306767	0.903	rs11253462	chr10:889323	T/G	cg25019033	chr10:957182	NA	-0.51	-9.27	-0.4	7.01e-19	Eosinophil percentage of granulocytes;
LGG	trans	rs3780486	0.846	rs10758192	chr9:33131651	G/A	cg20290983	chr6:43655470	MRPS18A	1.12	25.09	0.76	2.42e-88	IgG glycosylation;
LGG	cis	rs10884984	0.874	rs12357803	chr10:112278449	A/T	cg18756771	chr10:112261994	DUSP5	0.66	11.08	0.46	1.82e-25	Facial morphology (factor 22);
LGG	trans	rs8002861	0.935	rs4101376	chr13:44469835	C/T	cg17145862	chr1:211918768	LPGAT1	-0.98	-26.26	-0.77	9.94e-94	Leprosy;
LGG	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg26924012	chr15:45694286	SPATA5L1	1.04	22.06	0.72	2.97e-74	Homoarginine levels;
LGG	cis	rs4927850	0.957	rs4927851	chr3:195751853	A/G	cg19984853	chr3:195474125	MUC4	-0.38	-6.73	-0.3	5.09e-11	Pancreatic cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17086370	chr15:41849953	TYRO3	0.5	7.49	0.33	3.58e-13	Gut microbiome composition (summer);
LGG	cis	rs60871478	1.000	rs4719314	chr7:822523	A/G	cg27478167	chr7:817139	HEATR2	-0.44	-7.09	-0.31	4.96e-12	Cerebrospinal P-tau181p levels;
LGG	trans	rs9291683	0.527	rs3822241	chr4:10094931	G/A	cg26043149	chr18:55253948	FECH	-0.43	-7.04	-0.31	7.08e-12	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.49	7.86	0.34	2.7e-14	Cognitive performance;
LGG	cis	rs3820928	0.904	rs6735069	chr2:227893660	A/G	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.44	-0.33	4.92e-13	Pulmonary function;
LGG	trans	rs10435719	0.805	rs13269417	chr8:11791962	C/T	cg02002194	chr4:3960332	NA	-0.49	-9.1	-0.39	2.76e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs1799949	1.000	rs11651341	chr17:41428061	T/C	cg23758822	chr17:41437982	NA	0.87	15.57	0.59	2.99e-44	Menopause (age at onset);
LGG	cis	rs4774899	0.932	rs11857722	chr15:57566632	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs943466	0.513	rs943467	chr6:33731811	A/T	cg25922239	chr6:33757077	LEMD2	0.42	7.08	0.31	5.23e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs116095464	0.558	rs10076655	chr5:239464	G/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs2549003	1.000	rs2548999	chr5:131831058	G/T	cg21138405	chr5:131827807	IRF1	-0.35	-8.83	-0.38	2.14e-17	Asthma (sex interaction);
LGG	cis	rs7659604	0.540	rs28672860	chr4:122705051	G/A	cg19671926	chr4:122722719	EXOSC9	0.53	8.23	0.36	1.99e-15	Type 2 diabetes;
LGG	cis	rs2153535	0.580	rs7769020	chr6:8457724	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.57	0.5	2.26e-31	Motion sickness;
LGG	cis	rs2371030	0.900	rs2371031	chr2:211570074	A/C	cg18417063	chr2:211583084	NA	-0.64	-12.59	-0.51	1.82e-31	Non-small cell lung cancer;
LGG	cis	rs12497850	0.897	rs9850134	chr3:48957147	A/G	cg07636037	chr3:49044803	WDR6	1.1	28.03	0.79	8.03e-102	Parkinson's disease;
LGG	trans	rs1005277	0.579	rs1780137	chr10:38501475	C/G	cg27523141	chr10:43048294	ZNF37B	0.38	7.48	0.33	3.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4740619	0.810	rs10756714	chr9:15885041	A/G	cg14451791	chr9:16040625	NA	-0.39	-9.8	-0.41	1.03e-20	Body mass index;
LGG	cis	rs11148252	0.514	rs3783242	chr13:52717950	C/T	cg22398616	chr13:53314203	LECT1	-0.41	-7.96	-0.35	1.37e-14	Lewy body disease;
LGG	cis	rs722599	0.562	rs2193597	chr14:75234329	G/A	cg06637938	chr14:75390232	RPS6KL1	0.5	8.12	0.35	4.39e-15	IgG glycosylation;
LGG	cis	rs7666738	0.830	rs1534319	chr4:98964804	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17453880	0.750	rs10067084	chr5:151927189	A/T	cg12297329	chr5:152029980	NA	-0.63	-13.28	-0.53	2.41e-34	Subjective well-being;
LGG	cis	rs9479482	0.789	rs12204988	chr6:150339315	T/G	cg03788504	chr6:150331562	NA	-0.59	-13.57	-0.53	1.52e-35	Alopecia areata;
LGG	cis	rs9815354	0.767	rs11917248	chr3:41885723	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1577917	0.958	rs7739241	chr6:86575796	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.62	-0.37	1.09e-16	Response to antipsychotic treatment;
LGG	cis	rs2692947	0.644	rs1724125	chr2:96831355	G/A	cg22654517	chr2:96458247	NA	0.36	7.39	0.32	7.09e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg03517284	chr6:25882590	NA	-0.54	-10.37	-0.43	8.74e-23	Height;
LGG	cis	rs9916302	0.706	rs1054488	chr17:37687968	A/G	cg00129232	chr17:37814104	STARD3	-0.58	-8.65	-0.37	8.25e-17	Glomerular filtration rate (creatinine);
LGG	cis	rs870825	0.616	rs4519838	chr4:185628457	A/G	cg04058563	chr4:185651563	MLF1IP	1.04	22.68	0.73	3.93e-77	Blood protein levels;
LGG	cis	rs9549260	0.755	rs7335520	chr13:41196407	C/T	cg21288729	chr13:41239152	FOXO1	0.33	6.68	0.3	6.89e-11	Red blood cell count;
LGG	trans	rs1459104	1.000	rs12577269	chr11:55062905	C/T	cg15704280	chr7:45808275	SEPT13	0.72	6.9	0.31	1.69e-11	Body mass index;
LGG	trans	rs853679	0.556	rs67297533	chr6:28141253	G/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs28386778	0.897	rs2044125	chr17:61863184	A/C	cg11494091	chr17:61959527	GH2	-1.0	-24.66	-0.75	2.26e-86	Prudent dietary pattern;
LGG	cis	rs568617	1.000	rs694994	chr11:65653309	A/G	cg04055107	chr11:65626734	MUS81;CFL1	0.51	7.06	0.31	6.28e-12	Crohn's disease;
LGG	trans	rs9650657	0.537	rs4841457	chr8:10773511	T/G	cg08975724	chr8:8085496	FLJ10661	-0.47	-8.67	-0.37	7.25e-17	Neuroticism;
LGG	cis	rs986417	1.000	rs7160408	chr14:60977471	A/G	cg27398547	chr14:60952738	C14orf39	0.78	7.45	0.33	4.51e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9393692	0.620	rs9393697	chr6:26293841	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.45	-0.4	1.75e-19	Educational attainment;
LGG	cis	rs2153535	0.601	rs9406160	chr6:8464907	A/C	cg23788917	chr6:8435910	SLC35B3	0.52	9.0	0.39	5.8e-18	Motion sickness;
LGG	cis	rs10504229	0.728	rs17804666	chr8:58154473	C/T	cg02725872	chr8:58115012	NA	-0.93	-12.98	-0.52	4.31e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.44	-7.25	-0.32	1.8e-12	Longevity;Endometriosis;
LGG	cis	rs6582630	0.519	rs8189623	chr12:38351436	G/A	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11148252	0.840	rs3886077	chr13:52949053	C/A	cg22398616	chr13:53314203	LECT1	-0.46	-9.62	-0.41	4.45e-20	Lewy body disease;
LGG	cis	rs910187	0.678	rs7352690	chr20:45815352	C/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.48	-0.4	1.38e-19	Migraine;
LGG	cis	rs763121	0.853	rs2281019	chr22:39064378	T/A	cg06022373	chr22:39101656	GTPBP1	0.89	18.19	0.65	3.44e-56	Menopause (age at onset);
LGG	cis	rs8072100	0.727	rs4794052	chr17:45769236	T/C	cg25173405	chr17:45401733	C17orf57	-0.55	-9.11	-0.39	2.49e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4650994	0.571	rs6700047	chr1:178508742	G/A	cg19399532	chr1:178512495	C1orf220	-0.41	-8.0	-0.35	9.94e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2439831	0.867	rs2243434	chr15:43689867	A/T	cg15269541	chr15:43626905	ADAL	-0.45	-7.73	-0.34	6.97e-14	Lung cancer in ever smokers;
LGG	trans	rs10435719	0.610	rs76311455	chr8:11790526	C/G	cg08975724	chr8:8085496	FLJ10661	0.41	7.4	0.33	6.53e-13	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.18	-0.39	1.47e-18	Neuroticism;
LGG	cis	rs881375	0.967	rs2239658	chr9:123671837	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.64	12.05	0.49	2.8e-29	Rheumatoid arthritis;
LGG	cis	rs8072100	0.738	rs3736438	chr17:45486651	T/G	cg25173405	chr17:45401733	C17orf57	-0.53	-9.08	-0.39	3.13e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg02886208	chr11:14281011	SPON1	0.5	10.49	0.44	3.19e-23	Mitochondrial DNA levels;
LGG	cis	rs7932354	0.528	rs10838660	chr11:47152273	C/T	cg03339077	chr11:47165057	C11orf49	-0.53	-10.09	-0.42	9.1e-22	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs6430585	0.697	rs1050115	chr2:136511817	A/G	cg07169764	chr2:136633963	MCM6	1.27	23.91	0.74	7.19e-83	Corneal structure;
LGG	cis	rs11971779	0.555	rs6950143	chr7:139054418	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.93	0.31	1.4e-11	Diisocyanate-induced asthma;
LGG	cis	rs2404602	0.692	rs60658665	chr15:77042508	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.29	0.4	6.27e-19	Blood metabolite levels;
LGG	cis	rs79349575	0.783	rs4793996	chr17:47019597	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	cis	rs7582180	0.629	rs4851296	chr2:100949570	T/C	cg08297393	chr2:100937505	LONRF2	-0.56	-10.74	-0.45	3.57e-24	Intelligence (multi-trait analysis);
LGG	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg25457927	chr22:38595422	NA	-0.42	-10.57	-0.44	1.58e-23	Cutaneous nevi;
LGG	cis	rs7086627	0.515	rs10887894	chr10:82209952	A/G	cg00277334	chr10:82204260	NA	-0.53	-12.76	-0.51	3.52e-32	Post bronchodilator FEV1;
LGG	cis	rs17666538	0.535	rs168062	chr8:632444	T/A	cg02524346	chr8:600233	NA	1.13	11.16	0.46	9.09e-26	IgG glycosylation;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11190155	chr3:9975447	CRELD1	0.53	8.64	0.37	9.1e-17	Gut microbiome composition (summer);
LGG	cis	rs151997	0.962	rs26088	chr5:50172670	T/G	cg06027927	chr5:50259733	NA	0.67	11.09	0.46	1.7e-25	Callous-unemotional behaviour;
LGG	cis	rs2836974	0.897	rs35391055	chr21:40525516	G/A	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	2e-53	Cognitive function;
LGG	cis	rs1816752	0.870	rs73469543	chr13:24998970	T/C	cg22771759	chr13:24902376	NA	0.41	7.0	0.31	8.87e-12	Obesity-related traits;
LGG	cis	rs9463078	0.553	rs227837	chr6:44683123	A/G	cg25276700	chr6:44698697	NA	-0.39	-7.73	-0.34	6.82e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9487094	0.626	rs2273752	chr6:110059510	C/A	cg01125227	chr6:109776195	MICAL1	0.42	7.41	0.33	6.2e-13	Height;
LGG	cis	rs875971	0.862	rs4236208	chr7:65749078	C/T	cg23594656	chr7:65796392	TPST1	0.4	8.84	0.38	2.03e-17	Aortic root size;
LGG	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg27624424	chr6:160112604	SOD2	0.7	10.4	0.44	6.46e-23	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs1790761	0.692	rs10444362	chr11:67333090	G/A	cg08925882	chr11:67350491	GSTP1	-0.34	-6.68	-0.3	6.74e-11	Mean corpuscular volume;
LGG	trans	rs7939886	0.844	rs12421584	chr11:55937410	G/A	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs477895	0.838	rs12798333	chr11:64012784	G/A	cg04317338	chr11:64019027	PLCB3	0.66	7.94	0.35	1.56e-14	Mean platelet volume;
LGG	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg05044414	chr3:183734942	ABCC5	-0.56	-11.49	-0.47	4.83e-27	Anterior chamber depth;
LGG	cis	rs2243480	1.000	rs458291	chr7:65520479	C/A	cg18252515	chr7:66147081	NA	-1.4	-19.23	-0.67	5.22e-61	Diabetic kidney disease;
LGG	cis	rs11676348	0.772	rs6738953	chr2:218950036	C/A	cg00012203	chr2:219082015	ARPC2	-0.5	-8.71	-0.38	5.33e-17	Ulcerative colitis;
LGG	cis	rs2865126	0.743	rs1941550	chr18:10747590	T/C	cg21165219	chr18:10698044	FAM38B	-0.46	-7.46	-0.33	4.27e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs10838798	0.523	rs2019093	chr11:48196553	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.22	-0.32	2.15e-12	Height;
LGG	cis	rs1461503	0.966	rs1461502	chr11:122844927	C/G	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs506338	0.517	rs516117	chr11:64433444	T/C	cg19395706	chr11:64412079	NRXN2	0.41	8.02	0.35	8.77e-15	Body mass index;Urate levels;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg06654118	chr4:1303317	MAEA	0.47	8.12	0.35	4.3e-15	Obesity-related traits;
LGG	cis	rs4950322	0.517	rs116479391	chr1:146792659	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	trans	rs853679	0.546	rs200954	chr6:27838764	C/G	cg08344181	chr3:125677491	NA	-0.67	-7.58	-0.33	1.89e-13	Depression;
LGG	cis	rs7236492	0.572	rs7237333	chr18:77178511	G/A	cg15532942	chr18:77220712	NFATC1	0.51	7.33	0.32	1.04e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7210837	0.591	rs12942194	chr17:16790589	A/G	cg11294312	chr17:28900046	NA	-0.73	-9.11	-0.39	2.49e-18	Response to platinum-based chemotherapy (cisplatin);
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg12310025	chr6:25882481	NA	-0.44	-7.94	-0.35	1.59e-14	Height;
LGG	cis	rs4819052	0.819	rs7279136	chr21:46692287	C/T	cg06618935	chr21:46677482	NA	-0.5	-9.73	-0.41	1.83e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	0.825	rs59466412	chr7:65565358	A/G	cg23594656	chr7:65796392	TPST1	0.39	8.4	0.36	5.52e-16	Aortic root size;
LGG	cis	rs357618	0.931	rs394736	chr5:150847509	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs6696846	0.515	rs10900450	chr1:205106238	C/G	cg00889227	chr1:205173544	DSTYK	-0.3	-7.43	-0.33	5.43e-13	Red blood cell count;
LGG	cis	rs42648	0.596	rs6465251	chr7:89847881	C/G	cg25739043	chr7:89950458	NA	-0.34	-6.98	-0.31	1.04e-11	Homocysteine levels;
LGG	trans	rs2948294	0.588	rs12544596	chr8:8116346	A/T	cg16141378	chr3:129829833	LOC729375	-0.48	-10.96	-0.45	5.28e-25	Red cell distribution width;
LGG	cis	rs826838	0.616	rs11182893	chr12:38627715	C/G	cg04568710	chr12:38710424	ALG10B	-0.43	-9.55	-0.41	7.42e-20	Heart rate;
LGG	cis	rs4423214	1.000	rs4944955	chr11:71167677	C/T	cg05163923	chr11:71159392	DHCR7	0.73	14.42	0.56	3.53e-39	Vitamin D levels;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg04267008	chr7:1944627	MAD1L1	-0.68	-12.15	-0.49	1.16e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs644799	1.000	rs12291986	chr11:95523030	T/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.77	0.54	2.15e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17539620	0.624	rs62432738	chr6:154835674	T/C	cg17771515	chr6:154831774	CNKSR3	0.61	7.54	0.33	2.44e-13	Lipoprotein (a) levels;
LGG	cis	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg02972257	chr16:68554789	NA	-0.54	-8.27	-0.36	1.42e-15	Ulcerative colitis;
LGG	cis	rs4660214	0.789	rs1984142	chr1:39745608	G/C	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs283228	0.752	rs2852499	chr6:101841286	T/C	cg27451362	chr6:101846650	GRIK2	0.59	9.68	0.41	2.68e-20	Coenzyme Q10 levels;
LGG	cis	rs992157	0.835	rs13005100	chr2:219151767	C/T	cg00012203	chr2:219082015	ARPC2	-0.67	-12.09	-0.49	1.87e-29	Colorectal cancer;
LGG	cis	rs11997175	0.574	rs58858314	chr8:33658221	T/C	ch.8.33884649F	chr8:33765107	NA	0.38	7.12	0.31	4.24e-12	Body mass index;
LGG	cis	rs1957429	0.901	rs1957434	chr14:65349909	C/T	cg23373153	chr14:65346875	NA	1.14	15.75	0.59	4.67e-45	Pediatric areal bone mineral density (radius);
LGG	cis	rs262150	0.574	rs2730273	chr7:158797754	A/C	cg04111992	chr7:158790115	NA	-0.38	-7.68	-0.34	9.48e-14	Facial morphology (factor 20);
LGG	cis	rs17767392	1.000	rs34748537	chr14:71831683	C/G	cg02058870	chr14:72053146	SIPA1L1	0.46	9.15	0.39	1.87e-18	Mitral valve prolapse;
LGG	cis	rs1348850	0.526	rs7588049	chr2:178390778	C/T	cg23306229	chr2:178417860	TTC30B	-0.81	-9.44	-0.4	1.89e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10769945	0.679	rs7102920	chr11:1917872	C/T	cg23202291	chr11:1979235	NA	0.37	7.67	0.34	1.02e-13	DNA methylation (variation);
LGG	cis	rs9322193	0.884	rs2064521	chr6:149946472	A/C	cg07701084	chr6:150067640	NUP43	-0.7	-13.45	-0.53	5e-35	Lung cancer;
LGG	cis	rs12421382	0.639	rs12791519	chr11:109486754	A/G	cg07142201	chr11:109293216	C11orf87	0.49	8.36	0.36	7.37e-16	Schizophrenia;
LGG	cis	rs7107174	1.000	rs4627115	chr11:78007873	T/G	cg02023728	chr11:77925099	USP35	0.44	7.42	0.33	5.6e-13	Testicular germ cell tumor;
LGG	cis	rs6582630	0.638	rs12425531	chr12:38550387	A/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.08e-24	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12148488	0.816	rs11854975	chr15:75363876	C/T	cg09165964	chr15:75287851	SCAMP5	0.6	10.84	0.45	1.55e-24	Caffeine consumption;
LGG	cis	rs9325144	0.555	rs7955128	chr12:38684121	A/T	cg26384229	chr12:38710491	ALG10B	0.8	16.91	0.62	2.67e-50	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.764	rs9345710	chr6:66588391	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg12070911	chr6:150209640	RAET1E	0.32	7.83	0.34	3.32e-14	Lung cancer;
LGG	cis	rs10504229	1.000	rs57624567	chr8:58176995	T/C	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.43e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9636252	0.887	rs4669362	chr2:9268693	A/T	cg20341998	chr2:9276514	NA	0.39	7.44	0.33	5.1e-13	IgG glycosylation;
LGG	cis	rs896854	0.738	rs527234	chr8:95963798	C/G	cg16049864	chr8:95962084	TP53INP1	0.4	8.78	0.38	3.13e-17	Type 2 diabetes;
LGG	cis	rs11605275	1.000	rs16937347	chr11:20026717	A/G	cg14835545	chr11:20032148	NAV2	-0.88	-11.09	-0.46	1.67e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28386778	0.897	rs2727333	chr17:61876023	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.19	0.52	5.87e-34	Prudent dietary pattern;
LGG	trans	rs10986432	1	rs10986432	chr9:127570640	A/G	cg06100991	chr4:111119437	ELOVL6	0.61	6.69	0.3	6.32e-11	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg26174226	chr8:58114915	NA	-0.57	-7.87	-0.34	2.52e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs17021463	0.966	rs10856908	chr4:95222755	G/T	cg11021082	chr4:95130006	SMARCAD1	-0.59	-11.39	-0.47	1.1e-26	Testicular germ cell tumor;
LGG	cis	rs1497828	0.956	rs1013386	chr1:217566215	C/T	cg04411442	chr1:217543379	NA	0.45	7.43	0.33	5.37e-13	Dialysis-related mortality;
LGG	cis	rs1003719	0.762	rs2835598	chr21:38466669	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs1185460	0.904	rs1003081	chr11:118913993	A/G	cg12636538	chr11:118901039	SLC37A4	-0.49	-9.52	-0.4	9.93e-20	Coronary artery disease;
LGG	cis	rs8064299	1.000	rs8064299	chr17:72762646	C/A	cg25054828	chr17:72772726	NAT9;TMEM104	0.66	12.83	0.51	1.95e-32	Monocyte count;
LGG	cis	rs6952808	1.000	rs10260585	chr7:1889521	G/A	cg21782813	chr7:2030301	MAD1L1	0.48	11.01	0.46	3.27e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9487051	0.700	rs9400266	chr6:109596193	T/A	cg21918786	chr6:109611834	NA	-0.43	-8.0	-0.35	1.01e-14	Reticulocyte fraction of red cells;
LGG	cis	rs801193	0.569	rs7800620	chr7:66223688	T/C	cg12463550	chr7:65579703	CRCP	0.49	8.21	0.36	2.22e-15	Aortic root size;
LGG	cis	rs1707322	1.000	rs7553924	chr1:46352624	T/C	cg03146154	chr1:46216737	IPP	0.54	10.41	0.44	5.88e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs1728785	1.000	rs1749792	chr16:68569440	T/G	cg02972257	chr16:68554789	NA	-0.54	-8.29	-0.36	1.26e-15	Ulcerative colitis;
LGG	cis	rs9400467	0.537	rs12194283	chr6:111426029	A/G	cg15721981	chr6:111408429	SLC16A10	0.57	7.01	0.31	8.67e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs6502050	0.835	rs9898697	chr17:80100498	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs12421382	0.659	rs1371330	chr11:109382692	G/T	cg07142201	chr11:109293216	C11orf87	0.54	9.74	0.41	1.61e-20	Schizophrenia;
LGG	cis	rs9788333	0.962	rs34853044	chr13:21883784	C/T	cg06138931	chr13:21896616	NA	0.39	7.88	0.34	2.42e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs832540	0.512	rs33320	chr5:56206529	C/T	cg12654349	chr5:56205094	C5orf35	-0.45	-7.86	-0.34	2.66e-14	Coronary artery disease;
LGG	cis	rs801193	1.000	rs1553609	chr7:66197139	T/C	cg18876405	chr7:65276391	NA	0.6	11.02	0.46	3.13e-25	Aortic root size;
LGG	cis	rs60843830	1.000	rs60484953	chr2:221560	G/A	cg25945732	chr2:264204	ACP1;SH3YL1	0.81	14.9	0.57	2.79e-41	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs9290065	0.519	rs6441345	chr3:160696867	C/T	cg04691961	chr3:161091175	C3orf57	-0.42	-8.68	-0.37	6.77e-17	Kawasaki disease;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg06638463	chr19:10530633	PDE4A	0.4	6.77	0.3	3.95e-11	Bilirubin levels;
LGG	cis	rs2204008	0.714	rs11520135	chr12:38114863	C/T	cg13010199	chr12:38710504	ALG10B	0.7	13.94	0.54	3.94e-37	Bladder cancer;
LGG	cis	rs8028313	0.609	rs28735117	chr15:67933892	C/T	cg22044901	chr15:68126292	NA	-0.41	-7.19	-0.32	2.62e-12	Obesity;
LGG	cis	rs56011263	0.687	rs73221103	chr4:706740	T/C	cg05835009	chr4:710272	PCGF3	0.48	8.17	0.36	2.92e-15	White blood cell count;
LGG	cis	rs1200821	0.529	rs2475206	chr10:37802532	A/G	cg25427524	chr10:38739819	LOC399744	0.36	6.76	0.3	4.09e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs9790314	1.000	rs464766	chr3:161087592	C/G	cg04691961	chr3:161091175	C3orf57	-0.66	-15.88	-0.59	1.21e-45	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs8075061	chr17:61804723	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.59	-0.33	1.74e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6500602	0.819	rs3747580	chr16:4455675	G/A	cg05091796	chr16:4465799	CORO7	-0.99	-17.2	-0.62	1.3e-51	Schizophrenia;
LGG	cis	rs7928758	0.887	rs11820880	chr11:134268453	T/C	cg15243474	chr11:134282918	B3GAT1	1.19	15.31	0.58	4.15e-43	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.19	-0.32	2.68e-12	Life satisfaction;
LGG	cis	rs17689437	0.647	rs1645980	chr16:68571619	C/T	cg02972257	chr16:68554789	NA	-0.45	-7.5	-0.33	3.36e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg24623649	chr8:11872141	NA	0.3	6.95	0.31	1.24e-11	Myopia (pathological);
LGG	cis	rs7659604	0.540	rs10004284	chr4:122699222	A/T	cg20573242	chr4:122745356	CCNA2	-0.45	-7.93	-0.35	1.64e-14	Type 2 diabetes;
LGG	cis	rs1552244	0.554	rs3732964	chr3:10048839	C/G	cg00149659	chr3:10157352	C3orf10	0.59	8.45	0.37	3.81e-16	Alzheimer's disease;
LGG	cis	rs17253792	0.822	rs76472022	chr14:56053660	C/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.07	-0.49	2.3e-29	Putamen volume;
LGG	cis	rs3785574	0.962	rs57553639	chr17:61848499	C/T	cg06873352	chr17:61820015	STRADA	0.47	7.36	0.32	8.41e-13	Height;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg21782813	chr7:2030301	MAD1L1	0.55	14.21	0.55	2.6e-38	Bipolar disorder and schizophrenia;
LGG	cis	rs4727027	0.631	rs62507511	chr7:148796080	C/A	cg23583168	chr7:148888333	NA	-0.83	-15.51	-0.58	5.51e-44	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs8062405	0.824	rs28772958	chr16:28535305	A/G	cg00204512	chr16:28754710	NA	0.25	7.03	0.31	7.61e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9381107	0.860	rs9380845	chr6:9442251	G/T	cg14735645	chr6:9486422	NA	-0.42	-7.21	-0.32	2.32e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs12476592	0.516	rs7558796	chr2:63597108	T/A	cg17519650	chr2:63277830	OTX1	-0.51	-7.9	-0.34	2e-14	Childhood ear infection;
LGG	cis	rs3735485	0.738	rs28636402	chr7:45106877	C/T	cg03440944	chr7:45023329	C7orf40	-0.55	-9.58	-0.41	6.12e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs9329221	0.905	rs28507213	chr8:10250849	C/T	cg19847130	chr8:10466454	RP1L1	0.33	7.14	0.31	3.63e-12	Neuroticism;
LGG	cis	rs4481887	0.893	rs10888348	chr1:248448610	C/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.9	-0.42	4.36e-21	Common traits (Other);
LGG	cis	rs28595532	0.764	rs56359736	chr4:119769689	G/A	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	cis	rs7666738	0.753	rs6826709	chr4:98714553	C/G	cg05340658	chr4:99064831	C4orf37	0.5	8.24	0.36	1.74e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2224391	1.000	rs2773320	chr6:5261681	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.15	-0.35	3.35e-15	Height;
LGG	cis	rs7107174	1.000	rs4945261	chr11:77990260	A/G	cg27205649	chr11:78285834	NARS2	0.46	7.42	0.33	5.8e-13	Testicular germ cell tumor;
LGG	cis	rs4478037	1.000	rs59622575	chr3:33162249	A/C	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs1065656	0.563	rs391546	chr16:1915581	T/G	cg00490583	chr16:1843685	IGFALS	0.44	9.66	0.41	3.18e-20	Insulin-like growth factors;
LGG	cis	rs3741151	0.687	rs56857598	chr11:73234173	G/A	cg17517138	chr11:73019481	ARHGEF17	0.82	7.87	0.34	2.57e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg14926445	chr8:58193284	C8orf71	-0.8	-10.38	-0.43	7.66e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs57221529	0.546	rs72707044	chr5:677239	T/C	cg25482853	chr8:67687455	SGK3	0.99	11.44	0.47	7.66e-27	Lung disease severity in cystic fibrosis;
LGG	trans	rs7618501	1.000	rs34451146	chr3:49813013	C/T	cg21582582	chr3:182698605	DCUN1D1	0.52	9.74	0.41	1.59e-20	Intelligence (multi-trait analysis);
LGG	trans	rs9393777	0.920	rs35869525	chr6:26946687	C/T	cg06606381	chr12:133084897	FBRSL1	-1.12	-10.64	-0.44	8.19e-24	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs2924374	chr5:93151141	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.7	-9.43	-0.4	1.99e-19	Diabetic retinopathy;
LGG	cis	rs6867032	1.000	rs2129471	chr5:2016236	C/G	cg26168224	chr5:2018326	NA	1.29	31.13	0.82	1.41e-115	Gut microbiome composition (winter);
LGG	cis	rs9858542	0.537	rs34514189	chr3:49373045	A/G	cg00383909	chr3:49044727	WDR6	0.57	8.11	0.35	4.56e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2070488	0.965	rs2284820	chr3:38562579	C/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.77	-0.64	3.05e-54	Electrocardiographic conduction measures;
LGG	cis	rs916888	0.779	rs430685	chr17:44859148	T/C	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	-0.62	-9.6	-0.41	4.87e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs28386778	0.897	rs4968662	chr17:61834537	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.07	0.31	5.57e-12	Prudent dietary pattern;
LGG	cis	rs7208859	0.673	rs55904046	chr17:29215391	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.18	-0.32	2.72e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs68170813	0.562	rs78181351	chr7:106999301	A/G	cg02696742	chr7:106810147	HBP1	-0.72	-10.09	-0.42	9.27e-22	Coronary artery disease;
LGG	cis	rs4481887	1.000	rs4306162	chr1:248468509	C/T	cg13385794	chr1:248469461	NA	0.48	8.27	0.36	1.48e-15	Common traits (Other);
LGG	cis	rs780096	0.526	rs10182937	chr2:27651693	T/C	cg21747090	chr2:27597821	SNX17	-0.38	-6.78	-0.3	3.76e-11	Total body bone mineral density;
LGG	cis	rs1799949	0.965	rs11656945	chr17:41330265	A/G	cg25072359	chr17:41440525	NA	0.53	10.19	0.43	3.84e-22	Menopause (age at onset);
LGG	cis	rs9300255	0.722	rs12322888	chr12:123825559	A/G	cg00376283	chr12:123451042	ABCB9	0.55	8.57	0.37	1.6e-16	Neutrophil percentage of white cells;
LGG	cis	rs10463316	0.832	rs246482	chr5:150731857	C/G	cg03212797	chr5:150827313	SLC36A1	-0.5	-8.64	-0.37	9e-17	Metabolite levels (Pyroglutamine);
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg21782813	chr7:2030301	MAD1L1	0.38	8.36	0.36	7.39e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9911578	0.967	rs12603238	chr17:57130785	C/T	cg12560992	chr17:57184187	TRIM37	-0.92	-16.48	-0.61	2.35e-48	Intelligence (multi-trait analysis);
LGG	cis	rs34421088	0.560	rs2248316	chr8:11397073	A/C	cg27411982	chr8:10470053	RP1L1	-0.42	-7.41	-0.33	6.11e-13	Neuroticism;
LGG	cis	rs7618915	0.571	rs1961958	chr3:52585990	A/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.51	8.36	0.36	7.6e-16	Bipolar disorder;
LGG	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg25809561	chr17:30822961	MYO1D	-0.36	-8.41	-0.36	5.24e-16	Schizophrenia;
LGG	cis	rs9815354	1.000	rs114960066	chr3:41882323	A/G	cg03022575	chr3:42003672	ULK4	0.64	8.32	0.36	9.88e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs17270561	0.666	rs4711099	chr6:25741809	C/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	cis	rs7614738	1	rs7614738	chr3:49311131	C/G	cg03060546	chr3:49711283	APEH	0.58	9.46	0.4	1.54e-19	Red cell distribution width;
LGG	cis	rs3785574	0.924	rs2584641	chr17:61862889	A/G	cg06873352	chr17:61820015	STRADA	0.47	7.4	0.33	6.47e-13	Height;
LGG	cis	rs7010267	0.681	rs7842942	chr8:120008587	T/C	cg17171407	chr8:119960777	TNFRSF11B	0.39	10.07	0.42	1.03e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg11050988	chr7:1952600	MAD1L1	0.32	7.68	0.34	9.32e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs3858526	0.584	rs10769266	chr11:5858460	C/T	cg25319279	chr11:5960081	NA	-0.45	-7.27	-0.32	1.53e-12	DNA methylation (variation);
LGG	cis	rs6502050	0.835	rs62080004	chr17:80079079	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs1580019	0.921	rs1580023	chr7:32497881	G/A	cg06627557	chr7:32535165	LSM5;AVL9	0.79	15.0	0.57	9.75e-42	Cognitive ability;
LGG	cis	rs11834862	0.663	rs11246993	chr12:132689052	T/A	cg16245054	chr12:132698494	GALNT9	-0.44	-6.83	-0.3	2.74e-11	Anti-saccade response;
LGG	cis	rs7914558	1.000	rs11191542	chr10:104824324	T/A	cg04362960	chr10:104952993	NT5C2	0.55	10.72	0.45	4.37e-24	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg03506944	chr4:154074021	TRIM2	0.4	6.69	0.3	6.34e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs6554196	0.654	rs7684939	chr4:55509189	G/A	cg18836493	chr4:55524333	KIT	-0.41	-7.71	-0.34	7.83e-14	Monocyte count;
LGG	trans	rs9929218	0.954	rs9925923	chr16:68819614	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.74	-12.53	-0.5	3.24e-31	Colorectal cancer;
LGG	cis	rs17428076	0.874	rs62182374	chr2:172685682	T/C	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs9322193	0.923	rs17745062	chr6:150042215	T/A	cg09699651	chr6:150184138	LRP11	0.53	9.59	0.41	5.61e-20	Lung cancer;
LGG	cis	rs853679	0.517	rs9468292	chr6:28095355	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs17604090	0.529	rs10239226	chr7:29716312	C/G	cg19413766	chr7:29689036	LOC646762	-0.53	-7.6	-0.33	1.71e-13	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	trans	rs78049276	0.512	rs6820938	chr4:148395903	A/G	cg13149281	chr14:23389818	RBM23;PRMT5	-0.64	-9.86	-0.42	6.15e-21	Pulse pressure;
LGG	cis	rs2730245	0.505	rs2657360	chr7:158673604	A/G	cg01943577	chr7:158741284	NA	-0.45	-8.35	-0.36	7.87e-16	Height;
LGG	cis	rs963731	0.649	rs2060989	chr2:39293530	G/A	cg04010122	chr2:39346883	SOS1	-0.77	-7.5	-0.33	3.39e-13	Corticobasal degeneration;
LGG	cis	rs11874712	0.965	rs8083998	chr18:43673144	A/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs17221829	0.673	rs10830335	chr11:89403934	T/C	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.63	-0.37	1.02e-16	Anxiety in major depressive disorder;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg16103275	chr6:290800	DUSP22	0.49	7.96	0.35	1.33e-14	Menopause (age at onset);
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.58	0.37	1.47e-16	Bipolar disorder;
LGG	cis	rs10484885	0.878	rs111664889	chr6:90566427	G/T	cg13799429	chr6:90582589	CASP8AP2	-0.84	-10.65	-0.44	7.59e-24	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs1790761	0.692	rs1148883	chr11:67304686	A/G	cg09038676	chr11:67351608	GSTP1	-0.36	-7.31	-0.32	1.15e-12	Mean corpuscular volume;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21693780	chr2:15731793	DDX1	0.42	6.83	0.3	2.64e-11	Cognitive performance;
LGG	cis	rs11864453	0.647	rs10492813	chr16:72122463	A/G	cg01557791	chr16:72042693	DHODH	0.45	8.29	0.36	1.24e-15	Fibrinogen levels;
LGG	cis	rs56283067	0.887	rs7765371	chr6:44777204	G/A	cg18551225	chr6:44695536	NA	-0.66	-10.79	-0.45	2.27e-24	Total body bone mineral density;
LGG	cis	rs4664308	0.594	rs4665141	chr2:160890795	A/T	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.64	-0.48	1.2e-27	Idiopathic membranous nephropathy;
LGG	cis	rs9611565	0.512	rs9611667	chr22:42187015	C/T	cg06481639	chr22:41940642	POLR3H	-0.55	-7.66	-0.34	1.1e-13	Vitiligo;
LGG	cis	rs225245	0.782	rs178649	chr17:33908197	C/G	cg05299278	chr17:33885742	SLFN14	0.42	7.99	0.35	1.12e-14	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs17270561	0.609	rs4712959	chr6:25727057	C/T	cg12310025	chr6:25882481	NA	-0.45	-7.29	-0.32	1.32e-12	Iron status biomarkers;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg21926883	chr2:100939477	LONRF2	-0.67	-15.28	-0.58	5.78e-43	Intelligence (multi-trait analysis);
LGG	cis	rs4132509	0.895	rs12138168	chr1:244009113	A/G	cg21452805	chr1:244014465	NA	0.7	8.21	0.36	2.17e-15	RR interval (heart rate);
LGG	cis	rs6669919	1.000	rs6669919	chr1:211674383	T/C	cg10512769	chr1:211675356	NA	-0.7	-15.7	-0.59	8.07e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.694	rs5758347	chr22:41821019	G/T	cg06850241	chr22:41845214	NA	0.45	7.1	0.31	4.71e-12	Vitiligo;
LGG	cis	rs8141529	0.764	rs5752812	chr22:29225603	T/A	cg02153584	chr22:29168773	CCDC117	0.69	11.67	0.48	9.1e-28	Lymphocyte counts;
LGG	cis	rs10504229	1.000	rs66477954	chr8:58187810	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11252926	0.574	rs10904065	chr10:423226	G/T	cg18196295	chr10:418757	DIP2C	-0.72	-13.44	-0.53	5.35e-35	Psychosis in Alzheimer's disease;
LGG	cis	rs796364	0.762	rs13030712	chr2:200973569	G/A	cg23649088	chr2:200775458	C2orf69	0.63	10.3	0.43	1.48e-22	Schizophrenia;
LGG	cis	rs7017914	0.967	rs6999739	chr8:71637212	G/A	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16890600	chr5:98265530	NA	0.41	6.74	0.3	4.85e-11	Cognitive performance;
LGG	cis	rs5762813	0.561	rs5762821	chr22:29219472	G/A	cg15103426	chr22:29168792	CCDC117	0.66	7.0	0.31	9.11e-12	Hematocrit;Hemoglobin concentration;
LGG	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.96	10.75	0.45	3.31e-24	Lung cancer in ever smokers;
LGG	cis	rs2130392	0.503	rs2871418	chr4:185654723	A/G	cg21366198	chr4:185655624	MLF1IP	0.46	7.96	0.35	1.31e-14	Kawasaki disease;
LGG	cis	rs7208859	0.623	rs7220289	chr17:29103762	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.83	-10.21	-0.43	3.17e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7945705	0.791	rs12421789	chr11:8813956	G/A	cg21881798	chr11:8931708	C11orf17;ST5	-0.39	-8.04	-0.35	7.36e-15	Hemoglobin concentration;
LGG	cis	rs6860806	0.507	rs272872	chr5:131675864	C/T	cg07395648	chr5:131743802	NA	0.46	9.41	0.4	2.38e-19	Breast cancer;
LGG	cis	rs6951245	0.872	rs77569514	chr7:1085508	G/A	cg04025307	chr7:1156635	C7orf50	0.65	8.46	0.37	3.41e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1153858	1.000	rs1365610	chr15:45694610	C/T	cg21132104	chr15:45694354	SPATA5L1	0.73	11.13	0.46	1.14e-25	Homoarginine levels;
LGG	cis	rs2011503	1.000	rs2965179	chr19:19512755	G/A	cg11584989	chr19:19387371	SF4	0.74	12.12	0.49	1.54e-29	Bipolar disorder;
LGG	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg02002194	chr4:3960332	NA	0.4	7.12	0.31	4.17e-12	Morning vs. evening chronotype;
LGG	cis	rs240764	0.635	rs7748269	chr6:100936864	A/C	cg21058520	chr6:100914733	NA	0.48	8.5	0.37	2.66e-16	Neuroticism;
LGG	cis	rs2012796	1.000	rs12436146	chr14:81821282	A/G	cg02996355	chr14:81879375	NA	0.52	8.3	0.36	1.18e-15	Night sleep phenotypes;
LGG	cis	rs4481887	0.927	rs4347240	chr1:248475403	C/G	cg13385794	chr1:248469461	NA	0.49	8.33	0.36	9.17e-16	Common traits (Other);
LGG	cis	rs975739	0.695	rs1537065	chr13:78543386	A/G	cg07847733	chr13:78271382	SLAIN1	0.42	7.35	0.32	9.03e-13	Hair color;
LGG	cis	rs17030434	0.954	rs10000558	chr4:154766835	A/T	cg14289246	chr4:154710475	SFRP2	-0.71	-10.71	-0.45	4.45e-24	Electrocardiographic conduction measures;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg16270222	chr17:41446396	NA	-0.29	-7.03	-0.31	7.37e-12	Menopause (age at onset);
LGG	cis	rs9486715	0.838	rs9386576	chr6:96954717	C/T	cg06623918	chr6:96969491	KIAA0776	0.78	15.9	0.59	1e-45	Headache;
LGG	cis	rs35110281	0.548	rs7276316	chr21:45029333	A/T	cg01579765	chr21:45077557	HSF2BP	-0.4	-8.93	-0.38	9.85e-18	Mean corpuscular volume;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13284864	chr3:142895279	NA	0.46	7.14	0.31	3.64e-12	Gut microbiome composition (summer);
LGG	cis	rs9300255	0.602	rs1727316	chr12:123618603	C/T	cg05973401	chr12:123451056	ABCB9	0.48	7.36	0.32	8.38e-13	Neutrophil percentage of white cells;
LGG	cis	rs6121246	0.529	rs6060145	chr20:30178631	T/C	cg21427119	chr20:30132790	HM13	-0.57	-8.82	-0.38	2.42e-17	Mean corpuscular hemoglobin;
LGG	cis	rs657075	0.697	rs3788988	chr5:131706371	C/T	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg24375607	chr4:120327624	NA	0.66	10.92	0.45	7.52e-25	Corneal astigmatism;
LGG	cis	rs9858542	0.953	rs9814873	chr3:49454112	A/G	cg00383909	chr3:49044727	WDR6	0.46	7.51	0.33	3.05e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2227564	0.729	rs2688616	chr10:75650652	G/C	cg00564723	chr10:75632066	CAMK2G	-0.45	-8.86	-0.38	1.7e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg02733842	chr7:1102375	C7orf50	0.74	10.99	0.45	4.17e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs889398	0.771	rs4985448	chr16:69899395	A/G	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.87	-0.3	2.04e-11	Body mass index;
LGG	cis	rs7937682	0.889	rs1789361	chr11:111485334	T/C	cg08305652	chr11:111469057	NA	-0.44	-9.01	-0.39	5.23e-18	Primary sclerosing cholangitis;
LGG	trans	rs35110281	0.574	rs1836856	chr21:44964638	A/T	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.62	11.42	0.47	8.69e-27	Mean corpuscular volume;
LGG	cis	rs4423214	0.840	rs1792235	chr11:71181473	C/T	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.63e-25	Vitamin D levels;
LGG	cis	rs9329289	0.603	rs2458705	chr10:2541377	A/G	cg18171855	chr10:2543474	NA	0.45	8.0	0.35	9.75e-15	Age-related hearing impairment;
LGG	cis	rs9816226	0.590	rs869401	chr3:185826546	G/A	cg00760338	chr3:185826511	ETV5	0.97	17.98	0.64	3.38e-55	Obesity;Body mass index;
LGG	cis	rs1920116	0.778	rs2421829	chr3:169554264	T/C	cg00832555	chr3:169529716	LRRC34	0.38	6.68	0.3	6.97e-11	Glioma (high-grade);
LGG	cis	rs13082711	0.516	rs13084067	chr3:27358935	A/T	cg02860705	chr3:27208620	NA	0.8	14.25	0.55	1.76e-38	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs330048	0.545	rs11249913	chr8:9143521	G/T	cg16141378	chr3:129829833	LOC729375	0.32	6.9	0.31	1.68e-11	Systemic lupus erythematosus;
LGG	cis	rs7973719	0.833	rs7970916	chr12:7357746	T/C	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.62e-12	IgG glycosylation;
LGG	cis	rs9291683	0.546	rs13110307	chr4:10044364	T/C	cg11266682	chr4:10021025	SLC2A9	0.51	9.89	0.42	4.82e-21	Bone mineral density;
LGG	cis	rs977987	0.966	rs8055490	chr16:75497135	C/T	cg03315344	chr16:75512273	CHST6	0.59	11.73	0.48	5.25e-28	Dupuytren's disease;
LGG	cis	rs7044106	0.762	rs7849566	chr9:123460769	A/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.43	0.61	3.95e-48	Hip circumference adjusted for BMI;
LGG	cis	rs546131	0.928	rs499183	chr11:34836678	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.44	7.11	0.31	4.52e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs7618501	0.633	rs13060128	chr3:50025028	A/G	cg24308560	chr3:49941425	MST1R	0.23	7.18	0.32	2.8e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs9294662	chr6:66596018	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs10088262	0.629	rs7015861	chr8:124795613	C/T	cg20713898	chr8:124780851	FAM91A1	-0.5	-8.02	-0.35	8.48e-15	Pancreatic cancer;
LGG	cis	rs9291683	0.552	rs10939656	chr4:10014646	A/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-8.06	-0.35	6.64e-15	Bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06587054	chr3:183602662	PARL	0.44	6.76	0.3	4.24e-11	Gut microbiome composition (summer);
LGG	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg21226059	chr5:178986404	RUFY1	0.46	7.32	0.32	1.11e-12	Lung cancer;
LGG	cis	rs7666738	0.830	rs1426664	chr4:98988264	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg25525163	chr3:38178867	ACAA1;MYD88	0.44	6.98	0.31	1.06e-11	Cognitive performance;
LGG	cis	rs832540	0.695	rs702686	chr5:56201350	A/G	cg17809284	chr5:56205270	C5orf35	-0.5	-9.08	-0.39	3.06e-18	Coronary artery disease;
LGG	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg15325629	chr6:28072465	NA	0.95	7.41	0.33	5.85e-13	Parkinson's disease;
LGG	cis	rs774359	0.789	rs9969832	chr9:27493063	C/T	cg21249376	chr9:27528432	MOBKL2B	0.47	8.47	0.37	3.24e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs4689388	0.926	rs10937718	chr4:6295217	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs796364	0.715	rs11688872	chr2:201052418	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.75	-8.88	-0.38	1.48e-17	Schizophrenia;
LGG	cis	rs9715521	0.677	rs6822690	chr4:59853530	A/G	cg11281224	chr4:60001000	NA	-0.57	-10.05	-0.42	1.23e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs875971	0.929	rs12535036	chr7:65964063	G/T	cg11764359	chr7:65958608	NA	0.8	14.99	0.57	1.08e-41	Aortic root size;
LGG	cis	rs6815814	0.768	rs6851685	chr4:38893843	G/T	cg06935464	chr4:38784597	TLR10	0.47	7.11	0.31	4.29e-12	Breast cancer;
LGG	cis	rs875971	1.000	rs6961155	chr7:65933295	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg02083259	chr16:57220135	RSPRY1;FAM192A	-0.4	-6.76	-0.3	4.14e-11	Platelet count;
LGG	cis	rs7103648	0.695	rs12577643	chr11:47467172	A/T	cg20307385	chr11:47447363	PSMC3	0.92	20.34	0.69	3.39e-66	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs2274273	1.000	rs2147972	chr14:55598030	T/C	cg04306507	chr14:55594613	LGALS3	0.61	16.99	0.62	1.11e-50	Protein biomarker;
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11075029	chr15:45492679	SHF	0.44	7.52	0.33	2.92e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs3735485	0.800	rs1294970	chr7:45075683	A/G	cg03440944	chr7:45023329	C7orf40	0.55	9.38	0.4	2.97e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	trans	rs2204008	0.548	rs2320740	chr12:38166421	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.9	-0.38	1.31e-17	Bladder cancer;
LGG	cis	rs2013441	1.000	rs972966	chr17:20030992	G/C	cg13482628	chr17:19912719	NA	0.49	9.05	0.39	3.87e-18	Obesity-related traits;
LGG	trans	rs10838798	0.504	rs11039634	chr11:48297843	A/G	cg21153622	chr11:89784906	NA	-0.39	-6.69	-0.3	6.44e-11	Height;
LGG	cis	rs1790761	0.967	rs7131041	chr11:67230184	A/T	cg14500267	chr11:67383377	NA	-0.4	-7.23	-0.32	2.01e-12	Mean corpuscular volume;
LGG	cis	rs1620921	0.657	rs7383363	chr6:161274962	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.2	-0.32	2.42e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.728	rs72650853	chr8:58151473	G/A	cg26174226	chr8:58114915	NA	-0.52	-7.29	-0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs28595532	0.920	rs114940990	chr4:119758568	A/G	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.9e-21	Cannabis dependence symptom count;
LGG	cis	rs2243480	1.000	rs35396113	chr7:65495461	C/T	cg12463550	chr7:65579703	CRCP	0.75	8.08	0.35	5.63e-15	Diabetic kidney disease;
LGG	cis	rs76070545	0.551	rs10088427	chr8:104210692	G/A	cg03923813	chr8:104230441	BAALC	-1.16	-12.66	-0.51	9.23e-32	Alzheimer disease and age of onset;
LGG	cis	rs7481584	0.962	rs2237905	chr11:2976584	T/C	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.55	-0.37	1.76e-16	Calcium levels;
LGG	cis	rs9322193	0.923	rs9371486	chr6:150153226	T/C	cg05861140	chr6:150128134	PCMT1	-0.42	-8.72	-0.38	5.1e-17	Lung cancer;
LGG	cis	rs1552244	1.000	rs35741213	chr3:10087661	A/G	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	cis	rs4072980	0.524	rs28442147	chr1:38395410	T/A	cg18451016	chr1:38461880	NA	0.51	10.16	0.43	4.88e-22	Coronary artery disease;
LGG	cis	rs801193	1.000	rs10274773	chr7:66133578	G/A	cg18876405	chr7:65276391	NA	-0.59	-10.86	-0.45	1.28e-24	Aortic root size;
LGG	cis	rs1387259	0.859	rs2054905	chr12:48687951	A/G	cg21466736	chr12:48725269	NA	-0.36	-7.3	-0.32	1.28e-12	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs72781680	0.898	rs72782136	chr2:24047344	A/G	cg08917208	chr2:24149416	ATAD2B	0.8	9.1	0.39	2.71e-18	Lymphocyte counts;
LGG	cis	rs66573146	0.831	rs67702333	chr4:6983040	C/G	cg00086871	chr4:6988644	TBC1D14	1.12	10.36	0.43	9.06e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs7172677	0.768	rs2304901	chr15:75340722	G/A	cg14664628	chr15:75095509	CSK	0.62	10.19	0.43	3.79e-22	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs13392177	0.660	rs62185964	chr2:219073745	A/G	cg04731861	chr2:219085781	ARPC2	0.49	12.63	0.51	1.21e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs1790761	0.587	rs4930430	chr11:67294198	A/G	cg00864171	chr11:67383662	NA	0.49	8.7	0.37	5.99e-17	Mean corpuscular volume;
LGG	cis	rs2228479	0.541	rs12918575	chr16:89811151	A/G	cg00800038	chr16:89945340	TCF25	-0.69	-9.13	-0.39	2.17e-18	Skin colour saturation;
LGG	cis	rs9811920	0.809	rs6806323	chr3:99722564	C/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.49	-8.46	-0.37	3.67e-16	Axial length;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg16507663	chr6:150244633	RAET1G	0.45	8.43	0.36	4.56e-16	Lung cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15088822	chr5:140998632	DIAPH1	0.45	6.91	0.31	1.61e-11	Gut microbiome composition (summer);
LGG	cis	rs2980439	0.517	rs17594093	chr8:8106406	G/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.05	-0.35	6.83e-15	Neuroticism;
LGG	cis	rs875971	0.660	rs1860470	chr7:66103694	G/C	cg18876405	chr7:65276391	NA	-0.59	-10.75	-0.45	3.26e-24	Aortic root size;
LGG	cis	rs4919087	1.000	rs11189122	chr10:99072595	G/A	cg25902810	chr10:99078978	FRAT1	0.52	9.77	0.41	1.3e-20	Monocyte count;
LGG	cis	rs1865760	0.566	rs2032445	chr6:26044812	T/A	cg17691542	chr6:26056736	HIST1H1C	0.57	10.27	0.43	1.97e-22	Height;
LGG	cis	rs28386778	0.863	rs6504178	chr17:61812733	A/G	cg11494091	chr17:61959527	GH2	-1.0	-24.67	-0.75	1.98e-86	Prudent dietary pattern;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21251197	chr9:140514016	EHMT1;C9orf37	0.47	6.85	0.3	2.31e-11	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.710	rs6851130	chr4:120133712	G/A	cg24375607	chr4:120327624	NA	-0.56	-9.25	-0.39	8.54e-19	Corneal astigmatism;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg15556689	chr8:8085844	FLJ10661	-0.5	-9.19	-0.39	1.38e-18	Neuroticism;
LGG	cis	rs7084402	0.967	rs1649046	chr10:60326109	T/C	cg07615347	chr10:60278583	BICC1	0.63	18.21	0.65	2.89e-56	Refractive error;
LGG	cis	rs7618915	0.501	rs3852066	chr3:52621839	C/T	cg11645453	chr3:52864694	ITIH4	0.39	6.74	0.3	4.58e-11	Bipolar disorder;
LGG	cis	rs4665809	0.590	rs72809688	chr2:26516579	G/A	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.31	0.69	4.69e-66	Gut microbiome composition (summer);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05098233	chr16:475948	RAB11FIP3	0.46	6.82	0.3	2.77e-11	Gut microbiome composition (summer);
LGG	cis	rs3771570	1.000	rs1984598	chr2:242284824	G/A	cg21155796	chr2:242212141	HDLBP	0.62	8.36	0.36	7.68e-16	Prostate cancer;
LGG	cis	rs8180040	0.522	rs749512	chr3:47035900	C/T	cg16586182	chr3:47516702	SCAP	0.72	12.77	0.51	3.2e-32	Colorectal cancer;
LGG	cis	rs116095464	0.542	rs28650039	chr5:273954	C/A	cg22857025	chr5:266934	NA	-1.51	-26.45	-0.78	1.27e-94	Breast cancer;
LGG	cis	rs875971	0.895	rs12531677	chr7:65769086	G/A	cg18252515	chr7:66147081	NA	0.44	7.47	0.33	3.97e-13	Aortic root size;
LGG	cis	rs4538187	1.000	rs6732746	chr2:64089748	C/A	cg02541582	chr2:64069798	UGP2	0.61	14.54	0.56	9.78e-40	Systolic blood pressure;
LGG	cis	rs9309711	0.623	rs4641971	chr2:3481857	A/C	cg15506890	chr2:3487001	NA	0.59	11.49	0.47	4.7e-27	Neurofibrillary tangles;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg12708336	chr17:41446283	NA	-0.3	-6.97	-0.31	1.09e-11	Menopause (age at onset);
LGG	cis	rs7091068	0.671	rs591392	chr10:95406081	G/A	cg20715218	chr10:95462985	C10orf4	-0.59	-9.51	-0.4	1.08e-19	Urinary tract infection frequency;
LGG	cis	rs7222240	0.638	rs7219243	chr17:43112835	A/G	cg24806326	chr17:43207588	PLCD3	0.46	7.57	0.33	2.08e-13	Craniofacial microsomia;
LGG	cis	rs9329221	0.683	rs4598253	chr8:9890304	A/T	cg19847130	chr8:10466454	RP1L1	0.31	6.69	0.3	6.41e-11	Neuroticism;
LGG	trans	rs2898290	0.592	rs2736342	chr8:11347289	A/C	cg15556689	chr8:8085844	FLJ10661	-0.41	-7.33	-0.32	1.04e-12	Systolic blood pressure;
LGG	cis	rs10504229	1.000	rs72650899	chr8:58180525	G/T	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.91e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs11250098	0.567	rs4326350	chr8:10763655	C/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.89	0.34	2.13e-14	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.747	rs12048412	chr1:152977092	A/T	cg13444842	chr1:152974279	SPRR3	-0.45	-9.23	-0.39	9.98e-19	Inflammatory skin disease;
LGG	cis	rs7666738	0.830	rs17550610	chr4:99008273	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.36	0.36	7.53e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7100689	0.542	rs7096715	chr10:82195949	T/C	cg00277334	chr10:82204260	NA	-0.38	-8.18	-0.36	2.8e-15	Post bronchodilator FEV1;
LGG	cis	rs7119	0.717	rs12902852	chr15:77809016	C/G	cg10437265	chr15:77819839	NA	0.25	6.86	0.3	2.2e-11	Type 2 diabetes;
LGG	trans	rs61931739	0.817	rs2636084	chr12:34130210	G/A	cg13010199	chr12:38710504	ALG10B	0.48	9.36	0.4	3.46e-19	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.935	rs4741519	chr9:15623961	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.27	-0.43	1.95e-22	Body mass index;
LGG	cis	rs7222240	1.000	rs1978070	chr17:43144150	A/G	cg24806326	chr17:43207588	PLCD3	0.44	7.44	0.33	4.9e-13	Craniofacial microsomia;
LGG	cis	rs11098499	0.955	rs7685268	chr4:120162188	G/A	cg09307838	chr4:120376055	NA	0.73	12.2	0.49	7.38e-30	Corneal astigmatism;
LGG	cis	rs7811142	1.000	rs7809801	chr7:100072031	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-16.16	-0.6	6.37e-47	Platelet count;
LGG	cis	rs4604732	0.588	rs9943231	chr1:247629829	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.6	9.14	0.39	1.99e-18	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs72945132	0.660	rs12292191	chr11:70122426	T/C	cg14088196	chr11:70211408	PPFIA1	0.91	12.67	0.51	8.94e-32	Coronary artery disease;
LGG	cis	rs6952808	0.656	rs11764212	chr7:2067593	C/A	cg21782813	chr7:2030301	MAD1L1	0.52	12.97	0.52	4.81e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs4930103	0.935	rs4930098	chr11:2020955	G/C	cg23202291	chr11:1979235	NA	0.37	7.18	0.32	2.73e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs2836974	0.966	rs2836977	chr21:40666066	T/C	cg11644478	chr21:40555479	PSMG1	0.9	17.28	0.63	5.24e-52	Cognitive function;
LGG	trans	rs2562456	0.678	rs7260140	chr19:21523525	T/C	cg00806126	chr19:22604979	ZNF98	-0.55	-7.45	-0.33	4.75e-13	Pain;
LGG	cis	rs9611519	0.828	rs28814423	chr22:41452301	G/A	cg03806693	chr22:41940476	POLR3H	-0.53	-8.14	-0.35	3.8e-15	Neuroticism;
LGG	cis	rs2587949	0.509	rs2120510	chr3:4208610	G/A	cg16519197	chr3:4211558	NA	-0.36	-7.3	-0.32	1.24e-12	Periodontitis (DPAL);
LGG	cis	rs7959452	0.558	rs1478464	chr12:69779789	G/C	cg22834771	chr12:69754056	YEATS4	-0.43	-7.38	-0.32	7.23e-13	Blood protein levels;
LGG	cis	rs1801251	0.778	rs2250665	chr2:233752639	A/T	cg08000102	chr2:233561755	GIGYF2	-0.44	-7.14	-0.32	3.58e-12	Coronary artery disease;
LGG	cis	rs780096	0.506	rs1647265	chr2:27692261	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs9322193	0.923	rs10872651	chr6:150089409	A/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.9	-0.31	1.74e-11	Lung cancer;
LGG	cis	rs9322193	0.884	rs933055	chr6:150130837	A/G	cg08621203	chr6:150244597	RAET1G	0.4	6.82	0.3	2.79e-11	Lung cancer;
LGG	trans	rs2739330	0.828	rs5760108	chr22:24252668	G/T	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-11.32	-0.47	2.24e-26	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs708547	0.624	rs1718886	chr4:57849251	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.59	10.13	0.43	6.69e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs1008375	1.000	rs4235388	chr4:17682030	G/A	cg02297831	chr4:17616191	MED28	0.5	9.64	0.41	3.52e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12505749	0.542	rs17086853	chr4:57352319	A/G	cg07846311	chr4:57371927	ARL9	-0.32	-7.92	-0.35	1.75e-14	Airflow obstruction;
LGG	cis	rs7617773	0.539	rs13094496	chr3:48387050	G/C	cg11946769	chr3:48343235	NME6	0.53	8.92	0.38	1.05e-17	Coronary artery disease;
LGG	cis	rs2013441	0.866	rs2703811	chr17:20113975	G/A	cg13482628	chr17:19912719	NA	-0.41	-6.96	-0.31	1.17e-11	Obesity-related traits;
LGG	trans	rs208515	0.525	rs10498841	chr6:66663706	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.94	16.92	0.62	2.4e-50	Exhaled nitric oxide levels;
LGG	cis	rs11753937	0.887	rs375189	chr6:133608972	C/A	cg05493394	chr6:133562035	EYA4	0.25	7.0	0.31	9.31e-12	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs7143963	0.609	rs7140494	chr14:103291698	C/T	cg23020514	chr14:103360112	TRAF3	-0.39	-8.18	-0.36	2.81e-15	Body mass index;
LGG	cis	rs4927850	1.000	rs7627868	chr3:195753473	A/T	cg01181863	chr3:195395398	SDHAP2	-0.61	-9.66	-0.41	3.06e-20	Pancreatic cancer;
LGG	cis	rs4704187	0.687	rs9293643	chr5:74365053	C/T	cg03227963	chr5:74354835	NA	-0.31	-6.67	-0.3	7.25e-11	Response to amphetamines;
LGG	cis	rs4076764	0.914	rs7536270	chr1:163377379	T/C	cg24596788	chr1:163392923	NA	-0.71	-13.47	-0.53	4.02e-35	Motion sickness;
LGG	cis	rs6582630	0.622	rs11182005	chr12:38441292	G/A	cg04568710	chr12:38710424	ALG10B	-0.42	-9.36	-0.4	3.44e-19	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs2562456	0.754	rs112195516	chr19:21593651	A/G	cg00806126	chr19:22604979	ZNF98	-0.58	-7.68	-0.34	9.62e-14	Pain;
LGG	cis	rs757278	0.646	rs4730798	chr7:117354369	C/T	cg10524701	chr7:117356490	CTTNBP2	0.47	8.46	0.37	3.62e-16	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs12142240	0.698	rs67487250	chr1:46811333	T/C	cg25706281	chr1:46860511	FAAH	-0.29	-7.02	-0.31	7.82e-12	Menopause (age at onset);
LGG	cis	rs2011503	1.000	rs1989867	chr19:19447470	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.78	-0.3	3.56e-11	Bipolar disorder;
LGG	cis	rs9290877	0.667	rs7356022	chr3:188459669	C/T	cg17392043	chr3:188495102	LPP	-0.42	-7.31	-0.32	1.22e-12	IgE levels;
LGG	cis	rs9948	0.748	rs62156223	chr2:97412167	T/C	cg01990225	chr2:97406019	LMAN2L	-0.78	-7.69	-0.34	9.03e-14	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2016266	0.859	rs10747668	chr12:53737461	C/T	cg04065151	chr12:53682969	ESPL1	-0.5	-7.96	-0.35	1.37e-14	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs10504229	0.679	rs60869047	chr8:58053221	G/A	cg14926445	chr8:58193284	C8orf71	-0.73	-9.11	-0.39	2.46e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.659	rs11090049	chr22:41915329	C/T	cg06481639	chr22:41940642	POLR3H	-0.64	-9.13	-0.39	2.19e-18	Vitiligo;
LGG	cis	rs7635838	0.586	rs347617	chr3:11278211	C/T	cg00170343	chr3:11313890	ATG7	0.54	9.36	0.4	3.6e-19	HDL cholesterol;
LGG	cis	rs853679	0.517	rs9295759	chr6:28124469	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs11758351	0.587	rs10484436	chr6:26237155	C/T	cg23601095	chr6:26197514	HIST1H3D	0.69	8.7	0.37	5.81e-17	Gout;Renal underexcretion gout;
LGG	cis	rs2412208	0.664	rs12025462	chr1:7107665	C/T	cg20434152	chr1:7120926	CAMTA1	0.44	9.06	0.39	3.72e-18	Survival in sporadic amyotrophic lateral sclerosis;
LGG	cis	rs11758351	0.500	rs17533076	chr6:26183816	G/A	cg23601095	chr6:26197514	HIST1H3D	0.89	6.75	0.3	4.55e-11	Gout;Renal underexcretion gout;
LGG	trans	rs4332037	0.510	rs58673065	chr7:1885600	A/G	cg11693508	chr17:37793320	STARD3	0.52	8.4	0.36	5.58e-16	Bipolar disorder;
LGG	trans	rs6787172	0.702	rs827140	chr3:158004776	C/T	cg23275840	chr4:47708675	CORIN	0.41	8.74	0.38	4.34e-17	Subjective well-being;
LGG	trans	rs1941687	1.000	rs1941687	chr18:31334667	A/C	cg27147174	chr7:100797783	AP1S1	-0.52	-8.67	-0.37	7.3e-17	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs11155671	0.530	rs9383912	chr6:150206615	T/C	cg09699651	chr6:150184138	LRP11	0.57	11.03	0.46	2.79e-25	Testicular germ cell tumor;
LGG	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg13147721	chr7:65941812	NA	-0.83	-10.09	-0.42	8.77e-22	Diabetic kidney disease;
LGG	cis	rs6138458	0.961	rs11700073	chr20:24975215	C/G	cg26195577	chr20:24973756	C20orf3	1.25	26.44	0.78	1.45e-94	Blood protein levels;
LGG	cis	rs6694672	1.000	rs10754219	chr1:197165186	C/T	cg13682187	chr1:196946512	CFHR5	0.48	6.65	0.3	8.17e-11	Asthma;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01438737	chr20:42086396	SFRS6	0.4	7.0	0.31	9.32e-12	Bilirubin levels;
LGG	cis	rs7208859	0.673	rs3764421	chr17:29167653	A/C	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.95	-0.38	8.89e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs804292	0.763	rs8191514	chr8:11627113	C/G	cg26752888	chr8:11627280	NEIL2	1.06	16.81	0.62	7.57e-50	Alcohol dependence;Nicotine use;
LGG	cis	rs4481887	0.927	rs4409694	chr1:248485498	C/T	cg13385794	chr1:248469461	NA	0.49	8.27	0.36	1.41e-15	Common traits (Other);
LGG	cis	rs1949733	0.523	rs4619877	chr4:8543235	G/A	cg11789530	chr4:8429930	ACOX3	-0.67	-10.81	-0.45	1.86e-24	Response to antineoplastic agents;
LGG	cis	rs780094	0.500	rs4666002	chr2:27840640	G/C	cg27432699	chr2:27873401	GPN1	0.46	6.8	0.3	3.23e-11	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs988958	0.567	rs11894613	chr2:42268392	T/C	cg27252766	chr2:42229092	NA	0.51	8.06	0.35	6.35e-15	Hypospadias;
LGG	cis	rs4481887	0.708	rs28729425	chr1:248563027	T/C	cg01631408	chr1:248437212	OR2T33	-0.39	-7.11	-0.31	4.4e-12	Common traits (Other);
LGG	cis	rs11750568	0.967	rs931618	chr5:178514747	T/C	cg10208897	chr5:178548229	ADAMTS2	0.42	6.9	0.31	1.77e-11	Height;
LGG	cis	rs8133932	0.701	rs2330327	chr21:47305177	A/G	cg11214348	chr21:47283868	PCBP3	0.44	8.02	0.35	8.99e-15	Schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg26374823	chr8:15398053	TUSC3	0.37	6.7	0.3	6.25e-11	Cognitive performance;
LGG	cis	rs4924935	1.000	rs2158100	chr17:18811479	A/G	cg26378065	chr17:18585709	ZNF286B	-0.46	-7.65	-0.33	1.2e-13	Pancreatic cancer;
LGG	cis	rs1552244	1.000	rs7619340	chr3:10108178	C/T	cg00149659	chr3:10157352	C3orf10	0.86	10.79	0.45	2.4e-24	Alzheimer's disease;
LGG	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg25664220	chr3:72788482	NA	-0.33	-9.35	-0.4	3.9e-19	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs11792861	0.962	rs3750452	chr9:111801353	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.51	0.4	1.09e-19	Menarche (age at onset);
LGG	cis	rs12410462	0.636	rs114870233	chr1:227764842	G/A	cg04117972	chr1:227635322	NA	0.47	8.45	0.37	3.77e-16	Major depressive disorder;
LGG	trans	rs62103177	0.561	rs891488	chr18:77637424	T/C	cg05926928	chr17:57297772	GDPD1	-0.89	-13.58	-0.53	1.36e-35	Opioid sensitivity;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02234820	chr1:85358327	LPAR3	0.4	7.13	0.31	3.83e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs8078723	0.901	rs709591	chr17:38175561	T/A	cg17467752	chr17:38218738	THRA	0.74	13.85	0.54	9.36e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs9341808	0.754	rs3805907	chr6:80973665	A/G	cg08355045	chr6:80787529	NA	-0.39	-7.51	-0.33	2.99e-13	Sitting height ratio;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.32	-0.32	1.08e-12	Lung cancer;
LGG	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.54	0.5	2.88e-31	Colorectal cancer;
LGG	cis	rs1799949	0.550	rs2343818	chr17:41409774	G/A	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.31	0.32	1.17e-12	Menopause (age at onset);
LGG	trans	rs804280	0.509	rs7461273	chr8:11777977	C/G	cg02002194	chr4:3960332	NA	-0.49	-9.07	-0.39	3.47e-18	Myopia (pathological);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26869604	chr10:72142636	LRRC20	0.48	7.15	0.32	3.33e-12	Gut microbiome composition (summer);
LGG	cis	rs6747952	0.899	rs2880132	chr2:239082976	G/A	cg17459225	chr2:239074497	NA	0.42	7.64	0.33	1.22e-13	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3096299	0.632	rs8051537	chr16:89544384	T/A	cg05484508	chr16:89589025	SPG7	0.45	7.41	0.33	6.18e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs61931739	0.591	rs10743834	chr12:33916129	A/C	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs738127	chr22:21968221	G/A	cg05046821	chr22:21984468	YDJC	-0.38	-6.83	-0.3	2.6e-11	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19611418	chr2:131851282	FAM168B	0.51	7.57	0.33	2.08e-13	Gut microbiome composition (summer);
LGG	cis	rs7613875	0.600	rs2624848	chr3:50165101	T/C	cg14019146	chr3:50243930	SLC38A3	0.31	6.72	0.3	5.23e-11	Body mass index;
LGG	cis	rs2204008	0.837	rs11514225	chr12:38076270	G/A	cg26384229	chr12:38710491	ALG10B	0.97	22.25	0.72	3.96e-75	Bladder cancer;
LGG	cis	rs7249142	0.526	rs7256811	chr19:19283551	A/G	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	-0.44	-11.18	-0.46	7.29e-26	IgG glycosylation;
LGG	cis	rs4481887	0.893	rs28787378	chr1:248504447	C/T	cg00666640	chr1:248458726	OR2T12	0.55	8.92	0.38	1.11e-17	Common traits (Other);
LGG	cis	rs72781680	0.678	rs2551341	chr2:24014778	G/T	cg08917208	chr2:24149416	ATAD2B	0.63	8.23	0.36	1.94e-15	Lymphocyte counts;
LGG	cis	rs3733585	0.699	rs57574512	chr4:9960182	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs10504229	0.683	rs1495866	chr8:58141128	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.791	rs6505141	chr17:27998187	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.49	0.56	1.59e-39	Coffee consumption (cups per day);
LGG	cis	rs13418410	0.539	rs11677468	chr2:33839053	T/C	cg04131969	chr2:33951647	MYADML	-0.66	-12.14	-0.49	1.19e-29	Non-response to antidepressants and depression;
LGG	cis	rs17039065	0.920	rs12506757	chr4:109411903	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.59	7.21	0.32	2.35e-12	Gut microbiome composition (summer);
LGG	cis	rs2070488	0.662	rs7372545	chr3:38507570	T/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.68	12.05	0.49	2.73e-29	Electrocardiographic conduction measures;
LGG	cis	rs826838	0.804	rs6580755	chr12:39159190	C/T	cg13010199	chr12:38710504	ALG10B	0.71	14.8	0.57	7.7e-41	Heart rate;
LGG	cis	rs6577655	0.561	rs6577654	chr8:135593610	G/A	cg17885191	chr8:135476712	NA	0.58	8.48	0.37	3.1e-16	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg07005078	chr4:17578674	LAP3	0.37	6.88	0.3	1.96e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6743376	0.509	rs1530552	chr2:113818120	G/T	cg05949173	chr2:113825882	IL1F10	0.48	9.09	0.39	2.91e-18	Inflammatory biomarkers;
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg11494091	chr17:61959527	GH2	0.51	8.03	0.35	8.28e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs61990749	0.597	rs12896026	chr14:78244436	A/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.16	0.32	3.13e-12	Fibroblast growth factor basic levels;
LGG	cis	rs17253792	0.915	rs74580958	chr14:56181511	G/A	cg01858014	chr14:56050164	KTN1	-0.78	-9.98	-0.42	2.16e-21	Putamen volume;
LGG	cis	rs873946	0.590	rs7071777	chr10:134559976	T/A	cg26818010	chr10:134567672	INPP5A	-0.67	-10.66	-0.44	6.95e-24	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs9768139	0.935	rs10155946	chr7:158122116	C/T	cg25566285	chr7:158114605	PTPRN2	-0.97	-25.04	-0.76	3.88e-88	Calcium levels;
LGG	cis	rs262150	0.536	rs73167296	chr7:158783129	C/T	cg13444538	chr7:158905317	VIPR2	-0.41	-6.8	-0.3	3.23e-11	Facial morphology (factor 20);
LGG	cis	rs250677	0.687	rs250678	chr5:148434830	C/T	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.33	-0.32	1.04e-12	Breast cancer;
LGG	cis	rs12950390	0.853	rs11655336	chr17:45858836	A/G	cg24803719	chr17:45855879	NA	0.3	8.59	0.37	1.35e-16	IgG glycosylation;
LGG	cis	rs4718428	0.924	rs6971897	chr7:66412774	T/A	cg18252515	chr7:66147081	NA	-0.57	-9.18	-0.39	1.38e-18	Corneal structure;
LGG	cis	rs116095464	0.558	rs59284383	chr5:284525	C/G	cg22857025	chr5:266934	NA	-1.52	-26.82	-0.78	2.74e-96	Breast cancer;
LGG	cis	rs4006360	0.522	rs2874188	chr17:39244590	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9815354	0.812	rs73079324	chr3:41864564	T/C	cg03022575	chr3:42003672	ULK4	0.64	8.25	0.36	1.63e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9583531	0.600	rs754599	chr13:111354788	C/A	cg24331049	chr13:111365604	ING1	0.87	16.32	0.6	1.2e-47	Coronary artery disease;
LGG	cis	rs2797160	0.904	rs1777198	chr6:126007416	C/T	cg05901451	chr6:126070800	HEY2	0.45	7.41	0.33	5.91e-13	Endometrial cancer;
LGG	cis	rs11025559	0.796	rs11603462	chr11:20412180	C/A	cg19653624	chr11:20408972	PRMT3	-0.51	-8.44	-0.36	4.23e-16	Pursuit maintenance gain;
LGG	cis	rs6450176	1.000	rs59061738	chr5:53296557	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.69	-11.4	-0.47	1.02e-26	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	trans	rs561341	1.000	rs535151	chr17:30317405	C/T	cg27661571	chr11:113659931	NA	-0.62	-8.96	-0.38	8e-18	Hip circumference adjusted for BMI;
LGG	trans	rs6787172	0.651	rs6441198	chr3:158161499	T/C	cg23275840	chr4:47708675	CORIN	-0.36	-7.45	-0.33	4.69e-13	Subjective well-being;
LGG	cis	rs9886651	0.935	rs4524749	chr8:128805447	G/A	cg24514600	chr8:128805414	PVT1	-0.56	-13.04	-0.52	2.51e-33	Epithelial ovarian cancer;Serous invasive ovarian cancer;
LGG	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg22771759	chr13:24902376	NA	0.42	7.03	0.31	7.42e-12	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs62078305	chr17:80085326	G/A	cg16920238	chr17:80076378	CCDC57	0.32	7.31	0.32	1.22e-12	Life satisfaction;
LGG	cis	rs10504229	0.728	rs17804774	chr8:58155950	G/T	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs7310237	chr12:34483435	G/A	cg13010199	chr12:38710504	ALG10B	0.63	12.68	0.51	7.62e-32	Morning vs. evening chronotype;
LGG	cis	rs28647808	0.881	rs28622217	chr9:136267323	A/G	cg01472961	chr9:136215657	SNORD36B;MED22;SNORD24;RPL7A	0.73	7.0	0.31	8.79e-12	Blood protein levels;
LGG	cis	rs2235642	0.621	rs2667665	chr16:1569524	A/C	cg04525384	chr16:1557733	TELO2	0.45	7.99	0.35	1.08e-14	Coronary artery disease;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.54	-0.37	1.97e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.884	rs9397036	chr6:150172923	C/T	cg07701084	chr6:150067640	NUP43	0.61	11.26	0.46	3.74e-26	Lung cancer;
LGG	cis	rs2075371	0.764	rs1643034	chr7:134006176	A/G	cg11752832	chr7:134001865	SLC35B4	0.63	11.84	0.48	1.95e-28	Mean platelet volume;
LGG	trans	rs11098499	0.909	rs11723839	chr4:120299673	G/A	cg25214090	chr10:38739885	LOC399744	0.71	12.65	0.51	1.02e-31	Corneal astigmatism;
LGG	cis	rs2334880	0.678	rs6499520	chr16:71458100	C/T	cg06353428	chr16:71660113	MARVELD3	-0.74	-10.26	-0.43	2.22e-22	Malaria;
LGG	cis	rs6500602	0.893	rs4786490	chr16:4491190	C/T	cg26783146	chr16:4423632	VASN;CORO7	0.33	6.65	0.3	8.37e-11	Schizophrenia;
LGG	cis	rs2236267	0.564	rs8007372	chr14:88629117	C/T	cg02175263	chr14:88627849	NA	0.41	9.22	0.39	1.03e-18	Food antigen IgG levels;
LGG	cis	rs11608355	0.545	rs2302703	chr12:109898832	G/A	cg05360138	chr12:110035743	NA	0.84	12.13	0.49	1.41e-29	Neuroticism;
LGG	trans	rs9467711	0.606	rs9366653	chr6:26354247	G/A	cg08344181	chr3:125677491	NA	-0.62	-7.06	-0.31	6.13e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9815354	0.761	rs12186109	chr3:41836920	T/C	cg03022575	chr3:42003672	ULK4	0.8	9.44	0.4	1.76e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg09021430	chr5:549028	NA	-0.68	-9.27	-0.4	7.12e-19	Obesity-related traits;
LGG	cis	rs950027	0.815	rs1153835	chr15:45748607	G/C	cg26924012	chr15:45694286	SPATA5L1	0.53	9.05	0.39	4.13e-18	Response to fenofibrate (adiponectin levels);
LGG	cis	rs708547	0.874	rs1713978	chr4:57875879	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs28386778	0.897	rs2727320	chr17:61865325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.28	0.53	2.57e-34	Prudent dietary pattern;
LGG	cis	rs2952156	0.684	rs1877031	chr17:37814080	G/A	cg00129232	chr17:37814104	STARD3	-0.8	-17.58	-0.63	2.33e-53	Asthma;
LGG	cis	rs28830936	0.966	rs8025714	chr15:42120157	G/C	cg17847044	chr15:42102381	MAPKBP1	-0.57	-12.95	-0.52	6.23e-33	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg20415828	chr12:123011764	RSRC2;KNTC1	-0.46	-6.67	-0.3	7.16e-11	Systemic lupus erythematosus;
LGG	cis	rs908922	0.676	rs549044	chr1:152514332	C/T	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs357618	1.000	rs357624	chr5:150848701	A/G	cg03212797	chr5:150827313	SLC36A1	-0.42	-6.75	-0.3	4.35e-11	Basophil percentage of white cells;
LGG	cis	rs4604732	0.536	rs61184655	chr1:247651342	T/C	cg02104434	chr1:247694406	LOC148824;OR2C3	0.67	10.6	0.44	1.16e-23	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs9296404	1	rs9296404	chr6:42925803	T/C	cg10056627	chr6:42928773	GNMT	0.26	7.14	0.31	3.7e-12	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs4718428	0.705	rs11028	chr7:66276217	T/C	cg12165864	chr7:66369176	NA	-0.56	-9.09	-0.39	2.96e-18	Corneal structure;
LGG	cis	rs13108904	0.870	rs4974545	chr4:1271923	C/T	cg00684032	chr4:1343700	KIAA1530	0.47	9.19	0.39	1.31e-18	Obesity-related traits;
LGG	cis	rs9487094	0.813	rs12524502	chr6:109654221	A/G	cg16315928	chr6:109776240	MICAL1	0.48	8.12	0.35	4.29e-15	Height;
LGG	cis	rs9894429	0.505	rs35570626	chr17:79611084	A/G	cg10661904	chr17:79619235	PDE6G	-0.5	-10.24	-0.43	2.46e-22	Eye color traits;
LGG	cis	rs7618501	1.000	rs57648519	chr3:49813169	C/A	cg24110177	chr3:50126178	RBM5	-0.41	-7.0	-0.31	8.95e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12701220	0.522	rs12701455	chr7:1055409	A/G	cg07308232	chr7:1071921	C7orf50	-0.42	-7.03	-0.31	7.55e-12	Bronchopulmonary dysplasia;
LGG	cis	rs763121	0.853	rs1569716	chr22:38998519	C/A	cg06022373	chr22:39101656	GTPBP1	0.88	18.19	0.65	3.65e-56	Menopause (age at onset);
LGG	cis	rs9863	0.861	rs4930723	chr12:124423600	G/C	cg13487667	chr12:124434373	CCDC92	-0.37	-7.45	-0.33	4.6e-13	White blood cell count;
LGG	cis	rs4689388	0.890	rs4688991	chr4:6302220	C/G	cg25554036	chr4:6271136	WFS1	0.61	11.61	0.47	1.57e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs8065556	chr17:80091176	G/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4e-19	Life satisfaction;
LGG	cis	rs590121	0.876	rs589203	chr11:75275808	C/T	cg26104986	chr11:75275303	SERPINH1	-0.37	-8.61	-0.37	1.14e-16	Coronary artery disease;
LGG	cis	rs780096	0.526	rs780117	chr2:27698343	C/G	cg05484376	chr2:27715224	FNDC4	0.45	9.84	0.42	6.98e-21	Total body bone mineral density;
LGG	cis	rs60180747	1.000	rs35510028	chr15:66612079	C/G	cg11559852	chr15:66783310	MAP2K1;SNAPC5	0.54	9.69	0.41	2.52e-20	Testicular germ cell tumor;
LGG	cis	rs1153858	0.943	rs8038342	chr15:45651537	T/C	cg14582100	chr15:45693742	SPATA5L1	0.41	6.84	0.3	2.59e-11	Homoarginine levels;
LGG	cis	rs10824796	0.680	rs930509	chr10:54528353	C/G	cg27418851	chr10:54531653	MBL2	0.46	8.0	0.35	1.01e-14	Blood protein levels;
LGG	cis	rs6502050	0.835	rs3924780	chr17:80112978	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7666738	0.830	rs2865978	chr4:99017946	G/T	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1348850	0.914	rs4893957	chr2:178380409	A/G	cg27490568	chr2:178487706	NA	0.51	10.11	0.43	7.42e-22	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs11098499	0.865	rs28845498	chr4:120405186	G/A	cg24375607	chr4:120327624	NA	0.68	11.15	0.46	9.75e-26	Corneal astigmatism;
LGG	cis	rs6764363	0.762	rs598238	chr3:296849	C/T	cg02057681	chr3:285234	CHL1	0.38	6.98	0.31	1.01e-11	Sudden cardiac arrest;
LGG	cis	rs11098499	0.954	rs12508504	chr4:120410607	A/C	cg24375607	chr4:120327624	NA	0.67	11.03	0.46	2.89e-25	Corneal astigmatism;
LGG	cis	rs2249625	0.508	rs114505309	chr6:72892383	G/A	cg27608224	chr6:72922399	RIMS1	-0.34	-7.46	-0.33	4.42e-13	Acute urticaria and angioedema (non-steroidal anti-inflammatory drug-induced);
LGG	cis	rs832540	0.931	rs1466008	chr5:56213406	G/C	cg17809284	chr5:56205270	C5orf35	-0.38	-7.28	-0.32	1.46e-12	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08302365	chr9:135037896	NTNG2	0.47	7.01	0.31	8.26e-12	Gut microbiome composition (summer);
LGG	cis	rs2562456	0.724	rs58001930	chr19:21742863	C/T	cg00806126	chr19:22604979	ZNF98	-0.64	-9.45	-0.4	1.72e-19	Pain;
LGG	cis	rs9322193	0.566	rs9397070	chr6:150243209	T/C	cg01145232	chr6:150245071	RAET1G	-0.53	-9.7	-0.41	2.3e-20	Lung cancer;
LGG	cis	rs10504229	0.728	rs17804624	chr8:58154216	T/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs2154319	0.836	rs7553037	chr1:41507401	G/T	cg02290550	chr1:41487317	SLFNL1	-0.49	-9.04	-0.39	4.19e-18	Height;
LGG	trans	rs61931739	0.500	rs35030191	chr12:34548865	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs7133214	0.654	rs11049130	chr12:27923162	T/G	cg04279139	chr12:27925367	LOC100133893	-0.33	-6.98	-0.31	1.03e-11	Gut microbiota (functional units);
LGG	cis	rs7945705	0.935	rs2653593	chr11:8877317	G/A	cg00186954	chr11:8933980	ST5;C11orf17	-0.37	-7.75	-0.34	6.06e-14	Hemoglobin concentration;
LGG	cis	rs4987668	1.000	rs4987622	chr7:142579929	C/T	cg19410471	chr7:142636507	C7orf34	-0.47	-6.74	-0.3	4.85e-11	Cancer;
LGG	cis	rs7326068	0.610	rs2314719	chr13:21313282	G/A	cg04906043	chr13:21280425	IL17D	-0.49	-7.86	-0.34	2.65e-14	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs62238980	0.614	rs76363976	chr22:32383968	C/T	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs55665837	1.000	rs4412729	chr11:14439000	A/G	cg19336497	chr11:14380999	RRAS2	-0.46	-8.8	-0.38	2.71e-17	Vitamin D levels;
LGG	cis	rs936229	0.656	rs2290572	chr15:75130573	A/G	cg17294928	chr15:75287854	SCAMP5	0.51	8.96	0.38	8.25e-18	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs62400317	0.859	rs12209175	chr6:45194643	G/C	cg20913747	chr6:44695427	NA	-0.61	-9.98	-0.42	2.19e-21	Total body bone mineral density;
LGG	cis	rs5758511	0.689	rs17478227	chr22:42654327	C/G	cg15128208	chr22:42549153	NA	-0.77	-10.49	-0.44	3.08e-23	Birth weight;
LGG	cis	rs6951245	1.000	rs11766526	chr7:1101433	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.24	-0.7	2.02e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9914544	0.545	rs3803835	chr17:18793061	C/T	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs933688	1.000	rs1895448	chr5:90743854	C/T	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.09	17.27	0.63	5.79e-52	Smoking behavior;
LGG	cis	rs765787	0.530	rs4775837	chr15:45537684	G/T	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs273218	0.951	rs428213	chr5:53382790	T/G	ch.5.1024479R	chr5:53302184	ARL15	-0.61	-8.43	-0.36	4.57e-16	Migraine;
LGG	cis	rs13108904	0.967	rs1316419	chr4:1293997	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	0.7	13.0	0.52	3.58e-33	Obesity-related traits;
LGG	cis	rs2455601	0.882	rs10840139	chr11:8894838	T/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.69	-11.83	-0.48	2.1e-28	Schizophrenia;
LGG	cis	rs644799	1.000	rs472231	chr11:95532166	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs6582630	0.555	rs8189479	chr12:38308240	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.13	-0.39	2.1e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg06916706	chr16:4465613	CORO7	-0.74	-13.12	-0.52	1.2e-33	Schizophrenia;
LGG	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg07936489	chr17:37558343	FBXL20	-0.85	-15.97	-0.6	4.76e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs9650657	0.589	rs10107145	chr8:10758213	A/G	cg19847130	chr8:10466454	RP1L1	0.32	6.7	0.3	5.91e-11	Neuroticism;
LGG	cis	rs13108904	0.967	rs2293635	chr4:1291791	A/G	cg00689492	chr4:1303491	MAEA	0.51	8.77	0.38	3.36e-17	Obesity-related traits;
LGG	cis	rs3796619	0.924	rs11940546	chr4:1072485	C/T	cg27284194	chr4:1044797	NA	0.57	11.77	0.48	3.8e-28	Recombination rate (males);
LGG	cis	rs9915657	0.660	rs2241170	chr17:70070989	G/C	cg09344028	chr17:70110421	NA	0.54	11.62	0.48	1.46e-27	Thyroid hormone levels;
LGG	cis	rs10752881	1.000	rs6673559	chr1:182983197	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4919694	0.667	rs117927731	chr10:105112852	C/A	cg04362960	chr10:104952993	NT5C2	0.91	11.6	0.47	1.68e-27	Arsenic metabolism;
LGG	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg26384229	chr12:38710491	ALG10B	0.6	10.91	0.45	7.86e-25	Morning vs. evening chronotype;
LGG	cis	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg14541582	chr5:601475	NA	-0.53	-8.68	-0.37	7.02e-17	Obesity-related traits;
LGG	cis	rs2976388	1.000	rs10216533	chr8:143763690	G/A	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs9858542	0.953	rs11711485	chr3:49491983	G/T	cg00383909	chr3:49044727	WDR6	0.45	7.44	0.33	5.08e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6844506	0.565	rs10008153	chr4:185227184	C/T	cg12654155	chr4:185238627	NA	-0.49	-8.78	-0.38	3.11e-17	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs34311866	0.808	rs11248059	chr4:960331	C/G	cg07828340	chr4:882639	GAK	0.87	9.15	0.39	1.78e-18	Parkinson's disease;
LGG	cis	rs9393692	0.620	rs6908402	chr6:26293014	A/T	cg13736514	chr6:26305472	NA	-0.46	-9.27	-0.4	6.98e-19	Educational attainment;
LGG	cis	rs41271473	0.500	rs10916366	chr1:228894575	T/C	cg10167378	chr1:228756711	NA	0.51	8.77	0.38	3.45e-17	Chronic lymphocytic leukemia;
LGG	cis	rs7267979	0.714	rs6115107	chr20:25237390	A/G	cg08601574	chr20:25228251	PYGB	0.38	7.79	0.34	4.44e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4819052	0.851	rs9974628	chr21:46672647	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.7	-0.41	2.16e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs875971	1.000	rs778726	chr7:65828731	C/T	cg18876405	chr7:65276391	NA	0.55	9.98	0.42	2.3e-21	Aortic root size;
LGG	cis	rs6968355	0.789	rs2430480	chr7:104594348	G/A	cg03782966	chr7:104585482	NA	0.48	8.85	0.38	1.92e-17	Myopia (pathological);
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg00689492	chr4:1303491	MAEA	0.46	7.96	0.35	1.38e-14	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs4793197	chr17:41231902	C/T	cg23758822	chr17:41437982	NA	0.89	15.64	0.59	1.4e-44	Menopause (age at onset);
LGG	cis	rs868036	0.681	rs2241423	chr15:68086838	G/A	cg05925327	chr15:68127851	NA	-0.37	-7.64	-0.33	1.27e-13	Restless legs syndrome;
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg06221963	chr1:154839813	KCNN3	-0.52	-10.93	-0.45	6.63e-25	Prostate cancer;
LGG	cis	rs11785400	1.000	rs4327844	chr8:143733540	C/T	cg24634471	chr8:143751801	JRK	-0.54	-8.77	-0.38	3.51e-17	Schizophrenia;
LGG	cis	rs1008375	1.000	rs3815414	chr4:17606659	A/G	cg04450456	chr4:17643702	FAM184B	-0.33	-7.24	-0.32	1.85e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4665809	0.887	rs4665825	chr2:26333100	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.63	-0.33	1.38e-13	Gut microbiome composition (summer);
LGG	cis	rs12724450	0.793	rs4845	chr1:150280550	G/A	cg03818307	chr1:150480534	ECM1	0.49	6.86	0.3	2.18e-11	Blood protein levels;
LGG	cis	rs7582180	1.000	rs7588623	chr2:100913361	A/G	cg08297393	chr2:100937505	LONRF2	-0.57	-9.64	-0.41	3.64e-20	Intelligence (multi-trait analysis);
LGG	cis	rs62238980	0.614	rs76010922	chr22:32471678	G/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg03806693	chr22:41940476	POLR3H	0.88	14.66	0.56	2.92e-40	Vitiligo;
LGG	cis	rs13108904	0.557	rs1680041	chr4:1238521	C/T	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.64	-12.48	-0.5	5.1e-31	Obesity-related traits;
LGG	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg05753993	chr18:77199432	NFATC1	0.38	7.15	0.32	3.49e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.74	-0.38	4.18e-17	Life satisfaction;
LGG	trans	rs6601327	0.665	rs11249949	chr8:9655612	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.78e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9534288	0.830	rs2404963	chr13:46632836	C/T	cg15192986	chr13:46630673	CPB2	-0.81	-17.6	-0.63	1.87e-53	Blood protein levels;
LGG	cis	rs1707322	0.721	rs28641748	chr1:46212836	A/G	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4665809	0.652	rs6727974	chr2:26524639	A/G	cg22920501	chr2:26401640	FAM59B	0.38	7.84	0.34	3.19e-14	Gut microbiome composition (summer);
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25172604	chr17:41446521	NA	-0.3	-6.93	-0.31	1.44e-11	Menopause (age at onset);
LGG	cis	rs4713675	0.584	rs6457739	chr6:33673831	A/G	cg14003231	chr6:33640908	ITPR3	0.29	6.73	0.3	5.05e-11	Plateletcrit;
LGG	cis	rs11123170	0.542	rs11123169	chr2:113967075	C/T	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	-0.49	-8.6	-0.37	1.27e-16	Renal function-related traits (BUN);
LGG	cis	rs2115536	0.967	rs934137	chr15:80211768	T/C	cg00225070	chr15:80189496	MTHFS	0.37	6.83	0.3	2.62e-11	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.0	14.69	0.56	2.3e-40	Platelet count;
LGG	trans	rs9467711	0.606	rs2073527	chr6:26374978	T/C	cg01620082	chr3:125678407	NA	-0.63	-6.97	-0.31	1.11e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.799	rs12450683	chr17:61984299	C/G	cg07659893	chr17:61819838	STRADA	0.42	7.07	0.31	5.66e-12	Prudent dietary pattern;
LGG	cis	rs736408	0.527	rs2336147	chr3:52626443	T/C	cg10802521	chr3:52805072	NEK4	-0.39	-7.02	-0.31	8.06e-12	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4242434	0.854	rs3735893	chr8:22452704	A/G	cg02227867	chr8:22457446	C8orf58	-0.43	-8.19	-0.36	2.65e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs1005277	0.522	rs289647	chr10:37968278	A/G	cg00409905	chr10:38381863	ZNF37A	-0.6	-12.24	-0.49	4.77e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs950776	0.647	rs495956	chr15:78869930	C/T	cg17108064	chr15:78857060	CHRNA5	-0.45	-9.51	-0.4	1.07e-19	Sudden cardiac arrest;
LGG	cis	rs11971779	0.793	rs11543827	chr7:139032693	G/A	cg07862535	chr7:139043722	LUC7L2	0.5	8.21	0.36	2.24e-15	Diisocyanate-induced asthma;
LGG	cis	rs2180341	0.920	rs1073932	chr6:127682009	G/T	cg27446573	chr6:127587934	RNF146	1.14	22.34	0.72	1.53e-75	Breast cancer;
LGG	cis	rs55675132	0.510	rs12120851	chr1:115262845	T/C	cg12756093	chr1:115239321	AMPD1	0.48	6.81	0.3	3.13e-11	Schizophrenia;
LGG	cis	rs62064224	0.546	rs1018866	chr17:30829664	A/C	cg18200150	chr17:30822561	MYO1D	0.7	15.39	0.58	1.84e-43	Schizophrenia;
LGG	cis	rs13082711	0.871	rs73046194	chr3:27454558	C/T	cg02860705	chr3:27208620	NA	0.68	12.24	0.49	5.01e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	trans	rs453301	0.686	rs4840389	chr8:8884503	G/C	cg16141378	chr3:129829833	LOC729375	0.35	8.13	0.35	3.97e-15	Joint mobility (Beighton score);
LGG	cis	rs3768617	0.510	rs1886501	chr1:183095234	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	trans	rs7939886	0.920	rs11227449	chr11:55949409	A/G	cg15704280	chr7:45808275	SEPT13	0.83	7.72	0.34	6.99e-14	Myopia (pathological);
LGG	cis	rs6502050	0.835	rs7503225	chr17:80099639	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs5769765	0.624	rs2285187	chr22:50185432	A/G	cg26441486	chr22:50317300	CRELD2	0.37	6.69	0.3	6.66e-11	Schizophrenia;
LGG	cis	rs11148252	0.875	rs7987115	chr13:52962097	C/T	cg22398616	chr13:53314203	LECT1	-0.43	-8.96	-0.38	7.79e-18	Lewy body disease;
LGG	cis	rs9309473	0.950	rs10178678	chr2:73762236	A/G	cg20560298	chr2:73613845	ALMS1	-0.49	-8.0	-0.35	9.74e-15	Metabolite levels;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg16301924	chr13:53314226	LECT1	-0.48	-9.98	-0.42	2.2e-21	Lewy body disease;
LGG	cis	rs537626	1.000	rs612611	chr11:69307463	A/G	cg08353955	chr11:69289746	NA	-0.94	-13.7	-0.54	4.02e-36	Breast cancer (early onset);
LGG	cis	rs503341	0.756	rs612010	chr11:63591005	G/A	cg04362095	chr11:63592001	C11orf84	-0.55	-10.81	-0.45	1.93e-24	Pulse pressure;
LGG	cis	rs611744	0.647	rs2597658	chr8:109256014	C/T	cg21045802	chr8:109455806	TTC35	0.49	9.04	0.39	4.3e-18	Dupuytren's disease;
LGG	trans	rs6956675	0.915	rs7795023	chr7:62652291	C/T	cg01314568	chr7:57830625	NA	-0.48	-7.79	-0.34	4.52e-14	Obesity-related traits;
LGG	cis	rs72615157	0.697	rs2056726	chr7:99780283	G/A	cg13153964	chr7:100026424	MEPCE;ZCWPW1	0.73	10.56	0.44	1.69e-23	Lung function (FEV1/FVC);
LGG	cis	rs524281	0.861	rs12226649	chr11:65842047	T/C	cg16950941	chr11:66035639	RAB1B	-0.45	-6.71	-0.3	5.69e-11	Electroencephalogram traits;
LGG	cis	rs6502050	0.723	rs11650633	chr17:80083807	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.42	0.36	4.93e-16	Life satisfaction;
LGG	cis	rs5758511	0.680	rs5758662	chr22:42628088	T/C	cg15128208	chr22:42549153	NA	0.74	11.45	0.47	6.98e-27	Birth weight;
LGG	trans	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg13565492	chr6:43139072	SRF	-0.74	-8.97	-0.38	7.68e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4731207	0.698	rs4728009	chr7:124470961	A/C	cg05630886	chr7:124431682	NA	-0.31	-7.4	-0.33	6.41e-13	Cutaneous malignant melanoma;
LGG	cis	rs801193	1.000	rs2659912	chr7:66157999	G/C	cg11764359	chr7:65958608	NA	0.63	10.73	0.45	3.74e-24	Aortic root size;
LGG	cis	rs1152591	0.505	rs1152601	chr14:64667337	T/C	cg23250157	chr14:64679961	SYNE2	0.39	6.89	0.3	1.82e-11	Atrial fibrillation;
LGG	cis	rs9291683	0.527	rs73212848	chr4:10093299	T/C	cg00071950	chr4:10020882	SLC2A9	-0.37	-7.54	-0.33	2.45e-13	Bone mineral density;
LGG	cis	rs2133450	0.775	rs9860580	chr3:7292607	T/C	cg19930620	chr3:7340148	GRM7	-0.35	-7.69	-0.34	9.11e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs1577917	0.771	rs4145082	chr6:86352016	G/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.89	-17.64	-0.63	1.2e-53	Response to antipsychotic treatment;
LGG	cis	rs3749237	0.595	rs6784820	chr3:49450864	C/T	cg02487422	chr3:49467188	NICN1	-0.57	-10.67	-0.44	6.28e-24	Resting heart rate;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg18404041	chr3:52824283	ITIH1	-0.51	-10.02	-0.42	1.57e-21	Bipolar disorder;
LGG	cis	rs7582720	1.000	rs72934707	chr2:203707878	G/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.78	0.41	1.16e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs477692	0.905	rs576560	chr10:131420697	C/A	cg05714579	chr10:131428358	MGMT	0.67	14.11	0.55	7.08e-38	Response to temozolomide;
LGG	cis	rs2477686	0.526	rs1998759	chr1:2397174	C/T	cg06215416	chr1:2383473	NA	-0.5	-12.27	-0.5	3.55e-30	Non-obstructive azoospermia;
LGG	cis	rs61931739	0.534	rs4365131	chr12:34053308	T/C	cg06521331	chr12:34319734	NA	-0.63	-11.83	-0.48	2.21e-28	Morning vs. evening chronotype;
LGG	cis	rs8060686	0.641	rs55682260	chr16:68057880	G/A	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.42e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs11690935	0.959	rs12692970	chr2:172594197	T/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.81	-0.3	3.01e-11	Schizophrenia;
LGG	cis	rs8072100	0.837	rs62074055	chr17:45771933	G/C	cg19784903	chr17:45786737	TBKBP1	-0.34	-7.3	-0.32	1.3e-12	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs2964802	0.505	rs11957751	chr5:10819973	A/G	cg14521931	chr5:10832172	NA	0.74	15.99	0.6	3.91e-46	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6977660	0.714	rs10276518	chr7:19781325	C/A	cg05791153	chr7:19748676	TWISTNB	0.76	10.18	0.43	4.32e-22	Thyroid stimulating hormone;
LGG	cis	rs4363385	0.818	rs3806222	chr1:153002606	C/T	cg13444842	chr1:152974279	SPRR3	-0.43	-8.93	-0.38	1.01e-17	Inflammatory skin disease;
LGG	trans	rs8002861	0.967	rs9533690	chr13:44480598	T/C	cg12856521	chr11:46389249	DGKZ	0.43	7.52	0.33	2.94e-13	Leprosy;
LGG	cis	rs17776563	0.639	rs11631914	chr15:89114962	G/C	cg05013243	chr15:89149849	MIR1179	-0.36	-7.32	-0.32	1.11e-12	Thyroid hormone levels;
LGG	cis	rs701145	0.585	rs357498	chr3:153945495	G/A	cg12800244	chr3:153838788	SGEF	0.86	8.42	0.36	4.81e-16	Coronary artery disease;
LGG	cis	rs1555895	0.611	rs12774722	chr10:854675	G/A	cg09361094	chr10:834503	NA	-0.3	-7.97	-0.35	1.21e-14	Survival in rectal cancer;
LGG	cis	rs138880	0.542	rs9616393	chr22:50314809	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	0.91	10.32	0.43	1.29e-22	Schizophrenia;
LGG	cis	rs7833790	0.660	rs67666182	chr8:82772037	A/G	cg17211192	chr8:82754475	SNX16	0.7	11.53	0.47	3.35e-27	Diastolic blood pressure;
LGG	cis	rs2980439	0.818	rs2945249	chr8:8094726	G/A	cg14979609	chr8:8086686	FLJ10661	-0.32	-8.27	-0.36	1.42e-15	Neuroticism;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg09699651	chr6:150184138	LRP11	-0.46	-7.94	-0.35	1.5e-14	Lung cancer;
LGG	cis	rs9325144	0.748	rs1523121	chr12:39209652	A/G	cg13010199	chr12:38710504	ALG10B	-0.46	-7.27	-0.32	1.57e-12	Morning vs. evening chronotype;
LGG	cis	rs11920090	0.932	rs10513685	chr3:170724390	A/G	cg09710316	chr3:170744871	SLC2A2	-0.61	-8.62	-0.37	1.03e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs5771242	0.518	rs67881086	chr22:50673439	G/A	cg16473166	chr22:50639996	SELO	0.72	11.05	0.46	2.44e-25	Lung function (forced expiratory flow during mid-portion (25% and 75%) of forced vital capacity);
LGG	trans	rs8002861	0.641	rs2325085	chr13:44410060	G/A	cg12856521	chr11:46389249	DGKZ	0.52	9.34	0.4	4.19e-19	Leprosy;
LGG	cis	rs1552244	0.816	rs9847657	chr3:10173492	G/T	cg02579736	chr3:10068473	FANCD2;CIDECP	0.98	17.39	0.63	1.74e-52	Alzheimer's disease;
LGG	cis	rs6840360	0.642	rs1443088	chr4:152450126	G/A	cg17217059	chr4:152329364	FAM160A1	0.2	7.1	0.31	4.79e-12	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs71583484	chr5:131719130	G/A	cg06968155	chr5:131705112	SLC22A5	0.72	8.3	0.36	1.18e-15	Rheumatoid arthritis;
LGG	cis	rs6952808	0.723	rs57216949	chr7:2030287	G/T	cg22963979	chr7:1858916	MAD1L1	-0.5	-10.33	-0.43	1.18e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4642101	0.640	rs12629398	chr3:12826799	A/G	cg24848339	chr3:12840334	CAND2	0.44	10.22	0.43	3.05e-22	QRS complex (12-leadsum);
LGG	cis	rs7084402	0.967	rs1614258	chr10:60308407	C/T	cg07615347	chr10:60278583	BICC1	0.64	18.38	0.65	4.75e-57	Refractive error;
LGG	cis	rs806215	0.547	rs3824003	chr7:127469624	C/T	cg25922125	chr7:127225783	GCC1	-0.49	-7.2	-0.32	2.38e-12	Type 2 diabetes;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.64e-12	Lung cancer;
LGG	cis	rs8062405	0.691	rs11646653	chr16:28922149	C/T	cg16576597	chr16:28551801	NUPR1	-0.33	-7.22	-0.32	2.2e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs916888	0.773	rs199535	chr17:44822662	A/G	cg22433210	chr17:43662623	NA	0.9	15.0	0.57	1.02e-41	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3733585	0.673	rs9993410	chr4:9951264	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.27	-0.32	1.58e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	21.13	0.7	7.34e-70	Gut microbiome composition (summer);
LGG	cis	rs11622475	0.626	rs34533310	chr14:104352233	C/T	cg20488157	chr14:104394430	TDRD9	0.41	6.93	0.31	1.41e-11	Bipolar disorder;
LGG	cis	rs651907	0.557	rs11925001	chr3:101373966	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.43	-7.64	-0.33	1.24e-13	Colorectal cancer;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.71	-13.13	-0.52	1.06e-33	Longevity;Endometriosis;
LGG	cis	rs7937682	1.000	rs11608149	chr11:111535102	G/A	cg08305652	chr11:111469057	NA	0.43	8.19	0.36	2.63e-15	Primary sclerosing cholangitis;
LGG	cis	rs7169223	0.615	rs8038189	chr15:79099026	G/C	cg03762349	chr15:79060523	ADAMTS7	-0.36	-7.05	-0.31	6.47e-12	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	cis	rs41271473	1.000	rs1062060	chr1:228880021	A/G	cg10167378	chr1:228756711	NA	-0.55	-7.89	-0.34	2.27e-14	Chronic lymphocytic leukemia;
LGG	trans	rs61931739	0.517	rs2636074	chr12:34064056	C/T	cg26384229	chr12:38710491	ALG10B	0.73	14.58	0.56	6.62e-40	Morning vs. evening chronotype;
LGG	cis	rs2243480	1.000	rs2533288	chr7:66056711	C/G	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.62e-22	Diabetic kidney disease;
LGG	cis	rs11758351	1.000	rs16891401	chr6:26202337	G/A	cg06951627	chr6:26196580	NA	0.53	8.11	0.35	4.51e-15	Gout;Renal underexcretion gout;
LGG	cis	rs3785574	0.962	rs35448669	chr17:61938923	G/A	cg11494091	chr17:61959527	GH2	0.6	10.03	0.42	1.46e-21	Height;
LGG	cis	rs4454254	0.830	rs6994517	chr8:141050171	A/G	cg05910124	chr8:141057427	TRAPPC9	-0.28	-6.89	-0.31	1.79e-11	Pulse pressure;
LGG	cis	rs7552404	0.727	rs2172507	chr1:76331320	A/G	cg03433033	chr1:76189801	ACADM	-0.58	-8.96	-0.38	8.09e-18	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35306767	0.903	rs11812523	chr10:915638	C/T	cg20503657	chr10:835505	NA	0.75	10.22	0.43	2.98e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs887829	0.641	rs10167119	chr2:234589312	T/C	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.49	-8.4	-0.36	5.53e-16	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	cis	rs13392177	0.684	rs62185965	chr2:219073779	T/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.65	-0.33	1.21e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.45	-0.44	4.15e-23	Hip circumference adjusted for BMI;
LGG	cis	rs2120019	1.000	rs8033837	chr15:75353975	A/C	cg17294928	chr15:75287854	SCAMP5	-0.94	-16.85	-0.62	5.08e-50	Blood trace element (Zn levels);
LGG	cis	rs61931739	0.817	rs1687002	chr12:34170263	T/C	cg06521331	chr12:34319734	NA	-0.4	-7.14	-0.32	3.57e-12	Morning vs. evening chronotype;
LGG	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg19147804	chr7:1989927	MAD1L1	0.34	6.68	0.3	6.66e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs774359	0.797	rs4609281	chr9:27514962	G/T	cg14173147	chr9:27528300	MOBKL2B	-0.37	-7.54	-0.33	2.52e-13	Amyotrophic lateral sclerosis;
LGG	cis	rs7572644	0.699	rs7426295	chr2:28078994	G/A	cg27432699	chr2:27873401	GPN1	0.46	6.98	0.31	1.04e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs4975616	0.714	rs27069	chr5:1347128	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.8	-15.87	-0.59	1.27e-45	Lung cancer;
LGG	cis	rs875971	1.000	rs2042133	chr7:65931922	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	5e-17	Aortic root size;
LGG	cis	rs4631830	0.720	rs2843560	chr10:51512129	C/G	cg10326726	chr10:51549505	MSMB	0.62	12.57	0.5	2.17e-31	Prostate-specific antigen levels;
LGG	cis	rs17767294	0.541	rs733743	chr6:28327371	C/G	cg00426182	chr6:28072559	NA	-1.07	-8.54	-0.37	2e-16	Parkinson's disease;
LGG	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06850241	chr22:41845214	NA	-0.42	-6.77	-0.3	3.81e-11	Vitiligo;
LGG	cis	rs4650994	0.525	rs2493860	chr1:178541492	A/G	cg12486710	chr1:178512616	C1orf220	0.51	10.51	0.44	2.47e-23	HDL cholesterol levels;HDL cholesterol;
LGG	trans	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.73	-0.34	6.83e-14	Neuroticism;
LGG	cis	rs10504229	1.000	rs79561699	chr8:58170601	A/G	cg21724239	chr8:58056113	NA	0.44	6.79	0.3	3.48e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11758351	1.000	rs16891397	chr6:26200256	C/T	cg06951627	chr6:26196580	NA	0.53	8.04	0.35	7.36e-15	Gout;Renal underexcretion gout;
LGG	cis	rs7208859	0.623	rs216433	chr17:28921860	T/C	cg01831904	chr17:28903510	LRRC37B2	-0.94	-12.46	-0.5	6.45e-31	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4711350	0.723	rs608971	chr6:33702079	C/T	cg06471254	chr6:33690276	IP6K3	0.51	7.39	0.32	7.11e-13	Schizophrenia;
LGG	cis	rs3735485	0.723	rs6951729	chr7:45055578	T/G	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs453301	0.598	rs2921383	chr8:8892221	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.69	0.37	6.09e-17	Joint mobility (Beighton score);
LGG	cis	rs17102423	0.602	rs1270073	chr14:65566257	C/A	cg11161011	chr14:65562177	MAX	-0.66	-12.67	-0.51	8.71e-32	Obesity-related traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03535066	chr14:62228987	SNAPC1	0.44	7.7	0.34	8.11e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs9926296	0.632	rs7206546	chr16:89799079	C/T	cg26513180	chr16:89883248	FANCA	-0.62	-11.3	-0.47	2.53e-26	Vitiligo;
LGG	cis	rs6582630	0.554	rs7299735	chr12:38450890	A/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.5	-0.4	1.12e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6952808	0.609	rs10230383	chr7:1950113	T/C	cg14004847	chr7:1930337	MAD1L1	-0.53	-9.33	-0.4	4.42e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs7937890	0.505	rs4403769	chr11:14450176	C/T	cg02886208	chr11:14281011	SPON1	-0.41	-7.97	-0.35	1.24e-14	Mitochondrial DNA levels;
LGG	cis	rs35306767	0.903	rs11253492	chr10:936873	T/C	cg26597838	chr10:835615	NA	0.75	10.44	0.44	4.51e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs10504229	0.683	rs35244711	chr8:58117762	T/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2377058	0.924	rs76762453	chr16:89723602	G/A	cg07835443	chr16:89734986	C16orf55	-0.48	-8.17	-0.35	3.06e-15	Hip circumference adjusted for BMI;
LGG	trans	rs931812	0.757	rs4734014	chr8:101908844	A/G	cg20993868	chr7:22813445	NA	0.61	12.02	0.49	3.76e-29	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs11622475	1.000	rs11625697	chr14:104464800	C/T	cg20488157	chr14:104394430	TDRD9	0.56	9.14	0.39	1.9e-18	Bipolar disorder;
LGG	cis	rs853679	0.517	rs9393890	chr6:28063855	C/T	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs13108904	0.870	rs1564508	chr4:1244879	A/G	cg02018176	chr4:1364513	KIAA1530	0.38	8.81	0.38	2.54e-17	Obesity-related traits;
LGG	trans	rs7939886	0.920	rs7950386	chr11:55931513	C/T	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	cis	rs11877825	1.000	rs11877777	chr18:10566405	C/A	cg07277756	chr18:10589357	NA	0.56	10.18	0.43	4.17e-22	Gut microbiota (bacterial taxa);
LGG	trans	rs9467711	0.790	rs45527431	chr6:26599509	A/G	cg06606381	chr12:133084897	FBRSL1	-1.28	-11.68	-0.48	8.76e-28	Autism spectrum disorder or schizophrenia;
LGG	cis	rs155076	1.000	rs261407	chr13:21855213	C/A	cg14456004	chr13:21872349	NA	-1.16	-18.4	-0.65	3.76e-57	White matter hyperintensity burden;
LGG	cis	rs7937682	0.889	rs564086	chr11:111501079	C/G	cg08305652	chr11:111469057	NA	-0.43	-8.54	-0.37	1.92e-16	Primary sclerosing cholangitis;
LGG	cis	rs7267979	0.844	rs2257649	chr20:25263457	T/G	cg06421707	chr20:25228305	PYGB	0.42	8.8	0.38	2.83e-17	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg24829409	chr8:58192753	C8orf71	-0.66	-9.58	-0.41	5.78e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs6908034	0.607	rs78774173	chr6:19820686	T/C	cg02682789	chr6:19804855	NA	0.9	8.42	0.36	4.78e-16	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;
LGG	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg10523679	chr1:76189770	ACADM	-0.82	-13.81	-0.54	1.41e-36	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs898097	0.578	rs2380173	chr17:80909157	G/T	cg15664640	chr17:80829946	TBCD	-0.56	-11.25	-0.46	4.13e-26	Breast cancer;
LGG	cis	rs477895	0.713	rs3802933	chr11:63988102	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.31	0.47	2.33e-26	Mean platelet volume;
LGG	cis	rs10911232	0.507	rs9787327	chr1:182978459	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.89	0.38	1.34e-17	Hypertriglyceridemia;
LGG	cis	rs7236492	0.748	rs11660128	chr18:77227950	G/T	cg15532942	chr18:77220712	NFATC1	0.47	7.37	0.32	7.76e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs4132509	1.000	rs2290754	chr1:243806268	A/C	cg21452805	chr1:244014465	NA	0.63	7.72	0.34	7.19e-14	RR interval (heart rate);
LGG	cis	rs6089584	1.000	rs3787425	chr20:60559256	C/T	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs7617773	0.779	rs77957078	chr3:48331286	G/C	cg11946769	chr3:48343235	NME6	0.7	11.68	0.48	8.74e-28	Coronary artery disease;
LGG	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.14	-0.7	6.22e-70	Coronary artery disease;
LGG	trans	rs208520	0.690	rs12189780	chr6:66759619	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.96	17.77	0.64	3.01e-54	Exhaled nitric oxide output;
LGG	cis	rs1862618	0.853	rs1862619	chr5:56098256	T/A	cg03609598	chr5:56110824	MAP3K1	-0.49	-7.33	-0.32	1.01e-12	Initial pursuit acceleration;
LGG	cis	rs7619833	0.715	rs4973766	chr3:27413566	C/T	cg02860705	chr3:27208620	NA	0.43	8.56	0.37	1.62e-16	Breast cancer;
LGG	cis	rs25645	0.792	rs8077456	chr17:38128765	C/G	cg17467752	chr17:38218738	THRA	-0.54	-9.06	-0.39	3.68e-18	Myeloid white cell count;
LGG	cis	rs7851660	0.809	rs10984253	chr9:100664474	A/G	cg13688889	chr9:100608707	NA	-0.64	-12.8	-0.51	2.41e-32	Strep throat;
LGG	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg25019033	chr10:957182	NA	-0.55	-10.12	-0.43	7.26e-22	Eosinophil percentage of granulocytes;
LGG	trans	rs6787172	0.702	rs1730045	chr3:158015635	A/G	cg23275840	chr4:47708675	CORIN	0.41	8.79	0.38	2.98e-17	Subjective well-being;
LGG	cis	rs3768617	0.510	rs10911247	chr1:183076993	A/G	cg07928641	chr1:182991847	LAMC1	0.42	8.16	0.35	3.11e-15	Fuchs's corneal dystrophy;
LGG	cis	rs6952808	0.771	rs10265944	chr7:1918337	C/T	cg00106254	chr7:1943704	MAD1L1	-0.42	-7.13	-0.31	3.8e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11628318	0.614	rs12588817	chr14:103089210	G/A	cg12046867	chr14:103022105	NA	-0.43	-8.61	-0.37	1.19e-16	Platelet count;
LGG	cis	rs1018836	0.923	rs756569	chr8:91610957	G/A	cg16814680	chr8:91681699	NA	-0.84	-15.68	-0.59	9.72e-45	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs3740909	1.000	rs76038012	chr11:125896101	T/C	cg24940576	chr11:125904314	CDON	-0.48	-6.95	-0.31	1.28e-11	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg14555127	chr7:35841578	SEPT7	0.43	6.8	0.3	3.15e-11	Cognitive performance;
LGG	cis	rs657075	0.697	rs71583485	chr5:131719382	A/G	cg17951613	chr5:131705445	SLC22A5	0.64	7.25	0.32	1.75e-12	Rheumatoid arthritis;
LGG	cis	rs765787	0.556	rs12915965	chr15:45512647	T/C	cg25801113	chr15:45476975	SHF	-0.87	-19.06	-0.66	3.19e-60	Uric acid levels;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg03528353	chr17:61819722	STRADA	0.44	7.46	0.33	4.41e-13	Prudent dietary pattern;
LGG	cis	rs7618915	0.501	rs3733041	chr3:52731598	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.62	11.3	0.47	2.48e-26	Bipolar disorder;
LGG	trans	rs9467711	0.659	rs36162392	chr6:26569135	T/C	cg08344181	chr3:125677491	NA	-0.69	-7.32	-0.32	1.1e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs4499294	chr17:80148346	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs55879323	1	rs55879323	chr1:152168740	C/T	cg25272121	chr1:152190972	HRNR	-0.42	-8.55	-0.37	1.77e-16	Inflammatory skin disease;
LGG	trans	rs7939886	0.844	rs10501350	chr11:56058690	G/A	cg15704280	chr7:45808275	SEPT13	0.81	7.64	0.33	1.26e-13	Myopia (pathological);
LGG	cis	rs9611565	0.649	rs202625	chr22:41827082	G/A	cg03806693	chr22:41940476	POLR3H	1.08	19.67	0.67	4.63e-63	Vitiligo;
LGG	cis	rs514406	0.679	rs541852	chr1:53256834	A/G	cg24675658	chr1:53192096	ZYG11B	0.65	13.66	0.54	6.31e-36	Monocyte count;
LGG	cis	rs5756391	0.546	rs9607397	chr22:37315988	C/T	cg21209356	chr22:37319042	CSF2RB	0.4	9.26	0.4	7.71e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9560113	0.509	rs4771759	chr13:112209217	A/G	cg15979348	chr13:112237479	NA	-0.41	-7.01	-0.31	8.43e-12	Menarche (age at onset);
LGG	cis	rs7044106	0.762	rs4837789	chr9:123426256	G/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.48	0.61	2.26e-48	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.908	rs28499576	chr4:120386677	G/A	cg09307838	chr4:120376055	NA	0.82	13.79	0.54	1.67e-36	Corneal astigmatism;
LGG	cis	rs9399135	0.967	rs11754783	chr6:135347661	T/A	cg22676075	chr6:135203613	NA	0.37	6.76	0.3	4.29e-11	Red blood cell count;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg11673391	chr1:10459052	PGD	0.41	6.89	0.3	1.84e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs753778	0.667	rs10092439	chr8:142210881	C/T	cg23750338	chr8:142222470	SLC45A4	0.34	6.65	0.3	8.35e-11	Reticulocyte fraction of red cells;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs28530618	0.603	rs750401	chr20:31246638	G/C	cg13636640	chr20:31349939	DNMT3B	-0.42	-6.73	-0.3	5.14e-11	Birth weight;
LGG	cis	rs9487051	0.872	rs1111864	chr6:109611138	A/G	cg12927641	chr6:109611667	NA	-0.37	-7.15	-0.32	3.31e-12	Reticulocyte fraction of red cells;
LGG	cis	rs28386778	0.831	rs2584618	chr17:61923611	T/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.09	0.31	5e-12	Prudent dietary pattern;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00656411	chr7:140773422	NA	0.41	7.14	0.31	3.53e-12	Obesity-related traits;
LGG	cis	rs4319547	0.688	rs10847242	chr12:123079020	T/G	cg05707623	chr12:122985044	ZCCHC8	-0.46	-7.49	-0.33	3.54e-13	Body mass index;
LGG	cis	rs4319547	0.737	rs10846920	chr12:122943231	C/T	cg23029597	chr12:123009494	RSRC2	-0.88	-16.81	-0.62	7.73e-50	Body mass index;
LGG	cis	rs6120849	0.901	rs6058193	chr20:33734464	A/G	cg24642439	chr20:33292090	TP53INP2	0.49	6.69	0.3	6.37e-11	Protein C levels;
LGG	cis	rs798554	0.686	rs2527690	chr7:2854250	C/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.11	-0.35	4.74e-15	Height;
LGG	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11890956	chr21:40555474	PSMG1	-1.0	-22.0	-0.71	5.86e-74	Cognitive function;
LGG	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg17971929	chr21:40555470	PSMG1	-0.7	-13.01	-0.52	3.3e-33	Cognitive function;
LGG	cis	rs7666738	0.830	rs13141752	chr4:98893128	G/A	cg05340658	chr4:99064831	C4orf37	0.47	7.79	0.34	4.4e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg08975724	chr8:8085496	FLJ10661	-0.42	-7.87	-0.34	2.6e-14	Mood instability;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg16507663	chr6:150244633	RAET1G	0.42	7.89	0.34	2.26e-14	Lung cancer;
LGG	cis	rs2180341	0.521	rs12189967	chr6:127718058	G/A	cg27446573	chr6:127587934	RNF146	0.66	11.88	0.48	1.36e-28	Breast cancer;
LGG	cis	rs9858542	0.953	rs7646366	chr3:49470668	G/A	cg07274523	chr3:49395745	GPX1	0.58	9.81	0.41	9.42e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs7582180	0.838	rs6754867	chr2:100895081	A/G	cg05692746	chr2:100937584	LONRF2	0.47	7.69	0.34	9.14e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9557207	0.950	rs9805233	chr13:100014133	C/T	cg24509225	chr13:100037070	UBAC2	0.73	13.04	0.52	2.61e-33	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs9473924	0.505	rs9473949	chr6:50909659	T/A	cg14470998	chr6:50812995	TFAP2B	0.67	8.12	0.35	4.24e-15	Body mass index;
LGG	cis	rs2816316	1.000	rs1323292	chr1:192541021	G/A	cg02586212	chr1:192544902	RGS1	0.45	8.98	0.39	6.67e-18	Celiac disease;
LGG	cis	rs28386778	0.863	rs2727355	chr17:61931790	C/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.72	0.38	5.15e-17	Prudent dietary pattern;
LGG	cis	rs875971	0.756	rs4718328	chr7:65693337	A/G	cg11764359	chr7:65958608	NA	-0.74	-13.29	-0.53	2.28e-34	Aortic root size;
LGG	cis	rs7523050	0.643	rs12752417	chr1:109400639	A/C	cg08274380	chr1:109419600	GPSM2	-1.04	-11.45	-0.47	6.7399999999999993e-27	Fat distribution (HIV);
LGG	cis	rs7129556	0.906	rs72945508	chr11:77267537	G/C	cg12586386	chr11:77299805	AQP11	0.51	8.5	0.37	2.57e-16	Weight loss (gastric bypass surgery);
LGG	cis	rs709400	0.691	rs12888077	chr14:103872553	G/T	cg26031613	chr14:104095156	KLC1	-0.79	-14.2	-0.55	2.94e-38	Body mass index;
LGG	trans	rs116095464	0.614	rs78905930	chr5:246560	G/A	cg09048205	chr5:1608656	LOC728613	-0.48	-8.26	-0.36	1.5e-15	Breast cancer;
LGG	cis	rs4919087	1.000	rs4919087	chr10:99072507	C/T	cg25902810	chr10:99078978	FRAT1	-0.51	-9.6	-0.41	4.94e-20	Monocyte count;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18402987	chr7:1209562	NA	0.4	7.28	0.32	1.43e-12	Longevity;Endometriosis;
LGG	cis	rs68170813	0.559	rs6949961	chr7:106850755	G/T	cg02696742	chr7:106810147	HBP1	0.73	10.54	0.44	1.98e-23	Coronary artery disease;
LGG	cis	rs3780378	0.935	rs6476939	chr9:5084837	T/A	cg02405213	chr9:5042618	JAK2	-0.51	-8.76	-0.38	3.57e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs12477438	0.520	rs11123765	chr2:99768064	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs11155671	0.530	rs4869763	chr6:150211684	T/C	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	trans	rs11098499	0.955	rs1397608	chr4:120161744	A/G	cg25214090	chr10:38739885	LOC399744	0.62	11.22	0.46	5.07e-26	Corneal astigmatism;
LGG	cis	rs344364	0.511	rs1742464	chr16:1947335	A/G	cg26617929	chr16:1858877	NA	0.62	8.88	0.38	1.45e-17	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2836974	0.568	rs377098	chr21:40535216	G/A	cg17971929	chr21:40555470	PSMG1	-0.71	-13.42	-0.53	6.33e-35	Cognitive function;
LGG	trans	rs7178375	1.000	rs7178533	chr15:31215976	C/G	cg04373760	chr16:53404718	NA	0.53	8.06	0.35	6.56e-15	Hypertriglyceridemia;
LGG	cis	rs801193	0.569	rs7782587	chr7:66166472	C/T	cg18876405	chr7:65276391	NA	0.49	8.81	0.38	2.55e-17	Aortic root size;
LGG	cis	rs7766436	0.621	rs9348527	chr6:22604319	C/T	cg13666174	chr6:22585274	NA	-0.32	-7.76	-0.34	5.65e-14	Coronary artery disease;
LGG	cis	rs4684776	0.676	rs11714563	chr3:11313214	A/G	cg24705426	chr3:11550659	ATG7	-0.42	-7.46	-0.33	4.42e-13	Small vessel stroke;
LGG	cis	rs17221829	0.590	rs10830300	chr11:89363066	A/G	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.07	-0.39	3.36e-18	Anxiety in major depressive disorder;
LGG	cis	rs16854884	0.632	rs4563409	chr3:143682122	T/G	cg06585982	chr3:143692056	C3orf58	0.62	10.63	0.44	9.45e-24	Economic and political preferences (feminism/equality);
LGG	cis	rs8028182	0.636	rs8036758	chr15:75817562	G/A	cg20655648	chr15:75932815	IMP3	0.45	7.59	0.33	1.76e-13	Sudden cardiac arrest;
LGG	cis	rs317689	0.513	rs317659	chr12:69686132	T/A	cg20891283	chr12:69753455	YEATS4	0.71	12.8	0.51	2.5e-32	Response to diuretic therapy;
LGG	trans	rs3774749	0.565	rs2518796	chr3:50207075	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.52	8.79	0.38	2.93e-17	Intelligence (multi-trait analysis);
LGG	cis	rs929354	1.000	rs1182381	chr7:157043473	G/A	cg00092383	chr7:157075207	NA	0.42	7.35	0.32	9.32e-13	Body mass index;
LGG	cis	rs2019137	0.901	rs4849176	chr2:113977936	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.72	-12.96	-0.52	5.65e-33	Lymphocyte counts;
LGG	cis	rs2839186	0.508	rs12626873	chr21:47714848	G/T	cg12379764	chr21:47803548	PCNT	-0.65	-9.97	-0.42	2.39e-21	Testicular germ cell tumor;
LGG	cis	rs1129187	0.755	rs2274517	chr6:42932715	A/G	cg16590910	chr6:42928470	GNMT	-0.41	-11.76	-0.48	4.21e-28	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs12893668	0.572	rs2273175	chr14:104160141	T/C	cg23335576	chr14:104009727	NA	0.43	7.37	0.32	7.68e-13	Reticulocyte count;
LGG	cis	rs13118159	0.836	rs7655119	chr4:1372569	G/A	cg00684032	chr4:1343700	KIAA1530	0.44	8.68	0.37	6.77e-17	Longevity;
LGG	cis	rs7149337	0.804	rs4131981	chr14:51667504	A/T	cg23942311	chr14:51606299	NA	-0.3	-6.65	-0.3	8.47e-11	Cancer;
LGG	cis	rs3736594	0.513	rs62131881	chr2:27764781	G/T	cg27432699	chr2:27873401	GPN1	0.56	8.51	0.37	2.47e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs60843830	0.928	rs62114494	chr2:211317	C/T	cg04617936	chr2:214353	NA	-0.39	-7.21	-0.32	2.22e-12	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs10464366	0.746	rs6945402	chr7:39145385	A/T	cg10621924	chr7:39171070	POU6F2	0.45	9.23	0.39	9.81e-19	IgG glycosylation;
LGG	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg19455335	chr8:22457658	C8orf58	-0.46	-9.6	-0.41	5.14e-20	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	trans	rs61931739	0.500	rs7295779	chr12:34460652	T/C	cg26384229	chr12:38710491	ALG10B	0.86	18.9	0.66	1.86e-59	Morning vs. evening chronotype;
LGG	cis	rs2463822	0.748	rs2513053	chr11:62109473	T/A	cg06239285	chr11:62104954	ASRGL1	1.13	15.78	0.59	3.22e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs2836974	0.644	rs4818017	chr21:40690561	G/T	cg17971929	chr21:40555470	PSMG1	-0.68	-12.33	-0.5	2.1000000000000002e-30	Cognitive function;
LGG	cis	rs79839061	0.656	rs11726508	chr4:888937	C/T	cg07828340	chr4:882639	GAK	0.73	8.3	0.36	1.16e-15	Intelligence (multi-trait analysis);
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.27	-6.94	-0.31	1.33e-11	Total body bone mineral density;
LGG	trans	rs61931739	0.534	rs7310499	chr12:34212112	G/A	cg13010199	chr12:38710504	ALG10B	0.57	10.76	0.45	3.11e-24	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.850	rs11076619	chr16:89831243	C/A	cg26513180	chr16:89883248	FANCA	1.01	9.83	0.42	7.62e-21	Skin colour saturation;
LGG	cis	rs4918072	0.834	rs7073827	chr10:105708793	A/G	cg11005552	chr10:105648138	OBFC1	0.44	7.56	0.33	2.14e-13	Coronary artery disease;
LGG	cis	rs6424115	0.867	rs10917431	chr1:24174093	T/G	cg24699146	chr1:24152579	HMGCL	-0.27	-7.85	-0.34	2.84e-14	Immature fraction of reticulocytes;
LGG	cis	rs9715521	0.867	rs4860465	chr4:59832537	G/T	cg11281224	chr4:60001000	NA	-0.43	-7.2	-0.32	2.41e-12	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg26174226	chr8:58114915	NA	-0.53	-7.28	-0.32	1.4e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs7851660	0.933	rs1867277	chr9:100615914	A/G	cg13688889	chr9:100608707	NA	-0.69	-14.81	-0.57	6.98e-41	Strep throat;
LGG	cis	rs6582630	0.555	rs61932279	chr12:38349096	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-9.08	-0.39	3.04e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.48	-0.4	1.29e-19	Life satisfaction;
LGG	cis	rs7301826	0.627	rs4334059	chr12:131314214	T/C	cg11011512	chr12:131303247	STX2	0.39	8.39	0.36	5.76e-16	Plasma plasminogen activator levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19927028	chr5:64777838	ADAMTS6	0.46	6.83	0.3	2.61e-11	Gut microbiome composition (summer);
LGG	trans	rs2727020	0.553	rs4103567	chr11:49255389	C/T	cg15704280	chr7:45808275	SEPT13	-0.68	-12.48	-0.5	5.07e-31	Coronary artery disease;
LGG	cis	rs6669919	0.530	rs11587621	chr1:211668400	C/T	cg10512769	chr1:211675356	NA	0.93	23.5	0.74	5.89e-81	Intelligence (multi-trait analysis);
LGG	cis	rs6456156	0.805	rs6909252	chr6:167527097	C/T	cg07741184	chr6:167504864	NA	-0.31	-7.02	-0.31	8.05e-12	Primary biliary cholangitis;
LGG	cis	rs11644362	0.966	rs1433747	chr16:12992147	C/A	cg06890432	chr16:12997467	SHISA9	-0.32	-6.87	-0.3	2.14e-11	Positive affect;Subjective well-being;
LGG	trans	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg24247370	chr13:99142703	STK24	-0.42	-7.77	-0.34	5.01e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs1135214	chr17:41292323	T/C	cg05368731	chr17:41323189	NBR1	0.97	19.11	0.66	1.91e-60	Menopause (age at onset);
LGG	cis	rs6502050	0.637	rs74765203	chr17:80118223	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	cis	rs2963155	0.518	rs174048	chr5:142650404	T/C	cg17617527	chr5:142782415	NR3C1	0.97	12.73	0.51	4.86e-32	Breast cancer;
LGG	cis	rs910316	0.870	rs7147712	chr14:75670707	C/G	cg11812906	chr14:75593930	NEK9	-0.5	-9.06	-0.39	3.62e-18	Height;
LGG	cis	rs7737355	0.773	rs3756291	chr5:130926822	T/C	cg06307176	chr5:131281290	NA	0.53	8.81	0.38	2.53e-17	Life satisfaction;
LGG	cis	rs7618501	0.602	rs6780731	chr3:50017478	A/G	cg24308560	chr3:49941425	MST1R	0.22	6.78	0.3	3.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.920	rs115294251	chr4:119772833	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs3096299	0.509	rs4785691	chr16:89597221	A/G	cg02187348	chr16:89574699	SPG7	0.7	12.72	0.51	5.18e-32	Multiple myeloma (IgH translocation);
LGG	cis	rs6952808	0.929	rs12667688	chr7:1931030	C/T	cg05863683	chr7:1912471	MAD1L1	0.49	9.48	0.4	1.37e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs17604090	0.557	rs10279965	chr7:29717082	C/G	cg12525768	chr7:29689996	LOC646762	0.55	7.84	0.34	3.18e-14	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg14346243	chr4:90757452	SNCA	-0.4	-8.07	-0.35	6.28e-15	Dementia with Lewy bodies;
LGG	trans	rs9467711	0.606	rs67234939	chr6:26530419	A/G	cg01620082	chr3:125678407	NA	-0.6	-6.76	-0.3	4.2e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	15.38	0.58	2.08e-43	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4363385	0.818	rs10888524	chr1:153000125	A/G	cg13444842	chr1:152974279	SPRR3	-0.42	-8.77	-0.38	3.52e-17	Inflammatory skin disease;
LGG	cis	rs151997	0.925	rs27270	chr5:50183712	A/G	cg06027927	chr5:50259733	NA	-0.67	-10.96	-0.45	5.17e-25	Callous-unemotional behaviour;
LGG	cis	rs3749237	0.595	rs12489092	chr3:49550914	G/C	cg06212747	chr3:49208901	KLHDC8B	0.43	7.01	0.31	8.44e-12	Resting heart rate;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27654529	chr19:35418345	ZNF30	0.43	7.07	0.31	5.8e-12	Gut microbiome composition (summer);
LGG	cis	rs11674184	0.659	rs11679605	chr2:11722468	G/A	cg07314298	chr2:11723111	GREB1	-0.75	-15.82	-0.59	2.15e-45	Endometriosis;
LGG	cis	rs477692	1.000	rs479478	chr10:131428959	G/A	cg05714579	chr10:131428358	MGMT	0.56	11.55	0.47	2.84e-27	Response to temozolomide;
LGG	cis	rs8062405	0.755	rs62034355	chr16:28581038	G/C	cg07382826	chr16:28625726	SULT1A1	0.43	9.04	0.39	4.23e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs780096	0.506	rs1262430	chr2:27673798	T/C	cg27432699	chr2:27873401	GPN1	-0.48	-8.12	-0.35	4.17e-15	Total body bone mineral density;
LGG	cis	rs11155671	0.530	rs6939761	chr6:150210994	T/C	cg11878867	chr6:150167359	LRP11	-0.37	-7.74	-0.34	6.33e-14	Testicular germ cell tumor;
LGG	trans	rs7824557	0.602	rs11781375	chr8:11204532	A/G	cg06636001	chr8:8085503	FLJ10661	0.41	7.05	0.31	6.75e-12	Retinal vascular caliber;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg05596135	chr16:72128010	TXNL4B;DHX38	-0.47	-6.99	-0.31	9.84e-12	Systemic lupus erythematosus;
LGG	cis	rs9487094	0.670	rs34928881	chr6:109848049	A/G	cg16315928	chr6:109776240	MICAL1	0.46	8.06	0.35	6.57e-15	Height;
LGG	cis	rs28655083	0.956	rs7184198	chr16:77069490	T/G	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.56	-9.27	-0.4	7.09e-19	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs4667594	0.905	rs11679947	chr2:170008644	A/G	cg09507928	chr5:140027484	IK;NDUFA2	0.47	7.05	0.31	6.74e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs782590	0.967	rs17278044	chr2:55748217	G/C	cg18811423	chr2:55921094	PNPT1	0.87	20.02	0.68	1.05e-64	Metabolic syndrome;
LGG	cis	rs17384381	1.000	rs12133722	chr1:85873237	C/T	cg16011679	chr1:85725395	C1orf52	0.58	10.16	0.43	4.82e-22	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs9929218	0.861	rs3114409	chr16:68732049	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.86	-15.41	-0.58	1.43e-43	Colorectal cancer;
LGG	cis	rs10771431	0.597	rs3759275	chr12:9353828	A/T	cg08997352	chr12:9597637	DDX12	-0.75	-13.72	-0.54	3.57e-36	Breast size;
LGG	cis	rs113835537	0.502	rs7104378	chr11:66216675	A/G	cg24851651	chr11:66362959	CCS	0.44	7.71	0.34	7.89e-14	Airway imaging phenotypes;
LGG	cis	rs7267979	1.000	rs4815418	chr20:25382211	T/G	cg06421707	chr20:25228305	PYGB	-0.49	-10.54	-0.44	1.96e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs561341	1.000	rs693116	chr17:30246124	C/T	cg20587970	chr11:113659929	NA	-1.36	-24.15	-0.75	5.62e-84	Hip circumference adjusted for BMI;
LGG	cis	rs9596863	0.898	rs9568906	chr13:54335197	A/G	ch.13.53330881F	chr13:54432880	NA	0.54	7.32	0.32	1.09e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs7666738	0.578	rs1989109	chr4:98881246	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.3	0.36	1.19e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17270561	0.887	rs12201170	chr6:25866247	A/G	cg16482183	chr6:26056742	HIST1H1C	0.83	11.62	0.48	1.47e-27	Iron status biomarkers;
LGG	cis	rs6952808	0.792	rs4421257	chr7:1955152	T/C	cg00106254	chr7:1943704	MAD1L1	-0.45	-8.08	-0.35	5.57e-15	Bipolar disorder and schizophrenia;
LGG	trans	rs3733585	0.605	rs7656624	chr4:10121097	T/C	cg26043149	chr18:55253948	FECH	-0.46	-7.68	-0.34	9.52e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs3820928	0.874	rs7582251	chr2:227791703	G/T	cg11843606	chr2:227700838	RHBDD1	-0.45	-7.74	-0.34	6.4e-14	Pulmonary function;
LGG	cis	rs9487051	0.872	rs9386794	chr6:109611521	A/C	cg12927641	chr6:109611667	NA	-0.37	-7.11	-0.31	4.46e-12	Reticulocyte fraction of red cells;
LGG	cis	rs7811142	1.000	rs67239991	chr7:100046504	A/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.73	0.38	4.59e-17	Platelet count;
LGG	cis	rs17376456	0.569	rs10476520	chr5:93058290	A/C	cg25358565	chr5:93447407	FAM172A	0.85	11.64	0.48	1.18e-27	Diabetic retinopathy;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.64	-0.37	8.9e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg08621203	chr6:150244597	RAET1G	0.45	7.62	0.33	1.47e-13	Lung cancer;
LGG	cis	rs2228479	0.557	rs11648881	chr16:89862434	T/C	cg27400746	chr16:89904261	SPIRE2	-1.15	-16.4	-0.61	5.66e-48	Skin colour saturation;
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg19357499	chr8:144660631	NAPRT1	0.89	7.07	0.31	5.59e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs7100689	0.577	rs9420359	chr10:82054873	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.6	0.56	5.39e-40	Post bronchodilator FEV1;
LGG	cis	rs13082711	0.911	rs11709954	chr3:27421427	C/T	cg02860705	chr3:27208620	NA	0.84	15.58	0.59	2.73e-44	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7523050	0.730	rs7519107	chr1:109399367	A/C	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	cis	rs372883	0.967	rs1153280	chr21:30678072	A/G	cg24692254	chr21:30365293	RNF160	0.43	7.42	0.33	5.75e-13	Pancreatic cancer;
LGG	cis	rs12887734	0.524	rs17791722	chr14:104286210	C/T	cg26031613	chr14:104095156	KLC1	-0.56	-8.8	-0.38	2.71e-17	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7568458	0.777	rs12473819	chr2:85773061	A/G	cg02493740	chr2:85810744	VAMP5	-0.41	-7.29	-0.32	1.36e-12	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2228479	0.850	rs12598316	chr16:89916600	C/A	cg00800038	chr16:89945340	TCF25	-0.73	-8.33	-0.36	9.06e-16	Skin colour saturation;
LGG	cis	rs10197940	0.578	rs2432956	chr2:152287831	C/T	cg19508488	chr2:152266495	RIF1	-0.42	-6.8	-0.3	3.15e-11	Lung cancer;
LGG	cis	rs738322	0.772	rs9619724	chr22:38517880	T/G	cg03162506	chr22:38580953	NA	0.31	7.49	0.33	3.58e-13	Cutaneous nevi;
LGG	cis	rs3204270	0.639	rs6565620	chr17:79658100	C/T	cg18367735	chr17:79674897	NA	0.6	7.97	0.35	1.21e-14	Dental caries;
LGG	trans	rs12599106	0.624	rs2173885	chr16:34992749	G/A	cg14668821	chr17:77704760	ENPP7	0.43	8.47	0.37	3.37e-16	Menopause (age at onset);
LGG	cis	rs7568458	0.846	rs10179195	chr2:85762761	A/G	cg02493740	chr2:85810744	VAMP5	-0.41	-7.39	-0.32	6.74e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs1799949	1.000	rs12944430	chr17:41330820	C/G	cg05368731	chr17:41323189	NBR1	0.97	19.04	0.66	3.98e-60	Menopause (age at onset);
LGG	cis	rs12348691	0.503	rs907576	chr9:100615359	C/T	cg13688889	chr9:100608707	NA	-0.83	-16.32	-0.6	1.28e-47	Alopecia areata;
LGG	cis	rs3793683	1.000	rs3793683	chr10:134568387	G/T	cg27286337	chr10:134555280	INPP5A	-1.03	-21.98	-0.71	6.98e-74	Migraine;
LGG	cis	rs4689388	0.609	rs4234729	chr4:6286087	T/C	cg00701064	chr4:6280414	WFS1	0.59	10.73	0.45	3.92e-24	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs116305850	chr4:119779892	A/G	cg14228332	chr4:119757509	SEC24D	0.99	10.19	0.43	3.97e-22	Cannabis dependence symptom count;
LGG	cis	rs721917	0.506	rs2758556	chr10:81690985	G/T	cg25562619	chr10:81652821	NA	0.37	8.19	0.36	2.62e-15	Chronic obstructive pulmonary disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05002732	chr11:19262474	E2F8	0.52	7.48	0.33	3.71e-13	Gut microbiome composition (summer);
LGG	cis	rs3796352	1.000	rs11713206	chr3:52999243	A/G	cg12962167	chr3:53033115	SFMBT1	0.77	7.88	0.34	2.38e-14	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs4262150	0.920	rs67988891	chr5:152204741	C/G	cg12297329	chr5:152029980	NA	-0.64	-12.31	-0.5	2.43e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs4319547	0.585	rs7952868	chr12:122846949	A/G	cg23029597	chr12:123009494	RSRC2	-0.9	-16.19	-0.6	4.83e-47	Body mass index;
LGG	cis	rs7937682	0.921	rs7130753	chr11:111470567	C/T	cg19812747	chr11:111475976	SIK2	0.5	9.89	0.42	4.83e-21	Primary sclerosing cholangitis;
LGG	trans	rs1005277	0.579	rs2474574	chr10:38387295	C/T	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13118159	0.778	rs12640984	chr4:1338834	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	9.94	0.42	3.12e-21	Longevity;
LGG	cis	rs28386778	0.897	rs2665823	chr17:61885917	G/A	cg03528353	chr17:61819722	STRADA	0.45	7.57	0.33	2.05e-13	Prudent dietary pattern;
LGG	cis	rs1023500	0.507	rs6002600	chr22:42488906	G/A	cg05082376	chr22:42548792	NA	0.37	7.67	0.34	9.92e-14	Schizophrenia;
LGG	cis	rs6502050	0.731	rs76421195	chr17:80109326	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg12662530	chr10:64564276	ADO	-0.35	-6.67	-0.3	7.53e-11	Brain structure;
LGG	cis	rs7166081	1.000	rs35524716	chr15:67578987	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.3	-6.79	-0.3	3.53e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs62238980	0.614	rs79221399	chr22:32368918	C/A	cg00543991	chr22:32367038	NA	0.82	8.92	0.38	1.06e-17	Childhood ear infection;
LGG	cis	rs559928	0.548	rs11231713	chr11:63931849	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.35	0.32	8.91e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs78456975	0.506	rs10167704	chr2:1571037	G/C	cg01028140	chr2:1542097	TPO	-0.47	-8.65	-0.37	8.81e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs929354	0.709	rs1182363	chr7:157019151	A/G	cg05182265	chr7:156933206	UBE3C	0.37	7.48	0.33	3.74e-13	Body mass index;
LGG	cis	rs9517320	0.534	rs4772090	chr13:99150674	T/C	cg07423050	chr13:99094983	FARP1	-0.57	-11.06	-0.46	2.18e-25	Longevity;
LGG	trans	rs3857536	0.611	rs7748258	chr6:66932840	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.11e-14	Blood trace element (Cu levels);
LGG	cis	rs9916302	0.706	rs6503504	chr17:37514412	A/G	cg00129232	chr17:37814104	STARD3	0.57	8.54	0.37	1.92e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs10464366	0.746	rs12670510	chr7:39142146	A/G	cg15212455	chr7:39170539	POU6F2	0.47	10.76	0.45	3e-24	IgG glycosylation;
LGG	trans	rs9393777	0.920	rs13196692	chr6:27379119	C/T	cg01620082	chr3:125678407	NA	-1.01	-9.68	-0.41	2.75e-20	Intelligence (multi-trait analysis);
LGG	cis	rs9393777	0.778	rs77666565	chr6:26851415	G/A	cg12826209	chr6:26865740	GUSBL1	0.75	7.28	0.32	1.4e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1005277	0.579	rs2983343	chr10:38383332	A/G	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.2	-0.32	2.45e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs3784262	0.692	rs12914388	chr15:58283843	T/C	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.94	-0.31	1.34e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs2251260	0.735	rs1068190	chr14:62019573	A/G	cg23386212	chr14:62041363	NA	0.51	6.9	0.31	1.73e-11	Yeast infection;
LGG	cis	rs972578	0.645	rs738534	chr22:43237639	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.65	-0.3	8.18e-11	Mean platelet volume;
LGG	cis	rs72772090	0.539	rs56395748	chr5:96176893	G/T	cg00188032	chr5:96141721	ERAP1	0.55	7.21	0.32	2.35e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs5758659	1.000	rs134900	chr22:42683343	C/G	cg15557168	chr22:42548783	NA	-0.4	-9.18	-0.39	1.48e-18	Cognitive function;
LGG	cis	rs35110281	0.641	rs4818861	chr21:45123807	A/G	cg04455712	chr21:45112962	RRP1B	0.55	9.51	0.4	1.02e-19	Mean corpuscular volume;
LGG	cis	rs9457247	1.000	rs448060	chr6:167382622	A/G	cg07741184	chr6:167504864	NA	0.31	6.94	0.31	1.34e-11	Crohn's disease;
LGG	cis	rs35110281	0.659	rs11909064	chr21:45092095	G/C	cg04455712	chr21:45112962	RRP1B	0.52	9.86	0.42	6.06e-21	Mean corpuscular volume;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg13955432	chr7:117864720	ANKRD7	0.36	6.69	0.3	6.27e-11	Menarche (age at onset);
LGG	cis	rs10504229	0.645	rs35142596	chr8:58128151	C/T	cg02725872	chr8:58115012	NA	-1.03	-15.12	-0.57	2.83e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs7747724	0.692	rs9465891	chr6:20778559	T/C	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.37	-0.4	3.1400000000000002e-19	Bladder cancer;
LGG	trans	rs9393777	0.623	rs7773938	chr6:26474044	C/T	cg06606381	chr12:133084897	FBRSL1	-0.53	-6.82	-0.3	2.82e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg07211511	chr3:129823064	LOC729375	-0.64	-8.61	-0.37	1.19e-16	Blood pressure (smoking interaction);
LGG	trans	rs2832077	0.527	rs2776210	chr21:30268558	A/G	cg14791747	chr16:20752902	THUMPD1	-0.55	-9.9	-0.42	4.18e-21	Cognitive test performance;
LGG	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg20476274	chr7:133979776	SLC35B4	0.66	11.68	0.48	8.17e-28	Mean platelet volume;
LGG	cis	rs6547631	0.622	rs6740635	chr2:85933527	C/G	cg24620635	chr2:85921963	GNLY	0.51	10.2	0.43	3.48e-22	Blood protein levels;
LGG	cis	rs2839186	0.770	rs2839984	chr21:47671690	A/G	cg05896524	chr21:47604654	C21orf56	0.64	11.53	0.47	3.23e-27	Testicular germ cell tumor;
LGG	cis	rs8179	0.552	rs740047	chr7:92230162	A/G	cg15732164	chr7:92237376	CDK6	-0.45	-7.4	-0.33	6.46e-13	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs3793683	0.520	rs4880426	chr10:134590610	G/A	cg27297192	chr10:134578999	INPP5A	0.32	7.55	0.33	2.38e-13	Migraine;
LGG	trans	rs9388451	0.839	rs3799709	chr6:126078361	A/G	cg05039488	chr6:79577232	IRAK1BP1	-0.52	-9.61	-0.41	4.81e-20	Brugada syndrome;
LGG	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs6088590	0.965	rs6088620	chr20:33412022	A/G	cg24642439	chr20:33292090	TP53INP2	0.82	15.04	0.57	6.72e-42	Coronary artery disease;
LGG	cis	rs6952808	0.656	rs12699646	chr7:2093162	T/G	cg19147804	chr7:1989927	MAD1L1	0.57	11.51	0.47	3.92e-27	Bipolar disorder and schizophrenia;
LGG	cis	rs7615952	0.641	rs4422257	chr3:125774363	A/G	cg18479299	chr3:125709523	NA	-0.58	-7.48	-0.33	3.82e-13	Blood pressure (smoking interaction);
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.61	-10.63	-0.44	9.14e-24	Obesity-related traits;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg14675211	chr2:100938903	LONRF2	0.65	11.21	0.46	5.98e-26	Intelligence (multi-trait analysis);
LGG	cis	rs2224391	0.534	rs2773308	chr6:5246833	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	-0.58	-7.61	-0.33	1.55e-13	Height;
LGG	cis	rs13382275	1.000	rs13382275	chr2:965579	A/G	cg10902693	chr2:875509	NA	0.45	7.66	0.34	1.13e-13	Post bronchodilator FEV1 in COPD;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg19183879	chr15:85880815	NA	-0.48	-9.09	-0.39	2.93e-18	Coronary artery disease;
LGG	cis	rs28595532	0.920	rs17323034	chr4:119606518	G/A	cg14228332	chr4:119757509	SEC24D	0.98	9.77	0.41	1.27e-20	Cannabis dependence symptom count;
LGG	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs6032067	0.673	rs6017532	chr20:43904095	C/T	cg10761708	chr20:43804764	PI3	0.58	8.9	0.38	1.23e-17	Blood protein levels;
LGG	cis	rs1865760	0.566	rs9295686	chr6:26081983	G/C	cg17691542	chr6:26056736	HIST1H1C	0.57	10.29	0.43	1.62e-22	Height;
LGG	cis	rs2439831	0.867	rs2920781	chr15:43924682	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.92	10.63	0.44	9.01e-24	Lung cancer in ever smokers;
LGG	cis	rs9379850	0.527	rs9393704	chr6:26358775	T/C	cg12826209	chr6:26865740	GUSBL1	0.76	8.03	0.35	8.07e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg07791516	chr6:150247246	NA	0.32	6.92	0.31	1.47e-11	Lung cancer;
LGG	cis	rs3742264	0.656	rs9526133	chr13:46615001	T/A	cg15192986	chr13:46630673	CPB2	-0.37	-7.1	-0.31	4.75e-12	Blood protein levels;
LGG	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg07243736	chr16:783730	NARFL	0.4	6.87	0.3	2.06e-11	Height;
LGG	cis	rs67311347	0.955	rs1129200	chr3:40532257	T/C	cg13683864	chr3:40499215	RPL14	-1.09	-23.92	-0.74	6.61e-83	Renal cell carcinoma;
LGG	cis	rs12310956	0.515	rs115836245	chr12:33951369	T/C	cg06521331	chr12:34319734	NA	-0.59	-10.98	-0.45	4.49e-25	Morning vs. evening chronotype;
LGG	cis	rs9790314	0.791	rs6809256	chr3:161026513	G/A	cg04691961	chr3:161091175	C3orf57	-0.53	-12.16	-0.49	1.06e-29	Morning vs. evening chronotype;
LGG	cis	rs7762018	0.941	rs4716384	chr6:170109184	T/A	cg15038512	chr6:170123185	PHF10	0.51	6.68	0.3	6.72e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg15948088	chr11:109293068	C11orf87	0.45	8.13	0.35	3.91e-15	Schizophrenia;
LGG	cis	rs66561647	1.000	rs66561647	chr8:128971861	C/T	cg05480350	chr8:128972681	MIR1205;PVT1	0.47	8.19	0.36	2.61e-15	Hemoglobin concentration;
LGG	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg01028140	chr2:1542097	TPO	-0.47	-8.81	-0.38	2.57e-17	IgG glycosylation;
LGG	cis	rs4631830	0.863	rs2249986	chr10:51521684	T/G	cg10326726	chr10:51549505	MSMB	-0.7	-14.63	-0.56	4.06e-40	Prostate-specific antigen levels;
LGG	cis	rs1008375	0.966	rs10489036	chr4:17697687	A/G	cg02297831	chr4:17616191	MED28	0.46	8.36	0.36	7.22e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7552404	0.961	rs211710	chr1:76109038	G/A	cg22875332	chr1:76189707	ACADM	-0.61	-9.66	-0.41	3.11e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs3749237	0.964	rs1799845	chr3:49847623	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.09	0.39	3.02e-18	Resting heart rate;
LGG	cis	rs12188164	0.580	rs2672755	chr5:457249	G/T	cg00049323	chr5:472564	LOC25845	0.38	8.24	0.36	1.76e-15	Cystic fibrosis severity;
LGG	cis	rs701145	0.550	rs450115	chr3:153923418	A/C	cg12800244	chr3:153838788	SGEF	0.83	8.44	0.37	4.06e-16	Coronary artery disease;
LGG	cis	rs1865760	0.786	rs1436308	chr6:25939567	T/G	cg03517284	chr6:25882590	NA	-0.38	-6.74	-0.3	4.77e-11	Height;
LGG	cis	rs7618915	0.547	rs62255371	chr3:52747321	A/G	cg10802521	chr3:52805072	NEK4	-0.42	-7.15	-0.32	3.47e-12	Bipolar disorder;
LGG	cis	rs10464366	0.746	rs34792397	chr7:39146331	G/A	cg21665744	chr7:39171113	POU6F2	0.39	7.97	0.35	1.29e-14	IgG glycosylation;
LGG	cis	rs10256972	0.552	rs2949192	chr7:1203841	C/T	cg07308232	chr7:1071921	C7orf50	-0.51	-9.56	-0.41	6.8e-20	Longevity;Endometriosis;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.603	rs6985921	chr8:58150853	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-7.09	-0.31	4.96e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3806843	0.966	rs2563263	chr5:140137644	A/G	cg19875535	chr5:140030758	IK	0.53	10.88	0.45	1.08e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs12210905	0.688	rs12195783	chr6:27444345	A/G	cg15325629	chr6:28072465	NA	1.0	7.69	0.34	8.97e-14	Hip circumference adjusted for BMI;
LGG	cis	rs12762955	0.507	rs7095853	chr10:1040798	T/C	cg18964960	chr10:1102726	WDR37	-0.45	-6.66	-0.3	7.69e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs6032067	0.538	rs13042667	chr20:43739664	C/T	cg10761708	chr20:43804764	PI3	0.68	9.99	0.42	2.12e-21	Blood protein levels;
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.9	13.57	0.53	1.52e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7011049	0.915	rs113906680	chr8:53868320	T/C	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09864156	chr10:70939728	SUPV3L1	0.47	7.02	0.31	7.87e-12	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg07362569	chr17:61921086	SMARCD2	0.47	8.99	0.39	6.58e-18	Prudent dietary pattern;
LGG	cis	rs870825	0.932	rs10034861	chr4:185577450	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	18.34	0.65	7.27e-57	Blood protein levels;
LGG	cis	rs58688157	0.705	rs7122021	chr11:595810	A/G	cg01842473	chr11:617407	IRF7;MUPCDH	-0.56	-7.79	-0.34	4.32e-14	Systemic lupus erythematosus;
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg04025307	chr7:1156635	C7orf50	0.73	9.76	0.41	1.38e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs10805346	0.531	rs12498927	chr4:10115523	C/T	cg26043149	chr18:55253948	FECH	-0.4	-6.91	-0.31	1.65e-11	Urate levels in overweight individuals;Urate levels in obese individuals;
LGG	trans	rs7939886	0.920	rs17150102	chr11:55904382	A/C	cg03929089	chr4:120376271	NA	0.76	7.8	0.34	4.29e-14	Myopia (pathological);
LGG	cis	rs12477438	0.765	rs7605734	chr2:99644068	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	trans	rs916888	0.779	rs199528	chr17:44843136	C/T	cg22433210	chr17:43662623	NA	0.91	14.57	0.56	7.39e-40	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg08017756	chr2:100939284	LONRF2	-0.29	-6.93	-0.31	1.43e-11	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.619	rs12533585	chr7:65984605	G/C	cg18876405	chr7:65276391	NA	0.63	11.74	0.48	4.71e-28	Aortic root size;
LGG	cis	rs9911578	1.000	rs302854	chr17:56683612	G/A	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	trans	rs916888	0.610	rs199529	chr17:44837217	A/C	cg22968622	chr17:43663579	NA	0.93	17.91	0.64	7.28e-55	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs9543976	1.000	rs1535724	chr13:76183273	G/C	cg01531495	chr13:76123901	UCHL3	0.64	7.74	0.34	6.17e-14	Diabetic retinopathy;
LGG	cis	rs377457	1.000	rs4843575	chr16:85735642	G/A	cg08768472	chr16:85689701	KIAA0182	0.43	8.08	0.35	5.54e-15	Type 2 diabetes;
LGG	cis	rs2032447	0.869	rs199752	chr6:26012875	C/T	cg18357526	chr6:26021779	HIST1H4A	0.94	18.28	0.65	1.28e-56	Intelligence (multi-trait analysis);
LGG	trans	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg21659725	chr3:3221576	CRBN	-0.63	-10.04	-0.42	1.37e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3824344	0.507	rs2297105	chr9:37020622	A/C	cg14294708	chr9:37120828	ZCCHC7	-0.47	-7.83	-0.34	3.34e-14	Intelligence;
LGG	cis	rs6062302	0.522	rs2236503	chr20:62224595	G/A	cg16989086	chr20:62203971	PRIC285	0.49	7.13	0.31	3.97e-12	Glioblastoma;
LGG	cis	rs861020	0.710	rs7516902	chr1:210022179	A/G	cg05527609	chr1:210001259	C1orf107	0.73	10.99	0.45	4.13e-25	Orofacial clefts;
LGG	cis	rs2245008	0.671	rs907036	chr16:83989850	A/T	cg27171569	chr16:83987465	OSGIN1	0.72	16.16	0.6	6.4e-47	Pursuit maintenance gain;
LGG	cis	rs16922576	0.656	rs2093448	chr9:5230444	T/G	cg02405213	chr9:5042618	JAK2	-0.69	-12.34	-0.5	1.86e-30	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2404602	0.692	rs1116535	chr15:77009514	C/G	cg05677249	chr15:77158041	SCAPER	0.31	6.73	0.3	5.06e-11	Blood metabolite levels;
LGG	cis	rs6951245	0.529	rs10262070	chr7:1141738	C/T	cg02733842	chr7:1102375	C7orf50	0.42	7.35	0.32	8.82e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9549367	0.789	rs9577220	chr13:113908294	T/A	cg18105134	chr13:113819100	PROZ	-0.68	-13.96	-0.54	3.19e-37	Platelet distribution width;
LGG	cis	rs10865541	0.902	rs13399186	chr2:3423201	G/T	cg13173536	chr2:3403300	TTC15	-0.33	-6.83	-0.3	2.73e-11	Obesity-related traits;
LGG	cis	rs4242434	0.536	rs1871900	chr8:22481449	A/G	cg02227867	chr8:22457446	C8orf58	-0.37	-7.19	-0.32	2.69e-12	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs2842992	0.789	rs7758895	chr6:160193465	T/C	cg16489826	chr6:160211363	TCP1;MRPL18	0.77	12.81	0.51	2.34e-32	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs634534	0.562	rs642293	chr11:65730217	G/A	cg26695010	chr11:65641043	EFEMP2	-0.53	-9.1	-0.39	2.75e-18	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs4862750	0.872	rs7671914	chr4:187878165	A/G	cg22105103	chr4:187893119	NA	0.57	10.92	0.45	7.68e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs2153904	0.793	rs12748961	chr1:205676263	T/C	cg23034840	chr1:205782522	SLC41A1	-0.73	-8.38	-0.36	6.49e-16	Prostate-specific antigen levels;
LGG	cis	rs17767392	0.834	rs56362777	chr14:71735418	G/C	cg02058870	chr14:72053146	SIPA1L1	0.44	8.5	0.37	2.67e-16	Mitral valve prolapse;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04872869	chr1:28908637	SNORA16A;SNHG12	0.44	6.75	0.3	4.43e-11	Gut microbiome composition (summer);
LGG	cis	rs2075371	0.501	rs1643057	chr7:134027521	A/G	cg11752832	chr7:134001865	SLC35B4	0.48	8.38	0.36	6.18e-16	Mean platelet volume;
LGG	cis	rs2839186	0.872	rs13046834	chr21:47701485	T/C	cg12016809	chr21:47604291	C21orf56	0.49	8.51	0.37	2.45e-16	Testicular germ cell tumor;
LGG	cis	rs7572733	0.534	rs700688	chr2:198723833	A/G	cg00792783	chr2:198669748	PLCL1	-0.69	-11.25	-0.46	3.91e-26	Dermatomyositis;
LGG	cis	rs36093844	0.706	rs17817230	chr11:85554057	A/G	cg16165120	chr11:85566439	CCDC83	-0.46	-7.4	-0.33	6.47e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs9300255	0.509	rs641760	chr12:123518866	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.39	0.32	7.12e-13	Neutrophil percentage of white cells;
LGG	cis	rs2540226	0.530	rs2716687	chr2:39903463	C/T	cg18968196	chr2:39892502	TMEM178	-0.3	-8.25	-0.36	1.61e-15	Personality dimensions;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg04861929	chr11:109293070	C11orf87	-0.87	-17.5	-0.63	5.37e-53	Schizophrenia;
LGG	cis	rs13102973	0.932	rs6858552	chr4:135864734	C/T	cg14419869	chr4:135874104	NA	-0.57	-11.01	-0.46	3.37e-25	Subjective well-being;
LGG	cis	rs9322193	0.923	rs9322200	chr6:149951214	G/A	cg08621203	chr6:150244597	RAET1G	0.44	7.65	0.33	1.19e-13	Lung cancer;
LGG	cis	rs7666738	0.830	rs28619044	chr4:98789814	G/C	cg05340658	chr4:99064831	C4orf37	0.47	7.74	0.34	6.45e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11155671	0.530	rs7764376	chr6:150210344	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg20991723	chr1:152506922	NA	-0.67	-12.98	-0.52	4.38e-33	Hair morphology;
LGG	trans	rs7618501	0.633	rs2353579	chr3:50027774	C/T	cg21659725	chr3:3221576	CRBN	0.63	11.71	0.48	6.17e-28	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.527	rs10769595	chr11:49638212	A/G	cg15704280	chr7:45808275	SEPT13	-0.89	-14.24	-0.55	2.12e-38	Height;
LGG	cis	rs1665650	0.957	rs1638422	chr10:118488584	T/C	cg14919929	chr10:118506882	NA	0.49	8.61	0.37	1.15e-16	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg02725872	chr8:58115012	NA	-1.03	-15.3	-0.58	4.53e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	1.000	rs9322193	chr6:149919143	T/G	cg15971980	chr6:150254442	NA	0.46	8.6	0.37	1.23e-16	Lung cancer;
LGG	cis	rs7100689	0.725	rs2185425	chr10:82139941	T/C	cg01528321	chr10:82214614	TSPAN14	0.97	17.43	0.63	1.15e-52	Post bronchodilator FEV1;
LGG	cis	rs4845570	1.000	rs6673002	chr1:151743275	G/T	cg07092448	chr1:151763213	TDRKH	1.1	18.7	0.66	1.57e-58	Coronary artery disease;
LGG	cis	rs7312933	0.584	rs6582395	chr12:42700141	T/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.51	7.91	0.35	1.86e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs240764	0.717	rs13208757	chr6:101175014	C/T	cg21058520	chr6:100914733	NA	0.38	6.7	0.3	6.02e-11	Neuroticism;
LGG	cis	rs9914544	0.933	rs11871889	chr17:18771425	T/C	cg26378065	chr17:18585709	ZNF286B	0.52	9.67	0.41	2.91e-20	Educational attainment (years of education);
LGG	cis	rs9921222	0.585	rs7195617	chr16:376781	A/G	cg10349874	chr16:420996	TMEM8A;MRPL28	0.54	9.87	0.42	5.53e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs11098499	0.954	rs3733520	chr4:120423480	C/G	cg09307838	chr4:120376055	NA	0.81	13.79	0.54	1.7e-36	Corneal astigmatism;
LGG	cis	rs9303401	0.703	rs8077052	chr17:57208921	T/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.53	8.75	0.38	4.07e-17	Cognitive test performance;
LGG	trans	rs9467711	0.722	rs35144506	chr6:26739487	A/G	cg06606381	chr12:133084897	FBRSL1	-1.11	-9.86	-0.42	6.13e-21	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs977987	0.931	rs1424013	chr16:75495986	T/C	cg07303275	chr16:75499416	TMEM170A	0.42	7.56	0.33	2.16e-13	Dupuytren's disease;
LGG	cis	rs2274273	0.870	rs10144345	chr14:55847737	T/C	cg04306507	chr14:55594613	LGALS3	0.63	18.01	0.64	2.48e-55	Protein biomarker;
LGG	cis	rs6500602	0.623	rs9929311	chr16:4510426	T/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.49	10.31	0.43	1.4e-22	Schizophrenia;
LGG	cis	rs6669919	0.553	rs7546343	chr1:211671801	C/T	cg10512769	chr1:211675356	NA	-0.93	-23.57	-0.74	2.75e-81	Intelligence (multi-trait analysis);
LGG	cis	rs7824557	0.602	rs7815463	chr8:11210983	A/G	cg21775007	chr8:11205619	TDH	0.82	14.49	0.56	1.66e-39	Retinal vascular caliber;
LGG	cis	rs738322	0.600	rs4821751	chr22:38564457	T/C	cg03162506	chr22:38580953	NA	0.39	10.06	0.42	1.13e-21	Cutaneous nevi;
LGG	cis	rs60871478	1.000	rs62432252	chr7:802886	C/G	cg22643751	chr7:855365	UNC84A	0.37	7.0	0.31	8.8e-12	Cerebrospinal P-tau181p levels;
LGG	cis	rs2153535	0.580	rs9505448	chr6:8459804	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.08	0.39	3.18e-18	Motion sickness;
LGG	cis	rs62400317	0.731	rs17288320	chr6:45338703	T/C	cg18551225	chr6:44695536	NA	-0.56	-8.38	-0.36	6.46e-16	Total body bone mineral density;
LGG	trans	rs2204008	0.603	rs4397954	chr12:38089157	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.07	-0.39	3.48e-18	Bladder cancer;
LGG	cis	rs17366136	1.000	rs17366136	chr7:22601127	A/C	cg11260715	chr7:22602834	NA	0.4	6.85	0.3	2.29e-11	Coronary atherosclerosis (increased number of diseased vessels) (traffic exposure interaction);
LGG	cis	rs2051211	0.895	rs17037798	chr3:38555474	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.61	-9.32	-0.4	4.94e-19	QRS duration;
LGG	cis	rs12325245	0.536	rs12709002	chr16:58614337	A/C	cg01152986	chr16:58549298	SETD6	0.84	7.35	0.32	9.07e-13	Schizophrenia;
LGG	cis	rs1816752	0.870	rs9318529	chr13:24998328	A/G	cg02811702	chr13:24901961	NA	0.38	7.23	0.32	1.96e-12	Obesity-related traits;
LGG	cis	rs7726354	0.793	rs57841600	chr5:56005065	A/G	cg27303933	chr5:56029418	NA	0.48	6.77	0.3	3.83e-11	Breast cancer (early onset);
LGG	cis	rs868036	0.918	rs4776967	chr15:68033922	T/C	cg05925327	chr15:68127851	NA	-0.36	-8.36	-0.36	7.29e-16	Restless legs syndrome;
LGG	cis	rs9403521	0.898	rs12207002	chr6:143975422	G/A	cg18240653	chr6:144019428	PHACTR2	-0.63	-9.84	-0.42	7.41e-21	Obesity-related traits;
LGG	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg08297393	chr2:100937505	LONRF2	-0.54	-9.41	-0.4	2.42e-19	Intelligence (multi-trait analysis);
LGG	cis	rs986417	0.786	rs2038277	chr14:61083662	G/A	cg27398547	chr14:60952738	C14orf39	0.76	7.08	0.31	5.44e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs116095464	1.000	rs3936676	chr5:353677	T/C	cg22496380	chr5:211416	CCDC127	-1.16	-10.07	-0.42	1.06e-21	Breast cancer;
LGG	cis	rs7737355	0.812	rs40991	chr5:131000654	C/A	cg06307176	chr5:131281290	NA	0.57	9.31	0.4	5.1e-19	Life satisfaction;
LGG	cis	rs847577	0.609	rs17435590	chr7:97784061	T/C	cg13397024	chr7:97797637	LMTK2	-0.35	-6.69	-0.3	6.37e-11	Breast cancer;
LGG	trans	rs6601327	0.632	rs6980595	chr8:9651162	G/A	cg16141378	chr3:129829833	LOC729375	0.35	7.95	0.35	1.45e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs35110281	0.748	rs2838324	chr21:44999820	T/C	cg04455712	chr21:45112962	RRP1B	0.51	9.51	0.4	1.01e-19	Mean corpuscular volume;
LGG	trans	rs561341	1.000	rs117979353	chr17:30272866	A/G	cg20587970	chr11:113659929	NA	-1.36	-24.22	-0.75	2.55e-84	Hip circumference adjusted for BMI;
LGG	cis	rs868036	0.645	rs4492996	chr15:68113240	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.35	-7.79	-0.34	4.56e-14	Restless legs syndrome;
LGG	cis	rs10883723	0.810	rs7072351	chr10:104265047	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.73	13.98	0.54	2.73e-37	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6089829	0.962	rs4997812	chr20:61663153	T/G	cg03213289	chr20:61660250	NA	0.66	14.43	0.56	2.92e-39	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08402439	chr4:180980552	NA	0.47	8.04	0.35	7.6e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs10191773	0.535	rs72833432	chr2:113102746	T/C	cg24977338	chr2:113188963	RGPD8;RGPD5	-0.59	-9.15	-0.39	1.81e-18	Yeast infection;
LGG	cis	rs561341	1.000	rs72821952	chr17:30248133	T/A	cg13647721	chr17:30228624	UTP6	0.62	7.52	0.33	2.92e-13	Hip circumference adjusted for BMI;
LGG	cis	rs721917	0.506	rs2265961	chr10:81645857	C/T	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs12949688	0.967	rs12949028	chr17:55825470	A/C	cg12229367	chr17:55822335	NA	0.45	8.71	0.38	5.57e-17	Schizophrenia;
LGG	cis	rs61931739	0.534	rs10844819	chr12:34261389	G/T	cg06521331	chr12:34319734	NA	-0.64	-11.28	-0.46	3.17e-26	Morning vs. evening chronotype;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg06873352	chr17:61820015	STRADA	0.73	13.82	0.54	1.25e-36	Prudent dietary pattern;
LGG	cis	rs2247341	0.965	rs3752747	chr4:1737108	C/T	cg07465881	chr4:1713556	SLBP	-0.44	-6.91	-0.31	1.6e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs4730779	0.512	rs9648982	chr7:116983713	T/C	cg10524701	chr7:117356490	CTTNBP2	0.38	7.4	0.33	6.25e-13	Waist circumference;
LGG	cis	rs9814567	0.806	rs9841371	chr3:134320765	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.62	-11.13	-0.46	1.21e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs193541	0.632	rs4835896	chr5:122121240	C/T	cg19412675	chr5:122181750	SNX24	-0.53	-8.51	-0.37	2.39e-16	Glucose homeostasis traits;
LGG	cis	rs1023500	0.596	rs5751209	chr22:42451603	A/G	cg05082376	chr22:42548792	NA	-0.37	-7.31	-0.32	1.19e-12	Schizophrenia;
LGG	cis	rs9322193	0.962	rs3805749	chr6:150093682	C/T	cg02462569	chr6:150064036	NUP43	-0.4	-8.5	-0.37	2.65e-16	Lung cancer;
LGG	cis	rs13095912	0.785	rs6807927	chr3:185324933	A/G	cg11274856	chr3:185301563	NA	-0.49	-7.95	-0.35	1.41e-14	Systolic blood pressure;
LGG	cis	rs4930103	0.904	rs59121562	chr11:2025034	A/T	cg23202291	chr11:1979235	NA	0.41	7.83	0.34	3.27e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs2018683	1.000	rs2018683	chr7:29014195	G/T	cg19402173	chr7:128379420	CALU	-0.74	-14.31	-0.55	1.03e-38	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs4665809	0.590	rs62128457	chr2:26467347	C/A	cg22920501	chr2:26401640	FAM59B	0.44	9.07	0.39	3.36e-18	Gut microbiome composition (summer);
LGG	cis	rs2749592	0.513	rs1208708	chr10:38085576	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-8.31	-0.36	1.09e-15	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs17767392	0.834	rs61991193	chr14:71743789	C/T	cg02058870	chr14:72053146	SIPA1L1	0.43	8.24	0.36	1.78e-15	Mitral valve prolapse;
LGG	cis	rs1210638	0.706	rs2518798	chr22:18970403	T/C	cg12798833	chr22:18958832	DGCR5	-0.53	-9.29	-0.4	6.04e-19	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs561341	1.000	rs4795667	chr17:30244443	T/C	cg13647721	chr17:30228624	UTP6	0.65	8.37	0.36	6.69e-16	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.863	rs3760252	chr17:61852186	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	12.94	0.52	6.84e-33	Prudent dietary pattern;
LGG	cis	rs9902453	0.765	rs2127001	chr17:28098219	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.23	-0.55	2.19e-38	Coffee consumption (cups per day);
LGG	cis	rs11112613	0.609	rs11112585	chr12:105933442	A/G	cg03607813	chr12:105948248	NA	-0.59	-9.67	-0.41	2.82e-20	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	cis	rs4927850	0.752	rs7624460	chr3:195748530	C/T	cg01181863	chr3:195395398	SDHAP2	-0.73	-12.26	-0.5	4.04e-30	Pancreatic cancer;
LGG	cis	rs9322193	0.884	rs11155679	chr6:150080017	T/C	cg09699651	chr6:150184138	LRP11	0.49	7.96	0.35	1.38e-14	Lung cancer;
LGG	cis	rs34102591	0.826	rs71458829	chr12:124470747	G/A	cg13487667	chr12:124434373	CCDC92	-0.49	-7.0	-0.31	8.98e-12	Schizophrenia;
LGG	cis	rs240764	0.736	rs2007134	chr6:100926370	T/G	cg21058520	chr6:100914733	NA	0.47	8.36	0.36	7.16e-16	Neuroticism;
LGG	trans	rs8002861	0.967	rs2325071	chr13:44476793	T/C	cg17145862	chr1:211918768	LPGAT1	0.95	24.25	0.75	1.86e-84	Leprosy;
LGG	cis	rs1348850	0.507	rs10186934	chr2:178425998	T/C	cg23306229	chr2:178417860	TTC30B	0.74	8.04	0.35	7.62e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2228479	0.717	rs2286392	chr16:89809549	A/G	cg04287289	chr16:89883240	FANCA	0.77	8.42	0.36	4.58e-16	Skin colour saturation;
LGG	trans	rs1997103	1.000	rs6593238	chr7:55411048	A/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs834603	0.546	rs1704969	chr7:47467787	A/G	cg23694490	chr7:47445681	TNS3	-0.41	-11.8	-0.48	2.94e-28	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs1218582	0.774	rs4845679	chr1:154861187	G/T	cg03351412	chr1:154909251	PMVK	0.63	11.89	0.48	1.23e-28	Prostate cancer;
LGG	cis	rs763014	0.932	rs2269560	chr16:682442	A/C	cg00908189	chr16:619842	PIGQ	0.87	16.32	0.6	1.32e-47	Height;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg04160749	chr8:58172571	NA	-0.51	-7.99	-0.35	1.08e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs56283067	0.547	rs12192267	chr6:45393787	C/T	cg18551225	chr6:44695536	NA	-0.55	-7.93	-0.35	1.65e-14	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12505362	chr19:6373156	ALKBH7	0.48	7.43	0.33	5.17e-13	Gut microbiome composition (summer);
LGG	cis	rs367615	0.842	rs2578484	chr5:108950808	G/A	cg17395555	chr5:108820864	NA	-0.6	-8.64	-0.37	9.07e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7166081	0.950	rs72625778	chr15:67590103	A/G	cg05925327	chr15:68127851	NA	-0.34	-7.13	-0.31	3.92e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs208520	1.000	rs12190187	chr6:66973207	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.88	14.32	0.55	8.82e-39	Exhaled nitric oxide output;
LGG	cis	rs9303401	0.573	rs34097494	chr17:57171917	C/T	cg25039879	chr17:56429692	SUPT4H1	0.56	8.04	0.35	7.82e-15	Cognitive test performance;
LGG	cis	rs597539	0.652	rs514833	chr11:68657734	C/T	cg06028808	chr11:68637592	NA	0.73	12.51	0.5	3.8e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9815354	0.812	rs73071307	chr3:41798699	T/C	cg03022575	chr3:42003672	ULK4	0.78	9.0	0.39	6.04e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4319547	0.688	rs6489158	chr12:123110365	T/G	cg23029597	chr12:123009494	RSRC2	-0.53	-9.55	-0.41	7.71e-20	Body mass index;
LGG	cis	rs657075	0.697	rs34689843	chr5:131685256	A/C	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	trans	rs9467711	0.790	rs72843784	chr6:26498758	G/T	cg08344181	chr3:125677491	NA	-0.82	-7.92	-0.35	1.82e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12955299	chr17:58603540	APPBP2	-0.45	-6.91	-0.31	1.62e-11	Pancreatic cancer;
LGG	cis	rs72772090	0.539	rs11750464	chr5:96113031	C/T	cg00188032	chr5:96141721	ERAP1	-0.53	-6.99	-0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2762353	0.935	rs2817188	chr6:25807603	A/G	cg03264133	chr6:25882463	NA	-0.54	-10.22	-0.43	3.04e-22	Blood metabolite levels;
LGG	cis	rs1552244	0.882	rs56224841	chr3:10044014	A/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.23	-0.52	4.21e-34	Alzheimer's disease;
LGG	cis	rs344364	0.602	rs8044343	chr16:1881145	G/C	cg08610935	chr16:1836813	NUBP2	-0.44	-6.74	-0.3	4.77e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs2033732	0.954	rs10808859	chr8:85085400	A/T	cg05716166	chr8:85095498	RALYL	-0.52	-8.04	-0.35	7.73e-15	Body mass index;
LGG	cis	rs9783347	0.925	rs3802968	chr11:18343878	A/G	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs2075371	1.000	rs2244700	chr7:133987374	A/G	cg20476274	chr7:133979776	SLC35B4	0.74	14.38	0.56	5.17e-39	Mean platelet volume;
LGG	cis	rs727563	0.638	rs4820443	chr22:42193913	A/G	cg03806693	chr22:41940476	POLR3H	-1.01	-16.85	-0.62	4.98e-50	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6951245	1.000	rs78185558	chr7:1090183	G/C	cg20603222	chr7:1096387	C7orf50;GPR146	-0.97	-16.85	-0.62	4.97e-50	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs9354308	0.764	rs9294663	chr6:66596040	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.83	-0.3	2.6e-11	Metabolite levels;
LGG	cis	rs4595586	0.525	rs12825567	chr12:39386621	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.29	0.32	1.32e-12	Morning vs. evening chronotype;
LGG	cis	rs9868809	0.505	rs73080312	chr3:48737847	C/T	cg00383909	chr3:49044727	WDR6	1.03	11.33	0.47	1.93e-26	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9815354	0.767	rs73077375	chr3:41853058	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.31	0.4	5.06e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg00490583	chr16:1843685	IGFALS	-0.43	-7.16	-0.32	3.14e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9487094	0.961	rs1358998	chr6:109701218	C/T	cg16315928	chr6:109776240	MICAL1	-0.53	-9.13	-0.39	2.21e-18	Height;
LGG	cis	rs17286411	0.750	rs2288030	chr16:71914107	G/A	cg06353428	chr16:71660113	MARVELD3	0.41	7.35	0.32	9.18e-13	Blood protein levels;
LGG	cis	rs9399135	0.660	rs4267967	chr6:135272477	T/G	cg24558204	chr6:135376177	HBS1L	0.55	9.52	0.4	9.86e-20	Red blood cell count;
LGG	cis	rs13108904	0.518	rs4974603	chr4:1343168	C/T	cg05025164	chr4:1340916	KIAA1530	0.44	7.3	0.32	1.25e-12	Obesity-related traits;
LGG	cis	rs9522267	0.535	rs9522284	chr13:112229343	C/T	cg10483660	chr13:112241077	NA	-0.36	-7.88	-0.34	2.39e-14	Hepatitis;
LGG	cis	rs6669919	0.570	rs34293509	chr1:211690673	C/A	cg10512769	chr1:211675356	NA	-0.64	-11.89	-0.48	1.22e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs9899491	chr17:61934384	G/C	cg05941027	chr17:61774174	LIMD2	0.36	9.17	0.39	1.55e-18	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1062177	0.855	rs6884630	chr5:151268997	A/T	cg00977110	chr5:151150581	G3BP1	0.43	6.84	0.3	2.51e-11	Preschool internalizing problems;
LGG	cis	rs8032158	1.000	rs8032158	chr15:56194877	T/C	cg02198044	chr15:56286336	NEDD4	-0.71	-12.44	-0.5	7.8e-31	Keloid;
LGG	cis	rs2739330	0.828	rs4822454	chr22:24255208	G/A	cg24846343	chr22:24311635	DDTL	0.62	12.53	0.5	3.14e-31	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7747724	0.715	rs9465886	chr6:20768463	T/C	cg13405222	chr6:20811065	CDKAL1	-0.47	-9.38	-0.4	2.99e-19	Bladder cancer;
LGG	cis	rs36051895	0.632	rs7022901	chr9:5177680	C/G	cg02405213	chr9:5042618	JAK2	-0.77	-15.16	-0.58	1.89e-42	Pediatric autoimmune diseases;
LGG	cis	rs9311474	0.629	rs9853056	chr3:52555957	T/C	cg18404041	chr3:52824283	ITIH1	-0.38	-7.15	-0.32	3.51e-12	Electroencephalogram traits;
LGG	cis	rs6748734	0.948	rs4471886	chr2:241838622	T/C	cg07537917	chr2:241836409	C2orf54	-0.41	-8.26	-0.36	1.55e-15	Urinary metabolites;
LGG	cis	rs10504229	1.000	rs17816781	chr8:58186161	A/T	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1865760	0.516	rs9358903	chr6:26061949	A/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.92	0.35	1.8e-14	Height;
LGG	cis	rs9300255	0.543	rs1617156	chr12:123590165	T/C	cg05973401	chr12:123451056	ABCB9	0.5	7.48	0.33	3.87e-13	Neutrophil percentage of white cells;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	10.12	0.43	7.23e-22	Obesity-related traits;
LGG	trans	rs7395662	0.611	rs11040073	chr11:48855624	G/A	cg03929089	chr4:120376271	NA	0.44	7.16	0.32	3.24e-12	HDL cholesterol;
LGG	cis	rs4740619	0.810	rs7037908	chr9:15701695	G/A	cg14451791	chr9:16040625	NA	0.33	8.44	0.37	3.98e-16	Body mass index;
LGG	trans	rs1908814	0.516	rs10112958	chr8:11793140	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.17	-0.39	1.57e-18	Neuroticism;
LGG	cis	rs4253772	0.591	rs6007726	chr22:46650858	A/C	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6748734	1.000	rs11893118	chr2:241828308	C/G	cg04034577	chr2:241836375	C2orf54	-0.55	-11.66	-0.48	1.04e-27	Urinary metabolites;
LGG	trans	rs12517041	1.000	rs4701364	chr5:23301087	C/A	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-11.14	-0.46	1.04e-25	Calcium levels;
LGG	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.88	0.54	7.46e-37	Colorectal cancer;
LGG	cis	rs9611565	0.765	rs9607800	chr22:41784562	A/G	cg17554472	chr22:41940697	POLR3H	-0.45	-6.66	-0.3	7.56e-11	Vitiligo;
LGG	cis	rs11971779	0.680	rs6467843	chr7:139070523	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs2562456	0.755	rs2914646	chr19:21637161	A/C	cg00806126	chr19:22604979	ZNF98	0.58	8.05	0.35	7.21e-15	Pain;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24906202	chr15:73345212	NEO1	-0.42	-7.01	-0.31	8.31e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4268898	0.896	rs2702042	chr2:24546542	C/T	cg06627628	chr2:24431161	ITSN2	-0.52	-8.75	-0.38	3.99e-17	Asthma;
LGG	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs796364	0.625	rs1369843	chr2:201088171	A/G	cg17644776	chr2:200775616	C2orf69	0.55	7.87	0.34	2.62e-14	Schizophrenia;
LGG	cis	rs6089829	0.925	rs3746748	chr20:61667526	C/T	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	trans	rs1005277	0.579	rs2474608	chr10:38457109	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs9784649	0.891	rs57762467	chr5:25025700	C/T	cg11038491	chr20:34638489	LOC647979	-0.63	-7.96	-0.35	1.33e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2066819	1.000	rs773664	chr12:56702176	C/T	cg26714650	chr12:56694279	CS	1.49	18.31	0.65	9.68e-57	Psoriasis vulgaris;
LGG	cis	rs11250098	0.574	rs4240672	chr8:10767917	G/A	cg21775007	chr8:11205619	TDH	-0.46	-7.31	-0.32	1.16e-12	Morning vs. evening chronotype;
LGG	trans	rs1814175	0.817	rs7927373	chr11:49957640	A/C	cg03929089	chr4:120376271	NA	-1.04	-24.41	-0.75	3.43e-85	Height;
LGG	cis	rs6546550	0.901	rs6725425	chr2:70150674	T/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-7.98	-0.35	1.12e-14	Prevalent atrial fibrillation;
LGG	cis	rs6912958	0.874	rs2103764	chr6:88157392	T/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.58	-10.45	-0.44	4.25e-23	Monocyte percentage of white cells;
LGG	cis	rs8032158	1.000	rs28773028	chr15:56262339	C/G	cg02198044	chr15:56286336	NEDD4	-0.73	-12.76	-0.51	3.72e-32	Keloid;
LGG	cis	rs9815354	0.812	rs74947509	chr3:42006323	T/C	cg03022575	chr3:42003672	ULK4	0.77	8.99	0.39	6.1e-18	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs66573146	0.831	rs67602077	chr4:7024244	A/G	cg07817883	chr1:32538562	TMEM39B	1.49	11.95	0.49	7.42e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs13191362	0.935	rs67337490	chr6:162953961	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.75	7.39	0.32	6.85e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs589448	1.000	rs589448	chr12:69752200	A/G	cg22834771	chr12:69754056	YEATS4	-0.51	-8.81	-0.38	2.46e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1003719	0.788	rs2835577	chr21:38457457	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs17208368	0.628	rs2129366	chr16:55098616	A/G	cg11181171	chr16:55090946	NA	0.46	7.8	0.34	4.04e-14	Hypospadias;
LGG	cis	rs951366	0.559	rs823101	chr1:205667006	T/C	cg07157834	chr1:205819609	PM20D1	0.68	15.09	0.57	3.87e-42	Menarche (age at onset);
LGG	cis	rs9916302	0.821	rs11078916	chr17:37746307	T/C	cg00129232	chr17:37814104	STARD3	-0.71	-14.22	-0.55	2.41e-38	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	0.554	rs76243429	chr7:1152543	C/T	cg00364696	chr7:1142433	C7orf50	-0.4	-7.71	-0.34	7.56e-14	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.647	rs11072636	chr15:77185786	A/G	cg23625390	chr15:77176239	SCAPER	-0.73	-14.64	-0.56	3.8e-40	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs2271574	chr17:41327648	T/C	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	cis	rs11608355	0.508	rs12817730	chr12:109799330	G/A	cg19025524	chr12:109796872	NA	-0.47	-8.67	-0.37	7.48e-17	Neuroticism;
LGG	cis	rs10078	0.515	rs2672739	chr5:443447	A/C	cg26072250	chr5:443457	EXOC3;C5orf55	0.51	7.24	0.32	1.94e-12	Fat distribution (HIV);
LGG	trans	rs7746199	0.611	rs17750747	chr6:27730334	T/C	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7172689	1.000	rs58854988	chr15:81533262	T/C	cg11808699	chr15:81528661	IL16	-0.49	-10.02	-0.42	1.67e-21	Inattentive symptoms;
LGG	cis	rs27434	0.561	rs35134	chr5:96159523	A/G	cg16492584	chr5:96139282	ERAP1	-0.34	-6.74	-0.3	4.7e-11	Ankylosing spondylitis;
LGG	cis	rs614226	1.000	rs591992	chr12:121019323	T/C	cg21053147	chr12:120880522	NA	-0.55	-8.2	-0.36	2.44e-15	Type 1 diabetes nephropathy;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg19319069	chr7:129593010	UBE2H	-0.38	-6.72	-0.3	5.35e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs2294693	0.945	rs68031000	chr6:41008841	G/T	cg14769373	chr6:40998127	UNC5CL	-0.42	-6.74	-0.3	4.62e-11	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs62400317	0.821	rs62400268	chr6:45183011	C/T	cg18551225	chr6:44695536	NA	-0.63	-9.97	-0.42	2.39e-21	Total body bone mineral density;
LGG	cis	rs7481584	0.961	rs12797969	chr11:3019216	C/T	cg08468577	chr11:2973342	NAP1L4	-0.4	-8.04	-0.35	7.32e-15	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23264278	chr19:19051482	HOMER3	0.43	6.82	0.3	2.9100000000000002e-11	Gut microbiome composition (summer);
LGG	cis	rs2658782	1.000	rs2605582	chr11:93163799	C/T	cg15737290	chr11:93063684	CCDC67	0.58	8.62	0.37	1.05e-16	Pulmonary function decline;
LGG	cis	rs7129220	0.512	rs58652557	chr11:10121925	C/G	cg01453529	chr11:10209919	SBF2	-0.42	-6.86	-0.3	2.22e-11	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2797369	0.600	rs613338	chr6:101338159	G/A	cg27451362	chr6:101846650	GRIK2	0.67	9.16	0.39	1.64e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs644799	0.562	rs1254989	chr11:95508121	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.64	11.21	0.46	5.58e-26	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs34421088	0.560	rs2245250	chr8:11400680	G/A	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.78	-0.34	4.76e-14	Neuroticism;
LGG	cis	rs9487023	1	rs9487023	chr6:109590004	A/G	cg21918786	chr6:109611834	NA	-0.39	-7.2	-0.32	2.43e-12	Red blood cell count;Mean corpuscular hemoglobin concentration;Neutrophil percentage of white cells;Lymphocyte percentage of white cells;Mean corpuscular hemoglobin;High light scatter reticulocyte percentage of red cells;Mean corpuscular volume;
LGG	cis	rs6121246	0.529	rs6060195	chr20:30185638	C/T	cg13852791	chr20:30311386	BCL2L1	0.65	8.74	0.38	4.33e-17	Mean corpuscular hemoglobin;
LGG	cis	rs2629751	0.512	rs2723868	chr12:104422317	C/T	cg14987745	chr12:104360022	TDG	-0.56	-7.74	-0.34	6.38e-14	Hepatitis C induced liver fibrosis;
LGG	cis	rs62238980	0.614	rs4820060	chr22:32366415	C/T	cg02631450	chr22:32366979	NA	1.04	9.94	0.42	3.06e-21	Childhood ear infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg21028326	chr22:50683188	TUBGCP6	0.42	6.67	0.3	7.29e-11	Cognitive performance;
LGG	cis	rs62064224	0.902	rs17732573	chr17:30627664	C/T	cg18200150	chr17:30822561	MYO1D	-0.66	-13.94	-0.54	3.91e-37	Schizophrenia;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg00830817	chr11:109293614	C11orf87	0.41	6.91	0.31	1.63e-11	Schizophrenia;
LGG	cis	rs6089584	0.627	rs34496616	chr20:60561944	G/A	cg06470251	chr20:60548479	NA	0.46	8.19	0.36	2.58e-15	Body mass index;
LGG	cis	rs9560113	1.000	rs9560109	chr13:112180468	C/T	cg14154082	chr13:112174009	NA	0.42	9.38	0.4	3.03e-19	Menarche (age at onset);
LGG	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg19223190	chr17:80058835	NA	-0.48	-9.68	-0.41	2.69e-20	Life satisfaction;
LGG	cis	rs2075671	0.855	rs11974395	chr7:100282538	G/A	cg16850897	chr7:100343110	ZAN	-0.65	-9.73	-0.41	1.79e-20	Other erythrocyte phenotypes;
LGG	cis	rs7208859	0.623	rs7208441	chr17:29143863	C/T	cg19761014	chr17:28927070	LRRC37B2	0.61	7.31	0.32	1.16e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg04398451	chr17:18023971	MYO15A	0.74	15.55	0.59	3.72e-44	Total body bone mineral density;
LGG	cis	rs8038465	0.571	rs7176654	chr15:73999006	C/T	cg15420318	chr15:73925796	NPTN	-0.39	-6.75	-0.3	4.45e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs4481887	0.893	rs10158180	chr1:248481423	C/T	cg01631408	chr1:248437212	OR2T33	-0.52	-9.42	-0.4	2.23e-19	Common traits (Other);
LGG	cis	rs929354	0.772	rs1182360	chr7:157020550	C/G	cg00092383	chr7:157075207	NA	-0.39	-6.89	-0.3	1.85e-11	Body mass index;
LGG	cis	rs2153535	0.563	rs3117071	chr6:8537908	C/T	cg23788917	chr6:8435910	SLC35B3	0.54	9.1	0.39	2.77e-18	Motion sickness;
LGG	cis	rs3087591	0.960	rs12949230	chr17:29461899	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.57	0.56	7.31e-40	Hip circumference;
LGG	cis	rs1185460	0.546	rs474201	chr11:118958229	G/A	cg23280166	chr11:118938394	VPS11	0.47	8.13	0.35	4.06e-15	Coronary artery disease;
LGG	cis	rs7444	0.941	rs12484550	chr22:21941915	C/T	cg11654148	chr22:21984483	YDJC	-0.4	-7.79	-0.34	4.53e-14	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.884	rs11155689	chr6:150129606	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.95	0.31	1.21e-11	Lung cancer;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg08948841	chr4:1244042	CTBP1;C4orf42	0.76	14.44	0.56	2.65e-39	Obesity-related traits;
LGG	cis	rs10504229	1.000	rs66936919	chr8:58172868	C/G	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs2836974	0.800	rs73221174	chr21:40540939	T/C	cg17971929	chr21:40555470	PSMG1	0.9	17.29	0.63	4.68e-52	Cognitive function;
LGG	cis	rs1580019	0.587	rs1597555	chr7:32546118	T/G	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.85	0.3	2.29e-11	Cognitive ability;
LGG	cis	rs240764	0.711	rs240112	chr6:101059253	C/A	cg09795085	chr6:101329169	ASCC3	0.45	7.35	0.32	8.97e-13	Neuroticism;
LGG	trans	rs2727020	0.656	rs7925524	chr11:49437542	G/A	cg03929089	chr4:120376271	NA	-0.86	-14.97	-0.57	1.39e-41	Coronary artery disease;
LGG	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs13191362	1.000	rs34655790	chr6:163202739	G/A	cg06582575	chr6:163149167	PACRG;PARK2	0.92	9.87	0.42	5.58e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs6582630	0.537	rs3942440	chr12:38459672	A/G	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs796364	0.806	rs77853713	chr2:201006880	A/T	cg17644776	chr2:200775616	C2orf69	-0.6	-6.87	-0.3	2.1e-11	Schizophrenia;
LGG	cis	rs9409565	0.502	rs509022	chr9:97329271	G/C	cg13493766	chr9:97365869	FBP1	0.63	11.88	0.48	1.31e-28	Colorectal cancer (alcohol consumption interaction);
LGG	cis	rs4959677	0.755	rs6596884	chr6:2470233	C/T	cg20147862	chr6:2634573	C6orf195	-0.34	-7.04	-0.31	7.02e-12	Orthostatic hypotension;
LGG	cis	rs2120243	0.625	rs4482625	chr3:157096009	G/A	cg24825693	chr3:157122686	VEPH1	-0.46	-10.56	-0.44	1.65e-23	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs66782572	1	rs66782572	chr3:52567617	A/G	cg18404041	chr3:52824283	ITIH1	-0.39	-7.36	-0.32	8.3e-13	Hemoglobin concentration;
LGG	cis	rs2540226	0.761	rs10206408	chr2:39980482	G/A	cg13254588	chr2:40006314	THUMPD2	-0.39	-6.65	-0.3	8.2e-11	Personality dimensions;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs17685	0.712	rs6954569	chr7:75738885	T/A	cg19862616	chr7:65841803	NCRNA00174	1.08	26.08	0.77	6.23e-93	Coffee consumption;Coffee consumption (cups per day);
LGG	trans	rs7395662	0.697	rs11530291	chr11:48764203	C/G	cg03929089	chr4:120376271	NA	0.45	7.29	0.32	1.37e-12	HDL cholesterol;
LGG	cis	rs911263	0.590	rs6573834	chr14:68808398	T/C	cg18825221	chr14:68749962	RAD51L1	0.43	7.32	0.32	1.08e-12	Primary biliary cholangitis;
LGG	trans	rs7786808	0.778	rs34212455	chr7:158224490	C/T	cg02030672	chr11:45687055	CHST1	0.5	8.65	0.37	8.35e-17	Obesity-related traits;
LGG	cis	rs1707322	0.647	rs6686944	chr1:46156308	G/T	cg03146154	chr1:46216737	IPP	0.56	10.89	0.45	9.74e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3820068	0.580	rs12746773	chr1:16001588	C/T	cg05660106	chr1:15850417	CASP9	0.73	13.19	0.52	6.21e-34	Systolic blood pressure;
LGG	cis	rs2708240	0.539	rs2538994	chr7:147574509	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.24	-0.32	1.86e-12	QT interval (drug interaction);
LGG	cis	rs55665837	1.000	rs12295723	chr11:14450201	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-8.75	-0.38	4.15e-17	Vitamin D levels;
LGG	cis	rs8062405	1.000	rs62037367	chr16:28874547	C/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9522267	0.535	rs7323829	chr13:112232308	C/G	cg12773197	chr13:112238673	NA	-0.36	-7.43	-0.33	5.45e-13	Hepatitis;
LGG	cis	rs763014	0.931	rs3752567	chr16:628130	A/G	cg00908189	chr16:619842	PIGQ	0.84	15.6	0.59	2.12e-44	Height;
LGG	cis	rs4911259	0.552	rs11700082	chr20:31460244	A/G	cg13636640	chr20:31349939	DNMT3B	-0.64	-11.61	-0.47	1.65e-27	Inflammatory bowel disease;
LGG	cis	rs12410462	0.681	rs115956039	chr1:227661978	G/A	cg21459583	chr1:227974177	NA	0.58	8.43	0.36	4.3e-16	Major depressive disorder;
LGG	cis	rs7618915	0.547	rs7642198	chr3:52677960	T/C	cg10802521	chr3:52805072	NEK4	-0.43	-7.27	-0.32	1.5e-12	Bipolar disorder;
LGG	cis	rs700651	0.789	rs892514	chr2:198905270	T/C	cg00792783	chr2:198669748	PLCL1	0.58	9.12	0.39	2.25e-18	Intracranial aneurysm;
LGG	cis	rs3749237	1.000	rs1317140	chr3:49878652	G/A	cg02487422	chr3:49467188	NICN1	0.42	6.83	0.3	2.61e-11	Resting heart rate;
LGG	cis	rs61990749	0.500	rs8011337	chr14:78272626	T/G	cg02301378	chr14:78227641	SNW1;C14orf178	0.61	7.4	0.33	6.46e-13	Fibroblast growth factor basic levels;
LGG	cis	rs4803468	0.763	rs17318596	chr19:41937095	A/G	cg14132834	chr19:41945861	ATP5SL	-0.49	-9.57	-0.41	6.65e-20	Height;
LGG	cis	rs2880765	0.714	rs6497187	chr15:86011350	A/G	cg10818794	chr15:86012489	AKAP13	-0.36	-7.58	-0.33	1.84e-13	Coronary artery disease;
LGG	cis	rs3806843	0.576	rs246074	chr5:140307969	C/G	cg19875535	chr5:140030758	IK	0.36	7.1	0.31	4.74e-12	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2708240	0.577	rs851715	chr7:147526906	C/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.31	-7.02	-0.31	8.17e-12	QT interval (drug interaction);
LGG	trans	rs61931739	0.500	rs7489132	chr12:34539712	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.13	0.7	7.23e-70	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg05313129	chr8:58192883	C8orf71	-0.74	-9.78	-0.41	1.21e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs72945132	0.882	rs55738915	chr11:70190019	C/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.81	0.34	3.8e-14	Coronary artery disease;
LGG	cis	rs9388451	0.805	rs1028481	chr6:126106573	G/T	cg05901451	chr6:126070800	HEY2	-0.82	-17.53	-0.63	4.07e-53	Brugada syndrome;
LGG	cis	rs2635047	0.713	rs17723389	chr18:44762307	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.5	8.36	0.36	7.46e-16	Educational attainment;
LGG	cis	rs28386778	1.000	rs2955241	chr17:61968113	G/C	cg26338869	chr17:61819248	STRADA	0.57	9.49	0.4	1.24e-19	Prudent dietary pattern;
LGG	cis	rs6951245	1.000	rs78143408	chr7:1096846	G/A	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7674212	0.570	rs12501621	chr4:104095505	T/G	cg16532752	chr4:104119610	CENPE	-0.41	-7.2	-0.32	2.49e-12	Type 2 diabetes;
LGG	trans	rs634534	0.532	rs12794370	chr11:65770413	G/A	cg17712092	chr4:129076599	LARP1B	0.73	14.22	0.55	2.45e-38	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs6964587	1.000	rs10488510	chr7:91660225	G/T	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs892085	0.588	rs4804528	chr19:10886206	G/T	cg17710535	chr19:10819994	QTRT1	-0.48	-8.31	-0.36	1.09e-15	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs2180341	0.960	rs7756884	chr6:127684018	A/G	cg27446573	chr6:127587934	RNF146	1.14	22.57	0.72	1.25e-76	Breast cancer;
LGG	cis	rs11758351	0.925	rs78932312	chr6:26194869	A/G	cg06951627	chr6:26196580	NA	0.51	7.8	0.34	4.05e-14	Gout;Renal underexcretion gout;
LGG	cis	rs6502050	0.835	rs35192339	chr17:80119106	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs59918340	0.548	rs10102728	chr8:142205964	G/A	cg23750338	chr8:142222470	SLC45A4	0.5	9.99	0.42	2.09e-21	Immature fraction of reticulocytes;
LGG	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg14262678	chr6:151773367	RMND1;C6orf211	0.53	9.59	0.41	5.33e-20	Menarche (age at onset);
LGG	cis	rs74417235	0.639	rs7443642	chr5:154053450	A/G	cg08754654	chr5:154026448	NA	-0.53	-10.61	-0.44	1.14e-23	Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular hemoglobin concentration;
LGG	cis	rs3762637	0.882	rs7630833	chr3:122190424	C/T	cg24169773	chr3:122142474	KPNA1	-0.61	-10.15	-0.43	5.42e-22	LDL cholesterol levels;
LGG	cis	rs17270561	0.609	rs4711103	chr6:25742224	C/T	cg16482183	chr6:26056742	HIST1H1C	0.51	8.13	0.35	3.97e-15	Iron status biomarkers;
LGG	trans	rs1728785	0.901	rs821169	chr16:68630184	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.39	0.43	7.36e-23	Ulcerative colitis;
LGG	trans	rs931812	0.964	rs2102290	chr8:101919844	G/C	cg20993868	chr7:22813445	NA	0.66	12.66	0.51	9.6e-32	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2243480	1.000	rs6966322	chr7:65646754	A/G	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.54e-68	Diabetic kidney disease;
LGG	cis	rs7208859	0.673	rs12103588	chr17:29197460	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.1	-0.31	4.83e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs62400317	0.859	rs62436778	chr6:45120666	A/G	cg20913747	chr6:44695427	NA	-0.62	-10.36	-0.43	9.1e-23	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13987704	chr14:75348524	DLST	0.46	6.74	0.3	4.58e-11	Gut microbiome composition (summer);
LGG	cis	rs10193935	0.901	rs55978605	chr2:42573402	C/A	cg27598129	chr2:42591480	NA	-0.65	-9.72	-0.41	1.95e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9463078	0.605	rs13215618	chr6:44936568	A/G	cg25276700	chr6:44698697	NA	0.33	6.9	0.31	1.67e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs11758351	0.866	rs77205516	chr6:26205356	T/A	cg06951627	chr6:26196580	NA	0.51	7.82	0.34	3.53e-14	Gout;Renal underexcretion gout;
LGG	cis	rs526231	0.512	rs28022	chr5:102464367	T/C	cg23492399	chr5:102201601	PAM	-0.57	-8.34	-0.36	8.82e-16	Primary biliary cholangitis;
LGG	cis	rs9311474	0.508	rs12629701	chr3:52619836	T/C	cg14092988	chr3:52407081	DNAH1	0.29	7.9	0.34	2.02e-14	Electroencephalogram traits;
LGG	trans	rs61931739	0.500	rs11053177	chr12:34412829	G/A	cg13010199	chr12:38710504	ALG10B	0.64	12.83	0.51	1.87e-32	Morning vs. evening chronotype;
LGG	cis	rs4454254	1.000	rs4440615	chr8:141057641	G/A	cg06693505	chr8:141057453	TRAPPC9	-0.31	-6.79	-0.3	3.46e-11	Pulse pressure;
LGG	cis	rs10504229	0.683	rs56058640	chr8:58128862	C/T	cg21724239	chr8:58056113	NA	0.5	7.59	0.33	1.78e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs977987	0.866	rs12932606	chr16:75493944	C/T	cg07303275	chr16:75499416	TMEM170A	0.42	7.53	0.33	2.64e-13	Dupuytren's disease;
LGG	cis	rs6952808	0.823	rs10950448	chr7:1966492	G/C	cg11050988	chr7:1952600	MAD1L1	-0.39	-9.26	-0.4	7.39e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2762353	0.779	rs9393672	chr6:25842605	T/G	cg03517284	chr6:25882590	NA	-0.5	-9.48	-0.4	1.31e-19	Blood metabolite levels;
LGG	cis	rs13401104	0.796	rs1466206	chr2:237121221	G/C	cg15742758	chr2:237126235	ASB18	0.41	6.67	0.3	7.28e-11	Educational attainment;
LGG	trans	rs2562456	0.793	rs279807	chr19:21465822	C/T	cg00806126	chr19:22604979	ZNF98	-0.55	-7.39	-0.32	6.99e-13	Pain;
LGG	cis	rs972578	1.000	rs738377	chr22:43389570	C/T	cg01576275	chr22:43409880	NA	-0.23	-6.77	-0.3	3.86e-11	Mean platelet volume;
LGG	cis	rs4073582	0.595	rs555360	chr11:65960061	T/C	cg14036092	chr11:66035641	RAB1B	-0.46	-7.97	-0.35	1.29e-14	Gout;
LGG	cis	rs7811142	1.000	rs1073	chr7:100031612	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs3096299	0.967	rs2911257	chr16:89484134	C/G	cg08392591	chr16:89556376	ANKRD11	0.43	6.74	0.3	4.61e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs950169	0.580	rs1061737	chr15:85183790	G/C	cg24253500	chr15:84953950	NA	0.41	6.91	0.31	1.6e-11	Schizophrenia;
LGG	cis	rs67133203	0.904	rs10506299	chr12:51373014	C/T	cg14688905	chr12:51403056	SLC11A2	0.79	12.27	0.5	3.57e-30	Urinary tract infection frequency;
LGG	cis	rs2244613	0.832	rs7187684	chr16:55794951	C/T	cg27396498	chr16:55794478	CES4	-0.45	-9.16	-0.39	1.69e-18	Response to dabigatran etexilate treatment;
LGG	trans	rs853679	0.505	rs35781323	chr6:28144832	T/C	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs4918072	0.667	rs7920793	chr10:105706446	T/C	cg11005552	chr10:105648138	OBFC1	0.46	8.14	0.35	3.71e-15	Coronary artery disease;
LGG	cis	rs2346177	0.781	rs1447563	chr2:46637364	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.46	8.01	0.35	9.68e-15	HDL cholesterol;
LGG	cis	rs6500602	0.855	rs1139652	chr16:4476089	T/C	cg05091796	chr16:4465799	CORO7	-0.96	-16.63	-0.61	5.23e-49	Schizophrenia;
LGG	cis	rs10504229	0.817	rs10504230	chr8:58197150	A/G	cg22535103	chr8:58192502	C8orf71	0.99	14.55	0.56	8.8e-40	Developmental language disorder (linguistic errors);
LGG	cis	rs1847505	0.563	rs3127052	chr13:61410840	G/C	cg25164009	chr13:61490935	NA	-0.6	-9.96	-0.42	2.59e-21	Polychlorinated biphenyl levels;
LGG	trans	rs61931739	0.500	rs7955933	chr12:34473608	A/G	cg26384229	chr12:38710491	ALG10B	0.85	17.75	0.64	3.78e-54	Morning vs. evening chronotype;
LGG	cis	rs875971	0.540	rs781152	chr7:65479572	T/A	cg11987759	chr7:65425863	GUSB	-0.4	-7.75	-0.34	5.7e-14	Aortic root size;
LGG	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.04	0.35	7.61e-15	Homoarginine levels;
LGG	cis	rs9309473	1.000	rs7604682	chr2:73788026	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.77	-0.34	5.25e-14	Metabolite levels;
LGG	cis	rs3735485	0.800	rs55893574	chr7:45082425	T/C	cg03440944	chr7:45023329	C7orf40	-0.55	-9.41	-0.4	2.42e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs17270561	0.609	rs4711096	chr6:25727054	A/G	cg17691542	chr6:26056736	HIST1H1C	0.62	10.22	0.43	3.07e-22	Iron status biomarkers;
LGG	cis	rs6693567	0.565	rs696617	chr1:150376311	G/T	cg15654264	chr1:150340011	RPRD2	0.32	6.67	0.3	7.34e-11	Migraine;
LGG	cis	rs10504229	0.679	rs16921676	chr8:58052386	G/T	cg05313129	chr8:58192883	C8orf71	-0.64	-8.59	-0.37	1.31e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2028299	1.000	rs2028299	chr15:90374257	C/A	cg23731826	chr15:90371692	NA	0.37	8.68	0.37	6.65e-17	Type 2 diabetes;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg18652941	chr11:35160892	CD44	0.38	6.71	0.3	5.67e-11	Body mass index;
LGG	cis	rs10504229	0.953	rs114853497	chr8:58176176	A/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs6598955	0.671	rs11579354	chr1:26604071	T/G	cg07461501	chr17:79650226	HGS;ARL16	-0.74	-12.56	-0.5	2.52e-31	Obesity-related traits;
LGG	cis	rs2712184	0.935	rs2712169	chr2:217671349	G/A	cg05032264	chr2:217675019	NA	-0.51	-12.01	-0.49	3.99e-29	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs834603	0.965	rs700755	chr7:47445641	A/G	cg09696706	chr7:47479511	TNS3	0.31	6.75	0.3	4.3e-11	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs7786808	0.741	rs62479982	chr7:158227546	A/G	cg12438819	chr7:158236134	PTPRN2	0.34	9.05	0.39	3.96e-18	Obesity-related traits;
LGG	cis	rs11098499	0.954	rs1022145	chr4:120230979	A/G	cg24375607	chr4:120327624	NA	0.66	10.73	0.45	3.96e-24	Corneal astigmatism;
LGG	cis	rs1218582	0.772	rs877343	chr1:154910012	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.7	0.34	8.37e-14	Prostate cancer;
LGG	cis	rs9487094	0.670	rs12193719	chr6:109910254	C/G	cg01125227	chr6:109776195	MICAL1	0.44	7.69	0.34	8.76e-14	Height;
LGG	cis	rs10791097	0.720	rs7119425	chr11:130733185	C/T	cg12179176	chr11:130786555	SNX19	0.8	16.23	0.6	3.1e-47	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs597539	0.580	rs7935851	chr11:68731122	A/G	cg01988459	chr11:68622903	NA	-0.59	-12.18	-0.49	8.85e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7084402	0.967	rs11817440	chr10:60272369	T/C	cg07615347	chr10:60278583	BICC1	-0.62	-17.59	-0.63	1.99e-53	Refractive error;
LGG	cis	rs11992162	0.613	rs56094399	chr8:11797470	G/A	cg12395012	chr8:11607386	GATA4	0.42	7.64	0.33	1.27e-13	Monocyte count;
LGG	cis	rs951366	0.764	rs823141	chr1:205741426	T/C	cg23034840	chr1:205782522	SLC41A1	0.56	9.12	0.39	2.31e-18	Menarche (age at onset);
LGG	cis	rs2836950	0.565	rs7278297	chr21:40625752	A/C	cg11890956	chr21:40555474	PSMG1	-0.73	-12.81	-0.51	2.22e-32	Menarche (age at onset);
LGG	cis	rs1552244	0.882	rs6796419	chr3:10040812	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.96	-0.54	3.38e-37	Alzheimer's disease;
LGG	cis	rs9880211	0.948	rs1604793	chr3:136181070	G/C	cg21827317	chr3:136751795	NA	-0.49	-7.2	-0.32	2.39e-12	Body mass index;Height;
LGG	cis	rs7582180	0.629	rs36103184	chr2:100942634	G/A	cg08017756	chr2:100939284	LONRF2	-0.28	-6.75	-0.3	4.44e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.908	rs4677206	chr3:72780052	A/T	cg25664220	chr3:72788482	NA	0.32	8.99	0.39	6.35e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs9929218	0.529	rs35854485	chr16:68730855	C/G	cg04657470	chr2:198365150	HSPE1;HSPD1	1.03	24.85	0.76	3.1e-87	Colorectal cancer;
LGG	cis	rs10504229	0.683	rs61364624	chr8:58134339	T/A	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9393692	0.905	rs2393592	chr6:26285560	A/G	cg15665833	chr6:26285013	NA	0.38	7.45	0.33	4.71e-13	Educational attainment;
LGG	cis	rs10979	0.928	rs9496676	chr6:143895610	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.45	-0.5	6.79e-31	Hypospadias;
LGG	trans	rs1814175	0.588	rs10466497	chr11:49864381	A/T	cg03929089	chr4:120376271	NA	-0.94	-19.58	-0.67	1.25e-62	Height;
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.17e-13	Prudent dietary pattern;
LGG	cis	rs8180040	0.701	rs7625067	chr3:47095305	T/C	cg27129171	chr3:47204927	SETD2	0.83	16.0	0.6	3.3e-46	Colorectal cancer;
LGG	cis	rs7777484	0.534	rs2533886	chr7:2834869	C/T	cg23009067	chr7:2775923	GNA12	0.25	7.13	0.31	3.96e-12	Height;
LGG	cis	rs1865760	0.519	rs4360119	chr6:25815074	C/G	cg03264133	chr6:25882463	NA	-0.47	-7.21	-0.32	2.3e-12	Height;
LGG	cis	rs4909189	1.000	rs62493651	chr7:158135592	T/C	cg15736062	chr7:158136485	PTPRN2	-0.53	-9.58	-0.41	6.07e-20	Response to amphetamines;
LGG	trans	rs826838	0.967	rs11168299	chr12:38902028	G/T	cg06521331	chr12:34319734	NA	-0.45	-7.64	-0.33	1.24e-13	Heart rate;
LGG	cis	rs6582630	0.638	rs35864536	chr12:38472255	T/A	cg13010199	chr12:38710504	ALG10B	-0.53	-10.57	-0.44	1.59e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs919433	0.926	rs787997	chr2:198216271	A/G	cg00792783	chr2:198669748	PLCL1	0.44	6.99	0.31	9.57e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg18187862	chr3:45730750	SACM1L	-0.66	-11.03	-0.46	2.86e-25	Primary sclerosing cholangitis;
LGG	cis	rs7582720	0.887	rs72932755	chr2:203673563	A/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.59	0.41	5.47e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs7173743	0.750	rs12903355	chr15:79129145	A/T	cg00540400	chr15:79124168	NA	0.39	8.01	0.35	9.52e-15	Coronary artery disease;
LGG	cis	rs7937682	0.889	rs484013	chr11:111495779	G/A	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs10421328	0.784	rs12983292	chr19:19787767	G/A	cg03709012	chr19:19516395	GATAD2A	0.44	6.66	0.3	7.86e-11	Parental longevity (combined parental age at death);
LGG	cis	rs897984	0.542	rs11864806	chr16:31095204	G/C	cg02466173	chr16:30829666	NA	-0.42	-7.68	-0.34	9.28e-14	Dementia with Lewy bodies;
LGG	cis	rs9916302	0.706	rs649180	chr17:37464959	A/C	cg07936489	chr17:37558343	FBXL20	1.01	15.24	0.58	8.39e-43	Glomerular filtration rate (creatinine);
LGG	cis	rs3774749	0.565	rs2518795	chr3:50208819	C/T	cg14019146	chr3:50243930	SLC38A3	-0.42	-9.0	-0.39	5.69e-18	Intelligence (multi-trait analysis);
LGG	cis	rs60871478	1.000	rs7795258	chr7:795227	A/G	cg22643751	chr7:855365	UNC84A	0.36	6.98	0.31	1.01e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs10504229	1.000	rs112272435	chr8:58170371	A/G	cg22535103	chr8:58192502	C8orf71	-1.0	-15.44	-0.58	1.13e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs7582180	1.000	rs10865039	chr2:100907351	A/G	cg21926883	chr2:100939477	LONRF2	-0.54	-10.38	-0.43	7.71e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9354308	0.764	rs9294674	chr6:66605021	A/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs12477438	0.734	rs4851184	chr2:99666434	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.86	-15.41	-0.58	1.53e-43	Chronic sinus infection;
LGG	cis	rs9322193	0.884	rs1108889	chr6:150166569	A/G	cg08621203	chr6:150244597	RAET1G	0.47	8.0	0.35	9.89e-15	Lung cancer;
LGG	cis	rs644799	0.965	rs10831430	chr11:95509638	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.63	0.54	8.06e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs7143963	0.945	rs56330734	chr14:103292150	G/A	cg23020514	chr14:103360112	TRAF3	0.55	10.42	0.44	5.56e-23	Body mass index;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg19364635	chr2:38978654	SFRS7	-0.41	-6.84	-0.3	2.59e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6502050	0.835	rs66531647	chr17:80089022	G/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs3540	0.554	rs113942266	chr15:91072990	A/G	cg22089800	chr15:90895588	ZNF774	-0.68	-12.16	-0.49	1.04e-29	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg06873352	chr17:61820015	STRADA	0.74	14.01	0.55	1.91e-37	Prudent dietary pattern;
LGG	trans	rs11875185	0.510	rs74809346	chr18:55624205	A/T	cg15513957	chr14:69354734	ACTN1	-0.86	-8.71	-0.38	5.52e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7223966	0.655	rs9906924	chr17:61634538	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.53	7.9	0.34	2.01e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs7939886	0.764	rs7113688	chr11:55946865	C/T	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs9815354	1.000	rs2683695	chr3:41914928	C/T	cg03022575	chr3:42003672	ULK4	0.64	8.24	0.36	1.75e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1707322	0.682	rs28490344	chr1:46197948	C/T	cg03146154	chr1:46216737	IPP	0.56	11.02	0.46	3.06e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs17125944	0.686	rs7145440	chr14:53333717	A/G	cg00686598	chr14:53173677	PSMC6	-0.63	-6.78	-0.3	3.66e-11	Alzheimer's disease (late onset);
LGG	cis	rs2280630	0.529	rs6599274	chr3:39013948	T/C	cg01426195	chr3:39028469	NA	-0.71	-15.05	-0.57	5.67e-42	Verbal declarative memory;
LGG	cis	rs6500637	0.686	rs8048701	chr16:4913537	T/A	cg08329684	chr16:4932620	PPL	0.46	8.52	0.37	2.34e-16	Cancer;
LGG	cis	rs10911251	0.528	rs10911263	chr1:183115018	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.43	0.36	4.54e-16	Colorectal cancer;
LGG	trans	rs931812	0.895	rs13251731	chr8:101902528	C/G	cg20993868	chr7:22813445	NA	0.71	13.51	0.53	2.71e-35	Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs1555322	1.000	rs2425040	chr20:33858878	G/A	cg17927777	chr20:33865990	NA	0.72	7.63	0.33	1.33e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs6089584	0.816	rs744778	chr20:60631365	A/G	cg06108461	chr20:60628389	TAF4	-1.04	-21.03	-0.7	1.95e-69	Body mass index;
LGG	cis	rs8072100	0.701	rs4794053	chr17:45769551	G/A	cg25173405	chr17:45401733	C17orf57	-0.55	-9.11	-0.39	2.49e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs10754283	0.756	rs17441836	chr1:90135433	C/T	cg06121193	chr1:90282411	NA	-0.5	-9.13	-0.39	2.13e-18	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9944715	0.954	rs13381525	chr18:43747538	G/A	cg26436583	chr18:43649176	PSTPIP2	0.37	6.73	0.3	5e-11	Red cell distribution width;Mean corpuscular volume;
LGG	trans	rs2739330	0.652	rs2000469	chr22:24245292	A/G	cg06437703	chr8:37914619	EIF4EBP1	-0.56	-9.05	-0.39	3.86e-18	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9287719	0.967	rs6750891	chr2:10738563	T/C	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs6061231	0.837	rs6061235	chr20:60978524	C/G	cg22633769	chr20:60982531	CABLES2	0.5	6.87	0.3	2.14e-11	Colorectal cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16631698	chr10:3500383	NA	0.35	6.84	0.3	2.45e-11	Gut microbiome composition (summer);
LGG	trans	rs7726839	0.540	rs3762951	chr5:662613	C/G	cg25482853	chr8:67687455	SGK3	0.95	11.84	0.48	1.88e-28	Obesity-related traits;
LGG	cis	rs12291225	0.679	rs11023178	chr11:14310282	G/A	cg02886208	chr11:14281011	SPON1	-0.36	-6.82	-0.3	2.85e-11	Sense of smell;
LGG	cis	rs7927997	0.708	rs2155219	chr11:76299194	G/T	cg17647271	chr11:76299819	NA	-0.48	-8.6	-0.37	1.25e-16	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs10193935	0.901	rs13393459	chr2:42463124	C/T	cg27598129	chr2:42591480	NA	-0.63	-9.46	-0.4	1.61e-19	Colonoscopy-negative controls vs population controls;
LGG	trans	rs6601327	0.670	rs6990418	chr8:9422006	C/G	cg02002194	chr4:3960332	NA	-0.39	-6.83	-0.3	2.72e-11	Multiple myeloma (hyperdiploidy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24790589	chr12:123459803	ABCB9;OGFOD2	0.43	6.68	0.3	6.78e-11	Gut microbiome composition (summer);
LGG	cis	rs9368481	0.646	rs75843621	chr6:26967881	G/A	cg18867708	chr6:26865862	GUSBL1	-0.46	-7.65	-0.34	1.16e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs2841277	0.834	rs2841281	chr14:105394669	C/T	cg20978937	chr14:105399321	PLD4	-0.47	-10.32	-0.43	1.26e-22	Rheumatoid arthritis;
LGG	cis	rs10504229	0.683	rs11774697	chr8:58133119	G/A	cg02725872	chr8:58115012	NA	-1.06	-14.71	-0.56	1.92e-40	Developmental language disorder (linguistic errors);
LGG	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg19729930	chr2:74357872	NA	0.58	11.75	0.48	4.58e-28	Gestational age at birth (maternal effect);
LGG	cis	rs62238980	0.614	rs117534689	chr22:32392350	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs1799949	1.000	rs1399323	chr17:41332330	T/C	cg04503457	chr17:41445688	NA	-0.39	-9.38	-0.4	2.91e-19	Menopause (age at onset);
LGG	cis	rs6964587	0.934	rs6465344	chr7:91640273	G/A	cg17063962	chr7:91808500	NA	0.49	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	-0.6	-10.54	-0.44	2.04e-23	Lymphocyte counts;
LGG	cis	rs1707322	0.717	rs2991988	chr1:46082431	C/A	cg03146154	chr1:46216737	IPP	-0.55	-10.64	-0.44	8.57e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs4474465	0.790	rs10899554	chr11:78265667	T/G	cg27205649	chr11:78285834	NARS2	0.52	8.87	0.38	1.62e-17	Alzheimer's disease (survival time);
LGG	cis	rs7084402	0.935	rs1896246	chr10:60276068	A/G	cg07615347	chr10:60278583	BICC1	-0.64	-18.24	-0.65	2.15e-56	Refractive error;
LGG	cis	rs12493885	0.818	rs62276828	chr3:153775941	C/T	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs9303401	0.614	rs34843288	chr17:57103140	T/C	cg25039879	chr17:56429692	SUPT4H1	0.61	8.55	0.37	1.81e-16	Cognitive test performance;
LGG	cis	rs11690935	0.959	rs7355594	chr2:172639448	G/T	cg21435375	chr2:172878103	MAP1D	-0.31	-7.06	-0.31	6.3e-12	Schizophrenia;
LGG	cis	rs6502050	0.805	rs8082653	chr17:80162382	G/A	cg19223190	chr17:80058835	NA	0.43	8.4	0.36	5.62e-16	Life satisfaction;
LGG	cis	rs6752107	0.936	rs6431660	chr2:234167234	A/G	cg07618928	chr2:234183455	ATG16L1;SCARNA5	0.7	13.28	0.53	2.56e-34	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7249142	0.597	rs759999	chr19:19281207	A/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.54	-0.44	1.94e-23	IgG glycosylation;
LGG	cis	rs244731	0.920	rs244707	chr5:176555636	A/T	cg17509989	chr5:176798049	RGS14	0.57	7.88	0.34	2.41e-14	Urate levels in lean individuals;
LGG	cis	rs6762477	0.748	rs34877766	chr3:50234126	A/G	cg24110177	chr3:50126178	RBM5	-0.48	-8.06	-0.35	6.35e-15	Menarche (age at onset);
LGG	cis	rs1577917	0.796	rs12661231	chr6:86544471	T/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.58	-10.33	-0.43	1.15e-22	Response to antipsychotic treatment;
LGG	cis	rs365132	0.934	rs251844	chr5:176476605	T/A	cg16309518	chr5:176445507	NA	-0.55	-12.11	-0.49	1.57e-29	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs1862618	0.525	rs2662019	chr5:56263104	A/G	cg17809284	chr5:56205270	C5orf35	0.62	9.59	0.41	5.47e-20	Initial pursuit acceleration;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs10911232	0.507	rs10911194	chr1:182993025	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs2479106	0.892	rs12347057	chr9:126694094	T/A	cg16191174	chr9:126692580	DENND1A	0.49	7.39	0.33	6.69e-13	Polycystic ovary syndrome;
LGG	trans	rs11039798	0.920	rs12279378	chr11:48571030	A/C	cg15704280	chr7:45808275	SEPT13	0.77	8.93	0.38	9.88e-18	Axial length;
LGG	trans	rs35110281	0.641	rs9983670	chr21:45083425	A/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.54	9.32	0.4	4.69e-19	Mean corpuscular volume;
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.06	0.52	2.12e-33	Prudent dietary pattern;
LGG	cis	rs651907	0.535	rs4342086	chr3:101503765	G/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.05	0.35	6.95e-15	Colorectal cancer;
LGG	cis	rs9333075	0.507	rs17303526	chr10:15755580	C/T	cg14364212	chr10:15760690	ITGA8	0.46	9.19	0.39	1.31e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11748327	0.580	rs10069010	chr5:4011583	G/A	cg01025095	chr5:4101132	NA	-0.43	-7.06	-0.31	6.01e-12	Myocardial infarction;
LGG	cis	rs7512552	0.839	rs11577600	chr1:150407443	G/A	cg15654264	chr1:150340011	RPRD2	0.45	9.36	0.4	3.34e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs7819412	0.837	rs17724467	chr8:10975682	C/G	cg15556689	chr8:8085844	FLJ10661	-0.57	-10.42	-0.44	5.51e-23	Triglycerides;
LGG	cis	rs357618	1.000	rs357629	chr5:150850946	C/T	cg03212797	chr5:150827313	SLC36A1	0.42	6.73	0.3	5.09e-11	Basophil percentage of white cells;
LGG	cis	rs11190604	0.943	rs11190588	chr10:102273565	C/T	cg07080220	chr10:102295463	HIF1AN	0.7	11.78	0.48	3.37e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs10504229	1.000	rs78953746	chr8:58170608	A/G	cg05313129	chr8:58192883	C8orf71	-0.81	-12.33	-0.5	2.11e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs4731207	0.698	rs2402755	chr7:124448608	T/C	cg05630886	chr7:124431682	NA	0.33	7.69	0.34	8.94e-14	Cutaneous malignant melanoma;
LGG	cis	rs6952808	0.825	rs34296663	chr7:1935245	C/T	cg04267008	chr7:1944627	MAD1L1	-0.74	-13.14	-0.52	1e-33	Bipolar disorder and schizophrenia;
LGG	cis	rs3735485	0.760	rs4724345	chr7:45053442	T/C	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2439831	0.867	rs4583210	chr15:43660925	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	11.41	0.47	9.2e-27	Lung cancer in ever smokers;
LGG	cis	rs9322193	0.884	rs9383865	chr6:150173179	A/G	cg07701084	chr6:150067640	NUP43	0.61	11.3	0.47	2.47e-26	Lung cancer;
LGG	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	cg15522984	chr1:182991683	LAMC1	0.45	8.97	0.38	7.34e-18	Colorectal cancer;
LGG	cis	rs875971	0.767	rs1643394	chr7:65836094	A/G	cg23594656	chr7:65796392	TPST1	-0.4	-8.77	-0.38	3.4e-17	Aortic root size;
LGG	cis	rs939658	0.626	rs11636901	chr15:79446292	T/C	cg17916960	chr15:79447300	NA	-0.57	-10.4	-0.44	6.8e-23	Refractive error;
LGG	cis	rs28595532	0.920	rs114564223	chr4:119729953	A/G	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs782590	0.764	rs2054728	chr2:55818419	C/T	cg18811423	chr2:55921094	PNPT1	0.82	17.73	0.64	4.89e-54	Metabolic syndrome;
LGG	trans	rs826838	1.000	rs34254519	chr12:39041235	G/A	cg06521331	chr12:34319734	NA	-0.43	-7.46	-0.33	4.3e-13	Heart rate;
LGG	cis	rs6964587	1.000	rs7811564	chr7:91663364	A/G	cg17063962	chr7:91808500	NA	0.48	8.49	0.37	2.77e-16	Breast cancer;
LGG	cis	rs1865760	0.686	rs12210098	chr6:25963966	C/T	cg16482183	chr6:26056742	HIST1H1C	0.59	9.95	0.42	2.86e-21	Height;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg14789911	chr21:47582049	C21orf56	-0.46	-7.94	-0.35	1.52e-14	Testicular germ cell tumor;
LGG	cis	rs35740288	0.822	rs11629690	chr15:86287724	G/A	cg04173714	chr15:86211321	AKAP13	0.42	7.18	0.32	2.85e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg13852791	chr20:30311386	BCL2L1	0.7	11.1	0.46	1.54e-25	Mean corpuscular hemoglobin;
LGG	cis	rs240764	0.817	rs239232	chr6:101103038	G/A	cg09795085	chr6:101329169	ASCC3	0.46	7.72	0.34	7.14e-14	Neuroticism;
LGG	cis	rs4242434	0.819	rs2306518	chr8:22470308	A/G	cg02227867	chr8:22457446	C8orf58	-0.43	-8.19	-0.36	2.62e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs74781061	0.722	rs77102700	chr15:74896941	G/A	cg02384859	chr15:74862662	ARID3B	-0.38	-6.66	-0.3	7.89e-11	Endometriosis;
LGG	cis	rs930421	0.544	rs6719977	chr2:42985803	T/C	cg14631114	chr2:43023945	NA	0.44	9.44	0.4	1.89e-19	Attention deficit hyperactivity disorder;
LGG	cis	rs4430311	0.723	rs1870272	chr1:243924743	T/A	cg25706552	chr1:244017396	NA	-0.65	-16.3	-0.6	1.56e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg14227996	chr4:17616232	MED28	0.73	8.93	0.38	1.02e-17	Opioid sensitivity;
LGG	cis	rs9354308	0.764	rs9294670	chr6:66604710	A/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	cis	rs9303280	0.806	rs2305480	chr17:38062196	G/A	cg00129232	chr17:37814104	STARD3	-0.48	-8.82	-0.38	2.33e-17	Self-reported allergy;
LGG	cis	rs6088590	0.523	rs6059913	chr20:33143288	G/A	cg24642439	chr20:33292090	TP53INP2	0.55	9.15	0.39	1.77e-18	Coronary artery disease;
LGG	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.68	0.34	9.29e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9322193	0.962	rs9322219	chr6:150103399	C/T	cg15971980	chr6:150254442	NA	0.43	8.23	0.36	1.87e-15	Lung cancer;
LGG	trans	rs9329221	0.710	rs11785061	chr8:10259528	G/C	cg02002194	chr4:3960332	NA	-0.39	-6.77	-0.3	3.86e-11	Neuroticism;
LGG	cis	rs11690935	0.838	rs10432423	chr2:172753295	G/A	cg13550731	chr2:172543902	DYNC1I2	-0.97	-22.75	-0.73	1.85e-77	Schizophrenia;
LGG	cis	rs7833790	0.724	rs6473311	chr8:82726682	G/A	cg27398817	chr8:82754497	SNX16	-0.72	-11.32	-0.47	2.13e-26	Diastolic blood pressure;
LGG	cis	rs11971779	0.715	rs7781459	chr7:139093882	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs61931739	0.500	rs11053282	chr12:34561151	T/C	cg06521331	chr12:34319734	NA	-0.55	-9.42	-0.4	2.07e-19	Morning vs. evening chronotype;
LGG	cis	rs75229567	0.618	rs78294090	chr12:70209959	G/T	cg10114359	chr12:70132523	RAB3IP	1.23	10.42	0.44	5.52e-23	Triglyceride change in response to fenofibrate in statin-treated type 2 diabetes;
LGG	cis	rs999943	0.846	rs1570760	chr6:33622933	C/T	cg14003231	chr6:33640908	ITPR3	0.63	14.4	0.56	4.22e-39	Obesity (extreme);
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs910316	0.967	rs175498	chr14:75536369	G/A	cg11812906	chr14:75593930	NEK9	-0.51	-9.47	-0.4	1.47e-19	Height;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg18350739	chr11:68623251	NA	-0.89	-22.86	-0.73	5.37e-78	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs28448403	1	rs28448403	chr8:11305564	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.74	-0.3	4.63e-11	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs17270561	0.636	rs1165216	chr6:25797971	G/A	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs7208859	0.623	rs28433704	chr17:29084285	G/C	cg01831904	chr17:28903510	LRRC37B2	-0.86	-10.59	-0.44	1.3e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs11098499	0.863	rs1480936	chr4:120462861	C/T	cg24375607	chr4:120327624	NA	0.66	10.9	0.45	8.58e-25	Corneal astigmatism;
LGG	cis	rs7937890	0.900	rs7118682	chr11:14274550	T/G	cg22961513	chr11:14280813	SPON1	0.37	9.4	0.4	2.56e-19	Mitochondrial DNA levels;
LGG	cis	rs7937890	0.532	rs2575827	chr11:14475515	A/G	cg02886208	chr11:14281011	SPON1	-0.41	-7.89	-0.34	2.15e-14	Mitochondrial DNA levels;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.37	-8.66	-0.37	8e-17	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17270561	0.609	rs12529272	chr6:25731342	A/G	cg12310025	chr6:25882481	NA	-0.43	-7.09	-0.31	4.93e-12	Iron status biomarkers;
LGG	cis	rs6032067	0.516	rs6104085	chr20:43901302	A/C	cg10761708	chr20:43804764	PI3	0.46	7.35	0.32	8.92e-13	Blood protein levels;
LGG	cis	rs9400467	0.537	rs73528998	chr6:111445630	C/T	cg15721981	chr6:111408429	SLC16A10	0.58	7.12	0.31	4.18e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs28386778	0.687	rs59596917	chr17:61806264	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.14	0.31	3.62e-12	Prudent dietary pattern;
LGG	cis	rs2836950	0.565	rs2836942	chr21:40591381	A/G	cg17971929	chr21:40555470	PSMG1	-0.52	-8.93	-0.38	9.93e-18	Menarche (age at onset);
LGG	cis	rs6960043	0.748	rs10228561	chr7:15063961	C/T	cg19272540	chr7:15055459	NA	-0.36	-7.89	-0.34	2.25e-14	Type 2 diabetes;
LGG	cis	rs2228479	0.702	rs62053702	chr16:89860688	G/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.93	-0.35	1.66e-14	Skin colour saturation;
LGG	cis	rs2243480	0.803	rs35480979	chr7:65357084	A/G	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs9522267	0.737	rs9522285	chr13:112230701	C/T	cg10483660	chr13:112241077	NA	-0.38	-8.09	-0.35	5.23e-15	Hepatitis;
LGG	cis	rs3770081	1.000	rs78032828	chr2:86309032	G/A	cg01119172	chr2:86362222	SNORD94;PTCD3	0.66	7.13	0.31	3.97e-12	Facial emotion recognition (sad faces);
LGG	cis	rs11252926	0.673	rs10795161	chr10:497748	G/T	cg08603382	chr10:743973	NA	0.41	7.67	0.34	1.01e-13	Psychosis in Alzheimer's disease;
LGG	cis	rs4731207	0.596	rs7790975	chr7:124577944	A/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs12477438	1.000	rs17760953	chr2:99859863	G/A	cg08885076	chr2:99613938	TSGA10	-0.56	-10.37	-0.43	8.3300000000000006e-23	Chronic sinus infection;
LGG	cis	rs11764590	0.694	rs6977161	chr7:2099361	T/C	cg24189917	chr7:1970923	MAD1L1	-0.43	-7.12	-0.31	4.16e-12	Neuroticism;
LGG	cis	rs8046696	1	rs8046696	chr16:75442143	T/G	cg03315344	chr16:75512273	CHST6	0.53	10.63	0.44	9.49e-24	Coronary artery disease;
LGG	cis	rs526231	0.511	rs4421079	chr5:102369076	C/T	cg23492399	chr5:102201601	PAM	-0.57	-8.47	-0.37	3.27e-16	Primary biliary cholangitis;
LGG	cis	rs60180747	1.000	rs11631625	chr15:66608731	A/G	cg07575407	chr15:66541975	MEGF11	0.36	7.16	0.32	3.28e-12	Testicular germ cell tumor;
LGG	cis	rs11676348	0.846	rs7594532	chr2:219008000	T/C	cg00012203	chr2:219082015	ARPC2	-0.56	-10.16	-0.43	5.19e-22	Ulcerative colitis;
LGG	trans	rs800082	1.000	rs2575194	chr3:144284871	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.36	0.36	7.55e-16	Smoking behavior;
LGG	trans	rs1005277	0.579	rs1780136	chr10:38501453	A/G	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs490234	0.702	rs13285587	chr9:128233058	G/T	cg14078157	chr9:128172775	NA	-0.47	-8.92	-0.38	1.1e-17	Mean arterial pressure;
LGG	trans	rs2727020	0.566	rs10839234	chr11:49185524	C/T	cg15704280	chr7:45808275	SEPT13	-0.91	-18.91	-0.66	1.64e-59	Coronary artery disease;
LGG	cis	rs1451375	0.527	rs6950777	chr7:50597056	G/A	cg14593290	chr7:50529359	DDC	0.59	10.72	0.45	4.15e-24	Malaria;
LGG	cis	rs10189230	0.967	rs13026659	chr2:222353014	C/T	cg14652038	chr2:222343519	EPHA4	0.6	12.69	0.51	6.86e-32	Urate levels in lean individuals;
LGG	cis	rs433406	0.935	rs415055	chr11:131372210	C/T	cg27203895	chr11:131369037	NTM	-0.61	-13.29	-0.53	2.37e-34	Male fertility;
LGG	cis	rs523522	0.885	rs524735	chr12:121022099	T/C	cg12219531	chr12:120966889	COQ5	0.67	11.13	0.46	1.16e-25	High light scatter reticulocyte count;
LGG	cis	rs736408	0.511	rs12637632	chr3:52708073	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.41	-0.44	5.95e-23	Bipolar disorder;
LGG	cis	rs11148252	0.538	rs2897976	chr13:52715944	G/A	cg12458913	chr13:53173898	NA	0.55	9.9	0.42	4.2e-21	Lewy body disease;
LGG	cis	rs763121	0.853	rs6001204	chr22:39100239	T/C	cg06022373	chr22:39101656	GTPBP1	0.92	19.22	0.67	5.62e-61	Menopause (age at onset);
LGG	cis	rs243505	0.691	rs243483	chr7:148449163	A/G	cg18940274	chr7:148469757	CUL1	0.36	6.69	0.3	6.63e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2228479	0.850	rs17232630	chr16:89851179	C/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.42	-0.61	4.33e-48	Skin colour saturation;
LGG	cis	rs6502050	0.865	rs74480314	chr17:80117716	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.44	-0.33	5.05e-13	Life satisfaction;
LGG	cis	rs9381107	0.932	rs2103674	chr6:9451701	G/A	cg14735645	chr6:9486422	NA	-0.43	-7.29	-0.32	1.35e-12	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1355223	0.583	rs2116085	chr11:34884001	C/A	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.93	0.57	2.08e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2011503	1.000	rs4808968	chr19:19644402	C/T	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs1555322	1.000	rs2425036	chr20:33855981	G/C	cg17927777	chr20:33865990	NA	0.68	7.65	0.33	1.21e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs473651	0.904	rs508274	chr2:239337723	G/A	cg18131467	chr2:239335373	ASB1	1.02	23.7	0.74	7.11e-82	Multiple system atrophy;
LGG	cis	rs4595586	0.545	rs2388177	chr12:39364403	T/C	cg26384229	chr12:38710491	ALG10B	0.6	10.92	0.45	7.6e-25	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.702	rs17761816	chr16:4548832	C/G	cg19168338	chr16:4465731	CORO7	-0.73	-13.4	-0.53	7.82e-35	Schizophrenia;
LGG	cis	rs10504229	0.610	rs7840469	chr8:58146992	C/T	cg05313129	chr8:58192883	C8orf71	-0.64	-9.26	-0.4	7.39e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.729	rs169362	chr22:41827589	G/C	cg06634786	chr22:41940651	POLR3H	0.67	11.21	0.46	5.83e-26	Vitiligo;
LGG	cis	rs868036	1.000	rs4776975	chr15:68102220	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs2243480	1.000	rs34560516	chr7:65404092	A/T	cg18252515	chr7:66147081	NA	-1.34	-19.04	-0.66	4.02e-60	Diabetic kidney disease;
LGG	cis	rs7824557	0.628	rs2572387	chr8:11204165	C/T	cg15596359	chr8:11213517	TDH	-0.41	-8.74	-0.38	4.41e-17	Retinal vascular caliber;
LGG	cis	rs2439831	1.000	rs689754	chr15:43775895	A/G	cg15269541	chr15:43626905	ADAL	-0.42	-6.95	-0.31	1.22e-11	Lung cancer in ever smokers;
LGG	cis	rs3785574	0.962	rs2955235	chr17:61966950	A/C	cg06601766	chr17:61851465	DDX42;CCDC47	0.55	8.83	0.38	2.13e-17	Height;
LGG	cis	rs4696584	0.816	rs4696588	chr4:155405717	C/T	cg04517429	chr4:155413618	DCHS2	0.32	7.66	0.34	1.09e-13	Folding of antihelix;
LGG	cis	rs11122272	0.735	rs971534	chr1:231521971	C/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	trans	rs11098499	0.954	rs10008459	chr4:120394231	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.24	0.49	5.04e-30	Corneal astigmatism;
LGG	cis	rs10851411	0.730	rs2595938	chr15:42760159	A/G	cg21293051	chr15:42870591	STARD9	-0.45	-6.75	-0.3	4.42e-11	Glucose homeostasis traits;
LGG	cis	rs9646954	0.791	rs4851300	chr2:100958804	C/A	cg26150922	chr2:100937072	LONRF2	-0.49	-8.42	-0.36	4.91e-16	Intelligence (multi-trait analysis);
LGG	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg10253484	chr15:75165896	SCAMP2	-0.43	-7.22	-0.32	2.12e-12	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs10911232	0.507	rs61081633	chr1:182995608	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.87	0.42	5.71e-21	Hypertriglyceridemia;
LGG	cis	rs2228479	0.867	rs62052168	chr16:89947203	G/A	cg19635926	chr16:89946313	TCF25	0.8	8.26	0.36	1.55e-15	Skin colour saturation;
LGG	trans	rs7824557	0.527	rs2736305	chr8:11237773	T/C	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.73	-0.41	1.74e-20	Retinal vascular caliber;
LGG	cis	rs1387259	0.929	rs11168484	chr12:48633589	A/C	cg21466736	chr12:48725269	NA	-0.37	-7.43	-0.33	5.14e-13	Obstructive sleep apnea trait (apnea hypopnea index);
LGG	cis	rs7552404	0.727	rs11161626	chr1:76260837	C/T	cg22875332	chr1:76189707	ACADM	0.56	8.47	0.37	3.29e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs2847281	0.587	rs2542152	chr18:12782761	C/T	cg10925350	chr14:35591951	PPP2R3C;KIAA0391	-0.43	-6.97	-0.31	1.1e-11	C-reactive protein levels;Esophageal cancer (squamous cell);
LGG	cis	rs10504229	0.683	rs11774847	chr8:58140775	T/A	cg02725872	chr8:58115012	NA	-1.03	-14.08	-0.55	9.84e-38	Developmental language disorder (linguistic errors);
LGG	cis	rs9487051	1.000	rs9386795	chr6:109616528	G/A	cg21918786	chr6:109611834	NA	-0.43	-8.13	-0.35	3.91e-15	Reticulocyte fraction of red cells;
LGG	cis	rs7605378	1.000	rs797163	chr2:200696387	G/A	cg23649088	chr2:200775458	C2orf69	0.54	9.13	0.39	2.1e-18	Osteoporosis;
LGG	cis	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg02951883	chr7:2050386	MAD1L1	0.51	9.2	0.39	1.21e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs3091242	0.867	rs602052	chr1:25722206	T/C	cg03538708	chr1:25844672	NA	-0.37	-7.12	-0.31	4.09e-12	Erythrocyte sedimentation rate;
LGG	cis	rs7107174	1.000	rs2511182	chr11:77982130	G/C	cg27205649	chr11:78285834	NARS2	-0.48	-7.69	-0.34	9.17e-14	Testicular germ cell tumor;
LGG	cis	rs9768139	0.708	rs34267680	chr7:158115084	C/T	cg15736062	chr7:158136485	PTPRN2	-0.38	-7.09	-0.31	4.94e-12	Calcium levels;
LGG	cis	rs9388451	0.868	rs1268083	chr6:126049040	T/C	cg10911889	chr6:126070802	HEY2	-0.4	-6.8	-0.3	3.27e-11	Brugada syndrome;
LGG	trans	rs7395662	0.889	rs11039972	chr11:48759252	A/G	cg03929089	chr4:120376271	NA	0.45	7.3	0.32	1.29e-12	HDL cholesterol;
LGG	cis	rs17376456	0.932	rs3940842	chr5:93534858	C/A	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs2204008	0.743	rs11182052	chr12:38450421	T/C	cg13010199	chr12:38710504	ALG10B	0.68	14.18	0.55	3.72e-38	Bladder cancer;
LGG	cis	rs763121	0.626	rs5757236	chr22:39073824	T/C	cg06022373	chr22:39101656	GTPBP1	0.89	18.18	0.65	3.84e-56	Menopause (age at onset);
LGG	cis	rs6089829	0.962	rs6062776	chr20:61663736	A/G	cg08045932	chr20:61659980	NA	0.6	13.25	0.52	3.22e-34	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs7853377	0.689	rs7853254	chr9:86552049	C/T	cg12437157	chr9:86433764	GKAP1	0.4	6.88	0.3	1.89e-11	Height;
LGG	cis	rs1008375	0.966	rs11737844	chr4:17697421	A/C	cg18681998	chr4:17616180	MED28	0.73	15.07	0.57	4.93e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9322193	0.962	rs10214845	chr6:150104260	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.4	-0.44	6.36e-23	Lung cancer;
LGG	cis	rs6938	0.534	rs4886636	chr15:75196176	G/A	cg14664628	chr15:75095509	CSK	-0.55	-10.7	-0.45	5.13e-24	Breast cancer;
LGG	cis	rs7953249	1.000	rs7953249	chr12:121403724	A/G	cg14101638	chr12:121416612	HNF1A	0.37	8.54	0.37	2e-16	Invasive epithelial ovarian cancer;High-grade serous ovarian cancer;Chronic obstructive pulmonary disease-related biomarkers;N-glycan levels;Serous invasive ovarian cancer;Epithelial ovarian cancer;
LGG	cis	rs9322193	0.923	rs10782314	chr6:150056663	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.51	-0.33	3e-13	Lung cancer;
LGG	trans	rs9291683	0.507	rs3796837	chr4:10011321	C/G	cg26043149	chr18:55253948	FECH	0.4	6.65	0.3	8.25e-11	Bone mineral density;
LGG	cis	rs9303401	0.659	rs7223708	chr17:56896398	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.93	14.96	0.57	1.48e-41	Cognitive test performance;
LGG	cis	rs826838	0.651	rs12367384	chr12:38618460	G/T	cg13010199	chr12:38710504	ALG10B	0.62	12.08	0.49	2.22e-29	Heart rate;
LGG	cis	rs769267	0.965	rs2269873	chr19:19392401	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.31	0.36	1.05e-15	Tonsillectomy;
LGG	cis	rs62400317	0.859	rs12209161	chr6:45104321	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.21	-0.43	3.2800000000000002e-22	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.06	0.42	1.12e-21	Motion sickness;
LGG	cis	rs6951245	0.554	rs10246354	chr7:1132456	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-0.63	-11.54	-0.47	3.09e-27	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs5769765	0.862	rs9616380	chr22:50312225	T/C	cg02269571	chr22:50332266	NA	-0.71	-10.94	-0.45	6.4e-25	Schizophrenia;
LGG	cis	rs1129187	0.755	rs9471982	chr6:42935998	G/A	cg13397359	chr6:42928475	GNMT	0.56	15.63	0.59	1.58e-44	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs2204008	0.805	rs10881112	chr12:37956611	G/A	cg26384229	chr12:38710491	ALG10B	-0.8	-17.01	-0.62	8.97e-51	Bladder cancer;
LGG	cis	rs10504229	0.683	rs6980540	chr8:58127022	A/G	cg05313129	chr8:58192883	C8orf71	-0.74	-10.22	-0.43	3.05e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.757	rs6859757	chr5:93206042	C/T	cg19507638	chr5:93509721	C5orf36	-0.67	-9.33	-0.4	4.33e-19	Diabetic retinopathy;
LGG	cis	rs10911232	0.507	rs4652763	chr1:182994084	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.78	0.38	3.11e-17	Hypertriglyceridemia;
LGG	cis	rs1018836	0.608	rs6982329	chr8:91467488	A/G	cg16814680	chr8:91681699	NA	-0.58	-9.78	-0.41	1.14e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg07900786	chr7:45151525	TBRG4	-0.41	-7.05	-0.31	6.51e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs17445240	0.515	rs6760466	chr2:3707136	T/C	cg16123090	chr2:3699210	NA	0.58	8.29	0.36	1.2e-15	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs6502050	0.805	rs7503095	chr17:80107354	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2735413	0.918	rs4888731	chr16:78080418	A/G	cg04733911	chr16:78082701	NA	-0.78	-18.81	-0.66	4.66e-59	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs2204008	0.744	rs8186814	chr12:38335169	C/T	cg04568710	chr12:38710424	ALG10B	0.33	6.67	0.3	7.41e-11	Bladder cancer;
LGG	cis	rs16973500	0.808	rs72801797	chr16:71975300	A/G	cg00732059	chr16:71740210	PHLPP2	-0.6	-9.84	-0.42	6.9e-21	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7089973	0.872	rs7918388	chr10:116614563	T/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.68	0.34	9.66e-14	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1682361	1	rs1682361	chr3:136734014	G/C	cg03617693	chr3:136751559	NA	0.4	6.89	0.3	1.83e-11	Schizophrenia;
LGG	cis	rs11098499	0.821	rs28665282	chr4:120384186	C/T	cg09307838	chr4:120376055	NA	0.81	13.61	0.53	9.98e-36	Corneal astigmatism;
LGG	cis	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg09307838	chr4:120376055	NA	0.48	7.89	0.34	2.24e-14	Diastolic blood pressure;
LGG	trans	rs800082	0.839	rs17282884	chr3:144319905	C/T	cg24215973	chr2:240111563	HDAC4	0.48	8.03	0.35	7.86e-15	Smoking behavior;
LGG	cis	rs8063160	0.867	rs77381714	chr16:90078022	T/C	cg07984980	chr16:89898383	SPIRE2	0.92	8.16	0.35	3.09e-15	Red vs non-red hair color;Light vs. dark hair color;Brown vs. non-brown hair color;
LGG	cis	rs2033711	0.870	rs7409473	chr19:58939165	A/G	cg13877915	chr19:58951672	ZNF132	0.99	26.75	0.78	5.26e-96	Uric acid clearance;
LGG	cis	rs597539	0.652	rs674654	chr11:68698762	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.83	15.45	0.58	9.89e-44	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg06153925	chr17:78755379	RPTOR	0.39	6.75	0.3	4.46e-11	Myopia (pathological);
LGG	cis	rs11098499	0.863	rs34868248	chr4:120442430	A/G	cg09307838	chr4:120376055	NA	0.79	12.98	0.52	4.66e-33	Corneal astigmatism;
LGG	cis	rs7208859	0.673	rs61223749	chr17:29163747	G/A	cg19761014	chr17:28927070	LRRC37B2	0.58	6.77	0.3	3.96e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12540874	0.698	rs3823674	chr7:50571996	C/T	cg00647317	chr7:50633725	DDC	0.39	9.43	0.4	1.93e-19	Systemic sclerosis;
LGG	cis	rs227584	0.663	rs2040810	chr17:42243771	C/T	cg19774624	chr17:42201019	HDAC5	0.7	13.8	0.54	1.58e-36	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs397969	0.596	rs62066348	chr17:19899913	A/G	cg13482628	chr17:19912719	NA	0.52	8.51	0.37	2.4e-16	Platelet count;
LGG	cis	rs13177180	0.651	rs6893854	chr5:114865921	A/T	cg06507678	chr5:114919500	TMED7-TICAM2;TICAM2	-0.34	-7.28	-0.32	1.46e-12	Conotruncal heart defects (inherited effects);
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00166722	chr3:10149974	C3orf24	0.51	8.59	0.37	1.32e-16	Alzheimer's disease;
LGG	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg17330273	chr5:96107758	CAST;ERAP1	-0.59	-9.07	-0.39	3.35e-18	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs992157	0.698	rs6746089	chr2:219170377	A/G	cg00012203	chr2:219082015	ARPC2	0.65	11.58	0.47	2e-27	Colorectal cancer;
LGG	cis	rs736408	0.608	rs35004449	chr3:52852897	G/T	cg11645453	chr3:52864694	ITIH4	0.62	9.72	0.41	1.86e-20	Bipolar disorder;
LGG	trans	rs2562456	0.833	rs55875743	chr19:21566195	G/T	cg00806126	chr19:22604979	ZNF98	-0.57	-7.58	-0.33	1.87e-13	Pain;
LGG	cis	rs4132509	0.744	rs6687181	chr1:243878518	C/T	cg25706552	chr1:244017396	NA	0.48	6.7	0.3	6.15e-11	RR interval (heart rate);
LGG	trans	rs7395662	0.525	rs1945189	chr11:48418889	A/G	cg00717180	chr2:96193071	NA	-0.44	-7.85	-0.34	2.88e-14	HDL cholesterol;
LGG	cis	rs6960043	0.818	rs13220985	chr7:15062694	A/G	cg19272540	chr7:15055459	NA	0.35	7.73	0.34	6.89e-14	Type 2 diabetes;
LGG	cis	rs9522267	0.535	rs9515453	chr13:112234612	T/C	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs9660992	0.736	rs1180734	chr1:205255438	A/G	cg21545522	chr1:205238299	TMCC2	0.43	7.87	0.34	2.49e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs4665809	0.531	rs34081866	chr2:26475940	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs12681287	0.609	rs13281414	chr8:87495254	A/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.72	-0.34	7.24e-14	Caudate activity during reward;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.59	0.44	1.27e-23	Prudent dietary pattern;
LGG	cis	rs4727027	0.870	rs62507485	chr7:148764182	C/T	cg23583168	chr7:148888333	NA	-0.81	-15.18	-0.58	1.5e-42	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg23782820	chr8:58130467	NA	0.56	8.42	0.36	4.81e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs2072732	0.861	rs56398543	chr1:2950237	G/A	cg22517653	chr1:2918612	NA	-0.45	-6.99	-0.31	9.66e-12	Plateletcrit;
LGG	cis	rs12780845	0.522	rs17464824	chr10:17210822	A/C	cg01003015	chr10:17271136	VIM	-0.45	-7.77	-0.34	5.17e-14	Homocysteine levels;
LGG	cis	rs2880765	0.835	rs4514633	chr15:86041017	T/G	cg10818794	chr15:86012489	AKAP13	-0.37	-7.97	-0.35	1.28e-14	Coronary artery disease;
LGG	cis	rs1015291	0.799	rs10841379	chr12:19992303	A/G	cg25401612	chr12:20009446	NA	-0.34	-7.13	-0.31	3.78e-12	Diastolic blood pressure;
LGG	cis	rs11608355	0.515	rs2287184	chr12:109970251	T/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.18e-29	Neuroticism;
LGG	cis	rs758324	0.580	rs35566767	chr5:131606049	C/G	cg06968155	chr5:131705112	SLC22A5	0.59	6.88	0.3	1.94e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6951245	0.810	rs117800627	chr7:1081075	G/C	cg24642844	chr7:1081250	C7orf50	-0.8	-13.25	-0.52	3.31e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2274273	0.840	rs6573020	chr14:55871452	C/T	cg04306507	chr14:55594613	LGALS3	0.61	17.23	0.62	9.46e-52	Protein biomarker;
LGG	cis	rs11605275	1.000	rs11604179	chr11:20024759	G/A	cg14835545	chr11:20032148	NAV2	-0.97	-10.73	-0.45	3.75e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1465370	0.720	rs2402995	chr7:130016595	C/T	cg06917763	chr7:130033247	NA	0.33	7.24	0.32	1.86e-12	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for body mass index;
LGG	cis	rs603424	0.509	rs6584362	chr10:102087113	G/T	cg10365880	chr10:102089681	PKD2L1	-0.46	-7.48	-0.33	3.67e-13	Phospholipid levels (plasma);Palmitic acid (16:0) levels;Palmitoleic acid (16:1n-7) levels;Mean platelet volume;Serum metabolite levels;Blood metabolite levels;Vaccenic acid (18:1n-7) levels;Metabolic traits;Coronary artery disease;Blood metabolite ratios;Glycerophospholipid levels;
LGG	cis	rs9322193	0.887	rs9767113	chr6:150039293	T/C	cg09699651	chr6:150184138	LRP11	0.52	9.16	0.39	1.71e-18	Lung cancer;
LGG	cis	rs6502050	0.835	rs62078304	chr17:80085224	G/A	cg19223190	chr17:80058835	NA	-0.44	-8.53	-0.37	2.14e-16	Life satisfaction;
LGG	cis	rs7727544	0.654	rs4705849	chr5:131559199	T/A	cg07395648	chr5:131743802	NA	-0.41	-8.89	-0.38	1.37e-17	Blood metabolite levels;
LGG	cis	rs17270561	0.666	rs9356988	chr6:25777481	G/A	cg03264133	chr6:25882463	NA	-0.47	-7.55	-0.33	2.32e-13	Iron status biomarkers;
LGG	cis	rs780096	0.506	rs1647286	chr2:27714517	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs763121	0.719	rs138699	chr22:39129708	G/A	cg06022373	chr22:39101656	GTPBP1	0.83	14.42	0.56	3.29e-39	Menopause (age at onset);
LGG	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	cg07928641	chr1:182991847	LAMC1	0.47	9.21	0.39	1.12e-18	Fuchs's corneal dystrophy;
LGG	cis	rs9467773	1.000	rs9357010	chr6:26527945	C/G	cg09904177	chr6:26538194	HMGN4	0.79	18.26	0.65	1.71e-56	Intelligence (multi-trait analysis);
LGG	cis	rs7811142	0.830	rs77861211	chr7:99962096	T/C	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.57	8.44	0.36	4.23e-16	Platelet count;
LGG	cis	rs1218582	0.510	rs2878411	chr1:154823545	C/T	cg09359103	chr1:154839909	KCNN3	-0.38	-7.38	-0.32	7.19e-13	Prostate cancer;
LGG	cis	rs7044106	1.000	rs7044106	chr9:123494062	C/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.58	9.02	0.39	4.91e-18	Hip circumference adjusted for BMI;
LGG	cis	rs3748682	0.861	rs2291297	chr1:38272660	G/A	cg12658694	chr1:38397304	INPP5B	0.39	7.2	0.32	2.51e-12	Hypothyroidism;
LGG	cis	rs13082711	0.519	rs13091103	chr3:27229122	G/C	cg02860705	chr3:27208620	NA	0.96	17.31	0.63	4.03e-52	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.46	-8.64	-0.37	9.23e-17	Obesity-related traits;
LGG	cis	rs10504229	0.679	rs6995378	chr8:58113933	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.86e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9399135	0.684	rs1135205	chr6:135281795	C/T	cg22676075	chr6:135203613	NA	0.4	7.07	0.31	5.61e-12	Red blood cell count;
LGG	cis	rs11123170	0.529	rs35606997	chr2:113973350	G/A	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.55	8.31	0.36	1.06e-15	Renal function-related traits (BUN);
LGG	cis	rs2153535	0.580	rs7763190	chr6:8484197	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs763121	0.853	rs2281021	chr22:39064667	T/C	cg21395723	chr22:39101663	GTPBP1	0.37	6.68	0.3	7.04e-11	Menopause (age at onset);
LGG	cis	rs67478160	0.643	rs12880821	chr14:104276049	C/T	cg26031613	chr14:104095156	KLC1	-0.47	-7.65	-0.34	1.16e-13	Schizophrenia;
LGG	cis	rs4555082	0.794	rs2735827	chr14:105710600	T/A	cg06808227	chr14:105710500	BRF1	-0.64	-11.51	-0.47	3.96e-27	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7944735	0.817	rs7101582	chr11:47714610	G/A	cg15704280	chr7:45808275	SEPT13	0.58	7.31	0.32	1.17e-12	Intraocular pressure;
LGG	cis	rs17092148	0.887	rs4911431	chr20:33158318	G/A	cg12302830	chr20:33297742	TP53INP2	-0.44	-6.96	-0.31	1.21e-11	Neuroticism;
LGG	cis	rs9911578	1.000	rs654778	chr17:56736473	A/C	cg05425664	chr17:57184151	TRIM37	-0.62	-9.93	-0.42	3.5e-21	Intelligence (multi-trait analysis);
LGG	cis	rs12148488	0.763	rs12900072	chr15:75307148	G/A	cg10253484	chr15:75165896	SCAMP2	-0.43	-6.93	-0.31	1.44e-11	Caffeine consumption;
LGG	cis	rs34172651	0.517	rs8059004	chr16:24837905	G/A	cg00339695	chr16:24857497	SLC5A11	0.42	7.33	0.32	1.02e-12	Intelligence (multi-trait analysis);
LGG	trans	rs9467711	0.606	rs9393718	chr6:26407482	G/A	cg08344181	chr3:125677491	NA	-0.65	-7.33	-0.32	1.03e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-11.0	-0.46	3.68e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4918072	0.793	rs4615949	chr10:105704611	A/G	cg11005552	chr10:105648138	OBFC1	0.46	7.47	0.33	4.08e-13	Coronary artery disease;
LGG	cis	rs7766436	0.885	rs4711020	chr6:22582920	A/G	cg13666174	chr6:22585274	NA	-0.51	-11.95	-0.49	6.96e-29	Coronary artery disease;
LGG	cis	rs6952808	0.756	rs4719311	chr7:1881813	C/T	cg05863683	chr7:1912471	MAD1L1	0.39	7.13	0.31	3.85e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2295359	0.892	rs6688383	chr1:67655954	C/T	cg12940439	chr1:67600707	NA	-0.45	-8.96	-0.38	8.22e-18	Psoriasis;
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.87	-0.34	2.46e-14	Total body bone mineral density;
LGG	cis	rs898097	0.585	rs9893200	chr17:80893028	A/C	cg10494973	chr17:80897199	TBCD	-0.42	-7.47	-0.33	4.14e-13	Breast cancer;
LGG	cis	rs6500395	1.000	rs8052196	chr16:48691644	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs10504229	0.636	rs114725691	chr8:58054292	C/T	cg02725872	chr8:58115012	NA	-0.9	-12.28	-0.5	3.48e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs9467711	0.606	rs12174631	chr6:26373150	C/T	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1023500	0.505	rs2143139	chr22:42614401	G/C	cg15557168	chr22:42548783	NA	-0.47	-10.03	-0.42	1.5e-21	Schizophrenia;
LGG	cis	rs9359856	0.517	rs72919948	chr6:90509389	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.82	-10.55	-0.44	1.84e-23	Bipolar disorder;
LGG	trans	rs12579753	1.000	rs34894912	chr12:82228721	A/G	cg07923666	chr12:49932857	KCNH3	-0.52	-7.8	-0.34	4.13e-14	Resting heart rate;
LGG	cis	rs6456042	0.893	rs9295324	chr6:166573712	G/A	cg11088901	chr6:166572345	T	-0.36	-7.54	-0.33	2.42e-13	Asthma;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg24654547	chr16:68057165	DUS2L;DDX28	-0.49	-7.1	-0.31	4.79e-12	Systemic lupus erythematosus;
LGG	cis	rs858239	0.537	rs6955115	chr7:23227144	A/G	cg23682824	chr7:23144976	KLHL7	0.41	6.8	0.3	3.24e-11	Cerebrospinal fluid biomarker levels;
LGG	trans	rs3942852	0.915	rs905477	chr11:48148606	T/C	cg03929089	chr4:120376271	NA	-0.64	-8.91	-0.38	1.14e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs72945132	0.823	rs12292240	chr11:70152612	T/C	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs17401966	1.000	rs6700866	chr1:10306038	A/G	cg15208524	chr1:10270712	KIF1B	0.46	7.86	0.34	2.64e-14	Hepatocellular carcinoma;
LGG	cis	rs7617480	0.648	rs6801211	chr3:48774420	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	8.1	0.35	4.75e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs1552244	1.000	rs6442150	chr3:10122575	T/C	cg08888203	chr3:10149979	C3orf24	0.58	9.84	0.42	7.12e-21	Alzheimer's disease;
LGG	cis	rs653465	0.679	rs11129264	chr3:27146294	A/G	cg02860705	chr3:27208620	NA	-0.4	-7.68	-0.34	9.77e-14	Breast cancer (early onset);
LGG	cis	rs151234	0.741	rs56236750	chr16:28594711	C/T	cg01378222	chr16:28622494	SULT1A1	-0.73	-9.96	-0.42	2.56e-21	Platelet distribution width;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg16507663	chr6:150244633	RAET1G	0.51	10.37	0.43	8.44e-23	Lung cancer;
LGG	cis	rs9486719	0.843	rs2499792	chr6:96846264	A/C	cg06623918	chr6:96969491	KIAA0776	0.73	9.78	0.41	1.21e-20	Migraine;Coronary artery disease;
LGG	cis	rs7666738	0.830	rs4699594	chr4:98980775	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9611565	0.659	rs12483786	chr22:41938536	A/G	cg06850241	chr22:41845214	NA	-0.43	-6.69	-0.3	6.43e-11	Vitiligo;
LGG	cis	rs561341	0.739	rs8070554	chr17:30216868	A/T	cg13647721	chr17:30228624	UTP6	-0.76	-10.94	-0.45	5.95e-25	Hip circumference adjusted for BMI;
LGG	cis	rs3126085	1.000	rs11204971	chr1:152259078	A/G	cg26876637	chr1:152193138	HRNR	-0.49	-7.01	-0.31	8.24e-12	Atopic dermatitis;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg04503457	chr17:41445688	NA	-0.39	-9.21	-0.39	1.16e-18	Menopause (age at onset);
LGG	trans	rs35110281	0.627	rs7283362	chr21:44973667	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.63	11.53	0.47	3.36e-27	Mean corpuscular volume;
LGG	cis	rs17767392	0.846	rs2332576	chr14:71765507	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.38	-8.76	-0.38	3.78e-17	Mitral valve prolapse;
LGG	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg19338460	chr6:170058176	WDR27	-0.59	-8.08	-0.35	5.71e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs12478296	0.792	rs3924263	chr2:243005167	A/C	cg06360820	chr2:242988706	NA	-0.99	-12.76	-0.51	3.5e-32	Obesity-related traits;
LGG	cis	rs3785574	0.621	rs1051684	chr17:62006497	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.89	-17.15	-0.62	2.14e-51	Height;
LGG	cis	rs4819052	0.620	rs421619	chr21:46546115	C/A	cg19498844	chr21:46707878	POFUT2;LOC642852	0.53	7.98	0.35	1.17e-14	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9393777	0.513	rs9379893	chr6:26584668	A/G	cg12826209	chr6:26865740	GUSBL1	-0.86	-12.94	-0.52	6.84e-33	Intelligence (multi-trait analysis);
LGG	cis	rs4423214	0.840	rs2017686	chr11:71187061	C/G	cg10847948	chr11:71163743	NADSYN1	0.64	11.26	0.46	3.53e-26	Vitamin D levels;
LGG	cis	rs2470578	0.740	rs2060628	chr3:17275173	G/C	cg20981856	chr3:17787350	NA	0.35	6.79	0.3	3.44e-11	Schizophrenia;
LGG	cis	rs2841277	0.708	rs10083374	chr14:105402994	T/C	cg17340268	chr14:105411764	AHNAK2	-0.41	-7.66	-0.34	1.12e-13	Rheumatoid arthritis;
LGG	cis	rs17345786	0.906	rs11710016	chr3:101120030	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	-0.55	-8.29	-0.36	1.21e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7011049	0.687	rs7815780	chr8:53863922	C/A	cg26025543	chr8:53854495	NA	0.6	8.5	0.37	2.58e-16	Systolic blood pressure;
LGG	cis	rs861020	1.000	rs632746	chr1:209982515	C/T	cg05527609	chr1:210001259	C1orf107	0.74	10.15	0.43	5.24e-22	Orofacial clefts;
LGG	cis	rs9354352	0.818	rs9453548	chr6:66691885	T/C	cg07460842	chr6:66804631	NA	-0.67	-12.52	-0.5	3.62e-31	Initial pursuit acceleration in psychotic disorders;
LGG	cis	rs3806843	0.966	rs3756338	chr5:140180561	A/G	cg19875535	chr5:140030758	IK	0.51	10.34	0.43	1.1e-22	Depressive symptoms (multi-trait analysis);
LGG	trans	rs6952808	0.582	rs11763870	chr7:2027448	T/C	cg04565464	chr8:145669602	NFKBIL2	-0.4	-6.9	-0.31	1.69e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs12188164	0.561	rs2251843	chr5:457955	C/T	cg00473462	chr5:472545	LOC25845	-0.37	-7.03	-0.31	7.48e-12	Cystic fibrosis severity;
LGG	cis	rs74781061	0.929	rs8038730	chr15:74793344	T/C	cg02384859	chr15:74862662	ARID3B	-0.34	-7.07	-0.31	5.62e-12	Endometriosis;
LGG	cis	rs12410462	0.551	rs12059899	chr1:227863409	A/G	cg04117972	chr1:227635322	NA	0.44	8.07	0.35	6.01e-15	Major depressive disorder;
LGG	cis	rs6831352	0.918	rs7670241	chr4:100059619	G/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs4950322	0.542	rs12046706	chr1:146661337	G/T	cg22381352	chr1:146742008	CHD1L	-0.45	-7.69	-0.34	8.66e-14	Protein quantitative trait loci;
LGG	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg09873164	chr1:152488093	CRCT1	0.63	15.69	0.59	8.46e-45	Hair morphology;
LGG	cis	rs4742903	0.935	rs1450681	chr9:106932435	A/G	cg14250997	chr9:106856677	SMC2	0.4	8.21	0.36	2.3e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg20964023	chr14:91976739	SMEK1	0.38	6.65	0.3	8.11e-11	Eye color traits;
LGG	cis	rs6495122	0.644	rs62029217	chr15:75261899	C/T	cg09165964	chr15:75287851	SCAMP5	0.64	12.23	0.49	5.36e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9393777	0.513	rs7754159	chr6:26620312	G/A	cg12826209	chr6:26865740	GUSBL1	0.83	12.15	0.49	1.17e-29	Intelligence (multi-trait analysis);
LGG	cis	rs2439831	0.681	rs956391	chr15:43617493	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	-1.01	-13.25	-0.52	3.47e-34	Lung cancer in ever smokers;
LGG	cis	rs7681440	0.904	rs6816469	chr4:90772885	G/C	cg20003494	chr4:90757398	SNCA	-0.42	-8.31	-0.36	1.09e-15	Dementia with Lewy bodies;
LGG	cis	rs10197940	0.624	rs13393122	chr2:152413315	A/G	cg19508488	chr2:152266495	RIF1	0.61	10.74	0.45	3.63e-24	Lung cancer;
LGG	cis	rs9534288	0.797	rs4337200	chr13:46531749	G/A	cg15192986	chr13:46630673	CPB2	-0.6	-12.92	-0.51	7.82e-33	Blood protein levels;
LGG	cis	rs11064837	0.550	rs7304996	chr12:120094699	C/A	cg25937854	chr12:120150414	CIT	-0.67	-11.13	-0.46	1.13e-25	Schizophrenia;
LGG	cis	rs6735179	0.761	rs6723862	chr2:1779260	T/C	cg10160682	chr2:1713001	PXDN	-0.49	-7.92	-0.35	1.82e-14	Response to antipsychotic treatment;
LGG	cis	rs9814567	1.000	rs4368544	chr3:134300014	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs853679	0.517	rs9368558	chr6:28133306	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs17270561	0.609	rs1892248	chr6:25768914	C/T	cg03517284	chr6:25882590	NA	-0.42	-6.94	-0.31	1.34e-11	Iron status biomarkers;
LGG	cis	rs35110281	0.681	rs162343	chr21:44957072	A/G	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.1	-0.39	2.73e-18	Mean corpuscular volume;
LGG	cis	rs1801251	0.893	rs11687128	chr2:233608901	T/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	5.91e-19	Coronary artery disease;
LGG	cis	rs17270561	0.636	rs11794	chr6:25701718	G/A	cg12310025	chr6:25882481	NA	-0.42	-6.72	-0.3	5.51e-11	Iron status biomarkers;
LGG	cis	rs17854409	0.881	rs6011430	chr20:61497014	C/T	cg06598544	chr20:61472147	COL9A3	0.87	10.42	0.44	5.43e-23	Obesity-related traits;
LGG	cis	rs7444	0.941	rs2283789	chr22:21944478	T/G	cg15846791	chr22:21984385	YDJC	-0.45	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.93	-0.54	4.52e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs2735413	0.802	rs5008070	chr16:78096404	T/C	cg04733911	chr16:78082701	NA	0.74	17.19	0.62	1.34e-51	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs4665809	0.590	rs3806514	chr2:26466772	C/T	cg08470875	chr2:26401718	FAM59B	0.42	8.28	0.36	1.35e-15	Gut microbiome composition (summer);
LGG	cis	rs2439831	0.850	rs28696802	chr15:44140395	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.82	8.75	0.38	4.14e-17	Lung cancer in ever smokers;
LGG	cis	rs6594713	0.603	rs6879257	chr5:112845803	C/T	cg12552261	chr5:112820674	MCC	0.61	7.61	0.33	1.58e-13	Brain cytoarchitecture;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg16524936	chr4:1340807	KIAA1530	-0.43	-7.24	-0.32	1.86e-12	Longevity;
LGG	cis	rs745821	0.541	rs4939637	chr18:48109325	A/G	cg18923635	chr18:48083994	NA	0.39	7.35	0.32	8.97e-13	Diastolic blood pressure;
LGG	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg23422044	chr7:1970798	MAD1L1	-0.75	-12.58	-0.5	1.92e-31	Bipolar disorder;
LGG	cis	rs477692	0.935	rs568918	chr10:131414455	A/G	cg05714579	chr10:131428358	MGMT	0.66	14.05	0.55	1.4e-37	Response to temozolomide;
LGG	cis	rs11628318	0.515	rs9324049	chr14:103096352	T/C	cg12046867	chr14:103022105	NA	-0.4	-7.59	-0.33	1.81e-13	Platelet count;
LGG	cis	rs2762353	0.776	rs765285	chr6:25828242	G/C	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs10163483	chr17:80110396	C/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs9910055	0.718	rs2526022	chr17:42213216	C/T	cg08499158	chr17:42289980	UBTF	-0.58	-11.19	-0.46	6.79e-26	Total body bone mineral density;
LGG	cis	rs7493	0.950	rs7785705	chr7:95033803	A/T	cg17330251	chr7:94953956	PON1	-0.43	-8.47	-0.37	3.25e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs11711311	0.668	rs11718061	chr3:113341826	C/T	cg06805542	chr3:113465803	ATP6V1A;NAA50	0.39	7.0	0.31	8.81e-12	IgG glycosylation;
LGG	cis	rs62244186	0.715	rs13321717	chr3:44667455	C/A	cg02073558	chr3:44770973	ZNF501	0.71	13.61	0.53	1.05e-35	Depressive symptoms;
LGG	cis	rs67460515	0.531	rs13315565	chr3:160754626	G/C	cg03342759	chr3:160939853	NMD3	-0.67	-11.26	-0.46	3.8e-26	Parkinson's disease;
LGG	cis	rs13108043	0.511	rs13106574	chr4:87769929	T/C	cg11209507	chr4:87813803	C4orf36	0.64	8.27	0.36	1.46e-15	Red blood cell count;
LGG	cis	rs10504229	0.775	rs17804888	chr8:58158315	G/T	cg22535103	chr8:58192502	C8orf71	0.95	13.17	0.52	7.51e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs7511006	1.000	rs7290710	chr22:50677454	C/T	cg08875078	chr22:50639485	SELO	0.45	7.3	0.32	1.26e-12	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs12595334	chr15:67485156	C/T	cg05925327	chr15:68127851	NA	-0.31	-6.65	-0.3	8.4e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs877282	0.700	rs816311	chr10:796490	C/A	cg17470449	chr10:769945	NA	0.52	6.77	0.3	4.03e-11	Uric acid levels;
LGG	cis	rs72717009	0.825	rs7529425	chr1:161479599	G/A	cg23840854	chr1:161414152	NA	-0.72	-8.78	-0.38	3.26e-17	Rheumatoid arthritis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10520319	chr1:32666035	CCDC28B	0.47	7.14	0.31	3.69e-12	Gut microbiome composition (summer);
LGG	cis	rs5769765	0.908	rs9616213	chr22:50317851	T/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.9	-13.02	-0.52	3.11e-33	Schizophrenia;
LGG	cis	rs55728055	0.661	rs62237772	chr22:31964975	A/C	cg15823100	chr22:32027580	PISD	-0.81	-8.97	-0.38	7.63e-18	Age-related hearing impairment;
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg18050959	chr15:68126178	NA	-0.37	-6.98	-0.31	1.01e-11	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs684232	0.666	rs423887	chr17:593600	A/G	cg15660573	chr17:549704	VPS53	-0.69	-13.75	-0.54	2.69e-36	Prostate cancer;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.21	-0.32	2.29e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs877282	0.898	rs11253347	chr10:765769	A/G	cg22713356	chr15:30763199	NA	0.51	7.52	0.33	2.82e-13	Uric acid levels;
LGG	cis	rs8114671	0.527	rs3736802	chr20:33604042	T/C	cg24642439	chr20:33292090	TP53INP2	-0.58	-9.67	-0.41	2.98e-20	Height;
LGG	cis	rs6674970	1.000	rs4970941	chr1:151068546	A/G	cg11822372	chr1:151115635	SEMA6C	0.49	8.76	0.38	3.82e-17	Childhood ear infection;
LGG	cis	rs28386778	0.897	rs2665796	chr17:61923716	G/C	cg26338869	chr17:61819248	STRADA	0.58	9.83	0.42	7.65e-21	Prudent dietary pattern;
LGG	cis	rs59918340	0.728	rs4961340	chr8:142232002	G/A	cg23750338	chr8:142222470	SLC45A4	0.59	12.3	0.5	2.81e-30	Immature fraction of reticulocytes;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg23241637	chr2:185463803	ZNF804A	-0.42	-7.59	-0.33	1.83e-13	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs875971	0.540	rs35510581	chr7:65578777	G/A	cg00343986	chr7:65444356	GUSB	-0.4	-6.66	-0.3	7.77e-11	Aortic root size;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg16507663	chr6:150244633	RAET1G	0.51	10.36	0.43	9.28e-23	Testicular germ cell tumor;
LGG	cis	rs597539	0.616	rs72945243	chr11:68633358	T/C	cg06028808	chr11:68637592	NA	0.75	13.12	0.52	1.18e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs57046232	0.531	rs6054146	chr20:6335865	G/T	cg21095983	chr6:86352623	SYNCRIP	0.42	7.02	0.31	7.76e-12	Colorectal cancer;
LGG	cis	rs62064224	0.791	rs17806082	chr17:30705346	G/C	cg18200150	chr17:30822561	MYO1D	0.79	18.73	0.66	1.07e-58	Schizophrenia;
LGG	cis	rs4927850	1.000	rs7627706	chr3:195753353	A/C	cg00031303	chr3:195681400	NA	0.51	8.08	0.35	5.75e-15	Pancreatic cancer;
LGG	cis	rs2762353	0.935	rs1165215	chr6:25798932	G/A	cg18357526	chr6:26021779	HIST1H4A	0.55	9.49	0.4	1.23e-19	Blood metabolite levels;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11603023	0.772	rs540800	chr11:118565651	A/G	cg20110707	chr11:118481992	PHLDB1	0.47	9.09	0.39	2.96e-18	Cholesterol, total;
LGG	cis	rs881375	1.000	rs7037140	chr9:123656327	T/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.63	11.84	0.48	1.93e-28	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs6781811	chr3:10121922	A/G	cg00166722	chr3:10149974	C3orf24	-0.52	-8.81	-0.38	2.63e-17	Alzheimer's disease;
LGG	cis	rs6964587	0.933	rs6465350	chr7:91768615	G/A	cg17063962	chr7:91808500	NA	0.53	9.74	0.41	1.65e-20	Breast cancer;
LGG	cis	rs4665809	0.590	rs7588328	chr2:26469788	G/A	cg08470875	chr2:26401718	FAM59B	0.42	8.17	0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs9549367	0.713	rs3024756	chr13:113822950	G/C	cg00898013	chr13:113819073	PROZ	-0.49	-9.65	-0.41	3.38e-20	Platelet distribution width;
LGG	cis	rs3812831	0.629	rs7318527	chr13:114946956	C/T	cg25338242	chr13:114786047	RASA3	0.39	6.96	0.31	1.15e-11	Schizophrenia;
LGG	cis	rs2019137	0.560	rs7578633	chr2:113978650	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.84	16.35	0.61	9.01e-48	Lymphocyte counts;
LGG	cis	rs10791097	0.677	rs11222359	chr11:130730648	A/G	cg09137382	chr11:130731461	NA	0.42	8.01	0.35	9.65e-15	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg07274523	chr3:49395745	GPX1	0.58	9.69	0.41	2.34e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg08824895	chr13:115047677	UPF3A	0.42	7.16	0.32	3.18e-12	Schizophrenia;
LGG	cis	rs4820294	1.000	rs4820294	chr22:38071043	G/A	cg21798802	chr22:38057573	PDXP	0.6	13.92	0.54	4.72e-37	Fat distribution (HIV);
LGG	cis	rs477895	0.713	rs11607165	chr11:63963947	T/G	cg04317338	chr11:64019027	PLCB3	0.67	8.19	0.36	2.51e-15	Mean platelet volume;
LGG	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg24623649	chr8:11872141	NA	-0.3	-7.14	-0.31	3.69e-12	Systolic blood pressure;
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg13736514	chr6:26305472	NA	0.34	6.81	0.3	3.08e-11	Intelligence (multi-trait analysis);
LGG	cis	rs11252926	0.537	rs4881255	chr10:453638	T/C	cg18196295	chr10:418757	DIP2C	0.62	12.42	0.5	9.13e-31	Psychosis in Alzheimer's disease;
LGG	cis	rs638893	0.636	rs1784295	chr11:118660932	A/G	cg22253036	chr11:118662786	DDX6	0.43	6.67	0.3	7.22e-11	Vitiligo;
LGG	trans	rs11992162	0.636	rs4841642	chr8:11798334	C/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	7.76e-13	Monocyte count;
LGG	cis	rs11748327	0.580	rs3943033	chr5:4012303	C/T	cg01025095	chr5:4101132	NA	0.43	6.99	0.31	9.38e-12	Myocardial infarction;
LGG	cis	rs6502050	0.769	rs9916231	chr17:80119645	A/G	cg07959490	chr17:80112427	CCDC57	-0.45	-8.91	-0.38	1.2e-17	Life satisfaction;
LGG	cis	rs10929925	0.898	rs1880802	chr2:6144770	A/G	cg00493617	chr2:6141445	NA	0.31	6.85	0.3	2.41e-11	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);Body mass index;BMI in non-smokers;BMI (adjusted for smoking behaviour);
LGG	cis	rs11252926	0.550	rs11252134	chr10:442599	G/A	cg08603382	chr10:743973	NA	0.38	6.9	0.31	1.7e-11	Psychosis in Alzheimer's disease;
LGG	cis	rs12421382	0.659	rs1439511	chr11:109392839	G/T	cg27471124	chr11:109292789	C11orf87	-0.48	-8.85	-0.38	1.85e-17	Schizophrenia;
LGG	cis	rs9916302	0.821	rs12938268	chr17:37572139	G/A	cg00129232	chr17:37814104	STARD3	-0.61	-11.37	-0.47	1.42e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs4363385	0.693	rs6656812	chr1:152930254	C/T	cg13444842	chr1:152974279	SPRR3	0.4	7.52	0.33	2.88e-13	Inflammatory skin disease;
LGG	cis	rs9457247	0.534	rs2757053	chr6:167380338	A/C	cg18261144	chr6:167370276	RNASET2	-0.37	-7.68	-0.34	9.72e-14	Crohn's disease;
LGG	cis	rs6500395	1.000	rs7190106	chr16:48705542	C/T	cg16662043	chr16:48846231	NA	0.38	7.36	0.32	8.2e-13	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs873946	0.648	rs3793673	chr10:134547732	A/C	cg06453172	chr10:134556979	INPP5A	-0.56	-8.46	-0.37	3.44e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2204008	0.548	rs8189475	chr12:38037115	C/T	cg26384229	chr12:38710491	ALG10B	0.82	18.27	0.65	1.43e-56	Bladder cancer;
LGG	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg23752985	chr2:85803571	VAMP8	0.43	8.51	0.37	2.44e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7818345	0.712	rs13261442	chr8:19352333	C/G	cg06699216	chr8:19333253	CSGALNACT1	-0.39	-8.58	-0.37	1.48e-16	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs4253772	0.550	rs6008762	chr22:46736228	T/C	cg09461388	chr22:46763229	CELSR1	-0.68	-7.09	-0.31	5.08e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7811142	1.000	rs11764818	chr7:100043055	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs2011503	1.000	rs11670882	chr19:19649748	C/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.08	0.31	5.31e-12	Bipolar disorder;
LGG	cis	rs7808935	0.628	rs12666442	chr7:27937203	C/T	cg22168087	chr7:27702803	HIBADH	0.71	9.71	0.41	2.05e-20	Prostate cancer;
LGG	trans	rs656319	0.674	rs1484639	chr8:9983224	T/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.94	-0.38	9.4e-18	Myopia (pathological);
LGG	cis	rs7191439	0.728	rs8043924	chr16:88787704	G/C	cg02389323	chr16:88786976	FAM38A	0.93	12.11	0.49	1.58e-29	Plateletcrit;
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg11764359	chr7:65958608	NA	-0.73	-13.18	-0.52	6.43e-34	Aortic root size;
LGG	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg04990556	chr1:26633338	UBXN11	-0.68	-13.89	-0.54	6.65e-37	Obesity-related traits;
LGG	cis	rs9463078	0.845	rs9349315	chr6:45172289	A/G	cg25276700	chr6:44698697	NA	-0.41	-8.54	-0.37	1.99e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.72	14.85	0.57	4.26e-41	Obesity-related traits;
LGG	cis	rs6951245	1.000	rs80212261	chr7:1114012	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.21	-0.7	2.93e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6815814	0.950	rs56357984	chr4:38806462	G/A	cg06935464	chr4:38784597	TLR10	0.59	7.84	0.34	3.18e-14	Breast cancer;
LGG	trans	rs2204008	0.627	rs1851117	chr12:38398987	G/T	cg06521331	chr12:34319734	NA	-0.51	-8.88	-0.38	1.49e-17	Bladder cancer;
LGG	cis	rs9611565	0.659	rs28530678	chr22:41934961	G/C	cg06634786	chr22:41940651	POLR3H	-0.79	-12.65	-0.51	1.03e-31	Vitiligo;
LGG	cis	rs28595532	1.000	rs115915387	chr4:119640854	C/T	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs3771570	1.000	rs55645375	chr2:242269024	A/G	cg21155796	chr2:242212141	HDLBP	0.73	9.27	0.4	6.88e-19	Prostate cancer;
LGG	cis	rs1153858	1.000	rs4625670	chr15:45652926	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs8070624	0.543	rs11078409	chr17:17876296	C/G	cg24612305	chr17:17875800	TOM1L2;LRRC48	0.79	15.84	0.59	1.88e-45	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08655493	chr21:33765248	URB1;C21orf119	0.5	8.09	0.35	5.21e-15	Gut microbiome composition (summer);
LGG	cis	rs2046867	0.862	rs2322612	chr3:72830058	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.28	0.32	1.49e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs3747547	0.710	rs16934658	chr9:37950543	C/A	cg13774184	chr9:37916125	SHB	-0.72	-8.02	-0.35	8.98e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs877282	0.891	rs11595385	chr10:800539	A/G	cg17470449	chr10:769945	NA	0.63	7.7	0.34	8.35e-14	Uric acid levels;
LGG	cis	rs60843830	1.000	rs60149603	chr2:285421	A/G	cg12623918	chr2:306882	NA	0.55	10.12	0.43	6.87e-22	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6500602	0.727	rs2160567	chr16:4535557	C/T	cg08645402	chr16:4508243	NA	0.51	9.92	0.42	3.72e-21	Schizophrenia;
LGG	cis	rs875971	0.862	rs778684	chr7:65836403	A/T	cg23594656	chr7:65796392	TPST1	-0.4	-8.98	-0.39	6.88e-18	Aortic root size;
LGG	cis	rs7695597	0.684	rs3946906	chr4:185175421	C/T	cg12654155	chr4:185238627	NA	-0.41	-7.38	-0.32	7.32e-13	Night sleep phenotypes;
LGG	cis	rs7954584	0.505	rs11043278	chr12:122412145	C/T	cg22168489	chr12:122356033	WDR66	0.41	9.56	0.41	6.87e-20	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg07677032	chr17:61819896	STRADA	-0.64	-11.39	-0.47	1.18e-26	Prudent dietary pattern;
LGG	cis	rs9479482	0.967	rs11752529	chr6:150347971	C/T	cg07549998	chr6:150325970	RAET1K	-0.37	-6.89	-0.3	1.84e-11	Alopecia areata;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09131135	chr2:27886635	SLC4A1AP;SUPT7L	0.42	6.87	0.3	2.05e-11	Cognitive performance;
LGG	cis	rs936229	0.954	rs936230	chr15:75145098	C/T	cg14664628	chr15:75095509	CSK	0.98	21.34	0.7	7.36e-71	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs1552244	0.872	rs6771931	chr3:10113408	C/G	cg16606324	chr3:10149918	C3orf24	0.54	7.19	0.32	2.62e-12	Alzheimer's disease;
LGG	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg01181863	chr3:195395398	SDHAP2	-0.63	-10.0	-0.42	1.83e-21	Pancreatic cancer;
LGG	cis	rs3806843	0.801	rs2531358	chr5:140117437	A/G	cg19875535	chr5:140030758	IK	-0.58	-12.3	-0.5	2.73e-30	Depressive symptoms (multi-trait analysis);
LGG	cis	rs773506	0.602	rs10761110	chr9:93929884	A/G	cg14446406	chr9:93919335	NA	0.64	11.28	0.46	2.98e-26	Type 2 diabetes nephropathy;
LGG	cis	rs7953508	0.587	rs9634212	chr12:93993266	C/A	cg18151635	chr12:93972918	NA	-0.45	-7.86	-0.34	2.75e-14	Pubertal anthropometrics;
LGG	cis	rs72945132	0.882	rs67822447	chr11:70230972	G/T	cg14191688	chr11:70257035	CTTN	0.56	8.12	0.35	4.24e-15	Coronary artery disease;
LGG	cis	rs11148252	0.967	rs11620062	chr13:52994026	T/G	cg12458913	chr13:53173898	NA	0.71	14.71	0.56	1.88e-40	Lewy body disease;
LGG	trans	rs61931739	0.649	rs815043	chr12:33722599	C/T	cg26384229	chr12:38710491	ALG10B	0.48	8.61	0.37	1.16e-16	Morning vs. evening chronotype;
LGG	cis	rs7786808	0.707	rs11770299	chr7:158228822	G/A	cg12438819	chr7:158236134	PTPRN2	0.34	8.97	0.38	7.12e-18	Obesity-related traits;
LGG	cis	rs1729951	0.575	rs1654925	chr3:136690391	C/T	cg21827317	chr3:136751795	NA	-0.53	-10.06	-0.42	1.16e-21	Neuroticism;
LGG	cis	rs1577917	1.000	rs12201741	chr6:86602619	G/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-12.89	-0.51	1.1e-32	Response to antipsychotic treatment;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg26283127	chr17:1639552	WDR81	0.33	6.68	0.3	6.73e-11	Menarche (age at onset);
LGG	cis	rs2133450	0.526	rs12492754	chr3:7346656	A/G	cg19930620	chr3:7340148	GRM7	-0.42	-9.29	-0.4	5.83e-19	Early response to risperidone in schizophrenia;
LGG	cis	rs2040771	0.740	rs9605960	chr22:19214636	G/C	cg02655711	chr22:19163373	SLC25A1	0.47	8.48	0.37	2.95e-16	Metabolite levels (small molecules and protein measures);
LGG	cis	rs4690686	0.500	rs4690688	chr4:177264192	G/C	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs13108904	0.521	rs4974609	chr4:1356924	A/C	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.48	-8.51	-0.37	2.44e-16	Obesity-related traits;
LGG	cis	rs2839186	0.706	rs2839188	chr21:47692798	C/T	cg05896524	chr21:47604654	C21orf56	0.66	10.74	0.45	3.7e-24	Testicular germ cell tumor;
LGG	cis	rs6028335	0.610	rs6729	chr20:37668272	A/G	cg16355469	chr20:37678765	NA	0.6	8.01	0.35	9.26e-15	Alcohol and nicotine co-dependence;
LGG	trans	rs725344	1.000	rs7659722	chr4:54675400	T/C	cg01654820	chr16:10675123	EMP2	-0.54	-6.68	-0.3	6.88e-11	Serum VEGFR2 concentration;
LGG	cis	rs3785574	0.705	rs2665856	chr17:61982721	T/A	cg06601766	chr17:61851465	DDX42;CCDC47	-0.51	-7.98	-0.35	1.14e-14	Height;
LGG	cis	rs7618915	0.501	rs11130308	chr3:52639257	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.48	0.47	5.16e-27	Bipolar disorder;
LGG	trans	rs783540	0.809	rs3970696	chr15:83263756	A/T	cg18393722	chr15:85113863	UBE2QP1	0.38	6.66	0.3	7.92e-11	Schizophrenia;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg05368731	chr17:41323189	NBR1	0.96	18.92	0.66	1.43e-59	Menopause (age at onset);
LGG	cis	rs10504229	0.645	rs56670121	chr8:58138872	C/T	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs41271473	0.948	rs11585206	chr1:228824848	C/T	cg00850481	chr1:228891306	NA	-0.49	-7.63	-0.33	1.31e-13	Chronic lymphocytic leukemia;
LGG	cis	rs908922	0.627	rs1053588	chr1:152488063	C/T	cg20991723	chr1:152506922	NA	-0.69	-14.16	-0.55	4.52e-38	Hair morphology;
LGG	cis	rs6951245	1.000	rs75016635	chr7:1094121	G/A	cg12692727	chr7:1102344	C7orf50	0.49	6.82	0.3	2.79e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1580019	0.587	rs6968990	chr7:32552159	C/T	cg07520158	chr7:32535189	LSM5;AVL9	-0.59	-9.94	-0.42	3.18e-21	Cognitive ability;
LGG	cis	rs2708240	0.936	rs4140925	chr7:147578597	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	3.04e-11	QT interval (drug interaction);
LGG	cis	rs11074306	0.561	rs28609514	chr15:28070777	G/C	cg26402630	chr15:28053930	OCA2	0.37	7.37	0.32	7.69e-13	Uveal melanoma;
LGG	cis	rs7647973	0.626	rs11720705	chr3:49753788	A/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.62	-0.33	1.48e-13	Menarche (age at onset);
LGG	cis	rs7172689	0.908	rs58076056	chr15:81567576	G/A	cg11808699	chr15:81528661	IL16	-0.48	-9.69	-0.41	2.41e-20	Inattentive symptoms;
LGG	cis	rs7208859	0.673	rs216411	chr17:28903493	T/C	cg01831904	chr17:28903510	LRRC37B2	0.9	11.88	0.48	1.32e-28	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10243591	chr14:21656260	NA	0.32	7.48	0.33	3.77e-13	Menarche (age at onset);
LGG	cis	rs701145	0.556	rs357502	chr3:153955950	C/T	cg12800244	chr3:153838788	SGEF	0.57	8.12	0.35	4.34e-15	Coronary artery disease;
LGG	cis	rs62103177	0.810	rs62103197	chr18:77632923	G/A	cg20368463	chr18:77673604	PQLC1	0.58	7.48	0.33	3.76e-13	Opioid sensitivity;
LGG	cis	rs11758351	0.789	rs4496782	chr6:26184617	T/C	cg16885296	chr6:26284938	NA	0.37	6.87	0.3	2.05e-11	Gout;Renal underexcretion gout;
LGG	cis	rs7756236	0.538	rs6936598	chr6:36626096	T/C	cg08179530	chr6:36648295	CDKN1A	0.42	6.69	0.3	6.59e-11	QRS duration;
LGG	cis	rs7847628	0.587	rs1060817	chr9:123583192	A/G	cg09833538	chr9:123605306	PSMD5;LOC253039	0.6	10.63	0.44	8.91e-24	Birth weight;
LGG	cis	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg21775007	chr8:11205619	TDH	0.83	15.48	0.58	7.35e-44	Retinal vascular caliber;
LGG	cis	rs9810259	0.508	rs9853146	chr3:12299313	C/T	cg15873301	chr3:12045459	SYN2	0.44	7.44	0.33	5.08e-13	Platelet count;
LGG	cis	rs7172677	1.000	rs4479194	chr15:75422131	C/T	cg14664628	chr15:75095509	CSK	-0.46	-7.03	-0.31	7.46e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs9291683	0.552	rs10939655	chr4:10014642	A/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.43	0.4	2.06e-19	Bone mineral density;
LGG	trans	rs3857536	0.813	rs6455083	chr6:66935406	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.46	-7.74	-0.34	6.37e-14	Blood trace element (Cu levels);
LGG	cis	rs2762353	0.935	rs3757131	chr6:25783909	C/T	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.35	-0.4	3.78e-19	Blood metabolite levels;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25072359	chr17:41440525	NA	0.52	10.18	0.43	4.32e-22	Menopause (age at onset);
LGG	cis	rs7309	0.935	rs10930013	chr2:162070325	G/A	cg22496339	chr2:162101262	NA	-0.53	-11.71	-0.48	6.13e-28	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);Educational attainment;
LGG	cis	rs9341835	0.608	rs2800017	chr6:64158077	C/T	cg00787780	chr6:64151745	NA	-0.44	-8.13	-0.35	3.89e-15	Schizophrenia;
LGG	cis	rs10464366	0.746	rs11760807	chr7:39142377	G/A	cg21665744	chr7:39171113	POU6F2	0.39	7.97	0.35	1.23e-14	IgG glycosylation;
LGG	cis	rs11239187	0.523	rs35473674	chr10:45090153	T/C	cg03916630	chr10:45065415	NA	0.42	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs9596863	1.000	rs1545659	chr13:54433788	G/A	ch.13.53330881F	chr13:54432880	NA	-0.5	-7.19	-0.32	2.54e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs607541	1.000	rs2099880	chr15:45935074	T/C	cg26924012	chr15:45694286	SPATA5L1	0.53	7.4	0.33	6.58e-13	Obesity-related traits;
LGG	cis	rs9322193	0.924	rs9498382	chr6:149932118	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.67	-0.41	2.9e-20	Lung cancer;
LGG	cis	rs10991814	0.920	rs78181783	chr9:94032205	C/T	cg14446406	chr9:93919335	NA	-0.73	-8.14	-0.35	3.56e-15	Neutrophil percentage of granulocytes;
LGG	trans	rs6787172	0.622	rs9867617	chr3:158077344	G/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.27	-0.32	1.49e-12	Subjective well-being;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg15971980	chr6:150254442	NA	0.45	8.58	0.37	1.41e-16	Lung cancer;
LGG	cis	rs6456042	0.893	rs1056053	chr6:166571443	C/T	cg11088901	chr6:166572345	T	-0.38	-8.01	-0.35	9.16e-15	Asthma;
LGG	cis	rs17345786	1.000	rs7641261	chr3:101279006	C/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.53	9.09	0.39	2.95e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7618915	0.547	rs1561337	chr3:52659963	C/T	cg18099408	chr3:52552593	STAB1	-0.34	-6.78	-0.3	3.67e-11	Bipolar disorder;
LGG	trans	rs12310956	0.532	rs35366144	chr12:33992000	C/G	cg26384229	chr12:38710491	ALG10B	0.81	15.99	0.6	3.93e-46	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg24829409	chr8:58192753	C8orf71	-0.62	-8.26	-0.36	1.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6993813	0.620	rs7016585	chr8:120030098	C/A	cg17171407	chr8:119960777	TNFRSF11B	0.31	7.76	0.34	5.5e-14	Bone mineral density (hip);
LGG	cis	rs2228479	0.867	rs73276534	chr16:89950557	A/G	cg06558623	chr16:89946397	TCF25	0.92	12.02	0.49	3.76e-29	Skin colour saturation;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg11841349	chr3:9791615	OGG1	-0.42	-7.09	-0.31	4.88e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs8114671	0.562	rs6088646	chr20:33505937	T/C	cg24642439	chr20:33292090	TP53INP2	0.44	7.04	0.31	7.12e-12	Height;
LGG	cis	rs2241941	0.840	rs10500882	chr11:20629837	A/G	cg09136245	chr11:20631761	SLC6A5	0.44	8.09	0.35	5.35e-15	Obesity-related traits;
LGG	cis	rs4906332	1.000	rs17617094	chr14:103893428	T/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.92	-0.35	1.72e-14	Coronary artery disease;
LGG	cis	rs3806843	0.549	rs246012	chr5:140336277	C/T	cg19875535	chr5:140030758	IK	0.38	7.56	0.33	2.23e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs79349575	0.756	rs4793605	chr17:47035869	T/C	cg16584676	chr17:46985605	UBE2Z	0.49	8.36	0.36	7.31e-16	Type 2 diabetes;
LGG	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.32	-0.32	1.11e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs941408	0.515	rs12610096	chr19:2778129	C/T	cg22153745	chr1:153894579	GATAD2B	-0.57	-8.6	-0.37	1.23e-16	Total cholesterol levels;
LGG	trans	rs2898290	0.622	rs4840567	chr8:11347625	A/G	cg02002194	chr4:3960332	NA	0.47	9.2	0.39	1.25e-18	Systolic blood pressure;
LGG	cis	rs9814567	0.963	rs36006513	chr3:134291913	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	12.98	0.52	4.63e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.683	rs56204590	chr8:58131642	T/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs826838	0.935	rs11169511	chr12:39175802	T/C	cg06521331	chr12:34319734	NA	-0.44	-7.51	-0.33	3.1e-13	Heart rate;
LGG	cis	rs17767392	0.881	rs35620527	chr14:71915703	A/G	cg02058870	chr14:72053146	SIPA1L1	0.39	8.14	0.35	3.63e-15	Mitral valve prolapse;
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg18402987	chr7:1209562	NA	0.4	7.32	0.32	1.09e-12	Longevity;Endometriosis;
LGG	trans	rs2204008	0.743	rs2127952	chr12:37995364	G/T	cg06521331	chr12:34319734	NA	-0.54	-9.79	-0.41	1.09e-20	Bladder cancer;
LGG	cis	rs12230513	0.838	rs7297323	chr12:55941692	A/C	cg19537932	chr12:55886519	OR6C68	-0.37	-6.65	-0.3	8.07e-11	Contrast sensitivity;
LGG	cis	rs2153535	0.541	rs9379207	chr6:8458186	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.28	0.43	1.81e-22	Motion sickness;
LGG	cis	rs4704187	0.640	rs74719230	chr5:74431888	G/C	cg03227963	chr5:74354835	NA	0.31	6.71	0.3	5.75e-11	Response to amphetamines;
LGG	cis	rs854765	0.547	rs6502632	chr17:17913057	A/G	cg04398451	chr17:18023971	MYO15A	-0.73	-15.26	-0.58	6.84e-43	Total body bone mineral density;
LGG	cis	rs3096299	0.685	rs12935112	chr16:89542858	C/T	cg05484508	chr16:89589025	SPG7	-0.45	-7.26	-0.32	1.68e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs9329289	1.000	rs9329289	chr10:2542389	A/G	cg05625103	chr10:2543513	NA	0.42	8.06	0.35	6.49e-15	Age-related hearing impairment;
LGG	cis	rs7954584	0.567	rs11043243	chr12:122356370	G/C	cg12705353	chr12:122356852	WDR66	0.24	6.65	0.3	8.36e-11	Mean corpuscular volume;
LGG	cis	rs35306767	0.903	rs7074642	chr10:878359	A/G	cg25019033	chr10:957182	NA	-0.54	-10.02	-0.42	1.62e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs9815354	1.000	rs1052501	chr3:41925398	C/T	cg03022575	chr3:42003672	ULK4	-0.65	-8.31	-0.36	1.08e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6502050	0.835	rs4523985	chr17:80154466	C/A	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.36e-20	Life satisfaction;
LGG	cis	rs6598955	0.670	rs7520517	chr1:26556385	A/C	cg10402321	chr1:26617780	UBXN11	-0.35	-6.73	-0.3	5.02e-11	Obesity-related traits;
LGG	cis	rs4356932	1.000	rs6814817	chr4:76951170	C/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs10893109	0.538	rs1901878	chr11:123798849	A/G	cg12387464	chr11:123775935	OR8D4	0.38	8.24	0.36	1.85e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs28595532	0.920	rs116231457	chr4:119762396	A/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.592	rs12484467	chr22:41957610	T/C	cg17376030	chr22:41985996	PMM1	0.62	9.75	0.41	1.55e-20	Vitiligo;
LGG	cis	rs6500637	0.580	rs5013674	chr16:4932470	G/A	cg04440724	chr16:4920505	UBN1	0.57	11.93	0.48	8.74e-29	Cancer;
LGG	cis	rs7552404	0.924	rs1146579	chr1:76209792	C/T	cg22875332	chr1:76189707	ACADM	-0.61	-10.72	-0.45	4.36e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs727505	0.721	rs56269941	chr7:124768732	T/A	cg23710748	chr7:124431027	NA	-0.43	-8.31	-0.36	1.09e-15	Lewy body disease;
LGG	cis	rs6719977	0.543	rs6544594	chr2:42977579	C/T	cg14631114	chr2:43023945	NA	0.48	10.14	0.43	6.11e-22	Hyperactive-impulsive symptoms;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg21872543	chr2:27603766	ZNF513	0.46	6.68	0.3	6.7e-11	Hip circumference;
LGG	cis	rs72781680	0.566	rs72796106	chr2:23901362	A/C	cg08917208	chr2:24149416	ATAD2B	0.62	7.12	0.31	4.16e-12	Lymphocyte counts;
LGG	cis	rs870825	0.655	rs67380800	chr4:185623788	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.71	0.73	2.88e-77	Blood protein levels;
LGG	cis	rs6500602	0.702	rs6500606	chr16:4502514	A/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.45	-9.59	-0.41	5.35e-20	Schizophrenia;
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg05064044	chr6:292385	DUSP22	-0.66	-11.21	-0.46	5.89e-26	Menopause (age at onset);
LGG	cis	rs2576037	0.623	rs2576042	chr18:44577461	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.51	-10.14	-0.43	6e-22	Personality dimensions;
LGG	cis	rs3735485	0.800	rs7385926	chr7:45062828	G/A	cg03440944	chr7:45023329	C7orf40	0.55	9.44	0.4	1.84e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs11864453	1.000	rs2278027	chr16:72051369	A/G	cg01557791	chr16:72042693	DHODH	-0.63	-11.73	-0.48	5.14e-28	Fibrinogen levels;
LGG	cis	rs11098499	0.954	rs3733524	chr4:120423729	T/C	cg09307838	chr4:120376055	NA	0.81	13.21	0.52	5.15e-34	Corneal astigmatism;
LGG	cis	rs16973500	0.808	rs112121746	chr16:71874983	G/A	cg00732059	chr16:71740210	PHLPP2	-0.61	-9.75	-0.41	1.52e-20	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs2250402	0.510	rs8031319	chr15:40323692	A/G	cg16127683	chr15:40268777	EIF2AK4	-0.91	-9.87	-0.42	5.73e-21	Corneal curvature;
LGG	cis	rs7249142	0.549	rs7260127	chr19:19280499	C/T	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	0.28	8.13	0.35	3.96e-15	IgG glycosylation;
LGG	cis	rs2762353	0.595	rs9467591	chr6:25742699	C/T	cg12310025	chr6:25882481	NA	-0.73	-14.45	-0.56	2.61e-39	Blood metabolite levels;
LGG	cis	rs7811142	0.779	rs111312383	chr7:99905325	C/T	cg11814155	chr7:99998594	ZCWPW1	0.61	8.83	0.38	2.23e-17	Platelet count;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg23029494	chr19:50167926	IRF3;BCL2L12	-0.4	-6.67	-0.3	7.42e-11	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs17685	0.753	rs4573217	chr7:75733946	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.85	0.77	7.24e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs16854884	0.657	rs4611822	chr3:143735544	C/T	cg06585982	chr3:143692056	C3orf58	0.61	10.57	0.44	1.59e-23	Economic and political preferences (feminism/equality);
LGG	cis	rs11758351	0.866	rs56186759	chr6:26207181	C/T	cg11342453	chr6:26196699	NA	0.48	6.69	0.3	6.42e-11	Gout;Renal underexcretion gout;
LGG	cis	rs2204008	0.545	rs1663283	chr12:38132039	G/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.98	-0.35	1.13e-14	Bladder cancer;
LGG	cis	rs283228	0.617	rs997900	chr6:101774154	A/G	cg27451362	chr6:101846650	GRIK2	0.86	13.49	0.53	3.16e-35	Coenzyme Q10 levels;
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg17202724	chr17:61916730	SMARCD2	0.49	10.96	0.45	5.45e-25	Prudent dietary pattern;
LGG	cis	rs2880765	0.566	rs17553249	chr15:86006694	A/G	cg13263323	chr15:86062960	AKAP13	-0.34	-6.81	-0.3	3.11e-11	Coronary artery disease;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.42	7.23	0.32	2.04e-12	Longevity;
LGG	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg20848291	chr7:100343083	ZAN	-0.66	-9.79	-0.41	1.08e-20	Other erythrocyte phenotypes;
LGG	cis	rs13217239	0.646	rs4269366	chr6:27016413	C/T	cg09904177	chr6:26538194	HMGN4	0.38	6.85	0.3	2.4e-11	Schizophrenia;
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg22398616	chr13:53314203	LECT1	-0.48	-9.89	-0.42	4.78e-21	Lewy body disease;
LGG	cis	rs4950322	0.570	rs17356492	chr1:146767770	T/C	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg15490075	chr13:100150979	NA	0.53	7.18	0.32	2.8e-12	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs12762228	chr10:880854	G/A	cg08847335	chr10:891726	LARP4B	-0.53	-9.0	-0.39	6.07e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.0	-15.49	-0.58	6.92e-44	Platelet count;
LGG	cis	rs908922	0.676	rs1538083	chr1:152517116	A/G	cg03606772	chr1:152487856	CRCT1	0.29	6.68	0.3	6.69e-11	Hair morphology;
LGG	trans	rs1728785	0.901	rs6499186	chr16:68660565	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.77	11.81	0.48	2.66e-28	Ulcerative colitis;
LGG	trans	rs66573146	0.634	rs55633489	chr4:6988745	C/A	cg07817883	chr1:32538562	TMEM39B	1.26	11.97	0.49	6.11e-29	Granulocyte percentage of myeloid white cells;
LGG	cis	rs769267	0.930	rs10402451	chr19:19608537	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.46	0.56	2.15e-39	Tonsillectomy;
LGG	cis	rs9487051	1.000	rs6568570	chr6:109613241	T/G	cg21918786	chr6:109611834	NA	-0.44	-8.19	-0.36	2.61e-15	Reticulocyte fraction of red cells;
LGG	trans	rs6952808	0.931	rs12537430	chr7:1868761	A/G	cg24247370	chr13:99142703	STK24	0.37	6.65	0.3	8.49e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs4555082	0.789	rs2816649	chr14:105708326	A/G	cg13114125	chr14:105738426	BRF1	-0.85	-17.2	-0.62	1.32e-51	Mean platelet volume;Platelet distribution width;
LGG	cis	rs2072499	0.778	rs41265025	chr1:156163906	C/T	cg25208724	chr1:156163844	SLC25A44	1.13	20.34	0.69	3.31e-66	Testicular germ cell tumor;
LGG	cis	rs11690935	0.686	rs10165126	chr2:172820315	C/T	cg21435375	chr2:172878103	MAP1D	-0.33	-7.59	-0.33	1.84e-13	Schizophrenia;
LGG	cis	rs240764	0.554	rs6570970	chr6:101233082	C/A	cg09795085	chr6:101329169	ASCC3	0.47	8.1	0.35	4.86e-15	Neuroticism;
LGG	cis	rs55665837	1.000	rs12364959	chr11:14507435	T/C	cg19336497	chr11:14380999	RRAS2	-0.45	-8.79	-0.38	2.84e-17	Vitamin D levels;
LGG	cis	rs1451375	0.617	rs12671474	chr7:50591395	C/A	cg20336341	chr7:50628841	DDC	0.43	7.61	0.33	1.52e-13	Malaria;
LGG	trans	rs7980799	0.933	rs11052705	chr12:33588388	T/C	cg26384229	chr12:38710491	ALG10B	-0.51	-8.96	-0.38	8.25e-18	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.44	7.59	0.33	1.8e-13	Longevity;
LGG	cis	rs2839186	0.786	rs7409792	chr21:47691729	C/A	cg13732083	chr21:47605072	C21orf56	0.47	7.89	0.34	2.17e-14	Testicular germ cell tumor;
LGG	cis	rs9322193	0.923	rs11155677	chr6:150078089	C/G	cg16507663	chr6:150244633	RAET1G	0.46	8.66	0.37	7.97e-17	Lung cancer;
LGG	cis	rs5769765	0.773	rs6520065	chr22:50294470	A/T	cg02269571	chr22:50332266	NA	-0.63	-10.09	-0.42	8.96e-22	Schizophrenia;
LGG	cis	rs7202877	0.706	rs42472	chr16:75473320	T/A	cg03315344	chr16:75512273	CHST6	-0.49	-6.77	-0.3	3.89e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs4481887	0.927	rs10788765	chr1:248445642	A/G	cg13385794	chr1:248469461	NA	-0.46	-7.68	-0.34	9.77e-14	Common traits (Other);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	31.49	0.83	3.59e-117	Prudent dietary pattern;
LGG	cis	rs7582180	0.627	rs4149523	chr2:101007039	T/C	cg14675211	chr2:100938903	LONRF2	0.61	10.69	0.44	5.4e-24	Intelligence (multi-trait analysis);
LGG	cis	rs977987	0.806	rs12051326	chr16:75437887	G/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.71	0.3	5.73e-11	Dupuytren's disease;
LGG	cis	rs9547692	1.000	rs9531993	chr13:37475197	G/C	cg01493522	chr13:37497338	NA	-0.49	-8.26	-0.36	1.58e-15	Coronary artery disease;
LGG	cis	rs1005224	0.864	rs11625011	chr14:76144828	G/A	cg25116370	chr14:76127843	TTLL5;C14orf1	-0.41	-7.0	-0.31	9.02e-12	Large artery stroke;
LGG	cis	rs10276381	0.579	rs58696040	chr7:28148387	A/G	cg23620719	chr7:28220237	JAZF1	0.7	7.37	0.32	7.86e-13	Crohn's disease;
LGG	trans	rs11875185	0.510	rs17754576	chr18:55600971	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs7614311	0.636	rs17344090	chr3:64004101	T/C	cg22134162	chr3:63841271	THOC7	-0.41	-7.36	-0.32	8.29e-13	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs6500602	0.647	rs1659497	chr16:4594635	G/A	cg05091796	chr16:4465799	CORO7	0.62	10.21	0.43	3.24e-22	Schizophrenia;
LGG	cis	rs368123	1.000	rs434012	chr6:160738800	T/C	cg07349212	chr6:160770346	SLC22A3	-0.36	-7.8	-0.34	4.04e-14	Waist circumference;
LGG	cis	rs9486719	1.000	rs12193732	chr6:96942609	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.66	-0.44	7.03e-24	Migraine;Coronary artery disease;
LGG	trans	rs61931739	0.929	rs7955240	chr12:34066388	G/A	cg13010199	chr12:38710504	ALG10B	-0.45	-8.83	-0.38	2.2e-17	Morning vs. evening chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg04811762	chr6:150039439	LATS1	0.4	6.91	0.31	1.64e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs28588043	1.000	rs16863934	chr1:170981149	A/G	cg03458344	chr1:170964477	C1orf129	-0.52	-7.46	-0.33	4.26e-13	Number of children (6+ vs. 0 or 1);
LGG	cis	rs4789693	0.518	rs6502117	chr17:80452592	G/C	cg04308225	chr17:80449738	NA	0.59	9.95	0.42	2.82e-21	Glucocorticoid-induced osteonecrosis;
LGG	cis	rs953387	0.910	rs1123848	chr2:136945029	C/T	cg07169764	chr2:136633963	MCM6	0.53	8.74	0.38	4.33e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs8067545	0.611	rs9898080	chr17:20035257	A/G	cg09818912	chr17:20140352	CYTSB	-0.33	-7.67	-0.34	9.95e-14	Schizophrenia;
LGG	cis	rs17270561	0.666	rs1937129	chr6:25789132	A/G	cg12310025	chr6:25882481	NA	-0.45	-7.39	-0.33	6.7e-13	Iron status biomarkers;
LGG	trans	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg06521331	chr12:34319734	NA	-0.52	-8.98	-0.39	7.09e-18	Bladder cancer;
LGG	cis	rs8114671	0.836	rs2104083	chr20:33649133	G/A	cg07148914	chr20:33460835	GGT7	-0.49	-8.13	-0.35	3.9e-15	Height;
LGG	cis	rs4684776	1.000	rs62245864	chr3:11417126	C/T	cg24705426	chr3:11550659	ATG7	-0.43	-7.62	-0.33	1.43e-13	Small vessel stroke;
LGG	cis	rs72945132	0.882	rs7937984	chr11:70144254	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs4969178	0.965	rs4969179	chr17:76391454	A/C	cg20026190	chr17:76395443	PGS1	0.57	9.99	0.42	2e-21	HDL cholesterol levels;
LGG	cis	rs7824557	0.713	rs9286062	chr8:11118527	G/A	cg15596359	chr8:11213517	TDH	0.33	6.66	0.3	7.9e-11	Retinal vascular caliber;
LGG	cis	rs2228479	0.764	rs35518096	chr16:89961140	C/A	cg04013166	chr16:89971882	TCF25	0.54	7.22	0.32	2.12e-12	Skin colour saturation;
LGG	cis	rs4919087	0.590	rs7915926	chr10:99054052	C/T	cg25902810	chr10:99078978	FRAT1	-0.45	-7.2	-0.32	2.38e-12	Monocyte count;
LGG	cis	rs7617773	0.817	rs6794644	chr3:48330037	T/C	cg11946769	chr3:48343235	NME6	0.63	10.62	0.44	9.81e-24	Coronary artery disease;
LGG	trans	rs2018683	0.624	rs6462119	chr7:29003725	G/C	cg19402173	chr7:128379420	CALU	-0.73	-13.26	-0.52	3.11e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs1881797	1.000	rs1881796	chr1:247688931	G/A	cg11166453	chr1:247681781	NA	0.62	9.75	0.41	1.54e-20	Acute lymphoblastic leukemia (childhood);
LGG	trans	rs8073060	0.586	rs17638867	chr17:34052513	C/T	cg19694781	chr19:47549865	TMEM160	1.14	17.65	0.63	1.03e-53	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs6502050	0.871	rs8066137	chr17:80074316	T/C	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs7923609	0.967	rs10761758	chr10:65172747	A/T	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.68	-0.3	6.67e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1816752	1.000	rs9507341	chr13:25006578	G/T	cg22771759	chr13:24902376	NA	-0.47	-7.96	-0.35	1.31e-14	Obesity-related traits;
LGG	cis	rs561341	0.609	rs4795659	chr17:30187139	C/G	cg13647721	chr17:30228624	UTP6	-0.74	-9.39	-0.4	2.71e-19	Hip circumference adjusted for BMI;
LGG	cis	rs7086627	0.515	rs10887895	chr10:82210011	A/G	cg01528321	chr10:82214614	TSPAN14	0.65	11.75	0.48	4.26e-28	Post bronchodilator FEV1;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg20607798	chr8:58055168	NA	0.62	7.27	0.32	1.56e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9911578	0.967	rs686425	chr17:56776730	A/G	cg12560992	chr17:57184187	TRIM37	0.89	15.79	0.59	2.97e-45	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs9379789	chr6:25745579	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.07	-0.31	5.71e-12	Iron status biomarkers;
LGG	cis	rs9487094	0.961	rs9487068	chr6:109671845	G/C	cg16315928	chr6:109776240	MICAL1	0.53	8.93	0.38	1.04e-17	Height;
LGG	cis	rs2439831	0.850	rs7183809	chr15:44120868	T/G	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.64	0.37	8.91e-17	Lung cancer in ever smokers;
LGG	cis	rs10256972	0.732	rs1574108	chr7:1105805	T/C	cg16145915	chr7:1198662	ZFAND2A	-0.54	-9.41	-0.4	2.37e-19	Longevity;Endometriosis;
LGG	cis	rs7659604	0.539	rs7686200	chr4:122764553	C/T	cg06713675	chr4:122721982	EXOSC9	-0.67	-11.26	-0.46	3.53e-26	Type 2 diabetes;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg21724239	chr8:58056113	NA	0.63	9.24	0.39	8.92e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs1799949	1.000	rs2175957	chr17:41286822	T/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs2077654	0.822	rs7932122	chr11:17431361	A/G	cg25308976	chr11:17434268	ABCC8	-0.84	-10.02	-0.42	1.62e-21	Gout;
LGG	trans	rs1814175	0.817	rs4084376	chr11:49831160	T/C	cg15704280	chr7:45808275	SEPT13	-1.09	-27.27	-0.79	2.36e-98	Height;
LGG	cis	rs36051895	0.632	rs12340617	chr9:5164492	G/C	cg02405213	chr9:5042618	JAK2	-0.77	-14.32	-0.55	8.83e-39	Pediatric autoimmune diseases;
LGG	cis	rs9322193	0.962	rs10872653	chr6:150100043	A/C	cg00424166	chr6:150045504	NUP43	-0.32	-6.65	-0.3	8.12e-11	Lung cancer;
LGG	cis	rs6582630	0.537	rs1829579	chr12:38420555	A/G	cg26384229	chr12:38710491	ALG10B	0.94	21.78	0.71	6.28e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12210905	1.000	rs3800310	chr6:27206843	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.62	-7.11	-0.31	4.5e-12	Hip circumference adjusted for BMI;
LGG	cis	rs826838	0.616	rs2387921	chr12:38624767	T/C	cg26384229	chr12:38710491	ALG10B	-0.67	-13.36	-0.53	1.12e-34	Heart rate;
LGG	cis	rs9322193	0.736	rs3805750	chr6:150112201	G/A	cg02462569	chr6:150064036	NUP43	-0.36	-7.62	-0.33	1.4e-13	Lung cancer;
LGG	cis	rs9486719	0.895	rs3734239	chr6:96996244	A/G	cg18709589	chr6:96969512	KIAA0776	-0.47	-7.15	-0.32	3.41e-12	Migraine;Coronary artery disease;
LGG	cis	rs2404602	0.583	rs35707798	chr15:76565026	G/C	cg23625390	chr15:77176239	SCAPER	0.41	7.78	0.34	4.75e-14	Blood metabolite levels;
LGG	cis	rs7943191	0.810	rs7942154	chr11:62337163	G/A	cg11742103	chr11:62369870	EML3;MTA2	0.56	12.28	0.5	3.22e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs9894429	0.646	rs7406825	chr17:79619188	C/T	cg18240062	chr17:79603768	NPLOC4	0.61	10.08	0.42	9.48e-22	Eye color traits;
LGG	cis	rs3808502	0.563	rs12549150	chr8:11422936	C/T	cg24623649	chr8:11872141	NA	0.33	7.92	0.35	1.72e-14	Neuroticism;
LGG	cis	rs7959452	0.535	rs11615712	chr12:69619736	A/T	cg11871910	chr12:69753446	YEATS4	-0.65	-12.51	-0.5	3.73e-31	Blood protein levels;
LGG	cis	rs6500602	0.702	rs56895104	chr16:4548132	G/A	cg05091796	chr16:4465799	CORO7	-0.61	-10.0	-0.42	1.87e-21	Schizophrenia;
LGG	cis	rs916888	0.610	rs199452	chr17:44801340	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.47	8.14	0.35	3.61e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs80130819	0.515	rs1476608	chr12:48493731	C/T	cg24011408	chr12:48396354	COL2A1	0.54	6.7	0.3	5.97e-11	Prostate cancer;
LGG	cis	rs55728055	0.661	rs62237857	chr22:32039311	G/A	cg15162869	chr22:32027605	PISD	-0.69	-7.29	-0.32	1.39e-12	Age-related hearing impairment;
LGG	cis	rs8041227	0.509	rs4779847	chr15:31529087	G/T	cg25017403	chr15:31516404	NA	0.28	7.2	0.32	2.44e-12	Eosinophilic esophagitis;
LGG	cis	rs4302748	0.862	rs11971718	chr7:36184620	T/C	cg24442661	chr7:36192818	EEPD1	0.57	7.49	0.33	3.53e-13	Platelet count;
LGG	cis	rs769267	0.895	rs2965189	chr19:19519518	G/T	cg20644253	chr19:19431407	KIAA0892;SF4	0.57	9.67	0.41	2.78e-20	Tonsillectomy;
LGG	cis	rs17711722	0.701	rs781143	chr7:65439879	G/C	cg11987759	chr7:65425863	GUSB	-0.41	-8.02	-0.35	8.45e-15	Calcium levels;
LGG	cis	rs7917772	0.582	rs11191352	chr10:104372244	A/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.61	11.69	0.48	7.82e-28	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12497850	0.931	rs62262517	chr3:49134914	T/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.39	6.8	0.3	3.25e-11	Parkinson's disease;
LGG	cis	rs6502050	0.835	rs8065565	chr17:80115399	A/G	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs16986825	0.714	rs5762857	chr22:29247097	A/G	cg15103426	chr22:29168792	CCDC117	0.66	6.91	0.31	1.59e-11	Pancreatic cancer;
LGG	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.63	-0.72	6.81e-77	Primary sclerosing cholangitis;
LGG	cis	rs7712401	0.601	rs35847506	chr5:122327108	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.72	-0.3	5.35e-11	Mean platelet volume;
LGG	trans	rs826838	0.585	rs12296822	chr12:38625829	A/T	cg06521331	chr12:34319734	NA	0.43	7.65	0.33	1.18e-13	Heart rate;
LGG	cis	rs3749237	0.595	rs4855877	chr3:49448527	T/C	cg03060546	chr3:49711283	APEH	0.73	13.19	0.52	6.21e-34	Resting heart rate;
LGG	trans	rs208520	0.874	rs208517	chr6:66947040	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.91	-15.46	-0.58	8.81e-44	Exhaled nitric oxide output;
LGG	cis	rs10850519	0.502	rs1874902	chr12:115950699	C/T	cg18639984	chr12:115943877	NA	-0.35	-6.79	-0.3	3.46e-11	Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10398950	chr17:37618454	CDK12	0.46	6.92	0.31	1.56e-11	Gut microbiome composition (summer);
LGG	cis	rs9611565	0.659	rs9611602	chr22:41908405	T/C	cg06634786	chr22:41940651	POLR3H	-0.78	-12.73	-0.51	5.08e-32	Vitiligo;
LGG	cis	rs3733585	0.673	rs4311316	chr4:9955971	A/C	cg25986240	chr4:9926439	SLC2A9	-0.39	-7.98	-0.35	1.15e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs908922	0.676	rs945789	chr1:152512705	C/A	cg20991723	chr1:152506922	NA	-0.7	-14.33	-0.55	7.93e-39	Hair morphology;
LGG	cis	rs17453880	0.750	rs2964237	chr5:151927597	T/C	cg12297329	chr5:152029980	NA	-0.61	-13.0	-0.52	3.85e-33	Subjective well-being;
LGG	cis	rs12586317	0.620	rs28404080	chr14:35539418	G/T	cg16230307	chr14:35515116	FAM177A1	0.89	13.16	0.52	8.15e-34	Psoriasis;
LGG	trans	rs9467711	0.606	rs2393667	chr6:26421345	T/C	cg08344181	chr3:125677491	NA	-0.64	-7.23	-0.32	2.05e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7618915	0.570	rs11714088	chr3:52758942	A/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.16	-0.32	3.29e-12	Bipolar disorder;
LGG	cis	rs2019137	0.967	rs895412	chr2:113973964	T/C	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.32	-0.5	2.31e-30	Lymphocyte counts;
LGG	cis	rs6724607	0.875	rs9630991	chr2:191432139	G/A	cg20818283	chr2:191399100	TMEM194B	0.32	7.57	0.33	2.07e-13	Pulse pressure;
LGG	cis	rs9462846	0.691	rs7744454	chr6:42914041	C/G	cg02353165	chr6:42928485	GNMT	0.31	7.27	0.32	1.55e-12	Blood protein levels;
LGG	cis	rs7945705	0.818	rs2742552	chr11:8876852	C/T	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-9.14	-0.39	2.02e-18	Hemoglobin concentration;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg24779751	chr19:36545850	WDR62;THAP8	-0.39	-7.45	-0.33	4.57e-13	Iris color (L* coordinate);
LGG	cis	rs4555082	0.957	rs2816628	chr14:105736134	T/G	cg27165867	chr14:105738592	BRF1	-0.47	-8.01	-0.35	9.27e-15	Mean platelet volume;Platelet distribution width;
LGG	cis	rs62238980	0.614	rs117826138	chr22:32398149	T/C	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs13108904	0.935	rs922698	chr4:1282722	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.67	-12.2	-0.49	7.06e-30	Obesity-related traits;
LGG	cis	rs10895140	0.756	rs2508733	chr11:101496593	G/T	cg23650423	chr11:101454676	TRPC6	0.4	6.71	0.3	5.54e-11	Menarche (age at onset);
LGG	cis	rs7927592	0.913	rs7118897	chr11:68360680	G/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.47	-0.37	3.18e-16	Total body bone mineral density;
LGG	trans	rs11992162	0.905	rs7836953	chr8:11835712	A/G	cg06636001	chr8:8085503	FLJ10661	0.52	9.79	0.41	1.07e-20	Monocyte count;
LGG	cis	rs9640161	0.750	rs11765644	chr7:150026339	C/G	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.81	-17.08	-0.62	4.54e-51	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg16482183	chr6:26056742	HIST1H1C	0.54	9.84	0.42	7.24e-21	Height;
LGG	cis	rs225245	0.791	rs7216391	chr17:34024706	G/A	cg05299278	chr17:33885742	SLFN14	0.43	8.21	0.36	2.18e-15	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs4148087	0.505	rs10084554	chr21:43623281	G/T	cg08841829	chr21:43638893	ABCG1	-0.41	-7.15	-0.32	3.45e-12	Eating disorder in bipolar disorder;
LGG	cis	rs6502050	0.835	rs4789678	chr17:80101078	C/T	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs644799	0.710	rs3017756	chr11:95537358	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.39	6.65	0.3	8.15e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1577917	0.958	rs12190603	chr6:86475718	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.36	-0.5	1.66e-30	Response to antipsychotic treatment;
LGG	cis	rs1348850	0.874	rs6742951	chr2:178340766	G/C	cg27490568	chr2:178487706	NA	0.51	9.91	0.42	4.14e-21	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs8058578	1.000	rs8051050	chr16:30687909	A/G	cg02466173	chr16:30829666	NA	-0.56	-10.18	-0.43	4.23e-22	Multiple myeloma;
LGG	cis	rs13108904	0.967	rs900029	chr4:1279145	C/T	cg05025164	chr4:1340916	KIAA1530	0.49	8.31	0.36	1.05e-15	Obesity-related traits;
LGG	trans	rs11976180	1.000	rs1919948	chr7:143762843	T/G	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs10504229	0.593	rs12155520	chr8:58014318	C/T	cg14926445	chr8:58193284	C8orf71	-0.71	-8.49	-0.37	2.8e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9303280	0.651	rs59716545	chr17:38031857	T/G	cg00129232	chr17:37814104	STARD3	-0.48	-8.76	-0.38	3.84e-17	Self-reported allergy;
LGG	cis	rs11148252	0.774	rs7334583	chr13:52930352	G/T	cg12458913	chr13:53173898	NA	-0.67	-13.25	-0.52	3.5e-34	Lewy body disease;
LGG	cis	rs17818399	0.645	rs35870739	chr2:46784231	A/C	cg02822958	chr2:46747628	ATP6V1E2	0.48	7.26	0.32	1.68e-12	Height;
LGG	cis	rs4642101	0.793	rs6763619	chr3:12822147	T/G	cg05775895	chr3:12838266	CAND2	0.65	11.77	0.48	3.69e-28	QRS complex (12-leadsum);
LGG	cis	rs9487051	0.834	rs351728	chr6:109549099	T/C	cg21918786	chr6:109611834	NA	-0.38	-6.83	-0.3	2.6e-11	Reticulocyte fraction of red cells;
LGG	cis	rs1109114	0.934	rs10079296	chr5:148613189	A/G	cg06539116	chr5:148597365	ABLIM3	0.59	15.43	0.58	1.2e-43	Body mass index;
LGG	cis	rs651907	0.588	rs2860329	chr3:101632426	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.43	7.95	0.35	1.42e-14	Colorectal cancer;
LGG	cis	rs7824557	0.614	rs2060459	chr8:11212599	C/T	cg21775007	chr8:11205619	TDH	0.8	14.18	0.55	3.56e-38	Retinal vascular caliber;
LGG	cis	rs12701220	0.689	rs12533004	chr7:1095410	C/T	cg26769984	chr7:1090371	C7orf50	0.46	7.28	0.32	1.46e-12	Bronchopulmonary dysplasia;
LGG	cis	rs11098499	0.909	rs10014719	chr4:120320715	G/A	cg24375607	chr4:120327624	NA	0.68	10.97	0.45	4.76e-25	Corneal astigmatism;
LGG	cis	rs977987	0.806	rs2865531	chr16:75390316	T/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.68	0.3	6.71e-11	Dupuytren's disease;
LGG	cis	rs16854884	0.770	rs1530478	chr3:143819553	C/T	cg06585982	chr3:143692056	C3orf58	0.54	8.92	0.38	1.05e-17	Economic and political preferences (feminism/equality);
LGG	cis	rs4538187	0.950	rs11691987	chr2:64147999	T/C	cg19915305	chr2:64069682	UGP2	-0.7	-15.83	-0.59	2e-45	Systolic blood pressure;
LGG	cis	rs7727544	0.642	rs7705189	chr5:131623358	C/T	cg07395648	chr5:131743802	NA	0.43	9.39	0.4	2.78e-19	Blood metabolite levels;
LGG	cis	rs2243480	0.803	rs55700941	chr7:65389800	T/A	cg13147721	chr7:65941812	NA	-0.8	-9.54	-0.41	8.42e-20	Diabetic kidney disease;
LGG	cis	rs826838	0.935	rs11168761	chr12:38997211	C/A	cg26384229	chr12:38710491	ALG10B	1.04	27.12	0.78	1.11e-97	Heart rate;
LGG	cis	rs1535500	0.935	rs11753141	chr6:39283083	G/A	cg13075951	chr6:39282393	KCNK17	0.26	6.84	0.3	2.44e-11	Type 2 diabetes;
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.63	12.81	0.51	2.36e-32	Prudent dietary pattern;
LGG	cis	rs1003719	0.788	rs11911508	chr21:38470504	T/C	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.53	0.63	3.9e-53	Eye color traits;
LGG	cis	rs2576037	0.526	rs2156050	chr18:44455873	A/G	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.92	0.35	1.77e-14	Personality dimensions;
LGG	cis	rs9354308	0.764	rs6931427	chr6:66568995	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.88	-0.3	2.01e-11	Metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19987840	chr4:123844099	SPATA5;NUDT6	0.47	6.99	0.31	9.82e-12	Gut microbiome composition (summer);
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg02475777	chr4:1388615	CRIPAK	0.41	7.44	0.33	5.09e-13	Longevity;
LGG	cis	rs2404602	0.692	rs35498563	chr15:76958868	C/T	cg15268244	chr15:77196840	NA	-0.31	-6.88	-0.3	1.93e-11	Blood metabolite levels;
LGG	cis	rs947474	0.838	rs1570527	chr10:6404700	A/C	cg19837174	chr10:6389707	NA	0.55	7.7	0.34	8.13e-14	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs11711311	0.955	rs2124105	chr3:113406003	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.42	-7.37	-0.32	7.9e-13	IgG glycosylation;
LGG	cis	rs12142240	0.698	rs72885198	chr1:46812888	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.79	-0.3	3.49e-11	Menopause (age at onset);
LGG	trans	rs9650657	0.801	rs7018334	chr8:10612075	G/A	cg16141378	chr3:129829833	LOC729375	0.32	6.97	0.31	1.13e-11	Neuroticism;
LGG	cis	rs12997796	0.556	rs12477737	chr2:86930966	G/T	cg25203885	chr2:87302643	LOC285074	-0.55	-6.69	-0.3	6.38e-11	Schizophrenia;
LGG	cis	rs875971	1.000	rs4717292	chr7:65895598	G/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs12568771	0.505	rs2477134	chr1:17633572	A/C	cg19159961	chr1:17633534	PADI4	0.41	9.36	0.4	3.53e-19	IgA nephropathy;
LGG	cis	rs75059851	1.000	rs75059851	chr11:133822569	A/G	cg17703048	chr11:133852993	NA	-0.76	-12.72	-0.51	5.12e-32	Schizophrenia;
LGG	cis	rs12476592	0.602	rs2028887	chr2:63716223	A/G	cg17519650	chr2:63277830	OTX1	-0.45	-7.11	-0.31	4.29e-12	Childhood ear infection;
LGG	cis	rs9457247	0.508	rs7760495	chr6:167506795	C/T	cg07741184	chr6:167504864	NA	0.39	8.96	0.38	7.94e-18	Crohn's disease;
LGG	cis	rs9309711	0.621	rs11127428	chr2:3471146	T/C	cg15506890	chr2:3487001	NA	-0.49	-9.17	-0.39	1.51e-18	Neurofibrillary tangles;
LGG	cis	rs8049040	0.586	rs8060176	chr16:71456757	T/C	cg08717414	chr16:71523259	ZNF19	-0.45	-7.05	-0.31	6.57e-12	Blood protein levels;
LGG	cis	rs1475911	0.708	rs66994219	chr21:43521647	G/A	cg24372256	chr21:43528868	UMODL1;C21orf128	-0.57	-9.52	-0.4	9.86e-20	IgG glycosylation;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.49	0.4	1.18e-19	Bipolar disorder;
LGG	cis	rs7077256	0.564	rs35193693	chr10:65321247	A/T	cg02276361	chr10:65351566	REEP3	-0.33	-6.69	-0.3	6.45e-11	Intelligence (multi-trait analysis);
LGG	cis	rs1010254	0.510	rs72806384	chr5:151703958	A/G	cg12297329	chr5:152029980	NA	-0.47	-6.89	-0.3	1.82e-11	Optic nerve measurement (cup area);
LGG	trans	rs7618501	1.000	rs2271961	chr3:49878113	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.77	-0.51	3.33e-32	Intelligence (multi-trait analysis);
LGG	cis	rs4750440	0.706	rs4503425	chr10:14019034	C/G	cg27542038	chr10:14027202	FRMD4A	-0.67	-12.68	-0.51	8.14e-32	Adiponectin levels;
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.75	-0.54	2.5e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs9926296	0.569	rs4785708	chr16:89796569	C/T	cg23057051	chr16:89984268	MC1R	0.35	6.85	0.3	2.43e-11	Vitiligo;
LGG	cis	rs654950	0.934	rs654220	chr1:42002556	A/T	cg16096631	chr1:42092165	HIVEP3	-0.41	-8.33	-0.36	9.24e-16	Airway imaging phenotypes;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg00424166	chr6:150045504	NUP43	-0.33	-6.78	-0.3	3.74e-11	Lung cancer;
LGG	cis	rs1577917	0.771	rs3812133	chr6:86354411	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.49	-7.2	-0.32	2.5e-12	Response to antipsychotic treatment;
LGG	cis	rs1062753	0.771	rs932376	chr22:42614362	T/C	cg15128208	chr22:42549153	NA	0.49	8.21	0.36	2.26e-15	Response to serotonin reuptake inhibitors in major depressive disorder (plasma drug and metabolite levels);
LGG	trans	rs6601327	0.613	rs7835002	chr8:9455045	G/C	cg16141378	chr3:129829833	LOC729375	-0.32	-6.99	-0.31	9.39e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs9473924	0.542	rs9473939	chr6:50877477	T/G	cg14470998	chr6:50812995	TFAP2B	0.66	7.99	0.35	1.05e-14	Body mass index;
LGG	trans	rs561341	0.505	rs548298	chr17:30297494	C/A	cg27661571	chr11:113659931	NA	-0.67	-9.58	-0.41	5.98e-20	Hip circumference adjusted for BMI;
LGG	cis	rs6461049	0.800	rs3800909	chr7:2159594	C/G	cg22963979	chr7:1858916	MAD1L1	-0.38	-7.52	-0.33	2.95e-13	Schizophrenia;
LGG	cis	rs754423	0.701	rs10143490	chr14:52504261	G/C	cg05884192	chr14:52515736	NID2	0.33	7.03	0.31	7.28e-12	Craniofacial microsomia;
LGG	cis	rs763121	0.853	rs2235230	chr22:39124467	A/G	cg06022373	chr22:39101656	GTPBP1	-0.87	-17.01	-0.62	8.97e-51	Menopause (age at onset);
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg05313129	chr8:58192883	C8orf71	-0.72	-10.08	-0.42	1.01e-21	Developmental language disorder (linguistic errors);
LGG	cis	rs7192750	0.563	rs7184486	chr16:71886530	T/A	cg06353428	chr16:71660113	MARVELD3	0.66	10.56	0.44	1.75e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs9381040	1.000	rs2093396	chr6:41155000	G/A	cg09580153	chr6:41068724	NFYA;LOC221442	-0.43	-7.33	-0.32	1.04e-12	Alzheimer's disease (late onset);
LGG	trans	rs7395662	1.000	rs7949348	chr11:48493801	G/C	cg03929089	chr4:120376271	NA	-0.44	-7.09	-0.31	5.2e-12	HDL cholesterol;
LGG	cis	rs3749237	0.595	rs11720264	chr3:49580347	C/T	cg02487422	chr3:49467188	NICN1	0.58	10.83	0.45	1.69e-24	Resting heart rate;
LGG	cis	rs780096	0.527	rs11127044	chr2:27740404	C/G	cg02592271	chr2:27665507	KRTCAP3	-0.31	-8.1	-0.35	5.09e-15	Total body bone mineral density;
LGG	trans	rs6076960	0.652	rs6085467	chr20:6259004	T/C	cg17788362	chr6:86352627	SYNCRIP	0.53	9.31	0.4	4.98e-19	Smooth-surface caries;
LGG	cis	rs11628318	0.853	rs7140280	chr14:103026991	C/T	cg23461800	chr14:103021989	NA	-0.5	-9.61	-0.41	4.51e-20	Platelet count;
LGG	cis	rs11885103	0.791	rs12619562	chr2:590698	C/G	cg21195176	chr2:593345	NA	-0.37	-7.12	-0.31	4.15e-12	Heschl's gyrus morphology;
LGG	cis	rs7570971	0.617	rs1869829	chr2:135877562	C/T	cg07169764	chr2:136633963	MCM6	-0.68	-11.63	-0.48	1.38e-27	Blood metabolite levels;Body mass index;Cholesterol, total;
LGG	cis	rs9303280	0.806	rs10445308	chr17:37938047	C/T	cg00129232	chr17:37814104	STARD3	-0.44	-8.16	-0.35	3.08e-15	Self-reported allergy;
LGG	cis	rs6952808	0.609	rs12699449	chr7:1951227	G/C	cg13880726	chr7:1868755	MAD1L1	0.41	7.36	0.32	8.5e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs1328862	chr6:8526681	A/T	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.38e-31	Motion sickness;
LGG	cis	rs920590	0.684	rs57462676	chr8:19670848	G/C	cg03894339	chr8:19674705	INTS10	0.66	10.6	0.44	1.22e-23	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2985684	1.000	rs11157696	chr14:50105746	C/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	-0.41	-6.79	-0.3	3.43e-11	Carotid intima media thickness;
LGG	cis	rs62064224	0.703	rs62065492	chr17:30822607	C/T	cg18200150	chr17:30822561	MYO1D	0.88	22.04	0.72	3.83e-74	Schizophrenia;
LGG	trans	rs800082	1.000	rs4681378	chr3:144308005	C/T	cg24215973	chr2:240111563	HDAC4	-0.5	-8.72	-0.38	4.95e-17	Smoking behavior;
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs72650860	chr8:58153111	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.47	-0.44	3.5e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.654	rs619727	chr11:68627535	A/G	cg07511668	chr11:68622177	NA	0.5	9.41	0.4	2.35e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7503807	0.688	rs7503186	chr17:78590472	G/C	cg18469159	chr17:78755841	RPTOR	-0.37	-6.83	-0.3	2.6e-11	Obesity;
LGG	cis	rs11997175	1.000	rs6468201	chr8:33746854	G/C	ch.8.33884649F	chr8:33765107	NA	0.37	6.73	0.3	5.04e-11	Body mass index;
LGG	cis	rs7582180	0.903	rs13008568	chr2:100896242	A/G	cg05692746	chr2:100937584	LONRF2	-0.59	-9.67	-0.41	2.91e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.755	rs4788074	chr16:28593597	A/G	cg07382826	chr16:28625726	SULT1A1	-0.42	-8.93	-0.38	9.77e-18	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7241530	0.636	rs66549018	chr18:75904099	C/A	cg14642773	chr18:75888474	NA	0.47	9.27	0.4	6.9e-19	Educational attainment (years of education);
LGG	cis	rs6952808	0.594	rs3778964	chr7:2138109	C/T	cg10950524	chr7:2139216	MAD1L1	0.33	7.0	0.31	8.93e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs10911232	0.507	rs4652772	chr1:183023696	C/G	ch.1.3577855R	chr1:183094577	LAMC1	-0.42	-8.35	-0.36	8.16e-16	Hypertriglyceridemia;
LGG	cis	rs9311474	0.539	rs12489828	chr3:52567014	G/T	cg07507251	chr3:52567010	NT5DC2	0.35	7.06	0.31	6.26e-12	Electroencephalogram traits;
LGG	cis	rs6582630	0.555	rs10880612	chr12:38509427	A/G	cg04568710	chr12:38710424	ALG10B	0.36	7.44	0.33	4.79e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs1978968	0.763	rs9605474	chr22:18463297	A/G	cg03078520	chr22:18463400	MICAL3	-0.68	-14.82	-0.57	6.07e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg15979348	chr13:112237479	NA	0.48	8.29	0.36	1.26e-15	Menarche (age at onset);
LGG	trans	rs2727020	0.894	rs1880438	chr11:49370698	A/G	cg15704280	chr7:45808275	SEPT13	-0.81	-13.59	-0.53	1.27e-35	Coronary artery disease;
LGG	cis	rs2730245	1.000	rs2657365	chr7:158722753	A/T	cg24397884	chr7:158709396	WDR60	-1.05	-24.65	-0.75	2.59e-86	Height;
LGG	cis	rs11155671	0.530	rs7742993	chr6:150205095	G/A	cg05861140	chr6:150128134	PCMT1	-0.3	-7.0	-0.31	9.07e-12	Testicular germ cell tumor;
LGG	cis	rs854765	0.562	rs2955381	chr17:17945500	G/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs9397585	0.857	rs9371660	chr6:153374555	C/G	cg17707550	chr6:153380415	RGS17	0.62	14.47	0.56	2.05e-39	Body mass index;
LGG	cis	rs9300255	0.544	rs1716175	chr12:123658388	A/T	cg05973401	chr12:123451056	ABCB9	0.51	7.32	0.32	1.07e-12	Neutrophil percentage of white cells;
LGG	cis	rs17270561	0.553	rs6456696	chr6:25741408	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs11122272	0.701	rs2491402	chr1:231494338	T/C	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.6	-10.47	-0.44	3.65e-23	Hemoglobin concentration;
LGG	cis	rs7084402	0.967	rs1658447	chr10:60313174	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.51	-0.33	3.13e-13	Refractive error;
LGG	cis	rs798554	0.543	rs1639065	chr7:2893339	T/C	cg27476859	chr7:2772710	GNA12	0.44	8.3	0.36	1.13e-15	Height;
LGG	cis	rs2839186	0.934	rs2839194	chr21:47699437	T/G	cg13126279	chr21:47581558	C21orf56	-0.47	-8.24	-0.36	1.83e-15	Testicular germ cell tumor;
LGG	cis	rs2011503	1.000	rs80200208	chr19:19554725	C/T	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.75e-29	Bipolar disorder;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg11494091	chr17:61959527	GH2	0.5	7.86	0.34	2.62e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7208859	0.623	rs55961983	chr17:29119286	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.34	0.32	9.57e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs10435719	0.647	rs10092605	chr8:11787395	T/G	cg13009111	chr11:71350975	NA	0.35	7.76	0.34	5.62e-14	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs17270561	0.666	rs9356987	chr6:25739187	C/A	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs7582180	0.790	rs4851288	chr2:100920451	T/C	cg08297393	chr2:100937505	LONRF2	-0.52	-9.68	-0.41	2.57e-20	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-8.19	-0.36	2.57e-15	Aortic root size;
LGG	cis	rs208520	1.000	rs12199876	chr6:66989469	A/G	cg07460842	chr6:66804631	NA	0.9	14.84	0.57	5.02e-41	Exhaled nitric oxide output;
LGG	cis	rs4430311	0.723	rs10157763	chr1:243995041	T/C	cg25706552	chr1:244017396	NA	-0.66	-16.26	-0.6	2.31e-47	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs7166081	1.000	rs4776909	chr15:67542349	T/A	cg05925327	chr15:68127851	NA	-0.32	-6.81	-0.3	3.12e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs747782	0.527	rs7113857	chr11:48141859	G/T	cg15704280	chr7:45808275	SEPT13	0.7	7.26	0.32	1.68e-12	Intraocular pressure;
LGG	cis	rs4704846	1.000	rs10061463	chr5:156537760	A/C	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.48	-0.33	3.83e-13	Blood protein levels;
LGG	cis	rs1153858	0.621	rs12913645	chr15:45555066	G/A	cg10760299	chr15:45669010	GATM	-0.37	-7.07	-0.31	5.9e-12	Homoarginine levels;
LGG	trans	rs1005277	0.541	rs1740741	chr10:38515334	C/T	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.79	-0.3	3.43e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs9322193	0.962	rs9688750	chr6:149978769	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.03	-0.31	7.28e-12	Lung cancer;
LGG	cis	rs2762353	0.779	rs6905614	chr6:25840485	G/T	cg07061783	chr6:25882402	NA	-0.39	-6.98	-0.31	1.04e-11	Blood metabolite levels;
LGG	cis	rs875971	0.545	rs17138156	chr7:65714695	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.54	10.28	0.43	1.88e-22	Aortic root size;
LGG	trans	rs656319	0.580	rs13252589	chr8:10005526	A/G	cg12395012	chr8:11607386	GATA4	0.39	6.98	0.31	1.03e-11	Myopia (pathological);
LGG	trans	rs7829975	0.510	rs2921073	chr8:8307643	C/T	cg16141378	chr3:129829833	LOC729375	-0.5	-12.12	-0.49	1.44e-29	Mood instability;
LGG	trans	rs17685	0.753	rs4398845	chr7:75716781	G/A	cg19862616	chr7:65841803	NCRNA00174	1.07	25.7	0.77	3.77e-91	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs2404602	0.647	rs55778276	chr15:77136590	T/A	cg23625390	chr15:77176239	SCAPER	-0.73	-14.4	-0.56	4.15e-39	Blood metabolite levels;
LGG	cis	rs9790314	0.846	rs4470535	chr3:160974468	G/A	cg04691961	chr3:161091175	C3orf57	-0.55	-12.49	-0.5	4.67e-31	Morning vs. evening chronotype;
LGG	cis	rs7223966	1.000	rs56057198	chr17:61733332	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-6.9	-0.31	1.71e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2730245	0.545	rs2788472	chr7:158649304	T/C	cg14689365	chr7:158441557	NCAPG2	0.62	10.21	0.43	3.42e-22	Height;
LGG	cis	rs10504229	0.906	rs113857287	chr8:58191683	T/C	cg22535103	chr8:58192502	C8orf71	-1.06	-16.22	-0.6	3.47e-47	Developmental language disorder (linguistic errors);
LGG	cis	rs6504108	0.522	rs12603380	chr17:46204408	G/A	cg02219949	chr17:45927392	SP6	0.41	7.75	0.34	5.8e-14	Body mass index;
LGG	cis	rs1949733	0.523	rs56053534	chr4:8542876	G/A	cg13073564	chr4:8508604	NA	0.42	7.2	0.32	2.45e-12	Response to antineoplastic agents;
LGG	cis	rs17739167	0.550	rs11634233	chr15:42224563	G/A	cg20935245	chr15:42234343	EHD4	0.44	8.54	0.37	1.97e-16	Monocyte count;
LGG	cis	rs11191419	1	rs11191419	chr10:104612335	T/A	cg04362960	chr10:104952993	NT5C2	0.51	9.17	0.39	1.54e-18	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	trans	rs453301	0.571	rs330048	chr8:9087278	A/C	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.62	-0.41	4.18e-20	Joint mobility (Beighton score);
LGG	cis	rs17030434	0.871	rs74380369	chr4:154730273	C/T	cg14289246	chr4:154710475	SFRP2	-0.62	-10.08	-0.42	1.01e-21	Electrocardiographic conduction measures;
LGG	cis	rs1568889	0.838	rs10835273	chr11:28156598	T/C	cg06544937	chr11:28130018	METT5D1;KIF18A	0.86	19.24	0.67	4.89e-61	Bipolar disorder;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.35	6.93	0.31	1.42e-11	Aortic root size;
LGG	cis	rs11155671	0.530	rs7757984	chr6:150208651	A/G	cg16507663	chr6:150244633	RAET1G	0.51	10.58	0.44	1.46e-23	Testicular germ cell tumor;
LGG	cis	rs4680	1.000	rs4680	chr22:19951271	C/T	cg22546130	chr22:19950026	COMT	0.36	8.6	0.37	1.25e-16	Blood metabolite levels;
LGG	cis	rs79349575	0.681	rs56080003	chr17:47019049	A/T	cg16584676	chr17:46985605	UBE2Z	0.49	8.45	0.37	3.95e-16	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17466768	chr2:25194156	DNAJC27	0.4	6.72	0.3	5.34e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1018836	0.608	rs2142146	chr8:91464808	T/C	cg16814680	chr8:91681699	NA	-0.59	-9.96	-0.42	2.59e-21	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs3793683	0.597	rs12767469	chr10:134587261	C/G	cg13271783	chr10:134563150	INPP5A	-0.51	-7.72	-0.34	7.13e-14	Migraine;
LGG	cis	rs10504229	1.000	rs60454728	chr8:58173781	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs2404602	0.552	rs11636612	chr15:76959530	C/T	cg15268244	chr15:77196840	NA	0.42	7.94	0.35	1.55e-14	Blood metabolite levels;
LGG	cis	rs6838801	0.892	rs10518153	chr4:77573615	C/T	cg17476223	chr4:77663285	SHROOM3	0.39	6.9	0.31	1.67e-11	Cleft lip with or without cleft palate;
LGG	trans	rs57221529	0.654	rs11740553	chr5:672593	C/T	cg11887960	chr12:57824829	NA	0.58	6.75	0.3	4.38e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs7107174	1.000	rs2511169	chr11:77965321	T/C	cg02023728	chr11:77925099	USP35	0.43	7.74	0.34	6.49e-14	Testicular germ cell tumor;
LGG	cis	rs7927592	0.913	rs7115374	chr11:68300076	G/T	cg20283391	chr11:68216788	NA	-0.52	-8.49	-0.37	2.73e-16	Total body bone mineral density;
LGG	cis	rs11098499	0.779	rs10016060	chr4:120298412	A/G	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg03959625	chr15:84868606	LOC388152	0.47	7.09	0.31	5e-12	Schizophrenia;
LGG	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg26408565	chr15:76604113	ETFA	-0.39	-6.74	-0.3	4.75e-11	Blood metabolite levels;
LGG	cis	rs1801251	1.000	rs35085837	chr2:233624363	A/G	cg08000102	chr2:233561755	GIGYF2	0.57	9.29	0.4	6.2800000000000005e-19	Coronary artery disease;
LGG	cis	rs668210	0.793	rs1151514	chr11:65758854	G/A	cg02202077	chr11:65769826	EIF1AD;BANF1	0.7	9.41	0.4	2.35e-19	Cerebrospinal fluid biomarker levels;
LGG	trans	rs11039798	1.000	rs6485908	chr11:48652198	C/T	cg03929089	chr4:120376271	NA	-0.71	-8.18	-0.36	2.75e-15	Axial length;
LGG	cis	rs4690686	0.500	rs17062804	chr4:177262892	A/G	cg17059388	chr4:177262070	NA	1.03	24.19	0.75	3.4e-84	Essential tremor;
LGG	cis	rs17767392	0.958	rs7156313	chr14:72052310	G/C	cg13720639	chr14:72061746	SIPA1L1	0.39	8.45	0.37	3.67e-16	Mitral valve prolapse;
LGG	cis	rs11229555	0.874	rs10896788	chr11:58292976	G/A	cg15696309	chr11:58395628	NA	-0.99	-17.58	-0.63	2.27e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7824557	0.510	rs1435274	chr8:11235910	G/A	cg12395012	chr8:11607386	GATA4	0.39	6.9	0.31	1.67e-11	Retinal vascular caliber;
LGG	cis	rs6459788	0.934	rs10251462	chr7:157258183	C/G	cg06271696	chr7:157225062	NA	-0.37	-7.66	-0.34	1.09e-13	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs10504229	0.679	rs72649119	chr8:58040301	T/C	cg20607798	chr8:58055168	NA	0.6	7.23	0.32	2.05e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9303401	0.632	rs7502541	chr17:57241019	G/C	cg02118635	chr17:56770003	RAD51C;TEX14	0.51	8.38	0.36	6.59e-16	Cognitive test performance;
LGG	trans	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.66	0.48	9.65e-28	Corneal astigmatism;
LGG	cis	rs10504229	0.683	rs11786043	chr8:58133174	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs798554	0.679	rs2527681	chr7:2892384	A/T	cg19524238	chr7:2802976	GNA12	0.38	9.1	0.39	2.72e-18	Height;
LGG	cis	rs6754311	0.731	rs218174	chr2:136658345	C/T	cg07169764	chr2:136633963	MCM6	-0.77	-12.67	-0.51	8.68e-32	Mosquito bite size;
LGG	cis	rs2576037	0.583	rs512699	chr18:44374681	C/T	cg26155939	chr18:44337853	ST8SIA5	0.38	7.23	0.32	2.07e-12	Personality dimensions;
LGG	cis	rs899997	0.862	rs57260218	chr15:78973772	C/T	cg09845145	chr15:78292470	TBC1D2B	-0.59	-10.21	-0.43	3.42e-22	Coronary artery disease or large artery stroke;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs6951245	0.744	rs10265736	chr7:1172465	C/T	cg03188948	chr7:1209495	NA	0.71	10.19	0.43	3.95e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2415984	0.579	rs10135740	chr14:46957379	G/A	cg14871534	chr14:47121158	RPL10L	-0.57	-10.14	-0.43	6.17e-22	Number of children ever born;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18124201	chr20:46414952	SULF2	0.41	7.21	0.32	2.37e-12	Obesity-related traits;
LGG	cis	rs9467773	0.572	rs13213953	chr6:26594534	T/A	cg11502198	chr6:26597334	ABT1	0.7	12.0	0.49	4.69e-29	Intelligence (multi-trait analysis);
LGG	cis	rs28595532	0.841	rs115233595	chr4:119744214	T/C	cg21605333	chr4:119757512	SEC24D	1.43	14.59	0.56	6.37e-40	Cannabis dependence symptom count;
LGG	cis	rs28386778	0.897	rs2036911	chr17:61794839	A/T	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	cis	rs7177699	0.557	rs7164479	chr15:79123054	C/T	cg00540400	chr15:79124168	NA	0.52	11.24	0.46	4.42e-26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg17462381	chr3:132441365	NCRNA00119;NPHP3	0.64	7.1	0.31	4.68e-12	Intelligence (multi-trait analysis);
LGG	cis	rs977987	0.741	rs10514393	chr16:75344476	C/T	cg03315344	chr16:75512273	CHST6	0.48	9.52	0.4	9.28e-20	Dupuytren's disease;
LGG	cis	rs61931739	0.500	rs11053203	chr12:34456593	C/T	cg06521331	chr12:34319734	NA	-0.56	-9.76	-0.41	1.35e-20	Morning vs. evening chronotype;
LGG	cis	rs2952156	0.959	rs1495102	chr17:37832093	T/C	cg00129232	chr17:37814104	STARD3	-0.7	-14.16	-0.55	4.28e-38	Asthma;
LGG	cis	rs12950390	0.853	rs28589850	chr17:45855713	A/G	cg00777063	chr17:45855553	NA	-0.32	-6.77	-0.3	4.02e-11	IgG glycosylation;
LGG	cis	rs6748734	1.000	rs10933518	chr2:241838091	A/C	cg04034577	chr2:241836375	C2orf54	-0.52	-11.41	-0.47	9.37e-27	Urinary metabolites;
LGG	cis	rs2652834	1.000	rs2652833	chr15:63396885	C/A	cg05507819	chr15:63340323	TPM1	0.58	7.85	0.34	3.02e-14	HDL cholesterol;
LGG	trans	rs330071	0.686	rs4841139	chr8:9249210	C/T	cg15556689	chr8:8085844	FLJ10661	0.38	6.76	0.3	4.12e-11	Acne (severe);
LGG	cis	rs7208859	0.524	rs59923796	chr17:29064919	G/A	cg13385521	chr17:29058706	SUZ12P	0.93	10.9	0.45	9.15e-25	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9926296	0.744	rs460984	chr16:89713174	C/T	cg26513180	chr16:89883248	FANCA	-0.53	-9.09	-0.39	2.8e-18	Vitiligo;
LGG	cis	rs12421382	0.570	rs10789736	chr11:109478039	G/C	cg16359550	chr11:109292809	C11orf87	0.43	8.3	0.36	1.14e-15	Schizophrenia;
LGG	cis	rs4242434	0.787	rs1545837	chr8:22477807	T/C	cg19455335	chr8:22457658	C8orf58	-0.41	-8.43	-0.36	4.27e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs898097	0.801	rs68141193	chr17:80878816	C/T	cg15664640	chr17:80829946	TBCD	-0.78	-14.97	-0.57	1.33e-41	Breast cancer;
LGG	cis	rs62380364	0.626	rs618741	chr5:88064012	C/T	cg22951263	chr5:87985283	NA	-0.54	-10.01	-0.42	1.76e-21	Intelligence (multi-trait analysis);
LGG	cis	rs769267	0.929	rs2965180	chr19:19491973	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	-0.59	-10.05	-0.42	1.31e-21	Tonsillectomy;
LGG	cis	rs3857536	0.544	rs208453	chr6:66906841	A/T	cg07460842	chr6:66804631	NA	-0.69	-11.69	-0.48	7.39e-28	Blood trace element (Cu levels);
LGG	cis	rs2762353	0.808	rs1165176	chr6:25830298	A/G	cg03264133	chr6:25882463	NA	-0.59	-11.19	-0.46	6.7e-26	Blood metabolite levels;
LGG	cis	rs2404602	0.692	rs4886829	chr15:77091182	G/T	cg23625390	chr15:77176239	SCAPER	0.48	9.28	0.4	6.36e-19	Blood metabolite levels;
LGG	cis	rs4481887	0.927	rs4244187	chr1:248493511	T/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.2	-0.39	1.23e-18	Common traits (Other);
LGG	cis	rs9393692	0.905	rs989134	chr6:26336224	A/C	cg05868516	chr6:26286170	HIST1H4H	0.45	7.53	0.33	2.73e-13	Educational attainment;
LGG	trans	rs9329221	0.741	rs13271489	chr8:9803712	T/C	cg12395012	chr8:11607386	GATA4	0.43	7.34	0.32	9.78e-13	Neuroticism;
LGG	cis	rs758324	0.755	rs555662	chr5:131350903	G/A	cg06307176	chr5:131281290	NA	0.48	6.88	0.3	2e-11	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs897984	0.806	rs8052245	chr16:30916430	C/G	cg02466173	chr16:30829666	NA	0.47	8.51	0.37	2.45e-16	Dementia with Lewy bodies;
LGG	cis	rs6762477	0.748	rs11717349	chr3:50223977	C/T	cg05623727	chr3:50126028	RBM5	-0.39	-8.3	-0.36	1.17e-15	Menarche (age at onset);
LGG	cis	rs34929064	0.512	rs2157958	chr7:22706707	C/T	cg23521230	chr7:22704884	NA	0.43	7.99	0.35	1.05e-14	Major depression and alcohol dependence;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs75804782	0.521	rs72994970	chr2:239426992	G/A	cg01134436	chr17:81009848	B3GNTL1	0.79	8.46	0.37	3.67e-16	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.679	rs11783557	chr8:58030644	A/G	cg26174226	chr8:58114915	NA	-0.51	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg13537196	chr9:15553060	C9orf93	-0.45	-6.65	-0.3	8.48e-11	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.674	rs1011413	chr21:40638241	A/G	cg11644478	chr21:40555479	PSMG1	-0.76	-14.05	-0.55	1.32e-37	Cognitive function;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.71	-0.38	5.24e-17	Lung cancer;
LGG	cis	rs796364	1.000	rs35220450	chr2:200780737	T/C	cg17644776	chr2:200775616	C2orf69	-0.59	-6.97	-0.31	1.08e-11	Schizophrenia;
LGG	cis	rs7582180	0.614	rs10193204	chr2:101004540	A/G	cg05692746	chr2:100937584	LONRF2	0.64	11.7	0.48	7.31e-28	Intelligence (multi-trait analysis);
LGG	cis	rs9815354	0.638	rs111465678	chr3:41864405	C/A	cg03022575	chr3:42003672	ULK4	0.67	8.59	0.37	1.36e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs1348850	0.513	rs6730406	chr2:178492722	C/T	cg27490568	chr2:178487706	NA	0.68	12.91	0.51	8.49e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2243480	1.000	rs2420170	chr7:65656053	T/C	cg12463550	chr7:65579703	CRCP	-0.77	-8.38	-0.36	6.21e-16	Diabetic kidney disease;
LGG	cis	rs12477438	0.520	rs13030961	chr2:99799520	C/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	17.63	0.63	1.29e-53	Chronic sinus infection;
LGG	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg06453172	chr10:134556979	INPP5A	-0.51	-7.89	-0.34	2.24e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs589448	0.902	rs315138	chr12:69764850	A/T	cg14784868	chr12:69753453	YEATS4	1.0	24.04	0.75	1.77e-83	Cerebrospinal fluid biomarker levels;
LGG	trans	rs9354308	0.933	rs12203567	chr6:66589062	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.09	0.42	9e-22	Metabolite levels;
LGG	cis	rs7659604	0.521	rs10001697	chr4:122677737	G/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-8.0	-0.35	9.75e-15	Type 2 diabetes;
LGG	trans	rs11088226	0.681	rs11700670	chr21:33938615	T/C	cg09050820	chr6:167586206	TCP10L2	0.89	12.51	0.5	3.91e-31	Gastritis;
LGG	cis	rs3008870	0.755	rs2755251	chr1:67496425	G/T	cg08660285	chr1:67390436	MIER1;WDR78	0.68	14.42	0.56	3.3e-39	Lymphocyte percentage of white cells;
LGG	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg22437258	chr11:111473054	SIK2	0.55	9.6	0.41	5.01e-20	Primary sclerosing cholangitis;
LGG	cis	rs12597458	0.789	rs7186207	chr16:72035359	C/T	cg01557791	chr16:72042693	DHODH	-0.72	-14.53	-0.56	1.17e-39	Prostate cancer;
LGG	cis	rs2602381	0.599	rs2602379	chr2:234583062	C/T	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.4	-7.15	-0.32	3.37e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs3768617	0.706	rs4129858	chr1:183004334	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.97	0.31	1.12e-11	Fuchs's corneal dystrophy;
LGG	cis	rs8177179	0.967	rs9869311	chr3:133451613	C/T	cg24879335	chr3:133465180	TF	0.44	7.34	0.32	9.99e-13	Iron status biomarkers (transferrin levels);
LGG	cis	rs4474465	1.000	rs2063728	chr11:78185636	G/C	cg02023728	chr11:77925099	USP35	0.4	6.97	0.31	1.1e-11	Alzheimer's disease (survival time);
LGG	cis	rs9322193	0.639	rs4869756	chr6:150207496	G/A	cg01145232	chr6:150245071	RAET1G	0.46	8.45	0.37	3.89e-16	Lung cancer;
LGG	cis	rs2016266	0.819	rs7397757	chr12:53652684	A/G	cg04065151	chr12:53682969	ESPL1	0.6	9.95	0.42	2.94e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs877426	0.609	rs56287057	chr13:114829267	C/A	cg00571178	chr13:114841904	RASA3	-0.46	-8.45	-0.37	3.8e-16	Facial morphology (factor 14, intercanthal width);
LGG	trans	rs826838	0.935	rs11169508	chr12:39173385	C/T	cg06521331	chr12:34319734	NA	-0.43	-7.32	-0.32	1.11e-12	Heart rate;
LGG	cis	rs2028414	0.512	rs752265	chr14:105361934	T/C	cg13750949	chr14:105293957	NA	0.54	8.88	0.38	1.51e-17	IgG glycosylation;
LGG	cis	rs9322193	0.923	rs66516768	chr6:149993135	C/T	cg04369109	chr6:150039330	LATS1	-0.42	-7.08	-0.31	5.49e-12	Lung cancer;
LGG	cis	rs9522267	0.502	rs9522281	chr13:112222389	G/A	cg14952266	chr13:112191215	NA	0.52	10.96	0.45	5.22e-25	Hepatitis;
LGG	cis	rs2243480	0.803	rs36004293	chr7:65416512	T/C	cg12463550	chr7:65579703	CRCP	0.73	8.33	0.36	9.56e-16	Diabetic kidney disease;
LGG	cis	rs17711722	0.727	rs781151	chr7:65479878	T/C	cg11987759	chr7:65425863	GUSB	-0.4	-7.75	-0.34	5.7e-14	Calcium levels;
LGG	trans	rs11885103	0.519	rs2685263	chr2:549873	C/G	cg12228919	chr15:44955936	SPG11	0.39	6.66	0.3	7.68e-11	Heschl's gyrus morphology;
LGG	cis	rs7493	0.760	rs17876092	chr7:95053313	C/A	cg08461772	chr7:95026248	PON3	0.35	7.43	0.33	5.35e-13	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs12188164	0.610	rs6555242	chr5:416546	A/C	cg26076054	chr5:421317	AHRR	-0.44	-7.44	-0.33	5.06e-13	Cystic fibrosis severity;
LGG	trans	rs11098499	0.863	rs3775845	chr4:120432447	T/C	cg25214090	chr10:38739885	LOC399744	0.66	11.55	0.47	2.61e-27	Corneal astigmatism;
LGG	cis	rs6712932	0.962	rs2053241	chr2:105842228	G/A	cg26874229	chr2:105853672	NA	-0.34	-7.3	-0.32	1.3e-12	Type 2 diabetes;
LGG	cis	rs2976388	0.578	rs3736010	chr8:143817503	T/C	cg10596483	chr8:143751796	JRK	-0.48	-6.76	-0.3	4.05e-11	Urinary tract infection frequency;
LGG	cis	rs4566357	0.615	rs12474622	chr2:227912793	A/G	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.05	-0.39	3.88e-18	Coronary artery disease;
LGG	cis	rs17376456	0.877	rs12153506	chr5:93360953	T/G	cg25358565	chr5:93447407	FAM172A	1.32	16.39	0.61	6.21e-48	Diabetic retinopathy;
LGG	cis	rs1847505	0.501	rs3119870	chr13:61407633	C/G	cg25164009	chr13:61490935	NA	0.5	8.66	0.37	8e-17	Polychlorinated biphenyl levels;
LGG	trans	rs7824557	0.602	rs7839053	chr8:11207431	C/T	cg15556689	chr8:8085844	FLJ10661	0.42	7.18	0.32	2.76e-12	Retinal vascular caliber;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.16	0.49	9.95e-30	Prudent dietary pattern;
LGG	trans	rs1945213	0.694	rs11227181	chr11:55856053	C/T	cg03929089	chr4:120376271	NA	0.81	11.15	0.46	9.59e-26	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg12463550	chr7:65579703	CRCP	0.73	7.71	0.34	7.8500000000000006e-14	Diabetic kidney disease;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.76	-0.3	4.09e-11	Total body bone mineral density;
LGG	cis	rs10504229	0.906	rs2270609	chr8:58194684	G/A	cg22535103	chr8:58192502	C8orf71	-1.05	-15.87	-0.59	1.35e-45	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg18681998	chr4:17616180	MED28	0.83	18.45	0.65	2.31e-57	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3007729	0.509	rs6665151	chr1:18800247	A/G	cg04846421	chr1:18800208	NA	-0.62	-12.23	-0.49	5.36e-30	Diabetic retinopathy;
LGG	cis	rs854765	0.647	rs854790	chr17:18028318	C/G	cg05444541	chr17:17804740	TOM1L2	-0.56	-11.7	-0.48	7.12e-28	Total body bone mineral density;
LGG	cis	rs798554	0.591	rs1182193	chr7:2869240	A/G	cg05793240	chr7:2802953	GNA12	0.28	6.72	0.3	5.37e-11	Height;
LGG	cis	rs2243480	1.000	rs778704	chr7:65863467	T/C	cg18252515	chr7:66147081	NA	-1.43	-20.76	-0.69	3.88e-68	Diabetic kidney disease;
LGG	cis	rs1559088	0.803	rs10405770	chr19:33616549	C/T	cg17764715	chr19:33622953	WDR88	0.51	9.01	0.39	5.52e-18	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs28386778	0.933	rs2665804	chr17:61951836	G/T	cg11494091	chr17:61959527	GH2	1.04	26.44	0.78	1.39e-94	Prudent dietary pattern;
LGG	cis	rs1978968	0.763	rs9605480	chr22:18465105	G/A	cg03078520	chr22:18463400	MICAL3	-0.67	-14.26	-0.55	1.66e-38	Presence of antiphospholipid antibodies;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25846022	chr1:78444909	FUBP1	0.5	8.5	0.37	2.66e-16	Gut microbiota (bacterial taxa);
LGG	trans	rs9929218	0.954	rs4552018	chr16:68822854	T/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.71	-11.84	-0.48	1.98e-28	Colorectal cancer;
LGG	cis	rs10845606	1.000	rs10845607	chr12:12835228	C/T	cg09462578	chr12:12878428	APOLD1	-0.51	-7.13	-0.31	3.8e-12	Systemic lupus erythematosus;
LGG	cis	rs11214589	0.651	rs11214596	chr11:113264511	C/G	cg14159747	chr11:113255604	NA	0.3	8.19	0.36	2.56e-15	Neuroticism;
LGG	trans	rs1728785	1.000	rs7118	chr16:68600855	G/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.41	0.44	6.07e-23	Ulcerative colitis;
LGG	cis	rs4930103	0.935	rs2071095	chr11:2020627	C/A	cg08461457	chr11:2027003	NA	0.4	7.72	0.34	7.37e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs17504614	0.549	rs67300886	chr2:51059557	C/A	cg23851515	chr2:51057218	NRXN1	0.49	7.97	0.35	1.22e-14	Educational attainment (years of education);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02481015	chr6:163148718	PACRG;PARK2	0.5	8.02	0.35	8.85e-15	Gut microbiome composition (summer);
LGG	cis	rs55728055	0.661	rs56411340	chr22:31984476	G/T	cg15162869	chr22:32027605	PISD	-0.76	-7.84	-0.34	3.21e-14	Age-related hearing impairment;
LGG	cis	rs10504229	0.863	rs75954631	chr8:58166194	C/A	cg08219700	chr8:58056026	NA	0.44	6.88	0.3	1.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17102423	0.755	rs12880781	chr14:65576257	C/T	cg26396452	chr14:65542826	MAX	0.43	8.35	0.36	8.19e-16	Obesity-related traits;
LGG	cis	rs9560113	0.806	rs9560112	chr13:112183320	A/G	cg14952266	chr13:112191215	NA	-0.41	-7.39	-0.32	6.73e-13	Menarche (age at onset);
LGG	cis	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg08975724	chr8:8085496	FLJ10661	0.44	8.45	0.37	3.71e-16	Mood instability;
LGG	cis	rs473651	0.967	rs483042	chr2:239335320	A/G	cg08773314	chr2:239334832	ASB1	0.42	8.03	0.35	7.89e-15	Multiple system atrophy;
LGG	cis	rs9325144	0.647	rs7980932	chr12:38921583	G/T	cg26384229	chr12:38710491	ALG10B	-0.73	-13.99	-0.54	2.5e-37	Morning vs. evening chronotype;
LGG	cis	rs13191362	1.000	rs13210412	chr6:163019478	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.55	0.33	2.4e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7582180	0.663	rs10199518	chr2:100946041	G/A	cg21926883	chr2:100939477	LONRF2	-0.69	-16.58	-0.61	8.47e-49	Intelligence (multi-trait analysis);
LGG	cis	rs10751667	0.666	rs4074234	chr11:977715	C/G	cg22143635	chr11:980567	AP2A2	0.45	8.27	0.36	1.39e-15	Alzheimer's disease (late onset);
LGG	cis	rs2839186	0.732	rs55904887	chr21:47707811	A/G	cg13126279	chr21:47581558	C21orf56	-0.46	-7.93	-0.35	1.68e-14	Testicular germ cell tumor;
LGG	cis	rs854765	0.547	rs2955384	chr17:17939573	C/T	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.52	-0.61	1.5e-48	Total body bone mineral density;
LGG	cis	rs4954585	0.683	rs10221893	chr2:137013606	C/T	cg07169764	chr2:136633963	MCM6	-0.46	-7.34	-0.32	9.96e-13	Colorectal cancer;
LGG	cis	rs9926296	0.585	rs8058009	chr16:89856439	G/C	cg08547343	chr16:90038815	CENPBD1;AFG3L1	-0.57	-7.94	-0.35	1.54e-14	Vitiligo;
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.59	-0.41	5.27e-20	Life satisfaction;
LGG	cis	rs10479542	0.896	rs4701130	chr5:178982416	C/T	cg19626725	chr5:178986131	RUFY1	-0.46	-7.61	-0.33	1.51e-13	Lung cancer;
LGG	cis	rs6952808	0.723	rs4721282	chr7:2025040	A/G	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.83	-0.38	2.21e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs62441303	chr6:150088683	A/G	cg11878867	chr6:150167359	LRP11	-0.48	-9.89	-0.42	4.8e-21	Lung cancer;
LGG	cis	rs9308433	0.505	rs867446	chr1:214502322	G/T	cg06198575	chr1:214491504	SMYD2	0.51	7.56	0.33	2.24e-13	IgG glycosylation;
LGG	cis	rs5750830	0.649	rs5750818	chr22:39820885	A/G	cg04986931	chr22:39850128	NA	0.34	7.8	0.34	4.05e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2839186	0.967	rs2839191	chr21:47695395	C/G	cg13012494	chr21:47604986	C21orf56	0.5	8.55	0.37	1.86e-16	Testicular germ cell tumor;
LGG	cis	rs2404602	0.692	rs34272342	chr15:77012276	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.14	0.39	2.02e-18	Blood metabolite levels;
LGG	cis	rs4443100	0.670	rs3788338	chr22:23412058	G/A	cg21100191	chr22:23484243	RTDR1	0.54	7.98	0.35	1.14e-14	Serum parathyroid hormone levels;
LGG	cis	rs35110281	0.626	rs162388	chr21:44936032	G/A	cg04455712	chr21:45112962	RRP1B	0.46	8.85	0.38	1.87e-17	Mean corpuscular volume;
LGG	cis	rs240764	0.658	rs9322212	chr6:101248474	T/C	cg21058520	chr6:100914733	NA	0.38	6.68	0.3	6.68e-11	Neuroticism;
LGG	cis	rs61931739	0.546	rs7297354	chr12:33700556	T/C	cg06521331	chr12:34319734	NA	0.4	6.89	0.3	1.82e-11	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg14500267	chr11:67383377	NA	0.42	7.72	0.34	7.31e-14	Mean corpuscular volume;
LGG	cis	rs17445774	0.857	rs6435043	chr2:200900974	C/G	cg23649088	chr2:200775458	C2orf69	0.59	9.97	0.42	2.46e-21	LDL cholesterol to HDL cholesterol ratio;
LGG	cis	rs1577917	0.696	rs2842603	chr6:86336337	G/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.16	-0.35	3.15e-15	Response to antipsychotic treatment;
LGG	cis	rs8180040	0.654	rs6766230	chr3:47196209	C/A	cg16586182	chr3:47516702	SCAP	-0.74	-13.38	-0.53	9.66e-35	Colorectal cancer;
LGG	cis	rs593982	0.920	rs1151500	chr11:65481166	T/C	cg08755490	chr11:65554678	OVOL1	0.7	8.59	0.37	1.31e-16	Atopic dermatitis;
LGG	cis	rs4919087	0.748	rs793517	chr10:98987522	A/G	cg25902810	chr10:99078978	FRAT1	-0.41	-6.95	-0.31	1.21e-11	Monocyte count;
LGG	cis	rs2404602	0.655	rs8028294	chr15:77084877	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.82	-0.3	2.77e-11	Blood metabolite levels;
LGG	cis	rs6088580	0.660	rs6087592	chr20:33114503	A/G	cg24642439	chr20:33292090	TP53INP2	0.56	9.33	0.4	4.45e-19	Glomerular filtration rate (creatinine);
LGG	cis	rs1927790	0.727	rs9554339	chr13:96970274	G/C	cg02571835	chr13:96230311	CLDN10	-0.35	-7.12	-0.31	4.11e-12	Body mass index;
LGG	cis	rs986417	0.818	rs1950311	chr14:60989604	A/C	cg27398547	chr14:60952738	C14orf39	0.69	6.79	0.3	3.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg22920501	chr2:26401640	FAM59B	-0.45	-9.19	-0.39	1.33e-18	Gut microbiome composition (summer);
LGG	cis	rs4330281	0.647	rs10510477	chr3:17721297	T/C	cg20981856	chr3:17787350	NA	-0.4	-7.58	-0.33	1.95e-13	Schizophrenia;
LGG	trans	rs9467711	0.720	rs9348716	chr6:26375658	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.64	-0.37	9.53e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9527	0.590	rs7087459	chr10:104790999	T/C	cg04362960	chr10:104952993	NT5C2	0.57	10.57	0.44	1.53e-23	Arsenic metabolism;
LGG	cis	rs6502050	0.769	rs8079122	chr17:80120427	G/T	cg10505658	chr17:80084571	CCDC57	-0.4	-8.03	-0.35	8.41e-15	Life satisfaction;
LGG	cis	rs9611565	0.512	rs139572	chr22:42214532	C/T	cg06481639	chr22:41940642	POLR3H	-0.54	-7.07	-0.31	5.64e-12	Vitiligo;
LGG	cis	rs9399135	0.967	rs7741515	chr6:135374368	C/G	cg24558204	chr6:135376177	HBS1L	-0.55	-9.87	-0.42	5.65e-21	Red blood cell count;
LGG	trans	rs6598955	0.572	rs6598951	chr1:26592714	G/T	cg07461501	chr17:79650226	HGS;ARL16	-0.78	-13.23	-0.52	3.92e-34	Obesity-related traits;
LGG	cis	rs1129187	0.755	rs9471988	chr6:42944773	T/C	cg13397359	chr6:42928475	GNMT	0.57	15.63	0.59	1.59e-44	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs10504229	0.638	rs7826839	chr8:58132075	G/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9790314	0.967	rs9821201	chr3:160996155	G/C	cg04691961	chr3:161091175	C3orf57	-0.63	-14.99	-0.57	1.1e-41	Morning vs. evening chronotype;
LGG	cis	rs11105298	0.891	rs11105310	chr12:89918677	C/A	cg00757033	chr12:89920650	WDR51B	0.63	9.19	0.39	1.28e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6831352	0.918	rs17218288	chr4:100058030	A/T	cg13256891	chr4:100009986	ADH5	-0.56	-9.75	-0.41	1.53e-20	Alcohol dependence;
LGG	cis	rs11676348	0.808	rs61700947	chr2:219046171	C/G	cg04731861	chr2:219085781	ARPC2	-0.31	-7.34	-0.32	9.63e-13	Ulcerative colitis;
LGG	cis	rs4555082	1.000	rs4277291	chr14:105759009	A/G	cg27165867	chr14:105738592	BRF1	-0.45	-7.77	-0.34	5.16e-14	Mean platelet volume;Platelet distribution width;
LGG	cis	rs12477438	0.520	rs57242893	chr2:99942848	A/C	cg23527387	chr2:100056660	REV1	0.44	9.81	0.41	9.41e-21	Chronic sinus infection;
LGG	cis	rs11608355	1.000	rs10774692	chr12:109862324	G/T	cg19025524	chr12:109796872	NA	-0.49	-9.29	-0.4	6.26e-19	Neuroticism;
LGG	cis	rs7223966	0.960	rs11659013	chr17:61869559	C/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.49	-7.68	-0.34	9.68e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7633857	0.512	rs10936215	chr3:160652271	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.59	-0.41	5.3e-20	Educational attainment (years of education);
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg18379455	chr17:41446167	NA	-0.33	-7.59	-0.33	1.73e-13	Menopause (age at onset);
LGG	cis	rs17270561	0.609	rs4712970	chr6:25770707	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.17e-19	Iron status biomarkers;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg25346576	chr17:28443852	CCDC55;MIR423	0.43	7.7	0.34	8.12e-14	Bilirubin levels;
LGG	trans	rs804280	0.509	rs13268030	chr8:11783073	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.38	0.32	7.51e-13	Myopia (pathological);
LGG	cis	rs1784581	0.599	rs1789992	chr6:162401854	A/G	cg17173639	chr6:162384350	PARK2	-0.75	-16.59	-0.61	7.92e-49	Itch intensity from mosquito bite;
LGG	trans	rs8073060	0.586	rs7208672	chr17:33989759	G/A	cg19694781	chr19:47549865	TMEM160	-1.15	-17.4	-0.63	1.55e-52	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs700651	0.789	rs1147169	chr2:198901395	C/T	cg00792783	chr2:198669748	PLCL1	-0.58	-9.03	-0.39	4.55e-18	Intracranial aneurysm;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10106091	chr12:117176294	C12orf49;RNFT2	0.42	6.87	0.3	2.06e-11	Cognitive performance;
LGG	cis	rs7927592	0.513	rs630225	chr11:68194611	A/C	cg16797656	chr11:68205561	LRP5	0.56	10.52	0.44	2.39e-23	Total body bone mineral density;
LGG	cis	rs7215564	0.818	rs1032130	chr17:78610636	A/G	cg16980736	chr17:78789706	RPTOR	0.64	8.33	0.36	8.98e-16	Myopia (pathological);
LGG	cis	rs8062405	1.000	rs61737565	chr16:28855522	G/C	cg07382826	chr16:28625726	SULT1A1	0.35	7.26	0.32	1.69e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs16944613	0.588	rs6496698	chr15:91135558	A/G	cg26821196	chr15:91095069	CRTC3	0.51	7.33	0.32	1.07e-12	Colorectal cancer;
LGG	cis	rs6088590	0.561	rs6087605	chr20:33180624	G/T	cg06115741	chr20:33292138	TP53INP2	0.52	8.72	0.38	5.18e-17	Coronary artery disease;
LGG	cis	rs62238980	0.614	rs33954001	chr22:32506050	C/G	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs2439831	0.867	rs2255042	chr15:43834318	A/G	cg15269541	chr15:43626905	ADAL	0.42	7.02	0.31	7.76e-12	Lung cancer in ever smokers;
LGG	cis	rs1046896	0.576	rs8067360	chr17:80694826	T/C	cg08200770	chr17:80723486	TBCD	-0.41	-7.96	-0.35	1.35e-14	Glycated hemoglobin levels;
LGG	trans	rs11039798	1.000	rs7125559	chr11:48984207	C/G	cg15704280	chr7:45808275	SEPT13	0.79	9.0	0.39	5.98e-18	Axial length;
LGG	cis	rs295140	0.605	rs159321	chr2:201184713	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-6.96	-0.31	1.15e-11	QT interval;
LGG	cis	rs17641971	0.684	rs4873093	chr8:49974740	G/T	cg00325661	chr8:49890786	NA	0.54	10.1	0.42	8.13e-22	Blood metabolite levels;
LGG	cis	rs1046896	0.553	rs8073413	chr17:80836005	G/A	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.86	0.3	2.21e-11	Glycated hemoglobin levels;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg05941027	chr17:61774174	LIMD2	0.34	8.65	0.37	8.23e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs62400317	0.701	rs12194924	chr6:44961513	T/C	cg20913747	chr6:44695427	NA	-0.66	-11.35	-0.47	1.71e-26	Total body bone mineral density;
LGG	cis	rs12477438	0.765	rs6749059	chr2:99591021	G/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.76	-0.51	3.74e-32	Chronic sinus infection;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg00933542	chr6:150070202	PCMT1	0.38	6.73	0.3	5.02e-11	Lung cancer;
LGG	cis	rs10504229	0.683	rs16921819	chr8:58107936	G/T	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.37	8.75	0.38	3.91e-17	Schizophrenia;
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg10189774	chr4:17578691	LAP3	0.41	7.52	0.33	2.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs10504229	0.520	rs55967509	chr8:57992448	A/G	cg14926445	chr8:58193284	C8orf71	-0.66	-8.25	-0.36	1.61e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4742903	0.967	rs2274725	chr9:106864570	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.46	0.37	3.5e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs1691799	0.899	rs1168294	chr12:66733988	T/C	cg16791601	chr12:66731901	HELB	-0.66	-15.53	-0.59	4.4e-44	White blood cell count (basophil);
LGG	trans	rs7829975	0.606	rs6601274	chr8:8799059	T/G	cg27411982	chr8:10470053	RP1L1	-0.45	-7.69	-0.34	8.99e-14	Mood instability;
LGG	cis	rs5758659	0.622	rs129856	chr22:42399396	C/G	cg15557168	chr22:42548783	NA	-0.34	-7.67	-0.34	1.02e-13	Cognitive function;
LGG	cis	rs4256922	0.752	rs1133222	chr10:52516665	C/T	cg12289553	chr10:52500425	ASAH2B	-0.46	-8.72	-0.38	4.83e-17	Urate levels in lean individuals;
LGG	cis	rs2188554	0.675	rs916727	chr7:116988685	C/T	cg10524701	chr7:117356490	CTTNBP2	-0.37	-7.36	-0.32	8.56e-13	Esophageal adenocarcinoma;
LGG	cis	rs6951245	1.000	rs78628466	chr7:1068453	G/C	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg27523141	chr10:43048294	ZNF37B	0.38	7.48	0.33	3.77e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs61906588	0.672	rs6589548	chr11:116362136	A/G	cg12564567	chr11:116371188	NA	-0.39	-7.03	-0.31	7.45e-12	Post bronchodilator FEV1 in COPD;
LGG	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg15522984	chr1:182991683	LAMC1	0.49	10.07	0.42	1.04e-21	Colorectal cancer;
LGG	cis	rs3806843	0.735	rs778595	chr5:140036681	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.72	-0.3	5.2e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs34172651	0.502	rs12930727	chr16:24838497	G/T	cg02428538	chr16:24856791	SLC5A11	0.5	8.09	0.35	5.28e-15	Intelligence (multi-trait analysis);
LGG	trans	rs9784649	0.771	rs72755810	chr5:25039139	A/C	cg11038491	chr20:34638489	LOC647979	-0.7	-10.32	-0.43	1.32e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12765878	0.557	rs10883928	chr10:105615074	C/T	cg11005552	chr10:105648138	OBFC1	-0.72	-12.42	-0.5	9.04e-31	Coronary artery disease;
LGG	cis	rs4808199	0.947	rs2099333	chr19:19605963	C/T	cg03709012	chr19:19516395	GATAD2A	1.08	17.55	0.63	3.13e-53	Nonalcoholic fatty liver disease;
LGG	cis	rs66887589	0.592	rs28580295	chr4:120278873	C/T	cg09307838	chr4:120376055	NA	0.53	8.95	0.38	8.81e-18	Diastolic blood pressure;
LGG	cis	rs7481584	1.000	rs7481584	chr11:3029089	G/A	cg08468577	chr11:2973342	NAP1L4	-0.38	-7.66	-0.34	1.1e-13	Calcium levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06608945	chr2:219082296	ARPC2	0.46	6.71	0.3	5.73e-11	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.669	rs12603821	chr17:62006432	G/A	cg02127607	chr17:61920694	SMARCD2	-0.39	-6.84	-0.3	2.55e-11	Prudent dietary pattern;
LGG	cis	rs7829975	0.593	rs2921077	chr8:8304502	C/T	cg08975724	chr8:8085496	FLJ10661	0.46	8.89	0.38	1.36e-17	Mood instability;
LGG	cis	rs875971	0.723	rs28391294	chr7:65654315	T/C	cg23594656	chr7:65796392	TPST1	0.4	8.81	0.38	2.6e-17	Aortic root size;
LGG	cis	rs2072499	0.554	rs1052067	chr1:156206121	C/T	cg25208724	chr1:156163844	SLC25A44	0.95	15.03	0.57	6.88e-42	Testicular germ cell tumor;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg00166722	chr3:10149974	C3orf24	0.49	7.72	0.34	7.38e-14	Alzheimer's disease;
LGG	cis	rs10416265	0.516	rs1270252	chr19:33623604	G/A	cg27124370	chr19:33622961	WDR88	-0.48	-6.65	-0.3	8.49e-11	Bone properties (heel);
LGG	cis	rs13102973	0.899	rs11735890	chr4:135902143	A/G	cg14419869	chr4:135874104	NA	0.45	8.24	0.36	1.81e-15	Subjective well-being;
LGG	cis	rs9322193	0.923	rs9800736	chr6:149982417	A/G	cg09699651	chr6:150184138	LRP11	0.52	9.23	0.39	9.64e-19	Lung cancer;
LGG	cis	rs6831352	0.918	rs2602895	chr4:100045840	C/T	cg13256891	chr4:100009986	ADH5	0.56	9.79	0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs1005277	0.579	rs1780115	chr10:38524773	C/T	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-7.04	-0.31	7.03e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs12282928	0.704	rs4980430	chr11:48298269	G/A	cg26585981	chr11:48327164	OR4S1	-0.41	-7.1	-0.31	4.71e-12	Migraine - clinic-based;
LGG	cis	rs9393692	0.557	rs61534839	chr6:26305623	C/T	cg00631329	chr6:26305371	NA	-0.44	-7.11	-0.31	4.44e-12	Educational attainment;
LGG	trans	rs6088590	1.000	rs6088615	chr20:33400474	C/T	cg23991721	chr19:1237877	C19orf26	0.38	6.68	0.3	6.96e-11	Coronary artery disease;
LGG	cis	rs4731207	0.698	rs12533560	chr7:124561882	T/C	cg05630886	chr7:124431682	NA	-0.32	-7.58	-0.33	1.84e-13	Cutaneous malignant melanoma;
LGG	cis	rs911119	0.779	rs3761280	chr20:23620076	A/G	cg16589663	chr20:23618590	CST3	0.47	6.75	0.3	4.46e-11	Chronic kidney disease;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg23131131	chr22:24373011	LOC391322	-0.48	-7.86	-0.34	2.65e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2933343	0.700	rs6787833	chr3:128656184	A/G	cg25356066	chr3:128598488	ACAD9	0.44	6.65	0.3	8.11e-11	IgG glycosylation;
LGG	cis	rs7937682	0.883	rs512669	chr11:111467893	G/A	cg19812747	chr11:111475976	SIK2	-0.48	-10.05	-0.42	1.27e-21	Primary sclerosing cholangitis;
LGG	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg05535760	chr7:792225	HEATR2	0.94	14.54	0.56	9.79e-40	Cerebrospinal P-tau181p levels;
LGG	cis	rs7223966	0.883	rs2955250	chr17:61959740	C/T	cg22520471	chr17:61851767	DDX42;CCDC47	0.4	6.71	0.3	5.83e-11	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7523050	0.643	rs7519293	chr1:109399543	A/G	cg08274380	chr1:109419600	GPSM2	0.99	11.76	0.48	4.08e-28	Fat distribution (HIV);
LGG	trans	rs9388451	0.559	rs1777210	chr6:126098916	T/G	cg05039488	chr6:79577232	IRAK1BP1	-0.6	-10.91	-0.45	8.1e-25	Brugada syndrome;
LGG	cis	rs10504229	0.953	rs66815941	chr8:58187306	C/T	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs1552244	1.000	rs7610821	chr3:10136150	C/T	cg16606324	chr3:10149918	C3orf24	0.54	7.23	0.32	1.96e-12	Alzheimer's disease;
LGG	cis	rs11690935	0.959	rs6758704	chr2:172655097	T/C	cg21435375	chr2:172878103	MAP1D	-0.32	-7.26	-0.32	1.7e-12	Schizophrenia;
LGG	cis	rs4948496	1.000	rs4948496	chr10:63805617	T/C	cg07520810	chr10:63809149	ARID5B	0.36	6.9	0.31	1.71e-11	Systemic lupus erythematosus;
LGG	trans	rs11577318	0.853	rs17645	chr1:26646730	A/G	cg07461501	chr17:79650226	HGS;ARL16	0.52	9.7	0.41	2.18e-20	Granulocyte percentage of myeloid white cells;
LGG	cis	rs9326248	0.520	rs236919	chr11:117095361	A/G	cg20608306	chr11:116969690	SIK3	0.34	10.12	0.43	6.8e-22	Blood protein levels;
LGG	cis	rs2635047	0.756	rs34939493	chr18:44795621	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.46	7.62	0.33	1.4e-13	Educational attainment;
LGG	cis	rs6952808	0.608	rs58120505	chr7:2029867	T/C	cg22963979	chr7:1858916	MAD1L1	-0.47	-9.21	-0.39	1.12e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs367943	0.666	rs10064031	chr5:112970924	C/G	cg12552261	chr5:112820674	MCC	0.53	9.43	0.4	2e-19	Type 2 diabetes;
LGG	cis	rs899997	1.000	rs11072800	chr15:79045857	C/T	cg10852096	chr15:79043040	NA	0.27	7.73	0.34	6.63e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs9399135	0.967	rs1041480	chr6:135373076	G/T	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.07e-19	Red blood cell count;
LGG	cis	rs11750568	0.904	rs1826864	chr5:178509565	C/T	cg10208897	chr5:178548229	ADAMTS2	0.42	6.84	0.3	2.57e-11	Height;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19172750	chr17:66287499	ARSG;SLC16A6	0.45	6.66	0.3	7.62e-11	Gut microbiome composition (summer);
LGG	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg00938859	chr5:1591904	SDHAP3	0.89	13.14	0.52	9.22e-34	Breast cancer;
LGG	cis	rs7937682	0.889	rs7948236	chr11:111499933	C/A	cg08305652	chr11:111469057	NA	-0.43	-8.52	-0.37	2.26e-16	Primary sclerosing cholangitis;
LGG	trans	rs7618501	0.602	rs2624816	chr3:50117312	T/G	cg21659725	chr3:3221576	CRBN	-0.64	-11.89	-0.48	1.26e-28	Intelligence (multi-trait analysis);
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg05556477	chr5:131705319	SLC22A5	0.86	10.32	0.43	1.31e-22	Rheumatoid arthritis;
LGG	cis	rs873946	0.586	rs12767391	chr10:134573844	A/G	cg13271783	chr10:134563150	INPP5A	0.54	8.44	0.37	4.22e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs17253792	0.822	rs75991559	chr14:56092419	A/T	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs4474465	1.000	rs10899520	chr11:78183370	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.65	-0.37	8.27e-17	Alzheimer's disease (survival time);
LGG	cis	rs2153535	0.580	rs9378554	chr6:8488468	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs763014	0.966	rs4247097	chr16:654224	G/A	cg07343612	chr16:622815	PIGQ	-0.76	-15.92	-0.59	8.31e-46	Height;
LGG	cis	rs13191362	1.000	rs13204439	chr6:163015358	A/C	cg21926612	chr6:163149169	PACRG;PARK2	-0.84	-9.85	-0.42	6.69e-21	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg05863683	chr7:1912471	MAD1L1	0.42	8.3	0.36	1.17e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7666738	0.830	rs1593573	chr4:98925293	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6951245	0.554	rs4724294	chr7:1139695	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-0.57	-10.78	-0.45	2.48e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6489882	0.867	rs2384072	chr12:113367422	T/C	cg25319449	chr12:113376135	OAS3	-0.41	-7.62	-0.33	1.43e-13	Chronic lymphocytic leukemia;
LGG	cis	rs9911578	0.967	rs6503893	chr17:57149695	G/A	cg12560992	chr17:57184187	TRIM37	0.93	16.62	0.61	5.28e-49	Intelligence (multi-trait analysis);
LGG	cis	rs7615952	0.576	rs4646759	chr3:125822946	G/C	cg05084668	chr3:125655381	ALG1L	-0.58	-7.68	-0.34	9.28e-14	Blood pressure (smoking interaction);
LGG	trans	rs3808502	0.526	rs1042701	chr8:11422045	G/A	cg13009111	chr11:71350975	NA	-0.3	-6.66	-0.3	7.78e-11	Neuroticism;
LGG	cis	rs11190604	0.767	rs10883491	chr10:102196071	G/T	cg07570687	chr10:102243282	WNT8B	0.42	7.53	0.33	2.63e-13	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs4843747	0.636	rs11117358	chr16:88105053	T/A	cg00711542	chr16:29343894	RUNDC2C	0.39	6.72	0.3	5.42e-11	Menopause (age at onset);
LGG	cis	rs911555	0.504	rs8021368	chr14:104074810	G/A	cg24130564	chr14:104152367	KLC1	-0.77	-17.21	-0.62	1.19e-51	Intelligence (multi-trait analysis);
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg23594656	chr7:65796392	TPST1	-0.42	-9.32	-0.4	4.9e-19	Aortic root size;
LGG	cis	rs12908161	1.000	rs11632465	chr15:85282045	A/T	cg24253500	chr15:84953950	NA	0.42	6.89	0.3	1.85e-11	Schizophrenia;
LGG	cis	rs6461049	0.800	rs2398706	chr7:2156338	A/T	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.11	-0.35	4.47e-15	Schizophrenia;
LGG	cis	rs2576037	0.583	rs10070	chr18:44388899	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.52	10.45	0.44	4.2e-23	Personality dimensions;
LGG	cis	rs28386778	0.863	rs2251164	chr17:61884120	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.55	0.33	2.37e-13	Prudent dietary pattern;
LGG	cis	rs74781061	0.929	rs4887159	chr15:74865882	G/A	cg02384859	chr15:74862662	ARID3B	-0.34	-6.98	-0.31	1.03e-11	Endometriosis;
LGG	cis	rs6546550	0.867	rs7592647	chr2:70139134	C/T	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.14	-0.35	3.59e-15	Prevalent atrial fibrillation;
LGG	cis	rs2243480	0.901	rs2456483	chr7:65461575	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.15	0.35	3.4e-15	Diabetic kidney disease;
LGG	cis	rs503341	0.756	rs480874	chr11:63591965	A/T	cg04362095	chr11:63592001	C11orf84	-0.55	-10.81	-0.45	1.93e-24	Pulse pressure;
LGG	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg06582575	chr6:163149167	PACRG;PARK2	0.74	7.26	0.32	1.7e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7666738	0.612	rs6830172	chr4:99093947	G/A	cg05340658	chr4:99064831	C4orf37	0.43	7.1	0.31	4.78e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11785693	0.865	rs7815144	chr8:4970788	G/T	cg26367366	chr8:4980734	NA	-0.94	-14.91	-0.57	2.38e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs4740619	0.875	rs10810442	chr9:15759359	G/A	cg14451791	chr9:16040625	NA	-0.4	-10.4	-0.44	6.8e-23	Body mass index;
LGG	cis	rs11608355	0.545	rs7315846	chr12:109908617	T/C	cg05360138	chr12:110035743	NA	0.84	12.02	0.49	3.87e-29	Neuroticism;
LGG	cis	rs4481887	1.000	rs7525344	chr1:248467565	C/T	cg00666640	chr1:248458726	OR2T12	-0.61	-10.0	-0.42	1.98e-21	Common traits (Other);
LGG	cis	rs8067545	0.611	rs8066143	chr17:20048355	A/C	cg13482628	chr17:19912719	NA	0.54	10.24	0.43	2.63e-22	Schizophrenia;
LGG	cis	rs7618915	0.501	rs2164885	chr3:52731269	T/C	cg15147215	chr3:52552868	STAB1	-0.36	-6.8	-0.3	3.21e-11	Bipolar disorder;
LGG	cis	rs4713118	0.516	rs4713142	chr6:28106347	T/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Parkinson's disease;
LGG	cis	rs62238980	0.614	rs117067740	chr22:32407944	C/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	trans	rs11098499	0.588	rs2389874	chr4:120554991	A/G	cg25214090	chr10:38739885	LOC399744	-0.51	-9.35	-0.4	3.81e-19	Corneal astigmatism;
LGG	trans	rs2727020	0.619	rs1829979	chr11:49436875	T/G	cg03929089	chr4:120376271	NA	-0.86	-12.93	-0.52	7.08e-33	Coronary artery disease;
LGG	cis	rs13394619	0.605	rs12476152	chr2:11747960	T/C	cg07314298	chr2:11723111	GREB1	0.35	7.27	0.32	1.52e-12	Endometriosis;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg08188268	chr10:116634841	FAM160B1	-0.33	-6.87	-0.3	2.08e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs868036	0.609	rs16951304	chr15:68089618	T/C	cg05925327	chr15:68127851	NA	-0.43	-8.73	-0.38	4.7e-17	Restless legs syndrome;
LGG	trans	rs7824557	0.591	rs2293859	chr8:11216761	T/G	cg02002194	chr4:3960332	NA	-0.39	-7.01	-0.31	8.28e-12	Retinal vascular caliber;
LGG	cis	rs2734839	0.964	rs1076563	chr11:113295909	A/C	cg14159747	chr11:113255604	NA	0.27	7.06	0.31	6.24e-12	Information processing speed;
LGG	trans	rs970548	0.643	rs7068039	chr10:45932264	T/C	cg14222797	chr10:16859974	RSU1	-0.55	-6.81	-0.3	3.11e-11	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	cis	rs9467773	0.844	rs2393669	chr6:26503873	C/T	cg11502198	chr6:26597334	ABT1	0.54	9.35	0.4	3.64e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4919044	0.808	rs1222605	chr10:94804200	T/C	cg05127821	chr10:94822908	CYP26C1	-0.45	-7.97	-0.35	1.27e-14	Coronary artery disease;
LGG	cis	rs11190604	0.943	rs11190581	chr10:102243387	T/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.12	0.46	1.31e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs2404602	0.710	rs2469541	chr15:76562118	C/T	cg15268244	chr15:77196840	NA	0.33	7.1	0.31	4.86e-12	Blood metabolite levels;
LGG	cis	rs1799949	0.965	rs4239149	chr17:41328095	A/G	cg05368731	chr17:41323189	NBR1	-0.87	-17.0	-0.62	1.02e-50	Menopause (age at onset);
LGG	cis	rs4891159	0.790	rs683306	chr18:74112473	C/G	cg24786174	chr18:74118243	ZNF516	-0.57	-13.5	-0.53	2.94e-35	Longevity;
LGG	cis	rs9399135	0.967	rs12661423	chr6:135349570	C/T	cg22676075	chr6:135203613	NA	0.37	6.67	0.3	7.26e-11	Red blood cell count;
LGG	cis	rs10876993	0.749	rs703832	chr12:58024626	G/C	cg18357645	chr12:58087776	OS9	0.67	11.45	0.47	6.76e-27	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs3780486	0.801	rs56687083	chr9:33132134	A/G	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.75	-0.57	1.27e-40	IgG glycosylation;
LGG	cis	rs7726839	1.000	rs7726839	chr5:618586	A/G	cg09021430	chr5:549028	NA	-0.71	-13.09	-0.52	1.61e-33	Obesity-related traits;
LGG	cis	rs4742903	0.967	rs10991119	chr9:106905277	C/T	cg14250997	chr9:106856677	SMC2	-0.39	-8.38	-0.36	6.17e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs950169	0.887	rs35986397	chr15:84955107	G/A	cg24253500	chr15:84953950	NA	0.58	10.4	0.44	6.55e-23	Schizophrenia;
LGG	cis	rs9291683	0.526	rs7695555	chr4:10001656	T/C	cg00071950	chr4:10020882	SLC2A9	0.37	7.44	0.33	5.08e-13	Bone mineral density;
LGG	trans	rs3206736	0.548	rs73110562	chr7:35069923	G/A	cg14337134	chr7:102920323	DPY19L2P2	0.41	7.22	0.32	2.15e-12	Diastolic blood pressure;
LGG	trans	rs2980439	0.783	rs2948305	chr8:8098577	G/A	cg21775007	chr8:11205619	TDH	0.44	7.06	0.31	6.08e-12	Neuroticism;
LGG	cis	rs6500602	0.701	rs4786500	chr16:4525265	A/G	cg05091796	chr16:4465799	CORO7	0.76	12.51	0.5	4.01e-31	Schizophrenia;
LGG	cis	rs2839186	0.934	rs13049797	chr21:47707582	T/C	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.72e-15	Testicular germ cell tumor;
LGG	cis	rs2228479	0.702	rs12599561	chr16:89894358	C/G	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.78	-0.34	4.79e-14	Skin colour saturation;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs367943	0.966	rs444322	chr5:112815399	C/T	cg27587195	chr5:112824172	MCC	-0.45	-7.34	-0.32	9.39e-13	Type 2 diabetes;
LGG	cis	rs10206020	0.797	rs72778008	chr2:1573182	T/G	cg12573674	chr2:1569213	NA	-0.64	-10.13	-0.43	6.39e-22	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs34610878	chr3:52759169	G/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.54	0.41	8.48e-20	Bipolar disorder;
LGG	cis	rs708547	0.581	rs13121027	chr4:57813369	C/T	cg16868167	chr4:57843880	C4orf14;POLR2B	-0.47	-7.89	-0.34	2.26e-14	Response to bleomycin (chromatid breaks);
LGG	cis	rs4474465	0.850	rs4559714	chr11:78257302	C/T	cg27205649	chr11:78285834	NARS2	0.5	8.52	0.37	2.33e-16	Alzheimer's disease (survival time);
LGG	cis	rs4430311	0.723	rs6429435	chr1:243945131	T/C	cg25706552	chr1:244017396	NA	-0.65	-15.93	-0.6	6.95e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs798554	0.959	rs798558	chr7:2758935	T/G	cg19717773	chr7:2847554	GNA12	-0.34	-6.91	-0.31	1.65e-11	Height;
LGG	cis	rs9322193	0.887	rs4870139	chr6:149896318	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.38	0.32	7.37e-13	Lung cancer;
LGG	cis	rs4851266	1.000	rs11695383	chr2:100826098	G/T	cg21926883	chr2:100939477	LONRF2	-0.45	-8.17	-0.36	2.93e-15	Educational attainment;
LGG	cis	rs4006360	0.614	rs6416914	chr17:39262850	A/G	cg16985667	chr17:39306289	KRTAP4-5	-0.47	-9.47	-0.4	1.45e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs2032447	1.000	rs2032447	chr6:26044369	A/G	cg18357526	chr6:26021779	HIST1H4A	0.82	15.78	0.59	3.45e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.962	rs4552	chr6:150132319	A/T	cg16507663	chr6:150244633	RAET1G	0.42	7.91	0.35	1.86e-14	Lung cancer;
LGG	trans	rs9866825	1.000	rs9866825	chr3:8250790	A/C	cg14959291	chr3:96532006	EPHA6	0.42	7.08	0.31	5.41e-12	QT interval;
LGG	cis	rs2742417	1.000	rs2742368	chr3:45752293	C/A	cg04837898	chr3:45731254	SACM1L	-0.38	-7.58	-0.33	1.94e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs1568889	1.000	rs2354427	chr11:28049623	T/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs28386778	0.863	rs8076760	chr17:61920497	T/C	cg06873352	chr17:61820015	STRADA	0.74	13.88	0.54	6.83e-37	Prudent dietary pattern;
LGG	cis	rs8031584	0.678	rs8028173	chr15:31155749	A/G	cg08704250	chr15:31115839	NA	-0.48	-8.64	-0.37	8.95e-17	Huntington's disease progression;
LGG	cis	rs763014	0.966	rs4984677	chr16:671682	A/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.7	-0.59	7.86e-45	Height;
LGG	trans	rs6471915	0.702	rs1010515	chr8:62000208	C/G	cg06789412	chr3:101405552	RPL24	0.42	7.08	0.31	5.35e-12	Prudent dietary pattern;
LGG	trans	rs7395662	0.929	rs10839173	chr11:48930758	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.83	-0.34	3.39e-14	HDL cholesterol;
LGG	cis	rs2739330	0.929	rs5751777	chr22:24267047	C/T	cg12419862	chr22:24373484	LOC391322	-0.91	-19.15	-0.66	1.19e-60	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.13	-0.31	3.85e-12	Personality dimensions;
LGG	cis	rs10267417	0.603	rs10950761	chr7:19912106	C/T	cg05791153	chr7:19748676	TWISTNB	0.53	6.96	0.31	1.16e-11	Night sleep phenotypes;
LGG	cis	rs1348850	0.526	rs10930802	chr2:178460095	A/G	cg27490568	chr2:178487706	NA	0.84	14.51	0.56	1.42e-39	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs755249	0.567	rs61779275	chr1:39820310	C/T	cg18385671	chr1:39797026	MACF1	0.43	7.32	0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2285947	1.000	rs10228845	chr7:21583617	G/A	cg03697024	chr7:21583438	DNAH11	0.35	8.69	0.37	6.23e-17	Multiple cancers (lung cancer, gastric cancer, and squamous cell carcinoma);
LGG	cis	rs9300255	0.544	rs1790130	chr12:123701270	A/C	cg00376283	chr12:123451042	ABCB9	0.63	10.12	0.43	7.09e-22	Neutrophil percentage of white cells;
LGG	cis	rs7481584	0.564	rs7948848	chr11:2981896	G/A	cg05729581	chr11:3078854	CARS	0.43	7.41	0.33	6.25e-13	Calcium levels;
LGG	cis	rs9894429	0.646	rs9904137	chr17:79613925	C/T	cg10661904	chr17:79619235	PDE6G	-0.5	-10.31	-0.43	1.37e-22	Eye color traits;
LGG	cis	rs9788682	0.633	rs2656070	chr15:78730252	A/G	cg06917634	chr15:78832804	PSMA4	0.53	8.14	0.35	3.76e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs2377585	0.563	rs11046832	chr12:8847970	T/G	cg03761649	chr12:8850719	RIMKLB	0.47	7.9	0.34	1.98e-14	Reticulocyte fraction of red cells;
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg19524238	chr7:2802976	GNA12	0.38	8.97	0.38	7.68e-18	Height;
LGG	cis	rs2415984	0.540	rs1494095	chr14:46960671	T/C	cg14871534	chr14:47121158	RPL10L	0.58	10.3	0.43	1.57e-22	Number of children ever born;
LGG	trans	rs7615952	0.641	rs6805074	chr3:125772274	T/A	cg07211511	chr3:129823064	LOC729375	-0.62	-8.66	-0.37	8.2e-17	Blood pressure (smoking interaction);
LGG	cis	rs4780401	0.728	rs8057398	chr16:11780629	G/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.14	-0.31	3.66e-12	Rheumatoid arthritis;
LGG	cis	rs11627756	0.958	rs2146431	chr14:103071861	A/G	cg12046867	chr14:103022105	NA	0.44	8.41	0.36	5.3e-16	Mean platelet volume;
LGG	cis	rs877426	0.681	rs75632431	chr13:114814916	A/G	cg00571178	chr13:114841904	RASA3	-0.56	-10.19	-0.43	3.83e-22	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs854765	0.547	rs2955353	chr17:17948979	T/C	cg24612305	chr17:17875800	TOM1L2;LRRC48	-0.77	-15.49	-0.58	6.34e-44	Total body bone mineral density;
LGG	cis	rs2456568	0.548	rs4753113	chr11:93660974	G/A	cg26875233	chr11:93583750	C11orf90	-0.43	-8.35	-0.36	7.94e-16	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs62025270	0.547	rs386346	chr15:86194559	A/T	cg25843651	chr15:86329602	KLHL25	0.55	9.32	0.4	4.73e-19	Idiopathic pulmonary fibrosis;
LGG	cis	rs7208859	0.725	rs7210904	chr17:29170205	G/A	cg19761014	chr17:28927070	LRRC37B2	0.53	6.67	0.3	7.1e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs28386778	0.769	rs6504179	chr17:61812995	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.62	12.31	0.5	2.62e-30	Prudent dietary pattern;
LGG	cis	rs75920871	0.588	rs6589580	chr11:116819873	G/A	cg01368799	chr11:117014884	PAFAH1B2	-0.56	-7.85	-0.34	2.83e-14	Subjective well-being;
LGG	cis	rs9381107	0.860	rs9369385	chr6:9477277	A/G	cg14735645	chr6:9486422	NA	-0.5	-8.11	-0.35	4.47e-15	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs6685188	0.843	rs1775139	chr1:205672357	C/G	cg14893161	chr1:205819251	PM20D1	0.48	7.85	0.34	2.97e-14	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs7824557	0.620	rs6996368	chr8:11182704	G/A	cg21775007	chr8:11205619	TDH	0.8	14.26	0.55	1.59e-38	Retinal vascular caliber;
LGG	cis	rs77633900	0.881	rs80003765	chr15:76657075	T/A	cg21673338	chr15:77095150	SCAPER	-0.61	-7.86	-0.34	2.68e-14	Non-glioblastoma glioma;Glioma;
LGG	cis	rs6062302	0.522	rs6089929	chr20:62219679	C/T	cg16989086	chr20:62203971	PRIC285	0.49	7.18	0.32	2.76e-12	Glioblastoma;
LGG	cis	rs12949688	0.651	rs4793915	chr17:55838163	C/T	cg12582317	chr17:55822272	NA	0.53	12.57	0.5	2.2e-31	Schizophrenia;
LGG	cis	rs2777491	0.507	rs34040639	chr15:41760807	A/G	cg18705301	chr15:41695430	NDUFAF1	-1.34	-33.32	-0.84	4.55e-125	Ulcerative colitis;
LGG	trans	rs11992162	0.636	rs4841644	chr8:11798433	A/C	cg02002194	chr4:3960332	NA	-0.44	-8.09	-0.35	5.11e-15	Monocyte count;
LGG	cis	rs12681366	0.683	rs2470746	chr8:95395808	A/G	cg13257157	chr8:95487014	RAD54B	-0.37	-6.81	-0.3	2.96e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs4731207	0.596	rs6466979	chr7:124648029	T/A	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6500602	0.727	rs4786515	chr16:4578133	T/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.35	7.38	0.32	7.38e-13	Schizophrenia;
LGG	cis	rs4363385	0.719	rs4845501	chr1:152937401	A/G	cg07796016	chr1:152779584	LCE1C	-0.48	-7.64	-0.33	1.23e-13	Inflammatory skin disease;
LGG	cis	rs9303280	0.806	rs35736272	chr17:38032680	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-8.86	-0.38	1.74e-17	Self-reported allergy;
LGG	cis	rs12950390	0.893	rs12325760	chr17:45840886	C/T	cg06532163	chr17:45867833	NA	0.55	9.1	0.39	2.79e-18	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg26174226	chr8:58114915	NA	-0.59	-8.56	-0.37	1.62e-16	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.683	rs814359	chr8:9883132	T/G	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.09	-0.46	1.72e-25	Neuroticism;
LGG	cis	rs4819852	0.723	rs2238790	chr22:19983014	G/A	cg06346307	chr22:19949965	COMT	-0.29	-7.23	-0.32	2.06e-12	Pulse pressure;
LGG	cis	rs9790314	0.638	rs1374793	chr3:160638505	G/A	cg03342759	chr3:160939853	NMD3	0.43	7.29	0.32	1.39e-12	Morning vs. evening chronotype;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg18891615	chr8:101962925	YWHAZ	-0.43	-6.85	-0.3	2.36e-11	Pancreatic cancer;
LGG	cis	rs11741688	0.631	rs4444956	chr5:178325515	A/G	cg13312174	chr5:178288687	ZNF354B	-0.38	-7.31	-0.32	1.19e-12	Sleep duration;
LGG	cis	rs8044868	0.502	rs9927526	chr16:72189184	C/G	cg23815491	chr16:72088622	HP	0.37	7.79	0.34	4.55e-14	Body mass index (change over time) in cancer or chronic obstructive pulmonary disease;Body mass index (change over time) in cancer;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.16	-0.62	1.91e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12681287	0.640	rs6992287	chr8:87418960	G/A	cg27223183	chr8:87520930	FAM82B	0.5	7.76	0.34	5.3e-14	Caudate activity during reward;
LGG	trans	rs853679	0.546	rs55690788	chr6:28436145	T/C	cg01620082	chr3:125678407	NA	-1.1	-10.66	-0.44	6.87e-24	Depression;
LGG	trans	rs35365539	1	rs35365539	chr3:49794347	A/AC	cg21659725	chr3:3221576	CRBN	-0.92	-20.58	-0.69	2.57e-67	Blood protein levels;
LGG	cis	rs7226408	0.857	rs72892516	chr18:34665048	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.12	-0.31	4.11e-12	Obesity-related traits;
LGG	cis	rs17221829	0.899	rs10160328	chr11:89462164	A/G	cg02982614	chr11:89391479	FOLH1B	-0.35	-7.5	-0.33	3.22e-13	Anxiety in major depressive disorder;
LGG	cis	rs67311347	0.955	rs2123999	chr3:40378738	C/T	cg13683864	chr3:40499215	RPL14	-1.0	-21.38	-0.7	4.76e-71	Renal cell carcinoma;
LGG	trans	rs7829975	0.511	rs1401390	chr8:8136410	C/T	cg02002194	chr4:3960332	NA	-0.52	-10.22	-0.43	2.99e-22	Mood instability;
LGG	cis	rs6940638	1.000	rs12215773	chr6:27039233	T/C	cg09904177	chr6:26538194	HMGN4	-0.58	-7.84	-0.34	3.11e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2898290	0.622	rs7822109	chr8:11349147	T/C	cg21775007	chr8:11205619	TDH	-0.44	-7.19	-0.32	2.59e-12	Systolic blood pressure;
LGG	cis	rs11112613	0.713	rs73184083	chr12:105952593	T/A	cg03607813	chr12:105948248	NA	0.59	10.85	0.45	1.32e-24	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;
LGG	trans	rs2018683	0.707	rs2391717	chr7:28971162	G/C	cg19402173	chr7:128379420	CALU	-0.53	-9.26	-0.4	7.54e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs9487051	0.768	rs458740	chr6:109525527	C/T	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5e-12	Reticulocyte fraction of red cells;
LGG	cis	rs12701220	0.894	rs10257744	chr7:1045612	C/T	cg02733842	chr7:1102375	C7orf50	-0.47	-7.39	-0.32	6.96e-13	Bronchopulmonary dysplasia;
LGG	cis	rs8072100	0.967	rs8078880	chr17:45676526	G/C	cg25173405	chr17:45401733	C17orf57	0.46	7.95	0.35	1.41e-14	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs9875589	0.509	rs2731336	chr3:14091908	G/A	cg19554555	chr3:13937349	NA	-0.57	-10.24	-0.43	2.48e-22	Ovarian reserve;
LGG	cis	rs11718455	1.000	rs36071827	chr3:44054261	A/G	cg21419209	chr3:44054225	NA	-0.45	-7.16	-0.32	3.29e-12	Coronary artery disease;
LGG	cis	rs950169	1.000	rs11638297	chr15:84782417	A/C	cg24253500	chr15:84953950	NA	0.58	10.46	0.44	3.94e-23	Schizophrenia;
LGG	cis	rs4689592	0.503	rs10516184	chr4:7060959	C/T	cg26116260	chr4:7069785	GRPEL1	1.03	15.4	0.58	1.64e-43	Monocyte percentage of white cells;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs1348850	0.632	rs12467363	chr2:178502512	C/T	cg22681709	chr2:178499509	PDE11A	-0.53	-9.63	-0.41	4.02e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4474465	1.000	rs1355921	chr11:78139279	C/T	cg27205649	chr11:78285834	NARS2	-0.48	-7.82	-0.34	3.56e-14	Alzheimer's disease (survival time);
LGG	cis	rs1862618	0.802	rs42769	chr5:56144152	G/A	cg12654349	chr5:56205094	C5orf35	-0.66	-10.48	-0.44	3.31e-23	Initial pursuit acceleration;
LGG	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg03609598	chr5:56110824	MAP3K1	-0.53	-7.78	-0.34	4.67e-14	Initial pursuit acceleration;
LGG	trans	rs12310956	0.532	rs7979535	chr12:33947450	A/C	cg26384229	chr12:38710491	ALG10B	-0.8	-15.83	-0.59	2.05e-45	Morning vs. evening chronotype;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg06112835	chr11:68658793	MRPL21	0.63	10.38	0.43	7.82e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs6601327	0.678	rs10106040	chr8:9612413	C/G	cg12395012	chr8:11607386	GATA4	-0.38	-6.77	-0.3	3.93e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs13108904	0.743	rs11729037	chr4:1387298	A/G	cg16399632	chr4:1244006	CTBP1;C4orf42	0.57	10.96	0.45	5.11e-25	Obesity-related traits;
LGG	cis	rs9462027	0.606	rs2038841	chr6:34738203	T/C	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs116095464	0.510	rs60844864	chr5:267000	A/G	cg22857025	chr5:266934	NA	-1.49	-25.44	-0.76	5.87e-90	Breast cancer;
LGG	trans	rs12310956	0.510	rs7302434	chr12:33886819	G/A	cg13010199	chr12:38710504	ALG10B	0.46	8.92	0.38	1.09e-17	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.717	rs17233678	chr16:89809962	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.35	-0.36	8.03e-16	Skin colour saturation;
LGG	cis	rs67478160	0.584	rs2295147	chr14:104195664	A/G	cg26031613	chr14:104095156	KLC1	0.46	7.48	0.33	3.73e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg08677398	chr8:58056175	NA	0.43	7.2	0.32	2.38e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs7829975	0.774	rs35039922	chr8:8675325	A/T	cg02002194	chr4:3960332	NA	-0.42	-7.75	-0.34	5.97e-14	Mood instability;
LGG	cis	rs7615952	0.576	rs6780025	chr3:125815624	A/C	cg18479299	chr3:125709523	NA	-0.58	-7.34	-0.32	9.51e-13	Blood pressure (smoking interaction);
LGG	cis	rs7737355	0.947	rs6884741	chr5:130894613	A/G	cg06307176	chr5:131281290	NA	0.6	9.75	0.41	1.5e-20	Life satisfaction;
LGG	cis	rs67311347	1.000	rs12492035	chr3:40467110	G/A	cg13683864	chr3:40499215	RPL14	-1.14	-26.77	-0.78	4.25e-96	Renal cell carcinoma;
LGG	cis	rs4731207	0.596	rs3903522	chr7:124668142	G/A	cg05630886	chr7:124431682	NA	-0.33	-7.55	-0.33	2.33e-13	Cutaneous malignant melanoma;
LGG	cis	rs9486719	1.000	rs72931061	chr6:96880285	G/A	cg06623918	chr6:96969491	KIAA0776	-0.75	-10.56	-0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs9796	0.558	rs6492993	chr15:41526104	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.59	-10.19	-0.43	3.82e-22	Menopause (age at onset);
LGG	cis	rs4722166	0.604	rs2390715	chr7:22783878	A/C	cg05265849	chr7:22767390	IL6	0.42	7.85	0.34	2.87e-14	Lung cancer;
LGG	cis	rs3736594	1.000	rs12477908	chr2:27987046	A/C	cg27432699	chr2:27873401	GPN1	-0.54	-8.9	-0.38	1.25e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	trans	rs2948294	0.588	rs4840913	chr8:8116906	A/C	cg16141378	chr3:129829833	LOC729375	-0.47	-10.74	-0.45	3.46e-24	Red cell distribution width;
LGG	cis	rs9388451	0.626	rs3799712	chr6:126075103	A/G	cg05901451	chr6:126070800	HEY2	-0.68	-12.91	-0.51	9.16e-33	Brugada syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09906751	chr10:64133883	ZNF365	0.44	6.81	0.3	2.99e-11	Gut microbiome composition (summer);
LGG	cis	rs11249608	0.548	rs10479520	chr5:178451447	C/A	cg21905437	chr5:178450457	ZNF879	0.46	6.65	0.3	8.26e-11	Pubertal anthropometrics;
LGG	cis	rs9916302	0.904	rs4795356	chr17:37535631	C/T	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs1719271	0.831	rs1684032	chr15:65185884	G/T	cg11671771	chr15:65133392	PLEKHO2	-0.5	-6.91	-0.31	1.62e-11	Platelet count;
LGG	cis	rs35740288	0.787	rs2291048	chr15:86225658	A/T	cg04173714	chr15:86211321	AKAP13	-0.46	-8.0	-0.35	1.03e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs209489	1.000	rs209514	chr6:53205808	G/A	cg15607103	chr6:53167650	ELOVL5	-0.52	-7.44	-0.33	5.05e-13	Survival in colorectal cancer (distant metastatic);
LGG	trans	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg09048205	chr5:1608656	LOC728613	0.48	8.27	0.36	1.39e-15	Breast cancer;
LGG	cis	rs12477438	0.572	rs10170063	chr2:99655639	A/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.32	-0.58	3.88e-43	Chronic sinus infection;
LGG	cis	rs6540556	0.608	rs12129718	chr1:209912540	C/T	cg23920097	chr1:209922102	NA	-0.4	-7.05	-0.31	6.54e-12	Red blood cell count;
LGG	cis	rs10464366	0.843	rs6957662	chr7:39110829	C/T	cg10621924	chr7:39171070	POU6F2	0.42	8.43	0.36	4.51e-16	IgG glycosylation;
LGG	trans	rs28595532	0.720	rs72670233	chr4:119316237	C/G	cg26518628	chr1:97050305	NA	-0.81	-6.86	-0.3	2.25e-11	Cannabis dependence symptom count;
LGG	cis	rs6496044	0.568	rs1982743	chr15:86068759	A/T	cg13263323	chr15:86062960	AKAP13	-0.39	-8.48	-0.37	3.06e-16	Interstitial lung disease;
LGG	trans	rs11875185	0.510	rs17754570	chr18:55597922	T/C	cg15513957	chr14:69354734	ACTN1	-0.92	-8.76	-0.38	3.74e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs74781061	0.932	rs8023479	chr15:74853678	A/G	cg02384859	chr15:74862662	ARID3B	-0.34	-7.29	-0.32	1.33e-12	Endometriosis;
LGG	cis	rs2842992	0.872	rs1570318	chr6:160111473	C/T	cg19482086	chr6:160211437	TCP1;MRPL18	0.8	13.38	0.53	9.56e-35	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9443189	0.526	rs10943250	chr6:76208445	C/G	cg01950844	chr6:76311363	SENP6	0.74	9.47	0.4	1.38e-19	Prostate cancer;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs875971	0.545	rs75840613	chr7:65841386	G/A	cg11764359	chr7:65958608	NA	0.63	9.79	0.41	1.09e-20	Aortic root size;
LGG	trans	rs826838	0.935	rs980571	chr12:39127532	C/G	cg06521331	chr12:34319734	NA	0.43	7.58	0.33	1.92e-13	Heart rate;
LGG	cis	rs17345786	0.861	rs74768235	chr3:101142821	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.53	7.7	0.34	8.54e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05665937	chr4:1216051	CTBP1	0.49	9.03	0.39	4.71e-18	Obesity-related traits;
LGG	trans	rs61931739	0.534	rs4931772	chr12:34044590	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.12	0.43	6.79e-22	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.673	rs73265624	chr17:29232066	G/A	cg13385521	chr17:29058706	SUZ12P	0.78	8.7	0.37	5.94e-17	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7937682	0.883	rs1613778	chr11:111456105	G/C	cg08305652	chr11:111469057	NA	-0.45	-9.1	-0.39	2.7e-18	Primary sclerosing cholangitis;
LGG	cis	rs3733585	0.699	rs10001964	chr4:9959275	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.87e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6665290	0.582	rs72764213	chr1:227207391	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.25	-40.21	-0.88	3.9e-153	Myeloid white cell count;
LGG	cis	rs17767392	0.681	rs17767266	chr14:71681331	T/C	cg13720639	chr14:72061746	SIPA1L1	-0.34	-6.97	-0.31	1.09e-11	Mitral valve prolapse;
LGG	cis	rs6964587	1.000	rs10245095	chr7:91710845	A/G	cg17063962	chr7:91808500	NA	0.49	8.66	0.37	7.66e-17	Breast cancer;
LGG	cis	rs3845702	0.668	rs12693215	chr2:180826007	A/C	cg01881094	chr2:180872142	CWC22	-1.25	-16.82	-0.62	7.03e-50	Schizophrenia;
LGG	cis	rs3857067	0.806	rs7678054	chr4:95093855	A/G	cg11021082	chr4:95130006	SMARCAD1	0.4	7.23	0.32	2.06e-12	QT interval;
LGG	cis	rs745080	1.000	rs7159631	chr14:52934531	G/A	cg23333723	chr14:53022898	GPR137C	-0.33	-7.17	-0.32	3.07e-12	Orofacial clefts;
LGG	cis	rs372883	0.600	rs2832293	chr21:30738872	C/G	cg08807101	chr21:30365312	RNF160	0.61	10.25	0.43	2.43e-22	Pancreatic cancer;
LGG	cis	rs4862750	0.914	rs1346127	chr4:187876389	C/T	cg03647317	chr4:187891568	NA	0.42	8.94	0.38	9.66e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs898097	0.783	rs11650335	chr17:80835111	A/G	cg22432760	chr17:80829718	TBCD	0.4	6.95	0.31	1.23e-11	Breast cancer;
LGG	cis	rs459571	0.920	rs455073	chr9:136909141	G/C	cg13789015	chr9:136890014	NCRNA00094	0.58	10.93	0.45	6.91e-25	Platelet distribution width;
LGG	cis	rs55871839	0.708	rs10093993	chr8:59811454	T/C	cg07426533	chr8:59803705	TOX	-0.58	-13.27	-0.52	2.73e-34	Pneumonia;
LGG	cis	rs2635047	0.638	rs2684840	chr18:44737230	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.82	0.3	2.92e-11	Educational attainment;
LGG	cis	rs11603023	1.000	rs11603023	chr11:118486067	T/C	cg19006130	chr11:118478252	PHLDB1	0.41	6.81	0.3	3.01e-11	Cholesterol, total;
LGG	cis	rs4332037	0.901	rs7791299	chr7:1935598	T/C	cg12591125	chr7:1885375	MAD1L1	0.44	6.7	0.3	6.05e-11	Bipolar disorder;
LGG	cis	rs2932538	0.961	rs6537746	chr1:113163529	C/T	cg22162597	chr1:113214053	CAPZA1	-0.63	-11.76	-0.48	4.07e-28	Systolic blood pressure;Diastolic blood pressure;Hypertension;Blood pressure;
LGG	cis	rs2760061	0.819	rs3094913	chr1:228206980	T/C	cg01200585	chr1:228362443	C1orf69	0.46	7.98	0.35	1.19e-14	Diastolic blood pressure;
LGG	cis	rs1348850	0.526	rs6723014	chr2:178410586	G/A	cg27490568	chr2:178487706	NA	0.82	14.3	0.55	1.13e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4076764	0.846	rs4255362	chr1:163424630	G/A	cg06092702	chr1:163392909	NA	-0.41	-7.36	-0.32	8.25e-13	Motion sickness;
LGG	cis	rs11997175	0.740	rs6991071	chr8:33814103	G/A	ch.8.33884649F	chr8:33765107	NA	0.41	7.87	0.34	2.46e-14	Body mass index;
LGG	cis	rs657075	0.697	rs4646194	chr5:131649062	C/A	cg21948465	chr5:131705150	SLC22A5	0.67	7.55	0.33	2.3e-13	Rheumatoid arthritis;
LGG	cis	rs769267	0.930	rs3794993	chr19:19611550	G/T	cg11584989	chr19:19387371	SF4	0.39	7.05	0.31	6.51e-12	Tonsillectomy;
LGG	cis	rs9322193	0.884	rs11155669	chr6:149954637	T/C	cg04369109	chr6:150039330	LATS1	-0.42	-7.13	-0.31	3.86e-12	Lung cancer;
LGG	cis	rs4262150	0.693	rs3924315	chr5:152302638	T/A	cg12297329	chr5:152029980	NA	0.58	11.23	0.46	4.8e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs6952808	0.964	rs6945719	chr7:1932688	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.42	-0.4	2.22e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs2270927	0.510	rs6453213	chr5:75579518	A/G	cg13563193	chr19:33072644	PDCD5	0.86	10.35	0.43	1.03e-22	Mean corpuscular volume;
LGG	cis	rs2470578	0.792	rs2060629	chr3:17279526	T/C	cg20981856	chr3:17787350	NA	0.35	6.75	0.3	4.41e-11	Schizophrenia;
LGG	cis	rs4330281	0.715	rs7609916	chr3:17804464	A/G	cg20981856	chr3:17787350	NA	-0.4	-7.25	-0.32	1.74e-12	Schizophrenia;
LGG	cis	rs8114671	0.562	rs2378294	chr20:33500378	G/A	cg24642439	chr20:33292090	TP53INP2	0.44	6.99	0.31	9.69e-12	Height;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg18350739	chr11:68623251	NA	-0.87	-22.26	-0.72	3.61e-75	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9875589	0.509	rs11128679	chr3:14075245	C/T	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.73	0.41	1.79e-20	Ovarian reserve;
LGG	cis	rs7769051	0.711	rs7758703	chr6:133085417	T/C	cg07930552	chr6:133119739	C6orf192	0.86	11.23	0.46	4.99e-26	Type 2 diabetes nephropathy;
LGG	cis	rs4906332	1.000	rs8004780	chr14:103853360	A/C	cg26031613	chr14:104095156	KLC1	-0.5	-7.64	-0.33	1.29e-13	Coronary artery disease;
LGG	cis	rs6831352	0.918	rs2602894	chr4:100045647	A/G	cg13256891	chr4:100009986	ADH5	0.56	9.79	0.41	1.07e-20	Alcohol dependence;
LGG	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg03517284	chr6:25882590	NA	-0.44	-7.06	-0.31	6.01e-12	Height;
LGG	cis	rs1218582	0.772	rs4240875	chr1:154885782	G/A	cg09359103	chr1:154839909	KCNN3	-0.51	-10.55	-0.44	1.83e-23	Prostate cancer;
LGG	cis	rs6951245	0.554	rs75075857	chr7:1140298	C/T	cg00364696	chr7:1142433	C7orf50	-0.39	-7.63	-0.33	1.34e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6496932	0.755	rs56909106	chr15:85864048	A/C	cg19183879	chr15:85880815	NA	0.42	6.74	0.3	4.79e-11	Central corneal thickness;Corneal structure;
LGG	cis	rs7674212	0.539	rs6854709	chr4:104129786	A/G	cg16532752	chr4:104119610	CENPE	-0.41	-7.14	-0.31	3.63e-12	Type 2 diabetes;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg20578329	chr17:80767326	TBCD	0.39	7.19	0.32	2.6e-12	Glycated hemoglobin levels;
LGG	cis	rs10504229	0.679	rs16921683	chr8:58053270	T/C	cg22535103	chr8:58192502	C8orf71	-0.79	-10.43	-0.44	5.22e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11098499	0.644	rs7693919	chr4:120540571	G/A	cg25214090	chr10:38739885	LOC399744	0.57	10.41	0.44	5.97e-23	Corneal astigmatism;
LGG	cis	rs13108904	0.901	rs2293634	chr4:1291711	T/G	cg06654118	chr4:1303317	MAEA	0.4	6.78	0.3	3.68e-11	Obesity-related traits;
LGG	cis	rs1355223	0.552	rs2421743	chr11:34882840	C/T	cg11058730	chr11:34937778	PDHX;APIP	0.77	14.95	0.57	1.63e-41	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12950390	0.814	rs11659069	chr17:45834275	G/T	cg00777063	chr17:45855553	NA	-0.32	-6.73	-0.3	4.99e-11	IgG glycosylation;
LGG	cis	rs4555082	0.834	rs28846738	chr14:105745781	A/G	cg13114125	chr14:105738426	BRF1	-0.85	-16.26	-0.6	2.29e-47	Mean platelet volume;Platelet distribution width;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg02002194	chr4:3960332	NA	-0.46	-8.71	-0.38	5.58e-17	Retinal vascular caliber;
LGG	cis	rs8177253	0.965	rs4854761	chr3:133498789	A/G	cg01448562	chr3:133502909	NA	0.75	14.1	0.55	7.76e-38	Iron status biomarkers;
LGG	cis	rs6784615	0.744	rs2109557	chr3:52448913	A/G	cg16850945	chr3:52488229	TNNC1;NISCH	-0.7	-7.72	-0.34	7.29e-14	Waist-hip ratio;
LGG	cis	rs2854207	0.505	rs2466957	chr17:61961230	G/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.41	0.33	6.17e-13	Height;
LGG	cis	rs10504229	0.562	rs2014516	chr8:58128288	C/A	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08280861	chr8:58055591	NA	0.54	6.86	0.3	2.19e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7312933	0.584	rs7974654	chr12:42630466	C/A	cg19980929	chr12:42632907	YAF2	0.39	8.98	0.39	6.64e-18	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1728785	0.901	rs11865339	chr16:68565296	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.21	-0.36	2.25e-15	Ulcerative colitis;
LGG	cis	rs11690935	0.959	rs77280952	chr2:172620151	G/C	cg21435375	chr2:172878103	MAP1D	-0.31	-6.95	-0.31	1.28e-11	Schizophrenia;
LGG	cis	rs9296092	0.560	rs9469506	chr6:33527897	A/G	cg13560919	chr6:33536144	NA	-1.05	-22.06	-0.72	3.21e-74	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10504229	0.728	rs17215851	chr8:58154160	A/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4954585	0.708	rs10200263	chr2:137007429	C/T	cg05194412	chr2:137003533	NA	0.37	7.95	0.35	1.4e-14	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg07959490	chr17:80112427	CCDC57	-0.46	-9.09	-0.39	3.01e-18	Life satisfaction;
LGG	cis	rs8177253	0.665	rs10935074	chr3:133441692	T/G	cg16414030	chr3:133502952	NA	-0.48	-7.92	-0.35	1.81e-14	Iron status biomarkers;
LGG	cis	rs798766	1.000	rs798724	chr4:1704643	C/T	cg00006948	chr4:1768889	NA	-0.49	-6.75	-0.3	4.34e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs951366	0.668	rs823154	chr1:205762406	C/T	cg13453750	chr1:205783389	SLC41A1	-0.49	-9.77	-0.41	1.22e-20	Menarche (age at onset);
LGG	cis	rs2479724	0.901	rs2185798	chr6:41773576	G/C	cg17623882	chr6:41773611	USP49	0.52	9.17	0.39	1.53e-18	Menarche (age at onset);
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.38	-7.7	-0.34	8.46e-14	Personality dimensions;
LGG	cis	rs9457247	0.602	rs13204839	chr6:167471119	G/A	cg07741184	chr6:167504864	NA	0.44	10.24	0.43	2.64e-22	Crohn's disease;
LGG	cis	rs2404602	0.684	rs57682236	chr15:76868478	G/A	cg23625390	chr15:77176239	SCAPER	-0.73	-14.49	-0.56	1.69e-39	Blood metabolite levels;
LGG	cis	rs2404602	0.716	rs2404736	chr15:76875943	T/C	cg15268244	chr15:77196840	NA	-0.31	-6.83	-0.3	2.67e-11	Blood metabolite levels;
LGG	trans	rs7824557	0.527	rs2572447	chr8:11239510	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.1	0.35	5.04e-15	Retinal vascular caliber;
LGG	cis	rs6952808	0.595	rs3778982	chr7:2166233	T/C	cg11050988	chr7:1952600	MAD1L1	-0.33	-7.77	-0.34	4.99e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs2404602	0.655	rs4886507	chr15:77209694	T/C	cg23625390	chr15:77176239	SCAPER	0.46	9.04	0.39	4.31e-18	Blood metabolite levels;
LGG	cis	rs798554	0.757	rs1182181	chr7:2873247	C/G	cg19524238	chr7:2802976	GNA12	0.38	8.66	0.37	7.94e-17	Height;
LGG	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg04731861	chr2:219085781	ARPC2	-0.49	-12.52	-0.5	3.64e-31	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	trans	rs1973993	0.603	rs1925833	chr1:97023641	C/A	cg10631902	chr5:14652156	NA	-0.37	-6.96	-0.31	1.14e-11	Weight;
LGG	cis	rs10464366	0.879	rs10464368	chr7:39121581	C/T	cg10621924	chr7:39171070	POU6F2	0.41	8.25	0.36	1.71e-15	IgG glycosylation;
LGG	cis	rs17767392	0.958	rs8010616	chr14:72019108	A/G	cg02058870	chr14:72053146	SIPA1L1	-0.46	-9.52	-0.4	9.36e-20	Mitral valve prolapse;
LGG	cis	rs2841277	0.708	rs9671643	chr14:105408030	A/G	cg15352829	chr14:105391018	PLD4	-0.47	-11.39	-0.47	1.14e-26	Rheumatoid arthritis;
LGG	cis	rs6502050	0.769	rs9898542	chr17:80119682	C/T	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs526231	0.578	rs10515337	chr5:102301368	C/T	cg23492399	chr5:102201601	PAM	0.61	9.29	0.4	6.1e-19	Primary biliary cholangitis;
LGG	cis	rs789852	1.000	rs789850	chr3:194325496	T/C	cg18000598	chr3:194342907	TMEM44	-0.86	-8.09	-0.35	5.22e-15	QT interval;
LGG	cis	rs2075371	0.796	rs10954440	chr7:134005657	C/T	cg20476274	chr7:133979776	SLC35B4	0.7	13.06	0.52	1.99e-33	Mean platelet volume;
LGG	cis	rs2282802	0.635	rs269767	chr5:139536922	A/G	cg26211634	chr5:139558579	C5orf32	0.33	7.27	0.32	1.5e-12	Intelligence (multi-trait analysis);
LGG	cis	rs9311474	0.508	rs7652191	chr3:52610415	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.29	0.46	2.75e-26	Electroencephalogram traits;
LGG	cis	rs2075371	1.000	rs2598294	chr7:133991690	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.5	0.58	5.94e-44	Mean platelet volume;
LGG	cis	rs752092	0.775	rs4965806	chr15:101752435	G/A	cg19997662	chr15:101784653	CHSY1	-0.79	-15.96	-0.6	5.29e-46	Corneal structure;
LGG	cis	rs8025790	0.508	rs12902812	chr15:67909279	C/T	cg27219399	chr15:67835830	MAP2K5	0.32	7.01	0.31	8.57e-12	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs7681440	0.845	rs6843084	chr4:90766230	T/C	cg01966878	chr4:90757139	SNCA	-0.35	-7.34	-0.32	9.84e-13	Dementia with Lewy bodies;
LGG	cis	rs41342147	0.660	rs7559564	chr2:242239918	G/A	cg10173475	chr2:242152697	ANO7	-0.6	-9.02	-0.39	4.99e-18	Vitiligo;
LGG	cis	rs4950322	0.570	rs72692946	chr1:146791684	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.19	-0.36	2.52e-15	Protein quantitative trait loci;
LGG	cis	rs1865760	0.566	rs9358904	chr6:26068566	C/T	cg18357526	chr6:26021779	HIST1H4A	0.46	7.71	0.34	7.96e-14	Height;
LGG	cis	rs2108225	0.837	rs7810937	chr7:107447500	A/G	cg18560240	chr7:107437656	SLC26A3	-0.58	-10.31	-0.43	1.46e-22	Ulcerative colitis;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg13395646	chr4:1353034	KIAA1530	-0.53	-9.18	-0.39	1.44e-18	Obesity-related traits;
LGG	cis	rs72827839	0.516	rs72833461	chr17:45938105	T/G	cg02219949	chr17:45927392	SP6	0.44	7.55	0.33	2.38e-13	Ease of getting up in the morning;
LGG	cis	rs10256972	0.616	rs6463001	chr7:1108272	A/C	cg11360546	chr7:1094263	C7orf50	-0.39	-7.25	-0.32	1.77e-12	Longevity;Endometriosis;
LGG	trans	rs916888	0.821	rs199514	chr17:44856881	G/A	cg22968622	chr17:43663579	NA	-1.01	-18.88	-0.66	2.25e-59	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg12738264	chr7:148725795	PDIA4	0.48	7.44	0.33	4.95e-13	Gut microbiome composition (summer);
LGG	cis	rs12908161	0.959	rs2175567	chr15:85200946	C/G	cg24253500	chr15:84953950	NA	0.42	7.0	0.31	8.96e-12	Schizophrenia;
LGG	cis	rs4660214	0.789	rs1180375	chr1:39881040	G/C	cg18385671	chr1:39797026	MACF1	0.47	9.7	0.41	2.15e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs4975709	0.589	rs4975745	chr5:1861058	G/C	cg15595755	chr5:1867978	NA	0.51	10.3	0.43	1.48e-22	Cardiovascular disease risk factors;
LGG	cis	rs10540	0.915	rs35389167	chr11:460765	A/G	cg19913688	chr11:428466	ANO9	-0.69	-8.7	-0.37	5.9e-17	Body mass index;
LGG	cis	rs17270561	0.609	rs1892245	chr6:25764833	G/T	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs526231	0.543	rs7709726	chr5:102327463	A/G	cg23492399	chr5:102201601	PAM	0.57	8.87	0.38	1.56e-17	Primary biliary cholangitis;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg21782813	chr7:2030301	MAD1L1	0.39	8.54	0.37	1.9e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs28830936	0.966	rs17678552	chr15:42066190	T/C	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.35	-7.15	-0.32	3.43e-12	Diastolic blood pressure;
LGG	cis	rs1799949	0.965	rs799917	chr17:41244936	G/A	cg05368731	chr17:41323189	NBR1	0.85	16.57	0.61	9.36e-49	Menopause (age at onset);
LGG	cis	rs7824557	0.778	rs3808502	chr8:11179458	G/T	cg21775007	chr8:11205619	TDH	0.67	11.48	0.47	4.91e-27	Retinal vascular caliber;
LGG	cis	rs597539	0.652	rs667989	chr11:68685776	T/A	cg18350739	chr11:68623251	NA	-0.85	-21.32	-0.7	8.97e-71	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4535497	0.525	rs4975639	chr5:1108250	A/G	cg18322822	chr5:1119648	NA	0.42	7.77	0.34	5.11e-14	Mean corpuscular hemoglobin concentration;
LGG	cis	rs12188164	0.543	rs2672757	chr5:454732	A/G	cg26076054	chr5:421317	AHRR	0.42	7.81	0.34	3.96e-14	Cystic fibrosis severity;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg15352829	chr14:105391018	PLD4	-0.46	-11.32	-0.47	2.07e-26	Rheumatoid arthritis;
LGG	cis	rs7312933	0.531	rs1796380	chr12:42791543	T/G	cg19980929	chr12:42632907	YAF2	-0.34	-7.65	-0.33	1.21e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs28386778	0.863	rs3760256	chr17:61821161	A/G	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.13	33.55	0.84	4.77e-126	Prudent dietary pattern;
LGG	cis	rs11628318	0.614	rs12590775	chr14:103150623	A/G	cg01864069	chr14:103024347	NA	0.47	8.1	0.35	4.85e-15	Platelet count;
LGG	cis	rs4356932	0.934	rs4859603	chr4:76965747	A/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs7364180	0.582	rs139568	chr22:42210985	C/T	cg03806693	chr22:41940476	POLR3H	0.55	9.27	0.4	7e-19	Alzheimer's disease biomarkers;
LGG	cis	rs4704846	1.000	rs375940	chr5:156545612	A/G	cg12943317	chr5:156479607	HAVCR1	-0.57	-7.26	-0.32	1.66e-12	Blood protein levels;
LGG	cis	rs701145	0.585	rs6769099	chr3:153852442	T/C	cg17054900	chr3:154042577	DHX36	0.79	9.35	0.4	3.76e-19	Coronary artery disease;
LGG	trans	rs1994135	0.617	rs10844644	chr12:33735871	A/G	cg13010199	chr12:38710504	ALG10B	0.48	8.53	0.37	2.1e-16	Resting heart rate;
LGG	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Body mass index;
LGG	cis	rs4460629	0.742	rs11264312	chr1:155075888	T/C	cg13808842	chr1:155066096	NA	-0.29	-7.04	-0.31	7.09e-12	Serum magnesium levels;
LGG	cis	rs6952808	0.931	rs12537479	chr7:1868995	A/G	cg19147804	chr7:1989927	MAD1L1	0.46	8.53	0.37	2.13e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs317689	0.718	rs160827	chr12:69770147	G/A	cg20891283	chr12:69753455	YEATS4	0.8	13.06	0.52	2.08e-33	Response to diuretic therapy;
LGG	cis	rs17209837	0.607	rs1558375	chr7:87079069	T/C	cg00919237	chr7:87102261	ABCB4	-0.78	-15.65	-0.59	1.3e-44	Gallbladder cancer;
LGG	cis	rs4481887	0.861	rs4309013	chr1:248480768	C/T	cg00666640	chr1:248458726	OR2T12	0.57	9.11	0.39	2.59e-18	Common traits (Other);
LGG	cis	rs60695258	0.550	rs6531948	chr4:87972968	T/C	cg01323104	chr4:87958903	AFF1	0.24	6.78	0.3	3.57e-11	Hematocrit;
LGG	cis	rs936229	0.798	rs1869959	chr15:75147332	A/C	cg14664628	chr15:75095509	CSK	-0.98	-21.45	-0.71	2.11e-71	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs35264875	0.851	rs72930611	chr11:68863659	G/T	cg23740940	chr11:68924746	NA	0.43	6.81	0.3	2.96e-11	Blond vs. brown hair color;
LGG	cis	rs3742264	0.656	rs7325308	chr13:46514662	C/T	cg15192986	chr13:46630673	CPB2	-0.35	-6.69	-0.3	6.41e-11	Blood protein levels;
LGG	cis	rs2832191	1.000	rs2832183	chr21:30482150	G/A	cg08807101	chr21:30365312	RNF160	-0.81	-15.75	-0.59	4.43e-45	Dental caries;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05025164	chr4:1340916	KIAA1530	-0.49	-8.48	-0.37	3.04e-16	Obesity-related traits;
LGG	cis	rs7659604	0.502	rs13128434	chr4:122672461	A/C	cg19748678	chr4:122722346	EXOSC9	-0.44	-7.76	-0.34	5.31e-14	Type 2 diabetes;
LGG	trans	rs12310956	0.532	rs7967627	chr12:33974669	G/T	cg13010199	chr12:38710504	ALG10B	0.52	9.93	0.42	3.47e-21	Morning vs. evening chronotype;
LGG	cis	rs4363385	0.835	rs431242	chr1:153050414	G/A	cg07796016	chr1:152779584	LCE1C	-0.41	-6.95	-0.31	1.25e-11	Inflammatory skin disease;
LGG	cis	rs6951245	0.935	rs11766669	chr7:1063593	C/T	cg24642844	chr7:1081250	C7orf50	-0.79	-13.31	-0.53	1.93e-34	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11298680	chr1:28559461	DNAJC8	0.46	7.46	0.33	4.42e-13	Cognitive performance;
LGG	trans	rs7824557	0.767	rs1897951	chr8:11169854	C/T	cg16141378	chr3:129829833	LOC729375	-0.39	-8.63	-0.37	1.01e-16	Retinal vascular caliber;
LGG	cis	rs17508449	0.505	rs78491726	chr1:114327469	T/C	cg26035817	chr1:114414802	PTPN22	-0.45	-7.02	-0.31	7.82e-12	Leprosy;
LGG	cis	rs12477438	0.501	rs12992218	chr2:99753834	G/A	cg08885076	chr2:99613938	TSGA10	0.42	8.9	0.38	1.29e-17	Chronic sinus infection;
LGG	cis	rs9322193	0.847	rs12234128	chr6:149948689	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.18	0.32	2.74e-12	Lung cancer;
LGG	cis	rs6582630	0.621	rs10880656	chr12:38571220	A/C	cg13010199	chr12:38710504	ALG10B	-0.55	-10.97	-0.45	4.8e-25	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs853679	0.546	rs35744819	chr6:28318331	G/T	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.36	-0.5	1.52e-30	Depression;
LGG	cis	rs1719271	0.614	rs12905711	chr15:65126353	C/A	cg11671771	chr15:65133392	PLEKHO2	-0.5	-6.73	-0.3	4.89e-11	Platelet count;
LGG	cis	rs3206736	0.663	rs329571	chr7:35095787	C/G	cg13400248	chr7:35225412	NA	0.44	8.16	0.35	3.2e-15	Diastolic blood pressure;
LGG	cis	rs1153858	1.000	rs4775895	chr15:45617957	T/A	cg10760299	chr15:45669010	GATM	0.39	7.55	0.33	2.32e-13	Homoarginine levels;
LGG	cis	rs804280	0.565	rs1466785	chr8:11623456	C/T	cg12395012	chr8:11607386	GATA4	-0.58	-11.45	-0.47	6.7e-27	Myopia (pathological);
LGG	cis	rs8017423	0.605	rs4904676	chr14:90819220	G/A	cg04374321	chr14:90722782	PSMC1	-0.65	-12.86	-0.51	1.41e-32	Mortality in heart failure;
LGG	cis	rs6988985	0.703	rs7016594	chr8:143950352	G/A	cg10324643	chr8:143916377	GML	0.39	7.85	0.34	2.85e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	trans	rs804280	0.518	rs34266352	chr8:11791462	G/A	cg16141378	chr3:129829833	LOC729375	-0.36	-8.13	-0.35	4.06e-15	Myopia (pathological);
LGG	cis	rs1867631	0.585	rs12094526	chr1:67126114	A/G	cg13052034	chr1:66999238	SGIP1	0.33	6.75	0.3	4.41e-11	Menopause (age at onset);
LGG	cis	rs11800820	0.536	rs10924739	chr1:246632947	A/G	cg16700716	chr1:246684329	NA	-0.41	-7.29	-0.32	1.35e-12	Obesity-related traits;
LGG	trans	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs7615952	0.608	rs35668111	chr3:125544635	C/T	cg05084668	chr3:125655381	ALG1L	-0.68	-8.59	-0.37	1.31e-16	Blood pressure (smoking interaction);
LGG	cis	rs2173063	1.000	rs79103559	chr15:93127028	C/T	cg07052004	chr15:93132129	NA	0.68	7.14	0.31	3.75e-12	Subcutaneous adipose tissue;
LGG	cis	rs1577917	0.771	rs9450290	chr6:86233397	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	12.06	0.49	2.55e-29	Response to antipsychotic treatment;
LGG	cis	rs17345786	0.628	rs11718446	chr3:101552553	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.52	-8.87	-0.38	1.59e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7011049	1.000	rs11985687	chr8:53832602	G/A	cg26025543	chr8:53854495	NA	0.73	9.65	0.41	3.44e-20	Systolic blood pressure;
LGG	cis	rs2836974	0.800	rs12482857	chr21:40514861	T/C	cg17971929	chr21:40555470	PSMG1	0.87	15.89	0.59	1.1e-45	Cognitive function;
LGG	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg18898632	chr2:242989856	NA	-0.78	-10.01	-0.42	1.8e-21	Obesity-related traits;
LGG	cis	rs933688	0.938	rs7705465	chr5:90680949	G/A	cg02339078	chr5:90679543	LOC100129716;ARRDC3	0.93	18.07	0.64	1.29e-55	Smoking behavior;
LGG	cis	rs9815354	0.857	rs1474219	chr3:42000913	G/A	cg03022575	chr3:42003672	ULK4	-0.63	-8.12	-0.35	4.36e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs13108904	0.905	rs1680074	chr4:1279621	G/A	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-9.11	-0.39	2.56e-18	Obesity-related traits;
LGG	cis	rs1862618	0.853	rs9283717	chr5:56078659	G/A	cg17809284	chr5:56205270	C5orf35	-0.52	-8.42	-0.36	4.61e-16	Initial pursuit acceleration;
LGG	cis	rs798554	0.796	rs2158694	chr7:2863443	T/G	cg19717773	chr7:2847554	GNA12	-0.33	-6.94	-0.31	1.29e-11	Height;
LGG	cis	rs9322193	0.923	rs7740278	chr6:149961252	C/T	cg12070911	chr6:150209640	RAET1E	0.3	7.2	0.32	2.38e-12	Lung cancer;
LGG	trans	rs2898290	0.622	rs978803	chr8:11343475	C/T	cg13009111	chr11:71350975	NA	0.3	6.79	0.3	3.38e-11	Systolic blood pressure;
LGG	cis	rs66573146	0.808	rs73202120	chr4:7005588	A/G	cg00086871	chr4:6988644	TBC1D14	1.07	10.36	0.43	9.52e-23	Granulocyte percentage of myeloid white cells;
LGG	cis	rs4423214	1.000	rs3794060	chr11:71187679	C/T	cg05163923	chr11:71159392	DHCR7	0.71	13.83	0.54	1.18e-36	Vitamin D levels;
LGG	trans	rs2197308	0.565	rs4123923	chr12:37857684	T/C	cg06521331	chr12:34319734	NA	-0.54	-9.26	-0.4	7.96e-19	Morning vs. evening chronotype;
LGG	cis	rs10256972	0.504	rs3735687	chr7:1066297	A/G	cg06145435	chr7:1022769	CYP2W1	0.3	6.75	0.3	4.46e-11	Longevity;Endometriosis;
LGG	cis	rs7223966	0.960	rs2319990	chr17:61705397	T/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.49	-0.33	3.49e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs11971779	0.680	rs6962366	chr7:139043867	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.01	0.31	8.24e-12	Diisocyanate-induced asthma;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20385120	chr15:90895810	ZNF774	0.49	7.36	0.32	8.63e-13	Gut microbiome composition (summer);
LGG	cis	rs7483296	0.705	rs1460913	chr11:115404152	C/T	cg02820646	chr11:115398838	NA	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels (HVA/MHPG ratio);Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	cis	rs3806843	0.607	rs246044	chr5:140330656	C/T	cg19875535	chr5:140030758	IK	0.37	7.41	0.33	5.92e-13	Depressive symptoms (multi-trait analysis);
LGG	cis	rs4262150	0.810	rs17565505	chr5:152064433	A/G	cg12297329	chr5:152029980	NA	0.79	15.06	0.57	5.42e-42	Bipolar disorder and schizophrenia;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg00800038	chr16:89945340	TCF25	-0.7	-7.96	-0.35	1.35e-14	Skin colour saturation;
LGG	cis	rs11203032	0.831	rs10788638	chr10:90950683	A/G	cg16672925	chr10:90967113	CH25H	0.51	7.96	0.35	1.31e-14	Heart failure;
LGG	cis	rs2739330	0.892	rs5751776	chr22:24266954	A/C	cg24846343	chr22:24311635	DDTL	0.62	12.82	0.51	2.03e-32	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2243480	1.000	rs313814	chr7:65503293	C/A	cg12463550	chr7:65579703	CRCP	0.76	8.11	0.35	4.67e-15	Diabetic kidney disease;
LGG	cis	rs910316	1.000	rs4322591	chr14:75600697	C/T	cg08847533	chr14:75593920	NEK9	0.62	12.02	0.49	3.64e-29	Height;
LGG	cis	rs7010267	0.668	rs4563920	chr8:119993689	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.39	10.12	0.43	7.28e-22	Total body bone mineral density (age 45-60);
LGG	trans	rs330071	0.500	rs17662123	chr8:9246837	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.36	0.32	8.45e-13	Acne (severe);
LGG	cis	rs3106136	1.000	rs3106134	chr4:95128091	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.45	-7.69	-0.34	8.7e-14	Capecitabine sensitivity;
LGG	cis	rs7927592	0.871	rs871212	chr11:68348695	T/A	cg01657329	chr11:68192670	LRP5	-0.49	-8.46	-0.37	3.63e-16	Total body bone mineral density;
LGG	cis	rs10884984	0.754	rs1889567	chr10:112266771	C/T	cg18756771	chr10:112261994	DUSP5	0.66	11.79	0.48	3.11e-28	Facial morphology (factor 22);
LGG	cis	rs8141529	0.588	rs10222249	chr22:29257147	A/G	cg15103426	chr22:29168792	CCDC117	0.65	8.89	0.38	1.38e-17	Lymphocyte counts;
LGG	cis	rs826838	0.935	rs1719855	chr12:39127242	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs13118159	0.509	rs10023473	chr4:1375285	C/T	cg02018176	chr4:1364513	KIAA1530	0.64	15.84	0.59	1.82e-45	Longevity;
LGG	trans	rs11098499	0.863	rs1480940	chr4:120457682	T/C	cg25214090	chr10:38739885	LOC399744	0.68	11.89	0.48	1.25e-28	Corneal astigmatism;
LGG	cis	rs9815354	0.857	rs73830583	chr3:41996948	C/T	cg03022575	chr3:42003672	ULK4	0.8	9.34	0.4	4.02e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg06238570	chr21:40685208	BRWD1	0.43	6.77	0.3	4.01e-11	Cognitive function;
LGG	cis	rs35123781	1.000	rs627817	chr5:139054506	A/G	cg21230503	chr5:139085173	NA	0.31	7.32	0.32	1.13e-12	Schizophrenia;
LGG	cis	rs7267979	1.000	rs2482941	chr20:25361216	T/C	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1799949	0.965	rs799912	chr17:41257134	T/C	cg25072359	chr17:41440525	NA	0.49	9.73	0.41	1.8e-20	Menopause (age at onset);
LGG	trans	rs12478296	0.591	rs12468297	chr2:242996474	A/G	cg01596870	chr19:55963115	NA	-0.46	-7.65	-0.33	1.14e-13	Obesity-related traits;
LGG	cis	rs3106136	0.872	rs2059606	chr4:95255278	C/T	cg11021082	chr4:95130006	SMARCAD1	0.4	6.84	0.3	2.51e-11	Capecitabine sensitivity;
LGG	cis	rs7647973	0.769	rs6772452	chr3:49040462	A/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.45	7.86	0.34	2.76e-14	Menarche (age at onset);
LGG	cis	rs7107174	1.000	rs2512550	chr11:77943848	C/T	cg02023728	chr11:77925099	USP35	0.44	7.86	0.34	2.67e-14	Testicular germ cell tumor;
LGG	cis	rs2153535	0.580	rs6914276	chr6:8450435	A/T	cg23788917	chr6:8435910	SLC35B3	-0.52	-8.65	-0.37	8.35e-17	Motion sickness;
LGG	cis	rs58688157	0.705	rs12795572	chr11:590999	G/A	cg16486109	chr11:613632	IRF7	0.42	7.12	0.31	4.05e-12	Systemic lupus erythematosus;
LGG	cis	rs1697139	0.967	rs1705396	chr5:66510876	T/C	cg16691251	chr5:66510806	NA	-0.37	-7.64	-0.33	1.3e-13	Breast cancer;
LGG	cis	rs73416724	1.000	rs111467122	chr6:43334547	C/T	cg26312998	chr6:43337775	ZNF318	0.61	8.57	0.37	1.59e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1552244	0.882	rs3846168	chr3:9996925	C/T	cg00149659	chr3:10157352	C3orf10	0.74	9.56	0.41	7.09e-20	Alzheimer's disease;
LGG	cis	rs2470578	0.792	rs767685	chr3:17324733	C/T	cg20981856	chr3:17787350	NA	-0.36	-6.94	-0.31	1.3e-11	Schizophrenia;
LGG	cis	rs2742417	1.000	rs2673047	chr3:45743113	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs4664308	0.967	rs17241792	chr2:160915205	C/T	cg03641300	chr2:160917029	PLA2R1	-0.87	-18.45	-0.65	2.13e-57	Idiopathic membranous nephropathy;
LGG	cis	rs6942756	1.000	rs67820265	chr7:128887925	A/G	cg02491457	chr7:128862824	NA	-0.77	-14.09	-0.55	8.72e-38	White matter hyperintensity burden;
LGG	cis	rs55823223	0.503	rs9906971	chr17:73848477	A/G	cg10935138	chr17:73851978	WBP2	0.53	7.93	0.35	1.61e-14	Psoriasis;
LGG	cis	rs853679	0.517	rs55747925	chr6:28044337	T/C	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.67	-0.34	1.05e-13	Depression;
LGG	cis	rs13102973	1.000	rs7439938	chr4:135897696	G/A	cg14419869	chr4:135874104	NA	-0.56	-10.36	-0.43	9.64e-23	Subjective well-being;
LGG	cis	rs12477438	0.798	rs6736064	chr2:99658201	G/A	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs7633770	0.769	rs3796371	chr3:46667224	C/T	cg11219411	chr3:46661640	NA	0.59	14.2	0.55	2.9e-38	Coronary artery disease;
LGG	cis	rs1218582	0.772	rs4845688	chr1:154884142	T/C	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.58	-0.33	1.91e-13	Prostate cancer;
LGG	cis	rs9914988	0.887	rs4795456	chr17:27072463	G/A	cg20469991	chr17:27169893	C17orf63	-0.56	-6.87	-0.3	2.11e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs2235573	0.625	rs1883471	chr22:38417510	T/C	cg19894588	chr14:64061835	NA	0.51	8.44	0.37	4.04e-16	Glioblastoma;Glioma;
LGG	cis	rs11920090	0.858	rs11929535	chr3:170710456	C/T	cg09710316	chr3:170744871	SLC2A2	0.65	8.4	0.36	5.47e-16	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs2074193	0.826	rs215349	chr12:47734467	A/T	cg02516419	chr12:47771422	NA	0.7	14.18	0.55	3.73e-38	Migraine with aura;
LGG	cis	rs10504229	1.000	rs74546828	chr8:58171678	A/G	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	1.000	rs55717005	chr2:243041071	T/A	cg18898632	chr2:242989856	NA	-0.79	-9.81	-0.41	9.24e-21	Obesity-related traits;
LGG	cis	rs2011503	1.000	rs34067609	chr19:19653524	G/A	cg11584989	chr19:19387371	SF4	0.74	12.06	0.49	2.63e-29	Bipolar disorder;
LGG	cis	rs8062405	0.929	rs11150609	chr16:28870596	A/G	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4930103	0.534	rs2063550	chr11:1979223	G/C	cg03175030	chr11:2018143	H19;MIR675	-0.38	-7.14	-0.31	3.61e-12	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs10779751	1.000	rs1010447	chr1:11269796	A/G	cg08854313	chr1:11322531	MTOR	0.71	14.43	0.56	3.02e-39	Body mass index;
LGG	cis	rs7020830	1.000	rs7020830	chr9:37085184	A/T	cg14294708	chr9:37120828	ZCCHC7	1.12	30.29	0.82	6.8e-112	Schizophrenia;
LGG	cis	rs1218582	0.741	rs7544528	chr1:154844585	C/T	cg12436631	chr1:155007014	DCST1;DCST2	0.42	8.4	0.36	5.68e-16	Prostate cancer;
LGG	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg26384229	chr12:38710491	ALG10B	0.93	21.87	0.71	2.52e-73	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs10504229	0.906	rs17805439	chr8:58172400	T/C	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs208520	0.802	rs208516	chr6:66946119	T/C	cg07460842	chr6:66804631	NA	-0.92	-15.89	-0.59	1.11e-45	Exhaled nitric oxide output;
LGG	trans	rs7395662	1.000	rs11039851	chr11:48600839	A/G	cg03929089	chr4:120376271	NA	-0.45	-7.3	-0.32	1.29e-12	HDL cholesterol;
LGG	cis	rs9457247	0.765	rs9457256	chr6:167436461	T/C	cg07741184	chr6:167504864	NA	0.41	9.2	0.39	1.19e-18	Crohn's disease;
LGG	cis	rs801193	1.000	rs2659889	chr7:66217112	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.83e-11	Aortic root size;
LGG	cis	rs12291225	0.679	rs7934671	chr11:14305101	C/T	cg02886208	chr11:14281011	SPON1	-0.36	-6.9	-0.31	1.67e-11	Sense of smell;
LGG	trans	rs7618501	0.633	rs4688757	chr3:50035323	T/C	cg21659725	chr3:3221576	CRBN	0.66	12.43	0.5	8.47e-31	Intelligence (multi-trait analysis);
LGG	cis	rs589448	0.967	rs634512	chr12:69754012	C/T	cg22834771	chr12:69754056	YEATS4	-0.51	-8.9	-0.38	1.3e-17	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7107174	1.000	rs2512535	chr11:77971468	C/T	cg02023728	chr11:77925099	USP35	0.45	7.88	0.34	2.34e-14	Testicular germ cell tumor;
LGG	cis	rs9322193	0.607	rs12204653	chr6:150213021	C/G	cg13206674	chr6:150067644	NUP43	0.44	7.68	0.34	9.36e-14	Lung cancer;
LGG	cis	rs59918340	0.764	rs753779	chr8:142228809	T/C	cg23750338	chr8:142222470	SLC45A4	0.61	12.61	0.51	1.51e-31	Immature fraction of reticulocytes;
LGG	cis	rs875971	0.522	rs56028712	chr7:65466565	C/T	cg11987759	chr7:65425863	GUSB	-0.42	-8.31	-0.36	1.08e-15	Aortic root size;
LGG	cis	rs7659604	0.540	rs4833769	chr4:122672970	A/C	cg19671926	chr4:122722719	EXOSC9	-0.48	-7.39	-0.32	6.92e-13	Type 2 diabetes;
LGG	cis	rs2228479	0.557	rs34420680	chr16:89809171	C/T	cg00800038	chr16:89945340	TCF25	-0.7	-7.95	-0.35	1.48e-14	Skin colour saturation;
LGG	cis	rs2050392	0.858	rs2250569	chr10:30698914	G/C	cg25182066	chr10:30743637	MAP3K8	-0.51	-10.75	-0.45	3.24e-24	Inflammatory bowel disease;
LGG	trans	rs2243480	1.000	rs160644	chr7:65558186	C/T	cg10756647	chr7:56101905	PSPH	0.77	9.32	0.4	4.81e-19	Diabetic kidney disease;
LGG	cis	rs2916247	0.954	rs7461004	chr8:93088828	T/G	cg10183463	chr8:93005414	RUNX1T1	0.37	7.51	0.33	3.06e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6840360	0.550	rs7689266	chr4:152561048	T/C	cg22705602	chr4:152727874	NA	-0.31	-7.51	-0.33	2.99e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs2153535	0.580	rs4404802	chr6:8442052	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.47e-31	Motion sickness;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg02951883	chr7:2050386	MAD1L1	-0.78	-17.23	-0.63	8.89e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs6088580	0.524	rs7269596	chr20:33229063	T/C	cg08999081	chr20:33150536	PIGU	-0.3	-7.13	-0.31	3.8e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs7737355	0.773	rs4705895	chr5:131102194	T/C	cg06307176	chr5:131281290	NA	0.54	8.93	0.38	1.01e-17	Life satisfaction;
LGG	cis	rs7811142	0.775	rs1059129	chr7:99926522	A/G	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.01	14.73	0.56	1.56e-40	Platelet count;
LGG	cis	rs2011503	1.000	rs1557723	chr19:19443033	A/G	cg11584989	chr19:19387371	SF4	-0.74	-12.26	-0.5	3.95e-30	Bipolar disorder;
LGG	cis	rs796364	0.951	rs2881593	chr2:201000347	A/G	cg23649088	chr2:200775458	C2orf69	-0.67	-9.69	-0.41	2.4e-20	Schizophrenia;
LGG	cis	rs9910055	0.529	rs183462	chr17:42183376	G/C	cg19774624	chr17:42201019	HDAC5	0.65	11.59	0.47	1.92e-27	Total body bone mineral density;
LGG	cis	rs9325144	0.671	rs12818797	chr12:39019409	A/G	cg13010199	chr12:38710504	ALG10B	-0.55	-10.19	-0.43	3.96e-22	Morning vs. evening chronotype;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg13383153	chr19:36980459	ZNF566	0.41	6.81	0.3	3.05e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs16976116	0.901	rs8027098	chr15:55492269	C/T	cg11288833	chr15:55489084	RSL24D1	0.56	7.61	0.33	1.56e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7829975	0.560	rs6994131	chr8:8550958	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.01	-0.35	9.38e-15	Mood instability;
LGG	cis	rs7166081	0.672	rs12441715	chr15:67860587	G/A	cg18050959	chr15:68126178	NA	-0.38	-7.01	-0.31	8.22e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10504229	0.728	rs72650855	chr8:58152570	A/G	cg02725872	chr8:58115012	NA	-0.94	-13.13	-0.52	1.11e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs7129556	0.859	rs11237236	chr11:77312790	G/A	cg12586386	chr11:77299805	AQP11	0.52	8.05	0.35	7.22e-15	Weight loss (gastric bypass surgery);
LGG	cis	rs9322193	0.962	rs9688412	chr6:150124283	A/G	cg12070911	chr6:150209640	RAET1E	-0.3	-7.3	-0.32	1.28e-12	Lung cancer;
LGG	cis	rs9487094	0.670	rs2024853	chr6:109819954	T/A	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	7.15e-15	Height;
LGG	cis	rs17818399	0.815	rs17819022	chr2:46850571	G/A	cg02822958	chr2:46747628	ATP6V1E2	0.45	7.09	0.31	4.91e-12	Height;
LGG	cis	rs6956675	0.534	rs1879840	chr7:62653307	C/T	cg08930214	chr7:62859557	LOC100287834	-0.38	-7.13	-0.31	3.87e-12	Obesity-related traits;
LGG	cis	rs1218582	0.772	rs2102423	chr1:154916068	A/G	cg06221963	chr1:154839813	KCNN3	-0.49	-9.88	-0.42	5.09e-21	Prostate cancer;
LGG	cis	rs2236293	0.965	rs1885371	chr9:35837859	T/C	cg12876594	chr9:35791798	NPR2	0.38	7.12	0.31	4.27e-12	Blood protein levels;
LGG	cis	rs2075466	0.514	rs3747614	chr16:4908667	C/T	cg04440724	chr16:4920505	UBN1	0.6	8.7	0.37	6.03e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13217239	0.574	rs9366680	chr6:27006123	A/T	cg12292205	chr6:26970375	C6orf41	0.53	10.2	0.43	3.45e-22	Schizophrenia;
LGG	cis	rs1862618	0.671	rs2591961	chr5:56238597	A/G	cg12654349	chr5:56205094	C5orf35	0.58	10.01	0.42	1.72e-21	Initial pursuit acceleration;
LGG	cis	rs7618915	0.547	rs34173654	chr3:52634605	T/C	cg14092988	chr3:52407081	DNAH1	0.32	8.43	0.36	4.42e-16	Bipolar disorder;
LGG	cis	rs6121246	0.908	rs6089094	chr20:30431771	C/T	cg04935436	chr20:30431758	NA	0.4	7.05	0.31	6.52e-12	Mean corpuscular hemoglobin;
LGG	cis	rs7512552	0.809	rs698923	chr1:150379159	G/A	cg15654264	chr1:150340011	RPRD2	0.46	9.43	0.4	1.95e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17321999	0.516	rs10495774	chr2:30506676	C/T	cg05247661	chr2:30472410	LBH	-0.64	-7.99	-0.35	1.07e-14	Systemic lupus erythematosus;
LGG	cis	rs79057730	0.599	rs4720893	chr7:804434	G/A	cg11064039	chr7:766100	PRKAR1B;HEATR2	0.69	7.58	0.33	1.94e-13	Initial pursuit acceleration;
LGG	cis	rs1023500	0.573	rs133382	chr22:42471774	C/T	cg15557168	chr22:42548783	NA	-0.4	-8.61	-0.37	1.12e-16	Schizophrenia;
LGG	cis	rs7208859	0.725	rs9891656	chr17:29243355	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.71	-9.2	-0.39	1.26e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg23131131	chr22:24373011	LOC391322	-0.48	-7.96	-0.35	1.35e-14	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs561341	1.000	rs510264	chr17:30323414	A/G	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.03e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9325144	0.647	rs12229104	chr12:39110811	T/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.52	-0.33	2.95e-13	Morning vs. evening chronotype;
LGG	cis	rs2594989	0.943	rs2252601	chr3:11481234	A/G	cg01796438	chr3:11312864	ATG7	-0.55	-7.56	-0.33	2.14e-13	Circulating chemerin levels;
LGG	cis	rs7618915	1.000	rs3852063	chr3:52349204	A/G	cg14092988	chr3:52407081	DNAH1	0.42	11.25	0.46	4.06e-26	Bipolar disorder;
LGG	cis	rs6952808	1.000	rs6977733	chr7:1886725	A/T	cg05863683	chr7:1912471	MAD1L1	-0.41	-7.72	-0.34	7.27e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs4481887	0.800	rs4514268	chr1:248444600	T/G	cg13385794	chr1:248469461	NA	0.48	8.19	0.36	2.55e-15	Common traits (Other);
LGG	cis	rs7918232	0.941	rs1755399	chr10:27394958	A/G	cg14442939	chr10:27389572	ANKRD26	0.75	11.11	0.46	1.35e-25	Breast cancer;
LGG	cis	rs6121246	0.567	rs6060262	chr20:30193071	A/C	cg13852791	chr20:30311386	BCL2L1	0.66	8.67	0.37	7.61e-17	Mean corpuscular hemoglobin;
LGG	cis	rs11764590	0.694	rs55860148	chr7:2105594	G/A	cg07027305	chr7:2059796	MAD1L1	-0.35	-8.46	-0.37	3.49e-16	Neuroticism;
LGG	cis	rs10479542	0.702	rs13183521	chr5:178975606	A/G	cg00080972	chr5:178986291	RUFY1	-0.41	-6.92	-0.31	1.49e-11	Lung cancer;
LGG	cis	rs9291683	0.551	rs62295971	chr4:9978142	G/A	cg25986240	chr4:9926439	SLC2A9	-0.48	-10.48	-0.44	3.36e-23	Bone mineral density;
LGG	cis	rs4665809	0.590	rs10179959	chr2:26426403	G/A	cg22920501	chr2:26401640	FAM59B	-0.44	-9.07	-0.39	3.46e-18	Gut microbiome composition (summer);
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	0.48	8.53	0.37	2.14e-16	Obesity-related traits;
LGG	cis	rs9894429	0.646	rs9905639	chr17:79614154	A/G	cg10661904	chr17:79619235	PDE6G	-0.5	-10.31	-0.43	1.37e-22	Eye color traits;
LGG	cis	rs3812831	0.643	rs7322339	chr13:114929726	C/A	cg08824895	chr13:115047677	UPF3A	0.4	6.91	0.31	1.62e-11	Schizophrenia;
LGG	cis	rs12699477	0.545	rs117125814	chr7:1910681	T/G	cg21782813	chr7:2030301	MAD1L1	0.46	11.13	0.46	1.19e-25	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs17226498	chr16:89840631	T/C	cg19635926	chr16:89946313	TCF25	0.73	7.37	0.32	8.16e-13	Skin colour saturation;
LGG	cis	rs2075371	0.829	rs35897242	chr7:134004041	G/A	cg11752832	chr7:134001865	SLC35B4	0.65	11.88	0.48	1.34e-28	Mean platelet volume;
LGG	cis	rs992157	0.687	rs10206984	chr2:219066980	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.28	0.43	1.88e-22	Colorectal cancer;
LGG	cis	rs13118159	0.550	rs4974614	chr4:1373489	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.51	8.23	0.36	1.97e-15	Longevity;
LGG	trans	rs4295623	0.559	rs2409836	chr8:11689228	T/G	cg15556689	chr8:8085844	FLJ10661	0.42	7.26	0.32	1.65e-12	Morning vs. evening chronotype;
LGG	cis	rs1348850	0.632	rs4470372	chr2:178505857	G/A	cg05169160	chr2:178484487	TTC30A	0.34	6.65	0.3	8.2e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9849248	0.627	rs6551276	chr3:88192484	T/C	cg14530983	chr3:88190749	ZNF654	-0.58	-7.91	-0.35	1.85e-14	Menarche (age at onset);
LGG	cis	rs72634258	0.945	rs12736494	chr1:8136016	G/A	cg00042356	chr1:8021962	PARK7	0.83	10.25	0.43	2.25e-22	Inflammatory bowel disease;
LGG	trans	rs208515	0.525	rs12204452	chr6:66680325	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.95	17.12	0.62	3.03e-51	Exhaled nitric oxide levels;
LGG	cis	rs5769765	0.955	rs5770750	chr22:50276828	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.54	-0.33	2.51e-13	Schizophrenia;
LGG	cis	rs796364	0.760	rs74993507	chr2:201068684	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.51	-0.37	2.47e-16	Schizophrenia;
LGG	cis	rs752010	0.806	rs10890148	chr1:42091517	T/C	cg06885757	chr1:42089581	HIVEP3	0.54	12.09	0.49	2.04e-29	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs950169	0.919	rs12915589	chr15:84734464	T/C	cg03959625	chr15:84868606	LOC388152	0.56	8.72	0.38	5.07e-17	Schizophrenia;
LGG	cis	rs3784262	0.692	rs3784256	chr15:58263046	T/A	cg12031962	chr15:58353849	ALDH1A2	-0.33	-7.16	-0.32	3.12e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	trans	rs7829975	0.711	rs12682352	chr8:8646246	A/G	cg02002194	chr4:3960332	NA	-0.46	-8.77	-0.38	3.31e-17	Mood instability;
LGG	cis	rs16854884	0.770	rs1530477	chr3:143819506	A/G	cg06585982	chr3:143692056	C3orf58	-0.53	-8.76	-0.38	3.74e-17	Economic and political preferences (feminism/equality);
LGG	cis	rs300703	0.515	rs440617	chr2:189818	A/G	cg21211680	chr2:198530	NA	-1.17	-20.34	-0.69	3.51e-66	Blood protein levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01785339	chr1:224544456	CNIH4	0.42	6.78	0.3	3.7e-11	Cognitive performance;
LGG	cis	rs3008870	0.651	rs2815376	chr1:67508531	G/A	cg02640540	chr1:67518911	SLC35D1	0.49	9.85	0.42	6.8e-21	Lymphocyte percentage of white cells;
LGG	cis	rs12135191	0.544	rs10802528	chr1:236506815	T/G	cg21399712	chr1:236511386	NA	-0.39	-7.92	-0.35	1.83e-14	Urate levels (BMI interaction);
LGG	cis	rs7618915	0.547	rs4130905	chr3:52709831	A/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.35	-0.43	9.76e-23	Bipolar disorder;
LGG	cis	rs892085	0.559	rs4804526	chr19:10871470	G/C	cg17710535	chr19:10819994	QTRT1	-0.48	-8.47	-0.37	3.32e-16	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs7927771	0.864	rs2293577	chr11:47437202	C/T	cg20307385	chr11:47447363	PSMC3	0.58	10.7	0.45	5e-24	Subjective well-being;
LGG	cis	rs2361710	0.704	rs4889979	chr17:78121707	T/A	cg09238746	chr17:78121135	EIF4A3	-0.6	-10.28	-0.43	1.75e-22	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs273218	0.573	rs10513033	chr5:53333477	T/C	ch.5.1024479R	chr5:53302184	ARL15	-0.93	-14.04	-0.55	1.43e-37	Migraine;
LGG	cis	rs7666738	0.830	rs28417716	chr4:98864859	C/T	cg05340658	chr4:99064831	C4orf37	0.47	7.84	0.34	3.21e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1318772	0.867	rs4705554	chr5:112886896	G/A	cg12552261	chr5:112820674	MCC	-0.69	-7.45	-0.33	4.47e-13	F-cell distribution;
LGG	cis	rs1144	0.537	rs916705	chr7:104589690	C/A	cg03782966	chr7:104585482	NA	0.34	7.82	0.34	3.69e-14	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for body mass index;
LGG	cis	rs11098499	0.954	rs13113483	chr4:120309039	C/T	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	cis	rs17270561	0.609	rs7769908	chr6:25760539	G/A	cg17691542	chr6:26056736	HIST1H1C	0.65	10.9	0.45	8.45e-25	Iron status biomarkers;
LGG	trans	rs7395662	0.500	rs7947055	chr11:48977086	C/T	cg00717180	chr2:96193071	NA	0.43	7.56	0.33	2.26e-13	HDL cholesterol;
LGG	cis	rs11098499	0.954	rs6838814	chr4:120392443	G/A	cg24375607	chr4:120327624	NA	0.67	11.09	0.46	1.63e-25	Corneal astigmatism;
LGG	cis	rs4689592	0.523	rs3857179	chr4:7070496	T/A	cg19539972	chr4:7069911	GRPEL1	0.67	9.91	0.42	4.12e-21	Monocyte percentage of white cells;
LGG	cis	rs12999616	0.696	rs56035334	chr2:98329047	T/G	cg26665480	chr2:98280029	ACTR1B	0.56	8.15	0.35	3.42e-15	Colorectal cancer;
LGG	cis	rs2242194	0.515	rs10908453	chr1:155006091	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.89	21.65	0.71	2.71e-72	Schizophrenia;
LGG	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg20913747	chr6:44695427	NA	-0.61	-10.25	-0.43	2.35e-22	Total body bone mineral density;
LGG	cis	rs62025270	0.631	rs55968154	chr15:86268630	G/A	cg25843651	chr15:86329602	KLHL25	0.58	8.9	0.38	1.25e-17	Idiopathic pulmonary fibrosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07318050	chr1:233086124	C1orf57	0.44	6.81	0.3	3.13e-11	Gut microbiome composition (summer);
LGG	cis	rs11096990	0.656	rs2066786	chr4:39302029	T/C	cg24403649	chr4:39172243	NA	0.38	6.66	0.3	7.85e-11	Cognitive function;
LGG	cis	rs9581857	0.547	rs75800999	chr13:28055293	A/G	cg01674679	chr13:27998804	GTF3A	-0.63	-7.4	-0.33	6.2800000000000005e-13	Psychosis proneness (hypomanic personality scale and perceptual aberration scale);
LGG	cis	rs2153535	0.580	rs9406165	chr6:8488837	C/T	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	cis	rs11622475	0.953	rs6576012	chr14:104400159	T/C	cg12183467	chr14:104352244	NA	0.45	7.55	0.33	2.33e-13	Bipolar disorder;
LGG	cis	rs763121	0.925	rs9611008	chr22:39098787	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	17.74	0.64	4.22e-54	Menopause (age at onset);
LGG	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg13010199	chr12:38710504	ALG10B	0.55	10.81	0.45	2e-24	Heart rate;
LGG	trans	rs9354308	0.901	rs2814096	chr6:66566131	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.59	9.98	0.42	2.19e-21	Metabolite levels;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg22662362	chr6:99873484	SFRS18	-0.47	-6.84	-0.3	2.48e-11	Systemic lupus erythematosus;
LGG	trans	rs1941687	0.505	rs8091920	chr18:31303557	C/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.22	-0.46	5.13e-26	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs35146811	0.586	rs34213597	chr7:99591021	C/T	cg22906224	chr7:99728672	NA	0.55	8.42	0.36	4.86e-16	Coronary artery disease;
LGG	cis	rs7945718	0.621	rs11022464	chr11:12685477	T/C	cg25843174	chr11:12811716	TEAD1	0.34	7.19	0.32	2.55e-12	Educational attainment (years of education);
LGG	cis	rs2050392	0.687	rs608693	chr10:30734971	G/A	cg25182066	chr10:30743637	MAP3K8	-0.56	-11.46	-0.47	5.89e-27	Inflammatory bowel disease;
LGG	cis	rs8072100	0.738	rs9915222	chr17:45448615	G/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.08	-0.39	3.07e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17376456	0.877	rs10057605	chr5:93443950	T/G	cg19507638	chr5:93509721	C5orf36	-0.72	-9.94	-0.42	3.13e-21	Diabetic retinopathy;
LGG	cis	rs537930	0.734	rs479632	chr5:134364518	C/G	cg24576358	chr5:134350122	NA	0.36	6.83	0.3	2.63e-11	Height;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13276752	chr17:57970287	TUBD1;RPS6KB1	0.41	6.76	0.3	4.24e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs35110281	0.714	rs7277539	chr21:45053011	A/G	cg01579765	chr21:45077557	HSF2BP	-0.39	-8.89	-0.38	1.39e-17	Mean corpuscular volume;
LGG	cis	rs2456568	0.835	rs8181533	chr11:93638614	C/T	cg26875233	chr11:93583750	C11orf90	-0.34	-6.69	-0.3	6.51e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs6032067	1.000	rs6032069	chr20:43867388	C/T	cg10761708	chr20:43804764	PI3	-0.76	-11.8	-0.48	2.72e-28	Blood protein levels;
LGG	cis	rs6882046	0.513	rs42850	chr5:88019474	G/A	cg22951263	chr5:87985283	NA	-0.57	-10.5	-0.44	2.83e-23	Intelligence (multi-trait analysis);Educational attainment (years of education);Neuroticism;Educational attainment (college completion);Educational attainment;
LGG	cis	rs317689	0.684	rs315125	chr12:69758884	C/T	cg11871910	chr12:69753446	YEATS4	0.8	13.73	0.54	3.27e-36	Response to diuretic therapy;
LGG	cis	rs4948102	0.731	rs4535700	chr7:56045448	T/C	cg17215666	chr7:56131930	SUMF2	0.43	6.68	0.3	7.05e-11	Plasma homocysteine levels (post-methionine load test);
LGG	cis	rs2180341	0.597	rs11154397	chr6:127646649	G/C	cg27446573	chr6:127587934	RNF146	0.73	13.28	0.53	2.62e-34	Breast cancer;
LGG	cis	rs977987	0.778	rs4243112	chr16:75321031	T/C	cg07303275	chr16:75499416	TMEM170A	0.36	6.74	0.3	4.79e-11	Dupuytren's disease;
LGG	cis	rs4975709	0.610	rs4975706	chr5:1860365	G/T	cg01114163	chr5:1856713	NA	-0.41	-7.19	-0.32	2.58e-12	Cardiovascular disease risk factors;
LGG	cis	rs67133203	0.606	rs11169727	chr12:51557964	G/A	cg14688905	chr12:51403056	SLC11A2	0.64	9.66	0.41	3.01e-20	Urinary tract infection frequency;
LGG	cis	rs9487094	0.922	rs2275650	chr6:109668288	C/T	cg01125227	chr6:109776195	MICAL1	0.54	9.39	0.4	2.72e-19	Height;
LGG	cis	rs2303745	0.544	rs6512180	chr19:17399153	C/T	cg04248312	chr19:17393744	ANKLE1	-0.64	-10.55	-0.44	1.89e-23	Systemic lupus erythematosus;
LGG	cis	rs6951245	1.000	rs77760339	chr7:1083927	G/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.34	-0.69	3.5e-66	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7166081	1.000	rs9806377	chr15:67612062	A/G	cg24231037	chr15:68117551	LBXCOR1	-0.32	-7.23	-0.32	2.05e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4650994	0.524	rs2476558	chr1:178580953	C/T	cg12486710	chr1:178512616	C1orf220	-0.51	-10.56	-0.44	1.73e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs727563	0.636	rs2187795	chr22:42092225	C/A	cg06634786	chr22:41940651	POLR3H	0.77	12.18	0.49	8.39e-30	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs7044106	0.708	rs959558	chr9:123368911	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.08	0.6	1.57e-46	Hip circumference adjusted for BMI;
LGG	trans	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg06437703	chr8:37914619	EIF4EBP1	-0.63	-11.14	-0.46	1.06e-25	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs875971	0.862	rs6460279	chr7:65662761	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-6.79	-0.3	3.37e-11	Aortic root size;
LGG	cis	rs1862618	0.853	rs190414	chr5:56116772	C/A	cg03609598	chr5:56110824	MAP3K1	-0.54	-8.05	-0.35	7.02e-15	Initial pursuit acceleration;
LGG	cis	rs10256972	0.967	rs7799110	chr7:1039065	A/G	cg04025307	chr7:1156635	C7orf50	0.44	7.77	0.34	5.17e-14	Longevity;Endometriosis;
LGG	cis	rs28386778	0.897	rs894407	chr17:61901641	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs12362504	0.504	rs7929338	chr11:9895885	T/C	cg07197493	chr11:9884649	SBF2	-0.36	-6.82	-0.3	2.78e-11	Survival in pancreatic cancer;
LGG	cis	rs11885103	0.692	rs2683974	chr2:570110	G/A	cg21195176	chr2:593345	NA	0.41	7.64	0.33	1.26e-13	Heschl's gyrus morphology;
LGG	cis	rs308971	0.656	rs307582	chr3:12085149	T/C	cg02700894	chr3:12045449	SYN2	0.48	6.93	0.31	1.38e-11	Fasting blood insulin (BMI interaction);
LGG	cis	rs7937682	0.961	rs7119563	chr11:111543916	T/A	cg09085632	chr11:111637200	PPP2R1B	1.17	25.28	0.76	2.99e-89	Primary sclerosing cholangitis;
LGG	cis	rs1799949	0.965	rs799910	chr17:41279561	G/C	cg01879757	chr17:41196368	BRCA1	-0.41	-8.34	-0.36	8.75e-16	Menopause (age at onset);
LGG	cis	rs2247341	0.965	rs2854917	chr4:1720550	T/C	cg08446824	chr4:1720184	TMEM129	-0.68	-13.11	-0.52	1.3e-33	Hip circumference adjusted for BMI;Height;
LGG	cis	rs11146838	1	rs11146838	chr10:39149977	A/T	cg14646974	chr10:38645378	HSD17B7P2	-0.42	-6.93	-0.31	1.44e-11	Breast cancer;
LGG	cis	rs6723226	0.593	rs176401	chr2:32636511	A/T	cg02381751	chr2:32503542	YIPF4	-0.7	-11.89	-0.48	1.29e-28	Intelligence (multi-trait analysis);
LGG	cis	rs7493	1.000	rs2158806	chr7:95051998	A/C	cg08461772	chr7:95026248	PON3	0.37	8.08	0.35	5.87e-15	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs523522	0.962	rs4767904	chr12:120930798	T/G	cg12219531	chr12:120966889	COQ5	0.63	10.36	0.43	9.27e-23	High light scatter reticulocyte count;
LGG	cis	rs6088580	0.634	rs4258875	chr20:32924895	C/A	cg06115741	chr20:33292138	TP53INP2	-0.51	-8.42	-0.36	4.73e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs1005277	0.602	rs2504142	chr10:38383793	C/T	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.51	-0.33	3.02e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1790761	0.505	rs6591256	chr11:67349899	A/G	cg09038676	chr11:67351608	GSTP1	0.36	7.1	0.31	4.72e-12	Mean corpuscular volume;
LGG	cis	rs11229555	0.874	rs11229505	chr11:58274155	T/C	cg15696309	chr11:58395628	NA	-0.99	-17.37	-0.63	2.12e-52	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2075671	0.903	rs62482252	chr7:100274063	C/A	cg20848291	chr7:100343083	ZAN	-0.69	-10.09	-0.42	9.19e-22	Other erythrocyte phenotypes;
LGG	cis	rs2479106	0.892	rs2479102	chr9:126683955	T/C	cg16191174	chr9:126692580	DENND1A	0.45	6.77	0.3	4e-11	Polycystic ovary syndrome;
LGG	cis	rs11758351	0.660	rs16891443	chr6:26221937	A/C	cg01420254	chr6:26195488	NA	0.85	10.96	0.45	5.09e-25	Gout;Renal underexcretion gout;
LGG	trans	rs7819412	0.806	rs17723229	chr8:10930069	A/C	cg08975724	chr8:8085496	FLJ10661	-0.5	-9.49	-0.4	1.18e-19	Triglycerides;
LGG	cis	rs10256972	0.577	rs6962809	chr7:1208889	A/G	cg11360546	chr7:1094263	C7orf50	-0.37	-6.77	-0.3	3.88e-11	Longevity;Endometriosis;
LGG	cis	rs7226408	0.600	rs8093040	chr18:34553284	C/T	cg15022739	chr18:34823045	BRUNOL4	0.42	9.1	0.39	2.67e-18	Obesity-related traits;
LGG	cis	rs765787	0.530	rs4544188	chr15:45535393	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.44	-7.4	-0.33	6.55e-13	Uric acid levels;
LGG	cis	rs6963495	0.818	rs73192126	chr7:105175415	T/C	cg21420622	chr7:105162941	PUS7	-0.44	-6.65	-0.3	8.12e-11	Bipolar disorder (body mass index interaction);
LGG	cis	rs5750830	0.546	rs4821891	chr22:39785381	C/T	cg04986931	chr22:39850128	NA	0.33	7.64	0.33	1.25e-13	Intelligence (multi-trait analysis);
LGG	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg16141378	chr3:129829833	LOC729375	-0.33	-7.37	-0.32	7.98e-13	Monocyte count;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg02462569	chr6:150064036	NUP43	-0.41	-8.83	-0.38	2.17e-17	Lung cancer;
LGG	trans	rs9467711	0.606	rs9348709	chr6:26360311	G/A	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	trans	rs11098499	0.779	rs80242894	chr4:120375752	G/A	cg25214090	chr10:38739885	LOC399744	0.69	12.1	0.49	1.72e-29	Corneal astigmatism;
LGG	cis	rs796364	1.000	rs281771	chr2:200812202	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-9.56	-0.41	7.19e-20	Schizophrenia;
LGG	cis	rs4650994	0.544	rs2761469	chr1:178590638	A/C	cg12486710	chr1:178512616	C1orf220	-0.51	-10.53	-0.44	2.15e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2762353	0.603	rs12201071	chr6:25778055	C/T	cg03264133	chr6:25882463	NA	0.48	8.63	0.37	9.67e-17	Blood metabolite levels;
LGG	cis	rs12410462	0.581	rs113827839	chr1:227547180	C/T	cg04117972	chr1:227635322	NA	0.57	9.37	0.4	3.12e-19	Major depressive disorder;
LGG	cis	rs9357271	0.956	rs7759629	chr6:38351500	G/A	cg07362130	chr6:38359646	BTBD9	-0.45	-10.25	-0.43	2.26e-22	Restless legs syndrome;
LGG	cis	rs6838801	0.892	rs13108785	chr4:77576070	A/C	cg17476223	chr4:77663285	SHROOM3	0.37	6.77	0.3	3.82e-11	Cleft lip with or without cleft palate;
LGG	cis	rs868036	1.000	rs4325504	chr15:68055570	A/G	cg24231037	chr15:68117551	LBXCOR1	0.32	7.8	0.34	4.08e-14	Restless legs syndrome;
LGG	trans	rs1814175	0.511	rs61905634	chr11:49819736	G/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.32	-0.5	2.3e-30	Height;
LGG	cis	rs7580658	0.963	rs2090574	chr2:128131391	C/A	cg10021288	chr2:128175891	PROC	-0.65	-13.43	-0.53	5.94e-35	Protein C levels;
LGG	cis	rs11792861	0.926	rs11788825	chr9:111829757	T/G	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.68	0.41	2.55e-20	Menarche (age at onset);
LGG	cis	rs657075	0.697	rs4646200	chr5:131671136	T/C	cg06968155	chr5:131705112	SLC22A5	0.77	8.91	0.38	1.17e-17	Rheumatoid arthritis;
LGG	cis	rs736408	0.522	rs11716747	chr3:52748857	C/T	cg15147215	chr3:52552868	STAB1	-0.36	-6.94	-0.31	1.31e-11	Bipolar disorder;
LGG	cis	rs4727027	0.866	rs1405124	chr7:148779618	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.44	6.68	0.3	7.02e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2204008	0.606	rs6582502	chr12:38543352	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.88	-0.45	1.02e-24	Bladder cancer;
LGG	cis	rs4319547	0.695	rs1803290	chr12:122865029	T/C	cg23029597	chr12:123009494	RSRC2	0.93	17.24	0.63	8.17e-52	Body mass index;
LGG	cis	rs6500602	0.929	rs6500603	chr16:4497537	G/C	cg08645402	chr16:4508243	NA	0.48	8.74	0.38	4.32e-17	Schizophrenia;
LGG	cis	rs11792861	0.555	rs4978767	chr9:111762925	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.65	11.19	0.46	7e-26	Menarche (age at onset);
LGG	cis	rs10875746	0.669	rs61940962	chr12:48595477	A/C	cg24011408	chr12:48396354	COL2A1	-0.58	-7.63	-0.33	1.32e-13	Longevity (90 years and older);
LGG	cis	rs2070488	0.804	rs13063978	chr3:38476538	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	14.93	0.57	1.97e-41	Electrocardiographic conduction measures;
LGG	cis	rs10752881	1.000	rs10737237	chr1:182989269	A/G	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	trans	rs7824557	0.547	rs2409745	chr8:11076635	G/T	cg08975724	chr8:8085496	FLJ10661	0.5	9.67	0.41	2.76e-20	Retinal vascular caliber;
LGG	cis	rs4474465	1.000	rs7943815	chr11:78173160	A/G	cg27205649	chr11:78285834	NARS2	-0.49	-8.46	-0.37	3.62e-16	Alzheimer's disease (survival time);
LGG	cis	rs876084	0.505	rs7459865	chr8:121115611	A/T	cg06265175	chr8:121136014	COL14A1	0.46	9.3	0.4	5.77e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs477895	0.653	rs3824854	chr11:63885305	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.13	0.46	1.19e-25	Mean platelet volume;
LGG	cis	rs2594989	0.708	rs2594997	chr3:11365739	A/T	cg01796438	chr3:11312864	ATG7	-0.57	-7.95	-0.35	1.48e-14	Circulating chemerin levels;
LGG	cis	rs875971	0.830	rs6967708	chr7:65657313	A/T	cg23594656	chr7:65796392	TPST1	0.4	8.81	0.38	2.6e-17	Aortic root size;
LGG	cis	rs3816183	0.530	rs6758688	chr2:42856780	A/G	cg14631114	chr2:43023945	NA	0.36	7.01	0.31	8.26e-12	Hypospadias;
LGG	cis	rs9393692	0.905	rs6916289	chr6:26289122	A/T	cg00631329	chr6:26305371	NA	-0.56	-10.37	-0.43	8.5e-23	Educational attainment;
LGG	cis	rs947211	0.750	rs5014255	chr1:205753870	C/A	cg24503407	chr1:205819492	PM20D1	0.46	7.91	0.34	1.97e-14	Parkinson's disease;
LGG	cis	rs11229555	0.874	rs11229519	chr11:58310587	C/T	cg15696309	chr11:58395628	NA	-0.99	-17.58	-0.63	2.27e-53	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs453301	0.597	rs7001187	chr8:8792782	G/A	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.88	-0.3	2.01e-11	Joint mobility (Beighton score);
LGG	cis	rs796364	0.806	rs112486506	chr2:201073947	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg09285095	chr22:46440394	LOC100271722	0.42	7.41	0.33	6.09e-13	Dupuytren's disease;
LGG	cis	rs9359856	0.636	rs4706345	chr6:90301565	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.63	-8.53	-0.37	2.14e-16	Bipolar disorder;
LGG	cis	rs9790314	0.967	rs336541	chr3:161056698	A/C	cg03342759	chr3:160939853	NMD3	-0.63	-11.12	-0.46	1.25e-25	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs12478296	1.000	rs56136197	chr2:243043877	T/C	cg06360820	chr2:242988706	NA	-0.9	-11.52	-0.47	3.6e-27	Obesity-related traits;
LGG	cis	rs988958	0.565	rs34818443	chr2:42233809	C/T	cg27428208	chr2:42229179	NA	0.48	7.51	0.33	2.98e-13	Hypospadias;
LGG	cis	rs365132	0.875	rs353495	chr5:176430723	T/C	cg16309518	chr5:176445507	NA	-0.51	-11.19	-0.46	6.76e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg25801113	chr15:45476975	SHF	0.91	21.26	0.7	1.69e-70	Uric acid levels;
LGG	cis	rs10214930	0.697	rs6462029	chr7:27581495	T/C	cg22168087	chr7:27702803	HIBADH	0.47	7.04	0.31	6.79e-12	Hypospadias;
LGG	cis	rs6952808	0.723	rs4721287	chr7:2028663	A/C	cg04267008	chr7:1944627	MAD1L1	-0.66	-11.66	-0.48	9.76e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs4959677	0.935	rs3966800	chr6:2493113	A/T	cg20147862	chr6:2634573	C6orf195	-0.41	-8.88	-0.38	1.45e-17	Orthostatic hypotension;
LGG	cis	rs6032067	1.000	rs6032066	chr20:43857700	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.72e-28	Blood protein levels;
LGG	cis	rs6540556	0.723	rs12116437	chr1:209897027	G/A	cg23920097	chr1:209922102	NA	-0.43	-7.28	-0.32	1.49e-12	Red blood cell count;
LGG	cis	rs2153535	0.580	rs5001322	chr6:8451608	A/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.98	0.39	7.02e-18	Motion sickness;
LGG	cis	rs6502050	0.723	rs11657069	chr17:80083809	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs9309473	1.000	rs13421462	chr2:73719875	A/C	cg20560298	chr2:73613845	ALMS1	-0.47	-7.75	-0.34	5.73e-14	Metabolite levels;
LGG	cis	rs8067545	0.578	rs4925087	chr17:20024582	A/C	cg13482628	chr17:19912719	NA	0.55	10.34	0.43	1.09e-22	Schizophrenia;
LGG	cis	rs1552244	1.000	rs35993975	chr3:10067794	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.46	-0.5	6.25e-31	Alzheimer's disease;
LGG	cis	rs6088590	1.000	rs6087625	chr20:33342477	A/G	cg08999081	chr20:33150536	PIGU	-0.31	-7.39	-0.32	6.76e-13	Coronary artery disease;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg17470184	chr11:118478236	PHLDB1	0.42	7.34	0.32	9.87e-13	Cholesterol, total;
LGG	cis	rs9534288	0.797	rs7996875	chr13:46612836	C/T	cg15192986	chr13:46630673	CPB2	0.59	13.09	0.52	1.56e-33	Blood protein levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg14665389	chr10:114710815	TCF7L2	0.46	6.8	0.3	3.21e-11	Gut microbiome composition (summer);
LGG	cis	rs7103648	0.864	rs10742802	chr11:47432725	T/G	cg20307385	chr11:47447363	PSMC3	0.97	23.89	0.74	8.62e-83	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs6500395	1.000	rs7188741	chr16:48607966	T/C	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.46e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6840360	0.642	rs4235219	chr4:152346103	T/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.06	0.31	6.18e-12	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	0.507	rs4719580	chr7:19784847	G/T	cg05791153	chr7:19748676	TWISTNB	0.64	9.26	0.4	7.45e-19	Thyroid stimulating hormone;
LGG	cis	rs61931739	0.555	rs1482982	chr12:33691601	C/T	cg06521331	chr12:34319734	NA	0.4	6.87	0.3	2.1e-11	Morning vs. evening chronotype;
LGG	cis	rs875971	0.660	rs1860468	chr7:66107252	T/C	cg11764359	chr7:65958608	NA	-0.58	-9.66	-0.41	3.15e-20	Aortic root size;
LGG	cis	rs7208859	0.623	rs1061346	chr17:29114229	G/A	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9644630	0.813	rs4922036	chr8:19328219	G/A	cg06562184	chr8:19319451	CSGALNACT1	0.34	6.66	0.3	7.55e-11	Oropharynx cancer;
LGG	cis	rs61931739	0.500	rs11053290	chr12:34582392	C/T	cg06521331	chr12:34319734	NA	0.55	9.79	0.41	1.08e-20	Morning vs. evening chronotype;
LGG	cis	rs977987	0.843	rs11149820	chr16:75422760	G/A	cg03315344	chr16:75512273	CHST6	0.51	10.35	0.43	9.81e-23	Dupuytren's disease;
LGG	trans	rs7939886	0.920	rs12223067	chr11:55915420	C/A	cg02254774	chr11:50257496	LOC441601	0.57	6.74	0.3	4.66e-11	Myopia (pathological);
LGG	trans	rs9914544	1.000	rs1634411	chr17:18833810	C/T	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.15	-0.32	3.38e-12	Educational attainment (years of education);
LGG	trans	rs916888	0.821	rs70602	chr17:44859715	T/C	cg06925179	chr17:43578568	NA	-0.41	-9.65	-0.41	3.28e-20	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2841277	0.770	rs10149193	chr14:105403474	C/T	cg15352829	chr14:105391018	PLD4	-0.48	-11.62	-0.48	1.42e-27	Rheumatoid arthritis;
LGG	cis	rs36051895	0.623	rs17426903	chr9:5203292	A/C	cg02405213	chr9:5042618	JAK2	-0.71	-12.04	-0.49	3.21e-29	Pediatric autoimmune diseases;
LGG	cis	rs2075371	1.000	rs2241335	chr7:133979368	C/T	cg20476274	chr7:133979776	SLC35B4	0.77	15.45	0.58	1.02e-43	Mean platelet volume;
LGG	cis	rs2905347	0.696	rs2905319	chr7:22697141	G/C	cg23521230	chr7:22704884	NA	0.4	7.17	0.32	3.06e-12	Major depression and alcohol dependence;
LGG	trans	rs7824557	0.564	rs6601584	chr8:11232343	C/G	cg16141378	chr3:129829833	LOC729375	0.39	8.69	0.37	6.26e-17	Retinal vascular caliber;
LGG	cis	rs10256972	0.552	rs2960831	chr7:1201192	A/T	cg03188948	chr7:1209495	NA	0.46	8.4	0.36	5.7e-16	Longevity;Endometriosis;
LGG	cis	rs9815354	0.812	rs73081370	chr3:41916258	G/C	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6500395	0.962	rs17826468	chr16:48568271	A/G	cg04672837	chr16:48644449	N4BP1	0.52	8.49	0.37	2.88e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6504108	0.624	rs17620033	chr17:46291414	G/A	cg02219949	chr17:45927392	SP6	0.43	8.11	0.35	4.62e-15	Body mass index;
LGG	cis	rs12950390	0.893	rs72831644	chr17:45824391	T/C	cg06532163	chr17:45867833	NA	0.54	8.95	0.38	8.39e-18	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg07659893	chr17:61819838	STRADA	0.48	8.09	0.35	5.4e-15	Prudent dietary pattern;
LGG	cis	rs12200782	0.932	rs12189841	chr6:26544798	A/T	cg11502198	chr6:26597334	ABT1	-0.86	-7.4	-0.33	6.52e-13	Small cell lung carcinoma;
LGG	cis	rs2415984	0.579	rs61993337	chr14:46965297	C/T	cg14871534	chr14:47121158	RPL10L	-0.59	-10.33	-0.43	1.24e-22	Number of children ever born;
LGG	cis	rs9311474	0.629	rs7639267	chr3:52568805	G/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.43	7.36	0.32	8.27e-13	Electroencephalogram traits;
LGG	cis	rs4664304	0.802	rs17830307	chr2:160871799	T/C	cg03641300	chr2:160917029	PLA2R1	-0.48	-8.57	-0.37	1.59e-16	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs12549902	0.800	rs4736999	chr8:41506152	C/G	cg21772509	chr8:41503840	NKX6-3	0.79	16.85	0.62	4.95e-50	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs6952808	0.792	rs35582663	chr7:1948756	G/A	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.82	-0.54	1.35e-36	Bipolar disorder and schizophrenia;
LGG	cis	rs7607369	0.637	rs17462630	chr2:219286541	C/G	cg01130898	chr2:219473002	PLCD4	0.42	6.79	0.3	3.48e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs4302748	0.862	rs35940984	chr7:36187333	C/G	cg24442661	chr7:36192818	EEPD1	0.56	7.34	0.32	9.65e-13	Platelet count;
LGG	cis	rs62238980	0.614	rs117369974	chr22:32537177	C/T	cg00543991	chr22:32367038	NA	0.79	8.53	0.37	2.06e-16	Childhood ear infection;
LGG	cis	rs981844	0.961	rs62325108	chr4:154679767	G/A	cg14289246	chr4:154710475	SFRP2	0.71	11.72	0.48	5.74e-28	Response to statins (LDL cholesterol change);
LGG	cis	rs1881797	0.872	rs12404733	chr1:247690417	A/C	cg21399703	chr1:247681439	NA	0.63	11.49	0.47	4.85e-27	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs17401966	0.838	rs2182326	chr1:10385664	G/A	cg19773385	chr1:10388646	KIF1B	-0.46	-9.97	-0.42	2.54e-21	Hepatocellular carcinoma;
LGG	cis	rs1909881	0.574	rs1604254	chr8:96474663	A/G	cg04203453	chr8:96504381	NA	-0.54	-9.95	-0.42	2.98e-21	Obesity-related traits;
LGG	cis	rs1218582	0.741	rs11264291	chr1:154914797	C/T	cg24250549	chr1:154909240	PMVK	0.74	14.64	0.56	3.89e-40	Prostate cancer;
LGG	cis	rs28595532	0.920	rs114420700	chr4:119751297	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9612	1.000	rs3786954	chr19:44272346	A/G	cg08581076	chr19:44259116	C19orf61	0.51	8.94	0.38	9.62e-18	Exhaled nitric oxide output;
LGG	cis	rs4808199	0.649	rs17216693	chr19:19666574	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.5	8.28	0.36	1.34e-15	Nonalcoholic fatty liver disease;
LGG	cis	rs6502050	0.835	rs9900072	chr17:80114360	C/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs7010267	0.740	rs11573885	chr8:119949165	T/C	cg17171407	chr8:119960777	TNFRSF11B	-0.32	-7.93	-0.35	1.71e-14	Total body bone mineral density (age 45-60);
LGG	cis	rs7129556	0.728	rs34130561	chr11:77496691	A/T	cg12586386	chr11:77299805	AQP11	0.46	7.43	0.33	5.23e-13	Weight loss (gastric bypass surgery);
LGG	cis	rs883565	0.740	rs6780772	chr3:39087764	A/G	cg01426195	chr3:39028469	NA	-0.71	-16.0	-0.6	3.44e-46	Handedness;
LGG	cis	rs3739821	1.000	rs3739821	chr9:130702477	A/G	cg21181453	chr9:130700954	DPM2	0.34	7.77	0.34	5.19e-14	Glaucoma (primary angle closure);
LGG	cis	rs826838	0.900	rs11169301	chr12:39128497	C/A	cg26384229	chr12:38710491	ALG10B	1.0	25.07	0.76	2.92e-88	Heart rate;
LGG	trans	rs6601327	0.550	rs4422774	chr8:9522011	A/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.43	-0.33	5.2e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg09873164	chr1:152488093	CRCT1	0.63	15.55	0.59	3.58e-44	Hair morphology;
LGG	cis	rs1318772	0.932	rs71577453	chr5:112886608	G/T	cg12552261	chr5:112820674	MCC	0.69	7.45	0.33	4.47e-13	F-cell distribution;
LGG	cis	rs67385638	0.802	rs72872555	chr11:5310169	G/A	cg12559170	chr11:5275217	HBG2	0.52	11.75	0.48	4.47e-28	Hemoglobin levels;
LGG	cis	rs2276314	0.857	rs28375959	chr18:33601534	T/G	cg05985134	chr18:33552581	C18orf21	0.63	9.72	0.41	1.97e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs8031584	1.000	rs35607976	chr15:31277788	T/C	cg08704250	chr15:31115839	NA	-0.43	-7.58	-0.33	1.97e-13	Huntington's disease progression;
LGG	cis	rs897984	0.568	rs8063565	chr16:30883965	G/C	cg02466173	chr16:30829666	NA	0.51	8.38	0.36	6.56e-16	Dementia with Lewy bodies;
LGG	cis	rs11098499	0.863	rs1155576	chr4:120450159	A/C	cg24375607	chr4:120327624	NA	0.65	10.74	0.45	3.58e-24	Corneal astigmatism;
LGG	cis	rs2562152	0.654	rs216600	chr16:110165	T/C	cg02949481	chr16:131562	MPG	0.64	8.82	0.38	2.4e-17	Glioblastoma;
LGG	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg08975724	chr8:8085496	FLJ10661	0.38	6.98	0.31	1.02e-11	Monocyte count;
LGG	cis	rs2228479	1.000	rs62052180	chr16:89963289	C/G	cg27400746	chr16:89904261	SPIRE2	-0.98	-15.7	-0.59	8e-45	Skin colour saturation;
LGG	cis	rs11608355	0.545	rs4766603	chr12:109892106	T/C	cg05360138	chr12:110035743	NA	0.84	12.14	0.49	1.24e-29	Neuroticism;
LGG	cis	rs4629180	0.586	rs1995826	chr2:102129420	A/G	cg16435561	chr2:102091048	RFX8	-0.48	-8.82	-0.38	2.38e-17	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs2479724	0.776	rs12523672	chr6:41749692	T/G	cg17623882	chr6:41773611	USP49	0.49	8.46	0.37	3.52e-16	Menarche (age at onset);
LGG	cis	rs12286929	0.610	rs12807135	chr11:115053508	G/C	cg04055981	chr11:115044050	NA	0.38	7.03	0.31	7.41e-12	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.95	-0.31	1.21e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2074585	0.517	rs11635361	chr15:91081791	G/T	cg22089800	chr15:90895588	ZNF774	-0.52	-8.64	-0.37	9.53e-17	Basophil percentage of granulocytes;White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs11122272	0.735	rs2491410	chr1:231532287	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.64	-11.51	-0.47	3.83e-27	Hemoglobin concentration;
LGG	cis	rs11748327	0.919	rs72731435	chr5:4048526	T/C	cg01025095	chr5:4101132	NA	-0.55	-9.07	-0.39	3.41e-18	Myocardial infarction;
LGG	cis	rs7481584	1.000	rs756693	chr11:3027889	A/G	cg25174290	chr11:3078921	CARS	-0.48	-8.27	-0.36	1.47e-15	Calcium levels;
LGG	cis	rs2070488	0.861	rs2067082	chr3:38438182	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.79	16.23	0.6	3.24e-47	Electrocardiographic conduction measures;
LGG	cis	rs9472414	0.510	rs227840	chr6:44686304	C/G	cg20913747	chr6:44695427	NA	-0.5	-8.28	-0.36	1.33e-15	Height;
LGG	cis	rs17030434	0.953	rs10010787	chr4:154692059	G/A	cg14289246	chr4:154710475	SFRP2	-0.76	-11.76	-0.48	4.21e-28	Electrocardiographic conduction measures;
LGG	cis	rs7011049	0.908	rs11986701	chr8:53833480	G/T	cg26025543	chr8:53854495	NA	0.73	9.66	0.41	3.02e-20	Systolic blood pressure;
LGG	cis	rs7312933	0.566	rs11181454	chr12:42746486	T/C	cg19980929	chr12:42632907	YAF2	-0.34	-7.66	-0.34	1.08e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7107174	0.901	rs2912	chr11:77926292	G/A	cg27205649	chr11:78285834	NARS2	-0.46	-7.46	-0.33	4.27e-13	Testicular germ cell tumor;
LGG	cis	rs2444240	0.905	rs670855	chr11:120001695	C/T	cg16005559	chr11:120040616	NA	-0.3	-6.76	-0.3	4.12e-11	Corneal curvature;
LGG	cis	rs1552244	0.882	rs9312044	chr3:10037481	T/C	cg00166722	chr3:10149974	C3orf24	0.51	8.7	0.37	5.93e-17	Alzheimer's disease;
LGG	trans	rs9329221	0.510	rs4841282	chr8:9975604	C/A	cg02002194	chr4:3960332	NA	-0.41	-7.62	-0.33	1.44e-13	Neuroticism;
LGG	cis	rs7659604	0.689	rs59131059	chr4:122666357	C/T	cg06713675	chr4:122721982	EXOSC9	-0.44	-7.1	-0.31	4.68e-12	Type 2 diabetes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg16854524	chr4:83931902	LIN54	0.41	6.93	0.31	1.43e-11	Parental extreme longevity (95 years and older);
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-0.96	-16.67	-0.61	3.18e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.861	rs6990796	chr8:58183097	G/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs3092073	0.624	rs11696623	chr20:44580380	C/T	cg27529037	chr20:44575021	PCIF1	0.39	7.34	0.32	9.37e-13	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.871	rs62079994	chr17:80076516	T/C	cg16920238	chr17:80076378	CCDC57	0.35	8.14	0.35	3.75e-15	Life satisfaction;
LGG	cis	rs11123170	0.640	rs2863240	chr2:113970116	C/T	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.65	-10.99	-0.45	4.09e-25	Renal function-related traits (BUN);
LGG	cis	rs9322193	0.923	rs9767105	chr6:149980727	A/G	cg09699651	chr6:150184138	LRP11	0.51	8.86	0.38	1.69e-17	Lung cancer;
LGG	cis	rs10504229	0.639	rs2291764	chr8:58142943	A/C	cg20607798	chr8:58055168	NA	0.7	7.82	0.34	3.55e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs9462027	0.628	rs6899938	chr6:34749113	A/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs858239	0.539	rs6461695	chr7:23197784	C/A	cg23682824	chr7:23144976	KLHL7	0.41	6.69	0.3	6.64e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs13108904	0.557	rs1250086	chr4:1248051	G/A	cg19318889	chr4:1322082	MAEA	-0.4	-7.14	-0.31	3.62e-12	Obesity-related traits;
LGG	cis	rs9348739	1	rs9348739	chr6:26923099	G/C	cg12826209	chr6:26865740	GUSBL1	0.78	9.2	0.39	1.19e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs700651	0.789	rs6434949	chr2:198855510	T/A	cg00792783	chr2:198669748	PLCL1	0.68	11.09	0.46	1.65e-25	Intracranial aneurysm;
LGG	cis	rs2228479	0.850	rs11640209	chr16:89807828	C/A	cg26513180	chr16:89883248	FANCA	1.02	9.81	0.41	8.98e-21	Skin colour saturation;
LGG	cis	rs3858526	0.584	rs10742809	chr11:5862532	G/T	cg25319279	chr11:5960081	NA	0.41	6.93	0.31	1.39e-11	DNA methylation (variation);
LGG	cis	rs1008375	0.800	rs62296338	chr4:17613425	G/T	cg16339924	chr4:17578868	LAP3	0.67	11.33	0.47	2.01e-26	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3099143	1.000	rs111908804	chr15:77123773	C/G	cg21673338	chr15:77095150	SCAPER	-0.66	-9.77	-0.41	1.22e-20	Recalcitrant atopic dermatitis;
LGG	cis	rs11148252	0.538	rs9535885	chr13:52726524	A/G	cg22398616	chr13:53314203	LECT1	-0.48	-9.75	-0.41	1.51e-20	Lewy body disease;
LGG	cis	rs7829975	0.501	rs2980769	chr8:8320291	G/A	cg06636001	chr8:8085503	FLJ10661	0.55	10.71	0.45	4.63e-24	Mood instability;
LGG	cis	rs2274273	0.624	rs11158034	chr14:55753560	C/T	cg04306507	chr14:55594613	LGALS3	0.54	12.5	0.5	4.12e-31	Protein biomarker;
LGG	cis	rs7727544	0.716	rs6863213	chr5:131575932	C/T	cg24060327	chr5:131705240	SLC22A5	-0.43	-7.18	-0.32	2.89e-12	Blood metabolite levels;
LGG	cis	rs35146811	0.844	rs12705070	chr7:99656927	A/G	cg13334819	chr7:99746414	C7orf59	-0.45	-7.0	-0.31	9.02e-12	Coronary artery disease;
LGG	cis	rs11123170	0.640	rs931472	chr2:113969948	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	-0.47	-8.3	-0.36	1.19e-15	Renal function-related traits (BUN);
LGG	cis	rs9557207	0.756	rs9554563	chr13:99827392	C/G	cg24509225	chr13:100037070	UBAC2	0.58	10.87	0.45	1.14e-24	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs16854884	0.770	rs951865	chr3:143812677	G/A	cg06585982	chr3:143692056	C3orf58	0.55	8.85	0.38	1.9e-17	Economic and political preferences (feminism/equality);
LGG	trans	rs7395662	0.853	rs4882062	chr11:48453271	A/G	cg00717180	chr2:96193071	NA	0.42	7.48	0.33	3.68e-13	HDL cholesterol;
LGG	cis	rs9322193	0.961	rs9767713	chr6:149909377	T/G	cg09699651	chr6:150184138	LRP11	0.5	8.74	0.38	4.29e-17	Lung cancer;
LGG	cis	rs10504229	1.000	rs75037501	chr8:58170136	T/G	cg21724239	chr8:58056113	NA	0.43	6.69	0.3	6.59e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs34421088	0.576	rs2736369	chr8:11101398	G/A	cg27411982	chr8:10470053	RP1L1	-0.46	-7.34	-0.32	9.83e-13	Neuroticism;
LGG	cis	rs11700980	0.636	rs11701464	chr21:30285392	C/T	cg08807101	chr21:30365312	RNF160	0.62	7.32	0.32	1.14e-12	QRS complex (12-leadsum);
LGG	cis	rs28588043	0.938	rs28845241	chr1:170974087	C/A	cg03458344	chr1:170964477	C1orf129	-0.51	-7.3	-0.32	1.28e-12	Number of children (6+ vs. 0 or 1);
LGG	cis	rs3768617	0.510	rs7542640	chr1:183063738	G/A	cg15522984	chr1:182991683	LAMC1	0.47	9.46	0.4	1.59e-19	Fuchs's corneal dystrophy;
LGG	cis	rs16854884	0.586	rs4561830	chr3:143735572	C/T	cg06585982	chr3:143692056	C3orf58	0.67	12.21	0.49	6.39e-30	Economic and political preferences (feminism/equality);
LGG	cis	rs7937890	0.874	rs6486191	chr11:14403739	G/A	cg02886208	chr11:14281011	SPON1	-0.45	-9.3	-0.4	5.67e-19	Mitochondrial DNA levels;
LGG	cis	rs1788820	0.957	rs1652375	chr18:21109269	T/C	cg14672496	chr18:21087552	C18orf8	0.39	7.34	0.32	9.56e-13	Body mass index;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg02018176	chr4:1364513	KIAA1530	0.38	8.57	0.37	1.58e-16	Obesity-related traits;
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg19847130	chr8:10466454	RP1L1	0.31	7.09	0.31	5.1e-12	Neuroticism;
LGG	cis	rs2470578	0.792	rs2084572	chr3:17315758	A/G	cg20981856	chr3:17787350	NA	0.36	6.83	0.3	2.67e-11	Schizophrenia;
LGG	cis	rs2439831	0.681	rs11858152	chr15:43634196	T/C	cg15269541	chr15:43626905	ADAL	-0.44	-7.72	-0.34	7.16e-14	Lung cancer in ever smokers;
LGG	cis	rs1153858	1.000	rs7494956	chr15:45668565	T/C	cg26924012	chr15:45694286	SPATA5L1	1.05	22.15	0.72	1.12e-74	Homoarginine levels;
LGG	cis	rs7582180	0.700	rs4851303	chr2:100962064	T/C	cg08297393	chr2:100937505	LONRF2	-0.54	-10.34	-0.43	1.14e-22	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg25358565	chr5:93447407	FAM172A	-0.68	-9.76	-0.41	1.36e-20	Diabetic retinopathy;
LGG	cis	rs4253772	0.515	rs6008591	chr22:46703664	T/C	cg24881330	chr22:46731750	TRMU	0.7	7.2	0.32	2.39e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2074193	0.627	rs215385	chr12:47760437	T/C	cg02516419	chr12:47771422	NA	-0.7	-10.36	-0.43	9.46e-23	Migraine with aura;
LGG	cis	rs7107174	0.688	rs881361	chr11:78128047	C/G	cg02023728	chr11:77925099	USP35	0.44	7.58	0.33	1.95e-13	Testicular germ cell tumor;
LGG	cis	rs778371	0.723	rs1078323	chr2:233681512	T/G	cg08000102	chr2:233561755	GIGYF2	-0.68	-10.92	-0.45	7.2e-25	Schizophrenia;
LGG	cis	rs6679073	1.000	rs10494874	chr1:205754688	C/G	cg14159672	chr1:205819179	PM20D1	0.45	7.26	0.32	1.66e-12	Prostate-specific antigen levels;
LGG	cis	rs240764	0.578	rs9399688	chr6:101215786	C/T	cg09795085	chr6:101329169	ASCC3	0.48	8.18	0.36	2.81e-15	Neuroticism;
LGG	cis	rs9522267	0.559	rs9522300	chr13:112236668	C/G	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.66e-14	Hepatitis;
LGG	trans	rs9329221	0.537	rs2062331	chr8:9979992	C/T	cg16141378	chr3:129829833	LOC729375	0.37	8.61	0.37	1.15e-16	Neuroticism;
LGG	cis	rs7618915	0.547	rs6976	chr3:52728804	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.58	0.33	1.88e-13	Bipolar disorder;
LGG	trans	rs6601327	0.634	rs12679956	chr8:9584849	G/A	cg12395012	chr8:11607386	GATA4	0.37	6.72	0.3	5.45e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.799	rs11491185	chr17:80151101	C/T	cg19223190	chr17:80058835	NA	0.43	8.39	0.36	5.98e-16	Life satisfaction;
LGG	cis	rs13392177	0.660	rs10932762	chr2:219076213	G/C	cg20019365	chr2:219134978	PNKD;AAMP	-0.47	-7.65	-0.33	1.21e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs769267	0.930	rs7254927	chr19:19404786	C/G	cg03709012	chr19:19516395	GATAD2A	0.8	15.24	0.58	8.5e-43	Tonsillectomy;
LGG	cis	rs28386778	0.901	rs2665855	chr17:61965143	A/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	11.94	0.49	7.68e-29	Prudent dietary pattern;
LGG	cis	rs950776	0.518	rs12910100	chr15:78822667	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	cis	rs8180040	0.966	rs6765990	chr3:47542894	G/A	cg27129171	chr3:47204927	SETD2	0.79	15.31	0.58	4.36e-43	Colorectal cancer;
LGG	cis	rs1816752	0.590	rs61947036	chr13:25017682	T/C	cg02811702	chr13:24901961	NA	0.4	7.51	0.33	3.07e-13	Obesity-related traits;
LGG	cis	rs7937890	0.695	rs17557844	chr11:14262559	A/G	cg22961513	chr11:14280813	SPON1	0.32	7.34	0.32	9.82e-13	Mitochondrial DNA levels;
LGG	cis	rs4268898	1.000	rs10195436	chr2:24436112	C/T	cg06627628	chr2:24431161	ITSN2	0.51	8.49	0.37	2.91e-16	Asthma;
LGG	trans	rs62103177	0.525	rs612913	chr18:77845882	A/G	cg05926928	chr17:57297772	GDPD1	-0.93	-11.95	-0.49	7.44e-29	Opioid sensitivity;
LGG	cis	rs3784262	1.000	rs7165247	chr15:58251786	C/T	cg12031962	chr15:58353849	ALDH1A2	0.38	8.38	0.36	6.53e-16	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs10170846	0.861	rs12694582	chr2:223521955	G/C	cg25565276	chr2:223520875	FARSB	0.64	11.26	0.46	3.69e-26	Schizophrenia (inflammation and infection response interaction);
LGG	cis	rs4862750	0.874	rs6822062	chr4:187895553	T/C	cg06074448	chr4:187884817	NA	-0.59	-12.91	-0.51	8.7e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4237845	0.611	rs7298370	chr12:58318897	C/T	cg02175503	chr12:58329896	NA	0.85	17.1	0.62	3.56e-51	Intelligence (multi-trait analysis);
LGG	cis	rs801193	0.904	rs4718405	chr7:66254646	A/G	cg18876405	chr7:65276391	NA	0.59	11.04	0.46	2.68e-25	Aortic root size;
LGG	cis	rs6011674	1.000	rs74589786	chr20:61860939	C/T	cg14895298	chr20:61867178	BIRC7	-0.43	-6.89	-0.3	1.85e-11	Response to cytadine analogues (cytosine arabinoside);
LGG	cis	rs1153858	1.000	rs10444821	chr15:45647236	C/T	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06586915	chr7:65958596	NA	0.63	9.93	0.42	3.27e-21	Gut microbiome composition (summer);
LGG	cis	rs7647973	0.710	rs9869120	chr3:49624065	T/C	cg03060546	chr3:49711283	APEH	0.59	7.77	0.34	5.19e-14	Menarche (age at onset);
LGG	cis	rs668210	0.793	rs590531	chr11:65773939	C/A	cg02202077	chr11:65769826	EIF1AD;BANF1	-0.74	-9.73	-0.41	1.75e-20	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7465272	1.000	rs35900184	chr8:143693411	C/T	cg10104451	chr8:143696006	ARC	-0.7	-10.1	-0.42	8.56e-22	Bipolar disorder and schizophrenia;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg02947993	chr11:27528506	LIN7C;BDNFOS	-0.48	-7.19	-0.32	2.6e-12	Systemic lupus erythematosus;
LGG	cis	rs12738007	0.967	rs10915233	chr1:29475975	G/A	cg11747820	chr1:29584023	PTPRU	-0.31	-7.2	-0.32	2.48e-12	Schizophrenia;
LGG	trans	rs12599106	0.648	rs12447240	chr16:34928236	C/T	cg07332563	chr6:291687	DUSP22	0.58	9.63	0.41	4.02e-20	Menopause (age at onset);
LGG	cis	rs9325144	0.650	rs6582624	chr12:38733475	A/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.8	-0.45	2.12e-24	Morning vs. evening chronotype;
LGG	trans	rs11992162	1.000	rs7460395	chr8:11835375	C/T	cg08975724	chr8:8085496	FLJ10661	0.4	7.49	0.33	3.62e-13	Monocyte count;
LGG	cis	rs9325144	0.723	rs11169535	chr12:39183494	C/T	cg04568710	chr12:38710424	ALG10B	-0.33	-6.78	-0.3	3.62e-11	Morning vs. evening chronotype;
LGG	cis	rs4689642	1.000	rs1875337	chr4:7215653	T/C	cg21353189	chr4:7228343	SORCS2	0.3	7.51	0.33	3.1e-13	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs11764590	0.724	rs62444917	chr7:2107262	A/C	cg23422044	chr7:1970798	MAD1L1	-0.46	-8.34	-0.36	8.55e-16	Neuroticism;
LGG	cis	rs6087990	0.735	rs2424920	chr20:31385452	T/C	cg13636640	chr20:31349939	DNMT3B	0.81	16.65	0.61	3.93e-49	Ulcerative colitis;
LGG	cis	rs2629540	0.765	rs7097177	chr10:126539839	A/G	cg08799069	chr10:126477246	METTL10	-0.58	-12.36	-0.5	1.59e-30	Cocaine dependence;
LGG	cis	rs2304069	0.837	rs10041451	chr5:149385197	A/C	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.6	7.95	0.35	1.49e-14	HIV-1 control;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg01222684	chr5:159435961	TTC1	-0.41	-7.13	-0.31	3.93e-12	Liver disease severity in Alagille syndrome;
LGG	cis	rs4430311	0.723	rs7552659	chr1:243983723	T/C	cg25706552	chr1:244017396	NA	-0.65	-16.01	-0.6	3.03e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs10206020	0.921	rs6605278	chr2:1547230	C/T	cg01028140	chr2:1542097	TPO	-0.54	-9.81	-0.41	8.8e-21	IgG glycosylation;
LGG	cis	rs9527	0.590	rs943039	chr10:104825132	C/T	cg04362960	chr10:104952993	NT5C2	0.57	10.75	0.45	3.23e-24	Arsenic metabolism;
LGG	trans	rs6951245	0.872	rs11768895	chr7:1063691	T/C	cg13565492	chr6:43139072	SRF	-0.56	-7.26	-0.32	1.6e-12	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12617721	0.645	rs114544871	chr2:99045485	T/G	cg18455616	chr2:99124870	INPP4A	0.29	8.69	0.37	6.44e-17	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs796364	0.789	rs176008	chr2:200814720	A/T	cg17644776	chr2:200775616	C2orf69	0.57	7.13	0.31	3.81e-12	Schizophrenia;
LGG	cis	rs1552244	1.000	rs7622963	chr3:10139825	C/T	cg00149659	chr3:10157352	C3orf10	0.85	11.13	0.46	1.19e-25	Alzheimer's disease;
LGG	cis	rs7927997	0.623	rs4494327	chr11:76294836	A/T	cg17647271	chr11:76299819	NA	-0.48	-8.49	-0.37	2.74e-16	Gut microbiota (functional units);Crohn's disease;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.11	0.35	4.66e-15	Prudent dietary pattern;
LGG	cis	rs7681440	0.869	rs7680557	chr4:90763360	C/A	cg20003494	chr4:90757398	SNCA	-0.43	-8.57	-0.37	1.6e-16	Dementia with Lewy bodies;
LGG	cis	rs2481665	0.902	rs1013293	chr1:62570321	G/A	cg18591186	chr1:62594603	INADL	-0.54	-11.56	-0.47	2.55e-27	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1865760	0.622	rs9968910	chr6:26072095	A/C	cg18357526	chr6:26021779	HIST1H4A	0.48	7.0	0.31	8.96e-12	Height;
LGG	cis	rs977987	0.843	rs35737321	chr16:75439185	A/T	cg03315344	chr16:75512273	CHST6	0.51	10.33	0.43	1.15e-22	Dupuytren's disease;
LGG	cis	rs7249142	0.549	rs3787040	chr19:19297292	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.29	-8.01	-0.35	9.27e-15	IgG glycosylation;
LGG	cis	rs1007190	0.881	rs8073674	chr17:42969337	A/C	cg15406952	chr17:42872593	NA	1.05	13.86	0.54	8.36e-37	DNA methylation (variation);
LGG	cis	rs7737355	0.812	rs42256	chr5:130705906	T/C	cg06307176	chr5:131281290	NA	-0.49	-8.14	-0.35	3.7e-15	Life satisfaction;
LGG	cis	rs6696846	0.630	rs6692706	chr1:205158561	G/T	cg21545522	chr1:205238299	TMCC2	0.39	7.29	0.32	1.36e-12	Red blood cell count;
LGG	cis	rs62400317	0.859	rs10948211	chr6:45156767	G/A	cg18551225	chr6:44695536	NA	-0.63	-10.14	-0.43	5.7e-22	Total body bone mineral density;
LGG	cis	rs17376456	1.000	rs34013242	chr5:93507947	C/T	cg19507638	chr5:93509721	C5orf36	-0.69	-9.5	-0.4	1.1e-19	Diabetic retinopathy;
LGG	cis	rs3818285	0.544	rs7899805	chr10:111671177	G/A	cg00817464	chr10:111662876	XPNPEP1	-0.57	-10.37	-0.43	8.51e-23	Superior crus of antihelix expression;
LGG	cis	rs11098499	0.754	rs1814813	chr4:120258207	G/T	cg09307838	chr4:120376055	NA	-0.7	-11.89	-0.48	1.21e-28	Corneal astigmatism;
LGG	cis	rs6466055	0.720	rs7357199	chr7:105019355	G/C	cg04380332	chr7:105027541	SRPK2	-0.4	-7.41	-0.33	6.2e-13	Schizophrenia;
LGG	cis	rs8058578	0.943	rs7197770	chr16:30715908	T/C	cg05768032	chr16:30646687	NA	0.42	7.07	0.31	5.75e-12	Multiple myeloma;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00495681	chr13:53174319	NA	-0.5	-8.98	-0.39	6.81e-18	Lewy body disease;
LGG	cis	rs2470578	0.740	rs1449879	chr3:17277391	A/G	cg20981856	chr3:17787350	NA	0.35	6.68	0.3	6.92e-11	Schizophrenia;
LGG	cis	rs1008375	0.872	rs6831115	chr4:17640463	A/G	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7811142	0.945	rs34989573	chr7:100097895	C/T	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.14	18.49	0.65	1.43e-57	Platelet count;
LGG	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg15268244	chr15:77196840	NA	-0.33	-7.32	-0.32	1.11e-12	Blood metabolite levels;
LGG	cis	rs10499694	0.844	rs10499695	chr7:50618604	A/G	cg00647317	chr7:50633725	DDC	0.41	10.08	0.42	9.86e-22	Body mass index;
LGG	cis	rs6519955	0.765	rs7292527	chr22:46423125	G/T	cg23564243	chr22:46441127	LOC100271722	0.43	7.43	0.33	5.39e-13	Dupuytren's disease;
LGG	cis	rs10504229	0.906	rs56138544	chr8:58184558	A/C	cg02725872	chr8:58115012	NA	-0.77	-10.95	-0.45	5.57e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs3806843	0.931	rs13168670	chr5:140146899	T/C	cg19875535	chr5:140030758	IK	0.53	11.12	0.46	1.29e-25	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6964587	0.933	rs10271174	chr7:91785970	A/G	cg17063962	chr7:91808500	NA	0.54	10.18	0.43	4.06e-22	Breast cancer;
LGG	cis	rs10504229	0.639	rs72650811	chr8:58115661	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11583043	0.918	rs6693456	chr1:101424561	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.43	8.53	0.37	2.08e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs6502050	0.835	rs35131307	chr17:80128439	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.73	-0.34	6.82e-14	Life satisfaction;
LGG	cis	rs6952808	0.895	rs12669518	chr7:1921429	G/C	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.79	-0.38	2.96e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs875971	0.964	rs6978429	chr7:65959876	T/G	cg12463550	chr7:65579703	CRCP	0.52	8.7	0.37	5.93e-17	Aortic root size;
LGG	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg26031613	chr14:104095156	KLC1	-0.61	-9.42	-0.4	2.08e-19	Reticulocyte count;
LGG	cis	rs2836974	0.829	rs8128191	chr21:40527311	A/G	cg11644478	chr21:40555479	PSMG1	0.93	17.69	0.64	6.94e-54	Cognitive function;
LGG	cis	rs1003719	0.715	rs1981433	chr21:38542223	T/G	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.31	-0.58	4.35e-43	Eye color traits;
LGG	cis	rs7618915	0.570	rs2336145	chr3:52629750	A/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.1	-0.31	4.65e-12	Bipolar disorder;
LGG	cis	rs11148252	0.624	rs6561682	chr13:53266297	A/G	cg05335186	chr13:53173507	NA	-0.45	-8.61	-0.37	1.19e-16	Lewy body disease;
LGG	cis	rs4635969	0.718	rs27068	chr5:1347239	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.52	-7.8	-0.34	4.05e-14	Testicular germ cell tumor;Testicular germ cell cancer;
LGG	cis	rs7223966	1.000	rs11654335	chr17:61797579	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.66	10.97	0.45	4.72e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs17208368	0.628	rs4784473	chr16:55093016	C/T	cg09947736	chr16:55091198	NA	0.68	12.92	0.51	8.16e-33	Hypospadias;
LGG	cis	rs12643440	0.538	rs12641321	chr4:17141393	G/C	cg22650099	chr4:17144496	NA	-0.5	-8.52	-0.37	2.34e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs6598955	0.724	rs10902737	chr1:26635716	G/A	cg10402321	chr1:26617780	UBXN11	-0.37	-6.9	-0.31	1.76e-11	Obesity-related traits;
LGG	cis	rs834603	0.575	rs940861	chr7:47469429	A/T	cg09696706	chr7:47479511	TNS3	0.35	7.82	0.34	3.59e-14	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2288073	0.801	rs10175668	chr2:24367275	G/A	cg06627628	chr2:24431161	ITSN2	-0.52	-8.45	-0.37	3.92e-16	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs908922	0.676	rs2181172	chr1:152491794	A/G	cg09873164	chr1:152488093	CRCT1	0.63	15.53	0.59	4.54e-44	Hair morphology;
LGG	cis	rs7267979	1.000	rs6115182	chr20:25410259	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.4	-0.44	6.53e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs757081	0.658	rs214076	chr11:17300257	T/C	cg15432903	chr11:17409602	KCNJ11	-0.41	-7.32	-0.32	1.08e-12	Systolic blood pressure;
LGG	cis	rs2274273	0.837	rs10131913	chr14:55787420	A/G	cg04306507	chr14:55594613	LGALS3	0.64	18.05	0.64	1.53e-55	Protein biomarker;
LGG	cis	rs787274	1.000	rs787280	chr9:115539085	C/T	cg13803584	chr9:115635662	SNX30	-0.56	-7.83	-0.34	3.27e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	trans	rs9944715	0.954	rs1808946	chr18:43854860	A/G	cg01718231	chr17:29326311	RNF135	-0.42	-6.65	-0.3	8.46e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs55665837	0.540	rs1007392	chr11:14774591	A/G	cg19336497	chr11:14380999	RRAS2	-0.4	-7.54	-0.33	2.58e-13	Vitamin D levels;
LGG	cis	rs9733	0.650	rs2048558	chr1:150571730	A/G	cg13175981	chr1:150552382	MCL1	0.6	10.35	0.43	9.86e-23	Tonsillectomy;
LGG	cis	rs9522267	0.966	rs9515443	chr13:112197387	T/C	cg10483660	chr13:112241077	NA	-0.38	-7.64	-0.33	1.29e-13	Hepatitis;
LGG	cis	rs16976116	0.951	rs6493768	chr15:55484294	T/A	cg11288833	chr15:55489084	RSL24D1	0.55	7.55	0.33	2.27e-13	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs367615	0.918	rs10070104	chr5:108866438	C/T	cg17395555	chr5:108820864	NA	-0.66	-9.45	-0.4	1.73e-19	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs899997	1.000	rs9888691	chr15:79010046	T/C	cg07120314	chr15:79043507	NA	-0.72	-17.06	-0.62	5.55e-51	Coronary artery disease or large artery stroke;
LGG	cis	rs3859192	0.557	rs12602514	chr17:38159745	A/G	cg17467752	chr17:38218738	THRA	-0.58	-9.65	-0.41	3.33e-20	White blood cell count;
LGG	cis	rs10131894	0.635	rs174997	chr14:75434806	G/A	cg11812906	chr14:75593930	NEK9	-0.43	-7.85	-0.34	2.86e-14	Coronary artery disease;
LGG	cis	rs2228479	1.000	rs12596492	chr16:89957169	T/G	cg04287289	chr16:89883240	FANCA	0.77	7.55	0.33	2.39e-13	Skin colour saturation;
LGG	cis	rs2083460	1	rs2083460	chr15:89574484	T/C	cg09489435	chr15:89561491	NA	-0.51	-6.79	-0.3	3.4e-11	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs6500395	1.000	rs12597928	chr16:48714366	G/A	cg16662043	chr16:48846231	NA	-0.37	-7.29	-0.32	1.31e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs6951245	0.935	rs61753396	chr7:1105372	A/G	cg13565492	chr6:43139072	SRF	-0.75	-9.02	-0.39	5.16e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3858526	0.959	rs61876223	chr11:5943393	G/A	cg02574844	chr11:5959923	NA	-0.57	-8.86	-0.38	1.7e-17	DNA methylation (variation);
LGG	cis	rs7084402	0.967	rs1649072	chr10:60298112	G/A	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.57	9.74	0.41	1.66e-20	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg11859384	chr17:80120422	CCDC57	-0.44	-7.75	-0.34	5.94e-14	Life satisfaction;
LGG	cis	rs17014483	1.000	rs3017914	chr4:89654165	T/C	cg01026744	chr4:89619053	NAP1L5;HERC3	0.61	6.76	0.3	4.13e-11	Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs8133932	0.736	rs4819159	chr21:47285605	A/G	cg13695288	chr21:47294981	PCBP3	-0.37	-7.43	-0.33	5.21e-13	Schizophrenia;
LGG	cis	rs68170813	0.523	rs4730241	chr7:107057361	G/A	cg02696742	chr7:106810147	HBP1	-0.74	-10.22	-0.43	3.14e-22	Coronary artery disease;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg14926445	chr8:58193284	C8orf71	-0.82	-10.63	-0.44	9.08e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs651907	0.557	rs34624546	chr3:101374226	T/G	cg12386194	chr3:101231763	SENP7	0.45	8.05	0.35	6.99e-15	Colorectal cancer;
LGG	cis	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg18252515	chr7:66147081	NA	-1.42	-20.51	-0.69	5.3e-67	Diabetic kidney disease;
LGG	cis	rs9816226	0.591	rs80080062	chr3:185812169	C/G	cg00760338	chr3:185826511	ETV5	-0.82	-10.24	-0.43	2.6e-22	Obesity;Body mass index;
LGG	cis	rs5750830	0.649	rs5750815	chr22:39798449	T/C	cg11247378	chr22:39784982	NA	-0.32	-9.28	-0.4	6.7e-19	Intelligence (multi-trait analysis);
LGG	cis	rs3087591	0.708	rs7502834	chr17:29689430	G/A	cg24425628	chr17:29625626	OMG;NF1	0.61	12.59	0.51	1.82e-31	Hip circumference;
LGG	cis	rs4262150	0.543	rs72795364	chr5:151918935	G/A	cg12297329	chr5:152029980	NA	-0.67	-12.01	-0.49	4.12e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs1899546	1.000	rs11027852	chr11:24399181	G/T	cg05377417	chr17:59940892	BRIP1	-0.42	-7.83	-0.34	3.27e-14	Autism spectrum disorder or schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07192821	chr15:45003560	B2M	0.43	7.23	0.32	2.07e-12	Cognitive performance;
LGG	cis	rs67478160	0.643	rs11626377	chr14:104234357	G/A	cg26031613	chr14:104095156	KLC1	-0.46	-7.56	-0.33	2.21e-13	Schizophrenia;
LGG	trans	rs3857536	0.813	rs7757647	chr6:66947207	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.75	-0.34	5.9e-14	Blood trace element (Cu levels);
LGG	cis	rs6933660	0.745	rs9371517	chr6:151739810	G/T	cg02564969	chr6:151773285	C6orf211;RMND1	0.45	8.17	0.35	3.03e-15	Menarche (age at onset);
LGG	cis	rs10504229	0.654	rs903705	chr8:58128185	T/A	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1978968	0.956	rs35089989	chr22:18424298	T/C	cg03078520	chr22:18463400	MICAL3	-0.59	-10.99	-0.45	3.95e-25	Presence of antiphospholipid antibodies;
LGG	cis	rs796364	0.951	rs3098341	chr2:200792498	G/T	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs4731207	0.596	rs12534466	chr7:124668423	A/G	cg05630886	chr7:124431682	NA	-0.31	-7.09	-0.31	5.01e-12	Cutaneous malignant melanoma;
LGG	cis	rs6089829	0.962	rs3746747	chr20:61667631	T/C	cg08045932	chr20:61659980	NA	0.58	12.32	0.5	2.27e-30	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs2204008	0.687	rs1733404	chr12:38123395	G/T	cg26384229	chr12:38710491	ALG10B	-0.89	-20.34	-0.69	3.57e-66	Bladder cancer;
LGG	trans	rs61931739	0.517	rs1197562	chr12:34122037	G/A	cg13010199	chr12:38710504	ALG10B	0.53	10.5	0.44	2.86e-23	Morning vs. evening chronotype;
LGG	cis	rs57221529	0.608	rs11749927	chr5:668842	C/T	cg01221209	chr5:554886	NA	-0.45	-6.67	-0.3	7.36e-11	Lung disease severity in cystic fibrosis;
LGG	cis	rs4689592	0.619	rs3796908	chr4:7061378	G/A	cg06697600	chr4:7070879	GRPEL1	-0.54	-9.15	-0.39	1.85e-18	Monocyte percentage of white cells;
LGG	trans	rs7786808	0.712	rs2335170	chr7:158207101	G/A	cg02030672	chr11:45687055	CHST1	0.58	10.48	0.44	3.3e-23	Obesity-related traits;
LGG	trans	rs61931739	0.629	rs708146	chr12:33731808	C/G	cg13010199	chr12:38710504	ALG10B	0.37	6.75	0.3	4.48e-11	Morning vs. evening chronotype;
LGG	cis	rs344364	0.511	rs2982433	chr16:1954508	A/G	cg00490583	chr16:1843685	IGFALS	-0.4	-6.93	-0.31	1.46e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7166081	1.000	rs4776913	chr15:67580356	A/C	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.76	-0.3	4.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs2760061	0.598	rs673726	chr1:228120173	T/C	cg01200585	chr1:228362443	C1orf69	-0.45	-8.06	-0.35	6.78e-15	Diastolic blood pressure;
LGG	cis	rs12519773	0.662	rs6883741	chr5:92491481	T/A	cg18783429	chr5:92414398	NA	0.27	6.65	0.3	8.2e-11	Migraine;
LGG	cis	rs7193541	0.826	rs56143602	chr16:74694692	T/C	cg01733217	chr16:74700730	RFWD3	0.88	20.61	0.69	1.8e-67	Multiple myeloma;
LGG	cis	rs1218582	0.772	rs6669791	chr1:154845484	G/T	cg03351412	chr1:154909251	PMVK	0.67	12.92	0.51	8.05e-33	Prostate cancer;
LGG	cis	rs1799949	1.000	rs1545764	chr17:41424565	G/A	cg23758822	chr17:41437982	NA	0.9	15.97	0.6	4.7e-46	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115242199	chr4:119728652	A/C	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs9611565	0.607	rs132792	chr22:42062822	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.22	-0.39	1.06e-18	Vitiligo;
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.23	0.36	1.85e-15	Bipolar disorder;
LGG	cis	rs929354	0.742	rs10274687	chr7:156933181	T/G	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs752010	0.871	rs2038976	chr1:42094498	A/G	cg16096631	chr1:42092165	HIVEP3	0.75	20.85	0.7	1.44e-68	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs3845702	1.000	rs10497555	chr2:180864967	A/G	cg01881094	chr2:180872142	CWC22	0.92	13.9	0.54	6.15e-37	Schizophrenia;
LGG	cis	rs4242434	0.927	rs11136093	chr8:22479988	C/G	cg19455335	chr8:22457658	C8orf58	-0.43	-8.65	-0.37	8.79e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs3733585	0.699	rs10017674	chr4:9967053	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.19e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs17270561	0.779	rs12210620	chr6:25884785	T/C	cg16482183	chr6:26056742	HIST1H1C	0.73	11.05	0.46	2.43e-25	Iron status biomarkers;
LGG	cis	rs2832191	1.000	rs2832184	chr21:30483265	C/T	cg08807101	chr21:30365312	RNF160	-0.8	-15.74	-0.59	5.17e-45	Dental caries;
LGG	cis	rs12477438	0.798	rs1349779	chr2:99645055	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.81	-0.51	2.22e-32	Chronic sinus infection;
LGG	cis	rs4665809	0.590	rs4665837	chr2:26434022	C/A	cg08470875	chr2:26401718	FAM59B	-0.42	-8.17	-0.35	3.01e-15	Gut microbiome composition (summer);
LGG	cis	rs2729354	0.729	rs2848634	chr11:57252328	G/A	cg24343310	chr11:57249947	NA	0.42	8.07	0.35	5.95e-15	Blood protein levels;
LGG	cis	rs2131877	0.830	rs62285227	chr3:194880597	G/C	cg07250128	chr3:194833983	C3orf21	0.45	7.46	0.33	4.18e-13	Non-small cell lung cancer;
LGG	cis	rs7432375	0.901	rs11919030	chr3:136348599	G/A	cg21827317	chr3:136751795	NA	0.47	8.55	0.37	1.76e-16	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	trans	rs10958605	0.761	rs966169	chr8:40037659	A/G	cg07482373	chr22:50689843	HDAC10	0.39	6.67	0.3	7.51e-11	Parkinson's disease (motor and cognition);
LGG	cis	rs17021463	0.643	rs17311521	chr4:95298060	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.28	-0.32	1.46e-12	Testicular germ cell tumor;
LGG	cis	rs41271473	0.526	rs72765760	chr1:228743222	G/A	cg10167378	chr1:228756711	NA	0.69	9.58	0.41	5.79e-20	Chronic lymphocytic leukemia;
LGG	cis	rs62238980	0.614	rs75091642	chr22:32449078	C/A	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs1847202	0.859	rs4490296	chr3:72949197	C/A	cg25664220	chr3:72788482	NA	-0.26	-7.64	-0.33	1.28e-13	Motion sickness;
LGG	cis	rs2802728	0.881	rs2039837	chr1:243582224	T/C	cg05593162	chr1:243577377	SDCCAG8	0.49	6.79	0.3	3.44e-11	Toenail selenium levels;
LGG	cis	rs6089584	0.888	rs2892060	chr20:60617955	G/T	cg06108461	chr20:60628389	TAF4	-1.02	-20.33	-0.69	3.91e-66	Body mass index;
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7.17e-23	Bipolar disorder;
LGG	cis	rs8114671	0.836	rs6142294	chr20:33671497	A/G	cg07148914	chr20:33460835	GGT7	-0.5	-8.3	-0.36	1.19e-15	Height;
LGG	cis	rs3747547	0.710	rs16934659	chr9:37950604	T/C	cg13774184	chr9:37916125	SHB	-0.72	-8.02	-0.35	8.98e-15	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg03499777	chr13:98085463	RAP2A	0.43	7.84	0.34	3.21e-14	Bilirubin levels;
LGG	cis	rs67460515	0.500	rs1345156	chr3:160649272	G/T	cg04691961	chr3:161091175	C3orf57	0.39	7.41	0.33	6.01e-13	Parkinson's disease;
LGG	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg15596359	chr8:11213517	TDH	-0.38	-7.72	-0.34	7e-14	Retinal vascular caliber;
LGG	cis	rs28386778	0.863	rs6919	chr17:61909485	A/T	cg07677032	chr17:61819896	STRADA	-0.67	-12.5	-0.5	4.35e-31	Prudent dietary pattern;
LGG	cis	rs9611565	0.506	rs4822020	chr22:41700203	C/T	cg03806693	chr22:41940476	POLR3H	-0.76	-12.75	-0.51	3.91e-32	Vitiligo;
LGG	cis	rs10504229	1.000	rs58382845	chr8:58169851	A/C	cg05313129	chr8:58192883	C8orf71	-0.81	-12.47	-0.5	5.68e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs9900972	0.918	rs8065599	chr17:76877073	T/C	cg00961940	chr17:76876995	TIMP2	0.46	8.49	0.37	2.89e-16	Obesity-related traits;
LGG	cis	rs11122272	0.735	rs2250734	chr1:231485958	G/A	cg10503236	chr1:231470652	EXOC8	-0.38	-7.44	-0.33	4.98e-13	Hemoglobin concentration;
LGG	cis	rs9560113	1.000	rs9560103	chr13:112174253	G/A	cg14952266	chr13:112191215	NA	-0.42	-7.68	-0.34	9.8e-14	Menarche (age at onset);
LGG	trans	rs11976180	1.000	rs2371248	chr7:143764189	C/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.38	-6.82	-0.3	2.8e-11	Obesity-related traits;
LGG	cis	rs921968	0.643	rs832799	chr2:219490111	C/A	cg01130898	chr2:219473002	PLCD4	-0.39	-6.81	-0.3	3.01e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7927592	0.731	rs11228288	chr11:68353550	A/G	cg01657329	chr11:68192670	LRP5	-0.57	-10.79	-0.45	2.27e-24	Total body bone mineral density;
LGG	cis	rs7638995	0.878	rs3968927	chr3:69183404	C/T	cg26574240	chr3:69171822	LMOD3	-0.74	-10.77	-0.45	2.74e-24	Alzheimer's disease (late onset);
LGG	cis	rs4919044	1.000	rs17108043	chr10:94770697	A/G	cg05127821	chr10:94822908	CYP26C1	0.46	7.47	0.33	4.06e-13	Coronary artery disease;
LGG	cis	rs10463554	0.750	rs26257	chr5:102550531	C/T	cg23492399	chr5:102201601	PAM	-0.56	-8.24	-0.36	1.82e-15	Parkinson's disease;
LGG	cis	rs12549902	0.966	rs6990613	chr8:41515130	A/G	cg21772509	chr8:41503840	NKX6-3	0.86	19.04	0.66	4e-60	Corrected insulin response;Corrected insulin response adjusted for insulin sensitivity index;Insulin levels adjusted for BMI;Type 2 diabetes;
LGG	cis	rs2832191	0.692	rs2254872	chr21:30414724	C/T	cg24692254	chr21:30365293	RNF160	1.04	29.41	0.81	5.58e-108	Dental caries;
LGG	cis	rs977987	0.778	rs35415181	chr16:75403124	T/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.84	0.3	2.52e-11	Dupuytren's disease;
LGG	cis	rs6500602	0.702	rs2304634	chr16:4500544	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.37	7.95	0.35	1.46e-14	Schizophrenia;
LGG	cis	rs736408	0.677	rs2286798	chr3:52821177	G/T	cg11645453	chr3:52864694	ITIH4	-0.4	-6.67	-0.3	7.32e-11	Bipolar disorder;
LGG	cis	rs57221529	0.766	rs72703075	chr5:592819	C/T	cg14541582	chr5:601475	NA	-0.72	-10.89	-0.45	9.81e-25	Lung disease severity in cystic fibrosis;
LGG	cis	rs2282032	0.527	rs41309248	chr14:90767386	C/T	cg04374321	chr14:90722782	PSMC1	0.49	8.14	0.35	3.73e-15	Longevity;
LGG	cis	rs6502050	0.835	rs11077971	chr17:80090629	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.86e-13	Life satisfaction;
LGG	trans	rs9650657	0.504	rs2409724	chr8:11041642	A/T	cg08975724	chr8:8085496	FLJ10661	-0.46	-8.71	-0.38	5.34e-17	Neuroticism;
LGG	cis	rs8014204	0.570	rs7147721	chr14:75186010	A/G	cg06637938	chr14:75390232	RPS6KL1	0.77	15.32	0.58	3.62e-43	Caffeine consumption;
LGG	cis	rs3096299	0.719	rs2911262	chr16:89515041	C/T	cg08392591	chr16:89556376	ANKRD11	0.53	8.43	0.36	4.29e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs3858526	0.874	rs10838879	chr11:5950169	C/T	cg13902645	chr11:5959945	NA	-0.73	-11.41	-0.47	9.66e-27	DNA methylation (variation);
LGG	cis	rs16854884	0.558	rs6768153	chr3:143667429	C/A	cg06585982	chr3:143692056	C3orf58	0.66	11.68	0.48	8.16e-28	Economic and political preferences (feminism/equality);
LGG	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-0.63	-10.03	-0.42	1.54e-21	Chronic sinus infection;
LGG	cis	rs2762353	0.776	rs942379	chr6:25849620	A/G	cg12310025	chr6:25882481	NA	-0.59	-11.38	-0.47	1.28e-26	Blood metabolite levels;
LGG	cis	rs7100689	0.784	rs1870142	chr10:82182296	G/A	cg00277334	chr10:82204260	NA	-0.34	-6.65	-0.3	8.46e-11	Post bronchodilator FEV1;
LGG	cis	rs7216064	0.589	rs7213585	chr17:66062316	A/T	cg02705964	chr17:66097276	LOC651250	0.46	8.18	0.36	2.76e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs10754283	0.967	rs12058749	chr1:90105604	C/T	cg21401794	chr1:90099060	LRRC8C	0.56	11.61	0.47	1.63e-27	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs9557207	0.756	rs9554562	chr13:99826058	C/T	cg24509225	chr13:100037070	UBAC2	0.58	10.67	0.44	6.63e-24	Peripheral arterial disease (traffic-related air pollution interaction);Inflammatory bowel disease;
LGG	cis	rs8067545	0.611	rs12949481	chr17:20190974	C/A	cg13482628	chr17:19912719	NA	-0.55	-10.32	-0.43	1.29e-22	Schizophrenia;
LGG	cis	rs873946	0.648	rs12767126	chr10:134556992	C/T	cg27297192	chr10:134578999	INPP5A	0.31	6.73	0.3	4.97e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs6580649	0.941	rs7959755	chr12:48446318	T/A	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs7937682	0.881	rs4936678	chr11:111625085	C/T	cg09085632	chr11:111637200	PPP2R1B	1.16	23.36	0.74	2.57e-80	Primary sclerosing cholangitis;
LGG	cis	rs4702718	0.616	rs7733385	chr5:10712199	G/A	cg14521931	chr5:10832172	NA	-0.44	-8.38	-0.36	6.47e-16	Obesity-related traits;
LGG	cis	rs875971	0.800	rs427557	chr7:65519250	A/G	cg11764359	chr7:65958608	NA	0.69	12.16	0.49	1.04e-29	Aortic root size;
LGG	cis	rs11711311	1.000	rs1043132	chr3:113528689	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.68	14.01	0.55	1.96e-37	IgG glycosylation;
LGG	cis	rs1816752	0.652	rs2902356	chr13:24988471	C/T	cg22771759	chr13:24902376	NA	0.42	6.96	0.31	1.16e-11	Obesity-related traits;
LGG	trans	rs7819412	0.745	rs7017567	chr8:10933699	T/A	cg11608241	chr8:8085544	FLJ10661	-0.3	-6.83	-0.3	2.67e-11	Triglycerides;
LGG	cis	rs11209002	0.614	rs4655515	chr1:67566898	T/C	cg02640540	chr1:67518911	SLC35D1	0.43	7.27	0.32	1.54e-12	Crohn's disease;
LGG	cis	rs72781680	0.948	rs72790326	chr2:24126153	C/T	cg08917208	chr2:24149416	ATAD2B	0.81	9.49	0.4	1.23e-19	Lymphocyte counts;
LGG	cis	rs6502050	0.777	rs11077969	chr17:80085633	A/G	cg16920238	chr17:80076378	CCDC57	0.32	7.31	0.32	1.21e-12	Life satisfaction;
LGG	trans	rs7395662	1.000	rs10838944	chr11:48559571	T/C	cg15704280	chr7:45808275	SEPT13	-0.5	-8.12	-0.35	4.2e-15	HDL cholesterol;
LGG	cis	rs9911578	0.692	rs411988	chr17:56709034	G/A	cg12560992	chr17:57184187	TRIM37	0.64	11.01	0.46	3.22e-25	Intelligence (multi-trait analysis);
LGG	trans	rs7395662	0.864	rs12366262	chr11:48563472	T/A	cg03929089	chr4:120376271	NA	-0.45	-7.31	-0.32	1.15e-12	HDL cholesterol;
LGG	cis	rs1552244	1.000	rs7637888	chr3:10080722	T/C	cg18621852	chr3:10150065	C3orf24	0.4	6.66	0.3	8.01e-11	Alzheimer's disease;
LGG	cis	rs1008375	1.000	rs4698199	chr4:17656738	G/C	cg15017067	chr4:17643749	FAM184B	0.32	7.43	0.33	5.17e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12230513	0.732	rs61956303	chr12:55818071	C/A	cg19537932	chr12:55886519	OR6C68	-0.59	-10.79	-0.45	2.34e-24	Contrast sensitivity;
LGG	cis	rs561341	0.941	rs8066156	chr17:30361629	A/G	cg13647721	chr17:30228624	UTP6	0.65	8.44	0.37	4.2e-16	Hip circumference adjusted for BMI;
LGG	cis	rs11785400	0.762	rs7017931	chr8:143726728	A/G	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg17470184	chr11:118478236	PHLDB1	0.53	9.54	0.41	8.42e-20	Systemic lupus erythematosus;
LGG	cis	rs769267	0.895	rs2916074	chr19:19530270	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.2	0.55	3.12e-38	Tonsillectomy;
LGG	cis	rs12048904	0.619	rs10875347	chr1:101333737	T/C	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.54	9.89	0.42	4.68e-21	Multiple sclerosis;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg17274953	chr19:15947906	NA	0.46	7.13	0.31	3.94e-12	Hip circumference;
LGG	cis	rs8141529	0.632	rs5762803	chr22:29193638	G/C	cg02153584	chr22:29168773	CCDC117	0.64	10.05	0.42	1.3e-21	Lymphocyte counts;
LGG	cis	rs10979	1.000	rs1054752	chr6:143890097	G/A	cg25407410	chr6:143891975	LOC285740	-0.72	-12.46	-0.5	6.35e-31	Hypospadias;
LGG	cis	rs477895	0.653	rs12797120	chr11:63906819	C/T	cg19465662	chr11:63993652	NUDT22;TRPT1	0.86	11.17	0.46	8e-26	Mean platelet volume;
LGG	cis	rs2153535	0.541	rs9328471	chr6:8468842	T/C	cg21535247	chr6:8435926	SLC35B3	0.6	10.19	0.43	3.77e-22	Motion sickness;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02932736	chr1:67896194	SERBP1	0.41	6.73	0.3	5.14e-11	Cognitive performance;
LGG	cis	rs13118159	0.801	rs13147602	chr4:1332175	A/G	cg05165339	chr4:1420672	NA	-0.31	-8.35	-0.36	7.86e-16	Longevity;
LGG	cis	rs7928758	0.562	rs1561613	chr11:134294571	A/T	cg22777979	chr11:134283252	B3GAT1	-0.76	-9.26	-0.4	7.72e-19	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs516946	0.797	rs10106563	chr8:41533200	C/A	cg01678292	chr8:41522873	ANK1	0.35	7.46	0.33	4.38e-13	Type 2 diabetes;
LGG	cis	rs2070488	0.965	rs7640050	chr3:38525864	A/C	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.09	0.64	1.06e-55	Electrocardiographic conduction measures;
LGG	cis	rs9815354	0.812	rs73071239	chr3:41992610	C/A	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3768617	0.610	rs10911228	chr1:183049792	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.71	0.3	5.8200000000000003e-11	Fuchs's corneal dystrophy;
LGG	cis	rs986417	1.000	rs1254265	chr14:60840478	T/C	cg27398547	chr14:60952738	C14orf39	-0.73	-7.03	-0.31	7.3e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.799	rs58538819	chr17:80107153	G/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.6	-0.41	5.12e-20	Life satisfaction;
LGG	cis	rs6502050	0.835	rs10163496	chr17:80110867	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs73416724	1.000	rs74766084	chr6:43287804	G/A	cg26312998	chr6:43337775	ZNF318	0.6	8.39	0.36	5.74e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs1790761	0.501	rs4930210	chr11:67404726	G/T	cg14500267	chr11:67383377	NA	-0.38	-7.09	-0.31	5.06e-12	Mean corpuscular volume;
LGG	cis	rs798554	0.797	rs798494	chr7:2798294	C/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.84	-0.3	2.47e-11	Height;
LGG	cis	rs2862064	1.000	rs905211	chr5:156447218	A/T	cg12943317	chr5:156479607	HAVCR1	-0.78	-10.25	-0.43	2.31e-22	Platelet count;
LGG	cis	rs6952808	0.689	rs12668156	chr7:2019875	G/A	cg05863683	chr7:1912471	MAD1L1	0.47	9.18	0.39	1.44e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs4538187	0.806	rs34777730	chr2:64250804	T/C	cg19915305	chr2:64069682	UGP2	-0.66	-14.93	-0.57	2.05e-41	Systolic blood pressure;
LGG	cis	rs10504229	0.775	rs56082079	chr8:58163732	T/C	cg08677398	chr8:58056175	NA	0.57	9.17	0.39	1.53e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs514406	0.825	rs487453	chr1:53271225	T/C	cg08859206	chr1:53392774	SCP2	0.33	6.78	0.3	3.65e-11	Monocyte count;
LGG	trans	rs34421088	0.548	rs2618443	chr8:11384556	A/G	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.78	-0.34	4.68e-14	Neuroticism;
LGG	trans	rs59698941	0.607	rs17516645	chr5:132184083	C/G	cg20453861	chr2:158687877	ACVR1	-0.39	-6.69	-0.3	6.46e-11	Apolipoprotein A-IV levels;
LGG	cis	rs7582720	1.000	rs72932774	chr2:203685728	C/T	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.69	0.41	2.46e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs1595825	0.838	rs60079260	chr2:198673636	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.68	-0.3	6.85e-11	Ulcerative colitis;
LGG	cis	rs79349575	0.691	rs28528789	chr17:46986616	C/T	cg16584676	chr17:46985605	UBE2Z	-0.52	-9.25	-0.39	8.6e-19	Type 2 diabetes;
LGG	cis	rs8180040	0.966	rs2062278	chr3:47416761	C/T	cg16586182	chr3:47516702	SCAP	-0.8	-16.27	-0.6	2.21e-47	Colorectal cancer;
LGG	cis	rs477895	0.639	rs35858916	chr11:63950529	T/G	cg04317338	chr11:64019027	PLCB3	0.67	8.24	0.36	1.73e-15	Mean platelet volume;
LGG	cis	rs1707322	0.721	rs12091503	chr1:46107868	T/C	cg03146154	chr1:46216737	IPP	0.58	11.14	0.46	1.03e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs28386778	0.897	rs2028567	chr17:61915326	G/A	cg19143629	chr17:61920732	SMARCD2	0.42	7.31	0.32	1.15e-12	Prudent dietary pattern;
LGG	cis	rs2730245	1.000	rs2730245	chr7:158724789	G/C	cg11984989	chr7:158649758	WDR60	-0.96	-19.83	-0.68	8.36e-64	Height;
LGG	cis	rs3768617	0.510	rs10752903	chr1:183100863	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs1008375	0.966	rs6837664	chr4:17697835	G/C	cg16339924	chr4:17578868	LAP3	0.5	8.4	0.36	5.66e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7568458	0.846	rs2028900	chr2:85767735	A/G	cg17127132	chr2:85788382	GGCX	-0.47	-8.18	-0.36	2.78e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs228769	0.673	rs375677	chr17:42108974	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	-0.51	-7.71	-0.34	7.72e-14	Bone mineral density (hip);Bone mineral density (spine);
LGG	cis	rs2839186	0.967	rs17176131	chr21:47705237	T/C	cg08742575	chr21:47604166	C21orf56	0.48	8.26	0.36	1.59e-15	Testicular germ cell tumor;
LGG	cis	rs2228479	0.850	rs62052212	chr16:89981960	G/A	cg00800038	chr16:89945340	TCF25	-0.66	-7.83	-0.34	3.35e-14	Skin colour saturation;
LGG	cis	rs5757676	0.858	rs6001585	chr22:39812986	G/T	cg04986931	chr22:39850128	NA	0.37	7.67	0.34	1.05e-13	IgG glycosylation;
LGG	trans	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg16141378	chr3:129829833	LOC729375	-0.34	-7.32	-0.32	1.07e-12	Neuroticism;
LGG	cis	rs262150	0.501	rs2730206	chr7:158815173	G/C	cg09640425	chr7:158790006	NA	-0.36	-6.76	-0.3	4.08e-11	Facial morphology (factor 20);
LGG	cis	rs657075	0.697	rs56996855	chr5:131689638	T/C	cg17951613	chr5:131705445	SLC22A5	0.68	7.66	0.34	1.08e-13	Rheumatoid arthritis;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg08888203	chr3:10149979	C3orf24	-0.53	-9.15	-0.39	1.89e-18	Alzheimer's disease;
LGG	cis	rs7010267	0.687	rs13264791	chr8:120013090	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.32	8.2	0.36	2.41e-15	Total body bone mineral density (age 45-60);
LGG	cis	rs1008375	1.000	rs1008374	chr4:17683219	G/A	cg02297831	chr4:17616191	MED28	0.5	9.46	0.4	1.58e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs71444571	1	rs71444571	chr12:123771015	G/A	cg05973401	chr12:123451056	ABCB9	-0.48	-6.91	-0.31	1.65e-11	Lymphocyte percentage of white cells;
LGG	cis	rs60871478	1.000	rs62432253	chr7:802928	A/G	cg22643751	chr7:855365	UNC84A	0.43	7.69	0.34	9.2e-14	Cerebrospinal P-tau181p levels;
LGG	cis	rs67311347	0.544	rs6599088	chr3:40329288	T/C	cg13683864	chr3:40499215	RPL14	-0.82	-16.46	-0.61	2.86e-48	Renal cell carcinoma;
LGG	cis	rs4975616	0.869	rs467095	chr5:1336221	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.4	-0.65	3.63e-57	Lung cancer;
LGG	cis	rs7582180	0.629	rs11685250	chr2:100955137	C/T	cg08017756	chr2:100939284	LONRF2	-0.28	-6.68	-0.3	6.99e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3096299	0.685	rs3803682	chr16:89544636	C/T	cg05484508	chr16:89589025	SPG7	0.46	7.45	0.33	4.67e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7940866	0.804	rs3910266	chr11:130814272	A/C	cg12179176	chr11:130786555	SNX19	0.77	14.76	0.57	1.1e-40	Schizophrenia;
LGG	cis	rs9325144	0.600	rs10880934	chr12:38730455	C/T	cg04568710	chr12:38710424	ALG10B	-0.42	-8.68	-0.37	6.96e-17	Morning vs. evening chronotype;
LGG	cis	rs736408	0.609	rs2230534	chr3:52802402	A/C	cg18404041	chr3:52824283	ITIH1	-0.54	-10.32	-0.43	1.32e-22	Bipolar disorder;
LGG	cis	rs9534288	0.830	rs940	chr13:46627480	C/G	cg15192986	chr13:46630673	CPB2	-0.78	-17.04	-0.62	7.12e-51	Blood protein levels;
LGG	cis	rs12153243	0.686	rs7732768	chr5:142933619	C/T	cg13907255	chr5:142895549	NA	0.5	8.89	0.38	1.39e-17	Migraine;
LGG	cis	rs2361710	0.668	rs4889830	chr17:78114528	G/A	cg06718696	chr17:78121285	EIF4A3	0.44	6.99	0.31	9.71e-12	Reticulocyte fraction of red cells;Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Immature fraction of reticulocytes;
LGG	cis	rs847649	0.621	rs2222539	chr7:102674786	G/A	cg18108683	chr7:102477205	FBXL13	0.53	10.83	0.45	1.57e-24	Morning vs. evening chronotype;
LGG	cis	rs2921073	0.510	rs2976945	chr8:8270871	G/T	cg12253571	chr8:8283032	NA	-0.31	-6.75	-0.3	4.38e-11	Parkinson's disease;
LGG	cis	rs6582630	0.638	rs10880620	chr12:38517467	A/G	cg13010199	chr12:38710504	ALG10B	-0.56	-11.3	-0.46	2.68e-26	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7746199	0.736	rs13210634	chr6:27646492	A/G	cg06606381	chr12:133084897	FBRSL1	-1.24	-11.48	-0.47	5.12e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs55883249	1.000	rs17453724	chr2:9764001	A/G	cg23886495	chr2:9695866	ADAM17	0.67	9.64	0.41	3.56e-20	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg01411255	chr17:61851458	DDX42;CCDC47	-0.5	-8.43	-0.36	4.3e-16	Prudent dietary pattern;
LGG	cis	rs36051895	0.659	rs72699590	chr9:5041690	C/G	cg02405213	chr9:5042618	JAK2	-0.84	-16.06	-0.6	1.9e-46	Pediatric autoimmune diseases;
LGG	cis	rs6495122	0.699	rs4886410	chr15:75065644	G/C	cg10253484	chr15:75165896	SCAMP2	-0.49	-7.76	-0.34	5.42e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs1278769	0.735	rs12585036	chr13:113535741	C/T	cg00823993	chr13:113535758	ATP11A	0.65	9.8	0.41	9.92e-21	Interstitial lung disease;
LGG	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg06640241	chr16:89574553	SPG7	0.84	15.12	0.57	3e-42	Multiple myeloma (IgH translocation);
LGG	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.52	-0.33	2.9e-13	Personality dimensions;
LGG	cis	rs7312933	0.618	rs6582394	chr12:42686189	A/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.5	7.71	0.34	7.53e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.71	-0.41	2.04e-20	Bipolar disorder and schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12174498	chr8:80942140	MRPS28	0.43	7.15	0.32	3.39e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs3219090	0.566	rs6677172	chr1:226542114	G/C	cg17127702	chr1:226594323	PARP1	-0.31	-9.73	-0.41	1.79e-20	Melanoma;
LGG	cis	rs8053891	0.507	rs10852510	chr16:72026041	G/A	cg14768367	chr16:72042858	DHODH	0.38	6.83	0.3	2.71e-11	Coronary artery disease;
LGG	trans	rs916888	0.773	rs9896243	chr17:44826056	C/G	cg01341218	chr17:43662625	NA	0.87	15.33	0.58	3.35e-43	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1577917	0.958	rs6900436	chr6:86506288	T/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.53	-8.8	-0.38	2.76e-17	Response to antipsychotic treatment;
LGG	cis	rs1799949	1.000	rs11649954	chr17:41420035	A/G	cg25072359	chr17:41440525	NA	0.52	10.15	0.43	5.51e-22	Menopause (age at onset);
LGG	cis	rs10781543	0.776	rs4378078	chr9:139375962	A/G	cg14169450	chr9:139327907	INPP5E	0.38	6.88	0.3	1.98e-11	Monocyte percentage of white cells;
LGG	cis	rs6489882	0.867	rs6489869	chr12:113363922	A/C	cg25319449	chr12:113376135	OAS3	-0.4	-7.38	-0.32	7.38e-13	Chronic lymphocytic leukemia;
LGG	trans	rs7824557	0.542	rs4841567	chr8:11440019	G/A	cg16141378	chr3:129829833	LOC729375	0.47	11.36	0.47	1.47e-26	Retinal vascular caliber;
LGG	cis	rs36051895	0.632	rs2149552	chr9:5132838	A/G	cg02405213	chr9:5042618	JAK2	-0.79	-15.44	-0.58	1.1e-43	Pediatric autoimmune diseases;
LGG	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg18876405	chr7:65276391	NA	0.68	12.78	0.51	3.1e-32	Aortic root size;
LGG	cis	rs6426558	0.502	rs2813970	chr1:227410637	C/T	cg10327440	chr1:227177885	CDC42BPA	0.6	9.77	0.41	1.27e-20	Neutrophil percentage of white cells;
LGG	cis	rs10504229	0.683	rs7835498	chr8:58129780	A/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs2153535	0.541	rs1414352	chr6:8485547	A/C	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs1577917	0.883	rs2782263	chr6:86791307	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.42	-7.27	-0.32	1.54e-12	Response to antipsychotic treatment;
LGG	cis	rs13108904	0.935	rs4246685	chr4:1279727	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.75	15.64	0.59	1.44e-44	Obesity-related traits;
LGG	cis	rs826838	0.559	rs1843891	chr12:38617018	T/C	cg04568710	chr12:38710424	ALG10B	0.38	8.26	0.36	1.6e-15	Heart rate;
LGG	cis	rs782590	0.967	rs1975484	chr2:55803167	T/A	cg18811423	chr2:55921094	PNPT1	0.89	20.4	0.69	1.75e-66	Metabolic syndrome;
LGG	cis	rs4808199	0.948	rs2074301	chr19:19381715	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.12	0.31	4.22e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs497273	0.552	rs1179939	chr12:121326876	G/C	cg02419362	chr12:121203948	SPPL3	-0.48	-8.46	-0.37	3.54e-16	Systemic lupus erythematosus;
LGG	cis	rs8053891	0.615	rs2000999	chr16:72108093	G/A	cg23815491	chr16:72088622	HP	0.47	7.87	0.34	2.52e-14	Coronary artery disease;
LGG	cis	rs4665809	0.878	rs892448	chr2:26366205	A/G	cg26119090	chr2:26468346	HADHA;HADHB	-0.88	-14.78	-0.57	8.93e-41	Gut microbiome composition (summer);
LGG	cis	rs7937682	0.889	rs493810	chr11:111491888	G/T	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg08508337	chr8:144660607	NAPRT1	0.91	7.07	0.31	5.74e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs73001065	0.591	rs11668386	chr19:19531910	A/G	cg03709012	chr19:19516395	GATAD2A	0.97	10.96	0.45	5.04e-25	LDL cholesterol;
LGG	cis	rs4076764	0.958	rs6691127	chr1:163384831	T/C	cg24596788	chr1:163392923	NA	-0.72	-13.95	-0.54	3.5e-37	Motion sickness;
LGG	cis	rs9325144	0.647	rs7316392	chr12:39064381	T/G	cg26384229	chr12:38710491	ALG10B	-0.73	-13.82	-0.54	1.24e-36	Morning vs. evening chronotype;
LGG	cis	rs988958	0.565	rs13030802	chr2:42237344	T/C	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs7166081	1.000	rs8031500	chr15:67519040	C/T	cg18050959	chr15:68126178	NA	-0.37	-6.76	-0.3	4.09e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs17376456	0.825	rs35426871	chr5:93291613	C/T	cg25358565	chr5:93447407	FAM172A	1.28	15.82	0.59	2.29e-45	Diabetic retinopathy;
LGG	cis	rs8062405	0.755	rs12447461	chr16:28582941	C/A	cg16576597	chr16:28551801	NUPR1	0.43	10.29	0.43	1.61e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7923609	0.967	rs10761751	chr10:65154885	A/G	cg08743896	chr10:65200160	JMJD1C	-0.3	-6.69	-0.3	6.5e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs4819052	0.851	rs7276591	chr21:46680156	C/T	cg19498844	chr21:46707878	POFUT2;LOC642852	0.74	13.21	0.52	4.92e-34	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs2549003	1.000	rs6873426	chr5:131818631	G/T	cg21138405	chr5:131827807	IRF1	0.38	10.11	0.43	7.3e-22	Asthma (sex interaction);
LGG	cis	rs7590720	1.000	rs934156	chr2:216901482	C/T	cg12620499	chr2:216877984	MREG	-0.73	-13.08	-0.52	1.79e-33	Alcohol dependence;
LGG	cis	rs7945705	0.747	rs2653605	chr11:8993309	C/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.43	-8.96	-0.38	7.87e-18	Hemoglobin concentration;
LGG	cis	rs7659604	0.521	rs6822155	chr4:122673274	C/A	cg19671926	chr4:122722719	EXOSC9	0.48	7.46	0.33	4.2e-13	Type 2 diabetes;
LGG	cis	rs6502050	0.835	rs7220639	chr17:80146866	G/A	cg11859384	chr17:80120422	CCDC57	-0.44	-7.65	-0.33	1.21e-13	Life satisfaction;
LGG	cis	rs12143943	0.835	rs12730457	chr1:204548132	C/A	cg20240347	chr1:204465584	NA	-0.34	-7.46	-0.33	4.44e-13	Cognitive performance;
LGG	cis	rs12711979	0.509	rs10178286	chr2:3823821	A/G	cg17052675	chr2:3827356	NA	0.5	9.52	0.4	9.27e-20	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs4650994	0.571	rs6425486	chr1:178528822	G/A	cg19399532	chr1:178512495	C1orf220	-0.38	-7.31	-0.32	1.22e-12	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs10504229	0.683	rs73603874	chr8:58108340	G/A	cg08677398	chr8:58056175	NA	0.51	8.02	0.35	8.83e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs78456975	0.622	rs11888851	chr2:1518254	C/G	cg26248373	chr2:1572462	NA	-0.61	-7.89	-0.34	2.2e-14	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7044106	0.762	rs1470307	chr9:123433039	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.74	0.61	1.53e-49	Hip circumference adjusted for BMI;
LGG	cis	rs7192750	0.562	rs152838	chr16:72105702	C/T	cg06353428	chr16:71660113	MARVELD3	0.77	7.83	0.34	3.25e-14	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs503734	0.629	rs2553424	chr3:101103470	C/T	cg27318481	chr3:100970896	IMPG2	-0.36	-7.24	-0.32	1.89e-12	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs721917	0.525	rs2244001	chr10:81648569	G/A	cg25562619	chr10:81652821	NA	-0.36	-8.25	-0.36	1.6e-15	Chronic obstructive pulmonary disease;
LGG	cis	rs7412746	0.622	rs72704654	chr1:150826410	G/A	cg15448220	chr1:150897856	SETDB1	0.39	7.16	0.32	3.09e-12	Melanoma;
LGG	cis	rs1008375	0.932	rs6845288	chr4:17665498	A/T	cg16339924	chr4:17578868	LAP3	-0.65	-11.09	-0.46	1.59e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9311474	0.629	rs4282054	chr3:52566065	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.42	7.19	0.32	2.57e-12	Electroencephalogram traits;
LGG	cis	rs10463554	0.963	rs11955683	chr5:102326696	A/G	cg23492399	chr5:102201601	PAM	-0.53	-8.24	-0.36	1.74e-15	Parkinson's disease;
LGG	cis	rs722599	0.683	rs8014695	chr14:75301617	C/G	cg06637938	chr14:75390232	RPS6KL1	0.55	8.95	0.38	8.78e-18	IgG glycosylation;
LGG	cis	rs3749237	0.615	rs55957735	chr3:49438158	G/A	cg07636037	chr3:49044803	WDR6	0.6	10.46	0.44	3.81e-23	Resting heart rate;
LGG	cis	rs4006360	0.514	rs1588393	chr17:39247900	T/C	cg16985667	chr17:39306289	KRTAP4-5	-0.45	-10.0	-0.42	1.88e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7552404	0.655	rs5745336	chr1:76273519	G/A	cg03433033	chr1:76189801	ACADM	0.65	9.95	0.42	2.94e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9910055	0.529	rs400460	chr17:42182770	A/G	cg16434002	chr17:42200994	HDAC5	0.43	7.61	0.33	1.51e-13	Total body bone mineral density;
LGG	cis	rs208520	0.690	rs10455595	chr6:66738034	T/C	cg07460842	chr6:66804631	NA	0.96	17.95	0.64	4.53e-55	Exhaled nitric oxide output;
LGG	cis	rs7149337	0.837	rs10132658	chr14:51677599	C/T	cg23942311	chr14:51606299	NA	0.36	7.92	0.35	1.75e-14	Cancer;
LGG	cis	rs28735056	0.596	rs3744879	chr18:77679006	G/C	cg05491587	chr18:77659695	KCNG2	0.39	7.19	0.32	2.7e-12	Schizophrenia;
LGG	cis	rs4727027	0.754	rs917124	chr7:148851213	C/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	8.5	0.37	2.63e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs1552244	0.935	rs35586456	chr3:10116938	A/G	cg16606324	chr3:10149918	C3orf24	0.54	7.2	0.32	2.46e-12	Alzheimer's disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg09193981	chr12:6644606	GAPDH	0.38	6.9	0.31	1.73e-11	Obesity-related traits;
LGG	cis	rs7267979	1.000	rs6050573	chr20:25366065	C/G	cg06421707	chr20:25228305	PYGB	0.48	10.39	0.43	7.34e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs11992162	0.967	rs4841661	chr8:11832769	T/C	cg02002194	chr4:3960332	NA	-0.47	-8.99	-0.39	6.47e-18	Monocyte count;
LGG	cis	rs10504229	0.593	rs12216730	chr8:58003894	C/T	cg11062466	chr8:58055876	NA	0.44	7.06	0.31	6.13e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.8e-17	Lung cancer;
LGG	cis	rs35123781	0.696	rs356433	chr5:139071193	C/T	cg21230503	chr5:139085173	NA	0.31	7.22	0.32	2.11e-12	Schizophrenia;
LGG	cis	rs62238980	0.614	rs2018440	chr22:32433889	G/A	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs2935183	1	rs2935183	chr17:45607572	T/G	cg25173405	chr17:45401733	C17orf57	0.48	8.23	0.36	1.97e-15	Multiple sclerosis or amyotrophic lateral sclerosis;
LGG	cis	rs2576037	0.526	rs6507714	chr18:44519574	A/G	cg23302884	chr18:44338147	ST8SIA5	-0.34	-6.85	-0.3	2.33e-11	Personality dimensions;
LGG	cis	rs2832191	0.791	rs8134407	chr21:30476586	G/A	cg08807101	chr21:30365312	RNF160	0.85	17.33	0.63	3.05e-52	Dental caries;
LGG	cis	rs246180	0.521	rs30245	chr16:14378042	G/T	cg16694702	chr16:14394816	NA	-0.33	-6.75	-0.3	4.35e-11	Male-pattern baldness;
LGG	cis	rs3733585	0.699	rs7699609	chr4:9961059	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.74	0.34	6.35e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7312933	0.558	rs11181422	chr12:42718552	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.1	-0.35	4.89e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs10504229	0.953	rs17805380	chr8:58171128	C/A	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs929596	0.531	rs2741013	chr2:234509911	C/T	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.52	-8.25	-0.36	1.68e-15	Total bilirubin levels in HIV-1 infection;
LGG	cis	rs910316	0.967	rs119076	chr14:75572419	G/T	cg11812906	chr14:75593930	NEK9	-0.51	-9.65	-0.41	3.27e-20	Height;
LGG	cis	rs10504229	0.679	rs12375285	chr8:58040084	G/A	cg22535103	chr8:58192502	C8orf71	-0.77	-10.34	-0.43	1.12e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs8077889	1.000	rs17675122	chr17:41886190	A/G	cg26893861	chr17:41843967	DUSP3	0.93	15.6	0.59	2.06e-44	Triglycerides;
LGG	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.54	0.81	1.46e-108	Chronic sinus infection;
LGG	cis	rs2404602	1.000	rs12443137	chr15:76840832	G/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.8	-0.34	4.26e-14	Blood metabolite levels;
LGG	cis	rs896854	0.967	rs2879813	chr8:95960947	A/G	cg16049864	chr8:95962084	TP53INP1	-0.43	-9.58	-0.41	5.79e-20	Type 2 diabetes;
LGG	cis	rs3126085	0.736	rs11581433	chr1:152283236	T/C	cg26876637	chr1:152193138	HRNR	-0.52	-8.1	-0.35	4.76e-15	Atopic dermatitis;
LGG	cis	rs10504073	0.647	rs10105794	chr8:50012793	G/C	cg00325661	chr8:49890786	NA	0.69	13.45	0.53	4.6e-35	Blood metabolite ratios;
LGG	cis	rs12586317	0.620	rs28870452	chr14:35536878	C/A	cg16230307	chr14:35515116	FAM177A1	0.89	13.09	0.52	1.49e-33	Psoriasis;
LGG	trans	rs7395662	0.892	rs9667579	chr11:48730148	C/T	cg00717180	chr2:96193071	NA	0.41	7.27	0.32	1.56e-12	HDL cholesterol;
LGG	cis	rs4243830	0.737	rs11122091	chr1:6609559	C/A	cg22792644	chr1:6614718	TAS1R1;NOL9	-0.8	-12.66	-0.51	9.08e-32	Body mass index;
LGG	cis	rs875971	0.505	rs1167386	chr7:65513096	G/A	cg18876405	chr7:65276391	NA	-0.67	-12.57	-0.5	2.25e-31	Aortic root size;
LGG	cis	rs9910055	0.531	rs6503490	chr17:42246656	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.7	0.51	6.69e-32	Total body bone mineral density;
LGG	cis	rs61192259	0.840	rs4714161	chr6:38411359	G/T	cg07362130	chr6:38359646	BTBD9	-0.29	-6.73	-0.3	5.08e-11	Restless legs syndrome;
LGG	cis	rs7666738	0.925	rs34423396	chr4:99049031	T/A	cg05340658	chr4:99064831	C4orf37	0.44	6.97	0.31	1.07e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9487094	0.922	rs1321328	chr6:109976385	G/C	cg01125227	chr6:109776195	MICAL1	0.52	8.76	0.38	3.62e-17	Height;
LGG	cis	rs11148252	0.595	rs9526968	chr13:53240183	T/C	cg12458913	chr13:53173898	NA	0.88	20.67	0.69	1.02e-67	Lewy body disease;
LGG	cis	rs5769707	0.681	rs135879	chr22:50018651	C/T	cg06623630	chr22:50017776	C22orf34	-0.51	-10.28	-0.43	1.86e-22	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs274567	0.501	rs2631368	chr5:131705297	T/G	cg07395648	chr5:131743802	NA	0.48	9.88	0.42	5.3e-21	Blood metabolite levels;
LGG	cis	rs2074193	0.826	rs215347	chr12:47734161	A/G	cg02516419	chr12:47771422	NA	0.7	14.12	0.55	6.45e-38	Migraine with aura;
LGG	cis	rs1153858	1.000	rs1145081	chr15:45679667	C/G	cg21132104	chr15:45694354	SPATA5L1	0.7	10.37	0.43	8.87e-23	Homoarginine levels;
LGG	cis	rs13118159	0.550	rs4974611	chr4:1358449	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.48	7.63	0.33	1.35e-13	Longevity;
LGG	cis	rs2131877	0.830	rs60922537	chr3:194842785	C/G	cg07250128	chr3:194833983	C3orf21	0.42	7.02	0.31	7.93e-12	Non-small cell lung cancer;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg26174226	chr8:58114915	NA	-0.52	-7.65	-0.33	1.2e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs9388451	0.657	rs4895799	chr6:126052729	C/T	cg05039488	chr6:79577232	IRAK1BP1	-0.47	-8.43	-0.36	4.57e-16	Brugada syndrome;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg04863758	chr4:1303710	MAEA	-0.4	-6.82	-0.3	2.88e-11	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs2297930	chr6:150039496	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-10.09	-0.42	9.36e-22	Lung cancer;
LGG	cis	rs4253772	0.637	rs8139035	chr22:46651367	A/G	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	cis	rs13108904	0.935	rs2199956	chr4:1248919	A/G	cg02018176	chr4:1364513	KIAA1530	0.42	9.56	0.41	7.23e-20	Obesity-related traits;
LGG	cis	rs7635838	0.819	rs4684072	chr3:11514860	A/G	cg00170343	chr3:11313890	ATG7	0.4	6.8	0.3	3.24e-11	HDL cholesterol;
LGG	cis	rs1754541	1.000	rs625146	chr1:101624468	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.36	-6.67	-0.3	7.43e-11	Eosinophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Sum eosinophil basophil counts;
LGG	cis	rs2836950	0.565	rs2836934	chr21:40564885	A/C	cg11644478	chr21:40555479	PSMG1	-0.61	-10.27	-0.43	1.95e-22	Menarche (age at onset);
LGG	cis	rs9916302	0.904	rs8066704	chr17:37477218	C/T	cg07936489	chr17:37558343	FBXL20	0.85	16.07	0.6	1.68e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs9462027	0.628	rs9462015	chr6:34739726	T/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.27	-0.46	3.29e-26	Systemic lupus erythematosus;
LGG	cis	rs559928	1.000	rs641168	chr11:64146289	C/G	cg19465662	chr11:63993652	NUDT22;TRPT1	-0.53	-6.87	-0.3	2.06e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs72772090	0.539	rs2042386	chr5:96156783	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.92	0.31	1.51e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7615952	0.599	rs6766327	chr3:125723677	C/G	cg05084668	chr3:125655381	ALG1L	-0.57	-7.65	-0.34	1.16e-13	Blood pressure (smoking interaction);
LGG	cis	rs2066819	0.892	rs2066807	chr12:56740682	C/G	cg26714650	chr12:56694279	CS	-1.59	-16.49	-0.61	2.05e-48	Psoriasis vulgaris;
LGG	cis	rs61008539	0.853	rs10950611	chr7:861094	G/T	cg05535760	chr7:792225	HEATR2	-0.46	-7.97	-0.35	1.25e-14	Perceived unattractiveness to mosquitoes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01358551	chr19:47353761	AP2S1	0.44	7.5	0.33	3.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs7683537	0.725	rs28837443	chr4:185641497	G/A	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Systemic lupus erythematosus;
LGG	cis	rs9815354	0.812	rs17284313	chr3:41986787	G/T	cg03022575	chr3:42003672	ULK4	-0.82	-9.5	-0.4	1.17e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7937682	0.961	rs491937	chr11:111494947	A/T	cg19812747	chr11:111475976	SIK2	-0.49	-10.21	-0.43	3.24e-22	Primary sclerosing cholangitis;
LGG	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg11742103	chr11:62369870	EML3;MTA2	0.56	12.23	0.49	5.12e-30	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs11122272	0.735	rs2749708	chr1:231529610	G/A	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.38e-12	Hemoglobin concentration;
LGG	cis	rs514406	0.644	rs7529978	chr1:53204705	G/A	cg24675658	chr1:53192096	ZYG11B	0.6	13.08	0.52	1.78e-33	Monocyte count;
LGG	cis	rs1355223	0.583	rs2941060	chr11:34879154	G/A	cg11058730	chr11:34937778	PDHX;APIP	0.74	14.64	0.56	3.79e-40	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs858239	0.601	rs4440529	chr7:23168751	G/C	cg23682824	chr7:23144976	KLHL7	0.4	6.68	0.3	6.83e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs8170	0.603	rs7249329	chr19:17423373	G/T	cg04749549	chr19:17459798	NA	-0.39	-7.3	-0.32	1.28e-12	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs12210905	0.920	rs6911234	chr6:27086859	T/A	cg23155468	chr6:27110703	HIST1H2BK	-0.66	-7.95	-0.35	1.45e-14	Hip circumference adjusted for BMI;
LGG	cis	rs2404602	0.716	rs7174953	chr15:76906847	A/C	cg23625390	chr15:77176239	SCAPER	0.47	9.03	0.39	4.61e-18	Blood metabolite levels;
LGG	cis	rs2180341	0.920	rs6906717	chr6:127596782	C/A	cg27446573	chr6:127587934	RNF146	1.12	21.83	0.71	3.72e-73	Breast cancer;
LGG	cis	rs2153535	0.580	rs6929206	chr6:8447961	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.93	0.38	9.72e-18	Motion sickness;
LGG	trans	rs853679	0.607	rs34662244	chr6:28073881	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.95	-0.38	8.94e-18	Depression;
LGG	cis	rs4936894	0.500	rs7111729	chr11:124093172	C/G	cg27160556	chr11:124181099	OR8D1	-0.48	-11.23	-0.46	4.94e-26	Aging (time to death);
LGG	cis	rs35306767	0.903	rs11253475	chr10:907262	C/A	cg08847335	chr10:891726	LARP4B	-0.51	-9.17	-0.39	1.55e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs509477	0.775	rs273364	chr18:32594465	G/C	cg23791764	chr18:32556832	MAPRE2	0.47	7.56	0.33	2.14e-13	Cerebrospinal fluid AB1-42 levels;
LGG	cis	rs8031584	0.958	rs61997079	chr15:31238271	G/C	cg14298792	chr15:30685198	CHRFAM7A	-0.44	-6.87	-0.3	2.14e-11	Huntington's disease progression;
LGG	cis	rs798554	0.718	rs1636247	chr7:2881917	A/G	cg13628971	chr7:2884303	GNA12	0.55	11.14	0.46	1.08e-25	Height;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg26236440	chr2:113341947	CHCHD5	0.4	7.08	0.31	5.35e-12	Obesity-related traits;
LGG	cis	rs6500602	0.963	rs7201012	chr16:4480682	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.36	7.49	0.33	3.53e-13	Schizophrenia;
LGG	cis	rs9611565	0.694	rs5758368	chr22:41862288	C/T	cg06481639	chr22:41940642	POLR3H	-0.58	-8.68	-0.37	6.72e-17	Vitiligo;
LGG	cis	rs10751667	0.643	rs10751669	chr11:942344	C/G	cg22143635	chr11:980567	AP2A2	-0.42	-7.81	-0.34	3.95e-14	Alzheimer's disease (late onset);
LGG	cis	rs36051895	0.695	rs11794708	chr9:5023441	G/A	cg02405213	chr9:5042618	JAK2	-0.83	-14.59	-0.56	6.04e-40	Pediatric autoimmune diseases;
LGG	cis	rs1153858	0.945	rs7182300	chr15:45634928	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.5e-77	Homoarginine levels;
LGG	cis	rs3008870	0.920	rs2755253	chr1:67470843	C/T	cg08660285	chr1:67390436	MIER1;WDR78	0.86	19.37	0.67	1.21e-61	Lymphocyte percentage of white cells;
LGG	cis	rs7851660	0.874	rs1443436	chr9:100631298	T/A	cg13688889	chr9:100608707	NA	-0.58	-11.63	-0.48	1.27e-27	Strep throat;
LGG	cis	rs1801251	1.000	rs283471	chr2:233656627	G/A	cg25237894	chr2:233734115	C2orf82	0.63	11.59	0.47	1.92e-27	Coronary artery disease;
LGG	trans	rs8002861	0.875	rs12867890	chr13:44423088	A/G	cg12856521	chr11:46389249	DGKZ	-0.4	-6.87	-0.3	2.13e-11	Leprosy;
LGG	cis	rs45544231	0.593	rs1075367	chr16:52555002	G/A	cg09051775	chr16:52580266	TOX3	-0.4	-6.75	-0.3	4.32e-11	Restless legs syndrome;
LGG	trans	rs916888	0.773	rs199457	chr17:44795469	C/T	cg07870213	chr5:140052090	DND1	0.94	17.79	0.64	2.42e-54	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2273669	0.667	rs113477421	chr6:109310268	C/T	cg05315195	chr6:109294784	ARMC2	-0.66	-8.3	-0.36	1.14e-15	Prostate cancer;
LGG	cis	rs9322193	0.884	rs7743823	chr6:150170880	A/G	cg15971980	chr6:150254442	NA	0.44	8.23	0.36	1.87e-15	Lung cancer;
LGG	cis	rs919433	0.963	rs12469546	chr2:198178826	T/C	cg00792783	chr2:198669748	PLCL1	-0.45	-7.06	-0.31	6.22e-12	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6500395	0.963	rs6500404	chr16:48690083	C/T	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7937890	1.000	rs2970334	chr11:14329355	C/T	cg22961513	chr11:14280813	SPON1	0.35	8.5	0.37	2.6e-16	Mitochondrial DNA levels;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg21547190	chr19:33793141	CEBPA;LOC80054	-0.3	-6.76	-0.3	4.19e-11	Intelligence (multi-trait analysis);
LGG	cis	rs35110281	0.720	rs162394	chr21:44943550	C/G	cg01579765	chr21:45077557	HSF2BP	0.39	8.61	0.37	1.13e-16	Mean corpuscular volume;
LGG	cis	rs4132509	0.649	rs12038981	chr1:243866855	G/A	cg21452805	chr1:244014465	NA	0.95	10.23	0.43	2.71e-22	RR interval (heart rate);
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg26578617	chr4:90757533	SNCA	-0.45	-9.16	-0.39	1.74e-18	Dementia with Lewy bodies;
LGG	cis	rs5769765	1.000	rs738711	chr22:50282603	A/G	cg26441486	chr22:50317300	CRELD2	-0.41	-7.54	-0.33	2.51e-13	Schizophrenia;
LGG	cis	rs11098499	0.874	rs7661020	chr4:120106982	T/C	cg24375607	chr4:120327624	NA	0.58	9.5	0.4	1.11e-19	Corneal astigmatism;
LGG	cis	rs597539	0.652	rs488363	chr11:68658298	C/G	cg06028808	chr11:68637592	NA	0.73	12.51	0.5	3.8e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17376456	0.569	rs6879620	chr5:93119893	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	-0.7	-9.31	-0.4	5.06e-19	Diabetic retinopathy;
LGG	cis	rs9303401	0.659	rs36093395	chr17:56957357	C/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.77	0.57	9.82e-41	Cognitive test performance;
LGG	trans	rs1459104	0.866	rs12804916	chr11:54831763	G/A	cg03929089	chr4:120376271	NA	0.7	6.86	0.3	2.21e-11	Body mass index;
LGG	cis	rs66573146	0.656	rs66905212	chr4:6949508	G/C	cg26116260	chr4:7069785	GRPEL1	-0.97	-8.66	-0.37	7.88e-17	Granulocyte percentage of myeloid white cells;
LGG	cis	rs2011503	1.000	rs111406321	chr19:19637437	G/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	6.88	0.3	1.99e-11	Bipolar disorder;
LGG	cis	rs2120243	0.592	rs1456110	chr3:157106072	G/A	cg24825693	chr3:157122686	VEPH1	-0.48	-11.21	-0.46	5.63e-26	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs9910055	0.529	rs228749	chr17:42174570	A/G	cg09913183	chr17:42254507	C17orf65;ASB16	-0.45	-7.82	-0.34	3.56e-14	Total body bone mineral density;
LGG	trans	rs7246760	0.737	rs57296518	chr19:9819950	A/G	cg02900749	chr2:68251473	NA	-0.96	-10.33	-0.43	1.24e-22	Pursuit maintenance gain;
LGG	cis	rs10274279	0.614	rs12540318	chr7:157398102	C/T	cg09270525	chr7:157391030	PTPRN2	0.85	11.35	0.47	1.7e-26	Myopia (pathological);
LGG	cis	rs67311347	1.000	rs17078511	chr3:40396254	A/G	cg13683864	chr3:40499215	RPL14	-0.99	-20.36	-0.69	2.84e-66	Renal cell carcinoma;
LGG	cis	rs62238980	0.614	rs75142210	chr22:32398992	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs6502050	0.835	rs9674648	chr17:80096756	A/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.9	-0.34	2e-14	Life satisfaction;
LGG	cis	rs12477438	0.520	rs34766932	chr2:99737273	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.2	0.62	1.3e-51	Chronic sinus infection;
LGG	cis	rs243505	0.691	rs243486	chr7:148448221	A/C	cg18940274	chr7:148469757	CUL1	0.36	6.68	0.3	7.08e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11676348	0.808	rs12694430	chr2:219015799	T/C	cg00012203	chr2:219082015	ARPC2	-0.5	-8.79	-0.38	2.89e-17	Ulcerative colitis;
LGG	cis	rs11123170	0.650	rs2289897	chr2:113977454	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.68	10.88	0.45	1.08e-24	Renal function-related traits (BUN);
LGG	cis	rs6426558	0.515	rs7412928	chr1:227332148	C/T	cg10327440	chr1:227177885	CDC42BPA	-0.61	-10.07	-0.42	1.06e-21	Neutrophil percentage of white cells;
LGG	cis	rs7582180	0.663	rs2309800	chr2:100992086	C/T	cg14675211	chr2:100938903	LONRF2	0.61	10.78	0.45	2.43e-24	Intelligence (multi-trait analysis);
LGG	cis	rs9902453	0.838	rs9646438	chr17:28209091	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.67	13.0	0.52	3.65e-33	Coffee consumption (cups per day);
LGG	cis	rs2688608	0.592	rs13013	chr10:75562161	C/A	cg00564723	chr10:75632066	CAMK2G	-0.3	-6.77	-0.3	3.99e-11	Inflammatory bowel disease;
LGG	cis	rs6582630	0.502	rs11520261	chr12:38332019	T/G	cg26384229	chr12:38710491	ALG10B	0.84	18.9	0.66	1.81e-59	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs7312933	1.000	rs11181308	chr12:42445259	A/G	cg19980929	chr12:42632907	YAF2	0.35	7.62	0.33	1.42e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs4862750	0.872	rs9997374	chr4:187877549	T/A	cg22105103	chr4:187893119	NA	0.57	10.93	0.45	6.98e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6952808	1.000	rs12540579	chr7:1882227	C/A	cg13880726	chr7:1868755	MAD1L1	0.47	8.07	0.35	6e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs3099143	1.000	rs3102710	chr15:77061148	T/C	cg21673338	chr15:77095150	SCAPER	-0.66	-10.28	-0.43	1.88e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs936229	0.668	rs67411922	chr15:75187612	A/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-11.08	-0.46	1.8e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7681440	0.835	rs6532198	chr4:90798870	C/T	cg14346243	chr4:90757452	SNCA	-0.38	-7.68	-0.34	9.78e-14	Dementia with Lewy bodies;
LGG	cis	rs889398	0.641	rs9936723	chr16:69884854	G/A	cg00738113	chr16:70207722	CLEC18C	-0.27	-7.65	-0.34	1.17e-13	Body mass index;
LGG	cis	rs13118159	0.641	rs4974598	chr4:1313220	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.51	8.73	0.38	4.51e-17	Longevity;
LGG	cis	rs838147	0.844	rs8105137	chr19:49249888	G/A	cg13540341	chr19:49222985	MAMSTR	0.44	10.54	0.44	2.03e-23	Dietary macronutrient intake;
LGG	trans	rs1005277	0.540	rs2224248	chr10:38451886	A/G	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs10832963	1.000	rs10832956	chr11:18645668	A/G	cg20219074	chr11:18656078	SPTY2D1	0.81	15.61	0.59	1.99e-44	Breast cancer;
LGG	cis	rs2708977	0.933	rs2464914	chr2:97179828	A/G	cg01950434	chr2:97203154	ARID5A	-0.6	-9.58	-0.41	5.81e-20	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs651907	0.557	rs34376498	chr3:101480156	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.17	-0.32	2.9e-12	Colorectal cancer;
LGG	cis	rs4722166	0.630	rs2091115	chr7:22810166	G/T	cg05265849	chr7:22767390	IL6	0.37	7.09	0.31	4.98e-12	Lung cancer;
LGG	cis	rs769267	0.965	rs12460764	chr19:19431963	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.84	-0.54	1.06e-36	Tonsillectomy;
LGG	cis	rs2839186	0.900	rs56840278	chr21:47708933	T/G	cg12016809	chr21:47604291	C21orf56	0.48	8.25	0.36	1.7e-15	Testicular germ cell tumor;
LGG	cis	rs780096	0.506	rs780100	chr2:27652153	G/T	cg05484376	chr2:27715224	FNDC4	0.45	9.82	0.42	8.27e-21	Total body bone mineral density;
LGG	cis	rs360798	0.512	rs34104251	chr2:62995183	A/G	cg17519650	chr2:63277830	OTX1	-0.47	-7.57	-0.33	2.11e-13	Coronary artery disease;
LGG	cis	rs11190604	0.731	rs10883480	chr10:102163821	G/T	cg07080220	chr10:102295463	HIF1AN	-0.56	-9.81	-0.41	8.89e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8062405	1.000	rs62036617	chr16:28827498	T/C	cg09754948	chr16:28834200	ATXN2L	0.49	7.9	0.34	1.99e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7172689	1.000	rs7172611	chr15:81540969	A/G	cg11808699	chr15:81528661	IL16	-0.5	-10.24	-0.43	2.61e-22	Inattentive symptoms;
LGG	cis	rs1823874	0.581	rs11855419	chr15:100327480	A/G	cg16400843	chr15:100339927	C15orf51	-0.41	-6.77	-0.3	4e-11	IgG glycosylation;
LGG	cis	rs2120243	0.572	rs2305620	chr3:157127586	C/T	cg24825693	chr3:157122686	VEPH1	-0.59	-13.47	-0.53	4.06e-35	Hepatocellular carcinoma in hepatitis B infection;
LGG	cis	rs4242434	0.927	rs35952885	chr8:22491622	T/G	cg00599393	chr8:22457479	C8orf58	-0.46	-8.39	-0.36	6.04e-16	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs853679	0.517	rs3823180	chr6:28061744	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs3741151	0.773	rs7110369	chr11:73160946	C/A	cg17517138	chr11:73019481	ARHGEF17	0.89	8.79	0.38	3.04e-17	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs8053891	0.906	rs12926408	chr16:71994451	G/C	cg00732059	chr16:71740210	PHLPP2	-0.34	-6.78	-0.3	3.72e-11	Coronary artery disease;
LGG	cis	rs6977660	0.714	rs12333747	chr7:19814394	G/A	cg05791153	chr7:19748676	TWISTNB	0.75	10.57	0.44	1.48e-23	Thyroid stimulating hormone;
LGG	cis	rs17209837	1.000	rs17275514	chr7:87122030	A/G	cg00919237	chr7:87102261	ABCB4	-0.74	-11.57	-0.47	2.19e-27	Gallbladder cancer;
LGG	cis	rs11758351	1.000	rs2143346	chr6:26198449	C/G	cg06951627	chr6:26196580	NA	-0.52	-7.88	-0.34	2.4e-14	Gout;Renal underexcretion gout;
LGG	cis	rs4888262	0.545	rs4243108	chr16:74692453	A/G	cg01733217	chr16:74700730	RFWD3	-0.94	-18.13	-0.64	6.39e-56	Testicular germ cell tumor;
LGG	cis	rs17666538	0.585	rs6559065	chr8:623156	G/C	cg23958373	chr8:599963	NA	1.17	11.81	0.48	2.66e-28	IgG glycosylation;
LGG	trans	rs9818758	0.545	rs9853352	chr3:49813258	C/T	cg21659725	chr3:3221576	CRBN	0.69	7.29	0.32	1.38e-12	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs13108904	0.870	rs3775094	chr4:1238859	G/A	cg00684032	chr4:1343700	KIAA1530	0.43	8.34	0.36	8.49e-16	Obesity-related traits;
LGG	cis	rs796364	1.000	rs281762	chr2:200799201	C/G	cg23649088	chr2:200775458	C2orf69	0.62	8.15	0.35	3.34e-15	Schizophrenia;
LGG	cis	rs9322193	0.847	rs880246	chr6:150167108	G/A	cg07791516	chr6:150247246	NA	0.33	6.87	0.3	2.12e-11	Lung cancer;
LGG	trans	rs7777677	0.925	rs4726544	chr7:142367113	A/T	cg18540325	chr9:33795118	PRSS3	-0.4	-7.32	-0.32	1.11e-12	Alcoholic chronic pancreatitis;
LGG	cis	rs888194	0.601	rs2058806	chr12:109996343	C/A	cg19025524	chr12:109796872	NA	-0.35	-6.95	-0.31	1.28e-11	Neuroticism;
LGG	cis	rs10464366	0.560	rs12701692	chr7:39135551	A/G	cg10621924	chr7:39171070	POU6F2	0.4	8.36	0.36	7.6e-16	IgG glycosylation;
LGG	cis	rs10504229	0.683	rs10504225	chr8:58145121	A/T	cg26174226	chr8:58114915	NA	-0.59	-8.46	-0.37	3.41e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs11874712	1.000	rs2298787	chr18:43669980	T/C	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.02	-0.49	3.75e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg14926445	chr8:58193284	C8orf71	-0.92	-13.54	-0.53	1.92e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.591	rs721717	chr7:66130292	G/T	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	trans	rs116095464	0.558	rs2288457	chr5:231270	C/T	cg09048205	chr5:1608656	LOC728613	-0.48	-8.27	-0.36	1.47e-15	Breast cancer;
LGG	cis	rs9790314	0.846	rs899275	chr3:161042104	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-12.32	-0.5	2.23e-30	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.738	rs9342514	chr6:66591188	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	trans	rs116095464	0.850	rs10055295	chr5:243749	G/A	cg09048205	chr5:1608656	LOC728613	-0.49	-8.36	-0.36	7.59e-16	Breast cancer;
LGG	cis	rs11122272	0.735	rs2808583	chr1:231512587	G/C	cg10503236	chr1:231470652	EXOC8	-0.36	-6.95	-0.31	1.28e-11	Hemoglobin concentration;
LGG	cis	rs28655083	0.529	rs645878	chr16:77099974	G/A	cg01753188	chr16:77233325	SYCE1L;MON1B	0.4	6.93	0.31	1.39e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9783347	0.643	rs10741743	chr11:18347994	G/C	cg03595886	chr11:18357587	GTF2H1	-0.51	-12.64	-0.51	1.18e-31	Pancreatic cancer;
LGG	cis	rs6940638	0.744	rs858964	chr6:27142614	C/G	cg12826209	chr6:26865740	GUSBL1	-0.43	-7.18	-0.32	2.73e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2739330	0.828	rs2877178	chr22:24251517	C/T	cg12419862	chr22:24373484	LOC391322	-0.87	-17.48	-0.63	6.5e-53	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs908922	0.676	rs7530609	chr1:152526812	C/A	cg09873164	chr1:152488093	CRCT1	0.61	14.98	0.57	1.24e-41	Hair morphology;
LGG	cis	rs7618915	0.571	rs33964154	chr3:52596914	A/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.0	-0.31	9.01e-12	Bipolar disorder;
LGG	trans	rs4843747	0.749	rs12102841	chr16:88072574	C/G	cg26811252	chr16:29126840	RRN3P2	-0.74	-11.7	-0.48	6.85e-28	Menopause (age at onset);
LGG	cis	rs1801251	1.000	rs11555646	chr2:233599904	A/C	cg08000102	chr2:233561755	GIGYF2	0.57	9.26	0.4	7.72e-19	Coronary artery disease;
LGG	cis	rs2243480	1.000	rs160639	chr7:65579987	C/G	cg12463550	chr7:65579703	CRCP	0.79	8.77	0.38	3.32e-17	Diabetic kidney disease;
LGG	cis	rs2576037	0.562	rs477826	chr18:44397649	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.51	-8.6	-0.37	1.27e-16	Personality dimensions;
LGG	cis	rs10865541	0.902	rs12476309	chr2:3404845	C/T	cg11642891	chr2:3452563	TTC15	-0.47	-9.45	-0.4	1.63e-19	Obesity-related traits;
LGG	trans	rs1005277	0.505	rs10827836	chr10:38215441	A/G	cg17830980	chr10:43048298	ZNF37B	0.44	9.59	0.41	5.3e-20	Extrinsic epigenetic age acceleration;
LGG	cis	rs4330281	0.587	rs7632989	chr3:17462283	G/T	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.79e-11	Schizophrenia;
LGG	cis	rs7202877	0.706	rs247447	chr16:75486648	A/G	cg03315344	chr16:75512273	CHST6	-0.51	-6.92	-0.31	1.53e-11	Type 2 diabetes;Type 1 diabetes;
LGG	cis	rs250677	0.687	rs168750	chr5:148446756	A/G	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.16	-0.32	3.14e-12	Breast cancer;
LGG	cis	rs10262624	0.528	rs5029444	chr7:23737795	T/C	cg20363699	chr7:23626180	CLK2P	0.29	6.8	0.3	3.24e-11	Schizophrenia;
LGG	cis	rs7312933	0.558	rs1796384	chr12:42780568	G/A	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.5	-7.99	-0.35	1.06e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs2243480	1.000	rs7794661	chr7:65389730	T/C	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs62238980	0.614	rs45494991	chr22:32545762	C/T	cg00543991	chr22:32367038	NA	0.77	8.65	0.37	8.29e-17	Childhood ear infection;
LGG	cis	rs7681440	0.967	rs1372517	chr4:90755909	G/A	cg26578617	chr4:90757533	SNCA	-0.44	-8.81	-0.38	2.44e-17	Dementia with Lewy bodies;
LGG	cis	rs4696584	0.816	rs72731016	chr4:155410731	G/C	cg13738195	chr4:155413469	DCHS2	-0.38	-7.67	-0.34	1.03e-13	Folding of antihelix;
LGG	cis	rs763014	0.966	rs4984675	chr16:670117	T/C	cg00908189	chr16:619842	PIGQ	0.88	16.66	0.61	3.78e-49	Height;
LGG	cis	rs7172677	0.732	rs2289583	chr15:75311036	C/A	cg14664628	chr15:75095509	CSK	0.67	10.73	0.45	3.8e-24	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2479724	0.905	rs2251274	chr6:41839438	T/G	cg17623882	chr6:41773611	USP49	-0.52	-9.28	-0.4	6.38e-19	Menarche (age at onset);
LGG	cis	rs9326248	0.581	rs7120515	chr11:116991926	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.7	12.44	0.5	7.2e-31	Blood protein levels;
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg00713939	chr8:144660590	NAPRT1	0.9	7.09	0.31	5.19e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs2227564	0.794	rs2688607	chr10:75663736	C/T	cg00564723	chr10:75632066	CAMK2G	0.43	8.71	0.38	5.35e-17	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs1008375	1.000	rs10805358	chr4:17652450	A/C	cg02297831	chr4:17616191	MED28	0.49	9.26	0.4	7.7e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg21475434	chr5:93447410	FAM172A	0.71	7.25	0.32	1.72e-12	Diabetic retinopathy;
LGG	cis	rs1129187	0.686	rs6458313	chr6:42922018	A/G	cg14338887	chr6:42928500	GNMT	0.27	8.67	0.37	7.53e-17	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1408799	0.750	rs7466934	chr9:12619840	C/T	cg05274944	chr9:12693694	TYRP1	0.32	7.5	0.33	3.24e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs6997458	0.902	rs1472360	chr8:86305198	T/C	cg02393479	chr8:86352350	CA3	-0.32	-6.87	-0.3	2.06e-11	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs7904985	1.000	rs12358144	chr10:88114486	C/G	cg07322936	chr10:88137208	NA	-0.48	-7.14	-0.31	3.7e-12	Barrett's esophagus;
LGG	cis	rs873946	0.586	rs3793685	chr10:134569316	G/A	cg27297192	chr10:134578999	INPP5A	0.33	7.18	0.32	2.8e-12	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs981844	0.775	rs17371274	chr4:154738713	A/G	cg14289246	chr4:154710475	SFRP2	0.67	11.03	0.46	2.89e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.32	6.8	0.3	3.15e-11	Schizophrenia;
LGG	cis	rs62400317	0.859	rs10948219	chr6:45229307	A/T	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs2153535	0.580	rs7743418	chr6:8438128	A/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.63	0.51	1.24e-31	Motion sickness;
LGG	cis	rs2652834	0.851	rs10851723	chr15:63416335	G/T	cg05507819	chr15:63340323	TPM1	0.49	6.98	0.31	1.06e-11	HDL cholesterol;
LGG	cis	rs9880211	0.800	rs1872239	chr3:136503911	C/T	cg21827317	chr3:136751795	NA	-0.47	-6.91	-0.31	1.64e-11	Body mass index;Height;
LGG	trans	rs4332037	0.950	rs56403963	chr7:1946130	C/G	cg22232500	chr2:134024266	NCKAP5	0.68	9.28	0.4	6.48e-19	Bipolar disorder;
LGG	cis	rs708547	0.874	rs1718868	chr4:57881215	G/T	cg16868167	chr4:57843880	C4orf14;POLR2B	0.67	10.15	0.43	5.42e-22	Response to bleomycin (chromatid breaks);
LGG	cis	rs2463822	0.858	rs2513077	chr11:62105925	A/G	cg06239285	chr11:62104954	ASRGL1	-1.13	-15.82	-0.59	2.21e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs758324	0.812	rs4280859	chr5:131246941	A/T	cg06307176	chr5:131281290	NA	-0.53	-8.76	-0.38	3.62e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg17178900	chr1:205818956	PM20D1	0.58	12.91	0.51	8.93e-33	Menarche (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg00361696	chr5:139780805	ANKHD1;ANKHD1-EIF4EBP3	0.39	6.99	0.31	9.34e-12	Obesity-related traits;
LGG	cis	rs9916302	0.784	rs34473775	chr17:37396201	G/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.46	-0.47	5.94e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs34172651	0.517	rs12927710	chr16:24790282	A/C	cg02428538	chr16:24856791	SLC5A11	-0.71	-10.85	-0.45	1.32e-24	Intelligence (multi-trait analysis);
LGG	cis	rs873946	0.557	rs4880427	chr10:134591389	T/C	cg26818010	chr10:134567672	INPP5A	-0.75	-11.5	-0.47	4.24e-27	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4865875	1.000	rs4865873	chr5:54100027	A/G	cg22421804	chr5:54100067	NA	-0.51	-7.72	-0.34	7.13e-14	Sense of smell;
LGG	cis	rs8141529	0.748	rs5762881	chr22:29289346	C/A	cg02153584	chr22:29168773	CCDC117	0.6	9.77	0.41	1.29e-20	Lymphocyte counts;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19545348	chr1:211434133	RCOR3	0.47	7.95	0.35	1.48e-14	Gut microbiome composition (summer);
LGG	cis	rs6840360	0.593	rs2089811	chr4:152685171	C/T	cg22705602	chr4:152727874	NA	0.4	10.08	0.42	9.52e-22	Intelligence (multi-trait analysis);
LGG	cis	rs2273669	0.667	rs12202145	chr6:109357829	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.52	-0.37	2.34e-16	Prostate cancer;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg26451873	chr13:26829095	CDK8	0.41	7.26	0.32	1.65e-12	Bilirubin levels;
LGG	cis	rs12765878	1.000	rs9325507	chr10:105645622	C/T	cg11005552	chr10:105648138	OBFC1	1.04	26.81	0.78	3.01e-96	Coronary artery disease;
LGG	cis	rs7811142	1.000	rs73161762	chr7:100014846	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	14.69	0.56	2.31e-40	Platelet count;
LGG	cis	rs908922	0.676	rs533917	chr1:152518294	A/G	cg03606772	chr1:152487856	CRCT1	0.28	6.64	0.3	8.61e-11	Hair morphology;
LGG	cis	rs7312933	0.618	rs6582390	chr12:42634586	C/T	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.49	7.6	0.33	1.6e-13	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs6831352	0.918	rs2851249	chr4:100044822	T/C	cg12011299	chr4:100065546	ADH4	0.43	8.58	0.37	1.46e-16	Alcohol dependence;
LGG	cis	rs2597513	0.799	rs2731341	chr3:13562575	C/G	cg24006715	chr3:13568212	NA	0.64	10.57	0.44	1.57e-23	Hip circumference adjusted for BMI;Height;
LGG	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg10760299	chr15:45669010	GATM	0.4	7.95	0.35	1.48e-14	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs9478291	chr6:150050570	A/G	cg13206674	chr6:150067644	NUP43	0.68	16.14	0.6	8.25e-47	Lung cancer;
LGG	cis	rs7662987	0.517	rs1311618	chr4:100012612	A/G	cg13256891	chr4:100009986	ADH5	0.57	9.73	0.41	1.79e-20	Smoking initiation;
LGG	cis	rs1153858	1.000	rs7163720	chr15:45639374	G/A	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.73	0.34	6.88e-14	Homoarginine levels;
LGG	cis	rs10504229	1.000	rs17805332	chr8:58169798	A/G	cg02725872	chr8:58115012	NA	-0.76	-10.94	-0.45	6.25e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs1008375	0.646	rs13146455	chr4:17565617	T/G	cg18681998	chr4:17616180	MED28	-0.8	-15.02	-0.57	8.25e-42	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1799949	0.965	rs4793204	chr17:41279298	A/G	cg05368731	chr17:41323189	NBR1	0.95	18.72	0.66	1.21e-58	Menopause (age at onset);
LGG	cis	rs2204008	0.626	rs11520260	chr12:38330092	C/T	cg26384229	chr12:38710491	ALG10B	0.94	21.0	0.7	2.88e-69	Bladder cancer;
LGG	cis	rs11608355	0.521	rs6606707	chr12:109830241	T/G	cg19025524	chr12:109796872	NA	-0.58	-12.97	-0.52	4.88e-33	Neuroticism;
LGG	cis	rs2470578	0.792	rs2733502	chr3:17274422	C/T	cg20981856	chr3:17787350	NA	0.36	6.79	0.3	3.54e-11	Schizophrenia;
LGG	cis	rs9467160	0.559	rs2753911	chr6:24442288	C/T	cg20631270	chr6:24437470	GPLD1	0.52	9.18	0.39	1.41e-18	Liver enzyme levels;
LGG	cis	rs10464366	0.746	rs62442210	chr7:39146328	G/T	cg10621924	chr7:39171070	POU6F2	0.45	9.24	0.39	9.15e-19	IgG glycosylation;
LGG	cis	rs7618915	0.547	rs13085331	chr3:52627486	G/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.05	-0.31	6.65e-12	Bipolar disorder;
LGG	cis	rs9905704	0.624	rs8080071	chr17:57093825	C/T	cg05425664	chr17:57184151	TRIM37	0.45	7.2	0.32	2.48e-12	Testicular germ cell tumor;
LGG	cis	rs798554	0.524	rs2283784	chr7:2855337	T/C	cg18446336	chr7:2847575	GNA12	-0.32	-8.25	-0.36	1.7e-15	Height;
LGG	cis	rs3008870	0.536	rs2208576	chr1:67513401	C/G	cg02640540	chr1:67518911	SLC35D1	-0.52	-10.1	-0.42	8.6e-22	Lymphocyte percentage of white cells;
LGG	cis	rs2019137	0.560	rs6707386	chr2:113981022	G/A	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	12.95	0.52	6.08e-33	Lymphocyte counts;
LGG	cis	rs870825	0.860	rs72703521	chr4:185603080	T/C	cg04058563	chr4:185651563	MLF1IP	1.03	19.45	0.67	4.85e-62	Blood protein levels;
LGG	trans	rs1908814	0.541	rs7824267	chr8:11794279	G/T	cg16141378	chr3:129829833	LOC729375	-0.36	-8.02	-0.35	8.61e-15	Neuroticism;
LGG	cis	rs2820315	0.867	rs2819346	chr1:201882087	A/C	cg10061532	chr1:201886748	LMOD1	0.34	7.2	0.32	2.5e-12	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs473651	0.935	rs541128	chr2:239336449	A/G	cg21699342	chr2:239360505	ASB1	0.4	7.79	0.34	4.36e-14	Multiple system atrophy;
LGG	cis	rs12493885	0.769	rs57354204	chr3:153755718	C/T	cg12800244	chr3:153838788	SGEF	-0.72	-8.66	-0.37	8.11e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs55665837	1.000	rs12288873	chr11:14450465	C/T	cg19336497	chr11:14380999	RRAS2	-0.44	-8.75	-0.38	4.15e-17	Vitamin D levels;
LGG	cis	rs2976388	0.692	rs2585175	chr8:143781289	G/C	cg06565975	chr8:143823917	SLURP1	0.35	8.79	0.38	2.87e-17	Urinary tract infection frequency;
LGG	cis	rs7772486	0.875	rs1331645	chr6:146398407	C/G	cg23711669	chr6:146136114	FBXO30	0.39	6.81	0.3	3.02e-11	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11148252	0.774	rs6561666	chr13:52930045	A/G	cg12458913	chr13:53173898	NA	0.67	13.18	0.52	6.49e-34	Lewy body disease;
LGG	cis	rs12545109	0.800	rs2670054	chr8:57421616	C/T	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg11764359	chr7:65958608	NA	-0.73	-13.18	-0.52	6.43e-34	Aortic root size;
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg15133208	chr4:90757351	SNCA	-0.34	-7.67	-0.34	1.04e-13	Dementia with Lewy bodies;
LGG	cis	rs11148252	0.595	rs4885117	chr13:53153027	T/C	cg00495681	chr13:53174319	NA	0.81	17.18	0.62	1.47e-51	Lewy body disease;
LGG	cis	rs12541335	0.536	rs4266653	chr8:22169087	A/G	cg18135555	chr8:22132992	PIWIL2	0.38	9.65	0.41	3.39e-20	Hypertriglyceridemia;
LGG	cis	rs9814567	1.000	rs9289475	chr3:134236459	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.25	-0.52	3.28e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs6714710	0.557	rs17490429	chr2:98449024	G/A	cg26665480	chr2:98280029	ACTR1B	0.61	9.96	0.42	2.72e-21	Posterior cortical atrophy and Alzheimer's disease;
LGG	trans	rs8073060	0.544	rs1080352	chr17:34002362	A/G	cg19694781	chr19:47549865	TMEM160	-1.16	-18.06	-0.64	1.4e-55	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs28595532	0.920	rs56046676	chr4:119766733	A/G	cg21605333	chr4:119757512	SEC24D	1.49	15.04	0.57	6.65e-42	Cannabis dependence symptom count;
LGG	cis	rs7215564	0.908	rs35103651	chr17:78666732	T/C	cg16980736	chr17:78789706	RPTOR	-0.62	-8.15	-0.35	3.43e-15	Myopia (pathological);
LGG	cis	rs10159302	0.636	rs267644	chr1:57790529	C/G	cg23691223	chr1:57785036	DAB1	-0.43	-7.85	-0.34	2.88e-14	HIV-1 control;
LGG	cis	rs875971	1.000	rs6958484	chr7:65599446	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.95	-0.42	2.88e-21	Aortic root size;
LGG	cis	rs9354308	0.714	rs4710541	chr6:66584320	T/C	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs593982	0.920	rs1151501	chr11:65484883	A/G	cg08755490	chr11:65554678	OVOL1	0.69	8.13	0.35	3.82e-15	Atopic dermatitis;
LGG	cis	rs644799	0.562	rs671320	chr11:95578780	G/T	cg25622487	chr11:95524042	FAM76B;CEP57	0.69	12.23	0.49	5.54e-30	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg00405596	chr8:11794950	NA	0.65	11.5	0.47	4.17e-27	Neuroticism;
LGG	cis	rs1129187	0.755	rs3818554	chr6:42934620	C/T	cg05552183	chr6:42928497	GNMT	0.44	13.24	0.52	3.54e-34	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs4665809	0.590	rs3792007	chr2:26497541	C/T	cg26119090	chr2:26468346	HADHA;HADHB	1.08	20.65	0.69	1.25e-67	Gut microbiome composition (summer);
LGG	trans	rs11148252	0.777	rs9535889	chr13:52733634	C/G	cg18335740	chr13:41363409	SLC25A15	0.54	9.55	0.41	7.69e-20	Lewy body disease;
LGG	cis	rs4906332	1.000	rs7155822	chr14:103922390	A/G	cg26031613	chr14:104095156	KLC1	-0.53	-8.04	-0.35	7.44e-15	Coronary artery disease;
LGG	cis	rs708547	0.836	rs1625691	chr4:57845740	T/C	cg16868167	chr4:57843880	C4orf14;POLR2B	0.74	12.23	0.49	5.2e-30	Response to bleomycin (chromatid breaks);
LGG	cis	rs7737355	0.947	rs3776030	chr5:130776738	A/G	cg06307176	chr5:131281290	NA	-0.55	-9.23	-0.39	9.49e-19	Life satisfaction;
LGG	cis	rs7216064	1.000	rs7221651	chr17:65832390	A/G	cg12091567	chr17:66097778	LOC651250	0.6	8.8	0.38	2.83e-17	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs6977660	1.000	rs13231036	chr7:19806141	G/A	cg05791153	chr7:19748676	TWISTNB	0.58	8.73	0.38	4.79e-17	Thyroid stimulating hormone;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg03528353	chr17:61819722	STRADA	0.44	7.51	0.33	3.11e-13	Prudent dietary pattern;
LGG	cis	rs4950322	0.515	rs12060046	chr1:146720934	T/C	cg22381352	chr1:146742008	CHD1L	-0.47	-7.84	-0.34	3.18e-14	Protein quantitative trait loci;
LGG	cis	rs854765	0.547	rs9912096	chr17:17896673	A/C	cg05444541	chr17:17804740	TOM1L2	-0.69	-16.44	-0.61	3.52e-48	Total body bone mineral density;
LGG	cis	rs6762	0.748	rs1130663	chr11:837582	G/A	cg16425592	chr11:842748	TSPAN4;POLR2L	-0.64	-11.19	-0.46	7.01e-26	Mean platelet volume;
LGG	cis	rs7737355	0.773	rs31589	chr5:131004646	G/A	cg06307176	chr5:131281290	NA	0.53	8.75	0.38	4.1e-17	Life satisfaction;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg16060761	chr17:80687452	NA	-0.54	-9.81	-0.41	9.12e-21	Glycated hemoglobin levels;
LGG	trans	rs12579753	0.833	rs12579530	chr12:82163930	A/C	cg07923666	chr12:49932857	KCNH3	-0.5	-7.97	-0.35	1.26e-14	Resting heart rate;
LGG	cis	rs4731207	0.662	rs7357296	chr7:124532716	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.55	-0.33	2.4e-13	Cutaneous malignant melanoma;
LGG	cis	rs4731207	0.596	rs10954062	chr7:124636460	T/C	cg05630886	chr7:124431682	NA	-0.3	-6.83	-0.3	2.68e-11	Cutaneous malignant melanoma;
LGG	cis	rs6461049	0.765	rs10224497	chr7:2149967	A/G	cg14004847	chr7:1930337	MAD1L1	-0.49	-8.83	-0.38	2.16e-17	Schizophrenia;
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg07959490	chr17:80112427	CCDC57	-0.38	-7.01	-0.31	8.61e-12	Life satisfaction;
LGG	cis	rs28595532	0.920	rs116550416	chr4:119753467	A/C	cg14228332	chr4:119757509	SEC24D	1.01	10.19	0.43	3.82e-22	Cannabis dependence symptom count;
LGG	cis	rs651907	0.535	rs58658478	chr3:101511667	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.44	0.5	7.42e-31	Colorectal cancer;
LGG	cis	rs7552404	0.727	rs5745390	chr1:76306591	A/C	cg22875332	chr1:76189707	ACADM	0.57	8.63	0.37	9.7e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs7613875	0.600	rs2856238	chr3:50158191	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.42	7.24	0.32	1.83e-12	Body mass index;
LGG	cis	rs506338	0.517	rs530775	chr11:64426933	A/G	cg19395706	chr11:64412079	NRXN2	0.41	7.87	0.34	2.59e-14	Body mass index;Urate levels;
LGG	cis	rs62238980	0.614	rs77167216	chr22:32386313	G/C	cg00543991	chr22:32367038	NA	0.78	8.67	0.37	7.6e-17	Childhood ear infection;
LGG	cis	rs9308433	0.553	rs1048791	chr1:214511519	T/C	cg06198575	chr1:214491504	SMYD2	0.5	7.48	0.33	3.83e-13	IgG glycosylation;
LGG	cis	rs6089829	0.855	rs6062781	chr20:61667128	G/A	cg18188782	chr20:61659543	NA	0.4	6.8	0.3	3.27e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs8062405	0.964	rs7193733	chr16:28875482	A/G	cg07382826	chr16:28625726	SULT1A1	0.36	7.4	0.33	6.34e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs875971	0.862	rs6971059	chr7:66067032	A/G	cg23594656	chr7:65796392	TPST1	0.41	9.21	0.39	1.14e-18	Aortic root size;
LGG	cis	rs7928758	0.943	rs77478906	chr11:134264596	T/C	cg25213107	chr11:134282864	B3GAT1	1.19	14.23	0.55	2.21e-38	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs13108904	0.875	rs1564509	chr4:1236562	C/G	cg02018176	chr4:1364513	KIAA1530	0.37	8.43	0.36	4.54e-16	Obesity-related traits;
LGG	cis	rs10851478	0.558	rs17478694	chr15:49738542	C/G	cg08060515	chr15:49448048	GALK2;COPS2	0.41	7.34	0.32	9.65e-13	Oral cavity cancer;
LGG	trans	rs561341	0.505	rs2344319	chr17:30406189	G/C	cg20587970	chr11:113659929	NA	-1.35	-17.95	-0.64	4.37e-55	Hip circumference adjusted for BMI;
LGG	cis	rs2070488	1.000	rs13074025	chr3:38455704	C/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.83	17.37	0.63	1.99e-52	Electrocardiographic conduction measures;
LGG	cis	rs12478296	1.000	rs67535150	chr2:243046099	A/G	cg18898632	chr2:242989856	NA	-0.81	-9.97	-0.42	2.49e-21	Obesity-related traits;
LGG	cis	rs2290402	0.536	rs2061846	chr4:852484	A/G	cg09237302	chr4:906077	GAK	-0.43	-7.45	-0.33	4.67e-13	Type 2 diabetes;
LGG	cis	rs8062405	1.000	rs55830740	chr16:28847149	G/C	cg09754948	chr16:28834200	ATXN2L	0.48	7.7	0.34	8.14e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7394190	0.748	rs3740293	chr10:75406141	A/C	cg07699608	chr10:75541558	CHCHD1	0.49	6.91	0.31	1.62e-11	Incident atrial fibrillation;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg08035479	chr8:58172643	NA	-0.53	-8.11	-0.35	4.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.678	rs4724725	chr7:1214751	G/A	cg24642844	chr7:1081250	C7orf50	-0.63	-9.75	-0.41	1.54e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2084898	0.943	rs2077784	chr11:120024874	G/A	cg07435449	chr11:120005650	TRIM29	-0.67	-7.8	-0.34	4.12e-14	Stroke (pediatric);
LGG	cis	rs992157	1.000	rs4791	chr2:219138940	C/T	cg20019365	chr2:219134978	PNKD;AAMP	0.67	11.46	0.47	5.99e-27	Colorectal cancer;
LGG	cis	rs317689	0.581	rs315132	chr12:69761996	G/C	cg14784868	chr12:69753453	YEATS4	0.75	12.69	0.51	6.88e-32	Response to diuretic therapy;
LGG	cis	rs17376456	0.825	rs13155452	chr5:93164449	C/T	cg19507638	chr5:93509721	C5orf36	0.59	8.18	0.36	2.68e-15	Diabetic retinopathy;
LGG	cis	rs4660214	0.666	rs629093	chr1:39833503	A/G	cg18385671	chr1:39797026	MACF1	0.47	9.97	0.42	2.52e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10193935	0.786	rs13416119	chr2:42462930	A/G	cg27598129	chr2:42591480	NA	-0.57	-6.92	-0.31	1.54e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs514406	0.560	rs1889033	chr1:53211887	A/G	cg24675658	chr1:53192096	ZYG11B	0.61	12.76	0.51	3.59e-32	Monocyte count;
LGG	cis	rs2153535	0.601	rs4140585	chr6:8503298	T/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.24	0.43	2.56e-22	Motion sickness;
LGG	cis	rs9768139	0.708	rs6459858	chr7:158115055	A/G	cg02855558	chr7:158107723	PTPRN2	-0.4	-7.17	-0.32	2.96e-12	Calcium levels;
LGG	cis	rs10256972	0.685	rs10263665	chr7:1110628	A/G	cg26224354	chr7:1096374	C7orf50;GPR146	-0.4	-7.97	-0.35	1.27e-14	Longevity;Endometriosis;
LGG	cis	rs2075371	0.829	rs727202	chr7:133947942	A/G	cg11752832	chr7:134001865	SLC35B4	0.55	9.69	0.41	2.37e-20	Mean platelet volume;
LGG	cis	rs3858526	1.000	rs3858527	chr11:5959848	G/A	cg25319279	chr11:5960081	NA	-0.54	-8.53	-0.37	2.09e-16	DNA methylation (variation);
LGG	cis	rs2380220	0.541	rs72928277	chr6:96079745	G/T	cg04719120	chr6:96025338	MANEA	-0.55	-7.76	-0.34	5.36e-14	Behavioural disinhibition (generation interaction);
LGG	cis	rs131656	1	rs131656	chr22:21917450	G/A	cg05046821	chr22:21984468	YDJC	-0.39	-7.04	-0.31	7.13e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs981844	0.961	rs56148270	chr4:154660874	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.39	0.47	1.19e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg13206674	chr6:150067644	NUP43	0.41	8.63	0.37	9.71e-17	Testicular germ cell tumor;
LGG	trans	rs4512344	0.510	rs35181953	chr8:11435049	G/A	cg14979609	chr8:8086686	FLJ10661	0.28	6.71	0.3	5.56e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs12497850	0.897	rs6795025	chr3:49081247	T/C	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.78	-0.3	3.56e-11	Parkinson's disease;
LGG	cis	rs9560113	0.960	rs9560101	chr13:112173798	G/A	cg10483660	chr13:112241077	NA	0.34	6.76	0.3	4.27e-11	Menarche (age at onset);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg22605179	chr22:29664171	EWSR1;RHBDD3	0.4	7.12	0.31	4.1e-12	Obesity-related traits;
LGG	trans	rs61931739	0.500	rs11053274	chr12:34547605	G/A	cg13010199	chr12:38710504	ALG10B	0.67	12.91	0.51	8.59e-33	Morning vs. evening chronotype;
LGG	cis	rs9329221	0.527	rs10903328	chr8:10332167	G/C	cg21775007	chr8:11205619	TDH	0.46	7.08	0.31	5.54e-12	Neuroticism;
LGG	cis	rs11574514	0.744	rs7185536	chr16:67992164	A/G	cg09738193	chr16:67926317	PSKH1	-0.77	-7.28	-0.32	1.43e-12	Crohn's disease;
LGG	cis	rs13108904	0.870	rs13132584	chr4:1251504	G/T	cg06654118	chr4:1303317	MAEA	0.47	8.05	0.35	7.26e-15	Obesity-related traits;
LGG	cis	rs4363385	0.747	rs4478766	chr1:152984906	G/A	cg13444842	chr1:152974279	SPRR3	-0.44	-9.07	-0.39	3.34e-18	Inflammatory skin disease;
LGG	cis	rs9972944	0.756	rs2318868	chr17:63767592	G/T	cg07283582	chr17:63770753	CCDC46	-0.43	-8.34	-0.36	8.65e-16	Total body bone mineral density;
LGG	cis	rs41271473	1.000	rs41271473	chr1:228880296	G/A	cg00850481	chr1:228891306	NA	-0.48	-8.25	-0.36	1.71e-15	Chronic lymphocytic leukemia;
LGG	cis	rs12615966	0.651	rs72830476	chr2:105414655	A/C	cg16465502	chr2:105461796	NA	1.0	11.47	0.47	5.62e-27	Pancreatic cancer;
LGG	cis	rs6500602	0.702	rs11076834	chr16:4549583	C/G	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.42	8.98	0.39	6.98e-18	Schizophrenia;
LGG	trans	rs1814175	0.791	rs1722023	chr11:49908136	G/C	cg15704280	chr7:45808275	SEPT13	-1.07	-26.97	-0.78	5.72e-97	Height;
LGG	cis	rs2072499	0.966	rs6427304	chr1:156156789	A/G	cg25208724	chr1:156163844	SLC25A44	1.24	30.45	0.82	1.33e-112	Testicular germ cell tumor;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg10802521	chr3:52805072	NEK4	-0.42	-7.37	-0.32	8.06e-13	Bipolar disorder;
LGG	cis	rs2201728	0.714	rs1353621	chr4:100241575	T/C	cg07219303	chr4:100140905	ADH6	-0.36	-6.68	-0.3	6.7e-11	Cardiac Troponin-T levels;
LGG	cis	rs7954584	0.567	rs7132055	chr12:122346034	A/G	cg01765077	chr12:122356316	WDR66	-0.28	-7.69	-0.34	8.8e-14	Mean corpuscular volume;
LGG	cis	rs644799	0.930	rs587123	chr11:95560539	T/G	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.85	0.34	2.83e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2841277	0.708	rs11623422	chr14:105407031	A/G	cg21017887	chr14:105400489	NA	0.43	8.61	0.37	1.12e-16	Rheumatoid arthritis;
LGG	cis	rs13108904	0.901	rs1680073	chr4:1280337	G/A	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.28	-0.43	1.79e-22	Obesity-related traits;
LGG	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg17691542	chr6:26056736	HIST1H1C	0.54	9.78	0.41	1.15e-20	Height;
LGG	cis	rs1008375	0.863	rs4698632	chr4:17614894	T/C	cg04450456	chr4:17643702	FAM184B	0.33	6.88	0.3	1.95e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7107174	0.892	rs12281104	chr11:78046940	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.58	-0.33	1.9e-13	Testicular germ cell tumor;
LGG	cis	rs2066819	0.818	rs703830	chr12:56701872	T/C	cg26714650	chr12:56694279	CS	1.49	18.31	0.65	9.68e-57	Psoriasis vulgaris;
LGG	cis	rs796364	0.951	rs35618222	chr2:201065777	C/G	cg12253985	chr2:200820533	C2orf60;C2orf47	0.55	7.61	0.33	1.5700000000000001e-13	Schizophrenia;
LGG	trans	rs561341	1.000	rs501312	chr17:30329066	A/G	cg20587970	chr11:113659929	NA	-1.34	-23.95	-0.74	4.46e-83	Hip circumference adjusted for BMI;
LGG	cis	rs9549367	0.713	rs576463	chr13:113846614	C/T	cg00898013	chr13:113819073	PROZ	0.47	9.82	0.42	8.56e-21	Platelet distribution width;
LGG	cis	rs2243480	0.901	rs57126451	chr7:65416306	T/C	cg13147721	chr7:65941812	NA	-0.72	-8.93	-0.38	9.85e-18	Diabetic kidney disease;
LGG	cis	rs657075	0.697	rs3805668	chr5:131646588	G/A	cg07538946	chr5:131705188	SLC22A5	0.65	7.71	0.34	7.74e-14	Rheumatoid arthritis;
LGG	cis	rs12478296	0.901	rs67423532	chr2:243004719	A/G	cg18898632	chr2:242989856	NA	-0.74	-8.87	-0.38	1.56e-17	Obesity-related traits;
LGG	cis	rs4478037	1.000	rs4074416	chr3:33161729	A/G	cg19404215	chr3:33155277	CRTAP	0.87	11.08	0.46	1.79e-25	Major depressive disorder;
LGG	cis	rs6496044	0.611	rs6496055	chr15:86070688	A/G	cg10818794	chr15:86012489	AKAP13	-0.31	-6.69	-0.3	6.47e-11	Interstitial lung disease;
LGG	cis	rs10479542	0.806	rs4700835	chr5:178976313	A/G	cg09060608	chr5:178986726	RUFY1	0.46	8.16	0.35	3.19e-15	Lung cancer;
LGG	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg24189917	chr7:1970923	MAD1L1	-0.49	-7.41	-0.33	5.86e-13	Bipolar disorder;
LGG	cis	rs11096990	0.855	rs2711990	chr4:39151736	A/C	cg24403649	chr4:39172243	NA	-0.49	-7.94	-0.35	1.51e-14	Cognitive function;
LGG	cis	rs796364	1.000	rs281774	chr2:200814572	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.73	9.56	0.41	7.19e-20	Schizophrenia;
LGG	cis	rs9322193	0.962	rs4380763	chr6:149999222	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.05	-0.31	6.48e-12	Lung cancer;
LGG	cis	rs12421382	0.690	rs2716049	chr11:109609889	A/C	cg04861929	chr11:109293070	C11orf87	0.57	9.68	0.41	2.59e-20	Schizophrenia;
LGG	cis	rs7829975	0.501	rs74345345	chr8:8578435	C/G	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.28	-0.32	1.46e-12	Mood instability;
LGG	cis	rs2033711	0.870	rs7259841	chr19:58951123	T/C	cg26874164	chr19:58962979	ZNF324B	0.4	7.79	0.34	4.57e-14	Uric acid clearance;
LGG	cis	rs6723226	0.804	rs17428810	chr2:32736043	T/C	cg02381751	chr2:32503542	YIPF4	-0.68	-10.28	-0.43	1.8e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs9467711	0.606	rs2073531	chr6:26375256	A/G	cg01620082	chr3:125678407	NA	-0.63	-6.97	-0.31	1.11e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs992157	0.798	rs10206064	chr2:219157959	T/C	cg04731861	chr2:219085781	ARPC2	-0.44	-10.85	-0.45	1.36e-24	Colorectal cancer;
LGG	cis	rs7937682	0.575	rs1346180	chr11:111715570	G/C	cg09085632	chr11:111637200	PPP2R1B	1.0	20.25	0.69	8.95e-66	Primary sclerosing cholangitis;
LGG	cis	rs6500602	0.592	rs28789232	chr16:4447552	C/A	cg26783146	chr16:4423632	VASN;CORO7	-0.4	-7.16	-0.32	3.15e-12	Schizophrenia;
LGG	trans	rs7819412	0.511	rs35558344	chr8:11434232	C/T	cg06636001	chr8:8085503	FLJ10661	-0.59	-11.24	-0.46	4.55e-26	Triglycerides;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg04287289	chr16:89883240	FANCA	0.77	7.56	0.33	2.15e-13	Skin colour saturation;
LGG	cis	rs2224391	0.534	rs2753229	chr6:5246633	T/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.55	-7.31	-0.32	1.16e-12	Height;
LGG	cis	rs11649743	0.957	rs4795218	chr17:36078510	G/A	cg21250756	chr17:36077300	HNF1B	0.38	10.59	0.44	1.26e-23	Prostate cancer;Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12230513	0.732	rs61957764	chr12:55867916	G/A	cg19537932	chr12:55886519	OR6C68	-0.61	-10.98	-0.45	4.45e-25	Contrast sensitivity;
LGG	cis	rs11690935	0.632	rs9789538	chr2:172618474	G/C	cg13550731	chr2:172543902	DYNC1I2	0.7	14.08	0.55	9.54e-38	Schizophrenia;
LGG	cis	rs1005277	0.579	rs2472178	chr10:38384750	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.44	-6.93	-0.31	1.38e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2153535	0.580	rs6905237	chr6:8471790	A/T	cg23788917	chr6:8435910	SLC35B3	0.52	9.01	0.39	5.61e-18	Motion sickness;
LGG	cis	rs7133214	0.771	rs10842978	chr12:27925677	C/G	cg04279139	chr12:27925367	LOC100133893	0.34	7.4	0.33	6.62e-13	Gut microbiota (functional units);
LGG	cis	rs35110281	0.837	rs2838340	chr21:45076373	A/G	cg04455712	chr21:45112962	RRP1B	0.51	9.86	0.42	6.19e-21	Mean corpuscular volume;
LGG	cis	rs12530845	0.767	rs7784162	chr7:135305886	G/T	cg14938629	chr7:135305875	NUP205	-0.37	-7.25	-0.32	1.73e-12	Red blood cell traits;
LGG	cis	rs1046896	0.628	rs12452314	chr17:80723362	A/G	cg02711726	chr17:80685570	FN3KRP	-0.6	-11.07	-0.46	2.05e-25	Glycated hemoglobin levels;
LGG	cis	rs9322193	0.566	rs4869767	chr6:150245110	A/G	cg15971980	chr6:150254442	NA	-0.45	-7.15	-0.32	3.46e-12	Lung cancer;
LGG	cis	rs9911578	0.967	rs3826353	chr17:57075299	C/T	cg12560992	chr17:57184187	TRIM37	0.89	15.57	0.59	2.89e-44	Intelligence (multi-trait analysis);
LGG	cis	rs796364	0.806	rs203767	chr2:200902411	G/A	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs2952156	0.920	rs903502	chr17:37829604	C/T	cg07936489	chr17:37558343	FBXL20	-0.5	-8.33	-0.36	9.43e-16	Asthma;
LGG	cis	rs6582630	0.524	rs10785494	chr12:38532431	C/G	cg13010199	chr12:38710504	ALG10B	-0.54	-10.96	-0.45	5.03e-25	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs11098499	0.820	rs11737395	chr4:120520704	C/G	cg25214090	chr10:38739885	LOC399744	0.65	11.5	0.47	4.29e-27	Corneal astigmatism;
LGG	cis	rs3771570	0.786	rs62186378	chr2:242211554	G/A	cg21155796	chr2:242212141	HDLBP	0.76	9.57	0.41	6.25e-20	Prostate cancer;
LGG	cis	rs9831754	0.756	rs7653140	chr3:78419340	C/G	cg06138941	chr3:78371609	NA	-0.82	-16.08	-0.6	1.53e-46	Calcium levels;
LGG	cis	rs6582630	0.554	rs8189625	chr12:38401177	C/T	cg13010199	chr12:38710504	ALG10B	-0.53	-10.47	-0.44	3.55e-23	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs62025270	0.576	rs55639123	chr15:86160268	A/G	cg25843651	chr15:86329602	KLHL25	0.55	8.22	0.36	2.08e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs4650994	1.000	rs6660445	chr1:178528871	C/T	cg19399532	chr1:178512495	C1orf220	0.43	8.3	0.36	1.13e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4664304	1.000	rs55977890	chr2:160776866	C/T	cg03641300	chr2:160917029	PLA2R1	-0.43	-7.57	-0.33	2.03e-13	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2839186	0.872	rs2250213	chr21:47674275	G/A	cg13012494	chr21:47604986	C21orf56	0.54	9.32	0.4	4.93e-19	Testicular germ cell tumor;
LGG	trans	rs4295623	0.504	rs11250160	chr8:11592717	G/A	cg27411982	chr8:10470053	RP1L1	-0.38	-6.65	-0.3	8.29e-11	Morning vs. evening chronotype;
LGG	cis	rs6964587	0.967	rs34344935	chr7:91835436	G/A	cg17063962	chr7:91808500	NA	0.53	9.59	0.41	5.4e-20	Breast cancer;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg20808462	chr4:2243252	HAUS3	0.41	6.75	0.3	4.55e-11	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2204008	0.630	rs1283300	chr12:38150227	C/T	cg13010199	chr12:38710504	ALG10B	-0.54	-10.54	-0.44	1.96e-23	Bladder cancer;
LGG	cis	rs9487051	0.872	rs1111865	chr6:109610863	A/G	cg12927641	chr6:109611667	NA	0.38	7.16	0.32	3.18e-12	Reticulocyte fraction of red cells;
LGG	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg12654349	chr5:56205094	C5orf35	-0.62	-9.76	-0.41	1.35e-20	Initial pursuit acceleration;
LGG	cis	rs1577917	0.916	rs7759727	chr6:86518878	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.7	-0.48	7.11e-28	Response to antipsychotic treatment;
LGG	cis	rs2346177	0.513	rs1530625	chr2:46658067	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.62	-12.21	-0.49	6.59e-30	HDL cholesterol;
LGG	cis	rs4481887	1.000	rs10788775	chr1:248471945	C/G	cg01631408	chr1:248437212	OR2T33	-0.54	-9.81	-0.41	8.87e-21	Common traits (Other);
LGG	cis	rs752010	0.714	rs2148635	chr1:42082452	C/T	cg16096631	chr1:42092165	HIVEP3	-0.74	-21.57	-0.71	5.93e-72	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2114646	0.731	rs67019508	chr2:170638106	T/C	cg17598339	chr2:170624727	NA	0.35	6.73	0.3	5.15e-11	Obesity-related traits;
LGG	cis	rs738322	0.646	rs132972	chr22:38562056	T/C	cg25457927	chr22:38595422	NA	-0.35	-8.44	-0.37	4.01e-16	Cutaneous nevi;
LGG	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.39	6.88	0.3	1.95e-11	Personality dimensions;
LGG	cis	rs7618915	0.508	rs13065851	chr3:52644836	T/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.57	9.63	0.41	4.1e-20	Bipolar disorder;
LGG	cis	rs7143963	1.000	rs72704727	chr14:103357249	C/T	cg23020514	chr14:103360112	TRAF3	0.49	9.25	0.39	8.37e-19	Body mass index;
LGG	cis	rs6087990	0.806	rs992472	chr20:31385269	G/T	cg13636640	chr20:31349939	DNMT3B	0.93	20.16	0.68	2.35e-65	Ulcerative colitis;
LGG	cis	rs7107174	1.000	rs2511187	chr11:77985849	T/A	cg02023728	chr11:77925099	USP35	0.44	7.56	0.33	2.22e-13	Testicular germ cell tumor;
LGG	cis	rs13082711	0.522	rs574955	chr3:27351000	T/C	cg02860705	chr3:27208620	NA	0.58	11.02	0.46	2.95e-25	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs34467563	0.521	rs6992547	chr8:97329943	A/G	cg22138393	chr8:97340270	PTDSS1	0.31	7.95	0.35	1.39e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs11645898	0.935	rs11647125	chr16:72243277	T/C	cg14768367	chr16:72042858	DHODH	-0.73	-10.18	-0.43	4.08e-22	Blood protein levels;
LGG	cis	rs9596837	0.514	rs2785814	chr13:54275000	A/G	ch.13.53330881F	chr13:54432880	NA	-0.41	-6.69	-0.3	6.3e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs7819412	0.522	rs3021495	chr8:10994743	C/G	cg16141378	chr3:129829833	LOC729375	0.33	6.91	0.31	1.65e-11	Triglycerides;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.47	10.01	0.42	1.82e-21	Schizophrenia;
LGG	cis	rs457717	0.706	rs460374	chr5:75943853	A/T	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.31	6.9	0.31	1.72e-11	Hearing impairment;
LGG	cis	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg13010199	chr12:38710504	ALG10B	0.55	11.04	0.46	2.64e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs916888	0.610	rs199453	chr17:44800946	C/T	cg26656751	chr17:43910226	CRHR1	0.34	6.99	0.31	9.61e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs8079658	0.951	rs114298253	chr17:63833653	C/G	cg18091269	chr17:63822838	CCDC46	-0.41	-6.89	-0.31	1.78e-11	Post bronchodilator FEV1;
LGG	cis	rs2455799	0.574	rs2470534	chr3:15701054	C/G	cg16303742	chr3:15540471	COLQ	0.42	8.46	0.37	3.66e-16	Mean platelet volume;
LGG	cis	rs654950	0.806	rs941971	chr1:42040893	T/C	cg06885757	chr1:42089581	HIVEP3	-0.65	-15.39	-0.58	1.81e-43	Airway imaging phenotypes;
LGG	cis	rs11166927	0.548	rs9324514	chr8:140830241	A/G	cg16909799	chr8:140841666	TRAPPC9	0.67	14.97	0.57	1.35e-41	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs7208859	0.623	rs11652358	chr17:29205480	T/C	cg19761014	chr17:28927070	LRRC37B2	0.58	6.75	0.3	4.39e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs12421382	0.614	rs12575538	chr11:109390966	C/A	cg07142201	chr11:109293216	C11orf87	0.5	9.18	0.39	1.48e-18	Schizophrenia;
LGG	cis	rs4936894	0.500	rs10893161	chr11:124075848	T/C	cg27160556	chr11:124181099	OR8D1	-0.44	-10.02	-0.42	1.66e-21	Aging (time to death);
LGG	cis	rs4253772	0.550	rs55926596	chr22:46682955	C/T	cg00784671	chr22:46762841	CELSR1	-0.65	-7.41	-0.33	5.89e-13	LDL cholesterol;Cholesterol, total;
LGG	trans	rs503734	0.502	rs571391	chr3:100963154	C/T	cg00355188	chr10:134053962	STK32C	0.35	6.92	0.31	1.56e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs7582180	0.903	rs2309818	chr2:100898634	G/T	cg26150922	chr2:100937072	LONRF2	-0.53	-9.38	-0.4	2.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6815814	0.851	rs17582893	chr4:38886420	G/A	cg06935464	chr4:38784597	TLR10	0.56	7.97	0.35	1.21e-14	Breast cancer;
LGG	trans	rs9951602	0.512	rs9304070	chr18:76654890	A/C	cg02800362	chr5:177631904	HNRNPAB	0.78	13.58	0.53	1.33e-35	Obesity-related traits;
LGG	cis	rs2587949	0.615	rs1817574	chr3:4201685	T/A	cg16519197	chr3:4211558	NA	-0.34	-7.0	-0.31	8.84e-12	Periodontitis (DPAL);
LGG	trans	rs9650657	0.504	rs10108347	chr8:11033517	G/C	cg15556689	chr8:8085844	FLJ10661	-0.46	-8.39	-0.36	6.08e-16	Neuroticism;
LGG	cis	rs7769051	0.711	rs9493437	chr6:133088405	A/T	cg07930552	chr6:133119739	C6orf192	0.87	11.21	0.46	5.81e-26	Type 2 diabetes nephropathy;
LGG	cis	rs12476592	0.602	rs262525	chr2:63893158	A/G	cg17519650	chr2:63277830	OTX1	-0.44	-6.71	-0.3	5.53e-11	Childhood ear infection;
LGG	cis	rs1506403	0.945	rs371588	chr7:142819944	A/G	cg11323483	chr7:142828068	PIP	-0.39	-7.19	-0.32	2.7e-12	Cancer;
LGG	cis	rs1865760	0.865	rs1541987	chr6:25950397	A/G	cg18357526	chr6:26021779	HIST1H4A	-0.44	-7.31	-0.32	1.16e-12	Height;
LGG	cis	rs7647973	0.626	rs1352889	chr3:49652148	T/C	cg13072238	chr3:49761600	GMPPB	-0.54	-7.32	-0.32	1.1e-12	Menarche (age at onset);
LGG	cis	rs3126085	0.935	rs1390488	chr1:152199500	T/C	cg26876637	chr1:152193138	HRNR	0.56	9.02	0.39	4.98e-18	Atopic dermatitis;
LGG	cis	rs9398803	0.965	rs9388490	chr6:126704795	C/T	cg19875578	chr6:126661172	C6orf173	0.56	10.17	0.43	4.56e-22	Male-pattern baldness;
LGG	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.81	0.3	3.05e-11	Parkinson's disease;
LGG	trans	rs62103177	0.673	rs7242867	chr18:77603270	A/T	cg05926928	chr17:57297772	GDPD1	0.96	15.47	0.58	7.85e-44	Opioid sensitivity;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.5	8.53	0.37	2.07e-16	Longevity;
LGG	trans	rs9467711	0.606	rs68072215	chr6:26377927	T/C	cg01620082	chr3:125678407	NA	-0.63	-6.77	-0.3	3.87e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2070677	0.935	rs4582924	chr10:135409033	T/G	cg20169779	chr10:135381914	SYCE1	-1.04	-13.23	-0.52	4.2e-34	Gout;
LGG	cis	rs4853012	0.941	rs4852329	chr2:74354544	A/G	cg05890377	chr2:74357713	NA	0.52	9.77	0.41	1.27e-20	Gestational age at birth (maternal effect);
LGG	cis	rs10193935	1.000	rs10185742	chr2:42429666	A/G	cg27598129	chr2:42591480	NA	-0.62	-9.38	-0.4	3e-19	Colonoscopy-negative controls vs population controls;
LGG	cis	rs644799	0.965	rs687529	chr11:95545587	T/A	cg25622487	chr11:95524042	FAM76B;CEP57	0.79	13.92	0.54	4.72e-37	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9910055	0.960	rs9911991	chr17:42278916	G/C	cg10896456	chr17:42255109	ASB16;C17orf65	0.48	8.04	0.35	7.38e-15	Total body bone mineral density;
LGG	cis	rs7615952	0.599	rs67575510	chr3:125742355	C/G	cg05084668	chr3:125655381	ALG1L	-0.56	-7.53	-0.33	2.76e-13	Blood pressure (smoking interaction);
LGG	trans	rs9650657	0.547	rs11250099	chr8:10818657	C/T	cg15556689	chr8:8085844	FLJ10661	0.46	8.35	0.36	7.86e-16	Neuroticism;
LGG	cis	rs737693	1.000	rs72983513	chr11:102728985	T/C	cg14995062	chr11:102826570	MMP13	0.5	6.73	0.3	4.93e-11	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs561341	0.941	rs2428341	chr17:30317295	C/T	cg00745463	chr17:30367425	LRRC37B	-0.66	-9.85	-0.42	6.46e-21	Hip circumference adjusted for BMI;
LGG	cis	rs1008375	0.966	rs3775923	chr4:17585625	T/C	cg02297831	chr4:17616191	MED28	0.44	8.01	0.35	9.61e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs500492	0.542	rs421245	chr16:1074458	G/C	cg08273874	chr16:1060765	NA	-0.58	-8.27	-0.36	1.47e-15	Polycystic ovary syndrome;
LGG	cis	rs561341	0.528	rs11650908	chr17:30195425	T/C	cg13647721	chr17:30228624	UTP6	-0.67	-9.42	-0.4	2.13e-19	Hip circumference adjusted for BMI;
LGG	cis	rs4731207	0.623	rs28807101	chr7:124598826	A/G	cg05630886	chr7:124431682	NA	-0.32	-7.32	-0.32	1.11e-12	Cutaneous malignant melanoma;
LGG	cis	rs2228479	0.557	rs57071566	chr16:89889327	T/G	cg04287289	chr16:89883240	FANCA	0.89	8.45	0.37	3.86e-16	Skin colour saturation;
LGG	cis	rs2354432	0.556	rs59180647	chr1:146772062	C/T	cg25205988	chr1:146714368	CHD1L	-1.43	-14.66	-0.56	3.1e-40	Mitochondrial DNA levels;
LGG	cis	rs4969178	0.600	rs4969183	chr17:76393372	A/G	cg02836325	chr17:76403955	PGS1	-0.79	-17.36	-0.63	2.45e-52	HDL cholesterol levels;
LGG	trans	rs7395662	1.000	rs6485888	chr11:48605339	A/T	cg03929089	chr4:120376271	NA	-0.45	-7.23	-0.32	2.02e-12	HDL cholesterol;
LGG	cis	rs9788721	0.934	rs1051730	chr15:78894339	G/A	cg18825076	chr15:78729989	IREB2	-0.45	-7.2	-0.32	2.48e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg15704280	chr7:45808275	SEPT13	-0.5	-8.11	-0.35	4.44e-15	HDL cholesterol;
LGG	cis	rs9790314	0.846	rs4856714	chr3:160961824	T/C	cg04691961	chr3:161091175	C3orf57	-0.53	-12.27	-0.5	3.65e-30	Morning vs. evening chronotype;
LGG	trans	rs67340775	0.541	rs200973	chr6:27858421	A/G	cg01620082	chr3:125678407	NA	-0.66	-8.65	-0.37	8.39e-17	Lung cancer in ever smokers;
LGG	cis	rs2273669	0.667	rs11754955	chr6:109287459	A/G	cg05315195	chr6:109294784	ARMC2	-0.64	-8.34	-0.36	8.78e-16	Prostate cancer;
LGG	cis	rs17689437	0.671	rs1645929	chr16:68591350	A/G	cg02972257	chr16:68554789	NA	-0.44	-7.46	-0.33	4.34e-13	HIV-1 viral setpoint;Response to antipsychotic treatment in schizophrenia (reasoning);
LGG	cis	rs701145	0.585	rs357477	chr3:153892717	A/G	cg17054900	chr3:154042577	DHX36	0.78	9.16	0.39	1.68e-18	Coronary artery disease;
LGG	cis	rs9788333	0.962	rs12584792	chr13:21887208	C/T	cg19500098	chr13:21900506	NA	0.42	8.45	0.37	3.83e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6912958	0.781	rs7757636	chr6:88256092	T/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.5	-8.88	-0.38	1.46e-17	Monocyte percentage of white cells;
LGG	cis	rs9487094	0.670	rs12197180	chr6:109821890	A/T	cg01125227	chr6:109776195	MICAL1	0.44	7.71	0.34	7.71e-14	Height;
LGG	cis	rs754423	0.532	rs941625	chr14:52547735	A/G	cg06782686	chr14:52535964	NID2	-0.29	-6.72	-0.3	5.43e-11	Craniofacial microsomia;
LGG	cis	rs1062746	0.771	rs10514621	chr16:87369578	G/T	cg02258303	chr16:87377426	FBXO31	-0.59	-11.94	-0.49	7.84e-29	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-9.46	-0.4	1.58e-19	Skin colour saturation;
LGG	cis	rs7133214	0.771	rs12372599	chr12:27922419	G/A	cg04279139	chr12:27925367	LOC100133893	-0.33	-7.03	-0.31	7.42e-12	Gut microbiota (functional units);
LGG	cis	rs2115536	0.730	rs12898642	chr15:80182050	T/C	cg11839771	chr15:80205821	ST20	-0.37	-8.18	-0.36	2.84e-15	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs5762813	0.561	rs73170679	chr22:29271088	G/T	cg15103426	chr22:29168792	CCDC117	0.64	6.7	0.3	6.21e-11	Hematocrit;Hemoglobin concentration;
LGG	cis	rs9308731	0.966	rs3827536	chr2:111920741	G/T	cg26001287	chr2:111877753	BCL2L11	-0.39	-7.85	-0.34	2.92e-14	Chronic lymphocytic leukemia;
LGG	cis	rs1555322	0.530	rs2297789	chr20:33867248	A/T	cg03689076	chr20:33865952	NA	0.62	8.01	0.35	9.16e-15	Attention deficit hyperactivity disorder;
LGG	cis	rs9397585	0.588	rs9371676	chr6:153445965	C/A	cg17707550	chr6:153380415	RGS17	0.45	9.99	0.42	2.06e-21	Body mass index;
LGG	cis	rs2859741	0.528	rs3753776	chr1:37480144	C/T	cg09363841	chr1:37513479	NA	-0.57	-11.39	-0.47	1.15e-26	Forced expiratory volume in 1 second (environmental tobacco smoke interaction);
LGG	trans	rs877282	0.891	rs11253406	chr10:796297	G/A	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs9814567	1.000	rs9968172	chr3:134231251	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.08	0.52	1.7e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg22535103	chr8:58192502	C8orf71	-1.02	-14.57	-0.56	7.68e-40	Developmental language disorder (linguistic errors);
LGG	cis	rs1728785	0.892	rs9928950	chr16:68557114	G/A	cg02972257	chr16:68554789	NA	0.65	9.23	0.39	9.97e-19	Ulcerative colitis;
LGG	cis	rs7937682	0.883	rs1789351	chr11:111456436	T/A	cg19812747	chr11:111475976	SIK2	-0.49	-10.3	-0.43	1.49e-22	Primary sclerosing cholangitis;
LGG	cis	rs9322193	0.962	rs2275045	chr6:150163911	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.14	-0.31	3.72e-12	Lung cancer;
LGG	cis	rs6665290	0.935	rs1929864	chr1:227195500	T/G	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs7089973	0.872	rs11818114	chr10:116634878	G/C	cg08188268	chr10:116634841	FAM160B1	0.34	7.55	0.33	2.42e-13	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs11650494	0.908	rs11650087	chr17:47362923	T/A	cg08112188	chr17:47440006	ZNF652	1.33	15.73	0.59	5.36e-45	Prostate cancer;
LGG	cis	rs35110281	0.744	rs230644	chr21:44917183	C/T	cg04455712	chr21:45112962	RRP1B	-0.54	-10.27	-0.43	1.97e-22	Mean corpuscular volume;
LGG	cis	rs651907	0.935	rs2929922	chr3:101587934	A/T	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.38	7.37	0.32	7.89e-13	Colorectal cancer;
LGG	cis	rs739401	0.572	rs739400	chr11:3016520	G/A	cg05729581	chr11:3078854	CARS	-0.52	-8.8	-0.38	2.65e-17	Longevity;
LGG	cis	rs9322193	0.962	rs7818	chr6:150132092	A/G	cg00424166	chr6:150045504	NUP43	-0.33	-6.99	-0.31	9.55e-12	Lung cancer;
LGG	cis	rs2354432	0.556	rs7516165	chr1:146866418	G/T	cg25205988	chr1:146714368	CHD1L	1.19	11.64	0.48	1.25e-27	Mitochondrial DNA levels;
LGG	cis	rs11098499	0.530	rs114866537	chr4:120258608	A/T	cg09307838	chr4:120376055	NA	0.67	11.64	0.48	1.23e-27	Corneal astigmatism;
LGG	trans	rs11992162	0.573	rs13264994	chr8:11782759	G/A	cg16141378	chr3:129829833	LOC729375	0.32	7.28	0.32	1.48e-12	Monocyte count;
LGG	cis	rs9815354	1.000	rs9839399	chr3:41928044	G/A	cg03022575	chr3:42003672	ULK4	-0.64	-8.25	-0.36	1.69e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2576037	0.526	rs2571024	chr18:44557877	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-8.06	-0.35	6.56e-15	Personality dimensions;
LGG	cis	rs2404602	0.692	rs58361452	chr15:76973372	T/C	cg23625390	chr15:77176239	SCAPER	0.47	9.13	0.39	2.11e-18	Blood metabolite levels;
LGG	cis	rs1568889	1.000	rs11604085	chr11:28141002	G/A	cg06544937	chr11:28130018	METT5D1;KIF18A	0.76	14.15	0.55	4.94e-38	Bipolar disorder;
LGG	cis	rs13108904	0.967	rs4642180	chr4:1278914	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg06925236	chr11:68039653	C11orf24	0.56	8.92	0.38	1.06e-17	Gut microbiome composition (summer);
LGG	cis	rs10504229	0.683	rs62621195	chr8:58133964	G/A	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs4853012	0.887	rs2280644	chr2:74358411	G/A	cg19729930	chr2:74357872	NA	0.51	10.3	0.43	1.53e-22	Gestational age at birth (maternal effect);
LGG	cis	rs10911251	0.546	rs3359	chr1:183112041	G/C	cg07928641	chr1:182991847	LAMC1	0.44	8.76	0.38	3.69e-17	Colorectal cancer;
LGG	cis	rs12477438	0.501	rs11683188	chr2:99724512	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	1.14	29.2	0.81	4.65e-107	Chronic sinus infection;
LGG	cis	rs8062405	1.000	rs7498665	chr16:28883241	A/G	cg09754948	chr16:28834200	ATXN2L	0.48	7.67	0.34	9.9e-14	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs988958	0.530	rs12712818	chr2:42236321	C/T	cg27428208	chr2:42229179	NA	0.49	7.73	0.34	6.78e-14	Hypospadias;
LGG	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg27432699	chr2:27873401	GPN1	0.7	14.26	0.55	1.64e-38	Oral cavity cancer;
LGG	cis	rs7945718	1.000	rs7945718	chr11:12748819	A/G	cg25843174	chr11:12811716	TEAD1	0.41	8.43	0.36	4.37e-16	Educational attainment (years of education);
LGG	cis	rs4820294	0.669	rs7287340	chr22:38054325	C/T	cg21798802	chr22:38057573	PDXP	0.39	8.51	0.37	2.38e-16	Fat distribution (HIV);
LGG	cis	rs11155671	0.530	rs2342770	chr6:150216685	C/T	cg07701084	chr6:150067640	NUP43	0.43	7.91	0.35	1.86e-14	Testicular germ cell tumor;
LGG	cis	rs644799	1.000	rs596277	chr11:95566886	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2280630	0.898	rs1828678	chr3:39195517	C/G	cg01426195	chr3:39028469	NA	-0.48	-9.19	-0.39	1.38e-18	Verbal declarative memory;
LGG	cis	rs796364	0.951	rs281769	chr2:200809709	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.32	0.4	4.71e-19	Schizophrenia;
LGG	cis	rs56011263	0.687	rs4690188	chr4:703930	G/C	cg17689763	chr4:710664	PCGF3	-0.8	-16.74	-0.61	1.57e-49	White blood cell count;
LGG	cis	rs858239	0.600	rs10256524	chr7:23144947	T/C	cg23682824	chr7:23144976	KLHL7	0.45	7.8	0.34	4.12e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs79976124	0.837	rs75346757	chr6:66648386	A/T	cg07460842	chr6:66804631	NA	0.73	12.56	0.5	2.52e-31	Type 2 diabetes;
LGG	cis	rs62064224	0.614	rs728718	chr17:30708960	T/G	cg18200150	chr17:30822561	MYO1D	0.48	9.15	0.39	1.76e-18	Schizophrenia;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.47	8.65	0.37	8.43e-17	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09293699	chr16:81040972	CENPN;C16orf61	0.48	7.78	0.34	4.6e-14	Cognitive performance;
LGG	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg19077165	chr18:44547161	KATNAL2	-0.5	-8.94	-0.38	9.37e-18	Educational attainment;
LGG	cis	rs3820068	0.656	rs72645829	chr1:15889748	A/G	cg05660106	chr1:15850417	CASP9	1.13	23.72	0.74	5.7e-82	Systolic blood pressure;
LGG	cis	rs1451375	0.698	rs56233242	chr7:50634053	C/A	cg20336341	chr7:50628841	DDC	0.35	6.79	0.3	3.48e-11	Malaria;
LGG	cis	rs7659604	0.502	rs13108419	chr4:122687238	A/G	cg19748678	chr4:122722346	EXOSC9	-0.52	-9.4	-0.4	2.53e-19	Type 2 diabetes;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg07414097	chr2:232646663	PDE6D	0.46	7.38	0.32	7.46e-13	Cognitive performance;
LGG	cis	rs10256972	0.521	rs7811577	chr7:1102829	C/G	cg09177884	chr7:1199841	ZFAND2A	-0.51	-8.95	-0.38	8.77e-18	Longevity;Endometriosis;
LGG	cis	rs17655565	1.000	rs2276399	chr12:52705269	G/A	cg08257133	chr12:52711352	KRT83	0.56	7.89	0.34	2.22e-14	Plasma amyloid beta peptide concentrations (ABx-42);
LGG	cis	rs7615952	0.641	rs12488180	chr3:125782236	C/T	cg06494592	chr3:125709126	NA	-0.53	-6.77	-0.3	3.95e-11	Blood pressure (smoking interaction);
LGG	cis	rs2839186	0.869	rs17176513	chr21:47682428	A/G	cg08742575	chr21:47604166	C21orf56	0.48	8.27	0.36	1.42e-15	Testicular germ cell tumor;
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.57	-9.64	-0.41	3.58e-20	Obesity-related traits;
LGG	cis	rs17401966	0.838	rs61775885	chr1:10281445	T/C	cg19773385	chr1:10388646	KIF1B	-0.5	-10.5	-0.44	2.88e-23	Hepatocellular carcinoma;
LGG	cis	rs7618915	0.532	rs13060675	chr3:52674300	T/G	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.65	0.37	8.54e-17	Bipolar disorder;
LGG	trans	rs7939886	0.920	rs79521305	chr11:55811332	G/A	cg03929089	chr4:120376271	NA	0.82	8.52	0.37	2.26e-16	Myopia (pathological);
LGG	trans	rs9467711	0.606	rs34273322	chr6:26415409	T/A	cg08344181	chr3:125677491	NA	-0.63	-7.2	-0.32	2.41e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12477438	0.765	rs62154638	chr2:99639584	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs350251	0.651	rs17216341	chr16:12158825	C/T	cg02910054	chr16:12241554	SNX29	-0.4	-6.87	-0.3	2.02e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9487094	0.644	rs1960325	chr6:109913308	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.02	0.35	8.96e-15	Height;
LGG	cis	rs2839186	0.584	rs2032111	chr21:47904569	G/A	cg05896524	chr21:47604654	C21orf56	0.46	7.63	0.33	1.37e-13	Testicular germ cell tumor;
LGG	trans	rs9467711	0.559	rs6920256	chr6:26537801	G/A	cg06606381	chr12:133084897	FBRSL1	-0.81	-8.55	-0.37	1.82e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12478296	1.000	rs73007138	chr2:243007041	C/T	cg06360820	chr2:242988706	NA	-1.1	-12.88	-0.51	1.14e-32	Obesity-related traits;
LGG	cis	rs4780401	0.933	rs12926451	chr16:11819569	A/C	cg01061890	chr16:11836724	TXNDC11	0.44	7.4	0.33	6.52e-13	Rheumatoid arthritis;
LGG	cis	rs17021463	0.676	rs62320932	chr4:95307037	C/T	cg11021082	chr4:95130006	SMARCAD1	0.4	6.89	0.31	1.8e-11	Testicular germ cell tumor;
LGG	cis	rs116095464	0.558	rs9312979	chr5:222057	A/C	cg22496380	chr5:211416	CCDC127	-1.33	-18.47	-0.65	1.75e-57	Breast cancer;
LGG	cis	rs916888	0.697	rs199516	chr17:44856485	C/T	cg20120463	chr17:44301886	NA	0.45	7.06	0.31	6.03e-12	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6066825	0.555	rs4810849	chr20:47289944	C/T	cg18078177	chr20:47281410	PREX1	0.5	8.27	0.36	1.39e-15	Colorectal cancer;
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.44e-16	Life satisfaction;
LGG	cis	rs7552404	0.921	rs10873685	chr1:76218818	A/C	cg22875332	chr1:76189707	ACADM	0.62	10.25	0.43	2.39e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9926296	0.605	rs12599180	chr16:89839306	C/T	cg04287289	chr16:89883240	FANCA	-0.76	-15.23	-0.58	9.19e-43	Vitiligo;
LGG	cis	rs7659604	0.540	rs7698889	chr4:122671324	G/T	cg19671926	chr4:122722719	EXOSC9	0.47	7.15	0.32	3.5e-12	Type 2 diabetes;
LGG	cis	rs2576037	0.526	rs10853544	chr18:44474194	T/C	cg23302884	chr18:44338147	ST8SIA5	-0.41	-8.31	-0.36	1.05e-15	Personality dimensions;
LGG	cis	rs1008375	0.863	rs7680984	chr4:17600884	A/G	cg16339924	chr4:17578868	LAP3	0.65	11.1	0.46	1.49e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.863	rs6858592	chr4:120458692	G/A	cg09307838	chr4:120376055	NA	0.78	13.09	0.52	1.56e-33	Corneal astigmatism;
LGG	cis	rs6502050	0.805	rs9915071	chr17:80119138	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs6071166	0.901	rs6027421	chr20:37332259	C/A	cg10737118	chr20:37354790	SLC32A1	-0.4	-6.96	-0.31	1.17e-11	circulating leptin levels adjusted for BMI;circulating leptin levels;
LGG	trans	rs7829975	0.626	rs332040	chr8:8730488	G/A	cg16141378	chr3:129829833	LOC729375	-0.43	-10.33	-0.43	1.16e-22	Mood instability;
LGG	cis	rs561341	0.609	rs7209493	chr17:30197323	A/G	cg13647721	chr17:30228624	UTP6	-0.73	-9.42	-0.4	2.22e-19	Hip circumference adjusted for BMI;
LGG	cis	rs17854409	0.881	rs12625401	chr20:61472939	A/T	cg06598544	chr20:61472147	COL9A3	-0.9	-10.18	-0.43	4.3e-22	Obesity-related traits;
LGG	cis	rs514406	0.679	rs11585495	chr1:53244331	T/C	cg08859206	chr1:53392774	SCP2	0.46	9.03	0.39	4.51e-18	Monocyte count;
LGG	cis	rs763121	0.813	rs4821807	chr22:39065582	A/G	cg06022373	chr22:39101656	GTPBP1	0.88	18.06	0.64	1.46e-55	Menopause (age at onset);
LGG	cis	rs12540874	0.542	rs3807562	chr7:50566671	G/A	cg00647317	chr7:50633725	DDC	0.37	9.19	0.39	1.28e-18	Systemic sclerosis;
LGG	cis	rs2640806	0.505	rs6981384	chr8:97361730	A/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.25	0.32	1.7e-12	Obesity-related traits;
LGG	cis	rs4631830	0.720	rs113082846	chr10:51502802	G/C	cg16070123	chr10:51489643	NA	-0.41	-7.5	-0.33	3.3e-13	Prostate-specific antigen levels;
LGG	cis	rs1552244	1.000	rs6791810	chr3:10124444	A/G	cg18621852	chr3:10150065	C3orf24	-0.39	-6.7	-0.3	6.05e-11	Alzheimer's disease;
LGG	cis	rs9790314	0.967	rs460165	chr3:161087710	G/A	cg03342759	chr3:160939853	NMD3	-0.62	-10.83	-0.45	1.6e-24	Morning vs. evening chronotype;
LGG	trans	rs11039798	0.512	rs1988465	chr11:49011303	C/T	cg15704280	chr7:45808275	SEPT13	0.73	10.16	0.43	4.83e-22	Axial length;
LGG	cis	rs8072100	0.607	rs9894594	chr17:45461383	A/G	cg08085267	chr17:45401833	C17orf57	-0.5	-9.21	-0.39	1.15e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs11039798	0.588	rs59777067	chr11:49015350	C/T	cg03929089	chr4:120376271	NA	0.71	9.88	0.42	5.02e-21	Axial length;
LGG	cis	rs28386778	0.897	rs9912557	chr17:61784963	C/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.25	-0.58	7.8e-43	Prudent dietary pattern;
LGG	cis	rs12600856	1	rs12600856	chr17:38163295	T/C	cg17467752	chr17:38218738	THRA	0.74	13.94	0.54	4.03e-37	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;White blood cell count;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	trans	rs1032833	0.732	rs3731739	chr2:179970037	C/T	cg23654767	chr2:101192981	PDCL3	0.55	7.04	0.31	7.21e-12	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);
LGG	cis	rs2836974	0.627	rs7278985	chr21:40653767	C/T	cg06238570	chr21:40685208	BRWD1	-0.51	-8.61	-0.37	1.19e-16	Cognitive function;
LGG	cis	rs7635838	0.684	rs346079	chr3:11328139	G/A	cg00170343	chr3:11313890	ATG7	0.5	8.66	0.37	7.96e-17	HDL cholesterol;
LGG	cis	rs13118159	0.801	rs7690727	chr4:1340811	C/A	cg00684032	chr4:1343700	KIAA1530	0.46	9.27	0.4	7.13e-19	Longevity;
LGG	cis	rs7954584	0.504	rs10840633	chr12:122377511	A/T	cg10207240	chr12:122356781	WDR66	0.27	7.81	0.34	3.76e-14	Mean corpuscular volume;
LGG	cis	rs897080	0.552	rs1067318	chr2:44634509	A/C	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.92e-11	Height;
LGG	cis	rs7567389	0.744	rs6430934	chr2:128000833	T/C	cg11380483	chr2:127933992	NA	-0.37	-6.98	-0.31	1.02e-11	Self-rated health;
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg07234876	chr8:600039	NA	-1.17	-11.59	-0.47	1.83e-27	IgG glycosylation;
LGG	cis	rs6952808	0.929	rs34145223	chr7:1926237	G/A	cg20295408	chr7:1910781	MAD1L1	-0.48	-8.3	-0.36	1.19e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg05861140	chr6:150128134	PCMT1	-0.44	-9.94	-0.42	3.03e-21	Lung cancer;
LGG	cis	rs920590	0.643	rs13280085	chr8:19669959	G/T	cg03894339	chr8:19674705	INTS10	-0.51	-8.66	-0.37	7.88e-17	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7223966	1.000	rs113134232	chr17:61715461	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.45	7.38	0.32	7.24e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8060686	0.641	rs12446007	chr16:68189054	C/T	cg27539214	chr16:67997921	SLC12A4	-0.5	-7.66	-0.34	1.12e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs35425515	0.706	rs34113615	chr10:98869594	C/T	cg09122387	chr10:98855762	SLIT1	0.72	8.97	0.38	7.4e-18	Bipolar disorder;
LGG	trans	rs2243480	1.000	rs160655	chr7:65533214	T/C	cg10756647	chr7:56101905	PSPH	0.77	8.75	0.38	4.1e-17	Diabetic kidney disease;
LGG	cis	rs4330281	0.580	rs9310519	chr3:17576505	G/A	cg20981856	chr3:17787350	NA	0.37	6.73	0.3	5.18e-11	Schizophrenia;
LGG	cis	rs55788414	0.932	rs9921666	chr16:81181669	T/C	cg06400318	chr16:81190750	PKD1L2	-0.8	-10.14	-0.43	5.91e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs2839186	0.934	rs13046494	chr21:47707430	A/C	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs2739330	0.828	rs5760099	chr22:24248414	G/A	cg24846343	chr22:24311635	DDTL	0.6	11.65	0.48	1.06e-27	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2290416	0.892	rs62522165	chr8:144675379	C/T	cg04293180	chr8:144700367	TSTA3	0.9	6.97	0.31	1.12e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs2304069	0.909	rs30831	chr5:149359053	C/T	cg22760475	chr5:149380129	HMGXB3;TIGD6	-0.9	-14.01	-0.55	1.92e-37	HIV-1 control;
LGG	cis	rs6840360	0.593	rs2175409	chr4:152701656	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.13	-0.43	6.5600000000000005e-22	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs11784908	chr8:58131472	T/C	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs9916302	0.800	rs9892675	chr17:37549200	C/T	cg00129232	chr17:37814104	STARD3	0.59	9.66	0.41	3.03e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs6800768	0.663	rs62253424	chr3:24093919	C/A	cg10674438	chr3:24145617	LOC152024	-0.49	-8.8	-0.38	2.64e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs988958	0.526	rs36036427	chr2:42252889	G/A	cg27428208	chr2:42229179	NA	0.48	7.58	0.33	1.91e-13	Hypospadias;
LGG	cis	rs1982963	0.901	rs2516589	chr14:52512610	A/G	cg05884192	chr14:52515736	NID2	-0.35	-7.69	-0.34	8.94e-14	Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg02394578	chr1:197191366	NA	0.3	6.65	0.3	8.17e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs911263	0.603	rs911254	chr14:68805323	A/T	cg18825221	chr14:68749962	RAD51L1	0.38	8.22	0.36	2e-15	Primary biliary cholangitis;
LGG	cis	rs1218582	0.741	rs11264281	chr1:154867221	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.43	8.63	0.37	9.79e-17	Prostate cancer;
LGG	cis	rs12580194	0.593	rs7485991	chr12:55789129	T/C	cg19537932	chr12:55886519	OR6C68	-0.56	-10.29	-0.43	1.74e-22	Cancer;
LGG	cis	rs2842992	0.915	rs2842980	chr6:160100116	A/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.73	11.62	0.48	1.49e-27	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4237845	0.537	rs59401446	chr12:58259564	G/A	cg02175503	chr12:58329896	NA	0.54	9.12	0.39	2.35e-18	Intelligence (multi-trait analysis);
LGG	cis	rs4927850	0.501	rs9881504	chr3:195656614	A/G	cg12923728	chr3:195709715	SDHAP1	-0.6	-10.51	-0.44	2.52e-23	Pancreatic cancer;
LGG	cis	rs9322193	0.923	rs9800806	chr6:150061486	G/T	cg07701084	chr6:150067640	NUP43	0.7	13.71	0.54	3.68e-36	Lung cancer;
LGG	cis	rs2688482	0.557	rs2550236	chr3:195522321	A/G	cg07341007	chr3:195489909	MUC4	0.55	8.22	0.36	2.07e-15	Lung disease severity in cystic fibrosis;
LGG	cis	rs881375	0.935	rs7034390	chr9:123646488	A/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.5	8.91	0.38	1.15e-17	Rheumatoid arthritis;
LGG	cis	rs7937682	0.889	rs521155	chr11:111492563	G/A	cg22437258	chr11:111473054	SIK2	0.56	9.9	0.42	4.37e-21	Primary sclerosing cholangitis;
LGG	cis	rs11971779	0.523	rs10279160	chr7:139090761	A/G	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs2274273	0.870	rs4597235	chr14:55851987	A/G	cg04306507	chr14:55594613	LGALS3	0.63	17.94	0.64	5.2e-55	Protein biomarker;
LGG	cis	rs8180040	0.764	rs11716539	chr3:47186503	G/T	cg16586182	chr3:47516702	SCAP	-0.79	-15.22	-0.58	9.97e-43	Colorectal cancer;
LGG	cis	rs9611565	0.694	rs202665	chr22:41814401	A/G	cg06481639	chr22:41940642	POLR3H	0.55	8.14	0.35	3.6e-15	Vitiligo;
LGG	trans	rs34421088	0.532	rs2736388	chr8:11159588	T/C	cg02002194	chr4:3960332	NA	-0.42	-7.44	-0.33	4.87e-13	Neuroticism;
LGG	cis	rs1620921	0.505	rs9458031	chr6:161210119	G/A	cg01280913	chr6:161186852	NA	-0.48	-9.77	-0.41	1.25e-20	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs368123	0.961	rs368235	chr6:160724808	G/A	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.16	-0.32	3.25e-12	Waist circumference;
LGG	cis	rs10743315	0.557	rs1552750	chr12:19356505	A/T	cg02471346	chr12:19282374	PLEKHA5	0.87	8.31	0.36	1.09e-15	Gut microbiota (bacterial taxa);
LGG	trans	rs7395662	0.890	rs1847652	chr11:48975013	A/G	cg03929089	chr4:120376271	NA	0.43	7.02	0.31	7.75e-12	HDL cholesterol;
LGG	cis	rs151997	0.962	rs27268	chr5:50184778	T/C	cg06027927	chr5:50259733	NA	0.68	11.09	0.46	1.66e-25	Callous-unemotional behaviour;
LGG	cis	rs7829975	0.514	rs2920983	chr8:8268063	G/C	cg06636001	chr8:8085503	FLJ10661	0.54	10.37	0.43	8.44e-23	Mood instability;
LGG	cis	rs7236492	0.688	rs7241538	chr18:77191247	C/T	cg15532942	chr18:77220712	NFATC1	0.46	7.54	0.33	2.46e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2204008	0.570	rs1315664	chr12:38138274	A/G	cg26384229	chr12:38710491	ALG10B	-0.69	-13.51	-0.53	2.65e-35	Bladder cancer;
LGG	cis	rs60843830	1.000	rs6709534	chr2:217334	G/C	cg12623918	chr2:306882	NA	0.5	9.43	0.4	1.92e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1005277	0.579	rs9418322	chr10:38377296	G/T	cg03665457	chr10:38645376	HSD17B7P2	-0.47	-7.4	-0.33	6.52e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs7726839	0.540	rs12517638	chr5:645484	C/T	cg25482853	chr8:67687455	SGK3	0.94	11.98	0.49	5.31e-29	Obesity-related traits;
LGG	cis	rs5750830	0.620	rs1007337	chr22:39781585	C/T	cg04986931	chr22:39850128	NA	0.35	7.86	0.34	2.69e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.539	rs12999417	chr2:99865548	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	-1.01	-23.81	-0.74	2.12e-82	Chronic sinus infection;
LGG	cis	rs2224391	0.628	rs2753245	chr6:5258092	G/C	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.39	-0.32	6.88e-13	Height;
LGG	trans	rs2235573	0.594	rs12157609	chr22:38432277	C/T	cg19894588	chr14:64061835	NA	0.51	8.56	0.37	1.63e-16	Glioblastoma;Glioma;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg06112835	chr11:68658793	MRPL21	0.62	10.43	0.44	5.03e-23	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9358372	0.574	rs34799469	chr6:20830828	A/G	cg13405222	chr6:20811065	CDKAL1	-0.45	-9.27	-0.4	7.21e-19	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs8002861	0.727	rs9525850	chr13:44402100	C/T	cg17145862	chr1:211918768	LPGAT1	-0.7	-14.43	-0.56	2.94e-39	Leprosy;
LGG	cis	rs769267	1.000	rs7246748	chr19:19433105	C/T	cg17414380	chr19:19431394	KIAA0892;SF4	-0.52	-8.44	-0.37	3.95e-16	Tonsillectomy;
LGG	cis	rs929354	0.772	rs6971896	chr7:156978412	C/T	cg17757837	chr7:157058334	UBE3C	0.77	15.61	0.59	1.86e-44	Body mass index;
LGG	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg07636037	chr3:49044803	WDR6	-0.62	-6.66	-0.3	7.61e-11	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4242434	0.927	rs10095121	chr8:22538426	A/G	cg02227867	chr8:22457446	C8orf58	-0.44	-8.3	-0.36	1.15e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs7226408	0.857	rs11664715	chr18:34435068	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg18515171	chr17:58156344	HEATR6	0.42	6.71	0.3	5.67e-11	Cognitive performance;
LGG	cis	rs17102423	0.755	rs7154852	chr14:65553822	C/A	cg11161011	chr14:65562177	MAX	-0.78	-15.87	-0.59	1.37e-45	Obesity-related traits;
LGG	cis	rs2204008	0.539	rs2703682	chr12:38107969	A/G	cg04568710	chr12:38710424	ALG10B	0.38	7.92	0.35	1.74e-14	Bladder cancer;
LGG	cis	rs1003719	0.788	rs1155787	chr21:38448069	G/A	cg10648535	chr21:38446584	PIGP;TTC3	0.85	17.57	0.63	2.42e-53	Eye color traits;
LGG	cis	rs2075671	0.903	rs10953300	chr7:100263784	C/G	cg21055462	chr7:100276975	NA	0.45	9.56	0.41	7.03e-20	Other erythrocyte phenotypes;
LGG	trans	rs7824557	0.628	rs34237267	chr8:11197301	G/C	cg02002194	chr4:3960332	NA	-0.38	-6.7	-0.3	6.04e-11	Retinal vascular caliber;
LGG	cis	rs3733585	0.605	rs4697926	chr4:10124567	G/T	cg08250081	chr4:10125330	NA	0.5	9.78	0.41	1.16e-20	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs35110281	0.713	rs1378079	chr21:45011187	A/G	cg04455712	chr21:45112962	RRP1B	0.52	9.82	0.42	8.7e-21	Mean corpuscular volume;
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg05091796	chr16:4465799	CORO7	-0.61	-9.97	-0.42	2.42e-21	Schizophrenia;
LGG	cis	rs79149102	0.579	rs12594117	chr15:75323648	C/G	cg09165964	chr15:75287851	SCAMP5	-0.8	-8.9	-0.38	1.3e-17	Lung cancer;
LGG	cis	rs2694528	0.800	rs290511	chr5:60264439	G/T	cg11474532	chr5:59995715	DEPDC1B	-0.72	-7.57	-0.33	2.07e-13	Parkinson's disease;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.32	0.69	4.25e-66	Alzheimer's disease;
LGG	cis	rs75920871	0.528	rs682048	chr11:116828320	T/G	cg20608306	chr11:116969690	SIK3	-0.38	-10.25	-0.43	2.29e-22	Subjective well-being;
LGG	cis	rs858239	0.932	rs1728320	chr7:23319789	T/G	cg23682824	chr7:23144976	KLHL7	0.4	6.74	0.3	4.71e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7582180	0.663	rs1114595	chr2:100960072	T/A	cg26150922	chr2:100937072	LONRF2	-0.59	-11.64	-0.48	1.22e-27	Intelligence (multi-trait analysis);
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs8072100	0.782	rs62074054	chr17:45771816	T/C	cg08085267	chr17:45401833	C17orf57	-0.54	-9.93	-0.42	3.39e-21	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs6088580	0.634	rs2184836	chr20:32963369	A/G	cg24642439	chr20:33292090	TP53INP2	-0.57	-9.52	-0.4	9.4e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs17453880	0.890	rs12522261	chr5:152054825	G/A	cg12297329	chr5:152029980	NA	-0.9	-23.55	-0.74	3.52e-81	Subjective well-being;
LGG	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg13256891	chr4:100009986	ADH5	0.49	9.19	0.39	1.37e-18	Alcohol dependence;
LGG	cis	rs8040855	0.559	rs6496801	chr15:85728399	G/A	cg04831495	chr15:85060580	GOLGA6L5	0.36	7.25	0.32	1.77e-12	Bulimia nervosa;
LGG	cis	rs6732160	0.691	rs11886257	chr2:73416873	C/T	cg01422370	chr2:73384389	NA	0.47	9.05	0.39	4.04e-18	Intelligence (multi-trait analysis);
LGG	cis	rs6445975	0.715	rs6790764	chr3:58265950	C/T	cg24175188	chr3:58374923	PXK	0.39	7.35	0.32	8.99e-13	Systemic lupus erythematosus;
LGG	cis	rs4363385	0.782	rs310105	chr1:153022253	A/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.88	-0.38	1.44e-17	Inflammatory skin disease;
LGG	cis	rs2075671	0.903	rs62482249	chr7:100262357	C/A	cg16850897	chr7:100343110	ZAN	-0.64	-9.21	-0.39	1.18e-18	Other erythrocyte phenotypes;
LGG	cis	rs11098499	0.754	rs1980026	chr4:120251643	C/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs875971	0.929	rs778682	chr7:65837934	A/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs765787	0.530	rs4774542	chr15:45526026	A/C	cg25801113	chr15:45476975	SHF	-0.86	-19.37	-0.67	1.12e-61	Uric acid levels;
LGG	cis	rs7582180	0.614	rs4149518	chr2:101013649	A/G	cg14675211	chr2:100938903	LONRF2	0.67	12.2	0.49	7e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10193935	1.000	rs10180528	chr2:42436723	T/A	cg27598129	chr2:42591480	NA	-0.61	-9.21	-0.39	1.18e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9322193	0.884	rs9688794	chr6:149953257	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.55	-0.41	7.41e-20	Lung cancer;
LGG	cis	rs7208859	0.673	rs9891179	chr17:29208160	G/T	cg01831904	chr17:28903510	LRRC37B2	-0.76	-8.96	-0.38	7.69e-18	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2204008	0.840	rs11181795	chr12:38401129	A/G	cg13010199	chr12:38710504	ALG10B	0.7	14.31	0.55	9.98e-39	Bladder cancer;
LGG	trans	rs6787172	0.622	rs7639867	chr3:158099176	C/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.35	-0.32	9.3e-13	Subjective well-being;
LGG	cis	rs6952808	0.965	rs4719318	chr7:1887930	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.26	-0.32	1.61e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs8141529	0.702	rs8137262	chr22:29292135	C/T	cg02153584	chr22:29168773	CCDC117	0.59	9.35	0.4	3.69e-19	Lymphocyte counts;
LGG	cis	rs13108904	0.518	rs4974602	chr4:1342391	C/T	cg20887711	chr4:1340912	KIAA1530	0.45	7.9	0.34	2.11e-14	Obesity-related traits;
LGG	cis	rs7582180	0.739	rs10195793	chr2:100925803	A/G	cg05692746	chr2:100937584	LONRF2	-0.62	-11.12	-0.46	1.27e-25	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs67077711	chr8:58139769	G/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs11690935	0.921	rs7594711	chr2:172895637	T/G	cg13550731	chr2:172543902	DYNC1I2	-0.99	-22.88	-0.73	4.34e-78	Schizophrenia;
LGG	cis	rs919433	0.679	rs6737060	chr2:198524885	G/C	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs9486719	1.000	rs6923212	chr6:97061940	A/G	cg18709589	chr6:96969512	KIAA0776	-0.5	-7.63	-0.33	1.31e-13	Migraine;Coronary artery disease;
LGG	cis	rs1461503	0.900	rs7115852	chr11:122831830	G/A	cg27398637	chr11:122830231	C11orf63	-0.7	-14.49	-0.56	1.69e-39	Menarche (age at onset);
LGG	trans	rs61931739	0.500	rs12367292	chr12:33998075	T/C	cg13010199	chr12:38710504	ALG10B	0.57	10.61	0.44	1.11e-23	Morning vs. evening chronotype;
LGG	cis	rs2916247	1.000	rs2979854	chr8:92978039	G/A	cg10183463	chr8:93005414	RUNX1T1	0.38	7.9	0.34	2.01e-14	Intelligence (multi-trait analysis);
LGG	cis	rs8056893	0.842	rs1111571	chr16:68363181	A/G	cg07273125	chr16:68295692	NA	-0.36	-6.81	-0.3	3.12e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs4774899	0.932	rs11629653	chr15:57585644	G/A	cg08128148	chr15:57256372	TCF12	-0.32	-7.3	-0.32	1.3e-12	Urinary tract infection frequency;
LGG	cis	rs10504229	0.775	rs10504228	chr8:58162053	T/G	cg26174226	chr8:58114915	NA	-0.51	-7.18	-0.32	2.84e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs12493885	0.818	rs73158491	chr3:153764112	T/C	cg12800244	chr3:153838788	SGEF	-0.82	-8.95	-0.38	8.88e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8068544	0.606	rs77681389	chr17:40154419	T/C	cg18442075	chr17:40169520	DNAJC7;NKIRAS2	-1.31	-14.45	-0.56	2.5e-39	Reticulocyte fraction of red cells;Reticulocyte count;
LGG	cis	rs6066825	0.605	rs4325821	chr20:47224787	T/C	cg18078177	chr20:47281410	PREX1	0.47	7.74	0.34	6.5e-14	Colorectal cancer;
LGG	cis	rs593982	1.000	rs118030231	chr11:65501905	G/A	cg08755490	chr11:65554678	OVOL1	-0.74	-10.4	-0.44	6.45e-23	Atopic dermatitis;
LGG	cis	rs597539	0.652	rs514296	chr11:68654182	G/T	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.35	0.61	9.14e-48	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs738322	0.839	rs133015	chr22:38572526	C/G	cg25457927	chr22:38595422	NA	-0.46	-12.12	-0.49	1.41e-29	Cutaneous nevi;
LGG	trans	rs970548	0.697	rs11239534	chr10:45968590	A/T	cg20477318	chr10:51623047	TIMM23	-0.69	-8.16	-0.35	3.19e-15	Total cholesterol levels;Cholesterol, total;HDL cholesterol;HDL cholesterol levels;
LGG	trans	rs61931739	0.500	rs7303318	chr12:34467789	T/C	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs9910055	0.659	rs112114764	chr17:42201041	G/T	cg09913183	chr17:42254507	C17orf65;ASB16	-0.66	-12.43	-0.5	8.04e-31	Total body bone mineral density;
LGG	cis	rs35740288	0.753	rs4843095	chr15:86275131	T/G	cg07943548	chr15:86304357	KLHL25	-0.36	-6.99	-0.31	9.73e-12	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7617773	0.817	rs745116	chr3:48272536	T/G	cg11946769	chr3:48343235	NME6	0.63	10.46	0.44	3.93e-23	Coronary artery disease;
LGG	cis	rs10927875	0.864	rs12135073	chr1:16167799	C/T	cg07117364	chr1:16154769	NA	0.51	8.2	0.36	2.35e-15	Dilated cardiomyopathy;
LGG	trans	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg16141378	chr3:129829833	LOC729375	-0.36	-7.89	-0.34	2.2e-14	Retinal vascular caliber;
LGG	cis	rs2204008	0.837	rs11168387	chr12:37962818	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.87	-0.51	1.25e-32	Bladder cancer;
LGG	cis	rs9926296	0.527	rs1800335	chr16:89846195	A/G	cg04287289	chr16:89883240	FANCA	0.81	17.41	0.63	1.38e-52	Vitiligo;
LGG	cis	rs2019137	0.539	rs6755040	chr2:113981137	T/C	cg17445212	chr2:113993313	PAX8;LOC440839;LOC654433	0.61	11.14	0.46	1.05e-25	Lymphocyte counts;
LGG	cis	rs736408	0.540	rs4687637	chr3:52634092	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.38	-0.32	7.63e-13	Bipolar disorder;
LGG	trans	rs2727020	0.754	rs1851990	chr11:49413336	C/T	cg15704280	chr7:45808275	SEPT13	-0.9	-15.93	-0.6	7.45e-46	Coronary artery disease;
LGG	cis	rs4684776	0.867	rs13062308	chr3:11355139	C/T	cg24705426	chr3:11550659	ATG7	-0.46	-8.72	-0.38	5.04e-17	Small vessel stroke;
LGG	trans	rs7980799	0.682	rs61927702	chr12:33631695	A/G	cg26384229	chr12:38710491	ALG10B	-0.65	-11.93	-0.48	8.86e-29	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs6089584	0.566	rs6061963	chr20:60607480	C/G	cg13770153	chr20:60521292	NA	-0.46	-7.62	-0.33	1.43e-13	Body mass index;
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs77633900	0.772	rs2957560	chr15:76700310	A/T	cg21673338	chr15:77095150	SCAPER	-0.63	-8.32	-0.36	9.76e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs4820294	0.961	rs62236664	chr22:38059427	T/C	cg00292662	chr22:38071168	LGALS1	0.89	24.41	0.75	3.45e-85	Fat distribution (HIV);
LGG	cis	rs3091242	0.934	rs666686	chr1:25719511	A/G	cg23205692	chr1:25664452	TMEM50A	0.5	10.92	0.45	7.6e-25	Erythrocyte sedimentation rate;
LGG	cis	rs17428076	0.681	rs62182424	chr2:172751723	C/G	cg21435375	chr2:172878103	MAP1D	0.42	7.6	0.33	1.71e-13	Myopia;
LGG	cis	rs796364	0.664	rs3106089	chr2:200884615	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.76	9.11	0.39	2.57e-18	Schizophrenia;
LGG	cis	rs1003719	0.591	rs9636914	chr21:38589732	A/G	cg10648535	chr21:38446584	PIGP;TTC3	0.65	11.36	0.47	1.46e-26	Eye color traits;
LGG	cis	rs2243480	1.000	rs4718269	chr7:65200778	C/G	cg13147721	chr7:65941812	NA	0.8	9.92	0.42	3.76e-21	Diabetic kidney disease;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.38	0.32	7.43e-13	Prudent dietary pattern;
LGG	trans	rs9329221	0.686	rs35840352	chr8:10239807	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.01	-0.31	8.33e-12	Neuroticism;
LGG	trans	rs6076960	0.629	rs6054031	chr20:6233657	C/G	cg17788362	chr6:86352627	SYNCRIP	0.51	8.72	0.38	4.93e-17	Smooth-surface caries;
LGG	cis	rs734999	0.588	rs4648652	chr1:2535758	A/G	cg15627072	chr1:2432621	PLCH2	0.33	7.47	0.33	4.12e-13	Ulcerative colitis;
LGG	cis	rs7552404	0.731	rs11161845	chr1:76367559	T/C	cg22875332	chr1:76189707	ACADM	0.59	8.77	0.38	3.42e-17	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs11920090	0.932	rs2292620	chr3:170724036	T/C	cg09710316	chr3:170744871	SLC2A2	0.67	8.92	0.38	1.13e-17	Fasting blood glucose;Fasting blood glucose (BMI interaction);Homeostasis model assessment of beta-cell function;
LGG	cis	rs17604090	0.775	rs76480599	chr7:29689180	A/G	cg12658982	chr7:29603541	PRR15	-0.35	-6.67	-0.3	7.22e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs2735413	0.563	rs117731654	chr16:78047347	A/G	cg04733911	chr16:78082701	NA	0.56	7.45	0.33	4.77e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs644799	0.511	rs11021301	chr11:95485145	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.59	9.37	0.4	3.31e-19	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13108904	0.967	rs1732107	chr4:1276758	G/A	cg05665937	chr4:1216051	CTBP1	-0.58	-10.87	-0.45	1.1e-24	Obesity-related traits;
LGG	cis	rs6733011	0.542	rs6542860	chr2:99679376	C/G	cg23527387	chr2:100056660	REV1	0.36	7.86	0.34	2.74e-14	Bipolar disorder;
LGG	cis	rs3784262	0.669	rs7180059	chr15:58288172	C/T	cg12031962	chr15:58353849	ALDH1A2	-0.33	-6.99	-0.31	9.76e-12	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs6502050	0.871	rs8080366	chr17:80067298	A/G	cg16920238	chr17:80076378	CCDC57	0.34	7.84	0.34	3.15e-14	Life satisfaction;
LGG	cis	rs2963155	0.518	rs6196	chr5:142661490	A/G	cg17617527	chr5:142782415	NR3C1	0.95	12.49	0.5	4.57e-31	Breast cancer;
LGG	cis	rs8014204	0.566	rs12587457	chr14:75164141	C/T	cg17347104	chr14:75034677	LTBP2	-0.37	-6.7	-0.3	6.13e-11	Caffeine consumption;
LGG	cis	rs2658782	0.738	rs2605628	chr11:93261560	C/A	cg15737290	chr11:93063684	CCDC67	0.47	6.75	0.3	4.42e-11	Pulmonary function decline;
LGG	trans	rs853679	0.546	rs71537572	chr6:27970715	T/C	cg01620082	chr3:125678407	NA	-1.0	-9.81	-0.41	8.84e-21	Depression;
LGG	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.05e-20	Aortic root size;
LGG	cis	rs10504229	0.679	rs72649131	chr8:58054288	G/T	cg21724239	chr8:58056113	NA	0.49	7.33	0.32	1.01e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg20916646	chr4:852691	GAK	0.48	8.36	0.36	7.26e-16	Sjögren's syndrome;
LGG	trans	rs73191547	1.000	rs11787370	chr8:10030902	G/T	cg06636001	chr8:8085503	FLJ10661	0.45	7.78	0.34	4.89e-14	Schizophrenia;
LGG	cis	rs66887589	0.616	rs6843509	chr4:120220196	G/A	cg09307838	chr4:120376055	NA	0.5	8.22	0.36	2.08e-15	Diastolic blood pressure;
LGG	cis	rs71403859	0.570	rs78972826	chr16:71454264	A/G	cg08717414	chr16:71523259	ZNF19	-1.15	-13.7	-0.54	4.34e-36	Post bronchodilator FEV1;
LGG	cis	rs12477438	0.501	rs60257640	chr2:100074487	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.44	-6.84	-0.3	2.49e-11	Chronic sinus infection;
LGG	cis	rs17401966	0.838	rs4846212	chr1:10370312	T/C	cg19773385	chr1:10388646	KIF1B	-0.47	-9.92	-0.42	3.69e-21	Hepatocellular carcinoma;
LGG	cis	rs17767392	0.829	rs35796129	chr14:71758598	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.41	-9.09	-0.39	2.92e-18	Mitral valve prolapse;
LGG	cis	rs758324	0.947	rs6596040	chr5:131198777	C/T	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6502050	0.734	rs9674631	chr17:80096525	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.32	-0.4	4.81e-19	Life satisfaction;
LGG	cis	rs9926296	0.605	rs8047486	chr16:89854025	A/T	cg07648498	chr16:89883185	FANCA	0.39	6.64	0.3	8.61e-11	Vitiligo;
LGG	cis	rs952623	0.649	rs6974522	chr7:39073372	G/C	cg20302533	chr7:39170763	POU6F2	0.32	7.72	0.34	7.09e-14	Intelligence (multi-trait analysis);
LGG	cis	rs4930103	1.000	rs4929983	chr11:2024579	C/T	cg03175030	chr11:2018143	H19;MIR675	-0.55	-10.34	-0.43	1.08e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	trans	rs561341	1.000	rs72823787	chr17:30283809	A/T	cg27661571	chr11:113659931	NA	-0.7	-9.63	-0.41	3.91e-20	Hip circumference adjusted for BMI;
LGG	cis	rs35306767	0.501	rs4880763	chr10:1147045	G/A	cg25019033	chr10:957182	NA	-0.45	-7.64	-0.33	1.3e-13	Eosinophil percentage of granulocytes;
LGG	trans	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg08712808	chr3:7342929	GRM7	-0.32	-7.16	-0.32	3.18e-12	Asthma;
LGG	cis	rs1557765	0.527	rs4756887	chr11:17394597	T/G	cg15432903	chr11:17409602	KCNJ11	0.5	9.1	0.39	2.64e-18	Body mass index;Social communication problems;
LGG	cis	rs10050311	0.746	rs969734	chr4:87665384	A/G	cg11209507	chr4:87813803	C4orf36	0.54	6.98	0.31	1.06e-11	Insulin-related traits;
LGG	cis	rs60871478	0.592	rs4275123	chr7:857352	A/G	cg22643751	chr7:855365	UNC84A	-0.52	-10.52	-0.44	2.36e-23	Cerebrospinal P-tau181p levels;
LGG	cis	rs7618501	0.516	rs2856236	chr3:50161717	A/C	cg05623727	chr3:50126028	RBM5	-0.36	-7.78	-0.34	4.67e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7523273	0.565	rs2796239	chr1:207902206	G/A	cg22525895	chr1:207977042	MIR29B2	-0.45	-8.6	-0.37	1.28e-16	Schizophrenia;
LGG	cis	rs9811920	0.609	rs4244711	chr3:99657205	A/G	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	-0.53	-9.07	-0.39	3.44e-18	Axial length;
LGG	cis	rs881375	0.933	rs4837799	chr9:123668326	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.52	9.45	0.4	1.69e-19	Rheumatoid arthritis;
LGG	cis	rs877282	0.945	rs71491311	chr10:791747	G/A	cg17470449	chr10:769945	NA	0.62	7.64	0.33	1.27e-13	Uric acid levels;
LGG	cis	rs6714710	0.580	rs57804205	chr2:98454472	G/A	cg26665480	chr2:98280029	ACTR1B	0.58	9.42	0.4	2.09e-19	Posterior cortical atrophy and Alzheimer's disease;
LGG	cis	rs4919087	0.926	rs953097	chr10:98981914	T/C	cg25902810	chr10:99078978	FRAT1	0.53	9.88	0.42	5.13e-21	Monocyte count;
LGG	cis	rs72772090	0.710	rs10515244	chr5:96078337	C/G	cg17330273	chr5:96107758	CAST;ERAP1	-0.53	-8.2	-0.36	2.44e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.679	rs16920056	chr8:58106218	C/A	cg21724239	chr8:58056113	NA	0.51	7.56	0.33	2.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs17345786	0.954	rs17508319	chr3:101318903	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.57	8.77	0.38	3.31e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7566780	0.575	rs4240228	chr2:16688759	G/T	cg09580478	chr2:16689509	NA	0.46	7.25	0.32	1.72e-12	Orofacial clefts;Cleft lip with or without cleft palate;
LGG	trans	rs7873102	0.702	rs7028020	chr9:38007747	C/T	cg02712746	chr6:13574844	SIRT5	-0.4	-6.82	-0.3	2.86e-11	Brain structure;
LGG	cis	rs10463554	0.853	rs2241565	chr5:102301937	A/T	cg23492399	chr5:102201601	PAM	-0.57	-8.77	-0.38	3.56e-17	Parkinson's disease;
LGG	cis	rs72945132	0.638	rs627079	chr11:70165505	G/T	cg14191688	chr11:70257035	CTTN	0.47	7.34	0.32	9.71e-13	Coronary artery disease;
LGG	cis	rs7587476	0.601	rs17489363	chr2:215674341	A/G	cg04004882	chr2:215674386	BARD1	-0.54	-8.42	-0.36	4.71e-16	Neuroblastoma;
LGG	cis	rs4535700	0.501	rs28678267	chr7:56009490	A/G	cg17215666	chr7:56131930	SUMF2	-0.44	-6.77	-0.3	3.81e-11	Macular telangiectasia type 2;
LGG	cis	rs11225247	0.881	rs11225236	chr11:102250098	C/T	cg06323957	chr11:102217781	BIRC2	0.8	7.02	0.31	7.86e-12	Vein graft stenosis in coronary artery bypass grafting;
LGG	cis	rs12325245	0.536	rs12924708	chr16:58567643	G/A	cg01152986	chr16:58549298	SETD6	0.85	7.39	0.32	7.06e-13	Schizophrenia;
LGG	cis	rs6976053	0.868	rs314374	chr7:100456611	G/C	cg03098644	chr7:100410630	EPHB4	-0.4	-7.15	-0.32	3.31e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs240764	0.658	rs4840148	chr6:101182500	G/A	cg09795085	chr6:101329169	ASCC3	-0.48	-8.31	-0.36	1.05e-15	Neuroticism;
LGG	cis	rs4917300	0.626	rs902821	chr8:143100074	G/A	cg06573787	chr8:143070187	NA	0.49	8.52	0.37	2.22e-16	Amyotrophic lateral sclerosis;
LGG	cis	rs10463554	1.000	rs11949145	chr5:102330256	G/T	cg23492399	chr5:102201601	PAM	-0.53	-8.24	-0.36	1.74e-15	Parkinson's disease;
LGG	cis	rs6815814	0.808	rs11721824	chr4:38767749	G/A	cg06935464	chr4:38784597	TLR10	0.52	7.0	0.31	8.9e-12	Breast cancer;
LGG	cis	rs8028313	0.731	rs4331293	chr15:67987801	A/G	cg05925327	chr15:68127851	NA	-0.32	-6.65	-0.3	8.43e-11	Obesity;
LGG	cis	rs12579753	1.000	rs7963577	chr12:82174115	T/C	cg07988820	chr12:82153109	PPFIA2	-0.77	-11.17	-0.46	8.19e-26	Resting heart rate;
LGG	trans	rs3960554	0.808	rs2286829	chr7:75677739	G/A	cg19862616	chr7:65841803	NCRNA00174	0.85	12.5	0.5	4.09e-31	Eotaxin levels;
LGG	cis	rs4642101	0.628	rs1003080	chr3:12811628	C/T	cg24848339	chr3:12840334	CAND2	-0.4	-9.07	-0.39	3.28e-18	QRS complex (12-leadsum);
LGG	cis	rs1799949	1.000	rs2271573	chr17:41327621	A/G	cg12708336	chr17:41446283	NA	-0.31	-7.08	-0.31	5.49e-12	Menopause (age at onset);
LGG	cis	rs2463822	1.000	rs72921501	chr11:62115622	A/T	cg06239285	chr11:62104954	ASRGL1	-1.16	-15.68	-0.59	9.08e-45	Chronic obstructive pulmonary disease-related biomarkers;
LGG	trans	rs61931739	0.635	rs1525895	chr12:33966496	A/G	cg26384229	chr12:38710491	ALG10B	0.59	11.1	0.46	1.46e-25	Morning vs. evening chronotype;
LGG	cis	rs12291225	0.535	rs12806025	chr11:14413817	G/A	cg19336497	chr11:14380999	RRAS2	-0.51	-10.07	-0.42	1.05e-21	Sense of smell;
LGG	cis	rs3845702	1.000	rs3768839	chr2:180835992	G/A	cg01881094	chr2:180872142	CWC22	-0.9	-13.89	-0.54	6.48e-37	Schizophrenia;
LGG	cis	rs9463078	0.774	rs4446571	chr6:45257662	T/C	cg25276700	chr6:44698697	NA	-0.4	-8.53	-0.37	2.08e-16	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs8064024	0.676	rs9938805	chr16:4877553	A/C	cg04440724	chr16:4920505	UBN1	0.44	8.94	0.38	9.23e-18	Cancer;
LGG	cis	rs13108904	0.901	rs1316394	chr4:1315820	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.68	12.58	0.5	1.96e-31	Obesity-related traits;
LGG	cis	rs72772090	0.539	rs72773981	chr5:96156059	A/C	cg17330273	chr5:96107758	CAST;ERAP1	-0.55	-8.21	-0.36	2.23e-15	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs2816062	0.747	rs2816049	chr1:18893768	A/G	cg10574377	chr1:18908098	NA	0.35	6.94	0.31	1.29e-11	Urate levels in lean individuals;
LGG	cis	rs10256972	0.967	rs1881122	chr7:1040946	A/T	cg07308232	chr7:1071921	C7orf50	-0.62	-11.88	-0.48	1.32e-28	Longevity;Endometriosis;
LGG	cis	rs11190604	1.000	rs2489034	chr10:102319192	C/T	cg07080220	chr10:102295463	HIF1AN	0.73	12.13	0.49	1.35e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs17826219	0.706	rs8075357	chr17:29057197	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.37	-0.36	6.7e-16	Body mass index;
LGG	cis	rs7192380	0.639	rs12448486	chr16:69802878	G/A	cg00738113	chr16:70207722	CLEC18C	0.36	10.1	0.42	8.24e-22	Sjögren's syndrome;
LGG	cis	rs6952808	1.000	rs4721121	chr7:1892565	A/G	cg19147804	chr7:1989927	MAD1L1	-0.51	-9.78	-0.41	1.2e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs4950322	0.570	rs4593887	chr1:146705892	T/C	cg22381352	chr1:146742008	CHD1L	-0.46	-7.69	-0.34	9.05e-14	Protein quantitative trait loci;
LGG	cis	rs757081	0.676	rs567033	chr11:17207010	C/T	cg15432903	chr11:17409602	KCNJ11	-0.42	-7.75	-0.34	5.86e-14	Systolic blood pressure;
LGG	cis	rs801193	0.967	rs2707849	chr7:66152712	T/C	cg00343986	chr7:65444356	GUSB	0.39	6.72	0.3	5.27e-11	Aortic root size;
LGG	cis	rs4650994	0.593	rs2761459	chr1:178551576	G/A	cg19399532	chr1:178512495	C1orf220	-0.39	-7.36	-0.32	8.42e-13	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs769267	0.930	rs4808967	chr19:19640524	A/G	cg11584989	chr19:19387371	SF4	0.38	6.77	0.3	3.98e-11	Tonsillectomy;
LGG	cis	rs72945132	0.882	rs6592537	chr11:70172975	C/T	cg14088196	chr11:70211408	PPFIA1	0.92	12.98	0.52	4.44e-33	Coronary artery disease;
LGG	cis	rs6942756	1.000	rs7778277	chr7:128978805	C/T	cg02491457	chr7:128862824	NA	-0.73	-13.13	-0.52	1.03e-33	White matter hyperintensity burden;
LGG	cis	rs9303401	0.659	rs62083436	chr17:57031742	G/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.82	0.57	6.12e-41	Cognitive test performance;
LGG	cis	rs10267417	0.603	rs7804164	chr7:19905105	G/C	cg05791153	chr7:19748676	TWISTNB	0.57	7.41	0.33	6.09e-13	Night sleep phenotypes;
LGG	cis	rs8070128	0.568	rs3935506	chr17:17882059	G/A	cg05444541	chr17:17804740	TOM1L2	-0.73	-15.06	-0.57	5.5e-42	Total body bone mineral density;
LGG	cis	rs951366	0.789	rs7536483	chr1:205718858	A/T	cg13453750	chr1:205783389	SLC41A1	-0.39	-7.57	-0.33	2.01e-13	Menarche (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07702853	chr1:150254280	C1orf51	0.43	6.7	0.3	6.21e-11	Gut microbiome composition (summer);
LGG	cis	rs12497850	0.865	rs7649458	chr3:48920127	C/T	cg06212747	chr3:49208901	KLHDC8B	0.65	11.09	0.46	1.7e-25	Parkinson's disease;
LGG	cis	rs7617480	0.617	rs7610519	chr3:48746427	C/G	cg20833759	chr3:49053208	WDR6;DALRD3	0.49	8.31	0.36	1.08e-15	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	trans	rs7824557	0.707	rs3808519	chr8:11142970	C/G	cg02002194	chr4:3960332	NA	-0.5	-9.15	-0.39	1.84e-18	Retinal vascular caliber;
LGG	cis	rs2688608	0.698	rs2633313	chr10:75683865	C/T	cg10168709	chr10:75599394	CAMK2G	-0.35	-6.98	-0.31	1.01e-11	Inflammatory bowel disease;
LGG	cis	rs7937682	0.575	rs1940391	chr11:111776891	G/A	cg09085632	chr11:111637200	PPP2R1B	1.02	21.01	0.7	2.47e-69	Primary sclerosing cholangitis;
LGG	cis	rs7223966	1.000	rs17549954	chr17:61707032	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.3	-0.32	1.25e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg15147215	chr3:52552868	STAB1	-0.36	-6.82	-0.3	2.82e-11	Bipolar disorder;
LGG	cis	rs3741404	0.931	rs594942	chr11:64006292	T/C	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.41	-7.71	-0.34	7.78e-14	Platelet count;
LGG	cis	rs1975974	0.511	rs17052375	chr17:21743877	G/A	cg18423549	chr17:21743878	NA	-0.54	-8.15	-0.35	3.45e-15	Psoriasis;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg02018176	chr4:1364513	KIAA1530	-0.45	-10.23	-0.43	2.68e-22	Obesity-related traits;
LGG	cis	rs6951245	0.938	rs78351779	chr7:1097023	G/C	cg18402987	chr7:1209562	NA	0.67	9.14	0.39	1.99e-18	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11605275	0.892	rs16937352	chr11:20032010	G/C	cg14835545	chr11:20032148	NAV2	-0.96	-11.38	-0.47	1.26e-26	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg01657329	chr11:68192670	LRP5	0.62	10.3	0.43	1.58e-22	Bone mineral density (spine);
LGG	trans	rs9364554	0.506	rs3125055	chr6:160736787	A/T	cg14214745	chr3:9975533	CRELD1	0.81	6.65	0.3	8.29e-11	Prostate cancer (SNP x SNP interaction);Prostate cancer;
LGG	cis	rs9291683	0.530	rs998675	chr4:9948829	A/G	cg11266682	chr4:10021025	SLC2A9	0.47	9.06	0.39	3.72e-18	Bone mineral density;
LGG	cis	rs9915657	0.870	rs12600458	chr17:70130545	C/T	cg09344028	chr17:70110421	NA	0.45	9.86	0.42	6.18e-21	Thyroid hormone levels;
LGG	cis	rs4689592	0.587	rs3822269	chr4:7069901	T/C	cg19539972	chr4:7069911	GRPEL1	0.76	11.06	0.46	2.16e-25	Monocyte percentage of white cells;
LGG	cis	rs757978	0.543	rs12477089	chr2:242265313	C/A	cg10173475	chr2:242152697	ANO7	-0.5	-7.69	-0.34	8.89e-14	Chronic lymphocytic leukemia;
LGG	cis	rs7811142	0.779	rs77370288	chr7:99947897	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.5	0.37	2.62e-16	Platelet count;
LGG	trans	rs7824557	0.564	rs34389419	chr8:11229319	C/G	cg06636001	chr8:8085503	FLJ10661	-0.55	-9.73	-0.41	1.72e-20	Retinal vascular caliber;
LGG	cis	rs4363385	0.626	rs1108410	chr1:153005662	T/C	cg13444842	chr1:152974279	SPRR3	-0.49	-9.84	-0.42	6.88e-21	Inflammatory skin disease;
LGG	trans	rs2898290	0.500	rs11998678	chr8:11830150	A/G	cg13009111	chr11:71350975	NA	-0.37	-8.56	-0.37	1.62e-16	Systolic blood pressure;
LGG	cis	rs7582180	0.663	rs6542930	chr2:100944383	T/A	cg26150922	chr2:100937072	LONRF2	-0.6	-11.83	-0.48	2.07e-28	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	0.832	rs17050674	chr3:10027258	T/C	cg00149659	chr3:10157352	C3orf10	0.73	9.11	0.39	2.41e-18	Alzheimer's disease;
LGG	cis	rs7726839	0.540	rs72705097	chr5:655067	G/A	cg09021430	chr5:549028	NA	-0.68	-9.57	-0.41	6.43e-20	Obesity-related traits;
LGG	cis	rs9902453	0.933	rs9898353	chr17:28451865	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.83	0.51	1.8e-32	Coffee consumption (cups per day);
LGG	cis	rs2916247	1.000	rs13251018	chr8:93053581	G/T	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.32	-0.36	9.97e-16	Intelligence (multi-trait analysis);
LGG	cis	rs8062405	0.964	rs62036614	chr16:28824685	T/C	cg07382826	chr16:28625726	SULT1A1	0.36	7.5	0.33	3.38e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg02352203	chr17:78518437	RPTOR	0.41	7.54	0.33	2.57e-13	Menarche (age at onset);
LGG	cis	rs7824557	0.593	rs11774673	chr8:11191537	T/C	cg21775007	chr8:11205619	TDH	0.81	14.18	0.55	3.82e-38	Retinal vascular caliber;
LGG	cis	rs1865760	0.566	rs9295688	chr6:26084217	G/A	cg12310025	chr6:25882481	NA	-0.37	-6.69	-0.3	6.49e-11	Height;
LGG	cis	rs9291683	0.538	rs11727199	chr4:10036190	C/T	cg08250081	chr4:10125330	NA	0.41	8.1	0.35	5.02e-15	Bone mineral density;
LGG	cis	rs12586317	0.547	rs60152856	chr14:35421373	G/A	cg05294307	chr14:35346193	BAZ1A	-0.54	-7.52	-0.33	2.93e-13	Psoriasis;
LGG	cis	rs9322193	0.567	rs7747457	chr6:150213502	T/A	cg09217309	chr6:150244204	RAET1G	0.42	7.57	0.33	2.09e-13	Lung cancer;
LGG	cis	rs6952808	0.689	rs871924	chr7:2047845	A/G	cg19147804	chr7:1989927	MAD1L1	-0.54	-11.16	-0.46	8.78e-26	Bipolar disorder and schizophrenia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10922622	chr9:108210153	FSD1L	0.42	6.92	0.31	1.47e-11	Cognitive performance;
LGG	cis	rs12497850	1.000	rs10865952	chr3:48744484	A/G	cg06212747	chr3:49208901	KLHDC8B	0.63	10.52	0.44	2.43e-23	Parkinson's disease;
LGG	cis	rs6582630	0.519	rs7305570	chr12:38349285	G/A	cg13010199	chr12:38710504	ALG10B	0.68	13.84	0.54	1.08e-36	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs11741688	0.557	rs6600994	chr5:178336005	T/A	cg13312174	chr5:178288687	ZNF354B	-0.35	-6.89	-0.31	1.8e-11	Sleep duration;
LGG	cis	rs10214930	0.560	rs42089	chr7:27702940	C/T	cg22168087	chr7:27702803	HIBADH	-0.61	-9.91	-0.42	4.09e-21	Hypospadias;
LGG	cis	rs9399135	0.967	rs4896119	chr6:135293391	C/T	cg22676075	chr6:135203613	NA	0.37	6.69	0.3	6.4e-11	Red blood cell count;
LGG	cis	rs11190604	0.767	rs11190533	chr10:102190792	T/C	cg07080220	chr10:102295463	HIF1AN	0.57	9.92	0.42	3.82e-21	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs283228	0.798	rs1933357	chr6:101787411	C/G	cg27451362	chr6:101846650	GRIK2	0.64	10.49	0.44	3.15e-23	Coenzyme Q10 levels;
LGG	cis	rs9463078	0.547	rs2038557	chr6:44740471	G/A	cg25276700	chr6:44698697	NA	0.39	7.92	0.35	1.79e-14	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs1475718	0.526	rs7848481	chr9:137120661	T/C	cg21243944	chr9:137118148	NA	-0.31	-7.7	-0.34	8.39e-14	Immature fraction of reticulocytes;Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9303280	0.901	rs12950743	chr17:38049233	T/C	cg00129232	chr17:37814104	STARD3	-0.48	-9.17	-0.39	1.5e-18	Self-reported allergy;
LGG	cis	rs2228479	0.681	rs4287569	chr16:89957815	A/G	cg04013166	chr16:89971882	TCF25	0.52	7.07	0.31	5.75e-12	Skin colour saturation;
LGG	cis	rs17023223	0.537	rs7532510	chr1:119594236	A/G	cg05756136	chr1:119680316	WARS2	-0.42	-8.67	-0.37	7.4e-17	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;
LGG	cis	rs1552244	0.938	rs7625049	chr3:10115619	C/T	cg00149659	chr3:10157352	C3orf10	0.83	10.67	0.44	6.46e-24	Alzheimer's disease;
LGG	cis	rs11123170	0.543	rs2166421	chr2:113990242	T/C	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.48	7.57	0.33	1.97e-13	Renal function-related traits (BUN);
LGG	cis	rs146201400	1	rs146201400	chr1:26645955	G/GA	cg10402321	chr1:26617780	UBXN11	-0.45	-7.53	-0.33	2.73e-13	Monocyte percentage of white cells;
LGG	trans	rs9354308	0.764	rs3960019	chr6:66586066	T/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.42	-7.1	-0.31	4.66e-12	Metabolite levels;
LGG	cis	rs4930103	0.935	rs4930101	chr11:2021859	G/T	cg08461457	chr11:2027003	NA	0.4	7.96	0.35	1.33e-14	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs657075	0.697	rs34695718	chr5:131645532	A/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.2	0.36	2.37e-15	Rheumatoid arthritis;
LGG	cis	rs7811142	0.830	rs11771936	chr7:99943283	A/G	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.17	18.7	0.66	1.61e-58	Platelet count;
LGG	cis	rs11239187	0.927	rs11499071	chr10:45110800	A/C	cg03916630	chr10:45065415	NA	0.34	7.56	0.33	2.12e-13	Body mass index;
LGG	cis	rs12142240	0.698	rs41534051	chr1:46828734	A/G	cg00530320	chr1:46809349	NSUN4	0.43	8.0	0.35	1.03e-14	Menopause (age at onset);
LGG	cis	rs11190604	1.000	rs11190541	chr10:102203071	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	10.95	0.45	5.55e-25	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs1814175	0.745	rs7483456	chr11:49774613	C/T	cg11707556	chr5:10655725	ANKRD33B	-0.59	-12.19	-0.49	7.9e-30	Height;
LGG	cis	rs7726839	0.526	rs55647623	chr5:567747	T/C	cg14541582	chr5:601475	NA	-0.57	-9.11	-0.39	2.58e-18	Obesity-related traits;
LGG	cis	rs854037	0.759	rs68023515	chr5:57092162	T/C	cg08523694	chr5:57076192	NA	0.57	7.12	0.31	4.02e-12	Birth weight;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.62	-0.41	4.25e-20	Obesity-related traits;
LGG	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg08344181	chr3:125677491	NA	-0.91	-9.18	-0.39	1.42e-18	Depression;
LGG	cis	rs7927592	0.913	rs7127948	chr11:68363062	G/A	cg20283391	chr11:68216788	NA	-0.52	-8.53	-0.37	2.02e-16	Total body bone mineral density;
LGG	cis	rs2243480	0.901	rs13237344	chr7:66022256	T/A	cg12463550	chr7:65579703	CRCP	0.75	8.23	0.36	1.99e-15	Diabetic kidney disease;
LGG	cis	rs2732480	0.577	rs2450994	chr12:48721832	G/A	cg24011408	chr12:48396354	COL2A1	0.48	7.69	0.34	8.97e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs754205	0.672	rs2289047	chr13:110407815	C/A	cg05430997	chr13:110397189	NA	-0.38	-6.65	-0.3	8.23e-11	Reticulocyte fraction of red cells;
LGG	cis	rs769267	0.825	rs1469713	chr19:19528806	A/G	cg11584989	chr19:19387371	SF4	0.4	7.18	0.32	2.74e-12	Tonsillectomy;
LGG	cis	rs13118159	0.573	rs4974618	chr4:1373663	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.57	9.31	0.4	5.29e-19	Longevity;
LGG	cis	rs4740619	0.905	rs10962099	chr9:15611443	A/G	cg14451791	chr9:16040625	NA	-0.41	-10.52	-0.44	2.47e-23	Body mass index;
LGG	cis	rs4481887	0.741	rs7540715	chr1:248544206	C/T	cg00666640	chr1:248458726	OR2T12	0.54	8.97	0.38	7.67e-18	Common traits (Other);
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.46	0.61	3.02e-48	Platelet count;
LGG	cis	rs9358372	0.574	rs9368238	chr6:20800170	G/C	cg13405222	chr6:20811065	CDKAL1	-0.46	-9.35	-0.4	3.89e-19	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.28	0.32	1.44e-12	Prudent dietary pattern;
LGG	cis	rs7617773	1.000	rs12496784	chr3:48186267	C/T	cg11946769	chr3:48343235	NME6	-0.5	-8.06	-0.35	6.74e-15	Coronary artery disease;
LGG	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg24060327	chr5:131705240	SLC22A5	-0.44	-7.34	-0.32	9.44e-13	Blood metabolite levels;
LGG	cis	rs6121246	0.559	rs6058352	chr20:30269179	T/C	cg13852791	chr20:30311386	BCL2L1	0.94	18.63	0.65	3.35e-58	Mean corpuscular hemoglobin;
LGG	cis	rs9549367	0.789	rs6577034	chr13:113879900	T/C	cg18105134	chr13:113819100	PROZ	-0.68	-13.86	-0.54	9.01e-37	Platelet distribution width;
LGG	cis	rs344364	0.511	rs1742469	chr16:1950244	C/T	cg26897989	chr16:1907736	C16orf73	-0.85	-13.95	-0.54	3.51e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs10754283	0.967	rs7519971	chr1:90108743	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs11190604	1.000	rs10883505	chr10:102280772	C/T	cg07570687	chr10:102243282	WNT8B	0.44	7.34	0.32	9.85e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4595586	0.545	rs17546375	chr12:39407248	C/A	cg26384229	chr12:38710491	ALG10B	0.61	10.99	0.45	4.02e-25	Morning vs. evening chronotype;
LGG	cis	rs17826219	0.568	rs7213925	chr17:29121634	A/G	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.26	-0.36	1.58e-15	Body mass index;
LGG	trans	rs7824557	0.569	rs10106207	chr8:11015338	C/T	cg06636001	chr8:8085503	FLJ10661	-0.58	-11.0	-0.46	3.53e-25	Retinal vascular caliber;
LGG	trans	rs12599106	0.707	rs2163977	chr16:34916134	A/G	cg02985366	chr16:32360428	NA	-0.46	-7.16	-0.32	3.19e-12	Menopause (age at onset);
LGG	trans	rs61931739	0.500	rs11052994	chr12:34065843	C/T	cg13010199	chr12:38710504	ALG10B	0.56	10.58	0.44	1.37e-23	Morning vs. evening chronotype;
LGG	cis	rs1790761	0.692	rs674783	chr11:67339076	C/T	cg09038676	chr11:67351608	GSTP1	-0.36	-7.27	-0.32	1.57e-12	Mean corpuscular volume;
LGG	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs28386778	0.897	rs2727328	chr17:61923564	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.1	-0.57	3.48e-42	Prudent dietary pattern;
LGG	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg22467129	chr15:76604101	ETFA	-0.46	-7.9	-0.34	1.99e-14	Blood metabolite levels;
LGG	cis	rs6500602	0.627	rs863501	chr16:4588394	G/C	cg05091796	chr16:4465799	CORO7	0.77	12.27	0.5	3.69e-30	Schizophrenia;
LGG	cis	rs11758351	1.000	rs79264785	chr6:26194121	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.38	0.4	2.96e-19	Gout;Renal underexcretion gout;
LGG	cis	rs2201728	0.967	rs2173199	chr4:100171379	G/A	cg07219303	chr4:100140905	ADH6	-0.42	-8.4	-0.36	5.45e-16	Cardiac Troponin-T levels;
LGG	cis	rs2439831	0.850	rs3759790	chr15:44121030	G/A	cg27015174	chr15:43622946	ADAL;LCMT2	0.81	8.64	0.37	8.91e-17	Lung cancer in ever smokers;
LGG	cis	rs7829975	0.606	rs11776838	chr8:8794801	C/T	cg06636001	chr8:8085503	FLJ10661	-0.44	-7.93	-0.35	1.68e-14	Mood instability;
LGG	cis	rs12477438	0.798	rs17708218	chr2:99696284	C/A	cg08885076	chr2:99613938	TSGA10	-0.59	-12.09	-0.49	2.05e-29	Chronic sinus infection;
LGG	trans	rs2727020	0.615	rs4980435	chr11:49591576	G/A	cg15704280	chr7:45808275	SEPT13	-1.02	-23.11	-0.73	3.77e-79	Coronary artery disease;
LGG	cis	rs4750440	0.676	rs12779988	chr10:14020404	T/A	cg27542038	chr10:14027202	FRMD4A	-0.68	-12.81	-0.51	2.25e-32	Adiponectin levels;
LGG	trans	rs7819412	0.522	rs10088853	chr8:10987967	G/A	cg06636001	chr8:8085503	FLJ10661	-0.45	-7.59	-0.33	1.77e-13	Triglycerides;
LGG	trans	rs826838	1.000	rs10880914	chr12:38720543	C/T	cg06521331	chr12:34319734	NA	-0.45	-7.77	-0.34	5.1e-14	Heart rate;
LGG	cis	rs7811142	0.830	rs6979910	chr7:99940630	A/C	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.87	-0.42	5.43e-21	Platelet count;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg12405833	chr16:12070719	RUNDC2A	-0.45	-7.12	-0.31	4.05e-12	Pancreatic cancer;
LGG	cis	rs4474465	0.790	rs4945292	chr11:78254424	T/A	cg27205649	chr11:78285834	NARS2	0.51	8.8	0.38	2.72e-17	Alzheimer's disease (survival time);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08767027	chr8:136469773	KHDRBS3	0.54	8.29	0.36	1.27e-15	Gut microbiome composition (summer);
LGG	cis	rs1790761	0.504	rs61894496	chr11:67391907	C/T	cg23188684	chr11:67383651	NA	0.61	10.72	0.45	4.35e-24	Mean corpuscular volume;
LGG	cis	rs16922576	0.640	rs12343727	chr9:5215926	A/G	cg02405213	chr9:5042618	JAK2	-0.63	-11.64	-0.48	1.18e-27	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7412746	0.611	rs2271076	chr1:150916657	C/T	cg15448220	chr1:150897856	SETDB1	0.36	6.71	0.3	5.67e-11	Melanoma;
LGG	trans	rs453301	0.598	rs10104303	chr8:8834528	A/T	cg27411982	chr8:10470053	RP1L1	0.46	8.09	0.35	5.1e-15	Joint mobility (Beighton score);
LGG	cis	rs9522267	0.535	rs12583489	chr13:112233455	G/A	cg10483660	chr13:112241077	NA	-0.35	-7.73	-0.34	6.85e-14	Hepatitis;
LGG	cis	rs758324	0.812	rs601441	chr5:131284433	C/T	cg06307176	chr5:131281290	NA	-0.54	-8.77	-0.38	3.4e-17	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs13118159	0.872	rs4974605	chr4:1346389	C/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-8.1	-0.35	4.76e-15	Longevity;
LGG	trans	rs2898290	0.512	rs899366	chr8:11430485	G/A	cg02002194	chr4:3960332	NA	-0.43	-7.18	-0.32	2.72e-12	Systolic blood pressure;
LGG	cis	rs6502050	0.835	rs67149434	chr17:80128007	G/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.31	-0.36	1.05e-15	Life satisfaction;
LGG	trans	rs826838	1.000	rs7299124	chr12:39002661	T/C	cg06521331	chr12:34319734	NA	-0.46	-7.87	-0.34	2.57e-14	Heart rate;
LGG	cis	rs3733585	0.699	rs4473653	chr4:9971058	A/G	cg08250081	chr4:10125330	NA	-0.36	-6.82	-0.3	2.85e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs7781557	0.696	rs55849741	chr7:102584069	C/G	cg18108683	chr7:102477205	FBXL13	-0.54	-8.1	-0.35	5.06e-15	Colorectal adenoma (advanced);
LGG	cis	rs11700980	0.551	rs2832010	chr21:30110378	T/C	cg24692254	chr21:30365293	RNF160	-0.48	-6.66	-0.3	7.91e-11	QRS complex (12-leadsum);
LGG	cis	rs1865760	0.713	rs7766342	chr6:25990674	C/A	cg18357526	chr6:26021779	HIST1H4A	0.49	8.13	0.35	3.99e-15	Height;
LGG	cis	rs11608355	0.521	rs7978210	chr12:109835990	A/G	cg19025524	chr12:109796872	NA	-0.57	-12.61	-0.51	1.57e-31	Neuroticism;
LGG	cis	rs60843830	0.661	rs11674477	chr2:105822	C/G	cg25945732	chr2:264204	ACP1;SH3YL1	0.52	8.87	0.38	1.63e-17	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1023500	0.505	rs134899	chr22:42683030	T/G	cg17050807	chr22:42548356	NA	-0.39	-7.54	-0.33	2.54e-13	Schizophrenia;
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg13939156	chr17:80058883	NA	0.47	9.16	0.39	1.73e-18	Life satisfaction;
LGG	cis	rs10089	1.000	rs4836360	chr5:127458161	T/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.78	12.01	0.49	4.02e-29	Ileal carcinoids;
LGG	cis	rs6743226	0.603	rs11678750	chr2:242200919	T/C	cg10021735	chr2:242295487	FARP2	0.4	7.06	0.31	6.16e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs1008375	0.806	rs13139898	chr4:17706928	T/G	cg18681998	chr4:17616180	MED28	-0.72	-14.36	-0.56	5.98e-39	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4689388	0.890	rs13130845	chr4:6297646	A/C	cg25554036	chr4:6271136	WFS1	0.63	11.72	0.48	5.9e-28	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs283228	0.958	rs2629985	chr6:101826897	C/T	cg27451362	chr6:101846650	GRIK2	0.54	9.04	0.39	4.2e-18	Coenzyme Q10 levels;
LGG	cis	rs6951245	1.000	rs75488469	chr7:1102122	A/G	cg02733842	chr7:1102375	C7orf50	0.74	11.1	0.46	1.5e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4689388	0.926	rs28420833	chr4:6279504	G/A	cg25554036	chr4:6271136	WFS1	0.65	12.39	0.5	1.17e-30	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs629535	0.773	rs489206	chr8:70064883	T/C	cg21567404	chr3:27674614	NA	0.4	6.74	0.3	4.86e-11	Dupuytren's disease;
LGG	cis	rs9910055	0.529	rs425038	chr17:42182028	T/C	cg16434002	chr17:42200994	HDAC5	0.46	8.21	0.36	2.15e-15	Total body bone mineral density;
LGG	cis	rs11155671	0.530	rs9969044	chr6:150209204	A/G	cg13206674	chr6:150067644	NUP43	0.41	8.63	0.37	9.81e-17	Testicular germ cell tumor;
LGG	cis	rs657075	0.697	rs35834048	chr5:131695336	C/T	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs2204008	0.605	rs4608149	chr12:38132057	G/C	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs7695597	0.732	rs62340463	chr4:185180965	T/C	cg12654155	chr4:185238627	NA	-0.41	-7.32	-0.32	1.12e-12	Night sleep phenotypes;
LGG	cis	rs1010254	0.510	rs17543712	chr5:151715526	C/G	cg12297329	chr5:152029980	NA	-0.47	-6.78	-0.3	3.75e-11	Optic nerve measurement (cup area);
LGG	cis	rs4820294	1.000	rs62236668	chr22:38063870	G/A	cg08835221	chr22:38071607	LGALS1	0.27	7.55	0.33	2.4e-13	Fat distribution (HIV);
LGG	cis	rs950027	0.549	rs12909409	chr15:45608582	T/G	cg26924012	chr15:45694286	SPATA5L1	-0.57	-9.75	-0.41	1.44e-20	Response to fenofibrate (adiponectin levels);
LGG	cis	rs7249142	0.561	rs4808185	chr19:19296217	A/G	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.42	-10.66	-0.44	6.9e-24	IgG glycosylation;
LGG	cis	rs3820928	0.647	rs2115597	chr2:227791218	T/C	cg05526886	chr2:227700861	RHBDD1	-0.41	-7.14	-0.31	3.69e-12	Pulmonary function;
LGG	cis	rs9487094	0.626	rs11153215	chr6:110053721	T/G	cg16315928	chr6:109776240	MICAL1	0.44	7.55	0.33	2.39e-13	Height;
LGG	cis	rs13118159	0.505	rs1250128	chr4:1257311	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.44	-7.95	-0.35	1.45e-14	Longevity;
LGG	cis	rs9640161	0.789	rs34728606	chr7:150054694	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-11.27	-0.46	3.4e-26	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs10504229	0.683	rs2101864	chr8:58113226	C/T	cg08280861	chr8:58055591	NA	0.54	6.82	0.3	2.89e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7208859	0.623	rs9911784	chr17:29124580	A/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2708240	1.000	rs7794345	chr7:147568142	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.72	-0.3	5.35e-11	QT interval (drug interaction);
LGG	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg08305652	chr11:111469057	NA	-0.45	-9.25	-0.39	8.19e-19	Primary sclerosing cholangitis;
LGG	cis	rs11122272	0.735	rs2491404	chr1:231512127	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs77956314	0.515	rs60940473	chr12:117462582	C/T	cg02017074	chr12:117425053	FBXW8	-0.55	-7.58	-0.33	1.94e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs9325144	0.647	rs35138700	chr12:38804474	C/T	cg13010199	chr12:38710504	ALG10B	-0.56	-10.65	-0.44	7.7e-24	Morning vs. evening chronotype;
LGG	cis	rs9522267	0.511	rs1163626	chr13:112225200	A/C	cg12773197	chr13:112238673	NA	-0.36	-7.48	-0.33	3.65e-13	Hepatitis;
LGG	trans	rs7824557	0.505	rs2736313	chr8:11086942	C/T	cg08975724	chr8:8085496	FLJ10661	0.48	9.02	0.39	4.94e-18	Retinal vascular caliber;
LGG	cis	rs736408	0.609	rs1029871	chr3:52797634	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.46	0.37	3.52e-16	Bipolar disorder;
LGG	cis	rs4363385	0.818	rs2711	chr1:153005156	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.31e-17	Inflammatory skin disease;
LGG	cis	rs873946	0.564	rs35831787	chr10:134546346	T/C	cg06453172	chr10:134556979	INPP5A	-0.47	-7.53	-0.33	2.67e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs838147	0.844	rs12975033	chr19:49249443	A/T	cg13540341	chr19:49222985	MAMSTR	0.45	10.39	0.43	7.3e-23	Dietary macronutrient intake;
LGG	cis	rs1865760	0.964	rs6932113	chr6:25913098	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.82	-0.34	3.49e-14	Height;
LGG	trans	rs11039798	0.588	rs643668	chr11:48413399	C/G	cg15704280	chr7:45808275	SEPT13	-0.7	-9.71	-0.41	2.1e-20	Axial length;
LGG	cis	rs57221529	0.766	rs72706606	chr5:558609	T/C	cg14541582	chr5:601475	NA	-0.68	-10.44	-0.44	4.88e-23	Lung disease severity in cystic fibrosis;
LGG	trans	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs6762	0.692	rs7928925	chr11:839155	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.69	-11.75	-0.48	4.56e-28	Mean platelet volume;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg07747251	chr5:1868357	NA	0.46	9.26	0.4	7.45e-19	Cardiovascular disease risk factors;
LGG	cis	rs3020736	0.500	rs6002618	chr22:42507859	G/C	cg05082376	chr22:42548792	NA	0.37	7.77	0.34	5.03e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7166081	0.738	rs28399271	chr15:67710011	G/A	cg25173464	chr15:68126554	NA	-0.34	-7.09	-0.31	4.91e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs1552244	0.572	rs17032426	chr3:10167112	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.9	-11.79	-0.48	2.99e-28	Alzheimer's disease;
LGG	cis	rs4919087	0.620	rs1253427	chr10:98981092	G/A	cg25902810	chr10:99078978	FRAT1	-0.42	-6.71	-0.3	5.71e-11	Monocyte count;
LGG	cis	rs13190036	1.000	rs3733875	chr5:176637240	G/T	cg06733329	chr5:176740039	MXD3	0.48	6.72	0.3	5.4e-11	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs8177253	0.574	rs6775042	chr3:133442245	G/T	cg08048268	chr3:133502702	NA	-0.45	-7.93	-0.35	1.61e-14	Iron status biomarkers;
LGG	cis	rs7582720	1.000	rs75141346	chr2:203685119	A/G	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.8	9.69	0.41	2.46e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs10504229	0.683	rs11786527	chr8:58131344	G/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7786808	0.608	rs7784758	chr7:158214386	A/G	cg12438819	chr7:158236134	PTPRN2	0.31	8.28	0.36	1.31e-15	Obesity-related traits;
LGG	cis	rs981844	0.712	rs6535957	chr4:154749862	C/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.72	-0.41	1.84e-20	Response to statins (LDL cholesterol change);
LGG	trans	rs11039798	0.920	rs11500574	chr11:48713986	A/T	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg18252515	chr7:66147081	NA	1.44	20.72	0.69	5.54e-68	Diabetic kidney disease;
LGG	cis	rs4862750	0.832	rs10007858	chr4:187877492	A/G	cg22105103	chr4:187893119	NA	0.57	10.86	0.45	1.24e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	8.43	0.36	4.36e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs9814567	1.000	rs4417907	chr3:134291363	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.09	-0.52	1.5e-33	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg24829409	chr8:58192753	C8orf71	-0.62	-8.89	-0.38	1.38e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg23979677	chr14:67981515	TMEM229B	-0.4	-7.05	-0.31	6.43e-12	Iris color (L* coordinate);
LGG	cis	rs8064024	1.000	rs8064024	chr16:4855279	C/T	cg08329684	chr16:4932620	PPL	-0.44	-9.85	-0.42	6.66e-21	Cancer;
LGG	cis	rs8072100	0.905	rs8077106	chr17:45653291	T/G	cg19784903	chr17:45786737	TBKBP1	0.33	7.41	0.33	6.22e-13	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	0.501	rs2343819	chr17:41409653	T/G	cg25172604	chr17:41446521	NA	-0.31	-7.12	-0.31	4.15e-12	Menopause (age at onset);
LGG	cis	rs4919694	1.000	rs10509760	chr10:104634107	A/G	cg04362960	chr10:104952993	NT5C2	1.1	15.55	0.59	3.48e-44	Arsenic metabolism;
LGG	cis	rs6500602	0.787	rs7204624	chr16:4459834	A/G	cg02048412	chr16:4421654	VASN;CORO7	0.28	6.97	0.31	1.1e-11	Schizophrenia;
LGG	cis	rs6429082	0.755	rs291367	chr1:235690800	G/A	cg26050004	chr1:235667680	B3GALNT2	0.7	11.97	0.49	5.7e-29	Adiposity;
LGG	cis	rs36093844	0.752	rs17744606	chr11:85565450	C/T	cg16165120	chr11:85566439	CCDC83	-0.46	-7.35	-0.32	9.18e-13	IgG response to Plasmodium falciparum antigens (GLURP, MSP2 FC27, MSP2 3D7);
LGG	cis	rs4942783	0.647	rs9526167	chr13:31580145	T/C	cg22761482	chr13:31579400	NA	-0.43	-7.86	-0.34	2.72e-14	Subjective well-being;
LGG	cis	rs9325144	0.647	rs7487395	chr12:38865660	C/A	cg04568710	chr12:38710424	ALG10B	-0.39	-8.07	-0.35	5.96e-15	Morning vs. evening chronotype;
LGG	cis	rs826838	0.967	rs1684413	chr12:39128704	G/A	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	cis	rs17376456	0.877	rs13156865	chr5:93390908	C/A	cg19507638	chr5:93509721	C5orf36	-0.69	-9.56	-0.41	6.95e-20	Diabetic retinopathy;
LGG	cis	rs1008375	1.000	rs4642241	chr4:17617111	T/C	cg18681998	chr4:17616180	MED28	0.87	20.06	0.68	7.4e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs921968	0.612	rs573555	chr2:219348888	A/C	cg01130898	chr2:219473002	PLCD4	-0.4	-6.79	-0.3	3.48e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs3008870	0.677	rs2815354	chr1:67483642	A/T	cg11518657	chr1:67396239	MIER1	0.48	7.28	0.32	1.49e-12	Lymphocyte percentage of white cells;
LGG	cis	rs2721195	0.967	rs1480000	chr8:145702007	C/T	cg08302650	chr8:145750040	LRRC24;LRRC14	0.39	8.48	0.37	3.14e-16	Age at first birth;
LGG	cis	rs9291683	0.567	rs12499857	chr4:9995376	G/A	cg16147221	chr4:10020634	SLC2A9	0.37	6.94	0.31	1.32e-11	Bone mineral density;
LGG	cis	rs477692	0.625	rs4751104	chr10:131405358	G/A	cg05714579	chr10:131428358	MGMT	-0.82	-19.02	-0.66	4.85e-60	Response to temozolomide;
LGG	cis	rs6977660	0.714	rs4721824	chr7:19785898	A/G	cg07541023	chr7:19748670	TWISTNB	0.6	8.27	0.36	1.46e-15	Thyroid stimulating hormone;
LGG	cis	rs2820315	0.867	rs2820322	chr1:201880300	T/C	cg10061532	chr1:201886748	LMOD1	0.32	6.85	0.3	2.35e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs7666738	0.791	rs10022061	chr4:98926821	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.42	0.36	4.85e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs17767392	1.000	rs34011442	chr14:71779083	G/A	cg02058870	chr14:72053146	SIPA1L1	0.47	9.52	0.4	9.68e-20	Mitral valve prolapse;
LGG	cis	rs4788570	0.584	rs6499530	chr16:71723089	C/G	cg06353428	chr16:71660113	MARVELD3	1.25	20.32	0.69	4.13e-66	Intelligence (multi-trait analysis);
LGG	cis	rs6554196	0.686	rs6554195	chr4:55500714	G/T	cg18836493	chr4:55524333	KIT	-0.41	-7.65	-0.33	1.19e-13	Monocyte count;
LGG	cis	rs1218582	0.661	rs4845695	chr1:154911798	A/G	cg12436631	chr1:155007014	DCST1;DCST2	0.48	9.35	0.4	3.72e-19	Prostate cancer;
LGG	cis	rs7659604	0.502	rs11098640	chr4:122675875	G/A	cg19671926	chr4:122722719	EXOSC9	0.47	7.29	0.32	1.39e-12	Type 2 diabetes;
LGG	cis	rs8064029	1.000	rs8060576	chr16:4908956	A/G	cg04440724	chr16:4920505	UBN1	0.59	7.23	0.32	1.96e-12	Cancer;
LGG	cis	rs2836974	1.000	rs28360661	chr21:40681972	G/C	cg06238570	chr21:40685208	BRWD1	0.46	6.96	0.31	1.16e-11	Cognitive function;
LGG	cis	rs6738485	0.507	rs66569888	chr2:106886967	G/A	cg16099169	chr2:106886729	NA	-0.37	-7.79	-0.34	4.45e-14	Pursuit maintenance gain;Pursuit maintenance gain in psychotic disorders;
LGG	cis	rs1577917	0.839	rs1596990	chr6:86550692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.48	-8.32	-0.36	1e-15	Response to antipsychotic treatment;
LGG	cis	rs804292	0.800	rs36018280	chr8:11619397	G/A	cg12395012	chr8:11607386	GATA4	0.52	7.22	0.32	2.12e-12	Alcohol dependence;Nicotine use;
LGG	cis	rs9291683	0.609	rs4622999	chr4:10003395	C/G	cg16147221	chr4:10020634	SLC2A9	0.38	6.99	0.31	9.91e-12	Bone mineral density;
LGG	cis	rs3816183	0.716	rs6715204	chr2:43088470	C/A	cg14631114	chr2:43023945	NA	0.42	7.5	0.33	3.34e-13	Hypospadias;
LGG	cis	rs7943191	0.805	rs12226821	chr11:62369018	C/G	cg13298116	chr11:62369859	EML3;MTA2	0.6	12.95	0.52	5.83e-33	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);
LGG	cis	rs3812831	0.662	rs418027	chr13:114929344	A/C	cg22348356	chr13:114891224	RASA3	0.4	7.73	0.34	6.66e-14	Schizophrenia;
LGG	cis	rs10504229	0.639	rs2318146	chr8:58114873	T/G	cg08677398	chr8:58056175	NA	0.51	8.01	0.35	9.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.609	rs10274300	chr7:1950405	C/G	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.03	-0.49	3.38e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2274273	0.840	rs10136596	chr14:55836773	A/G	cg04306507	chr14:55594613	LGALS3	0.61	16.92	0.62	2.44e-50	Protein biomarker;
LGG	cis	rs2247341	0.515	rs35313041	chr4:1696103	C/T	cg08629884	chr4:1719983	TMEM129	-0.38	-6.96	-0.31	1.19e-11	Hip circumference adjusted for BMI;Height;
LGG	cis	rs239198	0.602	rs9377240	chr6:101323752	C/T	cg09795085	chr6:101329169	ASCC3	0.44	7.19	0.32	2.55e-12	Menarche (age at onset);
LGG	cis	rs12220165	1	rs12220165	chr10:69339164	C/G	cg25104868	chr10:69634168	NA	0.5	7.06	0.31	5.94e-12	Optic disc area;
LGG	cis	rs617791	0.508	rs1047464	chr11:65769456	A/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	8.97	0.38	7.61e-18	Breast cancer;
LGG	cis	rs36051895	0.632	rs10815165	chr9:5149138	T/C	cg02405213	chr9:5042618	JAK2	-0.77	-14.56	-0.56	8.37e-40	Pediatric autoimmune diseases;
LGG	cis	rs17604090	0.793	rs10226095	chr7:29690059	A/G	cg12658982	chr7:29603541	PRR15	0.34	6.67	0.3	7.23e-11	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs9814567	1.000	rs6785027	chr3:134211649	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.5	0.53	2.92e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs1949733	0.523	rs62287455	chr4:8544994	A/T	cg13073564	chr4:8508604	NA	0.42	7.26	0.32	1.63e-12	Response to antineoplastic agents;
LGG	cis	rs2832077	0.506	rs2832085	chr21:30155258	G/T	cg08807101	chr21:30365312	RNF160	-0.6	-9.67	-0.41	2.82e-20	Cognitive test performance;
LGG	cis	rs2836974	0.897	rs35123057	chr21:40711689	C/T	cg11890956	chr21:40555474	PSMG1	1.07	21.96	0.71	8.92e-74	Cognitive function;
LGG	cis	rs8180040	0.620	rs9875235	chr3:47083621	G/A	cg16586182	chr3:47516702	SCAP	-0.73	-13.24	-0.52	3.81e-34	Colorectal cancer;
LGG	cis	rs55794721	0.509	rs4649085	chr1:25778832	G/A	cg02931644	chr1:25747376	RHCE	0.44	9.66	0.41	3.22e-20	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs1832886	1	rs1832886	chr10:94477539	G/A	cg25093409	chr10:94429542	NA	0.38	7.01	0.31	8.29e-12	Body mass index;
LGG	cis	rs8078723	1.000	rs3826331	chr17:38150492	T/C	cg17467752	chr17:38218738	THRA	-0.72	-13.38	-0.53	9.48e-35	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs644799	0.544	rs1622515	chr11:95523433	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.63	10.97	0.45	4.96e-25	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs61306359	chr8:58134646	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs7911264	0.739	rs7071905	chr10:94386122	T/G	cg25093409	chr10:94429542	NA	0.48	9.54	0.41	7.99e-20	Inflammatory bowel disease;
LGG	cis	rs769267	0.965	rs7254230	chr19:19434350	C/T	cg02546618	chr19:19431379	KIAA0892;SF4	-0.46	-7.65	-0.33	1.2e-13	Tonsillectomy;
LGG	cis	rs1552244	0.882	rs68080705	chr3:10025743	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.85e-33	Alzheimer's disease;
LGG	cis	rs4936891	0.520	rs17760637	chr11:123880581	T/C	cg22125253	chr11:123886957	OR10G4	-0.49	-8.22	-0.36	2.09e-15	Male fertility;
LGG	trans	rs11250098	0.516	rs7843666	chr8:10742059	G/A	cg16141378	chr3:129829833	LOC729375	0.33	7.34	0.32	9.64e-13	Morning vs. evening chronotype;
LGG	cis	rs897984	0.684	rs6950	chr16:30995669	T/C	cg00531865	chr16:30841666	NA	0.55	11.55	0.47	2.83e-27	Dementia with Lewy bodies;
LGG	cis	rs2070488	0.965	rs1984312	chr3:38538466	G/T	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.84	-17.96	-0.64	4.18e-55	Electrocardiographic conduction measures;
LGG	cis	rs798554	0.679	rs2533868	chr7:2886559	G/A	cg19524238	chr7:2802976	GNA12	0.38	9.07	0.39	3.52e-18	Height;
LGG	cis	rs10465746	0.905	rs1324484	chr1:84382844	T/C	cg10977910	chr1:84465055	TTLL7	0.52	9.42	0.4	2.12e-19	Obesity-related traits;
LGG	cis	rs10220309	0.501	rs4899763	chr14:80641302	C/T	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.12e-11	Lung function (FEV1);
LGG	cis	rs1799949	0.773	rs2137990	chr17:41317896	T/A	cg25172604	chr17:41446521	NA	0.29	6.81	0.3	2.98e-11	Menopause (age at onset);
LGG	trans	rs6582630	0.572	rs7315897	chr12:38449081	C/T	cg06521331	chr12:34319734	NA	0.43	7.72	0.34	7.17e-14	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9457247	0.967	rs1590257	chr6:167377782	G/T	cg07741184	chr6:167504864	NA	-0.31	-6.94	-0.31	1.34e-11	Crohn's disease;
LGG	cis	rs1994135	0.654	rs11052759	chr12:33724126	G/A	cg06521331	chr12:34319734	NA	-0.51	-8.44	-0.37	4.22e-16	Resting heart rate;
LGG	trans	rs12599106	0.839	rs3853177	chr16:34498532	A/G	cg21548813	chr6:291882	DUSP22	-0.51	-8.92	-0.38	1.1e-17	Menopause (age at onset);
LGG	cis	rs12893668	0.703	rs35498576	chr14:104025893	T/C	cg26031613	chr14:104095156	KLC1	-0.58	-9.19	-0.39	1.31e-18	Reticulocyte count;
LGG	cis	rs2688482	0.512	rs3103953	chr3:195520597	G/A	cg08521684	chr3:195488725	MUC4	-0.57	-7.42	-0.33	5.67e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs9916302	0.861	rs11078896	chr17:37415544	C/T	cg00129232	chr17:37814104	STARD3	-0.61	-11.43	-0.47	7.87e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs2668423	0.502	rs7254913	chr19:1388320	A/G	cg02639931	chr19:1387894	NDUFS7	0.98	24.51	0.75	1.1e-85	Nonalcoholic fatty liver disease;
LGG	cis	rs988958	0.565	rs11889038	chr2:42238233	G/A	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs2455799	0.613	rs3856830	chr3:15806520	A/C	cg16303742	chr3:15540471	COLQ	-0.4	-8.02	-0.35	8.56e-15	Mean platelet volume;
LGG	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg17376030	chr22:41985996	PMM1	0.56	9.18	0.39	1.41e-18	Vitiligo;
LGG	cis	rs344364	0.529	rs186941	chr16:1930088	T/C	cg00490583	chr16:1843685	IGFALS	0.45	7.52	0.33	2.87e-13	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs7267979	1.000	rs2424712	chr20:25416942	T/C	cg06421707	chr20:25228305	PYGB	0.48	10.45	0.44	4.24e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs516946	1.000	rs28602970	chr8:41524505	A/G	cg21772509	chr8:41503840	NKX6-3	-0.54	-8.42	-0.36	4.93e-16	Type 2 diabetes;
LGG	cis	rs4918072	0.667	rs34312189	chr10:105706383	T/G	cg11005552	chr10:105648138	OBFC1	0.42	7.19	0.32	2.54e-12	Coronary artery disease;
LGG	cis	rs3733585	0.781	rs6449183	chr4:9970691	C/A	cg25986240	chr4:9926439	SLC2A9	0.45	9.44	0.4	1.78e-19	Cleft plate (environmental tobacco smoke interaction);
LGG	trans	rs6921919	0.673	rs13201681	chr6:28394680	C/T	cg08344181	chr3:125677491	NA	-0.92	-9.17	-0.39	1.6e-18	Autism spectrum disorder or schizophrenia;
LGG	trans	rs637571	0.726	rs669371	chr11:65674153	G/T	cg17712092	chr4:129076599	LARP1B	-0.86	-18.25	-0.65	1.85e-56	Eosinophil percentage of white cells;
LGG	cis	rs763014	0.931	rs7191939	chr16:630089	C/T	cg04911050	chr16:677664	RAB40C	0.35	6.96	0.31	1.17e-11	Height;
LGG	cis	rs35740288	0.770	rs11635190	chr15:86148531	C/T	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs7215564	0.908	rs4889883	chr17:78664374	C/A	cg16980736	chr17:78789706	RPTOR	-0.62	-8.19	-0.36	2.61e-15	Myopia (pathological);
LGG	cis	rs12188164	0.610	rs57433159	chr5:418725	C/T	cg21972741	chr5:435613	AHRR	0.41	7.32	0.32	1.11e-12	Cystic fibrosis severity;
LGG	cis	rs9308731	0.644	rs10189015	chr2:111918472	G/A	cg19992207	chr2:111874495	ACOXL	-0.38	-6.94	-0.31	1.35e-11	Chronic lymphocytic leukemia;
LGG	cis	rs919433	0.854	rs13013049	chr2:198208664	C/T	cg00792783	chr2:198669748	PLCL1	-0.44	-6.85	-0.3	2.41e-11	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs3091242	0.934	rs686631	chr1:25719599	A/T	cg27572855	chr1:25598939	RHD	0.5	11.4	0.47	1.09e-26	Erythrocyte sedimentation rate;
LGG	cis	rs3812831	0.662	rs407531	chr13:114929218	G/A	cg25866889	chr13:114914595	NA	-0.35	-7.13	-0.31	3.88e-12	Schizophrenia;
LGG	cis	rs61776719	0.747	rs28428561	chr1:38434306	G/A	cg04673462	chr1:38461896	NA	-0.57	-12.37	-0.5	1.41e-30	Coronary artery disease;
LGG	cis	rs62064224	0.614	rs2286645	chr17:30696292	C/T	cg25809561	chr17:30822961	MYO1D	0.37	8.75	0.38	3.94e-17	Schizophrenia;
LGG	cis	rs10463554	0.963	rs62362546	chr5:102351319	C/T	cg23492399	chr5:102201601	PAM	-0.51	-7.59	-0.33	1.78e-13	Parkinson's disease;
LGG	cis	rs4474465	0.736	rs4945291	chr11:78254413	C/T	cg27205649	chr11:78285834	NARS2	0.49	8.44	0.37	4.21e-16	Alzheimer's disease (survival time);
LGG	cis	rs9291683	0.588	rs17246745	chr4:9994583	T/C	cg08250081	chr4:10125330	NA	0.4	7.62	0.33	1.4e-13	Bone mineral density;
LGG	cis	rs7666738	0.830	rs34671152	chr4:98978177	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.33	0.36	9.38e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11748327	0.580	rs2131593	chr5:4012486	A/G	cg01025095	chr5:4101132	NA	-0.43	-7.07	-0.31	5.58e-12	Myocardial infarction;
LGG	cis	rs6138458	1.000	rs227621	chr20:24910528	A/C	cg26195577	chr20:24973756	C20orf3	1.22	25.55	0.76	1.82e-90	Blood protein levels;
LGG	cis	rs9790314	0.521	rs1450522	chr3:161077630	A/G	cg04691961	chr3:161091175	C3orf57	-0.49	-10.06	-0.42	1.19e-21	Morning vs. evening chronotype;
LGG	cis	rs4474465	0.688	rs7124803	chr11:78280822	T/G	cg27205649	chr11:78285834	NARS2	0.6	11.33	0.47	1.95e-26	Alzheimer's disease (survival time);
LGG	cis	rs2290416	0.579	rs58573550	chr8:144681714	G/A	cg04293180	chr8:144700367	TSTA3	0.89	6.83	0.3	2.72e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs2839186	0.900	rs59828751	chr21:47708918	A/G	cg12379764	chr21:47803548	PCNT	-0.45	-7.71	-0.34	7.71e-14	Testicular germ cell tumor;
LGG	cis	rs12701220	0.895	rs10262866	chr7:1019536	G/A	cg26769984	chr7:1090371	C7orf50	0.54	8.9	0.38	1.24e-17	Bronchopulmonary dysplasia;
LGG	cis	rs1577917	1.000	rs11758849	chr6:86708262	G/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.76	-13.25	-0.52	3.25e-34	Response to antipsychotic treatment;
LGG	cis	rs6940638	0.688	rs6921388	chr6:27080205	A/G	cg12826209	chr6:26865740	GUSBL1	0.47	7.88	0.34	2.34e-14	Intelligence (multi-trait analysis);
LGG	cis	rs6964587	0.967	rs7783414	chr7:91785957	C/T	cg17063962	chr7:91808500	NA	0.53	9.8	0.41	9.81e-21	Breast cancer;
LGG	cis	rs35306767	0.903	rs12249634	chr10:872744	G/A	cg26597838	chr10:835615	NA	0.74	10.22	0.43	2.9e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs4595586	0.655	rs11831499	chr12:39310114	A/T	cg26384229	chr12:38710491	ALG10B	0.48	8.84	0.38	2.02e-17	Morning vs. evening chronotype;
LGG	cis	rs7246657	0.722	rs2972458	chr19:38135403	T/C	cg23950597	chr19:37808831	NA	0.53	7.85	0.34	3.01e-14	Coronary artery calcification;
LGG	trans	rs1728785	0.901	rs933713	chr16:68581378	C/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs6831352	0.589	rs2924584	chr4:99988208	A/G	cg12011299	chr4:100065546	ADH4	0.47	10.57	0.44	1.53e-23	Alcohol dependence;
LGG	cis	rs6840360	0.615	rs2406973	chr4:152608339	G/T	cg22705602	chr4:152727874	NA	0.36	8.89	0.38	1.4e-17	Intelligence (multi-trait analysis);
LGG	trans	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg02002194	chr4:3960332	NA	-0.47	-8.96	-0.38	8.3e-18	Neuroticism;
LGG	cis	rs2652822	0.525	rs35594365	chr15:63520154	T/C	cg02713581	chr15:63449717	RPS27L	0.4	6.7	0.3	6.13e-11	Metabolic traits;
LGG	cis	rs2204008	0.774	rs7959048	chr12:37948276	T/A	cg26384229	chr12:38710491	ALG10B	0.95	21.48	0.71	1.52e-71	Bladder cancer;
LGG	cis	rs798554	0.591	rs1713913	chr7:2895627	C/T	cg27476859	chr7:2772710	GNA12	0.47	8.99	0.39	6.42e-18	Height;
LGG	cis	rs2046867	0.818	rs11929144	chr3:72868234	T/C	cg25664220	chr3:72788482	NA	-0.33	-9.2	-0.39	1.2e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6456156	0.586	rs1407315	chr6:167468659	A/G	cg07741184	chr6:167504864	NA	0.4	9.14	0.39	2.04e-18	Primary biliary cholangitis;
LGG	cis	rs6061231	0.740	rs11698650	chr20:60958374	A/T	cg23531748	chr20:60969906	CABLES2	0.43	7.8	0.34	4.12e-14	Colorectal cancer;
LGG	cis	rs427394	0.582	rs274667	chr5:6710771	A/G	cg15145174	chr5:6755386	POLS	0.41	7.82	0.34	3.68e-14	Menopause (age at onset);
LGG	cis	rs4319547	0.695	rs10744211	chr12:122931820	A/G	cg23029597	chr12:123009494	RSRC2	-0.94	-17.17	-0.62	1.76e-51	Body mass index;
LGG	cis	rs68170813	0.559	rs79705824	chr7:106848325	T/C	cg02696742	chr7:106810147	HBP1	-0.74	-10.64	-0.44	8.77e-24	Coronary artery disease;
LGG	cis	rs7011049	1.000	rs11997774	chr8:53833370	T/A	cg26025543	chr8:53854495	NA	0.73	9.66	0.41	3.02e-20	Systolic blood pressure;
LGG	cis	rs151997	1.000	rs72758246	chr5:50246783	G/C	cg06027927	chr5:50259733	NA	0.65	10.71	0.45	4.65e-24	Callous-unemotional behaviour;
LGG	cis	rs911555	0.546	rs28798508	chr14:104068970	T/C	cg23335576	chr14:104009727	NA	0.39	6.7	0.3	6.07e-11	Intelligence (multi-trait analysis);
LGG	cis	rs34783982	0.510	rs34526927	chr15:89529176	A/G	cg09489435	chr15:89561491	NA	-0.38	-7.23	-0.32	2.07e-12	Squamous cell lung carcinoma;
LGG	trans	rs11039798	0.507	rs56994343	chr11:48896970	G/A	cg03929089	chr4:120376271	NA	0.71	9.82	0.42	8.67e-21	Axial length;
LGG	cis	rs7633857	0.595	rs7640874	chr3:160672617	T/A	cg04691961	chr3:161091175	C3orf57	-0.44	-9.12	-0.39	2.36e-18	Educational attainment (years of education);
LGG	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg12463550	chr7:65579703	CRCP	0.75	8.15	0.35	3.4e-15	Diabetic kidney disease;
LGG	cis	rs7098414	0.511	rs10788603	chr10:82148137	G/T	cg01528321	chr10:82214614	TSPAN14	0.69	12.3	0.5	2.84e-30	Post bronchodilator FEV1;
LGG	cis	rs7511006	0.798	rs11703673	chr22:50652427	A/G	cg08875078	chr22:50639485	SELO	-0.43	-6.69	-0.3	6.43e-11	Obesity-related traits;
LGG	trans	rs116095464	0.558	rs10068203	chr5:206618	C/T	cg09048205	chr5:1608656	LOC728613	-0.52	-8.45	-0.37	3.82e-16	Breast cancer;
LGG	cis	rs6684428	0.536	rs11206686	chr1:56394673	A/G	cg11651538	chr1:56320950	NA	-0.43	-8.32	-0.36	9.770000000000001e-16	Airflow obstruction;
LGG	cis	rs9660992	1.000	rs1779410	chr1:205248759	A/G	cg21545522	chr1:205238299	TMCC2	0.38	7.12	0.31	4.08e-12	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs9303401	0.614	rs62084384	chr17:57126842	G/A	cg25039879	chr17:56429692	SUPT4H1	0.62	8.61	0.37	1.14e-16	Cognitive test performance;
LGG	cis	rs1983891	0.706	rs745548	chr6:41557117	G/T	cg20194872	chr6:41519635	FOXP4	-0.5	-8.67	-0.37	7.34e-17	Prostate cancer;
LGG	cis	rs1107366	0.593	rs12635766	chr3:125930021	T/C	cg11252792	chr3:125932053	NA	0.78	17.33	0.63	3.31e-52	Metabolite levels;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg19147804	chr7:1989927	MAD1L1	-0.54	-10.03	-0.42	1.5e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs12893597	1.000	rs35788287	chr14:76814313	A/G	cg20290672	chr14:76816747	NA	-0.48	-7.03	-0.31	7.53e-12	Maximal oxygen uptake response;
LGG	cis	rs597539	0.652	rs546382	chr11:68704264	C/T	cg06112835	chr11:68658793	MRPL21	0.61	10.24	0.43	2.46e-22	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6089584	0.627	rs55875402	chr20:60559925	G/A	cg06108461	chr20:60628389	TAF4	-0.64	-11.11	-0.46	1.39e-25	Body mass index;
LGG	cis	rs11764590	0.715	rs11766468	chr7:2082604	G/A	cg02825527	chr7:2087843	MAD1L1	-0.53	-8.79	-0.38	3.05e-17	Neuroticism;
LGG	cis	rs1008375	1.000	rs10939744	chr4:17664473	G/T	cg02297831	chr4:17616191	MED28	0.5	9.36	0.4	3.57e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72827839	0.793	rs72823527	chr17:46098810	G/T	cg02219949	chr17:45927392	SP6	0.52	7.92	0.35	1.76e-14	Ease of getting up in the morning;
LGG	cis	rs936229	1.000	rs4886615	chr15:75131661	A/G	cg14664628	chr15:75095509	CSK	-1.02	-22.19	-0.72	7.58e-75	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs4819052	0.655	rs2330103	chr21:46694514	C/T	cg06618935	chr21:46677482	NA	-0.36	-7.04	-0.31	6.8e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs6089829	0.962	rs6089824	chr20:61659207	A/G	cg08862035	chr2:2617432	NA	0.43	6.95	0.31	1.25e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs9486719	0.948	rs2499813	chr6:96875338	T/C	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs2228479	0.850	rs11649100	chr16:89798179	A/G	cg06558623	chr16:89946397	TCF25	1.12	12.22	0.49	6.01e-30	Skin colour saturation;
LGG	cis	rs2797369	0.769	rs12199600	chr6:101594847	C/T	cg27451362	chr6:101846650	GRIK2	0.77	10.3	0.43	1.51e-22	Renal function-related traits (eGRFcrea);
LGG	cis	rs2231884	0.697	rs11227332	chr11:65623739	A/G	cg26695010	chr11:65641043	EFEMP2	-0.51	-7.04	-0.31	7.04e-12	Inflammatory bowel disease;
LGG	cis	rs16944613	0.588	rs12438183	chr15:91139244	T/C	cg26821196	chr15:91095069	CRTC3	0.5	7.08	0.31	5.41e-12	Colorectal cancer;
LGG	cis	rs35146811	0.586	rs10267212	chr7:99595422	T/C	cg22906224	chr7:99728672	NA	0.53	8.52	0.37	2.31e-16	Coronary artery disease;
LGG	cis	rs7843479	0.601	rs11135764	chr8:21814004	A/G	cg17168535	chr8:21777572	XPO7	0.82	16.26	0.6	2.38e-47	Mean corpuscular volume;
LGG	cis	rs514406	0.584	rs11205997	chr1:53195271	G/C	cg16325326	chr1:53192061	ZYG11B	-0.91	-25.63	-0.77	7.69e-91	Monocyte count;
LGG	cis	rs9487051	0.766	rs351748	chr6:109532296	C/T	cg21918786	chr6:109611834	NA	0.43	7.96	0.35	1.37e-14	Reticulocyte fraction of red cells;
LGG	cis	rs10851411	0.647	rs62022308	chr15:42734162	G/T	cg21293051	chr15:42870591	STARD9	0.47	6.91	0.31	1.6e-11	Glucose homeostasis traits;
LGG	cis	rs921968	0.541	rs4674310	chr2:219318078	T/C	cg10223061	chr2:219282414	VIL1	0.3	6.77	0.3	3.86e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs9929218	0.953	rs28608872	chr16:68802038	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.83	-0.51	1.93e-32	Colorectal cancer;
LGG	cis	rs4481887	0.741	rs6682957	chr1:248535639	T/G	cg01631408	chr1:248437212	OR2T33	-0.38	-6.82	-0.3	2.81e-11	Common traits (Other);
LGG	cis	rs881375	1.000	rs881375	chr9:123652898	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.51	9.3	0.4	5.52e-19	Rheumatoid arthritis;
LGG	trans	rs7819412	0.545	rs11781155	chr8:10917560	C/T	cg16141378	chr3:129829833	LOC729375	0.37	7.72	0.34	7.13e-14	Triglycerides;
LGG	cis	rs75920871	0.588	rs1940626	chr11:116828121	T/C	cg20608306	chr11:116969690	SIK3	-0.41	-10.81	-0.45	1.96e-24	Subjective well-being;
LGG	trans	rs7819412	0.521	rs11777887	chr8:11036799	C/G	cg06636001	chr8:8085503	FLJ10661	0.46	7.98	0.35	1.14e-14	Triglycerides;
LGG	cis	rs4330281	0.608	rs6442679	chr3:17397851	C/T	cg20981856	chr3:17787350	NA	0.36	6.82	0.3	2.87e-11	Schizophrenia;
LGG	cis	rs9393692	0.557	rs62394769	chr6:26326182	C/T	cg13736514	chr6:26305472	NA	-0.48	-9.19	-0.39	1.28e-18	Educational attainment;
LGG	cis	rs3617	0.625	rs2240915	chr3:52859526	T/A	cg11645453	chr3:52864694	ITIH4	0.44	7.4	0.33	6.63e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs8141529	0.748	rs6005936	chr22:29289250	T/C	cg02153584	chr22:29168773	CCDC117	0.6	9.86	0.42	6.28e-21	Lymphocyte counts;
LGG	cis	rs861020	0.606	rs695140	chr1:210005061	G/A	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs2988277	0.713	rs10800313	chr1:167429985	C/T	cg09179987	chr1:167433047	CD247	-0.33	-7.45	-0.33	4.73e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9287719	0.674	rs10929690	chr2:10805974	T/C	cg02196655	chr2:10830764	NOL10	0.49	8.64	0.37	9.13e-17	Prostate cancer;
LGG	cis	rs877282	0.755	rs1769242	chr10:787896	T/C	cg17470449	chr10:769945	NA	0.53	6.86	0.3	2.16e-11	Uric acid levels;
LGG	cis	rs9354308	0.899	rs2814153	chr6:66557611	T/A	cg07460842	chr6:66804631	NA	0.56	9.27	0.4	7.33e-19	Metabolite levels;
LGG	cis	rs4077515	0.874	rs35670379	chr9:139270606	T/C	cg21253087	chr9:139290292	SNAPC4	0.36	7.45	0.33	4.47e-13	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9543976	0.920	rs9543992	chr13:76175074	G/A	cg01531495	chr13:76123901	UCHL3	0.63	7.61	0.33	1.58e-13	Diabetic retinopathy;
LGG	cis	rs4716602	0.596	rs13221649	chr7:156160793	G/A	cg16983916	chr7:156159713	NA	-0.49	-9.51	-0.4	1.04e-19	Anti-saccade response;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg23782820	chr8:58130467	NA	0.49	6.88	0.3	1.92e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg06634786	chr22:41940651	POLR3H	0.77	12.27	0.5	3.83e-30	Vitiligo;
LGG	cis	rs6502050	0.835	rs67634087	chr17:80118168	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.6	-0.41	5.12e-20	Life satisfaction;
LGG	trans	rs6582630	0.555	rs10880625	chr12:38526612	A/C	cg06521331	chr12:34319734	NA	-0.5	-8.68	-0.37	6.65e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs12477438	0.501	rs11688004	chr2:99735052	G/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.91	21.15	0.7	5.44e-70	Chronic sinus infection;
LGG	cis	rs2576037	0.901	rs2576036	chr18:44587102	G/T	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.42	8.12	0.35	4.33e-15	Personality dimensions;
LGG	trans	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg07393940	chr7:158741817	NA	-0.58	-10.77	-0.45	2.8e-24	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12482904	0.779	rs11203201	chr21:43823726	C/G	cg23042151	chr21:43824109	UBASH3A	-0.45	-7.79	-0.34	4.33e-14	Vitiligo;
LGG	cis	rs796364	1.000	rs10178177	chr2:200829993	G/A	cg23649088	chr2:200775458	C2orf69	0.6	7.78	0.34	4.73e-14	Schizophrenia;
LGG	cis	rs6977660	0.943	rs12668201	chr7:19831610	A/C	cg05791153	chr7:19748676	TWISTNB	-0.59	-8.83	-0.38	2.13e-17	Thyroid stimulating hormone;
LGG	cis	rs653465	0.739	rs1357245	chr3:27186602	C/T	cg02860705	chr3:27208620	NA	-0.39	-7.69	-0.34	8.9e-14	Breast cancer (early onset);
LGG	cis	rs8072100	0.713	rs3871595	chr17:45511388	C/T	cg25173405	chr17:45401733	C17orf57	-0.54	-9.11	-0.39	2.41e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs4555082	0.834	rs4412909	chr14:105759226	T/C	cg27165867	chr14:105738592	BRF1	-0.43	-6.97	-0.31	1.09e-11	Mean platelet volume;Platelet distribution width;
LGG	cis	rs875971	1.000	rs2077593	chr7:65892530	A/G	cg18876405	chr7:65276391	NA	0.55	9.79	0.41	1.12e-20	Aortic root size;
LGG	cis	rs17376456	0.877	rs10072592	chr5:93405989	C/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.15	0.43	5.36e-22	Diabetic retinopathy;
LGG	cis	rs1639906	0.507	rs1004643	chr7:2185324	G/C	cg20308403	chr7:2120281	MAD1L1	-0.44	-8.91	-0.38	1.18e-17	Colonoscopy-negative controls vs population controls;
LGG	cis	rs11122272	0.735	rs2486730	chr1:231534987	T/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.17	-0.46	7.99e-26	Hemoglobin concentration;
LGG	cis	rs240764	0.817	rs239230	chr6:101105862	C/A	cg09795085	chr6:101329169	ASCC3	0.46	7.76	0.34	5.32e-14	Neuroticism;
LGG	cis	rs28386778	0.897	rs4638645	chr17:61828349	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.58	0.5	1.93e-31	Prudent dietary pattern;
LGG	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.99	10.75	0.45	3.4e-24	Lung cancer in ever smokers;
LGG	cis	rs769267	0.965	rs4808938	chr19:19401218	G/A	cg03709012	chr19:19516395	GATAD2A	0.8	15.24	0.58	8.5e-43	Tonsillectomy;
LGG	cis	rs7737355	0.947	rs2191001	chr5:131096677	C/G	cg06307176	chr5:131281290	NA	0.57	9.46	0.4	1.61e-19	Life satisfaction;
LGG	cis	rs6489785	0.701	rs568297	chr12:121221763	C/T	cg02419362	chr12:121203948	SPPL3	0.44	6.87	0.3	2.09e-11	Longevity;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs2294693	0.947	rs9296351	chr6:40988102	T/C	cg14769373	chr6:40998127	UNC5CL	-0.41	-7.33	-0.32	1.06e-12	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs2976388	1.000	rs1045547	chr8:143763757	T/G	cg06565975	chr8:143823917	SLURP1	-0.4	-10.26	-0.43	2.19e-22	Urinary tract infection frequency;
LGG	cis	rs6667605	0.527	rs12046118	chr1:2540343	A/C	cg20673091	chr1:2541236	MMEL1	0.78	19.1	0.66	2.06e-60	Inflammatory bowel disease;Ulcerative colitis;
LGG	cis	rs745821	0.540	rs8083350	chr18:48086236	G/C	cg18923635	chr18:48083994	NA	0.42	7.53	0.33	2.6e-13	Diastolic blood pressure;
LGG	cis	rs2880765	0.835	rs4842887	chr15:86035810	T/C	cg13263323	chr15:86062960	AKAP13	-0.35	-7.33	-0.32	1.05e-12	Coronary artery disease;
LGG	trans	rs7395662	0.571	rs4881998	chr11:48525186	C/T	cg21153622	chr11:89784906	NA	-0.39	-6.66	-0.3	7.59e-11	HDL cholesterol;
LGG	trans	rs853679	0.760	rs9357067	chr6:28210293	C/G	cg06606381	chr12:133084897	FBRSL1	-0.62	-7.94	-0.35	1.58e-14	Depression;
LGG	cis	rs9287719	0.967	rs10206225	chr2:10758657	A/G	cg02196655	chr2:10830764	NOL10	-0.43	-7.43	-0.33	5.25e-13	Prostate cancer;
LGG	cis	rs4671458	0.948	rs1829526	chr2:63464879	A/G	cg17519650	chr2:63277830	OTX1	-0.64	-8.29	-0.36	1.27e-15	Subjective well-being;
LGG	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg05941027	chr17:61774174	LIMD2	0.31	7.65	0.34	1.15e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs8002861	0.875	rs12872943	chr13:44410553	G/A	cg12856521	chr11:46389249	DGKZ	-0.4	-6.82	-0.3	2.92e-11	Leprosy;
LGG	cis	rs10504229	0.683	rs35840293	chr8:58117634	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs12579753	0.879	rs7971664	chr12:82264101	T/C	cg07988820	chr12:82153109	PPFIA2	-0.59	-8.57	-0.37	1.51e-16	Resting heart rate;
LGG	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg21385522	chr1:16154831	NA	0.56	10.3	0.43	1.5e-22	Systolic blood pressure;
LGG	cis	rs2115536	0.967	rs3826008	chr15:80189805	G/T	cg11839771	chr15:80205821	ST20	-0.34	-7.24	-0.32	1.89e-12	Eosinophil counts;Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs35306767	0.855	rs12781100	chr10:838636	C/T	cg26597838	chr10:835615	NA	0.94	12.84	0.51	1.74e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs3087591	0.639	rs2854333	chr17:29713300	T/C	cg24425628	chr17:29625626	OMG;NF1	0.6	12.42	0.5	9.32e-31	Hip circumference;
LGG	cis	rs6930083	0.713	rs1321309	chr6:36638636	G/A	cg08179530	chr6:36648295	CDKN1A	-0.73	-13.39	-0.53	8.88e-35	Coronary artery disease;
LGG	cis	rs1008375	0.900	rs7658447	chr4:17579415	T/C	cg02297831	chr4:17616191	MED28	0.43	7.69	0.34	9.04e-14	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3812831	0.695	rs10467349	chr13:114939441	A/G	cg25338242	chr13:114786047	RASA3	0.39	7.18	0.32	2.82e-12	Schizophrenia;
LGG	cis	rs977987	0.864	rs40446	chr16:75496658	T/C	cg03315344	chr16:75512273	CHST6	-0.57	-11.16	-0.46	8.79e-26	Dupuytren's disease;
LGG	cis	rs10504229	0.683	rs6982990	chr8:58115275	C/T	cg08677398	chr8:58056175	NA	-0.5	-7.97	-0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs16854884	0.632	rs1910691	chr3:143656905	G/A	cg06585982	chr3:143692056	C3orf58	0.67	12.02	0.49	3.86e-29	Economic and political preferences (feminism/equality);
LGG	cis	rs10752881	1.000	rs10911185	chr1:182971747	G/C	cg07245641	chr1:182991651	LAMC1	0.42	9.81	0.41	8.86e-21	Colorectal cancer;
LGG	cis	rs4969178	0.965	rs16971105	chr17:76393975	G/T	cg02836325	chr17:76403955	PGS1	-0.71	-14.42	-0.56	3.24e-39	HDL cholesterol levels;
LGG	cis	rs6732160	0.613	rs62151837	chr2:73390396	G/T	cg01422370	chr2:73384389	NA	0.58	10.18	0.43	4.27e-22	Intelligence (multi-trait analysis);
LGG	trans	rs8073060	0.586	rs2428464	chr17:34021994	C/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs12497850	1.000	rs4858828	chr3:48724811	C/T	cg07636037	chr3:49044803	WDR6	1.02	23.19	0.73	1.54e-79	Parkinson's disease;
LGG	cis	rs651907	0.514	rs12636047	chr3:101434449	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.23	-0.32	1.97e-12	Colorectal cancer;
LGG	cis	rs4595586	0.545	rs7973338	chr12:39380704	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.75	0.45	3.2e-24	Morning vs. evening chronotype;
LGG	cis	rs12493885	0.769	rs61791540	chr3:153757041	G/A	cg12800244	chr3:153838788	SGEF	-0.75	-8.58	-0.37	1.43e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	trans	rs6952808	0.792	rs2056481	chr7:1955435	A/G	cg24247370	chr13:99142703	STK24	-0.39	-7.18	-0.32	2.85e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs11583043	0.918	rs58029001	chr1:101393409	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.45	9.11	0.39	2.4e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs7945705	0.712	rs61876274	chr11:9019190	A/T	cg21881798	chr11:8931708	C11orf17;ST5	0.51	10.9	0.45	9.11e-25	Hemoglobin concentration;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.02	-0.31	8.14e-12	Bipolar disorder;
LGG	cis	rs972578	1.000	rs2284098	chr22:43401772	A/G	cg01576275	chr22:43409880	NA	-0.23	-6.76	-0.3	4.28e-11	Mean platelet volume;
LGG	cis	rs4774899	0.869	rs12900589	chr15:57373236	T/C	cg08128148	chr15:57256372	TCF12	-0.3	-7.19	-0.32	2.6e-12	Urinary tract infection frequency;
LGG	trans	rs877282	0.797	rs11253329	chr10:753200	A/T	cg22713356	chr15:30763199	NA	0.48	7.32	0.32	1.1e-12	Uric acid levels;
LGG	cis	rs7814319	0.700	rs3808385	chr8:97273513	C/T	cg20787634	chr8:97240163	UQCRB	-0.69	-13.92	-0.54	4.84e-37	Lung function (FVC);
LGG	cis	rs1862618	0.853	rs863840	chr5:56128999	C/G	cg12654349	chr5:56205094	C5orf35	-0.61	-9.36	-0.4	3.57e-19	Initial pursuit acceleration;
LGG	cis	rs4732038	0.565	rs706193	chr7:134269909	A/G	cg06906464	chr7:134288099	NA	-0.72	-20.95	-0.7	4.77e-69	Longevity;
LGG	cis	rs5758511	0.680	rs1033459	chr22:42619067	A/G	cg15128208	chr22:42549153	NA	0.74	11.33	0.47	1.93e-26	Birth weight;
LGG	cis	rs12701220	0.948	rs12690826	chr7:1081618	A/G	cg26769984	chr7:1090371	C7orf50	0.56	9.67	0.41	2.78e-20	Bronchopulmonary dysplasia;
LGG	cis	rs17767392	1.000	rs35854505	chr14:71841477	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-9.02	-0.39	5.11e-18	Mitral valve prolapse;
LGG	cis	rs6951245	1.000	rs74785791	chr7:1088494	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.09	-20.49	-0.69	6.56e-67	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11650494	0.908	rs73324308	chr17:47405338	T/G	cg08112188	chr17:47440006	ZNF652	1.3	15.35	0.58	2.76e-43	Prostate cancer;
LGG	cis	rs765787	0.530	rs12910270	chr15:45512086	G/A	cg25801113	chr15:45476975	SHF	-0.87	-19.09	-0.66	2.27e-60	Uric acid levels;
LGG	cis	rs1577917	0.839	rs12055653	chr6:86546663	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.5	-0.44	2.77e-23	Response to antipsychotic treatment;
LGG	trans	rs783540	1.000	rs1267657	chr15:83215251	T/C	cg18393722	chr15:85113863	UBE2QP1	-0.42	-6.97	-0.31	1.12e-11	Schizophrenia;
LGG	cis	rs11148252	0.774	rs7993748	chr13:52941631	C/T	cg12458913	chr13:53173898	NA	0.65	12.71	0.51	6.1e-32	Lewy body disease;
LGG	trans	rs4650994	1.000	rs10913571	chr1:178526648	A/T	cg05059571	chr16:84539110	KIAA1609	-0.43	-8.02	-0.35	8.78e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs760805	0.900	rs1005733	chr1:25261960	T/A	cg22509179	chr1:25234806	RUNX3	-0.66	-13.8	-0.54	1.53e-36	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17301259	0.509	rs4352770	chr7:88407694	C/A	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.01	-0.31	8.67e-12	Heschl's gyrus morphology;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22904679	chr16:1031428	SOX8	0.47	6.95	0.31	1.23e-11	Gut microbiome composition (summer);
LGG	cis	rs2072732	0.808	rs74048148	chr1:2954031	A/G	cg08733933	chr1:2954429	NA	-0.4	-8.53	-0.37	2.17e-16	Plateletcrit;
LGG	cis	rs11583043	1.000	rs6682873	chr1:101470906	C/A	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.48	8.32	0.36	9.66e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs4319547	0.626	rs11057882	chr12:122875046	A/G	cg23029597	chr12:123009494	RSRC2	-0.93	-17.27	-0.63	5.92e-52	Body mass index;
LGG	cis	rs10197940	0.510	rs7557092	chr2:152423459	T/A	cg19508488	chr2:152266495	RIF1	0.54	8.47	0.37	3.29e-16	Lung cancer;
LGG	cis	rs4253772	0.550	rs715515	chr22:46720921	G/A	cg00784671	chr22:46762841	CELSR1	-0.62	-7.03	-0.31	7.62e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs10911251	0.546	rs12034436	chr1:183114797	A/G	cg15522984	chr1:182991683	LAMC1	0.43	8.56	0.37	1.73e-16	Colorectal cancer;
LGG	cis	rs2839186	0.934	rs17182538	chr21:47705673	C/A	cg13732083	chr21:47605072	C21orf56	0.47	7.84	0.34	3.23e-14	Testicular germ cell tumor;
LGG	cis	rs7618501	0.602	rs2240326	chr3:50128386	G/A	cg24110177	chr3:50126178	RBM5	0.57	10.54	0.44	1.99e-23	Intelligence (multi-trait analysis);
LGG	cis	rs9486719	0.947	rs6916232	chr6:96985959	A/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.78	0.45	2.51e-24	Migraine;Coronary artery disease;
LGG	cis	rs12210905	0.925	rs72838262	chr6:27008517	G/C	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.5	-0.33	3.39e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10883723	0.810	rs10748823	chr10:104274465	C/G	cg11453585	chr10:104263688	ACTR1A;SUFU	0.76	15.25	0.58	7.96e-43	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17376456	0.877	rs10213956	chr5:93460839	C/T	cg21475434	chr5:93447410	FAM172A	0.7	7.14	0.31	3.72e-12	Diabetic retinopathy;
LGG	cis	rs28655083	1.000	rs8059347	chr16:77068259	C/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.5	-7.94	-0.35	1.55e-14	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs12153243	0.565	rs17341585	chr5:142871503	G/A	cg13907255	chr5:142895549	NA	-0.47	-7.88	-0.34	2.29e-14	Migraine;
LGG	cis	rs11992186	0.505	rs7845203	chr8:8145440	A/G	cg08975724	chr8:8085496	FLJ10661	0.45	8.32	0.36	9.59e-16	Neuroticism;
LGG	cis	rs7582180	0.726	rs4438499	chr2:100876789	A/G	cg08297393	chr2:100937505	LONRF2	0.44	7.78	0.34	4.8e-14	Intelligence (multi-trait analysis);
LGG	cis	rs950776	0.518	rs2869055	chr15:78822388	G/C	cg16751781	chr15:78858589	CHRNA5	-0.43	-8.74	-0.38	4.38e-17	Sudden cardiac arrest;
LGG	cis	rs8180040	0.903	rs11130124	chr3:47292183	T/C	cg27129171	chr3:47204927	SETD2	0.83	15.96	0.6	5.28e-46	Colorectal cancer;
LGG	cis	rs9303401	0.614	rs35057477	chr17:57097064	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.31	0.55	1.03e-38	Cognitive test performance;
LGG	cis	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg19084075	chr6:26124329	HIST1H2AC;HIST1H2BC	0.71	6.81	0.3	3.07e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs2072732	0.861	rs72856440	chr1:2956582	A/G	cg22517653	chr1:2918612	NA	-0.44	-6.72	-0.3	5.39e-11	Plateletcrit;
LGG	cis	rs2797160	0.905	rs1418640	chr6:125999866	G/A	cg05901451	chr6:126070800	HEY2	-0.43	-7.22	-0.32	2.12e-12	Endometrial cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19003389	chr17:17876154	LRRC48;TOM1L2	0.43	7.34	0.32	9.67e-13	Gut microbiome composition (summer);
LGG	cis	rs757278	0.646	rs11768272	chr7:117347082	G/A	cg10524701	chr7:117356490	CTTNBP2	0.46	8.25	0.36	1.66e-15	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs10504229	1.000	rs56168206	chr8:58184485	G/A	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs4363385	0.782	rs394859	chr1:153025704	T/C	cg13444842	chr1:152974279	SPRR3	-0.43	-8.78	-0.38	3.13e-17	Inflammatory skin disease;
LGG	trans	rs61931739	0.890	rs1705748	chr12:34133171	A/G	cg26384229	chr12:38710491	ALG10B	0.64	12.67	0.51	8.25e-32	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.554	rs4488814	chr3:10002400	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	-0.72	-12.98	-0.52	4.32e-33	Alzheimer's disease;
LGG	cis	rs62064224	0.818	rs11080181	chr17:30701210	C/T	cg18200150	chr17:30822561	MYO1D	0.78	18.03	0.64	2.01e-55	Schizophrenia;
LGG	cis	rs2228479	0.681	rs11642428	chr16:89971909	A/T	cg00800038	chr16:89945340	TCF25	-0.58	-8.16	-0.35	3.24e-15	Skin colour saturation;
LGG	cis	rs7618915	0.501	rs3755798	chr3:52741160	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.23	0.39	9.96e-19	Bipolar disorder;
LGG	cis	rs9322193	0.962	rs952165	chr6:150120036	T/C	cg11878867	chr6:150167359	LRP11	-0.48	-9.91	-0.42	4.13e-21	Lung cancer;
LGG	cis	rs4563143	0.663	rs2218396	chr19:29236392	C/T	cg12756686	chr19:29218302	NA	0.74	12.39	0.5	1.16e-30	Methadone dose in opioid dependence;
LGG	cis	rs3761218	1.000	rs4815603	chr20:3772527	A/T	cg25011176	chr20:3776985	CDC25B	-0.47	-7.32	-0.32	1.14e-12	Bipolar disorder;
LGG	cis	rs2072732	0.861	rs12039132	chr1:2949355	C/T	cg08733933	chr1:2954429	NA	-0.42	-8.59	-0.37	1.3e-16	Plateletcrit;
LGG	cis	rs9326248	1.000	rs9326248	chr11:116999225	A/C	cg11861562	chr11:117069780	TAGLN	0.25	6.74	0.3	4.73e-11	Blood protein levels;
LGG	cis	rs6754311	0.550	rs3213889	chr2:136511575	A/G	cg07169764	chr2:136633963	MCM6	-0.78	-13.64	-0.54	7.61e-36	Mosquito bite size;
LGG	cis	rs6867032	0.958	rs4975795	chr5:2015390	G/A	cg26168224	chr5:2018326	NA	1.28	30.44	0.82	1.43e-112	Gut microbiome composition (winter);
LGG	cis	rs7824557	0.651	rs6601582	chr8:11207367	C/A	cg21775007	chr8:11205619	TDH	0.83	15.44	0.58	1.15e-43	Retinal vascular caliber;
LGG	cis	rs4820294	0.669	rs732857	chr22:38060850	C/T	cg26138144	chr22:38071188	LGALS1	0.68	15.52	0.59	4.74e-44	Fat distribution (HIV);
LGG	trans	rs11148252	0.500	rs342768	chr13:53208882	C/T	cg18335740	chr13:41363409	SLC25A15	0.79	18.37	0.65	5.26e-57	Lewy body disease;
LGG	cis	rs4262150	0.883	rs72802890	chr5:152255145	G/T	cg12297329	chr5:152029980	NA	-0.65	-12.34	-0.5	1.99e-30	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs9901076	chr17:80170020	G/A	cg23985595	chr17:80112537	CCDC57	-0.49	-9.67	-0.41	2.91e-20	Life satisfaction;
LGG	trans	rs2727020	0.729	rs6485965	chr11:49166730	C/T	cg00717180	chr2:96193071	NA	0.38	6.85	0.3	2.43e-11	Coronary artery disease;
LGG	trans	rs7618501	1.000	rs1491986	chr3:49739086	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.86	-0.51	1.43e-32	Intelligence (multi-trait analysis);
LGG	cis	rs11122272	0.735	rs2486745	chr1:231505717	T/C	cg10503236	chr1:231470652	EXOC8	-0.37	-7.28	-0.32	1.45e-12	Hemoglobin concentration;
LGG	cis	rs11148252	0.875	rs9596651	chr13:52938582	A/G	cg05335186	chr13:53173507	NA	-0.44	-9.02	-0.39	4.98e-18	Lewy body disease;
LGG	cis	rs526231	0.511	rs34823	chr5:102438291	C/T	cg23492399	chr5:102201601	PAM	0.57	8.38	0.36	6.2e-16	Primary biliary cholangitis;
LGG	cis	rs2066819	1.000	rs11575234	chr12:56744276	C/G	cg26714650	chr12:56694279	CS	-1.45	-16.54	-0.61	1.23e-48	Psoriasis vulgaris;
LGG	cis	rs1577917	0.883	rs1337854	chr6:86724015	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.45	7.83	0.34	3.37e-14	Response to antipsychotic treatment;
LGG	cis	rs16867321	0.694	rs4666853	chr2:181439671	C/T	cg23363182	chr2:181467187	NA	0.43	8.58	0.37	1.43e-16	Obesity;
LGG	cis	rs6430585	0.640	rs3816155	chr2:136552526	A/C	cg07169764	chr2:136633963	MCM6	-1.27	-23.99	-0.74	2.95e-83	Corneal structure;
LGG	cis	rs6121246	0.580	rs6121016	chr20:30245239	C/T	cg13852791	chr20:30311386	BCL2L1	0.75	11.32	0.47	2.15e-26	Mean corpuscular hemoglobin;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04213235	chr1:145826932	GPR89A	0.56	8.95	0.38	8.97e-18	Gut microbiome composition (summer);
LGG	cis	rs4665809	0.590	rs2384361	chr2:26452209	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-1.07	-21.0	-0.7	2.76e-69	Gut microbiome composition (summer);
LGG	cis	rs2797160	1.000	rs1954361	chr6:126001423	C/G	cg05901451	chr6:126070800	HEY2	-0.44	-7.45	-0.33	4.66e-13	Endometrial cancer;
LGG	cis	rs7223966	1.000	rs7220892	chr17:61908316	G/A	cg11494091	chr17:61959527	GH2	0.51	8.19	0.36	2.51e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs6430585	0.702	rs73958637	chr2:136546927	C/T	cg07169764	chr2:136633963	MCM6	1.27	24.15	0.75	5.42e-84	Corneal structure;
LGG	cis	rs910316	0.763	rs4556	chr14:75476071	G/C	cg08847533	chr14:75593920	NEK9	0.55	10.18	0.43	4.41e-22	Height;
LGG	cis	rs6088590	1.000	rs10048849	chr20:33419680	C/T	cg24642439	chr20:33292090	TP53INP2	0.81	14.5	0.56	1.55e-39	Coronary artery disease;
LGG	cis	rs858239	0.600	rs7776644	chr7:23119307	C/T	cg23682824	chr7:23144976	KLHL7	0.43	7.47	0.33	4.06e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs2290416	0.892	rs76108894	chr8:144673533	G/A	cg04293180	chr8:144700367	TSTA3	0.89	6.83	0.3	2.72e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs7192750	0.583	rs8046916	chr16:72047751	C/G	cg14768367	chr16:72042858	DHODH	-0.83	-8.63	-0.37	9.92e-17	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs936229	0.749	rs7497201	chr15:75190690	A/G	cg10253484	chr15:75165896	SCAMP2	-0.68	-11.08	-0.46	1.8e-25	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs2019137	0.868	rs6755639	chr2:113981810	A/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.64	11.45	0.47	6.5e-27	Lymphocyte counts;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03505427	chr20:47662643	CSE1L	0.41	6.87	0.3	2.08e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs11123170	0.542	rs28522253	chr2:113967387	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.62	9.33	0.4	4.49e-19	Renal function-related traits (BUN);
LGG	cis	rs7904985	0.889	rs1078789	chr10:88110247	C/T	cg07322936	chr10:88137208	NA	-0.45	-7.23	-0.32	1.95e-12	Barrett's esophagus;
LGG	cis	rs6598955	0.543	rs57564009	chr1:26557618	A/T	cg04990556	chr1:26633338	UBXN11	0.72	10.58	0.44	1.46e-23	Obesity-related traits;
LGG	cis	rs10504229	0.639	rs55687236	chr8:58105856	C/T	cg20607798	chr8:58055168	NA	0.7	7.83	0.34	3.35e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10207628	1.000	rs1530047	chr2:127848936	A/C	cg06223080	chr2:127868745	NA	-0.75	-13.97	-0.54	2.81e-37	Psychosis and Alzheimer's disease;
LGG	cis	rs6424115	0.867	rs4649119	chr1:24171543	C/G	cg24699146	chr1:24152579	HMGCL	-0.27	-7.84	-0.34	3.09e-14	Immature fraction of reticulocytes;
LGG	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg13770153	chr20:60521292	NA	-0.49	-7.93	-0.35	1.63e-14	Body mass index;
LGG	cis	rs12478296	1.000	rs11899408	chr2:243014630	A/G	cg18898632	chr2:242989856	NA	-0.84	-10.84	-0.45	1.53e-24	Obesity-related traits;
LGG	cis	rs1577917	0.876	rs1582126	chr6:86697205	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.65	-0.44	7.55e-24	Response to antipsychotic treatment;
LGG	cis	rs498079	1.000	rs498079	chr6:133562456	G/C	cg06181518	chr6:133562196	EYA4	0.42	7.13	0.31	3.91e-12	Total body bone mineral density;
LGG	cis	rs17209837	1.000	rs67721532	chr7:87084403	A/G	cg00919237	chr7:87102261	ABCB4	-0.71	-11.27	-0.46	3.23e-26	Gallbladder cancer;
LGG	cis	rs6951245	0.935	rs76525951	chr7:1096013	C/T	cg03188948	chr7:1209495	NA	0.64	8.22	0.36	2.13e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11608355	0.538	rs12228876	chr12:109796799	C/A	cg19025524	chr12:109796872	NA	-0.59	-12.75	-0.51	4.01e-32	Neuroticism;
LGG	cis	rs6951245	0.935	rs118132455	chr7:1068232	C/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.08	-20.0	-0.68	1.29e-64	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg16974379	chr10:38146505	ZNF248	0.52	8.05	0.35	7.21e-15	Gut microbiome composition (summer);
LGG	trans	rs4427176	0.507	rs7462910	chr8:9579986	C/T	cg16141378	chr3:129829833	LOC729375	-0.34	-6.74	-0.3	4.66e-11	Mosquito bite size;
LGG	trans	rs9951602	0.512	rs8098115	chr18:76653986	G/T	cg02800362	chr5:177631904	HNRNPAB	0.78	13.62	0.53	9.34e-36	Obesity-related traits;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg23985595	chr17:80112537	CCDC57	-0.48	-9.62	-0.41	4.18e-20	Life satisfaction;
LGG	cis	rs1707322	1.000	rs6675222	chr1:46326576	G/T	cg03146154	chr1:46216737	IPP	0.54	10.46	0.44	4.01e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs6495122	0.651	rs11636952	chr15:75114322	T/C	cg20040747	chr15:74715105	SEMA7A	0.38	7.81	0.34	3.78e-14	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs3749237	1.000	rs3749237	chr3:49770032	C/T	cg03060546	chr3:49711283	APEH	0.59	9.04	0.39	4.31e-18	Resting heart rate;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg05240614	chr19:49122848	RPL18;SPHK2	-0.4	-6.68	-0.3	6.98e-11	Pancreatic cancer;
LGG	cis	rs42648	0.869	rs10251227	chr7:89892286	T/G	cg25739043	chr7:89950458	NA	-0.39	-8.29	-0.36	1.25e-15	Homocysteine levels;
LGG	cis	rs12477438	0.700	rs10190421	chr2:99670711	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs7326068	0.610	rs4769134	chr13:21438871	G/A	cg04906043	chr13:21280425	IL17D	-0.45	-7.25	-0.32	1.76e-12	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs988958	0.530	rs6724482	chr2:42236010	A/C	cg27428208	chr2:42229179	NA	0.48	7.66	0.34	1.09e-13	Hypospadias;
LGG	cis	rs4332037	0.506	rs62442924	chr7:1989976	C/T	cg12432903	chr7:1882776	MAD1L1	0.43	6.77	0.3	3.91e-11	Bipolar disorder;
LGG	cis	rs700651	0.789	rs116165148	chr2:198888347	T/G	cg00792783	chr2:198669748	PLCL1	0.64	10.35	0.43	9.95e-23	Intracranial aneurysm;
LGG	cis	rs1008375	0.966	rs3796813	chr4:17591648	A/G	cg16339924	chr4:17578868	LAP3	0.63	10.98	0.45	4.2e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.647	rs11634266	chr15:77093461	A/G	cg23625390	chr15:77176239	SCAPER	-0.73	-14.56	-0.56	8.22e-40	Blood metabolite levels;
LGG	cis	rs9549367	0.789	rs57747440	chr13:113894750	C/A	cg00898013	chr13:113819073	PROZ	-0.43	-8.62	-0.37	1.07e-16	Platelet distribution width;
LGG	cis	rs875971	0.540	rs736270	chr7:65428822	T/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.49	10.08	0.42	9.6e-22	Aortic root size;
LGG	cis	rs7312774	0.618	rs12316476	chr12:107343326	C/G	cg16260113	chr12:107380972	MTERFD3	0.94	8.76	0.38	3.79e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs10504229	0.906	rs7003276	chr8:58173089	A/T	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6032067	0.929	rs6032070	chr20:43869795	A/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.79e-28	Blood protein levels;
LGG	cis	rs709400	0.894	rs56017123	chr14:104075277	G/A	cg24130564	chr14:104152367	KLC1	-0.42	-8.04	-0.35	7.69e-15	Body mass index;
LGG	cis	rs11671005	0.735	rs3826682	chr19:58918748	C/T	cg13877915	chr19:58951672	ZNF132	0.59	8.38	0.36	6.39e-16	Mean platelet volume;
LGG	cis	rs116095464	0.558	rs1541822	chr5:269234	A/C	cg22496380	chr5:211416	CCDC127	1.23	17.7	0.64	6.26e-54	Breast cancer;
LGG	cis	rs7619833	0.625	rs6551183	chr3:27281198	G/T	cg02860705	chr3:27208620	NA	0.4	7.74	0.34	6.34e-14	Breast cancer;
LGG	cis	rs657075	0.697	rs13184379	chr5:131678145	G/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.72	0.3	5.2e-11	Rheumatoid arthritis;
LGG	cis	rs6088580	0.634	rs6088502	chr20:33037644	A/T	cg08999081	chr20:33150536	PIGU	0.39	9.72	0.41	1.91e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs7618915	0.547	rs11130311	chr3:52675005	T/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.45	-0.44	4.46e-23	Bipolar disorder;
LGG	cis	rs9899728	0.539	rs56267297	chr17:73046996	T/C	cg27626185	chr17:73056755	KCTD2	-1.03	-12.17	-0.49	9.47e-30	Alzheimer's disease or small vessel stroke;
LGG	cis	rs981844	1.000	rs56232929	chr4:154665700	A/G	cg14289246	chr4:154710475	SFRP2	0.7	11.64	0.48	1.22e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs7223966	1.000	rs9901507	chr17:61765524	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.4	-0.33	6.32e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2832077	0.527	rs9980449	chr21:30224889	G/C	cg24692254	chr21:30365293	RNF160	-0.7	-13.1	-0.52	1.45e-33	Cognitive test performance;
LGG	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg12560992	chr17:57184187	TRIM37	0.91	15.92	0.59	7.98e-46	Intelligence (multi-trait analysis);
LGG	cis	rs4555082	0.718	rs28513571	chr14:105709592	C/A	cg27165867	chr14:105738592	BRF1	-0.44	-7.31	-0.32	1.21e-12	Mean platelet volume;Platelet distribution width;
LGG	cis	rs751728	0.664	rs747694	chr6:33736490	A/G	cg25922239	chr6:33757077	LEMD2	0.4	6.78	0.3	3.6e-11	Crohn's disease;
LGG	cis	rs2522056	1.000	rs2106854	chr5:131769174	C/T	cg07395648	chr5:131743802	NA	0.41	7.18	0.32	2.85e-12	Lymphocyte counts;Fibrinogen;
LGG	cis	rs3785574	0.924	rs2727292	chr17:61893747	A/G	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs10504229	0.775	rs17805026	chr8:58160637	A/C	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	0.830	rs1063945	chr7:99930447	C/T	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.1	-0.42	8.49e-22	Platelet count;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg06873352	chr17:61820015	STRADA	-0.7	-12.39	-0.5	1.16e-30	Prudent dietary pattern;
LGG	cis	rs2075371	0.796	rs35440439	chr7:134006094	C/T	cg11752832	chr7:134001865	SLC35B4	0.62	11.21	0.46	5.91e-26	Mean platelet volume;
LGG	cis	rs12200782	1.000	rs3927423	chr6:26393487	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.06	-0.31	6.22e-12	Small cell lung carcinoma;
LGG	cis	rs6547741	1.000	rs6737921	chr2:27839107	T/C	cg22903471	chr2:27725779	GCKR	0.39	8.75	0.38	4.14e-17	Oral cavity cancer;
LGG	cis	rs7312774	0.618	rs3803122	chr12:107354680	G/A	cg16260113	chr12:107380972	MTERFD3	0.95	8.82	0.38	2.41e-17	Severe influenza A (H1N1) infection;
LGG	cis	rs8177253	1.000	rs1358023	chr3:133484393	T/C	cg01448562	chr3:133502909	NA	-0.75	-14.0	-0.55	2.21e-37	Iron status biomarkers;
LGG	cis	rs2985684	0.789	rs1957979	chr14:50063332	A/G	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.42	6.92	0.31	1.54e-11	Carotid intima media thickness;
LGG	cis	rs9747201	0.925	rs62078748	chr17:80055325	C/T	cg21453758	chr17:80185943	SLC16A3	-0.34	-6.96	-0.31	1.16e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6500602	0.727	rs8051389	chr16:4570570	C/T	cg01673284	chr16:4527211	HMOX2	0.33	6.85	0.3	2.34e-11	Schizophrenia;
LGG	trans	rs1493916	0.905	rs1586988	chr18:31396001	G/C	cg04226714	chr8:49833948	SNAI2	-0.5	-9.09	-0.39	2.85e-18	Life satisfaction;
LGG	cis	rs6582630	0.555	rs34730221	chr12:38405140	C/T	cg26384229	chr12:38710491	ALG10B	-0.85	-19.19	-0.67	7.69e-61	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9322193	0.923	rs9322208	chr6:149979683	A/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.58	-0.41	5.89e-20	Lung cancer;
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg11494091	chr17:61959527	GH2	1.0	24.7	0.75	1.59e-86	Prudent dietary pattern;
LGG	cis	rs7580658	0.550	rs62160290	chr2:128200695	C/T	cg10021288	chr2:128175891	PROC	-0.67	-13.5	-0.53	2.94e-35	Protein C levels;
LGG	trans	rs2840044	1.000	rs225304	chr17:33921857	G/T	cg19694781	chr19:47549865	TMEM160	-0.55	-9.06	-0.39	3.55e-18	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs2074193	0.614	rs1642941	chr12:47767039	G/C	cg02516419	chr12:47771422	NA	-0.58	-8.61	-0.37	1.18e-16	Migraine with aura;
LGG	trans	rs7819412	0.936	rs7814499	chr8:11040647	A/G	cg02002194	chr4:3960332	NA	0.41	7.73	0.34	6.95e-14	Triglycerides;
LGG	cis	rs8062405	0.824	rs7191618	chr16:28565667	C/G	cg00198680	chr16:28758506	NA	0.3	7.54	0.33	2.55e-13	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs7617480	0.585	rs7373072	chr3:48960017	T/A	cg06212747	chr3:49208901	KLHDC8B	0.47	7.16	0.32	3.16e-12	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs35306767	0.953	rs7908138	chr10:962978	C/T	cg25019033	chr10:957182	NA	-0.6	-12.69	-0.51	7e-32	Eosinophil percentage of granulocytes;
LGG	cis	rs1799949	1.000	rs8176212	chr17:41226601	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.26	-0.32	1.69e-12	Menopause (age at onset);
LGG	cis	rs2224391	0.628	rs2753231	chr6:5248915	C/A	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-7.43	-0.33	5.2e-13	Height;
LGG	cis	rs2204008	0.777	rs11179774	chr12:38219559	A/C	cg13010199	chr12:38710504	ALG10B	0.7	13.99	0.55	2.46e-37	Bladder cancer;
LGG	trans	rs57221529	0.766	rs72703064	chr5:587825	T/C	cg11887960	chr12:57824829	NA	0.6	7.33	0.32	1.07e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs11764590	0.950	rs55683212	chr7:2078855	G/C	cg02825527	chr7:2087843	MAD1L1	-0.46	-8.4	-0.36	5.7e-16	Neuroticism;
LGG	cis	rs2413583	0.536	rs17304621	chr22:39690791	C/T	cg17798944	chr22:39715225	SNORD43;RPL3	0.67	7.76	0.34	5.62e-14	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs10504229	0.683	rs56408763	chr8:58137276	G/A	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12048904	0.647	rs7528268	chr1:101329295	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.73	17.01	0.62	8.85e-51	Multiple sclerosis;
LGG	cis	rs7107174	0.892	rs1893449	chr11:77968977	G/C	cg02023728	chr11:77925099	USP35	0.44	7.5	0.33	3.37e-13	Testicular germ cell tumor;
LGG	trans	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg02002194	chr4:3960332	NA	0.49	9.26	0.4	7.66e-19	Mood instability;
LGG	cis	rs875971	0.862	rs57866200	chr7:65565392	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.71	-0.3	5.75e-11	Aortic root size;
LGG	cis	rs1008375	0.932	rs12500912	chr4:17603318	C/T	cg02297831	chr4:17616191	MED28	0.49	8.81	0.38	2.49e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500395	1.000	rs11641458	chr16:48670845	C/T	cg16662043	chr16:48846231	NA	0.36	7.15	0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6502050	0.871	rs8072702	chr17:80074280	C/T	cg11859384	chr17:80120422	CCDC57	0.45	7.81	0.34	3.85e-14	Life satisfaction;
LGG	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg08250081	chr4:10125330	NA	0.41	8.0	0.35	1.03e-14	Bone mineral density;
LGG	cis	rs7397814	0.558	rs4764447	chr12:9579109	C/T	cg27502298	chr12:9555721	NA	0.81	15.19	0.58	1.43e-42	IgG glycosylation;
LGG	cis	rs7586879	0.559	rs13387729	chr2:25076126	A/G	cg04586622	chr2:25135609	ADCY3	0.4	10.5	0.44	2.76e-23	Body mass index;
LGG	trans	rs7395662	0.746	rs8186207	chr11:48765365	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.22	-0.32	2.2e-12	HDL cholesterol;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01013600	chr19:49141177	DBP;SEC1	0.43	6.98	0.31	1.03e-11	Cognitive performance;
LGG	cis	rs62064224	0.614	rs9916114	chr17:30766950	T/C	cg18200150	chr17:30822561	MYO1D	0.5	9.42	0.4	2.19e-19	Schizophrenia;
LGG	cis	rs17767392	0.958	rs12889866	chr14:71937439	C/T	cg02058870	chr14:72053146	SIPA1L1	0.46	9.11	0.39	2.54e-18	Mitral valve prolapse;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.52	-0.53	2.34e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs6951245	0.580	rs77101766	chr7:1122438	A/G	cg09177884	chr7:1199841	ZFAND2A	-0.45	-6.65	-0.3	8.48e-11	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1620921	0.594	rs28597670	chr6:161271643	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.34	-0.32	9.54e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs11688302	1	rs11688302	chr2:136960483	C/T	cg07169764	chr2:136633963	MCM6	0.51	8.41	0.36	5.1e-16	Mosquito bite size;
LGG	cis	rs7647973	0.560	rs7638154	chr3:49299375	C/A	cg07636037	chr3:49044803	WDR6	0.95	20.55	0.69	3.64e-67	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs10276077	chr7:65728411	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.34	-6.7	-0.3	6.16e-11	Aortic root size;
LGG	cis	rs17373728	0.526	rs9886508	chr8:76152991	C/T	cg07016329	chr8:76221503	NA	0.47	8.58	0.37	1.4e-16	Diabetic kidney disease;
LGG	cis	rs7208859	0.673	rs73277964	chr17:29179201	A/T	cg01831904	chr17:28903510	LRRC37B2	-0.72	-8.54	-0.37	1.89e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8017423	0.967	rs8009493	chr14:90690083	G/C	cg04374321	chr14:90722782	PSMC1	0.88	18.58	0.65	5.5e-58	Mortality in heart failure;
LGG	cis	rs13108904	0.935	rs1732102	chr4:1277924	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.48	-8.9	-0.38	1.26e-17	Obesity-related traits;
LGG	cis	rs11098499	0.569	rs10023641	chr4:120258410	C/G	cg09307838	chr4:120376055	NA	0.67	11.73	0.48	5.48e-28	Corneal astigmatism;
LGG	cis	rs1552244	0.554	rs58020561	chr3:10054682	A/G	cg02579736	chr3:10068473	FANCD2;CIDECP	0.74	12.89	0.51	1.05e-32	Alzheimer's disease;
LGG	cis	rs7582180	0.629	rs12621892	chr2:100947124	G/C	cg08017756	chr2:100939284	LONRF2	-0.28	-6.67	-0.3	7.42e-11	Intelligence (multi-trait analysis);
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg14074117	chr16:1909714	C16orf73	-0.54	-7.94	-0.35	1.55e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs888194	0.738	rs2058807	chr12:109973273	T/C	cg19025524	chr12:109796872	NA	-0.36	-7.17	-0.32	2.96e-12	Neuroticism;
LGG	cis	rs17102423	0.723	rs8181937	chr14:65555707	A/C	cg26396452	chr14:65542826	MAX	0.43	8.49	0.37	2.93e-16	Obesity-related traits;
LGG	trans	rs9650657	0.707	rs6984744	chr8:10616265	A/C	cg08975724	chr8:8085496	FLJ10661	-0.37	-6.78	-0.3	3.62e-11	Neuroticism;
LGG	cis	rs9357271	1.000	rs9357269	chr6:38355497	A/C	cg07362130	chr6:38359646	BTBD9	-0.48	-11.01	-0.46	3.35e-25	Restless legs syndrome;
LGG	trans	rs1005277	0.579	rs2505257	chr10:38372664	A/G	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.26	-0.55	1.72e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs41271473	1.000	rs11587994	chr1:228860072	A/C	cg10167378	chr1:228756711	NA	0.59	8.45	0.37	3.83e-16	Chronic lymphocytic leukemia;
LGG	cis	rs4665809	1.000	rs10202478	chr2:26276049	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.83	-13.36	-0.53	1.13e-34	Gut microbiome composition (summer);
LGG	cis	rs6708331	0.646	rs12713688	chr2:70369503	G/C	cg01613454	chr2:70366299	NA	0.54	9.4	0.4	2.58e-19	Obesity-related traits;
LGG	cis	rs7444	0.941	rs5754352	chr22:21964951	C/T	cg15846791	chr22:21984385	YDJC	-0.44	-6.73	-0.3	5.15e-11	Systemic lupus erythematosus;
LGG	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg25174290	chr11:3078921	CARS	0.76	16.43	0.61	3.88e-48	Longevity;
LGG	cis	rs7312933	0.558	rs1796388	chr12:42785987	G/C	cg11827402	chr12:42719852	PPHLN1;ZCRB1	-0.51	-8.2	-0.36	2.45e-15	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs28386778	0.897	rs1062791	chr17:61896487	C/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.32	0.84	4.67e-125	Prudent dietary pattern;
LGG	cis	rs6952808	0.609	rs6970033	chr7:1948087	G/A	cg11050988	chr7:1952600	MAD1L1	-0.47	-12.14	-0.49	1.19e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs12497850	0.931	rs4974080	chr3:49030828	A/C	cg06212747	chr3:49208901	KLHDC8B	0.65	11.14	0.46	1.03e-25	Parkinson's disease;
LGG	cis	rs711245	0.698	rs848642	chr2:36782886	G/A	cg09467607	chr2:36825704	FEZ2	0.47	8.9	0.38	1.23e-17	Height;
LGG	cis	rs6866344	0.570	rs1071882	chr5:178136040	C/T	cg10224037	chr5:178157518	ZNF354A	0.77	12.85	0.51	1.57e-32	Neutrophil percentage of white cells;
LGG	cis	rs4862750	0.872	rs13101408	chr4:187894777	G/A	cg03452623	chr4:187889614	NA	-1.05	-29.83	-0.81	7.36e-110	Lobe attachment (rater-scored or self-reported);
LGG	trans	rs892961	1.000	rs892961	chr17:75400100	A/T	cg13675319	chr9:31254329	NA	0.61	6.67	0.3	7.32e-11	Airflow obstruction;
LGG	cis	rs1348850	0.626	rs1901825	chr2:178225331	A/T	cg27490568	chr2:178487706	NA	0.38	7.59	0.33	1.75e-13	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1799949	1.000	rs35956818	chr17:41422985	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.38	0.32	7.58e-13	Menopause (age at onset);
LGG	cis	rs668210	0.947	rs610497	chr11:65765551	C/T	cg02202077	chr11:65769826	EIF1AD;BANF1	0.74	10.75	0.45	3.17e-24	Cerebrospinal fluid biomarker levels;
LGG	cis	rs943466	0.911	rs111352628	chr6:33742490	A/G	cg07519485	chr6:33762594	MLN	0.57	11.58	0.47	2.04e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs1580019	0.563	rs10486509	chr7:32585443	C/G	cg06133097	chr7:32552212	AVL9	0.38	7.17	0.32	3.07e-12	Cognitive ability;
LGG	cis	rs755249	0.567	rs61783376	chr1:39769000	T/C	cg18385671	chr1:39797026	MACF1	0.44	7.49	0.33	3.63e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10504229	1.000	rs3814486	chr8:58191226	A/T	cg05313129	chr8:58192883	C8orf71	-0.8	-12.38	-0.5	1.32e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs2797160	1.000	rs1777183	chr6:126011995	A/C	cg05901451	chr6:126070800	HEY2	0.44	7.36	0.32	8.25e-13	Endometrial cancer;
LGG	cis	rs9400467	0.506	rs78344470	chr6:111761783	G/A	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.7	0.3	5.91e-11	Blood metabolite levels;Amino acid levels;
LGG	trans	rs11976180	1.000	rs7777389	chr7:143744802	T/A	cg00397059	chr6:132031294	CTAGE9;ENPP3	-0.37	-6.7	-0.3	6.23e-11	Obesity-related traits;
LGG	cis	rs611744	0.967	rs686630	chr8:109233239	G/C	cg21045802	chr8:109455806	TTC35	0.38	6.73	0.3	5.08e-11	Dupuytren's disease;
LGG	cis	rs35306767	0.903	rs12260800	chr10:927933	T/C	cg26597838	chr10:835615	NA	0.75	10.25	0.43	2.35e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs12949688	0.845	rs740439	chr17:55804463	G/C	cg12582317	chr17:55822272	NA	0.62	16.06	0.6	1.85e-46	Schizophrenia;
LGG	cis	rs9322193	1.000	rs9377229	chr6:149928791	C/T	cg12070911	chr6:150209640	RAET1E	0.28	6.82	0.3	2.93e-11	Lung cancer;
LGG	cis	rs801193	1.000	rs6975195	chr7:66124774	T/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.43	-8.92	-0.38	1.13e-17	Aortic root size;
LGG	cis	rs7267979	1.000	rs2500405	chr20:25360826	A/G	cg06421707	chr20:25228305	PYGB	-0.47	-10.11	-0.43	7.91e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9362426	0.608	rs6940716	chr6:88142979	A/G	cg06087457	chr6:88040249	C6orf162;GJB7	-0.47	-8.9	-0.38	1.28e-17	Depressive episodes in bipolar disorder;
LGG	cis	rs4819052	0.851	rs2255766	chr21:46683777	C/T	cg06618935	chr21:46677482	NA	-0.49	-9.71	-0.41	2.05e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	trans	rs1728785	1.000	rs8058314	chr16:68584151	G/A	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.47	0.44	3.55e-23	Ulcerative colitis;
LGG	cis	rs10197940	0.662	rs10173699	chr2:152281561	C/G	cg06191203	chr2:152266755	RIF1	0.46	7.93	0.35	1.7e-14	Lung cancer;
LGG	trans	rs12517041	1.000	rs1366452	chr5:23279222	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.87	-0.45	1.18e-24	Calcium levels;
LGG	cis	rs6426558	0.537	rs6662583	chr1:227383889	A/G	cg10327440	chr1:227177885	CDC42BPA	-0.6	-9.96	-0.42	2.73e-21	Neutrophil percentage of white cells;
LGG	cis	rs3099143	0.908	rs3102716	chr15:77051003	T/G	cg21673338	chr15:77095150	SCAPER	-0.66	-10.34	-0.43	1.07e-22	Recalcitrant atopic dermatitis;
LGG	cis	rs10504229	0.906	rs72650894	chr8:58179734	C/T	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg20887711	chr4:1340912	KIAA1530	0.62	12.7	0.51	6.5e-32	Longevity;
LGG	cis	rs6951245	1.000	rs28379681	chr7:1070539	C/T	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3087591	0.659	rs757377	chr17:29720426	G/A	cg24425628	chr17:29625626	OMG;NF1	0.59	12.14	0.49	1.24e-29	Hip circumference;
LGG	trans	rs1814175	0.645	rs4598671	chr11:50003191	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.72	-15.91	-0.59	8.82e-46	Height;
LGG	trans	rs3942852	0.806	rs4752893	chr11:48118604	C/T	cg15704280	chr7:45808275	SEPT13	-0.66	-9.35	-0.4	3.77e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs240110	0.546	rs12525818	chr6:101263484	C/T	cg09795085	chr6:101329169	ASCC3	0.43	6.93	0.31	1.41e-11	Neuroticism;
LGG	cis	rs5769707	0.967	rs9616333	chr22:50050847	G/A	cg20744362	chr22:50050164	C22orf34	0.4	7.75	0.34	5.71e-14	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs1908814	0.516	rs11996277	chr8:11800031	G/A	cg12395012	chr8:11607386	GATA4	-0.41	-7.45	-0.33	4.67e-13	Neuroticism;
LGG	cis	rs12200782	0.505	rs1535275	chr6:26520767	G/C	cg09904177	chr6:26538194	HMGN4	0.63	9.51	0.4	1.03e-19	Small cell lung carcinoma;
LGG	cis	rs3768617	0.510	rs2296300	chr1:183099701	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	trans	rs72991	0.793	rs4936620	chr11:121228617	A/G	cg27192990	chr6:129479024	LAMA2	-0.42	-7.01	-0.31	8.61e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6752107	0.936	rs10195395	chr2:234206504	T/C	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.23	0.32	2e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9942416	0.660	rs2307113	chr5:74998264	C/T	cg19683494	chr5:74908142	NA	0.45	6.93	0.31	1.4e-11	Age-related disease endophenotypes;
LGG	trans	rs7829975	0.846	rs1879957	chr8:8544808	T/C	cg02002194	chr4:3960332	NA	0.46	8.78	0.38	3.29e-17	Mood instability;
LGG	cis	rs4665809	1.000	rs2289022	chr2:26350136	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.99	-0.52	4.06e-33	Gut microbiome composition (summer);
LGG	cis	rs899997	0.862	rs12912524	chr15:78952756	G/A	cg17734273	chr15:78292508	TBC1D2B	-0.33	-7.91	-0.35	1.9e-14	Coronary artery disease or large artery stroke;
LGG	cis	rs7582180	0.903	rs7421891	chr2:100902166	G/A	cg26150922	chr2:100937072	LONRF2	-0.53	-9.39	-0.4	2.82e-19	Intelligence (multi-trait analysis);
LGG	cis	rs9650657	0.513	rs4841459	chr8:10782442	A/C	cg27411982	chr8:10470053	RP1L1	-0.46	-7.85	-0.34	2.94e-14	Neuroticism;
LGG	cis	rs7084402	0.967	rs1658442	chr10:60318897	G/A	cg07615347	chr10:60278583	BICC1	0.62	17.35	0.63	2.62e-52	Refractive error;
LGG	cis	rs9859260	0.744	rs492349	chr3:195784192	G/A	cg02975922	chr3:195473998	MUC4	0.45	7.15	0.32	3.36e-12	Mean corpuscular volume;
LGG	cis	rs6500602	0.727	rs11644481	chr16:4581002	T/G	cg01673284	chr16:4527211	HMOX2	0.33	6.85	0.3	2.31e-11	Schizophrenia;
LGG	cis	rs8012	0.517	rs1060218	chr19:13008607	G/T	cg04657146	chr19:12876947	HOOK2	-0.44	-7.11	-0.31	4.33e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs4517514	0.509	rs10830434	chr11:89912652	T/C	cg14505434	chr11:89522851	NA	0.61	7.84	0.34	3.2e-14	Trans fatty acid levels;
LGG	cis	rs62238980	0.614	rs116845703	chr22:32376250	T/G	cg00543991	chr22:32367038	NA	0.8	8.75	0.38	4e-17	Childhood ear infection;
LGG	cis	rs9486719	0.857	rs4486027	chr6:96911886	T/C	cg06623918	chr6:96969491	KIAA0776	-0.73	-11.25	-0.46	3.94e-26	Migraine;Coronary artery disease;
LGG	cis	rs17253792	0.822	rs28392709	chr14:56093685	G/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.4	-0.5	1.07e-30	Putamen volume;
LGG	cis	rs1577917	0.538	rs7755996	chr6:86423720	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	0.61	11.14	0.46	1.05e-25	Response to antipsychotic treatment;
LGG	cis	rs1348850	0.793	rs13020788	chr2:178480714	C/A	cg22681709	chr2:178499509	PDE11A	-0.51	-9.43	-0.4	1.95e-19	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs4740619	0.967	rs35146544	chr9:15693225	C/G	cg14451791	chr9:16040625	NA	-0.39	-9.67	-0.41	2.87e-20	Body mass index;
LGG	cis	rs2228479	0.850	rs62054609	chr16:89816569	C/A	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg02461776	chr11:598696	PHRF1	0.42	6.87	0.3	2.05e-11	Systemic lupus erythematosus;
LGG	cis	rs2228479	0.850	rs62056102	chr16:89941438	T/C	cg00800038	chr16:89945340	TCF25	-0.72	-8.7	-0.37	5.75e-17	Skin colour saturation;
LGG	cis	rs2153535	0.580	rs9378551	chr6:8463744	A/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.33	0.5	2.03e-30	Motion sickness;
LGG	cis	rs2243480	1.000	rs7456042	chr7:65299778	T/C	cg18252515	chr7:66147081	NA	-1.33	-18.98	-0.66	7.3e-60	Diabetic kidney disease;
LGG	cis	rs7493	1.000	rs2299265	chr7:95048870	C/G	cg17330251	chr7:94953956	PON1	-0.43	-8.38	-0.36	6.2e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs7824557	0.507	rs7010590	chr8:11062882	C/T	cg27411982	chr8:10470053	RP1L1	0.45	7.81	0.34	3.93e-14	Retinal vascular caliber;
LGG	cis	rs4481887	1.000	rs4244179	chr1:248470984	T/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.8	-0.41	9.78e-21	Common traits (Other);
LGG	cis	rs977987	0.806	rs8050059	chr16:75388731	C/T	cg07303275	chr16:75499416	TMEM170A	0.37	6.81	0.3	3.05e-11	Dupuytren's disease;
LGG	cis	rs2013441	0.508	rs12453332	chr17:19969297	C/A	cg13482628	chr17:19912719	NA	0.42	7.15	0.32	3.48e-12	Obesity-related traits;
LGG	cis	rs10752881	1.000	rs10911191	chr1:182984524	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.89e-17	Colorectal cancer;
LGG	trans	rs6076960	0.629	rs6054008	chr20:6212370	C/T	cg24759859	chr6:86352639	SYNCRIP	0.43	7.05	0.31	6.53e-12	Smooth-surface caries;
LGG	cis	rs9649465	0.967	rs10487806	chr7:123314446	C/T	cg03229431	chr7:123269106	ASB15	0.41	9.01	0.39	5.57e-18	Migraine;
LGG	trans	rs6601327	0.607	rs6992666	chr8:9586704	A/C	cg06636001	chr8:8085503	FLJ10661	-0.42	-7.58	-0.33	1.9e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs3008870	0.583	rs2031495	chr1:67421714	G/T	cg11518657	chr1:67396239	MIER1	0.48	7.17	0.32	3.05e-12	Lymphocyte percentage of white cells;
LGG	cis	rs7937682	0.889	rs12360825	chr11:111528786	A/T	cg09085632	chr11:111637200	PPP2R1B	-1.15	-25.96	-0.77	2.41e-92	Primary sclerosing cholangitis;
LGG	trans	rs9914544	0.545	rs4510081	chr17:18798846	A/C	cg21372672	chr17:16614065	CCDC144A	-0.36	-7.89	-0.34	2.17e-14	Educational attainment (years of education);
LGG	cis	rs6976053	0.868	rs10953305	chr7:100492568	G/A	cg03098644	chr7:100410630	EPHB4	-0.4	-7.01	-0.31	8.58e-12	Plasminogen activator inhibitor type 1 levels (PAI-1);
LGG	cis	rs701145	0.585	rs1609205	chr3:153793923	G/A	cg12800244	chr3:153838788	SGEF	0.83	8.95	0.38	8.36e-18	Coronary artery disease;
LGG	cis	rs7727544	0.735	rs272879	chr5:131670546	C/G	cg07395648	chr5:131743802	NA	-0.56	-13.23	-0.52	4.25e-34	Blood metabolite levels;
LGG	cis	rs28386778	0.701	rs2727337	chr17:61991966	G/A	cg02127607	chr17:61920694	SMARCD2	-0.47	-8.45	-0.37	3.82e-16	Prudent dietary pattern;
LGG	cis	rs2739330	0.753	rs4822452	chr22:24254363	C/T	cg23131131	chr22:24373011	LOC391322	-0.5	-8.44	-0.37	4.08e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs2839186	0.933	rs56955294	chr21:47708953	A/G	cg11766577	chr21:47581405	C21orf56	-0.47	-8.23	-0.36	1.88e-15	Testicular germ cell tumor;
LGG	cis	rs6912958	0.754	rs2268994	chr6:88185386	A/T	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.51	-0.37	2.51e-16	Monocyte percentage of white cells;
LGG	cis	rs2729354	0.520	rs2729377	chr11:57250084	T/C	cg24343310	chr11:57249947	NA	0.42	8.07	0.35	5.95e-15	Blood protein levels;
LGG	cis	rs561341	0.714	rs55925849	chr17:30253085	C/T	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.48	-0.44	3.3e-23	Hip circumference adjusted for BMI;
LGG	cis	rs2880765	0.835	rs7163958	chr15:86045215	G/A	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs37004	0.748	rs380145	chr5:1328897	C/T	cg07493874	chr5:1342172	CLPTM1L	-0.6	-8.5	-0.37	2.71e-16	Prostate-specific antigen levels;
LGG	trans	rs1200821	0.559	rs9418267	chr10:37819951	A/G	cg17830980	chr10:43048298	ZNF37B	0.31	6.81	0.3	3.13e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs4481887	1.000	rs4244183	chr1:248471222	G/A	cg01631408	chr1:248437212	OR2T33	-0.54	-9.82	-0.42	8.62e-21	Common traits (Other);
LGG	cis	rs7827545	1.000	rs6992097	chr8:135565844	G/A	cg17885191	chr8:135476712	NA	0.44	7.09	0.31	5.14e-12	Hypertension (SNP x SNP interaction);
LGG	cis	rs992157	0.835	rs7585702	chr2:219146607	T/C	cg00012203	chr2:219082015	ARPC2	-0.68	-12.13	-0.49	1.35e-29	Colorectal cancer;
LGG	cis	rs4555082	0.874	rs11622166	chr14:105759763	C/A	cg13114125	chr14:105738426	BRF1	-0.85	-15.73	-0.59	5.93e-45	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9818758	0.607	rs9837625	chr3:49215966	C/T	cg00383909	chr3:49044727	WDR6	0.98	12.33	0.5	2.16e-30	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs13108904	0.901	rs7668661	chr4:1300172	A/G	cg00689492	chr4:1303491	MAEA	0.47	8.09	0.35	5.16e-15	Obesity-related traits;
LGG	cis	rs7166081	1.000	rs8042237	chr15:67556625	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.29	-6.65	-0.3	8.45e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs9443645	0.527	rs9343870	chr6:79789473	T/G	cg18132916	chr6:79620363	NA	-0.27	-7.02	-0.31	7.97e-12	Intelligence (multi-trait analysis);
LGG	cis	rs58688157	0.960	rs1131665	chr11:613208	T/C	cg02461776	chr11:598696	PHRF1	0.42	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs4909189	1.000	rs71547530	chr7:158135503	A/G	cg15736062	chr7:158136485	PTPRN2	-0.52	-9.1	-0.39	2.77e-18	Response to amphetamines;
LGG	cis	rs28595532	0.920	rs116145969	chr4:119770908	T/C	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22493809	chr1:120838387	FAM72B	0.45	7.41	0.33	6.18e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs526231	0.578	rs1898672	chr5:102293853	A/T	cg23492399	chr5:102201601	PAM	0.59	9.07	0.39	3.5e-18	Primary biliary cholangitis;
LGG	cis	rs11771526	1.000	rs62457533	chr7:32355334	G/A	cg27532318	chr7:32358331	NA	0.88	8.29	0.36	1.26e-15	Body mass index;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs10078	0.571	rs2721028	chr5:443849	A/G	cg24955955	chr5:415729	AHRR	0.82	10.92	0.45	7.36e-25	Fat distribution (HIV);
LGG	trans	rs12517041	1.000	rs6889624	chr5:23304501	C/T	ch.8.1293020R	chr8:59333349	UBXN2B	-0.78	-11.35	-0.47	1.67e-26	Calcium levels;
LGG	cis	rs12410462	0.551	rs7539151	chr1:227841743	C/T	cg04117972	chr1:227635322	NA	0.42	7.64	0.33	1.26e-13	Major depressive disorder;
LGG	cis	rs72827839	0.516	rs111630961	chr17:45938097	T/G	cg23391107	chr17:45924227	SP6	0.59	9.51	0.4	1.04e-19	Ease of getting up in the morning;
LGG	cis	rs62103177	0.810	rs62103188	chr18:77627661	G/A	cg03511173	chr18:77590860	NA	0.62	7.77	0.34	5.16e-14	Opioid sensitivity;
LGG	cis	rs1005277	0.579	rs2505248	chr10:38459097	A/G	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.47	-0.33	4.16e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs2273669	0.667	rs7761290	chr6:109326621	T/G	cg05315195	chr6:109294784	ARMC2	-0.66	-8.73	-0.38	4.78e-17	Prostate cancer;
LGG	cis	rs7582180	0.903	rs2309825	chr2:100905101	A/C	cg14675211	chr2:100938903	LONRF2	0.49	7.5	0.33	3.31e-13	Intelligence (multi-trait analysis);
LGG	cis	rs2019137	0.539	rs11123170	chr2:113978940	C/G	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	13.0	0.52	3.66e-33	Lymphocyte counts;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg05941027	chr17:61774174	LIMD2	0.37	8.75	0.38	3.97e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9462027	0.539	rs2814963	chr6:34708908	C/T	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-11.02	-0.46	2.95e-25	Systemic lupus erythematosus;
LGG	cis	rs4629710	0.545	rs3777477	chr6:131534374	T/C	cg12606694	chr6:131520996	AKAP7	0.48	8.17	0.36	2.86e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs2439831	0.867	rs28461955	chr15:43661459	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	11.41	0.47	9.2e-27	Lung cancer in ever smokers;
LGG	cis	rs8180040	0.620	rs11709660	chr3:47074927	G/A	cg27129171	chr3:47204927	SETD2	-0.81	-14.98	-0.57	1.16e-41	Colorectal cancer;
LGG	cis	rs2153535	0.504	rs5001323	chr6:8451605	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	9.0	0.39	5.71e-18	Motion sickness;
LGG	cis	rs6951245	0.744	rs1133122	chr7:1192572	C/A	cg20603222	chr7:1096387	C7orf50;GPR146	-0.81	-13.38	-0.53	9.22e-35	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs12618769	0.597	rs17032120	chr2:99082938	A/G	cg18455616	chr2:99124870	INPP4A	-0.28	-8.21	-0.36	2.21e-15	Bipolar disorder;
LGG	cis	rs68170813	0.559	rs12532967	chr7:106937418	T/C	cg02696742	chr7:106810147	HBP1	-0.75	-10.56	-0.44	1.69e-23	Coronary artery disease;
LGG	cis	rs17270561	0.609	rs1165156	chr6:25792978	T/C	cg03264133	chr6:25882463	NA	-0.46	-7.53	-0.33	2.7e-13	Iron status biomarkers;
LGG	cis	rs62400317	0.859	rs114017772	chr6:45113862	T/C	cg20913747	chr6:44695427	NA	-0.62	-10.32	-0.43	1.32e-22	Total body bone mineral density;
LGG	cis	rs4595586	0.545	rs969468	chr12:39367278	A/C	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs9549367	0.713	rs9549356	chr13:113851633	A/G	cg00898013	chr13:113819073	PROZ	-0.5	-9.96	-0.42	2.75e-21	Platelet distribution width;
LGG	cis	rs769267	0.930	rs4808208	chr19:19650096	A/G	cg01262667	chr19:19385393	TM6SF2	0.43	10.72	0.45	4.14e-24	Tonsillectomy;
LGG	cis	rs35306767	0.859	rs11817793	chr10:878895	C/T	cg08847335	chr10:891726	LARP4B	-0.48	-8.78	-0.38	3.3e-17	Eosinophil percentage of granulocytes;
LGG	trans	rs7395662	0.889	rs11517696	chr11:48940073	C/A	cg00717180	chr2:96193071	NA	-0.43	-7.61	-0.33	1.58e-13	HDL cholesterol;
LGG	cis	rs28595532	0.920	rs112016126	chr4:119726528	C/T	cg14228332	chr4:119757509	SEC24D	0.98	10.0	0.42	1.89e-21	Cannabis dependence symptom count;
LGG	cis	rs1799949	1.000	rs11652332	chr17:41295489	G/A	cg25072359	chr17:41440525	NA	0.53	10.16	0.43	5.03e-22	Menopause (age at onset);
LGG	cis	rs17428076	0.681	rs62183851	chr2:172925252	C/T	cg21435375	chr2:172878103	MAP1D	0.42	7.53	0.33	2.63e-13	Myopia;
LGG	cis	rs10504073	0.669	rs818559	chr8:50035806	C/T	cg00325661	chr8:49890786	NA	0.69	13.53	0.53	2.31e-35	Blood metabolite ratios;
LGG	cis	rs1003719	0.715	rs2835644	chr21:38545610	G/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs875971	0.545	rs10950029	chr7:65634321	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.53	10.19	0.43	4.01e-22	Aortic root size;
LGG	cis	rs11169552	0.510	rs10783384	chr12:51117994	A/G	cg12884762	chr12:50931848	DIP2B	-0.4	-7.65	-0.34	1.17e-13	Colorectal cancer;
LGG	cis	rs1816752	0.774	rs7986162	chr13:25000079	C/T	cg22771759	chr13:24902376	NA	0.42	7.09	0.31	5.05e-12	Obesity-related traits;
LGG	cis	rs7618501	0.699	rs6446187	chr3:49907111	C/A	cg24110177	chr3:50126178	RBM5	-0.53	-9.46	-0.4	1.58e-19	Intelligence (multi-trait analysis);
LGG	cis	rs2046867	0.862	rs2322611	chr3:72830087	T/G	cg25664220	chr3:72788482	NA	-0.33	-9.21	-0.39	1.12e-18	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1046896	0.521	rs3848403	chr17:80693899	C/T	cg02398342	chr17:80708632	TBCD;FN3K	0.5	9.68	0.41	2.71e-20	Glycated hemoglobin levels;
LGG	cis	rs6430585	0.527	rs1438303	chr2:136429857	C/T	cg07169764	chr2:136633963	MCM6	1.0	16.57	0.61	8.89e-49	Corneal structure;
LGG	cis	rs35883536	0.588	rs955338	chr1:101108794	G/C	cg06223162	chr1:101003688	GPR88	0.34	7.7	0.34	8.25e-14	Monocyte count;
LGG	cis	rs10504229	1.000	rs58053450	chr8:58173348	T/C	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs727505	0.866	rs17327181	chr7:124720303	A/G	cg23710748	chr7:124431027	NA	-0.49	-9.17	-0.39	1.54e-18	Lewy body disease;
LGG	cis	rs2033711	0.728	rs4801586	chr19:58934528	A/G	cg00825309	chr19:58991885	ZNF446	-0.46	-9.37	-0.4	3.23e-19	Uric acid clearance;
LGG	cis	rs875971	0.522	rs1617484	chr7:65463095	G/A	cg11764359	chr7:65958608	NA	0.54	9.24	0.39	9.14e-19	Aortic root size;
LGG	cis	rs12048904	0.505	rs11166508	chr1:101233511	A/G	cg00063077	chr1:101360652	SLC30A7;EXTL2	-0.55	-12.36	-0.5	1.55e-30	Multiple sclerosis;
LGG	cis	rs10504229	0.683	rs113492050	chr8:58130046	A/G	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	1.000	rs2036264	chr7:65799904	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.88	-0.42	5.23e-21	Aortic root size;
LGG	cis	rs6942756	0.806	rs9641846	chr7:128873679	G/A	cg02491457	chr7:128862824	NA	0.66	12.5	0.5	4.11e-31	White matter hyperintensity burden;
LGG	cis	rs5769765	0.818	rs8140681	chr22:50292081	C/A	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.73e-27	Schizophrenia;
LGG	cis	rs3858526	0.752	rs11040173	chr11:6009378	A/G	cg05234568	chr11:5960015	NA	0.63	10.13	0.43	6.57e-22	DNA methylation (variation);
LGG	cis	rs7312933	1.000	rs10880230	chr12:42450253	G/A	cg01943504	chr12:42538901	GXYLT1	-0.41	-6.74	-0.3	4.72e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs12477438	0.520	rs7604557	chr2:99747829	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	1.28	39.63	0.88	6.77e-151	Chronic sinus infection;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg15971980	chr6:150254442	NA	0.44	8.25	0.36	1.71e-15	Lung cancer;
LGG	cis	rs2032447	0.714	rs129129	chr6:25961029	A/G	cg18357526	chr6:26021779	HIST1H4A	0.84	15.43	0.58	1.26e-43	Intelligence (multi-trait analysis);
LGG	cis	rs3858526	0.883	rs10769326	chr11:5934358	C/T	cg25319279	chr11:5960081	NA	-0.55	-8.83	-0.38	2.2e-17	DNA methylation (variation);
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg12070911	chr6:150209640	RAET1E	0.27	6.92	0.31	1.54e-11	Testicular germ cell tumor;
LGG	cis	rs2732480	0.557	rs923397	chr12:48720392	G/A	cg21466736	chr12:48725269	NA	-0.39	-7.89	-0.34	2.21e-14	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg27400746	chr16:89904261	SPIRE2	-1.14	-16.8	-0.62	8.11e-50	Skin colour saturation;
LGG	cis	rs35740288	0.770	rs55740125	chr15:86155736	G/A	cg07943548	chr15:86304357	KLHL25	-0.32	-6.64	-0.3	8.55e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4824093	0.610	rs60036544	chr22:50264019	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.79	-6.93	-0.31	1.43e-11	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs2640806	0.645	rs62514609	chr8:97333825	A/G	cg22138393	chr8:97340270	PTDSS1	0.32	8.15	0.35	3.36e-15	Obesity-related traits;
LGG	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg18252515	chr7:66147081	NA	-0.41	-7.03	-0.31	7.31e-12	Aortic root size;
LGG	cis	rs1318772	0.932	rs419483	chr5:112844587	G/A	cg12552261	chr5:112820674	MCC	0.69	7.48	0.33	3.8e-13	F-cell distribution;
LGG	cis	rs10504229	0.683	rs6998040	chr8:58110155	G/T	cg22535103	chr8:58192502	C8orf71	0.91	12.46	0.5	6.19e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs55665837	1.000	rs11023227	chr11:14459087	T/C	cg19336497	chr11:14380999	RRAS2	-0.44	-8.68	-0.37	6.59e-17	Vitamin D levels;
LGG	cis	rs2976388	1.000	rs2920280	chr8:143761144	G/C	cg06565975	chr8:143823917	SLURP1	-0.42	-10.43	-0.44	4.99e-23	Urinary tract infection frequency;
LGG	cis	rs7666738	0.924	rs62318940	chr4:99064768	C/T	cg05340658	chr4:99064831	C4orf37	0.43	6.92	0.31	1.51e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1696756	0.877	rs1663223	chr17:77826509	A/G	cg07923794	chr17:77834237	NA	-0.8	-11.9	-0.48	1.14e-28	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg22920501	chr2:26401640	FAM59B	-0.38	-7.62	-0.33	1.43e-13	Gut microbiome composition (summer);
LGG	cis	rs875971	0.862	rs2024192	chr7:66041447	G/T	cg12463550	chr7:65579703	CRCP	-0.5	-8.32	-0.36	9.61e-16	Aortic root size;
LGG	cis	rs62400317	0.859	rs62400326	chr6:45287465	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.29	-0.43	1.67e-22	Total body bone mineral density;
LGG	cis	rs362296	0.671	rs3095074	chr4:3261152	G/A	cg06533319	chr4:3265114	C4orf44	0.51	10.0	0.42	1.86e-21	Parental longevity (mother's age at death);
LGG	cis	rs7824557	0.606	rs1047950	chr8:11185096	G/C	cg15596359	chr8:11213517	TDH	-0.41	-8.57	-0.37	1.53e-16	Retinal vascular caliber;
LGG	cis	rs9303401	0.659	rs12952325	chr17:56899371	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.92	15.19	0.58	1.49e-42	Cognitive test performance;
LGG	cis	rs561341	0.843	rs879944	chr17:30242803	A/G	cg00745463	chr17:30367425	LRRC37B	-0.62	-9.34	-0.4	4.19e-19	Hip circumference adjusted for BMI;
LGG	cis	rs60843830	0.964	rs17713568	chr2:242132	G/A	cg12623918	chr2:306882	NA	0.52	9.73	0.41	1.7e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs1008375	0.966	rs3733576	chr4:17586703	T/C	cg10189774	chr4:17578691	LAP3	0.38	6.8	0.3	3.25e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs12478296	1.000	rs55777943	chr2:243040686	T/C	cg18898632	chr2:242989856	NA	-0.88	-10.53	-0.44	2.14e-23	Obesity-related traits;
LGG	cis	rs75920871	0.925	rs61903421	chr11:116961802	A/T	cg20608306	chr11:116969690	SIK3	-0.34	-6.96	-0.31	1.15e-11	Subjective well-being;
LGG	cis	rs7973719	0.868	rs12825629	chr12:7355583	T/C	cg07052231	chr12:7363540	PEX5	0.4	7.14	0.31	3.67e-12	IgG glycosylation;
LGG	cis	rs12188164	0.900	rs72717425	chr5:438809	C/T	cg21972741	chr5:435613	AHRR	0.4	7.43	0.33	5.16e-13	Cystic fibrosis severity;
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.44	7.65	0.34	1.14e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8067545	0.611	rs757494	chr17:20150340	C/T	cg13482628	chr17:19912719	NA	-0.53	-10.09	-0.42	9.28e-22	Schizophrenia;
LGG	cis	rs17270561	0.636	rs6456697	chr6:25741434	A/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs644799	1.000	rs473148	chr11:95628606	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.75	12.8	0.51	2.55e-32	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17376456	0.569	rs1349711	chr5:93179032	C/T	cg25358565	chr5:93447407	FAM172A	-0.8	-11.26	-0.46	3.74e-26	Diabetic retinopathy;
LGG	cis	rs1555895	0.543	rs1555898	chr10:853783	T/C	cg09361094	chr10:834503	NA	-0.29	-7.81	-0.34	3.94e-14	Survival in rectal cancer;
LGG	cis	rs3540	0.512	rs3862434	chr15:91080387	C/T	cg22089800	chr15:90895588	ZNF774	0.66	12.38	0.5	1.3e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs888194	0.738	rs7298565	chr12:109937534	A/G	cg19025524	chr12:109796872	NA	0.36	7.33	0.32	1.06e-12	Neuroticism;
LGG	trans	rs3808502	0.647	rs7821302	chr8:11236572	T/A	cg02002194	chr4:3960332	NA	0.44	7.91	0.35	1.93e-14	Neuroticism;
LGG	cis	rs11679564	0.714	rs10490657	chr2:37178255	C/T	cg14987922	chr2:37194071	STRN	0.47	7.4	0.33	6.38e-13	Immature fraction of reticulocytes;
LGG	cis	rs11123170	0.640	rs1015754	chr2:113967990	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.0	-0.35	9.95e-15	Renal function-related traits (BUN);
LGG	cis	rs8177253	0.828	rs8177259	chr3:133480388	T/C	cg11941060	chr3:133502564	NA	-0.49	-8.32	-0.36	1.02e-15	Iron status biomarkers;
LGG	cis	rs12282928	0.694	rs1872023	chr11:48343659	C/A	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs2587949	0.615	rs1403124	chr3:4213033	C/A	cg16519197	chr3:4211558	NA	0.32	6.74	0.3	4.75e-11	Periodontitis (DPAL);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02182114	chr7:139876578	LOC100134229;JHDM1D	0.48	8.28	0.36	1.34e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs7312933	0.526	rs1669892	chr12:42811305	G/A	cg19980929	chr12:42632907	YAF2	-0.34	-7.72	-0.34	7.28e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7959452	0.535	rs7133487	chr12:69774377	G/A	cg14784868	chr12:69753453	YEATS4	0.9	20.06	0.68	7.3e-65	Blood protein levels;
LGG	cis	rs10504229	1.000	rs67237174	chr8:58175776	T/C	cg05313129	chr8:58192883	C8orf71	-0.79	-12.24	-0.49	4.76e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs6693567	0.586	rs875514	chr1:150484555	C/G	cg15654264	chr1:150340011	RPRD2	0.32	6.67	0.3	7.38e-11	Migraine;
LGG	cis	rs2842992	0.789	rs2146163	chr6:160224346	T/C	cg19482086	chr6:160211437	TCP1;MRPL18	0.84	13.83	0.54	1.18e-36	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9814567	1.000	rs4367113	chr3:134287975	G/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.3	-0.53	2.05e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	trans	rs6601327	0.700	rs12114661	chr8:9573154	G/A	cg06636001	chr8:8085503	FLJ10661	-0.43	-7.62	-0.33	1.43e-13	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1577917	0.958	rs6454488	chr6:86450842	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.52	-8.7	-0.38	5.66e-17	Response to antipsychotic treatment;
LGG	cis	rs17039065	0.920	rs11725434	chr4:109432750	G/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.6	7.29	0.32	1.38e-12	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.623	rs34487437	chr8:10243803	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	6.77	0.3	3.79e-11	Neuroticism;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.19	19.96	0.68	2.13e-64	Platelet count;
LGG	cis	rs950776	0.518	rs12910289	chr15:78822065	T/G	cg17108064	chr15:78857060	CHRNA5	0.46	10.0	0.42	1.93e-21	Sudden cardiac arrest;
LGG	cis	rs7647973	1.000	rs3905330	chr3:49550774	A/G	cg06212747	chr3:49208901	KLHDC8B	0.52	8.19	0.36	2.65e-15	Menarche (age at onset);
LGG	trans	rs7829975	0.545	rs13261926	chr8:8551610	T/C	cg16141378	chr3:129829833	LOC729375	0.37	7.95	0.35	1.43e-14	Mood instability;
LGG	cis	rs11785400	1.000	rs9720653	chr8:143731939	T/G	cg10596483	chr8:143751796	JRK	0.57	9.29	0.4	5.85e-19	Schizophrenia;
LGG	cis	rs12188164	0.620	rs56070387	chr5:482531	A/T	cg26076054	chr5:421317	AHRR	-0.52	-7.66	-0.34	1.09e-13	Cystic fibrosis severity;
LGG	cis	rs9948	0.881	rs7594727	chr2:97489870	A/C	cg26665480	chr2:98280029	ACTR1B	0.66	7.24	0.32	1.87e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2839186	0.508	rs6518278	chr21:47640571	A/G	cg12016809	chr21:47604291	C21orf56	-0.47	-7.09	-0.31	4.92e-12	Testicular germ cell tumor;
LGG	cis	rs780096	0.545	rs11695549	chr2:27586155	A/C	cg22903471	chr2:27725779	GCKR	-0.57	-12.95	-0.52	6.09e-33	Total body bone mineral density;
LGG	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.35e-21	Colorectal cancer;
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	10.96	0.45	5.41e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12474201	0.928	rs35825831	chr2:46932544	T/G	cg06386533	chr2:46925753	SOCS5	0.79	14.66	0.56	3.03e-40	Height;
LGG	cis	rs9487094	0.961	rs11967108	chr6:109675243	T/C	cg01125227	chr6:109776195	MICAL1	0.52	9.0	0.39	5.77e-18	Height;
LGG	cis	rs17376456	1.000	rs4547912	chr5:93571190	G/T	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	8.35	0.36	7.79e-16	Diabetic retinopathy;
LGG	cis	rs7226408	0.802	rs59419623	chr18:34450368	G/A	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs240764	0.658	rs4463266	chr6:101223997	C/T	cg09795085	chr6:101329169	ASCC3	-0.48	-8.15	-0.35	3.46e-15	Neuroticism;
LGG	cis	rs6912958	0.781	rs9450752	chr6:88300013	A/G	cg08069147	chr6:88032118	GJB7;C6orf162	-0.48	-8.61	-0.37	1.19e-16	Monocyte percentage of white cells;
LGG	trans	rs9858542	0.953	rs3811697	chr3:49590770	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.5	-8.09	-0.35	5.26e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9910055	0.529	rs408282	chr17:42182267	A/G	cg16434002	chr17:42200994	HDAC5	0.45	7.95	0.35	1.48e-14	Total body bone mineral density;
LGG	cis	rs9611565	0.694	rs202637	chr22:41853928	A/G	cg06634786	chr22:41940651	POLR3H	0.77	12.05	0.49	2.9e-29	Vitiligo;
LGG	cis	rs6582630	0.502	rs12815350	chr12:38439921	A/T	cg13010199	chr12:38710504	ALG10B	0.66	13.22	0.52	4.62e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2050392	0.624	rs303444	chr10:30729347	C/T	cg25182066	chr10:30743637	MAP3K8	-0.61	-12.47	-0.5	5.72e-31	Inflammatory bowel disease;
LGG	cis	rs7959452	0.530	rs12811632	chr12:69755003	G/A	cg22834771	chr12:69754056	YEATS4	-0.43	-7.35	-0.32	8.87e-13	Blood protein levels;
LGG	cis	rs2282032	0.527	rs57011283	chr14:90767165	G/T	cg14092571	chr14:90743983	NA	0.42	7.52	0.33	2.81e-13	Longevity;
LGG	cis	rs2130392	1.000	rs3796689	chr4:185649866	C/A	cg04058563	chr4:185651563	MLF1IP	0.49	10.52	0.44	2.35e-23	Kawasaki disease;
LGG	cis	rs10504229	0.683	rs55660024	chr8:58128943	G/A	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs6840360	0.571	rs4696278	chr4:152558978	A/G	cg25486957	chr4:152246857	NA	-0.5	-8.22	-0.36	2e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg08280861	chr8:58055591	NA	0.61	7.48	0.33	3.68e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.557	rs176887	chr10:38406094	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.44	0.37	4.16e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs72945132	0.769	rs11235754	chr11:70136092	C/T	cg14191688	chr11:70257035	CTTN	0.53	7.78	0.34	4.67e-14	Coronary artery disease;
LGG	cis	rs6032067	0.683	rs16989763	chr20:43779963	T/C	cg10761708	chr20:43804764	PI3	0.59	9.06	0.39	3.8e-18	Blood protein levels;
LGG	trans	rs916888	0.779	rs430685	chr17:44859148	T/C	cg22433210	chr17:43662623	NA	-0.87	-14.27	-0.55	1.44e-38	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7010267	0.746	rs13250753	chr8:119906692	C/G	cg17171407	chr8:119960777	TNFRSF11B	-0.39	-9.86	-0.42	5.92e-21	Total body bone mineral density (age 45-60);
LGG	cis	rs7223966	1.000	rs6504168	chr17:61697469	G/T	cg11494091	chr17:61959527	GH2	0.49	7.85	0.34	2.99e-14	Hip circumference adjusted for BMI;Body mass index;
LGG	trans	rs2204008	0.678	rs61929520	chr12:38446800	T/C	cg06521331	chr12:34319734	NA	0.43	7.79	0.34	4.54e-14	Bladder cancer;
LGG	cis	rs7831492	0.564	rs57596574	chr8:41609843	G/A	cg17182837	chr8:41585554	ANK1	-0.59	-10.63	-0.44	9.18e-24	Colorectal cancer;
LGG	cis	rs9322193	0.962	rs4870048	chr6:150155460	A/G	cg07701084	chr6:150067640	NUP43	0.63	11.86	0.48	1.62e-28	Lung cancer;
LGG	cis	rs4930103	0.935	rs11042170	chr11:2021625	C/T	cg18511798	chr11:2018149	H19;MIR675	-0.72	-14.81	-0.57	6.57e-41	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs17270561	0.609	rs2154218	chr6:25776290	T/C	cg17691542	chr6:26056736	HIST1H1C	0.63	10.59	0.44	1.33e-23	Iron status biomarkers;
LGG	cis	rs11696845	0.787	rs6031771	chr20:43363590	C/T	cg25301532	chr20:43378953	KCNK15	0.44	10.44	0.44	4.58e-23	Obesity-related traits;
LGG	cis	rs6951245	0.872	rs74360401	chr7:1067403	G/A	cg24642844	chr7:1081250	C7orf50	-0.82	-13.63	-0.54	7.95e-36	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg09826692	chr7:83378891	NA	0.38	7.47	0.33	4.15e-13	Menarche (age at onset);
LGG	cis	rs2404602	0.698	rs12909656	chr15:76664378	A/T	cg15268244	chr15:77196840	NA	0.43	9.41	0.4	2.3e-19	Blood metabolite levels;
LGG	cis	rs832540	0.864	rs252908	chr5:56120686	T/C	cg12654349	chr5:56205094	C5orf35	-0.37	-6.67	-0.3	7.24e-11	Coronary artery disease;
LGG	cis	rs9788682	0.747	rs2656074	chr15:78741384	T/C	cg06917634	chr15:78832804	PSMA4	0.53	8.12	0.35	4.16e-15	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs15676	0.561	rs10739736	chr9:131577981	A/T	cg04621255	chr9:131581398	ENDOG	-0.38	-6.77	-0.3	4.03e-11	Blood metabolite levels;
LGG	cis	rs7647973	0.961	rs7638750	chr3:49452957	A/T	cg07636037	chr3:49044803	WDR6	-0.75	-13.28	-0.53	2.46e-34	Menarche (age at onset);
LGG	cis	rs2410601	0.562	rs13275125	chr8:18898352	T/A	cg03215416	chr8:18823341	PSD3	-0.43	-7.68	-0.34	9.58e-14	Urinary albumin excretion rate in type 1 diabetes;
LGG	cis	rs3106136	0.933	rs35718240	chr4:95164030	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.46	-7.81	-0.34	3.84e-14	Capecitabine sensitivity;
LGG	cis	rs10861342	0.786	rs11112386	chr12:105538758	A/G	cg23923672	chr12:105501055	KIAA1033	0.82	7.39	0.32	6.98e-13	IgG glycosylation;
LGG	cis	rs2439831	0.850	rs7168158	chr15:44050376	G/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	10.64	0.44	8.61e-24	Lung cancer in ever smokers;
LGG	cis	rs11992162	0.967	rs11250185	chr8:11833123	G/C	cg00405596	chr8:11794950	NA	0.43	7.29	0.32	1.32e-12	Monocyte count;
LGG	cis	rs13108904	0.870	rs3775092	chr4:1240962	C/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.73	13.26	0.52	2.91e-34	Obesity-related traits;
LGG	cis	rs2576037	0.562	rs9959877	chr18:44522293	T/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.91	19.35	0.67	1.51e-61	Personality dimensions;
LGG	cis	rs4481887	0.927	rs10888340	chr1:248440381	C/T	cg01631408	chr1:248437212	OR2T33	-0.55	-9.92	-0.42	3.57e-21	Common traits (Other);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16854524	chr4:83931902	LIN54	-0.46	-6.74	-0.3	4.75e-11	Systemic lupus erythematosus;
LGG	cis	rs6502050	0.835	rs11658335	chr17:80084821	C/T	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs7666738	0.830	rs1115616	chr4:99006603	A/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2692947	0.740	rs11695514	chr2:96548068	C/T	cg22654517	chr2:96458247	NA	0.38	7.41	0.33	6e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs2975734	0.736	rs4841300	chr8:10112595	T/C	cg06636001	chr8:8085503	FLJ10661	-0.47	-7.82	-0.34	3.71e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs9487094	0.670	rs13203587	chr6:109820962	C/T	cg16315928	chr6:109776240	MICAL1	0.46	8.05	0.35	6.9e-15	Height;
LGG	cis	rs7726839	0.561	rs6555357	chr5:560923	A/G	cg01221209	chr5:554886	NA	-0.49	-8.07	-0.35	6.25e-15	Obesity-related traits;
LGG	cis	rs8062405	0.723	rs4788079	chr16:28559363	C/A	cg16576597	chr16:28551801	NUPR1	0.43	10.19	0.43	3.9e-22	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6088590	0.965	rs910869	chr20:33292777	C/T	cg06115741	chr20:33292138	TP53INP2	0.6	10.15	0.43	5.42e-22	Coronary artery disease;
LGG	cis	rs7444	0.941	rs73166632	chr22:21946173	A/G	cg05046821	chr22:21984468	YDJC	-0.38	-6.97	-0.31	1.07e-11	Systemic lupus erythematosus;
LGG	cis	rs13108904	0.870	rs3733338	chr4:1241472	G/A	cg20743744	chr4:1243849	C4orf42;CTBP1	0.49	9.01	0.39	5.6e-18	Obesity-related traits;
LGG	cis	rs244731	0.959	rs6556307	chr5:176641434	C/T	cg17509989	chr5:176798049	RGS14	0.58	8.41	0.36	4.96e-16	Urate levels in lean individuals;
LGG	trans	rs9393777	0.920	rs66462181	chr6:27091661	T/C	cg01620082	chr3:125678407	NA	-1.02	-9.24	-0.39	8.88e-19	Intelligence (multi-trait analysis);
LGG	cis	rs6500602	0.727	rs11076837	chr16:4569440	C/T	cg05091796	chr16:4465799	CORO7	-0.6	-9.77	-0.41	1.25e-20	Schizophrenia;
LGG	cis	rs1863824	0.625	rs10887599	chr10:88168780	G/A	cg07322936	chr10:88137208	NA	-0.52	-8.44	-0.37	4.12e-16	Schizophrenia;
LGG	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg03264133	chr6:25882463	NA	0.53	10.0	0.42	1.85e-21	Blood metabolite levels;
LGG	cis	rs56283067	0.847	rs56300373	chr6:44690904	C/T	cg18551225	chr6:44695536	NA	-0.7	-12.26	-0.49	4.22e-30	Total body bone mineral density;
LGG	cis	rs1505368	0.567	rs2054617	chr2:213355890	T/C	cg16329650	chr2:213403929	ERBB4	0.5	8.97	0.38	7.41e-18	Symmetrical dimethylarginine levels;
LGG	cis	rs13108904	0.560	rs11247994	chr4:1343720	G/A	cg22903657	chr4:1355424	KIAA1530	-0.32	-7.02	-0.31	8.15e-12	Obesity-related traits;
LGG	cis	rs2011503	0.943	rs2965195	chr19:19463032	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.36	-7.28	-0.32	1.4e-12	Bipolar disorder;
LGG	cis	rs798554	1.000	rs798554	chr7:2759795	C/T	cg13628971	chr7:2884303	GNA12	0.5	9.79	0.41	1.08e-20	Height;
LGG	cis	rs2204008	0.522	rs12370263	chr12:38113311	A/G	cg26384229	chr12:38710491	ALG10B	0.87	18.99	0.66	7.2e-60	Bladder cancer;
LGG	cis	rs12447804	1.000	rs12447804	chr16:58075282	C/T	cg03859792	chr16:58121049	NA	0.47	7.09	0.31	5.03e-12	Pulmonary function;Pulmonary function (smoking interaction);
LGG	cis	rs2236267	0.545	rs4301957	chr14:88576142	G/T	cg02175263	chr14:88627849	NA	-0.35	-8.0	-0.35	9.76e-15	Food antigen IgG levels;
LGG	cis	rs9303401	0.538	rs10515155	chr17:56481944	A/G	cg25039879	chr17:56429692	SUPT4H1	0.76	11.11	0.46	1.36e-25	Cognitive test performance;
LGG	cis	rs10504229	0.871	rs10504227	chr8:58162005	G/A	cg11062466	chr8:58055876	NA	0.52	8.95	0.38	8.81e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4843185	0.763	rs9534	chr16:85711502	C/T	cg26571870	chr16:85723150	GINS2	0.4	7.53	0.33	2.69e-13	Platelet distribution width;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg17607973	chr7:100027408	MEPCE;ZCWPW1	0.5	8.51	0.37	2.52e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs12367572	0.641	rs4285943	chr12:45404768	A/C	cg04608330	chr12:45269318	NELL2	0.41	6.72	0.3	5.45e-11	Gut microbiome composition (summer);
LGG	cis	rs3785574	0.962	rs2727332	chr17:61878584	T/A	cg11494091	chr17:61959527	GH2	0.6	10.18	0.43	4.39e-22	Height;
LGG	cis	rs11025559	0.812	rs10766678	chr11:20507180	A/G	cg19653624	chr11:20408972	PRMT3	-0.51	-8.64	-0.37	8.96e-17	Pursuit maintenance gain;
LGG	cis	rs990171	1.000	rs2272129	chr2:103040249	C/T	cg05295703	chr2:102895712	NA	-0.56	-9.7	-0.41	2.2e-20	Lymphocyte counts;
LGG	cis	rs2303319	1.000	rs60767767	chr2:162185558	C/T	cg13806767	chr2:162164127	PSMD14	-0.66	-7.79	-0.34	4.35e-14	Cognitive function;
LGG	cis	rs9807989	0.839	rs1974675	chr2:102986375	G/A	cg03938978	chr2:103052716	IL18RAP	0.31	6.84	0.3	2.5e-11	Asthma;
LGG	cis	rs12188164	0.686	rs72711367	chr5:418494	A/G	cg00976097	chr5:421733	AHRR	-0.47	-7.72	-0.34	7.08e-14	Cystic fibrosis severity;
LGG	cis	rs4237845	0.816	rs61935769	chr12:58294344	G/A	cg02175503	chr12:58329896	NA	0.62	11.01	0.46	3.35e-25	Intelligence (multi-trait analysis);
LGG	cis	rs9381040	0.655	rs6939989	chr6:41020205	A/G	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.03	-0.31	7.66e-12	Alzheimer's disease (late onset);
LGG	cis	rs9291683	0.668	rs2241474	chr4:10086015	T/C	cg00071950	chr4:10020882	SLC2A9	0.36	7.59	0.33	1.8e-13	Bone mineral density;
LGG	cis	rs7824557	0.701	rs4568582	chr8:11160495	A/T	cg21775007	chr8:11205619	TDH	0.62	10.16	0.43	5.18e-22	Retinal vascular caliber;
LGG	cis	rs873946	0.586	rs12782567	chr10:134576709	C/G	cg06453172	chr10:134556979	INPP5A	0.55	8.36	0.36	7.37e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs12497850	0.897	rs7432989	chr3:49105136	A/G	cg18654377	chr3:49208889	KLHDC8B	-0.44	-6.78	-0.3	3.66e-11	Parkinson's disease;
LGG	cis	rs1018836	0.828	rs12548806	chr8:91564256	C/T	cg16814680	chr8:91681699	NA	-0.73	-13.24	-0.52	3.74e-34	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs6089829	0.889	rs6090206	chr20:61668363	G/A	cg08045932	chr20:61659980	NA	0.6	13.11	0.52	1.27e-33	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs739401	0.595	rs2237903	chr11:2967901	C/T	cg25174290	chr11:3078921	CARS	0.68	13.55	0.53	1.84e-35	Longevity;
LGG	cis	rs950169	0.919	rs17300292	chr15:84762568	G/C	cg24253500	chr15:84953950	NA	0.6	10.91	0.45	8.06e-25	Schizophrenia;
LGG	cis	rs9460578	0.537	rs77072299	chr6:20812017	A/G	cg13405222	chr6:20811065	CDKAL1	0.76	17.3	0.63	4.25e-52	Breast cancer;
LGG	cis	rs2688608	0.592	rs7909544	chr10:75484004	G/C	cg23231163	chr10:75533350	FUT11	-0.41	-6.84	-0.3	2.55e-11	Inflammatory bowel disease;
LGG	cis	rs2898290	0.622	rs11250140	chr8:11346592	A/C	cg21775007	chr8:11205619	TDH	-0.45	-7.3	-0.32	1.25e-12	Systolic blood pressure;
LGG	cis	rs62238980	0.614	rs78247456	chr22:32442531	G/C	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs887829	0.569	rs3821242	chr2:234637803	T/C	cg04696494	chr2:234620385	UGT1A5;UGT1A6;UGT1A10;UGT1A9;UGT1A7;UGT1A8	-0.42	-7.78	-0.34	4.79e-14	Metabolic traits;Bilirubin levels;Cholelithiasis-related traits in sickle cell anemia;Metabolite levels;Total bilirubin levels in HIV-1 infection;Serum metabolite levels;Blood metabolite levels;
LGG	trans	rs3808502	0.526	rs7843987	chr8:11422130	T/C	cg02002194	chr4:3960332	NA	0.51	9.73	0.41	1.78e-20	Neuroticism;
LGG	cis	rs1816752	0.638	rs9578730	chr13:24999683	G/A	cg02811702	chr13:24901961	NA	0.38	7.18	0.32	2.84e-12	Obesity-related traits;
LGG	cis	rs6685188	0.920	rs10751444	chr1:205662144	A/G	cg14893161	chr1:205819251	PM20D1	-0.56	-8.96	-0.38	8.27e-18	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs28386778	0.863	rs1376110	chr17:61779927	A/C	cg03528353	chr17:61819722	STRADA	0.45	7.66	0.34	1.08e-13	Prudent dietary pattern;
LGG	cis	rs9354308	0.764	rs9283821	chr6:66596125	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.79	-0.3	3.53e-11	Metabolite levels;
LGG	cis	rs12188164	1.000	rs56042615	chr5:437667	G/A	cg00976097	chr5:421733	AHRR	-0.41	-6.94	-0.31	1.33e-11	Cystic fibrosis severity;
LGG	cis	rs60843830	1.000	rs17713729	chr2:249092	A/C	cg12623918	chr2:306882	NA	0.52	9.72	0.41	1.86e-20	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12135191	0.967	rs17567019	chr1:236465416	C/T	cg21399712	chr1:236511386	NA	-0.38	-7.35	-0.32	8.87e-13	Urate levels (BMI interaction);
LGG	cis	rs2816062	0.735	rs2816045	chr1:18892999	A/G	cg10574377	chr1:18908098	NA	0.35	6.86	0.3	2.23e-11	Urate levels in lean individuals;
LGG	cis	rs735539	0.914	rs7997065	chr13:21273796	A/G	cg04906043	chr13:21280425	IL17D	0.55	9.62	0.41	4.44e-20	Dental caries;
LGG	cis	rs4742903	1.000	rs3739736	chr9:106857908	G/A	cg14250997	chr9:106856677	SMC2	0.41	8.52	0.37	2.28e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs6088590	0.523	rs6088536	chr20:33189106	T/C	cg06115741	chr20:33292138	TP53INP2	0.52	8.6	0.37	1.2e-16	Coronary artery disease;
LGG	cis	rs9324022	0.929	rs9635298	chr14:101172542	C/T	cg18089426	chr14:101175970	NA	0.7	11.2	0.46	6.33e-26	Plateletcrit;
LGG	cis	rs7084402	0.967	rs7921207	chr10:60270235	G/T	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.94e-55	Refractive error;
LGG	cis	rs599083	0.530	rs546803	chr11:68186392	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-7.59	-0.33	1.74e-13	Bone mineral density (spine);
LGG	cis	rs10911232	0.507	rs3934697	chr1:183027512	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs9322193	0.962	rs62439843	chr6:149997657	T/C	cg00424166	chr6:150045504	NUP43	-0.34	-7.21	-0.32	2.32e-12	Lung cancer;
LGG	cis	rs7769051	0.803	rs56148066	chr6:133230115	G/A	cg22852734	chr6:133119734	C6orf192	0.96	10.88	0.45	1.06e-24	Type 2 diabetes nephropathy;
LGG	cis	rs6502050	0.723	rs4789698	chr17:80179786	C/T	cg23985595	chr17:80112537	CCDC57	-0.4	-7.39	-0.32	6.86e-13	Life satisfaction;
LGG	cis	rs1055129	0.584	rs9895947	chr17:73908566	A/C	cg08125733	chr17:73851984	WBP2	0.43	7.26	0.32	1.62e-12	White matter hyperintensity burden;
LGG	cis	rs9354308	0.764	rs1938098	chr6:66599700	G/A	cg07460842	chr6:66804631	NA	-0.4	-6.77	-0.3	3.96e-11	Metabolite levels;
LGG	cis	rs6748734	0.581	rs10207380	chr2:241860911	A/G	cg14055004	chr2:241860995	NA	0.31	7.69	0.34	9.01e-14	Urinary metabolites;
LGG	cis	rs9611565	0.879	rs5758307	chr22:41750219	A/G	cg03806693	chr22:41940476	POLR3H	-0.85	-14.82	-0.57	5.97e-41	Vitiligo;
LGG	cis	rs9291683	0.546	rs12504565	chr4:10045145	G/A	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs503734	0.533	rs906380	chr3:100905910	A/G	cg27318481	chr3:100970896	IMPG2	0.35	7.53	0.33	2.66e-13	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs62344088	0.744	rs76038312	chr5:229005	A/G	cg22496380	chr5:211416	CCDC127	-1.3	-10.91	-0.45	8.33e-25	Asthma (childhood onset);
LGG	cis	rs3761847	0.593	rs10985140	chr9:123822837	G/A	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.29	0.36	1.21e-15	Rheumatoid arthritis;
LGG	cis	rs2652822	0.509	rs6494394	chr15:63440938	A/G	cg02713581	chr15:63449717	RPS27L	0.41	6.66	0.3	7.92e-11	Metabolic traits;
LGG	cis	rs283228	0.798	rs683830	chr6:101753403	C/A	cg27451362	chr6:101846650	GRIK2	0.65	10.56	0.44	1.68e-23	Coenzyme Q10 levels;
LGG	cis	rs1927790	0.616	rs1925119	chr13:96939586	C/A	cg02571835	chr13:96230311	CLDN10	-0.35	-7.39	-0.32	6.89e-13	Body mass index;
LGG	cis	rs10435719	0.764	rs10103485	chr8:11787563	C/T	cg00405596	chr8:11794950	NA	0.62	10.93	0.45	6.84e-25	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.1	29.56	0.81	1.17e-108	Prudent dietary pattern;
LGG	cis	rs6500602	0.826	rs9925719	chr16:4461861	A/G	cg06916706	chr16:4465613	CORO7	-1.17	-24.27	-0.75	1.58e-84	Schizophrenia;
LGG	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.44	-0.33	5.04e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7267979	1.000	rs4815421	chr20:25386509	G/A	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1005277	0.579	rs1780116	chr10:38526621	C/T	cg25427524	chr10:38739819	LOC399744	-0.66	-12.22	-0.49	5.69e-30	Extrinsic epigenetic age acceleration;
LGG	cis	rs342442	0.808	rs2869643	chr4:88072503	A/C	cg21988461	chr4:88008667	AFF1	0.26	6.87	0.3	2.1e-11	Response to radiotherapy in prostate cancer (toxicity, urinary frequency);
LGG	cis	rs7584330	0.737	rs7595979	chr2:238364492	G/T	cg16989719	chr2:238392110	NA	-0.32	-6.87	-0.3	2.12e-11	Prostate cancer;
LGG	cis	rs9467773	1.000	rs9467797	chr6:26568473	A/T	cg11502198	chr6:26597334	ABT1	0.59	10.11	0.43	7.78e-22	Intelligence (multi-trait analysis);
LGG	cis	rs34172651	0.517	rs874484	chr16:24803242	T/C	cg00339695	chr16:24857497	SLC5A11	0.4	6.85	0.3	2.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs12643440	0.538	rs60281935	chr4:17143251	G/A	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs1008375	0.966	rs2191504	chr4:17675592	C/G	cg02297831	chr4:17616191	MED28	0.51	9.67	0.41	2.78e-20	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3768617	0.510	rs10752899	chr1:183081241	T/G	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs72945132	0.882	rs7114200	chr11:70186099	C/A	cg13802316	chr11:70253460	CTTN	-0.59	-7.49	-0.33	3.51e-13	Coronary artery disease;
LGG	trans	rs116095464	0.867	rs10061296	chr5:312253	G/A	cg00938859	chr5:1591904	SDHAP3	0.82	8.73	0.38	4.62e-17	Breast cancer;
LGG	cis	rs6502050	0.835	rs34867501	chr17:80121358	T/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs7044106	0.762	rs10984974	chr9:123421556	C/T	cg09419670	chr9:123605666	PSMD5;LOC253039	0.86	16.92	0.62	2.38e-50	Hip circumference adjusted for BMI;
LGG	cis	rs763014	0.966	rs7198877	chr16:661439	A/G	cg00908189	chr16:619842	PIGQ	0.87	16.31	0.6	1.35e-47	Height;
LGG	cis	rs7267979	0.873	rs7453	chr20:25207074	A/G	cg08601574	chr20:25228251	PYGB	0.34	6.73	0.3	5.03e-11	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs1256061	0.624	rs1256046	chr14:64729356	A/C	cg21174375	chr14:64681225	SYNE2	0.36	6.72	0.3	5.47e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs7572733	0.935	rs700691	chr2:198727852	A/G	cg00792783	chr2:198669748	PLCL1	0.49	8.42	0.36	4.59e-16	Dermatomyositis;
LGG	cis	rs2742417	0.603	rs2064064	chr3:45759995	C/T	cg04837898	chr3:45731254	SACM1L	-0.47	-9.42	-0.4	2.17e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs35306767	0.714	rs10508206	chr10:1075777	A/C	cg25019033	chr10:957182	NA	-0.45	-8.49	-0.37	2.73e-16	Eosinophil percentage of granulocytes;
LGG	cis	rs7927771	0.800	rs35996350	chr11:47389223	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-10.45	-0.44	4.16e-23	Subjective well-being;
LGG	cis	rs6868223	0.617	rs6861765	chr5:33642625	A/C	cg10594543	chr5:33649717	ADAMTS12	0.66	15.64	0.59	1.43e-44	Mortality in heart failure;
LGG	cis	rs9815354	0.857	rs6798152	chr3:42023558	A/T	cg03022575	chr3:42003672	ULK4	0.68	8.03	0.35	8.41e-15	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs10754283	0.967	rs10801759	chr1:90113745	A/G	cg06121193	chr1:90282411	NA	-0.37	-7.18	-0.32	2.86e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs11792861	0.816	rs3818932	chr9:111664178	T/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.64	10.38	0.43	7.98e-23	Menarche (age at onset);
LGG	cis	rs8040855	0.621	rs6496796	chr15:85726848	T/C	cg19183879	chr15:85880815	NA	0.4	7.31	0.32	1.18e-12	Bulimia nervosa;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg15586393	chr4:1244086	CTBP1;C4orf42	-0.62	-10.87	-0.45	1.13e-24	Obesity-related traits;
LGG	cis	rs4700695	0.719	rs27086	chr5:65453185	A/G	cg21114390	chr5:65439923	SFRS12	-0.72	-10.53	-0.44	2.22e-23	Facial morphology (factor 19);
LGG	cis	rs6952808	0.542	rs10243920	chr7:1950385	G/A	cg19147804	chr7:1989927	MAD1L1	-0.56	-11.19	-0.46	6.61e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs72652906	chr8:58188360	C/A	cg21724239	chr8:58056113	NA	0.42	6.69	0.3	6.39e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.762	rs10491783	chr9:123450155	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.85	16.5	0.61	2.01e-48	Hip circumference adjusted for BMI;
LGG	trans	rs1005277	0.579	rs932538	chr10:38381314	T/C	cg27523141	chr10:43048294	ZNF37B	0.43	8.53	0.37	2.13e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs8013055	0.796	rs4075105	chr14:106000231	C/T	cg19700328	chr14:106028568	NA	-0.61	-10.09	-0.42	8.65e-22	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs2404602	0.575	rs11072611	chr15:76947983	A/G	cg23625390	chr15:77176239	SCAPER	0.67	12.31	0.5	2.46e-30	Blood metabolite levels;
LGG	cis	rs943466	1.000	rs755495	chr6:33734128	A/G	cg07519485	chr6:33762594	MLN	-0.56	-11.38	-0.47	1.24e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs11693319	0.920	rs1565286	chr2:179749373	C/A	cg17765952	chr2:179737173	CCDC141	0.59	9.49	0.4	1.23e-19	Blood pressure measurement (cold pressor test);
LGG	cis	rs7444	0.941	rs5749485	chr22:21938224	A/C	cg15846791	chr22:21984385	YDJC	-0.45	-7.09	-0.31	4.96e-12	Systemic lupus erythematosus;
LGG	cis	rs6929812	0.546	rs2393962	chr6:27462824	T/C	cg18711553	chr6:27366782	ZNF391	-0.47	-8.98	-0.39	6.79e-18	Neuroticism (multi-trait analysis);
LGG	cis	rs12421382	0.659	rs35527696	chr11:109379944	T/A	cg11473876	chr11:109292803	C11orf87	0.48	9.48	0.4	1.34e-19	Schizophrenia;
LGG	cis	rs9325144	0.555	rs12424003	chr12:38688140	C/T	cg04568710	chr12:38710424	ALG10B	-0.43	-9.17	-0.39	1.59e-18	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.906	rs7842482	chr8:58167720	A/T	cg23782820	chr8:58130467	NA	0.46	7.29	0.32	1.36e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs3805752	chr6:150116626	C/T	cg07701084	chr6:150067640	NUP43	0.68	12.62	0.51	1.39e-31	Lung cancer;
LGG	cis	rs4740619	0.782	rs3119699	chr9:15572744	T/A	cg14451791	chr9:16040625	NA	-0.34	-8.59	-0.37	1.32e-16	Body mass index;
LGG	cis	rs798554	0.757	rs1182198	chr7:2862906	C/T	cg19717773	chr7:2847554	GNA12	-0.34	-6.94	-0.31	1.34e-11	Height;
LGG	cis	rs10927875	0.864	rs1976402	chr1:16143779	G/A	cg21385522	chr1:16154831	NA	-1.03	-18.61	-0.65	3.8e-58	Dilated cardiomyopathy;
LGG	cis	rs13082711	0.522	rs569960	chr3:27329540	C/T	cg02860705	chr3:27208620	NA	0.59	11.51	0.47	3.87e-27	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs7927771	0.965	rs12787112	chr11:47687147	A/G	cg20307385	chr11:47447363	PSMC3	-0.48	-8.52	-0.37	2.31e-16	Subjective well-being;
LGG	cis	rs12282928	0.959	rs2170663	chr11:48319806	A/T	cg26585981	chr11:48327164	OR4S1	-0.43	-6.96	-0.31	1.16e-11	Migraine - clinic-based;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg08975724	chr8:8085496	FLJ10661	0.41	7.48	0.33	3.66e-13	Morning vs. evening chronotype;
LGG	cis	rs7937682	0.855	rs7934922	chr11:111500026	T/C	cg19812747	chr11:111475976	SIK2	-0.48	-9.84	-0.42	7.02e-21	Primary sclerosing cholangitis;
LGG	trans	rs7824557	0.933	rs6601576	chr8:11100275	A/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.71	-0.34	7.79e-14	Retinal vascular caliber;
LGG	cis	rs7444	0.883	rs7445	chr22:21977047	C/T	cg11654148	chr22:21984483	YDJC	-0.38	-7.34	-0.32	9.86e-13	Systemic lupus erythematosus;
LGG	cis	rs4664304	0.772	rs17830558	chr2:160878364	A/C	cg03641300	chr2:160917029	PLA2R1	-0.5	-8.99	-0.39	6.4e-18	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs6952808	1.000	rs4256490	chr7:1890764	G/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.59	-0.44	1.32e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs45430	1.000	rs45430	chr21:42746081	C/T	cg22778903	chr21:42741698	MX2	0.44	8.71	0.38	5.34e-17	Melanoma;
LGG	cis	rs12200782	0.932	rs12202419	chr6:26465384	G/T	cg11502198	chr6:26597334	ABT1	0.83	7.18	0.32	2.85e-12	Small cell lung carcinoma;
LGG	cis	rs735539	0.521	rs2585901	chr13:21420271	G/A	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs796364	1.000	rs796364	chr2:200716119	C/A	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.84	0.45	1.52e-24	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg05533552	chr11:34074141	CAPRIN1	0.46	7.79	0.34	4.37e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs870825	0.616	rs7660939	chr4:185640792	T/C	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs9910055	0.762	rs2526020	chr17:42216588	G/T	cg13607699	chr17:42295918	UBTF	0.66	11.37	0.47	1.34e-26	Total body bone mineral density;
LGG	cis	rs875971	1.000	rs35149210	chr7:65929925	T/C	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs9747201	1.000	rs9303020	chr17:80163247	C/T	cg09264619	chr17:80180166	NA	-0.51	-10.15	-0.43	5.4e-22	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2032447	0.530	rs9356996	chr6:26008487	C/A	cg12310025	chr6:25882481	NA	-0.46	-8.48	-0.37	3.09e-16	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01669482	chr16:25043131	NA	0.46	7.39	0.32	6.98e-13	Gut microbiome composition (summer);
LGG	trans	rs11098499	0.818	rs7688802	chr4:120451668	G/A	cg25214090	chr10:38739885	LOC399744	0.67	11.79	0.48	2.98e-28	Corneal astigmatism;
LGG	cis	rs6977660	0.714	rs9969171	chr7:19827328	T/C	cg05791153	chr7:19748676	TWISTNB	0.74	10.36	0.43	9.46e-23	Thyroid stimulating hormone;
LGG	cis	rs4891159	0.548	rs690414	chr18:74117840	T/C	cg24786174	chr18:74118243	ZNF516	0.68	17.12	0.62	2.79e-51	Longevity;
LGG	cis	rs6502050	0.835	rs34673303	chr17:80085144	G/C	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs9783347	1.000	rs10832921	chr11:18380835	C/T	cg03595886	chr11:18357587	GTF2H1	-0.36	-7.41	-0.33	5.93e-13	Pancreatic cancer;
LGG	cis	rs7927771	0.524	rs10838774	chr11:47856114	A/G	cg20307385	chr11:47447363	PSMC3	0.56	10.83	0.45	1.59e-24	Subjective well-being;
LGG	cis	rs7089973	0.604	rs1924034	chr10:116578539	C/T	cg03647239	chr10:116582469	FAM160B1	0.43	7.33	0.32	1.01e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs9322193	0.884	rs1125	chr6:149979416	G/A	cg09699651	chr6:150184138	LRP11	0.48	7.67	0.34	1.06e-13	Lung cancer;
LGG	cis	rs11230563	1.000	rs2074227	chr11:60776781	T/C	cg10158843	chr11:60776172	CD6	0.59	10.42	0.44	5.75e-23	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs910316	0.737	rs175499	chr14:75535927	G/A	cg08847533	chr14:75593920	NEK9	-0.53	-10.08	-0.42	9.93e-22	Height;
LGG	cis	rs6502050	0.761	rs12150321	chr17:80061558	T/C	cg13939156	chr17:80058883	NA	0.55	11.23	0.46	4.96e-26	Life satisfaction;
LGG	cis	rs847649	0.699	rs10241865	chr7:102527517	G/A	cg18108683	chr7:102477205	FBXL13	-0.63	-13.63	-0.54	8.05e-36	Morning vs. evening chronotype;
LGG	cis	rs7172677	0.768	rs72730585	chr15:75353906	A/G	cg10253484	chr15:75165896	SCAMP2	0.52	7.65	0.33	1.19e-13	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs780096	0.527	rs12471703	chr2:27738854	C/T	cg05484376	chr2:27715224	FNDC4	0.46	9.94	0.42	3.18e-21	Total body bone mineral density;
LGG	cis	rs28595532	0.920	rs115372254	chr4:119771735	T/C	cg21605333	chr4:119757512	SEC24D	1.44	15.1	0.57	3.66e-42	Cannabis dependence symptom count;
LGG	trans	rs7618501	1.000	rs11709680	chr3:49745188	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.89	-0.51	1.08e-32	Intelligence (multi-trait analysis);
LGG	cis	rs943466	1.000	rs61662306	chr6:33746697	G/A	cg07519485	chr6:33762594	MLN	0.57	11.55	0.47	2.8e-27	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs12893668	0.572	rs11846404	chr14:104156108	C/G	cg23335576	chr14:104009727	NA	0.42	7.25	0.32	1.74e-12	Reticulocyte count;
LGG	cis	rs6502050	0.835	rs34774430	chr17:80181919	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.26	-0.4	7.55e-19	Life satisfaction;
LGG	cis	rs2204008	0.837	rs11495722	chr12:38337245	G/A	cg26384229	chr12:38710491	ALG10B	0.98	22.0	0.71	6.02e-74	Bladder cancer;
LGG	cis	rs7580658	0.929	rs4662575	chr2:128022215	C/T	cg10021288	chr2:128175891	PROC	-0.63	-13.06	-0.52	2e-33	Protein C levels;
LGG	cis	rs13394619	0.533	rs12615856	chr2:11746177	C/T	cg07314298	chr2:11723111	GREB1	0.39	7.88	0.34	2.42e-14	Endometriosis;
LGG	cis	rs7481584	0.581	rs366422	chr11:3053873	C/T	cg08508325	chr11:3079039	CARS	0.42	8.14	0.35	3.81e-15	Calcium levels;
LGG	cis	rs798554	0.836	rs798500	chr7:2790685	C/T	cg14668632	chr7:2872130	GNA12	0.38	7.77	0.34	5.28e-14	Height;
LGG	cis	rs28374715	0.681	rs28687846	chr15:41599902	C/T	cg18705301	chr15:41695430	NDUFAF1	-1.28	-29.79	-0.81	1.11e-109	Ulcerative colitis;
LGG	cis	rs2898290	0.593	rs1600252	chr8:11345644	A/G	cg21775007	chr8:11205619	TDH	-0.44	-7.23	-0.32	2.06e-12	Systolic blood pressure;
LGG	cis	rs9309473	0.861	rs6546857	chr2:73837955	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.75	-0.34	5.78e-14	Metabolite levels;
LGG	cis	rs701145	0.586	rs355785	chr3:153990251	T/G	cg17054900	chr3:154042577	DHX36	0.99	12.47	0.5	5.44e-31	Coronary artery disease;
LGG	cis	rs2228479	0.850	rs11644804	chr16:89976224	G/A	cg00800038	chr16:89945340	TCF25	-0.59	-7.2	-0.32	2.42e-12	Skin colour saturation;
LGG	cis	rs7216064	0.553	rs62084690	chr17:66035411	A/G	cg02705964	chr17:66097276	LOC651250	-0.38	-7.0	-0.31	9e-12	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1008375	1.000	rs2315561	chr4:17679695	C/T	cg07005078	chr4:17578674	LAP3	0.37	7.02	0.31	8.05e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7927592	0.717	rs7126451	chr11:68257386	A/G	cg01657329	chr11:68192670	LRP5	0.55	10.33	0.43	1.17e-22	Total body bone mineral density;
LGG	cis	rs3858526	0.834	rs7116627	chr11:5985550	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.29	-0.43	1.65e-22	DNA methylation (variation);
LGG	cis	rs12477438	0.520	rs4340581	chr2:99725025	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.56	0.78	4.09e-95	Chronic sinus infection;
LGG	cis	rs7552404	1.000	rs6672180	chr1:76123973	C/G	cg22875332	chr1:76189707	ACADM	0.6	10.13	0.43	6.71e-22	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4727027	0.933	rs12540094	chr7:148847178	A/G	cg12479418	chr7:148823350	ZNF425;ZNF398	-0.44	-6.72	-0.3	5.29e-11	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs892085	0.681	rs10417071	chr19:10872431	G/T	cg17710535	chr19:10819994	QTRT1	0.51	9.09	0.39	2.96e-18	Psoriasis vulgaris;Psoriasis;
LGG	cis	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg03665457	chr10:38645376	HSD17B7P2	-0.48	-7.62	-0.33	1.49e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs1552244	0.882	rs13099507	chr3:10031603	G/A	cg00149659	chr3:10157352	C3orf10	0.74	9.06	0.39	3.56e-18	Alzheimer's disease;
LGG	cis	rs9504361	1.000	rs9504361	chr6:577820	C/T	cg13471009	chr6:564609	EXOC2	0.32	6.8	0.3	3.25e-11	Eosinophil percentage of white cells;Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;Psoriasis;Pit-and-Fissure caries;Eosinophil counts;
LGG	cis	rs12497850	0.931	rs9311433	chr3:48863835	T/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.73	0.3	5.11e-11	Parkinson's disease;
LGG	cis	rs3540	0.512	rs8033595	chr15:91083353	G/A	cg22089800	chr15:90895588	ZNF774	-0.66	-12.3	-0.5	2.65e-30	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs8067545	0.750	rs7208025	chr17:19997870	T/C	cg13482628	chr17:19912719	NA	0.63	12.45	0.5	6.69e-31	Schizophrenia;
LGG	trans	rs9650657	0.644	rs4395858	chr8:10521021	C/T	cg02002194	chr4:3960332	NA	-0.45	-8.37	-0.36	6.96e-16	Neuroticism;
LGG	cis	rs11586313	0.571	rs11583382	chr1:152874096	G/A	cg13444842	chr1:152974279	SPRR3	-0.41	-7.81	-0.34	3.98e-14	Vitamin D levels;
LGG	cis	rs11239187	0.586	rs749000	chr10:45077099	G/C	cg03916630	chr10:45065415	NA	0.35	8.4	0.36	5.68e-16	Body mass index;
LGG	cis	rs769267	0.965	rs2315024	chr19:19423817	T/A	cg20644253	chr19:19431407	KIAA0892;SF4	0.58	9.55	0.41	7.5e-20	Tonsillectomy;
LGG	cis	rs2635047	0.967	rs9960264	chr18:44606996	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.39	7.36	0.32	8.43e-13	Educational attainment;
LGG	cis	rs2239547	0.522	rs2581805	chr3:52979050	T/C	cg11645453	chr3:52864694	ITIH4	-0.67	-10.33	-0.43	1.17e-22	Schizophrenia;
LGG	cis	rs7742824	1.000	rs73429729	chr6:44086727	C/A	cg04074908	chr6:44101190	TMEM63B	0.68	13.34	0.53	1.35e-34	Major depressive disorder;
LGG	cis	rs4930103	0.590	rs3809101	chr11:1967271	C/T	cg06197492	chr11:2016605	H19	0.49	10.21	0.43	3.26e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs3858526	1.000	rs11039787	chr11:5965611	C/T	cg02574844	chr11:5959923	NA	-0.61	-9.33	-0.4	4.26e-19	DNA methylation (variation);
LGG	trans	rs61931739	1.000	rs11502817	chr12:34010676	T/C	cg13010199	chr12:38710504	ALG10B	-0.44	-8.08	-0.35	5.83e-15	Morning vs. evening chronotype;
LGG	cis	rs6750047	0.585	rs4670235	chr2:38272528	C/T	cg07380506	chr2:38303506	CYP1B1	0.43	7.1	0.31	4.72e-12	Cutaneous malignant melanoma;Melanoma;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg03175768	chr16:88368467	NA	0.35	6.99	0.31	9.57e-12	Electrocardiographic conduction measures;
LGG	cis	rs2228479	0.702	rs2074963	chr16:89877269	T/C	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.8	-0.34	4.27e-14	Skin colour saturation;
LGG	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg18681998	chr4:17616180	MED28	-0.86	-17.99	-0.64	3.09e-55	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs3206736	0.575	rs75847838	chr7:35106396	G/A	cg13400248	chr7:35225412	NA	0.54	9.46	0.4	1.59e-19	Diastolic blood pressure;
LGG	cis	rs735539	0.645	rs7995773	chr13:21251235	T/C	cg04906043	chr13:21280425	IL17D	-0.53	-8.7	-0.37	5.77e-17	Dental caries;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg24448245	chr7:66461718	SBDS;TYW1	0.39	7.09	0.31	5.04e-12	Body mass index;
LGG	cis	rs1008375	1.000	rs7697889	chr4:17617961	G/T	cg02297831	chr4:17616191	MED28	0.5	9.43	0.4	2.05e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs801193	1.000	rs7785213	chr7:66138978	A/C	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.44	-9.03	-0.39	4.5e-18	Aortic root size;
LGG	cis	rs7113850	0.541	rs11826483	chr11:24237730	C/T	ch.11.24196551F	chr11:24239977	NA	0.91	10.51	0.44	2.65e-23	Bone fracture in osteoporosis;
LGG	cis	rs5758511	0.680	rs5758687	chr22:42656588	A/T	cg00645731	chr22:42541494	CYP2D7P1	0.46	7.58	0.33	1.9e-13	Birth weight;
LGG	cis	rs2739330	0.828	rs2330635	chr22:24251344	T/C	cg09033563	chr22:24373618	LOC391322	-0.5	-8.38	-0.36	6.27e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs9467711	0.606	rs66827971	chr6:26365766	T/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12618769	0.597	rs4851131	chr2:99036802	A/C	cg18455616	chr2:99124870	INPP4A	0.29	8.49	0.37	2.86e-16	Bipolar disorder;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg20060089	chr17:41561319	DHX8	0.4	6.72	0.3	5.35e-11	Bipolar disorder;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg07511668	chr11:68622177	NA	0.51	9.68	0.41	2.59e-20	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs3749237	0.595	rs3870337	chr3:49557095	G/T	cg02487422	chr3:49467188	NICN1	0.58	10.66	0.44	7e-24	Resting heart rate;
LGG	trans	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg06521331	chr12:34319734	NA	0.45	8.08	0.35	5.87e-15	Bladder cancer;
LGG	cis	rs16944613	0.541	rs4566137	chr15:91097964	A/G	cg26821196	chr15:91095069	CRTC3	0.57	8.73	0.38	4.51e-17	Colorectal cancer;
LGG	cis	rs6546550	0.901	rs11126251	chr2:70163434	A/C	cg02498382	chr2:70120550	SNRNP27	-0.43	-8.09	-0.35	5.24e-15	Prevalent atrial fibrillation;
LGG	cis	rs6582630	0.502	rs10880450	chr12:38440294	G/C	cg13010199	chr12:38710504	ALG10B	0.63	12.67	0.51	8.31e-32	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6598955	0.671	rs11579630	chr1:26612297	C/A	cg04990556	chr1:26633338	UBXN11	0.6	8.15	0.35	3.46e-15	Obesity-related traits;
LGG	cis	rs774359	0.763	rs10435784	chr9:27490332	T/G	cg14173147	chr9:27528300	MOBKL2B	-0.4	-8.3	-0.36	1.14e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs10752881	1.000	rs10797813	chr1:182989366	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs10883723	0.810	rs2281879	chr10:104268877	C/G	cg05096777	chr10:104283225	SUFU	0.33	7.41	0.33	6.01e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs523522	0.926	rs10774555	chr12:120971978	G/A	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs62064224	0.703	rs62065493	chr17:30822620	C/G	cg09324608	chr17:30823087	MYO1D	0.33	7.97	0.35	1.28e-14	Schizophrenia;
LGG	cis	rs4665809	1.000	rs750452	chr2:26324995	G/A	cg22920501	chr2:26401640	FAM59B	-0.37	-7.51	-0.33	3.17e-13	Gut microbiome composition (summer);
LGG	cis	rs897984	0.568	rs4889651	chr16:30895545	C/T	cg02466173	chr16:30829666	NA	-0.52	-8.89	-0.38	1.33e-17	Dementia with Lewy bodies;
LGG	cis	rs3733585	0.673	rs6814664	chr4:9956228	C/T	cg08250081	chr4:10125330	NA	-0.37	-7.06	-0.31	6.2e-12	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs13108904	0.539	rs13135102	chr4:1330983	A/C	cg25897951	chr4:1244024	CTBP1;C4orf42	0.6	10.06	0.42	1.11e-21	Obesity-related traits;
LGG	trans	rs8002861	0.515	rs9525846	chr13:44390857	A/C	cg12856521	chr11:46389249	DGKZ	0.47	6.89	0.3	1.87e-11	Leprosy;
LGG	cis	rs561341	1.000	rs527256	chr17:30321293	C/G	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs13191362	0.935	rs34934114	chr6:163082480	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.5	7.23	0.32	2.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7937890	0.507	rs4463820	chr11:14556342	A/G	cg02886208	chr11:14281011	SPON1	-0.4	-7.88	-0.34	2.44e-14	Mitochondrial DNA levels;
LGG	cis	rs4538187	0.585	rs2969395	chr2:64253741	A/T	cg02541582	chr2:64069798	UGP2	0.56	11.73	0.48	5.23e-28	Systolic blood pressure;
LGG	cis	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg09085632	chr11:111637200	PPP2R1B	-1.09	-24.13	-0.75	6.58e-84	Primary sclerosing cholangitis;
LGG	cis	rs975739	0.801	rs1279664	chr13:78368817	A/G	cg07847733	chr13:78271382	SLAIN1	0.39	7.14	0.32	3.54e-12	Hair color;
LGG	cis	rs6951245	0.554	rs58210047	chr7:1149381	G/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.56	9.42	0.4	2.21e-19	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs6951245	1.000	rs11763020	chr7:1060288	C/T	cg13565492	chr6:43139072	SRF	-0.71	-8.73	-0.38	4.7e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs123509	0.913	rs121993	chr3:42776601	T/C	cg12982090	chr3:42733453	KBTBD5	0.95	16.01	0.6	3.22e-46	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg18681998	chr4:17616180	MED28	0.86	19.83	0.68	7.97e-64	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs6762477	0.748	rs11714286	chr3:50185508	G/A	cg21659725	chr3:3221576	CRBN	-0.46	-7.43	-0.33	5.17e-13	Menarche (age at onset);
LGG	cis	rs8016982	0.548	rs7149294	chr14:81711565	T/C	cg01989461	chr14:81687754	GTF2A1	0.59	8.73	0.38	4.76e-17	Schizophrenia;
LGG	cis	rs2836974	0.613	rs2245455	chr21:40548087	A/T	cg11890956	chr21:40555474	PSMG1	-0.73	-13.32	-0.53	1.67e-34	Cognitive function;
LGG	cis	rs9815354	1.000	rs6797165	chr3:41887777	A/G	cg03022575	chr3:42003672	ULK4	0.65	8.38	0.36	6.33e-16	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs2019137	0.539	rs4849177	chr2:113982584	T/C	cg07772999	chr2:113993052	PAX8;LOC440839;LOC654433	0.69	13.04	0.52	2.42e-33	Lymphocyte counts;
LGG	cis	rs2739330	0.828	rs2186366	chr22:24254113	A/G	cg25703541	chr22:24373054	LOC391322	0.88	17.42	0.63	1.28e-52	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs12971120	0.947	rs3764509	chr18:72167124	C/G	cg26446133	chr18:72167187	CNDP2	-0.75	-17.05	-0.62	5.78e-51	Refractive error;
LGG	trans	rs1814175	0.817	rs10769617	chr11:49810421	G/A	cg03929089	chr4:120376271	NA	-1.04	-24.65	-0.75	2.69e-86	Height;
LGG	cis	rs17092148	0.652	rs76324086	chr20:33079392	T/G	cg12302830	chr20:33297742	TP53INP2	0.4	6.7	0.3	6.21e-11	Neuroticism;
LGG	trans	rs1005277	0.579	rs2472181	chr10:38386764	T/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs3091242	0.933	rs10903130	chr1:25769221	A/T	cg03538708	chr1:25844672	NA	-0.36	-6.74	-0.3	4.65e-11	Erythrocyte sedimentation rate;
LGG	trans	rs11098499	0.754	rs1849457	chr4:120254355	A/G	cg25214090	chr10:38739885	LOC399744	0.6	10.74	0.45	3.55e-24	Corneal astigmatism;
LGG	cis	rs698833	0.819	rs2340809	chr2:44536249	A/G	cg00619915	chr2:44497795	NA	-0.44	-6.85	-0.3	2.3e-11	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs6540556	0.769	rs9430017	chr1:209925058	C/T	cg05527609	chr1:210001259	C1orf107	-0.52	-6.95	-0.31	1.22e-11	Red blood cell count;
LGG	cis	rs67311347	1.000	rs34762643	chr3:40475433	C/T	cg13683864	chr3:40499215	RPL14	-0.97	-20.12	-0.68	3.86e-65	Renal cell carcinoma;
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25517755	chr10:38738941	LOC399744	-0.37	-6.7	-0.3	6.22e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs10911251	0.546	rs7473	chr1:183114634	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.74	0.38	4.42e-17	Colorectal cancer;
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg01272081	chr9:32551527	TOPORS	0.38	6.97	0.31	1.12e-11	Bilirubin levels;
LGG	cis	rs936229	0.871	rs2290574	chr15:75135447	T/C	cg14664628	chr15:75095509	CSK	-1.01	-22.34	-0.72	1.5e-75	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs7849585	0.792	rs10858251	chr9:139132240	C/A	cg14094347	chr9:139131620	QSOX2	-0.48	-9.21	-0.39	1.12e-18	Height;
LGG	trans	rs2243480	0.803	rs34804747	chr7:65412942	G/C	cg10756647	chr7:56101905	PSPH	0.82	10.2	0.43	3.5e-22	Diabetic kidney disease;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg07701084	chr6:150067640	NUP43	0.68	12.77	0.51	3.33e-32	Lung cancer;
LGG	cis	rs17539620	0.624	rs7770107	chr6:154836862	A/G	cg17771515	chr6:154831774	CNKSR3	0.61	7.54	0.33	2.44e-13	Lipoprotein (a) levels;
LGG	cis	rs7786808	0.525	rs10253961	chr7:158194858	G/A	cg15440763	chr7:158190612	PTPRN2	-0.43	-9.01	-0.39	5.38e-18	Obesity-related traits;
LGG	cis	rs4819052	0.851	rs28616694	chr21:46674786	G/C	cg06618935	chr21:46677482	NA	-0.49	-9.57	-0.41	6.5e-20	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs7512552	0.839	rs698919	chr1:150387000	A/G	cg15654264	chr1:150340011	RPRD2	0.45	9.23	0.39	1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs1014246	0.848	rs10787714	chr10:118459384	G/T	cg14919929	chr10:118506882	NA	0.61	11.45	0.47	6.73e-27	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs3206736	0.548	rs328895	chr7:35016387	G/C	cg13400248	chr7:35225412	NA	0.54	9.35	0.4	3.78e-19	Diastolic blood pressure;
LGG	trans	rs9354308	0.899	rs2802056	chr6:66546219	C/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.07	0.42	1.07e-21	Metabolite levels;
LGG	cis	rs7208859	0.510	rs216402	chr17:28917126	A/T	cg13385521	chr17:29058706	SUZ12P	0.9	10.22	0.43	2.96e-22	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7552404	1.000	rs12091720	chr1:76186949	G/A	cg03433033	chr1:76189801	ACADM	0.82	14.19	0.55	3.43e-38	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6712932	0.962	rs10496390	chr2:105838791	C/T	cg27422857	chr2:105853526	NA	-0.4	-7.45	-0.33	4.5e-13	Type 2 diabetes;
LGG	cis	rs975739	1.000	rs1766343	chr13:78384971	T/A	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.8e-11	Hair color;
LGG	cis	rs1034435	0.547	rs6008741	chr22:48897881	G/A	cg05992904	chr22:48892994	FAM19A5	-0.69	-11.98	-0.49	5.6e-29	Late-onset Alzheimer's disease;
LGG	cis	rs61931739	0.534	rs11053020	chr12:34111092	C/G	cg06521331	chr12:34319734	NA	-0.61	-11.06	-0.46	2.15e-25	Morning vs. evening chronotype;
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg05665937	chr4:1216051	CTBP1	-0.55	-10.27	-0.43	2.05e-22	Obesity-related traits;
LGG	cis	rs453301	0.624	rs2288671	chr8:8860894	T/C	cg15556689	chr8:8085844	FLJ10661	0.42	7.5	0.33	3.24e-13	Joint mobility (Beighton score);
LGG	cis	rs4481887	0.741	rs28589987	chr1:248564785	T/C	cg15454534	chr1:248569605	OR2T1	0.39	6.84	0.3	2.46e-11	Common traits (Other);
LGG	cis	rs6951245	1.000	rs118059236	chr7:1073202	A/C	cg21664854	chr7:1097933	C7orf50;GPR146	0.97	14.33	0.55	7.9e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs35110281	0.627	rs1836855	chr21:44965414	C/G	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.64	11.64	0.48	1.2100000000000001e-27	Mean corpuscular volume;
LGG	cis	rs968451	0.789	rs5757603	chr22:39677128	A/G	cg17798944	chr22:39715225	SNORD43;RPL3	0.81	13.25	0.52	3.39e-34	Primary biliary cholangitis;
LGG	cis	rs2084898	1.000	rs55920307	chr11:120042846	A/G	cg13907859	chr11:120009124	TRIM29	0.9	12.2	0.49	7.16e-30	Stroke (pediatric);
LGG	cis	rs644799	1.000	rs481630	chr11:95582447	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	21.36	0.7	6.04e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11488569	chr9:130186546	ZNF79	0.45	7.43	0.33	5.34e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9902453	0.934	rs7211246	chr17:28485762	A/G	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.72	0.51	5.16e-32	Coffee consumption (cups per day);
LGG	cis	rs9783347	0.600	rs10766468	chr11:18321943	C/T	cg03595886	chr11:18357587	GTF2H1	-0.48	-11.73	-0.48	5.32e-28	Pancreatic cancer;
LGG	cis	rs225245	0.694	rs321616	chr17:33882720	C/T	cg05299278	chr17:33885742	SLFN14	0.45	8.8	0.38	2.81e-17	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs9517320	0.515	rs9556972	chr13:99209815	C/T	cg03701759	chr13:99174930	STK24	-0.37	-7.21	-0.32	2.34e-12	Longevity;
LGG	cis	rs61884328	0.733	rs77654484	chr11:47206594	C/A	cg03339077	chr11:47165057	C11orf49	0.62	6.68	0.3	6.9e-11	Total body bone mineral density (age over 60);
LGG	cis	rs3785574	0.962	rs2727280	chr17:61918082	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.53	7.98	0.35	1.14e-14	Height;
LGG	cis	rs8180040	0.764	rs4683324	chr3:47251284	T/C	cg16586182	chr3:47516702	SCAP	-0.8	-15.37	-0.58	2.26e-43	Colorectal cancer;
LGG	cis	rs1799949	0.965	rs8176322	chr17:41195773	A/G	cg23758822	chr17:41437982	NA	0.85	14.9	0.57	2.56e-41	Menopause (age at onset);
LGG	cis	rs35306767	0.903	rs12250937	chr10:900209	C/T	cg08847335	chr10:891726	LARP4B	-0.51	-9.08	-0.39	3.18e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs2228479	0.618	rs62052174	chr16:89950901	G/A	cg04287289	chr16:89883240	FANCA	0.73	7.78	0.34	4.76e-14	Skin colour saturation;
LGG	cis	rs12971120	0.891	rs2278158	chr18:72178300	G/T	cg25817165	chr18:72167213	CNDP2	-0.64	-12.86	-0.51	1.48e-32	Refractive error;
LGG	cis	rs2576037	0.558	rs7244778	chr18:44541915	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.53	10.99	0.45	3.89e-25	Personality dimensions;
LGG	cis	rs12701220	0.894	rs8591	chr7:1036799	C/T	cg20821713	chr7:1055600	C7orf50	-0.53	-8.58	-0.37	1.47e-16	Bronchopulmonary dysplasia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07613693	chr19:59031343	ZBTB45	0.44	6.65	0.3	8.33e-11	Gut microbiome composition (summer);
LGG	cis	rs2012796	0.956	rs7146802	chr14:81820515	A/G	cg02996355	chr14:81879375	NA	0.51	8.14	0.35	3.79e-15	Night sleep phenotypes;
LGG	cis	rs6502050	0.830	rs8074436	chr17:80158422	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.28	-0.4	6.76e-19	Life satisfaction;
LGG	cis	rs4664308	0.618	rs17830904	chr2:160891688	C/T	cg03641300	chr2:160917029	PLA2R1	0.61	11.58	0.47	2.12e-27	Idiopathic membranous nephropathy;
LGG	cis	rs12190007	0.604	rs7382308	chr6:169732276	A/C	cg16388071	chr6:169726476	NA	-0.5	-10.61	-0.44	1.05e-23	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs11775506	chr8:58133639	G/T	cg24829409	chr8:58192753	C8orf71	-0.73	-10.34	-0.43	1.11e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg11494091	chr17:61959527	GH2	1.0	24.63	0.75	3.29e-86	Prudent dietary pattern;
LGG	cis	rs9359856	0.510	rs6937244	chr6:90468465	C/A	cg13799429	chr6:90582589	CASP8AP2	0.85	13.25	0.52	3.47e-34	Bipolar disorder;
LGG	cis	rs10504229	1.000	rs17216648	chr8:58169429	C/T	cg26174226	chr8:58114915	NA	-0.45	-6.68	-0.3	6.8e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs9300255	0.568	rs1727300	chr12:123664205	C/T	cg00376283	chr12:123451042	ABCB9	0.64	10.23	0.43	2.86e-22	Neutrophil percentage of white cells;
LGG	cis	rs2862064	1.000	rs4407618	chr5:156445875	A/C	cg12943317	chr5:156479607	HAVCR1	-0.77	-10.23	-0.43	2.86e-22	Platelet count;
LGG	cis	rs131777	0.547	rs131753	chr22:51022862	A/G	cg05418105	chr22:50981406	NA	-0.61	-10.46	-0.44	3.86e-23	Mean corpuscular volume;Mean corpuscular hemoglobin;
LGG	cis	rs11098499	0.775	rs2002049	chr4:120257417	A/G	cg24375607	chr4:120327624	NA	0.59	10.0	0.42	1.9e-21	Corneal astigmatism;
LGG	cis	rs936229	0.690	rs2472300	chr15:75033909	A/G	cg14664628	chr15:75095509	CSK	-0.94	-18.41	-0.65	3.43e-57	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs9914988	0.943	rs7215310	chr17:27088626	G/T	cg20469991	chr17:27169893	C17orf63	-0.61	-7.61	-0.33	1.53e-13	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs7818345	0.637	rs3923920	chr8:19359184	A/G	cg01280390	chr8:19363452	CSGALNACT1	-0.44	-10.8	-0.45	2.16e-24	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7552404	0.924	rs1498317	chr1:76171984	A/C	cg10523679	chr1:76189770	ACADM	0.83	16.26	0.6	2.31e-47	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6028335	0.674	rs16987712	chr20:37601243	A/G	cg16355469	chr20:37678765	NA	0.6	7.98	0.35	1.14e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg05368731	chr17:41323189	NBR1	0.89	17.65	0.63	1.07e-53	Menopause (age at onset);
LGG	cis	rs273218	1.000	rs156384	chr5:53371333	A/G	ch.5.1024479R	chr5:53302184	ARL15	0.63	9.02	0.39	4.97e-18	Migraine;
LGG	cis	rs17092148	1.000	rs6060025	chr20:33326876	A/G	cg12302830	chr20:33297742	TP53INP2	-0.47	-7.81	-0.34	3.81e-14	Neuroticism;
LGG	cis	rs1395	0.744	rs9653564	chr2:27472618	G/A	cg23587288	chr2:27483067	SLC30A3	-0.36	-8.19	-0.36	2.52e-15	Blood metabolite levels;
LGG	cis	rs11122272	0.735	rs2474631	chr1:231541341	T/A	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.61	-10.87	-0.45	1.19e-24	Hemoglobin concentration;
LGG	cis	rs769267	0.965	rs2017964	chr19:19387149	T/C	cg17414380	chr19:19431394	KIAA0892;SF4	0.52	8.22	0.36	2.03e-15	Tonsillectomy;
LGG	cis	rs72945132	0.882	rs55915603	chr11:70210067	G/T	cg00319359	chr11:70116639	PPFIA1	0.74	7.85	0.34	3e-14	Coronary artery disease;
LGG	cis	rs1348850	0.561	rs4893956	chr2:178373452	C/T	cg23306229	chr2:178417860	TTC30B	0.72	8.77	0.38	3.38e-17	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg15268244	chr15:77196840	NA	-0.31	-6.87	-0.3	2.06e-11	Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs9912283	chr17:29110373	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg16339924	chr4:17578868	LAP3	0.65	11.05	0.46	2.43e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg09307838	chr4:120376055	NA	0.8	13.41	0.53	7.15e-35	Corneal astigmatism;
LGG	cis	rs3096299	0.658	rs4291902	chr16:89560315	G/C	cg02187348	chr16:89574699	SPG7	0.65	10.89	0.45	9.79e-25	Multiple myeloma (IgH translocation);
LGG	cis	rs2481665	0.777	rs17379217	chr1:62545085	C/T	cg18591186	chr1:62594603	INADL	-0.5	-10.06	-0.42	1.18e-21	BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2439831	0.867	rs2899082	chr15:43656043	A/G	cg15269541	chr15:43626905	ADAL	-0.44	-7.42	-0.33	5.77e-13	Lung cancer in ever smokers;
LGG	cis	rs10504229	0.639	rs67002486	chr8:58117218	A/G	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7580658	0.724	rs6712213	chr2:127998230	G/A	cg10021288	chr2:128175891	PROC	-0.62	-12.69	-0.51	7.1e-32	Protein C levels;
LGG	cis	rs6429082	0.627	rs2016437	chr1:235539355	T/G	cg26050004	chr1:235667680	B3GALNT2	-0.56	-8.9	-0.38	1.29e-17	Adiposity;
LGG	cis	rs9549367	0.789	rs9549716	chr13:113908478	G/A	cg18105134	chr13:113819100	PROZ	-0.68	-13.96	-0.54	3.19e-37	Platelet distribution width;
LGG	cis	rs6582630	0.638	rs61931383	chr12:38513845	G/A	cg04568710	chr12:38710424	ALG10B	-0.43	-9.53	-0.4	8.93e-20	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs2777491	0.915	rs8032838	chr15:41605632	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.96	-19.41	-0.67	7.7e-62	Ulcerative colitis;
LGG	cis	rs8062405	0.698	rs8046545	chr16:28915217	G/A	cg07382826	chr16:28625726	SULT1A1	-0.38	-7.33	-0.32	1.01e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg04267008	chr7:1944627	MAD1L1	0.59	9.94	0.42	3.07e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs1799949	1.000	rs11653069	chr17:41283377	C/T	cg18379455	chr17:41446167	NA	-0.33	-7.55	-0.33	2.41e-13	Menopause (age at onset);
LGG	trans	rs4332037	0.510	rs11762803	chr7:1886805	A/G	cg11693508	chr17:37793320	STARD3	0.52	8.38	0.36	6.58e-16	Bipolar disorder;
LGG	cis	rs6061231	0.761	rs2427312	chr20:60970591	C/T	cg24112000	chr20:60950667	NA	-0.42	-7.31	-0.32	1.19e-12	Colorectal cancer;
LGG	cis	rs8072100	0.782	rs28507314	chr17:45551402	C/T	cg08085267	chr17:45401833	C17orf57	-0.54	-10.55	-0.44	1.85e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg23758822	chr17:41437982	NA	0.9	15.78	0.59	3.22e-45	Menopause (age at onset);
LGG	cis	rs10464366	0.746	rs4723821	chr7:39141532	A/G	cg18850127	chr7:39170497	POU6F2	0.6	14.6	0.56	5.64e-40	IgG glycosylation;
LGG	cis	rs6087771	0.651	rs6060775	chr20:30286191	A/G	cg13852791	chr20:30311386	BCL2L1	0.73	13.28	0.53	2.54e-34	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs9910055	0.762	rs11080007	chr17:42265442	A/G	cg10896456	chr17:42255109	ASB16;C17orf65	-0.45	-7.86	-0.34	2.72e-14	Total body bone mineral density;
LGG	cis	rs13108904	0.870	rs3755924	chr4:1238363	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.35	0.53	1.26e-34	Obesity-related traits;
LGG	cis	rs763121	0.626	rs5750643	chr22:39009017	A/G	cg21395723	chr22:39101663	GTPBP1	0.37	6.67	0.3	7.12e-11	Menopause (age at onset);
LGG	cis	rs910316	0.737	rs175424	chr14:75626257	T/C	cg11812906	chr14:75593930	NEK9	-0.45	-8.2	-0.36	2.34e-15	Height;
LGG	cis	rs7474896	0.515	rs662928	chr10:38316216	G/T	cg00409905	chr10:38381863	ZNF37A	0.48	7.08	0.31	5.48e-12	Obesity (extreme);
LGG	cis	rs774359	0.744	rs12115670	chr9:27486172	C/G	cg21249376	chr9:27528432	MOBKL2B	0.46	8.27	0.36	1.44e-15	Amyotrophic lateral sclerosis;
LGG	cis	rs2228479	0.702	rs12600047	chr16:89831630	G/A	cg04287289	chr16:89883240	FANCA	0.89	8.63	0.37	1.01e-16	Skin colour saturation;
LGG	cis	rs6496044	0.527	rs7163068	chr15:86072466	T/C	cg13263323	chr15:86062960	AKAP13	-0.39	-8.47	-0.37	3.17e-16	Interstitial lung disease;
LGG	cis	rs1816752	0.905	rs9581026	chr13:24997926	C/A	cg22771759	chr13:24902376	NA	0.42	7.22	0.32	2.08e-12	Obesity-related traits;
LGG	cis	rs10504130	0.569	rs7820177	chr8:52836933	A/T	cg22653915	chr8:52722023	PXDNL	-0.54	-9.62	-0.41	4.33e-20	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs933688	1.000	rs11950530	chr5:90688740	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg17644776	chr2:200775616	C2orf69	-0.52	-8.43	-0.36	4.26e-16	Osteoporosis;
LGG	cis	rs2762353	0.553	rs9467581	chr6:25710548	C/T	cg03264133	chr6:25882463	NA	0.7	13.37	0.53	1e-34	Blood metabolite levels;
LGG	cis	rs1577917	0.958	rs1335442	chr6:86466692	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.65	-10.82	-0.45	1.72e-24	Response to antipsychotic treatment;
LGG	cis	rs793571	0.566	rs610877	chr15:59103328	C/A	cg05156742	chr15:59063176	FAM63B	0.58	9.7	0.41	2.31e-20	Schizophrenia;
LGG	cis	rs7399018	0.739	rs6580811	chr12:51612501	T/C	cg25754956	chr12:51612065	POU6F1	0.64	10.22	0.43	2.97e-22	Cisplatin-induced ototoxicity;
LGG	cis	rs6502050	0.835	rs4789724	chr17:80150546	G/A	cg10505658	chr17:80084571	CCDC57	-0.4	-8.23	-0.36	1.94e-15	Life satisfaction;
LGG	cis	rs10791323	0.569	rs10736608	chr11:133740048	C/T	cg06766960	chr11:133703094	NA	-0.5	-10.05	-0.42	1.3e-21	Childhood ear infection;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg22156867	chr6:37467762	C6orf129	0.41	6.98	0.31	1.02e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4631830	0.965	rs7070301	chr10:51543070	T/G	cg16070123	chr10:51489643	NA	-0.38	-6.95	-0.31	1.22e-11	Prostate-specific antigen levels;
LGG	cis	rs9534288	0.659	rs1581846	chr13:46650686	G/A	cg15192986	chr13:46630673	CPB2	-0.66	-13.81	-0.54	1.48e-36	Blood protein levels;
LGG	cis	rs9290065	0.538	rs6809206	chr3:160755708	G/A	cg03342759	chr3:160939853	NMD3	-0.54	-9.13	-0.39	2.2e-18	Kawasaki disease;
LGG	trans	rs1600249	0.562	rs17153419	chr8:11394233	C/T	cg02002194	chr4:3960332	NA	0.42	6.95	0.31	1.28e-11	Rheumatoid arthritis;
LGG	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.77	0.3	4.01e-11	Parkinson's disease;
LGG	cis	rs769267	0.930	rs4808955	chr19:19552413	T/C	cg03709012	chr19:19516395	GATAD2A	0.85	17.14	0.62	2.34e-51	Tonsillectomy;
LGG	cis	rs6964587	1.000	rs36021614	chr7:91717490	C/G	cg17063962	chr7:91808500	NA	0.48	8.45	0.37	3.81e-16	Breast cancer;
LGG	cis	rs514024	0.520	rs836333	chr9:130486384	C/T	cg13643465	chr9:130375613	STXBP1	0.57	10.58	0.44	1.44e-23	Eating disorders (purging via substances);
LGG	cis	rs7623687	0.681	rs73079003	chr3:49832788	G/A	cg19401529	chr3:49056140	DALRD3	0.74	7.08	0.31	5.35e-12	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Coronary artery disease;
LGG	trans	rs8073060	0.544	rs9912939	chr17:34005264	T/G	cg19694781	chr19:47549865	TMEM160	-1.16	-17.67	-0.63	9.11e-54	Immature fraction of reticulocytes;Platelet count;Platelet distribution width;
LGG	cis	rs657075	0.697	rs35948329	chr5:131686452	T/A	cg24060327	chr5:131705240	SLC22A5	0.62	6.77	0.3	3.93e-11	Rheumatoid arthritis;
LGG	cis	rs1908814	0.516	rs7812563	chr8:11794488	T/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.75e-14	Neuroticism;
LGG	cis	rs77741769	0.571	rs3861797	chr12:121255334	T/C	cg02419362	chr12:121203948	SPPL3	0.53	9.21	0.39	1.1e-18	Mean corpuscular volume;
LGG	cis	rs2074193	0.569	rs215348	chr12:47734294	C/T	cg02516419	chr12:47771422	NA	-0.51	-7.48	-0.33	3.66e-13	Migraine with aura;
LGG	trans	rs9929218	0.953	rs3118235	chr16:68732977	A/G	cg04657470	chr2:198365150	HSPE1;HSPD1	0.85	14.2	0.55	2.88e-38	Colorectal cancer;
LGG	cis	rs9611565	0.694	rs202616	chr22:41822221	C/G	cg03806693	chr22:41940476	POLR3H	1.08	19.39	0.67	9.63e-62	Vitiligo;
LGG	cis	rs1659258	0.614	rs1258399	chr2:88622423	A/G	cg00685853	chr2:88648947	NA	-0.45	-6.78	-0.3	3.67e-11	Visceral fat;
LGG	cis	rs1256061	0.564	rs1256043	chr14:64734282	A/G	cg21174375	chr14:64681225	SYNE2	0.36	6.71	0.3	5.53e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs1497828	0.956	rs2815229	chr1:217535088	T/C	cg04411442	chr1:217543379	NA	-0.47	-8.02	-0.35	8.51e-15	Dialysis-related mortality;
LGG	cis	rs11229555	0.645	rs72917641	chr11:58227320	A/C	cg15696309	chr11:58395628	NA	-0.96	-15.5	-0.58	5.72e-44	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17321999	0.516	rs7606266	chr2:30501997	C/T	cg05247661	chr2:30472410	LBH	0.64	7.99	0.35	1.09e-14	Systemic lupus erythematosus;
LGG	cis	rs7618915	0.547	rs33967311	chr3:52683864	G/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.02	-0.31	8.05e-12	Bipolar disorder;
LGG	cis	rs11785693	0.862	rs73183618	chr8:4988340	T/C	cg26367366	chr8:4980734	NA	0.93	14.93	0.57	1.95e-41	Neuroticism (multi-trait analysis);Neuroticism;
LGG	cis	rs372883	0.613	rs1153274	chr21:30660026	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-11.85	-0.48	1.79e-28	Pancreatic cancer;
LGG	cis	rs875971	0.798	rs57739047	chr7:65972566	A/T	cg11764359	chr7:65958608	NA	0.74	13.4	0.53	7.66e-35	Aortic root size;
LGG	cis	rs4690686	0.500	rs7683662	chr4:177272004	A/T	cg17059388	chr4:177262070	NA	1.0	23.07	0.73	5.57e-79	Essential tremor;
LGG	cis	rs4631830	0.695	rs11004584	chr10:51500088	G/T	cg10326726	chr10:51549505	MSMB	-0.64	-12.75	-0.51	3.85e-32	Prostate-specific antigen levels;
LGG	cis	rs7811142	1.000	rs67040465	chr7:100083078	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.59	8.88	0.38	1.44e-17	Platelet count;
LGG	cis	rs1408799	0.743	rs7026116	chr9:12633981	T/A	cg05274944	chr9:12693694	TYRP1	0.33	7.49	0.33	3.44e-13	Eye color;Blue vs. green eyes;
LGG	cis	rs4319547	0.915	rs11058402	chr12:122981053	A/G	cg23029597	chr12:123009494	RSRC2	-0.96	-18.2	-0.65	3.02e-56	Body mass index;
LGG	cis	rs9322193	0.607	rs10457852	chr6:150201720	C/T	cg11878867	chr6:150167359	LRP11	-0.46	-8.06	-0.35	6.4e-15	Lung cancer;
LGG	cis	rs5769707	0.521	rs9616715	chr22:50058582	C/T	cg20744362	chr22:50050164	C22orf34	0.41	7.13	0.31	3.82e-12	Monocyte count;Monocyte percentage of white cells;
LGG	cis	rs12421382	0.511	rs2212430	chr11:109289538	C/T	cg11473876	chr11:109292803	C11orf87	0.79	17.43	0.63	1.11e-52	Schizophrenia;
LGG	cis	rs700651	0.752	rs7592556	chr2:198891021	G/A	cg00792783	chr2:198669748	PLCL1	0.66	10.63	0.44	8.99e-24	Intracranial aneurysm;
LGG	cis	rs2228479	1.000	rs4257207	chr16:89947861	T/A	cg03036210	chr16:89904091	SPIRE2	-0.61	-7.55	-0.33	2.31e-13	Skin colour saturation;
LGG	cis	rs17767392	0.846	rs34281405	chr14:71780587	G/A	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.74	-0.38	4.36e-17	Mitral valve prolapse;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11905131	chr22:24372483	LOC391322	-0.47	-8.33	-0.36	8.93e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11190604	1.000	rs7100386	chr10:102301417	C/T	cg07080220	chr10:102295463	HIF1AN	0.71	12.08	0.49	2.05e-29	Palmitoleic acid (16:1n-7) levels;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg15811753	chr2:65454775	ACTR2	0.44	6.67	0.3	7.25e-11	Hip circumference;
LGG	cis	rs67366981	0.800	rs55939042	chr14:77691186	T/A	cg22824376	chr14:77648248	TMEM63C	0.67	7.47	0.33	4e-13	Obsessive-compulsive symptoms;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg01988459	chr11:68622903	NA	-0.63	-12.24	-0.49	4.79e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12681288	0.823	rs2600518	chr8:1007214	A/T	cg15309053	chr8:964076	NA	0.33	6.72	0.3	5.34e-11	Schizophrenia;
LGG	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg18477163	chr1:228402036	OBSCN	-0.26	-7.07	-0.31	5.63e-12	Diastolic blood pressure;
LGG	cis	rs6502050	0.764	rs7215277	chr17:80159283	C/A	cg11859384	chr17:80120422	CCDC57	-0.43	-7.58	-0.33	1.93e-13	Life satisfaction;
LGG	cis	rs897080	0.552	rs1067378	chr2:44648047	A/G	cg00619915	chr2:44497795	NA	-0.49	-6.88	-0.3	1.99e-11	Height;
LGG	cis	rs755249	0.567	rs3754346	chr1:39814960	C/T	cg18385671	chr1:39797026	MACF1	0.44	7.46	0.33	4.28e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2070677	0.935	rs12256349	chr10:135409632	G/A	cg20169779	chr10:135381914	SYCE1	-1.04	-13.23	-0.52	4.2e-34	Gout;
LGG	cis	rs17666538	0.585	rs1037393	chr8:622634	G/C	cg23958373	chr8:599963	NA	1.17	11.81	0.48	2.66e-28	IgG glycosylation;
LGG	cis	rs7215564	0.908	rs35878324	chr17:78677530	C/T	cg16980736	chr17:78789706	RPTOR	-0.72	-9.16	-0.39	1.67e-18	Myopia (pathological);
LGG	trans	rs11875185	0.510	rs118131977	chr18:55602324	T/A	cg15513957	chr14:69354734	ACTN1	-0.92	-8.77	-0.38	3.39e-17	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs9487094	0.961	rs12528822	chr6:109661541	C/G	cg16315928	chr6:109776240	MICAL1	0.55	9.36	0.4	3.52e-19	Height;
LGG	cis	rs9368481	0.761	rs9348746	chr6:26970357	C/G	cg12292205	chr6:26970375	C6orf41	-0.77	-15.66	-0.59	1.19e-44	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12153243	0.686	rs12152870	chr5:142898255	C/T	cg13907255	chr5:142895549	NA	-0.5	-8.64	-0.37	8.87e-17	Migraine;
LGG	cis	rs13108904	0.934	rs13128045	chr4:1305309	C/T	cg06654118	chr4:1303317	MAEA	0.49	8.55	0.37	1.8e-16	Obesity-related traits;
LGG	cis	rs4557101	0.625	rs7626194	chr3:73535636	C/T	cg24173753	chr3:73529447	PDZRN3	0.35	7.22	0.32	2.1e-12	QT interval;
LGG	cis	rs10504229	0.683	rs55986917	chr8:58137210	C/T	cg11062466	chr8:58055876	NA	0.54	8.81	0.38	2.55e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7166081	1.000	rs8026870	chr15:67511389	G/A	cg05925327	chr15:68127851	NA	-0.32	-6.84	-0.3	2.44e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs9329221	0.621	rs12156350	chr8:10268516	T/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.74	-0.38	4.33e-17	Neuroticism;
LGG	cis	rs7949030	0.626	rs7930896	chr11:62325272	A/G	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.36	0.61	8.31e-48	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg06886374	chr16:1844152	IGFALS	-0.44	-7.99	-0.35	1.1e-14	Insulin-like growth factors;
LGG	cis	rs6582630	0.555	rs1906260	chr12:38601013	T/G	cg26384229	chr12:38710491	ALG10B	1.0	24.02	0.74	2.27e-83	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7939886	0.920	rs17150117	chr11:55941186	T/C	cg15704280	chr7:45808275	SEPT13	0.83	7.84	0.34	3.07e-14	Myopia (pathological);
LGG	trans	rs3808502	0.549	rs4841564	chr8:11425809	T/G	cg08975724	chr8:8085496	FLJ10661	-0.48	-9.18	-0.39	1.45e-18	Neuroticism;
LGG	cis	rs17376456	0.877	rs17083460	chr5:93462354	A/G	cg19507638	chr5:93509721	C5orf36	-0.71	-9.92	-0.42	3.74e-21	Diabetic retinopathy;
LGG	cis	rs2282802	0.660	rs4463213	chr5:139545748	G/A	cg26211634	chr5:139558579	C5orf32	-0.36	-7.93	-0.35	1.64e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2274273	0.662	rs67588230	chr14:55667030	C/T	cg04306507	chr14:55594613	LGALS3	0.52	12.02	0.49	3.7e-29	Protein biomarker;
LGG	cis	rs2721195	0.967	rs1985022	chr8:145684031	C/T	cg11211951	chr8:145729740	GPT	0.51	11.69	0.48	7.49e-28	Age at first birth;
LGG	cis	rs2274273	0.623	rs1187883	chr14:55488234	T/C	cg04306507	chr14:55594613	LGALS3	-0.41	-9.87	-0.42	5.65e-21	Protein biomarker;
LGG	cis	rs4481887	0.790	rs6587440	chr1:248415662	A/G	cg13385794	chr1:248469461	NA	0.42	7.18	0.32	2.81e-12	Common traits (Other);
LGG	cis	rs72945132	0.882	rs4567496	chr11:70193208	A/T	cg00319359	chr11:70116639	PPFIA1	0.73	7.71	0.34	7.61e-14	Coronary artery disease;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12792894	chr1:115123975	BCAS2	0.27	6.74	0.3	4.87e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs2952156	1.000	rs4252627	chr17:37868715	C/T	cg00129232	chr17:37814104	STARD3	-0.74	-15.56	-0.59	3.27e-44	Asthma;
LGG	cis	rs10937275	0.826	rs71322421	chr3:186640688	T/A	cg26193484	chr3:186648175	ST6GAL1	0.87	8.92	0.38	1.06e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs3741404	0.825	rs11603384	chr11:63949095	G/A	cg18225595	chr11:63971243	STIP1	0.63	11.79	0.48	2.99e-28	Platelet count;
LGG	trans	rs11992162	0.636	rs4841645	chr8:11798684	G/T	cg02002194	chr4:3960332	NA	0.44	7.97	0.35	1.26e-14	Monocyte count;
LGG	cis	rs951366	0.789	rs823097	chr1:205681370	G/A	cg07157834	chr1:205819609	PM20D1	0.73	16.52	0.61	1.49e-48	Menarche (age at onset);
LGG	cis	rs754466	0.580	rs1054608	chr10:79543308	T/G	cg17075019	chr10:79541650	NA	-0.98	-22.53	-0.72	1.86e-76	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs780096	0.546	rs8179225	chr2:27737181	A/G	cg02592271	chr2:27665507	KRTCAP3	-0.32	-8.14	-0.35	3.76e-15	Total body bone mineral density;
LGG	cis	rs6594499	0.872	rs6594498	chr5:110458351	G/A	cg04022379	chr5:110408740	TSLP	0.41	7.56	0.33	2.23e-13	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7949030	0.626	rs7943191	chr11:62328551	A/G	cg22862634	chr11:62369728	EML3;MTA2	0.65	15.19	0.58	1.35e-42	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg24922022	chr4:827675	NA	0.39	8.15	0.35	3.48e-15	Systemic sclerosis;
LGG	cis	rs600550	0.588	rs7943848	chr11:60092590	T/C	cg05040360	chr11:60102449	MS4A6E	-0.36	-7.76	-0.34	5.39e-14	Lipoprotein-associated phospholipase A2 activity and mass;
LGG	cis	rs9303401	0.659	rs2072316	chr17:56604813	G/T	cg02118635	chr17:56770003	RAD51C;TEX14	0.92	14.75	0.57	1.26e-40	Cognitive test performance;
LGG	cis	rs7107174	1.000	rs10899486	chr11:78072398	A/G	cg02023728	chr11:77925099	USP35	0.46	7.95	0.35	1.44e-14	Testicular germ cell tumor;
LGG	cis	rs72945132	0.882	rs7128969	chr11:70205017	C/A	cg14088196	chr11:70211408	PPFIA1	0.95	13.2	0.52	5.56e-34	Coronary artery disease;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07157834	chr1:205819609	PM20D1	0.73	16.65	0.61	4.12e-49	Menarche (age at onset);
LGG	cis	rs9549367	0.601	rs558869	chr13:113849932	G/T	cg00898013	chr13:113819073	PROZ	0.47	9.8	0.41	9.86e-21	Platelet distribution width;
LGG	cis	rs9814567	1.000	rs9289471	chr3:134230811	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.72	-13.46	-0.53	4.35e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs4865875	0.901	rs6450251	chr5:54101834	C/T	cg22421804	chr5:54100067	NA	0.51	7.72	0.34	7.13e-14	Sense of smell;
LGG	cis	rs2797369	0.600	rs72951137	chr6:101323202	G/C	cg27451362	chr6:101846650	GRIK2	0.68	9.19	0.39	1.38e-18	Renal function-related traits (eGRFcrea);
LGG	cis	rs7824557	0.564	rs2572400	chr8:11234367	T/G	cg15596359	chr8:11213517	TDH	0.42	8.74	0.38	4.33e-17	Retinal vascular caliber;
LGG	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.89	0.57	2.97e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6952808	0.692	rs56727870	chr7:2029940	T/C	cg18279126	chr7:2041391	MAD1L1	0.32	6.65	0.3	8.36e-11	Bipolar disorder and schizophrenia;
LGG	trans	rs7939886	0.920	rs11227158	chr11:55843795	A/G	cg03929089	chr4:120376271	NA	0.79	8.19	0.36	2.51e-15	Myopia (pathological);
LGG	cis	rs12956009	0.583	rs11663609	chr18:44862757	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.44	7.14	0.31	3.6e-12	Educational attainment (years of education);
LGG	cis	rs7945705	0.818	rs2653613	chr11:8879105	C/T	cg21881798	chr11:8931708	C11orf17;ST5	-0.53	-11.75	-0.48	4.57e-28	Hemoglobin concentration;
LGG	cis	rs10895140	0.709	rs2154996	chr11:101480817	G/A	cg23650423	chr11:101454676	TRPC6	-0.43	-7.0	-0.31	9.08e-12	Menarche (age at onset);
LGG	cis	rs2354432	0.556	rs57388899	chr1:146773422	T/C	cg25205988	chr1:146714368	CHD1L	-1.28	-15.19	-0.58	1.44e-42	Mitochondrial DNA levels;
LGG	cis	rs870825	0.860	rs62339895	chr4:185598681	A/G	cg04058563	chr4:185651563	MLF1IP	-1.02	-20.36	-0.69	2.96e-66	Blood protein levels;
LGG	cis	rs28386778	0.897	rs2584601	chr17:61940977	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	32.96	0.84	1.58e-123	Prudent dietary pattern;
LGG	trans	rs7824557	0.628	rs3174048	chr8:11184937	G/A	cg06636001	chr8:8085503	FLJ10661	0.41	7.04	0.31	7.06e-12	Retinal vascular caliber;
LGG	cis	rs362296	0.511	rs2857861	chr4:3323767	C/T	cg06533319	chr4:3265114	C4orf44	-0.39	-8.31	-0.36	1.08e-15	Parental longevity (mother's age at death);
LGG	cis	rs3096299	0.933	rs2930219	chr16:89492049	G/A	cg08392591	chr16:89556376	ANKRD11	0.43	6.71	0.3	5.81e-11	Multiple myeloma (IgH translocation);
LGG	cis	rs6547741	1.000	rs6756238	chr2:27841305	G/A	cg27432699	chr2:27873401	GPN1	0.7	14.26	0.55	1.64e-38	Oral cavity cancer;
LGG	cis	rs2404602	0.684	rs8037847	chr15:76856551	C/T	cg23625390	chr15:77176239	SCAPER	-0.7	-13.77	-0.54	2.08e-36	Blood metabolite levels;
LGG	cis	rs9849248	0.574	rs7650068	chr3:88229090	A/G	cg14530983	chr3:88190749	ZNF654	-0.57	-7.78	-0.34	4.86e-14	Menarche (age at onset);
LGG	cis	rs6743376	0.556	rs2515402	chr2:113820580	C/A	cg05949173	chr2:113825882	IL1F10	0.51	9.74	0.41	1.59e-20	Inflammatory biomarkers;
LGG	cis	rs12477438	0.798	rs6740267	chr2:99561867	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.72	-12.37	-0.5	1.44e-30	Chronic sinus infection;
LGG	cis	rs1707322	1.000	rs4390216	chr1:46266456	C/T	cg03146154	chr1:46216737	IPP	0.54	10.28	0.43	1.78e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2797369	0.600	rs72951161	chr6:101336765	T/G	cg27451362	chr6:101846650	GRIK2	0.67	8.85	0.38	1.8e-17	Renal function-related traits (eGRFcrea);
LGG	cis	rs981844	0.775	rs62323979	chr4:154752935	T/C	cg14289246	chr4:154710475	SFRP2	0.67	10.92	0.45	7.11e-25	Response to statins (LDL cholesterol change);
LGG	cis	rs12497850	0.931	rs7628719	chr3:48995487	C/T	cg07636037	chr3:49044803	WDR6	1.07	26.45	0.78	1.31e-94	Parkinson's disease;
LGG	cis	rs7113850	0.541	rs74708033	chr11:24223512	C/T	ch.11.24196551F	chr11:24239977	NA	0.9	10.17	0.43	4.49e-22	Bone fracture in osteoporosis;
LGG	trans	rs6598955	0.670	rs7522905	chr1:26609259	C/T	cg07461501	chr17:79650226	HGS;ARL16	0.38	8.04	0.35	7.45e-15	Obesity-related traits;
LGG	cis	rs4076764	0.846	rs12036398	chr1:163422204	C/T	cg06092702	chr1:163392909	NA	0.43	7.77	0.34	5.15e-14	Motion sickness;
LGG	cis	rs2576037	0.796	rs2571030	chr18:44573854	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.43	-8.27	-0.36	1.41e-15	Personality dimensions;
LGG	cis	rs2243480	1.000	rs13220979	chr7:65363204	G/A	cg13147721	chr7:65941812	NA	-0.75	-9.27	-0.4	7.31e-19	Diabetic kidney disease;
LGG	cis	rs1555322	0.530	rs2425047	chr20:33871675	G/T	cg17927777	chr20:33865990	NA	-0.74	-10.95	-0.45	5.72e-25	Attention deficit hyperactivity disorder;
LGG	cis	rs7937682	0.663	rs3867466	chr11:111668256	A/C	cg09085632	chr11:111637200	PPP2R1B	1.01	19.62	0.67	8.29e-63	Primary sclerosing cholangitis;
LGG	cis	rs740698	0.521	rs9891713	chr17:60789405	C/T	cg13195520	chr17:60813227	MARCH10	0.56	12.75	0.51	3.96e-32	Pulse pressure;
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg13047869	chr3:10149882	C3orf24	0.45	7.49	0.33	3.63e-13	Alzheimer's disease;
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg04861929	chr11:109293070	C11orf87	0.55	9.94	0.42	3.14e-21	Schizophrenia;
LGG	cis	rs17376456	1.000	rs6867042	chr5:93555761	C/T	cg25358565	chr5:93447407	FAM172A	1.36	16.52	0.61	1.52e-48	Diabetic retinopathy;
LGG	cis	rs10752881	0.905	rs10797830	chr1:183036274	A/T	cg07245641	chr1:182991651	LAMC1	0.42	9.67	0.41	2.98e-20	Colorectal cancer;
LGG	cis	rs344364	0.511	rs2982446	chr16:1947153	C/T	cg14074117	chr16:1909714	C16orf73	-0.54	-8.02	-0.35	8.53e-15	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs769267	0.895	rs2965182	chr19:19548246	A/G	cg03709012	chr19:19516395	GATAD2A	0.86	17.48	0.63	6.5e-53	Tonsillectomy;
LGG	cis	rs6952808	0.594	rs3778969	chr7:2139990	A/G	cg22963979	chr7:1858916	MAD1L1	0.42	8.16	0.35	3.16e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs2692947	0.631	rs2312954	chr2:96772447	C/T	cg22654517	chr2:96458247	NA	-0.37	-7.56	-0.33	2.13e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs17767392	0.958	rs36093218	chr14:71872073	G/C	cg02058870	chr14:72053146	SIPA1L1	0.45	9.04	0.39	4.23e-18	Mitral valve prolapse;
LGG	trans	rs3780486	0.541	rs10738909	chr9:33148834	T/C	cg04842962	chr6:43655489	MRPS18A	0.8	14.88	0.57	3.46e-41	IgG glycosylation;
LGG	cis	rs1008375	0.646	rs13145480	chr4:17565143	T/C	cg18681998	chr4:17616180	MED28	-0.78	-15.24	-0.58	8.68e-43	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs295140	0.506	rs295136	chr2:201141002	G/C	cg23649088	chr2:200775458	C2orf69	0.41	6.93	0.31	1.41e-11	QT interval;
LGG	cis	rs9880211	0.800	rs79876804	chr3:136494150	A/G	cg21827317	chr3:136751795	NA	-0.47	-6.89	-0.3	1.88e-11	Body mass index;Height;
LGG	cis	rs2153535	0.580	rs9379213	chr6:8474945	G/A	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.06e-18	Motion sickness;
LGG	cis	rs9287719	0.967	rs6432113	chr2:10744889	C/T	cg02196655	chr2:10830764	NOL10	0.44	7.46	0.33	4.39e-13	Prostate cancer;
LGG	cis	rs12824058	0.831	rs7485200	chr12:130811641	C/T	cg24838063	chr12:130822603	PIWIL1	0.7	13.26	0.52	2.96e-34	Menopause (age at onset);
LGG	cis	rs62238980	0.614	rs117194706	chr22:32491317	C/G	cg00543991	chr22:32367038	NA	0.78	8.55	0.37	1.86e-16	Childhood ear infection;
LGG	trans	rs75804782	0.510	rs10186447	chr2:239467168	C/T	cg01134436	chr17:81009848	B3GNTL1	0.69	7.42	0.33	5.66e-13	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg01879757	chr17:41196368	BRCA1	-0.43	-8.74	-0.38	4.31e-17	Menopause (age at onset);
LGG	cis	rs17376456	0.597	rs6869110	chr5:93355531	G/A	cg19507638	chr5:93509721	C5orf36	0.4	7.21	0.32	2.34e-12	Diabetic retinopathy;
LGG	cis	rs7444	0.941	rs181366	chr22:21933780	C/T	cg15846791	chr22:21984385	YDJC	-0.45	-6.9	-0.31	1.67e-11	Systemic lupus erythematosus;
LGG	trans	rs11895698	1	rs11895698	chr2:239338495	C/T	cg01134436	chr17:81009848	B3GNTL1	0.67	7.95	0.35	1.47e-14	Chronotype;
LGG	cis	rs9549367	0.789	rs2287251	chr13:113889499	A/G	cg00898013	chr13:113819073	PROZ	-0.44	-8.64	-0.37	9.02e-17	Platelet distribution width;
LGG	cis	rs7100689	0.646	rs4468295	chr10:82119276	C/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	trans	rs6598955	0.614	rs1134584	chr1:26608828	G/A	cg07461501	chr17:79650226	HGS;ARL16	0.37	7.83	0.34	3.24e-14	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg05861140	chr6:150128134	PCMT1	-0.43	-9.69	-0.41	2.42e-20	Lung cancer;
LGG	cis	rs5758659	1.000	rs134869	chr22:42652074	G/A	cg15557168	chr22:42548783	NA	-0.41	-9.01	-0.39	5.29e-18	Cognitive function;
LGG	cis	rs2635047	0.837	rs2571009	chr18:44650279	A/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.4	7.71	0.34	7.89e-14	Educational attainment;
LGG	trans	rs2727020	0.563	rs10769582	chr11:49474040	T/C	cg03929089	chr4:120376271	NA	-0.96	-20.07	-0.68	6.06e-65	Coronary artery disease;
LGG	cis	rs1577917	0.958	rs2324817	chr6:86462654	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.41	-0.5	1.02e-30	Response to antipsychotic treatment;
LGG	cis	rs2075371	0.933	rs432336	chr7:133949064	A/G	cg11752832	chr7:134001865	SLC35B4	0.58	10.49	0.44	2.93e-23	Mean platelet volume;
LGG	cis	rs2342371	0.805	rs55997345	chr3:196218353	T/C	cg15048948	chr3:196158458	UBXN7	0.42	6.96	0.31	1.15e-11	Fat distribution (HIV);
LGG	cis	rs4654899	0.865	rs6664532	chr1:21515800	G/A	cg05370193	chr1:21551575	ECE1	0.29	6.68	0.3	6.69e-11	Superior frontal gyrus grey matter volume;
LGG	cis	rs2243480	0.706	rs34466769	chr7:65453292	A/C	cg18252515	chr7:66147081	NA	-1.06	-14.97	-0.57	1.3e-41	Diabetic kidney disease;
LGG	cis	rs1348850	0.526	rs59972556	chr2:178399561	A/G	cg27490568	chr2:178487706	NA	0.81	14.31	0.55	1.02e-38	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg25897951	chr4:1244024	CTBP1;C4orf42	0.72	13.35	0.53	1.26e-34	Obesity-related traits;
LGG	cis	rs4474465	0.850	rs4944203	chr11:78220629	A/C	cg27205649	chr11:78285834	NARS2	0.47	8.14	0.35	3.78e-15	Alzheimer's disease (survival time);
LGG	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg24675658	chr1:53192096	ZYG11B	0.49	9.75	0.41	1.44e-20	Monocyte count;
LGG	cis	rs8005677	0.828	rs4981450	chr14:23389304	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.44	-0.33	5.05e-13	Cognitive ability (multi-trait analysis);
LGG	cis	rs35661897	0.920	rs12476220	chr2:227312391	A/C	cg03426602	chr2:227312417	NA	0.44	6.95	0.31	1.27e-11	Urinary tract infection frequency;
LGG	cis	rs11155671	0.530	rs6933882	chr6:150210802	A/G	cg05861140	chr6:150128134	PCMT1	-0.31	-7.13	-0.31	3.89e-12	Testicular germ cell tumor;
LGG	cis	rs7249142	0.549	rs2283623	chr19:19283027	G/C	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.26	-6.96	-0.31	1.14e-11	IgG glycosylation;
LGG	cis	rs4262150	0.810	rs72797262	chr5:152018288	C/A	cg12297329	chr5:152029980	NA	-0.8	-15.52	-0.58	4.98e-44	Bipolar disorder and schizophrenia;
LGG	cis	rs17125944	0.505	rs2274275	chr14:53235728	G/T	cg13660082	chr14:53194042	PSMC6	-0.54	-7.64	-0.33	1.25e-13	Alzheimer's disease (late onset);
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg22963979	chr7:1858916	MAD1L1	-0.45	-8.99	-0.39	6.36e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2629540	0.889	rs7090422	chr10:126439361	T/A	cg08799069	chr10:126477246	METTL10	-0.68	-14.43	-0.56	2.93e-39	Cocaine dependence;
LGG	cis	rs11190604	0.943	rs3750631	chr10:102279294	A/G	cg07570687	chr10:102243282	WNT8B	0.44	7.34	0.32	9.85e-13	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11098499	0.697	rs11941899	chr4:120382758	C/A	cg24375607	chr4:120327624	NA	0.67	11.07	0.46	2e-25	Corneal astigmatism;
LGG	cis	rs1862618	0.671	rs72644088	chr5:56241019	G/A	cg17809284	chr5:56205270	C5orf35	0.55	10.27	0.43	1.98e-22	Initial pursuit acceleration;
LGG	cis	rs9322193	0.651	rs9322188	chr6:149909491	A/G	cg07701084	chr6:150067640	NUP43	-0.62	-11.4	-0.47	1.05e-26	Lung cancer;
LGG	cis	rs3858526	0.834	rs7939099	chr11:5995792	G/A	cg05234568	chr11:5960015	NA	-0.64	-10.29	-0.43	1.6400000000000001e-22	DNA methylation (variation);
LGG	cis	rs597539	0.690	rs11228383	chr11:68623228	T/G	cg04772025	chr11:68637568	NA	0.76	12.97	0.52	4.8e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9457247	0.602	rs9459854	chr6:167465882	C/T	cg07741184	chr6:167504864	NA	0.44	10.07	0.42	1.03e-21	Crohn's disease;
LGG	cis	rs7095944	0.614	rs12570348	chr10:126438963	A/C	cg08799069	chr10:126477246	METTL10	0.48	10.23	0.43	2.69e-22	Asthma;
LGG	cis	rs6840360	0.593	rs10222925	chr4:152690215	A/G	cg22705602	chr4:152727874	NA	-0.4	-10.29	-0.43	1.74e-22	Intelligence (multi-trait analysis);
LGG	cis	rs6088580	0.601	rs6059827	chr20:33016358	C/T	cg08999081	chr20:33150536	PIGU	0.41	10.28	0.43	1.84e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs4555082	0.834	rs28489970	chr14:105748862	T/C	cg10792982	chr14:105748885	BRF1	0.66	13.1	0.52	1.39e-33	Mean platelet volume;Platelet distribution width;
LGG	cis	rs597539	0.690	rs635529	chr11:68626294	C/T	cg04008888	chr11:68622739	NA	-0.56	-11.73	-0.48	5.32e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11758351	1.000	rs80259160	chr6:26190199	C/T	cg23601095	chr6:26197514	HIST1H3D	0.73	9.48	0.4	1.38e-19	Gout;Renal underexcretion gout;
LGG	cis	rs2762353	0.595	rs12207313	chr6:25741027	G/C	cg03517284	chr6:25882590	NA	0.66	12.84	0.51	1.69e-32	Blood metabolite levels;
LGG	cis	rs4862750	0.832	rs9995958	chr4:187901764	G/A	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs13108904	0.934	rs13134106	chr4:1302902	A/G	cg04863758	chr4:1303710	MAEA	0.45	7.74	0.34	6.45e-14	Obesity-related traits;
LGG	cis	rs7582180	0.606	rs10174145	chr2:100932488	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.57	-0.47	2.21e-27	Intelligence (multi-trait analysis);
LGG	cis	rs7100689	0.622	rs1340373	chr10:82129250	G/A	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs113835537	0.529	rs4930379	chr11:66255674	G/A	cg24851651	chr11:66362959	CCS	0.43	7.59	0.33	1.75e-13	Airway imaging phenotypes;
LGG	cis	rs12188164	0.965	rs11745789	chr5:450777	T/C	cg26850624	chr5:429559	AHRR	-0.36	-7.97	-0.35	1.29e-14	Cystic fibrosis severity;
LGG	cis	rs8177253	0.665	rs4525863	chr3:133436136	C/A	cg01448562	chr3:133502909	NA	-0.53	-8.29	-0.36	1.2e-15	Iron status biomarkers;
LGG	cis	rs240764	0.631	rs9322174	chr6:101204193	G/C	cg09795085	chr6:101329169	ASCC3	-0.45	-7.69	-0.34	9.1e-14	Neuroticism;
LGG	cis	rs7618915	0.570	rs11130319	chr3:52755592	A/T	cg18404041	chr3:52824283	ITIH1	-0.54	-10.49	-0.44	3.1e-23	Bipolar disorder;
LGG	cis	rs4595586	0.545	rs12833238	chr12:39373898	T/C	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs12464483	0.524	rs2256411	chr2:30886860	C/A	cg03795903	chr2:30669940	LCLAT1	0.51	6.9	0.31	1.75e-11	Pre-treatment pain in head and neck squamous cell carcinoma;
LGG	cis	rs10752881	0.967	rs10911186	chr1:182972542	A/G	cg07245641	chr1:182991651	LAMC1	0.43	9.82	0.42	8.21e-21	Colorectal cancer;
LGG	trans	rs73198271	0.603	rs571130	chr8:8593691	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.79	0.3	3.5e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs1372520	0.873	rs2737026	chr4:90779823	A/G	cg15133208	chr4:90757351	SNCA	-0.37	-7.37	-0.32	7.88e-13	Neuroticism;
LGG	cis	rs28595532	0.920	rs116062544	chr4:119735548	G/C	cg11846333	chr4:119757529	SEC24D	0.86	7.9	0.34	2.04e-14	Cannabis dependence symptom count;
LGG	cis	rs12701220	0.842	rs10236293	chr7:1032637	G/A	cg26769984	chr7:1090371	C7orf50	0.53	8.79	0.38	2.85e-17	Bronchopulmonary dysplasia;
LGG	cis	rs694739	1.000	rs646153	chr11:64089588	C/T	cg22916017	chr11:64110731	CCDC88B	0.5	10.39	0.43	7.42e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9486719	0.948	rs2499817	chr6:96878321	C/T	cg06623918	chr6:96969491	KIAA0776	0.75	10.56	0.44	1.73e-23	Migraine;Coronary artery disease;
LGG	cis	rs7949030	1.000	rs3018561	chr11:62392229	C/A	cg13298116	chr11:62369859	EML3;MTA2	-0.59	-13.75	-0.54	2.67e-36	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs28830936	0.510	rs11070349	chr15:42085017	A/C	cg17847044	chr15:42102381	MAPKBP1	-0.78	-26.1	-0.77	5.48e-93	Diastolic blood pressure;
LGG	cis	rs62238980	0.614	rs77949114	chr22:32453504	T/C	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs11677416	1.000	rs1878320	chr2:113544467	T/C	cg27083787	chr2:113543245	IL1A	0.53	8.82	0.38	2.35e-17	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs1847202	0.859	rs13096870	chr3:72948172	G/A	cg25664220	chr3:72788482	NA	-0.25	-7.54	-0.33	2.43e-13	Motion sickness;
LGG	cis	rs6951245	0.744	rs10275401	chr7:1213943	A/C	cg04025307	chr7:1156635	C7orf50	0.75	10.28	0.43	1.82e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6951245	0.572	rs79396675	chr7:1055047	C/T	cg26224354	chr7:1096374	C7orf50;GPR146	-1.01	-12.93	-0.52	7.23e-33	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9747201	1.000	rs56051385	chr17:80126712	T/C	cg21453758	chr17:80185943	SLC16A3	-0.35	-7.43	-0.33	5.45e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10479542	0.701	rs10479541	chr5:178981003	G/C	cg00080972	chr5:178986291	RUFY1	0.45	6.88	0.3	1.98e-11	Lung cancer;
LGG	cis	rs4730250	0.707	rs257372	chr7:106796977	T/G	cg02696742	chr7:106810147	HBP1	-0.81	-11.48	-0.47	5.03e-27	Osteoarthritis;
LGG	cis	rs2688608	0.618	rs28553894	chr10:75489843	C/A	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.34	-0.32	9.4e-13	Inflammatory bowel disease;
LGG	cis	rs7811142	1.000	rs67471932	chr7:100009985	C/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.96	0.7	4.22e-69	Platelet count;
LGG	cis	rs2290416	0.792	rs62522167	chr8:144678034	G/A	cg16316162	chr8:144660157	NAPRT1	0.75	6.81	0.3	3.06e-11	Attention deficit hyperactivity disorder;
LGG	cis	rs1957429	0.901	rs7141985	chr14:65345670	C/T	cg23373153	chr14:65346875	NA	1.1	13.59	0.53	1.21e-35	Pediatric areal bone mineral density (radius);
LGG	cis	rs9322193	0.923	rs4870509	chr6:150023348	C/G	cg05861140	chr6:150128134	PCMT1	-0.44	-9.95	-0.42	2.89e-21	Lung cancer;
LGG	cis	rs7095944	0.614	rs1055256	chr10:126446592	A/G	cg08799069	chr10:126477246	METTL10	-0.49	-11.39	-0.47	1.11e-26	Asthma;
LGG	cis	rs17102423	0.755	rs884683	chr14:65574482	C/T	cg11161011	chr14:65562177	MAX	-0.77	-14.96	-0.57	1.53e-41	Obesity-related traits;
LGG	cis	rs4148087	1.000	rs4148100	chr21:43640169	T/C	cg15319517	chr21:43638949	ABCG1	-0.49	-6.65	-0.3	8.29e-11	Eating disorder in bipolar disorder;
LGG	trans	rs3749237	0.964	rs35210174	chr3:49812606	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.58	9.16	0.39	1.73e-18	Resting heart rate;
LGG	cis	rs317689	0.918	rs689415	chr12:69738139	A/G	cg19645103	chr12:69753606	YEATS4	0.49	6.8	0.3	3.15e-11	Response to diuretic therapy;
LGG	trans	rs9354308	0.727	rs9363480	chr6:66601316	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.73	-0.3	5.01e-11	Metabolite levels;
LGG	cis	rs6674970	0.933	rs12134957	chr1:151045419	A/G	cg11822372	chr1:151115635	SEMA6C	0.48	8.55	0.37	1.85e-16	Childhood ear infection;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21119962	chr1:246670217	SMYD3	0.44	6.65	0.3	8.44e-11	Gut microbiome composition (summer);
LGG	cis	rs1008375	0.966	rs2315553	chr4:17627332	T/C	cg04450456	chr4:17643702	FAM184B	0.32	7.16	0.32	3.2e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1552244	0.935	rs35515831	chr3:10071362	G/A	cg16606324	chr3:10149918	C3orf24	0.54	7.13	0.31	3.82e-12	Alzheimer's disease;
LGG	cis	rs4924935	1.000	rs35341640	chr17:18818228	G/A	cg26378065	chr17:18585709	ZNF286B	-0.45	-7.5	-0.33	3.29e-13	Pancreatic cancer;
LGG	cis	rs300774	0.925	rs300720	chr2:134472	A/G	cg04617936	chr2:214353	NA	-0.5	-7.67	-0.34	1.01e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs3096299	0.642	rs12934829	chr16:89523349	T/A	cg08392591	chr16:89556376	ANKRD11	0.55	8.8	0.38	2.83e-17	Multiple myeloma (IgH translocation);
LGG	cis	rs7937612	0.543	rs496248	chr11:120323214	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.33	-7.55	-0.33	2.37e-13	Intraocular pressure;
LGG	cis	rs447735	0.587	rs258335	chr16:89720944	G/A	cg04240660	chr16:89714849	CHMP1A	-0.39	-6.92	-0.31	1.5e-11	Hemoglobin concentration;
LGG	cis	rs561341	1.000	rs1557731	chr17:30321567	T/G	cg13647721	chr17:30228624	UTP6	0.63	8.23	0.36	1.94e-15	Hip circumference adjusted for BMI;
LGG	cis	rs6028335	0.674	rs59072291	chr20:37622010	T/A	cg16355469	chr20:37678765	NA	0.59	7.8	0.34	4.26e-14	Alcohol and nicotine co-dependence;
LGG	cis	rs6500395	0.926	rs11076571	chr16:48598064	A/G	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9302635	0.513	rs8050238	chr16:72154187	C/T	cg23815491	chr16:72088622	HP	0.49	9.0	0.39	5.68e-18	Blood protein levels;
LGG	cis	rs561341	1.000	rs113115092	chr17:30284164	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9976767	0.932	rs3746924	chr21:43826391	T/C	cg23042151	chr21:43824109	UBASH3A	-0.48	-9.85	-0.42	6.71e-21	Type 1 diabetes;
LGG	trans	rs4714291	0.698	rs2983144	chr6:40046724	G/A	cg02267698	chr19:7991119	CTXN1	-0.62	-9.97	-0.42	2.53e-21	Strep throat;
LGG	cis	rs3096299	0.504	rs4785574	chr16:89568875	A/G	cg02187348	chr16:89574699	SPG7	0.63	10.52	0.44	2.29e-23	Multiple myeloma (IgH translocation);
LGG	trans	rs1493916	0.777	rs1493910	chr18:31318376	A/G	cg27147174	chr7:100797783	AP1S1	-0.63	-11.67	-0.48	8.93e-28	Life satisfaction;
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg04234412	chr22:24373322	LOC391322	-0.72	-14.57	-0.56	7.34e-40	Liver enzyme levels (gamma-glutamyl transferase);
LGG	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg13010199	chr12:38710504	ALG10B	0.46	8.21	0.36	2.2e-15	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs11096990	0.634	rs11736790	chr4:39256324	G/A	cg24403649	chr4:39172243	NA	0.38	6.78	0.3	3.73e-11	Cognitive function;
LGG	cis	rs6088590	1.000	rs11698996	chr20:33449739	C/G	cg06115741	chr20:33292138	TP53INP2	0.53	7.9	0.34	2.11e-14	Coronary artery disease;
LGG	cis	rs62400317	0.859	rs12199871	chr6:45307682	C/T	cg18551225	chr6:44695536	NA	-0.61	-10.1	-0.42	8.36e-22	Total body bone mineral density;
LGG	cis	rs9329221	0.741	rs13264066	chr8:9804075	C/G	cg19847130	chr8:10466454	RP1L1	0.34	7.06	0.31	6.24e-12	Neuroticism;
LGG	trans	rs7395662	0.816	rs12420341	chr11:48893384	C/T	cg15704280	chr7:45808275	SEPT13	-0.48	-7.85	-0.34	2.83e-14	HDL cholesterol;
LGG	trans	rs561341	0.941	rs4625780	chr17:30249214	A/C	cg20587970	chr11:113659929	NA	-1.19	-20.18	-0.68	2.03e-65	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.933	rs2665801	chr17:61952100	C/T	cg19143629	chr17:61920732	SMARCD2	0.4	6.78	0.3	3.79e-11	Prudent dietary pattern;
LGG	cis	rs7122539	0.646	rs543191	chr11:66583779	T/G	cg01599099	chr11:66649832	PC	0.37	7.36	0.32	8.5e-13	HIV-1 susceptibility;
LGG	cis	rs7223966	1.000	rs8078462	chr17:61857937	T/G	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.42	7.18	0.32	2.72e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs8067287	0.762	rs11651352	chr17:16824909	A/G	cg26910001	chr17:16838321	NA	0.48	8.91	0.38	1.19e-17	Diabetic kidney disease;
LGG	cis	rs9326248	0.510	rs4938332	chr11:116930798	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.63	10.94	0.45	6.22e-25	Blood protein levels;
LGG	cis	rs4443100	0.837	rs6003490	chr22:23388447	G/A	cg14186256	chr22:23484241	RTDR1	0.43	6.77	0.3	3.84e-11	Serum parathyroid hormone levels;
LGG	cis	rs10504229	0.906	rs58251024	chr8:58172259	G/C	cg02725872	chr8:58115012	NA	-0.77	-10.92	-0.45	7.67e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12738007	0.933	rs61783707	chr1:29543700	A/T	cg11747820	chr1:29584023	PTPRU	-0.36	-8.09	-0.35	5.27e-15	Schizophrenia;
LGG	cis	rs1790761	0.692	rs614080	chr11:67347287	G/A	cg08355456	chr11:67383691	NA	0.51	8.81	0.38	2.61e-17	Mean corpuscular volume;
LGG	cis	rs734999	0.545	rs3890745	chr1:2553624	C/T	cg20673091	chr1:2541236	MMEL1	-0.78	-18.69	-0.66	1.7e-58	Ulcerative colitis;
LGG	cis	rs6840360	0.593	rs3805356	chr4:152680701	C/T	cg22705602	chr4:152727874	NA	0.39	9.82	0.42	8.56e-21	Intelligence (multi-trait analysis);
LGG	cis	rs929596	0.564	rs2741028	chr2:234518914	G/A	cg26799339	chr2:234664336	UGT1A10;UGT1A6;UGT1A8;UGT1A4;UGT1A3;UGT1A9;UGT1A7;UGT1A5	-0.58	-9.28	-0.4	6.64e-19	Total bilirubin levels in HIV-1 infection;
LGG	trans	rs7395662	1.000	rs7479498	chr11:48660499	G/A	cg03929089	chr4:120376271	NA	-0.45	-7.41	-0.33	5.85e-13	HDL cholesterol;
LGG	cis	rs17376456	0.825	rs17314074	chr5:93161467	T/C	cg17533458	chr5:92956826	FAM172A;MIR2277	0.88	9.13	0.39	2.18e-18	Diabetic retinopathy;
LGG	cis	rs6088580	0.602	rs6059834	chr20:33019299	A/G	cg08999081	chr20:33150536	PIGU	0.41	10.31	0.43	1.42e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs7208859	0.623	rs11658945	chr17:29122509	T/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.82	0.45	1.71e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs1005277	0.579	rs9299760	chr10:38377920	C/T	cg17830980	chr10:43048298	ZNF37B	-0.63	-14.42	-0.56	3.29e-39	Extrinsic epigenetic age acceleration;
LGG	cis	rs79149102	0.579	rs74247779	chr15:75397131	G/A	cg09165964	chr15:75287851	SCAMP5	-0.71	-7.22	-0.32	2.19e-12	Lung cancer;
LGG	cis	rs9911578	0.967	rs7214892	chr17:57065401	G/A	cg05425664	chr17:57184151	TRIM37	-0.65	-10.25	-0.43	2.29e-22	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.742	rs7679860	chr4:1333987	C/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.36	6.82	0.3	2.93e-11	Longevity;
LGG	cis	rs4363385	0.818	rs561143	chr1:153010734	C/T	cg13444842	chr1:152974279	SPRR3	-0.42	-8.65	-0.37	8.26e-17	Inflammatory skin disease;
LGG	cis	rs2354432	0.556	rs885305	chr1:146786080	G/A	cg25205988	chr1:146714368	CHD1L	-1.43	-14.5	-0.56	1.55e-39	Mitochondrial DNA levels;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg16920238	chr17:80076378	CCDC57	0.36	8.13	0.35	4.07e-15	Life satisfaction;
LGG	cis	rs2832077	0.883	rs11702413	chr21:30188395	A/C	cg08807101	chr21:30365312	RNF160	-0.58	-7.97	-0.35	1.27e-14	Cognitive test performance;
LGG	cis	rs4975709	0.589	rs4975746	chr5:1861069	G/A	cg12288994	chr5:1860383	NA	0.78	15.96	0.6	5.07e-46	Cardiovascular disease risk factors;
LGG	cis	rs736801	0.754	rs2706336	chr5:131799961	T/C	cg07395648	chr5:131743802	NA	0.51	10.68	0.44	6.22e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs6952808	0.792	rs11771973	chr7:1950440	C/G	cg02951883	chr7:2050386	MAD1L1	-0.7	-13.9	-0.54	5.67e-37	Bipolar disorder and schizophrenia;
LGG	cis	rs4315565	0.541	rs7580085	chr2:69282900	C/A	cg13358873	chr2:69271042	ANTXR1	0.51	7.65	0.34	1.17e-13	Height;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg12161460	chr21:40818036	SH3BGR	-0.41	-7.59	-0.33	1.78e-13	Iris color (L* coordinate);
LGG	cis	rs31872	0.526	rs810277	chr5:140452494	A/G	cg19650706	chr5:140594406	PCDHB13	-0.65	-11.55	-0.47	2.83e-27	Visceral adipose tissue adjusted for BMI;
LGG	cis	rs910316	0.967	rs175502	chr14:75533679	A/G	cg11812906	chr14:75593930	NEK9	-0.52	-9.69	-0.41	2.37e-20	Height;
LGG	cis	rs769267	0.895	rs2905435	chr19:19495954	G/A	cg03709012	chr19:19516395	GATAD2A	-0.85	-17.31	-0.63	3.82e-52	Tonsillectomy;
LGG	trans	rs61931739	0.500	rs6488218	chr12:34452587	T/C	cg04568710	chr12:38710424	ALG10B	0.34	7.18	0.32	2.76e-12	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.515	rs111560858	chr3:10166845	G/A	cg08888203	chr3:10149979	C3orf24	0.57	8.01	0.35	9.54e-15	Alzheimer's disease;
LGG	cis	rs13082711	0.911	rs57317249	chr3:27515854	A/C	cg02860705	chr3:27208620	NA	0.69	12.3	0.5	2.66e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs11585357	0.689	rs2977293	chr1:17599444	C/T	cg08277548	chr1:17600880	PADI3	-0.55	-7.38	-0.32	7.45e-13	Hair shape;
LGG	cis	rs7917772	0.503	rs7087665	chr10:104282418	T/C	cg05096777	chr10:104283225	SUFU	0.33	7.27	0.32	1.57e-12	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs2415984	0.562	rs34368760	chr14:46928532	T/A	cg14871534	chr14:47121158	RPL10L	0.44	7.42	0.33	5.54e-13	Number of children ever born;
LGG	cis	rs10861342	1.000	rs10861358	chr12:105559563	G/A	cg23923672	chr12:105501055	KIAA1033	0.77	7.31	0.32	1.2e-12	IgG glycosylation;
LGG	cis	rs9291683	0.566	rs13122689	chr4:10044648	A/G	cg25986240	chr4:9926439	SLC2A9	-0.36	-7.24	-0.32	1.85e-12	Bone mineral density;
LGG	cis	rs7010267	0.596	rs1905778	chr8:120021848	A/C	cg17171407	chr8:119960777	TNFRSF11B	0.35	8.96	0.38	7.84e-18	Total body bone mineral density (age 45-60);
LGG	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4927850	1.000	rs4927850	chr3:195751630	C/T	cg00031303	chr3:195681400	NA	-0.52	-8.27	-0.36	1.47e-15	Pancreatic cancer;
LGG	cis	rs2290159	0.848	rs6771385	chr3:12639419	A/G	cg23032965	chr3:12705835	RAF1	0.56	8.45	0.37	3.82e-16	Cholesterol, total;
LGG	cis	rs67133203	0.904	rs1048230	chr12:51386066	A/G	cg14688905	chr12:51403056	SLC11A2	0.78	12.1	0.49	1.79e-29	Urinary tract infection frequency;
LGG	cis	rs5769765	1.000	rs768618	chr22:50286827	G/A	cg26441486	chr22:50317300	CRELD2	0.41	7.51	0.33	2.99e-13	Schizophrenia;
LGG	trans	rs7395662	0.817	rs1848151	chr11:48692658	G/A	cg00717180	chr2:96193071	NA	-0.41	-7.34	-0.32	9.48e-13	HDL cholesterol;
LGG	cis	rs7572733	0.935	rs4410288	chr2:198819824	C/T	cg00792783	chr2:198669748	PLCL1	0.48	8.1	0.35	4.77e-15	Dermatomyositis;
LGG	cis	rs2948294	0.545	rs11776397	chr8:8115161	C/T	cg06636001	chr8:8085503	FLJ10661	0.56	10.15	0.43	5.31e-22	Red cell distribution width;
LGG	cis	rs2228479	0.850	rs74251570	chr16:89910068	C/A	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.74	-0.34	6.42e-14	Skin colour saturation;
LGG	cis	rs9359856	0.518	rs10944447	chr6:90194008	C/T	cg13799429	chr6:90582589	CASP8AP2	-0.48	-6.7	-0.3	5.95e-11	Bipolar disorder;
LGG	cis	rs7590368	0.673	rs17365181	chr2:10937980	T/C	cg15705551	chr2:10952987	PDIA6	0.57	7.41	0.33	6e-13	Educational attainment (years of education);
LGG	trans	rs11039798	0.920	rs12417899	chr11:49017552	G/A	cg15704280	chr7:45808275	SEPT13	0.76	7.94	0.35	1.57e-14	Axial length;
LGG	cis	rs5769765	0.862	rs138856	chr22:50199378	G/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.64	-8.98	-0.39	6.59e-18	Schizophrenia;
LGG	cis	rs3849570	1.000	rs78242412	chr3:81747219	A/G	cg07356753	chr3:81810745	GBE1	-0.49	-7.96	-0.35	1.31e-14	Waist circumference;Body mass index;
LGG	cis	rs780094	0.564	rs4665978	chr2:27648726	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-11.91	-0.48	1.07e-28	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg19441908	chr8:41529140	ANK1	-0.41	-7.3	-0.32	1.29e-12	Type 2 diabetes;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg02127607	chr17:61920694	SMARCD2	0.48	8.75	0.38	3.99e-17	Prudent dietary pattern;
LGG	cis	rs35110281	0.592	rs10211901	chr21:45122573	G/A	cg01579765	chr21:45077557	HSF2BP	-0.37	-8.17	-0.36	2.91e-15	Mean corpuscular volume;
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.98	0.35	1.18e-14	Prudent dietary pattern;
LGG	cis	rs939658	0.805	rs35462901	chr15:79442201	C/T	cg17916960	chr15:79447300	NA	-0.66	-12.79	-0.51	2.73e-32	Refractive error;
LGG	cis	rs10875746	0.669	rs2279464	chr12:48690409	C/T	cg24011408	chr12:48396354	COL2A1	-0.58	-7.44	-0.33	4.86e-13	Longevity (90 years and older);
LGG	cis	rs13118159	0.509	rs7681872	chr4:1376735	G/A	cg15586393	chr4:1244086	CTBP1;C4orf42	0.49	7.95	0.35	1.46e-14	Longevity;
LGG	cis	rs9322193	0.923	rs9689084	chr6:149960784	G/A	cg09699651	chr6:150184138	LRP11	0.51	8.98	0.39	6.63e-18	Lung cancer;
LGG	cis	rs344364	0.518	rs1657129	chr16:1945826	G/A	cg26897989	chr16:1907736	C16orf73	-0.85	-14.04	-0.55	1.54e-37	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs977987	0.872	rs2161648	chr16:75314629	T/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.7	0.3	6.15e-11	Dupuytren's disease;
LGG	cis	rs9948	0.786	rs62156234	chr2:97436292	C/G	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs9457247	1.000	rs421214	chr6:167396629	A/G	cg07741184	chr6:167504864	NA	0.31	6.86	0.3	2.27e-11	Crohn's disease;
LGG	cis	rs17666538	0.539	rs1703925	chr8:608279	A/G	cg23958373	chr8:599963	NA	1.2	12.05	0.49	2.85e-29	IgG glycosylation;
LGG	cis	rs35264875	1.000	rs72928644	chr11:68849845	A/G	cg01403660	chr11:68851641	TPCN2	0.51	7.19	0.32	2.58e-12	Blond vs. brown hair color;
LGG	cis	rs7223966	1.000	rs7214312	chr17:61870863	A/G	cg05941027	chr17:61774174	LIMD2	0.37	9.64	0.41	3.75e-20	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2274273	0.714	rs7154889	chr14:55806885	G/A	cg04306507	chr14:55594613	LGALS3	0.63	18.04	0.64	1.71e-55	Protein biomarker;
LGG	cis	rs9322193	0.962	rs1889473	chr6:150146621	C/G	cg16507663	chr6:150244633	RAET1G	0.42	7.99	0.35	1.09e-14	Lung cancer;
LGG	trans	rs7824557	0.564	rs2572404	chr8:11199584	A/G	cg16141378	chr3:129829833	LOC729375	-0.38	-8.63	-0.37	9.58e-17	Retinal vascular caliber;
LGG	cis	rs28595532	0.920	rs114414928	chr4:119728188	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.85	0.34	3e-14	Cannabis dependence symptom count;
LGG	cis	rs2739330	0.828	rs2154593	chr22:24252085	A/G	cg15242686	chr22:24348715	GSTTP1	0.37	6.86	0.3	2.24e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9858542	0.953	rs9818590	chr3:49525096	A/G	cg07274523	chr3:49395745	GPX1	0.58	9.85	0.42	6.72e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg06873684	chr19:4472059	HDGF2	-0.41	-6.83	-0.3	2.68e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs7172677	0.501	rs8041446	chr15:75394517	C/T	cg14664628	chr15:75095509	CSK	0.51	9.09	0.39	3e-18	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs657075	0.640	rs71583475	chr5:131662507	A/C	cg21911579	chr5:131705225	SLC22A5	0.68	7.67	0.34	1.02e-13	Rheumatoid arthritis;
LGG	cis	rs9611565	0.659	rs4822034	chr22:41931010	T/C	cg06481639	chr22:41940642	POLR3H	-0.62	-9.18	-0.39	1.39e-18	Vitiligo;
LGG	cis	rs7044106	0.791	rs7036196	chr9:123479457	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.67	12.33	0.5	2.02e-30	Hip circumference adjusted for BMI;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg06074448	chr4:187884817	NA	-0.61	-14.01	-0.55	2.03e-37	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs1355223	1.000	rs1355222	chr11:34758716	C/G	cg11058730	chr11:34937778	PDHX;APIP	-0.44	-7.17	-0.32	2.99e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg10065182	chr12:49182837	ADCY6	-0.43	-6.69	-0.3	6.31e-11	Pancreatic cancer;
LGG	cis	rs10904908	1.000	rs10904908	chr10:17260290	A/G	cg01003015	chr10:17271136	VIM	-0.52	-8.7	-0.38	5.63e-17	Total cholesterol levels;Cholesterol, total;
LGG	cis	rs6952808	0.782	rs4236271	chr7:1881369	C/T	cg04267008	chr7:1944627	MAD1L1	-0.58	-9.27	-0.4	7.05e-19	Bipolar disorder and schizophrenia;
LGG	trans	rs9858542	0.953	rs6997	chr3:49453834	C/T	cg21659725	chr3:3221576	CRBN	-0.62	-10.08	-0.42	9.71e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2594989	0.943	rs2606737	chr3:11398654	A/G	cg01796438	chr3:11312864	ATG7	-0.54	-7.18	-0.32	2.87e-12	Circulating chemerin levels;
LGG	cis	rs7681440	0.835	rs7668531	chr4:90791819	G/T	cg20003494	chr4:90757398	SNCA	-0.41	-8.04	-0.35	7.7e-15	Dementia with Lewy bodies;
LGG	cis	rs6952808	0.609	rs10232234	chr7:1948110	G/T	cg02951883	chr7:2050386	MAD1L1	-0.63	-12.03	-0.49	3.46e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	0.961	rs35844156	chr17:61837568	G/A	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.75	-0.38	4.06e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12912251	0.948	rs34281605	chr15:38989674	G/A	cg01338139	chr15:38987640	C15orf53	-0.55	-8.72	-0.38	4.98e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs6456156	0.586	rs9457266	chr6:167482555	T/C	cg07741184	chr6:167504864	NA	0.41	9.33	0.4	4.49e-19	Primary biliary cholangitis;
LGG	cis	rs1799949	0.501	rs35399157	chr17:41411602	G/C	cg12708336	chr17:41446283	NA	-0.31	-7.37	-0.32	7.92e-13	Menopause (age at onset);
LGG	cis	rs10875746	0.669	rs10431526	chr12:48690143	A/G	cg24011408	chr12:48396354	COL2A1	-0.57	-7.49	-0.33	3.62e-13	Longevity (90 years and older);
LGG	cis	rs7481584	0.962	rs756692	chr11:2973244	G/A	cg25174290	chr11:3078921	CARS	-0.48	-8.25	-0.36	1.71e-15	Calcium levels;
LGG	cis	rs12210905	1.000	rs9357034	chr6:27243425	C/G	cg23155468	chr6:27110703	HIST1H2BK	-0.62	-7.04	-0.31	6.88e-12	Hip circumference adjusted for BMI;
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.61	0.33	1.55e-13	Menopause (age at onset);
LGG	cis	rs801193	0.548	rs7805152	chr7:66209253	C/T	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.34	6.77	0.3	3.87e-11	Aortic root size;
LGG	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg06634786	chr22:41940651	POLR3H	-0.74	-12.49	-0.5	4.91e-31	Vitiligo;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg27288936	chr19:11308266	KANK2	0.55	6.94	0.31	1.34e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs17194529	chr8:58105647	A/G	cg21724239	chr8:58056113	NA	0.61	9.18	0.39	1.49e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.33	-0.32	1.02e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4006360	0.579	rs1817965	chr17:39244724	A/T	cg16985667	chr17:39306289	KRTAP4-5	-0.51	-11.24	-0.46	4.54e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs9443645	0.869	rs9443626	chr6:79629564	G/C	cg18132916	chr6:79620363	NA	-0.32	-8.98	-0.39	6.94e-18	Intelligence (multi-trait analysis);
LGG	cis	rs28830936	0.966	rs2303518	chr15:42109975	T/G	cg13300911	chr15:42119951	JMJD7;MAPKBP1;JMJD7-PLA2G4B	-0.34	-6.87	-0.3	2.09e-11	Diastolic blood pressure;
LGG	cis	rs734999	0.588	rs2843402	chr1:2528682	T/C	cg15627072	chr1:2432621	PLCH2	-0.38	-8.36	-0.36	7.49e-16	Ulcerative colitis;
LGG	cis	rs6952808	1.000	rs4449693	chr7:1884630	G/C	cg10360139	chr7:1886902	MAD1L1	-0.44	-7.73	-0.34	6.57e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.54	-0.37	1.95e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1018836	0.923	rs9643298	chr8:91552502	G/A	cg16814680	chr8:91681699	NA	-0.81	-15.38	-0.58	2.04e-43	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7590368	1.000	rs2884289	chr2:10959724	G/A	cg15705551	chr2:10952987	PDIA6	0.62	9.12	0.39	2.35e-18	Educational attainment (years of education);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg06438056	chr1:33502433	AK2	0.63	7.21	0.32	2.23e-12	Intelligence (multi-trait analysis);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg25880573	chr1:24073129	TCEB3	-0.3	-6.77	-0.3	3.85e-11	Bipolar disorder;
LGG	cis	rs10504229	0.683	rs66893068	chr8:58144238	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.17	-0.58	1.71e-42	Developmental language disorder (linguistic errors);
LGG	cis	rs2730245	0.592	rs2657385	chr7:158649373	A/G	cg14689365	chr7:158441557	NCAPG2	0.62	10.34	0.43	1.06e-22	Height;
LGG	cis	rs68170813	0.559	rs10953530	chr7:106827796	A/C	cg02696742	chr7:106810147	HBP1	-0.72	-10.75	-0.45	3.22e-24	Coronary artery disease;
LGG	cis	rs796364	0.806	rs55985986	chr2:201120987	A/C	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.69	-8.2	-0.36	2.34e-15	Schizophrenia;
LGG	cis	rs472402	0.560	rs2288444	chr5:6619923	A/G	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.45	-7.3	-0.32	1.3e-12	Response to amphetamines;
LGG	cis	rs7044106	0.791	rs7036766	chr9:123479621	G/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.44	7.11	0.31	4.32e-12	Hip circumference adjusted for BMI;
LGG	cis	rs2289583	0.642	rs67624860	chr15:75391557	A/G	cg10253484	chr15:75165896	SCAMP2	0.44	7.06	0.31	6.08e-12	Systemic lupus erythematosus;
LGG	cis	rs78456975	1.000	rs28742145	chr2:1562671	T/C	cg26248373	chr2:1572462	NA	-0.69	-8.88	-0.38	1.51e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs679087	0.932	rs10843507	chr12:29931056	C/A	cg14258853	chr12:29935411	TMTC1	0.41	8.48	0.37	2.97e-16	Schizophrenia;
LGG	cis	rs657075	0.697	rs36108085	chr5:131686479	T/G	cg20453264	chr5:131705742	SLC22A5	0.66	8.37	0.36	7.04e-16	Rheumatoid arthritis;
LGG	cis	rs3813359	0.545	rs17058566	chr6:130554712	T/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs780096	0.526	rs704795	chr2:27716494	G/A	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.83	-0.3	2.7e-11	Total body bone mineral density;
LGG	cis	rs1059312	1.000	rs2291350	chr12:129283711	G/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.95	-0.64	4.59e-55	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.863	rs8128026	chr21:40533702	T/C	cg17971929	chr21:40555470	PSMG1	0.89	17.59	0.63	1.96e-53	Cognitive function;
LGG	cis	rs17376456	0.877	rs28418572	chr5:93144161	A/C	cg19507638	chr5:93509721	C5orf36	-0.67	-9.38	-0.4	3.05e-19	Diabetic retinopathy;
LGG	cis	rs1552244	0.810	rs35711405	chr3:10116939	C/T	cg08888203	chr3:10149979	C3orf24	0.57	9.52	0.4	9.32e-20	Alzheimer's disease;
LGG	cis	rs4474465	1.000	rs6592779	chr11:78197283	G/C	cg02023728	chr11:77925099	USP35	0.4	6.9	0.31	1.75e-11	Alzheimer's disease (survival time);
LGG	cis	rs9487094	0.601	rs4945831	chr6:109761437	A/G	cg01125227	chr6:109776195	MICAL1	0.41	7.1	0.31	4.58e-12	Height;
LGG	cis	rs7568458	0.709	rs11895401	chr2:85753847	C/T	cg17127132	chr2:85788382	GGCX	0.49	7.94	0.35	1.54e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs7156960	0.540	rs4903393	chr14:76734188	A/C	cg13981132	chr14:76734493	NA	-0.31	-6.75	-0.3	4.5e-11	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7712401	0.601	rs30059	chr5:122297509	G/A	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs4926611	0.863	rs2177957	chr1:54082487	C/T	cg23596471	chr1:54105337	GLIS1	-0.44	-8.52	-0.37	2.22e-16	Hand grip strength;
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg21782813	chr7:2030301	MAD1L1	0.53	12.93	0.52	7e-33	Bipolar disorder and schizophrenia;
LGG	trans	rs561341	0.654	rs6505265	chr17:30172580	C/T	cg20587970	chr11:113659929	NA	0.83	11.1	0.46	1.49e-25	Hip circumference adjusted for BMI;
LGG	cis	rs2455799	0.573	rs2174172	chr3:15768579	C/A	cg16303742	chr3:15540471	COLQ	-0.4	-8.01	-0.35	9.67e-15	Mean platelet volume;
LGG	cis	rs657075	0.697	rs57600888	chr5:131654053	C/A	cg21911579	chr5:131705225	SLC22A5	0.68	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs801193	0.548	rs2109297	chr7:66122384	G/A	cg23594656	chr7:65796392	TPST1	0.37	8.31	0.36	1.06e-15	Aortic root size;
LGG	cis	rs7223966	1.000	rs11079508	chr17:61750066	T/C	cg05941027	chr17:61774174	LIMD2	0.37	9.5	0.4	1.13e-19	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7301826	0.610	rs4759789	chr12:131296380	A/C	cg11011512	chr12:131303247	STX2	0.42	8.97	0.38	7.18e-18	Plasma plasminogen activator levels;
LGG	cis	rs9611565	0.659	rs9611610	chr22:41949259	A/G	cg06850241	chr22:41845214	NA	-0.47	-7.28	-0.32	1.4e-12	Vitiligo;
LGG	cis	rs11931598	0.513	rs3857170	chr4:7003366	A/T	cg12864912	chr4:6988209	TBC1D14	-0.5	-9.54	-0.41	8.53e-20	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs7166081	1.000	rs35997299	chr15:67507590	C/T	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.86	-0.3	2.21e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	trans	rs55986470	0.641	rs11904817	chr2:239382914	G/T	cg01134436	chr17:81009848	B3GNTL1	0.65	7.45	0.33	4.77e-13	Chronotype;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg05793240	chr7:2802953	GNA12	0.36	8.23	0.36	1.98e-15	Height;
LGG	cis	rs1957429	0.614	rs73279833	chr14:65352523	A/G	cg23373153	chr14:65346875	NA	-1.08	-12.07	-0.49	2.26e-29	Pediatric areal bone mineral density (radius);
LGG	cis	rs651907	0.535	rs34263427	chr3:101507805	A/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.62	12.51	0.5	4e-31	Colorectal cancer;
LGG	trans	rs11039798	0.588	rs12278284	chr11:48612063	G/C	cg03929089	chr4:120376271	NA	0.72	9.68	0.41	2.65e-20	Axial length;
LGG	cis	rs9322193	0.884	rs2342858	chr6:150127103	C/T	cg13206674	chr6:150067644	NUP43	0.64	14.63	0.56	4.21e-40	Lung cancer;
LGG	cis	rs2762353	0.935	rs1165195	chr6:25815080	T/G	cg07061783	chr6:25882402	NA	-0.37	-6.73	-0.3	5.02e-11	Blood metabolite levels;
LGG	cis	rs1793639	0.616	rs9667087	chr11:131984142	C/T	cg13908476	chr11:131942942	NTM	-0.49	-9.7	-0.41	2.31e-20	Myopia;
LGG	cis	rs11690935	0.589	rs2271758	chr2:172701157	T/G	cg13550731	chr2:172543902	DYNC1I2	0.7	13.9	0.54	6.07e-37	Schizophrenia;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg05335186	chr13:53173507	NA	-0.49	-10.22	-0.43	3.05e-22	Lewy body disease;
LGG	cis	rs7192750	0.586	rs4788564	chr16:71891862	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.47	0.44	3.63e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs55794721	0.509	rs873308	chr1:25758655	A/G	cg23205692	chr1:25664452	TMEM50A	-0.5	-10.67	-0.44	6.39e-24	Plateletcrit;Mean corpuscular volume;
LGG	cis	rs1401999	1.000	rs6443926	chr3:183706630	A/C	cg05044414	chr3:183734942	ABCC5	0.77	16.86	0.62	4.33e-50	Anterior chamber depth;
LGG	cis	rs7928758	1.000	rs7108503	chr11:134280766	A/G	cg22777979	chr11:134283252	B3GAT1	0.81	10.93	0.45	6.89e-25	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs35110281	0.774	rs2838327	chr21:45018566	A/C	cg01579765	chr21:45077557	HSF2BP	-0.4	-9.27	-0.4	7.12e-19	Mean corpuscular volume;
LGG	cis	rs17321999	1.000	rs906867	chr2:30478628	A/G	cg05247661	chr2:30472410	LBH	0.54	8.94	0.38	9.52e-18	Systemic lupus erythematosus;
LGG	cis	rs1008375	1.000	rs10027755	chr4:17615954	G/C	cg18681998	chr4:17616180	MED28	0.88	20.19	0.68	1.75e-65	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	0.566	rs9358902	chr6:26058570	C/G	cg03264133	chr6:25882463	NA	-0.38	-6.66	-0.3	8.01e-11	Height;
LGG	cis	rs41342147	0.660	rs77807882	chr2:242242181	A/G	cg10173475	chr2:242152697	ANO7	-0.6	-9.01	-0.39	5.29e-18	Vitiligo;
LGG	cis	rs2075671	0.810	rs12531792	chr7:100280624	G/A	cg00334542	chr7:100209784	MOSPD3	-0.54	-7.54	-0.33	2.53e-13	Other erythrocyte phenotypes;
LGG	cis	rs8048589	0.558	rs34565142	chr16:12231347	C/T	cg02910054	chr16:12241554	SNX29	0.63	9.7	0.41	2.26e-20	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs11971779	0.680	rs6954547	chr7:139054734	C/T	cg07862535	chr7:139043722	LUC7L2	0.42	6.97	0.31	1.08e-11	Diisocyanate-induced asthma;
LGG	cis	rs9527	0.641	rs34130454	chr10:104903638	A/G	cg05308233	chr10:104796373	CNNM2	-0.3	-6.75	-0.3	4.37e-11	Arsenic metabolism;
LGG	cis	rs9952991	0.941	rs45450798	chr18:12792940	C/G	cg23544223	chr18:12777786	NA	-0.55	-7.85	-0.34	2.97e-14	Inflammatory skin disease;
LGG	cis	rs4481887	0.927	rs12042598	chr1:248482016	C/T	cg13385794	chr1:248469461	NA	0.49	8.45	0.37	3.81e-16	Common traits (Other);
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07659893	chr17:61819838	STRADA	0.47	7.8	0.34	4.16e-14	Prudent dietary pattern;
LGG	cis	rs7044106	0.762	rs10984972	chr9:123409864	T/C	cg13460057	chr9:123605234	PSMD5;LOC253039	0.45	7.23	0.32	2.03e-12	Hip circumference adjusted for BMI;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg02127607	chr17:61920694	SMARCD2	0.47	8.63	0.37	9.69e-17	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs2489049	chr10:102350732	G/A	cg07080220	chr10:102295463	HIF1AN	0.66	11.23	0.46	4.81e-26	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8058578	0.775	rs8046391	chr16:30836648	G/C	cg02466173	chr16:30829666	NA	-0.55	-10.07	-0.42	1.1e-21	Multiple myeloma;
LGG	cis	rs9911578	0.933	rs2531725	chr17:56517962	G/A	cg12560992	chr17:57184187	TRIM37	0.87	15.2	0.58	1.28e-42	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs11658740	chr17:61751069	A/G	cg01411255	chr17:61851458	DDX42;CCDC47	-0.48	-7.37	-0.32	7.78e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs1577917	0.958	rs12203457	chr6:86689277	T/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.55	-9.34	-0.4	4.02e-19	Response to antipsychotic treatment;
LGG	cis	rs7659604	0.502	rs28522256	chr4:122709266	C/T	cg19671926	chr4:122722719	EXOSC9	0.54	8.31	0.36	1.04e-15	Type 2 diabetes;
LGG	cis	rs9354308	0.764	rs9351531	chr6:66589985	A/G	cg07460842	chr6:66804631	NA	-0.41	-6.99	-0.31	9.71e-12	Metabolite levels;
LGG	cis	rs11758351	0.660	rs113208674	chr6:26210465	C/G	cg01420254	chr6:26195488	NA	0.85	11.06	0.46	2.14e-25	Gout;Renal underexcretion gout;
LGG	cis	rs7572733	0.840	rs700654	chr2:198643421	G/A	cg00792783	chr2:198669748	PLCL1	0.47	7.99	0.35	1.07e-14	Dermatomyositis;
LGG	cis	rs9894429	0.682	rs7406360	chr17:79591545	G/A	cg10661904	chr17:79619235	PDE6G	-0.4	-8.12	-0.35	4.25e-15	Eye color traits;
LGG	cis	rs9419702	0.614	rs7907614	chr10:133532208	T/C	cg04492858	chr10:133558786	NA	0.43	8.61	0.37	1.18e-16	Survival in rectal cancer;
LGG	cis	rs9611565	0.879	rs5758311	chr22:41759375	G/T	cg03806693	chr22:41940476	POLR3H	-0.86	-14.87	-0.57	3.77e-41	Vitiligo;
LGG	cis	rs8179	0.700	rs42039	chr7:92244422	A/G	cg15732164	chr7:92237376	CDK6	0.52	9.82	0.42	8.1e-21	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;White blood cell count;Myeloid white cell count;Granulocyte count;White blood cell count (basophil);
LGG	cis	rs13191362	1.000	rs13209728	chr6:162997533	A/C	cg21926612	chr6:163149169	PACRG;PARK2	0.87	10.21	0.43	3.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs7618915	0.547	rs12496634	chr3:52709259	A/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.53	8.68	0.37	6.95e-17	Bipolar disorder;
LGG	cis	rs1129187	0.755	rs9462856	chr6:42926024	T/C	cg24101359	chr6:42928495	GNMT	0.53	14.77	0.57	9.68e-41	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7215564	0.822	rs2340769	chr17:78755271	C/T	cg06153925	chr17:78755379	RPTOR	-0.45	-7.54	-0.33	2.47e-13	Myopia (pathological);
LGG	cis	rs4423214	0.840	rs1792234	chr11:71182018	T/C	cg05163923	chr11:71159392	DHCR7	-0.64	-11.09	-0.46	1.63e-25	Vitamin D levels;
LGG	trans	rs61931739	0.500	rs11053201	chr12:34453903	T/A	cg26384229	chr12:38710491	ALG10B	0.96	21.28	0.7	1.46e-70	Morning vs. evening chronotype;
LGG	cis	rs1008375	0.932	rs4698628	chr4:17608620	A/G	cg07005078	chr4:17578674	LAP3	0.39	7.14	0.32	3.55e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6500395	1.000	rs9936454	chr16:48617782	T/G	cg16662043	chr16:48846231	NA	0.36	7.05	0.31	6.48e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs769267	0.965	rs12977937	chr19:19429975	C/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.16	0.35	3.29e-15	Tonsillectomy;
LGG	cis	rs644799	0.625	rs1255175	chr11:95471186	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.37	6.68	0.3	6.82e-11	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4971059	0.654	rs10157801	chr1:155120012	A/G	cg13808842	chr1:155066096	NA	-0.28	-6.95	-0.31	1.24e-11	Breast cancer;
LGG	cis	rs9644630	0.897	rs17128525	chr8:19364006	C/T	cg06562184	chr8:19319451	CSGALNACT1	-0.34	-6.89	-0.31	1.78e-11	Oropharynx cancer;
LGG	cis	rs732765	1.000	rs13391	chr14:75370123	C/T	cg06637938	chr14:75390232	RPS6KL1	-0.49	-7.0	-0.31	9.03e-12	Non-small cell lung cancer;
LGG	cis	rs9291683	0.588	rs34501273	chr4:9996996	C/T	cg00071950	chr4:10020882	SLC2A9	0.4	8.3	0.36	1.19e-15	Bone mineral density;
LGG	cis	rs2204008	0.666	rs67792345	chr12:38204698	T/C	cg13010199	chr12:38710504	ALG10B	0.68	13.11	0.52	1.3e-33	Bladder cancer;
LGG	cis	rs4750440	0.706	rs10796148	chr10:14016900	G/A	cg00551146	chr10:14014579	FRMD4A	0.28	6.94	0.31	1.35e-11	Adiponectin levels;
LGG	cis	rs2243480	1.000	rs6949812	chr7:65387101	G/A	cg12463550	chr7:65579703	CRCP	0.75	8.34	0.36	8.75e-16	Diabetic kidney disease;
LGG	cis	rs735396	1.000	rs2259816	chr12:121435587	A/C	cg02403541	chr12:121454288	C12orf43	-0.53	-8.73	-0.38	4.6e-17	N-glycan levels;
LGG	trans	rs9329221	0.772	rs7824675	chr8:10243418	G/T	cg16141378	chr3:129829833	LOC729375	0.37	8.48	0.37	2.96e-16	Neuroticism;
LGG	cis	rs240764	0.658	rs35168784	chr6:101183499	C/T	cg09795085	chr6:101329169	ASCC3	-0.47	-7.95	-0.35	1.44e-14	Neuroticism;
LGG	cis	rs4689592	0.513	rs3857178	chr4:7066516	G/A	cg02503808	chr4:7069936	GRPEL1	0.9	14.17	0.55	4.16e-38	Monocyte percentage of white cells;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01114951	chr1:117664707	TRIM45	0.39	6.66	0.3	7.66e-11	Bipolar disorder;
LGG	cis	rs9911578	0.935	rs117819974	chr17:57002324	C/T	cg05425664	chr17:57184151	TRIM37	-0.63	-10.07	-0.42	1.04e-21	Intelligence (multi-trait analysis);
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg07701084	chr6:150067640	NUP43	0.67	12.57	0.5	2.2e-31	Lung cancer;
LGG	trans	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg12045294	chr17:78518616	RPTOR	-0.47	-7.29	-0.32	1.32e-12	Glycated hemoglobin levels;
LGG	cis	rs2540226	0.627	rs2192686	chr2:39928722	A/G	cg02886589	chr2:39892450	TMEM178	0.26	7.0	0.31	9.07e-12	Personality dimensions;
LGG	cis	rs9596863	1.000	rs7328970	chr13:54424225	G/C	ch.13.53330881F	chr13:54432880	NA	-0.48	-6.81	-0.3	3.11e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs2019137	0.560	rs4849179	chr2:113985170	C/T	cg21482265	chr2:113992762	PAX8;LOC440839;LOC654433	0.6	11.77	0.48	3.86e-28	Lymphocyte counts;
LGG	cis	rs9487094	0.517	rs3778474	chr6:109695985	G/A	cg16315928	chr6:109776240	MICAL1	0.44	7.78	0.34	4.91e-14	Height;
LGG	cis	rs548181	0.545	rs4486648	chr11:125610589	T/A	cg03464685	chr11:125439445	EI24	-1.21	-17.03	-0.62	7.71e-51	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs2486288	0.656	rs2413773	chr15:45549442	C/A	cg26924012	chr15:45694286	SPATA5L1	-0.59	-9.85	-0.42	6.36e-21	Glomerular filtration rate;
LGG	cis	rs2249694	0.520	rs11815623	chr10:135329133	A/G	cg20169779	chr10:135381914	SYCE1	-0.54	-7.39	-0.32	7.11e-13	Obesity-related traits;
LGG	cis	rs7512552	0.839	rs1260459	chr1:150348253	T/G	cg15654264	chr1:150340011	RPRD2	0.45	9.21	0.39	1.1e-18	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs17826219	0.561	rs11655876	chr17:29017150	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.5	-0.37	2.55e-16	Body mass index;
LGG	cis	rs28595532	0.920	rs17257945	chr4:119666465	T/A	cg14228332	chr4:119757509	SEC24D	0.98	9.49	0.4	1.23e-19	Cannabis dependence symptom count;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg03709012	chr19:19516395	GATAD2A	0.84	16.83	0.62	6.17e-50	Tonsillectomy;
LGG	cis	rs4862750	0.957	rs4861733	chr4:187903933	C/T	cg07414643	chr4:187882934	NA	0.53	11.03	0.46	2.72e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs798554	0.610	rs2644304	chr7:2878779	T/C	cg27476859	chr7:2772710	GNA12	0.52	10.12	0.43	7.08e-22	Height;
LGG	cis	rs3741151	0.773	rs7931767	chr11:73239207	A/G	cg17517138	chr11:73019481	ARHGEF17	0.82	7.89	0.34	2.18e-14	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg16920238	chr17:80076378	CCDC57	0.32	7.32	0.32	1.11e-12	Life satisfaction;
LGG	cis	rs9300255	0.596	rs1727331	chr12:123718879	C/G	cg00376283	chr12:123451042	ABCB9	-0.64	-11.07	-0.46	2.06e-25	Neutrophil percentage of white cells;
LGG	cis	rs17401966	1.000	rs11576866	chr1:10414432	A/G	cg15208524	chr1:10270712	KIF1B	0.44	7.24	0.32	1.85e-12	Hepatocellular carcinoma;
LGG	cis	rs17270561	0.609	rs9356986	chr6:25739119	T/C	cg16482183	chr6:26056742	HIST1H1C	0.51	8.08	0.35	5.87e-15	Iron status biomarkers;
LGG	cis	rs7937682	0.883	rs484834	chr11:111465761	G/C	cg09085632	chr11:111637200	PPP2R1B	-1.05	-22.52	-0.72	2.2e-76	Primary sclerosing cholangitis;
LGG	cis	rs10463316	0.817	rs58892766	chr5:150776115	T/C	cg03212797	chr5:150827313	SLC36A1	-0.56	-9.66	-0.41	3.18e-20	Metabolite levels (Pyroglutamine);
LGG	cis	rs9790314	0.503	rs6441374	chr3:161064540	A/T	cg04691961	chr3:161091175	C3orf57	-0.48	-10.16	-0.43	4.99e-22	Morning vs. evening chronotype;
LGG	cis	rs1799949	0.965	rs12947782	chr17:41279882	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.47	7.6	0.33	1.71e-13	Menopause (age at onset);
LGG	cis	rs981844	0.683	rs1105495	chr4:154756867	T/C	cg14289246	chr4:154710475	SFRP2	-0.57	-9.81	-0.41	8.94e-21	Response to statins (LDL cholesterol change);
LGG	cis	rs4722166	0.508	rs1474348	chr7:22767908	C/G	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	9.38e-16	Lung cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg09172817	chr18:9915098	VAPA	0.46	7.51	0.33	3.15e-13	Cognitive performance;
LGG	cis	rs6032067	0.673	rs13042474	chr20:43893068	G/T	cg10761708	chr20:43804764	PI3	0.6	9.2	0.39	1.27e-18	Blood protein levels;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg25564901	chr17:17140463	FLCN	0.41	6.69	0.3	6.42e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10979	1.000	rs9484768	chr6:143887928	C/T	cg25407410	chr6:143891975	LOC285740	-0.72	-12.47	-0.5	5.64e-31	Hypospadias;
LGG	trans	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg19862616	chr7:65841803	NCRNA00174	0.76	8.03	0.35	7.95e-15	Mononucleosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20540327	chr15:72668275	HEXA;C15orf34	0.54	8.75	0.38	4.14e-17	Gut microbiome composition (summer);
LGG	cis	rs3087591	0.960	rs12942479	chr17:29461912	T/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.57	0.56	7.31e-40	Hip circumference;
LGG	cis	rs2067615	0.579	rs10861667	chr12:107194776	T/G	cg15890332	chr12:107067104	RFX4	0.4	11.59	0.47	1.83e-27	Heart rate;
LGG	cis	rs10464366	0.798	rs885352	chr7:39116168	A/G	cg21665744	chr7:39171113	POU6F2	0.34	6.73	0.3	4.88e-11	IgG glycosylation;
LGG	cis	rs6066825	0.644	rs2092492	chr20:47338650	A/G	cg18078177	chr20:47281410	PREX1	0.45	7.63	0.33	1.38e-13	Colorectal cancer;
LGG	cis	rs4423214	1.000	rs11606631	chr11:71164121	C/A	cg05163923	chr11:71159392	DHCR7	0.71	13.95	0.54	3.65e-37	Vitamin D levels;
LGG	cis	rs6459804	0.566	rs76186270	chr7:157512420	C/T	cg01625945	chr7:157512322	PTPRN2	-0.47	-9.67	-0.41	2.79e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs9527	0.615	rs7899622	chr10:104727333	C/T	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.21e-23	Arsenic metabolism;
LGG	cis	rs9611565	0.527	rs2234053	chr22:41777315	G/T	cg03806693	chr22:41940476	POLR3H	-0.98	-17.46	-0.63	7.93e-53	Vitiligo;
LGG	cis	rs1008375	1.000	rs10440301	chr4:17663199	G/A	cg18681998	chr4:17616180	MED28	0.82	17.62	0.63	1.44e-53	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11039798	0.588	rs113800184	chr11:48756855	G/A	cg03929089	chr4:120376271	NA	0.71	9.81	0.41	8.94e-21	Axial length;
LGG	cis	rs7914558	0.966	rs4532960	chr10:104667406	C/T	cg04362960	chr10:104952993	NT5C2	0.53	10.02	0.42	1.58e-21	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs9462846	0.725	rs6927188	chr6:42912589	C/T	cg02353165	chr6:42928485	GNMT	-0.33	-7.7	-0.34	8.41e-14	Blood protein levels;
LGG	cis	rs4629710	0.568	rs67021539	chr6:131552900	A/G	cg12606694	chr6:131520996	AKAP7	0.51	8.44	0.37	4.21e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs2066819	1.000	rs2629447	chr12:56700809	G/A	cg26734620	chr12:56694298	CS	-0.74	-6.83	-0.3	2.75e-11	Psoriasis vulgaris;
LGG	cis	rs1372356	0.816	rs4904421	chr14:88538685	C/T	cg18078958	chr14:88630771	NA	0.31	7.55	0.33	2.42e-13	Food antigen IgG levels;
LGG	cis	rs12540874	0.524	rs4947684	chr7:50637799	G/A	cg00647317	chr7:50633725	DDC	0.46	11.33	0.47	1.94e-26	Systemic sclerosis;
LGG	cis	rs17401966	0.838	rs6541089	chr1:10402785	A/G	cg15208524	chr1:10270712	KIF1B	0.42	7.41	0.33	6.21e-13	Hepatocellular carcinoma;
LGG	cis	rs12477438	0.539	rs720228	chr2:99704547	A/G	cg26064155	chr2:99771622	LIPT1;TSGA10	1.04	26.5	0.78	7.45e-95	Chronic sinus infection;
LGG	cis	rs2032447	0.670	rs198845	chr6:26107790	A/C	cg03264133	chr6:25882463	NA	-0.49	-8.84	-0.38	1.99e-17	Intelligence (multi-trait analysis);
LGG	cis	rs853679	0.598	rs9380054	chr6:28067537	G/A	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs6964587	1.000	rs7785971	chr7:91736794	T/A	cg17063962	chr7:91808500	NA	0.51	9.24	0.39	8.85e-19	Breast cancer;
LGG	cis	rs977747	0.933	rs10789504	chr1:47676531	T/A	cg03885399	chr1:47691550	TAL1	-0.33	-6.85	-0.3	2.35e-11	Body mass index;
LGG	cis	rs9467773	0.836	rs1624440	chr6:26433329	G/A	cg11502198	chr6:26597334	ABT1	-0.56	-9.6	-0.41	5.07e-20	Intelligence (multi-trait analysis);
LGG	cis	rs8058578	0.633	rs113448632	chr16:30898219	C/T	cg02466173	chr16:30829666	NA	-0.52	-8.62	-0.37	1.04e-16	Multiple myeloma;
LGG	cis	rs6500602	0.674	rs8051695	chr16:4536621	T/C	cg05091796	chr16:4465799	CORO7	-0.76	-12.57	-0.5	2.23e-31	Schizophrenia;
LGG	trans	rs617791	0.530	rs10896073	chr11:65762814	T/C	cg17712092	chr4:129076599	LARP1B	-0.57	-9.6	-0.41	4.91e-20	Breast cancer;
LGG	cis	rs78456975	1.000	rs13413356	chr2:1553849	G/T	cg26248373	chr2:1572462	NA	-0.71	-9.07	-0.39	3.47e-18	Placebo response in major depressive disorder (% change in symptom score);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg23924007	chr4:140099401	NA	-0.5	-7.39	-0.32	7.1e-13	Systemic lupus erythematosus;
LGG	cis	rs55883249	0.957	rs17362839	chr2:9754439	T/C	cg23886495	chr2:9695866	ADAM17	0.69	9.91	0.42	3.92e-21	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs559928	0.606	rs56311067	chr11:63931607	C/T	cg02228329	chr11:64053129	BAD;GPR137	0.59	6.99	0.31	9.53e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs4253772	0.530	rs715518	chr22:46754177	C/G	cg09461388	chr22:46763229	CELSR1	-0.7	-7.23	-0.32	1.99e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs7010267	0.902	rs10505348	chr8:119972696	A/G	cg17171407	chr8:119960777	TNFRSF11B	0.4	10.37	0.43	8.28e-23	Total body bone mineral density (age 45-60);
LGG	cis	rs11122272	0.614	rs78172021	chr1:231525160	A/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs763121	0.853	rs2072795	chr22:39064209	A/G	cg06022373	chr22:39101656	GTPBP1	-0.89	-18.13	-0.64	6.75e-56	Menopause (age at onset);
LGG	cis	rs7568458	0.875	rs2044474	chr2:85758790	G/A	cg17127132	chr2:85788382	GGCX	0.44	7.72	0.34	7.02e-14	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs752010	0.695	rs10789408	chr1:42106579	T/C	cg16096631	chr1:42092165	HIVEP3	0.54	12.84	0.51	1.72e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7847628	0.765	rs10985024	chr9:123516812	A/G	cg09586646	chr9:123605570	PSMD5;LOC253039	0.62	9.28	0.4	6.45e-19	Birth weight;
LGG	cis	rs2836974	0.865	rs34778912	chr21:40667037	T/G	cg11890956	chr21:40555474	PSMG1	1.16	29.07	0.8	1.73e-106	Cognitive function;
LGG	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg05729249	chr7:766119	PRKAR1B;HEATR2	0.88	16.24	0.6	2.76e-47	Subjective well-being;
LGG	cis	rs7084402	0.967	rs1658477	chr10:60289607	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.38	-0.32	7.59e-13	Refractive error;
LGG	cis	rs155076	1.000	rs9509638	chr13:21860193	G/A	cg14456004	chr13:21872349	NA	-1.18	-18.7	-0.66	1.57e-58	White matter hyperintensity burden;
LGG	cis	rs9611565	0.644	rs2413652	chr22:42097238	C/T	cg17376030	chr22:41985996	PMM1	-0.56	-9.13	-0.39	2.12e-18	Vitiligo;
LGG	cis	rs8141529	0.748	rs132528	chr22:29295898	C/T	cg02153584	chr22:29168773	CCDC117	-0.61	-9.85	-0.42	6.58e-21	Lymphocyte counts;
LGG	cis	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg09085632	chr11:111637200	PPP2R1B	0.98	18.91	0.66	1.58e-59	Primary sclerosing cholangitis;
LGG	cis	rs11227306	0.934	rs7940691	chr11:65640906	C/T	cg26695010	chr11:65641043	EFEMP2	0.5	8.31	0.36	1.11e-15	DNA methylation (variation);
LGG	cis	rs2836974	0.897	rs8133146	chr21:40614298	T/C	cg11644478	chr21:40555479	PSMG1	0.91	17.29	0.63	4.85e-52	Cognitive function;
LGG	cis	rs2842992	0.747	rs9365095	chr6:160192928	T/G	cg11366901	chr6:160182831	ACAT2	1.08	16.69	0.61	2.52e-49	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs6952808	0.895	rs4513875	chr7:1928159	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	12.16	0.49	1.04e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs2153535	0.580	rs9393023	chr6:8469994	T/G	cg07606381	chr6:8435919	SLC35B3	0.69	12.59	0.51	1.79e-31	Motion sickness;
LGG	cis	rs9902453	0.791	rs3115100	chr17:28045744	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.71	14.42	0.56	3.38e-39	Coffee consumption (cups per day);
LGG	cis	rs12505749	0.542	rs55915354	chr4:57370023	G/T	cg07846311	chr4:57371927	ARL9	-0.33	-8.02	-0.35	8.65e-15	Airflow obstruction;
LGG	cis	rs6500395	1.000	rs9933187	chr16:48556573	A/C	cg04672837	chr16:48644449	N4BP1	-0.52	-8.58	-0.37	1.47e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs1005277	0.579	rs1548255	chr10:38417193	T/C	cg17219203	chr10:38645113	HSD17B7P2	-0.48	-7.53	-0.33	2.75e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs6840360	1.000	rs7669977	chr4:152677527	T/C	cg22705602	chr4:152727874	NA	-0.26	-6.66	-0.3	7.69e-11	Intelligence (multi-trait analysis);
LGG	cis	rs2880765	0.835	rs7169632	chr15:86044667	T/G	cg10818794	chr15:86012489	AKAP13	-0.38	-8.11	-0.35	4.53e-15	Coronary artery disease;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg24829409	chr8:58192753	C8orf71	-0.79	-11.23	-0.46	4.87e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7811142	1.000	rs7794485	chr7:100068936	T/C	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.0	14.9	0.57	2.8e-41	Platelet count;
LGG	cis	rs9596863	0.799	rs9591531	chr13:54308253	G/A	ch.13.53330881F	chr13:54432880	NA	0.51	6.69	0.3	6.47e-11	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9747201	0.862	rs57596657	chr17:80147978	C/T	cg09264619	chr17:80180166	NA	-0.5	-10.05	-0.42	1.28e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs2652834	0.821	rs7174174	chr15:63372327	A/G	cg05507819	chr15:63340323	TPM1	-0.51	-7.05	-0.31	6.5e-12	HDL cholesterol;
LGG	cis	rs10540	0.584	rs10751659	chr11:437559	C/T	cg19913688	chr11:428466	ANO9	0.68	10.63	0.44	9.39e-24	Body mass index;
LGG	trans	rs12682352	0.605	rs60707155	chr8:8724415	C/T	cg02002194	chr4:3960332	NA	-0.4	-7.06	-0.31	6.25e-12	Neuroticism;
LGG	cis	rs240764	0.658	rs9498390	chr6:101241438	T/A	cg21058520	chr6:100914733	NA	0.39	6.84	0.3	2.57e-11	Neuroticism;
LGG	cis	rs2933343	0.951	rs1055128	chr3:128591048	C/T	cg25356066	chr3:128598488	ACAD9	0.46	6.68	0.3	7e-11	IgG glycosylation;
LGG	cis	rs11148252	0.846	rs8001624	chr13:53002995	T/C	cg05335186	chr13:53173507	NA	0.48	10.16	0.43	4.91e-22	Lewy body disease;
LGG	cis	rs7044106	0.791	rs735110	chr9:123488940	T/A	cg13460057	chr9:123605234	PSMD5;LOC253039	0.48	7.72	0.34	7.47e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1107366	0.722	rs10934753	chr3:125906179	G/A	cg11252792	chr3:125932053	NA	0.6	12.04	0.49	3.2e-29	Metabolite levels;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg14646974	chr10:38645378	HSD17B7P2	-0.46	-7.31	-0.32	1.14e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9611565	0.877	rs3817999	chr22:41747717	A/G	cg06481639	chr22:41940642	POLR3H	0.49	7.63	0.33	1.32e-13	Vitiligo;
LGG	cis	rs4936894	0.500	rs4936917	chr11:124179656	G/T	cg27160556	chr11:124181099	OR8D1	-0.47	-10.79	-0.45	2.23e-24	Aging (time to death);
LGG	cis	rs651907	0.557	rs36002990	chr3:101437862	G/A	cg12386194	chr3:101231763	SENP7	0.43	7.57	0.33	2.02e-13	Colorectal cancer;
LGG	cis	rs1568889	1.000	rs7937117	chr11:28370038	C/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.8	14.78	0.57	9.01e-41	Bipolar disorder;
LGG	cis	rs9849248	0.574	rs7610494	chr3:88252023	G/C	cg14530983	chr3:88190749	ZNF654	-0.56	-7.73	-0.34	6.92e-14	Menarche (age at onset);
LGG	cis	rs1799949	0.930	rs56729776	chr17:41422131	C/T	cg01879757	chr17:41196368	BRCA1	-0.43	-8.66	-0.37	8.02e-17	Menopause (age at onset);
LGG	cis	rs9611565	0.802	rs132916	chr22:41806768	C/G	cg06481639	chr22:41940642	POLR3H	0.48	7.24	0.32	1.93e-12	Vitiligo;
LGG	cis	rs6089584	1.000	rs6089587	chr20:60564829	C/T	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg23625390	chr15:77176239	SCAPER	-0.71	-14.32	-0.55	9.42e-39	Blood metabolite levels;
LGG	cis	rs981844	1.000	rs116588966	chr4:154664794	T/C	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	7.87e-27	Response to statins (LDL cholesterol change);
LGG	cis	rs16912285	0.591	rs12796137	chr11:24364459	T/G	ch.11.24196551F	chr11:24239977	NA	0.86	12.1	0.49	1.74e-29	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs12477438	0.501	rs34272114	chr2:99737443	A/C	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	cis	rs3087591	0.919	rs12103563	chr17:29607228	A/T	cg24425628	chr17:29625626	OMG;NF1	-0.73	-15.15	-0.58	2.22e-42	Hip circumference;
LGG	cis	rs10504229	0.683	rs16921814	chr8:58107421	A/T	cg08280861	chr8:58055591	NA	0.56	7.01	0.31	8.42e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs10791323	0.559	rs10750549	chr11:133730820	A/G	cg00579200	chr11:133705235	NA	-0.59	-11.28	-0.46	3.01e-26	Childhood ear infection;
LGG	cis	rs9322193	0.923	rs3924871	chr6:149983216	G/A	cg00933542	chr6:150070202	PCMT1	0.39	7.08	0.31	5.47e-12	Lung cancer;
LGG	cis	rs12912251	0.947	rs12898460	chr15:38986813	C/T	cg01338139	chr15:38987640	C15orf53	-0.55	-8.84	-0.38	2.08e-17	Bipolar disorder;Bipolar disorder or major depressive disorder (combined);
LGG	cis	rs12421382	0.659	rs11213103	chr11:109385935	A/G	cg11473876	chr11:109292803	C11orf87	0.48	9.56	0.41	6.76e-20	Schizophrenia;
LGG	cis	rs13108043	0.511	rs72874293	chr4:87764384	T/A	cg11209507	chr4:87813803	C4orf36	0.61	7.76	0.34	5.41e-14	Red blood cell count;
LGG	cis	rs4853012	0.752	rs13413795	chr2:74349839	G/A	cg19729930	chr2:74357872	NA	0.57	12.28	0.5	3.27e-30	Gestational age at birth (maternal effect);
LGG	cis	rs6952808	0.862	rs4721167	chr7:1933224	C/T	cg11050988	chr7:1952600	MAD1L1	-0.41	-9.84	-0.42	7.33e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs12493885	0.769	rs61791508	chr3:153750816	A/G	cg12800244	chr3:153838788	SGEF	-0.74	-8.89	-0.38	1.36e-17	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs10504229	0.683	rs7843919	chr8:58130792	T/C	cg22535103	chr8:58192502	C8orf71	-0.9	-12.51	-0.5	4.03e-31	Developmental language disorder (linguistic errors);
LGG	cis	rs4272321	1	rs4272321	chr7:157951835	A/G	cg23602909	chr7:157956050	PTPRN2	-1.11	-28.04	-0.79	7.73e-102	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg23395165	chr19:4483111	HDGF2	0.41	7.48	0.33	3.64e-13	Electrocardiographic conduction measures;
LGG	cis	rs7786877	0.723	rs10487157	chr7:100214487	C/G	cg20848291	chr7:100343083	ZAN	-0.6	-8.48	-0.37	3.14e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg25019033	chr10:957182	NA	-0.56	-9.28	-0.4	6.72e-19	Eosinophil percentage of granulocytes;
LGG	cis	rs283228	0.958	rs4103516	chr6:101828259	C/T	cg27451362	chr6:101846650	GRIK2	0.54	9.04	0.39	4.2e-18	Coenzyme Q10 levels;
LGG	cis	rs7552404	0.696	rs1417405	chr1:76457797	T/C	cg10523679	chr1:76189770	ACADM	0.7	10.05	0.42	1.26e-21	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs6598955	0.543	rs112752634	chr1:26534217	G/A	cg04990556	chr1:26633338	UBXN11	0.72	10.56	0.44	1.73e-23	Obesity-related traits;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg16507663	chr6:150244633	RAET1G	0.43	8.17	0.35	3.06e-15	Lung cancer;
LGG	cis	rs2839186	0.770	rs2839171	chr21:47673247	C/T	cg12016809	chr21:47604291	C21orf56	-0.58	-10.5	-0.44	2.83e-23	Testicular germ cell tumor;
LGG	cis	rs4430311	0.688	rs1352162	chr1:243717682	A/G	cg25706552	chr1:244017396	NA	-0.63	-15.24	-0.58	8.73e-43	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs17270561	0.553	rs9379784	chr6:25725506	A/G	cg16482183	chr6:26056742	HIST1H1C	0.51	8.15	0.35	3.55e-15	Iron status biomarkers;
LGG	cis	rs6763768	0.541	rs35495179	chr3:53285424	G/C	cg16894138	chr3:53270350	TKT	0.4	7.61	0.33	1.56e-13	Bacterial meningitis;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg26398791	chr1:38455867	SF3A3	0.4	6.91	0.31	1.62e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs1008375	0.966	rs2286773	chr4:17616214	C/A	cg18681998	chr4:17616180	MED28	0.9	20.69	0.69	7.66e-68	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs9527	0.567	rs6584539	chr10:104879402	G/C	cg04362960	chr10:104952993	NT5C2	0.56	10.37	0.43	8.18e-23	Arsenic metabolism;
LGG	cis	rs1978968	0.869	rs5992931	chr22:18455914	G/A	cg03078520	chr22:18463400	MICAL3	-0.71	-14.98	-0.57	1.14e-41	Presence of antiphospholipid antibodies;
LGG	cis	rs344364	0.511	rs1742460	chr16:1945441	G/C	cg09830162	chr16:1889614	FAHD1;C16orf73	-0.48	-7.16	-0.32	3.23e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs6952808	0.689	rs4719391	chr7:2048136	T/C	cg19147804	chr7:1989927	MAD1L1	-0.54	-11.11	-0.46	1.36e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs4727027	0.933	rs12532104	chr7:148864233	A/C	cg23583168	chr7:148888333	NA	-0.87	-16.91	-0.62	2.73e-50	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs10504229	1.000	rs17805602	chr8:58179915	A/G	cg26174226	chr8:58114915	NA	-0.45	-6.66	-0.3	7.58e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6931421	0.800	rs12662365	chr6:80905389	T/A	cg08355045	chr6:80787529	NA	0.41	7.48	0.33	3.68e-13	Sitting height ratio;
LGG	cis	rs10979	1.000	rs9386032	chr6:143887492	A/G	cg25407410	chr6:143891975	LOC285740	-0.71	-12.42	-0.5	9.07e-31	Hypospadias;
LGG	cis	rs742614	0.875	rs3888736	chr20:32479793	C/A	cg06304546	chr20:32448765	NA	-0.48	-8.67	-0.37	7.27e-17	Stearic acid (18:0) levels;
LGG	trans	rs2727020	0.701	rs7949044	chr11:49597334	C/T	cg03929089	chr4:120376271	NA	-0.92	-16.61	-0.61	5.9e-49	Coronary artery disease;
LGG	cis	rs9902453	0.935	rs9905950	chr17:28431198	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.68	13.13	0.52	1.1e-33	Coffee consumption (cups per day);
LGG	cis	rs6502050	0.805	rs7406137	chr17:80084465	T/C	cg11859384	chr17:80120422	CCDC57	0.46	8.14	0.35	3.78e-15	Life satisfaction;
LGG	cis	rs3858526	0.792	rs12363478	chr11:5987775	C/T	cg25319279	chr11:5960081	NA	-0.54	-8.46	-0.37	3.53e-16	DNA methylation (variation);
LGG	cis	rs12519773	0.641	rs4489042	chr5:92428154	G/C	cg18783429	chr5:92414398	NA	0.31	7.41	0.33	5.9e-13	Migraine;
LGG	cis	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg14979609	chr8:8086686	FLJ10661	-0.28	-7.01	-0.31	8.72e-12	Neuroticism;
LGG	cis	rs4919044	0.641	rs7905234	chr10:94719384	A/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.13	-0.31	3.95e-12	Coronary artery disease;
LGG	cis	rs1059312	0.966	rs12368452	chr12:129277164	C/A	cg21616243	chr12:129299702	MGC16384;SLC15A4	-0.79	-17.57	-0.63	2.52e-53	Systemic lupus erythematosus;
LGG	cis	rs11992162	0.967	rs4840601	chr8:11828730	G/C	cg00405596	chr8:11794950	NA	0.4	6.93	0.31	1.4e-11	Monocyte count;
LGG	cis	rs9311474	0.508	rs17052256	chr3:52593119	A/G	cg18404041	chr3:52824283	ITIH1	-0.51	-9.91	-0.42	4.15e-21	Electroencephalogram traits;
LGG	cis	rs10504229	0.683	rs56192850	chr8:58135356	A/G	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9611565	0.921	rs3927	chr22:41722864	A/G	cg03806693	chr22:41940476	POLR3H	-0.9	-15.85	-0.59	1.7e-45	Vitiligo;
LGG	cis	rs17767392	0.756	rs61989256	chr14:71729964	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.4	-8.58	-0.37	1.42e-16	Mitral valve prolapse;
LGG	cis	rs17002988	0.568	rs7698326	chr4:79082750	T/A	cg07442568	chr4:78980533	FRAS1	0.42	6.71	0.3	5.53e-11	Uric acid levels;
LGG	cis	rs6142618	0.523	rs2377473	chr20:30850248	C/T	cg00028034	chr20:30779307	TSPYL3	0.35	7.33	0.32	1.05e-12	Inflammatory bowel disease;
LGG	cis	rs12142240	0.698	rs12385696	chr1:46818836	A/G	cg00530320	chr1:46809349	NSUN4	0.46	8.02	0.35	9.04e-15	Menopause (age at onset);
LGG	cis	rs514406	0.793	rs12402415	chr1:53218539	G/T	cg16325326	chr1:53192061	ZYG11B	-0.75	-17.78	-0.64	2.6e-54	Monocyte count;
LGG	cis	rs12681288	0.676	rs34435811	chr8:990630	T/A	cg04851639	chr8:1020857	NA	-0.41	-8.53	-0.37	2.16e-16	Schizophrenia;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg19143629	chr17:61920732	SMARCD2	0.43	7.37	0.32	7.71e-13	Prudent dietary pattern;
LGG	cis	rs769267	0.965	rs8103496	chr19:19386015	A/G	cg11584989	chr19:19387371	SF4	0.44	7.91	0.35	1.86e-14	Tonsillectomy;
LGG	cis	rs10463316	0.894	rs10062856	chr5:150768196	C/G	cg03212797	chr5:150827313	SLC36A1	-0.58	-10.18	-0.43	4.4e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs6062788	0.811	rs11698110	chr20:61701531	T/C	cg04883260	chr20:61718941	NA	0.31	7.04	0.31	7.18e-12	Body mass index;
LGG	cis	rs28595532	0.920	rs114207133	chr4:119755140	T/C	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs9768139	0.708	rs60487292	chr7:158115342	G/A	cg15736062	chr7:158136485	PTPRN2	-0.4	-7.63	-0.33	1.35e-13	Calcium levels;
LGG	cis	rs7568458	0.846	rs6738645	chr2:85783128	T/G	cg17127132	chr2:85788382	GGCX	0.49	8.52	0.37	2.21e-16	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg02127607	chr17:61920694	SMARCD2	0.46	8.27	0.36	1.46e-15	Prudent dietary pattern;
LGG	cis	rs1461503	0.934	rs930983	chr11:122834414	A/G	cg27398637	chr11:122830231	C11orf63	-0.68	-13.62	-0.53	9.07e-36	Menarche (age at onset);
LGG	trans	rs7829975	0.535	rs17683510	chr8:8500724	A/G	cg16141378	chr3:129829833	LOC729375	-0.33	-7.55	-0.33	2.36e-13	Mood instability;
LGG	cis	rs9397585	0.857	rs7747583	chr6:153371768	G/T	cg17707550	chr6:153380415	RGS17	-0.63	-15.07	-0.57	5.03e-42	Body mass index;
LGG	cis	rs2334880	0.836	rs9939458	chr16:71667131	T/G	cg06353428	chr16:71660113	MARVELD3	1.28	21.61	0.71	4e-72	Malaria;
LGG	cis	rs4732038	0.526	rs706192	chr7:134270195	G/A	cg06906464	chr7:134288099	NA	-0.72	-20.95	-0.7	4.77e-69	Longevity;
LGG	cis	rs4253772	0.550	rs6008613	chr22:46707924	G/T	cg24881330	chr22:46731750	TRMU	0.71	7.21	0.32	2.27e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs79911532	0.515	rs78085898	chr7:75703215	T/C	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	cis	rs6500602	0.673	rs1861652	chr16:4505331	C/T	cg00688539	chr16:4524775	NMRAL1;HMOX2	0.36	7.34	0.32	9.47e-13	Schizophrenia;
LGG	cis	rs2842992	0.724	rs2273827	chr6:160211339	C/A	cg27624424	chr6:160112604	SOD2	0.6	9.37	0.4	3.11e-19	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs972578	0.765	rs9611957	chr22:43297397	G/A	cg01576275	chr22:43409880	NA	-0.22	-6.75	-0.3	4.34e-11	Mean platelet volume;
LGG	cis	rs2228479	0.850	rs62052714	chr16:89857180	T/C	cg19635926	chr16:89946313	TCF25	0.72	7.1	0.31	4.86e-12	Skin colour saturation;
LGG	cis	rs875971	0.545	rs6979636	chr7:65741625	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	0.55	10.71	0.45	4.77e-24	Aortic root size;
LGG	cis	rs9290877	0.667	rs9881900	chr3:188456990	A/G	cg17392043	chr3:188495102	LPP	-0.42	-7.26	-0.32	1.7e-12	IgE levels;
LGG	cis	rs6088590	1.000	rs6087632	chr20:33407704	A/C	cg24642439	chr20:33292090	TP53INP2	0.82	14.87	0.57	3.61e-41	Coronary artery disease;
LGG	trans	rs1997103	0.954	rs1997099	chr7:55405540	T/C	cg20935933	chr6:143382018	AIG1	0.56	8.84	0.38	2.04e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs898097	0.756	rs56249965	chr17:80806603	C/G	cg16060761	chr17:80687452	NA	0.47	7.5	0.33	3.25e-13	Breast cancer;
LGG	cis	rs7223966	1.000	rs7209435	chr17:61712964	T/C	cg17202724	chr17:61916730	SMARCD2	-0.44	-8.77	-0.38	3.33e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs826838	0.967	rs2069211	chr12:39128892	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg11786005	chr6:170863399	PSMB1;TBP	-0.54	-7.89	-0.34	2.2e-14	Systemic lupus erythematosus;
LGG	cis	rs74781061	0.929	rs11072495	chr15:74891131	G/T	cg02384859	chr15:74862662	ARID3B	-0.34	-7.17	-0.32	3.02e-12	Endometriosis;
LGG	cis	rs2836974	0.526	rs418359	chr21:40536734	T/C	cg17971929	chr21:40555470	PSMG1	-0.71	-13.42	-0.53	6.33e-35	Cognitive function;
LGG	cis	rs17253792	0.822	rs112238223	chr14:56056144	C/A	cg01858014	chr14:56050164	KTN1	-0.9	-12.08	-0.49	2.23e-29	Putamen volume;
LGG	trans	rs853679	0.760	rs11962305	chr6:28199937	G/C	cg08344181	chr3:125677491	NA	-0.48	-6.83	-0.3	2.64e-11	Depression;
LGG	cis	rs9364220	0.794	rs9346650	chr6:168492963	C/T	cg02770688	chr6:168491649	NA	-0.38	-6.97	-0.31	1.08e-11	Attention deficit hyperactivity disorder (inattention symptoms);Attention deficit hyperactivity disorder (combined symptoms);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg05603938	chr12:6960421	USP5;CDCA3	0.44	7.81	0.34	3.8e-14	Bipolar disorder;
LGG	trans	rs7824557	0.767	rs2164273	chr8:11168499	A/G	cg06636001	chr8:8085503	FLJ10661	0.56	10.43	0.44	5.24e-23	Retinal vascular caliber;
LGG	cis	rs2735413	0.563	rs72800908	chr16:78046518	T/A	cg04733911	chr16:78082701	NA	0.57	7.47	0.33	4.16e-13	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs62400317	0.859	rs2093900	chr6:45176683	C/T	cg18551225	chr6:44695536	NA	-0.63	-10.0	-0.42	1.85e-21	Total body bone mineral density;
LGG	cis	rs10256972	0.684	rs2363279	chr7:1096143	A/G	cg11360546	chr7:1094263	C7orf50	-0.43	-7.68	-0.34	9.45e-14	Longevity;Endometriosis;
LGG	cis	rs7647973	0.925	rs6446256	chr3:49224210	A/G	cg06212747	chr3:49208901	KLHDC8B	0.54	8.46	0.37	3.56e-16	Menarche (age at onset);
LGG	trans	rs4332037	1.000	rs62442899	chr7:1948454	C/T	cg11693508	chr17:37793320	STARD3	0.73	10.38	0.43	7.85e-23	Bipolar disorder;
LGG	cis	rs546131	0.642	rs836950	chr11:34852020	C/G	cg06937548	chr11:34938143	PDHX;APIP	-0.47	-7.58	-0.33	1.94e-13	Lung disease severity in cystic fibrosis;
LGG	cis	rs4595586	0.545	rs12813151	chr12:39363405	C/G	cg13010199	chr12:38710504	ALG10B	-0.41	-7.29	-0.32	1.38e-12	Morning vs. evening chronotype;
LGG	trans	rs826838	0.967	rs1719852	chr12:39128531	A/G	cg06521331	chr12:34319734	NA	0.43	7.64	0.33	1.23e-13	Heart rate;
LGG	trans	rs453301	0.571	rs2929305	chr8:9085217	G/A	cg16141378	chr3:129829833	LOC729375	0.39	9.31	0.4	5.19e-19	Joint mobility (Beighton score);
LGG	cis	rs10504229	1.000	rs66840104	chr8:58190001	C/T	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.634	rs6088498	chr20:33020446	A/G	cg08999081	chr20:33150536	PIGU	0.4	10.14	0.43	5.8e-22	Glomerular filtration rate (creatinine);
LGG	cis	rs9291683	0.632	rs11734786	chr4:10041499	A/C	cg25986240	chr4:9926439	SLC2A9	-0.42	-8.89	-0.38	1.37e-17	Bone mineral density;
LGG	cis	rs12949688	0.601	rs10083839	chr17:55835623	C/T	cg12582317	chr17:55822272	NA	0.48	11.05	0.46	2.36e-25	Schizophrenia;
LGG	cis	rs9527	0.544	rs11191549	chr10:104846797	C/T	cg05308233	chr10:104796373	CNNM2	-0.32	-7.12	-0.31	4.2e-12	Arsenic metabolism;
LGG	cis	rs2708977	0.966	rs749027	chr2:97203137	A/C	cg01950434	chr2:97203154	ARID5A	-0.59	-9.4	-0.4	2.47e-19	Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4665809	0.590	rs6730310	chr2:26419470	C/G	cg26119090	chr2:26468346	HADHA;HADHB	-1.09	-21.42	-0.71	3.15e-71	Gut microbiome composition (summer);
LGG	cis	rs1153858	1.000	rs28679834	chr15:45616206	C/T	cg05280133	chr15:45670068	GATM;LOC145663	0.42	7.58	0.33	1.84e-13	Homoarginine levels;
LGG	cis	rs9322193	0.962	rs7745915	chr6:150155247	C/T	cg13206674	chr6:150067644	NUP43	0.63	14.22	0.55	2.44e-38	Lung cancer;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg00424166	chr6:150045504	NUP43	-0.36	-7.4	-0.33	6.58e-13	Lung cancer;
LGG	cis	rs6963495	0.818	rs1355614	chr7:105179176	A/G	cg21420622	chr7:105162941	PUS7	-0.45	-7.13	-0.31	3.92e-12	Bipolar disorder (body mass index interaction);
LGG	cis	rs10463554	0.892	rs158401	chr5:102415468	A/G	cg23492399	chr5:102201601	PAM	-0.5	-7.47	-0.33	3.9e-13	Parkinson's disease;
LGG	cis	rs2243480	0.901	rs3813708	chr7:65305632	C/A	cg13147721	chr7:65941812	NA	-0.79	-9.57	-0.41	6.7e-20	Diabetic kidney disease;
LGG	cis	rs262150	0.522	rs2527182	chr7:158813812	A/G	cg04111992	chr7:158790115	NA	-0.36	-7.33	-0.32	1.05e-12	Facial morphology (factor 20);
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg19223190	chr17:80058835	NA	0.46	8.39	0.36	5.78e-16	Life satisfaction;
LGG	cis	rs11877825	0.826	rs9961960	chr18:10570303	A/G	cg07277756	chr18:10589357	NA	-0.56	-10.53	-0.44	2.11e-23	Gut microbiota (bacterial taxa);
LGG	trans	rs7613875	0.620	rs7430334	chr3:50078221	T/C	cg21659725	chr3:3221576	CRBN	-0.55	-9.74	-0.41	1.61e-20	Body mass index;
LGG	cis	rs1008375	0.933	rs6847966	chr4:17634255	G/A	cg16339924	chr4:17578868	LAP3	0.6	10.42	0.44	5.75e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs1814175	0.647	rs28456013	chr11:50047629	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.5	-9.6	-0.41	5.04e-20	Height;
LGG	cis	rs7818345	0.595	rs58551730	chr8:19316627	T/A	cg01280390	chr8:19363452	CSGALNACT1	0.33	7.45	0.33	4.48e-13	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs657075	0.697	rs3792882	chr5:131645111	C/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.65	0.33	1.2e-13	Rheumatoid arthritis;
LGG	cis	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg14646974	chr10:38645378	HSD17B7P2	-0.45	-7.15	-0.32	3.46e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs722599	0.599	rs3825708	chr14:75200697	C/T	cg06637938	chr14:75390232	RPS6KL1	0.48	7.71	0.34	7.63e-14	IgG glycosylation;
LGG	cis	rs7659604	0.521	rs4833234	chr4:122694799	T/C	cg20573242	chr4:122745356	CCNA2	-0.46	-7.88	-0.34	2.34e-14	Type 2 diabetes;
LGG	cis	rs10883723	0.775	rs7917158	chr10:104246471	C/A	cg05096777	chr10:104283225	SUFU	0.32	7.12	0.31	4.18e-12	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs10992471	0.756	rs10992303	chr9:95082804	A/G	cg13798575	chr9:95087839	CENPP;NOL8	-0.45	-7.08	-0.31	5.47e-12	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	cis	rs798554	0.610	rs1182209	chr7:2808595	C/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.22	-0.36	2.11e-15	Height;
LGG	cis	rs7582180	0.629	rs11686799	chr2:100956055	C/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.9e-48	Intelligence (multi-trait analysis);
LGG	cis	rs2640806	0.656	rs6468500	chr8:97340004	C/G	cg22138393	chr8:97340270	PTDSS1	0.32	8.24	0.36	1.75e-15	Obesity-related traits;
LGG	cis	rs9341808	0.690	rs9343970	chr6:80881289	C/G	cg08355045	chr6:80787529	NA	0.41	7.87	0.34	2.56e-14	Sitting height ratio;
LGG	cis	rs3617	0.573	rs4687680	chr3:52907372	G/A	cg11645453	chr3:52864694	ITIH4	0.45	7.65	0.33	1.17e-13	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9322193	0.961	rs2064520	chr6:149924786	A/T	cg12070911	chr6:150209640	RAET1E	0.31	7.59	0.33	1.83e-13	Lung cancer;
LGG	trans	rs3960554	0.867	rs10239209	chr7:75804085	G/A	cg19862616	chr7:65841803	NCRNA00174	0.87	12.63	0.51	1.29e-31	Eotaxin levels;
LGG	cis	rs7191439	0.584	rs8048897	chr16:88744470	T/G	cg02389323	chr16:88786976	FAM38A	0.86	8.08	0.35	5.81e-15	Plateletcrit;
LGG	cis	rs250677	0.687	rs250671	chr5:148446523	T/C	cg18129178	chr5:148520854	ABLIM3	-0.44	-7.16	-0.32	3.14e-12	Breast cancer;
LGG	cis	rs283228	0.798	rs2787558	chr6:101783876	T/C	cg27451362	chr6:101846650	GRIK2	0.63	10.45	0.44	4.31e-23	Coenzyme Q10 levels;
LGG	cis	rs10504229	0.724	rs72649117	chr8:58037639	A/G	cg02725872	chr8:58115012	NA	-0.84	-12.02	-0.49	3.74e-29	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.609	rs66477547	chr8:58105763	A/C	cg11062466	chr8:58055876	NA	0.54	8.62	0.37	1.09e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.6	9.87	0.42	5.77e-21	Height;
LGG	cis	rs11583043	0.957	rs6667932	chr1:101503755	G/A	cg00063077	chr1:101360652	SLC30A7;EXTL2	0.44	7.95	0.35	1.41e-14	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs796364	0.806	rs1106400	chr2:201004089	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.55	-6.84	-0.3	2.5e-11	Schizophrenia;
LGG	cis	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg21775007	chr8:11205619	TDH	0.74	12.69	0.51	7.28e-32	Retinal vascular caliber;
LGG	cis	rs12477438	0.520	rs4850897	chr2:99768419	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.73	15.43	0.58	1.17e-43	Chronic sinus infection;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg02976543	chr2:239197607	PER2	0.47	7.95	0.35	1.42e-14	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs208515	0.525	rs12204706	chr6:66669930	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.94	-17.12	-0.62	2.81e-51	Exhaled nitric oxide levels;
LGG	cis	rs4262150	0.667	rs7444191	chr5:152251433	G/A	cg12297329	chr5:152029980	NA	0.6	11.7	0.48	6.88e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.923	rs9800871	chr6:149965676	A/G	cg04369109	chr6:150039330	LATS1	-0.42	-7.01	-0.31	8.67e-12	Lung cancer;
LGG	cis	rs62481355	0.963	rs11768389	chr7:127150250	T/C	cg25922125	chr7:127225783	GCC1	-0.5	-7.25	-0.32	1.71e-12	Type 2 diabetes;
LGG	cis	rs11239187	0.523	rs12416330	chr10:45101377	G/A	cg03916630	chr10:45065415	NA	0.42	7.63	0.33	1.36e-13	Body mass index;
LGG	cis	rs1790761	0.520	rs12805884	chr11:67387977	G/A	cg14500267	chr11:67383377	NA	-0.41	-7.11	-0.31	4.47e-12	Mean corpuscular volume;
LGG	cis	rs2777491	1.000	rs2730055	chr15:41735708	C/A	cg18705301	chr15:41695430	NDUFAF1	-0.99	-20.18	-0.68	1.89e-65	Ulcerative colitis;
LGG	cis	rs9309473	0.950	rs6546860	chr2:73844249	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.61	-0.33	1.5e-13	Metabolite levels;
LGG	cis	rs6840360	0.571	rs4696099	chr4:152501951	C/G	cg22705602	chr4:152727874	NA	-0.33	-7.69	-0.34	8.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7582180	0.607	rs6725052	chr2:100935817	G/A	cg14675211	chr2:100938903	LONRF2	0.69	12.4	0.5	1.1e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10256972	0.713	rs10435026	chr7:1065948	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.51	-8.72	-0.38	4.95e-17	Longevity;Endometriosis;
LGG	cis	rs60871478	1.000	rs62432860	chr7:807522	G/C	cg04727924	chr7:799746	HEATR2	-0.47	-7.57	-0.33	2.07e-13	Cerebrospinal P-tau181p levels;
LGG	cis	rs1008375	0.966	rs10939758	chr4:17698255	C/T	cg02297831	chr4:17616191	MED28	0.43	8.03	0.35	8.39e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs899997	0.862	rs8032552	chr15:78971136	T/C	cg14912033	chr15:79043428	NA	0.34	8.16	0.35	3.14e-15	Coronary artery disease or large artery stroke;
LGG	cis	rs6500602	0.893	rs8061742	chr16:4489436	T/C	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.37	7.71	0.34	8.03e-14	Schizophrenia;
LGG	cis	rs10893109	0.538	rs2045070	chr11:123796924	C/T	cg12387464	chr11:123775935	OR8D4	-0.39	-8.25	-0.36	1.61e-15	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs9783347	0.857	rs4150561	chr11:18354877	T/C	cg15585147	chr11:18324498	HPS5	0.43	9.09	0.39	2.98e-18	Pancreatic cancer;
LGG	cis	rs7824557	0.603	rs6995404	chr8:11182148	C/G	cg21775007	chr8:11205619	TDH	0.78	13.75	0.54	2.46e-36	Retinal vascular caliber;
LGG	cis	rs17221829	0.733	rs35757457	chr11:89358250	T/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.13	-0.39	2.19e-18	Anxiety in major depressive disorder;
LGG	cis	rs6743226	0.580	rs11677414	chr2:242237797	G/A	cg10021735	chr2:242295487	FARP2	0.4	6.99	0.31	9.53e-12	Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;
LGG	cis	rs10504229	1.000	rs72650900	chr8:58185675	T/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs2236736	chr17:61938248	G/T	cg19143629	chr17:61920732	SMARCD2	0.43	7.38	0.32	7.43e-13	Prudent dietary pattern;
LGG	cis	rs2820315	1.000	rs2250377	chr1:201860626	A/G	cg10061532	chr1:201886748	LMOD1	-0.33	-6.9	-0.31	1.68e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	cis	rs1129187	0.755	rs13215983	chr6:42924193	C/T	cg10056627	chr6:42928773	GNMT	0.26	7.13	0.31	3.84e-12	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs28735056	0.904	rs12962619	chr18:77628832	T/C	cg05491587	chr18:77659695	KCNG2	-0.41	-7.35	-0.32	9.34e-13	Schizophrenia;
LGG	cis	rs2976388	0.967	rs2978981	chr8:143759137	C/T	cg06565975	chr8:143823917	SLURP1	-0.43	-10.76	-0.45	2.91e-24	Urinary tract infection frequency;
LGG	cis	rs7395581	0.797	rs10838681	chr11:47275064	C/T	cg03339077	chr11:47165057	C11orf49	0.4	6.67	0.3	7.31e-11	HDL cholesterol;
LGG	cis	rs747650	0.892	rs1976142	chr11:47225694	T/C	cg03339077	chr11:47165057	C11orf49	-0.55	-10.37	-0.43	8.19e-23	Acne (severe);
LGG	cis	rs11583043	0.831	rs6667818	chr1:101412313	A/T	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	9.08	0.39	3.19e-18	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs752010	0.714	rs2182606	chr1:42082375	T/C	cg06885757	chr1:42089581	HIVEP3	0.57	13.37	0.53	1e-34	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2486288	0.656	rs11637920	chr15:45550905	T/C	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs3126085	0.935	rs4845740	chr1:152183310	G/A	cg26876637	chr1:152193138	HRNR	0.54	8.82	0.38	2.38e-17	Atopic dermatitis;
LGG	cis	rs7927771	0.965	rs11039416	chr11:47846711	G/A	cg20307385	chr11:47447363	PSMC3	-0.49	-8.65	-0.37	8.71e-17	Subjective well-being;
LGG	cis	rs1124376	1.000	rs61457790	chr3:20136186	G/A	cg05072819	chr3:20081367	KAT2B	0.63	8.35	0.36	7.74e-16	Bipolar disorder and schizophrenia;
LGG	trans	rs3780486	0.718	rs7859454	chr9:33119583	T/A	cg20290983	chr6:43655470	MRPS18A	0.83	12.06	0.49	2.54e-29	IgG glycosylation;
LGG	cis	rs9329221	0.905	rs10283145	chr8:10241411	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.56	-0.33	2.23e-13	Neuroticism;
LGG	cis	rs734999	0.505	rs10797439	chr1:2540364	G/A	cg20673091	chr1:2541236	MMEL1	0.78	19.1	0.66	2.06e-60	Ulcerative colitis;
LGG	cis	rs10214930	0.697	rs759269	chr7:27592347	C/T	cg22168087	chr7:27702803	HIBADH	0.46	6.8	0.3	3.14e-11	Hypospadias;
LGG	cis	rs2456568	0.802	rs8181567	chr11:93637209	C/T	cg26875233	chr11:93583750	C11orf90	-0.35	-6.85	-0.3	2.34e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	trans	rs6921919	0.778	rs67381177	chr6:28411941	G/C	cg06606381	chr12:133084897	FBRSL1	-1.33	-12.34	-0.5	1.98e-30	Autism spectrum disorder or schizophrenia;
LGG	cis	rs12220238	1.000	rs11000936	chr10:75992383	A/T	cg19889307	chr10:75911429	ADK;AP3M1	0.85	12.07	0.49	2.27e-29	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs763121	0.853	rs8142098	chr22:39058757	T/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.48	0.63	6.84e-53	Menopause (age at onset);
LGG	trans	rs61931739	0.500	rs34703942	chr12:34583776	T/C	cg26384229	chr12:38710491	ALG10B	-0.85	-18.02	-0.64	2.04e-55	Morning vs. evening chronotype;
LGG	cis	rs10504229	0.683	rs55807014	chr8:58131801	T/C	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.869	rs894280	chr4:90760883	C/T	cg26578617	chr4:90757533	SNCA	-0.47	-9.53	-0.4	8.84e-20	Dementia with Lewy bodies;
LGG	cis	rs7582180	0.614	rs9973737	chr2:100942296	T/C	cg08297393	chr2:100937505	LONRF2	-0.55	-10.49	-0.44	2.96e-23	Intelligence (multi-trait analysis);
LGG	cis	rs908922	0.676	rs7518654	chr1:152517845	C/G	cg20991723	chr1:152506922	NA	-0.7	-13.8	-0.54	1.6e-36	Hair morphology;
LGG	cis	rs2032447	0.507	rs478349	chr6:25894057	T/C	cg03517284	chr6:25882590	NA	-0.86	-16.27	-0.6	2.08e-47	Intelligence (multi-trait analysis);
LGG	cis	rs807669	0.504	rs8141941	chr22:19166263	G/A	cg02655711	chr22:19163373	SLC25A1	0.53	9.85	0.42	6.34e-21	Metabolite levels;
LGG	cis	rs12493885	0.818	rs7641039	chr3:153768638	A/C	cg17054900	chr3:154042577	DHX36	0.58	7.56	0.33	2.26e-13	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs8077889	0.917	rs4793038	chr17:41916761	A/T	cg26893861	chr17:41843967	DUSP3	0.9	15.45	0.58	1.04e-43	Triglycerides;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg01818597	chr11:63741913	COX8A	-0.46	-6.78	-0.3	3.74e-11	Systemic lupus erythematosus;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20588892	chr5:87565114	TMEM161B	0.45	6.75	0.3	4.48e-11	Gut microbiome composition (summer);
LGG	trans	rs561341	0.830	rs7218801	chr17:30217778	A/G	cg27661571	chr11:113659931	NA	0.57	7.82	0.34	3.55e-14	Hip circumference adjusted for BMI;
LGG	cis	rs4820294	0.770	rs7285699	chr22:38066556	A/C	cg26138144	chr22:38071188	LGALS1	0.67	15.37	0.58	2.27e-43	Fat distribution (HIV);
LGG	cis	rs9788682	0.624	rs518425	chr15:78883813	A/G	cg06917634	chr15:78832804	PSMA4	-0.42	-6.76	-0.3	4.21e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	trans	rs7829975	0.714	rs4841042	chr8:8664622	A/G	cg19847130	chr8:10466454	RP1L1	0.31	6.87	0.3	2.11e-11	Mood instability;
LGG	cis	rs9443645	0.901	rs3805747	chr6:79672522	A/G	cg18132916	chr6:79620363	NA	-0.31	-8.64	-0.37	9.26e-17	Intelligence (multi-trait analysis);
LGG	cis	rs4409675	0.576	rs1474908	chr1:28213213	C/T	cg23691781	chr1:28212827	C1orf38	-0.42	-9.59	-0.41	5.28e-20	Corneal astigmatism;
LGG	cis	rs9419702	0.568	rs7093241	chr10:133556596	G/A	cg20568497	chr10:133558893	NA	0.35	7.73	0.34	6.94e-14	Survival in rectal cancer;
LGG	cis	rs10752881	1.000	rs8179262	chr1:182973186	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs17767392	0.958	rs12885344	chr14:72003224	G/A	cg02058870	chr14:72053146	SIPA1L1	0.45	8.96	0.38	8.01e-18	Mitral valve prolapse;
LGG	cis	rs9914544	0.762	rs4322727	chr17:18798573	A/T	cg26378065	chr17:18585709	ZNF286B	-0.43	-8.07	-0.35	6.01e-15	Educational attainment (years of education);
LGG	cis	rs3087591	0.919	rs7406870	chr17:29590617	G/A	cg24425628	chr17:29625626	OMG;NF1	0.73	14.22	0.55	2.59e-38	Hip circumference;
LGG	cis	rs1865760	0.566	rs1971509	chr6:26085777	T/C	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs3784262	0.669	rs4646559	chr15:58354258	A/G	cg12031962	chr15:58353849	ALDH1A2	-0.32	-6.86	-0.3	2.28e-11	Barrett's esophagus;Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);
LGG	cis	rs4689388	0.856	rs10016157	chr4:6294414	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4650994	0.789	rs2761471	chr1:178599348	A/C	cg12486710	chr1:178512616	C1orf220	-0.4	-8.08	-0.35	5.66e-15	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs9467773	0.620	rs2451737	chr6:26619041	T/C	cg11502198	chr6:26597334	ABT1	0.7	12.87	0.51	1.26e-32	Intelligence (multi-trait analysis);
LGG	cis	rs72615157	0.561	rs113844570	chr7:99873778	A/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	0.75	10.22	0.43	3.12e-22	Lung function (FEV1/FVC);
LGG	cis	rs7647973	1.000	rs10155014	chr3:49432321	C/T	cg07636037	chr3:49044803	WDR6	0.77	13.76	0.54	2.39e-36	Menarche (age at onset);
LGG	cis	rs7044106	0.791	rs4837793	chr9:123483621	G/A	cg09833538	chr9:123605306	PSMD5;LOC253039	0.43	7.03	0.31	7.67e-12	Hip circumference adjusted for BMI;
LGG	cis	rs9816226	0.645	rs16860471	chr3:185847441	G/T	cg00760338	chr3:185826511	ETV5	-0.79	-10.37	-0.43	8.34e-23	Obesity;Body mass index;
LGG	cis	rs870825	0.929	rs871254	chr4:185589226	G/C	cg04058563	chr4:185651563	MLF1IP	1.03	18.65	0.65	2.64e-58	Blood protein levels;
LGG	cis	rs2299587	0.582	rs17515033	chr8:17898518	A/T	cg18067069	chr8:17937731	ASAH1	-0.32	-7.58	-0.33	1.94e-13	Economic and political preferences;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.65	0.3	8.03e-11	Longevity;
LGG	cis	rs2276314	1.000	rs4799832	chr18:33559646	T/C	cg05985134	chr18:33552581	C18orf21	0.65	10.29	0.43	1.63e-22	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs8058578	0.832	rs3812999	chr16:30773605	G/T	cg00531865	chr16:30841666	NA	-0.56	-11.43	-0.47	7.83e-27	Multiple myeloma;
LGG	cis	rs8114671	0.562	rs6060064	chr20:33406339	C/G	cg24642439	chr20:33292090	TP53INP2	-0.44	-7.09	-0.31	5.08e-12	Height;
LGG	cis	rs6748734	0.548	rs12618707	chr2:241874559	T/C	cg14055004	chr2:241860995	NA	-0.28	-7.47	-0.33	3.97e-13	Urinary metabolites;
LGG	cis	rs6951245	0.935	rs61910751	chr7:1097895	A/G	cg21664854	chr7:1097933	C7orf50;GPR146	0.98	14.44	0.56	2.78e-39	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2404602	0.669	rs1875885	chr15:76638081	G/A	cg15268244	chr15:77196840	NA	-0.32	-7.12	-0.31	4.17e-12	Blood metabolite levels;
LGG	cis	rs6466055	0.692	rs13226540	chr7:104999901	G/A	cg04380332	chr7:105027541	SRPK2	-0.38	-7.02	-0.31	7.72e-12	Schizophrenia;
LGG	cis	rs36051895	0.588	rs12340895	chr9:5076691	C/G	cg02405213	chr9:5042618	JAK2	0.84	15.51	0.58	5.67e-44	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.679	rs11786328	chr8:58039269	A/G	cg14926445	chr8:58193284	C8orf71	-0.78	-9.48	-0.4	1.31e-19	Developmental language disorder (linguistic errors);
LGG	trans	rs2727020	0.553	rs11040400	chr11:49518296	C/A	cg03929089	chr4:120376271	NA	-0.96	-20.22	-0.68	1.24e-65	Coronary artery disease;
LGG	cis	rs6502050	0.805	rs62080003	chr17:80078957	C/T	cg23985595	chr17:80112537	CCDC57	0.47	9.53	0.4	9.03e-20	Life satisfaction;
LGG	cis	rs1729951	0.546	rs12054219	chr3:136677472	G/A	cg21827317	chr3:136751795	NA	0.53	9.86	0.42	6.24e-21	Neuroticism;
LGG	cis	rs6540556	0.679	rs11808690	chr1:209891450	T/G	cg23920097	chr1:209922102	NA	-0.42	-7.03	-0.31	7.42e-12	Red blood cell count;
LGG	cis	rs6977660	0.891	rs10226962	chr7:19819464	T/C	cg07541023	chr7:19748670	TWISTNB	0.49	7.62	0.33	1.46e-13	Thyroid stimulating hormone;
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg11859384	chr17:80120422	CCDC57	-0.44	-7.68	-0.34	9.24e-14	Life satisfaction;
LGG	cis	rs17221829	0.733	rs11018728	chr11:89415942	G/A	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.66	-0.37	8.01e-17	Anxiety in major depressive disorder;
LGG	cis	rs7615952	0.599	rs67566088	chr3:125768973	C/A	cg18479299	chr3:125709523	NA	-0.58	-7.51	-0.33	3.07e-13	Blood pressure (smoking interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg03284175	chr1:146643471	PRKAB2	-0.42	-6.96	-0.31	1.15e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs12501370	0.959	rs1876493	chr4:41044938	C/G	cg23738842	chr13:20135942	NA	-0.42	-7.42	-0.33	5.75e-13	Iris color (L* coordinate);
LGG	cis	rs3735485	0.843	rs12702111	chr7:45023302	A/G	cg03440944	chr7:45023329	C7orf40	0.56	9.49	0.4	1.2e-19	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs2197308	0.765	rs2387436	chr12:37935337	C/T	cg26384229	chr12:38710491	ALG10B	-0.8	-17.31	-0.63	3.88e-52	Morning vs. evening chronotype;
LGG	cis	rs2221894	0.506	rs74783515	chr8:28848539	G/T	cg07962641	chr8:28805897	HMBOX1	-0.54	-7.99	-0.35	1.1e-14	Obesity-related traits;
LGG	cis	rs4262150	0.508	rs10036750	chr5:151920039	T/C	cg12297329	chr5:152029980	NA	-0.66	-11.94	-0.49	7.67e-29	Bipolar disorder and schizophrenia;
LGG	cis	rs9596863	0.898	rs35863857	chr13:54372546	A/G	ch.13.53330881F	chr13:54432880	NA	0.52	7.09	0.31	5.18e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs11191205	0.644	rs11191062	chr10:103366645	T/C	cg15320455	chr10:103880129	LDB1	0.51	7.38	0.32	7.63e-13	Intelligence (multi-trait analysis);
LGG	cis	rs4746818	1.000	rs6480383	chr10:70890482	C/T	cg04149295	chr10:70884716	VPS26A	0.49	7.44	0.33	4.84e-13	Left atrial antero-posterior diameter;
LGG	cis	rs7586879	0.558	rs6718510	chr2:25122323	A/C	cg04586622	chr2:25135609	ADCY3	0.46	12.71	0.51	5.87e-32	Body mass index;
LGG	cis	rs1729951	0.575	rs361237	chr3:136702414	A/G	cg12473912	chr3:136751656	NA	0.45	7.71	0.34	7.95e-14	Neuroticism;
LGG	cis	rs7618915	0.547	rs34215106	chr3:52659124	T/C	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.68	0.41	2.63e-20	Bipolar disorder;
LGG	cis	rs10256972	0.967	rs4723338	chr7:1036241	A/G	cg04025307	chr7:1156635	C7orf50	0.46	8.03	0.35	8.06e-15	Longevity;Endometriosis;
LGG	cis	rs35851103	0.627	rs58602899	chr8:11848833	G/T	cg00405596	chr8:11794950	NA	0.48	8.17	0.35	2.99e-15	Neuroticism;
LGG	cis	rs34044649	0.840	rs1675570	chr7:155650500	G/C	cg17395211	chr7:155654226	NA	-0.39	-7.67	-0.34	1e-13	Triptolide cytotoxicity;
LGG	cis	rs9322193	0.923	rs12174349	chr6:150039148	G/A	cg07701084	chr6:150067640	NUP43	0.71	13.79	0.54	1.75e-36	Lung cancer;
LGG	cis	rs7928758	0.887	rs11822935	chr11:134271771	T/C	cg22777979	chr11:134283252	B3GAT1	0.98	13.21	0.52	4.73e-34	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs2287838	0.704	rs12977419	chr19:10000199	T/C	cg07950397	chr19:10022659	OLFM2	0.29	6.68	0.3	6.85e-11	Sleep duration;
LGG	cis	rs5771225	0.505	rs5771111	chr22:50695946	C/G	cg08875078	chr22:50639485	SELO	0.47	6.75	0.3	4.38e-11	Late-onset Alzheimer's disease;
LGG	cis	rs10504229	0.953	rs75545548	chr8:58172816	T/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	trans	rs9329221	0.736	rs34381075	chr8:10243785	C/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.17	0.32	2.95e-12	Neuroticism;
LGG	cis	rs1552244	0.935	rs66493421	chr3:10092569	G/A	cg08888203	chr3:10149979	C3orf24	0.59	9.39	0.4	2.72e-19	Alzheimer's disease;
LGG	cis	rs7662987	0.517	rs2602883	chr4:100040914	A/T	cg12011299	chr4:100065546	ADH4	0.4	7.86	0.34	2.69e-14	Smoking initiation;
LGG	cis	rs7119	0.717	rs16968835	chr15:77734261	G/A	cg05673287	chr15:77411982	SGK269	-0.43	-9.13	-0.39	2.21e-18	Type 2 diabetes;
LGG	cis	rs597539	0.652	rs501799	chr11:68631240	G/T	cg06028808	chr11:68637592	NA	0.75	13.21	0.52	5.15e-34	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs738322	0.718	rs3761445	chr22:38595411	G/A	cg25457927	chr22:38595422	NA	0.5	13.41	0.53	6.86e-35	Cutaneous nevi;
LGG	cis	rs9560113	1.000	rs60374273	chr13:112179206	A/T	cg10483660	chr13:112241077	NA	0.36	7.03	0.31	7.22e-12	Menarche (age at onset);
LGG	cis	rs11252926	0.502	rs7072510	chr10:455596	C/T	cg16386425	chr10:429943	DIP2C	-0.47	-9.84	-0.42	7.24e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs11874712	1.000	rs8089150	chr18:43674300	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs490234	0.676	rs1129	chr9:128199873	A/G	cg14078157	chr9:128172775	NA	0.53	10.02	0.42	1.59e-21	Mean arterial pressure;
LGG	cis	rs2404602	0.647	rs4886837	chr15:77156417	A/G	cg15268244	chr15:77196840	NA	0.47	10.17	0.43	4.58e-22	Blood metabolite levels;
LGG	cis	rs988958	0.565	rs13030999	chr2:42237410	T/C	cg27428208	chr2:42229179	NA	0.5	7.56	0.33	2.23e-13	Hypospadias;
LGG	cis	rs888194	0.690	rs7964021	chr12:109997645	G/C	cg19025524	chr12:109796872	NA	-0.35	-6.95	-0.31	1.28e-11	Neuroticism;
LGG	cis	rs6495122	0.644	rs11630087	chr15:75261673	G/T	cg09165964	chr15:75287851	SCAMP5	0.64	12.23	0.49	5.36e-30	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs9322193	0.923	rs2342765	chr6:150180009	C/G	cg16507663	chr6:150244633	RAET1G	0.43	8.13	0.35	4.02e-15	Lung cancer;
LGG	cis	rs11098499	0.691	rs9307471	chr4:120261262	G/A	cg24375607	chr4:120327624	NA	0.53	9.01	0.39	5.51e-18	Corneal astigmatism;
LGG	cis	rs1577917	0.917	rs35738006	chr6:86646309	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.77	-13.58	-0.53	1.31e-35	Response to antipsychotic treatment;
LGG	trans	rs7937682	0.632	rs11214037	chr11:111773296	C/T	cg18187862	chr3:45730750	SACM1L	-0.59	-9.55	-0.41	7.53e-20	Primary sclerosing cholangitis;
LGG	cis	rs240764	0.658	rs9390681	chr6:101218994	A/T	cg09795085	chr6:101329169	ASCC3	-0.47	-8.15	-0.35	3.52e-15	Neuroticism;
LGG	cis	rs10861342	1.000	rs2888841	chr12:105493750	C/T	cg23923672	chr12:105501055	KIAA1033	0.79	6.68	0.3	6.7e-11	IgG glycosylation;
LGG	trans	rs629535	0.821	rs660144	chr8:70035629	T/C	cg21567404	chr3:27674614	NA	0.4	6.66	0.3	7.57e-11	Dupuytren's disease;
LGG	cis	rs988958	0.565	rs56407905	chr2:42236607	G/A	cg19376973	chr2:42229025	NA	0.67	9.5	0.4	1.1e-19	Hypospadias;
LGG	cis	rs9906944	0.933	rs9906710	chr17:47091283	C/A	cg10950924	chr17:47092072	IGF2BP1	-0.36	-6.72	-0.3	5.27e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs2243480	1.000	rs34136756	chr7:65381256	A/G	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs9322193	0.923	rs12526675	chr6:150050676	A/C	cg05861140	chr6:150128134	PCMT1	0.44	10.06	0.42	1.16e-21	Lung cancer;
LGG	cis	rs7149337	0.780	rs4369569	chr14:51689181	C/G	cg23942311	chr14:51606299	NA	-0.39	-8.7	-0.37	5.95e-17	Cancer;
LGG	cis	rs5743618	0.537	rs7694115	chr4:38779094	A/G	cg06935464	chr4:38784597	TLR10	0.37	6.7	0.3	5.97e-11	Asthma;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs9393777	0.513	rs9368450	chr6:26652489	A/C	cg12826209	chr6:26865740	GUSBL1	0.83	12.27	0.5	3.8e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10851411	0.606	rs11635889	chr15:42818987	T/C	cg21293051	chr15:42870591	STARD9	0.49	6.94	0.31	1.33e-11	Glucose homeostasis traits;
LGG	cis	rs7107174	1.000	rs4245459	chr11:78065959	T/G	cg02023728	chr11:77925099	USP35	0.46	7.86	0.34	2.79e-14	Testicular germ cell tumor;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg08219700	chr8:58056026	NA	0.45	7.05	0.31	6.48e-12	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18173830	chr6:4776623	CDYL	0.55	8.92	0.38	1.09e-17	Gut microbiome composition (summer);
LGG	cis	rs11785400	0.762	rs1137522	chr8:143739020	A/C	cg10596483	chr8:143751796	JRK	0.52	8.15	0.35	3.52e-15	Schizophrenia;
LGG	cis	rs9952991	0.941	rs9952749	chr18:12780456	A/G	cg23544223	chr18:12777786	NA	0.62	9.4	0.4	2.49e-19	Inflammatory skin disease;
LGG	cis	rs7659604	0.540	rs67150579	chr4:122704331	T/A	cg20573242	chr4:122745356	CCNA2	-0.46	-7.89	-0.34	2.18e-14	Type 2 diabetes;
LGG	cis	rs2271404	0.506	rs12989775	chr2:111998827	C/G	cg23466623	chr2:111982296	NA	-0.35	-6.77	-0.3	3.91e-11	Atopic dermatitis;
LGG	cis	rs7737355	0.898	rs32109	chr5:131041590	C/T	cg06307176	chr5:131281290	NA	0.56	9.32	0.4	4.74e-19	Life satisfaction;
LGG	cis	rs7937682	0.681	rs7107378	chr11:111401840	C/A	cg09085632	chr11:111637200	PPP2R1B	0.71	12.42	0.5	9.16e-31	Primary sclerosing cholangitis;
LGG	trans	rs12579753	0.827	rs7311917	chr12:82187551	G/T	cg07923666	chr12:49932857	KCNH3	-0.52	-7.86	-0.34	2.7e-14	Resting heart rate;
LGG	trans	rs330048	0.545	rs719409	chr8:9151226	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.3	0.36	1.13e-15	Systemic lupus erythematosus;
LGG	cis	rs1707322	0.686	rs2991987	chr1:46081422	C/G	cg03146154	chr1:46216737	IPP	-0.57	-11.05	-0.46	2.26e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs2439831	0.681	rs540031	chr15:43608855	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	12.5	0.5	4.41e-31	Lung cancer in ever smokers;
LGG	trans	rs6601327	0.641	rs12155819	chr8:9572679	A/G	cg02002194	chr4:3960332	NA	0.39	7.11	0.31	4.57e-12	Multiple myeloma (hyperdiploidy);
LGG	cis	rs4555082	0.957	rs2816608	chr14:105718407	A/G	cg27165867	chr14:105738592	BRF1	0.47	8.34	0.36	8.4e-16	Mean platelet volume;Platelet distribution width;
LGG	cis	rs6952808	0.692	rs60755037	chr7:2030104	G/A	cg18279126	chr7:2041391	MAD1L1	0.32	6.65	0.3	8.36e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs7412746	0.658	rs7526489	chr1:150726238	C/T	cg15448220	chr1:150897856	SETDB1	0.39	7.3	0.32	1.24e-12	Melanoma;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24399406	chr17:33895357	NA	-0.42	-7.11	-0.31	4.38e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs9302635	0.515	rs36033103	chr16:72142038	G/T	cg08717414	chr16:71523259	ZNF19	-0.69	-7.0	-0.31	8.96e-12	Blood protein levels;
LGG	trans	rs6582630	0.531	rs3850000	chr12:38483752	T/C	cg06521331	chr12:34319734	NA	-0.5	-8.86	-0.38	1.72e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9460578	0.673	rs4645410	chr6:20873848	A/G	cg13405222	chr6:20811065	CDKAL1	0.64	11.26	0.46	3.56e-26	Breast cancer;
LGG	cis	rs28386778	0.863	rs9207	chr17:61823899	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs4076764	0.958	rs12022261	chr1:163398422	A/G	cg24596788	chr1:163392923	NA	-0.72	-13.75	-0.54	2.59e-36	Motion sickness;
LGG	cis	rs3789045	0.615	rs11240748	chr1:204453320	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.42	-8.94	-0.38	9.6e-18	Educational attainment (college completion);
LGG	trans	rs2243480	1.000	rs4718270	chr7:65202407	A/G	cg10756647	chr7:56101905	PSPH	0.82	9.8	0.41	9.84e-21	Diabetic kidney disease;
LGG	cis	rs7811142	0.887	rs111972532	chr7:100069088	T/C	cg11814155	chr7:99998594	ZCWPW1	0.61	9.37	0.4	3.1e-19	Platelet count;
LGG	cis	rs2050392	0.517	rs603072	chr10:30755778	C/T	cg25182066	chr10:30743637	MAP3K8	0.65	13.66	0.54	6.21e-36	Inflammatory bowel disease;
LGG	trans	rs1459104	1.000	rs34696917	chr11:55190939	C/T	cg15704280	chr7:45808275	SEPT13	0.71	6.82	0.3	2.81e-11	Body mass index;
LGG	cis	rs10782582	0.569	rs4549990	chr1:76125075	A/G	cg03433033	chr1:76189801	ACADM	-0.44	-7.0	-0.31	9.13e-12	Daytime sleep phenotypes;
LGG	cis	rs10504229	0.639	rs66667899	chr8:58117065	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.62	-0.44	9.93e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs4846217	1.000	rs6679596	chr1:10454502	A/T	cg17425144	chr1:10567563	PEX14	-0.58	-7.83	-0.34	3.25e-14	Platelet count;
LGG	cis	rs62064224	0.738	rs2344972	chr17:30633671	G/C	cg25809561	chr17:30822961	MYO1D	0.33	7.56	0.33	2.22e-13	Schizophrenia;
LGG	cis	rs6867032	1.000	rs7729761	chr5:2015783	G/T	cg26168224	chr5:2018326	NA	1.29	31.33	0.82	1.82e-116	Gut microbiome composition (winter);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg01061025	chr1:212209225	INTS7;DTL	0.48	7.74	0.34	6.19e-14	Cognitive performance;
LGG	cis	rs17641971	0.684	rs7005693	chr8:49987965	A/C	cg00325661	chr8:49890786	NA	0.57	10.91	0.45	7.94e-25	Blood metabolite levels;
LGG	trans	rs7819412	0.549	rs28887839	chr8:11000413	C/T	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.82	-0.3	2.8e-11	Triglycerides;
LGG	cis	rs9611565	0.559	rs1006407	chr22:41972032	T/C	cg17376030	chr22:41985996	PMM1	0.67	10.15	0.43	5.31e-22	Vitiligo;
LGG	cis	rs28595532	0.545	rs17594782	chr4:119250877	G/T	cg21605333	chr4:119757512	SEC24D	0.72	8.22	0.36	2.03e-15	Cannabis dependence symptom count;
LGG	cis	rs736408	0.774	rs4687551	chr3:52823448	C/T	cg14092988	chr3:52407081	DNAH1	-0.31	-8.18	-0.36	2.82e-15	Bipolar disorder;
LGG	cis	rs10463316	0.894	rs1876619	chr5:150744773	G/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.4	-0.44	6.41e-23	Metabolite levels (Pyroglutamine);
LGG	cis	rs6977660	0.714	rs10251774	chr7:19790489	T/C	cg05791153	chr7:19748676	TWISTNB	0.77	10.31	0.43	1.47e-22	Thyroid stimulating hormone;
LGG	cis	rs8048589	0.558	rs35208076	chr16:12228169	C/T	cg02910054	chr16:12241554	SNX29	0.65	9.98	0.42	2.26e-21	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs9644630	0.901	rs13276417	chr8:19350199	C/T	cg01280390	chr8:19363452	CSGALNACT1	0.6	16.9	0.62	2.84e-50	Oropharynx cancer;
LGG	cis	rs7607369	0.526	rs10498060	chr2:219431291	G/A	cg01130898	chr2:219473002	PLCD4	0.47	6.73	0.3	5.15e-11	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs8177253	1.000	rs8177248	chr3:133479626	C/T	cg08048268	chr3:133502702	NA	-0.6	-11.14	-0.46	1.05e-25	Iron status biomarkers;
LGG	cis	rs9487094	0.644	rs13201430	chr6:109956050	C/T	cg01125227	chr6:109776195	MICAL1	0.42	7.45	0.33	4.65e-13	Height;
LGG	cis	rs12887734	0.524	rs12888002	chr14:104238647	T/C	cg24130564	chr14:104152367	KLC1	-0.37	-6.7	-0.3	6.09e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs17301259	0.548	rs4728772	chr7:88403590	G/C	cg24975898	chr7:88426025	ZNF804B;MGC26647	-0.32	-7.08	-0.31	5.43e-12	Heschl's gyrus morphology;
LGG	cis	rs9341808	0.683	rs7771449	chr6:80919977	C/T	cg08355045	chr6:80787529	NA	0.41	7.88	0.34	2.44e-14	Sitting height ratio;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg26268016	chr7:112580305	C7orf60	-0.5	-7.34	-0.32	9.7e-13	Systemic lupus erythematosus;
LGG	cis	rs4237845	0.551	rs116263297	chr12:58273445	A/C	cg00677455	chr12:58241039	CTDSP2	0.4	7.22	0.32	2.09e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.680	rs16921675	chr8:58052082	A/G	cg21724239	chr8:58056113	NA	0.47	7.03	0.31	7.54e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.569	rs13242290	chr7:66121885	G/A	cg11764359	chr7:65958608	NA	-0.71	-12.83	-0.51	1.92e-32	Aortic root size;
LGG	cis	rs10915437	0.515	rs4408122	chr1:4197418	A/G	cg27165836	chr1:4193882	NA	-0.38	-7.46	-0.33	4.22e-13	Migraine - clinic-based;
LGG	cis	rs17767392	0.958	rs35760654	chr14:71983757	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.21	-0.39	1.11e-18	Mitral valve prolapse;
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg23758822	chr17:41437982	NA	0.88	15.59	0.59	2.31e-44	Menopause (age at onset);
LGG	cis	rs1799949	1.000	rs8176145	chr17:41249094	A/G	cg18379455	chr17:41446167	NA	-0.31	-7.08	-0.31	5.34e-12	Menopause (age at onset);
LGG	cis	rs1153858	1.000	rs2467863	chr15:45641880	G/A	cg21132104	chr15:45694354	SPATA5L1	0.73	11.19	0.46	6.85e-26	Homoarginine levels;
LGG	cis	rs7098414	0.511	rs4934126	chr10:82151598	A/G	cg00277334	chr10:82204260	NA	-0.34	-7.55	-0.33	2.33e-13	Post bronchodilator FEV1;
LGG	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg19507638	chr5:93509721	C5orf36	-0.71	-9.93	-0.42	3.53e-21	Diabetic retinopathy;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00648153	chr6:74364149	SLC17A5	0.56	8.68	0.37	6.71e-17	Gut microbiome composition (summer);
LGG	cis	rs9467773	0.525	rs1535274	chr6:26520747	A/C	cg11502198	chr6:26597334	ABT1	0.73	13.34	0.53	1.46e-34	Intelligence (multi-trait analysis);
LGG	trans	rs6582630	0.519	rs11495373	chr12:38275470	T/C	cg06521331	chr12:34319734	NA	-0.51	-8.88	-0.38	1.43e-17	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9783347	0.621	rs4150589	chr11:18360251	C/T	cg03595886	chr11:18357587	GTF2H1	-0.5	-12.51	-0.5	4.07e-31	Pancreatic cancer;
LGG	cis	rs2073300	0.609	rs2281428	chr20:23400050	C/T	cg12062639	chr20:23401060	NAPB	0.93	9.05	0.39	3.99e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs561341	0.556	rs542244	chr17:30307242	T/C	cg00745463	chr17:30367425	LRRC37B	-0.74	-10.62	-0.44	1.01e-23	Hip circumference adjusted for BMI;
LGG	cis	rs6732160	0.809	rs13387480	chr2:73371007	C/T	cg01422370	chr2:73384389	NA	0.54	10.46	0.44	3.8e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.719	rs11841989	chr13:24997698	C/A	cg22771759	chr13:24902376	NA	0.43	7.44	0.33	5.09e-13	Obesity-related traits;
LGG	cis	rs62064224	0.589	rs2344976	chr17:30685935	T/C	cg18200150	chr17:30822561	MYO1D	0.47	9.06	0.39	3.58e-18	Schizophrenia;
LGG	trans	rs66573146	0.656	rs57454756	chr4:6958582	C/T	cg07817883	chr1:32538562	TMEM39B	1.4	12.85	0.51	1.54e-32	Granulocyte percentage of myeloid white cells;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg05754148	chr16:3507555	NAT15	0.41	7.4	0.33	6.57e-13	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs7817188	chr8:58129549	C/T	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs17376456	0.569	rs1026279	chr5:93209581	C/A	cg25358565	chr5:93447407	FAM172A	-0.84	-11.59	-0.47	1.88e-27	Diabetic retinopathy;
LGG	cis	rs10911363	0.659	rs7518244	chr1:183434807	C/T	cg23894439	chr1:183413866	NA	-0.49	-9.1	-0.39	2.65e-18	Systemic lupus erythematosus;
LGG	cis	rs2016266	0.784	rs10747666	chr12:53716836	G/A	cg04065151	chr12:53682969	ESPL1	-0.57	-9.71	-0.41	2.11e-20	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs7208859	0.673	rs11655623	chr17:29162173	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.11	-0.31	4.34e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs8060686	0.641	rs76501820	chr16:68114582	G/A	cg27539214	chr16:67997921	SLC12A4	-0.49	-7.61	-0.33	1.56e-13	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs4295623	0.559	rs4841600	chr8:11688148	T/C	cg27411982	chr8:10470053	RP1L1	0.4	6.73	0.3	5.04e-11	Morning vs. evening chronotype;
LGG	cis	rs10782582	0.593	rs2147039	chr1:76143166	C/T	cg03433033	chr1:76189801	ACADM	-0.44	-6.95	-0.31	1.27e-11	Daytime sleep phenotypes;
LGG	trans	rs28735056	0.620	rs12456484	chr18:77677315	C/G	cg05926928	chr17:57297772	GDPD1	0.52	8.66	0.37	7.84e-17	Schizophrenia;
LGG	cis	rs651907	0.535	rs35810977	chr3:101531380	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.19	0.49	8.01e-30	Colorectal cancer;
LGG	cis	rs72945132	0.882	rs12294540	chr11:70118973	A/T	cg14191688	chr11:70257035	CTTN	0.53	7.62	0.33	1.49e-13	Coronary artery disease;
LGG	cis	rs7666738	0.861	rs13139309	chr4:99020916	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.4	0.36	5.7e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg08847335	chr10:891726	LARP4B	-0.51	-9.14	-0.39	1.9e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04436714	chr1:90309218	LRRC8D	0.54	8.29	0.36	1.24e-15	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg00106254	chr7:1943704	MAD1L1	-0.44	-7.48	-0.33	3.86e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs425277	0.585	rs3107157	chr1:2061969	A/G	cg21442419	chr1:2182373	SKI	0.46	8.84	0.38	1.99e-17	Height;
LGG	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06481639	chr22:41940642	POLR3H	0.56	8.43	0.36	4.35e-16	Cannabis dependence symptom count;
LGG	cis	rs55863869	0.748	rs7585334	chr2:179620951	C/T	cg02880032	chr2:179629472	TTN	-0.47	-6.69	-0.3	6.45e-11	QT interval;
LGG	trans	rs7746199	0.736	rs17749927	chr6:27669976	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.7	-0.37	5.75e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs9354308	0.868	rs8180586	chr6:66548669	C/G	cg07460842	chr6:66804631	NA	-0.47	-7.94	-0.35	1.6e-14	Metabolite levels;
LGG	cis	rs867371	1.000	rs4778982	chr15:82475272	T/G	cg00614314	chr15:82944287	LOC80154	0.59	9.66	0.41	3.2e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs2153535	0.553	rs2984099	chr6:8637274	C/T	cg23788917	chr6:8435910	SLC35B3	-0.68	-9.8	-0.41	9.64e-21	Motion sickness;
LGG	cis	rs2371030	0.965	rs4673548	chr2:211571627	T/C	cg18417063	chr2:211583084	NA	-0.64	-12.47	-0.5	5.69e-31	Non-small cell lung cancer;
LGG	cis	rs17666538	0.585	rs1669733	chr8:606696	C/T	cg23958373	chr8:599963	NA	-1.2	-12.14	-0.49	1.19e-29	IgG glycosylation;
LGG	cis	rs1978968	1.000	rs5013014	chr22:18449927	T/C	cg03078520	chr22:18463400	MICAL3	-0.63	-12.67	-0.51	8.35e-32	Presence of antiphospholipid antibodies;
LGG	cis	rs11971779	0.941	rs7800795	chr7:139080348	A/G	cg07862535	chr7:139043722	LUC7L2	0.67	10.2	0.43	3.69e-22	Diisocyanate-induced asthma;
LGG	cis	rs12477438	0.520	rs2171359	chr2:99795360	T/C	cg08885076	chr2:99613938	TSGA10	0.43	9.3	0.4	5.52e-19	Chronic sinus infection;
LGG	cis	rs1799949	1.000	rs1960605	chr17:41305397	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.55	0.33	2.33e-13	Menopause (age at onset);
LGG	cis	rs4423214	0.592	rs79634040	chr11:71230169	G/C	cg10847948	chr11:71163743	NADSYN1	0.58	8.77	0.38	3.57e-17	Vitamin D levels;
LGG	cis	rs243505	0.660	rs3807451	chr7:148538622	T/C	cg18940274	chr7:148469757	CUL1	-0.35	-6.74	-0.3	4.86e-11	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2228479	0.541	rs9806913	chr16:89953773	A/G	cg06558623	chr16:89946397	TCF25	0.92	11.97	0.49	5.89e-29	Skin colour saturation;
LGG	cis	rs7020830	0.898	rs13289199	chr9:37278064	A/T	cg14294708	chr9:37120828	ZCCHC7	1.13	31.37	0.82	1.18e-116	Schizophrenia;
LGG	cis	rs11967485	0.614	rs62435825	chr6:157178775	C/A	cg23222435	chr6:157204239	ARID1B	-0.79	-7.26	-0.32	1.66e-12	Calcium levels;
LGG	cis	rs12291225	0.679	rs10832240	chr11:14304744	C/T	cg19336497	chr11:14380999	RRAS2	-0.58	-11.74	-0.48	4.68e-28	Sense of smell;
LGG	cis	rs4356932	1.000	rs4371639	chr4:76946569	G/T	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.71	-0.3	5.66e-11	Blood protein levels;
LGG	cis	rs2964802	0.505	rs7715280	chr5:10809219	C/T	cg14521931	chr5:10832172	NA	-0.75	-16.51	-0.61	1.76e-48	Major depressive disorder;Recurrent major depressive disorder;
LGG	cis	rs972578	0.791	rs4820503	chr22:43408940	C/T	cg01576275	chr22:43409880	NA	-0.26	-7.88	-0.34	2.37e-14	Mean platelet volume;
LGG	cis	rs899997	1.000	rs12899940	chr15:79001699	A/G	cg14912033	chr15:79043428	NA	0.41	10.46	0.44	3.85e-23	Coronary artery disease or large artery stroke;
LGG	cis	rs1799949	0.930	rs1554063	chr17:41287145	T/C	cg23758822	chr17:41437982	NA	0.84	15.05	0.57	5.67e-42	Menopause (age at onset);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13393964	chr16:20753279	THUMPD1	0.47	7.37	0.32	7.98e-13	Gut microbiome composition (summer);
LGG	cis	rs714515	0.934	rs9425299	chr1:172359100	C/T	cg01573306	chr1:172330400	DNM3	0.33	7.4	0.33	6.49e-13	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs4774899	0.932	rs12902581	chr15:57553384	A/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.28	-0.32	1.47e-12	Urinary tract infection frequency;
LGG	cis	rs1799949	0.965	rs34633610	chr17:41419385	A/G	cg25172604	chr17:41446521	NA	-0.3	-6.83	-0.3	2.6e-11	Menopause (age at onset);
LGG	trans	rs3857536	0.813	rs9354403	chr6:66943426	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.45	-7.73	-0.34	6.9e-14	Blood trace element (Cu levels);
LGG	cis	rs4919687	0.679	rs12762176	chr10:104499232	A/T	cg25143771	chr10:104629124	AS3MT	0.38	6.69	0.3	6.5500000000000006e-11	Colorectal cancer;
LGG	cis	rs11628318	0.713	rs1998419	chr14:103050397	C/G	cg12046867	chr14:103022105	NA	-0.81	-15.71	-0.59	6.73e-45	Platelet count;
LGG	cis	rs7614311	0.681	rs12631045	chr3:63856085	T/C	cg22134162	chr3:63841271	THOC7	-0.36	-6.94	-0.31	1.36e-11	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs1008375	1.000	rs10011865	chr4:17645710	G/A	cg15017067	chr4:17643749	FAM184B	0.31	7.33	0.32	1.06e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7937890	0.874	rs2303972	chr11:14303282	T/A	cg02251663	chr11:14281053	SPON1	0.35	8.58	0.37	1.41e-16	Mitochondrial DNA levels;
LGG	cis	rs798554	0.679	rs11973498	chr7:2886873	C/A	cg14668632	chr7:2872130	GNA12	-0.33	-6.94	-0.31	1.34e-11	Height;
LGG	cis	rs1003719	0.751	rs55740803	chr21:38542761	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.26	-0.58	6.85e-43	Eye color traits;
LGG	cis	rs13126513	0.708	rs883028	chr4:100451375	A/G	cg05468953	chr4:100565104	NA	0.4	8.06	0.35	6.72e-15	Metabolite levels (MHPG);
LGG	cis	rs6800768	0.633	rs60635484	chr3:24101328	G/A	cg10674438	chr3:24145617	LOC152024	-0.48	-8.74	-0.38	4.43e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs657075	0.697	rs71583478	chr5:131688824	C/T	cg06968155	chr5:131705112	SLC22A5	0.76	8.71	0.38	5.37e-17	Rheumatoid arthritis;
LGG	cis	rs793571	0.590	rs4775094	chr15:59115995	A/G	cg05156742	chr15:59063176	FAM63B	0.58	9.73	0.41	1.75e-20	Schizophrenia;
LGG	cis	rs4969178	0.965	rs8071889	chr17:76398101	A/G	cg05887092	chr17:76393375	PGS1	0.72	15.72	0.59	6.1e-45	HDL cholesterol levels;
LGG	cis	rs7208859	0.623	rs9916725	chr17:29107471	A/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4430311	0.723	rs7551241	chr1:243943907	A/G	cg25706552	chr1:244017396	NA	-0.65	-15.93	-0.6	6.95e-46	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs1799949	1.000	rs33920795	chr17:41329010	A/G	cg23758822	chr17:41437982	NA	0.87	15.46	0.58	9.35e-44	Menopause (age at onset);
LGG	trans	rs1814175	0.645	rs28454367	chr11:50045708	G/A	cg03929089	chr4:120376271	NA	-0.94	-19.86	-0.68	5.8e-64	Height;
LGG	cis	rs10504229	0.581	rs10108204	chr8:58150472	T/A	cg21724239	chr8:58056113	NA	0.7	15.6	0.59	2.21e-44	Developmental language disorder (linguistic errors);
LGG	cis	rs10186029	0.582	rs12052695	chr2:214003559	G/T	cg08319019	chr2:214017104	IKZF2	0.4	7.12	0.31	4.12e-12	Systemic sclerosis;
LGG	cis	rs3008870	0.755	rs3929738	chr1:67397865	T/C	cg02640540	chr1:67518911	SLC35D1	0.38	7.4	0.33	6.26e-13	Lymphocyte percentage of white cells;
LGG	trans	rs1005277	0.579	rs1780130	chr10:38485378	T/A	cg23533926	chr12:111358616	MYL2	-0.41	-6.82	-0.3	2.88e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs13108904	0.650	rs3796618	chr4:1349602	T/A	cg23835219	chr4:1244017	CTBP1;C4orf42	0.55	9.71	0.41	2.14e-20	Obesity-related traits;
LGG	cis	rs35306767	0.903	rs34270014	chr10:904666	T/C	cg26597838	chr10:835615	NA	0.74	10.06	0.42	1.12e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs6732160	0.845	rs11894833	chr2:73388418	G/T	cg01422370	chr2:73384389	NA	-0.54	-10.65	-0.44	7.56e-24	Intelligence (multi-trait analysis);
LGG	cis	rs7582720	1.000	rs72934764	chr2:203758521	C/A	cg15057621	chr2:203777863	WDR12;ALS2CR8	0.81	9.77	0.41	1.28e-20	Coronary artery disease or ischemic stroke;Coronary artery disease or large artery stroke;
LGG	cis	rs9549367	0.789	rs9549715	chr13:113908240	G/C	cg00898013	chr13:113819073	PROZ	-0.43	-8.6	-0.37	1.2e-16	Platelet distribution width;
LGG	cis	rs11785400	0.793	rs9774627	chr8:143731267	G/A	cg10596483	chr8:143751796	JRK	0.51	7.96	0.35	1.3e-14	Schizophrenia;
LGG	cis	rs6951245	1.000	rs113066613	chr7:1094128	T/C	cg26224354	chr7:1096374	C7orf50;GPR146	-1.12	-20.93	-0.7	6.35e-69	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1552244	1.000	rs17032276	chr3:10076975	A/C	cg08888203	chr3:10149979	C3orf24	0.57	9.54	0.41	8.44e-20	Alzheimer's disease;
LGG	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg27523141	chr10:43048294	ZNF37B	0.42	8.32	0.36	9.93e-16	Extrinsic epigenetic age acceleration;
LGG	trans	rs7824557	0.843	rs2736375	chr8:11115749	C/T	cg16141378	chr3:129829833	LOC729375	0.41	9.19	0.39	1.35e-18	Retinal vascular caliber;
LGG	cis	rs367615	0.704	rs6889301	chr5:108835181	C/T	cg17395555	chr5:108820864	NA	0.88	15.99	0.6	3.69e-46	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs11877825	0.826	rs9676146	chr18:10571489	A/T	cg25239095	chr18:10589360	NA	0.49	9.06	0.39	3.68e-18	Gut microbiota (bacterial taxa);
LGG	cis	rs950027	0.620	rs1426932	chr15:45687256	T/C	cg26924012	chr15:45694286	SPATA5L1	0.67	12.04	0.49	3.07e-29	Response to fenofibrate (adiponectin levels);
LGG	cis	rs6460942	0.915	rs6966791	chr7:12439714	T/C	cg06484146	chr7:12443880	VWDE	-0.41	-7.16	-0.32	3.2e-12	Coronary artery disease;
LGG	cis	rs7843479	0.930	rs4871903	chr8:21827833	C/T	cg17168535	chr8:21777572	XPO7	-0.57	-9.23	-0.39	9.99e-19	Mean corpuscular volume;
LGG	cis	rs4740619	0.689	rs1410445	chr9:15927816	G/A	cg14451791	chr9:16040625	NA	-0.41	-10.32	-0.43	1.31e-22	Body mass index;
LGG	cis	rs7811142	0.830	rs7341507	chr7:99951315	A/G	cg23667466	chr7:100026434	MEPCE;ZCWPW1	0.96	14.26	0.55	1.74e-38	Platelet count;
LGG	cis	rs372883	0.648	rs4817279	chr21:30638285	T/C	cg24692254	chr21:30365293	RNF160	-0.65	-11.84	-0.48	2.02e-28	Pancreatic cancer;
LGG	cis	rs11098499	0.820	rs28578366	chr4:120536905	A/G	cg24375607	chr4:120327624	NA	-0.64	-10.58	-0.44	1.45e-23	Corneal astigmatism;
LGG	trans	rs7819412	0.806	rs2898256	chr8:10932695	G/C	cg02002194	chr4:3960332	NA	0.43	7.83	0.34	3.39e-14	Triglycerides;
LGG	cis	rs897984	0.553	rs2335013	chr16:30877346	T/G	cg00531865	chr16:30841666	NA	0.55	10.58	0.44	1.42e-23	Dementia with Lewy bodies;
LGG	cis	rs60843830	1.000	rs3791221	chr2:226933	A/G	cg00108164	chr2:264199	ACP1;SH3YL1	0.5	8.51	0.37	2.48e-16	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs11169552	0.580	rs7134976	chr12:51010092	T/C	cg12884762	chr12:50931848	DIP2B	-0.41	-7.66	-0.34	1.12e-13	Colorectal cancer;
LGG	cis	rs11227306	0.934	rs2303385	chr11:65640562	G/A	cg26695010	chr11:65641043	EFEMP2	0.5	8.28	0.36	1.31e-15	DNA methylation (variation);
LGG	cis	rs9393813	1.000	rs6913166	chr6:27355460	C/T	cg18711553	chr6:27366782	ZNF391	-0.52	-9.6	-0.41	5.19e-20	Bipolar disorder;
LGG	cis	rs7847628	0.587	rs10760117	chr9:123586737	T/G	cg09419670	chr9:123605666	PSMD5;LOC253039	1.1	31.26	0.82	3.75e-116	Birth weight;
LGG	cis	rs7829975	0.742	rs1533059	chr8:8684953	A/G	cg06636001	chr8:8085503	FLJ10661	-0.5	-9.16	-0.39	1.62e-18	Mood instability;
LGG	cis	rs4262150	0.705	rs72804800	chr5:152330518	C/T	cg12297329	chr5:152029980	NA	-0.68	-11.2	-0.46	6.04e-26	Bipolar disorder and schizophrenia;
LGG	cis	rs769267	0.965	rs2916068	chr19:19516433	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.15	0.55	4.92e-38	Tonsillectomy;
LGG	trans	rs4332037	0.950	rs10267593	chr7:1937261	G/A	cg10840412	chr1:235813424	GNG4	0.6	8.15	0.35	3.52e-15	Bipolar disorder;
LGG	cis	rs6500395	1.000	rs11643264	chr16:48558462	A/G	cg04672837	chr16:48644449	N4BP1	0.52	8.55	0.37	1.81e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	trans	rs2898290	0.622	rs978804	chr8:11343673	C/T	cg02002194	chr4:3960332	NA	0.49	9.48	0.4	1.35e-19	Systolic blood pressure;
LGG	cis	rs11190604	1.000	rs10883512	chr10:102308516	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	12.12	0.49	1.53e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs4819052	0.851	rs1056100	chr21:46678711	A/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.51	8.47	0.37	3.28e-16	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs56775891	1.000	rs6650631	chr18:77566535	G/C	cg24058013	chr18:77568902	NA	-0.46	-7.48	-0.33	3.79e-13	Schizophrenia;
LGG	trans	rs7726839	0.561	rs3915384	chr5:573395	G/T	cg25482853	chr8:67687455	SGK3	0.79	10.65	0.44	7.62e-24	Obesity-related traits;
LGG	cis	rs12477438	0.520	rs2516830	chr2:99773702	T/G	cg08885076	chr2:99613938	TSGA10	0.37	8.13	0.35	4.08e-15	Chronic sinus infection;
LGG	cis	rs1059312	1.000	rs3825180	chr12:129279242	A/G	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.78	17.36	0.63	2.37e-52	Systemic lupus erythematosus;
LGG	cis	rs1729951	0.575	rs1682333	chr3:136688618	G/A	cg21827317	chr3:136751795	NA	0.53	10.02	0.42	1.64e-21	Neuroticism;
LGG	cis	rs1008375	0.966	rs2315645	chr4:17579678	G/C	cg07005078	chr4:17578674	LAP3	0.38	6.99	0.31	9.6e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs41271473	0.687	rs13349	chr1:228881129	A/G	cg16512390	chr1:228756714	NA	0.43	6.87	0.3	2.07e-11	Chronic lymphocytic leukemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10324419	chr4:175205038	FBXO8;KIAA1712	0.48	7.37	0.32	8.15e-13	Gut microbiome composition (summer);
LGG	cis	rs10979	0.571	rs9386039	chr6:143916992	A/T	cg25407410	chr6:143891975	LOC285740	0.52	7.53	0.33	2.72e-13	Hypospadias;
LGG	cis	rs9815354	0.812	rs73081372	chr3:41917993	C/T	cg03022575	chr3:42003672	ULK4	0.81	9.48	0.4	1.3e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6831352	1.000	rs6837685	chr4:100049145	G/A	cg13256891	chr4:100009986	ADH5	0.55	9.73	0.41	1.7e-20	Alcohol dependence;
LGG	cis	rs2851682	0.572	rs174570	chr11:61597212	C/T	cg19610905	chr11:61596333	FADS2	-0.61	-7.54	-0.33	2.56e-13	Gestational age at birth (child effect);Trans fatty acid levels;
LGG	cis	rs28386778	0.704	rs1051688	chr17:62006433	G/C	cg07362569	chr17:61921086	SMARCD2	-0.41	-7.7	-0.34	8.34e-14	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs2873638	chr8:58114593	G/A	cg02725872	chr8:58115012	NA	-1.05	-15.39	-0.58	1.83e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs9902453	0.904	rs4077465	chr17:28300144	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	13.94	0.54	3.88e-37	Coffee consumption (cups per day);
LGG	cis	rs6076065	0.723	rs1419009	chr20:23365094	G/A	cg12633918	chr20:23549525	CST9L	-0.35	-6.65	-0.3	8.19e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs4716602	0.596	rs10244786	chr7:156157989	C/T	cg16983916	chr7:156159713	NA	-0.48	-9.3	-0.4	5.53e-19	Anti-saccade response;
LGG	cis	rs6933660	0.745	rs9322320	chr6:151751908	C/G	cg17179660	chr6:151773299	C6orf211;RMND1	-0.49	-8.49	-0.37	2.84e-16	Menarche (age at onset);
LGG	cis	rs57502260	0.679	rs72936524	chr11:68275898	G/A	cg01657329	chr11:68192670	LRP5	-0.57	-7.23	-0.32	2.05e-12	Total body bone mineral density (age 45-60);
LGG	cis	rs6696846	0.740	rs12125465	chr1:205074854	C/A	cg00857998	chr1:205179979	DSTYK	0.56	9.04	0.39	4.32e-18	Red blood cell count;
LGG	cis	rs68170813	0.559	rs1989814	chr7:107045076	A/G	cg02696742	chr7:106810147	HBP1	-0.75	-10.42	-0.44	5.59e-23	Coronary artery disease;
LGG	cis	rs72945132	0.769	rs3781644	chr11:70190375	G/A	cg00319359	chr11:70116639	PPFIA1	0.72	7.76	0.34	5.31e-14	Coronary artery disease;
LGG	cis	rs12421382	0.614	rs11213102	chr11:109385853	G/A	cg04861929	chr11:109293070	C11orf87	0.52	9.61	0.41	4.75e-20	Schizophrenia;
LGG	cis	rs7267979	0.934	rs2261753	chr20:25262291	G/A	cg06421707	chr20:25228305	PYGB	0.47	10.2	0.43	3.65e-22	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg26224354	chr7:1096374	C7orf50;GPR146	-1.13	-21.17	-0.7	4.72e-70	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9381040	0.655	rs2268192	chr6:41024626	T/C	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.12	-0.31	4.17e-12	Alzheimer's disease (late onset);
LGG	cis	rs1153858	0.943	rs28605551	chr15:45641720	C/T	cg10760299	chr15:45669010	GATM	0.4	7.97	0.35	1.23e-14	Homoarginine levels;
LGG	cis	rs6459788	0.685	rs13226469	chr7:157235777	G/A	cg06271696	chr7:157225062	NA	-0.58	-12.42	-0.5	9.4e-31	Epstein-Barr virus copy number in lymphoblastoid cell lines;
LGG	cis	rs559928	0.606	rs11231726	chr11:63987339	C/T	cg18225595	chr11:63971243	STIP1	0.54	7.28	0.32	1.44e-12	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	trans	rs916888	0.647	rs199449	chr17:44808902	G/A	cg04703951	chr17:43578652	NA	0.29	6.67	0.3	7.48e-11	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1046896	0.594	rs67813226	chr17:80851134	G/A	cg08200770	chr17:80723486	TBCD	-0.48	-8.33	-0.36	9.33e-16	Glycated hemoglobin levels;
LGG	cis	rs8060686	0.641	rs1125332	chr16:68227780	A/G	cg04539111	chr16:67997858	SLC12A4	-0.42	-6.71	-0.3	5.68e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs12477438	0.765	rs2309521	chr2:99592069	C/T	cg08885076	chr2:99613938	TSGA10	-0.5	-10.56	-0.44	1.65e-23	Chronic sinus infection;
LGG	cis	rs4853012	0.941	rs60291089	chr2:74344890	T/G	cg05890377	chr2:74357713	NA	0.49	9.83	0.42	8.01e-21	Gestational age at birth (maternal effect);
LGG	cis	rs10256972	0.684	rs4724039	chr7:1111633	A/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.53	-0.33	2.74e-13	Longevity;Endometriosis;
LGG	cis	rs875971	0.767	rs61348003	chr7:66005934	C/T	cg23594656	chr7:65796392	TPST1	-0.42	-9.26	-0.4	7.64e-19	Aortic root size;
LGG	trans	rs11650494	0.908	rs9907478	chr17:47395729	C/T	cg11430096	chr6:110968061	CDK19	0.68	7.08	0.31	5.42e-12	Prostate cancer;
LGG	cis	rs7647973	0.580	rs12629759	chr3:49237394	T/C	cg06212747	chr3:49208901	KLHDC8B	0.74	13.19	0.52	5.99e-34	Menarche (age at onset);
LGG	cis	rs11874712	1.000	rs9945606	chr18:43673325	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.49	-10.67	-0.44	6.8e-24	Migraine - clinic-based;
LGG	cis	rs17021463	0.844	rs17311008	chr4:95274653	A/G	cg11021082	chr4:95130006	SMARCAD1	0.48	8.7	0.37	5.71e-17	Testicular germ cell tumor;
LGG	cis	rs523522	0.962	rs10774549	chr12:120891172	C/T	cg12219531	chr12:120966889	COQ5	0.66	10.77	0.45	2.68e-24	High light scatter reticulocyte count;
LGG	cis	rs6500395	0.926	rs9929569	chr16:48677584	C/T	cg16662043	chr16:48846231	NA	0.37	7.24	0.32	1.89e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2204008	0.560	rs1315354	chr12:38165716	A/G	cg04568710	chr12:38710424	ALG10B	-0.37	-7.87	-0.34	2.52e-14	Bladder cancer;
LGG	cis	rs67133203	0.606	rs10747602	chr12:51435629	C/G	cg14688905	chr12:51403056	SLC11A2	-0.5	-8.4	-0.36	5.66e-16	Urinary tract infection frequency;
LGG	cis	rs7727544	0.582	rs6896703	chr5:131521295	C/G	cg07395648	chr5:131743802	NA	0.4	8.62	0.37	1.05e-16	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13764828	chr3:10547555	ATP2B2	0.45	7.07	0.31	5.63e-12	Gut microbiome composition (summer);
LGG	cis	rs9403521	0.673	rs7748882	chr6:143991712	T/C	cg18240653	chr6:144019428	PHACTR2	-0.61	-10.68	-0.44	5.96e-24	Obesity-related traits;
LGG	cis	rs34044649	0.840	rs1675567	chr7:155651011	C/T	cg17395211	chr7:155654226	NA	-0.38	-7.24	-0.32	1.93e-12	Triptolide cytotoxicity;
LGG	cis	rs6784615	0.744	rs13071708	chr3:52322680	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.69	7.65	0.33	1.21e-13	Waist-hip ratio;
LGG	cis	rs9660992	0.542	rs17345153	chr1:205179997	A/G	cg00857998	chr1:205179979	DSTYK	0.57	9.04	0.39	4.31e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs1790761	0.559	rs10896190	chr11:67406123	T/C	cg01069141	chr11:67398826	TBX10;NUDT8	0.42	8.0	0.35	9.8e-15	Mean corpuscular volume;
LGG	cis	rs721399	0.553	rs10095072	chr8:18244662	G/T	cg18736775	chr8:18248649	NAT2	-0.72	-11.95	-0.49	6.88e-29	Blood metabolite levels;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg08127348	chr19:17448311	GTPBP3	0.49	7.46	0.33	4.36e-13	Gut microbiome composition (summer);
LGG	trans	rs877282	1.000	rs12773872	chr10:771939	T/C	cg22713356	chr15:30763199	NA	0.57	8.59	0.37	1.34e-16	Uric acid levels;
LGG	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg02273617	chr15:68117586	LBXCOR1	-0.32	-7.18	-0.32	2.75e-12	Restless legs syndrome;
LGG	cis	rs62238980	0.522	rs79367011	chr22:32450245	G/T	cg02631450	chr22:32366979	NA	0.98	9.35	0.4	3.84e-19	Childhood ear infection;
LGG	cis	rs868036	0.718	rs8030456	chr15:68076856	C/T	cg05925327	chr15:68127851	NA	-0.38	-7.75	-0.34	5.99e-14	Restless legs syndrome;
LGG	cis	rs1691799	0.867	rs1039056	chr12:66760391	C/T	cg16791601	chr12:66731901	HELB	-0.65	-15.16	-0.58	1.94e-42	White blood cell count (basophil);
LGG	cis	rs8114671	0.562	rs6120739	chr20:33405227	A/G	cg24642439	chr20:33292090	TP53INP2	0.45	7.25	0.32	1.75e-12	Height;
LGG	cis	rs6952808	0.792	rs12536261	chr7:1953571	G/A	cg04267008	chr7:1944627	MAD1L1	-0.76	-13.96	-0.54	3.38e-37	Bipolar disorder and schizophrenia;
LGG	trans	rs1005277	0.579	rs2472183	chr10:38392495	T/G	cg25373794	chr1:162760220	HSD17B7	-0.43	-6.91	-0.31	1.66e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7255436	0.898	rs7252574	chr19:8441779	C/T	cg10811474	chr19:8428787	ANGPTL4	-0.38	-6.8	-0.3	3.3e-11	HDL cholesterol;
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg16920238	chr17:80076378	CCDC57	-0.32	-7.3	-0.32	1.25e-12	Life satisfaction;
LGG	cis	rs78456975	0.739	rs72776248	chr2:1521314	A/G	cg26248373	chr2:1572462	NA	-0.68	-8.35	-0.36	8.16e-16	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6502050	0.871	rs6502051	chr17:80059332	A/C	cg16920238	chr17:80076378	CCDC57	0.34	7.91	0.35	1.86e-14	Life satisfaction;
LGG	cis	rs4906332	1.000	rs55930273	chr14:103960298	G/A	cg26031613	chr14:104095156	KLC1	-0.5	-7.61	-0.33	1.6e-13	Coronary artery disease;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs6831352	0.918	rs4699713	chr4:100060513	C/T	cg12011299	chr4:100065546	ADH4	-0.43	-8.64	-0.37	8.97e-17	Alcohol dependence;
LGG	cis	rs3096299	0.658	rs12443705	chr16:89547054	C/G	cg08392591	chr16:89556376	ANKRD11	0.62	9.94	0.42	3.16e-21	Multiple myeloma (IgH translocation);
LGG	cis	rs2739330	0.791	rs4822458	chr22:24265659	C/T	cg25703541	chr22:24373054	LOC391322	-0.89	-17.71	-0.64	5.95e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs3785574	0.962	rs2584621	chr17:61912436	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	1.15	27.69	0.79	2.8e-100	Height;
LGG	cis	rs2120019	0.935	rs34835684	chr15:75331805	T/G	cg17294928	chr15:75287854	SCAMP5	-0.97	-18.32	-0.65	8.65e-57	Blood trace element (Zn levels);
LGG	cis	rs7762018	0.891	rs3088346	chr6:170149793	T/C	cg17545662	chr6:170176663	C6orf70	0.66	8.57	0.37	1.5e-16	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs6121246	0.909	rs6119651	chr20:30259246	G/T	cg21427119	chr20:30132790	HM13	-0.41	-7.13	-0.31	3.93e-12	Mean corpuscular hemoglobin;
LGG	cis	rs9388451	0.626	rs7748729	chr6:126077381	C/T	cg05901451	chr6:126070800	HEY2	-0.69	-13.19	-0.52	5.94e-34	Brugada syndrome;
LGG	cis	rs9322193	0.962	rs62441335	chr6:150113794	G/A	cg11878867	chr6:150167359	LRP11	-0.49	-10.02	-0.42	1.59e-21	Lung cancer;
LGG	cis	rs7089973	0.966	rs55711292	chr10:116604870	T/G	cg08188268	chr10:116634841	FAM160B1	0.32	6.82	0.3	2.88e-11	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs13118159	0.550	rs4974612	chr4:1364543	A/G	cg05025164	chr4:1340916	KIAA1530	0.89	17.6	0.63	1.88e-53	Longevity;
LGG	cis	rs13108904	0.967	rs12502916	chr4:1276349	G/A	cg04863758	chr4:1303710	MAEA	-0.4	-6.82	-0.3	2.9e-11	Obesity-related traits;
LGG	trans	rs6952808	0.771	rs10244946	chr7:1921068	A/G	cg24247370	chr13:99142703	STK24	0.39	7.19	0.32	2.55e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs2842992	0.672	rs7738253	chr6:160193917	G/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.78	13.08	0.52	1.69e-33	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs8060686	0.641	rs79323429	chr16:68084594	A/G	cg27539214	chr16:67997921	SLC12A4	-0.48	-7.46	-0.33	4.17e-13	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3768617	0.510	rs2027078	chr1:183073478	G/A	cg07245641	chr1:182991651	LAMC1	0.4	9.11	0.39	2.46e-18	Fuchs's corneal dystrophy;
LGG	cis	rs8114671	0.836	rs745849	chr20:33572178	G/A	cg24642439	chr20:33292090	TP53INP2	-0.52	-8.38	-0.36	6.36e-16	Height;
LGG	cis	rs7011049	0.841	rs7819865	chr8:53870344	C/A	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs1790761	0.632	rs625978	chr11:67344664	C/T	cg14500267	chr11:67383377	NA	0.45	8.5	0.37	2.56e-16	Mean corpuscular volume;
LGG	cis	rs7017914	0.967	rs34677078	chr8:71617715	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs13108904	0.710	rs11937232	chr4:1207597	G/C	cg16399632	chr4:1244006	CTBP1;C4orf42	0.6	11.42	0.47	8.49e-27	Obesity-related traits;
LGG	cis	rs2576037	0.523	rs590923	chr18:44404259	G/C	cg26155939	chr18:44337853	ST8SIA5	-0.39	-7.13	-0.31	3.89e-12	Personality dimensions;
LGG	cis	rs4639966	0.589	rs480958	chr11:118577990	G/A	cg00145757	chr11:118478637	PHLDB1	0.43	7.49	0.33	3.54e-13	Systemic lupus erythematosus;
LGG	cis	rs3857747	0.827	rs4364550	chr7:40458304	A/G	cg00420559	chr7:40367873	C7orf10	-0.38	-7.82	-0.34	3.54e-14	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs11155671	0.530	rs4870080	chr6:150202644	T/C	cg16507663	chr6:150244633	RAET1G	0.49	9.96	0.42	2.67e-21	Testicular germ cell tumor;
LGG	trans	rs11098499	0.874	rs10022508	chr4:120115228	A/G	cg25214090	chr10:38739885	LOC399744	0.61	10.69	0.44	5.28e-24	Corneal astigmatism;
LGG	cis	rs4987668	0.867	rs4987605	chr7:142582725	T/C	cg19410471	chr7:142636507	C7orf34	0.46	6.69	0.3	6.54e-11	Cancer;
LGG	cis	rs7552404	1.000	rs211723	chr1:76103030	C/T	cg22875332	chr1:76189707	ACADM	-0.62	-9.8	-0.41	1e-20	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1005277	0.579	rs176886	chr10:38403974	C/T	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.53e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs4851266	0.702	rs11123820	chr2:100871186	A/G	cg21926883	chr2:100939477	LONRF2	-0.46	-8.19	-0.36	2.54e-15	Educational attainment;
LGG	cis	rs9463078	0.691	rs1852986	chr6:45329489	C/G	cg25276700	chr6:44698697	NA	-0.32	-6.64	-0.3	8.55e-11	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs2841277	0.708	rs10083496	chr14:105402786	G/A	cg17340268	chr14:105411764	AHNAK2	-0.39	-7.38	-0.32	7.38e-13	Rheumatoid arthritis;
LGG	cis	rs7923837	0.865	rs35978445	chr10:94424422	G/A	cg25093409	chr10:94429542	NA	0.35	6.66	0.3	7.58e-11	Body mass index;Multiple sclerosis;
LGG	cis	rs2228479	0.867	rs62052187	chr16:89973071	G/A	cg19635926	chr16:89946313	TCF25	0.72	8.42	0.36	4.86e-16	Skin colour saturation;
LGG	cis	rs10504229	1.000	rs59383954	chr8:58189689	G/A	cg14926445	chr8:58193284	C8orf71	-0.93	-13.64	-0.54	7.76e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs9324022	0.584	rs72698722	chr14:101181881	C/T	cg18089426	chr14:101175970	NA	0.66	11.91	0.48	1.03e-28	Plateletcrit;
LGG	cis	rs523522	0.962	rs12309824	chr12:120990582	A/C	cg12219531	chr12:120966889	COQ5	0.66	11.06	0.46	2.08e-25	High light scatter reticulocyte count;
LGG	cis	rs1978968	0.731	rs9605467	chr22:18461166	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.86	-0.54	8.45e-37	Presence of antiphospholipid antibodies;
LGG	cis	rs1153858	1.000	rs4534782	chr15:45652933	G/A	cg26924012	chr15:45694286	SPATA5L1	1.05	22.61	0.72	8.4e-77	Homoarginine levels;
LGG	cis	rs56283067	0.578	rs2894641	chr6:45393174	A/G	cg18551225	chr6:44695536	NA	-0.55	-7.97	-0.35	1.29e-14	Total body bone mineral density;
LGG	cis	rs2011503	1.000	rs45631651	chr19:19638743	A/G	cg11584989	chr19:19387371	SF4	0.74	12.1	0.49	1.79e-29	Bipolar disorder;
LGG	cis	rs9399135	0.967	rs1014020	chr6:135334426	C/A	cg24558204	chr6:135376177	HBS1L	0.52	9.46	0.4	1.62e-19	Red blood cell count;
LGG	cis	rs950169	0.920	rs2135551	chr15:84707851	A/G	cg24253500	chr15:84953950	NA	0.59	10.79	0.45	2.24e-24	Schizophrenia;
LGG	cis	rs308971	0.572	rs307559	chr3:12094965	G/T	cg15873301	chr3:12045459	SYN2	0.54	7.82	0.34	3.51e-14	Fasting blood insulin (BMI interaction);
LGG	cis	rs1620921	0.563	rs2489936	chr6:161280325	C/T	cg01280913	chr6:161186852	NA	-0.36	-7.19	-0.32	2.6e-12	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs7829975	0.840	rs572366	chr8:8578794	A/T	cg02002194	chr4:3960332	NA	-0.48	-8.97	-0.38	7.17e-18	Mood instability;
LGG	cis	rs2576037	0.583	rs12386118	chr18:44540376	C/G	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.56	11.21	0.46	5.83e-26	Personality dimensions;
LGG	trans	rs2204008	0.623	rs1607878	chr12:38376000	A/G	cg06521331	chr12:34319734	NA	-0.52	-9.56	-0.41	7.12e-20	Bladder cancer;
LGG	cis	rs537930	0.925	rs299377	chr5:134344902	A/G	cg24576358	chr5:134350122	NA	0.48	10.19	0.43	3.78e-22	Height;
LGG	cis	rs2243480	1.000	rs10807702	chr7:65767843	C/T	cg13147721	chr7:65941812	NA	-0.84	-9.95	-0.42	2.77e-21	Diabetic kidney disease;
LGG	cis	rs3858526	0.883	rs11039686	chr11:5948725	T/C	cg05234568	chr11:5960015	NA	-0.7	-11.7	-0.48	7.03e-28	DNA methylation (variation);
LGG	cis	rs76419734	0.510	rs28391170	chr4:106629246	A/C	cg11477892	chr4:106580295	NA	-0.43	-6.89	-0.3	1.82e-11	Post bronchodilator FEV1;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07840538	chr7:99097998	ZNF394	0.44	7.68	0.34	9.75e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs155076	1.000	rs261423	chr13:21852331	A/C	cg14456004	chr13:21872349	NA	-1.17	-18.37	-0.65	5.09e-57	White matter hyperintensity burden;
LGG	cis	rs796364	0.806	rs76568708	chr2:200929531	C/T	cg17644776	chr2:200775616	C2orf69	-0.61	-6.99	-0.31	9.57e-12	Schizophrenia;
LGG	cis	rs9420907	0.579	rs1977230	chr10:105656616	G/A	cg11005552	chr10:105648138	OBFC1	0.66	7.05	0.31	6.62e-12	Telomere length;
LGG	cis	rs12368653	0.701	rs238517	chr12:58117737	T/G	cg20892847	chr12:58011875	NA	0.32	6.66	0.3	7.93e-11	Multiple sclerosis;
LGG	cis	rs11098499	0.863	rs34308924	chr4:120481431	T/C	cg24375607	chr4:120327624	NA	0.67	11.14	0.46	1.09e-25	Corneal astigmatism;
LGG	trans	rs7824557	0.836	rs765731	chr8:11121498	T/A	cg02002194	chr4:3960332	NA	0.47	8.63	0.37	9.61e-17	Retinal vascular caliber;
LGG	cis	rs4262150	0.726	rs4958567	chr5:152015597	T/G	cg12297329	chr5:152029980	NA	-0.83	-17.25	-0.63	7.75e-52	Bipolar disorder and schizophrenia;
LGG	cis	rs17270561	0.583	rs6937800	chr6:25765943	A/G	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs9325144	0.555	rs2387855	chr12:38687964	T/G	cg04568710	chr12:38710424	ALG10B	0.4	8.71	0.38	5.24e-17	Morning vs. evening chronotype;
LGG	cis	rs2841277	0.676	rs10438247	chr14:105411781	G/A	cg15352829	chr14:105391018	PLD4	-0.47	-11.4	-0.47	1.09e-26	Rheumatoid arthritis;
LGG	cis	rs10220309	0.501	rs1491504	chr14:80638440	G/T	cg08183125	chr14:80678293	DIO2	-0.44	-6.97	-0.31	1.12e-11	Lung function (FEV1);
LGG	cis	rs3857747	0.861	rs10263494	chr7:40428906	G/A	cg00420559	chr7:40367873	C7orf10	0.36	7.18	0.32	2.71e-12	3-hydroxypropylmercapturic acid levels in smokers;
LGG	cis	rs3735485	0.800	rs2079321	chr7:45044313	C/A	cg03440944	chr7:45023329	C7orf40	0.55	9.59	0.41	5.59e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs11630290	1.000	rs72750987	chr15:63999112	G/C	cg12036633	chr15:63758958	NA	-0.63	-8.7	-0.37	6.03e-17	Iris characteristics;
LGG	cis	rs7737355	0.853	rs7730810	chr5:130781179	T/C	cg06307176	chr5:131281290	NA	-0.51	-8.51	-0.37	2.42e-16	Life satisfaction;
LGG	cis	rs295140	0.566	rs295141	chr2:201163556	C/T	cg23649088	chr2:200775458	C2orf69	-0.4	-7.01	-0.31	8.7e-12	QT interval;
LGG	cis	rs7614311	0.681	rs6801346	chr3:63947128	A/G	cg22134162	chr3:63841271	THOC7	0.43	7.71	0.34	7.6e-14	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs11785400	0.793	rs35985277	chr8:143736137	C/T	cg24634471	chr8:143751801	JRK	0.5	7.74	0.34	6.48e-14	Schizophrenia;
LGG	cis	rs2832191	0.755	rs2832193	chr21:30493589	T/C	cg08807101	chr21:30365312	RNF160	-0.83	-16.61	-0.61	6.41e-49	Dental caries;
LGG	cis	rs1506636	1.000	rs652497	chr7:123423671	G/T	cg03229431	chr7:123269106	ASB15	0.73	17.88	0.64	9.97e-55	Plateletcrit;Platelet count;
LGG	cis	rs644799	0.965	rs502521	chr11:95533557	T/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.51e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs11603023	0.874	rs577396	chr11:118499469	C/G	cg19006130	chr11:118478252	PHLDB1	0.4	7.09	0.31	5.01e-12	Cholesterol, total;
LGG	cis	rs2228479	0.557	rs62054639	chr16:89821489	C/T	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs7208859	0.614	rs216412	chr17:28903394	A/G	cg01831904	chr17:28903510	LRRC37B2	0.92	12.26	0.5	3.99e-30	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2204008	0.837	rs11612125	chr12:38213212	C/T	cg26384229	chr12:38710491	ALG10B	0.97	22.09	0.72	2.26e-74	Bladder cancer;
LGG	cis	rs9790314	0.521	rs13084731	chr3:161086020	G/A	cg03342759	chr3:160939853	NMD3	-0.61	-10.47	-0.44	3.7e-23	Morning vs. evening chronotype;
LGG	cis	rs2839186	0.656	rs8128380	chr21:47665693	C/T	cg12016809	chr21:47604291	C21orf56	0.43	6.99	0.31	9.59e-12	Testicular germ cell tumor;
LGG	cis	rs6951245	0.572	rs60918895	chr7:1039036	C/T	cg02733842	chr7:1102375	C7orf50	0.68	8.1	0.35	5.02e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg24654547	chr16:68057165	DUS2L;DDX28	0.47	7.94	0.35	1.51e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs881375	0.678	rs10760129	chr9:123700183	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.54	9.99	0.42	2e-21	Rheumatoid arthritis;
LGG	cis	rs6952808	0.531	rs73039217	chr7:2178731	G/A	cg11050988	chr7:1952600	MAD1L1	-0.31	-7.24	-0.32	1.94e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs7607369	0.637	rs3888879	chr2:219290676	C/T	cg10223061	chr2:219282414	VIL1	0.4	8.74	0.38	4.42e-17	Red blood cell count;Amyotrophic lateral sclerosis;
LGG	cis	rs11764590	0.756	rs17132130	chr7:2108036	G/C	cg02951883	chr7:2050386	MAD1L1	0.43	7.02	0.31	8.17e-12	Neuroticism;
LGG	cis	rs9322193	0.847	rs9383844	chr6:150037404	T/C	cg12070911	chr6:150209640	RAET1E	0.31	7.65	0.33	1.18e-13	Lung cancer;
LGG	cis	rs6495122	0.699	rs12905199	chr15:75070196	A/G	cg20040747	chr15:74715105	SEMA7A	0.41	8.97	0.38	7.55e-18	Caffeine consumption;Diastolic blood pressure;Coffee consumption;
LGG	cis	rs2658782	0.951	rs72972364	chr11:93122128	C/T	cg15737290	chr11:93063684	CCDC67	-0.55	-7.86	-0.34	2.67e-14	Pulmonary function decline;
LGG	cis	rs7833790	0.724	rs1054078	chr8:82712153	A/G	cg23324259	chr8:82754387	SNX16	-0.39	-6.75	-0.3	4.54e-11	Diastolic blood pressure;
LGG	cis	rs9322193	0.923	rs2297932	chr6:150039361	C/G	cg16507663	chr6:150244633	RAET1G	0.47	8.92	0.38	1.11e-17	Lung cancer;
LGG	cis	rs6920965	0.507	rs4285341	chr6:126205589	T/G	cg05901451	chr6:126070800	HEY2	-0.49	-8.61	-0.37	1.11e-16	High light scatter reticulocyte count;
LGG	cis	rs6866344	0.570	rs11740283	chr5:178136440	T/C	cg03877680	chr5:178157825	ZNF354A	0.81	14.02	0.55	1.71e-37	Neutrophil percentage of white cells;
LGG	cis	rs8056893	0.921	rs2863979	chr16:68331890	G/A	cg07273125	chr16:68295692	NA	0.36	6.83	0.3	2.63e-11	Blood metabolite ratios;Glomerular filtration rate (creatinine);Blood metabolite levels;
LGG	cis	rs7208859	0.623	rs28627615	chr17:29145817	G/C	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9398803	0.830	rs2039735	chr6:126745076	T/C	cg19875578	chr6:126661172	C6orf173	0.58	10.47	0.44	3.66e-23	Male-pattern baldness;
LGG	cis	rs3733585	0.699	rs4276278	chr4:9948870	T/C	cg11266682	chr4:10021025	SLC2A9	-0.42	-8.14	-0.35	3.66e-15	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs503734	0.653	rs4683917	chr3:101186025	C/A	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg20645649	chr9:127624485	RPL35	0.44	7.09	0.31	5.13e-12	Gut microbiome composition (summer);
LGG	cis	rs798554	0.680	rs2533889	chr7:2900309	G/C	cg05793240	chr7:2802953	GNA12	0.36	8.52	0.37	2.24e-16	Height;
LGG	cis	rs13421350	0.579	rs56892098	chr2:173303065	C/T	cg15021238	chr2:173305865	ITGA6	-0.82	-9.11	-0.39	2.44e-18	Diabetic kidney disease;
LGG	trans	rs61931739	0.500	rs12146843	chr12:34451738	T/G	cg13010199	chr12:38710504	ALG10B	0.64	12.88	0.51	1.12e-32	Morning vs. evening chronotype;
LGG	cis	rs4660214	0.666	rs2275188	chr1:39748921	G/A	cg18385671	chr1:39797026	MACF1	-0.45	-9.53	-0.4	9.11e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00307073	chr7:116502428	CAPZA2	0.49	7.61	0.33	1.54e-13	Gut microbiome composition (summer);
LGG	cis	rs947211	0.948	rs863725	chr1:205751196	C/T	cg26354017	chr1:205819088	PM20D1	0.47	7.85	0.34	2.86e-14	Parkinson's disease;
LGG	trans	rs7939886	0.920	rs12221509	chr11:56045987	C/T	cg15704280	chr7:45808275	SEPT13	0.81	7.54	0.33	2.47e-13	Myopia (pathological);
LGG	cis	rs13108904	0.935	rs1680072	chr4:1281695	T/G	cg13395646	chr4:1353034	KIAA1530	0.49	8.24	0.36	1.72e-15	Obesity-related traits;
LGG	cis	rs2380220	0.678	rs4308568	chr6:96009525	A/C	cg04719120	chr6:96025338	MANEA	-0.52	-7.48	-0.33	3.65e-13	Behavioural disinhibition (generation interaction);
LGG	cis	rs7633770	0.841	rs11130100	chr3:46679198	A/T	cg11219411	chr3:46661640	NA	-0.61	-14.89	-0.57	2.87e-41	Coronary artery disease;
LGG	cis	rs6500602	1.000	rs11647946	chr16:4462836	G/A	cg10063637	chr16:4524514	NMRAL1;HMOX2	0.4	8.07	0.35	6.24e-15	Schizophrenia;
LGG	trans	rs2204008	0.604	rs2320521	chr12:38253789	A/G	cg06521331	chr12:34319734	NA	-0.51	-8.79	-0.38	2.93e-17	Bladder cancer;
LGG	trans	rs9467711	0.656	rs34961555	chr6:26199903	C/T	cg06606381	chr12:133084897	FBRSL1	-1.14	-9.6	-0.41	5e-20	Autism spectrum disorder or schizophrenia;
LGG	cis	rs11148252	0.532	rs9526975	chr13:53255804	C/T	cg22398616	chr13:53314203	LECT1	-0.38	-7.47	-0.33	3.9e-13	Lewy body disease;
LGG	cis	rs1018836	0.923	rs2157607	chr8:91600268	A/G	cg16814680	chr8:91681699	NA	-0.85	-15.9	-0.59	9.34e-46	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2404602	0.647	rs12904149	chr15:77043652	A/C	cg23625390	chr15:77176239	SCAPER	-0.71	-13.77	-0.54	2.1e-36	Blood metabolite levels;
LGG	cis	rs6502050	0.799	rs8069827	chr17:80089168	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.34	-0.32	9.48e-13	Life satisfaction;
LGG	cis	rs8054556	0.669	rs12931955	chr16:30013066	A/G	cg06326092	chr16:30034487	C16orf92	0.36	7.12	0.31	4.02e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9527	0.637	rs7085104	chr10:104628873	A/G	cg04362960	chr10:104952993	NT5C2	0.54	9.62	0.41	4.19e-20	Arsenic metabolism;
LGG	cis	rs2760061	0.626	rs2796057	chr1:228124414	G/C	cg01200585	chr1:228362443	C1orf69	-0.43	-7.68	-0.34	9.37e-14	Diastolic blood pressure;
LGG	trans	rs2553218	0.690	rs8032415	chr15:54851945	A/G	cg20979786	chr7:74072997	GTF2I	-0.4	-6.72	-0.3	5.4e-11	Immune response to smallpox vaccine (IL-6);
LGG	cis	rs12464559	0.649	rs3922997	chr2:152609704	C/T	cg01189475	chr2:152685088	ARL5A	0.75	6.71	0.3	5.77e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs9287719	0.967	rs4613248	chr2:10744051	C/T	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.23e-13	Prostate cancer;
LGG	cis	rs875971	0.830	rs778715	chr7:65849209	C/T	cg18252515	chr7:66147081	NA	-0.42	-7.03	-0.31	7.66e-12	Aortic root size;
LGG	cis	rs6500602	0.928	rs3747581	chr16:4462619	A/G	cg19168338	chr16:4465731	CORO7	-0.95	-18.9	-0.66	1.72e-59	Schizophrenia;
LGG	cis	rs6977660	1.000	rs13233821	chr7:19813637	A/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.55	0.33	2.37e-13	Thyroid stimulating hormone;
LGG	cis	rs7216064	1.000	rs58551145	chr17:65837235	A/G	cg12091567	chr17:66097778	LOC651250	-0.64	-9.38	-0.4	2.9e-19	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs3747547	0.892	rs1976936	chr9:37955433	G/A	cg13774184	chr9:37916125	SHB	-0.71	-6.99	-0.31	9.69e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs975739	0.902	rs977882	chr13:78372698	C/T	cg07847733	chr13:78271382	SLAIN1	0.37	6.74	0.3	4.84e-11	Hair color;
LGG	cis	rs9682041	0.569	rs11914970	chr3:170112307	T/G	cg11886554	chr3:170076028	SKIL	0.55	7.21	0.32	2.31e-12	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs736408	0.509	rs2590838	chr3:52622086	G/A	cg18099408	chr3:52552593	STAB1	-0.34	-7.05	-0.31	6.67e-12	Bipolar disorder;
LGG	cis	rs13118159	0.550	rs10016557	chr4:1363628	C/T	cg20743744	chr4:1243849	C4orf42;CTBP1	-0.41	-6.92	-0.31	1.55e-11	Longevity;
LGG	cis	rs11229555	0.645	rs12805062	chr11:58214584	A/G	cg15696309	chr11:58395628	NA	-0.95	-15.41	-0.58	1.54e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs9611565	0.592	rs5758406	chr22:42076641	A/G	cg17376030	chr22:41985996	PMM1	-0.59	-9.61	-0.41	4.79e-20	Vitiligo;
LGG	cis	rs13118159	0.550	rs11946956	chr4:1369094	T/G	cg26479374	chr4:1243980	CTBP1;C4orf42	0.41	7.16	0.32	3.15e-12	Longevity;
LGG	trans	rs9650657	0.589	rs6985109	chr8:10761585	A/G	cg15556689	chr8:8085844	FLJ10661	0.48	8.5	0.37	2.61e-16	Neuroticism;
LGG	cis	rs7822232	0.908	rs4977164	chr8:145144912	T/G	cg14631276	chr8:145163102	KIAA1875	-1.18	-11.22	-0.46	5.22e-26	Blood metabolite levels;
LGG	cis	rs3096299	0.748	rs2965822	chr16:89444677	A/T	cg06640241	chr16:89574553	SPG7	0.67	11.2	0.46	6.26e-26	Multiple myeloma (IgH translocation);
LGG	cis	rs929354	0.651	rs6951298	chr7:156949149	T/C	cg05182265	chr7:156933206	UBE3C	-0.36	-7.41	-0.33	6.05e-13	Body mass index;
LGG	cis	rs989128	0.600	rs9913677	chr17:48628581	T/A	cg20467136	chr17:48638190	CACNA1G	0.46	6.85	0.3	2.4e-11	Type 2 diabetes;
LGG	cis	rs4851266	0.966	rs13026283	chr2:100842638	C/T	cg21926883	chr2:100939477	LONRF2	-0.44	-7.97	-0.35	1.23e-14	Educational attainment;
LGG	cis	rs17767294	0.541	rs72845050	chr6:27610070	A/C	cg10122326	chr6:28072925	NA	0.89	6.94	0.31	1.36e-11	Parkinson's disease;
LGG	cis	rs9322193	0.884	rs9383864	chr6:150173105	T/C	cg11878867	chr6:150167359	LRP11	-0.59	-12.61	-0.51	1.45e-31	Lung cancer;
LGG	cis	rs36051895	0.632	rs10815166	chr9:5149920	T/G	cg02405213	chr9:5042618	JAK2	-0.76	-14.27	-0.55	1.47e-38	Pediatric autoimmune diseases;
LGG	trans	rs6076960	0.652	rs3843045	chr20:6264593	C/T	cg24759859	chr6:86352639	SYNCRIP	-0.41	-6.81	-0.3	3.09e-11	Smooth-surface caries;
LGG	trans	rs4332037	0.722	rs4719332	chr7:1914681	G/A	cg10840412	chr1:235813424	GNG4	0.56	7.38	0.32	7.39e-13	Bipolar disorder;
LGG	cis	rs1971762	0.527	rs7976398	chr12:54028862	T/C	cg06632207	chr12:54070931	ATP5G2	0.23	7.23	0.32	2.01e-12	Height;
LGG	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg06304787	chr16:88772962	CTU2;RNF166	0.64	7.45	0.33	4.76e-13	Autism spectrum disorder-related traits;
LGG	cis	rs9677476	0.774	rs1973016	chr2:232117513	C/G	cg23338755	chr2:231921595	PSMD1	0.45	6.74	0.3	4.87e-11	Food antigen IgG levels;
LGG	cis	rs4731207	0.967	rs3807544	chr7:124400705	G/A	cg05630886	chr7:124431682	NA	0.31	7.34	0.32	9.75e-13	Cutaneous malignant melanoma;
LGG	cis	rs12950390	0.776	rs4793646	chr17:45853966	A/C	cg00777063	chr17:45855553	NA	-0.32	-6.68	-0.3	6.76e-11	IgG glycosylation;
LGG	cis	rs208520	0.526	rs7776413	chr6:66783241	A/G	cg07460842	chr6:66804631	NA	-1.13	-30.69	-0.82	1.12e-113	Exhaled nitric oxide output;
LGG	cis	rs9368481	0.678	rs62402024	chr6:26923976	T/C	cg18867708	chr6:26865862	GUSBL1	0.44	7.17	0.32	3e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs780096	0.587	rs6760828	chr2:27579231	T/C	cg22903471	chr2:27725779	GCKR	-0.54	-12.29	-0.5	3.13e-30	Total body bone mineral density;
LGG	cis	rs703842	0.963	rs2069506	chr12:58142854	C/A	cg04478727	chr12:58166393	METTL1;FAM119B	0.51	7.91	0.35	1.86e-14	Multiple sclerosis;
LGG	cis	rs1153858	1.000	rs7181167	chr15:45686236	C/G	cg21132104	chr15:45694354	SPATA5L1	0.74	11.26	0.46	3.6e-26	Homoarginine levels;
LGG	cis	rs875971	0.862	rs2088653	chr7:65808608	G/A	cg18252515	chr7:66147081	NA	0.43	7.29	0.32	1.35e-12	Aortic root size;
LGG	cis	rs950776	0.518	rs2292117	chr15:78834689	C/T	cg17108064	chr15:78857060	CHRNA5	0.47	10.07	0.42	1.06e-21	Sudden cardiac arrest;
LGG	cis	rs911186	0.812	rs35454259	chr6:27254475	G/A	cg12292205	chr6:26970375	C6orf41	-0.49	-7.62	-0.33	1.44e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9611565	0.559	rs132761	chr22:42004371	C/T	cg06634786	chr22:41940651	POLR3H	0.79	12.59	0.51	1.82e-31	Vitiligo;
LGG	cis	rs7590368	0.706	rs56268818	chr2:10956011	C/T	cg15705551	chr2:10952987	PDIA6	0.58	7.56	0.33	2.26e-13	Educational attainment (years of education);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00085830	chr1:182808254	DHX9	0.45	7.53	0.33	2.73e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs1506636	1.000	rs614645	chr7:123442349	T/C	cg03229431	chr7:123269106	ASB15	0.72	16.37	0.61	7.81e-48	Plateletcrit;Platelet count;
LGG	cis	rs6466055	0.720	rs1204058	chr7:104958129	T/G	cg04380332	chr7:105027541	SRPK2	0.4	7.43	0.33	5.29e-13	Schizophrenia;
LGG	cis	rs10504229	1.000	rs73609760	chr8:58192170	A/G	cg11062466	chr8:58055876	NA	0.48	8.19	0.36	2.6e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs16921606	chr8:58034477	A/C	cg24829409	chr8:58192753	C8orf71	-0.61	-8.7	-0.37	5.86e-17	Developmental language disorder (linguistic errors);
LGG	trans	rs1005277	0.602	rs1831315	chr10:38473353	T/C	cg04469686	chr1:162760199	HSD17B7	-0.48	-7.8	-0.34	4.19e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs12580194	0.593	rs61071395	chr12:55721228	G/C	cg19537932	chr12:55886519	OR6C68	-0.52	-9.1	-0.39	2.77e-18	Cancer;
LGG	cis	rs6988985	0.818	rs3802228	chr8:143992218	A/G	cg10324643	chr8:143916377	GML	0.42	8.77	0.38	3.49e-17	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2842992	0.830	rs2495279	chr6:160138796	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.69	11.72	0.48	5.94e-28	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs2228479	1.000	rs2228479	chr16:89985940	G/A	cg06558623	chr16:89946397	TCF25	1.17	13.27	0.52	2.88e-34	Skin colour saturation;
LGG	trans	rs6142102	0.812	rs6120440	chr20:32517585	A/G	cg00789423	chr1:45241714	SNORD46;RPS8	0.46	6.96	0.31	1.15e-11	Skin pigmentation;
LGG	cis	rs12188164	0.931	rs72717407	chr5:424653	G/A	cg26076054	chr5:421317	AHRR	-0.48	-7.95	-0.35	1.48e-14	Cystic fibrosis severity;
LGG	cis	rs2270450	0.959	rs34964632	chr6:46648129	A/G	cg10156739	chr6:46714674	LOC100287718	-0.35	-8.27	-0.36	1.48e-15	Hashimoto thyroiditis versus Graves' disease;
LGG	cis	rs4242434	0.857	rs11777808	chr8:22462755	A/C	cg03733263	chr8:22462867	KIAA1967	1.12	32.64	0.83	3.64e-122	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs62244186	0.627	rs3935212	chr3:44460954	G/A	cg02073558	chr3:44770973	ZNF501	0.65	11.73	0.48	5.26e-28	Depressive symptoms;
LGG	trans	rs4130344	0.935	rs11725623	chr4:159732671	A/G	cg20256403	chr2:97523850	ANKRD39	-0.42	-7.37	-0.32	7.73e-13	Intelligence (multi-trait analysis);
LGG	trans	rs747782	0.585	rs1316604	chr11:48279796	G/A	cg15704280	chr7:45808275	SEPT13	0.74	8.69	0.37	6.53e-17	Intraocular pressure;
LGG	cis	rs10771431	0.597	rs10843144	chr12:9357577	C/T	cg00504896	chr12:9437009	LOC642846	-0.44	-8.15	-0.35	3.36e-15	Breast size;
LGG	cis	rs5758659	0.904	rs5758653	chr22:42613485	G/T	cg15128208	chr22:42549153	NA	-0.46	-8.94	-0.38	9.39e-18	Cognitive function;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08366277	chr3:172429092	NCEH1	0.4	6.67	0.3	7.37e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs10504229	0.683	rs11785258	chr8:58132893	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs477692	1.000	rs473073	chr10:131429646	G/T	cg05714579	chr10:131428358	MGMT	0.56	11.54	0.47	3e-27	Response to temozolomide;
LGG	cis	rs6500602	0.561	rs62039231	chr16:4519548	A/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.43	8.39	0.36	6.1e-16	Schizophrenia;
LGG	cis	rs1185460	0.804	rs13929	chr11:118915755	G/C	cg12636538	chr11:118901039	SLC37A4	0.47	9.34	0.4	3.97e-19	Coronary artery disease;
LGG	cis	rs2303745	0.589	rs8103523	chr19:17398269	A/G	cg04248312	chr19:17393744	ANKLE1	-0.66	-10.96	-0.45	5.02e-25	Systemic lupus erythematosus;
LGG	cis	rs9522267	0.535	rs9522296	chr13:112234340	C/T	cg10483660	chr13:112241077	NA	0.36	7.71	0.34	7.89e-14	Hepatitis;
LGG	cis	rs7811142	1.000	rs60844404	chr7:100080474	A/T	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.87	0.38	1.62e-17	Platelet count;
LGG	cis	rs2629540	0.586	rs10794183	chr10:126536609	G/C	cg08799069	chr10:126477246	METTL10	-0.62	-11.82	-0.48	2.31e-28	Cocaine dependence;
LGG	cis	rs11581903	0.568	rs6686035	chr1:53080008	A/C	cg19751897	chr1:52520827	TXNDC12;BTF3L4	0.6	7.83	0.34	3.28e-14	Joint mobility (Beighton score);
LGG	trans	rs1005277	0.579	rs2472176	chr10:38382921	T/C	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.43	-0.33	5.31e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs801193	0.569	rs6978178	chr7:66123084	G/A	cg12463550	chr7:65579703	CRCP	-0.49	-8.2	-0.36	2.4e-15	Aortic root size;
LGG	cis	rs1552244	0.872	rs7646073	chr3:10097405	G/A	cg00166722	chr3:10149974	C3orf24	0.53	8.9	0.38	1.25e-17	Alzheimer's disease;
LGG	cis	rs11711311	1.000	rs12632983	chr3:113481913	A/C	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.65	13.49	0.53	3.15e-35	IgG glycosylation;
LGG	cis	rs453301	0.653	rs7016139	chr8:8895470	A/G	cg15556689	chr8:8085844	FLJ10661	-0.43	-7.65	-0.34	1.17e-13	Joint mobility (Beighton score);
LGG	cis	rs9322193	0.962	rs9689269	chr6:150112997	G/A	cg12070911	chr6:150209640	RAET1E	0.29	6.94	0.31	1.36e-11	Lung cancer;
LGG	cis	rs11628318	0.802	rs6575926	chr14:103050183	G/A	cg01864069	chr14:103024347	NA	-0.75	-12.18	-0.49	8.78e-30	Platelet count;
LGG	cis	rs1865760	0.827	rs9461227	chr6:25960815	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	cis	rs2075371	0.611	rs11762920	chr7:134018514	C/T	cg11752832	chr7:134001865	SLC35B4	0.49	8.27	0.36	1.41e-15	Mean platelet volume;
LGG	cis	rs9291683	0.552	rs3796832	chr4:10015865	C/T	cg25986240	chr4:9926439	SLC2A9	-0.41	-8.61	-0.37	1.14e-16	Bone mineral density;
LGG	cis	rs62238980	0.614	rs5998272	chr22:32560045	A/C	cg02631450	chr22:32366979	NA	0.91	8.91	0.38	1.18e-17	Childhood ear infection;
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg06028808	chr11:68637592	NA	0.72	12.54	0.5	2.83e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs113835537	0.529	rs57207756	chr11:66270360	C/T	cg24851651	chr11:66362959	CCS	0.44	7.47	0.33	3.93e-13	Airway imaging phenotypes;
LGG	cis	rs2836974	0.931	rs8132285	chr21:40655752	T/C	cg11644478	chr21:40555479	PSMG1	0.91	17.91	0.64	6.87e-55	Cognitive function;
LGG	trans	rs853679	0.546	rs13195291	chr6:28169241	G/A	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs787274	1.000	rs787276	chr9:115551891	T/C	cg13803584	chr9:115635662	SNX30	-0.57	-7.86	-0.34	2.71e-14	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs6502050	0.835	rs4789722	chr17:80151881	G/A	cg13939156	chr17:80058883	NA	-0.44	-8.45	-0.37	3.9e-16	Life satisfaction;
LGG	cis	rs875971	0.964	rs60193905	chr7:65971260	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.7	-0.37	5.68e-17	Aortic root size;
LGG	cis	rs9322193	0.923	rs3798761	chr6:150004779	A/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.65	-0.44	8.03e-24	Lung cancer;
LGG	cis	rs834603	0.687	rs13231464	chr7:47481211	A/G	cg23694490	chr7:47445681	TNS3	0.45	12.34	0.5	1.91e-30	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9902453	0.817	rs12051834	chr17:28192785	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.69	13.69	0.54	4.48e-36	Coffee consumption (cups per day);
LGG	cis	rs10504229	0.679	rs7813252	chr8:58136389	C/G	cg11062466	chr8:58055876	NA	0.54	8.85	0.38	1.91e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs7681440	0.904	rs7680761	chr4:90763510	A/T	cg15133208	chr4:90757351	SNCA	-0.39	-8.9	-0.38	1.25e-17	Dementia with Lewy bodies;
LGG	cis	rs6940638	1.000	rs6940638	chr6:27046250	A/G	cg09904177	chr6:26538194	HMGN4	-0.58	-7.79	-0.34	4.38e-14	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.716	rs7164813	chr15:76708066	T/C	cg23625390	chr15:77176239	SCAPER	0.48	9.49	0.4	1.19e-19	Blood metabolite levels;
LGG	cis	rs151234	0.565	rs11401	chr16:28602991	A/G	cg01378222	chr16:28622494	SULT1A1	-0.57	-8.78	-0.38	3.1e-17	Platelet distribution width;
LGG	cis	rs926938	0.520	rs969273	chr1:115256669	G/A	cg12756093	chr1:115239321	AMPD1	-0.52	-9.37	-0.4	3.19e-19	Autism;
LGG	cis	rs2797369	0.656	rs609522	chr6:101350518	C/G	cg27451362	chr6:101846650	GRIK2	0.76	10.51	0.44	2.49e-23	Renal function-related traits (eGRFcrea);
LGG	cis	rs6732160	0.588	rs1430345	chr2:73370682	A/G	cg01422370	chr2:73384389	NA	0.57	9.93	0.42	3.47e-21	Intelligence (multi-trait analysis);
LGG	cis	rs2404602	0.735	rs2436996	chr15:76817420	C/T	cg15268244	chr15:77196840	NA	0.43	9.24	0.39	9.03e-19	Blood metabolite levels;
LGG	cis	rs7103648	0.603	rs3740688	chr11:47380340	G/T	cg20307385	chr11:47447363	PSMC3	0.68	13.62	0.53	9.59e-36	Diastolic blood pressure;Systolic blood pressure;
LGG	cis	rs2228479	0.702	rs2074903	chr16:89811663	T/C	cg04287289	chr16:89883240	FANCA	0.88	8.45	0.37	3.78e-16	Skin colour saturation;
LGG	cis	rs1371867	0.846	rs1660338	chr8:101242757	C/G	cg06636551	chr8:101224915	SPAG1	-0.48	-8.99	-0.39	6.2e-18	Atrioventricular conduction;
LGG	trans	rs12599106	0.660	rs12919333	chr16:34991336	C/T	cg01171360	chr6:293285	DUSP22	-0.58	-9.54	-0.41	8.1e-20	Menopause (age at onset);
LGG	cis	rs7122539	0.646	rs682842	chr11:66568943	A/G	cg01599099	chr11:66649832	PC	-0.38	-7.8	-0.34	4.17e-14	HIV-1 susceptibility;
LGG	cis	rs16937	0.711	rs6675633	chr1:205100480	G/A	cg00889227	chr1:205173544	DSTYK	-0.3	-7.4	-0.33	6.65e-13	Schizophrenia;
LGG	cis	rs3096299	0.719	rs2965818	chr16:89510494	A/G	cg08392591	chr16:89556376	ANKRD11	0.53	8.27	0.36	1.42e-15	Multiple myeloma (IgH translocation);
LGG	cis	rs208520	0.874	rs208456	chr6:66907942	A/G	cg07460842	chr6:66804631	NA	-0.93	-15.1	-0.57	3.38e-42	Exhaled nitric oxide output;
LGG	cis	rs3206736	0.548	rs328936	chr7:35047579	T/A	cg13400248	chr7:35225412	NA	0.54	9.5	0.4	1.09e-19	Diastolic blood pressure;
LGG	cis	rs4746818	0.901	rs7914719	chr10:70903832	T/C	cg11621586	chr10:70884670	VPS26A	1.18	21.7	0.71	1.5299999999999999e-72	Left atrial antero-posterior diameter;
LGG	cis	rs13108904	0.967	rs11727167	chr4:1285521	A/G	cg00684032	chr4:1343700	KIAA1530	0.51	9.97	0.42	2.46e-21	Obesity-related traits;
LGG	cis	rs9398803	0.865	rs4897181	chr6:126753564	C/T	cg19875578	chr6:126661172	C6orf173	0.58	10.53	0.44	2.19e-23	Male-pattern baldness;
LGG	cis	rs12220238	0.722	rs7073340	chr10:76402277	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.53	6.98	0.31	1.01e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs5769765	0.955	rs8135816	chr22:50291976	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.76	-11.43	-0.47	7.73e-27	Schizophrenia;
LGG	cis	rs10504229	0.636	rs117439064	chr8:58055279	A/G	cg14926445	chr8:58193284	C8orf71	-0.84	-10.11	-0.43	7.57e-22	Developmental language disorder (linguistic errors);
LGG	trans	rs7824557	0.602	rs7816636	chr8:11205654	T/A	cg15556689	chr8:8085844	FLJ10661	0.43	7.3	0.32	1.25e-12	Retinal vascular caliber;
LGG	trans	rs11098499	0.657	rs7664458	chr4:120371967	A/G	cg25214090	chr10:38739885	LOC399744	0.69	12.3	0.5	2.89e-30	Corneal astigmatism;
LGG	cis	rs796364	0.951	rs10931888	chr2:201022952	T/G	cg23649088	chr2:200775458	C2orf69	-0.59	-7.84	-0.34	3.12e-14	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg13065938	chr1:186344998	TPR;C1orf27;MIR548F1	0.41	6.93	0.31	1.42e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4332037	0.508	rs60238952	chr7:1914350	A/G	cg23422044	chr7:1970798	MAD1L1	-0.63	-10.81	-0.45	1.98e-24	Bipolar disorder;
LGG	cis	rs3806843	0.735	rs801188	chr5:140066916	G/T	cg16577123	chr5:140027231	NDUFA2;IK	-0.43	-6.9	-0.31	1.69e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs2228479	0.557	rs62056064	chr16:89903843	G/A	cg06558623	chr16:89946397	TCF25	1.2	13.26	0.52	3.02e-34	Skin colour saturation;
LGG	cis	rs2573652	0.674	rs11630619	chr15:100543367	G/A	cg14911520	chr15:100542628	ADAMTS17	-0.29	-7.14	-0.31	3.72e-12	Height;
LGG	cis	rs7246657	0.722	rs958305	chr19:38189440	A/G	cg23950597	chr19:37808831	NA	0.52	7.94	0.35	1.53e-14	Coronary artery calcification;
LGG	cis	rs4819052	1.000	rs2838830	chr21:46664227	T/G	cg02159808	chr21:46707872	POFUT2;LOC642852	0.67	10.37	0.43	8.45e-23	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs9443645	0.808	rs2050661	chr6:79661125	T/C	cg18132916	chr6:79620363	NA	-0.31	-8.64	-0.37	9.26e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6500395	0.926	rs8057164	chr16:48563466	A/G	cg16662043	chr16:48846231	NA	0.36	6.99	0.31	9.82e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs4742903	0.901	rs10122512	chr9:106898410	C/T	cg14250997	chr9:106856677	SMC2	0.39	8.2	0.36	2.31e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	trans	rs9929218	0.954	rs35444713	chr16:68824492	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.69	-0.51	6.82e-32	Colorectal cancer;
LGG	cis	rs10911251	0.528	rs6669199	chr1:183082421	C/A	cg07928641	chr1:182991847	LAMC1	0.46	9.28	0.4	6.51e-19	Colorectal cancer;
LGG	cis	rs35306767	0.807	rs34885925	chr10:919032	G/C	cg08847335	chr10:891726	LARP4B	-0.54	-8.95	-0.38	8.31e-18	Eosinophil percentage of granulocytes;
LGG	cis	rs113352275	1	rs113352275	chr15:78840567	C/T	cg06917634	chr15:78832804	PSMA4	-0.62	-8.96	-0.38	7.83e-18	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs10782582	0.532	rs78106188	chr1:76137836	A/G	cg10523679	chr1:76189770	ACADM	-0.42	-6.93	-0.31	1.41e-11	Daytime sleep phenotypes;
LGG	cis	rs12421382	0.636	rs34802147	chr11:109380008	C/T	cg11473876	chr11:109292803	C11orf87	0.45	9.2	0.39	1.23e-18	Schizophrenia;
LGG	cis	rs6500602	0.927	rs7200817	chr16:4480598	G/C	cg08645402	chr16:4508243	NA	0.47	8.62	0.37	1.09e-16	Schizophrenia;
LGG	cis	rs4774899	0.932	rs4774252	chr15:57582325	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.31	-0.32	1.19e-12	Urinary tract infection frequency;
LGG	cis	rs10752881	0.740	rs1889307	chr1:183049389	T/A	cg07245641	chr1:182991651	LAMC1	0.42	9.63	0.41	4e-20	Colorectal cancer;
LGG	trans	rs916888	0.687	rs199456	chr17:44797919	C/T	cg04703951	chr17:43578652	NA	0.4	8.05	0.35	6.88e-15	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs11711311	1.000	rs2603789	chr3:113470479	T/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.46	-8.28	-0.36	1.38e-15	IgG glycosylation;
LGG	trans	rs11039798	1.000	rs7125913	chr11:48984318	G/A	cg15704280	chr7:45808275	SEPT13	0.79	9.0	0.39	5.98e-18	Axial length;
LGG	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg00376283	chr12:123451042	ABCB9	0.66	11.49	0.47	4.76e-27	Neutrophil percentage of white cells;
LGG	cis	rs2153535	0.580	rs9328483	chr6:8521295	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	8.99	0.39	6.17e-18	Motion sickness;
LGG	cis	rs722599	0.651	rs12887044	chr14:75255659	C/T	cg06637938	chr14:75390232	RPS6KL1	0.54	8.75	0.38	4.1e-17	IgG glycosylation;
LGG	cis	rs4975709	0.838	rs4975753	chr5:1880865	T/C	cg12288994	chr5:1860383	NA	0.72	12.19	0.49	7.66e-30	Cardiovascular disease risk factors;
LGG	cis	rs2404602	0.684	rs1011084	chr15:77007480	C/G	cg23625390	chr15:77176239	SCAPER	-0.69	-13.55	-0.53	1.88e-35	Blood metabolite levels;
LGG	cis	rs1461503	0.966	rs1461501	chr11:122844416	A/G	cg27398637	chr11:122830231	C11orf63	-0.7	-13.88	-0.54	6.89e-37	Menarche (age at onset);
LGG	cis	rs10028187	0.865	rs713248	chr4:154408454	A/G	cg24020152	chr4:154419554	KIAA0922	0.46	9.85	0.42	6.63e-21	High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;
LGG	cis	rs3849046	0.817	rs409273	chr5:137913882	A/G	cg10920316	chr5:137946599	NA	-0.47	-7.68	-0.34	9.45e-14	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg05623727	chr3:50126028	RBM5	-0.4	-8.63	-0.37	9.71e-17	Body mass index;
LGG	trans	rs9784649	1.000	rs56156666	chr5:24999440	A/T	cg11038491	chr20:34638489	LOC647979	-0.6	-7.85	-0.34	2.82e-14	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.31	-0.43	1.43e-22	Hip circumference adjusted for BMI;
LGG	cis	rs769267	0.896	rs7253807	chr19:19631444	A/T	cg03709012	chr19:19516395	GATAD2A	0.82	15.94	0.6	6.64e-46	Tonsillectomy;
LGG	cis	rs2739330	0.791	rs9612520	chr22:24269459	G/T	cg11141652	chr22:24348549	GSTTP1	0.4	6.95	0.31	1.21e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6942756	0.806	rs10257620	chr7:128901429	C/A	cg02491457	chr7:128862824	NA	0.66	12.29	0.5	3.09e-30	White matter hyperintensity burden;
LGG	cis	rs71386933	0.543	rs36114735	chr16:72017683	C/T	cg08717414	chr16:71523259	ZNF19	-0.89	-9.5	-0.4	1.17e-19	Post bronchodilator FEV1;
LGG	cis	rs10267417	0.603	rs10233354	chr7:19895372	C/T	cg05791153	chr7:19748676	TWISTNB	0.63	8.21	0.36	2.28e-15	Night sleep phenotypes;
LGG	cis	rs6964587	1.000	rs11971885	chr7:91674807	T/C	cg17063962	chr7:91808500	NA	0.45	7.82	0.34	3.66e-14	Breast cancer;
LGG	cis	rs1881396	0.891	rs2141372	chr2:27827196	G/T	cg27432699	chr2:27873401	GPN1	0.56	8.57	0.37	1.59e-16	Nonalcoholic fatty liver disease;
LGG	cis	rs881375	0.715	rs10760119	chr9:123646060	T/C	cg09586646	chr9:123605570	PSMD5;LOC253039	0.53	9.88	0.42	4.96e-21	Rheumatoid arthritis;
LGG	cis	rs738322	0.600	rs6001030	chr22:38555904	T/G	cg03162506	chr22:38580953	NA	0.39	9.56	0.41	6.95e-20	Cutaneous nevi;
LGG	cis	rs5753037	0.543	rs131287	chr22:30158463	C/T	cg01021169	chr22:30184971	ASCC2	-0.38	-7.5	-0.33	3.4e-13	Type 1 diabetes;
LGG	cis	rs12936587	0.535	rs6502615	chr17:17612023	C/T	cg01246520	chr17:17644344	RAI1	0.36	8.47	0.37	3.3e-16	Hip circumference;Coronary artery disease or large artery stroke;Coronary heart disease;Coronary artery disease;
LGG	trans	rs2727020	0.731	rs10450572	chr11:49281073	T/C	cg03929089	chr4:120376271	NA	0.9	18.18	0.65	3.72e-56	Coronary artery disease;
LGG	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg02227867	chr8:22457446	C8orf58	-0.46	-8.91	-0.38	1.19e-17	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs28386778	0.897	rs2665833	chr17:61906846	T/C	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs7208859	0.623	rs3752019	chr17:29151705	C/T	cg13385521	chr17:29058706	SUZ12P	0.84	9.62	0.41	4.22e-20	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9359856	0.510	rs17294495	chr6:90445753	T/G	cg13799429	chr6:90582589	CASP8AP2	-0.85	-12.94	-0.52	6.65e-33	Bipolar disorder;
LGG	cis	rs2230307	0.536	rs12733952	chr1:100611571	A/G	cg24955406	chr1:100503596	HIAT1	0.58	8.35	0.36	8e-16	Carotid intima media thickness;
LGG	cis	rs17345786	0.667	rs7622940	chr3:101133155	T/C	cg12386194	chr3:101231763	SENP7	0.62	10.6	0.44	1.24e-23	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10186029	0.676	rs4673720	chr2:213941581	G/A	cg08319019	chr2:214017104	IKZF2	0.48	8.43	0.36	4.35e-16	Systemic sclerosis;
LGG	cis	rs9291683	0.595	rs10939665	chr4:10037628	T/C	cg11266682	chr4:10021025	SLC2A9	0.55	11.2	0.46	6.34e-26	Bone mineral density;
LGG	cis	rs9322193	0.923	rs9372044	chr6:150102003	G/A	cg15971980	chr6:150254442	NA	0.45	8.51	0.37	2.4e-16	Lung cancer;
LGG	cis	rs6426558	0.537	rs10495253	chr1:227471820	A/T	cg10327440	chr1:227177885	CDC42BPA	0.62	10.26	0.43	2.19e-22	Neutrophil percentage of white cells;
LGG	cis	rs4680	1.000	rs165722	chr22:19949013	C/T	cg23601416	chr22:19950040	COMT	0.37	9.21	0.39	1.17e-18	Blood metabolite levels;
LGG	trans	rs28595532	0.920	rs28538455	chr4:119486817	T/C	cg26518628	chr1:97050305	NA	-0.83	-6.82	-0.3	2.85e-11	Cannabis dependence symptom count;
LGG	cis	rs422249	0.547	rs102275	chr11:61557803	T/C	cg19610905	chr11:61596333	FADS2	-0.77	-14.24	-0.55	1.95e-38	Trans fatty acid levels;
LGG	cis	rs7918232	0.941	rs10741128	chr10:27411509	G/A	cg14442939	chr10:27389572	ANKRD26	0.72	11.01	0.46	3.5e-25	Breast cancer;
LGG	cis	rs6502050	0.764	rs35713597	chr17:80119016	C/G	cg23985595	chr17:80112537	CCDC57	-0.47	-9.49	-0.4	1.18e-19	Life satisfaction;
LGG	cis	rs6582630	0.519	rs12819814	chr12:38332568	G/C	cg13010199	chr12:38710504	ALG10B	0.67	13.38	0.53	9.4e-35	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs4740619	0.661	rs10810486	chr9:15943599	C/T	cg14451791	chr9:16040625	NA	-0.4	-9.84	-0.42	6.98e-21	Body mass index;
LGG	cis	rs2032447	0.798	rs807212	chr6:26065621	A/G	cg18357526	chr6:26021779	HIST1H4A	0.91	17.84	0.64	1.42e-54	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.517	rs10844738	chr12:34059503	T/A	cg13010199	chr12:38710504	ALG10B	0.51	9.88	0.42	5.32e-21	Morning vs. evening chronotype;
LGG	cis	rs2070488	1.000	rs2276540	chr3:38512507	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.85	18.15	0.64	5.54e-56	Electrocardiographic conduction measures;
LGG	cis	rs56011263	0.687	rs11734460	chr4:705074	C/T	cg17689763	chr4:710664	PCGF3	-0.79	-16.54	-0.61	1.25e-48	White blood cell count;
LGG	trans	rs1003719	0.715	rs762139	chr21:38568475	A/T	cg01844324	chr22:40742266	ADSL	0.39	7.22	0.32	2.08e-12	Eye color traits;
LGG	cis	rs2188554	0.639	rs11978434	chr7:117231852	T/C	cg10524701	chr7:117356490	CTTNBP2	0.4	6.88	0.3	2.01e-11	Esophageal adenocarcinoma;
LGG	cis	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg12826209	chr6:26865740	GUSBL1	0.75	8.04	0.35	7.49e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6502050	0.835	rs8064935	chr17:80180178	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-8.83	-0.38	2.13e-17	Life satisfaction;
LGG	trans	rs9650657	0.556	rs6601530	chr8:10671272	G/A	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.94	-0.31	1.32e-11	Neuroticism;
LGG	cis	rs2404602	0.692	rs12911174	chr15:77149943	G/A	cg22467129	chr15:76604101	ETFA	-0.42	-7.04	-0.31	6.88e-12	Blood metabolite levels;
LGG	trans	rs2278034	0.516	rs9829709	chr3:195616673	G/A	cg16724585	chr3:197361211	NA	-0.43	-7.88	-0.34	2.42e-14	Bronchopulmonary dysplasia;
LGG	cis	rs947211	0.898	rs1772156	chr1:205752894	T/C	cg26354017	chr1:205819088	PM20D1	0.47	7.85	0.34	2.82e-14	Parkinson's disease;
LGG	cis	rs6539267	0.847	rs17217845	chr12:106697802	C/T	cg00173435	chr12:106696525	TCP11L2	-0.61	-8.36	-0.36	7.54e-16	Tourette syndrome;
LGG	cis	rs7589342	0.628	rs35866817	chr2:106402569	T/C	cg16077055	chr2:106428750	NCK2	0.3	7.23	0.32	1.97e-12	Addiction;
LGG	trans	rs9858542	1.000	rs2172252	chr3:49678307	A/T	cg21665057	chr3:196295764	WDR53;FBXO45	-0.47	-7.41	-0.33	5.92e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs6951245	1.000	rs78185801	chr7:1096367	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.06	0.46	2.24e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs1420338	0.967	rs4720151	chr7:34160523	G/A	cg01275685	chr7:34179230	BMPER	-0.48	-8.38	-0.36	6.32e-16	Estrone/androstenedione ratio in resected early stage-receptor positive breast cancer;
LGG	cis	rs8062405	1.000	rs62036657	chr16:28844365	G/A	cg00204512	chr16:28754710	NA	0.26	7.2	0.32	2.42e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs9902453	0.845	rs2617875	chr17:28090024	G/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.7	14.06	0.55	1.16e-37	Coffee consumption (cups per day);
LGG	trans	rs61931739	0.500	rs7133447	chr12:34041901	A/G	cg26384229	chr12:38710491	ALG10B	0.71	14.38	0.56	4.8e-39	Morning vs. evening chronotype;
LGG	cis	rs804280	1.000	rs804281	chr8:11611865	A/G	cg12395012	chr8:11607386	GATA4	-0.73	-14.96	-0.57	1.44e-41	Myopia (pathological);
LGG	trans	rs12599106	0.770	rs12445057	chr16:34970274	C/G	cg07332563	chr6:291687	DUSP22	-0.58	-9.7	-0.41	2.22e-20	Menopause (age at onset);
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.52	-13.84	-0.54	1.06e-36	Tonsillectomy;
LGG	cis	rs11190604	1.000	rs79831012	chr10:102237059	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	11.05	0.46	2.41e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7937682	0.632	rs7112886	chr11:111743232	T/C	cg22437258	chr11:111473054	SIK2	-0.41	-6.86	-0.3	2.21e-11	Primary sclerosing cholangitis;
LGG	trans	rs7829975	0.774	rs35431455	chr8:8673736	T/C	cg00405596	chr8:11794950	NA	0.44	7.41	0.33	5.93e-13	Mood instability;
LGG	trans	rs6499188	0.571	rs1645975	chr16:68564448	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs2153535	0.580	rs9328486	chr6:8528008	T/C	cg07606381	chr6:8435919	SLC35B3	0.69	12.68	0.51	7.45e-32	Motion sickness;
LGG	cis	rs9381040	0.655	rs2268190	chr6:41030226	C/T	cg25110423	chr6:41068646	NFYA;LOC221442	-0.37	-7.12	-0.31	4.17e-12	Alzheimer's disease (late onset);
LGG	trans	rs35110281	0.776	rs229357	chr21:44982717	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.66	12.28	0.5	3.2e-30	Mean corpuscular volume;
LGG	cis	rs4984778	0.750	rs7198064	chr16:1272472	C/T	cg07748719	chr16:1272498	TPSG1	0.47	9.51	0.4	1.04e-19	Blood protein levels;
LGG	cis	rs959260	0.528	rs4559942	chr17:73309269	G/A	cg14668889	chr17:73230827	NUP85	-0.54	-9.24	-0.39	8.89e-19	Systemic lupus erythematosus;
LGG	cis	rs4689592	0.523	rs6446565	chr4:7074027	A/G	cg19539972	chr4:7069911	GRPEL1	0.69	10.04	0.42	1.4e-21	Monocyte percentage of white cells;
LGG	cis	rs8072100	0.512	rs3809863	chr17:45385012	C/T	cg25173405	chr17:45401733	C17orf57	-0.53	-9.18	-0.39	1.47e-18	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17376456	0.569	rs68122392	chr5:93077807	A/T	cg25358565	chr5:93447407	FAM172A	0.86	11.75	0.48	4.3e-28	Diabetic retinopathy;
LGG	cis	rs12142240	0.698	rs7515598	chr1:46818479	C/T	cg25706281	chr1:46860511	FAAH	-0.28	-6.82	-0.3	2.84e-11	Menopause (age at onset);
LGG	cis	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg09085632	chr11:111637200	PPP2R1B	-1.19	-28.36	-0.8	2.63e-103	Primary sclerosing cholangitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11032070	chr20:31172387	NA	0.52	8.04	0.35	7.54e-15	Gut microbiome composition (summer);
LGG	cis	rs6665290	0.669	rs3768421	chr1:227177193	G/A	cg05696931	chr1:227175867	NA	-0.41	-8.22	-0.36	2.07e-15	Myeloid white cell count;
LGG	cis	rs137603	1.000	rs137607	chr22:39695505	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.44	-7.4	-0.33	6.37e-13	Primary biliary cholangitis;
LGG	trans	rs2243480	1.000	rs1796228	chr7:66033084	G/A	cg10756647	chr7:56101905	PSPH	0.8	9.44	0.4	1.83e-19	Diabetic kidney disease;
LGG	cis	rs9818758	0.607	rs80170003	chr3:48951640	T/C	cg00383909	chr3:49044727	WDR6	1.12	13.64	0.54	7.91e-36	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs4481887	0.646	rs28421649	chr1:248548122	G/C	cg01631408	chr1:248437212	OR2T33	-0.37	-6.77	-0.3	3.86e-11	Common traits (Other);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15044954	chr7:89874365	C7orf63	0.49	7.88	0.34	2.34e-14	Gut microbiome composition (summer);
LGG	cis	rs2404602	0.608	rs17361504	chr15:76601871	A/G	cg23625390	chr15:77176239	SCAPER	0.41	7.86	0.34	2.77e-14	Blood metabolite levels;
LGG	cis	rs926392	0.932	rs4812360	chr20:37689259	A/G	cg16355469	chr20:37678765	NA	0.41	6.74	0.3	4.7e-11	Dialysis-related mortality;
LGG	cis	rs7223966	1.000	rs11657081	chr17:61792339	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.41	7.19	0.32	2.58e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2721195	1.000	rs1871541	chr8:145681713	G/T	cg11211951	chr8:145729740	GPT	-0.52	-12.13	-0.49	1.37e-29	Age at first birth;
LGG	trans	rs6582630	0.537	rs8189533	chr12:38391068	A/G	cg06521331	chr12:34319734	NA	-0.55	-9.35	-0.4	3.75e-19	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs60843830	0.964	rs62114538	chr2:256116	G/T	cg04617936	chr2:214353	NA	-0.36	-6.74	-0.3	4.66e-11	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13191362	1.000	rs13218900	chr6:163081638	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.5	7.23	0.32	2.04e-12	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs4665809	1.000	rs4665817	chr2:26305167	G/A	cg22920501	chr2:26401640	FAM59B	-0.41	-7.97	-0.35	1.29e-14	Gut microbiome composition (summer);
LGG	cis	rs798554	0.600	rs2679259	chr7:2885322	C/G	cg19524238	chr7:2802976	GNA12	0.33	7.91	0.34	1.97e-14	Height;
LGG	cis	rs9810089	0.843	rs11717954	chr3:136112109	A/G	cg21827317	chr3:136751795	NA	0.44	7.57	0.33	2.05e-13	Gestational age at birth (child effect);
LGG	cis	rs10504229	0.636	rs72649133	chr8:58054681	G/A	cg26174226	chr8:58114915	NA	-0.57	-7.63	-0.33	1.31e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7726839	0.555	rs4541696	chr5:581053	A/G	cg01221209	chr5:554886	NA	-0.46	-9.67	-0.41	2.97e-20	Obesity-related traits;
LGG	cis	rs6752107	0.901	rs11687982	chr2:234149039	C/T	cg23050873	chr2:234184376	ATG16L1;SCARNA5	0.4	7.12	0.31	4.19e-12	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs9325144	0.555	rs7968322	chr12:38792348	T/C	cg13010199	chr12:38710504	ALG10B	-0.56	-10.72	-0.45	4.39e-24	Morning vs. evening chronotype;
LGG	cis	rs123509	0.687	rs73077208	chr3:42835205	G/A	cg10144569	chr3:42726640	KBTBD5	-0.48	-6.81	-0.3	2.98e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs12188164	0.965	rs56146525	chr5:442571	A/C	cg26076054	chr5:421317	AHRR	-0.46	-7.6	-0.33	1.71e-13	Cystic fibrosis severity;
LGG	cis	rs17270561	0.609	rs1318016	chr6:25764704	A/T	cg03517284	chr6:25882590	NA	-0.42	-6.98	-0.31	1.04e-11	Iron status biomarkers;
LGG	cis	rs13108904	0.901	rs12642410	chr4:1308409	A/G	cg20887711	chr4:1340912	KIAA1530	0.52	9.5	0.4	1.11e-19	Obesity-related traits;
LGG	cis	rs1799949	1.000	rs2070834	chr17:41242285	T/G	cg25072359	chr17:41440525	NA	0.51	9.76	0.41	1.37e-20	Menopause (age at onset);
LGG	cis	rs7249142	0.549	rs2239369	chr19:19292405	A/T	cg24446071	chr19:19281270	LOC729991-MEF2B;MEF2B	0.44	11.14	0.46	1.07e-25	IgG glycosylation;
LGG	cis	rs62045849	0.557	rs9938463	chr16:89183772	A/G	cg08015503	chr16:89190385	ACSF3	-0.63	-7.47	-0.33	4.05e-13	Red blood cell count;
LGG	cis	rs7618915	0.501	rs2336149	chr3:52692124	G/A	cg14092988	chr3:52407081	DNAH1	0.29	7.87	0.34	2.54e-14	Bipolar disorder;
LGG	cis	rs9291683	0.552	rs11736410	chr4:10017241	G/A	cg00071950	chr4:10020882	SLC2A9	0.45	9.42	0.4	2.17e-19	Bone mineral density;
LGG	cis	rs7085104	0.632	rs6162	chr10:104596981	G/A	cg04362960	chr10:104952993	NT5C2	0.49	9.28	0.4	6.34e-19	Immature fraction of reticulocytes;Schizophrenia;
LGG	cis	rs2455601	0.786	rs2568068	chr11:8977830	A/G	cg21881798	chr11:8931708	C11orf17;ST5	-0.55	-9.76	-0.41	1.35e-20	Schizophrenia;
LGG	cis	rs7223966	1.000	rs28463311	chr17:61919643	C/T	cg11494091	chr17:61959527	GH2	0.51	8.1	0.35	4.94e-15	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs7011049	1.000	rs72648407	chr8:53857144	C/T	cg26025543	chr8:53854495	NA	0.75	9.91	0.42	4.07e-21	Systolic blood pressure;
LGG	cis	rs7267979	1.000	rs4813566	chr20:25386465	G/T	cg06421707	chr20:25228305	PYGB	-0.48	-10.42	-0.44	5.5e-23	Liver enzyme levels (alkaline phosphatase);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg09507928	chr5:140027484	IK;NDUFA2	0.42	7.27	0.32	1.52e-12	Bipolar disorder;
LGG	cis	rs796364	0.951	rs769952	chr2:200734368	C/T	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.8	0.45	2.03e-24	Schizophrenia;
LGG	trans	rs67340775	0.541	rs200974	chr6:27855845	A/G	cg01620082	chr3:125678407	NA	-0.66	-8.18	-0.36	2.69e-15	Lung cancer in ever smokers;
LGG	cis	rs9911578	0.967	rs11079354	chr17:56594460	G/A	cg05425664	chr17:57184151	TRIM37	0.62	9.87	0.42	5.51e-21	Intelligence (multi-trait analysis);
LGG	cis	rs8032158	1.000	rs28770330	chr15:56248743	T/G	cg02198044	chr15:56286336	NEDD4	-0.73	-12.79	-0.51	2.84e-32	Keloid;
LGG	trans	rs941408	0.963	rs1640267	chr19:2789337	T/C	cg22153745	chr1:153894579	GATAD2B	-0.69	-10.83	-0.45	1.62e-24	Total cholesterol levels;
LGG	cis	rs10504229	0.906	rs61638902	chr8:58193511	A/C	cg05313129	chr8:58192883	C8orf71	-0.8	-12.52	-0.5	3.44e-31	Developmental language disorder (linguistic errors);
LGG	trans	rs1478897	0.898	rs2248932	chr8:11391650	A/G	cg02002194	chr4:3960332	NA	0.42	7.52	0.33	2.84e-13	Systemic lupus erythematosus;
LGG	cis	rs6952808	0.582	rs10479762	chr7:2045351	T/C	cg11050988	chr7:1952600	MAD1L1	0.34	8.18	0.36	2.74e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg23985595	chr17:80112537	CCDC57	-0.47	-9.54	-0.41	8.01e-20	Life satisfaction;
LGG	cis	rs7824557	0.525	rs12682349	chr8:11245303	C/G	cg15596359	chr8:11213517	TDH	-0.37	-7.45	-0.33	4.69e-13	Retinal vascular caliber;
LGG	cis	rs910187	0.605	rs8124918	chr20:45811860	A/G	cg27589058	chr20:45804311	EYA2	-0.36	-9.31	-0.4	5.12e-19	Migraine;
LGG	cis	rs12410462	0.551	rs1923819	chr1:227874314	C/T	cg23173402	chr1:227635558	NA	-0.35	-6.83	-0.3	2.74e-11	Major depressive disorder;
LGG	cis	rs7811142	1.000	rs60478351	chr7:100089017	C/T	cg23667466	chr7:100026434	MEPCE;ZCWPW1	1.01	15.65	0.59	1.27e-44	Platelet count;
LGG	trans	rs9467711	0.659	rs35277236	chr6:26562269	G/T	cg08344181	chr3:125677491	NA	-0.69	-7.33	-0.32	1.07e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4650994	1.000	rs10798619	chr1:178532517	A/G	cg19399532	chr1:178512495	C1orf220	0.43	8.45	0.37	3.69e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2963155	0.518	rs72801054	chr5:142687742	T/C	cg17617527	chr5:142782415	NR3C1	0.97	11.99	0.49	5.13e-29	Breast cancer;
LGG	cis	rs1008375	0.966	rs3796812	chr4:17582051	G/A	cg02297831	chr4:17616191	MED28	0.47	8.79	0.38	2.86e-17	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs72781680	0.898	rs55841168	chr2:24007926	T/C	cg08917208	chr2:24149416	ATAD2B	0.79	9.04	0.39	4.31e-18	Lymphocyte counts;
LGG	cis	rs28735056	0.565	rs12957336	chr18:77716889	A/G	cg05491587	chr18:77659695	KCNG2	0.39	7.16	0.32	3.15e-12	Schizophrenia;
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg16507663	chr6:150244633	RAET1G	0.51	10.6	0.44	1.21e-23	Testicular germ cell tumor;
LGG	cis	rs11155671	0.530	rs7774787	chr6:150209432	G/A	cg07701084	chr6:150067640	NUP43	0.43	7.94	0.35	1.56e-14	Testicular germ cell tumor;
LGG	cis	rs11155671	0.530	rs4458704	chr6:150232879	A/C	cg09217309	chr6:150244204	RAET1G	0.46	8.38	0.36	6.55e-16	Testicular germ cell tumor;
LGG	cis	rs7937682	0.924	rs7924683	chr11:111555796	C/A	cg22437258	chr11:111473054	SIK2	0.55	9.52	0.4	9.61e-20	Primary sclerosing cholangitis;
LGG	cis	rs1256531	0.661	rs10135541	chr14:65836281	C/T	cg15999311	chr14:65749247	NA	0.81	6.74	0.3	4.73e-11	Conduct disorder (symptom count);
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg07414643	chr4:187882934	NA	0.55	11.32	0.47	2.16e-26	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs763121	0.853	rs2284073	chr22:39105948	T/C	cg06022373	chr22:39101656	GTPBP1	0.93	19.54	0.67	1.83e-62	Menopause (age at onset);
LGG	cis	rs3096299	0.685	rs3803681	chr16:89544756	C/T	cg06640241	chr16:89574553	SPG7	0.91	17.15	0.62	2.1e-51	Multiple myeloma (IgH translocation);
LGG	cis	rs999943	0.774	rs12212284	chr6:33640874	T/A	cg14003231	chr6:33640908	ITPR3	0.68	15.33	0.58	3.47e-43	Obesity (extreme);
LGG	cis	rs1048238	0.506	rs6668183	chr1:16173814	G/C	cg22431228	chr1:16359049	CLCNKA	-0.4	-7.32	-0.32	1.12e-12	Systolic blood pressure;
LGG	cis	rs826838	0.586	rs1843903	chr12:38627524	C/T	cg04568710	chr12:38710424	ALG10B	0.34	7.12	0.31	4.28e-12	Heart rate;
LGG	trans	rs11098499	0.569	rs55845118	chr4:120290913	T/C	cg25214090	chr10:38739885	LOC399744	0.62	11.18	0.46	7.42e-26	Corneal astigmatism;
LGG	cis	rs10504229	0.728	rs17215676	chr8:58152915	G/T	cg08219700	chr8:58056026	NA	0.44	6.93	0.31	1.45e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs6952808	0.717	rs10950422	chr7:1926577	T/C	cg21782813	chr7:2030301	MAD1L1	0.44	10.29	0.43	1.69e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs6964587	0.839	rs6950538	chr7:91417816	T/C	cg17063962	chr7:91808500	NA	0.39	6.82	0.3	2.93e-11	Breast cancer;
LGG	cis	rs16937	0.711	rs11240390	chr1:205179457	A/G	cg00889227	chr1:205173544	DSTYK	-0.31	-7.61	-0.33	1.53e-13	Schizophrenia;
LGG	cis	rs2228479	1.000	rs62052213	chr16:89991963	C/T	cg00800038	chr16:89945340	TCF25	-0.67	-7.91	-0.35	1.86e-14	Skin colour saturation;
LGG	cis	rs3862435	0.572	rs2601165	chr15:90908934	C/G	cg22089800	chr15:90895588	ZNF774	-0.56	-6.97	-0.31	1.12e-11	Response to exercise (triglyceride level interaction);
LGG	cis	rs4862750	0.832	rs6419953	chr4:187900509	T/A	cg06074448	chr4:187884817	NA	-0.59	-13.11	-0.52	1.25e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs151997	0.962	rs27936	chr5:50181418	T/A	cg06027927	chr5:50259733	NA	0.68	11.19	0.46	7.15e-26	Callous-unemotional behaviour;
LGG	trans	rs9914544	0.564	rs9906799	chr17:18795317	A/G	cg21372672	chr17:16614065	CCDC144A	-0.37	-7.99	-0.35	1.12e-14	Educational attainment (years of education);
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg21782813	chr7:2030301	MAD1L1	0.49	11.12	0.46	1.28e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9388451	0.839	rs4897157	chr6:126102981	A/T	cg10911889	chr6:126070802	HEY2	0.43	7.3	0.32	1.23e-12	Brugada syndrome;
LGG	cis	rs2304069	0.545	rs12153714	chr5:149395254	A/G	cg12661370	chr5:149340060	SLC26A2	0.49	8.3	0.36	1.13e-15	HIV-1 control;
LGG	cis	rs4746818	1.000	rs906218	chr10:70960913	C/T	cg04149295	chr10:70884716	VPS26A	0.45	6.69	0.3	6.51e-11	Left atrial antero-posterior diameter;
LGG	cis	rs9399135	0.967	rs9389258	chr6:135361140	T/C	cg24558204	chr6:135376177	HBS1L	0.52	9.51	0.4	1.04e-19	Red blood cell count;
LGG	cis	rs17826219	0.568	rs9898097	chr17:29072672	T/G	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Body mass index;
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg26479374	chr4:1243980	CTBP1;C4orf42	-0.5	-9.56	-0.41	7e-20	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg04503457	chr17:41445688	NA	-0.38	-9.09	-0.39	2.94e-18	Menopause (age at onset);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg02761093	chr13:22245020	FGF9	0.45	7.3	0.32	1.25e-12	Cognitive performance;
LGG	cis	rs1580019	0.665	rs34147895	chr7:32531796	G/C	cg07520158	chr7:32535189	LSM5;AVL9	0.54	8.6	0.37	1.26e-16	Cognitive ability;
LGG	cis	rs9906944	0.707	rs4794020	chr17:47111399	C/T	cg09029085	chr17:47094198	IGF2BP1	0.31	8.26	0.36	1.57e-15	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg25214090	chr10:38739885	LOC399744	0.7	12.51	0.5	3.97e-31	Corneal astigmatism;
LGG	cis	rs397969	0.596	rs9901294	chr17:19888501	G/A	cg13482628	chr17:19912719	NA	0.5	8.47	0.37	3.34e-16	Platelet count;
LGG	cis	rs9611565	0.546	rs132793	chr22:42063681	A/G	cg06634786	chr22:41940651	POLR3H	0.77	12.04	0.49	3.01e-29	Vitiligo;
LGG	cis	rs877282	0.583	rs112372193	chr10:826602	A/G	cg01169559	chr10:831247	NA	0.52	9.14	0.39	1.92e-18	Uric acid levels;
LGG	cis	rs9596863	0.898	rs35359752	chr13:54364643	T/C	ch.13.53330881F	chr13:54432880	NA	0.52	7.02	0.31	7.94e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	trans	rs55821297	0.590	rs7667370	chr4:111333601	G/T	cg10580549	chr19:53101634	ZNF137	0.56	7.13	0.31	3.77e-12	Iris color (a* coordinate);
LGG	trans	rs2161208	0.545	rs10071511	chr5:85372505	G/A	cg01787110	chr1:109008453	NBPF6	-0.44	-6.68	-0.3	6.84e-11	Daytime sleep phenotypes;
LGG	cis	rs2204008	0.744	rs11514358	chr12:38255526	G/A	cg26384229	chr12:38710491	ALG10B	0.96	21.63	0.71	3.12e-72	Bladder cancer;
LGG	cis	rs9467773	1.000	rs11756120	chr6:26529808	G/C	cg11502198	chr6:26597334	ABT1	0.54	9.39	0.4	2.74e-19	Intelligence (multi-trait analysis);
LGG	cis	rs4891159	0.548	rs11150952	chr18:74128188	T/C	cg24786174	chr18:74118243	ZNF516	0.68	17.4	0.63	1.56e-52	Longevity;
LGG	cis	rs2486288	0.656	rs2413771	chr15:45553140	A/G	cg15395560	chr15:45543142	SLC28A2	0.41	6.77	0.3	3.8e-11	Glomerular filtration rate;
LGG	cis	rs11123170	0.543	rs4849180	chr2:113985186	C/G	cg19083407	chr2:113993142	PAX8;LOC440839;LOC654433	0.48	7.1	0.31	4.59e-12	Renal function-related traits (BUN);
LGG	cis	rs11214589	0.747	rs10891536	chr11:113209428	C/G	cg14159747	chr11:113255604	NA	0.28	7.44	0.33	4.83e-13	Neuroticism;
LGG	cis	rs17376456	0.597	rs7733142	chr5:93322795	C/A	cg19507638	chr5:93509721	C5orf36	0.4	7.25	0.32	1.73e-12	Diabetic retinopathy;
LGG	cis	rs1799949	0.894	rs36062488	chr17:41337472	C/T	cg04503457	chr17:41445688	NA	0.4	9.91	0.42	3.93e-21	Menopause (age at onset);
LGG	cis	rs9902453	0.904	rs4528633	chr17:28356136	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs1865760	1.000	rs9358895	chr6:25924655	C/T	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs4474465	0.915	rs12272791	chr11:78159426	G/A	cg27205649	chr11:78285834	NARS2	-0.51	-8.54	-0.37	1.94e-16	Alzheimer's disease (survival time);
LGG	cis	rs10504229	1.000	rs57186557	chr8:58177277	A/G	cg22535103	chr8:58192502	C8orf71	-1.01	-16.02	-0.6	2.8600000000000002e-46	Developmental language disorder (linguistic errors);
LGG	cis	rs4862750	0.837	rs1863404	chr4:187874654	T/C	cg10295955	chr4:187884368	NA	-1.13	-29.79	-0.81	1.04e-109	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4363385	0.667	rs2066004	chr1:152922896	A/G	cg07796016	chr1:152779584	LCE1C	-0.45	-6.98	-0.31	1.06e-11	Inflammatory skin disease;
LGG	cis	rs6960043	0.818	rs12699673	chr7:15049604	T/C	cg19272540	chr7:15055459	NA	0.35	7.96	0.35	1.32e-14	Type 2 diabetes;
LGG	cis	rs9322193	0.962	rs9322206	chr6:149962617	T/C	cg11878867	chr6:150167359	LRP11	-0.49	-9.97	-0.42	2.35e-21	Lung cancer;
LGG	trans	rs2727020	0.734	rs1164664	chr11:49295542	T/G	cg03929089	chr4:120376271	NA	0.77	12.37	0.5	1.41e-30	Coronary artery disease;
LGG	cis	rs12188164	0.543	rs890972	chr5:462465	C/A	cg00473462	chr5:472545	LOC25845	0.35	6.69	0.3	6.37e-11	Cystic fibrosis severity;
LGG	trans	rs4843747	0.605	rs4072779	chr16:88107290	C/T	cg00711542	chr16:29343894	RUNDC2C	0.4	6.82	0.3	2.81e-11	Menopause (age at onset);
LGG	cis	rs10791323	0.569	rs2156679	chr11:133742304	C/T	cg15485101	chr11:133734466	NA	0.52	9.23	0.39	9.98e-19	Childhood ear infection;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg16879192	chr19:12721607	ZNF490;ZNF791	0.46	7.39	0.32	7.15e-13	Cognitive performance;
LGG	cis	rs897080	0.516	rs1067361	chr2:44661217	G/C	cg00619915	chr2:44497795	NA	-0.48	-6.75	-0.3	4.43e-11	Height;
LGG	cis	rs13108904	0.870	rs13115355	chr4:1261576	G/A	cg13395646	chr4:1353034	KIAA1530	-0.49	-8.47	-0.37	3.18e-16	Obesity-related traits;
LGG	cis	rs1978968	1.000	rs1076542	chr22:18446452	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	0.61	12.42	0.5	8.75e-31	Presence of antiphospholipid antibodies;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg14490972	chr6:43484812	POLR1C;YIPF3	-0.41	-6.83	-0.3	2.61e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11792861	0.781	rs2151426	chr9:111743797	A/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.63	9.86	0.42	5.96e-21	Menarche (age at onset);
LGG	cis	rs6594713	0.642	rs13171630	chr5:112837037	C/T	cg12552261	chr5:112820674	MCC	0.64	7.96	0.35	1.35e-14	Brain cytoarchitecture;
LGG	cis	rs4474465	1.000	rs10793313	chr11:78169310	C/T	cg27205649	chr11:78285834	NARS2	-0.51	-8.62	-0.37	1.04e-16	Alzheimer's disease (survival time);
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.94	-0.31	1.32e-11	Prostate cancer;
LGG	cis	rs9611565	0.512	rs1983576	chr22:42166486	G/A	cg03806693	chr22:41940476	POLR3H	1.04	17.67	0.63	9.1e-54	Vitiligo;
LGG	cis	rs2075671	0.903	rs62483570	chr7:100300649	C/T	cg21055462	chr7:100276975	NA	0.45	9.49	0.4	1.21e-19	Other erythrocyte phenotypes;
LGG	cis	rs9863	0.861	rs77020228	chr12:124418472	C/G	cg13487667	chr12:124434373	CCDC92	-0.36	-7.15	-0.32	3.49e-12	White blood cell count;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.15	0.32	3.47e-12	Prudent dietary pattern;
LGG	cis	rs1577917	0.682	rs1173419	chr6:86402163	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.47	-8.19	-0.36	2.61e-15	Response to antipsychotic treatment;
LGG	cis	rs2717559	0.541	rs12549240	chr8:143881380	C/T	cg06565975	chr8:143823917	SLURP1	-0.32	-8.08	-0.35	5.74e-15	Urinary tract infection frequency;
LGG	cis	rs9487051	1.000	rs6568569	chr6:109613196	C/A	cg21918786	chr6:109611834	NA	-0.44	-8.19	-0.36	2.61e-15	Reticulocyte fraction of red cells;
LGG	cis	rs975722	0.671	rs713134	chr7:117115256	C/T	cg10524701	chr7:117356490	CTTNBP2	0.46	10.16	0.43	4.98e-22	Coronary artery disease;
LGG	cis	rs847649	0.842	rs869332	chr7:102632247	A/G	cg18108683	chr7:102477205	FBXL13	-0.6	-12.8	-0.51	2.45e-32	Morning vs. evening chronotype;
LGG	trans	rs7618501	0.722	rs9853458	chr3:49783211	A/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.66	-12.93	-0.52	7.28e-33	Intelligence (multi-trait analysis);
LGG	cis	rs10463554	0.927	rs34800	chr5:102426503	C/T	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs514406	0.644	rs7552663	chr1:53204352	C/T	cg16325326	chr1:53192061	ZYG11B	-0.82	-21.45	-0.71	2.26e-71	Monocyte count;
LGG	cis	rs651907	0.535	rs11716558	chr3:101528481	T/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.19	0.36	2.53e-15	Colorectal cancer;
LGG	cis	rs9513627	1.000	rs7321269	chr13:100126271	C/T	cg15490075	chr13:100150979	NA	-0.66	-6.97	-0.31	1.13e-11	Obesity-related traits;
LGG	cis	rs2221894	0.506	rs36118625	chr8:28762798	A/G	cg07962641	chr8:28805897	HMBOX1	-0.53	-7.77	-0.34	5.16e-14	Obesity-related traits;
LGG	cis	rs1696756	0.816	rs2650242	chr17:77827360	A/T	cg07923794	chr17:77834237	NA	-0.76	-11.74	-0.48	5e-28	Glucocorticoid-induced osteonecrosis (age 10 years and older);
LGG	trans	rs7615952	0.733	rs13314847	chr3:125644788	C/T	cg07211511	chr3:129823064	LOC729375	-1.36	-21.17	-0.7	4.77e-70	Blood pressure (smoking interaction);
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg00864171	chr11:67383662	NA	0.56	9.62	0.41	4.41e-20	Mean corpuscular volume;
LGG	cis	rs2180341	0.920	rs9398836	chr6:127576497	T/G	cg27446573	chr6:127587934	RNF146	1.11	22.01	0.72	5.07e-74	Breast cancer;
LGG	cis	rs1008375	1.000	rs10939738	chr4:17604295	G/C	cg18681998	chr4:17616180	MED28	0.86	18.7	0.66	1.47e-58	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs796364	1.000	rs281794	chr2:200846666	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	0.75	9.64	0.41	3.64e-20	Schizophrenia;
LGG	cis	rs57502260	0.915	rs75202638	chr11:68210421	C/T	cg01657329	chr11:68192670	LRP5	-0.58	-7.48	-0.33	3.73e-13	Total body bone mineral density (age 45-60);
LGG	cis	rs62238980	0.614	rs41430344	chr22:32381973	C/T	cg00543991	chr22:32367038	NA	0.77	8.6	0.37	1.26e-16	Childhood ear infection;
LGG	cis	rs62400317	0.826	rs4400216	chr6:45237955	T/G	cg18551225	chr6:44695536	NA	-0.62	-10.21	-0.43	3.19e-22	Total body bone mineral density;
LGG	cis	rs7027203	0.759	rs10761282	chr9:96586175	G/A	cg13679303	chr9:96623674	NA	-0.37	-6.73	-0.3	5.06e-11	DNA methylation (variation);
LGG	cis	rs28386778	0.863	rs9897229	chr17:61782325	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.64	13.17	0.52	7.17e-34	Prudent dietary pattern;
LGG	trans	rs1728785	0.818	rs1728769	chr16:68564186	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.66	10.45	0.44	4.36e-23	Ulcerative colitis;
LGG	cis	rs1978968	0.731	rs9605464	chr22:18459922	C/T	cg00227156	chr22:18463646	MICAL3;MIR648	-0.65	-13.73	-0.54	3.14e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs5769765	0.908	rs9616390	chr22:50314289	G/C	cg22709217	chr22:50311962	ALG12;CRELD2	-0.97	-13.98	-0.54	2.57e-37	Schizophrenia;
LGG	cis	rs9322193	0.923	rs9688861	chr6:149959060	G/T	cg15971980	chr6:150254442	NA	0.44	8.24	0.36	1.76e-15	Lung cancer;
LGG	cis	rs2739330	0.796	rs5760097	chr22:24247794	G/C	cg09033563	chr22:24373618	LOC391322	-0.5	-8.19	-0.36	2.64e-15	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9858542	0.953	rs10640	chr3:49454277	G/A	cg03060546	chr3:49711283	APEH	-0.64	-10.52	-0.44	2.39e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs826838	0.802	rs10785619	chr12:38742897	T/A	cg13010199	chr12:38710504	ALG10B	0.72	15.88	0.59	1.15e-45	Heart rate;
LGG	cis	rs4430311	0.723	rs12749316	chr1:243792781	G/A	cg25706552	chr1:244017396	NA	-0.64	-15.71	-0.59	7.13e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg11385684	chr2:12858604	TRIB2	0.4	7.16	0.32	3.14e-12	Obesity-related traits;
LGG	cis	rs7949030	0.626	rs72927213	chr11:62351198	G/C	cg11742103	chr11:62369870	EML3;MTA2	0.65	16.29	0.6	1.72e-47	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs4006360	0.578	rs9893220	chr17:39231963	C/A	cg16985667	chr17:39306289	KRTAP4-5	-0.46	-10.05	-0.42	1.3e-21	Bipolar disorder and schizophrenia;
LGG	cis	rs7945705	0.870	rs4929922	chr11:8975776	A/G	cg00186954	chr11:8933980	ST5;C11orf17	-0.34	-6.8	-0.3	3.33e-11	Hemoglobin concentration;
LGG	cis	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg21775007	chr8:11205619	TDH	-0.54	-8.8	-0.38	2.72e-17	Neuroticism;
LGG	cis	rs1949733	0.636	rs16842498	chr4:8539529	C/T	cg13073564	chr4:8508604	NA	0.42	7.4	0.33	6.29e-13	Response to antineoplastic agents;
LGG	cis	rs8133932	0.701	rs2839021	chr21:47280016	C/T	cg11214348	chr21:47283868	PCBP3	-0.41	-7.53	-0.33	2.63e-13	Schizophrenia;
LGG	cis	rs10170846	0.572	rs12620873	chr2:223419528	A/C	cg25565276	chr2:223520875	FARSB	0.82	13.53	0.53	2.17e-35	Schizophrenia (inflammation and infection response interaction);
LGG	trans	rs3960554	0.808	rs9801125	chr7:75792451	C/T	cg19862616	chr7:65841803	NCRNA00174	0.87	12.31	0.5	2.55e-30	Eotaxin levels;
LGG	cis	rs155076	1.000	rs658244	chr13:21850976	T/C	cg06138931	chr13:21896616	NA	-0.45	-7.34	-0.32	9.35e-13	White matter hyperintensity burden;
LGG	cis	rs854572	0.600	rs705382	chr7:94955221	C/G	cg17330251	chr7:94953956	PON1	-0.6	-15.25	-0.58	7.9e-43	Paraoxonase activity;
LGG	cis	rs1865760	0.519	rs2275904	chr6:25768085	T/C	cg03264133	chr6:25882463	NA	-0.48	-7.51	-0.33	3.08e-13	Height;
LGG	cis	rs963731	0.579	rs1454220	chr2:39277108	G/A	cg04010122	chr2:39346883	SOS1	-0.76	-7.39	-0.32	6.82e-13	Corticobasal degeneration;
LGG	cis	rs12586317	0.547	rs12435454	chr14:35466997	A/G	cg16230307	chr14:35515116	FAM177A1	0.93	13.68	0.54	5.33e-36	Psoriasis;
LGG	cis	rs2228479	0.850	rs11648433	chr16:89965055	G/A	cg06558623	chr16:89946397	TCF25	1.2	14.09	0.55	8.72e-38	Skin colour saturation;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg17607973	chr7:100027408	MEPCE;ZCWPW1	-0.41	-6.79	-0.3	3.45e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs875971	0.862	rs949930	chr7:65766822	C/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.05	-0.31	6.48e-12	Aortic root size;
LGG	cis	rs35306767	0.953	rs11253521	chr10:976416	G/C	cg26597838	chr10:835615	NA	0.65	9.82	0.42	8.34e-21	Eosinophil percentage of granulocytes;
LGG	cis	rs12724450	0.793	rs34964511	chr1:150298015	C/T	cg03818307	chr1:150480534	ECM1	0.49	6.95	0.31	1.21e-11	Blood protein levels;
LGG	cis	rs8067545	0.611	rs2189709	chr17:20083226	T/A	cg09818912	chr17:20140352	CYTSB	0.32	7.53	0.33	2.71e-13	Schizophrenia;
LGG	cis	rs12421382	0.659	rs2028337	chr11:109380887	G/C	cg04861929	chr11:109293070	C11orf87	0.55	10.09	0.42	9.03e-22	Schizophrenia;
LGG	cis	rs1008375	0.932	rs6841784	chr4:17626418	G/A	cg18681998	chr4:17616180	MED28	0.86	18.19	0.65	3.41e-56	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs17106184	0.536	rs3789586	chr1:51054322	A/G	cg07174182	chr1:51127561	FAF1	-0.37	-6.81	-0.3	3.02e-11	Type 2 diabetes;
LGG	cis	rs6582630	0.502	rs11514371	chr12:38306306	G/C	cg26384229	chr12:38710491	ALG10B	0.92	20.57	0.69	2.79e-67	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs17767392	0.881	rs7140501	chr14:72023175	C/G	cg02058870	chr14:72053146	SIPA1L1	-0.45	-9.39	-0.4	2.68e-19	Mitral valve prolapse;
LGG	cis	rs1552244	0.554	rs3732965	chr3:10048760	A/C	cg00149659	chr3:10157352	C3orf10	0.58	8.37	0.36	6.86e-16	Alzheimer's disease;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg21871583	chr3:15374148	SH3BP5	0.51	6.7	0.3	6.02e-11	Intelligence (multi-trait analysis);
LGG	trans	rs7618501	0.699	rs1317154	chr3:49910084	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.51	9.23	0.39	9.91e-19	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.967	rs175451	chr14:75589729	C/T	cg08847533	chr14:75593920	NEK9	-0.59	-11.38	-0.47	1.21e-26	Height;
LGG	cis	rs11098499	0.754	rs12506610	chr4:120241659	T/C	cg09307838	chr4:120376055	NA	0.72	12.42	0.5	9.37e-31	Corneal astigmatism;
LGG	cis	rs6504108	0.624	rs758999	chr17:46206015	C/T	cg02219949	chr17:45927392	SP6	0.43	8.19	0.36	2.62e-15	Body mass index;
LGG	cis	rs7618915	0.571	rs67539070	chr3:52711974	T/C	cg18099408	chr3:52552593	STAB1	-0.36	-7.07	-0.31	5.74e-12	Bipolar disorder;
LGG	cis	rs12586317	0.548	rs12590678	chr14:35602956	C/T	cg05294307	chr14:35346193	BAZ1A	-0.51	-7.19	-0.32	2.62e-12	Psoriasis;
LGG	cis	rs9311474	0.508	rs3796353	chr3:52593230	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.54	9.26	0.4	7.65e-19	Electroencephalogram traits;
LGG	cis	rs2708240	0.967	rs2080156	chr7:147571384	G/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.82	-0.3	2.9e-11	QT interval (drug interaction);
LGG	cis	rs35146811	0.625	rs858514	chr7:99825748	A/G	cg22906224	chr7:99728672	NA	-0.58	-9.32	-0.4	4.87e-19	Coronary artery disease;
LGG	cis	rs12410462	0.515	rs10916192	chr1:227852584	A/G	cg04117972	chr1:227635322	NA	0.45	8.22	0.36	2.12e-15	Major depressive disorder;
LGG	cis	rs6032067	0.641	rs13042991	chr20:43767178	A/G	cg10761708	chr20:43804764	PI3	0.74	11.11	0.46	1.4e-25	Blood protein levels;
LGG	cis	rs55823223	0.648	rs936393	chr17:73847613	A/G	cg14829360	chr17:73884958	NA	-0.75	-12.32	-0.5	2.23e-30	Psoriasis;
LGG	cis	rs11662586	0.517	rs7230837	chr18:77695384	A/T	cg20368463	chr18:77673604	PQLC1	0.69	14.24	0.55	2.02e-38	Exploratory eye movement dysfunction in schizophrenia (responsive search score);
LGG	cis	rs875971	1.000	rs778710	chr7:65854834	T/C	cg11764359	chr7:65958608	NA	0.79	14.78	0.57	9.14e-41	Aortic root size;
LGG	cis	rs17401966	0.540	rs11121557	chr1:10448260	T/G	cg17425144	chr1:10567563	PEX14	-0.43	-9.91	-0.42	3.91e-21	Hepatocellular carcinoma;
LGG	cis	rs963731	0.649	rs297149	chr2:39324469	G/C	cg04010122	chr2:39346883	SOS1	-0.91	-7.99	-0.35	1.11e-14	Corticobasal degeneration;
LGG	cis	rs832540	1.000	rs252914	chr5:56198150	A/C	cg14703610	chr5:56206110	C5orf35	0.43	7.39	0.32	6.87e-13	Coronary artery disease;
LGG	cis	rs2075671	0.903	rs11760602	chr7:100264128	G/C	cg21055462	chr7:100276975	NA	0.45	9.45	0.4	1.74e-19	Other erythrocyte phenotypes;
LGG	trans	rs853679	0.607	rs13201308	chr6:28130089	C/T	cg06606381	chr12:133084897	FBRSL1	-1.29	-12.1	-0.49	1.72e-29	Depression;
LGG	cis	rs1639906	0.895	rs3800926	chr7:2205956	G/A	cg20308403	chr7:2120281	MAD1L1	-0.38	-7.74	-0.34	6.5e-14	Colonoscopy-negative controls vs population controls;
LGG	trans	rs61931739	0.890	rs1705750	chr12:34142648	C/T	cg26384229	chr12:38710491	ALG10B	0.65	12.59	0.51	1.84e-31	Morning vs. evening chronotype;
LGG	cis	rs7208859	0.623	rs9899268	chr17:29150255	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.39	-0.36	5.8e-16	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7811142	1.000	rs67315960	chr7:100015124	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.2	20.9	0.7	8.31e-69	Platelet count;
LGG	cis	rs875971	0.862	rs10950043	chr7:65988610	T/C	cg18252515	chr7:66147081	NA	-0.43	-7.29	-0.32	1.38e-12	Aortic root size;
LGG	cis	rs28386778	0.897	rs2727330	chr17:61925498	A/G	cg11494091	chr17:61959527	GH2	-0.96	-21.3	-0.7	1.11e-70	Prudent dietary pattern;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg08017756	chr2:100939284	LONRF2	-0.29	-6.9	-0.31	1.71e-11	Intelligence (multi-trait analysis);
LGG	cis	rs734999	0.545	rs28690427	chr1:2571823	A/G	cg18854424	chr1:2615690	NA	-0.36	-7.17	-0.32	2.9e-12	Ulcerative colitis;
LGG	cis	rs34421088	0.560	rs2248325	chr8:11396874	A/G	cg00405596	chr8:11794950	NA	-0.39	-6.73	-0.3	5.13e-11	Neuroticism;
LGG	cis	rs28386778	0.897	rs2727287	chr17:61904728	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.36	-0.58	2.61e-43	Prudent dietary pattern;
LGG	trans	rs208520	0.955	rs12202599	chr6:67001573	A/G	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.81	12.97	0.52	5.16e-33	Exhaled nitric oxide output;
LGG	cis	rs7951870	0.673	rs13448	chr11:46695414	T/C	cg03339077	chr11:47165057	C11orf49	0.4	6.8	0.3	3.17e-11	Schizophrenia;
LGG	cis	rs1790761	0.505	rs4320958	chr11:67310334	G/A	cg00290607	chr11:67383545	NA	-0.5	-8.7	-0.37	5.78e-17	Mean corpuscular volume;
LGG	cis	rs72945132	0.825	rs7950280	chr11:70213455	G/T	cg00319359	chr11:70116639	PPFIA1	0.72	7.86	0.34	2.67e-14	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg19016517	chr19:36036881	TMEM147	0.39	7.02	0.31	7.84e-12	Obesity-related traits;
LGG	cis	rs79149102	0.579	rs2304904	chr15:75315975	G/A	cg09165964	chr15:75287851	SCAMP5	-0.83	-8.55	-0.37	1.85e-16	Lung cancer;
LGG	trans	rs7395662	0.591	rs4882110	chr11:48558249	G/T	cg15704280	chr7:45808275	SEPT13	-0.58	-10.01	-0.42	1.82e-21	HDL cholesterol;
LGG	cis	rs473651	0.904	rs472247	chr2:239362573	G/A	cg18131467	chr2:239335373	ASB1	1.02	23.54	0.74	3.93e-81	Multiple system atrophy;
LGG	cis	rs894344	0.572	rs16905167	chr8:135550073	T/C	cg09855544	chr8:135498122	ZFAT	0.43	7.67	0.34	1.04e-13	Systolic blood pressure;
LGG	cis	rs11599315	0.507	rs12218307	chr10:1341914	G/A	cg09624528	chr10:1369823	ADARB2	0.56	10.9	0.45	8.81e-25	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2712184	0.756	rs2024487	chr2:217663271	C/T	cg05032264	chr2:217675019	NA	0.42	9.2	0.39	1.22e-18	Glomerular filtration rate;Glomerular filtration rate in non diabetics (creatinine);
LGG	cis	rs752092	1.000	rs11636578	chr15:101787969	T/C	cg25114630	chr15:101792522	CHSY1	0.58	9.79	0.41	1.08e-20	Corneal structure;
LGG	cis	rs8078723	1.000	rs2227336	chr17:38174855	T/G	cg17467752	chr17:38218738	THRA	0.74	13.85	0.54	9.36e-37	C-reactive protein and white blood cell count;Neutrophil count;White blood cell count;White blood cell count (neutrophil);
LGG	cis	rs9611565	0.765	rs767593	chr22:41779971	G/T	cg06481639	chr22:41940642	POLR3H	-0.54	-8.01	-0.35	9.29e-15	Vitiligo;
LGG	cis	rs58688157	0.705	rs12419618	chr11:611531	G/A	cg16486109	chr11:613632	IRF7	0.41	6.9	0.31	1.73e-11	Systemic lupus erythematosus;
LGG	cis	rs8062405	0.824	rs240702	chr16:28531353	C/T	cg16576597	chr16:28551801	NUPR1	0.36	8.48	0.37	2.99e-16	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs2243480	1.000	rs313807	chr7:65499481	C/T	cg12463550	chr7:65579703	CRCP	0.77	8.16	0.35	3.14e-15	Diabetic kidney disease;
LGG	cis	rs2594989	0.943	rs2454492	chr3:11507793	G/A	cg01796438	chr3:11312864	ATG7	-0.52	-7.09	-0.31	5.2e-12	Circulating chemerin levels;
LGG	cis	rs9815354	0.761	rs1851149	chr3:42021708	T/C	cg03022575	chr3:42003672	ULK4	-0.62	-7.63	-0.33	1.31e-13	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs12681288	0.676	rs2701910	chr8:1001246	G/T	cg04851639	chr8:1020857	NA	-0.44	-9.07	-0.39	3.33e-18	Schizophrenia;
LGG	cis	rs6502050	0.835	rs12051747	chr17:80114814	T/C	cg23985595	chr17:80112537	CCDC57	-0.46	-9.25	-0.4	8.04e-19	Life satisfaction;
LGG	cis	rs12893668	0.703	rs34186780	chr14:104027595	T/G	cg23335576	chr14:104009727	NA	0.51	8.81	0.38	2.6e-17	Reticulocyte count;
LGG	cis	rs7122539	0.646	rs7930203	chr11:66583759	A/G	cg01599099	chr11:66649832	PC	0.48	9.79	0.41	1.09e-20	HIV-1 susceptibility;
LGG	cis	rs7226408	0.790	rs55935783	chr18:34346120	A/C	cg15022739	chr18:34823045	BRUNOL4	-0.45	-6.76	-0.3	4.3e-11	Obesity-related traits;
LGG	cis	rs11148252	0.574	rs7139495	chr13:53283318	A/G	cg16301924	chr13:53314226	LECT1	-0.35	-6.89	-0.31	1.79e-11	Lewy body disease;
LGG	cis	rs17227506	0.805	rs13254681	chr8:13438670	C/A	cg03566418	chr8:13424080	C8orf48	0.44	6.83	0.3	2.72e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs3924048	0.547	rs72642661	chr1:12612873	C/G	cg00291366	chr1:12616550	NA	0.37	9.01	0.39	5.5e-18	Optic cup area;
LGG	cis	rs11785400	0.642	rs4256574	chr8:143725705	C/T	cg24634471	chr8:143751801	JRK	0.49	7.48	0.33	3.69e-13	Schizophrenia;
LGG	cis	rs9938149	0.767	rs58577366	chr16:88323323	T/C	cg05435882	chr16:88311214	NA	0.4	6.76	0.3	4.27e-11	Corneal structure;Central corneal thickness;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg00106254	chr7:1943704	MAD1L1	-0.41	-7.11	-0.31	4.45e-12	Bipolar disorder and schizophrenia;
LGG	cis	rs1568889	1.000	rs12802830	chr11:28321196	G/T	cg06544937	chr11:28130018	METT5D1;KIF18A	0.73	13.07	0.52	1.94e-33	Bipolar disorder;
LGG	cis	rs12421382	0.636	rs1439519	chr11:109378438	A/G	cg00830817	chr11:109293614	C11orf87	0.42	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs2404602	1.000	rs4886818	chr15:76880939	G/A	cg15268244	chr15:77196840	NA	-0.34	-7.59	-0.33	1.78e-13	Blood metabolite levels;
LGG	cis	rs1408799	0.695	rs13288636	chr9:12721806	A/G	cg05274944	chr9:12693694	TYRP1	-0.34	-8.21	-0.36	2.19e-15	Eye color;Blue vs. green eyes;
LGG	cis	rs7582180	0.629	rs11686649	chr2:100946701	T/C	cg26150922	chr2:100937072	LONRF2	-0.6	-11.81	-0.48	2.66e-28	Intelligence (multi-trait analysis);
LGG	cis	rs80282103	0.764	rs7093915	chr10:1107341	A/G	cg08668510	chr10:1095578	IDI1	-0.76	-8.46	-0.37	3.56e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs559928	0.606	rs11605856	chr11:63925528	C/T	cg18225595	chr11:63971243	STIP1	0.56	7.58	0.33	1.85e-13	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs2290416	0.892	rs3829012	chr8:144664656	C/T	cg13282195	chr8:144660772	NAPRT1	0.93	7.44	0.33	4.86e-13	Attention deficit hyperactivity disorder;
LGG	cis	rs4740619	0.619	rs10738426	chr9:16041615	T/C	cg14451791	chr9:16040625	NA	-0.42	-11.39	-0.47	1.17e-26	Body mass index;
LGG	cis	rs72781680	0.898	rs6712524	chr2:24083925	T/C	cg08917208	chr2:24149416	ATAD2B	0.81	9.53	0.41	8.55e-20	Lymphocyte counts;
LGG	cis	rs875971	1.000	rs2087647	chr7:65593188	C/A	cg23594656	chr7:65796392	TPST1	0.39	8.51	0.37	2.36e-16	Aortic root size;
LGG	cis	rs2131877	0.830	rs62285217	chr3:194871405	G/A	cg07250128	chr3:194833983	C3orf21	0.4	6.72	0.3	5.26e-11	Non-small cell lung cancer;
LGG	cis	rs644799	0.965	rs549695	chr11:95617788	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.42	7.23	0.32	2.03e-12	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs2228479	0.850	rs62054638	chr16:89821131	G/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs11098499	0.779	rs7699346	chr4:120310542	C/T	cg09307838	chr4:120376055	NA	0.81	13.34	0.53	1.4e-34	Corneal astigmatism;
LGG	cis	rs2153535	0.580	rs1335643	chr6:8488021	T/G	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs7512552	0.839	rs6703652	chr1:150465953	T/G	cg15654264	chr1:150340011	RPRD2	0.45	9.26	0.4	7.96e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs6912958	1.000	rs6937823	chr6:88160386	G/C	cg08069147	chr6:88032118	GJB7;C6orf162	-0.59	-10.68	-0.44	5.82e-24	Monocyte percentage of white cells;
LGG	cis	rs9549367	0.789	rs8001506	chr13:113867153	A/C	cg18105134	chr13:113819100	PROZ	-0.67	-13.97	-0.54	2.8e-37	Platelet distribution width;
LGG	cis	rs7618501	0.519	rs3774750	chr3:50208406	C/G	cg24110177	chr3:50126178	RBM5	0.43	7.19	0.32	2.56e-12	Intelligence (multi-trait analysis);
LGG	cis	rs12893597	0.715	rs34486942	chr14:76831530	G/A	cg20290672	chr14:76816747	NA	-0.5	-7.66	-0.34	1.1e-13	Maximal oxygen uptake response;
LGG	cis	rs240764	0.817	rs12207086	chr6:101150463	G/A	cg09795085	chr6:101329169	ASCC3	-0.45	-7.59	-0.33	1.77e-13	Neuroticism;
LGG	cis	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg09783858	chr11:65769428	EIF1AD;BANF1	0.51	8.97	0.38	7.61e-18	Breast cancer;
LGG	cis	rs1577917	1.000	rs12201735	chr6:86656939	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.73	-13.06	-0.52	2.17e-33	Response to antipsychotic treatment;
LGG	cis	rs9815354	0.812	rs73069208	chr3:41939198	C/T	cg03022575	chr3:42003672	ULK4	0.82	9.56	0.41	7e-20	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs9467711	0.559	rs9393727	chr6:26500011	C/G	cg12826209	chr6:26865740	GUSBL1	0.79	8.98	0.39	6.7e-18	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs28491091	chr7:65669064	G/T	cg11764359	chr7:65958608	NA	-0.73	-12.99	-0.52	3.95e-33	Aortic root size;
LGG	cis	rs9875589	0.509	rs6442423	chr3:14016062	G/A	cg19554555	chr3:13937349	NA	-0.55	-9.85	-0.42	6.49e-21	Ovarian reserve;
LGG	cis	rs12681288	0.550	rs12675410	chr8:957845	T/C	cg15309053	chr8:964076	NA	0.42	9.02	0.39	5e-18	Schizophrenia;
LGG	cis	rs7760949	0.963	rs4142889	chr6:13918461	T/A	cg27413430	chr6:13925136	RNF182	0.43	6.73	0.3	5.07e-11	Mean corpuscular hemoglobin concentration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25509428	chr10:75118432	TTC18	0.45	6.75	0.3	4.44e-11	Gut microbiome composition (summer);
LGG	cis	rs1218582	0.741	rs6656494	chr1:154839799	A/G	cg03351412	chr1:154909251	PMVK	0.68	13.1	0.52	1.49e-33	Prostate cancer;
LGG	trans	rs6076960	0.713	rs3865568	chr20:6249339	A/G	cg17788362	chr6:86352627	SYNCRIP	0.54	9.14	0.39	1.97e-18	Smooth-surface caries;
LGG	cis	rs9393777	0.513	rs9393739	chr6:26646966	T/G	cg12826209	chr6:26865740	GUSBL1	0.81	12.12	0.49	1.45e-29	Intelligence (multi-trait analysis);
LGG	trans	rs8002861	0.870	rs12865116	chr13:44440441	C/G	cg17145862	chr1:211918768	LPGAT1	-0.92	-21.78	-0.71	6.16e-73	Leprosy;
LGG	cis	rs4771450	0.962	rs1360340	chr13:103971811	T/G	cg02987523	chr13:103978230	NA	-0.32	-6.82	-0.3	2.86e-11	Uric acid levels;
LGG	cis	rs3813359	0.545	rs17058571	chr6:130555572	T/C	cg23281432	chr6:130554730	NA	0.5	6.81	0.3	3.01e-11	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs2119480	0.762	rs401084	chr13:111310086	C/G	cg16216153	chr13:111290848	CARKD	-0.35	-6.85	-0.3	2.41e-11	Diastolic blood pressure;
LGG	cis	rs3768617	0.510	rs20563	chr1:183085755	C/T	cg15522984	chr1:182991683	LAMC1	-0.46	-9.16	-0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6546537	1.000	rs6727435	chr2:69864236	C/A	cg10773587	chr2:69614142	GFPT1	-0.47	-7.98	-0.35	1.16e-14	Serum thyroid-stimulating hormone levels;
LGG	cis	rs1153858	1.000	rs4271549	chr15:45652730	G/A	cg14582100	chr15:45693742	SPATA5L1	0.41	6.82	0.3	2.78e-11	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs9479494	chr6:150060244	A/G	cg09699651	chr6:150184138	LRP11	0.53	9.57	0.41	6.36e-20	Lung cancer;
LGG	cis	rs9660992	0.674	rs1151784	chr1:205232447	C/T	cg21545522	chr1:205238299	TMCC2	0.49	9.0	0.39	6.08e-18	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7100689	0.580	rs10736366	chr10:82207921	C/T	cg01528321	chr10:82214614	TSPAN14	0.82	14.89	0.57	3.06e-41	Post bronchodilator FEV1;
LGG	cis	rs2439831	0.850	rs12441127	chr15:44021175	T/C	cg27015174	chr15:43622946	ADAL;LCMT2	0.88	9.61	0.41	4.55e-20	Lung cancer in ever smokers;
LGG	cis	rs34734847	0.750	rs3829290	chr12:121126438	T/C	cg21892295	chr12:121157589	UNC119B	-0.4	-7.54	-0.33	2.56e-13	Mean corpuscular volume;
LGG	trans	rs561341	1.000	rs8073186	chr17:30244956	T/C	cg27661571	chr11:113659931	NA	-0.58	-8.47	-0.37	3.37e-16	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.923	rs2184370	chr6:150164378	G/A	cg07701084	chr6:150067640	NUP43	0.68	12.64	0.51	1.09e-31	Lung cancer;
LGG	cis	rs10504229	0.683	rs16921810	chr8:58106067	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.715	rs12368462	chr12:38336116	C/G	cg13010199	chr12:38710504	ALG10B	0.69	13.82	0.54	1.25e-36	Bladder cancer;
LGG	cis	rs9910055	0.593	rs2905983	chr17:42212429	T/G	cg19774624	chr17:42201019	HDAC5	0.94	20.05	0.68	8.1e-65	Total body bone mineral density;
LGG	cis	rs9926296	0.546	rs7187436	chr16:89845110	A/T	cg07440826	chr16:89882328	FANCA	-0.26	-7.01	-0.31	8.34e-12	Vitiligo;
LGG	cis	rs12681287	0.547	rs13260345	chr8:87483721	T/C	cg27223183	chr8:87520930	FAM82B	-0.5	-7.68	-0.34	9.4e-14	Caudate activity during reward;
LGG	cis	rs526231	0.543	rs34765	chr5:102506864	G/C	cg23492399	chr5:102201601	PAM	-0.57	-8.4	-0.36	5.62e-16	Primary biliary cholangitis;
LGG	cis	rs3762637	0.823	rs59569049	chr3:122238788	A/T	cg24169773	chr3:122142474	KPNA1	-0.62	-10.58	-0.44	1.41e-23	LDL cholesterol levels;
LGG	cis	rs17376456	0.877	rs10061080	chr5:93420559	A/G	cg09848695	chr5:92956644	FAM172A;MIR2277	0.9	9.94	0.42	3.23e-21	Diabetic retinopathy;
LGG	cis	rs12911832	1.000	rs12911961	chr15:58985867	C/T	cg05156742	chr15:59063176	FAM63B	0.57	9.03	0.39	4.51e-18	Schizophrenia;
LGG	cis	rs7937682	0.889	rs578022	chr11:111490552	G/T	cg19812747	chr11:111475976	SIK2	-0.51	-10.75	-0.45	3.25e-24	Primary sclerosing cholangitis;
LGG	cis	rs769267	0.965	rs1469712	chr19:19528821	C/A	cg26732615	chr19:19648335	CILP2;YJEFN3	0.53	14.5	0.56	1.58e-39	Tonsillectomy;
LGG	cis	rs3768617	0.510	rs10797846	chr1:183087485	A/T	cg07928641	chr1:182991847	LAMC1	0.46	9.25	0.4	8.14e-19	Fuchs's corneal dystrophy;
LGG	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg22563815	chr15:78856949	CHRNA5	-0.29	-7.11	-0.31	4.36e-12	Sudden cardiac arrest;
LGG	cis	rs10256972	0.869	rs1007766	chr7:1034903	G/A	cg07308232	chr7:1071921	C7orf50	-0.6	-11.47	-0.47	5.71e-27	Longevity;Endometriosis;
LGG	cis	rs4595586	0.545	rs6580892	chr12:39370237	G/C	cg13010199	chr12:38710504	ALG10B	0.41	7.38	0.32	7.45e-13	Morning vs. evening chronotype;
LGG	cis	rs6089584	0.853	rs1746280	chr20:60577821	C/G	cg13770153	chr20:60521292	NA	-0.63	-9.72	-0.41	1.88e-20	Body mass index;
LGG	cis	rs2576037	0.562	rs514371	chr18:44351943	G/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.55	-9.19	-0.39	1.32e-18	Personality dimensions;
LGG	cis	rs3749237	0.595	rs1464567	chr3:49459252	C/G	cg07636037	chr3:49044803	WDR6	-0.57	-9.68	-0.41	2.55e-20	Resting heart rate;
LGG	cis	rs9611565	0.625	rs9607819	chr22:41958862	C/G	cg17376030	chr22:41985996	PMM1	0.54	8.5	0.37	2.61e-16	Vitiligo;
LGG	cis	rs6121246	0.954	rs6089093	chr20:30421459	C/T	cg21427119	chr20:30132790	HM13	-0.45	-7.46	-0.33	4.2e-13	Mean corpuscular hemoglobin;
LGG	cis	rs6952808	0.595	rs3778984	chr7:2166514	T/C	cg19147804	chr7:1989927	MAD1L1	-0.55	-10.95	-0.45	5.8e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs537930	0.925	rs578475	chr5:134354896	C/G	cg24576358	chr5:134350122	NA	0.43	8.88	0.38	1.43e-17	Height;
LGG	cis	rs12950390	0.548	rs62076098	chr17:45860584	C/T	cg06532163	chr17:45867833	NA	0.4	7.03	0.31	7.28e-12	IgG glycosylation;
LGG	trans	rs6787172	0.702	rs827112	chr3:157979983	T/A	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs7929679	0.551	rs906902	chr11:34780278	A/G	cg06937548	chr11:34938143	PDHX;APIP	-0.43	-7.35	-0.32	8.88e-13	Chronic obstructive pulmonary disease-related biomarkers;Lung disease severity in cystic fibrosis;
LGG	cis	rs3106136	0.546	rs2632417	chr4:95137542	G/C	cg11021082	chr4:95130006	SMARCAD1	-0.58	-10.92	-0.45	7.51e-25	Capecitabine sensitivity;
LGG	cis	rs1003719	0.788	rs2835599	chr21:38466937	G/T	cg10648535	chr21:38446584	PIGP;TTC3	0.82	16.65	0.61	4e-49	Eye color traits;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg27144592	chr16:783916	NARFL	0.42	7.03	0.31	7.57e-12	Height;
LGG	cis	rs240764	0.507	rs9404033	chr6:101211541	A/T	cg09795085	chr6:101329169	ASCC3	0.44	7.15	0.32	3.4e-12	Neuroticism;
LGG	cis	rs12477438	1.000	rs12477438	chr2:99841085	T/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.01	-15.39	-0.58	1.93e-43	Chronic sinus infection;
LGG	cis	rs883565	0.528	rs9311200	chr3:38953896	C/T	cg01426195	chr3:39028469	NA	-0.59	-12.54	-0.5	2.8e-31	Handedness;
LGG	cis	rs10504229	0.683	rs56741275	chr8:58136108	C/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs73001065	0.901	rs3794991	chr19:19610596	C/T	cg03709012	chr19:19516395	GATAD2A	0.92	8.13	0.35	3.96e-15	LDL cholesterol;
LGG	cis	rs7666738	1.000	rs13106934	chr4:99028685	C/T	cg05340658	chr4:99064831	C4orf37	0.42	6.71	0.3	5.6e-11	Colonoscopy-negative controls vs population controls;
LGG	cis	rs4740619	0.740	rs10962147	chr9:15771170	A/G	cg14451791	chr9:16040625	NA	0.35	8.81	0.38	2.55e-17	Body mass index;
LGG	cis	rs12210905	0.622	rs116198502	chr6:26915015	A/G	cg23155468	chr6:27110703	HIST1H2BK	-0.58	-7.51	-0.33	3.09e-13	Hip circumference adjusted for BMI;
LGG	cis	rs3741404	0.609	rs641430	chr11:63869531	C/T	cg05016508	chr11:63871570	FLRT1;MACROD1	-0.39	-7.9	-0.34	2.09e-14	Platelet count;
LGG	cis	rs2276314	1.000	rs4573997	chr18:33552568	C/T	cg19628046	chr18:33552617	C18orf21	0.54	7.83	0.34	3.32e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	trans	rs61931739	0.534	rs11052979	chr12:34035774	G/T	cg13010199	chr12:38710504	ALG10B	0.57	10.63	0.44	9.1e-24	Morning vs. evening chronotype;
LGG	cis	rs643506	0.874	rs613292	chr11:111668805	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.97	0.31	1.07e-11	Breast cancer;
LGG	cis	rs7737355	0.898	rs10079359	chr5:130758283	A/G	cg06307176	chr5:131281290	NA	-0.52	-8.78	-0.38	3.18e-17	Life satisfaction;
LGG	cis	rs2228479	0.557	rs2293584	chr16:89888686	C/G	cg26513180	chr16:89883248	FANCA	1.02	9.6	0.41	5.2e-20	Skin colour saturation;
LGG	cis	rs208520	0.690	rs1738970	chr6:66809491	T/G	cg07460842	chr6:66804631	NA	-0.98	-18.64	-0.65	2.97e-58	Exhaled nitric oxide output;
LGG	cis	rs7681440	0.904	rs6532192	chr4:90764131	G/A	cg18258770	chr4:90757814	SNCA	-0.42	-7.72	-0.34	7.49e-14	Dementia with Lewy bodies;
LGG	cis	rs9354308	0.727	rs9345720	chr6:66615832	A/C	cg07460842	chr6:66804631	NA	-0.42	-7.05	-0.31	6.35e-12	Metabolite levels;
LGG	cis	rs4819052	0.851	rs58644915	chr21:46669912	T/C	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	8.97	0.38	7.33e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1018836	0.608	rs6998106	chr8:91479755	G/T	cg16814680	chr8:91681699	NA	-0.59	-9.79	-0.41	1.1e-20	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs7829975	0.774	rs13259216	chr8:8673601	A/C	cg15556689	chr8:8085844	FLJ10661	0.46	8.35	0.36	8.06e-16	Mood instability;
LGG	cis	rs9916302	0.904	rs6503519	chr17:37706578	A/G	cg00129232	chr17:37814104	STARD3	-0.61	-11.57	-0.47	2.2e-27	Glomerular filtration rate (creatinine);
LGG	cis	rs9311474	0.659	rs7638808	chr3:52572056	C/T	cg15147215	chr3:52552868	STAB1	0.39	7.44	0.33	4.99e-13	Electroencephalogram traits;
LGG	trans	rs7824557	0.564	rs13268126	chr8:11230574	G/A	cg16141378	chr3:129829833	LOC729375	0.37	8.13	0.35	3.83e-15	Retinal vascular caliber;
LGG	cis	rs28655083	0.529	rs682081	chr16:77103050	T/C	cg01753188	chr16:77233325	SYCE1L;MON1B	0.43	7.38	0.32	7.35e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs977987	0.815	rs11149818	chr16:75419373	G/A	cg07303275	chr16:75499416	TMEM170A	0.36	6.66	0.3	7.81e-11	Dupuytren's disease;
LGG	trans	rs9325144	0.560	rs7980635	chr12:38668355	G/T	cg06521331	chr12:34319734	NA	0.44	7.59	0.33	1.79e-13	Morning vs. evening chronotype;
LGG	cis	rs11967485	0.534	rs62435827	chr6:157189490	A/C	cg23222435	chr6:157204239	ARID1B	-0.79	-7.22	-0.32	2.15e-12	Calcium levels;
LGG	cis	rs28386778	0.897	rs1062788	chr17:61896127	C/G	cg07677032	chr17:61819896	STRADA	0.67	12.5	0.5	4.47e-31	Prudent dietary pattern;
LGG	cis	rs4780401	0.678	rs7193441	chr16:11764821	C/T	cg01061890	chr16:11836724	TXNDC11	-0.43	-7.12	-0.31	4.26e-12	Rheumatoid arthritis;
LGG	cis	rs12477438	0.561	rs2084988	chr2:99655755	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.88	-15.35	-0.58	2.79e-43	Chronic sinus infection;
LGG	cis	rs10504229	0.728	rs55812114	chr8:58157453	C/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs2228479	0.850	rs11646766	chr16:89838578	A/T	cg27400746	chr16:89904261	SPIRE2	-1.13	-16.94	-0.62	1.96e-50	Skin colour saturation;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg18455759	chr8:126443767	TRIB1	0.37	6.68	0.3	7.04e-11	Obesity-related traits;
LGG	cis	rs643506	0.845	rs607327	chr11:111695709	C/T	cg09085632	chr11:111637200	PPP2R1B	0.43	6.89	0.31	1.81e-11	Breast cancer;
LGG	cis	rs3126085	0.935	rs12729662	chr1:152185750	G/A	cg26876637	chr1:152193138	HRNR	-0.51	-7.88	-0.34	2.4e-14	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg05422957	chr4:122873181	TRPC3	0.46	7.47	0.33	4.12e-13	Gut microbiome composition (summer);
LGG	cis	rs4660214	0.614	rs11205802	chr1:39699114	C/T	cg18385671	chr1:39797026	MACF1	-0.45	-9.47	-0.4	1.5e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs67133203	0.851	rs11169642	chr12:51363511	G/A	cg14688905	chr12:51403056	SLC11A2	0.76	11.59	0.47	1.95e-27	Urinary tract infection frequency;
LGG	cis	rs1697139	0.583	rs17289614	chr5:66541592	G/A	cg11553311	chr5:66541588	NA	0.45	10.01	0.42	1.76e-21	Breast cancer;
LGG	cis	rs427394	0.802	rs274694	chr5:6734079	A/G	cg15145174	chr5:6755386	POLS	-0.4	-7.63	-0.33	1.34e-13	Menopause (age at onset);
LGG	cis	rs10435719	0.902	rs12681142	chr8:11802601	T/C	cg21775007	chr8:11205619	TDH	0.44	6.9	0.31	1.68e-11	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs2204008	0.658	rs11495742	chr12:38395688	C/A	cg26384229	chr12:38710491	ALG10B	0.98	21.31	0.7	1.03e-70	Bladder cancer;
LGG	cis	rs7819412	0.545	rs11985603	chr8:10918393	G/A	cg21775007	chr8:11205619	TDH	-0.45	-6.96	-0.31	1.14e-11	Triglycerides;
LGG	cis	rs899997	1.000	rs7182694	chr15:79045030	C/T	cg09845145	chr15:78292470	TBC1D2B	0.69	14.02	0.55	1.88e-37	Coronary artery disease or large artery stroke;
LGG	cis	rs208520	0.545	rs6899712	chr6:66749670	T/C	cg07460842	chr6:66804631	NA	1.1	28.69	0.8	8.99e-105	Exhaled nitric oxide output;
LGG	cis	rs11064837	0.504	rs117140346	chr12:120056619	A/C	cg25937854	chr12:120150414	CIT	-0.58	-10.11	-0.43	7.78e-22	Schizophrenia;
LGG	cis	rs1969363	0.531	rs11495331	chr12:38110702	A/G	cg26384229	chr12:38710491	ALG10B	0.68	13.11	0.52	1.34e-33	Morning vs. evening chronotype;
LGG	cis	rs6500602	0.964	rs2896893	chr16:4478559	T/A	cg19168338	chr16:4465731	CORO7	-0.9	-18.17	-0.65	4.25e-56	Schizophrenia;
LGG	cis	rs4664308	0.935	rs4292050	chr2:160940899	G/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.87	-0.64	1.02e-54	Idiopathic membranous nephropathy;
LGG	cis	rs6500602	0.701	rs8129	chr16:4562351	A/G	cg01673284	chr16:4527211	HMOX2	0.35	6.91	0.31	1.56e-11	Schizophrenia;
LGG	cis	rs13421350	0.710	rs6726739	chr2:173320380	A/G	cg15021238	chr2:173305865	ITGA6	0.44	7.61	0.33	1.53e-13	Diabetic kidney disease;
LGG	cis	rs1707322	1.000	rs946524	chr1:46487560	A/G	cg03146154	chr1:46216737	IPP	-0.52	-9.93	-0.42	3.33e-21	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs3540	0.597	rs1978151	chr15:91037300	C/T	cg22089800	chr15:90895588	ZNF774	0.69	12.8	0.51	2.43e-32	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	trans	rs9467711	0.659	rs35680819	chr6:26455814	T/C	cg06606381	chr12:133084897	FBRSL1	-1.07	-10.47	-0.44	3.57e-23	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9947295	0.649	rs57958293	chr18:11778839	T/C	cg14735704	chr18:11749182	GNAL	0.49	7.42	0.33	5.61e-13	QT interval (drug interaction);
LGG	cis	rs6952808	0.501	rs4721429	chr7:2171704	T/C	cg04267008	chr7:1944627	MAD1L1	-0.57	-9.73	-0.41	1.83e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.510	rs3768616	chr1:183103551	T/C	cg15522984	chr1:182991683	LAMC1	0.45	8.84	0.38	2.08e-17	Fuchs's corneal dystrophy;
LGG	cis	rs210142	1.000	rs210142	chr6:33546837	T/C	cg24505687	chr6:33548425	BAK1	0.57	9.06	0.39	3.77e-18	Platelet count;Plateletcrit;Chronic lymphocytic leukemia;
LGG	cis	rs1707322	0.721	rs4559551	chr1:46167533	T/C	cg03146154	chr1:46216737	IPP	0.56	10.91	0.45	8.11e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7927771	0.697	rs11039307	chr11:47611152	C/T	cg20307385	chr11:47447363	PSMC3	-0.42	-7.6	-0.33	1.71e-13	Subjective well-being;
LGG	cis	rs4862750	0.794	rs1030382	chr4:187903782	T/G	cg03647317	chr4:187891568	NA	-0.41	-8.95	-0.38	8.95e-18	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs10504229	0.813	rs6999878	chr8:58197243	C/G	cg05313129	chr8:58192883	C8orf71	-0.66	-9.66	-0.41	3.1e-20	Developmental language disorder (linguistic errors);
LGG	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg17294928	chr15:75287854	SCAMP5	0.6	11.19	0.46	6.56e-26	Breast cancer;
LGG	cis	rs796364	1.000	rs281763	chr2:200794870	C/T	cg17644776	chr2:200775616	C2orf69	0.58	7.23	0.32	2e-12	Schizophrenia;
LGG	cis	rs75920871	0.528	rs7941428	chr11:116903384	C/G	cg01368799	chr11:117014884	PAFAH1B2	-0.51	-7.4	-0.33	6.2800000000000005e-13	Subjective well-being;
LGG	cis	rs7945705	0.902	rs2568059	chr11:8884161	T/C	cg00186954	chr11:8933980	ST5;C11orf17	-0.38	-7.94	-0.35	1.58e-14	Hemoglobin concentration;
LGG	cis	rs2153535	0.580	rs6597318	chr6:8437289	G/A	cg07606381	chr6:8435919	SLC35B3	0.69	12.66	0.51	9.76e-32	Motion sickness;
LGG	cis	rs6951245	0.554	rs78999139	chr7:1138525	G/A	cg24642844	chr7:1081250	C7orf50	-0.45	-8.52	-0.37	2.27e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6445975	0.572	rs4320076	chr3:58405284	T/G	cg24175188	chr3:58374923	PXK	-0.57	-9.32	-0.4	4.62e-19	Systemic lupus erythematosus;
LGG	cis	rs4843747	0.671	rs8053377	chr16:88106465	A/G	cg09044154	chr16:88155775	NA	-0.49	-7.47	-0.33	3.97e-13	Menopause (age at onset);
LGG	cis	rs2576037	0.583	rs641366	chr18:44430326	C/T	cg23302884	chr18:44338147	ST8SIA5	-0.48	-9.8	-0.41	9.6e-21	Personality dimensions;
LGG	cis	rs4262150	0.767	rs17453481	chr5:151949017	A/C	cg12297329	chr5:152029980	NA	-0.79	-14.97	-0.57	1.28e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs12541335	0.639	rs7834182	chr8:22163112	G/A	cg18135555	chr8:22132992	PIWIL2	0.4	10.48	0.44	3.45e-23	Hypertriglyceridemia;
LGG	cis	rs10911232	0.507	rs2151669	chr1:183055398	T/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs1865760	0.963	rs1540273	chr6:25924158	T/C	cg16482183	chr6:26056742	HIST1H1C	0.53	9.43	0.4	1.99e-19	Height;
LGG	cis	rs1552244	0.882	rs67631672	chr3:10004768	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.79	-12.44	-0.5	7.45e-31	Alzheimer's disease;
LGG	cis	rs9790314	1.000	rs9790314	chr3:161019558	T/C	cg04691961	chr3:161091175	C3orf57	-0.61	-14.3	-0.55	1.13e-38	Morning vs. evening chronotype;
LGG	trans	rs1493916	1.000	rs4799729	chr18:31393521	C/T	cg27147174	chr7:100797783	AP1S1	0.7	13.19	0.52	6.17e-34	Life satisfaction;
LGG	cis	rs4975709	0.569	rs2077269	chr5:1863506	C/T	cg04080417	chr5:1859792	NA	-0.53	-8.86	-0.38	1.74e-17	Cardiovascular disease risk factors;
LGG	cis	rs9322193	0.923	rs9800614	chr6:149965740	G/A	cg05861140	chr6:150128134	PCMT1	-0.43	-9.59	-0.41	5.56e-20	Lung cancer;
LGG	cis	rs889398	0.771	rs3790080	chr16:69902139	A/G	cg00738113	chr16:70207722	CLEC18C	-0.24	-6.88	-0.3	2.01e-11	Body mass index;
LGG	cis	rs2361718	0.590	rs4527052	chr17:78140910	A/G	cg21238619	chr17:78079768	GAA	-0.35	-7.16	-0.32	3.21e-12	Yeast infection;
LGG	cis	rs4650994	0.525	rs2493848	chr1:178547838	T/A	cg19399532	chr1:178512495	C1orf220	-0.54	-10.96	-0.45	5.19e-25	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs1862618	0.573	rs2591962	chr5:56237155	G/A	cg08400814	chr5:56204995	C5orf35	0.53	8.25	0.36	1.63e-15	Initial pursuit acceleration;
LGG	cis	rs3087591	0.521	rs1013948	chr17:29530709	C/T	cg24425628	chr17:29625626	OMG;NF1	0.65	9.47	0.4	1.5e-19	Hip circumference;
LGG	cis	rs7681440	0.904	rs35424815	chr4:90767877	C/T	cg26578617	chr4:90757533	SNCA	-0.45	-9.2	-0.39	1.25e-18	Dementia with Lewy bodies;
LGG	trans	rs66887589	0.807	rs13134517	chr4:120405262	G/A	cg25214090	chr10:38739885	LOC399744	0.38	6.96	0.31	1.15e-11	Diastolic blood pressure;
LGG	cis	rs57221529	0.766	rs12521051	chr5:560440	A/G	cg07777115	chr5:623756	CEP72	0.57	7.17	0.32	3.04e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs763014	0.931	rs7192508	chr16:630367	C/T	cg09263875	chr16:632152	PIGQ	0.64	12.67	0.51	8.29e-32	Height;
LGG	cis	rs10504229	0.679	rs75402323	chr8:58136227	A/G	cg23782820	chr8:58130467	NA	0.56	8.35	0.36	7.84e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7618915	0.547	rs2286800	chr3:52778051	C/T	cg18404041	chr3:52824283	ITIH1	-0.55	-10.39	-0.43	7.17e-23	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg09699651	chr6:150184138	LRP11	0.53	9.48	0.4	1.31e-19	Lung cancer;
LGG	cis	rs597539	0.652	rs482172	chr11:68668437	C/A	cg04008888	chr11:68622739	NA	-0.55	-11.81	-0.48	2.46e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10276381	0.685	rs56398224	chr7:28205748	A/AT	cg23620719	chr7:28220237	JAZF1	0.81	8.3	0.36	1.19e-15	Crohn's disease;
LGG	cis	rs4704846	0.950	rs6555853	chr5:156541451	C/T	cg12943317	chr5:156479607	HAVCR1	-0.59	-7.47	-0.33	4.15e-13	Blood protein levels;
LGG	cis	rs9914988	0.832	rs35033748	chr17:27179590	T/C	cg20469991	chr17:27169893	C17orf63	-0.53	-6.72	-0.3	5.41e-11	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	trans	rs9329221	0.537	rs13264586	chr8:9979385	T/C	cg15556689	chr8:8085844	FLJ10661	0.45	8.2	0.36	2.31e-15	Neuroticism;
LGG	cis	rs798554	0.836	rs798502	chr7:2789880	G/T	cg18446336	chr7:2847575	GNA12	0.3	7.2	0.32	2.51e-12	Height;
LGG	trans	rs1814175	0.645	rs28478790	chr11:50054322	C/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.86	-0.71	2.62e-73	Height;
LGG	cis	rs2544523	0.511	rs2544535	chr2:15906778	A/G	cg26669897	chr2:15909070	NA	0.46	12.72	0.51	5.1e-32	Asthma or chronic obstructive pulmonary disease;
LGG	cis	rs7605378	1.000	rs769954	chr2:200692159	C/G	cg23649088	chr2:200775458	C2orf69	-0.53	-9.04	-0.39	4.44e-18	Osteoporosis;
LGG	cis	rs11758351	0.866	rs11757394	chr6:26206694	G/C	cg23601095	chr6:26197514	HIST1H3D	0.72	9.21	0.39	1.11e-18	Gout;Renal underexcretion gout;
LGG	cis	rs57927100	0.734	rs1436138	chr17:75316880	A/G	cg18271897	chr17:75316784	SEPT9	0.51	14.45	0.56	2.41e-39	Systolic blood pressure;
LGG	cis	rs7084402	0.935	rs1427195	chr10:60278967	T/C	cg07615347	chr10:60278583	BICC1	-0.63	-18.14	-0.64	5.7e-56	Refractive error;
LGG	cis	rs4517514	0.509	rs11018875	chr11:89876356	T/C	cg21153622	chr11:89784906	NA	-0.6	-6.74	-0.3	4.77e-11	Trans fatty acid levels;
LGG	trans	rs7246760	1.000	rs58137206	chr19:9856624	G/A	cg02900749	chr2:68251473	NA	-1.02	-11.21	-0.46	5.85e-26	Pursuit maintenance gain;
LGG	cis	rs568617	0.953	rs583887	chr11:65644027	T/C	cg26695010	chr11:65641043	EFEMP2	0.48	6.91	0.31	1.58e-11	Crohn's disease;
LGG	cis	rs28374715	0.627	rs28516832	chr15:41367036	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.97	-15.82	-0.59	2.28e-45	Ulcerative colitis;
LGG	cis	rs13401104	0.587	rs7581196	chr2:237151098	A/C	cg15742758	chr2:237126235	ASB18	-0.38	-6.81	-0.3	3.01e-11	Educational attainment;
LGG	cis	rs10504229	0.683	rs17194792	chr8:58107195	A/C	cg21724239	chr8:58056113	NA	0.62	9.1	0.39	2.64e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs4665809	0.941	rs6735145	chr2:26270302	T/C	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-12.9	-0.51	9.5e-33	Gut microbiome composition (summer);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg07928105	chr7:75368414	HIP1	0.62	7.07	0.31	5.75e-12	Intelligence (multi-trait analysis);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg03952484	chr1:149899818	SF3B4	0.55	8.77	0.38	3.47e-17	Gut microbiome composition (summer);
LGG	cis	rs10791323	0.538	rs1105494	chr11:133698733	A/C	cg06766960	chr11:133703094	NA	0.53	10.24	0.43	2.63e-22	Childhood ear infection;
LGG	cis	rs769267	0.930	rs751856	chr19:19602945	A/G	cg11584989	chr19:19387371	SF4	0.39	7.16	0.32	3.17e-12	Tonsillectomy;
LGG	cis	rs4788570	0.584	rs979790	chr16:71665985	A/T	cg06353428	chr16:71660113	MARVELD3	-1.24	-15.95	-0.6	6.09e-46	Intelligence (multi-trait analysis);
LGG	cis	rs9906944	0.707	rs1523136	chr17:47144532	A/G	cg10950924	chr17:47092072	IGF2BP1	-0.37	-6.7	-0.3	5.9e-11	Intelligence (multi-trait analysis);Body fat percentage;
LGG	trans	rs9657904	0.774	rs28427229	chr3:105559032	G/A	cg14088669	chr1:158435396	OR10K1	0.42	7.95	0.35	1.4e-14	Multiple sclerosis;
LGG	cis	rs12580194	0.593	rs12578879	chr12:55797773	C/T	cg19537932	chr12:55886519	OR6C68	-0.58	-10.51	-0.44	2.68e-23	Cancer;
LGG	cis	rs10504229	0.683	rs55881798	chr8:58106406	T/C	cg11062466	chr8:58055876	NA	0.54	8.74	0.38	4.22e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs5742933	0.948	rs7592066	chr2:190643518	C/T	cg04003228	chr2:190539410	ANKAR	-0.48	-7.0	-0.31	8.87e-12	Ferritin levels;
LGG	cis	rs7119	0.717	rs8042307	chr15:77804013	A/G	cg10437265	chr15:77819839	NA	0.25	6.86	0.3	2.21e-11	Type 2 diabetes;
LGG	cis	rs1218582	0.741	rs883718	chr1:154846274	C/T	cg16318349	chr1:154917307	PBXIP1	-0.26	-6.94	-0.31	1.32e-11	Prostate cancer;
LGG	cis	rs2439831	1.000	rs550239	chr15:43720197	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.76	0.45	2.91e-24	Lung cancer in ever smokers;
LGG	cis	rs947474	0.793	rs4750316	chr10:6393260	C/G	cg19837174	chr10:6389707	NA	0.58	8.64	0.37	9.52e-17	Type 1 diabetes;Rheumatoid arthritis;
LGG	cis	rs2916247	1.000	rs6987284	chr8:93018479	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.41	-8.72	-0.38	5.16e-17	Intelligence (multi-trait analysis);
LGG	cis	rs6977660	0.941	rs4721825	chr7:19823427	A/C	cg05791153	chr7:19748676	TWISTNB	0.59	8.93	0.38	1e-17	Thyroid stimulating hormone;
LGG	cis	rs12421382	0.507	rs10890995	chr11:109327622	A/G	cg16359550	chr11:109292809	C11orf87	-0.7	-14.6	-0.56	5.76e-40	Schizophrenia;
LGG	cis	rs977987	0.806	rs4888416	chr16:75449176	C/G	cg03315344	chr16:75512273	CHST6	0.51	10.21	0.43	3.21e-22	Dupuytren's disease;
LGG	cis	rs2204008	0.571	rs1117803	chr12:38281007	C/G	cg26384229	chr12:38710491	ALG10B	-0.63	-12.23	-0.49	5.12e-30	Bladder cancer;
LGG	trans	rs7937682	0.889	rs10749984	chr11:111492861	T/C	cg18187862	chr3:45730750	SACM1L	0.57	9.49	0.4	1.22e-19	Primary sclerosing cholangitis;
LGG	cis	rs6933660	0.800	rs2046371	chr6:151754744	G/A	cg02564969	chr6:151773285	C6orf211;RMND1	0.42	7.32	0.32	1.1e-12	Menarche (age at onset);
LGG	cis	rs4794106	0.792	rs847682	chr17:48208274	C/T	cg13893634	chr17:48229117	PPP1R9B	-0.55	-9.55	-0.41	7.8500000000000006e-20	Temporomandibular joint disorder;
LGG	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg11812906	chr14:75593930	NEK9	-0.43	-7.7	-0.34	8.58e-14	Height;
LGG	cis	rs10426930	0.621	rs10409229	chr19:5009545	C/T	cg15621731	chr19:5074616	KDM4B	-0.29	-6.65	-0.3	8.52e-11	Monocyte percentage of white cells;
LGG	cis	rs7123876	0.717	rs58249351	chr11:72463462	G/A	cg04827223	chr11:72435913	ARAP1	-0.45	-7.62	-0.33	1.45e-13	Body mass index;
LGG	cis	rs2594989	0.943	rs6784861	chr3:11465568	T/C	cg01796438	chr3:11312864	ATG7	-0.55	-7.56	-0.33	2.25e-13	Circulating chemerin levels;
LGG	cis	rs2243480	1.000	rs34933526	chr7:65383199	A/G	cg18252515	chr7:66147081	NA	-1.32	-18.88	-0.66	2.17e-59	Diabetic kidney disease;
LGG	cis	rs67311347	1.000	rs67311347	chr3:40533243	G/A	cg24209194	chr3:40518798	ZNF619	0.47	7.35	0.32	8.78e-13	Renal cell carcinoma;
LGG	trans	rs7395662	1.000	rs11039862	chr11:48618306	A/G	cg00717180	chr2:96193071	NA	-0.43	-7.53	-0.33	2.77e-13	HDL cholesterol;
LGG	cis	rs9329221	0.537	rs12678797	chr8:9978919	A/G	cg19847130	chr8:10466454	RP1L1	0.31	6.87	0.3	2.1e-11	Neuroticism;
LGG	cis	rs6502050	0.787	rs59251877	chr17:80056498	G/A	cg07959490	chr17:80112427	CCDC57	0.37	7.27	0.32	1.55e-12	Life satisfaction;
LGG	cis	rs4919694	0.572	rs72846714	chr10:104878454	G/A	cg04362960	chr10:104952993	NT5C2	0.88	13.41	0.53	7.14e-35	Arsenic metabolism;
LGG	cis	rs28374715	0.662	rs522063	chr15:41476209	A/G	cg18705301	chr15:41695430	NDUFAF1	0.98	17.59	0.63	2.12e-53	Ulcerative colitis;
LGG	cis	rs12681366	0.659	rs2470742	chr8:95398157	G/C	cg13257157	chr8:95487014	RAD54B	-0.37	-6.81	-0.3	2.96e-11	Nonsyndromic cleft lip with cleft palate;
LGG	cis	rs1153858	1.000	rs1554521	chr15:45664189	A/T	cg05280133	chr15:45670068	GATM;LOC145663	-0.43	-7.93	-0.35	1.64e-14	Homoarginine levels;
LGG	cis	rs10256972	0.577	rs4999286	chr7:1199506	C/G	cg15112475	chr7:1198522	ZFAND2A	-0.38	-6.82	-0.3	2.86e-11	Longevity;Endometriosis;
LGG	trans	rs561341	0.556	rs542244	chr17:30307242	T/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs11148252	0.904	rs9568734	chr13:53004222	G/A	cg22398616	chr13:53314203	LECT1	-0.55	-12.18	-0.49	8.81e-30	Lewy body disease;
LGG	cis	rs6952808	0.564	rs73038441	chr7:2139286	T/C	cg00106254	chr7:1943704	MAD1L1	-0.43	-7.57	-0.33	1.98e-13	Bipolar disorder and schizophrenia;
LGG	trans	rs6076960	0.623	rs6038407	chr20:6267326	A/G	cg24759859	chr6:86352639	SYNCRIP	0.43	7.12	0.31	4.07e-12	Smooth-surface caries;
LGG	cis	rs7681440	0.835	rs1899389	chr4:90802998	G/A	cg20003494	chr4:90757398	SNCA	-0.41	-8.04	-0.35	7.7e-15	Dementia with Lewy bodies;
LGG	cis	rs1008375	0.931	rs3796814	chr4:17602033	G/C	cg04450456	chr4:17643702	FAM184B	0.32	6.84	0.3	2.46e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1865760	0.865	rs1115920	chr6:25954027	A/G	cg18357526	chr6:26021779	HIST1H4A	0.44	7.25	0.32	1.76e-12	Height;
LGG	cis	rs4262150	0.883	rs6579959	chr5:152107383	C/T	cg12297329	chr5:152029980	NA	-0.63	-11.85	-0.48	1.82e-28	Bipolar disorder and schizophrenia;
LGG	cis	rs9911578	1.000	rs2333332	chr17:56631054	A/G	cg12560992	chr17:57184187	TRIM37	-0.89	-15.85	-0.59	1.62e-45	Intelligence (multi-trait analysis);
LGG	cis	rs6430585	0.591	rs724326	chr2:136485971	T/C	cg07169764	chr2:136633963	MCM6	0.94	15.76	0.59	4.28e-45	Corneal structure;
LGG	cis	rs3126085	0.935	rs11584340	chr1:152285930	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-8.1	-0.35	4.76e-15	Atopic dermatitis;
LGG	cis	rs3750965	1.000	rs4930643	chr11:68818936	A/G	cg23121140	chr11:68816938	TPCN2	0.36	7.02	0.31	8.15e-12	Hair color;
LGG	cis	rs898097	0.528	rs2243523	chr17:80680449	G/T	cg15664640	chr17:80829946	TBCD	-0.53	-9.78	-0.41	1.18e-20	Breast cancer;
LGG	cis	rs1865760	0.622	rs10946807	chr6:26079638	T/C	cg18357526	chr6:26021779	HIST1H4A	0.48	6.99	0.31	9.8e-12	Height;
LGG	trans	rs4635383	0.696	rs6504780	chr17:50767156	A/T	cg07077115	chr13:28024429	MTIF3	-0.39	-6.67	-0.3	7.47e-11	Body fat mass;
LGG	cis	rs62400317	0.859	rs12196217	chr6:45204921	C/T	cg18551225	chr6:44695536	NA	-0.62	-9.8	-0.41	1.03e-20	Total body bone mineral density;
LGG	cis	rs4696584	0.816	rs6536014	chr4:155403068	C/T	cg04517429	chr4:155413618	DCHS2	0.31	7.32	0.32	1.09e-12	Folding of antihelix;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg02002194	chr4:3960332	NA	-0.51	-9.95	-0.42	2.85e-21	Neuroticism;
LGG	trans	rs7939886	0.920	rs17150117	chr11:55941186	T/C	cg03929089	chr4:120376271	NA	0.73	6.85	0.3	2.37e-11	Myopia (pathological);
LGG	cis	rs7618915	0.571	rs6805539	chr3:52609710	T/A	cg14092988	chr3:52407081	DNAH1	0.32	8.39	0.36	5.94e-16	Bipolar disorder;
LGG	cis	rs4950322	0.570	rs72692905	chr1:146773253	C/T	cg22381352	chr1:146742008	CHD1L	-0.5	-8.13	-0.35	4.1e-15	Protein quantitative trait loci;
LGG	cis	rs870825	0.616	rs7682505	chr4:185640648	C/T	cg04058563	chr4:185651563	MLF1IP	1.02	22.41	0.72	7.18e-76	Blood protein levels;
LGG	cis	rs60871478	1.000	rs62432251	chr7:801855	T/G	cg05535760	chr7:792225	HEATR2	0.8	12.97	0.52	5.03e-33	Cerebrospinal P-tau181p levels;
LGG	cis	rs4740619	0.740	rs10810446	chr9:15782358	C/G	cg14451791	chr9:16040625	NA	0.34	8.85	0.38	1.85e-17	Body mass index;
LGG	cis	rs11252926	0.527	rs11252754	chr10:538637	G/A	cg18196295	chr10:418757	DIP2C	0.46	8.61	0.37	1.14e-16	Psychosis in Alzheimer's disease;
LGG	trans	rs11782517	0.920	rs4258008	chr8:10115960	T/C	cg16141378	chr3:129829833	LOC729375	-0.39	-7.36	-0.32	8.64e-13	Nose size;
LGG	cis	rs7580658	0.895	rs62157549	chr2:128066007	A/G	cg10021288	chr2:128175891	PROC	-0.62	-12.77	-0.51	3.26e-32	Protein C levels;
LGG	cis	rs981844	0.617	rs4077965	chr4:154710520	G/C	cg14289246	chr4:154710475	SFRP2	0.66	11.31	0.47	2.42e-26	Response to statins (LDL cholesterol change);
LGG	cis	rs1005277	0.579	rs2505196	chr10:38393563	G/A	cg25427524	chr10:38739819	LOC399744	-0.63	-11.57	-0.47	2.27e-27	Extrinsic epigenetic age acceleration;
LGG	cis	rs975722	0.646	rs4458806	chr7:117092658	A/G	cg10524701	chr7:117356490	CTTNBP2	-0.42	-9.45	-0.4	1.73e-19	Coronary artery disease;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg20349687	chr2:88927127	EIF2AK3	0.38	6.76	0.3	4.25e-11	Obesity-related traits;
LGG	cis	rs3733585	0.699	rs6449202	chr4:9974043	T/C	cg08250081	chr4:10125330	NA	-0.38	-7.38	-0.32	7.3e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs2011503	1.000	rs6511029	chr19:19471419	G/T	cg26732615	chr19:19648335	CILP2;YJEFN3	-0.34	-6.67	-0.3	7.15e-11	Bipolar disorder;
LGG	cis	rs8028182	0.636	rs8036884	chr15:75862893	T/C	cg20655648	chr15:75932815	IMP3	0.44	7.3	0.32	1.28e-12	Sudden cardiac arrest;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg27400746	chr16:89904261	SPIRE2	-1.15	-17.07	-0.62	4.9e-51	Skin colour saturation;
LGG	cis	rs2576037	0.583	rs616900	chr18:44410849	T/A	cg26155939	chr18:44337853	ST8SIA5	-0.38	-7.1	-0.31	4.8e-12	Personality dimensions;
LGG	cis	rs12615966	1.000	rs12615966	chr2:105378957	A/G	cg16465502	chr2:105461796	NA	-0.87	-10.41	-0.44	5.87e-23	Pancreatic cancer;
LGG	cis	rs6840360	0.642	rs11099819	chr4:152430178	T/C	cg17217059	chr4:152329364	FAM160A1	0.21	7.3	0.32	1.22e-12	Intelligence (multi-trait analysis);
LGG	cis	rs7017914	0.967	rs1596566	chr8:71698576	A/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.81	-0.3	2.99e-11	Bone mineral density;
LGG	cis	rs2635047	0.542	rs2684814	chr18:44754103	C/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	-0.47	-8.01	-0.35	9.24e-15	Educational attainment;
LGG	cis	rs4975709	0.610	rs6886669	chr5:1867830	T/C	cg12288994	chr5:1860383	NA	0.75	14.33	0.55	8.25e-39	Cardiovascular disease risk factors;
LGG	cis	rs6500602	0.893	rs4786489	chr16:4485527	G/A	cg08345575	chr16:4524283	NMRAL1;HMOX2	0.31	7.1	0.31	4.65e-12	Schizophrenia;
LGG	cis	rs4846580	0.660	rs10863481	chr1:219878128	G/A	cg08034750	chr1:219919793	NA	0.4	7.01	0.31	8.22e-12	Total body bone mineral density;
LGG	cis	rs908922	0.676	rs4845784	chr1:152494583	G/C	cg03606772	chr1:152487856	CRCT1	0.31	7.22	0.32	2.16e-12	Hair morphology;
LGG	cis	rs2075671	0.855	rs62483567	chr7:100286435	G/A	cg21055462	chr7:100276975	NA	0.46	9.89	0.42	4.65e-21	Other erythrocyte phenotypes;
LGG	cis	rs3617	0.573	rs9850563	chr3:52912214	G/A	cg11645453	chr3:52864694	ITIH4	-0.47	-7.97	-0.35	1.21e-14	Red blood cell count;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7119038	0.509	rs10892257	chr11:118579327	G/A	cg19182353	chr11:118479428	PHLDB1	0.38	6.95	0.31	1.23e-11	Sjögren's syndrome;
LGG	cis	rs62400317	0.826	rs12194682	chr6:45320520	T/A	cg18551225	chr6:44695536	NA	-0.63	-10.43	-0.44	5.32e-23	Total body bone mineral density;
LGG	trans	rs7246760	0.867	rs66927855	chr19:9811728	C/T	cg02900749	chr2:68251473	NA	-1.01	-10.66	-0.44	6.84e-24	Pursuit maintenance gain;
LGG	cis	rs2832191	0.967	rs2898160	chr21:30487496	A/G	cg08807101	chr21:30365312	RNF160	-0.8	-15.72	-0.59	6.07e-45	Dental caries;
LGG	cis	rs7937682	0.924	rs4630327	chr11:111539327	C/T	cg08305652	chr11:111469057	NA	0.43	8.54	0.37	1.95e-16	Primary sclerosing cholangitis;
LGG	cis	rs11674184	0.525	rs4669755	chr2:11748585	A/C	cg07314298	chr2:11723111	GREB1	0.62	13.08	0.52	1.8e-33	Endometriosis;
LGG	cis	rs951366	0.538	rs3761919	chr1:205694720	G/A	cg24503407	chr1:205819492	PM20D1	-0.4	-7.18	-0.32	2.75e-12	Menarche (age at onset);
LGG	cis	rs6500602	0.610	rs1659499	chr16:4595269	G/A	cg06916706	chr16:4465613	CORO7	0.71	12.38	0.5	1.36e-30	Schizophrenia;
LGG	cis	rs10463554	0.927	rs469094	chr5:102423579	A/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs17221829	0.733	rs12797439	chr11:89376199	T/C	cg02982614	chr11:89391479	FOLH1B	-0.41	-9.14	-0.39	2e-18	Anxiety in major depressive disorder;
LGG	cis	rs432925	0.576	rs11866815	chr16:387867	C/T	cg12437481	chr16:420112	MRPL28	-0.57	-8.87	-0.38	1.55e-17	Morning vs. evening chronotype;
LGG	cis	rs2153535	0.580	rs2143356	chr6:8517675	C/T	cg23788917	chr6:8435910	SLC35B3	0.53	8.96	0.38	8.22e-18	Motion sickness;
LGG	cis	rs2742417	1.000	rs2742438	chr3:45743390	G/T	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs2180341	0.814	rs9401958	chr6:127736357	T/G	cg27446573	chr6:127587934	RNF146	0.93	17.54	0.63	3.54e-53	Breast cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg15310387	chr8:142737232	NA	-0.4	-7.04	-0.31	7e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs1862618	0.802	rs252900	chr5:56185281	T/A	cg17809284	chr5:56205270	C5orf35	-0.55	-8.88	-0.38	1.44e-17	Initial pursuit acceleration;
LGG	cis	rs704010	0.669	rs704006	chr10:80842974	G/A	cg17823346	chr10:80848143	ZMIZ1	0.3	6.87	0.3	2.04e-11	Breast cancer;
LGG	cis	rs3126085	0.515	rs1923506	chr1:152359700	A/T	cg26876637	chr1:152193138	HRNR	-0.43	-6.67	-0.3	7.24e-11	Atopic dermatitis;
LGG	cis	rs11148252	0.846	rs13431	chr13:52987477	G/C	cg22398616	chr13:53314203	LECT1	-0.46	-9.68	-0.41	2.68e-20	Lewy body disease;
LGG	cis	rs7017914	0.840	rs13254851	chr8:71689034	T/C	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.84	-0.3	2.5e-11	Bone mineral density;
LGG	cis	rs952623	0.611	rs10435033	chr7:39054837	G/A	cg18850127	chr7:39170497	POU6F2	0.36	8.14	0.35	3.74e-15	Intelligence (multi-trait analysis);
LGG	cis	rs986417	0.892	rs11622577	chr14:60814981	A/T	cg27398547	chr14:60952738	C14orf39	-0.72	-6.92	-0.31	1.5e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs644799	1.000	rs568668	chr11:95528209	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs7395662	1.000	rs6485907	chr11:48651695	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.09	-0.35	5.2e-15	HDL cholesterol;
LGG	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg17971929	chr21:40555470	PSMG1	0.87	17.24	0.63	8.16e-52	Cognitive function;
LGG	trans	rs7824557	0.545	rs2736303	chr8:11236850	C/T	cg02002194	chr4:3960332	NA	0.44	7.92	0.35	1.81e-14	Retinal vascular caliber;
LGG	cis	rs7980799	0.682	rs10844611	chr12:33603544	T/C	cg06521331	chr12:34319734	NA	0.4	6.75	0.3	4.33e-11	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs1552244	0.882	rs66559400	chr3:10012551	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs3793683	0.545	rs12784407	chr10:134589631	A/G	cg27286337	chr10:134555280	INPP5A	0.87	13.56	0.53	1.64e-35	Migraine;
LGG	trans	rs7869550	0.901	rs7033487	chr9:119129257	C/T	cg20043202	chr10:124765622	IKZF5	-0.36	-6.97	-0.31	1.1e-11	Height;
LGG	cis	rs28595532	0.920	rs17258830	chr4:119725543	A/T	cg11846333	chr4:119757529	SEC24D	-0.85	-7.86	-0.34	2.73e-14	Cannabis dependence symptom count;
LGG	cis	rs62400317	0.762	rs72865923	chr6:44878942	T/G	cg18551225	chr6:44695536	NA	-0.68	-11.31	-0.47	2.3e-26	Total body bone mineral density;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04079263	chr3:48344007	NME6	0.41	6.98	0.31	1.04e-11	Gut microbiome composition (summer);
LGG	cis	rs2836974	0.932	rs6517523	chr21:40557332	T/C	cg11890956	chr21:40555474	PSMG1	1.19	29.42	0.81	4.82e-108	Cognitive function;
LGG	trans	rs11722228	0.508	rs2241473	chr4:10085949	G/A	cg26043149	chr18:55253948	FECH	0.91	15.96	0.6	5.41e-46	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs2404602	0.716	rs4886813	chr15:76838221	C/T	cg22467129	chr15:76604101	ETFA	0.42	6.95	0.31	1.22e-11	Blood metabolite levels;
LGG	cis	rs12898370	0.651	rs11634056	chr15:77539914	G/A	cg17802220	chr15:77601643	NA	-0.53	-10.25	-0.43	2.38e-22	Risky sexual behaviors (alcohol dependence interaction);
LGG	cis	rs62103177	0.608	rs4799115	chr18:77736365	A/T	cg20368463	chr18:77673604	PQLC1	-0.56	-7.32	-0.32	1.07e-12	Opioid sensitivity;
LGG	cis	rs3857067	0.967	rs964843	chr4:95032367	G/A	cg11021082	chr4:95130006	SMARCAD1	-0.42	-7.81	-0.34	3.88e-14	QT interval;
LGG	cis	rs933688	1.000	rs35712350	chr5:90679519	C/T	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.16	0.68	2.48e-65	Smoking behavior;
LGG	cis	rs597539	0.690	rs578791	chr11:68625809	C/T	cg01988459	chr11:68622903	NA	-0.64	-12.7	-0.51	6.64e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs2708240	1.000	rs2538992	chr7:147579075	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.81	-0.3	3.04e-11	QT interval (drug interaction);
LGG	cis	rs1799949	1.000	rs11657053	chr17:41191129	G/T	cg25172604	chr17:41446521	NA	-0.31	-6.94	-0.31	1.37e-11	Menopause (age at onset);
LGG	cis	rs1008375	0.932	rs2302391	chr4:17660237	T/C	cg04450456	chr4:17643702	FAM184B	0.33	7.12	0.31	4.1e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs12439619	0.508	rs8032033	chr15:82457896	G/C	cg04831495	chr15:85060580	GOLGA6L5	-0.41	-8.32	-0.36	1.01e-15	Intelligence (multi-trait analysis);
LGG	cis	rs700651	0.757	rs6748683	chr2:198878008	T/A	cg00792783	chr2:198669748	PLCL1	0.66	10.49	0.44	3.07e-23	Intracranial aneurysm;
LGG	cis	rs4731207	0.596	rs1600745	chr7:124585183	G/C	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs9879311	0.866	rs775017	chr3:10398964	T/C	cg11030744	chr3:10328490	GHRL;GHRLOS	0.34	6.71	0.3	5.63e-11	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7927592	0.956	rs7104877	chr11:68377602	G/T	cg20283391	chr11:68216788	NA	0.47	7.62	0.33	1.46e-13	Total body bone mineral density;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03284175	chr1:146643471	PRKAB2	0.48	8.15	0.35	3.55e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg19168338	chr16:4465731	CORO7	-0.74	-13.72	-0.54	3.43e-36	Schizophrenia;
LGG	cis	rs1799949	1.000	rs36036395	chr17:41181297	T/C	cg25288140	chr17:41278341	BRCA1;NBR2	0.46	7.28	0.32	1.45e-12	Menopause (age at onset);
LGG	cis	rs4862750	0.914	rs1991256	chr4:187875330	A/G	cg11301795	chr4:187892539	NA	-0.95	-24.88	-0.76	2.34e-87	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7737355	0.947	rs6596029	chr5:130899079	T/C	cg06307176	chr5:131281290	NA	0.56	9.38	0.4	2.99e-19	Life satisfaction;
LGG	cis	rs9902453	0.726	rs3115092	chr17:28036350	C/T	cg26525008	chr17:28256777	EFCAB5;SSH2	0.72	14.68	0.56	2.38e-40	Coffee consumption (cups per day);
LGG	cis	rs875971	0.545	rs1638724	chr7:66040481	A/G	cg11764359	chr7:65958608	NA	-0.63	-9.77	-0.41	1.23e-20	Aortic root size;
LGG	cis	rs9747201	0.925	rs8072670	chr17:80159566	T/C	cg09264619	chr17:80180166	NA	-0.51	-10.04	-0.42	1.37e-21	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs992157	0.710	rs12694432	chr2:219082330	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.6	10.25	0.43	2.37e-22	Colorectal cancer;
LGG	cis	rs9487094	0.689	rs9487069	chr6:109679855	A/C	cg16315928	chr6:109776240	MICAL1	0.44	7.69	0.34	8.75e-14	Height;
LGG	cis	rs4253772	0.591	rs9615343	chr22:46690824	C/G	cg09461388	chr22:46763229	CELSR1	-0.67	-7.09	-0.31	4.96e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs17270561	0.609	rs4711097	chr6:25732314	C/T	cg17691542	chr6:26056736	HIST1H1C	0.62	10.11	0.43	7.39e-22	Iron status biomarkers;
LGG	cis	rs801193	0.935	rs2659899	chr7:66186721	A/G	cg00343986	chr7:65444356	GUSB	0.4	6.77	0.3	3.97e-11	Aortic root size;
LGG	trans	rs826838	1.000	rs826889	chr12:39101076	G/A	cg06521331	chr12:34319734	NA	0.4	7.19	0.32	2.58e-12	Heart rate;
LGG	trans	rs1005277	0.579	rs1740742	chr10:38518860	C/T	cg23533926	chr12:111358616	MYL2	-0.45	-7.44	-0.33	4.93e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4660214	0.666	rs2275187	chr1:39763242	C/T	cg18385671	chr1:39797026	MACF1	-0.45	-9.1	-0.39	2.61e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs10193935	0.818	rs2374428	chr2:42667961	T/C	cg27598129	chr2:42591480	NA	0.68	10.11	0.43	7.79e-22	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7172689	1.000	rs6495555	chr15:81548587	T/C	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs7681440	1.000	rs7681440	chr4:90756550	C/G	cg15133208	chr4:90757351	SNCA	0.37	8.42	0.36	4.87e-16	Dementia with Lewy bodies;
LGG	cis	rs45430	1.000	rs408825	chr21:42743496	A/G	cg22778903	chr21:42741698	MX2	-0.45	-8.95	-0.38	8.81e-18	Melanoma;
LGG	cis	rs2635047	0.565	rs2668759	chr18:44693711	T/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.93	0.31	1.43e-11	Educational attainment;
LGG	cis	rs62025270	0.632	rs62022915	chr15:86213596	G/A	cg25843651	chr15:86329602	KLHL25	0.57	8.58	0.37	1.47e-16	Idiopathic pulmonary fibrosis;
LGG	trans	rs75804782	0.641	rs72987328	chr2:239360097	C/T	cg01134436	chr17:81009848	B3GNTL1	0.85	8.88	0.38	1.46e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs3857536	0.776	rs1002764	chr6:66945760	C/A	cg07460842	chr6:66804631	NA	-0.45	-7.8	-0.34	4.12e-14	Blood trace element (Cu levels);
LGG	cis	rs514406	0.861	rs4926932	chr1:53247495	C/T	cg16325326	chr1:53192061	ZYG11B	-0.78	-18.6	-0.65	4.35e-58	Monocyte count;
LGG	cis	rs4622507	0.773	rs36054803	chr16:55054817	C/T	cg09947736	chr16:55091198	NA	0.57	10.15	0.43	5.47e-22	Social communication problems;
LGG	cis	rs9896933	0.708	rs9908751	chr17:80791830	C/T	cg20578329	chr17:80767326	TBCD	0.67	10.76	0.45	2.93e-24	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs4595586	1.000	rs1403521	chr12:39232007	A/G	cg26384229	chr12:38710491	ALG10B	0.41	7.3	0.32	1.23e-12	Morning vs. evening chronotype;
LGG	cis	rs2070997	0.517	rs9762	chr9:133762553	A/G	cg03924115	chr9:133768966	QRFP	0.42	8.09	0.35	5.48e-15	Response to amphetamines;
LGG	cis	rs2371030	1.000	rs2111713	chr2:211576458	G/A	cg18417063	chr2:211583084	NA	-0.64	-12.57	-0.5	2.27e-31	Non-small cell lung cancer;
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19374947	chr2:264754	SH3YL1;ACP1	0.51	7.5	0.33	3.33e-13	Hip circumference;
LGG	cis	rs2832077	0.883	rs35672956	chr21:30189042	T/C	cg24692254	chr21:30365293	RNF160	-0.57	-8.32	-0.36	9.76e-16	Cognitive test performance;
LGG	cis	rs6568686	0.786	rs9481155	chr6:111829239	A/G	cg21044968	chr6:111895086	TRAF3IP2	-0.42	-6.79	-0.3	3.38e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs11098499	0.874	rs6822498	chr4:120120183	T/C	cg09307838	chr4:120376055	NA	0.64	10.24	0.43	2.66e-22	Corneal astigmatism;
LGG	cis	rs975722	0.663	rs2896224	chr7:117090489	G/C	cg10524701	chr7:117356490	CTTNBP2	-0.41	-9.22	-0.39	1.08e-18	Coronary artery disease;
LGG	cis	rs6088590	1.000	rs6119512	chr20:33306904	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.53	0.33	2.72e-13	Coronary artery disease;
LGG	cis	rs4132509	0.744	rs10803156	chr1:243917776	G/C	cg21452805	chr1:244014465	NA	0.96	9.29	0.4	5.97e-19	RR interval (heart rate);
LGG	cis	rs12210905	1.000	rs72843611	chr6:27131382	C/T	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-7.86	-0.34	2.8e-14	Hip circumference adjusted for BMI;
LGG	cis	rs9611519	0.894	rs9611488	chr22:41462592	G/T	cg03806693	chr22:41940476	POLR3H	-0.54	-8.32	-0.36	1.03e-15	Neuroticism;
LGG	cis	rs1577917	0.804	rs2786854	chr6:86668740	C/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.81	-0.34	3.91e-14	Response to antipsychotic treatment;
LGG	cis	rs10504229	0.683	rs7460059	chr8:58111561	C/T	cg11062466	chr8:58055876	NA	0.54	8.83	0.38	2.13e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs8114671	0.552	rs2024635	chr20:33422614	G/A	cg24642439	chr20:33292090	TP53INP2	0.42	6.72	0.3	5.3e-11	Height;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg16041806	chr1:173991823	NA	-0.46	-6.78	-0.3	3.66e-11	Systemic lupus erythematosus;
LGG	cis	rs67460515	0.563	rs7618924	chr3:160855599	A/G	cg04691961	chr3:161091175	C3orf57	-0.42	-8.14	-0.35	3.66e-15	Parkinson's disease;
LGG	cis	rs11249608	0.548	rs6860309	chr5:178451428	T/C	cg21905437	chr5:178450457	ZNF879	0.46	6.7	0.3	5.97e-11	Pubertal anthropometrics;
LGG	cis	rs68170813	0.559	rs77829121	chr7:106968470	A/G	cg02696742	chr7:106810147	HBP1	-0.74	-10.4	-0.44	6.48e-23	Coronary artery disease;
LGG	cis	rs2739330	0.732	rs5760175	chr22:24399655	T/G	cg12419862	chr22:24373484	LOC391322	-1.13	-27.6	-0.79	7.53e-100	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs28595532	0.920	rs116023902	chr4:119725131	A/G	cg21605333	chr4:119757512	SEC24D	1.45	14.6	0.56	5.32e-40	Cannabis dependence symptom count;
LGG	cis	rs4423214	1.000	rs2276361	chr11:71169648	A/G	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.05	-0.52	2.27e-33	Vitamin D levels;
LGG	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.85	-0.3	2.33e-11	Hip circumference adjusted for BMI;
LGG	cis	rs4132509	1.000	rs6660534	chr1:243791642	A/C	cg25706552	chr1:244017396	NA	0.52	8.56	0.37	1.7e-16	RR interval (heart rate);
LGG	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg11041457	chr3:52719354	GNL3;PBRM1	0.48	8.04	0.35	7.34e-15	Electroencephalogram traits;
LGG	cis	rs295140	0.605	rs3769471	chr2:201195403	G/A	cg17644776	chr2:200775616	C2orf69	-0.44	-7.29	-0.32	1.35e-12	QT interval;
LGG	cis	rs9435341	0.929	rs1730865	chr1:107605611	A/C	cg09367891	chr1:107599246	PRMT6	0.59	9.73	0.41	1.76e-20	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs780096	0.525	rs13388159	chr2:27648284	A/T	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.87	-0.3	2.07e-11	Total body bone mineral density;
LGG	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg02855558	chr7:158107723	PTPRN2	-0.41	-7.37	-0.32	7.66e-13	Calcium levels;
LGG	cis	rs28386778	0.699	rs12451467	chr17:62008885	C/T	cg07659893	chr17:61819838	STRADA	-0.41	-6.68	-0.3	7.02e-11	Prudent dietary pattern;
LGG	cis	rs7172689	0.908	rs58843615	chr15:81563230	T/C	cg11808699	chr15:81528661	IL16	-0.48	-9.79	-0.41	1.05e-20	Inattentive symptoms;
LGG	cis	rs6831352	0.918	rs2851247	chr4:100046091	C/G	cg12011299	chr4:100065546	ADH4	-0.45	-8.61	-0.37	1.14e-16	Alcohol dependence;
LGG	cis	rs11874712	0.932	rs34907121	chr18:43677793	G/A	cg26436583	chr18:43649176	PSTPIP2	-0.54	-11.77	-0.48	3.7e-28	Migraine - clinic-based;
LGG	cis	rs6463523	0.898	rs66892628	chr7:759374	T/A	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.83	15.11	0.57	3.15e-42	Subjective well-being;
LGG	cis	rs13118159	0.527	rs1250119	chr4:1261336	G/A	cg05025164	chr4:1340916	KIAA1530	-0.84	-16.13	-0.6	8.68e-47	Longevity;
LGG	cis	rs876084	0.505	rs4871044	chr8:121158773	C/T	cg06265175	chr8:121136014	COL14A1	0.46	9.23	0.39	9.76e-19	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3858526	0.523	rs10742818	chr11:5882535	T/C	cg05234568	chr11:5960015	NA	-0.65	-11.46	-0.47	5.91e-27	DNA methylation (variation);
LGG	cis	rs12210905	0.541	rs62617138	chr6:27463766	C/A	cg00426182	chr6:28072559	NA	0.94	6.97	0.31	1.08e-11	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg05861140	chr6:150128134	PCMT1	-0.42	-9.46	-0.4	1.52e-19	Lung cancer;
LGG	cis	rs2587949	0.593	rs1872415	chr3:4211374	A/G	cg16519197	chr3:4211558	NA	0.32	6.76	0.3	4.24e-11	Periodontitis (DPAL);
LGG	cis	rs765787	0.505	rs1648302	chr15:45494238	A/G	cg24006582	chr15:45444508	DUOX1	-0.73	-14.14	-0.55	5.3e-38	Uric acid levels;
LGG	trans	rs2689154	1.000	rs2689154	chr1:238908353	C/G	cg09450713	chr16:50186778	PAPD5	-0.48	-7.38	-0.32	7.59e-13	Pancreatic cancer;
LGG	cis	rs6502050	0.799	rs7212023	chr17:80170354	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.12	-0.31	4.1e-12	Life satisfaction;
LGG	cis	rs7819412	1.000	rs7819412	chr8:11045161	A/G	cg24623649	chr8:11872141	NA	0.31	7.47	0.33	4.02e-13	Triglycerides;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg00800038	chr16:89945340	TCF25	-0.69	-8.1	-0.35	5.04e-15	Skin colour saturation;
LGG	cis	rs9487094	0.666	rs3734652	chr6:109786980	T/C	cg01125227	chr6:109776195	MICAL1	0.39	6.84	0.3	2.54e-11	Height;
LGG	cis	rs1580019	0.587	rs34488151	chr7:32548146	A/G	cg06133097	chr7:32552212	AVL9	-0.39	-7.26	-0.32	1.62e-12	Cognitive ability;
LGG	cis	rs7512552	0.809	rs696618	chr1:150376139	T/G	cg15654264	chr1:150340011	RPRD2	0.45	9.32	0.4	4.66e-19	Atopic dermatitis;Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs62012628	0.527	rs12438008	chr15:79084680	C/T	cg12645284	chr15:79092878	ADAMTS7	-0.42	-7.62	-0.33	1.44e-13	Diastolic blood pressure;
LGG	cis	rs11123170	0.543	rs12472361	chr2:113980645	C/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.65	0.37	8.58e-17	Renal function-related traits (BUN);
LGG	trans	rs2270927	1.000	rs4546360	chr5:75577563	T/C	cg13563193	chr19:33072644	PDCD5	0.88	11.62	0.48	1.49e-27	Mean corpuscular volume;
LGG	trans	rs7395662	0.963	rs2135680	chr11:48728425	T/C	cg03929089	chr4:120376271	NA	-0.44	-7.16	-0.32	3.22e-12	HDL cholesterol;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22687239	chr4:331435	ZNF141	0.46	6.94	0.31	1.35e-11	Gut microbiome composition (summer);
LGG	cis	rs868036	1.000	rs6494694	chr15:68057142	A/C	cg05925327	chr15:68127851	NA	0.37	8.7	0.37	5.91e-17	Restless legs syndrome;
LGG	cis	rs2228479	0.850	rs45524643	chr16:89815824	G/A	cg04287289	chr16:89883240	FANCA	0.88	8.58	0.37	1.4e-16	Skin colour saturation;
LGG	cis	rs3820928	0.874	rs10195072	chr2:227794452	G/A	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.85	-0.34	2.87e-14	Pulmonary function;
LGG	cis	rs72781680	1.000	rs17762782	chr2:24126493	A/G	cg08917208	chr2:24149416	ATAD2B	0.81	9.49	0.4	1.23e-19	Lymphocyte counts;
LGG	cis	rs13108904	0.905	rs34490749	chr4:1217981	A/G	cg02018176	chr4:1364513	KIAA1530	0.34	7.37	0.32	7.74e-13	Obesity-related traits;
LGG	cis	rs2766692	0.843	rs10873515	chr14:100766664	C/T	cg14866419	chr14:100704911	YY1	-0.53	-8.4	-0.36	5.7e-16	Electroencephalographic traits in alcoholism;
LGG	cis	rs13392177	0.543	rs12623716	chr2:219073018	C/T	cg20019365	chr2:219134978	PNKD;AAMP	-0.46	-7.27	-0.32	1.53e-12	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs12971120	0.947	rs8084109	chr18:72168312	T/A	cg26446133	chr18:72167187	CNDP2	-0.74	-17.01	-0.62	9.77e-51	Refractive error;
LGG	cis	rs2046867	0.862	rs67961837	chr3:72840877	T/G	cg26655873	chr3:72818019	SHQ1	0.35	6.9	0.31	1.67e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs6835098	0.608	rs2332668	chr4:174163360	A/G	cg08422745	chr4:174089978	GALNT7	-0.76	-13.59	-0.53	1.22e-35	Dementia and core Alzheimer's disease neuropathologic changes;
LGG	cis	rs6787391	0.933	rs9831844	chr3:4744047	A/G	cg11584376	chr3:4789075	ITPR1	0.37	7.49	0.33	3.4e-13	Breast cancer;
LGG	cis	rs854572	1.000	rs854572	chr7:94954696	C/G	cg01874867	chr7:94954059	PON1	-0.34	-7.69	-0.34	8.61e-14	Paraoxonase activity;
LGG	cis	rs10870270	1.000	rs6560694	chr10:133773448	G/A	cg17892150	chr10:133769511	PPP2R2D	-0.67	-13.61	-0.53	1.06e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	cis	rs78456975	0.689	rs13391992	chr2:1542153	G/A	cg26248373	chr2:1572462	NA	-0.76	-10.83	-0.45	1.63e-24	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs7833790	0.660	rs7839178	chr8:82763479	A/G	cg06027949	chr8:82754900	SNX16	0.54	8.45	0.37	3.71e-16	Diastolic blood pressure;
LGG	cis	rs17376456	0.877	rs7701974	chr5:93311417	C/T	cg25358565	chr5:93447407	FAM172A	1.3	16.06	0.6	1.8e-46	Diabetic retinopathy;
LGG	cis	rs4689388	0.581	rs4476672	chr4:6281496	A/G	cg25554036	chr4:6271136	WFS1	0.52	8.4	0.36	5.45e-16	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg12432903	chr7:1882776	MAD1L1	-0.56	-8.95	-0.38	8.94e-18	Bipolar disorder;
LGG	cis	rs77106637	0.789	rs76550717	chr11:72428172	A/G	cg03713592	chr11:72463424	ARAP1	0.42	7.5	0.33	3.21e-13	Type 2 diabetes;
LGG	cis	rs892961	0.899	rs72896162	chr17:75412521	A/G	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs2072732	0.768	rs57893585	chr1:2944671	T/A	cg08733933	chr1:2954429	NA	-0.44	-8.73	-0.38	4.7e-17	Plateletcrit;
LGG	cis	rs6121246	0.954	rs7266148	chr20:30431070	G/T	cg21427119	chr20:30132790	HM13	-0.43	-7.18	-0.32	2.89e-12	Mean corpuscular hemoglobin;
LGG	trans	rs66686620	1.000	rs6546473	chr2:69260357	C/T	cg22539505	chr3:50330110	IFRD2	0.47	6.79	0.3	3.51e-11	Breast cancer;
LGG	cis	rs11214589	0.620	rs34601878	chr11:113260898	G/A	cg14373873	chr11:113211441	TTC12	0.42	8.73	0.38	4.48e-17	Neuroticism;
LGG	cis	rs875971	0.928	rs2036263	chr7:65800197	C/T	cg18876405	chr7:65276391	NA	-0.55	-9.8	-0.41	9.56e-21	Aortic root size;
LGG	cis	rs6088590	0.965	rs6087619	chr20:33288511	C/G	cg06115741	chr20:33292138	TP53INP2	0.59	10.04	0.42	1.35e-21	Coronary artery disease;
LGG	cis	rs938554	0.876	rs737267	chr4:9934744	G/T	cg25986240	chr4:9926439	SLC2A9	0.38	7.11	0.31	4.34e-12	Blood metabolite levels;
LGG	cis	rs7000551	0.505	rs73227818	chr8:22243325	T/C	cg12081754	chr8:22256438	SLC39A14	1.15	23.53	0.74	4.3e-81	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs6424115	1.000	rs1018396	chr1:24133612	G/A	cg24699146	chr1:24152579	HMGCL	0.25	7.61	0.33	1.59e-13	Immature fraction of reticulocytes;
LGG	trans	rs6089829	0.890	rs6062775	chr20:61663650	T/C	cg23505145	chr19:12996616	KLF1	0.4	7.12	0.31	4.16e-12	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs28595532	0.764	rs116158926	chr4:119730572	C/T	cg21605333	chr4:119757512	SEC24D	1.5	14.94	0.57	1.78e-41	Cannabis dependence symptom count;
LGG	cis	rs9894429	0.789	rs6565611	chr17:79598319	T/C	cg18240062	chr17:79603768	NPLOC4	0.81	15.29	0.58	5.37e-43	Eye color traits;
LGG	trans	rs1997103	0.954	rs2177809	chr7:55378125	T/C	cg20935933	chr6:143382018	AIG1	0.58	8.87	0.38	1.55e-17	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg21211680	chr2:198530	NA	1.2	15.85	0.59	1.66e-45	Blood protein levels;
LGG	trans	rs79911532	0.515	rs76083953	chr7:75698576	G/C	cg19862616	chr7:65841803	NCRNA00174	0.73	7.65	0.33	1.19e-13	Mononucleosis;
LGG	cis	rs4819052	0.679	rs28623526	chr21:46712324	T/C	cg06618935	chr21:46677482	NA	-0.37	-7.19	-0.32	2.7e-12	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs1978968	0.956	rs8135939	chr22:18434284	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.57	-10.83	-0.45	1.68e-24	Presence of antiphospholipid antibodies;
LGG	cis	rs9467773	0.572	rs9467737	chr6:26381630	T/C	cg09904177	chr6:26538194	HMGN4	-0.41	-7.29	-0.32	1.32e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.683	rs73605816	chr8:58117167	T/C	cg21724239	chr8:58056113	NA	0.51	7.62	0.33	1.42e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	0.684	rs8182243	chr17:66018505	T/C	cg02705964	chr17:66097276	LOC651250	-0.47	-8.27	-0.36	1.45e-15	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs1799949	1.000	rs8176120	chr17:41261233	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.86	0.66	2.81e-59	Menopause (age at onset);
LGG	cis	rs60843830	0.623	rs55932737	chr2:107543	C/T	cg25945732	chr2:264204	ACP1;SH3YL1	0.54	9.32	0.4	4.63e-19	Spherical equivalent (joint analysis main effects and education interaction);
LGG	trans	rs2204008	0.840	rs7957966	chr12:37953629	A/G	cg06521331	chr12:34319734	NA	0.51	9.36	0.4	3.55e-19	Bladder cancer;
LGG	cis	rs2576037	0.796	rs2247221	chr18:44580082	C/T	cg23302884	chr18:44338147	ST8SIA5	0.36	6.97	0.31	1.07e-11	Personality dimensions;
LGG	cis	rs7017914	0.967	rs7842851	chr8:71663805	A/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.38	-6.85	-0.3	2.33e-11	Bone mineral density;
LGG	cis	rs6598955	0.724	rs12732295	chr1:26602251	C/T	cg10402321	chr1:26617780	UBXN11	-0.36	-7.17	-0.32	3.07e-12	Obesity-related traits;
LGG	cis	rs11758351	0.500	rs74974409	chr6:26194402	A/G	cg11342453	chr6:26196699	NA	0.82	6.99	0.31	9.53e-12	Gout;Renal underexcretion gout;
LGG	trans	rs1814175	0.817	rs2866545	chr11:49630824	A/C	cg15704280	chr7:45808275	SEPT13	-1.08	-25.88	-0.77	5.15e-92	Height;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.29	-0.58	5.21e-43	Prudent dietary pattern;
LGG	cis	rs11700980	0.636	rs114711857	chr21:30260199	T/C	cg24692254	chr21:30365293	RNF160	-0.63	-7.51	-0.33	3.15e-13	QRS complex (12-leadsum);
LGG	trans	rs34421088	0.623	rs4841515	chr8:11097166	C/T	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.21	-0.36	2.18e-15	Neuroticism;
LGG	cis	rs7615952	0.641	rs2365019	chr3:125808135	T/C	cg18479299	chr3:125709523	NA	-0.57	-7.15	-0.32	3.48e-12	Blood pressure (smoking interaction);
LGG	cis	rs2880765	0.835	rs7168860	chr15:86037030	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.33	-0.32	1.02e-12	Coronary artery disease;
LGG	trans	rs9354308	0.764	rs2105453	chr6:66601978	G/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.4	-6.74	-0.3	4.79e-11	Metabolite levels;
LGG	cis	rs7811142	0.830	rs6955367	chr7:99961194	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.15	20.03	0.68	9.54e-65	Platelet count;
LGG	cis	rs2841277	0.645	rs28380382	chr14:105410827	C/T	cg15352829	chr14:105391018	PLD4	-0.47	-11.35	-0.47	1.69e-26	Rheumatoid arthritis;
LGG	cis	rs7619833	0.620	rs10049490	chr3:27241776	G/T	cg02860705	chr3:27208620	NA	0.42	8.36	0.36	7.39e-16	Breast cancer;
LGG	cis	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg24623649	chr8:11872141	NA	-0.29	-6.79	-0.3	3.52e-11	Triglycerides;
LGG	cis	rs7647973	0.696	rs3087866	chr3:49054692	A/G	cg06212747	chr3:49208901	KLHDC8B	0.46	6.81	0.3	3.01e-11	Menarche (age at onset);
LGG	cis	rs6456156	0.526	rs3093025	chr6:167532731	A/G	cg07741184	chr6:167504864	NA	-0.35	-7.75	-0.34	5.95e-14	Primary biliary cholangitis;
LGG	cis	rs1799949	1.000	rs3092988	chr17:41201702	C/T	cg18379455	chr17:41446167	NA	-0.31	-7.14	-0.31	3.71e-12	Menopause (age at onset);
LGG	cis	rs1865760	0.663	rs9379815	chr6:25980116	T/A	cg18357526	chr6:26021779	HIST1H4A	0.49	8.16	0.35	3.19e-15	Height;
LGG	cis	rs7226408	0.857	rs17652450	chr18:34473583	T/C	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs6977660	0.619	rs10950752	chr7:19781531	A/G	cg05791153	chr7:19748676	TWISTNB	0.65	9.41	0.4	2.42e-19	Thyroid stimulating hormone;
LGG	cis	rs3733585	0.699	rs6449174	chr4:9966422	C/T	cg25986240	chr4:9926439	SLC2A9	0.37	7.56	0.33	2.25e-13	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs752092	1.000	rs11247277	chr15:101784664	A/G	cg19997662	chr15:101784653	CHSY1	-0.91	-20.34	-0.69	3.44e-66	Corneal structure;
LGG	cis	rs1348850	0.645	rs11887886	chr2:178425730	C/T	cg27490568	chr2:178487706	NA	0.72	13.12	0.52	1.19e-33	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs9858542	0.953	rs1801143	chr3:49570200	C/T	cg03060546	chr3:49711283	APEH	-0.61	-9.96	-0.42	2.57e-21	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs35110281	0.666	rs2236665	chr21:45108987	C/A	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.57	10.08	0.42	9.48e-22	Mean corpuscular volume;
LGG	cis	rs868036	0.634	rs8028313	chr15:68043057	C/G	cg22044901	chr15:68126292	NA	-0.4	-6.89	-0.31	1.81e-11	Restless legs syndrome;
LGG	cis	rs258892	0.895	rs10059897	chr5:72080538	C/T	cg21869765	chr5:72125136	TNPO1	-0.42	-6.67	-0.3	7.14e-11	Small cell lung carcinoma;
LGG	cis	rs12541335	0.639	rs4871994	chr8:22206038	G/A	cg09517075	chr8:22133004	PIWIL2	0.42	9.3	0.4	5.38e-19	Hypertriglyceridemia;
LGG	cis	rs7819412	0.775	rs34094119	chr8:10935898	A/G	cg21775007	chr8:11205619	TDH	-0.51	-8.26	-0.36	1.57e-15	Triglycerides;
LGG	cis	rs9674544	0.757	rs6504593	chr17:47132819	T/C	cg10950924	chr17:47092072	IGF2BP1	-0.48	-9.37	-0.4	3.27e-19	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);
LGG	cis	rs17253792	0.822	rs58569951	chr14:56152245	T/C	cg01858014	chr14:56050164	KTN1	-0.91	-12.55	-0.5	2.58e-31	Putamen volume;
LGG	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg22563815	chr15:78856949	CHRNA5	0.27	6.79	0.3	3.41e-11	Sudden cardiac arrest;
LGG	trans	rs7819412	0.765	rs17783634	chr8:11054097	C/A	cg06636001	chr8:8085503	FLJ10661	-0.55	-10.3	-0.43	1.56e-22	Triglycerides;
LGG	cis	rs6502050	0.871	rs8082577	chr17:80070581	T/C	cg09264619	chr17:80180166	NA	0.35	6.95	0.31	1.22e-11	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23377693	chr6:43597122	MAD2L1BP;GTPBP2	0.46	6.82	0.3	2.88e-11	Gut microbiome composition (summer);
LGG	cis	rs1577917	0.566	rs2842611	chr6:86302034	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.6	-11.24	-0.46	4.41e-26	Response to antipsychotic treatment;
LGG	cis	rs6466055	0.748	rs10281422	chr7:104844519	G/A	cg04380332	chr7:105027541	SRPK2	-0.37	-7.05	-0.31	6.67e-12	Schizophrenia;
LGG	cis	rs711245	0.518	rs11886145	chr2:36825716	C/G	cg15105969	chr2:36825350	FEZ2	0.62	10.26	0.43	2.23e-22	Height;
LGG	cis	rs3812049	1.000	rs3812049	chr5:127418850	C/G	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.61	9.86	0.42	6.04e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs34734847	0.787	rs695949	chr12:121149736	A/G	cg21892295	chr12:121157589	UNC119B	-0.37	-6.96	-0.31	1.14e-11	Mean corpuscular volume;
LGG	cis	rs780096	0.526	rs11127013	chr2:27692973	A/G	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.37	-0.32	8.08e-13	Total body bone mineral density;
LGG	cis	rs12410462	0.502	rs114121935	chr1:227959336	A/G	cg21459583	chr1:227974177	NA	0.67	10.71	0.45	4.59e-24	Major depressive disorder;
LGG	cis	rs4253772	0.637	rs6008357	chr22:46652104	T/G	cg24881330	chr22:46731750	TRMU	0.71	8.72	0.38	4.84e-17	LDL cholesterol;Cholesterol, total;
LGG	trans	rs7819412	0.511	rs10108511	chr8:11435516	T/C	cg13009111	chr11:71350975	NA	-0.32	-7.03	-0.31	7.33e-12	Triglycerides;
LGG	trans	rs11098499	0.954	rs4577559	chr4:120404043	T/G	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs8038465	0.622	rs7182124	chr15:73915254	C/T	cg15420318	chr15:73925796	NPTN	0.49	8.38	0.36	6.63e-16	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs7249142	0.562	rs11085253	chr19:19277517	A/G	cg26504305	chr19:19281019	LOC729991-MEF2B;MEF2B	-0.3	-8.41	-0.36	5.1e-16	IgG glycosylation;
LGG	cis	rs35883536	1.000	rs1577508	chr1:101089289	T/C	cg06223162	chr1:101003688	GPR88	0.29	6.86	0.3	2.21e-11	Monocyte count;
LGG	cis	rs15676	0.947	rs2759009	chr9:131599008	C/T	cg04621255	chr9:131581398	ENDOG	-0.42	-7.36	-0.32	8.6e-13	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs3924781	chr17:80113130	T/C	cg11859384	chr17:80120422	CCDC57	-0.45	-7.98	-0.35	1.12e-14	Life satisfaction;
LGG	cis	rs854765	0.547	rs2955356	chr17:17964717	G/A	cg04398451	chr17:18023971	MYO15A	0.74	15.69	0.59	8.74e-45	Total body bone mineral density;
LGG	cis	rs61931739	0.500	rs6488215	chr12:34434803	A/T	cg06521331	chr12:34319734	NA	-0.54	-9.84	-0.42	6.89e-21	Morning vs. evening chronotype;
LGG	cis	rs3789045	0.774	rs4252733	chr1:204516918	C/T	cg17419461	chr1:204415978	PIK3C2B	-0.45	-8.82	-0.38	2.31e-17	Educational attainment (college completion);
LGG	cis	rs10504229	0.593	rs80174614	chr8:58024631	G/A	cg26174226	chr8:58114915	NA	-0.53	-7.15	-0.32	3.37e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs2303745	0.589	rs6512182	chr19:17399476	G/T	cg10664184	chr19:17420304	DDA1	0.54	8.28	0.36	1.36e-15	Systemic lupus erythematosus;
LGG	trans	rs826838	0.586	rs10880753	chr12:38628147	C/A	cg06521331	chr12:34319734	NA	0.42	7.56	0.33	2.11e-13	Heart rate;
LGG	cis	rs12681287	0.547	rs13267858	chr8:87510871	G/A	cg27223183	chr8:87520930	FAM82B	-0.5	-7.6	-0.33	1.6e-13	Caudate activity during reward;
LGG	trans	rs10100465	0.596	rs218009	chr8:118716275	A/G	cg24540913	chr10:102046174	BLOC1S2	-0.5	-7.06	-0.31	5.99e-12	Leprosy;
LGG	cis	rs10504229	1.000	rs67236942	chr8:58176525	T/C	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9952991	0.566	rs482160	chr18:12855646	A/G	cg23598886	chr18:12777645	NA	0.51	7.12	0.31	4.22e-12	Inflammatory skin disease;
LGG	cis	rs11716531	0.574	rs7624067	chr3:27267853	G/A	cg02860705	chr3:27208620	NA	0.77	14.28	0.55	1.34e-38	Diastolic blood pressure;
LGG	cis	rs41005	0.967	rs41006	chr2:8109348	A/G	cg03155496	chr2:8117019	LOC339788	0.88	19.51	0.67	2.71e-62	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs11931598	0.511	rs4689576	chr4:7025523	T/C	cg02503808	chr4:7069936	GRPEL1	0.42	7.04	0.31	6.9e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs3785574	0.886	rs62077504	chr17:61837734	A/G	cg11494091	chr17:61959527	GH2	0.61	10.26	0.43	2.09e-22	Height;
LGG	cis	rs1862618	0.620	rs2591967	chr5:56233551	C/G	cg17809284	chr5:56205270	C5orf35	0.54	10.2	0.43	3.57e-22	Initial pursuit acceleration;
LGG	cis	rs13082711	0.953	rs13096477	chr3:27490194	T/C	cg02860705	chr3:27208620	NA	0.83	15.01	0.57	9.23e-42	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs208515	0.525	rs10944869	chr6:66687576	G/T	cg07460842	chr6:66804631	NA	0.95	17.28	0.63	5.6e-52	Exhaled nitric oxide levels;
LGG	cis	rs6502050	0.805	rs56020943	chr17:80105248	C/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs1620921	0.967	rs1652502	chr6:161194542	C/T	cg01280913	chr6:161186852	NA	-0.35	-7.29	-0.32	1.35e-12	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs10504229	0.531	rs55923836	chr8:57999127	A/G	cg02725872	chr8:58115012	NA	-0.7	-10.52	-0.44	2.34e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs4930103	1.000	rs4930103	chr11:2024544	G/A	cg03175030	chr11:2018143	H19;MIR675	-0.55	-10.3	-0.43	1.49e-22	DNA methylation (parent-of-origin);DNA methylation (variation);
LGG	cis	rs561341	0.882	rs563539	chr17:30307958	A/G	cg13647721	chr17:30228624	UTP6	0.62	8.06	0.35	6.45e-15	Hip circumference adjusted for BMI;
LGG	cis	rs4363385	0.574	rs61813182	chr1:152943868	T/A	cg13444842	chr1:152974279	SPRR3	-0.51	-10.37	-0.43	8.85e-23	Inflammatory skin disease;
LGG	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg13385794	chr1:248469461	NA	0.49	8.17	0.35	3.02e-15	Common traits (Other);
LGG	cis	rs9326248	0.953	rs634960	chr11:117072963	T/C	cg01368799	chr11:117014884	PAFAH1B2	-0.61	-9.19	-0.39	1.28e-18	Blood protein levels;
LGG	cis	rs3748682	1.000	rs3748682	chr1:38279987	C/T	cg12658694	chr1:38397304	INPP5B	-0.37	-6.87	-0.3	2.04e-11	Hypothyroidism;
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg22168489	chr12:122356033	WDR66	0.43	9.71	0.41	2.09e-20	Mean corpuscular volume;
LGG	cis	rs2131877	0.830	rs62285224	chr3:194879086	A/G	cg07250128	chr3:194833983	C3orf21	0.45	7.57	0.33	2.08e-13	Non-small cell lung cancer;
LGG	cis	rs262147	0.610	rs2657363	chr7:158684273	C/T	cg24397884	chr7:158709396	WDR60	1.03	11.07	0.46	1.99e-25	Hippocampal volume;
LGG	cis	rs7084402	0.967	rs1649077	chr10:60293906	A/G	cg09696939	chr10:60272079	BICC1	-0.38	-7.42	-0.33	5.69e-13	Refractive error;
LGG	cis	rs7107174	1.000	rs10899456	chr11:78000155	C/G	cg27205649	chr11:78285834	NARS2	-0.45	-7.38	-0.32	7.39e-13	Testicular germ cell tumor;
LGG	cis	rs2470578	0.792	rs2596640	chr3:17288440	A/G	cg20981856	chr3:17787350	NA	0.35	6.7	0.3	6.08e-11	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11210881	chr11:113930500	ZBTB16	0.4	6.66	0.3	7.78e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs748404	0.578	rs478028	chr15:43610772	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.54	8.1	0.35	4.82e-15	Lung cancer;
LGG	cis	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg24308560	chr3:49941425	MST1R	0.23	7.23	0.32	2.07e-12	Intelligence (multi-trait analysis);
LGG	trans	rs1814175	0.817	rs4881627	chr11:49953955	C/A	cg11707556	chr5:10655725	ANKRD33B	-0.6	-12.25	-0.49	4.35e-30	Height;
LGG	cis	rs9790314	0.934	rs462413	chr3:161101587	T/C	cg04691961	chr3:161091175	C3orf57	-0.59	-13.39	-0.53	8.3e-35	Morning vs. evening chronotype;
LGG	cis	rs561341	1.000	rs546519	chr17:30297682	T/G	cg00745463	chr17:30367425	LRRC37B	-0.72	-10.55	-0.44	1.75e-23	Hip circumference adjusted for BMI;
LGG	cis	rs657075	0.697	rs3805669	chr5:131646762	A/G	cg17951613	chr5:131705445	SLC22A5	0.65	7.46	0.33	4.2e-13	Rheumatoid arthritis;
LGG	cis	rs634534	0.622	rs552130	chr11:65732800	T/C	cg02427764	chr11:65769310	BANF1;EIF1AD	0.45	7.49	0.33	3.53e-13	Sum eosinophil basophil counts;Eosinophil counts;
LGG	trans	rs9467711	0.651	rs17587226	chr6:25962304	C/T	cg01620082	chr3:125678407	NA	-0.75	-6.92	-0.31	1.48e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs72781680	1.000	rs72798418	chr2:24188922	A/G	cg08917208	chr2:24149416	ATAD2B	0.82	9.61	0.41	4.62e-20	Lymphocyte counts;
LGG	cis	rs6424115	1.000	rs974698	chr1:24132785	C/T	cg24699146	chr1:24152579	HMGCL	0.25	7.6	0.33	1.62e-13	Immature fraction of reticulocytes;
LGG	cis	rs4665809	1.000	rs4233710	chr2:26291565	G/A	cg22920501	chr2:26401640	FAM59B	-0.41	-8.05	-0.35	6.94e-15	Gut microbiome composition (summer);
LGG	cis	rs6952808	0.929	rs11768206	chr7:1932151	T/G	cg20295408	chr7:1910781	MAD1L1	-0.47	-8.02	-0.35	8.57e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	0.728	rs72650868	chr8:58155568	G/C	cg08677398	chr8:58056175	NA	0.57	9.2	0.39	1.18e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs11155671	0.530	rs3823021	chr6:150210999	G/C	cg07132326	chr6:150258058	NA	0.37	8.05	0.35	7.02e-15	Testicular germ cell tumor;
LGG	trans	rs66887589	0.777	rs1814815	chr4:120258091	C/T	cg25214090	chr10:38739885	LOC399744	0.4	7.42	0.33	5.75e-13	Diastolic blood pressure;
LGG	cis	rs7166081	1.000	rs72625777	chr15:67503808	G/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.0	-0.31	9.26e-12	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs75920871	0.748	rs7106662	chr11:116951385	T/C	cg20608306	chr11:116969690	SIK3	-0.38	-10.44	-0.44	4.77e-23	Subjective well-being;
LGG	cis	rs752010	0.714	rs10890144	chr1:42085397	G/T	cg16096631	chr1:42092165	HIVEP3	0.74	21.69	0.71	1.69e-72	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs11758351	0.866	rs77889957	chr6:26207435	A/G	cg06951627	chr6:26196580	NA	0.53	8.09	0.35	5.41e-15	Gout;Renal underexcretion gout;
LGG	cis	rs1728785	0.901	rs698711	chr16:68561955	C/T	cg02972257	chr16:68554789	NA	-0.54	-8.25	-0.36	1.6e-15	Ulcerative colitis;
LGG	cis	rs12477438	0.700	rs12467679	chr2:99654449	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.71	-12.11	-0.49	1.55e-29	Chronic sinus infection;
LGG	cis	rs2739330	0.731	rs4822450	chr22:24242887	C/T	cg25703541	chr22:24373054	LOC391322	-0.92	-18.19	-0.65	3.56e-56	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs11148252	0.508	rs1886542	chr13:52706281	A/C	cg12458913	chr13:53173898	NA	0.56	9.97	0.42	2.37e-21	Lewy body disease;
LGG	cis	rs1059312	0.932	rs4760592	chr12:129287149	G/C	cg23521905	chr12:129298690	SLC15A4;MGC16384	0.28	6.69	0.3	6.27e-11	Systemic lupus erythematosus;
LGG	cis	rs7937682	1.000	rs10789843	chr11:111576158	C/T	cg08305652	chr11:111469057	NA	0.43	8.24	0.36	1.79e-15	Primary sclerosing cholangitis;
LGG	cis	rs7119	0.717	rs12904254	chr15:77802585	C/A	cg10437265	chr15:77819839	NA	0.24	6.66	0.3	7.65e-11	Type 2 diabetes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg02759489	chr4:55098483	PDGFRA	0.43	7.34	0.32	9.8e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs6981523	0.553	rs11783890	chr8:11056388	T/C	cg16141378	chr3:129829833	LOC729375	0.33	6.92	0.31	1.53e-11	Neuroticism;
LGG	trans	rs1493916	1.000	rs12457802	chr18:31389865	A/G	cg27147174	chr7:100797783	AP1S1	0.69	13.03	0.52	2.85e-33	Life satisfaction;
LGG	cis	rs4330281	0.740	rs4643736	chr3:17792256	G/T	cg20981856	chr3:17787350	NA	-0.38	-6.95	-0.31	1.22e-11	Schizophrenia;
LGG	cis	rs17376456	0.825	rs17372057	chr5:93071916	C/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.93	10.69	0.44	5.54e-24	Diabetic retinopathy;
LGG	cis	rs6495367	1.000	rs1961579	chr15:79380516	G/A	cg17916960	chr15:79447300	NA	0.52	9.1	0.39	2.76e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs798554	0.797	rs1182183	chr7:2873136	C/T	cg05793240	chr7:2802953	GNA12	0.34	7.71	0.34	7.55e-14	Height;
LGG	cis	rs9322193	0.923	rs11155674	chr6:150032247	T/C	cg00424166	chr6:150045504	NUP43	-0.35	-7.34	-0.32	9.46e-13	Lung cancer;
LGG	cis	rs3733585	0.605	rs4697708	chr4:10121189	A/G	cg25986240	chr4:9926439	SLC2A9	0.38	7.72	0.34	7.16e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs6500395	1.000	rs9933237	chr16:48676562	T/C	cg04672837	chr16:48644449	N4BP1	0.54	8.96	0.38	8.18e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2576037	0.521	rs4986227	chr18:44595031	G/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.44	8.04	0.35	7.52e-15	Personality dimensions;
LGG	cis	rs34599045	0.522	rs12737395	chr1:152923046	G/A	cg07796016	chr1:152779584	LCE1C	-0.87	-8.04	-0.35	7.44e-15	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs888405	0.541	rs697287	chr3:64211102	G/A	cg02147797	chr3:64211204	PRICKLE2	0.51	6.96	0.31	1.16e-11	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);
LGG	cis	rs4740619	1.000	rs10756686	chr9:15634646	A/T	cg14451791	chr9:16040625	NA	-0.35	-8.8	-0.38	2.69e-17	Body mass index;
LGG	cis	rs7765175	0.598	rs9387128	chr6:113620948	G/T	cg26552650	chr6:113682475	NA	0.34	7.41	0.33	6.2e-13	Coronary artery calcification;
LGG	cis	rs4555082	0.834	rs2975217	chr14:105710238	A/C	cg13114125	chr14:105738426	BRF1	-0.83	-16.13	-0.6	9.47e-47	Mean platelet volume;Platelet distribution width;
LGG	cis	rs9611565	0.802	rs9611571	chr22:41784867	G/A	cg06481639	chr22:41940642	POLR3H	-0.51	-7.67	-0.34	1.02e-13	Vitiligo;
LGG	cis	rs4780401	0.782	rs933573	chr16:11793395	A/G	cg01061890	chr16:11836724	TXNDC11	0.46	7.74	0.34	6.28e-14	Rheumatoid arthritis;
LGG	cis	rs7044106	0.791	rs10984998	chr9:123481516	G/C	cg09419670	chr9:123605666	PSMD5;LOC253039	0.84	16.7	0.61	2.4e-49	Hip circumference adjusted for BMI;
LGG	cis	rs11098499	0.562	rs13101722	chr4:120555975	C/A	cg09307838	chr4:120376055	NA	-0.67	-11.61	-0.47	1.54e-27	Corneal astigmatism;
LGG	cis	rs10504229	0.593	rs2317990	chr8:58024168	G/T	cg05313129	chr8:58192883	C8orf71	-0.6	-7.81	-0.34	3.94e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs6547741	0.935	rs4666005	chr2:27855239	A/G	cg22903471	chr2:27725779	GCKR	0.37	8.52	0.37	2.27e-16	Oral cavity cancer;
LGG	cis	rs10752881	1.000	rs10752887	chr1:182990834	T/C	cg07928641	chr1:182991847	LAMC1	0.48	9.92	0.42	3.75e-21	Colorectal cancer;
LGG	trans	rs2994684	0.736	rs11008385	chr10:31453788	A/C	cg13917712	chr19:38714681	DPF1	0.34	7.25	0.32	1.71e-12	Response to antipsychotic treatment;
LGG	cis	rs6502050	0.835	rs4789665	chr17:80168097	A/C	cg16920238	chr17:80076378	CCDC57	-0.32	-7.18	-0.32	2.74e-12	Life satisfaction;
LGG	cis	rs9682041	0.736	rs34237232	chr3:170063753	C/T	cg11886554	chr3:170076028	SKIL	-0.86	-10.44	-0.44	4.57e-23	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs2019137	1.000	rs2019137	chr2:113973632	G/A	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	-0.69	-12.53	-0.5	3.26e-31	Lymphocyte counts;
LGG	cis	rs7249142	0.549	rs10854012	chr19:19295719	C/T	cg15207422	chr19:19280969	LOC729991-MEF2B;MEF2B	-0.27	-7.52	-0.33	2.95e-13	IgG glycosylation;
LGG	cis	rs7727544	0.716	rs4594848	chr5:131586598	C/A	cg07395648	chr5:131743802	NA	-0.43	-9.18	-0.39	1.45e-18	Blood metabolite levels;
LGG	cis	rs12618769	0.597	rs4850876	chr2:99112069	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.66	0.37	8.2e-17	Bipolar disorder;
LGG	cis	rs4262150	0.544	rs72795351	chr5:151910821	G/A	cg12297329	chr5:152029980	NA	-0.62	-11.12	-0.46	1.25e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs9814567	0.929	rs9855013	chr3:134240414	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.73	-13.37	-0.53	1.03e-34	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7568458	0.684	rs1048740	chr2:85764966	A/T	cg17127132	chr2:85788382	GGCX	0.51	8.11	0.35	4.46e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4363385	0.667	rs6675352	chr1:152936749	A/G	cg13444842	chr1:152974279	SPRR3	-0.41	-7.64	-0.33	1.23e-13	Inflammatory skin disease;
LGG	cis	rs10504229	0.953	rs78089850	chr8:58171557	A/G	cg02725872	chr8:58115012	NA	-0.77	-10.96	-0.45	5.02e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs12580194	0.593	rs61956272	chr12:55779559	A/T	cg19537932	chr12:55886519	OR6C68	-0.56	-10.24	-0.43	2.52e-22	Cancer;
LGG	cis	rs1881797	1.000	rs10158379	chr1:247686352	C/A	cg11166453	chr1:247681781	NA	0.64	10.04	0.42	1.34e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs986417	0.901	rs4901987	chr14:60987529	C/T	cg27398547	chr14:60952738	C14orf39	0.71	6.82	0.3	2.93e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs4356932	1.000	rs6532105	chr4:76953895	C/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.7	-0.3	6.24e-11	Blood protein levels;
LGG	cis	rs16933812	0.510	rs4880048	chr9:36989054	A/G	cg13738729	chr9:36989127	PAX5	-0.43	-9.57	-0.41	6.35e-20	Obesity-related traits;
LGG	cis	rs17270561	0.609	rs1317510	chr6:25778924	T/C	cg12310025	chr6:25882481	NA	-0.43	-7.08	-0.31	5.51e-12	Iron status biomarkers;
LGG	cis	rs3126085	0.935	rs1858480	chr1:152301735	A/G	cg26876637	chr1:152193138	HRNR	-0.52	-8.51	-0.37	2.38e-16	Atopic dermatitis;
LGG	cis	rs7223966	1.000	rs8078862	chr17:61854068	C/T	cg17202724	chr17:61916730	SMARCD2	-0.43	-8.56	-0.37	1.7e-16	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2820315	0.931	rs2644114	chr1:201864830	A/G	cg10061532	chr1:201886748	LMOD1	-0.33	-6.9	-0.31	1.68e-11	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Coronary artery disease;Body mass index in physically active individuals;
LGG	trans	rs2832077	0.527	rs2142375	chr21:30223742	G/A	cg14791747	chr16:20752902	THUMPD1	0.56	10.31	0.43	1.43e-22	Cognitive test performance;
LGG	cis	rs7635838	0.684	rs2606758	chr3:11353064	G/A	cg00170343	chr3:11313890	ATG7	0.51	8.77	0.38	3.55e-17	HDL cholesterol;
LGG	cis	rs7107174	1.000	rs58235466	chr11:78030886	T/C	cg27205649	chr11:78285834	NARS2	-0.46	-7.6	-0.33	1.69e-13	Testicular germ cell tumor;
LGG	cis	rs9858542	0.537	rs56038006	chr3:49362369	C/T	cg00383909	chr3:49044727	WDR6	0.58	8.15	0.35	3.52e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs3789045	0.560	rs3747634	chr1:204411063	C/T	cg17419461	chr1:204415978	PIK3C2B	0.6	10.86	0.45	1.27e-24	Educational attainment (college completion);
LGG	cis	rs9291683	0.530	rs4697698	chr4:9942577	C/T	cg11266682	chr4:10021025	SLC2A9	0.47	9.35	0.4	3.72e-19	Bone mineral density;
LGG	cis	rs13424612	1.000	rs7590071	chr2:240900947	G/C	cg01812947	chr2:240904978	NDUFA10	0.42	7.18	0.32	2.78e-12	Odorant perception (isobutyraldehyde);
LGG	cis	rs7000551	0.751	rs2469768	chr8:22381362	G/A	cg12081754	chr8:22256438	SLC39A14	0.65	12.14	0.49	1.2e-29	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	trans	rs6561151	0.681	rs4942249	chr13:44426804	C/A	cg17145862	chr1:211918768	LPGAT1	0.69	10.79	0.45	2.39e-24	Crohn's disease;
LGG	cis	rs9788721	0.836	rs17484235	chr15:78761414	C/G	cg18825076	chr15:78729989	IREB2	-0.61	-9.74	-0.41	1.61e-20	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs8053891	0.615	rs34042070	chr16:72101525	C/G	cg22337624	chr16:72126421	TXNL4B;DHX38	-0.46	-8.11	-0.35	4.55e-15	Coronary artery disease;
LGG	trans	rs2980439	0.818	rs2948300	chr8:8106508	C/T	cg02002194	chr4:3960332	NA	-0.5	-9.91	-0.42	3.85e-21	Neuroticism;
LGG	cis	rs2290416	0.892	rs77370907	chr8:144664975	G/C	cg19357499	chr8:144660631	NAPRT1	0.9	7.09	0.31	5.12e-12	Attention deficit hyperactivity disorder;
LGG	cis	rs875971	0.862	rs778707	chr7:65857027	G/A	cg18252515	chr7:66147081	NA	-0.44	-7.33	-0.32	1.01e-12	Aortic root size;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg23835219	chr4:1244017	CTBP1;C4orf42	0.83	16.67	0.61	3.34e-49	Obesity-related traits;
LGG	cis	rs796364	0.755	rs203762	chr2:200905136	C/A	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.76	-9.09	-0.39	2.81e-18	Schizophrenia;
LGG	trans	rs2797160	0.904	rs2326292	chr6:125999674	G/A	cg05039488	chr6:79577232	IRAK1BP1	-0.43	-7.15	-0.32	3.48e-12	Endometrial cancer;
LGG	cis	rs7666738	0.830	rs10012167	chr4:99048579	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.44e-16	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7824557	0.628	rs6988922	chr8:11194911	A/G	cg06636001	chr8:8085503	FLJ10661	0.42	7.24	0.32	1.82e-12	Retinal vascular caliber;
LGG	cis	rs7143963	0.943	rs72704737	chr14:103373434	C/G	cg23020514	chr14:103360112	TRAF3	0.47	8.78	0.38	3.26e-17	Body mass index;
LGG	cis	rs2404602	0.692	rs10444858	chr15:76962504	T/C	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.3e-12	Blood metabolite levels;
LGG	cis	rs7098414	0.511	rs10887826	chr10:82151380	C/T	cg01528321	chr10:82214614	TSPAN14	0.66	11.76	0.48	4.15e-28	Post bronchodilator FEV1;
LGG	cis	rs735539	0.521	rs2818994	chr13:21418410	G/A	cg04906043	chr13:21280425	IL17D	-0.47	-7.33	-0.32	1.02e-12	Dental caries;
LGG	cis	rs220324	1.000	rs467990	chr21:43582861	G/A	cg08841829	chr21:43638893	ABCG1	0.42	6.87	0.3	2.07e-11	Idiopathic osteonecrosis of the femoral head;
LGG	cis	rs9611565	0.659	rs12484175	chr22:41953739	A/C	cg03806693	chr22:41940476	POLR3H	-1.16	-21.49	-0.71	1.48e-71	Vitiligo;
LGG	trans	rs8002861	0.870	rs9567293	chr13:44447243	A/G	cg24399406	chr17:33895357	NA	-0.41	-6.81	-0.3	2.98e-11	Leprosy;
LGG	cis	rs7681440	0.904	rs12331318	chr4:90770255	A/G	cg06848047	chr4:90757629	SNCA	-0.41	-7.77	-0.34	5.06e-14	Dementia with Lewy bodies;
LGG	cis	rs17221829	0.703	rs10830336	chr11:89406461	G/A	cg02982614	chr11:89391479	FOLH1B	-0.39	-8.6	-0.37	1.29e-16	Anxiety in major depressive disorder;
LGG	cis	rs780094	0.585	rs3739095	chr2:27556721	C/T	cg22903471	chr2:27725779	GCKR	-0.51	-11.44	-0.47	7.65e-27	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs4919044	0.808	rs7895700	chr10:94791099	A/G	cg05127821	chr10:94822908	CYP26C1	-0.44	-7.9	-0.34	2.03e-14	Coronary artery disease;
LGG	cis	rs7618915	0.501	rs34754793	chr3:52629177	A/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.63	11.48	0.47	5.16e-27	Bipolar disorder;
LGG	cis	rs6951245	0.935	rs78573577	chr7:1089087	C/A	cg02733842	chr7:1102375	C7orf50	0.69	10.3	0.43	1.53e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9291683	0.597	rs11722989	chr4:10126139	A/G	cg00071950	chr4:10020882	SLC2A9	-0.33	-6.7	-0.3	6.1e-11	Bone mineral density;
LGG	cis	rs73001065	0.818	rs58847337	chr19:19726022	G/A	cg03709012	chr19:19516395	GATAD2A	0.75	6.98	0.31	1.03e-11	LDL cholesterol;
LGG	cis	rs2921036	0.529	rs2979192	chr8:8338147	C/T	cg06636001	chr8:8085503	FLJ10661	0.48	8.71	0.38	5.62e-17	Neuroticism;
LGG	cis	rs908922	0.676	rs578382	chr1:152514054	A/G	cg03606772	chr1:152487856	CRCT1	-0.3	-7.02	-0.31	7.81e-12	Hair morphology;
LGG	cis	rs7584330	0.910	rs6737914	chr2:238393434	A/G	cg16989719	chr2:238392110	NA	-0.34	-7.52	-0.33	2.83e-13	Prostate cancer;
LGG	cis	rs11123170	0.569	rs1049137	chr2:113975110	A/G	cg11763394	chr2:113992921	PAX8;LOC440839;LOC654433	0.58	8.78	0.38	3.14e-17	Renal function-related traits (BUN);
LGG	cis	rs7044106	0.791	rs4836830	chr9:123483668	A/G	cg13460057	chr9:123605234	PSMD5;LOC253039	0.46	7.35	0.32	9.26e-13	Hip circumference adjusted for BMI;
LGG	cis	rs10504229	0.596	rs6991216	chr8:58115586	T/C	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg26454730	chr18:11851233	GNAL;CHMP1B	0.42	6.71	0.3	5.7e-11	Gut microbiome composition (summer);
LGG	cis	rs4820294	0.669	rs9622677	chr22:38054262	A/C	cg00142150	chr22:38071001	LGALS1	0.68	13.0	0.52	3.67e-33	Fat distribution (HIV);
LGG	trans	rs61931739	0.534	rs6488189	chr12:33995865	C/T	cg13010199	chr12:38710504	ALG10B	0.57	10.64	0.44	8.3e-24	Morning vs. evening chronotype;
LGG	cis	rs9517320	1.000	rs7996629	chr13:99128037	C/T	cg07423050	chr13:99094983	FARP1	0.4	8.12	0.35	4.34e-15	Longevity;
LGG	cis	rs11190604	0.767	rs11190509	chr10:102156208	G/A	cg07570687	chr10:102243282	WNT8B	0.4	7.07	0.31	5.77e-12	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs13118159	0.550	rs9685761	chr4:1377942	C/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.47	7.46	0.33	4.28e-13	Longevity;
LGG	cis	rs28386778	0.863	rs58269663	chr17:61843130	G/A	cg03528353	chr17:61819722	STRADA	0.44	7.43	0.33	5.1e-13	Prudent dietary pattern;
LGG	cis	rs7301826	0.651	rs4759519	chr12:131289508	G/A	cg11011512	chr12:131303247	STX2	0.41	8.91	0.38	1.2e-17	Plasma plasminogen activator levels;
LGG	cis	rs2735413	0.564	rs2344491	chr16:78096154	A/G	cg04733911	chr16:78082701	NA	0.63	8.96	0.38	7.77e-18	Systolic blood pressure (alcohol consumption interaction);
LGG	cis	rs941764	0.601	rs1285835	chr14:91873792	C/T	cg10511902	chr14:91842949	CCDC88C	-0.51	-10.31	-0.43	1.36e-22	Breast cancer;
LGG	cis	rs7659604	0.537	rs6815973	chr4:122663430	A/T	cg20573242	chr4:122745356	CCNA2	-0.42	-6.72	-0.3	5.49e-11	Type 2 diabetes;
LGG	cis	rs1008375	0.863	rs10003291	chr4:17600728	A/C	cg02297831	chr4:17616191	MED28	0.47	8.43	0.36	4.47e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4665809	0.567	rs12999875	chr2:26414847	A/C	cg08470875	chr2:26401718	FAM59B	0.42	8.14	0.35	3.63e-15	Gut microbiome composition (summer);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg23634678	chr11:102963104	DCUN1D5	0.47	8.08	0.35	5.7e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs4650994	0.593	rs12033086	chr1:178540925	C/T	cg12486710	chr1:178512616	C1orf220	-0.34	-6.7	-0.3	6.14e-11	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs11122272	0.735	rs2790893	chr1:231508976	T/G	cg10503236	chr1:231470652	EXOC8	-0.37	-7.2	-0.32	2.5e-12	Hemoglobin concentration;
LGG	cis	rs6028335	0.610	rs72623594	chr20:37576255	G/A	cg16355469	chr20:37678765	NA	0.55	7.27	0.32	1.56e-12	Alcohol and nicotine co-dependence;
LGG	cis	rs11209002	0.738	rs1321154	chr1:67570703	T/C	cg02640540	chr1:67518911	SLC35D1	0.54	6.68	0.3	7.05e-11	Crohn's disease;
LGG	cis	rs12681288	0.862	rs935821	chr8:1022455	G/A	cg08648136	chr8:956695	NA	0.33	6.85	0.3	2.33e-11	Schizophrenia;
LGG	cis	rs36051895	0.664	rs17425819	chr9:5114773	C/T	cg02405213	chr9:5042618	JAK2	-0.78	-14.49	-0.56	1.72e-39	Pediatric autoimmune diseases;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00437443	chr6:11094621	LOC221710	0.57	8.58	0.37	1.49e-16	Gut microbiome composition (summer);
LGG	cis	rs5760092	0.755	rs11090298	chr22:24262061	G/A	cg04234412	chr22:24373322	LOC391322	0.7	10.77	0.45	2.76e-24	Urinary 1,3-butadiene metabolite levels in smokers;
LGG	cis	rs2576037	0.796	rs6507718	chr18:44581284	G/C	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	-0.41	-7.89	-0.34	2.17e-14	Personality dimensions;
LGG	cis	rs7615952	0.599	rs6779141	chr3:125709995	A/T	cg18479299	chr3:125709523	NA	-0.6	-7.78	-0.34	4.89e-14	Blood pressure (smoking interaction);
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06527865	chr1:234746497	IRF2BP2	-0.5	-7.32	-0.32	1.1e-12	Systemic lupus erythematosus;
LGG	cis	rs202629	1	rs202629	chr22:41849975	C/T	cg06634786	chr22:41940651	POLR3H	0.72	12.0	0.49	4.59e-29	Cannabis dependence symptom count;
LGG	cis	rs1707322	0.827	rs6694302	chr1:46245645	A/T	cg03146154	chr1:46216737	IPP	0.58	10.6	0.44	1.14e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs7395662	0.963	rs11039870	chr11:48626478	C/T	cg15704280	chr7:45808275	SEPT13	-0.5	-8.1	-0.35	4.79e-15	HDL cholesterol;
LGG	cis	rs10791323	0.569	rs10750542	chr11:133713436	T/C	cg00579200	chr11:133705235	NA	-0.59	-11.31	-0.47	2.42e-26	Childhood ear infection;
LGG	cis	rs6089584	0.546	rs6061980	chr20:60618877	G/A	cg06108461	chr20:60628389	TAF4	-0.74	-13.31	-0.53	1.89e-34	Body mass index;
LGG	cis	rs916888	0.773	rs199445	chr17:44817408	C/T	cg10780632	chr17:43973522	MAPT;LOC100128977;LOC100130148	0.65	10.25	0.43	2.35e-22	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4302748	0.862	rs11974973	chr7:36184850	A/T	cg24442661	chr7:36192818	EEPD1	-0.57	-7.57	-0.33	2.04e-13	Platelet count;
LGG	cis	rs4481887	0.927	rs4916087	chr1:248493833	T/C	cg01631408	chr1:248437212	OR2T33	-0.53	-9.49	-0.4	1.24e-19	Common traits (Other);
LGG	cis	rs2836950	0.545	rs8132424	chr21:40584412	A/T	cg11890956	chr21:40555474	PSMG1	0.72	12.36	0.5	1.63e-30	Menarche (age at onset);
LGG	cis	rs7529073	0.683	rs340882	chr1:214145731	C/G	cg00795024	chr1:214157026	NA	-0.29	-8.18	-0.36	2.68e-15	Schizophrenia;
LGG	cis	rs2694528	0.841	rs78406720	chr5:60385738	G/A	cg11474532	chr5:59995715	DEPDC1B	0.73	7.45	0.33	4.68e-13	Parkinson's disease;
LGG	trans	rs9858542	0.953	rs35261698	chr3:49537839	C/G	cg21665057	chr3:196295764	WDR53;FBXO45	-0.51	-8.33	-0.36	9.39e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs10256972	0.521	rs871019	chr7:1105230	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.57	-10.3	-0.43	1.57e-22	Longevity;Endometriosis;
LGG	trans	rs10435719	0.899	rs7815595	chr8:11792351	C/A	cg06636001	chr8:8085503	FLJ10661	0.51	9.18	0.39	1.48e-18	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs908922	0.676	rs2146120	chr1:152504200	A/T	cg09873164	chr1:152488093	CRCT1	0.61	14.51	0.56	1.36e-39	Hair morphology;
LGG	cis	rs7824557	0.602	rs7820895	chr8:11206262	T/C	cg21775007	chr8:11205619	TDH	0.82	14.36	0.56	5.93e-39	Retinal vascular caliber;
LGG	cis	rs13191362	1.000	rs34177053	chr6:163007772	T/C	cg18825119	chr6:163149453	PACRG;PARK2	0.45	7.67	0.34	1.03e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg06238570	chr21:40685208	BRWD1	0.53	8.71	0.38	5.5e-17	Cognitive function;
LGG	cis	rs6840360	0.642	rs2709818	chr4:152382634	A/G	cg17217059	chr4:152329364	FAM160A1	0.2	7.13	0.31	3.8e-12	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.569	rs1872746	chr12:33985843	T/C	cg26384229	chr12:38710491	ALG10B	0.62	12.38	0.5	1.33e-30	Morning vs. evening chronotype;
LGG	cis	rs9291683	0.620	rs11722946	chr4:10125990	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-8.01	-0.35	9.69e-15	Bone mineral density;
LGG	trans	rs926326	0.560	rs1980449	chr6:25629658	C/T	cg07093942	chr16:68278871	PLA2G15	-0.41	-7.12	-0.31	4.11e-12	Platelet count;
LGG	cis	rs28386778	0.799	rs2665802	chr17:61995030	A/T	cg11494091	chr17:61959527	GH2	-1.15	-34.54	-0.85	3.35e-130	Prudent dietary pattern;
LGG	cis	rs4144027	0.904	rs10438243	chr14:104345822	A/G	cg26031613	chr14:104095156	KLC1	0.44	7.17	0.32	3.02e-12	Blood metabolite levels;
LGG	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg04568710	chr12:38710424	ALG10B	0.35	6.96	0.31	1.18e-11	Bladder cancer;
LGG	trans	rs6600671	0.899	rs2319971	chr1:121226982	A/C	cg00646200	chr1:148855367	NA	0.61	11.84	0.48	1.94e-28	Hip geometry;
LGG	cis	rs963731	0.649	rs297152	chr2:39326734	G/T	cg04010122	chr2:39346883	SOS1	-0.82	-8.08	-0.35	5.65e-15	Corticobasal degeneration;
LGG	trans	rs6787172	0.905	rs1714507	chr3:158251432	A/T	cg23275840	chr4:47708675	CORIN	-0.35	-7.2	-0.32	2.42e-12	Subjective well-being;
LGG	cis	rs796364	1.000	rs281759	chr2:200787719	T/C	cg12253985	chr2:200820533	C2orf60;C2orf47	0.72	9.37	0.4	3.27e-19	Schizophrenia;
LGG	cis	rs13102973	0.564	rs4418034	chr4:135886650	T/A	cg14419869	chr4:135874104	NA	0.46	7.91	0.35	1.9e-14	Subjective well-being;
LGG	cis	rs2019137	0.936	rs12612729	chr2:113957048	G/A	cg12889195	chr2:113992843	PAX8;LOC440839;LOC654433	-0.66	-12.33	-0.5	2.13e-30	Lymphocyte counts;
LGG	cis	rs6500395	0.926	rs11645193	chr16:48594229	C/T	cg04672837	chr16:48644449	N4BP1	0.53	8.71	0.38	5.47e-17	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs6466055	0.669	rs10953468	chr7:104741842	A/T	cg04380332	chr7:105027541	SRPK2	-0.38	-7.24	-0.32	1.94e-12	Schizophrenia;
LGG	cis	rs7819412	0.645	rs4841508	chr8:11065003	C/A	cg21775007	chr8:11205619	TDH	-0.51	-8.07	-0.35	6.16e-15	Triglycerides;
LGG	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg04568710	chr12:38710424	ALG10B	0.33	6.72	0.3	5.4e-11	Bladder cancer;
LGG	cis	rs4805272	0.512	rs8106166	chr19:29339578	A/G	cg04546413	chr19:29218101	NA	-0.58	-7.94	-0.35	1.59e-14	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);
LGG	cis	rs796364	0.806	rs74771155	chr2:200913743	C/T	cg23649088	chr2:200775458	C2orf69	-0.58	-7.06	-0.31	6.13e-12	Schizophrenia;
LGG	cis	rs1506636	0.962	rs2896335	chr7:123376855	A/T	cg03229431	chr7:123269106	ASB15	-0.74	-18.49	-0.65	1.39e-57	Plateletcrit;Platelet count;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.13	17.84	0.64	1.5e-54	Alzheimer's disease;
LGG	cis	rs2276314	1.000	rs56050783	chr18:33553791	A/G	cg19628046	chr18:33552617	C18orf21	0.53	7.73	0.34	6.9e-14	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs7766436	0.767	rs7764914	chr6:22601548	T/G	cg13666174	chr6:22585274	NA	-0.35	-8.52	-0.37	2.19e-16	Coronary artery disease;
LGG	cis	rs4696584	0.755	rs56390496	chr4:155407940	A/T	cg13738195	chr4:155413469	DCHS2	-0.38	-7.68	-0.34	9.38e-14	Folding of antihelix;
LGG	cis	rs4253772	0.591	rs6519994	chr22:46656805	A/G	cg24881330	chr22:46731750	TRMU	-0.69	-8.6	-0.37	1.25e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs868036	0.609	rs2045960	chr15:68092079	G/A	cg22044901	chr15:68126292	NA	-0.41	-6.89	-0.3	1.84e-11	Restless legs syndrome;
LGG	trans	rs7824557	0.591	rs2736283	chr8:11225910	A/G	cg15556689	chr8:8085844	FLJ10661	-0.42	-7.15	-0.32	3.32e-12	Retinal vascular caliber;
LGG	cis	rs12479064	0.724	rs2305352	chr2:100015124	C/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.91	-0.45	7.76e-25	Chronic sinus infection;
LGG	cis	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.12	-0.49	1.46e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303280	0.773	rs12949100	chr17:38057189	G/A	cg00129232	chr17:37814104	STARD3	-0.47	-8.61	-0.37	1.13e-16	Self-reported allergy;
LGG	cis	rs657075	0.595	rs57750646	chr5:131680264	G/A	cg17951613	chr5:131705445	SLC22A5	0.65	7.44	0.33	4.99e-13	Rheumatoid arthritis;
LGG	cis	rs13217239	0.572	rs9379958	chr6:27066163	A/C	cg12292205	chr6:26970375	C6orf41	-0.55	-10.7	-0.45	5.1e-24	Schizophrenia;
LGG	cis	rs796364	0.906	rs281789	chr2:200780698	T/G	cg25936922	chr2:200820526	C2orf60;C2orf47	0.82	10.91	0.45	8.34e-25	Schizophrenia;
LGG	cis	rs2013441	0.932	rs2526488	chr17:20098617	T/A	cg13482628	chr17:19912719	NA	-0.51	-9.45	-0.4	1.76e-19	Obesity-related traits;
LGG	cis	rs9858542	1.000	rs34762726	chr3:49689210	G/A	cg07274523	chr3:49395745	GPX1	0.55	9.09	0.39	3.01e-18	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs910316	0.712	rs175015	chr14:75457075	A/C	cg06637938	chr14:75390232	RPS6KL1	-0.52	-9.4	-0.4	2.48e-19	Height;
LGG	cis	rs250677	0.916	rs17109279	chr5:148416581	A/G	cg18129178	chr5:148520854	ABLIM3	-0.41	-6.92	-0.31	1.47e-11	Breast cancer;
LGG	cis	rs7811142	0.720	rs112622797	chr7:99917416	G/A	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-0.96	-14.04	-0.55	1.42e-37	Platelet count;
LGG	cis	rs6121246	0.529	rs6060291	chr20:30198043	T/G	cg21427119	chr20:30132790	HM13	-0.56	-8.83	-0.38	2.17e-17	Mean corpuscular hemoglobin;
LGG	cis	rs11155671	0.517	rs9397058	chr6:150207249	C/T	cg19673125	chr6:150240577	RAET1G	0.36	8.86	0.38	1.73e-17	Testicular germ cell tumor;
LGG	cis	rs4950322	0.515	rs72691016	chr1:146717027	T/C	cg22381352	chr1:146742008	CHD1L	-0.49	-8.11	-0.35	4.73e-15	Protein quantitative trait loci;
LGG	cis	rs6502050	0.835	rs7406529	chr17:80080877	C/T	cg07959490	chr17:80112427	CCDC57	0.46	9.24	0.39	9.32e-19	Life satisfaction;
LGG	trans	rs7762018	0.607	rs7759404	chr6:170135728	A/G	cg06875740	chr19:51307921	C19orf48	-0.66	-8.23	-0.36	1.94e-15	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	trans	rs916888	0.610	rs199444	chr17:44818276	T/C	cg07870213	chr5:140052090	DND1	0.69	13.48	0.53	3.45e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs2916247	1.000	rs72671424	chr8:93056264	A/G	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.1	-0.35	4.88e-15	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.954	rs114134184	chr8:58181969	G/A	cg23782820	chr8:58130467	NA	0.43	6.65	0.3	8.41e-11	Developmental language disorder (linguistic errors);
LGG	trans	rs61931739	0.500	rs7311302	chr12:34557211	T/C	cg26384229	chr12:38710491	ALG10B	0.85	18.21	0.65	2.82e-56	Morning vs. evening chronotype;
LGG	cis	rs7444	0.941	rs2283790	chr22:21956653	C/T	cg05046821	chr22:21984468	YDJC	0.39	7.01	0.31	8.2e-12	Systemic lupus erythematosus;
LGG	cis	rs2836974	0.533	rs418298	chr21:40536654	A/T	cg11890956	chr21:40555474	PSMG1	0.99	21.18	0.7	3.87e-70	Cognitive function;
LGG	cis	rs4718428	0.705	rs13231140	chr7:66361618	C/G	cg13147721	chr7:65941812	NA	-0.44	-6.72	-0.3	5.26e-11	Corneal structure;
LGG	cis	rs6735179	0.565	rs73182756	chr2:1747826	A/G	cg08534653	chr2:1747700	PXDN	0.49	7.36	0.32	8.27e-13	Response to antipsychotic treatment;
LGG	trans	rs2018683	0.624	rs2286219	chr7:28998663	G/A	cg19402173	chr7:128379420	CALU	-0.73	-13.24	-0.52	3.6e-34	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs4760636	0.512	rs11168187	chr12:48044011	A/G	cg12761788	chr12:48120090	P11	0.48	7.67	0.34	1.03e-13	Urate levels;
LGG	cis	rs826838	0.935	rs1486357	chr12:39073675	A/G	cg13010199	chr12:38710504	ALG10B	0.72	15.1	0.57	3.48e-42	Heart rate;
LGG	cis	rs6582630	0.539	rs35114325	chr12:38320886	G/T	cg04568710	chr12:38710424	ALG10B	-0.41	-9.04	-0.39	4.14e-18	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs295137	0.725	rs1729413	chr2:201086663	T/G	cg17644776	chr2:200775616	C2orf69	0.48	8.15	0.35	3.32e-15	Asthma (bronchodilator response);
LGG	cis	rs28595532	0.920	rs55668908	chr4:119769799	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs58688157	0.880	rs12272314	chr11:590648	A/G	cg16486109	chr11:613632	IRF7	0.43	7.68	0.34	9.85e-14	Systemic lupus erythematosus;
LGG	cis	rs9560113	0.573	rs9560133	chr13:112240013	C/A	cg10483660	chr13:112241077	NA	0.45	9.3	0.4	5.63e-19	Menarche (age at onset);
LGG	cis	rs7954584	0.567	rs10840632	chr12:122375460	C/T	cg12705353	chr12:122356852	WDR66	0.25	6.79	0.3	3.48e-11	Mean corpuscular volume;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg01145232	chr6:150245071	RAET1G	0.33	6.99	0.31	9.45e-12	Testicular germ cell tumor;
LGG	cis	rs1577917	0.610	rs11752795	chr6:86287129	C/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.44	7.83	0.34	3.35e-14	Response to antipsychotic treatment;
LGG	cis	rs13421350	0.710	rs28595036	chr2:173320956	C/T	cg15021238	chr2:173305865	ITGA6	-0.44	-7.57	-0.33	2.04e-13	Diabetic kidney disease;
LGG	cis	rs9486719	0.843	rs2499796	chr6:96848364	A/G	cg06623918	chr6:96969491	KIAA0776	0.73	9.69	0.41	2.35e-20	Migraine;Coronary artery disease;
LGG	cis	rs6461049	0.800	rs1860831	chr7:2160931	T/C	cg14004847	chr7:1930337	MAD1L1	-0.52	-9.16	-0.39	1.66e-18	Schizophrenia;
LGG	cis	rs10911232	0.507	rs10797832	chr1:183044034	A/G	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	trans	rs7819412	0.669	rs4840549	chr8:10998955	A/G	cg08975724	chr8:8085496	FLJ10661	-0.39	-6.96	-0.31	1.2e-11	Triglycerides;
LGG	trans	rs11039798	1.000	rs7123704	chr11:48580535	G/A	cg15704280	chr7:45808275	SEPT13	0.78	9.03	0.39	4.79e-18	Axial length;
LGG	cis	rs6502050	0.865	rs56193110	chr17:80151501	A/G	cg19223190	chr17:80058835	NA	0.43	8.36	0.36	7.38e-16	Life satisfaction;
LGG	cis	rs9368481	0.729	rs10946881	chr6:26914611	C/T	cg18867708	chr6:26865862	GUSBL1	0.43	7.04	0.31	7.08e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7107174	0.581	rs11237485	chr11:78126011	G/A	cg02023728	chr11:77925099	USP35	0.45	7.74	0.34	6.25e-14	Testicular germ cell tumor;
LGG	cis	rs6594713	0.717	rs2914198	chr5:112950253	C/G	cg12552261	chr5:112820674	MCC	-0.61	-7.9	-0.34	2.09e-14	Brain cytoarchitecture;
LGG	cis	rs4363385	0.782	rs10788857	chr1:153024941	T/G	cg13444842	chr1:152974279	SPRR3	-0.43	-8.78	-0.38	3.08e-17	Inflammatory skin disease;
LGG	trans	rs1814175	0.645	rs1851857	chr11:49855589	A/C	cg03929089	chr4:120376271	NA	-0.94	-19.84	-0.68	7.33e-64	Height;
LGG	cis	rs943466	1.000	rs943462	chr6:33769578	G/A	cg07519485	chr6:33762594	MLN	0.56	11.16	0.46	8.73e-26	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;
LGG	cis	rs758324	0.891	rs635164	chr5:131312874	C/T	cg06307176	chr5:131281290	NA	-0.58	-9.42	-0.4	2.07e-19	Alzheimer's disease in APOE e4- carriers;
LGG	cis	rs6762	0.748	rs7928935	chr11:839127	G/A	cg07691484	chr11:842764	TSPAN4;POLR2L	-0.71	-11.98	-0.49	5.47e-29	Mean platelet volume;
LGG	cis	rs4683346	0.513	rs62247065	chr3:43066572	A/G	cg05453631	chr3:43117548	NA	-0.36	-7.17	-0.32	3.04e-12	Granulocyte percentage of myeloid white cells;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg10176160	chr3:184279528	EPHB3	0.47	7.11	0.31	4.41e-12	Gut microbiome composition (summer);
LGG	cis	rs6500602	0.739	rs4786502	chr16:4537104	T/C	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.4	7.78	0.34	4.61e-14	Schizophrenia;
LGG	cis	rs11722228	0.521	rs56403947	chr4:10112529	T/G	cg08250081	chr4:10125330	NA	0.68	12.39	0.5	1.23e-30	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs7605378	0.528	rs812760	chr2:200724372	C/T	cg17644776	chr2:200775616	C2orf69	0.72	12.94	0.52	6.45e-33	Osteoporosis;
LGG	cis	rs763014	0.966	rs7185390	chr16:666382	A/G	cg00908189	chr16:619842	PIGQ	0.87	16.5	0.61	1.92e-48	Height;
LGG	cis	rs2361718	0.967	rs12942941	chr17:78103013	C/T	cg27427491	chr17:78079615	GAA	-0.31	-8.21	-0.36	2.23e-15	Yeast infection;
LGG	cis	rs6768930	0.509	rs7634631	chr3:57753419	G/C	cg01571842	chr3:57934672	NA	0.3	6.65	0.3	8.22e-11	Obesity-related traits;
LGG	cis	rs12915845	0.529	rs7175106	chr15:89088724	G/C	cg05013243	chr15:89149849	MIR1179	0.36	7.33	0.32	1.04e-12	Menarche (age at onset);
LGG	cis	rs34172651	0.517	rs11639856	chr16:24788645	A/T	cg02428538	chr16:24856791	SLC5A11	0.67	10.27	0.43	1.97e-22	Intelligence (multi-trait analysis);
LGG	trans	rs2117032	0.659	rs4762694	chr12:21176987	A/G	cg02520519	chr3:4345006	SETMAR	0.4	6.96	0.31	1.15e-11	Bilirubin levels;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg03773681	chr2:63815918	MDH1;C2orf86	0.41	7.13	0.31	3.92e-12	Lung adenocarcinoma;
LGG	cis	rs1005277	0.563	rs2505216	chr10:38482830	T/C	cg00409905	chr10:38381863	ZNF37A	-0.65	-12.13	-0.49	1.39e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs6952808	0.771	rs10269191	chr7:1915731	A/G	cg11050988	chr7:1952600	MAD1L1	-0.43	-10.44	-0.44	4.64e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs7000551	0.659	rs2280521	chr8:22271995	G/T	cg12081754	chr8:22256438	SLC39A14	-0.63	-11.19	-0.46	7.03e-26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs4595586	0.545	rs7294600	chr12:39373416	A/G	cg26384229	chr12:38710491	ALG10B	0.59	10.78	0.45	2.57e-24	Morning vs. evening chronotype;
LGG	cis	rs2836974	0.666	rs4818015	chr21:40675493	A/C	cg11890956	chr21:40555474	PSMG1	0.97	20.27	0.69	7.4e-66	Cognitive function;
LGG	cis	rs9322193	0.924	rs9322189	chr6:149909933	T/C	cg11878867	chr6:150167359	LRP11	-0.5	-10.32	-0.43	1.31e-22	Lung cancer;
LGG	cis	rs62400317	0.859	rs72869127	chr6:45071712	T/C	cg18551225	chr6:44695536	NA	-0.62	-10.2	-0.43	3.55e-22	Total body bone mineral density;
LGG	cis	rs4430311	1.000	rs3008658	chr1:244023793	T/A	cg25706552	chr1:244017396	NA	-0.66	-16.72	-0.61	2.02e-49	Post-traumatic stress disorder (asjusted for relatedness);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg07421368	chr2:67624930	ETAA1	0.49	8.03	0.35	8.01e-15	Gut microbiome composition (summer);
LGG	cis	rs35740288	0.822	rs4843090	chr15:86220629	T/C	cg04173714	chr15:86211321	AKAP13	0.46	7.95	0.35	1.46e-14	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs9329221	0.905	rs13254263	chr8:10255181	A/G	cg27411982	chr8:10470053	RP1L1	-0.46	-7.76	-0.34	5.44e-14	Neuroticism;
LGG	cis	rs300774	1.000	rs400978	chr2:119437	A/G	cg04617936	chr2:214353	NA	-0.5	-7.37	-0.32	7.96e-13	Suicide attempts in bipolar disorder;
LGG	cis	rs953387	0.910	rs4954573	chr2:136927094	T/G	cg07169764	chr2:136633963	MCM6	0.54	8.91	0.38	1.16e-17	Arthritis (juvenile idiopathic);
LGG	cis	rs2760061	0.598	rs590657	chr1:228117581	A/C	cg01200585	chr1:228362443	C1orf69	-0.44	-7.79	-0.34	4.56e-14	Diastolic blood pressure;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg03762505	chr1:171750926	METTL13	-0.51	-7.5	-0.33	3.39e-13	Systemic lupus erythematosus;
LGG	cis	rs13191362	0.872	rs13206549	chr6:162978032	T/G	cg21926612	chr6:163149169	PACRG;PARK2	0.9	9.15	0.39	1.78e-18	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg25365783	chr7:108166722	PNPLA8	-0.42	-6.87	-0.3	2.11e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg00106254	chr7:1943704	MAD1L1	-0.5	-9.07	-0.39	3.5e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs13108904	0.837	rs4591539	chr4:1279938	G/C	cg05665937	chr4:1216051	CTBP1	0.59	11.0	0.46	3.63e-25	Obesity-related traits;
LGG	trans	rs3942852	0.712	rs2174129	chr11:48108557	A/C	cg15704280	chr7:45808275	SEPT13	-0.65	-9.13	-0.39	2.13e-18	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs7940866	0.874	rs7112616	chr11:130805334	T/C	cg12179176	chr11:130786555	SNX19	0.77	14.61	0.56	4.91e-40	Schizophrenia;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg05793240	chr7:2802953	GNA12	0.36	8.13	0.35	3.84e-15	Height;
LGG	cis	rs62064224	0.791	rs11653160	chr17:30717222	A/G	cg12561776	chr17:30844705	MYO1D	-0.27	-6.93	-0.31	1.38e-11	Schizophrenia;
LGG	cis	rs8114671	0.836	rs2038504	chr20:33648187	T/C	cg24642439	chr20:33292090	TP53INP2	-0.5	-8.3	-0.36	1.16e-15	Height;
LGG	cis	rs67311347	0.713	rs114569261	chr3:40314580	G/A	cg13683864	chr3:40499215	RPL14	-0.79	-15.6	-0.59	2.23e-44	Renal cell carcinoma;
LGG	cis	rs13108904	0.557	rs1250095	chr4:1239312	C/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.66	-12.17	-0.49	9.58e-30	Obesity-related traits;
LGG	cis	rs4555082	0.874	rs3000075	chr14:105713219	C/T	cg10792982	chr14:105748885	BRF1	-0.66	-13.83	-0.54	1.22e-36	Mean platelet volume;Platelet distribution width;
LGG	cis	rs10484885	0.887	rs114928443	chr6:90602455	A/T	cg13799429	chr6:90582589	CASP8AP2	-0.81	-11.29	-0.46	2.93e-26	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6951245	1.000	rs74366004	chr7:1088630	A/C	cg22907277	chr7:1156413	C7orf50	0.69	8.91	0.38	1.14e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13108904	0.652	rs2878539	chr4:1243877	C/T	cg25897951	chr4:1244024	CTBP1;C4orf42	0.68	12.21	0.49	6.59e-30	Obesity-related traits;
LGG	cis	rs9858542	0.953	rs6766131	chr3:49538932	T/C	cg03060546	chr3:49711283	APEH	-0.62	-10.27	-0.43	2.05e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs644799	1.000	rs3177463	chr11:95502128	G/C	cg03916912	chr11:95522834	CEP57;FAM76B	0.96	20.91	0.7	7.35e-69	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg17691542	chr6:26056736	HIST1H1C	0.55	9.83	0.42	7.63e-21	Height;
LGG	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.81	-0.34	3.89e-14	Colorectal cancer;
LGG	cis	rs1799949	1.000	rs33946455	chr17:41321846	C/T	cg25172604	chr17:41446521	NA	-0.31	-7.11	-0.31	4.45e-12	Menopause (age at onset);
LGG	cis	rs951366	0.873	rs823118	chr1:205723572	C/T	cg07157834	chr1:205819609	PM20D1	0.51	10.09	0.42	8.92e-22	Menarche (age at onset);
LGG	trans	rs9747201	1.000	rs4280305	chr17:80177069	A/C	cg07393940	chr7:158741817	NA	0.6	10.97	0.45	4.8e-25	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs7927771	0.524	rs12286721	chr11:47701528	G/T	cg20307385	chr11:47447363	PSMC3	-0.56	-10.99	-0.45	3.98e-25	Subjective well-being;
LGG	cis	rs28386778	0.830	rs7209321	chr17:61855668	A/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	30.66	0.82	1.53e-113	Prudent dietary pattern;
LGG	cis	rs523522	0.962	rs3742052	chr12:120966921	A/G	cg27279351	chr12:120934652	DYNLL1	0.8	12.92	0.51	7.76e-33	High light scatter reticulocyte count;
LGG	cis	rs2692947	0.683	rs1813381	chr2:96422939	C/T	cg22654517	chr2:96458247	NA	-0.36	-7.0	-0.31	9.16e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00860640	chr1:145516730	PEX11B;GNRHR2	0.4	6.69	0.3	6.39e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28735056	0.967	rs11660941	chr18:77630600	G/C	cg20368463	chr18:77673604	PQLC1	-0.49	-8.85	-0.38	1.81e-17	Schizophrenia;
LGG	cis	rs7927771	0.864	rs10838724	chr11:47527052	G/T	cg20307385	chr11:47447363	PSMC3	-0.44	-7.63	-0.33	1.34e-13	Subjective well-being;
LGG	cis	rs2916247	1.000	rs34711026	chr8:93029914	T/C	cg10183463	chr8:93005414	RUNX1T1	-0.4	-8.24	-0.36	1.78e-15	Intelligence (multi-trait analysis);
LGG	cis	rs7618915	0.547	rs8906	chr3:52739520	T/C	cg14092988	chr3:52407081	DNAH1	0.31	8.13	0.35	3.85e-15	Bipolar disorder;
LGG	cis	rs79976124	0.879	rs17511467	chr6:66627293	T/C	cg07460842	chr6:66804631	NA	0.74	12.73	0.51	5.04e-32	Type 2 diabetes;
LGG	cis	rs1799949	0.929	rs799906	chr17:41278116	T/C	cg23758822	chr17:41437982	NA	0.84	15.05	0.57	5.67e-42	Menopause (age at onset);
LGG	cis	rs4566357	0.615	rs12328878	chr2:227918962	G/A	cg11843606	chr2:227700838	RHBDD1	-0.5	-9.02	-0.39	4.93e-18	Coronary artery disease;
LGG	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg17294928	chr15:75287854	SCAMP5	-0.92	-16.82	-0.62	6.78e-50	Blood trace element (Zn levels);
LGG	cis	rs7326068	0.610	rs2013546	chr13:21386229	G/A	cg04906043	chr13:21280425	IL17D	-0.51	-8.01	-0.35	9.44e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs1401999	1.000	rs869417	chr3:183689138	T/C	cg01324343	chr3:183735012	ABCC5	0.85	18.13	0.64	6.85e-56	Anterior chamber depth;
LGG	cis	rs1552244	0.572	rs58862481	chr3:10164308	G/A	cg16606324	chr3:10149918	C3orf24	0.63	7.08	0.31	5.41e-12	Alzheimer's disease;
LGG	cis	rs10256972	0.758	rs7799391	chr7:1082566	C/G	cg11360546	chr7:1094263	C7orf50	-0.41	-7.39	-0.32	6.87e-13	Longevity;Endometriosis;
LGG	cis	rs7811142	0.830	rs118119933	chr7:99939050	C/T	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.24	18.67	0.66	2.16e-58	Platelet count;
LGG	cis	rs727563	0.552	rs4822045	chr22:41985958	C/A	cg03806693	chr22:41940476	POLR3H	-1.07	-17.93	-0.64	5.52e-55	Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs4727027	0.727	rs1568944	chr7:148873497	A/T	cg12479418	chr7:148823350	ZNF425;ZNF398	0.59	8.45	0.37	3.72e-16	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9309473	0.607	rs6546826	chr2:73599808	A/G	cg20560298	chr2:73613845	ALMS1	0.47	8.66	0.37	8.07e-17	Metabolite levels;
LGG	cis	rs1018836	0.923	rs7013893	chr8:91563137	G/A	cg16814680	chr8:91681699	NA	-0.8	-14.75	-0.57	1.28e-40	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs9463078	0.605	rs3799981	chr6:44882380	T/A	cg25276700	chr6:44698697	NA	0.34	6.99	0.31	9.47e-12	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs9309473	0.948	rs7607892	chr2:73818707	C/T	cg20560298	chr2:73613845	ALMS1	-0.47	-7.73	-0.34	6.81e-14	Metabolite levels;
LGG	cis	rs477895	0.838	rs1058735	chr11:64000410	C/G	cg04317338	chr11:64019027	PLCB3	0.66	8.17	0.35	2.96e-15	Mean platelet volume;
LGG	cis	rs12220238	1.000	rs11000941	chr10:76018301	A/G	cg19889307	chr10:75911429	ADK;AP3M1	0.8	10.88	0.45	1.05e-24	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs72781680	0.898	rs72796166	chr2:23939311	G/C	cg08917208	chr2:24149416	ATAD2B	0.86	9.24	0.39	8.88e-19	Lymphocyte counts;
LGG	trans	rs11039798	0.764	rs12418936	chr11:48986418	T/C	cg15704280	chr7:45808275	SEPT13	0.77	8.01	0.35	9.69e-15	Axial length;
LGG	cis	rs7191439	0.858	rs11076701	chr16:88774525	A/G	cg27087555	chr16:88793112	FAM38A	-1.41	-18.37	-0.65	4.96e-57	Plateletcrit;
LGG	cis	rs78487399	0.808	rs116451849	chr2:43662911	A/C	cg06169590	chr2:43455088	ZFP36L2;LOC100129726	-0.62	-6.69	-0.3	6.26e-11	Myeloid white cell count;Granulocyte count;Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Inflammatory bowel disease;
LGG	cis	rs3780486	0.846	rs73484568	chr9:33132492	G/A	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.75	-0.57	1.27e-40	IgG glycosylation;
LGG	cis	rs9397585	0.824	rs2295230	chr6:153365100	A/C	cg17707550	chr6:153380415	RGS17	0.62	14.39	0.56	4.49e-39	Body mass index;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01586524	chr8:67341819	RRS1	0.46	7.08	0.31	5.31e-12	Gut microbiome composition (summer);
LGG	cis	rs3820068	0.608	rs12092485	chr1:16048038	A/G	cg05660106	chr1:15850417	CASP9	0.78	13.53	0.53	2.21e-35	Systolic blood pressure;
LGG	cis	rs2739330	0.828	rs4820572	chr22:24250355	T/C	cg12419862	chr22:24373484	LOC391322	-0.88	-17.77	-0.64	3.17e-54	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9473924	0.542	rs9473925	chr6:50834565	T/C	cg14470998	chr6:50812995	TFAP2B	0.68	8.23	0.36	1.91e-15	Body mass index;
LGG	cis	rs11122272	0.735	rs2808580	chr1:231509259	A/G	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	-0.62	-11.19	-0.46	6.89e-26	Hemoglobin concentration;
LGG	cis	rs2204008	0.775	rs12369238	chr12:38176051	A/G	cg13010199	chr12:38710504	ALG10B	0.66	13.47	0.53	3.88e-35	Bladder cancer;
LGG	cis	rs2762353	0.935	rs1165213	chr6:25799676	A/G	cg12310025	chr6:25882481	NA	0.52	10.02	0.42	1.64e-21	Blood metabolite levels;
LGG	cis	rs796364	0.806	rs74724807	chr2:201005109	A/C	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.73	-8.67	-0.37	7.24e-17	Schizophrenia;
LGG	cis	rs12780845	0.540	rs10904896	chr10:17225826	G/A	cg01003015	chr10:17271136	VIM	-0.44	-7.56	-0.33	2.18e-13	Homocysteine levels;
LGG	cis	rs6952808	0.531	rs3800922	chr7:2184505	A/G	cg05863683	chr7:1912471	MAD1L1	0.43	8.3	0.36	1.14e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs10504229	1.000	rs76023408	chr8:58193345	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-13.53	-0.53	2.31e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs5750830	0.649	rs7949	chr22:39827553	G/A	cg11247378	chr22:39784982	NA	-0.31	-8.98	-0.39	6.75e-18	Intelligence (multi-trait analysis);
LGG	cis	rs7089973	0.604	rs11196939	chr10:116593175	A/G	cg03647239	chr10:116582469	FAM160B1	-0.42	-7.04	-0.31	6.82e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs4808199	0.895	rs10419672	chr19:19471241	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.37	7.24	0.32	1.92e-12	Nonalcoholic fatty liver disease;
LGG	cis	rs4974559	0.690	rs28641665	chr4:1288781	G/T	cg02980000	chr4:1222292	CTBP1	0.82	9.37	0.4	3.22e-19	Systolic blood pressure;
LGG	cis	rs951366	1.000	rs951366	chr1:205685352	C/T	cg14159672	chr1:205819179	PM20D1	0.48	9.07	0.39	3.52e-18	Menarche (age at onset);
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg22950153	chr15:65625378	IGDCC3	0.39	7.06	0.31	6.15e-12	Menarche (age at onset);
LGG	cis	rs9443645	0.901	rs9352669	chr6:79584141	T/G	cg18132916	chr6:79620363	NA	-0.31	-8.65	-0.37	8.52e-17	Intelligence (multi-trait analysis);
LGG	cis	rs589448	0.902	rs315124	chr12:69771727	G/A	cg14784868	chr12:69753453	YEATS4	1.0	23.89	0.74	8.97e-83	Cerebrospinal fluid biomarker levels;
LGG	cis	rs9300255	0.596	rs4460848	chr12:123677810	A/G	cg00376283	chr12:123451042	ABCB9	0.66	11.41	0.47	9.78e-27	Neutrophil percentage of white cells;
LGG	trans	rs6601327	0.665	rs10113155	chr8:9655358	T/C	cg16141378	chr3:129829833	LOC729375	0.35	7.92	0.35	1.78e-14	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1865760	0.713	rs6928951	chr6:25995554	C/T	cg18357526	chr6:26021779	HIST1H4A	0.48	8.0	0.35	9.96e-15	Height;
LGG	cis	rs815815	0.583	rs878665	chr2:47403129	G/T	cg27223769	chr2:47403360	CALM2	-0.5	-7.58	-0.33	1.93e-13	Dialysis-related mortality;
LGG	cis	rs9322193	0.962	rs4869966	chr6:150084850	A/G	cg05861140	chr6:150128134	PCMT1	-0.43	-9.8	-0.41	9.57e-21	Lung cancer;
LGG	cis	rs9486715	0.838	rs9320127	chr6:96865358	G/A	cg18709589	chr6:96969512	KIAA0776	0.41	8.04	0.35	7.56e-15	Headache;
LGG	cis	rs28595532	0.920	rs55806110	chr4:119742583	A/G	cg21605333	chr4:119757512	SEC24D	1.5	15.11	0.57	3.13e-42	Cannabis dependence symptom count;
LGG	cis	rs7551222	0.749	rs6594019	chr1:204568610	T/C	cg20240347	chr1:204465584	NA	-0.46	-8.96	-0.38	8.29e-18	Schizophrenia;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg11878867	chr6:150167359	LRP11	-0.51	-10.43	-0.44	5.19e-23	Lung cancer;
LGG	trans	rs9929218	0.551	rs2296408	chr16:68713823	A/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-1.13	-31.44	-0.83	6.03e-117	Colorectal cancer;
LGG	cis	rs1552244	1.000	rs6442146	chr3:10073544	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.15	20.55	0.69	3.53e-67	Alzheimer's disease;
LGG	trans	rs9354308	0.933	rs2022856	chr6:66568235	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.01	0.42	1.71e-21	Metabolite levels;
LGG	cis	rs4740619	0.716	rs10810505	chr9:15955155	C/T	cg14451791	chr9:16040625	NA	-0.4	-10.12	-0.43	7e-22	Body mass index;
LGG	cis	rs2916247	0.954	rs72671436	chr8:93077986	T/A	cg10183463	chr8:93005414	RUNX1T1	-0.38	-7.73	-0.34	6.65e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1983891	0.673	rs912883	chr6:41552040	T/C	cg20194872	chr6:41519635	FOXP4	0.53	9.07	0.39	3.53e-18	Prostate cancer;
LGG	cis	rs2404602	0.692	rs12902452	chr15:76921465	T/C	cg05677249	chr15:77158041	SCAPER	-0.32	-6.71	-0.3	5.56e-11	Blood metabolite levels;
LGG	trans	rs34421088	0.560	rs2248699	chr8:11393764	A/G	cg02002194	chr4:3960332	NA	0.53	10.67	0.44	6.32e-24	Neuroticism;
LGG	trans	rs2243480	1.000	rs431318	chr7:65511597	G/A	cg10756647	chr7:56101905	PSPH	0.83	9.55	0.41	7.27e-20	Diabetic kidney disease;
LGG	cis	rs8064024	0.650	rs12926178	chr16:4905915	C/T	cg04440724	chr16:4920505	UBN1	0.56	12.51	0.5	3.8e-31	Cancer;
LGG	cis	rs4774899	0.966	rs12901671	chr15:57514268	A/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.1	-0.31	4.71e-12	Urinary tract infection frequency;
LGG	cis	rs1348850	0.634	rs1534304	chr2:178489264	C/T	cg22681709	chr2:178499509	PDE11A	-0.44	-6.81	-0.3	2.97e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs801193	1.000	rs4279493	chr7:66226620	C/T	cg18876405	chr7:65276391	NA	0.6	11.06	0.46	2.25e-25	Aortic root size;
LGG	trans	rs9354308	0.899	rs1938059	chr6:66539291	G/A	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.07	0.42	1.07e-21	Metabolite levels;
LGG	cis	rs709400	1.000	rs7150141	chr14:104129352	G/A	cg26031613	chr14:104095156	KLC1	1.14	27.59	0.79	8.66e-100	Body mass index;
LGG	cis	rs7294478	0.648	rs2290237	chr12:7277236	T/A	cg01074767	chr12:7262137	C1RL;LOC283314	-0.42	-10.89	-0.45	9.97e-25	Neuritic plaque;
LGG	cis	rs12188164	0.515	rs11744936	chr5:412112	C/T	cg26076054	chr5:421317	AHRR	-0.43	-6.99	-0.31	9.95e-12	Cystic fibrosis severity;
LGG	trans	rs853679	0.546	rs35819751	chr6:27810569	A/G	cg06606381	chr12:133084897	FBRSL1	-1.3	-11.84	-0.48	1.89e-28	Depression;
LGG	cis	rs990171	1.000	rs11123931	chr2:103085660	A/G	cg05295703	chr2:102895712	NA	-0.51	-8.99	-0.39	6.2e-18	Lymphocyte counts;
LGG	cis	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg15148918	chr7:75625777	STYXL1	-0.7	-7.96	-0.35	1.34e-14	Mononucleosis;
LGG	cis	rs9906944	0.564	rs9674544	chr17:47084711	G/A	cg10950924	chr17:47092072	IGF2BP1	-0.47	-9.08	-0.39	3.12e-18	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs1552244	0.572	rs3843008	chr3:10173742	C/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.85	-10.65	-0.44	7.46e-24	Alzheimer's disease;
LGG	cis	rs9358372	0.711	rs7763704	chr6:20881404	A/T	cg13405222	chr6:20811065	CDKAL1	-0.59	-12.43	-0.5	8.42e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs6951245	0.706	rs28522260	chr7:1183964	C/A	cg21664854	chr7:1097933	C7orf50;GPR146	0.78	11.3	0.46	2.65e-26	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs13191362	1.000	rs66534429	chr6:163003322	A/G	cg21926612	chr6:163149169	PACRG;PARK2	0.88	10.25	0.43	2.3e-22	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	trans	rs11039798	0.588	rs584899	chr11:48431408	T/C	cg15704280	chr7:45808275	SEPT13	-0.7	-9.75	-0.41	1.44e-20	Axial length;
LGG	cis	rs6500395	0.962	rs9927888	chr16:48557764	A/T	cg16662043	chr16:48846231	NA	0.35	6.79	0.3	3.36e-11	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs701145	0.585	rs1727945	chr3:153882865	G/A	cg17054900	chr3:154042577	DHX36	0.82	9.77	0.41	1.28e-20	Coronary artery disease;
LGG	trans	rs7395662	0.517	rs11039885	chr11:48647107	A/G	cg00717180	chr2:96193071	NA	-0.49	-9.24	-0.39	9.13e-19	HDL cholesterol;
LGG	cis	rs1008375	0.932	rs3846356	chr4:17614176	C/T	cg04450456	chr4:17643702	FAM184B	0.32	6.81	0.3	3.09e-11	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs6977660	1.000	rs6977660	chr7:19805480	C/T	cg07541023	chr7:19748670	TWISTNB	0.47	7.33	0.32	1.07e-12	Thyroid stimulating hormone;
LGG	cis	rs9467773	0.626	rs6936006	chr6:26350565	A/G	cg09904177	chr6:26538194	HMGN4	-0.46	-8.3	-0.36	1.17e-15	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.546	rs739129	chr22:42118249	G/A	cg06634786	chr22:41940651	POLR3H	0.76	12.14	0.49	1.25e-29	Vitiligo;
LGG	cis	rs826838	0.935	rs11183940	chr12:38851642	A/G	cg26384229	chr12:38710491	ALG10B	1.06	28.12	0.79	3.3e-102	Heart rate;
LGG	cis	rs28386778	0.734	rs12946669	chr17:62006007	A/G	cg07362569	chr17:61921086	SMARCD2	0.41	7.69	0.34	8.73e-14	Prudent dietary pattern;
LGG	cis	rs7552404	0.807	rs2066183	chr1:76153745	A/G	cg03433033	chr1:76189801	ACADM	0.81	14.93	0.57	2.02e-41	Blood metabolite levels;Acylcarnitine levels;
LGG	trans	rs10792665	0.541	rs7106519	chr11:82628030	A/G	cg16536329	chr5:178368185	ZNF454	0.37	6.76	0.3	4.19e-11	Obesity-related traits;
LGG	trans	rs7615952	0.932	rs7629977	chr3:125649573	T/G	cg07211511	chr3:129823064	LOC729375	-1.33	-21.03	-0.7	1.99e-69	Blood pressure (smoking interaction);
LGG	cis	rs908922	0.676	rs4240884	chr1:152529792	C/T	cg03606772	chr1:152487856	CRCT1	-0.29	-6.86	-0.3	2.15e-11	Hair morphology;
LGG	cis	rs28386778	0.897	rs2584626	chr17:61903179	A/G	cg19143629	chr17:61920732	SMARCD2	0.42	7.27	0.32	1.5e-12	Prudent dietary pattern;
LGG	cis	rs11190604	1.000	rs7905961	chr10:102297391	G/C	cg07080220	chr10:102295463	HIF1AN	0.7	11.94	0.49	7.95e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs6121246	0.567	rs6060249	chr20:30190944	G/A	cg21427119	chr20:30132790	HM13	-0.57	-8.95	-0.38	8.59e-18	Mean corpuscular hemoglobin;
LGG	cis	rs79911532	0.515	rs80351761	chr7:75698945	G/A	cg15148918	chr7:75625777	STYXL1	-0.69	-7.95	-0.35	1.48e-14	Mononucleosis;
LGG	cis	rs12142240	0.698	rs56344958	chr1:46814518	G/A	cg14993813	chr1:46806288	NSUN4	-0.55	-8.99	-0.39	6.49e-18	Menopause (age at onset);
LGG	cis	rs3008870	1.000	rs11208976	chr1:67434411	A/G	cg08660285	chr1:67390436	MIER1;WDR78	-1.0	-23.87	-0.74	1.03e-82	Lymphocyte percentage of white cells;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.69	-0.34	9.16e-14	Height;
LGG	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg18404041	chr3:52824283	ITIH1	-0.49	-8.99	-0.39	6.18e-18	Electroencephalogram traits;
LGG	cis	rs9649465	0.967	rs7791183	chr7:123343719	A/G	cg03229431	chr7:123269106	ASB15	-0.4	-8.92	-0.38	1.13e-17	Migraine;
LGG	cis	rs155076	1.000	rs12870992	chr13:21846019	A/G	cg14456004	chr13:21872349	NA	1.15	17.9	0.64	7.34e-55	White matter hyperintensity burden;
LGG	cis	rs9549367	0.577	rs7335409	chr13:113810186	T/C	cg18105134	chr13:113819100	PROZ	0.7	12.13	0.49	1.35e-29	Platelet distribution width;
LGG	cis	rs6502050	0.835	rs8078950	chr17:80122327	T/G	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs9467773	0.620	rs2451711	chr6:26663110	A/G	cg09904177	chr6:26538194	HMGN4	0.67	13.82	0.54	1.23e-36	Intelligence (multi-trait analysis);
LGG	cis	rs12210905	0.920	rs72839469	chr6:27304539	G/A	cg15325629	chr6:28072465	NA	0.91	7.02	0.31	7.87e-12	Hip circumference adjusted for BMI;
LGG	cis	rs11252926	1.000	rs11252926	chr10:566379	C/T	cg08603382	chr10:743973	NA	-0.61	-11.65	-0.48	1.08e-27	Psychosis in Alzheimer's disease;
LGG	cis	rs7444	0.941	rs9619386	chr22:21979938	C/T	cg11654148	chr22:21984483	YDJC	-0.38	-7.28	-0.32	1.45e-12	Systemic lupus erythematosus;
LGG	cis	rs2032447	0.670	rs71557318	chr6:26118570	T/C	cg18357526	chr6:26021779	HIST1H4A	-0.76	-14.19	-0.55	3.26e-38	Intelligence (multi-trait analysis);
LGG	cis	rs17818399	0.548	rs1989720	chr2:46854364	C/T	cg26688816	chr2:46740690	ATP6V1E2	-0.45	-8.1	-0.35	4.75e-15	Height;
LGG	trans	rs12517041	1.000	rs995216	chr5:23285541	A/G	ch.8.1293020R	chr8:59333349	UBXN2B	-0.77	-10.98	-0.45	4.38e-25	Calcium levels;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg04369109	chr6:150039330	LATS1	0.42	7.0	0.31	9.27e-12	Lung cancer;
LGG	trans	rs3808502	0.527	rs2736389	chr8:11161310	C/A	cg02002194	chr4:3960332	NA	-0.46	-8.41	-0.36	5.17e-16	Neuroticism;
LGG	cis	rs1620921	0.505	rs13199812	chr6:161201960	T/C	cg01280913	chr6:161186852	NA	-0.5	-10.28	-0.43	1.8e-22	Lipoprotein (a) - cholesterol levels;
LGG	trans	rs804280	0.527	rs2686187	chr8:11654796	G/A	cg08975724	chr8:8085496	FLJ10661	0.36	6.65	0.3	8.19e-11	Myopia (pathological);
LGG	cis	rs3761847	0.593	rs1468673	chr9:123809890	C/T	cg09586646	chr9:123605570	PSMD5;LOC253039	0.45	8.2	0.36	2.32e-15	Rheumatoid arthritis;
LGG	cis	rs2067615	0.560	rs2044304	chr12:107184363	T/G	cg15890332	chr12:107067104	RFX4	0.4	11.86	0.48	1.59e-28	Heart rate;
LGG	cis	rs4727027	0.933	rs4727028	chr7:148874666	A/G	cg23583168	chr7:148888333	NA	0.86	16.77	0.61	1.14e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs9549367	0.826	rs35306827	chr13:113869045	G/A	cg18105134	chr13:113819100	PROZ	-0.71	-14.15	-0.55	5.13e-38	Platelet distribution width;
LGG	cis	rs870825	0.616	rs28579226	chr4:185650458	A/C	cg04058563	chr4:185651563	MLF1IP	1.03	22.82	0.73	8.54e-78	Blood protein levels;
LGG	cis	rs1801251	0.752	rs4144796	chr2:233562210	T/C	cg08000102	chr2:233561755	GIGYF2	0.55	9.29	0.4	6.17e-19	Coronary artery disease;
LGG	cis	rs10504229	0.683	rs72650849	chr8:58140323	A/G	cg08280861	chr8:58055591	NA	0.54	6.88	0.3	1.99e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs1568889	0.941	rs35357280	chr11:28322745	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.71	10.98	0.45	4.51e-25	Bipolar disorder;
LGG	cis	rs704795	0.836	rs1083865	chr2:27620827	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.25	-6.67	-0.3	7.25e-11	Menopause (age at onset);
LGG	cis	rs7927771	0.832	rs67116452	chr11:47385194	G/A	cg20307385	chr11:47447363	PSMC3	-0.56	-10.21	-0.43	3.29e-22	Subjective well-being;
LGG	cis	rs6459804	0.967	rs11762822	chr7:157507684	C/G	cg01625945	chr7:157512322	PTPRN2	-0.47	-10.77	-0.45	2.81e-24	Bipolar disorder and schizophrenia;
LGG	cis	rs2439831	0.850	rs558656	chr15:43723514	T/C	cg02155558	chr15:43621948	ADAL;LCMT2	0.86	10.66	0.44	6.96e-24	Lung cancer in ever smokers;
LGG	cis	rs10078	0.571	rs2561664	chr5:459793	T/C	cg08916839	chr5:415575	AHRR	0.99	14.15	0.55	4.9e-38	Fat distribution (HIV);
LGG	cis	rs2688608	0.618	rs28718766	chr10:75489844	C/A	cg23231163	chr10:75533350	FUT11	-0.43	-7.19	-0.32	2.6e-12	Inflammatory bowel disease;
LGG	cis	rs7100689	0.646	rs10788586	chr10:82117435	A/G	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	trans	rs7395662	0.963	rs4882094	chr11:48532460	T/C	cg15704280	chr7:45808275	SEPT13	-0.49	-8.01	-0.35	9.69e-15	HDL cholesterol;
LGG	cis	rs17376456	0.877	rs10070390	chr5:93452345	G/A	cg21475434	chr5:93447410	FAM172A	0.69	7.12	0.31	4.26e-12	Diabetic retinopathy;
LGG	trans	rs1908814	0.516	rs35391955	chr8:11796728	A/C	cg06636001	chr8:8085503	FLJ10661	0.5	9.08	0.39	3.19e-18	Neuroticism;
LGG	cis	rs929354	0.772	rs1182448	chr7:157021415	G/A	cg00092383	chr7:157075207	NA	0.39	6.74	0.3	4.6e-11	Body mass index;
LGG	cis	rs2131877	0.830	rs59910866	chr3:194876243	C/T	cg07250128	chr3:194833983	C3orf21	0.41	6.87	0.3	2.13e-11	Non-small cell lung cancer;
LGG	cis	rs9916302	0.904	rs13341996	chr17:37536862	C/T	cg00129232	chr17:37814104	STARD3	0.6	11.4	0.47	1.05e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs9296092	0.538	rs62405948	chr6:33522753	A/C	cg13560919	chr6:33536144	NA	-1.04	-21.81	-0.71	4.45e-73	Age at smoking initiation in chronic obstructive pulmonary disease;
LGG	cis	rs10504229	1.000	rs79311869	chr8:58195546	T/C	cg14926445	chr8:58193284	C8orf71	-0.91	-12.26	-0.5	3.9e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs17125944	0.615	rs6572867	chr14:53319283	C/T	cg00686598	chr14:53173677	PSMC6	-0.71	-7.31	-0.32	1.16e-12	Alzheimer's disease (late onset);
LGG	cis	rs6685188	0.925	rs12752037	chr1:205661614	A/C	cg07157834	chr1:205819609	PM20D1	-0.43	-7.37	-0.32	7.99e-13	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs2739330	0.752	rs2330634	chr22:24250795	C/G	cg12419862	chr22:24373484	LOC391322	-0.85	-16.85	-0.62	4.87e-50	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6952808	0.600	rs2895202	chr7:2131829	T/C	cg14004847	chr7:1930337	MAD1L1	-0.51	-8.56	-0.37	1.62e-16	Bipolar disorder and schizophrenia;
LGG	cis	rs4950322	0.570	rs72691004	chr1:146705955	G/A	cg22381352	chr1:146742008	CHD1L	-0.46	-7.65	-0.34	1.17e-13	Protein quantitative trait loci;
LGG	cis	rs4771450	0.962	rs4415889	chr13:103970701	G/A	cg02987523	chr13:103978230	NA	-0.32	-6.85	-0.3	2.33e-11	Uric acid levels;
LGG	cis	rs7552404	0.731	rs10873808	chr1:76406767	T/C	cg03433033	chr1:76189801	ACADM	0.66	9.5	0.4	1.13e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs4443100	0.792	rs9612223	chr22:23389142	T/G	cg14186256	chr22:23484241	RTDR1	0.43	6.9	0.31	1.76e-11	Serum parathyroid hormone levels;
LGG	cis	rs7208859	0.623	rs73269923	chr17:29102571	C/T	cg08994789	chr17:28903642	LRRC37B2	-0.69	-8.22	-0.36	2e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs330048	0.561	rs4840401	chr8:9148125	A/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.65	-0.33	1.17e-13	Systemic lupus erythematosus;
LGG	cis	rs2953174	0.786	rs8662	chr2:241517770	G/A	cg07929629	chr2:241523174	NA	0.56	7.78	0.34	4.84e-14	Bipolar disorder;
LGG	cis	rs8067545	0.611	rs1992561	chr17:20219119	G/A	cg09818912	chr17:20140352	CYTSB	0.32	7.37	0.32	7.73e-13	Schizophrenia;
LGG	cis	rs9398803	0.723	rs1262546	chr6:127075491	T/C	cg19875578	chr6:126661172	C6orf173	-0.51	-9.29	-0.4	6e-19	Male-pattern baldness;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg18876405	chr7:65276391	NA	0.54	9.66	0.41	3.18e-20	Aortic root size;
LGG	cis	rs1348850	0.632	rs13008857	chr2:178514468	G/A	cg22681709	chr2:178499509	PDE11A	-0.52	-9.53	-0.4	8.88e-20	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs7209395	1.000	rs16958921	chr17:64172189	A/G	cg19474267	chr17:64306194	PRKCA	-0.52	-8.33	-0.36	9.21e-16	&beta2-Glycoprotein I (β2-GPI) plasma levels;Weight;
LGG	cis	rs2635047	0.615	rs2684819	chr18:44710691	C/T	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.88	0.3	1.96e-11	Educational attainment;
LGG	cis	rs9462846	0.691	rs67059212	chr6:42913269	T/G	cg13397359	chr6:42928475	GNMT	0.43	9.54	0.41	8.48e-20	Blood protein levels;
LGG	cis	rs79149102	0.579	rs7173218	chr15:75315328	A/G	cg09165964	chr15:75287851	SCAMP5	-0.76	-8.6	-0.37	1.26e-16	Lung cancer;
LGG	cis	rs1873147	0.731	rs12902152	chr15:63313968	T/C	cg12160578	chr15:63334699	TPM1	-0.45	-7.2	-0.32	2.41e-12	Orofacial clefts;
LGG	cis	rs523522	1.000	rs523522	chr12:121020250	A/T	cg12219531	chr12:120966889	COQ5	0.66	11.02	0.46	3e-25	High light scatter reticulocyte count;
LGG	cis	rs876084	0.722	rs1401812	chr8:121042631	G/A	cg22335954	chr8:121166405	COL14A1	-0.32	-6.83	-0.3	2.74e-11	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7717393	1.000	rs10079754	chr5:155747951	G/C	cg01474424	chr5:155754231	SGCD	0.76	7.12	0.31	4.07e-12	Egg allergy;
LGG	cis	rs2777491	0.522	rs7173571	chr15:41712807	T/C	cg18705301	chr15:41695430	NDUFAF1	-0.52	-8.88	-0.38	1.49e-17	Ulcerative colitis;
LGG	cis	rs745080	0.519	rs67576130	chr14:52959294	C/T	cg23333723	chr14:53022898	GPR137C	-0.4	-7.92	-0.35	1.82e-14	Orofacial clefts;
LGG	cis	rs951366	0.553	rs10900522	chr1:205684067	T/C	cg11965913	chr1:205819406	PM20D1	-0.41	-6.66	-0.3	7.93e-11	Menarche (age at onset);
LGG	cis	rs2298450	0.717	rs62232370	chr21:37630225	G/A	cg02919814	chr21:37666008	DOPEY2	-0.43	-7.88	-0.34	2.39e-14	Schizophrenia;
LGG	cis	rs6952808	0.743	rs4721097	chr7:1877503	G/T	cg20295408	chr7:1910781	MAD1L1	-0.42	-6.89	-0.3	1.87e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs2282300	0.739	rs1933342	chr11:30312825	C/T	cg25418670	chr11:30344373	C11orf46	0.57	7.86	0.34	2.7e-14	Morning vs. evening chronotype;
LGG	cis	rs2251381	0.750	rs2251087	chr21:30527999	C/T	cg24692254	chr21:30365293	RNF160	0.83	17.33	0.63	3.07e-52	Selective IgA deficiency;
LGG	cis	rs10504229	0.906	rs2270608	chr8:58194688	T/C	cg08677398	chr8:58056175	NA	0.45	7.11	0.31	4.51e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs41271473	0.948	rs12144495	chr1:228810937	G/T	cg10167378	chr1:228756711	NA	-0.55	-7.63	-0.33	1.37e-13	Chronic lymphocytic leukemia;
LGG	cis	rs11671005	0.735	rs3826681	chr19:58918764	A/G	cg11952622	chr19:58962976	ZNF324B	-0.44	-6.77	-0.3	3.88e-11	Mean platelet volume;
LGG	cis	rs56011263	0.687	rs4690187	chr4:703813	C/T	cg20735989	chr4:730612	PCGF3	-0.61	-10.63	-0.44	9.12e-24	White blood cell count;
LGG	cis	rs8180040	0.726	rs1869869	chr3:47027833	G/A	cg16586182	chr3:47516702	SCAP	-0.78	-14.48	-0.56	1.84e-39	Colorectal cancer;
LGG	cis	rs10504229	0.775	rs55764517	chr8:58158238	G/A	cg14926445	chr8:58193284	C8orf71	-0.88	-11.56	-0.47	2.47e-27	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.818	rs1589389	chr12:38416041	G/A	cg26384229	chr12:38710491	ALG10B	-0.86	-19.82	-0.68	9.78e-64	Bladder cancer;
LGG	trans	rs7829975	0.714	rs12544992	chr8:8661681	C/G	cg02002194	chr4:3960332	NA	-0.42	-8.01	-0.35	9.11e-15	Mood instability;
LGG	cis	rs7503807	0.515	rs869190	chr17:78668593	G/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.32	-0.4	4.93e-19	Obesity;
LGG	cis	rs2841277	0.708	rs11851053	chr14:105407208	T/C	cg20978937	chr14:105399321	PLD4	0.49	11.16	0.46	8.67e-26	Rheumatoid arthritis;
LGG	cis	rs6500602	0.627	rs6500610	chr16:4529613	A/G	cg08645402	chr16:4508243	NA	0.49	8.88	0.38	1.45e-17	Schizophrenia;
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9487094	0.689	rs1074766	chr6:109681466	A/G	cg01125227	chr6:109776195	MICAL1	0.38	6.68	0.3	6.77e-11	Height;
LGG	cis	rs951366	0.764	rs708725	chr1:205744138	G/T	cg07167872	chr1:205819463	PM20D1	0.57	11.49	0.47	4.76e-27	Menarche (age at onset);
LGG	cis	rs6500602	0.702	rs2058812	chr16:4524443	C/G	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	7.99	0.35	1.07e-14	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19543068	chr14:92573078	ATXN3	0.46	7.0	0.31	8.92e-12	Gut microbiome composition (summer);
LGG	cis	rs7572733	0.901	rs6734096	chr2:198756459	T/G	cg00792783	chr2:198669748	PLCL1	0.49	8.49	0.37	2.86e-16	Dermatomyositis;
LGG	cis	rs1348850	0.526	rs935426	chr2:178369433	T/C	cg22681709	chr2:178499509	PDE11A	-0.52	-7.74	-0.34	6.11e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs2072499	0.750	rs55910626	chr1:156159909	C/G	cg24450063	chr1:156163899	SLC25A44	1.08	18.76	0.66	8.03e-59	Testicular germ cell tumor;
LGG	cis	rs9399137	0.507	rs7745289	chr6:135380327	A/G	cg24558204	chr6:135376177	HBS1L	0.62	10.79	0.45	2.39e-24	Glycated hemoglobin levels;Mean corpuscular volume;Hematology traits;HbA2 levels;Mean corpuscular hemoglobin;Hemoglobin levels;F-cell distribution;Platelet count;
LGG	cis	rs2439831	0.850	rs2957637	chr15:43951118	C/A	cg02155558	chr15:43621948	ADAL;LCMT2	0.93	10.74	0.45	3.65e-24	Lung cancer in ever smokers;
LGG	cis	rs17428076	0.874	rs17581347	chr2:172682601	T/C	cg21435375	chr2:172878103	MAP1D	0.41	8.85	0.38	1.9e-17	Myopia;
LGG	cis	rs6430585	0.528	rs16832440	chr2:136754183	G/A	cg07169764	chr2:136633963	MCM6	1.24	22.79	0.73	1.19e-77	Corneal structure;
LGG	cis	rs17666538	1.000	rs59631161	chr8:587808	G/T	cg07685180	chr8:600429	NA	-1.19	-10.28	-0.43	1.89e-22	IgG glycosylation;
LGG	cis	rs2692947	0.727	rs1657502	chr2:96795608	A/C	cg22654517	chr2:96458247	NA	0.37	8.12	0.35	4.31e-15	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs2470578	0.740	rs2596655	chr3:17232635	G/A	cg20981856	chr3:17787350	NA	0.36	6.7	0.3	5.92e-11	Schizophrenia;
LGG	cis	rs516946	0.950	rs508419	chr8:41522991	A/G	cg12439423	chr8:41522721	ANK1	-0.46	-8.58	-0.37	1.39e-16	Type 2 diabetes;
LGG	cis	rs7811142	1.000	rs11763511	chr7:100081944	G/A	cg00814883	chr7:100076585	TSC22D4	-0.71	-10.42	-0.44	5.69e-23	Platelet count;
LGG	cis	rs2404602	0.647	rs11637096	chr15:76931102	T/C	cg23625390	chr15:77176239	SCAPER	-0.68	-13.07	-0.52	1.81e-33	Blood metabolite levels;
LGG	cis	rs9291683	0.566	rs13115776	chr4:10040189	C/G	cg11266682	chr4:10021025	SLC2A9	0.51	9.91	0.42	4.17e-21	Bone mineral density;
LGG	cis	rs2032447	0.966	rs7756117	chr6:26046565	A/G	cg12310025	chr6:25882481	NA	0.53	9.93	0.42	3.39e-21	Intelligence (multi-trait analysis);
LGG	trans	rs6598955	0.671	rs12086573	chr1:26574330	G/A	cg07461501	chr17:79650226	HGS;ARL16	-0.77	-12.9	-0.51	9.53e-33	Obesity-related traits;
LGG	cis	rs4774830	0.744	rs12438427	chr15:56295062	A/T	cg24530489	chr15:56299380	NA	0.84	8.06	0.35	6.6e-15	Delta-5 desaturase activity;
LGG	cis	rs1153858	1.000	rs7179743	chr15:45638331	G/C	cg10760299	chr15:45669010	GATM	0.4	8.02	0.35	8.96e-15	Homoarginine levels;
LGG	cis	rs9322193	0.923	rs12175504	chr6:149985215	T/G	cg13206674	chr6:150067644	NUP43	0.67	15.62	0.59	1.72e-44	Lung cancer;
LGG	cis	rs9303401	1.000	rs7218362	chr17:56888299	A/G	cg02118635	chr17:56770003	RAD51C;TEX14	0.63	10.57	0.44	1.56e-23	Cognitive test performance;
LGG	cis	rs4664308	1.000	rs17831251	chr2:160914156	C/T	cg03641300	chr2:160917029	PLA2R1	-0.86	-17.99	-0.64	3.06e-55	Idiopathic membranous nephropathy;
LGG	cis	rs2749592	0.611	rs176888	chr10:38406161	C/A	cg25427524	chr10:38739819	LOC399744	-0.7	-13.94	-0.54	3.92e-37	Age-related hearing impairment (SNP x SNP interaction);
LGG	cis	rs796364	0.951	rs7586320	chr2:201068209	C/G	cg17644776	chr2:200775616	C2orf69	0.61	8.48	0.37	3.1e-16	Schizophrenia;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg00166722	chr3:10149974	C3orf24	0.57	8.14	0.35	3.68e-15	Alzheimer's disease;
LGG	cis	rs1552244	0.935	rs28815328	chr3:10062227	G/A	cg00149659	chr3:10157352	C3orf10	0.84	10.75	0.45	3.25e-24	Alzheimer's disease;
LGG	cis	rs283228	1.000	rs439291	chr6:101739478	A/G	cg27451362	chr6:101846650	GRIK2	0.53	8.82	0.38	2.26e-17	Coenzyme Q10 levels;
LGG	cis	rs1552244	0.935	rs6805869	chr3:10119917	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.87	-13.83	-0.54	1.19e-36	Alzheimer's disease;
LGG	cis	rs1008375	1.000	rs2872959	chr4:17677163	G/A	cg16339924	chr4:17578868	LAP3	-0.62	-10.96	-0.45	5.18e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs3942852	0.774	rs2270990	chr11:48184983	G/T	cg03929089	chr4:120376271	NA	-0.68	-9.95	-0.42	2.82e-21	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs6772849	0.896	rs35535737	chr3:128383406	G/A	cg08795948	chr3:128337044	NA	0.66	11.14	0.46	1.08e-25	Monocyte percentage of white cells;Monocyte count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg27301331	chr6:20401917	E2F3	0.5	7.63	0.33	1.31e-13	Gut microbiome composition (summer);
LGG	cis	rs6462411	0.938	rs28491320	chr7:3914679	A/G	cg18022346	chr7:3920534	SDK1	-0.35	-6.82	-0.3	2.94e-11	Quantitative traits;
LGG	trans	rs6787172	0.651	rs9843089	chr3:158153792	T/A	cg23275840	chr4:47708675	CORIN	-0.35	-7.26	-0.32	1.66e-12	Subjective well-being;
LGG	cis	rs4356932	1.000	rs10010920	chr4:76982733	C/A	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.71	-0.3	5.62e-11	Blood protein levels;
LGG	cis	rs698833	1.000	rs698833	chr2:44735438	A/G	cg18685995	chr2:44588913	PREPL;C2orf34	0.48	7.14	0.31	3.61e-12	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs1008375	1.000	rs6811887	chr4:17640858	C/T	cg02297831	chr4:17616191	MED28	0.49	9.29	0.4	6.21e-19	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs1775715	0.769	rs2799030	chr10:32172935	G/T	cg14930904	chr10:32216787	ARHGAP12	0.35	6.77	0.3	3.83e-11	Bipolar disorder with mood-incongruent psychosis;
LGG	cis	rs883565	0.569	rs6599273	chr3:38998552	T/G	cg01426195	chr3:39028469	NA	-0.6	-12.64	-0.51	1.09e-31	Handedness;
LGG	cis	rs9527	0.615	rs10883781	chr10:104581130	A/G	cg04362960	chr10:104952993	NT5C2	0.53	9.39	0.4	2.64e-19	Arsenic metabolism;
LGG	cis	rs4262150	0.810	rs55648729	chr5:152008902	G/T	cg12297329	chr5:152029980	NA	-0.8	-15.46	-0.58	9.21e-44	Bipolar disorder and schizophrenia;
LGG	trans	rs11992162	0.573	rs61468577	chr8:11784925	A/C	cg02002194	chr4:3960332	NA	0.44	8.14	0.35	3.82e-15	Monocyte count;
LGG	cis	rs6952808	1.000	rs4601204	chr7:1890925	C/T	cg05863683	chr7:1912471	MAD1L1	0.42	7.77	0.34	5.25e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs13118159	0.550	rs28733902	chr4:1374789	A/G	cg20743744	chr4:1243849	C4orf42;CTBP1	0.42	7.04	0.31	7.1e-12	Longevity;
LGG	cis	rs952623	0.649	rs6952464	chr7:39076327	C/T	cg18850127	chr7:39170497	POU6F2	0.35	8.05	0.35	7.24e-15	Intelligence (multi-trait analysis);
LGG	trans	rs7944735	0.508	rs7931089	chr11:47633506	G/A	cg15704280	chr7:45808275	SEPT13	0.61	6.72	0.3	5.24e-11	Intraocular pressure;
LGG	cis	rs4730250	0.707	rs257378	chr7:106801395	C/G	cg02696742	chr7:106810147	HBP1	-0.83	-11.6	-0.47	1.66e-27	Osteoarthritis;
LGG	cis	rs7647973	0.516	rs4955419	chr3:49200692	T/A	cg06212747	chr3:49208901	KLHDC8B	0.72	12.67	0.51	8.62e-32	Menarche (age at onset);
LGG	cis	rs7824557	0.614	rs5029571	chr8:11213389	C/T	cg15596359	chr8:11213517	TDH	-0.41	-8.37	-0.36	6.74e-16	Retinal vascular caliber;
LGG	cis	rs9303280	0.743	rs2941522	chr17:37910368	C/T	cg00129232	chr17:37814104	STARD3	0.47	8.86	0.38	1.76e-17	Self-reported allergy;
LGG	trans	rs11722228	0.508	rs61335146	chr4:10130793	G/C	cg26043149	chr18:55253948	FECH	0.97	17.94	0.64	5.17e-55	Gout;Urate levels;Serum uric acid levels;
LGG	cis	rs9322193	0.926	rs9766562	chr6:150109845	C/G	cg07701084	chr6:150067640	NUP43	0.66	12.37	0.5	1.49e-30	Lung cancer;
LGG	cis	rs7523273	0.606	rs859706	chr1:207962270	G/A	cg22525895	chr1:207977042	MIR29B2	-0.62	-12.04	-0.49	3.03e-29	Schizophrenia;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14735242	chr2:64371651	PELI1	0.41	6.84	0.3	2.52e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs9916302	0.861	rs8079590	chr17:37426201	T/C	cg07936489	chr17:37558343	FBXL20	-0.85	-15.92	-0.59	7.69e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs7937682	0.921	rs1944119	chr11:111436387	A/G	cg09085632	chr11:111637200	PPP2R1B	1.02	20.0	0.68	1.31e-64	Primary sclerosing cholangitis;
LGG	cis	rs2153535	0.580	rs4960411	chr6:8438231	C/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.23	0.43	2.68e-22	Motion sickness;
LGG	cis	rs11628318	0.614	rs72635192	chr14:103128646	C/T	cg12046867	chr14:103022105	NA	0.74	12.53	0.5	3.15e-31	Platelet count;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg07701084	chr6:150067640	NUP43	0.69	13.05	0.52	2.4e-33	Lung cancer;
LGG	cis	rs2070488	0.775	rs7647657	chr3:38573746	A/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.74	-14.24	-0.55	1.98e-38	Electrocardiographic conduction measures;
LGG	cis	rs2576037	0.526	rs7240239	chr18:44460037	T/C	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.19	-0.46	6.82e-26	Personality dimensions;
LGG	cis	rs9611565	0.765	rs202659	chr22:41811620	T/C	cg03806693	chr22:41940476	POLR3H	0.95	16.65	0.61	4.1e-49	Vitiligo;
LGG	cis	rs10504229	0.679	rs17801003	chr8:58050930	A/G	cg20607798	chr8:58055168	NA	0.7	8.02	0.35	8.54e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.728	rs59266065	chr8:58156236	A/G	cg22535103	chr8:58192502	C8orf71	-0.94	-13.17	-0.52	7.53e-34	Developmental language disorder (linguistic errors);
LGG	cis	rs2046867	0.818	rs17010184	chr3:72870242	A/T	cg26655873	chr3:72818019	SHQ1	-0.36	-7.03	-0.31	7.28e-12	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs1577917	1.000	rs12204015	chr6:86598334	C/A	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.67	-11.88	-0.48	1.41e-28	Response to antipsychotic treatment;
LGG	cis	rs2228479	0.702	rs11076620	chr16:89831520	A/T	cg03036210	chr16:89904091	SPIRE2	-0.65	-8.0	-0.35	1.02e-14	Skin colour saturation;
LGG	cis	rs593982	0.920	rs645621	chr11:65490756	T/C	cg08755490	chr11:65554678	OVOL1	0.72	8.8	0.38	2.65e-17	Atopic dermatitis;
LGG	cis	rs9788682	0.747	rs11637630	chr15:78899719	G/A	cg24631222	chr15:78858424	CHRNA5	-0.41	-6.68	-0.3	6.91e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs12950390	0.530	rs16947058	chr17:45825186	A/G	cg00777063	chr17:45855553	NA	0.3	6.96	0.31	1.13e-11	IgG glycosylation;
LGG	cis	rs9322193	0.566	rs3922947	chr6:150245992	G/A	cg08621203	chr6:150244597	RAET1G	-0.47	-7.02	-0.31	7.97e-12	Lung cancer;
LGG	cis	rs9807989	0.507	rs6706002	chr2:103006104	A/G	cg03938978	chr2:103052716	IL18RAP	0.41	9.54	0.41	8.04e-20	Asthma;
LGG	cis	rs17767392	0.881	rs35971049	chr14:72012219	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.39	-8.62	-0.37	1.08e-16	Mitral valve prolapse;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.57	0.53	1.45e-35	Obesity-related traits;
LGG	cis	rs11190604	1.000	rs2495743	chr10:102329739	G/C	cg07080220	chr10:102295463	HIF1AN	0.72	12.17	0.49	9.06e-30	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs16973500	0.808	rs112452788	chr16:71911198	C/T	cg09427745	chr16:71932006	KIAA0174	-0.5	-7.37	-0.32	7.82e-13	Response to anti-TNF therapy in rheumatoid arthritis;Attention deficit hyperactivity disorder and conduct disorder;
LGG	cis	rs7851660	0.967	rs7049054	chr9:100599969	T/G	cg13688889	chr9:100608707	NA	-0.69	-14.56	-0.56	8.14e-40	Strep throat;
LGG	cis	rs35306767	0.761	rs12770173	chr10:1027108	A/C	cg25019033	chr10:957182	NA	-0.58	-10.57	-0.44	1.57e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg07142201	chr11:109293216	C11orf87	0.51	9.29	0.4	6.02e-19	Schizophrenia;
LGG	cis	rs11018874	0.709	rs11018854	chr11:89835191	A/G	cg14505434	chr11:89522851	NA	0.65	8.15	0.35	3.39e-15	White blood cell types;
LGG	cis	rs12893597	0.580	rs12586708	chr14:76840497	C/T	cg20290672	chr14:76816747	NA	0.41	6.83	0.3	2.74e-11	Maximal oxygen uptake response;
LGG	cis	rs876084	0.505	rs9969404	chr8:121107102	A/C	cg06265175	chr8:121136014	COL14A1	0.47	9.62	0.41	4.19e-20	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9878978	0.660	rs62245707	chr3:2438184	T/C	cg21928760	chr3:2462534	CNTN4	0.47	9.0	0.39	5.85e-18	Blood pressure (smoking interaction);
LGG	cis	rs10893109	0.517	rs1377603	chr11:123775742	G/A	cg12387464	chr11:123775935	OR8D4	0.39	8.4	0.36	5.5e-16	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);
LGG	cis	rs2739330	0.828	rs5751770	chr22:24252842	A/G	cg10150615	chr22:24372951	LOC391322	-0.41	-6.89	-0.31	1.79e-11	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6502050	0.835	rs67682841	chr17:80117745	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	cis	rs10504229	1.000	rs61998258	chr8:58192284	T/C	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	0.679	rs17193048	chr8:58055392	G/A	cg08219700	chr8:58056026	NA	0.47	7.02	0.31	7.89e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs4732038	0.510	rs10275567	chr7:134272598	C/T	cg06906464	chr7:134288099	NA	0.66	17.04	0.62	6.48e-51	Longevity;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg23024448	chr19:51222118	NA	0.56	7.08	0.31	5.44e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1355223	0.573	rs2084970	chr11:34723729	G/A	cg11058730	chr11:34937778	PDHX;APIP	-0.45	-7.13	-0.31	3.95e-12	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs2880765	0.835	rs28874135	chr15:86031503	G/A	cg13263323	chr15:86062960	AKAP13	-0.35	-7.29	-0.32	1.32e-12	Coronary artery disease;
LGG	cis	rs11190604	1.000	rs2295780	chr10:102305965	A/G	cg07080220	chr10:102295463	HIF1AN	0.71	11.87	0.48	1.48e-28	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs7927592	0.913	rs2282563	chr11:68333200	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.35	-0.36	7.85e-16	Total body bone mineral density;
LGG	cis	rs6942756	0.712	rs6467241	chr7:128997838	A/G	cg02491457	chr7:128862824	NA	-0.62	-11.3	-0.46	2.54e-26	White matter hyperintensity burden;
LGG	cis	rs13082711	0.911	rs17019809	chr3:27509080	A/G	cg02860705	chr3:27208620	NA	0.7	12.37	0.5	1.4e-30	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs1865760	0.613	rs9295674	chr6:25912342	A/G	cg17691542	chr6:26056736	HIST1H1C	0.47	8.44	0.37	4.21e-16	Height;
LGG	cis	rs8005677	0.962	rs34917191	chr14:23387628	T/C	cg01529538	chr14:23388837	RBM23	0.37	6.68	0.3	6.88e-11	Cognitive ability (multi-trait analysis);
LGG	cis	rs13392177	0.684	rs11695527	chr2:219068103	A/G	cg20019365	chr2:219134978	PNKD;AAMP	0.46	7.59	0.33	1.75e-13	Pyoderma gangrenosum in inflammatory bowel disease;
LGG	cis	rs10895140	0.709	rs10895160	chr11:101507746	C/G	cg23650423	chr11:101454676	TRPC6	-0.43	-6.98	-0.31	1.03e-11	Menarche (age at onset);
LGG	cis	rs7824557	0.603	rs2736278	chr8:11219781	C/T	cg21775007	chr8:11205619	TDH	0.85	15.14	0.58	2.32e-42	Retinal vascular caliber;
LGG	trans	rs2243480	1.000	rs6970243	chr7:65388490	C/A	cg10756647	chr7:56101905	PSPH	0.83	10.13	0.43	6.67e-22	Diabetic kidney disease;
LGG	cis	rs7511006	1.000	rs17836662	chr22:50672154	A/G	cg08875078	chr22:50639485	SELO	-0.47	-7.68	-0.34	9.54e-14	Obesity-related traits;
LGG	trans	rs7618501	1.000	rs11716575	chr3:49744890	A/G	cg21659725	chr3:3221576	CRBN	-0.92	-20.4	-0.69	1.89e-66	Intelligence (multi-trait analysis);
LGG	cis	rs17376456	0.877	rs34673483	chr5:93315079	C/A	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs6032067	0.714	rs35343177	chr20:43845986	A/G	cg10761708	chr20:43804764	PI3	0.57	8.73	0.38	4.51e-17	Blood protein levels;
LGG	cis	rs41271473	0.649	rs11584348	chr1:228901357	T/C	cg10167378	chr1:228756711	NA	0.5	7.01	0.31	8.66e-12	Chronic lymphocytic leukemia;
LGG	cis	rs67133203	0.847	rs7978723	chr12:51448918	G/T	cg14688905	chr12:51403056	SLC11A2	0.68	10.28	0.43	1.86e-22	Urinary tract infection frequency;
LGG	cis	rs1552244	0.810	rs6809572	chr3:10100145	G/A	cg16606324	chr3:10149918	C3orf24	0.56	7.32	0.32	1.14e-12	Alzheimer's disease;
LGG	trans	rs1005277	0.579	rs2474572	chr10:38385316	A/G	cg25373794	chr1:162760220	HSD17B7	-0.42	-6.67	-0.3	7.21e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs2797369	0.550	rs1222365	chr6:101621735	C/T	cg27451362	chr6:101846650	GRIK2	-0.44	-7.02	-0.31	8.18e-12	Renal function-related traits (eGRFcrea);
LGG	cis	rs736408	1.000	rs736408	chr3:52835354	C/T	cg14092988	chr3:52407081	DNAH1	0.29	7.1	0.31	4.63e-12	Bipolar disorder;
LGG	cis	rs12617721	0.574	rs6542754	chr2:99025400	C/T	cg18455616	chr2:99124870	INPP4A	0.29	8.42	0.36	4.84e-16	Bipolar disorder with mood-incongruent psychosis;
LGG	trans	rs116095464	0.558	rs57335027	chr5:262907	A/G	cg00938859	chr5:1591904	SDHAP3	0.93	13.7	0.54	4.07e-36	Breast cancer;
LGG	cis	rs11608355	0.515	rs11613718	chr12:109912332	C/T	cg05360138	chr12:110035743	NA	0.84	12.04	0.49	3.12e-29	Neuroticism;
LGG	cis	rs36051895	0.632	rs10115335	chr9:5140963	A/T	cg02405213	chr9:5042618	JAK2	-0.76	-14.77	-0.57	9.86e-41	Pediatric autoimmune diseases;
LGG	cis	rs6762	0.748	rs3059	chr11:840319	C/T	cg10580341	chr11:889148	CHID1	-0.38	-6.99	-0.31	9.91e-12	Mean platelet volume;
LGG	cis	rs7264396	0.635	rs6058382	chr20:34553948	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.38	-6.86	-0.3	2.21e-11	Total cholesterol levels;
LGG	cis	rs7618915	0.501	rs35526119	chr3:52749334	C/T	cg18099408	chr3:52552593	STAB1	-0.36	-7.18	-0.32	2.84e-12	Bipolar disorder;
LGG	cis	rs516946	1.000	rs515071	chr8:41519462	C/T	cg01678292	chr8:41522873	ANK1	0.34	7.78	0.34	4.87e-14	Type 2 diabetes;
LGG	cis	rs875971	0.737	rs7803424	chr7:65880605	T/C	cg18876405	chr7:65276391	NA	0.54	9.7	0.41	2.16e-20	Aortic root size;
LGG	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg17971929	chr21:40555470	PSMG1	-0.68	-12.65	-0.51	1.03e-31	Cognitive function;
LGG	cis	rs1799949	1.000	rs8176109	chr17:41265776	A/G	cg18379455	chr17:41446167	NA	-0.32	-7.48	-0.33	3.87e-13	Menopause (age at onset);
LGG	cis	rs8180040	0.966	rs2291298	chr3:47555142	C/A	cg27129171	chr3:47204927	SETD2	0.78	14.73	0.56	1.5e-40	Colorectal cancer;
LGG	trans	rs7980799	0.682	rs7303356	chr12:33633599	C/G	cg13010199	chr12:38710504	ALG10B	-0.41	-7.56	-0.33	2.2e-13	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2346177	0.519	rs35509718	chr2:46696793	T/C	cg26688816	chr2:46740690	ATP6V1E2	-0.64	-12.2	-0.49	6.84e-30	HDL cholesterol;
LGG	cis	rs9611565	0.802	rs9611577	chr22:41793090	T/G	cg06634786	chr22:41940651	POLR3H	-0.71	-11.89	-0.48	1.27e-28	Vitiligo;
LGG	cis	rs11771526	0.901	rs78065961	chr7:32300967	C/T	cg13207630	chr7:32358064	NA	0.65	7.04	0.31	7.04e-12	Body mass index;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05046597	chr7:148823741	ZNF398;ZNF425	0.44	7.08	0.31	5.36e-12	Cognitive performance;
LGG	cis	rs2404602	0.716	rs1874944	chr15:76863928	A/G	cg22467129	chr15:76604101	ETFA	-0.43	-7.11	-0.31	4.33e-12	Blood metabolite levels;
LGG	cis	rs7249142	0.562	rs2314035	chr19:19284920	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.54	-0.44	2.07e-23	IgG glycosylation;
LGG	cis	rs3768617	0.546	rs2296296	chr1:183105399	C/G	cg07928641	chr1:182991847	LAMC1	0.42	8.25	0.36	1.68e-15	Fuchs's corneal dystrophy;
LGG	cis	rs16912285	0.535	rs6484040	chr11:24309809	C/A	ch.11.24196551F	chr11:24239977	NA	0.92	13.87	0.54	7.64e-37	Visceral adipose tissue/subcutaneous adipose tissue ratio;
LGG	trans	rs853679	0.546	rs35016036	chr6:28314880	C/T	cg06606381	chr12:133084897	FBRSL1	-1.32	-12.41	-0.5	9.79e-31	Depression;
LGG	cis	rs1218582	0.741	rs10908446	chr1:154869559	G/A	cg16318349	chr1:154917307	PBXIP1	-0.28	-7.7	-0.34	8.07e-14	Prostate cancer;
LGG	cis	rs3087591	0.960	rs2905787	chr17:29482381	G/A	cg24425628	chr17:29625626	OMG;NF1	0.69	13.8	0.54	1.58e-36	Hip circumference;
LGG	cis	rs9467773	0.620	rs2451744	chr6:26633463	G/T	cg09904177	chr6:26538194	HMGN4	0.67	13.84	0.54	1.04e-36	Intelligence (multi-trait analysis);
LGG	cis	rs1799949	1.000	rs11654731	chr17:41326940	G/A	cg23758822	chr17:41437982	NA	0.9	15.89	0.59	1.03e-45	Menopause (age at onset);
LGG	cis	rs11771526	0.892	rs11764802	chr7:32372978	C/T	cg27532318	chr7:32358331	NA	0.85	8.34	0.36	8.51e-16	Body mass index;
LGG	cis	rs2228479	0.557	rs12933317	chr16:89828220	A/G	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs35306767	0.903	rs11253460	chr10:887382	C/G	cg26597838	chr10:835615	NA	0.75	10.37	0.43	8.39e-23	Eosinophil percentage of granulocytes;
LGG	cis	rs3785574	0.927	rs2727313	chr17:61961914	A/G	cg06601766	chr17:61851465	DDX42;CCDC47	0.54	8.51	0.37	2.36e-16	Height;
LGG	cis	rs11583043	1.000	rs7535068	chr1:101490329	T/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	0.49	8.37	0.36	6.72e-16	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs798554	1.000	rs798545	chr7:2762386	C/T	cg19524238	chr7:2802976	GNA12	0.41	9.2	0.39	1.27e-18	Height;
LGG	cis	rs1949733	0.523	rs16842563	chr4:8545146	C/T	cg13073564	chr4:8508604	NA	0.41	7.15	0.32	3.31e-12	Response to antineoplastic agents;
LGG	cis	rs2072732	0.861	rs10909867	chr1:2961402	G/T	cg08733933	chr1:2954429	NA	-0.44	-8.78	-0.38	3.25e-17	Plateletcrit;
LGG	cis	rs2635047	0.935	rs2635050	chr18:44664131	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.54	9.42	0.4	2.1e-19	Educational attainment;
LGG	cis	rs12482904	0.747	rs28700238	chr21:43820573	A/T	cg23042151	chr21:43824109	UBASH3A	-0.55	-10.5	-0.44	2.71e-23	Vitiligo;
LGG	cis	rs3768617	0.510	rs10737245	chr1:183100884	G/A	cg07245641	chr1:182991651	LAMC1	0.42	9.49	0.4	1.18e-19	Fuchs's corneal dystrophy;
LGG	cis	rs651907	0.557	rs34457525	chr3:101435225	C/T	cg12386194	chr3:101231763	SENP7	0.43	7.53	0.33	2.63e-13	Colorectal cancer;
LGG	cis	rs7011049	0.818	rs113433913	chr8:53866718	C/G	cg26025543	chr8:53854495	NA	0.58	8.15	0.35	3.41e-15	Systolic blood pressure;
LGG	cis	rs1894633	0.540	rs9425315	chr1:172395512	C/T	cg01573306	chr1:172330400	DNM3	0.36	7.0	0.31	9.17e-12	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs6089829	0.926	rs6062395	chr20:61667904	A/G	cg08564027	chr20:61660810	NA	1.02	25.72	0.77	2.9e-91	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs457717	0.730	rs457182	chr5:75946328	G/A	cg02529909	chr5:75919850	F2RL2;IQGAP2	0.3	6.71	0.3	5.67e-11	Hearing impairment;
LGG	trans	rs9467711	0.651	rs7749414	chr6:26074884	G/T	cg06606381	chr12:133084897	FBRSL1	-0.78	-7.38	-0.32	7.28e-13	Autism spectrum disorder or schizophrenia;
LGG	cis	rs3768617	0.510	rs2296294	chr1:183095596	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Fuchs's corneal dystrophy;
LGG	cis	rs10256972	0.552	rs2949195	chr7:1202705	G/A	cg18765753	chr7:1198926	ZFAND2A	-0.46	-8.04	-0.35	7.69e-15	Longevity;Endometriosis;
LGG	cis	rs597539	0.731	rs664229	chr11:68624483	C/G	cg07511668	chr11:68622177	NA	0.5	9.25	0.39	8.19e-19	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10504229	0.679	rs72649115	chr8:58037631	T/G	cg08280861	chr8:58055591	NA	0.59	7.33	0.32	1.02e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1862618	0.853	rs866222	chr5:56184444	T/C	cg12654349	chr5:56205094	C5orf35	-0.67	-10.39	-0.43	7.23e-23	Initial pursuit acceleration;
LGG	cis	rs13108904	0.557	rs1250098	chr4:1238256	A/T	cg23835219	chr4:1244017	CTBP1;C4orf42	-0.66	-12.08	-0.49	2.2e-29	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs10872645	chr6:150063976	G/A	cg05861140	chr6:150128134	PCMT1	-0.46	-10.61	-0.44	1.09e-23	Lung cancer;
LGG	cis	rs7241530	0.595	rs12957925	chr18:75900192	G/A	cg14642773	chr18:75888474	NA	0.46	8.9	0.38	1.31e-17	Educational attainment (years of education);
LGG	cis	rs796364	0.774	rs112564437	chr2:201074048	G/C	cg17644776	chr2:200775616	C2orf69	-0.58	-8.62	-0.37	1.09e-16	Schizophrenia;
LGG	cis	rs757278	0.896	rs2189388	chr7:117398604	T/G	cg10524701	chr7:117356490	CTTNBP2	0.35	6.96	0.31	1.14e-11	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs7223966	1.000	rs55674647	chr17:61794195	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.46	7.42	0.33	5.84e-13	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4319547	0.695	rs11057797	chr12:122860732	G/A	cg05707623	chr12:122985044	ZCCHC8	0.66	9.8	0.41	9.67e-21	Body mass index;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg02127607	chr17:61920694	SMARCD2	0.47	8.57	0.37	1.5e-16	Prudent dietary pattern;
LGG	cis	rs2708377	0.656	rs73066852	chr12:11276541	A/G	cg25677688	chr12:11176386	TAS2R19;PRR4;PRH1	-0.62	-6.78	-0.3	3.77e-11	Bitter taste perception;
LGG	cis	rs6704644	0.651	rs3820744	chr2:234361548	T/C	cg27060346	chr2:234359958	DGKD	-0.58	-6.84	-0.3	2.48e-11	Bilirubin levels;
LGG	cis	rs853679	0.517	rs17711801	chr6:28092307	C/G	cg18032046	chr6:28092343	ZSCAN16	-0.57	-7.68	-0.34	9.57e-14	Depression;
LGG	cis	rs711245	0.637	rs11894187	chr2:36781708	T/A	cg01206211	chr2:36825736	FEZ2	0.46	8.07	0.35	5.98e-15	Height;
LGG	cis	rs10911232	0.507	rs4652765	chr1:182994147	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	cis	rs7792596	0.861	rs6970279	chr7:94014889	A/C	cg20814616	chr7:94014465	NA	0.38	6.71	0.3	5.62e-11	Intelligence;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg08684830	chr9:80851119	CEP78	-0.41	-6.9	-0.31	1.68e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs4330281	0.692	rs4908938	chr3:17787557	G/A	cg20981856	chr3:17787350	NA	-0.39	-7.17	-0.32	3.05e-12	Schizophrenia;
LGG	cis	rs2032447	0.869	rs2230655	chr6:26033506	A/G	cg07061783	chr6:25882402	NA	0.42	7.27	0.32	1.51e-12	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs76118562	chr8:57988110	G/C	cg26174226	chr8:58114915	NA	-0.59	-7.92	-0.35	1.74e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs10193935	0.901	rs3755304	chr2:42589921	A/G	cg27598129	chr2:42591480	NA	0.62	9.01	0.39	5.28e-18	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1799949	1.000	rs8176126	chr17:41259049	A/G	cg25072359	chr17:41440525	NA	-0.53	-10.1	-0.42	8.22e-22	Menopause (age at onset);
LGG	trans	rs9325144	0.647	rs11168819	chr12:39011082	C/A	cg06521331	chr12:34319734	NA	0.4	6.74	0.3	4.68e-11	Morning vs. evening chronotype;
LGG	cis	rs1552244	0.882	rs9757159	chr3:10039166	C/T	cg00166722	chr3:10149974	C3orf24	0.5	8.42	0.36	4.88e-16	Alzheimer's disease;
LGG	cis	rs2470578	0.792	rs283916	chr3:17329413	A/G	cg20981856	chr3:17787350	NA	0.35	6.78	0.3	3.59e-11	Schizophrenia;
LGG	trans	rs7824557	0.603	rs11250130	chr8:11214455	C/T	cg08975724	chr8:8085496	FLJ10661	-0.41	-7.57	-0.33	1.97e-13	Retinal vascular caliber;
LGG	cis	rs807669	1.000	rs807670	chr22:19154608	A/C	cg02655711	chr22:19163373	SLC25A1	0.65	13.18	0.52	6.67e-34	Metabolite levels;
LGG	cis	rs2404602	0.692	rs58889902	chr15:77173070	A/C	cg15268244	chr15:77196840	NA	-0.31	-6.79	-0.3	3.36e-11	Blood metabolite levels;
LGG	cis	rs4740619	0.616	rs1891210	chr9:15900348	G/T	cg14451791	chr9:16040625	NA	-0.29	-7.14	-0.31	3.72e-12	Body mass index;
LGG	cis	rs2576037	0.583	rs545344	chr18:44367079	A/G	cg23129478	chr18:44337922	ST8SIA5	-0.4	-7.72	-0.34	7.29e-14	Personality dimensions;
LGG	cis	rs6456042	1.000	rs3099300	chr6:166526499	A/G	cg11088901	chr6:166572345	T	-0.36	-7.36	-0.32	8.56e-13	Asthma;
LGG	cis	rs798554	0.797	rs798486	chr7:2803037	A/G	cg19524238	chr7:2802976	GNA12	0.4	9.19	0.39	1.29e-18	Height;
LGG	cis	rs2708240	1.000	rs2708243	chr7:147580412	A/T	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.27	-6.93	-0.31	1.46e-11	QT interval (drug interaction);
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg07959490	chr17:80112427	CCDC57	-0.47	-9.31	-0.4	5.16e-19	Life satisfaction;
LGG	trans	rs61931739	0.500	rs11053198	chr12:34444013	G/C	cg26384229	chr12:38710491	ALG10B	0.86	18.59	0.65	5.19e-58	Morning vs. evening chronotype;
LGG	cis	rs9462027	0.606	rs2814981	chr6:34581055	G/A	cg07306190	chr6:34760872	UHRF1BP1	-0.51	-10.31	-0.43	1.45e-22	Systemic lupus erythematosus;
LGG	cis	rs933688	1.000	rs186717	chr5:90780467	T/A	cg12630606	chr5:90679528	LOC100129716;ARRDC3	1.03	15.68	0.59	9.12e-45	Smoking behavior;
LGG	cis	rs2806731	0.581	rs1889996	chr13:54269950	T/G	ch.13.53330881F	chr13:54432880	NA	-0.42	-6.89	-0.3	1.84e-11	Obesity-related traits;
LGG	cis	rs12368653	0.666	rs799265	chr12:58112189	A/G	cg00700412	chr12:58011837	NA	0.37	7.41	0.33	5.85e-13	Multiple sclerosis;
LGG	cis	rs9660992	0.710	rs1668864	chr1:205248799	T/C	cg00857998	chr1:205179979	DSTYK	0.47	6.71	0.3	5.74e-11	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs6762	0.719	rs28620453	chr11:836971	G/C	cg10580341	chr11:889148	CHID1	-0.38	-7.05	-0.31	6.41e-12	Mean platelet volume;
LGG	cis	rs3858526	0.959	rs1840179	chr11:5949148	A/G	cg13902645	chr11:5959945	NA	-0.73	-11.35	-0.47	1.61e-26	DNA methylation (variation);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg19856822	chr3:101293068	PCNP	0.46	6.7	0.3	5.89e-11	Hip circumference;
LGG	cis	rs13040088	1.000	rs13040088	chr20:61549202	A/G	cg23096297	chr20:61557774	DIDO1	0.88	12.8	0.51	2.52e-32	Menopause (age at onset);
LGG	trans	rs6582630	0.576	rs2387836	chr12:38560070	A/G	cg06521331	chr12:34319734	NA	-0.42	-7.56	-0.33	2.13e-13	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs739401	0.527	rs423236	chr11:3065916	C/T	cg08508325	chr11:3079039	CARS	-0.6	-12.97	-0.52	4.85e-33	Longevity;
LGG	cis	rs9818758	0.607	rs35108630	chr3:49088356	T/A	cg00383909	chr3:49044727	WDR6	1.05	12.69	0.51	7.13e-32	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs8133932	0.906	rs8128820	chr21:47098766	A/G	cg11214348	chr21:47283868	PCBP3	-0.43	-7.07	-0.31	5.68e-12	Schizophrenia;
LGG	cis	rs9287719	0.967	rs715246	chr2:10736355	G/A	cg02196655	chr2:10830764	NOL10	-0.44	-7.47	-0.33	3.95e-13	Prostate cancer;
LGG	cis	rs2798269	1.000	rs4770172	chr13:22123676	A/G	cg18095732	chr13:22033692	ZDHHC20	-0.39	-6.82	-0.3	2.84e-11	PR segment;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg20555477	chr9:86594889	HNRNPK;RMI1	0.48	7.92	0.35	1.72e-14	Cognitive performance;
LGG	cis	rs778371	0.834	rs778363	chr2:233778896	A/G	cg08000102	chr2:233561755	GIGYF2	-0.57	-8.15	-0.35	3.34e-15	Schizophrenia;
LGG	trans	rs6952808	0.636	rs60605830	chr7:1949198	A/G	cg24247370	chr13:99142703	STK24	-0.38	-6.92	-0.31	1.53e-11	Bipolar disorder and schizophrenia;
LGG	cis	rs6502050	0.835	rs7221451	chr17:80089785	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.42	-0.33	5.59e-13	Life satisfaction;
LGG	cis	rs13118159	0.527	rs6599309	chr4:1388115	C/G	cg02018176	chr4:1364513	KIAA1530	0.64	15.31	0.58	3.99e-43	Longevity;
LGG	cis	rs11920354	0.642	rs9812878	chr3:47182787	T/C	cg27129171	chr3:47204927	SETD2	0.8	14.25	0.55	1.79e-38	Granulocyte count;Sum neutrophil eosinophil counts;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05525867	chr15:75661090	MAN2C1	-0.41	-6.91	-0.31	1.65e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	trans	rs11782517	0.883	rs13258235	chr8:10106503	A/G	cg16141378	chr3:129829833	LOC729375	0.36	6.79	0.3	3.4e-11	Nose size;
LGG	cis	rs6988985	0.765	rs6431	chr8:143993765	G/A	cg10324643	chr8:143916377	GML	0.38	7.63	0.33	1.31e-13	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2072499	1.000	rs2540173	chr1:156188214	A/G	cg24450063	chr1:156163899	SLC25A44	1.21	29.44	0.81	3.9e-108	Testicular germ cell tumor;
LGG	cis	rs7586879	0.828	rs11675013	chr2:25107208	G/A	cg04586622	chr2:25135609	ADCY3	0.35	8.58	0.37	1.48e-16	Body mass index;
LGG	cis	rs9397585	0.833	rs6927659	chr6:153397299	T/G	cg17707550	chr6:153380415	RGS17	0.51	11.27	0.46	3.42e-26	Body mass index;
LGG	cis	rs4731207	0.596	rs9641759	chr7:124666210	C/T	cg05630886	chr7:124431682	NA	-0.33	-7.52	-0.33	2.79e-13	Cutaneous malignant melanoma;
LGG	cis	rs8180040	0.966	rs60369822	chr3:47479735	A/C	cg27129171	chr3:47204927	SETD2	-0.8	-15.62	-0.59	1.67e-44	Colorectal cancer;
LGG	cis	rs2587949	0.615	rs2874813	chr3:4208715	T/G	cg16519197	chr3:4211558	NA	-0.33	-6.78	-0.3	3.76e-11	Periodontitis (DPAL);
LGG	cis	rs6502050	0.777	rs4625783	chr17:80086395	T/C	cg10505658	chr17:80084571	CCDC57	0.41	8.4	0.36	5.67e-16	Life satisfaction;
LGG	cis	rs12291225	0.839	rs4757244	chr11:14258655	A/G	cg19336497	chr11:14380999	RRAS2	0.46	8.9	0.38	1.23e-17	Sense of smell;
LGG	cis	rs11155671	0.530	rs6935829	chr6:150217811	C/T	cg07701084	chr6:150067640	NUP43	0.42	7.55	0.33	2.27e-13	Testicular germ cell tumor;
LGG	cis	rs9322193	0.851	rs9322194	chr6:149920249	C/T	cg00424166	chr6:150045504	NUP43	-0.37	-7.54	-0.33	2.46e-13	Lung cancer;
LGG	cis	rs7927592	0.913	rs7123564	chr11:68362164	C/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.43	-0.36	4.4e-16	Total body bone mineral density;
LGG	trans	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01341218	chr17:43662625	NA	-0.66	-11.86	-0.48	1.64e-28	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6088590	1.000	rs6088590	chr20:33313566	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.61	0.33	1.5700000000000001e-13	Coronary artery disease;
LGG	cis	rs2762353	0.808	rs1185978	chr6:25835895	A/G	cg07061783	chr6:25882402	NA	-0.4	-7.14	-0.32	3.58e-12	Blood metabolite levels;
LGG	cis	rs4474465	0.915	rs11237505	chr11:78171261	A/G	cg27205649	chr11:78285834	NARS2	-0.51	-8.58	-0.37	1.46e-16	Alzheimer's disease (survival time);
LGG	cis	rs9479482	1.000	rs13198863	chr6:150350781	T/G	cg06889755	chr6:150326021	RAET1K	-0.38	-7.83	-0.34	3.31e-14	Alopecia areata;
LGG	cis	rs80130819	0.515	rs1793956	chr12:48392914	C/G	cg24011408	chr12:48396354	COL2A1	0.69	8.21	0.36	2.21e-15	Prostate cancer;
LGG	cis	rs1005277	0.579	rs2474588	chr10:38420870	A/G	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.67	-0.34	9.9e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs10504229	0.683	rs17802743	chr8:58105897	C/T	cg14926445	chr8:58193284	C8orf71	-0.85	-10.48	-0.44	3.24e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs8180040	0.726	rs6774733	chr3:46991241	G/A	cg27129171	chr3:47204927	SETD2	0.8	14.57	0.56	7.2e-40	Colorectal cancer;
LGG	cis	rs4689388	0.926	rs4689394	chr4:6291003	C/G	cg25554036	chr4:6271136	WFS1	-0.61	-11.52	-0.47	3.52e-27	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs10267417	0.603	rs10950760	chr7:19912040	A/G	cg05791153	chr7:19748676	TWISTNB	-0.56	-7.43	-0.33	5.11e-13	Night sleep phenotypes;
LGG	trans	rs3857536	0.740	rs4710571	chr6:66890250	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.47	-8.13	-0.35	3.96e-15	Blood trace element (Cu levels);
LGG	cis	rs9322193	0.923	rs12205092	chr6:150082511	G/T	cg07701084	chr6:150067640	NUP43	0.68	12.74	0.51	4.44e-32	Lung cancer;
LGG	cis	rs7811142	1.000	rs2897358	chr7:100088640	C/G	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.85	0.38	1.92e-17	Platelet count;
LGG	cis	rs7819412	0.811	rs2409691	chr8:10943276	C/T	cg21775007	chr8:11205619	TDH	-0.5	-8.07	-0.35	6.16e-15	Triglycerides;
LGG	cis	rs9611565	0.649	rs202657	chr22:41844786	G/T	cg17376030	chr22:41985996	PMM1	-0.56	-8.97	-0.38	7.6e-18	Vitiligo;
LGG	cis	rs6500602	0.679	rs736685	chr16:4508606	T/C	cg06139259	chr16:4526053	HMOX2;NMRAL1	0.32	6.69	0.3	6.65e-11	Schizophrenia;
LGG	cis	rs7191439	0.583	rs9935872	chr16:88788477	A/G	cg27087555	chr16:88793112	FAM38A	-1.37	-19.92	-0.68	3.06e-64	Plateletcrit;
LGG	cis	rs2688608	0.592	rs3933085	chr10:75483331	C/T	cg00564723	chr10:75632066	CAMK2G	-0.33	-7.35	-0.32	8.85e-13	Inflammatory bowel disease;
LGG	cis	rs7122539	0.839	rs6591223	chr11:66609289	C/T	cg01599099	chr11:66649832	PC	0.39	7.8	0.34	4.2e-14	HIV-1 susceptibility;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg15586393	chr4:1244086	CTBP1;C4orf42	0.74	14.01	0.55	1.97e-37	Obesity-related traits;
LGG	cis	rs283228	0.550	rs2852497	chr6:101829166	C/T	cg27451362	chr6:101846650	GRIK2	0.94	14.18	0.55	3.82e-38	Coenzyme Q10 levels;
LGG	cis	rs2153535	0.580	rs9405391	chr6:8466548	C/T	cg07606381	chr6:8435919	SLC35B3	0.67	12.5	0.5	4.3e-31	Motion sickness;
LGG	cis	rs9902453	0.967	rs9904336	chr17:28357080	T/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.4	-0.53	7.89e-35	Coffee consumption (cups per day);
LGG	cis	rs9811920	0.609	rs793460	chr3:99615733	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.53	9.07	0.39	3.44e-18	Axial length;
LGG	cis	rs10504229	0.683	rs7820559	chr8:58142662	C/T	cg26174226	chr8:58114915	NA	-0.6	-8.61	-0.37	1.15e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg13647721	chr17:30228624	UTP6	0.64	7.96	0.35	1.3e-14	Hip circumference adjusted for BMI;
LGG	cis	rs1790761	0.806	rs11601325	chr11:67227006	G/A	cg24690094	chr11:67383802	NA	-0.4	-6.78	-0.3	3.66e-11	Mean corpuscular volume;
LGG	trans	rs9329221	0.510	rs6995837	chr8:9975675	T/C	cg08975724	chr8:8085496	FLJ10661	0.39	7.39	0.32	6.91e-13	Neuroticism;
LGG	cis	rs6568686	0.786	rs6910340	chr6:111863064	A/G	cg21044968	chr6:111895086	TRAF3IP2	-0.41	-6.79	-0.3	3.39e-11	Depressive and manic episodes in bipolar disorder;Depressive episodes in bipolar disorder;
LGG	cis	rs10504229	0.638	rs6981055	chr8:58113941	T/C	cg26174226	chr8:58114915	NA	-0.59	-8.49	-0.37	2.83e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs1218582	0.772	rs2335408	chr1:154915977	G/A	cg12436631	chr1:155007014	DCST1;DCST2	0.39	7.73	0.34	6.98e-14	Prostate cancer;
LGG	cis	rs2290159	0.800	rs11711419	chr3:12667784	A/T	cg23032965	chr3:12705835	RAF1	0.67	9.64	0.41	3.77e-20	Cholesterol, total;
LGG	cis	rs4665809	0.627	rs13032756	chr2:26489730	A/T	cg26119090	chr2:26468346	HADHA;HADHB	1.07	20.62	0.69	1.72e-67	Gut microbiome composition (summer);
LGG	cis	rs2952156	1.000	rs2643195	chr17:37853118	A/G	cg00129232	chr17:37814104	STARD3	-0.67	-13.38	-0.53	9.42e-35	Asthma;
LGG	cis	rs2243480	1.000	rs1701758	chr7:65470201	T/A	cg18252515	chr7:66147081	NA	-1.35	-18.77	-0.66	7.59e-59	Diabetic kidney disease;
LGG	cis	rs9311474	0.508	rs17052259	chr3:52593138	A/G	cg14092988	chr3:52407081	DNAH1	0.28	7.58	0.33	1.9e-13	Electroencephalogram traits;
LGG	cis	rs62400317	0.859	rs62438863	chr6:45040592	C/T	cg18551225	chr6:44695536	NA	-0.62	-10.07	-0.42	1.02e-21	Total body bone mineral density;
LGG	cis	rs6817170	0.719	rs11732163	chr4:154376222	G/A	cg07229402	chr4:154369277	NA	0.34	6.86	0.3	2.28e-11	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);
LGG	cis	rs2708240	0.577	rs851707	chr7:147534049	T/C	cg02373104	chr7:147601429	MIR548F3;CNTNAP2	-0.29	-6.68	-0.3	7.08e-11	QT interval (drug interaction);
LGG	cis	rs6573604	1.000	rs4902386	chr14:65778290	A/C	cg15999311	chr14:65749247	NA	-0.46	-6.7	-0.3	6.04e-11	N-glycan levels;
LGG	cis	rs4727027	0.870	rs1534196	chr7:148790591	G/A	cg23583168	chr7:148888333	NA	-0.87	-16.7	-0.61	2.34e-49	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs2880765	0.835	rs4344688	chr15:86043007	A/C	cg17133734	chr15:86042851	AKAP13	-0.29	-6.8	-0.3	3.16e-11	Coronary artery disease;
LGG	cis	rs7737355	0.947	rs1468303	chr5:130804400	T/C	cg06307176	chr5:131281290	NA	-0.55	-9.26	-0.4	7.9e-19	Life satisfaction;
LGG	cis	rs2032447	0.670	rs198850	chr6:26104670	A/C	cg12310025	chr6:25882481	NA	0.49	9.09	0.39	2.93e-18	Intelligence (multi-trait analysis);
LGG	cis	rs10754283	0.935	rs1934046	chr1:90119290	A/T	cg21401794	chr1:90099060	LRRC8C	-0.58	-11.68	-0.48	8.63e-28	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs250677	0.652	rs36045	chr5:148441184	A/G	cg18129178	chr5:148520854	ABLIM3	0.44	6.85	0.3	2.39e-11	Breast cancer;
LGG	cis	rs6952808	0.531	rs1107351	chr7:2177093	G/A	cg22963979	chr7:1858916	MAD1L1	-0.41	-8.1	-0.35	4.8e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs7618915	0.533	rs35107891	chr3:52613656	G/C	cg18404041	chr3:52824283	ITIH1	-0.55	-10.51	-0.44	2.57e-23	Bipolar disorder;
LGG	cis	rs6028335	0.610	rs12626028	chr20:37553900	G/C	cg16355469	chr20:37678765	NA	0.53	6.97	0.31	1.13e-11	Alcohol and nicotine co-dependence;
LGG	cis	rs5769765	0.908	rs9616217	chr22:50318946	C/T	cg26441486	chr22:50317300	CRELD2	0.41	7.08	0.31	5.24e-12	Schizophrenia;
LGG	cis	rs701145	0.585	rs2689330	chr3:153929990	T/C	cg12800244	chr3:153838788	SGEF	0.84	8.33	0.36	9.55e-16	Coronary artery disease;
LGG	cis	rs368123	1.000	rs474617	chr6:160700441	T/C	cg07349212	chr6:160770346	SLC22A3	-0.33	-6.99	-0.31	9.56e-12	Waist circumference;
LGG	cis	rs875971	0.862	rs13232191	chr7:65986648	A/G	cg18876405	chr7:65276391	NA	0.54	9.72	0.41	1.91e-20	Aortic root size;
LGG	cis	rs2404602	0.692	rs7350777	chr15:76985441	G/A	cg05677249	chr15:77158041	SCAPER	-0.31	-6.66	-0.3	7.61e-11	Blood metabolite levels;
LGG	cis	rs6502050	0.835	rs28481866	chr17:80105160	G/A	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	cis	rs798554	0.683	rs1636264	chr7:2864586	G/T	cg19524238	chr7:2802976	GNA12	0.35	8.05	0.35	6.93e-15	Height;
LGG	cis	rs2836974	0.897	rs34035316	chr21:40594023	T/C	cg11890956	chr21:40555474	PSMG1	1.19	30.84	0.82	2.62e-114	Cognitive function;
LGG	cis	rs4149577	1.000	rs4149577	chr12:6447522	C/T	cg11268190	chr12:6442526	TNFRSF1A	0.29	7.38	0.32	7.22e-13	Monocyte count;
LGG	cis	rs12950390	0.853	rs59513807	chr17:45867925	G/A	cg03474202	chr17:45855739	NA	-0.27	-7.96	-0.35	1.36e-14	IgG glycosylation;
LGG	cis	rs7246760	0.867	rs8112764	chr19:9748907	G/A	cg16876255	chr19:9731953	ZNF561	0.84	7.85	0.34	2.95e-14	Pursuit maintenance gain;
LGG	cis	rs28386778	0.897	rs2854213	chr17:61945631	T/C	cg07659893	chr17:61819838	STRADA	0.49	8.26	0.36	1.53e-15	Prudent dietary pattern;
LGG	cis	rs1499614	1.000	rs2707830	chr7:66167645	T/C	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs10752881	0.935	rs4652771	chr1:183023503	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.43	8.85	0.38	1.88e-17	Colorectal cancer;
LGG	cis	rs875971	0.502	rs6460311	chr7:66111873	C/T	cg11764359	chr7:65958608	NA	-0.62	-8.77	-0.38	3.5e-17	Aortic root size;
LGG	cis	rs2019137	0.539	rs4849181	chr2:113991970	A/G	cg21550016	chr2:113992930	PAX8;LOC440839;LOC654433	0.83	15.81	0.59	2.55e-45	Lymphocyte counts;
LGG	cis	rs11887277	0.868	rs6717682	chr2:27069211	A/G	cg12045002	chr2:27069975	DPYSL5	-0.32	-6.88	-0.3	1.97e-11	Obesity-related traits;
LGG	cis	rs7726839	0.561	rs72703046	chr5:580129	T/C	cg07777115	chr5:623756	CEP72	-0.51	-6.8	-0.3	3.27e-11	Obesity-related traits;
LGG	cis	rs2640806	0.505	rs17781856	chr8:97367550	C/T	cg22138393	chr8:97340270	PTDSS1	-0.28	-7.32	-0.32	1.12e-12	Obesity-related traits;
LGG	cis	rs10504229	0.595	rs76447299	chr8:58117395	A/G	cg20607798	chr8:58055168	NA	0.57	6.66	0.3	7.78e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7765175	1.000	rs7761223	chr6:113672943	C/T	cg26552650	chr6:113682475	NA	0.33	7.18	0.32	2.81e-12	Coronary artery calcification;
LGG	cis	rs10743315	0.557	rs10505840	chr12:19403729	G/T	cg02471346	chr12:19282374	PLEKHA5	0.84	7.87	0.34	2.45e-14	Gut microbiota (bacterial taxa);
LGG	cis	rs155076	1.000	rs2783107	chr13:21837532	C/A	cg06138931	chr13:21896616	NA	-0.42	-6.88	-0.3	1.89e-11	White matter hyperintensity burden;
LGG	cis	rs7586879	0.662	rs2384059	chr2:25100338	C/T	cg04586622	chr2:25135609	ADCY3	0.44	11.83	0.48	2.19e-28	Body mass index;
LGG	cis	rs3092073	0.624	rs3848719	chr20:44596545	G/A	cg27529037	chr20:44575021	PCIF1	0.41	7.79	0.34	4.47e-14	Intelligence (multi-trait analysis);
LGG	trans	rs7812879	0.564	rs12114115	chr8:11298606	C/T	cg06636001	chr8:8085503	FLJ10661	0.52	6.84	0.3	2.45e-11	Systemic lupus erythematosus;
LGG	cis	rs6762644	0.507	rs10212373	chr3:4762449	C/T	cg11584376	chr3:4789075	ITPR1	-0.4	-8.45	-0.37	3.91e-16	Breast cancer;
LGG	cis	rs12477438	0.520	rs1053544	chr2:100022270	G/A	cg23527387	chr2:100056660	REV1	0.45	9.81	0.41	9.2e-21	Chronic sinus infection;
LGG	trans	rs2197308	0.765	rs12230545	chr12:37927114	C/T	cg06521331	chr12:34319734	NA	0.52	9.62	0.41	4.17e-20	Morning vs. evening chronotype;
LGG	trans	rs4332037	0.722	rs60346318	chr7:1915824	C/G	cg10840412	chr1:235813424	GNG4	0.55	7.28	0.32	1.49e-12	Bipolar disorder;
LGG	cis	rs13064447	0.753	rs6442324	chr3:12746776	A/G	cg23032965	chr3:12705835	RAF1	0.49	7.36	0.32	8.72e-13	Major depression and alcohol dependence;
LGG	cis	rs10870270	0.830	rs10781571	chr10:133774316	G/C	cg17892150	chr10:133769511	PPP2R2D	-0.68	-13.56	-0.53	1.7000000000000001e-35	Amyotrophic lateral sclerosis in C9orf72 mutation positive individuals;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg15875120	chr10:15902605	FAM188A	0.42	6.91	0.31	1.59e-11	Cognitive performance;
LGG	cis	rs1558375	0.679	rs31672	chr7:87059699	C/T	cg00919237	chr7:87102261	ABCB4	0.56	9.95	0.42	2.8e-21	Gallbladder cancer;
LGG	trans	rs853679	1.000	rs853678	chr6:28297313	T/A	cg01620082	chr3:125678407	NA	-0.56	-7.2	-0.32	2.38e-12	Depression;
LGG	cis	rs62400317	0.859	rs10948201	chr6:45093494	A/C	cg20913747	chr6:44695427	NA	0.62	10.28	0.43	1.79e-22	Total body bone mineral density;
LGG	cis	rs11603023	0.569	rs573905	chr11:118572267	A/G	cg09426994	chr11:118478258	PHLDB1	0.41	7.09	0.31	4.98e-12	Cholesterol, total;
LGG	trans	rs7618501	0.633	rs12496973	chr3:50002245	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.9	0.34	2e-14	Intelligence (multi-trait analysis);
LGG	cis	rs12477438	0.798	rs1349778	chr2:99645011	G/C	cg08885076	chr2:99613938	TSGA10	-0.6	-12.4	-0.5	1.08e-30	Chronic sinus infection;
LGG	trans	rs12599106	0.625	rs12923277	chr16:34896261	G/A	cg05064044	chr6:292385	DUSP22	-0.64	-10.81	-0.45	1.94e-24	Menopause (age at onset);
LGG	cis	rs4481887	0.962	rs6686911	chr1:248476969	T/C	cg00666640	chr1:248458726	OR2T12	0.6	9.67	0.41	2.86e-20	Common traits (Other);
LGG	cis	rs9858542	1.000	rs9812791	chr3:49682311	G/A	cg00383909	chr3:49044727	WDR6	0.43	7.07	0.31	5.85e-12	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs11785400	0.612	rs10110864	chr8:143750072	A/G	cg10596483	chr8:143751796	JRK	0.51	8.14	0.35	3.59e-15	Schizophrenia;
LGG	cis	rs9796	0.870	rs8030306	chr15:41261821	T/A	cg18705301	chr15:41695430	NDUFAF1	-0.49	-8.42	-0.36	4.61e-16	Menopause (age at onset);
LGG	cis	rs1018836	0.892	rs5005585	chr8:91581975	A/G	cg16814680	chr8:91681699	NA	-0.72	-12.74	-0.51	4.24e-32	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs4423214	1.000	rs2002063	chr11:71163476	T/C	cg10847948	chr11:71163743	NADSYN1	-0.67	-13.08	-0.52	1.71e-33	Vitamin D levels;
LGG	cis	rs2153535	0.580	rs2327053	chr6:8443127	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.62	0.51	1.32e-31	Motion sickness;
LGG	cis	rs9435341	0.930	rs2232015	chr1:107599258	A/T	cg09367891	chr1:107599246	PRMT6	0.61	10.51	0.44	2.52e-23	Facial morphology (factor 21, depth of nasal alae);
LGG	cis	rs17776563	0.614	rs8182073	chr15:89131384	T/C	cg05013243	chr15:89149849	MIR1179	-0.34	-6.98	-0.31	1.05e-11	Thyroid hormone levels;
LGG	cis	rs3785574	0.962	rs2727324	chr17:61922102	G/C	cg11494091	chr17:61959527	GH2	0.61	10.45	0.44	4.48e-23	Height;
LGG	cis	rs7617480	0.648	rs6806356	chr3:48727636	G/A	cg20833759	chr3:49053208	WDR6;DALRD3	0.47	7.91	0.34	1.94e-14	Subjective well-being (multi-trait analysis);Menarche (age at onset);
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg08499158	chr17:42289980	UBTF	-0.55	-10.23	-0.43	2.73e-22	Total body bone mineral density;
LGG	cis	rs8095374	0.967	rs9947316	chr18:43777831	T/G	cg26436583	chr18:43649176	PSTPIP2	-0.38	-8.26	-0.36	1.5e-15	Clinical laboratory measurements;
LGG	cis	rs3771570	1.000	rs62186422	chr2:242249499	A/G	cg21155796	chr2:242212141	HDLBP	0.76	9.87	0.42	5.65e-21	Prostate cancer;
LGG	trans	rs4332037	0.539	rs57148375	chr7:2025001	G/C	cg22232500	chr2:134024266	NCKAP5	0.55	7.83	0.34	3.29e-14	Bipolar disorder;
LGG	cis	rs11227306	0.812	rs11227310	chr11:65584733	A/T	cg26695010	chr11:65641043	EFEMP2	-0.48	-7.5	-0.33	3.31e-13	DNA methylation (variation);
LGG	cis	rs3768617	0.528	rs3736888	chr1:183084607	A/G	cg15522984	chr1:182991683	LAMC1	0.46	9.16	0.39	1.64e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg16920238	chr17:80076378	CCDC57	-0.32	-7.27	-0.32	1.56e-12	Life satisfaction;
LGG	cis	rs867371	1.000	rs8042464	chr15:82465536	A/G	cg00614314	chr15:82944287	LOC80154	0.61	9.79	0.41	1.11e-20	Cognitive ability;Cognitive ability (multi-trait analysis);
LGG	cis	rs13118159	0.778	rs12650998	chr4:1338832	T/C	cg02018176	chr4:1364513	KIAA1530	0.45	10.88	0.45	1.03e-24	Longevity;
LGG	trans	rs34421088	0.623	rs2572433	chr8:11101041	C/T	cg16141378	chr3:129829833	LOC729375	-0.32	-6.76	-0.3	4.09e-11	Neuroticism;
LGG	cis	rs72960926	1.000	rs55813969	chr6:75099746	C/T	cg03266952	chr6:74778945	NA	-0.69	-6.82	-0.3	2.93e-11	Metabolite levels (MHPG);
LGG	cis	rs10489202	0.632	rs6659713	chr1:168072249	G/T	cg24449463	chr1:168025552	DCAF6	0.56	10.17	0.43	4.58e-22	Schizophrenia;
LGG	cis	rs11169552	0.510	rs10876047	chr12:50925285	C/G	cg12884762	chr12:50931848	DIP2B	-0.41	-7.79	-0.34	4.59e-14	Colorectal cancer;
LGG	cis	rs7582180	0.790	rs13020451	chr2:100927131	T/G	cg08297393	chr2:100937505	LONRF2	-0.53	-9.81	-0.41	9.46e-21	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.679	rs11783963	chr8:58130496	T/A	cg02725872	chr8:58115012	NA	-1.04	-15.37	-0.58	2.34e-43	Developmental language disorder (linguistic errors);
LGG	cis	rs2204008	0.529	rs1315350	chr12:38164282	C/A	cg04568710	chr12:38710424	ALG10B	-0.37	-7.9	-0.34	2.03e-14	Bladder cancer;
LGG	cis	rs7737355	0.812	rs10463886	chr5:130758893	A/T	cg06307176	chr5:131281290	NA	-0.52	-8.89	-0.38	1.35e-17	Life satisfaction;
LGG	cis	rs7818345	0.649	rs13250181	chr8:19328766	G/A	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.49	-0.4	1.24e-19	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs8067545	0.641	rs203460	chr17:19815286	G/C	cg13482628	chr17:19912719	NA	0.52	9.56	0.41	7.14e-20	Schizophrenia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg04677470	chr13:22247804	FGF9	0.46	7.03	0.31	7.6e-12	Gut microbiome composition (summer);
LGG	cis	rs9291683	0.530	rs17246501	chr4:9985710	A/C	cg25986240	chr4:9926439	SLC2A9	-0.45	-9.77	-0.41	1.27e-20	Bone mineral density;
LGG	cis	rs10504229	0.683	rs72650847	chr8:58136825	C/T	cg24829409	chr8:58192753	C8orf71	-0.77	-10.36	-0.43	9.02e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs3733585	0.699	rs6834893	chr4:9959123	C/T	cg08250081	chr4:10125330	NA	-0.36	-6.9	-0.31	1.74e-11	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs769267	0.930	rs4808964	chr19:19603692	A/C	cg01262667	chr19:19385393	TM6SF2	-0.44	-11.08	-0.46	1.82e-25	Tonsillectomy;
LGG	cis	rs42648	0.596	rs194523	chr7:89860574	A/T	cg25739043	chr7:89950458	NA	-0.33	-6.91	-0.31	1.61e-11	Homocysteine levels;
LGG	cis	rs1865760	1.000	rs1865760	chr6:25916979	C/T	cg17691542	chr6:26056736	HIST1H1C	0.57	10.16	0.43	5.1e-22	Height;
LGG	cis	rs17030434	0.954	rs11724154	chr4:154753108	G/T	cg14289246	chr4:154710475	SFRP2	-0.71	-11.21	-0.46	5.49e-26	Electrocardiographic conduction measures;
LGG	cis	rs6952808	0.798	rs28970524	chr7:1927484	C/T	cg21782813	chr7:2030301	MAD1L1	0.5	12.05	0.49	2.93e-29	Bipolar disorder and schizophrenia;
LGG	trans	rs7829975	0.508	rs1594437	chr8:8825875	T/C	cg27411982	chr8:10470053	RP1L1	0.41	7.19	0.32	2.65e-12	Mood instability;
LGG	cis	rs2245008	0.774	rs253135	chr16:83978843	A/C	cg08589960	chr16:83986755	OSGIN1	0.45	7.28	0.32	1.46e-12	Pursuit maintenance gain;
LGG	cis	rs3820068	0.580	rs12760698	chr1:16009814	G/A	cg05660106	chr1:15850417	CASP9	0.76	14.03	0.55	1.57e-37	Systolic blood pressure;
LGG	cis	rs1799949	1.000	rs11658754	chr17:41292739	G/A	cg01879757	chr17:41196368	BRCA1	-0.43	-8.69	-0.37	6.44e-17	Menopause (age at onset);
LGG	cis	rs35146811	0.735	rs1636978	chr7:99813912	G/A	cg22906224	chr7:99728672	NA	-0.57	-9.32	-0.4	4.72e-19	Coronary artery disease;
LGG	cis	rs12477438	0.798	rs1993230	chr2:99686079	T/C	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.73	-12.59	-0.51	1.75e-31	Chronic sinus infection;
LGG	cis	rs4808199	0.689	rs12979148	chr19:19406869	T/C	cg10763598	chr19:19431466	KIAA0892;SF4	0.6	7.49	0.33	3.58e-13	Nonalcoholic fatty liver disease;
LGG	cis	rs7853377	0.546	rs7869321	chr9:86520782	C/T	cg12437157	chr9:86433764	GKAP1	0.38	6.66	0.3	7.56e-11	Height;
LGG	cis	rs1847505	0.609	rs9317154	chr13:61560533	A/G	cg25164009	chr13:61490935	NA	-0.6	-11.73	-0.48	5.29e-28	Polychlorinated biphenyl levels;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg04212338	chr11:65153918	FRMD8	-0.43	-7.11	-0.31	4.29e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs657075	0.697	rs34757387	chr5:131652677	G/T	cg20453264	chr5:131705742	SLC22A5	0.64	8.21	0.36	2.23e-15	Rheumatoid arthritis;
LGG	cis	rs17039065	1.000	rs4449483	chr4:109401379	C/A	cg16022748	chr4:109541635	LOC285456;RPL34	0.56	6.83	0.3	2.65e-11	Gut microbiome composition (summer);
LGG	cis	rs13314892	0.764	rs79658882	chr3:69881186	T/A	cg17445875	chr3:69859618	MITF	-0.4	-7.79	-0.34	4.44e-14	QRS complex (12-leadsum);
LGG	cis	rs7084402	0.934	rs1658441	chr10:60323021	G/C	cg07615347	chr10:60278583	BICC1	0.63	18.14	0.64	6.27e-56	Refractive error;
LGG	cis	rs769267	0.930	rs10282	chr19:19619317	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.21	0.43	3.31e-22	Tonsillectomy;
LGG	cis	rs644799	0.965	rs11021305	chr11:95498269	A/G	cg25622487	chr11:95524042	FAM76B;CEP57	0.78	13.7	0.54	4.05e-36	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1570884	0.890	rs7333969	chr13:50123317	C/T	cg11801959	chr13:50123613	RCBTB1	-0.39	-7.14	-0.31	3.74e-12	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs240764	0.817	rs240115	chr6:101053069	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.66	0.34	1.08e-13	Neuroticism;
LGG	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg14703610	chr5:56206110	C5orf35	0.46	8.09	0.35	5.25e-15	Coronary artery disease;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg01587390	chr19:10221818	PPAN-P2RY11;P2RY11;PPAN	0.38	6.65	0.3	8.44e-11	Menarche (age at onset);
LGG	trans	rs11875185	0.510	rs73451171	chr18:55617845	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.01	-0.39	5.38e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs524281	1.000	rs489337	chr11:65854561	A/G	cg14541915	chr11:65894463	PACS1	-0.3	-6.85	-0.3	2.37e-11	Electroencephalogram traits;
LGG	cis	rs28595532	1.000	rs55634130	chr4:119655093	C/T	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs2576037	0.796	rs2571020	chr18:44584189	A/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.41	6.75	0.3	4.41e-11	Personality dimensions;
LGG	cis	rs72945132	0.619	rs61887436	chr11:70243337	C/T	cg14191688	chr11:70257035	CTTN	0.59	8.63	0.37	1.02e-16	Coronary artery disease;
LGG	cis	rs2731664	0.792	rs2731662	chr5:176872494	C/T	cg23176889	chr5:176863531	GRK6	0.65	13.05	0.52	2.38e-33	Intelligence (multi-trait analysis);
LGG	cis	rs9911578	0.740	rs368243	chr17:56708979	T/C	cg12560992	chr17:57184187	TRIM37	0.62	10.35	0.43	9.97e-23	Intelligence (multi-trait analysis);
LGG	cis	rs1580019	0.587	rs10951338	chr7:32560089	A/G	cg06627557	chr7:32535165	LSM5;AVL9	1.09	27.63	0.79	5.57e-100	Cognitive ability;
LGG	cis	rs644799	0.862	rs1150361	chr11:95633805	G/A	cg25478527	chr11:95522999	CEP57;FAM76B	0.43	7.35	0.32	8.97e-13	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs17428076	0.793	rs72881938	chr2:172628752	C/G	cg21435375	chr2:172878103	MAP1D	0.4	8.69	0.37	6.32e-17	Myopia;
LGG	cis	rs2342371	0.816	rs11707744	chr3:196213855	C/G	cg15048948	chr3:196158458	UBXN7	-0.42	-6.93	-0.31	1.42e-11	Fat distribution (HIV);
LGG	cis	rs2033711	0.503	rs7254299	chr19:58884965	A/G	cg13877915	chr19:58951672	ZNF132	0.53	9.45	0.4	1.69e-19	Uric acid clearance;
LGG	cis	rs10464366	0.510	rs62442212	chr7:39146896	A/C	cg21665744	chr7:39171113	POU6F2	0.35	7.47	0.33	4.1e-13	IgG glycosylation;
LGG	cis	rs2439831	0.681	rs478104	chr15:43594900	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.94	12.52	0.5	3.47e-31	Lung cancer in ever smokers;
LGG	cis	rs17270561	0.636	rs9393671	chr6:25789189	G/C	cg03517284	chr6:25882590	NA	0.41	6.81	0.3	2.95e-11	Iron status biomarkers;
LGG	cis	rs28595532	0.920	rs115090643	chr4:119729825	C/T	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.48e-14	Cannabis dependence symptom count;
LGG	cis	rs4481887	0.893	rs1934544	chr1:248505582	G/A	cg00666640	chr1:248458726	OR2T12	0.55	8.98	0.39	6.98e-18	Common traits (Other);
LGG	cis	rs10892173	0.791	rs954319	chr11:117686194	A/G	cg21640587	chr11:117668038	DSCAML1	0.47	7.95	0.35	1.44e-14	Myopia;
LGG	cis	rs9768139	0.708	rs35057023	chr7:158114748	G/A	cg25566285	chr7:158114605	PTPRN2	0.91	20.51	0.69	5.76e-67	Calcium levels;
LGG	cis	rs780096	0.546	rs2293571	chr2:27729480	C/T	cg05484376	chr2:27715224	FNDC4	0.46	10.07	0.42	1.1e-21	Total body bone mineral density;
LGG	cis	rs6502050	0.799	rs8066370	chr17:80102105	T/C	cg19223190	chr17:80058835	NA	0.44	8.46	0.37	3.48e-16	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg21580998	chr1:227751410	ZNF678	0.44	6.74	0.3	4.76e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	0.580	rs10257426	chr7:1213694	G/A	cg02733842	chr7:1102375	C7orf50	0.56	8.72	0.38	4.85e-17	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs8133932	0.654	rs379493	chr21:47360778	G/C	cg11214348	chr21:47283868	PCBP3	-0.4	-7.08	-0.31	5.39e-12	Schizophrenia;
LGG	cis	rs12615966	0.932	rs60048061	chr2:105368969	G/A	cg16465502	chr2:105461796	NA	0.89	10.12	0.43	7.24e-22	Pancreatic cancer;
LGG	cis	rs17270561	0.609	rs7754733	chr6:25745049	C/G	cg16482183	chr6:26056742	HIST1H1C	0.5	7.95	0.35	1.4e-14	Iron status biomarkers;
LGG	cis	rs8070128	0.601	rs8080602	chr17:17954728	G/C	cg05444541	chr17:17804740	TOM1L2	0.7	16.53	0.61	1.44e-48	Total body bone mineral density;
LGG	cis	rs2228479	0.850	rs2283565	chr16:89827556	G/T	cg26513180	chr16:89883248	FANCA	1.01	9.72	0.41	1.84e-20	Skin colour saturation;
LGG	cis	rs9325144	0.555	rs1843867	chr12:38703855	A/G	cg13010199	chr12:38710504	ALG10B	-0.59	-11.82	-0.48	2.35e-28	Morning vs. evening chronotype;
LGG	cis	rs17376456	0.877	rs12716460	chr5:93416733	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	0.86	9.24	0.39	9.28e-19	Diabetic retinopathy;
LGG	trans	rs916888	0.821	rs199506	chr17:44859031	A/G	cg22433210	chr17:43662623	NA	-0.84	-13.56	-0.53	1.65e-35	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs4242434	0.819	rs7826059	chr8:22512068	T/C	cg03733263	chr8:22462867	KIAA1967	-1.02	-25.03	-0.76	4.46e-88	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs13132184	0.507	rs4832748	chr4:38056045	C/T	cg24826020	chr4:38070998	TBC1D1	-0.49	-8.19	-0.36	2.6e-15	Verbal declarative memory;
LGG	cis	rs2643217	0.953	rs903530	chr15:38999048	A/G	cg10631289	chr15:39006617	NA	0.42	7.41	0.33	5.87e-13	Bipolar disorder and schizophrenia;
LGG	cis	rs2032447	0.641	rs442601	chr6:25934524	G/A	cg18357526	chr6:26021779	HIST1H4A	0.84	15.38	0.58	1.96e-43	Intelligence (multi-trait analysis);
LGG	cis	rs4076764	0.881	rs10917758	chr1:163430652	G/A	cg24596788	chr1:163392923	NA	-0.65	-12.13	-0.49	1.29e-29	Motion sickness;
LGG	cis	rs2730245	0.527	rs2527197	chr7:158735260	G/A	cg24397884	chr7:158709396	WDR60	-1.12	-17.44	-0.63	9.62e-53	Height;
LGG	cis	rs9640161	0.789	rs13223702	chr7:150058968	G/A	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.61	-11.2	-0.46	6.09e-26	Blood protein levels;Circulating chemerin levels;
LGG	trans	rs853679	0.607	rs34765154	chr6:28130450	G/A	cg08344181	chr3:125677491	NA	-0.88	-8.88	-0.38	1.5e-17	Depression;
LGG	cis	rs877282	0.583	rs11253424	chr10:813426	C/T	cg01169559	chr10:831247	NA	0.48	9.39	0.4	2.65e-19	Uric acid levels;
LGG	cis	rs12421382	0.659	rs1837396	chr11:109389257	G/A	cg15948088	chr11:109293068	C11orf87	0.46	8.32	0.36	9.59e-16	Schizophrenia;
LGG	cis	rs9291683	0.588	rs2240722	chr4:10020757	A/G	cg16147221	chr4:10020634	SLC2A9	0.37	6.87	0.3	2.12e-11	Bone mineral density;
LGG	cis	rs2839186	0.771	rs13049175	chr21:47641326	G/A	cg12379764	chr21:47803548	PCNT	0.42	7.22	0.32	2.12e-12	Testicular germ cell tumor;
LGG	cis	rs12738007	0.967	rs12032476	chr1:29529943	C/T	cg01115565	chr1:29584222	PTPRU	-0.25	-6.75	-0.3	4.4e-11	Schizophrenia;
LGG	cis	rs10911251	0.546	rs1051473	chr1:183114146	T/C	cg15522984	chr1:182991683	LAMC1	0.43	8.58	0.37	1.41e-16	Colorectal cancer;
LGG	cis	rs17345786	0.906	rs59359251	chr3:101146362	A/C	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.54	7.86	0.34	2.62e-14	Colonoscopy-negative controls vs population controls;
LGG	cis	rs13096760	1	rs13096760	chr3:49476806	T/C	cg06212747	chr3:49208901	KLHDC8B	0.44	7.14	0.31	3.65e-12	Intelligence (multi-trait analysis);
LGG	cis	rs757278	0.591	rs34927137	chr7:117294730	C/T	cg10524701	chr7:117356490	CTTNBP2	0.42	7.47	0.33	3.93e-13	Response to methotrexate in juvenile idiopathic arthritis;
LGG	cis	rs8062405	0.754	rs149299	chr16:28485141	T/C	cg16576597	chr16:28551801	NUPR1	0.32	7.09	0.31	5.04e-12	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs4662750	0.580	rs4662742	chr2:128350744	C/A	cg10021288	chr2:128175891	PROC	0.37	6.96	0.31	1.2e-11	Renal cell carcinoma;
LGG	cis	rs763121	0.853	rs7289577	chr22:39042214	C/G	cg06022373	chr22:39101656	GTPBP1	0.87	17.76	0.64	3.47e-54	Menopause (age at onset);
LGG	trans	rs56114371	0.777	rs200481	chr6:27773832	A/T	cg01620082	chr3:125678407	NA	-0.79	-9.11	-0.39	2.52e-18	Breast cancer;
LGG	cis	rs977987	0.872	rs3743609	chr16:75467021	G/C	cg03315344	chr16:75512273	CHST6	0.52	10.28	0.43	1.86e-22	Dupuytren's disease;
LGG	cis	rs17270561	0.636	rs7775354	chr6:25745266	T/A	cg03264133	chr6:25882463	NA	-0.48	-7.73	-0.34	6.64e-14	Iron status biomarkers;
LGG	cis	rs7829975	0.600	rs1719381	chr8:8602344	T/C	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.19	-0.36	2.56e-15	Mood instability;
LGG	cis	rs9790314	1.000	rs456611	chr3:161097268	A/G	cg03342759	chr3:160939853	NMD3	-0.62	-10.57	-0.44	1.53e-23	Morning vs. evening chronotype;
LGG	cis	rs11123170	0.503	rs28679654	chr2:113967617	C/T	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	0.49	7.16	0.32	3.18e-12	Renal function-related traits (BUN);
LGG	cis	rs239198	0.578	rs13193416	chr6:101299602	A/T	cg09795085	chr6:101329169	ASCC3	0.44	7.23	0.32	1.95e-12	Menarche (age at onset);
LGG	trans	rs62103177	0.789	rs7242289	chr18:77603291	C/T	cg05926928	chr17:57297772	GDPD1	1.41	23.22	0.73	1.17e-79	Opioid sensitivity;
LGG	cis	rs9354308	0.764	rs1938109	chr6:66614727	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.67	-0.3	7.52e-11	Metabolite levels;
LGG	trans	rs853679	0.607	rs34166054	chr6:28065801	T/C	cg01620082	chr3:125678407	NA	-1.06	-10.43	-0.44	4.97e-23	Depression;
LGG	cis	rs2072499	0.966	rs2853646	chr1:156189626	C/T	cg24450063	chr1:156163899	SLC25A44	1.17	25.11	0.76	1.99e-88	Testicular germ cell tumor;
LGG	cis	rs9596863	0.898	rs7328896	chr13:54334206	A/T	ch.13.53330881F	chr13:54432880	NA	0.54	7.34	0.32	9.96e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs9322193	0.923	rs1080670	chr6:149941297	C/G	cg07701084	chr6:150067640	NUP43	0.7	13.7	0.54	4.26e-36	Lung cancer;
LGG	cis	rs2797369	0.570	rs2770333	chr6:101573555	C/T	cg27451362	chr6:101846650	GRIK2	0.56	8.23	0.36	1.89e-15	Renal function-related traits (eGRFcrea);
LGG	cis	rs5758659	0.657	rs5758587	chr22:42517636	C/G	cg15557168	chr22:42548783	NA	0.35	8.01	0.35	9.55e-15	Cognitive function;
LGG	cis	rs9858542	0.953	rs6809216	chr3:49412559	G/A	cg00383909	chr3:49044727	WDR6	0.45	7.39	0.32	6.72e-13	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs637571	0.522	rs528736	chr11:65705108	A/G	cg17985854	chr11:65770987	BANF1;EIF1AD	0.42	7.04	0.31	6.78e-12	Eosinophil percentage of white cells;
LGG	cis	rs7106204	0.514	rs12291514	chr11:24360203	T/C	ch.11.24196551F	chr11:24239977	NA	0.85	11.97	0.49	5.89e-29	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs10191773	0.589	rs11676628	chr2:112953355	A/G	cg04979063	chr2:113191202	RGPD5;RGPD8	-0.71	-8.79	-0.38	3e-17	Yeast infection;
LGG	cis	rs3764563	1.000	rs586608	chr19:15694168	C/T	cg20725493	chr19:15740067	CYP4F8	0.56	6.71	0.3	5.78e-11	Inflammatory biomarkers;
LGG	cis	rs539514	0.563	rs7991448	chr13:76334061	G/A	cg04757411	chr13:76259545	LMO7	-0.28	-7.03	-0.31	7.47e-12	Type 1 diabetes;
LGG	cis	rs9322193	0.923	rs10872649	chr6:150080590	T/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.19	-0.32	2.58e-12	Lung cancer;
LGG	cis	rs990171	0.955	rs6708413	chr2:103063369	C/T	cg05295703	chr2:102895712	NA	-0.53	-9.16	-0.39	1.67e-18	Lymphocyte counts;
LGG	cis	rs7249142	0.573	rs2238668	chr19:19282597	A/G	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.13	-0.35	3.84e-15	IgG glycosylation;
LGG	cis	rs11018904	0.608	rs35700249	chr11:89931927	A/C	cg16176437	chr11:89678848	NA	0.55	8.34	0.36	8.35e-16	Intelligence (multi-trait analysis);
LGG	cis	rs28386778	0.742	rs3020617	chr17:61947303	A/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.49	0.4	1.24e-19	Prudent dietary pattern;
LGG	cis	rs3206736	0.548	rs328902	chr7:35020843	C/T	cg13400248	chr7:35225412	NA	0.54	9.49	0.4	1.26e-19	Diastolic blood pressure;
LGG	cis	rs2836950	0.527	rs2836948	chr21:40599677	T/C	cg17971929	chr21:40555470	PSMG1	-0.52	-8.87	-0.38	1.63e-17	Menarche (age at onset);
LGG	cis	rs9419702	0.568	rs10782366	chr10:133557866	G/A	cg20568497	chr10:133558893	NA	0.34	7.4	0.33	6.32e-13	Survival in rectal cancer;
LGG	cis	rs9322193	0.810	rs62439811	chr6:149961552	C/T	cg00424166	chr6:150045504	NUP43	-0.35	-7.15	-0.32	3.51e-12	Lung cancer;
LGG	cis	rs10214930	0.697	rs12672811	chr7:27684883	T/C	cg22168087	chr7:27702803	HIBADH	0.45	6.74	0.3	4.79e-11	Hypospadias;
LGG	cis	rs10540	1.000	rs35811812	chr11:498442	G/A	cg03576123	chr11:487126	PTDSS2	-1.2	-16.14	-0.6	7.95e-47	Body mass index;
LGG	cis	rs9911578	0.900	rs717828	chr17:56535932	A/G	cg12560992	chr17:57184187	TRIM37	0.87	15.29	0.58	5.17e-43	Intelligence (multi-trait analysis);
LGG	cis	rs9517320	0.517	rs4772097	chr13:99194652	C/A	cg07423050	chr13:99094983	FARP1	-0.55	-10.74	-0.45	3.57e-24	Longevity;
LGG	cis	rs1865760	1.000	rs12209482	chr6:25909229	T/G	cg03264133	chr6:25882463	NA	-0.43	-7.7	-0.34	8.25e-14	Height;
LGG	cis	rs921968	0.541	rs634590	chr2:219372768	C/A	cg01130898	chr2:219473002	PLCD4	-0.42	-7.27	-0.32	1.58e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs11771526	0.681	rs62457535	chr7:32358710	C/G	cg27511599	chr7:32358540	NA	0.63	6.76	0.3	4.06e-11	Body mass index;
LGG	cis	rs17092148	0.652	rs61341205	chr20:33072578	A/G	cg12302830	chr20:33297742	TP53INP2	0.42	6.95	0.31	1.28e-11	Neuroticism;
LGG	trans	rs7937682	0.632	rs2070894	chr11:111780837	G/A	cg18187862	chr3:45730750	SACM1L	-0.6	-9.68	-0.41	2.75e-20	Primary sclerosing cholangitis;
LGG	cis	rs9463078	0.739	rs1293467	chr6:44769204	C/G	cg25276700	chr6:44698697	NA	0.43	9.18	0.39	1.49e-18	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs4253772	0.591	rs11703848	chr22:46685131	A/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.78e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg18357645	chr12:58087776	OS9	0.4	6.69	0.3	6.37e-11	Multiple sclerosis;
LGG	cis	rs10267417	0.603	rs7791170	chr7:19905411	T/A	cg05791153	chr7:19748676	TWISTNB	0.54	7.11	0.31	4.51e-12	Night sleep phenotypes;
LGG	cis	rs2228479	0.850	rs11649162	chr16:89807131	C/A	cg27400746	chr16:89904261	SPIRE2	-1.14	-17.01	-0.62	9.12e-51	Skin colour saturation;
LGG	trans	rs9329221	0.905	rs6601451	chr8:10243681	C/G	cg15556689	chr8:8085844	FLJ10661	-0.54	-9.88	-0.42	5.34e-21	Neuroticism;
LGG	cis	rs7824557	0.527	rs2572449	chr8:11239137	A/G	cg15596359	chr8:11213517	TDH	-0.4	-8.32	-0.36	9.74e-16	Retinal vascular caliber;
LGG	cis	rs1799949	1.000	rs11653253	chr17:41182662	G/A	cg04503457	chr17:41445688	NA	-0.39	-9.18	-0.39	1.49e-18	Menopause (age at onset);
LGG	cis	rs2980439	0.818	rs2948294	chr8:8094961	A/G	cg06636001	chr8:8085503	FLJ10661	0.68	14.07	0.55	1.13e-37	Neuroticism;
LGG	cis	rs644799	0.965	rs545342	chr11:95545369	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.87	0.34	2.56e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs13314892	0.881	rs62250970	chr3:69815837	G/A	cg17445875	chr3:69859618	MITF	-0.35	-7.12	-0.31	4.12e-12	QRS complex (12-leadsum);
LGG	cis	rs4689592	0.622	rs2276968	chr4:7070118	T/G	cg06697600	chr4:7070879	GRPEL1	-0.56	-9.19	-0.39	1.31e-18	Monocyte percentage of white cells;
LGG	cis	rs1799949	1.000	rs4793194	chr17:41218333	G/A	cg25072359	chr17:41440525	NA	0.52	10.08	0.42	9.57e-22	Menopause (age at onset);
LGG	cis	rs1552244	1.000	rs61052895	chr3:10147516	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.16	19.91	0.68	3.69e-64	Alzheimer's disease;
LGG	cis	rs780096	0.527	rs59644396	chr2:27646083	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.71	0.41	2.08e-20	Total body bone mineral density;
LGG	cis	rs12971120	0.947	rs7241558	chr18:72169267	A/T	cg26446133	chr18:72167187	CNDP2	-0.74	-16.86	-0.62	4.39e-50	Refractive error;
LGG	cis	rs9358372	0.711	rs9366367	chr6:20887326	A/T	cg13405222	chr6:20811065	CDKAL1	-0.6	-12.56	-0.5	2.32e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs713587	0.566	rs497567	chr2:25335089	G/A	cg04586622	chr2:25135609	ADCY3	-0.32	-7.83	-0.34	3.36e-14	Body mass index in non-asthmatics;
LGG	cis	rs72827839	0.846	rs56407566	chr17:46148155	C/T	cg02219949	chr17:45927392	SP6	0.54	8.13	0.35	4.06e-15	Ease of getting up in the morning;
LGG	cis	rs559928	0.556	rs734762	chr11:63912189	G/C	cg05555928	chr11:63887634	MACROD1	-0.78	-10.43	-0.44	4.9e-23	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs873946	0.648	rs12767283	chr10:134557094	C/G	cg27286337	chr10:134555280	INPP5A	0.89	13.01	0.52	3.28e-33	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs11190604	1.000	rs11190572	chr10:102232879	A/G	cg07080220	chr10:102295463	HIF1AN	0.64	11.01	0.46	3.37e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs643506	0.790	rs688095	chr11:111678771	T/C	cg09085632	chr11:111637200	PPP2R1B	0.43	6.97	0.31	1.13e-11	Breast cancer;
LGG	cis	rs4728302	0.594	rs6978383	chr7:133721697	G/A	cg10665199	chr7:133106180	EXOC4	0.41	6.98	0.31	1.04e-11	Intelligence;Intelligence (multi-trait analysis);
LGG	cis	rs7223966	1.000	rs13380863	chr17:61780793	G/A	cg23090583	chr17:61904693	PSMC5;FTSJ3	0.67	10.96	0.45	5e-25	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9747201	0.862	rs11651738	chr17:80178691	A/T	cg13939156	chr17:80058883	NA	-0.42	-7.32	-0.32	1.13e-12	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg20349687	chr2:88927127	EIF2AK3	-0.43	-7.16	-0.32	3.1e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs13108904	0.870	rs12499546	chr4:1255194	C/T	cg05025164	chr4:1340916	KIAA1530	0.43	7.2	0.32	2.39e-12	Obesity-related traits;
LGG	cis	rs2576037	0.583	rs9304336	chr18:44461687	T/C	cg01059449	chr18:44338099	ST8SIA5	-0.39	-8.47	-0.37	3.19e-16	Personality dimensions;
LGG	cis	rs6061231	0.583	rs2427313	chr20:60970675	G/A	cg23531748	chr20:60969906	CABLES2	0.43	7.37	0.32	7.68e-13	Colorectal cancer;
LGG	cis	rs10504229	0.639	rs11781834	chr8:58133422	C/T	cg20607798	chr8:58055168	NA	0.58	6.68	0.3	6.84e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.754	rs11724409	chr4:120252361	A/G	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs2173063	1.000	rs74029119	chr15:93129628	C/T	cg07052004	chr15:93132129	NA	0.66	7.39	0.32	7e-13	Subcutaneous adipose tissue;
LGG	cis	rs62238980	0.614	rs74450143	chr22:32416692	A/G	cg02631450	chr22:32366979	NA	0.99	9.4	0.4	2.45e-19	Childhood ear infection;
LGG	cis	rs35123781	1.000	rs35123781	chr5:139065180	A/G	cg21230503	chr5:139085173	NA	0.33	7.7	0.34	8.53e-14	Schizophrenia;
LGG	cis	rs61931739	0.649	rs708144	chr12:33731158	T/C	cg06521331	chr12:34319734	NA	-0.39	-6.86	-0.3	2.23e-11	Morning vs. evening chronotype;
LGG	cis	rs2842992	0.830	rs2758320	chr6:160070676	T/G	cg11366901	chr6:160182831	ACAT2	1.0	15.12	0.57	2.89e-42	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs7765175	0.813	rs17177955	chr6:113639421	G/A	cg26552650	chr6:113682475	NA	-0.32	-6.9	-0.31	1.68e-11	Coronary artery calcification;
LGG	cis	rs9858542	0.903	rs9875617	chr3:49634696	G/A	cg07274523	chr3:49395745	GPX1	0.57	9.43	0.4	2.01e-19	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs17826219	0.568	rs9903854	chr17:29153998	C/T	cg01831904	chr17:28903510	LRRC37B2	-0.77	-9.3	-0.4	5.56e-19	Body mass index;
LGG	cis	rs7633857	0.532	rs9839984	chr3:160768912	C/T	cg03342759	chr3:160939853	NMD3	-0.59	-10.05	-0.42	1.26e-21	Educational attainment (years of education);
LGG	cis	rs7503807	0.515	rs12939413	chr17:78679449	C/T	cg08454507	chr17:78755406	RPTOR	-0.47	-9.35	-0.4	3.66e-19	Obesity;
LGG	cis	rs2599510	0.811	rs437764	chr2:32516378	C/T	cg02381751	chr2:32503542	YIPF4	0.52	8.4	0.36	5.36e-16	Interleukin-18 levels;
LGG	cis	rs1577917	0.958	rs7747897	chr6:86647349	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.57	-9.6	-0.41	5.25e-20	Response to antipsychotic treatment;
LGG	cis	rs6463523	0.815	rs66886645	chr7:763853	C/A	cg14391382	chr7:866102	UNC84A	0.54	9.94	0.42	3.12e-21	Subjective well-being;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg09699651	chr6:150184138	LRP11	0.5	8.75	0.38	3.86e-17	Lung cancer;
LGG	trans	rs7829975	0.688	rs6601703	chr8:8380224	A/G	cg19847130	chr8:10466454	RP1L1	-0.32	-7.21	-0.32	2.24e-12	Mood instability;
LGG	cis	rs12681288	0.748	rs7000148	chr8:1016383	G/C	cg15309053	chr8:964076	NA	0.39	8.02	0.35	8.71e-15	Schizophrenia;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg11062466	chr8:58055876	NA	0.44	7.78	0.34	4.82e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs597539	0.652	rs602805	chr11:68662076	A/T	cg06112835	chr11:68658793	MRPL21	0.6	9.82	0.42	8.31e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs721917	0.565	rs2255601	chr10:81704559	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.47	-0.33	4.02e-13	Chronic obstructive pulmonary disease;
LGG	cis	rs2404602	0.692	rs12594556	chr15:77165363	G/A	cg23625390	chr15:77176239	SCAPER	0.47	9.29	0.4	6.2800000000000005e-19	Blood metabolite levels;
LGG	cis	rs10911232	0.507	rs4129857	chr1:183004547	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.95	0.42	3e-21	Hypertriglyceridemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg15731816	chr14:75230414	YLPM1	0.53	8.49	0.37	2.85e-16	Gut microbiome composition (summer);
LGG	cis	rs829402	1.000	rs829396	chr1:22003793	A/G	cg20288655	chr1:21985693	RAP1GAP	0.71	11.08	0.46	1.84e-25	High light scatter reticulocyte count;
LGG	cis	rs10504229	0.773	rs1874374	chr8:58194422	A/G	cg24829409	chr8:58192753	C8orf71	-0.85	-11.91	-0.48	1.06e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs67460515	0.892	rs2100238	chr3:161058055	T/A	cg04691961	chr3:161091175	C3orf57	-0.47	-9.7	-0.41	2.22e-20	Parkinson's disease;
LGG	cis	rs7222240	1.000	rs2337437	chr17:43096229	G/T	cg24806326	chr17:43207588	PLCD3	0.47	7.91	0.35	1.9e-14	Craniofacial microsomia;
LGG	cis	rs1639906	0.965	rs1637750	chr7:2227811	A/G	cg02951883	chr7:2050386	MAD1L1	0.39	7.27	0.32	1.53e-12	Colonoscopy-negative controls vs population controls;
LGG	cis	rs10089	0.951	rs736969	chr5:127466347	G/C	cg25462716	chr5:127418816	SLC12A2;FLJ33630	0.77	11.93	0.48	8.44e-29	Ileal carcinoids;
LGG	cis	rs7647973	0.961	rs10154992	chr3:49276077	C/T	cg06212747	chr3:49208901	KLHDC8B	0.53	8.31	0.36	1.1e-15	Menarche (age at onset);
LGG	cis	rs548181	0.736	rs1941558	chr11:125425606	C/T	cg03464685	chr11:125439445	EI24	1.41	21.41	0.71	3.29e-71	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg26384229	chr12:38710491	ALG10B	0.75	14.73	0.56	1.49e-40	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.718	rs1165160	chr6:25864456	A/G	cg18357526	chr6:26021779	HIST1H4A	0.62	11.06	0.46	2.21e-25	Blood metabolite levels;
LGG	cis	rs2133450	0.712	rs1546236	chr3:7366676	G/A	cg19930620	chr3:7340148	GRM7	-0.36	-7.93	-0.35	1.64e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs6502050	0.731	rs35156322	chr17:80096323	T/C	cg07959490	chr17:80112427	CCDC57	-0.47	-9.37	-0.4	3.28e-19	Life satisfaction;
LGG	cis	rs6500602	0.964	rs2304633	chr16:4496973	T/A	cg08645402	chr16:4508243	NA	0.48	8.79	0.38	2.92e-17	Schizophrenia;
LGG	cis	rs7552404	0.731	rs931507	chr1:76401577	G/A	cg10523679	chr1:76189770	ACADM	-0.73	-11.49	-0.47	4.89e-27	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg13206674	chr6:150067644	NUP43	0.58	12.61	0.51	1.53e-31	Lung cancer;
LGG	cis	rs4820294	1.000	rs713835	chr22:38064650	C/T	cg26138144	chr22:38071188	LGALS1	0.91	24.34	0.75	7.06e-85	Fat distribution (HIV);
LGG	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg11890956	chr21:40555474	PSMG1	1.14	26.05	0.77	9.27e-93	Cognitive function;
LGG	trans	rs804280	1.000	rs804280	chr8:11612698	G/T	cg02002194	chr4:3960332	NA	-0.48	-8.94	-0.38	9.55e-18	Myopia (pathological);
LGG	cis	rs34421088	0.576	rs2572436	chr8:11099209	C/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.23	-0.32	2.06e-12	Neuroticism;
LGG	cis	rs9309711	0.560	rs6548164	chr2:3472665	C/T	cg10845886	chr2:3471009	TTC15	0.48	9.61	0.41	4.72e-20	Neurofibrillary tangles;
LGG	cis	rs1908814	0.516	rs11250178	chr8:11800234	A/C	cg24623649	chr8:11872141	NA	0.3	7.03	0.31	7.44e-12	Neuroticism;
LGG	cis	rs13102973	0.646	rs7670551	chr4:135895130	C/T	cg14419869	chr4:135874104	NA	0.47	7.97	0.35	1.22e-14	Subjective well-being;
LGG	cis	rs28595532	0.841	rs115851302	chr4:119776504	C/T	cg11846333	chr4:119757529	SEC24D	0.81	7.74	0.34	6.29e-14	Cannabis dependence symptom count;
LGG	cis	rs17666538	0.585	rs336437	chr8:636251	A/C	cg23958373	chr8:599963	NA	1.13	11.45	0.47	6.96e-27	IgG glycosylation;
LGG	cis	rs4639966	0.836	rs7124498	chr11:118616253	G/A	cg20309703	chr11:118481025	PHLDB1	-0.48	-7.24	-0.32	1.84e-12	Systemic lupus erythematosus;
LGG	cis	rs240764	0.635	rs12664707	chr6:100919579	A/C	cg21058520	chr6:100914733	NA	0.45	7.93	0.35	1.68e-14	Neuroticism;
LGG	trans	rs11782517	0.920	rs13248589	chr8:10105599	C/T	cg16141378	chr3:129829833	LOC729375	-0.36	-6.74	-0.3	4.6e-11	Nose size;
LGG	cis	rs11239187	0.586	rs12254041	chr10:45079025	G/A	cg03916630	chr10:45065415	NA	0.35	8.47	0.37	3.29e-16	Body mass index;
LGG	trans	rs11098499	0.818	rs12498599	chr4:120468503	C/T	cg25214090	chr10:38739885	LOC399744	0.65	11.54	0.47	2.96e-27	Corneal astigmatism;
LGG	cis	rs8072100	0.875	rs9635762	chr17:45648446	A/C	cg08085267	chr17:45401833	C17orf57	0.58	11.47	0.47	5.64e-27	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	trans	rs7395662	1.000	rs4882136	chr11:48615311	T/A	cg00717180	chr2:96193071	NA	-0.43	-7.49	-0.33	3.43e-13	HDL cholesterol;
LGG	trans	rs7829975	0.593	rs2921051	chr8:8320104	C/A	cg27411982	chr8:10470053	RP1L1	0.43	7.56	0.33	2.23e-13	Mood instability;
LGG	cis	rs7586879	0.575	rs6744205	chr2:25133148	T/C	cg04586622	chr2:25135609	ADCY3	0.47	12.88	0.51	1.12e-32	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01087382	chr6:91297190	MAP3K7	0.47	8.07	0.35	6.24e-15	Gut microbiota (bacterial taxa);
LGG	cis	rs2731664	0.792	rs335468	chr5:176892349	A/G	cg23176889	chr5:176863531	GRK6	0.64	13.07	0.52	1.81e-33	Intelligence (multi-trait analysis);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg14490972	chr6:43484812	POLR1C;YIPF3	0.54	9.41	0.4	2.37e-19	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.835	rs8075086	chr17:80092649	A/G	cg07959490	chr17:80112427	CCDC57	-0.47	-9.34	-0.4	4e-19	Life satisfaction;
LGG	cis	rs1799949	0.683	rs55737636	chr17:41264739	C/T	cg25072359	chr17:41440525	NA	0.5	9.92	0.42	3.81e-21	Menopause (age at onset);
LGG	trans	rs1997103	1.000	rs6973337	chr7:55411534	T/C	cg20935933	chr6:143382018	AIG1	0.55	8.54	0.37	1.9e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs6988985	0.626	rs6392	chr8:143956925	T/C	cg10324643	chr8:143916377	GML	0.4	8.07	0.35	6.03e-15	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs4332037	0.762	rs11770612	chr7:1915493	A/C	cg12432903	chr7:1882776	MAD1L1	0.48	7.15	0.32	3.48e-12	Bipolar disorder;
LGG	cis	rs2455799	0.613	rs2470547	chr3:15737610	T/C	cg16303742	chr3:15540471	COLQ	-0.4	-7.8	-0.34	4e-14	Mean platelet volume;
LGG	cis	rs28386778	0.897	rs2727290	chr17:61894728	G/T	cg06601766	chr17:61851465	DDX42;CCDC47	0.43	7.05	0.31	6.72e-12	Prudent dietary pattern;
LGG	cis	rs734999	0.611	rs10797431	chr1:2501222	G/T	cg18854424	chr1:2615690	NA	0.36	7.46	0.33	4.43e-13	Ulcerative colitis;
LGG	cis	rs6988985	0.765	rs6471581	chr8:143986919	C/T	cg10324643	chr8:143916377	GML	0.39	7.8	0.34	4.28e-14	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs2173063	1.000	rs74029108	chr15:93125767	C/T	cg07052004	chr15:93132129	NA	0.62	6.99	0.31	9.58e-12	Subcutaneous adipose tissue;
LGG	cis	rs6580649	0.941	rs72644842	chr12:48448274	A/G	cg24011408	chr12:48396354	COL2A1	-0.54	-6.78	-0.3	3.6e-11	Lung cancer;
LGG	cis	rs2842992	0.692	rs1128661	chr6:160211554	T/G	cg11366901	chr6:160182831	ACAT2	0.9	14.58	0.56	6.88e-40	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs9381040	0.610	rs2057002	chr6:41022962	G/T	cg04346459	chr6:41068666	NFYA;LOC221442	-0.38	-6.79	-0.3	3.44e-11	Alzheimer's disease (late onset);
LGG	cis	rs7208859	0.623	rs11657777	chr17:29091785	T/C	cg19761014	chr17:28927070	LRRC37B2	0.62	7.33	0.32	1e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs4925386	1.000	rs4925389	chr20:60922512	G/A	cg24112000	chr20:60950667	NA	0.37	8.72	0.38	5.02e-17	Colorectal cancer;Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs709400	0.628	rs7154246	chr14:103876794	G/A	cg12935359	chr14:103987150	CKB	0.4	6.67	0.3	7.33e-11	Body mass index;
LGG	cis	rs9467711	0.591	rs13196552	chr6:25974204	A/G	cg21479132	chr6:26055353	NA	0.82	7.91	0.34	1.98e-14	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6558530	0.666	rs6558520	chr8:1697573	T/C	cg25947184	chr8:1697459	NA	0.47	8.2	0.36	2.41e-15	Systolic blood pressure;
LGG	cis	rs4268898	0.636	rs72787383	chr2:24583861	G/A	cg06627628	chr2:24431161	ITSN2	-0.78	-12.51	-0.5	3.95e-31	Asthma;
LGG	cis	rs10779751	0.575	rs2791655	chr1:11128654	A/G	cg08854313	chr1:11322531	MTOR	-0.65	-13.45	-0.53	4.82e-35	Body mass index;
LGG	cis	rs1005277	0.505	rs7069702	chr10:38247359	G/T	cg25427524	chr10:38739819	LOC399744	0.69	14.12	0.55	6.65e-38	Extrinsic epigenetic age acceleration;
LGG	cis	rs9926296	0.643	rs12596429	chr16:89841374	T/C	cg23057051	chr16:89984268	MC1R	-0.35	-6.89	-0.3	1.86e-11	Vitiligo;
LGG	cis	rs7927592	0.871	rs11228284	chr11:68322767	A/T	cg01657329	chr11:68192670	LRP5	-0.49	-8.37	-0.36	6.77e-16	Total body bone mineral density;
LGG	cis	rs11792861	0.926	rs59904140	chr9:111910051	C/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.56	8.54	0.37	2e-16	Menarche (age at onset);
LGG	cis	rs9487051	0.768	rs463503	chr6:109525757	T/C	cg21918786	chr6:109611834	NA	-0.39	-7.09	-0.31	5e-12	Reticulocyte fraction of red cells;
LGG	cis	rs858239	0.600	rs4409314	chr7:23127952	T/C	cg23682824	chr7:23144976	KLHL7	0.45	7.73	0.34	6.9e-14	Cerebrospinal fluid biomarker levels;
LGG	cis	rs4927850	0.918	rs4361313	chr3:195752260	A/G	cg19984853	chr3:195474125	MUC4	-0.38	-6.73	-0.3	5.09e-11	Pancreatic cancer;
LGG	cis	rs6089584	0.962	rs6142913	chr20:60566950	A/G	cg06108461	chr20:60628389	TAF4	-0.9	-16.63	-0.61	5.18e-49	Body mass index;
LGG	cis	rs9309473	0.950	rs10198549	chr2:73794404	A/G	cg20560298	chr2:73613845	ALMS1	-0.47	-7.68	-0.34	9.64e-14	Metabolite levels;
LGG	cis	rs1218582	0.710	rs7553195	chr1:154837796	T/C	cg24250549	chr1:154909240	PMVK	0.73	14.57	0.56	7.42e-40	Prostate cancer;
LGG	cis	rs1129187	0.967	rs3805952	chr6:42937126	C/T	cg02353165	chr6:42928485	GNMT	0.52	16.02	0.6	2.93e-46	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs7618915	0.547	rs62255362	chr3:52699741	C/G	cg18099408	chr3:52552593	STAB1	-0.36	-7.13	-0.31	3.86e-12	Bipolar disorder;
LGG	cis	rs1862618	0.853	rs1559282	chr5:56099375	T/A	cg17809284	chr5:56205270	C5orf35	-0.49	-8.07	-0.35	6.19e-15	Initial pursuit acceleration;
LGG	cis	rs12493885	0.818	rs10935971	chr3:153773945	C/T	cg12800244	chr3:153838788	SGEF	-0.82	-9.1	-0.39	2.7e-18	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs755249	0.567	rs4660603	chr1:39736334	C/G	cg18385671	chr1:39797026	MACF1	-0.41	-7.35	-0.32	9.35e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs12643440	0.538	rs4435747	chr4:17139645	C/T	cg22650099	chr4:17144496	NA	-0.5	-8.62	-0.37	1.08e-16	Metabolite levels (Pyroglutamine);
LGG	cis	rs4589502	0.512	rs4395023	chr15:67097208	G/A	cg09911534	chr15:67153556	NA	-0.46	-7.19	-0.32	2.66e-12	Lung cancer (smoking interaction);
LGG	cis	rs2304069	0.954	rs1469691	chr5:149386716	G/A	cg10852222	chr5:149380144	HMGXB3;TIGD6	0.6	7.82	0.34	3.51e-14	HIV-1 control;
LGG	cis	rs6964587	1.000	rs13230588	chr7:91615427	C/A	cg17063962	chr7:91808500	NA	0.48	8.52	0.37	2.29e-16	Breast cancer;
LGG	cis	rs9309473	1.000	rs6756987	chr2:73687077	G/T	cg20560298	chr2:73613845	ALMS1	-0.45	-7.5	-0.33	3.22e-13	Metabolite levels;
LGG	trans	rs11039798	0.588	rs10838979	chr11:48626810	T/G	cg03929089	chr4:120376271	NA	0.71	9.79	0.41	1.05e-20	Axial length;
LGG	cis	rs4481887	0.741	rs28468416	chr1:248564451	G/T	cg01631408	chr1:248437212	OR2T33	-0.39	-6.94	-0.31	1.31e-11	Common traits (Other);
LGG	cis	rs10504229	0.679	rs11781858	chr8:58038406	C/T	cg22535103	chr8:58192502	C8orf71	-0.84	-10.8	-0.45	2.04e-24	Developmental language disorder (linguistic errors);
LGG	cis	rs3736594	0.722	rs12993377	chr2:27952767	G/C	cg27432699	chr2:27873401	GPN1	-0.58	-9.34	-0.4	4.04e-19	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs910316	1.000	rs12889309	chr14:75593902	C/T	cg06637938	chr14:75390232	RPS6KL1	0.56	10.31	0.43	1.39e-22	Height;
LGG	cis	rs2832077	0.943	rs2832094	chr21:30165910	G/A	cg03476357	chr21:30257390	N6AMT1	-0.55	-8.38	-0.36	6.4e-16	Cognitive test performance;
LGG	cis	rs734999	0.566	rs10752747	chr1:2524915	G/T	cg20673091	chr1:2541236	MMEL1	0.8	18.61	0.65	4.22e-58	Ulcerative colitis;
LGG	cis	rs12282928	0.959	rs7124318	chr11:48338030	C/T	cg26585981	chr11:48327164	OR4S1	0.45	7.23	0.32	1.96e-12	Migraine - clinic-based;
LGG	cis	rs4727027	0.866	rs2373438	chr7:148780287	C/A	cg23583168	chr7:148888333	NA	-0.86	-16.44	-0.61	3.48e-48	Eosinophil counts;Sum eosinophil basophil counts;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;Eosinophil percentage of white cells;
LGG	cis	rs6502050	0.731	rs11867299	chr17:80088675	C/A	cg10505658	chr17:80084571	CCDC57	-0.41	-8.38	-0.36	6.38e-16	Life satisfaction;
LGG	cis	rs875971	1.000	rs6946143	chr7:65579722	A/C	cg18252515	chr7:66147081	NA	-0.42	-6.99	-0.31	9.46e-12	Aortic root size;
LGG	cis	rs10504229	0.683	rs7827014	chr8:58132230	G/A	cg08677398	chr8:58056175	NA	0.5	7.97	0.35	1.27e-14	Developmental language disorder (linguistic errors);
LGG	cis	rs28386778	0.897	rs1877318	chr17:61819960	G/A	cg26338869	chr17:61819248	STRADA	0.59	9.91	0.42	4.12e-21	Prudent dietary pattern;
LGG	trans	rs12310956	0.532	rs11608842	chr12:33951121	C/T	cg26384229	chr12:38710491	ALG10B	0.71	14.08	0.55	9.48e-38	Morning vs. evening chronotype;
LGG	cis	rs9486715	0.867	rs12207471	chr6:96963782	A/G	cg18709589	chr6:96969512	KIAA0776	0.42	8.21	0.36	2.19e-15	Headache;
LGG	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg19748678	chr4:122722346	EXOSC9	0.67	13.49	0.53	3.22e-35	Type 2 diabetes;
LGG	cis	rs7246760	1.000	rs59867671	chr19:9933558	G/C	cg16876255	chr19:9731953	ZNF561	0.78	7.21	0.32	2.25e-12	Pursuit maintenance gain;
LGG	cis	rs10949662	1.000	rs11765189	chr7:157535977	A/G	cg01625945	chr7:157512322	PTPRN2	-0.33	-6.98	-0.31	1.05e-11	Intelligence (multi-trait analysis);
LGG	cis	rs3858526	0.676	rs10838772	chr11:5895754	T/C	cg13902645	chr11:5959945	NA	-0.66	-10.18	-0.43	4.24e-22	DNA methylation (variation);
LGG	cis	rs365132	0.875	rs353491	chr5:176432947	C/G	cg16309518	chr5:176445507	NA	-0.52	-11.55	-0.47	2.75e-27	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs2404602	0.735	rs4886800	chr15:76678692	A/G	cg15268244	chr15:77196840	NA	0.38	7.86	0.34	2.76e-14	Blood metabolite levels;
LGG	cis	rs1580019	0.587	rs7806941	chr7:32553319	G/T	cg06133097	chr7:32552212	AVL9	-0.39	-7.41	-0.33	6.22e-13	Cognitive ability;
LGG	trans	rs9467711	0.606	rs9379856	chr6:26366836	A/C	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs28386778	0.799	rs2727322	chr17:61921706	G/A	cg17202724	chr17:61916730	SMARCD2	-0.62	-15.12	-0.57	2.91e-42	Prudent dietary pattern;
LGG	cis	rs11711311	0.747	rs11928494	chr3:113343219	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.4	-7.21	-0.32	2.29e-12	IgG glycosylation;
LGG	cis	rs4774899	0.932	rs5014892	chr15:57553674	C/G	cg08128148	chr15:57256372	TCF12	-0.31	-7.25	-0.32	1.74e-12	Urinary tract infection frequency;
LGG	cis	rs899997	1.000	rs11072794	chr15:79006582	A/G	cg22753661	chr15:79092743	ADAMTS7	0.41	6.95	0.31	1.21e-11	Coronary artery disease or large artery stroke;
LGG	cis	rs2839186	0.872	rs13052495	chr21:47707474	G/A	cg08742575	chr21:47604166	C21orf56	0.47	8.17	0.35	3.05e-15	Testicular germ cell tumor;
LGG	cis	rs12142240	0.698	rs6696777	chr1:46810970	A/G	cg25706281	chr1:46860511	FAAH	-0.29	-7.02	-0.31	7.82e-12	Menopause (age at onset);
LGG	cis	rs4862750	0.872	rs6811569	chr4:187897988	A/G	cg07414643	chr4:187882934	NA	-0.55	-11.49	-0.47	4.59e-27	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7998202	0.667	rs282578	chr13:113358584	A/G	cg17218041	chr13:113365319	ATP11A	-0.45	-7.46	-0.33	4.34e-13	Glycated hemoglobin levels;
LGG	cis	rs80282103	0.618	rs74117850	chr10:1165777	T/C	cg08668510	chr10:1095578	IDI1	0.8	7.71	0.34	7.7e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs12956009	0.583	rs9653016	chr18:44894189	G/A	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.43	7.05	0.31	6.4e-12	Educational attainment (years of education);
LGG	cis	rs1908814	0.516	rs13279577	chr8:11793096	C/G	cg24623649	chr8:11872141	NA	0.29	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs155076	0.938	rs485361	chr13:21845826	G/T	cg25811766	chr13:21894605	NA	-0.55	-7.38	-0.32	7.19e-13	White matter hyperintensity burden;
LGG	cis	rs7833790	0.777	rs1005850	chr8:82692255	G/A	cg17211192	chr8:82754475	SNX16	-0.74	-11.5	-0.47	4.2e-27	Diastolic blood pressure;
LGG	cis	rs35740288	0.770	rs10520592	chr15:86114142	G/C	cg04173714	chr15:86211321	AKAP13	0.48	8.84	0.38	2.09e-17	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs4330281	0.626	rs9815204	chr3:17631880	C/T	cg20981856	chr3:17787350	NA	0.39	7.12	0.31	4.24e-12	Schizophrenia;
LGG	cis	rs3858526	0.834	rs7128847	chr11:6003111	C/T	cg25319279	chr11:5960081	NA	-0.52	-8.21	-0.36	2.18e-15	DNA methylation (variation);
LGG	cis	rs4689592	0.523	rs4256224	chr4:7074583	T/C	cg03847636	chr4:7070632	GRPEL1	-0.49	-6.83	-0.3	2.69e-11	Monocyte percentage of white cells;
LGG	trans	rs75804782	0.521	rs56121087	chr2:239435766	A/G	cg01134436	chr17:81009848	B3GNTL1	0.79	8.68	0.37	7.02e-17	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs11676348	0.846	rs13009946	chr2:219007752	A/C	cg00012203	chr2:219082015	ARPC2	-0.55	-9.84	-0.42	7.42e-21	Ulcerative colitis;
LGG	trans	rs7618501	1.000	rs11130221	chr3:49819102	C/G	cg21582582	chr3:182698605	DCUN1D1	0.52	9.74	0.41	1.66e-20	Intelligence (multi-trait analysis);
LGG	cis	rs709400	0.628	rs12879085	chr14:103874420	G/A	cg26031613	chr14:104095156	KLC1	-0.8	-14.36	-0.55	6.39e-39	Body mass index;
LGG	cis	rs2073300	0.609	rs17757228	chr20:23351288	A/T	cg12062639	chr20:23401060	NAPB	0.93	9.03	0.39	4.52e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs881375	0.967	rs1008382	chr9:123681255	C/G	cg09419670	chr9:123605666	PSMD5;LOC253039	0.65	12.21	0.49	6.51e-30	Rheumatoid arthritis;
LGG	trans	rs10242455	0.557	rs73403272	chr7:99134208	T/G	cg09045935	chr12:6379348	NA	0.89	7.84	0.34	3.04e-14	Blood metabolite levels;
LGG	cis	rs9596863	0.634	rs9316653	chr13:54292061	A/T	ch.13.53330881F	chr13:54432880	NA	0.47	7.63	0.33	1.39e-13	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs3768617	0.565	rs2027080	chr1:183074415	C/T	cg07928641	chr1:182991847	LAMC1	0.44	8.79	0.38	2.95e-17	Fuchs's corneal dystrophy;
LGG	cis	rs10504229	0.679	rs1442125	chr8:58036258	A/C	cg22535103	chr8:58192502	C8orf71	0.76	10.24	0.43	2.61e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs801193	0.660	rs10950049	chr7:66230860	T/C	cg12463550	chr7:65579703	CRCP	0.49	8.29	0.36	1.27e-15	Aortic root size;
LGG	cis	rs910316	1.000	rs10142865	chr14:75555624	G/A	cg08847533	chr14:75593920	NEK9	0.63	12.24	0.49	4.87e-30	Height;
LGG	cis	rs72615157	0.634	rs79986079	chr7:99802044	C/T	cg12813108	chr7:99719912	CNPY4	-0.64	-10.06	-0.42	1.13e-21	Lung function (FEV1/FVC);
LGG	cis	rs2839186	0.872	rs13052233	chr21:47707284	G/T	cg13732083	chr21:47605072	C21orf56	0.46	7.72	0.34	7.25e-14	Testicular germ cell tumor;
LGG	cis	rs28386778	0.966	rs2854206	chr17:61947203	G/A	cg11494091	chr17:61959527	GH2	1.04	26.39	0.78	2.47e-94	Prudent dietary pattern;
LGG	cis	rs72945132	1.000	rs56913804	chr11:70114673	G/A	cg00319359	chr11:70116639	PPFIA1	0.69	7.38	0.32	7.45e-13	Coronary artery disease;
LGG	cis	rs875971	0.929	rs778692	chr7:65872449	A/G	cg23594656	chr7:65796392	TPST1	-0.39	-8.67	-0.37	7.36e-17	Aortic root size;
LGG	cis	rs2228479	0.867	rs57492102	chr16:89975572	A/G	cg19635926	chr16:89946313	TCF25	0.69	7.85	0.34	2.9e-14	Skin colour saturation;
LGG	cis	rs12188164	1.000	rs12188678	chr5:428231	T/C	cg26076054	chr5:421317	AHRR	-0.48	-7.95	-0.35	1.48e-14	Cystic fibrosis severity;
LGG	cis	rs78456975	1.000	rs78456975	chr2:1554190	T/G	cg26248373	chr2:1572462	NA	-0.7	-8.76	-0.38	3.6e-17	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6815814	0.950	rs73236633	chr4:38839319	T/C	cg06935464	chr4:38784597	TLR10	0.55	7.46	0.33	4.28e-13	Breast cancer;
LGG	cis	rs11603023	0.804	rs527619	chr11:118563286	G/A	cg19182353	chr11:118479428	PHLDB1	-0.56	-11.05	-0.46	2.42e-25	Cholesterol, total;
LGG	cis	rs651907	0.557	rs3094295	chr3:101401995	T/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.68	14.34	0.55	7.28e-39	Colorectal cancer;
LGG	cis	rs6502050	0.830	rs7219036	chr17:80161119	T/C	cg09264619	chr17:80180166	NA	-0.38	-7.71	-0.34	7.92e-14	Life satisfaction;
LGG	cis	rs780096	0.505	rs12475426	chr2:27599132	G/A	cg05484376	chr2:27715224	FNDC4	0.45	9.62	0.41	4.27e-20	Total body bone mineral density;
LGG	cis	rs9796	0.621	rs12324159	chr15:41462468	G/A	cg18705301	chr15:41695430	NDUFAF1	-0.58	-9.83	-0.42	7.96e-21	Menopause (age at onset);
LGG	trans	rs9354308	0.899	rs2802055	chr6:66545756	T/C	cg15611600	chr13:45563400	KIAA1704;NUFIP1	0.6	10.03	0.42	1.54e-21	Metabolite levels;
LGG	cis	rs1552244	0.882	rs112621205	chr3:10017916	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.83	-13.03	-0.52	2.89e-33	Alzheimer's disease;
LGG	cis	rs9926296	0.605	rs1800287	chr16:89858525	C/G	cg26513180	chr16:89883248	FANCA	0.95	21.39	0.71	4.05e-71	Vitiligo;
LGG	cis	rs7681440	0.904	rs2301135	chr4:90758389	G/C	cg01966878	chr4:90757139	SNCA	-0.38	-7.82	-0.34	3.61e-14	Dementia with Lewy bodies;
LGG	trans	rs11875185	0.510	rs78878637	chr18:55633044	T/G	cg15513957	chr14:69354734	ACTN1	-0.94	-9.26	-0.4	7.48e-19	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	trans	rs7726839	0.540	rs57306627	chr5:597643	T/C	cg27053975	chr1:166958233	MAEL	-0.47	-6.65	-0.3	8.18e-11	Obesity-related traits;
LGG	cis	rs7147624	0.683	rs8017258	chr14:66231017	C/G	cg03016385	chr14:66212404	NA	0.64	7.19	0.32	2.55e-12	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs72781680	0.566	rs6714016	chr2:23899948	A/G	cg08917208	chr2:24149416	ATAD2B	0.58	7.01	0.31	8.28e-12	Lymphocyte counts;
LGG	cis	rs12497850	0.863	rs4858799	chr3:48728204	G/C	cg20833759	chr3:49053208	WDR6;DALRD3	0.38	6.74	0.3	4.72e-11	Parkinson's disease;
LGG	cis	rs6938	0.597	rs11856413	chr15:75199892	A/G	cg09165964	chr15:75287851	SCAMP5	0.64	12.07	0.49	2.39e-29	Breast cancer;
LGG	cis	rs7927771	0.864	rs11604680	chr11:47457539	A/G	cg20307385	chr11:47447363	PSMC3	-0.57	-10.12	-0.43	6.87e-22	Subjective well-being;
LGG	cis	rs6586163	0.872	rs7910660	chr10:90743197	G/A	cg03111039	chr10:90751583	FAS;ACTA2	-0.41	-7.13	-0.31	3.92e-12	Chronic lymphocytic leukemia;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01943843	chr1:16939983	NBPF1	0.43	7.06	0.31	5.99e-12	Gut microbiome composition (summer);
LGG	trans	rs7246760	0.500	rs35390466	chr19:9943017	G/T	cg02900749	chr2:68251473	NA	-0.7	-7.55	-0.33	2.32e-13	Pursuit maintenance gain;
LGG	cis	rs10256972	0.528	rs7784607	chr7:1178694	A/G	cg07308232	chr7:1071921	C7orf50	-0.55	-9.81	-0.41	9.48e-21	Longevity;Endometriosis;
LGG	cis	rs561341	0.883	rs4450460	chr17:30201309	C/T	cg13647721	chr17:30228624	UTP6	-0.76	-9.87	-0.42	5.36e-21	Hip circumference adjusted for BMI;
LGG	cis	rs1577917	0.958	rs13213899	chr6:86473140	C/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.66	-10.89	-0.45	9.59e-25	Response to antipsychotic treatment;
LGG	cis	rs7618501	0.633	rs2624843	chr3:49997963	G/A	cg24308560	chr3:49941425	MST1R	0.23	7.07	0.31	5.82e-12	Intelligence (multi-trait analysis);
LGG	cis	rs972578	0.740	rs737782	chr22:43397563	C/G	cg01576275	chr22:43409880	NA	-0.24	-7.32	-0.32	1.11e-12	Mean platelet volume;
LGG	trans	rs6601327	0.665	rs9286060	chr8:9653145	A/C	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.89	-0.3	1.82e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs1577917	1.000	rs2812972	chr6:86669880	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.65	-11.5	-0.47	4.1e-27	Response to antipsychotic treatment;
LGG	cis	rs7599312	0.534	rs10207878	chr2:213409337	A/G	cg16329650	chr2:213403929	ERBB4	0.78	16.61	0.61	5.91e-49	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs10751667	0.643	rs7396407	chr11:929374	A/T	cg22143635	chr11:980567	AP2A2	0.42	7.73	0.34	6.76e-14	Alzheimer's disease (late onset);
LGG	cis	rs2408955	0.522	rs973398	chr12:48491048	A/G	cg24011408	chr12:48396354	COL2A1	-0.57	-9.58	-0.41	5.81e-20	Glycated hemoglobin levels;
LGG	cis	rs10883723	0.773	rs11191303	chr10:104255158	T/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.88	0.57	3.4e-41	Allergic disease (asthma, hay fever or eczema);
LGG	cis	rs7481584	1.000	rs12789474	chr11:3024139	T/G	cg25174290	chr11:3078921	CARS	-0.48	-8.31	-0.36	1.07e-15	Calcium levels;
LGG	cis	rs12618769	0.652	rs72823788	chr2:99213080	C/T	cg18455616	chr2:99124870	INPP4A	0.27	7.84	0.34	3.2e-14	Bipolar disorder;
LGG	cis	rs6997458	0.785	rs13255540	chr8:86343581	T/C	cg02393479	chr8:86352350	CA3	-0.33	-7.12	-0.31	4.26e-12	Reticulocyte count;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;
LGG	cis	rs9902453	0.967	rs9913074	chr17:28481199	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	0.64	12.83	0.51	1.94e-32	Coffee consumption (cups per day);
LGG	trans	rs6825911	0.680	rs6823889	chr4:111386427	G/A	cg10580549	chr19:53101634	ZNF137	0.47	7.13	0.31	3.82e-12	Blood pressure;
LGG	cis	rs2278491	0.528	rs4514005	chr8:117782385	C/T	cg23513447	chr8:117778558	UTP23	-0.53	-7.04	-0.31	6.79e-12	Body mass index;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg01672886	chr3:133525182	SRPRB	0.44	7.51	0.33	3.02e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs9322193	0.884	rs11155675	chr6:150064019	T/C	cg13206674	chr6:150067644	NUP43	0.66	13.97	0.54	2.83e-37	Lung cancer;
LGG	trans	rs7829975	0.714	rs7823757	chr8:8670177	T/A	cg21775007	chr8:11205619	TDH	0.45	7.37	0.32	7.91e-13	Mood instability;
LGG	cis	rs2133450	0.712	rs1033006	chr3:7369624	A/G	cg19930620	chr3:7340148	GRM7	-0.36	-7.8	-0.34	4.21e-14	Early response to risperidone in schizophrenia;
LGG	cis	rs7737355	0.773	rs1422870	chr5:130942624	G/T	cg06307176	chr5:131281290	NA	0.52	8.6	0.37	1.26e-16	Life satisfaction;
LGG	cis	rs875971	1.000	rs7783613	chr7:65805261	C/T	cg12463550	chr7:65579703	CRCP	-0.51	-8.49	-0.37	2.84e-16	Aortic root size;
LGG	cis	rs35306767	0.855	rs2050944	chr10:918910	T/C	cg26597838	chr10:835615	NA	0.75	10.15	0.43	5.31e-22	Eosinophil percentage of granulocytes;
LGG	cis	rs6795744	0.570	rs114230864	chr3:14054815	G/A	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.48	-7.05	-0.31	6.61e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6500602	0.702	rs11076835	chr16:4549618	G/A	cg14951292	chr16:4525986	HMOX2;NMRAL1	0.32	6.91	0.31	1.66e-11	Schizophrenia;
LGG	cis	rs9815354	1.000	rs17062109	chr3:41810364	C/T	cg03022575	chr3:42003672	ULK4	0.62	7.93	0.35	1.63e-14	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs6424115	1.000	rs6697805	chr1:24151996	C/A	cg15997130	chr1:24165203	NA	-0.49	-13.51	-0.53	2.8e-35	Immature fraction of reticulocytes;
LGG	cis	rs12310956	0.532	rs1525897	chr12:33941033	C/T	cg06521331	chr12:34319734	NA	-0.62	-11.05	-0.46	2.4e-25	Morning vs. evening chronotype;
LGG	cis	rs4862750	0.872	rs7658314	chr4:187900356	T/C	cg07414643	chr4:187882934	NA	0.57	11.93	0.48	8.57e-29	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs2456568	0.802	rs11020586	chr11:93638547	G/A	cg26875233	chr11:93583750	C11orf90	-0.35	-6.84	-0.3	2.45e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs9354308	0.764	rs4602704	chr6:66603971	C/T	cg07460842	chr6:66804631	NA	-0.39	-6.69	-0.3	6.4e-11	Metabolite levels;
LGG	trans	rs66887589	0.616	rs11731675	chr4:120212514	T/C	cg25214090	chr10:38739885	LOC399744	0.46	8.4	0.36	5.5e-16	Diastolic blood pressure;
LGG	cis	rs1348850	0.651	rs4893935	chr2:178240601	C/G	cg22681709	chr2:178499509	PDE11A	-0.4	-7.77	-0.34	4.98e-14	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10751667	0.643	rs10902244	chr11:949981	A/G	cg22143635	chr11:980567	AP2A2	0.42	7.78	0.34	4.65e-14	Alzheimer's disease (late onset);
LGG	cis	rs1865760	0.613	rs9379805	chr6:25938764	T/A	cg17691542	chr6:26056736	HIST1H1C	0.5	8.68	0.37	6.77e-17	Height;
LGG	cis	rs4356932	0.967	rs4859605	chr4:76965822	C/G	cg25799590	chr4:76943062	CXCL10;ART3	-0.4	-6.78	-0.3	3.62e-11	Blood protein levels;
LGG	cis	rs9611565	0.729	rs73176689	chr22:41782633	T/C	cg06850241	chr22:41845214	NA	-0.43	-6.9	-0.31	1.71e-11	Vitiligo;
LGG	cis	rs2153535	0.584	rs55945625	chr6:8371367	C/T	cg07606381	chr6:8435919	SLC35B3	-0.58	-10.18	-0.43	4.12e-22	Motion sickness;
LGG	cis	rs7552404	0.924	rs1146574	chr1:76202671	A/G	cg22875332	chr1:76189707	ACADM	0.59	10.51	0.44	2.48e-23	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs35160687	0.644	rs4610056	chr2:86553250	T/C	cg23655155	chr2:86332777	POLR1A;PTCD3	0.37	6.85	0.3	2.36e-11	Night sleep phenotypes;
LGG	cis	rs9359856	0.564	rs34732313	chr6:90368380	G/A	cg13799429	chr6:90582589	CASP8AP2	-0.75	-9.64	-0.41	3.75e-20	Bipolar disorder;
LGG	cis	rs4666002	0.789	rs13030973	chr2:27928797	T/C	cg27432699	chr2:27873401	GPN1	0.56	7.81	0.34	3.99e-14	Phospholipid levels (plasma);
LGG	cis	rs58649573	0.552	rs2075064	chr9:126783847	C/T	cg14112217	chr9:126806003	NA	0.4	7.92	0.35	1.84e-14	Post-traumatic stress disorder;
LGG	cis	rs753955	0.592	rs4769288	chr13:24360434	T/G	cg25267304	chr13:24462978	PCOTH;MIPEP	-0.41	-7.33	-0.32	1.05e-12	Lung cancer;
LGG	trans	rs7980799	0.649	rs2389218	chr12:33680929	C/A	cg26384229	chr12:38710491	ALG10B	0.68	12.42	0.5	9.01e-31	Heart rate;Heart rate variability traits (RMSSD);
LGG	cis	rs2070488	0.766	rs4679050	chr3:38482007	G/A	cg01465620	chr3:38496096	LOC100128640;ACVR2B	0.76	14.93	0.57	1.97e-41	Electrocardiographic conduction measures;
LGG	cis	rs769267	1.000	rs7247309	chr19:19439631	A/T	cg03709012	chr19:19516395	GATAD2A	-0.81	-15.82	-0.59	2.34e-45	Tonsillectomy;
LGG	cis	rs9397585	0.599	rs9478387	chr6:153402903	G/C	cg17707550	chr6:153380415	RGS17	-0.45	-9.9	-0.42	4.43e-21	Body mass index;
LGG	cis	rs1371867	0.846	rs2439458	chr8:101297984	T/C	cg06636551	chr8:101224915	SPAG1	-0.45	-8.47	-0.37	3.17e-16	Atrioventricular conduction;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg07594247	chr2:113993304	PAX8;LOC440839;LOC654433	-0.6	-10.25	-0.43	2.42e-22	Lymphocyte counts;
LGG	cis	rs2067615	0.524	rs9971765	chr12:107092299	G/A	cg15890332	chr12:107067104	RFX4	0.43	12.63	0.51	1.28e-31	Heart rate;
LGG	cis	rs9644630	0.658	rs4427190	chr8:19321385	C/T	cg06699216	chr8:19333253	CSGALNACT1	0.44	10.08	0.42	9.75e-22	Oropharynx cancer;
LGG	cis	rs131805	1.000	rs3091397	chr22:50957520	C/T	cg05418105	chr22:50981406	NA	-0.64	-10.33	-0.43	1.22e-22	Granulocyte percentage of myeloid white cells;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg22464182	chr2:148602625	ACVR2A	0.41	6.66	0.3	7.86e-11	Cognitive performance;
LGG	cis	rs638893	0.898	rs577121	chr11:118690550	C/T	cg22253036	chr11:118662786	DDX6	0.44	7.52	0.33	2.93e-13	Vitiligo;
LGG	cis	rs3816183	0.585	rs10172447	chr2:42881725	A/G	cg14631114	chr2:43023945	NA	0.36	6.87	0.3	2.12e-11	Hypospadias;
LGG	cis	rs6500602	0.634	rs2270365	chr16:4526758	G/A	cg07160937	chr16:4524620	NMRAL1;HMOX2	0.41	8.03	0.35	7.91e-15	Schizophrenia;
LGG	trans	rs6906287	0.625	rs9320649	chr6:118693665	A/G	cg17646418	chr6:166911767	RPS6KA2	0.37	6.65	0.3	8.39e-11	Electrocardiographic conduction measures;
LGG	cis	rs6952808	0.723	rs1107592	chr7:2041432	C/T	cg22963979	chr7:1858916	MAD1L1	0.48	10.11	0.43	7.42e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs2576037	0.523	rs1539881	chr18:44477897	C/T	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.4	-0.53	7.63e-35	Personality dimensions;
LGG	cis	rs921968	0.643	rs1516086	chr2:219431535	C/T	cg01130898	chr2:219473002	PLCD4	-0.39	-6.68	-0.3	6.98e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs6665290	0.901	rs61834001	chr1:227197411	C/T	cg10327440	chr1:227177885	CDC42BPA	-1.29	-45.85	-0.91	3.11e-174	Myeloid white cell count;
LGG	cis	rs11650494	0.908	rs11656535	chr17:47425588	C/T	cg08112188	chr17:47440006	ZNF652	1.3	15.35	0.58	2.76e-43	Prostate cancer;
LGG	cis	rs12410462	0.551	rs12059899	chr1:227863409	A/G	cg23173402	chr1:227635558	NA	0.36	6.88	0.3	1.94e-11	Major depressive disorder;
LGG	cis	rs9513627	1.000	rs73556170	chr13:100121612	T/A	cg15490075	chr13:100150979	NA	-0.66	-6.96	-0.31	1.19e-11	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs16921937	chr8:58145010	A/G	cg08280861	chr8:58055591	NA	0.54	6.91	0.31	1.63e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs916888	0.610	rs199454	chr17:44800110	G/A	cg15921436	chr17:44337874	NA	-0.44	-10.39	-0.43	7.2e-23	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs988958	0.675	rs11894053	chr2:42229545	C/T	cg27428208	chr2:42229179	NA	-0.52	-9.01	-0.39	5.55e-18	Hypospadias;
LGG	cis	rs13082711	0.554	rs4973729	chr3:27390637	G/A	cg02860705	chr3:27208620	NA	0.94	17.13	0.62	2.53e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs77633900	0.772	rs283799	chr15:76752834	A/C	cg21673338	chr15:77095150	SCAPER	-0.64	-8.46	-0.37	3.56e-16	Non-glioblastoma glioma;Glioma;
LGG	cis	rs9815354	0.812	rs4547673	chr3:41952303	A/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs3808502	0.526	rs7822958	chr8:11422442	C/A	cg19847130	chr8:10466454	RP1L1	0.31	6.78	0.3	3.59e-11	Neuroticism;
LGG	cis	rs17209837	0.646	rs10452935	chr7:87094247	A/T	cg25823085	chr7:87105416	ABCB4	0.3	7.39	0.32	7.01e-13	Gallbladder cancer;
LGG	cis	rs3764563	0.935	rs622886	chr19:15698696	C/T	cg20725493	chr19:15740067	CYP4F8	0.58	6.83	0.3	2.68e-11	Inflammatory biomarkers;
LGG	cis	rs300703	0.654	rs393277	chr2:121539	G/T	cg24565620	chr2:194026	NA	0.68	9.8	0.41	9.58e-21	Blood protein levels;
LGG	cis	rs17270561	0.609	rs4145217	chr6:25743997	T/C	cg03517284	chr6:25882590	NA	-0.43	-7.06	-0.31	6.11e-12	Iron status biomarkers;
LGG	cis	rs11792861	0.926	rs118011482	chr9:111770626	G/C	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.32	0.4	4.95e-19	Menarche (age at onset);
LGG	cis	rs2243480	1.000	rs313799	chr7:65494330	A/G	cg18252515	chr7:66147081	NA	-1.37	-19.19	-0.67	8.26e-61	Diabetic kidney disease;
LGG	trans	rs6600671	0.691	rs6600662	chr1:121230790	C/T	cg00646200	chr1:148855367	NA	0.41	7.33	0.32	1.04e-12	Hip geometry;
LGG	trans	rs2243480	0.901	rs58207111	chr7:65486723	C/T	cg10756647	chr7:56101905	PSPH	0.83	9.8	0.41	9.64e-21	Diabetic kidney disease;
LGG	trans	rs6787172	0.677	rs7621674	chr3:157992751	C/T	cg23275840	chr4:47708675	CORIN	0.42	8.91	0.38	1.17e-17	Subjective well-being;
LGG	cis	rs4909189	1.000	rs62493650	chr7:158135570	G/T	cg06219351	chr7:158114137	PTPRN2	-0.82	-14.18	-0.55	3.61e-38	Response to amphetamines;
LGG	cis	rs7192750	0.586	rs62053803	chr16:71989413	G/A	cg06353428	chr16:71660113	MARVELD3	0.67	10.94	0.45	6.07e-25	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs2404602	0.684	rs62026898	chr15:76944371	C/A	cg23625390	chr15:77176239	SCAPER	-0.72	-14.46	-0.56	2.24e-39	Blood metabolite levels;
LGG	cis	rs2842992	0.789	rs2842969	chr6:160145364	C/T	cg16489826	chr6:160211363	TCP1;MRPL18	0.72	12.11	0.49	1.59e-29	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs4689388	0.853	rs13108780	chr4:6294630	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.27	0.4	6.98e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs60843830	0.964	rs17713879	chr2:254215	G/A	cg12623918	chr2:306882	NA	0.49	9.14	0.39	2.04e-18	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs6952808	0.760	rs11764960	chr7:1950532	G/A	cg05863683	chr7:1912471	MAD1L1	0.46	9.06	0.39	3.65e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs8180040	0.966	rs56351005	chr3:47430186	G/T	cg16586182	chr3:47516702	SCAP	0.78	15.62	0.59	1.83e-44	Colorectal cancer;
LGG	cis	rs2204008	0.743	rs2132212	chr12:38039405	G/A	cg04568710	chr12:38710424	ALG10B	0.33	7.12	0.31	4.12e-12	Bladder cancer;
LGG	cis	rs1729951	0.546	rs361246	chr3:136695667	G/A	cg12473912	chr3:136751656	NA	0.44	7.69	0.34	8.94e-14	Neuroticism;
LGG	trans	rs2204008	0.774	rs9669565	chr12:38294428	C/A	cg06521331	chr12:34319734	NA	-0.5	-8.75	-0.38	3.91e-17	Bladder cancer;
LGG	cis	rs9522267	0.535	rs9522298	chr13:112234457	C/A	cg14952266	chr13:112191215	NA	0.52	10.97	0.45	4.86e-25	Hepatitis;
LGG	cis	rs17767392	0.509	rs72726677	chr14:71695208	T/A	cg13720639	chr14:72061746	SIPA1L1	-0.32	-6.69	-0.3	6.51e-11	Mitral valve prolapse;
LGG	cis	rs17504614	0.634	rs11125326	chr2:51047313	A/C	cg23851515	chr2:51057218	NRXN1	0.47	7.65	0.34	1.14e-13	Educational attainment (years of education);
LGG	cis	rs6909430	1.000	rs1126239	chr6:98748005	A/C	cg12860156	chr6:98744658	NA	-0.45	-7.02	-0.31	8.01e-12	Quantitative traits;
LGG	cis	rs8028182	0.636	rs28623700	chr15:75849714	T/A	cg20655648	chr15:75932815	IMP3	0.44	7.27	0.32	1.59e-12	Sudden cardiac arrest;
LGG	cis	rs1862618	0.853	rs832551	chr5:56180112	T/G	cg08400814	chr5:56204995	C5orf35	-0.46	-7.35	-0.32	8.86e-13	Initial pursuit acceleration;
LGG	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg02118635	chr17:56770003	RAD51C;TEX14	0.88	14.07	0.55	1.1e-37	Cognitive test performance;
LGG	cis	rs8135665	0.600	rs8142379	chr22:38450971	G/A	cg19171272	chr22:38449367	NA	-0.46	-8.44	-0.37	4.19e-16	Advanced age-related macular degeneration;Age-related macular degeneration;
LGG	cis	rs11676348	0.783	rs13035513	chr2:218960680	C/T	cg00012203	chr2:219082015	ARPC2	-0.56	-9.97	-0.42	2.46e-21	Ulcerative colitis;
LGG	cis	rs28386778	0.897	rs2236737	chr17:61938100	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.33	0.43	1.18e-22	Prudent dietary pattern;
LGG	cis	rs11122272	0.701	rs2474628	chr1:231526000	C/T	cg10503236	chr1:231470652	EXOC8	-0.37	-7.21	-0.32	2.24e-12	Hemoglobin concentration;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg06023702	chr2:71454313	PAIP2B	-0.46	-6.73	-0.3	4.88e-11	Systemic lupus erythematosus;
LGG	cis	rs651907	0.557	rs11924013	chr3:101366698	G/A	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.69	14.88	0.57	3.46e-41	Colorectal cancer;
LGG	cis	rs66716358	0.716	rs10838254	chr11:44317862	C/A	cg16977035	chr11:44330474	ALX4	0.36	9.19	0.39	1.38e-18	Monobrow;
LGG	cis	rs701145	0.585	rs1727923	chr3:153786303	C/T	cg17054900	chr3:154042577	DHX36	-0.77	-9.28	-0.4	6.3e-19	Coronary artery disease;
LGG	cis	rs1185460	0.565	rs10892325	chr11:118912702	T/C	cg24687335	chr11:118901407	SLC37A4	-0.62	-11.23	-0.46	4.76e-26	Coronary artery disease;
LGG	cis	rs7107174	1.000	rs2511166	chr11:77964331	T/C	cg02023728	chr11:77925099	USP35	0.43	7.76	0.34	5.29e-14	Testicular germ cell tumor;
LGG	trans	rs8002861	0.727	rs9533652	chr13:44419532	A/G	cg12856521	chr11:46389249	DGKZ	-0.5	-9.15	-0.39	1.83e-18	Leprosy;
LGG	trans	rs11098499	0.863	rs3775841	chr4:120425777	A/C	cg25214090	chr10:38739885	LOC399744	0.66	11.51	0.47	3.8e-27	Corneal astigmatism;
LGG	cis	rs9322193	0.886	rs2065663	chr6:150081467	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.01	-0.31	8.31e-12	Lung cancer;
LGG	cis	rs561341	0.883	rs4795661	chr17:30201774	T/A	cg12193833	chr17:30244370	NA	0.28	6.99	0.31	9.6e-12	Hip circumference adjusted for BMI;
LGG	trans	rs2727020	0.930	rs1164686	chr11:49291822	C/T	cg03929089	chr4:120376271	NA	0.79	14.03	0.55	1.63e-37	Coronary artery disease;
LGG	cis	rs7917772	0.636	rs2486757	chr10:104535145	C/T	cg04362960	chr10:104952993	NT5C2	-0.48	-7.98	-0.35	1.2e-14	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs13108904	0.870	rs4974542	chr4:1250908	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	0.74	13.75	0.54	2.5e-36	Obesity-related traits;
LGG	cis	rs13108904	0.935	rs1620928	chr4:1279124	C/T	cg05665937	chr4:1216051	CTBP1	-0.49	-8.79	-0.38	3.03e-17	Obesity-related traits;
LGG	cis	rs1008375	0.932	rs13127157	chr4:17618049	A/G	cg02297831	chr4:17616191	MED28	-0.47	-8.35	-0.36	7.83e-16	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2250402	0.510	rs7535	chr15:40328575	G/C	cg01081584	chr15:40268610	EIF2AK4	-0.92	-9.8	-0.41	9.85e-21	Corneal curvature;
LGG	cis	rs62400317	0.859	rs1324536	chr6:45116261	C/T	cg18551225	chr6:44695536	NA	0.58	9.23	0.39	9.4e-19	Total body bone mineral density;
LGG	cis	rs10155981	0.510	rs28439106	chr7:22592349	T/C	cg06110297	chr7:22589830	NA	-0.71	-7.21	-0.32	2.33e-12	Bilirubin levels;
LGG	cis	rs6438424	0.521	rs10934426	chr3:117717570	T/G	cg07910724	chr3:117604411	NA	0.32	8.56	0.37	1.73e-16	Menarche (age at onset);
LGG	cis	rs4595586	0.525	rs10506132	chr12:39404599	C/T	cg26384229	chr12:38710491	ALG10B	0.65	11.81	0.48	2.58e-28	Morning vs. evening chronotype;
LGG	cis	rs4262150	0.810	rs17565365	chr5:152056234	C/T	cg12297329	chr5:152029980	NA	-0.79	-14.99	-0.57	1.09e-41	Bipolar disorder and schizophrenia;
LGG	cis	rs3768617	0.510	rs2296291	chr1:183079509	C/T	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.51e-19	Fuchs's corneal dystrophy;
LGG	trans	rs1814175	0.592	rs1794161	chr11:49898825	A/C	cg15704280	chr7:45808275	SEPT13	-0.99	-21.77	-0.71	7.13e-73	Height;
LGG	cis	rs7659604	0.540	rs28615388	chr4:122678418	C/T	cg19748678	chr4:122722346	EXOSC9	-0.45	-7.88	-0.34	2.38e-14	Type 2 diabetes;
LGG	cis	rs2116941	1.000	rs7250265	chr19:10339818	G/C	cg01850179	chr19:10340795	S1PR2	-0.65	-10.19	-0.43	3.92e-22	Pulse pressure;
LGG	cis	rs5758659	0.967	rs5751250	chr22:42639645	T/G	cg15128208	chr22:42549153	NA	-0.46	-9.03	-0.39	4.78e-18	Cognitive function;
LGG	cis	rs832540	0.931	rs832399	chr5:56222358	A/T	cg12654349	chr5:56205094	C5orf35	-0.42	-7.61	-0.33	1.52e-13	Coronary artery disease;
LGG	cis	rs28386778	0.830	rs2597637	chr17:61875066	T/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.67	0.37	7.43e-17	Prudent dietary pattern;
LGG	trans	rs747782	0.639	rs17198985	chr11:48183565	T/C	cg15704280	chr7:45808275	SEPT13	0.7	7.8	0.34	4e-14	Intraocular pressure;
LGG	cis	rs9896933	0.778	rs80243549	chr17:80821485	G/T	cg15664640	chr17:80829946	TBCD	-0.67	-9.13	-0.39	2.13e-18	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs7589342	0.929	rs6725519	chr2:106445209	A/G	cg16077055	chr2:106428750	NCK2	-0.32	-8.32	-0.36	1.01e-15	Addiction;
LGG	cis	rs1799949	0.602	rs8176199	chr17:41230524	T/G	cg05368731	chr17:41323189	NBR1	0.89	14.02	0.55	1.78e-37	Menopause (age at onset);
LGG	cis	rs894734	0.535	rs2366142	chr12:54323148	T/C	cg12374095	chr12:54320830	NA	-0.4	-7.22	-0.32	2.2e-12	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimetabolite drugs);
LGG	cis	rs6450176	0.909	rs67199213	chr5:53290648	A/G	ch.5.1024479R	chr5:53302184	ARL15	-0.66	-10.79	-0.45	2.22e-24	HDL cholesterol levels;HDL cholesterol;Adiponectin levels;
LGG	cis	rs1620921	0.565	rs59536962	chr6:161264131	A/G	cg01280913	chr6:161186852	NA	-0.36	-7.41	-0.33	5.88e-13	Lipoprotein (a) - cholesterol levels;
LGG	cis	rs6977660	1.000	rs2107403	chr7:19819025	G/C	cg07541023	chr7:19748670	TWISTNB	0.48	7.44	0.33	4.79e-13	Thyroid stimulating hormone;
LGG	cis	rs950169	1.000	rs1818950	chr15:84722521	A/G	cg24253500	chr15:84953950	NA	0.59	10.7	0.45	5.11e-24	Schizophrenia;
LGG	cis	rs1124376	1.000	rs4417886	chr3:20108511	C/T	cg05072819	chr3:20081367	KAT2B	0.64	8.26	0.36	1.5e-15	Bipolar disorder and schizophrenia;
LGG	cis	rs78456975	0.622	rs11896517	chr2:1518112	A/G	cg01028140	chr2:1542097	TPO	-0.45	-7.15	-0.32	3.36e-12	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs9951602	0.512	rs12454617	chr18:76656007	C/T	cg24134504	chr18:76639479	NA	-0.47	-8.28	-0.36	1.34e-15	Obesity-related traits;
LGG	cis	rs9515201	0.627	rs9521730	chr13:111031180	C/T	cg06243866	chr13:111019493	COL4A2	-0.69	-13.44	-0.53	5.13e-35	White matter hyperintensity burden;
LGG	cis	rs11168618	0.626	rs2731095	chr12:48881808	G/C	cg24011408	chr12:48396354	COL2A1	-0.42	-6.69	-0.3	6.6e-11	Adiponectin levels;
LGG	cis	rs6763768	0.606	rs13062474	chr3:53331547	C/T	cg16894138	chr3:53270350	TKT	0.41	7.89	0.34	2.24e-14	Bacterial meningitis;
LGG	cis	rs4302748	0.818	rs1882064	chr7:36188616	G/A	cg24442661	chr7:36192818	EEPD1	0.55	7.28	0.32	1.41e-12	Platelet count;
LGG	cis	rs8017423	0.967	rs7142513	chr14:90705182	T/C	cg04374321	chr14:90722782	PSMC1	0.87	18.22	0.65	2.59e-56	Mortality in heart failure;
LGG	cis	rs1218582	0.772	rs4845693	chr1:154911257	A/G	cg16680214	chr1:154839983	KCNN3	0.41	7.83	0.34	3.28e-14	Prostate cancer;
LGG	cis	rs10504130	0.502	rs16916968	chr8:52844411	A/G	cg22653915	chr8:52722023	PXDNL	-0.5	-8.89	-0.38	1.42e-17	Venous thromboembolism (SNP x SNP interaction);
LGG	cis	rs651907	0.557	rs11710533	chr3:101351472	G/A	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.72	12.93	0.52	7.32e-33	Colorectal cancer;
LGG	cis	rs977987	0.788	rs7184525	chr16:75437186	A/G	cg07303275	chr16:75499416	TMEM170A	0.37	6.79	0.3	3.48e-11	Dupuytren's disease;
LGG	cis	rs9467711	0.651	rs71557316	chr6:26072981	G/A	cg21479132	chr6:26055353	NA	0.74	6.76	0.3	4.04e-11	Autism spectrum disorder or schizophrenia;
LGG	cis	rs6988985	0.678	rs7011889	chr8:144005260	A/C	cg10324643	chr8:143916377	GML	0.47	9.62	0.41	4.17e-20	Plasma androstenedione levels in resected early stage-receptor positive breast cancer;
LGG	cis	rs4073221	0.520	rs2002965	chr3:18201026	A/G	cg07694806	chr3:18168406	NA	-0.65	-7.91	-0.35	1.88e-14	Parkinson's disease;
LGG	trans	rs35110281	0.632	rs9306160	chr21:45107562	T/C	cg18724061	chr6:27861294	HIST1H2AM;HIST1H2BO	0.59	10.27	0.43	1.93e-22	Mean corpuscular volume;
LGG	trans	rs9858542	0.953	rs11719996	chr3:49525958	T/C	cg21665057	chr3:196295764	WDR53;FBXO45	-0.52	-8.51	-0.37	2.5e-16	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs977987	0.778	rs4888412	chr16:75443196	A/G	cg03315344	chr16:75512273	CHST6	0.51	10.2	0.43	3.54e-22	Dupuytren's disease;
LGG	cis	rs9611565	0.625	rs12483991	chr22:41935285	A/G	cg17376030	chr22:41985996	PMM1	0.47	7.56	0.33	2.22e-13	Vitiligo;
LGG	cis	rs3733346	0.529	rs6842493	chr4:914638	T/C	cg23939001	chr4:940644	TMEM175	0.69	16.42	0.61	4.28e-48	Sjögren's syndrome;
LGG	cis	rs1978968	0.751	rs5992139	chr22:18458636	A/G	cg00227156	chr22:18463646	MICAL3;MIR648	-0.66	-13.8	-0.54	1.52e-36	Presence of antiphospholipid antibodies;
LGG	cis	rs1003719	0.679	rs2835638	chr21:38534533	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.36	-0.58	2.52e-43	Eye color traits;
LGG	cis	rs9322193	0.566	rs4869768	chr6:150245203	A/G	cg08621203	chr6:150244597	RAET1G	-0.48	-7.12	-0.31	4.1e-12	Lung cancer;
LGG	cis	rs7786808	0.653	rs7810861	chr7:158212633	G/A	cg15440763	chr7:158190612	PTPRN2	0.47	10.06	0.42	1.13e-21	Obesity-related traits;
LGG	cis	rs5756391	0.524	rs2413436	chr22:37312561	A/G	cg21209356	chr22:37319042	CSF2RB	0.38	8.64	0.37	9.5e-17	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs7819412	0.806	rs10113808	chr8:10926892	C/A	cg27411982	chr8:10470053	RP1L1	-0.44	-7.44	-0.33	4.93e-13	Triglycerides;
LGG	cis	rs9816226	0.591	rs75160594	chr3:185810481	C/G	cg00760338	chr3:185826511	ETV5	-0.81	-9.99	-0.42	2.12e-21	Obesity;Body mass index;
LGG	cis	rs7241530	0.775	rs11081529	chr18:75902735	C/T	cg14642773	chr18:75888474	NA	-0.45	-9.43	-0.4	1.99e-19	Educational attainment (years of education);
LGG	cis	rs4975616	0.836	rs460073	chr5:1336459	T/C	cg07493874	chr5:1342172	CLPTM1L	-0.89	-18.17	-0.65	4.47e-56	Lung cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg26597500	chr13:73356092	PIBF1;DIS3	0.4	6.94	0.31	1.31e-11	Bipolar disorder;
LGG	cis	rs875971	0.862	rs6947339	chr7:65888470	T/C	cg18876405	chr7:65276391	NA	0.54	9.5	0.4	1.15e-19	Aortic root size;
LGG	cis	rs2439831	0.850	rs694985	chr15:43813387	A/G	cg02155558	chr15:43621948	ADAL;LCMT2	0.83	9.79	0.41	1.1e-20	Lung cancer in ever smokers;
LGG	cis	rs804280	0.517	rs7815179	chr8:11792048	C/G	cg12395012	chr8:11607386	GATA4	-0.43	-7.66	-0.34	1.13e-13	Myopia (pathological);
LGG	trans	rs11875185	0.915	rs72937689	chr18:55617931	C/T	cg15513957	chr14:69354734	ACTN1	-0.69	-7.51	-0.33	3.07e-13	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs17401966	0.838	rs1556916	chr1:10403482	G/A	cg19773385	chr1:10388646	KIF1B	-0.46	-9.92	-0.42	3.65e-21	Hepatocellular carcinoma;
LGG	cis	rs780094	0.544	rs2303370	chr2:27651375	C/T	cg02592271	chr2:27665507	KRTCAP3	-0.31	-7.95	-0.35	1.45e-14	Calcium levels;Fasting blood insulin;Metabolic traits;Triglyceride levels;Fasting plasma glucose;Urate levels in overweight individuals;Urate levels in obese individuals;Uric acid levels;Height;Age-related diseases, mortality and associated endophenotypes;Renal underexcretion gout;Fasting blood glucose (BMI interaction);Urate levels;Gondoic acid (20:1n-9) levels;Fasting blood insulin (BMI interaction);Triglycerides;Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);Type 2 diabetes;Nonalcoholic fatty liver disease;Hypertriglyceridemia;C-reactive protein;Age-related disease endophenotypes;LDL cholesterol;Metabolic syndrome;Crohn's disease;Alcohol consumption (drinks per week);Homeostasis model assessment of insulin resistance;Alcohol consumption;Red blood cell count;Fasting blood glucose;
LGG	cis	rs6430585	0.527	rs62168792	chr2:136415217	A/G	cg07169764	chr2:136633963	MCM6	0.98	16.13	0.6	8.62e-47	Corneal structure;
LGG	cis	rs41278232	0.841	rs3810504	chr20:62678549	C/T	cg03065311	chr20:62601662	ZNF512B	0.59	8.7	0.37	5.82e-17	Tonsillectomy;
LGG	cis	rs6502050	0.835	rs12950475	chr17:80118924	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.6e-20	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19006841	chr15:45491101	SHF	0.49	7.25	0.32	1.81e-12	Gut microbiome composition (summer);
LGG	cis	rs28386778	0.897	rs6504185	chr17:61848792	A/G	cg06873352	chr17:61820015	STRADA	0.74	13.92	0.54	4.79e-37	Prudent dietary pattern;
LGG	trans	rs9929218	1.000	rs8045022	chr16:68807087	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.76	-12.82	-0.51	2e-32	Colorectal cancer;
LGG	cis	rs6121246	0.865	rs6089055	chr20:30324045	C/T	cg04935436	chr20:30431758	NA	0.43	7.39	0.32	6.91e-13	Mean corpuscular hemoglobin;
LGG	trans	rs1814175	0.817	rs10839318	chr11:49657511	G/C	cg03929089	chr4:120376271	NA	-1.03	-23.58	-0.74	2.44e-81	Height;
LGG	cis	rs4731207	0.698	rs6415362	chr7:124530650	T/C	cg05630886	chr7:124431682	NA	-0.33	-7.7	-0.34	8.03e-14	Cutaneous malignant melanoma;
LGG	cis	rs9513627	0.833	rs73556129	chr13:100113167	C/T	cg15490075	chr13:100150979	NA	-0.64	-6.75	-0.3	4.53e-11	Obesity-related traits;
LGG	cis	rs986417	0.606	rs7156375	chr14:61110627	G/A	cg27398547	chr14:60952738	C14orf39	0.65	6.72	0.3	5.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7119	0.717	rs12901338	chr15:77804900	T/A	cg10437265	chr15:77819839	NA	0.25	6.82	0.3	2.8e-11	Type 2 diabetes;
LGG	cis	rs73787773	0.741	rs17253030	chr5:111465546	C/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.61	-7.48	-0.33	3.8e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs9358372	0.711	rs12198243	chr6:20880842	C/A	cg13405222	chr6:20811065	CDKAL1	-0.59	-12.43	-0.5	8.42e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs17428076	0.794	rs56133507	chr2:172818467	T/G	cg21435375	chr2:172878103	MAP1D	0.41	7.49	0.33	3.64e-13	Myopia;
LGG	cis	rs6952808	0.929	rs11761270	chr7:1923695	C/T	cg04267008	chr7:1944627	MAD1L1	-0.72	-12.52	-0.5	3.63e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs975722	0.516	rs2051718	chr7:117025243	G/A	cg10524701	chr7:117356490	CTTNBP2	0.4	8.76	0.38	3.76e-17	Coronary artery disease;
LGG	cis	rs875971	0.862	rs7782704	chr7:65805366	G/A	cg18876405	chr7:65276391	NA	-0.55	-9.8	-0.41	9.56e-21	Aortic root size;
LGG	cis	rs7811142	0.943	rs10241492	chr7:99994813	A/G	cg18515655	chr7:100026757	MEPCE;ZCWPW1	-1.01	-16.03	-0.6	2.63e-46	Platelet count;
LGG	cis	rs877426	0.681	rs7317369	chr13:114816738	C/G	cg25338242	chr13:114786047	RASA3	0.46	6.93	0.31	1.38e-11	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs3820068	0.705	rs927206	chr1:15893338	C/T	cg05660106	chr1:15850417	CASP9	1.17	25.13	0.76	1.5e-88	Systolic blood pressure;
LGG	cis	rs1003719	0.680	rs2835670	chr21:38581114	T/C	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.78	-0.57	8.96e-41	Eye color traits;
LGG	cis	rs763121	0.853	rs2413545	chr22:39092524	C/T	cg06022373	chr22:39101656	GTPBP1	0.88	17.77	0.64	3.09e-54	Menopause (age at onset);
LGG	cis	rs1046896	0.553	rs56775875	chr17:80831291	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.85	0.3	2.37e-11	Glycated hemoglobin levels;
LGG	cis	rs11190604	0.945	rs11190573	chr10:102233172	T/C	cg07080220	chr10:102295463	HIF1AN	0.64	11.01	0.46	3.37e-25	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs11148252	0.574	rs3742297	chr13:53278067	T/C	cg16301924	chr13:53314226	LECT1	-0.37	-7.34	-0.32	9.75e-13	Lewy body disease;
LGG	trans	rs7395662	0.963	rs115181013	chr11:48575801	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.56	-0.33	2.15e-13	HDL cholesterol;
LGG	cis	rs9486719	0.802	rs2983896	chr6:97029871	G/A	cg18709589	chr6:96969512	KIAA0776	-0.45	-7.59	-0.33	1.77e-13	Migraine;Coronary artery disease;
LGG	cis	rs7937682	0.883	rs517982	chr11:111462687	T/C	cg22437258	chr11:111473054	SIK2	0.54	9.49	0.4	1.23e-19	Primary sclerosing cholangitis;
LGG	cis	rs7666738	0.830	rs3907021	chr4:99038668	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.43	0.36	4.51e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs1577917	0.816	rs1838952	chr6:86601144	G/A	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.45	-7.91	-0.35	1.87e-14	Response to antipsychotic treatment;
LGG	cis	rs240764	0.631	rs9386250	chr6:101204126	A/G	cg21058520	chr6:100914733	NA	0.39	6.73	0.3	5.02e-11	Neuroticism;
LGG	cis	rs62238980	0.614	rs74534759	chr22:32383419	T/G	cg00543991	chr22:32367038	NA	0.8	8.91	0.38	1.17e-17	Childhood ear infection;
LGG	cis	rs773506	0.866	rs1972090	chr9:94083790	A/T	cg14446406	chr9:93919335	NA	-0.42	-7.74	-0.34	6.17e-14	Type 2 diabetes nephropathy;
LGG	cis	rs9322193	0.884	rs9371201	chr6:150145001	C/T	cg08621203	chr6:150244597	RAET1G	0.42	6.72	0.3	5.25e-11	Lung cancer;
LGG	cis	rs9790314	1.000	rs6775627	chr3:160953609	A/G	cg03342759	chr3:160939853	NMD3	-0.66	-11.78	-0.48	3.53e-28	Morning vs. evening chronotype;
LGG	cis	rs35771425	1.000	rs11580728	chr1:211614280	C/T	cg10512769	chr1:211675356	NA	-0.7	-11.51	-0.47	3.83e-27	Educational attainment (years of education);
LGG	cis	rs1799949	0.864	rs60309406	chr17:41435665	C/T	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.25	0.32	1.73e-12	Menopause (age at onset);
LGG	cis	rs611744	0.647	rs11774904	chr8:109273435	G/A	cg18478394	chr8:109455254	TTC35	0.42	8.43	0.36	4.35e-16	Dupuytren's disease;
LGG	cis	rs6121246	0.529	rs6060359	chr20:30209740	A/G	cg13852791	chr20:30311386	BCL2L1	0.66	8.78	0.38	3.23e-17	Mean corpuscular hemoglobin;
LGG	cis	rs9916302	0.706	rs12950186	chr17:37393395	A/C	cg00129232	chr17:37814104	STARD3	-0.57	-8.36	-0.36	7.25e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs7647973	0.580	rs12637576	chr3:49237334	C/T	cg06212747	chr3:49208901	KLHDC8B	0.73	13.11	0.52	1.31e-33	Menarche (age at onset);
LGG	cis	rs77741769	0.571	rs11065284	chr12:121266621	G/A	cg02419362	chr12:121203948	SPPL3	0.53	9.26	0.4	7.77e-19	Mean corpuscular volume;
LGG	trans	rs1005277	0.579	rs1740737	chr10:38499365	G/T	cg27523141	chr10:43048294	ZNF37B	0.39	7.53	0.33	2.73e-13	Extrinsic epigenetic age acceleration;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24555656	chr7:99717359	TAF6;CNPY4	0.48	7.18	0.32	2.88e-12	Gut microbiome composition (summer);
LGG	cis	rs826838	1.000	rs4768328	chr12:39129315	C/T	cg26384229	chr12:38710491	ALG10B	-0.9	-21.25	-0.7	1.97e-70	Heart rate;
LGG	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg01620082	chr3:125678407	NA	-0.97	-8.91	-0.38	1.19e-17	Autism spectrum disorder or schizophrenia;
LGG	cis	rs61931739	0.517	rs11612493	chr12:34114272	A/C	cg06521331	chr12:34319734	NA	-0.62	-11.2	-0.46	6.01e-26	Morning vs. evening chronotype;
LGG	cis	rs2072499	0.966	rs1137703	chr1:156184458	T/C	cg25208724	chr1:156163844	SLC25A44	1.21	28.65	0.8	1.29e-104	Testicular germ cell tumor;
LGG	trans	rs1908814	0.516	rs13281315	chr8:11794855	C/G	cg06636001	chr8:8085503	FLJ10661	0.51	9.22	0.39	1.02e-18	Neuroticism;
LGG	cis	rs9287719	0.967	rs6712406	chr2:10754420	A/G	cg02196655	chr2:10830764	NOL10	-0.44	-7.46	-0.33	4.39e-13	Prostate cancer;
LGG	cis	rs754466	0.580	rs10430530	chr10:79582812	T/C	cg17075019	chr10:79541650	NA	-0.96	-21.24	-0.7	2.15e-70	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs6087771	0.642	rs6060403	chr20:30221104	C/A	cg13852791	chr20:30311386	BCL2L1	0.82	13.07	0.52	1.97e-33	Subcortical brain region volumes;Putamen volume;
LGG	cis	rs2072499	0.932	rs2736613	chr1:156196016	T/C	cg24450063	chr1:156163899	SLC25A44	1.14	24.94	0.76	1.2e-87	Testicular germ cell tumor;
LGG	cis	rs2153535	0.563	rs1796687	chr6:8536118	C/G	cg23788917	chr6:8435910	SLC35B3	0.52	8.89	0.38	1.34e-17	Motion sickness;
LGG	cis	rs2731664	0.792	rs2630763	chr5:176901005	T/A	cg23176889	chr5:176863531	GRK6	-0.63	-12.45	-0.5	6.64e-31	Intelligence (multi-trait analysis);
LGG	cis	rs2072732	0.904	rs9661525	chr1:2952840	A/C	cg08733933	chr1:2954429	NA	-0.38	-8.44	-0.37	4.13e-16	Plateletcrit;
LGG	cis	rs4474465	0.920	rs10899535	chr11:78216237	G/A	cg27205649	chr11:78285834	NARS2	0.47	8.13	0.35	4.1e-15	Alzheimer's disease (survival time);
LGG	cis	rs875971	0.522	rs4718286	chr7:65292764	A/G	cg11987759	chr7:65425863	GUSB	-0.41	-7.96	-0.35	1.33e-14	Aortic root size;
LGG	cis	rs9467773	1.000	rs9393729	chr6:26514166	C/T	cg09904177	chr6:26538194	HMGN4	0.79	18.24	0.65	1.98e-56	Intelligence (multi-trait analysis);
LGG	cis	rs13118159	0.509	rs9683830	chr4:1377873	A/G	cg02071572	chr4:1403502	NA	0.4	6.95	0.31	1.25e-11	Longevity;
LGG	cis	rs10489202	1.000	rs2420	chr1:167886502	A/T	cg24449463	chr1:168025552	DCAF6	-0.59	-9.46	-0.4	1.56e-19	Schizophrenia;
LGG	cis	rs12765878	0.934	rs58543155	chr10:105643244	G/A	cg11005552	chr10:105648138	OBFC1	1.04	27.05	0.78	2.38e-97	Coronary artery disease;
LGG	cis	rs17376456	0.597	rs7708175	chr5:93381182	A/G	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.8	-0.34	4.18e-14	Diabetic retinopathy;
LGG	cis	rs7106204	0.925	rs3924745	chr11:24223001	G/A	ch.11.24196551F	chr11:24239977	NA	1.01	16.15	0.6	7.26e-47	Response to Homoharringtonine (cytotoxicity);
LGG	cis	rs4689388	0.853	rs1079214	chr4:6282157	T/C	cg14416269	chr4:6271139	WFS1	0.51	9.21	0.39	1.1e-18	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs975739	1.000	rs1279674	chr13:78389826	T/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.73	0.3	5.13e-11	Hair color;
LGG	cis	rs889312	0.500	rs252905	chr5:56118875	C/T	cg12654349	chr5:56205094	C5orf35	-0.37	-6.75	-0.3	4.5e-11	Breast cancer;Breast cancer (early onset);
LGG	cis	rs10791097	0.629	rs11222361	chr11:130731424	T/G	cg12179176	chr11:130786555	SNX19	0.77	14.9	0.57	2.67e-41	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs7552404	0.731	rs11588578	chr1:76400539	T/G	cg22875332	chr1:76189707	ACADM	0.57	8.56	0.37	1.71e-16	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs2290159	0.615	rs7610956	chr3:12677158	A/G	cg23032965	chr3:12705835	RAF1	0.66	9.2	0.39	1.22e-18	Cholesterol, total;
LGG	cis	rs2153535	0.580	rs4960413	chr6:8438466	C/T	cg21535247	chr6:8435926	SLC35B3	0.59	10.22	0.43	3.01e-22	Motion sickness;
LGG	cis	rs6952407	1	rs6952407	chr7:66045512	A/G	cg00343986	chr7:65444356	GUSB	-0.41	-6.93	-0.31	1.44e-11	Cotinine glucuronidation;
LGG	cis	rs12497850	0.931	rs9311432	chr3:48850443	T/A	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	cis	rs7945718	0.839	rs11022511	chr11:12834638	A/T	cg25843174	chr11:12811716	TEAD1	0.39	7.89	0.34	2.25e-14	Educational attainment (years of education);
LGG	cis	rs12586317	0.547	rs10134907	chr14:35499211	A/C	cg16230307	chr14:35515116	FAM177A1	0.92	13.57	0.53	1.55e-35	Psoriasis;
LGG	trans	rs7824557	0.614	rs10503421	chr8:11221313	C/T	cg06636001	chr8:8085503	FLJ10661	0.47	8.22	0.36	2.05e-15	Retinal vascular caliber;
LGG	cis	rs6868223	0.617	rs10074763	chr5:33640665	C/T	cg10594543	chr5:33649717	ADAMTS12	0.66	15.53	0.59	4.61e-44	Mortality in heart failure;
LGG	cis	rs4253772	0.550	rs11703564	chr22:46722194	G/A	cg00784671	chr22:46762841	CELSR1	-0.63	-7.16	-0.32	3.1e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2997447	0.681	rs11247854	chr1:26399230	C/T	cg20415053	chr1:26527928	CATSPER4	-0.3	-7.37	-0.32	8.08e-13	QRS complex (12-leadsum);
LGG	cis	rs171408	1.000	rs171408	chr3:8608920	G/A	cg03557445	chr3:8615444	LOH3CR2A	-0.49	-8.83	-0.38	2.17e-17	Mitral valve prolapse;
LGG	cis	rs7215564	0.730	rs76584516	chr17:78549237	A/G	cg16980736	chr17:78789706	RPTOR	-0.65	-8.19	-0.36	2.66e-15	Myopia (pathological);
LGG	cis	rs4561483	0.801	rs251723	chr16:11953080	G/C	cg08843971	chr16:11963173	GSPT1	-0.67	-17.48	-0.63	6.91e-53	Testicular germ cell tumor;
LGG	trans	rs7819412	0.775	rs4545055	chr8:10935366	T/C	cg15556689	chr8:8085844	FLJ10661	-0.53	-9.64	-0.41	3.7799999999999997e-20	Triglycerides;
LGG	cis	rs4595586	0.545	rs12816546	chr12:39398913	C/T	cg13010199	chr12:38710504	ALG10B	0.41	7.46	0.33	4.21e-13	Morning vs. evening chronotype;
LGG	cis	rs7172689	1.000	rs60493572	chr15:81543705	C/T	cg11808699	chr15:81528661	IL16	-0.51	-10.53	-0.44	2.15e-23	Inattentive symptoms;
LGG	cis	rs28386778	0.897	rs1982400	chr17:61793818	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.16	0.35	3.26e-15	Prudent dietary pattern;
LGG	cis	rs1182196	0.533	rs2527521	chr7:2904928	A/G	cg05793240	chr7:2802953	GNA12	-0.27	-6.82	-0.3	2.88e-11	Plateletcrit;
LGG	cis	rs7226408	0.749	rs4539671	chr18:34435006	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-6.96	-0.31	1.2e-11	Obesity-related traits;
LGG	cis	rs875971	1.000	rs778685	chr7:65836176	G/T	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs2832077	0.943	rs2832097	chr21:30173340	A/T	cg03476357	chr21:30257390	N6AMT1	0.58	8.85	0.38	1.81e-17	Cognitive test performance;
LGG	cis	rs1799949	1.000	rs8176083	chr17:41275151	G/C	cg05368731	chr17:41323189	NBR1	0.98	19.12	0.66	1.68e-60	Menopause (age at onset);
LGG	cis	rs7765175	0.698	rs3851199	chr6:113666719	T/C	cg26552650	chr6:113682475	NA	0.34	7.67	0.34	1.01e-13	Coronary artery calcification;
LGG	cis	rs41005	0.967	rs193928	chr2:8107899	T/C	cg03155496	chr2:8117019	LOC339788	0.88	19.54	0.67	1.84e-62	Response to anti-TNF therapy in rheumatoid arthritis;
LGG	cis	rs12188164	0.543	rs2434695	chr5:464177	C/G	cg00473462	chr5:472545	LOC25845	0.36	6.73	0.3	5.16e-11	Cystic fibrosis severity;
LGG	cis	rs4660214	0.666	rs597311	chr1:39820926	T/G	cg18385671	chr1:39797026	MACF1	0.46	9.65	0.41	3.32e-20	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs1691799	0.867	rs1027400	chr12:66760922	A/T	cg16791601	chr12:66731901	HELB	-0.65	-15.1	-0.57	3.49e-42	White blood cell count (basophil);
LGG	cis	rs35306767	0.855	rs34318754	chr10:890714	G/A	cg25019033	chr10:957182	NA	-0.53	-8.98	-0.39	7.03e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs10117734	0.632	rs10974525	chr9:4417406	A/G	cg19556208	chr14:24630405	IRF9	0.42	7.05	0.31	6.7e-12	Parental extreme longevity (95 years and older);
LGG	cis	rs8062405	0.755	rs56272201	chr16:28580685	A/G	cg16576597	chr16:28551801	NUPR1	0.43	9.91	0.42	4.08e-21	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs11760633	0.672	rs6460870	chr7:1843200	C/G	cg22232500	chr2:134024266	NCKAP5	0.52	7.21	0.32	2.25e-12	Coronary artery disease;
LGG	cis	rs9948	0.655	rs2280356	chr2:97366324	C/T	cg01990225	chr2:97406019	LMAN2L	0.72	7.67	0.34	1.04e-13	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs868036	1.000	rs4776377	chr15:68103387	T/C	cg24231037	chr15:68117551	LBXCOR1	-0.31	-7.66	-0.34	1.09e-13	Restless legs syndrome;
LGG	cis	rs6500602	0.702	rs9929475	chr16:4540885	C/T	cg10063637	chr16:4524514	NMRAL1;HMOX2	-0.39	-8.13	-0.35	3.85e-15	Schizophrenia;
LGG	trans	rs459571	0.635	rs379471	chr9:136890649	G/A	cg09836344	chr4:1243392	C4orf42;CTBP1	-0.71	-12.25	-0.49	4.32e-30	Platelet distribution width;
LGG	cis	rs490234	0.576	rs3104554	chr9:128152615	C/T	cg14078157	chr9:128172775	NA	-0.46	-8.55	-0.37	1.83e-16	Mean arterial pressure;
LGG	cis	rs7582180	0.817	rs2309820	chr2:100899676	T/C	cg26150922	chr2:100937072	LONRF2	-0.53	-9.38	-0.4	2.94e-19	Intelligence (multi-trait analysis);
LGG	cis	rs12497850	0.897	rs9884022	chr3:48956862	G/C	cg06212747	chr3:49208901	KLHDC8B	0.64	10.83	0.45	1.61e-24	Parkinson's disease;
LGG	cis	rs28595532	0.920	rs17324821	chr4:119770716	A/G	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs10876993	0.928	rs813854	chr12:58071347	A/G	cg18357645	chr12:58087776	OS9	0.68	12.4	0.5	1.1e-30	Celiac disease or Rheumatoid arthritis;
LGG	trans	rs7937682	0.961	rs11601674	chr11:111634354	C/T	cg18187862	chr3:45730750	SACM1L	0.69	11.61	0.47	1.54e-27	Primary sclerosing cholangitis;
LGG	cis	rs7147624	1.000	rs1009465	chr14:65970370	G/C	cg03016385	chr14:66212404	NA	-0.77	-9.72	-0.41	1.96e-20	Chronic obstructive pulmonary disease-related biomarkers;
LGG	cis	rs933688	1.000	rs7715402	chr5:90679504	T/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.11	19.44	0.67	5.35e-62	Smoking behavior;
LGG	trans	rs4332037	0.624	rs56256289	chr7:1892529	C/T	cg11693508	chr17:37793320	STARD3	0.63	9.5	0.4	1.1e-19	Bipolar disorder;
LGG	cis	rs7932354	0.528	rs7947878	chr11:47028531	C/T	cg03339077	chr11:47165057	C11orf49	-0.52	-9.87	-0.42	5.67e-21	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs763121	0.819	rs5757126	chr22:38923675	T/C	cg06022373	chr22:39101656	GTPBP1	0.86	16.9	0.62	2.88e-50	Menopause (age at onset);
LGG	cis	rs7084402	0.967	rs7091440	chr10:60271372	T/A	cg07615347	chr10:60278583	BICC1	-0.63	-17.9	-0.64	7.56e-55	Refractive error;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19444155	chr15:49338748	SECISBP2L	0.56	6.71	0.3	5.62e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9611565	0.729	rs2413646	chr22:41906325	C/T	cg17376030	chr22:41985996	PMM1	0.58	9.1	0.39	2.72e-18	Vitiligo;
LGG	cis	rs916888	0.773	rs199534	chr17:44824213	T/G	cg20120463	chr17:44301886	NA	-0.48	-7.45	-0.33	4.52e-13	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs3820928	0.874	rs13430941	chr2:227904447	G/A	cg11843606	chr2:227700838	RHBDD1	-0.43	-7.31	-0.32	1.18e-12	Pulmonary function;
LGG	cis	rs769267	0.930	rs3794990	chr19:19610030	A/G	cg17414380	chr19:19431394	KIAA0892;SF4	0.51	8.37	0.36	6.8e-16	Tonsillectomy;
LGG	cis	rs763014	0.966	rs4984903	chr16:680695	A/G	cg07343612	chr16:622815	PIGQ	-0.76	-15.81	-0.59	2.41e-45	Height;
LGG	cis	rs9322193	0.923	rs57012784	chr6:149948827	G/A	cg16507663	chr6:150244633	RAET1G	0.44	8.3	0.36	1.14e-15	Lung cancer;
LGG	cis	rs4555082	0.830	rs2735812	chr14:105727575	A/G	cg06808227	chr14:105710500	BRF1	-0.64	-11.12	-0.46	1.27e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs4862750	0.872	rs6836781	chr4:187899701	G/A	cg10295955	chr4:187884368	NA	-1.15	-31.93	-0.83	4.43e-119	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7726839	0.540	rs61731455	chr5:665295	A/G	cg16400903	chr5:693638	TPPP	0.48	7.09	0.31	5.1e-12	Obesity-related traits;
LGG	trans	rs7746199	0.736	rs34965299	chr6:27521856	A/G	cg08344181	chr3:125677491	NA	-0.87	-8.74	-0.38	4.22e-17	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs651907	0.557	rs2288272	chr3:101378476	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.42	-7.52	-0.33	2.82e-13	Colorectal cancer;
LGG	cis	rs897984	0.609	rs55979739	chr16:31049155	A/G	cg02466173	chr16:30829666	NA	-0.41	-7.2	-0.32	2.53e-12	Dementia with Lewy bodies;
LGG	cis	rs6500602	0.702	rs6500605	chr16:4502410	C/T	cg10295110	chr16:4524375	NMRAL1;HMOX2	0.42	7.52	0.33	2.93e-13	Schizophrenia;
LGG	trans	rs1814175	0.684	rs1827015	chr11:49585241	A/G	cg15704280	chr7:45808275	SEPT13	-0.96	-18.39	-0.65	4.01e-57	Height;
LGG	cis	rs10463554	0.927	rs34802	chr5:102427005	T/C	cg23492399	chr5:102201601	PAM	-0.52	-7.77	-0.34	4.98e-14	Parkinson's disease;
LGG	cis	rs1909881	0.872	rs10956954	chr8:96513903	A/G	cg04203453	chr8:96504381	NA	-1.08	-18.36	-0.65	5.69e-57	Obesity-related traits;
LGG	cis	rs1799949	0.965	rs9897425	chr17:41430179	C/G	cg18379455	chr17:41446167	NA	-0.33	-8.02	-0.35	8.92e-15	Menopause (age at onset);
LGG	cis	rs801193	0.660	rs2659897	chr7:66187715	A/G	cg23594656	chr7:65796392	TPST1	0.35	7.68	0.34	9.83e-14	Aortic root size;
LGG	cis	rs503734	0.666	rs6441608	chr3:101181028	G/A	cg27318481	chr3:100970896	IMPG2	0.35	7.19	0.32	2.53e-12	Inflammatory bowel disease;Crohn's disease;
LGG	trans	rs7824557	0.564	rs2572379	chr8:11237480	A/G	cg06636001	chr8:8085503	FLJ10661	-0.53	-9.57	-0.41	6.25e-20	Retinal vascular caliber;
LGG	cis	rs13108904	0.901	rs6851528	chr4:1296009	G/A	cg20887711	chr4:1340912	KIAA1530	0.62	12.15	0.49	1.07e-29	Obesity-related traits;
LGG	cis	rs2013441	0.965	rs2386485	chr17:20095246	G/A	cg09818912	chr17:20140352	CYTSB	0.29	6.66	0.3	7.92e-11	Obesity-related traits;
LGG	cis	rs60843830	1.000	rs59937473	chr2:271797	G/A	cg04617936	chr2:214353	NA	-0.4	-7.37	-0.32	8.09e-13	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs13118159	0.836	rs2293630	chr4:1342521	G/A	cg16405210	chr4:1374714	KIAA1530	-0.64	-11.61	-0.47	1.59e-27	Longevity;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg05164570	chr5:140071033	HARS;HARS2	0.42	6.75	0.3	4.38e-11	Cognitive performance;
LGG	cis	rs9902453	0.765	rs2467334	chr17:28135508	A/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.29	-0.55	1.29e-38	Coffee consumption (cups per day);
LGG	trans	rs1005277	0.579	rs1740732	chr10:38491385	C/T	cg23533926	chr12:111358616	MYL2	-0.43	-7.14	-0.31	3.55e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs9910055	0.636	rs7089	chr17:42269017	T/C	cg16434002	chr17:42200994	HDAC5	-0.56	-10.31	-0.43	1.46e-22	Total body bone mineral density;
LGG	trans	rs9650657	0.645	rs4841409	chr8:10516374	C/T	cg08975724	chr8:8085496	FLJ10661	0.42	8.02	0.35	8.46e-15	Neuroticism;
LGG	cis	rs1401999	0.714	rs7646621	chr3:183640865	A/C	cg20387954	chr3:183756860	HTR3D	-0.49	-9.65	-0.41	3.36e-20	Anterior chamber depth;
LGG	cis	rs4478137	0.824	rs10857353	chr4:164215835	A/G	cg06758707	chr4:164254230	NPY1R	-0.7	-12.98	-0.52	4.61e-33	Subjective well-being (multi-trait analysis);Subjective well-being;
LGG	cis	rs6952808	0.723	rs60432611	chr7:2029629	G/C	cg14004847	chr7:1930337	MAD1L1	-0.55	-9.73	-0.41	1.75e-20	Bipolar disorder and schizophrenia;
LGG	cis	rs10915437	1.000	rs10915437	chr1:4183006	A/G	cg27165836	chr1:4193882	NA	0.36	7.24	0.32	1.88e-12	Migraine - clinic-based;
LGG	cis	rs77956314	0.515	rs4238051	chr12:117366299	A/G	cg02017074	chr12:117425053	FBXW8	0.55	7.63	0.33	1.34e-13	Subcortical brain region volumes;Hippocampal volume;
LGG	cis	rs11785400	0.762	rs7007349	chr8:143722673	T/C	cg10596483	chr8:143751796	JRK	0.51	8.0	0.35	9.76e-15	Schizophrenia;
LGG	cis	rs208520	0.802	rs208496	chr6:66930786	G/C	cg07460842	chr6:66804631	NA	-0.93	-16.03	-0.6	2.42e-46	Exhaled nitric oxide output;
LGG	cis	rs873946	0.586	rs61862838	chr10:134572282	C/T	cg06453172	chr10:134556979	INPP5A	-0.56	-8.35	-0.36	8.06e-16	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs1707322	0.650	rs4660879	chr1:46105401	C/A	cg03146154	chr1:46216737	IPP	0.57	11.01	0.46	3.42e-25	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs892961	0.965	rs312856	chr17:75401598	A/G	cg05865280	chr17:75406074	SEPT9	0.42	10.17	0.43	4.62e-22	Airflow obstruction;
LGG	cis	rs11098499	0.542	rs7677836	chr4:120310638	T/A	cg09307838	chr4:120376055	NA	0.81	13.51	0.53	2.7e-35	Corneal astigmatism;
LGG	trans	rs1814175	0.676	rs1851859	chr11:49860405	A/T	cg15704280	chr7:45808275	SEPT13	-0.99	-21.79	-0.71	5.51e-73	Height;
LGG	cis	rs9326248	1.000	rs3736120	chr11:117032125	G/T	cg11861562	chr11:117069780	TAGLN	0.25	6.8	0.3	3.22e-11	Blood protein levels;
LGG	cis	rs2228479	0.557	rs11641726	chr16:89891619	G/A	cg00800038	chr16:89945340	TCF25	-0.7	-7.96	-0.35	1.33e-14	Skin colour saturation;
LGG	cis	rs7493	0.950	rs12704794	chr7:95036133	A/T	cg17330251	chr7:94953956	PON1	-0.43	-8.49	-0.37	2.74e-16	Yu-Zhi constitution type in type 2 diabetes;
LGG	cis	rs4650994	0.935	rs4652306	chr1:178528206	T/C	cg12486710	chr1:178512616	C1orf220	0.42	8.45	0.37	3.87e-16	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4363385	0.747	rs6689609	chr1:152967588	G/A	cg13444842	chr1:152974279	SPRR3	-0.45	-9.24	-0.39	9.15e-19	Inflammatory skin disease;
LGG	cis	rs11711311	0.955	rs12636536	chr3:113474226	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.67	14.03	0.55	1.55e-37	IgG glycosylation;
LGG	cis	rs7737355	1.000	rs40396	chr5:130708044	C/G	cg06307176	chr5:131281290	NA	-0.51	-8.59	-0.37	1.34e-16	Life satisfaction;
LGG	cis	rs7582180	0.629	rs12612809	chr2:100951616	G/T	cg14675211	chr2:100938903	LONRF2	0.68	12.3	0.5	2.74e-30	Intelligence (multi-trait analysis);
LGG	cis	rs6502050	0.835	rs4789672	chr17:80126603	T/C	cg23985595	chr17:80112537	CCDC57	-0.48	-9.64	-0.41	3.67e-20	Life satisfaction;
LGG	trans	rs2270927	0.510	rs35764719	chr5:75573550	G/T	cg13563193	chr19:33072644	PDCD5	0.83	9.92	0.42	3.83e-21	Mean corpuscular volume;
LGG	cis	rs11190604	1.000	rs7088512	chr10:102303498	G/T	cg07570687	chr10:102243282	WNT8B	0.42	6.96	0.31	1.15e-11	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8060686	0.545	rs12596883	chr16:68172416	A/T	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.71	-0.3	5.83e-11	HDL cholesterol;Metabolic syndrome;
LGG	cis	rs3741404	1.000	rs3741404	chr11:63999240	G/C	cg19465662	chr11:63993652	NUDT22;TRPT1	0.96	17.84	0.64	1.43e-54	Platelet count;
LGG	cis	rs873946	0.564	rs12242672	chr10:134555609	A/T	cg27286337	chr10:134555280	INPP5A	0.89	14.14	0.55	5.51e-38	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs4862750	0.872	rs13143414	chr4:187878213	G/A	cg27532560	chr4:187881888	NA	-0.59	-13.29	-0.53	2.33e-34	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4975616	0.869	rs380286	chr5:1320247	G/A	cg06550200	chr5:1325588	CLPTM1L	-0.64	-11.5	-0.47	4.24e-27	Lung cancer;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg22520471	chr17:61851767	DDX42;CCDC47	0.59	11.78	0.48	3.37e-28	Prudent dietary pattern;
LGG	cis	rs1046896	0.576	rs8082558	chr17:80695501	G/A	cg15664640	chr17:80829946	TBCD	0.45	8.25	0.36	1.64e-15	Glycated hemoglobin levels;
LGG	cis	rs28386778	0.735	rs2727336	chr17:61991965	G/C	cg07677032	chr17:61819896	STRADA	-0.61	-11.01	-0.46	3.42e-25	Prudent dietary pattern;
LGG	cis	rs2576037	0.583	rs8098948	chr18:44512332	C/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.44	8.4	0.36	5.69e-16	Personality dimensions;
LGG	cis	rs7727544	0.735	rs272842	chr5:131656517	A/G	cg24060327	chr5:131705240	SLC22A5	-0.5	-8.68	-0.37	7e-17	Blood metabolite levels;
LGG	cis	rs12142240	0.698	rs17357676	chr1:46812444	A/G	cg00530320	chr1:46809349	NSUN4	0.45	8.27	0.36	1.46e-15	Menopause (age at onset);
LGG	cis	rs28386778	0.724	rs35092235	chr17:61944621	T/C	cg17202724	chr17:61916730	SMARCD2	-0.62	-14.98	-0.57	1.23e-41	Prudent dietary pattern;
LGG	cis	rs7267979	0.714	rs3787082	chr20:25235736	A/T	cg08601574	chr20:25228251	PYGB	0.39	7.83	0.34	3.32e-14	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs9393777	0.513	rs11967852	chr6:26612870	G/T	cg12826209	chr6:26865740	GUSBL1	0.83	12.15	0.49	1.17e-29	Intelligence (multi-trait analysis);
LGG	trans	rs1005277	0.541	rs2505193	chr10:38394638	G/C	cg17830980	chr10:43048298	ZNF37B	-0.62	-14.47	-0.56	2.05e-39	Extrinsic epigenetic age acceleration;
LGG	trans	rs1005277	0.579	rs1621040	chr10:38497232	T/C	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.29	-0.53	2.17e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs58688157	0.960	rs1055382	chr11:612182	T/C	cg01842473	chr11:617407	IRF7;MUPCDH	-0.63	-9.51	-0.4	1.05e-19	Systemic lupus erythematosus;
LGG	cis	rs2153535	0.580	rs4639392	chr6:8446547	A/G	cg07606381	chr6:8435919	SLC35B3	0.68	12.59	0.5	1.85e-31	Motion sickness;
LGG	cis	rs7937682	0.921	rs4534611	chr11:111440425	C/G	cg22437258	chr11:111473054	SIK2	0.5	8.5	0.37	2.56e-16	Primary sclerosing cholangitis;
LGG	cis	rs6831352	0.918	rs17218108	chr4:100055755	T/C	cg13256891	chr4:100009986	ADH5	-0.56	-9.77	-0.41	1.3e-20	Alcohol dependence;
LGG	cis	rs17767392	1.000	rs34528131	chr14:71861278	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.42	-8.98	-0.39	6.67e-18	Mitral valve prolapse;
LGG	cis	rs11098499	0.954	rs13107475	chr4:120393011	A/T	cg09307838	chr4:120376055	NA	0.82	13.85	0.54	9.55e-37	Corneal astigmatism;
LGG	trans	rs7829975	0.688	rs7837587	chr8:8378992	T/C	cg02002194	chr4:3960332	NA	-0.51	-10.26	-0.43	2.2e-22	Mood instability;
LGG	cis	rs9309473	0.950	rs6711001	chr2:73850820	C/G	cg20560298	chr2:73613845	ALMS1	-0.44	-7.21	-0.32	2.3e-12	Metabolite levels;
LGG	cis	rs4629180	0.675	rs10184144	chr2:102104978	C/T	cg16435561	chr2:102091048	RFX8	0.46	8.6	0.37	1.2e-16	Chronic rhinosinusitis with nasal polyps;
LGG	cis	rs875971	0.929	rs12673810	chr7:65923853	T/A	cg23594656	chr7:65796392	TPST1	-0.39	-8.72	-0.38	4.97e-17	Aortic root size;
LGG	cis	rs11622475	1.000	rs10136440	chr14:104397367	C/A	cg12183467	chr14:104352244	NA	0.45	7.52	0.33	2.86e-13	Bipolar disorder;
LGG	cis	rs7223966	1.000	rs2854218	chr17:61942940	A/G	cg05941027	chr17:61774174	LIMD2	0.35	8.69	0.37	6.5e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs2120019	1.000	rs12910644	chr15:75358388	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-19.43	-0.67	5.92e-62	Blood trace element (Zn levels);
LGG	cis	rs1021993	0.545	rs17014337	chr1:209527465	T/C	cg24446417	chr1:209558027	NA	-0.7	-10.15	-0.43	5.61e-22	Gut microbiome composition (winter);
LGG	cis	rs11718455	0.960	rs1852036	chr3:44003862	C/T	cg21419209	chr3:44054225	NA	-0.41	-6.79	-0.3	3.47e-11	Coronary artery disease;
LGG	cis	rs9560113	0.843	rs9555808	chr13:112181284	A/T	cg10483660	chr13:112241077	NA	0.36	7.05	0.31	6.68e-12	Menarche (age at onset);
LGG	cis	rs4555082	0.830	rs2816614	chr14:105727359	C/T	cg06808227	chr14:105710500	BRF1	-0.64	-11.1	-0.46	1.54e-25	Mean platelet volume;Platelet distribution width;
LGG	cis	rs1843834	0.755	rs10197382	chr2:225574650	T/C	cg22455342	chr2:225449267	CUL3	0.48	8.16	0.35	3.26e-15	IgE levels in asthmatics (D.p. specific);
LGG	cis	rs9291683	0.530	rs6449196	chr4:9973660	C/T	cg25986240	chr4:9926439	SLC2A9	0.48	10.3	0.43	1.57e-22	Bone mineral density;
LGG	cis	rs10754283	0.967	rs10801760	chr1:90113824	G/A	cg21401794	chr1:90099060	LRRC8C	0.57	12.28	0.5	3.23e-30	Amyotrophic lateral sclerosis (sporadic);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg11841349	chr3:9791615	OGG1	0.48	7.7	0.34	8.47e-14	Cognitive performance;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01947301	chr1:205718900	NUCKS1	-0.46	-7.32	-0.32	1.12e-12	Gut microbiome composition (summer);
LGG	cis	rs7618915	0.501	rs12635140	chr3:52738165	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	-0.61	-10.99	-0.45	4.1e-25	Bipolar disorder;
LGG	trans	rs6601327	0.632	rs4841220	chr8:9656059	T/G	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.95	-0.31	1.22e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs6502050	0.835	rs8078795	chr17:80126320	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs11098499	0.908	rs11729050	chr4:120300066	T/C	cg24375607	chr4:120327624	NA	0.67	10.95	0.45	5.9e-25	Corneal astigmatism;
LGG	cis	rs2535633	0.594	rs2581789	chr3:53096230	C/T	cg11645453	chr3:52864694	ITIH4	-0.47	-7.72	-0.34	7.13e-14	Body mass index;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg24334809	chr2:178483498	TTC30A	-0.4	-6.88	-0.3	1.9e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs6089584	0.924	rs6142906	chr20:60552554	G/C	cg06470251	chr20:60548479	NA	0.54	9.48	0.4	1.28e-19	Body mass index;
LGG	cis	rs17270561	0.609	rs7450798	chr6:25719280	T/A	cg17691542	chr6:26056736	HIST1H1C	0.62	10.26	0.43	2.07e-22	Iron status biomarkers;
LGG	cis	rs1550582	1.000	rs62523710	chr8:135538773	T/C	cg17885191	chr8:135476712	NA	0.67	10.27	0.43	2.03e-22	Educational attainment;
LGG	cis	rs798554	0.679	rs1636253	chr7:2885123	A/G	cg05793240	chr7:2802953	GNA12	0.33	7.87	0.34	2.55e-14	Height;
LGG	cis	rs12681288	0.550	rs60530879	chr8:958381	G/C	cg15309053	chr8:964076	NA	0.42	9.07	0.39	3.29e-18	Schizophrenia;
LGG	cis	rs972578	0.765	rs4820499	chr22:43375141	T/C	cg01576275	chr22:43409880	NA	-0.25	-7.65	-0.34	1.16e-13	Mean platelet volume;
LGG	cis	rs4936894	0.500	rs12362791	chr11:124128232	C/T	cg27160556	chr11:124181099	OR8D1	-0.44	-10.25	-0.43	2.29e-22	Aging (time to death);
LGG	cis	rs28735056	0.933	rs56181785	chr18:77633629	G/A	cg20368463	chr18:77673604	PQLC1	-0.49	-8.47	-0.37	3.22e-16	Schizophrenia;
LGG	cis	rs11676348	0.846	rs7607437	chr2:219008392	A/G	cg00012203	chr2:219082015	ARPC2	-0.58	-10.57	-0.44	1.57e-23	Ulcerative colitis;
LGG	cis	rs137603	0.502	rs137627	chr22:39716341	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	-0.71	-13.91	-0.54	5.11e-37	Primary biliary cholangitis;
LGG	cis	rs13336428	0.730	rs28653458	chr16:1525850	T/C	cg07835181	chr16:1525278	CLCN7	0.68	11.69	0.48	7.82e-28	Bone mineral density;
LGG	cis	rs10504073	0.584	rs56074306	chr8:49940282	C/T	cg00325661	chr8:49890786	NA	0.78	15.31	0.58	4.08e-43	Blood metabolite ratios;
LGG	cis	rs1978968	0.763	rs9605481	chr22:18465677	C/T	cg03078520	chr22:18463400	MICAL3	-0.69	-14.51	-0.56	1.3e-39	Presence of antiphospholipid antibodies;
LGG	cis	rs2273669	0.667	rs10457187	chr6:109336051	G/A	cg05315195	chr6:109294784	ARMC2	-0.64	-8.49	-0.37	2.81e-16	Prostate cancer;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg18197146	chr6:41747905	FRS3;PRICKLE4	0.49	7.37	0.32	8.12e-13	Gut microbiome composition (summer);
LGG	cis	rs593531	0.571	rs6592557	chr11:74086642	T/C	cg18195628	chr11:73498948	MRPL48	-0.41	-6.93	-0.31	1.43e-11	Neuroticism;
LGG	cis	rs6558530	0.640	rs7844748	chr8:1702343	C/T	cg22756942	chr8:1746360	NA	-0.41	-6.82	-0.3	2.78e-11	Systolic blood pressure;
LGG	cis	rs10979	1.000	rs9321923	chr6:143897206	A/G	cg25407410	chr6:143891975	LOC285740	-0.73	-12.57	-0.5	2.2e-31	Hypospadias;
LGG	cis	rs12701220	0.817	rs1058729	chr7:1087283	C/T	cg26769984	chr7:1090371	C7orf50	0.53	9.45	0.4	1.75e-19	Bronchopulmonary dysplasia;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19720917	chr19:36606221	POLR2I;TBCB	0.47	7.48	0.33	3.65e-13	Cognitive performance;
LGG	cis	rs9910055	0.659	rs227584	chr17:42225547	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.66	12.5	0.5	4.1e-31	Total body bone mineral density;
LGG	cis	rs6076065	0.748	rs4815198	chr20:23343491	T/C	cg12633918	chr20:23549525	CST9L	-0.33	-6.79	-0.3	3.41e-11	Facial morphology (factor 15, philtrum width);
LGG	trans	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg13010199	chr12:38710504	ALG10B	0.51	9.92	0.42	3.68e-21	Morning vs. evening chronotype;
LGG	cis	rs9322193	0.884	rs7769115	chr6:150169932	C/T	cg08621203	chr6:150244597	RAET1G	0.47	8.12	0.35	4.22e-15	Lung cancer;
LGG	cis	rs2842992	0.724	rs1128670	chr6:160211636	G/A	cg26839252	chr6:160211577	TCP1;MRPL18	0.47	8.13	0.35	3.97e-15	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs8012	0.517	rs17706531	chr19:13015530	A/G	cg06417478	chr19:12876846	HOOK2	-0.41	-6.76	-0.3	4.27e-11	Mean corpuscular hemoglobin;Mean corpuscular volume;Blood metabolite levels;
LGG	cis	rs4332037	0.950	rs62442895	chr7:1936938	G/A	cg24189917	chr7:1970923	MAD1L1	-0.6	-8.87	-0.38	1.55e-17	Bipolar disorder;
LGG	cis	rs1552244	1.000	rs17032295	chr3:10086680	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.19	20.86	0.7	1.35e-68	Alzheimer's disease;
LGG	cis	rs1799949	0.794	rs116409325	chr17:41445460	C/A	cg23758822	chr17:41437982	NA	0.91	15.96	0.6	5.08e-46	Menopause (age at onset);
LGG	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg14092988	chr3:52407081	DNAH1	0.31	7.98	0.35	1.18e-14	Electroencephalogram traits;
LGG	cis	rs9921222	0.564	rs9923059	chr16:381590	C/A	cg00101154	chr16:420108	MRPL28	-0.64	-10.02	-0.42	1.6e-21	Bone mineral density (spine);Bone mineral density;
LGG	cis	rs6500395	0.962	rs9937623	chr16:48571590	A/T	cg16662043	chr16:48846231	NA	-0.37	-7.16	-0.32	3.2e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9329221	1.000	rs9329221	chr8:10240202	G/T	cg21775007	chr8:11205619	TDH	0.49	7.82	0.34	3.57e-14	Neuroticism;
LGG	cis	rs9322193	0.923	rs10782317	chr6:150075047	C/T	cg08621203	chr6:150244597	RAET1G	-0.46	-8.05	-0.35	7.15e-15	Lung cancer;
LGG	cis	rs10744422	1.000	rs7139055	chr12:123364198	A/G	cg25930673	chr12:123319894	HIP1R	0.75	9.58	0.41	5.81e-20	Schizophrenia;
LGG	cis	rs2235642	0.750	rs1894649	chr16:1657284	C/G	cg09025071	chr16:1593152	IFT140;TMEM204	0.37	8.99	0.39	6.16e-18	Coronary artery disease;
LGG	cis	rs9462027	0.628	rs2814957	chr6:34702689	C/G	cg07306190	chr6:34760872	UHRF1BP1	-0.54	-10.99	-0.45	4.07e-25	Systemic lupus erythematosus;
LGG	cis	rs2243480	1.000	rs35421653	chr7:65363429	C/A	cg12463550	chr7:65579703	CRCP	0.74	8.02	0.35	8.92e-15	Diabetic kidney disease;
LGG	cis	rs344364	0.511	rs2917515	chr16:1945271	G/C	cg00046913	chr16:1877150	HAGH;FAHD1	-0.56	-6.97	-0.31	1.06e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9644630	0.897	rs4921654	chr8:19359974	G/T	cg06699216	chr8:19333253	CSGALNACT1	0.5	12.08	0.49	2.18e-29	Oropharynx cancer;
LGG	trans	rs916888	0.773	rs169201	chr17:44790203	A/G	cg10053473	chr17:62856997	LRRC37A3	-0.95	-15.04	-0.57	6.57e-42	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs6748734	0.857	rs10933638	chr2:241794655	G/A	cg04034577	chr2:241836375	C2orf54	-0.48	-10.13	-0.43	6.25e-22	Urinary metabolites;
LGG	trans	rs61931739	0.534	rs11053029	chr12:34131766	G/T	cg13010199	chr12:38710504	ALG10B	0.58	11.12	0.46	1.27e-25	Morning vs. evening chronotype;
LGG	cis	rs2862064	0.872	rs4704734	chr5:156480406	G/A	cg12943317	chr5:156479607	HAVCR1	-0.81	-10.85	-0.45	1.41e-24	Platelet count;
LGG	cis	rs593982	1.000	rs665191	chr11:65493658	G/A	cg08755490	chr11:65554678	OVOL1	0.74	10.52	0.44	2.34e-23	Atopic dermatitis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg22052758	chr12:50451005	ACCN2	0.43	6.75	0.3	4.5e-11	Gut microbiome composition (summer);
LGG	cis	rs2228479	0.850	rs3785281	chr16:89824263	G/C	cg06558623	chr16:89946397	TCF25	1.15	12.6	0.51	1.65e-31	Skin colour saturation;
LGG	cis	rs1552244	1.000	rs6807846	chr3:10134491	G/T	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.86	-13.7	-0.54	4.09e-36	Alzheimer's disease;
LGG	cis	rs9322193	0.736	rs10457851	chr6:150096352	T/A	cg12070911	chr6:150209640	RAET1E	0.29	6.93	0.31	1.38e-11	Lung cancer;
LGG	cis	rs1799949	0.931	rs9912203	chr17:41445145	A/G	cg05368731	chr17:41323189	NBR1	-0.9	-17.85	-0.64	1.28e-54	Menopause (age at onset);
LGG	trans	rs9329221	0.507	rs12678938	chr8:10016969	C/T	cg06636001	chr8:8085503	FLJ10661	-0.54	-9.73	-0.41	1.7e-20	Neuroticism;
LGG	trans	rs7824557	0.628	rs7815802	chr8:11190647	G/C	cg06636001	chr8:8085503	FLJ10661	0.42	7.33	0.32	1.02e-12	Retinal vascular caliber;
LGG	cis	rs17270561	0.609	rs12203927	chr6:25732690	A/G	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg07519485	chr6:33762594	MLN	-0.31	-6.83	-0.3	2.61e-11	Crohn's disease;
LGG	cis	rs2640806	0.505	rs11997620	chr8:97366139	C/T	cg22138393	chr8:97340270	PTDSS1	0.28	7.27	0.32	1.5e-12	Obesity-related traits;
LGG	cis	rs283228	0.617	rs683149	chr6:101745522	C/T	cg27451362	chr6:101846650	GRIK2	0.86	13.5	0.53	3.05e-35	Coenzyme Q10 levels;
LGG	cis	rs6502050	0.805	rs9898326	chr17:80119582	C/T	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs9487051	0.872	rs9398197	chr6:109609988	C/A	cg12927641	chr6:109611667	NA	-0.36	-6.91	-0.31	1.65e-11	Reticulocyte fraction of red cells;
LGG	cis	rs2594989	0.887	rs9850117	chr3:11571991	C/T	cg01796438	chr3:11312864	ATG7	0.55	7.38	0.32	7.3e-13	Circulating chemerin levels;
LGG	cis	rs9398803	0.687	rs853962	chr6:127027650	G/T	cg19875578	chr6:126661172	C6orf173	-0.52	-9.66	-0.41	3.15e-20	Male-pattern baldness;
LGG	cis	rs4938330	0.608	rs2238006	chr11:117087792	A/C	cg01368799	chr11:117014884	PAFAH1B2	-0.58	-7.53	-0.33	2.77e-13	Blood protein levels;
LGG	cis	rs11864453	0.762	rs6416742	chr16:72149061	C/T	cg01557791	chr16:72042693	DHODH	-0.57	-10.03	-0.42	1.45e-21	Fibrinogen levels;
LGG	cis	rs8017423	0.967	rs11627429	chr14:90689232	G/A	cg04374321	chr14:90722782	PSMC1	-0.91	-18.84	-0.66	3.37e-59	Mortality in heart failure;
LGG	cis	rs698813	0.674	rs6759891	chr2:44496005	C/T	cg00619915	chr2:44497795	NA	-0.61	-8.62	-0.37	1.04e-16	Adverse response to chemotherapy in breast cancer (alopecia) (paclitaxel);
LGG	cis	rs496547	0.520	rs11216963	chr11:118580814	G/A	cg20309703	chr11:118481025	PHLDB1	0.4	6.86	0.3	2.23e-11	Hip minimal joint space width;
LGG	cis	rs2836974	0.965	rs34578707	chr21:40675167	G/A	cg06238570	chr21:40685208	BRWD1	0.45	6.94	0.31	1.36e-11	Cognitive function;
LGG	cis	rs28386778	0.897	rs1470697	chr17:61799840	T/C	cg07659893	chr17:61819838	STRADA	0.48	8.15	0.35	3.38e-15	Prudent dietary pattern;
LGG	trans	rs12599106	0.792	rs12597352	chr16:34638507	A/T	cg18110333	chr6:292329	DUSP22	-0.56	-9.88	-0.42	4.96e-21	Menopause (age at onset);
LGG	cis	rs17376456	0.825	rs13156202	chr5:93157721	C/T	cg25358565	chr5:93447407	FAM172A	-1.26	-15.6	-0.59	2.2e-44	Diabetic retinopathy;
LGG	cis	rs28386778	0.830	rs67905415	chr17:61841236	G/A	cg11494091	chr17:61959527	GH2	0.99	24.14	0.75	6.1e-84	Prudent dietary pattern;
LGG	cis	rs4262150	0.883	rs4260728	chr5:152225997	C/A	cg12297329	chr5:152029980	NA	-0.68	-12.61	-0.51	1.56e-31	Bipolar disorder and schizophrenia;
LGG	cis	rs514406	0.729	rs534070	chr1:53308858	T/G	cg24675658	chr1:53192096	ZYG11B	-0.58	-12.18	-0.49	8.68e-30	Monocyte count;
LGG	cis	rs2195525	0.572	rs3814758	chr11:119217818	A/G	cg01451205	chr11:119252210	USP2	0.41	6.81	0.3	3.02e-11	Urate levels;
LGG	cis	rs10504229	1.000	rs67096506	chr8:58195655	G/A	cg14926445	chr8:58193284	C8orf71	-0.92	-12.7	-0.51	6.77e-32	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.886	rs10872652	chr6:150096439	C/T	cg09699651	chr6:150184138	LRP11	0.49	8.68	0.37	6.7e-17	Lung cancer;
LGG	cis	rs9916302	0.904	rs4794807	chr17:37531718	T/A	cg07936489	chr17:37558343	FBXL20	0.85	15.88	0.59	1.2e-45	Glomerular filtration rate (creatinine);
LGG	cis	rs6089584	0.927	rs2296081	chr20:60572663	G/T	cg12751644	chr20:60527061	NA	-0.3	-7.18	-0.32	2.83e-12	Body mass index;
LGG	cis	rs801193	0.569	rs10950050	chr7:66239588	A/C	cg23594656	chr7:65796392	TPST1	-0.35	-7.85	-0.34	3.01e-14	Aortic root size;
LGG	cis	rs4740619	0.933	rs7859788	chr9:15710606	A/T	cg14451791	chr9:16040625	NA	-0.39	-9.95	-0.42	2.98e-21	Body mass index;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05754148	chr16:3507555	NAT15	-0.42	-7.02	-0.31	7.71e-12	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs921968	0.643	rs537520	chr2:219381852	A/G	cg02985541	chr2:219472218	PLCD4	0.29	6.9	0.31	1.67e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs7932354	0.528	rs1965952	chr11:47181040	G/A	cg03339077	chr11:47165057	C11orf49	0.55	10.48	0.44	3.24e-23	Bone mineral density (hip);Bone mineral density;
LGG	cis	rs3849570	0.961	rs3772896	chr3:81751968	C/T	cg07356753	chr3:81810745	GBE1	-0.5	-8.09	-0.35	5.38e-15	Waist circumference;Body mass index;
LGG	cis	rs10504229	1.000	rs1390411	chr8:58194146	C/A	cg02725872	chr8:58115012	NA	-0.79	-11.28	-0.46	3.15e-26	Developmental language disorder (linguistic errors);
LGG	cis	rs7044106	0.791	rs2416797	chr9:123480600	C/A	cg09419670	chr9:123605666	PSMD5;LOC253039	0.83	16.48	0.61	2.48e-48	Hip circumference adjusted for BMI;
LGG	cis	rs2576037	0.526	rs2510444	chr18:44376849	G/T	cg19077165	chr18:44547161	KATNAL2	-0.6	-11.2	-0.46	6.18e-26	Personality dimensions;
LGG	cis	rs988958	0.526	rs36109745	chr2:42252990	C/A	cg27252766	chr2:42229092	NA	0.5	7.19	0.32	2.57e-12	Hypospadias;
LGG	cis	rs34330	0.562	rs11055023	chr12:12853197	A/G	cg04607235	chr12:12878440	APOLD1	-0.62	-8.79	-0.38	3.04e-17	Systemic lupus erythematosus;
LGG	cis	rs9358372	0.711	rs4077405	chr6:20876683	C/T	cg13405222	chr6:20811065	CDKAL1	-0.59	-12.51	-0.5	3.79e-31	Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs2629540	0.889	rs10901815	chr10:126435598	G/A	cg08799069	chr10:126477246	METTL10	-0.68	-14.5	-0.56	1.53e-39	Cocaine dependence;
LGG	cis	rs12210905	1.000	rs72843607	chr6:27110715	C/A	cg23155468	chr6:27110703	HIST1H2BK	-0.69	-8.22	-0.36	2.04e-15	Hip circumference adjusted for BMI;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg17019866	chr8:121457656	MTBP;MRPL13	0.42	6.76	0.3	4.24e-11	Cognitive performance;
LGG	cis	rs4774899	0.752	rs2920267	chr15:57351029	C/T	cg08128148	chr15:57256372	TCF12	-0.29	-7.12	-0.31	4.1e-12	Urinary tract infection frequency;
LGG	cis	rs3799379	0.530	rs10456045	chr6:26404958	A/G	cg12826209	chr6:26865740	GUSBL1	-0.49	-7.33	-0.32	1.04e-12	Intelligence (multi-trait analysis);
LGG	cis	rs1790761	0.520	rs4930461	chr11:67394895	A/G	cg14500267	chr11:67383377	NA	0.41	7.05	0.31	6.73e-12	Mean corpuscular volume;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg05128566	chr7:95401838	DYNC1I1	0.57	6.65	0.3	8.52e-11	Intelligence (multi-trait analysis);
LGG	trans	rs61931739	0.817	rs1705771	chr12:34174950	C/G	cg13010199	chr12:38710504	ALG10B	0.44	8.53	0.37	2.11e-16	Morning vs. evening chronotype;
LGG	cis	rs2228479	0.702	rs17226841	chr16:89828484	C/T	cg03036210	chr16:89904091	SPIRE2	-0.66	-7.97	-0.35	1.23e-14	Skin colour saturation;
LGG	cis	rs17270561	0.609	rs4132072	chr6:25717843	C/T	cg03264133	chr6:25882463	NA	-0.48	-7.69	-0.34	8.79e-14	Iron status biomarkers;
LGG	cis	rs7712401	0.601	rs30060	chr5:122296700	T/C	cg19412675	chr5:122181750	SNX24	0.42	6.96	0.31	1.17e-11	Mean platelet volume;
LGG	cis	rs6952808	0.575	rs6950330	chr7:1953606	T/C	cg21782813	chr7:2030301	MAD1L1	0.39	9.09	0.39	2.91e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs2985684	0.625	rs4900931	chr14:50022793	A/T	cg02151108	chr14:50098012	C14orf104	-0.41	-8.84	-0.38	2.06e-17	Carotid intima media thickness;
LGG	cis	rs1577917	0.876	rs66986937	chr6:86532191	A/C	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	-0.64	-10.63	-0.44	9.24e-24	Response to antipsychotic treatment;
LGG	cis	rs6684428	0.536	rs6660000	chr1:56399554	G/C	cg11651538	chr1:56320950	NA	-0.45	-8.47	-0.37	3.39e-16	Airflow obstruction;
LGG	cis	rs61990749	0.597	rs2267759	chr14:78147615	C/T	cg02301378	chr14:78227641	SNW1;C14orf178	-0.57	-7.17	-0.32	3.05e-12	Fibroblast growth factor basic levels;
LGG	trans	rs1728785	1.000	rs1170439	chr16:68608511	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.69	10.48	0.44	3.31e-23	Ulcerative colitis;
LGG	cis	rs6547741	0.844	rs7382	chr2:27873415	G/A	cg22903471	chr2:27725779	GCKR	-0.37	-8.13	-0.35	3.88e-15	Oral cavity cancer;
LGG	trans	rs853679	0.760	rs11967137	chr6:28199764	A/G	cg01620082	chr3:125678407	NA	-0.51	-6.93	-0.31	1.42e-11	Depression;
LGG	cis	rs2742417	1.000	rs2673038	chr3:45748632	A/G	cg04837898	chr3:45731254	SACM1L	-0.37	-7.47	-0.33	3.99e-13	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9902453	1.000	rs9912741	chr17:28359511	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.67	-13.35	-0.53	1.28e-34	Coffee consumption (cups per day);
LGG	cis	rs2032447	0.517	rs7767546	chr6:25904067	T/C	cg12310025	chr6:25882481	NA	-0.85	-16.81	-0.62	7.72e-50	Intelligence (multi-trait analysis);
LGG	cis	rs1816752	0.875	rs1050110	chr13:25009485	C/G	cg22771759	chr13:24902376	NA	0.42	7.09	0.31	5.04e-12	Obesity-related traits;
LGG	cis	rs12545109	0.800	rs1553969	chr8:57420187	A/G	cg19413350	chr8:57351067	NA	-0.42	-6.91	-0.31	1.61e-11	Obesity-related traits;
LGG	cis	rs10504229	0.545	rs56394419	chr8:58128982	T/C	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs2235642	0.826	rs8053605	chr16:1594158	G/A	cg09025071	chr16:1593152	IFT140;TMEM204	0.41	9.91	0.42	4.14e-21	Coronary artery disease;
LGG	trans	rs116095464	0.614	rs10061564	chr5:271329	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs473651	0.935	rs515412	chr2:239345394	A/T	cg18131467	chr2:239335373	ASB1	1.0	22.61	0.72	7.86e-77	Multiple system atrophy;
LGG	cis	rs58688157	0.705	rs7943546	chr11:612148	T/C	cg03576123	chr11:487126	PTDSS2	-0.49	-6.75	-0.3	4.33e-11	Systemic lupus erythematosus;
LGG	cis	rs8060686	0.641	rs55790290	chr16:68180242	A/G	cg09117114	chr16:67998030	SLC12A4	-0.38	-6.85	-0.3	2.39e-11	HDL cholesterol;Metabolic syndrome;
LGG	trans	rs7613875	0.580	rs2624819	chr3:50010571	G/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.38	6.69	0.3	6.3e-11	Body mass index;
LGG	trans	rs12992463	0.728	rs12478745	chr2:22541141	A/G	cg15687138	chr1:151138326	SCNM1;LYSMD1	-0.48	-6.92	-0.31	1.48e-11	Systemic lupus erythematosus;
LGG	cis	rs4851266	1.000	rs13013169	chr2:100814087	A/C	cg21926883	chr2:100939477	LONRF2	-0.43	-7.7	-0.34	8.05e-14	Educational attainment;
LGG	trans	rs116095464	0.558	rs6866776	chr5:264495	C/T	cg09048205	chr5:1608656	LOC728613	-0.49	-8.42	-0.36	4.88e-16	Breast cancer;
LGG	cis	rs8114671	0.933	rs2103971	chr20:33786256	T/C	cg07148914	chr20:33460835	GGT7	-0.42	-6.74	-0.3	4.7e-11	Height;
LGG	cis	rs4906332	0.966	rs12185021	chr14:103927805	A/G	cg26031613	chr14:104095156	KLC1	-0.52	-7.85	-0.34	2.97e-14	Coronary artery disease;
LGG	cis	rs7552404	0.889	rs380075	chr1:76106961	T/A	cg22875332	chr1:76189707	ACADM	-0.64	-10.66	-0.44	7.09e-24	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg00149659	chr3:10157352	C3orf10	1.17	13.72	0.54	3.38e-36	Alzheimer's disease;
LGG	cis	rs1707322	0.717	rs28396194	chr1:46213227	C/T	cg03146154	chr1:46216737	IPP	0.56	10.64	0.44	8.69e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs7264396	0.690	rs2425183	chr20:34450621	T/C	cg23207816	chr20:34252616	CPNE1;RBM12	0.49	7.18	0.32	2.84e-12	Total cholesterol levels;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg25172604	chr17:41446521	NA	-0.3	-6.83	-0.3	2.6e-11	Menopause (age at onset);
LGG	cis	rs8064029	0.881	rs760117	chr16:4941047	C/T	cg04440724	chr16:4920505	UBN1	-0.67	-7.93	-0.35	1.71e-14	Cancer;
LGG	cis	rs4862750	0.758	rs2375915	chr4:187896255	A/C	cg22105103	chr4:187893119	NA	0.58	11.03	0.46	2.89e-25	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs28386778	0.897	rs2584639	chr17:61863732	C/T	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs7084402	0.967	rs11006171	chr10:60278487	C/T	cg07615347	chr10:60278583	BICC1	-0.62	-17.81	-0.64	2.02e-54	Refractive error;
LGG	cis	rs6693567	0.526	rs834239	chr1:150375458	C/A	cg15654264	chr1:150340011	RPRD2	0.32	6.68	0.3	6.7e-11	Migraine;
LGG	cis	rs736801	0.808	rs2248116	chr5:131804347	C/A	cg07395648	chr5:131743802	NA	0.51	10.63	0.44	9.6e-24	Breast cancer;Mosquito bite size;
LGG	cis	rs1712517	0.525	rs7911488	chr10:105154089	A/G	cg04362960	chr10:104952993	NT5C2	-0.49	-8.15	-0.35	3.44e-15	Migraine;
LGG	cis	rs4853012	0.838	rs4429500	chr2:74345336	A/G	cg05890377	chr2:74357713	NA	0.47	9.54	0.41	8.26e-20	Gestational age at birth (maternal effect);
LGG	cis	rs11997175	0.967	rs11993169	chr8:33738004	G/T	ch.8.33884649F	chr8:33765107	NA	0.37	6.68	0.3	6.86e-11	Body mass index;
LGG	cis	rs6952808	0.595	rs3778983	chr7:2166319	T/G	cg19147804	chr7:1989927	MAD1L1	-0.5	-10.12	-0.43	7.17e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4924590	0.513	rs4244586	chr15:42238759	T/G	cg20935245	chr15:42234343	EHD4	0.35	6.82	0.3	2.78e-11	Lymphocyte percentage of white cells;Sum basophil neutrophil counts;Granulocyte count;
LGG	trans	rs2727020	0.521	rs11039902	chr11:48679467	A/G	cg03929089	chr4:120376271	NA	-0.56	-9.89	-0.42	4.7e-21	Coronary artery disease;
LGG	cis	rs919433	0.679	rs1902249	chr2:198521356	T/C	cg00792783	chr2:198669748	PLCL1	0.55	8.96	0.38	7.8e-18	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	trans	rs12579753	0.917	rs10129029	chr12:82180324	G/A	cg07923666	chr12:49932857	KCNH3	-0.51	-7.79	-0.34	4.31e-14	Resting heart rate;
LGG	cis	rs7937682	0.889	rs541198	chr11:111475340	A/G	cg09085632	chr11:111637200	PPP2R1B	-1.09	-23.55	-0.74	3.41e-81	Primary sclerosing cholangitis;
LGG	cis	rs6977660	0.714	rs13225018	chr7:19816567	C/T	cg05791153	chr7:19748676	TWISTNB	0.77	10.11	0.43	7.53e-22	Thyroid stimulating hormone;
LGG	cis	rs9290877	0.667	rs9858643	chr3:188464910	C/T	cg17392043	chr3:188495102	LPP	-0.46	-8.09	-0.35	5.35e-15	IgE levels;
LGG	cis	rs10504229	0.679	rs73681882	chr8:58030038	A/G	cg22535103	chr8:58192502	C8orf71	-0.73	-10.0	-0.42	1.9e-21	Developmental language disorder (linguistic errors);
LGG	trans	rs7762018	0.891	rs3749882	chr6:170151766	C/T	cg11441553	chr12:57614120	NXPH4	-0.59	-7.45	-0.33	4.65e-13	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs9596863	0.898	rs8000553	chr13:54344501	C/T	ch.13.53330881F	chr13:54432880	NA	0.53	7.16	0.32	3.15e-12	Epilepsy and lamotrigine-induced maculopapular eruptions;
LGG	cis	rs60180747	0.863	rs11635184	chr15:66714743	A/G	cg07575407	chr15:66541975	MEGF11	0.35	6.91	0.31	1.66e-11	Testicular germ cell tumor;
LGG	cis	rs3808502	0.525	rs9650661	chr8:11427133	G/T	cg24623649	chr8:11872141	NA	-0.31	-7.35	-0.32	9.29e-13	Neuroticism;
LGG	cis	rs75059851	0.756	rs11223652	chr11:133841207	A/G	cg20042908	chr11:133852938	NA	-0.77	-14.25	-0.55	1.79e-38	Schizophrenia;
LGG	cis	rs1799949	0.965	rs11654051	chr17:41419656	C/T	cg23758822	chr17:41437982	NA	0.9	15.9	0.59	9.66e-46	Menopause (age at onset);
LGG	trans	rs1005277	0.557	rs1854563	chr10:38434961	G/A	cg27523141	chr10:43048294	ZNF37B	0.42	8.41	0.36	5.3e-16	Extrinsic epigenetic age acceleration;
LGG	cis	rs2243480	1.000	rs9769882	chr7:65642925	T/C	cg12463550	chr7:65579703	CRCP	-0.78	-8.38	-0.36	6.34e-16	Diabetic kidney disease;
LGG	cis	rs2415984	0.579	rs754962	chr14:46962719	T/C	cg14871534	chr14:47121158	RPL10L	0.58	10.26	0.43	2.2e-22	Number of children ever born;
LGG	cis	rs6500395	1.000	rs2129243	chr16:48646852	A/T	cg04672837	chr16:48644449	N4BP1	0.55	9.04	0.39	4.19e-18	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs2290405	0.527	rs7663192	chr4:923947	T/C	cg04824913	chr4:887549	GAK	0.85	17.98	0.64	3.25e-55	Systemic sclerosis;
LGG	cis	rs6894249	1.000	rs6894249	chr5:131797547	A/G	cg21138405	chr5:131827807	IRF1	0.24	6.66	0.3	7.85e-11	Asthma;
LGG	trans	rs61931739	1.000	rs61931739	chr12:34089973	C/T	cg26384229	chr12:38710491	ALG10B	-0.61	-11.02	-0.46	3.11e-25	Morning vs. evening chronotype;
LGG	cis	rs7737355	1.000	rs27708	chr5:130743541	C/T	cg06307176	chr5:131281290	NA	-0.54	-8.99	-0.39	6.57e-18	Life satisfaction;
LGG	cis	rs651907	0.535	rs11919389	chr3:101424458	T/C	cg11279151	chr3:101281821	RG9MTD1	-0.4	-7.18	-0.32	2.74e-12	Colorectal cancer;
LGG	cis	rs13108904	0.875	rs73069950	chr4:1276045	C/A	cg05665937	chr4:1216051	CTBP1	-0.57	-10.59	-0.44	1.31e-23	Obesity-related traits;
LGG	cis	rs10754283	0.967	rs10922679	chr1:90100925	T/C	cg06121193	chr1:90282411	NA	-0.37	-7.15	-0.32	3.31e-12	Amyotrophic lateral sclerosis (sporadic);
LGG	cis	rs7937612	1.000	rs11601535	chr11:120333801	A/G	cg24566217	chr11:120254723	ARHGEF12	-0.53	-12.77	-0.51	3.42e-32	Intraocular pressure;
LGG	cis	rs9650657	0.501	rs3021500	chr8:11023997	G/C	cg27411982	chr8:10470053	RP1L1	-0.47	-8.13	-0.35	3.94e-15	Neuroticism;
LGG	cis	rs3540	0.513	rs12905756	chr15:90924047	C/T	cg22089800	chr15:90895588	ZNF774	0.73	13.55	0.53	1.81e-35	Allergic disease (asthma, hay fever or eczema);Lymphocyte counts;
LGG	cis	rs1129187	0.935	rs4987173	chr6:42931224	G/A	cg24101359	chr6:42928495	GNMT	0.57	16.73	0.61	1.67e-49	Alzheimer's disease in APOE e4+ carriers;
LGG	trans	rs2840044	1.000	rs9891800	chr17:33895015	G/C	cg19694781	chr19:47549865	TMEM160	0.53	8.83	0.38	2.24e-17	Response to radiotherapy in cancer (late toxicity);
LGG	cis	rs1665650	0.874	rs7093835	chr10:118492612	C/T	cg14919929	chr10:118506882	NA	-0.49	-8.57	-0.37	1.58e-16	Colorectal cancer;
LGG	cis	rs11724804	0.532	rs7657611	chr4:880558	G/C	cg04824913	chr4:887549	GAK	0.44	6.72	0.3	5.4e-11	Primary biliary cholangitis;Limited cutaneous systemic scleroderma;
LGG	cis	rs7712401	0.601	rs246273	chr5:122280975	G/A	cg19412675	chr5:122181750	SNX24	0.43	7.22	0.32	2.15e-12	Mean platelet volume;
LGG	cis	rs9443189	0.570	rs659807	chr6:76293435	C/A	cg01950844	chr6:76311363	SENP6	0.75	10.04	0.42	1.32e-21	Prostate cancer;
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg01245787	chr4:71859630	DCK	0.42	7.23	0.32	2.06e-12	Bipolar disorder;
LGG	cis	rs1005277	0.579	rs1740735	chr10:38497777	A/C	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.36	-0.32	8.58e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs4862750	0.872	rs6821507	chr4:187876829	G/T	cg03452623	chr4:187889614	NA	1.04	30.48	0.82	9.41e-113	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs7208859	0.623	rs59447372	chr17:29057585	C/T	cg19761014	chr17:28927070	LRRC37B2	0.63	7.54	0.33	2.54e-13	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs2235573	0.625	rs10427673	chr22:38427551	G/C	cg19171272	chr22:38449367	NA	-0.56	-11.01	-0.46	3.3e-25	Glioblastoma;Glioma;
LGG	cis	rs6831352	0.840	rs17817868	chr4:100060623	C/T	cg13256891	chr4:100009986	ADH5	-0.55	-9.66	-0.41	3.21e-20	Alcohol dependence;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07657236	chr3:19190202	KCNH8	0.4	7.04	0.31	6.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4253772	0.591	rs9615935	chr22:46686115	T/G	cg00784671	chr22:46762841	CELSR1	-0.62	-7.34	-0.32	9.78e-13	LDL cholesterol;Cholesterol, total;
LGG	cis	rs2576037	0.526	rs2576051	chr18:44557884	G/A	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	-0.54	-11.07	-0.46	1.9e-25	Personality dimensions;
LGG	cis	rs1799949	0.965	rs6503726	chr17:41284742	T/C	cg18379455	chr17:41446167	NA	-0.32	-7.67	-0.34	1.04e-13	Menopause (age at onset);
LGG	cis	rs4319547	0.695	rs10773167	chr12:122934001	C/T	cg05707623	chr12:122985044	ZCCHC8	-0.7	-10.24	-0.43	2.63e-22	Body mass index;
LGG	cis	rs2839186	0.526	rs59977673	chr21:47922091	C/T	cg12379764	chr21:47803548	PCNT	-0.45	-7.88	-0.34	2.31e-14	Testicular germ cell tumor;
LGG	cis	rs6840360	0.571	rs875668	chr4:152525661	C/T	cg22705602	chr4:152727874	NA	-0.32	-7.81	-0.34	3.91e-14	Intelligence (multi-trait analysis);
LGG	cis	rs7310409	0.544	rs1169292	chr12:121426478	C/T	cg02403541	chr12:121454288	C12orf43	0.54	8.52	0.37	2.29e-16	Liver enzyme levels (gamma-glutamyl transferase);C-reactive protein;Pancreatic cancer;
LGG	cis	rs28386778	0.897	rs8073515	chr17:61795328	A/C	cg01411255	chr17:61851458	DDX42;CCDC47	0.6	10.49	0.44	3.02e-23	Prudent dietary pattern;
LGG	cis	rs7954584	0.560	rs745327	chr12:122456524	T/C	cg22168489	chr12:122356033	WDR66	-0.37	-8.16	-0.35	3.11e-15	Mean corpuscular volume;
LGG	cis	rs36051895	0.522	rs12341844	chr9:5177872	C/T	cg02405213	chr9:5042618	JAK2	-0.77	-15.03	-0.57	7.16e-42	Pediatric autoimmune diseases;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg05313129	chr8:58192883	C8orf71	-0.62	-8.36	-0.36	7.65e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs7432375	0.580	rs4678441	chr3:136532828	T/C	cg21827317	chr3:136751795	NA	0.43	7.81	0.34	3.92e-14	Neuroticism;Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs1894633	0.574	rs10489286	chr1:172312919	A/G	cg01573306	chr1:172330400	DNM3	0.42	7.34	0.32	9.45e-13	Waist circumference adjusted for BMI in active individuals;Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Breast cancer;Waist circumference adjusted for body mass index;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs12477438	0.605	rs4585080	chr2:99557327	T/C	cg08885076	chr2:99613938	TSGA10	-0.52	-10.81	-0.45	1.98e-24	Chronic sinus infection;
LGG	cis	rs9527	0.590	rs12355120	chr10:104852166	T/G	cg05308233	chr10:104796373	CNNM2	-0.31	-6.84	-0.3	2.6e-11	Arsenic metabolism;
LGG	cis	rs798554	0.757	rs1182188	chr7:2869985	T/C	cg19524238	chr7:2802976	GNA12	0.37	8.6	0.37	1.25e-16	Height;
LGG	cis	rs1005277	0.541	rs2263163	chr10:38389887	G/A	cg03665457	chr10:38645376	HSD17B7P2	-0.46	-7.33	-0.32	1.01e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs7503807	0.515	rs12450876	chr17:78682630	A/G	cg22878693	chr17:78755604	RPTOR	-0.56	-9.34	-0.4	4.01e-19	Obesity;
LGG	trans	rs6747952	0.899	rs2121404	chr2:239083826	A/G	cg17763188	chr8:6692148	XKR5	0.43	7.19	0.32	2.54e-12	Mean corpuscular hemoglobin concentration;
LGG	cis	rs2413583	0.591	rs115371106	chr22:39726809	G/A	cg17798944	chr22:39715225	SNORD43;RPL3	0.68	7.65	0.33	1.2e-13	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;
LGG	cis	rs2386661	0.523	rs7896088	chr10:5652286	C/T	cg17085576	chr10:5658249	NA	-0.34	-6.69	-0.3	6.63e-11	Breast cancer;
LGG	cis	rs1153858	1.000	rs8042786	chr15:45703539	T/C	cg05280133	chr15:45670068	GATM;LOC145663	0.44	8.11	0.35	4.54e-15	Homoarginine levels;
LGG	cis	rs7647973	1.000	rs2140270	chr3:49439440	A/G	cg06212747	chr3:49208901	KLHDC8B	-0.49	-7.69	-0.34	8.96e-14	Menarche (age at onset);
LGG	cis	rs875971	0.862	rs778734	chr7:65814849	C/G	cg18876405	chr7:65276391	NA	0.55	9.76	0.41	1.35e-20	Aortic root size;
LGG	cis	rs62209	0.752	rs11256935	chr10:11004177	C/T	cg26901096	chr10:10994189	LOC254312	0.59	8.66	0.37	7.76e-17	Alzheimer's disease (late onset);
LGG	cis	rs1927790	0.759	rs9556567	chr13:96985036	A/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.96	-0.31	1.18e-11	Body mass index;
LGG	cis	rs10262624	0.528	rs722294	chr7:23746585	A/C	cg26309111	chr7:23720005	C7orf46	0.4	8.38	0.36	6.57e-16	Schizophrenia;
LGG	cis	rs6089584	1.000	rs6089583	chr20:60563624	G/A	cg06470251	chr20:60548479	NA	0.53	9.24	0.39	9.05e-19	Body mass index;
LGG	cis	rs4975709	0.569	rs1684965	chr5:1865248	A/G	cg14773178	chr5:1868261	NA	0.39	8.66	0.37	7.71e-17	Cardiovascular disease risk factors;
LGG	cis	rs4474465	0.850	rs10793328	chr11:78256868	A/G	cg27205649	chr11:78285834	NARS2	0.5	8.53	0.37	2.1e-16	Alzheimer's disease (survival time);
LGG	cis	rs858239	0.539	rs6975852	chr7:23186654	T/C	cg23682824	chr7:23144976	KLHL7	0.42	6.87	0.3	2.05e-11	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7681440	0.804	rs763443	chr4:90819961	T/C	cg14346243	chr4:90757452	SNCA	-0.4	-7.97	-0.35	1.25e-14	Dementia with Lewy bodies;
LGG	cis	rs10504229	0.679	rs12679941	chr8:58051812	G/T	cg22535103	chr8:58192502	C8orf71	-0.79	-10.55	-0.44	1.78e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs9549260	0.755	rs2755219	chr13:41169625	A/G	cg21288729	chr13:41239152	FOXO1	0.33	6.65	0.3	8.46e-11	Red blood cell count;
LGG	cis	rs12505749	0.542	rs6849183	chr4:57329936	C/T	cg07846311	chr4:57371927	ARL9	0.32	7.48	0.33	3.73e-13	Airflow obstruction;
LGG	cis	rs11148252	0.846	rs7323666	chr13:53006058	T/C	cg00495681	chr13:53174319	NA	0.56	10.55	0.44	1.85e-23	Lewy body disease;
LGG	trans	rs116095464	0.558	rs7714335	chr5:263513	T/C	cg09048205	chr5:1608656	LOC728613	-0.48	-8.12	-0.35	4.11e-15	Breast cancer;
LGG	cis	rs1707322	0.752	rs11211173	chr1:46219376	C/T	cg03146154	chr1:46216737	IPP	0.56	10.75	0.45	3.4e-24	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs853679	0.517	rs35227624	chr6:28132726	A/G	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.74	-0.34	6.18e-14	Depression;
LGG	cis	rs116095464	0.558	rs7731089	chr5:290422	A/C	cg22496380	chr5:211416	CCDC127	-1.25	-17.85	-0.64	1.31e-54	Breast cancer;
LGG	cis	rs2576037	0.583	rs8094654	chr18:44527397	C/T	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.53	-9.15	-0.39	1.81e-18	Personality dimensions;
LGG	cis	rs2072732	0.861	rs67630839	chr1:2951989	C/T	cg22517653	chr1:2918612	NA	-0.45	-6.89	-0.3	1.82e-11	Plateletcrit;
LGG	cis	rs55788414	1.000	rs7499792	chr16:81184318	C/T	cg06400318	chr16:81190750	PKD1L2	-0.81	-10.16	-0.43	5.06e-22	Left ventricular obstructive tract defect (maternal effect);
LGG	cis	rs7646881	0.812	rs9864589	chr3:158430706	A/G	cg19483011	chr3:158453295	NA	-0.57	-7.78	-0.34	4.88e-14	Tetralogy of Fallot;
LGG	cis	rs2658782	0.901	rs11601056	chr11:93229161	C/T	cg15737290	chr11:93063684	CCDC67	-0.49	-6.97	-0.31	1.12e-11	Pulmonary function decline;
LGG	cis	rs796364	0.806	rs11679658	chr2:200923081	A/G	cg23649088	chr2:200775458	C2orf69	-0.58	-7.05	-0.31	6.62e-12	Schizophrenia;
LGG	cis	rs2795502	1.000	rs2142991	chr10:43341105	C/T	cg20628663	chr10:43360327	NA	-0.42	-8.7	-0.37	5.94e-17	Blood protein levels;
LGG	cis	rs9914544	1.000	rs67411574	chr17:18797337	A/G	cg26378065	chr17:18585709	ZNF286B	0.51	9.51	0.4	1.05e-19	Educational attainment (years of education);
LGG	cis	rs8014204	0.836	rs7150254	chr14:75299101	G/A	cg06637938	chr14:75390232	RPS6KL1	0.78	15.64	0.59	1.44e-44	Caffeine consumption;
LGG	cis	rs12893668	0.637	rs12892038	chr14:104068629	G/A	cg26031613	chr14:104095156	KLC1	-0.63	-10.03	-0.42	1.47e-21	Reticulocyte count;
LGG	cis	rs1401999	1.000	rs4148575	chr3:183702275	A/G	cg01324343	chr3:183735012	ABCC5	0.86	18.13	0.64	6.39e-56	Anterior chamber depth;
LGG	cis	rs8014204	0.905	rs8014289	chr14:75377352	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.88	-19.17	-0.67	1.02e-60	Caffeine consumption;
LGG	cis	rs4917300	0.650	rs6981779	chr8:143071927	A/G	cg06573787	chr8:143070187	NA	-0.75	-15.82	-0.59	2.32e-45	Amyotrophic lateral sclerosis;
LGG	cis	rs875971	0.862	rs6460290	chr7:65809106	G/A	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.35	-7.04	-0.31	7.03e-12	Aortic root size;
LGG	cis	rs7833790	0.963	rs28823280	chr8:82777716	G/A	cg23324259	chr8:82754387	SNX16	0.44	7.06	0.31	6.22e-12	Diastolic blood pressure;
LGG	cis	rs4788570	0.615	rs10852502	chr16:71652072	C/A	cg06353428	chr16:71660113	MARVELD3	1.27	20.18	0.68	1.92e-65	Intelligence (multi-trait analysis);
LGG	cis	rs963731	0.649	rs6544183	chr2:39186339	C/T	cg04010122	chr2:39346883	SOS1	-0.78	-7.0	-0.31	9.24e-12	Corticobasal degeneration;
LGG	cis	rs28655083	0.529	rs662101	chr16:77105405	G/T	cg01753188	chr16:77233325	SYCE1L;MON1B	-0.44	-7.51	-0.33	3.1400000000000003e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs796364	0.806	rs6435041	chr2:200867144	A/G	cg17644776	chr2:200775616	C2orf69	0.59	6.75	0.3	4.48e-11	Schizophrenia;
LGG	cis	rs965513	1.000	rs1588635	chr9:100537802	A/C	cg13688889	chr9:100608707	NA	-0.5	-8.91	-0.38	1.14e-17	Thyroid cancer;Thyroid cancer (Papillary, radiation-related);
LGG	cis	rs10463554	0.963	rs27970	chr5:102486723	G/C	cg23492399	chr5:102201601	PAM	-0.51	-7.63	-0.33	1.36e-13	Parkinson's disease;
LGG	cis	rs9611565	0.921	rs2235846	chr22:41741042	G/C	cg06481639	chr22:41940642	POLR3H	-0.47	-7.29	-0.32	1.36e-12	Vitiligo;
LGG	cis	rs7582180	0.627	rs2099611	chr2:101021090	A/G	cg08297393	chr2:100937505	LONRF2	-0.53	-10.11	-0.43	7.71e-22	Intelligence (multi-trait analysis);
LGG	cis	rs7223966	0.960	rs8082651	chr17:61675292	A/G	cg11494091	chr17:61959527	GH2	0.46	7.23	0.32	1.99e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs12477438	0.798	rs12468419	chr2:99579680	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	-0.58	-10.28	-0.43	1.87e-22	Chronic sinus infection;
LGG	cis	rs60695258	0.550	rs2007132	chr4:87972585	G/T	cg01323104	chr4:87958903	AFF1	0.24	6.78	0.3	3.57e-11	Hematocrit;
LGG	cis	rs7617773	1.000	rs9832957	chr3:48185266	A/G	cg11946769	chr3:48343235	NME6	-0.56	-9.02	-0.39	5.01e-18	Coronary artery disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25971440	chr7:108166545	PNPLA8	0.46	7.02	0.31	8.16e-12	Gut microbiome composition (summer);
LGG	cis	rs16944613	0.541	rs6496688	chr15:91090381	G/A	cg26821196	chr15:91095069	CRTC3	0.58	8.69	0.37	6.51e-17	Colorectal cancer;
LGG	cis	rs60695258	0.594	rs6531946	chr4:87965391	T/A	cg11209507	chr4:87813803	C4orf36	0.46	7.93	0.35	1.64e-14	Hematocrit;
LGG	cis	rs12220238	1.000	rs11000887	chr10:75897542	C/T	cg19889307	chr10:75911429	ADK;AP3M1	0.82	11.36	0.47	1.44e-26	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs911555	0.692	rs7146215	chr14:103915908	A/G	cg24130564	chr14:104152367	KLC1	0.37	6.96	0.31	1.14e-11	Intelligence (multi-trait analysis);
LGG	cis	rs9443645	0.901	rs9448596	chr6:79629429	T/C	cg18132916	chr6:79620363	NA	-0.32	-8.98	-0.39	6.94e-18	Intelligence (multi-trait analysis);
LGG	cis	rs951366	0.646	rs1772159	chr1:205759195	G/A	cg13453750	chr1:205783389	SLC41A1	-0.49	-9.61	-0.41	4.61e-20	Menarche (age at onset);
LGG	cis	rs13108904	0.557	rs1680030	chr4:1245500	A/T	cg05665937	chr4:1216051	CTBP1	-0.42	-7.43	-0.33	5.34e-13	Obesity-related traits;
LGG	cis	rs11785400	0.793	rs9297969	chr8:143723237	A/G	cg10596483	chr8:143751796	JRK	0.51	7.99	0.35	1.08e-14	Schizophrenia;
LGG	cis	rs28386778	1.000	rs2665849	chr17:61953670	T/C	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.11	30.72	0.82	8.35e-114	Prudent dietary pattern;
LGG	cis	rs780096	0.526	rs7594812	chr2:27611469	A/G	cg05484376	chr2:27715224	FNDC4	0.45	9.62	0.41	4.22e-20	Total body bone mineral density;
LGG	cis	rs10875595	0.723	rs62378371	chr5:140680211	G/A	cg24830062	chr5:140700576	TAF7	-0.58	-7.15	-0.32	3.48e-12	Pulmonary function decline;
LGG	cis	rs6951245	1.000	rs78896566	chr7:1080182	C/G	cg20603222	chr7:1096387	C7orf50;GPR146	-0.98	-16.71	-0.61	2.26e-49	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2898290	0.622	rs13272061	chr8:11352261	G/T	cg21775007	chr8:11205619	TDH	-0.45	-7.25	-0.32	1.77e-12	Systolic blood pressure;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg04369109	chr6:150039330	LATS1	-0.43	-7.16	-0.32	3.16e-12	Lung cancer;
LGG	cis	rs34330	0.562	rs11055024	chr12:12858969	A/G	cg04607235	chr12:12878440	APOLD1	-0.62	-8.85	-0.38	1.89e-17	Systemic lupus erythematosus;
LGG	cis	rs7599312	0.534	rs2128321	chr2:213405276	G/T	cg20637307	chr2:213403960	ERBB4	0.75	17.11	0.62	3.13e-51	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs9549367	0.529	rs55946737	chr13:113810014	A/G	cg18105134	chr13:113819100	PROZ	-0.77	-12.97	-0.52	4.91e-33	Platelet distribution width;
LGG	cis	rs3087591	0.960	rs8080679	chr17:29602610	A/G	cg24425628	chr17:29625626	OMG;NF1	0.7	14.56	0.56	8.63e-40	Hip circumference;
LGG	trans	rs877282	1.000	rs112522746	chr10:772288	T/C	cg22713356	chr15:30763199	NA	0.56	8.6	0.37	1.26e-16	Uric acid levels;
LGG	cis	rs3768617	0.510	rs2027076	chr1:183073407	C/A	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Fuchs's corneal dystrophy;
LGG	cis	rs35851103	0.600	rs4841662	chr8:11843758	A/G	cg00405596	chr8:11794950	NA	-0.47	-8.15	-0.35	3.54e-15	Neuroticism;
LGG	cis	rs10504229	0.626	rs6999005	chr8:58159585	A/G	cg08035479	chr8:58172643	NA	-0.53	-8.16	-0.35	3.1e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs9549367	0.713	rs3024743	chr13:113821430	C/T	cg18105134	chr13:113819100	PROZ	-0.76	-15.96	-0.6	5.39e-46	Platelet distribution width;
LGG	cis	rs657075	0.643	rs71583471	chr5:131654167	C/T	cg21911579	chr5:131705225	SLC22A5	0.68	7.66	0.34	1.11e-13	Rheumatoid arthritis;
LGG	cis	rs4253772	0.550	rs6007818	chr22:46703776	C/T	cg24881330	chr22:46731750	TRMU	0.69	7.12	0.31	4.23e-12	LDL cholesterol;Cholesterol, total;
LGG	cis	rs6502050	0.765	rs55905076	chr17:80105441	G/A	cg19223190	chr17:80058835	NA	0.43	8.28	0.36	1.36e-15	Life satisfaction;
LGG	cis	rs2832191	0.716	rs7284006	chr21:30475186	T/A	cg08807101	chr21:30365312	RNF160	0.92	19.3	0.67	2.42e-61	Dental caries;
LGG	cis	rs10791097	0.592	rs7116068	chr11:130732739	A/C	cg12179176	chr11:130786555	SNX19	-0.87	-17.81	-0.64	1.9e-54	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6502050	0.835	rs4789737	chr17:80123269	G/A	cg11859384	chr17:80120422	CCDC57	-0.45	-7.84	-0.34	3.21e-14	Life satisfaction;
LGG	cis	rs12477438	0.520	rs6756650	chr2:99801800	T/C	cg26064155	chr2:99771622	LIPT1;TSGA10	1.0	24.72	0.75	1.26e-86	Chronic sinus infection;
LGG	cis	rs9311474	0.508	rs11720243	chr3:52618018	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.32	-0.32	1.08e-12	Electroencephalogram traits;
LGG	cis	rs3858526	0.727	rs10769353	chr11:5954809	C/T	cg05234568	chr11:5960015	NA	0.74	14.57	0.56	7.15e-40	DNA methylation (variation);
LGG	cis	rs78456975	0.628	rs13426896	chr2:1554768	C/T	cg26248373	chr2:1572462	NA	-0.82	-11.85	-0.48	1.71e-28	Placebo response in major depressive disorder (% change in symptom score);
LGG	cis	rs6502050	0.835	rs6502059	chr17:80082886	T/C	cg09264619	chr17:80180166	NA	0.37	7.39	0.32	7.03e-13	Life satisfaction;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg02577203	chr11:47869805	NUP160	0.45	7.13	0.31	3.88e-12	Gut microbiome composition (summer);
LGG	cis	rs7737355	0.853	rs26004	chr5:130988955	G/T	cg06307176	chr5:131281290	NA	0.53	8.65	0.37	8.72e-17	Life satisfaction;
LGG	cis	rs7811142	0.887	rs4074838	chr7:100032665	G/A	cg11814155	chr7:99998594	ZCWPW1	0.6	9.26	0.4	7.59e-19	Platelet count;
LGG	cis	rs8072100	0.837	rs8070463	chr17:45768836	A/G	cg08085267	chr17:45401833	C17orf57	-0.61	-11.99	-0.49	4.93e-29	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs17504614	0.591	rs10460541	chr2:51074629	G/C	cg23851515	chr2:51057218	NRXN1	0.44	7.28	0.32	1.48e-12	Educational attainment (years of education);
LGG	cis	rs2797369	0.656	rs592463	chr6:101349002	G/A	cg27451362	chr6:101846650	GRIK2	0.76	10.51	0.44	2.49e-23	Renal function-related traits (eGRFcrea);
LGG	trans	rs9467711	0.606	rs12176317	chr6:26372786	A/G	cg08344181	chr3:125677491	NA	-0.6	-7.0	-0.31	8.92e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs709596	chr7:65825913	A/G	cg18252515	chr7:66147081	NA	-0.41	-6.93	-0.31	1.38e-11	Aortic root size;
LGG	cis	rs9788333	0.888	rs35880230	chr13:21885972	A/G	cg25811766	chr13:21894605	NA	0.75	13.74	0.54	2.84e-36	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs3770081	1.000	rs6750765	chr2:86300308	C/T	cg23655155	chr2:86332777	POLR1A;PTCD3	-0.99	-8.4	-0.36	5.41e-16	Facial emotion recognition (sad faces);
LGG	cis	rs62103177	0.564	rs11874805	chr18:77697110	T/C	cg20368463	chr18:77673604	PQLC1	0.6	7.95	0.35	1.41e-14	Opioid sensitivity;
LGG	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg02002194	chr4:3960332	NA	0.44	8.2	0.36	2.42e-15	Monocyte count;
LGG	cis	rs17376456	0.569	rs7713956	chr5:93133185	T/C	cg19507638	chr5:93509721	C5orf36	0.41	6.89	0.3	1.87e-11	Diabetic retinopathy;
LGG	cis	rs9910055	1.000	rs9895423	chr17:42285740	T/C	cg16434002	chr17:42200994	HDAC5	-0.48	-8.11	-0.35	4.48e-15	Total body bone mineral density;
LGG	cis	rs2180341	0.781	rs6913350	chr6:127570560	C/T	cg24812749	chr6:127587940	RNF146	0.8	13.47	0.53	4.13e-35	Breast cancer;
LGG	cis	rs4356203	0.905	rs6486354	chr11:17200108	T/C	cg15432903	chr11:17409602	KCNJ11	-0.38	-7.18	-0.32	2.71e-12	Schizophrenia;Schizophrenia or bipolar disorder;
LGG	cis	rs10504229	1.000	rs67384205	chr8:58180348	C/G	cg02725872	chr8:58115012	NA	-0.77	-10.98	-0.45	4.53e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs6088580	0.608	rs8114616	chr20:32969092	G/T	cg24642439	chr20:33292090	TP53INP2	-0.54	-9.16	-0.39	1.71e-18	Glomerular filtration rate (creatinine);
LGG	cis	rs1552244	0.816	rs56387520	chr3:10042782	C/T	cg02579736	chr3:10068473	FANCD2;CIDECP	1.04	17.23	0.63	8.99e-52	Alzheimer's disease;
LGG	trans	rs11997175	0.846	rs11776207	chr8:33765126	G/T	cg04794505	chr9:128508709	PBX3	0.39	6.81	0.3	3e-11	Body mass index;
LGG	cis	rs7928758	0.887	rs75474440	chr11:134267092	C/T	cg25213107	chr11:134282864	B3GAT1	1.25	15.05	0.57	6.1e-42	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs651907	0.557	rs12629954	chr3:101360623	C/A	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.84	0.34	3.21e-14	Colorectal cancer;
LGG	cis	rs4974559	0.947	rs10000012	chr4:1357325	C/G	cg02980000	chr4:1222292	CTBP1	-0.66	-8.25	-0.36	1.7e-15	Systolic blood pressure;
LGG	cis	rs734999	0.588	rs6668149	chr1:2558308	A/C	cg20673091	chr1:2541236	MMEL1	-0.75	-18.35	-0.65	6.11e-57	Ulcerative colitis;
LGG	cis	rs597539	0.654	rs655816	chr11:68626405	A/G	cg21862992	chr11:68658383	NA	0.52	8.76	0.38	3.57e-17	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs9902453	0.904	rs55633288	chr17:28368196	G/A	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.69	-13.79	-0.54	1.81e-36	Coffee consumption (cups per day);
LGG	cis	rs6909430	0.808	rs1487451	chr6:98579210	G/A	cg12860156	chr6:98744658	NA	0.44	7.6	0.33	1.62e-13	Quantitative traits;
LGG	cis	rs12368653	0.584	rs7295422	chr12:58099736	G/A	cg20892847	chr12:58011875	NA	0.36	7.35	0.32	8.84e-13	Multiple sclerosis;
LGG	cis	rs597539	0.654	rs7107137	chr11:68623712	A/G	cg21963583	chr11:68658836	MRPL21	0.6	10.04	0.42	1.37e-21	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs28595532	0.920	rs116516492	chr4:119734247	C/G	cg14228332	chr4:119757509	SEC24D	1.01	10.29	0.43	1.62e-22	Cannabis dependence symptom count;
LGG	cis	rs7301826	1.000	rs10848205	chr12:131280714	A/G	cg11011512	chr12:131303247	STX2	0.34	7.3	0.32	1.24e-12	Plasma plasminogen activator levels;
LGG	cis	rs7100689	0.784	rs17678947	chr10:82136333	T/C	cg01528321	chr10:82214614	TSPAN14	0.96	17.02	0.62	7.94e-51	Post bronchodilator FEV1;
LGG	cis	rs41271473	0.519	rs9660783	chr1:228886880	C/T	cg01967586	chr1:228894546	NA	0.35	7.29	0.32	1.31e-12	Chronic lymphocytic leukemia;
LGG	cis	rs5750830	0.649	rs4821894	chr22:39809820	G/C	cg04986931	chr22:39850128	NA	0.34	7.63	0.33	1.36e-13	Intelligence (multi-trait analysis);
LGG	cis	rs910316	0.737	rs175048	chr14:75479894	A/T	cg06637938	chr14:75390232	RPS6KL1	-0.51	-9.07	-0.39	3.5e-18	Height;
LGG	cis	rs2412459	1.000	rs6492925	chr15:40304170	T/G	cg20255370	chr15:40268687	EIF2AK4	-0.79	-9.12	-0.39	2.26e-18	Response to haloperidol in psychosis;
LGG	cis	rs7208859	0.623	rs8080882	chr17:29081146	G/A	cg01831904	chr17:28903510	LRRC37B2	-0.85	-10.51	-0.44	2.51e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs986417	0.818	rs767602	chr14:61098624	G/T	cg27398547	chr14:60952738	C14orf39	0.75	7.49	0.33	3.47e-13	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.863	rs3760254	chr17:61851751	T/G	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.07	0.49	2.31e-29	Prudent dietary pattern;
LGG	cis	rs270601	0.955	rs273911	chr5:131661526	C/G	cg07395648	chr5:131743802	NA	-0.49	-9.99	-0.42	2.01e-21	Acylcarnitine levels;
LGG	cis	rs8177253	0.896	rs34252038	chr3:133490621	G/T	cg01448562	chr3:133502909	NA	-0.73	-13.61	-0.53	9.85e-36	Iron status biomarkers;
LGG	cis	rs8025790	0.508	rs4776370	chr15:67904511	T/C	cg22044901	chr15:68126292	NA	-0.42	-7.67	-0.34	1.05e-13	Body mass index (joint analysis main effects and physical activity interaction);Body mass index;Body mass index in physically active individuals;
LGG	cis	rs9875589	0.509	rs11927267	chr3:14073992	T/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	0.47	9.73	0.41	1.79e-20	Ovarian reserve;
LGG	cis	rs769267	0.965	rs2965191	chr19:19453521	T/G	cg03709012	chr19:19516395	GATAD2A	-0.82	-15.9	-0.59	9.32e-46	Tonsillectomy;
LGG	cis	rs6582630	0.638	rs12231073	chr12:38526901	T/G	cg13010199	chr12:38710504	ALG10B	-0.55	-11.15	-0.46	1.01e-25	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs929354	0.557	rs62491947	chr7:156960813	G/A	cg05182265	chr7:156933206	UBE3C	-0.36	-7.42	-0.33	5.66e-13	Body mass index;
LGG	cis	rs4944092	1.000	rs4944092	chr11:75909619	C/T	cg04588336	chr11:75916460	WNT11	-0.41	-9.52	-0.4	9.74e-20	PR interval;
LGG	cis	rs6868223	0.617	rs4242081	chr5:33647057	C/A	cg10594543	chr5:33649717	ADAMTS12	0.66	15.56	0.59	3.28e-44	Mortality in heart failure;
LGG	cis	rs8031584	0.678	rs4779790	chr15:31164595	T/C	cg08704250	chr15:31115839	NA	-0.49	-8.68	-0.37	6.56e-17	Huntington's disease progression;
LGG	cis	rs9604529	0.759	rs77777032	chr13:114625889	T/C	cg03343631	chr13:114764489	RASA3	-0.53	-7.02	-0.31	7.8e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8177253	0.829	rs9813689	chr3:133514822	C/T	cg11941060	chr3:133502564	NA	-0.53	-8.98	-0.39	6.86e-18	Iron status biomarkers;
LGG	cis	rs6764363	0.646	rs369038	chr3:298867	G/A	cg02057681	chr3:285234	CHL1	0.38	6.88	0.3	1.9e-11	Sudden cardiac arrest;
LGG	cis	rs295140	0.526	rs295114	chr2:201195602	C/T	cg17644776	chr2:200775616	C2orf69	0.46	7.77	0.34	5.28e-14	QT interval;
LGG	cis	rs2089162	1	rs2089162	chr15:78739763	A/G	cg18825076	chr15:78729989	IREB2	-0.6	-9.65	-0.41	3.35e-20	Post bronchodilator FEV1/FVC ratio in COPD;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs644799	1.000	rs580255	chr11:95577929	T/C	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.89	0.34	2.18e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs9308433	0.529	rs59864830	chr1:214474889	A/G	cg06198575	chr1:214491504	SMYD2	0.52	7.7	0.34	8.13e-14	IgG glycosylation;
LGG	cis	rs7241530	0.610	rs57260166	chr18:75894041	C/T	cg14642773	chr18:75888474	NA	0.48	9.23	0.39	9.48e-19	Educational attainment (years of education);
LGG	cis	rs4563143	0.634	rs113736470	chr19:29240125	G/A	cg14983838	chr19:29218262	NA	0.7	11.68	0.48	8.75e-28	Methadone dose in opioid dependence;
LGG	cis	rs975739	0.872	rs1668631	chr13:78373159	A/C	cg07847733	chr13:78271382	SLAIN1	0.37	6.73	0.3	5.04e-11	Hair color;
LGG	cis	rs6088580	0.524	rs6088565	chr20:33254986	A/C	cg07148914	chr20:33460835	GGT7	-0.51	-8.05	-0.35	6.81e-15	Glomerular filtration rate (creatinine);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg19492446	chr18:35145650	BRUNOL4	0.49	7.87	0.34	2.56e-14	Cognitive performance;
LGG	cis	rs10267417	0.603	rs4634527	chr7:19911019	C/G	cg05791153	chr7:19748676	TWISTNB	0.58	7.7	0.34	8.05e-14	Night sleep phenotypes;
LGG	cis	rs950169	0.922	rs62028133	chr15:84919375	A/C	cg24253500	chr15:84953950	NA	0.58	10.47	0.44	3.74e-23	Schizophrenia;
LGG	cis	rs7726839	0.540	rs12520279	chr5:657291	T/C	cg14541582	chr5:601475	NA	-0.7	-10.77	-0.45	2.68e-24	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs62441279	chr6:150042330	G/A	cg16507663	chr6:150244633	RAET1G	0.45	8.62	0.37	1.05e-16	Lung cancer;
LGG	cis	rs6977660	0.714	rs10232870	chr7:19818040	A/G	cg05791153	chr7:19748676	TWISTNB	0.75	10.46	0.44	4.12e-23	Thyroid stimulating hormone;
LGG	cis	rs1218582	0.772	rs1976559	chr1:154879788	A/T	cg24250549	chr1:154909240	PMVK	0.76	15.62	0.59	1.76e-44	Prostate cancer;
LGG	cis	rs1003719	0.715	rs9974494	chr21:38566566	C/T	cg10648535	chr21:38446584	PIGP;TTC3	-0.79	-15.29	-0.58	5.37e-43	Eye color traits;
LGG	cis	rs7940866	0.903	rs11222421	chr11:130872351	A/T	cg12179176	chr11:130786555	SNX19	0.73	13.34	0.53	1.46e-34	Schizophrenia;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg07160278	chr7:100027354	MEPCE;ZCWPW1	1.18	19.61	0.67	8.53e-63	Platelet count;
LGG	cis	rs951366	0.789	rs823137	chr1:205738302	C/T	cg24503407	chr1:205819492	PM20D1	0.82	20.14	0.68	2.86e-65	Menarche (age at onset);
LGG	cis	rs5769765	1.000	rs768619	chr22:50287266	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.36	-0.47	1.55e-26	Schizophrenia;
LGG	cis	rs694739	0.687	rs11231771	chr11:64140642	T/G	cg02228329	chr11:64053129	BAD;GPR137	0.78	14.94	0.57	1.87e-41	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs9914988	0.943	rs11656256	chr17:27153553	G/A	cg20469991	chr17:27169893	C17orf63	-0.59	-7.28	-0.32	1.44e-12	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Glycated hemoglobin levels;
LGG	cis	rs12477438	0.953	rs3851334	chr2:99794704	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.07	-16.14	-0.6	8.08e-47	Chronic sinus infection;
LGG	cis	rs6088580	0.634	rs3736762	chr20:33037336	C/T	cg24642439	chr20:33292090	TP53INP2	0.57	9.63	0.41	4.04e-20	Glomerular filtration rate (creatinine);
LGG	cis	rs9916302	0.904	rs7221875	chr17:37543328	G/A	cg00129232	chr17:37814104	STARD3	0.6	11.24	0.46	4.59e-26	Glomerular filtration rate (creatinine);
LGG	cis	rs4332037	0.539	rs3823624	chr7:2110346	T/C	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.07	-0.35	6.06e-15	Bipolar disorder;
LGG	cis	rs368123	1.000	rs429671	chr6:160718312	T/C	cg07349212	chr6:160770346	SLC22A3	-0.34	-7.18	-0.32	2.8e-12	Waist circumference;
LGG	trans	rs7824557	0.767	rs3808509	chr8:11163256	G/T	cg02002194	chr4:3960332	NA	-0.52	-9.8	-0.41	1e-20	Retinal vascular caliber;
LGG	trans	rs66759488	0.739	rs10851451	chr15:47608991	A/G	cg10156125	chr4:115520072	UGT8	-0.35	-7.24	-0.32	1.91e-12	Lung cancer;
LGG	cis	rs17376456	0.569	rs2045019	chr5:93201971	C/T	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.64	-8.54	-0.37	1.94e-16	Diabetic retinopathy;
LGG	cis	rs7617773	0.743	rs7621785	chr3:48343708	T/C	cg11946769	chr3:48343235	NME6	0.71	11.62	0.48	1.49e-27	Coronary artery disease;
LGG	cis	rs6951245	1.000	rs77346188	chr7:1114023	C/A	cg02733842	chr7:1102375	C7orf50	0.73	10.81	0.45	1.89e-24	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs3768617	0.510	rs10752895	chr1:183068505	C/G	cg15522984	chr1:182991683	LAMC1	0.46	9.25	0.39	8.49e-19	Fuchs's corneal dystrophy;
LGG	cis	rs6952808	1.000	rs6954521	chr7:1886865	C/A	cg04267008	chr7:1944627	MAD1L1	-0.64	-10.61	-0.44	1.1e-23	Bipolar disorder and schizophrenia;
LGG	cis	rs6594713	0.577	rs10078214	chr5:112915702	A/C	cg12552261	chr5:112820674	MCC	0.5	7.0	0.31	9.22e-12	Brain cytoarchitecture;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg24575275	chr7:1094737	C7orf50	-0.38	-7.33	-0.32	1.06e-12	Longevity;Endometriosis;
LGG	cis	rs861020	0.630	rs627069	chr1:210004613	C/G	cg05527609	chr1:210001259	C1orf107	0.6	9.69	0.41	2.52e-20	Orofacial clefts;
LGG	cis	rs10270805	0.667	rs4721503	chr7:16494407	A/G	cg08416764	chr7:16501619	SOSTDC1	-0.54	-7.2	-0.32	2.4e-12	Response to statin therapy;
LGG	cis	rs17453880	0.963	rs6872161	chr5:151947543	T/A	cg10931792	chr5:152022470	NA	0.38	8.02	0.35	8.75e-15	Subjective well-being;
LGG	cis	rs17102423	0.602	rs1007914	chr14:65566261	C/A	cg26396452	chr14:65542826	MAX	0.44	8.77	0.38	3.51e-17	Obesity-related traits;
LGG	cis	rs28595532	0.920	rs114213539	chr4:119758794	G/C	cg21605333	chr4:119757512	SEC24D	1.49	14.9	0.57	2.8e-41	Cannabis dependence symptom count;
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg19365062	chr6:127440000	RSPO3	0.57	6.67	0.3	7.25e-11	Intelligence (multi-trait analysis);
LGG	cis	rs798766	1.000	rs3099555	chr4:1725651	T/C	cg00006948	chr4:1768889	NA	-0.49	-6.83	-0.3	2.73e-11	Bladder cancer;Urinary bladder cancer;
LGG	cis	rs12210905	1.000	rs72843644	chr6:27211601	A/C	cg15325629	chr6:28072465	NA	0.83	6.81	0.3	3.12e-11	Hip circumference adjusted for BMI;
LGG	cis	rs75920871	0.512	rs6589583	chr11:116863766	C/T	cg20608306	chr11:116969690	SIK3	-0.38	-10.28	-0.43	1.79e-22	Subjective well-being;
LGG	cis	rs10256972	0.630	rs10282584	chr7:1081442	C/T	cg16127845	chr7:1126423	GPER;C7orf50	-0.27	-7.01	-0.31	8.67e-12	Longevity;Endometriosis;
LGG	trans	rs7824557	0.836	rs2736378	chr8:11119760	G/A	cg02002194	chr4:3960332	NA	0.46	8.44	0.37	4.18e-16	Retinal vascular caliber;
LGG	cis	rs597539	0.652	rs673821	chr11:68678718	G/T	cg04008888	chr11:68622739	NA	-0.54	-11.44	-0.47	7.5e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7552404	0.731	rs1493367	chr1:76344011	C/A	cg10523679	chr1:76189770	ACADM	-0.73	-11.25	-0.46	3.92e-26	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9329221	0.512	rs12546887	chr8:10292876	C/T	cg21775007	chr8:11205619	TDH	0.46	7.08	0.31	5.52e-12	Neuroticism;
LGG	cis	rs1577917	0.958	rs12195776	chr6:86488599	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.53	-0.5	3.14e-31	Response to antipsychotic treatment;
LGG	trans	rs916888	0.610	rs199530	chr17:44836653	C/T	cg22968622	chr17:43663579	NA	-0.75	-14.34	-0.55	7.73e-39	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs7223966	1.000	rs8067431	chr17:61817048	T/C	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.18	0.32	2.78e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs10504229	0.728	rs78765835	chr8:58154337	A/G	cg05313129	chr8:58192883	C8orf71	-0.75	-10.44	-0.44	4.51e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs11098499	0.710	rs4145952	chr4:120155806	C/A	cg24375607	chr4:120327624	NA	0.52	8.84	0.38	2.03e-17	Corneal astigmatism;
LGG	cis	rs2839186	0.500	rs13049893	chr21:47707054	C/T	cg12379764	chr21:47803548	PCNT	-0.65	-10.18	-0.43	4.25e-22	Testicular germ cell tumor;
LGG	trans	rs7939886	0.920	rs4612826	chr11:55948005	C/A	cg03929089	chr4:120376271	NA	0.73	6.84	0.3	2.54e-11	Myopia (pathological);
LGG	cis	rs2730245	0.636	rs2657382	chr7:158650941	G/A	cg24397884	chr7:158709396	WDR60	0.88	17.36	0.63	2.21e-52	Height;
LGG	cis	rs10256972	0.706	rs12701969	chr7:1121849	A/G	cg16145915	chr7:1198662	ZFAND2A	-0.65	-11.41	-0.47	9.28e-27	Longevity;Endometriosis;
LGG	trans	rs453301	0.686	rs3989373	chr8:8911308	G/T	cg27411982	chr8:10470053	RP1L1	-0.45	-7.67	-0.34	1.04e-13	Joint mobility (Beighton score);
LGG	trans	rs11098499	0.954	rs11098524	chr4:120390032	A/G	cg18145806	chr8:23022692	TNFRSF10D	-0.34	-6.69	-0.3	6.66e-11	Corneal astigmatism;
LGG	cis	rs12368653	0.666	rs799267	chr12:58113158	C/T	cg12615879	chr12:58013172	SLC26A10	0.31	6.88	0.3	1.96e-11	Multiple sclerosis;
LGG	cis	rs1185460	0.565	rs538478	chr11:118925341	C/T	cg23280166	chr11:118938394	VPS11	-0.48	-8.34	-0.36	8.79e-16	Coronary artery disease;
LGG	cis	rs2299587	0.841	rs2237849	chr8:17874882	A/C	cg18067069	chr8:17937731	ASAH1	-0.28	-6.66	-0.3	7.94e-11	Economic and political preferences;
LGG	cis	rs4242434	0.819	rs6999893	chr8:22465427	T/C	cg19455335	chr8:22457658	C8orf58	-0.4	-8.26	-0.36	1.59e-15	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs72781680	0.898	rs72788302	chr2:24107246	C/T	cg08917208	chr2:24149416	ATAD2B	0.92	9.69	0.41	2.43e-20	Lymphocyte counts;
LGG	cis	rs873946	0.590	rs12783478	chr10:134550700	A/G	cg06453172	chr10:134556979	INPP5A	-0.48	-7.53	-0.33	2.63e-13	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs2276314	0.748	rs4799839	chr18:33597531	T/C	cg05985134	chr18:33552581	C18orf21	0.63	9.72	0.41	1.97e-20	Endometriosis;Drug-induced torsades de pointes;
LGG	cis	rs12579753	0.871	rs4255611	chr12:82215969	C/A	cg07988820	chr12:82153109	PPFIA2	-0.75	-10.95	-0.45	5.73e-25	Resting heart rate;
LGG	cis	rs6951245	1.000	rs79617366	chr7:1111958	G/C	cg03188948	chr7:1209495	NA	0.64	8.28	0.36	1.3e-15	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs4689642	0.507	rs28584625	chr4:7218452	C/T	cg21353189	chr4:7228343	SORCS2	0.32	6.75	0.3	4.38e-11	Attention function in attention deficit hyperactive disorder;
LGG	cis	rs6502050	0.799	rs9675196	chr17:80096655	C/T	cg10505658	chr17:80084571	CCDC57	-0.41	-8.44	-0.37	4.13e-16	Life satisfaction;
LGG	cis	rs9322193	0.923	rs4242279	chr6:150160951	C/T	cg15971980	chr6:150254442	NA	0.46	8.39	0.36	6.13e-16	Lung cancer;
LGG	trans	rs7613875	0.663	rs6762477	chr3:50093209	G/A	cg21659725	chr3:3221576	CRBN	-0.55	-9.64	-0.41	3.69e-20	Body mass index;
LGG	cis	rs17376456	1.000	rs61132622	chr5:93539684	G/A	cg09848695	chr5:92956644	FAM172A;MIR2277	0.92	10.1	0.43	8e-22	Diabetic retinopathy;
LGG	cis	rs2635047	0.638	rs12968552	chr18:44702502	A/C	cg24750912	chr18:44543259	TCEB3CL;KATNAL2	0.37	6.89	0.3	1.85e-11	Educational attainment;
LGG	cis	rs1008375	0.966	rs3775924	chr4:17585984	T/C	cg16339924	chr4:17578868	LAP3	0.63	11.03	0.46	2.87e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs9329221	0.592	rs7832708	chr8:10190040	C/T	cg00405596	chr8:11794950	NA	0.42	7.17	0.32	2.94e-12	Neuroticism;
LGG	cis	rs9393692	0.905	rs7450556	chr6:26299900	C/T	cg05868516	chr6:26286170	HIST1H4H	0.47	8.22	0.36	2.09e-15	Educational attainment;
LGG	cis	rs559928	0.557	rs7122408	chr11:63898826	G/T	cg02228329	chr11:64053129	BAD;GPR137	0.58	6.76	0.3	4.13e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs67311347	1.000	rs73078162	chr3:40477109	G/A	cg24209194	chr3:40518798	ZNF619	0.44	6.77	0.3	3.94e-11	Renal cell carcinoma;
LGG	cis	rs62025270	0.576	rs17633959	chr15:86144181	A/T	cg25843651	chr15:86329602	KLHL25	0.54	8.14	0.35	3.73e-15	Idiopathic pulmonary fibrosis;
LGG	cis	rs2760061	0.626	rs594916	chr1:228133544	C/A	cg01200585	chr1:228362443	C1orf69	-0.44	-7.7	-0.34	8.52e-14	Diastolic blood pressure;
LGG	cis	rs13082711	0.595	rs17681498	chr3:27331258	T/C	cg02860705	chr3:27208620	NA	0.92	17.16	0.62	1.9e-51	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs4478037	0.822	rs3924695	chr3:33122085	C/T	cg19404215	chr3:33155277	CRTAP	0.73	8.9	0.38	1.25e-17	Major depressive disorder;
LGG	cis	rs2011503	0.941	rs11670775	chr19:19649636	A/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.34	6.76	0.3	4.12e-11	Bipolar disorder;
LGG	cis	rs6938	0.534	rs12907898	chr15:75207872	C/T	cg10253484	chr15:75165896	SCAMP2	-0.4	-6.68	-0.3	7.02e-11	Breast cancer;
LGG	cis	rs2153535	0.504	rs4493781	chr6:8473941	G/C	cg23788917	chr6:8435910	SLC35B3	0.52	8.77	0.38	3.42e-17	Motion sickness;
LGG	cis	rs4132509	0.895	rs6674314	chr1:243920895	A/G	cg21452805	chr1:244014465	NA	0.68	8.23	0.36	1.85e-15	RR interval (heart rate);
LGG	cis	rs2439831	0.867	rs16957630	chr15:43642780	A/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs3806843	0.932	rs2563257	chr5:140140529	A/G	cg19875535	chr5:140030758	IK	-0.52	-10.79	-0.45	2.34e-24	Depressive symptoms (multi-trait analysis);
LGG	cis	rs6952808	0.692	rs12666575	chr7:2004421	C/T	cg00106254	chr7:1943704	MAD1L1	-0.46	-7.83	-0.34	3.4e-14	Bipolar disorder and schizophrenia;
LGG	trans	rs7829975	0.744	rs2409092	chr8:8682192	A/T	cg27411982	chr8:10470053	RP1L1	0.41	7.03	0.31	7.3e-12	Mood instability;
LGG	cis	rs147120681	1	rs147120681	chr1:101239293	CT/C	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.38	-7.72	-0.34	7.22e-14	Neutrophil percentage of white cells;Lymphocyte percentage of white cells;
LGG	cis	rs7647973	0.710	rs1532204	chr3:49609477	C/G	cg13072238	chr3:49761600	GMPPB	-0.55	-7.06	-0.31	6.26e-12	Menarche (age at onset);
LGG	trans	rs783540	0.967	rs783527	chr15:83285847	C/T	cg16105309	chr15:79090380	ADAMTS7	0.43	7.6	0.33	1.67e-13	Schizophrenia;
LGG	trans	rs11992162	0.597	rs7011924	chr8:11780593	G/A	cg16141378	chr3:129829833	LOC729375	0.31	6.82	0.3	2.84e-11	Monocyte count;
LGG	cis	rs77741769	0.529	rs3901854	chr12:121225526	C/T	cg02419362	chr12:121203948	SPPL3	0.55	9.47	0.4	1.4e-19	Mean corpuscular volume;
LGG	cis	rs9362426	1.000	rs173334	chr6:88080223	T/C	cg06087457	chr6:88040249	C6orf162;GJB7	0.52	9.98	0.42	2.21e-21	Depressive episodes in bipolar disorder;
LGG	cis	rs4737010	0.530	rs4026	chr8:41645710	C/T	cg17182837	chr8:41585554	ANK1	-0.53	-7.85	-0.34	2.94e-14	Lymphocyte counts;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;Reticulocyte count;Reticulocyte fraction of red cells;Mean corpuscular volume;Immature fraction of reticulocytes;Mean corpuscular hemoglobin concentration;
LGG	cis	rs72772090	0.539	rs11747179	chr5:96112969	C/T	cg00188032	chr5:96141721	ERAP1	0.53	6.99	0.31	9.44e-12	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs10504229	0.683	rs11787247	chr8:58131528	G/T	cg24829409	chr8:58192753	C8orf71	-0.74	-10.5	-0.44	2.83e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs12479254	0.537	rs56211918	chr2:242497274	G/T	cg24828208	chr2:242500484	BOK	-0.37	-9.36	-0.4	3.4e-19	Brain structure;
LGG	cis	rs11641365	0.517	rs73262667	chr16:88779753	C/T	cg00034003	chr16:88779146	CTU2	0.83	11.39	0.47	1.18e-26	Autism spectrum disorder-related traits;
LGG	cis	rs2075371	0.611	rs35428392	chr7:134019645	G/A	cg11752832	chr7:134001865	SLC35B4	0.48	7.91	0.35	1.91e-14	Mean platelet volume;
LGG	cis	rs801193	0.548	rs6975044	chr7:66227482	C/T	cg18876405	chr7:65276391	NA	0.5	8.96	0.38	7.72e-18	Aortic root size;
LGG	cis	rs10540	1.000	rs117339389	chr11:505025	T/A	cg19913688	chr11:428466	ANO9	-0.64	-8.04	-0.35	7.84e-15	Body mass index;
LGG	cis	rs8177253	1.000	rs3811647	chr3:133484029	G/A	cg16414030	chr3:133502952	NA	-0.6	-10.39	-0.43	7.22e-23	Iron status biomarkers;
LGG	cis	rs2836950	0.501	rs13047518	chr21:40707307	G/A	cg11644478	chr21:40555479	PSMG1	-0.56	-9.16	-0.39	1.73e-18	Menarche (age at onset);
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg11584989	chr19:19387371	SF4	0.4	7.22	0.32	2.19e-12	Tonsillectomy;
LGG	trans	rs7824557	0.767	rs6985460	chr8:11171087	A/C	cg02002194	chr4:3960332	NA	-0.52	-9.82	-0.42	8.35e-21	Retinal vascular caliber;
LGG	cis	rs17270561	0.609	rs9358879	chr6:25742918	C/G	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs13108904	0.870	rs2335855	chr4:1237968	T/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.63	13.09	0.52	1.63e-33	Obesity-related traits;
LGG	trans	rs2243480	1.000	rs958550	chr7:65635679	C/T	cg10756647	chr7:56101905	PSPH	-0.67	-7.62	-0.33	1.49e-13	Diabetic kidney disease;
LGG	cis	rs9322193	0.809	rs9479808	chr6:150072464	A/T	cg00933542	chr6:150070202	PCMT1	0.4	7.21	0.32	2.36e-12	Lung cancer;
LGG	cis	rs10186029	0.676	rs1025820	chr2:213933778	T/G	cg08319019	chr2:214017104	IKZF2	0.47	8.3	0.36	1.13e-15	Systemic sclerosis;
LGG	cis	rs7385804	0.761	rs576236	chr7:100316975	C/T	cg16850897	chr7:100343110	ZAN	0.44	7.07	0.31	5.84e-12	Iron status biomarkers;Mean corpuscular hemoglobin;Hematocrit;Iron status biomarkers (transferrin saturation);Red blood cell count;Iron status biomarkers (iron levels);Mean corpuscular volume;Hematological parameters;
LGG	cis	rs798554	0.610	rs1182173	chr7:2878016	C/G	cg27476859	chr7:2772710	GNA12	0.51	10.05	0.42	1.21e-21	Height;
LGG	cis	rs9611565	0.659	rs4822035	chr22:41935912	A/G	cg06634786	chr22:41940651	POLR3H	0.74	11.85	0.48	1.84e-28	Vitiligo;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00859112	chr14:99736559	BCL11B	0.47	6.95	0.31	1.22e-11	Gut microbiome composition (summer);
LGG	cis	rs6461049	0.765	rs1476887	chr7:2151633	T/C	cg05863683	chr7:1912471	MAD1L1	0.39	7.67	0.34	1.02e-13	Schizophrenia;
LGG	cis	rs9948	0.786	rs62152775	chr2:97448474	G/T	cg01990225	chr2:97406019	LMAN2L	-0.68	-7.09	-0.31	4.98e-12	Erectile dysfunction and prostate cancer treatment;
LGG	cis	rs2836974	0.666	rs11910705	chr21:40685604	C/T	cg11644478	chr21:40555479	PSMG1	-0.71	-12.64	-0.51	1.14e-31	Cognitive function;
LGG	cis	rs3768617	0.811	rs4350171	chr1:182982148	C/T	ch.1.3577855R	chr1:183094577	LAMC1	0.35	6.73	0.3	5.06e-11	Fuchs's corneal dystrophy;
LGG	cis	rs4665809	0.838	rs6546749	chr2:26306288	T/C	cg22920501	chr2:26401640	FAM59B	-0.41	-7.97	-0.35	1.29e-14	Gut microbiome composition (summer);
LGG	cis	rs3126085	0.799	rs11589532	chr1:152176539	G/A	cg26876637	chr1:152193138	HRNR	-0.52	-8.05	-0.35	6.8e-15	Atopic dermatitis;
LGG	cis	rs568617	0.859	rs1204650	chr11:65645580	A/C	cg26695010	chr11:65641043	EFEMP2	0.48	6.91	0.31	1.58e-11	Crohn's disease;
LGG	cis	rs9341808	0.718	rs3828754	chr6:80900640	C/G	cg08355045	chr6:80787529	NA	0.41	7.86	0.34	2.75e-14	Sitting height ratio;
LGG	cis	rs597539	0.521	rs2060982	chr11:68612927	A/G	cg18350739	chr11:68623251	NA	-0.53	-12.18	-0.49	8.8e-30	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs7829975	0.902	rs485107	chr8:8581408	C/G	cg06636001	chr8:8085503	FLJ10661	-0.49	-8.95	-0.38	8.51e-18	Mood instability;
LGG	cis	rs6951245	1.000	rs79327308	chr7:1108141	A/C	cg18402987	chr7:1209562	NA	0.71	9.6	0.41	5.16e-20	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9322193	0.847	rs56103941	chr6:150137231	A/G	cg11878867	chr6:150167359	LRP11	-0.54	-11.1	-0.46	1.5e-25	Lung cancer;
LGG	cis	rs1008375	0.898	rs10008445	chr4:17593978	G/T	cg16339924	chr4:17578868	LAP3	0.63	10.92	0.45	7.52e-25	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg01258499	chr20:30540016	PDRG1	0.44	6.69	0.3	6.58e-11	Gut microbiome composition (summer);
LGG	cis	rs4948275	0.550	rs7904815	chr10:63136612	G/A	cg02023345	chr10:63212226	TMEM26	0.42	7.89	0.34	2.12e-14	Night sleep phenotypes;
LGG	cis	rs10781543	0.810	rs11145756	chr9:139364585	A/G	cg14169450	chr9:139327907	INPP5E	0.38	7.09	0.31	5.11e-12	Monocyte percentage of white cells;
LGG	cis	rs5769765	0.862	rs9616386	chr22:50313179	G/A	cg26441486	chr22:50317300	CRELD2	0.42	7.37	0.32	7.65e-13	Schizophrenia;
LGG	cis	rs209489	0.892	rs9463888	chr6:53109761	T/C	cg15607103	chr6:53167650	ELOVL5	0.59	7.22	0.32	2.1e-12	Survival in colorectal cancer (distant metastatic);
LGG	cis	rs6696846	0.791	rs10158848	chr1:205061192	C/T	cg21545522	chr1:205238299	TMCC2	0.37	6.98	0.31	9.98e-12	Red blood cell count;
LGG	cis	rs4906332	0.966	rs12894275	chr14:103901424	A/G	cg26031613	chr14:104095156	KLC1	0.52	7.74	0.34	6.14e-14	Coronary artery disease;
LGG	cis	rs7122257	0.524	rs7110449	chr11:11151111	A/T	cg16931664	chr11:11169707	NA	0.27	7.96	0.35	1.32e-14	Cerebrospinal fluid biomarker levels;
LGG	trans	rs3206736	0.576	rs17205723	chr7:35116436	A/G	cg14337134	chr7:102920323	DPY19L2P2	-0.43	-7.52	-0.33	2.85e-13	Diastolic blood pressure;
LGG	cis	rs6121246	0.529	rs58757492	chr20:30181425	G/A	cg13852791	chr20:30311386	BCL2L1	0.63	8.48	0.37	3.06e-16	Mean corpuscular hemoglobin;
LGG	trans	rs7395662	0.504	rs2019666	chr11:48437729	C/T	cg00717180	chr2:96193071	NA	-0.44	-7.83	-0.34	3.27e-14	HDL cholesterol;
LGG	cis	rs11650494	0.710	rs76305536	chr17:47488913	G/A	cg08112188	chr17:47440006	ZNF652	1.17	12.48	0.5	5.27e-31	Prostate cancer;
LGG	cis	rs17428076	0.793	rs56275355	chr2:172710180	G/A	cg21435375	chr2:172878103	MAP1D	0.41	8.79	0.38	2.97e-17	Myopia;
LGG	cis	rs7582180	0.629	rs11685406	chr2:100946638	A/G	cg05692746	chr2:100937584	LONRF2	-0.66	-12.28	-0.5	3.42e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10504229	0.593	rs113184543	chr8:58042950	A/G	cg11062466	chr8:58055876	NA	0.46	7.55	0.33	2.3e-13	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg00544901	chr19:49999417	RPS11	0.4	6.68	0.3	6.89e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1814175	0.645	rs10839456	chr11:49964093	C/T	cg03929089	chr4:120376271	NA	-0.94	-19.74	-0.68	2.16e-63	Height;
LGG	cis	rs10819861	0.645	rs3802440	chr9:98859938	G/C	cg14508093	chr9:98862825	NA	0.29	6.8	0.3	3.26e-11	Electrocardiographic traits;
LGG	cis	rs3735485	0.738	rs28489420	chr7:45088623	T/C	cg03440944	chr7:45023329	C7orf40	-0.56	-9.59	-0.41	5.31e-20	Granulocyte count;White blood cell count;Neutrophil count;Sum basophil neutrophil counts;Myeloid white cell count;Sum neutrophil eosinophil counts;Monocyte percentage of white cells;Lymphocyte counts;Granulocyte percentage of myeloid white cells;
LGG	cis	rs62238980	0.614	rs117535757	chr22:32373437	A/G	cg00543991	chr22:32367038	NA	0.82	9.0	0.39	5.79e-18	Childhood ear infection;
LGG	cis	rs11166927	0.548	rs2100803	chr8:140839371	A/C	cg16909799	chr8:140841666	TRAPPC9	-0.68	-14.85	-0.57	4.69e-41	Pediatric non-alcoholic fatty liver disease activity score;
LGG	cis	rs1865760	0.566	rs3752419	chr6:26027433	C/T	cg18357526	chr6:26021779	HIST1H4A	0.45	7.49	0.33	3.52e-13	Height;
LGG	trans	rs7819412	0.511	rs2409797	chr8:11433780	T/C	cg16141378	chr3:129829833	LOC729375	0.42	9.78	0.41	1.13e-20	Triglycerides;
LGG	cis	rs9926296	0.624	rs1110331	chr16:89774396	A/G	cg08949735	chr16:89699720	DPEP1	-0.38	-7.62	-0.33	1.43e-13	Vitiligo;
LGG	cis	rs6088590	1.000	rs6120705	chr20:33313740	T/C	cg08999081	chr20:33150536	PIGU	0.32	7.53	0.33	2.72e-13	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs12174716	chr6:149965623	C/T	cg13206674	chr6:150067644	NUP43	0.67	15.38	0.58	2.09e-43	Lung cancer;
LGG	cis	rs453301	0.606	rs6601279	chr8:8908231	G/A	cg06636001	chr8:8085503	FLJ10661	-0.46	-8.25	-0.36	1.63e-15	Joint mobility (Beighton score);
LGG	trans	rs853679	0.607	rs13207345	chr6:28265572	C/T	cg01620082	chr3:125678407	NA	-1.08	-10.68	-0.44	6.08e-24	Depression;
LGG	trans	rs208520	0.661	rs207079	chr6:66770462	C/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.95	-17.2	-0.62	1.25e-51	Exhaled nitric oxide output;
LGG	cis	rs1499614	1.000	rs2141924	chr7:66186246	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.17	-0.43	4.71e-22	Gout;
LGG	cis	rs55728055	0.661	rs16989334	chr22:32016092	A/G	cg01338084	chr22:32026380	PISD	1.5	12.89	0.51	1.11e-32	Age-related hearing impairment;
LGG	cis	rs875971	0.964	rs11765965	chr7:65842221	A/G	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs28386778	0.830	rs6504180	chr17:61813169	T/C	cg11494091	chr17:61959527	GH2	0.99	24.16	0.75	5.07e-84	Prudent dietary pattern;
LGG	cis	rs933688	0.938	rs7708782	chr5:90718517	T/C	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.14	18.88	0.66	2.15e-59	Smoking behavior;
LGG	cis	rs6879260	1.000	rs10903252	chr5:179733934	T/C	cg23248424	chr5:179741104	GFPT2	-0.59	-10.61	-0.44	1.05e-23	Height;
LGG	trans	rs6582630	0.555	rs11182429	chr12:38526679	A/C	cg06521331	chr12:34319734	NA	-0.48	-8.46	-0.37	3.67e-16	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs28386778	0.897	rs7501614	chr17:61802612	T/C	cg07677032	chr17:61819896	STRADA	0.67	12.6	0.51	1.74e-31	Prudent dietary pattern;
LGG	cis	rs1799949	0.965	rs33925201	chr17:41280682	A/G	cg25172604	chr17:41446521	NA	-0.31	-7.19	-0.32	2.6e-12	Menopause (age at onset);
LGG	cis	rs3008870	1.000	rs12132068	chr1:67451924	G/T	cg02640540	chr1:67518911	SLC35D1	-0.38	-6.86	-0.3	2.25e-11	Lymphocyte percentage of white cells;
LGG	cis	rs9534288	0.699	rs2146886	chr13:46646711	C/T	cg15192986	chr13:46630673	CPB2	-0.7	-14.79	-0.57	8.44e-41	Blood protein levels;
LGG	cis	rs62238980	0.614	rs75691061	chr22:32381222	G/A	cg02631450	chr22:32366979	NA	1.01	9.68	0.41	2.73e-20	Childhood ear infection;
LGG	cis	rs10504229	1.000	rs73609762	chr8:58192695	A/G	cg11062466	chr8:58055876	NA	0.48	8.28	0.36	1.31e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs7106204	0.748	rs7947388	chr11:24224903	A/G	ch.11.24196551F	chr11:24239977	NA	1.0	15.98	0.6	4.35e-46	Response to Homoharringtonine (cytotoxicity);
LGG	trans	rs7647973	0.593	rs62262730	chr3:49808274	T/G	cg21659725	chr3:3221576	CRBN	0.56	7.25	0.32	1.76e-12	Menarche (age at onset);
LGG	cis	rs6951245	1.000	rs6951245	chr7:1058193	G/A	cg02733842	chr7:1102375	C7orf50	0.67	10.14	0.43	5.87e-22	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs9534288	0.797	rs2182483	chr13:46582600	C/T	cg15192986	chr13:46630673	CPB2	-0.6	-13.18	-0.52	6.48e-34	Blood protein levels;
LGG	cis	rs6076065	0.612	rs11905630	chr20:23326165	G/C	cg12633918	chr20:23549525	CST9L	-0.35	-6.66	-0.3	7.79e-11	Facial morphology (factor 15, philtrum width);
LGG	cis	rs6582630	0.593	rs12816835	chr12:38533304	C/T	cg26384229	chr12:38710491	ALG10B	-0.66	-13.23	-0.52	3.92e-34	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs6461049	0.800	rs3778977	chr7:2159746	C/T	cg00106254	chr7:1943704	MAD1L1	-0.39	-6.72	-0.3	5.24e-11	Schizophrenia;
LGG	cis	rs17102423	0.615	rs7147987	chr14:65538131	A/G	cg16583315	chr14:65563665	MAX	-0.36	-7.06	-0.31	6.19e-12	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs9890558	chr17:29110355	T/C	cg08994789	chr17:28903642	LRRC37B2	-0.68	-8.21	-0.36	2.19e-15	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2204008	0.577	rs11520050	chr12:38051839	G/A	cg06521331	chr12:34319734	NA	-0.53	-9.08	-0.39	3.12e-18	Bladder cancer;
LGG	cis	rs13118159	0.934	rs2878608	chr4:1354286	C/G	cg13395646	chr4:1353034	KIAA1530	-0.45	-8.0	-0.35	1.01e-14	Longevity;
LGG	cis	rs9397585	0.667	rs6557259	chr6:153412938	A/G	cg12989544	chr6:153429875	RGS17	0.31	6.82	0.3	2.93e-11	Body mass index;
LGG	cis	rs7084402	0.967	rs1619284	chr10:60302515	C/T	cg07615347	chr10:60278583	BICC1	0.64	18.74	0.66	9.76e-59	Refractive error;
LGG	cis	rs6456156	0.875	rs55802221	chr6:167517320	G/A	cg07741184	chr6:167504864	NA	-0.37	-8.14	-0.35	3.76e-15	Primary biliary cholangitis;
LGG	cis	rs4268898	0.679	rs2551181	chr2:24437548	C/T	cg06627628	chr2:24431161	ITSN2	0.73	11.97	0.49	5.98e-29	Asthma;
LGG	cis	rs875971	0.862	rs778702	chr7:65864835	G/A	cg11764359	chr7:65958608	NA	0.74	13.24	0.52	3.75e-34	Aortic root size;
LGG	cis	rs7582180	0.629	rs13025184	chr2:100944842	A/G	cg21926883	chr2:100939477	LONRF2	-0.69	-16.32	-0.6	1.25e-47	Intelligence (multi-trait analysis);
LGG	cis	rs17504614	0.634	rs68157830	chr2:51066869	T/C	cg23851515	chr2:51057218	NRXN1	0.45	7.47	0.33	3.98e-13	Educational attainment (years of education);
LGG	cis	rs11098499	0.780	rs7692994	chr4:120427489	C/A	cg24375607	chr4:120327624	NA	0.59	9.81	0.41	9.1e-21	Corneal astigmatism;
LGG	cis	rs1799949	1.000	rs4793212	chr17:41302750	T/C	cg25072359	chr17:41440525	NA	0.54	10.19	0.43	4.05e-22	Menopause (age at onset);
LGG	cis	rs10504229	1.000	rs67344620	chr8:58187537	C/A	cg08677398	chr8:58056175	NA	0.44	7.38	0.32	7.47e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs3785574	0.650	rs7406102	chr17:62004749	G/A	cg11494091	chr17:61959527	GH2	-0.67	-11.83	-0.48	2.12e-28	Height;
LGG	cis	rs2153535	0.601	rs2015281	chr6:8539673	G/A	cg07606381	chr6:8435919	SLC35B3	0.68	12.56	0.5	2.37e-31	Motion sickness;
LGG	cis	rs372883	0.563	rs1153293	chr21:30691325	C/T	cg24692254	chr21:30365293	RNF160	0.68	12.5	0.5	4.26e-31	Pancreatic cancer;
LGG	cis	rs10504229	0.593	rs16921626	chr8:58040359	C/T	cg08677398	chr8:58056175	NA	0.44	6.96	0.31	1.14e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7264396	0.790	rs2425115	chr20:34322418	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.81	-0.34	3.95e-14	Total cholesterol levels;
LGG	cis	rs763014	0.593	rs28455838	chr16:681966	T/C	cg09263875	chr16:632152	PIGQ	0.67	13.39	0.53	8.3e-35	Height;
LGG	trans	rs7618501	0.633	rs11925192	chr3:50038664	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.44	7.88	0.34	2.33e-14	Intelligence (multi-trait analysis);
LGG	cis	rs9900972	0.918	rs4789940	chr17:76877671	G/T	cg00961940	chr17:76876995	TIMP2	0.45	8.98	0.39	6.79e-18	Obesity-related traits;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg26479374	chr4:1243980	CTBP1;C4orf42	0.6	11.86	0.48	1.68e-28	Obesity-related traits;
LGG	cis	rs2230307	0.536	rs526128	chr1:100473427	T/A	cg24955406	chr1:100503596	HIAT1	0.56	8.05	0.35	6.88e-15	Carotid intima media thickness;
LGG	cis	rs9462027	0.628	rs10947521	chr6:34689377	G/T	cg07306190	chr6:34760872	UHRF1BP1	0.53	10.74	0.45	3.68e-24	Systemic lupus erythematosus;
LGG	cis	rs1552244	0.554	rs6786636	chr3:10045703	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.62	-10.89	-0.45	1.01e-24	Alzheimer's disease;
LGG	trans	rs11039798	0.588	rs7108164	chr11:48626363	A/C	cg15704280	chr7:45808275	SEPT13	0.73	10.12	0.43	7.26e-22	Axial length;
LGG	cis	rs10861342	1.000	rs1076	chr12:105562788	C/T	cg23923672	chr12:105501055	KIAA1033	-0.77	-6.73	-0.3	5.11e-11	IgG glycosylation;
LGG	cis	rs17401966	1.000	rs1049887	chr1:10460485	T/C	cg19773385	chr1:10388646	KIF1B	-0.46	-8.59	-0.37	1.32e-16	Hepatocellular carcinoma;
LGG	trans	rs3808502	0.563	rs12549144	chr8:11422861	C/G	cg02002194	chr4:3960332	NA	-0.5	-9.62	-0.41	4.31e-20	Neuroticism;
LGG	trans	rs11098499	0.908	rs11098527	chr4:120399906	A/G	cg25214090	chr10:38739885	LOC399744	0.69	12.38	0.5	1.34e-30	Corneal astigmatism;
LGG	cis	rs9814567	1.000	rs6793487	chr3:134299426	C/G	cg06109529	chr3:134205091	CEP63;ANAPC13	0.72	13.4	0.53	7.77e-35	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9486715	0.867	rs4839687	chr6:96951732	C/A	cg06623918	chr6:96969491	KIAA0776	0.78	15.92	0.59	7.84e-46	Headache;
LGG	cis	rs3820068	0.532	rs72645862	chr1:15920366	A/G	cg05660106	chr1:15850417	CASP9	0.87	17.71	0.64	6e-54	Systolic blood pressure;
LGG	cis	rs765787	0.530	rs4775834	chr15:45537511	C/T	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs5756391	0.546	rs5750338	chr22:37316125	G/A	cg21209356	chr22:37319042	CSF2RB	0.42	9.5	0.4	1.14e-19	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs10174077	0.874	rs4664490	chr2:152471923	C/G	cg06191203	chr2:152266755	RIF1	0.4	6.96	0.31	1.15e-11	Squamous cell lung carcinoma;
LGG	cis	rs10911232	0.507	rs10797829	chr1:183033228	C/T	cg15522984	chr1:182991683	LAMC1	-0.48	-9.9	-0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs9322193	0.926	rs9383546	chr6:150143879	T/A	cg08621203	chr6:150244597	RAET1G	0.41	7.0	0.31	9.33e-12	Lung cancer;
LGG	cis	rs1799949	0.965	rs9911630	chr17:41188342	A/G	cg12708336	chr17:41446283	NA	-0.32	-7.7	-0.34	8.42e-14	Menopause (age at onset);
LGG	cis	rs2228479	0.850	rs62054224	chr16:89892071	C/T	cg19635926	chr16:89946313	TCF25	0.75	7.32	0.32	1.08e-12	Skin colour saturation;
LGG	cis	rs13102973	0.899	rs4479760	chr4:135867474	T/C	cg14419869	chr4:135874104	NA	0.58	11.08	0.46	1.8e-25	Subjective well-being;
LGG	cis	rs7618915	0.501	rs12486554	chr3:52742537	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-9.98	-0.42	2.21e-21	Bipolar disorder;
LGG	cis	rs798554	0.660	rs2644274	chr7:2854380	A/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.15	-0.35	3.47e-15	Height;
LGG	cis	rs899997	0.773	rs8032156	chr15:78964498	A/G	cg07120314	chr15:79043507	NA	-0.67	-12.14	-0.49	1.26e-29	Coronary artery disease or large artery stroke;
LGG	cis	rs2046867	0.818	rs62249875	chr3:72911858	G/A	cg01043669	chr3:72786069	NA	0.41	6.91	0.31	1.6e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9388451	0.626	rs3734637	chr6:126081319	G/T	cg05901451	chr6:126070800	HEY2	-0.67	-12.7	-0.51	6.52e-32	Brugada syndrome;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg09558872	chr19:9929784	FBXL12	0.43	6.72	0.3	5.24e-11	Gut microbiome composition (summer);
LGG	cis	rs6466055	0.720	rs7800928	chr7:105007470	T/C	cg04380332	chr7:105027541	SRPK2	-0.39	-7.21	-0.32	2.37e-12	Schizophrenia;
LGG	cis	rs7107174	1.000	rs72931639	chr11:78036703	C/T	cg27205649	chr11:78285834	NARS2	-0.47	-7.6	-0.33	1.71e-13	Testicular germ cell tumor;
LGG	cis	rs12681287	0.517	rs34596274	chr8:87517679	C/T	cg27223183	chr8:87520930	FAM82B	-0.5	-7.43	-0.33	5.12e-13	Caudate activity during reward;
LGG	cis	rs7186908	1.000	rs7186908	chr16:72220373	G/C	cg01557791	chr16:72042693	DHODH	-0.53	-8.02	-0.35	8.74e-15	Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs7226408	0.901	rs11081986	chr18:34683307	T/A	cg15022739	chr18:34823045	BRUNOL4	-0.44	-7.13	-0.31	3.99e-12	Obesity-related traits;
LGG	cis	rs9357271	0.956	rs7748599	chr6:38363213	A/G	cg07362130	chr6:38359646	BTBD9	-0.44	-9.92	-0.42	3.6e-21	Restless legs syndrome;
LGG	cis	rs208520	0.690	rs851459	chr6:66813989	A/G	cg07460842	chr6:66804631	NA	-0.98	-18.64	-0.65	2.97e-58	Exhaled nitric oxide output;
LGG	cis	rs4959677	0.901	rs4959678	chr6:2503173	C/A	cg23817096	chr6:1620687	NA	-0.31	-7.38	-0.32	7.52e-13	Orthostatic hypotension;
LGG	cis	rs9902453	0.765	rs2729448	chr17:28091953	T/C	cg26525008	chr17:28256777	EFCAB5;SSH2	-0.71	-14.24	-0.55	2.01e-38	Coffee consumption (cups per day);
LGG	cis	rs28386778	0.897	rs8069969	chr17:61822223	T/G	cg07362569	chr17:61921086	SMARCD2	0.5	9.63	0.41	4.02e-20	Prudent dietary pattern;
LGG	cis	rs11148252	0.840	rs4369550	chr13:52744910	A/G	cg05335186	chr13:53173507	NA	0.48	9.9	0.42	4.42e-21	Lewy body disease;
LGG	cis	rs8067545	0.641	rs1638525	chr17:19848594	G/C	cg04132472	chr17:19861366	AKAP10	0.25	7.14	0.31	3.66e-12	Schizophrenia;
LGG	trans	rs7395662	0.895	rs1827971	chr11:48718502	C/G	cg15704280	chr7:45808275	SEPT13	-0.48	-7.95	-0.35	1.47e-14	HDL cholesterol;
LGG	cis	rs4926298	1.000	rs1077151	chr19:13151108	A/G	cg04657146	chr19:12876947	HOOK2	-0.41	-6.86	-0.3	2.25e-11	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs2297928	chr6:150039720	G/C	cg00933542	chr6:150070202	PCMT1	0.39	7.16	0.32	3.23e-12	Lung cancer;
LGG	cis	rs7726839	0.555	rs7720419	chr5:589343	A/T	cg09021430	chr5:549028	NA	-0.86	-20.77	-0.69	3.32e-68	Obesity-related traits;
LGG	trans	rs17685	0.753	rs1104878	chr7:75685593	G/T	cg19862616	chr7:65841803	NCRNA00174	1.07	26.03	0.77	1.08e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs8072100	0.748	rs9912592	chr17:45556945	G/A	cg08085267	chr17:45401833	C17orf57	-0.54	-10.58	-0.44	1.41e-23	Very long-chain saturated fatty acid levels (fatty acid 20:0);
LGG	cis	rs651907	0.557	rs35850993	chr3:101437433	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.48	7.89	0.34	2.23e-14	Colorectal cancer;
LGG	cis	rs16989760	0.661	rs67935422	chr22:32020413	G/A	cg01338084	chr22:32026380	PISD	1.48	12.53	0.5	3.11e-31	Age-related hearing impairment;
LGG	cis	rs981844	1.000	rs1116636	chr4:154657151	C/T	cg14289246	chr4:154710475	SFRP2	0.69	11.43	0.47	8.26e-27	Response to statins (LDL cholesterol change);
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg05300158	chr4:140477727	SETD7	-0.41	-6.78	-0.3	3.6e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs10504229	0.728	rs17215753	chr8:58153764	A/G	cg02725872	chr8:58115012	NA	-0.93	-12.99	-0.52	3.97e-33	Developmental language disorder (linguistic errors);
LGG	cis	rs2294693	0.947	rs10155663	chr6:40994301	T/G	cg14769373	chr6:40998127	UNC5CL	-0.42	-7.39	-0.32	6.91e-13	Gastric cancer;Non-cardia gastric cancer;
LGG	cis	rs1799949	1.000	rs4793215	chr17:41318932	G/A	cg12708336	chr17:41446283	NA	-0.31	-7.18	-0.32	2.77e-12	Menopause (age at onset);
LGG	cis	rs3096299	0.967	rs2965827	chr16:89457350	A/C	cg08822215	chr16:89438651	ANKRD11	0.38	7.45	0.33	4.7e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs7928758	0.887	rs11825120	chr11:134271805	A/G	cg25213107	chr11:134282864	B3GAT1	1.12	14.0	0.55	2.11e-37	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs9348729	1	rs9348729	chr6:26664268	T/C	cg12826209	chr6:26865740	GUSBL1	0.81	11.98	0.49	5.22e-29	Intelligence (multi-trait analysis);
LGG	cis	rs1707322	0.927	rs6690386	chr1:46253011	C/T	cg03146154	chr1:46216737	IPP	0.56	10.48	0.44	3.25e-23	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg00986762	chr1:36107072	PSMB2	0.43	7.37	0.32	7.95e-13	Cognitive performance;
LGG	cis	rs898097	0.691	rs7222773	chr17:80907283	A/G	cg15664640	chr17:80829946	TBCD	0.54	10.77	0.45	2.86e-24	Breast cancer;
LGG	cis	rs13118159	0.509	rs1882098	chr4:1352431	T/C	cg16405210	chr4:1374714	KIAA1530	-0.86	-16.09	-0.6	1.35e-46	Longevity;
LGG	cis	rs12540874	0.895	rs4245556	chr7:50661661	C/T	cg00647317	chr7:50633725	DDC	0.47	11.93	0.48	8.64e-29	Systemic sclerosis;
LGG	cis	rs75920871	0.858	rs17120280	chr11:116942132	G/A	cg20608306	chr11:116969690	SIK3	-0.33	-6.73	-0.3	4.96e-11	Subjective well-being;
LGG	cis	rs7953508	0.750	rs11107119	chr12:93983132	T/A	cg18151635	chr12:93972918	NA	-0.48	-8.54	-0.37	1.91e-16	Pubertal anthropometrics;
LGG	cis	rs7208859	0.623	rs7217984	chr17:29092766	G/A	cg13385521	chr17:29058706	SUZ12P	0.92	10.74	0.45	3.42e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9858542	0.953	rs6446272	chr3:49463287	G/A	cg03060546	chr3:49711283	APEH	-0.62	-10.25	-0.43	2.37e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00831358	chr1:32254081	NA	0.49	7.39	0.32	6.8e-13	Gut microbiome composition (summer);
LGG	cis	rs5742933	0.779	rs114408326	chr2:190581396	C/T	cg10453823	chr2:190539512	ANKAR	-0.47	-6.93	-0.31	1.43e-11	Ferritin levels;
LGG	cis	rs875971	0.830	rs778711	chr7:65851657	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.05e-15	Aortic root size;
LGG	cis	rs708547	0.830	rs1713994	chr4:57868367	G/A	cg16868167	chr4:57843880	C4orf14;POLR2B	0.73	11.92	0.48	9.41e-29	Response to bleomycin (chromatid breaks);
LGG	cis	rs12042938	0.935	rs1417585	chr1:231803604	C/T	cg23162821	chr1:231664172	TSNAX-DISC1;TSNAX	0.57	10.33	0.43	1.24e-22	Neuranatomic and neurocognitive phenotypes;
LGG	cis	rs1552244	0.572	rs6442154	chr3:10168785	A/G	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.67	-0.48	9.59e-28	Alzheimer's disease;
LGG	cis	rs2640806	0.505	rs11988031	chr8:97366859	T/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.24	0.32	1.93e-12	Obesity-related traits;
LGG	cis	rs10779751	1.000	rs11121710	chr1:11313244	T/C	cg08854313	chr1:11322531	MTOR	0.75	16.56	0.61	1.04e-48	Body mass index;
LGG	cis	rs12464559	0.649	rs3768658	chr2:152677674	T/C	cg01189475	chr2:152685088	ARL5A	0.74	6.65	0.3	8.5e-11	Response to cognitive-behavioural therapy in anxiety disorder;
LGG	cis	rs4423214	0.650	rs4245442	chr11:71220909	T/C	cg05163923	chr11:71159392	DHCR7	0.61	10.56	0.44	1.75e-23	Vitamin D levels;
LGG	cis	rs2115630	0.967	rs11073731	chr15:85355113	C/A	cg12501888	chr15:85177176	SCAND2	-0.41	-6.7	-0.3	5.96e-11	P wave terminal force;
LGG	cis	rs12926788	0.689	rs34365165	chr16:24856208	G/A	cg02428538	chr16:24856791	SLC5A11	-0.68	-10.26	-0.43	2.08e-22	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs2303745	0.589	rs6512179	chr19:17399105	T/C	cg10664184	chr19:17420304	DDA1	0.54	8.26	0.36	1.5e-15	Systemic lupus erythematosus;
LGG	trans	rs225245	0.791	rs7406966	chr17:34013636	A/C	cg19694781	chr19:47549865	TMEM160	-0.41	-6.94	-0.31	1.29e-11	Reticulocyte count;Reticulocyte fraction of red cells;High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;
LGG	cis	rs908922	0.676	rs11581947	chr1:152482587	G/A	cg03606772	chr1:152487856	CRCT1	0.29	6.97	0.31	1.11e-11	Hair morphology;
LGG	cis	rs736408	0.924	rs2535629	chr3:52833219	C/T	cg14092988	chr3:52407081	DNAH1	0.3	7.67	0.34	1.03e-13	Bipolar disorder;
LGG	cis	rs73787773	0.644	rs76564228	chr5:111479971	A/G	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.56	-7.19	-0.32	2.69e-12	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs1008375	1.000	rs2872958	chr4:17665032	A/G	cg16339924	chr4:17578868	LAP3	0.6	10.45	0.44	4.21e-23	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2439831	0.717	rs7165471	chr15:43644788	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.88	10.73	0.45	3.83e-24	Lung cancer in ever smokers;
LGG	cis	rs6685188	0.920	rs6676110	chr1:205662977	G/A	cg11965913	chr1:205819406	PM20D1	-0.53	-8.29	-0.36	1.24e-15	White blood cell count (basophil);Basophil percentage of white cells;
LGG	cis	rs3780486	0.801	rs10971424	chr9:33138775	T/C	cg13443165	chr9:33130375	B4GALT1	-0.75	-14.76	-0.57	1.13e-40	IgG glycosylation;
LGG	cis	rs7084402	0.967	rs1649038	chr10:60330439	G/A	cg09696939	chr10:60272079	BICC1	-0.37	-7.27	-0.32	1.5e-12	Refractive error;
LGG	cis	rs2739330	0.627	rs9608219	chr22:24274119	G/C	cg11141652	chr22:24348549	GSTTP1	0.4	6.99	0.31	9.7e-12	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs17376456	0.569	rs6556834	chr5:93123067	C/T	cg19507638	chr5:93509721	C5orf36	0.43	7.0	0.31	8.8e-12	Diabetic retinopathy;
LGG	cis	rs12477438	0.520	rs1044575	chr2:99812070	G/A	cg14399236	chr2:99771627	LIPT1;TSGA10	0.81	17.17	0.62	1.68e-51	Chronic sinus infection;
LGG	cis	rs9322193	0.607	rs12527391	chr6:150203292	T/C	cg07701084	chr6:150067640	NUP43	0.49	7.47	0.33	3.98e-13	Lung cancer;
LGG	cis	rs6502050	0.842	rs7218075	chr17:80076808	C/G	cg19223190	chr17:80058835	NA	-0.45	-8.82	-0.38	2.35e-17	Life satisfaction;
LGG	cis	rs589448	0.535	rs12423794	chr12:69713018	G/A	cg11871910	chr12:69753446	YEATS4	0.81	16.67	0.61	3.32e-49	Cerebrospinal fluid biomarker levels;
LGG	cis	rs1799949	1.000	rs16940	chr17:41245237	A/G	cg25288140	chr17:41278341	BRCA1;NBR2	0.45	7.08	0.31	5.46e-12	Menopause (age at onset);
LGG	cis	rs10504229	0.775	rs17804840	chr8:58157045	C/T	cg20607798	chr8:58055168	NA	0.64	7.51	0.33	3.09e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs344364	0.602	rs2437744	chr16:1908451	C/T	cg08610935	chr16:1836813	NUBP2	0.44	6.86	0.3	2.18e-11	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9747201	1.000	rs12451470	chr17:80177532	G/A	cg14673194	chr17:80132900	CCDC57	-0.44	-7.67	-0.34	1e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6463523	0.933	rs6974151	chr7:758269	T/C	cg06242242	chr7:766104	PRKAR1B;HEATR2	0.84	15.2	0.58	1.3e-42	Subjective well-being;
LGG	cis	rs977987	0.778	rs62059846	chr16:75430809	T/A	cg07303275	chr16:75499416	TMEM170A	0.37	6.74	0.3	4.71e-11	Dupuytren's disease;
LGG	cis	rs8005677	1.000	rs8006396	chr14:23380850	A/G	cg25600027	chr14:23388339	RBM23	-0.44	-7.25	-0.32	1.8e-12	Cognitive ability (multi-trait analysis);
LGG	cis	rs2404602	0.536	rs11072599	chr15:76774508	T/C	cg23625390	chr15:77176239	SCAPER	0.39	7.35	0.32	9.06e-13	Blood metabolite levels;
LGG	trans	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg06521331	chr12:34319734	NA	-0.51	-8.83	-0.38	2.13e-17	Bladder cancer;
LGG	cis	rs4746818	1.000	rs6480384	chr10:70890757	C/T	cg11621586	chr10:70884670	VPS26A	1.19	23.03	0.73	8.55e-79	Left atrial antero-posterior diameter;
LGG	cis	rs875971	0.638	rs7793569	chr7:66116633	T/G	cg18252515	chr7:66147081	NA	0.41	6.89	0.3	1.87e-11	Aortic root size;
LGG	cis	rs599083	0.530	rs2508834	chr11:68175354	C/T	cg16797656	chr11:68205561	LRP5	-0.46	-7.51	-0.33	3.06e-13	Bone mineral density (spine);
LGG	cis	rs10791097	0.765	rs4622274	chr11:130729486	C/T	cg09137382	chr11:130731461	NA	0.4	7.75	0.34	5.7e-14	Autism spectrum disorder or schizophrenia;Schizophrenia;
LGG	cis	rs6062509	0.839	rs6062298	chr20:62301970	G/A	cg27236539	chr20:62289627	RTEL1	0.46	6.99	0.31	9.79e-12	Prostate cancer;
LGG	cis	rs79149102	0.579	rs7166105	chr15:75343942	A/G	cg17294928	chr15:75287854	SCAMP5	0.77	8.59	0.37	1.35e-16	Lung cancer;
LGG	cis	rs11098499	0.863	rs1010740	chr4:120463409	C/T	cg24375607	chr4:120327624	NA	-0.66	-10.88	-0.45	1.08e-24	Corneal astigmatism;
LGG	cis	rs11671005	0.735	rs3826683	chr19:58918733	T/C	cg13877915	chr19:58951672	ZNF132	0.59	8.38	0.36	6.39e-16	Mean platelet volume;
LGG	cis	rs7811142	1.000	rs60257855	chr7:100026780	G/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.47	0.61	2.66e-48	Platelet count;
LGG	cis	rs13082711	0.911	rs2371065	chr3:27494589	A/C	cg02860705	chr3:27208620	NA	0.73	13.17	0.52	7.03e-34	Systolic blood pressure;Diastolic blood pressure;Blood pressure;
LGG	cis	rs2576037	0.562	rs13381557	chr18:44513371	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.52	-8.85	-0.38	1.85e-17	Personality dimensions;
LGG	cis	rs4642101	0.765	rs6791647	chr3:12826425	C/T	cg05775895	chr3:12838266	CAND2	-0.65	-11.63	-0.48	1.34e-27	QRS complex (12-leadsum);
LGG	cis	rs10504229	0.953	rs57131327	chr8:58171895	T/C	cg24829409	chr8:58192753	C8orf71	-0.85	-13.51	-0.53	2.78e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs736408	0.632	rs2240919	chr3:52831701	C/G	cg11645453	chr3:52864694	ITIH4	0.45	7.17	0.32	2.99e-12	Bipolar disorder;
LGG	cis	rs9682041	1.000	rs57508070	chr3:170074374	C/A	cg11886554	chr3:170076028	SKIL	0.97	11.44	0.47	7.53e-27	Glomerular filtration rate in non diabetics (creatinine);Glomerular filtration rate (creatinine);
LGG	cis	rs34684276	1	rs34684276	chr15:78813155	G/A	cg18825076	chr15:78729989	IREB2	-0.46	-7.45	-0.33	4.57e-13	Nicotine dependence;Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs7646881	0.812	rs59192661	chr3:158459027	T/C	cg19483011	chr3:158453295	NA	-0.61	-8.16	-0.35	3.08e-15	Tetralogy of Fallot;
LGG	cis	rs6951245	1.000	rs78861357	chr7:1095418	C/T	cg20603222	chr7:1096387	C7orf50;GPR146	-1.01	-17.15	-0.62	2.22e-51	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs55728055	0.661	rs62237775	chr22:31965401	A/G	cg15162869	chr22:32027605	PISD	-0.75	-7.74	-0.34	6.25e-14	Age-related hearing impairment;
LGG	cis	rs4481887	0.861	rs4486480	chr1:248449714	C/T	cg01631408	chr1:248437212	OR2T33	-0.57	-10.02	-0.42	1.56e-21	Common traits (Other);
LGG	cis	rs1878931	0.697	rs10048148	chr16:3417450	C/G	cg26668626	chr16:3451006	ZNF174;ZNF434	0.97	21.84	0.71	3.29e-73	Body mass index (adult);
LGG	cis	rs4919044	0.641	rs11187225	chr10:94714427	C/G	cg05127821	chr10:94822908	CYP26C1	-0.41	-7.09	-0.31	4.92e-12	Coronary artery disease;
LGG	cis	rs9291683	0.620	rs7699512	chr4:10125808	C/T	cg08250081	chr4:10125330	NA	-0.38	-7.46	-0.33	4.2e-13	Bone mineral density;
LGG	cis	rs7474896	0.537	rs1208683	chr10:38093723	A/G	cg25427524	chr10:38739819	LOC399744	0.47	6.99	0.31	9.83e-12	Obesity (extreme);
LGG	cis	rs2224391	1.000	rs2753246	chr6:5261845	A/G	cg09085698	chr6:5261316	LYRM4;FARS2	-0.56	-8.24	-0.36	1.83e-15	Height;
LGG	cis	rs2635047	1.000	rs2635043	chr18:44679769	A/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.53	9.21	0.39	1.13e-18	Educational attainment;
LGG	cis	rs7647973	1.000	rs13322887	chr3:49555583	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.51	-7.92	-0.35	1.83e-14	Menarche (age at onset);
LGG	cis	rs2836950	0.501	rs2836980	chr21:40687618	G/T	cg17971929	chr21:40555470	PSMG1	-0.53	-8.95	-0.38	8.55e-18	Menarche (age at onset);
LGG	trans	rs9467711	0.606	rs9393711	chr6:26370659	C/T	cg06606381	chr12:133084897	FBRSL1	-0.82	-8.58	-0.37	1.44e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs4243830	1.000	rs34757678	chr1:6583270	C/G	cg22792644	chr1:6614718	TAS1R1;NOL9	0.82	11.47	0.47	5.69e-27	Body mass index;
LGG	cis	rs875971	0.862	rs4718383	chr7:66108409	T/C	cg11764359	chr7:65958608	NA	-0.73	-12.38	-0.5	1.29e-30	Aortic root size;
LGG	cis	rs988958	0.675	rs35297530	chr2:42224825	G/C	cg19376973	chr2:42229025	NA	0.62	9.8	0.41	9.93e-21	Hypospadias;
LGG	cis	rs4262150	0.842	rs55752615	chr5:152138718	C/T	cg12297329	chr5:152029980	NA	-0.7	-12.78	-0.51	3.08e-32	Bipolar disorder and schizophrenia;
LGG	cis	rs798554	0.634	rs6978692	chr7:2857411	C/T	cg18446336	chr7:2847575	GNA12	-0.31	-8.13	-0.35	3.96e-15	Height;
LGG	cis	rs9910055	0.573	rs228768	chr17:42191893	A/C	cg09913183	chr17:42254507	C17orf65;ASB16	0.49	9.01	0.39	5.5e-18	Total body bone mineral density;
LGG	cis	rs6502050	0.871	rs6502056	chr17:80070912	C/G	cg11859384	chr17:80120422	CCDC57	0.45	7.86	0.34	2.79e-14	Life satisfaction;
LGG	cis	rs7226408	0.600	rs1683510	chr18:34650282	T/G	cg15022739	chr18:34823045	BRUNOL4	-0.43	-9.18	-0.39	1.4e-18	Obesity-related traits;
LGG	cis	rs13108904	0.934	rs13125338	chr4:1278435	A/C	cg06654118	chr4:1303317	MAEA	0.47	8.04	0.35	7.32e-15	Obesity-related traits;
LGG	cis	rs1865760	0.928	rs9295673	chr6:25912094	T/G	cg03517284	chr6:25882590	NA	-0.41	-7.4	-0.33	6.38e-13	Height;
LGG	cis	rs9896933	0.775	rs615630	chr17:80730527	T/C	cg15664640	chr17:80829946	TBCD	0.69	9.59	0.41	5.46e-20	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9560113	1.000	rs9555804	chr13:112179751	T/C	cg14952266	chr13:112191215	NA	-0.42	-7.64	-0.33	1.25e-13	Menarche (age at onset);
LGG	cis	rs7172689	0.908	rs11637642	chr15:81559324	C/T	cg11808699	chr15:81528661	IL16	0.46	9.4	0.4	2.61e-19	Inattentive symptoms;
LGG	trans	rs61931739	0.513	rs1463634	chr12:33899621	A/G	cg13010199	chr12:38710504	ALG10B	0.48	9.09	0.39	2.87e-18	Morning vs. evening chronotype;
LGG	cis	rs2762353	0.524	rs3923	chr6:25783315	T/C	cg03517284	chr6:25882590	NA	0.5	9.03	0.39	4.69e-18	Blood metabolite levels;
LGG	cis	rs12282928	0.617	rs11039638	chr11:48306990	T/G	cg26585981	chr11:48327164	OR4S1	0.41	7.16	0.32	3.19e-12	Migraine - clinic-based;
LGG	cis	rs2180341	0.782	rs6912750	chr6:127723081	A/T	cg27446573	chr6:127587934	RNF146	0.9	17.11	0.62	3.38e-51	Breast cancer;
LGG	cis	rs921968	0.541	rs578450	chr2:219401237	C/T	cg10223061	chr2:219282414	VIL1	-0.3	-6.65	-0.3	8.43e-11	Mean corpuscular hemoglobin concentration;
LGG	cis	rs9640161	0.789	rs10952250	chr7:150025966	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.75	-15.8	-0.59	2.82e-45	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs1218582	0.688	rs58629129	chr1:154910930	T/C	cg09359103	chr1:154839909	KCNN3	-0.52	-9.88	-0.42	5.03e-21	Prostate cancer;
LGG	cis	rs13108904	0.846	rs4045131	chr4:1228797	A/G	cg15586393	chr4:1244086	CTBP1;C4orf42	0.64	11.3	0.46	2.53e-26	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs6899661	chr6:150139229	T/C	cg07701084	chr6:150067640	NUP43	0.65	12.28	0.5	3.33e-30	Lung cancer;
LGG	trans	rs11026407	0.967	rs7127246	chr11:22060228	C/G	cg13226139	chr14:45605129	FKBP3;FANCM	0.76	7.22	0.32	2.18e-12	Plasma thyroid-stimulating hormone levels;
LGG	cis	rs3796352	1.000	rs71301814	chr3:53117663	G/A	cg12962167	chr3:53033115	SFMBT1	0.78	8.02	0.35	8.79e-15	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs11105298	0.891	rs10858909	chr12:89935387	C/T	cg00757033	chr12:89920650	WDR51B	0.63	9.07	0.39	3.31e-18	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;
LGG	cis	rs861020	0.563	rs35898529	chr1:210053096	G/A	cg09163369	chr1:210001066	C1orf107	-0.37	-6.73	-0.3	5.17e-11	Orofacial clefts;
LGG	cis	rs7727544	0.594	rs10479000	chr5:131607402	T/C	cg07395648	chr5:131743802	NA	-0.44	-9.43	-0.4	2.06e-19	Blood metabolite levels;
LGG	cis	rs6840360	0.593	rs6847844	chr4:152693246	C/T	cg22705602	chr4:152727874	NA	-0.4	-10.26	-0.43	2.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs911263	0.961	rs17105278	chr14:68728479	T/C	cg18825221	chr14:68749962	RAD51L1	-0.5	-10.6	-0.44	1.22e-23	Primary biliary cholangitis;
LGG	cis	rs7959452	0.535	rs7135092	chr12:69658330	T/C	cg20891283	chr12:69753455	YEATS4	0.73	13.64	0.54	7.88e-36	Blood protein levels;
LGG	cis	rs796364	0.906	rs281784	chr2:200749749	T/A	cg23649088	chr2:200775458	C2orf69	0.61	8.15	0.35	3.36e-15	Schizophrenia;
LGG	cis	rs6502050	0.835	rs56095560	chr17:80151304	C/T	cg23985595	chr17:80112537	CCDC57	-0.48	-9.71	-0.41	2.02e-20	Life satisfaction;
LGG	cis	rs6784615	0.744	rs34332947	chr3:52353119	G/T	cg16850945	chr3:52488229	TNNC1;NISCH	0.7	7.86	0.34	2.72e-14	Waist-hip ratio;
LGG	cis	rs1577917	1.000	rs12207305	chr6:86723502	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.74	-13.06	-0.52	2.17e-33	Response to antipsychotic treatment;
LGG	cis	rs9311474	0.502	rs4687624	chr3:52563572	C/T	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.47	7.58	0.33	1.92e-13	Electroencephalogram traits;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg12682392	chr2:65215361	SLC1A4	0.4	7.0	0.31	8.95e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs7326068	0.610	rs9578316	chr13:21340088	C/T	cg04906043	chr13:21280425	IL17D	-0.51	-8.15	-0.35	3.5e-15	Schizophrenia, bipolar disorder and depression (combined);
LGG	cis	rs6834538	1.000	rs7665050	chr4:113521476	G/C	cg05166686	chr4:113558556	LARP7;C4orf21	0.54	8.6	0.37	1.28e-16	Free thyroxine concentration;
LGG	cis	rs6502050	0.835	rs8081783	chr17:80117388	G/A	cg13939156	chr17:80058883	NA	-0.45	-8.81	-0.38	2.53e-17	Life satisfaction;
LGG	cis	rs3087591	1.000	rs7214792	chr17:29460673	G/A	cg24425628	chr17:29625626	OMG;NF1	0.7	14.57	0.56	7.31e-40	Hip circumference;
LGG	cis	rs9303401	0.614	rs2007993	chr17:56590643	T/C	cg10487724	chr17:56770010	TEX14;RAD51C	0.91	14.92	0.57	2.31e-41	Cognitive test performance;
LGG	trans	rs57221529	0.766	rs72703065	chr5:588123	C/A	cg11887960	chr12:57824829	NA	0.6	7.33	0.32	1.07e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs1670533	1.000	rs6599278	chr4:1058798	C/T	cg27284194	chr4:1044797	NA	0.58	10.47	0.44	3.72e-23	Recombination rate (females);
LGG	cis	rs4747241	0.739	rs2394861	chr10:74078627	T/C	cg25082487	chr10:74091975	NA	0.38	7.07	0.31	5.75e-12	Heschl's gyrus morphology;
LGG	cis	rs1693575	0.624	rs1693567	chr8:101677386	T/C	cg06874326	chr8:101662790	SNX31	-0.37	-7.3	-0.32	1.29e-12	Cerebrospinal fluid clusterin levels;
LGG	cis	rs877426	0.634	rs867438	chr13:114757361	C/T	cg25338242	chr13:114786047	RASA3	0.47	7.02	0.31	7.79e-12	Facial morphology (factor 14, intercanthal width);
LGG	cis	rs28386778	0.897	rs2854208	chr17:61946885	C/T	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.65	13.14	0.52	9.44e-34	Prudent dietary pattern;
LGG	trans	rs11148252	0.774	rs56033750	chr13:52747278	A/C	cg18335740	chr13:41363409	SLC25A15	0.62	12.29	0.5	3.12e-30	Lewy body disease;
LGG	cis	rs2018055	0.644	rs34431655	chr6:117803676	C/G	cg14611402	chr6:117803162	DCBLD1	0.29	8.54	0.37	1.95e-16	Diastolic blood pressure;
LGG	cis	rs9309711	0.961	rs11692184	chr2:3480710	C/T	cg10845886	chr2:3471009	TTC15	-0.66	-13.38	-0.53	9.62e-35	Neurofibrillary tangles;
LGG	cis	rs4660306	0.677	rs781059	chr1:45934562	A/G	cg15896098	chr1:45966115	MMACHC;CCDC163P	-0.41	-6.74	-0.3	4.61e-11	Homocysteine levels;
LGG	cis	rs1784581	0.706	rs9346895	chr6:162431168	T/C	cg17173639	chr6:162384350	PARK2	0.76	17.96	0.64	3.94e-55	Itch intensity from mosquito bite;
LGG	cis	rs4740619	0.689	rs10756725	chr9:15952222	G/A	cg14451791	chr9:16040625	NA	-0.4	-9.96	-0.42	2.64e-21	Body mass index;
LGG	trans	rs7819412	0.564	rs2244648	chr8:11450422	A/G	cg15556689	chr8:8085844	FLJ10661	0.52	9.54	0.41	8.25e-20	Triglycerides;
LGG	cis	rs6696846	0.749	rs61822566	chr1:205078660	T/C	cg00857998	chr1:205179979	DSTYK	0.47	7.55	0.33	2.36e-13	Red blood cell count;
LGG	cis	rs1395	0.744	rs11126936	chr2:27483101	A/C	cg23587288	chr2:27483067	SLC30A3	0.35	8.05	0.35	6.97e-15	Blood metabolite levels;
LGG	cis	rs367943	0.712	rs26961	chr5:112736779	A/G	cg12552261	chr5:112820674	MCC	0.57	10.3	0.43	1.57e-22	Type 2 diabetes;
LGG	cis	rs28595532	0.920	rs114649974	chr4:119735341	T/C	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs13108904	0.539	rs13145722	chr4:1338422	T/A	cg05025164	chr4:1340916	KIAA1530	0.46	7.58	0.33	1.93e-13	Obesity-related traits;
LGG	trans	rs61931739	0.534	rs35056575	chr12:34142914	A/T	cg13010199	chr12:38710504	ALG10B	0.59	11.09	0.46	1.6e-25	Morning vs. evening chronotype;
LGG	cis	rs1949733	0.701	rs871768	chr4:8454938	G/A	cg13073564	chr4:8508604	NA	-0.53	-10.89	-0.45	9.67e-25	Response to antineoplastic agents;
LGG	trans	rs617791	0.508	rs10791837	chr11:65774596	C/T	cg17712092	chr4:129076599	LARP1B	-0.57	-9.57	-0.41	6.45e-20	Breast cancer;
LGG	cis	rs35110281	0.748	rs9981460	chr21:45030965	T/A	cg04455712	chr21:45112962	RRP1B	0.52	9.71	0.41	2.14e-20	Mean corpuscular volume;
LGG	cis	rs651907	0.557	rs11917569	chr3:101355063	G/C	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.42	0.53	6.5e-35	Colorectal cancer;
LGG	cis	rs1790761	0.667	rs591434	chr11:67337814	C/T	cg23188684	chr11:67383651	NA	0.52	8.83	0.38	2.18e-17	Mean corpuscular volume;
LGG	cis	rs2290402	0.536	rs4690339	chr4:854712	T/C	cg09237302	chr4:906077	GAK	-0.43	-7.42	-0.33	5.77e-13	Type 2 diabetes;
LGG	cis	rs116095464	0.558	rs6555052	chr5:224268	G/A	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	cis	rs12478296	0.685	rs12473450	chr2:242991746	C/T	cg06360820	chr2:242988706	NA	-0.97	-13.33	-0.53	1.57e-34	Obesity-related traits;
LGG	cis	rs1065656	0.589	rs391543	chr16:1915583	T/G	cg26897989	chr16:1907736	C16orf73	0.53	10.06	0.42	1.2e-21	Insulin-like growth factors;
LGG	cis	rs801193	0.636	rs10233806	chr7:66118248	G/C	cg12463550	chr7:65579703	CRCP	-0.49	-8.31	-0.36	1.04e-15	Aortic root size;
LGG	cis	rs73787773	0.668	rs57349429	chr5:111479794	A/T	cg02288001	chr5:111496931	NCRNA00219;SNORA13	-0.57	-7.56	-0.33	2.13e-13	Itch intensity from mosquito bite adjusted by bite size;
LGG	cis	rs11583043	0.708	rs12754497	chr1:101571888	A/G	cg16556008	chr1:101360663	SLC30A7;EXTL2	-0.5	-8.06	-0.35	6.59e-15	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs9322193	0.923	rs4870050	chr6:150160053	G/A	cg15971980	chr6:150254442	NA	0.46	8.39	0.36	6.13e-16	Lung cancer;
LGG	cis	rs10504229	0.906	rs56130194	chr8:58197061	C/A	cg02725872	chr8:58115012	NA	-0.79	-10.47	-0.44	3.67e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs875971	0.830	rs12673450	chr7:66009220	G/A	cg18876405	chr7:65276391	NA	0.55	9.43	0.4	2e-19	Aortic root size;
LGG	cis	rs10504229	0.815	rs55855654	chr8:58164299	T/G	cg14926445	chr8:58193284	C8orf71	-0.89	-11.71	-0.48	6.34e-28	Developmental language disorder (linguistic errors);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg08963122	chr2:62081768	FAM161A	0.4	6.86	0.3	2.2e-11	Gut microbiota (bacterial taxa);
LGG	trans	rs1459104	0.925	rs114730832	chr11:55189642	T/G	cg15704280	chr7:45808275	SEPT13	0.73	6.93	0.31	1.42e-11	Body mass index;
LGG	cis	rs1497828	0.956	rs9441482	chr1:217571282	T/A	cg04411442	chr1:217543379	NA	0.47	7.8	0.34	4.03e-14	Dialysis-related mortality;
LGG	cis	rs9640161	0.617	rs56019796	chr7:150009226	T/C	cg12556325	chr7:150026731	C7orf29;LRRC61	-0.7	-14.66	-0.56	2.97e-40	Blood protein levels;Circulating chemerin levels;
LGG	cis	rs597539	0.616	rs473997	chr11:68639481	C/T	cg04772025	chr11:68637568	NA	0.75	13.09	0.52	1.53e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs6933660	0.800	rs3800273	chr6:151759035	G/C	cg10883421	chr6:151773342	RMND1;C6orf211	0.71	14.97	0.57	1.26e-41	Menarche (age at onset);
LGG	cis	rs6582618	1	rs6582618	chr12:38726137	A/G	cg13010199	chr12:38710504	ALG10B	0.56	10.62	0.44	9.81e-24	Morning vs. evening chronotype;
LGG	cis	rs2439831	0.850	rs61390361	chr15:44159842	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.9	9.51	0.4	1.05e-19	Lung cancer in ever smokers;
LGG	cis	rs17428076	0.872	rs62183808	chr2:172880075	G/A	cg21435375	chr2:172878103	MAP1D	0.46	9.89	0.42	4.89e-21	Myopia;
LGG	cis	rs10479542	0.642	rs6879665	chr5:178974581	T/A	cg09060608	chr5:178986726	RUFY1	0.44	6.91	0.31	1.6e-11	Lung cancer;
LGG	cis	rs5769765	0.773	rs9616208	chr22:50313359	G/A	cg26441486	chr22:50317300	CRELD2	0.43	7.44	0.33	4.88e-13	Schizophrenia;
LGG	cis	rs694739	0.595	rs11606015	chr11:64136877	C/G	cg22916017	chr11:64110731	CCDC88B	0.46	9.37	0.4	3.19e-19	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs2901656	0.652	rs3213563	chr1:172412995	T/C	cg03748243	chr1:172413542	C1orf105;PIGC	0.31	7.07	0.31	5.88e-12	Red cell distribution width;Platelet distribution width;
LGG	cis	rs1129187	0.967	rs6941212	chr6:42915920	A/G	cg24101359	chr6:42928495	GNMT	0.56	16.4	0.61	5.72e-48	Alzheimer's disease in APOE e4+ carriers;
LGG	cis	rs1577917	0.958	rs11755864	chr6:86691791	A/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.71	-12.51	-0.5	3.87e-31	Response to antipsychotic treatment;
LGG	cis	rs7928758	0.943	rs7929612	chr11:134268634	C/T	cg25213107	chr11:134282864	B3GAT1	1.1	13.58	0.53	1.42e-35	Alcohol consumption (maxi-drinks);N-glycan levels;
LGG	cis	rs1577917	0.655	rs9444352	chr6:86257535	G/T	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.43	7.78	0.34	4.7e-14	Response to antipsychotic treatment;
LGG	cis	rs9875589	0.915	rs9835402	chr3:13954396	A/G	cg14375111	chr3:14165186	TMEM43;CHCHD4	-0.38	-7.41	-0.33	6.05e-13	Ovarian reserve;
LGG	cis	rs10991814	0.920	rs77732008	chr9:94014752	G/A	cg14446406	chr9:93919335	NA	-0.75	-8.49	-0.37	2.89e-16	Neutrophil percentage of granulocytes;
LGG	cis	rs7017914	0.869	rs11987511	chr8:71645871	C/T	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.8	-0.3	3.14e-11	Bone mineral density;
LGG	cis	rs597539	0.690	rs615644	chr11:68621806	G/C	cg04008888	chr11:68622739	NA	-0.56	-11.49	-0.47	4.55e-27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg05665937	chr4:1216051	CTBP1	0.57	10.66	0.44	6.82e-24	Obesity-related traits;
LGG	cis	rs734999	0.572	rs4310388	chr1:2507415	G/T	cg18854424	chr1:2615690	NA	0.37	7.37	0.32	7.72e-13	Ulcerative colitis;
LGG	cis	rs67385638	0.802	rs11036635	chr11:5308896	C/T	cg12559170	chr11:5275217	HBG2	0.5	11.48	0.47	5.35e-27	Hemoglobin levels;
LGG	cis	rs2235642	0.533	rs17135391	chr16:1605606	C/T	cg04525384	chr16:1557733	TELO2	0.43	6.86	0.3	2.25e-11	Coronary artery disease;
LGG	cis	rs3816183	1.000	rs6544597	chr2:43013593	T/G	cg27299406	chr2:43020013	HAAO	-0.28	-6.79	-0.3	3.37e-11	Hypospadias;
LGG	cis	rs7659604	0.728	rs6852923	chr4:122688324	G/A	cg05802129	chr4:122689817	NA	-0.41	-7.12	-0.31	4.27e-12	Type 2 diabetes;
LGG	cis	rs2204008	0.689	rs1581357	chr12:38391479	C/G	cg04568710	chr12:38710424	ALG10B	0.34	6.8	0.3	3.14e-11	Bladder cancer;
LGG	cis	rs11583043	0.708	rs12734559	chr1:101563001	G/A	cg15686842	chr1:101360669	SLC30A7;EXTL2	0.44	6.65	0.3	8.3e-11	Ulcerative colitis;Inflammatory bowel disease;
LGG	cis	rs2224391	0.590	rs2753235	chr6:5252182	C/T	cg09085698	chr6:5261316	LYRM4;FARS2	0.54	7.28	0.32	1.44e-12	Height;
LGG	cis	rs7662987	0.517	rs1453874	chr4:100022724	G/A	cg12011299	chr4:100065546	ADH4	0.4	7.89	0.34	2.19e-14	Smoking initiation;
LGG	cis	rs4242434	0.597	rs876714	chr8:22482799	A/G	cg00599393	chr8:22457479	C8orf58	-0.43	-7.94	-0.35	1.59e-14	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs806215	0.950	rs3735642	chr7:127224286	A/G	cg25922125	chr7:127225783	GCC1	-0.79	-10.69	-0.45	5.27e-24	Type 2 diabetes;
LGG	cis	rs6598955	1.000	rs6598955	chr1:26619649	C/T	cg04990556	chr1:26633338	UBXN11	0.75	14.39	0.56	4.64e-39	Obesity-related traits;
LGG	trans	rs6928289	0.810	rs12525010	chr6:137655848	C/T	cg00090767	chr14:65569376	MAX	0.44	7.16	0.32	3.28e-12	Thiazide-induced adverse metabolic effects in hypertensive patients;
LGG	cis	rs2439831	0.702	rs7175032	chr15:44060236	C/T	cg27015174	chr15:43622946	ADAL;LCMT2	0.83	8.99	0.39	6.25e-18	Lung cancer in ever smokers;
LGG	cis	rs9457247	0.871	rs1811121	chr6:167403539	T/C	cg07741184	chr6:167504864	NA	0.32	6.97	0.31	1.08e-11	Crohn's disease;
LGG	cis	rs2227564	0.729	rs2688615	chr10:75651499	C/G	cg00564723	chr10:75632066	CAMK2G	-0.45	-9.03	-0.39	4.64e-18	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs1814175	0.619	rs847644	chr11:49918418	G/A	cg15704280	chr7:45808275	SEPT13	-0.99	-21.63	-0.71	3.07e-72	Height;
LGG	cis	rs41271473	1.000	rs11583565	chr1:228880135	C/T	cg10167378	chr1:228756711	NA	0.56	7.91	0.35	1.88e-14	Chronic lymphocytic leukemia;
LGG	cis	rs2404602	1.000	rs2404741	chr15:76851735	C/T	cg22467129	chr15:76604101	ETFA	-0.46	-7.72	-0.34	7.45e-14	Blood metabolite levels;
LGG	trans	rs61931739	0.500	rs7489130	chr12:34539674	C/A	cg13010199	chr12:38710504	ALG10B	0.68	13.25	0.52	3.46e-34	Morning vs. evening chronotype;
LGG	cis	rs868036	0.718	rs3784710	chr15:68072458	T/C	cg05925327	chr15:68127851	NA	-0.36	-7.27	-0.32	1.57e-12	Restless legs syndrome;
LGG	cis	rs9650657	0.504	rs7813802	chr8:11033976	C/T	cg21775007	chr8:11205619	TDH	0.41	6.83	0.3	2.75e-11	Neuroticism;
LGG	cis	rs10256972	0.567	rs2960835	chr7:1202963	A/G	cg18765753	chr7:1198926	ZFAND2A	-0.46	-7.95	-0.35	1.48e-14	Longevity;Endometriosis;
LGG	trans	rs1814175	0.935	rs6485999	chr11:49658986	G/C	cg11707556	chr5:10655725	ANKRD33B	-0.58	-11.48	-0.47	5.14e-27	Height;
LGG	cis	rs796364	0.806	rs10445791	chr2:201078307	C/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.7	-8.42	-0.36	4.63e-16	Schizophrenia;
LGG	cis	rs3087591	0.708	rs7406783	chr17:29689980	A/G	cg24425628	chr17:29625626	OMG;NF1	0.6	12.55	0.5	2.6e-31	Hip circumference;
LGG	cis	rs34599045	0.522	rs35000490	chr1:153050149	G/A	cg07796016	chr1:152779584	LCE1C	-0.9	-7.27	-0.32	1.5e-12	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs61931739	0.534	rs10844828	chr12:34303109	C/T	cg26384229	chr12:38710491	ALG10B	0.71	14.52	0.56	1.18e-39	Morning vs. evening chronotype;
LGG	cis	rs8180040	0.620	rs6768722	chr3:47079112	G/A	cg16586182	chr3:47516702	SCAP	-0.73	-13.25	-0.52	3.48e-34	Colorectal cancer;
LGG	cis	rs2133450	0.712	rs1396403	chr3:7365357	A/G	cg19930620	chr3:7340148	GRM7	-0.38	-8.22	-0.36	2.11e-15	Early response to risperidone in schizophrenia;
LGG	cis	rs1595825	0.945	rs73056880	chr2:198822292	G/A	cg00982548	chr2:198649783	BOLL	-0.51	-6.83	-0.3	2.67e-11	Ulcerative colitis;
LGG	cis	rs13191362	1.000	rs35818596	chr6:163001874	C/G	cg18825119	chr6:163149453	PACRG;PARK2	0.47	7.82	0.34	3.68e-14	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs6121246	0.529	rs2889528	chr20:30210021	C/T	cg21427119	chr20:30132790	HM13	-0.58	-9.02	-0.39	5.15e-18	Mean corpuscular hemoglobin;
LGG	cis	rs4927850	0.881	rs7624638	chr3:195748729	C/T	cg02975922	chr3:195473998	MUC4	-0.53	-8.79	-0.38	3.05e-17	Pancreatic cancer;
LGG	cis	rs7223966	0.960	rs7212379	chr17:61706122	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	-0.47	-7.28	-0.32	1.45e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs9910055	0.607	rs13726	chr17:42239561	C/T	cg16434002	chr17:42200994	HDAC5	-0.53	-9.76	-0.41	1.32e-20	Total body bone mineral density;
LGG	cis	rs9858542	0.903	rs35999162	chr3:49597230	C/G	cg03060546	chr3:49711283	APEH	-0.64	-10.51	-0.44	2.55e-23	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs4713675	0.565	rs4713659	chr6:33667839	A/G	cg14003231	chr6:33640908	ITPR3	0.29	6.92	0.31	1.52e-11	Plateletcrit;
LGG	cis	rs28386778	0.897	rs2727323	chr17:61921999	G/T	cg11494091	chr17:61959527	GH2	1.0	24.56	0.75	6.8399999999999993e-86	Prudent dietary pattern;
LGG	cis	rs397969	0.607	rs169413	chr17:19849745	G/A	cg13482628	chr17:19912719	NA	0.51	8.3	0.36	1.12e-15	Platelet count;
LGG	cis	rs12479064	0.694	rs11896520	chr2:99995517	C/T	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.75	-10.84	-0.45	1.47e-24	Chronic sinus infection;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg24475210	chr4:6642433	MRFAP1	0.39	6.67	0.3	7.39e-11	Lung adenocarcinoma;
LGG	cis	rs806215	1.000	rs327511	chr7:127257261	G/T	cg25922125	chr7:127225783	GCC1	0.67	9.8	0.41	1.01e-20	Type 2 diabetes;
LGG	cis	rs9611565	0.659	rs9607812	chr22:41941243	G/A	cg03806693	chr22:41940476	POLR3H	-1.17	-22.11	-0.72	1.76e-74	Vitiligo;
LGG	cis	rs11098499	1.000	rs28374891	chr4:120183550	G/A	cg09307838	chr4:120376055	NA	0.71	11.8	0.48	2.85e-28	Corneal astigmatism;
LGG	cis	rs9815354	0.812	rs4299460	chr3:41952445	A/C	cg03022575	chr3:42003672	ULK4	0.81	9.49	0.4	1.26e-19	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4423214	0.879	rs1790353	chr11:71136730	C/T	cg05163923	chr11:71159392	DHCR7	-0.65	-11.3	-0.46	2.6e-26	Vitamin D levels;
LGG	cis	rs11971779	0.553	rs10085770	chr7:139100349	G/A	cg07862535	chr7:139043722	LUC7L2	0.42	7.04	0.31	6.88e-12	Diisocyanate-induced asthma;
LGG	cis	rs7917772	0.582	rs4917978	chr10:104366353	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	-0.6	-11.63	-0.48	1.35e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	trans	rs10435719	0.902	rs7459983	chr8:11807221	T/C	cg16141378	chr3:129829833	LOC729375	-0.37	-8.2	-0.36	2.4e-15	C-reactive protein levels or triglyceride levels (pleiotropy);
LGG	cis	rs9818758	0.607	rs11719220	chr3:49245201	A/G	cg00383909	chr3:49044727	WDR6	1.0	12.53	0.5	3.36e-31	High light scatter reticulocyte percentage of red cells;Reticulocyte fraction of red cells;Reticulocyte count;Glycated hemoglobin levels;
LGG	cis	rs344364	0.602	rs12719796	chr16:1921197	A/G	cg06886374	chr16:1844152	IGFALS	-0.44	-7.96	-0.35	1.31e-14	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs3768617	0.565	rs10752898	chr1:183077896	A/G	cg15522984	chr1:182991683	LAMC1	0.45	9.07	0.39	3.48e-18	Fuchs's corneal dystrophy;
LGG	cis	rs2836974	0.899	rs2836938	chr21:40574191	C/T	cg11890956	chr21:40555474	PSMG1	1.18	29.78	0.81	1.24e-109	Cognitive function;
LGG	cis	rs3096299	0.559	rs9931073	chr16:89568513	G/C	cg02187348	chr16:89574699	SPG7	0.62	10.14	0.43	6.05e-22	Multiple myeloma (IgH translocation);
LGG	cis	rs6674970	0.748	rs56299877	chr1:151115645	C/T	cg11822372	chr1:151115635	SEMA6C	-0.79	-14.46	-0.56	2.23e-39	Childhood ear infection;
LGG	cis	rs8062405	1.000	rs4788101	chr16:28867804	C/T	cg16576597	chr16:28551801	NUPR1	0.3	6.69	0.3	6.6e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	cis	rs1949733	1.000	rs6858542	chr4:8511547	C/G	cg13073564	chr4:8508604	NA	0.55	10.25	0.43	2.45e-22	Response to antineoplastic agents;
LGG	trans	rs7937682	0.587	rs611607	chr11:111349765	C/T	cg18187862	chr3:45730750	SACM1L	0.44	7.45	0.33	4.51e-13	Primary sclerosing cholangitis;
LGG	cis	rs4665809	0.549	rs13001722	chr2:26521530	T/C	cg08470875	chr2:26401718	FAM59B	0.4	7.47	0.33	4.02e-13	Gut microbiome composition (summer);
LGG	cis	rs997295	0.618	rs3784698	chr15:68007582	G/C	cg22044901	chr15:68126292	NA	0.4	7.16	0.32	3.16e-12	Motion sickness;
LGG	cis	rs477692	0.870	rs475250	chr10:131412558	C/G	cg05714579	chr10:131428358	MGMT	0.64	13.54	0.53	1.94e-35	Response to temozolomide;
LGG	cis	rs4740619	0.556	rs1359954	chr9:16039223	A/G	cg14451791	chr9:16040625	NA	-0.43	-11.56	-0.47	2.57e-27	Body mass index;
LGG	cis	rs9311474	0.508	rs7614498	chr3:52618941	A/T	cg18404041	chr3:52824283	ITIH1	-0.52	-10.07	-0.42	1.05e-21	Electroencephalogram traits;
LGG	trans	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg15556689	chr8:8085844	FLJ10661	0.43	7.27	0.32	1.53e-12	Retinal vascular caliber;
LGG	cis	rs6951245	0.938	rs113642700	chr7:1105654	C/T	cg04025307	chr7:1156635	C7orf50	0.67	8.58	0.37	1.47e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11711311	1.000	rs9879760	chr3:113457948	G/A	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.69	14.22	0.55	2.43e-38	IgG glycosylation;
LGG	cis	rs6933660	0.646	rs9397051	chr6:151778325	C/T	cg14262678	chr6:151773367	RMND1;C6orf211	0.64	11.4	0.47	1.01e-26	Menarche (age at onset);
LGG	cis	rs875971	0.505	rs6955582	chr7:65431686	A/G	cg00343986	chr7:65444356	GUSB	0.49	8.66	0.37	7.96e-17	Aortic root size;
LGG	cis	rs12497850	0.931	rs7430501	chr3:48890119	C/T	cg06212747	chr3:49208901	KLHDC8B	0.64	10.91	0.45	8.4e-25	Parkinson's disease;
LGG	cis	rs1018836	0.847	rs2285231	chr8:91545387	G/T	cg16814680	chr8:91681699	NA	-0.79	-14.46	-0.56	2.21e-39	Ejection fraction in Tripanosoma cruzi seropositivity;
LGG	cis	rs13108904	0.901	rs13112706	chr4:1303682	G/T	cg26479374	chr4:1243980	CTBP1;C4orf42	0.57	11.27	0.46	3.37e-26	Obesity-related traits;
LGG	cis	rs10504229	0.683	rs72649187	chr8:58108320	A/G	cg14926445	chr8:58193284	C8orf71	-0.81	-10.51	-0.44	2.61e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs6933660	0.745	rs6912830	chr6:151743629	A/C	cg14416726	chr6:151773293	C6orf211;RMND1	-0.68	-12.68	-0.51	8.02e-32	Menarche (age at onset);
LGG	trans	rs11039798	1.000	rs11039978	chr11:48760237	A/G	cg03929089	chr4:120376271	NA	0.74	8.55	0.37	1.85e-16	Axial length;
LGG	cis	rs9398803	0.865	rs9388495	chr6:126782457	G/A	cg19875578	chr6:126661172	C6orf173	0.56	10.17	0.43	4.53e-22	Male-pattern baldness;
LGG	cis	rs34467563	0.740	rs7818041	chr8:97383138	T/C	cg22138393	chr8:97340270	PTDSS1	0.31	7.67	0.34	1.04e-13	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3768617	0.565	rs4233194	chr1:183060917	G/C	cg15522984	chr1:182991683	LAMC1	0.44	8.74	0.38	4.32e-17	Fuchs's corneal dystrophy;
LGG	cis	rs1048257	0.553	rs2819421	chr14:105408811	A/G	cg14403583	chr14:105418241	AHNAK2	-0.77	-15.44	-0.58	1.05e-43	Systemic lupus erythematosus;
LGG	cis	rs9487094	0.670	rs12197838	chr6:109993291	G/A	cg16315928	chr6:109776240	MICAL1	0.46	8.04	0.35	7.4e-15	Height;
LGG	cis	rs1799949	1.000	rs915945	chr17:41179864	C/T	cg05368731	chr17:41323189	NBR1	0.96	18.02	0.64	2.15e-55	Menopause (age at onset);
LGG	cis	rs7818345	0.569	rs4484715	chr8:19358296	T/G	cg01280390	chr8:19363452	CSGALNACT1	0.45	10.91	0.45	8.08e-25	Language performance in older adults (adjusted for episodic memory);
LGG	cis	rs7911264	0.765	rs2421941	chr10:94345909	G/A	cg25093409	chr10:94429542	NA	0.46	8.83	0.38	2.14e-17	Inflammatory bowel disease;
LGG	cis	rs17539620	0.565	rs9918393	chr6:154843268	G/A	cg17771515	chr6:154831774	CNKSR3	0.64	7.69	0.34	9.21e-14	Lipoprotein (a) levels;
LGG	cis	rs17270561	0.609	rs9393658	chr6:25730438	C/T	cg03517284	chr6:25882590	NA	-0.43	-7.11	-0.31	4.34e-12	Iron status biomarkers;
LGG	cis	rs7660883	0.897	rs236996	chr4:88005203	A/G	cg21988461	chr4:88008667	AFF1	0.34	9.83	0.42	7.62e-21	HDL cholesterol levels;
LGG	cis	rs2243480	1.000	rs1873494	chr7:65649899	T/C	cg13147721	chr7:65941812	NA	0.84	10.11	0.43	7.7e-22	Diabetic kidney disease;
LGG	trans	rs1493916	0.967	rs34341086	chr18:31400141	C/T	cg27147174	chr7:100797783	AP1S1	-0.7	-12.93	-0.52	7.35e-33	Life satisfaction;
LGG	cis	rs2284367	0.545	rs61880787	chr11:34413865	C/T	cg07815068	chr11:34380695	NA	-0.5	-6.86	-0.3	2.23e-11	Blood protein levels;
LGG	cis	rs9322193	0.884	rs10872646	chr6:150067675	A/G	cg02462569	chr6:150064036	NUP43	-0.41	-8.85	-0.38	1.9e-17	Lung cancer;
LGG	cis	rs12540874	0.728	rs3807563	chr7:50566390	C/T	cg00647317	chr7:50633725	DDC	0.43	10.7	0.45	5.0600000000000004e-24	Systemic sclerosis;
LGG	cis	rs8141529	0.748	rs132531	chr22:29297365	C/T	cg15103426	chr22:29168792	CCDC117	-0.6	-9.25	-0.39	8.41e-19	Lymphocyte counts;
LGG	cis	rs7215564	0.908	rs35128297	chr17:78652909	A/C	cg06153925	chr17:78755379	RPTOR	0.4	6.91	0.31	1.61e-11	Myopia (pathological);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg20203792	chr4:20701925	PACRGL	0.42	7.39	0.32	6.74e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs17666538	0.591	rs7818950	chr8:643831	C/T	cg20325293	chr4:54244256	FIP1L1	-0.77	-7.84	-0.34	3.14e-14	IgG glycosylation;
LGG	cis	rs2075371	0.501	rs1421469	chr7:134028260	C/G	cg20476274	chr7:133979776	SLC35B4	0.5	8.95	0.38	8.72e-18	Mean platelet volume;
LGG	cis	rs9911578	0.805	rs12601867	chr17:56455260	C/G	cg05425664	chr17:57184151	TRIM37	0.57	8.83	0.38	2.14e-17	Intelligence (multi-trait analysis);
LGG	cis	rs61931739	0.534	rs10844791	chr12:34211659	C/T	cg06521331	chr12:34319734	NA	-0.63	-11.48	-0.47	5.29e-27	Morning vs. evening chronotype;
LGG	trans	rs9929218	0.953	rs17772411	chr16:68810923	T/C	cg04657470	chr2:198365150	HSPE1;HSPD1	-0.75	-12.8	-0.51	2.5e-32	Colorectal cancer;
LGG	cis	rs11252926	0.770	rs4880736	chr10:680133	C/G	cg08603382	chr10:743973	NA	0.61	11.87	0.48	1.53e-28	Psychosis in Alzheimer's disease;
LGG	cis	rs12477438	0.798	rs4850891	chr2:99574642	A/G	cg08885076	chr2:99613938	TSGA10	-0.59	-12.1	-0.49	1.81e-29	Chronic sinus infection;
LGG	cis	rs10193935	1.000	rs13391906	chr2:42538617	C/G	cg27598129	chr2:42591480	NA	-0.64	-9.68	-0.41	2.65e-20	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6582630	0.519	rs4406888	chr12:38293312	A/C	cg26384229	chr12:38710491	ALG10B	0.91	20.4	0.69	1.85e-66	Drug-induced liver injury (flucloxacillin);
LGG	trans	rs7824557	0.628	rs11991153	chr8:11203107	A/T	cg06636001	chr8:8085503	FLJ10661	0.41	7.09	0.31	5.09e-12	Retinal vascular caliber;
LGG	cis	rs12908161	0.960	rs17599989	chr15:85285536	A/G	cg03959625	chr15:84868606	LOC388152	0.49	7.26	0.32	1.67e-12	Schizophrenia;
LGG	cis	rs4595586	0.545	rs925829	chr12:39364167	A/G	cg13010199	chr12:38710504	ALG10B	0.42	7.63	0.33	1.37e-13	Morning vs. evening chronotype;
LGG	cis	rs11785400	0.793	rs4736364	chr8:143742113	C/T	cg24634471	chr8:143751801	JRK	0.5	7.63	0.33	1.3e-13	Schizophrenia;
LGG	cis	rs13108904	0.846	rs9631805	chr4:1283035	T/C	cg16399632	chr4:1244006	CTBP1;C4orf42	-0.61	-11.53	-0.47	3.16e-27	Obesity-related traits;
LGG	cis	rs2404602	0.647	rs7165053	chr15:76978918	A/G	cg15268244	chr15:77196840	NA	0.49	10.52	0.44	2.36e-23	Blood metabolite levels;
LGG	trans	rs7395662	0.591	rs11039776	chr11:48516706	G/A	cg00717180	chr2:96193071	NA	-0.46	-8.3	-0.36	1.19e-15	HDL cholesterol;
LGG	trans	rs9447700	1.000	rs6453904	chr6:77173869	C/T	cg10880177	chr5:1729256	NA	0.38	7.5	0.33	3.26e-13	Menarche (age at onset);
LGG	trans	rs2624839	0.679	rs2624835	chr3:50209049	G/A	cg21665057	chr3:196295764	WDR53;FBXO45	0.49	7.69	0.34	8.75e-14	Intelligence (multi-trait analysis);
LGG	cis	rs62380364	0.613	rs254781	chr5:88000636	C/T	cg22951263	chr5:87985283	NA	-0.55	-10.12	-0.43	7.12e-22	Intelligence (multi-trait analysis);
LGG	cis	rs75059851	0.756	rs11223650	chr11:133840647	A/G	cg17703048	chr11:133852993	NA	-0.86	-15.79	-0.59	3.08e-45	Schizophrenia;
LGG	cis	rs10504229	0.953	rs57669205	chr8:58172253	T/C	cg23782820	chr8:58130467	NA	0.44	6.72	0.3	5.41e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs4704187	0.687	rs7735937	chr5:74441700	G/A	cg03227963	chr5:74354835	NA	0.31	6.66	0.3	7.77e-11	Response to amphetamines;
LGG	cis	rs4332037	0.615	rs62435127	chr7:1884937	A/G	cg24189917	chr7:1970923	MAD1L1	-0.5	-7.7	-0.34	8.56e-14	Bipolar disorder;
LGG	cis	rs470119	1.000	rs131801	chr22:50966634	G/T	cg12969734	chr22:50962224	SCO2	0.67	12.54	0.5	2.91e-31	Mean corpuscular hemoglobin;
LGG	cis	rs769267	0.930	rs1054284	chr19:19616953	T/G	cg26732615	chr19:19648335	CILP2;YJEFN3	0.52	14.04	0.55	1.42e-37	Tonsillectomy;
LGG	cis	rs1799949	0.965	rs6503727	chr17:41312859	C/T	cg05368731	chr17:41323189	NBR1	0.86	16.66	0.61	3.82e-49	Menopause (age at onset);
LGG	trans	rs61931739	0.635	rs1405025	chr12:33908491	C/T	cg13010199	chr12:38710504	ALG10B	0.45	8.44	0.37	4.02e-16	Morning vs. evening chronotype;
LGG	cis	rs4332037	0.707	rs10268797	chr7:1873756	C/G	cg24189917	chr7:1970923	MAD1L1	0.48	7.32	0.32	1.13e-12	Bipolar disorder;
LGG	cis	rs2243480	0.901	rs778687	chr7:65835819	G/A	cg12463550	chr7:65579703	CRCP	0.77	8.33	0.36	9.17e-16	Diabetic kidney disease;
LGG	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg24642439	chr20:33292090	TP53INP2	0.83	15.18	0.58	1.51e-42	Coronary artery disease;
LGG	cis	rs3768617	0.510	rs10797839	chr1:183077797	A/G	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Fuchs's corneal dystrophy;
LGG	trans	rs1814175	0.791	rs10219223	chr11:49791468	A/T	cg15704280	chr7:45808275	SEPT13	-1.08	-26.91	-0.78	1.05e-96	Height;
LGG	cis	rs11711311	1.000	rs9855613	chr3:113448455	G/A	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.45	-8.1	-0.35	4.89e-15	IgG glycosylation;
LGG	cis	rs1538970	0.962	rs3219472	chr1:45804050	A/G	cg05343316	chr1:45956843	TESK2	-0.68	-10.67	-0.44	6.31e-24	Platelet count;
LGG	trans	rs12599106	0.715	rs34006830	chr16:34878550	C/A	cg26668828	chr6:292823	DUSP22	-0.67	-11.45	-0.47	6.56e-27	Menopause (age at onset);
LGG	cis	rs826838	0.586	rs10785554	chr12:38628749	T/A	cg04568710	chr12:38710424	ALG10B	0.37	8.0	0.35	1.03e-14	Heart rate;
LGG	trans	rs116095464	1.000	rs62346511	chr5:208265	C/T	cg00938859	chr5:1591904	SDHAP3	0.82	7.22	0.32	2.2e-12	Breast cancer;
LGG	trans	rs561341	1.000	rs55643307	chr17:30263074	T/C	cg27661571	chr11:113659931	NA	-0.72	-9.62	-0.41	4.22e-20	Hip circumference adjusted for BMI;
LGG	cis	rs7568458	0.837	rs3770098	chr2:85805367	C/A	cg17127132	chr2:85788382	GGCX	0.46	8.13	0.35	3.82e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs4423214	0.840	rs3794057	chr11:71186744	G/A	cg05163923	chr11:71159392	DHCR7	-0.65	-11.17	-0.46	7.9e-26	Vitamin D levels;
LGG	cis	rs9768139	0.524	rs6459860	chr7:158136362	C/A	cg06219351	chr7:158114137	PTPRN2	0.72	12.9	0.51	9.32e-33	Calcium levels;
LGG	cis	rs1580019	0.844	rs1037322	chr7:32501857	C/T	cg06627557	chr7:32535165	LSM5;AVL9	0.85	15.77	0.59	3.88e-45	Cognitive ability;
LGG	trans	rs9929218	0.559	rs55907909	chr16:68805805	C/T	cg04657470	chr2:198365150	HSPE1;HSPD1	0.88	18.43	0.65	2.72e-57	Colorectal cancer;
LGG	cis	rs2228479	0.850	rs17233664	chr16:89810628	C/T	cg04287289	chr16:89883240	FANCA	0.89	8.6	0.37	1.23e-16	Skin colour saturation;
LGG	trans	rs17685	0.753	rs1637039	chr7:75693009	C/T	cg19862616	chr7:65841803	NCRNA00174	1.07	25.91	0.77	4.12e-92	Coffee consumption;Coffee consumption (cups per day);
LGG	cis	rs9926296	0.682	rs467357	chr16:89717397	A/G	cg04287289	chr16:89883240	FANCA	-0.45	-8.02	-0.35	8.71e-15	Vitiligo;
LGG	trans	rs9914544	0.545	rs9915343	chr17:18766494	A/G	cg21372672	chr17:16614065	CCDC144A	-0.35	-7.53	-0.33	2.7e-13	Educational attainment (years of education);
LGG	trans	rs79911532	0.515	rs112615204	chr7:75760909	C/T	cg19862616	chr7:65841803	NCRNA00174	0.74	7.68	0.34	9.68e-14	Mononucleosis;
LGG	cis	rs2762353	0.845	rs35720558	chr6:25784800	A/C	cg03517284	chr6:25882590	NA	0.51	9.4	0.4	2.54e-19	Blood metabolite levels;
LGG	cis	rs597539	0.552	rs6591360	chr11:68718669	G/T	cg04008888	chr11:68622739	NA	-0.51	-11.07	-0.46	2.04e-25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs11096990	0.855	rs2566178	chr4:39156814	G/C	cg24403649	chr4:39172243	NA	-0.48	-7.69	-0.34	9.05e-14	Cognitive function;
LGG	cis	rs7264396	0.635	rs6058344	chr20:34475038	A/G	cg04508476	chr20:34239394	CPNE1;RBM12	-0.41	-7.35	-0.32	9.22e-13	Total cholesterol levels;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg04073608	chr11:65268100	MALAT1	0.43	7.01	0.31	8.52e-12	Cognitive performance;
LGG	cis	rs7249142	0.549	rs62135499	chr19:19294237	T/C	cg01726393	chr19:19281461	LOC729991-MEF2B;MEF2B	-0.3	-8.09	-0.35	5.45e-15	IgG glycosylation;
LGG	cis	rs2239547	0.618	rs13083728	chr3:52868445	G/A	cg11645453	chr3:52864694	ITIH4	0.72	11.25	0.46	4.12e-26	Schizophrenia;
LGG	cis	rs6502050	0.835	rs8067138	chr17:80111026	T/C	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	trans	rs561341	0.883	rs6505274	chr17:30344581	G/T	cg27661571	chr11:113659931	NA	-0.64	-9.07	-0.39	3.32e-18	Hip circumference adjusted for BMI;
LGG	cis	rs9322193	0.962	rs9397357	chr6:150133601	G/A	cg16507663	chr6:150244633	RAET1G	0.42	7.94	0.35	1.6e-14	Lung cancer;
LGG	cis	rs4950322	0.542	rs3766520	chr1:146686228	C/T	cg22381352	chr1:146742008	CHD1L	-0.49	-8.12	-0.35	4.4e-15	Protein quantitative trait loci;
LGG	cis	rs9878978	0.690	rs2874300	chr3:2447751	A/G	cg21928760	chr3:2462534	CNTN4	0.39	7.69	0.34	8.97e-14	Blood pressure (smoking interaction);
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg14926445	chr8:58193284	C8orf71	-0.81	-10.49	-0.44	3.07e-23	Developmental language disorder (linguistic errors);
LGG	cis	rs7394190	0.748	rs11000772	chr10:75533988	T/G	cg07699608	chr10:75541558	CHCHD1	0.55	7.33	0.32	1.03e-12	Incident atrial fibrillation;
LGG	cis	rs12477438	0.520	rs10865029	chr2:99718298	C/T	cg26064155	chr2:99771622	LIPT1;TSGA10	0.99	24.38	0.75	4.68e-85	Chronic sinus infection;
LGG	cis	rs9633740	1.000	rs1870138	chr10:82269611	A/G	cg01528321	chr10:82214614	TSPAN14	1.07	16.6	0.61	6.51e-49	Post bronchodilator FEV1;
LGG	cis	rs892961	0.932	rs7224442	chr17:75413439	A/G	cg05865280	chr17:75406074	SEPT9	0.43	10.35	0.43	9.97e-23	Airflow obstruction;
LGG	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg13736514	chr6:26305472	NA	-0.48	-9.86	-0.42	5.86e-21	Educational attainment;
LGG	cis	rs757081	0.667	rs60173525	chr11:17259967	A/G	cg15432903	chr11:17409602	KCNJ11	-0.55	-9.11	-0.39	2.43e-18	Systolic blood pressure;
LGG	cis	rs11190604	1.000	rs10883500	chr10:102238324	T/G	cg07570687	chr10:102243282	WNT8B	0.45	7.88	0.34	2.33e-14	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs8133932	0.701	rs9637207	chr21:47283359	A/G	cg13695288	chr21:47294981	PCBP3	-0.36	-7.3	-0.32	1.26e-12	Schizophrenia;
LGG	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.14	0.39	1.95e-18	Colorectal cancer;
LGG	cis	rs9329221	0.905	rs17709397	chr8:10249861	G/A	cg21775007	chr8:11205619	TDH	-0.51	-8.22	-0.36	2.06e-15	Neuroticism;
LGG	cis	rs2730245	0.550	rs2788478	chr7:158672619	A/G	cg18245976	chr7:158708271	WDR60	-0.59	-10.8	-0.45	2.14e-24	Height;
LGG	cis	rs7923609	0.540	rs2393985	chr10:65315005	G/T	cg02276361	chr10:65351566	REEP3	-0.31	-6.82	-0.3	2.77e-11	Educational attainment;Liver enzyme levels (alkaline phosphatase);
LGG	cis	rs6088580	0.601	rs6059872	chr20:33082775	C/A	cg06115741	chr20:33292138	TP53INP2	0.51	8.36	0.36	7.62e-16	Glomerular filtration rate (creatinine);
LGG	cis	rs4788570	0.538	rs16973286	chr16:71552257	C/A	cg06353428	chr16:71660113	MARVELD3	-1.03	-13.85	-0.54	9.66e-37	Intelligence (multi-trait analysis);
LGG	cis	rs12824058	0.831	rs11616174	chr12:130814503	A/G	cg23887609	chr12:130822674	PIWIL1	0.55	9.76	0.41	1.33e-20	Menopause (age at onset);
LGG	trans	rs8002861	0.967	rs7321596	chr13:44472255	G/A	cg12856521	chr11:46389249	DGKZ	0.44	7.64	0.33	1.24e-13	Leprosy;
LGG	cis	rs888194	0.690	rs7134594	chr12:110000193	C/T	cg19025524	chr12:109796872	NA	-0.35	-7.09	-0.31	4.89e-12	Neuroticism;
LGG	cis	rs4862750	0.832	rs6836426	chr4:187897837	T/G	cg06074448	chr4:187884817	NA	-0.59	-12.98	-0.52	4.29e-33	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs3816183	1.000	rs3816183	chr2:43015719	C/T	cg14631114	chr2:43023945	NA	-0.51	-9.59	-0.41	5.27e-20	Hypospadias;
LGG	cis	rs2839186	0.721	rs3788252	chr21:47661235	C/T	cg12379764	chr21:47803548	PCNT	-0.4	-6.88	-0.3	1.9e-11	Testicular germ cell tumor;
LGG	cis	rs7312933	0.703	rs12371615	chr12:42563989	C/G	cg11827402	chr12:42719852	PPHLN1;ZCRB1	0.45	6.83	0.3	2.73e-11	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs1008375	0.931	rs7672369	chr4:17604825	A/G	cg10189774	chr4:17578691	LAP3	0.42	7.37	0.32	7.86e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs7208859	0.623	rs35916850	chr17:29011173	G/A	cg13385521	chr17:29058706	SUZ12P	0.91	10.55	0.44	1.89e-23	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9326248	1.000	rs4938344	chr11:117003749	G/A	cg11861562	chr11:117069780	TAGLN	0.26	6.95	0.31	1.28e-11	Blood protein levels;
LGG	cis	rs9322193	0.884	rs9322210	chr6:150016576	G/A	cg02462569	chr6:150064036	NUP43	-0.4	-8.69	-0.37	6.35e-17	Lung cancer;
LGG	trans	rs116095464	0.558	rs28635197	chr5:279071	T/C	cg09048205	chr5:1608656	LOC728613	-0.49	-8.32	-0.36	1e-15	Breast cancer;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg16507663	chr6:150244633	RAET1G	0.48	8.59	0.37	1.34e-16	Lung cancer;
LGG	cis	rs4720575	0.868	rs7779776	chr7:47092914	C/G	cg00036614	chr7:47093842	NA	-0.5	-9.91	-0.42	4.15e-21	Angiotensin-converting enzyme inhibitor intolerance;
LGG	cis	rs634534	0.622	rs501353	chr11:65739549	T/G	cg26695010	chr11:65641043	EFEMP2	-0.58	-10.21	-0.43	3.21e-22	Sum eosinophil basophil counts;Eosinophil counts;
LGG	cis	rs11792861	0.926	rs7855282	chr9:111802614	T/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.59	9.38	0.4	3.02e-19	Menarche (age at onset);
LGG	cis	rs17331151	0.505	rs34182518	chr3:52743854	G/A	cg16850945	chr3:52488229	TNNC1;NISCH	0.52	6.83	0.3	2.64e-11	Immune reponse to smallpox (secreted IL-2);
LGG	cis	rs1062746	0.544	rs3762182	chr16:87326113	A/G	cg02258303	chr16:87377426	FBXO31	0.44	8.2	0.36	2.33e-15	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs7572733	0.935	rs1595824	chr2:198874006	C/T	cg00792783	chr2:198669748	PLCL1	0.45	7.52	0.33	2.87e-13	Dermatomyositis;
LGG	trans	rs561341	0.941	rs4525554	chr17:30312819	T/C	cg27661571	chr11:113659931	NA	-0.69	-9.56	-0.41	7e-20	Hip circumference adjusted for BMI;
LGG	cis	rs597539	0.652	rs553875	chr11:68695144	T/G	cg01988459	chr11:68622903	NA	-0.63	-12.81	-0.51	2.34e-32	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs951366	0.789	rs823121	chr1:205724302	A/G	cg13453750	chr1:205783389	SLC41A1	0.39	7.59	0.33	1.77e-13	Menarche (age at onset);
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg19228665	chr17:1787078	RPA1	-0.35	-6.94	-0.31	1.3e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs7572733	0.534	rs2574832	chr2:198704818	T/G	cg00792783	chr2:198669748	PLCL1	0.69	11.17	0.46	8.05e-26	Dermatomyositis;
LGG	cis	rs3816183	0.716	rs10169957	chr2:43081439	A/G	cg14631114	chr2:43023945	NA	0.44	7.96	0.35	1.35e-14	Hypospadias;
LGG	cis	rs10504229	0.593	rs16921589	chr8:58024387	C/A	cg11062466	chr8:58055876	NA	0.44	6.86	0.3	2.27e-11	Developmental language disorder (linguistic errors);
LGG	cis	rs7552404	1.000	rs1498316	chr1:76159198	G/A	cg22875332	chr1:76189707	ACADM	0.6	9.5	0.4	1.12e-19	Blood metabolite levels;Acylcarnitine levels;
LGG	cis	rs9479482	1.000	rs11754987	chr6:150351204	G/A	cg16395133	chr6:150326394	RAET1K	0.27	6.67	0.3	7.48e-11	Alopecia areata;
LGG	cis	rs2839186	0.843	rs17182671	chr21:47696238	T/C	cg11766577	chr21:47581405	C21orf56	-0.48	-8.57	-0.37	1.58e-16	Testicular germ cell tumor;
LGG	cis	rs11239187	0.586	rs9783143	chr10:45119052	A/C	cg03916630	chr10:45065415	NA	0.29	6.67	0.3	7.4e-11	Body mass index;
LGG	cis	rs6121246	0.865	rs77130187	chr20:30269060	G/A	cg21427119	chr20:30132790	HM13	-0.42	-6.75	-0.3	4.32e-11	Mean corpuscular hemoglobin;
LGG	cis	rs9325144	0.600	rs11183505	chr12:38759110	G/T	cg13010199	chr12:38710504	ALG10B	-0.57	-10.73	-0.45	3.81e-24	Morning vs. evening chronotype;
LGG	cis	rs853679	0.517	rs4713146	chr6:28111536	A/T	cg18032046	chr6:28092343	ZSCAN16	-0.58	-7.71	-0.34	7.87e-14	Depression;
LGG	trans	rs116095464	0.681	rs10060016	chr5:241100	T/C	cg00938859	chr5:1591904	SDHAP3	0.91	13.56	0.53	1.66e-35	Breast cancer;
LGG	cis	rs2228479	0.850	rs12599473	chr16:89827435	A/C	cg27400746	chr16:89904261	SPIRE2	-1.16	-17.39	-0.63	1.76e-52	Skin colour saturation;
LGG	cis	rs13108904	0.870	rs2279281	chr4:1245277	T/G	cg13395646	chr4:1353034	KIAA1530	-0.46	-7.96	-0.35	1.38e-14	Obesity-related traits;
LGG	cis	rs300774	0.925	rs1531374	chr2:127773	A/C	cg04617936	chr2:214353	NA	-0.49	-7.46	-0.33	4.2e-13	Suicide attempts in bipolar disorder;
LGG	trans	rs7618501	0.633	rs2883057	chr3:49998282	C/T	cg21659725	chr3:3221576	CRBN	0.66	12.28	0.5	3.49e-30	Intelligence (multi-trait analysis);
LGG	cis	rs2120019	0.567	rs8029351	chr15:75177237	A/C	cg17294928	chr15:75287854	SCAMP5	-0.78	-11.06	-0.46	2.12e-25	Blood trace element (Zn levels);
LGG	cis	rs4688759	0.609	rs113176147	chr3:49534439	G/T	cg00383909	chr3:49044727	WDR6	1.07	11.56	0.47	2.56e-27	Blood protein levels;
LGG	cis	rs1003719	0.680	rs2835664	chr21:38573429	G/A	cg10648535	chr21:38446584	PIGP;TTC3	-0.77	-14.86	-0.57	4.11e-41	Eye color traits;
LGG	cis	rs17376456	0.877	rs12109629	chr5:93359702	A/G	cg25358565	chr5:93447407	FAM172A	1.32	16.39	0.61	6.21e-48	Diabetic retinopathy;
LGG	cis	rs295140	0.526	rs295113	chr2:201197816	C/G	cg17644776	chr2:200775616	C2orf69	0.44	7.49	0.33	3.54e-13	QT interval;
LGG	cis	rs3733585	0.699	rs6856127	chr4:9965443	T/C	cg25986240	chr4:9926439	SLC2A9	0.38	7.75	0.34	6.06e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs9326248	0.813	rs588534	chr11:117068504	A/G	cg01368799	chr11:117014884	PAFAH1B2	0.59	7.65	0.34	1.14e-13	Blood protein levels;
LGG	cis	rs1577917	0.839	rs1838956	chr6:86565263	A/C	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.59	-10.5	-0.44	2.77e-23	Response to antipsychotic treatment;
LGG	cis	rs68170813	0.559	rs10953534	chr7:106913718	A/G	cg02696742	chr7:106810147	HBP1	0.72	10.27	0.43	1.95e-22	Coronary artery disease;
LGG	trans	rs6074022	0.956	rs1569723	chr20:44742064	A/C	cg16660274	chr2:127976928	NA	-0.43	-7.25	-0.32	1.8e-12	Crohn's disease;Inflammatory bowel disease;Multiple sclerosis;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg11506157	chr5:53155508	NA	0.45	7.39	0.32	6.82e-13	Gut microbiome composition (summer);
LGG	cis	rs614226	1.000	rs1614223	chr12:120964043	T/C	cg27489772	chr12:121021490	NA	0.59	7.83	0.34	3.37e-14	Type 1 diabetes nephropathy;
LGG	trans	rs1814175	0.817	rs4881658	chr11:49941123	G/A	cg15704280	chr7:45808275	SEPT13	-1.08	-26.86	-0.78	1.72e-96	Height;
LGG	cis	rs6732160	0.809	rs6728959	chr2:73383327	C/T	cg01422370	chr2:73384389	NA	0.54	10.51	0.44	2.63e-23	Intelligence (multi-trait analysis);
LGG	cis	rs12762955	0.529	rs2387213	chr10:1051420	C/T	cg25019033	chr10:957182	NA	-0.33	-6.9	-0.31	1.74e-11	Response to angiotensin II receptor blocker therapy;
LGG	cis	rs28386778	0.897	rs6504184	chr17:61842408	A/T	cg23090583	chr17:61904693	PSMC5;FTSJ3	1.12	33.07	0.84	5.25e-124	Prudent dietary pattern;
LGG	cis	rs10504229	0.683	rs7827881	chr8:58132137	C/T	cg05313129	chr8:58192883	C8orf71	-0.73	-10.17	-0.43	4.55e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs2370759	0.945	rs10508773	chr10:32575444	C/T	cg01819863	chr10:32635814	EPC1	1.12	15.69	0.59	8.92e-45	Sexual dysfunction (female);
LGG	cis	rs7582180	0.585	rs13031711	chr2:100939433	T/C	cg21926883	chr2:100939477	LONRF2	-0.7	-16.59	-0.61	7.47e-49	Intelligence (multi-trait analysis);
LGG	trans	rs853679	0.546	rs483143	chr6:27846744	G/C	cg01620082	chr3:125678407	NA	-0.78	-8.96	-0.38	8.18e-18	Depression;
LGG	cis	rs372883	0.901	rs8133749	chr21:30615935	C/T	cg24692254	chr21:30365293	RNF160	-0.43	-7.69	-0.34	8.97e-14	Pancreatic cancer;
LGG	cis	rs155076	1.000	rs261406	chr13:21855854	G/A	cg06138931	chr13:21896616	NA	-0.45	-7.38	-0.32	7.34e-13	White matter hyperintensity burden;
LGG	cis	rs801193	0.569	rs881285	chr7:66119420	A/G	cg11764359	chr7:65958608	NA	-0.71	-12.89	-0.51	1.03e-32	Aortic root size;
LGG	trans	rs75804782	0.625	rs72984594	chr2:239470169	G/A	cg01134436	chr17:81009848	B3GNTL1	0.73	7.79	0.34	4.44e-14	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg08677398	chr8:58056175	NA	0.45	7.43	0.33	5.2e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs11096990	0.821	rs76235093	chr4:39282777	G/A	cg24403649	chr4:39172243	NA	-0.45	-7.3	-0.32	1.24e-12	Cognitive function;
LGG	cis	rs2204008	0.694	rs10880262	chr12:38328696	C/T	cg13010199	chr12:38710504	ALG10B	0.59	11.23	0.46	4.7e-26	Bladder cancer;
LGG	cis	rs2841277	0.616	rs1048257	chr14:105404384	T/C	cg22072935	chr14:105399595	NA	0.52	10.12	0.43	7.21e-22	Rheumatoid arthritis;
LGG	cis	rs7927771	0.864	rs755554	chr11:47432034	G/C	cg20307385	chr11:47447363	PSMC3	0.57	10.44	0.44	4.56e-23	Subjective well-being;
LGG	cis	rs11252926	0.598	rs4881256	chr10:453831	T/A	cg16386425	chr10:429943	DIP2C	-0.47	-9.61	-0.41	4.74e-20	Psychosis in Alzheimer's disease;
LGG	cis	rs4242434	0.892	rs34269854	chr8:22465160	G/C	cg00599393	chr8:22457479	C8orf58	-0.48	-8.98	-0.39	6.87e-18	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs57590327	0.555	rs2053805	chr3:81738414	T/C	cg07356753	chr3:81810745	GBE1	-0.51	-8.25	-0.36	1.69e-15	Extraversion;
LGG	cis	rs7712401	0.541	rs6867714	chr5:122382059	T/G	cg19412675	chr5:122181750	SNX24	0.5	8.06	0.35	6.79e-15	Mean platelet volume;
LGG	cis	rs2404602	0.735	rs2454454	chr15:76823647	A/G	cg23625390	chr15:77176239	SCAPER	-0.61	-12.05	-0.49	2.91e-29	Blood metabolite levels;
LGG	trans	rs3812049	0.784	rs2617617	chr5:127455008	C/T	cg16011800	chr17:1958478	HIC1	-0.67	-10.03	-0.42	1.5e-21	Lymphocyte counts;Red cell distribution width;
LGG	cis	rs447735	0.587	rs7188458	chr16:89726484	A/G	cg03605463	chr16:89740564	NA	0.48	8.15	0.35	3.4e-15	Hemoglobin concentration;
LGG	cis	rs1005277	0.579	rs2474594	chr10:38426661	G/C	cg00409905	chr10:38381863	ZNF37A	-0.64	-12.12	-0.49	1.53e-29	Extrinsic epigenetic age acceleration;
LGG	cis	rs1816752	0.783	rs7139527	chr13:24985512	G/A	cg02811702	chr13:24901961	NA	0.4	7.3	0.32	1.24e-12	Obesity-related traits;
LGG	trans	rs2204008	0.728	rs11495375	chr12:38282631	G/A	cg06521331	chr12:34319734	NA	-0.52	-8.95	-0.38	8.41e-18	Bladder cancer;
LGG	cis	rs9547692	0.938	rs12427600	chr13:37460648	C/T	cg02985381	chr13:37494744	SMAD9	-0.69	-12.34	-0.5	1.91e-30	Coronary artery disease;
LGG	cis	rs4478858	0.684	rs4949373	chr1:31741577	G/A	cg19084893	chr1:31688959	NA	0.32	6.88	0.3	2e-11	Alcohol dependence;
LGG	cis	rs4740619	0.875	rs10962142	chr9:15756094	A/G	cg14451791	chr9:16040625	NA	-0.4	-10.65	-0.44	7.58e-24	Body mass index;
LGG	cis	rs9322193	0.962	rs9322220	chr6:150104033	G/C	cg16507663	chr6:150244633	RAET1G	0.44	8.23	0.36	1.99e-15	Lung cancer;
LGG	cis	rs7084402	0.967	rs1820542	chr10:60315643	T/C	cg07615347	chr10:60278583	BICC1	0.63	17.84	0.64	1.52e-54	Refractive error;
LGG	cis	rs4604732	0.589	rs78689516	chr1:247626274	C/T	cg02104434	chr1:247694406	LOC148824;OR2C3	0.59	8.89	0.38	1.33e-17	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);
LGG	cis	rs28595532	0.920	rs56227053	chr4:119772460	C/T	cg14228332	chr4:119757509	SEC24D	0.96	10.21	0.43	3.33e-22	Cannabis dependence symptom count;
LGG	cis	rs1005277	0.579	rs11011461	chr10:38431427	G/A	cg18963800	chr10:38644991	HSD17B7P2	-0.48	-7.68	-0.34	9.3e-14	Extrinsic epigenetic age acceleration;
LGG	cis	rs453301	0.653	rs1562211	chr8:8902424	A/G	cg08975724	chr8:8085496	FLJ10661	-0.45	-8.54	-0.37	1.99e-16	Joint mobility (Beighton score);
LGG	cis	rs789859	0.869	rs1773225	chr3:194403578	A/G	cg02072170	chr3:194406190	FAM43A	0.39	7.42	0.33	5.65e-13	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;
LGG	cis	rs559928	0.606	rs12419038	chr11:63912736	A/G	cg22408430	chr11:63883266	MACROD1;FLRT1	-0.39	-6.74	-0.3	4.74e-11	Inflammatory bowel disease;Crohn's disease;Ulcerative colitis;
LGG	cis	rs10504229	0.953	rs75253516	chr8:58171547	C/A	cg24829409	chr8:58192753	C8orf71	-0.85	-13.41	-0.53	7.19e-35	Developmental language disorder (linguistic errors);
LGG	cis	rs4660214	0.568	rs6692769	chr1:39683175	G/C	cg18385671	chr1:39797026	MACF1	-0.44	-9.4	-0.4	2.52e-19	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	trans	rs11148252	0.744	rs4884354	chr13:53017474	T/C	cg18335740	chr13:41363409	SLC25A15	0.6	11.83	0.48	2.1e-28	Lewy body disease;
LGG	cis	rs3820928	0.874	rs3752895	chr2:227886773	A/G	cg11843606	chr2:227700838	RHBDD1	-0.46	-7.88	-0.34	2.31e-14	Pulmonary function;
LGG	cis	rs6951245	0.872	rs113119264	chr7:1080564	G/A	cg03188948	chr7:1209495	NA	0.64	8.41	0.36	4.98e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs2153535	0.580	rs6913100	chr6:8456855	A/G	cg23788917	chr6:8435910	SLC35B3	0.53	9.07	0.39	3.41e-18	Motion sickness;
LGG	trans	rs10506458	0.834	rs55966529	chr12:63384114	A/C	cg03429785	chr15:59498649	MYO1E;LDHAL6B	-1.37	-21.21	-0.7	2.86e-70	Hemostatic factors and hematological phenotypes;
LGG	cis	rs13108904	0.901	rs7673398	chr4:1300077	G/A	cg05025164	chr4:1340916	KIAA1530	0.55	9.75	0.41	1.46e-20	Obesity-related traits;
LGG	cis	rs1568889	1.000	rs12287732	chr11:28120845	A/G	cg06544937	chr11:28130018	METT5D1;KIF18A	0.79	15.22	0.58	1.08e-42	Bipolar disorder;
LGG	cis	rs9322193	0.923	rs12660304	chr6:150060783	A/G	cg00424166	chr6:150045504	NUP43	-0.34	-7.03	-0.31	7.21e-12	Lung cancer;
LGG	cis	rs757278	0.591	rs34637736	chr7:117294301	C/T	cg10524701	chr7:117356490	CTTNBP2	0.45	8.04	0.35	7.39e-15	Response to methotrexate in juvenile idiopathic arthritis;
LGG	trans	rs1493916	0.837	rs9945976	chr18:31409314	C/T	cg27147174	chr7:100797783	AP1S1	-0.63	-11.79	-0.48	3.04e-28	Life satisfaction;
LGG	cis	rs9910055	0.530	rs11656758	chr17:42301541	A/G	cg19774624	chr17:42201019	HDAC5	-0.58	-10.19	-0.43	3.94e-22	Total body bone mineral density;
LGG	cis	rs12681288	0.862	rs34510005	chr8:1018943	T/C	cg08648136	chr8:956695	NA	0.35	7.12	0.31	4.17e-12	Schizophrenia;
LGG	cis	rs7811142	1.000	rs11771241	chr7:99994785	G/A	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.11	17.19	0.62	1.35e-51	Platelet count;
LGG	trans	rs7647973	0.554	rs13096480	chr3:49658084	A/G	cg21659725	chr3:3221576	CRBN	-0.55	-7.47	-0.33	3.93e-13	Menarche (age at onset);
LGG	cis	rs7786808	0.741	rs35059736	chr7:158224692	C/T	cg15440763	chr7:158190612	PTPRN2	0.45	9.26	0.4	7.75e-19	Obesity-related traits;
LGG	trans	rs6575793	0.512	rs7147982	chr14:101046649	C/T	cg09399377	chr6:136611038	BCLAF1	0.5	7.28	0.32	1.42e-12	Menarche (age at onset);
LGG	cis	rs3768617	0.510	rs4651142	chr1:183097386	A/T	ch.1.3577855R	chr1:183094577	LAMC1	0.45	8.94	0.38	9.53e-18	Fuchs's corneal dystrophy;
LGG	cis	rs6831352	0.703	rs4235435	chr4:100039578	C/T	cg13256891	chr4:100009986	ADH5	0.54	9.55	0.41	7.74e-20	Alcohol dependence;
LGG	cis	rs6459804	1.000	rs6459806	chr7:157510483	C/G	cg15733309	chr7:157513707	PTPRN2	0.61	14.76	0.57	1.09e-40	Bipolar disorder and schizophrenia;
LGG	cis	rs854765	1.000	rs854765	chr17:18012730	T/C	cg05444541	chr17:17804740	TOM1L2	0.61	14.49	0.56	1.73e-39	Total body bone mineral density;
LGG	cis	rs35771425	0.750	rs17189000	chr1:211549432	G/A	cg10512769	chr1:211675356	NA	-0.68	-9.32	-0.4	4.76e-19	Educational attainment (years of education);
LGG	cis	rs1580019	0.522	rs10951340	chr7:32562408	G/A	cg14728415	chr7:32535168	LSM5;AVL9	0.43	6.97	0.31	1.11e-11	Cognitive ability;
LGG	cis	rs988958	0.675	rs35637955	chr2:42217686	A/C	cg27428208	chr2:42229179	NA	0.51	9.08	0.39	3.2e-18	Hypospadias;
LGG	trans	rs9467711	0.606	rs9358930	chr6:26357011	C/T	cg06606381	chr12:133084897	FBRSL1	-0.83	-8.56	-0.37	1.63e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs10911251	0.546	rs1547715	chr1:183113952	A/G	cg07928641	chr1:182991847	LAMC1	0.46	9.4	0.4	2.48e-19	Colorectal cancer;
LGG	cis	rs12421382	0.659	rs1866530	chr11:109380899	T/A	cg00830817	chr11:109293614	C11orf87	0.42	6.83	0.3	2.63e-11	Schizophrenia;
LGG	cis	rs1008375	1.000	rs1860597	chr4:17657650	C/T	cg04450456	chr4:17643702	FAM184B	0.34	7.61	0.33	1.58e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs11748327	0.580	rs2398653	chr5:4021075	T/C	cg01025095	chr5:4101132	NA	-0.44	-7.18	-0.32	2.81e-12	Myocardial infarction;
LGG	cis	rs1008375	0.931	rs1860592	chr4:17577028	C/G	cg10189774	chr4:17578691	LAP3	0.41	7.52	0.33	2.93e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs2180341	0.751	rs9388553	chr6:127574044	A/G	cg24812749	chr6:127587940	RNF146	0.83	13.86	0.54	8.37e-37	Breast cancer;
LGG	cis	rs240764	0.618	rs846778	chr6:101273147	T/C	cg09795085	chr6:101329169	ASCC3	0.45	7.46	0.33	4.44e-13	Neuroticism;
LGG	trans	rs7746199	0.736	rs35848276	chr6:27521096	C/T	cg06606381	chr12:133084897	FBRSL1	-1.25	-11.5	-0.47	4.17e-27	Gait speed in old age;Autism spectrum disorder or schizophrenia;
LGG	cis	rs7647973	0.626	rs4855845	chr3:49687043	T/C	cg03060546	chr3:49711283	APEH	0.63	8.78	0.38	3.26e-17	Menarche (age at onset);
LGG	cis	rs834603	0.575	rs834609	chr7:47456846	T/C	cg09696706	chr7:47479511	TNS3	0.36	8.02	0.35	8.47e-15	Sum neutrophil eosinophil counts;Sum basophil neutrophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	trans	rs853679	0.766	rs9368561	chr6:28168343	C/T	cg08344181	chr3:125677491	NA	-0.64	-7.58	-0.33	1.94e-13	Depression;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg07786668	chr16:73092391	ZFHX3	0.5	8.44	0.37	4.11e-16	Gut microbiota (bacterial taxa);
LGG	cis	rs6502050	0.799	rs9911129	chr17:80087819	C/T	cg23985595	chr17:80112537	CCDC57	-0.47	-9.58	-0.41	5.96e-20	Life satisfaction;
LGG	cis	rs34891900	0.507	rs5992088	chr22:18135912	C/T	cg19898043	chr22:18121309	BCL2L13	-0.55	-9.05	-0.39	3.89e-18	Sum neutrophil eosinophil counts;
LGG	cis	rs736408	0.570	rs11130327	chr3:52793239	A/G	cg14092988	chr3:52407081	DNAH1	0.3	8.0	0.35	9.8e-15	Bipolar disorder;
LGG	trans	rs11992162	0.560	rs13276386	chr8:11797421	T/A	cg06636001	chr8:8085503	FLJ10661	0.47	8.31	0.36	1.1e-15	Monocyte count;
LGG	cis	rs9815354	0.812	rs56728371	chr3:41999381	T/A	cg03022575	chr3:42003672	ULK4	0.78	9.11	0.39	2.48e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs4718428	0.705	rs62465692	chr7:66295745	T/C	cg12165864	chr7:66369176	NA	-0.57	-9.22	-0.39	1.08e-18	Corneal structure;
LGG	cis	rs13108904	0.967	rs900027	chr4:1279360	G/A	cg08948841	chr4:1244042	CTBP1;C4orf42	0.74	13.59	0.53	1.17e-35	Obesity-related traits;
LGG	cis	rs11098499	0.863	rs11723090	chr4:120490592	T/C	cg24375607	chr4:120327624	NA	0.68	11.2	0.46	6.41e-26	Corneal astigmatism;
LGG	cis	rs950169	0.840	rs4842853	chr15:84942304	G/T	cg24253500	chr15:84953950	NA	0.58	10.43	0.44	4.94e-23	Schizophrenia;
LGG	cis	rs9790314	0.589	rs4679662	chr3:160603024	T/C	cg04691961	chr3:161091175	C3orf57	0.41	8.64	0.37	9.15e-17	Morning vs. evening chronotype;
LGG	cis	rs3087591	1.000	rs9902427	chr17:29625430	G/A	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.53	-0.56	1.13e-39	Hip circumference;
LGG	cis	rs362296	0.698	rs3095082	chr4:3263617	C/A	cg06533319	chr4:3265114	C4orf44	0.52	10.81	0.45	1.96e-24	Parental longevity (mother's age at death);
LGG	cis	rs7572644	0.564	rs12995865	chr2:28025066	A/C	cg27432699	chr2:27873401	GPN1	0.47	6.88	0.3	1.95e-11	Response to carboplatin and paclitaxel in ovarian cancer (Caspase 3/7 EC50);
LGG	cis	rs9399135	0.935	rs987690	chr6:135350379	A/G	cg24558204	chr6:135376177	HBS1L	0.53	9.72	0.41	1.96e-20	Red blood cell count;
LGG	cis	rs3820068	0.603	rs59558854	chr1:15971399	T/G	cg05660106	chr1:15850417	CASP9	0.84	17.34	0.63	3.03e-52	Systolic blood pressure;
LGG	trans	rs116095464	0.558	rs10055354	chr5:243794	G/A	cg00938859	chr5:1591904	SDHAP3	0.91	13.48	0.53	3.75e-35	Breast cancer;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg21782813	chr7:2030301	MAD1L1	0.39	9.05	0.39	4.11e-18	Bipolar disorder and schizophrenia;
LGG	cis	rs365132	0.875	rs2940521	chr5:176339209	A/C	cg16309518	chr5:176445507	NA	-0.51	-11.19	-0.46	6.9e-26	Menarche and menopause (age at onset);Menopause (age at onset);
LGG	cis	rs10504229	0.636	rs115738451	chr8:58055133	A/T	cg05313129	chr8:58192883	C8orf71	-0.66	-8.62	-0.37	1.06e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs13191362	0.935	rs66635391	chr6:162964577	G/A	cg18825119	chr6:163149453	PACRG;PARK2	0.49	7.37	0.32	8.16e-13	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs35160687	0.901	rs12472676	chr2:86510815	T/C	cg10973622	chr2:86423274	IMMT	0.39	6.73	0.3	5.15e-11	Night sleep phenotypes;
LGG	trans	rs2727020	0.619	rs11040300	chr11:49269984	C/A	cg11707556	chr5:10655725	ANKRD33B	0.57	9.81	0.41	9.4499999999999992e-21	Coronary artery disease;
LGG	cis	rs10504229	1.000	rs59797486	chr8:58174435	T/C	cg14926445	chr8:58193284	C8orf71	-0.93	-13.67	-0.54	5.45e-36	Developmental language disorder (linguistic errors);
LGG	cis	rs3771570	1.000	rs73004382	chr2:242382192	C/T	cg21155796	chr2:242212141	HDLBP	0.77	10.1	0.42	8.59e-22	Prostate cancer;
LGG	cis	rs1005277	0.522	rs7072977	chr10:37940440	C/A	cg00409905	chr10:38381863	ZNF37A	-0.64	-13.13	-0.52	1.05e-33	Extrinsic epigenetic age acceleration;
LGG	cis	rs7011049	0.778	rs113126427	chr8:53867467	T/C	cg26025543	chr8:53854495	NA	0.59	8.39	0.36	6.02e-16	Systolic blood pressure;
LGG	cis	rs6582630	0.519	rs80226845	chr12:38528231	C/A	cg04568710	chr12:38710424	ALG10B	0.34	7.1	0.31	4.69e-12	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs9644630	0.672	rs12542081	chr8:19317786	G/T	cg06699216	chr8:19333253	CSGALNACT1	-0.43	-9.77	-0.41	1.23e-20	Oropharynx cancer;
LGG	cis	rs804280	0.564	rs4639	chr8:11644751	A/G	cg12395012	chr8:11607386	GATA4	-0.53	-10.46	-0.44	4e-23	Myopia (pathological);
LGG	cis	rs3096299	0.685	rs8050512	chr16:89552320	C/G	cg08392591	chr16:89556376	ANKRD11	0.6	9.69	0.41	2.41e-20	Multiple myeloma (IgH translocation);
LGG	cis	rs752010	0.714	rs7552928	chr1:42086664	C/T	cg16096631	chr1:42092165	HIVEP3	0.76	22.33	0.72	1.71e-75	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs7246760	1.000	rs58137206	chr19:9856624	G/A	cg16876255	chr19:9731953	ZNF561	0.72	6.79	0.3	3.39e-11	Pursuit maintenance gain;
LGG	cis	rs4808199	0.948	rs12982276	chr19:19459800	T/C	cg26732615	chr19:19648335	CILP2;YJEFN3	0.39	7.87	0.34	2.5e-14	Nonalcoholic fatty liver disease;
LGG	cis	rs1552244	1.000	rs111392584	chr3:10075991	A/G	cg00149659	chr3:10157352	C3orf10	0.85	10.83	0.45	1.7e-24	Alzheimer's disease;
LGG	trans	rs4843747	0.671	rs9933794	chr16:88116981	T/C	cg00711542	chr16:29343894	RUNDC2C	0.41	7.17	0.32	2.96e-12	Menopause (age at onset);
LGG	cis	rs10504229	0.683	rs6995355	chr8:58113870	C/T	cg05313129	chr8:58192883	C8orf71	-0.72	-10.11	-0.43	7.31e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs55986470	0.763	rs11888775	chr2:239424876	C/T	cg18131467	chr2:239335373	ASB1	0.55	6.74	0.3	4.87e-11	Chronotype;
LGG	cis	rs7044106	0.664	rs7861679	chr9:123375589	A/G	cg09419670	chr9:123605666	PSMD5;LOC253039	-0.83	-15.24	-0.58	8.62e-43	Hip circumference adjusted for BMI;
LGG	cis	rs933688	1.000	rs6866191	chr5:90746852	G/A	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	19.11	0.66	1.98e-60	Smoking behavior;
LGG	cis	rs651907	0.535	rs12631513	chr3:101517476	A/C	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.68	12.29	0.5	2.97e-30	Colorectal cancer;
LGG	cis	rs2635047	1.000	rs2635047	chr18:44736336	C/T	cg19077165	chr18:44547161	KATNAL2	-0.46	-7.93	-0.35	1.62e-14	Educational attainment;
LGG	cis	rs514406	0.708	rs514881	chr1:53336737	A/G	cg08859206	chr1:53392774	SCP2	0.42	7.68	0.34	9.27e-14	Monocyte count;
LGG	cis	rs10504229	0.683	rs903706	chr8:58128134	T/G	cg05313129	chr8:58192883	C8orf71	-0.73	-10.13	-0.43	6.5e-22	Developmental language disorder (linguistic errors);
LGG	cis	rs12474201	0.963	rs3829835	chr2:46925789	C/T	cg06386533	chr2:46925753	SOCS5	0.78	14.42	0.56	3.52e-39	Height;
LGG	cis	rs8177253	0.555	rs4481157	chr3:133464684	G/A	cg16414030	chr3:133502952	NA	-0.42	-7.06	-0.31	6.06e-12	Iron status biomarkers;
LGG	cis	rs694739	0.930	rs574087	chr11:64102948	A/G	cg22916017	chr11:64110731	CCDC88B	0.5	10.48	0.44	3.19e-23	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs4959677	0.868	rs12208100	chr6:2481688	T/A	cg23817096	chr6:1620687	NA	-0.32	-7.57	-0.33	2.03e-13	Orthostatic hypotension;
LGG	cis	rs9534288	0.742	rs1022952	chr13:46649348	C/T	cg15192986	chr13:46630673	CPB2	0.7	13.48	0.53	3.5e-35	Blood protein levels;
LGG	cis	rs2204008	0.775	rs11182513	chr12:38560252	G/C	cg26384229	chr12:38710491	ALG10B	0.99	23.44	0.74	1.04e-80	Bladder cancer;
LGG	cis	rs1784581	0.674	rs3016555	chr6:162391421	T/C	cg17173639	chr6:162384350	PARK2	-0.76	-17.23	-0.63	8.89e-52	Itch intensity from mosquito bite;
LGG	cis	rs9906944	0.545	rs11079851	chr17:47092310	G/C	cg10950924	chr17:47092072	IGF2BP1	-0.49	-9.51	-0.4	1.09e-19	Intelligence (multi-trait analysis);Body fat percentage;
LGG	cis	rs597539	0.652	rs613128	chr11:68638058	G/T	cg04772025	chr11:68637568	NA	0.77	13.85	0.54	9.8e-37	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs4750440	0.706	rs10796148	chr10:14016900	G/A	cg27542038	chr10:14027202	FRMD4A	-0.66	-12.62	-0.51	1.44e-31	Adiponectin levels;
LGG	cis	rs6960043	0.875	rs2215382	chr7:15055010	C/G	cg19272540	chr7:15055459	NA	0.34	7.77	0.34	5.28e-14	Type 2 diabetes;
LGG	cis	rs9403521	0.673	rs7772565	chr6:143993070	A/T	cg18240653	chr6:144019428	PHACTR2	0.59	10.4	0.44	6.32e-23	Obesity-related traits;
LGG	cis	rs41271473	0.750	rs72751931	chr1:228887129	G/T	cg10167378	chr1:228756711	NA	0.53	7.76	0.34	5.57e-14	Chronic lymphocytic leukemia;
LGG	cis	rs13132184	0.507	rs2303422	chr4:38091800	C/T	cg24826020	chr4:38070998	TBC1D1	-0.49	-8.27	-0.36	1.45e-15	Verbal declarative memory;
LGG	cis	rs5758511	0.680	rs34107327	chr22:42648353	T/G	cg00645731	chr22:42541494	CYP2D7P1	0.49	7.98	0.35	1.15e-14	Birth weight;
LGG	cis	rs2836974	0.897	rs13047678	chr21:40708853	C/T	cg11644478	chr21:40555479	PSMG1	0.85	14.93	0.57	1.9e-41	Cognitive function;
LGG	cis	rs2836974	0.544	rs8128919	chr21:40711862	C/T	cg17971929	chr21:40555470	PSMG1	0.6	10.28	0.43	1.85e-22	Cognitive function;
LGG	cis	rs1552244	0.882	rs13099136	chr3:10031431	G/A	cg02579736	chr3:10068473	FANCD2;CIDECP	1.05	17.69	0.64	6.75e-54	Alzheimer's disease;
LGG	cis	rs41271473	0.526	rs10916337	chr1:228714902	C/T	cg16512390	chr1:228756714	NA	0.62	8.07	0.35	5.98e-15	Chronic lymphocytic leukemia;
LGG	cis	rs10504229	1.000	rs73591706	chr8:58195633	C/T	cg02725872	chr8:58115012	NA	-0.78	-10.5	-0.44	2.9e-23	Developmental language disorder (linguistic errors);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg24774340	chr7:65579933	CRCP	0.5	7.37	0.32	7.75e-13	Gut microbiome composition (summer);
LGG	cis	rs42648	0.617	rs11563435	chr7:89900207	A/C	cg25739043	chr7:89950458	NA	-0.34	-7.18	-0.32	2.74e-12	Homocysteine levels;
LGG	cis	rs10504229	0.575	rs4590436	chr8:57996539	A/C	cg24829409	chr8:58192753	C8orf71	-0.49	-7.47	-0.33	4.06e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs55944282	chr8:58180821	A/G	cg11062466	chr8:58055876	NA	0.47	8.2	0.36	2.35e-15	Developmental language disorder (linguistic errors);
LGG	cis	rs55728055	0.661	rs73162112	chr22:32045449	G/A	cg15162869	chr22:32027605	PISD	-0.7	-7.37	-0.32	7.92e-13	Age-related hearing impairment;
LGG	cis	rs6795744	0.901	rs112911837	chr3:13906925	C/T	cg19554555	chr3:13937349	NA	0.59	7.07	0.31	5.79e-12	Glomerular filtration rate (creatinine);
LGG	cis	rs6951245	0.872	rs77434655	chr7:1098405	G/A	cg02733842	chr7:1102375	C7orf50	0.74	11.04	0.46	2.48e-25	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs6580649	0.824	rs1635534	chr12:48386553	A/G	cg24011408	chr12:48396354	COL2A1	0.6	7.06	0.31	6.07e-12	Lung cancer;
LGG	cis	rs11626933	1.000	rs2236402	chr14:90734378	C/G	cg14092571	chr14:90743983	NA	-0.78	-15.77	-0.59	3.81e-45	Gut microbiota (bacterial taxa);
LGG	cis	rs9309473	0.950	rs6546858	chr2:73838613	G/A	cg20560298	chr2:73613845	ALMS1	-0.46	-7.71	-0.34	7.8500000000000006e-14	Metabolite levels;
LGG	cis	rs611744	0.647	rs579162	chr8:109254842	A/G	cg18478394	chr8:109455254	TTC35	0.42	8.45	0.37	3.78e-16	Dupuytren's disease;
LGG	cis	rs12216125	0.549	rs9358905	chr6:26077839	T/A	cg12310025	chr6:25882481	NA	-0.38	-6.74	-0.3	4.72e-11	Iron status biomarkers;
LGG	trans	rs61931739	0.500	rs73103774	chr12:34482279	C/T	cg26384229	chr12:38710491	ALG10B	0.96	21.33	0.7	8.2e-71	Morning vs. evening chronotype;
LGG	trans	rs2204008	0.744	rs8189486	chr12:38244968	C/T	cg06521331	chr12:34319734	NA	-0.52	-8.97	-0.38	7.62e-18	Bladder cancer;
LGG	cis	rs17767392	0.958	rs61989373	chr14:71935156	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.43	-9.24	-0.39	8.79e-19	Mitral valve prolapse;
LGG	cis	rs597539	0.652	rs496616	chr11:68672800	G/C	cg04772025	chr11:68637568	NA	0.74	13.07	0.52	1.89e-33	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs12478296	1.000	rs55742408	chr2:243041077	G/A	cg06360820	chr2:242988706	NA	-0.9	-11.53	-0.47	3.41e-27	Obesity-related traits;
LGG	cis	rs9322193	0.923	rs9505823	chr6:149950035	A/C	cg02462569	chr6:150064036	NUP43	-0.41	-8.88	-0.38	1.44e-17	Lung cancer;
LGG	cis	rs7811142	0.943	rs111757992	chr7:100016354	A/C	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs3096299	0.967	rs2965935	chr16:89481274	C/T	cg02187348	chr16:89574699	SPG7	-0.43	-7.1	-0.31	4.59e-12	Multiple myeloma (IgH translocation);
LGG	cis	rs17711722	0.727	rs2658585	chr7:65461941	A/T	cg00343986	chr7:65444356	GUSB	0.49	8.61	0.37	1.13e-16	Calcium levels;
LGG	cis	rs2204008	0.506	rs11495470	chr12:38026904	C/T	cg04568710	chr12:38710424	ALG10B	0.35	7.36	0.32	8.38e-13	Bladder cancer;
LGG	cis	rs1153858	1.000	rs67744121	chr15:45677237	C/G	cg05280133	chr15:45670068	GATM;LOC145663	0.44	7.96	0.35	1.31e-14	Homoarginine levels;
LGG	cis	rs490234	0.783	rs4838278	chr9:128403509	T/C	cg14078157	chr9:128172775	NA	-0.48	-8.88	-0.38	1.47e-17	Mean arterial pressure;
LGG	cis	rs11608355	0.521	rs1119271	chr12:109819727	A/T	cg19025524	chr12:109796872	NA	-0.57	-12.6	-0.51	1.67e-31	Neuroticism;
LGG	trans	rs7937682	0.889	rs11213969	chr11:111528441	A/G	cg18187862	chr3:45730750	SACM1L	0.66	10.9	0.45	8.68e-25	Primary sclerosing cholangitis;
LGG	cis	rs2243480	1.000	rs6460274	chr7:65628484	T/A	cg12463550	chr7:65579703	CRCP	-0.78	-8.43	-0.36	4.33e-16	Diabetic kidney disease;
LGG	cis	rs7444	0.941	rs2298429	chr22:21983260	A/G	cg11654148	chr22:21984483	YDJC	-0.39	-7.52	-0.33	2.83e-13	Systemic lupus erythematosus;
LGG	cis	rs2114646	0.731	rs57629067	chr2:170632033	T/G	cg17598339	chr2:170624727	NA	0.36	6.96	0.31	1.18e-11	Obesity-related traits;
LGG	cis	rs3749237	0.595	rs11130196	chr3:49490149	A/C	cg06212747	chr3:49208901	KLHDC8B	0.43	7.0	0.31	9.21e-12	Resting heart rate;
LGG	cis	rs6500602	0.964	rs62039173	chr16:4463846	G/A	cg09626363	chr16:4524711	NMRAL1;HMOX2	0.38	7.36	0.32	8.4e-13	Schizophrenia;
LGG	cis	rs1475911	0.671	rs12483409	chr21:43521902	G/A	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.57	-11.33	-0.47	1.96e-26	IgG glycosylation;
LGG	cis	rs2243480	1.000	rs2460422	chr7:65601505	C/T	cg13147721	chr7:65941812	NA	-0.83	-10.06	-0.42	1.14e-21	Diabetic kidney disease;
LGG	cis	rs2439831	0.681	rs2242067	chr15:43699303	C/T	cg02155558	chr15:43621948	ADAL;LCMT2	0.91	10.33	0.43	1.2e-22	Lung cancer in ever smokers;
LGG	cis	rs7937682	0.883	rs549143	chr11:111463779	C/T	cg19812747	chr11:111475976	SIK2	-0.48	-10.13	-0.43	6.67e-22	Primary sclerosing cholangitis;
LGG	cis	rs8016982	1.000	rs12147118	chr14:81652975	A/C	cg01989461	chr14:81687754	GTF2A1	-0.64	-12.62	-0.51	1.44e-31	Schizophrenia;
LGG	cis	rs977987	0.835	rs8057535	chr16:75347941	C/T	cg03315344	chr16:75512273	CHST6	0.49	9.84	0.42	7.24e-21	Dupuytren's disease;
LGG	cis	rs7394190	0.688	rs3812629	chr10:75407290	G/A	cg07699608	chr10:75541558	CHCHD1	0.57	7.83	0.34	3.41e-14	Incident atrial fibrillation;
LGG	trans	rs7824557	0.527	rs57629785	chr8:11235150	C/A	cg08975724	chr8:8085496	FLJ10661	-0.44	-8.17	-0.35	2.89e-15	Retinal vascular caliber;
LGG	trans	rs9944715	0.734	rs9967220	chr18:43780059	C/T	cg01718231	chr17:29326311	RNF135	-0.42	-6.67	-0.3	7.51e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs644799	0.965	rs2950522	chr11:95524719	C/T	cg25478527	chr11:95522999	CEP57;FAM76B	0.46	7.88	0.34	2.34e-14	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	trans	rs3808502	0.525	rs13280813	chr8:11425105	G/T	cg02002194	chr4:3960332	NA	0.5	9.62	0.41	4.33e-20	Neuroticism;
LGG	cis	rs3812831	0.635	rs6560937	chr13:114945991	C/G	cg06611532	chr13:114900021	NA	0.29	7.25	0.32	1.8e-12	Schizophrenia;
LGG	cis	rs11148252	0.574	rs73186430	chr13:53232891	T/C	cg16301924	chr13:53314226	LECT1	-0.37	-7.48	-0.33	3.74e-13	Lewy body disease;
LGG	cis	rs2865126	0.818	rs2865129	chr18:10763995	C/T	cg21165219	chr18:10698044	FAM38B	-0.45	-7.37	-0.32	7.84e-13	Metabolite levels (5-HIAA/ MHPG Ratio);
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg13299548	chr22:32146269	C22orf30	0.47	7.06	0.31	6.07e-12	Gut microbiome composition (summer);
LGG	cis	rs11098499	0.708	rs11732686	chr4:120252330	C/A	cg24375607	chr4:120327624	NA	0.6	10.22	0.43	3.12e-22	Corneal astigmatism;
LGG	cis	rs9393692	0.875	rs6939589	chr6:26289203	C/T	cg00294572	chr6:26285232	NA	-0.41	-7.57	-0.33	2.08e-13	Educational attainment;
LGG	cis	rs28680850	0.541	rs1024549	chr8:1377191	C/T	cg06035437	chr8:1398411	NA	0.64	8.66	0.37	7.98e-17	Triglycerides;
LGG	cis	rs28386778	0.787	rs2665827	chr17:61961350	G/C	cg26338869	chr17:61819248	STRADA	0.57	9.32	0.4	4.66e-19	Prudent dietary pattern;
LGG	cis	rs12368653	0.693	rs2640610	chr12:58037435	T/A	cg18357645	chr12:58087776	OS9	0.4	6.84	0.3	2.6e-11	Multiple sclerosis;
LGG	cis	rs250677	0.958	rs17109282	chr5:148416677	A/G	cg18129178	chr5:148520854	ABLIM3	0.41	6.86	0.3	2.2e-11	Breast cancer;
LGG	cis	rs10197940	0.662	rs72860233	chr2:152289767	G/A	cg06191203	chr2:152266755	RIF1	-0.46	-8.12	-0.35	4.23e-15	Lung cancer;
LGG	cis	rs3820928	0.874	rs2228557	chr2:227872182	G/A	cg11843606	chr2:227700838	RHBDD1	-0.44	-7.52	-0.33	2.89e-13	Pulmonary function;
LGG	cis	rs5769765	0.955	rs9616366	chr22:50301178	C/T	cg22709217	chr22:50311962	ALG12;CRELD2	-0.77	-11.66	-0.48	1.02e-27	Schizophrenia;
LGG	cis	rs875971	0.825	rs1860472	chr7:66082723	T/C	cg12463550	chr7:65579703	CRCP	-0.5	-8.22	-0.36	1.99e-15	Aortic root size;
LGG	cis	rs3771570	0.901	rs3771587	chr2:242409701	A/G	cg21155796	chr2:242212141	HDLBP	0.7	9.33	0.4	4.41e-19	Prostate cancer;
LGG	trans	rs7613875	0.620	rs11721204	chr3:49982765	C/T	cg21665057	chr3:196295764	WDR53;FBXO45	0.41	7.0	0.31	9.32e-12	Body mass index;
LGG	cis	rs981844	0.712	rs1037650	chr4:154737657	G/A	cg14289246	chr4:154710475	SFRP2	-0.57	-9.77	-0.41	1.3e-20	Response to statins (LDL cholesterol change);
LGG	cis	rs4409675	0.548	rs1000432	chr1:28225119	T/C	cg23691781	chr1:28212827	C1orf38	0.39	10.44	0.44	4.81e-23	Corneal astigmatism;
LGG	cis	rs4319547	0.737	rs10773176	chr12:122944713	A/G	cg23029597	chr12:123009494	RSRC2	-0.88	-16.92	-0.62	2.35e-50	Body mass index;
LGG	cis	rs3219090	0.861	rs2570369	chr1:226605765	T/C	cg17127702	chr1:226594323	PARP1	0.39	12.44	0.5	7.76e-31	Melanoma;
LGG	cis	rs9457247	0.508	rs6941355	chr6:167506238	A/G	cg07741184	chr6:167504864	NA	0.37	8.47	0.37	3.17e-16	Crohn's disease;
LGG	trans	rs9329221	0.741	rs9650622	chr8:9804292	G/T	cg15556689	chr8:8085844	FLJ10661	-0.45	-7.73	-0.34	6.65e-14	Neuroticism;
LGG	cis	rs10911232	0.507	rs4397624	chr1:183053131	C/T	cg15522984	chr1:182991683	LAMC1	0.48	9.9	0.42	4.29e-21	Hypertriglyceridemia;
LGG	cis	rs472402	0.580	rs7706809	chr5:6635971	G/T	cg07758902	chr5:6633253	NSUN2;SRD5A1	-0.44	-7.1	-0.31	4.76e-12	Response to amphetamines;
LGG	cis	rs1046896	0.514	rs67735447	chr17:80823042	G/T	cg22027946	chr17:80790580	TBCD;ZNF750	0.4	6.98	0.31	1.01e-11	Glycated hemoglobin levels;
LGG	cis	rs875971	0.619	rs2302918	chr7:66000932	A/G	cg11764359	chr7:65958608	NA	0.61	10.44	0.44	4.89e-23	Aortic root size;
LGG	cis	rs2370759	0.945	rs74625866	chr10:32597618	A/T	cg01819863	chr10:32635814	EPC1	1.11	15.64	0.59	1.36e-44	Sexual dysfunction (female);
LGG	cis	rs1385374	0.858	rs10847698	chr12:129300222	T/C	cg21616243	chr12:129299702	MGC16384;SLC15A4	0.63	6.87	0.3	2.07e-11	Systemic lupus erythematosus;
LGG	cis	rs798554	0.797	rs2107964	chr7:2863574	G/A	cg14668632	chr7:2872130	GNA12	-0.35	-7.01	-0.31	8.21e-12	Height;
LGG	cis	rs9611565	0.694	rs9611591	chr22:41830212	G/A	cg17554472	chr22:41940697	POLR3H	0.44	6.69	0.3	6.58e-11	Vitiligo;
LGG	cis	rs2976388	0.609	rs2585149	chr8:143793320	T/C	cg06565975	chr8:143823917	SLURP1	0.35	9.03	0.39	4.78e-18	Urinary tract infection frequency;
LGG	cis	rs2046867	0.862	rs62252362	chr3:72855218	A/G	cg26655873	chr3:72818019	SHQ1	0.36	7.34	0.32	9.38e-13	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs847577	0.609	rs6965016	chr7:97807882	C/A	cg13397024	chr7:97797637	LMTK2	-0.36	-6.8	-0.3	3.16e-11	Breast cancer;
LGG	cis	rs694739	0.541	rs61886926	chr11:64133552	C/T	cg23796481	chr11:64053134	BAD;GPR137	0.71	12.94	0.52	6.52e-33	Alopecia areata;Crohn's disease;Psoriasis vulgaris;
LGG	cis	rs1401999	0.659	rs4912518	chr3:183752027	C/T	cg20387954	chr3:183756860	HTR3D	-0.81	-16.39	-0.61	6.11e-48	Anterior chamber depth;
LGG	trans	rs1994135	0.669	rs10844628	chr12:33697065	T/C	cg13010199	chr12:38710504	ALG10B	0.47	8.47	0.37	3.19e-16	Resting heart rate;
LGG	cis	rs721917	0.506	rs7914360	chr10:81657758	A/G	cg25562619	chr10:81652821	NA	-0.34	-7.9	-0.34	1.99e-14	Chronic obstructive pulmonary disease;
LGG	cis	rs4423214	0.592	rs1790349	chr11:71142350	A/G	cg10847948	chr11:71163743	NADSYN1	0.59	8.63	0.37	1.01e-16	Vitamin D levels;
LGG	cis	rs992157	0.835	rs10932768	chr2:219146199	T/A	cg00012203	chr2:219082015	ARPC2	-0.68	-12.19	-0.49	7.57e-30	Colorectal cancer;
LGG	cis	rs2985684	0.802	rs8015368	chr14:50020510	G/A	cg15316458	chr14:50087796	RPL36AL;MGAT2	0.41	6.82	0.3	2.77e-11	Carotid intima media thickness;
LGG	cis	rs644799	0.525	rs3016206	chr11:95536724	T/C	cg25622487	chr11:95524042	FAM76B;CEP57	0.84	15.52	0.59	4.73e-44	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs4927850	0.723	rs7630825	chr3:195753740	T/C	cg02975922	chr3:195473998	MUC4	-0.46	-7.52	-0.33	2.77e-13	Pancreatic cancer;
LGG	cis	rs7614311	0.731	rs56263032	chr3:63863022	G/A	cg22134162	chr3:63841271	THOC7	-0.45	-8.08	-0.35	5.78e-15	Lung function (FVC);Lung function (FEV1);
LGG	cis	rs701145	0.640	rs357506	chr3:153932403	A/C	cg17054900	chr3:154042577	DHX36	0.91	10.03	0.42	1.43e-21	Coronary artery disease;
LGG	cis	rs10911232	0.507	rs6660111	chr1:183014289	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.79	0.41	1.08e-20	Hypertriglyceridemia;
LGG	cis	rs78545713	0.649	rs11753717	chr6:26220202	G/C	cg01420254	chr6:26195488	NA	0.79	7.45	0.33	4.67e-13	Iron status biomarkers (total iron binding capacity);
LGG	cis	rs4918072	0.793	rs7074532	chr10:105702042	T/G	cg11005552	chr10:105648138	OBFC1	0.45	7.37	0.32	8.12e-13	Coronary artery disease;
LGG	cis	rs67478160	0.654	rs4906365	chr14:104229230	G/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.25	-0.32	1.8e-12	Schizophrenia;
LGG	cis	rs7618915	0.547	rs10780035	chr3:52764624	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.46	0.4	1.53e-19	Bipolar disorder;
LGG	cis	rs35740288	0.770	rs11634707	chr15:86151867	A/G	cg07943548	chr15:86304357	KLHL25	-0.33	-6.79	-0.3	3.48e-11	Eosinophil percentage of white cells;Neutrophil percentage of granulocytes;Eosinophil percentage of granulocytes;
LGG	cis	rs2117029	0.587	rs1865157	chr12:49522786	C/A	cg24176009	chr12:49580217	TUBA1A	0.65	12.66	0.51	9.3900000000000005e-32	Intelligence (multi-trait analysis);
LGG	trans	rs951252	0.504	rs11734405	chr4:146081096	C/T	cg14421490	chr14:81687491	GTF2A1	0.46	6.98	0.31	1.01e-11	Hip circumference;
LGG	cis	rs9880211	0.699	rs9809269	chr3:136429906	T/A	cg21827317	chr3:136751795	NA	-0.49	-6.72	-0.3	5.48e-11	Body mass index;Height;
LGG	cis	rs4650994	0.544	rs4132058	chr1:178505557	A/C	cg19399532	chr1:178512495	C1orf220	0.56	11.48	0.47	5.25e-27	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs2576037	0.501	rs7245049	chr18:44528213	G/A	cg16215983	chr18:44544982	KATNAL2;TCEB3CL	0.41	7.99	0.35	1.05e-14	Personality dimensions;
LGG	cis	rs367615	0.680	rs31592	chr5:108986836	T/G	cg17395555	chr5:108820864	NA	0.51	6.65	0.3	8.03e-11	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs7166081	1.000	rs4776348	chr15:67533304	T/C	cg05925327	chr15:68127851	NA	-0.32	-6.72	-0.3	5.51e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs36051895	0.659	rs12343867	chr9:5074189	T/C	cg02405213	chr9:5042618	JAK2	-0.84	-15.85	-0.59	1.68e-45	Pediatric autoimmune diseases;
LGG	trans	rs9467711	0.651	rs34888489	chr6:26073375	C/A	cg08344181	chr3:125677491	NA	-0.79	-7.04	-0.31	7.17e-12	Autism spectrum disorder or schizophrenia;
LGG	cis	rs7917772	0.560	rs4919664	chr10:104363408	A/C	cg11453585	chr10:104263688	ACTR1A;SUFU	0.6	11.56	0.47	2.49e-27	Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);White blood cell count;Waist-to-hip ratio adjusted for body mass index;
LGG	cis	rs8170	0.603	rs971693	chr19:17422649	G/C	cg04749549	chr19:17459798	NA	-0.38	-6.95	-0.31	1.26e-11	Breast cancer (estrogen-receptor negative);Breast Cancer in BRCA1 mutation carriers;Ovarian cancer;Breast cancer;Epithelial ovarian cancer;
LGG	cis	rs36051895	0.632	rs1590803	chr9:5177533	T/C	cg02405213	chr9:5042618	JAK2	-0.75	-14.75	-0.57	1.19e-40	Pediatric autoimmune diseases;
LGG	cis	rs2576037	0.623	rs2576040	chr18:44582027	A/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	0.5	8.61	0.37	1.14e-16	Personality dimensions;
LGG	cis	rs6582630	0.599	rs8189525	chr12:38424982	A/C	cg26384229	chr12:38710491	ALG10B	0.64	12.52	0.5	3.43e-31	Drug-induced liver injury (flucloxacillin);
LGG	cis	rs35306767	0.903	rs12244355	chr10:944465	T/C	cg25019033	chr10:957182	NA	-0.52	-9.56	-0.41	6.93e-20	Eosinophil percentage of granulocytes;
LGG	cis	rs888194	0.738	rs1045255	chr12:109973979	G/C	cg08884029	chr12:110012500	MVK;MMAB	-0.32	-6.68	-0.3	7.02e-11	Neuroticism;
LGG	cis	rs2742417	0.565	rs2673031	chr3:45756986	A/G	cg04837898	chr3:45731254	SACM1L	-0.47	-9.32	-0.4	4.58e-19	Response to anti-depressant treatment in major depressive disorder;
LGG	cis	rs9815354	0.638	rs73073267	chr3:42021163	A/T	cg03022575	chr3:42003672	ULK4	0.74	8.17	0.35	3.04e-15	Pulse pressure;Diastolic blood pressure;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25749966	chr3:52443976	BAP1;PHF7	0.46	6.88	0.3	2.01e-11	Gut microbiome composition (summer);
LGG	cis	rs951366	0.903	rs823116	chr1:205720483	G/A	cg11965913	chr1:205819406	PM20D1	0.59	11.13	0.46	1.21e-25	Menarche (age at onset);
LGG	cis	rs1829883	0.862	rs2460655	chr5:98797742	C/T	cg08333243	chr5:99726346	NA	-0.36	-6.7	-0.3	6.09e-11	Hemostatic factors and hematological phenotypes;
LGG	cis	rs17376456	0.597	rs11135401	chr5:93365716	G/A	cg17533458	chr5:92956826	FAM172A;MIR2277	-0.55	-7.8	-0.34	4.09e-14	Diabetic retinopathy;
LGG	cis	rs9354308	0.738	rs9363483	chr6:66610269	A/C	cg07460842	chr6:66804631	NA	-0.39	-6.65	-0.3	8.23e-11	Metabolite levels;
LGG	cis	rs2228479	0.850	rs11640188	chr16:89807732	C/T	cg26513180	chr16:89883248	FANCA	1.02	9.81	0.41	8.98e-21	Skin colour saturation;
LGG	cis	rs6142618	0.562	rs6142615	chr20:30712439	G/T	cg00028034	chr20:30779307	TSPYL3	0.37	8.09	0.35	5.45e-15	Inflammatory bowel disease;
LGG	cis	rs4689388	0.926	rs4234730	chr4:6296343	A/G	cg00701064	chr4:6280414	WFS1	0.75	16.54	0.61	1.24e-48	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs7819412	0.740	rs11250119	chr8:11037034	C/T	cg16141378	chr3:129829833	LOC729375	0.33	7.58	0.33	1.9e-13	Triglycerides;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg19729279	chr5:133861951	PHF15	0.46	6.95	0.31	1.23e-11	Gut microbiome composition (summer);
LGG	cis	rs7765175	0.698	rs34133524	chr6:113667078	A/T	cg26552650	chr6:113682475	NA	0.34	7.62	0.33	1.45e-13	Coronary artery calcification;
LGG	trans	rs7395662	0.890	rs4882133	chr11:48593450	T/C	cg00717180	chr2:96193071	NA	-0.43	-7.55	-0.33	2.31e-13	HDL cholesterol;
LGG	cis	rs12618769	0.597	rs2278213	chr2:99136059	A/G	cg18455616	chr2:99124870	INPP4A	0.29	8.68	0.37	6.75e-17	Bipolar disorder;
LGG	cis	rs11764590	0.694	rs7801349	chr7:2085553	T/C	cg07027305	chr7:2059796	MAD1L1	-0.33	-8.22	-0.36	2.1e-15	Neuroticism;
LGG	cis	rs17345786	1.000	rs3762729	chr3:101308874	C/T	cg21474964	chr3:101395104	ZBTB11;LOC100009676	0.56	8.55	0.37	1.83e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs2404618	0.587	rs6994849	chr8:1492839	G/T	cg02903104	chr8:1507517	DLGAP2	-0.36	-7.57	-0.33	2.03e-13	Lung cancer;
LGG	cis	rs6951245	0.572	rs79489623	chr7:1045632	C/T	cg02733842	chr7:1102375	C7orf50	0.72	8.37	0.36	6.74e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg15596359	chr8:11213517	TDH	-0.43	-8.86	-0.38	1.69e-17	Retinal vascular caliber;
LGG	cis	rs873946	0.504	rs3793681	chr10:134564451	T/C	cg13271783	chr10:134563150	INPP5A	-0.51	-7.99	-0.35	1.06e-14	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs3096299	0.967	rs28575874	chr16:89469890	C/T	cg02187348	chr16:89574699	SPG7	0.45	7.37	0.32	8.08e-13	Multiple myeloma (IgH translocation);
LGG	cis	rs1865760	0.964	rs3799373	chr6:25929173	A/C	cg12310025	chr6:25882481	NA	-0.43	-7.75	-0.34	5.87e-14	Height;
LGG	cis	rs6952808	0.792	rs34269264	chr7:1948712	C/T	cg00106254	chr7:1943704	MAD1L1	-0.49	-8.64	-0.37	8.9e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs765787	0.530	rs4775835	chr15:45537553	T/C	cg25801113	chr15:45476975	SHF	0.87	19.88	0.68	5.09e-64	Uric acid levels;
LGG	cis	rs10504229	0.953	rs2270610	chr8:58194669	A/G	cg02725872	chr8:58115012	NA	-0.79	-10.96	-0.45	5.41e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs9322193	0.962	rs7752089	chr6:150160434	A/G	cg07701084	chr6:150067640	NUP43	0.67	12.48	0.5	5.19e-31	Lung cancer;
LGG	cis	rs9443645	0.527	rs1415859	chr6:79794858	A/G	cg18132916	chr6:79620363	NA	-0.27	-6.97	-0.31	1.12e-11	Intelligence (multi-trait analysis);
LGG	cis	rs6062788	0.504	rs8124644	chr20:61699728	C/T	cg00291292	chr20:61702795	NA	0.47	9.04	0.39	4.22e-18	Body mass index;
LGG	cis	rs17270561	0.609	rs2275905	chr6:25768106	G/A	cg16482183	chr6:26056742	HIST1H1C	0.57	9.29	0.4	6.11e-19	Iron status biomarkers;
LGG	cis	rs77633900	0.614	rs280029	chr15:77031235	A/G	cg21673338	chr15:77095150	SCAPER	-0.66	-10.26	-0.43	2.19e-22	Non-glioblastoma glioma;Glioma;
LGG	cis	rs911186	0.680	rs34783558	chr6:27171700	T/C	cg12292205	chr6:26970375	C6orf41	-0.64	-8.43	-0.36	4.32e-16	Autism spectrum disorder or schizophrenia;
LGG	cis	rs875971	0.862	rs13226170	chr7:65999298	G/A	cg12463550	chr7:65579703	CRCP	0.5	8.31	0.36	1.07e-15	Aortic root size;
LGG	cis	rs11758351	1.000	rs41266807	chr6:26199822	A/G	cg11342453	chr6:26196699	NA	0.49	6.81	0.3	3.06e-11	Gout;Renal underexcretion gout;
LGG	cis	rs12421382	0.614	rs12418763	chr11:109390360	C/T	cg16359550	chr11:109292809	C11orf87	0.4	7.93	0.35	1.66e-14	Schizophrenia;
LGG	cis	rs9462027	0.628	rs9469914	chr6:34827693	A/T	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.77	-0.45	2.69e-24	Systemic lupus erythematosus;
LGG	cis	rs7824557	0.579	rs10098322	chr8:11196295	C/G	cg21775007	chr8:11205619	TDH	0.8	14.14	0.55	5.64e-38	Retinal vascular caliber;
LGG	cis	rs9815354	0.812	rs73071325	chr3:41809989	T/G	cg03022575	chr3:42003672	ULK4	0.79	9.17	0.39	1.58e-18	Pulse pressure;Diastolic blood pressure;
LGG	cis	rs7824557	0.767	rs11250127	chr8:11170209	G/A	cg15596359	chr8:11213517	TDH	-0.35	-7.05	-0.31	6.7e-12	Retinal vascular caliber;
LGG	cis	rs7227917	0.536	rs72916036	chr18:45515486	G/C	cg22195133	chr18:45534586	NA	0.72	6.67	0.3	7.45e-11	Lung cancer in ever smokers;
LGG	cis	rs858239	0.570	rs10242166	chr7:23162799	A/G	cg23682824	chr7:23144976	KLHL7	0.44	7.41	0.33	6.06e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs17604090	0.823	rs28415620	chr7:29701104	T/C	cg19413766	chr7:29689036	LOC646762	-0.56	-7.0	-0.31	8.79e-12	Facial emotion recognition;Facial emotion recognition (sad faces);
LGG	cis	rs61931739	0.649	rs815043	chr12:33722599	C/T	cg06521331	chr12:34319734	NA	-0.39	-6.8	-0.3	3.17e-11	Morning vs. evening chronotype;
LGG	cis	rs2204008	0.837	rs1842599	chr12:37986081	G/A	cg13010199	chr12:38710504	ALG10B	-0.61	-12.74	-0.51	4.46e-32	Bladder cancer;
LGG	cis	rs75920871	0.588	rs10892054	chr11:116868221	C/T	cg20608306	chr11:116969690	SIK3	-0.41	-10.96	-0.45	5.06e-25	Subjective well-being;
LGG	cis	rs7017914	0.902	rs10504481	chr8:71699517	T/G	cg23757474	chr8:71581111	LACTB2;XKR9	-0.37	-6.78	-0.3	3.71e-11	Bone mineral density;
LGG	cis	rs2816316	0.887	rs2760522	chr1:192529414	C/G	cg10861751	chr1:192544716	RGS1	0.33	6.68	0.3	7.07e-11	Celiac disease;
LGG	cis	rs13108904	0.934	rs13124383	chr4:1299986	C/T	cg08948841	chr4:1244042	CTBP1;C4orf42	0.72	13.19	0.52	5.7e-34	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs11657391	chr17:29194287	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.61	-7.2	-0.32	2.37e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	trans	rs2727020	0.595	rs10839281	chr11:49483373	A/C	cg15704280	chr7:45808275	SEPT13	-1.02	-22.87	-0.73	5.27e-78	Coronary artery disease;
LGG	cis	rs58616815	0.857	rs1891232	chr10:92158576	A/T	cg17905462	chr10:92153495	NA	-0.25	-6.64	-0.3	8.56e-11	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;
LGG	cis	rs11628318	0.614	rs8010455	chr14:103164681	A/G	cg23461800	chr14:103021989	NA	0.5	7.82	0.34	3.72e-14	Platelet count;
LGG	cis	rs3087591	0.920	rs11080150	chr17:29629326	A/G	cg24425628	chr17:29625626	OMG;NF1	-0.69	-14.4	-0.56	4.14e-39	Hip circumference;
LGG	cis	rs11997175	0.574	rs872489	chr8:33646401	T/C	ch.8.33884649F	chr8:33765107	NA	0.39	7.22	0.32	2.16e-12	Body mass index;
LGG	cis	rs988958	0.526	rs7592119	chr2:42243667	T/A	cg19376973	chr2:42229025	NA	0.64	9.62	0.41	4.44e-20	Hypospadias;
LGG	cis	rs7712401	0.601	rs36099390	chr5:122317719	G/A	cg19412675	chr5:122181750	SNX24	-0.41	-6.76	-0.3	4.1e-11	Mean platelet volume;
LGG	cis	rs34421088	0.560	rs2245357	chr8:11399484	A/T	cg19847130	chr8:10466454	RP1L1	0.31	7.09	0.31	4.95e-12	Neuroticism;
LGG	trans	rs3780486	0.846	rs2209948	chr9:33138247	G/A	cg04842962	chr6:43655489	MRPS18A	1.12	24.45	0.75	2.26e-85	IgG glycosylation;
LGG	cis	rs28386778	0.897	rs2584617	chr17:61925298	C/T	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.3	0.43	1.53e-22	Prudent dietary pattern;
LGG	cis	rs7223966	1.000	rs3817181	chr17:61776538	G/C	cg17202724	chr17:61916730	SMARCD2	-0.45	-8.77	-0.38	3.42e-17	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs4242434	0.927	rs2272718	chr8:22457388	G/A	cg03733263	chr8:22462867	KIAA1967	1.12	28.64	0.8	1.5e-104	Exploratory eye movement dysfunction in schizophrenia (cognitive search score);
LGG	cis	rs73086581	1.000	rs6107393	chr20:3987738	C/T	cg02187196	chr20:3869020	PANK2	0.8	11.22	0.46	5.26e-26	Response to antidepressants in depression;
LGG	cis	rs6940638	0.662	rs6915678	chr6:27235866	T/G	cg09904177	chr6:26538194	HMGN4	-0.41	-6.98	-0.31	1.03e-11	Intelligence (multi-trait analysis);
LGG	cis	rs8067545	0.611	rs7219908	chr17:20043036	A/G	cg09818912	chr17:20140352	CYTSB	-0.32	-7.64	-0.33	1.26e-13	Schizophrenia;
LGG	cis	rs769267	0.740	rs2965185	chr19:19525792	T/C	cg03709012	chr19:19516395	GATAD2A	0.66	11.3	0.46	2.63e-26	Tonsillectomy;
LGG	cis	rs7786808	0.530	rs6459875	chr7:158186141	C/T	cg09998033	chr7:158218633	PTPRN2	0.54	9.86	0.42	5.83e-21	Obesity-related traits;
LGG	cis	rs2576037	0.526	rs4890707	chr18:44497724	C/G	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	16.73	0.61	1.81e-49	Personality dimensions;
LGG	cis	rs875971	0.830	rs427575	chr7:65519219	A/G	cg12463550	chr7:65579703	CRCP	0.46	7.61	0.33	1.5e-13	Aortic root size;
LGG	cis	rs1401999	0.690	rs6773408	chr3:183716609	G/T	cg05044414	chr3:183734942	ABCC5	0.67	14.04	0.55	1.51e-37	Anterior chamber depth;
LGG	cis	rs7249142	0.562	rs2239370	chr19:19292674	T/C	cg19540702	chr19:19281175	LOC729991-MEF2B;MEF2B	-0.41	-10.55	-0.44	1.77e-23	IgG glycosylation;
LGG	cis	rs1363119	1.000	rs59384167	chr19:18444518	C/A	cg02383626	chr19:18455508	PGPEP1	0.76	17.0	0.62	1.05e-50	Intelligence (multi-trait analysis);
LGG	cis	rs7618501	0.602	rs9311446	chr3:50092226	G/A	cg05623727	chr3:50126028	RBM5	-0.33	-7.08	-0.31	5.55e-12	Intelligence (multi-trait analysis);
LGG	cis	rs3806843	0.735	rs3776129	chr5:140072292	G/A	cg16577123	chr5:140027231	NDUFA2;IK	-0.42	-6.74	-0.3	4.82e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs1030268	0.607	rs34218501	chr7:133210375	G/A	cg10665199	chr7:133106180	EXOC4	0.5	7.16	0.32	3.2e-12	Intelligence (multi-trait analysis);
LGG	cis	rs11967485	0.609	rs62435818	chr6:157160073	G/A	cg23222435	chr6:157204239	ARID1B	-0.81	-7.36	-0.32	8.19e-13	Calcium levels;
LGG	cis	rs6952808	1.000	rs4721122	chr7:1893311	C/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.75	0.34	5.76e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs1801251	1.000	rs7578299	chr2:233573469	G/T	cg08000102	chr2:233561755	GIGYF2	0.57	9.22	0.39	1.08e-18	Coronary artery disease;
LGG	cis	rs3820068	0.603	rs3795763	chr1:15959977	C/T	cg05660106	chr1:15850417	CASP9	0.85	17.54	0.63	3.49e-53	Systolic blood pressure;
LGG	cis	rs561341	1.000	rs1681718	chr17:30296445	G/A	cg00745463	chr17:30367425	LRRC37B	-0.75	-10.63	-0.44	9.3e-24	Hip circumference adjusted for BMI;
LGG	cis	rs11148252	0.904	rs9536079	chr13:53030565	G/A	cg12458913	chr13:53173898	NA	0.75	15.63	0.59	1.61e-44	Lewy body disease;
LGG	cis	rs9322193	0.887	rs3777949	chr6:149917157	G/A	cg12070911	chr6:150209640	RAET1E	0.3	7.06	0.31	6.13e-12	Lung cancer;
LGG	cis	rs62238980	0.614	rs75805646	chr22:32441396	A/G	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs7833790	1.000	rs7460277	chr8:82709777	T/C	cg27398817	chr8:82754497	SNX16	-0.8	-11.62	-0.48	1.42e-27	Diastolic blood pressure;
LGG	cis	rs1153858	1.000	rs1145074	chr15:45703824	T/A	cg21132104	chr15:45694354	SPATA5L1	0.72	10.6	0.44	1.16e-23	Homoarginine levels;
LGG	cis	rs9515201	0.884	rs11838776	chr13:111040681	G/A	cg06243866	chr13:111019493	COL4A2	-0.5	-8.02	-0.35	8.89e-15	White matter hyperintensity burden;
LGG	cis	rs1008375	0.797	rs6843530	chr4:17593605	G/T	cg02297831	chr4:17616191	MED28	0.49	8.99	0.39	6.48e-18	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs4906332	0.901	rs4900575	chr14:103899169	G/C	cg26031613	chr14:104095156	KLC1	-0.52	-7.93	-0.35	1.6e-14	Coronary artery disease;
LGG	cis	rs739401	0.611	rs7394974	chr11:3038868	C/T	cg08508325	chr11:3079039	CARS	-0.61	-13.23	-0.52	3.91e-34	Longevity;
LGG	cis	rs1552244	1.000	rs6772315	chr3:10113644	G/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.84	-12.91	-0.51	8.83e-33	Alzheimer's disease;
LGG	trans	rs832540	0.866	rs252894	chr5:56224339	A/C	cg17187048	chr2:122407283	CLASP1	-0.42	-6.8	-0.3	3.18e-11	Coronary artery disease;
LGG	cis	rs12230513	0.732	rs61957765	chr12:55868561	T/C	cg19537932	chr12:55886519	OR6C68	-0.61	-10.92	-0.45	7.38e-25	Contrast sensitivity;
LGG	cis	rs4734806	1.000	rs36072167	chr8:105713240	A/G	cg01675814	chr8:105601641	LRP12	0.51	7.03	0.31	7.47e-12	Periodontitis (DPAL);
LGG	cis	rs7590368	0.673	rs2306922	chr2:10942520	C/T	cg15705551	chr2:10952987	PDIA6	0.57	7.35	0.32	9.06e-13	Educational attainment (years of education);
LGG	cis	rs2067615	0.579	rs10746066	chr12:107129108	G/A	cg15890332	chr12:107067104	RFX4	0.4	11.85	0.48	1.8e-28	Heart rate;
LGG	cis	rs9911578	1.000	rs4793950	chr17:56593111	T/C	cg12560992	chr17:57184187	TRIM37	-0.89	-15.84	-0.59	1.81e-45	Intelligence (multi-trait analysis);
LGG	cis	rs9300255	0.699	rs11057204	chr12:123725827	T/C	cg00376283	chr12:123451042	ABCB9	0.63	10.02	0.42	1.55e-21	Neutrophil percentage of white cells;
LGG	cis	rs1357245	0.534	rs58032458	chr3:27097505	T/G	cg02860705	chr3:27208620	NA	0.37	7.09	0.31	4.89e-12	Breast cancer;
LGG	cis	rs6694672	0.717	rs2151135	chr1:197106604	C/T	cg13682187	chr1:196946512	CFHR5	0.51	7.14	0.31	3.74e-12	Asthma;
LGG	cis	rs4665809	0.590	rs2303894	chr2:26508187	A/G	cg08470875	chr2:26401718	FAM59B	0.43	8.22	0.36	2.08e-15	Gut microbiome composition (summer);
LGG	cis	rs804280	0.509	rs10109241	chr8:11784985	A/T	cg00405596	chr8:11794950	NA	0.63	11.04	0.46	2.68e-25	Myopia (pathological);
LGG	cis	rs907683	0.545	rs3755054	chr2:220280974	C/T	cg15015639	chr2:220282977	DES	0.35	9.85	0.42	6.35e-21	Resting heart rate;
LGG	cis	rs8018808	0.935	rs176772	chr14:77881808	A/G	cg20045696	chr14:77926864	AHSA1	0.42	6.99	0.31	9.63e-12	Myeloid white cell count;
LGG	cis	rs2302777	0.507	rs9889716	chr17:38108298	A/G	cg17467752	chr17:38218738	THRA	0.45	6.94	0.31	1.36e-11	Multiple myeloma (hyperdiploidy);
LGG	cis	rs751728	0.588	rs7774620	chr6:33736285	T/A	cg25922239	chr6:33757077	LEMD2	0.41	6.98	0.31	1.05e-11	Crohn's disease;
LGG	cis	rs1707322	1.000	rs3922887	chr1:46473802	A/G	cg03146154	chr1:46216737	IPP	0.56	10.33	0.43	1.19e-22	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs11191205	0.686	rs10883676	chr10:103445325	A/C	cg15320455	chr10:103880129	LDB1	-0.54	-7.85	-0.34	2.94e-14	Intelligence (multi-trait analysis);
LGG	cis	rs1552244	1.000	rs7652935	chr3:10151138	T/C	cg16606324	chr3:10149918	C3orf24	0.52	6.85	0.3	2.31e-11	Alzheimer's disease;
LGG	cis	rs7166081	0.950	rs12917612	chr15:67491274	C/A	cg05925327	chr15:68127851	NA	-0.32	-6.8	-0.3	3.29e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs10206020	0.885	rs11899557	chr2:1576123	G/T	cg12573674	chr2:1569213	NA	-0.65	-10.37	-0.43	8.53e-23	IgG glycosylation;
LGG	cis	rs651907	0.535	rs34743741	chr3:101532448	C/T	cg11279151	chr3:101281821	RG9MTD1	-0.44	-7.84	-0.34	3.12e-14	Colorectal cancer;
LGG	trans	rs1891498	0.602	rs12408247	chr1:147244441	A/G	cg10234952	chr20:55926623	RAE1	0.42	6.79	0.3	3.55e-11	Cognitive performance;
LGG	cis	rs3740909	1.000	rs78196034	chr11:125891706	T/C	cg24940576	chr11:125904314	CDON	-0.48	-7.15	-0.32	3.31e-12	Blood protein levels;
LGG	cis	rs7833790	0.632	rs6415653	chr8:82702536	A/G	cg17211192	chr8:82754475	SNX16	-0.68	-11.52	-0.47	3.44e-27	Diastolic blood pressure;
LGG	cis	rs9534288	0.797	rs7331069	chr13:46564609	A/T	cg15192986	chr13:46630673	CPB2	0.59	12.98	0.52	4.61e-33	Blood protein levels;
LGG	cis	rs2239547	0.618	rs1573815	chr3:52870132	A/G	cg11645453	chr3:52864694	ITIH4	-0.69	-10.76	-0.45	2.93e-24	Schizophrenia;
LGG	cis	rs951366	0.789	rs823110	chr1:205701078	G/C	cg07157834	chr1:205819609	PM20D1	0.74	16.71	0.61	2.21e-49	Menarche (age at onset);
LGG	cis	rs4330281	0.647	rs7642719	chr3:17435581	G/A	cg20981856	chr3:17787350	NA	0.35	6.67	0.3	7.5e-11	Schizophrenia;
LGG	cis	rs9322193	0.847	rs9505972	chr6:150096391	A/C	cg13206674	chr6:150067644	NUP43	0.66	14.78	0.57	9.31e-41	Lung cancer;
LGG	cis	rs6952808	0.609	rs34967784	chr7:1949507	T/G	cg05863683	chr7:1912471	MAD1L1	0.41	7.92	0.35	1.79e-14	Bipolar disorder and schizophrenia;
LGG	cis	rs9322193	0.847	rs4870054	chr6:150169538	C/T	cg05861140	chr6:150128134	PCMT1	-0.41	-8.68	-0.37	7.02e-17	Lung cancer;
LGG	cis	rs9322193	0.923	rs9322209	chr6:150012362	A/G	cg15971980	chr6:150254442	NA	0.45	8.5	0.37	2.65e-16	Lung cancer;
LGG	cis	rs7192750	0.586	rs1981874	chr16:71897244	C/T	cg06353428	chr16:71660113	MARVELD3	-0.66	-10.46	-0.44	4.03e-23	LDL cholesterol levels;Total cholesterol levels;
LGG	cis	rs3096299	0.667	rs2965947	chr16:89518670	T/C	cg08392591	chr16:89556376	ANKRD11	0.53	8.41	0.36	5.24e-16	Multiple myeloma (IgH translocation);
LGG	cis	rs6539288	0.803	rs4479083	chr12:107321245	G/C	cg26297688	chr12:107349093	C12orf23	-0.37	-7.02	-0.31	7.78e-12	Total body bone mineral density;
LGG	cis	rs986417	0.786	rs7156379	chr14:61110634	G/C	cg27398547	chr14:60952738	C14orf39	0.73	6.72	0.3	5.45e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs57024841	0.517	rs28578007	chr9:139838690	T/C	cg00693599	chr9:139836323	FBXW5	0.42	7.45	0.33	4.69e-13	Beta-trace protein levels;
LGG	cis	rs4862750	0.914	rs11945845	chr4:187874136	T/C	cg03452623	chr4:187889614	NA	-1.04	-29.04	-0.8	2.46e-106	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs40363	0.645	rs1635392	chr16:3517581	T/C	cg26668626	chr16:3451006	ZNF174;ZNF434	-0.44	-6.8	-0.3	3.21e-11	Tuberculosis;
LGG	cis	rs7959452	0.590	rs28778648	chr12:69771911	C/A	cg11871910	chr12:69753446	YEATS4	0.92	22.06	0.72	2.94e-74	Blood protein levels;
LGG	cis	rs986417	1.000	rs11158293	chr14:61109020	G/C	cg27398547	chr14:60952738	C14orf39	0.73	6.8	0.3	3.24e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs60843830	1.000	rs7605824	chr2:280819	A/G	cg12623918	chr2:306882	NA	-0.52	-9.85	-0.42	6.65e-21	Spherical equivalent (joint analysis main effects and education interaction);
LGG	cis	rs12478296	1.000	rs73007129	chr2:243000555	T/C	cg06360820	chr2:242988706	NA	-1.12	-13.1	-0.52	1.44e-33	Obesity-related traits;
LGG	cis	rs2652834	0.851	rs4238372	chr15:63351488	G/A	cg05507819	chr15:63340323	TPM1	0.61	8.18	0.36	2.86e-15	HDL cholesterol;
LGG	cis	rs4925325	0.741	rs6142886	chr20:60511190	A/G	cg06108461	chr20:60628389	TAF4	0.61	8.72	0.38	5.06e-17	Obesity-related traits;
LGG	cis	rs9650657	0.645	rs11774552	chr8:10515679	C/T	cg27411982	chr8:10470053	RP1L1	-0.44	-7.57	-0.33	2.04e-13	Neuroticism;
LGG	cis	rs9472414	0.510	rs227845	chr6:44695338	C/A	cg20913747	chr6:44695427	NA	0.48	7.89	0.34	2.24e-14	Height;
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg21724239	chr8:58056113	NA	0.51	7.64	0.33	1.22e-13	Developmental language disorder (linguistic errors);
LGG	cis	rs62400317	0.859	rs10948214	chr6:45170466	T/C	cg18551225	chr6:44695536	NA	-0.63	-10.18	-0.43	4.35e-22	Total body bone mineral density;
LGG	cis	rs10504229	0.679	rs72649114	chr8:58037491	G/T	cg14926445	chr8:58193284	C8orf71	-0.69	-9.03	-0.39	4.76e-18	Developmental language disorder (linguistic errors);
LGG	cis	rs1475911	0.708	rs56109792	chr21:43520060	A/G	cg14562523	chr21:43528734	C21orf128;UMODL1	-0.58	-11.5	-0.47	4.34e-27	IgG glycosylation;
LGG	cis	rs28386778	1.000	rs28386778	chr17:61964815	T/C	cg07677032	chr17:61819896	STRADA	0.66	12.11	0.49	1.65e-29	Prudent dietary pattern;
LGG	cis	rs7011049	0.908	rs113206545	chr8:53858648	A/G	cg26025543	chr8:53854495	NA	0.74	9.77	0.41	1.23e-20	Systolic blood pressure;
LGG	trans	rs7824557	0.628	rs17797894	chr8:11212081	A/G	cg06636001	chr8:8085503	FLJ10661	0.4	6.93	0.31	1.4e-11	Retinal vascular caliber;
LGG	cis	rs2019137	0.836	rs4848318	chr2:113953952	T/C	cg21610815	chr2:113994035	PAX8;LOC654433;LOC440839	-0.49	-8.28	-0.36	1.32e-15	Lymphocyte counts;
LGG	cis	rs2073300	1.000	rs17830565	chr20:23444805	G/A	cg12062639	chr20:23401060	NAPB	0.86	6.92	0.31	1.5e-11	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs11190604	1.000	rs2495751	chr10:102327260	A/G	cg07080220	chr10:102295463	HIF1AN	0.73	12.11	0.49	1.62e-29	Palmitoleic acid (16:1n-7) levels;
LGG	cis	rs9768139	0.683	rs72505558	chr7:158113215	A/G	cg25566285	chr7:158114605	PTPRN2	0.91	20.64	0.69	1.38e-67	Calcium levels;
LGG	cis	rs67311347	0.544	rs12633295	chr3:40335292	G/T	cg24209194	chr3:40518798	ZNF619	-0.4	-6.83	-0.3	2.72e-11	Renal cell carcinoma;
LGG	cis	rs12477438	0.748	rs6712773	chr2:99585781	A/G	cg15544633	chr2:99771531	LIPT1;TSGA10	-1.02	-17.48	-0.63	6.23e-53	Chronic sinus infection;
LGG	cis	rs11711311	1.000	rs9827682	chr3:113450251	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.66	13.23	0.52	3.87e-34	IgG glycosylation;
LGG	cis	rs986417	0.818	rs4901993	chr14:61081453	G/A	cg27398547	chr14:60952738	C14orf39	0.68	7.05	0.31	6.38e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs804280	0.509	rs12719915	chr8:11786255	A/G	cg24623649	chr8:11872141	NA	-0.29	-6.89	-0.31	1.81e-11	Myopia (pathological);
LGG	cis	rs13191362	1.000	rs13201023	chr6:162981381	C/G	cg06582575	chr6:163149167	PACRG;PARK2	0.78	8.17	0.35	3.04e-15	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs1023500	0.573	rs13057094	chr22:42470317	T/C	cg04733989	chr22:42467013	NAGA	0.57	9.85	0.42	6.8e-21	Schizophrenia;
LGG	cis	rs4665809	1.000	rs4665819	chr2:26309073	A/G	cg22920501	chr2:26401640	FAM59B	-0.38	-7.61	-0.33	1.53e-13	Gut microbiome composition (summer);
LGG	cis	rs10193935	1.000	rs10173107	chr2:42420302	A/T	cg27598129	chr2:42591480	NA	-0.65	-9.67	-0.41	2.8e-20	Colonoscopy-negative controls vs population controls;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11338389	chr11:63742044	COX8A	0.44	7.29	0.32	1.31e-12	Gut microbiota (bacterial taxa);
LGG	cis	rs4901847	0.967	rs12897032	chr14:58557801	A/G	cg15908186	chr14:58618357	C14orf37	0.54	9.65	0.41	3.34e-20	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs870825	0.616	rs877276	chr4:185621249	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.48	0.72	3.19e-76	Blood protein levels;
LGG	cis	rs10791323	0.572	rs1114367	chr11:133737304	G/T	cg00579200	chr11:133705235	NA	-0.56	-10.79	-0.45	2.35e-24	Childhood ear infection;
LGG	cis	rs12615966	0.932	rs17030310	chr2:105391647	C/T	cg16465502	chr2:105461796	NA	-0.91	-11.11	-0.46	1.4e-25	Pancreatic cancer;
LGG	cis	rs7084402	0.967	rs1658486	chr10:60288081	A/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.99e-56	Refractive error;
LGG	cis	rs5758659	0.845	rs5758645	chr22:42598951	T/G	cg15557168	chr22:42548783	NA	-0.41	-8.99	-0.39	6.17e-18	Cognitive function;
LGG	cis	rs36051895	0.623	rs1120679	chr9:5248073	C/G	cg02405213	chr9:5042618	JAK2	-0.74	-13.31	-0.53	1.95e-34	Pediatric autoimmune diseases;
LGG	cis	rs9400467	0.506	rs12198556	chr6:111662338	C/T	cg21044968	chr6:111895086	TRAF3IP2	0.41	6.75	0.3	4.54e-11	Blood metabolite levels;Amino acid levels;
LGG	cis	rs4731207	0.596	rs7786384	chr7:124577270	C/T	cg05630886	chr7:124431682	NA	-0.3	-6.92	-0.31	1.49e-11	Cutaneous malignant melanoma;
LGG	cis	rs5769765	0.865	rs3788730	chr22:50244695	C/T	cg02269571	chr22:50332266	NA	0.63	10.03	0.42	1.53e-21	Schizophrenia;
LGG	cis	rs3096299	0.685	rs4238830	chr16:89540241	C/T	cg05484508	chr16:89589025	SPG7	0.46	7.43	0.33	5.34e-13	Multiple myeloma (IgH translocation);
LGG	trans	rs2821260	0.902	rs12131816	chr1:72529866	A/G	cg20811730	chr1:150293902	PRPF3	0.58	6.67	0.3	7.41e-11	Intelligence (multi-trait analysis);
LGG	cis	rs10752881	0.875	rs10797825	chr1:183024581	G/A	cg07928641	chr1:182991847	LAMC1	0.48	9.84	0.42	7.16e-21	Colorectal cancer;
LGG	cis	rs9322193	0.961	rs9285521	chr6:149906712	T/G	cg04369109	chr6:150039330	LATS1	-0.41	-6.68	-0.3	6.9e-11	Lung cancer;
LGG	cis	rs3764563	0.935	rs646816	chr19:15695101	T/G	cg20725493	chr19:15740067	CYP4F8	0.57	6.79	0.3	3.52e-11	Inflammatory biomarkers;
LGG	cis	rs344364	0.511	rs2982453	chr16:1949520	G/A	cg00490583	chr16:1843685	IGFALS	-0.41	-6.99	-0.31	9.9e-12	Glomerular filtration rate in chronic kidney disease;
LGG	cis	rs9397585	0.857	rs1856296	chr6:153388815	T/A	cg17707550	chr6:153380415	RGS17	0.61	14.29	0.55	1.21e-38	Body mass index;
LGG	cis	rs796364	0.806	rs10931889	chr2:201101900	G/T	cg12253985	chr2:200820533	C2orf60;C2orf47	-0.69	-8.43	-0.36	4.36e-16	Schizophrenia;
LGG	cis	rs9611519	0.964	rs2092563	chr22:41592677	G/A	cg03806693	chr22:41940476	POLR3H	-0.55	-8.47	-0.37	3.4e-16	Neuroticism;
LGG	cis	rs6951245	1.000	rs80031817	chr7:1096793	T/C	cg24642844	chr7:1081250	C7orf50	-0.85	-14.27	-0.55	1.53e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs7737355	0.898	rs3775999	chr5:130970090	T/C	cg06307176	chr5:131281290	NA	0.58	9.3	0.4	5.67e-19	Life satisfaction;
LGG	cis	rs3785574	0.962	rs13030	chr17:61908556	C/T	cg07677032	chr17:61819896	STRADA	0.42	6.68	0.3	6.97e-11	Height;
LGG	cis	rs763014	0.931	rs3752568	chr16:628302	A/G	cg07343612	chr16:622815	PIGQ	-0.75	-15.25	-0.58	8.07e-43	Height;
LGG	cis	rs13132184	0.586	rs57074632	chr4:38014156	A/G	cg24826020	chr4:38070998	TBC1D1	0.45	6.67	0.3	7.18e-11	Verbal declarative memory;
LGG	cis	rs17102423	0.531	rs2763888	chr14:65571493	T/C	cg26396452	chr14:65542826	MAX	0.49	10.17	0.43	4.44e-22	Obesity-related traits;
LGG	cis	rs2860975	1.000	rs7899746	chr10:96787859	T/C	cg09036531	chr10:96991505	NA	-0.48	-8.67	-0.37	7.44e-17	Immune response to smallpox vaccine (IL-6);
LGG	trans	rs72991	0.711	rs10892741	chr11:121225319	G/C	cg27192990	chr6:129479024	LAMA2	-0.43	-7.16	-0.32	3.11e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs8067545	0.611	rs9893832	chr17:20038273	A/G	cg09818912	chr17:20140352	CYTSB	-0.32	-7.64	-0.33	1.26e-13	Schizophrenia;
LGG	cis	rs875971	0.520	rs160645	chr7:65556307	A/G	cg05627663	chr7:65219948	SNORA22;CCT6P1	-0.55	-10.04	-0.42	1.34e-21	Aortic root size;
LGG	cis	rs61931739	0.564	rs7304271	chr12:33757011	G/T	cg06521331	chr12:34319734	NA	-0.39	-6.83	-0.3	2.63e-11	Morning vs. evening chronotype;
LGG	cis	rs754466	0.580	rs12354903	chr10:79536465	T/C	cg17075019	chr10:79541650	NA	-0.99	-22.08	-0.72	2.54e-74	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs10504229	0.683	rs2318147	chr8:58114931	C/T	cg23782820	chr8:58130467	NA	0.5	7.17	0.32	3.08e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs1153858	1.000	rs9788780	chr15:45685487	T/A	cg05280133	chr15:45670068	GATM;LOC145663	0.43	7.93	0.35	1.71e-14	Homoarginine levels;
LGG	cis	rs3741151	0.773	rs73542979	chr11:73127526	G/C	cg17517138	chr11:73019481	ARHGEF17	0.86	8.57	0.37	1.58e-16	GIP levels in response to oral glucose tolerance test (120 minutes);
LGG	cis	rs9311474	0.607	rs2015971	chr3:52546820	C/T	cg18099408	chr3:52552593	STAB1	-0.37	-7.0	-0.31	9.06e-12	Electroencephalogram traits;
LGG	cis	rs17401966	0.931	rs12130563	chr1:10428452	G/A	cg15208524	chr1:10270712	KIF1B	0.45	7.76	0.34	5.3e-14	Hepatocellular carcinoma;
LGG	cis	rs9400467	0.537	rs12211045	chr6:111498116	C/T	cg15721981	chr6:111408429	SLC16A10	0.6	7.02	0.31	7.73e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs798554	0.679	rs2644300	chr7:2883071	G/A	cg19717773	chr7:2847554	GNA12	-0.32	-6.76	-0.3	4.05e-11	Height;
LGG	cis	rs12612619	0.579	rs11887277	chr2:27083269	A/G	cg12045002	chr2:27069975	DPYSL5	-0.31	-6.77	-0.3	3.88e-11	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;
LGG	cis	rs6952808	0.531	rs4721441	chr7:2184060	A/G	cg21782813	chr7:2030301	MAD1L1	0.45	10.98	0.45	4.42e-25	Bipolar disorder and schizophrenia;
LGG	cis	rs28386778	0.830	rs2597636	chr17:61876010	A/G	cg07362569	chr17:61921086	SMARCD2	0.51	9.89	0.42	4.91e-21	Prudent dietary pattern;
LGG	cis	rs9393692	0.645	rs6939048	chr6:26327953	G/A	cg00631329	chr6:26305371	NA	-0.55	-9.75	-0.41	1.49e-20	Educational attainment;
LGG	cis	rs9311474	0.575	rs4434138	chr3:52556890	A/G	cg18404041	chr3:52824283	ITIH1	-0.46	-8.28	-0.36	1.29e-15	Electroencephalogram traits;
LGG	cis	rs933688	1.000	rs10073935	chr5:90742188	A/G	cg26981201	chr5:90679533	LOC100129716;ARRDC3	1.15	20.17	0.68	2.17e-65	Smoking behavior;
LGG	cis	rs6598955	0.670	rs11247892	chr1:26592727	A/G	cg10402321	chr1:26617780	UBXN11	-0.36	-7.05	-0.31	6.7e-12	Obesity-related traits;
LGG	cis	rs9322193	0.962	rs7740784	chr6:150154500	C/T	cg00933542	chr6:150070202	PCMT1	0.38	6.8	0.3	3.17e-11	Lung cancer;
LGG	trans	rs6956675	0.915	rs7790432	chr7:62631824	T/C	cg01314568	chr7:57830625	NA	-0.48	-7.82	-0.34	3.49e-14	Obesity-related traits;
LGG	cis	rs372883	0.613	rs1153289	chr21:30686212	G/T	cg24692254	chr21:30365293	RNF160	-0.65	-11.83	-0.48	2.07e-28	Pancreatic cancer;
LGG	cis	rs12780845	0.540	rs11254413	chr10:17204187	G/A	cg01003015	chr10:17271136	VIM	0.43	7.26	0.32	1.69e-12	Homocysteine levels;
LGG	cis	rs6500395	1.000	rs55671623	chr16:48631154	A/G	cg04672837	chr16:48644449	N4BP1	0.57	9.33	0.4	4.53e-19	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7617773	0.780	rs71323396	chr3:48374734	T/G	cg11946769	chr3:48343235	NME6	0.71	11.73	0.48	5.53e-28	Coronary artery disease;
LGG	cis	rs4862750	0.914	rs1991255	chr4:187875340	G/A	cg22105103	chr4:187893119	NA	0.57	10.88	0.45	1.04e-24	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs6466055	0.669	rs1142	chr7:104756326	C/T	cg04380332	chr7:105027541	SRPK2	-0.37	-7.07	-0.31	5.86e-12	Schizophrenia;
LGG	cis	rs2070433	0.500	rs2070435	chr21:47961711	C/T	cg12379764	chr21:47803548	PCNT	0.66	11.2	0.46	6.35e-26	Lymphocyte counts;
LGG	cis	rs9660992	0.573	rs1172139	chr1:205213962	G/A	cg00857998	chr1:205179979	DSTYK	0.5	7.91	0.35	1.87e-14	Mean corpuscular volume;Mean platelet volume;
LGG	cis	rs7166081	1.000	rs8038652	chr15:67552064	G/A	cg24231037	chr15:68117551	LBXCOR1	-0.31	-6.94	-0.31	1.34e-11	Waist circumference adjusted for BMI (adjusted for smoking behaviour);Waist circumference adjusted for BMI in non-smokers;Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI (joint analysis main effects and smoking interaction);
LGG	cis	rs736408	0.507	rs6445531	chr3:52717282	T/C	cg10802521	chr3:52805072	NEK4	-0.42	-7.36	-0.32	8.28e-13	Bipolar disorder;
LGG	cis	rs1570884	0.556	rs2146146	chr13:50170368	C/T	cg08779649	chr13:50194554	NA	0.36	9.11	0.39	2.48e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs2280630	0.529	rs6599010	chr3:39153222	C/T	cg01426195	chr3:39028469	NA	-0.7	-15.2	-0.58	1.32e-42	Verbal declarative memory;
LGG	trans	rs61931739	0.534	rs11053000	chr12:34079022	C/T	cg26384229	chr12:38710491	ALG10B	0.8	15.82	0.59	2.26e-45	Morning vs. evening chronotype;
LGG	cis	rs4740619	0.544	rs7857495	chr9:15813851	T/G	cg14451791	chr9:16040625	NA	0.32	7.86	0.34	2.81e-14	Body mass index;
LGG	cis	rs1577917	0.771	rs2842613	chr6:86305702	A/G	cg20289299	chr6:86388069	SNHG5;SNORD50B;SNORD50A	0.68	12.02	0.49	3.59e-29	Response to antipsychotic treatment;
LGG	cis	rs28386778	0.897	rs4968598	chr17:61835579	T/C	cg07659893	chr17:61819838	STRADA	0.48	7.98	0.35	1.16e-14	Prudent dietary pattern;
LGG	cis	rs6719977	0.510	rs1971138	chr2:42969270	C/T	cg14631114	chr2:43023945	NA	0.45	9.34	0.4	4.22e-19	Hyperactive-impulsive symptoms;
LGG	cis	rs17209837	0.607	rs2888611	chr7:87103670	C/G	cg00919237	chr7:87102261	ABCB4	0.79	16.06	0.6	1.89e-46	Gallbladder cancer;
LGG	cis	rs654384	0.510	rs60440642	chr7:4167947	T/C	cg04612959	chr7:4183976	SDK1	-0.34	-7.47	-0.33	4.14e-13	Positive affect;
LGG	cis	rs2153535	0.580	rs9505455	chr6:8478622	A/G	cg21535247	chr6:8435926	SLC35B3	0.59	10.14	0.43	5.9e-22	Motion sickness;
LGG	cis	rs11229555	0.645	rs12797488	chr11:58174653	A/T	cg15696309	chr11:58395628	NA	-0.96	-15.34	-0.58	3.16e-43	Ulcerative colitis;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11155671	0.530	rs9383940	chr6:150226059	T/G	cg09217309	chr6:150244204	RAET1G	0.47	8.52	0.37	2.3e-16	Testicular germ cell tumor;
LGG	cis	rs7246657	1.000	rs7246657	chr19:37747108	C/T	cg06328724	chr19:37958752	ZNF570;ZNF569	0.53	7.77	0.34	4.99e-14	Coronary artery calcification;
LGG	cis	rs7618501	1.000	rs3749241	chr3:49744392	A/G	cg24110177	chr3:50126178	RBM5	0.4	6.82	0.3	2.92e-11	Intelligence (multi-trait analysis);
LGG	cis	rs17453880	0.929	rs6859908	chr5:152049109	G/A	cg10931792	chr5:152022470	NA	0.41	8.82	0.38	2.29e-17	Subjective well-being;
LGG	cis	rs7143963	0.697	rs2273393	chr14:103357603	G/T	cg23020514	chr14:103360112	TRAF3	0.41	8.45	0.37	3.82e-16	Body mass index;
LGG	cis	rs926938	0.584	rs6689326	chr1:115369112	T/A	cg12756093	chr1:115239321	AMPD1	-0.48	-8.94	-0.38	9.07e-18	Autism;
LGG	cis	rs2842992	0.915	rs2758350	chr6:160118056	A/G	cg16489826	chr6:160211363	TCP1;MRPL18	0.68	11.32	0.47	2.17e-26	Age-related macular degeneration (geographic atrophy);
LGG	cis	rs597539	0.652	rs627731	chr11:68698663	A/C	cg04008888	chr11:68622739	NA	-0.55	-11.81	-0.48	2.45e-28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs17270561	0.608	rs4711102	chr6:25742075	T/C	cg12310025	chr6:25882481	NA	-0.44	-7.23	-0.32	2e-12	Iron status biomarkers;
LGG	cis	rs1008375	1.000	rs55939327	chr4:17642937	T/A	cg04450456	chr4:17643702	FAM184B	0.33	7.48	0.33	3.67e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	trans	rs10506458	0.915	rs60094497	chr12:63394838	T/G	cg22491629	chr6:157744540	C6orf35	-0.97	-13.41	-0.53	7.38e-35	Hemostatic factors and hematological phenotypes;
LGG	trans	rs783540	0.967	rs783523	chr15:83283555	A/G	cg16105309	chr15:79090380	ADAMTS7	-0.42	-7.53	-0.33	2.75e-13	Schizophrenia;
LGG	cis	rs7618915	0.571	rs1961959	chr3:52585760	G/C	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.52	8.55	0.37	1.75e-16	Bipolar disorder;
LGG	cis	rs4731207	0.698	rs7795492	chr7:124524131	C/T	cg05630886	chr7:124431682	NA	-0.32	-7.66	-0.34	1.12e-13	Cutaneous malignant melanoma;
LGG	cis	rs7811142	0.943	rs111493473	chr7:100049742	A/G	cg13153964	chr7:100026424	MEPCE;ZCWPW1	1.19	21.04	0.7	1.91e-69	Platelet count;
LGG	cis	rs12519773	0.526	rs4551051	chr5:92518724	T/C	cg18783429	chr5:92414398	NA	0.32	7.7	0.34	8.55e-14	Migraine;
LGG	trans	rs2727020	0.658	rs7111215	chr11:49430552	T/C	cg11707556	chr5:10655725	ANKRD33B	-0.56	-11.04	-0.46	2.49e-25	Coronary artery disease;
LGG	trans	rs7939886	0.920	rs78674679	chr11:56070898	A/G	cg15704280	chr7:45808275	SEPT13	0.81	7.37	0.32	8.08e-13	Myopia (pathological);
LGG	cis	rs11792861	0.926	rs76689835	chr9:111833792	G/A	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.55	0.41	7.29e-20	Menarche (age at onset);
LGG	trans	rs2018683	0.649	rs12536605	chr7:28970500	C/T	cg19402173	chr7:128379420	CALU	-0.53	-9.26	-0.4	7.5e-19	Response to irinotecan and platinum-based chemotherapy in non-small-cell lung cancer;
LGG	cis	rs17102423	0.651	rs2296316	chr14:65520246	A/G	cg11161011	chr14:65562177	MAX	-0.49	-8.88	-0.38	1.51e-17	Obesity-related traits;
LGG	cis	rs4332037	0.539	rs11764780	chr7:2020904	G/C	cg23422044	chr7:1970798	MAD1L1	-0.66	-11.36	-0.47	1.53e-26	Bipolar disorder;
LGG	cis	rs9303401	0.703	rs8072182	chr17:57211213	G/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.52	8.85	0.38	1.82e-17	Cognitive test performance;
LGG	cis	rs6952808	0.964	rs10950400	chr7:1882470	C/T	cg14004847	chr7:1930337	MAD1L1	-0.53	-8.68	-0.37	6.86e-17	Bipolar disorder and schizophrenia;
LGG	cis	rs546131	0.928	rs546521	chr11:34824773	G/C	cg06937548	chr11:34938143	PDHX;APIP	0.61	10.86	0.45	1.22e-24	Lung disease severity in cystic fibrosis;
LGG	cis	rs6952808	0.707	rs13244345	chr7:1973004	A/G	cg14004847	chr7:1930337	MAD1L1	-0.54	-9.26	-0.4	7.37e-19	Bipolar disorder and schizophrenia;
LGG	cis	rs1062746	1.000	rs1062746	chr16:87364650	A/G	cg02258303	chr16:87377426	FBXO31	-0.55	-10.74	-0.45	3.54e-24	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 2 peripheral neuropathy);
LGG	cis	rs804280	0.509	rs35626932	chr8:11786932	C/A	cg12395012	chr8:11607386	GATA4	-0.43	-7.73	-0.34	6.89e-14	Myopia (pathological);
LGG	cis	rs798554	0.679	rs2266922	chr7:2824707	G/A	cg27476859	chr7:2772710	GNA12	0.52	10.35	0.43	1.01e-22	Height;
LGG	trans	rs944961	0.782	rs7036147	chr9:122589164	A/G	cg21273125	chr15:89631790	ABHD2	-0.39	-6.72	-0.3	5.24e-11	Liver disease severity in Alagille syndrome;
LGG	cis	rs7618915	0.524	rs10433615	chr3:52638482	C/T	cg11041457	chr3:52719354	GNL3;PBRM1	0.56	9.59	0.41	5.39e-20	Bipolar disorder;
LGG	cis	rs7555523	0.830	rs12691500	chr1:165687761	A/G	cg24409356	chr1:165738333	TMCO1	0.71	8.69	0.37	6.32e-17	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs61990749	0.597	rs3783980	chr14:78219807	T/C	cg02301378	chr14:78227641	SNW1;C14orf178	0.57	7.02	0.31	7.73e-12	Fibroblast growth factor basic levels;
LGG	cis	rs72945132	0.882	rs11235739	chr11:70132780	C/T	cg14191688	chr11:70257035	CTTN	0.54	7.88	0.34	2.32e-14	Coronary artery disease;
LGG	cis	rs7659604	0.702	rs58649165	chr4:122693752	C/A	cg20573242	chr4:122745356	CCNA2	0.51	9.29	0.4	6.23e-19	Type 2 diabetes;
LGG	cis	rs72781680	1.000	rs7355559	chr2:24256946	G/T	cg08917208	chr2:24149416	ATAD2B	-0.8	-8.67	-0.37	7.25e-17	Lymphocyte counts;
LGG	cis	rs721399	1.000	rs1495745	chr8:18262723	T/G	cg18736775	chr8:18248649	NAT2	0.49	8.58	0.37	1.45e-16	Blood metabolite levels;
LGG	cis	rs67478160	0.704	rs12894254	chr14:104290949	G/C	cg26031613	chr14:104095156	KLC1	-0.45	-7.54	-0.33	2.55e-13	Schizophrenia;
LGG	cis	rs1355223	0.902	rs1258470	chr11:34729265	A/G	cg11058730	chr11:34937778	PDHX;APIP	0.41	6.89	0.31	1.79e-11	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs12220238	0.722	rs10509350	chr10:76383071	A/C	cg19889307	chr10:75911429	ADK;AP3M1	-0.51	-6.82	-0.3	2.89e-11	Soluble interleukin-2 receptor subunit alpha;
LGG	cis	rs936229	0.813	rs1378938	chr15:75096443	T/C	cg10253484	chr15:75165896	SCAMP2	-0.65	-9.72	-0.41	1.9e-20	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	cis	rs597539	0.652	rs611046	chr11:68631704	A/G	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.84	15.8	0.59	2.79e-45	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs10267417	0.603	rs10273239	chr7:19911524	T/C	cg05791153	chr7:19748676	TWISTNB	0.57	7.54	0.33	2.54e-13	Night sleep phenotypes;
LGG	cis	rs3749237	1.000	rs6804655	chr3:49738945	C/T	cg02487422	chr3:49467188	NICN1	0.42	6.82	0.3	2.82e-11	Resting heart rate;
LGG	cis	rs4332037	0.539	rs11762636	chr7:2061111	C/A	cg02825527	chr7:2087843	MAD1L1	-0.45	-8.11	-0.35	4.68e-15	Bipolar disorder;
LGG	cis	rs2576037	0.526	rs626217	chr18:44429182	T/G	cg07416455	chr18:44543612	TCEB3CL;KATNAL2	-0.63	-11.56	-0.47	2.52e-27	Personality dimensions;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg11028747	chr7:102104916	LRWD1;ALKBH4	0.4	6.69	0.3	6.4e-11	Gut microbiota (bacterial taxa);
LGG	cis	rs28386778	0.897	rs4968597	chr17:61805747	G/A	cg01411255	chr17:61851458	DDX42;CCDC47	0.59	10.42	0.44	5.43e-23	Prudent dietary pattern;
LGG	trans	rs8129326	0.718	rs2834481	chr21:35795370	C/T	cg07474852	chr4:123073612	NA	0.48	8.58	0.37	1.42e-16	Cancer;
LGG	cis	rs300703	0.816	rs434818	chr2:200477	G/A	cg24565620	chr2:194026	NA	-0.7	-9.3	-0.4	5.72e-19	Blood protein levels;
LGG	cis	rs10752881	0.743	rs10737244	chr1:183098417	G/A	ch.1.3577855R	chr1:183094577	LAMC1	0.45	9.04	0.39	4.38e-18	Colorectal cancer;
LGG	trans	rs55986470	0.759	rs66636130	chr2:239405748	G/A	cg01134436	chr17:81009848	B3GNTL1	0.8	8.56	0.37	1.72e-16	Chronotype;
LGG	cis	rs9677476	0.779	rs10177091	chr2:232109889	C/T	cg23338755	chr2:231921595	PSMD1	0.49	6.74	0.3	4.64e-11	Food antigen IgG levels;
LGG	trans	rs73198271	0.632	rs570396	chr8:8593652	A/G	cg16141378	chr3:129829833	LOC729375	0.34	6.86	0.3	2.28e-11	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs28595532	0.920	rs115226628	chr4:119639818	A/G	cg21605333	chr4:119757512	SEC24D	1.36	13.12	0.52	1.18e-33	Cannabis dependence symptom count;
LGG	cis	rs11148252	0.766	rs74697307	chr13:52897573	C/T	cg00495681	chr13:53174319	NA	-0.6	-11.25	-0.46	3.93e-26	Lewy body disease;
LGG	cis	rs752010	0.714	rs6664708	chr1:42083070	G/A	cg06885757	chr1:42089581	HIVEP3	0.58	13.66	0.54	6.07e-36	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs1218582	0.741	rs10908444	chr1:154840287	G/A	cg24250549	chr1:154909240	PMVK	0.75	15.44	0.58	1.12e-43	Prostate cancer;
LGG	cis	rs72627123	0.500	rs68148895	chr14:74529523	C/T	cg05179529	chr14:74551516	LIN52;ALDH6A1	0.49	6.73	0.3	5.08e-11	Morning vs. evening chronotype;
LGG	cis	rs11018904	0.906	rs10501713	chr11:89953013	G/A	cg27158573	chr11:89632121	NA	-0.41	-7.3	-0.32	1.23e-12	Intelligence (multi-trait analysis);
LGG	cis	rs2692947	0.770	rs6719831	chr2:96502590	A/C	cg22654517	chr2:96458247	NA	0.36	7.59	0.33	1.73e-13	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs7638909	0.512	rs11720166	chr3:38599812	C/G	cg01465620	chr3:38496096	LOC100128640;ACVR2B	-0.46	-7.74	-0.34	6.27e-14	Electrocardiographic conduction measures;
LGG	cis	rs9894429	1.000	rs7503679	chr17:79583843	G/C	cg18240062	chr17:79603768	NPLOC4	0.75	13.86	0.54	8.31e-37	Eye color traits;
LGG	cis	rs36051895	0.626	rs10283563	chr9:5075603	C/T	cg02405213	chr9:5042618	JAK2	-0.83	-15.74	-0.59	5.1e-45	Pediatric autoimmune diseases;
LGG	cis	rs2204008	0.807	rs10880234	chr12:38318353	C/T	cg26384229	chr12:38710491	ALG10B	0.92	19.69	0.68	3.83e-63	Bladder cancer;
LGG	cis	rs10949834	0.824	rs13236108	chr7:73521113	A/G	cg07137043	chr7:73588983	EIF4H	-0.59	-7.15	-0.32	3.44e-12	Verbal memory performance (residualized delayed recall change);
LGG	cis	rs1355223	0.583	rs2941044	chr11:34867444	A/C	cg11058730	chr11:34937778	PDHX;APIP	0.78	15.02	0.57	8.03e-42	Systemic lupus erythematosus and Systemic sclerosis;
LGG	cis	rs6500395	1.000	rs4785247	chr16:48687732	A/C	cg16662043	chr16:48846231	NA	-0.36	-7.15	-0.32	3.45e-12	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9291683	0.551	rs2240720	chr4:10020480	C/T	cg00071950	chr4:10020882	SLC2A9	0.45	9.47	0.4	1.41e-19	Bone mineral density;
LGG	cis	rs3858526	0.584	rs10734560	chr11:5864503	G/T	cg13902645	chr11:5959945	NA	-0.68	-11.43	-0.47	7.78e-27	DNA methylation (variation);
LGG	trans	rs7824557	0.603	rs2250028	chr8:11213589	T/G	cg08975724	chr8:8085496	FLJ10661	0.42	7.7	0.34	8.25e-14	Retinal vascular caliber;
LGG	cis	rs4740619	0.617	rs7873925	chr9:16027483	C/T	cg14451791	chr9:16040625	NA	-0.42	-11.12	-0.46	1.23e-25	Body mass index;
LGG	cis	rs13191362	1.000	rs34725898	chr6:163127302	C/T	cg18825119	chr6:163149453	PACRG;PARK2	0.47	6.86	0.3	2.28e-11	Body mass index;BMI in non-smokers;Body mass index (joint analysis main effects and physical activity interaction);BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and smoking interaction);
LGG	cis	rs2832077	0.943	rs11701777	chr21:30155828	T/C	cg24692254	chr21:30365293	RNF160	-0.56	-8.37	-0.36	6.93e-16	Cognitive test performance;
LGG	cis	rs7264396	0.747	rs2425151	chr20:34394541	C/T	cg04508476	chr20:34239394	CPNE1;RBM12	-0.43	-7.44	-0.33	4.96e-13	Total cholesterol levels;
LGG	cis	rs10876993	0.890	rs12302351	chr12:58062590	T/C	cg18357645	chr12:58087776	OS9	0.67	11.93	0.48	8.75e-29	Celiac disease or Rheumatoid arthritis;
LGG	cis	rs4147929	0.625	rs4147934	chr19:1065018	G/T	cg12082025	chr19:1064218	ABCA7	-0.47	-7.22	-0.32	2.08e-12	Alzheimer's disease (late onset);
LGG	cis	rs28595532	0.920	rs55649377	chr4:119752745	T/A	cg11846333	chr4:119757529	SEC24D	0.86	7.87	0.34	2.62e-14	Cannabis dependence symptom count;
LGG	cis	rs58649573	0.509	rs2055032	chr9:126789506	A/G	cg14112217	chr9:126806003	NA	0.39	7.68	0.34	9.31e-14	Post-traumatic stress disorder;
LGG	cis	rs2798269	0.586	rs1199949	chr13:22076091	T/C	cg18095732	chr13:22033692	ZDHHC20	-0.48	-8.6	-0.37	1.27e-16	PR segment;
LGG	cis	rs72781680	0.898	rs72798049	chr2:23958002	C/G	cg08917208	chr2:24149416	ATAD2B	0.79	9.01	0.39	5.52e-18	Lymphocyte counts;
LGG	cis	rs17376456	0.877	rs10055340	chr5:93317644	T/C	cg19507638	chr5:93509721	C5orf36	-0.68	-9.6	-0.41	5.12e-20	Diabetic retinopathy;
LGG	cis	rs4253772	0.591	rs6007747	chr22:46657261	A/G	cg24881330	chr22:46731750	TRMU	0.68	8.41	0.36	5.18e-16	LDL cholesterol;Cholesterol, total;
LGG	cis	rs11169552	0.510	rs10876070	chr12:51002088	A/C	cg12884762	chr12:50931848	DIP2B	-0.41	-7.72	-0.34	7.25e-14	Colorectal cancer;
LGG	cis	rs12210905	0.800	rs12201890	chr6:26662626	A/C	cg23155468	chr6:27110703	HIST1H2BK	-0.65	-8.15	-0.35	3.31e-15	Hip circumference adjusted for BMI;
LGG	cis	rs1927790	0.759	rs12585563	chr13:96991847	A/G	cg02571835	chr13:96230311	CLDN10	-0.34	-6.94	-0.31	1.33e-11	Body mass index;
LGG	cis	rs755249	0.567	rs72661961	chr1:39831768	A/G	cg18385671	chr1:39797026	MACF1	0.43	7.41	0.33	6.19e-13	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs28386778	0.966	rs2008053	chr17:61954918	G/C	cg07659893	chr17:61819838	STRADA	0.47	7.81	0.34	3.91e-14	Prudent dietary pattern;
LGG	cis	rs11252926	0.583	rs2066317	chr10:520309	C/T	cg18196295	chr10:418757	DIP2C	0.53	10.05	0.42	1.26e-21	Psychosis in Alzheimer's disease;
LGG	cis	rs7937682	0.562	rs630002	chr11:111377758	G/A	cg09085632	chr11:111637200	PPP2R1B	-0.75	-13.48	-0.53	3.69e-35	Primary sclerosing cholangitis;
LGG	cis	rs9325144	0.647	rs61937754	chr12:39060543	T/C	cg26384229	chr12:38710491	ALG10B	-0.73	-13.96	-0.54	3.24e-37	Morning vs. evening chronotype;
LGG	cis	rs28595532	0.920	rs115271785	chr4:119735748	A/T	cg14228332	chr4:119757509	SEC24D	1.01	10.3	0.43	1.59e-22	Cannabis dependence symptom count;
LGG	cis	rs9322193	0.607	rs7764677	chr6:150227333	C/T	cg09699651	chr6:150184138	LRP11	0.45	6.83	0.3	2.68e-11	Lung cancer;
LGG	cis	rs9302635	0.513	rs8061282	chr16:72155938	C/T	cg23815491	chr16:72088622	HP	0.51	9.55	0.41	7.79e-20	Blood protein levels;
LGG	cis	rs8016982	0.657	rs8021125	chr14:81704787	C/T	cg01989461	chr14:81687754	GTF2A1	-0.77	-18.14	-0.64	5.7e-56	Schizophrenia;
LGG	cis	rs13108904	0.901	rs4493484	chr4:1279944	G/A	cg00689492	chr4:1303491	MAEA	0.5	8.5	0.37	2.68e-16	Obesity-related traits;
LGG	cis	rs7208859	0.623	rs7223404	chr17:29107363	C/T	cg13385521	chr17:29058706	SUZ12P	0.92	10.83	0.45	1.58e-24	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7826238	0.509	rs2948288	chr8:8115304	A/G	cg06636001	chr8:8085503	FLJ10661	0.71	14.95	0.57	1.67e-41	Systolic blood pressure;
LGG	cis	rs7223966	1.000	rs7223966	chr17:61893398	G/A	cg25654072	chr17:61904446	PSMC5;FTSJ3	0.43	7.28	0.32	1.4e-12	Hip circumference adjusted for BMI;Body mass index;
LGG	cis	rs875971	0.862	rs1167390	chr7:65575893	G/A	cg18876405	chr7:65276391	NA	-0.54	-9.6	-0.41	5.03e-20	Aortic root size;
LGG	cis	rs62244186	0.627	rs12386385	chr3:44457540	A/G	cg02073558	chr3:44770973	ZNF501	0.66	11.87	0.48	1.48e-28	Depressive symptoms;
LGG	trans	rs7819412	0.643	rs7829396	chr8:10999583	C/T	cg06636001	chr8:8085503	FLJ10661	-0.48	-8.3	-0.36	1.18e-15	Triglycerides;
LGG	cis	rs2221894	0.506	rs11778263	chr8:28825422	C/G	cg07962641	chr8:28805897	HMBOX1	0.55	8.23	0.36	1.92e-15	Obesity-related traits;
LGG	cis	rs2836974	0.590	rs9974757	chr21:40617244	T/C	cg06238570	chr21:40685208	BRWD1	-0.52	-8.66	-0.37	7.87e-17	Cognitive function;
LGG	cis	rs4957048	0.577	rs56294732	chr5:568144	T/C	cg07777115	chr5:623756	CEP72	-0.51	-6.72	-0.3	5.48e-11	Ulcerative colitis;
LGG	cis	rs113835537	0.529	rs11227515	chr11:66287383	C/T	cg24851651	chr11:66362959	CCS	0.45	7.76	0.34	5.33e-14	Airway imaging phenotypes;
LGG	cis	rs6868223	1.000	rs6862356	chr5:33635634	C/T	cg10594543	chr5:33649717	ADAMTS12	0.55	12.0	0.49	4.31e-29	Mortality in heart failure;
LGG	cis	rs1218582	0.651	rs4845396	chr1:154828409	A/G	cg06221963	chr1:154839813	KCNN3	0.36	6.98	0.31	1.02e-11	Prostate cancer;
LGG	cis	rs882300	0.903	rs12472432	chr2:136919236	T/C	cg07169764	chr2:136633963	MCM6	0.46	7.64	0.33	1.24e-13	Multiple sclerosis;Electrocardiographic traits;
LGG	cis	rs854765	0.583	rs4077198	chr17:17834563	T/C	cg04398451	chr17:18023971	MYO15A	-0.6	-12.07	-0.49	2.45e-29	Total body bone mineral density;
LGG	cis	rs3849046	0.846	rs256006	chr5:137897094	A/G	cg10920316	chr5:137946599	NA	0.47	7.65	0.33	1.19e-13	Schizophrenia;Autism spectrum disorder or schizophrenia;
LGG	cis	rs73001065	1.000	rs56255430	chr19:19477877	A/C	cg03709012	chr19:19516395	GATAD2A	0.9	7.74	0.34	6.16e-14	LDL cholesterol;
LGG	cis	rs826838	1.000	rs1719830	chr12:39096992	T/G	cg13010199	chr12:38710504	ALG10B	-0.61	-13.04	-0.52	2.55e-33	Heart rate;
LGG	cis	rs4689592	0.503	rs2292461	chr4:7058473	C/T	cg19539972	chr4:7069911	GRPEL1	0.73	9.91	0.42	3.89e-21	Monocyte percentage of white cells;
LGG	cis	rs6951245	0.935	rs79067319	chr7:1065548	C/T	cg21664854	chr7:1097933	C7orf50;GPR146	0.95	14.25	0.55	1.91e-38	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs11931598	0.783	rs28385900	chr4:7050836	C/T	cg26116260	chr4:7069785	GRPEL1	0.54	9.53	0.4	8.96e-20	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Granulocyte count;Neutrophil count;Myeloid white cell count;
LGG	cis	rs7647973	1.000	rs62259944	chr3:49430883	G/A	cg06212747	chr3:49208901	KLHDC8B	-0.53	-8.01	-0.35	9.39e-15	Menarche (age at onset);
LGG	cis	rs283228	1.000	rs2787575	chr6:101825991	C/G	cg27451362	chr6:101846650	GRIK2	0.53	9.02	0.39	4.83e-18	Coenzyme Q10 levels;
LGG	cis	rs28595532	0.546	rs36058627	chr4:119233201	G/T	cg21605333	chr4:119757512	SEC24D	0.87	9.34	0.4	3.97e-19	Cannabis dependence symptom count;
LGG	cis	rs561341	0.941	rs72825736	chr17:30330286	G/A	cg12193833	chr17:30244370	NA	-0.28	-6.87	-0.3	2.11e-11	Hip circumference adjusted for BMI;
LGG	trans	rs7824557	0.545	rs2572380	chr8:11237477	A/G	cg02002194	chr4:3960332	NA	0.43	7.8	0.34	4e-14	Retinal vascular caliber;
LGG	cis	rs7824557	0.564	rs2736290	chr8:11234298	C/T	cg15596359	chr8:11213517	TDH	0.42	8.73	0.38	4.79e-17	Retinal vascular caliber;
LGG	trans	rs11992162	0.550	rs61426048	chr8:11784956	A/G	cg16141378	chr3:129829833	LOC729375	0.33	7.38	0.32	7.31e-13	Monocyte count;
LGG	cis	rs1005277	0.505	rs7099777	chr10:38183569	A/C	cg18963800	chr10:38644991	HSD17B7P2	0.41	6.83	0.3	2.61e-11	Extrinsic epigenetic age acceleration;
LGG	cis	rs7188861	0.813	rs2867937	chr16:11398798	A/T	cg01510278	chr16:11456238	NA	0.31	7.38	0.32	7.57e-13	HDL cholesterol;
LGG	cis	rs7172689	0.529	rs17875492	chr15:81587086	A/C	cg11808699	chr15:81528661	IL16	-0.46	-6.84	-0.3	2.49e-11	Inattentive symptoms;
LGG	trans	rs4927850	0.709	rs6783079	chr3:195652708	T/C	cg16724585	chr3:197361211	NA	-0.47	-7.66	-0.34	1.13e-13	Pancreatic cancer;
LGG	cis	rs950776	0.518	rs12916999	chr15:78826912	C/T	cg16751781	chr15:78858589	CHRNA5	0.47	9.32	0.4	4.88e-19	Sudden cardiac arrest;
LGG	cis	rs13118159	0.509	rs7688922	chr4:1361011	T/C	cg20743744	chr4:1243849	C4orf42;CTBP1	0.41	6.79	0.3	3.54e-11	Longevity;
LGG	cis	rs4951018	0.821	rs7529037	chr1:205637501	C/G	cg14159672	chr1:205819179	PM20D1	-0.37	-7.16	-0.32	3.13e-12	Prostate-specific antigen levels;
LGG	cis	rs9788682	0.748	rs667282	chr15:78863472	T/C	cg24631222	chr15:78858424	CHRNA5	0.43	6.87	0.3	2.07e-11	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs7914558	1.000	rs7071373	chr10:104771922	A/G	cg04362960	chr10:104952993	NT5C2	0.53	10.18	0.43	4.2e-22	Schizophrenia;Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);
LGG	trans	rs11875185	0.510	rs79983088	chr18:55628960	C/T	cg15513957	chr14:69354734	ACTN1	-0.92	-9.21	-0.39	1.17e-18	Antineutrophil cytoplasmic antibody-associated vasculitis;
LGG	cis	rs12421382	0.659	rs1837397	chr11:109389803	A/C	cg06719900	chr11:109292894	C11orf87	0.45	8.35	0.36	7.84e-16	Schizophrenia;
LGG	cis	rs12410462	0.591	rs2814060	chr1:227722228	A/G	cg04117972	chr1:227635322	NA	0.47	8.59	0.37	1.38e-16	Major depressive disorder;
LGG	cis	rs8017423	0.904	rs11159963	chr14:90805358	C/T	cg04374321	chr14:90722782	PSMC1	-0.86	-16.72	-0.61	1.89e-49	Mortality in heart failure;
LGG	cis	rs977987	0.931	rs11641430	chr16:75495276	T/C	cg03315344	chr16:75512273	CHST6	0.59	11.83	0.48	2.14e-28	Dupuytren's disease;
LGG	cis	rs7100689	0.646	rs4357632	chr10:82131783	C/T	cg01528321	chr10:82214614	TSPAN14	0.85	15.01	0.57	9.08e-42	Post bronchodilator FEV1;
LGG	cis	rs651907	0.535	rs34648996	chr3:101511202	A/G	cg23548719	chr3:101395035	LOC100009676;ZBTB11	0.5	8.15	0.35	3.31e-15	Colorectal cancer;
LGG	cis	rs5015933	1.000	rs10760395	chr9:128131861	G/A	cg14078157	chr9:128172775	NA	-0.36	-6.81	-0.3	3.02e-11	Body mass index;
LGG	cis	rs13118159	0.550	rs28614045	chr4:1374695	C/A	cg16405210	chr4:1374714	KIAA1530	-0.85	-16.12	-0.6	9.86e-47	Longevity;
LGG	cis	rs8177253	0.763	rs12769	chr3:133474328	G/A	cg16414030	chr3:133502952	NA	-0.54	-8.72	-0.38	4.89e-17	Iron status biomarkers;
LGG	cis	rs7312933	0.531	rs2708059	chr12:42851008	C/T	cg19980929	chr12:42632907	YAF2	-0.35	-7.95	-0.35	1.48e-14	Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);
LGG	cis	rs7666738	0.830	rs28456179	chr4:98991439	A/G	cg05340658	chr4:99064831	C4orf37	0.5	8.35	0.36	7.88e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs7666738	0.830	rs28587201	chr4:98991733	C/T	cg05340658	chr4:99064831	C4orf37	0.5	8.29	0.36	1.27e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs9814567	1.000	rs3846055	chr3:134203973	T/A	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.71	-12.61	-0.51	1.52e-31	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs9858542	0.537	rs67882627	chr3:49380441	A/T	cg00383909	chr3:49044727	WDR6	0.57	8.18	0.36	2.69e-15	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs9326248	0.559	rs1269329	chr11:116755041	T/C	cg01368799	chr11:117014884	PAFAH1B2	0.61	10.61	0.44	1.09e-23	Blood protein levels;
LGG	cis	rs2486288	0.656	rs11632777	chr15:45551045	C/T	cg15395560	chr15:45543142	SLC28A2	0.41	6.72	0.3	5.51e-11	Glomerular filtration rate;
LGG	cis	rs11155671	0.530	rs9968871	chr6:150209196	G/A	cg05861140	chr6:150128134	PCMT1	-0.32	-7.19	-0.32	2.61e-12	Testicular germ cell tumor;
LGG	cis	rs2228479	1.000	rs11642267	chr16:89957635	T/C	cg04287289	chr16:89883240	FANCA	0.77	7.55	0.33	2.39e-13	Skin colour saturation;
LGG	cis	rs3749237	0.595	rs1464568	chr3:49458266	G/A	cg02487422	chr3:49467188	NICN1	0.57	10.55	0.44	1.89e-23	Resting heart rate;
LGG	cis	rs490234	0.812	rs4838284	chr9:128446365	G/T	cg14078157	chr9:128172775	NA	-0.42	-7.15	-0.32	3.49e-12	Mean arterial pressure;
LGG	trans	rs9657904	0.950	rs7619449	chr3:105567228	C/T	cg14088669	chr1:158435396	OR10K1	-0.39	-6.76	-0.3	4.05e-11	Multiple sclerosis;
LGG	cis	rs4689388	0.816	rs13147655	chr4:6293474	A/G	cg14416269	chr4:6271139	WFS1	0.51	9.34	0.4	4.12e-19	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg25365794	chr17:8022404	ALOXE3	0.54	8.51	0.37	2.36e-16	Gut microbiome composition (summer);
LGG	cis	rs283228	0.617	rs697440	chr6:101734184	C/T	cg27451362	chr6:101846650	GRIK2	-0.83	-12.98	-0.52	4.43e-33	Coenzyme Q10 levels;
LGG	cis	rs57221529	0.766	rs17563576	chr5:560476	A/G	cg07777115	chr5:623756	CEP72	-0.57	-7.17	-0.32	3.04e-12	Lung disease severity in cystic fibrosis;
LGG	cis	rs367943	0.672	rs6594712	chr5:112715211	T/G	cg12552261	chr5:112820674	MCC	0.57	10.43	0.44	5.2e-23	Type 2 diabetes;
LGG	cis	rs6500602	0.682	rs3761679	chr16:4457907	C/G	cg02048412	chr16:4421654	VASN;CORO7	0.27	6.77	0.3	3.92e-11	Schizophrenia;
LGG	cis	rs972578	0.791	rs7290497	chr22:43324565	G/A	cg01576275	chr22:43409880	NA	-0.23	-6.91	-0.31	1.64e-11	Mean platelet volume;
LGG	cis	rs2120019	1.000	rs34237279	chr15:75361121	A/G	cg09165964	chr15:75287851	SCAMP5	-1.0	-19.95	-0.68	2.24e-64	Blood trace element (Zn levels);
LGG	cis	rs870825	0.655	rs10013685	chr4:185617785	C/T	cg04058563	chr4:185651563	MLF1IP	1.03	22.71	0.73	2.88e-77	Blood protein levels;
LGG	cis	rs67311347	1.000	rs1123019	chr3:40488280	C/T	cg13683864	chr3:40499215	RPL14	-1.13	-26.58	-0.78	3.22e-95	Renal cell carcinoma;
LGG	cis	rs1949733	0.917	rs10461079	chr4:8392724	G/A	cg11789530	chr4:8429930	ACOX3	-0.87	-16.8	-0.62	8.3e-50	Response to antineoplastic agents;
LGG	cis	rs7618915	0.571	rs6798246	chr3:52599922	G/A	cg14092988	chr3:52407081	DNAH1	0.32	8.44	0.37	4.05e-16	Bipolar disorder;
LGG	cis	rs2976388	0.587	rs2717606	chr8:143799496	G/A	cg06565975	chr8:143823917	SLURP1	0.36	9.17	0.39	1.58e-18	Urinary tract infection frequency;
LGG	cis	rs5769765	1.000	rs5770755	chr22:50280136	T/C	cg02269571	chr22:50332266	NA	0.63	9.98	0.42	2.17e-21	Schizophrenia;
LGG	cis	rs4819852	0.958	rs2238786	chr22:19975444	A/G	cg07821417	chr22:19972146	ARVCF	0.61	12.9	0.51	9.46e-33	Pulse pressure;
LGG	cis	rs2228479	0.571	rs62052183	chr16:89966921	C/A	cg26513180	chr16:89883248	FANCA	0.82	8.66	0.37	7.85e-17	Skin colour saturation;
LGG	cis	rs2228479	0.618	rs34689166	chr16:89860697	C/T	cg04287289	chr16:89883240	FANCA	0.9	8.73	0.38	4.49e-17	Skin colour saturation;
LGG	cis	rs12230513	0.732	rs67290413	chr12:55869876	T/C	cg19537932	chr12:55886519	OR6C68	-0.61	-10.92	-0.45	7.38e-25	Contrast sensitivity;
LGG	cis	rs1799949	0.965	rs8176193	chr17:41231516	C/T	cg05368731	chr17:41323189	NBR1	0.93	18.33	0.65	8.14e-57	Menopause (age at onset);
LGG	cis	rs28595532	0.920	rs115214765	chr4:119728167	C/T	cg21605333	chr4:119757512	SEC24D	1.49	14.91	0.57	2.51e-41	Cannabis dependence symptom count;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg23452458	chr17:45899388	OSBPL7	0.47	7.67	0.34	1.05e-13	Gut microbiome composition (summer);
LGG	cis	rs7551222	0.681	rs10900595	chr1:204511602	C/A	cg20240347	chr1:204465584	NA	-0.52	-10.05	-0.42	1.24e-21	Schizophrenia;
LGG	cis	rs769267	0.930	rs2288852	chr19:19605348	T/C	cg20644253	chr19:19431407	KIAA0892;SF4	0.6	10.28	0.43	1.89e-22	Tonsillectomy;
LGG	cis	rs4481887	0.676	rs7520659	chr1:248527586	C/A	cg01631408	chr1:248437212	OR2T33	-0.38	-7.1	-0.31	4.75e-12	Common traits (Other);
LGG	cis	rs9944715	0.954	rs8086956	chr18:43773903	A/G	cg26436583	chr18:43649176	PSTPIP2	-0.35	-6.64	-0.3	8.58e-11	Red cell distribution width;Mean corpuscular volume;
LGG	cis	rs6963495	0.818	rs73190151	chr7:105152887	C/T	cg19920283	chr7:105172520	RINT1	0.6	7.89	0.34	2.22e-14	Bipolar disorder (body mass index interaction);
LGG	cis	rs12540874	0.518	rs12718674	chr7:50627130	T/C	cg04490037	chr7:50633773	DDC	0.34	7.17	0.32	2.9e-12	Systemic sclerosis;
LGG	trans	rs7618501	1.000	rs6802890	chr3:49832261	A/G	cg21665057	chr3:196295764	WDR53;FBXO45	0.66	12.79	0.51	2.8e-32	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.846	rs9631804	chr4:1283032	A/T	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.56	-9.38	-0.4	2.89e-19	Obesity-related traits;
LGG	cis	rs1256061	0.646	rs1256056	chr14:64712626	A/G	cg23250157	chr14:64679961	SYNE2	0.38	6.82	0.3	2.93e-11	Hemoglobin concentration;Red blood cell count;Hematocrit;
LGG	cis	rs11098499	0.615	rs59867181	chr4:120556467	C/T	cg09307838	chr4:120376055	NA	-0.67	-11.65	-0.48	1.06e-27	Corneal astigmatism;
LGG	cis	rs2011503	0.509	rs884480	chr19:19773923	G/A	cg11584989	chr19:19387371	SF4	0.56	8.13	0.35	3.92e-15	Bipolar disorder;
LGG	trans	rs7210837	0.591	rs11657533	chr17:16804619	A/C	cg11294312	chr17:28900046	NA	-0.65	-8.02	-0.35	8.73e-15	Response to platinum-based chemotherapy (cisplatin);
LGG	trans	rs9467711	0.720	rs75782365	chr6:26408551	T/G	cg08344181	chr3:125677491	NA	-0.84	-8.05	-0.35	6.97e-15	Autism spectrum disorder or schizophrenia;
LGG	cis	rs9318086	0.624	rs9510909	chr13:24436760	C/T	cg25267304	chr13:24462978	PCOTH;MIPEP	0.51	9.75	0.41	1.48e-20	Myopia (pathological);
LGG	cis	rs9814567	0.752	rs6764764	chr3:134331167	C/T	cg06109529	chr3:134205091	CEP63;ANAPC13	0.57	9.1	0.39	2.67e-18	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs7811142	1.000	rs66632384	chr7:100018904	G/A	cg01860168	chr7:100026446	MEPCE;ZCWPW1	0.58	8.79	0.38	2.89e-17	Platelet count;
LGG	cis	rs367615	0.918	rs13173339	chr5:108871318	T/A	cg17395555	chr5:108820864	NA	0.62	8.8	0.38	2.67e-17	Colorectal cancer (SNP x SNP interaction);
LGG	cis	rs738322	0.805	rs2235344	chr22:38518083	G/A	cg03162506	chr22:38580953	NA	0.32	7.74	0.34	6.12e-14	Cutaneous nevi;
LGG	cis	rs28386778	0.897	rs9915552	chr17:61869095	G/A	cg22520471	chr17:61851767	DDX42;CCDC47	0.6	12.09	0.49	2e-29	Prudent dietary pattern;
LGG	cis	rs12477438	0.520	rs4402818	chr2:99717608	A/G	cg14399236	chr2:99771627	LIPT1;TSGA10	0.83	17.47	0.63	7.14e-53	Chronic sinus infection;
LGG	cis	rs561341	0.824	rs1978115	chr17:30220776	A/C	cg13647721	chr17:30228624	UTP6	0.76	10.05	0.42	1.22e-21	Hip circumference adjusted for BMI;
LGG	cis	rs11711311	1.000	rs34475696	chr3:113458293	T/C	cg06805542	chr3:113465803	ATP6V1A;NAA50	-0.43	-7.54	-0.33	2.54e-13	IgG glycosylation;
LGG	cis	rs2013441	1.000	rs2703772	chr17:20131453	C/A	cg09818912	chr17:20140352	CYTSB	0.29	6.7	0.3	6.11e-11	Obesity-related traits;
LGG	cis	rs6704644	0.584	rs56336977	chr2:234357496	C/T	cg27060346	chr2:234359958	DGKD	-0.6	-7.09	-0.31	4.93e-12	Bilirubin levels;
LGG	cis	rs4481887	0.861	rs10788776	chr1:248479177	T/C	cg01631408	chr1:248437212	OR2T33	-0.52	-9.5	-0.4	1.14e-19	Common traits (Other);
LGG	cis	rs9858542	0.903	rs17080528	chr3:49389842	C/T	cg07274523	chr3:49395745	GPX1	0.58	9.61	0.41	4.76e-20	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs2032447	0.832	rs10425	chr6:26056549	A/G	cg03517284	chr6:25882590	NA	-0.57	-11.06	-0.46	2.21e-25	Intelligence (multi-trait analysis);
LGG	cis	rs12188164	1.000	rs12188164	chr5:428236	C/A	cg15813090	chr5:442598	EXOC3;C5orf55	0.44	7.47	0.33	3.95e-13	Cystic fibrosis severity;
LGG	cis	rs10782582	0.593	rs74090712	chr1:76189098	A/G	cg10523679	chr1:76189770	ACADM	-0.41	-6.69	-0.3	6.52e-11	Daytime sleep phenotypes;
LGG	cis	rs9322193	0.886	rs9322198	chr6:149944908	T/C	cg00933542	chr6:150070202	PCMT1	0.38	7.04	0.31	7.04e-12	Lung cancer;
LGG	cis	rs754466	1.000	rs12220311	chr10:79681507	C/T	cg17075019	chr10:79541650	NA	-0.81	-13.85	-0.54	1e-36	Liver enzyme levels (gamma-glutamyl transferase);
LGG	cis	rs9768139	0.733	rs13309363	chr7:158122179	C/A	cg02855558	chr7:158107723	PTPRN2	-0.39	-7.03	-0.31	7.44e-12	Calcium levels;
LGG	cis	rs9325144	0.647	rs35254764	chr12:39102928	T/C	cg26384229	chr12:38710491	ALG10B	-0.71	-13.4	-0.53	7.62e-35	Morning vs. evening chronotype;
LGG	trans	rs7395662	0.570	rs11039737	chr11:48450200	G/A	cg21153622	chr11:89784906	NA	-0.4	-6.88	-0.3	1.93e-11	HDL cholesterol;
LGG	cis	rs873946	0.586	rs3793682	chr10:134564563	C/T	cg27297192	chr10:134578999	INPP5A	0.31	6.81	0.3	3.06e-11	Gestational age at birth in labor-initiated deliveries (child effect);Gestational age at birth (child effect);
LGG	cis	rs10911251	0.546	rs10911260	chr1:183106230	A/C	cg15522984	chr1:182991683	LAMC1	-0.45	-9.08	-0.39	3.23e-18	Colorectal cancer;
LGG	trans	rs4843747	0.749	rs72818535	chr16:88074039	G/A	cg26811252	chr16:29126840	RRN3P2	0.76	11.97	0.49	6.19e-29	Menopause (age at onset);
LGG	cis	rs28735056	0.935	rs537962	chr18:77592660	C/G	cg20368463	chr18:77673604	PQLC1	0.46	8.2	0.36	2.32e-15	Schizophrenia;
LGG	cis	rs3733585	0.664	rs17245436	chr4:9958169	A/G	cg11266682	chr4:10021025	SLC2A9	-0.41	-7.77	-0.34	5.22e-14	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs35306767	0.855	rs35666723	chr10:867346	A/G	cg25019033	chr10:957182	NA	-0.53	-9.07	-0.39	3.44e-18	Eosinophil percentage of granulocytes;
LGG	trans	rs7395662	0.927	rs12793888	chr11:48488056	A/G	cg15704280	chr7:45808275	SEPT13	-0.49	-8.03	-0.35	8.35e-15	HDL cholesterol;
LGG	cis	rs1519814	0.654	rs6469888	chr8:121018175	A/G	cg22335954	chr8:121166405	COL14A1	-0.45	-8.19	-0.36	2.66e-15	Breast cancer;
LGG	cis	rs6500602	0.702	rs4786511	chr16:4571645	C/T	cg06916706	chr16:4465613	CORO7	-0.72	-12.46	-0.5	6.31e-31	Schizophrenia;
LGG	cis	rs11718455	0.960	rs34241796	chr3:44000394	A/T	cg21419209	chr3:44054225	NA	-0.41	-6.78	-0.3	3.58e-11	Coronary artery disease;
LGG	cis	rs9462027	0.606	rs2744959	chr6:34616654	T/A	cg07306190	chr6:34760872	UHRF1BP1	-0.53	-10.55	-0.44	1.85e-23	Systemic lupus erythematosus;
LGG	cis	rs4665809	0.590	rs66477033	chr2:26472497	T/C	cg26119090	chr2:26468346	HADHA;HADHB	1.08	21.16	0.7	4.94e-70	Gut microbiome composition (summer);
LGG	cis	rs6089829	0.962	rs3899032	chr20:61658542	G/A	cg18188782	chr20:61659543	NA	0.4	6.71	0.3	5.64e-11	Prostate cancer (SNP x SNP interaction);
LGG	cis	rs12479064	0.724	rs4851203	chr2:99986932	T/C	cg15544633	chr2:99771531	LIPT1;TSGA10	-0.74	-10.9	-0.45	8.61e-25	Chronic sinus infection;
LGG	cis	rs11711311	0.712	rs11718013	chr3:113341661	A/G	cg15478005	chr3:113465772	ATP6V1A;NAA50	0.58	11.68	0.48	8.24e-28	IgG glycosylation;
LGG	trans	rs9388451	0.807	rs1269175	chr6:126040435	A/G	cg05039488	chr6:79577232	IRAK1BP1	0.52	9.37	0.4	3.1400000000000002e-19	Brugada syndrome;
LGG	trans	rs11098499	0.954	rs10031483	chr4:120422636	T/C	cg25214090	chr10:38739885	LOC399744	0.69	12.33	0.5	2.08e-30	Corneal astigmatism;
LGG	cis	rs6951245	0.638	rs4720486	chr7:1146764	G/A	cg03188948	chr7:1209495	NA	0.47	7.65	0.33	1.19e-13	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17376456	0.877	rs10476526	chr5:93461916	G/A	cg25358565	chr5:93447407	FAM172A	1.37	17.05	0.62	6.38e-51	Diabetic retinopathy;
LGG	cis	rs9811920	0.965	rs9849632	chr3:99867211	G/A	cg21419939	chr3:99598918	C3orf26;FILIP1L;MIR548G	0.48	8.37	0.36	6.88e-16	Axial length;
LGG	cis	rs9311474	0.607	rs13076398	chr3:52573096	G/A	cg10712668	chr3:52740153	GLT8D1;SPCS1	0.49	7.92	0.35	1.72e-14	Electroencephalogram traits;
LGG	cis	rs9916302	0.706	rs667239	chr17:37442241	A/G	cg00129232	chr17:37814104	STARD3	0.53	7.91	0.34	1.96e-14	Glomerular filtration rate (creatinine);
LGG	cis	rs7208859	0.623	rs11650973	chr17:29214045	G/A	cg08994789	chr17:28903642	LRRC37B2	-0.59	-7.08	-0.31	5.51e-12	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs9290877	0.552	rs9832630	chr3:188474832	C/T	cg17392043	chr3:188495102	LPP	-0.45	-8.11	-0.35	4.63e-15	IgE levels;
LGG	cis	rs3733346	0.553	rs6813110	chr4:942660	C/T	cg04824913	chr4:887549	GAK	0.42	7.24	0.32	1.93e-12	Sjögren's syndrome;
LGG	cis	rs6500395	0.962	rs9924483	chr16:48646258	C/T	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.17e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs7481584	1.000	rs12798150	chr11:3019260	C/T	cg08468577	chr11:2973342	NAP1L4	-0.39	-8.09	-0.35	5.41e-15	Calcium levels;
LGG	cis	rs1799949	0.965	rs8176161	chr17:41241390	C/A	cg18379455	chr17:41446167	NA	-0.32	-7.38	-0.32	7.3e-13	Menopause (age at onset);
LGG	cis	rs9309473	0.554	rs4330127	chr2:73581320	A/T	cg20560298	chr2:73613845	ALMS1	-0.48	-8.8	-0.38	2.79e-17	Metabolite levels;
LGG	cis	rs9322193	0.962	rs6903998	chr6:150152493	T/C	cg12070911	chr6:150209640	RAET1E	0.29	7.15	0.32	3.45e-12	Lung cancer;
LGG	trans	rs7824557	0.583	rs2736306	chr8:11239762	A/T	cg02002194	chr4:3960332	NA	-0.41	-7.43	-0.33	5.32e-13	Retinal vascular caliber;
LGG	cis	rs2243480	1.000	rs34192067	chr7:65887657	C/A	cg18252515	chr7:66147081	NA	-1.43	-20.76	-0.69	3.88e-68	Diabetic kidney disease;
LGG	cis	rs936229	0.813	rs4886629	chr15:75072558	G/C	cg14664628	chr15:75095509	CSK	-1.11	-24.24	-0.75	2.13e-84	Adverse response to chemotherapy (neutropenia/leucopenia) (carboplatin);
LGG	trans	rs736408	0.812	rs2071508	chr3:52826846	A/G	cg02005336	chr11:61560123	MIR611;C11orf10;FEN1	0.44	7.54	0.33	2.5e-13	Bipolar disorder;
LGG	cis	rs950169	0.579	rs12913054	chr15:84664456	A/G	cg24253500	chr15:84953950	NA	0.45	7.2	0.32	2.51e-12	Schizophrenia;
LGG	trans	rs941408	1.000	rs941406	chr19:2803623	A/G	cg22153745	chr1:153894579	GATAD2B	-0.66	-10.75	-0.45	3.27e-24	Total cholesterol levels;
LGG	trans	rs453301	0.571	rs2929454	chr8:9083854	A/C	cg16141378	chr3:129829833	LOC729375	0.39	9.3	0.4	5.61e-19	Joint mobility (Beighton score);
LGG	cis	rs4474465	0.850	rs4387376	chr11:78257662	T/C	cg27205649	chr11:78285834	NARS2	0.5	8.52	0.37	2.33e-16	Alzheimer's disease (survival time);
LGG	cis	rs3206736	0.548	rs6963995	chr7:35058349	C/T	cg13400248	chr7:35225412	NA	0.55	9.62	0.41	4.45e-20	Diastolic blood pressure;
LGG	cis	rs2239547	0.603	rs6789219	chr3:53098938	C/G	cg11645453	chr3:52864694	ITIH4	0.66	10.53	0.44	2.11e-23	Schizophrenia;
LGG	cis	rs6918586	0.616	rs198836	chr6:26113616	T/A	cg18357526	chr6:26021779	HIST1H4A	-0.55	-9.68	-0.41	2.75e-20	Schizophrenia;
LGG	trans	rs75804782	0.630	rs55708222	chr2:239287693	C/T	cg01134436	chr17:81009848	B3GNTL1	0.79	7.03	0.31	7.35e-12	Morning vs. evening chronotype;Chronotype;
LGG	cis	rs62400317	0.859	rs12153922	chr6:45256159	T/C	cg20913747	chr6:44695427	NA	-0.61	-10.26	-0.43	2.25e-22	Total body bone mineral density;
LGG	cis	rs9549367	0.737	rs9549712	chr13:113902355	G/A	cg18105134	chr13:113819100	PROZ	-0.69	-14.2	-0.55	3.14e-38	Platelet distribution width;
LGG	cis	rs2373794	0.583	rs6720270	chr2:40379861	T/C	cg17740179	chr2:40377776	SLC8A1	-0.8	-9.88	-0.42	5.17e-21	Asthma;
LGG	cis	rs17270561	0.636	rs12194699	chr6:25729229	G/C	cg03264133	chr6:25882463	NA	-0.47	-7.68	-0.34	9.58e-14	Iron status biomarkers;
LGG	cis	rs2299587	0.582	rs6981333	chr8:17910211	C/T	cg18067069	chr8:17937731	ASAH1	-0.33	-8.02	-0.35	8.88e-15	Economic and political preferences;
LGG	cis	rs7616215	0.519	rs2133664	chr3:46101774	T/A	cg13144783	chr3:46249795	CCR1	-0.35	-6.77	-0.3	3.81e-11	Behcet's disease;
LGG	cis	rs10463316	0.894	rs7710277	chr5:150767405	T/C	cg03212797	chr5:150827313	SLC36A1	-0.59	-10.28	-0.43	1.85e-22	Metabolite levels (Pyroglutamine);
LGG	cis	rs13108904	0.901	rs1316393	chr4:1315619	A/G	cg25897951	chr4:1244024	CTBP1;C4orf42	-0.66	-12.01	-0.49	4e-29	Obesity-related traits;
LGG	cis	rs644799	0.965	rs573758	chr11:95539591	G/T	cg03916912	chr11:95522834	CEP57;FAM76B	0.97	21.34	0.7	6.94e-71	Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);
LGG	cis	rs1345301	0.609	rs56389410	chr2:102867663	C/T	cg05295703	chr2:102895712	NA	0.49	9.87	0.42	5.73e-21	Waist circumference;
LGG	cis	rs7582180	0.629	rs10202326	chr2:100950237	A/G	cg05692746	chr2:100937584	LONRF2	-0.65	-12.17	-0.49	9.33e-30	Intelligence (multi-trait analysis);
LGG	cis	rs10911251	0.528	rs2333622	chr1:183075456	T/C	cg07245641	chr1:182991651	LAMC1	0.42	9.55	0.41	7.72e-20	Colorectal cancer;
LGG	cis	rs10911251	0.546	rs3768625	chr1:183078712	G/T	cg07245641	chr1:182991651	LAMC1	0.43	9.7	0.41	2.29e-20	Colorectal cancer;
LGG	cis	rs9858542	0.953	rs11715915	chr3:49455330	A/G	cg03060546	chr3:49711283	APEH	0.65	10.28	0.43	1.79e-22	Ulcerative colitis;Blood protein levels;Crohn's disease;
LGG	cis	rs977747	0.836	rs4926521	chr1:47674769	G/A	cg03885399	chr1:47691550	TAL1	-0.36	-7.74	-0.34	6.31e-14	Body mass index;
LGG	trans	rs6981523	0.517	rs13251510	chr8:10916974	A/G	cg06636001	chr8:8085503	FLJ10661	-0.52	-9.1	-0.39	2.7e-18	Neuroticism;
LGG	cis	rs780096	0.526	rs780107	chr2:27684734	A/G	cg21248554	chr2:27665150	KRTCAP3	-0.26	-6.82	-0.3	2.88e-11	Total body bone mineral density;
LGG	cis	rs2576037	0.583	rs4890343	chr18:44540969	G/A	cg23302884	chr18:44338147	ST8SIA5	-0.45	-9.02	-0.39	4.96e-18	Personality dimensions;
LGG	trans	rs1005277	0.579	rs2749616	chr10:38510993	A/T	cg17830980	chr10:43048298	ZNF37B	-0.59	-13.18	-0.52	6.86e-34	Extrinsic epigenetic age acceleration;
LGG	cis	rs9303401	0.614	rs34683543	chr17:56520036	C/A	cg10487724	chr17:56770010	TEX14;RAD51C	0.88	14.4	0.56	4.04e-39	Cognitive test performance;
LGG	cis	rs10504229	0.817	rs55891651	chr8:58167600	C/T	cg08677398	chr8:58056175	NA	0.41	7.0	0.31	9.2e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6121246	0.512	rs6060938	chr20:30363645	T/C	cg13852791	chr20:30311386	BCL2L1	0.96	19.2	0.67	7.07e-61	Mean corpuscular hemoglobin;
LGG	cis	rs2797160	0.967	rs1777224	chr6:126019527	T/C	cg05901451	chr6:126070800	HEY2	0.47	7.85	0.34	2.86e-14	Endometrial cancer;
LGG	cis	rs8180040	0.691	rs12489211	chr3:47221451	T/A	cg27129171	chr3:47204927	SETD2	0.84	16.31	0.6	1.37e-47	Colorectal cancer;
LGG	trans	rs7083345	0.807	rs6602221	chr10:7029094	C/T	cg03699307	chr16:75600014	GABARAPL2	0.46	7.6	0.33	1.67e-13	Gut microbiota (bacterial taxa);
LGG	trans	rs3942852	0.806	rs4752807	chr11:48128751	T/G	cg15704280	chr7:45808275	SEPT13	-0.66	-9.24	-0.39	8.63e-19	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs10895140	0.756	rs11224830	chr11:101412927	G/A	cg23650423	chr11:101454676	TRPC6	0.43	6.67	0.3	7.36e-11	Menarche (age at onset);
LGG	cis	rs7582180	0.845	rs11683088	chr2:100920667	C/T	cg21926883	chr2:100939477	LONRF2	-0.68	-15.88	-0.59	1.16e-45	Intelligence (multi-trait analysis);
LGG	cis	rs1559088	0.847	rs2287680	chr19:33608566	A/G	cg17764715	chr19:33622953	WDR88	-0.55	-9.76	-0.41	1.39e-20	Bone ultrasound measurement (broadband ultrasound attenuation);
LGG	cis	rs3857067	1.000	rs2865330	chr4:95004716	A/G	cg11021082	chr4:95130006	SMARCAD1	-0.4	-7.53	-0.33	2.67e-13	QT interval;
LGG	cis	rs6429082	0.783	rs390539	chr1:235679690	A/C	cg26050004	chr1:235667680	B3GALNT2	0.64	10.66	0.44	7.22e-24	Adiposity;
LGG	cis	rs1008375	1.000	rs6449319	chr4:17640283	T/A	cg04450456	chr4:17643702	FAM184B	0.33	7.41	0.33	6.02e-13	Parasitemia in Tripanosoma cruzi seropositivity;
LGG	cis	rs477692	0.673	rs1078847	chr10:131352115	T/C	cg05714579	chr10:131428358	MGMT	0.48	9.2	0.39	1.19e-18	Response to temozolomide;
LGG	cis	rs9322193	0.923	rs35967444	chr6:149996724	G/A	cg08621203	chr6:150244597	RAET1G	0.46	7.98	0.35	1.2e-14	Lung cancer;
LGG	cis	rs4650994	0.525	rs17361286	chr1:178521916	C/G	cg12486710	chr1:178512616	C1orf220	0.51	10.56	0.44	1.74e-23	HDL cholesterol levels;HDL cholesterol;
LGG	cis	rs4664308	0.618	rs17830940	chr2:160891768	T/C	cg03641300	chr2:160917029	PLA2R1	-0.61	-11.64	-0.48	1.19e-27	Idiopathic membranous nephropathy;
LGG	cis	rs6750047	0.609	rs2121259	chr2:38269475	T/C	cg07380506	chr2:38303506	CYP1B1	0.44	7.26	0.32	1.68e-12	Cutaneous malignant melanoma;Melanoma;
LGG	cis	rs8177253	0.798	rs9871148	chr3:133507509	T/C	cg16414030	chr3:133502952	NA	-0.65	-11.56	-0.47	2.59e-27	Iron status biomarkers;
LGG	cis	rs2576037	0.526	rs4890699	chr18:44541029	T/C	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.82	17.2	0.62	1.31e-51	Personality dimensions;
LGG	cis	rs1577917	0.958	rs12216074	chr6:86520002	C/G	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.69	-12.05	-0.49	2.75e-29	Response to antipsychotic treatment;
LGG	cis	rs4819052	0.851	rs2838839	chr21:46667858	C/G	cg02159808	chr21:46707872	POFUT2;LOC642852	-0.56	-9.2	-0.39	1.21e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs6541297	1.000	rs6686680	chr1:230280522	T/C	cg20703242	chr1:230279135	GALNT2	0.37	7.55	0.33	2.31e-13	Coronary artery disease;
LGG	cis	rs6502050	0.799	rs12603050	chr17:80104631	A/G	cg09264619	chr17:80180166	NA	-0.37	-7.47	-0.33	3.9e-13	Life satisfaction;
LGG	cis	rs1965732	1.000	rs6707320	chr2:3708966	A/G	cg15327641	chr2:3715039	ALLC	0.31	6.67	0.3	7.3e-11	Response to inhaled corticosteroid treatment in asthma (change in FEV1);
LGG	cis	rs10504073	0.647	rs4873098	chr8:50021041	T/C	cg00325661	chr8:49890786	NA	0.69	13.45	0.53	4.6e-35	Blood metabolite ratios;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg17848531	chr2:182756352	SSFA2	0.44	6.66	0.3	7.6e-11	Gut microbiome composition (summer);
LGG	cis	rs3219090	0.861	rs1858550	chr1:226608104	C/A	cg17127702	chr1:226594323	PARP1	0.38	11.94	0.49	8.11e-29	Melanoma;
LGG	cis	rs597539	0.617	rs669659	chr11:68635623	G/C	cg01988459	chr11:68622903	NA	-0.62	-12.48	-0.5	5.13e-31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	cis	rs1691799	0.836	rs1168334	chr12:66760972	A/G	cg16791601	chr12:66731901	HELB	-0.65	-15.16	-0.58	1.94e-42	White blood cell count (basophil);
LGG	cis	rs11148252	0.740	rs9536046	chr13:52955899	T/G	cg22398616	chr13:53314203	LECT1	-0.4	-8.11	-0.35	4.45e-15	Lewy body disease;
LGG	cis	rs10504229	0.953	rs59265461	chr8:58189701	A/T	cg02725872	chr8:58115012	NA	-0.77	-11.0	-0.46	3.6e-25	Developmental language disorder (linguistic errors);
LGG	cis	rs190217029	1	rs190217029	chr11:111092986	C/G	cg08450021	chr11:111101517	NA	-0.49	-7.03	-0.31	7.45e-12	Carotid plaque burden;
LGG	cis	rs2228479	0.867	rs11642451	chr16:89958127	T/C	cg04287289	chr16:89883240	FANCA	0.73	7.81	0.34	3.95e-14	Skin colour saturation;
LGG	cis	rs2228479	0.850	rs17226980	chr16:89825065	G/A	cg19635926	chr16:89946313	TCF25	0.74	7.34	0.32	9.66e-13	Skin colour saturation;
LGG	cis	rs9473924	0.580	rs67092917	chr6:50815333	G/T	cg14470998	chr6:50812995	TFAP2B	0.65	7.75	0.34	5.74e-14	Body mass index;
LGG	cis	rs13108904	0.870	rs4974577	chr4:1266046	G/A	cg00684032	chr4:1343700	KIAA1530	0.47	9.2	0.39	1.26e-18	Obesity-related traits;
LGG	cis	rs9788721	0.934	rs16969968	chr15:78882925	G/A	cg17108064	chr15:78857060	CHRNA5	-0.37	-7.32	-0.32	1.08e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;Emphysema imaging phenotypes;Emphysema distribution in smoking;Local histogram emphysema pattern;Post bronchodilator FEV1/FVC ratio in COPD;
LGG	cis	rs6430585	0.528	rs7573555	chr2:136694905	C/T	cg07169764	chr2:136633963	MCM6	-1.27	-25.28	-0.76	3.1e-89	Corneal structure;
LGG	cis	rs4665809	0.887	rs4665814	chr2:26273687	G/T	cg26119090	chr2:26468346	HADHA;HADHB	-0.8	-13.18	-0.52	6.58e-34	Gut microbiome composition (summer);
LGG	trans	rs9329221	0.521	rs4841294	chr8:10105068	G/T	cg08975724	chr8:8085496	FLJ10661	-0.38	-6.73	-0.3	4.88e-11	Neuroticism;
LGG	cis	rs9788682	0.947	rs12439240	chr15:78829091	T/C	cg24631222	chr15:78858424	CHRNA5	0.48	7.33	0.32	1.06e-12	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;
LGG	cis	rs4330281	0.669	rs4377510	chr3:17686288	G/A	cg20981856	chr3:17787350	NA	-0.38	-7.0	-0.31	9.09e-12	Schizophrenia;
LGG	cis	rs11168351	0.927	rs7971880	chr12:48391055	C/T	cg24011408	chr12:48396354	COL2A1	0.61	10.31	0.43	1.44e-22	Bipolar disorder and schizophrenia;
LGG	cis	rs4862750	0.872	rs7664463	chr4:187876686	A/C	cg06074448	chr4:187884817	NA	-0.59	-13.46	-0.53	4.22e-35	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs4690686	0.554	rs13141274	chr4:177285027	C/T	cg17059388	chr4:177262070	NA	0.61	12.58	0.5	1.92e-31	Essential tremor;
LGG	cis	rs10504229	1.000	rs66731170	chr8:58187895	C/G	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs782590	0.967	rs58003472	chr2:55797507	T/C	cg18811423	chr2:55921094	PNPT1	0.88	20.14	0.68	3.14e-65	Metabolic syndrome;
LGG	cis	rs8177253	0.530	rs8177177	chr3:133463195	A/G	cg01448562	chr3:133502909	NA	-0.44	-7.42	-0.33	5.8e-13	Iron status biomarkers;
LGG	cis	rs1408799	0.772	rs927868	chr9:12748795	G/T	cg05274944	chr9:12693694	TYRP1	0.35	8.39	0.36	5.81e-16	Eye color;Blue vs. green eyes;
LGG	cis	rs9503598	0.714	rs7758776	chr6:3452245	C/T	cg00476032	chr6:3446245	SLC22A23	0.63	13.74	0.54	2.97e-36	Cognitive ability (multi-trait analysis);Cognitive ability;Intelligence (multi-trait analysis);
LGG	trans	rs853679	1.000	rs1778508	chr6:28229881	C/T	cg06606381	chr12:133084897	FBRSL1	0.71	8.31	0.36	1.06e-15	Depression;
LGG	cis	rs9972944	0.899	rs9972954	chr17:63771050	T/C	cg07283582	chr17:63770753	CCDC46	0.44	8.75	0.38	4.04e-17	Total body bone mineral density;
LGG	cis	rs4819052	0.851	rs2838858	chr21:46681093	T/A	cg02159808	chr21:46707872	POFUT2;LOC642852	0.55	9.09	0.39	2.96e-18	Coronary artery calcified atherosclerotic plaque (90 or 130 HU threshold) in type 2 diabetes;
LGG	cis	rs300703	0.872	rs7568288	chr2:276908	C/G	cg24565620	chr2:194026	NA	-0.72	-9.07	-0.39	3.51e-18	Blood protein levels;
LGG	cis	rs11626933	1.000	rs4559843	chr14:90747488	T/C	cg14092571	chr14:90743983	NA	-0.81	-16.57	-0.61	9.38e-49	Gut microbiota (bacterial taxa);
LGG	cis	rs709400	0.930	rs10149249	chr14:104047757	C/T	cg26031613	chr14:104095156	KLC1	1.13	25.36	0.76	1.3e-89	Body mass index;
LGG	cis	rs4782309	0.544	rs6500488	chr16:88753865	A/G	cg27087555	chr16:88793112	FAM38A	-1.21	-12.18	-0.49	8.88e-30	Hair color;
LGG	cis	rs62238980	0.614	rs17744994	chr22:32413527	C/T	cg00543991	chr22:32367038	NA	0.79	8.61	0.37	1.18e-16	Childhood ear infection;
LGG	cis	rs9814567	0.727	rs4437193	chr3:134352344	A/G	cg06109529	chr3:134205091	CEP63;ANAPC13	-0.61	-10.94	-0.45	6.09e-25	Neurocognitive impairment in HIV-1 infection (dichotomous);
LGG	cis	rs3733585	0.773	rs13107466	chr4:10019390	G/A	cg11266682	chr4:10021025	SLC2A9	0.56	11.48	0.47	4.92e-27	Cleft plate (environmental tobacco smoke interaction);
LGG	cis	rs898097	0.690	rs12452304	chr17:80811659	G/A	cg15664640	chr17:80829946	TBCD	-0.81	-15.98	-0.6	4.11e-46	Breast cancer;
LGG	cis	rs9790314	0.747	rs1841526	chr3:160834682	A/G	cg03342759	chr3:160939853	NMD3	-0.57	-9.88	-0.42	5.3e-21	Morning vs. evening chronotype;
LGG	cis	rs1799949	1.000	rs35668327	chr17:41273095	G/A	cg04503457	chr17:41445688	NA	-0.38	-9.1	-0.39	2.63e-18	Menopause (age at onset);
LGG	cis	rs6430585	0.941	rs7589832	chr2:136504101	A/C	cg07169764	chr2:136633963	MCM6	0.99	18.51	0.65	1.13e-57	Corneal structure;
LGG	cis	rs1577917	1.000	rs2816815	chr6:86691656	C/T	cg17490806	chr6:86388072	SNHG5;SNORD50B;SNORD50A	-0.66	-11.57	-0.47	2.31e-27	Response to antipsychotic treatment;
LGG	cis	rs9611565	0.659	rs17367849	chr22:41923644	G/A	cg03806693	chr22:41940476	POLR3H	-1.14	-20.88	-0.7	9.83e-69	Vitiligo;
LGG	cis	rs17376456	0.825	rs10061377	chr5:93174513	T/C	cg09848695	chr5:92956644	FAM172A;MIR2277	0.96	10.79	0.45	2.32e-24	Diabetic retinopathy;
LGG	cis	rs11992162	0.967	rs10088415	chr8:11830825	A/G	cg00405596	chr8:11794950	NA	-0.41	-7.07	-0.31	5.66e-12	Monocyte count;
LGG	cis	rs977987	0.778	rs11858992	chr16:75411445	A/C	cg07303275	chr16:75499416	TMEM170A	0.37	6.75	0.3	4.32e-11	Dupuytren's disease;
LGG	cis	rs1806153	0.611	rs1806157	chr11:31840404	G/T	cg11990419	chr11:31841155	NA	0.34	7.99	0.35	1.06e-14	Neuroticism (multi-trait analysis);Neuroticism;Depressive symptoms;Depressive symptoms (multi-trait analysis);
LGG	cis	rs8062405	0.755	rs7186573	chr16:28587389	T/C	cg00198680	chr16:28758506	NA	0.28	6.76	0.3	4.08e-11	Cognitive ability (multi-trait analysis);Cognitive ability;
LGG	trans	rs1997103	1.000	rs6949244	chr7:55411301	C/G	cg20935933	chr6:143382018	AIG1	0.54	8.51	0.37	2.37e-16	QRS interval (sulfonylurea treatment interaction);
LGG	cis	rs7945718	0.967	rs7931147	chr11:12748884	C/A	cg25843174	chr11:12811716	TEAD1	0.37	7.69	0.34	8.7e-14	Educational attainment (years of education);
LGG	cis	rs240764	0.658	rs12202621	chr6:101220056	C/A	cg21058520	chr6:100914733	NA	0.39	6.76	0.3	4.24e-11	Neuroticism;
LGG	cis	rs7179456	0.545	rs585192	chr15:59052210	T/C	cg05156742	chr15:59063176	FAM63B	0.59	9.67	0.41	2.85e-20	Asperger disorder;
LGG	cis	rs17209837	0.915	rs12538707	chr7:87124268	T/C	cg00919237	chr7:87102261	ABCB4	-0.71	-11.11	-0.46	1.34e-25	Gallbladder cancer;
LGG	cis	rs1799949	1.000	rs1824889	chr17:41421876	C/G	cg16270222	chr17:41446396	NA	-0.29	-6.66	-0.3	7.69e-11	Menopause (age at onset);
LGG	cis	rs2640806	0.505	rs7007009	chr8:97364720	T/C	cg22138393	chr8:97340270	PTDSS1	0.28	7.12	0.31	4.09e-12	Obesity-related traits;
LGG	cis	rs2046867	0.908	rs62251649	chr3:72809610	A/C	cg26655873	chr3:72818019	SHQ1	0.34	6.77	0.3	3.88e-11	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;
LGG	cis	rs9790314	0.846	rs9809522	chr3:160983768	G/C	cg03342759	chr3:160939853	NMD3	-0.72	-14.02	-0.55	1.79e-37	Morning vs. evening chronotype;
LGG	cis	rs10464366	0.912	rs7785889	chr7:39106368	G/T	cg15212455	chr7:39170539	POU6F2	0.4	8.56	0.37	1.64e-16	IgG glycosylation;
LGG	cis	rs73086581	0.687	rs16989002	chr20:3850703	G/C	cg02187196	chr20:3869020	PANK2	0.9	12.38	0.5	1.33e-30	Response to antidepressants in depression;
LGG	cis	rs861020	0.606	rs629224	chr1:210005071	C/T	cg23166289	chr1:210001082	C1orf107	0.36	7.78	0.34	4.78e-14	Orofacial clefts;
LGG	cis	rs8048589	0.604	rs2175020	chr16:12219190	C/T	cg02910054	chr16:12241554	SNX29	0.54	8.34	0.36	8.62e-16	Homeostasis model assessment of insulin resistance (dietary factor interaction);Fasting insulin (dietary factor interaction);
LGG	cis	rs6546550	0.901	rs11893500	chr2:70154187	T/C	cg02498382	chr2:70120550	SNRNP27	-0.42	-7.95	-0.35	1.41e-14	Prevalent atrial fibrillation;
LGG	cis	rs68170813	0.652	rs117775624	chr7:107124113	C/T	cg02696742	chr7:106810147	HBP1	-0.67	-8.56	-0.37	1.73e-16	Coronary artery disease;
LGG	cis	rs9322193	0.923	rs9688350	chr6:150052113	A/T	cg12070911	chr6:150209640	RAET1E	0.31	7.56	0.33	2.25e-13	Lung cancer;
LGG	cis	rs1790761	0.505	rs34721562	chr11:67312708	T/C	cg00290607	chr11:67383545	NA	-0.47	-8.32	-0.36	1e-15	Mean corpuscular volume;
LGG	cis	rs9300255	0.596	rs10734900	chr12:123743445	G/A	cg05973401	chr12:123451056	ABCB9	0.51	8.14	0.35	3.68e-15	Neutrophil percentage of white cells;
LGG	cis	rs7568458	0.709	rs762684	chr2:85782023	G/A	cg17127132	chr2:85788382	GGCX	0.52	8.17	0.36	2.88e-15	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);
LGG	cis	rs2832191	0.720	rs4643617	chr21:30485278	T/C	cg24692254	chr21:30365293	RNF160	-0.96	-24.63	-0.75	3.23e-86	Dental caries;
LGG	cis	rs6977660	0.943	rs10225293	chr7:19840636	C/T	cg05791153	chr7:19748676	TWISTNB	-0.58	-9.01	-0.39	5.64e-18	Thyroid stimulating hormone;
LGG	cis	rs7635838	0.687	rs7625495	chr3:11377918	G/T	cg00170343	chr3:11313890	ATG7	0.49	8.58	0.37	1.45e-16	HDL cholesterol;
LGG	cis	rs6076065	0.548	rs6048740	chr20:23325047	G/A	cg11657817	chr20:23433608	CST11	0.38	7.4	0.33	6.53e-13	Facial morphology (factor 15, philtrum width);
LGG	trans	rs2471042	0.574	rs1493354	chr5:86174147	C/T	cg09825418	chr1:231377181	GNPAT;C1orf131	-0.43	-6.83	-0.3	2.75e-11	Adverse response to chemotherapy in breast cancer (alopecia) (anti-microtubule);
LGG	cis	rs10789491	1.000	rs10789491	chr1:47179310	A/G	cg15501359	chr1:47185051	KIAA0494	0.77	14.5	0.56	1.56e-39	Response to hepatitis C treatment;
LGG	cis	rs4774899	0.966	rs12912007	chr15:57411492	T/G	cg08128148	chr15:57256372	TCF12	-0.32	-7.51	-0.33	2.98e-13	Urinary tract infection frequency;
LGG	cis	rs2153535	0.580	rs9505467	chr6:8520219	G/A	cg21535247	chr6:8435926	SLC35B3	0.59	10.08	0.42	9.81e-22	Motion sickness;
LGG	trans	rs58106596	0.800	rs6737601	chr2:232572381	A/G	cg01370599	chr3:116745421	NA	0.65	9.6	0.41	5.24e-20	White blood cell count;Lymphocyte counts;
LGG	cis	rs72949976	0.864	rs62186566	chr2:214024421	G/A	cg08319019	chr2:214017104	IKZF2	-0.64	-10.92	-0.45	7.23e-25	Lung cancer;Squamous cell lung carcinoma;
LGG	cis	rs1034435	0.755	rs5767171	chr22:48891881	A/G	cg05992904	chr22:48892994	FAM19A5	-0.82	-16.67	-0.61	3.19e-49	Late-onset Alzheimer's disease;
LGG	cis	rs2576037	0.526	rs1789152	chr18:44433092	G/T	cg20875182	chr18:44561130	TCEB3B;KATNAL2	0.81	16.67	0.61	3.36e-49	Personality dimensions;
LGG	cis	rs4740619	0.846	rs451878	chr9:15636260	A/C	cg14451791	chr9:16040625	NA	0.33	8.35	0.36	8.24e-16	Body mass index;
LGG	cis	rs1570884	0.516	rs2094108	chr13:50171550	G/A	cg08779649	chr13:50194554	NA	0.36	9.13	0.39	2.21e-18	Sum basophil neutrophil counts;Sum neutrophil eosinophil counts;Neutrophil count;Myeloid white cell count;Granulocyte count;
LGG	cis	rs9560113	1.000	rs9555809	chr13:112181401	T/C	cg14154082	chr13:112174009	NA	0.42	9.27	0.4	6.81e-19	Menarche (age at onset);
LGG	cis	rs116095464	0.558	rs6881920	chr5:222411	T/C	cg22857025	chr5:266934	NA	-1.51	-26.58	-0.78	3.39e-95	Breast cancer;
LGG	trans	rs7937682	0.889	rs493865	chr11:111495178	A/C	cg18187862	chr3:45730750	SACM1L	0.57	9.43	0.4	1.95e-19	Primary sclerosing cholangitis;
LGG	cis	rs9487094	0.670	rs12192268	chr6:110011458	T/C	cg16315928	chr6:109776240	MICAL1	0.46	7.97	0.35	1.21e-14	Height;
LGG	cis	rs888194	0.738	rs7311187	chr12:109937907	C/T	cg19025524	chr12:109796872	NA	-0.35	-7.1	-0.31	4.63e-12	Neuroticism;
LGG	trans	rs4714291	1.000	rs847751	chr6:40035607	A/G	cg02267698	chr19:7991119	CTXN1	0.55	8.41	0.36	5.18e-16	Strep throat;
LGG	cis	rs7584262	0.740	rs13401161	chr2:42245267	C/T	cg19376973	chr2:42229025	NA	0.64	9.52	0.4	9.8e-20	Bone mineral density;
LGG	cis	rs10046574	0.519	rs17403948	chr7:135215169	C/T	cg27474649	chr7:135195673	CNOT4	-0.68	-8.87	-0.38	1.61e-17	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs9400467	0.537	rs56272203	chr6:111492436	C/A	cg15721981	chr6:111408429	SLC16A10	0.59	7.15	0.32	3.43e-12	Blood metabolite levels;Amino acid levels;
LGG	cis	rs9486719	0.857	rs2971609	chr6:97039665	A/G	cg18709589	chr6:96969512	KIAA0776	-0.46	-7.78	-0.34	4.68e-14	Migraine;Coronary artery disease;
LGG	cis	rs4970988	0.526	rs6655975	chr1:150542128	A/G	cg13175981	chr1:150552382	MCL1	0.43	6.7	0.3	6.07e-11	Urate levels;
LGG	cis	rs11792861	0.888	rs75543406	chr9:111816903	A/T	cg14432460	chr9:111696404	IKBKAP;C9orf6	0.61	9.6	0.41	5e-20	Menarche (age at onset);
LGG	cis	rs4302748	0.909	rs11763993	chr7:36172486	G/A	cg24442661	chr7:36192818	EEPD1	0.55	7.12	0.31	4.09e-12	Platelet count;
LGG	cis	rs9612	0.718	rs346522	chr19:44262545	C/T	cg08581076	chr19:44259116	C19orf61	-0.44	-7.72	-0.34	7.19e-14	Exhaled nitric oxide output;
LGG	cis	rs12950390	0.893	rs4239166	chr17:45847329	A/G	cg03474202	chr17:45855739	NA	-0.27	-7.89	-0.34	2.14e-14	IgG glycosylation;
LGG	cis	rs858239	0.670	rs6967526	chr7:23159241	C/A	cg23682824	chr7:23144976	KLHL7	0.43	7.37	0.32	7.8e-13	Cerebrospinal fluid biomarker levels;
LGG	cis	rs7208859	0.623	rs216445	chr17:28933576	A/G	cg01831904	chr17:28903510	LRRC37B2	-0.93	-11.39	-0.47	1.2e-26	Mean corpuscular hemoglobin;Mean corpuscular volume;
LGG	cis	rs7615952	0.932	rs13065725	chr3:125632289	C/A	cg05084668	chr3:125655381	ALG1L	-0.9	-10.91	-0.45	7.74e-25	Blood pressure (smoking interaction);
LGG	cis	rs6763768	0.853	rs11715213	chr3:53508133	C/A	cg16894138	chr3:53270350	TKT	0.41	7.84	0.34	3.1e-14	Bacterial meningitis;
LGG	cis	rs3736594	0.959	rs6547796	chr2:27975394	T/C	cg27432699	chr2:27873401	GPN1	-0.56	-9.11	-0.39	2.58e-18	Fasting blood glucose;Fasting blood glucose (BMI interaction);
LGG	cis	rs6433857	0.627	rs6741769	chr2:181500545	G/A	cg23363182	chr2:181467187	NA	-0.36	-7.13	-0.31	3.94e-12	Body mass index;
LGG	cis	rs7100689	0.622	rs10887798	chr10:82131613	G/A	cg01528321	chr10:82214614	TSPAN14	0.84	14.94	0.57	1.81e-41	Post bronchodilator FEV1;
LGG	cis	rs28386778	0.897	rs2584608	chr17:61936710	A/G	cg02127607	chr17:61920694	SMARCD2	0.48	8.63	0.37	9.86e-17	Prudent dietary pattern;
LGG	cis	rs7589342	0.839	rs12995333	chr2:106436366	A/C	cg14210321	chr2:106509881	NCK2	0.49	8.44	0.37	3.99e-16	Addiction;
LGG	trans	rs1728785	0.901	rs1170420	chr16:68635877	G/C	cg04657470	chr2:198365150	HSPE1;HSPD1	0.67	10.39	0.43	7.36e-23	Ulcerative colitis;
LGG	cis	rs7555523	0.830	rs6426936	chr1:165684707	C/T	cg24409356	chr1:165738333	TMCO1	-0.66	-8.05	-0.35	6.98e-15	Intraocular pressure;Glaucoma (high intraocular pressure);
LGG	cis	rs10504229	0.595	rs116490935	chr8:58117531	A/G	cg26174226	chr8:58114915	NA	-0.6	-8.63	-0.37	9.85e-17	Developmental language disorder (linguistic errors);
LGG	cis	rs56283067	0.887	rs12200892	chr6:44768925	T/C	cg20913747	chr6:44695427	NA	-0.66	-11.12	-0.46	1.23e-25	Total body bone mineral density;
LGG	cis	rs10256972	0.758	rs2280724	chr7:1064720	A/G	cg23978390	chr7:1156363	C7orf50	0.43	7.12	0.31	4.08e-12	Longevity;Endometriosis;
LGG	cis	rs4742903	0.933	rs10820608	chr9:106890840	A/G	cg14250997	chr9:106856677	SMC2	0.39	8.4	0.36	5.68e-16	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs7811142	1.000	rs6975514	chr7:100056220	T/C	cg21679810	chr7:100027352	MEPCE;ZCWPW1	1.09	16.82	0.62	6.69e-50	Platelet count;
LGG	cis	rs8028313	0.630	rs4776373	chr15:67960523	G/A	cg02273617	chr15:68117586	LBXCOR1	-0.34	-7.71	-0.34	7.75e-14	Obesity;
LGG	cis	rs4671458	0.572	rs17617855	chr2:63719887	T/C	cg17519650	chr2:63277830	OTX1	-0.54	-7.24	-0.32	1.87e-12	Subjective well-being;
LGG	cis	rs7582180	0.629	rs7597615	chr2:100954828	T/C	cg21926883	chr2:100939477	LONRF2	-0.69	-16.35	-0.61	8.9e-48	Intelligence (multi-trait analysis);
LGG	cis	rs6141769	0.542	rs4425162	chr20:31312916	A/G	cg13636640	chr20:31349939	DNMT3B	-0.45	-6.78	-0.3	3.75e-11	Subjective well-being;
LGG	cis	rs6500602	0.627	rs9934267	chr16:4534366	G/C	cg08645402	chr16:4508243	NA	0.49	8.83	0.38	2.25e-17	Schizophrenia;
LGG	trans	rs7824557	0.614	rs7816606	chr8:11205602	T/C	cg16141378	chr3:129829833	LOC729375	-0.32	-7.04	-0.31	7.19e-12	Retinal vascular caliber;
LGG	cis	rs2235573	0.551	rs139898	chr22:38399979	A/G	cg19171272	chr22:38449367	NA	-0.5	-9.25	-0.4	8.01e-19	Glioblastoma;Glioma;
LGG	trans	rs2243480	1.000	rs313824	chr7:65581207	C/T	cg10756647	chr7:56101905	PSPH	0.79	9.31	0.4	5.18e-19	Diabetic kidney disease;
LGG	cis	rs10489202	1.000	rs3767474	chr1:168062398	C/T	cg24449463	chr1:168025552	DCAF6	-0.63	-10.08	-0.42	9.62e-22	Schizophrenia;
LGG	cis	rs2134046	0.587	rs11854289	chr15:82558802	C/T	cg00614314	chr15:82944287	LOC80154	-0.41	-6.72	-0.3	5.38e-11	Cognitive ability;
LGG	cis	rs8013055	0.846	rs10147392	chr14:105978537	T/G	cg19700328	chr14:106028568	NA	-0.62	-10.38	-0.43	8.08e-23	IgG bisecting N-acetyl glucosamine phenotypes (multivariate analysis);
LGG	cis	rs801193	1.000	rs2707836	chr7:66160435	A/C	cg11764359	chr7:65958608	NA	0.63	10.84	0.45	1.54e-24	Aortic root size;
LGG	cis	rs9325144	0.560	rs10785562	chr12:38637419	A/C	cg04568710	chr12:38710424	ALG10B	-0.43	-9.3	-0.4	5.76e-19	Morning vs. evening chronotype;
LGG	cis	rs4417704	0.551	rs6760411	chr2:241884867	C/T	cg26818257	chr2:241905806	NA	-0.5	-11.55	-0.47	2.66e-27	Joint mobility (Beighton score);
LGG	cis	rs3845702	0.736	rs259810	chr2:180787821	T/C	cg01881094	chr2:180872142	CWC22	-1.18	-15.78	-0.59	3.32e-45	Schizophrenia;
LGG	cis	rs61931739	0.517	rs11052980	chr12:34036036	T/C	cg06521331	chr12:34319734	NA	-0.62	-11.9	-0.48	1.09e-28	Morning vs. evening chronotype;
LGG	trans	rs9354308	0.899	rs2814094	chr6:66536275	G/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.6	-10.14	-0.43	5.84e-22	Metabolite levels;
LGG	cis	rs7077256	0.564	rs7915339	chr10:65166770	G/C	cg02276361	chr10:65351566	REEP3	-0.33	-6.9	-0.31	1.77e-11	Intelligence (multi-trait analysis);
LGG	cis	rs4319547	0.728	rs61954974	chr12:123074169	T/C	cg05707623	chr12:122985044	ZCCHC8	-0.64	-9.49	-0.4	1.23e-19	Body mass index;
LGG	cis	rs5769765	0.773	rs9616378	chr22:50311973	A/G	cg22709217	chr22:50311962	ALG12;CRELD2	-0.98	-14.73	-0.56	1.48e-40	Schizophrenia;
LGG	cis	rs2456568	0.803	rs10831140	chr11:93640689	G/A	cg26875233	chr11:93583750	C11orf90	-0.34	-6.74	-0.3	4.86e-11	Response to serotonin reuptake inhibitors in major depressive disorder;
LGG	cis	rs7959452	0.557	rs7980883	chr12:69778914	C/T	cg22834771	chr12:69754056	YEATS4	-0.43	-7.54	-0.33	2.42e-13	Blood protein levels;
LGG	cis	rs12477438	0.520	rs2632283	chr2:99776000	C/G	cg26064155	chr2:99771622	LIPT1;TSGA10	0.9	21.14	0.7	6.21e-70	Chronic sinus infection;
LGG	cis	rs2836974	0.644	rs719230	chr21:40676307	C/T	cg06238570	chr21:40685208	BRWD1	-0.53	-8.87	-0.38	1.56e-17	Cognitive function;
LGG	cis	rs11677416	0.601	rs12469600	chr2:113572357	T/C	cg27083787	chr2:113543245	IL1A	0.51	7.98	0.35	1.16e-14	Response to antipsychotic treatment in schizophrenia (working memory);
LGG	cis	rs651907	0.514	rs12636046	chr3:101434448	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.65	13.66	0.54	6.03e-36	Colorectal cancer;
LGG	cis	rs10540	1.000	rs35068485	chr11:466032	A/T	cg03352830	chr11:487213	PTDSS2	0.88	11.2	0.46	6.31e-26	Body mass index;
LGG	cis	rs9291683	0.554	rs7668175	chr4:10125782	T/C	cg00071950	chr4:10020882	SLC2A9	-0.34	-6.92	-0.31	1.55e-11	Bone mineral density;
LGG	cis	rs10504229	0.775	rs56155911	chr8:58163247	C/T	cg21724239	chr8:58056113	NA	0.6	9.25	0.39	8.61e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs4430311	0.723	rs1809247	chr1:243882064	C/T	cg25706552	chr1:244017396	NA	-0.64	-15.83	-0.59	2.03e-45	Post-traumatic stress disorder (asjusted for relatedness);
LGG	cis	rs7605378	0.528	rs281791	chr2:200850402	A/G	cg25936922	chr2:200820526	C2orf60;C2orf47	-0.47	-7.69	-0.34	8.88e-14	Osteoporosis;
LGG	cis	rs6032067	0.929	rs6017511	chr20:43833132	C/T	cg10761708	chr20:43804764	PI3	0.76	11.8	0.48	2.81e-28	Blood protein levels;
LGG	cis	rs4423214	1.000	rs4944957	chr11:71168035	C/T	cg10847948	chr11:71163743	NADSYN1	0.64	12.48	0.5	5.06e-31	Vitamin D levels;
LGG	cis	rs780096	0.506	rs8395	chr2:27715207	T/A	cg17158414	chr2:27665306	KRTCAP3	-0.29	-7.32	-0.32	1.13e-12	Total body bone mineral density;
LGG	cis	rs6445975	0.666	rs4075152	chr3:58385194	C/T	cg24175188	chr3:58374923	PXK	0.53	8.75	0.38	3.9e-17	Systemic lupus erythematosus;
LGG	cis	rs9322193	0.884	rs10782312	chr6:149943805	G/T	cg15971980	chr6:150254442	NA	0.43	8.14	0.35	3.6e-15	Lung cancer;
LGG	cis	rs12049351	0.665	rs10753458	chr1:229575709	C/A	cg13547644	chr1:229569608	ACTA1	0.32	7.09	0.31	4.88e-12	Circulating myeloperoxidase levels (plasma);
LGG	cis	rs10504229	0.595	rs79077737	chr8:58117520	G/A	cg23782820	chr8:58130467	NA	0.57	8.43	0.36	4.56e-16	Developmental language disorder (linguistic errors);
LGG	cis	rs10504229	1.000	rs67630725	chr8:58185580	G/A	cg05313129	chr8:58192883	C8orf71	-0.8	-12.36	-0.5	1.58e-30	Developmental language disorder (linguistic errors);
LGG	cis	rs7216064	0.684	rs62084675	chr17:66027025	A/G	cg02705964	chr17:66097276	LOC651250	-0.47	-8.37	-0.36	6.96e-16	Lung adenocarcinoma;Lung cancer;EGFR mutation-positive lung adenocarcinoma;
LGG	cis	rs2692947	0.673	rs4907299	chr2:96780122	G/T	cg22654517	chr2:96458247	NA	0.35	7.01	0.31	8.48e-12	Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;
LGG	cis	rs4538187	0.865	rs35474183	chr2:63982523	C/T	cg02541582	chr2:64069798	UGP2	-0.56	-13.02	-0.52	2.98e-33	Systolic blood pressure;
LGG	cis	rs9457247	0.935	rs1187530	chr6:167376812	C/T	cg07741184	chr6:167504864	NA	-0.31	-6.9	-0.31	1.71e-11	Crohn's disease;
LGG	cis	rs11155671	0.530	rs6557133	chr6:150195384	G/T	cg07132326	chr6:150258058	NA	0.36	7.92	0.35	1.78e-14	Testicular germ cell tumor;
LGG	cis	rs769267	0.631	rs7252981	chr19:19692579	T/C	cg01262667	chr19:19385393	TM6SF2	-0.34	-7.99	-0.35	1.05e-14	Tonsillectomy;
LGG	cis	rs2273669	0.667	rs12208578	chr6:109369745	T/C	cg05315195	chr6:109294784	ARMC2	-0.61	-8.3	-0.36	1.11e-15	Prostate cancer;
LGG	cis	rs61861422	0.516	rs12412216	chr10:134393338	C/T	cg20090690	chr10:134436459	INPP5A	0.64	11.39	0.47	1.18e-26	Primary sclerosing cholangitis;
LGG	cis	rs2885056	0.830	rs2018810	chr19:10669172	A/G	cg08312369	chr19:10679775	CDKN2D	-0.51	-6.97	-0.31	1.1e-11	Red cell distribution width;
LGG	cis	rs12091966	0.553	rs7411578	chr1:231212252	C/A	cg26538035	chr1:231178722	NA	0.35	6.76	0.3	4.24e-11	Interleukin-4 levels;
LGG	cis	rs17221829	0.703	rs11018680	chr11:89364011	G/A	cg02982614	chr11:89391479	FOLH1B	-0.4	-9.13	-0.39	2.19e-18	Anxiety in major depressive disorder;
LGG	cis	rs6951245	0.872	rs75398423	chr7:1098414	T/G	cg22907277	chr7:1156413	C7orf50	0.68	8.63	0.37	1.01e-16	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	cis	rs17401966	0.838	rs12737239	chr1:10323973	C/G	cg19773385	chr1:10388646	KIF1B	-0.45	-9.83	-0.42	8.04e-21	Hepatocellular carcinoma;
LGG	cis	rs503341	0.756	rs10897450	chr11:63593219	G/C	cg04850017	chr11:63683019	RCOR2	0.31	7.79	0.34	4.4e-14	Pulse pressure;
LGG	cis	rs7715806	0.500	rs17649266	chr5:75001252	C/T	cg19683494	chr5:74908142	NA	-0.52	-6.94	-0.31	1.31e-11	Body mass index in physically active individuals;Body mass index;Body mass index (joint analysis main effects and physical activity interaction);
LGG	cis	rs714515	0.868	rs7546252	chr1:172368310	A/G	cg01573306	chr1:172330400	DNM3	0.33	7.14	0.32	3.53e-12	Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);
LGG	cis	rs977987	0.836	rs17685540	chr16:75323840	T/C	cg03315344	chr16:75512273	CHST6	0.49	9.97	0.42	2.53e-21	Dupuytren's disease;
LGG	cis	rs1005277	0.579	rs2800485	chr10:38542588	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.32	-0.32	1.09e-12	Extrinsic epigenetic age acceleration;
LGG	cis	rs4776059	1.000	rs35372377	chr15:52882281	G/A	cg22715398	chr15:52968154	KIAA1370	-0.5	-8.21	-0.36	2.28e-15	Schizophrenia;
LGG	cis	rs853679	0.517	rs9393888	chr6:28059217	G/C	cg23161317	chr6:28129485	ZNF389	0.33	6.67	0.3	7.39e-11	Depression;
LGG	cis	rs6088590	0.931	rs6088617	chr20:33408036	G/A	cg08999081	chr20:33150536	PIGU	0.32	7.42	0.33	5.63e-13	Coronary artery disease;
LGG	cis	rs2011503	0.882	rs1064395	chr19:19361735	C/T	cg26732615	chr19:19648335	CILP2;YJEFN3	0.35	7.12	0.31	4.22e-12	Bipolar disorder;
LGG	cis	rs7666738	0.830	rs6827516	chr4:98971740	T/C	cg05340658	chr4:99064831	C4orf37	0.5	8.32	0.36	1.01e-15	Colonoscopy-negative controls vs population controls;
LGG	cis	rs6088590	1.000	rs6119530	chr20:33403930	A/G	cg06115741	chr20:33292138	TP53INP2	0.59	9.83	0.42	7.8e-21	Coronary artery disease;
LGG	cis	rs875971	0.862	rs10250544	chr7:65766561	A/G	cg12463550	chr7:65579703	CRCP	-0.5	-8.37	-0.36	6.91e-16	Aortic root size;
LGG	cis	rs7811142	0.667	rs3873746	chr7:99935097	G/A	cg00814883	chr7:100076585	TSC22D4	-0.68	-9.92	-0.42	3.68e-21	Platelet count;
LGG	cis	rs727563	0.638	rs5996058	chr22:42141452	A/G	cg06634786	chr22:41940651	POLR3H	0.77	12.22	0.49	6e-30	Crohn's disease;Inflammatory bowel disease;
LGG	trans	rs34638657	0.518	rs2288050	chr16:82183403	C/T	cg15268622	chr1:167189846	POU2F1	0.41	6.99	0.31	9.67e-12	Lung adenocarcinoma;
LGG	cis	rs10771431	0.597	rs7976807	chr12:9352459	G/A	cg08997352	chr12:9597637	DDX12	-0.75	-13.77	-0.54	2.17e-36	Breast size;
LGG	trans	rs1005277	0.579	rs1780139	chr10:38503018	C/T	cg04469686	chr1:162760199	HSD17B7	-0.46	-7.45	-0.33	4.63e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs7666738	0.830	rs72882693	chr4:98960804	T/A	cg05340658	chr4:99064831	C4orf37	0.5	8.39	0.36	5.86e-16	Colonoscopy-negative controls vs population controls;
LGG	cis	rs79149102	0.579	rs73438569	chr15:75354486	T/A	cg09165964	chr15:75287851	SCAMP5	-0.75	-7.95	-0.35	1.49e-14	Lung cancer;
LGG	cis	rs7618915	0.501	rs34739010	chr3:52766122	A/G	cg14092988	chr3:52407081	DNAH1	0.3	7.95	0.35	1.4e-14	Bipolar disorder;
LGG	cis	rs6840360	0.517	rs4399967	chr4:152729312	T/A	cg22705602	chr4:152727874	NA	0.35	8.5	0.37	2.63e-16	Intelligence (multi-trait analysis);
LGG	cis	rs4742903	0.904	rs4373581	chr9:106977463	C/T	cg14250997	chr9:106856677	SMC2	0.4	8.31	0.36	1.05e-15	High-grade serous ovarian cancer;Breast cancer;
LGG	cis	rs3809863	0.602	rs7225700	chr17:45391804	T/C	cg25173405	chr17:45401733	C17orf57	-0.73	-13.0	-0.52	3.75e-33	Glaucoma (primary open-angle);
LGG	cis	rs1552244	1.000	rs113522867	chr3:10154503	T/C	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.88	-14.01	-0.55	2e-37	Alzheimer's disease;
LGG	cis	rs9322193	0.887	rs3734295	chr6:149915053	C/T	cg00933542	chr6:150070202	PCMT1	0.41	7.26	0.32	1.68e-12	Lung cancer;
LGG	cis	rs704	0.739	rs733914	chr17:26671196	C/G	cg10342447	chr17:26645325	TMEM97	-0.38	-7.05	-0.31	6.63e-12	Osteoprotegerin levels;
LGG	cis	rs2710642	0.566	rs2710651	chr2:63166379	G/A	cg17519650	chr2:63277830	OTX1	0.62	11.73	0.48	5.57e-28	LDL cholesterol levels;LDL cholesterol;
LGG	trans	rs2204008	0.630	rs12306932	chr12:38242029	C/T	cg06521331	chr12:34319734	NA	0.45	8.03	0.35	8.18e-15	Bladder cancer;
LGG	trans	rs1908814	0.516	rs7833079	chr8:11792129	A/G	cg02002194	chr4:3960332	NA	-0.49	-9.19	-0.39	1.3e-18	Neuroticism;
LGG	cis	rs6840360	0.571	rs62327274	chr4:152548012	C/T	cg25486957	chr4:152246857	NA	-0.5	-8.24	-0.36	1.77e-15	Intelligence (multi-trait analysis);
LGG	cis	rs17270561	0.609	rs7772382	chr6:25708116	C/T	cg03264133	chr6:25882463	NA	-0.47	-7.57	-0.33	1.97e-13	Iron status biomarkers;
LGG	cis	rs1552244	0.572	rs7645667	chr3:10157337	C/A	cg18598329	chr3:10140678	FANCD2;C3orf24	-0.89	-11.76	-0.48	4.09e-28	Alzheimer's disease;
LGG	cis	rs4077515	0.870	rs11793497	chr9:139271850	A/G	cg21253087	chr9:139290292	SNAPC4	0.35	7.1	0.31	4.62e-12	Ulcerative colitis;IgA nephropathy;Inflammatory bowel disease;Crohn's disease;
LGG	cis	rs11098499	0.826	rs12511640	chr4:120251248	T/C	cg09307838	chr4:120376055	NA	0.73	12.5	0.5	4.26e-31	Corneal astigmatism;
LGG	cis	rs597539	0.617	rs598353	chr11:68635770	C/A	cg11716795	chr11:68671300	MRPL21;IGHMBP2	0.86	16.13	0.6	8.94e-47	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;
LGG	trans	rs61332075	0.518	rs892839	chr2:239406446	G/A	cg01134436	chr17:81009848	B3GNTL1	0.64	7.22	0.32	2.09e-12	Lung function (FEV1/FVC);
LGG	cis	rs6960043	0.818	rs10238161	chr7:15053827	A/T	cg19272540	chr7:15055459	NA	0.34	7.72	0.34	7.41e-14	Type 2 diabetes;
LGG	cis	rs4722166	0.630	rs12700391	chr7:22777327	C/A	cg05265849	chr7:22767390	IL6	0.44	8.33	0.36	8.91e-16	Lung cancer;
LGG	cis	rs4917300	0.606	rs4917278	chr8:143095603	A/T	cg06573787	chr8:143070187	NA	-0.6	-10.04	-0.42	1.4e-21	Amyotrophic lateral sclerosis;
LGG	cis	rs7582180	0.715	rs764828	chr2:100908634	A/C	cg14675211	chr2:100938903	LONRF2	0.57	9.52	0.4	9.48e-20	Intelligence (multi-trait analysis);
LGG	cis	rs13108904	0.840	rs13106092	chr4:1257290	T/A	cg05025164	chr4:1340916	KIAA1530	0.43	7.18	0.32	2.82e-12	Obesity-related traits;
LGG	cis	rs60871478	0.838	rs7789321	chr7:800977	A/G	cg13798912	chr7:905769	UNC84A	0.54	6.86	0.3	2.27e-11	Cerebrospinal P-tau181p levels;
LGG	cis	rs7089973	0.604	rs11196932	chr10:116584386	C/T	cg08188268	chr10:116634841	FAM160B1	0.33	7.09	0.31	4.99e-12	Bipolar disorder or attention deficit hyperactivity disorder;
LGG	cis	rs1497828	0.869	rs2646838	chr1:217552687	C/G	cg04411442	chr1:217543379	NA	0.48	8.15	0.35	3.32e-15	Dialysis-related mortality;
LGG	cis	rs9322193	0.962	rs9689242	chr6:150109106	T/C	cg08621203	chr6:150244597	RAET1G	0.4	6.83	0.3	2.65e-11	Lung cancer;
LGG	cis	rs6066825	0.644	rs6125442	chr20:47331210	C/G	cg18078177	chr20:47281410	PREX1	0.46	7.73	0.34	6.53e-14	Colorectal cancer;
LGG	cis	rs1153858	1.000	rs1145085	chr15:45657804	A/G	cg26924012	chr15:45694286	SPATA5L1	1.02	21.22	0.7	2.51e-70	Homoarginine levels;
LGG	cis	rs1863824	0.595	rs61859067	chr10:88159997	G/A	cg07322936	chr10:88137208	NA	-0.51	-8.32	-0.36	9.89e-16	Schizophrenia;
LGG	cis	rs13108904	0.870	rs3755927	chr4:1238246	G/A	cg13395646	chr4:1353034	KIAA1530	-0.45	-7.74	-0.34	6.42e-14	Obesity-related traits;
LGG	cis	rs2576037	0.561	rs513775	chr18:44396334	T/C	cg19077165	chr18:44547161	KATNAL2	-0.7	-13.39	-0.53	8.88e-35	Personality dimensions;
LGG	cis	rs3747547	0.892	rs17516779	chr9:37955265	A/G	cg13774184	chr9:37916125	SHB	0.71	7.06	0.31	6.08e-12	Metabolite levels (Dihydroxy docosatrienoic acid);
LGG	cis	rs7084402	0.934	rs1649021	chr10:60286028	C/T	cg07615347	chr10:60278583	BICC1	0.63	18.16	0.64	4.81e-56	Refractive error;
LGG	cis	rs6912958	0.500	rs4707352	chr6:87929705	G/A	cg08069147	chr6:88032118	GJB7;C6orf162	-0.67	-12.54	-0.5	2.85e-31	Monocyte percentage of white cells;
LGG	cis	rs4689388	0.926	rs4688986	chr4:6285797	C/A	cg14416269	chr4:6271139	WFS1	0.53	9.83	0.42	7.67e-21	Type 2 diabetes and other traits;Type 2 diabetes;
LGG	cis	rs7937682	0.889	rs1789359	chr11:111475995	T/A	cg19812747	chr11:111475976	SIK2	-0.51	-10.79	-0.45	2.24e-24	Primary sclerosing cholangitis;
LGG	cis	rs34929064	0.536	rs2905306	chr7:22638818	C/T	cg18045685	chr7:22629474	NA	0.85	19.78	0.68	1.41e-63	Major depression and alcohol dependence;
LGG	cis	rs17345786	0.911	rs10936707	chr3:101324063	G/A	cg12386194	chr3:101231763	SENP7	0.7	12.09	0.49	1.9e-29	Colonoscopy-negative controls vs population controls;
LGG	cis	rs651907	0.535	rs9830943	chr3:101428899	T/G	cg03837452	chr3:101395095	ZBTB11;LOC100009676	0.66	13.57	0.53	1.44e-35	Colorectal cancer;
LGG	cis	rs12478296	1.000	rs55814222	chr2:243041166	C/T	cg06360820	chr2:242988706	NA	-0.89	-11.48	-0.47	5.23e-27	Obesity-related traits;
LGG	cis	rs1348850	0.632	rs12471621	chr2:178502353	T/C	cg05169160	chr2:178484487	TTC30A	0.34	6.64	0.3	8.62e-11	Alanine aminotransferase (ALT) levels after remission induction therapy in actute lymphoblastic leukemia (ALL);
LGG	cis	rs6964587	0.967	rs12538325	chr7:91757479	A/G	cg17063962	chr7:91808500	NA	0.52	9.27	0.4	7.04e-19	Breast cancer;
LGG	cis	rs875971	0.964	rs1643388	chr7:65844562	T/C	cg11764359	chr7:65958608	NA	0.79	14.81	0.57	6.87e-41	Aortic root size;
LGG	cis	rs2073300	0.609	rs6137938	chr20:23389127	C/G	cg12062639	chr20:23401060	NAPB	0.93	9.1	0.39	2.72e-18	Peripheral arterial disease (traffic-related air pollution interaction);
LGG	cis	rs6060960	0.502	rs6057968	chr20:30082779	A/T	cg13852791	chr20:30311386	BCL2L1	0.62	8.11	0.35	4.43e-15	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;
LGG	cis	rs12188164	0.965	rs72717430	chr5:444502	T/C	cg26850624	chr5:429559	AHRR	-0.36	-7.9	-0.34	2.06e-14	Cystic fibrosis severity;
LGG	cis	rs10791323	0.593	rs11223599	chr11:133717902	A/T	cg15485101	chr11:133734466	NA	-0.57	-10.13	-0.43	6.33e-22	Childhood ear infection;
LGG	cis	rs4356932	1.000	rs4401475	chr4:76975924	T/C	cg25799590	chr4:76943062	CXCL10;ART3	-0.39	-6.68	-0.3	6.68e-11	Blood protein levels;
LGG	cis	rs17767392	0.609	rs60526802	chr14:71680078	C/T	cg13720639	chr14:72061746	SIPA1L1	-0.34	-7.02	-0.31	7.75e-12	Mitral valve prolapse;
LGG	cis	rs1799949	1.000	rs8176265	chr17:41213996	C/T	cg05368731	chr17:41323189	NBR1	0.95	18.5	0.65	1.23e-57	Menopause (age at onset);
LGG	cis	rs7481584	0.924	rs12805661	chr11:3020740	C/T	cg08508325	chr11:3079039	CARS	0.38	7.0	0.31	9e-12	Calcium levels;
LGG	cis	rs6598163	0.564	rs12319878	chr12:132289989	C/T	cg07389463	chr12:132296394	NA	0.41	8.46	0.37	3.5e-16	Migraine;
LGG	trans	rs11935423	0.735	rs7693979	chr4:100464565	A/T	cg00498163	chr2:242821619	NA	0.36	6.95	0.31	1.27e-11	Gut microbiome composition (summer);
LGG	cis	rs6951245	1.000	rs884977	chr7:1066410	T/C	cg24642844	chr7:1081250	C7orf50	-0.73	-12.13	-0.49	1.33e-29	C-reactive protein levels or total cholesterol levels (pleiotropy);
LGG	trans	rs4332037	0.851	rs1403175	chr7:1964357	A/T	cg10840412	chr1:235813424	GNG4	-0.65	-8.79	-0.38	2.87e-17	Bipolar disorder;
LGG	cis	rs7712401	0.540	rs27617	chr5:122236534	T/A	cg19077854	chr5:122220652	SNX24	0.31	6.71	0.3	5.78e-11	Mean platelet volume;
LGG	cis	rs9487094	0.813	rs34320275	chr6:109757963	A/G	cg16315928	chr6:109776240	MICAL1	0.55	9.02	0.39	4.91e-18	Height;
LGG	cis	rs752010	0.695	rs12134166	chr1:42105867	C/T	cg06885757	chr1:42089581	HIVEP3	0.56	12.75	0.51	3.89e-32	Lupus nephritis in systemic lupus erythematosus;
LGG	cis	rs2721811	0.701	rs2529083	chr7:24702513	C/T	cg06301139	chr7:24798175	DFNA5	-0.38	-6.86	-0.3	2.15e-11	Depressive symptoms (multi-trait analysis);
LGG	cis	rs9896933	0.623	rs77166830	chr17:80833525	T/C	cg15369054	chr17:80825471	TBCD	0.51	6.79	0.3	3.51e-11	Bone mineral accretion in asthma (oral corticosteroid dose interaction);
LGG	cis	rs9322193	0.847	rs868375	chr6:150166041	T/A	cg08621203	chr6:150244597	RAET1G	0.42	7.25	0.32	1.74e-12	Lung cancer;
LGG	cis	rs1005277	0.579	rs1740747	chr10:38520465	G/A	cg17219203	chr10:38645113	HSD17B7P2	-0.47	-7.42	-0.33	5.82e-13	Extrinsic epigenetic age acceleration;
LGG	cis	rs950776	0.684	rs692780	chr15:78876505	C/G	cg06917634	chr15:78832804	PSMA4	-0.69	-12.82	-0.51	2.14e-32	Sudden cardiac arrest;
LGG	cis	rs56161922	1.000	rs4562622	chr1:207876577	A/C	cg09557387	chr1:207818395	CR1L	-0.94	-9.16	-0.39	1.64e-18	Response to paliperidone in schizophrenia (PANSS score);Response to paliperidone in schizophrenia (positive Marder score);
LGG	cis	rs924043	0.568	rs72503859	chr6:170396963	T/C	cg00389036	chr6:170409598	NA	0.55	6.9	0.31	1.67e-11	Type 1 diabetes;
LGG	cis	rs10504229	0.817	rs58957714	chr8:58195864	G/A	cg24829409	chr8:58192753	C8orf71	-0.87	-11.73	-0.48	5.09e-28	Developmental language disorder (linguistic errors);
LGG	cis	rs919433	0.726	rs11904247	chr2:198238424	T/G	cg00792783	chr2:198669748	PLCL1	0.48	7.41	0.33	6.17e-13	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);
LGG	cis	rs6500395	0.962	rs9941336	chr16:48652769	G/A	cg04672837	chr16:48644449	N4BP1	0.51	8.36	0.36	7.34e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs9911578	0.935	rs9893351	chr17:57023326	G/A	cg12560992	chr17:57184187	TRIM37	0.83	14.79	0.57	8.23e-41	Intelligence (multi-trait analysis);
LGG	cis	rs6933660	0.800	rs9383900	chr6:151782816	A/C	cg17179660	chr6:151773299	C6orf211;RMND1	-0.5	-8.62	-0.37	1.09e-16	Menarche (age at onset);
LGG	cis	rs73273528	1.000	rs73273528	chr20:50431113	C/T	cg12288473	chr20:50419274	SALL4	-0.84	-7.0	-0.31	9.05e-12	Interleukin-6 levels;
LGG	cis	rs9783347	0.714	rs4757638	chr11:18312953	G/A	cg03595886	chr11:18357587	GTF2H1	-0.46	-11.11	-0.46	1.34e-25	Pancreatic cancer;
LGG	cis	rs283228	0.917	rs2518338	chr6:101767150	G/T	cg27451362	chr6:101846650	GRIK2	0.53	8.96	0.38	8.08e-18	Coenzyme Q10 levels;
LGG	cis	rs11771526	0.901	rs7791914	chr7:32296754	A/G	cg13207630	chr7:32358064	NA	0.66	7.05	0.31	6.4e-12	Body mass index;
LGG	cis	rs6500395	0.963	rs12444902	chr16:48667126	G/T	cg04672837	chr16:48644449	N4BP1	0.5	8.45	0.37	3.83e-16	Response to tocilizumab in rheumatoid arthritis;
LGG	cis	rs735539	0.521	rs2818998	chr13:21369911	T/C	cg04906043	chr13:21280425	IL17D	-0.45	-7.13	-0.31	3.93e-12	Dental caries;
LGG	cis	rs2479724	0.818	rs9357369	chr6:41818202	A/C	cg17623882	chr6:41773611	USP49	-0.52	-9.28	-0.4	6.38e-19	Menarche (age at onset);
LGG	cis	rs4075765	0.881	rs17243098	chr11:26187117	A/T	cg19182008	chr11:26298241	NA	-0.77	-8.24	-0.36	1.76e-15	Cannabis dependence symptom count;
LGG	cis	rs10752881	1.000	rs6424880	chr1:182986679	C/T	cg07245641	chr1:182991651	LAMC1	0.42	9.66	0.41	3.03e-20	Colorectal cancer;
LGG	cis	rs4862750	0.872	rs6830426	chr4:187897270	T/A	cg10295955	chr4:187884368	NA	-1.16	-31.63	-0.83	8.47e-118	Lobe attachment (rater-scored or self-reported);
LGG	cis	rs9362426	0.608	rs6454613	chr6:88111989	T/A	cg06087457	chr6:88040249	C6orf162;GJB7	-0.44	-8.5	-0.37	2.64e-16	Depressive episodes in bipolar disorder;
LGG	cis	rs2204008	0.774	rs11495721	chr12:38337224	A/C	cg13010199	chr12:38710504	ALG10B	0.67	13.33	0.53	1.49e-34	Bladder cancer;
LGG	cis	rs7831492	0.564	rs7831530	chr8:41614567	G/A	cg17182837	chr8:41585554	ANK1	-0.6	-10.83	-0.45	1.59e-24	Colorectal cancer;
LGG	cis	rs8031584	1.000	rs11634216	chr15:31288670	G/A	cg19680485	chr15:31195859	MTMR15	-0.45	-6.84	-0.3	2.59e-11	Huntington's disease progression;
LGG	cis	rs13118159	0.767	rs2141656	chr4:1317192	C/T	cg05165339	chr4:1420672	NA	-0.3	-7.81	-0.34	3.91e-14	Longevity;
LGG	cis	rs1552244	0.832	rs73024591	chr3:10203194	A/T	cg08888203	chr3:10149979	C3orf24	0.53	8.51	0.37	2.45e-16	Alzheimer's disease;
LGG	cis	rs514406	0.644	rs6661196	chr1:53203664	A/G	cg24675658	chr1:53192096	ZYG11B	0.59	12.79	0.51	2.72e-32	Monocyte count;
LGG	cis	rs780096	0.526	rs1406295	chr2:27689700	A/G	cg22903471	chr2:27725779	GCKR	-0.56	-12.79	-0.51	2.65e-32	Total body bone mineral density;
LGG	cis	rs10504229	0.603	rs6985975	chr8:58150948	A/T	cg14926445	chr8:58193284	C8orf71	-0.45	-7.09	-0.31	4.96e-12	Developmental language disorder (linguistic errors);
LGG	cis	rs6502050	0.835	rs7208673	chr17:80165908	G/C	cg10505658	chr17:80084571	CCDC57	-0.42	-8.46	-0.37	3.42e-16	Life satisfaction;
LGG	cis	rs2204008	0.837	rs11611861	chr12:38357459	A/G	cg26384229	chr12:38710491	ALG10B	0.93	20.87	0.7	1.1e-68	Bladder cancer;
LGG	cis	rs4732038	0.565	rs12673319	chr7:134278968	G/C	cg06906464	chr7:134288099	NA	-0.72	-20.94	-0.7	5.15e-69	Longevity;
LGG	cis	rs916888	0.610	rs142167	chr17:44795234	C/T	cg01570182	chr17:44337453	NA	-0.5	-9.12	-0.39	2.25e-18	Post bronchodilator FEV1;Cognitive function;Intelligence (multi-trait analysis);Multiple system atrophy;
LGG	cis	rs1218582	0.772	rs4845689	chr1:154885524	A/G	cg06221963	chr1:154839813	KCNN3	-0.53	-11.07	-0.46	2.05e-25	Prostate cancer;
LGG	cis	rs35110281	0.837	rs2838343	chr21:45078035	C/T	cg01579765	chr21:45077557	HSF2BP	-0.42	-9.91	-0.42	4.14e-21	Mean corpuscular volume;
LGG	cis	rs8067545	0.750	rs11871651	chr17:19997425	T/C	cg09818912	chr17:20140352	CYTSB	-0.29	-6.86	-0.3	2.17e-11	Schizophrenia;
LGG	cis	rs9910055	0.762	rs227579	chr17:42223134	A/T	cg16434002	chr17:42200994	HDAC5	0.53	9.71	0.41	2.14e-20	Total body bone mineral density;
LGG	trans	rs1998584	0.901	rs10961191	chr9:13667639	A/C	cg07939768	chr17:27621433	NUFIP2	-0.41	-6.78	-0.3	3.59e-11	Survival in microsatellite instability low/stable colorectal cancer;
LGG	cis	rs11148252	0.740	rs3803264	chr13:52971893	A/G	cg00761968	chr13:53314142	LECT1	0.32	6.7	0.3	6.15e-11	Lewy body disease;
LGG	cis	rs2404602	0.647	rs11072631	chr15:77132909	T/C	cg23625390	chr15:77176239	SCAPER	-0.74	-14.58	-0.56	6.8100000000000004e-40	Blood metabolite levels;
LGG	cis	rs10504229	0.728	rs77197419	chr8:58150879	C/A	cg21724239	chr8:58056113	NA	0.6	9.3	0.4	5.57e-19	Developmental language disorder (linguistic errors);
LGG	cis	rs283228	0.535	rs62421963	chr6:101836326	G/A	cg27451362	chr6:101846650	GRIK2	1.01	15.38	0.58	1.95e-43	Coenzyme Q10 levels;
LGG	cis	rs722599	0.748	rs741096	chr14:75351487	A/G	cg06637938	chr14:75390232	RPS6KL1	-0.61	-10.23	-0.43	2.81e-22	IgG glycosylation;
LGG	trans	rs61931739	0.517	rs1844525	chr12:34103183	T/A	cg13010199	chr12:38710504	ALG10B	0.57	10.67	0.44	6.4e-24	Morning vs. evening chronotype;
LGG	trans	rs9650657	0.812	rs6601522	chr8:10629061	G/T	cg06636001	chr8:8085503	FLJ10661	-0.39	-6.89	-0.3	1.79e-11	Neuroticism;
LGG	cis	rs9467773	1.000	rs6456733	chr6:26566804	C/T	cg11502198	chr6:26597334	ABT1	0.58	10.02	0.42	1.6e-21	Intelligence (multi-trait analysis);
LGG	cis	rs763121	0.776	rs5757177	chr22:39007174	A/C	cg06022373	chr22:39101656	GTPBP1	0.88	17.45	0.63	9.17e-53	Menopause (age at onset);
LGG	trans	rs877282	0.945	rs10904556	chr10:789429	A/G	cg22713356	chr15:30763199	NA	0.57	8.62	0.37	1.03e-16	Uric acid levels;
LGG	cis	rs9291683	0.655	rs3822242	chr4:10094904	T/C	cg25986240	chr4:9926439	SLC2A9	0.34	7.02	0.31	7.85e-12	Bone mineral density;
LGG	cis	rs1865760	0.532	rs1061482	chr6:26086699	G/T	cg16482183	chr6:26056742	HIST1H1C	0.55	9.79	0.41	1.07e-20	Height;
LGG	cis	rs9486715	0.867	rs9480700	chr6:96965056	A/G	cg06623918	chr6:96969491	KIAA0776	0.78	15.76	0.59	4.13e-45	Headache;
LGG	cis	rs9611565	0.659	rs9607813	chr22:41941479	G/A	cg17376030	chr22:41985996	PMM1	0.56	8.82	0.38	2.4e-17	Vitiligo;
LGG	cis	rs7659604	0.676	rs4516739	chr4:122699741	G/T	cg05802129	chr4:122689817	NA	-0.4	-6.75	-0.3	4.56e-11	Type 2 diabetes;
LGG	cis	rs1865760	0.865	rs10946800	chr6:25957773	C/T	cg12310025	chr6:25882481	NA	-0.43	-7.96	-0.35	1.36e-14	Height;
LGG	trans	rs11992162	0.621	rs13268810	chr8:11797430	A/T	cg16141378	chr3:129829833	LOC729375	-0.33	-7.38	-0.32	7.42e-13	Monocyte count;
LGG	cis	rs1881797	1.000	rs68059491	chr1:247683070	C/T	cg18198730	chr1:247681584	NA	0.75	12.69	0.51	6.79e-32	Acute lymphoblastic leukemia (childhood);
LGG	cis	rs9992101	0.517	rs1912833	chr4:77242825	T/A	cg17010112	chr4:77227123	STBD1	-0.48	-9.98	-0.42	2.29e-21	Creatinine levels;
LGG	cis	rs9513627	0.573	rs7325697	chr13:100117793	A/G	cg25919922	chr13:100150906	NA	0.61	8.25	0.36	1.69e-15	Obesity-related traits;
LGG	cis	rs10791323	0.569	rs10750541	chr11:133713189	A/C	cg06766960	chr11:133703094	NA	0.55	10.77	0.45	2.75e-24	Childhood ear infection;
LGG	cis	rs10883723	0.773	rs7917402	chr10:104246690	C/T	cg11453585	chr10:104263688	ACTR1A;SUFU	0.75	14.99	0.57	1.07e-41	Allergic disease (asthma, hay fever or eczema);
LGG	trans	rs208520	0.661	rs7747492	chr6:66857788	A/T	cg15611600	chr13:45563400	KIAA1704;NUFIP1	-0.96	-17.75	-0.64	3.93e-54	Exhaled nitric oxide output;
LGG	cis	rs9916302	0.851	rs612209	chr17:37442713	G/C	cg07936489	chr17:37558343	FBXL20	0.85	16.0	0.6	3.49e-46	Glomerular filtration rate (creatinine);
LGG	cis	rs8064024	0.599	rs1876359	chr16:4930100	C/T	cg08329684	chr16:4932620	PPL	0.49	10.12	0.43	7.2e-22	Cancer;
LGG	cis	rs9790314	0.663	rs10513562	chr3:160743579	G/A	cg04691961	chr3:161091175	C3orf57	-0.41	-8.62	-0.37	1.07e-16	Morning vs. evening chronotype;